<SEC-DOCUMENT>0001193125-15-081081.txt : 20150306 <SEC-HEADER>0001193125-15-081081.hdr.sgml : 20150306 <ACCEPTANCE-DATETIME>20150306162742 ACCESSION NUMBER: 0001193125-15-081081 CONFORMED SUBMISSION TYPE: 10-K PUBLIC DOCUMENT COUNT: 14 CONFORMED PERIOD OF REPORT: 20141231 FILED AS OF DATE: 20150306 DATE AS OF CHANGE: 20150306 FILER: COMPANY DATA: COMPANY CONFORMED NAME: CYTOKINETICS INC CENTRAL INDEX KEY: 0001061983 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 943291317 FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-K SEC ACT: 1934 Act SEC FILE NUMBER: 000-50633 FILM NUMBER: 15682000 BUSINESS ADDRESS: STREET 1: 280 EAST GRAND AVENUE STREET 2: . CITY: SOUTH SAN FRANCISCO STATE: CA ZIP: 94080 BUSINESS PHONE: (650) 624-3000 MAIL ADDRESS: STREET 1: 280 EAST GRAND AVENUE CITY: SOUTH SAN FRANCISCO STATE: CA ZIP: 94080 </SEC-HEADER> <DOCUMENT> <TYPE>10-K <SEQUENCE>1 <FILENAME>d828167d10k.htm <DESCRIPTION>10-K <TEXT> <HTML><HEAD> <TITLE>10-K</TITLE> </HEAD> <BODY BGCOLOR="WHITE"> <h5 align="left"><a href="#toc">Table of Contents</a></h5> <P STYLE="line-height:2px;margin-top:0px;margin-bottom:0px;border-bottom:2pt solid #000000"> </P> <P STYLE="line-height:3px;margin-top:0px;margin-bottom:2px;border-bottom:0.5pt solid #000000"> </P> <P STYLE="margin-top:4px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="4"><B>UNITED STATES SECURITIES AND EXCHANGE COMMISSION </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="3"><B>Washington, D.C. 20549 </B></FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px"> </P><center> <P STYLE="line-height:6px;margin-top:0px;margin-bottom:2px;border-bottom:1pt solid #000000;width:21%"> </P></center> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="5"><B>Form 10-K </B></FONT></P><center> <P STYLE="line-height:6px;margin-top:0px;margin-bottom:2px;border-bottom:1pt solid #000000;width:21%"> </P></center> <P STYLE="margin-top:2px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(Mark One) </B></FONT></P> <TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%"> <TR> <TD WIDTH="2%"><FONT SIZE="1"> </FONT></TD> <TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B></B><FONT STYLE="FONT-FAMILY:WINGDINGS">þ</FONT><B></B><B></B></FONT></TD> <TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</B> </FONT></TD></TR></TABLE> <P STYLE="margin-top:6px;margin-bottom:0px; margin-left:6%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>For the fiscal year ended December 31, 2014 </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>or </B></FONT></P> <TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%"> <TR> <TD WIDTH="2%"><FONT SIZE="1"> </FONT></TD> <TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B></B><FONT STYLE="FONT-FAMILY:WINGDINGS">¨</FONT><B></B><B></B></FONT></TD> <TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</B> </FONT></TD></TR></TABLE> <P STYLE="margin-top:6px;margin-bottom:0px; margin-left:6%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>From the transition period from <U> </U> to <U> </U> </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Commission file number: 000-50633 </B></FONT></P> <P STYLE="margin-top:2px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="6"><B>CYTOKINETICS, INCORPORATED </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><I>(Exact name of registrant as specified in its charter) </I></FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px"> </P> <TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center"> <TR> <TD WIDTH="50%"></TD> <TD VALIGN="bottom" WIDTH="1%"></TD> <TD WIDTH="48%"></TD></TR> <TR> <TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Delaware</B></FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>94-3291317</B></FONT></TD></TR> <TR> <TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><I>(State or other jurisdiction of</I></FONT></P> <P STYLE="margin-top:0px;margin-bottom:1px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><I>incorporation or organization)</I></FONT></P></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><I>(I.R.S. Employer</I></FONT></P> <P STYLE="margin-top:0px;margin-bottom:1px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><I>Identification No.)</I></FONT></P></TD></TR> </TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px"> </P> <TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center"> <TR> <TD WIDTH="50%"></TD> <TD VALIGN="bottom" WIDTH="1%"></TD> <TD WIDTH="48%"></TD></TR> <TR> <TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>280 East Grand Avenue</B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:1px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>South San Francisco, CA</B></FONT></P></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>94080</B></FONT></TD></TR> <TR> <TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><I>(Address of principal executive offices)</I></FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><I>(Zip Code)</I></FONT></TD></TR> </TABLE> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(650) 624-3000 </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><I>(Registrant’s telephone number, including area code) </I></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Securities registered pursuant to Section 12(b) of the Act: </B></FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px"> </P> <TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center"> <TR> <TD WIDTH="47%"></TD> <TD VALIGN="bottom" WIDTH="2%"></TD> <TD WIDTH="48%"></TD></TR> <TR> <TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="border-bottom:1px solid #000000"> <P STYLE="margin-top:0px;margin-bottom:1px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Title of each class</B></FONT></P></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="border-bottom:1px solid #000000"> <P STYLE="margin-top:0px;margin-bottom:1px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Name of each exchange on which registered</B></FONT></P></TD></TR> <TR> <TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">Common Stock, $0.001 par value</FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">The NASDAQ Capital Market</FONT></TD></TR> </TABLE> <P STYLE="margin-top:6px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Securities registered pursuant to Section 12(g) of the Act: </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>None </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:3%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Yes <FONT STYLE="FONT-FAMILY:WINGDINGS">¨</FONT> No <FONT STYLE="FONT-FAMILY:WINGDINGS">þ</FONT> </FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:3%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act. Yes <FONT STYLE="FONT-FAMILY:WINGDINGS">¨</FONT> No <FONT STYLE="FONT-FAMILY:WINGDINGS">þ</FONT> </FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:3%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">Indicate by check mark whether the Registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes <FONT STYLE="FONT-FAMILY:WINGDINGS">þ</FONT> No <FONT STYLE="FONT-FAMILY:WINGDINGS">¨</FONT> </FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:3%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">Indicate by check mark whether the Registrant has submitted electronically and posted on its corporate Website, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§ 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). Yes <FONT STYLE="FONT-FAMILY:WINGDINGS">þ</FONT> No <FONT STYLE="FONT-FAMILY:WINGDINGS">¨</FONT> </FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:3%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">Indicate by check mark if disclosure of delinquent filers pursuant to Item 405 of Regulation S-K (§ 229.405 of this chapter) is not contained herein, and will not be contained, to the best of the Registrant’s knowledge, in definitive proxy or information statements incorporated by reference in Part III of this Form 10-K or any amendment to this Form 10-K. <FONT STYLE="FONT-FAMILY:WINGDINGS">þ</FONT></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:3%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">Indicate by check mark whether the Registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions of “large accelerated filer,” “accelerated filer” and “smaller reporting company” in Rule 12b-2 of the Exchange Act. </FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px"> </P> <TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center"> <TR> <TD WIDTH="22%"></TD> <TD VALIGN="bottom" WIDTH="1%"></TD> <TD WIDTH="17%"></TD> <TD VALIGN="bottom" WIDTH="1%"></TD> <TD WIDTH="20%"></TD> <TD VALIGN="bottom" WIDTH="1%"></TD> <TD WIDTH="38%"></TD></TR> <TR> <TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Large accelerated filer <FONT STYLE="FONT-FAMILY:WINGDINGS">¨</FONT></FONT></P></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Accelerated filer <FONT STYLE="FONT-FAMILY:WINGDINGS">þ</FONT></FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Non-accelerated filer <FONT STYLE="FONT-FAMILY:WINGDINGS">¨</FONT></FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">Smaller reporting company <FONT STYLE="FONT-FAMILY:WINGDINGS">¨</FONT></FONT></TD></TR> <TR> <TD VALIGN="top" COLSPAN="7" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">(Do not check if a smaller reporting company)</FONT></TD></TR> </TABLE> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:3%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">Indicate by check mark whether the Registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes <FONT STYLE="FONT-FAMILY:WINGDINGS">¨</FONT> No <FONT STYLE="FONT-FAMILY:WINGDINGS">þ</FONT> </FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:3%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">The aggregate market value of the voting and non-voting common equity held by non-affiliates was $174.5 million, computed by reference to the last sales price of $4.78 as reported by the NASDAQ Market as of the last business day of the Registrant’s most recently completed second fiscal quarter, June 30, 2014. This calculation does not reflect a determination that certain persons are affiliates of the Registrant for any other purpose. The number of shares of common stock held by non-affiliates excluded 106,337 shares of common stock held by directors, officers and affiliates of directors. The number of shares owned by affiliates of directors was determined based upon information supplied by such persons and upon Schedules 13D and 13G, if any, filed with the SEC. Exclusion of shares held by any person should not be construed to indicate that such person possesses the power, direct or indirect, to direct or cause the direction of the management or policies of the Registrant, that such person is controlled by or under common control with the Registrant, or that such persons are affiliates for any other purpose. </FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:3%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">The number of shares outstanding of the Registrant’s common stock on February 27, 2015 was 38,674,892 shares. </FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>DOCUMENTS INCORPORATED BY REFERENCE </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:3%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">Portions of the Registrant’s Proxy Statement for its 2015 Annual Meeting of Stockholders to be filed with the Securities and Exchange Commission, no later than 120 days after the end of the fiscal year, are incorporated by reference to Part III of this Annual Report on Form 10-K. </FONT></P> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px"> </P> <P STYLE="line-height:0px;margin-top:0px;margin-bottom:0px;border-bottom:0.5pt solid #000000"> </P> <P STYLE="line-height:4px;margin-top:0px;margin-bottom:2px;border-bottom:2pt solid #000000"> </P> <p Style='page-break-before:always'> <HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER"> <h5 align="left"><a href="#toc">Table of Contents</a></h5> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>CYTOKINETICS, INCORPORATED </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>FORM 10-K </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Year Ended December 31, 2014 </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><A NAME="toc"></A>INDEX </B></FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px"> </P> <TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center"> <TR> <TD WIDTH="7%"></TD> <TD VALIGN="bottom" WIDTH="2%"></TD> <TD WIDTH="86%"></TD> <TD VALIGN="bottom" WIDTH="2%"></TD> <TD></TD> <TD></TD> <TD></TD></TR> <TR> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Page</B></FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD></TR> <TR> <TD VALIGN="top" COLSPAN="3" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><A HREF="#toc828167_1">PART I </A></B></FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="top"></TD> <TD VALIGN="top"></TD> <TD VALIGN="top"></TD></TR> <TR> <TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Item 1.</FONT></P></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><A HREF="#toc828167_2">Business</A></FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">3</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD></TR> <TR> <TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Item 1A.</FONT></P></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><A HREF="#toc828167_3">Risk Factors</A></FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">23</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD></TR> <TR> <TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Item 1B.</FONT></P></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><A HREF="#toc828167_4">Unresolved Staff Comments</A></FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">49</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD></TR> <TR> <TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Item 2.</FONT></P></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><A HREF="#toc828167_5">Properties</A></FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">49</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD></TR> <TR> <TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Item 3.</FONT></P></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><A HREF="#toc828167_6">Legal Proceedings</A></FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">49</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD></TR> <TR> <TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Item 4.</FONT></P></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><A HREF="#toc828167_7">Mine Safety Disclosures</A></FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">49</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD></TR> <TR STYLE="font-size:1pt"> <TD HEIGHT="8" COLSPAN="3"></TD> <TD HEIGHT="8" COLSPAN="4"></TD></TR> <TR> <TD VALIGN="top" COLSPAN="3" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><A HREF="#toc828167_8">PART II </A></B></FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="top"></TD> <TD VALIGN="top"></TD> <TD VALIGN="top"></TD></TR> <TR> <TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Item 5.</FONT></P></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><A HREF="#toc828167_9">Market for Registrant’s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities</A></FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">50</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD></TR> <TR> <TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Item 6.</FONT></P></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><A HREF="#toc828167_10">Selected Financial Data</A></FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">52</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD></TR> <TR> <TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Item 7.</FONT></P></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><A HREF="#toc828167_11">Management’s Discussion and Analysis of Financial Condition and Results of Operations</A></FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">54</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD></TR> <TR> <TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Item 7A.</FONT></P></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><A HREF="#toc828167_12">Quantitative and Qualitative Disclosures About Market Risk</A></FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">79</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD></TR> <TR> <TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Item 8.</FONT></P></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><A HREF="#toc828167_13">Financial Statements and Supplementary Data</A></FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">80</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD></TR> <TR> <TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Item 9.</FONT></P></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><A HREF="#toc828167_14">Changes in and Disagreements With Accountants on Accounting and Financial Disclosure</A></FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">119</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD></TR> <TR> <TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Item 9A.</FONT></P></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><A HREF="#toc828167_15">Controls and Procedures</A></FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">119</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD></TR> <TR> <TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Item 9B.</FONT></P></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><A HREF="#toc828167_16">Other Information</A></FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">119</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD></TR> <TR STYLE="font-size:1pt"> <TD HEIGHT="8" COLSPAN="3"></TD> <TD HEIGHT="8" COLSPAN="4"></TD></TR> <TR> <TD VALIGN="top" COLSPAN="3" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><A HREF="#toc828167_17">PART III </A></B></FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="top"></TD> <TD VALIGN="top"></TD> <TD VALIGN="top"></TD></TR> <TR> <TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Item 10.</FONT></P></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><A HREF="#toc828167_18">Directors, Executive Officers and Corporate Governance</A></FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">120</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD></TR> <TR> <TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Item 11.</FONT></P></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><A HREF="#toc828167_19">Executive Compensation</A></FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">120</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD></TR> <TR> <TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Item 12.</FONT></P></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><A HREF="#toc828167_20">Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters</A></FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">120</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD></TR> <TR> <TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Item 13.</FONT></P></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><A HREF="#toc828167_21">Certain Relationships and Related Transactions, and Director Independence</A></FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">120</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD></TR> <TR> <TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Item 14.</FONT></P></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><A HREF="#toc828167_22">Principal Accounting Fees and Services</A></FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">120</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD></TR> <TR STYLE="font-size:1pt"> <TD HEIGHT="8" COLSPAN="3"></TD> <TD HEIGHT="8" COLSPAN="4"></TD></TR> <TR> <TD VALIGN="top" COLSPAN="3" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><A HREF="#toc828167_23">PART IV </A></B></FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="top"></TD> <TD VALIGN="top"></TD> <TD VALIGN="top"></TD></TR> <TR> <TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Item 15.</FONT></P></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><A HREF="#toc828167_24">Exhibits and Financial Statement Schedules </A></FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">121</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD></TR> <TR> <TD VALIGN="top" COLSPAN="3"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><A HREF="#toc828167_25">Signatures </A></FONT></P></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">127</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD></TR> </TABLE> <p Style='page-break-before:always'> <HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER"> <h5 align="left"><a href="#toc">Table of Contents</a></h5> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><A NAME="toc828167_1"></A>PART I </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">This report contains forward-looking statements indicating expectations about future performance and other forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended (the “Securities Act”), Section 21E of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), and the Private Securities Litigation Reform Act of 1995, that involve risks and uncertainties. We intend that such statements be protected by the safe harbor created thereby. Forward-looking statements involve risks and uncertainties and our actual results and the timing of events may differ significantly from the results discussed in the forward-looking statements. Examples of such forward-looking statements include, but are not limited to, statements about or relating to: </FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px"> </P> <TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%"> <TR> <TD WIDTH="4%"><FONT SIZE="1"> </FONT></TD> <TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">•</FONT></TD> <TD WIDTH="1%" VALIGN="top"><FONT SIZE="1"> </FONT></TD> <TD ALIGN="left" VALIGN="top"> <P ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">guidance concerning revenues, research and development expenses and general and administrative expenses for 2015; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px"> </P> <TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%"> <TR> <TD WIDTH="4%"><FONT SIZE="1"> </FONT></TD> <TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">•</FONT></TD> <TD WIDTH="1%" VALIGN="top"><FONT SIZE="1"> </FONT></TD> <TD ALIGN="left" VALIGN="top"> <P ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">the sufficiency of existing resources to fund our operations for at least the next 12 months; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px"> </P> <TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%"> <TR> <TD WIDTH="4%"><FONT SIZE="1"> </FONT></TD> <TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">•</FONT></TD> <TD WIDTH="1%" VALIGN="top"><FONT SIZE="1"> </FONT></TD> <TD ALIGN="left" VALIGN="top"> <P ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">our capital requirements and needs for additional financing; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px"> </P> <TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%"> <TR> <TD WIDTH="4%"><FONT SIZE="1"> </FONT></TD> <TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">•</FONT></TD> <TD WIDTH="1%" VALIGN="top"><FONT SIZE="1"> </FONT></TD> <TD ALIGN="left" VALIGN="top"> <P ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">the initiation, design, conduct, enrollment, progress, timing and scope of clinical trials and development activities for our drug candidates conducted by ourselves or our partners, Amgen Inc. and Astellas Pharma Inc. (“Astellas”), including the anticipated timing for initiation of clinical trials, anticipated rates of enrollment for clinical trials and anticipated timing of results becoming available or being announced from clinical trials; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px"> </P> <TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%"> <TR> <TD WIDTH="4%"><FONT SIZE="1"> </FONT></TD> <TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">•</FONT></TD> <TD WIDTH="1%" VALIGN="top"><FONT SIZE="1"> </FONT></TD> <TD ALIGN="left" VALIGN="top"> <P ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">the results from the clinical trials and non-clinical and preclinical studies of our drug candidates and other compounds, and the significance and utility of such results; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px"> </P> <TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%"> <TR> <TD WIDTH="4%"><FONT SIZE="1"> </FONT></TD> <TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">•</FONT></TD> <TD WIDTH="1%" VALIGN="top"><FONT SIZE="1"> </FONT></TD> <TD ALIGN="left" VALIGN="top"> <P ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">anticipated interactions with regulatory authorities; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px"> </P> <TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%"> <TR> <TD WIDTH="4%"><FONT SIZE="1"> </FONT></TD> <TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">•</FONT></TD> <TD WIDTH="1%" VALIGN="top"><FONT SIZE="1"> </FONT></TD> <TD ALIGN="left" VALIGN="top"> <P ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">the further development of tirasemtiv for the potential treatment of amyotrophic lateral sclerosis (“ALS”); </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px"> </P> <TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%"> <TR> <TD WIDTH="4%"><FONT SIZE="1"> </FONT></TD> <TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">•</FONT></TD> <TD WIDTH="1%" VALIGN="top"><FONT SIZE="1"> </FONT></TD> <TD ALIGN="left" VALIGN="top"> <P ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">the acceptance by regulatory authorities of the effects of tirasemtiv on respiratory function, including slow vital capacity, in patients with ALS as a Phase III clinical trial endpoint to support the registration of tirasemtiv as a treatment for ALS; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px"> </P> <TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%"> <TR> <TD WIDTH="4%"><FONT SIZE="1"> </FONT></TD> <TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">•</FONT></TD> <TD WIDTH="1%" VALIGN="top"><FONT SIZE="1"> </FONT></TD> <TD ALIGN="left" VALIGN="top"> <P ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">our and our partners’ plans or ability to conduct the continued research and development of our drug candidates and other compounds; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px"> </P> <TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%"> <TR> <TD WIDTH="4%"><FONT SIZE="1"> </FONT></TD> <TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">•</FONT></TD> <TD WIDTH="1%" VALIGN="top"><FONT SIZE="1"> </FONT></TD> <TD ALIGN="left" VALIGN="top"> <P ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">the potential advancement of omecamtiv mecarbil into Phase III clinical development; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px"> </P> <TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%"> <TR> <TD WIDTH="4%"><FONT SIZE="1"> </FONT></TD> <TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">•</FONT></TD> <TD WIDTH="1%" VALIGN="top"><FONT SIZE="1"> </FONT></TD> <TD ALIGN="left" VALIGN="top"> <P ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">our expected roles in research, development or commercialization under our strategic alliances with Amgen and Astellas; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px"> </P> <TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%"> <TR> <TD WIDTH="4%"><FONT SIZE="1"> </FONT></TD> <TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">•</FONT></TD> <TD WIDTH="1%" VALIGN="top"><FONT SIZE="1"> </FONT></TD> <TD ALIGN="left" VALIGN="top"> <P ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">the properties and potential benefits of, and the potential market opportunities for, our drug candidates and other compounds, including the potential indications for which they may be developed; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px"> </P> <TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%"> <TR> <TD WIDTH="4%"><FONT SIZE="1"> </FONT></TD> <TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">•</FONT></TD> <TD WIDTH="1%" VALIGN="top"><FONT SIZE="1"> </FONT></TD> <TD ALIGN="left" VALIGN="top"> <P ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">the sufficiency of the clinical trials conducted with our drug candidates to demonstrate that they are safe and efficacious; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px"> </P> <TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%"> <TR> <TD WIDTH="4%"><FONT SIZE="1"> </FONT></TD> <TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">•</FONT></TD> <TD WIDTH="1%" VALIGN="top"><FONT SIZE="1"> </FONT></TD> <TD ALIGN="left" VALIGN="top"> <P ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">our receipt of milestone payments, royalties, reimbursements and other funds from current or future partners under strategic alliances, such as with Amgen or Astellas; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px"> </P> <TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%"> <TR> <TD WIDTH="4%"><FONT SIZE="1"> </FONT></TD> <TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">•</FONT></TD> <TD WIDTH="1%" VALIGN="top"><FONT SIZE="1"> </FONT></TD> <TD ALIGN="left" VALIGN="top"> <P ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">our ability to continue to identify additional potential drug candidates that may be suitable for clinical development; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px"> </P> <TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%"> <TR> <TD WIDTH="4%"><FONT SIZE="1"> </FONT></TD> <TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">•</FONT></TD> <TD WIDTH="1%" VALIGN="top"><FONT SIZE="1"> </FONT></TD> <TD ALIGN="left" VALIGN="top"> <P ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">our plans or ability to commercialize drugs with or without a partner, including our intention to develop sales and marketing capabilities; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px"> </P> <TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%"> <TR> <TD WIDTH="4%"><FONT SIZE="1"> </FONT></TD> <TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">•</FONT></TD> <TD WIDTH="1%" VALIGN="top"><FONT SIZE="1"> </FONT></TD> <TD ALIGN="left" VALIGN="top"> <P ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">the focus, scope and size of our research and development activities and programs; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px"> </P> <TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%"> <TR> <TD WIDTH="4%"><FONT SIZE="1"> </FONT></TD> <TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">•</FONT></TD> <TD WIDTH="1%" VALIGN="top"><FONT SIZE="1"> </FONT></TD> <TD ALIGN="left" VALIGN="top"> <P ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">the utility of our focus on the biology of muscle function, and our ability to leverage our experience in muscle contractility to other muscle functions; </FONT></P></TD></TR></TABLE> <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1"> </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">1 </FONT></P> <p Style='page-break-before:always'> <HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER"> <h5 align="left"><a href="#toc">Table of Contents</a></h5> <TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%"> <TR> <TD WIDTH="4%"><FONT SIZE="1"> </FONT></TD> <TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">•</FONT></TD> <TD WIDTH="1%" VALIGN="top"><FONT SIZE="1"> </FONT></TD> <TD ALIGN="left" VALIGN="top"> <P ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">our ability to protect our intellectual property and avoid infringing the intellectual property rights of others; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px"> </P> <TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%"> <TR> <TD WIDTH="4%"><FONT SIZE="1"> </FONT></TD> <TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">•</FONT></TD> <TD WIDTH="1%" VALIGN="top"><FONT SIZE="1"> </FONT></TD> <TD ALIGN="left" VALIGN="top"> <P ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">expected future sources of revenue and capital; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px"> </P> <TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%"> <TR> <TD WIDTH="4%"><FONT SIZE="1"> </FONT></TD> <TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">•</FONT></TD> <TD WIDTH="1%" VALIGN="top"><FONT SIZE="1"> </FONT></TD> <TD ALIGN="left" VALIGN="top"> <P ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">losses, costs, expenses and expenditures; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px"> </P> <TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%"> <TR> <TD WIDTH="4%"><FONT SIZE="1"> </FONT></TD> <TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">•</FONT></TD> <TD WIDTH="1%" VALIGN="top"><FONT SIZE="1"> </FONT></TD> <TD ALIGN="left" VALIGN="top"> <P ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">future payments under loan and lease obligations; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px"> </P> <TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%"> <TR> <TD WIDTH="4%"><FONT SIZE="1"> </FONT></TD> <TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">•</FONT></TD> <TD WIDTH="1%" VALIGN="top"><FONT SIZE="1"> </FONT></TD> <TD ALIGN="left" VALIGN="top"> <P ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">potential competitors and competitive products; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px"> </P> <TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%"> <TR> <TD WIDTH="4%"><FONT SIZE="1"> </FONT></TD> <TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">•</FONT></TD> <TD WIDTH="1%" VALIGN="top"><FONT SIZE="1"> </FONT></TD> <TD ALIGN="left" VALIGN="top"> <P ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">retaining key personnel and recruiting additional key personnel; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px"> </P> <TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%"> <TR> <TD WIDTH="4%"><FONT SIZE="1"> </FONT></TD> <TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">•</FONT></TD> <TD WIDTH="1%" VALIGN="top"><FONT SIZE="1"> </FONT></TD> <TD ALIGN="left" VALIGN="top"> <P ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">expected timing for recognition of compensation cost related to unvested stock options; and </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px"> </P> <TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%"> <TR> <TD WIDTH="4%"><FONT SIZE="1"> </FONT></TD> <TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">•</FONT></TD> <TD WIDTH="1%" VALIGN="top"><FONT SIZE="1"> </FONT></TD> <TD ALIGN="left" VALIGN="top"> <P ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">the potential impact of recent accounting pronouncements on our financial position or results of operations. </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">Such forward-looking statements involve risks and uncertainties, including, but not limited to: </FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px"> </P> <TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%"> <TR> <TD WIDTH="4%"><FONT SIZE="1"> </FONT></TD> <TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">•</FONT></TD> <TD WIDTH="1%" VALIGN="top"><FONT SIZE="1"> </FONT></TD> <TD ALIGN="left" VALIGN="top"> <P ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">further clinical development of tirasemtiv for the potential treatment of ALS will require significant additional funding and we may be unable to obtain such additional funding on acceptable terms, if at all; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px"> </P> <TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%"> <TR> <TD WIDTH="4%"><FONT SIZE="1"> </FONT></TD> <TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">•</FONT></TD> <TD WIDTH="1%" VALIGN="top"><FONT SIZE="1"> </FONT></TD> <TD ALIGN="left" VALIGN="top"> <P ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">the U.S. Food and Drug Administration (“FDA”) and/or other regulatory authorities may not accept effects on respiratory function, including slow vital capacity, as an appropriate clinical trial endpoint to support the registration of tirasemtiv for the treatment of ALS; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px"> </P> <TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%"> <TR> <TD WIDTH="4%"><FONT SIZE="1"> </FONT></TD> <TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">•</FONT></TD> <TD WIDTH="1%" VALIGN="top"><FONT SIZE="1"> </FONT></TD> <TD ALIGN="left" VALIGN="top"> <P ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">Amgen’s decisions with respect to the timing, design and conduct of research and development activities for omecamtiv mecarbil and related compounds, including decisions to postpone or discontinue research or development activities relating to omecamtiv mecarbil and related compounds; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px"> </P> <TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%"> <TR> <TD WIDTH="4%"><FONT SIZE="1"> </FONT></TD> <TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">•</FONT></TD> <TD WIDTH="1%" VALIGN="top"><FONT SIZE="1"> </FONT></TD> <TD ALIGN="left" VALIGN="top"> <P ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">Astellas’ decisions with respect to the timing, design and conduct of research and development activities for CK-2127107 and other skeletal muscle activators, including decisions to postpone or discontinue research or development activities relating to CK-2127107 and other skeletal muscle activators; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px"> </P> <TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%"> <TR> <TD WIDTH="4%"><FONT SIZE="1"> </FONT></TD> <TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">•</FONT></TD> <TD WIDTH="1%" VALIGN="top"><FONT SIZE="1"> </FONT></TD> <TD ALIGN="left" VALIGN="top"> <P ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">our ability to enter into strategic partnership agreements for any of our programs on acceptable terms and conditions or in accordance with our planned timelines; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px"> </P> <TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%"> <TR> <TD WIDTH="4%"><FONT SIZE="1"> </FONT></TD> <TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">•</FONT></TD> <TD WIDTH="1%" VALIGN="top"><FONT SIZE="1"> </FONT></TD> <TD ALIGN="left" VALIGN="top"> <P ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">our ability to obtain additional financing on acceptable terms, if at all; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px"> </P> <TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%"> <TR> <TD WIDTH="4%"><FONT SIZE="1"> </FONT></TD> <TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">•</FONT></TD> <TD WIDTH="1%" VALIGN="top"><FONT SIZE="1"> </FONT></TD> <TD ALIGN="left" VALIGN="top"> <P ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">our receipt of funds and access to other resources under our current or future strategic alliances; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px"> </P> <TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%"> <TR> <TD WIDTH="4%"><FONT SIZE="1"> </FONT></TD> <TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">•</FONT></TD> <TD WIDTH="1%" VALIGN="top"><FONT SIZE="1"> </FONT></TD> <TD ALIGN="left" VALIGN="top"> <P ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">difficulties or delays in the development, testing, manufacturing or commercialization of our drug candidates; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px"> </P> <TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%"> <TR> <TD WIDTH="4%"><FONT SIZE="1"> </FONT></TD> <TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">•</FONT></TD> <TD WIDTH="1%" VALIGN="top"><FONT SIZE="1"> </FONT></TD> <TD ALIGN="left" VALIGN="top"> <P ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">difficulties or delays, or slower than anticipated patient enrollment, in our or partners’ clinical trials; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px"> </P> <TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%"> <TR> <TD WIDTH="4%"><FONT SIZE="1"> </FONT></TD> <TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">•</FONT></TD> <TD WIDTH="1%" VALIGN="top"><FONT SIZE="1"> </FONT></TD> <TD ALIGN="left" VALIGN="top"> <P ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">difficulties or delays in the manufacture and supply of clinical trial materials; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px"> </P> <TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%"> <TR> <TD WIDTH="4%"><FONT SIZE="1"> </FONT></TD> <TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">•</FONT></TD> <TD WIDTH="1%" VALIGN="top"><FONT SIZE="1"> </FONT></TD> <TD ALIGN="left" VALIGN="top"> <P ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">failure by our contract research organizations, contract manufacturing organizations and other vendors to properly fulfill their obligations or otherwise perform as expected; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px"> </P> <TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%"> <TR> <TD WIDTH="4%"><FONT SIZE="1"> </FONT></TD> <TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">•</FONT></TD> <TD WIDTH="1%" VALIGN="top"><FONT SIZE="1"> </FONT></TD> <TD ALIGN="left" VALIGN="top"> <P ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">results from non-clinical studies that may adversely impact the timing or the further development of our drug candidates and other compounds; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px"> </P> <TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%"> <TR> <TD WIDTH="4%"><FONT SIZE="1"> </FONT></TD> <TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">•</FONT></TD> <TD WIDTH="1%" VALIGN="top"><FONT SIZE="1"> </FONT></TD> <TD ALIGN="left" VALIGN="top"> <P ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">the possibility that the FDA or foreign regulatory agencies may delay or limit our or our partners’ ability to conduct clinical trials or may delay or withhold approvals for the manufacture and sale of our products; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px"> </P> <TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%"> <TR> <TD WIDTH="4%"><FONT SIZE="1"> </FONT></TD> <TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">•</FONT></TD> <TD WIDTH="1%" VALIGN="top"><FONT SIZE="1"> </FONT></TD> <TD ALIGN="left" VALIGN="top"> <P ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">changing standards of care and the introduction of products by competitors or alternative therapies for the treatment of indications we target that may limit the commercial potential of our drug candidates; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px"> </P> <TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%"> <TR> <TD WIDTH="4%"><FONT SIZE="1"> </FONT></TD> <TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">•</FONT></TD> <TD WIDTH="1%" VALIGN="top"><FONT SIZE="1"> </FONT></TD> <TD ALIGN="left" VALIGN="top"> <P ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">difficulties or delays in achieving market access and reimbursement for our drug candidates and the potential impacts of health care reform; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px"> </P> <TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%"> <TR> <TD WIDTH="4%"><FONT SIZE="1"> </FONT></TD> <TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">•</FONT></TD> <TD WIDTH="1%" VALIGN="top"><FONT SIZE="1"> </FONT></TD> <TD ALIGN="left" VALIGN="top"> <P ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">changes in laws and regulations applicable to drug development, commercialization or reimbursement; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px"> </P> <TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%"> <TR> <TD WIDTH="4%"><FONT SIZE="1"> </FONT></TD> <TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">•</FONT></TD> <TD WIDTH="1%" VALIGN="top"><FONT SIZE="1"> </FONT></TD> <TD ALIGN="left" VALIGN="top"> <P ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">the uncertainty of protection for our intellectual property, whether in the form of patents, trade secrets or otherwise; </FONT></P></TD></TR></TABLE> <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1"> </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">2 </FONT></P> <p Style='page-break-before:always'> <HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER"> <h5 align="left"><a href="#toc">Table of Contents</a></h5> <TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%"> <TR> <TD WIDTH="4%"><FONT SIZE="1"> </FONT></TD> <TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">•</FONT></TD> <TD WIDTH="1%" VALIGN="top"><FONT SIZE="1"> </FONT></TD> <TD ALIGN="left" VALIGN="top"> <P ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">potential infringement or misuse by us of the intellectual property rights of third parties; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px"> </P> <TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%"> <TR> <TD WIDTH="4%"><FONT SIZE="1"> </FONT></TD> <TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">•</FONT></TD> <TD WIDTH="1%" VALIGN="top"><FONT SIZE="1"> </FONT></TD> <TD ALIGN="left" VALIGN="top"> <P ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">activities and decisions of, and market conditions affecting, current and future strategic partners; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px"> </P> <TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%"> <TR> <TD WIDTH="4%"><FONT SIZE="1"> </FONT></TD> <TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">•</FONT></TD> <TD WIDTH="1%" VALIGN="top"><FONT SIZE="1"> </FONT></TD> <TD ALIGN="left" VALIGN="top"> <P ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">accrual information provided by our contract research organizations and other vendors; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px"> </P> <TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%"> <TR> <TD WIDTH="4%"><FONT SIZE="1"> </FONT></TD> <TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">•</FONT></TD> <TD WIDTH="1%" VALIGN="top"><FONT SIZE="1"> </FONT></TD> <TD ALIGN="left" VALIGN="top"> <P ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">potential ownership changes under Internal Revenue Code Section 382; and </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px"> </P> <TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%"> <TR> <TD WIDTH="4%"><FONT SIZE="1"> </FONT></TD> <TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">•</FONT></TD> <TD WIDTH="1%" VALIGN="top"><FONT SIZE="1"> </FONT></TD> <TD ALIGN="left" VALIGN="top"> <P ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">the timeliness and accuracy of information filed with the U.S. Securities and Exchange Commission (the “SEC”) by third parties. </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">In addition such statements are subject to the risks and uncertainties discussed in the “Risk Factors” section and elsewhere in this document. Such statements speak only as of the date on which they are made, and, except as required by law, we undertake no obligation to update any forward-looking statement to reflect events or circumstances after the date on which the statement is made or to reflect the occurrence of unanticipated events. New factors emerge from time to time, and it is not possible for us to predict which factors will arise. In addition, we cannot assess the impact of each factor on our business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><A NAME="toc828167_2"></A>Item 1. </B><B><I>Business</I></B><B> </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Overview </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">We were incorporated in Delaware in August 1997 as Cytokinetics, Incorporated. We are a clinical stage biopharmaceutical company focused on the discovery and development of novel small molecule therapeutics that modulate muscle function for the potential treatment of serious diseases and medical conditions. Our research and development activities relating to the biology of muscle function have evolved from our knowledge and expertise regarding the cytoskeleton, a complex biological infrastructure that plays a fundamental role within every human cell. Our most advanced research and development programs relate to the biology of muscle function and are directed to small molecule modulators of the contractility of skeletal or cardiac muscle. We are also conducting earlier-stage research directed to other compounds with the potential to modulate muscle contractility and other muscle functions, such as growth, energetics and metabolism. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">Our lead drug candidate from our skeletal muscle contractility program, tirasemtiv (formerly known as CK-2017357), is a fast skeletal muscle troponin activator. Cytokinetics retains exclusive rights to tirasemtiv and is independently developing this drug candidate for the potential treatment of ALS. We have conducted a Phase II clinical trials program for tirasemtiv, including a Phase IIb clinical trial in patients with ALS, known as BENEFIT-ALS (Blinded Evaluation of Neuromuscular Effects and Functional Improvement with Tirasemtiv in ALS). Based on the results of BENEFIT-ALS, we are planning to initiate a Phase III clinical development program for tirasemtiv in patients with ALS in 2015. Tirasemtiv has been granted orphan drug designation and fast track status by the FDA and orphan medicinal product designation by the European Medicines Agency, in each case for the potential treatment of ALS. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">We are also developing CK-2127107, a structurally distinct fast skeletal muscle troponin activator, under a strategic alliance with Astellas established in June 2013 and expanded in December 2014. Astellas holds an exclusive license to develop and commercialize CK-2127107 worldwide, subject to our development and commercialization participation rights. Under this strategic alliance, Cytokinetics conducted Phase I clinical trials of CK-2127107 and plans to initiate a Phase II clinical trial of CK-2127107 in patients with spinal muscular atrophy (SMA) in the second half of 2015. CK-2127107 is also being evaluated for potential use in other indications associated with muscle weakness. We are also conducting joint research with Astellas directed to next-generation skeletal muscle activators. Further details regarding our strategic alliance with Astellas can be found below in Item 1 of this report under “Research and Development Programs — Skeletal Muscle Contractility Program — CK-2127107 and Other Skeletal Muscle Activators — Astellas Strategic Alliance.” </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">Our lead drug candidate from our cardiac muscle contractility program, omecamtiv mecarbil (formerly known as CK-1827452), is a novel cardiac muscle myosin activator that is being developed under a strategic </FONT></P> <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1"> </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">3 </FONT></P> <p Style='page-break-before:always'> <HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER"> <h5 align="left"><a href="#toc">Table of Contents</a></h5> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2"> alliance with Amgen. In June 2013, we expanded this collaboration to include Japan. As a result, Amgen holds an exclusive license to develop and commercialize omecamtiv mecarbil worldwide, subject to our development and commercialization participation rights. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">A Phase II clinical trial of omecamtiv mecarbil, known as COSMIC-HF (Chronic Oral Study of Myosin Activation to Increase Contractility in Heart Failure), is ongoing. COSMIC-HF is designed to assess the pharmacokinetics and tolerability of omecamtiv mecarbil dosed orally in patients with heart failure and left ventricular systolic dysfunction and its effects on echocardiographic measures of cardiac function. An intravenous formulation of omecamtiv mecarbil was studied in a Phase IIb clinical trial known as ATOMIC-AHF (Acute Treatment with Omecamtiv Mecarbil to Increase Contractility in Acute Heart Failure), which was designed to evaluate the safety and efficacy of omecamtiv mecarbil in patients with left ventricular systolic dysfunction who are hospitalized with acute heart failure. We expect to continue our joint research with Amgen directed to next-generation compounds in our cardiac muscle contractility program through 2015. Further details regarding our strategic alliance with Amgen can be found below in Item 1 of this report under “Research and Development Programs — Cardiac Muscle Contractility Program — Amgen Strategic Alliance.” </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">All of our drug candidates have demonstrated evidence of potentially clinically relevant pharmacodynamic activity in humans. In 2015, we expect to continue to focus on translating the observed pharmacodynamic activity of these compounds into potentially meaningful clinical benefits for patients. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">Following is a summary of the planned clinical development activities for our drug candidates: </FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px"> </P> <TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center"> <TR> <TD WIDTH="19%"></TD> <TD VALIGN="bottom"></TD> <TD></TD> <TD VALIGN="bottom"></TD> <TD WIDTH="16%"></TD> <TD VALIGN="bottom"></TD> <TD WIDTH="16%"></TD> <TD VALIGN="bottom"></TD> <TD WIDTH="35%"></TD></TR> <TR STYLE="font-size:1pt"> <TD HEIGHT="5" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; padding-left:8px"> </TD> <TD HEIGHT="5" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000"> </TD> <TD HEIGHT="5" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000"> </TD> <TD HEIGHT="5" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000"> </TD> <TD HEIGHT="5" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000"> </TD></TR> <TR> <TD VALIGN="bottom" ALIGN="center" STYLE="BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-left:8px"> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Drug</B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Candidate</B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:1px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>(Mechanism of Action)</B></FONT></P></TD> <TD VALIGN="bottom" STYLE="BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom" ALIGN="center" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Partnership <BR>Status</B></FONT></TD> <TD VALIGN="bottom" STYLE="BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom" ALIGN="center" STYLE="BORDER-BOTTOM:1px solid #000000"> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Potential</B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:1px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Indication(s)</B></FONT></P></TD> <TD VALIGN="bottom" STYLE="BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom" ALIGN="center" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Stage of <BR>Development</B></FONT></TD> <TD VALIGN="bottom" STYLE="BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom" ALIGN="center" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-right:8px"> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Development Status and</B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:1px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Planned Development Activities</B></FONT></P></TD></TR> <TR> <TD VALIGN="bottom" COLSPAN="9" ALIGN="center" STYLE="BORDER-LEFT:1px solid #000000; BORDER-RIGHT:1px solid #000000; padding-left:8px; padding-right:8px"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Skeletal Muscle Contractility Program</B></FONT></TD></TR> <TR STYLE="font-size:1pt"> <TD HEIGHT="8" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; padding-left:8px"> </TD> <TD HEIGHT="8" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000"> </TD> <TD HEIGHT="8" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000"> </TD> <TD HEIGHT="8" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000"> </TD> <TD HEIGHT="8" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000"> </TD></TR> <TR> <TD VALIGN="top" STYLE="BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-left:8px"> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="1">Tirasemtiv</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="1">(fast skeletal muscle</FONT></P> <P STYLE="margin-top:0px;margin-bottom:1px; margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="1">troponin activator)</FONT></P></TD> <TD VALIGN="bottom" STYLE="BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1">Cytokinetics<BR>developing<BR>independently</FONT></TD> <TD VALIGN="bottom" STYLE="BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1">ALS</FONT></TD> <TD VALIGN="bottom" STYLE="BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1">Phase II</FONT></TD> <TD VALIGN="bottom" STYLE="BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="top" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-right:8px"> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="1">• We anticipate initiating a Phase III clinical development program for tirasemtiv in patients with ALS in the second quarter of 2015.</FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px"> </P> <P STYLE="margin-top:0px;margin-bottom:1px; margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="1">• We anticipate continuing our interactions with regulatory authorities regarding the further development of tirasemtiv throughout 2015.</FONT></P></TD></TR> <TR STYLE="font-size:1pt"> <TD HEIGHT="8" STYLE="BORDER-LEFT:1px solid #000000; padding-left:8px"> </TD> <TD HEIGHT="8" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000"> </TD> <TD HEIGHT="8" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000"> </TD> <TD HEIGHT="8" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000"> </TD> <TD HEIGHT="8" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-RIGHT:1px solid #000000"> </TD></TR> <TR> <TD VALIGN="top" STYLE="BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-left:8px"> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="1">CK-2127107</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="1">(fast skeletal muscle</FONT></P> <P STYLE="margin-top:0px;margin-bottom:1px; margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="1">troponin activator)</FONT></P></TD> <TD VALIGN="bottom" STYLE="BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1">Partnered<BR>with Astellas</FONT></TD> <TD VALIGN="bottom" STYLE="BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1">SMA</FONT></TD> <TD VALIGN="bottom" STYLE="BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1">Phase I</FONT></TD> <TD VALIGN="bottom" STYLE="BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="top" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-right:8px"> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="1">• We anticipate initiating a Phase II clinical trial in patients with SMA in the second half of 2015.</FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px"> </P> <P STYLE="margin-top:0px;margin-bottom:1px; margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="1">• Cytokinetics and Astellas continue to evaluate other indications which may be suitable for CK-2127107 or other skeletal sarcomere activators</FONT></P></TD></TR> <TR> <TD VALIGN="bottom" COLSPAN="9" ALIGN="center" STYLE="BORDER-LEFT:1px solid #000000; BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-left:8px; padding-right:8px"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Cardiac Muscle Contractility Program</B></FONT></TD></TR> <TR STYLE="font-size:1pt"> <TD HEIGHT="8" STYLE="BORDER-LEFT:1px solid #000000; padding-left:8px"> </TD> <TD HEIGHT="8" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000"> </TD> <TD HEIGHT="8" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000"> </TD> <TD HEIGHT="8" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000"> </TD> <TD HEIGHT="8" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-RIGHT:1px solid #000000"> </TD></TR> <TR> <TD VALIGN="top" STYLE="BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-left:8px"> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="1">Omecamtiv mecarbil</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="1">(cardiac muscle myosin</FONT></P> <P STYLE="margin-top:0px;margin-bottom:1px; margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="1">activator)</FONT></P></TD> <TD VALIGN="bottom" STYLE="BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1">Partnered<BR>with Amgen</FONT></TD> <TD VALIGN="bottom" STYLE="BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000"> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="1">heart failure</FONT></P> <P STYLE="margin-top:0px;margin-bottom:1px"><FONT STYLE="font-family:Times New Roman" SIZE="1">(oral administration)</FONT></P></TD> <TD VALIGN="bottom" STYLE="BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1">Phase II</FONT></TD> <TD VALIGN="bottom" STYLE="BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="top" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-right:8px"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="1">• We anticipate the enrollment of patients in the expansion phase of COSMIC-HF to conclude in the first quarter of 2015, and results from COSMIC-HF to be available in the second half of 2015.</FONT></P></TD></TR> <TR STYLE="font-size:1pt"> <TD HEIGHT="8" STYLE="BORDER-LEFT:1px solid #000000; padding-left:8px"> </TD> <TD HEIGHT="8" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000"> </TD> <TD HEIGHT="8" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000"> </TD> <TD HEIGHT="8" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000"> </TD> <TD HEIGHT="8" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-RIGHT:1px solid #000000"> </TD></TR> <TR> <TD VALIGN="top" STYLE="BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-left:8px"> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="1">Omecamtiv mecarbil</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="1">(cardiac muscle myosin</FONT></P> <P STYLE="margin-top:0px;margin-bottom:1px; margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="1">activator)</FONT></P></TD> <TD VALIGN="bottom" STYLE="BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1">Partnered<BR>with Amgen</FONT></TD> <TD VALIGN="bottom" STYLE="BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000"> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="1">heart failure</FONT></P> <P STYLE="margin-top:0px;margin-bottom:1px"><FONT STYLE="font-family:Times New Roman" SIZE="1">(IV administration)</FONT></P></TD> <TD VALIGN="bottom" STYLE="BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1">Phase II</FONT></TD> <TD VALIGN="bottom" STYLE="BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="top" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-right:8px"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="1">• ATOMIC-HF completed in 2013.</FONT></P></TD></TR> </TABLE> <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1"> </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">4 </FONT></P> <p Style='page-break-before:always'> <HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER"> <h5 align="left"><a href="#toc">Table of Contents</a></h5> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">All of our drug candidates have arisen from our cytoskeletal research activities. Our focus on the biology of the cytoskeleton distinguishes us from other biopharmaceutical companies, and potentially positions us to discover and develop novel therapeutics that may be useful for the treatment of severe diseases and medical conditions. Our research and development activities since our inception in 1997 have produced multiple drug candidates that have progressed into clinical testing. Each of these drug candidates has a novel mechanism of action compared to currently marketed drugs, which we believe validates our focus on the cytoskeleton as a productive area for drug discovery. We intend to leverage our experience in muscle contractility in order to expand our current pipeline, and expect to identify additional potential drug candidates that may be suitable for clinical development. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Corporate Strategy </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">Our goal is to discover, develop and commercialize novel drug products that modulate muscle function in ways that may benefit patients with serious diseases or medical conditions, with the intent of establishing a fully integrated biopharmaceutical company. We intend to achieve this by: </FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px"> </P> <TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%"> <TR> <TD WIDTH="4%"><FONT SIZE="1"> </FONT></TD> <TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">•</FONT></TD> <TD WIDTH="1%" VALIGN="top"><FONT SIZE="1"> </FONT></TD> <TD ALIGN="left" VALIGN="top"> <P ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>Focusing on drug discovery and development activities relating to the biology of muscle function.</I> We intend to capitalize on the knowledge and expertise we have acquired in each of our muscle contractility research and development programs. In these programs, we are investigating potential treatments for diseases or medical conditions where impaired regulation of the contractile function of muscle plays a key role and such diseases or conditions may be amenable to treatment by modulation of muscle contractility, such as heart failure, and medical conditions associated with skeletal muscle weakness or wasting. </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px"> </P> <TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%"> <TR> <TD WIDTH="4%"><FONT SIZE="1"> </FONT></TD> <TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">•</FONT></TD> <TD WIDTH="1%" VALIGN="top"><FONT SIZE="1"> </FONT></TD> <TD ALIGN="left" VALIGN="top"> <P ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>Leveraging our cytoskeletal expertise and proprietary technologies to increase the speed, efficiency and yield of our drug discovery and development processes.</I> We believe that our unique understanding of the cytoskeleton and our proprietary research technologies should enable us to discover and potentially to develop drug candidates with novel mechanisms of action that may offer potential benefits not provided by existing drugs and which may have application across a broad array of diseases and medical conditions. We expect that we may be able to leverage our expertise in muscle contractility to expand programs related to other areas of muscle function and which may extend to the potential treatment of other serious medical diseases and conditions. Progressing related programs in parallel may afford us an opportunity to build a broader business that could benefit from multiple products that serve related clinical and commercial needs associated with impaired muscle function, muscle weakness and fatigue. In addition, this strategy may enable us to diversify certain technical, financial and operating risks by advancing several drug candidates. </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px"> </P> <TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%"> <TR> <TD WIDTH="4%"><FONT SIZE="1"> </FONT></TD> <TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">•</FONT></TD> <TD WIDTH="1%" VALIGN="top"><FONT SIZE="1"> </FONT></TD> <TD ALIGN="left" VALIGN="top"> <P ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>Focusing on comprehensive development programs that may enhance the success of our activities directed to potential registration.</I> We believe that by focusing on disease areas with well-organized physician-investigator groups, significant unmet clinical needs, and strong patient and disease advocacy, we may enhance our effectiveness in enrolling and conducting clinical trials that may answer important questions about the dosing, tolerability, pharmacokinetics and pharmacodynamics as well as the potential safety and efficacy of our drug candidates. We believe that our considered clinical trial designs and well-executed development programs can improve our ability to realize value from our and our partners’ clinical development activities. We believe that our investing in these activities may result in more successful later-stage clinical development activities that may increase the likelihood of our achieving our objectives to develop effective therapeutics that may address the needs of patients with grievous diseases and conditions. </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px"> </P> <TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%"> <TR> <TD WIDTH="4%"><FONT SIZE="1"> </FONT></TD> <TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">•</FONT></TD> <TD WIDTH="1%" VALIGN="top"><FONT SIZE="1"> </FONT></TD> <TD ALIGN="left" VALIGN="top"> <P ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>Building development and commercialization capabilities directed at concentrated and growing markets. </I>We focus our drug discovery and development activities on disease areas for which there are serious unmet medical needs. In particular, we direct our activities to potential commercial opportunities in concentrated and tractable customer segments, such as hospital specialists and disease-specific centers of excellence, which may be addressed by a smaller, targeted sales force. In preparing for the potential </FONT></P></TD></TR></TABLE> <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1"> </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">5 </FONT></P> <p Style='page-break-before:always'> <HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER"> <h5 align="left"><a href="#toc">Table of Contents</a></h5> <TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%"> <TR> <TD WIDTH="6%"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="top"> <P ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2"> commercialization of our drug candidates directed to these markets, we are focusing our activities on a broad range of issues facing patients and payors, including the principal drivers of clinical and economic burdens associated with these diseases. We also seek to focus on opportunities that the multiple constituencies and stakeholders for these markets may recognize as creating value. Accordingly, targeting unmet medical needs in these areas may provide us competitive opportunities and support development of a franchise in diseases involving muscle weakness, wasting and fatigue. In these markets, we believe that a company with limited resources may be able to compete effectively against larger, more established companies with greater financial and commercial resources. For these opportunities, we intend to develop clinical development and sales and marketing capabilities with the goal of becoming a fully-integrated biopharmaceutical company. </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px"> </P> <TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%"> <TR> <TD WIDTH="4%"><FONT SIZE="1"> </FONT></TD> <TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">•</FONT></TD> <TD WIDTH="1%" VALIGN="top"><FONT SIZE="1"> </FONT></TD> <TD ALIGN="left" VALIGN="top"> <P ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>Establishing select strategic alliances to support our drug development programs while preserving significant development and commercialization rights.</I> We believe that such alliances may allow us to obtain financial support and to capitalize on the therapeutic area expertise and resources of our partners that can potentially accelerate the development and commercialization of our drug candidates. Where we deem appropriate, we plan to retain certain rights to participate in the development of drug candidates and commercialization of potential drugs arising from our programs and alliances, so that we can expand and capitalize on our own internal development capabilities and build our commercialization capabilities. </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Research and Development Programs </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">Our long-standing interest in the cytoskeleton has led us to focus our research and development activities on the biology of muscle function, and in particular, small molecule modulation of muscle contractility. We believe that our expertise in the modulation of muscle contractility is an important differentiator for us. Our preclinical and clinical experience in muscle contractility may position us to discover and develop additional novel therapies that have the potential to improve the health of patients with severe and debilitating diseases or medical conditions. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">Small molecules that affect muscle contractility may have several applications for a variety of serious diseases and medical conditions. For example, certain diseases and medical conditions associated with muscle weakness may be amenable to treatment by enhancing the contractility of skeletal muscle. Similarly, heart failure is a disease often characterized by impaired cardiac muscle contractility which may be treated by modulating the contractility of cardiac muscle. Because the modulation of the contractility of different types of muscle, such as cardiac muscle and skeletal muscle, may be relevant to multiple diseases or medical conditions, we believe we can leverage our expertise in these areas to more efficiently discover and develop as potential drugs compounds that modulate the applicable muscle type for multiple indications. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">We are currently developing a number of small molecule compounds arising from our muscle contractility programs. Tirasemtiv is our lead drug candidate from our skeletal muscle contractility program. Potential indications for which this drug candidate may be useful include skeletal muscle weakness associated with neuromuscular diseases, such as ALS. We have conducted a Phase II clinical trials program for tirasemtiv, and are planning to initiate a Phase III clinical development program of this drug candidate in patients with ALS in the second quarter of 2015. CK-2127107, another drug candidate from this program, is partnered with Astellas world-wide for the potential treatment of SMA and potentially other neuromuscular and non-neuromuscular indications associated with muscle weakness. We have conducted a Phase I clinical trials program for <FONT STYLE="white-space:nowrap">CK-2127107</FONT> under this collaboration. We anticipate initiating a Phase II clinical trial of CK-2127107 in patients with SMA in the second half of 2015. Cytokinetics and Astellas continue to evaluate other indications which may be suitable for CK-2127107 or other skeletal sarcomere activators under the collaboration. Omecamtiv mecarbil, a novel cardiac muscle myosin activator, is partnered with Amgen world-wide for the potential treatment of heart failure. Phase II clinical trials have been conducted with both intravenous and oral formulations of omecamtiv mecarbil. An intravenous formulation of omecamtiv mecarbil has been studied in a Phase IIb clinical trial in patients with acute heart failure, and an oral formulation of omecamtiv mecarbil is being studied in a Phase II clinical trial in patients with heart failure. </FONT></P> <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1"> </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">6 </FONT></P> <p Style='page-break-before:always'> <HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER"> <h5 align="left"><a href="#toc">Table of Contents</a></h5> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">We are continuing to conduct discovery, characterization and lead optimization activities for other compounds with the potential to modulate muscle contractility and other muscle functions, such as growth, energetics and metabolism. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Research and Development Expense. </I></B>Our research and development expenses were $44.4 million, $49.5 million and $35.6 million for 2014, 2013 and 2012, respectively. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Skeletal Muscle Contractility Program </I></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I><U>Overview</U></I>. Our skeletal muscle contractility program is focused on the activation of the skeletal sarcomere, the basic unit of skeletal muscle contraction. The skeletal sarcomere is a highly ordered cytoskeletal structure composed of skeletal muscle myosin, actin, and a set of regulatory proteins, which include the troponins and tropomyosin. This program leverages our expertise developed in our ongoing discovery and development of cardiac sarcomere activators, including the cardiac muscle myosin activator omecamtiv mecarbil. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">We believe that our skeletal sarcomere activators may lead to new therapeutic options for diseases and medical conditions associated with aging, muscle weakness and wasting and neuromuscular dysfunction. The clinical effects of muscle weakness and wasting, fatigue and loss of mobility can range from decreased quality of life to, in some instances, life-threatening complications. By directly improving skeletal muscle function, a small molecule activator of the skeletal sarcomere potentially could enhance functional performance and quality of life in patients suffering from diseases or medical conditions characterized or complicated by muscle weakness or wasting. These may include diseases and medical conditions associated with skeletal muscle weakness or wasting, such as ALS, claudication, myasthenia gravis, sarcopenia (general frailty associated with aging), post-surgical rehabilitation and cachexia in connection with heart failure or cancer. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">Tirasemtiv is the lead drug candidate from this program. Cytokinetics retains exclusive rights to tirasemtiv. We have conducted a Phase II clinical trials program for tirasemtiv, and are planning to initiate a Phase III clinical development program for this drug candidate in patients with ALS. We are also developing another drug candidate from this program, CK-2127107, which has been evaluated in Phase I clinical trials in collaboration with Astellas for potential indications associated with muscle weakness. We are planning to conduct a Phase II clinical trial for CK-2127107 in patients with SMA. Tirasemtiv and CK-2127107 are structurally distinct and selective small molecules that activate the fast skeletal muscle troponin complex in the sarcomere by increasing its sensitivity to calcium, leading to an increase in skeletal muscle contractility. Each of tirasemtiv and <FONT STYLE="white-space:nowrap">CK-2127107</FONT> has demonstrated pharmacological activity in preclinical models and evidence of potentially clinically relevant pharmacodynamic effects in humans. We are evaluating other potential indications for which tirasemtiv and CK-2127107 may be useful. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I><U>Tirasemtiv</U></I>. Tirasemtiv, a fast skeletal troponin activator, is the lead drug candidate from our skeletal muscle contractility program. We have conducted three “evidence of effect” Phase IIa clinical trials of tirasemtiv. These evidence of effect clinical trials were randomized, double-blind, placebo-controlled, three-period cross-over studies of single doses of tirasemtiv administered to patients with impaired muscle function. These studies were intended to translate the mechanism of action of tirasemtiv into potentially clinically relevant pharmacodynamic effects. The first of these trials was conducted in patients with ALS, a chronic and progressive disease in which the motor neurons die, thus denervating skeletal muscles and causing them to atrophy. This leads to weakness, fatigue, and eventually complete paralysis and death, primarily from respiratory complications. The second of these trials was conducted in patients with myasthenia gravis, a chronic, autoimmune, neuromuscular disease which is the most common primary disorder of neuromuscular transmission. The third of these trials was conducted in patients with symptoms of claudication, which is pain or cramping in the leg muscles due to inadequate blood flow during exercise, associated with peripheral artery disease. Evidence of potentially clinically relevant pharmacodynamic effects was observed in each of these trials. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">In 2014, we completed BENEFIT-ALS (Blinded Evaluation of Neuromuscular Effects and Functional Improvement with Tirasemtiv in ALS), a Phase IIb clinical trial of tirasemtiv in patients with ALS. We believe </FONT></P> <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1"> </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">7 </FONT></P> <p Style='page-break-before:always'> <HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER"> <h5 align="left"><a href="#toc">Table of Contents</a></h5> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2"> the results from BENEFIT-ALS support advancement into Phase III clinical development. We are planning to initiate a Phase III clinical development program for this drug candidate in patients with ALS by the end of 2015. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px; margin-left:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>Tirasemtiv Clinical Development </I></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2"><U>BENEFIT-ALS (Blinded Evaluation of Neuromuscular Effects and Functional Improvement with Tirasemtiv in ALS)</U>. In October 2012, we initiated BENEFIT-ALS, a Phase IIb, multi-national, double-blind, randomized, placebo-controlled, clinical trial designed to evaluate the safety, tolerability and efficacy of tirasemtiv in patients with ALS. BENEFIT-ALS enrolled patients in 73 centers in 8 countries. Patients enrolled in BENEFIT-ALS began treatment with open-label tirasemtiv at 125 mg twice daily. Patients who tolerated this open-label treatment for one week were randomized to receive 12 weeks of double-blind treatment with twice-daily oral ascending doses of tirasemtiv or placebo, beginning at 125 mg twice daily and increasing weekly up to 250 mg twice daily (or a dummy dose titration with placebo). Clinical assessments occurred every four weeks during double-blind treatment; patients also returned for follow-up evaluations at one and four weeks after their final dose of double-blind study medication. The primary efficacy analysis of BENEFIT-ALS compared the mean change from baseline in the ALS Functional Rating Scale in its revised form (ALSFRS-R), a clinically validated instrument designed to measure disease progression and changes in functional status, to the average of the scores obtained after 8 and 12 weeks of double-blind treatment on tirasemtiv versus placebo. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%;padding-bottom:0px; " ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">In April 2014, BENEFIT-ALS results were presented at the 66</FONT><FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">th</SUP></FONT><FONT STYLE="font-family:Times New Roman" SIZE="2"> Annual Meeting of the American Academy of Neurology. The trial enrolled 711 patients into the open-label phase of the trial; subsequently, 605 patients were randomized 1:1 to double-blind treatment with either tirasemtiv or placebo. BENEFIT-ALS did not achieve its primary efficacy endpoint, the mean change from baseline in the ALSFRS-R (-2.98 points in the tirasemtiv group versus -2.40 points in the placebo group; p = 0.11). Treatment with tirasemtiv resulted in a statistically significant and potentially clinically meaningful reduction in the decline of slow vital capacity (SVC), a measure of the strength of the skeletal muscles responsible for breathing. SVC has been shown to be an important predictor of disease progression and survival in prior trials of patients with ALS. At week 12, the decline in SVC from baseline was -3.12 for patients receiving tirasemtiv versus -8.66 for those receiving placebo (p < 0.0001). From week 0 to week 12, the slope of decline in SVC measured as percentage points per day was -0.0394 for patients receiving tirasemtiv versus -0.0905 for those receiving placebo (p = 0.0006). </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">The analyses of other pre-specified secondary efficacy endpoints in BENEFIT-ALS produced mixed results. The muscle strength mega-score, a measure of strength combining the data from several muscle groups in each patient, declined more slowly on tirasemtiv versus placebo. The difference in the rate of decline for sniff nasal inspiratory pressure (SNIP) was not statistically significant); however, SNIP decreased more on tirasemtiv compared with placebo in a statistically significant manner at 4 and 12 weeks. No differences in maximum voluntary ventilation and hand grip fatigue were observed on tirasemtiv versus placebo. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">Serious adverse events (SAEs) during double-blind treatment were more frequent on tirasemtiv than on placebo (9.0% vs. 5.4%). The most common SAE was respiratory failure which occurred in 1 patient on tirasemtiv and 3 patients on placebo. Confusional state and delirium occurred in 2 patients on tirasemtiv and no patients on placebo. More patients on tirasemtiv withdrew from the trial following randomization than on placebo (99 vs. 33 patients, respectively). Adverse events more common on tirasemtiv than on placebo (>10% difference) were dizziness, fatigue, and nausea. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">Throughout the remainder of 2014, we presented further results from BENEFIT-ALS. These results indicated that: </FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px"> </P> <TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%"> <TR> <TD WIDTH="4%"><FONT SIZE="1"> </FONT></TD> <TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">•</FONT></TD> <TD WIDTH="1%" VALIGN="top"><FONT SIZE="1"> </FONT></TD> <TD ALIGN="left" VALIGN="top"> <P ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">Differences in the decline in SVC on tirasemtiv versus placebo observed after 12 weeks of double-blind treatment were maintained for up to 4 weeks after discontinuation of treatment; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px"> </P> <TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%"> <TR> <TD WIDTH="4%"><FONT SIZE="1"> </FONT></TD> <TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">•</FONT></TD> <TD WIDTH="1%" VALIGN="top"><FONT SIZE="1"> </FONT></TD> <TD ALIGN="left" VALIGN="top"> <P ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">The reduced decline in SVC on tirasemtiv versus placebo was observed consistently across all subgroups of patients in BENEFIT-ALS that were examined; </FONT></P></TD></TR></TABLE> <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1"> </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">8 </FONT></P> <p Style='page-break-before:always'> <HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER"> <h5 align="left"><a href="#toc">Table of Contents</a></h5> <TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%"> <TR> <TD WIDTH="4%"><FONT SIZE="1"> </FONT></TD> <TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">•</FONT></TD> <TD WIDTH="1%" VALIGN="top"><FONT SIZE="1"> </FONT></TD> <TD ALIGN="left" VALIGN="top"> <P ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">The effects of tirasemtiv on SVC were observed at all doses studied and the concentration-response relationship was flat; and </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px"> </P> <TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%"> <TR> <TD WIDTH="4%"><FONT SIZE="1"> </FONT></TD> <TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">•</FONT></TD> <TD WIDTH="1%" VALIGN="top"><FONT SIZE="1"> </FONT></TD> <TD ALIGN="left" VALIGN="top"> <P ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">Riluzole did not increase plasma concentrations nor impact the tolerability of tirasemtiv. </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2"><U>Planned Phase III Clinical Development</U>: In October 2014, we announced that we had completed our review of results from BENEFIT-ALS and concluded that effects observed on SVC in patients treated with tirasemtiv were robust and potentially clinically meaningful. We have engaged with regulatory authorities in the U.S. and Europe regarding results from BENEFIT-ALS and plan to advance tirasemtiv into Phase III clinical development. While regulatory interactions are ongoing, we believe that current feedback from these regulatory authorities informs advancement of tirasemtiv to a Phase III clinical development program that is intended to potentially confirm and extend results from BENEFIT-ALS. Key clinical endpoints in the Phase III program will include measures of respiratory function after longer durations of treatment in patients with ALS, including effects on SVC. We have initiated non-clinical and clinical development planning activities for the Phase III program, and anticipate initiating the program in the second quarter of 2015. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>Tirasemtiv Strategic and Commercial Planning</I>. During 2014, we made preparations for the potential commercialization of tirasemtiv. These activities included interactions with manufacturers, and corporate development and commercial planning activities to support various scenarios. We expect to continue to engage extensively with ALS experts, both neuromuscular and pulmonary, and with payors, regulatory authorities and patient advocacy groups as we develop plans for the potential commercialization of tirasemtiv as a treatment for patients living with ALS. These commercialization plans will include market assessment and corporate development activities to support the launch of tirasemtiv in the U.S. and Europe, if appropriate. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2"><U>Background on ALS Market</U><I>.</I> Limited options exist for the treatment of patients with ALS, which affects as many as 30,000 Americans, with an estimated 5,600 new cases diagnosed each year in the U.S. Based on our primary market research, the per capita prevalence and incidence appears similar in the major European markets. ALS is 20% more common in men than women; however, with increasing age, the prevalence becomes more equal between men and women. The life expectancy of an ALS patient averages two to five years from the time of diagnosis, with 90 to 95% of those diagnosed with ALS having the sporadic form. Of the remaining ALS patient population, 5 to 10% have a family history of the disease (familial ALS). In cases of familial ALS, there is an approximately 50% chance each offspring will develop the disease. The majority of patients with ALS in the U.S. and Europe receive treatment at multidisciplinary centers that specialize in the unique needs of these patients. In the U.S., there are approximately 70 ALS centers of excellence, according to either the ALS Association or the Muscular Dystrophy Association. For most patients with ALS, death is usually due to respiratory failure because of diminished strength in the skeletal muscles responsible for breathing. We believe that the majority of ALS patients in the U.S. and Europe are treated at ALS centers of excellence; therefore, it is a concentrated market. We believe that there is a need for novel therapies to address the urgent unmet medical issues of this patient population which could be addressed by a small, targeted sales force. If tirasemtiv is approved by regulatory authorities in the U.S. or Europe for commercialization for ALS, we believe that these concentrated markets could be an affordable independent commercialization opportunity for Cytokinetics. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px; margin-left:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I><U>CK-2127107 and Other Skeletal Muscle Activators </U></I></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>Astellas Strategic Alliance</I>. CK-2127107 is being developed jointly by Cytokinetics and Astellas. In December 2014, we entered into an Amended and Restated License and Collaboration Agreement with Astellas (the “Amended Astellas Agreement”). This agreement superseded the License and Collaboration Agreement between Cytokinetics and Astellas of June 2013 (the “Original Astellas Agreement”). The Amended Astellas Agreement expanded the objective of the collaboration of advancing novel therapies for diseases and medical conditions associated with muscle weakness to include SMA and potentially other neuromuscular indications, in addition to the non-neuromuscular indications provided for in the Original Astellas Agreement. </FONT></P> <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1"> </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">9 </FONT></P> <p Style='page-break-before:always'> <HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER"> <h5 align="left"><a href="#toc">Table of Contents</a></h5> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">Under the Amended Astellas Agreement, we expanded the exclusive license previously granted Astellas under the Original Astellas Agreement to co-develop and commercialize CK-2127107 for potential application in non-neuromuscular indications worldwide to include certain neuromuscular indications as well. Concurrent with the expanded collaboration, the companies agreed to advance CK-2127107 into Phase II clinical development. Cytokinetics will conduct the initial Phase II clinical trial in patients with SMA. We anticipate initiating this trial in the second half of 2015. The development program may include other neuromuscular indications as the companies may agree. Cytokinetics and Astellas will jointly develop and may jointly commercialize CK-2127107 and other fast skeletal troponin activators in neuromuscular indications. Astellas will be responsible for the costs associated with the development of all collaboration products, including CK-2127107, subject to Cytokinetics’ option to co-fund certain development costs as described below. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">Under the Amended Astellas Agreement, the parties extended through 2016 their joint research program to identify next-generation skeletal muscle activators to be nominated as potential drug candidates. This research will be conducted at Astellas’ expense. Under the Amended Astellas Agreement, Astellas has exclusive rights to co-develop and commercialize CK-2127107 and other fast skeletal troponin activators in SMA and potentially other indications and other novel mechanism skeletal muscle activators in all indications, subject to certain Cytokinetics’ development and commercialization rights. Cytokinetics may co-promote and conduct certain commercial activities in the U.S., Canada and Europe under agreed scenarios. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">Cytokinetics retains an option to conduct early-stage development for certain agreed indications at its initial expense, subject to reimbursement if development continues under the collaboration. Under the Amended Astellas Agreement, Cytokinetics also retains an option to co-promote collaboration products containing fast skeletal muscle activators for neuromuscular indications in the U.S., Canada and Europe, in addition to its option to co-promote other collaboration products in the U.S. and Canada as provided for in the Original Astellas Agreement. Astellas will reimburse Cytokinetics for certain expenses associated with its co-promotion activities. The Amended Astellas Agreement also provides for Cytokinetics to lead certain activities relating to the commercialization of collaboration products for neuromuscular indications in the U.S., Canada and Europe under particular scenarios. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">Cytokinetics received an upfront payment of $30.0 million in connection with the execution of the Amended Astellas Agreement. Also, in conjunction with the execution of the Amended Astellas Agreement, we entered into a common stock purchase agreement which provided for the sale of 2,040,816 shares of our common stock to Astellas at a price per share of $4.90 and an aggregate purchase price of $10.0 million, which was received in December 2014. Pursuant to this agreement, Astellas agreed to certain trading and other restrictions with respect to our common stock. Concurrently, Cytokinetics earned a $15.0 million milestone payment relating to Astellas’ decision to advance CK-2127107 into Phase II clinical development. Cytokinetics is also eligible to potentially receive over $20.0 million in reimbursement of sponsored research and development activities during the next two years of the collaboration. Based on the achievement of pre-specified criteria, Cytokinetics may receive over $600.0 million in milestone payments relating to the development and commercial launch of collaboration products, including up to $112.0 million (of which Cytokinetics has now received $17.0 million) relating to early development of CK-2127107 and for later-stage development and commercial launch milestones for CK-2127107 in non-neuromuscular indications, and over $100.0 million in development and commercial launch milestones for CK-2127107 in each of SMA and other neuromuscular indications. Cytokinetics may also receive up to $200.0 million in payments for achievement of pre-specified sales milestones related to net sales of all collaboration products under the Amended Astellas Agreement. If Astellas commercializes any collaboration products, Cytokinetics will also receive royalties on sales of such collaboration products, including royalties ranging from the high single digits to the high teens on sales of products containing CK-2127107. Cytokinetics also holds an option to co-fund certain development costs for CK-2127107 and other compounds in exchange for increased milestone payments and royalties; such royalties may increase under certain scenarios to exceed twenty percent. In addition to the foregoing development, commercial launch and sales milestones, Cytokinetics may also receive payments for the achievement of pre-specified milestones relating to the joint research program. </FONT></P> <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1"> </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">10 </FONT></P> <p Style='page-break-before:always'> <HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER"> <h5 align="left"><a href="#toc">Table of Contents</a></h5> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">Cytokinetics retains the exclusive right to develop and commercialize tirasemtiv for the potential treatment of ALS and certain other neuromuscular disorders independently from the Amended Astellas Agreement. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px; margin-left:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>CK-2127107 Clinical Development </I></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">In October 2014, we announced the completion of five Phase I clinical trials evaluating CK-2127107 in healthy volunteers, and certain other Phase II readiness activities, all in connection with the agreed development plan under our collaboration with Astellas. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2"><U>Phase I Clinical Trials Program</U>: The Phase I clinical trials demonstrated that CK-2127107 appeared well-tolerated in healthy volunteers and that exposures generally increased across dose ranges studied. CK-2127107 increased the response of muscle to neuromuscular input in a dose and plasma concentration related fashion in healthy volunteers consistent with preclinical observations. In addition, an oral tablet formulation of <FONT STYLE="white-space:nowrap">CK-2127107</FONT> appears appropriate for use in Phase II clinical trials. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">CY 5011 was a double-blind, randomized, placebo-controlled study designed to assess the safety, tolerability, and pharmacokinetics of single ascending oral doses of CK-2127107 administered to healthy adult males. Planned single doses of CK-2127107 up to 4000 mg, the highest dose administered in this trial, were well-tolerated without an emerging pattern of adverse events observed; therefore, a maximum tolerated dose could not be defined. The pharmacokinetic profile of CK-2127107 was linear and dose-proportional across the dose range studied with a mean terminal half-life compatible with once or twice daily dosing. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">CY 5012 was a double-blind, randomized, placebo-controlled, parallel group study. The primary objective of CY 5012 was to assess the safety, tolerability, and pharmacokinetics of CK-2127107 following multiple ascending doses in healthy volunteers. This clinical trial consisted of three ascending dose cohorts of 12 young volunteers (ages 18-55), and two ascending dose cohorts of 12 elderly volunteers (ages 65-85), split evenly between men and women. In each cohort, volunteers received CK-2127107 or placebo in accordance with 2:1 randomization over a 10-day period. This clinical trial demonstrated that a 10-day course of CK-2127107, either 300 mg or 500 mg twice daily, was well-tolerated by both younger (18-55 years) and older (65-85 years) subjects. Plasma concentrations of CK-2127107 achieved steady state and no differences in pharmacokinetics between younger and older subjects were observed. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">CY 5013 was a Phase I randomized, placebo-controlled, single dose, 4-period crossover study of CK-2127107 in healthy male volunteers. CY 5013 was designed to evaluate the change in the force-frequency profile and its relationship to dose and plasma concentrations of CK-2127107. This clinical trial demonstrated that the response of skeletal muscle to nerve input increased with both the dose and plasma concentration of CK-2127107 and were most evident in the middle of the range of stimulation frequencies tested, consistent with preclinical observations. Compared to pre-dose measurements, statistically significant, placebo-corrected increases in skeletal muscle function were demonstrated at every time point tested after dosing. This clinical trial demonstrated that CK-2127107 amplified the response of muscle to nerve activation following a single dose of CK-2127107 in these subjects and that the results observed in preclinical models were translated into humans. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">CY 5014 was a Phase I clinical trial of CK-2127107 in healthy male volunteers. CY 5014 was a randomized, open-label, two-period crossover study designed to assess the relative oral bioavailability, pharmacokinetics, safety and tolerability of two oral formulations of CK-2127107. This clinical trial demonstrated that single doses of CK-2127107 in suspension, dosed at 300 mg and 1000 mg, were well-tolerated by all 25 healthy men enrolled and provided pharmacokinetic data on two different physical forms of CK-2127107 to inform ongoing development of tablet formulations for use in potential future trials. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">CY 5015 was an open-label, randomized, single dose study designed to evaluate the pharmacokinetics, in a fed and fasted state, of an oral tablet form of CK-2127107 in healthy male volunteers. This clinical trial demonstrated that single doses of CK-2127107, administered at doses of 250 mg, 500 mg and 1000 mg, were well-tolerated and appeared appropriate for use in potential future clinical trials. </FONT></P> <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1"> </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">11 </FONT></P> <p Style='page-break-before:always'> <HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER"> <h5 align="left"><a href="#toc">Table of Contents</a></h5> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2"><U>Planned Phase II Clinical Development</U>: Cytokinetics will conduct the initial Phase II clinical trial of CK-2127107 in patients with SMA. We anticipate initiating this trial in the second half of 2015. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>Background on SMA Market:</I> Spinal muscular atrophy (SMA) is a severe neuromuscular disease that occurs in 1 in every 6,000 to 10,000 live births each year resulting in a prevalence of 10,000 to 25,000 patients in the U.S., and is one of the most common fatal genetic disorders. SMA manifests in various degrees of severity as progressive muscle weakness resulting in respiratory and mobility impairment. There are four types of SMA, distinguished by the time of the initial onset of muscle weakness and the severity of related symptoms: Type I (severe), Type II (intermediate), Type III (juvenile) and Type IV (adult onset). Life expectancy and disease severity varies by type of SMA from Type I, who have the worst prognosis and a life expectancy of approximately two years from birth, to the Type IV, who have a normal life span but with gradual weakness in the proximal muscles of the extremities resulting in mobility issues. Few treatment options exist for these patients, resulting in a high unmet need for new therapeutic options to address symptoms and modify disease progression. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I><U>Ongoing Research in Skeletal Muscle Activators</U>. </I>Our research on the direct activation of skeletal muscle continues in two areas. We are conducting translational research in preclinical models of disease and muscle function with fast skeletal muscle troponin activators to explore the potential clinical applications of this novel mechanism in diseases or conditions associated with skeletal muscle dysfunction. We also intend to conduct preclinical research on other chemically and pharmacologically distinct mechanisms to activate the skeletal sarcomere. We are conducting a joint research program with Astellas directed to the discovery of next-generation skeletal muscle activators. Under the Amended Astellas Agreement, the joint research program will continue through 2016 and Astellas will reimburse us for certain research activities we perform. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Cardiac Muscle Contractility Program </I></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I><U>Overview</U>.</I> Our cardiac muscle contractility program is focused on the cardiac sarcomere, the basic unit of muscle contraction in the heart. The cardiac sarcomere is a highly ordered cytoskeletal structure composed of cardiac muscle myosin, actin and a set of regulatory proteins. This program is currently directed towards the discovery and development of small molecule cardiac muscle myosin activators with the goal of developing novel drugs to treat acute and chronic heart failure. Cardiac muscle myosin is the cytoskeletal motor protein in the cardiac muscle cell. It is directly responsible for converting chemical energy into the mechanical force, resulting in cardiac muscle contraction. This program is based on the hypothesis that activators of cardiac muscle myosin may address certain adverse properties of existing positive inotropic agents. Current positive inotropic agents, such as beta-adrenergic receptor agonists or inhibitors of phosphodiesterase activity, increase the concentration of intracellular calcium, thereby increasing cardiac sarcomere contractility. The effect on calcium levels, however, also has been linked to potentially life-threatening side effects. In contrast, our novel cardiac muscle myosin activators work by a mechanism that directly stimulates the activity of the cardiac muscle myosin motor protein, without increasing the intracellular calcium concentration. They accelerate the rate-limiting step of the myosin enzymatic cycle and shift it in favor of the force-producing state. Rather than increasing the velocity of cardiac contraction, this mechanism instead lengthens the systolic ejection time, which results in increased cardiac function in a potentially more oxygen-efficient manner. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I><U>Amgen Strategic Alliance</U>.</I> In December 2006, we entered into a collaboration and option agreement with Amgen to discover, develop and commercialize novel small molecule therapeutics, including omecamtiv mecarbil, that activate cardiac muscle contractility for potential applications in the treatment of heart failure (the “Amgen Agreement”). The agreement granted Amgen an option to obtain an exclusive license worldwide, except Japan, to develop and commercialize omecamtiv mecarbil and other drug candidates arising from the collaboration. In May 2009, Amgen exercised its option. As a result, Amgen became responsible for the development and commercialization of omecamtiv mecarbil and related compounds at its expense worldwide (excluding Japan), subject to our development and commercialization participation rights. Amgen reimburses us for certain research and development activities we perform under the collaboration. </FONT></P> <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1"> </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">12 </FONT></P> <p Style='page-break-before:always'> <HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER"> <h5 align="left"><a href="#toc">Table of Contents</a></h5> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">In June 2013, Cytokinetics and Amgen executed an amendment to the Amgen Agreement to include Japan, resulting in a worldwide collaboration (the “Amgen Agreement Amendment”). Under the terms of the Amgen Agreement Amendment, we received a non-refundable upfront license fee of $15.0 million in June 2013. Under the Amgen Agreement Amendment, we conducted a Phase I pharmacokinetic study intended to support inclusion of Japan in a potential Phase III clinical development program and potential global registration dossier for omecamtiv mecarbil. Amgen reimbursed us for the costs of this study. In addition, we are eligible to receive additional pre-commercialization milestone payments relating to the development of omecamtiv mecarbil in Japan of up to $50.0 million, and royalties on sales of omecamtiv mecarbil in Japan. In conjunction with the Amgen Agreement Amendment, we also entered into a common stock purchase agreement which provided for the sale of 1,404,100 shares of our common stock to Amgen at a price per share of $7.12 and an aggregate purchase price of $10.0 million which was received in June 2013. Pursuant to this agreement, Amgen agreed to certain trading and other restrictions with respect to our common stock. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">Under the Amgen Agreement as amended we are eligible for potential pre-commercialization and commercialization milestone payments of up to $650.0 million in the aggregate on omecamtiv mecarbil and other potential products arising from research under the collaboration, and royalties that escalate based on increasing levels of annual net sales of products commercialized under the agreement. The Amgen Agreement also provides for us to receive increased royalties by co-funding Phase III development costs of omecamtiv mecarbil and other drug candidates under the collaboration. If we elect to co-fund such costs, we would be entitled to co-promote the co-funded drug in North America and participate in agreed commercialization activities in institutional care settings, at Amgen’s expense. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">In July 2013, Amgen announced that it had granted an option to commercialize omecamtiv mecarbil in Europe to Servier, with Cytokinetics’ consent. The option and, if the option is exercised, the resulting commercialization sublicense to Servier, is subject to the terms and conditions of the Amgen Agreement. Amgen remains responsible for the performance of its obligations under the Amgen Agreement relating to Europe, including the payment of milestones and royalties relating to the development and commercialization of omecamtiv mecarbil in Europe. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I><U>Omecamtiv Mecarbil</U>.</I> Our lead drug candidate from this program is omecamtiv mecarbil, a novel cardiac muscle myosin activator. We expect omecamtiv mecarbil to be developed as a potential treatment across the continuum of care in heart failure both as an intravenous formulation for use in the hospital setting and as an oral formulation for use in the outpatient setting. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px; margin-left:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>Omecamtiv Mecarbil Clinical Development </I></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2"><U>COSMIC-HF</U>. In March 2013, we announced the initiation of dosing of patients in COSMIC-HF (Chronic Oral Study of Myosin Activation to Increase Contractility in Heart Failure). COSMIC-HF is a Phase II, double-blind, randomized, placebo-controlled, multicenter, clinical trial designed to assess the pharmacokinetics and tolerability of <I>omecamtiv mecarbil</I> dosed orally in patients with heart failure and left ventricular systolic dysfunction as well as its effects on echocardiographic measures of cardiac function. COSMIC-HF is being conducted by Amgen in collaboration with Cytokinetics. Cytokinetics and Amgen reviewed results from the dose escalation phase of COSMIC-HF and selected an oral formulation of omecamtiv mecarbil for evaluation in the expansion phase of the trial. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">The expansion phase of COSMIC-HF has enrolled approximately 450 patients from clinical sites internationally. Patients were randomized 1:1:1 to receive placebo, 25 mg, or 50 mg twice daily of omecamtiv mecarbil. Escalation to the 50 mg dose depended on the plasma concentration of omecamtiv mecarbil following 2 weeks of oral dosing at 25 mg twice daily. The primary objective of the expansion phase of this trial is to characterize the safety, tolerability, and pharmacokinetics of omecamtiv mecarbil dosed orally during 20 weeks of treatment. The secondary objectives are to assess the changes from baseline in systolic ejection time, stroke volume, left ventricular end-systolic diameter, left ventricular end-diastolic diameter, heart rate and N-terminal pro-brain natriuretic peptide (a biomarker associated with </FONT></P> <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1"> </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">13 </FONT></P> <p Style='page-break-before:always'> <HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER"> <h5 align="left"><a href="#toc">Table of Contents</a></h5> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2"> the severity of heart failure) during 20 weeks of treatment. Recently, the Data Monitoring Committee reviewed data from COSMIC-HF and recommended that the trial continue without any changes to the protocol. The expansion phase of COSMIC-HF has enrolled over 400 patients; over 200 of these patients have completed dosing. We anticipate that patient enrollment in COSMIC-HF will conclude in the first quarter of 2015. We anticipate that results from COSMIC-HF will be available in the second half of 2015. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2"><U>ATOMIC-AHF</U>. In 2013, results from ATOMIC-AHF (Acute Treatment with Omecamtiv Mecarbil to Increase Contractility in Acute Heart Failure) were presented at the European Society of Cardiology Congress and the Heart Failure Society of America Annual Scientific Meeting. ATOMIC-AHF was an international, randomized, double-blind, placebo-controlled, Phase IIb clinical trial of intravenous omecamtiv mecarbil in patients with left ventricular systolic dysfunction hospitalized with acutely decompensated heart failure. ATOMIC-AHF was conducted by Amgen in collaboration with Cytokinetics. This clinical trial enrolled over 600 patients in three sequential, ascending-dose cohorts. In each cohort, patients were randomized to receive omecamtiv mecarbil or placebo. The primary efficacy objective of this trial was to evaluate the effect of 48 hours of intravenous omecamtiv mecarbil compared to placebo on dyspnea (shortness of breath). The secondary objectives were to assess the safety and tolerability of three dose levels of intravenous omecamtiv mecarbil compared with placebo and to evaluate the effects of 48 hours of treatment with intravenous omecamtiv mecarbil on additional measures of dyspnea, patients’ global assessments, change in N-terminal pro brain-type natriuretic peptide (a biomarker associated with the severity of heart failure) and short-term clinical outcomes in these patients. In addition, the trial evaluated the relationship between plasma concentrations of omecamtiv mecarbil and echocardiographic parameters in patients with acute heart failure. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">The omecamtiv mecarbil treatment groups were not statistically different in their 7-point Likert scale dyspnea symptom response rates compared to the pooled placebo group (p=0.33); therefore, the primary endpoint was not met. Omecamtiv mecarbil demonstrated favorable dose- and concentration-related trends (nominal p=0.025 and nominal p=0.007, respectively) on dyspnea response. Improvement in dyspnea was observed in the highest omecamtiv mecarbil dose group when compared against its paired placebo group in the third cohort (dyspnea symptom response in 51 percent of subjects on omecamtiv mecarbil versus 37 percent on placebo, nominal p=0.03). The incidence of worsening heart failure within seven days of initiating treatment was 17 percent in the pooled placebo group and was 13 percent, 8 percent and 9 percent on omecamtiv mecarbil in the first, second and third cohorts, respectively. Systolic ejection time, the echocardiographic signature of omecamtiv mecarbil, increased in a concentration-dependent manner similar to that previously reported in healthy volunteers and stable heart failure patients. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">Rates of adverse events (AEs), serious AEs, adjudicated deaths and hospitalizations were similar between omecamtiv mecarbil and placebo groups. There were seven post-randomization myocardial infarctions in the treatment groups receiving omecamtiv mecarbil compared with three in the placebo groups (2.3 percent vs. 1.0 percent, respectively). However, there was no relationship between the maximum increase from the baseline troponin (a biomarker specific for cardiac muscle damage) and increasing plasma concentrations of omecamtiv mecarbil. Four of the myocardial infarctions occurred more than seven days following termination of the 48-hour drug infusion. The estimated plasma concentrations near the time of these events were zero. Three of these events occurred in patients who received omecamtiv mecarbil and one occurred in a patient who received placebo. One myocardial infarction occurred subsequent to a percutaneous coronary intervention in a patient who received omecamtiv mecarbil. One myocardial infarction occurred in a patient with sepsis who received placebo. Omecamtiv mecarbil was not associated with an increased incidence of tachyarrhythmias nor were heart rate or blood pressure adversely affected. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2"><U>Pharmacokinetics Bridging Study</U>. In 2014, we conducted CY 1211, a Phase I study comparing the tolerability and pharmacokinetics of omecamtiv mecarbil between Japanese and Caucasian healthy volunteers. Results from this trial indicated no clinically meaningful differences between the two groups studied. Data from CY 1211 are expected to inform plans for the development of omecamtiv mecarbil in Japan and the inclusion of Japan in potential global Phase III program. This trial was conducted by Cytokinetics in collaboration with Amgen. Amgen reimbursed us for the costs of the trial. </FONT></P> <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1"> </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">14 </FONT></P> <p Style='page-break-before:always'> <HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER"> <h5 align="left"><a href="#toc">Table of Contents</a></h5> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>Prior Clinical Experience with Omecamtiv Mecarbil.</I> Seven Phase I clinical trials of omecamtiv mecarbil have been conducted in healthy subjects: five conducted by Cytokinetics and two conducted by Amgen in collaboration with Cytokinetics. Cytokinetics has also conducted two Phase IIa clinical trials of omecamtiv mecarbil. These clinical trials were designed to evaluate the safety, tolerability, pharmacodynamic and pharmacokinetic profiles of both intravenous and oral formulations in a diversity of patients, including patients with stable heart failure and patients with ischemic cardiomyopathy. In these trials, omecamtiv mecarbil exhibited generally linear, dose-proportional pharmacokinetics across the dose ranges studied. The adverse effects observed at intolerable doses in humans appeared similar to the adverse findings which occurred in preclinical safety studies at similar plasma concentrations. These effects are believed to be related to the mechanism of action of this drug candidate which, at intolerable doses, resulted in an excessive prolongation of the systolic ejection time (i.e., the time in which the heart is contracting). However, these effects resolved promptly with discontinuation of the infusions of omecamtiv mecarbil. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">In January 2015, a manuscript titled, “Safety and Tolerability of Omecamtiv Mecarbil During Exercise in Patients With Ischemic Cardiomyopathy and Angina” was published in the journal JACC Heart Failure. This manuscript highlights the results from a previously reported Phase IIa clinical trial designed to evaluate the safety and tolerability of treatment of omecamtiv mecarbil during symptom-limited exercise in patients with ischemic cardiomyopathy and angina. The publication concluded that doses of omecamtiv mecarbil, which produce plasma concentrations previously shown to increase systolic function, were well tolerated during exercise in patients with ischemic cardiomyopathy and angina who were evaluated in this trial and that there was no indication that omecamtiv mecarbil increased the likelihood of myocardial ischemia in this high-risk population. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I><U>Ongoing Research in Cardiac Muscle Contractility</U>.</I> In 2013, we agreed with Amgen to additional research activities conducted in 2014 under the research plan directed to next-generation compounds in our cardiac muscle contractility program. We expect to continue our joint research program with Amgen through 2015. Under the Amgen Agreement, Amgen reimburses us for certain research activities we perform. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I><U>Background on Heart Failure Market</U></I>. Heart failure is a widespread and debilitating syndrome affecting millions of people in the United States. The high and rapidly growing prevalence of heart failure translates into significant hospitalization rates and associated societal costs. About 6.4 million people in the United States have heart failure, resulting in nearly one million hospital discharges with the primary diagnosis of heart failure and approximately 300,000 deaths each year. For people over 65 years of age, heart failure incidences approach 10 per 1000 and approximately 50% of people diagnosed with heart failure will die within 5 years of diagnosis. These numbers are increasing due to the aging of the U.S. population and an increased likelihood of survival following acute myocardial infarctions. The costs to society attributable to the prevalence of heart failure are high, especially as many chronic heart failure patients suffer repeated acute episodes. Despite currently available therapies, readmission rates for heart failure patients remain high. In general, the mortality following hospitalization for patients with heart failure is 10.4% at 30 days, 22% at one year and 42.3% at 5 years, despite the availability of therapeutic alternatives for treatment of these patients. These poor outcomes in the setting of current therapies points to the need for novel therapeutics that may offer further reductions in morbidity and mortality. The annual cost of heart failure to the U.S. health care system is estimated to be $32 billion and is predicted to grow 120% to almost $70 billion by the year 2030. Today, a portion of that cost is attributable to drugs used to treat each of chronic and acute heart failure. Approximately 70% of those costs are due to hospitalization, home health and physician care. In the U.S., Medicare is one of the largest payors for heart failure related costs. Approximately 50% of Medicare beneficiaries with heart failure are concentrated in the top 20% of the hospital referral regions in the U.S, which generally include 5 to 10 hospitals in a geographic area. New drug therapies that could reduce the number of hospitalizations could decrease the cost to the health care system. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Beyond Muscle Contractility </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">We have developed preclinical expertise in the mechanics of skeletal, cardiac and smooth muscle that extends from proteins to tissues to intact animal models. Our translational research in muscle contractility has </FONT></P> <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1"> </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">15 </FONT></P> <p Style='page-break-before:always'> <HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER"> <h5 align="left"><a href="#toc">Table of Contents</a></h5> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2"> enabled us to better understand the potential impact of small molecule compounds that increase skeletal or cardiac muscle contractility and to apply those findings to the further evaluation of our drug candidates in clinical populations. In addition to contractility, the other major functions of muscle include metabolism, growth and energetics, with each of these functions playing a role in certain diseases that could benefit from novel mechanism treatments. Accordingly, our knowledge of muscle contractility may serve as an entry point to the discovery of novel treatments for disorders involving muscle functions other than muscle contractility. We are leveraging our current understandings of muscle biology to investigate new ways of modulating these other aspects of muscle function for other potential therapeutic applications. For example, we are conducting research with compounds that affect muscle growth and that may have applications for serious diseases and medical conditions such as cachexia. Cachexia is a condition that can be associated with cancer, heart failure, chronic obstructive pulmonary disease or other conditions. This syndrome is characterized by the loss of muscle mass and may lead to weakness and disability. We are performing research on compounds that may increase muscle mass and which may impact patient functionality or potentially alter the course of diseases associated with muscle wasting. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Intellectual Property </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">Our policy is to seek patent protection for the technologies, inventions and improvements that we develop that we consider important to the advancement of our business. As of December 31, 2014, we owned or controlled 108 issued U.S. patents and over 150 additional pending U.S. and foreign patent applications. We also rely on trade secrets, technical know-how and continuing innovation to develop and maintain our competitive position. Our commercial success will depend on obtaining and maintaining patent protection and trade secret protection for our drug candidates and technologies and our successfully defending these patents against third-party challenges. We will only be able to protect our technologies from unauthorized use by third parties to the extent that valid and enforceable patents cover them or we maintain them as trade secrets. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">With regard to our drug candidates directed to muscle biology targets, we have a U.S. patent covering omecamtiv mecarbil and a U.S. patent covering our skeletal muscle sarcomere activators including, but not limited to, tirasemtiv, each of which will expire in 2027 unless extended. We also have additional U.S. and foreign patent applications pending for each of our drug candidates. It is not known or determinable whether other patents will issue from any of our other pending applications or what the expiration dates would be for any other patents that do issue. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">All of our drug candidates are still in clinical development and have not yet been approved by the FDA. If any of these drug candidates is approved, then pursuant to federal law, we may apply for an extension of the U.S. patent term for one patent covering the approved drug, which could extend the term of the applicable patent by up to a maximum of five additional years. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">The degree of future protection of our proprietary rights is uncertain because legal means may not adequately protect our rights or permit us to gain or keep our competitive advantage. Due to evolving legal standards relating to the patentability, validity and enforceability of patents covering pharmaceutical inventions and the claim scope of these patents, our ability to enforce our existing patents and to obtain and enforce patents that may issue from any pending or future patent applications is uncertain and involves complex legal, scientific and factual questions. The standards that the U.S. Patent and Trademark Office and its foreign counterparts use to grant patents are not always applied predictably or uniformly and are subject to change. To date, no consistent policy has emerged regarding the breadth of claims allowed in biotechnology and pharmaceutical patents. Thus, we cannot be sure that any patents will issue from any pending or future patent applications owned by or licensed to us. Even if patents do issue, we cannot be sure that the claims of these patents will be held valid or enforceable by a court of law, will provide us with any significant protection against competitive products, or will afford us a commercial advantage over competitive products. For example: </FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px"> </P> <TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%"> <TR> <TD WIDTH="4%"><FONT SIZE="1"> </FONT></TD> <TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">•</FONT></TD> <TD WIDTH="1%" VALIGN="top"><FONT SIZE="1"> </FONT></TD> <TD ALIGN="left" VALIGN="top"> <P ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">we or our licensors might not have been the first to make the inventions covered by each of our pending patent applications and issued patents; </FONT></P></TD></TR></TABLE> <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1"> </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">16 </FONT></P> <p Style='page-break-before:always'> <HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER"> <h5 align="left"><a href="#toc">Table of Contents</a></h5> <TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%"> <TR> <TD WIDTH="4%"><FONT SIZE="1"> </FONT></TD> <TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">•</FONT></TD> <TD WIDTH="1%" VALIGN="top"><FONT SIZE="1"> </FONT></TD> <TD ALIGN="left" VALIGN="top"> <P ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">we or our licensors might not have been the first to file patent applications for the inventions covered by our pending patent applications and issued patents; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px"> </P> <TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%"> <TR> <TD WIDTH="4%"><FONT SIZE="1"> </FONT></TD> <TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">•</FONT></TD> <TD WIDTH="1%" VALIGN="top"><FONT SIZE="1"> </FONT></TD> <TD ALIGN="left" VALIGN="top"> <P ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">others may independently develop similar or alternative technologies or duplicate any of our technologies without infringing our intellectual property rights; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px"> </P> <TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%"> <TR> <TD WIDTH="4%"><FONT SIZE="1"> </FONT></TD> <TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">•</FONT></TD> <TD WIDTH="1%" VALIGN="top"><FONT SIZE="1"> </FONT></TD> <TD ALIGN="left" VALIGN="top"> <P ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">some or all of our or our licensors’ pending patent applications may not result in issued patents or the claims that issue may be narrow in scope and not provide us with competitive advantages; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px"> </P> <TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%"> <TR> <TD WIDTH="4%"><FONT SIZE="1"> </FONT></TD> <TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">•</FONT></TD> <TD WIDTH="1%" VALIGN="top"><FONT SIZE="1"> </FONT></TD> <TD ALIGN="left" VALIGN="top"> <P ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">our and our licensors’ issued patents may not provide a basis for commercially viable drugs or therapies or may be challenged and invalidated by third parties; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px"> </P> <TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%"> <TR> <TD WIDTH="4%"><FONT SIZE="1"> </FONT></TD> <TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">•</FONT></TD> <TD WIDTH="1%" VALIGN="top"><FONT SIZE="1"> </FONT></TD> <TD ALIGN="left" VALIGN="top"> <P ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">our or our licensors’ patent applications or patents may be subject to interference, opposition or similar administrative proceedings that may result in a reduction in their scope or their loss altogether; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px"> </P> <TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%"> <TR> <TD WIDTH="4%"><FONT SIZE="1"> </FONT></TD> <TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">•</FONT></TD> <TD WIDTH="1%" VALIGN="top"><FONT SIZE="1"> </FONT></TD> <TD ALIGN="left" VALIGN="top"> <P ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">we may not develop additional proprietary technologies or drug candidates that are patentable; or </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px"> </P> <TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%"> <TR> <TD WIDTH="4%"><FONT SIZE="1"> </FONT></TD> <TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">•</FONT></TD> <TD WIDTH="1%" VALIGN="top"><FONT SIZE="1"> </FONT></TD> <TD ALIGN="left" VALIGN="top"> <P ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">the patents of others may prevent us or our partners from discovering, developing or commercializing our drug candidates. </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">The defense and prosecution of intellectual property infringement suits, interferences, oppositions and related legal and administrative proceedings are costly, time-consuming to pursue and divert resources. The outcome of these types of proceedings is uncertain and could significantly harm our business. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">Our ability to commercialize drugs depends on our ability to use, manufacture and sell those drugs without infringing the patents or other proprietary rights of third parties. U.S. and foreign issued patents and pending patent applications owned by third parties exist that may be relevant to the therapeutic areas and chemical compositions of our drug candidates. While we are aware of certain relevant patents and patent applications owned by third parties, there may be issued patents or pending applications of which we are not aware that could cover our drug candidates. Because patent applications are often not published immediately after filing, there may be currently pending applications, unknown to us, which could later result in issued patents that our activities with our drug candidates could infringe. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">The development of our drug candidates and the commercialization of any resulting drugs may be impacted by patents of companies engaged in competitive programs with significantly greater resources. This could result in the expenditure of significant legal fees and management resources. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">We also rely on trade secrets to protect our technology, especially where we do not believe patent protection is appropriate or obtainable. However, trade secrets are often difficult to protect, especially outside of the United States. While we believe that we use reasonable efforts to protect our trade secrets, our employees, consultants, contractors, partners and other advisors may unintentionally or willfully disclose our trade secrets to competitors. Enforcing a claim that a third party illegally obtained and is using our trade secrets would be expensive and time-consuming, and the outcome would be unpredictable. Even if we are able to maintain our trade secrets as confidential, our competitors may independently develop information that is equivalent or similar to our trade secrets. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">We seek to protect our intellectual property by requiring our employees, consultants, contractors and other advisors to execute nondisclosure and invention assignment agreements upon commencement of their employment or engagement, through which we seek to protect our intellectual property. Agreements with our employees also preclude them from bringing the proprietary information or materials of third parties to us. We also require confidentiality agreements or material transfer agreements from third parties that receive our confidential information or materials. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">For further details on the risks relating to our intellectual property, please see the risk factors under Item 1A of this report, including, but not limited to, the risk factors entitled “Our success depends substantially upon our </FONT></P> <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1"> </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">17 </FONT></P> <p Style='page-break-before:always'> <HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER"> <h5 align="left"><a href="#toc">Table of Contents</a></h5> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2"> ability to obtain and maintain intellectual property protection relating to our drug candidates and research technologies” and “If we are sued for infringing third party intellectual property rights, it will be costly and time-consuming, and an unfavorable outcome would have a significant adverse effect on our business.” </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Government Regulation </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">The FDA and comparable regulatory agencies in state and local jurisdictions and in foreign countries impose substantial requirements upon the clinical development, manufacture, marketing and distribution of drugs. These agencies and other federal, state and local entities regulate research and development activities and the testing, manufacture, quality control, labeling, storage, record keeping, approval, advertising and promotion of our drug candidates and drugs. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">In the United States, the FDA regulates drugs under the Federal Food, Drug and Cosmetic Act and implementing regulations. The process required by the FDA before our drug candidates may be marketed in the United States generally involves the following: </FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px"> </P> <TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%"> <TR> <TD WIDTH="4%"><FONT SIZE="1"> </FONT></TD> <TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">•</FONT></TD> <TD WIDTH="1%" VALIGN="top"><FONT SIZE="1"> </FONT></TD> <TD ALIGN="left" VALIGN="top"> <P ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">completion of extensive preclinical laboratory tests, preclinical animal studies and formulation studies, all performed in accordance with the FDA’s good laboratory practice regulations; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px"> </P> <TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%"> <TR> <TD WIDTH="4%"><FONT SIZE="1"> </FONT></TD> <TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">•</FONT></TD> <TD WIDTH="1%" VALIGN="top"><FONT SIZE="1"> </FONT></TD> <TD ALIGN="left" VALIGN="top"> <P ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">submission to the FDA of an investigational new drug application (“IND”), which must become effective before clinical trials may begin; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px"> </P> <TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%"> <TR> <TD WIDTH="4%"><FONT SIZE="1"> </FONT></TD> <TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">•</FONT></TD> <TD WIDTH="1%" VALIGN="top"><FONT SIZE="1"> </FONT></TD> <TD ALIGN="left" VALIGN="top"> <P ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">performance of adequate and well-controlled clinical trials to establish the safety and efficacy of the drug candidate for each proposed indication in accordance with good clinical practices; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px"> </P> <TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%"> <TR> <TD WIDTH="4%"><FONT SIZE="1"> </FONT></TD> <TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">•</FONT></TD> <TD WIDTH="1%" VALIGN="top"><FONT SIZE="1"> </FONT></TD> <TD ALIGN="left" VALIGN="top"> <P ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">submission of a new drug application (“NDA”) to the FDA, which must usually be accompanied by payment of a substantial user fee; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px"> </P> <TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%"> <TR> <TD WIDTH="4%"><FONT SIZE="1"> </FONT></TD> <TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">•</FONT></TD> <TD WIDTH="1%" VALIGN="top"><FONT SIZE="1"> </FONT></TD> <TD ALIGN="left" VALIGN="top"> <P ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">satisfactory completion of an FDA preapproval inspection of the manufacturing facilities at which the product is produced to assess compliance with current good manufacturing practice (“cGMP”) regulations and FDA audits of select clinical investigator sites to assess compliance with good clinical practices (“GCP”); and </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px"> </P> <TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%"> <TR> <TD WIDTH="4%"><FONT SIZE="1"> </FONT></TD> <TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">•</FONT></TD> <TD WIDTH="1%" VALIGN="top"><FONT SIZE="1"> </FONT></TD> <TD ALIGN="left" VALIGN="top"> <P ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">FDA review and approval of the NDA prior to any commercial marketing, sale or shipment of the drug. </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">Similar regulatory procedures generally apply in countries outside of the United States. This testing and approval process requires substantial time, effort and financial resources, and we cannot be certain that any approvals for our drug candidates will be granted on a timely basis, if at all. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">Nonclinical tests include laboratory evaluation of product chemistry, formulation and stability, and studies to evaluate toxicity and pharmacokinetics in animals. The results of nonclinical tests, together with manufacturing information and analytical data, are submitted as part of an IND application to the FDA. The IND automatically becomes effective 30 days after receipt by the FDA, unless the FDA, within the 30-day period, raises concerns or questions about the conduct of the clinical trial, including concerns that human research subjects may be exposed to unreasonable health risks. In such a case, the IND sponsor and the FDA must resolve any outstanding concerns before the clinical trial can begin. Our submission of an IND or a foreign equivalent, or those of our collaborators, may not result in authorization from the FDA or its foreign equivalent to commence a clinical trial. A separate submission to an existing IND must also be made for each successive clinical trial conducted during product development. Further, an independent institutional review board (“IRB”) or its foreign equivalent for each medical center proposing to conduct the clinical trial must review and approve the plan for any clinical trial before it commences at that center and it must monitor the clinical trial until completed. The FDA, the IRB or their foreign equivalents, or the clinical trial sponsor may suspend a clinical trial at any time on various grounds, including a finding that the subjects or patients are being exposed to an unacceptable health risk. </FONT></P> <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1"> </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">18 </FONT></P> <p Style='page-break-before:always'> <HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER"> <h5 align="left"><a href="#toc">Table of Contents</a></h5> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>Clinical Trials.</I> For purposes of an NDA or equivalent submission and approval, clinical trials are typically conducted in the following three sequential phases, which may overlap: </FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px"> </P> <TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%"> <TR> <TD WIDTH="4%"><FONT SIZE="1"> </FONT></TD> <TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">•</FONT></TD> <TD WIDTH="1%" VALIGN="top"><FONT SIZE="1"> </FONT></TD> <TD ALIGN="left" VALIGN="top"> <P ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>Phase I:</I> Phase I includes the initial introduction of a drug candidate into humans. These studies may be conducted in patients, but are usually conducted in healthy volunteer subjects. These studies are designed to determine the metabolic and pharmacologic actions of the drug candidate in humans, the side effects associated with increasing doses, and, if possible, to gain early evidence on effectiveness. During Phase I, sufficient information about the drug candidate’s pharmacokinetics and pharmacological effects should be obtained to permit the design of well-controlled, scientifically valid, Phase II trials. </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px"> </P> <TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%"> <TR> <TD WIDTH="4%"><FONT SIZE="1"> </FONT></TD> <TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">•</FONT></TD> <TD WIDTH="1%" VALIGN="top"><FONT SIZE="1"> </FONT></TD> <TD ALIGN="left" VALIGN="top"> <P ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>Phase II:</I> Phase II includes the early controlled clinical studies conducted to obtain some preliminary data on the effectiveness of the drug for a particular indication or indications in patients with the disease or condition. This phase of testing also helps determine the common short-term side effects and risks associated with the drug candidate. These clinical trials are generally conducted in a limited patient population to identify possible adverse effects and safety risks, to make an initial determination of potential efficacy of the drug candidate for specific targeted indications and to determine dose tolerance and optimal dosage. Multiple Phase II clinical trials may be conducted by the sponsor to obtain information prior to beginning larger and more expensive Phase III clinical trials. Phase IIa clinical trials generally are designed to study the pharmacokinetic or pharmacodynamic properties and to conduct a preliminary assessment of safety of the drug candidate over a measured dose response range. In some cases, a sponsor may decide to conduct a Phase IIb clinical trial, which is a second, typically larger, confirmatory Phase II trial that could, if positive and accepted by a regulatory authority, support approval of a drug candidate. </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px"> </P> <TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%"> <TR> <TD WIDTH="4%"><FONT SIZE="1"> </FONT></TD> <TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">•</FONT></TD> <TD WIDTH="1%" VALIGN="top"><FONT SIZE="1"> </FONT></TD> <TD ALIGN="left" VALIGN="top"> <P ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>Phase III:</I> If the Phase II clinical trials demonstrate that a dose range of the drug candidate is potentially effective and has an acceptable safety profile, Phase III clinical trials are then undertaken in large patient populations to further evaluate dosage, to provide substantial evidence of clinical efficacy and to further test for safety in an expanded and diverse patient population at multiple, geographically dispersed clinical trial sites. Phase III trials are also intended to provide an adequate basis for extrapolating the results to the general population and transmitting that information in the drug labeling. Phase III studies usually include several hundred to several thousand people. </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">At any time during the conduct of a clinical trial, the FDA or a foreign equivalent can impose a clinical hold on the trial if it believes the trial is unsafe or that the protocol is clearly deficient in design in meeting its stated objectives, which requires the conduct of the trial to cease until the clinical hold is removed. In some cases, the FDA or foreign equivalent may condition approval of marketing approval for a drug candidate on the sponsor’s agreement to conduct additional clinical trials to further assess the drug’s safety and effectiveness after marketing approval, known as Phase IV clinical trials. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">The clinical trials we conduct for our drug candidates, both before and after approval, and the results of those trials, are generally required to be included in a clinical trials registry database that is available and accessible to the public via the internet. A failure by us to properly participate in the clinical trial database registry could subject us to significant civil monetary penalties. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">Health care providers in the United States, including research institutions from which we or our partners obtain patient information, are subject to privacy rules under the Health Insurance Portability and Accountability Act of 1996 and state and local privacy laws. In the European Union, these entities are subject to the Directive 95/46-EC of the European Parliament on the protection of individuals with regard to the processing of personal data and individual European Union member states implementing additional legislation. Other countries have similar privacy legislation. We could face substantial penalties if we knowingly receive individually identifiable health information from a health care provider that has not satisfied the applicable privacy laws. In addition, certain privacy laws and genetic testing laws may apply directly to our operations and/or those of our partners and may impose restrictions on the use and dissemination of individuals’ health information and use of biological samples. </FONT></P> <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1"> </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">19 </FONT></P> <p Style='page-break-before:always'> <HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER"> <h5 align="left"><a href="#toc">Table of Contents</a></h5> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>New Drug/Marketing Approval Application.</I> The results of drug candidate development, preclinical testing and clinical trials are submitted to the FDA as part of an NDA. The NDA also must contain extensive manufacturing information. In addition, the FDA may require that a proposed Risk Evaluation and Mitigation Strategy, also known as a REMS, be submitted as part of the NDA if the FDA determines that it is necessary to ensure that the benefits of the drug outweigh its risks. Similar, and in some cases additional, requirements apply in foreign jurisdictions for marketing approval applications for drugs in those jurisdictions. The FDA may refer the NDA to an advisory committee for review, evaluation and recommendation as to whether the application should be approved. The FDA often, but not always, follows the advisory committee’s recommendations. The FDA may deny approval of an NDA by issuing a complete response letter if the applicable regulatory criteria are not satisfied, or it may require additional clinical data, including data in a pediatric population, or an additional Phase III clinical trial or impose other conditions that must be met in order to secure final approval for an NDA. Even if such data are submitted, the FDA may ultimately decide that the NDA does not satisfy the criteria for approval. Data from clinical trials are not always conclusive and the FDA may interpret data differently than we or our partners do. Once issued, the FDA or foreign equivalent may withdraw a drug approval if ongoing regulatory requirements are not met or if safety problems occur after the drug reaches the market. In addition, the FDA or its foreign counterparts may require further testing, including Phase IV clinical trials, and surveillance or restrictive distribution programs to monitor the effect of approved drugs which have been commercialized. The FDA and its foreign counterparts have the power to prevent or limit further marketing of a drug based on the results of these post-marketing programs. Drugs may be marketed only for the approved indications and in accordance with the provisions of the approved label. Further, if there are any modifications to a drug, including changes in indications, labeling or manufacturing processes or facilities, we may be required to submit and obtain prior FDA approval of a new NDA or NDA supplement, or the foreign equivalent, which may require us to develop additional data or conduct additional preclinical studies and clinical trials. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">Satisfaction of FDA regulations and requirements or similar requirements of state, local and foreign regulatory agencies typically takes several years. The actual time required may vary substantially based upon the type, complexity and novelty of the drug candidate or disease. Typically, if a drug candidate is intended to treat a chronic disease, as is the case with some of our drug candidates, safety and efficacy data must be gathered over an extended period of time. Government regulation may delay or prevent marketing of drug candidates for a considerable period of time and impose costly procedures upon our activities. The FDA or any other regulatory agency may not grant approvals for new indications for our drug candidates on a timely basis, if at all. Even if a drug candidate receives regulatory approval, the approval may be significantly limited to specific disease states, patient populations and dosages or restrictive distribution programs. Further, even after regulatory approval is obtained, later discovery of previously unknown problems with a drug may result in restrictions on the drug or even complete withdrawal of the drug from the market. Delays in obtaining, or failures to obtain, regulatory approvals for any of our drug candidates would harm our business. In addition, we cannot predict what future U.S. or foreign governmental regulations may be implemented. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>Orphan Drug Designation.</I> Some jurisdictions, including the United States, may designate drugs for relatively small patient populations as orphan drugs. The FDA grants orphan drug designation to drugs intended to treat a rare disease or condition, which is generally a disease or condition that affects fewer than 200,000 individuals in the United States. For example, the FDA has granted tirasemtiv an orphan drug designation for the treatment of ALS. In addition, the European Medicines Agency has granted tirasemtiv orphan medicinal product status for the treatment of ALS. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">An FDA orphan drug designation does not shorten the duration of the regulatory review and approval process. If a drug candidate which has an orphan drug designation receives the first FDA marketing approval for the indication for which the designation was granted, then the approved drug is entitled to orphan drug exclusivity. This means that the FDA may not approve another company’s application to market the same drug for the same indication for a period of seven years, except in certain circumstances, such as a showing of clinical superiority to the drug with orphan exclusivity or if the holder of the orphan drug designation cannot assure the availability of sufficient quantities of the orphan drug to meet the needs of patients with the disease or condition </FONT></P> <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1"> </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">20 </FONT></P> <p Style='page-break-before:always'> <HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER"> <h5 align="left"><a href="#toc">Table of Contents</a></h5> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2"> for which the designation was granted. Competitors may receive approval of different drugs or biologics for the indications for which the orphan drug has exclusivity. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>Fast Track Designation.</I> Fast track is a process designed by the FDA to facilitate the development and expedite the review of drugs to treat serious diseases and fill an unmet medical need. Tirasemtiv has been granted fast track designation by the FDA for the treatment of ALS. Although fast track designation does not affect the standards for approval, the benefits of this designation include scheduled meetings to seek FDA input into development plans, the option of submitting an NDA in sections rather than all components simultaneously, and the option of requesting evaluation of studies using surrogate endpoints, which are laboratory measurements or physical signs used as an indirect or substitute measurement representing a clinically meaningful outcome. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>Other Regulatory Requirements.</I> Any drugs manufactured or distributed by us or our partners pursuant to FDA approvals or their foreign counterparts are subject to continuing regulation by the applicable regulatory authority, including recordkeeping requirements and reporting of adverse experiences associated with the drug. Drug manufacturers and their subcontractors are required to register their establishments with the FDA and other applicable regulatory authorities, and are subject to periodic unannounced inspections by these regulatory authorities for compliance with ongoing regulatory requirements, including cGMPs, which impose certain procedural and documentation requirements upon us and our third-party manufacturers. Failure to comply with the statutory and regulatory requirements can subject a manufacturer to possible legal or regulatory action, such as warning letters, suspension of manufacturing, seizure of product, injunctive action or possible civil penalties. We cannot be certain that we or our present or future third-party manufacturers or suppliers will be able to comply with the cGMP regulations and other ongoing FDA and other regulatory requirements. If our present or future third-party manufacturers or suppliers are not able to comply with these requirements, the FDA or its foreign counterparts may halt our or our partners’ clinical trials, require us to recall a drug from distribution, or withdraw approval of the NDA for that drug. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">For further details on the risks relating to government regulation of our business, please see the risk factors under Item 1A of this report, including, but not limited to, the risk factor entitled “The regulatory approval process is expensive, time-consuming and uncertain and may prevent our partners or us from obtaining approvals to commercialize some or all of our drug candidates.” </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Competition </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">We compete in the segments of the pharmaceutical, biotechnology and other related markets that address neuromuscular and cardiovascular diseases and other diseases relating to muscle dysfunction, each of which is highly competitive. We face significant competition from most pharmaceutical companies and biotechnology companies that are also researching and selling products designed to address cardiovascular diseases and diseases and medical conditions associated with skeletal muscle weakness and wasting. Many of our competitors have significantly greater financial, manufacturing, marketing and drug development resources than we do. Large pharmaceutical companies in particular have extensive experience in clinical testing and in obtaining regulatory approvals for drugs. These companies also have significantly greater research capabilities than we do. In addition, many universities and private and public research institutes are active in research of neuromuscular and cardiovascular diseases and other diseases where there is muscle dysfunction, some in direct competition with us. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">We believe that our ability to successfully compete will depend on, among other things: </FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px"> </P> <TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%"> <TR> <TD WIDTH="4%"><FONT SIZE="1"> </FONT></TD> <TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">•</FONT></TD> <TD WIDTH="1%" VALIGN="top"><FONT SIZE="1"> </FONT></TD> <TD ALIGN="left" VALIGN="top"> <P ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">our drug candidates’ efficacy, safety and tolerability; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px"> </P> <TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%"> <TR> <TD WIDTH="4%"><FONT SIZE="1"> </FONT></TD> <TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">•</FONT></TD> <TD WIDTH="1%" VALIGN="top"><FONT SIZE="1"> </FONT></TD> <TD ALIGN="left" VALIGN="top"> <P ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">the speed and cost-effectiveness with which we develop our drug candidates; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px"> </P> <TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%"> <TR> <TD WIDTH="4%"><FONT SIZE="1"> </FONT></TD> <TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">•</FONT></TD> <TD WIDTH="1%" VALIGN="top"><FONT SIZE="1"> </FONT></TD> <TD ALIGN="left" VALIGN="top"> <P ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">the selection of suitable indications for which to develop our drug candidates; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px"> </P> <TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%"> <TR> <TD WIDTH="4%"><FONT SIZE="1"> </FONT></TD> <TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">•</FONT></TD> <TD WIDTH="1%" VALIGN="top"><FONT SIZE="1"> </FONT></TD> <TD ALIGN="left" VALIGN="top"> <P ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">the successful completion of clinical development and laboratory testing of our drug candidates; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px"> </P> <TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%"> <TR> <TD WIDTH="4%"><FONT SIZE="1"> </FONT></TD> <TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">•</FONT></TD> <TD WIDTH="1%" VALIGN="top"><FONT SIZE="1"> </FONT></TD> <TD ALIGN="left" VALIGN="top"> <P ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">the timing and scope of any regulatory approvals we or our partners obtain for our drug candidates; </FONT></P></TD></TR></TABLE> <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1"> </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">21 </FONT></P> <p Style='page-break-before:always'> <HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER"> <h5 align="left"><a href="#toc">Table of Contents</a></h5> <TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%"> <TR> <TD WIDTH="4%"><FONT SIZE="1"> </FONT></TD> <TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">•</FONT></TD> <TD WIDTH="1%" VALIGN="top"><FONT SIZE="1"> </FONT></TD> <TD ALIGN="left" VALIGN="top"> <P ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">our or our partners’ ability to manufacture and sell commercial quantities of our approved drugs to meet market demand; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px"> </P> <TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%"> <TR> <TD WIDTH="4%"><FONT SIZE="1"> </FONT></TD> <TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">•</FONT></TD> <TD WIDTH="1%" VALIGN="top"><FONT SIZE="1"> </FONT></TD> <TD ALIGN="left" VALIGN="top"> <P ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">acceptance of our drugs by physicians and other health care providers; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px"> </P> <TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%"> <TR> <TD WIDTH="4%"><FONT SIZE="1"> </FONT></TD> <TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">•</FONT></TD> <TD WIDTH="1%" VALIGN="top"><FONT SIZE="1"> </FONT></TD> <TD ALIGN="left" VALIGN="top"> <P ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">the willingness of third party payors to provide reimbursement for the use of our drugs; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px"> </P> <TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%"> <TR> <TD WIDTH="4%"><FONT SIZE="1"> </FONT></TD> <TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">•</FONT></TD> <TD WIDTH="1%" VALIGN="top"><FONT SIZE="1"> </FONT></TD> <TD ALIGN="left" VALIGN="top"> <P ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">our ability to protect our intellectual property and avoid infringing the intellectual property of others; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px"> </P> <TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%"> <TR> <TD WIDTH="4%"><FONT SIZE="1"> </FONT></TD> <TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">•</FONT></TD> <TD WIDTH="1%" VALIGN="top"><FONT SIZE="1"> </FONT></TD> <TD ALIGN="left" VALIGN="top"> <P ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">the quality and breadth of our technology; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px"> </P> <TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%"> <TR> <TD WIDTH="4%"><FONT SIZE="1"> </FONT></TD> <TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">•</FONT></TD> <TD WIDTH="1%" VALIGN="top"><FONT SIZE="1"> </FONT></TD> <TD ALIGN="left" VALIGN="top"> <P ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">our employees’ skills and our ability to recruit and retain skilled employees; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px"> </P> <TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%"> <TR> <TD WIDTH="4%"><FONT SIZE="1"> </FONT></TD> <TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">•</FONT></TD> <TD WIDTH="1%" VALIGN="top"><FONT SIZE="1"> </FONT></TD> <TD ALIGN="left" VALIGN="top"> <P ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">our cash flows under existing and potential future arrangements with licensees, partners and other parties; and </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px"> </P> <TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%"> <TR> <TD WIDTH="4%"><FONT SIZE="1"> </FONT></TD> <TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">•</FONT></TD> <TD WIDTH="1%" VALIGN="top"><FONT SIZE="1"> </FONT></TD> <TD ALIGN="left" VALIGN="top"> <P ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">the availability of substantial capital resources to fund development and commercialization activities. </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">Our competitors may develop drug candidates and market drugs that are less expensive and more effective than our future drugs or that may render our drugs obsolete. Our current or future competitors may also commercialize competing drugs before we or our partners can launch any drugs developed from our drug candidates. These organizations also compete with us to attract qualified personnel and potential parties for acquisitions, joint ventures or other strategic alliances. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">If tirasemtiv is approved for marketing by the FDA or other regulatory authorities for the treatment of ALS, it may then compete with other potential new therapies for ALS that are currently being developed by companies such as Neuraltus Pharmaceuticals, Inc., Isis Pharmaceuticals, Inc., Genervon Biopharmaceuticals, LLC, and GlaxoSmithKline plc. In addition, BrainStorm Cell Therapeutics and Neuralstem, Inc. are each conducting clinical development of stem cell therapies for the potential treatment of ALS. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">If CK-2127107 is approved by the FDA or other regulatory authorities for the potential treatment of SMA, potential competitors include Roche (in collaboration with PTC Therapeutics), AveXis, Inc., Pfizer Inc., Isis Pharmaceuticals, Inc., Trophos SA, and Bioblast Pharma, Ltd. Drugs that could compete with CK-2127107 could also compete against tirasemtiv in ALS or other neuromuscular diseases, should the appropriate clinical trials be conducted. If CK-2127107 is approved by the FDA for the potential treatment of non-neuromuscular indications associated with muscle weakness, potential competitors include Ligand Pharmaceuticals, Inc., which is developing LGD-4033, a selective androgen receptor modulator, for muscle wasting; and GTx, Inc., which is developing ostarine, a selective androgen receptor modulator, for cancer cachexia and potentially other indications; Regeneron Pharmaceuticals, Inc. (in collaboration with Sanofi), which is developing SAR391786, a monoclonal antibody targeted to GDF8, for sarcopenia; Eli Lilly & Company, which is developing LY2495655, a monoclonal antibody targeted to myostatin, for muscular atrophy after hip arthroplasty; Acceleron Pharma, which is developing ACE-083 for diseases such as inclusion body myositis and certain forms of muscular dystrophy; and Pfizer Inc., which is developing PF-06252616, a monoclonal antibody targeted to myostatin, in Duchenne muscular dystrophy. Novartis (in collaboration with Morphosys AG), is conducting clinical development with an activin type-IIB receptor antagonist, bimagrumab, to evaluate its ability to treat diseases involving the loss of muscle mass, strength and function. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">If omecamtiv mecarbil is approved for marketing by the FDA or other regulatory authorities for the treatment of heart failure, it would compete against other drugs used for the treatment of acute and chronic heart failure. These include generic drugs, such as milrinone, dobutamine or digoxin and branded drugs such as Natrecor (nesiritide) and Procoralan (ivabradine). Omecamtiv mecarbil could also potentially compete against other novel drug candidates and therapies in development, such as bucindolol, which is being developed by ARCA biopharma, Inc.; Reasanz (serelaxin) and LCZ-696, which are being developed by Novartis; cenderitide (CD-NP), which is being developed by Carpicor Therapeutics, Inc., TRV-027, which is being developed by Trevena; ularitide, which is being developed by Cardiorentis Ltd.; aladorian, which is being developed by ARMGO Pharma, Inc; TRV027, which is being developed by Trevena, Inc. in partnership with Forest </FONT></P> <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1"> </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">22 </FONT></P> <p Style='page-break-before:always'> <HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER"> <h5 align="left"><a href="#toc">Table of Contents</a></h5> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2"> Laboratories, Inc.; certain cardioprotectants which are being developed by Cardioxyl Pharmaceuticals, Inc.; glial growth factor (GGF-2) which is being developed by Acorda Therapeutics, Inc.; Neurocardin, which is being developed by Zensun Sci & Tech, Ltd; Mydicar, a genetically-targeted enzyme replacement therapy for advanced heart failure which is being developed by Celladon Corporation; and levosimendan, which was acquired for development by Oxygen Biotherapeutics, Inc. In addition, there are a number of medical devices being developed for the potential treatment of heart failure. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">For further details on the risks relating to our competitors, please see the risk factors under Item 1A of this report, including, but not limited to, the risk factor entitled “Our competitors may develop drugs that are less expensive, safer or more effective than ours, which may diminish or eliminate the commercial success of any drugs that we may commercialize.” </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Employees </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">As of December 31, 2014, our workforce consisted of 92 full-time employees, 30 of whom hold Ph.D. or M.D. degrees, or both, and 17 of whom hold other advanced degrees. Of our total full-time employees, 66 are engaged in research and development and 26 are engaged in business and new product development, finance and administration functions </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">We have no collective bargaining agreements with our employees, and we have not experienced any work stoppages. We believe that our relations with our employees are good. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Investor Information </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">We file electronically with the SEC our annual reports on Form 10-K, quarterly reports on Form 10-Q and current reports on Form 8-K pursuant to Section 13 or 15(d) of the Exchange Act. The public may read or copy any materials we file with the SEC at the SEC’s Public Reference Room at 100 F Street, NE, Washington, DC 20549. The public may obtain information on the operation of the Public Reference Room by calling the SEC at 1-800-SEC-0330. The SEC maintains an Internet site that contains reports, proxy and information statements, and other information regarding issuers that file electronically with the SEC. The address of that site is www.sec.gov. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">You may obtain a free copy of our annual reports on Form 10-K, quarterly reports on Form 10-Q and current reports on Form 8-K and amendments to those reports on the day of filing with the SEC on our website at www.cytokinetics.com or by contacting the Investor Relations Department at our corporate offices by calling 650-624-3060. The information found on our website is not part of this or any other report filed with or furnished to the SEC. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><A NAME="toc828167_3"></A>Item 1A. </B><B><I>Risk Factors</I></B><B> </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>In evaluating our business, you should carefully consider the following risks in addition to the other information in this report. Any of the following risks could materially and adversely affect our business, results of operations, financial condition or your investment in our securities, and many are beyond our control. The risks and uncertainties described below are not the only ones facing us. Additional risks and uncertainties not presently known to us, or that we currently see as immaterial, may also adversely affect our business. </I></FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Risks Related To Our Business </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>We have a history of significant losses and may not achieve or sustain profitability and, as a result, you may lose all or part of your investment. </I></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">We have generally incurred operating losses in each year since our inception in 1997, due to costs incurred in connection with our research and development activities and general and administrative costs associated with </FONT></P> <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1"> </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">23 </FONT></P> <p Style='page-break-before:always'> <HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER"> <h5 align="left"><a href="#toc">Table of Contents</a></h5> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2"> our operations. Our drug candidates are all in early and mid-stage clinical testing, and we and our partners must conduct significant additional clinical trials before we and our partners can seek the regulatory approvals necessary to begin commercial sales of our drugs. We expect to incur increasing losses for at least several more years, as we continue our research activities and conduct development of, and seek regulatory approvals for, our drug candidates, and commercialize any approved drugs. If our drug candidates fail or do not gain regulatory approval, or if our drugs do not achieve market acceptance, we will not be profitable. If we fail to become and remain profitable, or if we are unable to fund our continuing losses, you could lose all or part of your investment. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>We will need substantial additional capital in the future to sufficiently fund our operations. </I></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">We have consumed substantial amounts of capital to date, and our operating expenditures will increase over the next several years if we expand our research and development activities. We have funded all of our operations and capital expenditures with proceeds from private and public sales of our equity securities, strategic alliances with Amgen, Astellas and others, equipment financings, interest on investments and government grants. We believe that our existing cash and cash equivalents, short-term investments and interest earned on investments should be sufficient to meet our projected operating requirements for at least the next 12 months. We have based this estimate on assumptions that may prove to be wrong, and we could utilize our available capital resources sooner than we currently expect. Because of the numerous risks and uncertainties associated with the development of our drug candidates and other research and development activities, including risks and uncertainties that could impact the rate of progress of our development activities, we are unable to estimate with certainty the amounts of capital outlays and operating expenditures associated with these activities. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">For the foreseeable future, our operations will require significant additional funding, in large part due to our research and development expenses and the absence of any revenues from product sales. For example, we will require significant additional funding to enable us to conduct further development of tirasemtiv for the potential treatment of ALS, including any additional Phase III clinical trials that may be required by regulatory authorities to receive marketing approval for tirasemtiv. Until we can generate a sufficient amount of product revenue, we expect to raise future capital through strategic alliance and licensing arrangements, public or private equity offerings and debt financings. We do not currently have any commitments for future funding other than reimbursements, milestone and royalty payments that we may receive under our collaboration agreements with Amgen and Astellas. We may not receive any further funds under those agreements. Our ability to raise funds may be adversely impacted by current economic conditions. As a result of these and other factors, we do not know whether additional financing will be available when needed, or that, if available, such financing would be on terms favorable to our stockholders or us. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">To the extent that we raise additional funds through strategic alliances or licensing and other arrangements with third parties, we will likely have to relinquish valuable rights to our technologies, research programs or drug candidates, or grant licenses on terms that may not be favorable to us. To the extent that we raise additional funds by issuing equity securities, our stockholders will experience additional dilution and our share price may decline. To the extent that we raise additional funds through debt financing, the financing may involve covenants that restrict our business activities. In addition, funding from any of these sources, if needed, may not be available to us on favorable terms, or at all, or in accordance with our planned timelines. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">If we cannot raise the funds we need to operate our business, we will need to delay or discontinue certain research and development activities. For example, if we cannot raise the funds necessary to enable the conduct of further development for tirasemtiv for the potential treatment of ALS, our ability to continue the development of tirasemtiv will be delayed or suspended. If we delay or discontinue research and development activities, our stock price may be negatively affected. </FONT></P> <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1"> </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">24 </FONT></P> <p Style='page-break-before:always'> <HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER"> <h5 align="left"><a href="#toc">Table of Contents</a></h5> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>We have never generated, and may never generate, revenues from commercial sales of our drugs and we will not have drugs to market for at least several years, if ever. </I></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">We currently have no drugs for sale and we cannot guarantee that we will ever develop or obtain approval to market any drugs. To receive marketing approval for any drug candidate, we must demonstrate that the drug candidate satisfies rigorous standards of safety and efficacy to the FDA in the United States and other regulatory authorities abroad. We and our partners will need to conduct significant additional research and preclinical and clinical testing before we or our partners can file applications with the FDA or other regulatory authorities for approval of any of our drug candidates. In addition, to compete effectively, our drugs must be easy to use, cost-effective and economical to manufacture on a commercial scale, compared to other therapies available for the treatment of the same conditions. We may not achieve any of these objectives. Currently, our only drug candidates in clinical development are omecamtiv mecarbil for the potential treatment of heart failure, tirasemtiv for the potential treatment of ALS, and CK-2127107 for the potential treatment of SMA and potentially other neuromuscular and non-neuromuscular indications associated with muscle weakness. We cannot be certain that the clinical development of these or any future drug candidates will be successful, that they will receive the regulatory approvals required to commercialize them, that they will ultimately be accepted by prescribers or reimbursed by insurers or that any of our other research programs will yield a drug candidate suitable for clinical testing or commercialization. Our commercial revenues, if any, will be derived from sales of drugs that we do not expect to be commercially marketed for at least several years, if at all. The development of any one or all of these drug candidates may be discontinued at any stage of our clinical trials programs and we may not generate revenue from any of these drug candidates. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Clinical trials may fail to demonstrate the desired safety and efficacy of our drug candidates, which could prevent or significantly delay completion of clinical development and regulatory approval. </I></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">Prior to receiving approval to commercialize any of our drug candidates, we or our partners must adequately demonstrate to the satisfaction of FDA and foreign regulatory authorities that the drug candidate is sufficiently safe and effective with substantial evidence from well-controlled clinical trials. We or our partners will need to demonstrate efficacy in clinical trials for the treatment of specific indications and monitor safety throughout the clinical development process and following approval. None of our drug candidates have yet met the safety and efficacy standards required for regulatory approval for commercialization and they may never do so. In addition, for each of our preclinical compounds, we or our partners must adequately demonstrate satisfactory chemistry, formulation, stability and toxicity in order to submit an investigational new drug application (“IND”) to the FDA, or an equivalent application in foreign jurisdictions, that would allow us to advance that compound into clinical trials. Furthermore, we or our partners may need to submit separate INDs (or foreign equivalent) to different divisions within the FDA (or foreign regulatory authorities) in order to pursue clinical trials in different therapeutic areas. Each new IND (or foreign equivalent) must be reviewed by the new division before the clinical trial under its jurisdiction can proceed, entailing all the risks of delay inherent to regulatory review. If our or our partners’ current or future preclinical studies or clinical trials are unsuccessful, our business will be significantly harmed and our stock price could be negatively affected. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">All of our drug candidates are prone to the risks of failure inherent in drug development. Preclinical studies may not yield results that would adequately support the filing of an IND (or a foreign equivalent) with respect to our potential drug candidates. Even if the results of preclinical studies for a drug candidate are sufficient to support such a filing, the results of preclinical studies do not necessarily predict the results of clinical trials. As an example, because the physiology of animal species used in preclinical studies may vary substantially from other animal species and from humans, it may be difficult to assess with certainty whether a finding from a study in a particular animal species will result in similar findings in other animal species or in humans. For any of our drug candidates, the results from Phase I clinical trials in healthy volunteers and clinical results from Phase I and II trials in patients are not necessarily indicative of the results of later and larger clinical trials that are necessary to establish whether the drug candidate is safe and effective for the applicable indication. Likewise, interim results from a clinical trial may not be indicative of the final results from that trial, and results from early Phase II clinical trials may not be indicative of the results from later clinical trials. For example, early Phase II clinical </FONT></P> <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1"> </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">25 </FONT></P> <p Style='page-break-before:always'> <HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER"> <h5 align="left"><a href="#toc">Table of Contents</a></h5> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2"> trials of tirasemtiv in patients with ALS showed encouraging dose-related trends in measurements of the ALS Functional Rating Scale in its revised form (ALSFRS-R), a clinically validated instrument designed to measure disease progression and changes in functional status, for patients receiving tirasemtiv compared to those receiving placebo. However, BENEFIT-ALS, a Phase IIb clinical trial of tirasemtiv in patients with ALS, did not achieve its primary efficacy endpoint, the mean change from baseline in the ALSFRS-R for patients receiving tirasemtiv compared to those receiving placebo. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">In addition, while the clinical trials of our drug candidates are designed based on the available relevant information, such information may not accurately predict what actually occurs during the course of the trial itself, which may have consequences for the conduct of an ongoing clinical trial or for the eventual results of that trial. For example, the number of patients planned to be enrolled in a placebo-controlled clinical trial is determined in part by estimates relating to expected treatment effect and variability about the primary endpoint. These estimates are based upon earlier nonclinical and clinical studies of the drug candidate itself and clinical trials of other drugs thought to have similar effects in a similar patient population. If information gained during the conduct of the trial shows these estimates to be inaccurate, we may elect to adjust the enrollment accordingly, which may cause delays in completing the trial, additional expense or a statistical penalty to apply to the evaluation of the trial results. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">Furthermore, in view of the uncertainties inherent in drug development, such clinical trials may not be designed with focus on indications, patient populations, dosing regimens, endpoints, safety, efficacy or pharmacokinetic parameters or other variables that will provide the necessary safety or efficacy data to support regulatory approval to commercialize the resulting drugs. For example, we believe that effects on respiratory function, including slow vital capacity (SVC), may be appropriate as a clinical endpoint for tirasemtiv; however, regulatory authorities may not accept these effects as a clinical endpoint to support registration of tirasemtiv for the treatment of ALS. Clinical trials of our drug candidates are designed based on guidance or advice from regulatory agencies, which is subject to change during the development of the drug candidate at any time. Such a change in a regulatory agency’s guidance or advice may cause that agency to deem results from trials to be insufficient to support approval of the drug candidate and require further clinical trials of that drug candidate to be conducted. In addition, individual patient responses to the dose administered of a drug may vary in a manner that is difficult to predict. Also, the methods we select to assess particular safety, efficacy or pharmacokinetic parameters may not yield the same statistical precision in estimating our drug candidates’ effects as may other methodologies. Even if we believe the data collected from clinical trials of our drug candidates are promising, these data may not be sufficient to support approval by the FDA or foreign regulatory authorities. Non-clinical and clinical data can be interpreted in different ways. Accordingly, the FDA or foreign regulatory authorities could interpret these data in different ways from us or our partners, which could delay, limit or prevent regulatory approval. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">Administering any of our drug candidates or potential drug candidates may produce undesirable side effects, also known as adverse events. Toxicities and adverse events observed in preclinical studies for some compounds in a particular research and development program may also occur in preclinical studies or clinical trials of other compounds from the same program. Potential toxicity issues may arise from the effects of the active pharmaceutical ingredient itself or from impurities or degradants that are present in the active pharmaceutical ingredient or could form over time in the formulated drug candidate or the active pharmaceutical ingredient. These toxicities or adverse events could delay or prevent the filing of an IND (or a foreign equivalent) with respect to our drug candidates or potential drug candidates or cause us, our partners or the FDA or foreign regulatory authorities to modify, suspend or terminate clinical trials with respect to any drug candidate at any time during the development program. Further, the administration of two or more drugs contemporaneously can lead to interactions between them, and our drug candidates may interact with other drugs that trial subjects are taking. For example, co-administration of tirasemtiv and riluzole (an approved treatment for ALS) approximately doubles the average maximum riluzole plasma level. If the adverse events are severe or frequent enough to outweigh the potential efficacy of a drug candidate, the FDA or other regulatory authorities could deny approval of that drug candidate for any or all targeted indications. Even if one or more of our drug candidates were </FONT></P> <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1"> </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">26 </FONT></P> <p Style='page-break-before:always'> <HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER"> <h5 align="left"><a href="#toc">Table of Contents</a></h5> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2"> approved for sale as drugs, the occurrence of even a limited number of toxicities or adverse events when used in large populations may cause the FDA or foreign regulatory authorities to impose restrictions on, or stop, the further marketing of those drugs. Indications of potential adverse events or toxicities which do not seem significant during the course of clinical trials may later turn out to actually constitute serious adverse events or toxicities when a drug is used in large populations or for extended periods of time. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">We have observed certain adverse events in the clinical trials conducted with our drug candidates. For example, in BENEFIT-ALS, adverse events of dizziness, fatigue, nausea, confusional state, muscle spasms, somnolence (sleepiness), decreased appetite, headache, insomnia, dyspnea (difficulty breathing) and dysathria (difficulty speaking) occurred more frequently during treatment with tirasemtiv than with placebo. In addition, weight loss was significantly greater in patients with gastrointestinal adverse events (e.g., nausea and decreased appetite), which occurred more frequently on tirasemtiv than on placebo. In clinical trials of omecamtiv mecarbil, adverse events of chest discomfort, palpitations, dizziness and feeling hot, increases in heart rate, declines in blood pressure, electrocardiographic changes consistent with acute myocardial ischemia and transient rises in the MB fraction of creatine kinase and cardiac troponins I and T, which are indicative of myocardial infarction were observed during treatment with omecamtiv mecarbil. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">In addition, clinical trials of tirasemtiv and omecamtiv mecarbil enroll patients who typically suffer from serious diseases which put them at increased risk of death. These patients may die while receiving our drug candidates. In such circumstances, it may not be possible to exclude with certainty a causal relationship to our drug candidate, even though the responsible clinical investigator may view such an event as not study drug-related. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">Any failure or significant delay in completing preclinical studies or clinical trials for our drug candidates, or in receiving and maintaining regulatory approval for the sale of any resulting drugs, may significantly harm our business and negatively affect our stock price. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>The failure of a number of Phase III clinical trials evaluating other compounds as potential treatments for patients with ALS may suggest an increased risk that our planned Phase III clinical development program of tirasemtiv in patients with ALS will also fail. </I></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">The FDA has not approved any drug for the treatment of ALS since its approval of riluzole in 1995. In recent years, a number of Phase III clinical trials of potential treatments for ALS have failed to demonstrate the requisite efficacy for approval or for their continued development. These include Biogen Idec’s trial of dexpramipexole, known as EMPOWER, the National Institute of Neurological Disorders and Stroke’s trial of ceftriaxone, and Trophos SA’s trial of olesoxime. Tirasemtiv, like these compounds, may fail in Phase III clinical development if it does not show a statistically significant level of clinical efficacy or if the adverse event profile is too great compared to it benefits. Further, even if we believe the data collected from our planned Phase III clinical development program of tirasemtiv are promising and should support approval, the FDA or other regulatory authorities may not deem these data to be sufficient to support approval. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Clinical trials are expensive, time-consuming and subject to delay. </I></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">Clinical trials are subject to rigorous regulatory requirements and are very expensive, difficult and time-consuming to design and implement. The length of time and number of trial sites and patients required for clinical trials vary substantially based on the type, complexity, novelty, intended use of the drug candidate and safety concerns. We estimate that the clinical trials of our current drug candidates will each continue for several more years. However, the clinical trials for all or any of our drug candidates may take significantly longer to complete. The commencement and completion of our or our partners’ clinical trials could be delayed or prevented by many factors, including, but not limited to: </FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px"> </P> <TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%"> <TR> <TD WIDTH="4%"><FONT SIZE="1"> </FONT></TD> <TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">•</FONT></TD> <TD WIDTH="1%" VALIGN="top"><FONT SIZE="1"> </FONT></TD> <TD ALIGN="left" VALIGN="top"> <P ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">delays in obtaining, or inability to obtain, regulatory or other approvals to commence and conduct clinical trials in the manner we or our partners deem necessary for the appropriate and timely development of our drug candidates and commercialization of any resulting drugs; </FONT></P></TD></TR></TABLE> <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1"> </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">27 </FONT></P> <p Style='page-break-before:always'> <HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER"> <h5 align="left"><a href="#toc">Table of Contents</a></h5> <TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%"> <TR> <TD WIDTH="4%"><FONT SIZE="1"> </FONT></TD> <TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">•</FONT></TD> <TD WIDTH="1%" VALIGN="top"><FONT SIZE="1"> </FONT></TD> <TD ALIGN="left" VALIGN="top"> <P ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">delays in identifying and reaching agreement, or inability to identify and reach agreement, on acceptable terms, with prospective clinical trial sites and other entities involved in the conduct of our or our partners’ clinical trials; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px"> </P> <TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%"> <TR> <TD WIDTH="4%"><FONT SIZE="1"> </FONT></TD> <TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">•</FONT></TD> <TD WIDTH="1%" VALIGN="top"><FONT SIZE="1"> </FONT></TD> <TD ALIGN="left" VALIGN="top"> <P ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">delays or additional costs in developing, or inability to develop, appropriate formulations of our drug candidates for clinical trial use, including an appropriate modified release oral formulation for omecamtiv mecarbil; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px"> </P> <TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%"> <TR> <TD WIDTH="4%"><FONT SIZE="1"> </FONT></TD> <TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">•</FONT></TD> <TD WIDTH="1%" VALIGN="top"><FONT SIZE="1"> </FONT></TD> <TD ALIGN="left" VALIGN="top"> <P ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">slower than expected rates of patient recruitment and enrollment, including as a result of competition for patients with other clinical trials; limited numbers of patients that meet the enrollment criteria; patients’, investigators’ or trial sites’ reluctance to agree to the requirements of a protocol; or the introduction of alternative therapies or drugs by others; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px"> </P> <TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%"> <TR> <TD WIDTH="4%"><FONT SIZE="1"> </FONT></TD> <TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">•</FONT></TD> <TD WIDTH="1%" VALIGN="top"><FONT SIZE="1"> </FONT></TD> <TD ALIGN="left" VALIGN="top"> <P ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">for those drug candidates that are the subject of a strategic alliance, delays in reaching agreement with our partner as to appropriate development strategies; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px"> </P> <TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%"> <TR> <TD WIDTH="4%"><FONT SIZE="1"> </FONT></TD> <TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">•</FONT></TD> <TD WIDTH="1%" VALIGN="top"><FONT SIZE="1"> </FONT></TD> <TD ALIGN="left" VALIGN="top"> <P ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">a regulatory authority may require changes to a protocol for a clinical trial that then may require approval from regulatory agencies in other jurisdictions where the trial is being conducted; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px"> </P> <TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%"> <TR> <TD WIDTH="4%"><FONT SIZE="1"> </FONT></TD> <TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">•</FONT></TD> <TD WIDTH="1%" VALIGN="top"><FONT SIZE="1"> </FONT></TD> <TD ALIGN="left" VALIGN="top"> <P ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">an institutional review board (“IRB”) or its foreign equivalent may require changes to a protocol that then require approval from regulatory agencies and other IRBs and their foreign equivalents, or regulatory authorities may require changes to a protocol that then require approval from the IRBs or their foreign equivalents; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px"> </P> <TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%"> <TR> <TD WIDTH="4%"><FONT SIZE="1"> </FONT></TD> <TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">•</FONT></TD> <TD WIDTH="1%" VALIGN="top"><FONT SIZE="1"> </FONT></TD> <TD ALIGN="left" VALIGN="top"> <P ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">for clinical trials conducted in foreign countries, the time and resources required to identify, interpret and comply with foreign regulatory requirements or changes in those requirements, and political instability or natural disasters occurring in those countries; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px"> </P> <TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%"> <TR> <TD WIDTH="4%"><FONT SIZE="1"> </FONT></TD> <TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">•</FONT></TD> <TD WIDTH="1%" VALIGN="top"><FONT SIZE="1"> </FONT></TD> <TD ALIGN="left" VALIGN="top"> <P ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">lack of effectiveness of our drug candidates during clinical trials; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px"> </P> <TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%"> <TR> <TD WIDTH="4%"><FONT SIZE="1"> </FONT></TD> <TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">•</FONT></TD> <TD WIDTH="1%" VALIGN="top"><FONT SIZE="1"> </FONT></TD> <TD ALIGN="left" VALIGN="top"> <P ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">unforeseen safety issues; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px"> </P> <TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%"> <TR> <TD WIDTH="4%"><FONT SIZE="1"> </FONT></TD> <TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">•</FONT></TD> <TD WIDTH="1%" VALIGN="top"><FONT SIZE="1"> </FONT></TD> <TD ALIGN="left" VALIGN="top"> <P ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">inadequate supply, or delays in the manufacture or supply, of clinical trial materials; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px"> </P> <TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%"> <TR> <TD WIDTH="4%"><FONT SIZE="1"> </FONT></TD> <TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">•</FONT></TD> <TD WIDTH="1%" VALIGN="top"><FONT SIZE="1"> </FONT></TD> <TD ALIGN="left" VALIGN="top"> <P ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">uncertain dosing issues; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px"> </P> <TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%"> <TR> <TD WIDTH="4%"><FONT SIZE="1"> </FONT></TD> <TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">•</FONT></TD> <TD WIDTH="1%" VALIGN="top"><FONT SIZE="1"> </FONT></TD> <TD ALIGN="left" VALIGN="top"> <P ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">failure by us, our partners, or clinical research organizations, investigators or site personnel engaged by us or our partners to comply with good clinical practices and other applicable laws and regulations, including those concerning informed consent; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px"> </P> <TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%"> <TR> <TD WIDTH="4%"><FONT SIZE="1"> </FONT></TD> <TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">•</FONT></TD> <TD WIDTH="1%" VALIGN="top"><FONT SIZE="1"> </FONT></TD> <TD ALIGN="left" VALIGN="top"> <P ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">inability or unwillingness of investigators or their staffs to follow clinical protocols; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px"> </P> <TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%"> <TR> <TD WIDTH="4%"><FONT SIZE="1"> </FONT></TD> <TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">•</FONT></TD> <TD WIDTH="1%" VALIGN="top"><FONT SIZE="1"> </FONT></TD> <TD ALIGN="left" VALIGN="top"> <P ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">failure by our clinical research organizations, clinical manufacturing organizations and other third parties supporting our or our partners’ clinical trials to fulfill their obligations; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px"> </P> <TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%"> <TR> <TD WIDTH="4%"><FONT SIZE="1"> </FONT></TD> <TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">•</FONT></TD> <TD WIDTH="1%" VALIGN="top"><FONT SIZE="1"> </FONT></TD> <TD ALIGN="left" VALIGN="top"> <P ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">inability to monitor patients adequately during or after treatment; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px"> </P> <TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%"> <TR> <TD WIDTH="4%"><FONT SIZE="1"> </FONT></TD> <TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">•</FONT></TD> <TD WIDTH="1%" VALIGN="top"><FONT SIZE="1"> </FONT></TD> <TD ALIGN="left" VALIGN="top"> <P ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">introduction of new therapies or changes in standards of practice or regulatory guidance that render our drug candidates or their clinical trial endpoints obsolete; and </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px"> </P> <TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%"> <TR> <TD WIDTH="4%"><FONT SIZE="1"> </FONT></TD> <TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">•</FONT></TD> <TD WIDTH="1%" VALIGN="top"><FONT SIZE="1"> </FONT></TD> <TD ALIGN="left" VALIGN="top"> <P ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">results from non-clinical studies that may adversely impact the timing or further development of our drug candidates. </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">We do not know whether planned clinical trials will begin on time, or whether planned or currently ongoing clinical trials will need to be restructured or will be completed on schedule, if at all. Significant delays in clinical trials will impede our ability to commercialize our drug candidates and generate revenue and could significantly increase our development costs. </FONT></P> <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1"> </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">28 </FONT></P> <p Style='page-break-before:always'> <HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER"> <h5 align="left"><a href="#toc">Table of Contents</a></h5> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>We depend on Amgen for the conduct and funding of the development and commercialization of omecamtiv mecarbil. </I></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">Under our strategic alliance, Amgen holds an exclusive license to our drug candidate omecamtiv mecarbil worldwide. As a result, Amgen is responsible for the development and obtaining and maintaining regulatory approval of omecamtiv mecarbil for the potential treatment of heart failure worldwide. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">We do not control the development activities being conducted or that may be conducted in the future by Amgen, including, but not limited to, the timing of initiation, termination or completion of clinical trials, the analysis of data arising out of those clinical trials or the timing of release of data concerning those clinical trials, which may impact our ability to report on Amgen’s results. Amgen may conduct these activities more slowly or in a different manner than we would if we controlled the development of omecamtiv mecarbil. Amgen is responsible for filing future applications with the FDA or other regulatory authorities for approval of omecamtiv mecarbil and will be the owner of any marketing approvals issued by the FDA or other regulatory authorities for omecamtiv mecarbil. If the FDA or other regulatory authorities approve omecamtiv mecarbil, Amgen will also be responsible for the marketing and sale of the resulting drug, subject to our right to co-promote omecamtiv mecarbil in North America if we exercise our option to co-fund Phase III development costs of omecamtiv mecarbil under the collaboration. However, we cannot control whether Amgen will devote sufficient attention and resources to the development of omecamtiv mecarbil or will proceed in an expeditious manner, even if we do exercise our option to co-fund the development of omecamtiv mecarbil. Even if the FDA or other regulatory agencies approve omecamtiv mecarbil, Amgen may elect not to proceed with the commercialization of the resulting drug in one or more countries. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">If the results of one or more clinical trials with omecamtiv mecarbil do not meet Amgen’s expectations at any time, Amgen may elect to terminate further development of omecamtiv mecarbil or certain of the potential clinical trials for omecamtiv mecarbil, even if the actual number of patients treated at that time is relatively small. In addition, Amgen generally has discretion to elect whether to pursue or abandon the development of omecamtiv mecarbil and may terminate our strategic alliance for any reason upon six months prior notice. If Amgen abandons omecamtiv mecarbil, it would result in a delay in or could prevent us from commercializing omecamtiv mecarbil, and would delay and could prevent us from obtaining revenues for this drug candidate. Disputes may arise between us and Amgen, which may delay or cause the termination of any omecamtiv mecarbil clinical trials, result in significant litigation or cause Amgen to act in a manner that is not in our best interest. If development of omecamtiv mecarbil does not progress for these or any other reasons, we would not receive further milestone payments or royalties on product sales from Amgen with respect to omecamtiv mecarbil. If Amgen abandons development of omecamtiv mecarbil prior to regulatory approval or if it elects not to proceed with commercialization of the resulting drug following regulatory approval, we would have to seek a new partner for development or commercialization, curtail or abandon that development or commercialization, or undertake and fund the development of omecamtiv mecarbil or commercialization of the resulting drug ourselves. If we seek a new partner but are unable to do so on acceptable terms, or at all, or do not have sufficient funds to conduct the development or commercialization of omecamtiv mecarbil ourselves, we would have to curtail or abandon that development or commercialization, which could harm our business. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>We depend on Astellas for the conduct and funding of the development and commercialization of <FONT STYLE="white-space:nowrap">CK-2127107.</FONT> </I></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">In December 2014, we expanded our strategic alliance with Astellas focused on the research, development and commercialization of skeletal muscle activators, other than tirasemtiv and certain related compounds. The primary objective of the strategic alliance is to advance novel therapies for indications associated with muscle weakness. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">Under this strategic alliance, we have granted Astellas an exclusive license to co-develop and commercialize CK-2127107 for potential application in spinal muscular atrophy (SMA) and potentially other </FONT></P> <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1"> </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">29 </FONT></P> <p Style='page-break-before:always'> <HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER"> <h5 align="left"><a href="#toc">Table of Contents</a></h5> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2"> indications worldwide. We expect to conduct the early stage development of CK-2127107 including a Phase II clinical trial of patients with SMA. Unless otherwise agreed by the parties, Astellas will be primarily responsible for the conduct of subsequent development and commercialization activities for CK-2127107. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">We do not control the development activities that may be conducted by Astellas, including, but not limited to, the timing of initiation, termination or completion of clinical trials, the analysis of data arising out of those clinical trials or the timing of release of data concerning those clinical trials, which may impact our ability to report on Astellas’ results. Astellas may conduct these activities more slowly or in a different manner than we would. In general, Astellas is responsible for filing future applications with the FDA or other regulatory authorities for approval of CK-2127107 and will be the owner of any marketing approvals issued by the FDA or other regulatory authorities for CK-2127107. If the FDA or other regulatory authorities approve CK-2127107, Astellas will also be responsible for the marketing and sale of the resulting drug, subject to our right to co-promote the drug in the United States, Canada and, for neuromuscular indications, Europe. However, we cannot control whether Astellas will devote sufficient attention and resources to the development of CK-2127107 or will proceed in an expeditious manner. Even if the FDA or other regulatory agencies approve CK-2127107, Astellas may elect not to proceed with the commercialization of the resulting drug in one or more countries. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">If the results of one or more clinical trials with CK-2127107 do not meet Astellas’ expectations at any time, Astellas may elect to terminate further development of CK-2127107 or certain of the potential clinical trials for CK-2127107, even if the actual number of patients treated at that time is relatively small. In addition, Astellas generally has discretion to elect whether to pursue or abandon the development of CK-2127107. Astellas may terminate our strategic alliance in whole or in part for any reason upon six months prior notice at any time following expiration of the strategic alliance’s research term, which will expire December 31, 2016. If Astellas abandons CK-2127107, it would result in a delay in or could prevent us from further developing or commercializing CK-2127107, and would delay and could prevent us from obtaining revenues for this drug candidate. Disputes may arise between us and Astellas, which may delay or cause the termination of any CK-2127107 clinical trials, result in significant litigation or cause Astellas to act in a manner that is not in our best interest. If development of CK-2127107 does not progress for these or any other reasons, we would not receive further milestone payments or royalties on product sales from Astellas with respect to CK-2127107. If Astellas abandons development of CK-2127107 prior to regulatory approval or if it elects not to proceed with commercialization of the resulting drug following regulatory approval, we would have to seek a new partner for development or commercialization, curtail or abandon that development or commercialization, or undertake and fund the development of CK-2127107 or commercialization of the resulting drug ourselves. If we seek a new partner but are unable to do so on acceptable terms, or at all, or do not have sufficient funds to conduct the development or commercialization of CK-2127107 ourselves, we would have to curtail or abandon that development or commercialization, which could harm our business. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>If we do not enter into strategic alliances for our unpartnered drug candidates or research and development programs or fail to successfully maintain our current or future strategic alliances, we may have to reduce, delay or discontinue our advancement of our drug candidates and programs or expand our research and development capabilities and increase our expenditures. </I></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">Drug development is complicated and expensive. We currently have limited financial and operational resources to carry out drug development. Our strategy for developing, manufacturing and commercializing our drug candidates currently requires us to enter into and successfully maintain strategic alliances with pharmaceutical companies or other industry participants to advance our programs and reduce our expenditures on each program. Accordingly, the success of our development activities depends in large part on our current and future strategic partners’ performance, over which we have little or no control. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">We have retained exclusive rights to develop and commercialize tirasemtiv. We currently do not have a strategic partner for this drug candidate. We may seek one or more strategic partners or other arrangements with third parties to support further clinical development and commercialization of tirasemtiv. However, we may not </FONT></P> <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1"> </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">30 </FONT></P> <p Style='page-break-before:always'> <HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER"> <h5 align="left"><a href="#toc">Table of Contents</a></h5> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2"> be able to negotiate and enter into such strategic alliances or arrangements on acceptable terms, if at all, or in accordance with our planned timelines. If we are unable to enter into a strategic alliance for tirasemtiv, we will be unable to conduct further clinical development of tirasemtiv for the potential treatment of ALS unless we are able to acquire the funding to do so from another source. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">Our ability to commercialize drugs that we develop with our partners and that generate royalties from product sales depends on our partners’ abilities to assist us in establishing the safety and efficacy of our drug candidates, obtaining and maintaining regulatory approvals and achieving market acceptance of the drugs once commercialized. Our partners may elect to delay or terminate development of one or more drug candidates, independently develop drugs that could compete with ours or fail to commit sufficient resources to the marketing and distribution of drugs developed through their strategic alliances with us. Our partners may not proceed with the development and commercialization of our drug candidates with the same degree of urgency as we would because of other priorities they face. In addition, new business combinations or changes in a partner’s business strategy may adversely affect its willingness or ability to carry out its obligations under a strategic alliance. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">If we are not able to successfully maintain our existing strategic alliances or establish and successfully maintain additional strategic alliances, we will have to limit the size or scope of, or delay or discontinue, one or more of our drug development programs or research programs, or undertake and fund these programs ourselves. Alternatively, if we elect to continue to conduct any of these drug development programs or research programs on our own, we will need to expand our capability to conduct clinical development by bringing additional skills, technical expertise and resources into our organization. This would require significant additional funding, which may not be available to us on acceptable terms, or at all. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>To the extent we elect to fund the development of a drug candidate, such as omecamtiv mecarbil, tirasemtiv or CK-2127107, or the commercialization of a drug at our expense, we will need substantial additional funding. </I></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">The discovery, development and commercialization of new drugs is costly. As a result, to the extent we elect to fund the development of a drug candidate, such as omecamtiv mecarbil, tirasemtiv or CK-2127107, or the commercialization of a drug, we will need to raise additional capital to: </FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px"> </P> <TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%"> <TR> <TD WIDTH="4%"><FONT SIZE="1"> </FONT></TD> <TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">•</FONT></TD> <TD WIDTH="1%" VALIGN="top"><FONT SIZE="1"> </FONT></TD> <TD ALIGN="left" VALIGN="top"> <P ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">fund clinical trials and seek regulatory approvals; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px"> </P> <TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%"> <TR> <TD WIDTH="4%"><FONT SIZE="1"> </FONT></TD> <TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">•</FONT></TD> <TD WIDTH="1%" VALIGN="top"><FONT SIZE="1"> </FONT></TD> <TD ALIGN="left" VALIGN="top"> <P ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">expand our development capabilities; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px"> </P> <TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%"> <TR> <TD WIDTH="4%"><FONT SIZE="1"> </FONT></TD> <TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">•</FONT></TD> <TD WIDTH="1%" VALIGN="top"><FONT SIZE="1"> </FONT></TD> <TD ALIGN="left" VALIGN="top"> <P ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">engage third party manufacturers for such drug candidate or drug; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px"> </P> <TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%"> <TR> <TD WIDTH="4%"><FONT SIZE="1"> </FONT></TD> <TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">•</FONT></TD> <TD WIDTH="1%" VALIGN="top"><FONT SIZE="1"> </FONT></TD> <TD ALIGN="left" VALIGN="top"> <P ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">build or access commercialization capabilities; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px"> </P> <TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%"> <TR> <TD WIDTH="4%"><FONT SIZE="1"> </FONT></TD> <TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">•</FONT></TD> <TD WIDTH="1%" VALIGN="top"><FONT SIZE="1"> </FONT></TD> <TD ALIGN="left" VALIGN="top"> <P ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">implement additional internal systems and infrastructure; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px"> </P> <TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%"> <TR> <TD WIDTH="4%"><FONT SIZE="1"> </FONT></TD> <TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">•</FONT></TD> <TD WIDTH="1%" VALIGN="top"><FONT SIZE="1"> </FONT></TD> <TD ALIGN="left" VALIGN="top"> <P ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">maintain, defend and expand the scope of our intellectual property; and </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px"> </P> <TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%"> <TR> <TD WIDTH="4%"><FONT SIZE="1"> </FONT></TD> <TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">•</FONT></TD> <TD WIDTH="1%" VALIGN="top"><FONT SIZE="1"> </FONT></TD> <TD ALIGN="left" VALIGN="top"> <P ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">hire and support additional management and scientific personnel. </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">Our future funding requirements will depend on many factors, including, but not limited to: </FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px"> </P> <TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%"> <TR> <TD WIDTH="4%"><FONT SIZE="1"> </FONT></TD> <TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">•</FONT></TD> <TD WIDTH="1%" VALIGN="top"><FONT SIZE="1"> </FONT></TD> <TD ALIGN="left" VALIGN="top"> <P ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">the rate of progress and costs of our or our partners’ clinical trials and other research and development activities; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px"> </P> <TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%"> <TR> <TD WIDTH="4%"><FONT SIZE="1"> </FONT></TD> <TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">•</FONT></TD> <TD WIDTH="1%" VALIGN="top"><FONT SIZE="1"> </FONT></TD> <TD ALIGN="left" VALIGN="top"> <P ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">the costs and timing of seeking and obtaining regulatory approvals; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px"> </P> <TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%"> <TR> <TD WIDTH="4%"><FONT SIZE="1"> </FONT></TD> <TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">•</FONT></TD> <TD WIDTH="1%" VALIGN="top"><FONT SIZE="1"> </FONT></TD> <TD ALIGN="left" VALIGN="top"> <P ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">the costs associated with establishing manufacturing and commercialization capabilities; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px"> </P> <TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%"> <TR> <TD WIDTH="4%"><FONT SIZE="1"> </FONT></TD> <TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">•</FONT></TD> <TD WIDTH="1%" VALIGN="top"><FONT SIZE="1"> </FONT></TD> <TD ALIGN="left" VALIGN="top"> <P ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">the costs of filing, prosecuting, defending and enforcing any patent claims and other intellectual property rights; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px"> </P> <TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%"> <TR> <TD WIDTH="4%"><FONT SIZE="1"> </FONT></TD> <TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">•</FONT></TD> <TD WIDTH="1%" VALIGN="top"><FONT SIZE="1"> </FONT></TD> <TD ALIGN="left" VALIGN="top"> <P ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">the costs of acquiring or investing in businesses, products and technologies; </FONT></P></TD></TR></TABLE> <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1"> </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">31 </FONT></P> <p Style='page-break-before:always'> <HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER"> <h5 align="left"><a href="#toc">Table of Contents</a></h5> <TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%"> <TR> <TD WIDTH="4%"><FONT SIZE="1"> </FONT></TD> <TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">•</FONT></TD> <TD WIDTH="1%" VALIGN="top"><FONT SIZE="1"> </FONT></TD> <TD ALIGN="left" VALIGN="top"> <P ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">the effect of competing technological and market developments; and </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px"> </P> <TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%"> <TR> <TD WIDTH="4%"><FONT SIZE="1"> </FONT></TD> <TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">•</FONT></TD> <TD WIDTH="1%" VALIGN="top"><FONT SIZE="1"> </FONT></TD> <TD ALIGN="left" VALIGN="top"> <P ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">the status of, payment and other terms, and timing of any strategic alliance, licensing or other arrangements that we have entered into or may establish. </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">Until we can generate a sufficient amount of product revenue to finance our cash requirements, which we may never do, we expect to continue to finance our future cash needs primarily through strategic alliances, public or private equity offerings and debt financings. We cannot be certain that additional funding will be available on acceptable terms, or at all. If we are not able to secure additional funding when needed, we may have to delay, reduce the scope of or eliminate one or more of our clinical trials or research and development programs or future commercialization initiatives. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>We depend on contract research organizations to conduct our clinical trials and have limited control over their performance. </I></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">We have used and intend to continue to use contract research organizations (“CROs”) within and outside of the United States to conduct clinical trials of our drug candidates, such as tirasemtiv, CK-2127107 and omecamtiv mecarbil, and related activities. We do not have control over many aspects of our CROs’ activities, and cannot fully control the amount, timing or quality of resources that they devote to our programs. CROs may not assign as high a priority to our programs or pursue them as diligently as we would if we were undertaking these programs ourselves. The activities conducted by our CROs therefore may not be completed on schedule or in a satisfactory manner. CROs may also give higher priority to relationships with our competitors and potential competitors than to their relationships with us. Outside of the United States, we are particularly dependent on our CROs’ expertise in communicating with clinical trial sites and regulatory authorities and ensuring that our clinical trials and related activities and regulatory filings comply with applicable laws. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">Our CROs’ failure to carry out development activities on our behalf as agreed and in accordance with our and the FDA’s or other regulatory agencies’ requirements and applicable U.S. and foreign laws, or our failure to properly coordinate and manage these activities, could increase the cost of our operations and delay or prevent the development, approval and commercialization of our drug candidates. For example, in June 2013, we learned from our data management vendor for our BENEFIT-ALS clinical trial that a programming error in the electronic data capture system controlling study drug assignment caused 58 patients initially randomized to and treated with tirasemtiv to receive placebo instead at a certain trial visit and for the remainder of the trial. In order to maintain the originally intended statistical power of the trial, we amended the protocol to permit enrollment of approximately 680 patients, or 180 patients in addition to the 500 patients allowed under the existing protocol. This protocol amendment resulted in additional costs and delays in conducting BENEFIT-ALS. In addition, if a CRO fails to perform as agreed, our ability to collect damages may be contractually limited. If we fail to effectively manage the CROs carrying out the development of our drug candidates or if our CROs fail to perform as agreed, the commercialization of our drug candidates will be delayed or prevented. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>We have no manufacturing capacity and depend on our strategic partners and contract manufacturers to produce our clinical trial materials, including our drug candidates, and anticipate continued reliance on contract manufacturers for the development and commercialization of our potential drugs. </I></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">We do not currently operate manufacturing facilities for clinical or commercial production of our drug candidates. We have limited experience in drug formulation and manufacturing, and we lack the resources and the capabilities to manufacture any of our drug candidates on a clinical or commercial scale. Amgen has assumed responsibility to conduct these activities for the ongoing development of omecamtiv mecarbil worldwide. Following our conduct of the early development of CK-2127107, including the planned Phase II clinical trial in patients with SMA, Astellas will assume primary responsibility to conduct the manufacturing for the ongoing development of CK-2127107 worldwide. For tirasemtiv, we rely on a limited number of contract manufacturers. In particular, we rely on single-source contract manufacturers for the active pharmaceutical ingredient and the </FONT></P> <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1"> </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">32 </FONT></P> <p Style='page-break-before:always'> <HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER"> <h5 align="left"><a href="#toc">Table of Contents</a></h5> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2"> drug product supply for our clinical trials, as well as other materials required to conduct our clinical trials. We expect to rely on contract manufacturers to supply all future drug candidates for which we conduct development, as well as other materials required to conduct our clinical trials. If any of our existing or future contract manufacturers fail to perform satisfactorily, it could delay development or regulatory approval of our drug candidates or commercialization of our drugs, producing additional losses and depriving us of potential product revenues. In addition, if a contract manufacturer fails to perform as agreed, our ability to collect damages may be contractually limited. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">Our drug candidates require precise high-quality manufacturing. The failure to achieve and maintain high manufacturing standards, including failure to detect or control anticipated or unanticipated manufacturing errors or the frequent occurrence of such errors, could result in patient injury or death, discontinuance or delay of ongoing or planned clinical trials, delays or failures in product testing or delivery, cost overruns, product recalls or withdrawals and other problems that could seriously hurt our business. Contract drug manufacturers often encounter difficulties involving production yields, quality control and quality assurance and shortages of qualified personnel. These manufacturers are subject to stringent regulatory requirements, including the FDA’s current good manufacturing practices regulations and similar foreign laws and standards. Each contract manufacturer must pass a pre-approval inspection before we can obtain marketing approval for any of our drug candidates and following approval will be subject to ongoing periodic unannounced inspections by the FDA, the U.S. Drug Enforcement Agency and other regulatory agencies, to ensure strict compliance with current good manufacturing practices and other applicable government regulations and corresponding foreign laws and standards. We seek to ensure that our contract manufacturers comply fully with all applicable regulations, laws and standards. However, we do not have control over our contract manufacturers’ compliance with these regulations, laws and standards. If one of our contract manufacturers fails to pass its pre-approval inspection or maintain ongoing compliance at any time, the production of our drug candidates could be interrupted, resulting in delays or discontinuance of our clinical trials, additional costs and potentially lost revenues. In addition, failure of any third party manufacturers or us to comply with applicable regulations, including pre-or post-approval inspections and the current good manufacturing practice requirements of the FDA or other comparable regulatory agencies, could result in sanctions being imposed on us. These sanctions could include fines, injunctions, civil penalties, failure of regulatory authorities to grant marketing approval of our products, delay, suspension or withdrawal of approvals, license revocation, product seizures or recalls, operational restrictions and criminal prosecutions, any of which could significantly and adversely affect our business. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">In addition, our existing and future contract manufacturers may not perform as agreed or may not remain in the contract manufacturing business for the time required to successfully produce, store and distribute our drug candidates. If a natural disaster, business failure, strike or other difficulty occurs, we may be unable to replace these contract manufacturers in a timely or cost-effective manner and the production of our drug candidates would be interrupted, resulting in delays and additional costs. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">Switching manufacturers or manufacturing sites would be difficult and time-consuming because the number of potential manufacturers is limited. In addition, before a drug from any replacement manufacturer or manufacturing site can be commercialized, the FDA and, in some cases, foreign regulatory agencies, must approve that site. These approvals would require regulatory testing and compliance inspections. A new manufacturer or manufacturing site also would have to be educated in, or develop substantially equivalent processes for, production of our drugs and drug candidates. It may be difficult or impossible to transfer certain elements of a manufacturing process to a new manufacturer or for us to find a replacement manufacturer on acceptable terms quickly, or at all, either of which would delay or prevent our ability to develop drug candidates and commercialize any resulting drugs. </FONT></P> <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1"> </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">33 </FONT></P> <p Style='page-break-before:always'> <HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER"> <h5 align="left"><a href="#toc">Table of Contents</a></h5> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>We may not be able to successfully scale-up manufacturing of our drug candidates in sufficient quality and quantity, which would delay or prevent us from developing our drug candidates and commercializing resulting approved drugs, if any. </I></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">To date, our drug candidates have been manufactured in small quantities for preclinical studies and early and mid-stage clinical trials. In order to conduct larger scale or late-stage clinical trials for a drug candidate and for commercialization of the resulting drug if that drug candidate is approved for sale, we will need to manufacture it in larger quantities. We may not be able to successfully increase the manufacturing capacity for any of our drug candidates, whether in collaboration with third-party manufacturers or on our own, in a timely or cost-effective manner or at all. If a contract manufacturer makes improvements in the manufacturing process for our drug candidates, we may not own, or may have to share, the intellectual property rights to those improvements. Significant scale-up of manufacturing may require additional validation studies, which are costly and which regulatory authorities must review and approve. In addition, quality issues may arise during those scale-up activities because of the inherent properties of a drug candidate itself or of a drug candidate in combination with other components added during the manufacturing and packaging process, or during shipping and storage of the finished product or active pharmaceutical ingredients. If we are unable to successfully scale-up manufacture of any of our drug candidates in sufficient quality and quantity, the development of that drug candidate and regulatory approval or commercial launch for any resulting drugs may be delayed or there may be a shortage in supply, which could significantly harm our business. In addition, data demonstrating the stability of both drug substance and drug product using the commercial manufacturing process and at commercial scale are required for marketing applications. Failure to produce drug substance and drug products in a timely manner and obtain stability data could result in delay of submission of marketing applications. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>The mechanisms of action of our drug candidates are unproven, and we do not know whether we will be able to develop any drug of commercial value. </I></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">We have discovered and are currently developing drug candidates that have what we believe are novel mechanisms of action directed against cytoskeletal targets, and intend to continue to do so. Because no currently approved drugs appear to operate via the same biochemical mechanisms as our compounds, we cannot be certain that our drug candidates will result in commercially viable drugs that safely and effectively treat the indications for which we intend to develop them. The results we have seen for our compounds in preclinical models may not translate into similar results in humans, and results of early clinical trials in humans may not be predictive of the results of larger clinical trials that may later be conducted with our drug candidates. Even if we are successful in developing and receiving regulatory approval for a drug candidate for the treatment of a particular disease, we cannot be certain that it will be accepted by prescribers or be reimbursed by insurers or that we will also be able to develop and receive regulatory approval for that or other drug candidates for the treatment of other diseases. If we or our partners are unable to successfully develop and commercialize our drug candidates, our business will be materially harmed. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Our success depends substantially upon our ability to obtain and maintain intellectual property protection relating to our drug candidates, compounds and research technologies. </I></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">We own, or hold exclusive licenses to, a number of U.S. and foreign patents and patent applications directed to our drug candidates, compounds and research technologies. Our success depends on our ability to obtain patent protection both in the United States and in other countries for our drug candidates, their methods of manufacture and use, and our technologies. Our ability to protect our drug candidates, compounds and technologies from unauthorized or infringing use by third parties depends substantially on our ability to obtain and enforce our patents. If our issued patents and patent applications, if granted, do not adequately describe, enable or otherwise provide coverage of our technologies and drug candidates, including omecamtiv mecarbil, tirasemtiv and CK-2127107, we or our licensees would not be able to exclude others from developing or commercializing these drug candidates. Furthermore, the degree of future protection of our proprietary rights is uncertain because legal means may not adequately protect our rights or permit us to gain or keep our competitive advantage. </FONT></P> <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1"> </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">34 </FONT></P> <p Style='page-break-before:always'> <HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER"> <h5 align="left"><a href="#toc">Table of Contents</a></h5> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">Due to evolving legal standards relating to the patentability, validity and enforceability of patents covering pharmaceutical inventions and the claim scope of these patents, our ability to enforce our existing patents and to obtain and enforce patents that may issue from any pending or future patent applications is uncertain and involves complex legal, scientific and factual questions. The standards which the U.S. Patent and Trademark Office and its foreign counterparts use to grant patents are not always applied predictably or uniformly and are subject to change. To date, no consistent policy has emerged regarding the breadth of claims allowed in biotechnology and pharmaceutical patents. Thus, we cannot be sure that any patents will issue from any pending or future patent applications owned by or licensed to us. Even if patents do issue, we cannot be sure that the claims of these patents will be held valid or enforceable by a court of law, will provide us with any significant protection against competitive products, or will afford us a commercial advantage over competitive products. In particular: </FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px"> </P> <TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%"> <TR> <TD WIDTH="4%"><FONT SIZE="1"> </FONT></TD> <TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">•</FONT></TD> <TD WIDTH="1%" VALIGN="top"><FONT SIZE="1"> </FONT></TD> <TD ALIGN="left" VALIGN="top"> <P ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">we or our licensors might not have been the first to make the inventions covered by each of our pending patent applications and issued patents; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px"> </P> <TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%"> <TR> <TD WIDTH="4%"><FONT SIZE="1"> </FONT></TD> <TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">•</FONT></TD> <TD WIDTH="1%" VALIGN="top"><FONT SIZE="1"> </FONT></TD> <TD ALIGN="left" VALIGN="top"> <P ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">we or our licensors might not have been the first to file patent applications for the inventions covered by our pending patent applications and issued patents; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px"> </P> <TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%"> <TR> <TD WIDTH="4%"><FONT SIZE="1"> </FONT></TD> <TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">•</FONT></TD> <TD WIDTH="1%" VALIGN="top"><FONT SIZE="1"> </FONT></TD> <TD ALIGN="left" VALIGN="top"> <P ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">others may independently develop similar or alternative technologies or duplicate any of our technologies without infringing our intellectual property rights; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px"> </P> <TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%"> <TR> <TD WIDTH="4%"><FONT SIZE="1"> </FONT></TD> <TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">•</FONT></TD> <TD WIDTH="1%" VALIGN="top"><FONT SIZE="1"> </FONT></TD> <TD ALIGN="left" VALIGN="top"> <P ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">some or all of our or our licensors’ pending patent applications may not result in issued patents or the claims that issue may be narrow in scope and not provide us with competitive advantages; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px"> </P> <TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%"> <TR> <TD WIDTH="4%"><FONT SIZE="1"> </FONT></TD> <TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">•</FONT></TD> <TD WIDTH="1%" VALIGN="top"><FONT SIZE="1"> </FONT></TD> <TD ALIGN="left" VALIGN="top"> <P ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">our and our licensors’ issued patents may not provide a basis for commercially viable drugs or therapies or may be challenged and invalidated by third parties; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px"> </P> <TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%"> <TR> <TD WIDTH="4%"><FONT SIZE="1"> </FONT></TD> <TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">•</FONT></TD> <TD WIDTH="1%" VALIGN="top"><FONT SIZE="1"> </FONT></TD> <TD ALIGN="left" VALIGN="top"> <P ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">our or our licensors’ patent applications or patents may be subject to interference, opposition or similar administrative proceedings that may result in a reduction in their scope or their loss altogether; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px"> </P> <TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%"> <TR> <TD WIDTH="4%"><FONT SIZE="1"> </FONT></TD> <TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">•</FONT></TD> <TD WIDTH="1%" VALIGN="top"><FONT SIZE="1"> </FONT></TD> <TD ALIGN="left" VALIGN="top"> <P ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">we may not develop additional proprietary technologies or drug candidates that are patentable; or </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px"> </P> <TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%"> <TR> <TD WIDTH="4%"><FONT SIZE="1"> </FONT></TD> <TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">•</FONT></TD> <TD WIDTH="1%" VALIGN="top"><FONT SIZE="1"> </FONT></TD> <TD ALIGN="left" VALIGN="top"> <P ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">the patents of others may prevent us or our partners from discovering, developing or commercializing our drug candidates. </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">Patent protection is afforded on a country-by-country basis. Some foreign jurisdictions do not protect intellectual property rights to the same extent as in the United States. Many companies have encountered significant difficulties in protecting and defending intellectual property rights in foreign jurisdictions. Some of our development efforts are performed in countries outside of the United States through third party contractors. We may not be able to effectively monitor and assess intellectual property developed by these contractors. We therefore may not be able to effectively protect this intellectual property and could lose potentially valuable intellectual property rights. In addition, the legal protection afforded to inventors and owners of intellectual property in countries outside of the United States may not be as protective of intellectual property rights as in the United States. Therefore, we may be unable to acquire and protect intellectual property developed by these contractors to the same extent as if these development activities were being conducted in the United States. If we encounter difficulties in protecting our intellectual property rights in foreign jurisdictions, our business prospects could be substantially harmed. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">We rely on intellectual property assignment agreements with our corporate partners, employees, consultants, scientific advisors and other collaborators to grant us ownership of new intellectual property that is developed. These agreements may not result in the effective assignment to us of that intellectual property. As a result, our ownership of key intellectual property could be compromised. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">Changes in either the patent laws or their interpretation in the United States or other countries may diminish the value of our intellectual property or our ability to obtain patents. For example, the America Invents Act of 2011 may affect the scope, strength and enforceability of our patent rights in the United States or the nature of proceedings which may be brought by us related to our patent rights in the United States. </FONT></P> <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1"> </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">35 </FONT></P> <p Style='page-break-before:always'> <HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER"> <h5 align="left"><a href="#toc">Table of Contents</a></h5> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">If one or more products resulting from our drug candidates is approved for sale by the FDA and we do not have adequate intellectual property protection for those products, competitors could duplicate them for approval and sale in the United States without repeating the extensive testing required of us or our partners to obtain FDA approval. Regardless of any patent protection, under current law, an application for a generic version of a new chemical entity cannot be approved until at least five years after the FDA has approved the original product. When that period expires, or if that period is altered, the FDA could approve a generic version of our product regardless of our patent protection. An applicant for a generic version of our product may only be required to conduct a relatively inexpensive study to show that its product is bioequivalent to our product, and may not have to repeat the lengthy and expensive clinical trials that we or our partners conducted to demonstrate that the product is safe and effective. In the absence of adequate patent protection for our products in other countries, competitors may similarly be able to obtain regulatory approval in those countries of generic versions of our products. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">We also rely on trade secrets to protect our technology, particularly where we believe patent protection is not appropriate or obtainable. However, trade secrets are often difficult to protect, especially outside of the United States. While we endeavor to use reasonable efforts to protect our trade secrets, our or our partners’ employees, consultants, contractors or scientific and other advisors may unintentionally or willfully disclose our information to competitors. In addition, confidentiality agreements, if any, executed by those individuals may not be enforceable or provide meaningful protection for our trade secrets or other proprietary information in the event of unauthorized use or disclosure. Pursuing a claim that a third party had illegally obtained and was using our trade secrets would be expensive and time-consuming, and the outcome would be unpredictable. Even if we are able to maintain our trade secrets as confidential, if our competitors independently develop information equivalent or similar to our trade secrets, our business could be harmed. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">If we are not able to defend the patent or trade secret protection position of our technologies and drug candidates, then we will not be able to exclude competitors from developing or marketing competing drugs, and we may not generate enough revenue from product sales to justify the cost of development of our drugs or to achieve or maintain profitability. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>If we are sued for infringing third party intellectual property rights, it will be costly and time-consuming, and an unfavorable outcome could have a significant adverse effect on our business. </I></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">Our ability to commercialize drugs depends on our ability to use, manufacture and sell those drugs without infringing the patents or other proprietary rights of third parties. Numerous U.S. and foreign issued patents and pending patent applications owned by third parties exist in the therapeutic areas in which we are developing drug candidates and seeking new potential drug candidates. In addition, because patent applications can take several years to issue, there may be currently pending applications, unknown to us, which could later result in issued patents that our activities with our drug candidates could infringe. There may also be existing patents, unknown to us, that our activities with our drug candidates could infringe. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">Other future products of ours may be impacted by patents of companies engaged in competitive programs with significantly greater resources. Further development of these products could be impacted by these patents and result in significant legal fees. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">If a third party claims that our actions infringe its patents or other proprietary rights, we could face a number of issues that could seriously harm our competitive position, including, but not limited to: </FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px"> </P> <TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%"> <TR> <TD WIDTH="4%"><FONT SIZE="1"> </FONT></TD> <TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">•</FONT></TD> <TD WIDTH="1%" VALIGN="top"><FONT SIZE="1"> </FONT></TD> <TD ALIGN="left" VALIGN="top"> <P ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">infringement and other intellectual property claims that, even if meritless, can be costly and time-consuming to litigate, delay the regulatory approval process and divert management’s attention from our core business operations; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px"> </P> <TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%"> <TR> <TD WIDTH="4%"><FONT SIZE="1"> </FONT></TD> <TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">•</FONT></TD> <TD WIDTH="1%" VALIGN="top"><FONT SIZE="1"> </FONT></TD> <TD ALIGN="left" VALIGN="top"> <P ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">substantial damages for past infringement which we may have to pay if a court determines that our drugs or technologies infringe a third party’s patent or other proprietary rights; </FONT></P></TD></TR></TABLE> <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1"> </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">36 </FONT></P> <p Style='page-break-before:always'> <HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER"> <h5 align="left"><a href="#toc">Table of Contents</a></h5> <TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%"> <TR> <TD WIDTH="4%"><FONT SIZE="1"> </FONT></TD> <TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">•</FONT></TD> <TD WIDTH="1%" VALIGN="top"><FONT SIZE="1"> </FONT></TD> <TD ALIGN="left" VALIGN="top"> <P ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">a court prohibiting us from selling or licensing our drugs or technologies unless the holder licenses the patent or other proprietary rights to us, which it is not required to do; and </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px"> </P> <TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%"> <TR> <TD WIDTH="4%"><FONT SIZE="1"> </FONT></TD> <TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">•</FONT></TD> <TD WIDTH="1%" VALIGN="top"><FONT SIZE="1"> </FONT></TD> <TD ALIGN="left" VALIGN="top"> <P ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">if a license is available from a holder, we may have to pay substantial royalties or grant cross-licenses to our patents or other proprietary rights. </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">If any of these events occur, it could significantly harm our business and negatively affect our stock price. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>We may undertake infringement or other legal proceedings against third parties, causing us to spend substantial resources on litigation and exposing our own intellectual property portfolio to challenge. </I></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">Third parties may infringe our patents. To prevent infringement or unauthorized use, we may need to file infringement suits, which are expensive and time-consuming. In an infringement proceeding, a court may decide that one or more of our patents is invalid, unenforceable, or both. In this case, third parties may be able to use our technology without paying licensing fees or royalties. Even if the validity of our patents is upheld, a court may refuse to stop the other party from using the technology at issue on the ground that the other party’s activities are not covered by our patents. Policing unauthorized use of our intellectual property is difficult, and we may not be able to prevent misappropriation of our proprietary rights, particularly in countries where the laws may not protect such rights as fully as in the United States. In addition, third parties may affirmatively challenge our rights to, or the scope or validity of, our patent rights. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>We may become involved in disputes with our strategic partners over intellectual property ownership, and publications by our research collaborators and clinical investigators could impair our ability to obtain patent protection or protect our proprietary information, either of which would have a significant impact on our business. </I></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">Inventions discovered under our current or future strategic alliance agreements may become jointly owned by our strategic partners and us in some cases, and the exclusive property of one of us in other cases. Under some circumstances, it may be difficult to determine who owns a particular invention or whether it is jointly owned, and disputes could arise regarding ownership or use of those inventions. These disputes could be costly and time-consuming, and an unfavorable outcome could have a significant adverse effect on our business if we were not able to protect or license rights to these inventions. In addition, our research collaborators and clinical investigators generally have contractual rights to publish data arising from their work. Publications by our research collaborators and clinical investigators relating to our research and development programs, either with or without our consent, could benefit our current or potential competitors and may impair our ability to obtain patent protection or protect our proprietary information, which could significantly harm our business. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>We may be subject to claims that we or our employees have wrongfully used or disclosed trade secrets of their former employers. </I></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">Many of our employees were previously employed at universities or other biotechnology or pharmaceutical companies, including our competitors or potential competitors. Although no claims against us are currently pending, we may be subject to claims that these employees or we have inadvertently or otherwise used or disclosed trade secrets or other proprietary information of their former employers. Litigation may be necessary to defend against these claims. If we fail in defending these claims, in addition to paying monetary damages, we may lose valuable intellectual property rights or personnel. A loss of key research personnel or their work product could hamper or prevent our ability to develop and commercialize certain potential drugs, which could significantly harm our business. Even if we are successful in defending against these claims, litigation could result in substantial costs and distract management. </FONT></P> <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1"> </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">37 </FONT></P> <p Style='page-break-before:always'> <HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER"> <h5 align="left"><a href="#toc">Table of Contents</a></h5> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Our competitors may develop drugs that are less expensive, safer or more effective than ours, which may diminish or eliminate the commercial success of any drugs that we may commercialize. </I></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">We compete with companies that have developed drugs or are developing drug candidates for cardiovascular diseases, diseases and conditions associated with muscle weakness or wasting and other diseases for which our drug candidates may be useful treatments. For example, if tirasemtiv is approved for marketing by the FDA or other regulatory authorities for the treatment of ALS, it may then compete with other potential new therapies for ALS that are currently being developed by companies such as Neuraltus Pharmaceuticals, Inc., Isis Pharmaceuticals, Inc., Genervon Biopharmaceuticals, LLC, and GlaxoSmithKline plc. In addition, BrainStorm Cell Therapeutics and Neuralstem, Inc. are each conducting clinical development of stem cell therapies for the potential treatment of ALS. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">If CK-2127107 is approved by the FDA or other regulatory authorities for the potential treatment of SMA, potential competitors include Roche (in collaboration with PTC Therapeutics), AveXis, Inc., Pfizer Inc., Isis Pharmaceuticals, Inc., Trophos SA, and Bioblast Pharma, Ltd. Drugs that could compete with CK-2127107 could also compete against tirasemtiv in ALS or other neuromuscular diseases, should the appropriate clinical trials be conducted. If CK-2127107 is approved by the FDA for the potential treatment of non-neuromuscular indications associated with muscle weakness, potential competitors include Ligand Pharmaceuticals, Inc., which is developing LGD-4033, a selective androgen receptor modulator, for muscle wasting; and GTx, Inc., which is developing ostarine, a selective androgen receptor modulator, for cancer cachexia and potentially other indications; Regeneron Pharmaceuticals, Inc. (in collaboration with Sanofi), which is developing SAR391786, a monoclonal antibody targeted to GDF8, for sarcopenia; Eli Lilly & Company, which is developing LY2495655, a monoclonal antibody targeted to myostatin, for muscular atrophy after hip arthroplasty; Acceleron Pharma, which is developing ACE-083 for diseases such as inclusion body myositis and certain forms of muscular dystrophy; and Pfizer Inc., which is developing PF-06252616, a monoclonal antibody targeted to myostatin, in Duchenne muscular dystrophy. Novartis (in collaboration with Morphosys AG), is conducting clinical development with an activin type-IIB receptor antagonist, bimagrumab, to evaluate its ability to treat diseases involving the loss of muscle mass, strength and function. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">If omecamtiv mecarbil is approved for marketing by the FDA or other regulatory authorities for the treatment of heart failure, it would compete against other drugs used for the treatment of acute and chronic heart failure. These include generic drugs, such as milrinone, dobutamine or digoxin and branded drugs such as Natrecor (nesiritide) and Procoralan (ivabradine). Omecamtiv mecarbil could also potentially compete against other novel drug candidates and therapies in development, such as bucindolol, which is being developed by ARCA biopharma, Inc.; Reasanz (serelaxin) and LCZ-696, which are being developed by Novartis; cenderitide (CD-NP), which is being developed by Carpicor Therapeutics, Inc., TRV-027, which is being developed by Trevena; ularitide, which is being developed by Cardiorentis Ltd.; aladorian, which is being developed by ARMGO Pharma, Inc; TRV027, which is being developed by Trevena, Inc. in partnership with Forest Laboratories, Inc.; certain cardioprotectants which are being developed by Cardioxyl Pharmaceuticals, Inc.; glial growth factor (GGF-2) which is being developed by Acorda Therapeutics, Inc.; Neurocardin, which is being developed by Zensun Sci & Tech, Ltd; Mydicar, a genetically-targeted enzyme replacement therapy for advanced heart failure which is being developed by Celladon Corporation; and levosimendan, which was acquired for development by Oxygen Biotherapeutics, Inc. In addition, there are a number of medical devices being developed for the potential treatment of heart failure. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">Our competitors may: </FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px"> </P> <TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%"> <TR> <TD WIDTH="4%"><FONT SIZE="1"> </FONT></TD> <TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">•</FONT></TD> <TD WIDTH="1%" VALIGN="top"><FONT SIZE="1"> </FONT></TD> <TD ALIGN="left" VALIGN="top"> <P ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">develop drug candidates and market drugs that are less expensive or more effective than our future drugs; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px"> </P> <TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%"> <TR> <TD WIDTH="4%"><FONT SIZE="1"> </FONT></TD> <TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">•</FONT></TD> <TD WIDTH="1%" VALIGN="top"><FONT SIZE="1"> </FONT></TD> <TD ALIGN="left" VALIGN="top"> <P ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">commercialize competing drugs before we or our partners can launch any drugs developed from our drug candidates; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px"> </P> <TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%"> <TR> <TD WIDTH="4%"><FONT SIZE="1"> </FONT></TD> <TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">•</FONT></TD> <TD WIDTH="1%" VALIGN="top"><FONT SIZE="1"> </FONT></TD> <TD ALIGN="left" VALIGN="top"> <P ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">hold or obtain proprietary rights that could prevent us from commercializing our products; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px"> </P> <TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%"> <TR> <TD WIDTH="4%"><FONT SIZE="1"> </FONT></TD> <TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">•</FONT></TD> <TD WIDTH="1%" VALIGN="top"><FONT SIZE="1"> </FONT></TD> <TD ALIGN="left" VALIGN="top"> <P ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">initiate or withstand substantial price competition more successfully than we can; </FONT></P></TD></TR></TABLE> <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1"> </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">38 </FONT></P> <p Style='page-break-before:always'> <HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER"> <h5 align="left"><a href="#toc">Table of Contents</a></h5> <TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%"> <TR> <TD WIDTH="4%"><FONT SIZE="1"> </FONT></TD> <TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">•</FONT></TD> <TD WIDTH="1%" VALIGN="top"><FONT SIZE="1"> </FONT></TD> <TD ALIGN="left" VALIGN="top"> <P ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">more successfully recruit skilled scientific workers and management from the limited pool of available talent; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px"> </P> <TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%"> <TR> <TD WIDTH="4%"><FONT SIZE="1"> </FONT></TD> <TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">•</FONT></TD> <TD WIDTH="1%" VALIGN="top"><FONT SIZE="1"> </FONT></TD> <TD ALIGN="left" VALIGN="top"> <P ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">more effectively negotiate third-party licenses and strategic alliances; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px"> </P> <TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%"> <TR> <TD WIDTH="4%"><FONT SIZE="1"> </FONT></TD> <TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">•</FONT></TD> <TD WIDTH="1%" VALIGN="top"><FONT SIZE="1"> </FONT></TD> <TD ALIGN="left" VALIGN="top"> <P ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">take advantage of acquisition or other opportunities more readily than we can; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px"> </P> <TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%"> <TR> <TD WIDTH="4%"><FONT SIZE="1"> </FONT></TD> <TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">•</FONT></TD> <TD WIDTH="1%" VALIGN="top"><FONT SIZE="1"> </FONT></TD> <TD ALIGN="left" VALIGN="top"> <P ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">develop drug candidates and market drugs that increase the levels of safety or efficacy that our drug candidates will need to show in order to obtain regulatory approval; or </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px"> </P> <TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%"> <TR> <TD WIDTH="4%"><FONT SIZE="1"> </FONT></TD> <TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">•</FONT></TD> <TD WIDTH="1%" VALIGN="top"><FONT SIZE="1"> </FONT></TD> <TD ALIGN="left" VALIGN="top"> <P ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">introduce therapies or market drugs that render the market opportunity for our potential drugs obsolete. </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">We will compete for market share against large pharmaceutical and biotechnology companies and smaller companies that are collaborating with larger pharmaceutical companies, new companies, academic institutions, government agencies and other public and private research organizations. Many of these competitors, either alone or together with their partners, may develop new drug candidates that will compete with ours. Many of these competitors have larger research and development programs or substantially greater financial resources than we do. Our competitors may also have significantly greater experience in: </FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px"> </P> <TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%"> <TR> <TD WIDTH="4%"><FONT SIZE="1"> </FONT></TD> <TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">•</FONT></TD> <TD WIDTH="1%" VALIGN="top"><FONT SIZE="1"> </FONT></TD> <TD ALIGN="left" VALIGN="top"> <P ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">developing drug candidates; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px"> </P> <TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%"> <TR> <TD WIDTH="4%"><FONT SIZE="1"> </FONT></TD> <TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">•</FONT></TD> <TD WIDTH="1%" VALIGN="top"><FONT SIZE="1"> </FONT></TD> <TD ALIGN="left" VALIGN="top"> <P ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">undertaking preclinical testing and clinical trials; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px"> </P> <TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%"> <TR> <TD WIDTH="4%"><FONT SIZE="1"> </FONT></TD> <TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">•</FONT></TD> <TD WIDTH="1%" VALIGN="top"><FONT SIZE="1"> </FONT></TD> <TD ALIGN="left" VALIGN="top"> <P ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">building relationships with key customers and opinion-leading physicians; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px"> </P> <TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%"> <TR> <TD WIDTH="4%"><FONT SIZE="1"> </FONT></TD> <TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">•</FONT></TD> <TD WIDTH="1%" VALIGN="top"><FONT SIZE="1"> </FONT></TD> <TD ALIGN="left" VALIGN="top"> <P ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">obtaining and maintaining FDA and other regulatory approvals of drug candidates; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px"> </P> <TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%"> <TR> <TD WIDTH="4%"><FONT SIZE="1"> </FONT></TD> <TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">•</FONT></TD> <TD WIDTH="1%" VALIGN="top"><FONT SIZE="1"> </FONT></TD> <TD ALIGN="left" VALIGN="top"> <P ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">formulating and manufacturing drugs; and </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px"> </P> <TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%"> <TR> <TD WIDTH="4%"><FONT SIZE="1"> </FONT></TD> <TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">•</FONT></TD> <TD WIDTH="1%" VALIGN="top"><FONT SIZE="1"> </FONT></TD> <TD ALIGN="left" VALIGN="top"> <P ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">launching, marketing and selling drugs. </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">If our competitors market drugs that are less expensive, safer or more efficacious than our potential drugs, or that reach the market sooner than our potential drugs, we may not achieve commercial success. In addition, the life sciences industry is characterized by rapid technological change. If we fail to stay at the forefront of technological change, we may be unable to compete effectively. Our competitors may render our technologies obsolete by improving existing technological approaches or developing new or different approaches, potentially eliminating the advantages in our drug discovery process that we believe we derive from our research approach and proprietary technologies. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>We have been granted orphan designations in the U.S. and in the E.U. for tirasemtiv; however, there can be no guarantee that we will receive orphan approval for tirasemtiv nor that we will be able to prevent third parties from developing and commercializing products that are competitive to tirasemtiv. </I></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">We have been granted orphan drug designation in the U.S. by the FDA and orphan medicinal product designation by the European Medicines Agency, in each case for tirasemtiv for the potential treatment of ALS. In the U.S., upon approval from the FDA of an NDA, products granted orphan drug approval are generally provided with seven years of marketing exclusivity in the U.S., meaning the FDA will generally not approve applications for other product candidates for the same orphan indication that contain the same active ingredient. Even if we are the first to obtain approval of an orphan product and are granted exclusivity in the U.S., there are limited circumstances under which a later competitor product may be approved for the same indication during the seven-year period of marketing exclusivity, such as if the later product is shown to be clinically superior to our product or due to an inability to assure a sufficient quantity of the orphan drug. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">Orphan medicinal product status in Europe Union can provide up to 10 years of marketing exclusivity, meaning that another application for marketing authorization of a later similar medicinal product for the same therapeutic indication will generally not be approved in the European Union. Although we may have drug candidates that may obtain orphan drug exclusivity in Europe, the orphan approval and associated exclusivity </FONT></P> <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1"> </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">39 </FONT></P> <p Style='page-break-before:always'> <HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER"> <h5 align="left"><a href="#toc">Table of Contents</a></h5> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2"> period may be modified for several reasons, including a significant change to the orphan medicinal product designations or approval criteria after market authorization of the orphan product (<I>e.g</I>., product profitability exceeds the criteria for orphan drug designation), problems with the production or supply of the orphan drug or a competitor drug, although similar, is safer, more effective or otherwise clinically superior than the initial orphan drug. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">We are not guaranteed to maintain orphan status for tirasemtiv or to receive orphan status for tirasemtiv for any other indication or for any of our other drug candidates for any indication. If our drug candidates that are granted orphan status were to lose their status as orphan drugs or the marketing exclusivity provided for them in the U.S. or the European Union, our business and results of operations could be materially adversely affected. While orphan status for any of our products, if granted or maintained, would provide market exclusivity in the U.S. and the European Union for the time periods specified above, we would not be able to exclude other companies from manufacturing and/or selling products using the same active ingredient for the same indication beyond the exclusivity period applicable to our product on the basis of orphan drug status. Moreover, we cannot guarantee that another company will not receive approval before we do of an orphan drug application in the U.S. or the European Union for a product candidate that has the same active ingredient or is a similar medicinal product for the same indication as any of our drug candidates for which we plan to file for orphan designation and status. If that were to happen, our orphan drug applications for our drug candidate for that indication may not be approved until the competing company’s period of exclusivity has expired in the U.S. or the European Union, as applicable. Further, application of the orphan drug regulations in the U.S. and Europe is uncertain, and we cannot predict how the respective regulatory bodies will interpret and apply the regulations to our or our competitors’ products. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Our failure to attract and retain skilled personnel could impair our drug development and commercialization activities. </I></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">Our business depends on the performance of our senior management and key scientific and technical personnel. The loss of the services of any member of our senior management or key scientific or technical staff may significantly delay or prevent the achievement of drug development and other business objectives by diverting management’s attention to transition matters and identifying suitable replacements. We also rely on consultants and advisors to assist us in formulating our research and development strategy. All of our consultants and advisors are either self-employed or employed by other organizations, and they may have conflicts of interest or other commitments, such as consulting or advisory contracts with other organizations, that may affect their ability to contribute to us. In addition, if and as our business grows, we will need to recruit additional executive management and scientific and technical personnel. There is intense competition for skilled executives and employees with relevant scientific and technical expertise, and this competition is likely to continue. Our inability to attract and retain sufficient scientific, technical and managerial personnel could limit or delay our product development activities, which would adversely affect the development of our drug candidates and commercialization of our potential drugs and growth of our business. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Any future workforce and expense reductions may have an adverse impact on our internal programs and our ability to hire and retain skilled personnel. </I></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">Our future success will depend in large part upon our ability to attract and retain highly skilled personnel. In light of our continued need for funding and cost control, we may be required to implement future workforce and expense reductions, which could further limit our research and development activities. For example, in October 2011, we reduced our workforce by approximately 18% in order to reduce expenses and to focus resources primarily on our later-stage development programs for tirasemtiv and omecamtiv mecarbil and certain other research and development programs also directed to muscle biology. These headcount reductions and the cost control measures we have implemented may negatively affect our productivity and limit our research and development activities. We may have difficulty retaining and attracting such personnel as a result of a perceived risk of future workforce reductions. In addition, the implementation of any additional workforce or expense </FONT></P> <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1"> </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">40 </FONT></P> <p Style='page-break-before:always'> <HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER"> <h5 align="left"><a href="#toc">Table of Contents</a></h5> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2"> reduction programs may divert the efforts of our management team and other key employees, which could adversely affect our business. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>We may expand our development and clinical research capabilities and, as a result, we may encounter difficulties in managing our growth, which could disrupt our operations. </I></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">We may have growth in our expenditures, the number of our employees and the scope of our operations, in particular with respect to those drug candidates that we elect to develop or commercialize independently or together with a partner. To manage our anticipated future growth, we must continue to implement and improve our managerial, operational and financial systems, expand our facilities and continue to recruit and train additional qualified personnel. Due to our limited resources, we may not be able to effectively manage the expansion of our operations or recruit and train additional qualified personnel. The physical expansion of our operations may lead to significant costs and may divert our management and business development resources. Any inability to manage growth could delay the execution of our business plans or disrupt our operations. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>We currently have no sales or marketing capabilities and, if we are unable to enter into or maintain strategic alliances with marketing partners or to develop our own sales and marketing capabilities, we may not be successful in commercializing our potential drugs. </I></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">We currently have no sales, marketing or distribution capabilities. We plan to commercialize drugs that can be effectively marketed and sold in concentrated markets that do not require a large sales force to be competitive. To achieve this goal, we will need to establish our own specialized sales force and marketing organization with technical expertise and supporting distribution capabilities. Developing such an organization is expensive and time-consuming and could delay a product launch. In addition, we may not be able to develop this capacity efficiently, cost-effectively or at all, which could make us unable to commercialize our drugs. If we determine not to market our drugs on our own, we will depend on strategic alliances with third parties, such as Amgen and Astellas, which have established distribution systems and direct sales forces to commercialize them. If we are unable to enter into such arrangements on acceptable terms, we may not be able to successfully commercialize these drugs. To the extent that we are not successful in commercializing any drugs ourselves or through a strategic alliance, our product revenues and business will suffer and our stock price would decrease. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Our internal computer systems, or those of our CROs or other contractors or consultants, may fail or suffer security breaches, which could result in a material disruption of our drug development programs. </I></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">Despite the implementation of security measures, our internal computer systems and those of our CROs and other contractors and consultants are vulnerable to damage from computer viruses, unauthorized access, natural disasters, terrorism, war and telecommunication and electrical failures. While we have not experienced any such system failure, accident or security breach to date, if such an event were to occur and cause interruptions in our operations, it could result in a material disruption of our drug development programs. For example, the loss of clinical study data from completed or ongoing clinical studies for any of our drug candidates could result in delays in our regulatory approval efforts and significantly increase our costs to recover or reproduce the data. To the extent that any disruption or security breach were to result in a loss of or damage to our data or applications, or inappropriate disclosure of confidential or proprietary information, we could incur liability and the further development of our product candidates could be delayed. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Risks Related To Our Industry </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>The regulatory approval process is expensive, time-consuming and uncertain and may prevent our partners or us from obtaining approvals to commercialize some or all of our drug candidates. </I></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">The research, testing, manufacturing, selling and marketing of drugs are subject to extensive regulation by the FDA and other regulatory authorities in the United States and other countries, and regulations differ from </FONT></P> <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1"> </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">41 </FONT></P> <p Style='page-break-before:always'> <HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER"> <h5 align="left"><a href="#toc">Table of Contents</a></h5> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2"> country to country. Neither we nor our partners are permitted to market our potential drugs in the United States until we receive approval of a new drug application (“NDA”) from the FDA. Neither we nor our partners have received NDA or other marketing approval for any of our drug candidates. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">Obtaining NDA approval is a lengthy, expensive and uncertain process. In addition, failure to comply with FDA and other applicable foreign and U.S. regulatory requirements may subject us to administrative or judicially imposed sanctions. These include warning letters, civil and criminal penalties, injunctions, product seizure or detention, product recalls, total or partial suspension of production, and refusal to approve pending NDAs or supplements to approved NDAs. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">Regulatory approval of an NDA or NDA supplement is never guaranteed, and the approval process typically takes several years and is extremely expensive. The FDA and foreign regulatory agencies also have substantial discretion in the drug approval process, and the guidance and advice issued by such agencies is subject to change at any time. Despite the time and efforts exerted, failure can occur at any stage, and we may encounter problems that cause us to abandon clinical trials or to repeat or perform additional preclinical testing and clinical trials. The number and focus of preclinical studies and clinical trials that will be required for approval by the FDA and foreign regulatory agencies varies depending on the drug candidate, the disease or condition that the drug candidate is designed to address, and the regulations applicable to any particular drug candidate. In addition, the FDA may require that a proposed Risk Evaluation and Mitigation Strategy, also known as a REMS, be submitted as part of an NDA if the FDA determines that it is necessary to ensure that the benefits of the drug outweigh its risks. The FDA and foreign regulatory agencies can delay, limit or deny approval of a drug candidate for many reasons, including, but not limited to: </FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px"> </P> <TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%"> <TR> <TD WIDTH="4%"><FONT SIZE="1"> </FONT></TD> <TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">•</FONT></TD> <TD WIDTH="1%" VALIGN="top"><FONT SIZE="1"> </FONT></TD> <TD ALIGN="left" VALIGN="top"> <P ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">they might determine that a drug candidate is not safe or effective; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px"> </P> <TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%"> <TR> <TD WIDTH="4%"><FONT SIZE="1"> </FONT></TD> <TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">•</FONT></TD> <TD WIDTH="1%" VALIGN="top"><FONT SIZE="1"> </FONT></TD> <TD ALIGN="left" VALIGN="top"> <P ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">they might not find the data from nonclinical testing and clinical trials sufficient and could request that additional trials be performed; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px"> </P> <TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%"> <TR> <TD WIDTH="4%"><FONT SIZE="1"> </FONT></TD> <TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">•</FONT></TD> <TD WIDTH="1%" VALIGN="top"><FONT SIZE="1"> </FONT></TD> <TD ALIGN="left" VALIGN="top"> <P ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">they might not approve our, our partner’s or the contract manufacturer’s processes or facilities; or </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px"> </P> <TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%"> <TR> <TD WIDTH="4%"><FONT SIZE="1"> </FONT></TD> <TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">•</FONT></TD> <TD WIDTH="1%" VALIGN="top"><FONT SIZE="1"> </FONT></TD> <TD ALIGN="left" VALIGN="top"> <P ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">they might change their approval policies or adopt new regulations. </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">Even if we receive regulatory approval to manufacture and sell a drug in a particular regulatory jurisdiction, other jurisdictions’ regulatory authorities may not approve that drug for manufacture and sale. If we or our partners fail to receive and maintain regulatory approval for the sale of any drugs resulting from our drug candidates, it would significantly harm our business and negatively affect our stock price. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>If we or our partners receive regulatory approval for our drug candidates, we or they will be subject to ongoing obligations to and continued regulatory review by the FDA and foreign regulatory agencies, and may be subject to additional post-marketing obligations, all of which may result in significant expense and limit commercialization of our potential drugs. </I></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">Any regulatory approvals that we or our partners receive for our drug candidates may be subject to limitations on the indicated uses for which the drug may be marketed or require potentially costly post-marketing follow-up studies or compliance with a REMS. In addition, if the FDA or foreign regulatory agencies approves any of our drug candidates, the labeling, packaging, adverse event reporting, storage, advertising, promotion and record-keeping for the drug will be subject to extensive regulatory requirements. The subsequent discovery of previously unknown problems with the drug, including adverse events of unanticipated severity or frequency, or the discovery that adverse events or toxicities observed in preclinical research or clinical trials that were believed to be minor actually constitute much more serious problems, may result in restrictions on the marketing of the drug or withdrawal of the drug from the market. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">The FDA and foreign regulatory agencies may change their policies and additional government regulations may be enacted that could prevent or delay regulatory approval of our drug candidates. We cannot predict the </FONT></P> <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1"> </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">42 </FONT></P> <p Style='page-break-before:always'> <HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER"> <h5 align="left"><a href="#toc">Table of Contents</a></h5> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2"> likelihood, nature or extent of adverse government regulation that may arise from future legislation or administrative action, either in the United States or abroad. If we are not able to maintain regulatory compliance, we might not be permitted to market our drugs and our business would suffer. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>If physicians and patients do not accept our drugs, we may be unable to generate significant revenue, if any. </I></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">Even if our drug candidates obtain regulatory approval, the resulting drugs, if any, may not gain market acceptance among physicians, healthcare payors, patients and the medical community. Even if the clinical safety and efficacy of drugs developed from our drug candidates are established for purposes of approval, physicians may elect not to recommend these drugs for a variety of reasons including, but not limited to: </FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px"> </P> <TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%"> <TR> <TD WIDTH="4%"><FONT SIZE="1"> </FONT></TD> <TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">•</FONT></TD> <TD WIDTH="1%" VALIGN="top"><FONT SIZE="1"> </FONT></TD> <TD ALIGN="left" VALIGN="top"> <P ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">introduction of competitive drugs to the market; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px"> </P> <TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%"> <TR> <TD WIDTH="4%"><FONT SIZE="1"> </FONT></TD> <TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">•</FONT></TD> <TD WIDTH="1%" VALIGN="top"><FONT SIZE="1"> </FONT></TD> <TD ALIGN="left" VALIGN="top"> <P ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">clinical safety and efficacy of alternative drugs or treatments; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px"> </P> <TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%"> <TR> <TD WIDTH="4%"><FONT SIZE="1"> </FONT></TD> <TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">•</FONT></TD> <TD WIDTH="1%" VALIGN="top"><FONT SIZE="1"> </FONT></TD> <TD ALIGN="left" VALIGN="top"> <P ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">cost-effectiveness; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px"> </P> <TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%"> <TR> <TD WIDTH="4%"><FONT SIZE="1"> </FONT></TD> <TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">•</FONT></TD> <TD WIDTH="1%" VALIGN="top"><FONT SIZE="1"> </FONT></TD> <TD ALIGN="left" VALIGN="top"> <P ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">availability of coverage and reimbursement from health maintenance organizations and other third-party payors; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px"> </P> <TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%"> <TR> <TD WIDTH="4%"><FONT SIZE="1"> </FONT></TD> <TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">•</FONT></TD> <TD WIDTH="1%" VALIGN="top"><FONT SIZE="1"> </FONT></TD> <TD ALIGN="left" VALIGN="top"> <P ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">convenience and ease of administration; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px"> </P> <TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%"> <TR> <TD WIDTH="4%"><FONT SIZE="1"> </FONT></TD> <TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">•</FONT></TD> <TD WIDTH="1%" VALIGN="top"><FONT SIZE="1"> </FONT></TD> <TD ALIGN="left" VALIGN="top"> <P ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">prevalence and severity of adverse events; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px"> </P> <TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%"> <TR> <TD WIDTH="4%"><FONT SIZE="1"> </FONT></TD> <TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">•</FONT></TD> <TD WIDTH="1%" VALIGN="top"><FONT SIZE="1"> </FONT></TD> <TD ALIGN="left" VALIGN="top"> <P ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">other potential disadvantages relative to alternative treatment methods; or </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px"> </P> <TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%"> <TR> <TD WIDTH="4%"><FONT SIZE="1"> </FONT></TD> <TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">•</FONT></TD> <TD WIDTH="1%" VALIGN="top"><FONT SIZE="1"> </FONT></TD> <TD ALIGN="left" VALIGN="top"> <P ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">insufficient marketing and distribution support. </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">If our drugs fail to achieve market acceptance, we may not be able to generate significant revenue and our business would suffer. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>The coverage and reimbursement status of newly approved drugs is uncertain and failure to obtain adequate coverage and reimbursement could limit our ability to market any drugs we may develop and decrease our ability to generate revenue. </I></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">Even if one or more of our drug candidates is approved for sale, the commercial success of our drugs in both domestic and international markets will be substantially dependent on whether third-party coverage and reimbursement is available for our drugs by the medical profession for use by their patients, which is highly uncertain. Medicare, Medicaid, health maintenance organizations and other third-party payors are increasingly attempting to contain healthcare costs by limiting both coverage and the level of reimbursement of new drugs. As a result, they may not cover or provide adequate payment for our drugs. They may not view our drugs as cost-effective and reimbursement may not be available to consumers or may be insufficient to allow our drugs to be marketed on a competitive basis. If we are unable to obtain adequate coverage and reimbursement for our drugs, our ability to generate revenue will be adversely affected. Likewise, current and future legislative or regulatory efforts to control or reduce healthcare costs or reform government healthcare programs, such as the Patient Protection Affordable Care Act and the Health Care and Education Reconciliation Act of 2010, could result in lower prices or rejection of coverage and reimbursement for our potential drugs. Changes in coverage and reimbursement policies or healthcare cost containment initiatives that limit or restrict reimbursement for any of our drug candidates that are approved could cause our potential future revenues to decline. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>We may be subject to costly product liability or other liability claims and may not be able to obtain adequate insurance. </I></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">The use of our drug candidates in clinical trials may result in adverse events. We cannot predict all the possible harms or adverse events that may result from our clinical trials. We currently maintain limited product </FONT></P> <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1"> </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">43 </FONT></P> <p Style='page-break-before:always'> <HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER"> <h5 align="left"><a href="#toc">Table of Contents</a></h5> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2"> liability insurance. We may not have sufficient resources to pay for any liabilities resulting from a personal injury or other claim excluded from, or beyond the limit of, our insurance coverage. Our insurance does not cover third parties’ negligence or malpractice, and our clinical investigators and sites may have inadequate insurance or none at all. In addition, in order to conduct clinical trials or otherwise carry out our business, we may have to contractually assume liabilities for which we may not be insured. If we are unable to look to our own or a third party’s insurance to pay claims against us, we may have to pay any arising costs and damages ourselves, which may be substantial. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">In addition, if we commercially launch drugs based on our drug candidates, we will face even greater exposure to product liability claims. This risk exists even with respect to those drugs that are approved for commercial sale by the FDA and foreign regulatory agencies and manufactured in licensed and regulated facilities. We intend to secure additional limited product liability insurance coverage for drugs that we commercialize, but may not be able to obtain such insurance on acceptable terms with adequate coverage, or at reasonable costs. Even if we are ultimately successful in product liability litigation, the litigation would consume substantial amounts of our financial and managerial resources and may create adverse publicity, all of which would impair our ability to generate sales of the affected product and our other potential drugs. Moreover, product recalls may be issued at our discretion or at the direction of the FDA and foreign regulatory agencies, other governmental agencies or other companies having regulatory control for drug sales. Product recalls are generally expensive and often have an adverse effect on the reputation of the drugs being recalled and of the drug’s developer or manufacturer. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">We may be required to indemnify third parties against damages and other liabilities arising out of our development, commercialization and other business activities, which could be costly and time-consuming and distract management. If third parties that have agreed to indemnify us against damages and other liabilities arising from their activities do not fulfill their obligations, then we may be held responsible for those damages and other liabilities. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Our relationships with customers, healthcare providers, clinical trial sites and professionals and third-party payors will be subject to applicable anti-kickback, fraud and abuse and other laws and regulations, which could expose us to criminal sanctions, civil penalties, contractual damages, reputational harm and diminished profits and future earnings. </I></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">Healthcare providers, physicians and third-party payors play a primary role in the recommendation and prescription of any drug candidates for which we may obtain marketing approval. Our arrangements with customers, healthcare providers and professionals and third-party payors may expose us to broadly applicable fraud and abuse and other healthcare laws and regulations that may constrain the business or financial arrangements and relationships through which we develop, and may market, sell and distribute, our products for which we obtain marketing approval. Restrictions under applicable federal and state healthcare laws and regulations, include, but are not limited to, the following: </FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px"> </P> <TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%"> <TR> <TD WIDTH="4%"><FONT SIZE="1"> </FONT></TD> <TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">•</FONT></TD> <TD WIDTH="1%" VALIGN="top"><FONT SIZE="1"> </FONT></TD> <TD ALIGN="left" VALIGN="top"> <P ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">The federal healthcare anti-kickback statute prohibits, among other things, persons from knowingly and willfully soliciting, offering, receiving or providing remuneration, directly or indirectly, in cash or in kind, to induce or reward either the referral of an individual for, or the purchase, order or recommendation of, any good or service, for which payment may be made under federally funded healthcare programs such as Medicare and Medicaid. This statute has been broadly interpreted to apply to manufacturer arrangements with prescribers, purchasers and formulary managers, among others. Several other countries, including the United Kingdom, have enacted similar anti-kickback, fraud and abuse, and healthcare laws and regulations. </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px"> </P> <TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%"> <TR> <TD WIDTH="4%"><FONT SIZE="1"> </FONT></TD> <TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">•</FONT></TD> <TD WIDTH="1%" VALIGN="top"><FONT SIZE="1"> </FONT></TD> <TD ALIGN="left" VALIGN="top"> <P ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">The federal False Claims Act imposes civil penalties, including civil whistleblower or qui tam actions, against individuals or entities for knowingly presenting, or causing to be presented, to the federal government, claims for payment that are false or fraudulent or making a false statement to avoid, decrease or conceal an obligation to pay money to the federal government. The government and qui tam relators </FONT></P></TD></TR></TABLE> <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1"> </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">44 </FONT></P> <p Style='page-break-before:always'> <HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER"> <h5 align="left"><a href="#toc">Table of Contents</a></h5> <TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%"> <TR> <TD WIDTH="6%"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="top"> <P ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2"> have brought False Claims Act actions against pharmaceutical companies on the theory that their practices have caused false claims to be submitted to the government. There is also a separate false claims provision imposing criminal penalties. </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px"> </P> <TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%"> <TR> <TD WIDTH="4%"><FONT SIZE="1"> </FONT></TD> <TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">•</FONT></TD> <TD WIDTH="1%" VALIGN="top"><FONT SIZE="1"> </FONT></TD> <TD ALIGN="left" VALIGN="top"> <P ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">The federal Health Insurance Portability and Accountability Act of 1996, or HIPAA, as amended by the Health Information Technology for Economic and Clinical Health Act, imposes criminal and civil liability for executing a scheme to defraud any healthcare benefit program. HIPAA also imposes obligations, including mandatory contractual terms, with respect to safeguarding the privacy, security and transmission of individually identifiable health information. HIPAA also imposes criminal liability for knowingly and willfully falsifying, concealing or covering up a material fact or making any materially false statement in connection with the delivery of or payment for healthcare benefits, items or services. </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px"> </P> <TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%"> <TR> <TD WIDTH="4%"><FONT SIZE="1"> </FONT></TD> <TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">•</FONT></TD> <TD WIDTH="1%" VALIGN="top"><FONT SIZE="1"> </FONT></TD> <TD ALIGN="left" VALIGN="top"> <P ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">The federal Physician Sunshine Act requirements under the Patient Protection and Affordable Care Act of 2010, as amended by the Health Care and Education Reconciliation Act of 2010, referred to together as the Affordable Care Act, require manufacturers of drugs, devices, biologics and medical supplies to report to the Department of Health and Human Services information related to payments and other transfers of value made to or at the request of covered recipients, such as physicians and teaching hospitals, and physician ownership and investment interests in such manufacturers. Payments made to physicians and research institutions for clinical trials are included within the ambit of this law. </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px"> </P> <TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%"> <TR> <TD WIDTH="4%"><FONT SIZE="1"> </FONT></TD> <TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">•</FONT></TD> <TD WIDTH="1%" VALIGN="top"><FONT SIZE="1"> </FONT></TD> <TD ALIGN="left" VALIGN="top"> <P ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">Analogous state laws and regulations, such as state anti-kickback and false claims laws, may apply to sales or marketing arrangements and claims involving healthcare items or services reimbursed by non-governmental third-party payors, including private insurers, and some state laws require pharmaceutical companies to comply with the pharmaceutical industry’s voluntary compliance guidelines and the relevant compliance guidance promulgated by the federal government in addition to requiring drug manufacturers to report information related to payments to physicians and other health care providers or marketing expenditures. </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">Efforts to ensure that our business arrangements with third parties will comply with applicable healthcare laws and regulations will involve substantial costs. It is possible that governmental authorities will conclude that our business practices may not comply with current or future statutes, regulations or case law involving applicable fraud and abuse or other healthcare laws and regulations. If our operations are found to be in violation of any of these laws or any other governmental regulations that may apply to us, we may be subject to significant civil, criminal and administrative penalties, damages, fines, exclusion from government funded healthcare programs, such as Medicare and Medicaid, and the curtailment or restructuring of our operations. Exclusion, suspension and debarment from government funded healthcare programs would significantly impact our ability to commercialize, sell or distribute any drug. If any of the physicians or other providers or entities with whom we expect to do business are found to be not in compliance with applicable laws, they may be subject to criminal, civil or administrative sanctions, including exclusions from government funded healthcare programs. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">In addition, health care providers in the United States, including research institutions from which we or our partners obtain patient information, are subject to privacy rules under HIPAA and state and local privacy laws. In the European Union, these entities are subject to the Directive 95/46-EC of the European Parliament on the protection of individuals with regard to the processing of personal data and individual European Union member states implementing additional legislation. Other countries have similar privacy legislation. We could face substantial penalties if we knowingly receive individually identifiable health information from a health care provider that has not satisfied the applicable privacy laws. In addition, certain privacy laws and genetic testing laws may apply directly to our operations and/or those of our partners and may impose restrictions on the use and dissemination of individuals’ health information and use of biological samples. </FONT></P> <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1"> </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">45 </FONT></P> <p Style='page-break-before:always'> <HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER"> <h5 align="left"><a href="#toc">Table of Contents</a></h5> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Responding to any claims relating to improper handling, storage or disposal of the hazardous chemicals and radioactive and biological materials we use in our business could be time-consuming and costly. </I></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">Our research and development processes involve the controlled use of hazardous materials, including chemicals and radioactive and biological materials. Our operations produce hazardous waste products. We cannot eliminate the risk of accidental contamination or discharge and any resultant injury from those materials. Federal, state and local laws and regulations govern the use, manufacture, storage, handling and disposal of hazardous materials. We may be sued for any injury or contamination that results from our or third parties’ use of these materials. Compliance with environmental laws and regulations is expensive, and current or future environmental regulations may impair our research, development and production activities. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Our facilities in California are located near an earthquake fault, and an earthquake or other types of natural disasters, catastrophic events or resource shortages could disrupt our operations and adversely affect our results. </I></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">All of our facilities and our important documents and records, such as hard copies of our laboratory books and records for our drug candidates and compounds and our electronic business records, are located in our corporate headquarters at a single location in South San Francisco, California near active earthquake zones. If a natural disaster, such as an earthquake or flood, a catastrophic event such as a disease pandemic or terrorist attack, or a localized extended outage of critical utilities or transportation systems occurs, we could experience a significant business interruption. Our partners and other third parties on which we rely may also be subject to business interruptions from such events. In addition, California from time to time has experienced shortages of water, electric power and natural gas. Future shortages and conservation measures could disrupt our operations and cause expense, thus adversely affecting our business and financial results. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Risks Related To an Investment in Our Securities </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>We expect that our stock price will fluctuate significantly, and you may not be able to resell your shares at or at or above your investment price. </I></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">The stock market, particularly in recent years, has experienced significant volatility, particularly with respect to pharmaceutical, biotechnology and other life sciences company stocks, which often does not relate to the operating performance of the companies represented by the stock. Factors that could cause volatility in the market price of our common stock include, but are not limited to: </FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px"> </P> <TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%"> <TR> <TD WIDTH="4%"><FONT SIZE="1"> </FONT></TD> <TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">•</FONT></TD> <TD WIDTH="1%" VALIGN="top"><FONT SIZE="1"> </FONT></TD> <TD ALIGN="left" VALIGN="top"> <P ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">announcements concerning any of the clinical trials for our drug candidates, such as tirasemtiv for the potential treatment of ALS, CK-2127107 for the potential treatment of SMA or other indications associated with muscle weakness and omecamtiv mecarbil for the potential treatment of heart failure (including, but not limited to, the timing of initiation or completion of such trials and the results of such trials, and delays or discontinuations of such trials, including delays resulting from slower than expected or suspended patient enrollment or discontinuations resulting from a failure to meet pre-defined clinical end points); </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px"> </P> <TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%"> <TR> <TD WIDTH="4%"><FONT SIZE="1"> </FONT></TD> <TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">•</FONT></TD> <TD WIDTH="1%" VALIGN="top"><FONT SIZE="1"> </FONT></TD> <TD ALIGN="left" VALIGN="top"> <P ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">announcements concerning our strategic alliance with Amgen or Astellas or future strategic alliances; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px"> </P> <TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%"> <TR> <TD WIDTH="4%"><FONT SIZE="1"> </FONT></TD> <TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">•</FONT></TD> <TD WIDTH="1%" VALIGN="top"><FONT SIZE="1"> </FONT></TD> <TD ALIGN="left" VALIGN="top"> <P ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">failure or delays in entering additional drug candidates into clinical trials; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px"> </P> <TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%"> <TR> <TD WIDTH="4%"><FONT SIZE="1"> </FONT></TD> <TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">•</FONT></TD> <TD WIDTH="1%" VALIGN="top"><FONT SIZE="1"> </FONT></TD> <TD ALIGN="left" VALIGN="top"> <P ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">failure or discontinuation of any of our research programs; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px"> </P> <TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%"> <TR> <TD WIDTH="4%"><FONT SIZE="1"> </FONT></TD> <TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">•</FONT></TD> <TD WIDTH="1%" VALIGN="top"><FONT SIZE="1"> </FONT></TD> <TD ALIGN="left" VALIGN="top"> <P ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">issuance of new or changed securities analysts’ reports or recommendations; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px"> </P> <TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%"> <TR> <TD WIDTH="4%"><FONT SIZE="1"> </FONT></TD> <TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">•</FONT></TD> <TD WIDTH="1%" VALIGN="top"><FONT SIZE="1"> </FONT></TD> <TD ALIGN="left" VALIGN="top"> <P ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">failure or delay in establishing new strategic alliances, or the terms of those alliances; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px"> </P> <TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%"> <TR> <TD WIDTH="4%"><FONT SIZE="1"> </FONT></TD> <TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">•</FONT></TD> <TD WIDTH="1%" VALIGN="top"><FONT SIZE="1"> </FONT></TD> <TD ALIGN="left" VALIGN="top"> <P ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">market conditions in the pharmaceutical, biotechnology and other healthcare-related sectors; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px"> </P> <TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%"> <TR> <TD WIDTH="4%"><FONT SIZE="1"> </FONT></TD> <TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">•</FONT></TD> <TD WIDTH="1%" VALIGN="top"><FONT SIZE="1"> </FONT></TD> <TD ALIGN="left" VALIGN="top"> <P ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">actual or anticipated fluctuations in our quarterly financial and operating results; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px"> </P> <TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%"> <TR> <TD WIDTH="4%"><FONT SIZE="1"> </FONT></TD> <TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">•</FONT></TD> <TD WIDTH="1%" VALIGN="top"><FONT SIZE="1"> </FONT></TD> <TD ALIGN="left" VALIGN="top"> <P ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">developments or disputes concerning our intellectual property or other proprietary rights; </FONT></P></TD></TR></TABLE> <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1"> </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">46 </FONT></P> <p Style='page-break-before:always'> <HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER"> <h5 align="left"><a href="#toc">Table of Contents</a></h5> <TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%"> <TR> <TD WIDTH="4%"><FONT SIZE="1"> </FONT></TD> <TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">•</FONT></TD> <TD WIDTH="1%" VALIGN="top"><FONT SIZE="1"> </FONT></TD> <TD ALIGN="left" VALIGN="top"> <P ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">introduction of technological innovations or new products by us or our competitors; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px"> </P> <TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%"> <TR> <TD WIDTH="4%"><FONT SIZE="1"> </FONT></TD> <TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">•</FONT></TD> <TD WIDTH="1%" VALIGN="top"><FONT SIZE="1"> </FONT></TD> <TD ALIGN="left" VALIGN="top"> <P ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">issues in manufacturing our drug candidates or drugs; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px"> </P> <TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%"> <TR> <TD WIDTH="4%"><FONT SIZE="1"> </FONT></TD> <TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">•</FONT></TD> <TD WIDTH="1%" VALIGN="top"><FONT SIZE="1"> </FONT></TD> <TD ALIGN="left" VALIGN="top"> <P ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">market acceptance of our drugs; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px"> </P> <TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%"> <TR> <TD WIDTH="4%"><FONT SIZE="1"> </FONT></TD> <TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">•</FONT></TD> <TD WIDTH="1%" VALIGN="top"><FONT SIZE="1"> </FONT></TD> <TD ALIGN="left" VALIGN="top"> <P ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">third-party healthcare coverage and reimbursement policies; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px"> </P> <TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%"> <TR> <TD WIDTH="4%"><FONT SIZE="1"> </FONT></TD> <TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">•</FONT></TD> <TD WIDTH="1%" VALIGN="top"><FONT SIZE="1"> </FONT></TD> <TD ALIGN="left" VALIGN="top"> <P ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">FDA or other U.S. or foreign regulatory actions affecting us or our industry; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px"> </P> <TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%"> <TR> <TD WIDTH="4%"><FONT SIZE="1"> </FONT></TD> <TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">•</FONT></TD> <TD WIDTH="1%" VALIGN="top"><FONT SIZE="1"> </FONT></TD> <TD ALIGN="left" VALIGN="top"> <P ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">litigation or public concern about the safety of our drug candidates or drugs; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px"> </P> <TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%"> <TR> <TD WIDTH="4%"><FONT SIZE="1"> </FONT></TD> <TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">•</FONT></TD> <TD WIDTH="1%" VALIGN="top"><FONT SIZE="1"> </FONT></TD> <TD ALIGN="left" VALIGN="top"> <P ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">additions or departures of key personnel; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px"> </P> <TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%"> <TR> <TD WIDTH="4%"><FONT SIZE="1"> </FONT></TD> <TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">•</FONT></TD> <TD WIDTH="1%" VALIGN="top"><FONT SIZE="1"> </FONT></TD> <TD ALIGN="left" VALIGN="top"> <P ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">substantial sales of our common stock by our existing stockholders, whether or not related to our performance; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px"> </P> <TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%"> <TR> <TD WIDTH="4%"><FONT SIZE="1"> </FONT></TD> <TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">•</FONT></TD> <TD WIDTH="1%" VALIGN="top"><FONT SIZE="1"> </FONT></TD> <TD ALIGN="left" VALIGN="top"> <P ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">automated trading activity by algorithmic and high-frequency trading programs; and </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px"> </P> <TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%"> <TR> <TD WIDTH="4%"><FONT SIZE="1"> </FONT></TD> <TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">•</FONT></TD> <TD WIDTH="1%" VALIGN="top"><FONT SIZE="1"> </FONT></TD> <TD ALIGN="left" VALIGN="top"> <P ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">volatility in the stock prices of other companies in our industry or in the stock market generally. </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">These and other external factors may cause the market price and demand for our common stock to fluctuate substantially, which may limit or prevent investors from readily selling their shares of common stock and may otherwise negatively affect the liquidity of our common stock. In addition, when the market price of a stock has been volatile, holders of that stock have instituted securities class action litigation against the company that issued the stock. If any of our stockholders brought a lawsuit against us, we could incur substantial costs defending the lawsuit. Such a lawsuit could also divert our management’s time and attention. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>If the ownership of our common stock continues to be highly concentrated, it may prevent you and other stockholders from influencing significant corporate decisions and may result in conflicts of interest that could cause our stock price to decline. </I></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">As of February 27, 2015, our executive officers, directors and their affiliates beneficially owned or controlled approximately 6.6% of the outstanding shares of our common stock (after giving effect to the exercise of all outstanding vested and unvested options, restricted stock units and warrants). Accordingly, these executive officers, directors and their affiliates, acting as a group, will have substantial influence over the outcome of corporate actions requiring stockholder approval, including the election of directors, any merger, consolidation or sale of all or substantially all of our assets or any other significant corporate transactions. These stockholders may also delay or prevent a change of control of us, even if such a change of control would benefit our other stockholders. The significant concentration of stock ownership may adversely affect the trading price of our common stock due to investors’ perception that conflicts of interest may exist or arise. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Volatility in the stock prices of other companies may contribute to volatility in our stock price. </I></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">The stock market in general, and the NASDAQ stock exchanges and the market for technology companies in particular, have experienced significant price and volume fluctuations that have often been unrelated or disproportionate to the operating performance of those companies. Further, there has been particular volatility in the market prices of securities of early stage and clinical stage life sciences companies. These broad market and industry factors may seriously harm the market price of our common stock, regardless of our operating performance. In the past, following periods of volatility in the market price of a company’s securities, securities class action litigation has often been instituted. A securities class action suit against us could result in substantial costs, potential liabilities and the diversion of management’s attention and resources, and could harm our reputation and business. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Our common stock is thinly traded and there may not be an active, liquid trading market for our common stock. </I></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">There is no guarantee that an active trading market for our common stock will be maintained on NASDAQ, or that the volume of trading will be sufficient to allow for timely trades. Investors may not be able to sell their </FONT></P> <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1"> </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">47 </FONT></P> <p Style='page-break-before:always'> <HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER"> <h5 align="left"><a href="#toc">Table of Contents</a></h5> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2"> shares quickly or at the latest market price if trading in our stock is not active or if trading volume is limited. In addition, if trading volume in our common stock is limited, trades of relatively small numbers of shares may have a disproportionate effect on the market price of our common stock. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Our stockholders will experience substantial additional dilution if outstanding options or warrants are exercised for common stock. </I></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">As of February 27, 2015, there were 6,691,096 shares of common stock issuable upon the exercise of warrants, having a weighted average exercise price of $6.05 per share, and 4,147,929 shares of common stock issuable upon the exercise of stock options outstanding, having a weighted average exercise price of $11.50 per share. The exercise of outstanding options or warrants for common stock would be substantially dilutive to the outstanding shares of common stock. Any dilution or potential dilution may cause our stockholders to sell their shares, which would contribute to a downward movement in the stock price of our common stock. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Ownership changes may limit our ability to use our net operating losses and tax credits in the future. </I></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">In general, under Section 382 of the Internal Revenue Code (“Section 382”), a corporation that undergoes an ‘ownership change’ is subject to limitations on its ability to utilize its pre-change net operating losses and tax credits to offset future taxable income. We have performed a Section 382 analysis and do not believe that we have experienced an ownership change since 2006. A portion of our existing net operating losses and tax credits are subject to limitations arising from previous ownership changes. Future changes in our stock ownership, some of which are outside of our control, could result in an ownership change under Section 382 and result in additional limitations. We intend to continue to monitor public filings made by third parties with the SEC to assess whether an ownership change under Section 382 has occurred. Our ability to accurately assess any such ownership change is limited by the timeliness and accuracy of these public filings. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Evolving regulation of corporate governance and public disclosure may result in additional expenses, use of resources and continuing uncertainty. </I></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">Changing laws, regulations and standards relating to corporate governance and public disclosure, including the Sarbanes-Oxley Act of 2002, the Dodd-Frank Wall Street Reform and Consumer Protection Act of 2010 and new SEC regulations and NASDAQ Stock Market LLC rules create uncertainty for public companies. We regularly evaluate and monitor developments with respect to new and proposed laws, regulations and standards. We cannot accurately predict or estimate the amount of the additional costs we may incur in connection with complying with such laws, regulations and standards or the timing of these costs. For example, compliance with the internal control requirements of Section 404 of the Sarbanes-Oxley Act has to date required us to commit significant resources to document and test the adequacy of our internal control over financial reporting. We can provide no assurance as to conclusions of management or by our independent registered public accounting firm with respect to the effectiveness of our internal control over financial reporting in the future. In addition, the SEC has adopted regulations that require us to file corporate financial statement information in an interactive data format known as XBRL. We may incur significant costs and need to invest considerable resources to remain in compliance with these regulations. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">These new or changed laws, regulations and standards are subject to varying interpretations, in many cases due to their lack of specificity, and, as a result, their application in practice may evolve over time as new guidance is provided by regulatory and governing bodies. This could result in continuing uncertainty regarding compliance matters and higher costs necessitated by ongoing revisions to disclosure and governance practices. We intend to maintain high standards of corporate governance and public disclosure. As a result, we intend to invest the resources necessary to comply with evolving laws, regulations and standards, and this investment may result in increased general and administrative expenses and a diversion of management time and attention from revenue-generating activities to compliance activities. If our efforts to comply with new or changed laws, regulations and standards differ from the activities intended by regulatory or governing bodies, due to </FONT></P> <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1"> </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">48 </FONT></P> <p Style='page-break-before:always'> <HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER"> <h5 align="left"><a href="#toc">Table of Contents</a></h5> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2"> ambiguities related to practice or otherwise, regulatory authorities may initiate legal proceedings against us, which could be costly and time-consuming, and our reputation and business may be harmed. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>We have never paid dividends on our capital stock, and we do not anticipate paying any cash dividends in the foreseeable future. </I></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">We have paid no cash dividends on any of our classes of capital stock to date and we currently intend to retain our future earnings, if any, to fund the development and growth of our businesses. In addition, the terms of existing or any future debts may preclude us from paying these dividends. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><A NAME="toc828167_4"></A>Item 1B. </B><B><I>Unresolved Staff Comments</I></B><B> </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">None. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><A NAME="toc828167_5"> </A>Item 2. </B><B><I>Properties</I></B><B> </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">Our facilities consist of approximately 81,587 square feet of research and office space. We lease 50,195 square feet located at 280 East Grand Avenue, and 31,392 square feet at 256 East Grand Avenue, in South San Francisco, California until 2018 with an option to renew the lease for an additional three years. We believe that these facilities are suitable and adequate for our current needs. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><A NAME="toc828167_6"></A>Item 3. </B><B><I>Legal Proceedings</I></B><B> </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">On December 1, 2014, we filed a lawsuit in the U.S. District Court for the Northern District of California, captioned Cytokinetics, Inc. v. Pharm-Olam International, Ltd., Case No. 3:14-cv-05256 (the “California Lawsuit”). This lawsuit alleges fraudulent inducement, breach of contract and negligence by Pharm-Olam International, Ltd. (“Pharm-Olam”) in connection with its performance as the data management vendor for the BENEFIT-ALS clinical trial. Under the agreement between Pharm-Olam and us, Pharm-Olam was obligated to provide a variety of services, including building and maintaining the electronic system for BENEFIT-ALS that combined the electronic data capture (“EDC”) for clinical data and the interactive web response system (“IWRS”) used for patient randomization and treatment assignments to either tirasemtiv or placebo. Pharm-Olam’s failure to conduct these services in accordance with the agreement, regulatory requirements and industry standards resulted in programming errors in the IWRS which caused delay of the trial and additional expenses. We are seeking monetary damages from Pharm-Olam. On January 23, 2015, Pharm-Olam filed a motion to dismiss the complaint, or in the alternative, to transfer the California Lawsuit to U.S. District Court for the Middle District of North Carolina. The hearing on that motion is currently set for March 20, 2015. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">On November 28, 2014, Pharm-Olam filed a lawsuit in the U.S. District Court for the Middle District of North Carolina, captioned Pharm-Olam International, Ltd. v. Cytokinetics, Inc. and Datatrak International, Inc., Civil Action No. 1:14-cv-01000 (the “North Carolina Lawsuit”). In this lawsuit, Pharm-Olam is seeking declaratory judgments that (1) the limitation of liability provisions in the agreement between Pharm-Olam and us are enforceable and limit Pharm-Olam’s liability for the claims asserted by us to the direct services fees, and (2) Pharm-Olam’s subcontractor, Datatrak International, Inc. (“Datatrak”), the provider of the core EDC and IWRS system for BENEFIT-ALS, must indemnify, defend and hold harmless Pharm-Olam for the claims asserted against it by Cytokinetics, pursuant to the indemnification provision in the agreement between Pharm-Olam and Datatrak. On December 17, 2014, we filed a motion to dismiss or transfer the North Carolina Lawsuit to the U.S. District Court for the Northern District of California based on lack of jurisdiction and improper venue. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><A NAME="toc828167_7"></A>Item 4. </B><B><I>Mine Safety Disclosures</I></B><B> </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">Not applicable. </FONT></P> <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1"> </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">49 </FONT></P> <p Style='page-break-before:always'> <HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER"> <h5 align="left"><a href="#toc">Table of Contents</a></h5> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><A NAME="toc828167_8"></A>PART II </B></FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px"> </P> <TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%"> <TR> <TD WIDTH="8%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><A NAME="toc828167_9"></A>Item 5.</B></FONT></TD> <TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B></B><B><I>Market for Registrant’s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities</I></B><B> </B></FONT></TD></TR></TABLE> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">Prior to our initial public offering on April 29, 2004, there was no public market for our common stock. Our common stock was quoted under the symbol “CYTK” on the NASDAQ Global Market from the date of our initial public offering through December 19, 2012, and has since been quoted on the NASDAQ Capital Market. The following table sets forth the high and low closing sales price per share of our common stock as reported on the NASDAQ Global Market or NASDAQ Capital Market, as applicable, for the periods indicated (as adjusted for the one-for-six reverse split of our common stock which became effective June 24, 2013). </FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px"> </P> <TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="92%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center"> <TR> <TD WIDTH="83%"></TD> <TD VALIGN="bottom" WIDTH="4%"></TD> <TD></TD> <TD></TD> <TD></TD> <TD VALIGN="bottom" WIDTH="4%"></TD> <TD></TD> <TD></TD> <TD></TD></TR> <TR> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Closing Sale Price</B></FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD></TR> <TR> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>High</B></FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Low</B></FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD></TR> <TR BGCOLOR="#cceeff"> <TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>2013:</B></FONT></P></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"></TD> <TD VALIGN="bottom"></TD> <TD VALIGN="bottom"></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"></TD> <TD VALIGN="bottom"></TD> <TD VALIGN="bottom"></TD></TR> <TR> <TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">First Quarter</FONT></P></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD> <TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">7.14</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD> <TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">4.02</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD></TR> <TR BGCOLOR="#cceeff"> <TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Second Quarter</FONT></P></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD> <TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">12.96</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD> <TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">6.42</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD></TR> <TR> <TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Third Quarter</FONT></P></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD> <TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">13.82</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD> <TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">7.57</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD></TR> <TR BGCOLOR="#cceeff"> <TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Fourth Quarter</FONT></P></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD> <TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">7.47</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD> <TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">6.01</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD></TR> <TR> <TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>2014:</B></FONT></P></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"></TD> <TD VALIGN="bottom"></TD> <TD VALIGN="bottom"></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"></TD> <TD VALIGN="bottom"></TD> <TD VALIGN="bottom"></TD></TR> <TR BGCOLOR="#cceeff"> <TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">First Quarter</FONT></P></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD> <TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">10.55</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD> <TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">6.72</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD></TR> <TR> <TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Second Quarter</FONT></P></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD> <TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">12.99</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD> <TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">4.01</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD></TR> <TR BGCOLOR="#cceeff"> <TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Third Quarter</FONT></P></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD> <TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">4.90</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD> <TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">3.52</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD></TR> <TR> <TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Fourth Quarter</FONT></P></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD> <TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">8.01</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD> <TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">3.07</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD></TR> </TABLE> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">On February 27, 2015, the last reported sale price for our common stock on the NASDAQ Capital Market was $7.71 per share. We currently expect to retain future earnings, if any, for use in the operation and expansion of our business and have not paid and do not in the foreseeable future anticipate paying any cash dividends. As of February 27, 2015, there were 72 holders of record of our common stock. </FONT></P> <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1"> </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">50 </FONT></P> <p Style='page-break-before:always'> <HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER"> <h5 align="left"><a href="#toc">Table of Contents</a></h5> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Equity Compensation Information </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">Information regarding our equity compensation plans and the securities authorized for issuance thereunder is set forth in Part III, Item 12. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Comparison of Historical Cumulative Total Return Among Cytokinetics, Incorporated, the NASDAQ Stock Market (U.S.) Index and the NASDAQ Biotechnology Index(*) </B></FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px"> </P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"> <IMG SRC="g828167g88o03.jpg" ALT="LOGO"> </P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px"> </P> <TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%"> <TR> <TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">(*)</FONT></TD> <TD ALIGN="left" VALIGN="top"> <P ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">The above graph shows the cumulative total stockholder return of an investment of $100 in cash from December 31, 2009 through December 31, 2014 for: (i) our common stock; (ii) the NASDAQ Stock Market (U.S.) Index; and (iii) the NASDAQ Biotechnology Index. All values assume reinvestment of the full amount of all dividends. Stockholder returns over the indicated period should not be considered indicative of future stockholder returns. </FONT></P></TD></TR></TABLE> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px"> </P> <TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center"> <TR> <TD WIDTH="52%"></TD> <TD VALIGN="bottom" WIDTH="2%"></TD> <TD></TD> <TD></TD> <TD></TD> <TD VALIGN="bottom" WIDTH="2%"></TD> <TD></TD> <TD></TD> <TD></TD> <TD VALIGN="bottom" WIDTH="2%"></TD> <TD></TD> <TD></TD> <TD></TD> <TD VALIGN="bottom" WIDTH="2%"></TD> <TD></TD> <TD></TD> <TD></TD> <TD VALIGN="bottom" WIDTH="2%"></TD> <TD></TD> <TD></TD> <TD></TD> <TD VALIGN="bottom" WIDTH="2%"></TD> <TD></TD> <TD></TD> <TD></TD></TR> <TR> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>12/31/09</B></FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>12/31/10</B></FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>12/31/11</B></FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>12/31/12</B></FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>12/31/13</B></FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>12/31/14</B></FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD></TR> <TR BGCOLOR="#cceeff"> <TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Cytokinetics, Incorporated</FONT></P></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD> <TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">100.00</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD> <TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">71.82</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD> <TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">32.99</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD> <TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">22.68</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD> <TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">37.23</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD> <TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">45.88</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD></TR> <TR> <TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">NASDAQ Composite Index</FONT></P></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD> <TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">100.00</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD> <TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">116.91</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD> <TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">114.81</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD> <TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">133.07</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD> <TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">184.06</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD> <TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">208.71</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD></TR> <TR BGCOLOR="#cceeff"> <TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">NASDAQ Biotechnology Index</FONT></P></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD> <TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">100.00</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD> <TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">115.01</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD> <TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">128.59</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD> <TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">169.61</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD> <TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">324.80</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD> <TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">376.68</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD></TR> </TABLE> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">The information contained under this caption “Comparison of Historical Cumulative Total Return Among Cytokinetics, Incorporated, the NASDAQ Stock Market (U.S.) Index and the NASDAQ Biotechnology Index” shall not be deemed to be soliciting material or to be filed with the SEC, nor shall such information be incorporated by reference into any future filing under the Securities Act or the Exchange Act, except to the extent that we specifically incorporate it by reference into such filing. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Sales of Unregistered Securities </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">On December 26, 2014, we sold 2,040,816 shares of our common stock at a price per share of $4.90 and an aggregate purchase price of $10.0 million to Astellas. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">We relied on the exemption from registration contained in Section 4(2) of the Securities Act, and Regulation D, Rule 506 thereunder, in connection with the issuance and sale of the common stock to Astellas. </FONT></P> <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1"> </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">51 </FONT></P> <p Style='page-break-before:always'> <HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER"> <h5 align="left"><a href="#toc">Table of Contents</a></h5> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><A NAME="toc828167_10"></A>Item 6. </B><B><I>Selected Financial Data</I></B><B> </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">The following selected financial data should be read in conjunction with Item 7, “Management’s Discussion and Analysis of Financial Condition and Results of Operations” and Item 8, “Financial Statements and Supplemental Data” of this report on Form 10-K. </FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px"> </P> <TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="92%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center"> <TR> <TD WIDTH="44%"></TD> <TD VALIGN="bottom" WIDTH="5%"></TD> <TD></TD> <TD></TD> <TD></TD> <TD VALIGN="bottom" WIDTH="4%"></TD> <TD></TD> <TD></TD> <TD></TD> <TD VALIGN="bottom" WIDTH="4%"></TD> <TD></TD> <TD></TD> <TD></TD> <TD VALIGN="bottom" WIDTH="4%"></TD> <TD></TD> <TD></TD> <TD></TD> <TD VALIGN="bottom" WIDTH="4%"></TD> <TD></TD> <TD></TD> <TD></TD></TR> <TR> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom" COLSPAN="18" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Year Ended December 31,</B></FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD></TR> <TR> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>2014</B></FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>2013</B></FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>2012</B></FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>2011</B></FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>2010</B></FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD></TR> <TR> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom" COLSPAN="18" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>(In thousands, except per share amounts)</B></FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD></TR> <TR BGCOLOR="#cceeff"> <TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Statement of Operations Data:</B></FONT></P></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"></TD> <TD VALIGN="bottom"></TD> <TD VALIGN="bottom"></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"></TD> <TD VALIGN="bottom"></TD> <TD VALIGN="bottom"></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"></TD> <TD VALIGN="bottom"></TD> <TD VALIGN="bottom"></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"></TD> <TD VALIGN="bottom"></TD> <TD VALIGN="bottom"></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"></TD> <TD VALIGN="bottom"></TD> <TD VALIGN="bottom"></TD></TR> <TR> <TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Revenues:</FONT></P></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"></TD> <TD VALIGN="bottom"></TD> <TD VALIGN="bottom"></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"></TD> <TD VALIGN="bottom"></TD> <TD VALIGN="bottom"></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"></TD> <TD VALIGN="bottom"></TD> <TD VALIGN="bottom"></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"></TD> <TD VALIGN="bottom"></TD> <TD VALIGN="bottom"></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"></TD> <TD VALIGN="bottom"></TD> <TD VALIGN="bottom"></TD></TR> <TR BGCOLOR="#cceeff"> <TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Research and development revenues from related parties(1)</FONT></P></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD> <TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">19,538</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD> <TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">2,019</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD> <TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">4,177</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD> <TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">2,054</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD> <TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1,487</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD></TR> <TR> <TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Research and development, grant and other revenues</FONT></P></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">17,566</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">7,547</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">3,382</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1,946</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1,090</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD></TR> <TR BGCOLOR="#cceeff"> <TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">License revenues from related parties(1)</FONT></P></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">—</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">17,230</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">—</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">—</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">—</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD></TR> <TR> <TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">License revenues</FONT></P></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">9,836</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">3,852</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">—</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">—</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">—</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD></TR> <TR STYLE="font-size:1px"> <TD VALIGN="bottom"></TD> <TD VALIGN="bottom"> </TD> <TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000"> </P></TD> <TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000"> </P></TD> <TD> </TD> <TD VALIGN="bottom"> </TD> <TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000"> </P></TD> <TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000"> </P></TD> <TD> </TD> <TD VALIGN="bottom"> </TD> <TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000"> </P></TD> <TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000"> </P></TD> <TD> </TD> <TD VALIGN="bottom"> </TD> <TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000"> </P></TD> <TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000"> </P></TD> <TD> </TD> <TD VALIGN="bottom"> </TD> <TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000"> </P></TD> <TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000"> </P></TD> <TD> </TD></TR> <TR BGCOLOR="#cceeff"> <TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Total revenues</FONT></P></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">46,940</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">30,648</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">7,559</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">4,000</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">2,577</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD></TR> <TR STYLE="font-size:1px"> <TD VALIGN="bottom"></TD> <TD VALIGN="bottom"> </TD> <TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000"> </P></TD> <TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000"> </P></TD> <TD> </TD> <TD VALIGN="bottom"> </TD> <TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000"> </P></TD> <TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000"> </P></TD> <TD> </TD> <TD VALIGN="bottom"> </TD> <TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000"> </P></TD> <TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000"> </P></TD> <TD> </TD> <TD VALIGN="bottom"> </TD> <TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000"> </P></TD> <TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000"> </P></TD> <TD> </TD> <TD VALIGN="bottom"> </TD> <TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000"> </P></TD> <TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000"> </P></TD> <TD> </TD></TR> <TR> <TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Operating expenses:</FONT></P></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"></TD> <TD VALIGN="bottom"></TD> <TD VALIGN="bottom"></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"></TD> <TD VALIGN="bottom"></TD> <TD VALIGN="bottom"></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"></TD> <TD VALIGN="bottom"></TD> <TD VALIGN="bottom"></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"></TD> <TD VALIGN="bottom"></TD> <TD VALIGN="bottom"></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"></TD> <TD VALIGN="bottom"></TD> <TD VALIGN="bottom"></TD></TR> <TR BGCOLOR="#cceeff"> <TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Research and development</FONT></P></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">44,426</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">49,450</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">35,643</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">37,182</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">38,013</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD></TR> <TR> <TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">General and administrative</FONT></P></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">17,268</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">15,092</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">12,429</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">13,590</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">14,199</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD></TR> <TR BGCOLOR="#cceeff"> <TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Restructuring charges (reversals)</FONT></P></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">—</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">—</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(56</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">) </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1,192</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">—</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD></TR> <TR STYLE="font-size:1px"> <TD VALIGN="bottom"></TD> <TD VALIGN="bottom"> </TD> <TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000"> </P></TD> <TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000"> </P></TD> <TD> </TD> <TD VALIGN="bottom"> </TD> <TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000"> </P></TD> <TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000"> </P></TD> <TD> </TD> <TD VALIGN="bottom"> </TD> <TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000"> </P></TD> <TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000"> </P></TD> <TD> </TD> <TD VALIGN="bottom"> </TD> <TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000"> </P></TD> <TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000"> </P></TD> <TD> </TD> <TD VALIGN="bottom"> </TD> <TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000"> </P></TD> <TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000"> </P></TD> <TD> </TD></TR> <TR> <TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Total operating expenses</FONT></P></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">61,694</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">64,542</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">48,016</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">51,964</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">52,212</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD></TR> <TR STYLE="font-size:1px"> <TD VALIGN="bottom"></TD> <TD VALIGN="bottom"> </TD> <TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000"> </P></TD> <TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000"> </P></TD> <TD> </TD> <TD VALIGN="bottom"> </TD> <TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000"> </P></TD> <TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000"> </P></TD> <TD> </TD> <TD VALIGN="bottom"> </TD> <TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000"> </P></TD> <TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000"> </P></TD> <TD> </TD> <TD VALIGN="bottom"> </TD> <TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000"> </P></TD> <TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000"> </P></TD> <TD> </TD> <TD VALIGN="bottom"> </TD> <TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000"> </P></TD> <TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000"> </P></TD> <TD> </TD></TR> <TR BGCOLOR="#cceeff"> <TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Operating income loss</FONT></P></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(14,754</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">) </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(33,894</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">) </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(40,457</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">) </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(47,964</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">) </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(49,635</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">) </FONT></TD></TR> <TR> <TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Interest and other, net</FONT></P></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">108</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">177</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">87</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">104</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">172</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD></TR> <TR STYLE="font-size:1px"> <TD VALIGN="bottom"></TD> <TD VALIGN="bottom"> </TD> <TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000"> </P></TD> <TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000"> </P></TD> <TD> </TD> <TD VALIGN="bottom"> </TD> <TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000"> </P></TD> <TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000"> </P></TD> <TD> </TD> <TD VALIGN="bottom"> </TD> <TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000"> </P></TD> <TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000"> </P></TD> <TD> </TD> <TD VALIGN="bottom"> </TD> <TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000"> </P></TD> <TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000"> </P></TD> <TD> </TD> <TD VALIGN="bottom"> </TD> <TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000"> </P></TD> <TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000"> </P></TD> <TD> </TD></TR> <TR BGCOLOR="#cceeff"> <TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Income (loss) before income taxes</FONT></P></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(14,646</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">) </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(33,717</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">) </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(40,370</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">) </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(47,860</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">) </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(49,463</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">) </FONT></TD></TR> <TR> <TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Income tax provision (benefit)</FONT></P></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">—</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">—</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">—</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">—</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(176</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">) </FONT></TD></TR> <TR STYLE="font-size:1px"> <TD VALIGN="bottom"></TD> <TD VALIGN="bottom"> </TD> <TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000"> </P></TD> <TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000"> </P></TD> <TD> </TD> <TD VALIGN="bottom"> </TD> <TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000"> </P></TD> <TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000"> </P></TD> <TD> </TD> <TD VALIGN="bottom"> </TD> <TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000"> </P></TD> <TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000"> </P></TD> <TD> </TD> <TD VALIGN="bottom"> </TD> <TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000"> </P></TD> <TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000"> </P></TD> <TD> </TD> <TD VALIGN="bottom"> </TD> <TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000"> </P></TD> <TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000"> </P></TD> <TD> </TD></TR> <TR BGCOLOR="#cceeff"> <TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Net loss</FONT></P></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(14,646</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">) </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(33,717</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">) </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(40,370</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">) </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(47,860</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">) </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(49,287</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">) </FONT></TD></TR> <TR> <TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Deemed dividend related to beneficial conversion feature of convertible preferred stock</FONT></P></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">—</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">—</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(1,307</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">) </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(2,857</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">) </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">—</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD></TR> <TR STYLE="font-size:1px"> <TD VALIGN="bottom"></TD> <TD VALIGN="bottom"> </TD> <TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000"> </P></TD> <TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000"> </P></TD> <TD> </TD> <TD VALIGN="bottom"> </TD> <TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000"> </P></TD> <TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000"> </P></TD> <TD> </TD> <TD VALIGN="bottom"> </TD> <TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000"> </P></TD> <TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000"> </P></TD> <TD> </TD> <TD VALIGN="bottom"> </TD> <TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000"> </P></TD> <TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000"> </P></TD> <TD> </TD> <TD VALIGN="bottom"> </TD> <TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000"> </P></TD> <TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000"> </P></TD> <TD> </TD></TR> <TR BGCOLOR="#cceeff"> <TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Net loss allocable to common stockholders:</FONT></P></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD> <TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(14,646</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">) </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD> <TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(33,717</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">) </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD> <TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(41,677</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">) </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD> <TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(50,717</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">) </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD> <TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(49,287</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">) </FONT></TD></TR> <TR STYLE="font-size:1px"> <TD VALIGN="bottom"></TD> <TD VALIGN="bottom"> </TD> <TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000"> </P></TD> <TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000"> </P></TD> <TD> </TD> <TD VALIGN="bottom"> </TD> <TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000"> </P></TD> <TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000"> </P></TD> <TD> </TD> <TD VALIGN="bottom"> </TD> <TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000"> </P></TD> <TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000"> </P></TD> <TD> </TD> <TD VALIGN="bottom"> </TD> <TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000"> </P></TD> <TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000"> </P></TD> <TD> </TD> <TD VALIGN="bottom"> </TD> <TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000"> </P></TD> <TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000"> </P></TD> <TD> </TD></TR> <TR> <TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Net loss per share allocable to common stockholders:(2)</FONT></P></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"></TD> <TD VALIGN="bottom"></TD> <TD VALIGN="bottom"></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"></TD> <TD VALIGN="bottom"></TD> <TD VALIGN="bottom"></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"></TD> <TD VALIGN="bottom"></TD> <TD VALIGN="bottom"></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"></TD> <TD VALIGN="bottom"></TD> <TD VALIGN="bottom"></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"></TD> <TD VALIGN="bottom"></TD> <TD VALIGN="bottom"></TD></TR> <TR BGCOLOR="#cceeff"> <TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Basic</FONT></P></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD> <TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(0.41</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">) </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD> <TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(1.24</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">) </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD> <TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(2.30</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">) </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD> <TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(4.30</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">) </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD> <TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(4.61</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">) </FONT></TD></TR> <TR STYLE="font-size:1px"> <TD VALIGN="bottom"></TD> <TD VALIGN="bottom"> </TD> <TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000"> </P></TD> <TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000"> </P></TD> <TD> </TD> <TD VALIGN="bottom"> </TD> <TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000"> </P></TD> <TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000"> </P></TD> <TD> </TD> <TD VALIGN="bottom"> </TD> <TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000"> </P></TD> <TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000"> </P></TD> <TD> </TD> <TD VALIGN="bottom"> </TD> <TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000"> </P></TD> <TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000"> </P></TD> <TD> </TD> <TD VALIGN="bottom"> </TD> <TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000"> </P></TD> <TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000"> </P></TD> <TD> </TD></TR> <TR> <TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Diluted</FONT></P></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD> <TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(0.41</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">) </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD> <TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(1.24</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">) </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD> <TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(2.30</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">) </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD> <TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(4.30</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">) </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD> <TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(4.61</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">) </FONT></TD></TR> <TR STYLE="font-size:1px"> <TD VALIGN="bottom"></TD> <TD VALIGN="bottom"> </TD> <TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000"> </P></TD> <TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000"> </P></TD> <TD> </TD> <TD VALIGN="bottom"> </TD> <TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000"> </P></TD> <TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000"> </P></TD> <TD> </TD> <TD VALIGN="bottom"> </TD> <TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000"> </P></TD> <TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000"> </P></TD> <TD> </TD> <TD VALIGN="bottom"> </TD> <TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000"> </P></TD> <TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000"> </P></TD> <TD> </TD> <TD VALIGN="bottom"> </TD> <TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000"> </P></TD> <TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000"> </P></TD> <TD> </TD></TR> <TR BGCOLOR="#cceeff"> <TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Weighted average shares used in computing net loss per share allocable to common stockholders:(3)</FONT></P></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"></TD> <TD VALIGN="bottom"></TD> <TD VALIGN="bottom"></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"></TD> <TD VALIGN="bottom"></TD> <TD VALIGN="bottom"></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"></TD> <TD VALIGN="bottom"></TD> <TD VALIGN="bottom"></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"></TD> <TD VALIGN="bottom"></TD> <TD VALIGN="bottom"></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"></TD> <TD VALIGN="bottom"></TD> <TD VALIGN="bottom"></TD></TR> <TR> <TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Basic</FONT></P></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">35,709</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">27,275</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">18,107</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">11,800</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">10,694</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD></TR> <TR STYLE="font-size:1px"> <TD VALIGN="bottom"></TD> <TD VALIGN="bottom"> </TD> <TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000"> </P></TD> <TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000"> </P></TD> <TD> </TD> <TD VALIGN="bottom"> </TD> <TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000"> </P></TD> <TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000"> </P></TD> <TD> </TD> <TD VALIGN="bottom"> </TD> <TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000"> </P></TD> <TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000"> </P></TD> <TD> </TD> <TD VALIGN="bottom"> </TD> <TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000"> </P></TD> <TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000"> </P></TD> <TD> </TD> <TD VALIGN="bottom"> </TD> <TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000"> </P></TD> <TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000"> </P></TD> <TD> </TD></TR> <TR BGCOLOR="#cceeff"> <TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Diluted</FONT></P></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">35,709</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">27,275</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">18,107</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">11,800</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">10,694</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD></TR> <TR STYLE="font-size:1px"> <TD VALIGN="bottom"></TD> <TD VALIGN="bottom"> </TD> <TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000"> </P></TD> <TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000"> </P></TD> <TD> </TD> <TD VALIGN="bottom"> </TD> <TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000"> </P></TD> <TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000"> </P></TD> <TD> </TD> <TD VALIGN="bottom"> </TD> <TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000"> </P></TD> <TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000"> </P></TD> <TD> </TD> <TD VALIGN="bottom"> </TD> <TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000"> </P></TD> <TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000"> </P></TD> <TD> </TD> <TD VALIGN="bottom"> </TD> <TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000"> </P></TD> <TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000"> </P></TD> <TD> </TD></TR> </TABLE> <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1"> </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">52 </FONT></P> <p Style='page-break-before:always'> <HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER"> <h5 align="left"><a href="#toc">Table of Contents</a></h5> <TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="92%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center"> <TR> <TD WIDTH="50%"></TD> <TD VALIGN="bottom" WIDTH="4%"></TD> <TD></TD> <TD></TD> <TD></TD> <TD VALIGN="bottom" WIDTH="4%"></TD> <TD></TD> <TD></TD> <TD></TD> <TD VALIGN="bottom" WIDTH="4%"></TD> <TD></TD> <TD></TD> <TD></TD> <TD VALIGN="bottom" WIDTH="4%"></TD> <TD></TD> <TD></TD> <TD></TD> <TD VALIGN="bottom" WIDTH="4%"></TD> <TD></TD> <TD></TD> <TD></TD></TR> <TR> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom" COLSPAN="18" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>As of December 31,</B></FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD></TR> <TR> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>2014</B></FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>2013</B></FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>2012</B></FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>2011</B></FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>2010</B></FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD></TR> <TR> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom" COLSPAN="18" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>(In thousands)</B></FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD></TR> <TR BGCOLOR="#cceeff"> <TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Balance Sheet Data:</B></FONT></P></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"></TD> <TD VALIGN="bottom"></TD> <TD VALIGN="bottom"></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"></TD> <TD VALIGN="bottom"></TD> <TD VALIGN="bottom"></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"></TD> <TD VALIGN="bottom"></TD> <TD VALIGN="bottom"></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"></TD> <TD VALIGN="bottom"></TD> <TD VALIGN="bottom"></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"></TD> <TD VALIGN="bottom"></TD> <TD VALIGN="bottom"></TD></TR> <TR> <TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Cash and cash equivalents, investments, auction rate securities (“ARS”) and investment put option related to ARS</FONT></P></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD> <TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">83,228</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD> <TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">80,230</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD> <TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">74,000</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD> <TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">49,023</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD> <TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">72,845</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD></TR> <TR BGCOLOR="#cceeff"> <TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Restricted cash</FONT></P></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">—</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">—</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">—</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">196</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">788</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD></TR> <TR> <TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Working capital</FONT></P></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">107,276</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">52,634</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">69,322</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">46,548</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">66,174</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD></TR> <TR BGCOLOR="#cceeff"> <TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Total assets</FONT></P></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">132,968</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">83,188</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">77,551</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">52,773</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">77,992</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD></TR> <TR> <TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Long-term portion of equipment financing lines</FONT></P></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">—</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">—</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">—</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">—</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">152</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD></TR> <TR BGCOLOR="#cceeff"> <TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Accumulated deficit</FONT></P></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(497,243</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">) </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(482,597</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">) </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(448,880</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">) </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(408,510</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">) </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(360,650</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">) </FONT></TD></TR> <TR> <TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Total stockholders’ equity(2)</FONT></P></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">92,064</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">54,442</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">70,085</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">48,178</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">70,516</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD></TR> </TABLE> <P STYLE="line-height:8px;margin-top:0px;margin-bottom:2px;border-bottom:0.5pt solid #000000;width:10%"> </P> <TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%"> <TR> <TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">(1)</FONT></TD> <TD ALIGN="left" VALIGN="top"> <P ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">Revenues from related parties consisted of revenues recognized under our research and development arrangements with related parties, including Amgen and Astellas. See Note 7, “Related Parties and Related Party Transactions” in the Notes to Consolidated Financial Statements for further details. </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px"> </P> <TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%"> <TR> <TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">(2)</FONT></TD> <TD ALIGN="left" VALIGN="top"> <P ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">On June 24, 2013, we effected a one-for-six reverse stock split of our common stock through an amendment to our amended and restated certificate of incorporation (the “COI Amendment”). As of the effective time of the reverse stock split, every six shares of our issued and outstanding common stock were converted into one issued and outstanding share of common stock, without any change in par value per share. The reverse stock split affected all shares of our common stock outstanding immediately prior to the effective time of the reverse stock split, as well as the number of shares of common stock available for issuance under equity incentive plans. In addition, the reverse stock split effected a reduction in the number of shares of common stock issuable upon the conversion of shares of preferred stock or upon the exercise of stock options or warrants outstanding immediately prior to the effectiveness of the reverse stock split. No fractional shares were issued as a result of the reverse stock split. Stockholders who would otherwise have been entitled to receive a fractional share received cash payments in lieu thereof. In addition, the COI Amendment reduced the number of authorized shares of common stock to 81.5 million. </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:6px;margin-bottom:0px; margin-left:4%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">All references to shares of common stock and per share data for all periods presented in the accompanying selected financial data have been adjusted to reflect the reverse stock split on a retroactive basis. </FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px"> </P> <TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%"> <TR> <TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">(3)</FONT></TD> <TD ALIGN="left" VALIGN="top"> <P ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">In 2010, we sold 889,970 shares of common stock to Kingsbridge Capital Limited pursuant to the 2007 committed equity financing facility for net proceeds of $14.0 million. In April 2011, we sold 883,333 shares of common stock, 8,070 shares of Series A convertible preferred stock and warrants to purchase 1,114,168 shares of common stock to Deerfield Private Design Fund II, L.P., Deerfield Private Design International II, L.P., Deerfield Special Situations Fund, L.P., and Deerfield Special Situations Fund International Limited for net proceeds of approximately $19.9 million. In the fourth quarter of 2011, we sold 429,868 shares of common stock through McNicoll, Lewis & Vlak LLC (“MLV”) for net proceeds of $2.4 million. In June 2012, we issued to various investors (i) 9,320,176 shares of common stock for a purchase price of $4.56 per share, (ii) 23,026 shares of Series B convertible preferred stock for a purchase price of $760.00 per share, and (iii) warrants to purchase 7,894,704 shares of common stock at an exercise price of $5.28 per share, for aggregate gross proceeds of approximately $60.0 million. In 2012, we sold 432,724 shares of common stock through MLV for net proceeds of $2.8 million. In June 2013, we sold 1,404,100 shares of common stock to Amgen at a price per share of $7.12 and an aggregate purchase price of $10.0 million, pursuant to the Amgen Agreement Amendment. In 2013, we sold 1,170,583 shares of common stock through MLV for net proceeds of $7.5 million. In January, 2014 we sold 364,103 shares of common stock through MLV for net proceeds of $2.4 million. In February 2014, we sold 5,031,250 shares of common stock through an underwritten public offering at a price per share of $8.00 and net proceeds of $37.5 million. In December 2014, we sold 2,040,816 shares of common stock to Astellas at a price per share of $4.90 and an </FONT></P></TD></TR></TABLE> <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1"> </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">53 </FONT></P> <p Style='page-break-before:always'> <HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER"> <h5 align="left"><a href="#toc">Table of Contents</a></h5> <TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%"> <TR> <TD WIDTH="4%"><FONT SIZE="1"> </FONT></TD> <TD ALIGN="left" VALIGN="top"> <P ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2"> aggregate purchase price of $10.0 million. See Note 12, “Stockholders’ Equity” in the Notes to Consolidated Financial Statements for further details. </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><A NAME="toc828167_11"></A>Item 7. </B><B><I>Management’s Discussion and Analysis of Financial Condition and Results of Operations</I></B><B> </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">This discussion and analysis should be read in conjunction with our financial statements and accompanying notes included elsewhere in this report. Operating results are not necessarily indicative of results that may occur in future periods. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Overview </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">We were incorporated in Delaware in August 1997 as Cytokinetics, Incorporated. We are a clinical-stage biopharmaceutical company focused on the discovery and development of novel small molecule therapeutics that modulate muscle function for the potential treatment of serious diseases and medical conditions. Our research and development activities relating to the biology of muscle function have evolved from our knowledge and expertise regarding the cytoskeleton, a complex biological infrastructure that plays a fundamental role within every human cell. Our most advanced research and development programs relate to the biology of muscle function and are directed to small molecule modulators of the contractility of skeletal or cardiac muscle. Our earlier-stage research is directed to other compounds with the potential to modulate muscle contractility and other muscle functions, such as growth, energetics and metabolism. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">Our drug candidates currently in clinical development are our skeletal muscle activators tirasemtiv and <FONT STYLE="white-space:nowrap">CK-2127107,</FONT> and our cardiac muscle activator omecamtiv mecarbil. Cytokinetics retains exclusive rights to tirasemtiv, which is being evaluated for the potential treatment of amyotrophic lateral sclerosis (“ALS”). <FONT STYLE="white-space:nowrap">CK-2127107</FONT> is being evaluated for the potential treatment of spinal muscle atrophy (“SMA”) and for potential use in other indications associated with muscle weakness under a strategic alliance with Astellas Pharma Inc. (“Astellas”) established in June 2013 and expanded in December 2014. Omecamtiv mecarbil is being evaluated for the potential treatment of heart failure under a strategic alliance with Amgen established in 2006. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Muscle Contractility Programs </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Skeletal Muscle Contractility Program </I></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">Tirasemtiv is the lead drug candidate from this program. We retain exclusive rights to tirasemtiv. We have conducted a Phase II clinical development program for tirasemtiv, and are planning to initiate a Phase III clinical development program for this drug candidate in patients with ALS. We are also developing another drug candidate from this program, CK-2127107, which has been evaluated in Phase I clinical trials in collaboration with Astellas for potential indications associated with muscle weakness. We are planning to conduct a Phase II clinical trial for CK-2127107 in patients with SMA. Tirasemtiv and CK-2127107 are structurally distinct and selective small molecules that activate the fast skeletal muscle troponin complex in the sarcomere by increasing its sensitivity to calcium, leading to an increase in skeletal muscle contractility. Each of tirasemtiv and CK-2127107 has demonstrated pharmacological activity in preclinical models and evidence of potentially clinically relevant pharmacodynamic effects in humans. We are evaluating other potential indications for which tirasemtiv and <FONT STYLE="white-space:nowrap">CK-2127107</FONT> may be useful. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I><U>Tirasemtiv</U></I>. Tirasemtiv, a fast skeletal troponin activator, is the lead drug candidate from our skeletal muscle contractility program. We have conducted three “evidence of effect” Phase IIa clinical trials of tirasemtiv. These evidence of effect clinical trials were randomized, double-blind, placebo-controlled, three-period cross-over studies of single doses of tirasemtiv administered to patients with impaired muscle function. These studies were intended to translate the mechanism of action of tirasemtiv into potentially clinically relevant pharmacodynamic effects. The first of these trials was conducted in patients with ALS, a chronic and progressive disease in which the motor neurons die, thus denervating skeletal muscles and causing them to atrophy. This leads to weakness, fatigue, and eventually complete paralysis and death, primarily from respiratory </FONT></P> <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1"> </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">54 </FONT></P> <p Style='page-break-before:always'> <HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER"> <h5 align="left"><a href="#toc">Table of Contents</a></h5> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2"> complications. The second of these trials was conducted in patients with myasthenia gravis, a chronic, autoimmune, neuromuscular disease which is the most common primary disorder of neuromuscular transmission. The third of these trials was conducted in patients with symptoms of claudication, which is pain or cramping in the leg muscles due to inadequate blood flow during exercise, associated with peripheral artery disease. Evidence of potentially clinically relevant pharmacodynamic effects was observed in each of these trials. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">In 2014, we completed BENEFIT-ALS (Blinded Evaluation of Neuromuscular Effects and Functional Improvement with Tirasemtiv in ALS), a Phase IIb clinical trial of tirasemtiv in patients with ALS. We believe the results from BENEFIT-ALS support advancement of tirasemtiv into Phase III clinical development. We are planning to initiate a Phase III clinical development program for this drug candidate in patients with ALS in the second quarter of 2015. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px; margin-left:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>Tirasemtiv Clinical Development </I></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2"><U>BENEFIT-ALS (Blinded Evaluation of Neuromuscular Effects and Functional Improvement with Tirasemtiv in ALS)</U>. In October 2012, we initiated BENEFIT-ALS, a Phase IIb, multi-national, double-blind, randomized, placebo-controlled, clinical trial designed to evaluate the safety, tolerability and efficacy of tirasemtiv in patients with ALS. BENEFIT-ALS enrolled patients in 73 centers in 8 countries. Patients enrolled in BENEFIT-ALS began treatment with open-label tirasemtiv at 125 mg twice daily. Patients who tolerated this open-label treatment for one week were randomized to receive 12 weeks of double-blind treatment with twice-daily oral ascending doses of tirasemtiv or placebo, beginning at 125 mg twice daily and increasing weekly up to 250 mg twice daily (or a dummy dose titration with placebo). Clinical assessments occurred every four weeks during double-blind treatment; patients also returned for follow-up evaluations at one and four weeks after their final dose of double-blind study medication. The primary efficacy analysis of BENEFIT-ALS compared the mean change from baseline in the ALS Functional Rating Scale in its revised form (ALSFRS-R), a clinically validated instrument designed to measure disease progression and changes in functional status, to the average of the scores obtained after 8 and 12 weeks of double-blind treatment on tirasemtiv versus placebo. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%;padding-bottom:0px; " ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">In April 2014, BENEFIT-ALS results were presented at the 66</FONT><FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">th</SUP></FONT><FONT STYLE="font-family:Times New Roman" SIZE="2"> Annual Meeting of the American Academy of Neurology. 711 patients were enrolled into the open-label phase of the trial; subsequently, 605 patients were randomized 1:1 to double-blind treatment with either tirasemtiv or placebo. BENEFIT-ALS did not achieve its primary efficacy endpoint, the mean change from baseline in the ALSFRS-R (-2.98 points in the tirasemtiv group versus -2.40 points in the placebo group; p = 0.11). Treatment with tirasemtiv resulted in a statistically significant and potentially clinically meaningful reduction in the decline of slow vital capacity (SVC), a measure of the strength of the skeletal muscles responsible for breathing. SVC has been shown to be an important predictor of disease progression and survival in prior trials of patients with ALS. At week 12, the decline in SVC from baseline was -3.12 for patients receiving tirasemtiv versus -8.66 for those receiving placebo (p < 0.0001). From week 0 to week 12, the slope of decline in SVC measured as percentage points per day was -0.0394 for patients receiving tirasemtiv versus -0.0905 for those receiving placebo (p = 0.0006). </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">The analyses of other pre-specified secondary efficacy endpoints in BENEFIT-ALS produced mixed results. The muscle strength mega-score, a measure of strength combining the data from several muscle groups in each patient, declined more slowly on tirasemtiv versus placebo. The difference in the rate of decline for sniff nasal inspiratory pressure (SNIP) was not statistically significant); however, SNIP decreased more on tirasemtiv compared with placebo in a statistically significant manner at 4 and 12 weeks. No differences in maximum voluntary ventilation and hand grip fatigue were observed on tirasemtiv versus placebo. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">Serious adverse events (SAEs) during double-blind treatment were more frequent on tirasemtiv than on placebo (9.0% vs. 5.4%). The most common SAE was respiratory failure which occurred in 1 patient on tirasemtiv and 3 patients on placebo. Confusional state and delirium occurred in 2 patients on tirasemtiv and no patients on placebo. More patients on tirasemtiv withdrew from the trial following randomization than on placebo (99 vs. 33 patients, respectively). Adverse events more common on tirasemtiv than on placebo (>10% difference) were dizziness, fatigue, and nausea. </FONT></P> <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1"> </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">55 </FONT></P> <p Style='page-break-before:always'> <HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER"> <h5 align="left"><a href="#toc">Table of Contents</a></h5> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">Throughout the remainder of 2014, we presented further results from BENEFIT-ALS. These results indicated that: </FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px"> </P> <TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%"> <TR> <TD WIDTH="4%"><FONT SIZE="1"> </FONT></TD> <TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">•</FONT></TD> <TD WIDTH="1%" VALIGN="top"><FONT SIZE="1"> </FONT></TD> <TD ALIGN="left" VALIGN="top"> <P ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">Differences in the decline in SVC on tirasemtiv versus placebo observed after 12 weeks of double-blind treatment were maintained for up to 4 weeks after discontinuation of treatment; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px"> </P> <TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%"> <TR> <TD WIDTH="4%"><FONT SIZE="1"> </FONT></TD> <TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">•</FONT></TD> <TD WIDTH="1%" VALIGN="top"><FONT SIZE="1"> </FONT></TD> <TD ALIGN="left" VALIGN="top"> <P ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">The reduced decline in SVC on tirasemtiv versus placebo was observed consistently across all subgroups of patients in BENEFIT-ALS that were examined; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px"> </P> <TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%"> <TR> <TD WIDTH="4%"><FONT SIZE="1"> </FONT></TD> <TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">•</FONT></TD> <TD WIDTH="1%" VALIGN="top"><FONT SIZE="1"> </FONT></TD> <TD ALIGN="left" VALIGN="top"> <P ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">The effects of tirasemtiv on SVC were observed at all doses studied and the concentration-response relationship was flat; and </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px"> </P> <TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%"> <TR> <TD WIDTH="4%"><FONT SIZE="1"> </FONT></TD> <TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">•</FONT></TD> <TD WIDTH="1%" VALIGN="top"><FONT SIZE="1"> </FONT></TD> <TD ALIGN="left" VALIGN="top"> <P ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">Riluzole did not increase plasma concentrations nor impact the tolerability of tirasemtiv. </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2"><U>Planned Phase III Clinical Development</U>: In October 2014, we announced that we had completed our review of results from BENEFIT-ALS and concluded that effects observed on SVC in patients treated with tirasemtiv were robust and potentially clinically meaningful. We have engaged with regulatory authorities in the U.S. and Europe regarding results from BENEFIT-ALS and plan to advance tirasemtiv into Phase III clinical development. While regulatory interactions are ongoing, we believe that current feedback from these regulatory authorities informs advancement of tirasemtiv to a Phase III clinical development program that is intended to potentially confirm and extend results from BENEFIT-ALS. Key clinical endpoints in the Phase III program will include measures of respiratory function after longer durations of treatment in patients with ALS, including effects on SVC. We have initiated non-clinical and clinical development planning activities for the Phase III program, and anticipate initiating the program in the second quarter of 2015. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>Tirasemtiv Strategic and Commercial Planning</I>. During 2014, we made preparations for the potential commercialization of tirasemtiv. These activities included interactions with manufacturers, and corporate development and commercial planning activities to support various scenarios. We expect to continue to engage extensively with ALS experts, both neuromuscular and pulmonary, and with payors, regulatory authorities and patient advocacy groups as we develop plans for the commercialization of tirasemtiv as a potential treatment for patients living with ALS. These commercialization plans will include market assessment and corporate development activities to support the launch of tirasemtiv in the U.S. and Europe, if appropriate. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">The clinical trials program for tirasemtiv may proceed for several years, and we will not be in a position to generate any revenues or material net cash flows from sales of this drug candidate until the program is successfully completed, regulatory approval is achieved, and the drug is commercialized. Tirasemtiv is at too early a stage of development for us to predict if or when this may occur. Our expenditures will increase if and as we move tirasemtiv into later stage development. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px; margin-left:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I><U>CK-2127107 and Other Skeletal Muscle Activators </U></I></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>Astellas Strategic Alliance</I>. CK-2127107 is being developed jointly by Cytokinetics and Astellas. In December 2014, we entered into an Amended and Restated License and Collaboration Agreement with Astellas (the “Amended Astellas Agreement”). This agreement superseded the License and Collaboration Agreement between Cytokinetics and Astellas of June 2013 (the “Original Astellas Agreement”). The Amended Astellas Agreement expanded the objective of the collaboration of advancing novel therapies for diseases and medical conditions associated with muscle weakness to include SMA and potentially other neuromuscular indications, in addition to the non-neuromuscular indications provided for in the Original Astellas Agreement. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">Under the Amended Astellas Agreement, we expanded the exclusive license previously granted Astellas under the Original Astellas Agreement to co-develop and commercialize CK-2127107 for potential application in non-neuromuscular indications worldwide to include certain neuromuscular indications as well. Concurrent with the expanded collaboration, the companies agreed to advance CK-2127107 into Phase II clinical development. Cytokinetics will conduct the initial Phase II clinical trial in patients with SMA. We anticipate initiating this trial </FONT></P> <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1"> </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">56 </FONT></P> <p Style='page-break-before:always'> <HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER"> <h5 align="left"><a href="#toc">Table of Contents</a></h5> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2"> in the second half of 2015. The development program may include other neuromuscular indications as the companies may agree. Cytokinetics and Astellas will jointly develop and may jointly commercialize <FONT STYLE="white-space:nowrap">CK-2127107</FONT> and other fast skeletal troponin activators in neuromuscular indications. Astellas will be responsible for the costs associated with the development of all collaboration products, including CK-2127107, subject to Cytokinetics’ option to co-fund certain development costs as described below. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">Under the Amended Astellas Agreement, the parties extended through 2016 their joint research program to identify next-generation skeletal muscle activators to be nominated as potential drug candidates. This research will be conducted at Astellas’ expense. Under the Amended Astellas Agreement, Astellas has exclusive rights to co-develop and commercialize CK-2127107 and other fast skeletal troponin activators in SMA and potentially other indications and other novel mechanism skeletal muscle activators in all indications, subject to certain Cytokinetics’ development and commercialization rights. Cytokinetics may co-promote and conduct certain commercial activities in the U.S., Canada and Europe under agreed scenarios. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">Cytokinetics retains an option to conduct early-stage development for certain agreed indications at its initial expense, subject to reimbursement if development continues under the collaboration. Under the Amended Astellas Agreement, Cytokinetics also retains an option to co-promote collaboration products containing fast skeletal muscle activators for neuromuscular indications in the U.S., Canada and Europe, in addition to its option to co-promote other collaboration products in the U.S. and Canada as provided for in the Original Astellas Agreement. Astellas will reimburse Cytokinetics for certain expenses associated with its co-promotion activities. The Amended Astellas Agreement also provides for Cytokinetics to lead certain activities relating to the commercialization of collaboration products for neuromuscular indications in the U.S., Canada and Europe under particular scenarios. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">Cytokinetics received an upfront payment of $30.0 million in connection with the execution of the Amended Astellas Agreement. Also, in conjunction with the execution of the Amended Astellas Agreement, we also entered into a common stock purchase agreement which provided for the sale of 2,040,816 shares of our common stock to Astellas at a price per share of $4.90 and an aggregate purchase price of $10.0 million, which was received in December 2014. Pursuant to this agreement, Astellas agreed to certain trading and other restrictions with respect to our common stock. Concurrently, Cytokinetics earned a $15.0 million milestone payment relating to Astellas’ decision to advance CK-2127107 into Phase II clinical development. Cytokinetics is also eligible to potentially receive over $20.0 million in reimbursement of sponsored research and development activities during the next two years of the collaboration. Based on the achievement of pre-specified criteria, Cytokinetics may receive over $600.0 million in milestone payments relating to the development and commercial launch of collaboration products, including up to $112.0 million (of which Cytokinetics has now received $17.0 million) relating to early development of CK-2127107 and for later-stage development and commercial launch milestones for CK-2127107 in non-neuromuscular indications, and over $100.0 million in development and commercial launch milestones for CK-2127107 in each of SMA and other neuromuscular indications. Cytokinetics may also receive up to $200.0 million in payments for achievement of pre-specified sales milestones related to net sales of all collaboration products under the Amended Astellas Agreement. If Astellas commercializes any collaboration products, Cytokinetics will also receive royalties on sales of such collaboration products, including royalties ranging from the high single digits to the high teens on sales of products containing CK-2127107. Cytokinetics also holds an option to co-fund certain development costs for CK-2127107 and other compounds in exchange for increased milestone payments and royalties; such royalties may increase under certain scenarios to exceed twenty percent. In addition to the foregoing development, commercial and sales milestones, Cytokinetics may also receive payments for the achievement of pre-specified milestones relating to the joint research program. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">Cytokinetics retains the exclusive right to develop and commercialize tirasemtiv for the potential treatment of ALS and certain other neuromuscular disorders independently from the Amended Astellas Agreement. </FONT></P> <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1"> </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">57 </FONT></P> <p Style='page-break-before:always'> <HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER"> <h5 align="left"><a href="#toc">Table of Contents</a></h5> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>CK-2127107 Clinical Development </I></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2"><U>Phase I Clinical Trials Program</U>: In October 2014, we announced the completion of five Phase I clinical trials evaluating CK-2127107 in healthy volunteers, and certain other Phase II readiness activities, all in connection with the agreed development plan under our collaboration with Astellas. These Phase I clinical trials demonstrated that CK-2127107 appeared well-tolerated in healthy volunteers and that exposures generally increased across dose ranges studied. CK-2127107 increased the response of muscle to neuromuscular input in a dose and plasma concentration related fashion in healthy volunteers consistent with preclinical observations. In addition, an oral tablet formulation of CK-2127107 appears appropriate for use in Phase II clinical trials. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2"><U>Planned Phase II Clinical Development</U>: Cytokinetics will conduct the initial Phase II clinical trial of <FONT STYLE="white-space:nowrap">CK-2127107</FONT> in patients with SMA. We anticipate initiating this trial in the second half of 2015. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">The clinical trials programs for CK-2127107 may proceed for several years, and we will not be in a position to generate any revenues or material net cash flows from sales of this drug candidate until the program is successfully completed, regulatory approval is achieved, and the drug is commercialized. CK-2127107 is at too early a stage of development for us to predict if or when this may occur. Our expenditures will increase if Astellas terminates development of CK-2127107 or related compounds and we elect to develop them independently, or if we conduct early-stage development for certain agreed indications at our initial expense, subject to reimbursement if development continues under the collaboration. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I><U>Ongoing Research in Skeletal Muscle Activators</U>. </I>Our research on the direct activation of skeletal muscle continues in two areas. We are conducting translational research in preclinical models of disease and muscle function with fast skeletal muscle troponin activators to explore the potential clinical applications of this novel mechanism in diseases or conditions associated with skeletal muscle dysfunction. We also intend to conduct preclinical research on other chemically and pharmacologically distinct mechanisms to activate the skeletal sarcomere. We are conducting a joint research program with Astellas directed to the discovery of next-generation skeletal muscle activators. Under the Amended Astellas Agreement, the joint research program will continue through 2016 and Astellas will reimburse us for certain research activities we perform. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I><U>Research and Development Expenses</U>. </I>We recorded research and development expenses for activities relating to our skeletal muscle contractility program of approximately $32.9 million, $40.8 million and $24.9 million in the years ended December 31, 2014, 2013 and 2012, respectively. We recognized research and development revenue from Astellas of $32.4 million in 2014, consisting of milestone payments, and reimbursements of full-time employee equivalents (“FTEs”) and other expenses. We anticipate that our expenditures relating to the research and development of compounds in our skeletal muscle contractility program will increase significantly if and as we advance tirasemtiv, CK-2127107 or other compounds from this program into and through development. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Cardiac Muscle Contractility Program </I></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">Our lead drug candidate from this program is omecamtiv mecarbil, a novel cardiac muscle myosin activator. We expect omecamtiv mecarbil to be developed as a potential treatment across the continuum of care in heart failure both as an intravenous formulation for use in the hospital setting and as an oral formulation for use in the outpatient setting. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I><U>Amgen Strategic Alliance</U>.</I> In December 2006, we entered into a collaboration and option agreement with Amgen to discover, develop and commercialize novel small molecule therapeutics, including omecamtiv mecarbil, that activate cardiac muscle contractility for potential applications in the treatment of heart failure (the “Amgen Agreement”). The agreement granted Amgen an option to obtain an exclusive license worldwide, except Japan, to develop and commercialize omecamtiv mecarbil and other drug candidates arising from the collaboration. In May 2009, Amgen exercised its option. As a result, Amgen became responsible for the </FONT></P> <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1"> </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">58 </FONT></P> <p Style='page-break-before:always'> <HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER"> <h5 align="left"><a href="#toc">Table of Contents</a></h5> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2"> development and commercialization of omecamtiv mecarbil and related compounds at its expense worldwide (excluding Japan), subject to our development and commercialization participation rights. Amgen will reimburse us for certain research and development activities we perform under the collaboration. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">In June 2013, Cytokinetics and Amgen executed an amendment to the Amgen Agreement to include Japan, resulting in a worldwide collaboration (the “Amgen Agreement Amendment”). Under the terms of the Amgen Agreement Amendment, we received a non-refundable upfront license fee of $15.0 million in June 2013. Under the Amgen Agreement Amendment, we conducted a Phase I pharmacokinetic study intended to support inclusion of Japan in a potential Phase III clinical development program and potential global registration dossier for omecamtiv mecarbil. Amgen will reimburse us for the costs of this study. In addition, we are eligible to receive additional pre-commercialization milestone payments relating to the development of omecamtiv mecarbil in Japan of up to $50.0 million, and royalties on sales of omecamtiv mecarbil in Japan. In conjunction with the Amgen Agreement Amendment, we also entered into a common stock purchase agreement which provided for the sale of 1,404,100 shares of our common stock to Amgen at a price per share of $7.12 and an aggregate purchase price of $10.0 million which was received in June 2013. Pursuant to this agreement, Amgen agreed to certain trading and other restrictions with respect to our common stock. During 2014, we recorded $4.5 million in reimbursement of sponsored research and development activities relating to the Amgen Agreement. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">Under the Amgen Agreement as amended, we are eligible for potential pre-commercialization and commercialization milestone payments of up to $650.0 million in the aggregate on omecamtiv mecarbil and other potential products arising from research under the collaboration, and royalties that escalate based on increasing levels of annual net sales of products commercialized under the agreement. The Amgen Agreement also provides for us to receive increased royalties by co-funding Phase III development costs of omecamtiv mecarbil and other drug candidates under the collaboration. If we elect to co-fund such costs, we would be entitled to co-promote the co-funded drug in North America and participate in agreed commercialization activities in institutional care settings, at Amgen’s expense. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">In July 2013, Amgen announced that it had granted an option to commercialize omecamtiv mecarbil in Europe to Servier, with Cytokinetics’ consent. The option and, if the option is exercised, the resulting commercialization sublicense to Servier, is subject to the terms and conditions of the Amgen Agreement. Amgen remains responsible for the performance of its obligations under the Amgen Agreement relating to Europe, including the payment of milestones and royalties relating to the development and commercialization of omecamtiv mecarbil in Europe. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px; margin-left:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I><U>Omecamtiv Mecarbil Clinical Development </U></I></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2"><U>COSMIC-HF</U>. In March 2013, we announced the initiation of dosing of patients in COSMIC-HF (Chronic Oral Study of Myosin Activation to Increase Contractility in Heart Failure). COSMIC-HF is a Phase II, double-blind, randomized, placebo-controlled, multicenter, clinical trial designed to assess the pharmacokinetics and tolerability of <I>omecamtiv mecarbil</I> dosed orally in patients with heart failure and left ventricular systolic dysfunction as well as its effects on echocardiographic measures of cardiac function. COSMIC-HF is being conducted by Amgen in collaboration with Cytokinetics. Cytokinetics and Amgen reviewed results from the dose escalation phase of COSMIC-HF and selected an oral formulation of omecamtiv mecarbil for evaluation in the expansion phase of the trial. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">The expansion phase of COSMIC-HF has enrolled approximately 450 patients from approximately 95 clinical sites internationally. Patients will be randomized 1:1:1 to receive placebo, 25 mg, or 50 mg twice daily of omecamtiv mecarbil. Escalation to the 50 mg dose will depend on the plasma concentration of omecamtiv mecarbil following 2 weeks of oral dosing at 25 mg twice daily. The primary objective of the expansion phase of this trial is to characterize the safety, tolerability, and pharmacokinetics of omecamtiv mecarbil dosed orally during 20 weeks of treatment. The secondary objectives are to assess the changes from baseline in systolic ejection time, stroke volume, left ventricular end-systolic diameter, left ventricular </FONT></P> <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1"> </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">59 </FONT></P> <p Style='page-break-before:always'> <HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER"> <h5 align="left"><a href="#toc">Table of Contents</a></h5> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2"> <FONT STYLE="white-space:nowrap">end-diastolic</FONT> diameter, heart rate and N-terminal pro-brain natriuretic peptide (a biomarker associated with the severity of heart failure) during 20 weeks of treatment. In the fourth quarter of 2014, the Data Monitoring Committee reviewed data from COSMIC-HF and recommended that the trial continue without any changes to the protocol. The expansion phase of COSMIC-HF has enrolled over 400 patients; over 200 of these patients have completed dosing. We anticipate that patient enrollment in COSMIC-HF will conclude in the first quarter of 2015. We anticipate that results from COSMIC-HF will be available in the second half of 2015. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2"><U>ATOMIC-AHF</U>. In September 2013, results from ATOMIC-AHF (Acute Treatment with Omecamtiv Mecarbil to Increase Contractility in Acute Heart Failure) were presented at the European Society of Cardiology Congress and the Heart Failure Society of America Annual Scientific Meeting. ATOMIC-AHF was an international, randomized, double-blind, placebo-controlled, Phase IIb clinical trial of intravenous omecamtiv mecarbil in patients with left ventricular systolic dysfunction hospitalized with acutely decompensated heart failure. ATOMIC-AHF was conducted by Amgen in collaboration with Cytokinetics. This clinical trial enrolled over 600 patients in three sequential, ascending-dose cohorts. In each cohort, patients were randomized to receive omecamtiv mecarbil or placebo. The primary efficacy objective of this trial was to evaluate the effect of 48 hours of intravenous omecamtiv mecarbil compared to placebo on dyspnea (shortness of breath). The secondary objectives were to assess the safety and tolerability of three dose levels of intravenous omecamtiv mecarbil compared with placebo and to evaluate the effects of 48 hours of treatment with intravenous omecamtiv mecarbil on additional measures of dyspnea, patients’ global assessments, change in N-terminal pro brain-type natriuretic peptide (a biomarker associated with the severity of heart failure) and short-term clinical outcomes in these patients. In addition, the trial evaluated the relationship between plasma concentrations of omecamtiv mecarbil and echocardiographic parameters in patients with acute heart failure. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">The omecamtiv mecarbil treatment groups were not statistically different in their 7-point Likert scale dyspnea symptom response rates compared to the pooled placebo group (p=0.33); therefore, the primary endpoint was not met. Omecamtiv mecarbil demonstrated favorable dose- and concentration-related trends (nominal p=0.025 and nominal p=0.007, respectively) on dyspnea response. Improvement in dyspnea was observed in the highest omecamtiv mecarbil dose group when compared against its paired placebo group in the third cohort (dyspnea symptom response in 51 percent of subjects on omecamtiv mecarbil versus 37 percent on placebo, nominal p=0.03). The incidence of worsening heart failure within seven days of initiating treatment was 17 percent in the pooled placebo group and was 13 percent, 8 percent and 9 percent on omecamtiv mecarbil in the first, second and third cohorts, respectively. Systolic ejection time, the echocardiographic signature of omecamtiv mecarbil, increased in a concentration-dependent manner similar to that previously reported in healthy volunteers and stable heart failure patients. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">Rates of adverse events (AEs), serious AEs, adjudicated deaths and hospitalizations were similar between omecamtiv mecarbil and placebo groups. There were seven post-randomization myocardial infarctions in the treatment groups receiving omecamtiv mecarbil compared with three in the placebo groups (2.3 percent vs. 1.0 percent, respectively). However, there was no relationship between the maximum increase from the baseline troponin (a biomarker specific for cardiac muscle damage) and increasing plasma concentrations of omecamtiv mecarbil. Four of the myocardial infarctions occurred more than seven days following termination of the 48-hour drug infusion. The estimated plasma concentrations near the time of these events were zero. Three of these events occurred in patients who received omecamtiv mecarbil and one occurred in a patient who received placebo. One myocardial infarction occurred subsequent to a percutaneous coronary intervention in a patient who received omecamtiv mecarbil. One myocardial infarction occurred in a patient with sepsis who received placebo. Omecamtiv mecarbil was not associated with an increased incidence of tachyarrhythmias nor were heart rate or blood pressure adversely affected. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2"><U>Pharmacokinetics Bridging Study</U>. During the fourth quarter of 2014, we announced that CY 1211, a Phase I study comparing the tolerability and pharmacokinetics of omecamtiv mecarbil between Japanese and Caucasian healthy volunteers, had been completed and indicated no clinically meaningful differences between the two groups studied. Data from CY 1211 are expected to inform plans for the development of omecamtiv </FONT></P> <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1"> </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">60 </FONT></P> <p Style='page-break-before:always'> <HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER"> <h5 align="left"><a href="#toc">Table of Contents</a></h5> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2"> mecarbil in Japan and the inclusion of Japan in potential global Phase III program activities. This trial was conducted by Cytokinetics in collaboration with Amgen. Amgen reimbursed us for the costs of the trial. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>Prior Clinical Experience with Omecamtiv Mecarbil.</I> Seven Phase I clinical trials of omecamtiv mecarbil have been conducted in healthy subjects: five conducted by Cytokinetics and two conducted by Amgen in collaboration with Cytokinetics. Cytokinetics has also conducted two Phase IIa clinical trials of omecamtiv mecarbil. These clinical trials were designed to evaluate the safety, tolerability, pharmacodynamic and pharmacokinetic profiles of both intravenous and oral formulations in a diversity of patients, including patients with stable heart failure and patients with ischemic cardiomyopathy. In these trials, omecamtiv mecarbil exhibited generally linear, dose-proportional pharmacokinetics across the dose ranges studied. The adverse effects observed at intolerable doses in humans appeared similar to the adverse findings which occurred in preclinical safety studies at similar plasma concentrations. These effects are believed to be related to the mechanism of action of this drug candidate which, at intolerable doses, resulted in an excessive prolongation of the systolic ejection time (i.e., the time in which the heart is contracting). However, these effects resolved promptly with discontinuation of the infusions of omecamtiv mecarbil. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">The clinical trials program for omecamtiv mecarbil may proceed for several years, and we will not be in a position to generate any revenues or material net cash flows from sales of this drug candidate until the program is successfully completed, regulatory approval is achieved, and the drug is commercialized. Omecamtiv mecarbil is at too early a stage of development for us to predict if or when this may occur. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I><U>Ongoing Research in Cardiac Muscle Contractility</U>.</I> In 2013, we agreed with Amgen to additional research activities intended to be conducted through 2014 under the research plan directed to next-generation compounds in our cardiac muscle contractility program. We expect to continue our joint research program with Amgen through 2015. Under the Amgen Agreement, Amgen will reimburse us for certain research activities we perform. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I><U>Research and Development Expenses.</U></I> We funded all research and development costs associated with this program prior to Amgen’s option exercise in May 2009. We recorded research and development expenses for activities relating to our cardiac muscle contractility program of approximately $7.4 million, $3.4 million and $4.5 million in the years ended December 31, 2014, 2013 and 2012, respectively. We recognized research and development revenue from Amgen of $4.5 million in 2014, $2.0 million in 2013 and $4.2 million in 2012, consisting of reimbursements of FTEs and other expenses. We anticipate that our expenditures relating to the research and development of compounds in our cardiac muscle contractility program will increase if we participate in the future advancement of omecamtiv mecarbil through clinical development. Our expenditures will also increase if Amgen terminates development of omecamtiv mecarbil or related compounds and we elect to develop them independently, or if we elect to co-fund later-stage development of omecamtiv mecarbil or other compounds in our cardiac muscle contractility program under our collaboration and option agreement with Amgen. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Beyond Muscle Contractility </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">We have developed preclinical expertise in the mechanics of skeletal, cardiac and smooth muscle that extends from proteins to tissues to intact animal models. Our translational research in muscle contractility has enabled us to better understand the potential impact of small molecule compounds that increase skeletal or cardiac muscle contractility and to apply those findings to the further evaluation of our drug candidates in clinical populations. In addition to contractility, the other major functions of muscle include metabolism, growth and energetics, with each of these functions playing a role in certain diseases that could benefit from novel mechanism treatments. Accordingly, our knowledge of muscle contractility may serve as an entry point to the discovery of novel treatments for disorders involving muscle functions other than muscle contractility. We are leveraging our current understandings of muscle biology to investigate new ways of modulating these other aspects of muscle function for other potential therapeutic applications. For example, we are conducting research with compounds that affect muscle growth and that may have applications for serious diseases and medical </FONT></P> <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1"> </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">61 </FONT></P> <p Style='page-break-before:always'> <HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER"> <h5 align="left"><a href="#toc">Table of Contents</a></h5> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2"> conditions such as cachexia. Cachexia is a condition that can be associated with cancer, heart failure, chronic obstructive pulmonary disease or other conditions. This syndrome is characterized by the loss of muscle mass and may lead to weakness and disability. We are performing research on compounds that may increase muscle mass and which may impact patient functionality or potentially alter the course of diseases associated with muscle wasting. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Development Risks </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">The successful development of any of our drug candidates is highly uncertain. We cannot estimate with certainty or know the exact nature, timing and costs of the activities necessary to complete the development of any of our drug candidates or the date of completion of these development activities due to numerous risks and uncertainties, including, but not limited to: </FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px"> </P> <TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%"> <TR> <TD WIDTH="4%"><FONT SIZE="1"> </FONT></TD> <TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">•</FONT></TD> <TD WIDTH="1%" VALIGN="top"><FONT SIZE="1"> </FONT></TD> <TD ALIGN="left" VALIGN="top"> <P ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">the results of clinical trials of our drug candidates conducted by us or our partners may not support the further clinical development of those drug candidates; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px"> </P> <TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%"> <TR> <TD WIDTH="4%"><FONT SIZE="1"> </FONT></TD> <TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">•</FONT></TD> <TD WIDTH="1%" VALIGN="top"><FONT SIZE="1"> </FONT></TD> <TD ALIGN="left" VALIGN="top"> <P ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">further clinical development of tirasemtiv for the potential treatment of ALS will require significant additional funding and we may be unable to obtain such additional funding on acceptable terms, if at all; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px"> </P> <TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%"> <TR> <TD WIDTH="4%"><FONT SIZE="1"> </FONT></TD> <TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">•</FONT></TD> <TD WIDTH="1%" VALIGN="top"><FONT SIZE="1"> </FONT></TD> <TD ALIGN="left" VALIGN="top"> <P ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">the FDA and/or other regulatory authorities may not accept effects on respiratory function, including SVC, as an appropriate clinical trial endpoint to support the registration of tirasemtiv for the treatment of ALS; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px"> </P> <TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%"> <TR> <TD WIDTH="4%"><FONT SIZE="1"> </FONT></TD> <TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">•</FONT></TD> <TD WIDTH="1%" VALIGN="top"><FONT SIZE="1"> </FONT></TD> <TD ALIGN="left" VALIGN="top"> <P ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">decisions made by Amgen with respect to the development of omecamtiv mecarbil and by Astellas with respect to the development of CK-2127107; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px"> </P> <TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%"> <TR> <TD WIDTH="4%"><FONT SIZE="1"> </FONT></TD> <TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">•</FONT></TD> <TD WIDTH="1%" VALIGN="top"><FONT SIZE="1"> </FONT></TD> <TD ALIGN="left" VALIGN="top"> <P ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">the uncertainty of the timing of the initiation and completion of patient enrollment and treatment in our or our partners’ clinical trials; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px"> </P> <TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%"> <TR> <TD WIDTH="4%"><FONT SIZE="1"> </FONT></TD> <TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">•</FONT></TD> <TD WIDTH="1%" VALIGN="top"><FONT SIZE="1"> </FONT></TD> <TD ALIGN="left" VALIGN="top"> <P ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">the possibility of delays in the collection of clinical trial data and the uncertainty of the timing of the analyses of our clinical trial data after these trials have been initiated and completed; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px"> </P> <TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%"> <TR> <TD WIDTH="4%"><FONT SIZE="1"> </FONT></TD> <TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">•</FONT></TD> <TD WIDTH="1%" VALIGN="top"><FONT SIZE="1"> </FONT></TD> <TD ALIGN="left" VALIGN="top"> <P ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">our potential inability to obtain additional funding and resources for our development activities on acceptable terms, if at all, including, but not limited to, our potential inability to obtain or retain partners to assist in the design, management, conduct and funding of clinical trials; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px"> </P> <TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%"> <TR> <TD WIDTH="4%"><FONT SIZE="1"> </FONT></TD> <TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">•</FONT></TD> <TD WIDTH="1%" VALIGN="top"><FONT SIZE="1"> </FONT></TD> <TD ALIGN="left" VALIGN="top"> <P ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">failure by our clinical trial sites, clinical research organizations, clinical manufacturing organizations and other third parties supporting our or our partners’ clinical trials to fulfill their obligations or otherwise perform as expected; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px"> </P> <TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%"> <TR> <TD WIDTH="4%"><FONT SIZE="1"> </FONT></TD> <TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">•</FONT></TD> <TD WIDTH="1%" VALIGN="top"><FONT SIZE="1"> </FONT></TD> <TD ALIGN="left" VALIGN="top"> <P ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">delays or additional costs in manufacturing of our drug candidates for clinical trial use, including developing appropriate formulations of our drug candidates; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px"> </P> <TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%"> <TR> <TD WIDTH="4%"><FONT SIZE="1"> </FONT></TD> <TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">•</FONT></TD> <TD WIDTH="1%" VALIGN="top"><FONT SIZE="1"> </FONT></TD> <TD ALIGN="left" VALIGN="top"> <P ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">the uncertainty of clinical trial results, including variability in patient response; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px"> </P> <TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%"> <TR> <TD WIDTH="4%"><FONT SIZE="1"> </FONT></TD> <TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">•</FONT></TD> <TD WIDTH="1%" VALIGN="top"><FONT SIZE="1"> </FONT></TD> <TD ALIGN="left" VALIGN="top"> <P ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">the uncertainty of obtaining FDA or other foreign regulatory agency approval required for the clinical investigation of our drug candidates; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px"> </P> <TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%"> <TR> <TD WIDTH="4%"><FONT SIZE="1"> </FONT></TD> <TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">•</FONT></TD> <TD WIDTH="1%" VALIGN="top"><FONT SIZE="1"> </FONT></TD> <TD ALIGN="left" VALIGN="top"> <P ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">the uncertainty related to the development of commercial scale manufacturing processes and qualification of a commercial scale manufacturing facility; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px"> </P> <TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%"> <TR> <TD WIDTH="4%"><FONT SIZE="1"> </FONT></TD> <TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">•</FONT></TD> <TD WIDTH="1%" VALIGN="top"><FONT SIZE="1"> </FONT></TD> <TD ALIGN="left" VALIGN="top"> <P ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">the possibility that results from non-clinical studies may adversely impact the timing or further development of our drug candidates; and </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px"> </P> <TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%"> <TR> <TD WIDTH="4%"><FONT SIZE="1"> </FONT></TD> <TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">•</FONT></TD> <TD WIDTH="1%" VALIGN="top"><FONT SIZE="1"> </FONT></TD> <TD ALIGN="left" VALIGN="top"> <P ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">possible delays in the characterization, formulation and manufacture of drug candidates and other compounds. </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">If we fail to complete the development of any of our drug candidates in a timely manner, it could have a material adverse effect on our operations, financial position and liquidity. In addition, any failure by us or our </FONT></P> <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1"> </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">62 </FONT></P> <p Style='page-break-before:always'> <HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER"> <h5 align="left"><a href="#toc">Table of Contents</a></h5> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2"> partners to obtain, or any delay in obtaining, regulatory approvals for our drug candidates could have a material adverse effect on our results of operations. A further discussion of the risks and uncertainties associated with completing our programs as planned, or at all, and certain consequences of failing to do so are discussed further in the risk factors entitled “We will need substantial additional capital in the future to sufficiently fund our operations,” “We have never generated, and may never generate, revenues from commercial sales of our drugs and we may not have drugs to market for at least several years, if ever,” “Clinical trials may fail to demonstrate the desired safety and efficacy of our drug candidates, which could prevent or significantly delay completion of clinical development and regulatory approval” and “Clinical trials are expensive, time-consuming and subject to delay,” and other risk factors. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Revenues </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">Our current revenue sources are limited, and we do not expect to generate any revenue from product sales for several years, if at all. We have recognized revenues from our strategic alliances with Amgen, Astellas, Global Blood Therapeutics, Inc., formerly known as Global Blood Targeting, Inc. (“Global Blood”) and MyoKardia, Inc. (“MyoKardia”) and grant revenues from NINDS. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">In June 2013, we and Amgen executed an amendment (the “Amgen Agreement Amendment”) to the Amgen Agreement to include Japan, resulting in a worldwide collaboration. (See Note 7, “Related Parties and Related Party Transactions” in the Notes to Consolidated Financial Statements.) Under the terms of the Amgen Agreement Amendment, we received a non-refundable upfront license fee of $15.0 million in June 2013. In conjunction with the Amgen Agreement Amendment, we also entered into a common stock purchase agreement which provided for the sale of 1,404,100 shares of our common stock to Amgen at a price per share of $7.12 and an aggregate purchase price of $10.0 million, which was received in June 2013. Pursuant to this agreement, Amgen agreed to certain trading and other restrictions with respect to our common stock. Under the Amgen Agreement Amendment, we conducted a Phase I pharmacokinetic study intended to support inclusion of Japan in a potential Phase III clinical development program and potential global registration dossier for omecamtiv mecarbil. Amgen reimbursed us for the costs of this study. In addition, we are eligible to receive additional pre-commercialization milestone payments relating to the development of omecamtiv mecarbil in Japan of up to $50.0 million, and royalties on sales of omecamtiv mecarbil in Japan. In the fourth quarter of 2013, we determined that all conditions necessary for revenue recognition of the non-refundable upfront license fee under Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”) Topic 605-10 had been met and accordingly, in the fourth quarter of 2013, we recognized a total of $17.2 million in license revenue attributable to the Amgen Agreement Amendment. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">We have received reimbursements from Amgen for certain research and development activities, which we recorded as revenue as the related expenses were incurred. We may be eligible to receive further reimbursements from Amgen for certain research and development activities, which we will record as revenue if and when the related expenses are incurred. We record amounts received in advance of performance as deferred revenue. Revenues related to the reimbursement of FTEs were based on negotiated rates intended to approximate the costs for our FTEs. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">In July 2013, we received an upfront payment of $16.0 million in connection with the execution of the Original Astellas Agreement, establishing a collaboration directed to the research and development of skeletal muscle activators including CK-2127107 for potential application in non-neuromuscular indications associated with muscle weakness. This agreement provided for us to potentially receive over $24.0 million in reimbursement of sponsored research and development activities during the initial two years of the collaboration and for research and early and late stage development milestone payments based on various research and clinical milestones. We determined the license and the research and development services relating to the Original Astellas Agreement are a single unit of accounting as the license was determined to not have stand-alone value. Accordingly, we are recognizing this revenue using the proportional performance model. In 2013, we recognized $3.9 million of the $16.0 million upfront license fee as license revenue and as of December 31, 2013, we deferred </FONT></P> <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1"> </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">63 </FONT></P> <p Style='page-break-before:always'> <HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER"> <h5 align="left"><a href="#toc">Table of Contents</a></h5> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2"> the remaining $12.1 million. We also recognized $6.4 million in revenue in 2013 for reimbursement of sponsored research and development activities under the Original Astellas Agreement. In 2014 we recognized $9.8 million of the $16.0 million upfront license fee as license revenue and as of December 31, 2014, we deferred the remaining $2.3 million. Also in 2014 and under the Original Astellas Agreement, we recognized $15.4 million in revenue for reimbursement of sponsored research and development activities, $2.0 million in research and development milestone fees and $15.0 million in milestone fees in connection with the decision made by Astellas to advance CK-2127107 into Phase II clinical development. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">We received an upfront payment of $30.0 million in connection with the execution of the Amended Astellas Agreement. Also, in conjunction with the execution of the Amended Astellas Agreement, we entered into a common stock purchase agreement pursuant to which we sold 2,040,816 shares of our common stock to Astellas at a price per share of $4.90. The aggregate purchase price of $10.0 million was received in December 2014. We determined the fair value of the stock issued to Astellas to be $9.1 million. The excess of cash received over fair value of $0.9 million was deferred and will be recognized as revenue as services are performed over approximately 24 months. Pursuant to this agreement, Astellas agreed to certain trading and other restrictions with respect to our common stock. We determined that the license and the research and development services relating to the Amended Astellas Agreement are a single unit of accounting as the license was determined to not have stand-alone value. Accordingly, we are recognizing this revenue using the proportional performance model over the initial research term of the Amended Astellas Agreement. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">Concurrently with the execution of the Amended Astellas Agreement and related common stock purchase agreement, Cytokinetics received $15.0 million as a milestone payment relating to Astellas’ decision to advance CK-2127107 into Phase II clinical development. Cytokinetics is also eligible to potentially receive over $20.0 million in reimbursement of sponsored research and development activities during the next two years of the collaboration. Based on the achievement of pre-specified criteria, Cytokinetics may receive over $600.0 million in milestone payments relating to the development and commercial launch of collaboration products, including up to $112.0 million (of which Cytokinetics has now received $17.0 million) relating to early development of CK-2127107 and for later-stage development and commercial launch milestones for <FONT STYLE="white-space:nowrap">CK-2127107</FONT> in non-neuromuscular indications, and over $100.0 million in development and commercial launch milestones for CK-2127107 in each of SMA and other neuromuscular indications. Cytokinetics may also receive up to $200.0 million in payments for achievement of pre-specified sales milestones related to net sales of all collaboration products under the Amended Astellas Agreement. If Astellas commercializes any collaboration products, Cytokinetics will also receive royalties on sales of such collaboration products, including royalties ranging from the high single digits to the high teens on sales of products containing CK-2127107. Cytokinetics also holds an option to co-fund certain development costs for CK-2127107 and other compounds in exchange for increased milestone payments and royalties; such royalties may increase under certain scenarios to exceed twenty percent. In addition to the foregoing development, commercial launch and sales milestones, Cytokinetics may also receive payments for the achievement of pre-specified milestones relating to the joint research program. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">Because a substantial portion of our revenues for the foreseeable future will depend on achieving development and other pre-commercialization milestones under our strategic alliances with Amgen and Astellas, our results of operations may vary substantially from year to year. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">If one or more of our drug candidates is approved for sale as a drug, we expect that our future revenues will most likely be derived from royalties on sales from drugs licensed to Amgen and Astellas under our respective strategic alliances and from those licensed to future partners, and from direct sales of our drugs. We retain a product-by-product option to co-fund certain Phase III development activities under the Amgen Agreement, thereby potentially increasing our royalties and affording us co-promotion rights in North America. If we exercise our co-promotion rights under the Amgen Agreement, we are entitled to receive reimbursement for certain sales force costs we incur in support of our commercial activities. Under the Amended Astellas Agreement, we retain an option to co-promote collaboration products containing fast skeletal muscle activators for neuromuscular indications in the U.S., Canada and Europe, in addition to our option to co-promote other </FONT></P> <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1"> </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">64 </FONT></P> <p Style='page-break-before:always'> <HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER"> <h5 align="left"><a href="#toc">Table of Contents</a></h5> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2"> collaboration products in the U.S. and Canada as provided for in the Original Astellas Agreement. Astellas will reimburse us for certain expenses associated with our co-promotion activities. The Amended Astellas Agreement also provides for us to lead certain activities relating to the commercialization of collaboration products for neuromuscular indications in the U.S., Canada and Europe under particular scenarios. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">In August 2012, we entered into a collaboration agreement with MyoKardia. Under an agreed research plan, scientists from MyoKardia and our FTEs conducted research focused on small molecule therapeutics that inhibit cardiac sarcomere proteins. We provided MyoKardia access to certain research facilities, and provided FTEs and other resources at agreed reimbursement rates that approximated our costs. We were the primary obligor in the collaboration arrangement, and accordingly, we recorded expense reimbursements from MyoKardia as research and development revenue. The research plan ended as planned in August 2013. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">In July 2010 and in September 2012, the NINDS awarded us grants to support research and development of tirasemtiv directed to the potential treatment for myasthenia gravis for a period of up to three years. The grants were completed in June of 2013. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Research and Development </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">We incur research and development expenses associated with both partnered and our own research activities. We expect to incur research and development expenses for the clinical development of tirasemtiv. We expect to incur research and development expenses for CK-2127107 in accordance with agreed upon research and development plans with Astellas. We expect to incur research and development expenses for omecamtiv mecarbil and other next-generation compounds in our cardiac muscle contractility program in accordance with agreed upon research and development plans with Amgen. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">Research and development expenses related to any development and commercialization activities we elect to fund consist primarily of employee compensation, supplies and materials, costs for consultants and contract research and manufacturing, facilities costs and depreciation of equipment. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>General and Administrative Expenses </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">General and administrative expenses consist primarily of compensation for employees in executive and administrative functions, including, but not limited to, finance, human resources, legal, business and commercial development and strategic planning. Other significant costs include facilities costs, consulting costs and professional fees for accounting and legal services, including legal services associated with obtaining and maintaining patents and regulatory compliance. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Restructuring </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">In October 2011, we announced a restructuring plan pursuant to which we reduced our workforce. We completed all restructuring activities and recognized all anticipated restructuring charges by December 31, 2012. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Stock Compensation </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">The following table summarizes stock-based compensation related to stock options, restricted stock awards, restricted stock units, and employee stock purchases for 2014, 2013 and 2012 (in thousands): </FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px"> </P> <TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="92%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center"> <TR> <TD WIDTH="73%"></TD> <TD VALIGN="bottom" WIDTH="4%"></TD> <TD></TD> <TD></TD> <TD></TD> <TD VALIGN="bottom" WIDTH="4%"></TD> <TD></TD> <TD></TD> <TD></TD> <TD VALIGN="bottom" WIDTH="4%"></TD> <TD></TD> <TD></TD> <TD></TD></TR> <TR> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom" COLSPAN="10" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Years Ended December 31,</B></FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD></TR> <TR> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>2014</B></FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>2013</B></FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>2012</B></FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD></TR> <TR BGCOLOR="#cceeff"> <TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Research and development</FONT></P></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD> <TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1,361</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD> <TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1,538</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD> <TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1,801</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD></TR> <TR> <TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">General and administrative</FONT></P></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1,969</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">2,059</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1,982</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD></TR> <TR STYLE="font-size:1px"> <TD VALIGN="bottom"></TD> <TD VALIGN="bottom"> </TD> <TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000"> </P></TD> <TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000"> </P></TD> <TD> </TD> <TD VALIGN="bottom"> </TD> <TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000"> </P></TD> <TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000"> </P></TD> <TD> </TD> <TD VALIGN="bottom"> </TD> <TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000"> </P></TD> <TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000"> </P></TD> <TD> </TD></TR> <TR BGCOLOR="#cceeff"> <TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Stock-based compensation included in operating expenses</FONT></P></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD> <TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">3,330</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD> <TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">3,597</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD> <TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">3,783</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD></TR> <TR STYLE="font-size:1px"> <TD VALIGN="bottom"></TD> <TD VALIGN="bottom"> </TD> <TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000"> </P></TD> <TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000"> </P></TD> <TD> </TD> <TD VALIGN="bottom"> </TD> <TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000"> </P></TD> <TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000"> </P></TD> <TD> </TD> <TD VALIGN="bottom"> </TD> <TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000"> </P></TD> <TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000"> </P></TD> <TD> </TD></TR> </TABLE> <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1"> </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">65 </FONT></P> <p Style='page-break-before:always'> <HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER"> <h5 align="left"><a href="#toc">Table of Contents</a></h5> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">As of December 31, 2014, there was $5.7 million of unrecognized compensation cost related to unvested stock options, which is expected to be recognized over a weighted-average period of 2.52 years and $0.3 million of unrecognized compensation cost related to unvested restricted stock units, which is expected to be recognized over a weighted-average period of 0.83 years. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Income Taxes </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">We account for income taxes under the asset and liability method. Under this method, deferred tax assets and liabilities are determined based on the difference between the financial statement and tax basis of assets and liabilities using enacted tax rates in effect for the year in which the differences are expected to affect taxable income. Valuation allowances are established when necessary to reduce the deferred tax assets to the amounts expected to be realized. We did not record an income tax provision in the years ended December 31, 2014, 2013 or 2012 because we had a net taxable loss in these periods. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">Based upon the weight of available evidence, which includes our historical operating performance, reported cumulative net losses since inception and difficulty in accurately forecasting our future results, we maintained a full valuation allowance on the net deferred tax assets as of December 31, 2014, 2013 and 2012. The valuation allowance was determined pursuant to the accounting guidance for income taxes, which requires an assessment of both positive and negative evidence when determining whether it is more likely than not that deferred tax assets are recoverable. We intend to maintain a full valuation allowance on the U.S. deferred tax assets until sufficient positive evidence exists to support reversal of the valuation allowance. The valuation allowance increased by $1.0 million in 2014, $13.7 million in 2013 and $21.1 million in 2012. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">We also follow the accounting guidance that defines the threshold for recognizing the benefits of tax return positions in the financial statements as “more-likely-than-not” to be sustained by the taxing authorities based solely on the technical merits of the position. If the recognition threshold is met, the tax benefit is measured and recognized as the largest amount of tax benefit that, in our judgment, is greater than 50% likely to be realized. Historically, we have filed income tax returns with the federal Internal Revenue Service (“IRS”) and the state of California. For jurisdictions in which tax filings are made, we are subject to income tax examination for all fiscal years since inception. In general, the statute of limitations for tax liabilities for these years remains open for the purpose of adjusting the amounts of the losses and credits carried forward from those years. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">Interest accrued related to unrecognized tax benefits and penalties was zero for 2014, 2013 and 2012. We account for interest related to unrecognized tax benefits and penalties by classifying both as income tax expense in the financial statements in accordance with the accounting guidance for uncertainty in income taxes. We do not expect our unrecognized tax benefits to change materially over the next twelve months. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">In general, under Section 382 of the Internal Revenue Code (“Section 382”), a corporation that undergoes an “ownership change” is subject to limitations on its ability to utilize its pre-change net operating losses (“NOLs”) and tax credits to offset future taxable income. We have performed a Section 382 analysis and do not believe that we have experienced an ownership change since 2006. A portion of our existing NOLs and tax credits are subject to limitations arising from previous ownership changes. Future changes in our stock ownership, some of which are outside of our control, could result in an ownership change under Section 382 and result in additional limitations. </FONT></P> <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1"> </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">66 </FONT></P> <p Style='page-break-before:always'> <HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER"> <h5 align="left"><a href="#toc">Table of Contents</a></h5> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Results of Operations </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Years ended December 31, 2014, 2013 and 2012 </I></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>Revenues </I></FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px"> </P> <TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="92%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center"> <TR> <TD WIDTH="63%"></TD> <TD VALIGN="bottom" WIDTH="4%"></TD> <TD></TD> <TD></TD> <TD></TD> <TD VALIGN="bottom" WIDTH="4%"></TD> <TD></TD> <TD></TD> <TD></TD> <TD VALIGN="bottom" WIDTH="4%"></TD> <TD></TD> <TD></TD> <TD></TD> <TD VALIGN="bottom" WIDTH="4%"></TD> <TD></TD> <TD></TD> <TD></TD> <TD VALIGN="bottom" WIDTH="3%"></TD> <TD></TD> <TD></TD> <TD></TD></TR> <TR> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom" COLSPAN="10" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Years Ended December 31,</B></FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Increase<BR>(Decrease)</B></FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD></TR> <TR> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>2014</B></FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>2013</B></FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>2012</B></FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>2014</B></FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>2013</B></FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD></TR> <TR> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom" COLSPAN="18" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>(In millions)</B></FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD></TR> <TR BGCOLOR="#cceeff"> <TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Research and development revenues from related parties</FONT></P></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD> <TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">19.5</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD> <TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">2.0</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD> <TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">4.2</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD> <TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">17.5</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD> <TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(2.2</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">) </FONT></TD></TR> <TR> <TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Research and development, grant and other revenues</FONT></P></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">17.6</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">7.5</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">3.4</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">10.1</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">4.1</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD></TR> <TR BGCOLOR="#cceeff"> <TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">License revenues from related parties</FONT></P></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">—</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">17.2</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">—</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(17.2</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">) </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">17.2</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD></TR> <TR> <TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">License revenues</FONT></P></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">9.8</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">3.9</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">—</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">5.9</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">3.9</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD></TR> <TR STYLE="font-size:1px"> <TD VALIGN="bottom"></TD> <TD VALIGN="bottom"> </TD> <TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000"> </P></TD> <TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000"> </P></TD> <TD> </TD> <TD VALIGN="bottom"> </TD> <TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000"> </P></TD> <TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000"> </P></TD> <TD> </TD> <TD VALIGN="bottom"> </TD> <TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000"> </P></TD> <TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000"> </P></TD> <TD> </TD> <TD VALIGN="bottom"> </TD> <TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000"> </P></TD> <TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000"> </P></TD> <TD> </TD> <TD VALIGN="bottom"> </TD> <TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000"> </P></TD> <TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000"> </P></TD> <TD> </TD></TR> <TR BGCOLOR="#cceeff"> <TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Total revenues</FONT></P></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD> <TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">46.9</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD> <TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">30.6</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD> <TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">7.6</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD> <TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">16.3</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD> <TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">23.0</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD></TR> <TR STYLE="font-size:1px"> <TD VALIGN="bottom"></TD> <TD VALIGN="bottom"> </TD> <TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000"> </P></TD> <TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000"> </P></TD> <TD> </TD> <TD VALIGN="bottom"> </TD> <TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000"> </P></TD> <TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000"> </P></TD> <TD> </TD> <TD VALIGN="bottom"> </TD> <TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000"> </P></TD> <TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000"> </P></TD> <TD> </TD> <TD VALIGN="bottom"> </TD> <TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000"> </P></TD> <TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000"> </P></TD> <TD> </TD> <TD VALIGN="bottom"> </TD> <TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000"> </P></TD> <TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000"> </P></TD> <TD> </TD></TR> </TABLE> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">Research and development revenues from related parties refers to research and development revenues from our strategic alliances with Astellas and Amgen. Revenues from Astellas, which became a related party in December 2014, consisted of $15.0 million in milestone revenues. All research and development revenues from Astellas, prior to it becoming a related party and including a $2.0 million milestone fee recorded in the first quarter of 2014, are classified in research and development, grant and other revenues. Revenues from Amgen were $4.5 million, $2.0 million and $4.2 million in 2014, 2013 and 2012, respectively. Revenues from Amgen in 2014 consisted of reimbursement of internal costs of certain full-time employee equivalents, and recognition of allocated consideration relating to the execution of the Amgen Agreement Amendment in June 2013. Revenues from Amgen in 2013 and 2012 consisted of reimbursement of internal costs of certain full-time employee equivalents. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">Research and development, grant and other revenues in 2014 consisted primarily of $15.4 million of research and development revenues from our collaboration with Astellas, $2.0 million in milestone revenues from Astellas and $0.1 million in revenue from our collaboration with MyoKardia. Research and development, grant and other revenues in 2013 included $6.4 million of research program reimbursement revenues from our collaboration with Astellas and $1.0 million in revenue from our collaboration with MyoKardia. Research and development, grant and other revenues in 2012 of $3.4 million included grant revenue from the NINDS, revenue from Global Blood and revenue from MyoKardia. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">License revenues from related parties refers to license revenues from our strategic alliance with Amgen. Revenues from Amgen of $17.2 million in 2013 included recognition of an upfront license fee of $15.0 million, along with additional license revenues of $2.2 million, resulting from the allocation of a portion of the excess of the cash received over the fair value of the common stock issued contemporaneously to Amgen. In conjunction with the Amgen Agreement Amendment, we sold 1,404,100 shares of our common stock to Amgen for $10.0 million. We determined the fair value of the stock issued to Amgen to be $7.5 million. A portion of the excess of cash received over fair value of $2.5 million was also allocated to the services performed and was deferred and was recognized as revenue as services were performed. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">License revenues refers to license revenues from our collaboration with Astellas, prior to it becoming a related party in December 2014. License revenues included $9.8 and $3.9 million in 2014 and 2013, respectively, of the $16.0 million upfront license fee received from Astellas in July 2013 in connection with the execution of the Original Astellas Agreement. We are recognizing this revenue over the term of the research and development services using the proportional performance model. </FONT></P> <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1"> </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">67 </FONT></P> <p Style='page-break-before:always'> <HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER"> <h5 align="left"><a href="#toc">Table of Contents</a></h5> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>Research and development expenses </I></FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px"> </P> <TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="92%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center"> <TR> <TD WIDTH="62%"></TD> <TD VALIGN="bottom" WIDTH="4%"></TD> <TD></TD> <TD></TD> <TD></TD> <TD VALIGN="bottom" WIDTH="4%"></TD> <TD></TD> <TD></TD> <TD></TD> <TD VALIGN="bottom" WIDTH="4%"></TD> <TD></TD> <TD></TD> <TD></TD> <TD VALIGN="bottom" WIDTH="4%"></TD> <TD></TD> <TD></TD> <TD></TD> <TD VALIGN="bottom" WIDTH="3%"></TD> <TD></TD> <TD></TD> <TD></TD></TR> <TR> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom" COLSPAN="10" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Years Ended December 31,</B></FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Increase<BR>(Decrease)</B></FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD></TR> <TR> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>2014</B></FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>2013</B></FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>2012</B></FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>2014</B></FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>2013</B></FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD></TR> <TR> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom" COLSPAN="18" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>(In millions)</B></FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD></TR> <TR BGCOLOR="#cceeff"> <TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Research and development expenses</FONT></P></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD> <TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">44.4</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD> <TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">49.5</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD> <TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">35.6</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD> <TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(5.1</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">) </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD> <TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">13.9</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD></TR> </TABLE> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">Research and development expenses were $44.4 million and $49.5 million in 2014 and 2013, respectively. The decrease of $5.1 million in research and development expenses in 2014 was primarily due to decreased spending of $8.2 million for outsourced clinical and preclinical costs mainly due to the completion of the BENEFIT-ALS clinical trial earlier in 2014, partially offset by increased spending of $2.6 million personnel-related costs due to increased headcount. The increase of $13.9 million in research and development expenses in 2013 was primarily due to increased spending for outsourced clinical costs and laboratory costs totaling $14.0 million related to the BENEFIT-ALS clinical trial, partially offset by decreased spending for outsourced preclinical expense. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">From a program perspective, the $5.1 million decrease in in research and development spending in 2014 compared to 2013 was primarily due to reduced spending for our skeletal muscle contractility program, partially offset by increased spending for our cardiac muscle contractility program. The $13.9 million increase in research and development spending in 2013 compared to 2012 was primarily due to increased spending of $15.9 million for our skeletal muscle contractility program. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">The following presents our research and development expenses by program: </FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px"> </P> <TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="92%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center"> <TR> <TD WIDTH="62%"></TD> <TD VALIGN="bottom" WIDTH="4%"></TD> <TD></TD> <TD></TD> <TD></TD> <TD VALIGN="bottom" WIDTH="4%"></TD> <TD></TD> <TD></TD> <TD></TD> <TD VALIGN="bottom" WIDTH="4%"></TD> <TD></TD> <TD></TD> <TD></TD> <TD VALIGN="bottom" WIDTH="4%"></TD> <TD></TD> <TD></TD> <TD></TD> <TD VALIGN="bottom" WIDTH="3%"></TD> <TD></TD> <TD></TD> <TD></TD></TR> <TR> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom" COLSPAN="10" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Years Ended December 31,</B></FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Increase<BR>(Decrease)</B></FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD></TR> <TR> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>2014</B></FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>2013</B></FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>2012</B></FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>2014</B></FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>2013</B></FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD></TR> <TR> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom" COLSPAN="18" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>(In millions)</B></FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD></TR> <TR BGCOLOR="#cceeff"> <TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Cardiac muscle contractility</FONT></P></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD> <TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">7.4</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD> <TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">3.4</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD> <TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">4.5</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD> <TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">4.0</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD> <TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(1.1</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">) </FONT></TD></TR> <TR> <TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Skeletal muscle contractility</FONT></P></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">32.9</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">40.8</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">24.9</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(7.9</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">) </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">15.9</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD></TR> <TR BGCOLOR="#cceeff"> <TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Smooth muscle contractility</FONT></P></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">—</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">0.2</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.8</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(0.2</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">) </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(1.6</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">) </FONT></TD></TR> <TR> <TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">All other research programs</FONT></P></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">4.1</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">5.1</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">4.4</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(1.0</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">) </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">0.7</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD></TR> <TR STYLE="font-size:1px"> <TD VALIGN="bottom"></TD> <TD VALIGN="bottom"> </TD> <TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000"> </P></TD> <TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000"> </P></TD> <TD> </TD> <TD VALIGN="bottom"> </TD> <TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000"> </P></TD> <TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000"> </P></TD> <TD> </TD> <TD VALIGN="bottom"> </TD> <TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000"> </P></TD> <TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000"> </P></TD> <TD> </TD> <TD VALIGN="bottom"> </TD> <TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000"> </P></TD> <TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000"> </P></TD> <TD> </TD> <TD VALIGN="bottom"> </TD> <TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000"> </P></TD> <TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000"> </P></TD> <TD> </TD></TR> <TR BGCOLOR="#cceeff"> <TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Total research and development expenses</FONT></P></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD> <TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">44.4</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD> <TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">49.5</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD> <TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">35.6</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD> <TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(5.1</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">) </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD> <TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">13.9</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD></TR> <TR STYLE="font-size:1px"> <TD VALIGN="bottom"></TD> <TD VALIGN="bottom"> </TD> <TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000"> </P></TD> <TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000"> </P></TD> <TD> </TD> <TD VALIGN="bottom"> </TD> <TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000"> </P></TD> <TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000"> </P></TD> <TD> </TD> <TD VALIGN="bottom"> </TD> <TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000"> </P></TD> <TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000"> </P></TD> <TD> </TD> <TD VALIGN="bottom"> </TD> <TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000"> </P></TD> <TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000"> </P></TD> <TD> </TD> <TD VALIGN="bottom"> </TD> <TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000"> </P></TD> <TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000"> </P></TD> <TD> </TD></TR> </TABLE> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">Clinical development timelines, the likelihood of success and total completion costs vary significantly for each drug candidate and are difficult to estimate. We anticipate that we will determine on an ongoing basis which research and development programs to pursue and how much funding to direct to each program, taking into account the scientific and clinical success of each drug candidate. The lengthy process of seeking regulatory approvals and subsequent compliance with applicable regulations requires the expenditure of substantial resources. Any failure by us to obtain and maintain, or any delay in obtaining, regulatory approvals could cause our research and development expenditures to increase and, in turn, could have a material adverse effect on our results of operations. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">We expect our research and development expenditures to increase in 2015 compared to 2014 and that they will be in the range of $56.0 million to $59.0 million. We expect to continue development of our drug candidate tirasemtiv for the potential treatment of ALS. As part of our strategic alliance with Astellas, we expect to continue development of our drug candidate CK-2127107 for the potential treatment of SMA and potentially other diseases and medical conditions associated with muscle weakness or wasting. As part of our strategic alliance with Amgen, we expect to continue development of our drug candidate omecamtiv mecarbil for the potential treatment of heart failure. Non-cash expenses such as stock-based compensation and depreciation of approximately $1.5 million are included in our estimate of 2015 research and development expenses. </FONT></P> <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1"> </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">68 </FONT></P> <p Style='page-break-before:always'> <HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER"> <h5 align="left"><a href="#toc">Table of Contents</a></h5> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>General and administrative expenses </I></FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px"> </P> <TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="92%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center"> <TR> <TD WIDTH="64%"></TD> <TD VALIGN="bottom" WIDTH="4%"></TD> <TD></TD> <TD></TD> <TD></TD> <TD VALIGN="bottom" WIDTH="4%"></TD> <TD></TD> <TD></TD> <TD></TD> <TD VALIGN="bottom" WIDTH="4%"></TD> <TD></TD> <TD></TD> <TD></TD> <TD VALIGN="bottom" WIDTH="4%"></TD> <TD></TD> <TD></TD> <TD></TD> <TD VALIGN="bottom" WIDTH="4%"></TD> <TD></TD> <TD></TD> <TD></TD></TR> <TR> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom" COLSPAN="10" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Years Ended December 31,</B></FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Increase<BR>(Decrease)</B></FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD></TR> <TR> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>2014</B></FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>2013</B></FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>2012</B></FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>2014</B></FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>2013</B></FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD></TR> <TR> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom" COLSPAN="18" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>(In millions)</B></FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD></TR> <TR BGCOLOR="#cceeff"> <TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">General and administrative expenses</FONT></P></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD> <TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">17.3</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD> <TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">15.1</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD> <TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">12.4</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD> <TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">2.2</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD> <TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">2.7</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD></TR> </TABLE> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">General and administrative expenses increased in 2014 compared to 2013 and increased in 2013 compared to 2012. The increase of $2.2 million in 2014 was primarily due to increased spending of $0.9 million for personnel-related costs due to increased headcount, and $0.8 million for outside services mainly related to commercial development and market access assessment activities. The increase in 2013 was primarily due to increased spending of $1.7 million for personnel-related costs, $1.4 million for outside services and $0.2 million for legal expenses. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">We expect that general and administrative expenses in 2015 will increase compared to 2014 and will be in the range of $18.0 million to $20.0 million. Non-cash expenses such as stock-based compensation and depreciation of approximately $2.1 million are included in our estimate of 2015 general and administrative expenses. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>Interest and Other, net </I></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">Components of Interest and Other, net are as follows: </FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px"> </P> <TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="92%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center"> <TR> <TD WIDTH="65%"></TD> <TD VALIGN="bottom" WIDTH="5%"></TD> <TD></TD> <TD></TD> <TD></TD> <TD VALIGN="bottom" WIDTH="5%"></TD> <TD></TD> <TD></TD> <TD></TD> <TD VALIGN="bottom" WIDTH="5%"></TD> <TD></TD> <TD></TD> <TD></TD> <TD VALIGN="bottom" WIDTH="5%"></TD> <TD></TD> <TD></TD> <TD></TD> <TD VALIGN="bottom" WIDTH="4%"></TD> <TD></TD> <TD></TD> <TD></TD></TR> <TR> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom" COLSPAN="10" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Years Ended December 31,</B></FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Increase<BR>(Decrease)</B></FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD></TR> <TR> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>2014</B></FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>2013</B></FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>2012</B></FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>2014</B></FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>2013</B></FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD></TR> <TR> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom" COLSPAN="18" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>(In millions)</B></FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD></TR> <TR BGCOLOR="#cceeff"> <TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Interest income and other income</FONT></P></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD> <TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">0.1</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD> <TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">0.1</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD> <TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">0.1</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD> <TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">—</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD> <TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">—</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD></TR> <TR> <TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Interest expense and other expense</FONT></P></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">—</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">0.1</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">—</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(0.1</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">) </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">0.1</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD></TR> <TR STYLE="font-size:1px"> <TD VALIGN="bottom"></TD> <TD VALIGN="bottom"> </TD> <TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000"> </P></TD> <TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000"> </P></TD> <TD> </TD> <TD VALIGN="bottom"> </TD> <TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000"> </P></TD> <TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000"> </P></TD> <TD> </TD> <TD VALIGN="bottom"> </TD> <TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000"> </P></TD> <TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000"> </P></TD> <TD> </TD> <TD VALIGN="bottom"> </TD> <TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000"> </P></TD> <TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000"> </P></TD> <TD> </TD> <TD VALIGN="bottom"> </TD> <TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000"> </P></TD> <TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000"> </P></TD> <TD> </TD></TR> <TR BGCOLOR="#cceeff"> <TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Interest and Other, net</FONT></P></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD> <TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">0.1</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD> <TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">0.2</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD> <TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">0.1</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD> <TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(0.1</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">) </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD> <TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">0.1</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD></TR> <TR STYLE="font-size:1px"> <TD VALIGN="bottom"></TD> <TD VALIGN="bottom"> </TD> <TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000"> </P></TD> <TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000"> </P></TD> <TD> </TD> <TD VALIGN="bottom"> </TD> <TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000"> </P></TD> <TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000"> </P></TD> <TD> </TD> <TD VALIGN="bottom"> </TD> <TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000"> </P></TD> <TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000"> </P></TD> <TD> </TD> <TD VALIGN="bottom"> </TD> <TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000"> </P></TD> <TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000"> </P></TD> <TD> </TD> <TD VALIGN="bottom"> </TD> <TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000"> </P></TD> <TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000"> </P></TD> <TD> </TD></TR> </TABLE> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">Interest income and other income consisted primarily of interest income generated from our cash, cash equivalents and investments. Interest expense and other expense in 2013 consisted solely of net gains realized upon disposal of equipment. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Liquidity and Capital Resources </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">From August 5, 1997, our date of inception, through December 31, 2014, we funded our operations through the sale of equity securities, non-equity payments from collaborators, equipment financings, government grants and interest income. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">We have received net proceeds from the sale of equity securities of $489.1 million from August 5, 1997, the date of our inception, through December 31, 2014, excluding sales of equity to GlaxoSmithKline (“GSK”) Amgen and Astellas. Included in these proceeds are $94.0 million received upon closing of the initial public offering of our common stock in May 2004. In connection with execution of our collaboration and license agreement in 2001, GSK made a $14.0 million equity investment in Cytokinetics. GSK made additional equity investments in Cytokinetics in 2003 and 2004 of $3.0 million and $7.0 million, respectively. In January 2007, in connection with the execution of the Amgen Agreement, we received net proceeds of $32.9 million from a stock purchase agreement with Amgen. In June 2013, in conjunction with the Amgen Agreement Amendment, we sold 1,404,100 shares of common stock to Amgen for an aggregate purchase price of $10.0 million, which we received in June 2013. In December 2014, in connection with the Amended Astellas Agreement, we sold 2,040,816 shares of common stock to Astellas for an aggregate purchase price of $10.0 million. </FONT></P> <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1"> </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">69 </FONT></P> <p Style='page-break-before:always'> <HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER"> <h5 align="left"><a href="#toc">Table of Contents</a></h5> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">On a cumulative basis through December 31, 2014, we have received $128.7 million in non-equity payments from Amgen, $30.1 million in non-equity payments from Astellas, and $54.5 million in non-equity payments from GSK, in each case related to our strategic alliances. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>Amgen Agreement Amendment </I></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">In June 2013, we entered into the Amgen Agreement Amendment, which expanded our strategic alliance to include Japan (see Note 7, “Related Parties and Related Party Transactions” in the Notes to Consolidated Financial Statements). Under the terms of the Amgen Agreement Amendment, we received a non-refundable upfront license fee of $15.0 million in June 2013. In conjunction with the Amgen Agreement Amendment, we also entered into a common stock purchase agreement pursuant to which we sold 1,404,100 shares of our common stock to Amgen at a price per share of $7.12. The aggregate purchase price of $10.0 million was received in June 2013. We determined the fair value of the stock issued to Amgen to be $7.5 million. The excess of cash received over fair value of $2.5 million was deferred and was recognized as revenue as services were performed over approximately 12 months. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>Original Astellas Agreement </I></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">In June 2013, we entered into the Original Astellas Agreement (see Note 7, “Related Parties and Related Party Transactions” in the Notes to Consolidated Financial Statements). In July 2013, we received an upfront non-refundable license payment of $16.0 million in connection with the execution of the Original Astellas Agreement. Pursuant to that agreement. we were eligible to potentially receive approximately $25.5 million in reimbursement of sponsored research and development activities during the initial two years of the collaboration. In addition, the agreement also provided for payments for the achievement of pre-specified milestones relating to the joint research and development program. In 2014, we recognized revenue of $17.0 million relating to milestones under the Original Astellas Agreement. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>Amended Astellas Agreement </I></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">In December 2014, we entered into the Amended Astellas Agreement, which superseded the Original Astellas Agreement (see Note 7, “Related Parties and Related Party Transactions” in the Notes to Consolidated Financial Statements). Under the terms of the Amended Astellas Agreement, we received a non-refundable upfront license fee of $30.0 million in January 2015. In conjunction with the Amended Astellas Agreement, we also entered into a common stock purchase agreement pursuant to which we sold 2,040,816 shares common stock to Astellas at a price per share of $4.90. The aggregate purchase price of $10.0 million was received in December 2014. We determined the fair value of the stock issued to Astellas to be $9.1 million. The excess of cash received over fair value of $0.9 million was deferred and will be recognized as revenue as services are performed over approximately 24 months. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">Under the Amended Astellas Agreement, we are eligible to potentially receive over $20.0 million in reimbursement of sponsored research and development activities during the next two years of the collaboration. In addition, we may also receive payments for the achievement of pre-specified milestones relating to the Amended Astellas Agreement. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>April 2011 Private Offering </I></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">In April 2011, we entered into a securities purchase agreement with Deerfield Private Design Fund II, L.P., Deerfield Private Design International II, L.P., Deerfield Special Situations Fund, L.P., and Deerfield Special Situations Fund International Limited (collectively, “Deerfield”). In April 2011, pursuant to the agreement, we issued to Deerfield (i) 833,333 shares of common stock for a purchase price of $1.50 per share, (ii) 8,070 shares of Series A convertible preferred stock (the “Series A Preferred Stock”) for a purchase price of $1,500.00 per share, and (iii) warrants to purchase 1,114,168 shares of our common stock at an initial exercise price of </FONT></P> <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1"> </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">70 </FONT></P> <p Style='page-break-before:always'> <HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER"> <h5 align="left"><a href="#toc">Table of Contents</a></h5> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2"> $9.90 per share, for aggregate gross proceeds of approximately $20.1 million. After issuance costs of approximately $0.2 million, the net proceeds were approximately $19.9 million. The offering was made pursuant to a shelf registration statement that we filed with the SEC on November 10, 2008, which became effective on November 19, 2008 (File No. 333-155259). </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">On September 26, 2012, 8,070 shares of Series A Preferred Stock were converted into 1,345,000 shares of our common stock. The conversion was in accordance with the terms of the agreement with Deerfield under which the Series A Preferred Stock was issued in 2011. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>MLV </I></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">On June 10, 2011, we entered into an At-The-Market Issuance Sales Agreement (the “MLV Agreement”) with McNicoll, Lewis & Vlak LLC (“MLV”), pursuant to which we issued and sold, through January 2014, 2,397,278 shares for total net proceeds of approximately $15.2 million. Sales of our common stock through MLV in 2014 were 364,103 shares for net proceeds of approximately $2.4 million. No shares remain available to us for sale through the MLV Agreement. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>June 2012 Public Offerings </I></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">On June 20, 2012, we entered into underwriting agreements for two separate, concurrent offerings of our securities (the “June 2012 Public Offerings”). On June 25, 2012, pursuant to the underwriting agreements, in aggregate we issued to various investors (i) 9,320,176 shares of common stock for a purchase price of $4.56 per share, (ii) 23,026 shares of Series B convertible preferred stock (the “Series B Preferred Stock”) for a purchase price of $760.00 per share, and (iii) warrants to purchase 7,894,704 shares of our common stock at an exercise price of $5.28 per share, for aggregate gross proceeds of approximately $60.0 million. After issuance costs of approximately $4.0 million, the net proceeds from the June 2012 Public Offerings were approximately $56.0 million. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">The warrants issued in the June 2012 Public Offerings became exercisable upon issuance and will remain exercisable until June 25, 2017. The warrant holders are prohibited from exercising the warrants and obtaining shares of common stock if, as a result of such exercise, the holder and its affiliates would own more than 9.98% of the total number of shares of our common stock then issued and outstanding. We valued the warrants as of the date of issuance at $16.2 million using the Black-Scholes option pricing model and the following assumptions: a contractual term of five years, a risk-free interest rate of 0.73%, volatility of 76%, and the fair value of our common stock on the issuance date of $3.78. In February 2013, warrants to purchase 1,000 shares of our common stock at an exercise price of $5.28 per share were exercised in accordance with the June 2012 Public Offerings underwriting agreements. In April 2013, we issued 358,460 shares of common stock related to cashless exercise of warrants. As of December 31, 2014, warrants to purchase 6,577,928 shares of our common stock were outstanding and exercisable. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">In the first quarter of 2013, 4,000 shares of Series B Preferred Stock were converted into 666,667 shares of our common stock. In the second quarter of 2013, 15,026 shares of Series B Preferred Stock were converted into 2,504,333 shares of our common stock. In July, 2013, 4,000 shares of Series B Preferred Stock, which represented all remaining shares of Series B Preferred Stock, were converted into 666,681 shares of our common stock. The conversions were in accordance with the June 2012 Public Offerings underwriting agreements. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">The June 2012 Public Offerings were made pursuant to a shelf registration statement that we filed with the SEC on November 25, 2011, which became effective on December 8, 2011 (File No. 333-178189) and a supplemental shelf registration statement on Form S-3MEF that we filed with the SEC on June 20, 2012, which became effective on June 20, 2012 (File No. 333-182226). The closing of the June 2012 Public Offerings took place on June 25, 2012. </FONT></P> <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1"> </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">71 </FONT></P> <p Style='page-break-before:always'> <HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER"> <h5 align="left"><a href="#toc">Table of Contents</a></h5> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">The fair value of the common stock into which the Series B Preferred Stock was convertible exceeded the allocated purchase price of the Series B Preferred Stock by $1.3 million on the date of issuance, resulting in a beneficial conversion feature. We recognized the beneficial conversion feature as a one-time, non-cash, deemed dividend to the holders of Series B Preferred Stock on the date of issuance, which is the date the stock first became convertible. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>February 2014 Public Offering </I></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">On February 25, 2014, we closed an underwritten public offering for the issuance and sale of 5,031,250 shares of our common stock. The gross proceeds from this public offering were $40.3 million and net proceeds were $37.5 million, after deducting the underwriting discount and offering expenses. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>Sources and Uses of Cash </I></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">Our cash, cash equivalents and investments totaled $83.2 million at December 31, 2014, compared to $80.2 million at December 31, 2013. The increase of $3.0 million was primarily due to net proceeds received of $37.5 million from the February 2014 public offering and proceeds of $10.0 million from the sale of common stock to Astellas in December 2014, partially offset by the use of cash to fund operations. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">Net cash used in operating activities was $44.8 million in the year ended December 31, 2014 and was largely due to the ongoing research and development activities and recognition of deferred revenue for which payment had been received in prior periods. The net loss for the year ended December 31, 2014 included non-cash stock based compensation of $3.3 million. At December 31, 2014, deferred revenue of $33.6 million related largely to the deferral of revenue for Astellas based on the proportional performance model. Net cash used in operating activities was $7.7 million in the year ended December 31, 2013 and primarily resulted from the net loss of $33.7 million less $16.2 million of deferred revenue, $3.6 million of non-cash stock compensation expense and increased payables and accruals of $5.1 million. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">Net cash used in investing activities of $4.0 million in the year ended December 31, 2014 was primarily due to purchases of investments, which exceeded proceeds from the maturity of investments by $2.9 million, and purchases of property and equipment. Net cash used in investing activities was $1.5 million in the year ended December 31, 2013 and primarily consisted cash used to purchase investments, net of proceeds from the maturity of investments, of $1.0 million. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">Net cash provided by financing activities was $48.9 million in the year ended December 31, 2014 and primarily consisted of net proceeds of $37.5 million from the February 2014 public offering, net proceeds of $2.4 million from sales of our common stock pursuant to the MLV Agreement and proceeds of $9.1 million from the sale of common stock to Astellas. Net cash provided by financing activities was $14.5 million in the year ended December 31, 2013 and primarily consisted of the purchase of stock by Amgen (see Note 7, “Related Party Research and Development Arrangements”, in the Notes to Consolidated Financial Statements) and common stock sold pursuant to the MLV Agreement totaling $7.5 million. Repurchases of common stock in 2013 to satisfy employee withholding obligations totaled $0.6 million. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>Shelf Registration Statements.</I> In November 2011, we filed a shelf registration statement with the SEC, which was declared effective in December 2011 (the “December 2011 Shelf”). The December 2011 Shelf allowed us to issue securities from time to time for an aggregate offering price of up to $100.0 million. In June 2012, we filed a supplemental shelf registration statement with the SEC, which was declared effective in June 2012 (the “Supplemental Shelf”). The Supplemental Shelf allowed us to issue additional securities from time to time for an aggregate offering price of up to $20.0 million, and for a total aggregate offering price under the December 2011 Shelf and the Supplemental Shelf of up to $120.0 million. The December 2011 Shelf and the Supplemental Shelf expired in December 2014. </FONT></P> <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1"> </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">72 </FONT></P> <p Style='page-break-before:always'> <HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER"> <h5 align="left"><a href="#toc">Table of Contents</a></h5> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">In November 2013, we filed a shelf registration statement with the SEC, which was declared effective in December 2013 (the “December 2013 Shelf”). The December 2013 Shelf allowed us to issue common stock and preferred stock, and/or warrants to purchase any of such securities with a total value of up to $150.0 million. As of February 27, 2015, $109.7 million remains available to us under the December 2013 Shelf. The specific terms of offerings, if any, under the December 2013 Shelf will be established at the time of such offerings. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Contractual Obligations and Commitments </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">Our contractual obligations for the next five years and thereafter are as follows (in thousands): </FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px"> </P> <TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="92%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center"> <TR> <TD WIDTH="42%"></TD> <TD VALIGN="bottom" WIDTH="7%"></TD> <TD></TD> <TD></TD> <TD></TD> <TD VALIGN="bottom" WIDTH="7%"></TD> <TD></TD> <TD></TD> <TD></TD> <TD VALIGN="bottom" WIDTH="7%"></TD> <TD></TD> <TD></TD> <TD></TD> <TD VALIGN="bottom" WIDTH="7%"></TD> <TD></TD> <TD></TD> <TD></TD> <TD VALIGN="bottom" WIDTH="7%"></TD> <TD></TD> <TD></TD> <TD></TD></TR> <TR> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom" COLSPAN="18" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Payments Due by Period</B></FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD></TR> <TR> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Within<BR>One Year</B></FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>One to<BR>Three Years</B></FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Three to<BR>Five Years</B></FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>After<BR>Five Years</B></FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Total</B></FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD></TR> <TR BGCOLOR="#cceeff"> <TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Operating lease obligations(1)</FONT></P></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD> <TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">3,390</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD> <TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">7,130</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD> <TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1,860</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD> <TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">—</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD> <TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">12,380</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD></TR> <TR STYLE="font-size:1px"> <TD VALIGN="bottom"></TD> <TD VALIGN="bottom"> </TD> <TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000"> </P></TD> <TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000"> </P></TD> <TD> </TD> <TD VALIGN="bottom"> </TD> <TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000"> </P></TD> <TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000"> </P></TD> <TD> </TD> <TD VALIGN="bottom"> </TD> <TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000"> </P></TD> <TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000"> </P></TD> <TD> </TD> <TD VALIGN="bottom"> </TD> <TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000"> </P></TD> <TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000"> </P></TD> <TD> </TD> <TD VALIGN="bottom"> </TD> <TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000"> </P></TD> <TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000"> </P></TD> <TD> </TD></TR> </TABLE> <P STYLE="line-height:8px;margin-top:0px;margin-bottom:2px;border-bottom:0.5pt solid #000000;width:10%"> </P> <TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%"> <TR> <TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">(1)</FONT></TD> <TD ALIGN="left" VALIGN="top"> <P ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">Our long-term commitment under operating lease relates to payments under our facility lease in South San Francisco, California, which expires in 2018. </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">In future periods, we expect to incur substantial costs as we continue to expand our research programs and related research and development activities. We plan to continue development of our fast skeletal muscle troponin activator tirasemtiv for the potential treatment of ALS. We plan to continue development of our fast skeletal muscle troponin activator CK-2127107 for the potential treatment of SMA and potentially other diseases and conditions related to skeletal muscle weakness or wasting and research of potential next-generation compounds as part of our strategic alliance with Astellas. We plan to continue to support the development of our cardiac muscle myosin activator omecamtiv mecarbil for the potential treatment of heart failure and the research of potential next-generation compounds as part of our strategic alliance with Amgen. We expect to incur significant research and development expenses as we advance the research and development of compounds from our other muscle biology programs through research to candidate selection. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">Our future capital uses and requirements depend on numerous factors. These factors include, but are not limited to, the following: </FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px"> </P> <TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%"> <TR> <TD WIDTH="4%"><FONT SIZE="1"> </FONT></TD> <TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">•</FONT></TD> <TD WIDTH="1%" VALIGN="top"><FONT SIZE="1"> </FONT></TD> <TD ALIGN="left" VALIGN="top"> <P ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">the initiation, progress, timing, scope and completion of preclinical research, non-clinical development and clinical trials for our drug candidates and other compounds; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px"> </P> <TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%"> <TR> <TD WIDTH="4%"><FONT SIZE="1"> </FONT></TD> <TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">•</FONT></TD> <TD WIDTH="1%" VALIGN="top"><FONT SIZE="1"> </FONT></TD> <TD ALIGN="left" VALIGN="top"> <P ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">the time and costs involved in obtaining regulatory approvals; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px"> </P> <TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%"> <TR> <TD WIDTH="4%"><FONT SIZE="1"> </FONT></TD> <TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">•</FONT></TD> <TD WIDTH="1%" VALIGN="top"><FONT SIZE="1"> </FONT></TD> <TD ALIGN="left" VALIGN="top"> <P ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">delays that may be caused by requirements of regulatory agencies; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px"> </P> <TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%"> <TR> <TD WIDTH="4%"><FONT SIZE="1"> </FONT></TD> <TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">•</FONT></TD> <TD WIDTH="1%" VALIGN="top"><FONT SIZE="1"> </FONT></TD> <TD ALIGN="left" VALIGN="top"> <P ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">Amgen’s decisions with regard to funding of development and commercialization of omecamtiv mecarbil or other compounds for the potential treatment of heart failure under our collaboration; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px"> </P> <TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%"> <TR> <TD WIDTH="4%"><FONT SIZE="1"> </FONT></TD> <TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">•</FONT></TD> <TD WIDTH="1%" VALIGN="top"><FONT SIZE="1"> </FONT></TD> <TD ALIGN="left" VALIGN="top"> <P ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">Astellas’ decisions with regard to funding of development and commercialization of CK-2127107 or other skeletal muscle activators under our collaboration; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px"> </P> <TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%"> <TR> <TD WIDTH="4%"><FONT SIZE="1"> </FONT></TD> <TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">•</FONT></TD> <TD WIDTH="1%" VALIGN="top"><FONT SIZE="1"> </FONT></TD> <TD ALIGN="left" VALIGN="top"> <P ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">our level of funding for the development of current or future drug candidates; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px"> </P> <TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%"> <TR> <TD WIDTH="4%"><FONT SIZE="1"> </FONT></TD> <TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">•</FONT></TD> <TD WIDTH="1%" VALIGN="top"><FONT SIZE="1"> </FONT></TD> <TD ALIGN="left" VALIGN="top"> <P ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">the number of drug candidates we pursue; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px"> </P> <TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%"> <TR> <TD WIDTH="4%"><FONT SIZE="1"> </FONT></TD> <TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">•</FONT></TD> <TD WIDTH="1%" VALIGN="top"><FONT SIZE="1"> </FONT></TD> <TD ALIGN="left" VALIGN="top"> <P ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">the costs involved in filing and prosecuting patent applications and enforcing or defending patent claims; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px"> </P> <TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%"> <TR> <TD WIDTH="4%"><FONT SIZE="1"> </FONT></TD> <TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">•</FONT></TD> <TD WIDTH="1%" VALIGN="top"><FONT SIZE="1"> </FONT></TD> <TD ALIGN="left" VALIGN="top"> <P ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">our ability to establish and maintain selected strategic alliances required for the development of drug candidates and commercialization of our potential drugs; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px"> </P> <TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%"> <TR> <TD WIDTH="4%"><FONT SIZE="1"> </FONT></TD> <TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">•</FONT></TD> <TD WIDTH="1%" VALIGN="top"><FONT SIZE="1"> </FONT></TD> <TD ALIGN="left" VALIGN="top"> <P ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">our plans or ability to expand our drug development capabilities, including our capabilities to conduct clinical trials for our drug candidates; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px"> </P> <TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%"> <TR> <TD WIDTH="4%"><FONT SIZE="1"> </FONT></TD> <TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">•</FONT></TD> <TD WIDTH="1%" VALIGN="top"><FONT SIZE="1"> </FONT></TD> <TD ALIGN="left" VALIGN="top"> <P ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">our plans or ability to engage third party manufacturers for our drug candidates and potential drugs; </FONT></P></TD></TR></TABLE> <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1"> </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">73 </FONT></P> <p Style='page-break-before:always'> <HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER"> <h5 align="left"><a href="#toc">Table of Contents</a></h5> <TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%"> <TR> <TD WIDTH="4%"><FONT SIZE="1"> </FONT></TD> <TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">•</FONT></TD> <TD WIDTH="1%" VALIGN="top"><FONT SIZE="1"> </FONT></TD> <TD ALIGN="left" VALIGN="top"> <P ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">our plans or ability to build or access sales and marketing capabilities and to achieve market acceptance for potential drugs; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px"> </P> <TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%"> <TR> <TD WIDTH="4%"><FONT SIZE="1"> </FONT></TD> <TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">•</FONT></TD> <TD WIDTH="1%" VALIGN="top"><FONT SIZE="1"> </FONT></TD> <TD ALIGN="left" VALIGN="top"> <P ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">the expansion and advancement of our research programs; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px"> </P> <TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%"> <TR> <TD WIDTH="4%"><FONT SIZE="1"> </FONT></TD> <TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">•</FONT></TD> <TD WIDTH="1%" VALIGN="top"><FONT SIZE="1"> </FONT></TD> <TD ALIGN="left" VALIGN="top"> <P ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">the hiring of additional employees and consultants; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px"> </P> <TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%"> <TR> <TD WIDTH="4%"><FONT SIZE="1"> </FONT></TD> <TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">•</FONT></TD> <TD WIDTH="1%" VALIGN="top"><FONT SIZE="1"> </FONT></TD> <TD ALIGN="left" VALIGN="top"> <P ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">the expansion of our facilities; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px"> </P> <TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%"> <TR> <TD WIDTH="4%"><FONT SIZE="1"> </FONT></TD> <TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">•</FONT></TD> <TD WIDTH="1%" VALIGN="top"><FONT SIZE="1"> </FONT></TD> <TD ALIGN="left" VALIGN="top"> <P ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">the acquisition of technologies, products and other business opportunities that require financial commitments; and </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px"> </P> <TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%"> <TR> <TD WIDTH="4%"><FONT SIZE="1"> </FONT></TD> <TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">•</FONT></TD> <TD WIDTH="1%" VALIGN="top"><FONT SIZE="1"> </FONT></TD> <TD ALIGN="left" VALIGN="top"> <P ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">our revenues, if any, from successful development of our drug candidates and commercialization of potential drugs. </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">We have incurred an accumulated deficit of $497.2 million since inception and there can be no assurance that we will attain profitability. We are subject to risks common to clinical-stage companies including, but not limited to, development of new drug candidates, dependence on key personnel, and the ability to obtain additional capital as needed to fund our future plans. Our liquidity will be impaired if sufficient additional capital is not available on terms acceptable to us, if at all. To date, we have funded our operations primarily through sales of our common stock and convertible preferred stock, contract payments under our collaboration agreements, debt financing arrangements, grants and interest income. Until we achieve profitable operations, we intend to continue to fund operations through payments from strategic collaborations, additional sales of equity securities, grants and debt financings. We have never generated revenues from commercial sales of our drugs and may not have drugs to market for at least several years, if ever. Our success is dependent on our ability to obtain additional capital by entering into new strategic collaborations and/or through equity or debt financings, and ultimately on our and our collaborators’ ability to successfully develop and market one or more of our drug candidates. We cannot be certain that sufficient funds will be available from such collaborators or financings when needed or on satisfactory terms. Additionally, there can be no assurance that any of drugs based on our drug candidates will be accepted in the marketplace or that any future products can be developed or manufactured at an acceptable cost. These factors could have a material adverse effect on our future financial results, financial position and cash flows. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">Based on the current status of our development plans, we believe that our existing cash and cash equivalents, investments and interest earned on investments will be sufficient to meet our projected operating requirements for at least the next 12 months. If, at any time, our prospects for internally financing our research and development programs decline, we may decide to reduce research and development expenses by delaying, discontinuing or reducing our funding of development of one or more of our drug candidates or of other research and development programs. Alternatively, we might raise funds through strategic relationships, public or private financings or other arrangements. There can be no assurance that funding, if needed, will be available on attractive terms, or at all, or in accordance with our planned timelines. Furthermore, financing obtained through future strategic relationships may require us to forego certain commercialization and other rights to our drug candidates. Similarly, any additional equity financing may be dilutive to stockholders and debt financing, if available, may involve restrictive covenants. Our failure to raise capital as and when needed could have a negative impact on our financial condition and our ability to pursue our business strategy. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Off-balance Sheet Arrangements </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">We are not party to any off-balance sheet arrangements that have, or are reasonably likely to have, a material current or future effect on our financial condition, revenues or expenses, results of operations, liquidity, capital expenditures or capital resources. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Critical Accounting Policies and Estimates </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">Our discussion and analysis of our financial condition and results of operations are based on our financial statements, which have been prepared in accordance with accounting principles generally accepted in the </FONT></P> <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1"> </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">74 </FONT></P> <p Style='page-break-before:always'> <HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER"> <h5 align="left"><a href="#toc">Table of Contents</a></h5> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2"> United States. The preparation of these financial statements requires us to make estimates and judgments that affect the reported amounts of assets, liabilities and expenses and related disclosure of contingent assets and liabilities. We review our estimates on an ongoing basis. We base our estimates on historical experience and on various other assumptions that we believe to be reasonable under the circumstances. Actual results may differ from these estimates under different assumptions or conditions. While our significant accounting policies are described in more detail in the notes to our financial statements included in this Annual Report on Form 10-K, we believe the following accounting policies to be critical to the judgments and estimates used in the preparation of our financial statements. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Investments </I></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>Available-for-sale investments.</I> Our investments consist of municipal and government agency bonds, commercial paper, U.S. Treasury securities, and money market funds. We designate all investments as available-for-sale. Therefore, they are reported at fair value, with unrealized gains and losses recorded in accumulated other comprehensive income. See Note 3, “Cash Equivalents and Investments” in the Notes to Consolidated Financial Statements for further detailed discussion. Investments with original maturities greater than three months and remaining maturities less than one year are classified as short-term investments. Investments with remaining maturities greater than one year are classified as long-term investments. The amortized cost of debt securities in this category is adjusted for amortization of premiums and accretion of discounts to maturity. Such amortization is included in interest income. Realized gains and losses and declines in value judged to be other-than-temporary, if any, on available-for-sale securities are included in other income or expense. Interest and dividends on securities classified as available-for-sale are included in Interest and Other, net. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>Other-than-temporary impairment.</I> All of our available-for-sale investments are subject to a periodic impairment review. We recognize an impairment charge when a decline in the fair value of our investments below the cost basis is judged to be other-than-temporary. Factors considered by management in assessing whether an other-than-temporary impairment has occurred include: the nature of the investment; whether the decline in fair value is attributable to specific adverse conditions affecting the investment; the financial condition of the investee; the severity and the duration of the impairment; and whether we have the intent and ability to hold the investment to maturity. When we determine that an other-than-temporary impairment has occurred, the investment is written down to its market value at the end of the period in which we determine that an other-than-temporary decline occurred. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Revenue Recognition </I></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">We recognize revenue when the following criteria have been met: persuasive evidence of an arrangement exists; delivery has occurred or services have been rendered; the fee is fixed or determinable; and collectability is reasonably assured. Determination of whether persuasive evidence of an arrangement exists and whether delivery has occurred or services have been rendered are based on management’s judgments regarding the fixed nature of the fee charged for research performed and milestones met, and the collectability of those fees. Should changes in conditions cause management to determine these criteria are not met for certain future transactions, revenue recognized for any reporting period could be adversely affected. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">Revenue under our license and collaboration arrangements is recognized based on the performance requirements of the contract. Research and development revenues, which are earned under agreements with third parties for agreed research and development activities, may include non-refundable license fees, research and development funding, cost reimbursements and contingent milestones and royalties. Our collaborations prior to January 1, 2011 with multiple elements were evaluated and divided into separate units of accounting if certain criteria were met, including whether the delivered element had stand-alone value to the customer and whether there were vendor-specific objective and reliable evidence (“VSOE”) of the fair value of the undelivered items. The consideration we received was allocated among the separate units based on their respective fair values, and </FONT></P> <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1"> </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">75 </FONT></P> <p Style='page-break-before:always'> <HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER"> <h5 align="left"><a href="#toc">Table of Contents</a></h5> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2"> the applicable revenue recognition criteria were applied to each of the separate units. The consideration we received was combined and recognized as a single unit of accounting when criteria for separation were not met. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">On January 1, 2011, Accounting Standards Codification (“ASC”) Topic 605-25,<I> Revenue Recognition — Multiple-Element Arrangements</I> (“ASC 605-25”) on the recognition of revenues for agreements with multiple deliverables became effective and applies to any agreements we entered into on or after January 1, 2011. Under this updated guidance, revenue will be allocated to each element using a selling price hierarchy, where the selling price for an element is based on VSOE if available; third-party evidence (“TPE”), if available and VSOE is not available; or the best estimate of selling price, if neither VSOE nor TPE is available. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">Upfront, non-refundable licensing payments are assessed to determine whether or not the licensee is able to obtain stand-alone value from the license. Where the license does not have stand-alone value, non-refundable license fees are recognized as revenue as we perform under the applicable agreement. Where the level of effort is relatively consistent over the performance period, we recognize total fixed or determined revenue on a straight-line basis over the estimated period of expected performance. Where the license has stand-alone value, we recognize total license revenue at the time all revenue recognition criteria have been met. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">Also on January 1, 2011, ASC Topic 605-28, <I>Revenue Recognition — Milestone Method</I> (“ASC 605-28”) became effective and established the milestone method as an acceptable method of revenue recognition for certain contingent event-based payments under research and development arrangements. Under the milestone method, a payment that is contingent upon the achievement of a substantive milestone is recognized in its entirety in the period in which the milestone is achieved. A milestone is an event (i) that can be achieved based in whole or in part on either our performance or on the occurrence of a specific outcome resulting from our performance, (ii) for which there is substantive uncertainty at the date the arrangement is entered into that the event will be achieved, and (iii) that would result in additional payments being due to us. The determination that a milestone is substantive is based on management’s judgment and is made at the inception of the arrangement. Milestones are considered substantive when the consideration earned from the achievement of the milestone is (i) commensurate with either our performance to achieve the milestone or the enhancement of value of the item delivered as a result of a specific outcome resulting from our performance to achieve the milestone, (ii) relates solely to past performance and (iii) is reasonable relative to all deliverables and payment terms in the arrangement. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">Other contingent event-based payments received for which payment is either contingent solely upon the passage of time or the results of a collaborative partner’s performance are not considered milestones under ASC 605-28. In accordance with ASC 605-25<I>,</I> such payments will be recognized as revenue when all of the following criteria are met: (i) persuasive evidence of an arrangement exists, (ii) delivery has occurred or services have been rendered, (iii) price is fixed or determinable, (iv) and collectability is reasonably assured. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">For our collaborations entered into prior to January 1, 2011, we recognized and will continue to recognize milestone payments as revenue upon achievement of the milestone, provided the milestone payment was non-refundable, substantive effort and risk was involved in achieving the milestone and the amount of the milestone was reasonable in relation to the effort expended or risk associated with the achievement of the milestone. If these conditions were not met, we deferred the milestone payment and recognized it as revenue over the estimated period of performance under the contract as we completed our performance obligations. We have concluded that all of the future contingent milestone payments pursuant to our research and development arrangements entered into prior to January 1, 2011 are not considered substantive as they are the results of a collaborative partner’s performance. Therefore, they are not considered milestones under ASC 605-28. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">For our collaborations and material modifications entered into after January 1, 2011, we account for milestone payments under the provisions of ASC 605-28. We consider an event to be a milestone if there is substantive uncertainty at the date the arrangement is entered into that the event will be achieved, if the event can only be achieved with our performance, and if the achievement of the event results in payment to us. If we determine a milestone is substantive, we recognize revenue when payment is earned and becomes payable. For a milestone to be considered substantive, it must be achieved with our performance, be reasonable relative to the </FONT></P> <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1"> </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">76 </FONT></P> <p Style='page-break-before:always'> <HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER"> <h5 align="left"><a href="#toc">Table of Contents</a></h5> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2"> terms of the arrangement and be commensurate with our effort to achieve the milestone or commensurate with the enhanced value of the delivered item(s) as a result of the milestone achievement. If we determine a milestone is not substantive, we defer the payment and recognize revenue over the estimated period of performance as we complete our performance obligations. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">Research and development revenues and cost reimbursements are based upon negotiated rates for our FTEs and actual out-of-pocket costs. FTE rates are negotiated rates that are based upon our costs, and which we believe approximate fair value. Any amounts received in advance of performance are recorded as deferred revenue. None of the revenues recognized to date are refundable if the relevant research effort is not successful. In revenue arrangements in which both parties make payments to each other, we evaluate the payments to determine whether payments made by us will be recognized as a reduction of revenue or as expense. Revenue we recognize may be reduced by payments made to the other party under the arrangement unless we receive a separate and identifiable benefit in exchange for the payments and we can reasonably estimate the fair value of the benefit received. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">Funds received from third parties under grant arrangements are recorded as revenue if we are deemed to be the principal participant in the grant arrangement as the activities under the grant are part of our development programs. If we are not the principal participant, the grant funds are recorded as a reduction to research and development expense. Grant funds received are not refundable and are recognized when the related qualified research and development costs are incurred and when there is reasonable assurance that the funds will be received. Funds received in advance are recorded as deferred revenue. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Preclinical Study and Clinical Trial Accruals </I></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">A substantial portion of our preclinical studies and all of our clinical trials have been performed utilizing third-party contract research organizations (“CROs”) and other vendors. For preclinical studies, the significant factors used in estimating accruals include the percentage of work completed to date and contract milestones achieved. For clinical trial expenses, the significant factors used in estimating accruals include the number of patients enrolled, duration of enrollment and percentage of work completed to date. We monitor patient enrollment levels and related activities to the extent possible through internal reviews, correspondence and status meetings with CROs and review of contractual terms. Our estimates are dependent on the timeliness and accuracy of data provided by our CROs and other vendors. If we have incomplete or inaccurate data, we may under- or overestimate activity levels associated with various studies or clinical trials at a given point in time. In this event, we could record adjustments to research and development expenses in future periods when the actual activity levels become known. No material adjustments to preclinical study and clinical trial expenses have been recognized to date. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Stock-Based Compensation </I></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">We apply the accounting guidance for stock compensation, which establishes the accounting for share-based payment awards made to employees and directors, including employee stock options and employee stock purchases. Under this guidance, stock-based compensation cost is measured at the grant date based on the calculated fair value of the award, and is recognized as an expense on a straight-line basis over the employee’s requisite service period, generally the vesting period of the award. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">Under the guidance for stock compensation for non-employees, we measure the fair value of the award each period until the award is fully vested. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">As required under the accounting rules, we review our valuation assumptions at each grant date and, as a result, from time to time we will likely change the valuation assumptions we use to value stock based awards granted in future periods. The assumptions used in calculating the fair value of share-based payment awards represent management’s best estimates at the time, but these estimates involve inherent uncertainties and the application of management judgment. As a result, if conditions change and we use different assumptions, our stock-based compensation expense could be materially different in the future. In addition, we are required to estimate the expected forfeiture rate and recognize expense only for those shares expected to vest. If our actual </FONT></P> <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1"> </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">77 </FONT></P> <p Style='page-break-before:always'> <HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER"> <h5 align="left"><a href="#toc">Table of Contents</a></h5> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2"> forfeiture rate is materially different from our estimate, the stock-based compensation expense could be significantly different from what we have recorded in the current period. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Income Taxes </I></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">We account for income taxes under the asset and liability method. Under this method, deferred tax assets and liabilities are determined based on the difference between the financial statement and tax basis of assets and liabilities using enacted tax rates in effect for the year in which the differences are expected to affect taxable income. Valuation allowances are established when necessary to reduce the deferred tax assets to the amounts expected to be realized. We did not record an income tax provision in the years ended December 31, 2014, 2013 or 2012 because we had a net taxable loss in these periods. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">Based upon the weight of available evidence, which includes our historical operating performance, reported cumulative net losses since inception and difficulty in accurately forecasting our future results, we maintained a full valuation allowance on the net deferred tax assets as of December 31, 2014, 2013 and 2012. The valuation allowance was determined pursuant to the accounting guidance for income taxes, which requires an assessment of both positive and negative evidence when determining whether it is more likely than not that deferred tax assets are recoverable. We intend to maintain a full valuation allowance on the U.S. deferred tax assets until sufficient positive evidence exists to support reversal of the valuation allowance. The valuation allowance increased by $1.0 million in 2014, $13.7 million in 2013 and $21.1 million in 2012. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">We also follow the accounting guidance that defines the threshold for recognizing the benefits of tax return positions in the financial statements as “more-likely-than-not” to be sustained by the taxing authorities based solely on the technical merits of the position. If the recognition threshold is met, the tax benefit is measured and recognized as the largest amount of tax benefit that, in our judgment, is greater than 50% likely to be realized. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">The significant jurisdictions in which we file income tax returns are the United States and the state of California. For jurisdictions in which tax filings are made, we are subject to income tax examination for all fiscal years since inception. The IRS’s Large Business and International Division concluded its audit of the 2009 tax year with no material adjustments. However, in general, the statute of limitations for tax liabilities for these years remains open for the purpose of adjusting the amounts of the losses and credits carried forward from those years. We believe that we maintain adequate reserves for uncertain tax positions. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">Interest accrued related to unrecognized tax benefits and penalties was zero for 2014, 2013 and 2012. We account for interest related to unrecognized tax benefits and penalties by classifying both as income tax expense in the financial statements in accordance with the accounting guidance for uncertainty in income taxes. We do not expect our unrecognized tax benefits to change materially over the next twelve months. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">In general, under Section 382 of the Internal Revenue Code (“Section 382”), a corporation that undergoes an ‘ownership change’ is subject to limitations on its ability to utilize its pre-change net operating losses (“NOLs”) and tax credits to offset future taxable income. We have performed a Section 382 analysis and do not believe that we have experienced an ownership change since 2006. A portion of our existing NOLs and tax credits are subject to limitations arising from previous ownership changes. Future changes in our stock ownership, some of which are outside of our control, could result in an ownership change under Section 382 and result in additional limitations. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Recent Accounting Pronouncements </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">See “Recent Accounting Pronouncements” in Note 1, “Organization and Significant Accounting Policies” in the Notes to Consolidated Financial Statements for a discussion of recently adopted accounting pronouncements and accounting pronouncements not yet adopted, and their expected impact on our financial position and results of operations. </FONT></P> <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1"> </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">78 </FONT></P> <p Style='page-break-before:always'> <HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER"> <h5 align="left"><a href="#toc">Table of Contents</a></h5> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><A NAME="toc828167_12"></A>Item 7A. </B><B><I>Quantitative and Qualitative Disclosures About Market Risk</I></B><B> </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Interest Rate and Market Risk </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">Our exposure to market risk is limited to interest rate sensitivity, which is affected by changes in the general level of U.S. interest rates, particularly because the majority of our investments are in short-term debt securities. The primary objective of our investment activities is to preserve principal while at the same time maximizing the income we receive without significantly increasing risk. We are exposed to the impact of interest rate changes and changes in the market values of our investments. Our interest income is sensitive to changes in the general level of U.S. interest rates. Our exposure to market rate risk for changes in interest rates relates primarily to our investment portfolio. We have not used derivative financial instruments in our investment portfolio. We invest the majority of our excess cash in U.S. Treasuries and, by policy, limit the amount of credit exposure in any one issuer and investment class, with the exception of obligations of the U.S. Treasury and federal agencies, for which there are no such limits. We protect and preserve our invested funds by attempting to limit default, market and reinvestment risk. Investments in both fixed-rate and floating-rate interest-earning instruments carry a degree of interest rate risk. Fixed-rate securities may have their fair market value adversely impacted due to a rise in interest rates, while floating-rate securities may produce less income than expected if interest rates fall. Due in part to these factors, our future investment income may fall short of expectations due to changes in interest rates. To minimize risk, we maintain our portfolio of cash and cash equivalents and short- and long-term investments in a variety of interest-bearing instruments, including U.S. government and agency securities, high grade municipal and U.S. bonds and money market funds. Our investment portfolio of short- and long-term investments is subject to interest rate risk, and will fall in value if market interest rates increase. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">Our cash and cash equivalents are invested in highly liquid securities with maturities of three months or less at the time of purchase. Consequently, we do not consider our cash and cash equivalents to be subject to significant interest rate risk and have therefore excluded them from the table below. We do not have any foreign currency or derivative financial instruments. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">The table below presents the principal amounts and weighted average interest rates by year of maturity for our investment portfolio (dollars in thousands): </FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px"> </P> <TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="92%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center"> <TR> <TD WIDTH="65%"></TD> <TD VALIGN="bottom" WIDTH="7%"></TD> <TD></TD> <TD></TD> <TD></TD> <TD VALIGN="bottom" WIDTH="6%"></TD> <TD></TD> <TD></TD> <TD></TD> <TD VALIGN="bottom" WIDTH="6%"></TD> <TD></TD> <TD></TD> <TD></TD></TR> <TR> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>2015</B></FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Total</B></FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Fair Value at<BR>December 31,<BR>2014</B></FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD></TR> <TR BGCOLOR="#cceeff"> <TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Assets:</B></FONT></P></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"></TD> <TD VALIGN="bottom"></TD> <TD VALIGN="bottom"></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"></TD> <TD VALIGN="bottom"></TD> <TD VALIGN="bottom"></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"></TD> <TD VALIGN="bottom"></TD> <TD VALIGN="bottom"></TD></TR> <TR> <TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Investments</FONT></P></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD> <TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">63,013</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD> <TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">63,013</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD> <TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">63,013</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD></TR> <TR BGCOLOR="#cceeff"> <TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Average interest rate</FONT></P></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">0.17</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">% </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">0.17</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">% </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"></TD> <TD VALIGN="bottom"></TD> <TD VALIGN="bottom"></TD></TR> </TABLE> <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1"> </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">79 </FONT></P> <p Style='page-break-before:always'> <HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER"> <h5 align="left"><a href="#toc">Table of Contents</a></h5> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><A NAME="toc828167_13"></A>Item 8. </B><B><I>Financial Statements and Supplementary Data</I></B><B> </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>CYTOKINETICS, INCORPORATED </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>INDEX TO FINANCIAL STATEMENTS </B></FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px"> </P> <TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center"> <TR> <TD WIDTH="95%"></TD> <TD VALIGN="bottom" WIDTH="3%"></TD> <TD></TD> <TD></TD> <TD></TD></TR> <TR> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Page</B></FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD></TR> <TR> <TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><A HREF="#tx828167_50">Report of Independent Registered Public Accounting Firm</A></FONT></P></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">81</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD></TR> <TR> <TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><A HREF="#tx828167_51">Consolidated Balance Sheets</A></FONT></P></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">82</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD></TR> <TR> <TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><A HREF="#tx828167_52">Consolidated Statements of Comprehensive Loss</A></FONT></P></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">83</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD></TR> <TR> <TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><A HREF="#tx828167_53">Consolidated Statements of Stockholders’ Equity</A></FONT></P></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">84</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD></TR> <TR> <TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><A HREF="#tx828167_54">Consolidated Statements of Cash Flows</A></FONT></P></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">86</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD></TR> <TR> <TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><A HREF="#tx828167_55">Notes to Consolidated Financial Statements</A></FONT></P></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">87</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD></TR> </TABLE> <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1"> </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">80 </FONT></P> <p Style='page-break-before:always'> <HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER"> <h5 align="left"><a href="#toc">Table of Contents</a></h5> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><A NAME="tx828167_50"></A>REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">To the Board of Directors and Stockholders of Cytokinetics, Incorporated: </FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">In our opinion, the accompanying consolidated balance sheets and the related consolidated statements of comprehensive loss, of stockholders’ equity and of cash flows present fairly, in all material respects, the financial position of Cytokinetics, Incorporated at December 31, 2014 and December 31, 2013, and the results of its operations and its cash flows for each of the three years in the period ended December 31, 2014 in conformity with accounting principles generally accepted in the United States of America. Also in our opinion, the Company maintained, in all material respects, effective internal control over financial reporting as of December 31, 2014, based on criteria established in <I>Internal Control — Integrated Framework 2013</I> issued by the Committee of Sponsoring Organizations of the Treadway Commission (COSO). The Company’s management is responsible for these financial statements, for maintaining effective internal control over financial reporting and for its assessment of the effectiveness of internal control over financial reporting, included in the accompanying Management’s Report on Internal Control over Financial Reporting under Item 9A. Our responsibility is to express opinions on these financial statements and on the Company’s internal control over financial reporting based on our integrated audits. We conducted our audits in accordance with the standards of the Public Company Accounting Oversight Board (United States). Those standards require that we plan and perform the audits to obtain reasonable assurance about whether the financial statements are free of material misstatement and whether effective internal control over financial reporting was maintained in all material respects. Our audits of the financial statements included examining, on a test basis, evidence supporting the amounts and disclosures in the financial statements, assessing the accounting principles used and significant estimates made by management, and evaluating the overall financial statement presentation. Our audit of internal control over financial reporting included obtaining an understanding of internal control over financial reporting, assessing the risk that a material weakness exists, and testing and evaluating the design and operating effectiveness of internal control based on the assessed risk. Our audits also included performing such other procedures as we considered necessary in the circumstances. We believe that our audits provide a reasonable basis for our opinions. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">A company’s internal control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles. A company’s internal control over financial reporting includes those policies and procedures that (i) pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of the assets of the company; (ii) provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted accounting principles, and that receipts and expenditures of the company are being made only in accordance with authorizations of management and directors of the company; and (iii) provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use, or disposition of the company’s assets that could have a material effect on the financial statements. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Also, projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">/s/ PRICEWATERHOUSECOOPERS LLP </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">San Jose, CA </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">March 6, 2015 </FONT></P> <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1"> </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">81 </FONT></P> <p Style='page-break-before:always'> <HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER"> <h5 align="left"><a href="#toc">Table of Contents</a></h5> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>CYTOKINETICS, INCORPORATED </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><A NAME="tx828167_51"></A>CONSOLIDATED BALANCE SHEETS </B></FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px"> </P> <TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center"> <TR> <TD WIDTH="79%"></TD> <TD VALIGN="bottom" WIDTH="4%"></TD> <TD></TD> <TD></TD> <TD></TD> <TD VALIGN="bottom" WIDTH="4%"></TD> <TD></TD> <TD></TD> <TD></TD></TR> <TR> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>December 31,</B></FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD></TR> <TR> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>2014</B></FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>2013</B></FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD></TR> <TR> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom" COLSPAN="6" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>(In thousands, except</B></FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD></TR> <TR> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom" COLSPAN="6" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>share and per share data)</B></FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD></TR> <TR BGCOLOR="#cceeff"> <TD VALIGN="top" COLSPAN="8" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>ASSETS</B></FONT></TD> <TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B> </B></FONT></TD></TR> <TR> <TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Current assets:</FONT></P></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"></TD> <TD VALIGN="bottom"></TD> <TD VALIGN="bottom"></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"></TD> <TD VALIGN="bottom"></TD> <TD VALIGN="bottom"></TD></TR> <TR BGCOLOR="#cceeff"> <TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Cash and cash equivalents</FONT></P></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD> <TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">20,215</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD> <TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">20,158</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD></TR> <TR> <TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Short-term investments</FONT></P></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">63,013</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">57,570</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD></TR> <TR BGCOLOR="#cceeff"> <TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Related party accounts receivable</FONT></P></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">46,646</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">5</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD></TR> <TR> <TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Prepaid and other current assets</FONT></P></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1,257</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1,605</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD></TR> <TR STYLE="font-size:1px"> <TD VALIGN="bottom"></TD> <TD VALIGN="bottom"> </TD> <TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000"> </P></TD> <TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000"> </P></TD> <TD> </TD> <TD VALIGN="bottom"> </TD> <TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000"> </P></TD> <TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000"> </P></TD> <TD> </TD></TR> <TR BGCOLOR="#cceeff"> <TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Total current assets</FONT></P></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">131,131</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">79,338</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD></TR> <TR> <TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Property and equipment, net</FONT></P></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1,637</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1,221</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD></TR> <TR BGCOLOR="#cceeff"> <TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Long-term investments</FONT></P></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">—</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">2,502</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD></TR> <TR> <TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Other assets</FONT></P></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">200</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">127</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD></TR> <TR STYLE="font-size:1px"> <TD VALIGN="bottom"></TD> <TD VALIGN="bottom"> </TD> <TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000"> </P></TD> <TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000"> </P></TD> <TD> </TD> <TD VALIGN="bottom"> </TD> <TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000"> </P></TD> <TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000"> </P></TD> <TD> </TD></TR> <TR BGCOLOR="#cceeff"> <TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Total assets</FONT></P></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD> <TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">132,968</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD> <TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">83,188</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD></TR> <TR STYLE="font-size:1px"> <TD VALIGN="bottom"></TD> <TD VALIGN="bottom"> </TD> <TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000"> </P></TD> <TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000"> </P></TD> <TD> </TD> <TD VALIGN="bottom"> </TD> <TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000"> </P></TD> <TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000"> </P></TD> <TD> </TD></TR> <TR> <TD VALIGN="top" COLSPAN="8" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>LIABILITIES AND STOCKHOLDERS’ EQUITY</B></FONT></TD> <TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B> </B></FONT></TD></TR> <TR BGCOLOR="#cceeff"> <TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Current liabilities:</FONT></P></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"></TD> <TD VALIGN="bottom"></TD> <TD VALIGN="bottom"></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"></TD> <TD VALIGN="bottom"></TD> <TD VALIGN="bottom"></TD></TR> <TR> <TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Accounts payable</FONT></P></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD> <TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1,361</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD> <TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">3,709</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD></TR> <TR BGCOLOR="#cceeff"> <TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Accrued liabilities</FONT></P></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">5,400</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">8,272</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD></TR> <TR> <TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Deferred revenue, current</FONT></P></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">17,042</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">14,701</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD></TR> <TR BGCOLOR="#cceeff"> <TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Short-term portion of deferred rent</FONT></P></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">52</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">22</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD></TR> <TR STYLE="font-size:1px"> <TD VALIGN="bottom"></TD> <TD VALIGN="bottom"> </TD> <TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000"> </P></TD> <TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000"> </P></TD> <TD> </TD> <TD VALIGN="bottom"> </TD> <TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000"> </P></TD> <TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000"> </P></TD> <TD> </TD></TR> <TR> <TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Total current liabilities</FONT></P></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">23,855</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">26,704</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD></TR> <TR BGCOLOR="#cceeff"> <TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Deferred revenue, non-current</FONT></P></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">16,558</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1,500</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD></TR> <TR> <TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Long-term portion of deferred rent</FONT></P></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">491</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">542</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD></TR> <TR STYLE="font-size:1px"> <TD VALIGN="bottom"></TD> <TD VALIGN="bottom"> </TD> <TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000"> </P></TD> <TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000"> </P></TD> <TD> </TD> <TD VALIGN="bottom"> </TD> <TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000"> </P></TD> <TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000"> </P></TD> <TD> </TD></TR> <TR BGCOLOR="#cceeff"> <TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Total liabilities</FONT></P></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">40,904</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">28,746</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD></TR> <TR STYLE="font-size:1px"> <TD VALIGN="bottom"></TD> <TD VALIGN="bottom"> </TD> <TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000"> </P></TD> <TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000"> </P></TD> <TD> </TD> <TD VALIGN="bottom"> </TD> <TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000"> </P></TD> <TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000"> </P></TD> <TD> </TD></TR> <TR> <TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Commitments and contingencies (Note 10)</FONT></P></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"></TD> <TD VALIGN="bottom"></TD> <TD VALIGN="bottom"></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"></TD> <TD VALIGN="bottom"></TD> <TD VALIGN="bottom"></TD></TR> <TR BGCOLOR="#cceeff"> <TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Stockholders’ equity:</FONT></P></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"></TD> <TD VALIGN="bottom"></TD> <TD VALIGN="bottom"></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"></TD> <TD VALIGN="bottom"></TD> <TD VALIGN="bottom"></TD></TR> <TR> <TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Preferred stock, $0.001 par value:</FONT></P></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"></TD> <TD VALIGN="bottom"></TD> <TD VALIGN="bottom"></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"></TD> <TD VALIGN="bottom"></TD> <TD VALIGN="bottom"></TD></TR> <TR BGCOLOR="#cceeff"> <TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Authorized: 10,000,000 shares;</FONT></P></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"></TD> <TD VALIGN="bottom"></TD> <TD VALIGN="bottom"></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"></TD> <TD VALIGN="bottom"></TD> <TD VALIGN="bottom"></TD></TR> <TR> <TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Issued and outstanding: Series A Convertible Preferred Stock — zero shares at December 31, 2014 and December 31, 2013</FONT></P></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">—</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">—</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD></TR> <TR BGCOLOR="#cceeff"> <TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Common stock, $0.001 par value:</FONT></P></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"></TD> <TD VALIGN="bottom"></TD> <TD VALIGN="bottom"></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"></TD> <TD VALIGN="bottom"></TD> <TD VALIGN="bottom"></TD></TR> <TR> <TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Authorized: 81,500,000 shares;</FONT></P></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"></TD> <TD VALIGN="bottom"></TD> <TD VALIGN="bottom"></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"></TD> <TD VALIGN="bottom"></TD> <TD VALIGN="bottom"></TD></TR> <TR BGCOLOR="#cceeff"> <TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Issued and outstanding: 38,659,738 shares at December 31, 2014 and 30,681,624 shares at December 31, 2013</FONT></P></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">39</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">31</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD></TR> <TR> <TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Additional paid-in capital</FONT></P></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">589,272</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">537,001</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD></TR> <TR BGCOLOR="#cceeff"> <TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Accumulated other comprehensive income</FONT></P></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(4</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">) </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">7</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD></TR> <TR> <TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Accumulated deficit</FONT></P></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(497,243</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">) </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(482,597</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">) </FONT></TD></TR> <TR STYLE="font-size:1px"> <TD VALIGN="bottom"></TD> <TD VALIGN="bottom"> </TD> <TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000"> </P></TD> <TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000"> </P></TD> <TD> </TD> <TD VALIGN="bottom"> </TD> <TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000"> </P></TD> <TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000"> </P></TD> <TD> </TD></TR> <TR BGCOLOR="#cceeff"> <TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Total stockholders’ equity</FONT></P></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">92,064</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">54,442</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD></TR> <TR STYLE="font-size:1px"> <TD VALIGN="bottom"></TD> <TD VALIGN="bottom"> </TD> <TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000"> </P></TD> <TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000"> </P></TD> <TD> </TD> <TD VALIGN="bottom"> </TD> <TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000"> </P></TD> <TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000"> </P></TD> <TD> </TD></TR> <TR> <TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Total liabilities and stockholders’ equity</FONT></P></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD> <TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">132,968</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD> <TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">83,188</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD></TR> <TR STYLE="font-size:1px"> <TD VALIGN="bottom"></TD> <TD VALIGN="bottom"> </TD> <TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000"> </P></TD> <TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000"> </P></TD> <TD> </TD> <TD VALIGN="bottom"> </TD> <TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000"> </P></TD> <TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000"> </P></TD> <TD> </TD></TR> </TABLE> <P STYLE="margin-top:36px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">The accompanying notes are an integral part of these financial statements. </FONT></P> <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1"> </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">82 </FONT></P> <p Style='page-break-before:always'> <HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER"> <h5 align="left"><a href="#toc">Table of Contents</a></h5> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>CYTOKINETICS, INCORPORATED </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><A NAME="tx828167_52"></A>CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS </B></FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px"> </P> <TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center"> <TR> <TD WIDTH="73%"></TD> <TD VALIGN="bottom" WIDTH="3%"></TD> <TD></TD> <TD></TD> <TD></TD> <TD VALIGN="bottom" WIDTH="3%"></TD> <TD></TD> <TD></TD> <TD></TD> <TD VALIGN="bottom" WIDTH="3%"></TD> <TD></TD> <TD></TD> <TD></TD></TR> <TR> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom" COLSPAN="10" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Years Ended December 31,</B></FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD></TR> <TR> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>2014</B></FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>2013</B></FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>2012</B></FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD></TR> <TR> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom" COLSPAN="10" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>(In thousands, except per share data)</B></FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD></TR> <TR BGCOLOR="#cceeff"> <TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Revenues:</FONT></P></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"></TD> <TD VALIGN="bottom"></TD> <TD VALIGN="bottom"></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"></TD> <TD VALIGN="bottom"></TD> <TD VALIGN="bottom"></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"></TD> <TD VALIGN="bottom"></TD> <TD VALIGN="bottom"></TD></TR> <TR> <TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Research and development revenues from related parties</FONT></P></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD> <TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">19,538</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD> <TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">2,019</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD> <TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">4,177</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD></TR> <TR BGCOLOR="#cceeff"> <TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Research and development, grant and other revenues</FONT></P></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">17,566</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">7,547</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">3,382</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD></TR> <TR> <TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">License revenues from related parties</FONT></P></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">—</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">17,230</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">—</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD></TR> <TR BGCOLOR="#cceeff"> <TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">License revenues</FONT></P></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">9,836</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">3,852</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">—</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD></TR> <TR STYLE="font-size:1px"> <TD VALIGN="bottom"></TD> <TD VALIGN="bottom"> </TD> <TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000"> </P></TD> <TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000"> </P></TD> <TD> </TD> <TD VALIGN="bottom"> </TD> <TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000"> </P></TD> <TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000"> </P></TD> <TD> </TD> <TD VALIGN="bottom"> </TD> <TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000"> </P></TD> <TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000"> </P></TD> <TD> </TD></TR> <TR> <TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Total revenues</FONT></P></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">46,940</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">30,648</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">7,559</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD></TR> <TR STYLE="font-size:1px"> <TD VALIGN="bottom"></TD> <TD VALIGN="bottom"> </TD> <TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000"> </P></TD> <TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000"> </P></TD> <TD> </TD> <TD VALIGN="bottom"> </TD> <TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000"> </P></TD> <TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000"> </P></TD> <TD> </TD> <TD VALIGN="bottom"> </TD> <TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000"> </P></TD> <TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000"> </P></TD> <TD> </TD></TR> <TR BGCOLOR="#cceeff"> <TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Operating expenses:</FONT></P></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"></TD> <TD VALIGN="bottom"></TD> <TD VALIGN="bottom"></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"></TD> <TD VALIGN="bottom"></TD> <TD VALIGN="bottom"></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"></TD> <TD VALIGN="bottom"></TD> <TD VALIGN="bottom"></TD></TR> <TR> <TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Research and development</FONT></P></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">44,426</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">49,450</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">35,643</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD></TR> <TR BGCOLOR="#cceeff"> <TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">General and administrative</FONT></P></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">17,268</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">15,092</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">12,429</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD></TR> <TR> <TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Restructuring reversals</FONT></P></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">—</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">—</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(56</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">) </FONT></TD></TR> <TR STYLE="font-size:1px"> <TD VALIGN="bottom"></TD> <TD VALIGN="bottom"> </TD> <TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000"> </P></TD> <TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000"> </P></TD> <TD> </TD> <TD VALIGN="bottom"> </TD> <TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000"> </P></TD> <TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000"> </P></TD> <TD> </TD> <TD VALIGN="bottom"> </TD> <TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000"> </P></TD> <TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000"> </P></TD> <TD> </TD></TR> <TR BGCOLOR="#cceeff"> <TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Total operating expenses</FONT></P></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">61,694</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">64,542</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">48,016</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD></TR> <TR STYLE="font-size:1px"> <TD VALIGN="bottom"></TD> <TD VALIGN="bottom"> </TD> <TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000"> </P></TD> <TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000"> </P></TD> <TD> </TD> <TD VALIGN="bottom"> </TD> <TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000"> </P></TD> <TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000"> </P></TD> <TD> </TD> <TD VALIGN="bottom"> </TD> <TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000"> </P></TD> <TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000"> </P></TD> <TD> </TD></TR> <TR> <TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Operating loss</FONT></P></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(14,754</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">) </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(33,894</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">) </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(40,457</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">) </FONT></TD></TR> <TR BGCOLOR="#cceeff"> <TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Interest and other, net</FONT></P></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">108</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">177</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">87</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD></TR> <TR STYLE="font-size:1px"> <TD VALIGN="bottom"></TD> <TD VALIGN="bottom"> </TD> <TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000"> </P></TD> <TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000"> </P></TD> <TD> </TD> <TD VALIGN="bottom"> </TD> <TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000"> </P></TD> <TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000"> </P></TD> <TD> </TD> <TD VALIGN="bottom"> </TD> <TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000"> </P></TD> <TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000"> </P></TD> <TD> </TD></TR> <TR> <TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Loss before income taxes</FONT></P></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(14,646</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">) </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(33,717</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">) </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(40,370</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">) </FONT></TD></TR> <TR BGCOLOR="#cceeff"> <TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Income tax benefit</FONT></P></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">—</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">—</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">—</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD></TR> <TR STYLE="font-size:1px"> <TD VALIGN="bottom"></TD> <TD VALIGN="bottom"> </TD> <TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000"> </P></TD> <TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000"> </P></TD> <TD> </TD> <TD VALIGN="bottom"> </TD> <TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000"> </P></TD> <TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000"> </P></TD> <TD> </TD> <TD VALIGN="bottom"> </TD> <TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000"> </P></TD> <TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000"> </P></TD> <TD> </TD></TR> <TR> <TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Net loss</FONT></P></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(14,646</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">) </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(33,717</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">) </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(40,370</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">) </FONT></TD></TR> <TR BGCOLOR="#cceeff"> <TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Deemed dividend related to beneficial conversion feature of convertible preferred stock</FONT></P></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">—</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">—</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(1,307</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">) </FONT></TD></TR> <TR STYLE="font-size:1px"> <TD VALIGN="bottom"></TD> <TD VALIGN="bottom"> </TD> <TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000"> </P></TD> <TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000"> </P></TD> <TD> </TD> <TD VALIGN="bottom"> </TD> <TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000"> </P></TD> <TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000"> </P></TD> <TD> </TD> <TD VALIGN="bottom"> </TD> <TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000"> </P></TD> <TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000"> </P></TD> <TD> </TD></TR> <TR> <TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Net loss allocable to common stockholders</FONT></P></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD> <TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(14,646</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">) </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD> <TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(33,717</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">) </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD> <TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(41,677</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">) </FONT></TD></TR> <TR STYLE="font-size:1px"> <TD VALIGN="bottom"></TD> <TD VALIGN="bottom"> </TD> <TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000"> </P></TD> <TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000"> </P></TD> <TD> </TD> <TD VALIGN="bottom"> </TD> <TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000"> </P></TD> <TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000"> </P></TD> <TD> </TD> <TD VALIGN="bottom"> </TD> <TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000"> </P></TD> <TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000"> </P></TD> <TD> </TD></TR> <TR BGCOLOR="#cceeff"> <TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Net loss per share allocable to common stockholders — basic and diluted</FONT></P></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD> <TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(0.41</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">) </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD> <TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(1.24</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">) </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD> <TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(2.30</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">) </FONT></TD></TR> <TR STYLE="font-size:1px"> <TD VALIGN="bottom"></TD> <TD VALIGN="bottom"> </TD> <TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000"> </P></TD> <TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000"> </P></TD> <TD> </TD> <TD VALIGN="bottom"> </TD> <TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000"> </P></TD> <TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000"> </P></TD> <TD> </TD> <TD VALIGN="bottom"> </TD> <TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000"> </P></TD> <TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000"> </P></TD> <TD> </TD></TR> <TR> <TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Weighted-average number of shares used in computing net loss per share allocable to common stockholders — basic and diluted</FONT></P></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">35,709</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">27,275</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">18,107</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD></TR> <TR STYLE="font-size:1px"> <TD VALIGN="bottom"></TD> <TD VALIGN="bottom"> </TD> <TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000"> </P></TD> <TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000"> </P></TD> <TD> </TD> <TD VALIGN="bottom"> </TD> <TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000"> </P></TD> <TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000"> </P></TD> <TD> </TD> <TD VALIGN="bottom"> </TD> <TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000"> </P></TD> <TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000"> </P></TD> <TD> </TD></TR> <TR BGCOLOR="#cceeff"> <TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Other comprehensive gain (loss):</FONT></P></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"></TD> <TD VALIGN="bottom"></TD> <TD VALIGN="bottom"></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"></TD> <TD VALIGN="bottom"></TD> <TD VALIGN="bottom"></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"></TD> <TD VALIGN="bottom"></TD> <TD VALIGN="bottom"></TD></TR> <TR> <TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Unrealized gains (losses) on available-for-sale securities, net</FONT></P></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(11</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">) </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(11</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">) </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">15</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD></TR> <TR STYLE="font-size:1px"> <TD VALIGN="bottom"></TD> <TD VALIGN="bottom"> </TD> <TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000"> </P></TD> <TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000"> </P></TD> <TD> </TD> <TD VALIGN="bottom"> </TD> <TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000"> </P></TD> <TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000"> </P></TD> <TD> </TD> <TD VALIGN="bottom"> </TD> <TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000"> </P></TD> <TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000"> </P></TD> <TD> </TD></TR> <TR BGCOLOR="#cceeff"> <TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Comprehensive loss</FONT></P></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD> <TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(14,657</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">) </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD> <TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(33,728</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">) </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD> <TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(40,355</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">) </FONT></TD></TR> <TR STYLE="font-size:1px"> <TD VALIGN="bottom"></TD> <TD VALIGN="bottom"> </TD> <TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000"> </P></TD> <TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000"> </P></TD> <TD> </TD> <TD VALIGN="bottom"> </TD> <TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000"> </P></TD> <TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000"> </P></TD> <TD> </TD> <TD VALIGN="bottom"> </TD> <TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000"> </P></TD> <TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000"> </P></TD> <TD> </TD></TR> </TABLE> <P STYLE="margin-top:180px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">The accompanying notes are an integral part of these financial statements. </FONT></P> <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1"> </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">83 </FONT></P> <p Style='page-break-before:always'> <HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER"> <h5 align="left"><a href="#toc">Table of Contents</a></h5> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>CYTOKINETICS, INCORPORATED </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><A NAME="tx828167_53"></A>CONSOLIDATED STATEMENTS OF STOCKHOLDERS’ EQUITY </B></FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px"> </P> <TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center"> <TR> <TD WIDTH="44%"></TD> <TD VALIGN="bottom" WIDTH="2%"></TD> <TD></TD> <TD></TD> <TD></TD> <TD VALIGN="bottom" WIDTH="2%"></TD> <TD></TD> <TD></TD> <TD></TD> <TD VALIGN="bottom" WIDTH="2%"></TD> <TD></TD> <TD></TD> <TD></TD> <TD VALIGN="bottom" WIDTH="2%"></TD> <TD></TD> <TD></TD> <TD></TD> <TD VALIGN="bottom" WIDTH="2%"></TD> <TD></TD> <TD></TD> <TD></TD> <TD VALIGN="bottom" WIDTH="2%"></TD> <TD></TD> <TD></TD> <TD></TD> <TD VALIGN="bottom" WIDTH="2%"></TD> <TD></TD> <TD></TD> <TD></TD> <TD VALIGN="bottom" WIDTH="2%"></TD> <TD></TD> <TD></TD> <TD></TD></TR> <TR> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom" COLSPAN="6" STYLE="border-bottom:1px solid #000000"> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px"> </P> <P STYLE="margin-top:0px;margin-bottom:1px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Common Stock</B></FONT></P></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom" COLSPAN="6" STYLE="border-bottom:1px solid #000000"> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px"> </P> <P STYLE="margin-top:0px;margin-bottom:1px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Preferred Stock</B></FONT></P></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Additional<BR>Paid-In<BR>Capital</B></FONT></TD> <TD VALIGN="bottom" ROWSPAN="2"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Accumulated<BR>Other<BR>Comprehensive<BR>Income<BR>(Loss)</B></FONT></TD> <TD VALIGN="bottom" ROWSPAN="2"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B><BR>Accumulated<BR>Deficit</B></FONT></TD> <TD VALIGN="bottom" ROWSPAN="2"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Total<BR>Stockholders’<BR>Equity </B></FONT></TD> <TD VALIGN="bottom" ROWSPAN="2"><FONT SIZE="1"> </FONT></TD></TR> <TR> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Shares</B></FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Amount</B></FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Shares</B></FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Amount</B></FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD></TR> <TR> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom" COLSPAN="30" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>(In thousands, except share and per share data)</B></FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD></TR> <TR BGCOLOR="#cceeff"> <TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="1">Balance, December 31, 2011</FONT></P></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"> </FONT></TD> <TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">12,485,957</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">$</FONT></TD> <TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">13</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"> </FONT></TD> <TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">8,070</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">$</FONT></TD> <TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">—</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">$</FONT></TD> <TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">456,672</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">$</FONT></TD> <TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">3</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">$</FONT></TD> <TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">(408,510</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">) </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">$</FONT></TD> <TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">48,178</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"> </FONT></TD></TR> <TR> <TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="1">Issuance of common stock pursuant to ESPP at a weighted price of $4.32 per share</FONT></P></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"> </FONT></TD> <TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">15,010</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"> </FONT></TD> <TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">—</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"> </FONT></TD> <TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">—</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"> </FONT></TD> <TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">—</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"> </FONT></TD> <TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">65</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"> </FONT></TD> <TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">—</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"> </FONT></TD> <TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">—</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"> </FONT></TD> <TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">65</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"> </FONT></TD></TR> <TR BGCOLOR="#cceeff"> <TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="1">Issuance of common stock upon exercise of restricted stock units</FONT></P></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"> </FONT></TD> <TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">144,045</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"> </FONT></TD> <TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">—</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"> </FONT></TD> <TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">—</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"> </FONT></TD> <TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">—</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"> </FONT></TD> <TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">(401</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">) </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"> </FONT></TD> <TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">—</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"> </FONT></TD> <TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">—</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"> </FONT></TD> <TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">(401</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">) </FONT></TD></TR> <TR> <TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="1">Issuance of common stock pursuant to June 2012 public offerings at $4.56 per share, net of issuance costs of $2,139</FONT></P></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"> </FONT></TD> <TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">9,320,176</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"> </FONT></TD> <TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">9</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"> </FONT></TD> <TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">—</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"> </FONT></TD> <TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">—</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"> </FONT></TD> <TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">29,907</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"> </FONT></TD> <TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">—</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"> </FONT></TD> <TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">—</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"> </FONT></TD> <TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">29,916</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"> </FONT></TD></TR> <TR BGCOLOR="#cceeff"> <TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="1">Issuance of Series B convertible preferred stock pursuant to June 2012 public offerings at $760 per share, net of issuance costs of $881</FONT></P></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"> </FONT></TD> <TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">—</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"> </FONT></TD> <TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">—</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"> </FONT></TD> <TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">23,026</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"> </FONT></TD> <TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">—</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"> </FONT></TD> <TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">12,318</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"> </FONT></TD> <TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">—</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"> </FONT></TD> <TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">—</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"> </FONT></TD> <TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">12,318</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"> </FONT></TD></TR> <TR> <TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="1">Issuance of warrants pursuant to June 2012 public offerings, net of issuance costs of $984</FONT></P></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"> </FONT></TD> <TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">—</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"> </FONT></TD> <TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">—</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"> </FONT></TD> <TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">—</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"> </FONT></TD> <TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">—</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"> </FONT></TD> <TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">13,761</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"> </FONT></TD> <TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">—</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"> </FONT></TD> <TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">—</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"> </FONT></TD> <TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">13,761</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"> </FONT></TD></TR> <TR BGCOLOR="#cceeff"> <TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="1">Issuance of common stock to MLV at $6.30-$7.20 per share, net of commission and issuance costs of $89</FONT></P></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"> </FONT></TD> <TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">432,724</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"> </FONT></TD> <TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">1</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"> </FONT></TD> <TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">—</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"> </FONT></TD> <TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">—</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"> </FONT></TD> <TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">2,819</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"> </FONT></TD> <TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">—</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"> </FONT></TD> <TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">—</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"> </FONT></TD> <TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">2,820</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"> </FONT></TD></TR> <TR> <TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="1">Conversion of Series A convertible preferred stock to common stock at $1,000 per share</FONT></P></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"> </FONT></TD> <TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">1,345,000</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"> </FONT></TD> <TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">1</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"> </FONT></TD> <TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">(8,070</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">) </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"> </FONT></TD> <TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">—</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"> </FONT></TD> <TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">(1</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">) </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"> </FONT></TD> <TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">—</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"> </FONT></TD> <TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">—</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"> </FONT></TD> <TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">—</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"> </FONT></TD></TR> <TR BGCOLOR="#cceeff"> <TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="1">Stock-based compensation</FONT></P></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"> </FONT></TD> <TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">—</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"> </FONT></TD> <TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">—</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"> </FONT></TD> <TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">—</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"> </FONT></TD> <TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">—</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"> </FONT></TD> <TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">3,783</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"> </FONT></TD> <TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">—</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"> </FONT></TD> <TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">—</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"> </FONT></TD> <TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">3,783</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"> </FONT></TD></TR> <TR> <TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="1">Other comprehensive income</FONT></P></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"> </FONT></TD> <TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">—</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"> </FONT></TD> <TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">—</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"> </FONT></TD> <TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">—</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"> </FONT></TD> <TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">—</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"> </FONT></TD> <TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">—</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"> </FONT></TD> <TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">15</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"> </FONT></TD> <TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">—</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"> </FONT></TD> <TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">15</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"> </FONT></TD></TR> <TR BGCOLOR="#cceeff"> <TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="1">Net loss</FONT></P></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"> </FONT></TD> <TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">—</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"> </FONT></TD> <TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">—</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"> </FONT></TD> <TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">—</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"> </FONT></TD> <TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">—</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"> </FONT></TD> <TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">—</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"> </FONT></TD> <TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">—</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"> </FONT></TD> <TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">(40,370</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">) </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"> </FONT></TD> <TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">(40,370</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">) </FONT></TD></TR> <TR STYLE="font-size:1px"> <TD VALIGN="bottom"></TD> <TD VALIGN="bottom"> </TD> <TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000"> </P></TD> <TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000"> </P></TD> <TD> </TD> <TD VALIGN="bottom"> </TD> <TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000"> </P></TD> <TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000"> </P></TD> <TD> </TD> <TD VALIGN="bottom"> </TD> <TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000"> </P></TD> <TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000"> </P></TD> <TD> </TD> <TD VALIGN="bottom"> </TD> <TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000"> </P></TD> <TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000"> </P></TD> <TD> </TD> <TD VALIGN="bottom"> </TD> <TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000"> </P></TD> <TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000"> </P></TD> <TD> </TD> <TD VALIGN="bottom"> </TD> <TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000"> </P></TD> <TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000"> </P></TD> <TD> </TD> <TD VALIGN="bottom"> </TD> <TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000"> </P></TD> <TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000"> </P></TD> <TD> </TD> <TD VALIGN="bottom"> </TD> <TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000"> </P></TD> <TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000"> </P></TD> <TD> </TD></TR> <TR> <TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="1">Balance, December 31, 2012</FONT></P></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"> </FONT></TD> <TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">23,742,912</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"> </FONT></TD> <TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">24</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"> </FONT></TD> <TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">23,026</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"> </FONT></TD> <TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">—</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">$</FONT></TD> <TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">518,923</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"> </FONT></TD> <TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">18</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"> </FONT></TD> <TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">(448,880</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">) </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"> </FONT></TD> <TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">70,085</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"> </FONT></TD></TR> <TR BGCOLOR="#cceeff"> <TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="1">Issuance of common stock upon exercise of stock options for cash at $4.02-$11.10 per share</FONT></P></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"> </FONT></TD> <TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">21,397</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"> </FONT></TD> <TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">—</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"> </FONT></TD> <TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">—</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"> </FONT></TD> <TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">—</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"> </FONT></TD> <TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">114</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"> </FONT></TD> <TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">—</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"> </FONT></TD> <TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">—</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"> </FONT></TD> <TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">114</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"> </FONT></TD></TR> <TR> <TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="1">Issuance of common stock pursuant to ESPP at a weighted price of $3.66 per share</FONT></P></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"> </FONT></TD> <TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">14,985</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"> </FONT></TD> <TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">—</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"> </FONT></TD> <TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">—</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"> </FONT></TD> <TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">—</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"> </FONT></TD> <TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">55</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"> </FONT></TD> <TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">—</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"> </FONT></TD> <TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">—</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"> </FONT></TD> <TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">55</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"> </FONT></TD></TR> <TR BGCOLOR="#cceeff"> <TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="1">Issuance of common stock upon exercise of restricted stock units</FONT></P></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"> </FONT></TD> <TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">130,534</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"> </FONT></TD> <TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">—</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"> </FONT></TD> <TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">—</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"> </FONT></TD> <TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">—</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"> </FONT></TD> <TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">(623</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">) </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"> </FONT></TD> <TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">—</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"> </FONT></TD> <TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">—</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"> </FONT></TD> <TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">(623</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">) </FONT></TD></TR> <TR> <TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="1">Issuance of common stock to related party for $7.12 per share, net of issuance costs of $21</FONT></P></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"> </FONT></TD> <TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">1,404,100</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"> </FONT></TD> <TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">2</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"> </FONT></TD> <TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">—</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"> </FONT></TD> <TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">—</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"> </FONT></TD> <TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">7,448</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"> </FONT></TD> <TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">—</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"> </FONT></TD> <TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">—</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"> </FONT></TD> <TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">7,450</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"> </FONT></TD></TR> <TR BGCOLOR="#cceeff"> <TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="1">Issuance of common stock upon exercise of warrants</FONT></P></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"> </FONT></TD> <TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">359,460</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"> </FONT></TD> <TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">—</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"> </FONT></TD> <TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">—</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"> </FONT></TD> <TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">—</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"> </FONT></TD> <TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">5</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"> </FONT></TD> <TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">—</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"> </FONT></TD> <TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">—</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"> </FONT></TD> <TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">5</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"> </FONT></TD></TR> <TR> <TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="1">Conversion of Series B convertible preferred stock to common stock at $1,000 per share</FONT></P></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"> </FONT></TD> <TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">3,837,681</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"> </FONT></TD> <TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">4</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"> </FONT></TD> <TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">(23,026</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">) </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"> </FONT></TD> <TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">—</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"> </FONT></TD> <TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">(4</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">) </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"> </FONT></TD> <TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">—</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"> </FONT></TD> <TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">—</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"> </FONT></TD> <TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">—</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"> </FONT></TD></TR> <TR BGCOLOR="#cceeff"> <TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="1">Fractional shares settlement pursuant to reverse stock split</FONT></P></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"> </FONT></TD> <TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">(28</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">) </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"> </FONT></TD> <TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">—</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"> </FONT></TD> <TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">—</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"> </FONT></TD> <TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">—</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"> </FONT></TD> <TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">—</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"> </FONT></TD> <TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">—</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"> </FONT></TD> <TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">—</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"> </FONT></TD> <TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">—</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"> </FONT></TD></TR> <TR> <TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="1">Issuance of common stock to MLV at $6.50-$6.79 per share, net of commission and issuance costs of $232</FONT></P></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"> </FONT></TD> <TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">1,170,583</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"> </FONT></TD> <TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">1</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"> </FONT></TD> <TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">—</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"> </FONT></TD> <TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">—</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"> </FONT></TD> <TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">7,486</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"> </FONT></TD> <TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">—</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"> </FONT></TD> <TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">—</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"> </FONT></TD> <TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">7,487</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"> </FONT></TD></TR> <TR BGCOLOR="#cceeff"> <TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="1">Stock-based compensation</FONT></P></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"> </FONT></TD> <TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">—</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"> </FONT></TD> <TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">—</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"> </FONT></TD> <TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">—</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"> </FONT></TD> <TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">—</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"> </FONT></TD> <TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">3,597</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"> </FONT></TD> <TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">—</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"> </FONT></TD> <TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">—</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"> </FONT></TD> <TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">3,597</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"> </FONT></TD></TR> <TR> <TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="1">Other comprehensive loss</FONT></P></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"> </FONT></TD> <TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">—</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"> </FONT></TD> <TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">—</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"> </FONT></TD> <TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">—</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"> </FONT></TD> <TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">—</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"> </FONT></TD> <TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">—</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"> </FONT></TD> <TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">(11</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">) </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"> </FONT></TD> <TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">—</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"> </FONT></TD> <TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">(11</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">) </FONT></TD></TR> <TR BGCOLOR="#cceeff"> <TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="1">Net loss</FONT></P></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"> </FONT></TD> <TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">—</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"> </FONT></TD> <TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">—</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"> </FONT></TD> <TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">—</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"> </FONT></TD> <TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">—</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"> </FONT></TD> <TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">—</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"> </FONT></TD> <TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">—</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"> </FONT></TD> <TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">(33,717</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">) </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"> </FONT></TD> <TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">(33,717</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">) </FONT></TD></TR> <TR STYLE="font-size:1px"> <TD VALIGN="bottom"></TD> <TD VALIGN="bottom"> </TD> <TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000"> </P></TD> <TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000"> </P></TD> <TD> </TD> <TD VALIGN="bottom"> </TD> <TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000"> </P></TD> <TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000"> </P></TD> <TD> </TD> <TD VALIGN="bottom"> </TD> <TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000"> </P></TD> <TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000"> </P></TD> <TD> </TD> <TD VALIGN="bottom"> </TD> <TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000"> </P></TD> <TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000"> </P></TD> <TD> </TD> <TD VALIGN="bottom"> </TD> <TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000"> </P></TD> <TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000"> </P></TD> <TD> </TD> <TD VALIGN="bottom"> </TD> <TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000"> </P></TD> <TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000"> </P></TD> <TD> </TD> <TD VALIGN="bottom"> </TD> <TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000"> </P></TD> <TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000"> </P></TD> <TD> </TD> <TD VALIGN="bottom"> </TD> <TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000"> </P></TD> <TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000"> </P></TD> <TD> </TD></TR></TABLE> <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1"> </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">84 </FONT></P> <p Style='page-break-before:always'> <HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER"> <h5 align="left"><a href="#toc">Table of Contents</a></h5> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>CYTOKINETICS, INCORPORATED </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>CONSOLIDATED STATEMENTS OF STOCKHOLDERS’ EQUITY — (Continued) </B></FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px"> </P> <TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center"> <TR> <TD WIDTH="45%"></TD> <TD VALIGN="bottom" WIDTH="2%"></TD> <TD></TD> <TD></TD> <TD></TD> <TD VALIGN="bottom" WIDTH="2%"></TD> <TD></TD> <TD></TD> <TD></TD> <TD VALIGN="bottom" WIDTH="2%"></TD> <TD></TD> <TD></TD> <TD></TD> <TD VALIGN="bottom" WIDTH="2%"></TD> <TD></TD> <TD></TD> <TD></TD> <TD VALIGN="bottom" WIDTH="2%"></TD> <TD></TD> <TD></TD> <TD></TD> <TD VALIGN="bottom" WIDTH="2%"></TD> <TD></TD> <TD></TD> <TD></TD> <TD VALIGN="bottom" WIDTH="2%"></TD> <TD></TD> <TD></TD> <TD></TD> <TD VALIGN="bottom" WIDTH="2%"></TD> <TD></TD> <TD></TD> <TD></TD></TR> <TR> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom" COLSPAN="6" STYLE="border-bottom:1px solid #000000"> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px"> </P> <P STYLE="margin-top:0px;margin-bottom:1px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Common Stock</B></FONT></P></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom" COLSPAN="6" STYLE="border-bottom:1px solid #000000"> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px"> </P> <P STYLE="margin-top:0px;margin-bottom:1px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Preferred Stock</B></FONT></P></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Additional<BR>Paid-In<BR>Capital</B></FONT></TD> <TD VALIGN="bottom" ROWSPAN="2"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Accumulated<BR>Other<BR>Comprehensive<BR>Income<BR>(Loss)</B></FONT></TD> <TD VALIGN="bottom" ROWSPAN="2"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B><BR>Accumulated<BR>Deficit</B></FONT></TD> <TD VALIGN="bottom" ROWSPAN="2"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Total<BR>Stockholders’<BR>Equity </B></FONT></TD> <TD VALIGN="bottom" ROWSPAN="2"><FONT SIZE="1"> </FONT></TD></TR> <TR> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Shares</B></FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Amount</B></FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Shares</B></FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Amount</B></FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD></TR> <TR> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom" COLSPAN="30" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>(In thousands, except share and per share data)</B></FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD></TR> <TR BGCOLOR="#cceeff"> <TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="1">Balance, December 31, 2013</FONT></P></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"> </FONT></TD> <TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">30,681,624</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">$</FONT></TD> <TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">31</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"> </FONT></TD> <TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">—</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">$</FONT></TD> <TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">—</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">$</FONT></TD> <TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">537,001</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">$</FONT></TD> <TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">7</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">$</FONT></TD> <TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">(482,597</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">) </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">$</FONT></TD> <TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">54,442</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"> </FONT></TD></TR> <TR> <TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="1">Issuance of common stock upon exercise of stock options for cash at $6.00 per share</FONT></P></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"> </FONT></TD> <TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">390</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"> </FONT></TD> <TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">—</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"> </FONT></TD> <TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">—</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"> </FONT></TD> <TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">—</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"> </FONT></TD> <TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">2</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"> </FONT></TD> <TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">—</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"> </FONT></TD> <TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">—</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"> </FONT></TD> <TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">2</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"> </FONT></TD></TR> <TR BGCOLOR="#cceeff"> <TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="1">Issuance of common stock pursuant to ESPP at a weighted price of $3.38 per share</FONT></P></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"> </FONT></TD> <TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">19,726</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"> </FONT></TD> <TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">—</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"> </FONT></TD> <TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">—</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"> </FONT></TD> <TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">—</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"> </FONT></TD> <TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">67</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"> </FONT></TD> <TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">—</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"> </FONT></TD> <TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">—</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"> </FONT></TD> <TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">67</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"> </FONT></TD></TR> <TR> <TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="1">Issuance of common stock upon exercise of restricted stock units</FONT></P></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"> </FONT></TD> <TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">11,704</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"> </FONT></TD> <TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">—</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"> </FONT></TD> <TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">—</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"> </FONT></TD> <TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">—</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"> </FONT></TD> <TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">(96</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">) </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"> </FONT></TD> <TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">—</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"> </FONT></TD> <TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">—</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"> </FONT></TD> <TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">(96</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">) </FONT></TD></TR> <TR BGCOLOR="#cceeff"> <TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="1">Issuance of common stock upon exercise of warrants</FONT></P></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"> </FONT></TD> <TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">510,125</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"> </FONT></TD> <TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">1</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"> </FONT></TD> <TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">—</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"> </FONT></TD> <TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">—</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"> </FONT></TD> <TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">5</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"> </FONT></TD> <TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">—</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"> </FONT></TD> <TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">—</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"> </FONT></TD> <TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">6</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"> </FONT></TD></TR> <TR> <TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="1">Issuance of common stock to MLV at $6.64-$6.79 per share, net of commission and issuance costs of $74</FONT></P></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"> </FONT></TD> <TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">364,103</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"> </FONT></TD> <TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">—</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"> </FONT></TD> <TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">—</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"> </FONT></TD> <TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">—</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"> </FONT></TD> <TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">2,376</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"> </FONT></TD> <TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">—</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"> </FONT></TD> <TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">—</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"> </FONT></TD> <TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">2,376</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"> </FONT></TD></TR> <TR BGCOLOR="#cceeff"> <TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="1">Issuance of common stock to collaborative partner for $4.90 per share, net of issuance costs of $8</FONT></P></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"> </FONT></TD> <TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">2,040,816</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"> </FONT></TD> <TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">2</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"> </FONT></TD> <TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">—</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"> </FONT></TD> <TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">—</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"> </FONT></TD> <TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">9,100</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"> </FONT></TD> <TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">—</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"> </FONT></TD> <TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">—</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"> </FONT></TD> <TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">9,102</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"> </FONT></TD></TR> <TR> <TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="1">Issuance of common stock pursuant to February 2014 public offerings at $8.00 per share, net of issuance costs of $2,800</FONT></P></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"> </FONT></TD> <TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">5,031,250</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"> </FONT></TD> <TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">5</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"> </FONT></TD> <TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">—</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"> </FONT></TD> <TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">—</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"> </FONT></TD> <TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">37,487</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"> </FONT></TD> <TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">—</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"> </FONT></TD> <TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">—</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"> </FONT></TD> <TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">37,492</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"> </FONT></TD></TR> <TR BGCOLOR="#cceeff"> <TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="1">Stock-based compensation</FONT></P></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"> </FONT></TD> <TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">—</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"> </FONT></TD> <TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">—</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"> </FONT></TD> <TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">—</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"> </FONT></TD> <TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">—</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"> </FONT></TD> <TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">3,330</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"> </FONT></TD> <TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">—</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"> </FONT></TD> <TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">—</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"> </FONT></TD> <TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">3,330</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"> </FONT></TD></TR> <TR> <TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="1">Other comprehensive loss</FONT></P></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"> </FONT></TD> <TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">—</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"> </FONT></TD> <TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">—</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"> </FONT></TD> <TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">—</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"> </FONT></TD> <TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">—</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"> </FONT></TD> <TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">—</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"> </FONT></TD> <TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">(11</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">) </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"> </FONT></TD> <TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">—</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"> </FONT></TD> <TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">(11</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">) </FONT></TD></TR> <TR BGCOLOR="#cceeff"> <TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="1">Net loss</FONT></P></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"> </FONT></TD> <TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">—</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"> </FONT></TD> <TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">—</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"> </FONT></TD> <TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">—</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"> </FONT></TD> <TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">—</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"> </FONT></TD> <TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">—</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"> </FONT></TD> <TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">—</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"> </FONT></TD> <TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">(14,646</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">) </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"> </FONT></TD> <TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">(14,646</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">) </FONT></TD></TR> <TR STYLE="font-size:1px"> <TD VALIGN="bottom"></TD> <TD VALIGN="bottom"> </TD> <TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000"> </P></TD> <TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000"> </P></TD> <TD> </TD> <TD VALIGN="bottom"> </TD> <TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000"> </P></TD> <TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000"> </P></TD> <TD> </TD> <TD VALIGN="bottom"> </TD> <TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000"> </P></TD> <TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000"> </P></TD> <TD> </TD> <TD VALIGN="bottom"> </TD> <TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000"> </P></TD> <TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000"> </P></TD> <TD> </TD> <TD VALIGN="bottom"> </TD> <TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000"> </P></TD> <TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000"> </P></TD> <TD> </TD> <TD VALIGN="bottom"> </TD> <TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000"> </P></TD> <TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000"> </P></TD> <TD> </TD> <TD VALIGN="bottom"> </TD> <TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000"> </P></TD> <TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000"> </P></TD> <TD> </TD> <TD VALIGN="bottom"> </TD> <TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000"> </P></TD> <TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000"> </P></TD> <TD> </TD></TR> <TR> <TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="1">Balance, December 31, 2014</FONT></P></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"> </FONT></TD> <TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">38,659,738</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">$</FONT></TD> <TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">39</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"> </FONT></TD> <TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">—</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">$</FONT></TD> <TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">—</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">$</FONT></TD> <TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">589,272</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">$</FONT></TD> <TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">(4</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">) </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">$</FONT></TD> <TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">(497,243</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">) </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">$</FONT></TD> <TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">92,064</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"> </FONT></TD></TR> <TR STYLE="font-size:1px"> <TD VALIGN="bottom"></TD> <TD VALIGN="bottom"> </TD> <TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000"> </P></TD> <TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000"> </P></TD> <TD> </TD> <TD VALIGN="bottom"> </TD> <TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000"> </P></TD> <TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000"> </P></TD> <TD> </TD> <TD VALIGN="bottom"> </TD> <TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000"> </P></TD> <TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000"> </P></TD> <TD> </TD> <TD VALIGN="bottom"> </TD> <TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000"> </P></TD> <TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000"> </P></TD> <TD> </TD> <TD VALIGN="bottom"> </TD> <TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000"> </P></TD> <TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000"> </P></TD> <TD> </TD> <TD VALIGN="bottom"> </TD> <TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000"> </P></TD> <TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000"> </P></TD> <TD> </TD> <TD VALIGN="bottom"> </TD> <TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000"> </P></TD> <TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000"> </P></TD> <TD> </TD> <TD VALIGN="bottom"> </TD> <TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000"> </P></TD> <TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000"> </P></TD> <TD> </TD></TR> </TABLE> <P STYLE="font-size:132px;margin-top:0px;margin-bottom:0px"> </P> <P STYLE="margin-top:132px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">The accompanying notes are an integral part of these financial statements. </FONT></P> <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1"> </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">85 </FONT></P> <p Style='page-break-before:always'> <HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER"> <h5 align="left"><a href="#toc">Table of Contents</a></h5> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>CYTOKINETICS, INCORPORATED </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><A NAME="tx828167_54"></A>CONSOLIDATED STATEMENTS OF CASH FLOWS </B></FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px"> </P> <TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center"> <TR> <TD WIDTH="73%"></TD> <TD VALIGN="bottom" WIDTH="3%"></TD> <TD></TD> <TD></TD> <TD></TD> <TD VALIGN="bottom" WIDTH="3%"></TD> <TD></TD> <TD></TD> <TD></TD> <TD VALIGN="bottom" WIDTH="3%"></TD> <TD></TD> <TD></TD> <TD></TD></TR> <TR> <TD ROWSPAN="2" VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom" COLSPAN="10" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Years Ended December 31,</B></FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD></TR> <TR> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>2014</B></FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>2013</B></FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>2012</B></FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD></TR> <TR> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom" COLSPAN="10" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>(In thousands)</B></FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD></TR> <TR BGCOLOR="#cceeff"> <TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Cash flows from operating activities:</B></FONT></P></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"></TD> <TD VALIGN="bottom"></TD> <TD VALIGN="bottom"></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"></TD> <TD VALIGN="bottom"></TD> <TD VALIGN="bottom"></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"></TD> <TD VALIGN="bottom"></TD> <TD VALIGN="bottom"></TD></TR> <TR> <TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Net loss</FONT></P></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD> <TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(14,646</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">) </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD> <TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(33,717</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">) </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD> <TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(40,370</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">) </FONT></TD></TR> <TR BGCOLOR="#cceeff"> <TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Adjustments to reconcile net loss to net cash used in operating activities:</FONT></P></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"></TD> <TD VALIGN="bottom"></TD> <TD VALIGN="bottom"></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"></TD> <TD VALIGN="bottom"></TD> <TD VALIGN="bottom"></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"></TD> <TD VALIGN="bottom"></TD> <TD VALIGN="bottom"></TD></TR> <TR> <TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Depreciation and amortization of property and equipment</FONT></P></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">490</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">433</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">591</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD></TR> <TR BGCOLOR="#cceeff"> <TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Gain on disposal of equipment</FONT></P></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">—</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(79</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">) </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(2</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">) </FONT></TD></TR> <TR> <TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Non-cash restructuring expenses, net of reversals</FONT></P></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">—</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">—</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(56</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">) </FONT></TD></TR> <TR BGCOLOR="#cceeff"> <TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Stock-based compensation</FONT></P></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">3,330</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">3,597</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">3,783</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD></TR> <TR> <TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Gain on sale of investments</FONT></P></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(6</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">) </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">—</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">—</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD></TR> <TR BGCOLOR="#cceeff"> <TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Changes in operating assets and liabilities:</FONT></P></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"></TD> <TD VALIGN="bottom"></TD> <TD VALIGN="bottom"></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"></TD> <TD VALIGN="bottom"></TD> <TD VALIGN="bottom"></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"></TD> <TD VALIGN="bottom"></TD> <TD VALIGN="bottom"></TD></TR> <TR> <TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Related party accounts receivable</FONT></P></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(46,641</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">) </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">—</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">10</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD></TR> <TR BGCOLOR="#cceeff"> <TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Prepaid and other assets</FONT></P></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">274</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">818</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(320</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">) </FONT></TD></TR> <TR> <TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Accounts payable</FONT></P></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(2,178</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">) </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1,656</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">690</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD></TR> <TR BGCOLOR="#cceeff"> <TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Accrued and other liabilities</FONT></P></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(2,865</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">) </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">3,523</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">2,098</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD></TR> <TR> <TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Related party payables and accrued liabilities</FONT></P></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">—</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(150</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">) </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">138</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD></TR> <TR BGCOLOR="#cceeff"> <TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Deferred revenue</FONT></P></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">17,399</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">16,201</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">—</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD></TR> <TR STYLE="font-size:1px"> <TD VALIGN="bottom"></TD> <TD VALIGN="bottom"> </TD> <TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000"> </P></TD> <TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000"> </P></TD> <TD> </TD> <TD VALIGN="bottom"> </TD> <TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000"> </P></TD> <TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000"> </P></TD> <TD> </TD> <TD VALIGN="bottom"> </TD> <TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000"> </P></TD> <TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000"> </P></TD> <TD> </TD></TR> <TR> <TD VALIGN="top"> <P STYLE="margin-left:4.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Net cash used in operating activities</FONT></P></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(44,843</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">) </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(7,718</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">) </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(33,438</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">) </FONT></TD></TR> <TR STYLE="font-size:1px"> <TD VALIGN="bottom"></TD> <TD VALIGN="bottom"> </TD> <TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000"> </P></TD> <TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000"> </P></TD> <TD> </TD> <TD VALIGN="bottom"> </TD> <TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000"> </P></TD> <TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000"> </P></TD> <TD> </TD> <TD VALIGN="bottom"> </TD> <TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000"> </P></TD> <TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000"> </P></TD> <TD> </TD></TR> <TR BGCOLOR="#cceeff"> <TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Cash flows from investing activities:</B></FONT></P></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"></TD> <TD VALIGN="bottom"></TD> <TD VALIGN="bottom"></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"></TD> <TD VALIGN="bottom"></TD> <TD VALIGN="bottom"></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"></TD> <TD VALIGN="bottom"></TD> <TD VALIGN="bottom"></TD></TR> <TR> <TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Purchases of investments</FONT></P></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(107,043</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">) </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(79,434</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">) </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(92,788</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">) </FONT></TD></TR> <TR BGCOLOR="#cceeff"> <TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Proceeds from sales and maturities of investments</FONT></P></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">104,098</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">78,444</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">63,900</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD></TR> <TR> <TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Purchases of property and equipment</FONT></P></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(1,104</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">) </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(542</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">) </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(125</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">) </FONT></TD></TR> <TR BGCOLOR="#cceeff"> <TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Proceeds from sales of property and equipment</FONT></P></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">—</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">13</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">2</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD></TR> <TR> <TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Decrease in restricted cash</FONT></P></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">—</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">—</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">196</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD></TR> <TR STYLE="font-size:1px"> <TD VALIGN="bottom"></TD> <TD VALIGN="bottom"> </TD> <TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000"> </P></TD> <TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000"> </P></TD> <TD> </TD> <TD VALIGN="bottom"> </TD> <TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000"> </P></TD> <TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000"> </P></TD> <TD> </TD> <TD VALIGN="bottom"> </TD> <TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000"> </P></TD> <TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000"> </P></TD> <TD> </TD></TR> <TR BGCOLOR="#cceeff"> <TD VALIGN="top"> <P STYLE="margin-left:4.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Net cash used in investing activities</FONT></P></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(4,049</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">) </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(1,519</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">) </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(28,815</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">) </FONT></TD></TR> <TR STYLE="font-size:1px"> <TD VALIGN="bottom"></TD> <TD VALIGN="bottom"> </TD> <TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000"> </P></TD> <TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000"> </P></TD> <TD> </TD> <TD VALIGN="bottom"> </TD> <TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000"> </P></TD> <TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000"> </P></TD> <TD> </TD> <TD VALIGN="bottom"> </TD> <TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000"> </P></TD> <TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000"> </P></TD> <TD> </TD></TR> <TR> <TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Cash flows from financing activities:</B></FONT></P></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"></TD> <TD VALIGN="bottom"></TD> <TD VALIGN="bottom"></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"></TD> <TD VALIGN="bottom"></TD> <TD VALIGN="bottom"></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"></TD> <TD VALIGN="bottom"></TD> <TD VALIGN="bottom"></TD></TR> <TR BGCOLOR="#cceeff"> <TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Proceeds from public offerings of common stock, net of issuance costs</FONT></P></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">48,971</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">7,450</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">43,677</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD></TR> <TR> <TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Proceeds from draw down of committed equity financing facilities and at-the-market facility, net of commission and issuance costs</FONT></P></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">—</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">—</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">2,820</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD></TR> <TR BGCOLOR="#cceeff"> <TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Payments from stock based award activities and warrants, net</FONT></P></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(22</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">) </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">7,038</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(336</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">) </FONT></TD></TR> <TR> <TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Proceeds from issuance of preferred stock, net of issuance costs</FONT></P></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">—</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">—</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">12,318</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD></TR> <TR BGCOLOR="#cceeff"> <TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Repayment of equipment financing lines</FONT></P></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">—</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">—</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(152</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">) </FONT></TD></TR> <TR STYLE="font-size:1px"> <TD VALIGN="bottom"></TD> <TD VALIGN="bottom"> </TD> <TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000"> </P></TD> <TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000"> </P></TD> <TD> </TD> <TD VALIGN="bottom"> </TD> <TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000"> </P></TD> <TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000"> </P></TD> <TD> </TD> <TD VALIGN="bottom"> </TD> <TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000"> </P></TD> <TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000"> </P></TD> <TD> </TD></TR> <TR> <TD VALIGN="top"> <P STYLE="margin-left:4.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Net cash provided by financing activities</FONT></P></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">48,949</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">14,488</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">58,327</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD></TR> <TR STYLE="font-size:1px"> <TD VALIGN="bottom"></TD> <TD VALIGN="bottom"> </TD> <TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000"> </P></TD> <TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000"> </P></TD> <TD> </TD> <TD VALIGN="bottom"> </TD> <TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000"> </P></TD> <TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000"> </P></TD> <TD> </TD> <TD VALIGN="bottom"> </TD> <TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000"> </P></TD> <TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000"> </P></TD> <TD> </TD></TR> <TR BGCOLOR="#cceeff"> <TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Net increase (decrease) in cash and cash equivalents</FONT></P></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">57</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">5,251</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(3,926</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">) </FONT></TD></TR> <TR> <TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Cash and cash equivalents, beginning of period</FONT></P></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">20,158</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">14,907</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">18,833</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD></TR> <TR STYLE="font-size:1px"> <TD VALIGN="bottom"></TD> <TD VALIGN="bottom"> </TD> <TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000"> </P></TD> <TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000"> </P></TD> <TD> </TD> <TD VALIGN="bottom"> </TD> <TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000"> </P></TD> <TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000"> </P></TD> <TD> </TD> <TD VALIGN="bottom"> </TD> <TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000"> </P></TD> <TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000"> </P></TD> <TD> </TD></TR> <TR BGCOLOR="#cceeff"> <TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Cash and cash equivalents, end of period</FONT></P></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD> <TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">20,215</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD> <TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">20,158</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD> <TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">14,907</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD></TR> <TR STYLE="font-size:1px"> <TD VALIGN="bottom"></TD> <TD VALIGN="bottom"> </TD> <TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000"> </P></TD> <TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000"> </P></TD> <TD> </TD> <TD VALIGN="bottom"> </TD> <TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000"> </P></TD> <TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000"> </P></TD> <TD> </TD> <TD VALIGN="bottom"> </TD> <TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000"> </P></TD> <TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000"> </P></TD> <TD> </TD></TR> </TABLE> <P STYLE="margin-top:80px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">The accompanying notes are an integral part of these financial statements. </FONT></P> <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1"> </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">86 </FONT></P> <p Style='page-break-before:always'> <HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER"> <h5 align="left"><a href="#toc">Table of Contents</a></h5> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>CYTOKINETICS, INCORPORATED </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><A NAME="tx828167_55"></A>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Note 1 — Organization and Significant Accounting Policies </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Organization </I></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">Cytokinetics, Incorporated (the “Company”, “we” or “our”) was incorporated under the laws of the state of Delaware on August 5, 1997. The Company is a clinical stage biopharmaceutical company focused on the discovery and development of novel small molecule therapeutics that modulate muscle function for the potential treatment of serious diseases and medical conditions. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">The Company was in the development stage at December 31, 2012, as defined in Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”) Topic 915, “<I>Development Stage Entities</I>.” During the year ended December 31, 2013, the Company exited the development stage with the execution of the Amgen Agreement Amendment and the Original Astellas Agreement (See Note 7), from which the Company received significant revenues from its principal operations, indicative that the Company was no longer in the development stage. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">The Company’s financial statements contemplate the conduct of the Company’s operations in the normal course of business. The Company has incurred an accumulated deficit of $497.2 million since inception and there can be no assurance that the Company will attain profitability. The Company had a net loss of $14.6 million and net cash used in operations of $44.8 million for the year ended December 31, 2014. Cash, cash equivalents and investments increased to $83.2 million at December 31, 2014 from $80.2 million at December 31, 2013. The Company anticipates that it will continue to have operating losses and net cash outflows in future periods. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">The Company is subject to risks common to clinical stage biopharmaceutical companies including, but not limited to, development of new drug candidates, dependence on key personnel, and the ability to obtain additional capital as needed to fund its future plans. The Company’s liquidity will be impaired if sufficient additional capital is not available on terms acceptable to the Company. To date, the Company has funded its operations primarily through sales of its common stock and convertible preferred stock, contract payments under its collaboration agreements, debt financing arrangements, government grants and interest income. Until it achieves profitable operations, the Company intends to continue to fund operations through payments from strategic collaborations, additional sales of equity securities, grants and debt financings. The Company has never generated revenues from commercial sales of its drugs and may not obtain regulatory approval for commercialization for at least several years, if ever. The Company’s success is dependent on its ability to enter into new strategic collaborations and/or raise additional capital and to successfully develop and market one or more of its drug candidates. As a result, the Company may choose to raise additional capital through equity or debt financings to continue to fund its operations in the future. The Company cannot be certain that sufficient funds will be available from such a financing or through a collaborator when required or on satisfactory terms. Additionally, there can be no assurance that the Company’s drug candidates will be accepted in the marketplace or that any future products can be developed or manufactured at an acceptable cost. These factors could have a material adverse effect on the Company’s future financial results, financial position and cash flows. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">Based on the current status of its research and development plans, the Company believes that its existing cash, cash equivalents and investments at December 31, 2014 will be sufficient to fund its cash requirements for at least the next 12 months. If, at any time, the Company’s prospects for financing its research and development programs decline, the Company may decide to reduce research and development expenses by delaying, discontinuing or reducing its funding of one or more of its research or development programs. Alternatively, the Company might raise funds through strategic collaborations, public or private financings or other arrangements. Such funding, if needed, may not be available on favorable terms, or at all. The financial statements do not include any adjustments that might result from the outcome of this uncertainty. </FONT></P> <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1"> </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">87 </FONT></P> <p Style='page-break-before:always'> <HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER"> <h5 align="left"><a href="#toc">Table of Contents</a></h5> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>CYTOKINETICS, INCORPORATED </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS — (Continued) </B></FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px"> </P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Use of Estimates </I></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">The preparation of financial statements in conformity with accounting principles generally accepted in the United States requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosures of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Basis of Presentation </I></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">The consolidated financial statements include the accounts of Cytokinetics and its wholly owned subsidiary. The financial statements include all adjustments (consisting only of normal recurring adjustments) that management believes are necessary for the fair presentation of the balances and results for the periods presented. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Concentration of Credit Risk and Other Risks and Uncertainties </I></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">Financial instruments that potentially subject the Company to concentrations of risk consist principally of cash and cash equivalents, investments and accounts receivable. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">The Company’s cash, cash equivalents and investments are invested in deposits with three major financial institutions in the United States. Deposits in these banks may exceed the amount of insurance provided on such deposits. The Company has not experienced any realized losses on its deposits of cash, cash equivalents or investments. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">The economic turmoil in the United States in recent years, the extraordinary volatility in the stock markets and other current negative macroeconomic indicators could negatively impact the Company’s ability to raise the funds necessary to support its business and may materially adversely affect its business, operating results and financial condition. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">The Company performs an ongoing credit evaluation of its strategic partners’ financial conditions and generally does not require collateral to secure accounts receivable from its strategic partners. The Company’s exposure to credit risk associated with non-payment will be affected principally by conditions or occurrences within Amgen Inc. (“Amgen”) and Astellas Pharma Inc. (“Astellas”), its strategic partners. Approximately 10%, 63% and 55% of total revenues for the years ended December 31, 2014, 2013 and 2012, respectively, were derived from Amgen. Accounts receivable due from Amgen were $1.6 million and zero at December 31, 2014 and 2013, respectively. See also Note 7, “Related Party Transactions,” regarding the collaboration agreement with Amgen. Approximately 69% and 34% of total revenues for the years ended December 31, 2014 and 2013, respectively, were derived from Astellas. Accounts receivable due from Astellas were $45.0 million and zero at December 31, 2014 and 2013, respectively. See also Note 7, “Related Party Transactions,” regarding the collaboration agreement with Astellas. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">Drug candidates developed by the Company may require approvals or clearances from the U.S. Food and Drug Administration (“FDA”) or international regulatory agencies prior to commercialized sales. There can be no assurance that the Company’s drug candidates will receive any of the required approvals or clearances. If the Company was to be denied approval or clearance or any such approval or clearance was to be delayed, it would have a material adverse impact on the Company. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">The Company’s operations and employees are located in the United States. In the year ended December 31, 2014, 31% of the Company’s revenues were received from entities located in the United States and 69% were </FONT></P> <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1"> </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">88 </FONT></P> <p Style='page-break-before:always'> <HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER"> <h5 align="left"><a href="#toc">Table of Contents</a></h5> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>CYTOKINETICS, INCORPORATED </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS — (Continued) </B></FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px"> </P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2"> received from a Japanese entity. In the year ended December 31, 2013, 66% of the Company’s revenues were received from entities located in the United States and 34% were received from a Japanese entity. In the year ended December 31, 2012, all of the Company’s revenues were received from entities located in the United States or from United States affiliates of foreign corporations. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Cash and Cash Equivalents </I></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">The Company considers all highly liquid investments with a maturity of three months or less at the time of purchase to be cash equivalents. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Investments </I></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>Available-for-sale investments.</I> The Company’s investments consist of U.S. Treasury securities, money market funds, U.S. municipal and government agency bonds, and commercial paper. The Company designates all investments as available-for-sale and therefore reports them at fair value, based on quoted marked prices, with unrealized gains and losses recorded in accumulated other comprehensive loss. The cost of securities sold is based on the specific-identification method. Investments with original maturities greater than three months and remaining maturities of one year or less are classified as short-term investments. Investments with remaining maturities greater than one year are classified as long-term investments. The amortized cost of debt securities in this category is adjusted for amortization of premiums and accretion of discounts to maturity. Such amortization is included in interest income. Recognized gains and losses and declines in value judged to be other-than-temporary, if any, on available-for-sale securities are included in other income or expense. Interest and dividends on securities classified as available-for-sale are included in Interest and other, net. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>Other-than-temporary impairment.</I> All of the Company’s available-for-sale investments are subject to a periodic impairment review. The Company recognizes an impairment charge when a decline in the fair value of its investments below the cost basis is judged to be other-than-temporary. Factors considered by management in assessing whether an other-than-temporary impairment has occurred include: the nature of the investment; whether the decline in fair value is attributable to specific adverse conditions affecting the investment; the financial condition of the investee; the severity and the duration of the impairment; and whether the Company has the intent and ability to hold the investment to maturity. When the Company determines that an other-than-temporary impairment has occurred, the investment is written down to its market value at the end of the period in which it is determined that an other-than-temporary decline has occurred. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Property and Equipment </I></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">Property and equipment are stated at cost less accumulated depreciation and are depreciated on a straight-line basis over the estimated useful lives of the related assets, which are generally three years for computer equipment and software, five years for laboratory equipment and office equipment, and seven years for furniture and fixtures. Amortization of leasehold improvements is computed using the straight-line method over the shorter of the remaining lease term or the estimated useful life of the related assets, typically ranging from three to seven years. Upon sale or retirement of assets, the costs and related accumulated depreciation and amortization are removed from the balance sheet and the resulting gain or loss is reflected in operations. Maintenance and repairs are charged to operations as incurred. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Impairment of Long-lived Assets </I></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">In accordance with the accounting guidance for the impairment or disposal of long-lived assets, the Company reviews long-lived assets, including property and equipment, for impairment whenever events or </FONT></P> <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1"> </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">89 </FONT></P> <p Style='page-break-before:always'> <HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER"> <h5 align="left"><a href="#toc">Table of Contents</a></h5> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>CYTOKINETICS, INCORPORATED </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS — (Continued) </B></FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px"> </P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2"> changes in business circumstances indicate that the carrying amount of the assets may not be fully recoverable. Under the accounting guidance, an impairment loss would be recognized when estimated undiscounted future cash flows expected to result from the use of the asset and its eventual disposition are less than its carrying amount. Impairment, if any, is measured as the amount by which the carrying amount of a long-lived asset exceeds its fair value. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Revenue Recognition </I></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">The accounting guidance for revenue recognition requires that the following criteria must be met before revenue can be recognized: (i) persuasive evidence of an arrangement exists; (ii) delivery has occurred or services have been rendered; (iii) the fee is fixed or determinable; and (iv) collectability is reasonably assured. Determination of whether persuasive evidence of an arrangement exists and whether delivery has occurred or services have been rendered are based on management’s judgments regarding the fixed nature of the fee charged for research performed and milestones met, and the collectability of those fees. Should changes in conditions cause management to determine these criteria are not met for certain future transactions, revenue recognized for any reporting period could be adversely affected. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">Revenue under our license and collaboration arrangements is recognized based on the performance requirements of the contract. Research and development revenues, which are earned under agreements with third parties for agreed research and development activities, may include non-refundable license fees, research and development funding, cost reimbursements and contingent milestones and royalties. The Company’s collaborations prior to January 1, 2011 with multiple elements were evaluated and divided into separate units of accounting if certain criteria are met, including whether the delivered element has stand-alone value to the customer and whether there was vendor-specific objective and reliable evidence (“VSOE”) of the fair value of the undelivered items. The consideration the Company received was allocated among the separate units based on their respective fair values, and the applicable revenue recognition criteria were applied to each of the separate units. The consideration the Company received was combined and recognized as a single unit of accounting when criteria for separation were not met. On January 1, 2011, ASC Topic 605-25,<I> Revenue Recognition — Multiple-Element Arrangements</I> (“ASC 605-25”) on the recognition of revenues for agreements with multiple deliverables became effective and applies to any agreements the Company entered into on or after January 1, 2011. Under this updated guidance, revenue is allocated to each element using a selling price hierarchy, where the selling price for an element is based on VSOE if available; third-party evidence (“TPE”), if available and VSOE is not available; or the best estimate of selling price, if neither VSOE nor TPE is available. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">Upfront, non-refundable licensing payments are assessed to determine whether or not the licensee is able to obtain stand-alone value from the license. Where the license does not have stand-alone value, non-refundable license fees are recognized as revenue as the Company performs under the applicable agreement. Where the level of effort is relatively consistent over the performance period, the Company recognizes total fixed or determined revenue on a straight-line basis over the estimated period of expected performance. Where the license has stand-alone value, the Company recognizes total license revenue at the time all revenue recognition criteria have been met. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">ASC Topic 605-28,<I> Revenue Recognition — Milestone Method</I> (“ASC 605-28”), established the milestone method as an acceptable method of revenue recognition for certain contingent event-based payments under research and development arrangements. Under the milestone method, a payment that is contingent upon the achievement of a substantive milestone is recognized in its entirety in the period in which the milestone is achieved. A milestone is an event (i) that can be achieved based in whole or in part on either the Company’s performance or on the occurrence of a specific outcome resulting from the Company’s performance, (ii) for which there is substantive uncertainty at the date the arrangement is entered into that the event will be achieved, </FONT></P> <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1"> </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">90 </FONT></P> <p Style='page-break-before:always'> <HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER"> <h5 align="left"><a href="#toc">Table of Contents</a></h5> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>CYTOKINETICS, INCORPORATED </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS — (Continued) </B></FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px"> </P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2"> and (iii) that would result in additional payments being due to the Company. The determination that a milestone is substantive is judgmental and is made at the inception of the arrangement. Milestones are considered substantive when the consideration earned from the achievement of the milestone is (i) commensurate with either the Company’s performance to achieve the milestone or the enhancement of value of the item delivered as a result of a specific outcome resulting from the Company’s performance to achieve the milestone, (ii) relates solely to past performance and (iii) is reasonable relative to all deliverables and payment terms in the arrangement. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">Other contingent event-based payments received for which payment is either contingent solely upon the passage of time or the results of a collaborative partner’s performance are not considered milestones under ASC 605-28. In accordance with ASC 605-25<I>,</I> such payments will be recognized as revenue when all of the following criteria are met: (i) persuasive evidence of an arrangement exists, (ii) delivery has occurred or services have been rendered, (iii) price is fixed or determinable, and (iv) collectability is reasonably assured. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">Prior to January 1, 2011, the Company recognized and will continue to recognize milestone payments as revenue upon achievement of the milestone, provided the milestone payment was non-refundable, substantive effort and risk were involved in achieving the milestone and the amount of the milestone was reasonable in relation to the effort expended or risk associated with the achievement of the milestone. If these conditions were not met, the Company deferred the milestone payment and recognized it as revenue over the estimated period of performance under the contract as the Company completed its performance obligations. The Company has concluded that all of the future contingent milestone payments pursuant to its research and development arrangements entered into prior to January 1, 2011 are not considered substantive as they are the results of a collaborative partner’s performance. Therefore, they are not considered milestones under ASC 605-28. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">For collaborations and material modifications entered into after January 1, 2011, the Company accounts for milestone payments under the provisions of ASC 605-28. The Company considers an event to be a milestone if there is substantive uncertainty at the date the arrangement is entered into that the event will be achieved, if the event can only be achieved with the Company’s performance, and if the achievement of the event results in payment to the Company. If the Company determines a milestone is substantive, the Company recognizes revenue when payment is earned and becomes payable. For a milestone to be considered substantive, it must be achieved with the Company’s performance, be reasonable relative to the terms of the arrangement and be commensurate with the Company’s effort to achieve the milestone or commensurate with the enhanced value of the delivered item(s) as a result of the milestone achievement. If the Company determines a milestone is not substantive, the Company defers the payment and recognizes revenue over the estimated period of performance as the Company completes its performance obligations. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">Research and development revenues and cost reimbursements are based upon negotiated rates for the Company’s full-time employee equivalents (“FTE”) and actual out-of-pocket costs. FTE rates are negotiated rates that are based upon the Company’s costs, and which the Company believes approximate fair value. Any amounts received in advance of performance are recorded as deferred revenue. None of the revenues recognized to date are refundable if the relevant research effort is not successful. In revenue arrangements in which both parties make payments to each other, the Company evaluates the payments in accordance with the accounting guidance for arrangements under which consideration is given by a vendor to a customer, including a reseller of the vendor’s products, to determine whether payments made by us will be recognized as a reduction of revenue or as expense. In accordance with this guidance, revenue recognized by the Company may be reduced by payments made to the other party under the arrangement unless the Company receives a separate and identifiable benefit in exchange for the payments and the Company can reasonably estimate the fair value of the benefit received. The application of the accounting guidance for consideration given to a customer has had no material impact to the Company. </FONT></P> <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1"> </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">91 </FONT></P> <p Style='page-break-before:always'> <HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER"> <h5 align="left"><a href="#toc">Table of Contents</a></h5> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>CYTOKINETICS, INCORPORATED </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS — (Continued) </B></FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px"> </P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">Funds received from third parties under grant arrangements are recorded as revenue if the Company is deemed to be the principal participant in the grant arrangement as the activities under the grant are part of the Company’s development program. If the Company is not the principal participant, the grant funds are recorded as a reduction to research and development expense. Grant funds received are not refundable and are recognized when the related qualified research and development costs are incurred and when there is reasonable assurance that the funds will be received. Funds received in advance are recorded as deferred revenue. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Preclinical Studies and Clinical Trial Accruals </I></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">A substantial portion of the Company’s preclinical studies and all of the Company’s clinical trials have been performed by third-party contract research organizations (“CROs”) and other vendors. For preclinical studies, the significant factors used in estimating accruals include the percentage of work completed to date and contract milestones achieved. For clinical trial expenses, the significant factors used in estimating accruals include the number of patients enrolled, duration of enrollment and percentage of work completed to date. The Company monitors patient enrollment levels and related activities to the extent practicable through internal reviews, correspondence and status meetings with CROs, and review of contractual terms. The Company’s estimates are dependent on the timeliness and accuracy of data provided by its CROs and other vendors. If the Company has incomplete or inaccurate data, it may under- or overestimate activity levels associated with various studies or trials at a given point in time. In this event, it could record adjustments to research and development expenses in future periods when the actual activity level becomes known. No material adjustments to preclinical study and clinical trial expenses have been recognized to date. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Research and Development Expenditures </I></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">Research and development costs are charged to operations as incurred. Research and development expenses consist primarily of clinical manufacturing costs, preclinical study expenses, consulting and other third party costs, employee compensation, supplies and materials, allocation of overhead and occupancy costs, facilities costs and depreciation of equipment. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Retirement Plan </I></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">The Company sponsors a 401(k) defined contribution plan covering all employees. There were no employer contributions to the plan from inception through December 31, 2013. In 2014, employer contributions to the 401(k) plan were $336,000. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Income Taxes </I></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">The Company accounts for income taxes under the asset and liability method. Under this method, deferred tax assets and liabilities are determined based on the difference between the financial statement and tax basis of assets and liabilities using enacted tax rates in effect for the year in which the differences are expected to affect taxable income. Valuation allowances are established when necessary to reduce deferred tax assets to the amounts expected to be realized. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">The Company also follows the accounting guidance that defines the threshold for recognizing the benefits of tax return positions in the financial statements as “more-likely-than-not” to be sustained by the taxing authorities based solely on the technical merits of the position. If the recognition threshold is met, the tax benefit is measured and recognized as the largest amount of tax benefit that, in the Company’s judgment, is greater than 50% likely to be realized. </FONT></P> <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1"> </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">92 </FONT></P> <p Style='page-break-before:always'> <HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER"> <h5 align="left"><a href="#toc">Table of Contents</a></h5> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>CYTOKINETICS, INCORPORATED </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS — (Continued) </B></FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px"> </P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Comprehensive Loss </I></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">The Company follows the accounting standards for the reporting and presentation of comprehensive income (loss) and its components. On January 1, 2012, the Company adopted new accounting guidance and presents comprehensive income (loss) in a continuous statement of comprehensive income (loss) which replaced the statement of operations. Comprehensive loss includes all changes in stockholders’ equity during a period from non-owner sources. Comprehensive loss for each of the years ended December 31, 2014, 2013, and 2012 was equal to net loss adjusted for unrealized gains and losses on investments. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Segment Reporting </I></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">The Company has determined that it operates in only one segment. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Reverse Stock Split </I></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">On June 24, 2013, the Company effected a one-for-six reverse stock split of its common stock through an amendment to its amended and restated certificate of incorporation (the “COI Amendment”). As of the effective time of the reverse stock split, every six shares of the Company’s issued and outstanding common stock were converted into one issued and outstanding share of common stock, without any change in par value per share. The reverse stock split affected all shares of the Company’s common stock outstanding immediately prior to the effective time of the reverse stock split, as well as the number of shares of common stock available for issuance under the Company’s equity incentive plans. In addition, the reverse stock split effected a reduction in the number of shares of common stock issuable upon the conversion of shares of preferred stock or upon the exercise of stock options or warrants outstanding immediately prior to the effectiveness of the reverse stock split. No fractional shares were issued as a result of the reverse stock split. Stockholders who would otherwise have been entitled to receive a fractional share received cash payments in lieu thereof. In addition, the COI Amendment reduced the number of authorized shares of common stock to 81.5 million. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">As the par value per share of the Company’s common stock remained unchanged at $0.001 per share, a total of $139,000 was reclassified from common stock to additional paid-in capital. All references to shares of common stock and per share data for all periods presented in the accompanying financial statements and notes thereto have been adjusted to reflect the reverse stock split on a retroactive basis. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Stock-Based Compensation </I></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">The Company accounts for stock-based payment awards made to employees and directors, including employee stock options and employee stock purchases by measuring the stock-based compensation cost at the grant date based on the calculated fair value of the award, and recognizing expense on a straight-line basis over the employee’s requisite service period, generally the vesting period of the award. Stock compensation for non-employees is measured at the fair value of the award for each period until the award is fully vested. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">The Company reviews the valuation assumptions at each grant date and, as a result, from time to time it will likely change the valuation assumptions it uses to value stock based awards granted in future periods. The assumptions used in calculating the fair value of share-based payment awards represent management’s best estimates at the time, but these estimates involve inherent uncertainties and the application of management judgment. As a result, if conditions change and the management uses different assumptions, the Company’s stock-based compensation expense could be materially different in the future. In addition, the Company is required to estimate the expected forfeiture rate and recognize expense only for those shares expected to vest. If the actual forfeiture rate is materially different from management’s estimate, stock-based compensation expense could be significantly different from what has been recorded in the current period. </FONT></P> <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1"> </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">93 </FONT></P> <p Style='page-break-before:always'> <HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER"> <h5 align="left"><a href="#toc">Table of Contents</a></h5> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>CYTOKINETICS, INCORPORATED </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS — (Continued) </B></FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px"> </P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Recent Accounting Pronouncements </I></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>Recently Adopted Accounting Pronouncements </I></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">In July 2013, the FASB issued ASU 2013-11, <I>Presentation of an Unrecognized Tax Benefit When a Net Operating Loss Carryforward, a Similar Tax Loss, or a Tax Credit Carryforward Exists</I>. ASU 2013-11 amends accounting guidance on the presentation of an unrecognized tax benefit when a net operating loss carryforward, a similar tax loss, or tax credit carryforward exists. This new guidance requires entities, if certain criteria are met, to present an unrecognized tax benefit, or portion of an unrecognized tax benefit, in the financial statements as a reduction to a deferred tax asset for a net operating loss carryforward, a similar tax loss, or a tax credit carryforward when such items exist in the same taxing jurisdiction. The Company adopted ASU 2013-11 effective January 1, 2014 and the adoption of ASU 2013-11 did not have a material effect on its financial statements. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>Accounting Pronouncements Not Yet Adopted </I></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">In November 2014, the FASB issued ASU 2014-17, <I>Business Combinations (Topic 805) — Pushdown Accounting (a consensus of the FASB Emerging Issues Task Force).</I> This guidance provides the option for an acquired entity to apply pushdown accounting in its separately issued financial statements when a change-in-control event occurs. This guidance is effective beginning November 18, 2014, and is applicable to change-in-control events occurring after that date or applied to the most recent change-in-control event if financial statements have not yet been issued. The Company does not expect the adoption of ASU 2014-17 to have a material effect upon its financial statements. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">In August 2014, the FASB issued ASU 2014-15, <I>Presentation of Financial Statements — Going Concern (Subtopic 205-40): Disclosure of Uncertainties about an Entity’s Ability to Continue as a Going Concern. </I>ASU 214-15 requires management to assess an entity’s ability to continue as a going concern, and to provide related footnote disclosures in certain circumstances. ASU 2014-15 is effective for annual and interim reporting periods beginning on or after December 15, 2016 and early adoption is permitted. The Company does not expect the adoption of ASU 2014-15 to have a material effect upon its financial statements. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">In May 2014, the FASB issued ASU 2014-09, <I>Revenue from Contracts with Customers (Topic 606)</I>, which supersedes the revenue recognition requirements in ASC 605, <I>Revenue Recognition</I>. ASU 2014-09 stipulates that an entity should recognize revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. ASU 2014-09 also requires additional disclosure about the nature, amount, timing and uncertainty of revenue and cash flows arising from customer contracts, including significant judgments and changes in judgments and assets recognized from costs incurred to obtain or fulfill a contract. ASU 2014-09 is effective for annual and interim reporting periods beginning on or after December 15, 2016, and early adoption is not permitted. ASU 2014-09 permits the use of two transition methods, either retrospectively to each prior reporting period presented or as a cumulative-effect adjustment as of the date of adoption. The Company has not yet selected a transition method, and is currently evaluating the impact of the adoption of ASU 2014-09 on its consolidated financial statements. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">In April 2014, the FASB issued ASU 2014-08, <I>Reporting Discontinued Operations and Disclosures of Disposals of Components of an Entity</I>. ASU 2014-08 changes the criteria for determining which disposals can be presented as discontinued operations and modifies related disclosure requirements. This new guidance is effective for the Company beginning January 1, 2015. The Company does not expect the adoption of ASU 2014-08 to have a material effect upon its financial statements. </FONT></P> <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1"> </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">94 </FONT></P> <p Style='page-break-before:always'> <HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER"> <h5 align="left"><a href="#toc">Table of Contents</a></h5> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>CYTOKINETICS, INCORPORATED </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS — (Continued) </B></FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px"> </P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Note 2 — Net Loss Per Share </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">Basic net loss per share allocable to common stockholders is computed by dividing net loss allocable to common stockholders by the weighted average number of vested common shares outstanding during the period. Diluted net income loss per share allocable to common stockholders is computed by giving effect to all potentially dilutive common shares, including outstanding stock options, unvested restricted stock, warrants, convertible preferred stock and shares issuable under the Company’s Employee Stock Purchase Plan (“ESPP”), by applying the treasury stock method. The following is the calculation of basic and diluted net loss per share allocable to common stockholders (in thousands except per share data): </FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px"> </P> <TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="92%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center"> <TR> <TD WIDTH="66%"></TD> <TD VALIGN="bottom" WIDTH="5%"></TD> <TD></TD> <TD></TD> <TD></TD> <TD VALIGN="bottom" WIDTH="4%"></TD> <TD></TD> <TD></TD> <TD></TD> <TD VALIGN="bottom" WIDTH="4%"></TD> <TD></TD> <TD></TD> <TD></TD></TR> <TR> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom" COLSPAN="10" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Years Ended December 31,</B></FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD></TR> <TR> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>2014</B></FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>2013</B></FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>2012</B></FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD></TR> <TR BGCOLOR="#cceeff"> <TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Net loss</FONT></P></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD> <TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(14,646</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">) </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD> <TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(33,717</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">) </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD> <TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(40,370</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">) </FONT></TD></TR> <TR> <TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Deemed dividend related to beneficial conversion feature of convertible preferred stock</FONT></P></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">—</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">—</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(1,307</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">) </FONT></TD></TR> <TR STYLE="font-size:1px"> <TD VALIGN="bottom"></TD> <TD VALIGN="bottom"> </TD> <TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000"> </P></TD> <TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000"> </P></TD> <TD> </TD> <TD VALIGN="bottom"> </TD> <TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000"> </P></TD> <TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000"> </P></TD> <TD> </TD> <TD VALIGN="bottom"> </TD> <TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000"> </P></TD> <TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000"> </P></TD> <TD> </TD></TR> <TR BGCOLOR="#cceeff"> <TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Net loss allocable to common stockholders</FONT></P></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD> <TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(14,646</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">) </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD> <TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(33,717</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">) </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD> <TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(41,677</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">) </FONT></TD></TR> <TR STYLE="font-size:1px"> <TD VALIGN="bottom"></TD> <TD VALIGN="bottom"> </TD> <TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000"> </P></TD> <TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000"> </P></TD> <TD> </TD> <TD VALIGN="bottom"> </TD> <TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000"> </P></TD> <TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000"> </P></TD> <TD> </TD> <TD VALIGN="bottom"> </TD> <TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000"> </P></TD> <TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000"> </P></TD> <TD> </TD></TR> <TR> <TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Weighted-average shares used in computing net loss per share allocable to common stockholders — basic and diluted</FONT></P></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">35,709</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">27,275</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">18,107</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD></TR> <TR STYLE="font-size:1px"> <TD VALIGN="bottom"></TD> <TD VALIGN="bottom"> </TD> <TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000"> </P></TD> <TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000"> </P></TD> <TD> </TD> <TD VALIGN="bottom"> </TD> <TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000"> </P></TD> <TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000"> </P></TD> <TD> </TD> <TD VALIGN="bottom"> </TD> <TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000"> </P></TD> <TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000"> </P></TD> <TD> </TD></TR> <TR BGCOLOR="#cceeff"> <TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Net loss per share allocable to common stockholders — basic and diluted</FONT></P></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD> <TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(0.41</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">) </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD> <TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(1.24</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">) </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD> <TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(2.30</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">) </FONT></TD></TR> </TABLE> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">The following instruments were excluded from the computation of diluted net loss per common share allocable to common stockholders for the periods presented because their effect would have been antidilutive (in thousands): </FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px"> </P> <TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="92%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center"> <TR> <TD WIDTH="73%"></TD> <TD VALIGN="bottom" WIDTH="3%"></TD> <TD></TD> <TD></TD> <TD></TD> <TD VALIGN="bottom" WIDTH="3%"></TD> <TD></TD> <TD></TD> <TD></TD> <TD VALIGN="bottom" WIDTH="3%"></TD> <TD></TD> <TD></TD> <TD></TD></TR> <TR> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom" COLSPAN="10" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>December 31,</B></FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD></TR> <TR> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>2014</B></FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>2013</B></FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>2012</B></FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD></TR> <TR BGCOLOR="#cceeff"> <TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Options to purchase common stock</FONT></P></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">3,298</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">2,449</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1,791</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD></TR> <TR> <TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Warrants to purchase common stock</FONT></P></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">6,691</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">7,692</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">9,009</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD></TR> <TR BGCOLOR="#cceeff"> <TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Series B convertible preferred stock (as converted to common stock)</FONT></P></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">—</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">—</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">3,838</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD></TR> <TR> <TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Restricted stock units</FONT></P></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">63</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">42</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">217</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD></TR> <TR BGCOLOR="#cceeff"> <TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Shares issuable related to the ESPP</FONT></P></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">15</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">14</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">11</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD></TR> <TR STYLE="font-size:1px"> <TD VALIGN="bottom"></TD> <TD VALIGN="bottom"> </TD> <TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000"> </P></TD> <TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000"> </P></TD> <TD> </TD> <TD VALIGN="bottom"> </TD> <TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000"> </P></TD> <TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000"> </P></TD> <TD> </TD> <TD VALIGN="bottom"> </TD> <TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000"> </P></TD> <TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000"> </P></TD> <TD> </TD></TR> <TR> <TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Total shares</FONT></P></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">10,067</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">10,197</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">14,866</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD></TR> <TR STYLE="font-size:1px"> <TD VALIGN="bottom"></TD> <TD VALIGN="bottom"> </TD> <TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000"> </P></TD> <TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000"> </P></TD> <TD> </TD> <TD VALIGN="bottom"> </TD> <TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000"> </P></TD> <TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000"> </P></TD> <TD> </TD> <TD VALIGN="bottom"> </TD> <TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000"> </P></TD> <TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000"> </P></TD> <TD> </TD></TR> </TABLE> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Note 3 — Supplementary Cash Flow Data </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">Supplemental cash flow information was as follows (in thousands): </FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px"> </P> <TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="92%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center"> <TR> <TD WIDTH="78%"></TD> <TD VALIGN="bottom" WIDTH="6%"></TD> <TD></TD> <TD></TD> <TD></TD> <TD VALIGN="bottom" WIDTH="6%"></TD> <TD></TD> <TD></TD> <TD></TD> <TD VALIGN="bottom" WIDTH="5%"></TD> <TD></TD> <TD></TD> <TD></TD></TR> <TR> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom" COLSPAN="10" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Years Ended<BR>December 31,</B></FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD></TR> <TR> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>2014</B></FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>2013</B></FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>2012</B></FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD></TR> <TR BGCOLOR="#cceeff"> <TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Cash paid for interest</FONT></P></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD> <TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">—</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD> <TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">—</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD> <TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">3</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD></TR> <TR> <TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Cash paid for income taxes</FONT></P></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD></TR> <TR BGCOLOR="#cceeff"> <TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Significant non-cash investing and financing activities:</FONT></P></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"></TD> <TD VALIGN="bottom"></TD> <TD VALIGN="bottom"></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"></TD> <TD VALIGN="bottom"></TD> <TD VALIGN="bottom"></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"></TD> <TD VALIGN="bottom"></TD> <TD VALIGN="bottom"></TD></TR> <TR> <TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Purchases of property and equipment through accounts payable</FONT></P></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">170</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">193</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">116</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD></TR> <TR BGCOLOR="#cceeff"> <TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Purchases of property and equipment through accrued liabilities</FONT></P></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">27</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(2</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">) </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">37</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD></TR> <TR> <TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Purchases of property and equipment through trade in value of disposed property and equipment</FONT></P></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">—</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">81</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">—</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD></TR> </TABLE> <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1"> </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">95 </FONT></P> <p Style='page-break-before:always'> <HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER"> <h5 align="left"><a href="#toc">Table of Contents</a></h5> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>CYTOKINETICS, INCORPORATED </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS — (Continued) </B></FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px"> </P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Note 4 — Cash Equivalents and Investments </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Cash Equivalents and Available for Sale Investments </I></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">The amortized cost and fair value of cash equivalents and available for sale investments at December 31, 2014 and 2013 were as follows (in thousands): </FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px"> </P> <TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center"> <TR> <TD WIDTH="45%"></TD> <TD VALIGN="bottom" WIDTH="5%"></TD> <TD></TD> <TD></TD> <TD></TD> <TD VALIGN="bottom" WIDTH="5%"></TD> <TD></TD> <TD></TD> <TD></TD> <TD VALIGN="bottom" WIDTH="5%"></TD> <TD></TD> <TD></TD> <TD></TD> <TD VALIGN="bottom" WIDTH="5%"></TD> <TD></TD> <TD></TD> <TD></TD> <TD VALIGN="bottom" WIDTH="5%"></TD> <TD></TD> <TD></TD> <TD></TD></TR> <TR> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom" COLSPAN="18" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>December 31, 2014</B></FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD></TR> <TR> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Amortized<BR>Cost</B></FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Unrealized<BR>Gains</B></FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Unrealized<BR>Losses</B></FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Fair<BR>Value</B></FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Maturity<BR>Dates</B></FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD></TR> <TR BGCOLOR="#cceeff"> <TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Cash equivalents — money market funds</FONT></P></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD> <TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">16,932</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD> <TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">—</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD> <TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">—</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD> <TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">16,932</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"></TD> <TD VALIGN="bottom"></TD> <TD VALIGN="bottom"></TD></TR> <TR STYLE="font-size:1px"> <TD VALIGN="bottom"></TD> <TD VALIGN="bottom"> </TD> <TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000"> </P></TD> <TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000"> </P></TD> <TD> </TD> <TD VALIGN="bottom"> </TD> <TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000"> </P></TD> <TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000"> </P></TD> <TD> </TD> <TD VALIGN="bottom"> </TD> <TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000"> </P></TD> <TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000"> </P></TD> <TD> </TD> <TD VALIGN="bottom"> </TD> <TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000"> </P></TD> <TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000"> </P></TD> <TD> </TD> <TD VALIGN="bottom"> </TD> <TD VALIGN="bottom"></TD> <TD VALIGN="bottom"></TD> <TD VALIGN="bottom"></TD></TR> <TR> <TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Short-term investments — U.S. Treasury securities</FONT></P></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD> <TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">63,017</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD> <TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">3</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD> <TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(7</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">) </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD> <TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">63,013</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1/2015 — 12/2015</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD></TR> <TR STYLE="font-size:1px"> <TD VALIGN="bottom"></TD> <TD VALIGN="bottom"> </TD> <TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000"> </P></TD> <TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000"> </P></TD> <TD> </TD> <TD VALIGN="bottom"> </TD> <TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000"> </P></TD> <TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000"> </P></TD> <TD> </TD> <TD VALIGN="bottom"> </TD> <TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000"> </P></TD> <TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000"> </P></TD> <TD> </TD> <TD VALIGN="bottom"> </TD> <TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000"> </P></TD> <TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000"> </P></TD> <TD> </TD> <TD VALIGN="bottom"> </TD> <TD VALIGN="bottom"></TD> <TD VALIGN="bottom"></TD> <TD VALIGN="bottom"></TD></TR> <TR BGCOLOR="#cceeff"> <TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Long-term investments — U.S. Treasury securities</FONT></P></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD> <TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">—</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD> <TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">—</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD> <TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">—</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD> <TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">—</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"></TD> <TD VALIGN="bottom"></TD> <TD VALIGN="bottom"></TD></TR> <TR STYLE="font-size:1px"> <TD VALIGN="bottom"></TD> <TD VALIGN="bottom"> </TD> <TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000"> </P></TD> <TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000"> </P></TD> <TD> </TD> <TD VALIGN="bottom"> </TD> <TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000"> </P></TD> <TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000"> </P></TD> <TD> </TD> <TD VALIGN="bottom"> </TD> <TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000"> </P></TD> <TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000"> </P></TD> <TD> </TD> <TD VALIGN="bottom"> </TD> <TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000"> </P></TD> <TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000"> </P></TD> <TD> </TD> <TD VALIGN="bottom"> </TD> <TD VALIGN="bottom"></TD> <TD VALIGN="bottom"></TD> <TD VALIGN="bottom"></TD></TR> </TABLE> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px"> </P> <TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center"> <TR> <TD WIDTH="45%"></TD> <TD VALIGN="bottom" WIDTH="5%"></TD> <TD></TD> <TD></TD> <TD></TD> <TD VALIGN="bottom" WIDTH="5%"></TD> <TD></TD> <TD></TD> <TD></TD> <TD VALIGN="bottom" WIDTH="5%"></TD> <TD></TD> <TD></TD> <TD></TD> <TD VALIGN="bottom" WIDTH="5%"></TD> <TD></TD> <TD></TD> <TD></TD> <TD VALIGN="bottom" WIDTH="5%"></TD> <TD></TD> <TD></TD> <TD></TD></TR> <TR> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom" COLSPAN="18" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>December 31, 2013</B></FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD></TR> <TR> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Amortized<BR>Cost</B></FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Unrealized<BR>Gains</B></FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Unrealized<BR>Losses</B></FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Fair<BR>Value</B></FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Maturity<BR>Dates</B></FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD></TR> <TR BGCOLOR="#cceeff"> <TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Cash equivalents — money market funds</FONT></P></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD> <TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">15,858</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD> <TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">—</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD> <TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">—</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD> <TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">15,858</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"></TD> <TD VALIGN="bottom"></TD> <TD VALIGN="bottom"></TD></TR> <TR STYLE="font-size:1px"> <TD VALIGN="bottom"></TD> <TD VALIGN="bottom"> </TD> <TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000"> </P></TD> <TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000"> </P></TD> <TD> </TD> <TD VALIGN="bottom"> </TD> <TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000"> </P></TD> <TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000"> </P></TD> <TD> </TD> <TD VALIGN="bottom"> </TD> <TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000"> </P></TD> <TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000"> </P></TD> <TD> </TD> <TD VALIGN="bottom"> </TD> <TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000"> </P></TD> <TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000"> </P></TD> <TD> </TD> <TD VALIGN="bottom"> </TD> <TD VALIGN="bottom"></TD> <TD VALIGN="bottom"></TD> <TD VALIGN="bottom"></TD></TR> <TR> <TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Short-term investments — U.S. Treasury securities</FONT></P></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD> <TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">57,564</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD> <TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">7</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD> <TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(1</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">) </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD> <TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">57,570</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1/2014 — 12/2014</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD></TR> <TR STYLE="font-size:1px"> <TD VALIGN="bottom"></TD> <TD VALIGN="bottom"> </TD> <TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000"> </P></TD> <TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000"> </P></TD> <TD> </TD> <TD VALIGN="bottom"> </TD> <TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000"> </P></TD> <TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000"> </P></TD> <TD> </TD> <TD VALIGN="bottom"> </TD> <TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000"> </P></TD> <TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000"> </P></TD> <TD> </TD> <TD VALIGN="bottom"> </TD> <TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000"> </P></TD> <TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000"> </P></TD> <TD> </TD> <TD VALIGN="bottom"> </TD> <TD VALIGN="bottom"></TD> <TD VALIGN="bottom"></TD> <TD VALIGN="bottom"></TD></TR> <TR BGCOLOR="#cceeff"> <TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Long-term investments — U.S. Treasury securities</FONT></P></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD> <TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">2,502</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD> <TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">—</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD> <TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">—</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD> <TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">2,502</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1/2015</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD></TR> <TR STYLE="font-size:1px"> <TD VALIGN="bottom"></TD> <TD VALIGN="bottom"> </TD> <TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000"> </P></TD> <TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000"> </P></TD> <TD> </TD> <TD VALIGN="bottom"> </TD> <TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000"> </P></TD> <TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000"> </P></TD> <TD> </TD> <TD VALIGN="bottom"> </TD> <TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000"> </P></TD> <TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000"> </P></TD> <TD> </TD> <TD VALIGN="bottom"> </TD> <TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000"> </P></TD> <TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000"> </P></TD> <TD> </TD> <TD VALIGN="bottom"> </TD> <TD VALIGN="bottom"></TD> <TD VALIGN="bottom"></TD> <TD VALIGN="bottom"></TD></TR> </TABLE> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">As of December 31, 2014 and December 31, 2013, the Company’s U.S. Treasury securities classified as short-term investments had unrealized losses of approximately $7 and $1, respectively. The net unrealized loss at December 31, 2014 was primarily caused by increases in short-term interest rates subsequent to the purchase dates of the related securities. The net unrealized gain at December 31, 2013 was primarily caused by slight decreases in short-term interest rates subsequent to the purchase dates of the related securities. At December 31, 2014 there were no investments that had been in a continuous unrealized loss position for 12 months or longer. The Company collected the contractual cash flows on its U.S. Treasury securities that matured from January 1, 2015 through February 27, 2015 and expects to be able to collect all contractual cash flows on the remaining maturities of its U.S. Treasury securities. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">Interest income was as follows (in thousands): </FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px"> </P> <TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="92%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center"> <TR> <TD WIDTH="81%"></TD> <TD VALIGN="bottom" WIDTH="4%"></TD> <TD></TD> <TD></TD> <TD></TD> <TD VALIGN="bottom" WIDTH="4%"></TD> <TD></TD> <TD></TD> <TD></TD> <TD VALIGN="bottom" WIDTH="4%"></TD> <TD></TD> <TD></TD> <TD></TD></TR> <TR> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom" COLSPAN="10" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Years Ended<BR>December 31,</B></FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD></TR> <TR> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>2014</B></FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>2013</B></FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>2012</B></FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD></TR> <TR BGCOLOR="#cceeff"> <TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Interest income</FONT></P></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD> <TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">101</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD> <TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">96</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD> <TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">83</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD></TR> </TABLE> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">The Company has revised the previously reported disclosure of interest income for the year ended December 2013. The correction had no effect upon the consolidated statement of comprehensive loss amounts. </FONT></P> <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1"> </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">96 </FONT></P> <p Style='page-break-before:always'> <HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER"> <h5 align="left"><a href="#toc">Table of Contents</a></h5> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>CYTOKINETICS, INCORPORATED </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS — (Continued) </B></FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px"> </P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Note 5 — Fair Value Measurements </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">The Company adopted the fair value accounting guidance to value its financial assets and liabilities. Fair value is defined as the price that would be received for assets when sold or paid to transfer a liability in an orderly transaction between market participants at the measurement date (exit price). The Company utilizes market data or assumptions that the Company believes market participants would use in pricing the asset or liability, including assumptions about risk and the risks inherent in the inputs to the valuation technique. These inputs can be readily observable, market corroborated or generally unobservable. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">The Company primarily applies the market approach for recurring fair value measurements and endeavors to utilize the best information reasonably available. Accordingly, the Company utilizes valuation techniques that maximize the use of observable inputs and minimize the use of unobservable inputs to the extent possible, and considers the security issuers’ and the third-party insurers’ credit risk in its assessment of fair value. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">The Company classifies the determined fair value based on the observability of those inputs. Fair value accounting guidance establishes a fair value hierarchy that prioritizes the inputs used to measure fair value. The hierarchy gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (Level 1 measurement) and the lowest priority to unobservable inputs (Level 3 measurement). The three defined levels of the fair value hierarchy are as follows: </FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">Level 1 — Observable inputs, such as quoted prices in active markets for identical assets or liabilities; </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">Level 2 — Inputs, other than the quoted prices in active markets, that are observable either directly or through corroboration with observable market data; and </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">Level 3 — Unobservable inputs, for which there is little or no market data for the assets or liabilities, such as internally-developed valuation models. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">Financial assets measured at fair value on a recurring basis as of December 31, 2014 and 2013 are classified in the table below in one of the three categories described above (in thousands): </FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px"> </P> <TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="92%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center"> <TR> <TD WIDTH="56%"></TD> <TD VALIGN="bottom" WIDTH="7%"></TD> <TD></TD> <TD></TD> <TD></TD> <TD VALIGN="bottom" WIDTH="7%"></TD> <TD></TD> <TD></TD> <TD></TD> <TD VALIGN="bottom" WIDTH="7%"></TD> <TD></TD> <TD></TD> <TD></TD> <TD VALIGN="bottom" WIDTH="7%"></TD> <TD></TD> <TD></TD> <TD></TD></TR> <TR> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom" COLSPAN="14" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>December 31, 2014</B></FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD></TR> <TR> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom" COLSPAN="10" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Fair Value Measurements Using</B></FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Assets<BR>At Fair Value</B></FONT></TD> <TD VALIGN="bottom" ROWSPAN="2"><FONT SIZE="1"> </FONT></TD></TR> <TR> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B> Level 1 </B></FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B> Level 2 </B></FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B> Level 3 </B></FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD></TR> <TR BGCOLOR="#cceeff"> <TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Money market funds</FONT></P></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD> <TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">16,932</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD> <TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">—</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD> <TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">—</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD> <TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">16,932</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD></TR> <TR> <TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">U.S. Treasury securities</FONT></P></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">63,013</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">—</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">—</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">63,013</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD></TR> <TR STYLE="font-size:1px"> <TD VALIGN="bottom"></TD> <TD VALIGN="bottom"> </TD> <TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000"> </P></TD> <TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000"> </P></TD> <TD> </TD> <TD VALIGN="bottom"> </TD> <TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000"> </P></TD> <TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000"> </P></TD> <TD> </TD> <TD VALIGN="bottom"> </TD> <TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000"> </P></TD> <TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000"> </P></TD> <TD> </TD> <TD VALIGN="bottom"> </TD> <TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000"> </P></TD> <TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000"> </P></TD> <TD> </TD></TR> <TR BGCOLOR="#cceeff"> <TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Total</FONT></P></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD> <TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">79,945</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD> <TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">—</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD> <TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">—</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD> <TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">79,945</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD></TR> <TR STYLE="font-size:1px"> <TD VALIGN="bottom"></TD> <TD VALIGN="bottom"> </TD> <TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000"> </P></TD> <TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000"> </P></TD> <TD> </TD> <TD VALIGN="bottom"> </TD> <TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000"> </P></TD> <TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000"> </P></TD> <TD> </TD> <TD VALIGN="bottom"> </TD> <TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000"> </P></TD> <TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000"> </P></TD> <TD> </TD> <TD VALIGN="bottom"> </TD> <TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000"> </P></TD> <TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000"> </P></TD> <TD> </TD></TR> <TR> <TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Amounts included in:</FONT></P></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"></TD> <TD VALIGN="bottom"></TD> <TD VALIGN="bottom"></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"></TD> <TD VALIGN="bottom"></TD> <TD VALIGN="bottom"></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"></TD> <TD VALIGN="bottom"></TD> <TD VALIGN="bottom"></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"></TD> <TD VALIGN="bottom"></TD> <TD VALIGN="bottom"></TD></TR> <TR BGCOLOR="#cceeff"> <TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Cash and cash equivalents</FONT></P></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD> <TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">16,932</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD> <TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">—</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD> <TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">—</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD> <TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">16,932</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD></TR> <TR> <TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Short-term investments</FONT></P></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">63,013</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">—</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">—</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">63,013</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD></TR> <TR BGCOLOR="#cceeff"> <TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Long-term investments</FONT></P></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">—</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">—</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">—</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">—</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD></TR> <TR STYLE="font-size:1px"> <TD VALIGN="bottom"></TD> <TD VALIGN="bottom"> </TD> <TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000"> </P></TD> <TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000"> </P></TD> <TD> </TD> <TD VALIGN="bottom"> </TD> <TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000"> </P></TD> <TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000"> </P></TD> <TD> </TD> <TD VALIGN="bottom"> </TD> <TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000"> </P></TD> <TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000"> </P></TD> <TD> </TD> <TD VALIGN="bottom"> </TD> <TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000"> </P></TD> <TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000"> </P></TD> <TD> </TD></TR> <TR> <TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Total</FONT></P></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD> <TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">79,945</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD> <TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">—</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD> <TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">—</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD> <TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">79,945</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD></TR> <TR STYLE="font-size:1px"> <TD VALIGN="bottom"></TD> <TD VALIGN="bottom"> </TD> <TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000"> </P></TD> <TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000"> </P></TD> <TD> </TD> <TD VALIGN="bottom"> </TD> <TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000"> </P></TD> <TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000"> </P></TD> <TD> </TD> <TD VALIGN="bottom"> </TD> <TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000"> </P></TD> <TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000"> </P></TD> <TD> </TD> <TD VALIGN="bottom"> </TD> <TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000"> </P></TD> <TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000"> </P></TD> <TD> </TD></TR> </TABLE> <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1"> </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">97 </FONT></P> <p Style='page-break-before:always'> <HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER"> <h5 align="left"><a href="#toc">Table of Contents</a></h5> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>CYTOKINETICS, INCORPORATED </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS — (Continued) </B></FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px"> </P> <TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="92%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center"> <TR> <TD WIDTH="56%"></TD> <TD VALIGN="bottom" WIDTH="7%"></TD> <TD></TD> <TD></TD> <TD></TD> <TD VALIGN="bottom" WIDTH="7%"></TD> <TD></TD> <TD></TD> <TD></TD> <TD VALIGN="bottom" WIDTH="7%"></TD> <TD></TD> <TD></TD> <TD></TD> <TD VALIGN="bottom" WIDTH="7%"></TD> <TD></TD> <TD></TD> <TD></TD></TR> <TR> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom" COLSPAN="14" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>December 31, 2013</B></FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD></TR> <TR> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom" COLSPAN="10" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Fair Value Measurements Using</B></FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Assets<BR>At Fair Value</B></FONT></TD> <TD VALIGN="bottom" ROWSPAN="2"><FONT SIZE="1"> </FONT></TD></TR> <TR> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B> Level 1 </B></FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B> Level 2 </B></FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B> Level 3 </B></FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD></TR> <TR BGCOLOR="#cceeff"> <TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Money market funds</FONT></P></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD> <TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">15,858</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD> <TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">—</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD> <TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">—</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD> <TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">15,858</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD></TR> <TR> <TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">U.S. Treasury securities</FONT></P></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">60,072</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">—</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">—</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">60,072</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD></TR> <TR STYLE="font-size:1px"> <TD VALIGN="bottom"></TD> <TD VALIGN="bottom"> </TD> <TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000"> </P></TD> <TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000"> </P></TD> <TD> </TD> <TD VALIGN="bottom"> </TD> <TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000"> </P></TD> <TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000"> </P></TD> <TD> </TD> <TD VALIGN="bottom"> </TD> <TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000"> </P></TD> <TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000"> </P></TD> <TD> </TD> <TD VALIGN="bottom"> </TD> <TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000"> </P></TD> <TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000"> </P></TD> <TD> </TD></TR> <TR BGCOLOR="#cceeff"> <TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Total</FONT></P></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD> <TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">75,930</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD> <TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">—</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD> <TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">—</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD> <TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">75,930</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD></TR> <TR STYLE="font-size:1px"> <TD VALIGN="bottom"></TD> <TD VALIGN="bottom"> </TD> <TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000"> </P></TD> <TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000"> </P></TD> <TD> </TD> <TD VALIGN="bottom"> </TD> <TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000"> </P></TD> <TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000"> </P></TD> <TD> </TD> <TD VALIGN="bottom"> </TD> <TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000"> </P></TD> <TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000"> </P></TD> <TD> </TD> <TD VALIGN="bottom"> </TD> <TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000"> </P></TD> <TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000"> </P></TD> <TD> </TD></TR> <TR> <TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Amounts included in:</FONT></P></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"></TD> <TD VALIGN="bottom"></TD> <TD VALIGN="bottom"></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"></TD> <TD VALIGN="bottom"></TD> <TD VALIGN="bottom"></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"></TD> <TD VALIGN="bottom"></TD> <TD VALIGN="bottom"></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"></TD> <TD VALIGN="bottom"></TD> <TD VALIGN="bottom"></TD></TR> <TR BGCOLOR="#cceeff"> <TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Cash and cash equivalents</FONT></P></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD> <TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">15,858</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD> <TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">—</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD> <TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">—</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD> <TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">15,858</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD></TR> <TR> <TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Short-term investments</FONT></P></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">57,570</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">—</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">—</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">57,570</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD></TR> <TR BGCOLOR="#cceeff"> <TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Long-term investments</FONT></P></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">2,502</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">—</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">—</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">2,502</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD></TR> <TR STYLE="font-size:1px"> <TD VALIGN="bottom"></TD> <TD VALIGN="bottom"> </TD> <TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000"> </P></TD> <TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000"> </P></TD> <TD> </TD> <TD VALIGN="bottom"> </TD> <TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000"> </P></TD> <TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000"> </P></TD> <TD> </TD> <TD VALIGN="bottom"> </TD> <TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000"> </P></TD> <TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000"> </P></TD> <TD> </TD> <TD VALIGN="bottom"> </TD> <TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000"> </P></TD> <TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000"> </P></TD> <TD> </TD></TR> <TR> <TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Total</FONT></P></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD> <TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">75,930</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD> <TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">—</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD> <TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">—</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD> <TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">75,930</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD></TR> <TR STYLE="font-size:1px"> <TD VALIGN="bottom"></TD> <TD VALIGN="bottom"> </TD> <TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000"> </P></TD> <TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000"> </P></TD> <TD> </TD> <TD VALIGN="bottom"> </TD> <TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000"> </P></TD> <TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000"> </P></TD> <TD> </TD> <TD VALIGN="bottom"> </TD> <TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000"> </P></TD> <TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000"> </P></TD> <TD> </TD> <TD VALIGN="bottom"> </TD> <TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000"> </P></TD> <TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000"> </P></TD> <TD> </TD></TR> </TABLE> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">The valuation technique used to measure fair value for the Company’s Level 1 assets is a market approach, using prices and other relevant information generated by market transactions involving identical assets. As of December 31, 2014 and 2013, the Company had no financial assets measured at fair value on a recurring basis using significant Level 2 or Level 3 inputs. The carrying amount of the Company’s accounts receivable and accounts payable approximates fair value due to the short-term nature of these instruments. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Note 6 — Balance Sheet Components </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">Property and equipment balances were as follows (in thousands): </FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px"> </P> <TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="92%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center"> <TR> <TD WIDTH="77%"></TD> <TD VALIGN="bottom" WIDTH="6%"></TD> <TD></TD> <TD></TD> <TD></TD> <TD VALIGN="bottom" WIDTH="5%"></TD> <TD></TD> <TD></TD> <TD></TD></TR> <TR> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>December 31,</B></FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD></TR> <TR> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>2014</B></FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>2013</B></FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD></TR> <TR BGCOLOR="#cceeff"> <TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Property and equipment, net:</FONT></P></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"></TD> <TD VALIGN="bottom"></TD> <TD VALIGN="bottom"></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"></TD> <TD VALIGN="bottom"></TD> <TD VALIGN="bottom"></TD></TR> <TR> <TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Laboratory equipment</FONT></P></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD> <TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">15,299</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD> <TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">15,317</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD></TR> <TR BGCOLOR="#cceeff"> <TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Computer equipment and software</FONT></P></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">2,418</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">2,549</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD></TR> <TR> <TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Office equipment, furniture and fixtures</FONT></P></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">913</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1,050</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD></TR> <TR BGCOLOR="#cceeff"> <TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Leasehold improvements</FONT></P></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">3,334</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">3,297</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD></TR> <TR STYLE="font-size:1px"> <TD VALIGN="bottom"></TD> <TD VALIGN="bottom"> </TD> <TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000"> </P></TD> <TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000"> </P></TD> <TD> </TD> <TD VALIGN="bottom"> </TD> <TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000"> </P></TD> <TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000"> </P></TD> <TD> </TD></TR> <TR> <TD VALIGN="top"></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">21,964</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">22,213</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD></TR> <TR BGCOLOR="#cceeff"> <TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Less: Accumulated depreciation and amortization</FONT></P></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(20,327</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">) </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(20,992</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">) </FONT></TD></TR> <TR STYLE="font-size:1px"> <TD VALIGN="bottom"></TD> <TD VALIGN="bottom"> </TD> <TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000"> </P></TD> <TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000"> </P></TD> <TD> </TD> <TD VALIGN="bottom"> </TD> <TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000"> </P></TD> <TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000"> </P></TD> <TD> </TD></TR> <TR> <TD VALIGN="top"></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD> <TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1,637</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD> <TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1,221</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD></TR> <TR STYLE="font-size:1px"> <TD VALIGN="bottom"></TD> <TD VALIGN="bottom"> </TD> <TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000"> </P></TD> <TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000"> </P></TD> <TD> </TD> <TD VALIGN="bottom"> </TD> <TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000"> </P></TD> <TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000"> </P></TD> <TD> </TD></TR> </TABLE> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">Depreciation expense was $0.5 million, $0.4 million and $0.6 million for the years ended December 31, 2014, 2013 and 2012 respectively. </FONT></P> <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1"> </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">98 </FONT></P> <p Style='page-break-before:always'> <HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER"> <h5 align="left"><a href="#toc">Table of Contents</a></h5> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>CYTOKINETICS, INCORPORATED </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS — (Continued) </B></FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px"> </P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">Accrued liabilities were as follows (in thousands): </FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px"> </P> <TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="92%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center"> <TR> <TD WIDTH="82%"></TD> <TD VALIGN="bottom" WIDTH="4%"></TD> <TD></TD> <TD></TD> <TD></TD> <TD VALIGN="bottom" WIDTH="4%"></TD> <TD></TD> <TD></TD> <TD></TD></TR> <TR> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>December 31,</B></FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD></TR> <TR> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>2014</B></FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>2013</B></FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD></TR> <TR BGCOLOR="#cceeff"> <TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Accrued liabilities:</FONT></P></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"></TD> <TD VALIGN="bottom"></TD> <TD VALIGN="bottom"></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"></TD> <TD VALIGN="bottom"></TD> <TD VALIGN="bottom"></TD></TR> <TR> <TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Clinical and preclinical costs</FONT></P></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD> <TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">972</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD> <TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">4,975</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD></TR> <TR BGCOLOR="#cceeff"> <TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Consulting and professional fees</FONT></P></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">421</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">697</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD></TR> <TR> <TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Bonus</FONT></P></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">2,665</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1,614</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD></TR> <TR BGCOLOR="#cceeff"> <TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Vacation pay</FONT></P></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">915</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">778</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD></TR> <TR> <TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Other payroll related</FONT></P></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">110</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">93</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD></TR> <TR BGCOLOR="#cceeff"> <TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Other accrued expenses</FONT></P></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">317</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">115</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD></TR> <TR STYLE="font-size:1px"> <TD VALIGN="bottom"></TD> <TD VALIGN="bottom"> </TD> <TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000"> </P></TD> <TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000"> </P></TD> <TD> </TD> <TD VALIGN="bottom"> </TD> <TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000"> </P></TD> <TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000"> </P></TD> <TD> </TD></TR> <TR> <TD VALIGN="top"></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD> <TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">5,400</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD> <TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">8,272</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD></TR> <TR STYLE="font-size:1px"> <TD VALIGN="bottom"></TD> <TD VALIGN="bottom"> </TD> <TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000"> </P></TD> <TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000"> </P></TD> <TD> </TD> <TD VALIGN="bottom"> </TD> <TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000"> </P></TD> <TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000"> </P></TD> <TD> </TD></TR> </TABLE> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">Interest receivable on cash equivalents and investments of $109,000 and $215,000 is included in prepaid and other current assets at December 31, 2014 and 2013, respectively. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Note 7 — Related Parties and Related Party Transactions </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Research and Development Arrangements </I></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>Amgen Inc. (“Amgen”) </I></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">In December 2006, the Company entered into a collaboration and option agreement with Amgen to discover, develop and commercialize novel small molecule therapeutics, including omecamtiv mecarbil, that activate cardiac muscle contractility for potential applications in the treatment of heart failure (the “Amgen Agreement”). The agreement granted Amgen an option to obtain an exclusive license worldwide, except Japan, to develop and commercialize omecamtiv mecarbil and other drug candidates arising from the collaboration. In May 2009, Amgen exercised its option. As a result, Amgen became responsible for the development and commercialization of omecamtiv mecarbil and related compounds at its expense worldwide (excluding Japan), subject to the Company’s development and commercialization participation rights. Amgen reimburses the Company for certain research and development activities it performs under the collaboration. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">In June 2013, Cytokinetics and Amgen executed an amendment to the Amgen Agreement to include Japan, resulting in a worldwide collaboration (the “Amgen Agreement Amendment”). Under the terms of the Amgen Agreement Amendment, the Company received a non-refundable upfront license fee of $15.0 million in June 2013. Under the Amgen Agreement Amendment, the Company conducted a Phase I pharmacokinetic study intended to support inclusion of Japan in a potential Phase III clinical development program and potential global registration dossier for omecamtiv mecarbil. Amgen reimbursed the Company for the costs of this study. In addition, the Company is eligible to receive additional pre-commercialization milestone payments relating to the development of omecamtiv mecarbil and royalties on sales of omecamtiv mecarbil in Japan. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">In conjunction with the Amgen Agreement Amendment, the Company also entered into a common stock purchase agreement which provided for the sale of 1,404,100 shares of its common stock to Amgen at a price per share of $7.12 and an aggregate purchase price of $10.0 million, which was received in June 2013. The Company determined the fair value of the stock issued to Amgen to be $7.5 million. The excess of cash received over fair value of $2.5 million was initially deferred and allocated between the license and services based on their relative selling prices using best estimate of selling price. The allocated consideration was recognized as revenue as revenue criteria were satisfied, or as services were performed over approximately 12 months. Pursuant to this agreement, Amgen agreed to certain trading and other restrictions with respect to the Company’s common stock. </FONT></P> <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1"> </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">99 </FONT></P> <p Style='page-break-before:always'> <HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER"> <h5 align="left"><a href="#toc">Table of Contents</a></h5> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>CYTOKINETICS, INCORPORATED </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS — (Continued) </B></FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px"> </P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">The Company determined that the license to the Japan territory granted under the Amgen Agreement Amendment was a separate, non-contingent deliverable under the amendment. The Company determined that the license has stand-alone value based on Amgen’s internal product development capabilities since all relevant manufacturing know-how related to omecamtiv mecarbil was previously delivered to Amgen. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">In October 2013, the Company determined that the revenue recognition requirements under ASC 605-10 had been met and accordingly, recognized $17.2 million in license revenue attributable to the Amgen Agreement Amendment in the fourth quarter of 2013. In year ended December 31, 2014, the Company recognized the remaining $0.3 million of the previously deferred consideration attributable to the Amgen Agreement Amendment as research and development revenues from related parties. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">Under the Amgen Agreement, as amended, the Company is eligible for additional development milestone payments which are based on various clinical milestones, including the initiation of certain clinical studies, the submission of a drug candidate to certain regulatory authorities for marketing approval and the receipt of such approvals, and which could total over $350.0 million. Additionally, up to $300.0 million in commercial milestones could be received provided certain sales targets are met. Due to the nature of drug development, including the inherent risk of development and approval of drug candidates by regulatory authorities, it is not possible to estimate if and when these milestone payments could become due. The achievement of each of these milestones is dependent solely upon the results of Amgen’s development and commercialization activities and therefore none of these milestones was deemed to be substantive. During the period ended December 31, 2014, zero dollars were recognized for milestones achieved under the Amgen Agreement. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">The Amgen Agreement also provides for the Company to receive increased royalties by co-funding Phase III development costs of omecamtiv mecarbil and other drug candidates under the collaboration. If the Company elects to co-fund such costs, it would be entitled to co-promote the co-funded drug in North America and participate in agreed commercialization activities in institutional care settings, at Amgen’s expense. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">Pursuant to the Amgen Agreement, the Company has recognized research and development revenue from Amgen for reimbursements of internal costs of certain full-time employee equivalents, supporting a collaborative research program directed to the discovery of next-generation cardiac sarcomere activator compounds and of other costs related to that research program. These reimbursements were recorded as research and development revenues from related parties. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">Revenue from Amgen was as follows (in thousands): </FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px"> </P> <TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="92%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center"> <TR> <TD WIDTH="72%"></TD> <TD VALIGN="bottom" WIDTH="4%"></TD> <TD></TD> <TD></TD> <TD></TD> <TD VALIGN="bottom" WIDTH="4%"></TD> <TD></TD> <TD></TD> <TD></TD> <TD VALIGN="bottom" WIDTH="4%"></TD> <TD></TD> <TD></TD> <TD></TD></TR> <TR> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom" COLSPAN="10" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Years Ended December 31,</B></FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD></TR> <TR> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>2014</B></FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>2013</B></FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>2012</B></FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD></TR> <TR BGCOLOR="#cceeff"> <TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">License revenues from related parties</FONT></P></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD> <TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">—</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD> <TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">17,230</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD> <TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">—</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD></TR> <TR> <TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Research and development revenues from related parties:</FONT></P></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"></TD> <TD VALIGN="bottom"></TD> <TD VALIGN="bottom"></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"></TD> <TD VALIGN="bottom"></TD> <TD VALIGN="bottom"></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"></TD> <TD VALIGN="bottom"></TD> <TD VALIGN="bottom"></TD></TR> <TR BGCOLOR="#cceeff"> <TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Reimbursement of internal costs</FONT></P></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">4,260</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">2,019</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">4,174</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD></TR> <TR> <TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Reimbursement of other costs</FONT></P></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">—</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">—</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">3</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD></TR> <TR BGCOLOR="#cceeff"> <TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Allocated consideration</FONT></P></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">278</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">—</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">—</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD></TR> <TR STYLE="font-size:1px"> <TD VALIGN="bottom"></TD> <TD VALIGN="bottom"> </TD> <TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000"> </P></TD> <TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000"> </P></TD> <TD> </TD> <TD VALIGN="bottom"> </TD> <TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000"> </P></TD> <TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000"> </P></TD> <TD> </TD> <TD VALIGN="bottom"> </TD> <TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000"> </P></TD> <TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000"> </P></TD> <TD> </TD></TR> <TR> <TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Total revenues from Amgen</FONT></P></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD> <TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">4,538</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD> <TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">19,249</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD> <TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">4,177</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD></TR> <TR STYLE="font-size:1px"> <TD VALIGN="bottom"></TD> <TD VALIGN="bottom"> </TD> <TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000"> </P></TD> <TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000"> </P></TD> <TD> </TD> <TD VALIGN="bottom"> </TD> <TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000"> </P></TD> <TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000"> </P></TD> <TD> </TD> <TD VALIGN="bottom"> </TD> <TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000"> </P></TD> <TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000"> </P></TD> <TD> </TD></TR> </TABLE> <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1"> </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">100 </FONT></P> <p Style='page-break-before:always'> <HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER"> <h5 align="left"><a href="#toc">Table of Contents</a></h5> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>CYTOKINETICS, INCORPORATED </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS — (Continued) </B></FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px"> </P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Astellas Pharma Inc. (“Astellas”) </I></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>Original Astellas Agreement (Non-neuromuscular license) </I></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">In June 2013, the Company entered into a license and collaboration agreement with Astellas (the “Original Astellas Agreement”). The primary objective of the collaboration with Astellas is to advance novel therapies for diseases and medical conditions associated with muscle weakness. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">Under the Original Astellas Agreement, the Company granted Astellas an exclusive license to co-develop and jointly commercialize CK-2127107, a fast skeletal troponin activator, for potential application in non-neuromuscular indications worldwide. The Company was primarily responsible for the conduct of Phase I clinical trials and certain Phase II readiness activities for CK-2127107 and Astellas was primarily responsible for the conduct of subsequent development and commercialization activities for CK-2127107. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">In July 2013, the Company received an upfront, non-refundable license fee of $16.0 million in connection with the execution of the Original Astellas Agreement. Under the agreement, the Company was eligible to potentially receive approximately $25.5 million in reimbursement of sponsored research and development activities during the initial two years of the collaboration. The agreement also provided for research and early and late stage development milestone payments based on various research and clinical milestones, including the initiation of certain clinical studies, the submission for approval of a drug candidate to certain regulatory authorities for marketing approval and the commercial launch of collaboration products, and royalties on sales of commercialized products. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">At the inception of the Original Astellas Agreement, the Company deferred revenue related to the Original Astellas Agreement in accordance with ASC 605-25. The Company evaluated whether the delivered elements under the arrangement have value on a stand-alone basis. Upfront, non-refundable licensing payments are assessed to determine whether or not the licensee is able to obtain stand-alone value from the license. Where this is not the case, the Company does not consider the license deliverable to be a separate unit of accounting, and the revenue for the license fee is deferred and recognized in conjunction with the other deliverables that constitute the combined unit of accounting. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">The Company determined that the license and the research and development services are a single unit of accounting as the license was determined to not have stand-alone value. Accordingly, the Company is recognizing this revenue using the proportional performance model over the initial research term of the Original Astellas Agreement. During the year ended December 31, 2014, the Company recorded $9.8 million in license revenue based on the proportional performance model. As of December 31, 2014, the Company has recognized $13.7 million of the $16.0 million upfront license fee as license revenue, and has $2.3 million of deferred license revenue under the Original Astellas Agreement. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">Pursuant to the Original Astellas Agreement, the Company has recognized research and development revenue from Astellas for reimbursements of internal costs of certain full-time employee equivalents, supporting collaborative research and development programs, and of other costs related to those programs. During the year ended December 31, 2014, the Company recorded research and development revenue from Astellas of $8.9 million related to the reimbursement of internal costs and $6.5 million related to the reimbursement of other costs. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>Amended Astellas Agreement (Expansion to include neuromuscular indications) </I></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">On December 22, 2014, the Company entered into an amended and restated license and collaboration agreement with Astellas (the “Amended Astellas Agreement”). This agreement superseded the Original Astellas </FONT></P> <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1"> </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">101 </FONT></P> <p Style='page-break-before:always'> <HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER"> <h5 align="left"><a href="#toc">Table of Contents</a></h5> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>CYTOKINETICS, INCORPORATED </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS — (Continued) </B></FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px"> </P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2"> Agreement. The Amended Astellas Agreement expanded the objective of the collaboration of advancing novel therapies for diseases and medical conditions associated with muscle weakness to include SMA and potentially other neuromuscular indications, in addition to the non-neuromuscular indications provided for in the Original Astellas Agreement. Under the terms of the Amended Astellas Agreement, we received a non-refundable upfront license fee of $30.0 million in January 2015. Concurrently, the Company received $15.0 million as a milestone payment relating to Astellas’ decision to advance CK-2127107 into Phase II clinical development. The Company is also eligible to potentially receive over $20.0 million in reimbursement of sponsored research and development activities during the next two years of the collaboration. Under the Amended Astellas Agreement, the Company plans to conduct the initial Phase II clinical trial of CK-2127107 in patients with SMA. In addition, the Company is entitled to receive additional pre-commercialization milestone payments related to the development of CK-2127107 in neuromuscular indications, and royalties on sales of CK-2127107 in neuromuscular indications. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">The Company determined that the license and the research and development services relating to the Amended Astellas Agreement are a single unit of accounting as the license was determined to not have stand-alone value. Accordingly, the Company is recognizing this revenue over the initial research term of the Amended Astellas Agreement using the proportional performance model. As of December 31, 2014, the Company has recognized zero of the $30.0 million upfront license fee as license revenue and deferred the entire amount. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">The Company believes that each of the milestones related to research and early development under the Amended Astellas Agreement is substantive and can only be achieved with the Company’s past and current performance and each milestone will result in additional payments to the Company. During the period ended December 31, 2014, $17.0 million was recognized as milestone revenue for early development under this agreement. The Company is eligible to receive up to $2.0 million in research milestone payments for each future collaboration product candidate. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">The achievement of each of the late stage development milestones and the commercialization milestones are dependent solely upon the results of Astellas’ development activities and therefore these milestones were not deemed to be substantive. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">Under the Amended Astellas Agreement, additional research and early and late state development milestone payments which are based on various research and clinical milestones, including the initiation of certain clinical studies, the submission for approval of a drug candidate to certain regulatory authorities for marketing approval and the commercial launch of collaboration products could total over $600.0 million, including up to $95.0 million relating to CK-2127107 in non-neuromuscular indications, and over $100.0 million related to CK-2127107 in each of SMA and other neuromuscular indications. Additionally, $200.0 million in commercial milestones could be received under the Amended Astellas Agreement provided certain sales targets are met. Due to the nature of drug development, including the inherent risk of development and approval of drug candidates by regulatory authorities, it is not possible to estimate if and when these milestone payments could become due. </FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px"> </P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">In the event Astellas commercializes any collaboration products, the Company will receive royalties on sales of such collaboration products, including royalties ranging from the high single digits to the high teens on sales of products containing CK-2127107. Cytokinetics also holds an option to co-fund certain development costs for CK-2127107 and other compounds in exchange for increased milestone payments and royalties; such royalties may increase under certain scenarios to exceed twenty percent. Under the Amended Astellas Agreement, Cytokinetics retains an option to co-promote collaboration products containing fast skeletal muscle activators for neuromuscular indications in the U.S., Canada and Europe, in addition to its option to co-promote other collaboration products in the U.S. and Canada as provided for in the Original Astellas Agreement. Astellas will reimburse Cytokinetics for certain expenses associated with its co-promotion activities. The Amended </FONT></P> <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1"> </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">102 </FONT></P> <p Style='page-break-before:always'> <HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER"> <h5 align="left"><a href="#toc">Table of Contents</a></h5> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>CYTOKINETICS, INCORPORATED </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS — (Continued) </B></FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px"> </P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2"> Astellas Agreement also provides for Cytokinetics to lead certain activities relating to the commercialization of collaboration products for neuromuscular indications in the U.S., Canada and Europe under particular scenarios. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">In conjunction with the Amended Astellas Agreement, the Company also entered into a common stock purchase agreement which provided for the sale of 2,040,816 shares of its common stock to Astellas at a price per share of $4.90 and an aggregate purchase price of $10.0 million which was received in December 2014. Pursuant to this agreement, Astellas agreed to certain trading and other restrictions with respect to the Company’s common stock. The Company determined the fair value of the stock issued to Astellas to be $9.1 million. The excess of cash received over fair value of $0.9 million was deferred along with the license and research and development services. Allocated consideration will be recognized as revenue for the single unit of accounting above, as services are performed following the proportional performance model over the initial research term of the Amended Astellas Agreement. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">Following the common stock purchase, Astellas was determined to be a related party. As such, all revenue earned following the common stock purchase will be classified as related party revenue. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">Research and development revenue from Astellas was as follows (in thousands): </FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px"> </P> <TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="92%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center"> <TR> <TD WIDTH="71%"></TD> <TD VALIGN="bottom" WIDTH="9%"></TD> <TD></TD> <TD></TD> <TD></TD> <TD VALIGN="bottom" WIDTH="9%"></TD> <TD></TD> <TD></TD> <TD></TD></TR> <TR> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Year Ended<BR>December 31,<BR>2014</B></FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Year Ended<BR>December 31,<BR>2013</B></FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD></TR> <TR BGCOLOR="#cceeff"> <TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Research and development revenues with related parties:</FONT></P></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"></TD> <TD VALIGN="bottom"></TD> <TD VALIGN="bottom"></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"></TD> <TD VALIGN="bottom"></TD> <TD VALIGN="bottom"></TD></TR> <TR> <TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Research and development milestone fees</FONT></P></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD> <TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">15,000</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">—</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD></TR> <TR BGCOLOR="#cceeff"> <TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Research and development revenues:</FONT></P></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"></TD> <TD VALIGN="bottom"></TD> <TD VALIGN="bottom"></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"></TD> <TD VALIGN="bottom"></TD> <TD VALIGN="bottom"></TD></TR> <TR> <TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Reimbursement of internal costs</FONT></P></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">8,939</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">3,285</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD></TR> <TR BGCOLOR="#cceeff"> <TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Reimbursement of other costs</FONT></P></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">6,452</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">3,130</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD></TR> <TR> <TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Research and development milestone fees</FONT></P></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">2,000</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">—</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD></TR> <TR STYLE="font-size:1px"> <TD VALIGN="bottom"></TD> <TD VALIGN="bottom"> </TD> <TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000"> </P></TD> <TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000"> </P></TD> <TD> </TD> <TD VALIGN="bottom"> </TD> <TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000"> </P></TD> <TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000"> </P></TD> <TD> </TD></TR> <TR BGCOLOR="#cceeff"> <TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Total research and development revenue from Astellas</FONT></P></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD> <TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">32,391</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD> <TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">6,415</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD></TR> <TR STYLE="font-size:1px"> <TD VALIGN="bottom"></TD> <TD VALIGN="bottom"> </TD> <TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000"> </P></TD> <TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000"> </P></TD> <TD> </TD> <TD VALIGN="bottom"> </TD> <TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000"> </P></TD> <TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000"> </P></TD> <TD> </TD></TR> </TABLE> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">At December 31, 2014, the Company had $33.6 million of deferred revenue under the Amended Astellas Agreement, reflecting the unrecognized portion of the license revenue and prepayment on expenses expected to be incurred in the first quarter of 2015. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Note 8 — Other Research and Development Revenue Arrangements </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Grants </I></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">In 2010, the National Institute of Neurological Disorders and Strokes (“NINDS”) awarded to the Company a $2.8 million grant to support research and development of tirasemtiv directed to the potential treatment for myasthenia gravis for a period of up to three years. In September 2012, the NINDS awarded to us an additional $0.5 million under a separate grant. Management determined that the Company was the principal participant in the grant arrangements, and, accordingly, the Company recorded amounts earned under the arrangements as revenue. The grants were completed in June 2013. </FONT></P> <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1"> </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">103 </FONT></P> <p Style='page-break-before:always'> <HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER"> <h5 align="left"><a href="#toc">Table of Contents</a></h5> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>CYTOKINETICS, INCORPORATED </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS — (Continued) </B></FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px"> </P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">Total grant revenues were as follows (in thousands): </FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px"> </P> <TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="92%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center"> <TR> <TD WIDTH="79%"></TD> <TD VALIGN="bottom" WIDTH="4%"></TD> <TD></TD> <TD></TD> <TD></TD> <TD VALIGN="bottom" WIDTH="4%"></TD> <TD></TD> <TD></TD> <TD></TD> <TD VALIGN="bottom" WIDTH="4%"></TD> <TD></TD> <TD></TD> <TD></TD></TR> <TR> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom" COLSPAN="10" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Years Ended<BR>December 31,</B></FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD></TR> <TR> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>2014</B></FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>2013</B></FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>2012</B></FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD></TR> <TR BGCOLOR="#cceeff"> <TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">NINDS myasthenia gravis</FONT></P></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD> <TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">—</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD> <TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">69</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD> <TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1,308</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD></TR> <TR> <TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Other grant revenue</FONT></P></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">75</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">25</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">—</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD></TR> <TR STYLE="font-size:1px"> <TD VALIGN="bottom"></TD> <TD VALIGN="bottom"> </TD> <TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000"> </P></TD> <TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000"> </P></TD> <TD> </TD> <TD VALIGN="bottom"> </TD> <TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000"> </P></TD> <TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000"> </P></TD> <TD> </TD> <TD VALIGN="bottom"> </TD> <TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000"> </P></TD> <TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000"> </P></TD> <TD> </TD></TR> <TR BGCOLOR="#cceeff"> <TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Total grant revenue</FONT></P></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD> <TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">75</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD> <TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">94</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD> <TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1,308</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD></TR> <TR STYLE="font-size:1px"> <TD VALIGN="bottom"></TD> <TD VALIGN="bottom"> </TD> <TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000"> </P></TD> <TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000"> </P></TD> <TD> </TD> <TD VALIGN="bottom"> </TD> <TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000"> </P></TD> <TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000"> </P></TD> <TD> </TD> <TD VALIGN="bottom"> </TD> <TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000"> </P></TD> <TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000"> </P></TD> <TD> </TD></TR> </TABLE> <P STYLE="margin-top:18px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Global Blood Therapeutics, Inc. (“Global Blood”) </I></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">In October 2011, the Company entered into a collaboration agreement with Global Blood Therapeutics, Inc. (formerly called Global Blood Targeting, Inc.) (“Global Blood”). Under an agreed research plan, scientists from Global Blood and our FTEs conducted research focused on small molecule therapeutics that target the blood. The Company provided to Global Blood access to certain research facilities, FTEs and other resources at agreed reimbursement rates that approximated our costs. In April 2012, the Company extended this agreement through December 2012. The Company was the primary obligor in the collaboration arrangement, and accordingly, the Company recorded expense reimbursements from Global Blood as research and development revenue. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">Research and development revenue from Global Blood was as follows (in thousands): </FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px"> </P> <TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="92%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center"> <TR> <TD WIDTH="79%"></TD> <TD VALIGN="bottom" WIDTH="4%"></TD> <TD></TD> <TD></TD> <TD></TD> <TD VALIGN="bottom" WIDTH="4%"></TD> <TD></TD> <TD></TD> <TD></TD> <TD VALIGN="bottom" WIDTH="4%"></TD> <TD></TD> <TD></TD> <TD></TD></TR> <TR> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom" COLSPAN="10" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Years Ended December 31,</B></FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD></TR> <TR> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>2014</B></FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>2013</B></FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>2012</B></FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD></TR> <TR BGCOLOR="#cceeff"> <TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Expense reimbursements from Global Blood</FONT></P></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD> <TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">—</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD> <TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">14</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD> <TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1,479</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD></TR> <TR STYLE="font-size:1px"> <TD VALIGN="bottom"></TD> <TD VALIGN="bottom"> </TD> <TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000"> </P></TD> <TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000"> </P></TD> <TD> </TD> <TD VALIGN="bottom"> </TD> <TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000"> </P></TD> <TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000"> </P></TD> <TD> </TD> <TD VALIGN="bottom"> </TD> <TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000"> </P></TD> <TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000"> </P></TD> <TD> </TD></TR> </TABLE> <P STYLE="margin-top:18px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>MyoKardia, Inc. </I></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">In August 2012, the Company entered into a collaboration agreement with MyoKardia, Inc. Under an agreed research plan, scientists from MyoKardia and our FTEs conduct research focused on small molecule therapeutics that inhibit cardiac sarcomere proteins. The Company provided to MyoKardia access to certain research facilities, and continues to provide FTEs and other resources at agreed reimbursement rates that approximate our costs. The Company is the primary obligor in the collaboration arrangement, and accordingly, the Company records expense reimbursements from MyoKardia as research and development revenue. The research plan terminated as planned in August 2013. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">Research and development revenue from MyoKardia was as follows (in thousands): </FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px"> </P> <TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="92%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center"> <TR> <TD WIDTH="77%"></TD> <TD VALIGN="bottom" WIDTH="4%"></TD> <TD></TD> <TD></TD> <TD></TD> <TD VALIGN="bottom" WIDTH="4%"></TD> <TD></TD> <TD></TD> <TD></TD> <TD VALIGN="bottom" WIDTH="4%"></TD> <TD></TD> <TD></TD> <TD></TD></TR> <TR> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom" COLSPAN="10" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Years Ended December 31,</B></FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD></TR> <TR> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>2014</B></FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>2013</B></FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>2012</B></FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD></TR> <TR BGCOLOR="#cceeff"> <TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Research and development milestone fees</FONT></P></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD> <TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">100</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD> <TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">—</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD> <TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">—</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD></TR> <TR> <TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Expense reimbursements from MyoKardia</FONT></P></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">—</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1,024</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">595</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD></TR> <TR STYLE="font-size:1px"> <TD VALIGN="bottom"></TD> <TD VALIGN="bottom"> </TD> <TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000"> </P></TD> <TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000"> </P></TD> <TD> </TD> <TD VALIGN="bottom"> </TD> <TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000"> </P></TD> <TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000"> </P></TD> <TD> </TD> <TD VALIGN="bottom"> </TD> <TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000"> </P></TD> <TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000"> </P></TD> <TD> </TD></TR> <TR BGCOLOR="#cceeff"> <TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Research and development revenue from Myokardia</FONT></P></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD> <TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">100</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD> <TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1,024</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD> <TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">595</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD></TR> <TR STYLE="font-size:1px"> <TD VALIGN="bottom"></TD> <TD VALIGN="bottom"> </TD> <TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000"> </P></TD> <TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000"> </P></TD> <TD> </TD> <TD VALIGN="bottom"> </TD> <TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000"> </P></TD> <TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000"> </P></TD> <TD> </TD> <TD VALIGN="bottom"> </TD> <TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000"> </P></TD> <TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000"> </P></TD> <TD> </TD></TR> </TABLE> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Note 9 — Debt </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">In April 2006, the Company entered into an equipment financing agreement with GE Capital. As of December 31, 2011, the balance of equipment loans outstanding under this line was $152,000. The Company </FONT></P> <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1"> </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">104 </FONT></P> <p Style='page-break-before:always'> <HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER"> <h5 align="left"><a href="#toc">Table of Contents</a></h5> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>CYTOKINETICS, INCORPORATED </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS — (Continued) </B></FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px"> </P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2"> repaid the remaining outstanding equipment financing debt in March 2012 and no further funds are available under this line of credit. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Interest Expense </I></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">Total interest expense incurred by the Company was as follows (in thousands): </FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px"> </P> <TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="92%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center"> <TR> <TD WIDTH="77%"></TD> <TD VALIGN="bottom" WIDTH="6%"></TD> <TD></TD> <TD></TD> <TD></TD> <TD VALIGN="bottom" WIDTH="6%"></TD> <TD></TD> <TD></TD> <TD></TD> <TD VALIGN="bottom" WIDTH="6%"></TD> <TD></TD> <TD></TD> <TD></TD></TR> <TR> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom" COLSPAN="10" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Years Ended December 31,</B></FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD></TR> <TR> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>2014</B></FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>2013</B></FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>2012</B></FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD></TR> <TR BGCOLOR="#cceeff"> <TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Interest expense</FONT></P></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD> <TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">—</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD> <TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">—</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD> <TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">3</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD></TR> <TR STYLE="font-size:1px"> <TD VALIGN="bottom"></TD> <TD VALIGN="bottom"> </TD> <TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000"> </P></TD> <TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000"> </P></TD> <TD> </TD> <TD VALIGN="bottom"> </TD> <TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000"> </P></TD> <TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000"> </P></TD> <TD> </TD> <TD VALIGN="bottom"> </TD> <TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000"> </P></TD> <TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000"> </P></TD> <TD> </TD></TR> </TABLE> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Note 10 — Commitments and Contingencies </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Commitments </I></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">The Company leases office space and equipment under a non-cancelable operating lease that expires in 2018, with an option to extend the lease for an additional three-year period. The lease terms provide for rental payments on a graduated scale and the Company’s payment of certain operating expenses. The Company recognizes rent expense on a straight-line basis over the lease period. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px; text-indent:4%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">Rent expense was as follows (in thousands): </FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px"> </P> <TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="92%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center"> <TR> <TD WIDTH="73%"></TD> <TD VALIGN="bottom" WIDTH="4%"></TD> <TD></TD> <TD></TD> <TD></TD> <TD VALIGN="bottom" WIDTH="4%"></TD> <TD></TD> <TD></TD> <TD></TD> <TD VALIGN="bottom" WIDTH="4%"></TD> <TD></TD> <TD></TD> <TD></TD></TR> <TR> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom" COLSPAN="10" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Years Ended December 31,</B></FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD></TR> <TR> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>2014</B></FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>2013</B></FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>2012</B></FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD></TR> <TR BGCOLOR="#cceeff"> <TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Rent expense</FONT></P></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD> <TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">3,338</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD> <TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">3,306</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD> <TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">3,375</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD></TR> <TR STYLE="font-size:1px"> <TD VALIGN="bottom"></TD> <TD VALIGN="bottom"> </TD> <TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000"> </P></TD> <TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000"> </P></TD> <TD> </TD> <TD VALIGN="bottom"> </TD> <TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000"> </P></TD> <TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000"> </P></TD> <TD> </TD> <TD VALIGN="bottom"> </TD> <TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000"> </P></TD> <TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000"> </P></TD> <TD> </TD></TR> </TABLE> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">As of December 31, 2014, future minimum lease payments under noncancelable operating leases were as follows (in thousands): </FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px"> </P> <TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="92%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center"> <TR> <TD WIDTH="89%"></TD> <TD VALIGN="bottom" WIDTH="5%"></TD> <TD></TD> <TD></TD> <TD></TD></TR> <TR BGCOLOR="#cceeff"> <TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">2015</FONT></P></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD> <TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"> 3,390</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD></TR> <TR> <TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">2016</FONT></P></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">3,504</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD></TR> <TR BGCOLOR="#cceeff"> <TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">2017</FONT></P></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">3,626</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD></TR> <TR> <TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">2018</FONT></P></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1,860</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD></TR> <TR BGCOLOR="#cceeff"> <TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">2019</FONT></P></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">—</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD></TR> <TR> <TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Thereafter</FONT></P></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">—</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD></TR> <TR STYLE="font-size:1px"> <TD VALIGN="bottom"></TD> <TD VALIGN="bottom"> </TD> <TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000"> </P></TD> <TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000"> </P></TD> <TD> </TD></TR> <TR BGCOLOR="#cceeff"> <TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Total</FONT></P></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD> <TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">12,380</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD></TR> <TR STYLE="font-size:1px"> <TD VALIGN="bottom"></TD> <TD VALIGN="bottom"> </TD> <TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000"> </P></TD> <TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000"> </P></TD> <TD> </TD></TR> </TABLE> <P STYLE="margin-top:18px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Contingencies </I></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">In the ordinary course of business, the Company may provide indemnifications of varying scope and terms to vendors, lessors, business partners and other parties with respect to certain matters, including, but not limited to, losses arising out of the Company’s breach of such agreements, services to be provided by or on behalf of the Company, or from intellectual property infringement claims made by third parties. In addition, the Company has entered into indemnification agreements with its directors and certain of its officers and employees that will require the Company, among other things, to indemnify them against certain liabilities that may arise by reason of their status or service as directors, officers or employees. The Company maintains director and officer insurance, which may cover certain liabilities arising from its obligation to indemnify its directors and certain of its officers and employees, and former officers and directors in certain circumstances. The Company maintains product liability insurance and comprehensive general liability insurance, which may cover certain liabilities </FONT></P> <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1"> </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">105 </FONT></P> <p Style='page-break-before:always'> <HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER"> <h5 align="left"><a href="#toc">Table of Contents</a></h5> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>CYTOKINETICS, INCORPORATED </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS — (Continued) </B></FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px"> </P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2"> arising from its indemnification obligations. It is not possible to determine the maximum potential amount of exposure under these indemnification obligations due to the limited history of prior indemnification claims and the unique facts and circumstances involved in each particular indemnification obligation. Such indemnification obligations may not be subject to maximum loss clauses. Management is not currently aware of any matters that could have a material adverse effect on the financial position, results of operations or cash flows of the Company. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">In December 2014, the Company filed a lawsuit alleging fraudulent inducement, breach of contract and negligence on the part of a data management vendor for a clinical trial. The Company is seeking monetary damages. As this is a contingency that may result in a gain, no provision has been made in the financial statements. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Note 11 — Convertible Preferred Stock </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">As of December 31, 2010 there were 10,000,000 shares of preferred stock authorized and no shares outstanding. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">On April 18, 2011, the Company entered into a securities purchase agreement (the “Deerfield Agreement”) with Deerfield Private Design Fund II, L.P., Deerfield Private Design International II, L.P., Deerfield Special Situations Fund, L.P., and Deerfield Special Situations Fund International Limited (collectively, “Deerfield”). On April 20, 2011, pursuant to the Deerfield Agreement, the Company issued to Deerfield 8,070 shares of Series A convertible preferred stock (the “Series A Preferred Stock”) for a purchase price of $1,500.00 per share for net proceeds of approximately $9.3 million, as well as common stock and warrants that are discussed in Note 12 — Stockholders’ Equity. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">The fair value of the common stock into which the Series A Preferred Stock was convertible exceeded the allocated purchase price of the Series A Preferred Stock by $2.9 million on the date of issuance, resulting in a beneficial conversion feature. The Company recognized the beneficial conversion feature as a one-time, non-cash, deemed dividend to the holders of Series A Preferred Stock on the date of issuance, which is the date the stock first became convertible. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">On September 26, 2012, all 8,070 shares of Series A Preferred Stock were converted into 1,345,000 shares of our common stock. The conversion was in accordance with the terms of the agreement with Deerfield under which the Series A Preferred Stock was issued in 2011. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">On June 20, 2012, the Company entered into underwriting agreements for two separate, concurrent public offerings of the Company’s securities (the “June 2012 Public Offerings”). On June 25, 2012, pursuant to the underwriting agreements, in aggregate the Company issued to certain investors 23,026 shares of Series B convertible preferred stock (the “Series B Preferred Stock”) for a purchase price of $760.00 per share, for net proceeds of approximately $12.3 million. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">Each share of Series B Preferred Stock was convertible into common stock at any time at the holder’s option. However, the holder was prohibited from converting the Series B Preferred Stock into shares of common stock if, as a result of such conversion, the holder and its affiliates would own more than 9.98% of the total number of shares of common stock then issued and outstanding. In the event of the Company’s liquidation, dissolution, or winding up, holders of Series B Preferred Stock would receive a payment equal to $0.001 per share before any proceeds are distributed to the common stockholders. Shares of Series B Preferred Stock generally have no voting rights, except as required by law and except that the consent of holders of a majority of the outstanding Series B Preferred Stock is required to amend the terms of the Series B Preferred Stock. Holders of Series B Preferred Stock were not entitled to receive any dividends, unless and until specifically declared by </FONT></P> <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1"> </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">106 </FONT></P> <p Style='page-break-before:always'> <HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER"> <h5 align="left"><a href="#toc">Table of Contents</a></h5> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>CYTOKINETICS, INCORPORATED </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS — (Continued) </B></FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px"> </P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2"> the Company’s board of directors. The Series B Preferred Stock ranked senior to the Company’s common stock as to distributions of assets upon the Company’s liquidation, dissolution or winding up, whether voluntarily or involuntarily. The Series B Preferred Stock may have ranked senior to, on parity with or junior to any class or series of the Company’s capital stock created in the future depending upon the specific terms of such future stock issuance. As a result of the one-for-six reverse stock split effected in June 2013, the conversion ratio for Series B convertible preferred stock changed from 1,000 shares of common stock per share of Series B convertible preferred stock to 166.67 shares of common stock per share of Series B convertible preferred stock. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">The fair value of the common stock into which the Series B Preferred Stock is convertible exceeded the allocated purchase price of the Series B Preferred Stock by $1.3 million on the date of issuance, resulting in a beneficial conversion feature. The Company recognized the beneficial conversion feature as a one-time, non-cash, deemed dividend to the holders of Series B Preferred Stock on the date of issuance, which is the date the stock first became convertible. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">In the first quarter of 2013, 4,000 shares of Series B convertible preferred stock were converted into 666,667 shares of common stock. In the second quarter of 2013, 15,026 shares of Series B convertible preferred stock were converted into 2,504,334 shares of common stock. On July 2, 2013, 4,000 shares of Series B convertible preferred stock, which represented all remaining shares of Series B convertible preferred stock, were converted into 666,681 shares of common stock. The conversions were in accordance with the terms of the original agreement under which the Series B convertible preferred stock was issued in 2012. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">As of December 31, 2014 there were 10,000,000 shares of preferred stock authorized and no shares outstanding. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Note 12 — Stockholders’ Equity </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Accumulated Other Comprehensive Loss </I></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">In 2014, the Company reclassified insignificant amounts of unrealized gains (losses) in investments out of accumulated other comprehensive income into net loss. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Authorized Shares </I></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">On May 18, 2011, the stockholders approved an increase in the number of authorized shares of common stock from 170,000,000 to 245,000,000. The increase became effective in August 2011, when the Company filed the Certificate of Amendment of Amended and Restated Certificate of Incorporation with the Secretary of State of the State of Delaware. In June 2013, upon the stockholder approval of the one-for-six reverse stock split and the amendment to the Company’s amended and restated certificate of incorporation, the number of authorized shares of common stock was reduced to 81,500,000 (See Note 1). </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Common Stock Outstanding </I></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">On April 20, 2011, pursuant to the Deerfield Agreement, the Company issued to Deerfield (i) 883,333 shares of common stock for a purchase price of $9.00 per share, (ii) 8,070 shares of Series A Preferred Stock for a purchase price of $1,500.00 per share, and (iii) warrants to purchase 1,114,168 shares of the Company’s common stock at an initial exercise price of $9.90 per share, for aggregate gross proceeds of approximately $20.1 million. After issuance costs of approximately $0.2 million, the net proceeds were approximately $19.9 million. </FONT></P> <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1"> </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">107 </FONT></P> <p Style='page-break-before:always'> <HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER"> <h5 align="left"><a href="#toc">Table of Contents</a></h5> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>CYTOKINETICS, INCORPORATED </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS — (Continued) </B></FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px"> </P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">The offering was made pursuant to a shelf registration statement that the Company filed with the SEC on November 10, 2008, which became effective on November 19, 2008 (File No. 333-155259). The closing of the offering took place on April 20, 2011. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">In accordance with the accounting guidance for valuing stock and warrants when preferred stock, common stock and warrants are issued in a single transaction and all are to be accounted for as equity, the Company allocated the gross purchase proceeds using the relative fair value method. The fair value of the common stock issued to Deerfield was calculated based on the closing price of the stock on the commitment date as quoted on The NASDAQ Global Market. The Series A Preferred Stock was valued based on the fair value of the Company’s common stock on the commitment date times the conversion ratio of one share of preferred to one thousand shares of common stock. The fair value of the Series A Preferred Stock was determined to be essentially equivalent to the fair value of the common stock into which it is convertible, based on the preferred holders’ ability to immediately convert the Series A Preferred Stock to common stock and the fact that the liquidation preference of the Series A Preferred Stock is only $0.001 per share. The fair value of the warrants was determined using the Black-Scholes pricing model, as discussed above. The relative fair value ratio of each of the instruments issued was then applied to the total gross proceeds of $20.1 million, resulting in allocated purchase prices of $6.2 million for the common stock, $9.4 million for the Series A Preferred Stock and $4.5 million for the warrants. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">On September 26, 2012, all 8,070 shares of Series A Convertible Preferred Stock were converted into 1,345,000 shares of our common stock. The conversion was in accordance with the terms of the original agreement under which the Series A Convertible Preferred Stock was issued in 2011. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">In June 2011, the Company entered into an At-The-Market Issuance Sales Agreement (the “MLV Agreement”) with McNicoll, Lewis & Vlak LLC (“MLV”), pursuant to which the Company sold, through December 31, 2014, 2,397,278 shares of common stock through MLV for net proceeds of approximately $15.2 million. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">On June 25, 2012, pursuant to the June 2012 Public Offerings, in aggregate the Company issued to various investors (i) 9,320,176 shares of common stock for a purchase price of $4.56 per share, (ii) 23,026 shares of the Series B Preferred Stock for a purchase price of $760.00 per share, and (iii) warrants to purchase 7,894,704 shares of the Company’s common stock at an exercise price of $5.28 per share, for aggregate gross proceeds of approximately $60.0 million. After issuance costs of approximately $4.0 million, the net proceeds from the June 2012 Public Offerings were approximately $56.0 million. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">The offerings were made pursuant to a shelf registration statement that the Company filed with the SEC on November 25, 2011, which became effective on December 8, 2011 (File No. 333-178189) and a supplemental shelf registration statement on Form S-3MEF that the Company filed with the SEC on June 20, 2012, which became effective on June 20, 2012 (File No. 333-182226). The closing of the offerings took place on June 25, 2012. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">In accordance with the accounting guidance for valuing stock and warrants when stock is issued in conjunction with other securities, and the stock and other securities are to be accounted for as equity, the Company allocated the gross purchase proceeds using the relative fair value method. For accounting purposes, the June 2012 Public Offerings were considered to be one transaction. The fair value of the common stock issued in the June 2012 Public Offerings was calculated based on the closing price of the stock on the commitment date as quoted on The NASDAQ Global Market. The Series B Preferred Stock was valued based on the fair value of the Company’s common stock on the commitment date times the conversion ratio of one share of preferred stock to one thousand shares of common stock. The fair value of the Series B Preferred Stock was determined to be </FONT></P> <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1"> </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">108 </FONT></P> <p Style='page-break-before:always'> <HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER"> <h5 align="left"><a href="#toc">Table of Contents</a></h5> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>CYTOKINETICS, INCORPORATED </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS — (Continued) </B></FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px"> </P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2"> essentially equivalent to the fair value of the common stock into which it is convertible, based on the preferred holders’ ability to immediately convert the Series B Preferred Stock to common stock and the fact that the liquidation preference of the Series B Preferred Stock is only $0.001 per share. The fair value of the warrants was determined using the Black-Scholes pricing model, as discussed above. The relative fair value ratio of each of the instruments issued was then applied to the total gross proceeds of $60.0 million, resulting in allocated purchase prices of $32.1 million for the common stock, $13.2 million for the Series B Preferred Stock, and $14.7 million for the warrants. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">In conjunction with the Amgen Agreement Amendment (see Note 7), in June 2013, Amgen purchased 1,404,100 shares of the Company’s common stock at a price per share of $7.12 and an aggregate purchase price of $10.0 million, which was received in June 2013. Under the terms of this agreement, Amgen agreed to certain trading and other restrictions with respect to the Company’s common stock. The Company determined the fair value of the stock issued to Amgen to be $7.5 million. The excess of cash received over fair value of $2.5 million was deferred and is being allocated between the license and services based on their relative selling prices using best estimate of selling price. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">In February 2014, the Company closed an underwritten public offering for the issuance and sale of 5,031,250 shares of its common stock. The gross public offering proceeds were approximately $40.3 million. The net proceeds from the sale of the shares were approximately $37.5 million, after deducting the underwriting discount and offering expenses. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">In December 2014, the Company also entered into a common stock purchase agreement which provided for the sale of 2,040,816 shares of its common stock to Astellas at a price per share of $4.90 and an aggregate purchase price of $10.0 million, which was received in December 2014. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Warrants </I></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">On April 20, 2011, pursuant to the Deerfield Agreement, the Company issued to Deerfield warrants to purchase 1,114,168 shares of the Company’s common stock at an initial exercise price of $9.90 per share, for aggregate gross proceeds of approximately $4.5 million. After issuance costs of approximately $0.1 million, the net proceeds were approximately $4.4 million. The warrants issued to Deerfield became exercisable on October 20, 2011 and will remain exercisable until April 20, 2015. The warrant holders are prohibited from exercising the warrants and obtaining shares of common stock if, as a result of such exercise, the holder and its affiliates would own more than 9.98% of the total number of shares of the Company’s common stock then issued and outstanding. The Company valued the warrants as of the date of issuance at $5.8 million using the Black-Scholes option pricing model and the following assumptions: a contractual term of four years, a risk-free interest rate of 1.66%, volatility of 80%, and the fair value of the Company’s common stock on the issuance date of $9.12 ($1.52 before adjustment for the Company’s 2013 reverse stock split, see Note 1). </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">On June 25, 2012, pursuant to the June 2012 Public Offerings, the Company issued warrants to purchase 7,894,704 shares of the Company’s common stock at an exercise price of $5.28 per share, for an aggregate gross proceeds of approximately $14.7 million. The warrant holders are prohibited from exercising the warrants and obtaining shares of common stock if, as a result of such exercise, the holder and its affiliates would own more than 9.98% of the total number of shares of the Company’s common stock then issued and outstanding. The Company valued the warrants as of the date of issuance at $16.2 million using the Black-Scholes option pricing model and the following assumptions: a contractual term of five years, a risk-free interest rate of 0.73%, volatility of 76%, and the fair value of the Company’s common stock on the issuance date of $3.78 ($0.63 before adjustment for the Company’s 2013 reverse stock split, see Note 1). </FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px"><FONT SIZE="1"> </FONT></P> <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1"> </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">109 </FONT></P> <p Style='page-break-before:always'> <HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER"> <h5 align="left"><a href="#toc">Table of Contents</a></h5> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>CYTOKINETICS, INCORPORATED </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS — (Continued) </B></FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px"> </P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">In February 2013, warrants to purchase 1,000 shares of the Company’s common stock at an exercise price of $5.28 per share were cash exercised in accordance with the June 2012 Public Offerings underwriting agreements. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">In April 2013, the Company issued 358,460 shares of common stock related to cashless exercises of warrants in accordance with the June 2012 Public Offerings. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">Outstanding warrants as of December 31, 2014 were as follows: </FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px"> </P> <TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="92%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center"> <TR> <TD WIDTH="67%"></TD> <TD VALIGN="bottom" WIDTH="4%"></TD> <TD></TD> <TD></TD> <TD></TD> <TD VALIGN="bottom" WIDTH="4%"></TD> <TD></TD> <TD></TD> <TD></TD> <TD VALIGN="bottom" WIDTH="4%"></TD> <TD></TD> <TD></TD> <TD></TD></TR> <TR> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Number<BR>of Shares</B></FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Exercise<BR>Price</B></FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Expiration<BR>Date</B></FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD></TR> <TR BGCOLOR="#cceeff"> <TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Issued 4/20/2011</FONT></P></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1,114,168</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD> <TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">9.90</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">04/20/15</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD></TR> <TR> <TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Issued 6/25/2012</FONT></P></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">5,576,928</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD> <TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">5.28</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">06/25/17</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD></TR> </TABLE> <P STYLE="margin-top:18px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Stock Option Plans </I></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>2004 Plan </I></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">In January 2004, the Board of Directors adopted the 2004 Equity Incentive Plan (the “2004 Plan”), which was approved by the stockholders in February 2004. The 2004 Plan provides for the granting of incentive stock options, nonstatutory stock options, restricted stock, stock appreciation rights, stock performance units and stock performance shares to employees, directors and consultants. Under the 2004 Plan, options may be granted at prices not lower than 100% of the fair market value of the common stock on the date of grant for nonstatutory stock options and incentive stock options and may be granted for terms of up to ten years from the date of grant. Options granted to new employees generally vest 25% after one year and monthly thereafter over a period of four years. Options granted to existing employees generally vest monthly over a period of four years. At the May 2013 Annual Meeting of Stockholders, the number of shares of common stock authorized for issuance under the 2004 Plan was increased by 2,000,000. As of December 31, 2014, there were 1,270,478 shares of common stock reserved for issuance under the 2004 Plan. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>1997 Plan </I></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">In 1997, the Company adopted the 1997 Stock Option/Stock Issuance Plan (the “1997 Plan”). The Plan provides for the granting of stock options to employees and consultants of the Company. Options granted under the 1997 Plan may be either incentive stock options or nonstatutory stock options. Incentive stock options may be granted only to Company employees (including officers and directors who are also employees). Nonstatutory stock options may be granted to Company employees and consultants. Options under the Plan may be granted for terms of up to ten years from the date of grant as determined by the Board of Directors, provided, however, that (i) the exercise price of an incentive stock option and nonstatutory stock option shall not be less than 100% and 85% of the estimated fair market value of the shares on the date of grant, respectively, and (ii) with respect to any 10% stockholder, the exercise price of an incentive stock option or nonstatutory stock option shall not be less than 110% of the estimated fair market value of the shares on the date of grant and the term of the grant shall not exceed five years. Options may be exercisable immediately and are subject to repurchase options held by the Company which lapse over a maximum period of ten years at such times and under such conditions as determined by the Board of Directors. Options granted under the 1997 Plan generally vested over four or five years (generally 25% after one year and monthly thereafter). As of December 31, 2014, the Company had reserved no shares of common stock for issuance related to options outstanding under the 1997 Plan, and there were no shares available for future grants under the 1997 Plan. </FONT></P> <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1"> </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">110 </FONT></P> <p Style='page-break-before:always'> <HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER"> <h5 align="left"><a href="#toc">Table of Contents</a></h5> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>CYTOKINETICS, INCORPORATED </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS — (Continued) </B></FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px"> </P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">Activity under the two stock option plans was as follows: </FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px"> </P> <TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center"> <TR> <TD WIDTH="41%"></TD> <TD VALIGN="bottom" WIDTH="6%"></TD> <TD></TD> <TD></TD> <TD></TD> <TD VALIGN="bottom" WIDTH="6%"></TD> <TD></TD> <TD></TD> <TD></TD> <TD VALIGN="bottom" WIDTH="6%"></TD> <TD></TD> <TD></TD> <TD></TD> <TD VALIGN="bottom" WIDTH="6%"></TD> <TD></TD> <TD></TD> <TD></TD> <TD VALIGN="bottom" WIDTH="6%"></TD> <TD></TD> <TD></TD> <TD></TD></TR> <TR> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Shares<BR>Available for<BR>Grant of Option<BR>or Award</B></FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Stock Options<BR>Outstanding</B></FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Weighted<BR>Average Exercise<BR>Price per Share -<BR>Stock Options</B></FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Weighted<BR>Average Remaining<BR>Contractual Life</B></FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Aggregate<BR>Intrinsic<BR>Value</B></FONT><br><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>(in thousands)</B></FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD></TR> <TR BGCOLOR="#cceeff"> <TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Balance at December 31, 2011</FONT></P></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">585,476</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1,598,408</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">21.93</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"></TD> <TD VALIGN="bottom"></TD> <TD VALIGN="bottom"></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"></TD> <TD VALIGN="bottom"></TD> <TD VALIGN="bottom"></TD></TR> <TR> <TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Increase in authorized shares</FONT></P></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">416,667</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">—</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">—</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"></TD> <TD VALIGN="bottom"></TD> <TD VALIGN="bottom"></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"></TD> <TD VALIGN="bottom"></TD> <TD VALIGN="bottom"></TD></TR> <TR BGCOLOR="#cceeff"> <TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Options granted</FONT></P></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(403,108</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">) </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">403,108</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">6.14</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"></TD> <TD VALIGN="bottom"></TD> <TD VALIGN="bottom"></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"></TD> <TD VALIGN="bottom"></TD> <TD VALIGN="bottom"></TD></TR> <TR> <TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Options forfeited/expired</FONT></P></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">210,989</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(210,989</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">) </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">17.00</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"></TD> <TD VALIGN="bottom"></TD> <TD VALIGN="bottom"></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"></TD> <TD VALIGN="bottom"></TD> <TD VALIGN="bottom"></TD></TR> <TR BGCOLOR="#cceeff"> <TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Restricted stock units forfeited</FONT></P></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">68,702</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">—</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">—</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"></TD> <TD VALIGN="bottom"></TD> <TD VALIGN="bottom"></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"></TD> <TD VALIGN="bottom"></TD> <TD VALIGN="bottom"></TD></TR> <TR STYLE="font-size:1px"> <TD VALIGN="bottom"></TD> <TD VALIGN="bottom"> </TD> <TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000"> </P></TD> <TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000"> </P></TD> <TD> </TD> <TD VALIGN="bottom"> </TD> <TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000"> </P></TD> <TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000"> </P></TD> <TD> </TD> <TD VALIGN="bottom"> </TD> <TD VALIGN="bottom"></TD> <TD VALIGN="bottom"></TD> <TD VALIGN="bottom"></TD> <TD VALIGN="bottom"> </TD> <TD VALIGN="bottom"></TD> <TD VALIGN="bottom"></TD> <TD VALIGN="bottom"></TD> <TD VALIGN="bottom"> </TD> <TD VALIGN="bottom"></TD> <TD VALIGN="bottom"></TD> <TD VALIGN="bottom"></TD></TR> <TR> <TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Balance at December 31, 2012</FONT></P></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">878,726</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1,790,527</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">18.96</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"></TD> <TD VALIGN="bottom"></TD> <TD VALIGN="bottom"></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"></TD> <TD VALIGN="bottom"></TD> <TD VALIGN="bottom"></TD></TR> <TR BGCOLOR="#cceeff"> <TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Increase in authorized shares</FONT></P></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">2,000,000</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">—</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">—</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"></TD> <TD VALIGN="bottom"></TD> <TD VALIGN="bottom"></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"></TD> <TD VALIGN="bottom"></TD> <TD VALIGN="bottom"></TD></TR> <TR> <TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Options granted</FONT></P></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(797,629</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">) </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">797,629</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">5.95</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"></TD> <TD VALIGN="bottom"></TD> <TD VALIGN="bottom"></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"></TD> <TD VALIGN="bottom"></TD> <TD VALIGN="bottom"></TD></TR> <TR BGCOLOR="#cceeff"> <TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Restricted stock units granted</FONT></P></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(41,661</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">) </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">—</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">—</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"></TD> <TD VALIGN="bottom"></TD> <TD VALIGN="bottom"></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"></TD> <TD VALIGN="bottom"></TD> <TD VALIGN="bottom"></TD></TR> <TR> <TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Options exercised</FONT></P></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">—</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(21,397</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">) </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">5.32</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"></TD> <TD VALIGN="bottom"></TD> <TD VALIGN="bottom"></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"></TD> <TD VALIGN="bottom"></TD> <TD VALIGN="bottom"></TD></TR> <TR BGCOLOR="#cceeff"> <TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Options forfeited/expired</FONT></P></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">117,394</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(117,394</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">) </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">12.55</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"></TD> <TD VALIGN="bottom"></TD> <TD VALIGN="bottom"></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"></TD> <TD VALIGN="bottom"></TD> <TD VALIGN="bottom"></TD></TR> <TR> <TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Restricted stock units forfeited</FONT></P></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">4,999</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">—</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">—</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"></TD> <TD VALIGN="bottom"></TD> <TD VALIGN="bottom"></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"></TD> <TD VALIGN="bottom"></TD> <TD VALIGN="bottom"></TD></TR> <TR STYLE="font-size:1px"> <TD VALIGN="bottom"></TD> <TD VALIGN="bottom"> </TD> <TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000"> </P></TD> <TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000"> </P></TD> <TD> </TD> <TD VALIGN="bottom"> </TD> <TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000"> </P></TD> <TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000"> </P></TD> <TD> </TD> <TD VALIGN="bottom"> </TD> <TD VALIGN="bottom"></TD> <TD VALIGN="bottom"></TD> <TD VALIGN="bottom"></TD> <TD VALIGN="bottom"> </TD> <TD VALIGN="bottom"></TD> <TD VALIGN="bottom"></TD> <TD VALIGN="bottom"></TD> <TD VALIGN="bottom"> </TD> <TD VALIGN="bottom"></TD> <TD VALIGN="bottom"></TD> <TD VALIGN="bottom"></TD></TR> <TR BGCOLOR="#cceeff"> <TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Balance at December 31, 2013</FONT></P></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">2,161,829</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">2,449,365</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD> <TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">15.15</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"></TD> <TD VALIGN="bottom"></TD> <TD VALIGN="bottom"></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"></TD> <TD VALIGN="bottom"></TD> <TD VALIGN="bottom"></TD></TR> <TR> <TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Options granted</FONT></P></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(944,831</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">) </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">944,831</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">8.80</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"></TD> <TD VALIGN="bottom"></TD> <TD VALIGN="bottom"></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"></TD> <TD VALIGN="bottom"></TD> <TD VALIGN="bottom"></TD></TR> <TR BGCOLOR="#cceeff"> <TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Restricted stock units granted</FONT></P></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(43,500</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">) </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">—</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">—</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"></TD> <TD VALIGN="bottom"></TD> <TD VALIGN="bottom"></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"></TD> <TD VALIGN="bottom"></TD> <TD VALIGN="bottom"></TD></TR> <TR> <TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Options exercised</FONT></P></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">—</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(390</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">) </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">6.00</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"></TD> <TD VALIGN="bottom"></TD> <TD VALIGN="bottom"></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"></TD> <TD VALIGN="bottom"></TD> <TD VALIGN="bottom"></TD></TR> <TR BGCOLOR="#cceeff"> <TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Options forfeited/expired</FONT></P></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">95,980</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(95,980</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">) </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">39.74</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"></TD> <TD VALIGN="bottom"></TD> <TD VALIGN="bottom"></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"></TD> <TD VALIGN="bottom"></TD> <TD VALIGN="bottom"></TD></TR> <TR> <TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Restricted stock units forfeited</FONT></P></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1,000</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">—</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">—</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"></TD> <TD VALIGN="bottom"></TD> <TD VALIGN="bottom"></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"></TD> <TD VALIGN="bottom"></TD> <TD VALIGN="bottom"></TD></TR> <TR STYLE="font-size:1px"> <TD VALIGN="bottom"></TD> <TD VALIGN="bottom"> </TD> <TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000"> </P></TD> <TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000"> </P></TD> <TD> </TD> <TD VALIGN="bottom"> </TD> <TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000"> </P></TD> <TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000"> </P></TD> <TD> </TD> <TD VALIGN="bottom"> </TD> <TD VALIGN="bottom"></TD> <TD VALIGN="bottom"></TD> <TD VALIGN="bottom"></TD> <TD VALIGN="bottom"> </TD> <TD VALIGN="bottom"></TD> <TD VALIGN="bottom"></TD> <TD VALIGN="bottom"></TD> <TD VALIGN="bottom"> </TD> <TD VALIGN="bottom"></TD> <TD VALIGN="bottom"></TD> <TD VALIGN="bottom"></TD></TR> <TR BGCOLOR="#cceeff"> <TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Balance at December 31, 2014</FONT></P></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1,270,478</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">3,297,826</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD> <TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">12.62</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">6.79</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD> <TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">2,657</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD></TR> <TR STYLE="font-size:1px"> <TD VALIGN="bottom"></TD> <TD VALIGN="bottom"> </TD> <TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000"> </P></TD> <TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000"> </P></TD> <TD> </TD> <TD VALIGN="bottom"> </TD> <TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000"> </P></TD> <TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000"> </P></TD> <TD> </TD> <TD VALIGN="bottom"> </TD> <TD VALIGN="bottom"></TD> <TD VALIGN="bottom"></TD> <TD VALIGN="bottom"></TD> <TD VALIGN="bottom"> </TD> <TD VALIGN="bottom"></TD> <TD VALIGN="bottom"></TD> <TD VALIGN="bottom"></TD> <TD VALIGN="bottom"> </TD> <TD VALIGN="bottom"></TD> <TD VALIGN="bottom"></TD> <TD VALIGN="bottom"></TD></TR> <TR> <TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Exercisable at December 31, 2014</FONT></P></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"></TD> <TD VALIGN="bottom"></TD> <TD VALIGN="bottom"></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">2,140,754</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD> <TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">15.17</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">5.76</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD> <TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1,553</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD></TR> <TR BGCOLOR="#cceeff"> <TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Vested and expected to vest as of December 31, 2014</FONT></P></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"></TD> <TD VALIGN="bottom"></TD> <TD VALIGN="bottom"></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">3,277,489</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD> <TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">12.64</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">6.78</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD> <TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">2,642</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD></TR> </TABLE> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">Total intrinsic value of stock options exercised was $1,000, $107,000, and zero during the years ended December 31, 2014, 2013 and 2012, respectively. The intrinsic value is calculated as the difference between the market value as of December 31, 2014 and the exercise price of shares. The market value as of December 31, 2014 was $8.01 per share as reported by NASDAQ. The weighted average grant date fair value of stock options granted was $6.01, $3.85 and $3.89 per share during the years ended December 31, 2014, 2013 and 2012, respectively. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">The number of option shares vested was 601,647, 457,465 and 348,693 in 2014, 2013 and 2012, respectively. The grant date fair value of option shares vested was $3.0 million, $2.3 million and $2.4 million in 2014, 2013 and 2012, respectively. The Company has revised the previously reported disclosures of option shares vested and grant date fair value of option shares vested for the years ended December 31, 2013 and December 31, 2012. The corrections had no effect upon the statements of comprehensive loss amounts. </FONT></P> <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1"> </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">111 </FONT></P> <p Style='page-break-before:always'> <HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER"> <h5 align="left"><a href="#toc">Table of Contents</a></h5> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>CYTOKINETICS, INCORPORATED </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS — (Continued) </B></FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px"> </P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">Restricted stock unit activity was as follows: </FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px"> </P> <TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="92%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center"> <TR> <TD WIDTH="73%"></TD> <TD VALIGN="bottom" WIDTH="8%"></TD> <TD></TD> <TD></TD> <TD></TD> <TD VALIGN="bottom" WIDTH="7%"></TD> <TD></TD> <TD></TD> <TD></TD></TR> <TR> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Number of<BR>Shares</B></FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Weighted<BR>Average Award<BR>Date Fair Value<BR>per Share</B></FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD></TR> <TR BGCOLOR="#cceeff"> <TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Restricted stock units outstanding at December 31, 2011</FONT></P></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">517,535</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD> <TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">6.78</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD></TR> <TR> <TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Restricted stock units vested</FONT></P></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(231,935</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">) </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">6.78</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD></TR> <TR BGCOLOR="#cceeff"> <TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Restricted stock units forfeited</FONT></P></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(68,702</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">) </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">6.78</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD></TR> <TR STYLE="font-size:1px"> <TD VALIGN="bottom"></TD> <TD VALIGN="bottom"> </TD> <TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000"> </P></TD> <TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000"> </P></TD> <TD> </TD> <TD VALIGN="bottom"> </TD> <TD VALIGN="bottom"></TD> <TD VALIGN="bottom"></TD> <TD VALIGN="bottom"></TD></TR> <TR> <TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Restricted stock units outstanding at December 31, 2012</FONT></P></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">216,898</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">6.78</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD></TR> <TR BGCOLOR="#cceeff"> <TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Restricted stock units granted</FONT></P></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">41,661</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">6.00</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD></TR> <TR> <TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Restricted stock units vested</FONT></P></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(211,897</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">) </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">6.78</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD></TR> <TR BGCOLOR="#cceeff"> <TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Restricted stock units forfeited</FONT></P></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(4,999</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">) </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">6.78</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD></TR> <TR STYLE="font-size:1px"> <TD VALIGN="bottom"></TD> <TD VALIGN="bottom"> </TD> <TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000"> </P></TD> <TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000"> </P></TD> <TD> </TD> <TD VALIGN="bottom"> </TD> <TD VALIGN="bottom"></TD> <TD VALIGN="bottom"></TD> <TD VALIGN="bottom"></TD></TR> <TR> <TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Unvested restricted stock units outstanding at December 31, 2013</FONT></P></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">41,663</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">6.00</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD></TR> <TR BGCOLOR="#cceeff"> <TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Restricted stock units granted</FONT></P></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">43,500</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">9.65</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD></TR> <TR> <TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Restricted stock units vested</FONT></P></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(20,833</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">) </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">6.00</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD></TR> <TR BGCOLOR="#cceeff"> <TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Restricted stock units forfeited</FONT></P></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(1,000</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">) </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">6.00</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD></TR> <TR STYLE="font-size:1px"> <TD VALIGN="bottom"></TD> <TD VALIGN="bottom"> </TD> <TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000"> </P></TD> <TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000"> </P></TD> <TD> </TD> <TD VALIGN="bottom"> </TD> <TD VALIGN="bottom"></TD> <TD VALIGN="bottom"></TD> <TD VALIGN="bottom"></TD></TR> <TR> <TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Unvested restricted stock units outstanding at December 31, 2014</FONT></P></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">63,330</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD> <TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">8.51</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD></TR> <TR STYLE="font-size:1px"> <TD VALIGN="bottom"></TD> <TD VALIGN="bottom"> </TD> <TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000"> </P></TD> <TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000"> </P></TD> <TD> </TD> <TD VALIGN="bottom"> </TD> <TD VALIGN="bottom"></TD> <TD VALIGN="bottom"></TD> <TD VALIGN="bottom"></TD></TR> </TABLE> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">The grant date fair value of restricted stock units vested during the years ended December 31, 2014, 2013 and 2012 was $0.1 million, $1.4 million and $1.6 million, respectively. The Company measures compensation expense for restricted stock units at fair value on the grant date and recognizes the expense over the expected vesting period. The fair value for restricted stock units is based on the closing price of the Company’s common stock on the grant date. Unvested restricted stock awards are subject to repurchase at no cost to the Company. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Stock-Based Compensation </I></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">The Company applies the accounting guidance for stock compensation, which establishes accounting for share-based payment awards made to employees, non-employees and directors, including employee stock options and employee stock purchases. Under this guidance, stock-based compensation cost is measured at the grant date based on the calculated fair value of the award, and is recognized as an expense on a straight-line basis over the employee’s requisite service period, generally the vesting period of the award. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">The following table summarizes stock-based compensation related to stock options, restricted stock awards, restricted stock unit, and employee stock purchases (in thousands): </FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px"> </P> <TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="92%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center"> <TR> <TD WIDTH="73%"></TD> <TD VALIGN="bottom" WIDTH="4%"></TD> <TD></TD> <TD></TD> <TD></TD> <TD VALIGN="bottom" WIDTH="4%"></TD> <TD></TD> <TD></TD> <TD></TD> <TD VALIGN="bottom" WIDTH="4%"></TD> <TD></TD> <TD></TD> <TD></TD></TR> <TR> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom" COLSPAN="10" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Years Ended December 31,</B></FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD></TR> <TR> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>2014</B></FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>2013</B></FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>2012</B></FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD></TR> <TR BGCOLOR="#cceeff"> <TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Research and development</FONT></P></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD> <TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1,361</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD> <TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1,538</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD> <TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1,801</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD></TR> <TR> <TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">General and administrative</FONT></P></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1,969</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">2,059</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1,982</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD></TR> <TR STYLE="font-size:1px"> <TD VALIGN="bottom"></TD> <TD VALIGN="bottom"> </TD> <TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000"> </P></TD> <TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000"> </P></TD> <TD> </TD> <TD VALIGN="bottom"> </TD> <TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000"> </P></TD> <TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000"> </P></TD> <TD> </TD> <TD VALIGN="bottom"> </TD> <TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000"> </P></TD> <TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000"> </P></TD> <TD> </TD></TR> <TR BGCOLOR="#cceeff"> <TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Stock-based compensation included in operating expenses</FONT></P></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD> <TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">3,330</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD> <TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">3,597</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD> <TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">3,783</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD></TR> <TR STYLE="font-size:1px"> <TD VALIGN="bottom"></TD> <TD VALIGN="bottom"> </TD> <TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000"> </P></TD> <TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000"> </P></TD> <TD> </TD> <TD VALIGN="bottom"> </TD> <TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000"> </P></TD> <TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000"> </P></TD> <TD> </TD> <TD VALIGN="bottom"> </TD> <TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000"> </P></TD> <TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000"> </P></TD> <TD> </TD></TR> </TABLE> <P STYLE="margin-top:18px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>Employee Stock-Based Compensation </I></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">The Company uses the Black-Scholes option pricing model to determine the fair value of stock option grants to employees and directors and employee stock purchase plan shares. The key input assumptions used to estimate fair value of these awards include the exercise price of the award, the expected option term, the expected volatility of the Company’s stock over the option’s expected term, the risk-free interest rate over the option’s expected term, and the Company’s expected dividend yield, if any. </FONT></P> <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1"> </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">112 </FONT></P> <p Style='page-break-before:always'> <HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER"> <h5 align="left"><a href="#toc">Table of Contents</a></h5> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>CYTOKINETICS, INCORPORATED </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS — (Continued) </B></FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px"> </P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">The fair value of share-based payments was estimated on the date of grant using the Black-Scholes option pricing model based on the following weighted average assumptions: </FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px"> </P> <TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center"> <TR> <TD WIDTH="46%"></TD> <TD VALIGN="bottom" WIDTH="5%"></TD> <TD></TD> <TD></TD> <TD></TD> <TD VALIGN="bottom" WIDTH="5%"></TD> <TD></TD> <TD></TD> <TD></TD> <TD VALIGN="bottom" WIDTH="5%"></TD> <TD></TD> <TD></TD> <TD></TD> <TD VALIGN="bottom" WIDTH="5%"></TD> <TD></TD> <TD></TD> <TD></TD> <TD VALIGN="bottom" WIDTH="5%"></TD> <TD></TD> <TD></TD> <TD></TD> <TD VALIGN="bottom" WIDTH="5%"></TD> <TD></TD> <TD></TD> <TD></TD></TR> <TR> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Year Ended<BR>December 31, 2014</B></FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Year Ended<BR>December 31, 2013</B></FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Year Ended<BR>December 31, 2012</B></FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD></TR> <TR> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Employee<BR>Stock Options</B></FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>ESPP</B></FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Employee<BR>Stock Options</B></FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>ESPP</B></FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Employee<BR>Stock Options</B></FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>ESPP</B></FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD></TR> <TR BGCOLOR="#cceeff"> <TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Risk-free interest rate</FONT></P></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.9</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">% </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">0.2</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">% </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.1</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">% </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">0.2</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">% </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.1</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">% </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">0.2</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">% </FONT></TD></TR> <TR> <TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Volatility</FONT></P></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">77.1</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">% </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">86.0</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">% </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">73.2</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">% </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">74.6</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">% </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">71.1</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">% </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">72.0</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">% </FONT></TD></TR> <TR BGCOLOR="#cceeff"> <TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Expected term in years</FONT></P></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">6.30</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.25</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">6.20</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.25</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">6.13</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.25</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD></TR> <TR> <TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Expected dividend yield</FONT></P></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">0.0</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">% </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">0.0</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">% </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">0.0</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">% </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">0.0</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">% </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">0.0</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">% </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">0.0</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">% </FONT></TD></TR> </TABLE> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">The risk-free interest rate that the Company uses in the option pricing model is based on the U.S. Treasury zero-coupon issues with remaining terms similar to the expected terms of the options. The Company does not anticipate paying dividends in the foreseeable future and therefore uses an expected dividend yield of zero in the option pricing model. The Company is required to estimate forfeitures at the time of grant and revise those estimates in subsequent periods if actual forfeitures differ from those estimates. Historical data is used to estimate pre-vesting option forfeitures and record stock-based compensation expense only on those awards that are expected to vest. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">The Company uses its own historical exercise activity and extrapolates the life cycle of options outstanding to arrive at its estimated expected term for new option grants. The Company uses its own volatility history based on its stock’s trading history for the period subsequent to the Company’s initial public offering in April 2004. The Company measures compensation expense for awards of restricted stock and restricted stock units at fair value on the date of grant and recognizes the expense over the expected vesting period. The fair value for restricted stock and restricted stock unit awards is based on the closing price of the Company’s common stock on the date of grant. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">As of December 31, 2014, there was $5.7 million of unrecognized compensation cost related to unvested stock options, which is expected to be recognized over a weighted-average period of 2.52 years and $0.3 million of unrecognized compensation cost related to unvested restricted stock units, which is expected to be recognized over a weighted-average period of 0.83 years. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>Non-employee Stock-Based Compensation </I></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">The Company records stock option grants to non-employees, excluding directors, at their fair value on the measurement date. The measurement of stock-based compensation is subject to adjustment as the underlying equity instruments vest. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">There were no stock option grants to non-employees in the years ended December 31, 2014, 2013 or 2012. When terminating, if employees continue to provide service to the Company as consultants and their grants are permitted to continue to vest, the expense associated with the continued vesting of the related stock options is classified as non-employee stock compensation expense after the status change. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">In connection with services rendered by non-employees, the Company recorded stock-based compensation expense of $50,000, $104,000, and $56,000 in 2014, 2013 and 2012, respectively. </FONT></P> <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1"> </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">113 </FONT></P> <p Style='page-break-before:always'> <HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER"> <h5 align="left"><a href="#toc">Table of Contents</a></h5> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>CYTOKINETICS, INCORPORATED </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS — (Continued) </B></FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px"> </P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>ESPP </I></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">In January 2004, the Board of Directors adopted the ESPP, which was approved by the stockholders in February 2004. Under the ESPP, statutory employees may purchase common stock of the Company up to a specified maximum amount through payroll deductions. The stock is purchased semi-annually at a price equal to 85% of the fair market value at certain plan-defined dates. The Company issued 19,726, 14,985 and 15,010 shares of common stock during 2014, 2013 and 2012, respectively, pursuant to the ESPP at an average price of $3.38, $3.66 and $4.32 per share, in 2014, 2013 and 2012, respectively. At December 31, 2014 the Company had 170,170 shares of common stock reserved for issuance under the ESPP. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Note 13 — Income Taxes </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">The Company accounts for income taxes under the asset and liability method. Under this method, deferred tax assets and liabilities are determined based on the difference between the financial statement and tax basis of assets and liabilities using enacted tax rates in effect for the year in which the differences are expected to affect taxable income. Valuation allowances are established when necessary to reduce the deferred tax assets to the amounts expected to be realized. The Company did not record an income tax provision in the years ended December 31, 2014, 2013, or 2012 because the Company had a net taxable loss in the period. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">For financial statement purposes, loss before taxes includes the following components (in thousands): </FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px"> </P> <TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="92%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center"> <TR> <TD WIDTH="66%"></TD> <TD VALIGN="bottom" WIDTH="5%"></TD> <TD></TD> <TD></TD> <TD></TD> <TD VALIGN="bottom" WIDTH="4%"></TD> <TD></TD> <TD></TD> <TD></TD> <TD VALIGN="bottom" WIDTH="4%"></TD> <TD></TD> <TD></TD> <TD></TD></TR> <TR> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom" COLSPAN="10" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Years Ended<BR>December 31,</B></FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD></TR> <TR> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>2014</B></FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>2013</B></FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>2012</B></FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD></TR> <TR BGCOLOR="#cceeff"> <TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">United States</FONT></P></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD> <TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(14,646</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">) </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD> <TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(33,717</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">) </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD> <TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(40,370</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">) </FONT></TD></TR> <TR> <TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Foreign</FONT></P></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">—</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">—</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">—</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD></TR> <TR STYLE="font-size:1px"> <TD VALIGN="bottom"></TD> <TD VALIGN="bottom"> </TD> <TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000"> </P></TD> <TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000"> </P></TD> <TD> </TD> <TD VALIGN="bottom"> </TD> <TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000"> </P></TD> <TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000"> </P></TD> <TD> </TD> <TD VALIGN="bottom"> </TD> <TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000"> </P></TD> <TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000"> </P></TD> <TD> </TD></TR> <TR BGCOLOR="#cceeff"> <TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Total</FONT></P></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD> <TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(14,646</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">) </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD> <TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(33,717</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">) </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD> <TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(40,370</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">) </FONT></TD></TR> <TR STYLE="font-size:1px"> <TD VALIGN="bottom"></TD> <TD VALIGN="bottom"> </TD> <TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000"> </P></TD> <TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000"> </P></TD> <TD> </TD> <TD VALIGN="bottom"> </TD> <TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000"> </P></TD> <TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000"> </P></TD> <TD> </TD> <TD VALIGN="bottom"> </TD> <TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000"> </P></TD> <TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000"> </P></TD> <TD> </TD></TR> </TABLE> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">The Company recorded the following income tax provision as follows (in thousands): </FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px"> </P> <TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="92%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center"> <TR> <TD WIDTH="67%"></TD> <TD VALIGN="bottom" WIDTH="9%"></TD> <TD></TD> <TD></TD> <TD></TD> <TD VALIGN="bottom" WIDTH="9%"></TD> <TD></TD> <TD></TD> <TD></TD> <TD VALIGN="bottom" WIDTH="9%"></TD> <TD></TD> <TD></TD> <TD></TD></TR> <TR> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom" COLSPAN="10" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Years Ended<BR>December 31,</B></FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD></TR> <TR> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>2014</B></FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>2013</B></FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>2012</B></FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD></TR> <TR BGCOLOR="#cceeff"> <TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Current:</FONT></P></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"></TD> <TD VALIGN="bottom"></TD> <TD VALIGN="bottom"></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"></TD> <TD VALIGN="bottom"></TD> <TD VALIGN="bottom"></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"></TD> <TD VALIGN="bottom"></TD> <TD VALIGN="bottom"></TD></TR> <TR> <TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Federal</FONT></P></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD> <TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">—</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD> <TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">—</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD> <TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">—</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD></TR> <TR BGCOLOR="#cceeff"> <TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">State</FONT></P></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">—</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">—</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">—</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD></TR> <TR STYLE="font-size:1px"> <TD VALIGN="bottom"></TD> <TD VALIGN="bottom"> </TD> <TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000"> </P></TD> <TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000"> </P></TD> <TD> </TD> <TD VALIGN="bottom"> </TD> <TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000"> </P></TD> <TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000"> </P></TD> <TD> </TD> <TD VALIGN="bottom"> </TD> <TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000"> </P></TD> <TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000"> </P></TD> <TD> </TD></TR> <TR> <TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Total</FONT></P></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD> <TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">—</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD> <TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">—</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD> <TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">—</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD></TR> <TR STYLE="font-size:1px"> <TD VALIGN="bottom"></TD> <TD VALIGN="bottom"> </TD> <TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000"> </P></TD> <TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000"> </P></TD> <TD> </TD> <TD VALIGN="bottom"> </TD> <TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000"> </P></TD> <TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000"> </P></TD> <TD> </TD> <TD VALIGN="bottom"> </TD> <TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000"> </P></TD> <TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000"> </P></TD> <TD> </TD></TR> <TR BGCOLOR="#cceeff"> <TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Deferred:</FONT></P></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"></TD> <TD VALIGN="bottom"></TD> <TD VALIGN="bottom"></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"></TD> <TD VALIGN="bottom"></TD> <TD VALIGN="bottom"></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"></TD> <TD VALIGN="bottom"></TD> <TD VALIGN="bottom"></TD></TR> <TR> <TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Federal</FONT></P></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD> <TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">—</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD> <TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">—</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD> <TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">—</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD></TR> <TR BGCOLOR="#cceeff"> <TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">State</FONT></P></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">—</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">—</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">—</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD></TR> <TR STYLE="font-size:1px"> <TD VALIGN="bottom"></TD> <TD VALIGN="bottom"> </TD> <TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000"> </P></TD> <TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000"> </P></TD> <TD> </TD> <TD VALIGN="bottom"> </TD> <TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000"> </P></TD> <TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000"> </P></TD> <TD> </TD> <TD VALIGN="bottom"> </TD> <TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000"> </P></TD> <TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000"> </P></TD> <TD> </TD></TR> <TR> <TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Total</FONT></P></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD> <TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">—</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD> <TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">—</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD> <TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">—</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD></TR> <TR STYLE="font-size:1px"> <TD VALIGN="bottom"></TD> <TD VALIGN="bottom"> </TD> <TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000"> </P></TD> <TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000"> </P></TD> <TD> </TD> <TD VALIGN="bottom"> </TD> <TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000"> </P></TD> <TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000"> </P></TD> <TD> </TD> <TD VALIGN="bottom"> </TD> <TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000"> </P></TD> <TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000"> </P></TD> <TD> </TD></TR> </TABLE> <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1"> </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">114 </FONT></P> <p Style='page-break-before:always'> <HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER"> <h5 align="left"><a href="#toc">Table of Contents</a></h5> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>CYTOKINETICS, INCORPORATED </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS — (Continued) </B></FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px"> </P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">Deferred income taxes reflect the net tax effect of temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes. The significant components of the Company’s deferred tax assets and liabilities were as follows (in thousands): </FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px"> </P> <TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="92%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center"> <TR> <TD WIDTH="64%"></TD> <TD VALIGN="bottom" WIDTH="9%"></TD> <TD></TD> <TD></TD> <TD></TD> <TD VALIGN="bottom" WIDTH="8%"></TD> <TD></TD> <TD></TD> <TD></TD> <TD VALIGN="bottom" WIDTH="8%"></TD> <TD></TD> <TD></TD> <TD></TD></TR> <TR> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom" COLSPAN="10" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>As of December 31,</B></FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD></TR> <TR> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>2014</B></FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>2013</B></FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>2012</B></FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD></TR> <TR BGCOLOR="#cceeff"> <TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Deferred tax assets:</FONT></P></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"></TD> <TD VALIGN="bottom"></TD> <TD VALIGN="bottom"></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"></TD> <TD VALIGN="bottom"></TD> <TD VALIGN="bottom"></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"></TD> <TD VALIGN="bottom"></TD> <TD VALIGN="bottom"></TD></TR> <TR> <TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Depreciation and amortization</FONT></P></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD> <TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">780</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD> <TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">918</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD> <TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1,024</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD></TR> <TR BGCOLOR="#cceeff"> <TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Capitalized R&D</FONT></P></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">15,176</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">20,702</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">4,932</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD></TR> <TR> <TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Reserves and accruals</FONT></P></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">6,217</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">4,946</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">5,101</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD></TR> <TR BGCOLOR="#cceeff"> <TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Net operating losses</FONT></P></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">148,184</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">144,254</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">153,193</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD></TR> <TR> <TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Tax credits</FONT></P></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">34,543</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">33,043</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">25,943</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD></TR> <TR STYLE="font-size:1px"> <TD VALIGN="bottom"></TD> <TD VALIGN="bottom"> </TD> <TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000"> </P></TD> <TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000"> </P></TD> <TD> </TD> <TD VALIGN="bottom"> </TD> <TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000"> </P></TD> <TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000"> </P></TD> <TD> </TD> <TD VALIGN="bottom"> </TD> <TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000"> </P></TD> <TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000"> </P></TD> <TD> </TD></TR> <TR BGCOLOR="#cceeff"> <TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Total deferred tax assets</FONT></P></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">204,900</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">203,863</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">190,193</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD></TR> <TR> <TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Less: Valuation allowance</FONT></P></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(204,900</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">) </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(203,863</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">) </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(190,193</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">) </FONT></TD></TR> <TR STYLE="font-size:1px"> <TD VALIGN="bottom"></TD> <TD VALIGN="bottom"> </TD> <TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000"> </P></TD> <TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000"> </P></TD> <TD> </TD> <TD VALIGN="bottom"> </TD> <TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000"> </P></TD> <TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000"> </P></TD> <TD> </TD> <TD VALIGN="bottom"> </TD> <TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000"> </P></TD> <TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000"> </P></TD> <TD> </TD></TR> <TR BGCOLOR="#cceeff"> <TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Net deferred tax assets</FONT></P></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD> <TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">—</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD> <TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">—</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD> <TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">—</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD></TR> <TR STYLE="font-size:1px"> <TD VALIGN="bottom"></TD> <TD VALIGN="bottom"> </TD> <TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000"> </P></TD> <TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000"> </P></TD> <TD> </TD> <TD VALIGN="bottom"> </TD> <TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000"> </P></TD> <TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000"> </P></TD> <TD> </TD> <TD VALIGN="bottom"> </TD> <TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000"> </P></TD> <TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000"> </P></TD> <TD> </TD></TR> </TABLE> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">Realization of deferred tax assets is dependent upon future earnings, if any, the timing and amount of which are uncertain. Based upon the weight of available evidence, which includes the Company’s historical operating performance, reported cumulative net losses since inception and difficulty in accurately forecasting the Company’s future results, the Company maintained a full valuation allowance on the net deferred tax assets as of December 31, 2014, 2013 and 2013. The valuation allowance was determined pursuant to the accounting guidance for income taxes, which requires an assessment of both positive and negative evidence when determining whether it is more likely than not that deferred tax assets are recoverable. The Company intends to maintain a full valuation allowance on the U.S. deferred tax assets until sufficient positive evidence exists to support reversal of the valuation allowance. The valuation allowance increased by $1.0 million in 2014, $13.7 million in 2013 and $21.1 million in 2012. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">As a result of certain realization requirements of accounting guidance for stock compensation, the table of deferred tax assets and liabilities shown above does not include certain deferred tax assets at December 31, 2014, 2013 and 2012 that arose directly from tax deductions related to equity compensation in excess of compensation recognized for financial reporting. Approximately $1.9 million of Federal and California net operating losses are related to tax stock option deductions in excess of book deductions. This amount will be credited to stockholders’ equity when it is realized. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">The following are the Company’s valuation and qualifying accounts (in thousands): </FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px"> </P> <TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center"> <TR> <TD WIDTH="47%"></TD> <TD VALIGN="bottom" WIDTH="6%"></TD> <TD></TD> <TD></TD> <TD></TD> <TD VALIGN="bottom" WIDTH="6%"></TD> <TD></TD> <TD></TD> <TD></TD> <TD VALIGN="bottom" WIDTH="6%"></TD> <TD></TD> <TD></TD> <TD></TD> <TD VALIGN="bottom" WIDTH="6%"></TD> <TD></TD> <TD></TD> <TD></TD> <TD VALIGN="bottom" WIDTH="6%"></TD> <TD></TD> <TD></TD> <TD></TD></TR> <TR> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Balance at<BR>Beginning of<BR>Period</B></FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Charged to<BR>Expenses</B></FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Charged to<BR>Other Accounts</B></FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Deductions</B></FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Balance at<BR>End of Period</B></FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD></TR> <TR BGCOLOR="#cceeff"> <TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Year Ended December 31, 2012:</FONT></P></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"></TD> <TD VALIGN="bottom"></TD> <TD VALIGN="bottom"></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"></TD> <TD VALIGN="bottom"></TD> <TD VALIGN="bottom"></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"></TD> <TD VALIGN="bottom"></TD> <TD VALIGN="bottom"></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"></TD> <TD VALIGN="bottom"></TD> <TD VALIGN="bottom"></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"></TD> <TD VALIGN="bottom"></TD> <TD VALIGN="bottom"></TD></TR> <TR> <TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Deferred tax valuation allowance</FONT></P></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD> <TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">169,107</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD> <TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">21,086</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">—</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">—</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD> <TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">190,193</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD></TR> <TR BGCOLOR="#cceeff"> <TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Year Ended December 31, 2013:</FONT></P></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"></TD> <TD VALIGN="bottom"></TD> <TD VALIGN="bottom"></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"></TD> <TD VALIGN="bottom"></TD> <TD VALIGN="bottom"></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"></TD> <TD VALIGN="bottom"></TD> <TD VALIGN="bottom"></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"></TD> <TD VALIGN="bottom"></TD> <TD VALIGN="bottom"></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"></TD> <TD VALIGN="bottom"></TD> <TD VALIGN="bottom"></TD></TR> <TR> <TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Deferred tax valuation allowance</FONT></P></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD> <TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">190,193</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD> <TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">13,670</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">—</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">—</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD> <TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">203,863</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD></TR> <TR BGCOLOR="#cceeff"> <TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Year Ended December 31, 2014:</FONT></P></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"></TD> <TD VALIGN="bottom"></TD> <TD VALIGN="bottom"></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"></TD> <TD VALIGN="bottom"></TD> <TD VALIGN="bottom"></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"></TD> <TD VALIGN="bottom"></TD> <TD VALIGN="bottom"></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"></TD> <TD VALIGN="bottom"></TD> <TD VALIGN="bottom"></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"></TD> <TD VALIGN="bottom"></TD> <TD VALIGN="bottom"></TD></TR> <TR> <TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Deferred tax valuation allowance</FONT></P></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD> <TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">203,863</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD> <TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1,037</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">—</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">—</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD> <TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">204,900</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD></TR> </TABLE> <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1"> </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">115 </FONT></P> <p Style='page-break-before:always'> <HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER"> <h5 align="left"><a href="#toc">Table of Contents</a></h5> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>CYTOKINETICS, INCORPORATED </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS — (Continued) </B></FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px"> </P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">The following is a reconciliation of the statutory federal income tax rate to the Company’s effective tax rate: </FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px"> </P> <TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="92%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center"> <TR> <TD WIDTH="81%"></TD> <TD VALIGN="bottom" WIDTH="6%"></TD> <TD></TD> <TD></TD> <TD></TD> <TD VALIGN="bottom" WIDTH="5%"></TD> <TD></TD> <TD></TD> <TD></TD> <TD VALIGN="bottom" WIDTH="5%"></TD> <TD></TD> <TD></TD> <TD></TD></TR> <TR> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom" COLSPAN="10" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Years Ended<BR>December 31,</B></FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD></TR> <TR> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>2014</B></FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>2013</B></FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>2012</B></FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD></TR> <TR BGCOLOR="#cceeff"> <TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Tax at federal statutory tax rate</FONT></P></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(34</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)% </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(34</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)% </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(34</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)% </FONT></TD></TR> <TR> <TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">State income tax, net of federal tax benefit</FONT></P></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(1</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)% </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(4</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)% </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(6</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)% </FONT></TD></TR> <TR BGCOLOR="#cceeff"> <TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">State Apportionment</FONT></P></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">28</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">% </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">7</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">% </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">0</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">% </FONT></TD></TR> <TR> <TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Tax credits (net)</FONT></P></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(7</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)% </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(14</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)% </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(19</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)% </FONT></TD></TR> <TR BGCOLOR="#cceeff"> <TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Deferred tax assets (utilized) not benefited</FONT></P></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">7</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">% </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">41</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">% </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">56</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">% </FONT></TD></TR> <TR> <TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Stock-based compensation</FONT></P></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">5</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">% </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">2</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">% </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">0</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">% </FONT></TD></TR> <TR BGCOLOR="#cceeff"> <TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">NOL Expiration</FONT></P></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">2</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">% </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">% </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">2</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">% </FONT></TD></TR> <TR> <TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Other</FONT></P></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">0</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">% </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">% </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">% </FONT></TD></TR> <TR STYLE="font-size:1px"> <TD VALIGN="bottom"></TD> <TD VALIGN="bottom"> </TD> <TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000"> </P></TD> <TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000"> </P></TD> <TD> </TD> <TD VALIGN="bottom"> </TD> <TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000"> </P></TD> <TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000"> </P></TD> <TD> </TD> <TD VALIGN="bottom"> </TD> <TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000"> </P></TD> <TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000"> </P></TD> <TD> </TD></TR> <TR BGCOLOR="#cceeff"> <TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Total</FONT></P></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">0</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">% </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">0</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">% </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">0</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">% </FONT></TD></TR> <TR STYLE="font-size:1px"> <TD VALIGN="bottom"></TD> <TD VALIGN="bottom"> </TD> <TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000"> </P></TD> <TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000"> </P></TD> <TD> </TD> <TD VALIGN="bottom"> </TD> <TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000"> </P></TD> <TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000"> </P></TD> <TD> </TD> <TD VALIGN="bottom"> </TD> <TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000"> </P></TD> <TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000"> </P></TD> <TD> </TD></TR> </TABLE> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">The Company had federal net operating loss carryforwards of approximately $386.8 million and apportioned state net operating loss carryforwards of approximately $285.7 million before federal benefit at December 31, 2014. If not utilized, the federal and state operating loss carryforwards will begin to expire in various amounts beginning 2020 and 2015, respectively. The net operating loss carryforwards include deductions for stock options. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">The Company had general business credit of approximately $30.8 million and $13.3 million for federal and state income tax purposes, respectively, at December 31, 2014. Amounts are comprised of Research and Development Credits and Orphan Drug Credits. If not utilized, the federal carryforwards will expire in various amounts beginning in 2021. The California state credit can be carried forward indefinitely. Since its filing of its 2011 tax return, the Company has claimed the orphan drug credit. For qualifying expenses, the orphan drug credit offers an increased benefit relative to the research and development credit taken in years prior. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">As required by California state law, the Company apportions income to California based on a “market-based” sourcing approach. Accordingly, the Company’s California apportionment formula is sensitive to changes in the source of the Company’s mix of revenue. As a result of agreements in place in 2013, the Company adjusted deferred tax assets to reflect these changes. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">In general, under Section 382 of the Internal Revenue Code (“Section 382”), a corporation that undergoes an ‘ownership change’ is subject to limitations on its ability to utilize its pre-change net operating losses and tax credits to offset future taxable income. The Company has performed a section 382 analysis for the year ended December 31, 2014 and has not experienced an ownership change since 2006. A portion of the Company’s existing net operating losses and tax credits are subject to limitations arising from previous ownership changes. Future changes in the Company’s stock ownership, some of which are outside of our control, could result in an ownership change under Section 382 and result in additional limitations. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">Section 59(e) of the Internal Revenue Code allows a Company to capitalize R&D expenses. The Company elected to capitalize R&D expenses on its 2012 and 2013 tax returns after completing a reverse stock split in the second quarter of 2013. For 2014, the Company anticipates foregoing the election in its 2014 tax return as they do not anticipate an ownership change under Section 382. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">The Company follows the accounting guidance that prescribes a comprehensive model for how companies should recognize, measure, present, and disclose in their financial statements uncertain tax positions taken or </FONT></P> <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1"> </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">116 </FONT></P> <p Style='page-break-before:always'> <HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER"> <h5 align="left"><a href="#toc">Table of Contents</a></h5> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>CYTOKINETICS, INCORPORATED </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS — (Continued) </B></FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px"> </P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2"> expected to be taken on a tax return. Tax positions are initially recognized in the financial statements when it is more likely than not that the position will be sustained upon examination by the tax authorities. Such tax positions are initially and subsequently measured as the largest amount of tax benefit that is greater than 50% likely of being realized upon ultimate settlement with the tax authority assuming full knowledge of the position and relevant facts. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">The significant jurisdictions in which the Company files income tax returns are the United States and California. For jurisdictions in which tax filings are made, the Company is subject to income tax examination for all fiscal years since inception. The IRS’s Large Business and International Division concluded its audit of the 2009 tax year with no material adjustments. However, in general, the statute of limitations for tax liabilities for all years remains open for the purpose of adjusting the amounts of the losses and credits carried forward from those years. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">The following is a tabular reconciliation of the total amounts of unrecognized tax benefits (“UTBs”) (in thousands): </FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px"> </P> <TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center"> <TR> <TD WIDTH="55%"></TD> <TD VALIGN="bottom" WIDTH="10%"></TD> <TD></TD> <TD></TD> <TD></TD> <TD VALIGN="bottom" WIDTH="10%"></TD> <TD></TD> <TD></TD> <TD></TD> <TD VALIGN="bottom" WIDTH="10%"></TD> <TD></TD> <TD></TD> <TD></TD></TR> <TR> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Federal<BR>and State<BR>Tax</B></FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Federal Tax Benefit<BR>of State Income Tax<BR>UTBs</B></FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Unrecognized Income Tax<BR>Benefits - Net of Federal<BR>Benefit of State UTBs</B></FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD></TR> <TR BGCOLOR="#cceeff"> <TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Unrecognized tax benefits balance at December 31, 2012</FONT></P></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD> <TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">5,340</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD> <TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1,158</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD> <TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">4,182</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD></TR> <TR> <TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Addition for tax positions of prior years</FONT></P></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">24</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">8</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">16</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD></TR> <TR BGCOLOR="#cceeff"> <TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Addition for tax positions related to the current year</FONT></P></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">807</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">43</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">764</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD></TR> <TR STYLE="font-size:1px"> <TD VALIGN="bottom"></TD> <TD VALIGN="bottom"> </TD> <TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000"> </P></TD> <TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000"> </P></TD> <TD> </TD> <TD VALIGN="bottom"> </TD> <TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000"> </P></TD> <TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000"> </P></TD> <TD> </TD> <TD VALIGN="bottom"> </TD> <TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000"> </P></TD> <TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000"> </P></TD> <TD> </TD></TR> <TR> <TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Unrecognized tax benefits balance at December 31, 2013</FONT></P></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">6,171</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1,209</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">4,962</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD></TR> <TR BGCOLOR="#cceeff"> <TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Reductions for tax positions of prior years</FONT></P></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(85</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">) </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(29</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">) </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(56</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">) </FONT></TD></TR> <TR> <TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Addition for tax positions related to the current year</FONT></P></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">188</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">10</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">178</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD></TR> <TR STYLE="font-size:1px"> <TD VALIGN="bottom"></TD> <TD VALIGN="bottom"> </TD> <TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000"> </P></TD> <TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000"> </P></TD> <TD> </TD> <TD VALIGN="bottom"> </TD> <TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000"> </P></TD> <TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000"> </P></TD> <TD> </TD> <TD VALIGN="bottom"> </TD> <TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000"> </P></TD> <TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000"> </P></TD> <TD> </TD></TR> <TR BGCOLOR="#cceeff"> <TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Unrecognized tax benefits balance at December 31, 2014</FONT></P></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD> <TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">6,274</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD> <TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1,190</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD> <TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">5,084</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD></TR> <TR STYLE="font-size:1px"> <TD VALIGN="bottom"></TD> <TD VALIGN="bottom"> </TD> <TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000"> </P></TD> <TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000"> </P></TD> <TD> </TD> <TD VALIGN="bottom"> </TD> <TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000"> </P></TD> <TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000"> </P></TD> <TD> </TD> <TD VALIGN="bottom"> </TD> <TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000"> </P></TD> <TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000"> </P></TD> <TD> </TD></TR> </TABLE> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">Included in the balance of unrecognized tax benefits as of December 31, 2014, 2013 and 2012 are $5.1 million, $5.0 million and $4.2 million of tax benefits, respectively, that, if recognized, would result in adjustments to other tax accounts, primarily deferred taxes. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">The Company recognizes interest accrued related to unrecognized tax benefits and penalties as income tax expense. Related to the unrecognized tax benefits noted above, the Company did not accrue any penalties or interest during 2014, 2013 or 2012. The Company does not expect its unrecognized tax benefit to change materially over the next twelve months. </FONT></P> <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1"> </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">117 </FONT></P> <p Style='page-break-before:always'> <HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER"> <h5 align="left"><a href="#toc">Table of Contents</a></h5> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>CYTOKINETICS, INCORPORATED </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS — (Continued) </B></FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px"> </P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Note 14 — Interest and Other, Net </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">Components of Interest and Other, Net were as follows (in thousands): </FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px"> </P> <TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="92%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center"> <TR> <TD WIDTH="80%"></TD> <TD VALIGN="bottom" WIDTH="4%"></TD> <TD></TD> <TD></TD> <TD></TD> <TD VALIGN="bottom" WIDTH="4%"></TD> <TD></TD> <TD></TD> <TD></TD> <TD VALIGN="bottom" WIDTH="4%"></TD> <TD></TD> <TD></TD> <TD></TD></TR> <TR> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom" COLSPAN="10" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Years Ended<BR>December 31,</B></FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD></TR> <TR> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>2014</B></FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>2013</B></FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>2012</B></FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD></TR> <TR BGCOLOR="#cceeff"> <TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Interest income and other income</FONT></P></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD> <TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">108</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD> <TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">98</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD> <TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">89</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD></TR> <TR> <TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Interest expense and other expense</FONT></P></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">—</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">79</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(2</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">) </FONT></TD></TR> <TR STYLE="font-size:1px"> <TD VALIGN="bottom"></TD> <TD VALIGN="bottom"> </TD> <TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000"> </P></TD> <TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000"> </P></TD> <TD> </TD> <TD VALIGN="bottom"> </TD> <TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000"> </P></TD> <TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000"> </P></TD> <TD> </TD> <TD VALIGN="bottom"> </TD> <TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000"> </P></TD> <TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000"> </P></TD> <TD> </TD></TR> <TR BGCOLOR="#cceeff"> <TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Interest and Other, net</FONT></P></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD> <TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">108</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD> <TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">177</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD> <TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">87</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD></TR> <TR STYLE="font-size:1px"> <TD VALIGN="bottom"></TD> <TD VALIGN="bottom"> </TD> <TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000"> </P></TD> <TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000"> </P></TD> <TD> </TD> <TD VALIGN="bottom"> </TD> <TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000"> </P></TD> <TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000"> </P></TD> <TD> </TD> <TD VALIGN="bottom"> </TD> <TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000"> </P></TD> <TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000"> </P></TD> <TD> </TD></TR> </TABLE> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">Interest income and other income in all periods primarily consisted of interest income generated from the Company’s cash, cash equivalents and investments. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">Interest expense and other expense in 2013 consisted solely of net gains realized upon disposal of equipment. Interest expense and other expense in 2012 primarily consisted of interest expense on borrowings under equipment financing lines. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Note 15 — Quarterly Financial Data (Unaudited) </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">Quarterly results were as follows (in thousands, except per share data): </FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px"> </P> <TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center"> <TR> <TD WIDTH="64%"></TD> <TD VALIGN="bottom" WIDTH="4%"></TD> <TD></TD> <TD></TD> <TD></TD> <TD VALIGN="bottom" WIDTH="4%"></TD> <TD></TD> <TD></TD> <TD></TD> <TD VALIGN="bottom" WIDTH="4%"></TD> <TD></TD> <TD></TD> <TD></TD> <TD VALIGN="bottom" WIDTH="4%"></TD> <TD></TD> <TD></TD> <TD></TD></TR> <TR> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>First<BR>Quarter</B></FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Second<BR>Quarter</B></FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Third<BR>Quarter</B></FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Fourth<BR>Quarter</B></FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD></TR> <TR BGCOLOR="#cceeff"> <TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>2014</B></FONT></P></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"></TD> <TD VALIGN="bottom"></TD> <TD VALIGN="bottom"></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"></TD> <TD VALIGN="bottom"></TD> <TD VALIGN="bottom"></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"></TD> <TD VALIGN="bottom"></TD> <TD VALIGN="bottom"></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"></TD> <TD VALIGN="bottom"></TD> <TD VALIGN="bottom"></TD></TR> <TR> <TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Total revenues</FONT></P></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD> <TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">7,979</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD> <TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">7,788</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD> <TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">9,415</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD> <TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">21,758</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD></TR> <TR BGCOLOR="#cceeff"> <TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Net income (loss)</FONT></P></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(8,744</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">) </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(8,374</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">) </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(5,971</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">) </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">8,443</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD></TR> <TR> <TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Net income (loss) allocable to common stockholders</FONT></P></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(8,744</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">) </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(8,374</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">) </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(5,971</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">) </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">8,443</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD></TR> <TR BGCOLOR="#cceeff"> <TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Net income (loss) per share allocable to common stockholders — basic and diluted</FONT></P></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD> <TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(0.27</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">) </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD> <TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(0.23</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">) </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD> <TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(0.16</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">) </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD> <TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">0.23</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD></TR> <TR> <TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>2013</B></FONT></P></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"></TD> <TD VALIGN="bottom"></TD> <TD VALIGN="bottom"></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"></TD> <TD VALIGN="bottom"></TD> <TD VALIGN="bottom"></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"></TD> <TD VALIGN="bottom"></TD> <TD VALIGN="bottom"></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"></TD> <TD VALIGN="bottom"></TD> <TD VALIGN="bottom"></TD></TR> <TR BGCOLOR="#cceeff"> <TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Total revenues</FONT></P></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD> <TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">821</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD> <TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1,009</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD> <TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">4,469</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD> <TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">24,349</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD></TR> <TR> <TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Net income (loss)</FONT></P></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(12,619</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">) </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(15,041</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">) </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(12,588</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">) </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">6,531</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD></TR> <TR BGCOLOR="#cceeff"> <TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Net income (loss) allocable to common stockholders</FONT></P></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(12,619</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">) </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(15,041</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">) </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(12,588</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">) </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">6,531</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD></TR> <TR> <TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Net income (loss) per share allocable to common stockholders — basic</FONT></P></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD> <TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(0.53</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">) </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD> <TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(0.58</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">) </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD> <TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(0.43</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">) </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD> <TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">0.22</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD></TR> <TR BGCOLOR="#cceeff"> <TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Net income (loss) per share allocable to common stockholders — diluted</FONT></P></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD> <TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(0.53</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">) </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD> <TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(0.58</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">) </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD> <TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(0.43</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">) </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD> <TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">0.21</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD></TR> </TABLE> <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1"> </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">118 </FONT></P> <p Style='page-break-before:always'> <HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER"> <h5 align="left"><a href="#toc">Table of Contents</a></h5> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><A NAME="toc828167_14"></A>Item 9. </B><B><I>Changes in and Disagreements With Accountants on Accounting and Financial Disclosure</I></B><B> </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">None. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><A NAME="toc828167_15"></A>Item 9A. </B><B><I>Controls and Procedures</I></B><B> </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>Evaluation of Disclosure Controls and Procedures.</I> Our management evaluated, with the participation of our Chief Executive Officer and our Chief Financial Officer, the effectiveness of our disclosure controls and procedures (as defined in Rule 13a-15(e) under the Exchange Act) as of the end of the period covered by this Annual Report on Form 10-K. Based on this evaluation, our Chief Executive Officer and our Chief Financial Officer have concluded that the Company’s disclosure controls and procedures are effective. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>Management’s Report on Internal Control over Financial Reporting.</I> Our management is responsible for establishing and maintaining adequate internal control over financial reporting (as defined in Rule 13a-15(f) under the Exchange Act). Our management assessed the effectiveness of our internal control over financial reporting as of December 31, 2014. In making this assessment, our management used the criteria set forth by the Committee of Sponsoring Organizations of the Treadway Commission in Internal Control-Integrated Framework 2013. Our management has concluded that, as of December 31, 2014, our internal control over financial reporting is effective based on these criteria. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">Our independent registered public accounting firm, PricewaterhouseCoopers LLP, has audited the effectiveness of our internal control over financial reporting as of December 31, 2014, as stated in their report, which is included herein. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>Changes in Internal Control over Financial Reporting.</I> There was no change in our internal control over financial reporting that occurred during the quarter ended December 31, 2014 that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>Inherent Limitations on Effectiveness of Controls.</I> Our management, including our Chief Executive Officer and Chief Financial Officer, does not expect that our disclosure controls and procedures or our internal controls, will prevent all error and all fraud. A control system, no matter how well conceived and operated, can provide only reasonable, not absolute, assurance that the objectives of the control system are met. Further, the design of a control system must reflect the fact that there are resource constraints, and the benefits of controls must be considered relative to their costs. Because of the inherent limitations in all control systems, no evaluation of controls can provide absolute assurance that all control issues and instances of fraud, if any, within Cytokinetics have been detected. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><A NAME="toc828167_16"></A>Item 9B. </B><B><I>Other Information</I></B><B> </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">None. </FONT></P> <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1"> </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">119 </FONT></P> <p Style='page-break-before:always'> <HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER"> <h5 align="left"><a href="#toc">Table of Contents</a></h5> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><A NAME="toc828167_17"></A>PART III </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I></I></B><B><A NAME="toc828167_18"></A>Item 10.</B><B><I> Directors, Executive Officers and Corporate Governance </I></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">The information regarding our directors and executive officers, our director nominating process and our audit committee is incorporated by reference from our definitive Proxy Statement for our 2015 Annual Meeting of Stockholders, where it appears under the headings “Board of Directors” and “Executive Officers.” </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Section 16(a) Beneficial Ownership Reporting Compliance </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">The information regarding our Section 16 beneficial ownership reporting compliance is incorporated by reference from our definitive Proxy Statement described above, where it appears under the headings “Section 16(a) Beneficial Ownership Reporting Compliance.” </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Code of Ethics </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">We have adopted a Code of Ethics that applies to all directors, officers and employees of the Company. We publicize the Code of Ethics through posting the policy on our website, www.cytokinetics.com. We will disclose on our website any waivers of, or amendments to, our Code of Ethics within four business days following the date of such amendment or waiver. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><A NAME="toc828167_19"></A>Item 11. </B><B><I>Executive Compensation</I></B><B> </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">The information required by this Item is incorporated by reference from our definitive Proxy Statement referred to in Item 10 above, where it appears under the headings “Executive Compensation” and “Compensation Committee Interlocks and Insider Participation.” </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><A NAME="toc828167_20"></A>Item 12. </B><B><I>Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters</I></B><B> </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">The information required by this Item regarding security ownership of certain beneficial owners and management is incorporated by reference from our definitive Proxy Statement referred to in Item 10 above, where it appears under the heading “Security Ownership of Certain Beneficial Owners and Management.” </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">The following table summarizes the securities authorized for issuance under our equity compensation plans as of December 31, 2014: </FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px"> </P> <TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center"> <TR> <TD WIDTH="48%"></TD> <TD VALIGN="bottom" WIDTH="11%"></TD> <TD></TD> <TD></TD> <TD></TD> <TD VALIGN="bottom" WIDTH="11%"></TD> <TD></TD> <TD></TD> <TD></TD> <TD VALIGN="bottom" WIDTH="11%"></TD> <TD></TD> <TD></TD> <TD></TD></TR> <TR> <TD VALIGN="bottom" NOWRAP> <P STYLE="border-bottom:1px solid #000000;width:49pt"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Plan Category</B></FONT></P></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Number of Securities<BR>to be Issued<BR>Upon Exercise of<BR>Outstanding Options,<BR>Warrants and Rights</B></FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Weighted Average<BR>Exercise Price of<BR>Outstanding Options,<BR>Warrants and Rights</B></FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Number of Securities<BR>Remaining Available<BR>for Future Issuance<BR>Under Equity<BR>Compensation Plans</B></FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD></TR> <TR BGCOLOR="#cceeff"> <TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Equity compensation plans approved by stockholders</FONT></P></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">2,139,534</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD> <TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">15.17</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1,440,648</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">(1) </FONT></TD></TR> <TR> <TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Equity compensation plans not approved by stockholders</FONT></P></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">—</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">—</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">—</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD></TR> <TR STYLE="font-size:1px"> <TD VALIGN="bottom"></TD> <TD VALIGN="bottom"> </TD> <TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000"> </P></TD> <TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000"> </P></TD> <TD> </TD> <TD VALIGN="bottom"> </TD> <TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000"> </P></TD> <TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000"> </P></TD> <TD> </TD> <TD VALIGN="bottom"> </TD> <TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000"> </P></TD> <TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000"> </P></TD> <TD> </TD></TR> <TR BGCOLOR="#cceeff"> <TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Total</FONT></P></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">2,139,534</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD> <TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">15.17</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1,440,648</FONT></TD> <TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD></TR> <TR STYLE="font-size:1px"> <TD VALIGN="bottom"></TD> <TD VALIGN="bottom"> </TD> <TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000"> </P></TD> <TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000"> </P></TD> <TD> </TD> <TD VALIGN="bottom"> </TD> <TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000"> </P></TD> <TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000"> </P></TD> <TD> </TD> <TD VALIGN="bottom"> </TD> <TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000"> </P></TD> <TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000"> </P></TD> <TD> </TD></TR> </TABLE> <P STYLE="line-height:8px;margin-top:0px;margin-bottom:2px;border-bottom:0.5pt solid #000000;width:10%"> </P> <TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%"> <TR> <TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">(1)</FONT></TD> <TD ALIGN="left" VALIGN="top"> <P ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">Includes 170,170 shares of common stock reserved for issuance under the Employee Stock Purchase Plan. </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><A NAME="toc828167_21"></A>Item 13. </B><B><I>Certain Relationships and Related Transactions, and Director Independence</I></B><B> </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">The information required by this Item is incorporated by reference from our definitive Proxy Statement referred to in Item 10 above where it appears under the headings “Certain Business Relationships and Related Party Transactions” and “Board of Directors.” </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><A NAME="toc828167_22"></A>Item 14. </B><B><I>Principal Accounting Fees and Services</I></B><B> </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">The information required by this Item is incorporated by reference from our definitive Proxy Statement referred to in Item 10 above, where it appears under the heading “Principal Accountant Fees and Services.” </FONT></P> <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1"> </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">120 </FONT></P> <p Style='page-break-before:always'> <HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER"> <h5 align="left"><a href="#toc">Table of Contents</a></h5> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><A NAME="toc828167_23"></A>PART IV </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I></I></B><B><A NAME="toc828167_24"></A>Item 15.</B><B><I> Exhibits and Financial Statement Schedules </I></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">(a) The following documents are filed as part of this Form 10-K: </FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2"> (1) Financial Statements (included in Part II of this report): </FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px"> </P> <TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%"> <TR> <TD WIDTH="10%"><FONT SIZE="1"> </FONT></TD> <TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">•</FONT></TD> <TD WIDTH="1%" VALIGN="top"><FONT SIZE="1"> </FONT></TD> <TD ALIGN="left" VALIGN="top"> <P ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">Report of Independent Registered Public Accounting Firm </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px"> </P> <TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%"> <TR> <TD WIDTH="10%"><FONT SIZE="1"> </FONT></TD> <TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">•</FONT></TD> <TD WIDTH="1%" VALIGN="top"><FONT SIZE="1"> </FONT></TD> <TD ALIGN="left" VALIGN="top"> <P ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">Consolidated Balance Sheets </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px"> </P> <TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%"> <TR> <TD WIDTH="10%"><FONT SIZE="1"> </FONT></TD> <TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">•</FONT></TD> <TD WIDTH="1%" VALIGN="top"><FONT SIZE="1"> </FONT></TD> <TD ALIGN="left" VALIGN="top"> <P ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">Consolidated Statements of Comprehensive Loss </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px"> </P> <TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%"> <TR> <TD WIDTH="10%"><FONT SIZE="1"> </FONT></TD> <TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">•</FONT></TD> <TD WIDTH="1%" VALIGN="top"><FONT SIZE="1"> </FONT></TD> <TD ALIGN="left" VALIGN="top"> <P ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">Consolidated Statements of Stockholders’ Equity </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px"> </P> <TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%"> <TR> <TD WIDTH="10%"><FONT SIZE="1"> </FONT></TD> <TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">•</FONT></TD> <TD WIDTH="1%" VALIGN="top"><FONT SIZE="1"> </FONT></TD> <TD ALIGN="left" VALIGN="top"> <P ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">Consolidated Statements of Cash Flows </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px"> </P> <TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%"> <TR> <TD WIDTH="10%"><FONT SIZE="1"> </FONT></TD> <TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">•</FONT></TD> <TD WIDTH="1%" VALIGN="top"><FONT SIZE="1"> </FONT></TD> <TD ALIGN="left" VALIGN="top"> <P ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">Notes to Consolidated Financial Statements </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2"> (2) Financial Statement Schedules: </FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; margin-left:10%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">None — All financial statement schedules are omitted because the information is inapplicable or presented in the notes to the financial statements. </FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2"> (3) Exhibits: </FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px"> </P> <TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center"> <TR> <TD></TD> <TD VALIGN="bottom" WIDTH="5%"></TD> <TD WIDTH="41%"></TD> <TD VALIGN="bottom" WIDTH="3%"></TD> <TD></TD> <TD VALIGN="bottom" WIDTH="3%"></TD> <TD></TD> <TD VALIGN="bottom" WIDTH="3%"></TD> <TD></TD> <TD VALIGN="bottom" WIDTH="3%"></TD> <TD></TD> <TD VALIGN="bottom" WIDTH="3%"></TD> <TD></TD></TR> <TR> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom" COLSPAN="7" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Incorporated by Reference</B></FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD></TR> <TR> <TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Exhibit</B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:1px;border-bottom:1px solid #000000;width:25pt" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>No.</B></FONT></P></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom" ALIGN="center"> <P STYLE="border-bottom:1px solid #000000;width:28pt" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Exhibits</B></FONT></P></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom" ALIGN="center"> <P STYLE="border-bottom:1px solid #000000;width:19pt" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Form</B></FONT></P></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>File No.</B></FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Filing Date</B></FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Exh.<BR>No.</B></FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Filed<BR>Herewith</B></FONT></TD></TR> <TR STYLE="font-size:1pt"> <TD HEIGHT="8"></TD> <TD HEIGHT="8" COLSPAN="2"></TD> <TD HEIGHT="8" COLSPAN="2"></TD> <TD HEIGHT="8" COLSPAN="2"></TD> <TD HEIGHT="8" COLSPAN="2"></TD> <TD HEIGHT="8" COLSPAN="2"></TD> <TD HEIGHT="8" COLSPAN="2"></TD></TR> <TR> <TD VALIGN="top" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2"> 3.1</FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Amended and Restated Certificate of Incorporation.</FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="top" NOWRAP ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">S-3</FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="top" NOWRAP ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><FONT STYLE="white-space:nowrap">333-174869</FONT></FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="top" NOWRAP ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">June 13, 2011</FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="top" NOWRAP ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">3.1</FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="top"></TD></TR> <TR STYLE="font-size:1pt"> <TD HEIGHT="8"></TD> <TD HEIGHT="8" COLSPAN="2"></TD> <TD HEIGHT="8" COLSPAN="2"></TD> <TD HEIGHT="8" COLSPAN="2"></TD> <TD HEIGHT="8" COLSPAN="2"></TD> <TD HEIGHT="8" COLSPAN="2"></TD> <TD HEIGHT="8" COLSPAN="2"></TD></TR> <TR> <TD VALIGN="top" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2"> 3.2</FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Certificate of Amendment of Amended and Restated Certificate of Incorporation.</FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="top" NOWRAP ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">10-Q</FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="top" NOWRAP ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">000-50633</FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="top" NOWRAP ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">August 4, 2011</FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="top" NOWRAP ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">3.2</FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="top"></TD></TR> <TR STYLE="font-size:1pt"> <TD HEIGHT="8"></TD> <TD HEIGHT="8" COLSPAN="2"></TD> <TD HEIGHT="8" COLSPAN="2"></TD> <TD HEIGHT="8" COLSPAN="2"></TD> <TD HEIGHT="8" COLSPAN="2"></TD> <TD HEIGHT="8" COLSPAN="2"></TD> <TD HEIGHT="8" COLSPAN="2"></TD></TR> <TR> <TD VALIGN="top" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2"> 3.3</FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Certificate of Amendment of Amended and Restated Certificate of Incorporation.</FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="top" NOWRAP ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">8-K</FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="top" NOWRAP ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">000-50633</FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="top" NOWRAP ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">June 25, 2013</FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="top" NOWRAP ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">5.1</FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="top"></TD></TR> <TR STYLE="font-size:1pt"> <TD HEIGHT="8"></TD> <TD HEIGHT="8" COLSPAN="2"></TD> <TD HEIGHT="8" COLSPAN="2"></TD> <TD HEIGHT="8" COLSPAN="2"></TD> <TD HEIGHT="8" COLSPAN="2"></TD> <TD HEIGHT="8" COLSPAN="2"></TD> <TD HEIGHT="8" COLSPAN="2"></TD></TR> <TR> <TD VALIGN="top" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2"> 3.4</FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Amended and Restated Bylaws.</FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="top" NOWRAP ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">S-1</FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="top" NOWRAP ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">333-112261</FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="top" NOWRAP ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">January 27, 2004</FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="top" NOWRAP ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">3.2</FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="top"></TD></TR> <TR STYLE="font-size:1pt"> <TD HEIGHT="8"></TD> <TD HEIGHT="8" COLSPAN="2"></TD> <TD HEIGHT="8" COLSPAN="2"></TD> <TD HEIGHT="8" COLSPAN="2"></TD> <TD HEIGHT="8" COLSPAN="2"></TD> <TD HEIGHT="8" COLSPAN="2"></TD> <TD HEIGHT="8" COLSPAN="2"></TD></TR> <TR> <TD VALIGN="top" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2"> 3.5</FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Certificate of Designation of Preferences, Rights and Limitations of Series A Convertible Preferred Stock.</FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="top" NOWRAP ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">8-K</FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="top" NOWRAP ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">000-50633</FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="top" NOWRAP ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">April 18, 2011</FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="top" NOWRAP ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">4.5</FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="top"></TD></TR> <TR STYLE="font-size:1pt"> <TD HEIGHT="8"></TD> <TD HEIGHT="8" COLSPAN="2"></TD> <TD HEIGHT="8" COLSPAN="2"></TD> <TD HEIGHT="8" COLSPAN="2"></TD> <TD HEIGHT="8" COLSPAN="2"></TD> <TD HEIGHT="8" COLSPAN="2"></TD> <TD HEIGHT="8" COLSPAN="2"></TD></TR> <TR> <TD VALIGN="top" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2"> 3.6</FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Certificate of Designation of Preferences, Rights and Limitations of Series B Convertible Preferred Stock.</FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="top" NOWRAP ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">8-K</FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="top" NOWRAP ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">000-50633</FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="top" NOWRAP ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">June 20, 2012</FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="top" NOWRAP ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">4.1</FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="top"></TD></TR> <TR STYLE="font-size:1pt"> <TD HEIGHT="8"></TD> <TD HEIGHT="8" COLSPAN="2"></TD> <TD HEIGHT="8" COLSPAN="2"></TD> <TD HEIGHT="8" COLSPAN="2"></TD> <TD HEIGHT="8" COLSPAN="2"></TD> <TD HEIGHT="8" COLSPAN="2"></TD> <TD HEIGHT="8" COLSPAN="2"></TD></TR> <TR> <TD VALIGN="top" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2"> 4.1</FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Specimen Common Stock Certificate.</FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="top" NOWRAP ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">10-Q</FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="top" NOWRAP ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">000-50633</FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="top" NOWRAP ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">May 9, 2007</FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="top" NOWRAP ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">4.1</FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="top"></TD></TR> <TR STYLE="font-size:1pt"> <TD HEIGHT="8"></TD> <TD HEIGHT="8" COLSPAN="2"></TD> <TD HEIGHT="8" COLSPAN="2"></TD> <TD HEIGHT="8" COLSPAN="2"></TD> <TD HEIGHT="8" COLSPAN="2"></TD> <TD HEIGHT="8" COLSPAN="2"></TD> <TD HEIGHT="8" COLSPAN="2"></TD></TR> <TR> <TD VALIGN="top" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2"> 4.2</FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Registration Rights Agreement, dated as of December 29, 2006, by and between the Company and Amgen Inc.</FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="top" NOWRAP ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">8-K</FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="top" NOWRAP ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">000-50633</FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="top" NOWRAP ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">January 3, 2007</FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="top" NOWRAP ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">10.7</FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="top"></TD></TR></TABLE> <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1"> </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">121 </FONT></P> <p Style='page-break-before:always'> <HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER"> <h5 align="left"><a href="#toc">Table of Contents</a></h5> <TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center"> <TR> <TD></TD> <TD VALIGN="bottom" WIDTH="4%"></TD> <TD WIDTH="42%"></TD> <TD VALIGN="bottom" WIDTH="2%"></TD> <TD></TD> <TD VALIGN="bottom" WIDTH="2%"></TD> <TD></TD> <TD VALIGN="bottom" WIDTH="2%"></TD> <TD></TD> <TD VALIGN="bottom" WIDTH="2%"></TD> <TD></TD> <TD VALIGN="bottom" WIDTH="2%"></TD> <TD></TD></TR> <TR> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom" COLSPAN="7" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Incorporated by Reference</B></FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD></TR> <TR> <TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Exhibit</B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:1px;border-bottom:1px solid #000000;width:25pt" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>No.</B></FONT></P></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom" ALIGN="center"> <P STYLE="border-bottom:1px solid #000000;width:28pt" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Exhibits</B></FONT></P></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Form</B></FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>File No.</B></FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Filing Date</B></FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Exh.<BR>No.</B></FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Filed<BR>Herewith</B></FONT></TD></TR> <TR STYLE="font-size:1pt"> <TD HEIGHT="8"></TD> <TD HEIGHT="8" COLSPAN="2"></TD> <TD HEIGHT="8" COLSPAN="2"></TD> <TD HEIGHT="8" COLSPAN="2"></TD> <TD HEIGHT="8" COLSPAN="2"></TD> <TD HEIGHT="8" COLSPAN="2"></TD> <TD HEIGHT="8" COLSPAN="2"></TD></TR> <TR> <TD VALIGN="top" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2"> 4.3</FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Form of Warrant to Purchase Common Stock of Cytokinetics, Inc.</FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="top" NOWRAP ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">8-K</FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="top" NOWRAP ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">000-50633</FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="top" NOWRAP ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">April 18, 2011</FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="top" NOWRAP ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">10.68</FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="top"></TD></TR> <TR STYLE="font-size:1pt"> <TD HEIGHT="8"></TD> <TD HEIGHT="8" COLSPAN="2"></TD> <TD HEIGHT="8" COLSPAN="2"></TD> <TD HEIGHT="8" COLSPAN="2"></TD> <TD HEIGHT="8" COLSPAN="2"></TD> <TD HEIGHT="8" COLSPAN="2"></TD> <TD HEIGHT="8" COLSPAN="2"></TD></TR> <TR> <TD VALIGN="top" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2"> 4.4</FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Form of Common Stock Warrant Agreement</FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="top" NOWRAP ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">S-3</FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="top" NOWRAP ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">333-178189</FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="top" NOWRAP ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">November 25, 2011</FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="top" NOWRAP ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">4.4</FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="top"></TD></TR> <TR STYLE="font-size:1pt"> <TD HEIGHT="8"></TD> <TD HEIGHT="8" COLSPAN="2"></TD> <TD HEIGHT="8" COLSPAN="2"></TD> <TD HEIGHT="8" COLSPAN="2"></TD> <TD HEIGHT="8" COLSPAN="2"></TD> <TD HEIGHT="8" COLSPAN="2"></TD> <TD HEIGHT="8" COLSPAN="2"></TD></TR> <TR> <TD VALIGN="top" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2"> 4.5</FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Form of Preferred Stock Warrant Agreement</FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="top" NOWRAP ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">S-3</FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="top" NOWRAP ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">333-178189</FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="top" NOWRAP ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">November 25, 2011</FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="top" NOWRAP ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">4.5</FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="top"></TD></TR> <TR STYLE="font-size:1pt"> <TD HEIGHT="8"></TD> <TD HEIGHT="8" COLSPAN="2"></TD> <TD HEIGHT="8" COLSPAN="2"></TD> <TD HEIGHT="8" COLSPAN="2"></TD> <TD HEIGHT="8" COLSPAN="2"></TD> <TD HEIGHT="8" COLSPAN="2"></TD> <TD HEIGHT="8" COLSPAN="2"></TD></TR> <TR> <TD VALIGN="top" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2"> 4.6</FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Form of Warrant</FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="top" NOWRAP ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">10-Q</FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="top" NOWRAP ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">000-50633</FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="top" NOWRAP ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">August 6, 2012</FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="top" NOWRAP ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">4.6</FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="top"></TD></TR> <TR STYLE="font-size:1pt"> <TD HEIGHT="8"></TD> <TD HEIGHT="8" COLSPAN="2"></TD> <TD HEIGHT="8" COLSPAN="2"></TD> <TD HEIGHT="8" COLSPAN="2"></TD> <TD HEIGHT="8" COLSPAN="2"></TD> <TD HEIGHT="8" COLSPAN="2"></TD> <TD HEIGHT="8" COLSPAN="2"></TD></TR> <TR> <TD VALIGN="top" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2"> 4.7</FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Form of Common Stock Warrant and Warrant Certificate</FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="top" NOWRAP ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">S-3</FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="top" NOWRAP ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">333-192125</FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="top" NOWRAP ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">November 6, 2013</FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="top" NOWRAP ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">4.4</FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="top"></TD></TR> <TR STYLE="font-size:1pt"> <TD HEIGHT="8"></TD> <TD HEIGHT="8" COLSPAN="2"></TD> <TD HEIGHT="8" COLSPAN="2"></TD> <TD HEIGHT="8" COLSPAN="2"></TD> <TD HEIGHT="8" COLSPAN="2"></TD> <TD HEIGHT="8" COLSPAN="2"></TD> <TD HEIGHT="8" COLSPAN="2"></TD></TR> <TR> <TD VALIGN="top" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2"> 4.8</FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Form of Preferred Stock Warrant and Warrant Certificate</FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="top" NOWRAP ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">S-3</FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="top" NOWRAP ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">333-192125</FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="top" NOWRAP ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">November 6, 2013</FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="top" NOWRAP ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">4.5</FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="top"></TD></TR> <TR STYLE="font-size:1pt"> <TD HEIGHT="8"></TD> <TD HEIGHT="8" COLSPAN="2"></TD> <TD HEIGHT="8" COLSPAN="2"></TD> <TD HEIGHT="8" COLSPAN="2"></TD> <TD HEIGHT="8" COLSPAN="2"></TD> <TD HEIGHT="8" COLSPAN="2"></TD> <TD HEIGHT="8" COLSPAN="2"></TD></TR> <TR> <TD VALIGN="top" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2">10.1</FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">1997 Stock Option/Stock Issuance Plan</FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="top" NOWRAP ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">S-1</FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="top" NOWRAP ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">333-112261</FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="top" NOWRAP ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">January 27, 2004</FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="top" NOWRAP ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">10.2</FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="top"></TD></TR> <TR STYLE="font-size:1pt"> <TD HEIGHT="8"></TD> <TD HEIGHT="8" COLSPAN="2"></TD> <TD HEIGHT="8" COLSPAN="2"></TD> <TD HEIGHT="8" COLSPAN="2"></TD> <TD HEIGHT="8" COLSPAN="2"></TD> <TD HEIGHT="8" COLSPAN="2"></TD> <TD HEIGHT="8" COLSPAN="2"></TD></TR> <TR> <TD VALIGN="top" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2">10.2</FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">2004 Equity Incentive Plan, as amended</FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="top" NOWRAP ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">10-Q</FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="top" NOWRAP ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">000-50633</FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="top" NOWRAP ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">August 7, 2013</FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="top" NOWRAP ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">10.2</FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="top"></TD></TR> <TR STYLE="font-size:1pt"> <TD HEIGHT="8"></TD> <TD HEIGHT="8" COLSPAN="2"></TD> <TD HEIGHT="8" COLSPAN="2"></TD> <TD HEIGHT="8" COLSPAN="2"></TD> <TD HEIGHT="8" COLSPAN="2"></TD> <TD HEIGHT="8" COLSPAN="2"></TD> <TD HEIGHT="8" COLSPAN="2"></TD></TR> <TR> <TD VALIGN="top" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2">10.3</FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">2004 Employee Stock Purchase Plan</FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="top" NOWRAP ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">10-Q</FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="top" NOWRAP ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">000-50633</FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="top" NOWRAP ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">August 7, 2013</FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="top" NOWRAP ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">10.3</FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="top"></TD></TR> <TR STYLE="font-size:1pt"> <TD HEIGHT="8"></TD> <TD HEIGHT="8" COLSPAN="2"></TD> <TD HEIGHT="8" COLSPAN="2"></TD> <TD HEIGHT="8" COLSPAN="2"></TD> <TD HEIGHT="8" COLSPAN="2"></TD> <TD HEIGHT="8" COLSPAN="2"></TD> <TD HEIGHT="8" COLSPAN="2"></TD></TR> <TR> <TD VALIGN="top" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2">10.4</FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Build-to-Suit Lease, dated May 27, 1997, by and between Britannia Pointe Grand Limited Partnership and Metaxen, LLC.</FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="top" NOWRAP ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">S-1</FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="top" NOWRAP ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">333-112261</FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="top" NOWRAP ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">April 29, 2004</FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="top" NOWRAP ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">10.5</FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="top"></TD></TR> <TR STYLE="font-size:1pt"> <TD HEIGHT="8"></TD> <TD HEIGHT="8" COLSPAN="2"></TD> <TD HEIGHT="8" COLSPAN="2"></TD> <TD HEIGHT="8" COLSPAN="2"></TD> <TD HEIGHT="8" COLSPAN="2"></TD> <TD HEIGHT="8" COLSPAN="2"></TD> <TD HEIGHT="8" COLSPAN="2"></TD></TR> <TR> <TD VALIGN="top" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2">10.5</FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">First Amendment to Lease, dated April 13, 1998, by and between Britannia Pointe Grand Limited Partnership and Metaxen, LLC.</FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="top" NOWRAP ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">S-1</FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="top" NOWRAP ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">333-112261</FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="top" NOWRAP ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">January 27, 2004</FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="top" NOWRAP ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">10.6</FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="top"></TD></TR> <TR STYLE="font-size:1pt"> <TD HEIGHT="8"></TD> <TD HEIGHT="8" COLSPAN="2"></TD> <TD HEIGHT="8" COLSPAN="2"></TD> <TD HEIGHT="8" COLSPAN="2"></TD> <TD HEIGHT="8" COLSPAN="2"></TD> <TD HEIGHT="8" COLSPAN="2"></TD> <TD HEIGHT="8" COLSPAN="2"></TD></TR> <TR> <TD VALIGN="top" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2">10.6</FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Sublease Agreement, dated May 1, 1998, by and between the Company and Metaxen, LLC</FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="top" NOWRAP ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">S-1</FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="top" NOWRAP ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">333-112261</FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="top" NOWRAP ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">January 27, 2004</FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="top" NOWRAP ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">10.7</FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="top"></TD></TR> <TR STYLE="font-size:1pt"> <TD HEIGHT="8"></TD> <TD HEIGHT="8" COLSPAN="2"></TD> <TD HEIGHT="8" COLSPAN="2"></TD> <TD HEIGHT="8" COLSPAN="2"></TD> <TD HEIGHT="8" COLSPAN="2"></TD> <TD HEIGHT="8" COLSPAN="2"></TD> <TD HEIGHT="8" COLSPAN="2"></TD></TR> <TR> <TD VALIGN="top" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2">10.7</FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Sublease Agreement, dated March 1, 1999, by and between Metaxen, LLC and Exelixis Pharmaceuticals, Inc.</FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="top" NOWRAP ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">S-1</FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="top" NOWRAP ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">333-112261</FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="top" NOWRAP ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">January 27, 2004</FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="top" NOWRAP ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">10.8</FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="top"></TD></TR> <TR STYLE="font-size:1pt"> <TD HEIGHT="8"></TD> <TD HEIGHT="8" COLSPAN="2"></TD> <TD HEIGHT="8" COLSPAN="2"></TD> <TD HEIGHT="8" COLSPAN="2"></TD> <TD HEIGHT="8" COLSPAN="2"></TD> <TD HEIGHT="8" COLSPAN="2"></TD> <TD HEIGHT="8" COLSPAN="2"></TD></TR> <TR> <TD VALIGN="top" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2">10.8</FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Assignment and Assumption Agreement and Consent, dated July 11, 1999, by and among Exelixis Pharmaceuticals, Metaxen, LLC, Xenova Group PLC and Britannia Pointe Grande Limited Partnership</FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="top" NOWRAP ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">S-1</FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="top" NOWRAP ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">333-112261</FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="top" NOWRAP ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">January 27, 2004</FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="top" NOWRAP ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">10.9</FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="top"></TD></TR></TABLE> <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1"> </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">122 </FONT></P> <p Style='page-break-before:always'> <HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER"> <h5 align="left"><a href="#toc">Table of Contents</a></h5> <TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center"> <TR> <TD></TD> <TD VALIGN="bottom" WIDTH="6%"></TD> <TD WIDTH="37%"></TD> <TD VALIGN="bottom" WIDTH="4%"></TD> <TD></TD> <TD VALIGN="bottom" WIDTH="4%"></TD> <TD></TD> <TD VALIGN="bottom" WIDTH="4%"></TD> <TD></TD> <TD VALIGN="bottom" WIDTH="4%"></TD> <TD></TD> <TD VALIGN="bottom" WIDTH="4%"></TD> <TD></TD></TR> <TR> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom" COLSPAN="7" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Incorporated by Reference</B></FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD></TR> <TR> <TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Exhibit</B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:1px;border-bottom:1px solid #000000;width:25pt" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>No.</B></FONT></P></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom" ALIGN="center"> <P STYLE="border-bottom:1px solid #000000;width:28pt" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Exhibits</B></FONT></P></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Form</B></FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>File No.</B></FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Filing Date</B></FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Exh.<BR>No.</B></FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Filed<BR>Herewith</B></FONT></TD></TR> <TR STYLE="font-size:1pt"> <TD HEIGHT="8"></TD> <TD HEIGHT="8" COLSPAN="2"></TD> <TD HEIGHT="8" COLSPAN="2"></TD> <TD HEIGHT="8" COLSPAN="2"></TD> <TD HEIGHT="8" COLSPAN="2"></TD> <TD HEIGHT="8" COLSPAN="2"></TD> <TD HEIGHT="8" COLSPAN="2"></TD></TR> <TR> <TD VALIGN="top" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2"> 10.9</FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Second Amendment to Lease, dated July 11, 1999, by and between Britannia Pointe Grand Limited Partnership and Exelixis Pharmaceuticals, Inc.</FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="top" NOWRAP ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">S-1</FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="top" NOWRAP ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">333-112261</FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="top" NOWRAP ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">January 27, 2004</FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="top" NOWRAP ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">10.10</FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="top"></TD></TR> <TR STYLE="font-size:1pt"> <TD HEIGHT="8"></TD> <TD HEIGHT="8" COLSPAN="2"></TD> <TD HEIGHT="8" COLSPAN="2"></TD> <TD HEIGHT="8" COLSPAN="2"></TD> <TD HEIGHT="8" COLSPAN="2"></TD> <TD HEIGHT="8" COLSPAN="2"></TD> <TD HEIGHT="8" COLSPAN="2"></TD></TR> <TR> <TD VALIGN="top" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2"> 10.10</FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">First Amendment to Sublease Agreement, dated July 20, 1999, by and between the Company and Metaxen.</FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="top" NOWRAP ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">S-1</FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="top" NOWRAP ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">333-112261</FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="top" NOWRAP ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">January 27, 2004</FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="top" NOWRAP ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">10.11</FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="top"></TD></TR> <TR STYLE="font-size:1pt"> <TD HEIGHT="8"></TD> <TD HEIGHT="8" COLSPAN="2"></TD> <TD HEIGHT="8" COLSPAN="2"></TD> <TD HEIGHT="8" COLSPAN="2"></TD> <TD HEIGHT="8" COLSPAN="2"></TD> <TD HEIGHT="8" COLSPAN="2"></TD> <TD HEIGHT="8" COLSPAN="2"></TD></TR> <TR> <TD VALIGN="top" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2"> 10.11</FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Agreement and Consent, dated July 20, 1999, by and among Exelixis Pharmaceuticals, Inc., the Company and Britannia Pointe Grand Limited Partnership</FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="top" NOWRAP ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">S-1</FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="top" NOWRAP ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">333-112261</FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="top" NOWRAP ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">January 27, 2004</FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="top" NOWRAP ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">10.12</FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="top"></TD></TR> <TR STYLE="font-size:1pt"> <TD HEIGHT="8"></TD> <TD HEIGHT="8" COLSPAN="2"></TD> <TD HEIGHT="8" COLSPAN="2"></TD> <TD HEIGHT="8" COLSPAN="2"></TD> <TD HEIGHT="8" COLSPAN="2"></TD> <TD HEIGHT="8" COLSPAN="2"></TD> <TD HEIGHT="8" COLSPAN="2"></TD></TR> <TR> <TD VALIGN="top" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2"> 10.12</FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Amendment to Agreement and Consent, dated July 31, 2000, by and between the Company, Exelixis, Inc., and Britannia Pointe Grande Limited Partnership</FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="top" NOWRAP ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">S-1</FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="top" NOWRAP ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">333-112261</FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="top" NOWRAP ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">January 27, 2004</FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="top" NOWRAP ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">10.13</FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="top"></TD></TR> <TR STYLE="font-size:1pt"> <TD HEIGHT="8"></TD> <TD HEIGHT="8" COLSPAN="2"></TD> <TD HEIGHT="8" COLSPAN="2"></TD> <TD HEIGHT="8" COLSPAN="2"></TD> <TD HEIGHT="8" COLSPAN="2"></TD> <TD HEIGHT="8" COLSPAN="2"></TD> <TD HEIGHT="8" COLSPAN="2"></TD></TR> <TR> <TD VALIGN="top" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2"> 10.13</FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Assignment and Assumption of Lease, dated September 28, 2000, by and between the Company and Exelixis, Inc.</FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="top" NOWRAP ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">S-1</FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="top" NOWRAP ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">333-112261</FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="top" NOWRAP ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">January 27, 2004</FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="top" NOWRAP ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">10.14</FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="top"></TD></TR> <TR STYLE="font-size:1pt"> <TD HEIGHT="8"></TD> <TD HEIGHT="8" COLSPAN="2"></TD> <TD HEIGHT="8" COLSPAN="2"></TD> <TD HEIGHT="8" COLSPAN="2"></TD> <TD HEIGHT="8" COLSPAN="2"></TD> <TD HEIGHT="8" COLSPAN="2"></TD> <TD HEIGHT="8" COLSPAN="2"></TD></TR> <TR> <TD VALIGN="top" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2"> 10.14</FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Sublease Agreement, dated September 28, 2000, by and between the Company and Exelixis, Inc.</FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="top" NOWRAP ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">S-1</FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="top" NOWRAP ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">333-112261</FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="top" NOWRAP ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">January 27, 2004</FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="top" NOWRAP ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">10.15</FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="top"></TD></TR> <TR STYLE="font-size:1pt"> <TD HEIGHT="8"></TD> <TD HEIGHT="8" COLSPAN="2"></TD> <TD HEIGHT="8" COLSPAN="2"></TD> <TD HEIGHT="8" COLSPAN="2"></TD> <TD HEIGHT="8" COLSPAN="2"></TD> <TD HEIGHT="8" COLSPAN="2"></TD> <TD HEIGHT="8" COLSPAN="2"></TD></TR> <TR> <TD VALIGN="top" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2">*10.15</FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Collaboration and Option Agreement, dated as of December 29, 2006, by and between the Company and Amgen Inc.</FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="top" NOWRAP ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">10-K</FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="top" NOWRAP ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">000-50633</FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="top" NOWRAP ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">March 12, 2007</FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="top" NOWRAP ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">10.63</FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="top"></TD></TR> <TR STYLE="font-size:1pt"> <TD HEIGHT="8"></TD> <TD HEIGHT="8" COLSPAN="2"></TD> <TD HEIGHT="8" COLSPAN="2"></TD> <TD HEIGHT="8" COLSPAN="2"></TD> <TD HEIGHT="8" COLSPAN="2"></TD> <TD HEIGHT="8" COLSPAN="2"></TD> <TD HEIGHT="8" COLSPAN="2"></TD></TR> <TR> <TD VALIGN="top" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2"> 10.16</FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Common Stock Purchase Agreement, dated October 15, 2007, by and between the Company and Kingsbridge Capital Limited.</FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="top" NOWRAP ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">8-K</FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="top" NOWRAP ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">000-50633</FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="top" NOWRAP ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">October 15, 2007</FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="top" NOWRAP ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">10.66</FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="top"></TD></TR> <TR STYLE="font-size:1pt"> <TD HEIGHT="8"></TD> <TD HEIGHT="8" COLSPAN="2"></TD> <TD HEIGHT="8" COLSPAN="2"></TD> <TD HEIGHT="8" COLSPAN="2"></TD> <TD HEIGHT="8" COLSPAN="2"></TD> <TD HEIGHT="8" COLSPAN="2"></TD> <TD HEIGHT="8" COLSPAN="2"></TD></TR> <TR> <TD VALIGN="top" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2"> 10.17</FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Form of Indemnification Agreement between the Company and each of its directors and executive officers.</FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="top" NOWRAP ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">10-Q</FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="top" NOWRAP ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">000-50633</FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="top" NOWRAP ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">August 5, 2008</FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="top" NOWRAP ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">10.1</FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="top"></TD></TR> <TR STYLE="font-size:1pt"> <TD HEIGHT="8"></TD> <TD HEIGHT="8" COLSPAN="2"></TD> <TD HEIGHT="8" COLSPAN="2"></TD> <TD HEIGHT="8" COLSPAN="2"></TD> <TD HEIGHT="8" COLSPAN="2"></TD> <TD HEIGHT="8" COLSPAN="2"></TD> <TD HEIGHT="8" COLSPAN="2"></TD></TR> <TR> <TD VALIGN="top" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2">*10.18</FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Scientific Advisory Board Consulting Agreement, dated April 1, 2008, by and between the Company and James. H. Sabry.</FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="top" NOWRAP ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">8-K</FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="top" NOWRAP ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">000-50633</FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="top" NOWRAP ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">April 2, 2008</FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="top" NOWRAP ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">10.66</FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="top"></TD></TR></TABLE> <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1"> </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">123 </FONT></P> <p Style='page-break-before:always'> <HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER"> <h5 align="left"><a href="#toc">Table of Contents</a></h5> <TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center"> <TR> <TD></TD> <TD VALIGN="bottom" WIDTH="5%"></TD> <TD WIDTH="42%"></TD> <TD VALIGN="bottom" WIDTH="3%"></TD> <TD></TD> <TD VALIGN="bottom" WIDTH="3%"></TD> <TD></TD> <TD VALIGN="bottom" WIDTH="3%"></TD> <TD></TD> <TD VALIGN="bottom" WIDTH="3%"></TD> <TD></TD> <TD VALIGN="bottom" WIDTH="3%"></TD> <TD></TD></TR> <TR> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom" COLSPAN="7" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Incorporated by Reference</B></FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD></TR> <TR> <TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Exhibit</B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:1px;border-bottom:1px solid #000000;width:25pt" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>No.</B></FONT></P></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom" ALIGN="center"> <P STYLE="border-bottom:1px solid #000000;width:28pt" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Exhibits</B></FONT></P></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Form</B></FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>File No.</B></FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Filing Date</B></FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Exh.<BR>No.</B></FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Filed<BR>Herewith</B></FONT></TD></TR> <TR STYLE="font-size:1pt"> <TD HEIGHT="8"></TD> <TD HEIGHT="8" COLSPAN="2"></TD> <TD HEIGHT="8" COLSPAN="2"></TD> <TD HEIGHT="8" COLSPAN="2"></TD> <TD HEIGHT="8" COLSPAN="2"></TD> <TD HEIGHT="8" COLSPAN="2"></TD> <TD HEIGHT="8" COLSPAN="2"></TD></TR> <TR> <TD VALIGN="top" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2"> 10.19</FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Amended and Restated Executive Employment Agreement, dated May 21, 2007, by and between the Company and Robert Blum.</FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="top" NOWRAP ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">10-Q</FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="top" NOWRAP ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">000-50633</FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="top" NOWRAP ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">August 5, 2008</FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="top" NOWRAP ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">10.69</FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="top"></TD></TR> <TR STYLE="font-size:1pt"> <TD HEIGHT="8"></TD> <TD HEIGHT="8" COLSPAN="2"></TD> <TD HEIGHT="8" COLSPAN="2"></TD> <TD HEIGHT="8" COLSPAN="2"></TD> <TD HEIGHT="8" COLSPAN="2"></TD> <TD HEIGHT="8" COLSPAN="2"></TD> <TD HEIGHT="8" COLSPAN="2"></TD></TR> <TR> <TD VALIGN="top" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2"> 10.20</FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Form of Executive Employment Agreement between the Company and its executive officers.</FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="top" NOWRAP ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">10-Q</FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="top" NOWRAP ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">000-50633</FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="top" NOWRAP ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">August 5, 2008</FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="top" NOWRAP ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">10.68</FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="top"></TD></TR> <TR STYLE="font-size:1pt"> <TD HEIGHT="8"></TD> <TD HEIGHT="8" COLSPAN="2"></TD> <TD HEIGHT="8" COLSPAN="2"></TD> <TD HEIGHT="8" COLSPAN="2"></TD> <TD HEIGHT="8" COLSPAN="2"></TD> <TD HEIGHT="8" COLSPAN="2"></TD> <TD HEIGHT="8" COLSPAN="2"></TD></TR> <TR> <TD VALIGN="top" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2">*10.21</FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Amendment No. 1, dated June 17, 2008, to the Collaboration and Option Agreement by and between the Company and Amgen Inc.</FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="top" NOWRAP ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">10-K</FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="top" NOWRAP ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">000-50633</FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="top" NOWRAP ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">March 12, 2009</FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="top" NOWRAP ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">10.62</FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="top"></TD></TR> <TR STYLE="font-size:1pt"> <TD HEIGHT="8"></TD> <TD HEIGHT="8" COLSPAN="2"></TD> <TD HEIGHT="8" COLSPAN="2"></TD> <TD HEIGHT="8" COLSPAN="2"></TD> <TD HEIGHT="8" COLSPAN="2"></TD> <TD HEIGHT="8" COLSPAN="2"></TD> <TD HEIGHT="8" COLSPAN="2"></TD></TR> <TR> <TD VALIGN="top" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2">*10.22</FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Amendment No. 2, dated September 30, 2008, to the Collaboration and Option Agreement by and between the Company and Amgen Inc.</FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="top" NOWRAP ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">10-K</FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="top" NOWRAP ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">000-50633</FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="top" NOWRAP ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">March 12, 2009</FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="top" NOWRAP ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">10.63</FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="top"></TD></TR> <TR STYLE="font-size:1pt"> <TD HEIGHT="8"></TD> <TD HEIGHT="8" COLSPAN="2"></TD> <TD HEIGHT="8" COLSPAN="2"></TD> <TD HEIGHT="8" COLSPAN="2"></TD> <TD HEIGHT="8" COLSPAN="2"></TD> <TD HEIGHT="8" COLSPAN="2"></TD> <TD HEIGHT="8" COLSPAN="2"></TD></TR> <TR> <TD VALIGN="top" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2">*10.23</FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Amendment No. 3, dated October 31, 2008, to the Collaboration and Option Agreement by and between the Company and Amgen Inc.</FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="top" NOWRAP ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">10-K</FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="top" NOWRAP ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">000-50633</FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="top" NOWRAP ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">March 12, 2009</FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="top" NOWRAP ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">10.65</FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="top"></TD></TR> <TR STYLE="font-size:1pt"> <TD HEIGHT="8"></TD> <TD HEIGHT="8" COLSPAN="2"></TD> <TD HEIGHT="8" COLSPAN="2"></TD> <TD HEIGHT="8" COLSPAN="2"></TD> <TD HEIGHT="8" COLSPAN="2"></TD> <TD HEIGHT="8" COLSPAN="2"></TD> <TD HEIGHT="8" COLSPAN="2"></TD></TR> <TR> <TD VALIGN="top" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2">*10.24</FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Amendment No. 4, dated February 20, 2009, to the Collaboration and Option Agreement by and between the Company and Amgen Inc.</FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="top" NOWRAP ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">10-K</FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="top" NOWRAP ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">000-50633</FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="top" NOWRAP ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">March 12, 2009</FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="top" NOWRAP ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">10.67</FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="top"></TD></TR> <TR STYLE="font-size:1pt"> <TD HEIGHT="8"></TD> <TD HEIGHT="8" COLSPAN="2"></TD> <TD HEIGHT="8" COLSPAN="2"></TD> <TD HEIGHT="8" COLSPAN="2"></TD> <TD HEIGHT="8" COLSPAN="2"></TD> <TD HEIGHT="8" COLSPAN="2"></TD> <TD HEIGHT="8" COLSPAN="2"></TD></TR> <TR> <TD VALIGN="top" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2"> 10.25</FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Form of Amendment No. 1 to Amended and Restated Executive Employment Agreements.</FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="top" NOWRAP ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">10-K</FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="top" NOWRAP ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">000-50633</FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="top" NOWRAP ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">March 12, 2009</FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="top" NOWRAP ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">10.68</FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="top"></TD></TR> <TR STYLE="font-size:1pt"> <TD HEIGHT="8"></TD> <TD HEIGHT="8" COLSPAN="2"></TD> <TD HEIGHT="8" COLSPAN="2"></TD> <TD HEIGHT="8" COLSPAN="2"></TD> <TD HEIGHT="8" COLSPAN="2"></TD> <TD HEIGHT="8" COLSPAN="2"></TD> <TD HEIGHT="8" COLSPAN="2"></TD></TR> <TR> <TD VALIGN="top" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2"> 10.26</FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Third Amendment to Lease, dated December 10, 2010, by and between the Company and Britannia Pointe Grand Limited Partnership.</FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="top" NOWRAP ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">10-K</FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="top" NOWRAP ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">000-50633</FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="top" NOWRAP ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">March 11, 2011</FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="top" NOWRAP ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">10.65</FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="top"></TD></TR> <TR STYLE="font-size:1pt"> <TD HEIGHT="8"></TD> <TD HEIGHT="8" COLSPAN="2"></TD> <TD HEIGHT="8" COLSPAN="2"></TD> <TD HEIGHT="8" COLSPAN="2"></TD> <TD HEIGHT="8" COLSPAN="2"></TD> <TD HEIGHT="8" COLSPAN="2"></TD> <TD HEIGHT="8" COLSPAN="2"></TD></TR> <TR> <TD VALIGN="top" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2">*10.27</FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Amendment No. 5, dated November 1, 2011, to the Collaboration and Option Agreement by and between the Company and Amgen Inc.</FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="top" NOWRAP ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">10-K</FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="top" NOWRAP ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">000-50633</FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="top" NOWRAP ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">March 11, 2011</FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="top" NOWRAP ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">10.66</FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="top"></TD></TR></TABLE> <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1"> </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">124 </FONT></P> <p Style='page-break-before:always'> <HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER"> <h5 align="left"><a href="#toc">Table of Contents</a></h5> <TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center"> <TR> <TD></TD> <TD VALIGN="bottom" WIDTH="5%"></TD> <TD WIDTH="42%"></TD> <TD VALIGN="bottom" WIDTH="3%"></TD> <TD></TD> <TD VALIGN="bottom" WIDTH="3%"></TD> <TD></TD> <TD VALIGN="bottom" WIDTH="3%"></TD> <TD></TD> <TD VALIGN="bottom" WIDTH="3%"></TD> <TD></TD> <TD VALIGN="bottom" WIDTH="3%"></TD> <TD></TD></TR> <TR> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom" COLSPAN="7" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Incorporated by Reference</B></FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD></TR> <TR> <TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Exhibit</B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:1px;border-bottom:1px solid #000000;width:25pt" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>No.</B></FONT></P></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom" ALIGN="center"> <P STYLE="border-bottom:1px solid #000000;width:28pt" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Exhibits</B></FONT></P></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Form</B></FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>File No.</B></FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Filing Date</B></FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Exh.<BR>No.</B></FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Filed<BR>Herewith</B></FONT></TD></TR> <TR STYLE="font-size:1pt"> <TD HEIGHT="8"></TD> <TD HEIGHT="8" COLSPAN="2"></TD> <TD HEIGHT="8" COLSPAN="2"></TD> <TD HEIGHT="8" COLSPAN="2"></TD> <TD HEIGHT="8" COLSPAN="2"></TD> <TD HEIGHT="8" COLSPAN="2"></TD> <TD HEIGHT="8" COLSPAN="2"></TD></TR> <TR> <TD VALIGN="top" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2"> 10.28</FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Securities Purchase Agreement, dated April 18, 2011, between the Company and Deerfield Private Design Fund II, L.P., Deerfield Private Design International II, L.P., Deerfield Special Situations Fund, L.P., and Deerfield Special Situations Fund International Limited.</FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="top" NOWRAP ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">8-K</FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="top" NOWRAP ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">000-50633</FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="top" NOWRAP ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">April 18, 2011</FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="top" NOWRAP ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">10.67</FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="top"></TD></TR> <TR STYLE="font-size:1pt"> <TD HEIGHT="8"></TD> <TD HEIGHT="8" COLSPAN="2"></TD> <TD HEIGHT="8" COLSPAN="2"></TD> <TD HEIGHT="8" COLSPAN="2"></TD> <TD HEIGHT="8" COLSPAN="2"></TD> <TD HEIGHT="8" COLSPAN="2"></TD> <TD HEIGHT="8" COLSPAN="2"></TD></TR> <TR> <TD VALIGN="top" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2"> 10.29</FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">At the Market Issuance Sales Agreement, dated June 10, 2011, between the Company and McNicoll, Lewis & Vlak LLC.</FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="top" NOWRAP ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">8-K</FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="top" NOWRAP ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">000-50633</FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="top" NOWRAP ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">June 13, 2011</FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="top" NOWRAP ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">10.68</FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="top"></TD></TR> <TR STYLE="font-size:1pt"> <TD HEIGHT="8"></TD> <TD HEIGHT="8" COLSPAN="2"></TD> <TD HEIGHT="8" COLSPAN="2"></TD> <TD HEIGHT="8" COLSPAN="2"></TD> <TD HEIGHT="8" COLSPAN="2"></TD> <TD HEIGHT="8" COLSPAN="2"></TD> <TD HEIGHT="8" COLSPAN="2"></TD></TR> <TR> <TD VALIGN="top" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2">*10.30</FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Consulting Agreement between the Company and David J. Morgans, dated November 1, 2011.</FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="top" NOWRAP ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">10-K</FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="top" NOWRAP ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">000-50633</FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="top" NOWRAP ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">March 13, 2012</FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="top" NOWRAP ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">10.42</FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="top"></TD></TR> <TR STYLE="font-size:1pt"> <TD HEIGHT="8"></TD> <TD HEIGHT="8" COLSPAN="2"></TD> <TD HEIGHT="8" COLSPAN="2"></TD> <TD HEIGHT="8" COLSPAN="2"></TD> <TD HEIGHT="8" COLSPAN="2"></TD> <TD HEIGHT="8" COLSPAN="2"></TD> <TD HEIGHT="8" COLSPAN="2"></TD></TR> <TR> <TD VALIGN="top" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2">*10.31</FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Amendment No. 1, dated May 1, 2012, to Consulting Agreement between the Company and David J. Morgans, dated November 1, 2011.</FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="top" NOWRAP ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">10-Q</FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="top" NOWRAP ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">000-50633</FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="top" NOWRAP ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">May 4, 2012</FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="top" NOWRAP ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">10.43</FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="top"></TD></TR> <TR STYLE="font-size:1pt"> <TD HEIGHT="8"></TD> <TD HEIGHT="8" COLSPAN="2"></TD> <TD HEIGHT="8" COLSPAN="2"></TD> <TD HEIGHT="8" COLSPAN="2"></TD> <TD HEIGHT="8" COLSPAN="2"></TD> <TD HEIGHT="8" COLSPAN="2"></TD> <TD HEIGHT="8" COLSPAN="2"></TD></TR> <TR> <TD VALIGN="top" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2">*10.32</FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Amendment No. 2, dated October 30, 2012 to Consulting Agreement between the Company and David J. Morgans, dated November 1, 2011.</FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="top" NOWRAP ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">10-K</FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="top" NOWRAP ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">000-50633</FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="top" NOWRAP ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">March 15, 2013</FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="top" NOWRAP ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">10.44</FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="top"></TD></TR> <TR STYLE="font-size:1pt"> <TD HEIGHT="8"></TD> <TD HEIGHT="8" COLSPAN="2"></TD> <TD HEIGHT="8" COLSPAN="2"></TD> <TD HEIGHT="8" COLSPAN="2"></TD> <TD HEIGHT="8" COLSPAN="2"></TD> <TD HEIGHT="8" COLSPAN="2"></TD> <TD HEIGHT="8" COLSPAN="2"></TD></TR> <TR> <TD VALIGN="top" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2"> 10.33</FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Compensation Information for the Company’s Named Executive Officers.</FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="top" NOWRAP ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">8-K</FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="top" NOWRAP ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">000-50633</FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="top" NOWRAP ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">March 2, 2015</FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="top" NOWRAP ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">10.1</FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="top"></TD></TR> <TR STYLE="font-size:1pt"> <TD HEIGHT="8"></TD> <TD HEIGHT="8" COLSPAN="2"></TD> <TD HEIGHT="8" COLSPAN="2"></TD> <TD HEIGHT="8" COLSPAN="2"></TD> <TD HEIGHT="8" COLSPAN="2"></TD> <TD HEIGHT="8" COLSPAN="2"></TD> <TD HEIGHT="8" COLSPAN="2"></TD></TR> <TR> <TD VALIGN="top" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2"> 10.34</FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Form of Option Agreement.</FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="top" NOWRAP ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">10-K</FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="top" NOWRAP ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">000-50633</FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="top" NOWRAP ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">March 15, 2013</FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="top" NOWRAP ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">10.46</FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="top"></TD></TR> <TR STYLE="font-size:1pt"> <TD HEIGHT="8"></TD> <TD HEIGHT="8" COLSPAN="2"></TD> <TD HEIGHT="8" COLSPAN="2"></TD> <TD HEIGHT="8" COLSPAN="2"></TD> <TD HEIGHT="8" COLSPAN="2"></TD> <TD HEIGHT="8" COLSPAN="2"></TD> <TD HEIGHT="8" COLSPAN="2"></TD></TR> <TR> <TD VALIGN="top" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2"> 10.35</FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Form of Restricted Stock Unit Award Agreement.</FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="top" NOWRAP ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">10-K</FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="top" NOWRAP ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">000-50633</FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="top" NOWRAP ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">March 15, 2013</FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="top" NOWRAP ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">10.47</FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="top"></TD></TR> <TR STYLE="font-size:1pt"> <TD HEIGHT="8"></TD> <TD HEIGHT="8" COLSPAN="2"></TD> <TD HEIGHT="8" COLSPAN="2"></TD> <TD HEIGHT="8" COLSPAN="2"></TD> <TD HEIGHT="8" COLSPAN="2"></TD> <TD HEIGHT="8" COLSPAN="2"></TD> <TD HEIGHT="8" COLSPAN="2"></TD></TR> <TR> <TD VALIGN="top" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2"> 10.36</FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Common Stock Purchase Agreement dated June 11, 2013, by and between the Company and Amgen, Inc.</FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="top" NOWRAP ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">8-K</FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="top" NOWRAP ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">000-50633</FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="top" NOWRAP ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">June 12, 2013</FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="top" NOWRAP ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">10.48</FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="top"></TD></TR> <TR STYLE="font-size:1pt"> <TD HEIGHT="8"></TD> <TD HEIGHT="8" COLSPAN="2"></TD> <TD HEIGHT="8" COLSPAN="2"></TD> <TD HEIGHT="8" COLSPAN="2"></TD> <TD HEIGHT="8" COLSPAN="2"></TD> <TD HEIGHT="8" COLSPAN="2"></TD> <TD HEIGHT="8" COLSPAN="2"></TD></TR> <TR> <TD VALIGN="top" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2">*10.37</FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Amendment No. 6, dated June 11, 2013, to the Collaboration and Option Agreement by and between the Company and Amgen, Inc.</FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="top" NOWRAP ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">10-Q</FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="top" NOWRAP ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">000-50633</FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="top" NOWRAP ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">August 7, 2013</FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="top" NOWRAP ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">10.46</FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="top"></TD></TR> <TR STYLE="font-size:1pt"> <TD HEIGHT="8"></TD> <TD HEIGHT="8" COLSPAN="2"></TD> <TD HEIGHT="8" COLSPAN="2"></TD> <TD HEIGHT="8" COLSPAN="2"></TD> <TD HEIGHT="8" COLSPAN="2"></TD> <TD HEIGHT="8" COLSPAN="2"></TD> <TD HEIGHT="8" COLSPAN="2"></TD></TR> <TR> <TD VALIGN="top" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2"> 10.38</FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Form of Executive Employment Agreement between the Company and its executive officers.</FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="top" NOWRAP ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">10-K</FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="top" NOWRAP ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">000-50633</FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="top" NOWRAP ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">March 7, 2014</FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="top" NOWRAP ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">10.39</FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="top"></TD></TR> <TR STYLE="font-size:1pt"> <TD HEIGHT="8"></TD> <TD HEIGHT="8" COLSPAN="2"></TD> <TD HEIGHT="8" COLSPAN="2"></TD> <TD HEIGHT="8" COLSPAN="2"></TD> <TD HEIGHT="8" COLSPAN="2"></TD> <TD HEIGHT="8" COLSPAN="2"></TD> <TD HEIGHT="8" COLSPAN="2"></TD></TR> <TR> <TD VALIGN="top" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2"> 10.39</FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Common Stock Purchase Agreement by and between the Company and Astellas Pharma Inc. dated December 22, 2014.</FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="top" NOWRAP ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">8-K</FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="top" NOWRAP ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">000-50633</FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="top" NOWRAP ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">December 23, 2014</FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="top" NOWRAP ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">10.46</FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="top"></TD></TR></TABLE> <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1"> </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">125 </FONT></P> <p Style='page-break-before:always'> <HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER"> <h5 align="left"><a href="#toc">Table of Contents</a></h5> <TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center"> <TR> <TD></TD> <TD VALIGN="bottom" WIDTH="9%"></TD> <TD WIDTH="41%"></TD> <TD VALIGN="bottom" WIDTH="7%"></TD> <TD></TD> <TD VALIGN="bottom" WIDTH="7%"></TD> <TD></TD> <TD VALIGN="bottom" WIDTH="7%"></TD> <TD></TD> <TD VALIGN="bottom" WIDTH="7%"></TD> <TD></TD> <TD VALIGN="bottom" WIDTH="7%"></TD> <TD></TD></TR> <TR> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom" COLSPAN="7" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Incorporated by Reference</B></FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD></TR> <TR> <TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Exhibit</B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:1px;border-bottom:1px solid #000000;width:25pt" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>No.</B></FONT></P></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom" ALIGN="center"> <P STYLE="border-bottom:1px solid #000000;width:28pt" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Exhibits</B></FONT></P></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Form</B></FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>File No.</B></FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Filing Date</B></FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Exh.<BR>No.</B></FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Filed<BR>Herewith</B></FONT></TD></TR> <TR STYLE="font-size:1pt"> <TD HEIGHT="8"></TD> <TD HEIGHT="8" COLSPAN="2"></TD> <TD HEIGHT="8" COLSPAN="2"></TD> <TD HEIGHT="8" COLSPAN="2"></TD> <TD HEIGHT="8" COLSPAN="2"></TD> <TD HEIGHT="8" COLSPAN="2"></TD> <TD HEIGHT="8" COLSPAN="2"></TD></TR> <TR> <TD VALIGN="top" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2">*10.40</FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Amended and Restated License and Collaboration Agreement, dated December 22, 2014, by and between the Company and Astellas Pharma Inc.</FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="top"></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="top"></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="top"></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="top"></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="top" NOWRAP ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">X</FONT></TD></TR> <TR STYLE="font-size:1pt"> <TD HEIGHT="8"></TD> <TD HEIGHT="8" COLSPAN="2"></TD> <TD HEIGHT="8" COLSPAN="2"></TD> <TD HEIGHT="8" COLSPAN="2"></TD> <TD HEIGHT="8" COLSPAN="2"></TD> <TD HEIGHT="8" COLSPAN="2"></TD> <TD HEIGHT="8" COLSPAN="2"></TD></TR> <TR> <TD VALIGN="top" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2"> 23.1</FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Consent of Independent registered public accounting firm.</FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="top"></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="top"></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="top"></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="top"></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="top" NOWRAP ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">X</FONT></TD></TR> <TR STYLE="font-size:1pt"> <TD HEIGHT="8"></TD> <TD HEIGHT="8" COLSPAN="2"></TD> <TD HEIGHT="8" COLSPAN="2"></TD> <TD HEIGHT="8" COLSPAN="2"></TD> <TD HEIGHT="8" COLSPAN="2"></TD> <TD HEIGHT="8" COLSPAN="2"></TD> <TD HEIGHT="8" COLSPAN="2"></TD></TR> <TR> <TD VALIGN="top" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2"> 24.1</FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Power of Attorney (included in the signature page to this report).</FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="top"></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="top"></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="top"></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="top"></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="top"></TD></TR> <TR STYLE="font-size:1pt"> <TD HEIGHT="8"></TD> <TD HEIGHT="8" COLSPAN="2"></TD> <TD HEIGHT="8" COLSPAN="2"></TD> <TD HEIGHT="8" COLSPAN="2"></TD> <TD HEIGHT="8" COLSPAN="2"></TD> <TD HEIGHT="8" COLSPAN="2"></TD> <TD HEIGHT="8" COLSPAN="2"></TD></TR> <TR> <TD VALIGN="top" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2"> 31.1</FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Certification of Principal Executive Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.</FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="top"></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="top"></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="top"></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="top"></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="top" NOWRAP ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">X</FONT></TD></TR> <TR STYLE="font-size:1pt"> <TD HEIGHT="8"></TD> <TD HEIGHT="8" COLSPAN="2"></TD> <TD HEIGHT="8" COLSPAN="2"></TD> <TD HEIGHT="8" COLSPAN="2"></TD> <TD HEIGHT="8" COLSPAN="2"></TD> <TD HEIGHT="8" COLSPAN="2"></TD> <TD HEIGHT="8" COLSPAN="2"></TD></TR> <TR> <TD VALIGN="top" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2"> 31.2</FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Certification of Principal Financial Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.</FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="top"></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="top"></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="top"></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="top"></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="top" NOWRAP ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">X</FONT></TD></TR> <TR STYLE="font-size:1pt"> <TD HEIGHT="8"></TD> <TD HEIGHT="8" COLSPAN="2"></TD> <TD HEIGHT="8" COLSPAN="2"></TD> <TD HEIGHT="8" COLSPAN="2"></TD> <TD HEIGHT="8" COLSPAN="2"></TD> <TD HEIGHT="8" COLSPAN="2"></TD> <TD HEIGHT="8" COLSPAN="2"></TD></TR> <TR> <TD VALIGN="top" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2"> 32.1</FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Certifications of the Principal Executive Officer and the Principal Financial Officer pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 (18 U.S.C. Section 1350).</FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="top"></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="top"></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="top"></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="top"></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="top" NOWRAP ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">X</FONT></TD></TR> <TR STYLE="font-size:1pt"> <TD HEIGHT="8"></TD> <TD HEIGHT="8" COLSPAN="2"></TD> <TD HEIGHT="8" COLSPAN="2"></TD> <TD HEIGHT="8" COLSPAN="2"></TD> <TD HEIGHT="8" COLSPAN="2"></TD> <TD HEIGHT="8" COLSPAN="2"></TD> <TD HEIGHT="8" COLSPAN="2"></TD></TR> <TR> <TD VALIGN="top" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2">101.INS</FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">XBRL Instance Document.</FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="top"></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="top"></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="top"></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="top"></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="top" NOWRAP ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">X</FONT></TD></TR> <TR STYLE="font-size:1pt"> <TD HEIGHT="8"></TD> <TD HEIGHT="8" COLSPAN="2"></TD> <TD HEIGHT="8" COLSPAN="2"></TD> <TD HEIGHT="8" COLSPAN="2"></TD> <TD HEIGHT="8" COLSPAN="2"></TD> <TD HEIGHT="8" COLSPAN="2"></TD> <TD HEIGHT="8" COLSPAN="2"></TD></TR> <TR> <TD VALIGN="top" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2">101.SCH</FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">XBRL Taxonomy Extension Schema Document.</FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="top"></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="top"></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="top"></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="top"></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="top" NOWRAP ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">X</FONT></TD></TR> <TR STYLE="font-size:1pt"> <TD HEIGHT="8"></TD> <TD HEIGHT="8" COLSPAN="2"></TD> <TD HEIGHT="8" COLSPAN="2"></TD> <TD HEIGHT="8" COLSPAN="2"></TD> <TD HEIGHT="8" COLSPAN="2"></TD> <TD HEIGHT="8" COLSPAN="2"></TD> <TD HEIGHT="8" COLSPAN="2"></TD></TR> <TR> <TD VALIGN="top" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2">101.CAL</FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">XBRL Taxonomy Extension Calculation Linkbase Document.</FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="top"></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="top"></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="top"></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="top"></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="top" NOWRAP ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">X</FONT></TD></TR> <TR STYLE="font-size:1pt"> <TD HEIGHT="8"></TD> <TD HEIGHT="8" COLSPAN="2"></TD> <TD HEIGHT="8" COLSPAN="2"></TD> <TD HEIGHT="8" COLSPAN="2"></TD> <TD HEIGHT="8" COLSPAN="2"></TD> <TD HEIGHT="8" COLSPAN="2"></TD> <TD HEIGHT="8" COLSPAN="2"></TD></TR> <TR> <TD VALIGN="top" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2">101.DEF</FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">XBRL Taxonomy Extension Definition Linkbase Document.</FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="top"></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="top"></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="top"></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="top"></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="top" NOWRAP ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">X</FONT></TD></TR> <TR STYLE="font-size:1pt"> <TD HEIGHT="8"></TD> <TD HEIGHT="8" COLSPAN="2"></TD> <TD HEIGHT="8" COLSPAN="2"></TD> <TD HEIGHT="8" COLSPAN="2"></TD> <TD HEIGHT="8" COLSPAN="2"></TD> <TD HEIGHT="8" COLSPAN="2"></TD> <TD HEIGHT="8" COLSPAN="2"></TD></TR> <TR> <TD VALIGN="top" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2">101.LAB</FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">XBRL Taxonomy Extension Label Linkbase Document</FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="top"></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="top"></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="top"></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="top"></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="top" NOWRAP ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">X</FONT></TD></TR> <TR STYLE="font-size:1pt"> <TD HEIGHT="8"></TD> <TD HEIGHT="8" COLSPAN="2"></TD> <TD HEIGHT="8" COLSPAN="2"></TD> <TD HEIGHT="8" COLSPAN="2"></TD> <TD HEIGHT="8" COLSPAN="2"></TD> <TD HEIGHT="8" COLSPAN="2"></TD> <TD HEIGHT="8" COLSPAN="2"></TD></TR> <TR> <TD VALIGN="top" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2">101.PRE</FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">XBRL Taxonomy Extension Presentation Linkbase Document.</FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="top"></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="top"></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="top"></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="top"></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="top" NOWRAP ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">X</FONT></TD></TR> </TABLE> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px"> </P> <TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%"> <TR> <TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">*</FONT></TD> <TD ALIGN="left" VALIGN="top"> <P ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">Pursuant to a request for confidential treatment, portions of this Exhibit have been redacted from the publicly filed document and have been furnished separately to the Securities and Exchange Commission as required by Rule 406 under the Securities Act or Rule 24b-2 under the Exchange Act, as applicable. </FONT></P></TD></TR></TABLE> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px"> </P> <TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%"> <TR> <TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD ALIGN="left" VALIGN="top"> <P ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">(b) Exhibits </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:6px;margin-bottom:0px; margin-left:5%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">The exhibits listed under Item 15(a)(3) hereof are filed as part of this Form 10-K, other than Exhibit 32.1 which shall be deemed furnished. </FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px"> </P> <TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%"> <TR> <TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD ALIGN="left" VALIGN="top"> <P ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">(c) Financial Statement Schedules </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:6px;margin-bottom:0px; margin-left:5%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">None — All financial statement schedules are omitted because the information is inapplicable or presented in the notes to the financial statements. </FONT></P> <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1"> </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">126 </FONT></P> <p Style='page-break-before:always'> <HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER"> <h5 align="left"><a href="#toc">Table of Contents</a></h5> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><A NAME="toc828167_25"></A>SIGNATURES </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">Pursuant to the requirements of Section 13 or 15(d) of the Securities and Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. </FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px"> </P><DIV ALIGN="right"> <TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE"> <TR> <TD WIDTH="6%"></TD> <TD VALIGN="bottom" WIDTH="2%"></TD> <TD WIDTH="92%"></TD></TR> <TR> <TD VALIGN="top" COLSPAN="3"><FONT STYLE="font-family:Times New Roman" SIZE="2">CYTOKINETICS, INCORPORATED</FONT></TD></TR> <TR STYLE="font-size:1pt"> <TD HEIGHT="16"></TD> <TD HEIGHT="16" COLSPAN="2"></TD></TR> <TR> <TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">By:</FONT></P></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"> <P STYLE="margin-top:0px;margin-bottom:1px;border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2">/<SMALL>S</SMALL>/ R<SMALL>OBERT</SMALL> I. B<SMALL>LUM </SMALL></FONT></P></TD></TR> <TR> <TD VALIGN="top"></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Robert I. Blum</FONT></P> <P STYLE="margin-top:0px;margin-bottom:1px"><FONT STYLE="font-family:Times New Roman" SIZE="2">President, Chief Executive Officer and Director</FONT></P></TD></TR> </TABLE></DIV> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Dated: March 6, 2015 </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>POWER OF ATTORNEY </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">KNOW ALL PERSONS BY THESE PRESENTS, that each person whose signature appears below constitutes and appoints Robert I. Blum and Sharon A. Barbari, and each of them, his true and lawful attorneys-in-fact, each with full power of substitution, for him in any and all capacities, to sign any amendments to this Annual Report on Form 10-K and to file the same, with exhibits thereto and other documents in connection therewith, with the Securities and Exchange Commission, hereby ratifying and confirming all that each of said attorneys-in-fact or their substitute or substitutes may do or cause to be done by virtue hereof. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">Pursuant to the requirements of the Securities and Exchange Act of 1934, this report has been signed below by the following persons on behalf of the registrant and in the capacities and on the dates indicated. </FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px"> </P> <TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE"> <TR> <TD WIDTH="42%"></TD> <TD VALIGN="bottom" WIDTH="1%"></TD> <TD WIDTH="36%"></TD> <TD VALIGN="bottom" WIDTH="2%"></TD> <TD WIDTH="18%"></TD></TR> <TR> <TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE="border-bottom:1px solid #000000;width:33pt" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Signature</B></FONT></P></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE="border-bottom:1px solid #000000;width:15pt" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Title</B></FONT></P></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE="border-bottom:1px solid #000000;width:16pt" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Date</B></FONT></P></TD></TR> <TR STYLE="font-size:1pt"> <TD HEIGHT="16"></TD> <TD HEIGHT="16" COLSPAN="2"></TD> <TD HEIGHT="16" COLSPAN="2"></TD></TR> <TR> <TD VALIGN="bottom"> <P STYLE="margin-top:0px;margin-bottom:0px;border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2">/s/ R<SMALL>OBERT</SMALL> I. B<SMALL>LUM </SMALL></FONT></P> <P STYLE="margin-top:0px;margin-bottom:1px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Robert I. Blum</FONT></P></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="top" ALIGN="center"> <P STYLE="margin-left:1.00em; text-indent:-1.00em" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">President, Chief Executive Officer and Director (Principal Executive Officer)</FONT></P></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="top" NOWRAP ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">March 6, 2015</FONT></TD></TR> <TR STYLE="font-size:1pt"> <TD HEIGHT="16"></TD> <TD HEIGHT="16" COLSPAN="2"></TD> <TD HEIGHT="16" COLSPAN="2"></TD></TR> <TR> <TD VALIGN="top"> <P STYLE="margin-top:0px;margin-bottom:0px;border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2">/s/ S<SMALL>HARON</SMALL> A. B<SMALL>ARBARI</SMALL></FONT></P> <P STYLE="margin-top:0px;margin-bottom:1px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Sharon A. Barbari</FONT></P></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="top" ALIGN="center"> <P STYLE="margin-left:1.00em; text-indent:-1.00em" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">Executive Vice President, Finance and Chief Financial Officer (Principal Financial and Accounting Executive)</FONT></P></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="top" NOWRAP ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">March 6, 2015</FONT></TD></TR> <TR STYLE="font-size:1pt"> <TD HEIGHT="16"></TD> <TD HEIGHT="16" COLSPAN="2"></TD> <TD HEIGHT="16" COLSPAN="2"></TD></TR> <TR> <TD VALIGN="top"> <P STYLE="margin-top:0px;margin-bottom:0px;border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2">/s/ L. P<SMALL>ATRICK</SMALL> G<SMALL>AGE</SMALL>, P<SMALL>H</SMALL>.D.</FONT></P> <P STYLE="margin-top:0px;margin-bottom:1px"><FONT STYLE="font-family:Times New Roman" SIZE="2">L. Patrick Gage, Ph.D.</FONT></P></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="top" ALIGN="center"> <P STYLE="margin-left:1.00em; text-indent:-1.00em" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">Chairman of the Board of Directors</FONT></P></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="top" NOWRAP ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">March 6, 2015</FONT></TD></TR> <TR STYLE="font-size:1pt"> <TD HEIGHT="16"></TD> <TD HEIGHT="16" COLSPAN="2"></TD> <TD HEIGHT="16" COLSPAN="2"></TD></TR> <TR> <TD VALIGN="bottom"> <P STYLE="margin-top:0px;margin-bottom:0px;border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2">/s/ S<SMALL>ANTO</SMALL> J. C<SMALL>OSTA</SMALL></FONT></P> <P STYLE="margin-top:0px;margin-bottom:1px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Santo J. Costa</FONT></P></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="top" ALIGN="center"> <P STYLE="margin-left:1.00em; text-indent:-1.00em" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">Director</FONT></P></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="top" NOWRAP ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">March 6, 2015</FONT></TD></TR> <TR STYLE="font-size:1pt"> <TD HEIGHT="16"></TD> <TD HEIGHT="16" COLSPAN="2"></TD> <TD HEIGHT="16" COLSPAN="2"></TD></TR> <TR> <TD VALIGN="top"> <P STYLE="margin-top:0px;margin-bottom:0px;border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2">/s/ D<SMALL>ENISE</SMALL> M. G<SMALL>ILBERT</SMALL>, P<SMALL>H</SMALL>.D.</FONT></P> <P STYLE="margin-top:0px;margin-bottom:1px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Denise M. Gilbert, Ph.D.</FONT></P></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="top" ALIGN="center"> <P STYLE="margin-left:1.00em; text-indent:-1.00em" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">Director</FONT></P></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="top" NOWRAP ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">March 6, 2015</FONT></TD></TR> <TR STYLE="font-size:1pt"> <TD HEIGHT="16"></TD> <TD HEIGHT="16" COLSPAN="2"></TD> <TD HEIGHT="16" COLSPAN="2"></TD></TR> <TR> <TD VALIGN="top"> <P STYLE="margin-top:0px;margin-bottom:0px;border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2">/s/ J<SMALL>OHN</SMALL> T. H<SMALL>ENDERSON</SMALL>, M.B. C<SMALL>H</SMALL>.B.</FONT></P> <P STYLE="margin-top:0px;margin-bottom:1px"><FONT STYLE="font-family:Times New Roman" SIZE="2">John T. Henderson, M.B. Ch.B.</FONT></P></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="top" ALIGN="center"> <P STYLE="margin-left:1.00em; text-indent:-1.00em" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">Director</FONT></P></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="top" NOWRAP ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">March 6, 2015</FONT></TD></TR> <TR STYLE="font-size:1pt"> <TD HEIGHT="16"></TD> <TD HEIGHT="16" COLSPAN="2"></TD> <TD HEIGHT="16" COLSPAN="2"></TD></TR> <TR> <TD VALIGN="top"> <P STYLE="margin-top:0px;margin-bottom:0px;border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2">/s/ B. L<SMALL>YNNE</SMALL> P<SMALL>ARSHALL</SMALL>, E<SMALL>SQ</SMALL>.</FONT></P> <P STYLE="margin-top:0px;margin-bottom:1px"><FONT STYLE="font-family:Times New Roman" SIZE="2">B. Lynne Parshall, Esq.</FONT></P></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="top" ALIGN="center"> <P STYLE="margin-left:1.00em; text-indent:-1.00em" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">Director</FONT></P></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="top" NOWRAP ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">March 6, 2015</FONT></TD></TR> <TR STYLE="font-size:1pt"> <TD HEIGHT="16"></TD> <TD HEIGHT="16" COLSPAN="2"></TD> <TD HEIGHT="16" COLSPAN="2"></TD></TR> <TR> <TD VALIGN="top"> <P STYLE="margin-top:0px;margin-bottom:0px;border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2">/s/ S<SMALL>ANDFORD</SMALL> D. S<SMALL>MITH</SMALL></FONT></P> <P STYLE="margin-top:0px;margin-bottom:1px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Sandford D. Smith</FONT></P></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="top" ALIGN="center"> <P STYLE="margin-left:1.00em; text-indent:-1.00em" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">Director</FONT></P></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="top" NOWRAP ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">March 6, 2015</FONT></TD></TR> <TR STYLE="font-size:1pt"> <TD HEIGHT="16"></TD> <TD HEIGHT="16" COLSPAN="2"></TD> <TD HEIGHT="16" COLSPAN="2"></TD></TR> <TR> <TD VALIGN="top"> <P STYLE="margin-top:0px;margin-bottom:0px;border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2">/s/ W<SMALL>ENDELL</SMALL> W<SMALL>IERENGA</SMALL>, P<SMALL>H</SMALL>.D.</FONT></P> <P STYLE="margin-top:0px;margin-bottom:1px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Wendell Wierenga, Ph.D.</FONT></P></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="top" ALIGN="center"> <P STYLE="margin-left:1.00em; text-indent:-1.00em" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">Director</FONT></P></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="top" NOWRAP ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">March 6, 2015</FONT></TD></TR> </TABLE> <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1"> </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">127 </FONT></P> <p Style='page-break-before:always'> <HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER"> <h5 align="left"><a href="#toc">Table of Contents</a></h5> <TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center"> <TR> <TD></TD> <TD VALIGN="bottom" WIDTH="4%"></TD> <TD WIDTH="42%"></TD> <TD VALIGN="bottom" WIDTH="2%"></TD> <TD></TD> <TD VALIGN="bottom" WIDTH="2%"></TD> <TD></TD> <TD VALIGN="bottom" WIDTH="2%"></TD> <TD></TD> <TD VALIGN="bottom" WIDTH="2%"></TD> <TD></TD> <TD VALIGN="bottom" WIDTH="2%"></TD> <TD></TD></TR> <TR> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom" COLSPAN="7" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Incorporated by Reference</B></FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD></TR> <TR> <TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Exhibit</B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:1px;border-bottom:1px solid #000000;width:25pt" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>No.</B></FONT></P></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom" ALIGN="center"> <P STYLE="border-bottom:1px solid #000000;width:28pt" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Exhibits</B></FONT></P></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Form</B></FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>File No.</B></FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Filing Date</B></FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Exh.<BR>No.</B></FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Filed<BR>Herewith</B></FONT></TD></TR> <TR STYLE="font-size:1pt"> <TD HEIGHT="8"></TD> <TD HEIGHT="8" COLSPAN="2"></TD> <TD HEIGHT="8" COLSPAN="2"></TD> <TD HEIGHT="8" COLSPAN="2"></TD> <TD HEIGHT="8" COLSPAN="2"></TD> <TD HEIGHT="8" COLSPAN="2"></TD> <TD HEIGHT="8" COLSPAN="2"></TD></TR> <TR> <TD VALIGN="top" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2"> 3.1</FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Amended and Restated Certificate of Incorporation.</FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">S-3</FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">333-174869</FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">June 13, 2011</FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">3.1</FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="top"></TD></TR> <TR STYLE="font-size:1pt"> <TD HEIGHT="8"></TD> <TD HEIGHT="8" COLSPAN="2"></TD> <TD HEIGHT="8" COLSPAN="2"></TD> <TD HEIGHT="8" COLSPAN="2"></TD> <TD HEIGHT="8" COLSPAN="2"></TD> <TD HEIGHT="8" COLSPAN="2"></TD> <TD HEIGHT="8" COLSPAN="2"></TD></TR> <TR> <TD VALIGN="top" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2"> 3.2</FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Certificate of Amendment of Amended and Restated Certificate of Incorporation.</FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">10-Q</FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">000-50633</FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">August 4, 2011</FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">3.2</FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="top"></TD></TR> <TR STYLE="font-size:1pt"> <TD HEIGHT="8"></TD> <TD HEIGHT="8" COLSPAN="2"></TD> <TD HEIGHT="8" COLSPAN="2"></TD> <TD HEIGHT="8" COLSPAN="2"></TD> <TD HEIGHT="8" COLSPAN="2"></TD> <TD HEIGHT="8" COLSPAN="2"></TD> <TD HEIGHT="8" COLSPAN="2"></TD></TR> <TR> <TD VALIGN="top" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2"> 3.3</FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Certificate of Amendment of Amended and Restated Certificate of Incorporation.</FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">8-K</FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">000-50633</FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">June 25, 2013</FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">5.1</FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="top"></TD></TR> <TR STYLE="font-size:1pt"> <TD HEIGHT="8"></TD> <TD HEIGHT="8" COLSPAN="2"></TD> <TD HEIGHT="8" COLSPAN="2"></TD> <TD HEIGHT="8" COLSPAN="2"></TD> <TD HEIGHT="8" COLSPAN="2"></TD> <TD HEIGHT="8" COLSPAN="2"></TD> <TD HEIGHT="8" COLSPAN="2"></TD></TR> <TR> <TD VALIGN="top" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2"> 3.4</FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Amended and Restated Bylaws.</FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">S-1</FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">333-112261</FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">January 27, 2004</FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">3.2</FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="top"></TD></TR> <TR STYLE="font-size:1pt"> <TD HEIGHT="8"></TD> <TD HEIGHT="8" COLSPAN="2"></TD> <TD HEIGHT="8" COLSPAN="2"></TD> <TD HEIGHT="8" COLSPAN="2"></TD> <TD HEIGHT="8" COLSPAN="2"></TD> <TD HEIGHT="8" COLSPAN="2"></TD> <TD HEIGHT="8" COLSPAN="2"></TD></TR> <TR> <TD VALIGN="top" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2"> 3.5</FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Certificate of Designation of Preferences, Rights and Limitations of Series A Convertible Preferred Stock.</FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">8-K</FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">000-50633</FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">April 18, 2011</FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">4.5</FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="top"></TD></TR> <TR STYLE="font-size:1pt"> <TD HEIGHT="8"></TD> <TD HEIGHT="8" COLSPAN="2"></TD> <TD HEIGHT="8" COLSPAN="2"></TD> <TD HEIGHT="8" COLSPAN="2"></TD> <TD HEIGHT="8" COLSPAN="2"></TD> <TD HEIGHT="8" COLSPAN="2"></TD> <TD HEIGHT="8" COLSPAN="2"></TD></TR> <TR> <TD VALIGN="top" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2"> 3.6</FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Certificate of Designation of Preferences, Rights and Limitations of Series B Convertible Preferred Stock.</FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">8-K</FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">000-50633</FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">June 20, 2012</FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">4.1</FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="top"></TD></TR> <TR STYLE="font-size:1pt"> <TD HEIGHT="8"></TD> <TD HEIGHT="8" COLSPAN="2"></TD> <TD HEIGHT="8" COLSPAN="2"></TD> <TD HEIGHT="8" COLSPAN="2"></TD> <TD HEIGHT="8" COLSPAN="2"></TD> <TD HEIGHT="8" COLSPAN="2"></TD> <TD HEIGHT="8" COLSPAN="2"></TD></TR> <TR> <TD VALIGN="top" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2"> 4.1</FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Specimen Common Stock Certificate.</FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">10-Q</FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">000-50633</FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">May 9, 2007</FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">4.1</FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="top"></TD></TR> <TR STYLE="font-size:1pt"> <TD HEIGHT="8"></TD> <TD HEIGHT="8" COLSPAN="2"></TD> <TD HEIGHT="8" COLSPAN="2"></TD> <TD HEIGHT="8" COLSPAN="2"></TD> <TD HEIGHT="8" COLSPAN="2"></TD> <TD HEIGHT="8" COLSPAN="2"></TD> <TD HEIGHT="8" COLSPAN="2"></TD></TR> <TR> <TD VALIGN="top" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2"> 4.2</FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Registration Rights Agreement, dated as of December 29, 2006, by and between the Company and Amgen Inc.</FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">8-K</FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">000-50633</FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">January 3, 2007</FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">10.7</FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="top"></TD></TR> <TR STYLE="font-size:1pt"> <TD HEIGHT="8"></TD> <TD HEIGHT="8" COLSPAN="2"></TD> <TD HEIGHT="8" COLSPAN="2"></TD> <TD HEIGHT="8" COLSPAN="2"></TD> <TD HEIGHT="8" COLSPAN="2"></TD> <TD HEIGHT="8" COLSPAN="2"></TD> <TD HEIGHT="8" COLSPAN="2"></TD></TR> <TR> <TD VALIGN="top" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2"> 4.3</FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Form of Warrant to Purchase Common Stock of Cytokinetics, Inc.</FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">8-K</FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">000-50633</FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">April 18, 2011</FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">10.68</FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="top"></TD></TR> <TR STYLE="font-size:1pt"> <TD HEIGHT="8"></TD> <TD HEIGHT="8" COLSPAN="2"></TD> <TD HEIGHT="8" COLSPAN="2"></TD> <TD HEIGHT="8" COLSPAN="2"></TD> <TD HEIGHT="8" COLSPAN="2"></TD> <TD HEIGHT="8" COLSPAN="2"></TD> <TD HEIGHT="8" COLSPAN="2"></TD></TR> <TR> <TD VALIGN="top" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2"> 4.4</FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Form of Common Stock Warrant Agreement</FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">S-3</FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">333-178189</FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">November 25, 2011</FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">4.4</FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="top"></TD></TR> <TR STYLE="font-size:1pt"> <TD HEIGHT="8"></TD> <TD HEIGHT="8" COLSPAN="2"></TD> <TD HEIGHT="8" COLSPAN="2"></TD> <TD HEIGHT="8" COLSPAN="2"></TD> <TD HEIGHT="8" COLSPAN="2"></TD> <TD HEIGHT="8" COLSPAN="2"></TD> <TD HEIGHT="8" COLSPAN="2"></TD></TR> <TR> <TD VALIGN="top" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2"> 4.5</FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Form of Preferred Stock Warrant Agreement</FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">S-3</FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">333-178189</FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">November 25, 2011</FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">4.5</FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="top"></TD></TR> <TR STYLE="font-size:1pt"> <TD HEIGHT="8"></TD> <TD HEIGHT="8" COLSPAN="2"></TD> <TD HEIGHT="8" COLSPAN="2"></TD> <TD HEIGHT="8" COLSPAN="2"></TD> <TD HEIGHT="8" COLSPAN="2"></TD> <TD HEIGHT="8" COLSPAN="2"></TD> <TD HEIGHT="8" COLSPAN="2"></TD></TR> <TR> <TD VALIGN="top" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2"> 4.6</FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Form of Warrant</FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">10-Q</FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">000-50633</FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">August 6, 2012</FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">4.6</FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="top"></TD></TR> <TR STYLE="font-size:1pt"> <TD HEIGHT="8"></TD> <TD HEIGHT="8" COLSPAN="2"></TD> <TD HEIGHT="8" COLSPAN="2"></TD> <TD HEIGHT="8" COLSPAN="2"></TD> <TD HEIGHT="8" COLSPAN="2"></TD> <TD HEIGHT="8" COLSPAN="2"></TD> <TD HEIGHT="8" COLSPAN="2"></TD></TR> <TR> <TD VALIGN="top" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2"> 4.7</FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Form of Common Stock Warrant and Warrant Certificate</FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">S-3</FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">333-192125</FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">November 6, 2013</FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">4.4</FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="top"></TD></TR> <TR STYLE="font-size:1pt"> <TD HEIGHT="8"></TD> <TD HEIGHT="8" COLSPAN="2"></TD> <TD HEIGHT="8" COLSPAN="2"></TD> <TD HEIGHT="8" COLSPAN="2"></TD> <TD HEIGHT="8" COLSPAN="2"></TD> <TD HEIGHT="8" COLSPAN="2"></TD> <TD HEIGHT="8" COLSPAN="2"></TD></TR> <TR> <TD VALIGN="top" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2"> 4.8</FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Form of Preferred Stock Warrant and Warrant Certificate</FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">S-3</FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">333-192125</FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">November 6, 2013</FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">4.5</FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="top"></TD></TR> <TR STYLE="font-size:1pt"> <TD HEIGHT="8"></TD> <TD HEIGHT="8" COLSPAN="2"></TD> <TD HEIGHT="8" COLSPAN="2"></TD> <TD HEIGHT="8" COLSPAN="2"></TD> <TD HEIGHT="8" COLSPAN="2"></TD> <TD HEIGHT="8" COLSPAN="2"></TD> <TD HEIGHT="8" COLSPAN="2"></TD></TR> <TR> <TD VALIGN="top" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2">10.1</FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">1997 Stock Option/Stock Issuance Plan</FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">S-1</FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">333-112261</FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">January 27, 2004</FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">10.2</FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="top"></TD></TR> <TR STYLE="font-size:1pt"> <TD HEIGHT="8"></TD> <TD HEIGHT="8" COLSPAN="2"></TD> <TD HEIGHT="8" COLSPAN="2"></TD> <TD HEIGHT="8" COLSPAN="2"></TD> <TD HEIGHT="8" COLSPAN="2"></TD> <TD HEIGHT="8" COLSPAN="2"></TD> <TD HEIGHT="8" COLSPAN="2"></TD></TR> <TR> <TD VALIGN="top" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2">10.2</FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">2004 Equity Incentive Plan, as amended</FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">10-Q</FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">000-50633</FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">August 7, 2013</FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">10.2</FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="top"></TD></TR> <TR STYLE="font-size:1pt"> <TD HEIGHT="8"></TD> <TD HEIGHT="8" COLSPAN="2"></TD> <TD HEIGHT="8" COLSPAN="2"></TD> <TD HEIGHT="8" COLSPAN="2"></TD> <TD HEIGHT="8" COLSPAN="2"></TD> <TD HEIGHT="8" COLSPAN="2"></TD> <TD HEIGHT="8" COLSPAN="2"></TD></TR> <TR> <TD VALIGN="top" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2">10.3</FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">2004 Employee Stock Purchase Plan</FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">10-Q</FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">000-50633</FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">August 7, 2013</FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">10.3</FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="top"></TD></TR></TABLE> <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1"> </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">128 </FONT></P> <p Style='page-break-before:always'> <HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER"> <h5 align="left"><a href="#toc">Table of Contents</a></h5> <TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center"> <TR> <TD></TD> <TD VALIGN="bottom" WIDTH="6%"></TD> <TD WIDTH="37%"></TD> <TD VALIGN="bottom" WIDTH="4%"></TD> <TD></TD> <TD VALIGN="bottom" WIDTH="4%"></TD> <TD></TD> <TD VALIGN="bottom" WIDTH="4%"></TD> <TD></TD> <TD VALIGN="bottom" WIDTH="4%"></TD> <TD></TD> <TD VALIGN="bottom" WIDTH="4%"></TD> <TD></TD></TR> <TR> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom" COLSPAN="7" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Incorporated by Reference</B></FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD></TR> <TR> <TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Exhibit</B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:1px;border-bottom:1px solid #000000;width:25pt" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>No.</B></FONT></P></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom" ALIGN="center"> <P STYLE="border-bottom:1px solid #000000;width:28pt" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Exhibits</B></FONT></P></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Form</B></FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>File No.</B></FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Filing Date</B></FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Exh.<BR>No.</B></FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Filed<BR>Herewith</B></FONT></TD></TR> <TR STYLE="font-size:1pt"> <TD HEIGHT="8"></TD> <TD HEIGHT="8" COLSPAN="2"></TD> <TD HEIGHT="8" COLSPAN="2"></TD> <TD HEIGHT="8" COLSPAN="2"></TD> <TD HEIGHT="8" COLSPAN="2"></TD> <TD HEIGHT="8" COLSPAN="2"></TD> <TD HEIGHT="8" COLSPAN="2"></TD></TR> <TR> <TD VALIGN="top" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2">10.4</FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Build-to-Suit Lease, dated May 27, 1997, by and between Britannia Pointe Grand Limited Partnership and Metaxen, LLC.</FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="top" NOWRAP ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">S-1</FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="top" NOWRAP ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">333-112261</FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="top" NOWRAP ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">January 27, 2004</FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">10.5</FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="top"></TD></TR> <TR STYLE="font-size:1pt"> <TD HEIGHT="8"></TD> <TD HEIGHT="8" COLSPAN="2"></TD> <TD HEIGHT="8" COLSPAN="2"></TD> <TD HEIGHT="8" COLSPAN="2"></TD> <TD HEIGHT="8" COLSPAN="2"></TD> <TD HEIGHT="8" COLSPAN="2"></TD> <TD HEIGHT="8" COLSPAN="2"></TD></TR> <TR> <TD VALIGN="top" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2">10.5</FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">First Amendment to Lease, dated April 13, 1998, by and between Britannia Pointe Grand Limited Partnership and Metaxen, LLC.</FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="top" NOWRAP ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">S-1</FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="top" NOWRAP ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">333-112261</FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="top" NOWRAP ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">January 27, 2004</FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">10.6</FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="top"></TD></TR> <TR STYLE="font-size:1pt"> <TD HEIGHT="8"></TD> <TD HEIGHT="8" COLSPAN="2"></TD> <TD HEIGHT="8" COLSPAN="2"></TD> <TD HEIGHT="8" COLSPAN="2"></TD> <TD HEIGHT="8" COLSPAN="2"></TD> <TD HEIGHT="8" COLSPAN="2"></TD> <TD HEIGHT="8" COLSPAN="2"></TD></TR> <TR> <TD VALIGN="top" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2">10.6</FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Sublease Agreement, dated May 1, 1998, by and between the Company and Metaxen, LLC</FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="top" NOWRAP ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">S-1</FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="top" NOWRAP ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">333-112261</FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="top" NOWRAP ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">January 27, 2004</FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">10.7</FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="top"></TD></TR> <TR STYLE="font-size:1pt"> <TD HEIGHT="8"></TD> <TD HEIGHT="8" COLSPAN="2"></TD> <TD HEIGHT="8" COLSPAN="2"></TD> <TD HEIGHT="8" COLSPAN="2"></TD> <TD HEIGHT="8" COLSPAN="2"></TD> <TD HEIGHT="8" COLSPAN="2"></TD> <TD HEIGHT="8" COLSPAN="2"></TD></TR> <TR> <TD VALIGN="top" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2">10.7</FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Sublease Agreement, dated March 1, 1999, by and between Metaxen, LLC and Exelixis Pharmaceuticals, Inc.</FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="top" NOWRAP ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">S-1</FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="top" NOWRAP ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">333-112261</FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="top" NOWRAP ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">January 27, 2004</FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">10.8</FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="top"></TD></TR> <TR STYLE="font-size:1pt"> <TD HEIGHT="8"></TD> <TD HEIGHT="8" COLSPAN="2"></TD> <TD HEIGHT="8" COLSPAN="2"></TD> <TD HEIGHT="8" COLSPAN="2"></TD> <TD HEIGHT="8" COLSPAN="2"></TD> <TD HEIGHT="8" COLSPAN="2"></TD> <TD HEIGHT="8" COLSPAN="2"></TD></TR> <TR> <TD VALIGN="top" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2">10.8</FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Assignment and Assumption Agreement and Consent, dated July 11, 1999, by and among Exelixis Pharmaceuticals, Metaxen, LLC, Xenova Group PLC and Britannia Pointe Grande Limited Partnership</FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="top" NOWRAP ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">S-1</FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="top" NOWRAP ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">333-112261</FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="top" NOWRAP ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">January 27, 2004</FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">10.9</FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="top"></TD></TR> <TR STYLE="font-size:1pt"> <TD HEIGHT="8"></TD> <TD HEIGHT="8" COLSPAN="2"></TD> <TD HEIGHT="8" COLSPAN="2"></TD> <TD HEIGHT="8" COLSPAN="2"></TD> <TD HEIGHT="8" COLSPAN="2"></TD> <TD HEIGHT="8" COLSPAN="2"></TD> <TD HEIGHT="8" COLSPAN="2"></TD></TR> <TR> <TD VALIGN="top" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2">10.9</FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Second Amendment to Lease, dated July 11, 1999, by and between Britannia Pointe Grand Limited Partnership and Exelixis Pharmaceuticals, Inc.</FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="top" NOWRAP ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">S-1</FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="top" NOWRAP ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">333-112261</FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="top" NOWRAP ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">January 27, 2004</FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">10.10</FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="top"></TD></TR> <TR STYLE="font-size:1pt"> <TD HEIGHT="8"></TD> <TD HEIGHT="8" COLSPAN="2"></TD> <TD HEIGHT="8" COLSPAN="2"></TD> <TD HEIGHT="8" COLSPAN="2"></TD> <TD HEIGHT="8" COLSPAN="2"></TD> <TD HEIGHT="8" COLSPAN="2"></TD> <TD HEIGHT="8" COLSPAN="2"></TD></TR> <TR> <TD VALIGN="top" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2">10.10</FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">First Amendment to Sublease Agreement, dated July 20, 1999, by and between the Company and Metaxen.</FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="top" NOWRAP ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">S-1</FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="top" NOWRAP ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">333-112261</FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="top" NOWRAP ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">January 27, 2004</FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">10.11</FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="top"></TD></TR> <TR STYLE="font-size:1pt"> <TD HEIGHT="8"></TD> <TD HEIGHT="8" COLSPAN="2"></TD> <TD HEIGHT="8" COLSPAN="2"></TD> <TD HEIGHT="8" COLSPAN="2"></TD> <TD HEIGHT="8" COLSPAN="2"></TD> <TD HEIGHT="8" COLSPAN="2"></TD> <TD HEIGHT="8" COLSPAN="2"></TD></TR> <TR> <TD VALIGN="top" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2">10.11</FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Agreement and Consent, dated July 20, 1999, by and among Exelixis Pharmaceuticals, Inc., the Company and Britannia Pointe Grand Limited Partnership</FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="top" NOWRAP ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">S-1</FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="top" NOWRAP ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">333-112261</FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="top" NOWRAP ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">January 27, 2004</FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">10.12</FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="top"></TD></TR> <TR STYLE="font-size:1pt"> <TD HEIGHT="8"></TD> <TD HEIGHT="8" COLSPAN="2"></TD> <TD HEIGHT="8" COLSPAN="2"></TD> <TD HEIGHT="8" COLSPAN="2"></TD> <TD HEIGHT="8" COLSPAN="2"></TD> <TD HEIGHT="8" COLSPAN="2"></TD> <TD HEIGHT="8" COLSPAN="2"></TD></TR> <TR> <TD VALIGN="top" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2">10.12</FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Amendment to Agreement and Consent, dated July 31, 2000, by and between the Company, Exelixis, Inc., and Britannia Pointe Grande Limited Partnership</FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="top" NOWRAP ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">S-1</FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="top" NOWRAP ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">333-112261</FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="top" NOWRAP ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">January 27, 2004</FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">10.13</FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="top"></TD></TR> <TR STYLE="font-size:1pt"> <TD HEIGHT="8"></TD> <TD HEIGHT="8" COLSPAN="2"></TD> <TD HEIGHT="8" COLSPAN="2"></TD> <TD HEIGHT="8" COLSPAN="2"></TD> <TD HEIGHT="8" COLSPAN="2"></TD> <TD HEIGHT="8" COLSPAN="2"></TD> <TD HEIGHT="8" COLSPAN="2"></TD></TR> <TR> <TD VALIGN="top" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2">10.13</FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Assignment and Assumption of Lease, dated September 28, 2000, by and between the Company and Exelixis, Inc.</FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="top" NOWRAP ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">S-1</FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="top" NOWRAP ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">333-112261</FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="top" NOWRAP ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">January 27, 2004</FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">10.14</FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="top"></TD></TR></TABLE> <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1"> </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">129 </FONT></P> <p Style='page-break-before:always'> <HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER"> <h5 align="left"><a href="#toc">Table of Contents</a></h5> <TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center"> <TR> <TD></TD> <TD VALIGN="bottom" WIDTH="6%"></TD> <TD WIDTH="37%"></TD> <TD VALIGN="bottom" WIDTH="4%"></TD> <TD></TD> <TD VALIGN="bottom" WIDTH="4%"></TD> <TD></TD> <TD VALIGN="bottom" WIDTH="4%"></TD> <TD></TD> <TD VALIGN="bottom" WIDTH="4%"></TD> <TD></TD> <TD VALIGN="bottom" WIDTH="4%"></TD> <TD></TD></TR> <TR> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom" COLSPAN="7" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Incorporated by Reference</B></FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD></TR> <TR> <TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Exhibit</B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:1px;border-bottom:1px solid #000000;width:25pt" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>No.</B></FONT></P></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom" ALIGN="center"> <P STYLE="border-bottom:1px solid #000000;width:28pt" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Exhibits</B></FONT></P></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Form</B></FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>File No.</B></FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Filing Date</B></FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Exh.<BR>No.</B></FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Filed<BR>Herewith</B></FONT></TD></TR> <TR STYLE="font-size:1pt"> <TD HEIGHT="8"></TD> <TD HEIGHT="8" COLSPAN="2"></TD> <TD HEIGHT="8" COLSPAN="2"></TD> <TD HEIGHT="8" COLSPAN="2"></TD> <TD HEIGHT="8" COLSPAN="2"></TD> <TD HEIGHT="8" COLSPAN="2"></TD> <TD HEIGHT="8" COLSPAN="2"></TD></TR> <TR> <TD VALIGN="top" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2"> 10.14</FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Sublease Agreement, dated September 28, 2000, by and between the Company and Exelixis, Inc.</FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="top" NOWRAP ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">S-1</FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="top" NOWRAP ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">333-112261</FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="top" NOWRAP ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">January 27, 2004</FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">10.15</FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="top"></TD></TR> <TR STYLE="font-size:1pt"> <TD HEIGHT="8"></TD> <TD HEIGHT="8" COLSPAN="2"></TD> <TD HEIGHT="8" COLSPAN="2"></TD> <TD HEIGHT="8" COLSPAN="2"></TD> <TD HEIGHT="8" COLSPAN="2"></TD> <TD HEIGHT="8" COLSPAN="2"></TD> <TD HEIGHT="8" COLSPAN="2"></TD></TR> <TR> <TD VALIGN="top" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2">*10.15</FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Collaboration and Option Agreement, dated as of December 29, 2006, by and between the Company and Amgen Inc.</FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="top" NOWRAP ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">10-K</FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="top" NOWRAP ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">000-50633</FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="top" NOWRAP ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">March 12, 2007</FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">10.63</FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="top"></TD></TR> <TR STYLE="font-size:1pt"> <TD HEIGHT="8"></TD> <TD HEIGHT="8" COLSPAN="2"></TD> <TD HEIGHT="8" COLSPAN="2"></TD> <TD HEIGHT="8" COLSPAN="2"></TD> <TD HEIGHT="8" COLSPAN="2"></TD> <TD HEIGHT="8" COLSPAN="2"></TD> <TD HEIGHT="8" COLSPAN="2"></TD></TR> <TR> <TD VALIGN="top" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2"> 10.16</FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Common Stock Purchase Agreement, dated October 15, 2007, by and between the Company and Kingsbridge Capital Limited.</FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="top" NOWRAP ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">8-K</FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="top" NOWRAP ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">000-50633</FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="top" NOWRAP ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">October 15, 2007</FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">10.66</FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="top"></TD></TR> <TR STYLE="font-size:1pt"> <TD HEIGHT="8"></TD> <TD HEIGHT="8" COLSPAN="2"></TD> <TD HEIGHT="8" COLSPAN="2"></TD> <TD HEIGHT="8" COLSPAN="2"></TD> <TD HEIGHT="8" COLSPAN="2"></TD> <TD HEIGHT="8" COLSPAN="2"></TD> <TD HEIGHT="8" COLSPAN="2"></TD></TR> <TR> <TD VALIGN="top" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2"> 10.17</FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Form of Indemnification Agreement between the Company and each of its directors and executive officers.</FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="top" NOWRAP ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">10-Q</FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="top" NOWRAP ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">000-50633</FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="top" NOWRAP ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">August 5, 2008</FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">10.1</FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="top"></TD></TR> <TR STYLE="font-size:1pt"> <TD HEIGHT="8"></TD> <TD HEIGHT="8" COLSPAN="2"></TD> <TD HEIGHT="8" COLSPAN="2"></TD> <TD HEIGHT="8" COLSPAN="2"></TD> <TD HEIGHT="8" COLSPAN="2"></TD> <TD HEIGHT="8" COLSPAN="2"></TD> <TD HEIGHT="8" COLSPAN="2"></TD></TR> <TR> <TD VALIGN="top" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2">*10.18</FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Scientific Advisory Board Consulting Agreement, dated April 1, 2008, by and between the Company and James. H. Sabry.</FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="top" NOWRAP ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">8-K</FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="top" NOWRAP ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">000-50633</FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="top" NOWRAP ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">April 2, 2008</FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">10.66</FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="top"></TD></TR> <TR STYLE="font-size:1pt"> <TD HEIGHT="8"></TD> <TD HEIGHT="8" COLSPAN="2"></TD> <TD HEIGHT="8" COLSPAN="2"></TD> <TD HEIGHT="8" COLSPAN="2"></TD> <TD HEIGHT="8" COLSPAN="2"></TD> <TD HEIGHT="8" COLSPAN="2"></TD> <TD HEIGHT="8" COLSPAN="2"></TD></TR> <TR> <TD VALIGN="top" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2"> 10.19</FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Amended and Restated Executive Employment Agreement, dated May 21, 2007, by and between the Company and Robert Blum</FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="top" NOWRAP ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">10-Q</FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="top" NOWRAP ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">000-50633</FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="top" NOWRAP ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">August 5, 2008</FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">10.69</FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="top"></TD></TR> <TR STYLE="font-size:1pt"> <TD HEIGHT="8"></TD> <TD HEIGHT="8" COLSPAN="2"></TD> <TD HEIGHT="8" COLSPAN="2"></TD> <TD HEIGHT="8" COLSPAN="2"></TD> <TD HEIGHT="8" COLSPAN="2"></TD> <TD HEIGHT="8" COLSPAN="2"></TD> <TD HEIGHT="8" COLSPAN="2"></TD></TR> <TR> <TD VALIGN="top" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2"> 10.20</FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Form of Executive Employment Agreement between the Company and its executive officers.</FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="top" NOWRAP ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">10-Q</FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="top" NOWRAP ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">000-50633</FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="top" NOWRAP ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">August 5, 2008</FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">10.68</FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="top"></TD></TR> <TR STYLE="font-size:1pt"> <TD HEIGHT="8"></TD> <TD HEIGHT="8" COLSPAN="2"></TD> <TD HEIGHT="8" COLSPAN="2"></TD> <TD HEIGHT="8" COLSPAN="2"></TD> <TD HEIGHT="8" COLSPAN="2"></TD> <TD HEIGHT="8" COLSPAN="2"></TD> <TD HEIGHT="8" COLSPAN="2"></TD></TR> <TR> <TD VALIGN="top" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2">*10.21</FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Amendment No. 1, dated June 17, 2008, to the Collaboration and Option Agreement by and between the Company and Amgen Inc.</FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="top" NOWRAP ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">10-K</FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="top" NOWRAP ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">000-50633</FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="top" NOWRAP ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">March 12, 2009</FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">10.62</FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="top"></TD></TR> <TR STYLE="font-size:1pt"> <TD HEIGHT="8"></TD> <TD HEIGHT="8" COLSPAN="2"></TD> <TD HEIGHT="8" COLSPAN="2"></TD> <TD HEIGHT="8" COLSPAN="2"></TD> <TD HEIGHT="8" COLSPAN="2"></TD> <TD HEIGHT="8" COLSPAN="2"></TD> <TD HEIGHT="8" COLSPAN="2"></TD></TR> <TR> <TD VALIGN="top" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2">*10.22</FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Amendment No. 2, dated September 30, 2008, to the Collaboration and Option Agreement by and between the Company and Amgen Inc.</FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="top" NOWRAP ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">10-K</FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="top" NOWRAP ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">000-50633</FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="top" NOWRAP ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">March 12, 2009</FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">10.63</FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="top"></TD></TR> <TR STYLE="font-size:1pt"> <TD HEIGHT="8"></TD> <TD HEIGHT="8" COLSPAN="2"></TD> <TD HEIGHT="8" COLSPAN="2"></TD> <TD HEIGHT="8" COLSPAN="2"></TD> <TD HEIGHT="8" COLSPAN="2"></TD> <TD HEIGHT="8" COLSPAN="2"></TD> <TD HEIGHT="8" COLSPAN="2"></TD></TR> <TR> <TD VALIGN="top" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2">*10.23</FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Amendment No. 3, dated October 31, 2008, to the Collaboration and Option Agreement by and between the Company and Amgen Inc.</FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="top" NOWRAP ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">10-K</FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="top" NOWRAP ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">000-50633</FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="top" NOWRAP ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">March 12, 2009</FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">10.65</FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="top"></TD></TR></TABLE> <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1"> </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">130 </FONT></P> <p Style='page-break-before:always'> <HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER"> <h5 align="left"><a href="#toc">Table of Contents</a></h5> <TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center"> <TR> <TD></TD> <TD VALIGN="bottom" WIDTH="6%"></TD> <TD WIDTH="38%"></TD> <TD VALIGN="bottom" WIDTH="4%"></TD> <TD></TD> <TD VALIGN="bottom" WIDTH="4%"></TD> <TD></TD> <TD VALIGN="bottom" WIDTH="4%"></TD> <TD></TD> <TD VALIGN="bottom" WIDTH="4%"></TD> <TD></TD> <TD VALIGN="bottom" WIDTH="4%"></TD> <TD></TD></TR> <TR> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom" COLSPAN="7" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Incorporated by Reference</B></FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD></TR> <TR> <TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Exhibit</B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:1px;border-bottom:1px solid #000000;width:25pt" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>No.</B></FONT></P></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom" ALIGN="center"> <P STYLE="border-bottom:1px solid #000000;width:28pt" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Exhibits</B></FONT></P></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Form</B></FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>File No.</B></FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Filing Date</B></FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Exh.<BR>No.</B></FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Filed<BR>Herewith</B></FONT></TD></TR> <TR STYLE="font-size:1pt"> <TD HEIGHT="8"></TD> <TD HEIGHT="8" COLSPAN="2"></TD> <TD HEIGHT="8" COLSPAN="2"></TD> <TD HEIGHT="8" COLSPAN="2"></TD> <TD HEIGHT="8" COLSPAN="2"></TD> <TD HEIGHT="8" COLSPAN="2"></TD> <TD HEIGHT="8" COLSPAN="2"></TD></TR> <TR> <TD VALIGN="top" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2">*10.24</FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Amendment No. 4, dated February 20, 2009, to the Collaboration and Option Agreement by and between the Company and Amgen Inc.</FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="top" NOWRAP ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">10-K</FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="top" NOWRAP ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">000-50633</FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="top" NOWRAP ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">March 12, 2009</FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">10.67</FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="top"></TD></TR> <TR STYLE="font-size:1pt"> <TD HEIGHT="8"></TD> <TD HEIGHT="8" COLSPAN="2"></TD> <TD HEIGHT="8" COLSPAN="2"></TD> <TD HEIGHT="8" COLSPAN="2"></TD> <TD HEIGHT="8" COLSPAN="2"></TD> <TD HEIGHT="8" COLSPAN="2"></TD> <TD HEIGHT="8" COLSPAN="2"></TD></TR> <TR> <TD VALIGN="top" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2"> 10.25</FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Form of Amendment No. 1 to Amended and Restated Executive Employment Agreements.</FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="top" NOWRAP ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">10-K</FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="top" NOWRAP ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">000-50633</FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="top" NOWRAP ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">March 12, 2009</FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">10.68</FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="top"></TD></TR> <TR STYLE="font-size:1pt"> <TD HEIGHT="8"></TD> <TD HEIGHT="8" COLSPAN="2"></TD> <TD HEIGHT="8" COLSPAN="2"></TD> <TD HEIGHT="8" COLSPAN="2"></TD> <TD HEIGHT="8" COLSPAN="2"></TD> <TD HEIGHT="8" COLSPAN="2"></TD> <TD HEIGHT="8" COLSPAN="2"></TD></TR> <TR> <TD VALIGN="top" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2"> 10.26</FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Third Amendment to Lease, dated December 10, 2010, by and between the Company and Britannia Pointe Grand Limited Partnership.</FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="top" NOWRAP ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">10-K</FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="top" NOWRAP ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">000-50633</FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="top" NOWRAP ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">March 11, 2011</FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">10.65</FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="top"></TD></TR> <TR STYLE="font-size:1pt"> <TD HEIGHT="8"></TD> <TD HEIGHT="8" COLSPAN="2"></TD> <TD HEIGHT="8" COLSPAN="2"></TD> <TD HEIGHT="8" COLSPAN="2"></TD> <TD HEIGHT="8" COLSPAN="2"></TD> <TD HEIGHT="8" COLSPAN="2"></TD> <TD HEIGHT="8" COLSPAN="2"></TD></TR> <TR> <TD VALIGN="top" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2">*10.27</FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Amendment No. 5, dated November 1, 2011, to the Collaboration and Option Agreement by and between the Company and Amgen Inc.</FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="top" NOWRAP ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">10-K</FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="top" NOWRAP ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">000-50633</FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="top" NOWRAP ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">March 11, 2011</FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">10.66</FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="top"></TD></TR> <TR STYLE="font-size:1pt"> <TD HEIGHT="8"></TD> <TD HEIGHT="8" COLSPAN="2"></TD> <TD HEIGHT="8" COLSPAN="2"></TD> <TD HEIGHT="8" COLSPAN="2"></TD> <TD HEIGHT="8" COLSPAN="2"></TD> <TD HEIGHT="8" COLSPAN="2"></TD> <TD HEIGHT="8" COLSPAN="2"></TD></TR> <TR> <TD VALIGN="top" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2"> 10.28</FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Securities Purchase Agreement, dated April 18, 2011, between the Company and Deerfield Private Design Fund II, L.P., Deerfield Private Design International II, L.P., Deerfield Special Situations Fund, L.P., and Deerfield Special Situations Fund International Limited.</FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="top" NOWRAP ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">8-K</FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="top" NOWRAP ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">000-50633</FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="top" NOWRAP ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">April 18, 2011</FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">10.67</FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="top"></TD></TR> <TR STYLE="font-size:1pt"> <TD HEIGHT="8"></TD> <TD HEIGHT="8" COLSPAN="2"></TD> <TD HEIGHT="8" COLSPAN="2"></TD> <TD HEIGHT="8" COLSPAN="2"></TD> <TD HEIGHT="8" COLSPAN="2"></TD> <TD HEIGHT="8" COLSPAN="2"></TD> <TD HEIGHT="8" COLSPAN="2"></TD></TR> <TR> <TD VALIGN="top" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2"> 10.29</FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">At the Market Issuance Sales Agreement, dated June 10, 2011, between the Company and McNicoll, Lewis & Vlak LLC.</FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="top" NOWRAP ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">8-K</FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="top" NOWRAP ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">000-50633</FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="top" NOWRAP ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">June 13, 2011</FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">10.68</FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="top"></TD></TR> <TR STYLE="font-size:1pt"> <TD HEIGHT="8"></TD> <TD HEIGHT="8" COLSPAN="2"></TD> <TD HEIGHT="8" COLSPAN="2"></TD> <TD HEIGHT="8" COLSPAN="2"></TD> <TD HEIGHT="8" COLSPAN="2"></TD> <TD HEIGHT="8" COLSPAN="2"></TD> <TD HEIGHT="8" COLSPAN="2"></TD></TR> <TR> <TD VALIGN="top" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2">*10.30</FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Consulting Agreement between the Company and David J. Morgans, dated November 1, 2011.</FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="top" NOWRAP ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">10-K</FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="top" NOWRAP ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">000-50633</FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="top" NOWRAP ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">March 13, 2012</FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">10.42</FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="top"></TD></TR> <TR STYLE="font-size:1pt"> <TD HEIGHT="8"></TD> <TD HEIGHT="8" COLSPAN="2"></TD> <TD HEIGHT="8" COLSPAN="2"></TD> <TD HEIGHT="8" COLSPAN="2"></TD> <TD HEIGHT="8" COLSPAN="2"></TD> <TD HEIGHT="8" COLSPAN="2"></TD> <TD HEIGHT="8" COLSPAN="2"></TD></TR> <TR> <TD VALIGN="top" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2">*10.31</FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Amendment No. 1, dated May 1, 2012, to Consulting Agreement between the Company and David J. Morgans, dated November 1, 2011.</FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="top" NOWRAP ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">10-Q</FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="top" NOWRAP ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">000-50633</FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="top" NOWRAP ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">May 4, 2012</FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">10.43</FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="top"></TD></TR> <TR STYLE="font-size:1pt"> <TD HEIGHT="8"></TD> <TD HEIGHT="8" COLSPAN="2"></TD> <TD HEIGHT="8" COLSPAN="2"></TD> <TD HEIGHT="8" COLSPAN="2"></TD> <TD HEIGHT="8" COLSPAN="2"></TD> <TD HEIGHT="8" COLSPAN="2"></TD> <TD HEIGHT="8" COLSPAN="2"></TD></TR> <TR> <TD VALIGN="top" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2">*10.32</FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Amendment No. 2, dated October 30, 2012 to Consulting Agreement between the Company and David J. Morgans, dated November 1, 2011.</FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="top" NOWRAP ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">10-K</FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="top" NOWRAP ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">000-50633</FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="top" NOWRAP ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">March 15, 2013</FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">10.44</FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="top"></TD></TR> <TR STYLE="font-size:1pt"> <TD HEIGHT="8"></TD> <TD HEIGHT="8" COLSPAN="2"></TD> <TD HEIGHT="8" COLSPAN="2"></TD> <TD HEIGHT="8" COLSPAN="2"></TD> <TD HEIGHT="8" COLSPAN="2"></TD> <TD HEIGHT="8" COLSPAN="2"></TD> <TD HEIGHT="8" COLSPAN="2"></TD></TR> <TR> <TD VALIGN="top" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2"> 10.33</FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Compensation Information for the Company’s Named Executive Officers.</FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="top" NOWRAP ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">8-K</FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="top" NOWRAP ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">000-50633</FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="top" NOWRAP ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">March 2, 2015</FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">10.1</FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="top"></TD></TR></TABLE> <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1"> </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">131 </FONT></P> <p Style='page-break-before:always'> <HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER"> <h5 align="left"><a href="#toc">Table of Contents</a></h5> <TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center"> <TR> <TD></TD> <TD VALIGN="bottom" WIDTH="5%"></TD> <TD WIDTH="40%"></TD> <TD VALIGN="bottom" WIDTH="3%"></TD> <TD></TD> <TD VALIGN="bottom" WIDTH="3%"></TD> <TD></TD> <TD VALIGN="bottom" WIDTH="3%"></TD> <TD></TD> <TD VALIGN="bottom" WIDTH="3%"></TD> <TD></TD> <TD VALIGN="bottom" WIDTH="3%"></TD> <TD></TD></TR> <TR> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom" COLSPAN="7" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Incorporated by Reference</B></FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD></TR> <TR> <TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Exhibit</B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:1px;border-bottom:1px solid #000000;width:25pt" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>No.</B></FONT></P></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom" ALIGN="center"> <P STYLE="border-bottom:1px solid #000000;width:28pt" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Exhibits</B></FONT></P></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Form</B></FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>File No.</B></FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Filing Date</B></FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Exh.<BR>No.</B></FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Filed<BR>Herewith</B></FONT></TD></TR> <TR STYLE="font-size:1pt"> <TD HEIGHT="8"></TD> <TD HEIGHT="8" COLSPAN="2"></TD> <TD HEIGHT="8" COLSPAN="2"></TD> <TD HEIGHT="8" COLSPAN="2"></TD> <TD HEIGHT="8" COLSPAN="2"></TD> <TD HEIGHT="8" COLSPAN="2"></TD> <TD HEIGHT="8" COLSPAN="2"></TD></TR> <TR> <TD VALIGN="top" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2"> 10.34</FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Form of Option Agreement.</FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="top" NOWRAP ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">10-K</FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="top" NOWRAP ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">000-50633</FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="top" NOWRAP ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">March 15, 2013</FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">10.46</FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="top"></TD></TR> <TR STYLE="font-size:1pt"> <TD HEIGHT="8"></TD> <TD HEIGHT="8" COLSPAN="2"></TD> <TD HEIGHT="8" COLSPAN="2"></TD> <TD HEIGHT="8" COLSPAN="2"></TD> <TD HEIGHT="8" COLSPAN="2"></TD> <TD HEIGHT="8" COLSPAN="2"></TD> <TD HEIGHT="8" COLSPAN="2"></TD></TR> <TR> <TD VALIGN="top" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2"> 10.35</FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Form of Restricted Stock Unit Award Agreement.</FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="top" NOWRAP ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">10-K</FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="top" NOWRAP ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">000-50633</FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="top" NOWRAP ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">March 15, 2013</FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">10.47</FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="top"></TD></TR> <TR STYLE="font-size:1pt"> <TD HEIGHT="8"></TD> <TD HEIGHT="8" COLSPAN="2"></TD> <TD HEIGHT="8" COLSPAN="2"></TD> <TD HEIGHT="8" COLSPAN="2"></TD> <TD HEIGHT="8" COLSPAN="2"></TD> <TD HEIGHT="8" COLSPAN="2"></TD> <TD HEIGHT="8" COLSPAN="2"></TD></TR> <TR> <TD VALIGN="top" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2"> 10.36</FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Common Stock Purchase Agreement dated June 11, 2013, by and between the Company and Amgen, Inc.</FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="top" NOWRAP ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">8-K</FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="top" NOWRAP ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">000-50633</FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="top" NOWRAP ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">June 12, 2013</FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">10.48</FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="top"></TD></TR> <TR STYLE="font-size:1pt"> <TD HEIGHT="8"></TD> <TD HEIGHT="8" COLSPAN="2"></TD> <TD HEIGHT="8" COLSPAN="2"></TD> <TD HEIGHT="8" COLSPAN="2"></TD> <TD HEIGHT="8" COLSPAN="2"></TD> <TD HEIGHT="8" COLSPAN="2"></TD> <TD HEIGHT="8" COLSPAN="2"></TD></TR> <TR> <TD VALIGN="top" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2">*10.37</FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Amendment No. 6, dated June 11, 2013, to the Collaboration and Option Agreement by and between the Company and Amgen, Inc.</FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="top" NOWRAP ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">10-Q</FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="top" NOWRAP ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">000-50633</FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="top" NOWRAP ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">August 7, 2013</FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">10.46</FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="top"></TD></TR> <TR STYLE="font-size:1pt"> <TD HEIGHT="8"></TD> <TD HEIGHT="8" COLSPAN="2"></TD> <TD HEIGHT="8" COLSPAN="2"></TD> <TD HEIGHT="8" COLSPAN="2"></TD> <TD HEIGHT="8" COLSPAN="2"></TD> <TD HEIGHT="8" COLSPAN="2"></TD> <TD HEIGHT="8" COLSPAN="2"></TD></TR> <TR> <TD VALIGN="top" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2"> 10.38</FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Form of Executive Employment Agreement between the Company and its executive officers.</FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="top" NOWRAP ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">10-K</FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="top" NOWRAP ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">000-50633</FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="top" NOWRAP ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">March 7, 2014</FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">10.39</FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="top"></TD></TR> <TR STYLE="font-size:1pt"> <TD HEIGHT="8"></TD> <TD HEIGHT="8" COLSPAN="2"></TD> <TD HEIGHT="8" COLSPAN="2"></TD> <TD HEIGHT="8" COLSPAN="2"></TD> <TD HEIGHT="8" COLSPAN="2"></TD> <TD HEIGHT="8" COLSPAN="2"></TD> <TD HEIGHT="8" COLSPAN="2"></TD></TR> <TR> <TD VALIGN="top" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2"> 10.39</FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Common Stock Purchase Agreement by and between the Company and Astellas Pharma Inc. dated December 22, 2014.</FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="top" NOWRAP ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">8-K</FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="top" NOWRAP ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">000-50633</FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="top" NOWRAP ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">December 23, 2014</FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">10.46</FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="top"></TD></TR> <TR STYLE="font-size:1pt"> <TD HEIGHT="8"></TD> <TD HEIGHT="8" COLSPAN="2"></TD> <TD HEIGHT="8" COLSPAN="2"></TD> <TD HEIGHT="8" COLSPAN="2"></TD> <TD HEIGHT="8" COLSPAN="2"></TD> <TD HEIGHT="8" COLSPAN="2"></TD> <TD HEIGHT="8" COLSPAN="2"></TD></TR> <TR> <TD VALIGN="top" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2">*10.40</FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Amended and Restated License and Collaboration Agreement, dated December 22, 2014, by and between the Company and Astellas Pharma Inc.</FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="top"></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="top"></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="top"></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="top"></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">X</FONT></TD></TR> <TR STYLE="font-size:1pt"> <TD HEIGHT="8"></TD> <TD HEIGHT="8" COLSPAN="2"></TD> <TD HEIGHT="8" COLSPAN="2"></TD> <TD HEIGHT="8" COLSPAN="2"></TD> <TD HEIGHT="8" COLSPAN="2"></TD> <TD HEIGHT="8" COLSPAN="2"></TD> <TD HEIGHT="8" COLSPAN="2"></TD></TR> <TR> <TD VALIGN="top" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2"> 23.1</FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Consent of Independent registered public accounting firm.</FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="top"></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="top"></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="top"></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="top"></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">X</FONT></TD></TR> <TR STYLE="font-size:1pt"> <TD HEIGHT="8"></TD> <TD HEIGHT="8" COLSPAN="2"></TD> <TD HEIGHT="8" COLSPAN="2"></TD> <TD HEIGHT="8" COLSPAN="2"></TD> <TD HEIGHT="8" COLSPAN="2"></TD> <TD HEIGHT="8" COLSPAN="2"></TD> <TD HEIGHT="8" COLSPAN="2"></TD></TR> <TR> <TD VALIGN="top" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2"> 24.1</FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Power of Attorney (included in the signature page to this report).</FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="top"></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="top"></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="top"></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="top"></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="top"></TD></TR> <TR STYLE="font-size:1pt"> <TD HEIGHT="8"></TD> <TD HEIGHT="8" COLSPAN="2"></TD> <TD HEIGHT="8" COLSPAN="2"></TD> <TD HEIGHT="8" COLSPAN="2"></TD> <TD HEIGHT="8" COLSPAN="2"></TD> <TD HEIGHT="8" COLSPAN="2"></TD> <TD HEIGHT="8" COLSPAN="2"></TD></TR> <TR> <TD VALIGN="top" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2"> 31.1</FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Certification of Principal Executive Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.</FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="top"></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="top"></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="top"></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="top"></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">X</FONT></TD></TR> <TR STYLE="font-size:1pt"> <TD HEIGHT="8"></TD> <TD HEIGHT="8" COLSPAN="2"></TD> <TD HEIGHT="8" COLSPAN="2"></TD> <TD HEIGHT="8" COLSPAN="2"></TD> <TD HEIGHT="8" COLSPAN="2"></TD> <TD HEIGHT="8" COLSPAN="2"></TD> <TD HEIGHT="8" COLSPAN="2"></TD></TR> <TR> <TD VALIGN="top" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2"> 31.2</FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Certification of Principal Financial Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.</FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="top"></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="top"></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="top"></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="top"></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">X</FONT></TD></TR> <TR STYLE="font-size:1pt"> <TD HEIGHT="8"></TD> <TD HEIGHT="8" COLSPAN="2"></TD> <TD HEIGHT="8" COLSPAN="2"></TD> <TD HEIGHT="8" COLSPAN="2"></TD> <TD HEIGHT="8" COLSPAN="2"></TD> <TD HEIGHT="8" COLSPAN="2"></TD> <TD HEIGHT="8" COLSPAN="2"></TD></TR> <TR> <TD VALIGN="top" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2"> 32.1</FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Certifications of the Principal Executive Officer and the Principal Financial Officer pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 (18 U.S.C. Section 1350).</FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="top"></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="top"></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="top"></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="top"></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">X</FONT></TD></TR> <TR STYLE="font-size:1pt"> <TD HEIGHT="8"></TD> <TD HEIGHT="8" COLSPAN="2"></TD> <TD HEIGHT="8" COLSPAN="2"></TD> <TD HEIGHT="8" COLSPAN="2"></TD> <TD HEIGHT="8" COLSPAN="2"></TD> <TD HEIGHT="8" COLSPAN="2"></TD> <TD HEIGHT="8" COLSPAN="2"></TD></TR> <TR> <TD VALIGN="top" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2">101.INS</FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">XBRL Instance Document.</FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="top"></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="top"></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="top"></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="top"></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">X</FONT></TD></TR></TABLE> <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1"> </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">132 </FONT></P> <p Style='page-break-before:always'> <HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER"> <h5 align="left"><a href="#toc">Table of Contents</a></h5> <TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center"> <TR> <TD></TD> <TD VALIGN="bottom" WIDTH="9%"></TD> <TD WIDTH="41%"></TD> <TD VALIGN="bottom" WIDTH="7%"></TD> <TD></TD> <TD VALIGN="bottom" WIDTH="7%"></TD> <TD></TD> <TD VALIGN="bottom" WIDTH="7%"></TD> <TD></TD> <TD VALIGN="bottom" WIDTH="7%"></TD> <TD></TD> <TD VALIGN="bottom" WIDTH="7%"></TD> <TD></TD></TR> <TR> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom" COLSPAN="7" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Incorporated by Reference</B></FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD></TR> <TR> <TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Exhibit</B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:1px;border-bottom:1px solid #000000;width:25pt" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>No.</B></FONT></P></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom" ALIGN="center"> <P STYLE="border-bottom:1px solid #000000;width:28pt" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Exhibits</B></FONT></P></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Form</B></FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>File No.</B></FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Filing Date</B></FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Exh.<BR>No.</B></FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Filed<BR>Herewith</B></FONT></TD></TR> <TR STYLE="font-size:1pt"> <TD HEIGHT="8"></TD> <TD HEIGHT="8" COLSPAN="2"></TD> <TD HEIGHT="8" COLSPAN="2"></TD> <TD HEIGHT="8" COLSPAN="2"></TD> <TD HEIGHT="8" COLSPAN="2"></TD> <TD HEIGHT="8" COLSPAN="2"></TD> <TD HEIGHT="8" COLSPAN="2"></TD></TR> <TR> <TD VALIGN="top" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2">101.SCH</FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">XBRL Taxonomy Extension Schema Document.</FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="top"></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="top"></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="top"></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="top"></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">X</FONT></TD></TR> <TR STYLE="font-size:1pt"> <TD HEIGHT="8"></TD> <TD HEIGHT="8" COLSPAN="2"></TD> <TD HEIGHT="8" COLSPAN="2"></TD> <TD HEIGHT="8" COLSPAN="2"></TD> <TD HEIGHT="8" COLSPAN="2"></TD> <TD HEIGHT="8" COLSPAN="2"></TD> <TD HEIGHT="8" COLSPAN="2"></TD></TR> <TR> <TD VALIGN="top" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2">101.CAL</FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">XBRL Taxonomy Extension Calculation Linkbase Document.</FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="top"></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="top"></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="top"></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="top"></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">X</FONT></TD></TR> <TR STYLE="font-size:1pt"> <TD HEIGHT="8"></TD> <TD HEIGHT="8" COLSPAN="2"></TD> <TD HEIGHT="8" COLSPAN="2"></TD> <TD HEIGHT="8" COLSPAN="2"></TD> <TD HEIGHT="8" COLSPAN="2"></TD> <TD HEIGHT="8" COLSPAN="2"></TD> <TD HEIGHT="8" COLSPAN="2"></TD></TR> <TR> <TD VALIGN="top" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2">101.DEF</FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">XBRL Taxonomy Extension Definition Linkbase Document.</FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="top"></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="top"></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="top"></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="top"></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">X</FONT></TD></TR> <TR STYLE="font-size:1pt"> <TD HEIGHT="8"></TD> <TD HEIGHT="8" COLSPAN="2"></TD> <TD HEIGHT="8" COLSPAN="2"></TD> <TD HEIGHT="8" COLSPAN="2"></TD> <TD HEIGHT="8" COLSPAN="2"></TD> <TD HEIGHT="8" COLSPAN="2"></TD> <TD HEIGHT="8" COLSPAN="2"></TD></TR> <TR> <TD VALIGN="top" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2">101.LAB</FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">XBRL Taxonomy Extension Label Linkbase Document</FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="top"></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="top"></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="top"></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="top"></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">X</FONT></TD></TR> <TR STYLE="font-size:1pt"> <TD HEIGHT="8"></TD> <TD HEIGHT="8" COLSPAN="2"></TD> <TD HEIGHT="8" COLSPAN="2"></TD> <TD HEIGHT="8" COLSPAN="2"></TD> <TD HEIGHT="8" COLSPAN="2"></TD> <TD HEIGHT="8" COLSPAN="2"></TD> <TD HEIGHT="8" COLSPAN="2"></TD></TR> <TR> <TD VALIGN="top" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2">101.PRE</FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">XBRL Taxonomy Extension Presentation Linkbase Document.</FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="top"></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="top"></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="top"></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="top"></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">X</FONT></TD></TR> </TABLE> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px"> </P> <TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%"> <TR> <TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">*</FONT></TD> <TD ALIGN="left" VALIGN="top"> <P ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">Pursuant to a request for confidential treatment, portions of this Exhibit have been redacted from the publicly filed document and have been furnished separately to the Securities and Exchange Commission as required by Rule 406 under the Securities Act or Rule 24b-2 under the Exchange Act, as applicable. </FONT></P></TD></TR></TABLE> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px"> </P> <TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%"> <TR> <TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD ALIGN="left" VALIGN="top"> <P ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">(b) Exhibits </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:6px;margin-bottom:0px; margin-left:5%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">The exhibits listed under Item 15(a)(3) hereof are filed as part of this Form 10-K, other than Exhibit 32.1 which shall be deemed furnished. </FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px"> </P> <TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%"> <TR> <TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></TD> <TD ALIGN="left" VALIGN="top"> <P ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">(c) Financial Statement Schedules </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:6px;margin-bottom:0px; margin-left:5%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">None — All financial statement schedules are omitted because the information is inapplicable or presented in the notes to the financial statements. </FONT></P> <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1"> </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">133 </FONT></P> </BODY></HTML> </TEXT> </DOCUMENT> <DOCUMENT> <TYPE>EX-10.40 <SEQUENCE>2 <FILENAME>d828167dex1040.htm <DESCRIPTION>EX-10.40 <TEXT> <HTML><HEAD> <TITLE>EX-10.40</TITLE> </HEAD> <BODY BGCOLOR="WHITE"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 10.40 </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>EXECUTION COPY </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>CONFIDENTIAL </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt"> </P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%"> </P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Amended and Restated </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>License and Collaboration Agreement </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>by and between </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Cytokinetics, Inc. </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>and </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Astellas Pharma Inc. </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt"> </P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%"> </P></center> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt"> </P> <TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%"> <TR> <TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>[*] =</B></TD> <TD ALIGN="left" VALIGN="top"><B>Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. </B></TD></TR></TABLE> <p Style='page-break-before:always'> <HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>AMENDED AND RESTATED LICENSE AND COLLABORATION AGREEMENT </U></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This AMENDED AND RESTATED LICENSE AND COLLABORATION AGREEMENT (this “<B>Agreement</B>”) is made as of December 22, 2014 (the “<B>Amendment Effective Date</B>”), by and between <B>Cytokinetics, Inc.</B>, a corporation organized and existing under the laws of Delaware, having its principal place of business at 280 East Grand Avenue, South San Francisco, CA 94080, USA (“<B>Cytokinetics</B>”), and <B>Astellas Pharma Inc.</B>, a corporation organized and existing under the laws of Japan, having its registered office at 2-5-1, Nihonbashi-Honcho, Chuo-ku, Tokyo 103-8411, Japan (“<B>Astellas</B>”). Astellas and Cytokinetics are referred to in this Agreement individually as a “<B>Party</B>” and collectively as the “<B>Parties</B>.<B>”</B> </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>RECITALS </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">WHEREAS, Cytokinetics is a biopharmaceutical company directed to the research and development of small molecule compounds that modulate muscle function, and owns certain patents and know-how relating to skeletal sarcomere activators; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">WHEREAS, Astellas is a pharmaceutical company working to create and develop novel therapies; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">WHEREAS, Cytokinetics has conducted and continues to conduct research activities (including biochemistry, cellular characterization, chemistry and pharmacology) directed to the discovery of small molecules that activate the skeletal muscle sarcomere and early stage development relating thereto; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">WHEREAS, Astellas has conducted [*] </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">WHEREAS, Cytokinetics and Astellas are parties to a License and Collaboration Agreement, dated June 21, 2013 (the “<B>Effective Date</B>”), as previously amended (the “<B>Existing Agreement</B>”), pursuant to which they established a collaboration for the research and development and, if successful, commercialization of pharmaceutical products that contain certain fast skeletal [*] activators (except for Cytokinetics’ clinical development candidate <I>tirasemtiv</I> and related molecules) and certain other skeletal sarcomere activators, all under the terms and conditions set forth therein; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">WHEREAS, Cytokinetics has [*]; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">WHEREAS, the Existing Agreement provides for the collaborative research, development and commercialization of [*] Activators in the Licensed Indications, and the Parties now desire to expand the scope of collaboration for [*] Activators to include certain neuromuscular indications and to amend and restate the Existing Agreement; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">WHEREAS, Cytokinetics will retain the right to products that contain <I>tirasemtiv</I> and related molecules, and will develop and, if successful, commercialize such products outside the scope of this Agreement. </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt"> </P> <TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%"> <TR> <TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>[*] =</B></TD> <TD ALIGN="left" VALIGN="top"><B>Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. </B></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">1 </P> <p Style='page-break-before:always'> <HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER"> <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">NOW, THEREFORE, in consideration of the foregoing premises and the mutual covenants contained herein, the receipt and sufficiency of which are hereby acknowledged, Astellas and Cytokinetics hereby agree as follows: </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE 1 </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>DEFINITIONS </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The terms in this Agreement with initial letters capitalized shall have the meanings set forth below, or the meaning as designated in the indicated places throughout this Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.1</B> “<B>Active Ingredient</B>” means the clinically active material(s) that provide pharmacological activity in a pharmaceutical product (excluding formulation components such as coatings, stabilizers, excipients or solvents, adjuvants or controlled release technologies). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.2</B> “[*] <B>Indications</B>” means, for [*] Activators, (a) [*] pursuant to Section [*], and (b) any [*] Indication(s) [*] pursuant to Section [*]. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.3</B> “[*] <B>Indication</B>” means: (a) as of the Amendment Effective Date, any of the Indications set forth on <U><B>Exhibit L</B></U>; and (b) any other [*] Indication that may be added to <B>Exhibit L</B> as [*] Indication during the Term by written agreement of the Parties. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.4</B> “<B>Affiliate</B>” means, with respect to a Party, any Person that controls, is controlled by, or is under common control with that Party. For the purpose of this definition only, “control” (including, with correlative meaning, the terms “controlled by” and “under the common control”) means the actual power, either directly or indirectly through one or more intermediaries, to direct or cause the direction of the management and policies of such Person, whether by the ownership of more than fifty percent (50%) of the voting stocking of such Person, by contract or otherwise. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.5</B> “[*]” means [*]. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.6 </B>“<B>Astellas Know-How</B>” means all Know-How that is (a) Controlled by Astellas or its Affiliates during the Term and (b) reasonably necessary or useful for the Research, Development, Manufacture, Commercialization or Medical Affairs Activities of any Compound and/or Collaboration Product, provided, however, that Astellas Know-How specifically excludes Collaboration Know-How. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.7 </B>“<B>Astellas Patents</B>” means any Patent Right that is (a) Controlled by Astellas or its Affiliates during the Term and (b) reasonably necessary or useful for the Research, Development, Manufacture, Commercialization or Medical Affairs Activities of any Compound and/or Collaboration Product, provided, however, that Astellas Patents specifically exclude Collaboration Patents. The Astellas Patents existing as of the Effective Date are listed in <B><U>Exhibit A</U>.</B> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.8</B> “<B>Astellas Technology</B>” means Astellas Know-How and Astellas Patents. </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt"> </P> <TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%"> <TR> <TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>[*] =</B></TD> <TD ALIGN="left" VALIGN="top"><B>Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. </B></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2 </P> <p Style='page-break-before:always'> <HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER"> <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.9 </B>“<B>Astellas Territory</B>” means worldwide other than the Shared Territory. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.10</B> “<B>Business Day</B>” means a day other than a Saturday, Sunday or a day that is a statutory holiday in Japan or a bank holiday in New York, USA. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.11</B> “<B>Claims</B>” means all Third Party demands, claims, actions, proceedings and liability (whether criminal or civil, in contract, tort or otherwise) for losses, damages, reasonable legal costs and other reasonable expenses of any nature. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.12</B> “<B>CMC Activities</B>” means the chemistry, manufacturing, control and other activities necessary or useful for generating the CMC Information required for Marketing Approval of the Collaboration Products, including Manufacture of validation and/or clinical trial materials, which are necessary or useful to obtain Marketing Approval of the Collaboration Products. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.13</B> <B>“</B><B>CMC Information</B><B>”</B> means information related to the chemistry, manufacturing and controls of a Compound or a Collaboration Product, as specified by FDA, EMA or other applicable Regulatory Authority. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.14 “Collaboration” </B>means the collaboration of the Parties with respect to the Research, Development, Manufacture, Commercialization and Medical Affairs Activities of the Compounds and Collaboration Products in the Collaboration Indications (for [*] Activators) or the Field (for [*] Activators), as and to the extent set forth in this Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.15 </B>“<B>Collaboration Intellectual Property</B>” means any information and materials, including discoveries, improvements, modifications, processes, methods, assay, designs, protocols, formulas, data, inventions, algorithms, forecasts, profiles, strategies, plans, results, coordinates for compound/apo protein structures, expression constructs, know-how and trade secrets, patentable or otherwise, that is discovered, generated, conceived and/or reduced to practice by or on behalf either Party (including its Affiliates, employees, agents and contractors), whether solely or jointly, as a result of: (a) the performance of its activities under the Research Plan and/or (b) the performance of its activities under the Development Plan [*], in each case including all rights, title and interest in and to the intellectual property rights therein and thereto. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.16</B> “<B>Collaboration Indications</B>” means (a) Licensed Indications [*]); (b) [*] Indications; and (c) any [*] Indications. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.17</B> “<B>Collaboration Know-How</B>” means Know-How that is within the Collaboration Intellectual Property. </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt"> </P> <TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%"> <TR> <TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>[*] =</B></TD> <TD ALIGN="left" VALIGN="top"><B>Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. </B></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">3 </P> <p Style='page-break-before:always'> <HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER"> <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.18 </B>“<B>Collaboration Patents</B>” means Patent Rights that claim any Collaboration Intellectual Property, provided that any Patent Rights [*] Collaboration Patents. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.19</B> “<B>Collaboration Product</B>” means any pharmaceutical product containing a Compound, alone or in combination with other Active Ingredients, in any formulation or dosage form and for any mode of administration. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.20 </B>“<B>Commercialize</B>” or “<B>Commercialization</B>” means all activities directed to marketing, promoting, advertising, exhibiting, distributing (including management of wholesalers), detailing or selling a Collaboration Product in the Field (including importing and exporting activities in connection therewith). For the avoidance of doubt, Commercialization does not include Medical Affairs Activities. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.21</B> “<B>Committee</B>” means the JSC, JRC, JDC, JMC, JCC, JMAC, [*] or JPC, as applicable. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.22</B> “<B>Compound</B>” means any [*] Activator or [*] Activator. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.23</B> “<B>Compound Criteria</B>” means the criteria listed in <U><B>Exhibit B</B></U> for each of [*] Activators, [*] Activators and [*] Activators. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.24</B> “<B>Confidential Information</B>” of a Party means all Know-How, unpublished patent applications and other non-public information and data of a financial, commercial, business, operational or technical nature of such Party that is disclosed by or on behalf of such Party or any of its Affiliates or otherwise made available to the other Party or any of its Affiliates, in each case in connection with this Agreement, whether made available orally, visually, in writing or in electronic form. To the extent that Cytokinetics discloses to Astellas and/or its Affiliates any information relating to any [*] (such disclosure to be made at Cytokinetics’ sole discretion), such information shall also be deemed Confidential Information. Collaboration Intellectual Property shall be deemed Confidential Information of both Parties. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.25</B> “<B>Control</B>” or “<B>Controlled</B>” means, with respect to any Know-How, Patent Rights or other intellectual property rights, that a Party has the legal authority or right (whether by ownership, license or otherwise) to grant a license, sublicense, access or right to use (as applicable) under such Know-How, Patent Rights, or other intellectual property rights to the other Party on the terms and conditions set forth herein, in each case without breaching the terms of any agreement with a Third Party. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.26</B> “<B>Co-Promote</B>” and “<B>Co-Promotion</B>” means the promotional activities relating to the Collaboration Products directed to healthcare professionals or otherwise in furtherance of the Commercialization of the Collaboration Products to be conducted by Cytokinetics (whether alone </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt"> </P> <TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%"> <TR> <TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>[*] =</B></TD> <TD ALIGN="left" VALIGN="top"><B>Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. </B></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">4 </P> <p Style='page-break-before:always'> <HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"> or together with Astellas with respect to a particular Collaboration Product in a particular Indication) in the Co-Promotion Territory or Shared Territory in the event Cytokinetics exercises its rights under Section 9.6. For clarity, if [*] with respect to a particular [*] in accordance with Section [*] shall also be referred to as Co-Promote or Co-Promotion for the purpose of this Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.27</B> “<B>Co-Promotion Territory</B>” means: (a) the U.S.; and (b) Canada. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.28</B> “<B>Cytokinetics Commercialization Period</B>” means, on a [*], in the event [*] for a Collaboration Product with respect to [*] for which such Collaboration Product [*], and at the time of such [*] such Collaboration Product has [*] for any [*] Indication, [*] Indication or [*] Indication for which [*] such Collaboration Product is [*] if and when such Collaboration Product is [*] for any [*] Indication, [*] Indication or [*] Indication for which [*]. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.29 </B>“<B>Cytokinetics Know-How</B>” means all Know-How that is (a) Controlled by Cytokinetics or its Affiliates during the Term and (b) reasonably necessary or useful for the Research, Development, Manufacture, Commercialization or Medical Affairs Activities of any Compound and/or Collaboration Product, provided, however, that Cytokinetics Know-How specifically excludes Collaboration Know-How. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.30 </B>“<B>Cytokinetics Patents</B>” means any Patent Right that is (a) Controlled by Cytokinetics or its Affiliates during the Term and (b) reasonably necessary or useful for the Research, Development, Manufacture, Commercialization or Medical Affairs Activities of any Compound and/or Collaboration Product, provided, however, that Cytokinetics Patents specifically exclude Collaboration Patents. The Cytokinetics Patents existing as of the Effective Date are listed in <B><U>Exhibit C</U></B>. For clarity, Cytokinetics Patents shall include any Patent Rights arising after the Effective Date that [*] </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.31</B> “<B>Cytokinetics Technology</B>” means Cytokinetics Patents and Cytokinetics Know-How. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.32</B> “<B>Develop</B>” or “<B>Development</B>” means all development activities for any Compound or Collaboration Product that are directed to obtaining Marketing Approval(s) of the Collaboration Products, including: all non-clinical, preclinical and clinical activities, testing and studies of such Compound or Collaboration Product (including IND-Enabling Studies and translational research); manufacturing development, process and formulation development; toxicology, pharmacokinetic, pharmacodynamic, drug-drug interaction, safety, tolerability and pharmacological studies; </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt"> </P> <TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%"> <TR> <TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>[*] =</B></TD> <TD ALIGN="left" VALIGN="top"><B>Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. </B></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">5 </P> <p Style='page-break-before:always'> <HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"> distribution of such Compound or Collaboration Product for use in clinical trials (including placebos and comparators); statistical analyses; assay development; instrument design and development; protocol design and development; quality assurance and control; report writing; and the preparation, filing and prosecution of any MAA for such Collaboration Product; development activities directed to label expansion (including prescribing information) and/or obtaining Marketing Approval for one or more additional Indications or patient populations following initial Marketing Approval; development activities conducted after receipt of Marketing Approval which were a condition for the receipt of such Marketing Approval; and all regulatory activities related to any of the foregoing. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.33</B> “<B>Development Costs</B>” means the [*] costs incurred by or on account of a Party in performing Development in accordance with the Development Plan. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.34</B> “<B>Diligent Efforts</B>” means: (a) where applied to carrying out specific tasks and obligations of a Party under this Agreement, expending [*] to accomplish such task or obligation as such Party (on its own and/or acting through any of its Affiliates, sublicensees or subcontractors) would [*]; and (b) where applied to the Research, Development, Manufacture, and/or Commercialization of, or Medical Affairs Activities for, a Compound or Collaboration Product, the use of [*], in an [*], as [*], taking into account relevant factors including, without limitation, [*] and other relevant factors, including [*]. “Diligent Efforts” shall require that such Party (on its own and/or acting through any of its Affiliates, sublicensees or subcontractors), at a minimum: (i) promptly assign responsibility for such obligations to qualified personnel, set annual goals and objectives for carrying out such obligations, and monitor and hold personnel accountable for progress with respect to such goals and objectives; (ii) set and seek to achieve specific and meaningful objectives for carrying out such obligations, with timelines consistent with a comparable [*] program; and (iii) make and implement decisions and [*] designed to [*] with respect to such objectives. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.35</B> “<B>Dollars</B>” means the U.S. dollar, and <B>“$”</B> shall be interpreted accordingly. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.36</B> <B>“EMA”</B> means the European Medicines Agency or any successor entity thereto. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.37 “EU”</B> or the <B>“European Union”</B> means the European Union and its member states as of the Amendment Effective Date, which are: Austria, Belgium, Bulgaria, Croatia, Cyprus, </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt"> </P> <TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%"> <TR> <TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>[*] =</B></TD> <TD ALIGN="left" VALIGN="top"><B>Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. </B></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">6 </P> <p Style='page-break-before:always'> <HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"> Czech Republic, Denmark, Estonia, Finland, France, Germany, Greece, Hungary, Ireland, Italy, Latvia, Lithuania, Luxemburg, Malta, Netherlands, Poland, Portugal, Romania, Slovakia, Slovenia, Spain, Sweden, and the United Kingdom, as well as Norway and Iceland, and each of their successors to the extent such successors occupy the same territory. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.38</B> “<B>[*] Indication</B>” means, for [*] Activators: (a) SMA; and (b) any additional [*] Indication [*] pursuant to Section [*]. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.39</B> “<B>[*] Activator</B>” means (a) any small molecule compound that (i) is [*], (ii) has a specified level of stimulatory activity against any [*], as set forth in the applicable Compound Criteria, and (iii) the [*]; and (b) any [*] in subclause (a) above. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.40</B> “<B>[*] Activator</B>” means, subject to the final sentence of this paragraph, (a) any small molecule compound that (i) is [*], (ii) has a specified level of stimulatory activity against any [*], as set forth in the applicable Compound Criteria, and (iii) the [*]; and (b) any [*] in subclause (a) above. [*] Activators include [*], but exclude all [*]. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.41</B> “<B>FDA</B>” means the United States Food and Drug Administration or any successor entity thereto. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.42</B> “<B>Field</B>” means the treatment, prevention and/or amelioration of any diseases and medical conditions in humans. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.43</B> “<B>Filing</B>” of an MAA means the acceptance by a Regulatory Authority of an MAA for filing and review, if applicable, or otherwise the submission of such MAA. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.44</B> “<B>First Commercial Sale</B>” means, with respect to any Collaboration Product in any country or jurisdiction, the first sale of such Collaboration Product to a Third Party for distribution, use or consumption in such country or jurisdiction after the Marketing Approvals have been obtained for such Collaboration Product in such country or jurisdiction. </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt"> </P> <TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%"> <TR> <TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>[*] =</B></TD> <TD ALIGN="left" VALIGN="top"><B>Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. </B></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">7 </P> <p Style='page-break-before:always'> <HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER"> <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.45</B> <B></B>“<B>FTE</B><B></B>”<B></B> means the equivalent of a full-time individual’s work for a twelve (12) month period (consisting of a total of [*] hours per year of dedicated effort). Any person who devotes more or less than [*] hours per year on the applicable activities shall be treated as an FTE on a pro-rata basis, based upon the actual number of hours worked by such person on such activities, divided by [*]. For avoidance of doubt, the hours allocated to the work of general corporate or administrative personnel shall not be incorporated into FTE. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.46 </B>“<B>FTE Rate</B>” means an initial rate of [*] Dollars [*] per FTE per year for each Astellas and Cytokinetics, which shall apply through [*]. Thereafter, the FTE Rate shall be changed annually on a calendar year basis to reflect any year-to-year percentage increase or decrease (as the case may be) in the Consumer Price Index for All Urban Consumers for the U.S., as published by the U.S. Department of Labor, Bureau of Labor Statistics (“<B>CPI</B>”) (based on the change in the CPI from the most recent index available as of the Effective Date to the most recent index available as of the date of the calculation of such revised FTE Rate). The FTE Rate applicable to [*] shall be subject to the adjustment set forth in Section [*]. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.47 </B>“<B>GAAP</B>” means the U.S. generally accepted accounting principles. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.48 </B>“<B>Generic Product</B>” means, with respect to a Collaboration Product in a particular country, any pharmaceutical product that (a) contains the same Active Ingredients and formulation as such Collaboration Product; (b) [*] in such country and [*] in such country; and (c) is sold in such country by a Third Party that is not a sublicensee of Astellas or its Affiliates and did not purchase such product in a chain of distribution that included any of Astellas or its Affiliates or sublicensees. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.49 </B>“<B>Governmental Authority</B>” means any federal, state, national, state, provincial or local government, or political subdivision thereof, or any multinational organization or any authority, agency or commission entitled to exercise any administrative, executive, judicial, legislative, police, regulatory or taxing authority or power, any court or tribunal (or any department, bureau or division thereof, or any governmental arbitrator or arbitral body). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.50 </B>“<B>IFRS</B>” means International Financial Reporting Standards. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.51 </B>“<B>IND</B>” means any investigational new drug application, clinical trial application, clinical trial exemption or similar or equivalent application or submission for approval to conduct human clinical investigations filed with or submitted to a Regulatory Authority in conformance with the requirements of such Regulatory Authority. </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt"> </P> <TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%"> <TR> <TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>[*] =</B></TD> <TD ALIGN="left" VALIGN="top"><B>Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. </B></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">8 </P> <p Style='page-break-before:always'> <HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER"> <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.52 </B>“<B>IND-Enabling Studies</B>” means studies that are specifically required for an IND, including ADME (absorption, distribution, metabolism, and excretion), GLP toxicology studies, or studies required for the preparation of the CMC section of an IND, including studies related to analytical methods and purity analysis, and formulation and manufacturing development studies, all as necessary to obtain the permission of Regulatory Authorities to begin human clinical investigations. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.53 </B>“<B>Indication</B>” means any human diseases, syndromes and medical conditions that can be diagnosed, treated, prevented or ameliorated. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.54 </B>“<B>Initiate</B>” or “<B>Initiation</B>” means, with respect to a clinical trial of a Collaboration Product, the first dosing of the first human subject for such clinical trial. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.55 </B>“<B>Know-How</B>” means any information and materials, including discoveries, improvements, modifications, processes, methods, assays, designs, protocols, formulas, data, inventions, algorithms, forecasts, profiles, strategies, plans, results, coordinates for compound/apo protein structures, expression constructs, know-how and trade secrets (in each case, patentable, copyrightable or otherwise), but excluding any Patent Rights. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.56 </B>“<B>Law</B>” means any federal, state, local, foreign or multinational law, statute, standard, ordinance, code, rule, regulation, resolution or promulgation, or any order by any Governmental Authority, or any license, franchise, permit or similar right granted under any of the foregoing, or any similar provision having the force or effect of law. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.57 </B>“<B>Lead Compound</B>” means (a) Cytokinetics’ proprietary compound known as CK-2127107, which is the subject of the Lead Compound IND, and (b) any [*] in subclause (a) above.<U> </U> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.58 </B>“<B>Lead Compound IND</B>” means U.S. IND No. [*]. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.59 </B>“<B>Lead Product</B>” means a Collaboration Product that contains the Lead Compound. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.60 </B>“<B>Licensed Indications</B>” means the following Indications: (a) [*] non-neuromuscular diseases and conditions (e.g., [*]; and (b) [*]. </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt"> </P> <TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%"> <TR> <TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>[*] =</B></TD> <TD ALIGN="left" VALIGN="top"><B>Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. </B></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">9 </P> <p Style='page-break-before:always'> <HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER"> <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.61 </B>“<B>MAA</B>” or “<B>Marketing Authorization Application</B>” means an application to the appropriate Regulatory Authority for approval to commercially sell a Collaboration Product (but excluding pricing approval) in the Field in a particular jurisdiction (including, without limitation, a New Drug Application in the U.S.) and all amendments and supplements thereto. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.62 </B>“<B>Major EU Market Countries</B>” means [*]. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.63 </B>“<B>Major Market Countries</B>” means the [*].<U> </U> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.64 </B>“<B>Manufacture</B>” and “<B>Manufacturing</B>” mean activities directed to manufacturing, processing, filling, finishing, packaging, labeling, quality control, quality assurance testing and release, post-marketing validation testing, inventory control and management, storing and transporting any Compound and/or Collaboration Product. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.65 </B>“<B>Manufacturing Costs</B>” means, with respect to a particular Compound or Collaboration Product Manufactured and supplied by a Party pursuant to the Development Plan: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(a)</B> if such Compound or Collaboration Product is Manufactured by such Party’s Third Party manufacturer, [*] costs incurred by such Party in association therewith, including for [*] with respect thereto; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(b)</B> if such Compound or Collaboration Product is Manufactured by such Party itself, [*] including without limitation [*] manufacturing costs. Such [*] of Compound or Collaboration Product [*] and (ii) in accordance with IFRS (in the case of Astellas) or GAAP (in the case of Cytokinetics) consistently applied. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.66 </B>“<B>Marketing Approval</B>” means all approvals necessary for the commercial sale of a Collaboration Product in the Field in a given country or regulatory jurisdiction. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.67 </B>“<B>Medical Affairs Activities</B>”<B></B> means activities, in compliance with all the applicable Law, designed to ensure or improve appropriate medical use of, conduct medical education regarding, or further research regarding, the Compounds and the Collaboration Products or to increase disease state awareness, including by way of example: (a) activities of medical scientific liaisons, which shall mean the following functions: (x) conduct of service based medical activities including providing input and assistance with consultancy meetings, recommending </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt"> </P> <TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%"> <TR> <TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>[*] =</B></TD> <TD ALIGN="left" VALIGN="top"><B>Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. </B></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">10 </P> <p Style='page-break-before:always'> <HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">investigators for clinical trials and providing input in the design of such trials and other research related activities, and (y) delivery of non-promotional communications and conduct of non-promotional activities including presenting new clinical trial data and other scientific or disease state awareness information; (b) grants to support continuing medical education, symposia, or Third Party research related to Collaboration Products; (c) development, publication and dissemination of publications relating to the Compounds and the Collaboration Products and relevant disease states; (d) medical information services provided in response to inquiries communicated via sales representatives or received by letter, phone call or email; (e) conducting advisory board meetings or other consultant programs; (f) support of investigator-initiated trials; (g) managing relationships with cooperative groups, physician/hospital networks and disease state or patient and caregiver advocacy groups; (h) establishing and implementing risk, evaluation and mitigation strategies, (i) voluntary phase 4 trials or post-approval patient registries, (j) health economic and outcomes research (HEOR) activities, (k) independent medical education activities, and (l) non-promotional exhibiting at medical and scientific fora. For the purposes of clarity, post-approval clinical studies within the approved Indications, which were a condition for the receipt of Marketing Approval, shall be included within Development and shall not be included within Medical Affairs Activities. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.68</B> “<B>Net Sales</B>” means the gross amount billed or invoiced by or for the benefit of Astellas, its Affiliates, and its sublicensees to independent, unrelated persons in bona fide arm’s length transactions with respect to a Collaboration Product, less the following deductions, as allocable to such Collaboration Product (if not previously deducted from the amount invoiced): </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt"> </P> <TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%"> <TR> <TD WIDTH="8%"> </TD> <TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>(a)</B></TD> <TD ALIGN="left" VALIGN="top"><B></B>[*] </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt"> </P> <TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%"> <TR> <TD WIDTH="8%"> </TD> <TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>(b)</B></TD> <TD ALIGN="left" VALIGN="top"><B></B>[*] </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt"> </P> <TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%"> <TR> <TD WIDTH="8%"> </TD> <TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>(c)</B></TD> <TD ALIGN="left" VALIGN="top"><B></B>[*] </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt"> </P> <TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%"> <TR> <TD WIDTH="8%"> </TD> <TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>(d)</B></TD> <TD ALIGN="left" VALIGN="top"><B></B>[*] and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt"> </P> <TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%"> <TR> <TD WIDTH="8%"> </TD> <TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>(e)</B></TD> <TD ALIGN="left" VALIGN="top"><B></B>[*] </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If a single item falls into more than one of the categories set forth in clauses (a)-(e) above, such item may not be deducted more than once. </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt"> </P> <TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%"> <TR> <TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>[*] =</B></TD> <TD ALIGN="left" VALIGN="top"><B>Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. </B></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">11 </P> <p Style='page-break-before:always'> <HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER"> <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Sales between Astellas and its Affiliates and sublicensees shall be disregarded for purposes of calculating Net Sales except if such purchaser is a distributor, pharmacy or end user. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If a Collaboration Product either (i) is sold in the form of a combination product containing both a Compound and one or more Active Ingredient(s) as separate molecular entity(ies) that are not Compounds; or (ii) is sold in a form that contains (or is sold bundled with) a delivery device therefor (in either case ((i) or (ii)), a “<B>Combination Product</B>”), the Net Sales of such Collaboration Product for the purpose of calculating royalties and sales-based milestones owed under this Agreement for sales of such Collaboration Product, shall be determined as follows: first, Astellas shall determine the actual Net Sales of such Combination Product (using the above provisions) and then such amount shall be multiplied by the fraction A/(A+B), where A is the invoice price of such Collaboration Product, if sold separately, and B is the total invoice price of other Active Ingredient or delivery device in such Combination Product if sold separately. If any other Active Ingredient or delivery device in such Combination Product is not sold separately, Net Sales shall be calculated by multiplying actual Net Sales of such Combination Product by a fraction A/C where A is the invoice price of such Collaboration Product if sold separately, and C is the invoice price of such Combination Product. If neither such Collaboration Product nor any other Active Ingredient (or delivery device) in such Combination Product is sold separately, the adjustment to Net Sales shall be determined by the Parties in good faith to reasonably reflect the fair market value of the contribution of such Collaboration Product in such Combination Product to the total fair market value of such Combination Product. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">With respect to any sale of any Collaboration Product in a given country for any substantive consideration other than monetary consideration on arm’s length terms (which has the effect of reducing the invoiced amount below what it would have been in the absence of such non-monetary consideration), for purposes of calculating the Net Sales, such Collaboration Product shall be deemed to be sold exclusively for cash at the average Net Sales price charged to Third Parties for cash sales of such Collaboration Product in such country during the applicable reporting period (or if there were only <I>de minimis</I> cash sales in such country, at the fair market value as determined in good faith based on pricing in comparable markets). Notwithstanding the foregoing, Net Sales shall not include amounts (whether actually existing or deemed to exist for purposes of calculation) for Collaboration Products distributed for use in clinical trials. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Net Sales shall be calculated on an accrual basis, in a manner consistent with Astellas’ accounting policies for external reporting purposes, as consistently applied, in accordance with IFRS. To the extent any accrued amounts used in the calculation of Net Sales are estimates, such estimates shall be trued-up in accordance with Astellas’ accounting policies for external reporting purposes, as consistently applied, and Net Sales and related payments under this Agreement shall be reconciled as appropriate. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.69</B> [*<B>] Indication</B>” means (a) [*], and (b) any other Indication [*] that is designated by the JDC as a [*] Indication pursuant to Section [*]. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.70</B> [*<B>] Activators</B>” means [*] Activators and [*] Activators, and specifically excludes (a) [*] Activators, (b) [*], and (c) any compound targeting any [*]. </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt"> </P> <TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%"> <TR> <TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>[*] =</B></TD> <TD ALIGN="left" VALIGN="top"><B>Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. </B></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">12 </P> <p Style='page-break-before:always'> <HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER"> <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.71</B> “<B>Patent Rights</B>” means all patents and patent applications (which shall be deemed to include certificates of invention and applications for certificates of invention), including all divisionals, continuations, substitutions, continuations-in-part, re-examinations, reissues, additions, renewals, revalidations, extensions, registrations, pediatric exclusivity periods and supplemental protection certificates and the like of any such patents and patent applications, and any and all foreign equivalents of the foregoing. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.72</B> “<B>Person</B>” means any individual, partnership, limited liability company, firm, corporation, association, trust, unincorporated organization or other entity. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.73</B> “<B>Phase 1 Clinical Trial</B>” means a controlled human clinical trial of a Collaboration Product that would satisfy the requirements of 21 CFR 312.21(a) or corresponding foreign regulations, regardless of whether such trial is referred to as a “phase 1 clinical trial” in the Development Plan. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.74</B> “<B>Phase 2 Clinical Trial</B>” means a controlled human clinical trial of a Collaboration Product that would satisfy the requirements of 21 CFR 312.21(b) or corresponding foreign regulations, regardless of whether such trial is referred to as a “phase 2 clinical trial” in the Development Plan. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.75</B> “<B>Phase 3 Clinical Trial</B>” means a controlled or uncontrolled human clinical trial of a Collaboration Product that would satisfy the requirements of 21 CFR 312.21(c) or corresponding foreign regulations, regardless of whether such trial is referred to as a “phase 3 clinical trial” in the Development Plan. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.76</B> [*] means any [*] that is intended [*] may be necessary to [*] in the Development Plan. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.77</B> “<B>Regulatory Authority</B>” means any applicable Governmental Authority responsible for granting Marketing Approvals or pricing approvals for Collaboration Products, including the FDA, the EMA and any corresponding national or regional regulatory authorities. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.78</B> “<B>Regulatory Exclusivity</B>” means any exclusive marketing rights or data exclusivity rights conferred by any Regulatory Authority with respect to a pharmaceutical product other than patents, including, without limitation, orphan drug exclusivity, new chemical entity exclusivity, data exclusivity, pediatric exclusivity, rights conferred in the United States under the Hatch-Waxman Act or the FDA Modernization Act of 1997, or rights similar thereto outside the United States. </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt"> </P> <TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%"> <TR> <TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>[*] =</B></TD> <TD ALIGN="left" VALIGN="top"><B>Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. </B></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">13 </P> <p Style='page-break-before:always'> <HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER"> <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.79</B> “<B>Regulatory Materials</B>” means any regulatory application, submission, notification, communication, correspondence, registration and other filings made to, received from or otherwise conducted with a Regulatory Authority in order to Research a Compound and/or Develop, Manufacture, or Commercialize a Compound or Collaboration Product in the Field in a particular country or jurisdiction. “Regulatory Materials” includes any IND, MAA and Marketing Approval. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.80</B> “<B>Registration Dossier</B>” means the registration dossier designed to support Marketing Approval by the FDA and Marketing Approval in the EU (excluding any country-specific approvals for pricing or reimbursement). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.81</B> “<B>Research</B>” means all research activities conducted by or on behalf of either Party or the Parties jointly pursuant [*]. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.82</B> “<B>Retained Indications</B>” means Indications that are not Licensed Indications. Retained Indications include the Indications listed in <U><B>Exhibit D</B></U>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.83</B> [*] <B>Compounds</B>” means (a) Tirasemtiv, (b) any compositions of matter (i) falling within the scope of any of the generic formulas disclosed in the Patent Rights listed in <U><B>Exhibit E</B></U> (the “[*] <B>Patent Rights</B>”) and/or (ii) specifically disclosed in the [*] Patent Rights; and (c) any [*] in subclause (a) or (b) above. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.84 </B>“<B>Shared Territory</B>” means (a) the Co-Promotion Territory and (b) the European Union and Switzerland. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.85</B> [*] <B>Activator</B>” means (a) any small molecule compound that (i) is [*], (ii) has a specified level of stimulatory activity against any [*], as set forth in the applicable Compound Criteria, and (iii) the [*] and (b) any [*] in subclause (a) above. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.86</B> “<B>SMA</B>” means spinal muscular atrophy. </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt"> </P> <TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%"> <TR> <TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>[*] =</B></TD> <TD ALIGN="left" VALIGN="top"><B>Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. </B></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">14 </P> <p Style='page-break-before:always'> <HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER"> <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.87</B> “<B>Third Party</B>” means any Person other than a Party or an Affiliate of a Party. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.88</B> “<B>Tirasemtiv</B>” means Cytokinetics’ proprietary compound formerly known as CK-2017357. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.89 </B>“<B>United States</B>” or “<B>U.S.</B>” means the United States of America, including its fifty (50) states and the District of Columbia. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.90</B> “<B>Valid Claim</B>” means a claim of an issued and unexpired patent (as may be extended through supplementary protection certificate or patent term extension) or a pending patent application included within [*], which claim has not been revoked, held invalid or unenforceable by a patent office, court or other governmental agency of competent jurisdiction in a final and non-appealable judgment (or judgment from which no appeal was taken within the allowable time period) and has not been disclaimed, denied or admitted to be invalid or unenforceable through reissue, re-examination or disclaimer or otherwise. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.91</B> <B>Additional Definitions</B>. The following table identifies the location of definitions set forth in various Sections of the Agreement: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt"> </P> <TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center"> <TR> <TD WIDTH="91%"></TD> <TD VALIGN="bottom" WIDTH="8%"></TD> <TD></TD></TR> <TR STYLE="font-family:Times New Roman; font-size:8pt"> <TD VALIGN="bottom" NOWRAP> <P STYLE="border-bottom:1.00pt solid #000000; width:34.15pt; font-size:8pt; font-family:Times New Roman"><B>Definition</B></P></TD> <TD VALIGN="bottom"> </TD> <TD VALIGN="bottom" NOWRAP> <P STYLE="border-bottom:1.00pt solid #000000; width:24.85pt; font-size:8pt; font-family:Times New Roman"><B>Section</B></P></TD></TR> <TR STYLE="font-family:Times New Roman; font-size:10pt"> <TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Alliance Manager</P></TD> <TD VALIGN="bottom"> </TD> <TD VALIGN="bottom" NOWRAP>2.1</TD></TR> <TR STYLE="font-family:Times New Roman; font-size:10pt"> <TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">[*] Indication</P></TD> <TD VALIGN="bottom"> </TD> <TD VALIGN="bottom" NOWRAP>[*]</TD></TR> <TR STYLE="font-family:Times New Roman; font-size:10pt"> <TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">[*] Advance Invoice</P></TD> <TD VALIGN="bottom"> </TD> <TD VALIGN="bottom" NOWRAP>11.3(c)(i)</TD></TR> <TR STYLE="font-family:Times New Roman; font-size:10pt"> <TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">[*]</P></TD> <TD VALIGN="bottom"> </TD> <TD VALIGN="bottom" NOWRAP>[*]</TD></TR> <TR STYLE="font-family:Times New Roman; font-size:10pt"> <TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">[*]</P></TD> <TD VALIGN="bottom"> </TD> <TD VALIGN="bottom" NOWRAP>[*]</TD></TR> <TR STYLE="font-family:Times New Roman; font-size:10pt"> <TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">[*] True-Up Report</P></TD> <TD VALIGN="bottom"> </TD> <TD VALIGN="bottom" NOWRAP>11.3(c)(ii)</TD></TR> <TR STYLE="font-family:Times New Roman; font-size:10pt"> <TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">[*] Development Work</P></TD> <TD VALIGN="bottom"> </TD> <TD VALIGN="bottom" NOWRAP>[*]</TD></TR> <TR STYLE="font-family:Times New Roman; font-size:10pt"> <TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">[*] Date</P></TD> <TD VALIGN="bottom"> </TD> <TD VALIGN="bottom" NOWRAP>[*]</TD></TR> <TR STYLE="font-family:Times New Roman; font-size:10pt"> <TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">[*] Products</P></TD> <TD VALIGN="bottom"> </TD> <TD VALIGN="bottom" NOWRAP>14.3(a)</TD></TR> <TR STYLE="font-family:Times New Roman; font-size:10pt"> <TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Astellas [*]</P></TD> <TD VALIGN="bottom"> </TD> <TD VALIGN="bottom" NOWRAP>[*]</TD></TR> <TR STYLE="font-family:Times New Roman; font-size:10pt"> <TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Astellas Co-Promotion Notice</P></TD> <TD VALIGN="bottom"> </TD> <TD VALIGN="bottom" NOWRAP>9.6(b)(i)</TD></TR> <TR STYLE="font-family:Times New Roman; font-size:10pt"> <TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Astellas Indemnitee</P></TD> <TD VALIGN="bottom"> </TD> <TD VALIGN="bottom" NOWRAP>[*]</TD></TR> <TR STYLE="font-family:Times New Roman; font-size:10pt"> <TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Astellas [*]</P></TD> <TD VALIGN="bottom"> </TD> <TD VALIGN="bottom" NOWRAP>[*]</TD></TR> <TR STYLE="font-family:Times New Roman; font-size:10pt"> <TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Astellas [*]</P></TD> <TD VALIGN="bottom"> </TD> <TD VALIGN="bottom" NOWRAP>[*]</TD></TR> <TR STYLE="font-family:Times New Roman; font-size:10pt"> <TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Astellas [*]</P></TD> <TD VALIGN="bottom"> </TD> <TD VALIGN="bottom" NOWRAP>[*]</TD></TR> <TR STYLE="font-family:Times New Roman; font-size:10pt"> <TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Bankruptcy Code</P></TD> <TD VALIGN="bottom"> </TD> <TD VALIGN="bottom" NOWRAP>3.8</TD></TR> <TR STYLE="font-family:Times New Roman; font-size:10pt"> <TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Combination Product</P></TD> <TD VALIGN="bottom"> </TD> <TD VALIGN="bottom" NOWRAP>1.68</TD></TR> <TR STYLE="font-family:Times New Roman; font-size:10pt"> <TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Commercial Operating Team</P></TD> <TD VALIGN="bottom"> </TD> <TD VALIGN="bottom" NOWRAP>9.7</TD></TR> <TR STYLE="font-family:Times New Roman; font-size:10pt"> <TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Commercialization Plan</P></TD> <TD VALIGN="bottom"> </TD> <TD VALIGN="bottom" NOWRAP>9.3(a)</TD></TR> <TR STYLE="font-family:Times New Roman; font-size:10pt"> <TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">[*]</P></TD> <TD VALIGN="bottom"> </TD> <TD VALIGN="bottom" NOWRAP>[*]</TD></TR> <TR STYLE="font-family:Times New Roman; font-size:10pt"> <TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Confidentiality Agreement</P></TD> <TD VALIGN="bottom"> </TD> <TD VALIGN="bottom" NOWRAP>17.8</TD></TR> </TABLE> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt"> </P> <TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%"> <TR> <TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>[*] =</B></TD> <TD ALIGN="left" VALIGN="top"><B>Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. </B></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">15 </P> <p Style='page-break-before:always'> <HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER"> <TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center"> <TR> <TD WIDTH="93%"></TD> <TD VALIGN="bottom" WIDTH="6%"></TD> <TD></TD></TR> <TR STYLE="font-family:Times New Roman; font-size:10pt"> <TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Co-Promotion Agreement</P></TD> <TD VALIGN="bottom"></TD> <TD VALIGN="bottom" NOWRAP>9.6(g)</TD></TR> <TR STYLE="font-family:Times New Roman; font-size:10pt"> <TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">[*]</P></TD> <TD VALIGN="bottom"></TD> <TD VALIGN="bottom" NOWRAP>[*]</TD></TR> <TR STYLE="font-family:Times New Roman; font-size:10pt"> <TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Co-Promotion Matters</P></TD> <TD VALIGN="bottom"></TD> <TD VALIGN="bottom" NOWRAP>9.6(b)(i)</TD></TR> <TR STYLE="font-family:Times New Roman; font-size:10pt"> <TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">CY 5012</P></TD> <TD VALIGN="bottom"></TD> <TD VALIGN="bottom" NOWRAP>11.5(c)(i)</TD></TR> <TR STYLE="font-family:Times New Roman; font-size:10pt"> <TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cytokinetics Co-Funding Option</P></TD> <TD VALIGN="bottom"></TD> <TD VALIGN="bottom" NOWRAP>4.1(b)</TD></TR> <TR STYLE="font-family:Times New Roman; font-size:10pt"> <TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cytokinetics Co-Promotion Effort</P></TD> <TD VALIGN="bottom"></TD> <TD VALIGN="bottom" NOWRAP>9.6(c)</TD></TR> <TR STYLE="font-family:Times New Roman; font-size:10pt"> <TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cytokinetics Co-Promotion Recommendation</P></TD> <TD VALIGN="bottom"></TD> <TD VALIGN="bottom" NOWRAP>9.6(b)(ii)</TD></TR> <TR STYLE="font-family:Times New Roman; font-size:10pt"> <TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cytokinetics [*]</P></TD> <TD VALIGN="bottom"></TD> <TD VALIGN="bottom" NOWRAP>[*]</TD></TR> <TR STYLE="font-family:Times New Roman; font-size:10pt"> <TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cytokinetics Indemnitee</P></TD> <TD VALIGN="bottom"></TD> <TD VALIGN="bottom" NOWRAP>16.2</TD></TR> <TR STYLE="font-family:Times New Roman; font-size:10pt"> <TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cytokinetics [*]</P></TD> <TD VALIGN="bottom"></TD> <TD VALIGN="bottom" NOWRAP>[*]</TD></TR> <TR STYLE="font-family:Times New Roman; font-size:10pt"> <TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cytokinetics [*]</P></TD> <TD VALIGN="bottom"></TD> <TD VALIGN="bottom" NOWRAP>[*]</TD></TR> <TR STYLE="font-family:Times New Roman; font-size:10pt"> <TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cytokinetics Product Marks</P></TD> <TD VALIGN="bottom"></TD> <TD VALIGN="bottom" NOWRAP>12.5(b)</TD></TR> <TR STYLE="font-family:Times New Roman; font-size:10pt"> <TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cytokinetics Research FTEs</P></TD> <TD VALIGN="bottom"></TD> <TD VALIGN="bottom" NOWRAP>5.3</TD></TR> <TR STYLE="font-family:Times New Roman; font-size:10pt"> <TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cytokinetics [*]</P></TD> <TD VALIGN="bottom"></TD> <TD VALIGN="bottom" NOWRAP>[*]</TD></TR> <TR STYLE="font-family:Times New Roman; font-size:10pt"> <TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cytokinetics [*]</P></TD> <TD VALIGN="bottom"></TD> <TD VALIGN="bottom" NOWRAP>[*]</TD></TR> <TR STYLE="font-family:Times New Roman; font-size:10pt"> <TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Development Advance Invoice</P></TD> <TD VALIGN="bottom"></TD> <TD VALIGN="bottom" NOWRAP>11.3(a)(i)</TD></TR> <TR STYLE="font-family:Times New Roman; font-size:10pt"> <TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Development Plan</P></TD> <TD VALIGN="bottom"></TD> <TD VALIGN="bottom" NOWRAP>6.2(a)</TD></TR> <TR STYLE="font-family:Times New Roman; font-size:10pt"> <TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Development Program</P></TD> <TD VALIGN="bottom"></TD> <TD VALIGN="bottom" NOWRAP>6.2(a)</TD></TR> <TR STYLE="font-family:Times New Roman; font-size:10pt"> <TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Development Project Team</P></TD> <TD VALIGN="bottom"></TD> <TD VALIGN="bottom" NOWRAP>6.10</TD></TR> <TR STYLE="font-family:Times New Roman; font-size:10pt"> <TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Development True-Up Report</P></TD> <TD VALIGN="bottom"></TD> <TD VALIGN="bottom" NOWRAP>11.3(a)(ii)</TD></TR> <TR STYLE="font-family:Times New Roman; font-size:10pt"> <TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Disclosing Party</P></TD> <TD VALIGN="bottom"></TD> <TD VALIGN="bottom" NOWRAP>13.1(a)</TD></TR> <TR STYLE="font-family:Times New Roman; font-size:10pt"> <TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">[*]</P></TD> <TD VALIGN="bottom"></TD> <TD VALIGN="bottom" NOWRAP>[*]</TD></TR> <TR STYLE="font-family:Times New Roman; font-size:10pt"> <TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Earlier Milestone Event</P></TD> <TD VALIGN="bottom"></TD> <TD VALIGN="bottom" NOWRAP>11.5(b)(i)</TD></TR> <TR STYLE="font-family:Times New Roman; font-size:10pt"> <TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Early Stage Work</P></TD> <TD VALIGN="bottom"></TD> <TD VALIGN="bottom" NOWRAP>6.3(b)(ii)</TD></TR> <TR STYLE="font-family:Times New Roman; font-size:10pt"> <TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Established Commercial Infrastructure</P></TD> <TD VALIGN="bottom"></TD> <TD VALIGN="bottom" NOWRAP>9.9</TD></TR> <TR STYLE="font-family:Times New Roman; font-size:10pt"> <TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">[*]</P></TD> <TD VALIGN="bottom"></TD> <TD VALIGN="bottom" NOWRAP>[*]</TD></TR> <TR STYLE="font-family:Times New Roman; font-size:10pt"> <TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">[*] Indication</P></TD> <TD VALIGN="bottom"></TD> <TD VALIGN="bottom" NOWRAP>[*]</TD></TR> <TR STYLE="font-family:Times New Roman; font-size:10pt"> <TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">[*]</P></TD> <TD VALIGN="bottom"></TD> <TD VALIGN="bottom" NOWRAP>[*]</TD></TR> <TR STYLE="font-family:Times New Roman; font-size:10pt"> <TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">FCPA</P></TD> <TD VALIGN="bottom"></TD> <TD VALIGN="bottom" NOWRAP>17.7(a)</TD></TR> <TR STYLE="font-family:Times New Roman; font-size:10pt"> <TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">FCPA Covered Person</P></TD> <TD VALIGN="bottom"></TD> <TD VALIGN="bottom" NOWRAP>17.7(a)</TD></TR> <TR STYLE="font-family:Times New Roman; font-size:10pt"> <TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Federal Arbitration Act</P></TD> <TD VALIGN="bottom"></TD> <TD VALIGN="bottom" NOWRAP>17.6(a)</TD></TR> <TR STYLE="font-family:Times New Roman; font-size:10pt"> <TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">[*]</P></TD> <TD VALIGN="bottom"></TD> <TD VALIGN="bottom" NOWRAP>[*]</TD></TR> <TR STYLE="font-family:Times New Roman; font-size:10pt"> <TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Indemnified Party</P></TD> <TD VALIGN="bottom"></TD> <TD VALIGN="bottom" NOWRAP>16.3</TD></TR> <TR STYLE="font-family:Times New Roman; font-size:10pt"> <TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Indemnifying Party</P></TD> <TD VALIGN="bottom"></TD> <TD VALIGN="bottom" NOWRAP>16.3</TD></TR> <TR STYLE="font-family:Times New Roman; font-size:10pt"> <TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">[*] Rules</P></TD> <TD VALIGN="bottom"></TD> <TD VALIGN="bottom" NOWRAP>17.6(a)</TD></TR> <TR STYLE="font-family:Times New Roman; font-size:10pt"> <TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">JCC Determination</P></TD> <TD VALIGN="bottom"></TD> <TD VALIGN="bottom" NOWRAP>9.6(b)(ii)</TD></TR> <TR STYLE="font-family:Times New Roman; font-size:10pt"> <TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Joint Commercialization Committee or JCC</P></TD> <TD VALIGN="bottom"></TD> <TD VALIGN="bottom" NOWRAP>2.6</TD></TR> <TR STYLE="font-family:Times New Roman; font-size:10pt"> <TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Joint Development Committee or JDC</P></TD> <TD VALIGN="bottom"></TD> <TD VALIGN="bottom" NOWRAP>2.4</TD></TR> <TR STYLE="font-family:Times New Roman; font-size:10pt"> <TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Joint Manufacturing Committee or JMC</P></TD> <TD VALIGN="bottom"></TD> <TD VALIGN="bottom" NOWRAP>2.5</TD></TR> <TR STYLE="font-family:Times New Roman; font-size:10pt"> <TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Joint Medical Affairs Committee or JMAC</P></TD> <TD VALIGN="bottom"></TD> <TD VALIGN="bottom" NOWRAP>2.7</TD></TR> <TR STYLE="font-family:Times New Roman; font-size:10pt"> <TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Joint Patent Committee or JPC</P></TD> <TD VALIGN="bottom"></TD> <TD VALIGN="bottom" NOWRAP>2.8</TD></TR> <TR STYLE="font-family:Times New Roman; font-size:10pt"> <TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Joint Research Committee or JRC</P></TD> <TD VALIGN="bottom"></TD> <TD VALIGN="bottom" NOWRAP>2.3</TD></TR> <TR STYLE="font-family:Times New Roman; font-size:10pt"> <TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Joint Steering Committee or JSC</P></TD> <TD VALIGN="bottom"></TD> <TD VALIGN="bottom" NOWRAP>2.2</TD></TR> </TABLE> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt"> </P> <TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%"> <TR> <TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>[*] =</B></TD> <TD ALIGN="left" VALIGN="top"><B>Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. </B></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">16 </P> <p Style='page-break-before:always'> <HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER"> <TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center"> <TR> <TD WIDTH="93%"></TD> <TD VALIGN="bottom" WIDTH="6%"></TD> <TD></TD></TR> <TR STYLE="font-family:Times New Roman; font-size:10pt"> <TD VALIGN="top">[*] Regulatory Materials</TD> <TD VALIGN="bottom"></TD> <TD VALIGN="bottom" NOWRAP>7.2(a)</TD></TR> <TR STYLE="font-family:Times New Roman; font-size:10pt"> <TD VALIGN="top">Later Milestone Event</TD> <TD VALIGN="bottom"></TD> <TD VALIGN="bottom" NOWRAP>11.5(b)(i)</TD></TR> <TR STYLE="font-family:Times New Roman; font-size:10pt"> <TD VALIGN="top">Lead Compound [*]</TD> <TD VALIGN="bottom"></TD> <TD VALIGN="bottom" NOWRAP>[*]</TD></TR> <TR STYLE="font-family:Times New Roman; font-size:10pt"> <TD VALIGN="top">Lead Compound [*]</TD> <TD VALIGN="bottom"></TD> <TD VALIGN="bottom" NOWRAP>[*]</TD></TR> <TR STYLE="font-family:Times New Roman; font-size:10pt"> <TD VALIGN="top">[*] Products</TD> <TD VALIGN="bottom"></TD> <TD VALIGN="bottom" NOWRAP>[*]</TD></TR> <TR STYLE="font-family:Times New Roman; font-size:10pt"> <TD VALIGN="top">Medical Affairs Plan</TD> <TD VALIGN="bottom"></TD> <TD VALIGN="bottom" NOWRAP>10.3</TD></TR> <TR STYLE="font-family:Times New Roman; font-size:10pt"> <TD VALIGN="top">MSL</TD> <TD VALIGN="bottom"></TD> <TD VALIGN="bottom" NOWRAP>10.1</TD></TR> <TR STYLE="font-family:Times New Roman; font-size:10pt"> <TD VALIGN="top">[*]</TD> <TD VALIGN="bottom"></TD> <TD VALIGN="bottom" NOWRAP>[*]</TD></TR> <TR STYLE="font-family:Times New Roman; font-size:10pt"> <TD VALIGN="top">Neuromuscular Indications</TD> <TD VALIGN="bottom"></TD> <TD VALIGN="bottom" NOWRAP>9.6(a)</TD></TR> <TR STYLE="font-family:Times New Roman; font-size:10pt"> <TD VALIGN="top">[*]</TD> <TD VALIGN="bottom"></TD> <TD VALIGN="bottom" NOWRAP>[*]</TD></TR> <TR STYLE="font-family:Times New Roman; font-size:10pt"> <TD VALIGN="top">[*]</TD> <TD VALIGN="bottom"></TD> <TD VALIGN="bottom" NOWRAP>[*]</TD></TR> <TR STYLE="font-family:Times New Roman; font-size:10pt"> <TD VALIGN="top">Pharmacovigilance Agreement</TD> <TD VALIGN="bottom"></TD> <TD VALIGN="bottom" NOWRAP>7.5</TD></TR> <TR STYLE="font-family:Times New Roman; font-size:10pt"> <TD VALIGN="top">Phase 1 Work</TD> <TD VALIGN="bottom"></TD> <TD VALIGN="bottom" NOWRAP>6.3(b)(i)</TD></TR> <TR STYLE="font-family:Times New Roman; font-size:10pt"> <TD VALIGN="top">[*]</TD> <TD VALIGN="bottom"></TD> <TD VALIGN="bottom" NOWRAP>[*]</TD></TR> <TR STYLE="font-family:Times New Roman; font-size:10pt"> <TD VALIGN="top">[*]</TD> <TD VALIGN="bottom"></TD> <TD VALIGN="bottom" NOWRAP>[*]</TD></TR> <TR STYLE="font-family:Times New Roman; font-size:10pt"> <TD VALIGN="top">Product Infringement</TD> <TD VALIGN="bottom"></TD> <TD VALIGN="bottom" NOWRAP>12.4(a)</TD></TR> <TR STYLE="font-family:Times New Roman; font-size:10pt"> <TD VALIGN="top">Product Marks</TD> <TD VALIGN="bottom"></TD> <TD VALIGN="bottom" NOWRAP>12.5(a)</TD></TR> <TR STYLE="font-family:Times New Roman; font-size:10pt"> <TD VALIGN="top">Receiving Party</TD> <TD VALIGN="bottom"></TD> <TD VALIGN="bottom" NOWRAP>13.1(a)</TD></TR> <TR STYLE="font-family:Times New Roman; font-size:10pt"> <TD VALIGN="top">Remainder</TD> <TD VALIGN="bottom"></TD> <TD VALIGN="bottom" NOWRAP>12.4(f)</TD></TR> <TR STYLE="font-family:Times New Roman; font-size:10pt"> <TD VALIGN="top">Remedial Action</TD> <TD VALIGN="bottom"></TD> <TD VALIGN="bottom" NOWRAP>7.7</TD></TR> <TR STYLE="font-family:Times New Roman; font-size:10pt"> <TD VALIGN="top">Research Advance Invoice</TD> <TD VALIGN="bottom"></TD> <TD VALIGN="bottom" NOWRAP>11.2(a)</TD></TR> <TR STYLE="font-family:Times New Roman; font-size:10pt"> <TD VALIGN="top">Research Budget</TD> <TD VALIGN="bottom"></TD> <TD VALIGN="bottom" NOWRAP>5.3</TD></TR> <TR STYLE="font-family:Times New Roman; font-size:10pt"> <TD VALIGN="top">Research Plan</TD> <TD VALIGN="bottom"></TD> <TD VALIGN="bottom" NOWRAP>5.3</TD></TR> <TR STYLE="font-family:Times New Roman; font-size:10pt"> <TD VALIGN="top">Research Plan Costs</TD> <TD VALIGN="bottom"></TD> <TD VALIGN="bottom" NOWRAP>5.6</TD></TR> <TR STYLE="font-family:Times New Roman; font-size:10pt"> <TD VALIGN="top">Research Program</TD> <TD VALIGN="bottom"></TD> <TD VALIGN="bottom" NOWRAP>5.1</TD></TR> <TR STYLE="font-family:Times New Roman; font-size:10pt"> <TD VALIGN="top">Research Project Team</TD> <TD VALIGN="bottom"></TD> <TD VALIGN="bottom" NOWRAP>5.9</TD></TR> <TR STYLE="font-family:Times New Roman; font-size:10pt"> <TD VALIGN="top">Research Term</TD> <TD VALIGN="bottom"></TD> <TD VALIGN="bottom" NOWRAP>5.2</TD></TR> <TR STYLE="font-family:Times New Roman; font-size:10pt"> <TD VALIGN="top">Research True-Up Report</TD> <TD VALIGN="bottom"></TD> <TD VALIGN="bottom" NOWRAP>11.2(b)</TD></TR> <TR STYLE="font-family:Times New Roman; font-size:10pt"> <TD VALIGN="top">Responsible Committee</TD> <TD VALIGN="bottom"></TD> <TD VALIGN="bottom" NOWRAP>13.4</TD></TR> <TR STYLE="font-family:Times New Roman; font-size:10pt"> <TD VALIGN="top">[*] Product</TD> <TD VALIGN="bottom"></TD> <TD VALIGN="bottom" NOWRAP>[*]</TD></TR> <TR STYLE="font-family:Times New Roman; font-size:10pt"> <TD VALIGN="top">[*]</TD> <TD VALIGN="bottom"></TD> <TD VALIGN="bottom" NOWRAP>[*]</TD></TR> <TR STYLE="font-family:Times New Roman; font-size:10pt"> <TD VALIGN="top">Royalty Term</TD> <TD VALIGN="bottom"></TD> <TD VALIGN="bottom" NOWRAP>11.7(b)</TD></TR> <TR STYLE="font-family:Times New Roman; font-size:10pt"> <TD VALIGN="top">[*]</TD> <TD VALIGN="bottom"></TD> <TD VALIGN="bottom" NOWRAP>[*]</TD></TR> <TR STYLE="font-family:Times New Roman; font-size:10pt"> <TD VALIGN="top">SEC</TD> <TD VALIGN="bottom"></TD> <TD VALIGN="bottom" NOWRAP>13.5(b)</TD></TR> <TR STYLE="font-family:Times New Roman; font-size:10pt"> <TD VALIGN="top">Term</TD> <TD VALIGN="bottom"></TD> <TD VALIGN="bottom" NOWRAP>14.1</TD></TR> </TABLE> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt"> </P> <TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%"> <TR> <TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>[*] =</B></TD> <TD ALIGN="left" VALIGN="top"><B>Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. </B></TD></TR></TABLE> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">17 </P> <p Style='page-break-before:always'> <HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER"> <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.92 Interpretation.</B> In this Agreement, unless otherwise expressly specified: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(a)</B> The words “include”, “includes” and “including” shall be deemed to be followed by the phrase “without limitation”. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(b)</B> words denoting the singular shall include the plural and vice versa and words denoting any gender shall include all genders; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(c)</B> words such as “herein”, “hereof”, and “hereunder” refer to this Agreement as a whole and not merely to the particular provision in which such words appear; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(d)</B> “days” means calendar days; and </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(e)</B> the Exhibits and other attachments form part of the operative provision of this Agreement and references to “this Agreement” shall include references to the Exhibits and attachments. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE 2 </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>GOVERNANCE </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>2.1 Alliance Managers.</B> Each Party hereby appoints the person listed on <U><B>Exhibit F</B></U> to act as its alliance manager under this Agreement as of the Amendment Effective Date (the “<B>Alliance Manager</B>”). The Alliance Managers shall: (a) serve as the primary contact points between the Parties for the purpose of providing the other Party with information on the progress of such Party’s activities under this Agreement; (b) be primarily responsible for facilitating the flow of information and otherwise promoting communication, coordination and collaboration between the Parties; (c) act as advocates for the Collaboration as a whole; (d) have regular telephone calls; (e) use Diligent Efforts to facilitate the prompt resolution of any disputes; (f) attend as appropriate JRC, JDC, JMC, JCC and JMAC meetings; and (g) have the right to attend all other Committee and subcommittee meetings, all as non-voting members. An Alliance Manager may also bring any matter to the attention of any Committee if such Alliance Manager reasonably believes that such matter warrants such attention. Each Party may replace its Alliance Manager at any time upon written notice to the other Party. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>2.2 Joint Steering Committee.</B> The Parties shall establish a joint steering committee (the “<B>Joint Steering Committee</B>” or the “<B>JSC</B>”), composed of [*] of each Party, including the [*] under this Agreement and [*] under this Agreement. All JSC representatives will have sufficient authority within the applicable Party to make decisions [*] arising within the scope of the JSC’s responsibilities. Either Party may request that its own or the other Party’s personnel with expertise on a particular matter attend a JSC meeting where such matter will be discussed. The JSC shall in particular: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(a)</B> oversee and provide strategic direction to the Collaboration; </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt"> </P> <TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%"> <TR> <TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>[*] =</B></TD> <TD ALIGN="left" VALIGN="top"><B>Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. </B></TD></TR></TABLE> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">18 </P> <p Style='page-break-before:always'> <HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER"> <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(b)</B> oversee the integration and coordination of the Research, Development, Manufacture (as applicable), Commercialization and Medical Affairs Activities of the Compounds and Collaboration Products within the JSC member’s company; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(c)</B> provide a forum for discussion of the Research, Development, Manufacture, Commercialization and Medical Affairs Activities of the Compounds and Collaboration Products; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(d)</B> review the Parties’ progress against the Research Plan, Development Plan, Commercialization Plan and Medical Affairs Plan; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(e)</B> oversee the operation of the JRC, JDC, JMC, JCC, JMAC and JPC, including resolving any disputed matter of the JRC, JDC, JMC, JCC, JMAC and JPC; and </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(f) </B>perform such other duties as are expressly assigned to the JSC in this Agreement, and such other functions as appropriate to further the purposes of this Agreement as may be allocated to it by the Parties’ written agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>2.3 Joint Research Committee.</B> The Parties shall establish a joint research committee (the “<B>Joint Research Committee</B>” or the “<B>JRC</B>”), composed of [*] of each Party that have [*] in the research of compounds similar to the Compounds, to monitor and coordinate the Research of Compounds under the Collaboration. The JRC shall exist during the Research Term. All JRC representatives will have sufficient authority within the applicable Party to make decisions [*] arising within the scope of the JRC’s responsibilities. The JRC shall in particular: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(a)</B> coordinate the activities of the Parties under the Research Plan and oversee the implementation of the Research Plan; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(b)</B> prepare and approve annual or interim amendments to the Research Plan (including the Research Budget); </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(c)</B> provide a forum for and facilitate communications between the Parties with respect to the Research of Compounds; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(d)</B> establish joint subcommittees, as appropriate, to carry out its functions; and </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(e)</B> perform such other functions as may be appropriate to further the purposes of this Agreement with respect to the Research of Compounds. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>2.4 Joint Development Committee.</B> The Parties shall establish a joint development committee (the “<B>Joint Development Committee</B>” or the “<B>JDC</B>”), composed of [*] of each Party that have [*] in the development of products similar to the Compounds and Collaboration Products, to monitor and coordinate the Development of the Compounds and Collaboration Products under the Collaboration. All JDC representatives will have sufficient authority within the applicable Party to make decisions [*] </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt"> </P> <TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%"> <TR> <TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>[*] =</B></TD> <TD ALIGN="left" VALIGN="top"><B>Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. </B></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">19 </P> <p Style='page-break-before:always'> <HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">[*] arising with the scope of the JDC’s responsibilities. The JDC shall in particular: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(a)</B> coordinate the activities of the Parties under the Development Plan and oversee the implementation of the Development Plan; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(b)</B> establish the protocol and statistical analysis plan for each human clinical trial conducted under the Development Plan; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(c)</B> prepare and approve annual or interim amendments to the Development Plan (including the Cytokinetics Development Budget); </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(d)</B> provide a forum for and facilitate communications between the Parties with respect to the Development of the Compounds and Collaboration Products; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(e)</B> review the data and results of [*] a Collaboration Product [*] such Collaboration Product [*] in which case [*]; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(f)</B> monitor and coordinate all regulatory actions, communications and submissions for the Compounds and Collaboration Products under the Development Plan, including allocating related medical affairs responsibilities between the Parties; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(g) </B>until formation of the JMAC, oversee medical education activities and establish a joint review process for medical affairs materials, including disease state awareness, medical education and other non-promotional materials; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(h)</B> establish joint subcommittees, as appropriate, to carry out its functions; and </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(i)</B> perform such other functions as may be appropriate to further the purposes of this Agreement with respect to the Development of the Compounds and Collaboration Products. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>2.5 Joint Manufacturing Committee.</B> The Parties shall establish a joint manufacturing committee (the <B>“</B><B>Joint Manufacturing Committee</B>” or “<B>JMC</B>”), composed of up to [*] of each Party that have [*] in the manufacture of compounds and products similar to the Compounds and Collaboration Products, to monitor and oversee the CMC Activities and other activities related to the Manufacture of the Compounds and Collaboration Products for use under the Collaboration. All JMC representatives will have sufficient authority within the applicable Party to make decisions [*] arising within the scope of the JMC’s responsibilities. The JMC shall in particular: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(a)</B> discuss, approve and oversee implementation of and progress against the Development Plan and Commercialization Plan as they relate to CMC Activities; </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt"> </P> <TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%"> <TR> <TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>[*] =</B></TD> <TD ALIGN="left" VALIGN="top"><B>Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. </B></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">20 </P> <p Style='page-break-before:always'> <HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER"> <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(b)</B> coordinate and facilitate cooperation and flow of information between the Parties with respect to the Manufacture and supply of the Compounds and Collaboration Products for Development and Commercialization use in accordance with Article 8; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(c)</B> coordinate and facilitate the transfer of Manufacturing Know-How as and to the extent provided in Article 8; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(d)</B> establish joint subcommittees, as appropriate, to carry out its functions; and </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(e)</B> perform such other functions as may be appropriate to further the purposes of this Agreement with respect to the Manufacture of Compounds and Collaboration Products, as directed by the JDC or JCC (as applicable). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>2.6 Joint Commercialization Committee.</B> Unless otherwise agreed upon between the Parties, within [*], the Parties shall form and establish a joint commercialization committee (the “<B>Joint Commercialization Committee</B>” or “<B>JCC</B>”), composed of [*] of each Party that have [*] in the commercialization of products similar to the Collaboration Products, to monitor and oversee the Commercialization activities of the Collaboration Products under the Collaboration. All JCC representatives will have sufficient authority within the applicable Party to make decisions [*] arising within the scope of the JCC’s responsibilities. The JCC shall in particular: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(a)</B> coordinate the activities of the Parties under the Commercialization Plan and oversee the implementation of the Commercialization Plan; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(b)</B> prepare and approve annual or interim amendments to the Commercialization Plan; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(c)</B> provide a forum for and facilitate communications between the Parties with respect to the Commercialization of the Collaboration Products; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(d)</B> establish joint subcommittees, as appropriate, to carry out its functions; and </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(e)</B> perform such other functions as may be appropriate to further the purposes of this Agreement with respect to the Commercialization of the Collaboration Products. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>2.7 Joint Medical Affairs Committee.</B> Unless otherwise agreed upon between the Parties, [*] the Parties may agree upon, the Parties shall form and establish a joint medical affairs committee (the “<B>Joint Medical Affairs</B> </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt"> </P> <TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%"> <TR> <TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>[*] =</B></TD> <TD ALIGN="left" VALIGN="top"><B>Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. </B></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">21 </P> <p Style='page-break-before:always'> <HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Committee</B>” or “<B>JMAC</B>”), composed of [*] of each Party that have [*] in Medical Affairs Activities of products similar to the Collaboration Products, to monitor and oversee the Medical Affairs Activities for the Compounds and Collaboration Products under the Collaboration. All JMAC representatives will have sufficient authority within the applicable Party to make decisions [*] arising within the scope of the JMAC’s responsibilities. The JMAC shall in particular: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(a)</B> coordinate the activities of the Parties under the Medical Affairs Plan and oversee the implementation of the Medical Affairs Plan; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(b)</B> prepare and approve annual or interim amendments to the Medical Affairs Plan; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(c)</B> prepare and approve the protocol and statistical analysis plan for each human clinical trial to be conducted under the Medical Affairs Plan; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(d)</B> provide a forum for and facilitate communications between the Parties with respect to the Medical Affairs Activities for the Compounds and Collaboration Products; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(e)</B> establish a joint review process for medical affairs materials, including disease state awareness, medical education and other non-promotional materials; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(f) </B>establish joint subcommittees, as appropriate, to carry out its functions; and </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(g)</B> perform such other functions as may be appropriate to further the purposes of this Agreement with respect to the Medical Affairs Activities for the Compounds and Collaboration Products. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>2.8 Joint Patent Committee.</B> The Parties shall establish a joint patent committee (the “<B>Joint Patent Committee</B>” or “<B>JPC</B>”), composed of [*] representing each Party, to coordinate the prosecution and enforcement of Collaboration Patents under Article 12. Such patent counsel shall have sufficient authority within or on behalf of the applicable Party to make decisions [*] arising within the scope of the JPC’s responsibilities. The JPC shall in particular: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(a)</B> coordinate and facilitate the prosecution and enforcement of the Collaboration Patents, and make periodic reports of the same to the JSC and other Committees upon request; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(b)</B> discuss and develop patent strategy for Collaboration Patents, including making key decisions on drafting, filing, prosecution, maintenance, enforcement and defense of Collaboration Patents, as well as providing a forum for the Parties to discuss material issues and provide input to each other regarding Collaboration Patents; </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt"> </P> <TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%"> <TR> <TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>[*] =</B></TD> <TD ALIGN="left" VALIGN="top"><B>Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. </B></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">22 </P> <p Style='page-break-before:always'> <HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER"> <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(c)</B> determine which Patents are to be considered Collaboration Patents, and oversee the determination of inventorship of Collaboration Intellectual Property; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(d)</B> confer regarding patent term extensions and listings in the FDA’s Approved Drug Products with Therapeutic Equivalence Evaluations (known as the “Orange Book”) and its foreign counterparts; and </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(e)</B> perform such other functions as may be appropriate to further the purposes of this Agreement with respect to the patent prosecution and enforcement activities under this Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>2.9 [*</B>] In the event that [*] a Compound and corresponding Collaboration Product [*] under Section [*] such Compound and Collaboration Product [*], the Parties shall [*] and discuss and decide [*] such Compound and Collaboration Product [*]; provided that, with respect to [*] contemporaneously with or following the [*] as agreed by the Parties. [*] such Compound and Collaboration Products [*] taking into consideration [*] as well as the [*] the roles and responsibilities of each Party [*] such Compound and Collaboration Product. For clarity, [*] pursuant to Section [*] </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>2.10 Limitation of Committee Authority</B>. Each Committee shall only have the powers expressly assigned to it in this Article 2 and elsewhere in this Agreement and shall not have the authority to: (a) modify or amend the terms and conditions of this Agreement; (b) waive either Party’s compliance with the terms and conditions of under this Agreement; or (c) determine any such issue in a manner that would conflict with the express terms and conditions of this Agreement. </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt"> </P> <TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%"> <TR> <TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>[*] =</B></TD> <TD ALIGN="left" VALIGN="top"><B>Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. </B></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">23 </P> <p Style='page-break-before:always'> <HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER"> <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>2.11 Committee Membership and Meetings. </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(a) Committee Members</B>. The members of each Party on the JSC, JRC, JDC and JPC as of the Amendment Effective Date are set forth in <U><B>Exhibit F</B></U>. Each Party may replace its representatives on any Committee by written notice to the other Party. Each Party shall appoint one (1) of its representatives on each Committee to act as a co-chairperson of such Committee. The co-chairpersons shall jointly prepare and circulate agendas and reasonably detailed minutes for each Committee meeting within thirty (30) days of such meeting. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(b) Meetings</B>. Unless the Parties otherwise agree, each Committee shall hold meetings at such times as it elects to do so, but no less frequently than once every [*] for (i) the JRC; (ii) the JDC; (iii) the JMC; and (iv) the JCC. In all other circumstances, each Committee shall hold regular meetings no less frequently than once every [*] and more frequently as needed upon written request of either Party and consent of the other Party, which consent shall not be unreasonably withheld or delayed. Meetings of each Committee shall be held via teleconference, via videoconference or in person, provided that at least [*] per year for the [*] and [*] per year for the [*] shall be held in person (unless the Parties otherwise agree) at locations to be alternately selected by each Party. Each Party shall be responsible for all of its own expenses of participating in any Committee. No action taken at any meeting of a Committee shall be effective unless a representative of each Party is participating. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(c) Non-Member Attendance</B>. Each Party may from time to time invite a reasonable number of participants, in addition to its representatives, to attend the Committee meetings in a non-voting capacity; provided that if either Party intends to have any Third Party (including any consultant) attend such a meeting, such Party shall provide prior written notice to the other Party and shall ensure that such Third Party is bound by confidentiality and non-use obligations consistent with the terms of this Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>2.12 Continuity of Representation</B>. Notwithstanding the Parties’ respective right to replace its Alliance Manager and members of Committees by written notification to the other Party, each Party shall strive to maintain continuity in the representation of such Alliance Manager and Committee members. If a particular Committee ceases to exist but certain activities that have been overseen by such Committee are still ongoing, then the Parties shall by mutual written agreement allocate the responsibility for overseeing such activities to another then-operating Committee that is competent and suitable in authority and expertise. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>2.13 Decision-Making</B>. All decisions of each Committee shall be made by [*]. If after reasonable discussion and good faith consideration of each Party’s view on a particular matter before a Committee, the representatives of the Parties cannot reach an agreement as to such matter within [*] after such matter was brought to such Committee for resolution or after such matter has been referred to such Committee, such disagreement shall be referred to the JSC (in the case of disagreement of the JRC, JDC, JMC, JCC, JMAC, JPC or other joint subcommittees) </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt"> </P> <TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%"> <TR> <TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>[*] =</B></TD> <TD ALIGN="left" VALIGN="top"><B>Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. </B></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">24 </P> <p Style='page-break-before:always'> <HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"> for resolution. If the JSC cannot resolve such matter within [*] after such matter has been referred to them, then: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt"> </P> <TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%"> <TR> <TD WIDTH="8%"> </TD> <TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>(a)</B></TD> <TD ALIGN="left" VALIGN="top"><B>[*] [*]</B> for those set forth in Section [*] </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt"> </P> <TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%"> <TR> <TD WIDTH="8%"> </TD> <TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>(b)</B></TD> <TD ALIGN="left" VALIGN="top"><B>[*] [</B><B>*</B>]:<B></B><B></B> </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt"> </P> <TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%"> <TR> <TD WIDTH="13%"> </TD> <TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>(i)</B></TD> <TD ALIGN="left" VALIGN="top">pertaining to [*] as to whether to [*]; and/or </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt"> </P> <TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%"> <TR> <TD WIDTH="13%"> </TD> <TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>(ii)</B></TD> <TD ALIGN="left" VALIGN="top">pertaining to the following aspects of activities relating to [*]: </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:17%; font-size:10pt; font-family:Times New Roman"><B>(1)</B> the [*] Activators in any such Indication (including the related [*]) to generate the [*] as part of the Collaboration and the related [*] for so long as [*] such Development, including the generation of the [*] as set forth in Section [*] for which [*] is responsible under Section 6.3[*] related matters, but [*], as well as the [*]. For clarity, after [*] without the [*]; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:17%; font-size:10pt; font-family:Times New Roman"><B>(2)</B> the [*] Activators in any such [*], as set forth in more detail in Section [*]. For clarity, [*] shall not cover the [*], which shall be [*] subject to the [*] if the matter is [*] during the [*]; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:17%; font-size:10pt; font-family:Times New Roman"><B>(3)</B> the [*] Activators in any such [*] during the [*]; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:17%; font-size:10pt; font-family:Times New Roman"><B>(4)</B> if [*] for such [*] for such [*]; and </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt"> </P> <TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%"> <TR> <TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>[*] =</B></TD> <TD ALIGN="left" VALIGN="top"><B>Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. </B></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">25 </P> <p Style='page-break-before:always'> <HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER"> <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:17%; font-size:10pt; font-family:Times New Roman"><B>(5) </B>if [*] for such [*] for such [*] consistent with Article [*] set forth in this Section 2.13(b). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(c)</B> <B>[*]</B> The following issues in Sections 2.13(c)(i) through (v) below (the [*]) shall be subject to [*] </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman"><B>(i)</B> the [*] Indication ([*] Indication) as [*] Indication and the related [*] the Development Plan pertaining to the Development of one or more [*] Activator(s) in such Indication as set forth in Section [*]. For clarity, if the Parties [*] Indication ([*] Indication [*]) as [*] Indication, or on the [*] Development Plan pertaining to such Indication, then such [*] Indication shall [*] Indication; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman"><B>(ii)</B> the [*] Activator in any [*] Indications, including [*] to support (A) [*] such Compound and corresponding Collaboration Product [*]; and (B) [*] such Compound and corresponding Collaboration Product [*] with respect to such [*] Activator and [*] with respect thereto; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman"><B>(iii) </B>the [*] (but the related [*] subject to the [*] (as applicable) subject to the [*] if the matter is [*]) described in Sections [*] as subject to [*]; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman"><B>(iv)</B> the [*] set forth in the Development Plan [*], except for any [*]); and </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman"><B>(v)</B> any other decision [*] under this Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>[*]</B> </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt"> </P> <TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%"> <TR> <TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>[*] =</B></TD> <TD ALIGN="left" VALIGN="top"><B>Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. </B></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">26 </P> <p Style='page-break-before:always'> <HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER"> <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(d) [*]</B> </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman"><B>(i) </B>With respect to [*] the Development activities (which include [*] in connection with such Development activities to the extent provided in Article [*]) pursuant to Section [*] with respect to [*] as well as the related [*] (which shall be subject to [*]), unless such activities [*] under the Collaboration, in which case the status quo will remain in effect until the issue is resolved. For clarity, [*], such matters shall be [*]. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman"><B>(ii)</B> [*] with respect to [*] Indications [*] as set forth in Section [*]. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman"><B>(iii)</B> [*] Indication, the Party [*] shall have the [*] with respect to [*] as set forth in Section [*]. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman"><B>(iv)</B> The Party [*] Collaboration Product [*] will have the [*] with respect to [*]. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>2.14 Discontinuation of Participation on a Committee.</B> The activities to be performed by each Committee shall solely relate to governance under this Agreement, and are not intended to be or involve the delivery of services. Each Committee shall continue to exist until the first to occur of: (a) the Parties mutually agreeing to disband the Committee; or (b) Cytokinetics providing written notice to Astellas of its intention to disband and no longer participate in such Committee. Once the Parties mutually agree or Cytokinetics has provided written notice to disband such Committee, such Committee shall have no further obligations under this Agreement and, thereafter, the Alliance Managers shall be the contact persons for the exchange of information under this Agreement and decisions of such Committee shall be decisions as between the Parties, subject to the other terms and conditions of this Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>2.15 Budgets and Fiscal Years.</B> The Parties acknowledge that Astellas’ fiscal year runs from April 1 through March 31, while Cytokinetics’ fiscal year runs from January 1 through December 31. Accordingly, [*] relating to the Research, Development, Medical Affairs and Commercialization of the Compounds and Collaboration Products [*] </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt"> </P> <TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%"> <TR> <TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>[*] =</B></TD> <TD ALIGN="left" VALIGN="top"><B>Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. </B></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">27 </P> <p Style='page-break-before:always'> <HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE 3 </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>LICENSES </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>3.1 License to Astellas.</B> Subject to the terms and conditions of this Agreement, Cytokinetics hereby grants to Astellas the following royalty-bearing worldwide licenses [*] under the Cytokinetics Technology and Cytokinetics’ interest in the Collaboration Intellectual Property: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(a)</B> to Research (i) [*] Activators in the Collaboration Indications and (ii) [*] Activators in the Field, in each case pursuant to the Research Plan during the Research Term, which license shall be [*] as set forth in Section [*]; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(b)</B> to Develop (i) [*] Activators in the Collaboration Indications and (ii) [*] Activators in the Field, in each case pursuant to the Development Plan, which license shall be [*] as set forth in Section [*]; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(c)</B> to use [*] Activators and Collaboration Products containing [*] Activators in the Collaboration Indications and to make, have made, offer for sale, sell and otherwise Commercialize [*] Activators and Collaboration Products containing [*] Activators for use in the Collaboration Indications, [*] except as provided in Sections [*] below; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(d)</B> to use [*] Activators and Collaboration Products containing [*] Activators in the Field and to make, have made, offer for sale, sell and otherwise Commercialize [*] Activators and Collaboration Products containing [*] Activators for use in the Field, [*], except as provided in Sections [*] below; and </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(e)</B> to perform Medical Affairs Activities for the Compounds and Collaboration Products pursuant to the Medical Affairs Plan, [*], except as provided in Sections [*] below. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Subject to Section [*] the licenses granted by Cytokinetics to Astellas under this Agreement [*] to develop, make, have made, use, sell, offer for sale or otherwise commercialize [*] that is [*] with a Compound. </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt"> </P> <TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%"> <TR> <TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>[*] =</B></TD> <TD ALIGN="left" VALIGN="top"><B>Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. </B></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">28 </P> <p Style='page-break-before:always'> <HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER"> <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>3.2 Sublicense Rights.</B> Subject to the terms and conditions of this Agreement: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(a) </B>Further subject to Section [*] below, each Party may exercise its rights and perform its obligations under this Agreement by itself or through the engagement of any of its Affiliates [*] in the performance of this Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(b)</B> Each Party may sublicense the rights granted to it under Section [*] (as applicable) to one (1) or more Third Parties, provided, however, that such Party shall: (i) [*], and (ii) [*] the other Party [*]. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(c)</B> Notwithstanding the foregoing, [*] with respect to Collaboration Products [*] but in any event [*]. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(d)</B> Each Party shall remain directly responsible for all of its obligations under this Agreement that have been delegated, subcontracted or sublicensed to any of its Affiliates, sublicensees or subcontractors and shall ensure that such Affiliates, sublicensees and subcontractors comply with the terms and conditions of this Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>3.3 Cytokinetics’ Retained Rights.</B> Cytokinetics and its Affiliates hereby retain: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(a)</B> the rights to practice the Cytokinetics Technology and Cytokinetics’ interest in the Collaboration Intellectual Property to exercise its and their rights and perform its and their obligations under this Agreement, whether directly or through one or more licensees; and </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(b) </B>subject to Section [*] the exclusive rights to otherwise practice and license the Cytokinetics Technology and Cytokinetics’ interest in the Collaboration Intellectual Property outside the scope of the licenses granted to Astellas under Section 3.1, including researching, developing, manufacturing, having manufactured and commercializing [*] in the Retained Indications. </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt"> </P> <TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%"> <TR> <TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>[*] =</B></TD> <TD ALIGN="left" VALIGN="top"><B>Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. </B></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">29 </P> <p Style='page-break-before:always'> <HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER"> <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>3.4 License to Cytokinetics.</B> Subject to the terms and conditions of this Agreement, Astellas hereby grants to Cytokinetics the following fully paid-up licenses [*]: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(a) </B>under the Astellas Technology and Astellas’ interest in the Collaboration Intellectual Property to Research (i) [*] Activators in the Collaboration Indications and (ii) [*] Activators in the Field, in each case pursuant to the Research Plan during the Research Term, [*]; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(b) </B>under the Astellas Technology and Astellas’ interest in the Collaboration Intellectual Property to Develop the Compounds and Collaboration Products pursuant to the Development Plan, [*]; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(c) </B>under the Astellas Technology and Astellas’ interest in the Collaboration Intellectual Property to manufacture and have manufactured the Compounds and Collaboration Products pursuant to the Development Plan or Commercialization Plan as appropriate, [*]; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(d) </B>under the Astellas Technology and Astellas’ interest in the Collaboration Intellectual Property to Co-Promote the Collaboration Products in the Co-Promotion Territory (or Shared Territory, as applicable and as set forth in Section 9.6) pursuant to the Commercialization Plan upon Cytokinetics’ exercise of the Co-Promotion option under Section 9.6, [*]; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(e) </B>under the Astellas Technology and Astellas’ interest in the Collaboration Intellectual Property to Commercialize in the Shared Territory the Collaboration Products in any [*] Indication(s) [*]; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(f) </B>further subject to Section [*] under Astellas’ interest in the Collaboration Intellectual Property to research, develop, manufacture, have manufactured and commercialize [*] for uses in the Retained Indications worldwide, [*]; and </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(g) </B>under the Astellas Technology and Astellas’ interest in the Collaboration Intellectual Property to perform Medical Affairs Activities for the Compounds and Collaboration Products in the Co-Promotion Territory (or Shared Territory, as applicable and as set forth in Article 10) pursuant to the Medical Affairs Plan, [*]. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>3.5 No Implied Licenses; Negative Covenant.</B> Except as set forth herein, neither Party shall acquire any license or other intellectual property interest, by implication or otherwise, </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt"> </P> <TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%"> <TR> <TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>[*] =</B></TD> <TD ALIGN="left" VALIGN="top"><B>Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. </B></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">30 </P> <p Style='page-break-before:always'> <HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"> under or to any trademarks, Patent Rights, Know-How, or other intellectual properties owned or Controlled by the other Party. For clarity, the license granted to each Party under any particular Patent Rights or Know-How Controlled by the other Party shall confer exclusivity to the Party obtaining such license only to the extent the Party granting such license Controls the exclusive rights to such Patent Rights or Know-How. Neither Party shall, nor shall permit any of its Affiliates or sublicensees to, practice any Patent Rights or Know-How licensed to it by the other Party outside the scope of the license granted to it under this Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>3.6 [*]</B> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(a)</B> Except as set forth in Section [*] and subject to Sections [*] below, [*]: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman"><B>(i)</B> [*], other than [*] Activators for use in the [*] pursuant to this Agreement; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman"><B>(ii)</B> [*] Activators for use in the [*] (A) pursuant to this Agreement [*]; (B) pursuant to Section [*] or (C) as otherwise agreed by the Parties; or </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman"><B>(iii)</B> [*] for use in the [*] pursuant to this Agreement or the Collaboration. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(b)</B> Notwithstanding the foregoing, [*] will not be deemed to be conducted under or pursuant to this Agreement or the Collaboration. [*] shall mean any [*] for which the [*], but excluding any [*] means: (i) [*] unless and until the [*]; and (ii) any other [*] but only if the [*] </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt"> </P> <TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%"> <TR> <TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>[*] =</B></TD> <TD ALIGN="left" VALIGN="top"><B>Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. </B></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">31 </P> <p Style='page-break-before:always'> <HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">[*] </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(c)</B> [*] shall use Diligent Efforts to [*] Activator that is [*] the Collaboration Indications, including by [*] any Collaboration Product containing a [*] the Collaboration Indications, or [*] any Collaboration Product containing a [*]. So long as [*] set forth in this subsection (c), the [*] Collaboration Products [*] shall not, by itself, be deemed [*] under Section [*] of its obligations under this Section 3.6. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(d)</B> [*] shall use Diligent Efforts to [*] the Licensed Indications [*], including by [*] the Licensed Indications [*] the Licensed Indications [*]. So long as [*] set forth in this subsection (d), the [*] shall not, by itself, be deemed [*] under Section [*] of its obligations under this Section 3.6. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(e)</B> If either Party [*] and if such [*], as of the [*] such Party would [*] set forth in Section [*], then such Party shall [*] either (i) [*] of this Agreement, in which event [*] a Compound and/or Collaboration Product under this Agreement and subject to the terms and conditions hereunder and any [*] the Research, Development, Manufacture or Commercialization of [*], or (ii) [*]. Such Party’s [*] shall not be deemed [*] set forth in this Section 3.6; provided that such Party [*] under this Agreement and [*] the other Party [*] [*] as used in this Section 3.6(e), means [*] by such Party [*]. </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt"> </P> <TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%"> <TR> <TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>[*] =</B></TD> <TD ALIGN="left" VALIGN="top"><B>Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. </B></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">32 </P> <p Style='page-break-before:always'> <HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER"> <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(f) </B>If [*] with respect only to any of the [*] pursuant to Section [*] apply with respect to [*]. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>3.7 Subcontractors.</B> Each Party shall have the right to engage subcontractors for purposes of conducting activities assigned to it under this Agreement and grant a limited sublicense to such Third Parties solely for the purpose of performing such activities, provided that any such subcontractor is bound by written obligations of confidentiality and non-use consistent with this Agreement [*] and has agreed to [*] that relate to any Compounds or Collaboration Products or their use, manufacture or sale, which [*] as appropriate. Each Party shall remain directly responsible for any obligations under this Agreement that have been delegated or subcontracted to any subcontractor, and shall be directly responsible for the performance of its subcontractors. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>3.8 365(n) Rights.</B> All rights and licenses granted under or pursuant to any section of this Agreement, including the licenses granted under this Article 3 and Section 14.3, are and will otherwise be deemed to be for purposes of Section 365(n) of the United States Bankruptcy Code (Title 11, U.S. Code), as amended (the “<B>Bankruptcy Code</B>”), licenses of rights to “intellectual property” as defined in Section 101(35A) of the Bankruptcy Code. Each Party will retain and may fully exercise all of its respective rights and elections under the Bankruptcy Code. Each Party agrees that the other Party, as licensee of such rights under this Agreement, will retain and may fully exercise all of its rights and elections under the Bankruptcy Code or any other provisions of applicable Law outside the United States that provide similar protection for “intellectual property.” Each Party further agrees that, in the event of the commencement of a bankruptcy proceeding by or against such Party under the Bankruptcy Code or analogous provisions of applicable Law outside the United States, to the extent permitted by Law, [*] the Research and/or Development of the Compounds and/or Collaboration Products under this Agreement pursuant to the Research Plan and/or Development Plan, as appropriate, which, [*]. Additionally, upon request by the other Party, the bankruptcy Party shall [*]. </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt"> </P> <TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%"> <TR> <TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>[*] =</B></TD> <TD ALIGN="left" VALIGN="top"><B>Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. </B></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">33 </P> <p Style='page-break-before:always'> <HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE 4 </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>EXPANSION OF COLLABORATION </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>4.1 [*] Indications.</B> </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(a)</B> <B>Addition of [*] Indications.</B> In addition to SMA, the Parties may add one or more Retained Indication(s) [*] as [*] Indication(s) by mutual agreement. If a Party is interested in adding any such Indication as [*] Indication, such Party shall notify the other Party and provide the other Party with [*] for such Indication, and the Parties shall confer and discuss such proposed addition. Such Indication shall be added as [*] Indication [*] the Development Plan pertaining to the Development of [*] Activators in such Indication. If such Indication is added to the [*] Indications, the Parties shall [*] agreed by the Parties). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(b) Cytokinetics Co-Funding Option.</B> On a [*] Activator-by-[*] Activator basis, Cytokinetics shall have [*] option to co-fund [*] (the “<B>Cytokinetics Co-Funding Option</B>”). Cytokinetics may exercise the Cytokinetics Co-Funding Option for a particular [*] Activator by providing a written notice of option exercise to Astellas at any time [*] Indication for such [*] Activator. Astellas shall provide Cytokinetics with [*]. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(c)</B> <B>[*]</B>. If: (i) [*] for a particular [*] Activator, or (ii) [*] for such [*] Activator [*] with written notification [*] then in each case [*]. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(d) </B>[<B>*</B>] means, with respect to a particular [*] Activator, the [*], including, but not limited to, [*] regardless of the [*] pursuant to Section [*] in accordance with the Development Plan and [*] Indication(s) (including any [*], </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt"> </P> <TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%"> <TR> <TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>[*] =</B></TD> <TD ALIGN="left" VALIGN="top"><B>Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. </B></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">34 </P> <p Style='page-break-before:always'> <HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"> but excluding any [*]) to generate the [*] for a particular [*] Activator in [*] Indications. For clarity, [*] shall include the [*] for such [*] Activator with the [*], regardless of [*], but shall exclude the [*] in the Shared Territory, or [*] for such [*] Activator in a [*] in the Astellas Territory. [*] shall include the [*] of the Compound and Collaboration Product [*] but shall exclude the [*] necessary for the [*]. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>4.2 [*] Indications.</B> <B> </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(a)</B> <B>[*] Indications.</B> [*] one or more [*] a [*] Indication upon written notice to [*] Development activities for such Collaboration Product for such Indication. In connection with [*] shall provide [*] the Development Plan (including the [*]) pertaining to the Development of [*] Activators in such Indication(s) and [*] the JDC. If the JDC [*] and if the [*] will have the [*]. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(b) [*] [</B>*] shall have the right to [*] the [*] Indication [*] for such Indication [*]. If [*] shall also be [*] Development activities for such Indication pursuant to Section [*] shall continue to [*] ([*], to the extent practicable [*] Development program, and [*] under the Development Plan) [*] Development work [*] including, but not limited to, the [*] pertaining to such Indication subject to [*] set forth in Article [*]. [*] with respect to any [*] Indication [*] at any of the [*]: (i) [*] (for any [*] Indication) [*] such Indication to the Collaboration under Section [*]; (ii) if applicable, [*] with respect to the [*] the Development of the [*] </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt"> </P> <TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%"> <TR> <TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>[*] =</B></TD> <TD ALIGN="left" VALIGN="top"><B>Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. </B></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">35 </P> <p Style='page-break-before:always'> <HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"> [*] Activator in such Indication under Section [*] Development activities with respect to such Compound in such Indication; and/or (iii) if applicable, [*] with respect to the [*] Indication [*] the Development of a [*] in such Indication under Section [*] for such Indication. [*] related Development work [*] the Development Plan [*]. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(c) [*</B>] means with respect to a particular [*] Activator in [*] Indication, the [*], as well as any [*], but excluding any [*]). [*] Indication [*] shall include the [*] for [*] Activator with the [*], regardless of [*] but shall exclude the [*] in the Shared Territory, or [*] for [*] Activator in a [*] in the Astellas Territory, which [*] shall be [*] Indication [*] shall include the [*] but shall exclude the [*]. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE 5 </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>RESEARCH </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>5.1 General.</B> The Parties will conduct a research collaboration to discover, identify, characterize and optimize [*] Activators for further Development in the Licensed Indications and/or [*] Indications and [*] Activators in the Field pursuant to the Research Plan (the “<B>Research Program</B>”). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>5.2 Research Term.</B> The term of such Research Program (the “<B>Research Term</B>”) shall commence on the Effective Date and end on December 31, 2016. The Research Term may be extended by the Parties’ mutual written agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>5.3 Research Plan.</B> All Research activities under this Agreement shall be conducted pursuant to a comprehensive written Research plan for Astellas’ fiscal year during the Research Term (the “<B>Research Plan</B>”). The Research Plan shall allocate Research responsibilities between the Parties and shall set forth the objectives, activities and criteria for evaluation for such Research, as well as the timeline related thereto. The Research Plan shall also set forth the detailed budget </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt"> </P> <TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%"> <TR> <TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>[*] =</B></TD> <TD ALIGN="left" VALIGN="top"><B>Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. </B></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">36 </P> <p Style='page-break-before:always'> <HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B> </B>for such Research activities, including a minimum of [*] Cytokinetics FTEs that Astellas shall support annually [*] (the “<B>Cytokinetics Research FTEs</B>”), the number of Astellas FTEs committed by Astellas during the Research Term and outsourced costs (the “<B>Research Budget</B>”). From time to time during the Research Term, the JRC shall prepare updates and amendments, as appropriate, to the then-current Research Plan (including the Research Budget). In any event, the Research Plan for the forthcoming Astellas’ fiscal year shall be approved by [*] of the preceding year, provided that by [*] of each calendar year, the JRC shall agree upon a proposed budget for the following Astellas fiscal year with respect to costs other than for the Cytokinetics Research FTEs, and Astellas shall use good faith efforts to obtain internal approval for such proposed budget to become effective by [*]. The JRC shall have the right to approve updates and amendments to the Research Plan (including the Research Budget), provided that no amendment to the Research Plan (including the Research Budget) shall decrease the number of Cytokinetics Research FTEs supported by Astellas without Cytokinetics’ consent. Once approved by the JRC, such revised Research Plan shall replace the prior Research Plan. If the terms of the Research Plan contradict, or create inconsistencies or ambiguities with, the terms of this Agreement, then the terms of this Agreement shall govern. <B> </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>5.4 Conduct of Research</B>. Each Party shall use Diligent Efforts to carry out the Research activities assigned to it in the Research Plan and shall conduct such activities in good scientific manner, and in compliance with all applicable Laws. Each Party shall keep the other Party reasonably informed as to its progress in the conduct of the Research Plan through meetings of the JRC. At least [*] Business Days before each JRC meeting, each Party shall submit to the JRC a written summary of its Research activities since its prior report. All [*] under the Research Plan will be [*], provided that neither Party will be required to [*] where it reasonably believes that [*]. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>5.5 Research Records.</B> Each Party shall maintain complete, current and accurate records of all Research activities conducted by it hereunder, and all data and other information resulting from such activities. Such records shall fully and properly reflect all work done and results achieved in the performance of the Research activities in good scientific manner [*] to the extent [*]. After the Effective Date, upon reasonable request of [*] to be mutually agreed by the Parties, [*] that pertain to the Compounds and/or Collaboration Products or otherwise relate to the Research performed pursuant to the Research Plan [*] as described in the [*] shall be deemed Confidential Information [*]. </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt"> </P> <TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%"> <TR> <TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>[*] =</B></TD> <TD ALIGN="left" VALIGN="top"><B>Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. </B></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">37 </P> <p Style='page-break-before:always'> <HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER"> <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>5.6 Research Plan Costs</B>. Subject to this Section 5.6, Astellas shall be responsible for all the costs and expenses incurred by both Parties in performing the Research in accordance with the Research Plan (the “<B>Research Plan Costs</B>”) and shall reimburse Cytokinetics for the Research Plan Costs incurred by or on account of Cytokinetics in accordance with the Research Budget pursuant to Section 11.2. Research Plan Costs that are incurred by Cytokinetics and subject to reimbursement by Astellas shall include the costs of [*] set forth in the Research Plan, and [*]. During any given Astellas fiscal year, Astellas shall not be responsible for reimbursement of (i) any [*]; or (ii) any [*] the applicable Research Budget. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>5.7 Research in [*] Indications</B>. Notwithstanding anything to the contrary in this Agreement, the Parties may conduct Research of [*] Activators in one or more [*] Indications to [*], but only to the extent agreed and set forth in the Research Plan as part of the Research Program governed by this Article 5. Neither Party shall be obligated to agree to the conduct of any such Research. For clarity, the Parties may [*] the Collaboration in accordance with Article [*]. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>5.8 Other [*].</B> Each Party shall have the right to [*] the Research Plan solely for the purpose of [*], provided that such activities shall [*] and neither Party shall have the right to [*] the other Party or [*] the other Party in connection therewith. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>5.9 Research Project Team</B>. The Parties will establish a research project team (the “<B>Research Project Team</B>”) that will be responsible for managing, reviewing and implementing the performance of the day to day activities of both Parties for all stages of the Research Program, including review and decision making regarding lead optimization, safety evaluation, structural biology, computational chemistry and pharmacology. Each Party will have representation on the Research Project Team throughout the Research Program. The Research Project Team shall be subordinate to and governed by the JRC. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE 6 </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>DEVELOPMENT </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>6.1 General.</B> Subject to the terms and conditions of this Agreement, the Parties will collaborate with respect to the Development of the Compounds and Collaboration Products in the Collaboration Indications (for [*] Activators) or the Field (for [*] Activators) for Regulatory Approval under the direction of the JDC and </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt"> </P> <TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%"> <TR> <TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>[*] =</B></TD> <TD ALIGN="left" VALIGN="top"><B>Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. </B></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">38 </P> <p Style='page-break-before:always'> <HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">pursuant to the Development Plan, as set forth in more details below. The Parties intend to pursue Development of the Lead Compound and other Compounds and Collaboration Products broadly across an array of Indications. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>6.2 Development Plan.</B> <B> </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(a) </B>The Development of the Compounds and Collaboration Products under this Agreement (the “<B>Development Program</B>”) shall be conducted pursuant to a comprehensive written Development plan (the “<B>Development Plan</B>”). The Development Plan for each Compound and corresponding Collaboration Products shall set forth the timeline and details of: (i) all preclinical and clinical Development activities to be conducted by the Parties as necessary to generate data sufficient to meet the requirements for Marketing Approval of such Compound and corresponding Collaboration Products for each of the Indications as agreed by the Parties and set forth in the Development Plan; (ii) the protocol synopsis for each clinical trial included in such Development Plan; (iii) a Manufacturing plan; and (iv) any other Development activities that the Parties agree to pursue in collaboration for such Compound and corresponding Collaboration Products. The Parties agree that: (A) the Development Plan will contain detailed plans for at least [*] covered by the Development Plan, and summary plans for periods thereafter, and (B) the budget associated with such Development Plan shall be subject to the approval process set forth in Section 6.2(d). The Development Plan shall include a coordinated development and regulatory strategy, including the Parties’ respective roles in the development of each Collaboration Product and the countries in which Development of Collaboration Product will occur. The Development Plan shall also set forth: (1) a detailed budget of the Development activities to be [*]; (2) if Cytokinetics has exercised the Cytokinetics Co-Funding Option for a Collaboration Product and [*] for such Collaboration Product, a detailed budget for [*] of such Collaboration Product in the [*] Indications (the [*]); and (3) if [*] Indication [*] the Collaboration and [*] for such [*] Indication, a detailed budget for such [*] Indication Development Work (the “[<B>*] Indication Development Budget</B>”). Upon the other Party’s reasonable request, each Party shall [*] Development activities under the Development Plan. The [*] shall be included in the Development Plan and [*] shall be subject to JDC approval. For reference, the Development Plan in effect as of the Amendment Effective Date is [*] which was approved by the JDC and signed by the JDC co-chairs in [*]. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(b)</B> The initial focus of the Development Program was the conduct of Phase 1 Clinical Trials and Phase 2 readiness activities for the Lead Compound in 2013, with the [*] for the Lead Compound [*] </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt"> </P> <TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%"> <TR> <TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>[*] =</B></TD> <TD ALIGN="left" VALIGN="top"><B>Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. </B></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">39 </P> <p Style='page-break-before:always'> <HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER"> <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(c)</B> The Development Program in 2015 shall include the initial Phase 2 Clinical Trial of the Lead Compound in SMA. As of the Amendment Effective Date, the Parties have agreed on a [*] for such initial Phase 2 Clinical Trial within the document attached hereto as <U><B>Exhibit M</B></U>. Promptly after the Amendment Effective Date, the JDC shall update the Development Plan to include the conduct of such initial Phase 2 Clinical Trial in 2015, consistent with [*] set forth in such exhibit. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(d) </B>The JDC shall update the Development Plan (including [*] as applicable) at least annually, with such annual update to be finally approved no later than [*] of the preceding Astellas’ fiscal year, provided that [*] Indication [*] subject to the [*] the JDC (and [*] Indication [*]) after [*] for such Indication. By [*] of each calendar year starting on [*] Development activities are [*] the updated Development Plan, the JDC shall agree upon a proposed [*] for the following Astellas fiscal year beyond [*]. Astellas shall use good faith efforts to [*]. From time to time during the Term, the JDC shall prepare amendments, as appropriate, to the then-current Development Plan (including [*] as applicable), including adding additional Compounds and Collaboration Products as well as additional Indications [*] the Collaboration pursuant to Article [*] The JDC shall have the right to approve updates and amendments to the Development Plan (including [*] as applicable), provided that [*] subject to the [*] the JDC (and [* ]) after [*] for such Indication. Once approved by the JDC, such revised Development Plan shall replace the prior Development Plan. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(e)</B> If the terms of the Development Plan contradict, or create inconsistencies or ambiguities with, the terms of this Agreement, then the terms of this Agreement shall govern. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>6.3 Allocation of Development Responsibilities</B><B>.</B> The Development Plan shall allocate Development responsibilities of the Compounds and Collaboration Products between the Parties as follows: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(a) Astellas Responsibilities</B>. Subject to Sections 6.3(b), 6.3(c) and 6.3(d) below, Astellas shall be primarily responsible for the Development of (i) [*] Activators and corresponding Collaboration Products: (A) in the Licensed Indications and [*] Indications throughout the world; (B) in [*] Indications for [*] in the Shared Territory and [*] </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt"> </P> <TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%"> <TR> <TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>[*] =</B></TD> <TD ALIGN="left" VALIGN="top"><B>Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. </B></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">40 </P> <p Style='page-break-before:always'> <HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"> Development activities in Astellas Territory; and (C) and [*] Indications unless Astellas [*] the conduct of such [*] or as otherwise set forth in Article [*] and (ii) [*] Activators and corresponding Collaboration Products in the Field throughout the world, in each case pursuant to the Development Plan. While it is contemplated that Cytokinetics shall be responsible for the Phase 1 Work and Early Stage Work as described in subsection (b) below, the JDC may allocate to Astellas specific clinical and non<B>-</B>clinical activities to be conducted in parallel with the Phase 1 Work and/or Early Stage Work [*]. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(b) Cytokinetics Responsibilities</B>. Notwithstanding Section 6.3(a), Cytokinetics shall be responsible for the conduct of: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman"><B>(i) </B>the Phase 1 Clinical Trials of the Lead Compound (but excluding [*] Development activities in the Astellas Territory) and Phase 2 readiness activities in Licensed Indications (including [*] but excluding any activities allocated to Astellas pursuant to subsection (a) above) pursuant to the Development Plan through the initiation of the first Phase 2 Clinical Trial for the Lead Compound in Licensed Indications (the “<B>Phase 1 Work</B>”); </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman"><B>(ii)</B> the Development activities for the Lead Compound in [*] Indications prior to [*] (but excluding any [*] Development activities in the Astellas Territory ) (the “<B>Early Stage Work</B>”), including the [*] and the initiation of the initial Phase 2 Clinical Trial in SMA in 2015, and, subject to the Parties’ mutual agreement, in Licensed Indications; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman"><B>(iii)</B> other Development activities for the Lead Compound and other [*] Activators in [*] Indications allocated to Cytokinetics by the JDC, taking into consideration [*] of the Collaboration; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman"><B>(iv)</B> all Development activities for [*] Activators in [*] Indications to generate [*] for such Compounds in such Indications (the “[*] <B>Indication Development Work</B>”), including [*] (to the extent provided in Article [*]) in connection with such Development activities but excluding [*] for such [*] Indication and [*]; and </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman"><B>(v)</B> other Development activities under the Development Plan [*] [*]. </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt"> </P> <TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%"> <TR> <TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>[*] =</B></TD> <TD ALIGN="left" VALIGN="top"><B>Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. </B></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">41 </P> <p Style='page-break-before:always'> <HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER"> <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(c) Development in [*] Indications</B>. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman"><B>(i)</B> Notwithstanding Section [*] shall have the right, but not the obligation, to conduct Development activities for Compounds and Collaboration Products in [*] Indication(s) [*] as set forth in this Section 6.3(c) (“[<B>*</B><B>] Indication Development</B>”). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman"><B>(ii)</B> [*] and shall not be subject to the [*] set forth in Section [*]. [*] shall have the right, but not the obligation, to [*] Compounds and Collaboration Products [*] Indication pursuant to subsections (iv) through (vi) below. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman"><B>(iii)</B> In addition to [*] as set forth in subsection (ii) above, [*] Development Plan [*] Development activities for one or more Collaboration Products for [*] Indication, [*] Development activities for such Indication [*] the Development Plan [*] Development in such Indication in accordance with the Development Plan, [*] such Indication as a [*] Indication. Upon [*] such Indication [*] Indication, provided that, in [*] Development in such Indication under the Development Plan will [*] the Development and/or Commercialization of Compound and Collaboration Product in Indications [*] Developed and/or Commercialized [*] pursuant to the Development Plan and/or Commercialization Plan. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman"><B>(iv)</B> [*] Indication Development, [*] a reasonably [*] by the JDC, such [*] the Development Plan and such [*] Indication Development shall be conducted pursuant to such plan. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman"><B>(v)</B> [*] Indication Development as part of the regular JDC reporting cycle. Following the [*] Indication Development for a Compound and corresponding Collaboration Product in a [*] Indication Development as well as the [*] Indication Development for such Collaboration Product [*] as well as the [*] the Development of such Compound or Collaboration Product in such Indication [*] [*]); provided that if such [*] Indication is [*] as set forth in Section [*]. </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt"> </P> <TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%"> <TR> <TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>[*] =</B></TD> <TD ALIGN="left" VALIGN="top"><B>Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. </B></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">42 </P> <p Style='page-break-before:always'> <HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER"> <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman"><B>(vi)</B> [*] such Development work, then (A) [*] Indication Development [*] as set forth in Section [*] (B) [*] such Compound and Collaboration Product in such Indication as set forth in Section [*]; and (C) all [*] Development in such [*] Indication shall be subject to the [*] under this Agreement applicable to the Development for [*] Indications other than [*] Indication, and the [*] the Development Plan and Cytokinetics Development Budget to include such continued Development work in such [*] Indication, including allocation of the Parties’ respective responsibilities for [*] Development work (i.e., the Parties’ respective activities in [*]). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman"><B>(vii)</B> [*] such Development work, then such Compound and Collaboration Product will [*] Indication; provided that if the Development of such Compound or Collaboration Product in such [*] Indication [*] or otherwise by the Parties, then Section [*] shall apply. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(d) Development in [*] Indications; Lead Party Responsibilities</B>. Subject to [*] the Development of [*] Activators in [*] Indications, for as long as [*] such Development, the Parties [*] with respect to Development activities for [*] Indications, except that: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman"><B>(i) </B>Cytokinetics shall lead all [*] Indication Development Work, including [*] (to the extent provided in Article [*]) in connection with such Development activities, to generate [*] in the Shared Territory. Subject to Section 6.3(d)(iii), Astellas shall lead all [*] Indication Development Work, including all [*] (to the extent provided in Article [*]) in connection with such Development activities, pertaining to [*] in the Shared Territory and [*] in the Astellas Territory. For clarity, [*] for such Indication [*] such Indication and [*]. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman"><B>(ii) </B>Notwithstanding anything to the contrary, including Section [*] the Party designated to lead certain [*] Indication Development Work (which includes [*] and, to the extent provided in </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt"> </P> <TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%"> <TR> <TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>[*] =</B></TD> <TD ALIGN="left" VALIGN="top"><B>Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. </B></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">43 </P> <p Style='page-break-before:always'> <HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"> Article [*] in connection with such Development activities) shall have the right to make decisions concerning the operation of such activities without the approval of the JDC as far as such activities are being conducted under the Development Plan (but shall keep the JDC reasonably informed on its conduct of such activities, at a level of detail reasonably requested by the other Party, as part of the regular JDC reporting cycle); and </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman"><B>(iii) </B>In the event that [*] further right to [*] Indication Development Work for such Indication [*] shall have the [*] Indication [*], provided, however, that [*] shall consider in good faith [*] with respect to the [*] shall keep the JDC reasonably informed on its conduct of such Development activities at a level of detail [*] as part of the regular JDC reporting cycle. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>6.4 Development Costs. </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(a) General.</B> Except as set forth in Sections 6.4(b), (c) and (d) below, Astellas shall be solely responsible for all Development Costs incurred by or on behalf of either Party in performing Development activities under the Development Plan, and shall reimburse Cytokinetics for Development Costs incurred by Cytokinetics as set forth in Section 11.3(a), to the extent [*]. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(b) Development Costs for [*] Indication Development.</B> [*] the Development Costs incurred by or on behalf of [*] Indication Development (the “<B>[*] Indication Development Costs</B>”); provided that if [*] the Development of any Compound or Collaboration Product in any [*] Indication that were the [*] Indication Development after [*] as set forth in Section [*]. The Development Costs incurred by either Party in the continued Development in such Indication [*] Indication Development shall be [*] as set forth in Section [*] above. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(c) Development Costs in [*] Indications.</B> If [*] with respect to a [*] Activator and subject to the [*] set forth in Section [*] for such [*], to the extent [*] Budget as approved by the JDC [*]. [*] pursuant to Section [*]. [*] Development Costs for the [*] Indications. </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt"> </P> <TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%"> <TR> <TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>[*] =</B></TD> <TD ALIGN="left" VALIGN="top"><B>Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. </B></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">44 </P> <p Style='page-break-before:always'> <HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER"> <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(d) Development Costs in [*] Indications.</B> For all [*] Indications, subject to the [*] set forth in Section [*] Development Costs, provided that [*] Development Budget as approved by the JDC [*] pursuant to Section [*] Development Costs for [*] Indications, including the [*] Development activities [*] in the Shared Territory and [*] in Astellas Territory for [*] Activators in [*] Indications. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>6.5 Diligence</B>. <B> </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(a)</B> Each Party shall use Diligent Efforts to conduct the Development activities assigned to it under the Development Plan. Without limiting the foregoing, [*] </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman"><B>(i)</B> [*] set forth in the Development Plan; and </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman"><B>(ii)</B> [*] (i.e., a [*] Activator or [*] Activator) and [*]). If [*] for a particular [*] at any time after the [*] immediately following the [*] will be deemed to [*] pursuant to Section [*] with respect to Compounds and Collaboration Products [*] provided that [*]. In such event, Section [*] shall apply with respect to [*] shall no longer apply with respect to [*]. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(b) </B>[*] Compound or Collaboration Product if: (i) [*] such Compound or Collaboration Product are [*] Development Plan in a [*] such Compound or Collaboration Product, and [*] in accordance with the Development Plan; or (ii) [*] such Collaboration Product. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(c)</B> In the event of [*] Compound or Collaboration Product [*], the Parties shall [*]. In the event the [*] [*] shall be subject to [*] in accordance with [*] set forth in Section [*]. </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt"> </P> <TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%"> <TR> <TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>[*] =</B></TD> <TD ALIGN="left" VALIGN="top"><B>Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. </B></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">45 </P> <p Style='page-break-before:always'> <HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER"> <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(d)</B> Without limiting [*] set forth herein, [*] the Development of the Lead Compound and [*] the Lead Compound. [*] the Lead Compound [*] Indication [*] shall have the right (but not the obligation) to [*] [*] Indication [*] Indication and [*] the Lead Compound [*] Indication in accordance with Section [*]. [*] such Development [*] Indication shall [*] under Section [*] </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(e)</B> Without limiting [*] set forth herein, [*] Activators for Development [*] Indications, and [*] Activators for Development [*] Indication(s). [*] pertaining to the [*] Activators, [*] Development activities [*] Activator [*] Indication, then: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman"><B>(i)</B> [*] Activators with respect to [*] Indications [*] Indications [*] Indications; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman"><B>(ii) </B>[*] Activators [*] Indications [*] notwithstanding Section [*] Indications [*] provided that [*] Development activities for a [*] Activator [*] Indication [*] Development under the Development Plan [*] Activator in any [*] Indication or any [*] Indication under this Agreement; and </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman"><B>(iii)</B> [*] the Collaboration relating to [*] Activators [*] with respect to [*] Indications. [*] [*] Activators in the [*] Indications in accordance with this Section 6.5(e). </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt"> </P> <TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%"> <TR> <TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>[*] =</B></TD> <TD ALIGN="left" VALIGN="top"><B>Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. </B></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">46 </P> <p Style='page-break-before:always'> <HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER"> <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>6.6 Lead Compound Development; Advancement to Phase 2. </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(a)</B> Cytokinetics will be the Party responsible for continuing to conduct the Phase 1 Work as described in Section 6.3(b)(i). In connection therewith, Cytokinetics will continue to: (i) hold the Lead Compound IND; (ii) be the lead Party interacting with the Regulatory Authorities on matters pertaining to the Development of the Lead Compound and the Lead Product; and (iii) Manufacture and supply the Lead Compound and the Lead Product for use in such Development activities. Cytokinetics shall provide the JDC with the data and results from the Phase 1 Work on an ongoing basis. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(b)</B> Concurrently with Cytokinetics’ conduct of the Phase 1 Work, the Parties, through the JDC, shall jointly plan for the initiation of the first Phase 2 Clinical Trial for the Lead Compound by agreeing on the initial Indication to be pursued, drafting the study protocol and related documents and planning for the conduct of such Clinical Trial. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(c)</B> Promptly following completion of the Phase 1 Work (including any additional Phase 1 Clinical Trials, PK studies, formulation work or meetings with Regulatory Authorities that may be added through amendments to the Development Plan) by Cytokinetics, and other Phase 2a enabling studies conducted by Astellas in parallel with Phase 1 Work (including any additional studies or meetings with Regulatory Authorities that may be added through amendments to the Development Plan) and in any event, [*] the JDC will determine whether or not to advance the Lead Compound into a Phase 2 Clinical Trial (currently anticipated to be a Phase 2a study). Astellas may conduct Phase 2a enabling studies for the Lead Compound in accordance with the Development Plan prior to and following the Lead Compound [*] in accordance with the Development Plan [*] as determined by the JDC (e.g., [*]). “<B>Lead Compound [*]</B>” means the [*] from the applicable [*] if the JDC determines that such [*] the Lead Compound into the first Phase 2 Clinical Trial, provided that [*] described in the initial Development Plan. </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt"> </P> <TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%"> <TR> <TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>[*] =</B></TD> <TD ALIGN="left" VALIGN="top"><B>Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. </B></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">47 </P> <p Style='page-break-before:always'> <HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER"> <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(d)</B> As of the Amendment Effective Date, the JDC has decided to advance the Lead Compound into a Phase 2 Clinical Trial, and as the result of such decision, Astellas shall pay to Cytokinetics the fifteen million Dollars ($15,000,000) milestone payment set forth in Section 11.5(b)(i) for the achievement of such milestone within thirty (30) days after the Amendment Effective Date. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>6.7 Development Records</B>. Each Party shall maintain complete, current and accurate records of all Development activities conducted by it hereunder, and all data and other information resulting from such activities. Such records shall fully and properly reflect all work done and results achieved in the performance of the Development activities in good scientific manner [*]. Each Party shall document all non-clinical studies and clinical trials in formal written study reports according to applicable Laws and national and international guidelines (e.g., ICH, GCP, GLP, and GMP). Each Party shall have the right to review and copy such records maintained by the other Party at reasonable times and to obtain access to the original [*]. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>6.8 Data Exchange and Development Reports.</B> In addition to adverse event and safety data reporting obligations pursuant to Section 7.5, each Party shall promptly provide the other Party with copies of all data and results generated by or on behalf of such Party in the course of performing the Development hereunder (including final reports), and including, in each case of data arising from clinical trials, [*] as the JDC may agree from time to time. The Party receiving such data shall have the right to use and reference such data to perform its obligations or to exercise its rights under this Agreement, including as set forth in Section 7.1(f). Each Party shall provide the JDC with regular reports detailing its Development for the Collaboration Products, and the results of such Development at each regularly scheduled JDC meeting. The Parties shall discuss the status, progress and results of each Party’s Development at such JDC meetings. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>6.9 Advisory Panels; Medical Education Activities. </B>The Development Plan may also provide for advisory panels with key opinion leaders with respect to the Development of Collaboration Products to be held by one or both Parties. The Party organizing the advisory panel shall give the other Party written notice at least [*] in advance of any such advisory panel meetings, and the other Party shall have the right to attend such meetings. If the Parties agree to conduct non-promotional medical education activities and the JMAC has not been established at that time, the Parties shall conduct non-promotional medical education activities as part of the Development Activities under the Development Plan and under the oversight of the JDC, and [*] in connection therewith shall [*] provided that, if for any Collaboration Product, [*] such medical education activities [*] medical education activities for such Collaboration Product, then [*] shall have the right to conduct such medical education activities for such Collaboration Product under the JDC’s oversight, and, [*] </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt"> </P> <TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%"> <TR> <TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>[*] =</B></TD> <TD ALIGN="left" VALIGN="top"><B>Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. </B></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">48 </P> <p Style='page-break-before:always'> <HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">[*] such medical education activities shall be: (a) [*] medical education activities for such Collaboration Product under the Development Plan and (b) [*] such activities. If the non-promotional medical education activities [*] Compounds, the Parties shall discuss in good faith an appropriate [*] each Party. Nothing in this Section 6.9 will [*] scientific and/or medical conferences, or [*] continuing medical education activities [*] in connection with [*] Compounds. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>6.10 Development Project Team</B>. The Parties will establish a project team for each Compound (the “<B>Development Project Team</B>”) that will be responsible for managing, reviewing and implementing the performance of the day to day activities of both Parties for all stages of the Development Program for such Compound, including review and decision making regarding CMC, toxicology, clinical trial designs and regulatory filings and strategy. Each Party will have representation on the Development Project Team throughout the Development Program. The Development Project Team shall be subordinate to and governed by the JDC (except with respect to CMC issues, with respect to which the Development Project Team will be subordinate to and governed by the JMC). <B> </B></P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE 7 </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>REGULATORY </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>7.1 Regulatory Responsibilities. </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(a)</B> The Development Plan shall set forth the regulatory strategy for seeking Marketing Approval for the Compounds and Collaboration Products by the FDA, EMA and other Regulatory Authorities in [*] as agreed upon by the Parties. [*] Development under the Development Plan (including the [*] Development), [*] necessary to obtain and maintain Regulatory Approval of the Compounds and Collaboration Products in the Collaboration Indications (for [*] Activators) or the Field (for [*] Activators) throughout the world, which activities shall be conducted using Diligent Efforts and in accordance with the regulatory strategy set forth in the Development Plan. For the Development Plan, the regulatory strategy will be set by Astellas except where [*]; in such case [*]. For the Development Plan, Cytokinetics will set the regulatory strategy for [*] and other activities [*] except when [*] in the Shared Territory [*] [*]) for [*] Indications [*] in the Shared Territory, and Astellas will set the regulatory strategy for [*] Indications for the Astellas Territory. Except where [*] regulatory activities related to [*]. </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt"> </P> <TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%"> <TR> <TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>[*] =</B></TD> <TD ALIGN="left" VALIGN="top"><B>Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. </B></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">49 </P> <p Style='page-break-before:always'> <HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER"> <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(b)</B> Cytokinetics shall hold the Lead Compound IND during the conduct of the Early Stage Work. Prior to the [*], Cytokinetics shall transfer the Lead Compound IND [*] to Astellas, unless the JDC [*] as set forth in Section 6.3(b)(iii), in which case Cytokinetics shall continue to hold the Lead Compound IND and Regulatory Materials related to such Development work. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(c) </B>[*] Regulatory Materials for [*] Activators for [*] Indication to support the Development of such Compound in such Indications in the Shared Territory. If [*] Activator for [*] Indication or [*] Indication [*] Indication. [*] regulatory strategy in the Development Plan for [*] (but excluding [*] in the Shared Territory [*]) for such [*] Indications [*] in the Shared Territory. If [*] Indication, [*] regulatory activities related to [*] Activators for such Indication<B>. </B>If [*] the right to [*] a Collaboration Product in the Shared Territory [*] as set forth in Section [*] shall have the right to [*] pertaining to such Collaboration Product in the Shared Territory [*]. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(d)</B> In addition, [*] shall be responsible for [*] regulatory activities related to [*] Development (including [*] applicable Regulatory Authorities) until the JDC [*] the Development of [*] Indication under Section [*]. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(e)</B> [*] in connection with [*] under Sections 7.1(b), (c), and (d) will be [*] Indication [*] Indication [*], as applicable. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(f)</B> Astellas hereby grants Cytokinetics and its Affiliates and (sub)licensees the right to reference any IND and other Regulatory Materials Controlled by or on behalf of Astellas </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt"> </P> <TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%"> <TR> <TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>[*] =</B></TD> <TD ALIGN="left" VALIGN="top"><B>Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. </B></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">50 </P> <p Style='page-break-before:always'> <HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"> or its Affiliates for use in the Development by Cytokinetics in accordance with this Agreement, and Cytokinetics hereby grants Astellas, its Affiliates and sublicensees the right to reference any IND for Compounds and/or Collaboration Products and other Regulatory Materials Controlled by or on behalf of Cytokinetics or its Affiliates for use in the Development by Astellas, its Affiliates and sublicensees in accordance with this Agreement. Each Party hereby grants the other Party the right to use any data resulting from such Party’s activities under this Agreement to perform its obligations or to exercise its rights under this Agreement. Each Party may file its own IND(s) and other Regulatory Materials for each [*] Activator to support its Development work under this Agreement, which may cross reference the other Party’s IND(s) and other Regulatory Materials for such [*] Activator. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(g)</B> Except as set forth in Sections 7.1(b), (c) and (d) above and otherwise agreed in writing by the Parties, [*] shall be responsible, [*] for the Collaboration Products [*]. Without limiting the foregoing: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman"><B>(i) </B>Astellas shall file its own IND for the Development of the Lead Compound for the activities allocated to it under the Development Plan and Astellas shall have the right to cross reference the Lead Compound IND if necessary. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman"><B>(ii)</B> Astellas shall hold IND(s) and other Regulatory Materials for [*] Activators for each [*] Indication to support the Development of such Compound in such Indication in the Astellas Territory, and Astellas shall [*] for such Indication in the Astellas Territory. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman"><B>(iii)</B> [*] shall be responsible for regulatory activities related to [*] Activators for each [*] Indication, unless [*] for such Indication. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>7.2 Cooperation.</B> Each Party shall cooperate reasonably with the other Party with respect to key regulatory activities relating to the Compounds and Collaboration Products, shall provide such other Party with all reasonable assistance in the preparation and filing of Regulatory Materials relating to the Compounds and Collaboration Products, and shall keep such other Party reasonably and timely informed of its preparation and submission of all Regulatory Materials relating to the Compounds and Collaboration Products and the Regulatory Authorities’ review of such Regulatory Materials. Without limiting the foregoing, each Party: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(a)</B> shall consult with the other Party through the JDC or JCC, as applicable, regarding regulatory matters pertaining to [*] Regulatory Materials [*] relating to the Compounds and Collaboration Products, including plans, strategies, filings, reports, updates and supplements in connection therewith. As used herein, “[*] <B>Regulatory Materials</B>” means IND and MAA filings, [*] or materials </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt"> </P> <TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%"> <TR> <TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>[*] =</B></TD> <TD ALIGN="left" VALIGN="top"><B>Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. </B></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">51 </P> <p Style='page-break-before:always'> <HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"> that: (i) are [*] a Regulatory Authority; (ii) contain [*] such Regulatory Authority; (iii) contain [*] to such Regulatory Authority; or (iv) [*] the relevant Compound or Collaboration Product or its Development or Commercialization; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(b) </B>shall provide the other Party with drafts of any [*] Regulatory Materials for the Compounds and Collaboration Products to be submitted by such Party to the Regulatory Authority in [*] days prior to submission for review and comment (or if [*] such as in the event of [*] by Regulatory Authority that [*] but in no event in a manner that would [*] such reporting or response), and shall consider in good faith any comments received from the other Party; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(c) </B>shall provide the other Party with copies of [*] Regulatory Materials ([*] (as defined below)) submitted to the Regulatory Authority [*] for each calendar month as well as copies of [*] correspondence [*] received from the Regulatory Authority [*] pertaining to the Compounds and Collaboration Products for [*] Business Days [*] to a Regulatory Authority that: (i) is [*] from a Regulatory Authority or is in response to an administrative request or inquiry from a Regulatory Authority; (ii) contains [*] provided to such Regulatory Authority; (iii) contains [*] to such Regulatory Authority; (iv) [*] the receiving Regulatory Authority [*] to the relevant Compound or Collaboration Product or its Development or Commercialization; and (v) is required by Laws to be periodically filed to an existing IND or MAA. [*] includes correspondence such as [*], notifications and non-substantive amendments, but excludes all [*]; and </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(d) </B>shall provide the other Party written minutes or other records of any oral key discussions (such as Type A, Type B and Type C meetings in the U.S. and foreign similar or equivalent meetings) with the Regulatory Authority [*] pertaining to the Compounds and Collaboration Products promptly after any such discussion. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">For purpose of Section 7.2, the Parties shall establish a direct line of contact between the persons responsible for the overall regulatory strategies and activities for the Collaboration Products within each Party. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If any [*] to be provided under Section [*] was originally [*] the providing Party shall provide [*] [*] to the receiving Party at the [*] except the case where such Party reasonably believes such [*] such as in the event of [*] by Regulatory Authority that [*]. </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt"> </P> <TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%"> <TR> <TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>[*] =</B></TD> <TD ALIGN="left" VALIGN="top"><B>Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. </B></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">52 </P> <p Style='page-break-before:always'> <HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER"> <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>7.3 Meetings with Regulatory Authorities</B>. Each Party shall provide the other Party with at least [*] days advance notification of key in-person meeting or teleconference (such as [*] in the U.S. and foreign similar or equivalent meetings) with the Regulatory Authorities [*] that relates to the Development of the Compounds and Collaboration Products under the Development Plan. Such other Party shall have the right, but not the obligation, to have its representatives attend (but, unless otherwise requested by the Party responsible for such meeting, not participate in) such meetings. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>7.4 Product Complaints</B>. Each Party shall be responsible for handling product complaints (except for those covered by Section 7.5 below) arising pursuant to its Development of the Compounds and Collaboration Products in compliance with all applicable Laws. Each Party shall promptly provide the other Party with written notice of any such product complaint received by such Party and arising pursuant to its Development. Upon request of either Party, the Parties shall convene a meeting to discuss such product complaint and collaborate to resolve any such product complaint. Astellas shall be responsible for handling product complaints (except for those covered by Section 7.5 below) relating to marketed Collaboration Products in compliance with all applicable Laws. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>7.5 Adverse Events Reporting. </B>At least [*] prior to the [*] Development [*] Development or as otherwise may be required to satisfy regulatory requirements, the Parties shall enter into a pharmacovigilance and adverse event reporting agreement setting forth the worldwide pharmacovigilance procedures for the Parties with respect to the Collaboration Products, such as safety data sharing, adverse events reporting and prescription events monitoring (the “<B>Pharmacovigilance Agreement</B>”). Such procedures shall be in accordance with, and enable the Parties to fulfill, local and national regulatory reporting obligations under applicable Laws. A Party responsible for the first Pivotal Registration Study for a Collaboration Product in any Collaboration Indication shall establish, prior to the Initiation of the first Pivotal Registration Study for the applicable Collaboration Product, the global safety database for the Collaboration Products, and shall maintain such global safety database for so long as such Collaboration Product is under Development and/or Commercialization hereunder. The [*] to the extent [*] such Collaboration Product for use in a Collaboration Indication. Until the First Commercial Sale of a Collaboration Product, such responsible Party shall hold the primary responsibility for reporting quality complaints, adverse events and safety data related to the Collaboration Products to such database and to the applicable Regulatory Authorities, as well as responding to safety issues and to all requests of Regulatory Authorities related to the Collaboration Products, in each case [*] and to the extent required by the applicable </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt"> </P> <TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%"> <TR> <TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>[*] =</B></TD> <TD ALIGN="left" VALIGN="top"><B>Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. </B></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">53 </P> <p Style='page-break-before:always'> <HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"> Law. If each of the Parties is separately conducting Pivotal Registration Studies for the same Collaboration Product for the same Collaboration Indication, then Astellas shall hold the primary responsibility for establishing and maintaining the global safety database for such Collaboration Product and reporting quality complaints, adverse events and safety data; provided however, that the [*]. After the First Commercial Sale of a Collaboration Product, Astellas shall hold primary responsibility for reporting quality complaints, adverse events and safety data, except during the Cytokinetics Commercialization Period, in which case Cytokinetics shall hold primary responsibility for such activities [*], unless the Parties agree otherwise in writing. After the Cytokinetics Commercialization Period, Cytokinetics will transfer the global safety data in such global safety database for such Collaboration Product to Astellas. Each Party agrees to comply with its respective obligations under the Pharmacovigilance Agreement and to cause its Affiliates, licensees and sublicensees to comply with such obligations. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>7.6 Notification of Threatened Action</B>. Each Party shall immediately notify the other Party of any information it receives regarding any threatened or pending action, inspection or communication by any Regulatory Authority, which may affect the safety or efficacy claims of any Collaboration Product or the continued marketing of any Collaboration Product. Upon receipt of such information, the Parties shall promptly consult with each other in an effort to arrive at a mutually acceptable procedure for taking appropriate action. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>7.7 Remedial Actions</B>. Each Party shall notify the other immediately, and promptly confirm such notice in writing, if it obtains information indicating that any Collaboration Product may be subject to any recall, corrective action or other regulatory action with respect to the Collaboration Product taken by virtue of applicable Law (a “<B>Remedial Action</B>”). The Parties shall fully assist each other in gathering and evaluating such information as is necessary to determine the necessity of conducting a Remedial Action. Each Party shall (and, in case of Astellas, shall ensure that its Affiliates and sublicensees shall) maintain adequate records to permit the Parties to trace the Manufacture, distribution and use of the Collaboration Products. Astellas shall have sole discretion with respect to any matters relating to any Remedial Action, including the decision to commence such Remedial Action and the control over such Remedial Action, at its cost and expense. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>7.8 Collaboration Products [*].</B> Notwithstanding anything to the contrary in this Article 7, in the event that [*] Collaboration Product in the Shared Territory [*] pursuant to Section [*], then Sections [*] (with the Parties’ [*]) to such Collaboration Product in the Shared Territory [*]. </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt"> </P> <TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%"> <TR> <TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>[*] =</B></TD> <TD ALIGN="left" VALIGN="top"><B>Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. </B></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">54 </P> <p Style='page-break-before:always'> <HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE 8 </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>MANUFACTURING AND SUPPLY </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>8.1 General.</B> The Manufacture of the Compounds and Collaboration Products, including all process and formulation development in connection therewith, including CMC Activities, shall be overseen and coordinated by the JMC and conducted pursuant to the Manufacturing plan included in the Development Plan and the Commercialization Plan. At each regularly scheduled JMC meeting, each Party shall provide the JMC with reports summarizing its Manufacturing activities and the results of such activities and [*] Compound and Collaboration Product [*] such Party under this Agreement [*]. The Parties acknowledge that it is in the Collaboration’s interest that, for each Collaboration Product under Development, the clinical trial materials for Development be made with the same process under the JMC’s oversight. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>8.2 Transfer of Manufacturing Know-How to Astellas</B>. <B> </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(a) Technology Transfer. </B>The Parties intend that [*] the Manufacture of the Compounds and Collaboration Products (including the [*]). To this end, promptly following the [*] or at the timing agreed by the JMC but in any event [*] the Compounds and Collaboration Products for the [*] and provided that the [*] Development of such [*] the JMC shall establish the procedures for Cytokinetics to effect the transfer to Astellas of the Cytokinetics Know-How that is then being used by Cytokinetics or its Third Party manufacturer in the Manufacture of the Lead Compound and Lead Products, to the extent such Cytokinetics Know-How is not already in Astellas’ possession. Cytokinetics shall conduct such technology transfer as soon as practicable in accordance with such procedures, [*]. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(b) Assistance.</B> In connection with the transfer of Know-How under this Section 8.2, Cytokinetics shall provide reasonable technical assistance at Astellas’ request [*]. Such technical assistance shall be included as an element of the Development Plan [*]. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>8.3 [*] Supply</B>. Subject to Sections [*] shall be responsible, itself and/or through Affiliates or Third Party contract manufacturers, for the Manufacture and supply of [*] Compounds and Collaboration Products for use [*] in the Development and Commercialization under this Agreement, [*]. </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt"> </P> <TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%"> <TR> <TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>[*] =</B></TD> <TD ALIGN="left" VALIGN="top"><B>Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. </B></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">55 </P> <p Style='page-break-before:always'> <HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER"> <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>8.4 [*] Supply</B>. <B> </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(a) </B>Notwithstanding Section [*] (i) [*] shall Manufacture and supply the [*] as agreed by the JMC, under the Development Plan and the [*] associated therewith will be [*], (ii) [*] shall have the right, but not the obligation, to Manufacture and supply the Compounds and Collaboration Products to conduct [*] Development as set forth in [*], and (iii) if [*] Activator in [*] Indication, [*] have the obligation, and [*] shall have the right, to Manufacture and supply such Compound and related Collaboration Product for use in the Development and Commercialization of such Compound and Collaboration Product in such Indication. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(b)</B> With respect to [*] Development, [*] shall have the right to elect to either (i) [*] the applicable Compounds and Collaboration Products [*] Development if [*] Manufacturing such Compounds and Collaboration Products for [*] under the Development Plan, to be provided [*]; or (ii) [*] such Compound and/or Collaboration Products [*] in which event, [*] then being used by [*] the Manufacture of the Compounds and Collaboration Products to the extent necessary or useful for [*] Manufacture such Compounds and Collaboration Products. Promptly following [*] Development and provided that (x) the JDC [*] has determined to [*] in accordance with Section [*] and (y) [*] Manufactures or has Manufactured such Compound and/or Collaboration Products [*] for such Development work, the JMC shall [*] that is then being used [*] such Compound and such Collaboration Product, to the extent [*] is not already [*] as soon as practicable in accordance with [*]. In connection with the [*] under this Section 8.4, [*]. [*] shall be included [*] the Development Plan and [*]. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(c) </B>With respect to a [*] Activator in [*] Indication, where [*] such Indication: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman"><B>(i) </B>if [*] Manufacture and supply such Compound and related Collaboration Product for use in the Development and Commercialization of such Compound and Collaboration Product in such Indication, or if [*] Manufacture and supply [*] such Compound and Collaboration Product for such use, then such Party shall promptly notify the other Party, and [*] </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt"> </P> <TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%"> <TR> <TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>[*] =</B></TD> <TD ALIGN="left" VALIGN="top"><B>Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. </B></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">56 </P> <p Style='page-break-before:always'> <HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"> [*] then being used [*] Manufacture of such Compound and Collaboration Product to the extent [*] Manufacture such Compound and Collaboration Product. [*] Manufacture and supply such Compound and Collaboration Product [*] and for any [*] to the extent [*] to the extent that it [*] Development [*] Indication(s) and/or [*] Indication(s). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman"><B>(ii) </B>If the Parties agree, [*] Manufacture and supply, and [*], such Collaboration Product for use in the Development and Commercialization of such Collaboration Product in such Indication. In such event, [*] such Collaboration Product to the extent [*] Manufacture and supply under this Agreement (e.g., if Astellas is compensated for such Manufacture and supply [*]), and shall have [*] as set forth in Section [*] </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(d) </B>If [*] (e.g., to [*] a Compound or Collaboration Product or the Manufacture of a Compound or Collaboration Product) and [*] under Section [*] shall have the right to [*] and under the Development Plan. If [*] and the Parties [*] such Compound or Collaboration Product for a [*] Indication [*] by the Parties or [*] (i.e., [*] Indication or [*] Indication, as applicable) of the Development [*] in connection with [*]. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>8.5 Manufacturing Records.</B> Each Party shall promptly provide the other Party, upon its reasonable request for the purpose of this Agreement, copies of the Manufacturing records (including specifications, protocols, batch records, master batch records and other CMC Information) maintained by the first Party, its Affiliates or Third Party contractors pertaining to Compounds and Collaboration Products for such other Party’s use in connection with the Manufacture of the Compounds and/or Collaboration Products under this Agreement (and in the case of [*]). Each Party hereby grants the other Party the right to reference (and have referenced by its contract manufacturer) the Drug Master Files, if any, maintained by the first Party, its Affiliates or Third Party contractors pertaining to Compounds and Collaboration Products for such other Party’s use in connection with the Manufacture of the Compounds and/or Collaboration Products under this Agreement (and in the case of [*]). For as long as [*] </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt"> </P> <TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%"> <TR> <TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>[*] =</B></TD> <TD ALIGN="left" VALIGN="top"><B>Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. </B></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">57 </P> <p Style='page-break-before:always'> <HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"> [*] Manufacture any Collaboration Product pursuant to Section [*] shall have the right to [*] such Collaboration Product [*] (it being understood such [*] the Collaboration Product so long as [*]), upon reasonable request by [*] mutually agreed upon by Astellas and Cytokinetics, provided that [*] have the right to [*]. As between the Parties, all [*] shall be deemed [*]. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>8.6 Manufactured Products</B>. Each Party represents and warrants that all Compounds and Collaboration Products Manufactured and supplied by such Party for clinical trial and/or commercial use under this Agreement shall: (a) meet the applicable specifications; (b) be Manufactured in accordance with current Good Manufacturing Practices; and (c) be Manufactured in accordance with all applicable Laws, including any Governmental Authority requirements then in effect. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE 9 </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>COMMERCIALIZATION </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>9.1 General.</B> Astellas shall have the primary responsibility, at its own expense, for all aspects of (including the conduct of) the Commercialization of the Collaboration Products in the Collaboration Indications (for [*] Activators) or the Field (for [*]) throughout the world, subject to: (a) Cytokinetics’ right to Co-Promote one or more Collaboration Product(s) in the Co-Promotion Territory or Shared Territory, as applicable and as set forth below, (b) Cytokinetics’ right to establish certain Commercialization strategy in [*] Indications as set forth below, (c) Cytokinetics’ right to Commercialize the Collaboration Product(s) in [*] Indications in the Shared Territory during the Cytokinetics Commercialization Period, and (d) other terms and conditions of this Article 9. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>9.2 Commercial Diligence.</B> <B> </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(a) </B>Astellas shall use Diligent Efforts to Commercialize each Collaboration Product [*]. Without limiting the foregoing, and subject to subsection (b) below, Astellas shall [*] Collaboration Product [*] such Collaboration Product [*] in order to [*] such Collaboration Product, solely to the extent [*] such Collaboration Product [*] and provided that [*] to do so (the [*]). </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt"> </P> <TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%"> <TR> <TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>[*] =</B></TD> <TD ALIGN="left" VALIGN="top"><B>Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. </B></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">58 </P> <p Style='page-break-before:always'> <HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER"> <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(b) </B>[*] a Collaboration Product [*] it shall give written notice to [*] together with [*] with respect to the Commercialization of such Collaboration Product [*]. The Parties shall meet and confer in good faith [*] and seek to agree on (i) [*] such Collaboration Product [*], or (ii) whether [*] such Collaboration Product [*] in accordance with Section [*]. If the Parties [*] under Section [*] such Collaboration Product [*] such Collaboration Product [*] such Collaboration Product [*] within the applicable time period. If [*] will be deemed [*] pursuant to Section [*] with respect to such Collaboration Product [*] provided that [*] within the applicable time period. If [*] will continue to [*] such Collaboration Product [*]. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>9.3 Commercialization Plan.</B> <B> </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(a) </B>No later than [*], subject to Sections 9.3(d) and 9.3(e), Astellas shall prepare and provide to the JCC for review and discussion a written plan for the Commercialization of such Collaboration Product in an Astellas’ fiscal year (the “<B>Commercialization Plan</B>”). The Commercialization Plan shall include a reasonably detailed description of and anticipated timeline for the Parties’, their respective Affiliates’ and sublicensees’ Commercialization activities with respect to such Collaboration Product, including pre-launch plans, launch plans, market analytics, product forecasts, pricing assumptions and competitive intelligence. It is the Parties’ understanding that, [*] Astellas will be the Party primarily responsible for the conduct of the Commercialization activities under the Commercialization Plan. Each Party shall use Diligent Efforts to [*] of the collaboration under the Commercialization Plan (including [*]). The Parties agree that the Commercialization Plan and the applicable Commercialization strategy shall be consistent. </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt"> </P> <TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%"> <TR> <TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>[*] =</B></TD> <TD ALIGN="left" VALIGN="top"><B>Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. </B></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">59 </P> <p Style='page-break-before:always'> <HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER"> <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(b)</B> If Cytokinetics exercises its Co-Promotion option for a Collaboration Product, the Commercialization Plan shall also include a reasonably detailed description of and anticipated timeline for Cytokinetics’ Co-Promotion activities as well as a budget therefor, which shall be consistent with Section 9.6 below. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(c) </B>Subject to Sections 9.3(d) and 9.3(e)(ii), Astellas shall periodically (at least on an annual basis) prepare updates and amendments to its Commercialization Plan to reflect changes in its plans, including in response to changes in the marketplaces and related product forecasts, relative success of the Collaboration Products and other relevant factors influencing such plans and activities. Subject to Sections 9.3(d) and 9.3(e)(ii), Astellas shall submit all updates and amendments to its Commercialization Plan to the JCC for review and discussion. For clarity, the Commercialization budget is subject to the final determination by the JCC, subject to [*], subject to Section 9.8. Cytokinetics may perform [*] activities within the scope of its responsibilities under the Commercialization Plan, [*]. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(d)</B> The Commercialization Plan (and any amendment thereto) for any Collaboration Product (i) for a [*] Indication, (ii) for [*] Indication for which Cytokinetics exercises the Cytokinetics Co-Funding Option [*], and (iii) subject to Section 9.3(e) and Section 9.8, for [*] Indication, must be agreed by the JCC by [*]. Neither Party shall conduct any Commercialization activities that are inconsistent with such agreed-upon Commercialization Plan and any Co-Promotion Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(e)</B> With respect to the Commercialization of a Collaboration Product in [*] Indication, subject to Section 9.8, then: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman"><B>(i) </B>If Cytokinetics has an Established Commercial Infrastructure, Cytokinetics shall have [*] for the Commercialization strategy for such Collaboration Product for such Indication in the Shared Territory (but not for the Commercialization strategies with respect to such Collaboration Product as a whole), provided however, such Commercialization strategy and the overall Commercialization Plan shall be consistent. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman"><B>(ii) </B>Regardless of [*] as relates to the portions of the Commercialization Plan for such Collaboration Product that are specific to such Indication for the Shared Territory, as well as any update and/or amendment thereof. The Commercialization strategy with respect to [*] Indications includes the following [*]. </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt"> </P> <TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%"> <TR> <TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>[*] =</B></TD> <TD ALIGN="left" VALIGN="top"><B>Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. </B></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">60 </P> <p Style='page-break-before:always'> <HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER"> <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman"><B>(iii) </B>[*] the Shared Territory and the [*] Astellas and Cytokinetics as well as the [*] such Collaboration Product for such Indication, subject to the discussion and final determination by the JCC, taking into account [*]. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman"><B>(iv) </B>Notwithstanding anything to the contrary, the [*] for such Collaboration Product in such Indication in a particular country will have the decision making authority with respect [*] and other terms of sale for such Collaboration Product in such Indication for such country, provided that the other Party may conduct, [*]. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman"><B>(v) </B>If [*] the Collaboration Product(s) in such [*] Indication, but the Parties have not determined which Party will [*] for the Collaboration Product(s) in such [*] Indication under Section 9.8(b), then [*] shall be responsible for the pre-commercialization activities for the Collaboration Product in such [*] Indication. <B></B> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(f) </B>Subject to Section 9.3(c), Astellas shall be solely responsible for all costs incurred by or on behalf of either Party in performing their respective obligations under the Commercialization Plan except [*] (or [*] determined by the JCC), which shall be agreed between the Parties acting reasonably and in good faith and [*], for its Co-Promotion activities as set forth in the Co-Promotion Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>9.4 Patent Marking</B>. Astellas (and Cytokinetics, if it Commercializes any Collaboration Product in the Shared Territory in [*] Indication, where [*] for such Indication) shall mark all Collaboration Products with patent information in each country in accordance with the applicable Law and to the extent customary in such country, and shall require all of its Affiliates and sublicensees to do the same. To the extent permitted by applicable Law and customary, Astellas shall indicate on Collaboration Product packaging, advertisement and promotional materials that such Collaboration Product is licensed from Cytokinetics. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>9.5 Reports.</B> Astellas (and Cytokinetics, if (a) it exercises its Co-Promotion option or (b) it Commercializes any Collaboration Product in the Shared Territory in [*] Indication, where [*] for such Indication) shall update the JCC at each regularly scheduled JCC meeting regarding its Commercialization of the Collaboration Products. Each such update shall be in a form to be agreed by the JCC and shall </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt"> </P> <TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%"> <TR> <TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>[*] =</B></TD> <TD ALIGN="left" VALIGN="top"><B>Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. </B></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">61 </P> <p Style='page-break-before:always'> <HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"> summarize its, its Affiliates’ and its sublicensees’ significant Commercialization activities with respect to the Collaboration Products throughout the world. The update by Astellas will be at a level of detail reasonably requested by Cytokinetics and sufficient to enable Cytokinetics to determine Astellas’ compliance with its diligence obligations pursuant to Section 9.2. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>9.6 Co-Promotion Option</B>. <B> </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(a) </B>On a Collaboration Product-by-Collaboration Product, Indication-by-Indication, [*] basis, Cytokinetics shall have the right to elect to (i) co-promote each Collaboration Product in the Co-Promotion Territory, and (ii) co-promote or promote each Collaboration Product that contains a [*] Activator for [*] Indications, and, if Astellas is the Party Commercializing such Collaboration Product, for [*] Indications, (collectively “<B>Neuromuscular Indications</B>”) in the Shared Territory, all as set forth in this Section 9.6. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(b) </B>Unless otherwise agreed upon between the Parties, on a Collaboration Product-by-Collaboration Product, Indication-by-Indication, [*] basis, at least [*] prior to the [*] such Collaboration Product in such Indication [*] in the Co-Promotion Territory (or Shared Territory, for any Collaboration Product containing a [*] Activator in Neuromuscular Indications) as set forth in the then-current Development Plan (the “[<B>*</B>]), Astellas shall provide Cytokinetics with a written confirmation that [*]. Then: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman"><B>(i) </B>If the [*] Indication or [*] Indication, then, concurrent with [*] Astellas shall provide the JCC with a [*] on: (A) the [*] such Indication [*]; and (B) the [*] Astellas and Cytokinetics, for such Collaboration Product for such Indication [*]; and (C) [*] (such matters described in (A) and (B) collectively, the <B>“Co-Promotion Matters</B>”, and such notice, the “<B>Astellas Co-Promotion Notice</B>”). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman"><B>(ii) </B>If such [*] Indication, then, within [*] pursuant to Section 9.3(e)(iii), Cytokinetics shall provide the JCC with [*] the Co-Promotion Matters for such Collaboration Product for such Indication [*], as well as a [*] (the “<B>Cytokinetics Co-Promotion Recommendation</B>”). </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt"> </P> <TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%"> <TR> <TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>[*] =</B></TD> <TD ALIGN="left" VALIGN="top"><B>Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. </B></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">62 </P> <p Style='page-break-before:always'> <HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER"> <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman"><B>(iii) </B>The JCC shall discuss [*] on the Co-Promotion Matters (which Co-Promotion Matters shall be subject to [*] if the matter [*]), in each case within [*] after its receipt of such Astellas Co-Promotion Notice or Cytokinetics Co-Promotion Recommendation, as applicable, taking into account [*] of the Collaboration (the “<B>JCC Determination</B>”). Notwithstanding the foregoing, the JCC Determination will [*] which will be agreed by the Parties in the applicable Co-Promotion Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman"><B>(iv) </B>Within [*] after receiving the JCC Determination, Cytokinetics shall have the right to exercise its option to Co-Promote such Collaboration Product for such Indication [*] in the Co-Promotion Territory (or to Co-Promote such Collaboration Product for such Neuromuscular Indication [*] in the Shared Territory) pursuant to such JCC Determination by written notice to Astellas. If Cytokinetics fails to provide such written notice within such [*] period, then Cytokinetics shall be deemed to have elected not to exercise its Co-Promotion option for such Collaboration Product for such Indication [*]. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman"><B>(v) </B>In the event [*] determines that there is a reasonable likelihood that [*] such Collaboration Product for such Indication [*] shall promptly notify [*] in writing after such determination together with [*] therefor, and the [*] obligation to [*] obligation to [*] (and the period during which [*]) shall be extended accordingly based on such [*]. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(c) </B>If Cytokinetics exercises its Co-Promotion option to co-promote a Collaboration Product for a particular Indication [*] the Co-Promotion Territory (or Shared Territory, for any Collaboration Product containing a [*] Activator in Neuromuscular Indications), unless Cytokinetics terminates the Co-Promotion in accordance with Section 9.6(e) below, its Co-Promotion efforts for such Collaboration Product in such Indication (the “<B>Cytokinetics Co-Promotion Effort</B>”) shall be determined by the JCC on a Collaboration Product-by-Collaboration Product, Indication-by-Indication [*] basis, but in any event shall be no less than [*] particular Collaboration Products for a particular Indication [*] the Co-Promotion Territory (or Shared Territory, for any Collaboration Product containing a [*] Activator in Neuromuscular Indications), unless otherwise agreed in writing by the Parties. It is the Parties’ understanding that Cytokinetics Co-Promotion Effort for the first Indication approved for any Collaboration Product in the Co-Promotion Territory [*] shall not be required to exceed [*] </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt"> </P> <TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%"> <TR> <TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>[*] =</B></TD> <TD ALIGN="left" VALIGN="top"><B>Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. </B></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">63 </P> <p Style='page-break-before:always'> <HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER"> <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(d) </B>If Cytokinetics exercises its Co-Promotion option [*] a Collaboration Product that contains a [*] Activator for a particular Neuromuscular Indication [*] of the Shared Territory, unless Cytokinetics terminates the Co-Promotion in accordance with Section 9.6(e) below, Cytokinetics shall be responsible for [*] for such Collaboration Product for such Neuromuscular Indication and [*] of the Shared Territory (in which case, the Cytokinetics Co-Promotion Effort shall be [*] of the promotional efforts), unless otherwise agreed in writing by the Parties. For the avoidance of doubt, the Parties acknowledge that Cytokinetics’ exercise of its Co-Promotion option to [*] for the case where [*] are expected to be [*] of the Shared Territory for an Indication pursuant to the JCC Determination. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(e) </B>If Cytokinetics exercises its Co-Promotion option for a Collaboration Product for a particular Indication [*] of the Co-Promotion Territory (or Shared Territory, for any Collaboration Product containing a [*] Activator in Neuromuscular Indications), it shall have the right to continue to Co-Promote such Collaboration Product for as long as such Collaboration Product is being sold for such Indication [*]. Cytokinetics shall have the right to relinquish its Co-Promotion rights for such Collaboration Product for such Indication [*] written notification to Astellas, in which case the Parties shall reasonably cooperate to transition to Astellas all of Cytokinetics’ Co-Promotion activities with respect to such Collaboration Product for such Indication [*], so as to minimize disruption to sales activity and the Parties shall [*] for such transition. In such event, Cytokinetics shall withdraw its sales representatives from such Co-Promotion activities in a professional manner. If Cytokinetics [*] a Collaboration Product for the [*] such Collaboration Product is [*], then Cytokinetics shall have the right to [*] such Collaboration Product. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(f) </B>If Cytokinetics exercises its Co-Promotion option for a Collaboration Product, Astellas shall [*] in the Co-Promotion Territory (or Shared Territory as applicable) based on the Cytokinetics Co-Promotion Efforts. However, if [*] for a particular Indication [*] shall so notify [*] in the applicable [*], and the Parties will discuss in good faith through the JCC [*] </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt"> </P> <TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%"> <TR> <TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>[*] =</B></TD> <TD ALIGN="left" VALIGN="top"><B>Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. </B></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">64 </P> <p Style='page-break-before:always'> <HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"> [*] Cytokinetics’ exercise of its Co-Promotion option applicable to such Collaboration Product for such Indication [*]. In addition, the JCC shall take into account [*] sales force, such as [*] in each case [*]. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(g) </B>Promptly after Cytokinetics exercises its Co-Promotion option for a Collaboration Product in the Co-Promotion Territory (or Shared Territory, for any Collaboration Product containing a [*] Activator in Neuromuscular Indications), the Parties, in case of Astellas, Astellas and/or its Affiliate, as applicable, shall commence negotiations in good faith and enter into one or more co-promotion or promotion agreement(s) (the “<B>Co-Promotion Agreement</B>”) in accordance with the terms and conditions set forth in <B><U>Exhibit I</U></B> attached hereto for such Collaboration Product, allowing for any future exercise by Cytokinetics of its Co-Promotion option for the same Collaboration Product in other Indications subject to different allocation of Cytokinetics Co-Promotion efforts as applicable. The Parties shall use Diligent Efforts to enter into and execute the applicable Co-Promotion Agreement within [*] following Cytokinetics’ exercise of its Co-Promotion option. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>9.7 Commercial Operating Team</B>. The JCC will establish an operating team for each Collaboration Product (the “<B>Commercial Operating Team</B>”) [*] in which Cytokinetics exercises its Co-Promotion option, which will be responsible for managing, reviewing, and implementing the performance of the day-to-day responsibilities of both Parties for all stages of the commercialization program for such Collaboration Product [*] in accordance with the Commercialization Plan, including review and decision making regarding plans for manufacture, promotion, marketing, sale, and distribution. Each Party will have representation on the Commercial Operating Team for such Collaboration Product [*] throughout the commercialization of such Collaboration Product [*] under this Agreement. The Commercial Operating Team shall be subordinate to and governed by the JCC. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>9.8 Cytokinetics Commercialization Period.</B> Notwithstanding anything to the contrary, during the Cytokinetics Commercialization Period, Cytokinetics shall be responsible (subject to subsection (b) below) for the Commercialization of Collaboration Products in the Shared Territory for each [*] Indication for which [*]: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(a)</B> During the Cytokinetics Commercialization Period, if any, Cytokinetics shall have the sole right to Commercialize the Collaboration Product(s) in the Shared Territory, and Astellas shall have the sole right to Commercialize the Collaboration Product(s) in the Astellas Territory, in each case in accordance with the Commercialization Plan. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(b)</B> Specifically and without limiting the foregoing, during the Cytokinetics Commercialization Period, Cytokinetics [*] sales of such Collaboration Product(s) in the </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt"> </P> <TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%"> <TR> <TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>[*] =</B></TD> <TD ALIGN="left" VALIGN="top"><B>Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. </B></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">65 </P> <p Style='page-break-before:always'> <HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"> Shared Territory if at such time: (i) Cytokinetics has an Established Commercial Infrastructure and (ii) there is [*] Collaboration Product [*] Indication, and subject to the [*] set forth in Section [*]. If the foregoing conditions are not met, then (A) Astellas will [*] of such Collaboration Product(s) in the Shared Territory, and (B) the Parties shall discuss in good faith and agree on the [*] in connection with [*] subject to the payment obligations set forth in Section [*]. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(c)</B> At the end of the Cytokinetics Commercialization Period, Astellas shall [*] of such Collaboration Product(s) for all Collaboration Indications worldwide. If Cytokinetics [*] of such Collaboration Product(s) in the Shared Territory during the Cytokinetics Commercialization Period, the Parties shall collaborate to transition the [*] such Collaboration Product(s) in the Shared Territory from Cytokinetics to Astellas pursuant to a process to be agreed to by the JCC by consensus. The Parties will endeavor to [*] Cytokinetics and to [*] of the Collaboration. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>9.9 Established Commercial Infrastructure.</B> For the purpose of this Agreement, “<B>Established Commercial Infrastructure</B>” means, with respect to Cytokinetics, it has plans to launch within [*] or has launched one or more product(s), either under this Agreement or otherwise, that address a comparable market opportunity in the applicable therapeutic area. For clarity, Cytokinetics shall be deemed to have an Established Commercial Infrastructure in a country if Cytokinetics has received Marketing Approval for Tirasemtiv in such country, is readying for the launch of or launched Tirasemtiv, or is promoting one (1) or more other product(s), either under this Agreement or otherwise, or has in place the requisite capabilities to market, sell, and distribute Tirasemtiv in any Retained Indication or a Collaboration Product for [*] Indication. In the event that [*] in accordance with [*] set forth in Section [*]. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE 10 </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>MEDICAL AFFAIRS ACTIVITIES </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>10.1 General.</B> Subject to Cytokinetics’ right to field medical science liaisons (“<B>MSLs</B>”) for one or more Collaboration Product(s) in the Co-Promotion Territory or Shared Territory, as applicable, and other terms and conditions of this Article 10, Astellas shall have the primary responsibility, at its own expense, for all aspects of the Medical Affairs Activities of the Collaboration Products in the Collaboration Indications (for [*] Activators) or the Field (for [*] Activators) throughout the world, and the Parties shall have the rights and obligations for Medical Affairs Activities for the Collaboration Products in [*] Indications, all subject to Section 10.5(b), provided, however, that if any Law is to the contrary to a Medical Affairs Activities, the Parties will discuss in good faith to reasonably fit such Medical Affairs Activities to such Law. </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt"> </P> <TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%"> <TR> <TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>[*] =</B></TD> <TD ALIGN="left" VALIGN="top"><B>Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. </B></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">66 </P> <p Style='page-break-before:always'> <HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER"> <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>10.2 Diligence.</B> During [*] and thereafter, Astellas shall use Diligent Efforts to perform Medical Affairs Activities for each Collaboration Product [*] and to the extent appropriate [*]. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>10.3 Medical Affairs Plan.</B> The Parties shall coordinate with respect to the strategy and implementation of the Medical Affairs Activities with respect to each Collaboration Product in each Indication [*] for such Indication, and such coordination will be set forth in the Medical Affairs Plan. No later than [*] Collaboration Product, Astellas shall prepare and provide to the JMAC for review and discussion a written plan for the Medical Affairs Activities for such Collaboration Product (the “<B>Medical Affairs Plan</B>”), subject to Section 10.5 below. The Medical Affairs Plan shall include a reasonably detailed description of and anticipated timeline for the Parties’, their respective Affiliates’ and sublicensees’ Medical Affairs Activities with respect to such Collaboration Product. The Medical Affairs Plan shall also include a reasonably detailed description of and anticipated timeline for Cytokinetics’ MSLs’ activities during [*] such Collaboration Product (and thereafter if Cytokinetics exercises its Co-Promotion option for such Collaboration Product or if such Collaboration Product is Developed in [*] Indication), as well as a budget therefor, which shall be consistent with Section 10.5 below. Astellas shall periodically (at least on an annual basis) prepare updates and amendments to the Medical Affairs Plan to reflect changes in its plans, subject to Section 10.5. Astellas shall submit all updates and amendments to the Medical Affairs Plan to the JMAC for review and discussion. Astellas shall be solely responsible for all costs incurred by or on behalf of either Party in performing their respective obligations under the Medical Affairs Plan and shall pay [*] as set forth in the Medical Affairs Plan, except as set forth in Section 10.5(b)(ii)(1). For clarity, [*] Medical Affairs Activities [*] each Indication will be determined by the JMAC, subject to [*]. If and when [*] MSL support for the [*] Indications [*] for the [*] Indications and/or [*] Indications. Cytokinetics may perform additional activities within the scope of its responsibilities under the Medical Affairs Plan, in addition to those funded in the JMAC-approved budget, [*] for the [*] Indication and/or [*] Indications in the Shared Territory. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>10.4 Reports.</B> Astellas (and Cytokinetics, if it exercises the right to field its own MSLs in the Co-Promotion Territory or Shared Territory pursuant to Section 10.5) shall update the JMAC at each regularly scheduled JMAC meeting regarding its Medical Affairs Activities of the </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt"> </P> <TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%"> <TR> <TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>[*] =</B></TD> <TD ALIGN="left" VALIGN="top"><B>Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. </B></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">67 </P> <p Style='page-break-before:always'> <HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"> Collaboration Products. Each such update shall be in a form to be agreed by the JMAC and shall summarize its, its Affiliates’ and its sublicensees’ significant Medical Affairs Activities with respect to the Collaboration Products throughout the world. The update by a Party will be at a level of detail reasonably requested by the other Party and sufficient to enable such Party to determine the other Party’s compliance with its diligence obligations pursuant to Section 10.2. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>10.5 Medical Scientific Liaisons</B>. <B> </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(a) Licensed Indications and [*] Indications for Collaboration Products Containing [*] Activators; Field for all other Collaboration Products.</B> At (i) any time after [*] Indication or [*] Indication, or (ii) any time in connection with [*] Indication or any [*] Indication, Cytokinetics shall have the right to field its own MSLs in the Co-Promotion Territory (for [*] Activators in Licensed Indications and for Collaboration Products in the Field) or Shared Territory (for [*] Activators for [*] Indications and [*] Indications), in connection with such Pivotal Registration Study. The percentage of total MSL deployment by Cytokinetics shall be agreed upon by the Parties, but in any event shall be no less than [*] and no more than [*]. If Cytokinetics exercises the Cytokinetics Co-Funding Option, the portion of the Medical Affairs Plan specific to such Collaboration Product for the [*] Indication(s) and any amendment thereto [*], and Cytokinetics may prepare [*]. If Cytokinetics exercises the option to Co-Promote pursuant to Section 9.6 in any geographic region (i.e., Canada, the US, and EU plus Switzerland), Cytokinetics shall have the right to field MSLs [*] unless the Parties otherwise agree. Such MSLs of Cytokinetics shall perform certain Medical Affairs Activities allocated to them under the Medical Affairs Plan. Astellas shall reimburse the costs and expenses incurred by Cytokinetics in fielding the MSLs, which shall be calculated at a rate equal to [*]. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(b) [*] Indications.</B> For all [*] Indications: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman"><B>(i)</B> [*] a Collaboration Product in such Indication: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:17%; font-size:10pt; font-family:Times New Roman"><B>(1)</B> The terms of Section 10.5(a) shall also apply to such Indication in the Shared Territory. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:17%; font-size:10pt; font-family:Times New Roman"><B>(2)</B> The portion of the Medical Affairs Plan specific to such Collaboration Product for such Indication and any amendment thereto [*], and Cytokinetics may [*]. </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt"> </P> <TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%"> <TR> <TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>[*] =</B></TD> <TD ALIGN="left" VALIGN="top"><B>Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. </B></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">68 </P> <p Style='page-break-before:always'> <HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER"> <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:17%; font-size:10pt; font-family:Times New Roman"><B>(3)</B> Astellas will lead the conduct of and be responsible for the strategy for all Medical Affairs Activities with respect to such Collaboration Product in such Indication, except Cytokinetics will [*] for all Medical Affairs Activities which are specific to such Indication in the Shared Territory [*] Medical Affairs Activities with respect to such Collaboration Product [*]. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman"><B>(ii)</B> [*] a Collaboration Product in any [*] Indication, thereafter: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:17%; font-size:10pt; font-family:Times New Roman"><B>(1)</B> [*] the conduct of, and shall [*] Medical Affairs Activities for Collaboration Product in such Indication [*]; and </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:17%; font-size:10pt; font-family:Times New Roman"><B>(2)</B> [*] shall have the right, but not the obligation, to [*], and shall have [*] Medical Affairs Activities for Collaboration Product in such Indication [*]. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE 11 </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>FINANCIAL PROVISIONS </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>11.1 Upfront Payment; Equity Purchase.</B> <B> </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(a)</B> Astellas shall pay to Cytokinetics a one-time, non-refundable, non-creditable upfront payment of sixteen million Dollars ($16,000,000) within thirty (30) days after the Effective Date. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(b)</B> Astellas shall pay to Cytokinetics a one-time, non-refundable, non-creditable upfront payment of thirty million Dollars ($30,000,000) within thirty (30) days after the Amendment Effective Date. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(c)</B> Concurrent with the execution of this Amended and Restated Agreement, Astellas and Cytokinetics have entered into a Common Stock Purchase Agreement, pursuant to which Astellas will purchase from Cytokinetics ten million Dollars ($10,000,000) of Cytokinetics’ common stock. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>11.2 Reimbursement of Research Plan Costs.</B> Astellas shall reimburse Cytokinetics’ Research Plan Costs as follows: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(<B>a) Advance Payment.</B> Within [*] days of the Effective Date, Astellas shall pay to Cytokinetics an amount equal to Cytokinetics’ estimated Research Plan Costs </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt"> </P> <TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%"> <TR> <TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>[*] =</B></TD> <TD ALIGN="left" VALIGN="top"><B>Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. </B></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">69 </P> <p Style='page-break-before:always'> <HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"> (as set forth in the initial Research Budget) for the then-current calendar quarter. Thereafter, during the Research Term, Cytokinetics shall submit to Astellas an invoice setting forth Cytokinetics’ estimated Research Plan Costs based on the then-current Research Budget for the current calendar quarter, no later than [*] Business Days following the first day of such calendar quarter (the “<B>Research Advance Invoice</B>”). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(b) True-Up</B>. Within [*] days after the end of each calendar quarter during the Research Term, Cytokinetics shall submit to Astellas a reasonably detailed reconciliation report setting forth the actual Research Plan Costs incurred by or on account of Cytokinetics in such prior calendar quarter and any credits or deficits from the corresponding Research Advance Invoice previously provided for such quarter (the “<B>Research True-Up Report</B>”). If the estimated Research Plan Costs paid by Astellas pursuant to Section 11.2(a) above for such prior calendar quarter is less than Cytokinetics’ actual Research Plan Costs for such quarter, subject to Section 5.6, Astellas shall pay the deficit to Cytokinetics as described in this Section 11.2(b). If the estimated Research Plan Costs paid by Astellas pursuant to Section 11.2(a) above for such prior calendar quarter is more than Cytokinetics’ actual Research Plan Costs for such quarter, the excess shall be credited towards the Research Advance Invoice for the current calendar quarter (except where such invoice is the final such invoice to be provided by Cytokinetics, in which case the excess shall be refunded by Cytokinetics to Astellas within [*] days after the delivery of such invoice). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(c) Timing of Payment.</B> For ease of administration, Astellas shall pay Cytokinetics a single payment reflecting the amount due under the Research Advance Invoice for the current calendar quarter plus any deficits (or less any credits) reflected in the Research True-Up Report for the prior calendar quarter within the later of (i) [*] days of Astellas’ receipt of such Research Advance Invoice, or (ii) [*] days of Astellas’ receipt of such Research True-Up Report. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>11.3 Reimbursements and Sharing of Development Costs. </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(a) Reimbursement.</B> Astellas shall reimburse Cytokinetics’ Development Costs as follows: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman"><B>(i) Advance Payment.</B> Within [*] days of the Effective Date, Astellas shall pay to Cytokinetics an amount equal to Cytokinetics’ estimated Development Costs (as set forth in the initial Cytokinetics Development Budget) for the then-current calendar quarter. Thereafter, for each calendar quarter in which Cytokinetics is anticipated to conduct Development activities under the Development Plan (other than [*] Development), Cytokinetics shall submit to Astellas an invoice setting forth Cytokinetics’ estimated Development Costs based on the then-current Cytokinetics Development Budget for the current calendar quarter, no later than [*] Business Days following the first day of such calendar quarter (the “<B>Development Advance Invoice</B>”). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman"><B>(ii) True-Up</B>. Within [*] days after the end of each calendar quarter in which Cytokinetics has conducted Development activities under the Development Plan (other than </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt"> </P> <TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%"> <TR> <TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>[*] =</B></TD> <TD ALIGN="left" VALIGN="top"><B>Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. </B></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">70 </P> <p Style='page-break-before:always'> <HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"> [*] Development), Cytokinetics shall submit to Astellas a reasonably detailed reconciliation report setting forth the actual Development Costs incurred by or on account of Cytokinetics in such prior calendar quarter and any credits or deficits from the corresponding Development Advance Invoice previously provided for such quarter (the “<B>Development True-Up Report</B>”). If the estimated Development Costs paid by Astellas pursuant to Section 11.3(a)(i) above for such prior calendar quarter is less than Cytokinetics’ actual Development Costs for such quarter, then Astellas shall pay the deficit to Cytokinetics as described in this Section 11.3(a)(ii) to the extent such amounts do not exceed the applicable then-current [*] Budget as approved by the JDC by more than [*]. If the estimated Development Costs paid by Astellas pursuant to Section 11.3(a)(i) above for such prior calendar quarter is more than Cytokinetics’ actual Development Costs for such quarter, the excess shall be credited toward the Development Advance Invoice for the current calendar quarter (except where such invoice is the final such invoice to be provided by Cytokinetics, in which case the excess shall be refunded by Cytokinetics to Astellas within [*] days after the delivery of such invoice). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman"><B>(iii) Timing of Payment.</B> For ease of administration, Astellas shall pay Cytokinetics a single payment reflecting the amount due under the Development Advance Invoice for the current calendar quarter plus any deficits (or less any credits) reflected in the Development True-Up Report for the prior calendar quarter within the later of (1) [*] days of Astellas’ receipt of such Development Advance Invoice, or (2) [*] of Astellas’ receipt of such Development True-Up Report. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(b) Sharing of [*] Costs.</B> <B></B> </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman"><B>(i)</B> If Cytokinetics has exercised the Cytokinetics Co-Funding Option, [*] for a [*] Activator in [*] Indications, then within [*] days after the end of each calendar quarter during which Astellas has incurred any [*] Costs for such [*] Activators in [*] Indications (including such costs incurred by Cytokinetics and reimbursed by Astellas under Section 11.3(a)), Astellas shall submit to Cytokinetics a reasonably detailed accounting for, and an invoice for [*] Costs incurred during such calendar quarter. Subject to subsection (ii) below, Cytokinetics shall pay to Astellas the amount invoiced within [*] days after the receipt of the invoice, to the extent such amounts do not exceed the applicable then-current [*] Budget as approved by the JDC by more than [*]. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman"><B>(ii)</B> [*] subject to the following [*]: (1) [*] for its share of [*]; (2) Cytokinetics [*] at any given time; and (3) Cytokinetics [*] by more than [*] [*] is not intended to be [*] to continue to fulfill its obligations [*] (e.g., due to any modifications and/or additions to [*]. If Cytokinetics [*] any of the [*] shall be deemed [*] </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt"> </P> <TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%"> <TR> <TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>[*] =</B></TD> <TD ALIGN="left" VALIGN="top"><B>Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. </B></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">71 </P> <p Style='page-break-before:always'> <HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER"> <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(c) Sharing of [*] Development Costs.</B> For all [*] Indications for which [*] Activator in such Indication, then [*] Costs for such Indication as follows: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman"><B>(i) Advance Payment.</B> For each calendar quarter in which [*] Development Work for such [*] Activator in such Indication under the Development Plan, [*] shall submit to [*] an invoice setting forth [*] Costs for such [*] Activator in such Indication based on the then-current [*] Budget for the current calendar quarter, no later than [*] Business Days following the first day of such calendar quarter (the “[*] Advance Invoice”). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman"><B>(ii) True-Up</B>. Within [*] days after the end of each calendar quarter in which [*] Development Work for such [*] Activator in such Indication under the Development Plan, [*] shall submit to [*] a reasonably detailed reconciliation report setting forth the accounting for, and an invoice for [*] Development Costs for such [*] Activator in such Indication incurred by or on account of [*] in such prior calendar quarter and any credits or deficits from the corresponding [*] Advance Invoice previously provided for such quarter (the “[*] <B>True-Up Report</B>”). If the estimated [*] Development Costs paid by [*] pursuant to Section 11.3(c)(i) above for such prior calendar quarter is less than [*] Development Costs for such quarter, then [*] shall pay the deficit to [*] as described in this Section 11.3(c)(ii) to the extent such amounts do not exceed the applicable then-current [*] Development Budget as approved by the JDC by more than [*]. If the estimated [*] Development Costs paid by [*] pursuant to Section 11.3(c)(i) above for such prior calendar quarter is more than [*] Development Costs for such quarter, the excess shall be credited toward the [*] Advance Invoice for the current calendar quarter (except where such invoice is the final such invoice to be provided by [*] in which case the excess shall be refunded by [*] days after the delivery of such invoice). </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt"> </P> <TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%"> <TR> <TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>[*] =</B></TD> <TD ALIGN="left" VALIGN="top"><B>Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. </B></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">72 </P> <p Style='page-break-before:always'> <HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER"> <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman"><B>(iii) Timing of Payment.</B> For ease of administration, [*] shall pay [*] a single payment reflecting the amount due under the [*] Advance Invoice for the current calendar quarter plus any deficits (or less any credits) reflected in the [*] True-Up Report for the prior calendar quarter within the later of (1) [*] days of [*] receipt of such [*] Advance Invoice, or (2) [*] days of [*’] receipt of such [*] True-Up Report. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>11.4 Reimbursement of [*] Development Costs</B>. Astellas shall, within [*] days after the receipt of [*] Indication pursuant to Section [*)], pay to Cytokinetics an amount equal to [*] Development Costs, which shall be reported to the JDC pursuant to Section [*]. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>11.5 Research and Development Milestone Payments. </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(a) Research Milestones.</B> Astellas shall pay to Cytokinetics the non-refundable, non-creditable payment set forth in the table below upon [*] achievement of each milestone event for each Compound in accordance with Section 11.5(d): </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt"> </P> <TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="68%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center"> <TR> <TD WIDTH="79%"></TD> <TD VALIGN="bottom" WIDTH="18%"></TD> <TD></TD> <TD></TD> <TD></TD></TR> <TR STYLE="font-family:Times New Roman; font-size:8pt"> <TD VALIGN="bottom" NOWRAP> <P STYLE="border-bottom:1.00pt solid #000000; width:55.25pt; font-size:8pt; font-family:Times New Roman"><B>Milestone Event</B></P></TD> <TD VALIGN="bottom"> </TD> <TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE="border-bottom:1.00pt solid #000000; width:65.45pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Milestone Payment</B></P></TD> <TD VALIGN="bottom"> </TD></TR> <TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt"> <TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">[*]</P></TD> <TD VALIGN="bottom"> </TD> <TD VALIGN="bottom"> </TD> <TD VALIGN="bottom" ALIGN="right">[*]</TD> <TD NOWRAP VALIGN="bottom"> </TD></TR> <TR STYLE="font-family:Times New Roman; font-size:10pt"> <TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">[*]</P></TD> <TD VALIGN="bottom"> </TD> <TD VALIGN="bottom"> </TD> <TD VALIGN="bottom" ALIGN="right">[*]</TD> <TD NOWRAP VALIGN="bottom"> </TD></TR> </TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(b) Development Milestones.</B> <B></B> </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman"><B>(i) Existing Milestones.</B> Subject to Section 11.5(c), Astellas shall pay to Cytokinetics the non-refundable, non-creditable payment set forth in the table below upon [*] achievement of each milestone event (whether by or on behalf of </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt"> </P> <TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%"> <TR> <TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>[*] =</B></TD> <TD ALIGN="left" VALIGN="top"><B>Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. </B></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">73 </P> <p Style='page-break-before:always'> <HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"> Astellas or its Affiliates or sublicensees, or by or on behalf of Cytokinetics or its Affiliates) in accordance with Section 11.5(d): </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt"> </P> <TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center"> <TR> <TD WIDTH="62%"></TD> <TD VALIGN="bottom" WIDTH="6%"></TD> <TD></TD> <TD></TD> <TD></TD> <TD VALIGN="bottom" WIDTH="6%"></TD> <TD></TD> <TD></TD> <TD></TD> <TD VALIGN="bottom" WIDTH="6%"></TD> <TD></TD> <TD></TD> <TD></TD> <TD VALIGN="bottom" WIDTH="6%"></TD> <TD></TD> <TD></TD> <TD></TD></TR> <TR STYLE="font-family:Times New Roman; font-size:8pt"> <TD VALIGN="bottom" ROWSPAN="3" NOWRAP> <P STYLE="border-bottom:1.00pt solid #000000; width:55.25pt; font-size:8pt; font-family:Times New Roman"><B>Milestone Event</B></P></TD> <TD VALIGN="bottom"> </TD> <TD VALIGN="bottom" COLSPAN="14" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Milestone Payment</B></TD> <TD VALIGN="bottom"> </TD></TR> <TR STYLE="font-family:Times New Roman; font-size:8pt"> <TD VALIGN="bottom"> </TD> <TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>[*] Activator</B></TD> <TD VALIGN="bottom"> </TD> <TD VALIGN="bottom"> </TD> <TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>[*] Activator</B></TD> <TD VALIGN="bottom"> </TD></TR> <TR STYLE="font-family:Times New Roman; font-size:8pt"> <TD VALIGN="bottom"> </TD> <TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">Lead<BR>Compound/<br>Lead Product</TD> <TD VALIGN="bottom"> </TD> <TD VALIGN="bottom"> </TD> <TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">Collaboration<BR>Product<BR>containing a<BR>[*] Activator<BR>(other than the<BR>Lead<BR>Compound)</TD> <TD VALIGN="bottom"> </TD> <TD VALIGN="bottom"> </TD> <TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">Collaboration<BR>Product<BR>containing a<BR>[*] Activator</TD> <TD VALIGN="bottom"> </TD> <TD VALIGN="bottom"> </TD> <TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">Collaboration<BR>Product<BR>containing a<BR>[*] Activator</TD> <TD VALIGN="bottom"> </TD></TR> <TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt"> <TD VALIGN="top">[*]</TD> <TD VALIGN="bottom"> </TD> <TD VALIGN="bottom"> </TD> <TD VALIGN="bottom" ALIGN="right">[*].</TD> <TD NOWRAP VALIGN="bottom"> </TD> <TD VALIGN="bottom"> </TD> <TD VALIGN="bottom"> </TD> <TD VALIGN="bottom" ALIGN="right">[*]</TD> <TD NOWRAP VALIGN="bottom"> </TD> <TD VALIGN="bottom"> </TD> <TD VALIGN="bottom"> </TD> <TD VALIGN="bottom" ALIGN="right">[*]</TD> <TD NOWRAP VALIGN="bottom"> </TD> <TD VALIGN="bottom"> </TD> <TD VALIGN="bottom"> </TD> <TD VALIGN="bottom" ALIGN="right">[*]</TD> <TD NOWRAP VALIGN="bottom"> </TD></TR> <TR STYLE="font-family:Times New Roman; font-size:10pt"> <TD VALIGN="top">Initiation of CY 5012<SUP STYLE="font-size:85%; vertical-align:top">*1</SUP></TD> <TD VALIGN="bottom"> </TD> <TD VALIGN="bottom">$</TD> <TD VALIGN="bottom" ALIGN="right">2,000,000</TD> <TD NOWRAP VALIGN="bottom"> </TD> <TD VALIGN="bottom"> </TD> <TD VALIGN="bottom"> </TD> <TD VALIGN="bottom" ALIGN="right">n.a.</TD> <TD NOWRAP VALIGN="bottom"> </TD> <TD VALIGN="bottom"> </TD> <TD VALIGN="bottom"> </TD> <TD VALIGN="bottom" ALIGN="right">n.a.</TD> <TD NOWRAP VALIGN="bottom"> </TD> <TD VALIGN="bottom"> </TD> <TD VALIGN="bottom"> </TD> <TD VALIGN="bottom" ALIGN="right">n.a.</TD> <TD NOWRAP VALIGN="bottom"> </TD></TR> <TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt"> <TD VALIGN="top">JDC’s decision to enter into a Phase 2 Clinical Trial pursuant to Section 6.6(d)<SUP STYLE="font-size:85%; vertical-align:top">*1</SUP></TD> <TD VALIGN="bottom"> </TD> <TD VALIGN="bottom">$</TD> <TD VALIGN="bottom" ALIGN="right">15,000,000</TD> <TD NOWRAP VALIGN="bottom"> </TD> <TD VALIGN="bottom"> </TD> <TD VALIGN="bottom"> </TD> <TD VALIGN="bottom" ALIGN="right">n.a.</TD> <TD NOWRAP VALIGN="bottom"> </TD> <TD VALIGN="bottom"> </TD> <TD VALIGN="bottom"> </TD> <TD VALIGN="bottom" ALIGN="right">n.a.</TD> <TD NOWRAP VALIGN="bottom"> </TD> <TD VALIGN="bottom"> </TD> <TD VALIGN="bottom"> </TD> <TD VALIGN="bottom" ALIGN="right">n.a.</TD> <TD NOWRAP VALIGN="bottom"> </TD></TR> <TR STYLE="font-family:Times New Roman; font-size:10pt"> <TD VALIGN="top">[*]</TD> <TD VALIGN="bottom"> </TD> <TD VALIGN="bottom"> </TD> <TD VALIGN="bottom" ALIGN="right">[*]</TD> <TD NOWRAP VALIGN="bottom"> </TD> <TD VALIGN="bottom"> </TD> <TD VALIGN="bottom"> </TD> <TD VALIGN="bottom" ALIGN="right">[*]</TD> <TD NOWRAP VALIGN="bottom"> </TD> <TD VALIGN="bottom"> </TD> <TD VALIGN="bottom"> </TD> <TD VALIGN="bottom" ALIGN="right">[*]</TD> <TD NOWRAP VALIGN="bottom"> </TD> <TD VALIGN="bottom"> </TD> <TD VALIGN="bottom"> </TD> <TD VALIGN="bottom" ALIGN="right">[*]</TD> <TD NOWRAP VALIGN="bottom"> </TD></TR> <TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt"> <TD VALIGN="top">[*]</TD> <TD VALIGN="bottom"> </TD> <TD VALIGN="bottom"> </TD> <TD VALIGN="bottom" ALIGN="right">[*]</TD> <TD NOWRAP VALIGN="bottom"> </TD> <TD VALIGN="bottom"> </TD> <TD VALIGN="bottom"> </TD> <TD VALIGN="bottom" ALIGN="right">[*]</TD> <TD NOWRAP VALIGN="bottom"> </TD> <TD VALIGN="bottom"> </TD> <TD VALIGN="bottom"> </TD> <TD VALIGN="bottom" ALIGN="right">[*]</TD> <TD NOWRAP VALIGN="bottom"> </TD> <TD VALIGN="bottom"> </TD> <TD VALIGN="bottom"> </TD> <TD VALIGN="bottom" ALIGN="right">[*]</TD> <TD NOWRAP VALIGN="bottom"> </TD></TR> <TR STYLE="font-family:Times New Roman; font-size:10pt"> <TD VALIGN="top">[*]</TD> <TD VALIGN="bottom"> </TD> <TD VALIGN="bottom"> </TD> <TD VALIGN="bottom" ALIGN="right">[*]</TD> <TD NOWRAP VALIGN="bottom"> </TD> <TD VALIGN="bottom"> </TD> <TD VALIGN="bottom"> </TD> <TD VALIGN="bottom" ALIGN="right">[*]</TD> <TD NOWRAP VALIGN="bottom"> </TD> <TD VALIGN="bottom"> </TD> <TD VALIGN="bottom"> </TD> <TD VALIGN="bottom" ALIGN="right">[*]</TD> <TD NOWRAP VALIGN="bottom"> </TD> <TD VALIGN="bottom"> </TD> <TD VALIGN="bottom"> </TD> <TD VALIGN="bottom" ALIGN="right">[*]</TD> <TD NOWRAP VALIGN="bottom"> </TD></TR> <TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt"> <TD VALIGN="top">[*]</TD> <TD VALIGN="bottom"> </TD> <TD VALIGN="bottom"> </TD> <TD VALIGN="bottom" ALIGN="right">[*]</TD> <TD NOWRAP VALIGN="bottom"> </TD> <TD VALIGN="bottom"> </TD> <TD VALIGN="bottom"> </TD> <TD VALIGN="bottom" ALIGN="right">[*]</TD> <TD NOWRAP VALIGN="bottom"> </TD> <TD VALIGN="bottom"> </TD> <TD VALIGN="bottom"> </TD> <TD VALIGN="bottom" ALIGN="right">[*]</TD> <TD NOWRAP VALIGN="bottom"> </TD> <TD VALIGN="bottom"> </TD> <TD VALIGN="bottom"> </TD> <TD VALIGN="bottom" ALIGN="right">[*]</TD> <TD NOWRAP VALIGN="bottom"> </TD></TR> <TR STYLE="font-family:Times New Roman; font-size:10pt"> <TD VALIGN="top">[*]</TD> <TD VALIGN="bottom"> </TD> <TD VALIGN="bottom"> </TD> <TD VALIGN="bottom" ALIGN="right">[*]</TD> <TD NOWRAP VALIGN="bottom"> </TD> <TD VALIGN="bottom"> </TD> <TD VALIGN="bottom"> </TD> <TD VALIGN="bottom" ALIGN="right">[*]</TD> <TD NOWRAP VALIGN="bottom"> </TD> <TD VALIGN="bottom"> </TD> <TD VALIGN="bottom"> </TD> <TD VALIGN="bottom" ALIGN="right">[*]</TD> <TD NOWRAP VALIGN="bottom"> </TD> <TD VALIGN="bottom"> </TD> <TD VALIGN="bottom"> </TD> <TD VALIGN="bottom" ALIGN="right">[*]</TD> <TD NOWRAP VALIGN="bottom"> </TD></TR> <TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt"> <TD VALIGN="top">[*]</TD> <TD VALIGN="bottom"> </TD> <TD VALIGN="bottom"> </TD> <TD VALIGN="bottom" ALIGN="right">[*]</TD> <TD NOWRAP VALIGN="bottom"> </TD> <TD VALIGN="bottom"> </TD> <TD VALIGN="bottom"> </TD> <TD VALIGN="bottom" ALIGN="right">[*]</TD> <TD NOWRAP VALIGN="bottom"> </TD> <TD VALIGN="bottom"> </TD> <TD VALIGN="bottom"> </TD> <TD VALIGN="bottom" ALIGN="right">[*]</TD> <TD NOWRAP VALIGN="bottom"> </TD> <TD VALIGN="bottom"> </TD> <TD VALIGN="bottom"> </TD> <TD VALIGN="bottom" ALIGN="right">[*]</TD> <TD NOWRAP VALIGN="bottom"> </TD></TR> <TR STYLE="font-family:Times New Roman; font-size:10pt"> <TD VALIGN="top">[*]</TD> <TD VALIGN="bottom"> </TD> <TD VALIGN="bottom"> </TD> <TD VALIGN="bottom" ALIGN="right">[*]</TD> <TD NOWRAP VALIGN="bottom"> </TD> <TD VALIGN="bottom"> </TD> <TD VALIGN="bottom"> </TD> <TD VALIGN="bottom" ALIGN="right">[*]</TD> <TD NOWRAP VALIGN="bottom"> </TD> <TD VALIGN="bottom"> </TD> <TD VALIGN="bottom"> </TD> <TD VALIGN="bottom" ALIGN="right">[*]</TD> <TD NOWRAP VALIGN="bottom"> </TD> <TD VALIGN="bottom"> </TD> <TD VALIGN="bottom"> </TD> <TD VALIGN="bottom" ALIGN="right">[*]</TD> <TD NOWRAP VALIGN="bottom"> </TD></TR> <TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt"> <TD VALIGN="top">[*]</TD> <TD VALIGN="bottom"> </TD> <TD VALIGN="bottom"> </TD> <TD VALIGN="bottom" ALIGN="right">[*]</TD> <TD NOWRAP VALIGN="bottom"> </TD> <TD VALIGN="bottom"> </TD> <TD VALIGN="bottom"> </TD> <TD VALIGN="bottom" ALIGN="right">[*]</TD> <TD NOWRAP VALIGN="bottom"> </TD> <TD VALIGN="bottom"> </TD> <TD VALIGN="bottom"> </TD> <TD VALIGN="bottom" ALIGN="right">[*]</TD> <TD NOWRAP VALIGN="bottom"> </TD> <TD VALIGN="bottom"> </TD> <TD VALIGN="bottom"> </TD> <TD VALIGN="bottom" ALIGN="right">[*]</TD> <TD NOWRAP VALIGN="bottom"> </TD></TR> <TR STYLE="font-size:1px; "> <TD VALIGN="bottom"></TD> <TD VALIGN="bottom"> </TD> <TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000"> </P></TD> <TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000"> </P></TD> <TD> </TD> <TD VALIGN="bottom"> </TD> <TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000"> </P></TD> <TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000"> </P></TD> <TD> </TD> <TD VALIGN="bottom"> </TD> <TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000"> </P></TD> <TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000"> </P></TD> <TD> </TD> <TD VALIGN="bottom"> </TD> <TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000"> </P></TD> <TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000"> </P></TD> <TD> </TD></TR> <TR STYLE="font-family:Times New Roman; font-size:10pt"> <TD VALIGN="top">Total</TD> <TD VALIGN="bottom"></TD> <TD VALIGN="bottom"> </TD> <TD VALIGN="bottom" ALIGN="right">[*]</TD> <TD NOWRAP VALIGN="bottom"> </TD> <TD VALIGN="bottom"></TD> <TD VALIGN="bottom"> </TD> <TD VALIGN="bottom" ALIGN="right">[*]</TD> <TD NOWRAP VALIGN="bottom"> </TD> <TD VALIGN="bottom"></TD> <TD VALIGN="bottom"> </TD> <TD VALIGN="bottom" ALIGN="right">[*]</TD> <TD NOWRAP VALIGN="bottom"> </TD> <TD VALIGN="bottom"></TD> <TD VALIGN="bottom"> </TD> <TD VALIGN="bottom" ALIGN="right">[*]</TD> <TD NOWRAP VALIGN="bottom"> </TD></TR> <TR STYLE="font-size:1px; "> <TD VALIGN="bottom"></TD> <TD VALIGN="bottom"> </TD> <TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000"> </P></TD> <TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000"> </P></TD> <TD> </TD> <TD VALIGN="bottom"> </TD> <TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000"> </P></TD> <TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000"> </P></TD> <TD> </TD> <TD VALIGN="bottom"> </TD> <TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000"> </P></TD> <TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000"> </P></TD> <TD> </TD> <TD VALIGN="bottom"> </TD> <TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000"> </P></TD> <TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000"> </P></TD> <TD> </TD></TR> </TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Milestone events marked as *1 shall be referred to as “<B>Earlier Milestone Events</B>” and milestone events marked as *2 shall be referred to as “<B>Later Milestone Events</B>”. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman"><B>(ii) Additional Development Milestone for [*] Indications.</B> Subject to Section 11.5(c), Astellas shall pay to Cytokinetics non-refundable, non-creditable payment set forth in the table below, on a Compound-by-Compound and Indication-by-Indication </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt"> </P> <TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%"> <TR> <TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>[*] =</B></TD> <TD ALIGN="left" VALIGN="top"><B>Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. </B></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">74 </P> <p Style='page-break-before:always'> <HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"> basis, upon [*] achievement of each milestone event in [*] Indication(s) (whether by or on behalf of Astellas or its Affiliates or sublicensees, or by or on behalf of Cytokinetics or its Affiliates) in accordance with Section 11.5(d): </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt"> </P> <TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center"> <TR> <TD WIDTH="68%"></TD> <TD VALIGN="bottom" WIDTH="1%"></TD> <TD WIDTH="7%"></TD> <TD VALIGN="bottom" WIDTH="1%"></TD> <TD WIDTH="7%"></TD> <TD VALIGN="bottom" WIDTH="1%"></TD> <TD WIDTH="7%"></TD> <TD VALIGN="bottom" WIDTH="1%"></TD> <TD WIDTH="7%"></TD></TR> <TR STYLE="font-family:Times New Roman; font-size:8pt"> <TD VALIGN="bottom" ROWSPAN="2" NOWRAP> <P STYLE="border-bottom:1.00pt solid #000000; width:55.25pt; font-size:8pt; font-family:Times New Roman"><B>Milestone Event</B></P></TD> <TD VALIGN="bottom"> </TD> <TD VALIGN="bottom" COLSPAN="7" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Milestone Payment</B></P></TD></TR> <TR STYLE="font-family:Times New Roman; font-size:8pt"> <TD VALIGN="bottom"> </TD> <TD VALIGN="bottom" COLSPAN="3" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>For Lead Compound/<BR>Lead Product</B></P></TD> <TD VALIGN="bottom"> </TD> <TD VALIGN="bottom" COLSPAN="3" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>For each [*] Activator<BR>other than the Lead<BR>Compound</B></P></TD></TR> <TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt"> <TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">[*]</P></TD> <TD VALIGN="bottom"> </TD> <TD VALIGN="bottom" COLSPAN="3" ALIGN="right">[*]</TD> <TD VALIGN="bottom"> </TD> <TD VALIGN="bottom" COLSPAN="3" ALIGN="right">[*]</TD></TR> <TR STYLE="font-family:Times New Roman; font-size:10pt"> <TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">[*]</P></TD> <TD VALIGN="bottom"> </TD> <TD VALIGN="bottom" COLSPAN="3" ALIGN="right">[*]</TD> <TD VALIGN="bottom"> </TD> <TD VALIGN="bottom" COLSPAN="3" ALIGN="right">[*]</TD></TR> <TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt"> <TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Whether Cytokinetics exercises Cytokinetics Co-Funding Option [*]</P></TD> <TD VALIGN="bottom"> </TD> <TD VALIGN="bottom">If yes:</TD> <TD VALIGN="bottom"> </TD> <TD VALIGN="bottom">If no:</TD> <TD VALIGN="bottom"> </TD> <TD VALIGN="bottom">If yes:</TD> <TD VALIGN="bottom"> </TD> <TD VALIGN="bottom">If no:</TD></TR> <TR STYLE="font-family:Times New Roman; font-size:10pt"> <TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">[*]</P></TD> <TD VALIGN="bottom"> </TD> <TD VALIGN="bottom" ALIGN="right">[*]</TD> <TD VALIGN="bottom"> </TD> <TD VALIGN="bottom" ALIGN="right">[*]</TD> <TD VALIGN="bottom"> </TD> <TD VALIGN="bottom" ALIGN="right">[*]</TD> <TD VALIGN="bottom"> </TD> <TD VALIGN="bottom" ALIGN="right">[*]</TD></TR> <TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt"> <TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">[*]</P></TD> <TD VALIGN="bottom"> </TD> <TD VALIGN="bottom" ALIGN="right">[*]</TD> <TD VALIGN="bottom"> </TD> <TD VALIGN="bottom" ALIGN="right">[*]</TD> <TD VALIGN="bottom"> </TD> <TD VALIGN="bottom" ALIGN="right">[*]</TD> <TD VALIGN="bottom"> </TD> <TD VALIGN="bottom" ALIGN="right">[*]</TD></TR> <TR STYLE="font-family:Times New Roman; font-size:10pt"> <TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">[*]</P></TD> <TD VALIGN="bottom"> </TD> <TD VALIGN="bottom" ALIGN="right">[*]</TD> <TD VALIGN="bottom"> </TD> <TD VALIGN="bottom" ALIGN="right">[*]</TD> <TD VALIGN="bottom"> </TD> <TD VALIGN="bottom" ALIGN="right">[*]</TD> <TD VALIGN="bottom"> </TD> <TD VALIGN="bottom" ALIGN="right">[*]</TD></TR> <TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt"> <TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">[*]</P></TD> <TD VALIGN="bottom"> </TD> <TD VALIGN="bottom" ALIGN="right">[*]</TD> <TD VALIGN="bottom"> </TD> <TD VALIGN="bottom" ALIGN="right">[*]</TD> <TD VALIGN="bottom"> </TD> <TD VALIGN="bottom" ALIGN="right">[*]</TD> <TD VALIGN="bottom"> </TD> <TD VALIGN="bottom" ALIGN="right">[*]</TD></TR> <TR STYLE="font-family:Times New Roman; font-size:10pt"> <TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">[*]</P></TD> <TD VALIGN="bottom"> </TD> <TD VALIGN="bottom" ALIGN="right">[*]</TD> <TD VALIGN="bottom"> </TD> <TD VALIGN="bottom" ALIGN="right">[*]</TD> <TD VALIGN="bottom"> </TD> <TD VALIGN="bottom" ALIGN="right">[*]</TD> <TD VALIGN="bottom"> </TD> <TD VALIGN="bottom" ALIGN="right">[*]</TD></TR> <TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt"> <TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">[*]</P></TD> <TD VALIGN="bottom"> </TD> <TD VALIGN="bottom" ALIGN="right">[*]</TD> <TD VALIGN="bottom"> </TD> <TD VALIGN="bottom" ALIGN="right">[*]</TD> <TD VALIGN="bottom"> </TD> <TD VALIGN="bottom" ALIGN="right">[*]</TD> <TD VALIGN="bottom"> </TD> <TD VALIGN="bottom" ALIGN="right">[*]</TD></TR> <TR STYLE="font-family:Times New Roman; font-size:10pt"> <TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">[*]</P></TD> <TD VALIGN="bottom"> </TD> <TD VALIGN="bottom" ALIGN="right">[*]</TD> <TD VALIGN="bottom"> </TD> <TD VALIGN="bottom" ALIGN="right">[*]</TD> <TD VALIGN="bottom"> </TD> <TD VALIGN="bottom" ALIGN="right">[*]</TD> <TD VALIGN="bottom"> </TD> <TD VALIGN="bottom" ALIGN="right">[*]</TD></TR> <TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt"> <TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">[*]</P></TD> <TD VALIGN="bottom"> </TD> <TD VALIGN="bottom" ALIGN="right">[*]</TD> <TD VALIGN="bottom"> </TD> <TD VALIGN="bottom" ALIGN="right">[*]</TD> <TD VALIGN="bottom"> </TD> <TD VALIGN="bottom" ALIGN="right">[*]</TD> <TD VALIGN="bottom"> </TD> <TD VALIGN="bottom" ALIGN="right">[*]</TD></TR> <TR STYLE="font-size:1px; "> <TD VALIGN="bottom"></TD> <TD VALIGN="bottom"> </TD> <TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000"> </P></TD> <TD VALIGN="bottom"> </TD> <TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000"> </P></TD> <TD VALIGN="bottom"> </TD> <TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000"> </P></TD> <TD VALIGN="bottom"> </TD> <TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000"> </P></TD></TR> <TR STYLE="font-family:Times New Roman; font-size:10pt"> <TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total</P></TD> <TD VALIGN="bottom"></TD> <TD VALIGN="bottom" ALIGN="right">[*]</TD> <TD VALIGN="bottom"></TD> <TD VALIGN="bottom" ALIGN="right">[*]</TD> <TD VALIGN="bottom"></TD> <TD VALIGN="bottom" ALIGN="right">[*]</TD> <TD VALIGN="bottom"></TD> <TD VALIGN="bottom" ALIGN="right">[*]</TD></TR> <TR STYLE="font-size:1px; "> <TD VALIGN="bottom"></TD> <TD VALIGN="bottom"> </TD> <TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000"> </P></TD> <TD VALIGN="bottom"> </TD> <TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000"> </P></TD> <TD VALIGN="bottom"> </TD> <TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000"> </P></TD> <TD VALIGN="bottom"> </TD> <TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000"> </P></TD></TR> </TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman"><B>(iii) Additional Development Milestone for [*] Indications.</B> Subject to Section 11.5(c), with respect to each [*] Indication, then for so long as [*] such Indication, Astellas shall pay to Cytokinetics non-refundable, non-creditable payment set forth in the table below, on a Compound-by-Compound and Indication-by-Indication basis, upon [*] achievement of each milestone event in such Indication(s) (whether by or on behalf of Astellas or its Affiliates or </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt"> </P> <TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%"> <TR> <TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>[*] =</B></TD> <TD ALIGN="left" VALIGN="top"><B>Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. </B></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">75 </P> <p Style='page-break-before:always'> <HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"> sublicensees, or by or on behalf of Cytokinetics or its Affiliates) in accordance with Section 11.5(d): </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt"> </P> <TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="84%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center"> <TR> <TD WIDTH="58%"></TD> <TD VALIGN="bottom" WIDTH="19%"></TD> <TD></TD> <TD></TD> <TD></TD> <TD VALIGN="bottom" WIDTH="19%"></TD> <TD></TD> <TD></TD> <TD></TD></TR> <TR STYLE="font-family:Times New Roman; font-size:8pt"> <TD VALIGN="bottom" ROWSPAN="2" NOWRAP> <P STYLE="border-bottom:1.00pt solid #000000; width:55.25pt; font-size:8pt; font-family:Times New Roman"><B>Milestone Event</B></P></TD> <TD VALIGN="bottom"> </TD> <TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Milestone Payment</B></TD> <TD VALIGN="bottom"> </TD></TR> <TR STYLE="font-family:Times New Roman; font-size:8pt"> <TD VALIGN="bottom"> </TD> <TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>For Lead Compound/Lead<BR>Product</B></TD> <TD VALIGN="bottom"> </TD> <TD VALIGN="bottom"> </TD> <TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>For each [*] Activator other<BR>than the Lead Compound</B></TD> <TD VALIGN="bottom"> </TD></TR> <TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt"> <TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">[*]</P></TD> <TD VALIGN="bottom"> </TD> <TD VALIGN="bottom"> </TD> <TD VALIGN="bottom" ALIGN="right">[*]</TD> <TD NOWRAP VALIGN="bottom"> </TD> <TD VALIGN="bottom"> </TD> <TD VALIGN="bottom"> </TD> <TD VALIGN="bottom" ALIGN="right">[*]</TD> <TD NOWRAP VALIGN="bottom"> </TD></TR> <TR STYLE="font-family:Times New Roman; font-size:10pt"> <TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">[*]</P></TD> <TD VALIGN="bottom"> </TD> <TD VALIGN="bottom"> </TD> <TD VALIGN="bottom" ALIGN="right">[*]</TD> <TD NOWRAP VALIGN="bottom"> </TD> <TD VALIGN="bottom"> </TD> <TD VALIGN="bottom"> </TD> <TD VALIGN="bottom" ALIGN="right">[*]</TD> <TD NOWRAP VALIGN="bottom"> </TD></TR> <TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt"> <TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">[*]</P></TD> <TD VALIGN="bottom"> </TD> <TD VALIGN="bottom"> </TD> <TD VALIGN="bottom" ALIGN="right">[*]</TD> <TD NOWRAP VALIGN="bottom"> </TD> <TD VALIGN="bottom"> </TD> <TD VALIGN="bottom"> </TD> <TD VALIGN="bottom" ALIGN="right">[*]</TD> <TD NOWRAP VALIGN="bottom"> </TD></TR> <TR STYLE="font-family:Times New Roman; font-size:10pt"> <TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">[*]</P></TD> <TD VALIGN="bottom"> </TD> <TD VALIGN="bottom"> </TD> <TD VALIGN="bottom" ALIGN="right">[*]</TD> <TD NOWRAP VALIGN="bottom"> </TD> <TD VALIGN="bottom"> </TD> <TD VALIGN="bottom"> </TD> <TD VALIGN="bottom" ALIGN="right">[*]</TD> <TD NOWRAP VALIGN="bottom"> </TD></TR> <TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt"> <TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">[*]</P></TD> <TD VALIGN="bottom"> </TD> <TD VALIGN="bottom"> </TD> <TD VALIGN="bottom" ALIGN="right">[*]</TD> <TD NOWRAP VALIGN="bottom"> </TD> <TD VALIGN="bottom"> </TD> <TD VALIGN="bottom"> </TD> <TD VALIGN="bottom" ALIGN="right">[*]</TD> <TD NOWRAP VALIGN="bottom"> </TD></TR> <TR STYLE="font-family:Times New Roman; font-size:10pt"> <TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">[*]</P></TD> <TD VALIGN="bottom"> </TD> <TD VALIGN="bottom"> </TD> <TD VALIGN="bottom" ALIGN="right">[*]</TD> <TD NOWRAP VALIGN="bottom"> </TD> <TD VALIGN="bottom"> </TD> <TD VALIGN="bottom"> </TD> <TD VALIGN="bottom" ALIGN="right">[*]</TD> <TD NOWRAP VALIGN="bottom"> </TD></TR> <TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt"> <TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">[*]</P></TD> <TD VALIGN="bottom"> </TD> <TD VALIGN="bottom"> </TD> <TD VALIGN="bottom" ALIGN="right">[*]</TD> <TD NOWRAP VALIGN="bottom"> </TD> <TD VALIGN="bottom"> </TD> <TD VALIGN="bottom"> </TD> <TD VALIGN="bottom" ALIGN="right">[*]</TD> <TD NOWRAP VALIGN="bottom"> </TD></TR> <TR STYLE="font-family:Times New Roman; font-size:10pt"> <TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">[*]</P></TD> <TD VALIGN="bottom"> </TD> <TD VALIGN="bottom"> </TD> <TD VALIGN="bottom" ALIGN="right">[*]</TD> <TD NOWRAP VALIGN="bottom"> </TD> <TD VALIGN="bottom"> </TD> <TD VALIGN="bottom"> </TD> <TD VALIGN="bottom" ALIGN="right">[*]</TD> <TD NOWRAP VALIGN="bottom"> </TD></TR> <TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt"> <TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">[*]</P></TD> <TD VALIGN="bottom"> </TD> <TD VALIGN="bottom"> </TD> <TD VALIGN="bottom" ALIGN="right">[*]</TD> <TD NOWRAP VALIGN="bottom"> </TD> <TD VALIGN="bottom"> </TD> <TD VALIGN="bottom"> </TD> <TD VALIGN="bottom" ALIGN="right">[*]</TD> <TD NOWRAP VALIGN="bottom"> </TD></TR> <TR STYLE="font-family:Times New Roman; font-size:10pt"> <TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">[*]</P></TD> <TD VALIGN="bottom"> </TD> <TD VALIGN="bottom"> </TD> <TD VALIGN="bottom" ALIGN="right">[*]</TD> <TD NOWRAP VALIGN="bottom"> </TD> <TD VALIGN="bottom"> </TD> <TD VALIGN="bottom"> </TD> <TD VALIGN="bottom" ALIGN="right">[*]</TD> <TD NOWRAP VALIGN="bottom"> </TD></TR> <TR STYLE="font-size:1px; "> <TD VALIGN="bottom"></TD> <TD VALIGN="bottom"> </TD> <TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000"> </P></TD> <TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000"> </P></TD> <TD> </TD> <TD VALIGN="bottom"> </TD> <TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000"> </P></TD> <TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000"> </P></TD> <TD> </TD></TR> <TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt"> <TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total</P></TD> <TD VALIGN="bottom"></TD> <TD VALIGN="bottom"> </TD> <TD VALIGN="bottom" ALIGN="right">[*]</TD> <TD NOWRAP VALIGN="bottom"> </TD> <TD VALIGN="bottom"></TD> <TD VALIGN="bottom"> </TD> <TD VALIGN="bottom" ALIGN="right">[*]</TD> <TD NOWRAP VALIGN="bottom"> </TD></TR> <TR STYLE="font-size:1px; "> <TD VALIGN="bottom"></TD> <TD VALIGN="bottom"> </TD> <TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000"> </P></TD> <TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000"> </P></TD> <TD> </TD> <TD VALIGN="bottom"> </TD> <TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000"> </P></TD> <TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000"> </P></TD> <TD> </TD></TR> </TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(c) Interpretations of Section 11.5(b):</B> </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman"><B>(i)</B> “<B>CY 5012</B>” means the multiple ascending dose Phase 1 Clinical Trial for the Lead Compound as set forth in the Development Plan. For clarity, the first multiple ascending dose Phase 1 Clinical Trial for the Lead Compound conducted under the Development Plan will be deemed to be CY 5012 even if not specifically designated as CY 5012 in the Development Plan. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman"><B>(ii)</B> In the event the Parties disagree as to whether [*] the Parties shall meet and discuss in good faith. In the event the Parties cannot agree on the matter [*] in accordance with [*] set forth in Section [*]. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman"><B>(iii)</B> For determination of Astellas’ payment obligations set forth in Section 11.5(b), it is confirmed that, if a particular milestone for the [*] for a particular Collaboration Product, then [*] such Collaboration Product [*] such milestone. For clarity, [*] refers to the [*] the table above, e.g., [*]. </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt"> </P> <TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%"> <TR> <TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>[*] =</B></TD> <TD ALIGN="left" VALIGN="top"><B>Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. </B></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">76 </P> <p Style='page-break-before:always'> <HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER"> <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman"><B>(iv)</B> Notwithstanding the foregoing, the [*] Collaboration Products, regardless of [*] subject to Section [*]. For clarity, the [*] Sections [*]. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman"><B>(v)</B> The milestone payment obligation set forth in Section 11.5(b)(i) shall be [*]. Accordingly, and subject to Section [*] described in Section [*] Collaboration Product [*] Collaboration Products [*] </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman"><B>(vi) </B>The milestones in Section 11.5(b)(i) for [*] Activators shall be payable if such milestone event is achieved in [*] and the third milestone (i.e., JDC’s decision to enter into Phase 2 Clinical Trial), which may be achieved in either Licensed Indications or [*] Indications. Astellas acknowledges that such third milestone has been achieved as of the Amendment Effective Date and the corresponding milestone payment (fifteen million Dollars ($15,000,000)) shall be paid by Astellas within thirty (30) days after the Amendment Effective Date. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman"><B>(vii)</B> The milestone payment in in Section 11.5(b)(ii) marked by the asterisk [*] Indication. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman"><B>(viii)</B> If Cytokinetics exercises the Cytokinetics Co-Funding Option [*] then each subsequent milestone payment in Section 11.5(b)(ii) will be payable upon the occurrence of the corresponding milestone event for [*] triggering such milestone payment, it being understood that the [*] triggering milestone payments [*]. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman"><B>(ix)</B> If Cytokinetics does not exercise the Cytokinetics Co-Funding Option [*], then each subsequent milestone payment in Section 11.5(b)(ii) will be payable [*]. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman"><B>(x)</B> The milestone payment in in Section 11.5(b)(iii) marked by the asterisk (i.e., for the [*]) will be payable [*]. [*] milestone payments in Section 11.5(b)(iii) shall be payable for [*]. </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt"> </P> <TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%"> <TR> <TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>[*] =</B></TD> <TD ALIGN="left" VALIGN="top"><B>Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. </B></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">77 </P> <p Style='page-break-before:always'> <HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER"> <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(d) Notice and Payment.</B> Each Party shall notify the other Party in writing within [*] days after the achievement of any milestone set forth in this Section 11.5 by such Party, its Affiliates or its sublicensees. Astellas shall pay to Cytokinetics the applicable milestone payments within [*] days after the receipt of such notice from Cytokinetics (for milestones achieved by Cytokinetics, its Affiliates or (sub)licensees) or achievement of such milestone by Astellas or its Affiliates or sublicensees. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(e) [*] Indications.</B> If the JDC [*] a Collaboration Product in a [*] Indication after [*] then Astellas shall pay to Cytokinetics: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman"><B>(i)</B> [*] set forth in the table in Section [*] upon the achievement of [*] for such Collaboration Product [*] such achievement is [*] achievement of such [*] the Collaboration Product, as well as [*] achievement of the same [*] Collaboration Product in [*] Indication; or </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman"><B>(ii)</B> [*] set forth in the table in Section [*)] upon the achievement of [*] for such Collaboration Product [*] achieved in [*] Indication for the Collaboration Product. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman"><B>(iii)</B> It is confirmed that: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt"> </P> <TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%"> <TR> <TD WIDTH="4%"> </TD> <TD WIDTH="4%" VALIGN="top" ALIGN="left">(A)</TD> <TD ALIGN="left" VALIGN="top">Astellas’ milestone payment under Section [*] Indication shall [*] in Section [*] and Astellas’ milestone payment for [*] Indication under Section [*] in Section [*]. Astellas’ milestone payment under Section [*] in Section [*]; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt"> </P> <TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%"> <TR> <TD WIDTH="4%"> </TD> <TD WIDTH="4%" VALIGN="top" ALIGN="left">(B)</TD> <TD ALIGN="left" VALIGN="top">the achievement of [*] the Collaboration Products in a [*] Indication shall not trigger Astellas’ payment obligations for the [*] set forth in Section [*]; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt"> </P> <TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%"> <TR> <TD WIDTH="4%"> </TD> <TD WIDTH="4%" VALIGN="top" ALIGN="left">(C)</TD> <TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE="font-family:Times New Roman; font-size:10pt">upon [*] achievement of [*] the Collaboration Products in [*] Indication (irrespective of </P></TD></TR></TABLE> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt"> </P> <TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%"> <TR> <TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>[*] =</B></TD> <TD ALIGN="left" VALIGN="top"><B>Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. </B></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">78 </P> <p Style='page-break-before:always'> <HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER"> <TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%"> <TR> <TD WIDTH="8%"> </TD> <TD ALIGN="left" VALIGN="top"> whether such achievement takes place before the achievement of [*] Collaboration Product in a [*] Indication), Astellas shall make to Cytokinetics the milestone payment for [*] achievement of [*] such Collaboration Product in [*] Indication; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt"> </P> <TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%"> <TR> <TD WIDTH="4%"> </TD> <TD WIDTH="4%" VALIGN="top" ALIGN="left">(D)</TD> <TD ALIGN="left" VALIGN="top">achievement of [*] a Collaboration Product in a [*] Indication shall not be deemed to have achieved [*] and shall not trigger Astellas’ payment obligations for [*]. </TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>11.6 Commercial Milestones.</B> <B> </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(a) Commercial Milestones.</B> Astellas shall, in accordance with Section 11.6(b), pay to Cytokinetics the one-time, non-refundable, non-creditable payments set forth in the table below when the aggregated annual (based on Astellas’ fiscal year) worldwide Net Sales of all Collaboration Products first reach the values indicated below. For clarity, the milestone payments in this Section 11.6 shall [*] specified below is [*]. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt"> </P> <TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="68%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center"> <TR> <TD WIDTH="79%"></TD> <TD VALIGN="bottom" WIDTH="18%"></TD> <TD></TD> <TD></TD> <TD></TD></TR> <TR STYLE="font-family:Times New Roman; font-size:8pt"> <TD VALIGN="bottom" NOWRAP> <P STYLE="border-bottom:1.00pt solid #000000; width:197.85pt; font-size:8pt; font-family:Times New Roman"><B>Annual worldwide Net Sales of all Collaboration Products</B></P></TD> <TD VALIGN="bottom"> </TD> <TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Milestone Payments</B></TD> <TD VALIGN="bottom"> </TD></TR> <TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt"> <TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">[*]</P></TD> <TD VALIGN="bottom"> </TD> <TD VALIGN="bottom"> </TD> <TD VALIGN="bottom" ALIGN="right">[*]</TD> <TD NOWRAP VALIGN="bottom"> </TD></TR> <TR STYLE="font-family:Times New Roman; font-size:10pt"> <TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">[*]</P></TD> <TD VALIGN="bottom"> </TD> <TD VALIGN="bottom"> </TD> <TD VALIGN="bottom" ALIGN="right">[*]</TD> <TD NOWRAP VALIGN="bottom"> </TD></TR> <TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt"> <TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">[*]</P></TD> <TD VALIGN="bottom"> </TD> <TD VALIGN="bottom"> </TD> <TD VALIGN="bottom" ALIGN="right">[*]</TD> <TD NOWRAP VALIGN="bottom"> </TD></TR> <TR STYLE="font-family:Times New Roman; font-size:10pt"> <TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">[*]</P></TD> <TD VALIGN="bottom"> </TD> <TD VALIGN="bottom"> </TD> <TD VALIGN="bottom" ALIGN="right">[*]</TD> <TD NOWRAP VALIGN="bottom"> </TD></TR> </TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(b) Notice and Payment.</B> Astellas shall notify Cytokinetics in writing within [*] days after the end of the calendar quarter during which the aggregated annual worldwide Net Sales of all Collaboration Products first reach the values set forth in Section 11.6(a) above, and shall pay to Cytokinetics the applicable milestone payments concurrent with such notice. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>11.7 Royalty Payments for Products. </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(a) Royalty Rates.</B> Subject to the other terms of this Section 11.7, during the Royalty Term, Astellas shall make quarterly non-refundable, non-creditable royalty payments to Cytokinetics on the Net Sales of each Collaboration Product at the applicable royalty rate set forth below. Net Sales shall be aggregated on a Compound-by-Compound basis across all Indications. </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt"> </P> <TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%"> <TR> <TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>[*] =</B></TD> <TD ALIGN="left" VALIGN="top"><B>Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. </B></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">79 </P> <p Style='page-break-before:always'> <HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER"> <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman"><B>(i) [*] Activators.</B> The royalty rates set forth in the table below shall apply to Collaboration Product containing [*] Activator. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt"> </P> <TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="84%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center"> <TR> <TD WIDTH="50%"></TD> <TD VALIGN="bottom" WIDTH="1%"></TD> <TD WIDTH="48%"></TD></TR> <TR STYLE="font-family:Times New Roman; font-size:8pt"> <TD VALIGN="bottom" NOWRAP STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman"><B>Worldwide Net Sales of each Collaboration</B></P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman"><B>Product in an Astellas’ fiscal year</B></P></TD> <TD VALIGN="bottom"> </TD> <TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Royalty Rate for Net Sales of Collaboration</B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Product containing [*] Activator in such</B></P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Astellas’ fiscal year</B></P></TD></TR> <TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt"> <TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">[*]</P></TD> <TD VALIGN="bottom"> </TD> <TD VALIGN="bottom" ALIGN="right">[*]</TD></TR> <TR STYLE="font-family:Times New Roman; font-size:10pt"> <TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">[*]</P></TD> <TD VALIGN="bottom"> </TD> <TD VALIGN="bottom" ALIGN="right">[*]</TD></TR> <TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt"> <TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">[*]</P></TD> <TD VALIGN="bottom"> </TD> <TD VALIGN="bottom" ALIGN="right">[*]</TD></TR> <TR STYLE="font-family:Times New Roman; font-size:10pt"> <TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">[*]</P></TD> <TD VALIGN="bottom"> </TD> <TD VALIGN="bottom" ALIGN="right">[*]</TD></TR> </TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman"><B>(ii) [*] Activator Approved for [*] Indication(s) and/or [*].</B> The royalty rates set forth in the table below shall apply to each Collaboration Product containing a [*] Activator, unless and until any of the royalty rates set forth in Sections 11.7(a)(iii), (iv) and (v) below become applicable to such Collaboration Product. Once any of the royalty rates set forth in Sections 11.7(a)(iii), (iv) and (v) below become applicable to such Collaboration Product, the royalty rates set forth in this Section 11.7(a)(ii) shall no longer apply. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt"> </P> <TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center"> <TR> <TD WIDTH="34%"></TD> <TD VALIGN="bottom"></TD> <TD WIDTH="32%"></TD> <TD VALIGN="bottom" WIDTH="1%"></TD> <TD WIDTH="32%"></TD></TR> <TR STYLE="font-family:Times New Roman; font-size:8pt"> <TD VALIGN="bottom" ROWSPAN="2" NOWRAP> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman"><B>Worldwide Net Sales of each</B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman"><B>Collaboration Product in an</B></P> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1.00pt solid #000000; width:97.70pt; font-size:8pt; font-family:Times New Roman"><B>Astellas’ fiscal year</B></P></TD> <TD VALIGN="bottom"> </TD> <TD VALIGN="bottom" COLSPAN="3" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Royalty Rate for Net Sales in such Astellas’ fiscal year</B></P></TD></TR> <TR STYLE="font-family:Times New Roman; font-size:8pt"> <TD VALIGN="bottom"> </TD> <TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Lead Product</B></P></TD> <TD VALIGN="bottom"> </TD> <TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Collaboration Product</B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>containing [*] Activator</B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(other than the Lead</B></P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Compound)</B></P></TD></TR> <TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt"> <TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">[*]</P></TD> <TD VALIGN="bottom"> </TD> <TD VALIGN="bottom" ALIGN="right">[*]</TD> <TD VALIGN="bottom"> </TD> <TD VALIGN="bottom" ALIGN="right">[*]</TD></TR> <TR STYLE="font-family:Times New Roman; font-size:10pt"> <TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">[*]</P></TD> <TD VALIGN="bottom"> </TD> <TD VALIGN="bottom" ALIGN="right">[*]</TD> <TD VALIGN="bottom"> </TD> <TD VALIGN="bottom" ALIGN="right">[*]</TD></TR> <TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt"> <TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">[*]</P></TD> <TD VALIGN="bottom"> </TD> <TD VALIGN="bottom" ALIGN="right">[*]</TD> <TD VALIGN="bottom"> </TD> <TD VALIGN="bottom" ALIGN="right">[*]</TD></TR> <TR STYLE="font-family:Times New Roman; font-size:10pt"> <TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">[*]</P></TD> <TD VALIGN="bottom"> </TD> <TD VALIGN="bottom" ALIGN="right">[*]</TD> <TD VALIGN="bottom"> </TD> <TD VALIGN="bottom" ALIGN="right">[*]</TD></TR> </TABLE> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt"> </P> <TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%"> <TR> <TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>[*] =</B></TD> <TD ALIGN="left" VALIGN="top"><B>Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. </B></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">80 </P> <p Style='page-break-before:always'> <HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER"> <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman"><B>(iii) [*] Activator Approved for [*] Indication(s) ([*] Indications).</B> The royalty rates set forth in the table below shall apply to Collaboration Product containing a [*] Activator after the first Marketing Approval of such Collaboration Product in [*] Indication for which Cytokinetics exercises the Cytokinetics Co-Funding Option [*] for such Collaboration Product and [*] such Collaboration Product for [*] Indication. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt"> </P> <TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center"> <TR> <TD WIDTH="34%"></TD> <TD VALIGN="bottom"></TD> <TD WIDTH="32%"></TD> <TD VALIGN="bottom" WIDTH="1%"></TD> <TD WIDTH="32%"></TD></TR> <TR STYLE="font-family:Times New Roman; font-size:8pt"> <TD VALIGN="bottom" ROWSPAN="2" NOWRAP> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman"><B>Worldwide Net Sales of each</B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman"><B>Collaboration Product in an</B></P> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1.00pt solid #000000; width:97.70pt; font-size:8pt; font-family:Times New Roman"><B>Astellas’ fiscal year</B></P></TD> <TD VALIGN="bottom"> </TD> <TD VALIGN="bottom" COLSPAN="3" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Royalty Rate for Net Sales in such Astellas’ fiscal year</B></P></TD></TR> <TR STYLE="font-family:Times New Roman; font-size:8pt"> <TD VALIGN="bottom"> </TD> <TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Lead Product</B></P></TD> <TD VALIGN="bottom"> </TD> <TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Collaboration Product</B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>containing [*] Activator</B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(other than the Lead</B></P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Compound)</B></P></TD></TR> <TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt"> <TD VALIGN="top">[*]</TD> <TD VALIGN="bottom"> </TD> <TD VALIGN="bottom" ALIGN="right">[*]</TD> <TD VALIGN="bottom"> </TD> <TD VALIGN="bottom" ALIGN="right">[*]</TD></TR> <TR STYLE="font-family:Times New Roman; font-size:10pt"> <TD VALIGN="top">[*]</TD> <TD VALIGN="bottom"> </TD> <TD VALIGN="bottom" ALIGN="right">[*]</TD> <TD VALIGN="bottom"> </TD> <TD VALIGN="bottom" ALIGN="right">[*]</TD></TR> <TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt"> <TD VALIGN="top">[*]</TD> <TD VALIGN="bottom"> </TD> <TD VALIGN="bottom" ALIGN="right">[*]</TD> <TD VALIGN="bottom"> </TD> <TD VALIGN="bottom" ALIGN="right">[*]</TD></TR> <TR STYLE="font-family:Times New Roman; font-size:10pt"> <TD VALIGN="top">[*]</TD> <TD VALIGN="bottom"> </TD> <TD VALIGN="bottom" ALIGN="right">[*]</TD> <TD VALIGN="bottom"> </TD> <TD VALIGN="bottom" ALIGN="right">[*]</TD></TR> </TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman"><B>(iv) [*] Activator Approved for [*] Indication(s) and [*] Indication(s)/[*] Indication(s).</B> The royalty rates set forth in the table below shall apply to Collaboration Product containing a [*] Activator after the first Marketing Approval of such Collaboration Product for [*] Indication (except during the Cytokinetics Commercialization Period) and provided that such Collaboration Product has obtained Marketing Approval for a [*] Indication or [*] Indication, provided that: (A) where such Collaboration Product is approved for [*] Indication, if Cytokinetics either did not exercise the Cytokinetics Co-Funding Option or [*] for such Collaboration Product, then Astellas shall have the right to [*] as set forth in Section [*]; (B) if [*] for such Collaboration Product for such approved [*] Indication(s), then Cytokinetics shall have the right to [*] as set forth in Section [*]; and (C) if both the [*] apply, then Section [*] shall apply. </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt"> </P> <TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%"> <TR> <TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>[*] =</B></TD> <TD ALIGN="left" VALIGN="top"><B>Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. </B></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">81 </P> <p Style='page-break-before:always'> <HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER"> <TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center"> <TR> <TD WIDTH="62%"></TD> <TD VALIGN="bottom" WIDTH="17%"></TD> <TD></TD> <TD></TD> <TD></TD> <TD VALIGN="bottom" WIDTH="17%"></TD> <TD></TD> <TD></TD> <TD></TD></TR> <TR STYLE="font-family:Times New Roman; font-size:8pt"> <TD VALIGN="bottom" ROWSPAN="2" NOWRAP> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman"><B>Worldwide Net Sales of each</B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman"><B>Collaboration Product in an</B></P> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1.00pt solid #000000; width:97.70pt; font-size:8pt; font-family:Times New Roman"><B>Astellas’ fiscal year</B></P></TD> <TD VALIGN="bottom"> </TD> <TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Royalty Rate for Net Sales in such Astellas’ fiscal year</B></TD> <TD VALIGN="bottom"> </TD></TR> <TR STYLE="font-family:Times New Roman; font-size:8pt"> <TD VALIGN="bottom"> </TD> <TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Lead Product</B></TD> <TD VALIGN="bottom"> </TD> <TD VALIGN="bottom"> </TD> <TD VALIGN="middle" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Collaboration Product</B><br><B>containing [*] Activator</B><br><B>(other than the Lead</B><br><B>Compound)</B></TD> <TD VALIGN="bottom"> </TD></TR> <TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt"> <TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">[*]</P></TD> <TD VALIGN="bottom"> </TD> <TD VALIGN="bottom"> </TD> <TD VALIGN="bottom" ALIGN="right">[*]</TD> <TD NOWRAP VALIGN="bottom"> </TD> <TD VALIGN="bottom"> </TD> <TD VALIGN="bottom"> </TD> <TD VALIGN="bottom" ALIGN="right">[*]</TD> <TD NOWRAP VALIGN="bottom"> </TD></TR> <TR STYLE="font-family:Times New Roman; font-size:10pt"> <TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">[*]</P></TD> <TD VALIGN="bottom"> </TD> <TD VALIGN="bottom"> </TD> <TD VALIGN="bottom" ALIGN="right">[*]</TD> <TD NOWRAP VALIGN="bottom"> </TD> <TD VALIGN="bottom"> </TD> <TD VALIGN="bottom"> </TD> <TD VALIGN="bottom" ALIGN="right">[*]</TD> <TD NOWRAP VALIGN="bottom"> </TD></TR> <TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt"> <TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">[*]</P></TD> <TD VALIGN="bottom"> </TD> <TD VALIGN="bottom"> </TD> <TD VALIGN="bottom" ALIGN="right">[*]</TD> <TD NOWRAP VALIGN="bottom"> </TD> <TD VALIGN="bottom"> </TD> <TD VALIGN="bottom"> </TD> <TD VALIGN="bottom" ALIGN="right">[*]</TD> <TD NOWRAP VALIGN="bottom"> </TD></TR> <TR STYLE="font-family:Times New Roman; font-size:10pt"> <TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">[*]</P></TD> <TD VALIGN="bottom"> </TD> <TD VALIGN="bottom"> </TD> <TD VALIGN="bottom" ALIGN="right">[*]</TD> <TD NOWRAP VALIGN="bottom"> </TD> <TD VALIGN="bottom"> </TD> <TD VALIGN="bottom"> </TD> <TD VALIGN="bottom" ALIGN="right">[*]</TD> <TD NOWRAP VALIGN="bottom"> </TD></TR> </TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman"><B>(v) [*] Activator Approved for [*].</B> The royalty rates set forth in the table below shall apply to Collaboration Product containing a [*] Activator after the first Marketing Approval of such Collaboration Product for one or more [*] Indication(s) [*] such Collaboration Product obtains Marketing Approval in any [*] Indication or [*] Indication (except during the Cytokinetics Commercialization Period), provided that [*] for such Collaboration Product for any of [*] Indication(s), then [*] shall have the right to [*] as set forth in Section [*]. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt"> </P> <TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center"> <TR> <TD WIDTH="62%"></TD> <TD VALIGN="bottom" WIDTH="17%"></TD> <TD></TD> <TD></TD> <TD></TD> <TD VALIGN="bottom" WIDTH="17%"></TD> <TD></TD> <TD></TD> <TD></TD></TR> <TR STYLE="font-family:Times New Roman; font-size:8pt"> <TD VALIGN="bottom" ROWSPAN="2" NOWRAP> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman"><B>Worldwide Net Sales of each</B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman"><B>Collaboration Product in an</B></P> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1.00pt solid #000000; width:97.70pt; font-size:8pt; font-family:Times New Roman"><B>Astellas’ fiscal year</B></P></TD> <TD VALIGN="bottom"> </TD> <TD VALIGN="middle" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Royalty Rate for Net Sales in such Astellas’ fiscal year</B></TD> <TD VALIGN="bottom"> </TD></TR> <TR STYLE="font-family:Times New Roman; font-size:8pt"> <TD VALIGN="bottom"> </TD> <TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Lead Product</B></TD> <TD VALIGN="bottom"> </TD> <TD VALIGN="bottom"> </TD> <TD VALIGN="middle" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Collaboration Product<BR>containing [*] Activator<BR>(other than the Lead<BR>Compound)</B></TD> <TD VALIGN="bottom"> </TD></TR> <TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt"> <TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">[*]</P></TD> <TD VALIGN="bottom"> </TD> <TD VALIGN="bottom"> </TD> <TD VALIGN="bottom" ALIGN="right">[*]</TD> <TD NOWRAP VALIGN="bottom"> </TD> <TD VALIGN="bottom"> </TD> <TD VALIGN="bottom"> </TD> <TD VALIGN="bottom" ALIGN="right">[*]</TD> <TD NOWRAP VALIGN="bottom"> </TD></TR> <TR STYLE="font-family:Times New Roman; font-size:10pt"> <TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">[*]</P></TD> <TD VALIGN="bottom"> </TD> <TD VALIGN="bottom"> </TD> <TD VALIGN="bottom" ALIGN="right">[*]</TD> <TD NOWRAP VALIGN="bottom"> </TD> <TD VALIGN="bottom"> </TD> <TD VALIGN="bottom"> </TD> <TD VALIGN="bottom" ALIGN="right">[*]</TD> <TD NOWRAP VALIGN="bottom"> </TD></TR> <TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt"> <TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">[*]</P></TD> <TD VALIGN="bottom"> </TD> <TD VALIGN="bottom"> </TD> <TD VALIGN="bottom" ALIGN="right">[*]</TD> <TD NOWRAP VALIGN="bottom"> </TD> <TD VALIGN="bottom"> </TD> <TD VALIGN="bottom"> </TD> <TD VALIGN="bottom" ALIGN="right">[*]</TD> <TD NOWRAP VALIGN="bottom"> </TD></TR> <TR STYLE="font-family:Times New Roman; font-size:10pt"> <TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">[*]</P></TD> <TD VALIGN="bottom"> </TD> <TD VALIGN="bottom"> </TD> <TD VALIGN="bottom" ALIGN="right">[*]</TD> <TD NOWRAP VALIGN="bottom"> </TD> <TD VALIGN="bottom"> </TD> <TD VALIGN="bottom"> </TD> <TD VALIGN="bottom" ALIGN="right">[*]</TD> <TD NOWRAP VALIGN="bottom"> </TD></TR> </TABLE> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt"> </P> <TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%"> <TR> <TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>[*] =</B></TD> <TD ALIGN="left" VALIGN="top"><B>Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. </B></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">82 </P> <p Style='page-break-before:always'> <HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER"> <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman"><B>(vi) [*].</B> </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt"> </P> <TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%"> <TR> <TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>(1)</B></TD> <TD ALIGN="left" VALIGN="top"><B>[*]</B> Under circumstances where [*] has the right to [*] as set forth in this Section 11.7, and subject to Section 11.7(a)(vi)(3) below, the [*] set forth in this Section 11.7 or Section 11.8(b) shall [*] shall no longer apply. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt"> </P> <TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%"> <TR> <TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>(2)</B></TD> <TD ALIGN="left" VALIGN="top"><B>[*]</B> Under circumstances where [*] has the right to [*] as set forth in this Section 11.7 or Section 11.8(b), and subject to Section 11.7(a)(vi)(3) below, the [*] shall be [*] shall no longer apply. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt"> </P> <TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%"> <TR> <TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>(3)</B></TD> <TD ALIGN="left" VALIGN="top"><B></B><B></B>If, for a particular Collaboration Product, [*] under Section 11.7(a)(iv), then each Party shall [*] of the applicable [*] shall have the right to [*] under Section 11.7(a)(iv) but only [*] shall have the right to [*] but only [*].<B></B> </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt"> </P> <TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%"> <TR> <TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>(4)</B></TD> <TD ALIGN="left" VALIGN="top"><B></B>[*] means, with respect to a Collaboration Product [*] Indication(s) for which [*] for such [*] Indication. If [*] </TD></TR></TABLE> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt"> </P> <TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%"> <TR> <TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>[*] =</B></TD> <TD ALIGN="left" VALIGN="top"><B>Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. </B></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">83 </P> <p Style='page-break-before:always'> <HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER"> <TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%"> <TR> <TD WIDTH="4%"> </TD> <TD ALIGN="left" VALIGN="top">[*] such Collaboration Product and [*] such Collaboration Product, then the [*] such Collaboration Product [*] was deemed to have [*] such Collaboration Product pursuant to Section [*] such Collaboration Product and [*] will be included in the [*]. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt"> </P> <TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%"> <TR> <TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>(5)</B></TD> <TD ALIGN="left" VALIGN="top">[*] means, with respect to a Collaboration Product which [*] one or more [*] Indication(s), the [*] Indication(s). If [*] Indication [*] Indication(s) and [*] Indication [*] such Collaboration Product [*] </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(b) Royalty Term. </B>Astellas’ royalty payment obligations under this Agreement shall commence upon the First Commercial Sale of the first Collaboration Product anywhere in the world by Astellas, its Affiliates or its sublicensees, and shall continue, on a Collaboration Product-by-Collaboration Product and country-by-country basis, until the latest of (i) the expiration of the last to expire Valid Claim [*] such Collaboration Product in such country; (ii) the expiration of the last to expire Valid Claim [*] Collaboration Product, provided that [*] with respect to such Collaboration Product [*]; (iii) [the expiration of any Regulatory Exclusivity granted] with respect to such Collaboration Product in such country; and (iv) [*] years after the First Commercial Sale of such Collaboration Product in such country (the “Royalty Term”). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(c) [</B><B>*]</B> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman"><B>(i) </B>If a Collaboration Product is [*] in a country during the applicable Royalty Term [*] with respect to such Collaboration Product [*], and (i) such [*] in such country [*] or (ii) such [*] for such Collaboration Product in such country [*] in such country, then the [*] of such Collaboration Product in such country [*] so long as the [*] with respect to such Collaboration Product [*] in such country [*]. </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt"> </P> <TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%"> <TR> <TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>[*] =</B></TD> <TD ALIGN="left" VALIGN="top"><B>Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. </B></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">84 </P> <p Style='page-break-before:always'> <HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER"> <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman"><B>(ii) </B>If, for a particular Collaboration Product in a particular country, [*] the First Commercial Sale of such Collaboration Product in such country: (A) there is [*] such Collaboration Product [*]; and (B) the Royalty Term set forth in Section 11.7(b) [*] such Collaboration Product [*] such Collaboration Product [*] then the applicable [*] such Collaboration Product [*] so long as the [*] in this Section 11.7(c)(ii) [*]. This Section 11.7(c)(ii) shall not operate to [*] in Section [*]. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(d) Basis for Royalty</B>. This Section 11.7 is intended to provide for payments to Cytokinetics equal to the percentages of Net Sales set forth in this Section 11.7 for the duration of the Royalty Term. In establishing this payment structure, the Parties recognize, and Astellas acknowledges, the substantial value of the various actions and investments undertaken by Cytokinetics prior to the Effective Date and that Cytokinetics will undertake under this Agreement, and that the value of the Cytokinetics Technology licensed to Astellas hereunder resides substantially in Cytokinetics Know-How. As a result, the Parties attribute such value to Cytokinetics’ leading proprietary knowledge in the subject matter, including trade secrets, preclinical and clinical data pertaining to the Compounds and Collaboration Products, and regulatory filings made by Cytokinetics prior to the Effective Date, in each case created or generated by Cytokinetics through the expenditure of significant resources and as a result of Cytokinetics’ unique innovative capabilities. The Parties agree that because Cytokinetics is not separately compensated under this Agreement for such additional benefits, the royalties set forth above are appropriate for the duration of the Royalty Term. The Parties have agreed to the payment structure set forth herein as a convenient and fair mechanism for both Parties in order to compensate Cytokinetics for these additional benefits as part of the overall consideration for Cytokinetics to enter into this Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(e) Royalty Reports and Payment.</B> Within [*] days after each calendar quarter, commencing with the calendar quarter during which the First Commercial Sale of the first Collaboration Product is made anywhere in the world, Astellas shall provide Cytokinetics with a report that contains the following information for the applicable calendar quarter, on a Collaboration Product-by-Collaboration Product and country-by-country basis: (i) the amount of gross sales of the Collaboration Products, (ii) an itemized calculation of Net Sales showing deductions provided for in the definition of “Net Sales”, (iii) a calculation of the royalty payment due on such sales, including [*] in accordance with Section [*] and (iv) the exchange rate for such country. Within [*] days after each calendar quarter, Astellas shall pay in Dollars all royalties due to Cytokinetics with respect to Net Sales by Astellas, its Affiliates and their respective sublicensees for such calendar quarter. </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt"> </P> <TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%"> <TR> <TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>[*] =</B></TD> <TD ALIGN="left" VALIGN="top"><B>Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. </B></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">85 </P> <p Style='page-break-before:always'> <HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER"> <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>11.8 Payments during Cytokinetics Commercialization Period</B>. If a Collaboration Product [*] Indication(s) and [*] for a Collaboration Product in such Indication(s), then, during the Cytokinetics Commercialization Period: </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(a) Shared Territory</B>. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman"><B>(i) </B>If Cytokinetics is [*] such Collaboration Product in the Shared Territory, then [*] such Collaboration Product in the Shared Territory. Subject to agreement by the Parties regarding the [*] with respect to such Collaboration Product and [*], on a quarterly basis within [*] days after the end of each calendar quarter, [*] shall provide [*] with an itemized invoice for the [*] during such calendar quarter. [*] shall pay the amount of each such invoice within [*] days after its receipt. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman"><B>(ii)</B> If Astellas [*] of such Collaboration Product in the Shared Territory, then Astellas shall pay to Cytokinetics [*] for such Collaboration Product in the Shared Territory, which payment shall be made within [*] days after each calendar quarter and accompanied with a reasonably detailed report. Subject to agreement by the Parties regarding the [*], Astellas shall have the right to [*] during such calendar quarter. Concurrent with such payment, Astellas shall provide Cytokinetics with a report equivalent to the royalty report set forth in Section 11.7(e) and an itemized accounting for the [*]. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman"><B>(iii)</B> “[*]” means, to the extent applicable and [*] in accordance with the scope of [*] agreed by the Parties: (A) [*]); (B) any related [*]; and (C) [*] to be agreed by the Parties (which will not [*]) to cover related costs incurred by Astellas. For the convenience of the Parties, the Parties may agree on [*] Cytokinetics under Section [*] with respect to [*] Collaboration Product, Cytokinetics will [*] such Collaboration Product pursuant to Section [*] </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman"><B>(iv)</B> [*]” means the [*] (A) [*] the Collaboration Product; (B) [*]; (C) [*]; and (D) a reasonable [*] Collaboration Product [*]; in each case, only to the extent [*] mutually agreed [*] shall exclude any [*] Cytokinetics. </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt"> </P> <TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%"> <TR> <TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>[*] =</B></TD> <TD ALIGN="left" VALIGN="top"><B>Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. </B></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">86 </P> <p Style='page-break-before:always'> <HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER"> <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman"><B>(v)</B> If the Parties cannot reach agreement [*] each Party with [*] will meet in person and seek to resolve the matter prior to escalation to the JSC. If the matter is unresolved after escalation to the JSC[*] in accordance with [*] set forth in Section [*]. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(b) Astellas Territory</B>.<B> </B>If Astellas Commercializes such Collaboration Product in such Indication in the Astellas Territory, then Astellas shall make payments to Cytokinetics as follows:<B></B> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman"><B>(i) During the Cytokinetics Commercialization Period.</B> During the Cytokinetics Commercialization Period, Astellas shall make quarterly non-refundable, non-creditable royalty payments to Cytokinetics on the Net Sales of each Collaboration Product at the applicable royalty rate set forth below. Net Sales shall be aggregated on a Compound-by-Compound basis across all Indications. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt"> </P> <TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center"> <TR> <TD WIDTH="54%"></TD> <TD VALIGN="bottom" WIDTH="21%"></TD> <TD></TD> <TD></TD> <TD></TD> <TD VALIGN="bottom" WIDTH="21%"></TD> <TD></TD> <TD></TD> <TD></TD></TR> <TR STYLE="font-family:Times New Roman; font-size:8pt"> <TD VALIGN="bottom" ROWSPAN="2" NOWRAP STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman"><B>Net Sales in Astellas</B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman"><B>Territory of each</B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman"><B>Collaboration Product in an</B></P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman"><B>Astellas’ fiscal year</B></P></TD> <TD VALIGN="bottom"> </TD> <TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Royalty Rate for Net Sales in such Astellas’ fiscal year</B></TD> <TD VALIGN="bottom"> </TD></TR> <TR STYLE="font-family:Times New Roman; font-size:8pt"> <TD VALIGN="bottom"> </TD> <TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Lead Product</B></TD> <TD VALIGN="bottom"> </TD> <TD VALIGN="bottom"> </TD> <TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Collaboration Product<BR>containing [*] Activator</B><br><B>(other than the Lead<BR>Compound)</B></TD> <TD VALIGN="bottom"> </TD></TR> <TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt"> <TD VALIGN="top">[*]</TD> <TD VALIGN="bottom"> </TD> <TD VALIGN="bottom"> </TD> <TD VALIGN="bottom" ALIGN="right">[*]</TD> <TD NOWRAP VALIGN="bottom"> </TD> <TD VALIGN="bottom"> </TD> <TD VALIGN="bottom"> </TD> <TD VALIGN="bottom" ALIGN="right">[*]</TD> <TD NOWRAP VALIGN="bottom"> </TD></TR> <TR STYLE="font-family:Times New Roman; font-size:10pt"> <TD VALIGN="top">[*]</TD> <TD VALIGN="bottom"> </TD> <TD VALIGN="bottom"> </TD> <TD VALIGN="bottom" ALIGN="right">[*]</TD> <TD NOWRAP VALIGN="bottom"> </TD> <TD VALIGN="bottom"> </TD> <TD VALIGN="bottom"> </TD> <TD VALIGN="bottom" ALIGN="right">[*]</TD> <TD NOWRAP VALIGN="bottom"> </TD></TR> <TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt"> <TD VALIGN="top">[*]</TD> <TD VALIGN="bottom"> </TD> <TD VALIGN="bottom"> </TD> <TD VALIGN="bottom" ALIGN="right">[*]</TD> <TD NOWRAP VALIGN="bottom"> </TD> <TD VALIGN="bottom"> </TD> <TD VALIGN="bottom"> </TD> <TD VALIGN="bottom" ALIGN="right">[*]</TD> <TD NOWRAP VALIGN="bottom"> </TD></TR> <TR STYLE="font-family:Times New Roman; font-size:10pt"> <TD VALIGN="top">[*]</TD> <TD VALIGN="bottom"> </TD> <TD VALIGN="bottom"> </TD> <TD VALIGN="bottom" ALIGN="right">[*]</TD> <TD NOWRAP VALIGN="bottom"> </TD> <TD VALIGN="bottom"> </TD> <TD VALIGN="bottom"> </TD> <TD VALIGN="bottom" ALIGN="right">[*]</TD> <TD NOWRAP VALIGN="bottom"> </TD></TR> </TABLE> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt"> </P> <TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%"> <TR> <TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>[*] =</B></TD> <TD ALIGN="left" VALIGN="top"><B>Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. </B></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">87 </P> <p Style='page-break-before:always'> <HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER"> <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman"><B>(ii) After the Cytokinetics Commercialization Period.</B> After the Cytokinetics Commercialization Period, Astellas shall make quarterly non-refundable, non-creditable royalty payments to Cytokinetics on the Net Sales of each Collaboration Product at the royalty rates set forth in Section 11.7 (a)(iv) (if Astellas has [*] Indication or [*] Indication for such Collaboration Product in the applicable country) or Section 11.7(a)(v) (if Astellas has [*] Indication or [*] Indication for such Collaboration Product in the applicable country [*] Indication in such country for which [*]), but in each case [*] shall have the right to [*] as set forth in Section [*] provided that the [*]. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>11.9 Currency; Exchange Rate.</B> All payments to be made by a Party to the other Party under this Agreement shall be made in Dollars by bank wire transfer in immediately available funds to a bank account designated by written notice from the Party that receives the payment. The rate of exchange to be used in computing the amount of currency equivalent in Dollars for calculating Net Sales shall be made at the average quarterly rate as published by Bloomberg (based on 20:00 Tokyo time) for the applicable quarterly reporting period for which the payment is due, or such other source as the Parties may agree in writing. Astellas shall provide Cytokinetics with written documentation of the applicable average quarterly rate, in English, along with the applicable royalty report under Section 11.7(e). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>11.10 Late Payments.</B> If a Party does not receive payment from the other Party of any sum due to it on or before the due date therefor, simple interest shall thereafter accrue on the sum due to such receiving Party from the due date until the date of payment at a [*] or the [*]. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>11.11 Taxes. </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(a) Taxes on Income.</B> Each Party shall be solely responsible for the payment of all taxes imposed on its share of income arising directly or indirectly from the activities of the Parties under this Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(b) Tax Cooperation.</B> The Parties agree to cooperate with one another and use reasonable efforts to avoid or reduce tax withholding or similar obligations in respect of royalties, milestone payments, and other payments made by a Party to the other Party under this Agreement. To the extent such paying Party is required to deduct and withhold taxes on any payment to the other Party, such paying Party shall pay the amounts of such taxes to the proper Governmental Authority in a timely manner, and the sum payable to such other Party shall be increased to the extent necessary to ensure that such other Party receives a sum equal to the sum which it would have received had there been no such withholding tax. Notwithstanding the foregoing, if the paying Party is obliged to pay withholding taxes and the other Party reasonably foresees that it will </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt"> </P> <TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%"> <TR> <TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>[*] =</B></TD> <TD ALIGN="left" VALIGN="top"><B>Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. </B></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">88 </P> <p Style='page-break-before:always'> <HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"> be able to utilize as a tax credit any amounts withheld or deducted by such paying Party, such other Party shall immediately so notify and, upon such notice, with respect to the amount in question, such paying Party will be released from the obligation to increase the amount pursuant to this Section 11.11. Such other Party shall provide such paying Party any tax forms that may be reasonably necessary in order for such paying Party to not withhold tax or to withhold tax at a reduced rate under an applicable bilateral income tax treaty, to the extent legally able to do so. Such other Party shall use reasonable efforts to provide any such tax forms to such paying Party in advance of the due date. Each Party shall provide the other with reasonable assistance (i) to enable the recovery, as permitted by Law, of withholding taxes or similar obligations resulting from payments made under this Agreement and (ii) in connection with any audit by any tax authority relating to this Agreement. In the event the paying Party increased the amount of its payment to the other Party to account for any withholding tax, and such other Party later utilizes any such amount withheld by such paying Party to achieve any tax saving for the benefit of such other Party in the form of a tax deduction, such other Party shall notify such paying Party in writing of the amount of such tax saving and such paying Party shall have the right to credit such amount of tax saving against its future payment obligations to such other Party. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>11.12 Records and Audit Rights. </B>Each Party shall maintain complete and accurate records in sufficient detail to permit the other Party to confirm the accuracy of the amount of Research Plan Costs, Development Costs, [*] to be reimbursed, achievement of sales milestones, royalty payments and other amounts payable under this Agreement. Upon reasonable prior notice, such records shall be open during regular business hours for a period of [*] years from the creation of individual records for examination by an independent certified public accountant selected by the auditing Party and reasonably acceptable to the audited Party for the sole purpose of verifying for the auditing Party the accuracy of the financial reports furnished by the audited Party pursuant to this Agreement or of any payments made, or required to be made, by or to the audited Party pursuant to this Agreement. Such audits not occur more often than once each calendar year. Such auditor shall not disclose the audited Party’s Confidential Information to the auditing Party, except to the extent such disclosure is necessary to verify the accuracy of the financial reports furnished by the audited Party or the amount of payments to or by the audited Party under this Agreement. Any amounts shown to be owed but unpaid shall be paid within [*] days after the accountant’s report, plus interest (as set forth in Section 11.10) from the original due date. The auditing Party shall bear the full costs of such audit unless such audit reveals an overpayment to, or an underpayment by, the audited Party that resulted from a discrepancy in the financial report provided by the audited Party for the audited period, which underpayment or overpayment was more than [*] of the amount set forth in such report, in which case the audited Party shall reimburse the auditing Party for the costs for such audit. If any such overpayment exceeds such [*] amount, then the auditing Party will refund such amount to the audited Party within [*] days after the accountant’s report. On the other hand, if any such overpayment does not exceed such [*] amount, the auditing Party shall have the right to credit the amount of such overpayment against its future payment obligations to the audited Party, provided that such future payments are expected. </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt"> </P> <TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%"> <TR> <TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>[*] =</B></TD> <TD ALIGN="left" VALIGN="top"><B>Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. </B></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">89 </P> <p Style='page-break-before:always'> <HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE 12 </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>INTELLECTUAL PROPERTY RIGHTS </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>12.1 Ownership of Collaboration Intellectual Property.</B> <B> </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(a) </B>All Collaboration Intellectual Property shall be [*]. Each Party shall [*] in any Collaboration Intellectual Property [*] the other Party, subject to [*.] To the extent any Collaboration Intellectual Property is [*] a Party, such Party shall, [*] such Collaboration Intellectual Property to the extent [*] the other Party [*]. To the extent any Patent Right [*] any Collaboration Intellectual Property [*] such Patent Right to [*]. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(b) </B>The Parties shall cooperate with respect to the filing, prosecution, maintenance and enforcement of Collaboration Patents through the JPC. This Agreement shall be deemed a joint research agreement under 35 U.S.C. §102(c) or §103(c), as applicable, and any foreign counterparts entered into for the purpose of researching, identifying and developing Compounds and Collaboration Products under the terms set forth herein. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>12.2 Disclosure of Collaboration Intellectual Property.</B> Each Party shall promptly disclose to the other Party all Collaboration Intellectual Property, including all invention disclosures or other similar documents submitted to such Party by its, or its Affiliates’, directors, officers, employees, agents or independent contractors relating to such Collaboration Intellectual Property, and shall also respond promptly to reasonable requests from the other Party for additional information relating to such Collaboration Intellectual Property. Notwithstanding the foregoing, the Parties may [*] in connection with the Research Plan. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>12.3 Patent Prosecution. </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(a) Cytokinetics Sole Patents.</B> </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman"><B>(i)</B> Cytokinetics shall be responsible for filing, prosecuting and maintaining the Cytokinetics Patents[*]. Cytokinetics shall consult with Astellas and keep Astellas reasonably informed of the status of the Cytokinetics Patents and shall promptly provide Astellas with copies of material correspondence received from any patent </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt"> </P> <TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%"> <TR> <TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>[*] =</B></TD> <TD ALIGN="left" VALIGN="top"><B>Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. </B></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">90 </P> <p Style='page-break-before:always'> <HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"> authorities in connection therewith. In addition, Cytokinetics shall promptly provide Astellas with drafts of all proposed material filings and correspondences to any patent authorities with respect to the Cytokinetics Patents for Astellas’ review and comment prior to the submission of such proposed filings and correspondences. Cytokinetics shall confer with Astellas and reasonably consider Astellas’ comments prior to submitting such filings and correspondences, provided that Astellas shall provide such comments within [*] days of receiving the draft filings and correspondences from Cytokinetics. If Astellas does not provide comments within such period of time, then Astellas shall be deemed to have no comment to such proposed filings or correspondences. In case of disagreement between the Parties with respect to the filing, prosecution and maintenance of such Cytokinetics Patents, the final decision shall be made by Cytokinetics, subject to subsection (ii) below. For the purpose of this Article 12, “prosecution” shall include any post-grant proceeding including supplemental examination, post-grant review proceeding, inter parties review proceeding, patent interference proceeding, opposition proceeding, reexamination, patent term restoration (under but not limited to the U.S. Drug Price Competition and Patent Term Restoration Act), supplemental protection certificates or their equivalents, and patent term extensions. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman"><B>(ii) </B>Cytokinetics shall notify Astellas in writing of any decision to cease prosecution and/or maintenance of, any Cytokinetics Patents in any country. Cytokinetics shall provide such notice at least [*] days prior to any filing or payment due date, or any other due date that requires action in order to avoid loss of rights, in connection with such Cytokinetics Patent. Upon request by Astellas, Cytokinetics shall permit Astellas, at Astellas’ discretion and expense, to continue prosecution or maintenance of such Cytokinetics Patent in such country, and for as long as Astellas assumes such prosecution and maintenance at its own costs, such Cytokinetics Patent shall be [*]. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(b) Collaboration Patents.</B> </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman"><B>(i)</B> Astellas shall be responsible for filing, prosecuting and maintaining any Collaboration Patents, [*]. Astellas shall consult with Cytokinetics and keep Cytokinetics reasonably informed of the status of the Collaboration Patents and shall promptly provide Cytokinetics with copies of material correspondence received from any patent authorities in connection therewith. In addition, Astellas shall promptly provide Cytokinetics with drafts of all proposed material filings and correspondences to any patent authorities with respect to the Collaboration Patents for Cytokinetics’ review and comment prior to the submission of such proposed filings and correspondences. Astellas shall confer with Cytokinetics and reasonably consider Cytokinetics’ comments prior to submitting such filings and correspondences, provided that Cytokinetics shall provide such comments within [*] days of receiving the draft filings and correspondences from Astellas. If Cytokinetics does not provide comments within such period of time, then Cytokinetics shall be deemed to have no comment to such proposed filings or correspondences. In case of disagreement between the Parties with respect to the filing, prosecution and maintenance of such Collaboration Patents, the final decision shall be made by Astellas, subject to subsection (ii) below. </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt"> </P> <TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%"> <TR> <TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>[*] =</B></TD> <TD ALIGN="left" VALIGN="top"><B>Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. </B></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">91 </P> <p Style='page-break-before:always'> <HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER"> <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman"><B>(ii) </B>Astellas shall notify Cytokinetics in writing of any decision to cease prosecution and/or maintenance of, any Collaboration Patents in any country. Astellas shall provide such notice at least [*] days prior to any filing or payment due date, or any other due date that requires action in order to avoid loss of rights, in connection with such Collaboration Patent. In such event, Astellas shall permit Cytokinetics, at its discretion and expense, to continue prosecution or maintenance of such Collaboration Patent in such country, and for as long as Cytokinetics assumes such prosecution and maintenance at its own costs, such Collaboration Patent shall be [*]. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(c) Astellas Patents</B>. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman"><B>(i)</B> Astellas shall be responsible for filing, prosecuting and maintaining the Astellas Patents, [*]. Astellas shall keep Cytokinetics reasonably informed of the status of the Astellas Patents. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman"><B>(ii)</B> Astellas shall notify Cytokinetics in writing of any decision to cease prosecution and/or maintenance of, any Astellas Patents in any country. Astellas shall provide such notice at least [*] days prior to any filing or payment due date, or any other due date that requires action in order to avoid loss of rights, in connection with such Astellas Patent. In such event, Astellas shall permit Cytokinetics, at its discretion and expense, to continue prosecution or maintenance of such Astellas Patent in such country and, after such notice by Astellas, such Astellas Patent shall be [*]. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(d) Collaboration</B>. When a Party assumes the responsibilities for the prosecution and maintenance of a Patent under Section 12.3(a)(ii), 12.3(b)(ii), 12.3(c)(ii) or 14.3(c), the other Party shall promptly transfer to such Party the patent prosecution files for such Patent and provide reasonable assistance in the transfer of the prosecution responsibilities. The Party assuming such prosecution and maintenance responsibilities shall have the right to engage its own counsel to do so. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>12.4 Patent Enforcement. </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(a)</B> Each Party shall notify the other within [*] Business Days of becoming aware of any alleged or threatened infringement by a Third Party of any of the Cytokinetics Patents, Astellas Patents or Collaboration Patents, which infringement adversely affects or is expected to adversely affect the Development or Commercialization of any Collaboration Product, including any “patent certification” filed in the United States under 21 U.S.C. §355(b)(2) or 21 U.S.C. §355(j)(2) or similar provisions in other jurisdictions and of any declaratory judgment, opposition, or similar action alleging the invalidity, unenforceability or non-infringement of any of the Cytokinetics Patents, Astellas Patents or Collaboration Patents (collectively “<B>Product Infringemen</B>t”). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(b) </B>Astellas shall have the first right to bring and control any legal action in connection with any Product Infringement at its own expense as it reasonably determines appropriate, and Cytokinetics shall have the right to be represented in any such action by counsel of its choice. Astellas shall provide Cytokinetics and its counsel with copies all court filings and </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt"> </P> <TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%"> <TR> <TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>[*] =</B></TD> <TD ALIGN="left" VALIGN="top"><B>Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. </B></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">92 </P> <p Style='page-break-before:always'> <HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"> material supporting documentation, and, at the request of Cytokinetics, reasonable access to Astellas’ counsel for consultation, provided that, unless Cytokinetics is joined as a party to such action, any counsel retained by Cytokinetics shall not act as attorney of record for any such action, or conduct any legal proceedings as part of such action, unless specifically requested by Astellas and at Astellas’ expense. If Astellas decides not to bring such legal action, it shall so notify Cytokinetics promptly in writing and Cytokinetics shall have the right to bring and control any legal action in connection with such Product Infringement at its own expense as it reasonably determines appropriate after consultation with Astellas. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(c)</B> Cytokinetics shall have the exclusive right to enforce the Cytokinetics Patents for any infringement that is not a Product Infringement at its own expense as it reasonably determines appropriate. Astellas shall have the exclusive right to enforce the Astellas Patents for any infringement that is not a Product Infringement at its own expense as it reasonably determines appropriate. Each Party shall have the right to enforce the Collaboration Patents for any infringement that is not a Product Infringement at its own expense as it reasonably determines appropriate. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(d)</B> At the request of the Party bringing the action, the other Party shall provide reasonable assistance in connection therewith, including by executing reasonably appropriate documents, cooperating in discovery and joining as a party to the action if required. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(e)</B> In connection with any such proceeding, the Party bringing the action shall not enter into any settlement admitting the invalidity of, or otherwise impairing the other Party’s rights in, the Cytokinetics Patents, Astellas Patents or Collaboration Patents without the prior written consent of the other Party. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(f)</B> Any recoveries resulting from enforcement action relating to a claim of Product Infringement shall be first applied against payment of each Party’s costs and expenses in connection therewith. Any such recoveries in excess of such costs and expenses (the “<B>Remainder</B>”) shall be [*] provided that if the Product Infringement involves a Collaboration Product in [*] Indication [*] in the Shared Territory, and [*] for such Indication, the Remainder shall be paid to [*]. Any Remainder [*] in accordance with Section [*]. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>12.5 Trademarks.</B> <B> </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(a)</B> Except as set forth in Section 12.5(b) below, Astellas shall have the right to brand the Collaboration Products using any trademarks and trade names it determines appropriate for the Collaboration Products, which may vary by country or within a country (“<B>Product Marks</B>”). Astellas shall own all rights in the Product Marks and shall register and maintain the </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt"> </P> <TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%"> <TR> <TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>[*] =</B></TD> <TD ALIGN="left" VALIGN="top"><B>Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. </B></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">93 </P> <p Style='page-break-before:always'> <HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"> Product Marks in the countries and regions that it determines reasonably necessary, at Astellas’ cost and expense. If Cytokinetics exercises its Co-Promotion option for a Collaboration Product, Astellas shall mark such Collaboration Product in the Co-Promotion Territory (or Shared Territory, as applicable) with logos of both Astellas and Cytokinetics in equal prominence. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(b) </B>If Cytokinetics is Commercializing a Collaboration Product in an [*] Indication during the Cytokinetics Commercialization Period, Cytokinetics shall have the right to brand such Collaboration Product in the Shared Territory using any trademarks and trade names it determines appropriate for the Collaboration Products, which may vary by country or within a country (the “<B>Cytokinetics Product Marks</B>”). Cytokinetics shall own all rights in the Cytokinetics Product Marks and shall register and maintain the Cytokinetics Product Marks in the countries and regions in the Shared Territory that it determines reasonably necessary, at Cytokinetics’ cost and expense. After the Cytokinetics Commercialization Period, Astellas has the right to take over the Cytokinetics Product Marks (but not Cytokinetics’ name or its corporate marks) from Cytokinetics in the countries and regions in the Shared Territory without any additional compensation to Cytokinetics, provided that Astellas shall bear any costs and expenses incurred in connection with such transfer. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE 13 </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>CONFIDENTIALITY; PUBLICATION </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>13.1 Duty of Confidence.</B> Subject to the other provisions of this Article 13: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(a)</B> all Confidential Information of a Party (the “<B>Disclosing Party</B>”) shall be maintained in confidence and otherwise safeguarded by the other Party (the “<B>Receiving Party</B>”) and its Affiliates, using Diligent Efforts, but in any event no less than in the same manner and with the same protections as the Receiving Party maintains its own confidential information; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(b)</B> the Receiving Party may only use any such Confidential Information for the purposes of performing its obligations or exercising its rights under this Agreement; and </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(c)</B> the Receiving Party may disclose Confidential Information of the other Party to: (i) its Affiliates and sublicensees; and (ii) officers, employees, directors, agents, contractors, consultants and advisers of the Receiving Party and its Affiliates and sublicensees, in each case to the extent reasonably necessary for the purposes of, and for those matters undertaken pursuant to, this Agreement; provided that such Persons are bound by legally enforceable obligations to maintain the confidentiality of the Confidential Information in a manner consistent with the confidentiality provisions of this Agreement. </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt"> </P> <TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%"> <TR> <TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>[*] =</B></TD> <TD ALIGN="left" VALIGN="top"><B>Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. </B></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">94 </P> <p Style='page-break-before:always'> <HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER"> <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>13.2 Exceptions</B>. The foregoing obligations as to particular Confidential Information of a Disclosing Party shall not apply to the extent that the Receiving Party can demonstrate through competent evidence that such Confidential Information: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(a)</B> is known by the Receiving Party at the time of its receipt without an obligation of confidentiality, and not through a prior disclosure by the Disclosing Party, as documented by the Receiving Party’s business records; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(b)</B> is in the public domain before its receipt from the Disclosing Party, or thereafter enters the public domain through no fault of the Receiving Party; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(c)</B> is subsequently disclosed to the Receiving Party by a Third Party who may lawfully do so and is not under an obligation of confidentiality to the Disclosing Party; or </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(d)</B> is developed by the Receiving Party independently and without use of or reference to any Confidential Information received from the Disclosing Party, as documented by the Receiving Party’s business records. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">No combination of features or disclosures shall be deemed to fall within the foregoing exclusions merely because individual features are published or available to the general public or in the rightful possession of the Receiving Party, unless the combination itself and principle of operation are published or available to the general public or in the rightful possession of the Receiving Party. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>13.3 Authorized Disclosures</B><B>.</B> Notwithstanding the obligations set forth in Sections 13.1 and 13.5, a Party may disclose the other Party’s Confidential Information (including this Agreement and the terms herein) to the extent: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(a) </B>such disclosure: (i) is reasonably necessary for the filing or prosecuting Patent Rights as contemplated by this Agreement; (ii) is reasonably necessary in connection with regulatory filings for Collaboration Products; (iii) is reasonably necessary for the prosecuting or defending litigation as contemplated by this Agreement; or (iv) is made to any Third Party bound by written obligation of confidentiality and non-use substantially consistent with to those set forth under this Article 13 (subject to subsection (b) below with respect to [*]), to the extent otherwise necessary or appropriate in connection with the exercise of its rights or the performance of its obligations hereunder; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(b) </B>such disclosure is to [*], does not include the disclosure of Confidential Information relating to [*], and otherwise meets the requirements of subsection (a) above, in which case the Party [*] may agree with [*] of no less than [*] and in any event no less than [*]. Notwithstanding the foregoing, the subcontracting Party may request that the other Party grant a waiver to such requirement, which waiver shall not be unreasonably withheld or delayed and may be provided by e-mail. Each Party agrees to use Diligent Efforts to respond to a request for such a waiver within [*] Business Days. </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt"> </P> <TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%"> <TR> <TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>[*] =</B></TD> <TD ALIGN="left" VALIGN="top"><B>Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. </B></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">95 </P> <p Style='page-break-before:always'> <HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER"> <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(c) </B>such disclosure is reasonably necessary: (i) to such Party’s directors, attorneys, independent accountants or financial advisors for the sole purpose of enabling such directors, attorneys, independent accountants or financial advisors to provide advice to such Party, provided that in each such case on the condition that such directors, attorneys, independent accountants and financial advisors are bound by confidentiality and non-use obligations substantially consistent with those contained in this Agreement; or (ii) to actual or potential investors, acquirors, (sub)licensees and other financial or commercial partners solely for the purpose of evaluating or carrying out an actual or potential investment, acquisition or collaboration; provided that in each such case on the condition that such Persons are bound by confidentiality and non-use obligations substantially consistent with those contained in the Agreement; or </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(d)</B> such disclosure is required by judicial or administrative process, provided that in such event such Party shall promptly notify the other Party in writing of such required disclosure and provide the other Party an opportunity to challenge or limit the disclosure obligations. Confidential Information that is disclosed by judicial or administrative process shall remain otherwise subject to the confidentiality and non-use provisions of this Article 13, and the Party disclosing Confidential Information pursuant to law or court order shall take all steps reasonably necessary, including seeking of confidential treatment or a protective order, to ensure the continued confidential treatment of such Confidential Information. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>13.4 Publications</B><B>.</B> The JMAC (and prior to the establishment of the JMAC, the JRC (for Research-related publications) or the JDC (for Development-related publications)) (each of the JRC, JDC and the JMAC, the “<B>Responsible Committee</B>”) shall establish publication review and approval procedures for this Collaboration consistent with the publication policies of both Parties. The Parties shall review and approve any publication by either Party or its Affiliates or (sub)licensees relating to the Compounds or Collaboration Products, including scientific, health economic or pharmacoeconomic publications, in accordance with such procedures, considering Astellas’ and Cytokinetics’ interest in publishing the results of the work in the Research, Development, and Medical Affairs Activities in order to obtain recognition within the scientific or other applicable community and to advance the state of knowledge in the field, the need to protect Confidential Information and the Parties’ mutual interest in obtaining valid patent protection, protecting reasonable business interests and trade secret information, and having an integrated approach to developing one or more Collaboration Products for one or more Indications. Consequently, except for disclosures permitted pursuant to Sections 13.3 and 13.5, each Party and their Affiliates, employee(s) and consultant(s) shall deliver to the Responsible Committee for review and comment a copy of any proposed publication or presentation that pertains to any Compound or Collaboration Product, pursuant to a procedure to be established by the Responsible Committee (but excluding general corporate publications and presentations), any such comments to be provided within [*] days of receipt. The Responsible Committee shall have the right to require modifications of the publication or presentation: (a) to protect each Parties’ respective Confidential Information; (b) for trade secret reasons or business reasons; and/or (c) to delay such submission for an additional [*] days as may be reasonably necessary to seek patent protection for the information disclosed in such proposed submission. </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt"> </P> <TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%"> <TR> <TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>[*] =</B></TD> <TD ALIGN="left" VALIGN="top"><B>Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. </B></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">96 </P> <p Style='page-break-before:always'> <HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER"> <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>13.5 Publicity; Use of Names.</B> <B> </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(a)</B> The Parties have agreed on language of a joint press release announcing the restatement of the Agreement, which is attached hereto as <U><B>Exhibit J</B></U>, to be issued by the Parties promptly after the Amendment Effective Date. No other disclosure of the existence or the terms of this Agreement may be made by either Party or its Affiliates except as provided in Section 13.3 and this Section 13.5. No Party shall use the name, trademark, trade name or logo of the other Party, its Affiliates or their respective employees in any publicity, promotion, news release or disclosure relating to this Agreement or its subject matter, except as provided in this Section 13.5 or with the prior express written permission of the other Party, except as may be required by applicable Law. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(b)</B> A Party may disclose this Agreement in securities filings with the Securities Exchange Commission (the “<B>SEC</B>”) or equivalent foreign agency to the extent required by applicable Law. In such event, the Party seeking such disclosure shall prepare a proposed redacted version of this Agreement to request confidential treatment for this Agreement, and the other Party agrees to promptly (and in any event, no less than [*] Business Days after receipt of such proposed redactions) give its input in a reasonable manner in order to allow the Party seeking disclosure to file its request within the time lines prescribed by applicable Law. The Party seeking such disclosure shall reasonably consider any comments thereto provided by the other Party within such [*] Business Day period. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(c) </B>Each Party acknowledges that the other Party may be legally required to make public disclosures (including in filings with the Governmental Authorities or by issuing a press release) of certain terms of or material developments or material information generated under this Agreement and agrees that each Party may make such disclosures as required by Law, provided that the Party seeking such disclosure first provides the other Party a copy of the proposed disclosure, and shall reasonably consider any comments thereto provided by the other Party within [*] days after the receipt of such proposed disclosure, provided that in no event shall the Party having such disclosure obligation be required to delay its disclosure in a manner that may cause such Party to violate any Law or incur any legal liability. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(d) </B>Other than the press release set forth in <B><U>Exhibit J</U></B> and any press release issued pursuant to Section 13.5(c), the Parties agree that the portions of any other news release or other public announcement relating to this Agreement or the performance hereunder that would disclose information other than that already in the public domain, shall first be reviewed and approved by both Parties (with such approval not to be unreasonably withheld or delayed); provided, however, that notwithstanding the foregoing, Cytokinetics shall have the right to disclose publicly (including on its website): (i) the fact that it has entered into this Agreement; (ii) the commencement, progress, status, completion and key results of each clinical trials conducted by the Parties under this Agreement; (iii) the receipt of any milestone payments under this Agreement; (iv) Marketing Approval of any Collaboration Product; (v) the First Commercial Sale of any Collaboration Product; and (vi) royalties received from Astellas. For each such disclosure, unless Cytokinetics otherwise has the right to make such disclosure under this Article 13, Cytokinetics shall provide Astellas with a draft of such disclosure at least [*] Business Days prior </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt"> </P> <TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%"> <TR> <TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>[*] =</B></TD> <TD ALIGN="left" VALIGN="top"><B>Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. </B></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">97 </P> <p Style='page-break-before:always'> <HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"> to its intended release for Astellas’ review and comment, and shall consider Astellas’ comments in good faith. If Cytokinetics does not receive comments from Astellas within [*] Business Days, Cytokinetics shall have the right to make such disclosure without further delay. The Parties shall use reasonable efforts to coordinate the timing of such disclosures to be outside the trading hours of the NASDAQ and Tokyo stock markets, provided that neither Party shall be required to so delay such a disclosure where such delay would reasonably be expected to give rise to liability for or sanctions upon such Party in such Party’s sole judgment. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(e)</B> The Parties agree that after a disclosure pursuant to Section 13.5(b), a press release (including the initial press release) or other public announcement pursuant to Section 13.5(c) has been reviewed and approved by the other Party, either Party may make subsequent public disclosures reiterating such information without having to obtain the other Party’s prior consent or approval. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(f)</B> Each Party agrees that the other Party shall have the right to use such first Party’s name and logo in presentations, the company’s website, collateral materials and corporate overviews to describe the collaboration relationship, as well as in taglines of press releases issued pursuant to this Section 13.5. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>13.6 Attorney-Client Privilege</B>. Neither Party is waiving, nor shall be deemed to have waived or diminished, any of its attorney work product protections, attorney-client privileges or similar protections and privileges or the like as a result of disclosing information pursuant to this Agreement, or any of its Confidential Information (including Confidential Information related to pending or threatened litigation) to the Receiving Party, regardless of whether the Disclosing Party has asserted, or is or may be entitled to assert, such privileges and protections. The Parties: (a) share a common legal and commercial interest in such disclosure that is subject to such privileges and protections; (b) are or may become joint defendants in proceedings to which the information covered by such protections and privileges relates; (c) intend that such privileges and protections remain intact should either Party become subject to any actual or threatened proceeding to which the Disclosing Party’s Confidential Information covered by such protections and privileges relates; and (d) intend that after the Effective Date both the Receiving Party and the Disclosing Party shall have the right to assert such protections and privileges. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE 14 </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>TERM AND TERMINATION </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>14.1 Term.</B> The term of this Agreement shall commence upon the Effective Date and continue in full force and effect, on a Collaboration Product-by-Collaboration Product basis, until the expiration of the Royalty Term with respect to the applicable Collaboration Product, unless earlier terminated as set forth in Section 14.2 below (the “<B>Term</B>”). Upon expiration of the Royalty Term with respect to such Collaboration Product in such country, the license granted to Astellas under this Agreement with respect to such Collaboration Product in such country shall remain in effect on a perpetual, fully paid-up and royalty-free basis. </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt"> </P> <TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%"> <TR> <TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>[*] =</B></TD> <TD ALIGN="left" VALIGN="top"><B>Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. </B></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">98 </P> <p Style='page-break-before:always'> <HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER"> <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>14.2 Termination. </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(a) Termination by Astellas for Convenience.</B> At any time after the expiration of the Research Term, Astellas may terminate this Agreement for convenience in its entirety or on a [*] basis by providing written notice of termination to Cytokinetics, which notice includes an effective date of termination at least one hundred eighty (180) days after the date of the notice. [*]. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(b) Termination for Material Breach.</B> If either Party believes that the other is in material breach of its obligations hereunder or material breach of any representation or warranty set forth in this Agreement, then the non-breaching Party may deliver notice of such breach to the other Party. For all breaches other than a failure to make a payment as set forth in this Agreement, the allegedly breaching Party shall have [*] days from such notice to dispute or cure such breach. For any breach arising from a failure to make a payment set forth in this Agreement, the allegedly breaching Party shall have [*] days from the receipt of the notice to dispute or cure such breach. If the Party receiving notice of breach fails to cure, or fails to dispute, that breach within the applicable period set forth above, then the Party originally delivering the notice of breach may terminate this Agreement effective on written notice of termination to the other Party. If the allegedly breaching Party in good faith disputes such material breach or disputes the failure to cure or remedy such material breach and provides written notice of that dispute to the other Party within the applicable period set forth above, the matter shall be addressed under the dispute resolution provisions in Section 17.6(a), and the termination shall not become effective unless and until it has been determined under Section 17.6(a) that the allegedly breaching Party is in material breach of this Agreement. Notwithstanding the foregoing, if the material breach [*] and provided that such material breach [*] under this Section 14.2(b) shall be [*] set forth in Section [*] with respect to such [*] except as provided in Section [*]. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(c) Termination for Patent Challenge.</B> Except to the extent the following is unenforceable under the laws of a particular jurisdiction, Cytokinetics may terminate this Agreement if Astellas or its Affiliates or sublicensees, individually or in association with any other person or entity, commences a legal action challenging the validity, enforceability or scope of any Cytokinetics Patents. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(d) Termination for Bankruptcy.</B> Either Party may terminate this Agreement, if, at any time, the other Party files in any court or agency pursuant to any statute or regulation of any state, country or jurisdiction, a petition in bankruptcy or insolvency or for reorganization or for an arrangement or for the appointment of a receiver or trustee of such other Party or of its assets, or </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt"> </P> <TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%"> <TR> <TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>[*] =</B></TD> <TD ALIGN="left" VALIGN="top"><B>Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. </B></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">99 </P> <p Style='page-break-before:always'> <HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"> if the other Party proposes a written agreement of composition or extension of its debts, or if the other Party is served with an involuntary petition against it, filed in any insolvency proceeding, and such petition shall not be dismissed within [*] days after the filing thereof, or if the other Party proposes or is a party to any dissolution or liquidation, or if the other Party makes an assignment for the benefit of its creditors. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>14.3 Effect of Termination</B><B>.</B> Upon the termination (but not expiration) of this Agreement for any reason, all licenses and other rights granted to Astellas under the Cytokinetics Technology and Collaboration Intellectual Property shall terminate. In the case of a partial termination under Section 14.2(a) or 14.2(b), such licenses and rights will terminate solely with respect to [*]. In addition, the following consequences shall apply in the event of termination by Astellas pursuant to Section 14.2(a) or by Cytokinetics pursuant to Section 14.2(b), 14.2(c) or 14.2(d): </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(a) [*] Products</B>. Within [*] days after the effective date of termination, [*] Collaboration Products containing a [*] (the “[*] <B>Products</B>”). In addition, Astellas [*] Products. [*]. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(b) [*] Products</B>. [*] (i) in the event this Agreement is terminated with respect to [*] (other than [*] Product), such [*] Product; and/or (ii) in the event this Agreement is terminated with respect to [*] Products containing such [*] (other than [*] Product(s)), in each case in the Field [*] (such [*] Products, the “[*]<B> Products</B>”, and collectively with [*] Products, the “[<B>*] Products</B>”). [*] Products (other than any [*] Product) as follows:<B> </B> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman"><B>(i) </B>if on the effective date of such termination, the Parties have [*] for such [*] Product [*]; </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt"> </P> <TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%"> <TR> <TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>[*] =</B></TD> <TD ALIGN="left" VALIGN="top"><B>Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. </B></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">100 </P> <p Style='page-break-before:always'> <HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER"> <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman"><B>(ii) </B>if on the effective date of such termination, the Parties have [*] for such [*] Product but have [*] for such [*] Product [*]; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman"><B>(iii)</B> if on the effective date of such termination, the Parties have [*] for such [*] Product but have [*] for such [*] Product [*]; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman"><B>(iv)</B> if on the effective date of such termination, the Parties have [*] for such [*] Product but have [*] for such [*] Product [*]; and </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman"><B>(v)</B> if on the effective date of such termination, the Parties have [*] for such [*] Product and [*] for such [*] Product [*]. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In such event, Sections [*] shall apply to [*] (adjusted for [*]), and Section [*] shall no longer apply to the [*] Products. Cytokinetics may [*] by written notice to Astellas. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(c) Patent Prosecution and Enforcement</B>. After the effective date of termination, Astellas shall promptly transfer to Cytokinetics, and Cytokinetics shall thereafter be solely responsible for, the prosecution and maintenance of Collaboration Patents that are [*] under Section [*] under Section [*]. Cytokinetics shall have the first right to enforce at Cytokinetics’ sole cost the Collaboration Patents that are [*] under Section [*] and the Collaboration Patents that are [*] under Section [*], in each case against any infringement that adversely affects or is expected to adversely affect any [*] Product. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(d) Regulatory Materials; Data</B><B>.</B> Within thirty (30) days of the effective date of such termination, Astellas shall transfer and assign to Cytokinetics, at no cost to Cytokinetics, all Regulatory Materials relating to any [*] Products, data from preclinical, non-clinical and clinical studies conducted by or on behalf of Astellas, its Affiliates or sublicensees relating to any [*] Products and all pharmacovigilance data (including all adverse event databases) relating to any [*] Products. At Cytokinetics’ request, Astellas shall provide Cytokinetics with assistance with any inquiries and correspondence with Regulatory Authorities relating to any [*] Product for a period of [*] months after such termination. </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt"> </P> <TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%"> <TR> <TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>[*] =</B></TD> <TD ALIGN="left" VALIGN="top"><B>Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. </B></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">101 </P> <p Style='page-break-before:always'> <HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER"> <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(e) </B><B>Trademarks</B><B>.</B> Astellas shall transfer and assign, and shall ensure that its Affiliates transfer and assign, to Cytokinetics, at no cost to Cytokinetics, all Product Marks relating to any [*] Product and any applications therefor (excluding any such marks that include, in whole or part, any corporate name or logos of Astellas or its Affiliates or sublicensees). Cytokinetics and its Affiliates and licensees shall have the right to use other identifiers specific to such [*] Product (e.g., Astellas compound identifiers). Astellas shall also transfer to Cytokinetics any in-process applications for generic names for any [*] Product. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(f) Transition Assistance</B><B>.</B> Astellas shall provide the following transitional assistance, at its own cost unless specifically set forth below. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman"><B>(i) </B>If this Agreement is terminated in its entirety, Astellas shall promptly return to Cytokinetics all Know-How, data, materials and other Confidential Information made available to Astellas by Cytokinetics under this Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman"><B>(ii)</B> Upon request by Cytokinetics after termination of this Agreement, Astellas shall promptly provide Cytokinetics with a copy of each license agreement, collaboration agreement and/or vendor agreement then effective between Astellas (or its Affiliates) and a Third Party with respect to any [*] Product, or the Development, Manufacture and Commercialization thereof. Upon Cytokinetics’ request, Astellas shall use its Diligent Efforts to assign or sublicense, and shall ensure that its Affiliates assign or sublicense, to Cytokinetics any such agreement(s) and shall permit Cytokinetics access through any communication portal so established with such Third Party under any agreement so assigned to Cytokinetics. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman"><B>(iii)</B> Astellas shall, at Cytokinetics’ request after termination of this Agreement, transfer (including when available, in electronic format) all Astellas Know-How and Collaboration Know-How relating to any [*] Products to Cytokinetics or its designee, including without limitation: study protocols, study results, analytical methodologies, CMC Information (including bulk and final product manufacturing processes, batch records, vendor information and validation documentation), expert opinions, analyses, in each case to the extent such materials pertain to any [*] Products, and shall provide Cytokinetics reasonable technical assistance in connection therewith. From and after such time, all such Know-How shall be deemed Confidential Information of Cytokinetics. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman"><B>(iv) </B>Astellas shall transfer to Cytokinetics or its designee any and all inventory of [*] Products (including all research materials, final product, bulk drug substance, intermediates, work-in-process, formulation materials, reference standards, drug product clinical reserve samples, packaged retention samples, and the like) then in the possession of Astellas, its Affiliates or sublicensees at Astellas’ Manufacturing Costs. Astellas shall continue or have continued any ongoing stability studies pertaining to any materials so transferred if such studies will take less than [*] to complete. The Parties will agree on the procedures by which to transfer any longer stability studies to Cytokinetics or its designee in a manner that minimizes the disruption of such studies. </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt"> </P> <TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%"> <TR> <TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>[*] =</B></TD> <TD ALIGN="left" VALIGN="top"><B>Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. </B></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">102 </P> <p Style='page-break-before:always'> <HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER"> <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman"><B>(v)</B> If at the time of such termination, Cytokinetics or its Affiliates are not Manufacturing a particular [*] Product, then, at Cytokinetics’ request, Astellas shall: (A) continue to Manufacture and supply Cytokinetics with such [*] Product at [*] for a period of [*] year after such termination; (B) assign or transfer to Cytokinetics any Manufacturing agreement between Astellas and a Third Party contract manufacturer with respect to such [*] Product; and/or (C) transfer to Cytokinetics (or its designee) all Know-How and materials to enable Cytokinetics or such designee to assume the Manufacture and supply of such [*] Product and shall provide reasonable technical assistance in connection therewith; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman"><B>(vi) </B>If at the time of such termination, Astellas or its Affiliates are conducting any clinical trials for a [*] Product, then, at Cytokinetics’ election on a trial-by-trial basis: (A) Astellas shall fully cooperate, and shall ensure that its Affiliates fully cooperate, with Cytokinetics to transfer the conduct of all such clinical trials to Cytokinetics. [*] the conduct of such clinical trials after the effective date of such termination (except to the extent [*]); or (B) Astellas shall, [*], orderly wind-down the conduct of any such clinical trial which is not assumed by Cytokinetics under clause (A). In each case [*] in connection with the conduct or wind-down of all such clinical trials as of the effective date of such termination. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman"><B>(vii)</B> In addition to the foregoing, Astellas shall use its Diligent Efforts with respect to those activities for which it is responsible to ensure orderly transition and uninterrupted Development, Manufacturing, Commercialization and Medical Affairs Activities of [*] Products by Cytokinetics and to enable Cytokinetics to enter into an agreement with a Third Party to continue these activities with minimal disruption and delay. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman"><B>(viii)</B> Astellas shall transfer to Cytokinetics all rights to publications relating to any [*] Products (including data to be published, manuscript in preparation and pending publications). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(g) Termination Press Releases</B>. In the event of termination of this Agreement for any reason and subject to the provisions of Section 13.5, the Parties shall cooperate in good faith to coordinate public disclosure of such termination and the reasons therefor, and shall not, except to the extent required by applicable Law, disclose such information without the prior approval of the other Party. The principles to be observed in such disclosures shall be accuracy, compliance with applicable Law and regulatory guidance documents, and reasonable sensitivity to potential negative investor reaction to such news. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>14.4 Survival</B><B>.</B> Expiration or termination of this Agreement shall not relieve the Parties of any obligation accruing prior to such expiration or termination. Without limiting the foregoing, the provisions of Articles 1, 11 (solely with respect to payments accrued before the date of </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt"> </P> <TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%"> <TR> <TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>[*] =</B></TD> <TD ALIGN="left" VALIGN="top"><B>Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. </B></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">103 </P> <p Style='page-break-before:always'> <HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"> expiration or termination or [*]), 16 (solely with respect to Claims arising from actions and/or omissions during the Term) and 17, and Sections 3.4(f), 3.6(f), 3.8, 5.8, 8.6, 12.1(a), 12.1(b) (the second sentence only), 12.3(c), 12.3(d), 13.1, 13.2, 13.3, 13.5, 13.6, 14.3, 14.4, 14.5 and 15.5 shall survive the expiration or termination of this Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>14.5 Termination Not Sole Remedy</B><B>.</B> Termination is not the sole remedy under this Agreement and, whether or not termination is effected and notwithstanding anything contained in this Agreement to the contrary, all other remedies shall remain available except as agreed to otherwise herein. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE 15 </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>REPRESENTATIONS AND WARRANTIES </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>15.1 Representations and Warranties of Each Party</B><B>.</B> Each Party represents and warrants to the other Party as of the Effective Date that: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(a)</B> it is duly organized and validly existing under the laws of its jurisdiction of incorporation or formation, and has full corporate or other power and authority to enter into this Agreement and to carry out the provisions hereof; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(b)</B> it has the full right, power and authority to enter into this Agreement, to perform its obligations hereunder; and </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(c)</B> this Agreement has been duly executed by it and is legally binding upon it, enforceable in accordance with its terms, and does not conflict with any agreement, instrument or understanding, oral or written, to which it is a party or by which it may be bound, nor violate any material law or regulation of any court, governmental body or administrative or other agency having jurisdiction over it. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>15.2 Representations and Warranties by Cytokinetics.</B> Cytokinetics represents and warrants to Astellas as of the Effective Date that: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(a)</B> it has not previously assigned, transferred, conveyed or otherwise encumbered its right, title and interest in Cytokinetics Patents listed in <B><U>Exhibit C</U></B> in a manner that is inconsistent with the license granted to Astellas under Section 3.1; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(b) </B>to Cytokinetics’ knowledge, all Cytokinetics Patents are listed in <U><B>Exhibit C</B></U>; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(c)</B> it has the right to grant the license and rights herein to Astellas and it has not granted any license, right or interest in, to or under the Cytokinetics Patents listed in <B><U>Exhibit C</U></B> to any Third Party that is inconsistent with the license granted to Astellas under Section 3.1; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(d) </B>it has not received any written notice from any Third Party asserting or alleging that (i) the development of Cytokinetics Patents listed in<B> <U>Exhibit C</U></B> prior to the Effective Date or (ii) the practice of any Cytokinetics Know-How that is contemplated to be utilized in the Research Plan as the Research Plan exists as of the Effective Date, infringed or misappropriated the intellectual property rights of such Third Party; </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt"> </P> <TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%"> <TR> <TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>[*] =</B></TD> <TD ALIGN="left" VALIGN="top"><B>Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. </B></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">104 </P> <p Style='page-break-before:always'> <HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER"> <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(e) </B>to Cytokinetics’ knowledge, (i) the practice of Cytokinetics Patents listed in<B> <U>Exhibit C</U></B> prior to the Effective Date, and (ii) the practice of any Cytokinetics Know-How that is contemplated to be utilized in the Research Plan as the Research Plan exists as of the Effective Date, did not infringe any valid intellectual property rights owned or possessed by any Third Party and did not breach any obligation of confidentiality or non-use owed by Cytokinetics to a Third Party; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(f)</B> there are no judgments or settlements against or owed by Cytokinetics, and to Cytokinetics’ knowledge, there are no pending or threatened claims or litigation, in each case relating to Cytokinetics Patents listed in <B><U>Exhibit C</U></B>; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(g)</B> up to and including the Effective Date, Cytokinetics has made available to Astellas the Lead Compound IND and [*]; and </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(h)</B> Cytokinetics has sufficient legal and/or beneficial title and ownership in the Lead Compound IND to perform its rights and obligations under this Agreement; no Regulatory Authority has, to Cytokinetics’ knowledge, commenced or threatened to initiate any action or proceeding to refuse to file, reject, not approve, or withdraw the Lead Compound IND, nor has Cytokinetics received any notice to such effect; and to Cytokinetics’ knowledge, Cytokinetics is not in violation of any applicable Laws that could reasonably be expected to form the basis for such an action. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>15.3 Representations and Warranties by Astellas.</B> Astellas represents and warrants to Cytokinetics as of the Effective Date that: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(a)</B> it has not previously assigned, transferred, conveyed or otherwise encumbered its right, title and interest in Astellas Patent listed in <U><B>Exhibit A</B></U> in a manner that is inconsistent with the license granted to Cytokinetics under Section 3.4; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(b)</B> to Astellas’ knowledge, all Astellas Patents are listed in <U><B>Exhibit A</B></U>; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(c) </B>it has the right to grant the license and rights herein to Cytokinetics and it has not granted any license, right or interest in, to or under the Astellas Patents listed in <U><B>Exhibit A</B></U> to any Third Party that is inconsistent with the license granted to Cytokinetics under Section 3.4; </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt"> </P> <TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%"> <TR> <TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>[*] =</B></TD> <TD ALIGN="left" VALIGN="top"><B>Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. </B></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">105 </P> <p Style='page-break-before:always'> <HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER"> <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(d) </B>it has not received any written notice from any Third Party asserting or alleging that: (i) the development of Astellas Patents listed in <B><U>Exhibit A</U></B> prior to the Effective Date, or (ii) the practice of any Astellas Know-How that is contemplated to be utilized in the Research Plan as the Research Plan exists as of the Effective Date, infringed or misappropriated the intellectual property rights of such Third Party; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(e) </B>to Astellas’ knowledge, there are no [*]; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(f) </B>to Astellas’ knowledge, (i) the practice of Astellas Patents listed in <B><U>Exhibit A</U></B> prior to the Effective Date, and (ii) the practice of any Astellas Know-How that is contemplated to be utilized in the Research Plan as the Research Plan exists as of the Effective Date, did not infringe any valid intellectual property rights owned or possessed by any Third Party and did not breach any obligation of confidentiality or non-use owed by Astellas to a Third Party; and </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(g)</B> there are no judgments or settlements against or owed by Astellas, and to Astellas’ knowledge, there are no pending or threatened claims or litigation, in each case relating to Astellas Patents listed in <U><B>Exhibit A</B></U>. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>15.4 Mutual Covenants. </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(a) No Debarment</B>. In the course of the Research, Development, Manufacture and Commercialization of the Compounds and Collaboration Products, neither Party nor its Affiliates shall use any employee or consultant (including of any sublicensee), who has been debarred or disqualified by any Regulatory Authority, or, to such Party’s or its Affiliates’ knowledge, is the subject of debarment or disqualification proceedings by a Regulatory Authority. Each Party shall notify the other Party promptly upon becoming aware that any of its or its Affiliates’ employees or consultants has been debarred or is the subject of debarment or disqualification proceedings by any Regulatory Authority. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(b) Compliance</B>. Each Party and its Affiliates shall comply in all material respects with all applicable Laws (including all anti-bribery laws) in the Research, Development, Manufacture, Commercialization and Medical Affairs Activities of the Compounds and Collaboration Products and performance of its obligations under this Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>15.5 No Other Warranties.</B> EXCEPT AS EXPRESSLY STATED IN THIS ARTICLE 15, (A) NO REPRESENTATION, CONDITION OR WARRANTY WHATSOEVER IS MADE OR GIVEN BY OR ON BEHALF OF ASTELLAS OR CYTOKINETICS; AND (B) ALL OTHER CONDITIONS AND WARRANTIES WHETHER ARISING BY OPERATION OF LAW OR OTHERWISE ARE HEREBY EXPRESSLY EXCLUDED, INCLUDING ANY CONDITIONS AND WARRANTIES OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE OR NON-INFRINGEMENT. </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt"> </P> <TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%"> <TR> <TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>[*] =</B></TD> <TD ALIGN="left" VALIGN="top"><B>Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. </B></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">106 </P> <p Style='page-break-before:always'> <HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE 16 </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>INDEMNIFICATION; LIABILITY; INSURANCE </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>16.1 Indemnification by Cytokinetics.</B> Cytokinetics shall indemnify and hold Astellas, its Affiliates and sublicensees and their respective officers, directors, agents and employees (“<B>Astellas Indemnitees</B>”) harmless from and against any Claims against them to the extent arising or resulting from: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(a)</B> the Research, Development, Manufacture, Co-Promotion, or Commercialization or Medical Affairs Activities of the Compounds and/or Collaboration Products by Cytokinetics or any of its Affiliates, licensees, sublicensees, distributors or contractors; or </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(b)</B> the negligence, recklessness or willful misconduct of any of the Cytokinetics Indemnitees; or </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(c)</B> the breach of any of the warranties or representations made by Cytokinetics to Astellas under this Agreement; or </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(d)</B> the breach by Cytokinetics of its obligations pursuant to this Agreement; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">except in each case, to the extent such Claims result from the breach by any Astellas Indemnitee of any covenant, representation, warranty or other agreement made by Astellas in this Agreement or the negligence, recklessness or willful misconduct of any Astellas Indemnitee. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>16.2 Indemnification by Astellas.</B> Astellas shall indemnify and hold Cytokinetics, its Affiliates, and their respective officers, directors, agents and employees (“<B>Cytokinetics Indemnitees</B>”) harmless from and against any Claims arising under or related to this Agreement against them to the extent arising or resulting from: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(a)</B> the Research, Development, Manufacture, Commercialization or Medical Affairs Activities of the Compounds and/or Collaboration Products by Astellas or any of its Affiliates, licensees, sublicensees, distributors or contractors; or </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(b)</B> the negligence, recklessness or willful misconduct of any of the Astellas Indemnitees; or </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(c)</B> the breach of any of the warranties or representations made by Astellas to Cytokinetics under this Agreement; or </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(d)</B> any breach by Astellas of its obligations pursuant to this Agreement; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">except in each case, to the extent such Claims result from the breach by any Cytokinetics Indemnitee of any covenant, representation, warranty or other agreement made by Cytokinetics in this Agreement or the negligence, recklessness or willful misconduct of any Cytokinetics Indemnitee. </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt"> </P> <TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%"> <TR> <TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>[*] =</B></TD> <TD ALIGN="left" VALIGN="top"><B>Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. </B></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">107 </P> <p Style='page-break-before:always'> <HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER"> <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>16.3 Indemnification Procedure.</B> If either Party is seeking indemnification under Sections 16.1 or 16.2 (the <B>“</B><B>Indemnified Party</B><B>”</B>), it shall inform the other Party (the <B>“</B><B>Indemnifying Party</B><B>”</B>) of the Claim giving rise to the obligation to indemnify pursuant to such Section as soon as reasonably practicable after receiving notice of the Claim. The Indemnifying Party shall have the right to assume the defense of any such Claim for which it is obligated to indemnify the Indemnified Party. The Indemnified Party shall cooperate with the Indemnifying Party and the Indemnifying Party’s insurer as the Indemnifying Party may reasonably request, and at the Indemnifying Party’s cost and expense. The Indemnified Party shall have the right to participate, at its own expense and with counsel of its choice, in the defense of any Claim that has been assumed by the Indemnifying Party. Neither Party shall have the obligation to indemnify the other Party in connection with any settlement made without the Indemnifying Party’s written consent, which consent shall not be unreasonably withheld or delayed. If the Parties cannot agree as to the application of Section 16.1 or 16.2 as to any Claim, pending resolution of the dispute pursuant to Section 17.6(a), the Parties may conduct separate defenses of such Claims, with each Party retaining the right to claim indemnification from the other Party in accordance with Section 16.1 or 16.2 upon resolution of the underlying Claim. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>16.4 Mitigation of Loss.</B> Each Indemnified Party shall take and shall procure that its Affiliates take all such reasonable steps and action as are reasonably necessary or as the Indemnifying Party may reasonably require in order to mitigate any Claims (or potential losses or damages) under this Article 16. Nothing in this Agreement shall or shall be deemed to relieve any Party of any common law or other duty to mitigate any losses incurred by it. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>16.5 Limitation of Liability.</B> NEITHER PARTY SHALL BE LIABLE TO THE OTHER FOR ANY SPECIAL, CONSEQUENTIAL, INCIDENTAL, PUNITIVE, OR INDIRECT DAMAGES ARISING FROM OR RELATING TO ANY BREACH OF THIS AGREEMENT, REGARDLESS OF ANY NOTICE OF THE POSSIBILITY OF SUCH DAMAGES. NOTWITHSTANDING THE FOREGOING, NOTHING IN THIS SECTION 16.5 IS INTENDED TO OR SHALL LIMIT OR RESTRICT THE INDEMNIFICATION RIGHTS OR OBLIGATIONS OF ANY PARTY UNDER SECTION 16.1 OR 16.2, OR DAMAGES AVAILABLE FOR A PARTY’S BREACH OF ITS OBLIGATIONS RELATING TO CONFIDENTIALITY OR INTELLECTUAL PROPERTY HEREUNDER. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>16.6 Insurance</B>. Each Party shall procure and maintain insurance, including product liability insurance, with respect to its activities hereunder and which is consistent with normal business practices of prudent companies similarly situated at all times during which any Collaboration Product is being clinically tested in human subjects or commercially distributed or sold. Each Party shall provide the other Party with evidence of such insurance upon request and shall provide the other Party with written notice at least [*] days prior to the cancellation, non-renewal or material changes in such insurance. Such insurance shall not be construed to create a limit of either Party’s liability with respect to its indemnification obligations under this Article 16. </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt"> </P> <TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%"> <TR> <TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>[*] =</B></TD> <TD ALIGN="left" VALIGN="top"><B>Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. </B></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">108 </P> <p Style='page-break-before:always'> <HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE 17 </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>GENERAL PROVISIONS </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>17.1 Force Majeure.</B> Neither Party shall be held liable to the other Party nor be deemed to have defaulted under or breached this Agreement for failure or delay in performing any obligation under this Agreement to the extent such failure or delay is caused by or results from causes beyond the reasonable control of the affected Party, potentially including embargoes, war, acts of war (whether war be declared or not), acts of terrorism, insurrections, riots, civil commotions, strikes, lockouts or other labor disturbances, fire, floods, earthquakes or other acts of God, or acts, generally applicable action or inaction by any governmental authority (but excluding any government action or inaction that is specific to such Party, its Affiliates or sublicensees, such as revocation or non-renewal of such Party’s license to conduct business), or omissions or delays in acting by the other Party, or unavailability of materials related to the Manufacture of Compounds or Collaboration Products. The affected Party shall notify the other Party in writing of such force majeure circumstances as soon as reasonably practical, and shall promptly undertake and continue diligently all reasonable efforts necessary to cure such force majeure circumstances or to perform its obligations in spite of the ongoing circumstances. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>17.2 Assignment.</B> This Agreement may not be assigned or otherwise transferred, nor may any right or obligation hereunder be assigned or transferred, by either Party without the prior written consent of the other Party. Notwithstanding the foregoing, either Party may, without consent of the other Party, assign this Agreement and its rights and obligations hereunder in whole or in part to an Affiliate of such Party, or in whole to its successor-in-interest in connection with the sale of all or substantially all of its stock or its assets to which this Agreement relates, or in connection with a merger, acquisition or similar transaction. Any attempted assignment not in accordance with this Section 17.2 shall be null and void and of no legal effect. Any permitted assignee shall assume all assigned obligations of its assignor under this Agreement. The terms and conditions of this Agreement shall be binding upon, and shall inure to the benefit of, the Parties and their respected successors and permitted assigns. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>17.3 Severability.</B> If any one or more of the provisions contained in this Agreement is held invalid, illegal or unenforceable in any respect, the validity, legality and enforceability of the remaining provisions contained herein shall not in any way be affected or impaired thereby, unless the absence of the invalidated provision(s) adversely affects the substantive rights of the Parties. The Parties shall in such an instance use their best efforts to replace the invalid, illegal or unenforceable provision(s) with valid, legal and enforceable provision(s) which, insofar as practical, implement the purposes of this Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>17.4 Notices.</B> All notices which are required or permitted hereunder shall be in writing and sufficient if delivered personally, sent by facsimile (and promptly confirmed by personal </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt"> </P> <TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%"> <TR> <TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>[*] =</B></TD> <TD ALIGN="left" VALIGN="top"><B>Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. </B></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">109 </P> <p Style='page-break-before:always'> <HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"> delivery, registered or certified mail or overnight courier), sent by nationally-recognized overnight courier or sent by registered or certified mail, postage prepaid, return receipt requested, addressed as follows: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman">If to Cytokinetics: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:21%; font-size:10pt; font-family:Times New Roman">Cytokinetics, Inc. </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:21%; font-size:10pt; font-family:Times New Roman">280 East Grand Avenue </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:21%; font-size:10pt; font-family:Times New Roman">South San Francisco, CA 94080 </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:21%; font-size:10pt; font-family:Times New Roman">USA </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:21%; font-size:10pt; font-family:Times New Roman">Attn: President </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:21%; font-size:10pt; font-family:Times New Roman">Fax: 650-624-3010 </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:21%; font-size:10pt; font-family:Times New Roman">Copy to: General Counsel </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman">with a copy to: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:21%; font-size:10pt; font-family:Times New Roman">Cooley LLP </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:21%; font-size:10pt; font-family:Times New Roman">3175 Hanover Street </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:21%; font-size:10pt; font-family:Times New Roman">Palo Alto, CA 94304, USA </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:21%; font-size:10pt; font-family:Times New Roman">Attn: Robert L. Jones, Esq. </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:21%; font-size:10pt; font-family:Times New Roman">Fax: (650) 849-7400 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman">If to Astellas: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:21%; font-size:10pt; font-family:Times New Roman">Astellas Pharma Inc. </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:21%; font-size:10pt; font-family:Times New Roman">2-5-1, Nihonbashi-Honcho </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:21%; font-size:10pt; font-family:Times New Roman">Chuo-ku, Tokyo 103-8411 </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:21%; font-size:10pt; font-family:Times New Roman">Japan </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:21%; font-size:10pt; font-family:Times New Roman">Attn: Vice President, Legal & Compliance </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:21%; font-size:10pt; font-family:Times New Roman">Fax: [*] </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">or to such other address(es) as the Party to whom notice is to be given may have furnished to the other Party in writing in accordance herewith. Any such notice shall be deemed to have been given: (a) when delivered if personally delivered or sent by facsimile on a Business Day (or if delivered or sent on a non-Business Day, then on the next Business Day); (b) on the fifth (5th) Business Day after dispatch if sent by nationally-recognized overnight courier; or (c) on the tenth (10th) Business Day following the date of mailing, if sent by mail. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>17.5 Governing Law.</B> This Agreement shall be governed by and construed in accordance with the laws of the State of [*] and the patent laws of the United States without reference to any rules of conflict of laws. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>17.6 Dispute Resolution.</B> <B> </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(a)</B> The Parties shall negotiate in good faith and use reasonable efforts to settle any dispute, controversy or claim arising from or related to this Agreement or the breach thereof. If the Parties do not fully settle, and a Party wishes to pursue the matter, each such dispute, controversy or claim that is not a matter addressed in Section [*] shall be finally shall be </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt"> </P> <TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%"> <TR> <TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>[*] =</B></TD> <TD ALIGN="left" VALIGN="top"><B>Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. </B></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">110 </P> <p Style='page-break-before:always'> <HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B> </B>settled by binding arbitration administered by [*] pursuant to its [*] then in effect (the <B>“[*] Rules”</B>), except as otherwise provided herein. The arbitration shall be governed by the United States Federal Arbitration Act, 9 U.S.C. §§ 1-16 (the <B>“Federal Arbitration Act”</B>), to the exclusion of any inconsistent state laws. The U.S. Federal Rules of Civil Procedure shall govern discovery and the U.S. Federal Rules of Evidence shall govern evidence for the arbitration. The arbitration will be conducted in San Francisco, California and the Parties consent to the personal jurisdiction of the United States federal courts, for any case arising out of or otherwise related to this arbitration, its conduct and its enforcement. Any situation not expressly covered by this Agreement shall be decided in accordance with the [*] Rules. The arbitrator shall be one (1) neutral, independent and impartial arbitrator selected from a pool of retired federal judges to be presented to the Parties by [*]. Failing the agreement of the Parties as to the selection of the arbitrator within [*] days, the arbitrator shall be appointed by [*] in accordance with the [*] Rules. Notwithstanding any other provision of this Section 17.6(a), either Party shall have the right to seek and be granted exigent, injunctive or temporary relief in any court of competent jurisdiction. <B> </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(b)</B> Any unresolved dispute between the Parties under Section [*] as follows. The Parties shall agree on [*] both Parties and all of [*] relating to [*], each Party shall [*] and the other Party [*] with any relevant [*], each Party may [*] the other Party’s [*] may also [*]. The Parties [*] days after the Parties have [*], at which time each Party shall [*] to the Parties [*], provided that the [*]. Neither Party shall have any [*] without the participation of the other Party. Within [*] days after [*] on such [*] the Parties. The [*] by the Party [*]. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>17.7 Foreign Corrupt Practices Act Compliance. </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(a) Compliance with FCPA</B>. The U.S. government imposes and enforces prohibitions on the payment or transfer of anything of value to governments, government officials, political parties or political party officials (or relatives or associates of such officials) (“<B>FCPA Covered Person</B>”) for the purpose of illegally influencing them, whether directly or indirectly, to obtain or retain business. This U.S. law is referred to as the Foreign Corrupt Practices Act (“<B>FCPA</B>”), and it can have application to conduct of a U.S. corporation’s foreign subsidiaries, employees, agents and distributors. A summary of the law and related information can be found at http://www.justice.gov/criminal/fraud/fcpa. By signing this Agreement, each Party warrants that: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman"><B>(i)</B> It is familiar with the provisions and restrictions contained in the OECD Convention and FCPA. </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt"> </P> <TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%"> <TR> <TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>[*] =</B></TD> <TD ALIGN="left" VALIGN="top"><B>Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. </B></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">111 </P> <p Style='page-break-before:always'> <HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER"> <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman"><B>(ii)</B> It shall comply with the FCPA in marketing, selling and/or servicing the Collaboration Products under this Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman"><B>(iii)</B> It shall not, in the course of its duties under the Agreement, offer, promise, give, demand, seek or accept, directly or indirectly, any gift or payment, consideration or benefit in kind to any FCPA Covered Person that would or could be construed as an illegal or corrupt practice. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman"><B>(iv)</B> It is not an FCPA Covered Person or affiliated with any FCPA Covered Person. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman"><B>(v) </B>It shall immediately notify the other Party of any attempt by any FCPA Covered Person to directly or indirectly solicit, ask for, or attempt to extort anything of value from the first Party, and shall refuse any such solicitation, request or extortionate demand except a facilitating payment as expressly permitted under the FCPA. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(b) Compliance Certificate</B>. From time to time upon request from one Party, the other Party shall submit a compliance certificate in the form set forth in <U><B>Exhibit K</B></U> stating that (i) it fully understands its obligations under this Section 17.7 and any other applicable laws and regulations mentioned herein or as may come into existence from time to time after the Effective Date; (ii) it has been complying with this Section 17.7 and any other applicable laws and regulations mentioned herein or as may come into existence from time to time after the Effective Date; and (iii) it will continue to comply with this Section 17.7 and any other applicable laws and regulations mentioned herein or as may come into existence from time to time after the Effective Date. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(c) No Action</B>. In no event shall one Party be obligated under the Agreement to take any action or omit to take any action that such Party believes, in good faith, would cause it to be in violation of any applicable laws and regulations, including the anti-bribery laws referenced in this Section 17.7. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(d) Due Diligence</B>. Each Party shall have the right to visit the offices of the other Party from time to time during the term of the Agreement on an “as needed” basis and conduct due diligence in relation to the other Party’s business related to performance of its obligations under this Section 17.7 and may do so in the way it deems necessary, appropriate or desirable so as to ensure that the other Party complies with this Section 17.7 and any other applicable laws and regulations in its business operations. Each Party shall make every effort to cooperate fully with the other Party in any such due diligence. </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt"> </P> <TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%"> <TR> <TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>[*] =</B></TD> <TD ALIGN="left" VALIGN="top"><B>Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. </B></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">112 </P> <p Style='page-break-before:always'> <HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER"> <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(e) Audit</B>. In the event that one Party has reason to believe that a breach of any obligation of the other Party under this Section 17.7 has occurred or may occur, the first Party shall have the right to select an independent third party to conduct an audit of the other Party and review relevant books and records of the other Party, to satisfy itself that no breach has occurred. Unless otherwise required under applicable laws and regulations or by order of a competent court or regulatory authority, the first Party shall ensure that the selected independent third party will keep confidential all audited matters and the results of the audit. The first Party does reserve the right to disclose to the U.S. or foreign government, its agencies and/or any other government or non-government party, information relating to a possible violation by the other Party of any applicable law, including a violation of the FCPA or any other applicable anti-bribery law. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>17.8 Entire Agreement; Amendments.</B> This Agreement, together with the Exhibits hereto, contains the entire understanding of the Parties with respect to the collaboration and the licenses granted hereunder. Any other express or implied agreements and understandings, negotiations, writings and commitments, either oral or written, in respect to the collaboration and the licenses granted hereunder are superseded by the terms of this Agreement. The Exhibits to this Agreement are incorporated herein by reference and shall be deemed a part of this Agreement. This Agreement may be amended, or any term hereof modified, only by a written instrument duly executed by authorized representative(s) of both Parties hereto. The Parties agree that, effective as of the Effective Date, that certain Non-Disclosure Agreement between the Parties dated as of September 4, 2012, as amended (“<B>Confidentiality Agreement</B>”) shall be superseded by this Agreement, and that disclosures made prior to the Effective Date pursuant to the Confidentiality Agreement shall be subject to the confidentiality and non-use provisions of this Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>17.9 Headings.</B> The captions to the several Articles, Sections and subsections hereof are not a part of this Agreement, but are merely for convenience to assist in locating and reading the several Articles and Sections hereof. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>17.10 Independent Contractors.</B> Cytokinetics and Astellas are independent contractors and that the relationship between the two Parties shall not constitute a partnership, joint venture or agency. Neither Cytokinetics nor Astellas shall have the authority to make any statements, representations or commitments of any kind, or to take any action, which shall be binding on the other Party, without the prior written consent of the other Party. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>17.11 Waiver.</B> The waiver by either Party hereto of any right hereunder, or of any failure of the other Party to perform, or of any breach by the other Party, shall not be deemed a waiver of any other right hereunder or of any other breach by or failure of such other Party whether of a similar nature or otherwise. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>17.12 Cumulative Remedies.</B> No remedy referred to in this Agreement is intended to be exclusive, but each shall be cumulative and in addition to any other remedy referred to in this Agreement or otherwise available under law. </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt"> </P> <TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%"> <TR> <TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>[*] =</B></TD> <TD ALIGN="left" VALIGN="top"><B>Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. </B></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">113 </P> <p Style='page-break-before:always'> <HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER"> <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>17.13 Waiver of Rule of Construction.</B> Each Party has had the opportunity to consult with counsel in connection with the review, drafting and negotiation of this Agreement. Accordingly, no ambiguity in this Agreement shall be strictly construed against either Party. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>17.14 Business Day Requirements.</B> In the event that any notice or other action or omission is required to be taken by a Party under this Agreement on a day that is not a Business Day then such notice or other action or omission shall be deemed to be required to be taken on the next occurring Business Day. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>17.15 Translations.</B> This Agreement is in the English language only, which language shall be controlling in all respects, and all versions hereof in any other language shall be for accommodation only and shall not be binding upon the Parties. All communications and notices to be made or given pursuant to this Agreement, and any dispute proceeding related to or arising hereunder, shall be in the English language. If there is a discrepancy between any translation of this Agreement and this Agreement, this Agreement shall prevail. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>17.16 Further Actions.</B> Each Party agrees to execute, acknowledge and deliver such further instruments, and to do all such other acts, as necessary or appropriate in order to carry out the purposes and intent of this Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>17.17 Counterparts.</B> This Agreement may be executed in two or more counterparts by original signature, facsimile or PDF files, each of which shall be deemed an original, but all of which together shall constitute one and the same instrument. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><REMAINDER OF PAGE INTENTIONALLY LEFT BLANK> </B></P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt"> </P> <TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%"> <TR> <TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>[*] =</B></TD> <TD ALIGN="left" VALIGN="top"><B>Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. </B></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">114 </P> <p Style='page-break-before:always'> <HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">IN WITNESS WHEREOF, the Parties intending to be bound have caused this Agreement to be executed by their duly authorized representatives as of the Amendment Effective Date. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt"> </P> <TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt"> <TR> <TD WIDTH="7%"></TD> <TD VALIGN="bottom" WIDTH="1%"></TD> <TD WIDTH="42%"></TD> <TD VALIGN="bottom" WIDTH="1%"></TD> <TD></TD> <TD VALIGN="bottom" WIDTH="1%"></TD> <TD WIDTH="7%"></TD> <TD VALIGN="bottom" WIDTH="1%"></TD> <TD WIDTH="40%"></TD></TR> <TR STYLE="font-family:Times New Roman; font-size:10pt"> <TD VALIGN="top" COLSPAN="3"><B>Cytokinetics, Inc.</B></TD> <TD VALIGN="bottom"></TD> <TD VALIGN="bottom"></TD> <TD VALIGN="bottom"></TD> <TD VALIGN="bottom" COLSPAN="3"><B>Astellas Pharma Inc.</B></TD></TR> <TR STYLE="font-size:1pt"> <TD HEIGHT="16"></TD> <TD HEIGHT="16" COLSPAN="2"></TD> <TD HEIGHT="16" COLSPAN="2"></TD> <TD HEIGHT="16" COLSPAN="2"></TD> <TD HEIGHT="16" COLSPAN="2"></TD></TR> <TR STYLE="font-family:Times New Roman; font-size:10pt"> <TD VALIGN="top">By:</TD> <TD VALIGN="bottom"></TD> <TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Robert I. Blum</P></TD> <TD VALIGN="bottom"></TD> <TD VALIGN="bottom"></TD> <TD VALIGN="bottom"></TD> <TD VALIGN="bottom">By:</TD> <TD VALIGN="bottom"></TD> <TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Yoshihiko Hatanaka</P></TD></TR> <TR STYLE="font-family:Times New Roman; font-size:10pt"> <TD VALIGN="top">Name:</TD> <TD VALIGN="bottom"></TD> <TD VALIGN="bottom">Robert I. Blum</TD> <TD VALIGN="bottom"></TD> <TD VALIGN="bottom"></TD> <TD VALIGN="bottom"></TD> <TD VALIGN="bottom">Name:</TD> <TD VALIGN="bottom"></TD> <TD VALIGN="bottom">Yoshihiko Hatanaka</TD></TR> <TR STYLE="font-family:Times New Roman; font-size:10pt"> <TD VALIGN="top">Title:</TD> <TD VALIGN="bottom"></TD> <TD VALIGN="bottom">President and CEO</TD> <TD VALIGN="bottom"></TD> <TD VALIGN="bottom"></TD> <TD VALIGN="bottom"></TD> <TD VALIGN="bottom">Title:</TD> <TD VALIGN="bottom"></TD> <TD VALIGN="bottom">President and CEO</TD></TR> </TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><S<SMALL>IGNATURE</SMALL> P<SMALL>AGE</SMALL> <SMALL>OF</SMALL> <SMALL>THE</SMALL> A<SMALL>MENDED</SMALL> <SMALL>AND</SMALL> R<SMALL>ESTATED</SMALL> L<SMALL>ICENSE</SMALL> <SMALL>AND</SMALL> C<SMALL>OLLABORATION</SMALL> A<SMALL>GREEMENT</SMALL></B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><SMALL>BY</SMALL> <SMALL>AND</SMALL> <SMALL>BETWEEN</SMALL> </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>C<SMALL>YTOKINETICS</SMALL>, I<SMALL>NC</SMALL>. <SMALL>AND</SMALL> A<SMALL>STELLAS</SMALL> P<SMALL>HARMA</SMALL> I<SMALL>NC</SMALL>.> </B></P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt"> </P> <TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%"> <TR> <TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>[*] =</B></TD> <TD ALIGN="left" VALIGN="top"><B>Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. </B></TD></TR></TABLE> <p Style='page-break-before:always'> <HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>LIST OF EXHIBITS </B></P> <TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center"> <TR> <TD WIDTH="9%"></TD> <TD VALIGN="bottom" WIDTH="2%"></TD> <TD WIDTH="89%"></TD></TR> <TR STYLE="font-size:1pt"> <TD HEIGHT="16"></TD> <TD HEIGHT="16" COLSPAN="2"></TD></TR> <TR STYLE="font-family:Times New Roman; font-size:10pt"> <TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Exhibit A:</B></P></TD> <TD VALIGN="bottom"></TD> <TD VALIGN="bottom"><B>Existing Astellas Patents</B></TD></TR> <TR STYLE="font-family:Times New Roman; font-size:10pt"> <TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Exhibit B:</B></P></TD> <TD VALIGN="bottom"></TD> <TD VALIGN="bottom"><B>Compound Criteria</B></TD></TR> <TR STYLE="font-family:Times New Roman; font-size:10pt"> <TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Exhibit C:</B></P></TD> <TD VALIGN="bottom"></TD> <TD VALIGN="bottom"><B>Existing Cytokinetics Patents</B></TD></TR> <TR STYLE="font-family:Times New Roman; font-size:10pt"> <TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Exhibit D:</B></P></TD> <TD VALIGN="bottom"></TD> <TD VALIGN="bottom"><B>Retained Indications</B></TD></TR> <TR STYLE="font-family:Times New Roman; font-size:10pt"> <TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Exhibit E:</B></P></TD> <TD VALIGN="bottom"></TD> <TD VALIGN="bottom"><B>[*] Patent Rights</B></TD></TR> <TR STYLE="font-family:Times New Roman; font-size:10pt"> <TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Exhibit F:</B></P></TD> <TD VALIGN="bottom"></TD> <TD VALIGN="bottom"><B>Alliance Managers and Committee Members</B></TD></TR> <TR STYLE="font-family:Times New Roman; font-size:10pt"> <TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Exhibit G:</B></P></TD> <TD VALIGN="bottom"></TD> <TD VALIGN="bottom"><B>[Omitted]</B></TD></TR> <TR STYLE="font-family:Times New Roman; font-size:10pt"> <TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Exhibit H:</B></P></TD> <TD VALIGN="bottom"></TD> <TD VALIGN="bottom"><B>[Omitted]</B></TD></TR> <TR STYLE="font-family:Times New Roman; font-size:10pt"> <TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Exhibit I:</B></P></TD> <TD VALIGN="bottom"></TD> <TD VALIGN="bottom"><B>Term sheet for Co-Promotion Agreement</B></TD></TR> <TR STYLE="font-family:Times New Roman; font-size:10pt"> <TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Exhibit J:</B></P></TD> <TD VALIGN="bottom"></TD> <TD VALIGN="bottom"><B>Press Release for the Amended and Restated Agreement</B></TD></TR> <TR STYLE="font-family:Times New Roman; font-size:10pt"> <TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Exhibit K:</B></P></TD> <TD VALIGN="bottom"></TD> <TD VALIGN="bottom"><B>Form of Certificate of Compliance</B></TD></TR> <TR STYLE="font-family:Times New Roman; font-size:10pt"> <TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Exhibit L:</B></P></TD> <TD VALIGN="bottom"></TD> <TD VALIGN="bottom"><B>[*] Indications</B></TD></TR> <TR STYLE="font-family:Times New Roman; font-size:10pt"> <TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Exhibit M:</B></P></TD> <TD VALIGN="bottom"></TD> <TD VALIGN="bottom"><B>Certain Development Activities for SMA</B></TD></TR> </TABLE> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt"> </P> <TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%"> <TR> <TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>[*] =</B></TD> <TD ALIGN="left" VALIGN="top"><B>Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. </B></TD></TR></TABLE> <p Style='page-break-before:always'> <HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Exhibit A </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Existing Astellas Patents </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">[*] </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt"> </P> <TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%"> <TR> <TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>[*] =</B></TD> <TD ALIGN="left" VALIGN="top"><B>Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. </B></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-i </P> <p Style='page-break-before:always'> <HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Exhibit B </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Compound Criteria</B><SUP STYLE="font-size:85%; vertical-align:top"> 1</SUP> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">[*] </P> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:10%"> </P> <TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%"> <TR> <TD WIDTH="2%" VALIGN="top" ALIGN="left"><SUP STYLE="font-size:85%; vertical-align:top">1</SUP> </TD> <TD ALIGN="left" VALIGN="top">[*] </TD></TR></TABLE> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt"> </P> <TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%"> <TR> <TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>[*] =</B></TD> <TD ALIGN="left" VALIGN="top"><B>Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. </B></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">B-i </P> <p Style='page-break-before:always'> <HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">[*] </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt"> </P> <TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%"> <TR> <TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>[*] =</B></TD> <TD ALIGN="left" VALIGN="top"><B>Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. </B></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">B-ii </P> <p Style='page-break-before:always'> <HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Exhibit C </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Existing Cytokinetics Patents </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">[*] </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt"> </P> <TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%"> <TR> <TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>[*] =</B></TD> <TD ALIGN="left" VALIGN="top"><B>Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. </B></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">C-i </P> <p Style='page-break-before:always'> <HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">[*] </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt"> </P> <TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%"> <TR> <TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>[*] =</B></TD> <TD ALIGN="left" VALIGN="top"><B>Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. </B></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">C-ii </P> <p Style='page-break-before:always'> <HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">[*] </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt"> </P> <TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%"> <TR> <TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>[*] =</B></TD> <TD ALIGN="left" VALIGN="top"><B>Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. </B></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">C-iii </P> <p Style='page-break-before:always'> <HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Exhibit D </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Retained Indications </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">[*] </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt"> </P> <TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%"> <TR> <TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>[*] =</B></TD> <TD ALIGN="left" VALIGN="top"><B>Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. </B></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">D-i </P> <p Style='page-break-before:always'> <HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Exhibit E </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>[*] Patent Rights </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">[*] </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt"> </P> <TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%"> <TR> <TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>[*] =</B></TD> <TD ALIGN="left" VALIGN="top"><B>Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. </B></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">E-i </P> <p Style='page-break-before:always'> <HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">[*] </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt"> </P> <TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%"> <TR> <TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>[*] =</B></TD> <TD ALIGN="left" VALIGN="top"><B>Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. </B></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">E-ii </P> <p Style='page-break-before:always'> <HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">[*] </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt"> </P> <TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%"> <TR> <TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>[*] =</B></TD> <TD ALIGN="left" VALIGN="top"><B>Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. </B></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">E-iii </P> <p Style='page-break-before:always'> <HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">[*] </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt"> </P> <TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%"> <TR> <TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>[*] =</B></TD> <TD ALIGN="left" VALIGN="top"><B>Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. </B></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">E-iv </P> <p Style='page-break-before:always'> <HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Exhibit F </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Alliance Managers and Committee Members </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt"> </P> <TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="84%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center"> <TR> <TD WIDTH="82%"></TD> <TD VALIGN="bottom" WIDTH="8%"></TD> <TD></TD> <TD VALIGN="bottom" WIDTH="8%"></TD> <TD></TD></TR> <TR STYLE="font-family:Times New Roman; font-size:8pt"> <TD VALIGN="bottom"> </TD> <TD VALIGN="bottom"> </TD> <TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">Astellas</TD> <TD VALIGN="bottom"> </TD> <TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">Cytokinetics</TD></TR> <TR STYLE="font-family:Times New Roman; font-size:10pt"> <TD VALIGN="top">Joint Steering Committee</TD> <TD VALIGN="bottom"> </TD> <TD VALIGN="bottom">[*]</TD> <TD VALIGN="bottom"> </TD> <TD VALIGN="bottom">[*]</TD></TR> <TR STYLE="font-family:Times New Roman; font-size:10pt"> <TD VALIGN="top">Joint Research Committee</TD> <TD VALIGN="bottom"> </TD> <TD VALIGN="bottom">[*]</TD> <TD VALIGN="bottom"> </TD> <TD VALIGN="bottom">[*]</TD></TR> <TR STYLE="font-family:Times New Roman; font-size:10pt"> <TD VALIGN="top">Joint Development Committee</TD> <TD VALIGN="bottom"> </TD> <TD VALIGN="bottom">[*]</TD> <TD VALIGN="bottom"> </TD> <TD VALIGN="bottom">[*]</TD></TR> </TABLE> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt"> </P> <TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%"> <TR> <TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>[*] =</B></TD> <TD ALIGN="left" VALIGN="top"><B>Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. </B></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-i </P> <p Style='page-break-before:always'> <HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER"> <TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="84%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center"> <TR> <TD WIDTH="90%"></TD> <TD VALIGN="bottom" WIDTH="3%"></TD> <TD WIDTH="2%"></TD> <TD VALIGN="bottom" WIDTH="3%"></TD> <TD WIDTH="2%"></TD></TR> <TR STYLE="font-family:Times New Roman; font-size:8pt"> <TD VALIGN="bottom"> </TD> <TD VALIGN="bottom"> </TD> <TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center">[*]</P></TD> <TD VALIGN="bottom"> </TD> <TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center">[*]</P></TD></TR> <TR STYLE="font-family:Times New Roman; font-size:10pt"> <TD VALIGN="top">Joint Manufacturing Committee</TD> <TD VALIGN="bottom"> </TD> <TD VALIGN="bottom">[*]</TD> <TD VALIGN="bottom"> </TD> <TD VALIGN="bottom">[*]</TD></TR> <TR STYLE="font-family:Times New Roman; font-size:10pt"> <TD VALIGN="top">Joint Patent Committee</TD> <TD VALIGN="bottom"> </TD> <TD VALIGN="bottom">[*]</TD> <TD VALIGN="bottom"> </TD> <TD VALIGN="bottom">[*]</TD></TR> <TR STYLE="font-family:Times New Roman; font-size:10pt"> <TD VALIGN="top">Alliance Managers</TD> <TD VALIGN="bottom"> </TD> <TD VALIGN="bottom">[*]</TD> <TD VALIGN="bottom"> </TD> <TD VALIGN="bottom">[*]</TD></TR> </TABLE> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt"> </P> <TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%"> <TR> <TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>[*] =</B></TD> <TD ALIGN="left" VALIGN="top"><B>Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. </B></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-ii </P> <p Style='page-break-before:always'> <HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Exhibit I </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Term sheet for Co-Promotion Agreement for Collaboration Products </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This Exhibit I sets forth material terms and conditions that, together with the terms of Section 9.6 of the Agreement, shall be incorporated into a Co-Promotion Agreement to be negotiated and entered into by the Parties for the Collaboration Product for which Cytokinetics exercises its option to Co-Promote in accordance with Section 9.6 of the Agreement (such Collaboration Product, the “<B>Co-Promotion Product</B>”). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">[*] </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt"> </P> <TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%"> <TR> <TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>[*] =</B></TD> <TD ALIGN="left" VALIGN="top"><B>Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. </B></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">I-i </P> <p Style='page-break-before:always'> <HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">[*] </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt"> </P> <TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%"> <TR> <TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>[*] =</B></TD> <TD ALIGN="left" VALIGN="top"><B>Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. </B></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">I-ii </P> <p Style='page-break-before:always'> <HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">[*] </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt"> </P> <TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%"> <TR> <TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>[*] =</B></TD> <TD ALIGN="left" VALIGN="top"><B>Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. </B></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">I-iii </P> <p Style='page-break-before:always'> <HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">[*] </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt"> </P> <TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%"> <TR> <TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>[*] =</B></TD> <TD ALIGN="left" VALIGN="top"><B>Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. </B></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">I-iv </P> <p Style='page-break-before:always'> <HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Exhibit J </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Press Release </B></P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt"> </P> <TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%"> <TR> <TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>[*] =</B></TD> <TD ALIGN="left" VALIGN="top"><B>Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. </B></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">J-i </P> <p Style='page-break-before:always'> <HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER"> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center"> <IMG SRC="g828167ex10_40pg136.jpg" ALT="LOGO"> </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>CYTOKINETICS AND ASTELLAS ANNOUNCE EXPANSION OF COLLABORATION </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>FOR DEVELOPMENT OF CK-2127107 IN SPINAL MUSCULAR ATROPHY </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>AND OTHER NEUROMUSCULAR INDICATIONS </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><I>Cytokinetics Expects to Receive Over $75 Million in Committed Capital and Reimbursements For Planned Activities </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><I>Companies Plan to Initiate Phase II Clinical Trial in 2015 </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>South San Francisco, CA, and Tokyo, December 23, 2014 </I></B><B>–</B> Cytokinetics, Incorporated (NASDAQ:CYTK) and Astellas Pharma Inc. (Tokyo Stock Exchange: 4503, “Astellas”) announced today an amendment to their collaboration agreement focused on the research, development and commercialization of skeletal muscle activators. The companies have been jointly conducting research and development activities with the objective to advance novel skeletal sarcomere targeted therapies for diseases and medical conditions associated with muscle weakness in non-neuromuscular indications. The collaboration has been expanded to enable development of CK-2127107, a fast skeletal troponin activator, in Spinal Muscular Atrophy (SMA) and potentially other neuromuscular indications. As the companies have agreed, Cytokinetics will conduct a Phase II clinical trial of CK-2127107 in patients with SMA, which is planned to begin in 2015. Cytokinetics and Astellas will jointly develop and may jointly commercialize CK-2127107 and other fast skeletal troponin activators in neuromuscular indications. The companies have extended their joint research program focused on the discovery of additional skeletal sarcomere activators through 2016. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Upon execution of the amended agreement, Cytokinetics will receive $55 million from Astellas comprising $30 million as an upfront license fee, $10 million paid for Astellas’ purchase of Cytokinetics’ common stock and $15 million in a milestone payment in connection with the decision made by Astellas to advance CK-2127107 into Phase II clinical development. In addition, Cytokinetics expects to receive potentially over $20 million payable by Astellas to reimburse Cytokinetics for planned research and development expenses over the next 2 years. Under the amended agreement, Cytokinetics is eligible to receive over $600 million in pre-commercialization and commercialization milestone payments, of which over $100 million is payable for CK-2127107 in each of SMA and other neuromuscular indications. The agreed terms also provide for escalating royalties to Cytokinetics with increased sales. Cytokinetics retains the option to co-fund the development of CK-2127107 in SMA and other neuromuscular indications in exchange for increased milestone payments and royalties and, if Cytokinetics exercises its co-promotion option, Astellas will reimburse Cytokinetics for certain expenses associated with its promotion activities. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">“We are pleased to expand our collaboration with Astellas to enable the joint pursuit of CK-2127107 in SMA and other potential neuromuscular indications as well as the indications which were the initial focus of our collaboration,” stated Robert I. Blum, Cytokinetics’ President and Chief Executive Officer. “We are impressed with Astellas’ strategic vision for skeletal muscle activators and look forward to increasing the scope of our activities to prioritize the treatment of neuromuscular diseases that may benefit from our novel mechanism approach to increased muscle function and time to muscle fatigue.” </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">“We are excited to expand our collaboration with Cytokinetics and to advance this drug candidate into Phase II,” stated Yoshihiko Hatanaka, Astellas’ President and Chief Executive Officer. “We are encouraged by the result of the completed Phase I studies for CK-2127107 and are hopeful for the future of this new frontier of muscle biology. The expansion of our alliance is a testament to our productive collaboration together and illustrates the broad potential that we envision for this program.” </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Expanded Scope of Collaboration </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Cytokinetics and Astellas entered into collaboration in 2013. Cytokinetics exclusively licensed to Astellas the rights to co-develop and commercialize CK-2127107, a fast skeletal troponin activator drug candidate, for potential application in non-neuromuscular indications under the collaboration agreement. In accordance with the initial scope of the collaboration, Cytokinetics completed Phase I clinical development activities and other Phase II readiness activities. In connection with the </P> <p Style='page-break-before:always'> <HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Cytokinetics’ and Astellas’ Announcement Regarding Expansion of Skeletal Muscle Activator Collaboration </I></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Page 2 </I></P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt"> </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"> expanded collaboration, the companies have agreed to advance CK-2127107 into Phase II clinical development initially in SMA. The development program may include other neuromuscular indications as the companies may agree in the future. In connection with the expanded collaboration, Cytokinetics and Astellas have also agreed to extend their joint research program through 2016. Under the amended collaboration, Astellas has exclusive rights to co-develop and commercialize CK-2127107 and other fast skeletal troponin activators in non-neuromuscular indications and certain neuromuscular indications (including SMA) and other novel mechanism skeletal muscle activators in all indications, subject to certain Cytokinetics’ development and commercialization rights; Cytokinetics may co-promote and conduct certain commercial activities in North America and Europe under agreed scenarios. Outside the collaboration, Cytokinetics may continue to independently develop <I>tirasemtiv</I>, a fast skeletal troponin activator that recently completed a Phase II clinical trials program for the potential treatment of amyotrophic lateral sclerosis (ALS), in ALS and other neuromuscular indications subject to certain agreed limitations. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Cytokinetics Conference Call / Webcast </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Cytokinetics will host a conference call on January 5, 2015 at 8:30 a.m. Eastern Time. The conference call will be simultaneously webcast and will be accessible in the Investor Relations section of Cytokinetics’ Web site; for further information please go to www.cytokinetics.com. The live audio of the conference call is also accessible via telephone to investors, members of the news media and the general public by dialing either (866) 999-2985 (CYTK) (United States and Canada) or (706) 679-3078 (International) and typing in the passcode 52398702. An archived replay of the webcast will be available via Cytokinetics’ website until February 5, 2015. The replay will also be available via telephone from January 5, 2015 at 11:30 a.m. Eastern Time until February 5, 2015 by dialing (855) 859-2056 (United States and Canada) or (404) 537-3406 (International) and typing in the passcode 52398702. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>About CK-2127107 </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Skeletal muscle contractility is driven by the sarcomere, the fundamental unit of skeletal muscle contraction. It is a highly ordered cytoskeletal structure composed of several key proteins. Skeletal muscle myosin is the cytoskeletal motor protein that converts chemical energy into mechanical force through its interaction with actin. A set of regulatory proteins, which includes tropomyosin and several types of troponin, make the actin-myosin interaction dependent on changes in intracellular calcium levels. CK-2127107, a novel skeletal muscle activator arising from Cytokinetics’ skeletal muscle contractility program, slows the rate of calcium release from the regulatory troponin complex of fast skeletal muscle fibers, which sensitizes the sarcomere to calcium, leading to an increase in skeletal muscle contractility. CK-2127107 has demonstrated pharmacological activity that may lead to new therapeutic options for diseases associated with muscle weakness and fatigue. In non-clinical models of Spinal Muscular Atrophy, a skeletal muscle activator has demonstrated increases in skeletal submaximal muscle force in response to neuronal input and delays in the onset and reductions in the degree of muscle fatigue. CK-2127107 has been the subject of five completed Phase I clinical trials in healthy volunteers, which evaluated safety, tolerability, bioavailability, pharmacokinetics and pharmacodynamics. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>About Spinal Muscular Atrophy </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Spinal Muscular Atrophy (SMA) is a severe neuromuscular disease that occurs in 1 in every 6,000 to 10,000 live births each year and is one of the most common fatal genetic disorders. Spinal muscular atrophy manifests in various degrees of severity as progressive muscle weakness resulting in respiratory and mobility impairment. There are four types of SMA, named for time of the initial onset of muscle weakness and related symptoms: Type I (Infantile), Type II (Intermediate), Type III (Juvenile) and Type IV (Adult onset). Life expectancy and disease severity varies by type of SMA from Type I, who have the worst prognosis and a life expectancy of no more than 2 years from birth, to the Type IV, who have a normal life span but with gradual weakness in the proximal muscles of the extremities resulting in mobility issues. Few treatment options exist for these patients, resulting in a high unmet need for new therapeutic options to address symptoms and modify disease progression. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>About Cytokinetics </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Cytokinetics is a clinical-stage biopharmaceutical company focused on the discovery and development of novel small molecule therapeutics that modulate muscle function for the potential treatment of serious diseases and other medical conditions. Cytokinetics currently has three compounds in clinical development: <I>omecamtiv mecarbil</I> in Phase II for acute and chronic heart failure,<I> tirasemtiv</I> in Phase II for ALS and CK-2127107 progressing to Phase II in SMA. All of the company’s drug candidates have arisen from Cytokinetics’ muscle biology focused research activities and are directed towards the cytoskeleton. The cytoskeleton is a complex biological infrastructure that plays a fundamental role within every human cell. Additional information about Cytokinetics can be obtained at http://www.cytokinetics.com. </P> <p Style='page-break-before:always'> <HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Cytokinetics’ and Astellas’ Announcement Regarding Expansion of Skeletal Muscle Activator Collaboration </I></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Page 3 </I></P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt"> </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>About Astellas </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Astellas Pharma Inc., located in Tokyo, Japan, is a pharmaceutical company dedicated to improving the health of people around the world through the provision of innovative and reliable pharmaceuticals. Astellas has approximately 18,000 employees worldwide. The organization is committed to becoming a global category leader in Urology, Immunology (including Transplantation) and Infectious diseases, Oncology, Neuroscience and DM Complications and Kidney diseases. For more information on Astellas Pharma Inc., please visit the company website at www.astellas.com/en. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Forward-Looking Statements: Cytokinetics </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>This press release contains forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995 (the “Act”). Cytokinetics disclaims any intent or obligation to update these forward-looking statements, and claims the protection of the Act’s Safe Harbor for forward-looking statements. Examples of such statements include, but are not limited to, statements relating to Cytokinetics’ and Astellas’ planned research and development activities, including the expected timing, scope and conduct of a Phase II clinical trial of CK-2127107 in SMA; the significance and utility of preclinical and non-clinical study and clinical trial results; potential milestone payments, royalties and other payments; the expected roles of Cytokinetics and Astellas under the collaboration and in developing or commercializing drug candidates or products subject to the collaboration; the indications to be pursued under the collaboration; the potential size of markets for CK-2127107; Cytokinetics’ continued development of tirasemtiv; and the properties and potential benefits of Cytokinetics’ skeletal muscle activators, including CK-2127107. Such statements are based on management’s current expectations, but actual results may differ materially due to various risks and uncertainties, including, but not limited to, further clinical development of tirasemtiv in ALS patients will require significant additional funding, and Cytokinetics may be unable to obtain such additional funding on acceptable terms, if at all; potential difficulties or delays in the development, testing, regulatory approvals for trial commencement, progression or product sale or manufacturing, or production of Cytokinetics’ drug candidates that could slow or prevent clinical development or product approval, including risks that current and past results of clinical trials or preclinical studies may not be indicative of future clinical trials results, patient enrollment for or conduct of clinical trials may be difficult or delayed, Cytokinetics’ drug candidates may have adverse side effects or inadequate therapeutic efficacy, the U.S. Food and Drug Administration or foreign regulatory agencies may delay or limit Cytokinetics’ or its partners’ ability to conduct clinical trials, and Cytokinetics may be unable to obtain or maintain patent or trade secret protection for its intellectual property; Amgen’s and Astellas’ decisions with respect to the design, initiation, conduct, timing and continuation of development activities for omecamtiv mecarbil and CK-2127107, respectively; Cytokinetics may incur unanticipated research and development and other costs or be unable to obtain additional financing necessary to conduct development of its products; Cytokinetics may be unable to enter into future collaboration agreements for its drug candidates and programs on acceptable terms, if at all; standards of care may change, rendering Cytokinetics’ drug candidates obsolete; competitive products or alternative therapies may be developed by others for the treatment of indications Cytokinetics’ drug candidates and potential drug candidates may target; and risks and uncertainties relating to the timing and receipt of payments from its partners, including milestones and royalties on future potential product sales under Cytokinetics’ collaboration agreements with such partners. For further information regarding these and other risks related to Cytokinetics’ business, investors should consult Cytokinetics’ filings with the Securities and Exchange Commission. </I></P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Forward-Looking Statements: Astellas </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>This press release includes forward-looking statements based on assumptions and beliefs in light of the information currently available to management and subject to significant risks and uncertainties. Forward-looking statements include all statements other than statements of historical fact, including plans, strategies and expectations for the future, statements regarding the expected timing of filings and approvals relating to the transaction, the expected timing of the completion of the transaction, the ability to complete the transaction or to satisfy the various closing conditions, future revenues and profitability from or growth or any assumptions underlying any of the foregoing. Statements made in the future tense, and words such as “anticipate,” “expect,” “project,” “continue,” “believe,” “plan,” “estimate,” “pro forma,” “intend,” “potential,” “target,” “forecast,” “guidance,” “outlook,” “seek,” “assume,” “will,” “may,” “should,” and similar expressions are intended to qualify as forward-looking statements. Forward-looking statements are based on estimates and assumptions made by management that are believed to be reasonable, though they are inherently uncertain and difficult to predict. Investors and security holders are cautioned not to place undue reliance on these forward-looking statements. </I></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Actual financial results may differ materially depending on a number of factors including adverse economic conditions, currency exchange rate fluctuations, adverse legislative and regulatory developments, delays in new product launch, pricing and product initiatives of competitors, the inability of the company to market existing and new products effectively, </I></P> <p Style='page-break-before:always'> <HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Cytokinetics’ and Astellas’ Announcement Regarding Expansion of Skeletal Muscle Activator Collaboration </I></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Page 4 </I></P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt"> </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I> interruptions in production, infringements of the company’s intellectual property rights and the adverse outcome of material litigation. This press release contains information on pharmaceuticals (including compounds under development), but this information is not intended to make any representations or advertisements regarding the efficacy or effectiveness of these pharmaceuticals nor provide medical advice of any kind. </I></P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Contact: </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Cytokinetics, Inc. </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Joanna L. Goldstein </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Investors & Media </I></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Tel: (650) 624-3000 </I></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Fax: (650) 624-3010 </I></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Astellas Pharma Inc. </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Corporate Communications </I></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Tel: +81-3-3244-3201 </I></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Fax: +81-3-5201-7473 </I></P> <p Style='page-break-before:always'> <HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Exhibit K </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Form of Certificate of Compliance </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">I, [ ] of Astellas Pharma Inc., which is conducting business with Cytokinetics, Inc. per our License and Collaboration Agreement dated [ ]. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">I hereby acknowledge and certify that I am familiar and knowledgeable about the requirements of the FCPA and other applicable Anti-Corruption Laws and their requirements. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">I certify that Astellas has not, and will not, take any action in furtherance of an unlawful offer, promise, or payment to a foreign official that would cause Cytokinetics, Inc. to be in violation of the FCPA, any other applicable Anti-Corruption Law. I further certify that Astellas has made no agreement or commitment, directly or indirectly, which, if carried out in the future, would cause Cytokinetics, Inc. to be in violation of the FCPA or any other applicable Anti-Corruption Law. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">“<B>FCPA</B>” shall mean the U.S. Foreign Corrupt Practices Act (15 U.S.C. Section 78dd-1, et seq.) as amended. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">“<B>Anti-Corruption Laws</B>” shall mean all applicable laws, regulations, orders, judicial decisions, conventions and international financial institution rules regarding corruption, bribery, ethical business conduct, money laundering, political contributions, gifts and gratuities, or lawful expenses to public officials and private persons, agency relationships, commissions, lobbying, books and records, and financial controls. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt"> </P> <TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt"> <TR> <TD WIDTH="28%"></TD> <TD VALIGN="bottom" WIDTH="1%"></TD> <TD WIDTH="71%"></TD></TR> <TR STYLE="font-family:Times New Roman; font-size:10pt"> <TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Signature:</P></TD> <TD VALIGN="bottom"></TD> <TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman" ALIGN="right"> </P></TD></TR> <TR STYLE="font-family:Times New Roman; font-size:10pt"> <TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Printed Name:</P></TD> <TD VALIGN="bottom"></TD> <TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman" ALIGN="right"> </P></TD></TR> <TR STYLE="font-family:Times New Roman; font-size:10pt"> <TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Title:</P></TD> <TD VALIGN="bottom"></TD> <TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman" ALIGN="right"> </P></TD></TR> <TR STYLE="font-family:Times New Roman; font-size:10pt"> <TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Company:</P></TD> <TD VALIGN="bottom"></TD> <TD VALIGN="bottom">Astellas Pharma Inc.</TD></TR> <TR STYLE="font-family:Times New Roman; font-size:10pt"> <TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Dated:</P></TD> <TD VALIGN="bottom"></TD> <TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman" ALIGN="right"> </P></TD></TR> </TABLE> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt"> </P> <TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%"> <TR> <TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>[*] =</B></TD> <TD ALIGN="left" VALIGN="top"><B>Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. </B></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">K-i </P> <p Style='page-break-before:always'> <HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Form of Certificate of Compliance </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">I, [ ] of Cytokinetics, Inc., which is conducting business with Astellas Pharma Inc. per our License and Collaboration Agreement dated [ ]. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">I hereby acknowledge and certify that I am familiar and knowledgeable about the requirements of the FCPA and other applicable Anti-Corruption Laws and their requirements. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">I certify that Cytokinetics has not, and will not, take any action in furtherance of an unlawful offer, promise, or payment to a foreign official that would cause Astellas Pharma Inc. to be in violation of the FCPA, any other applicable Anti-Corruption Law. I further certify that Cytokinetics has made no agreement or commitment, directly or indirectly, which, if carried out in the future, would cause Astellas Pharma Inc. to be in violation of the FCPA or any other applicable Anti-Corruption Law. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">“<B>FCPA</B>” shall mean the U.S. Foreign Corrupt Practices Act (15 U.S.C. Section 78dd-1, et seq.) as amended. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">“<B>Anti-Corruption Laws</B>” shall mean all applicable laws, regulations, orders, judicial decisions, conventions and international financial institution rules regarding corruption, bribery, ethical business conduct, money laundering, political contributions, gifts and gratuities, or lawful expenses to public officials and private persons, agency relationships, commissions, lobbying, books and records, and financial controls. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt"> </P> <TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt"> <TR> <TD WIDTH="31%"></TD> <TD VALIGN="bottom" WIDTH="1%"></TD> <TD WIDTH="68%"></TD></TR> <TR STYLE="font-family:Times New Roman; font-size:10pt"> <TD VALIGN="top">Signature:</TD> <TD VALIGN="bottom"></TD> <TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman"> </P></TD></TR> <TR STYLE="font-family:Times New Roman; font-size:10pt"> <TD VALIGN="top">Printed Name:</TD> <TD VALIGN="bottom"></TD> <TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman"> </P></TD></TR> <TR STYLE="font-family:Times New Roman; font-size:10pt"> <TD VALIGN="top">Title:</TD> <TD VALIGN="bottom"></TD> <TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman"> </P></TD></TR> <TR STYLE="font-family:Times New Roman; font-size:10pt"> <TD VALIGN="top">Company:</TD> <TD VALIGN="bottom"></TD> <TD VALIGN="bottom">Cytokinetics, Inc.</TD></TR> <TR STYLE="font-family:Times New Roman; font-size:10pt"> <TD VALIGN="top">Dated:</TD> <TD VALIGN="bottom"></TD> <TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman"> </P></TD></TR> </TABLE> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt"> </P> <TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%"> <TR> <TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>[*] =</B></TD> <TD ALIGN="left" VALIGN="top"><B>Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. </B></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">K-ii </P> <p Style='page-break-before:always'> <HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Exhibit L </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>[*] Indications </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">1. [*] </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt"> </P> <TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%"> <TR> <TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>[*] =</B></TD> <TD ALIGN="left" VALIGN="top"><B>Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. </B></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">L-i </P> <p Style='page-break-before:always'> <HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Exhibit M </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Certain Development Activities for SMA </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">[*] </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt"> </P> <TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%"> <TR> <TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>[*] =</B></TD> <TD ALIGN="left" VALIGN="top"><B>Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. </B></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">M-i </P> </BODY></HTML> </TEXT> </DOCUMENT> <DOCUMENT> <TYPE>EX-23.1 <SEQUENCE>3 <FILENAME>d828167dex231.htm <DESCRIPTION>EX-23.1 <TEXT> <HTML><HEAD> <TITLE>EX-23.1</TITLE> </HEAD> <BODY BGCOLOR="WHITE"> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Exhibit 23.1 </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">We hereby consent to the incorporation by reference in the Registration Statement on Form S-3 (Nos. 333-174869, 333-178189, 333-182226, and 333-192125) and Form S-8 (Nos. 333-115146, 333-125973, 333-133323, 333-136524, 333-140963, 333-149713, 333-152850, 333-161116, 333-168520, 333-176089, 333-183091 and 333-190458 ) of Cytokinetics, Incorporated of our report dated March 6, 2015 relating to the financial statements and the effectiveness of internal control over financial reporting, which appears in this Form 10-K. </FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px"> </P> <TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE"> <TR> <TD WIDTH="100%"></TD></TR> <TR> <TD VALIGN="top"> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">/s/ PricewaterhouseCoopers LLP</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">San Jose, CA</FONT></P> <P STYLE="margin-top:0px;margin-bottom:1px"><FONT STYLE="font-family:Times New Roman" SIZE="2">March 6, 2015</FONT></P></TD></TR> </TABLE> </BODY></HTML> </TEXT> </DOCUMENT> <DOCUMENT> <TYPE>EX-31.1 <SEQUENCE>4 <FILENAME>d828167dex311.htm <DESCRIPTION>EX-31.1 <TEXT> <HTML><HEAD> <TITLE>EX-31.1</TITLE> </HEAD> <BODY BGCOLOR="WHITE"> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Exhibit 31.1 </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>PRINCIPAL EXECUTIVE OFFICER CERTIFICATION PURSUANT TO </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002 </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">I, Robert I. Blum, certify that: </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">1. I have reviewed this Annual Report on Form 10-K of Cytokinetics, Incorporated; </FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report; </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report; </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">4. The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in the Exchange Act Rules 13a-(f) and 15d-15(f)) for the registrant and have: </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">a. Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared; </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">b. Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles; </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">c. Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">d. Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">5. The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions): </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">a. All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">b. Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting. </FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px"> </P><DIV ALIGN="right"> <TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE"> <TR> <TD WIDTH="6%"></TD> <TD VALIGN="bottom" WIDTH="2%"></TD> <TD WIDTH="92%"></TD></TR> <TR> <TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">By:</FONT></P></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"> <P STYLE="margin-top:0px;margin-bottom:1px;border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2">/s/ Robert I. Blum</FONT></P></TD></TR> <TR> <TD VALIGN="top"></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Robert I. Blum,</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">President, Chief Executive Officer and Director</FONT></P> <P STYLE="margin-top:0px;margin-bottom:1px"><FONT STYLE="font-family:Times New Roman" SIZE="2">(Principal Executive Officer)</FONT></P></TD></TR> </TABLE></DIV> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Date: March 6, 2015 </FONT></P> </BODY></HTML> </TEXT> </DOCUMENT> <DOCUMENT> <TYPE>EX-31.2 <SEQUENCE>5 <FILENAME>d828167dex312.htm <DESCRIPTION>EX-31.2 <TEXT> <HTML><HEAD> <TITLE>EX-31.2</TITLE> </HEAD> <BODY BGCOLOR="WHITE"> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Exhibit 31.2 </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>PRINCIPAL FINANCIAL OFFICER CERTIFICATION PURSUANT TO </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002 </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">I, Sharon A. Barbari, certify that: </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">1. I have reviewed this Annual Report on Form 10-K of Cytokinetics, Incorporated; </FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report; </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report; </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">4. The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in the Exchange Act Rules 13a-(f) and 15d-15(f)) for the registrant and have: </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">a. Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared; </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">b. Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles; </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">c. Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">d. Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">5. The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions): </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">a. All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">b. Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting. </FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px"> </P><DIV ALIGN="right"> <TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE"> <TR> <TD WIDTH="6%"></TD> <TD VALIGN="bottom" WIDTH="2%"></TD> <TD WIDTH="92%"></TD></TR> <TR> <TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">By:</FONT></P></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"> <P STYLE="margin-top:0px;margin-bottom:1px;border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2">/s/ Sharon A. Barbari</FONT></P></TD></TR> <TR> <TD VALIGN="top"></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Sharon A. Barbari,</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Executive Vice President, Finance and Chief</FONT></P> <P STYLE="margin-top:0px;margin-bottom:1px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Financial Officer (Principal Financial Officer)</FONT></P></TD></TR> </TABLE></DIV> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Date March 6, 2015 </FONT></P> </BODY></HTML> </TEXT> </DOCUMENT> <DOCUMENT> <TYPE>EX-32.1 <SEQUENCE>6 <FILENAME>d828167dex321.htm <DESCRIPTION>EX-32.1 <TEXT> <HTML><HEAD> <TITLE>EX-32.1</TITLE> </HEAD> <BODY BGCOLOR="WHITE"> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Exhibit 32.1 </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>CEO and CFO CERTIFICATIONS PURSUANT TO </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>RULE 13a-14(b) AND SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(18 U.S.C. Section 1350) </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Pursuant to Rule 13a-14(b) and 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, Robert I. Blum, President, Chief Executive Officer and Director, and Sharon A. Barbari, Chief Financial Officer, of Cytokinetics, Incorporated (the “Company”), hereby certify that to the best of our knowledge: </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">1. The Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2014, and to which this certification is attached as Exhibit 32.1 (the “Annual Report”), fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, and </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">2. The information contained in this Annual Report fairly presents, in all material respects, the financial condition and results of operations of the Company. </FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px"> </P><DIV ALIGN="right"> <TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE"> <TR> <TD WIDTH="6%"></TD> <TD VALIGN="bottom" WIDTH="2%"></TD> <TD WIDTH="92%"></TD></TR> <TR> <TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">By:</FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"> <P STYLE="margin-top:0px;margin-bottom:1px;border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2">/s/ Robert I. Blum</FONT></P></TD></TR> <TR> <TD VALIGN="top"></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Robert I. Blum,</FONT></TD></TR> <TR> <TD VALIGN="top"></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">President, Chief Executive Officer and Director</FONT></TD></TR> <TR> <TD VALIGN="top"></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">(Principal Executive Officer)</FONT></TD></TR> <TR STYLE="font-size:1pt"> <TD HEIGHT="16"></TD> <TD HEIGHT="16" COLSPAN="2"></TD></TR> <TR> <TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">By:</FONT></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"> <P STYLE="margin-top:0px;margin-bottom:1px;border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2">/s/ Sharon A. Barbari</FONT></P></TD></TR> <TR> <TD VALIGN="top"></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Sharon A. Barbari,</FONT></TD></TR> <TR> <TD VALIGN="top"></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Executive Vice President, Finance and Chief</FONT></TD></TR> <TR> <TD VALIGN="top"></TD> <TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD> <TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Financial Officer (Principal Financial Officer)</FONT></TD></TR> </TABLE></DIV> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Date: March 6, 2015 </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">This certification accompanies the Form 10-K to which it relates, is not deemed filed with the Securities and Exchange Commission and is not to be incorporated by reference into any filing of Cytokinetics, Incorporated under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended (whether made before or after the date of the Form 10-K), irrespective of any general incorporation language contained in such filing. </FONT></P> </BODY></HTML> </TEXT> </DOCUMENT> <DOCUMENT> <TYPE>EX-101.INS <SEQUENCE>7 <FILENAME>cytk-20141231.xml <DESCRIPTION>XBRL INSTANCE DOCUMENT <TEXT> <XBRL> <?xml version="1.0" encoding="us-ascii" standalone="yes"?> <!-- RR Donnelley Xcelerate Instance Document, based on XBRL 2.1 http://www.rrdonnelley.com/ --> <!-- Version: 6.22.4 --> <!-- Round: 10 --> <!-- Creation date: 2015-03-05T19:06:47Z --> <!-- Copyright (c) 2005-2013 R.R. Donnelley & Sons Company All Rights Reserved. --> <xbrl xmlns="http://www.xbrl.org/2003/instance" xmlns:xbrll="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:us-gaap="http://fasb.org/us-gaap/2014-01-31" xmlns:dei="http://xbrl.sec.gov/dei/2014-01-31" xmlns:cytk="http://imetrix.edgar-online.com/20141231" xmlns:us-types="http://fasb.org/us-types/2014-01-31" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:stpr="http://xbrl.sec.gov/stpr/2011-01-31" xmlns:country="http://xbrl.sec.gov/country/2013-01-31" xmlns:currency="http://xbrl.sec.gov/currency/2014-01-31" xmlns:exch="http://xbrl.sec.gov/exch/2014-01-31" xmlns:naics="http://xbrl.sec.gov/naics/2011-01-31" xmlns:invest="http://xbrl.sec.gov/invest/2013-01-31" xmlns:sic="http://xbrl.sec.gov/sic/2011-01-31" xmlns:negated="http://www.xbrl.org/2009/role/negated" xmlns:num="http://www.xbrl.org/dtr/type/numeric" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:utr="http://www.xbrl.org/2009/utr"> <xbrll:schemaRef xlink:type="simple" xlink:arcrole="http://www.xbrl.org/2003/linkbase" xlink:href="cytk-20141231.xsd" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrll="http://www.xbrl.org/2003/linkbase" /> <us-gaap:CommonStockSharesAuthorized contextRef="eol_PE151383--1410-K0012_STD_0_20110518_0" unitRef="shares" decimals="INF" id="id_6895476_72F6ED24-5720-4169-A9B8-2CE9D0A66A86_1_0">170000000</us-gaap:CommonStockSharesAuthorized> <dei:EntityCommonStockSharesOutstanding contextRef="eol_PE151383--1410-K0012_STD_0_20150227_0" unitRef="shares" decimals="INF" id="id_6895476_719DD5F0-2E9A-450E-B7C0-E6D7E07576A8_2_500008">38674892</dei:EntityCommonStockSharesOutstanding> <cytk:GrossProceedsFromIssuanceOfStock contextRef="eol_PE151383--1410-K0012_STD_0_20110420_0" unitRef="iso4217_USD" decimals="-5" id="id_6895476_0036A474-B1E7-46AE-931E-902FB6224652_2001_3">20100000</cytk:GrossProceedsFromIssuanceOfStock> <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 contextRef="eol_PE151383--1410-K0012_STD_0_20110420_0_1271382x1559654" unitRef="iso4217_USD_per_shares" decimals="INF" id="id_6895476_F2A1F03D-DFC3-4B77-8908-14CCA725F68C_5001_1">9.90</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1> <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights contextRef="eol_PE151383--1410-K0012_STD_0_20110420_0_1271382x1559654" unitRef="shares" decimals="INF" id="id_6895476_F2A1F03D-DFC3-4B77-8908-14CCA725F68C_5001_0">1114168</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights> <cytk:PercentageLimitOnNumberOfSharesOfCommonStockExercisableByHolders contextRef="eol_PE151383--1410-K0012_STD_0_20110420_0_1271382x1559654" unitRef="pure" decimals="INF" id="id_6895476_F2A1F03D-DFC3-4B77-8908-14CCA725F68C_5001_5">0.0998</cytk:PercentageLimitOnNumberOfSharesOfCommonStockExercisableByHolders> <us-gaap:SharePrice contextRef="eol_PE151383--1410-K0012_STD_0_20110420_0_1271382x1559654_1276400x1269676" unitRef="iso4217_USD_per_shares" decimals="INF" id="id_6895476_2A1002B7-2537-4DD8-A459-A9553F6F62D8_1001_1">1500.00</us-gaap:SharePrice> <us-gaap:PreferredStockSharesIssued contextRef="eol_PE151383--1410-K0012_STD_0_20110420_0_1271382x1559654_1276400x1269676" unitRef="shares" decimals="INF" id="id_6895476_2A1002B7-2537-4DD8-A459-A9553F6F62D8_1001_0">8070</us-gaap:PreferredStockSharesIssued> <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 contextRef="eol_PE151383--1410-K0012_STD_0_20110420_0_1271382x1559654_1278975x1273442" unitRef="iso4217_USD_per_shares" decimals="INF" id="id_6895476_7D64BA49-07A9-41DB-8E2E-1CC4AA31C414_6001_5">9.90</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1> <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights contextRef="eol_PE151383--1410-K0012_STD_0_20110420_0_1271382x1559654_1278975x1273442" unitRef="shares" decimals="INF" id="id_6895476_7D64BA49-07A9-41DB-8E2E-1CC4AA31C414_6001_4">1114168</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights> <us-gaap:WarrantsNotSettleableInCashFairValueDisclosure contextRef="eol_PE151383--1410-K0012_STD_0_20110420_0_1271382x1559654_1278975x1273442" unitRef="iso4217_USD" decimals="-5" id="id_6895476_F2A1F03D-DFC3-4B77-8908-14CCA725F68C_6001_6">5800000</us-gaap:WarrantsNotSettleableInCashFairValueDisclosure> <cytk:EntitledPaymentPerShareDuringLiquidation contextRef="eol_PE151383--1410-K0012_STD_0_20110420_0_1276400x1269676" unitRef="iso4217_USD_per_shares" decimals="3" id="id_6895476_0036A474-B1E7-46AE-931E-902FB6224652_3001_0">0.001</cytk:EntitledPaymentPerShareDuringLiquidation> <cytk:GrossProceedsFromIssuanceOfStock contextRef="eol_PE151383--1410-K0012_STD_0_20110420_0_1276400x1269676" unitRef="iso4217_USD" decimals="-5" id="id_6895476_0036A474-B1E7-46AE-931E-902FB6224652_3001_5">9400000</cytk:GrossProceedsFromIssuanceOfStock> <cytk:GrossProceedsFromIssuanceOfStock contextRef="eol_PE151383--1410-K0012_STD_0_20110420_0_1276401x1270422" unitRef="iso4217_USD" decimals="-5" id="id_6895476_0036A474-B1E7-46AE-931E-902FB6224652_4001_4">6200000</cytk:GrossProceedsFromIssuanceOfStock> <cytk:GrossProceedsFromIssuanceOfStock contextRef="eol_PE151383--1410-K0012_STD_0_20110420_0_1278975x1273442" unitRef="iso4217_USD" decimals="-5" id="id_6895476_0036A474-B1E7-46AE-931E-902FB6224652_5001_6">4500000</cytk:GrossProceedsFromIssuanceOfStock> <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 contextRef="eol_PE151383--1410-K0012_STD_0_20130228_0_1278975x1376841" unitRef="iso4217_USD_per_shares" decimals="INF" id="id_6895476_1799E174-222A-4062-918E-1EEF494581D4_1001_1">5.28</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1> <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights contextRef="eol_PE151383--1410-K0012_STD_0_20130228_0_1278975x1376841" unitRef="shares" decimals="INF" id="id_6895476_1799E174-222A-4062-918E-1EEF494581D4_1001_0">1000</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights> <us-gaap:CommonStockSharesIssued contextRef="eol_PE151383--1410-K0012_STD_0_20140228_0_1271382x1382912" unitRef="shares" decimals="INF" id="id_6895476_3E87B441-B931-4418-AA68-79D383D423DB_2001_0">5031250</us-gaap:CommonStockSharesIssued> <cytk:GrossProceedsFromIssuanceOfStock contextRef="eol_PE151383--1410-K0012_STD_0_20140228_0_1271382x1382912" unitRef="iso4217_USD" decimals="-5" id="id_6895476_3E87B441-B931-4418-AA68-79D383D423DB_2001_1">40300000</cytk:GrossProceedsFromIssuanceOfStock> <us-gaap:CommonStockSharesIssued contextRef="eol_PE151383--1410-K0012_STD_0_20120625_0" unitRef="shares" decimals="INF" id="id_6895476_89872A42-7173-4DB8-AB4C-D0DCE3435133_1001_0">9320176</us-gaap:CommonStockSharesIssued> <us-gaap:SharePrice contextRef="eol_PE151383--1410-K0012_STD_0_20120625_0" unitRef="iso4217_USD_per_shares" decimals="INF" id="id_6895476_89872A42-7173-4DB8-AB4C-D0DCE3435133_1001_1">4.56</us-gaap:SharePrice> <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights contextRef="eol_PE151383--1410-K0012_STD_0_20120625_0" unitRef="shares" decimals="INF" id="id_6895476_89872A42-7173-4DB8-AB4C-D0DCE3435133_1001_4">7894704</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights> <us-gaap:SharePrice contextRef="eol_PE151383--1410-K0012_STD_0_20120625_0_1271382x1272538_1276400x1281157" unitRef="iso4217_USD_per_shares" decimals="INF" id="id_6895476_66294636-A6BA-4A64-9935-D90D4F7A0972_2002_2">760.00</us-gaap:SharePrice> <us-gaap:MinorityInterestOwnershipPercentageByNoncontrollingOwners contextRef="eol_PE151383--1410-K0012_STD_0_20120625_0_1271382x1559654" unitRef="pure" decimals="4" id="id_6895476_3E54C892-94D6-4C52-BFA8-8B816AFAFE5A_5001_3">0.0998</us-gaap:MinorityInterestOwnershipPercentageByNoncontrollingOwners> <us-gaap:LiabilitiesFairValueDisclosure contextRef="eol_PE151383--1410-K0012_STD_0_20120625_0_1271382x1559654_1278975x1273442" unitRef="iso4217_USD" decimals="-5" id="id_6895476_3E54C892-94D6-4C52-BFA8-8B816AFAFE5A_6001_4">16200000</us-gaap:LiabilitiesFairValueDisclosure> <us-gaap:PreferredStockNoParValue contextRef="eol_PE151383--1410-K0012_STD_0_20120625_0_1276400x1281157" unitRef="iso4217_USD_per_shares" decimals="INF" id="id_6895476_89872A42-7173-4DB8-AB4C-D0DCE3435133_2001_3">760.00</us-gaap:PreferredStockNoParValue> <us-gaap:PreferredStockSharesIssued contextRef="eol_PE151383--1410-K0012_STD_0_20120625_0_1276400x1281157" unitRef="shares" decimals="INF" id="id_6895476_66294636-A6BA-4A64-9935-D90D4F7A0972_3002_1">23026</us-gaap:PreferredStockSharesIssued> <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 contextRef="eol_PE151383--1410-K0012_STD_0_20120625_0_1278975x1273442" unitRef="iso4217_USD_per_shares" decimals="INF" id="id_6895476_89872A42-7173-4DB8-AB4C-D0DCE3435133_3001_5">5.28</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1> <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights contextRef="eol_PE151383--1410-K0012_STD_0_20120625_0_1278975x1273442" unitRef="shares" decimals="INF" id="id_6895476_3E54C892-94D6-4C52-BFA8-8B816AFAFE5A_7001_0">7894704</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights> <us-gaap:CommonStockSharesAuthorized contextRef="eol_PE151383--1410-K0012_STD_0_20110831_0" unitRef="shares" decimals="INF" id="id_6895476_72F6ED24-5720-4169-A9B8-2CE9D0A66A86_2_0">245000000</us-gaap:CommonStockSharesAuthorized> <cytk:EntitledPaymentPerShareDuringLiquidation contextRef="eol_PE151383--1410-K0012_STD_0_20120630_0_1276400x1281157" unitRef="iso4217_USD_per_shares" decimals="3" id="id_6895476_3FC5ED04-4EE6-46C9-A0D2-620382362F04_3001_4">0.001</cytk:EntitledPaymentPerShareDuringLiquidation> <us-gaap:CommonStockSharesIssued contextRef="eol_PE151383--1410-K0012_STD_0_20130630_0_1279431x1424859" unitRef="shares" decimals="INF" id="id_6895476_7F280FAF-8359-476C-AA21-F14004E0FF7E_3001_0">1404100</us-gaap:CommonStockSharesIssued> <us-gaap:SharePrice contextRef="eol_PE151383--1410-K0012_STD_0_20130630_0_1279431x1424859" unitRef="iso4217_USD_per_shares" decimals="INF" id="id_6895476_7F280FAF-8359-476C-AA21-F14004E0FF7E_3001_1">7.12</us-gaap:SharePrice> <dei:EntityPublicFloat contextRef="eol_PE151383--1410-K0012_STD_0_20140630_0" unitRef="iso4217_USD" decimals="-5" id="id_6895476_719DD5F0-2E9A-450E-B7C0-E6D7E07576A8_3_600009">174500000</dei:EntityPublicFloat> <us-gaap:PreferredStockSharesOutstanding contextRef="eol_PE151383--1410-K0012_STD_0_20101231_0_1276400x1270467" unitRef="shares" decimals="INF" id="id_6895476_19999B5D-5D25-495B-8668-B2DDF8D7D3B9_1001_1">0</us-gaap:PreferredStockSharesOutstanding> <us-gaap:PreferredStockSharesAuthorized contextRef="eol_PE151383--1410-K0012_STD_0_20101231_0_1276400x1270467" unitRef="shares" decimals="INF" id="id_6895476_19999B5D-5D25-495B-8668-B2DDF8D7D3B9_1001_0">10000000</us-gaap:PreferredStockSharesAuthorized> <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice contextRef="eol_PE151383--1410-K0012_STD_0_20111231_0" unitRef="iso4217_USD_per_shares" decimals="2" id="id_6895476_C3206D70-DEC9-4565-9145-8B70956A712D_1001_1">21.93</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice> <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant contextRef="eol_PE151383--1410-K0012_STD_0_20111231_0" unitRef="shares" decimals="INF" id="id_6895476_550670F2-8019-4594-8D89-8D38F90A7B79_1001_1">585476</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant> <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="eol_PE151383--1410-K0012_STD_0_20111231_0" unitRef="shares" decimals="INF" id="id_6895476_EAE02EAA-C88A-417D-A4E8-6DD5ADADA4AB_1001_1">1598408</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber> <us-gaap:StockholdersEquity contextRef="eol_PE151383--1410-K0012_STD_0_20111231_0" unitRef="iso4217_USD" decimals="-3" id="id_6895476_58E9B802-84A6-48EC-8C22-C0DD0182E686_1008_1">48178000</us-gaap:StockholdersEquity> <us-gaap:LineOfCredit contextRef="eol_PE151383--1410-K0012_STD_0_20111231_0" unitRef="iso4217_USD" decimals="0" id="id_6895476_4EE30960-F1F9-4223-95C9-EFB9AB540D3E_1_0">152000</us-gaap:LineOfCredit> <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="eol_PE151383--1410-K0012_STD_0_20111231_0" unitRef="iso4217_USD" decimals="-3" id="id_6895476_84756BCF-71FA-4E32-A511-A3DCED215C30_2001_31">18833000</us-gaap:CashAndCashEquivalentsAtCarryingValue> <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue contextRef="eol_PE151383--1410-K0012_STD_0_20111231_0_1270313x1271210" unitRef="iso4217_USD_per_shares" decimals="2" id="id_6895476_4396C4E5-DD06-4003-A485-BA06C7D8368D_1001_1">6.78</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue> <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber contextRef="eol_PE151383--1410-K0012_STD_0_20111231_0_1270313x1271210" unitRef="shares" decimals="INF" id="id_6895476_9D5C22B2-CCEF-4AED-B18A-0ACE42E2B15B_1001_1">517535</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber> <us-gaap:StockholdersEquity contextRef="eol_PE151383--1410-K0012_STD_0_20111231_0_1276401x1268669" unitRef="iso4217_USD" decimals="-3" id="id_6895476_58E9B802-84A6-48EC-8C22-C0DD0182E686_1006_1">3000</us-gaap:StockholdersEquity> <us-gaap:StockholdersEquity contextRef="eol_PE151383--1410-K0012_STD_0_20111231_0_1276401x1269588" unitRef="iso4217_USD" decimals="-3" id="id_6895476_58E9B802-84A6-48EC-8C22-C0DD0182E686_1007_1">-408510000</us-gaap:StockholdersEquity> <us-gaap:SharesOutstanding contextRef="eol_PE151383--1410-K0012_STD_0_20111231_0_1276401x1270422" unitRef="shares" decimals="INF" id="id_6895476_58E9B802-84A6-48EC-8C22-C0DD0182E686_1001_2">12485957</us-gaap:SharesOutstanding> <us-gaap:StockholdersEquity contextRef="eol_PE151383--1410-K0012_STD_0_20111231_0_1276401x1270422" unitRef="iso4217_USD" decimals="-3" id="id_6895476_58E9B802-84A6-48EC-8C22-C0DD0182E686_1001_1">13000</us-gaap:StockholdersEquity> <us-gaap:SharesOutstanding contextRef="eol_PE151383--1410-K0012_STD_0_20111231_0_1276401x1272805" unitRef="shares" decimals="INF" id="id_6895476_58E9B802-84A6-48EC-8C22-C0DD0182E686_1003_2">8070</us-gaap:SharesOutstanding> <us-gaap:StockholdersEquity contextRef="eol_PE151383--1410-K0012_STD_0_20111231_0_1276401x1273630" unitRef="iso4217_USD" decimals="-3" id="id_6895476_58E9B802-84A6-48EC-8C22-C0DD0182E686_1005_1">456672000</us-gaap:StockholdersEquity> <us-gaap:ValuationAllowancesAndReservesBalance contextRef="eol_PE151383--1410-K0012_STD_0_20111231_0_1279936x1276697" unitRef="iso4217_USD" decimals="-3" id="id_6895476_B444ABAD-A3F0-45D1-A8D2-D991236372AC_3001_1">169107000</us-gaap:ValuationAllowancesAndReservesBalance> <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice contextRef="eol_PE151383--1410-K0012_STD_0_20121231_0" unitRef="iso4217_USD_per_shares" decimals="2" id="id_6895476_C3206D70-DEC9-4565-9145-8B70956A712D_3001_5">18.96</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice> <us-gaap:SharePrice contextRef="eol_PE151383--1410-K0012_STD_0_20121231_0" unitRef="iso4217_USD_per_shares" decimals="INF" id="id_6895476_58E9B802-84A6-48EC-8C22-C0DD0182E686_3008_10">4.56</us-gaap:SharePrice> <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant contextRef="eol_PE151383--1410-K0012_STD_0_20121231_0" unitRef="shares" decimals="INF" id="id_6895476_550670F2-8019-4594-8D89-8D38F90A7B79_3001_6">878726</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant> <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="eol_PE151383--1410-K0012_STD_0_20121231_0" unitRef="shares" decimals="INF" id="id_6895476_EAE02EAA-C88A-417D-A4E8-6DD5ADADA4AB_3001_6">1790527</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber> <us-gaap:DeferredTaxAssetsValuationAllowance contextRef="eol_PE151383--1410-K0012_STD_0_20121231_0" unitRef="iso4217_USD" decimals="-3" id="id_6895476_4672B4FA-1C38-4D80-B654-6FAD4B61F0BF_1003_7">190193000</us-gaap:DeferredTaxAssetsValuationAllowance> <us-gaap:UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate contextRef="eol_PE151383--1410-K0012_STD_0_20121231_0" unitRef="iso4217_USD" decimals="-5" id="id_6895476_7D9A8A58-B70E-4462-8AC6-5461D478452D_1003_0">4200000</us-gaap:UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate> <us-gaap:IncomeTaxExaminationPenaltiesAndInterestAccrued contextRef="eol_PE151383--1410-K0012_STD_0_20121231_0" unitRef="iso4217_USD" decimals="INF" id="id_6895476_D97313CD-F829-4052-9EAB-BF6B1F4928E9_1003_0">0</us-gaap:IncomeTaxExaminationPenaltiesAndInterestAccrued> <us-gaap:StockholdersEquity contextRef="eol_PE151383--1410-K0012_STD_0_20121231_0" unitRef="iso4217_USD" decimals="-3" id="id_6895476_58E9B802-84A6-48EC-8C22-C0DD0182E686_3008_29">70085000</us-gaap:StockholdersEquity> <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="eol_PE151383--1410-K0012_STD_0_20121231_0" unitRef="iso4217_USD" decimals="-3" id="id_6895476_84756BCF-71FA-4E32-A511-A3DCED215C30_1003_31">14907000</us-gaap:CashAndCashEquivalentsAtCarryingValue> <us-gaap:DeferredTaxAssetsGross contextRef="eol_PE151383--1410-K0012_STD_0_20121231_0" unitRef="iso4217_USD" decimals="-3" id="id_6895476_4672B4FA-1C38-4D80-B654-6FAD4B61F0BF_1003_6">190193000</us-gaap:DeferredTaxAssetsGross> <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards contextRef="eol_PE151383--1410-K0012_STD_0_20121231_0" unitRef="iso4217_USD" decimals="-3" id="id_6895476_4672B4FA-1C38-4D80-B654-6FAD4B61F0BF_1003_4">153193000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards> <us-gaap:DeferredTaxAssetsNet contextRef="eol_PE151383--1410-K0012_STD_0_20121231_0" unitRef="iso4217_USD" decimals="-3" id="id_6895476_4672B4FA-1C38-4D80-B654-6FAD4B61F0BF_1003_8">0</us-gaap:DeferredTaxAssetsNet> <us-gaap:DeferredTaxAssetsTaxCreditCarryforwards contextRef="eol_PE151383--1410-K0012_STD_0_20121231_0" unitRef="iso4217_USD" decimals="-3" id="id_6895476_4672B4FA-1C38-4D80-B654-6FAD4B61F0BF_1003_5">25943000</us-gaap:DeferredTaxAssetsTaxCreditCarryforwards> <us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals contextRef="eol_PE151383--1410-K0012_STD_0_20121231_0" unitRef="iso4217_USD" decimals="-3" id="id_6895476_4672B4FA-1C38-4D80-B654-6FAD4B61F0BF_1003_3">5101000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals> <cytk:DeferredTaxAssetsCapitalizedResearchAndDevelopment contextRef="eol_PE151383--1410-K0012_STD_0_20121231_0" unitRef="iso4217_USD" decimals="-3" id="id_6895476_4672B4FA-1C38-4D80-B654-6FAD4B61F0BF_1003_2">4932000</cytk:DeferredTaxAssetsCapitalizedResearchAndDevelopment> <cytk:DeferredTaxAssetsDepreciationAndAmortization contextRef="eol_PE151383--1410-K0012_STD_0_20121231_0" unitRef="iso4217_USD" decimals="-3" id="id_6895476_4672B4FA-1C38-4D80-B654-6FAD4B61F0BF_1003_1">1024000</cytk:DeferredTaxAssetsDepreciationAndAmortization> <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue contextRef="eol_PE151383--1410-K0012_STD_0_20121231_0_1270313x1271210" unitRef="iso4217_USD_per_shares" decimals="2" id="id_6895476_4396C4E5-DD06-4003-A485-BA06C7D8368D_3001_4">6.78</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue> <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber contextRef="eol_PE151383--1410-K0012_STD_0_20121231_0_1270313x1271210" unitRef="shares" decimals="INF" id="id_6895476_9D5C22B2-CCEF-4AED-B18A-0ACE42E2B15B_3001_4">216898</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber> <us-gaap:StockholdersEquity contextRef="eol_PE151383--1410-K0012_STD_0_20121231_0_1276401x1268669" unitRef="iso4217_USD" decimals="-3" id="id_6895476_58E9B802-84A6-48EC-8C22-C0DD0182E686_3006_29">18000</us-gaap:StockholdersEquity> <us-gaap:StockholdersEquity contextRef="eol_PE151383--1410-K0012_STD_0_20121231_0_1276401x1269588" unitRef="iso4217_USD" decimals="-3" id="id_6895476_58E9B802-84A6-48EC-8C22-C0DD0182E686_3007_29">-448880000</us-gaap:StockholdersEquity> <us-gaap:SharesOutstanding contextRef="eol_PE151383--1410-K0012_STD_0_20121231_0_1276401x1270422" unitRef="shares" decimals="INF" id="id_6895476_58E9B802-84A6-48EC-8C22-C0DD0182E686_3001_30">23742912</us-gaap:SharesOutstanding> <us-gaap:StockholdersEquity contextRef="eol_PE151383--1410-K0012_STD_0_20121231_0_1276401x1270422" unitRef="iso4217_USD" decimals="-3" id="id_6895476_58E9B802-84A6-48EC-8C22-C0DD0182E686_3001_29">24000</us-gaap:StockholdersEquity> <cytk:StockIssuedDuringPeriodSharesSecuritiesPurchaseAgreement contextRef="eol_PE151383--1410-K0012_STD_0_20121231_0_1276401x1270422" unitRef="shares" decimals="INF" id="id_6895476_58E9B802-84A6-48EC-8C22-C0DD0182E686_3001_9">9320176</cytk:StockIssuedDuringPeriodSharesSecuritiesPurchaseAgreement> <us-gaap:SharesOutstanding contextRef="eol_PE151383--1410-K0012_STD_0_20121231_0_1276401x1272805" unitRef="shares" decimals="INF" id="id_6895476_58E9B802-84A6-48EC-8C22-C0DD0182E686_3003_30">23026</us-gaap:SharesOutstanding> <us-gaap:StockholdersEquity contextRef="eol_PE151383--1410-K0012_STD_0_20121231_0_1276401x1273630" unitRef="iso4217_USD" decimals="-3" id="id_6895476_58E9B802-84A6-48EC-8C22-C0DD0182E686_3005_29">518923000</us-gaap:StockholdersEquity> <us-gaap:ValuationAllowancesAndReservesBalance contextRef="eol_PE151383--1410-K0012_STD_0_20121231_0_1279936x1276697" unitRef="iso4217_USD" decimals="-3" id="id_6895476_B444ABAD-A3F0-45D1-A8D2-D991236372AC_2001_1">190193000</us-gaap:ValuationAllowancesAndReservesBalance> <us-gaap:UnrecognizedTaxBenefits contextRef="eol_PE151383--1410-K0012_STD_0_20121231_0_1280651x1297583" unitRef="iso4217_USD" decimals="-3" id="id_6895476_7B98D2F9-CACB-495E-A3F9-A79C5892451D_1002_1">1158000</us-gaap:UnrecognizedTaxBenefits> <us-gaap:UnrecognizedTaxBenefits contextRef="eol_PE151383--1410-K0012_STD_0_20121231_0_1280651x1497867" unitRef="iso4217_USD" decimals="-3" id="id_6895476_7B98D2F9-CACB-495E-A3F9-A79C5892451D_1003_1">4182000</us-gaap:UnrecognizedTaxBenefits> <us-gaap:UnrecognizedTaxBenefits contextRef="eol_PE151383--1410-K0012_STD_0_20121231_0_1280651x1520580" unitRef="iso4217_USD" decimals="-3" id="id_6895476_7B98D2F9-CACB-495E-A3F9-A79C5892451D_1001_1">5340000</us-gaap:UnrecognizedTaxBenefits> <us-gaap:CommonStockSharesIssued contextRef="eol_PE151383--1410-K0012_STD_0_20131231_0" unitRef="shares" decimals="INF" id="id_6895476_415AC1F8-2710-4285-9D91-1A668F81A543_2_31">30681624</us-gaap:CommonStockSharesIssued> <us-gaap:CommonStockSharesOutstanding contextRef="eol_PE151383--1410-K0012_STD_0_20131231_0" unitRef="shares" decimals="INF" id="id_6895476_415AC1F8-2710-4285-9D91-1A668F81A543_2_32">30681624</us-gaap:CommonStockSharesOutstanding> <us-gaap:CommonStockSharesAuthorized contextRef="eol_PE151383--1410-K0012_STD_0_20131231_0" unitRef="shares" decimals="INF" id="id_6895476_415AC1F8-2710-4285-9D91-1A668F81A543_2_30">81500000</us-gaap:CommonStockSharesAuthorized> <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice contextRef="eol_PE151383--1410-K0012_STD_0_20131231_0" unitRef="iso4217_USD_per_shares" decimals="2" id="id_6895476_C3206D70-DEC9-4565-9145-8B70956A712D_6001_11">15.15</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice> <us-gaap:CommonStockParOrStatedValuePerShare contextRef="eol_PE151383--1410-K0012_STD_0_20131231_0" unitRef="iso4217_USD_per_shares" decimals="INF" id="id_6895476_415AC1F8-2710-4285-9D91-1A668F81A543_2_29">0.001</us-gaap:CommonStockParOrStatedValuePerShare> <us-gaap:PreferredStockSharesAuthorized contextRef="eol_PE151383--1410-K0012_STD_0_20131231_0" unitRef="shares" decimals="INF" id="id_6895476_415AC1F8-2710-4285-9D91-1A668F81A543_2_24">10000000</us-gaap:PreferredStockSharesAuthorized> <us-gaap:PreferredStockParOrStatedValuePerShare contextRef="eol_PE151383--1410-K0012_STD_0_20131231_0" unitRef="iso4217_USD_per_shares" decimals="INF" id="id_6895476_415AC1F8-2710-4285-9D91-1A668F81A543_2_23">0.001</us-gaap:PreferredStockParOrStatedValuePerShare> <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant contextRef="eol_PE151383--1410-K0012_STD_0_20131231_0" unitRef="shares" decimals="INF" id="id_6895476_550670F2-8019-4594-8D89-8D38F90A7B79_6001_13">2161829</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant> <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="eol_PE151383--1410-K0012_STD_0_20131231_0" unitRef="shares" decimals="INF" id="id_6895476_EAE02EAA-C88A-417D-A4E8-6DD5ADADA4AB_6001_13">2449365</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber> <us-gaap:DeferredTaxAssetsValuationAllowance contextRef="eol_PE151383--1410-K0012_STD_0_20131231_0" unitRef="iso4217_USD" decimals="-3" id="id_6895476_4672B4FA-1C38-4D80-B654-6FAD4B61F0BF_1002_7">203863000</us-gaap:DeferredTaxAssetsValuationAllowance> <us-gaap:DeferredRevenueNoncurrent contextRef="eol_PE151383--1410-K0012_STD_0_20131231_0" unitRef="iso4217_USD" decimals="-3" id="id_6895476_415AC1F8-2710-4285-9D91-1A668F81A543_2_18">1500000</us-gaap:DeferredRevenueNoncurrent> <us-gaap:DeferredRentCreditCurrent contextRef="eol_PE151383--1410-K0012_STD_0_20131231_0" unitRef="iso4217_USD" decimals="-3" id="id_6895476_415AC1F8-2710-4285-9D91-1A668F81A543_2_16">22000</us-gaap:DeferredRentCreditCurrent> <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment contextRef="eol_PE151383--1410-K0012_STD_0_20131231_0" unitRef="iso4217_USD" decimals="-3" id="id_6895476_113D1BB7-2EFC-40A3-A61B-C5BE96CD52A4_2_6">20992000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment> <us-gaap:AccruedVacationCurrent contextRef="eol_PE151383--1410-K0012_STD_0_20131231_0" unitRef="iso4217_USD" decimals="-3" id="id_6895476_D457422F-4655-455B-8BCE-756F9E020BF2_2_4">778000</us-gaap:AccruedVacationCurrent> <us-gaap:LiabilitiesCurrent contextRef="eol_PE151383--1410-K0012_STD_0_20131231_0" unitRef="iso4217_USD" decimals="-3" id="id_6895476_415AC1F8-2710-4285-9D91-1A668F81A543_2_17">26704000</us-gaap:LiabilitiesCurrent> <us-gaap:AccruedBonusesCurrent contextRef="eol_PE151383--1410-K0012_STD_0_20131231_0" unitRef="iso4217_USD" decimals="-3" id="id_6895476_D457422F-4655-455B-8BCE-756F9E020BF2_2_3">1614000</us-gaap:AccruedBonusesCurrent> <us-gaap:UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate contextRef="eol_PE151383--1410-K0012_STD_0_20131231_0" unitRef="iso4217_USD" decimals="-5" id="id_6895476_7D9A8A58-B70E-4462-8AC6-5461D478452D_1002_0">5000000</us-gaap:UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate> <us-gaap:IncomeTaxExaminationPenaltiesAndInterestAccrued contextRef="eol_PE151383--1410-K0012_STD_0_20131231_0" unitRef="iso4217_USD" decimals="INF" id="id_6895476_D97313CD-F829-4052-9EAB-BF6B1F4928E9_1002_0">0</us-gaap:IncomeTaxExaminationPenaltiesAndInterestAccrued> <us-gaap:CommonStockValue contextRef="eol_PE151383--1410-K0012_STD_0_20131231_0" unitRef="iso4217_USD" decimals="-3" id="id_6895476_415AC1F8-2710-4285-9D91-1A668F81A543_2_28">31000</us-gaap:CommonStockValue> <us-gaap:CommitmentsAndContingencies contextRef="eol_PE151383--1410-K0012_STD_0_20131231_0" unitRef="iso4217_USD" xsi:nil="true" id="id_6895476_415AC1F8-2710-4285-9D91-1A668F81A543_2_21" /> <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax contextRef="eol_PE151383--1410-K0012_STD_0_20131231_0" unitRef="iso4217_USD" decimals="-3" id="id_6895476_415AC1F8-2710-4285-9D91-1A668F81A543_2_34">7000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax> <us-gaap:AccountsPayableCurrent contextRef="eol_PE151383--1410-K0012_STD_0_20131231_0" unitRef="iso4217_USD" decimals="-3" id="id_6895476_415AC1F8-2710-4285-9D91-1A668F81A543_2_13">3709000</us-gaap:AccountsPayableCurrent> <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="eol_PE151383--1410-K0012_STD_0_20131231_0" unitRef="iso4217_USD" decimals="-3" id="id_6895476_415AC1F8-2710-4285-9D91-1A668F81A543_2_35">-482597000</us-gaap:RetainedEarningsAccumulatedDeficit> <us-gaap:AccruedLiabilitiesCurrent contextRef="eol_PE151383--1410-K0012_STD_0_20131231_0" unitRef="iso4217_USD" decimals="-3" id="id_6895476_415AC1F8-2710-4285-9D91-1A668F81A543_2_14">8272000</us-gaap:AccruedLiabilitiesCurrent> <us-gaap:StockholdersEquity contextRef="eol_PE151383--1410-K0012_STD_0_20131231_0" unitRef="iso4217_USD" decimals="-3" id="id_6895476_415AC1F8-2710-4285-9D91-1A668F81A543_2_36">54442000</us-gaap:StockholdersEquity> <us-gaap:OtherAccruedLiabilitiesCurrent contextRef="eol_PE151383--1410-K0012_STD_0_20131231_0" unitRef="iso4217_USD" decimals="-3" id="id_6895476_D457422F-4655-455B-8BCE-756F9E020BF2_2_6">115000</us-gaap:OtherAccruedLiabilitiesCurrent> <us-gaap:LiabilitiesAndStockholdersEquity contextRef="eol_PE151383--1410-K0012_STD_0_20131231_0" unitRef="iso4217_USD" decimals="-3" id="id_6895476_415AC1F8-2710-4285-9D91-1A668F81A543_2_37">83188000</us-gaap:LiabilitiesAndStockholdersEquity> <us-gaap:AdditionalPaidInCapital contextRef="eol_PE151383--1410-K0012_STD_0_20131231_0" unitRef="iso4217_USD" decimals="-3" id="id_6895476_415AC1F8-2710-4285-9D91-1A668F81A543_2_33">537001000</us-gaap:AdditionalPaidInCapital> <us-gaap:AccruedProfessionalFeesCurrent contextRef="eol_PE151383--1410-K0012_STD_0_20131231_0" unitRef="iso4217_USD" decimals="-3" id="id_6895476_D457422F-4655-455B-8BCE-756F9E020BF2_2_2">697000</us-gaap:AccruedProfessionalFeesCurrent> <us-gaap:DeferredRevenueCurrent contextRef="eol_PE151383--1410-K0012_STD_0_20131231_0" unitRef="iso4217_USD" decimals="-3" id="id_6895476_415AC1F8-2710-4285-9D91-1A668F81A543_2_15">14701000</us-gaap:DeferredRevenueCurrent> <us-gaap:OtherEmployeeRelatedLiabilitiesCurrent contextRef="eol_PE151383--1410-K0012_STD_0_20131231_0" unitRef="iso4217_USD" decimals="-3" id="id_6895476_D457422F-4655-455B-8BCE-756F9E020BF2_2_5">93000</us-gaap:OtherEmployeeRelatedLiabilitiesCurrent> <us-gaap:Liabilities contextRef="eol_PE151383--1410-K0012_STD_0_20131231_0" unitRef="iso4217_USD" decimals="-3" id="id_6895476_415AC1F8-2710-4285-9D91-1A668F81A543_2_20">28746000</us-gaap:Liabilities> <us-gaap:DeferredRentCreditNoncurrent contextRef="eol_PE151383--1410-K0012_STD_0_20131231_0" unitRef="iso4217_USD" decimals="-3" id="id_6895476_415AC1F8-2710-4285-9D91-1A668F81A543_2_19">542000</us-gaap:DeferredRentCreditNoncurrent> <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="eol_PE151383--1410-K0012_STD_0_20131231_0" unitRef="iso4217_USD" decimals="-3" id="id_6895476_415AC1F8-2710-4285-9D91-1A668F81A543_2_2">20158000</us-gaap:CashAndCashEquivalentsAtCarryingValue> <us-gaap:PropertyPlantAndEquipmentNet contextRef="eol_PE151383--1410-K0012_STD_0_20131231_0" unitRef="iso4217_USD" decimals="-3" id="id_6895476_415AC1F8-2710-4285-9D91-1A668F81A543_2_7">1221000</us-gaap:PropertyPlantAndEquipmentNet> <us-gaap:DeferredTaxAssetsGross contextRef="eol_PE151383--1410-K0012_STD_0_20131231_0" unitRef="iso4217_USD" decimals="-3" id="id_6895476_4672B4FA-1C38-4D80-B654-6FAD4B61F0BF_1002_6">203863000</us-gaap:DeferredTaxAssetsGross> <us-gaap:AccountsReceivableRelatedPartiesCurrent contextRef="eol_PE151383--1410-K0012_STD_0_20131231_0" unitRef="iso4217_USD" decimals="-3" id="id_6895476_415AC1F8-2710-4285-9D91-1A668F81A543_2_4">5000</us-gaap:AccountsReceivableRelatedPartiesCurrent> <us-gaap:PropertyPlantAndEquipmentGross contextRef="eol_PE151383--1410-K0012_STD_0_20131231_0" unitRef="iso4217_USD" decimals="-3" id="id_6895476_113D1BB7-2EFC-40A3-A61B-C5BE96CD52A4_2_5">22213000</us-gaap:PropertyPlantAndEquipmentGross> <us-gaap:CashCashEquivalentsAndShortTermInvestments contextRef="eol_PE151383--1410-K0012_STD_0_20131231_0" unitRef="iso4217_USD" decimals="-5" id="id_6895476_5F9E7FBE-865B-4206-B2D7-3FAAEF82FB92_3_3">80200000</us-gaap:CashCashEquivalentsAndShortTermInvestments> <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards contextRef="eol_PE151383--1410-K0012_STD_0_20131231_0" unitRef="iso4217_USD" decimals="-3" id="id_6895476_4672B4FA-1C38-4D80-B654-6FAD4B61F0BF_1002_4">144254000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards> <us-gaap:LongTermInvestments contextRef="eol_PE151383--1410-K0012_STD_0_20131231_0" unitRef="iso4217_USD" decimals="-3" id="id_6895476_415AC1F8-2710-4285-9D91-1A668F81A543_2_8">2502000</us-gaap:LongTermInvestments> <us-gaap:Assets contextRef="eol_PE151383--1410-K0012_STD_0_20131231_0" unitRef="iso4217_USD" decimals="-3" id="id_6895476_415AC1F8-2710-4285-9D91-1A668F81A543_2_10">83188000</us-gaap:Assets> <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent contextRef="eol_PE151383--1410-K0012_STD_0_20131231_0" unitRef="iso4217_USD" decimals="-3" id="id_6895476_415AC1F8-2710-4285-9D91-1A668F81A543_2_3">57570000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent> <us-gaap:DeferredTaxAssetsNet contextRef="eol_PE151383--1410-K0012_STD_0_20131231_0" unitRef="iso4217_USD" decimals="-3" id="id_6895476_4672B4FA-1C38-4D80-B654-6FAD4B61F0BF_1002_8">0</us-gaap:DeferredTaxAssetsNet> <us-gaap:InterestReceivable contextRef="eol_PE151383--1410-K0012_STD_0_20131231_0" unitRef="iso4217_USD" decimals="0" id="id_6895476_8D329B4F-AC7D-4E87-82A9-04734BCBFBD3_2_0">215000</us-gaap:InterestReceivable> <us-gaap:DeferredTaxAssetsTaxCreditCarryforwards contextRef="eol_PE151383--1410-K0012_STD_0_20131231_0" unitRef="iso4217_USD" decimals="-3" id="id_6895476_4672B4FA-1C38-4D80-B654-6FAD4B61F0BF_1002_5">33043000</us-gaap:DeferredTaxAssetsTaxCreditCarryforwards> <us-gaap:OtherAssetsCurrent contextRef="eol_PE151383--1410-K0012_STD_0_20131231_0" unitRef="iso4217_USD" decimals="-3" id="id_6895476_415AC1F8-2710-4285-9D91-1A668F81A543_2_5">1605000</us-gaap:OtherAssetsCurrent> <us-gaap:OtherAssetsNoncurrent contextRef="eol_PE151383--1410-K0012_STD_0_20131231_0" unitRef="iso4217_USD" decimals="-3" id="id_6895476_415AC1F8-2710-4285-9D91-1A668F81A543_2_9">127000</us-gaap:OtherAssetsNoncurrent> <us-gaap:AssetsCurrent contextRef="eol_PE151383--1410-K0012_STD_0_20131231_0" unitRef="iso4217_USD" decimals="-3" id="id_6895476_415AC1F8-2710-4285-9D91-1A668F81A543_2_6">79338000</us-gaap:AssetsCurrent> <us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals contextRef="eol_PE151383--1410-K0012_STD_0_20131231_0" unitRef="iso4217_USD" decimals="-3" id="id_6895476_4672B4FA-1C38-4D80-B654-6FAD4B61F0BF_1002_3">4946000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals> <cytk:DeferredTaxAssetsCapitalizedResearchAndDevelopment contextRef="eol_PE151383--1410-K0012_STD_0_20131231_0" unitRef="iso4217_USD" decimals="-3" id="id_6895476_4672B4FA-1C38-4D80-B654-6FAD4B61F0BF_1002_2">20702000</cytk:DeferredTaxAssetsCapitalizedResearchAndDevelopment> <cytk:AccruedClinicalAndPreclinicalCostsCurrent contextRef="eol_PE151383--1410-K0012_STD_0_20131231_0" unitRef="iso4217_USD" decimals="-3" id="id_6895476_D457422F-4655-455B-8BCE-756F9E020BF2_2_1">4975000</cytk:AccruedClinicalAndPreclinicalCostsCurrent> <cytk:DeferredTaxAssetsDepreciationAndAmortization contextRef="eol_PE151383--1410-K0012_STD_0_20131231_0" unitRef="iso4217_USD" decimals="-3" id="id_6895476_4672B4FA-1C38-4D80-B654-6FAD4B61F0BF_1002_1">918000</cytk:DeferredTaxAssetsDepreciationAndAmortization> <us-gaap:AssetsFairValueDisclosureRecurring contextRef="eol_PE151383--1410-K0012_STD_0_20131231_0_1269038x1269048" unitRef="iso4217_USD" decimals="INF" id="id_6895476_81507991-A4C3-4B03-B481-7472E2A8A109_1002_0">0</us-gaap:AssetsFairValueDisclosureRecurring> <us-gaap:AssetsFairValueDisclosure contextRef="eol_PE151383--1410-K0012_STD_0_20131231_0_1269038x1269048_1274212x1280237_1275672x1274022" unitRef="iso4217_USD" decimals="-3" id="id_6895476_D3746E4A-E07A-4CB9-90BF-ECC5CBC77FC7_2002_9">0</us-gaap:AssetsFairValueDisclosure> <us-gaap:AssetsFairValueDisclosure contextRef="eol_PE151383--1410-K0012_STD_0_20131231_0_1269038x1269048_1274607x1276380_1275672x1274022" unitRef="iso4217_USD" decimals="-3" id="id_6895476_D3746E4A-E07A-4CB9-90BF-ECC5CBC77FC7_3002_10">0</us-gaap:AssetsFairValueDisclosure> <us-gaap:AssetsFairValueDisclosure contextRef="eol_PE151383--1410-K0012_STD_0_20131231_0_1269038x1269048_1275669x1274813_1275672x1274022" unitRef="iso4217_USD" decimals="-3" id="id_6895476_D3746E4A-E07A-4CB9-90BF-ECC5CBC77FC7_4002_8">0</us-gaap:AssetsFairValueDisclosure> <us-gaap:AssetsFairValueDisclosure contextRef="eol_PE151383--1410-K0012_STD_0_20131231_0_1269038x1269048_1275669x1277587_1275672x1274022" unitRef="iso4217_USD" decimals="-3" id="id_6895476_D3746E4A-E07A-4CB9-90BF-ECC5CBC77FC7_5002_7">0</us-gaap:AssetsFairValueDisclosure> <us-gaap:AssetsFairValueDisclosure contextRef="eol_PE151383--1410-K0012_STD_0_20131231_0_1269038x1269048_1275672x1274022" unitRef="iso4217_USD" decimals="-3" id="id_6895476_D3746E4A-E07A-4CB9-90BF-ECC5CBC77FC7_1002_12">0</us-gaap:AssetsFairValueDisclosure> <us-gaap:AssetsFairValueDisclosure contextRef="eol_PE151383--1410-K0012_STD_0_20131231_0_1269038x1269048_1275672x1274022_1278604x1435842" unitRef="iso4217_USD" decimals="-3" id="id_6895476_D3746E4A-E07A-4CB9-90BF-ECC5CBC77FC7_6002_11">0</us-gaap:AssetsFairValueDisclosure> <us-gaap:AssetsFairValueDisclosure contextRef="eol_PE151383--1410-K0012_STD_0_20131231_0_1269038x1272304_1274212x1280237_1275672x1274022" unitRef="iso4217_USD" decimals="-3" id="id_6895476_D3746E4A-E07A-4CB9-90BF-ECC5CBC77FC7_2001_9">15858000</us-gaap:AssetsFairValueDisclosure> <us-gaap:AssetsFairValueDisclosure contextRef="eol_PE151383--1410-K0012_STD_0_20131231_0_1269038x1272304_1274607x1276380_1275672x1274022" unitRef="iso4217_USD" decimals="-3" id="id_6895476_D3746E4A-E07A-4CB9-90BF-ECC5CBC77FC7_3001_10">57570000</us-gaap:AssetsFairValueDisclosure> <us-gaap:AssetsFairValueDisclosure contextRef="eol_PE151383--1410-K0012_STD_0_20131231_0_1269038x1272304_1275669x1274813_1275672x1274022" unitRef="iso4217_USD" decimals="-3" id="id_6895476_D3746E4A-E07A-4CB9-90BF-ECC5CBC77FC7_4001_8">60072000</us-gaap:AssetsFairValueDisclosure> <us-gaap:AssetsFairValueDisclosure contextRef="eol_PE151383--1410-K0012_STD_0_20131231_0_1269038x1272304_1275669x1277587_1275672x1274022" unitRef="iso4217_USD" decimals="-3" id="id_6895476_D3746E4A-E07A-4CB9-90BF-ECC5CBC77FC7_5001_7">15858000</us-gaap:AssetsFairValueDisclosure> <us-gaap:AssetsFairValueDisclosure contextRef="eol_PE151383--1410-K0012_STD_0_20131231_0_1269038x1272304_1275672x1274022" unitRef="iso4217_USD" decimals="-3" id="id_6895476_D3746E4A-E07A-4CB9-90BF-ECC5CBC77FC7_1001_12">75930000</us-gaap:AssetsFairValueDisclosure> <us-gaap:AssetsFairValueDisclosure contextRef="eol_PE151383--1410-K0012_STD_0_20131231_0_1269038x1272304_1275672x1274022_1278604x1435842" unitRef="iso4217_USD" decimals="-3" id="id_6895476_D3746E4A-E07A-4CB9-90BF-ECC5CBC77FC7_6001_11">2502000</us-gaap:AssetsFairValueDisclosure> <us-gaap:AssetsFairValueDisclosureRecurring contextRef="eol_PE151383--1410-K0012_STD_0_20131231_0_1269038x1275680" unitRef="iso4217_USD" decimals="INF" id="id_6895476_81507991-A4C3-4B03-B481-7472E2A8A109_2002_1">0</us-gaap:AssetsFairValueDisclosureRecurring> <us-gaap:AssetsFairValueDisclosure contextRef="eol_PE151383--1410-K0012_STD_0_20131231_0_1269038x1275680_1274212x1280237_1275672x1274022" unitRef="iso4217_USD" decimals="-3" id="id_6895476_D3746E4A-E07A-4CB9-90BF-ECC5CBC77FC7_2003_9">0</us-gaap:AssetsFairValueDisclosure> <us-gaap:AssetsFairValueDisclosure contextRef="eol_PE151383--1410-K0012_STD_0_20131231_0_1269038x1275680_1274607x1276380_1275672x1274022" unitRef="iso4217_USD" decimals="-3" id="id_6895476_D3746E4A-E07A-4CB9-90BF-ECC5CBC77FC7_3003_10">0</us-gaap:AssetsFairValueDisclosure> <us-gaap:AssetsFairValueDisclosure contextRef="eol_PE151383--1410-K0012_STD_0_20131231_0_1269038x1275680_1275669x1274813_1275672x1274022" unitRef="iso4217_USD" decimals="-3" id="id_6895476_D3746E4A-E07A-4CB9-90BF-ECC5CBC77FC7_4003_8">0</us-gaap:AssetsFairValueDisclosure> <us-gaap:AssetsFairValueDisclosure contextRef="eol_PE151383--1410-K0012_STD_0_20131231_0_1269038x1275680_1275669x1277587_1275672x1274022" unitRef="iso4217_USD" decimals="-3" id="id_6895476_D3746E4A-E07A-4CB9-90BF-ECC5CBC77FC7_5003_7">0</us-gaap:AssetsFairValueDisclosure> <us-gaap:AssetsFairValueDisclosure contextRef="eol_PE151383--1410-K0012_STD_0_20131231_0_1269038x1275680_1275672x1274022" unitRef="iso4217_USD" decimals="-3" id="id_6895476_D3746E4A-E07A-4CB9-90BF-ECC5CBC77FC7_1003_12">0</us-gaap:AssetsFairValueDisclosure> <us-gaap:AssetsFairValueDisclosure contextRef="eol_PE151383--1410-K0012_STD_0_20131231_0_1269038x1275680_1275672x1274022_1278604x1435842" unitRef="iso4217_USD" decimals="-3" id="id_6895476_D3746E4A-E07A-4CB9-90BF-ECC5CBC77FC7_6003_11">0</us-gaap:AssetsFairValueDisclosure> <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue contextRef="eol_PE151383--1410-K0012_STD_0_20131231_0_1270313x1271210" unitRef="iso4217_USD_per_shares" decimals="2" id="id_6895476_4396C4E5-DD06-4003-A485-BA06C7D8368D_5001_8">6.00</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue> <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber contextRef="eol_PE151383--1410-K0012_STD_0_20131231_0_1270313x1271210" unitRef="shares" decimals="INF" id="id_6895476_9D5C22B2-CCEF-4AED-B18A-0ACE42E2B15B_5001_8">41663</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber> <us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax contextRef="eol_PE151383--1410-K0012_STD_0_20131231_0_1270365x1274813_1274212x1276380" unitRef="iso4217_USD" decimals="-3" id="id_6895476_5953821E-651A-43AE-83D1-8E91E00151B4_4005_2">7000</us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax> <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis contextRef="eol_PE151383--1410-K0012_STD_0_20131231_0_1270365x1274813_1274212x1276380" unitRef="iso4217_USD" decimals="-3" id="id_6895476_5953821E-651A-43AE-83D1-8E91E00151B4_4005_1">57564000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis> <us-gaap:AvailableForSaleSecurities contextRef="eol_PE151383--1410-K0012_STD_0_20131231_0_1270365x1274813_1274212x1276380" unitRef="iso4217_USD" decimals="-3" id="id_6895476_5953821E-651A-43AE-83D1-8E91E00151B4_4005_4">57570000</us-gaap:AvailableForSaleSecurities> <us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax contextRef="eol_PE151383--1410-K0012_STD_0_20131231_0_1270365x1274813_1274212x1276380" unitRef="iso4217_USD" decimals="-3" id="id_6895476_5953821E-651A-43AE-83D1-8E91E00151B4_4005_3">1000</us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax> <us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax contextRef="eol_PE151383--1410-K0012_STD_0_20131231_0_1270365x1274813_1274212x1435842" unitRef="iso4217_USD" decimals="-3" id="id_6895476_5953821E-651A-43AE-83D1-8E91E00151B4_4006_2">0</us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax> <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis contextRef="eol_PE151383--1410-K0012_STD_0_20131231_0_1270365x1274813_1274212x1435842" unitRef="iso4217_USD" decimals="-3" id="id_6895476_5953821E-651A-43AE-83D1-8E91E00151B4_4006_1">2502000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis> <us-gaap:AvailableForSaleSecurities contextRef="eol_PE151383--1410-K0012_STD_0_20131231_0_1270365x1274813_1274212x1435842" unitRef="iso4217_USD" decimals="-3" id="id_6895476_5953821E-651A-43AE-83D1-8E91E00151B4_4006_4">2502000</us-gaap:AvailableForSaleSecurities> <us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax contextRef="eol_PE151383--1410-K0012_STD_0_20131231_0_1270365x1274813_1274212x1435842" unitRef="iso4217_USD" decimals="-3" id="id_6895476_5953821E-651A-43AE-83D1-8E91E00151B4_4006_3">0</us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax> <us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax contextRef="eol_PE151383--1410-K0012_STD_0_20131231_0_1270365x1277587_1274212x1270374" unitRef="iso4217_USD" decimals="-3" id="id_6895476_5953821E-651A-43AE-83D1-8E91E00151B4_4004_2">0</us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax> <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis contextRef="eol_PE151383--1410-K0012_STD_0_20131231_0_1270365x1277587_1274212x1270374" unitRef="iso4217_USD" decimals="-3" id="id_6895476_5953821E-651A-43AE-83D1-8E91E00151B4_4004_1">15858000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis> <us-gaap:AvailableForSaleSecurities contextRef="eol_PE151383--1410-K0012_STD_0_20131231_0_1270365x1277587_1274212x1270374" unitRef="iso4217_USD" decimals="-3" id="id_6895476_5953821E-651A-43AE-83D1-8E91E00151B4_4004_4">15858000</us-gaap:AvailableForSaleSecurities> <us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax contextRef="eol_PE151383--1410-K0012_STD_0_20131231_0_1270365x1277587_1274212x1270374" unitRef="iso4217_USD" decimals="-3" id="id_6895476_5953821E-651A-43AE-83D1-8E91E00151B4_4004_3">0</us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax> <us-gaap:AssetsFairValueDisclosure contextRef="eol_PE151383--1410-K0012_STD_0_20131231_0_1274212x1280237_1275672x1274022" unitRef="iso4217_USD" decimals="-3" id="id_6895476_D3746E4A-E07A-4CB9-90BF-ECC5CBC77FC7_2004_9">15858000</us-gaap:AssetsFairValueDisclosure> <us-gaap:AssetsFairValueDisclosure contextRef="eol_PE151383--1410-K0012_STD_0_20131231_0_1274607x1276380_1275672x1274022" unitRef="iso4217_USD" decimals="-3" id="id_6895476_D3746E4A-E07A-4CB9-90BF-ECC5CBC77FC7_3004_10">57570000</us-gaap:AssetsFairValueDisclosure> <us-gaap:AssetsFairValueDisclosure contextRef="eol_PE151383--1410-K0012_STD_0_20131231_0_1275669x1274813_1275672x1274022" unitRef="iso4217_USD" decimals="-3" id="id_6895476_D3746E4A-E07A-4CB9-90BF-ECC5CBC77FC7_4004_8">60072000</us-gaap:AssetsFairValueDisclosure> <us-gaap:AssetsFairValueDisclosure contextRef="eol_PE151383--1410-K0012_STD_0_20131231_0_1275669x1277587_1275672x1274022" unitRef="iso4217_USD" decimals="-3" id="id_6895476_D3746E4A-E07A-4CB9-90BF-ECC5CBC77FC7_5004_7">15858000</us-gaap:AssetsFairValueDisclosure> <us-gaap:AssetsFairValueDisclosure contextRef="eol_PE151383--1410-K0012_STD_0_20131231_0_1275672x1274022" unitRef="iso4217_USD" decimals="-3" id="id_6895476_D3746E4A-E07A-4CB9-90BF-ECC5CBC77FC7_1004_12">75930000</us-gaap:AssetsFairValueDisclosure> <us-gaap:AssetsFairValueDisclosure contextRef="eol_PE151383--1410-K0012_STD_0_20131231_0_1275672x1274022_1278604x1435842" unitRef="iso4217_USD" decimals="-3" id="id_6895476_D3746E4A-E07A-4CB9-90BF-ECC5CBC77FC7_6004_11">2502000</us-gaap:AssetsFairValueDisclosure> <us-gaap:PropertyPlantAndEquipmentGross contextRef="eol_PE151383--1410-K0012_STD_0_20131231_0_1276136x1280724" unitRef="iso4217_USD" decimals="-3" id="id_6895476_113D1BB7-2EFC-40A3-A61B-C5BE96CD52A4_1002_4">3297000</us-gaap:PropertyPlantAndEquipmentGross> <us-gaap:PropertyPlantAndEquipmentGross contextRef="eol_PE151383--1410-K0012_STD_0_20131231_0_1276136x1329743" unitRef="iso4217_USD" decimals="-3" id="id_6895476_113D1BB7-2EFC-40A3-A61B-C5BE96CD52A4_2002_3">1050000</us-gaap:PropertyPlantAndEquipmentGross> <us-gaap:PropertyPlantAndEquipmentGross contextRef="eol_PE151383--1410-K0012_STD_0_20131231_0_1276136x1362982" unitRef="iso4217_USD" decimals="-3" id="id_6895476_113D1BB7-2EFC-40A3-A61B-C5BE96CD52A4_3002_2">2549000</us-gaap:PropertyPlantAndEquipmentGross> <us-gaap:PropertyPlantAndEquipmentGross contextRef="eol_PE151383--1410-K0012_STD_0_20131231_0_1276136x1457720" unitRef="iso4217_USD" decimals="-3" id="id_6895476_113D1BB7-2EFC-40A3-A61B-C5BE96CD52A4_4002_1">15317000</us-gaap:PropertyPlantAndEquipmentGross> <us-gaap:PreferredStockSharesOutstanding contextRef="eol_PE151383--1410-K0012_STD_0_20131231_0_1276400x1269676" unitRef="shares" decimals="INF" id="id_6895476_415AC1F8-2710-4285-9D91-1A668F81A543_1002_27">0</us-gaap:PreferredStockSharesOutstanding> <us-gaap:PreferredStockSharesIssued contextRef="eol_PE151383--1410-K0012_STD_0_20131231_0_1276400x1269676" unitRef="shares" decimals="INF" id="id_6895476_415AC1F8-2710-4285-9D91-1A668F81A543_1002_26">0</us-gaap:PreferredStockSharesIssued> <us-gaap:PreferredStockValue contextRef="eol_PE151383--1410-K0012_STD_0_20131231_0_1276400x1269676" unitRef="iso4217_USD" decimals="-3" id="id_6895476_415AC1F8-2710-4285-9D91-1A668F81A543_1002_25">0</us-gaap:PreferredStockValue> <us-gaap:StockholdersEquity contextRef="eol_PE151383--1410-K0012_STD_0_20131231_0_1276401x1268669" unitRef="iso4217_USD" decimals="-3" id="id_6895476_58E9B802-84A6-48EC-8C22-C0DD0182E686_8006_58">7000</us-gaap:StockholdersEquity> <us-gaap:StockholdersEquity contextRef="eol_PE151383--1410-K0012_STD_0_20131231_0_1276401x1269588" unitRef="iso4217_USD" decimals="-3" id="id_6895476_58E9B802-84A6-48EC-8C22-C0DD0182E686_8007_58">-482597000</us-gaap:StockholdersEquity> <us-gaap:SharesOutstanding contextRef="eol_PE151383--1410-K0012_STD_0_20131231_0_1276401x1270422" unitRef="shares" decimals="INF" id="id_6895476_58E9B802-84A6-48EC-8C22-C0DD0182E686_8001_59">30681624</us-gaap:SharesOutstanding> <us-gaap:StockholdersEquity contextRef="eol_PE151383--1410-K0012_STD_0_20131231_0_1276401x1270422" unitRef="iso4217_USD" decimals="-3" id="id_6895476_58E9B802-84A6-48EC-8C22-C0DD0182E686_8001_58">31000</us-gaap:StockholdersEquity> <us-gaap:StockholdersEquity contextRef="eol_PE151383--1410-K0012_STD_0_20131231_0_1276401x1273630" unitRef="iso4217_USD" decimals="-3" id="id_6895476_58E9B802-84A6-48EC-8C22-C0DD0182E686_8005_58">537001000</us-gaap:StockholdersEquity> <us-gaap:AccountsReceivableRelatedParties contextRef="eol_PE151383--1410-K0012_STD_0_20131231_0_1279431x1424859" unitRef="iso4217_USD" decimals="-5" id="id_6895476_D076CC70-CB7C-4170-BD50-2E3EFE86EE58_2002_1">0</us-gaap:AccountsReceivableRelatedParties> <us-gaap:ValuationAllowancesAndReservesBalance contextRef="eol_PE151383--1410-K0012_STD_0_20131231_0_1279936x1276697" unitRef="iso4217_USD" decimals="-3" id="id_6895476_B444ABAD-A3F0-45D1-A8D2-D991236372AC_2002_1">203863000</us-gaap:ValuationAllowancesAndReservesBalance> <us-gaap:UnrecognizedTaxBenefits contextRef="eol_PE151383--1410-K0012_STD_0_20131231_0_1280651x1297583" unitRef="iso4217_USD" decimals="-3" id="id_6895476_7B98D2F9-CACB-495E-A3F9-A79C5892451D_3002_4">1209000</us-gaap:UnrecognizedTaxBenefits> <us-gaap:UnrecognizedTaxBenefits contextRef="eol_PE151383--1410-K0012_STD_0_20131231_0_1280651x1497867" unitRef="iso4217_USD" decimals="-3" id="id_6895476_7B98D2F9-CACB-495E-A3F9-A79C5892451D_3003_4">4962000</us-gaap:UnrecognizedTaxBenefits> <us-gaap:UnrecognizedTaxBenefits contextRef="eol_PE151383--1410-K0012_STD_0_20131231_0_1280651x1520580" unitRef="iso4217_USD" decimals="-3" id="id_6895476_7B98D2F9-CACB-495E-A3F9-A79C5892451D_3001_4">6171000</us-gaap:UnrecognizedTaxBenefits> <us-gaap:AccountsReceivableRelatedParties contextRef="eol_PE151383--1410-K0012_STD_0_20131231_0_1281318x1434297" unitRef="iso4217_USD" decimals="-5" id="id_6895476_B1D541CA-9025-4D78-9ABD-27AABA32983C_2002_1">0</us-gaap:AccountsReceivableRelatedParties> <us-gaap:CommonStockSharesIssued contextRef="eol_PE151383--1410-K0012_STD_0_20141231_0" unitRef="shares" decimals="INF" id="id_6895476_415AC1F8-2710-4285-9D91-1A668F81A543_1_31">38659738</us-gaap:CommonStockSharesIssued> <us-gaap:CommonStockSharesOutstanding contextRef="eol_PE151383--1410-K0012_STD_0_20141231_0" unitRef="shares" decimals="INF" id="id_6895476_415AC1F8-2710-4285-9D91-1A668F81A543_1_32">38659738</us-gaap:CommonStockSharesOutstanding> <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber contextRef="eol_PE151383--1410-K0012_STD_0_20141231_0" unitRef="shares" decimals="INF" id="id_6895476_EAE02EAA-C88A-417D-A4E8-6DD5ADADA4AB_10001_21">3277489</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber> <us-gaap:CommonStockSharesAuthorized contextRef="eol_PE151383--1410-K0012_STD_0_20141231_0" unitRef="shares" decimals="INF" id="id_6895476_415AC1F8-2710-4285-9D91-1A668F81A543_1_30">81500000</us-gaap:CommonStockSharesAuthorized> <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice contextRef="eol_PE151383--1410-K0012_STD_0_20141231_0" unitRef="iso4217_USD_per_shares" decimals="2" id="id_6895476_C3206D70-DEC9-4565-9145-8B70956A712D_9001_17">12.62</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice> <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber contextRef="eol_PE151383--1410-K0012_STD_0_20141231_0" unitRef="shares" decimals="INF" id="id_6895476_EAE02EAA-C88A-417D-A4E8-6DD5ADADA4AB_10001_20">2140754</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber> <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice contextRef="eol_PE151383--1410-K0012_STD_0_20141231_0" unitRef="iso4217_USD_per_shares" decimals="2" id="id_6895476_C3206D70-DEC9-4565-9145-8B70956A712D_9001_18">15.17</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice> <us-gaap:SharePrice contextRef="eol_PE151383--1410-K0012_STD_0_20141231_0" unitRef="iso4217_USD_per_shares" decimals="INF" id="id_6895476_58E9B802-84A6-48EC-8C22-C0DD0182E686_12008_81">8</us-gaap:SharePrice> <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice contextRef="eol_PE151383--1410-K0012_STD_0_20141231_0" unitRef="iso4217_USD_per_shares" decimals="2" id="id_6895476_C3206D70-DEC9-4565-9145-8B70956A712D_9001_19">12.64</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice> <us-gaap:CommonStockParOrStatedValuePerShare contextRef="eol_PE151383--1410-K0012_STD_0_20141231_0" unitRef="iso4217_USD_per_shares" decimals="INF" id="id_6895476_415AC1F8-2710-4285-9D91-1A668F81A543_1_29">0.001</us-gaap:CommonStockParOrStatedValuePerShare> <us-gaap:PreferredStockSharesAuthorized contextRef="eol_PE151383--1410-K0012_STD_0_20141231_0" unitRef="shares" decimals="INF" id="id_6895476_415AC1F8-2710-4285-9D91-1A668F81A543_1_24">10000000</us-gaap:PreferredStockSharesAuthorized> <us-gaap:PreferredStockParOrStatedValuePerShare contextRef="eol_PE151383--1410-K0012_STD_0_20141231_0" unitRef="iso4217_USD_per_shares" decimals="INF" id="id_6895476_415AC1F8-2710-4285-9D91-1A668F81A543_1_23">0.001</us-gaap:PreferredStockParOrStatedValuePerShare> <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant contextRef="eol_PE151383--1410-K0012_STD_0_20141231_0" unitRef="shares" decimals="INF" id="id_6895476_550670F2-8019-4594-8D89-8D38F90A7B79_9001_19">1270478</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant> <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="eol_PE151383--1410-K0012_STD_0_20141231_0" unitRef="shares" decimals="INF" id="id_6895476_EAE02EAA-C88A-417D-A4E8-6DD5ADADA4AB_10001_19">3297826</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber> <us-gaap:DeferredTaxAssetsValuationAllowance contextRef="eol_PE151383--1410-K0012_STD_0_20141231_0" unitRef="iso4217_USD" decimals="-3" id="id_6895476_4672B4FA-1C38-4D80-B654-6FAD4B61F0BF_1001_7">204900000</us-gaap:DeferredTaxAssetsValuationAllowance> <us-gaap:DeferredRevenueNoncurrent contextRef="eol_PE151383--1410-K0012_STD_0_20141231_0" unitRef="iso4217_USD" decimals="-3" id="id_6895476_415AC1F8-2710-4285-9D91-1A668F81A543_1_18">16558000</us-gaap:DeferredRevenueNoncurrent> <us-gaap:DeferredRentCreditCurrent contextRef="eol_PE151383--1410-K0012_STD_0_20141231_0" unitRef="iso4217_USD" decimals="-3" id="id_6895476_415AC1F8-2710-4285-9D91-1A668F81A543_1_16">52000</us-gaap:DeferredRentCreditCurrent> <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment contextRef="eol_PE151383--1410-K0012_STD_0_20141231_0" unitRef="iso4217_USD" decimals="-3" id="id_6895476_113D1BB7-2EFC-40A3-A61B-C5BE96CD52A4_1_6">20327000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment> <us-gaap:AccruedVacationCurrent contextRef="eol_PE151383--1410-K0012_STD_0_20141231_0" unitRef="iso4217_USD" decimals="-3" id="id_6895476_D457422F-4655-455B-8BCE-756F9E020BF2_1_4">915000</us-gaap:AccruedVacationCurrent> <us-gaap:OperatingLeasesFutureMinimumPaymentsDueThereafter contextRef="eol_PE151383--1410-K0012_STD_0_20141231_0" unitRef="iso4217_USD" decimals="-3" id="id_6895476_15E66D59-C8F3-4B24-A406-43DCC5F5C3F5_1_5">0</us-gaap:OperatingLeasesFutureMinimumPaymentsDueThereafter> <us-gaap:LiabilitiesCurrent contextRef="eol_PE151383--1410-K0012_STD_0_20141231_0" unitRef="iso4217_USD" decimals="-3" id="id_6895476_415AC1F8-2710-4285-9D91-1A668F81A543_1_17">23855000</us-gaap:LiabilitiesCurrent> <us-gaap:AccruedBonusesCurrent contextRef="eol_PE151383--1410-K0012_STD_0_20141231_0" unitRef="iso4217_USD" decimals="-3" id="id_6895476_D457422F-4655-455B-8BCE-756F9E020BF2_1_3">2665000</us-gaap:AccruedBonusesCurrent> <us-gaap:UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate contextRef="eol_PE151383--1410-K0012_STD_0_20141231_0" unitRef="iso4217_USD" decimals="-5" id="id_6895476_7D9A8A58-B70E-4462-8AC6-5461D478452D_1001_0">5100000</us-gaap:UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate> <us-gaap:IncomeTaxExaminationPenaltiesAndInterestAccrued contextRef="eol_PE151383--1410-K0012_STD_0_20141231_0" unitRef="iso4217_USD" decimals="INF" id="id_6895476_D97313CD-F829-4052-9EAB-BF6B1F4928E9_1001_0">0</us-gaap:IncomeTaxExaminationPenaltiesAndInterestAccrued> <us-gaap:CommonStockValue contextRef="eol_PE151383--1410-K0012_STD_0_20141231_0" unitRef="iso4217_USD" decimals="-3" id="id_6895476_415AC1F8-2710-4285-9D91-1A668F81A543_1_28">39000</us-gaap:CommonStockValue> <us-gaap:CommitmentsAndContingencies contextRef="eol_PE151383--1410-K0012_STD_0_20141231_0" unitRef="iso4217_USD" xsi:nil="true" id="id_6895476_415AC1F8-2710-4285-9D91-1A668F81A543_1_21" /> <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax contextRef="eol_PE151383--1410-K0012_STD_0_20141231_0" unitRef="iso4217_USD" decimals="-3" id="id_6895476_415AC1F8-2710-4285-9D91-1A668F81A543_1_34">-4000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax> <us-gaap:AccountsPayableCurrent contextRef="eol_PE151383--1410-K0012_STD_0_20141231_0" unitRef="iso4217_USD" decimals="-3" id="id_6895476_415AC1F8-2710-4285-9D91-1A668F81A543_1_13">1361000</us-gaap:AccountsPayableCurrent> <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="eol_PE151383--1410-K0012_STD_0_20141231_0" unitRef="iso4217_USD" decimals="-3" id="id_6895476_415AC1F8-2710-4285-9D91-1A668F81A543_1_35">-497243000</us-gaap:RetainedEarningsAccumulatedDeficit> <us-gaap:OperatingLeasesFutureMinimumPaymentsDueInFourYears contextRef="eol_PE151383--1410-K0012_STD_0_20141231_0" unitRef="iso4217_USD" decimals="-3" id="id_6895476_15E66D59-C8F3-4B24-A406-43DCC5F5C3F5_1_3">1860000</us-gaap:OperatingLeasesFutureMinimumPaymentsDueInFourYears> <us-gaap:AccruedLiabilitiesCurrent contextRef="eol_PE151383--1410-K0012_STD_0_20141231_0" unitRef="iso4217_USD" decimals="-3" id="id_6895476_415AC1F8-2710-4285-9D91-1A668F81A543_1_14">5400000</us-gaap:AccruedLiabilitiesCurrent> <us-gaap:StockholdersEquity contextRef="eol_PE151383--1410-K0012_STD_0_20141231_0" unitRef="iso4217_USD" decimals="-3" id="id_6895476_415AC1F8-2710-4285-9D91-1A668F81A543_1_36">92064000</us-gaap:StockholdersEquity> <us-gaap:OtherAccruedLiabilitiesCurrent contextRef="eol_PE151383--1410-K0012_STD_0_20141231_0" unitRef="iso4217_USD" decimals="-3" id="id_6895476_D457422F-4655-455B-8BCE-756F9E020BF2_1_6">317000</us-gaap:OtherAccruedLiabilitiesCurrent> <us-gaap:OperatingLeasesFutureMinimumPaymentsDue contextRef="eol_PE151383--1410-K0012_STD_0_20141231_0" unitRef="iso4217_USD" decimals="-3" id="id_6895476_15E66D59-C8F3-4B24-A406-43DCC5F5C3F5_1_6">12380000</us-gaap:OperatingLeasesFutureMinimumPaymentsDue> <us-gaap:OperatingLeasesFutureMinimumPaymentsDueInFiveYears contextRef="eol_PE151383--1410-K0012_STD_0_20141231_0" unitRef="iso4217_USD" decimals="-3" id="id_6895476_15E66D59-C8F3-4B24-A406-43DCC5F5C3F5_1_4">0</us-gaap:OperatingLeasesFutureMinimumPaymentsDueInFiveYears> <us-gaap:OperatingLeasesFutureMinimumPaymentsDueInThreeYears contextRef="eol_PE151383--1410-K0012_STD_0_20141231_0" unitRef="iso4217_USD" decimals="-3" id="id_6895476_15E66D59-C8F3-4B24-A406-43DCC5F5C3F5_1_2">3626000</us-gaap:OperatingLeasesFutureMinimumPaymentsDueInThreeYears> <us-gaap:LiabilitiesAndStockholdersEquity contextRef="eol_PE151383--1410-K0012_STD_0_20141231_0" unitRef="iso4217_USD" decimals="-3" id="id_6895476_415AC1F8-2710-4285-9D91-1A668F81A543_1_37">132968000</us-gaap:LiabilitiesAndStockholdersEquity> <us-gaap:AdditionalPaidInCapital contextRef="eol_PE151383--1410-K0012_STD_0_20141231_0" unitRef="iso4217_USD" decimals="-3" id="id_6895476_415AC1F8-2710-4285-9D91-1A668F81A543_1_33">589272000</us-gaap:AdditionalPaidInCapital> <us-gaap:AccruedProfessionalFeesCurrent contextRef="eol_PE151383--1410-K0012_STD_0_20141231_0" unitRef="iso4217_USD" decimals="-3" id="id_6895476_D457422F-4655-455B-8BCE-756F9E020BF2_1_2">421000</us-gaap:AccruedProfessionalFeesCurrent> <us-gaap:DeferredRevenueCurrent contextRef="eol_PE151383--1410-K0012_STD_0_20141231_0" unitRef="iso4217_USD" decimals="-3" id="id_6895476_415AC1F8-2710-4285-9D91-1A668F81A543_1_15">17042000</us-gaap:DeferredRevenueCurrent> <us-gaap:OtherEmployeeRelatedLiabilitiesCurrent contextRef="eol_PE151383--1410-K0012_STD_0_20141231_0" unitRef="iso4217_USD" decimals="-3" id="id_6895476_D457422F-4655-455B-8BCE-756F9E020BF2_1_5">110000</us-gaap:OtherEmployeeRelatedLiabilitiesCurrent> <us-gaap:OperatingLeasesFutureMinimumPaymentsDueInTwoYears contextRef="eol_PE151383--1410-K0012_STD_0_20141231_0" unitRef="iso4217_USD" decimals="-3" id="id_6895476_15E66D59-C8F3-4B24-A406-43DCC5F5C3F5_1_1">3504000</us-gaap:OperatingLeasesFutureMinimumPaymentsDueInTwoYears> <us-gaap:LineOfCredit contextRef="eol_PE151383--1410-K0012_STD_0_20141231_0" unitRef="iso4217_USD" decimals="INF" id="id_6895476_4EE30960-F1F9-4223-95C9-EFB9AB540D3E_2_0">0</us-gaap:LineOfCredit> <us-gaap:Liabilities contextRef="eol_PE151383--1410-K0012_STD_0_20141231_0" unitRef="iso4217_USD" decimals="-3" id="id_6895476_415AC1F8-2710-4285-9D91-1A668F81A543_1_20">40904000</us-gaap:Liabilities> <us-gaap:DeferredRentCreditNoncurrent contextRef="eol_PE151383--1410-K0012_STD_0_20141231_0" unitRef="iso4217_USD" decimals="-3" id="id_6895476_415AC1F8-2710-4285-9D91-1A668F81A543_1_19">491000</us-gaap:DeferredRentCreditNoncurrent> <us-gaap:OperatingLeasesFutureMinimumPaymentsDueCurrent contextRef="eol_PE151383--1410-K0012_STD_0_20141231_0" unitRef="iso4217_USD" decimals="-3" id="id_6895476_15E66D59-C8F3-4B24-A406-43DCC5F5C3F5_1_0">3390000</us-gaap:OperatingLeasesFutureMinimumPaymentsDueCurrent> <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="eol_PE151383--1410-K0012_STD_0_20141231_0" unitRef="iso4217_USD" decimals="-3" id="id_6895476_415AC1F8-2710-4285-9D91-1A668F81A543_1_2">20215000</us-gaap:CashAndCashEquivalentsAtCarryingValue> <us-gaap:PropertyPlantAndEquipmentNet contextRef="eol_PE151383--1410-K0012_STD_0_20141231_0" unitRef="iso4217_USD" decimals="-3" id="id_6895476_415AC1F8-2710-4285-9D91-1A668F81A543_1_7">1637000</us-gaap:PropertyPlantAndEquipmentNet> <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue contextRef="eol_PE151383--1410-K0012_STD_0_20141231_0" unitRef="iso4217_USD" decimals="-3" id="id_6895476_9E1BFA4C-FA98-45D3-8FCE-5ADCB8D3B92C_1001_1">2657000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue> <us-gaap:DeferredTaxAssetsGross contextRef="eol_PE151383--1410-K0012_STD_0_20141231_0" unitRef="iso4217_USD" decimals="-3" id="id_6895476_4672B4FA-1C38-4D80-B654-6FAD4B61F0BF_1001_6">204900000</us-gaap:DeferredTaxAssetsGross> <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue contextRef="eol_PE151383--1410-K0012_STD_0_20141231_0" unitRef="iso4217_USD" decimals="-3" id="id_6895476_9E1BFA4C-FA98-45D3-8FCE-5ADCB8D3B92C_1001_3">2642000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue> <us-gaap:AccountsReceivableRelatedPartiesCurrent contextRef="eol_PE151383--1410-K0012_STD_0_20141231_0" unitRef="iso4217_USD" decimals="-3" id="id_6895476_415AC1F8-2710-4285-9D91-1A668F81A543_1_4">46646000</us-gaap:AccountsReceivableRelatedPartiesCurrent> <us-gaap:PropertyPlantAndEquipmentGross contextRef="eol_PE151383--1410-K0012_STD_0_20141231_0" unitRef="iso4217_USD" decimals="-3" id="id_6895476_113D1BB7-2EFC-40A3-A61B-C5BE96CD52A4_1_5">21964000</us-gaap:PropertyPlantAndEquipmentGross> <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1 contextRef="eol_PE151383--1410-K0012_STD_0_20141231_0" unitRef="iso4217_USD" decimals="-3" id="id_6895476_9E1BFA4C-FA98-45D3-8FCE-5ADCB8D3B92C_1001_2">1553000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1> <us-gaap:CashCashEquivalentsAndShortTermInvestments contextRef="eol_PE151383--1410-K0012_STD_0_20141231_0" unitRef="iso4217_USD" decimals="-5" id="id_6895476_5F9E7FBE-865B-4206-B2D7-3FAAEF82FB92_2_3">83200000</us-gaap:CashCashEquivalentsAndShortTermInvestments> <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards contextRef="eol_PE151383--1410-K0012_STD_0_20141231_0" unitRef="iso4217_USD" decimals="-3" id="id_6895476_4672B4FA-1C38-4D80-B654-6FAD4B61F0BF_1001_4">148184000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards> <us-gaap:LongTermInvestments contextRef="eol_PE151383--1410-K0012_STD_0_20141231_0" unitRef="iso4217_USD" decimals="-3" id="id_6895476_415AC1F8-2710-4285-9D91-1A668F81A543_1_8">0</us-gaap:LongTermInvestments> <us-gaap:Assets contextRef="eol_PE151383--1410-K0012_STD_0_20141231_0" unitRef="iso4217_USD" decimals="-3" id="id_6895476_415AC1F8-2710-4285-9D91-1A668F81A543_1_10">132968000</us-gaap:Assets> <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent contextRef="eol_PE151383--1410-K0012_STD_0_20141231_0" unitRef="iso4217_USD" decimals="-3" id="id_6895476_415AC1F8-2710-4285-9D91-1A668F81A543_1_3">63013000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent> <us-gaap:DeferredTaxAssetsNet contextRef="eol_PE151383--1410-K0012_STD_0_20141231_0" unitRef="iso4217_USD" decimals="-3" id="id_6895476_4672B4FA-1C38-4D80-B654-6FAD4B61F0BF_1001_8">0</us-gaap:DeferredTaxAssetsNet> <us-gaap:InterestReceivable contextRef="eol_PE151383--1410-K0012_STD_0_20141231_0" unitRef="iso4217_USD" decimals="0" id="id_6895476_8D329B4F-AC7D-4E87-82A9-04734BCBFBD3_1_0">109000</us-gaap:InterestReceivable> <us-gaap:AvailableForSaleSecuritiesContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss contextRef="eol_PE151383--1410-K0012_STD_0_20141231_0" unitRef="iso4217_USD" decimals="INF" id="id_6895476_FC5D6B10-2950-4D77-93DA-2D46C596CBF7_3001_1">0</us-gaap:AvailableForSaleSecuritiesContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss> <us-gaap:DeferredTaxAssetsTaxCreditCarryforwards contextRef="eol_PE151383--1410-K0012_STD_0_20141231_0" unitRef="iso4217_USD" decimals="-3" id="id_6895476_4672B4FA-1C38-4D80-B654-6FAD4B61F0BF_1001_5">34543000</us-gaap:DeferredTaxAssetsTaxCreditCarryforwards> <us-gaap:OtherAssetsCurrent contextRef="eol_PE151383--1410-K0012_STD_0_20141231_0" unitRef="iso4217_USD" decimals="-3" id="id_6895476_415AC1F8-2710-4285-9D91-1A668F81A543_1_5">1257000</us-gaap:OtherAssetsCurrent> <us-gaap:OtherAssetsNoncurrent contextRef="eol_PE151383--1410-K0012_STD_0_20141231_0" unitRef="iso4217_USD" decimals="-3" id="id_6895476_415AC1F8-2710-4285-9D91-1A668F81A543_1_9">200000</us-gaap:OtherAssetsNoncurrent> <us-gaap:AssetsCurrent contextRef="eol_PE151383--1410-K0012_STD_0_20141231_0" unitRef="iso4217_USD" decimals="-3" id="id_6895476_415AC1F8-2710-4285-9D91-1A668F81A543_1_6">131131000</us-gaap:AssetsCurrent> <us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals contextRef="eol_PE151383--1410-K0012_STD_0_20141231_0" unitRef="iso4217_USD" decimals="-3" id="id_6895476_4672B4FA-1C38-4D80-B654-6FAD4B61F0BF_1001_3">6217000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals> <cytk:DeferredTaxAssetsCapitalizedResearchAndDevelopment contextRef="eol_PE151383--1410-K0012_STD_0_20141231_0" unitRef="iso4217_USD" decimals="-3" id="id_6895476_4672B4FA-1C38-4D80-B654-6FAD4B61F0BF_1001_2">15176000</cytk:DeferredTaxAssetsCapitalizedResearchAndDevelopment> <cytk:AccruedClinicalAndPreclinicalCostsCurrent contextRef="eol_PE151383--1410-K0012_STD_0_20141231_0" unitRef="iso4217_USD" decimals="-3" id="id_6895476_D457422F-4655-455B-8BCE-756F9E020BF2_1_1">972000</cytk:AccruedClinicalAndPreclinicalCostsCurrent> <cytk:NumberOfFinancialInstitutions contextRef="eol_PE151383--1410-K0012_STD_0_20141231_0" unitRef="Financial_Institution" decimals="INF" id="id_6895476_906BA3A0-8C8C-4AE0-921B-667A6A3C36A0_1001_0">3</cytk:NumberOfFinancialInstitutions> <cytk:DeferredTaxAssetsDepreciationAndAmortization contextRef="eol_PE151383--1410-K0012_STD_0_20141231_0" unitRef="iso4217_USD" decimals="-3" id="id_6895476_4672B4FA-1C38-4D80-B654-6FAD4B61F0BF_1001_1">780000</cytk:DeferredTaxAssetsDepreciationAndAmortization> <us-gaap:AssetsFairValueDisclosureRecurring contextRef="eol_PE151383--1410-K0012_STD_0_20141231_0_1269038x1269048" unitRef="iso4217_USD" decimals="INF" id="id_6895476_81507991-A4C3-4B03-B481-7472E2A8A109_1001_0">0</us-gaap:AssetsFairValueDisclosureRecurring> <us-gaap:AssetsFairValueDisclosure contextRef="eol_PE151383--1410-K0012_STD_0_20141231_0_1269038x1269048_1274212x1280237_1275672x1274022" unitRef="iso4217_USD" decimals="-3" id="id_6895476_D3746E4A-E07A-4CB9-90BF-ECC5CBC77FC7_9002_3">0</us-gaap:AssetsFairValueDisclosure> <us-gaap:AssetsFairValueDisclosure contextRef="eol_PE151383--1410-K0012_STD_0_20141231_0_1269038x1269048_1274607x1276380_1275672x1274022" unitRef="iso4217_USD" decimals="-3" id="id_6895476_D3746E4A-E07A-4CB9-90BF-ECC5CBC77FC7_10002_4">0</us-gaap:AssetsFairValueDisclosure> <us-gaap:AssetsFairValueDisclosure contextRef="eol_PE151383--1410-K0012_STD_0_20141231_0_1269038x1269048_1275669x1274813_1275672x1274022" unitRef="iso4217_USD" decimals="-3" id="id_6895476_D3746E4A-E07A-4CB9-90BF-ECC5CBC77FC7_11002_2">0</us-gaap:AssetsFairValueDisclosure> <us-gaap:AssetsFairValueDisclosure contextRef="eol_PE151383--1410-K0012_STD_0_20141231_0_1269038x1269048_1275669x1277587_1275672x1274022" unitRef="iso4217_USD" decimals="-3" id="id_6895476_D3746E4A-E07A-4CB9-90BF-ECC5CBC77FC7_12002_1">0</us-gaap:AssetsFairValueDisclosure> <us-gaap:AssetsFairValueDisclosure contextRef="eol_PE151383--1410-K0012_STD_0_20141231_0_1269038x1269048_1275672x1274022" unitRef="iso4217_USD" decimals="-3" id="id_6895476_D3746E4A-E07A-4CB9-90BF-ECC5CBC77FC7_7002_6">0</us-gaap:AssetsFairValueDisclosure> <us-gaap:AssetsFairValueDisclosure contextRef="eol_PE151383--1410-K0012_STD_0_20141231_0_1269038x1269048_1275672x1274022_1278604x1435842" unitRef="iso4217_USD" decimals="-3" id="id_6895476_D3746E4A-E07A-4CB9-90BF-ECC5CBC77FC7_13002_5">0</us-gaap:AssetsFairValueDisclosure> <us-gaap:AssetsFairValueDisclosure contextRef="eol_PE151383--1410-K0012_STD_0_20141231_0_1269038x1272304_1274212x1280237_1275672x1274022" unitRef="iso4217_USD" decimals="-3" id="id_6895476_D3746E4A-E07A-4CB9-90BF-ECC5CBC77FC7_9001_3">16932000</us-gaap:AssetsFairValueDisclosure> <us-gaap:AssetsFairValueDisclosure contextRef="eol_PE151383--1410-K0012_STD_0_20141231_0_1269038x1272304_1274607x1276380_1275672x1274022" unitRef="iso4217_USD" decimals="-3" id="id_6895476_D3746E4A-E07A-4CB9-90BF-ECC5CBC77FC7_10001_4">63013000</us-gaap:AssetsFairValueDisclosure> <us-gaap:AssetsFairValueDisclosure contextRef="eol_PE151383--1410-K0012_STD_0_20141231_0_1269038x1272304_1275669x1274813_1275672x1274022" unitRef="iso4217_USD" decimals="-3" id="id_6895476_D3746E4A-E07A-4CB9-90BF-ECC5CBC77FC7_11001_2">63013000</us-gaap:AssetsFairValueDisclosure> <us-gaap:AssetsFairValueDisclosure contextRef="eol_PE151383--1410-K0012_STD_0_20141231_0_1269038x1272304_1275669x1277587_1275672x1274022" unitRef="iso4217_USD" decimals="-3" id="id_6895476_D3746E4A-E07A-4CB9-90BF-ECC5CBC77FC7_12001_1">16932000</us-gaap:AssetsFairValueDisclosure> <us-gaap:AssetsFairValueDisclosure contextRef="eol_PE151383--1410-K0012_STD_0_20141231_0_1269038x1272304_1275672x1274022" unitRef="iso4217_USD" decimals="-3" id="id_6895476_D3746E4A-E07A-4CB9-90BF-ECC5CBC77FC7_7001_6">79945000</us-gaap:AssetsFairValueDisclosure> <us-gaap:AssetsFairValueDisclosure contextRef="eol_PE151383--1410-K0012_STD_0_20141231_0_1269038x1272304_1275672x1274022_1278604x1435842" unitRef="iso4217_USD" decimals="-3" id="id_6895476_D3746E4A-E07A-4CB9-90BF-ECC5CBC77FC7_13001_5">0</us-gaap:AssetsFairValueDisclosure> <us-gaap:AssetsFairValueDisclosureRecurring contextRef="eol_PE151383--1410-K0012_STD_0_20141231_0_1269038x1275680" unitRef="iso4217_USD" decimals="INF" id="id_6895476_81507991-A4C3-4B03-B481-7472E2A8A109_2001_1">0</us-gaap:AssetsFairValueDisclosureRecurring> <us-gaap:AssetsFairValueDisclosure contextRef="eol_PE151383--1410-K0012_STD_0_20141231_0_1269038x1275680_1274212x1280237_1275672x1274022" unitRef="iso4217_USD" decimals="-3" id="id_6895476_D3746E4A-E07A-4CB9-90BF-ECC5CBC77FC7_9003_3">0</us-gaap:AssetsFairValueDisclosure> <us-gaap:AssetsFairValueDisclosure contextRef="eol_PE151383--1410-K0012_STD_0_20141231_0_1269038x1275680_1274607x1276380_1275672x1274022" unitRef="iso4217_USD" decimals="-3" id="id_6895476_D3746E4A-E07A-4CB9-90BF-ECC5CBC77FC7_10003_4">0</us-gaap:AssetsFairValueDisclosure> <us-gaap:AssetsFairValueDisclosure contextRef="eol_PE151383--1410-K0012_STD_0_20141231_0_1269038x1275680_1275669x1274813_1275672x1274022" unitRef="iso4217_USD" decimals="-3" id="id_6895476_D3746E4A-E07A-4CB9-90BF-ECC5CBC77FC7_11003_2">0</us-gaap:AssetsFairValueDisclosure> <us-gaap:AssetsFairValueDisclosure contextRef="eol_PE151383--1410-K0012_STD_0_20141231_0_1269038x1275680_1275669x1277587_1275672x1274022" unitRef="iso4217_USD" decimals="-3" id="id_6895476_D3746E4A-E07A-4CB9-90BF-ECC5CBC77FC7_12003_1">0</us-gaap:AssetsFairValueDisclosure> <us-gaap:AssetsFairValueDisclosure contextRef="eol_PE151383--1410-K0012_STD_0_20141231_0_1269038x1275680_1275672x1274022" unitRef="iso4217_USD" decimals="-3" id="id_6895476_D3746E4A-E07A-4CB9-90BF-ECC5CBC77FC7_7003_6">0</us-gaap:AssetsFairValueDisclosure> <us-gaap:AssetsFairValueDisclosure contextRef="eol_PE151383--1410-K0012_STD_0_20141231_0_1269038x1275680_1275672x1274022_1278604x1435842" unitRef="iso4217_USD" decimals="-3" id="id_6895476_D3746E4A-E07A-4CB9-90BF-ECC5CBC77FC7_13003_5">0</us-gaap:AssetsFairValueDisclosure> <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue contextRef="eol_PE151383--1410-K0012_STD_0_20141231_0_1270313x1271210" unitRef="iso4217_USD_per_shares" decimals="2" id="id_6895476_4396C4E5-DD06-4003-A485-BA06C7D8368D_8001_12">8.51</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue> <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber contextRef="eol_PE151383--1410-K0012_STD_0_20141231_0_1270313x1271210" unitRef="shares" decimals="INF" id="id_6895476_9D5C22B2-CCEF-4AED-B18A-0ACE42E2B15B_8001_12">63330</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber> <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions contextRef="eol_PE151383--1410-K0012_STD_0_20141231_0_1270313x1271212" unitRef="iso4217_USD" decimals="-5" id="id_6895476_5F253034-A3E2-4A92-8DC5-D01804806735_1002_1">300000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions> <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions contextRef="eol_PE151383--1410-K0012_STD_0_20141231_0_1270313x1275629" unitRef="iso4217_USD" decimals="-5" id="id_6895476_5F253034-A3E2-4A92-8DC5-D01804806735_1001_0">5700000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions> <us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax contextRef="eol_PE151383--1410-K0012_STD_0_20141231_0_1270365x1274813_1274212x1276380" unitRef="iso4217_USD" decimals="-3" id="id_6895476_5953821E-651A-43AE-83D1-8E91E00151B4_4002_2">3000</us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax> <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis contextRef="eol_PE151383--1410-K0012_STD_0_20141231_0_1270365x1274813_1274212x1276380" unitRef="iso4217_USD" decimals="-3" id="id_6895476_5953821E-651A-43AE-83D1-8E91E00151B4_4002_1">63017000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis> <us-gaap:AvailableForSaleSecurities contextRef="eol_PE151383--1410-K0012_STD_0_20141231_0_1270365x1274813_1274212x1276380" unitRef="iso4217_USD" decimals="-3" id="id_6895476_5953821E-651A-43AE-83D1-8E91E00151B4_4002_4">63013000</us-gaap:AvailableForSaleSecurities> <us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax contextRef="eol_PE151383--1410-K0012_STD_0_20141231_0_1270365x1274813_1274212x1276380" unitRef="iso4217_USD" decimals="-3" id="id_6895476_5953821E-651A-43AE-83D1-8E91E00151B4_4002_3">7000</us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax> <us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax contextRef="eol_PE151383--1410-K0012_STD_0_20141231_0_1270365x1274813_1274212x1435842" unitRef="iso4217_USD" decimals="-3" id="id_6895476_5953821E-651A-43AE-83D1-8E91E00151B4_4003_2">0</us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax> <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis contextRef="eol_PE151383--1410-K0012_STD_0_20141231_0_1270365x1274813_1274212x1435842" unitRef="iso4217_USD" decimals="-3" id="id_6895476_5953821E-651A-43AE-83D1-8E91E00151B4_4003_1">0</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis> <us-gaap:AvailableForSaleSecurities contextRef="eol_PE151383--1410-K0012_STD_0_20141231_0_1270365x1274813_1274212x1435842" unitRef="iso4217_USD" decimals="-3" id="id_6895476_5953821E-651A-43AE-83D1-8E91E00151B4_4003_4">0</us-gaap:AvailableForSaleSecurities> <us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax contextRef="eol_PE151383--1410-K0012_STD_0_20141231_0_1270365x1274813_1274212x1435842" unitRef="iso4217_USD" decimals="-3" id="id_6895476_5953821E-651A-43AE-83D1-8E91E00151B4_4003_3">0</us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax> <us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax contextRef="eol_PE151383--1410-K0012_STD_0_20141231_0_1270365x1277587_1274212x1270374" unitRef="iso4217_USD" decimals="-3" id="id_6895476_5953821E-651A-43AE-83D1-8E91E00151B4_4001_2">0</us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax> <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis contextRef="eol_PE151383--1410-K0012_STD_0_20141231_0_1270365x1277587_1274212x1270374" unitRef="iso4217_USD" decimals="-3" id="id_6895476_5953821E-651A-43AE-83D1-8E91E00151B4_4001_1">16932000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis> <us-gaap:AvailableForSaleSecurities contextRef="eol_PE151383--1410-K0012_STD_0_20141231_0_1270365x1277587_1274212x1270374" unitRef="iso4217_USD" decimals="-3" id="id_6895476_5953821E-651A-43AE-83D1-8E91E00151B4_4001_4">16932000</us-gaap:AvailableForSaleSecurities> <us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax contextRef="eol_PE151383--1410-K0012_STD_0_20141231_0_1270365x1277587_1274212x1270374" unitRef="iso4217_USD" decimals="-3" id="id_6895476_5953821E-651A-43AE-83D1-8E91E00151B4_4001_3">0</us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax> <us-gaap:PreferredStockSharesIssued contextRef="eol_PE151383--1410-K0012_STD_0_20141231_0_1271382x1511257" unitRef="shares" decimals="INF" id="id_6895476_8A8F0701-BBA5-4387-AD6C-5E09ADAEB480_2001_0">2397278</us-gaap:PreferredStockSharesIssued> <us-gaap:AssetsFairValueDisclosure contextRef="eol_PE151383--1410-K0012_STD_0_20141231_0_1274212x1280237_1275672x1274022" unitRef="iso4217_USD" decimals="-3" id="id_6895476_D3746E4A-E07A-4CB9-90BF-ECC5CBC77FC7_9004_3">16932000</us-gaap:AssetsFairValueDisclosure> <us-gaap:DeferredRevenue contextRef="eol_PE151383--1410-K0012_STD_0_20141231_0_1274544x1398741_1277337x1317063_1279431x1434297" unitRef="iso4217_USD" decimals="-5" id="id_6895476_8F3077E6-41FF-4940-BA00-DABA022D23D7_2001_4">900000</us-gaap:DeferredRevenue> <us-gaap:DeferredRevenue contextRef="eol_PE151383--1410-K0012_STD_0_20141231_0_1274544x1398741_1277337x1486283_1279431x1434297" unitRef="iso4217_USD" decimals="-5" id="id_6895476_F8E2956D-0212-47E3-95E1-66B87A6BD033_2001_2">30000000</us-gaap:DeferredRevenue> <us-gaap:CommonStockSharesIssued contextRef="eol_PE151383--1410-K0012_STD_0_20141231_0_1274544x1398741_1279431x1434297" unitRef="shares" decimals="INF" id="id_6895476_8F3077E6-41FF-4940-BA00-DABA022D23D7_3001_0">2040816</us-gaap:CommonStockSharesIssued> <us-gaap:SharePrice contextRef="eol_PE151383--1410-K0012_STD_0_20141231_0_1274544x1398741_1279431x1434297" unitRef="iso4217_USD_per_shares" decimals="INF" id="id_6895476_8F3077E6-41FF-4940-BA00-DABA022D23D7_3001_1">4.90</us-gaap:SharePrice> <us-gaap:DeferredRevenue contextRef="eol_PE151383--1410-K0012_STD_0_20141231_0_1274544x1398741_1279431x1434297" unitRef="iso4217_USD" decimals="-5" id="id_6895476_E6CFC5C8-F704-4F1E-B1FF-506F9A6E167E_1001_0">33600000</us-gaap:DeferredRevenue> <us-gaap:AssetsFairValueDisclosure contextRef="eol_PE151383--1410-K0012_STD_0_20141231_0_1274607x1276380_1275672x1274022" unitRef="iso4217_USD" decimals="-3" id="id_6895476_D3746E4A-E07A-4CB9-90BF-ECC5CBC77FC7_10004_4">63013000</us-gaap:AssetsFairValueDisclosure> <us-gaap:AssetsFairValueDisclosure contextRef="eol_PE151383--1410-K0012_STD_0_20141231_0_1275669x1274813_1275672x1274022" unitRef="iso4217_USD" decimals="-3" id="id_6895476_D3746E4A-E07A-4CB9-90BF-ECC5CBC77FC7_11004_2">63013000</us-gaap:AssetsFairValueDisclosure> <us-gaap:AssetsFairValueDisclosure contextRef="eol_PE151383--1410-K0012_STD_0_20141231_0_1275669x1277587_1275672x1274022" unitRef="iso4217_USD" decimals="-3" id="id_6895476_D3746E4A-E07A-4CB9-90BF-ECC5CBC77FC7_12004_1">16932000</us-gaap:AssetsFairValueDisclosure> <us-gaap:AssetsFairValueDisclosure contextRef="eol_PE151383--1410-K0012_STD_0_20141231_0_1275672x1274022" unitRef="iso4217_USD" decimals="-3" id="id_6895476_D3746E4A-E07A-4CB9-90BF-ECC5CBC77FC7_7004_6">79945000</us-gaap:AssetsFairValueDisclosure> <us-gaap:AssetsFairValueDisclosure contextRef="eol_PE151383--1410-K0012_STD_0_20141231_0_1275672x1274022_1278604x1435842" unitRef="iso4217_USD" decimals="-3" id="id_6895476_D3746E4A-E07A-4CB9-90BF-ECC5CBC77FC7_13004_5">0</us-gaap:AssetsFairValueDisclosure> <us-gaap:PropertyPlantAndEquipmentGross contextRef="eol_PE151383--1410-K0012_STD_0_20141231_0_1276136x1280724" unitRef="iso4217_USD" decimals="-3" id="id_6895476_113D1BB7-2EFC-40A3-A61B-C5BE96CD52A4_1001_4">3334000</us-gaap:PropertyPlantAndEquipmentGross> <us-gaap:PropertyPlantAndEquipmentGross contextRef="eol_PE151383--1410-K0012_STD_0_20141231_0_1276136x1329743" unitRef="iso4217_USD" decimals="-3" id="id_6895476_113D1BB7-2EFC-40A3-A61B-C5BE96CD52A4_2001_3">913000</us-gaap:PropertyPlantAndEquipmentGross> <us-gaap:PropertyPlantAndEquipmentGross contextRef="eol_PE151383--1410-K0012_STD_0_20141231_0_1276136x1362982" unitRef="iso4217_USD" decimals="-3" id="id_6895476_113D1BB7-2EFC-40A3-A61B-C5BE96CD52A4_3001_2">2418000</us-gaap:PropertyPlantAndEquipmentGross> <us-gaap:PropertyPlantAndEquipmentGross contextRef="eol_PE151383--1410-K0012_STD_0_20141231_0_1276136x1457720" unitRef="iso4217_USD" decimals="-3" id="id_6895476_113D1BB7-2EFC-40A3-A61B-C5BE96CD52A4_4001_1">15299000</us-gaap:PropertyPlantAndEquipmentGross> <us-gaap:PreferredStockSharesOutstanding contextRef="eol_PE151383--1410-K0012_STD_0_20141231_0_1276400x1269676" unitRef="shares" decimals="INF" id="id_6895476_415AC1F8-2710-4285-9D91-1A668F81A543_1001_27">0</us-gaap:PreferredStockSharesOutstanding> <us-gaap:PreferredStockSharesIssued contextRef="eol_PE151383--1410-K0012_STD_0_20141231_0_1276400x1269676" unitRef="shares" decimals="INF" id="id_6895476_415AC1F8-2710-4285-9D91-1A668F81A543_1001_26">0</us-gaap:PreferredStockSharesIssued> <us-gaap:PreferredStockValue contextRef="eol_PE151383--1410-K0012_STD_0_20141231_0_1276400x1269676" unitRef="iso4217_USD" decimals="-3" id="id_6895476_415AC1F8-2710-4285-9D91-1A668F81A543_1001_25">0</us-gaap:PreferredStockValue> <us-gaap:PreferredStockSharesOutstanding contextRef="eol_PE151383--1410-K0012_STD_0_20141231_0_1276400x1270467" unitRef="shares" decimals="INF" id="id_6895476_E009613E-FE1A-45B6-A48C-79BD187F3550_1001_1">0</us-gaap:PreferredStockSharesOutstanding> <us-gaap:PreferredStockSharesAuthorized contextRef="eol_PE151383--1410-K0012_STD_0_20141231_0_1276400x1270467" unitRef="shares" decimals="INF" id="id_6895476_E009613E-FE1A-45B6-A48C-79BD187F3550_1001_0">10000000</us-gaap:PreferredStockSharesAuthorized> <cytk:EntitledPaymentPerShareDuringLiquidation contextRef="eol_PE151383--1410-K0012_STD_0_20141231_0_1276400x1281157" unitRef="iso4217_USD_per_shares" decimals="3" id="id_6895476_06E5B969-7873-4624-AA5E-ED310048E641_1001_1">0.001</cytk:EntitledPaymentPerShareDuringLiquidation> <cytk:PercentageLimitOnNumberOfSharesOfCommonStockExercisableByHolders contextRef="eol_PE151383--1410-K0012_STD_0_20141231_0_1276400x1281157" unitRef="pure" decimals="INF" id="id_6895476_06E5B969-7873-4624-AA5E-ED310048E641_1001_0">0.0998</cytk:PercentageLimitOnNumberOfSharesOfCommonStockExercisableByHolders> <us-gaap:StockholdersEquity contextRef="eol_PE151383--1410-K0012_STD_0_20141231_0_1276401x1268669" unitRef="iso4217_USD" decimals="-3" id="id_6895476_58E9B802-84A6-48EC-8C22-C0DD0182E686_12006_86">-4000</us-gaap:StockholdersEquity> <us-gaap:StockholdersEquity contextRef="eol_PE151383--1410-K0012_STD_0_20141231_0_1276401x1269588" unitRef="iso4217_USD" decimals="-3" id="id_6895476_58E9B802-84A6-48EC-8C22-C0DD0182E686_12007_86">-497243000</us-gaap:StockholdersEquity> <us-gaap:SharesOutstanding contextRef="eol_PE151383--1410-K0012_STD_0_20141231_0_1276401x1270422" unitRef="shares" decimals="INF" id="id_6895476_58E9B802-84A6-48EC-8C22-C0DD0182E686_12001_87">38659738</us-gaap:SharesOutstanding> <us-gaap:StockholdersEquity contextRef="eol_PE151383--1410-K0012_STD_0_20141231_0_1276401x1270422" unitRef="iso4217_USD" decimals="-3" id="id_6895476_58E9B802-84A6-48EC-8C22-C0DD0182E686_12001_86">39000</us-gaap:StockholdersEquity> <cytk:StockIssuedDuringPeriodSharesSecuritiesPurchaseAgreement contextRef="eol_PE151383--1410-K0012_STD_0_20141231_0_1276401x1270422" unitRef="shares" decimals="INF" id="id_6895476_58E9B802-84A6-48EC-8C22-C0DD0182E686_12001_80">5031250</cytk:StockIssuedDuringPeriodSharesSecuritiesPurchaseAgreement> <us-gaap:StockholdersEquity contextRef="eol_PE151383--1410-K0012_STD_0_20141231_0_1276401x1273630" unitRef="iso4217_USD" decimals="-3" id="id_6895476_58E9B802-84A6-48EC-8C22-C0DD0182E686_12005_86">589272000</us-gaap:StockholdersEquity> <us-gaap:DeferredRevenue contextRef="eol_PE151383--1410-K0012_STD_0_20141231_0_1277337x1317063_1279431x1424859" unitRef="iso4217_USD" decimals="-5" id="id_6895476_7F280FAF-8359-476C-AA21-F14004E0FF7E_2002_4">2500000</us-gaap:DeferredRevenue> <us-gaap:DeferredRevenue contextRef="eol_PE151383--1410-K0012_STD_0_20141231_0_1277337x1486283_1279431x1434297" unitRef="iso4217_USD" decimals="-5" id="id_6895476_029BFB08-6E6C-4557-8196-AF677A9BF516_3001_3">2300000</us-gaap:DeferredRevenue> <us-gaap:AccountsReceivableRelatedParties contextRef="eol_PE151383--1410-K0012_STD_0_20141231_0_1279431x1424859" unitRef="iso4217_USD" decimals="-5" id="id_6895476_D076CC70-CB7C-4170-BD50-2E3EFE86EE58_2001_1">1600000</us-gaap:AccountsReceivableRelatedParties> <us-gaap:ValuationAllowancesAndReservesBalance contextRef="eol_PE151383--1410-K0012_STD_0_20141231_0_1279936x1276697" unitRef="iso4217_USD" decimals="-3" id="id_6895476_B444ABAD-A3F0-45D1-A8D2-D991236372AC_2003_5">204900000</us-gaap:ValuationAllowancesAndReservesBalance> <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 contextRef="eol_PE151383--1410-K0012_STD_0_20141231_0_1280248x1351779" unitRef="iso4217_USD_per_shares" decimals="INF" id="id_6895476_F7BC438C-6E3A-421D-B041-23B846FFE104_1002_2">5.28</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1> <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights contextRef="eol_PE151383--1410-K0012_STD_0_20141231_0_1280248x1351779" unitRef="shares" decimals="INF" id="id_6895476_F7BC438C-6E3A-421D-B041-23B846FFE104_1002_1">5576928</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights> <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 contextRef="eol_PE151383--1410-K0012_STD_0_20141231_0_1280248x1413008" unitRef="iso4217_USD_per_shares" decimals="INF" id="id_6895476_F7BC438C-6E3A-421D-B041-23B846FFE104_1001_2">9.90</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1> <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights contextRef="eol_PE151383--1410-K0012_STD_0_20141231_0_1280248x1413008" unitRef="shares" decimals="INF" id="id_6895476_F7BC438C-6E3A-421D-B041-23B846FFE104_1001_1">1114168</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights> <us-gaap:OperatingLossCarryforwards contextRef="eol_PE151383--1410-K0012_STD_0_20141231_0_1280651x1276398" unitRef="iso4217_USD" decimals="-5" id="id_6895476_0EF73AD1-38D5-4AA8-BDA2-BB195F3CE389_3001_2">285700000</us-gaap:OperatingLossCarryforwards> <us-gaap:OperatingLossCarryforwards contextRef="eol_PE151383--1410-K0012_STD_0_20141231_0_1280651x1280458" unitRef="iso4217_USD" decimals="-5" id="id_6895476_0EF73AD1-38D5-4AA8-BDA2-BB195F3CE389_4001_0">386800000</us-gaap:OperatingLossCarryforwards> <us-gaap:UnrecognizedTaxBenefits contextRef="eol_PE151383--1410-K0012_STD_0_20141231_0_1280651x1297583" unitRef="iso4217_USD" decimals="-3" id="id_6895476_7B98D2F9-CACB-495E-A3F9-A79C5892451D_5002_7">1190000</us-gaap:UnrecognizedTaxBenefits> <us-gaap:UnrecognizedTaxBenefits contextRef="eol_PE151383--1410-K0012_STD_0_20141231_0_1280651x1497867" unitRef="iso4217_USD" decimals="-3" id="id_6895476_7B98D2F9-CACB-495E-A3F9-A79C5892451D_5003_7">5084000</us-gaap:UnrecognizedTaxBenefits> <us-gaap:UnrecognizedTaxBenefits contextRef="eol_PE151383--1410-K0012_STD_0_20141231_0_1280651x1520580" unitRef="iso4217_USD" decimals="-3" id="id_6895476_7B98D2F9-CACB-495E-A3F9-A79C5892451D_5001_7">6274000</us-gaap:UnrecognizedTaxBenefits> <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance contextRef="eol_PE151383--1410-K0012_STD_0_20141231_0_1280964x1277228" unitRef="shares" decimals="INF" id="id_6895476_AA51EB59-4301-48A7-8417-F8ADFF1F04A4_2001_3">170170</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance> <us-gaap:SharePrice contextRef="eol_PE151383--1410-K0012_STD_0_20141231_0_1280964x1294890" unitRef="iso4217_USD_per_shares" decimals="INF" id="id_6895476_945DE61A-5FF4-4863-A406-B144CAADCC72_2001_2">8.01</us-gaap:SharePrice> <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance contextRef="eol_PE151383--1410-K0012_STD_0_20141231_0_1280964x1294890" unitRef="shares" decimals="INF" id="id_6895476_58CB623A-E885-445D-B29D-69E6E82D9786_4001_8">0</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance> <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant contextRef="eol_PE151383--1410-K0012_STD_0_20141231_0_1280964x1294890" unitRef="shares" decimals="INF" id="id_6895476_58CB623A-E885-445D-B29D-69E6E82D9786_4001_9">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant> <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance contextRef="eol_PE151383--1410-K0012_STD_0_20141231_0_1280964x1403278" unitRef="shares" decimals="INF" id="id_6895476_0AF6DB82-B080-4B35-841A-44AE3BB5C9C4_3001_9">1270478</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance> <us-gaap:AccountsReceivableRelatedParties contextRef="eol_PE151383--1410-K0012_STD_0_20141231_0_1281318x1434297" unitRef="iso4217_USD" decimals="-5" id="id_6895476_B1D541CA-9025-4D78-9ABD-27AABA32983C_2001_1">45000000</us-gaap:AccountsReceivableRelatedParties> <cytk:PotentialAmountsReceivableUnderCollaborationAgreement contextRef="eol_PE151383--1410-K0012_STD_1_20141222_0_1269523x1275948_1274544x1398741_1279431x1434297_1279908x1479887" unitRef="iso4217_USD" decimals="-5" id="id_6895476_9D5D7EED-692C-4E1B-B06F-CE4D4287EA26_1001_2">200000000</cytk:PotentialAmountsReceivableUnderCollaborationAgreement> <cytk:PotentialAmountsReceivableUnderCollaborationAgreement contextRef="eol_PE151383--1410-K0012_STD_1_20141222_0_1269523x1275948_1274544x1398741_1279431x1434297_1279908x1621938" unitRef="iso4217_USD" decimals="-5" id="id_6895476_9D5D7EED-692C-4E1B-B06F-CE4D4287EA26_2001_1">95000000</cytk:PotentialAmountsReceivableUnderCollaborationAgreement> <cytk:PotentialAmountsReceivableUnderCollaborationAgreement contextRef="eol_PE151383--1410-K0012_STD_1_20141222_0_1269523x1277596_1274544x1398741_1279431x1434297" unitRef="iso4217_USD" decimals="-5" id="id_6895476_9D5D7EED-692C-4E1B-B06F-CE4D4287EA26_3001_0">600000000</cytk:PotentialAmountsReceivableUnderCollaborationAgreement> <cytk:PotentialAmountsReceivableUnderCollaborationAgreement contextRef="eol_PE151383--1410-K0012_STD_1_20141222_0_1269523x1277596_1274544x1398741_1279431x1434297_1279908x1621939" unitRef="iso4217_USD" decimals="-5" id="id_6895476_9D5D7EED-692C-4E1B-B06F-CE4D4287EA26_4001_3">100000000</cytk:PotentialAmountsReceivableUnderCollaborationAgreement> <cytk:ResearchCollaborationAndLicenseAgreementPeriod contextRef="eol_PE151383--1410-K0012_STD_1_20141222_0_1274544x1398741_1279431x1434297" id="id_6895476_39DDA2A7-B6C6-4F69-B04A-C19806DC871F_1001_0">P2Y</cytk:ResearchCollaborationAndLicenseAgreementPeriod> <cytk:PotentialAmountsReceivableUnderCollaborationAgreement contextRef="eol_PE151383--1410-K0012_STD_1_20141222_0_1274544x1398741_1279431x1434297" unitRef="iso4217_USD" decimals="-5" id="id_6895476_39DDA2A7-B6C6-4F69-B04A-C19806DC871F_1001_1">20000000</cytk:PotentialAmountsReceivableUnderCollaborationAgreement> <cytk:IssuanceCostOfWarrant contextRef="eol_PE151383--1410-K0012_STD_1_20110420_0" unitRef="iso4217_USD" decimals="-5" id="id_6895476_F2A1F03D-DFC3-4B77-8908-14CCA725F68C_1_3">100000</cytk:IssuanceCostOfWarrant> <cytk:PreferredStockConversionRatio contextRef="eol_PE151383--1410-K0012_STD_1_20110420_0" unitRef="pure" decimals="3" id="id_6895476_0036A474-B1E7-46AE-931E-902FB6224652_1_1">0.001</cytk:PreferredStockConversionRatio> <us-gaap:ProceedsFromIssuanceOfCommonStock contextRef="eol_PE151383--1410-K0012_STD_1_20110420_0_1271382x1398639" unitRef="iso4217_USD" decimals="-5" id="id_6895476_7D64BA49-07A9-41DB-8E2E-1CC4AA31C414_1001_8">19900000</us-gaap:ProceedsFromIssuanceOfCommonStock> <cytk:IssuanceCostOfWarrant contextRef="eol_PE151383--1410-K0012_STD_1_20110420_0_1271382x1398639" unitRef="iso4217_USD" decimals="-5" id="id_6895476_7D64BA49-07A9-41DB-8E2E-1CC4AA31C414_1001_7">200000</cytk:IssuanceCostOfWarrant> <cytk:NetProceedsFromIssuanceOfWarrants contextRef="eol_PE151383--1410-K0012_STD_1_20110420_0_1271382x1559654" unitRef="iso4217_USD" decimals="-5" id="id_6895476_F2A1F03D-DFC3-4B77-8908-14CCA725F68C_1001_4">4400000</cytk:NetProceedsFromIssuanceOfWarrants> <us-gaap:StockIssuedDuringPeriodSharesNewIssues contextRef="eol_PE151383--1410-K0012_STD_1_20110420_0_1271382x1559654_1276400x1269676" unitRef="shares" decimals="INF" id="id_6895476_7D64BA49-07A9-41DB-8E2E-1CC4AA31C414_2001_2">8070</us-gaap:StockIssuedDuringPeriodSharesNewIssues> <us-gaap:ProceedsFromIssuanceOfPreferredStockAndPreferenceStock contextRef="eol_PE151383--1410-K0012_STD_1_20110420_0_1271382x1559654_1276400x1269676" unitRef="iso4217_USD" decimals="-5" id="id_6895476_2A1002B7-2537-4DD8-A459-A9553F6F62D8_1_2">9300000</us-gaap:ProceedsFromIssuanceOfPreferredStockAndPreferenceStock> <cytk:FairValuePerShareOfCommonStock contextRef="eol_PE151383--1410-K0012_STD_1_20110420_0_1271382x1559654_1276400x1388560_1278975x1273442" unitRef="iso4217_USD_per_shares" decimals="2" id="id_6895476_F2A1F03D-DFC3-4B77-8908-14CCA725F68C_2001_9">9.12</cytk:FairValuePerShareOfCommonStock> <cytk:FairValuePerShareOfCommonStock contextRef="eol_PE151383--1410-K0012_STD_1_20110420_0_1271382x1559654_1276400x1476082_1278975x1273442" unitRef="iso4217_USD_per_shares" decimals="2" id="id_6895476_F2A1F03D-DFC3-4B77-8908-14CCA725F68C_3001_10">1.52</cytk:FairValuePerShareOfCommonStock> <us-gaap:EquityIssuancePerShareAmount contextRef="eol_PE151383--1410-K0012_STD_1_20110420_0_1271382x1559654_1276401x1270422" unitRef="iso4217_USD_per_shares" decimals="2" id="id_6895476_7D64BA49-07A9-41DB-8E2E-1CC4AA31C414_3001_1">9.00</us-gaap:EquityIssuancePerShareAmount> <us-gaap:StockIssuedDuringPeriodSharesNewIssues contextRef="eol_PE151383--1410-K0012_STD_1_20110420_0_1271382x1559654_1276401x1270422" unitRef="shares" decimals="INF" id="id_6895476_7D64BA49-07A9-41DB-8E2E-1CC4AA31C414_3001_0">883333</us-gaap:StockIssuedDuringPeriodSharesNewIssues> <us-gaap:FairValueAssumptionsExpectedVolatilityRate contextRef="eol_PE151383--1410-K0012_STD_1_20110420_0_1271382x1559654_1278975x1273442" unitRef="pure" decimals="2" id="id_6895476_F2A1F03D-DFC3-4B77-8908-14CCA725F68C_4001_8">0.80</us-gaap:FairValueAssumptionsExpectedVolatilityRate> <us-gaap:FairValueAssumptionsRiskFreeInterestRate contextRef="eol_PE151383--1410-K0012_STD_1_20110420_0_1271382x1559654_1278975x1273442" unitRef="pure" decimals="4" id="id_6895476_F2A1F03D-DFC3-4B77-8908-14CCA725F68C_4001_7">0.0166</us-gaap:FairValueAssumptionsRiskFreeInterestRate> <us-gaap:EquityIssuancePerShareAmount contextRef="eol_PE151383--1410-K0012_STD_1_20110420_0_1276400x1269676" unitRef="iso4217_USD_per_shares" decimals="2" id="id_6895476_7D64BA49-07A9-41DB-8E2E-1CC4AA31C414_4001_3">1500.00</us-gaap:EquityIssuancePerShareAmount> <us-gaap:ConversionOfStockSharesConverted1 contextRef="eol_PE151383--1410-K0012_STD_1_20110420_0_1276400x1269676" unitRef="shares" decimals="INF" id="id_6895476_0036A474-B1E7-46AE-931E-902FB6224652_1001_2">1000</us-gaap:ConversionOfStockSharesConverted1> <cytk:NumberOfConcurrentPublicOfferings contextRef="eol_PE151383--1410-K0012_STD_1_20120620_0" unitRef="PublicOffering" decimals="INF" id="id_6895476_66294636-A6BA-4A64-9935-D90D4F7A0972_1_0">2</cytk:NumberOfConcurrentPublicOfferings> <us-gaap:PaymentsOfStockIssuanceCosts contextRef="eol_PE151383--1410-K0012_STD_1_20120625_0" unitRef="iso4217_USD" decimals="-5" id="id_6895476_89872A42-7173-4DB8-AB4C-D0DCE3435133_1_7">4000000</us-gaap:PaymentsOfStockIssuanceCosts> <us-gaap:ProceedsFromIssuanceOrSaleOfEquity contextRef="eol_PE151383--1410-K0012_STD_1_20120625_0" unitRef="iso4217_USD" decimals="-5" id="id_6895476_89872A42-7173-4DB8-AB4C-D0DCE3435133_1_6">60000000</us-gaap:ProceedsFromIssuanceOrSaleOfEquity> <cytk:ProceedsFromIssuanceOrSaleOfStockAndWarrant contextRef="eol_PE151383--1410-K0012_STD_1_20120625_0" unitRef="iso4217_USD" decimals="-5" id="id_6895476_89872A42-7173-4DB8-AB4C-D0DCE3435133_1_8">56000000</cytk:ProceedsFromIssuanceOrSaleOfStockAndWarrant> <cytk:FairValuePerShareOfCommonStock contextRef="eol_PE151383--1410-K0012_STD_1_20120625_0_1271382x1559654_1276400x1388560" unitRef="iso4217_USD_per_shares" decimals="2" id="id_6895476_3E54C892-94D6-4C52-BFA8-8B816AFAFE5A_1001_8">3.78</cytk:FairValuePerShareOfCommonStock> <cytk:FairValuePerShareOfCommonStock contextRef="eol_PE151383--1410-K0012_STD_1_20120625_0_1271382x1559654_1276400x1476082" unitRef="iso4217_USD_per_shares" decimals="2" id="id_6895476_3E54C892-94D6-4C52-BFA8-8B816AFAFE5A_2001_9">0.63</cytk:FairValuePerShareOfCommonStock> <us-gaap:FairValueAssumptionsExpectedTerm contextRef="eol_PE151383--1410-K0012_STD_1_20120625_0_1271382x1559654_1278975x1273442" id="id_6895476_3E54C892-94D6-4C52-BFA8-8B816AFAFE5A_3001_5">P5Y</us-gaap:FairValueAssumptionsExpectedTerm> <us-gaap:FairValueAssumptionsExpectedVolatilityRate contextRef="eol_PE151383--1410-K0012_STD_1_20120625_0_1271382x1559654_1278975x1273442" unitRef="pure" decimals="2" id="id_6895476_3E54C892-94D6-4C52-BFA8-8B816AFAFE5A_3001_7">0.76</us-gaap:FairValueAssumptionsExpectedVolatilityRate> <us-gaap:FairValueAssumptionsRiskFreeInterestRate contextRef="eol_PE151383--1410-K0012_STD_1_20120625_0_1271382x1559654_1278975x1273442" unitRef="pure" decimals="4" id="id_6895476_3E54C892-94D6-4C52-BFA8-8B816AFAFE5A_3001_6">0.0073</us-gaap:FairValueAssumptionsRiskFreeInterestRate> <us-gaap:ProceedsFromIssuanceOfPreferredStockAndPreferenceStock contextRef="eol_PE151383--1410-K0012_STD_1_20120625_0_1276400x1281157" unitRef="iso4217_USD" decimals="-5" id="id_6895476_66294636-A6BA-4A64-9935-D90D4F7A0972_1002_3">12300000</us-gaap:ProceedsFromIssuanceOfPreferredStockAndPreferenceStock> <cytk:ProceedsFromIssuanceOfUnit contextRef="eol_PE151383--1410-K0012_STD_1_20120625_0_1278975x1273442" unitRef="iso4217_USD" decimals="-5" id="id_6895476_3E54C892-94D6-4C52-BFA8-8B816AFAFE5A_4001_2">14700000</cytk:ProceedsFromIssuanceOfUnit> <us-gaap:StockholdersEquityNoteStockSplitConversionRatio1 contextRef="eol_PE151383--1410-K0012_STD_1_20130624_0" unitRef="pure" decimals="3" id="id_6895476_F4F8A908-2CA8-4F3B-8B91-6AA61E4E25C3_2_0">0.167</us-gaap:StockholdersEquityNoteStockSplitConversionRatio1> <us-gaap:ConversionOfStockSharesConverted1 contextRef="eol_PE151383--1410-K0012_STD_1_20130702_0_1276400x1281157" unitRef="shares" decimals="INF" id="id_6895476_AFDDCC73-DDEC-4EF6-8B23-09AF6BA9ADD4_1003_0">4000</us-gaap:ConversionOfStockSharesConverted1> <us-gaap:ConversionOfStockSharesIssued1 contextRef="eol_PE151383--1410-K0012_STD_1_20130702_0_1276401x1270422" unitRef="shares" decimals="INF" id="id_6895476_AFDDCC73-DDEC-4EF6-8B23-09AF6BA9ADD4_2003_1">666681</us-gaap:ConversionOfStockSharesIssued1> <us-gaap:ConversionOfStockSharesConverted1 contextRef="eol_PE151383--1410-K0012_STD_1_20120926_0_1271382x1559654_1276400x1269676" unitRef="shares" decimals="INF" id="id_6895476_57DC6C9C-2D45-4581-B939-1BB2B8AF0564_1_0">1345000</us-gaap:ConversionOfStockSharesConverted1> <us-gaap:ConversionOfStockSharesConverted1 contextRef="eol_PE151383--1410-K0012_STD_1_20120926_0_1276400x1269676" unitRef="shares" decimals="INF" id="id_6895476_17F46932-09D7-49BE-B11B-FFE352C5CFC2_1001_0">8070</us-gaap:ConversionOfStockSharesConverted1> <us-gaap:ConversionOfStockSharesIssued1 contextRef="eol_PE151383--1410-K0012_STD_1_20120926_0_1276401x1270422" unitRef="shares" decimals="INF" id="id_6895476_17F46932-09D7-49BE-B11B-FFE352C5CFC2_2001_1">1345000</us-gaap:ConversionOfStockSharesIssued1> <us-gaap:ProceedsFromIssuanceOfCommonStock contextRef="eol_PE151383--1410-K0012_STD_28_20140228_0_1271382x1382912" unitRef="iso4217_USD" decimals="-5" id="id_6895476_3E87B441-B931-4418-AA68-79D383D423DB_1001_2">37500000</us-gaap:ProceedsFromIssuanceOfCommonStock> <cytk:NumberOfIssuedSharesOfCommonStockRelatedToCashlessExerciseOfWarrants contextRef="eol_PE151383--1410-K0012_STD_30_20130430_0" unitRef="shares" decimals="INF" id="id_6895476_3F1F3628-49D8-4488-B2FE-674EF9E9FAEE_1_0">358460</cytk:NumberOfIssuedSharesOfCommonStockRelatedToCashlessExerciseOfWarrants> <cytk:ResearchDevelopmentGrant contextRef="eol_PE151383--1410-K0012_STD_30_20120930_0" unitRef="iso4217_USD" decimals="-5" id="id_6895476_4A8B6E37-A1AD-4F76-85D8-A31CABCB09BD_1_0">500000</cytk:ResearchDevelopmentGrant> <us-gaap:StockholdersEquityNoteStockSplit contextRef="eol_PE151383--1410-K0012_STD_30_20130630_0" id="id_6895476_473719C9-D076-449E-9431-6E23C9B3AD4C_1_1">As a result of the one-for-six reverse stock split effected in June 2013, the conversion ratio for Series B convertible preferred stock changed from 1,000 shares of common stock per share of Series B convertible preferred stock to 166.67 shares of common stock per share of Series B convertible preferred stock.</us-gaap:StockholdersEquityNoteStockSplit> <us-gaap:StockholdersEquityNoteStockSplitConversionRatio1 contextRef="eol_PE151383--1410-K0012_STD_30_20130630_0" unitRef="pure" decimals="3" id="id_6895476_473719C9-D076-449E-9431-6E23C9B3AD4C_1_0">0.167</us-gaap:StockholdersEquityNoteStockSplitConversionRatio1> <us-gaap:StockholdersEquityNoteChangesInCapitalStructureSubsequentChangesToNumberOfCommonShares contextRef="eol_PE151383--1410-K0012_STD_30_20130630_0_1276400x1281157" unitRef="shares" decimals="INF" id="id_6895476_473719C9-D076-449E-9431-6E23C9B3AD4C_1001_3">166.67</us-gaap:StockholdersEquityNoteChangesInCapitalStructureSubsequentChangesToNumberOfCommonShares> <us-gaap:ConversionOfStockSharesConverted1 contextRef="eol_PE151383--1410-K0012_STD_30_20130630_0_1276400x1281157" unitRef="shares" decimals="INF" id="id_6895476_473719C9-D076-449E-9431-6E23C9B3AD4C_1001_2">1000</us-gaap:ConversionOfStockSharesConverted1> <us-gaap:ProceedsFromIssuanceOfCommonStock contextRef="eol_PE151383--1410-K0012_STD_30_20130630_0_1279431x1424859" unitRef="iso4217_USD" decimals="-5" id="id_6895476_7F280FAF-8359-476C-AA21-F14004E0FF7E_1001_2">10000000</us-gaap:ProceedsFromIssuanceOfCommonStock> <us-gaap:LicenseCosts contextRef="eol_PE151383--1410-K0012_STD_30_20130630_0_1279431x1424859" unitRef="iso4217_USD" decimals="-5" id="id_6895476_237A3F64-676A-48E9-9CB9-A7D475F2002B_1001_0">15000000</us-gaap:LicenseCosts> <us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned contextRef="eol_PE151383--1410-K0012_STD_31_20130731_0_1279431x1434297" unitRef="iso4217_USD" decimals="-5" id="id_6895476_777952DA-C6F7-4181-8D5F-96A24E8BA82B_1001_0">16000000</us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned> <cytk:ResearchCollaborationAndLicenseAgreementPeriod contextRef="eol_PE151383--1410-K0012_STD_31_20130731_0_1279431x1434297" id="id_6895476_777952DA-C6F7-4181-8D5F-96A24E8BA82B_1001_2">P2Y</cytk:ResearchCollaborationAndLicenseAgreementPeriod> <cytk:PotentialAmountsReceivableUnderCollaborationAgreement contextRef="eol_PE151383--1410-K0012_STD_31_20130731_0_1279431x1434297" unitRef="iso4217_USD" decimals="-5" id="id_6895476_777952DA-C6F7-4181-8D5F-96A24E8BA82B_1001_1">25500000</cytk:PotentialAmountsReceivableUnderCollaborationAgreement> <us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned contextRef="eol_PE151383--1410-K0012_STD_31_20150131_0_1271378x1273350_1274544x1398741_1279431x1434297" unitRef="iso4217_USD" decimals="-5" id="id_6895476_83EA2D1D-5914-48DC-9AD2-0CA8DE5D49BF_1001_0">30000000</us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned> <cytk:MilestonePaymentsReceivedUnderArrangements contextRef="eol_PE151383--1410-K0012_STD_31_20150131_0_1271378x1273350_1274544x1398741_1279431x1434297" unitRef="iso4217_USD" decimals="-5" id="id_6895476_83EA2D1D-5914-48DC-9AD2-0CA8DE5D49BF_1001_1">15000000</cytk:MilestonePaymentsReceivedUnderArrangements> <cytk:ResearchDevelopmentGrant contextRef="eol_PE151383--1410-K0012_STD_365_20101231_0" unitRef="iso4217_USD" decimals="-5" id="id_6895476_4A8B6E37-A1AD-4F76-85D8-A31CABCB09BD_2_0">2800000</cytk:ResearchDevelopmentGrant> <cytk:PeriodForPotentialTreatment contextRef="eol_PE151383--1410-K0012_STD_365_20101231_0" id="id_6895476_4A8B6E37-A1AD-4F76-85D8-A31CABCB09BD_2_1">P3Y</cytk:PeriodForPotentialTreatment> <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice contextRef="eol_PE151383--1410-K0012_STD_365_20131231_0" unitRef="iso4217_USD_per_shares" decimals="2" id="id_6895476_C3206D70-DEC9-4565-9145-8B70956A712D_7001_8">5.32</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice> <us-gaap:EffectiveIncomeTaxRateContinuingOperations contextRef="eol_PE151383--1410-K0012_STD_365_20131231_0" unitRef="pure" decimals="2" id="id_6895476_14EF385A-3844-4F78-AE65-D20D0D541C15_2_8">0.00</us-gaap:EffectiveIncomeTaxRateContinuingOperations> <us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits contextRef="eol_PE151383--1410-K0012_STD_365_20131231_0" unitRef="pure" decimals="2" id="id_6895476_14EF385A-3844-4F78-AE65-D20D0D541C15_2_3">-0.14</us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits> <us-gaap:NetCashProvidedByUsedInOperatingActivitiesContinuingOperations contextRef="eol_PE151383--1410-K0012_STD_365_20131231_0" unitRef="iso4217_USD" decimals="-3" id="id_6895476_84756BCF-71FA-4E32-A511-A3DCED215C30_2_15">-7718000</us-gaap:NetCashProvidedByUsedInOperatingActivitiesContinuingOperations> <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit contextRef="eol_PE151383--1410-K0012_STD_365_20131231_0" unitRef="iso4217_USD_per_shares" decimals="INF" id="id_6895476_58E9B802-84A6-48EC-8C22-C0DD0182E686_9008_34">11.1</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit> <us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes contextRef="eol_PE151383--1410-K0012_STD_365_20131231_0" unitRef="pure" decimals="2" id="id_6895476_14EF385A-3844-4F78-AE65-D20D0D541C15_2_1">-0.04</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes> <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross contextRef="eol_PE151383--1410-K0012_STD_365_20131231_0" unitRef="shares" decimals="INF" id="id_6895476_550670F2-8019-4594-8D89-8D38F90A7B79_7001_8">797629</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross> <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod contextRef="eol_PE151383--1410-K0012_STD_365_20131231_0" unitRef="shares" decimals="INF" id="id_6895476_EAE02EAA-C88A-417D-A4E8-6DD5ADADA4AB_7001_8">797629</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod> <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized contextRef="eol_PE151383--1410-K0012_STD_365_20131231_0" unitRef="shares" decimals="INF" id="id_6895476_550670F2-8019-4594-8D89-8D38F90A7B79_7001_7">2000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized> <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted contextRef="eol_PE151383--1410-K0012_STD_365_20131231_0" unitRef="shares" decimals="-3" id="id_6895476_09173C79-2713-49DF-8107-C7F99AA4E397_2_3">27275000</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted> <us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments contextRef="eol_PE151383--1410-K0012_STD_365_20131231_0" unitRef="pure" decimals="2" id="id_6895476_14EF385A-3844-4F78-AE65-D20D0D541C15_2_7">0.01</us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments> <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice contextRef="eol_PE151383--1410-K0012_STD_365_20131231_0" unitRef="iso4217_USD_per_shares" decimals="2" id="id_6895476_C3206D70-DEC9-4565-9145-8B70956A712D_7001_9">12.55</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice> <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod contextRef="eol_PE151383--1410-K0012_STD_365_20131231_0" unitRef="shares" decimals="INF" id="id_6895476_EAE02EAA-C88A-417D-A4E8-6DD5ADADA4AB_7001_11">117394</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod> <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice contextRef="eol_PE151383--1410-K0012_STD_365_20131231_0" unitRef="iso4217_USD_per_shares" decimals="2" id="id_6895476_C3206D70-DEC9-4565-9145-8B70956A712D_7001_6">5.95</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice> <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit contextRef="eol_PE151383--1410-K0012_STD_365_20131231_0" unitRef="iso4217_USD_per_shares" decimals="INF" id="id_6895476_58E9B802-84A6-48EC-8C22-C0DD0182E686_9008_33">4.02</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit> <us-gaap:EarningsPerShareBasicAndDiluted contextRef="eol_PE151383--1410-K0012_STD_365_20131231_0" unitRef="iso4217_USD_per_shares" decimals="2" id="id_6895476_09173C79-2713-49DF-8107-C7F99AA4E397_2_4">-1.24</us-gaap:EarningsPerShareBasicAndDiluted> <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate contextRef="eol_PE151383--1410-K0012_STD_365_20131231_0" unitRef="pure" decimals="2" id="id_6895476_14EF385A-3844-4F78-AE65-D20D0D541C15_2_0">-0.34</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate> <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="eol_PE151383--1410-K0012_STD_365_20131231_0" unitRef="shares" decimals="-3" id="id_6895476_3E2C7E3E-7982-4F2C-A6E3-5C7781C1D9F7_2_5">10197000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount> <us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost contextRef="eol_PE151383--1410-K0012_STD_365_20131231_0" unitRef="pure" decimals="2" id="id_6895476_14EF385A-3844-4F78-AE65-D20D0D541C15_2_5">0.02</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost> <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures contextRef="eol_PE151383--1410-K0012_STD_365_20131231_0" unitRef="iso4217_USD" decimals="-3" id="id_6895476_58E9B802-84A6-48EC-8C22-C0DD0182E686_9008_38">-623000</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures> <us-gaap:RevenueFromGrants contextRef="eol_PE151383--1410-K0012_STD_365_20131231_0" unitRef="iso4217_USD" decimals="-3" id="id_6895476_FD977883-B531-4443-8A85-7DBADCAD1197_2_2">94000</us-gaap:RevenueFromGrants> <us-gaap:RepaymentsOfSecuredDebt contextRef="eol_PE151383--1410-K0012_STD_365_20131231_0" unitRef="iso4217_USD" decimals="-3" id="id_6895476_84756BCF-71FA-4E32-A511-A3DCED215C30_2_28">0</us-gaap:RepaymentsOfSecuredDebt> <us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt contextRef="eol_PE151383--1410-K0012_STD_365_20131231_0" unitRef="iso4217_USD" decimals="-3" id="id_6895476_84756BCF-71FA-4E32-A511-A3DCED215C30_2_17">79434000</us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt> <us-gaap:IncreaseDecreaseInRestrictedCash contextRef="eol_PE151383--1410-K0012_STD_365_20131231_0" unitRef="iso4217_USD" decimals="-3" id="id_6895476_84756BCF-71FA-4E32-A511-A3DCED215C30_2_21">0</us-gaap:IncreaseDecreaseInRestrictedCash> <us-gaap:IncomeTaxesPaidNet contextRef="eol_PE151383--1410-K0012_STD_365_20131231_0" unitRef="iso4217_USD" decimals="-3" id="id_6895476_822093A4-C207-4594-84E4-6C13CA36E168_2_1">1000</us-gaap:IncomeTaxesPaidNet> <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign contextRef="eol_PE151383--1410-K0012_STD_365_20131231_0" unitRef="iso4217_USD" decimals="-3" id="id_6895476_7D9738C0-6CE1-4E3E-8312-71FD14F9FEB0_2_1">0</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign> <us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount contextRef="eol_PE151383--1410-K0012_STD_365_20131231_0" unitRef="iso4217_USD" decimals="-5" id="id_6895476_172A3583-D769-410E-B05B-9FA47EC31BD7_2_0">13700000</us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount> <us-gaap:OtherComprehensiveIncomeLossNetOfTax contextRef="eol_PE151383--1410-K0012_STD_365_20131231_0" unitRef="iso4217_USD" decimals="-3" id="id_6895476_58E9B802-84A6-48EC-8C22-C0DD0182E686_9008_56">-11000</us-gaap:OtherComprehensiveIncomeLossNetOfTax> <us-gaap:LicenseAndServicesRevenue contextRef="eol_PE151383--1410-K0012_STD_365_20131231_0" unitRef="iso4217_USD" decimals="-3" id="id_6895476_FF4E9404-B9B3-415C-99EC-66EC22E2B2E7_2_4">3852000</us-gaap:LicenseAndServicesRevenue> <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets contextRef="eol_PE151383--1410-K0012_STD_365_20131231_0" unitRef="iso4217_USD" decimals="-3" id="id_6895476_84756BCF-71FA-4E32-A511-A3DCED215C30_2_10">-818000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets> <us-gaap:GainLossOnSaleOfPropertyPlantEquipment contextRef="eol_PE151383--1410-K0012_STD_365_20131231_0" unitRef="iso4217_USD" decimals="-3" id="id_6895476_84756BCF-71FA-4E32-A511-A3DCED215C30_2_4">79000</us-gaap:GainLossOnSaleOfPropertyPlantEquipment> <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan contextRef="eol_PE151383--1410-K0012_STD_365_20131231_0" unitRef="iso4217_USD" decimals="-3" id="id_6895476_58E9B802-84A6-48EC-8C22-C0DD0182E686_9008_35">55000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan> <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="eol_PE151383--1410-K0012_STD_365_20131231_0" unitRef="iso4217_USD" decimals="-3" id="id_6895476_58E9B802-84A6-48EC-8C22-C0DD0182E686_9008_31">114000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised> <us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax contextRef="eol_PE151383--1410-K0012_STD_365_20131231_0" unitRef="iso4217_USD" decimals="-3" id="id_6895476_FF4E9404-B9B3-415C-99EC-66EC22E2B2E7_2_21">-11000</us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax> <us-gaap:OperatingIncomeLoss contextRef="eol_PE151383--1410-K0012_STD_365_20131231_0" unitRef="iso4217_USD" decimals="-3" id="id_6895476_FF4E9404-B9B3-415C-99EC-66EC22E2B2E7_2_11">-33894000</us-gaap:OperatingIncomeLoss> <us-gaap:IncreaseDecreaseInDueFromRelatedPartiesCurrent contextRef="eol_PE151383--1410-K0012_STD_365_20131231_0" unitRef="iso4217_USD" decimals="-3" id="id_6895476_84756BCF-71FA-4E32-A511-A3DCED215C30_2_9">0</us-gaap:IncreaseDecreaseInDueFromRelatedPartiesCurrent> <us-gaap:ComprehensiveIncomeNetOfTax contextRef="eol_PE151383--1410-K0012_STD_365_20131231_0" unitRef="iso4217_USD" decimals="-3" id="id_6895476_FF4E9404-B9B3-415C-99EC-66EC22E2B2E7_2_22">-33728000</us-gaap:ComprehensiveIncomeNetOfTax> <us-gaap:NonoperatingIncomeExpense contextRef="eol_PE151383--1410-K0012_STD_365_20131231_0" unitRef="iso4217_USD" decimals="-3" id="id_6895476_73255E91-D164-4B6A-A45B-4757187E85BA_2_2">177000</us-gaap:NonoperatingIncomeExpense> <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments contextRef="eol_PE151383--1410-K0012_STD_365_20131231_0" unitRef="iso4217_USD" decimals="-3" id="id_6895476_7D9738C0-6CE1-4E3E-8312-71FD14F9FEB0_2_2">-33717000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments> <us-gaap:GainOnSaleOfInvestments contextRef="eol_PE151383--1410-K0012_STD_365_20131231_0" unitRef="iso4217_USD" decimals="-3" id="id_6895476_84756BCF-71FA-4E32-A511-A3DCED215C30_2_7">0</us-gaap:GainOnSaleOfInvestments> <us-gaap:Revenues contextRef="eol_PE151383--1410-K0012_STD_365_20131231_0" unitRef="iso4217_USD" decimals="-3" id="id_6895476_FF4E9404-B9B3-415C-99EC-66EC22E2B2E7_2_5">30648000</us-gaap:Revenues> <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment contextRef="eol_PE151383--1410-K0012_STD_365_20131231_0" unitRef="iso4217_USD" decimals="-3" id="id_6895476_84756BCF-71FA-4E32-A511-A3DCED215C30_2_19">542000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment> <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic contextRef="eol_PE151383--1410-K0012_STD_365_20131231_0" unitRef="iso4217_USD" decimals="-3" id="id_6895476_09173C79-2713-49DF-8107-C7F99AA4E397_2_2">-33717000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic> <us-gaap:NetIncomeLoss contextRef="eol_PE151383--1410-K0012_STD_365_20131231_0" unitRef="iso4217_USD" decimals="-3" id="id_6895476_58E9B802-84A6-48EC-8C22-C0DD0182E686_9008_57">-33717000</us-gaap:NetIncomeLoss> <us-gaap:InvestmentIncomeInterest contextRef="eol_PE151383--1410-K0012_STD_365_20131231_0" unitRef="iso4217_USD" decimals="-3" id="id_6895476_944F757B-AF2C-42F5-8AB2-26CA07F38C19_2_0">96000</us-gaap:InvestmentIncomeInterest> <us-gaap:InterestPaid contextRef="eol_PE151383--1410-K0012_STD_365_20131231_0" unitRef="iso4217_USD" decimals="-3" id="id_6895476_822093A4-C207-4594-84E4-6C13CA36E168_2_0">0</us-gaap:InterestPaid> <us-gaap:InterestAndOtherIncome contextRef="eol_PE151383--1410-K0012_STD_365_20131231_0" unitRef="iso4217_USD" decimals="-3" id="id_6895476_73255E91-D164-4B6A-A45B-4757187E85BA_2_0">98000</us-gaap:InterestAndOtherIncome> <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="eol_PE151383--1410-K0012_STD_365_20131231_0" unitRef="iso4217_USD" decimals="-3" id="id_6895476_58E9B802-84A6-48EC-8C22-C0DD0182E686_9008_55">3597000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue> <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic contextRef="eol_PE151383--1410-K0012_STD_365_20131231_0" unitRef="iso4217_USD" decimals="-3" id="id_6895476_7D9738C0-6CE1-4E3E-8312-71FD14F9FEB0_2_0">-33717000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic> <us-gaap:AllocatedShareBasedCompensationExpense contextRef="eol_PE151383--1410-K0012_STD_365_20131231_0" unitRef="iso4217_USD" decimals="-3" id="id_6895476_4ED78B6B-525C-4A06-A788-E5CE58B1F0CD_2_2">3597000</us-gaap:AllocatedShareBasedCompensationExpense> <us-gaap:DeferredIncomeTaxExpenseBenefit contextRef="eol_PE151383--1410-K0012_STD_365_20131231_0" unitRef="iso4217_USD" decimals="-3" id="id_6895476_313A5609-80D0-44B6-B522-EDB92ECD334E_2_7">0</us-gaap:DeferredIncomeTaxExpenseBenefit> <us-gaap:DepreciationDepletionAndAmortization contextRef="eol_PE151383--1410-K0012_STD_365_20131231_0" unitRef="iso4217_USD" decimals="-3" id="id_6895476_84756BCF-71FA-4E32-A511-A3DCED215C30_2_3">433000</us-gaap:DepreciationDepletionAndAmortization> <us-gaap:IncreaseDecreaseInDeferredRevenue contextRef="eol_PE151383--1410-K0012_STD_365_20131231_0" unitRef="iso4217_USD" decimals="-3" id="id_6895476_84756BCF-71FA-4E32-A511-A3DCED215C30_2_14">16201000</us-gaap:IncreaseDecreaseInDeferredRevenue> <us-gaap:InterestExpense contextRef="eol_PE151383--1410-K0012_STD_365_20131231_0" unitRef="iso4217_USD" decimals="-3" id="id_6895476_42B95EC7-417F-4E86-8649-AA2AAA9B2184_2_0">0</us-gaap:InterestExpense> <us-gaap:ProceedsFromIssuanceOfPreferredStockAndPreferenceStock contextRef="eol_PE151383--1410-K0012_STD_365_20131231_0" unitRef="iso4217_USD" decimals="-3" id="id_6895476_84756BCF-71FA-4E32-A511-A3DCED215C30_2_27">0</us-gaap:ProceedsFromIssuanceOfPreferredStockAndPreferenceStock> <us-gaap:ResearchAndDevelopmentExpense contextRef="eol_PE151383--1410-K0012_STD_365_20131231_0" unitRef="iso4217_USD" decimals="-3" id="id_6895476_FF4E9404-B9B3-415C-99EC-66EC22E2B2E7_2_7">49450000</us-gaap:ResearchAndDevelopmentExpense> <us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit contextRef="eol_PE151383--1410-K0012_STD_365_20131231_0" unitRef="iso4217_USD" decimals="-3" id="id_6895476_313A5609-80D0-44B6-B522-EDB92ECD334E_2_6">0</us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit> <us-gaap:RestructuringCharges contextRef="eol_PE151383--1410-K0012_STD_365_20131231_0" unitRef="iso4217_USD" decimals="-3" id="id_6895476_FF4E9404-B9B3-415C-99EC-66EC22E2B2E7_2_9">0</us-gaap:RestructuringCharges> <us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease contextRef="eol_PE151383--1410-K0012_STD_365_20131231_0" unitRef="iso4217_USD" decimals="-3" id="id_6895476_84756BCF-71FA-4E32-A511-A3DCED215C30_2_30">5251000</us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease> <us-gaap:IncomeTaxExpenseBenefit contextRef="eol_PE151383--1410-K0012_STD_365_20131231_0" unitRef="iso4217_USD" decimals="-3" id="id_6895476_8E079FDA-A4BC-47E2-A9A9-72879770E667_2_0">0</us-gaap:IncomeTaxExpenseBenefit> <us-gaap:OperatingLeasesRentExpenseNet contextRef="eol_PE151383--1410-K0012_STD_365_20131231_0" unitRef="iso4217_USD" decimals="-3" id="id_6895476_BCDA57D7-0AE7-485E-8998-1C33E525DE09_2_0">3306000</us-gaap:OperatingLeasesRentExpenseNet> <us-gaap:CurrentFederalTaxExpenseBenefit contextRef="eol_PE151383--1410-K0012_STD_365_20131231_0" unitRef="iso4217_USD" decimals="-3" id="id_6895476_313A5609-80D0-44B6-B522-EDB92ECD334E_2_1">0</us-gaap:CurrentFederalTaxExpenseBenefit> <us-gaap:Depreciation contextRef="eol_PE151383--1410-K0012_STD_365_20131231_0" unitRef="iso4217_USD" decimals="-5" id="id_6895476_39F2804C-5F74-4B61-9FD9-4D6A1871D4BD_2_0">400000</us-gaap:Depreciation> <us-gaap:NetCashProvidedByUsedInFinancingActivitiesContinuingOperations contextRef="eol_PE151383--1410-K0012_STD_365_20131231_0" unitRef="iso4217_USD" decimals="-3" id="id_6895476_84756BCF-71FA-4E32-A511-A3DCED215C30_2_29">14488000</us-gaap:NetCashProvidedByUsedInFinancingActivitiesContinuingOperations> <us-gaap:ProceedsFromIssuanceOfCommonStock contextRef="eol_PE151383--1410-K0012_STD_365_20131231_0" unitRef="iso4217_USD" decimals="-3" id="id_6895476_84756BCF-71FA-4E32-A511-A3DCED215C30_2_24">7450000</us-gaap:ProceedsFromIssuanceOfCommonStock> <us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment contextRef="eol_PE151383--1410-K0012_STD_365_20131231_0" unitRef="iso4217_USD" decimals="-3" id="id_6895476_84756BCF-71FA-4E32-A511-A3DCED215C30_2_20">13000</us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment> <us-gaap:CurrentStateAndLocalTaxExpenseBenefit contextRef="eol_PE151383--1410-K0012_STD_365_20131231_0" unitRef="iso4217_USD" decimals="-3" id="id_6895476_313A5609-80D0-44B6-B522-EDB92ECD334E_2_2">0</us-gaap:CurrentStateAndLocalTaxExpenseBenefit> <us-gaap:IncreaseDecreaseInAccruedLiabilities contextRef="eol_PE151383--1410-K0012_STD_365_20131231_0" unitRef="iso4217_USD" decimals="-3" id="id_6895476_84756BCF-71FA-4E32-A511-A3DCED215C30_2_12">3523000</us-gaap:IncreaseDecreaseInAccruedLiabilities> <us-gaap:InterestAndDebtExpense contextRef="eol_PE151383--1410-K0012_STD_365_20131231_0" unitRef="iso4217_USD" decimals="-3" id="id_6895476_73255E91-D164-4B6A-A45B-4757187E85BA_2_1">-79000</us-gaap:InterestAndDebtExpense> <us-gaap:NetCashProvidedByUsedInInvestingActivitiesContinuingOperations contextRef="eol_PE151383--1410-K0012_STD_365_20131231_0" unitRef="iso4217_USD" decimals="-3" id="id_6895476_84756BCF-71FA-4E32-A511-A3DCED215C30_2_22">-1519000</us-gaap:NetCashProvidedByUsedInInvestingActivitiesContinuingOperations> <us-gaap:NoncashOrPartNoncashAcquisitionFixedAssetsAcquired1 contextRef="eol_PE151383--1410-K0012_STD_365_20131231_0" unitRef="iso4217_USD" decimals="-3" id="id_6895476_822093A4-C207-4594-84E4-6C13CA36E168_2_3">193000</us-gaap:NoncashOrPartNoncashAcquisitionFixedAssetsAcquired1> <us-gaap:CurrentIncomeTaxExpenseBenefit contextRef="eol_PE151383--1410-K0012_STD_365_20131231_0" unitRef="iso4217_USD" decimals="-3" id="id_6895476_313A5609-80D0-44B6-B522-EDB92ECD334E_2_3">0</us-gaap:CurrentIncomeTaxExpenseBenefit> <us-gaap:CostsAndExpenses contextRef="eol_PE151383--1410-K0012_STD_365_20131231_0" unitRef="iso4217_USD" decimals="-3" id="id_6895476_FF4E9404-B9B3-415C-99EC-66EC22E2B2E7_2_10">64542000</us-gaap:CostsAndExpenses> <us-gaap:RestructuringCostsAndAssetImpairmentCharges contextRef="eol_PE151383--1410-K0012_STD_365_20131231_0" unitRef="iso4217_USD" decimals="-3" id="id_6895476_84756BCF-71FA-4E32-A511-A3DCED215C30_2_5">0</us-gaap:RestructuringCostsAndAssetImpairmentCharges> <us-gaap:GeneralAndAdministrativeExpense contextRef="eol_PE151383--1410-K0012_STD_365_20131231_0" unitRef="iso4217_USD" decimals="-3" id="id_6895476_FF4E9404-B9B3-415C-99EC-66EC22E2B2E7_2_8">15092000</us-gaap:GeneralAndAdministrativeExpense> <us-gaap:IncreaseDecreaseInDueToRelatedPartiesCurrent contextRef="eol_PE151383--1410-K0012_STD_365_20131231_0" unitRef="iso4217_USD" decimals="-3" id="id_6895476_84756BCF-71FA-4E32-A511-A3DCED215C30_2_13">-150000</us-gaap:IncreaseDecreaseInDueToRelatedPartiesCurrent> <us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities contextRef="eol_PE151383--1410-K0012_STD_365_20131231_0" unitRef="iso4217_USD" decimals="-3" id="id_6895476_84756BCF-71FA-4E32-A511-A3DCED215C30_2_18">78444000</us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities> <us-gaap:ShareBasedCompensation contextRef="eol_PE151383--1410-K0012_STD_365_20131231_0" unitRef="iso4217_USD" decimals="-3" id="id_6895476_84756BCF-71FA-4E32-A511-A3DCED215C30_2_6">3597000</us-gaap:ShareBasedCompensation> <us-gaap:DeferredFederalIncomeTaxExpenseBenefit contextRef="eol_PE151383--1410-K0012_STD_365_20131231_0" unitRef="iso4217_USD" decimals="-3" id="id_6895476_313A5609-80D0-44B6-B522-EDB92ECD334E_2_5">0</us-gaap:DeferredFederalIncomeTaxExpenseBenefit> <us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount contextRef="eol_PE151383--1410-K0012_STD_365_20131231_0" unitRef="iso4217_USD" decimals="INF" id="id_6895476_415AD002-83D0-4FE9-B832-5E67DD6E4E77_1_0">0</us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount> <us-gaap:IncreaseDecreaseInAccountsPayableTrade contextRef="eol_PE151383--1410-K0012_STD_365_20131231_0" unitRef="iso4217_USD" decimals="-3" id="id_6895476_84756BCF-71FA-4E32-A511-A3DCED215C30_2_11">1656000</us-gaap:IncreaseDecreaseInAccountsPayableTrade> <us-gaap:OtherPreferredStockDividendsAndAdjustments contextRef="eol_PE151383--1410-K0012_STD_365_20131231_0" unitRef="iso4217_USD" decimals="-3" id="id_6895476_09173C79-2713-49DF-8107-C7F99AA4E397_2_1">0</us-gaap:OtherPreferredStockDividendsAndAdjustments> <cytk:IssuanceOfCommonStockEmployeeStockPurchasePlanPricePerShare contextRef="eol_PE151383--1410-K0012_STD_365_20131231_0" unitRef="iso4217_USD_per_shares" decimals="INF" id="id_6895476_58E9B802-84A6-48EC-8C22-C0DD0182E686_9008_37">3.66</cytk:IssuanceOfCommonStockEmployeeStockPurchasePlanPricePerShare> <cytk:EffectiveIncomeTaxRateReconciliationNetOperatingLossExpiration contextRef="eol_PE151383--1410-K0012_STD_365_20131231_0" unitRef="pure" decimals="2" id="id_6895476_14EF385A-3844-4F78-AE65-D20D0D541C15_2_6">0.01</cytk:EffectiveIncomeTaxRateReconciliationNetOperatingLossExpiration> <cytk:ShareBasedCompensationArrangementByShareBasedPaymentSharesAvailableForGrantAwardOptionsExercisedInPeriodGross contextRef="eol_PE151383--1410-K0012_STD_365_20131231_0" unitRef="shares" decimals="0" id="id_6895476_550670F2-8019-4594-8D89-8D38F90A7B79_7001_10">0</cytk:ShareBasedCompensationArrangementByShareBasedPaymentSharesAvailableForGrantAwardOptionsExercisedInPeriodGross> <cytk:StockIssuedDuringPeriodValueNewIssuesToRelatedParty contextRef="eol_PE151383--1410-K0012_STD_365_20131231_0" unitRef="iso4217_USD" decimals="-3" id="id_6895476_58E9B802-84A6-48EC-8C22-C0DD0182E686_9008_40">7450000</cytk:StockIssuedDuringPeriodValueNewIssuesToRelatedParty> <cytk:ProceedsFromDrawDownOfCommittedEquityFinancingFacilitiesAndAtMarketFacilityNetOfIssuanceCosts contextRef="eol_PE151383--1410-K0012_STD_365_20131231_0" unitRef="iso4217_USD" decimals="-3" id="id_6895476_84756BCF-71FA-4E32-A511-A3DCED215C30_2_25">0</cytk:ProceedsFromDrawDownOfCommittedEquityFinancingFacilitiesAndAtMarketFacilityNetOfIssuanceCosts> <cytk:SharesAvailableForGrantOfOptionsOrAwardsOptionsForfeitedExpired contextRef="eol_PE151383--1410-K0012_STD_365_20131231_0" unitRef="shares" decimals="INF" id="id_6895476_550670F2-8019-4594-8D89-8D38F90A7B79_7001_11">117394</cytk:SharesAvailableForGrantOfOptionsOrAwardsOptionsForfeitedExpired> <cytk:LicenseRevenuesFromRelatedParties contextRef="eol_PE151383--1410-K0012_STD_365_20131231_0" unitRef="iso4217_USD" decimals="-3" id="id_6895476_FF4E9404-B9B3-415C-99EC-66EC22E2B2E7_2_3">17230000</cytk:LicenseRevenuesFromRelatedParties> <cytk:IssuanceOfCommonStockToRelatedPartyForCashPerShare contextRef="eol_PE151383--1410-K0012_STD_365_20131231_0" unitRef="iso4217_USD_per_shares" decimals="2" id="id_6895476_58E9B802-84A6-48EC-8C22-C0DD0182E686_9008_42">7.12</cytk:IssuanceOfCommonStockToRelatedPartyForCashPerShare> <cytk:IssuanceOfCommonStockToRelatedPartyIssuanceCosts contextRef="eol_PE151383--1410-K0012_STD_365_20131231_0" unitRef="iso4217_USD" decimals="-3" id="id_6895476_58E9B802-84A6-48EC-8C22-C0DD0182E686_9008_43">21000</cytk:IssuanceOfCommonStockToRelatedPartyIssuanceCosts> <cytk:EffectiveIncomeTaxRateReconciliationDeferredTaxAssetsUtilizedNotBenefited contextRef="eol_PE151383--1410-K0012_STD_365_20131231_0" unitRef="pure" decimals="2" id="id_6895476_14EF385A-3844-4F78-AE65-D20D0D541C15_2_4">0.41</cytk:EffectiveIncomeTaxRateReconciliationDeferredTaxAssetsUtilizedNotBenefited> <cytk:StockIssuedDuringPeriodValueExerciseOfWarrants contextRef="eol_PE151383--1410-K0012_STD_365_20131231_0" unitRef="iso4217_USD" decimals="-3" id="id_6895476_58E9B802-84A6-48EC-8C22-C0DD0182E686_9008_44">5000</cytk:StockIssuedDuringPeriodValueExerciseOfWarrants> <cytk:ResearchAndDevelopmentRevenuesFromRelatedParties contextRef="eol_PE151383--1410-K0012_STD_365_20131231_0" unitRef="iso4217_USD" decimals="-3" id="id_6895476_FF4E9404-B9B3-415C-99EC-66EC22E2B2E7_2_1">2019000</cytk:ResearchAndDevelopmentRevenuesFromRelatedParties> <cytk:ProceedsAndPaymentsFromStockBasedAwardAndWarrantsNetOfIssuanceCosts contextRef="eol_PE151383--1410-K0012_STD_365_20131231_0" unitRef="iso4217_USD" decimals="-3" id="id_6895476_84756BCF-71FA-4E32-A511-A3DCED215C30_2_26">-7038000</cytk:ProceedsAndPaymentsFromStockBasedAwardAndWarrantsNetOfIssuanceCosts> <cytk:ResearchAndDevelopmentGrantAndOtherRevenues contextRef="eol_PE151383--1410-K0012_STD_365_20131231_0" unitRef="iso4217_USD" decimals="-3" id="id_6895476_FF4E9404-B9B3-415C-99EC-66EC22E2B2E7_2_2">7547000</cytk:ResearchAndDevelopmentGrantAndOtherRevenues> <cytk:EffectiveIncomeTaxRateReconciliationStateApportionment contextRef="eol_PE151383--1410-K0012_STD_365_20131231_0" unitRef="pure" decimals="2" id="id_6895476_14EF385A-3844-4F78-AE65-D20D0D541C15_2_2">0.07</cytk:EffectiveIncomeTaxRateReconciliationStateApportionment> <cytk:NoncashOrPartNoncashAcquisitionFixedAssetsAcquiredTradeInValue contextRef="eol_PE151383--1410-K0012_STD_365_20131231_0" unitRef="iso4217_USD" decimals="-3" id="id_6895476_822093A4-C207-4594-84E4-6C13CA36E168_2_5">81000</cytk:NoncashOrPartNoncashAcquisitionFixedAssetsAcquiredTradeInValue> <cytk:IncreaseDecreaseInNoncashOrPartNoncashAcquisitionFixedAssetsAcquiredThroughAccruedLiabilities contextRef="eol_PE151383--1410-K0012_STD_365_20131231_0" unitRef="iso4217_USD" decimals="-3" id="id_6895476_822093A4-C207-4594-84E4-6C13CA36E168_2_4">-2000</cytk:IncreaseDecreaseInNoncashOrPartNoncashAcquisitionFixedAssetsAcquiredThroughAccruedLiabilities> <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="eol_PE151383--1410-K0012_STD_365_20131231_0_1268687x1271212" unitRef="shares" decimals="-3" id="id_6895476_3E2C7E3E-7982-4F2C-A6E3-5C7781C1D9F7_1002_3">42000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount> <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="eol_PE151383--1410-K0012_STD_365_20131231_0_1268687x1273442" unitRef="shares" decimals="-3" id="id_6895476_3E2C7E3E-7982-4F2C-A6E3-5C7781C1D9F7_2002_1">7692000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount> <cytk:AvailableForSaleSecuritiesMaturityDate contextRef="eol_PE151383--1410-K0012_STD_365_20131231_0_1269523x1275948_1270365x1274813_1274212x1276380" id="id_6895476_5953821E-651A-43AE-83D1-8E91E00151B4_2005_6">2014-12</cytk:AvailableForSaleSecuritiesMaturityDate> <cytk:AvailableForSaleSecuritiesMaturityDate contextRef="eol_PE151383--1410-K0012_STD_365_20131231_0_1269523x1277596_1270365x1274813_1274212x1276380" id="id_6895476_5953821E-651A-43AE-83D1-8E91E00151B4_3005_5">2014-01</cytk:AvailableForSaleSecuritiesMaturityDate> <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod contextRef="eol_PE151383--1410-K0012_STD_365_20131231_0_1270313x1271210" unitRef="shares" decimals="INF" id="id_6895476_9D5C22B2-CCEF-4AED-B18A-0ACE42E2B15B_6001_7">4999</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod> <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue contextRef="eol_PE151383--1410-K0012_STD_365_20131231_0_1270313x1271210" unitRef="iso4217_USD_per_shares" decimals="2" id="id_6895476_4396C4E5-DD06-4003-A485-BA06C7D8368D_6001_5">6.00</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue> <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod contextRef="eol_PE151383--1410-K0012_STD_365_20131231_0_1270313x1271210" unitRef="shares" decimals="INF" id="id_6895476_9D5C22B2-CCEF-4AED-B18A-0ACE42E2B15B_6001_6">211897</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod> <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod contextRef="eol_PE151383--1410-K0012_STD_365_20131231_0_1270313x1271210" unitRef="shares" decimals="INF" id="id_6895476_9D5C22B2-CCEF-4AED-B18A-0ACE42E2B15B_6001_5">41661</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod> <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue contextRef="eol_PE151383--1410-K0012_STD_365_20131231_0_1270313x1271210" unitRef="iso4217_USD_per_shares" decimals="2" id="id_6895476_4396C4E5-DD06-4003-A485-BA06C7D8368D_6001_6">6.78</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue> <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue contextRef="eol_PE151383--1410-K0012_STD_365_20131231_0_1270313x1271210" unitRef="iso4217_USD_per_shares" decimals="2" id="id_6895476_4396C4E5-DD06-4003-A485-BA06C7D8368D_6001_7">6.78</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue> <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod contextRef="eol_PE151383--1410-K0012_STD_365_20131231_0_1270313x1271212" unitRef="shares" decimals="INF" id="id_6895476_550670F2-8019-4594-8D89-8D38F90A7B79_8001_12">4999</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod> <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod contextRef="eol_PE151383--1410-K0012_STD_365_20131231_0_1270313x1271212" unitRef="shares" decimals="INF" id="id_6895476_EAE02EAA-C88A-417D-A4E8-6DD5ADADA4AB_8001_12">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod> <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross contextRef="eol_PE151383--1410-K0012_STD_365_20131231_0_1270313x1271212" unitRef="shares" decimals="INF" id="id_6895476_EAE02EAA-C88A-417D-A4E8-6DD5ADADA4AB_8001_9">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross> <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod contextRef="eol_PE151383--1410-K0012_STD_365_20131231_0_1270313x1271212" unitRef="shares" decimals="INF" id="id_6895476_550670F2-8019-4594-8D89-8D38F90A7B79_8001_9">41661</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod> <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue contextRef="eol_PE151383--1410-K0012_STD_365_20131231_0_1270313x1271212" unitRef="iso4217_USD" decimals="-5" id="id_6895476_25E57D28-4973-461D-96F3-FC38BA8FEA62_1002_0">1400000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue> <cytk:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedInPeriodWeightedAverageExercisePrice contextRef="eol_PE151383--1410-K0012_STD_365_20131231_0_1270313x1271212" unitRef="iso4217_USD_per_shares" decimals="0" id="id_6895476_C3206D70-DEC9-4565-9145-8B70956A712D_8001_7">0</cytk:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedInPeriodWeightedAverageExercisePrice> <cytk:ShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentOtherThanOptionForfeituresInPeriodWeightedAverageExercisePrice contextRef="eol_PE151383--1410-K0012_STD_365_20131231_0_1270313x1271212" unitRef="iso4217_USD_per_shares" decimals="0" id="id_6895476_C3206D70-DEC9-4565-9145-8B70956A712D_8001_10">0</cytk:ShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentOtherThanOptionForfeituresInPeriodWeightedAverageExercisePrice> <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate contextRef="eol_PE151383--1410-K0012_STD_365_20131231_0_1270313x1275629" unitRef="pure" decimals="3" id="id_6895476_A776E96A-A480-479E-9B5C-9A756B15D08A_3_3">0.000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate> <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="eol_PE151383--1410-K0012_STD_365_20131231_0_1270313x1275629" id="id_6895476_A776E96A-A480-479E-9B5C-9A756B15D08A_3_2">P6Y2M12D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1> <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate contextRef="eol_PE151383--1410-K0012_STD_365_20131231_0_1270313x1275629" unitRef="pure" decimals="3" id="id_6895476_A776E96A-A480-479E-9B5C-9A756B15D08A_3_0">0.011</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate> <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate contextRef="eol_PE151383--1410-K0012_STD_365_20131231_0_1270313x1275629" unitRef="pure" decimals="3" id="id_6895476_A776E96A-A480-479E-9B5C-9A756B15D08A_3_1">0.732</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate> <cytk:AvailableForSaleSecuritiesMaturityDate contextRef="eol_PE151383--1410-K0012_STD_365_20131231_0_1270365x1274813_1274212x1435842" id="id_6895476_5953821E-651A-43AE-83D1-8E91E00151B4_6_7">2015-01</cytk:AvailableForSaleSecuritiesMaturityDate> <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate contextRef="eol_PE151383--1410-K0012_STD_365_20131231_0_1271382x1277228" unitRef="pure" decimals="3" id="id_6895476_A776E96A-A480-479E-9B5C-9A756B15D08A_4_3">0.000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate> <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="eol_PE151383--1410-K0012_STD_365_20131231_0_1271382x1277228" id="id_6895476_A776E96A-A480-479E-9B5C-9A756B15D08A_4_2">P1Y3M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1> <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate contextRef="eol_PE151383--1410-K0012_STD_365_20131231_0_1271382x1277228" unitRef="pure" decimals="3" id="id_6895476_A776E96A-A480-479E-9B5C-9A756B15D08A_4_0">0.002</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate> <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate contextRef="eol_PE151383--1410-K0012_STD_365_20131231_0_1271382x1277228" unitRef="pure" decimals="3" id="id_6895476_A776E96A-A480-479E-9B5C-9A756B15D08A_4_1">0.746</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate> <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="eol_PE151383--1410-K0012_STD_365_20131231_0_1271382x1277228" unitRef="shares" decimals="-3" id="id_6895476_3E2C7E3E-7982-4F2C-A6E3-5C7781C1D9F7_3002_4">14000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount> <cytk:IssuanceOfCommonStockToMlvAtPerShareUpperLimit contextRef="eol_PE151383--1410-K0012_STD_365_20131231_0_1271382x1511257" unitRef="iso4217_USD_per_shares" decimals="2" id="id_6895476_58E9B802-84A6-48EC-8C22-C0DD0182E686_10008_53">6.79</cytk:IssuanceOfCommonStockToMlvAtPerShareUpperLimit> <cytk:IssuanceOfCommonStockToMlvNetOfCommissionAndIssuanceCosts contextRef="eol_PE151383--1410-K0012_STD_365_20131231_0_1271382x1511257" unitRef="iso4217_USD" decimals="-3" id="id_6895476_58E9B802-84A6-48EC-8C22-C0DD0182E686_10008_54">232000</cytk:IssuanceOfCommonStockToMlvNetOfCommissionAndIssuanceCosts> <cytk:IssuanceOfCommonStockToMlvAtPerShareLowerLimit contextRef="eol_PE151383--1410-K0012_STD_365_20131231_0_1271382x1511257" unitRef="iso4217_USD_per_shares" decimals="1" id="id_6895476_58E9B802-84A6-48EC-8C22-C0DD0182E686_10008_52">6.5</cytk:IssuanceOfCommonStockToMlvAtPerShareLowerLimit> <cytk:StockIssuedDuringPeriodValueAtMarketIssuanceSalesAgreement contextRef="eol_PE151383--1410-K0012_STD_365_20131231_0_1271382x1511257" unitRef="iso4217_USD" decimals="-3" id="id_6895476_58E9B802-84A6-48EC-8C22-C0DD0182E686_10008_50">7487000</cytk:StockIssuedDuringPeriodValueAtMarketIssuanceSalesAgreement> <cytk:StockIssuedDuringPeriodSharesAtMarketIssuanceSalesAgreement contextRef="eol_PE151383--1410-K0012_STD_365_20131231_0_1271382x1511257_1276401x1270422" unitRef="shares" decimals="INF" id="id_6895476_58E9B802-84A6-48EC-8C22-C0DD0182E686_10001_51">1170583</cytk:StockIssuedDuringPeriodSharesAtMarketIssuanceSalesAgreement> <cytk:StockIssuedDuringPeriodValueAtMarketIssuanceSalesAgreement contextRef="eol_PE151383--1410-K0012_STD_365_20131231_0_1271382x1511257_1276401x1270422" unitRef="iso4217_USD" decimals="-3" id="id_6895476_58E9B802-84A6-48EC-8C22-C0DD0182E686_10001_50">1000</cytk:StockIssuedDuringPeriodValueAtMarketIssuanceSalesAgreement> <cytk:StockIssuedDuringPeriodValueAtMarketIssuanceSalesAgreement contextRef="eol_PE151383--1410-K0012_STD_365_20131231_0_1271382x1511257_1276401x1273630" unitRef="iso4217_USD" decimals="-3" id="id_6895476_58E9B802-84A6-48EC-8C22-C0DD0182E686_10005_50">7486000</cytk:StockIssuedDuringPeriodValueAtMarketIssuanceSalesAgreement> <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="eol_PE151383--1410-K0012_STD_365_20131231_0_1272720x1275629" unitRef="shares" decimals="-3" id="id_6895476_3E2C7E3E-7982-4F2C-A6E3-5C7781C1D9F7_4002_0">2449000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount> <us-gaap:ReimbursementRevenue contextRef="eol_PE151383--1410-K0012_STD_365_20131231_0_1272896x1454595" unitRef="iso4217_USD" decimals="-3" id="id_6895476_097E51C1-D472-4642-91F0-D1638561D10B_1002_1">1024000</us-gaap:ReimbursementRevenue> <cytk:ResearchAndDevelopmentRevenueFromCollaboration contextRef="eol_PE151383--1410-K0012_STD_365_20131231_0_1272896x1454595" unitRef="iso4217_USD" decimals="-3" id="id_6895476_097E51C1-D472-4642-91F0-D1638561D10B_1002_2">1024000</cytk:ResearchAndDevelopmentRevenueFromCollaboration> <cytk:ResearchAndDevelopmentRevenue contextRef="eol_PE151383--1410-K0012_STD_365_20131231_0_1272896x1454595" unitRef="iso4217_USD" decimals="-3" id="id_6895476_097E51C1-D472-4642-91F0-D1638561D10B_1002_0">0</cytk:ResearchAndDevelopmentRevenue> <us-gaap:RevenueFromGrants contextRef="eol_PE151383--1410-K0012_STD_365_20131231_0_1272896x1507815" unitRef="iso4217_USD" decimals="-3" id="id_6895476_FD977883-B531-4443-8A85-7DBADCAD1197_1002_0">69000</us-gaap:RevenueFromGrants> <us-gaap:ReimbursementRevenue contextRef="eol_PE151383--1410-K0012_STD_365_20131231_0_1272896x1537165" unitRef="iso4217_USD" decimals="-3" id="id_6895476_C614CF06-9CB5-403B-B2F4-C612F97ACB77_1002_0">14000</us-gaap:ReimbursementRevenue> <us-gaap:RevenueFromGrants contextRef="eol_PE151383--1410-K0012_STD_365_20131231_0_1272896x1621940" unitRef="iso4217_USD" decimals="-3" id="id_6895476_FD977883-B531-4443-8A85-7DBADCAD1197_2002_1">25000</us-gaap:RevenueFromGrants> <us-gaap:ConcentrationRiskPercentage1 contextRef="eol_PE151383--1410-K0012_STD_365_20131231_0_1273333x1269843" unitRef="pure" decimals="2" id="id_6895476_C3137FA3-DA71-4E40-BD85-F7C46617CB80_1002_1">0.34</us-gaap:ConcentrationRiskPercentage1> <us-gaap:ConcentrationRiskPercentage1 contextRef="eol_PE151383--1410-K0012_STD_365_20131231_0_1273333x1271500" unitRef="pure" decimals="2" id="id_6895476_C3137FA3-DA71-4E40-BD85-F7C46617CB80_2002_0">0.66</us-gaap:ConcentrationRiskPercentage1> <us-gaap:AllocatedShareBasedCompensationExpense contextRef="eol_PE151383--1410-K0012_STD_365_20131231_0_1274159x1269133" unitRef="iso4217_USD" decimals="-3" id="id_6895476_4ED78B6B-525C-4A06-A788-E5CE58B1F0CD_1002_1">2059000</us-gaap:AllocatedShareBasedCompensationExpense> <us-gaap:AllocatedShareBasedCompensationExpense contextRef="eol_PE151383--1410-K0012_STD_365_20131231_0_1274159x1269570" unitRef="iso4217_USD" decimals="-3" id="id_6895476_4ED78B6B-525C-4A06-A788-E5CE58B1F0CD_2002_0">1538000</us-gaap:AllocatedShareBasedCompensationExpense> <us-gaap:UnrealizedGainLossOnInvestments contextRef="eol_PE151383--1410-K0012_STD_365_20131231_0_1274212x1276380" unitRef="iso4217_USD" decimals="-3" id="id_6895476_FC5D6B10-2950-4D77-93DA-2D46C596CBF7_2002_0">-1000</us-gaap:UnrealizedGainLossOnInvestments> <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="eol_PE151383--1410-K0012_STD_365_20131231_0_1276400x1281157" unitRef="shares" decimals="-3" id="id_6895476_3E2C7E3E-7982-4F2C-A6E3-5C7781C1D9F7_5002_2">0</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount> <cytk:ConversionPricePerShareOfPreferredStockToCommonStock contextRef="eol_PE151383--1410-K0012_STD_365_20131231_0_1276400x1281157" unitRef="iso4217_USD_per_shares" decimals="INF" id="id_6895476_58E9B802-84A6-48EC-8C22-C0DD0182E686_11008_48">1000</cytk:ConversionPricePerShareOfPreferredStockToCommonStock> <us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities contextRef="eol_PE151383--1410-K0012_STD_365_20131231_0_1276400x1281157_1276401x1270422" unitRef="shares" decimals="INF" id="id_6895476_58E9B802-84A6-48EC-8C22-C0DD0182E686_11001_47">3837681</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities> <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities contextRef="eol_PE151383--1410-K0012_STD_365_20131231_0_1276400x1281157_1276401x1270422" unitRef="iso4217_USD" decimals="-3" id="id_6895476_58E9B802-84A6-48EC-8C22-C0DD0182E686_11001_46">4000</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities> <us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities contextRef="eol_PE151383--1410-K0012_STD_365_20131231_0_1276400x1281157_1276401x1272805" unitRef="shares" decimals="INF" id="id_6895476_58E9B802-84A6-48EC-8C22-C0DD0182E686_11003_47">-23026</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities> <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities contextRef="eol_PE151383--1410-K0012_STD_365_20131231_0_1276400x1281157_1276401x1273630" unitRef="iso4217_USD" decimals="-3" id="id_6895476_58E9B802-84A6-48EC-8C22-C0DD0182E686_11005_46">-4000</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities> <us-gaap:OtherComprehensiveIncomeLossNetOfTax contextRef="eol_PE151383--1410-K0012_STD_365_20131231_0_1276401x1268669" unitRef="iso4217_USD" decimals="-3" id="id_6895476_58E9B802-84A6-48EC-8C22-C0DD0182E686_9006_56">-11000</us-gaap:OtherComprehensiveIncomeLossNetOfTax> <us-gaap:NetIncomeLoss contextRef="eol_PE151383--1410-K0012_STD_365_20131231_0_1276401x1269588" unitRef="iso4217_USD" decimals="-3" id="id_6895476_58E9B802-84A6-48EC-8C22-C0DD0182E686_9007_57">-33717000</us-gaap:NetIncomeLoss> <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans contextRef="eol_PE151383--1410-K0012_STD_365_20131231_0_1276401x1270422" unitRef="shares" decimals="INF" id="id_6895476_58E9B802-84A6-48EC-8C22-C0DD0182E686_9001_36">14985</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans> <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures contextRef="eol_PE151383--1410-K0012_STD_365_20131231_0_1276401x1270422" unitRef="shares" decimals="INF" id="id_6895476_58E9B802-84A6-48EC-8C22-C0DD0182E686_9001_39">130534</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures> <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised contextRef="eol_PE151383--1410-K0012_STD_365_20131231_0_1276401x1270422" unitRef="shares" decimals="INF" id="id_6895476_58E9B802-84A6-48EC-8C22-C0DD0182E686_9001_32">21397</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised> <cytk:StockIssuedDuringPeriodValueNewIssuesToRelatedParty contextRef="eol_PE151383--1410-K0012_STD_365_20131231_0_1276401x1270422" unitRef="iso4217_USD" decimals="-3" id="id_6895476_58E9B802-84A6-48EC-8C22-C0DD0182E686_9001_40">2000</cytk:StockIssuedDuringPeriodValueNewIssuesToRelatedParty> <cytk:FractionalSharesFromReverseStockSplitShare contextRef="eol_PE151383--1410-K0012_STD_365_20131231_0_1276401x1270422" unitRef="shares" decimals="INF" id="id_6895476_58E9B802-84A6-48EC-8C22-C0DD0182E686_9001_49">-28</cytk:FractionalSharesFromReverseStockSplitShare> <cytk:StockIssuedDuringPeriodSharesExerciseOfWarrants contextRef="eol_PE151383--1410-K0012_STD_365_20131231_0_1276401x1270422" unitRef="shares" decimals="INF" id="id_6895476_58E9B802-84A6-48EC-8C22-C0DD0182E686_9001_45">359460</cytk:StockIssuedDuringPeriodSharesExerciseOfWarrants> <cytk:StockIssuedDuringPeriodSharesNewIssuesToRelatedParty contextRef="eol_PE151383--1410-K0012_STD_365_20131231_0_1276401x1270422" unitRef="shares" decimals="INF" id="id_6895476_58E9B802-84A6-48EC-8C22-C0DD0182E686_9001_41">1404100</cytk:StockIssuedDuringPeriodSharesNewIssuesToRelatedParty> <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans contextRef="eol_PE151383--1410-K0012_STD_365_20131231_0_1276401x1272805" unitRef="shares" decimals="INF" id="id_6895476_58E9B802-84A6-48EC-8C22-C0DD0182E686_9003_36">0</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans> <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures contextRef="eol_PE151383--1410-K0012_STD_365_20131231_0_1276401x1272805" unitRef="shares" decimals="INF" id="id_6895476_58E9B802-84A6-48EC-8C22-C0DD0182E686_9003_39">0</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures> <cytk:StockIssuedDuringPeriodSharesExerciseOfWarrants contextRef="eol_PE151383--1410-K0012_STD_365_20131231_0_1276401x1272805" unitRef="shares" decimals="INF" id="id_6895476_58E9B802-84A6-48EC-8C22-C0DD0182E686_9003_45">0</cytk:StockIssuedDuringPeriodSharesExerciseOfWarrants> <cytk:StockIssuedDuringPeriodSharesNewIssuesToRelatedParty contextRef="eol_PE151383--1410-K0012_STD_365_20131231_0_1276401x1272805" unitRef="shares" decimals="INF" id="id_6895476_58E9B802-84A6-48EC-8C22-C0DD0182E686_9003_41">0</cytk:StockIssuedDuringPeriodSharesNewIssuesToRelatedParty> <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures contextRef="eol_PE151383--1410-K0012_STD_365_20131231_0_1276401x1273630" unitRef="iso4217_USD" decimals="-3" id="id_6895476_58E9B802-84A6-48EC-8C22-C0DD0182E686_9005_38">-623000</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures> <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan contextRef="eol_PE151383--1410-K0012_STD_365_20131231_0_1276401x1273630" unitRef="iso4217_USD" decimals="-3" id="id_6895476_58E9B802-84A6-48EC-8C22-C0DD0182E686_9005_35">55000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan> <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="eol_PE151383--1410-K0012_STD_365_20131231_0_1276401x1273630" unitRef="iso4217_USD" decimals="-3" id="id_6895476_58E9B802-84A6-48EC-8C22-C0DD0182E686_9005_31">114000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised> <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="eol_PE151383--1410-K0012_STD_365_20131231_0_1276401x1273630" unitRef="iso4217_USD" decimals="-3" id="id_6895476_58E9B802-84A6-48EC-8C22-C0DD0182E686_9005_55">3597000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue> <cytk:StockIssuedDuringPeriodValueNewIssuesToRelatedParty contextRef="eol_PE151383--1410-K0012_STD_365_20131231_0_1276401x1273630" unitRef="iso4217_USD" decimals="-3" id="id_6895476_58E9B802-84A6-48EC-8C22-C0DD0182E686_9005_40">7448000</cytk:StockIssuedDuringPeriodValueNewIssuesToRelatedParty> <cytk:StockIssuedDuringPeriodValueExerciseOfWarrants contextRef="eol_PE151383--1410-K0012_STD_365_20131231_0_1276401x1273630" unitRef="iso4217_USD" decimals="-3" id="id_6895476_58E9B802-84A6-48EC-8C22-C0DD0182E686_9005_44">5000</cytk:StockIssuedDuringPeriodValueExerciseOfWarrants> <us-gaap:ConcentrationRiskPercentage1 contextRef="eol_PE151383--1410-K0012_STD_365_20131231_0_1279431x1424859" unitRef="pure" decimals="2" id="id_6895476_D076CC70-CB7C-4170-BD50-2E3EFE86EE58_1002_0">0.63</us-gaap:ConcentrationRiskPercentage1> <us-gaap:LicenseAndServicesRevenue contextRef="eol_PE151383--1410-K0012_STD_365_20131231_0_1279431x1424859" unitRef="iso4217_USD" decimals="-3" id="id_6895476_DA0EFEFC-F120-4996-B278-29668E08DD78_1002_0">17230000</us-gaap:LicenseAndServicesRevenue> <us-gaap:RevenueFromRelatedParties contextRef="eol_PE151383--1410-K0012_STD_365_20131231_0_1279431x1424859" unitRef="iso4217_USD" decimals="-3" id="id_6895476_DA0EFEFC-F120-4996-B278-29668E08DD78_1002_4">0</us-gaap:RevenueFromRelatedParties> <cytk:RelatedPartyResearchAndDevelopmentRevenue contextRef="eol_PE151383--1410-K0012_STD_365_20131231_0_1279431x1424859" unitRef="iso4217_USD" decimals="-3" id="id_6895476_DA0EFEFC-F120-4996-B278-29668E08DD78_1002_5">19249000</cytk:RelatedPartyResearchAndDevelopmentRevenue> <cytk:ReimbursementOfInternalResearchAndDevelopmentCost contextRef="eol_PE151383--1410-K0012_STD_365_20131231_0_1279431x1424859" unitRef="iso4217_USD" decimals="-3" id="id_6895476_DA0EFEFC-F120-4996-B278-29668E08DD78_1002_2">2019000</cytk:ReimbursementOfInternalResearchAndDevelopmentCost> <cytk:ReimbursementOfOtherResearchAndDevelopmentCost contextRef="eol_PE151383--1410-K0012_STD_365_20131231_0_1279431x1424859" unitRef="iso4217_USD" decimals="-3" id="id_6895476_DA0EFEFC-F120-4996-B278-29668E08DD78_1002_3">0</cytk:ReimbursementOfOtherResearchAndDevelopmentCost> <cytk:RelatedPartyResearchAndDevelopmentRevenue contextRef="eol_PE151383--1410-K0012_STD_365_20131231_0_1279431x1434297" unitRef="iso4217_USD" decimals="-3" id="id_6895476_CE89805E-4ADE-44CE-AB36-26227C885BB2_2_6">6415000</cytk:RelatedPartyResearchAndDevelopmentRevenue> <cytk:ReimbursementOfInternalResearchAndDevelopmentCost contextRef="eol_PE151383--1410-K0012_STD_365_20131231_0_1279431x1434297" unitRef="iso4217_USD" decimals="-3" id="id_6895476_CE89805E-4ADE-44CE-AB36-26227C885BB2_2_3">3285000</cytk:ReimbursementOfInternalResearchAndDevelopmentCost> <cytk:ReimbursementOfOtherResearchAndDevelopmentCost contextRef="eol_PE151383--1410-K0012_STD_365_20131231_0_1279431x1434297" unitRef="iso4217_USD" decimals="-3" id="id_6895476_CE89805E-4ADE-44CE-AB36-26227C885BB2_2_4">3130000</cytk:ReimbursementOfOtherResearchAndDevelopmentCost> <us-gaap:ValuationAllowancesAndReservesChargedToCostAndExpense contextRef="eol_PE151383--1410-K0012_STD_365_20131231_0_1279936x1276697" unitRef="iso4217_USD" decimals="-3" id="id_6895476_B444ABAD-A3F0-45D1-A8D2-D991236372AC_2_2">13670000</us-gaap:ValuationAllowancesAndReservesChargedToCostAndExpense> <us-gaap:ValuationAllowancesAndReservesChargedToOtherAccounts contextRef="eol_PE151383--1410-K0012_STD_365_20131231_0_1279936x1276697" unitRef="iso4217_USD" decimals="-3" id="id_6895476_B444ABAD-A3F0-45D1-A8D2-D991236372AC_2_3">0</us-gaap:ValuationAllowancesAndReservesChargedToOtherAccounts> <us-gaap:ValuationAllowancesAndReservesDeductions contextRef="eol_PE151383--1410-K0012_STD_365_20131231_0_1279936x1276697" unitRef="iso4217_USD" decimals="-3" id="id_6895476_B444ABAD-A3F0-45D1-A8D2-D991236372AC_2_4">0</us-gaap:ValuationAllowancesAndReservesDeductions> <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions contextRef="eol_PE151383--1410-K0012_STD_365_20131231_0_1280651x1297583" unitRef="iso4217_USD" decimals="-3" id="id_6895476_7B98D2F9-CACB-495E-A3F9-A79C5892451D_4002_2">8000</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions> <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions contextRef="eol_PE151383--1410-K0012_STD_365_20131231_0_1280651x1297583" unitRef="iso4217_USD" decimals="-3" id="id_6895476_7B98D2F9-CACB-495E-A3F9-A79C5892451D_4002_3">43000</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions> <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions contextRef="eol_PE151383--1410-K0012_STD_365_20131231_0_1280651x1497867" unitRef="iso4217_USD" decimals="-3" id="id_6895476_7B98D2F9-CACB-495E-A3F9-A79C5892451D_4003_2">16000</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions> <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions contextRef="eol_PE151383--1410-K0012_STD_365_20131231_0_1280651x1497867" unitRef="iso4217_USD" decimals="-3" id="id_6895476_7B98D2F9-CACB-495E-A3F9-A79C5892451D_4003_3">764000</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions> <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions contextRef="eol_PE151383--1410-K0012_STD_365_20131231_0_1280651x1520580" unitRef="iso4217_USD" decimals="-3" id="id_6895476_7B98D2F9-CACB-495E-A3F9-A79C5892451D_4001_2">24000</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions> <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions contextRef="eol_PE151383--1410-K0012_STD_365_20131231_0_1280651x1520580" unitRef="iso4217_USD" decimals="-3" id="id_6895476_7B98D2F9-CACB-495E-A3F9-A79C5892451D_4001_3">807000</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions> <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans contextRef="eol_PE151383--1410-K0012_STD_365_20131231_0_1280964x1277228" unitRef="shares" decimals="INF" id="id_6895476_AA51EB59-4301-48A7-8417-F8ADFF1F04A4_1002_1">14985</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans> <cytk:EmployeeStockPurchasePlansAveragePricePerShare contextRef="eol_PE151383--1410-K0012_STD_365_20131231_0_1280964x1277228" unitRef="iso4217_USD_per_shares" decimals="2" id="id_6895476_AA51EB59-4301-48A7-8417-F8ADFF1F04A4_1002_2">3.66</cytk:EmployeeStockPurchasePlansAveragePricePerShare> <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue contextRef="eol_PE151383--1410-K0012_STD_365_20131231_0_1280964x1294890" unitRef="iso4217_USD_per_shares" decimals="2" id="id_6895476_945DE61A-5FF4-4863-A406-B144CAADCC72_1002_1">3.85</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue> <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares contextRef="eol_PE151383--1410-K0012_STD_365_20131231_0_1280964x1294890" unitRef="shares" decimals="INF" id="id_6895476_945DE61A-5FF4-4863-A406-B144CAADCC72_1002_3">457465</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares> <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1 contextRef="eol_PE151383--1410-K0012_STD_365_20131231_0_1280964x1294890" unitRef="iso4217_USD" decimals="-5" id="id_6895476_945DE61A-5FF4-4863-A406-B144CAADCC72_1002_4">2300000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1> <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue contextRef="eol_PE151383--1410-K0012_STD_365_20131231_0_1280964x1294890" unitRef="iso4217_USD" decimals="0" id="id_6895476_945DE61A-5FF4-4863-A406-B144CAADCC72_1002_0">107000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue> <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross contextRef="eol_PE151383--1410-K0012_STD_365_20131231_0_1280964x1424733" unitRef="shares" decimals="INF" id="id_6895476_7DACACCF-F580-4FD5-9779-AA02BBB20B57_1002_0">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross> <us-gaap:AllocatedShareBasedCompensationExpense contextRef="eol_PE151383--1410-K0012_STD_365_20131231_0_1280964x1424733" unitRef="iso4217_USD" decimals="-3" id="id_6895476_D2960C5C-51C9-488D-A130-57FE536B4931_1002_0">104000</us-gaap:AllocatedShareBasedCompensationExpense> <us-gaap:ConcentrationRiskPercentage1 contextRef="eol_PE151383--1410-K0012_STD_365_20131231_0_1281318x1434297" unitRef="pure" decimals="2" id="id_6895476_B1D541CA-9025-4D78-9ABD-27AABA32983C_1002_0">0.34</us-gaap:ConcentrationRiskPercentage1> <us-gaap:BasisOfAccountingPolicyPolicyTextBlock contextRef="eol_PE151383--1410-K0012_STD_365_20141231_0" id="id_6895476_EA0B2B7E-CA38-40F5-B46A-2833451E82DA_1_0"><div> <p style="MARGIN-BOTTOM: 0px; MARGIN-LEFT: 2%; MARGIN-TOP: 18px"> <font style="FONT-FAMILY: Times New Roman" size="2"><b><i>Basis of Presentation</i></b></font></p> <p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 6px; TEXT-INDENT: 4%" align="justify"><font style="FONT-FAMILY: Times New Roman" size="2">The consolidated financial statements include the accounts of Cytokinetics and its wholly owned subsidiary. The financial statements include all adjustments (consisting only of normal recurring adjustments) that management believes are necessary for the fair presentation of the balances and results for the periods presented.</font></p> </div></us-gaap:BasisOfAccountingPolicyPolicyTextBlock> <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock contextRef="eol_PE151383--1410-K0012_STD_365_20141231_0" id="id_6895476_40153C4B-53E4-4198-86DB-356A30D42234_1_0"><div> <p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 18px"><font style="FONT-FAMILY: Times New Roman" size="2"><b>Note 10&#xA0;&#x2014; Commitments and Contingencies</b></font></p> <p style="MARGIN-BOTTOM: 0px; MARGIN-LEFT: 2%; MARGIN-TOP: 6px"> <font style="FONT-FAMILY: Times New Roman" size="2"><b><i>Commitments</i></b></font></p> <p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 6px; TEXT-INDENT: 4%" align="justify"><font style="FONT-FAMILY: Times New Roman" size="2">The Company leases office space and equipment under a non-cancelable operating lease that expires in 2018, with an option to extend the lease for an additional three-year period. The lease terms provide for rental payments on a graduated scale and the Company&#x2019;s payment of certain operating expenses. The Company recognizes rent expense on a straight-line basis over the lease period.</font></p> <p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 18px; TEXT-INDENT: 4%" align="justify"><font style="FONT-FAMILY: Times New Roman" size="2">Rent expense was as follows (in thousands):</font></p> <p style="MARGIN-BOTTOM: 0px; FONT-SIZE: 12px; MARGIN-TOP: 0px"> &#xA0;</p> <table style="BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="92%" align="center" border="0"> <tr> <td width="73%"></td> <td valign="bottom" width="4%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="4%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="4%"></td> <td></td> <td></td> <td></td> </tr> <tr> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="10" align="center"><font style="FONT-FAMILY: Times New Roman" size="1"><b>Years Ended December&#xA0;31,</b></font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> </tr> <tr> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" align="center"><font style="FONT-FAMILY: Times New Roman" size="1"><b>2014</b></font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" align="center"><font style="FONT-FAMILY: Times New Roman" size="1"><b>2013</b></font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" align="center"><font style="FONT-FAMILY: Times New Roman" size="1"><b>2012</b></font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> </tr> <tr bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: Times New Roman" size="2">Rent expense</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">3,338</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">3,306</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">3,375</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td>&#xA0;</td> </tr> </table> <p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 12px; TEXT-INDENT: 4%" align="justify"><font style="FONT-FAMILY: Times New Roman" size="2">As of December&#xA0;31, 2014, future minimum lease payments under noncancelable operating leases were as follows (in thousands):</font></p> <p style="MARGIN-BOTTOM: 0px; FONT-SIZE: 12px; MARGIN-TOP: 0px"> &#xA0;</p> <table style="BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="92%" align="center" border="0"> <tr> <td width="89%"></td> <td valign="bottom" width="5%"></td> <td></td> <td></td> <td></td> </tr> <tr bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: Times New Roman" size="2">2015</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">3,390</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> </tr> <tr> <td valign="top"> <p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: Times New Roman" size="2">2016</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">3,504</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> </tr> <tr bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: Times New Roman" size="2">2017</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">3,626</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> </tr> <tr> <td valign="top"> <p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: Times New Roman" size="2">2018</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">1,860</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> </tr> <tr bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: Times New Roman" size="2">2019</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" nowrap="nowrap" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">&#x2014;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> </tr> <tr> <td valign="top"> <p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: Times New Roman" size="2">Thereafter</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" nowrap="nowrap" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">&#x2014;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> </tr> <tr bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-LEFT: 2em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: Times New Roman" size="2">Total</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">12,380</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td>&#xA0;</td> </tr> </table> <p style="MARGIN-BOTTOM: 0px; MARGIN-LEFT: 2%; MARGIN-TOP: 18px"> <font style="FONT-FAMILY: Times New Roman" size="2"><b><i>Contingencies</i></b></font></p> <p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 6px; TEXT-INDENT: 4%" align="justify"><font style="FONT-FAMILY: Times New Roman" size="2">In the ordinary course of business, the Company may provide indemnifications of varying scope and terms to vendors, lessors, business partners and other parties with respect to certain matters, including, but not limited to, losses arising out of the Company&#x2019;s breach of such agreements, services to be provided by or on behalf of the Company, or from intellectual property infringement claims made by third parties. In addition, the Company has entered into indemnification agreements with its directors and certain of its officers and employees that will require the Company, among other things, to indemnify them against certain liabilities that may arise by reason of their status or service as directors, officers or employees. The Company maintains director and officer insurance, which may cover certain liabilities arising from its obligation to indemnify its directors and certain of its officers and employees, and former officers and directors in certain circumstances. The Company maintains product liability insurance and comprehensive general liability insurance, which may cover certain liabilities arising from its indemnification obligations. It is not possible to determine the maximum potential amount of exposure under these indemnification obligations due to the limited history of prior indemnification claims and the unique facts and circumstances involved in each particular indemnification obligation. Such indemnification obligations may not be subject to maximum loss clauses. Management is not currently aware of any matters that could have a material adverse effect on the financial position, results of operations or cash flows of the Company.</font></p> <p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 12px; TEXT-INDENT: 4%" align="justify"><font style="FONT-FAMILY: Times New Roman" size="2">In December 2014, the Company filed a lawsuit alleging fraudulent inducement, breach of contract and negligence on the part of a data management vendor for a clinical trial. The Company is seeking monetary damages. As this is a contingency that may result in a gain, no provision has been made in the financial statements.</font></p> </div></us-gaap:CommitmentsAndContingenciesDisclosureTextBlock> <us-gaap:DebtDisclosureTextBlock contextRef="eol_PE151383--1410-K0012_STD_365_20141231_0" id="id_6895476_1F2450EE-039F-4E79-AB02-24EDC7C76564_1_0"><div> <p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 18px"><font style="FONT-FAMILY: Times New Roman" size="2"><b>Note&#xA0;9&#xA0;&#x2014; Debt</b></font></p> <p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 6px; TEXT-INDENT: 4%" align="justify"><font style="FONT-FAMILY: Times New Roman" size="2">In April 2006, the Company entered into an equipment financing agreement with GE Capital. As of December&#xA0;31, 2011, the balance of equipment loans outstanding under this line was $152,000. The Company repaid the remaining outstanding equipment financing debt in March 2012 and no further funds are available under this line of credit.</font></p> <p style="MARGIN-BOTTOM: 0px; MARGIN-LEFT: 2%; MARGIN-TOP: 18px"> <font style="FONT-FAMILY: Times New Roman" size="2"><b><i>Interest Expense</i></b></font></p> <p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 6px; TEXT-INDENT: 4%" align="justify"><font style="FONT-FAMILY: Times New Roman" size="2">Total interest expense incurred by the Company was as follows (in thousands):</font></p> <p style="MARGIN-BOTTOM: 0px; FONT-SIZE: 12px; MARGIN-TOP: 0px"> &#xA0;</p> <table style="BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="92%" align="center" border="0"> <tr> <td width="77%"></td> <td valign="bottom" width="6%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="6%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="6%"></td> <td></td> <td></td> <td></td> </tr> <tr> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="10" align="center"><font style="FONT-FAMILY: Times New Roman" size="1"><b>Years&#xA0;Ended&#xA0;December&#xA0;31,</b></font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> </tr> <tr> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" align="center"><font style="FONT-FAMILY: Times New Roman" size="1"><b>2014</b></font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" align="center"><font style="FONT-FAMILY: Times New Roman" size="1"><b>2013</b></font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" align="center"><font style="FONT-FAMILY: Times New Roman" size="1"><b>2012</b></font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> </tr> <tr bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: Times New Roman" size="2">Interest expense</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td> <td valign="bottom" nowrap="nowrap" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">&#x2014;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td> <td valign="bottom" nowrap="nowrap" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">&#x2014;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">3</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td>&#xA0;</td> </tr> </table> </div></us-gaap:DebtDisclosureTextBlock> <us-gaap:EarningsPerShareTextBlock contextRef="eol_PE151383--1410-K0012_STD_365_20141231_0" id="id_6895476_A06C0A86-86E5-4A2E-A941-F939E74CAAD4_1_0"><div> <p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 0px"><font style="FONT-FAMILY: Times New Roman" size="2"><b>Note 2 &#x2014; Net Loss Per Share</b></font></p> <p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 6px; TEXT-INDENT: 4%" align="justify"><font style="FONT-FAMILY: Times New Roman" size="2">Basic net loss per share allocable to common stockholders is computed by dividing net loss allocable to common stockholders by the weighted average number of vested common shares outstanding during the period. Diluted net income loss per share allocable to common stockholders is computed by giving effect to all potentially dilutive common shares, including outstanding stock options, unvested restricted stock, warrants, convertible preferred stock and shares issuable under the Company&#x2019;s Employee Stock Purchase Plan (&#x201C;ESPP&#x201D;), by applying the treasury stock method. The following is the calculation of basic and diluted net loss per share allocable to common stockholders (in thousands except per share data):</font></p> <p style="MARGIN-BOTTOM: 0px; FONT-SIZE: 12px; MARGIN-TOP: 0px"> &#xA0;</p> <table style="BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="92%" align="center" border="0"> <tr> <td width="66%"></td> <td valign="bottom" width="5%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="4%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="4%"></td> <td></td> <td></td> <td></td> </tr> <tr> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="10" align="center"><font style="FONT-FAMILY: Times New Roman" size="1"><b>Years Ended December&#xA0;31,</b></font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> </tr> <tr> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" align="center"><font style="FONT-FAMILY: Times New Roman" size="1"><b>2014</b></font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" align="center"><font style="FONT-FAMILY: Times New Roman" size="1"><b>2013</b></font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" align="center"><font style="FONT-FAMILY: Times New Roman" size="1"><b>2012</b></font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> </tr> <tr bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: Times New Roman" size="2">Net loss</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">(14,646</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">)&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">(33,717</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">)&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">(40,370</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">)&#xA0;</font></td> </tr> <tr> <td valign="top"> <p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: Times New Roman" size="2">Deemed dividend related to beneficial conversion feature of convertible preferred stock</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" nowrap="nowrap" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">&#x2014;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" nowrap="nowrap" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">&#x2014;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">(1,307</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">)&#xA0;</font></td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> </tr> <tr bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: Times New Roman" size="2">Net loss allocable to common stockholders</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">(14,646</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">)&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">(33,717</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">)&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">(41,677</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">)&#xA0;</font></td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td>&#xA0;</td> </tr> <tr> <td valign="top"> <p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: Times New Roman" size="2">Weighted-average shares used in computing net loss per share allocable to common stockholders&#xA0;&#x2014; basic and diluted</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">35,709</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">27,275</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">18,107</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td>&#xA0;</td> </tr> <tr bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: Times New Roman" size="2">Net loss per share allocable to common stockholders &#x2014; basic and&#xA0;diluted</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">(0.41</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">)&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">(1.24</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">)&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">(2.30</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">)&#xA0;</font></td> </tr> </table> <p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 12px; TEXT-INDENT: 4%" align="justify"><font style="FONT-FAMILY: Times New Roman" size="2">The following instruments were excluded from the computation of diluted net loss per common share allocable to common stockholders for the periods presented because their effect would have been antidilutive (in thousands):</font></p> <p style="MARGIN-BOTTOM: 0px; FONT-SIZE: 12px; MARGIN-TOP: 0px"> &#xA0;</p> <table style="BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="92%" align="center" border="0"> <tr> <td width="73%"></td> <td valign="bottom" width="3%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="3%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="3%"></td> <td></td> <td></td> <td></td> </tr> <tr> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="10" align="center"><font style="FONT-FAMILY: Times New Roman" size="1"><b>December&#xA0;31,</b></font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> </tr> <tr> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" align="center"><font style="FONT-FAMILY: Times New Roman" size="1"><b>2014</b></font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" align="center"><font style="FONT-FAMILY: Times New Roman" size="1"><b>2013</b></font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" align="center"><font style="FONT-FAMILY: Times New Roman" size="1"><b>2012</b></font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> </tr> <tr bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: Times New Roman" size="2">Options to purchase common stock</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">3,298</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">2,449</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">1,791</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> </tr> <tr> <td valign="top"> <p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: Times New Roman" size="2">Warrants to purchase common stock</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">6,691</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">7,692</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">9,009</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> </tr> <tr bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: Times New Roman" size="2">Series B convertible preferred stock (as converted to common stock)</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" nowrap="nowrap" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">&#x2014;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" nowrap="nowrap" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">&#x2014;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">3,838</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> </tr> <tr> <td valign="top"> <p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: Times New Roman" size="2">Restricted stock units</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">63</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">42</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">217</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> </tr> <tr bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: Times New Roman" size="2">Shares issuable related to the ESPP</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">15</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">14</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">11</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> </tr> <tr> <td valign="top"> <p style="MARGIN-LEFT: 2em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: Times New Roman" size="2">Total shares</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">10,067</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">10,197</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">14,866</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td>&#xA0;</td> </tr> </table> </div></us-gaap:EarningsPerShareTextBlock> <us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock contextRef="eol_PE151383--1410-K0012_STD_365_20141231_0" id="id_6895476_C30774B1-AD2F-4339-8B8C-CCA9459E4E83_1_0"><div> <p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 0px; TEXT-INDENT: 4%" align="justify"><font style="FONT-FAMILY: Times New Roman" size="2">The following is a reconciliation of the statutory federal income tax rate to the Company&#x2019;s effective tax rate:</font></p> <p style="MARGIN-BOTTOM: 0px; FONT-SIZE: 12px; MARGIN-TOP: 0px"> &#xA0;</p> <table style="BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="92%" align="center" border="0"> <tr> <td width="81%"></td> <td valign="bottom" width="6%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="5%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="5%"></td> <td></td> <td></td> <td></td> </tr> <tr> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="10" align="center"><font style="FONT-FAMILY: Times New Roman" size="1"><b>Years Ended<br /> December&#xA0;31,</b></font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> </tr> <tr> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" align="center"><font style="FONT-FAMILY: Times New Roman" size="1"><b>2014</b></font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" align="center"><font style="FONT-FAMILY: Times New Roman" size="1"><b>2013</b></font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" align="center"><font style="FONT-FAMILY: Times New Roman" size="1"><b>2012</b></font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> </tr> <tr bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: Times New Roman" size="2">Tax at federal statutory tax rate</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">(34</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">)%&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">(34</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">)%&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">(34</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">)%&#xA0;</font></td> </tr> <tr> <td valign="top"> <p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: Times New Roman" size="2">State income tax, net of federal tax benefit</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">(1</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">)%&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">(4</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">)%&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">(6</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">)%&#xA0;</font></td> </tr> <tr bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: Times New Roman" size="2">State Apportionment</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">28</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">%&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">7</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">%&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">0</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">%&#xA0;</font></td> </tr> <tr> <td valign="top"> <p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: Times New Roman" size="2">Tax credits (net)</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">(7</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">)%&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">(14</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">)%&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">(19</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">)%&#xA0;</font></td> </tr> <tr bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: Times New Roman" size="2">Deferred tax assets (utilized) not benefited</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">7</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">%&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">41</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">%&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">56</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">%&#xA0;</font></td> </tr> <tr> <td valign="top"> <p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: Times New Roman" size="2">Stock-based compensation</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">5</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">%&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">2</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">%&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">0</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">%&#xA0;</font></td> </tr> <tr bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: Times New Roman" size="2">NOL Expiration</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">2</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">%&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">1</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">%&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">2</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">%&#xA0;</font></td> </tr> <tr> <td valign="top"> <p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: Times New Roman" size="2">Other</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">0</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">%&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">1</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">%&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">1</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">%&#xA0;</font></td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> </tr> <tr bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-LEFT: 2em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: Times New Roman" size="2">Total</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">0</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">%&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">0</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">%&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">0</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">%&#xA0;</font></td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td>&#xA0;</td> </tr> </table> </div></us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock> <us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock contextRef="eol_PE151383--1410-K0012_STD_365_20141231_0" id="id_6895476_9E71BE64-7F56-4583-B4D5-BE36FD84652F_1_0"><div> <p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 0px; TEXT-INDENT: 4%" align="justify"><font style="FONT-FAMILY: Times New Roman" size="2">Restricted stock unit activity was as follows:</font></p> <p style="MARGIN-BOTTOM: 0px; FONT-SIZE: 12px; MARGIN-TOP: 0px"> &#xA0;</p> <table style="BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="92%" align="center" border="0"> <tr> <td width="73%"></td> <td valign="bottom" width="8%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="7%"></td> <td></td> <td></td> <td></td> </tr> <tr> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" align="center"><font style="FONT-FAMILY: Times New Roman" size="1"><b>Number&#xA0;of<br /> Shares</b></font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" align="center"><font style="FONT-FAMILY: Times New Roman" size="1"><b>Weighted<br /> Average&#xA0;Award<br /> Date&#xA0;Fair&#xA0;Value<br /> per&#xA0;Share</b></font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> </tr> <tr bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: Times New Roman" size="2">Restricted stock units outstanding at December&#xA0;31, 2011</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">517,535</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">6.78</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> </tr> <tr> <td valign="top"> <p style="MARGIN-LEFT: 2em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: Times New Roman" size="2">Restricted stock units vested</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">(231,935</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">)&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">6.78</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> </tr> <tr bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-LEFT: 2em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: Times New Roman" size="2">Restricted stock units forfeited</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">(68,702</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">)&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">6.78</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr> <td valign="top"> <p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: Times New Roman" size="2">Restricted stock units outstanding at December&#xA0;31, 2012</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">216,898</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">6.78</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> </tr> <tr bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-LEFT: 2em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: Times New Roman" size="2">Restricted stock units granted</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">41,661</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">6.00</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> </tr> <tr> <td valign="top"> <p style="MARGIN-LEFT: 2em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: Times New Roman" size="2">Restricted stock units vested</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">(211,897</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">)&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">6.78</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> </tr> <tr bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-LEFT: 2em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: Times New Roman" size="2">Restricted stock units forfeited</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">(4,999</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">)&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">6.78</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr> <td valign="top"> <p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: Times New Roman" size="2">Unvested restricted stock units outstanding at December&#xA0;31, 2013</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">41,663</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">6.00</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> </tr> <tr bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-LEFT: 2em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: Times New Roman" size="2">Restricted stock units granted</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">43,500</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">9.65</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> </tr> <tr> <td valign="top"> <p style="MARGIN-LEFT: 2em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: Times New Roman" size="2">Restricted stock units vested</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">(20,833</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">)&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">6.00</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> </tr> <tr bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-LEFT: 2em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: Times New Roman" size="2">Restricted stock units forfeited</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">(1,000</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">)&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">6.00</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr> <td valign="top"> <p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: Times New Roman" size="2">Unvested restricted stock units outstanding at December&#xA0;31, 2014</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">63,330</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">8.51</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> </table> </div></us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock> <us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock contextRef="eol_PE151383--1410-K0012_STD_365_20141231_0" id="id_6895476_81563CA3-514D-45D6-9A86-5F0985838309_1_0"><div> <p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 0px; TEXT-INDENT: 4%" align="justify"><font style="FONT-FAMILY: Times New Roman" size="2">The fair value of share-based payments was estimated on the date of grant using the Black-Scholes option pricing model based on the following weighted average assumptions:</font></p> <p style="MARGIN-BOTTOM: 0px; FONT-SIZE: 12px; MARGIN-TOP: 0px"> &#xA0;</p> <table style="BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="100%" align="center" border="0"> <tr> <td width="46%"></td> <td valign="bottom" width="5%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="5%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="5%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="5%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="5%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="5%"></td> <td></td> <td></td> <td></td> </tr> <tr> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="6" align="center"><font style="FONT-FAMILY: Times New Roman" size="1"><b>Year Ended<br /> December&#xA0;31, 2014</b></font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="6" align="center"><font style="FONT-FAMILY: Times New Roman" size="1"><b>Year Ended<br /> December&#xA0;31, 2013</b></font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="6" align="center"><font style="FONT-FAMILY: Times New Roman" size="1"><b>Year Ended<br /> December&#xA0;31, 2012</b></font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> </tr> <tr> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" align="center"><font style="FONT-FAMILY: Times New Roman" size="1"><b>Employee<br /> Stock&#xA0;Options</b></font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" align="center"><font style="FONT-FAMILY: Times New Roman" size="1"><b>ESPP</b></font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" align="center"><font style="FONT-FAMILY: Times New Roman" size="1"><b>Employee<br /> Stock&#xA0;Options</b></font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" align="center"><font style="FONT-FAMILY: Times New Roman" size="1"><b>ESPP</b></font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" align="center"><font style="FONT-FAMILY: Times New Roman" size="1"><b>Employee<br /> Stock&#xA0;Options</b></font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" align="center"><font style="FONT-FAMILY: Times New Roman" size="1"><b>ESPP</b></font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> </tr> <tr bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: Times New Roman" size="2">Risk-free interest rate</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">1.9</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">%&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">0.2</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">%&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">1.1</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">%&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">0.2</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">%&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">1.1</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">%&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">0.2</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">%&#xA0;</font></td> </tr> <tr> <td valign="top"> <p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: Times New Roman" size="2">Volatility</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">77.1</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">%&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">86.0</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">%&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">73.2</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">%&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">74.6</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">%&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">71.1</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">%&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">72.0</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">%&#xA0;</font></td> </tr> <tr bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: Times New Roman" size="2">Expected term in years</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">6.30</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">1.25</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">6.20</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">1.25</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">6.13</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">1.25</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> </tr> <tr> <td valign="top"> <p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: Times New Roman" size="2">Expected dividend yield</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">0.0</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">%&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">0.0</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">%&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">0.0</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">%&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">0.0</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">%&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">0.0</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">%&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">0.0</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">%&#xA0;</font></td> </tr> </table> </div></us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock> <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1 contextRef="eol_PE151383--1410-K0012_STD_365_20141231_0" id="id_6895476_3C5D1DA4-14B7-4F1F-B924-42BFE68F3162_2001_3">P6Y9M11D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1> <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice contextRef="eol_PE151383--1410-K0012_STD_365_20141231_0" unitRef="iso4217_USD_per_shares" decimals="2" id="id_6895476_C3206D70-DEC9-4565-9145-8B70956A712D_11001_14">6.00</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice> <dei:DocumentType contextRef="eol_PE151383--1410-K0012_STD_365_20141231_0" id="id_6895476_BB2FF52D-3F86-4944-B60D-74EA496D7B67_1_0">10-K</dei:DocumentType> <dei:EntityRegistrantName contextRef="eol_PE151383--1410-K0012_STD_365_20141231_0" id="id_6895476_719DD5F0-2E9A-450E-B7C0-E6D7E07576A8_1_400001">CYTOKINETICS INC</dei:EntityRegistrantName> <dei:EntityWellKnownSeasonedIssuer contextRef="eol_PE151383--1410-K0012_STD_365_20141231_0" id="id_6895476_719DD5F0-2E9A-450E-B7C0-E6D7E07576A8_1_400004">No</dei:EntityWellKnownSeasonedIssuer> <dei:TradingSymbol contextRef="eol_PE151383--1410-K0012_STD_365_20141231_0" id="id_6895476_719DD5F0-2E9A-450E-B7C0-E6D7E07576A8_1_400000">CYTK</dei:TradingSymbol> <us-gaap:CompensationRelatedCostsPolicyTextBlock contextRef="eol_PE151383--1410-K0012_STD_365_20141231_0" id="id_6895476_8C77CC6B-9FE8-4F7E-B120-7B2AFC554B96_1_0"><div> <p style="MARGIN-BOTTOM: 0px; MARGIN-LEFT: 2%; MARGIN-TOP: 18px"> <font style="FONT-FAMILY: Times New Roman" size="2"><b><i>Stock-Based Compensation</i></b></font></p> <p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 6px; TEXT-INDENT: 4%" align="justify"><font style="FONT-FAMILY: Times New Roman" size="2">The Company accounts for stock-based payment awards made to employees and directors, including employee stock options and employee stock purchases by measuring the stock-based compensation cost at the grant date based on the calculated fair value of the award, and recognizing expense on a straight-line basis over the employee&#x2019;s requisite service period, generally the vesting period of the award. Stock compensation for non-employees is measured at the fair value of the award for each period until the award is fully vested.</font></p> <p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 12px; TEXT-INDENT: 4%" align="justify"><font style="FONT-FAMILY: Times New Roman" size="2">The Company reviews the valuation assumptions at each grant date and, as a result, from time to time it will likely change the valuation assumptions it uses to value stock based awards granted in future periods. The assumptions used in calculating the fair value of share-based payment awards represent management&#x2019;s best estimates at the time, but these estimates involve inherent uncertainties and the application of management judgment. As a result, if conditions change and the management uses different assumptions, the Company&#x2019;s stock-based compensation expense could be materially different in the future. In addition, the Company is required to estimate the expected forfeiture rate and recognize expense only for those shares expected to vest. If the actual forfeiture rate is materially different from management&#x2019;s estimate, stock-based compensation expense could be significantly different from what has been recorded in the current period.</font></p> </div></us-gaap:CompensationRelatedCostsPolicyTextBlock> <us-gaap:ComprehensiveIncomePolicyPolicyTextBlock contextRef="eol_PE151383--1410-K0012_STD_365_20141231_0" id="id_6895476_A022AEFB-3314-4C2F-872D-2A1B82F427CD_1_0"><div> <p style="MARGIN-BOTTOM: 0px; MARGIN-LEFT: 2%; MARGIN-TOP: 0px"> <font style="FONT-FAMILY: Times New Roman" size="2"><b><i>Comprehensive Loss</i></b></font></p> <p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 6px; TEXT-INDENT: 4%" align="justify"><font style="FONT-FAMILY: Times New Roman" size="2">The Company follows the accounting standards for the reporting and presentation of comprehensive income (loss) and its components. On January&#xA0;1, 2012, the Company adopted new accounting guidance and presents comprehensive income (loss) in a continuous statement of comprehensive income (loss) which replaced the statement of operations. Comprehensive loss includes all changes in stockholders&#x2019; equity during a period from non-owner sources. Comprehensive loss for each of the years ended December&#xA0;31, 2014, 2013, and 2012 was equal to net loss adjusted for unrealized gains and losses on investments.</font></p> </div></us-gaap:ComprehensiveIncomePolicyPolicyTextBlock> <us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock contextRef="eol_PE151383--1410-K0012_STD_365_20141231_0" id="id_6895476_E699CBD1-AA09-4AC4-9684-6419B135077C_1_0"><div> <p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 12px; TEXT-INDENT: 4%" align="justify"><font style="FONT-FAMILY: Times New Roman" size="2">Financial assets measured at fair value on a recurring basis as of December&#xA0;31, 2014 and 2013 are classified in the table below in one of the three categories described above (in thousands):</font></p> <p style="MARGIN-BOTTOM: 0px; FONT-SIZE: 12px; MARGIN-TOP: 0px"> &#xA0;</p> <table style="BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="92%" align="center" border="0"> <tr> <td width="56%"></td> <td valign="bottom" width="7%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="7%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="7%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="7%"></td> <td></td> <td></td> <td></td> </tr> <tr> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="14" align="center"><font style="FONT-FAMILY: Times New Roman" size="1"><b>December&#xA0;31, 2014</b></font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> </tr> <tr> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="10" align="center"><font style="FONT-FAMILY: Times New Roman" size="1"><b>Fair&#xA0;Value&#xA0;Measurements&#xA0;Using</b></font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" rowspan="2" colspan="2" align="center"><font style="FONT-FAMILY: Times New Roman" size="1"><b>Assets<br /> At&#xA0;Fair&#xA0;Value</b></font></td> <td valign="bottom" rowspan="2"><font size="1">&#xA0;</font></td> </tr> <tr> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" align="center"><font style="FONT-FAMILY: Times New Roman" size="1"><b>&#xA0;&#xA0;Level&#xA0;1&#xA0;&#xA0;</b></font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" align="center"><font style="FONT-FAMILY: Times New Roman" size="1"><b>&#xA0;&#xA0;Level&#xA0;2&#xA0;&#xA0;</b></font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" align="center"><font style="FONT-FAMILY: Times New Roman" size="1"><b>&#xA0;&#xA0;Level&#xA0;3&#xA0;&#xA0;</b></font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> </tr> <tr bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: Times New Roman" size="2">Money market funds</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">16,932</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td> <td valign="bottom" nowrap="nowrap" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">&#x2014;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td> <td valign="bottom" nowrap="nowrap" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">&#x2014;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">16,932</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> </tr> <tr> <td valign="top"> <p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: Times New Roman" size="2">U.S. Treasury securities</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">63,013</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" nowrap="nowrap" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">&#x2014;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" nowrap="nowrap" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">&#x2014;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">63,013</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> </tr> <tr bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-LEFT: 3em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: Times New Roman" size="2">Total</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">79,945</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td> <td valign="bottom" nowrap="nowrap" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">&#x2014;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td> <td valign="bottom" nowrap="nowrap" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">&#x2014;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">79,945</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td>&#xA0;</td> </tr> <tr> <td valign="top"> <p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: Times New Roman" size="2">Amounts included in:</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-LEFT: 2em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: Times New Roman" size="2">Cash and cash equivalents</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">16,932</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td> <td valign="bottom" nowrap="nowrap" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">&#x2014;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td> <td valign="bottom" nowrap="nowrap" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">&#x2014;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">16,932</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> </tr> <tr> <td valign="top"> <p style="MARGIN-LEFT: 2em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: Times New Roman" size="2">Short-term investments</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">63,013</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" nowrap="nowrap" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">&#x2014;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" nowrap="nowrap" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">&#x2014;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">63,013</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> </tr> <tr bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-LEFT: 2em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: Times New Roman" size="2">Long-term investments</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" nowrap="nowrap" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">&#x2014;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" nowrap="nowrap" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">&#x2014;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" nowrap="nowrap" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">&#x2014;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" nowrap="nowrap" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">&#x2014;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> </tr> <tr> <td valign="top"> <p style="MARGIN-LEFT: 3em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: Times New Roman" size="2">Total</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">79,945</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td> <td valign="bottom" nowrap="nowrap" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">&#x2014;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td> <td valign="bottom" nowrap="nowrap" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">&#x2014;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">79,945</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td>&#xA0;</td> </tr> </table> <p style="MARGIN-BOTTOM: 0px; FONT-SIZE: 12px; MARGIN-TOP: 0px"> &#xA0;</p> <table style="BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="92%" align="center" border="0"> <tr> <td width="56%"></td> <td valign="bottom" width="7%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="7%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="7%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="7%"></td> <td></td> <td></td> <td></td> </tr> <tr> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="14" align="center"><font style="FONT-FAMILY: Times New Roman" size="1"><b>December&#xA0;31, 2013</b></font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> </tr> <tr> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="10" align="center"><font style="FONT-FAMILY: Times New Roman" size="1"><b>Fair&#xA0;Value&#xA0;Measurements&#xA0;Using</b></font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" rowspan="2" colspan="2" align="center"><font style="FONT-FAMILY: Times New Roman" size="1"><b>Assets<br /> At&#xA0;Fair&#xA0;Value</b></font></td> <td valign="bottom" rowspan="2"><font size="1">&#xA0;</font></td> </tr> <tr> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" align="center"><font style="FONT-FAMILY: Times New Roman" size="1"><b>&#xA0;&#xA0;Level&#xA0;1&#xA0;&#xA0;</b></font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" align="center"><font style="FONT-FAMILY: Times New Roman" size="1"><b>&#xA0;&#xA0;Level&#xA0;2&#xA0;&#xA0;</b></font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" align="center"><font style="FONT-FAMILY: Times New Roman" size="1"><b>&#xA0;&#xA0;Level&#xA0;3&#xA0;&#xA0;</b></font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> </tr> <tr bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: Times New Roman" size="2">Money market funds</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">15,858</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td> <td valign="bottom" nowrap="nowrap" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">&#x2014;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td> <td valign="bottom" nowrap="nowrap" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">&#x2014;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">15,858</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> </tr> <tr> <td valign="top"> <p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: Times New Roman" size="2">U.S. Treasury securities</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">60,072</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" nowrap="nowrap" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">&#x2014;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" nowrap="nowrap" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">&#x2014;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">60,072</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> </tr> <tr bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-LEFT: 3em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: Times New Roman" size="2">Total</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">75,930</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td> <td valign="bottom" nowrap="nowrap" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">&#x2014;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td> <td valign="bottom" nowrap="nowrap" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">&#x2014;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">75,930</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td>&#xA0;</td> </tr> <tr> <td valign="top"> <p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: Times New Roman" size="2">Amounts included in:</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-LEFT: 2em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: Times New Roman" size="2">Cash and cash equivalents</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">15,858</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td> <td valign="bottom" nowrap="nowrap" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">&#x2014;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td> <td valign="bottom" nowrap="nowrap" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">&#x2014;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">15,858</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> </tr> <tr> <td valign="top"> <p style="MARGIN-LEFT: 2em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: Times New Roman" size="2">Short-term investments</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">57,570</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" nowrap="nowrap" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">&#x2014;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" nowrap="nowrap" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">&#x2014;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">57,570</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> </tr> <tr bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-LEFT: 2em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: Times New Roman" size="2">Long-term investments</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">2,502</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" nowrap="nowrap" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">&#x2014;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" nowrap="nowrap" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">&#x2014;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">2,502</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> </tr> <tr> <td valign="top"> <p style="MARGIN-LEFT: 3em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: Times New Roman" size="2">Total</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">75,930</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td> <td valign="bottom" nowrap="nowrap" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">&#x2014;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td> <td valign="bottom" nowrap="nowrap" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">&#x2014;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">75,930</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td>&#xA0;</td> </tr> </table> </div></us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock> <us-gaap:IncomeTaxPolicyTextBlock contextRef="eol_PE151383--1410-K0012_STD_365_20141231_0" id="id_6895476_5C1C609C-416B-474C-974C-199801F54679_1_0"><div> <p style="MARGIN-BOTTOM: 0px; MARGIN-LEFT: 2%; MARGIN-TOP: 18px"> <font style="FONT-FAMILY: Times New Roman" size="2"><b><i>Income Taxes</i></b></font></p> <p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 6px; TEXT-INDENT: 4%" align="justify"><font style="FONT-FAMILY: Times New Roman" size="2">The Company accounts for income taxes under the asset and liability method. Under this method, deferred tax assets and liabilities are determined based on the difference between the financial statement and tax basis of assets and liabilities using enacted tax rates in effect for the year in which the differences are expected to affect taxable income. Valuation allowances are established when necessary to reduce deferred tax assets to the amounts expected to be realized.</font></p> <p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 12px; TEXT-INDENT: 4%" align="justify"><font style="FONT-FAMILY: Times New Roman" size="2">The Company also follows the accounting guidance that defines the threshold for recognizing the benefits of tax return positions in the financial statements as &#x201C;more-likely-than-not&#x201D; to be sustained by the taxing authorities based solely on the technical merits of the position. If the recognition threshold is met, the tax benefit is measured and recognized as the largest amount of tax benefit that, in the Company&#x2019;s judgment, is greater than 50% likely to be realized.</font></p> </div></us-gaap:IncomeTaxPolicyTextBlock> <us-gaap:InvestmentPolicyTextBlock contextRef="eol_PE151383--1410-K0012_STD_365_20141231_0" id="id_6895476_B9A8A994-699A-4BF2-AB8D-A8ADDBD75B75_1_0"><div> <p style="MARGIN-BOTTOM: 0px; MARGIN-LEFT: 2%; MARGIN-TOP: 18px"> <font style="FONT-FAMILY: Times New Roman" size="2"><b><i>Investments</i></b></font></p> <p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 6px; TEXT-INDENT: 4%" align="justify"><font style="FONT-FAMILY: Times New Roman" size="2"><i>Available-for-sale investments.</i>&#xA0;&#xA0;&#xA0;&#xA0;The Company&#x2019;s investments consist of U.S.&#xA0;Treasury securities, money market funds, U.S.&#xA0;municipal and government agency bonds, and commercial paper. The Company designates all investments as available-for-sale and therefore reports them at fair value, based on quoted marked prices, with unrealized gains and losses recorded in accumulated other comprehensive loss. The cost of securities sold is based on the specific-identification method. Investments with original maturities greater than three months and remaining maturities of one year or less are classified as short-term investments. Investments with remaining maturities greater than one year are classified as long-term investments. The amortized cost of debt securities in this category is adjusted for amortization of premiums and accretion of discounts to maturity. Such amortization is included in interest income. Recognized gains and losses and declines in value judged to be other-than-temporary, if any, on available-for-sale securities are included in other income or expense. Interest and dividends on securities classified as available-for-sale are included in Interest and other, net.</font></p> <p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 12px; TEXT-INDENT: 4%" align="justify"><font style="FONT-FAMILY: Times New Roman" size="2"><i>Other-than-temporary impairment.</i>&#xA0;&#xA0;&#xA0;&#xA0;All of the Company&#x2019;s available-for-sale investments are subject to a periodic impairment review. The Company recognizes an impairment charge when a decline in the fair value of its investments below the cost basis is judged to be other-than-temporary. Factors considered by management in assessing whether an other-than-temporary impairment has occurred include: the nature of the investment; whether the decline in fair value is attributable to specific adverse conditions affecting the investment; the financial condition of the investee; the severity and the duration of the impairment; and whether the Company has the intent and ability to hold the investment to maturity. When the Company determines that an other-than-temporary impairment has occurred, the investment is written down to its market value at the end of the period in which it is determined that an other-than-temporary decline has occurred.</font></p> </div></us-gaap:InvestmentPolicyTextBlock> <us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock contextRef="eol_PE151383--1410-K0012_STD_365_20141231_0" id="id_6895476_79E53E39-3C99-4210-B773-EB1EC50BFCE0_1_0"><div> <p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 12px; TEXT-INDENT: 4%" align="justify"><font style="FONT-FAMILY: Times New Roman" size="2">The following instruments were excluded from the computation of diluted net loss per common share allocable to common stockholders for the periods presented because their effect would have been antidilutive (in thousands):</font></p> <p style="MARGIN-BOTTOM: 0px; FONT-SIZE: 12px; MARGIN-TOP: 0px"> &#xA0;</p> <table style="BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="92%" align="center" border="0"> <tr> <td width="73%"></td> <td valign="bottom" width="3%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="3%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="3%"></td> <td></td> <td></td> <td></td> </tr> <tr> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="10" align="center"><font style="FONT-FAMILY: Times New Roman" size="1"><b>December&#xA0;31,</b></font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> </tr> <tr> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" align="center"><font style="FONT-FAMILY: Times New Roman" size="1"><b>2014</b></font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" align="center"><font style="FONT-FAMILY: Times New Roman" size="1"><b>2013</b></font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" align="center"><font style="FONT-FAMILY: Times New Roman" size="1"><b>2012</b></font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> </tr> <tr bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: Times New Roman" size="2">Options to purchase common stock</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">3,298</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">2,449</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">1,791</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> </tr> <tr> <td valign="top"> <p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: Times New Roman" size="2">Warrants to purchase common stock</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">6,691</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">7,692</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">9,009</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> </tr> <tr bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: Times New Roman" size="2">Series B convertible preferred stock (as converted to common stock)</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" nowrap="nowrap" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">&#x2014;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" nowrap="nowrap" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">&#x2014;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">3,838</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> </tr> <tr> <td valign="top"> <p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: Times New Roman" size="2">Restricted stock units</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">63</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">42</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">217</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> </tr> <tr bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: Times New Roman" size="2">Shares issuable related to the ESPP</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">15</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">14</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">11</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> </tr> <tr> <td valign="top"> <p style="MARGIN-LEFT: 2em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: Times New Roman" size="2">Total shares</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">10,067</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">10,197</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">14,866</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td>&#xA0;</td> </tr> </table> </div></us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock> <us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock contextRef="eol_PE151383--1410-K0012_STD_365_20141231_0" id="id_6895476_1E2CC723-6ED2-4178-8E8F-CE52A4792FF5_1_0"><div> <p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 12px; TEXT-INDENT: 4%" align="justify"><font style="FONT-FAMILY: Times New Roman" size="2">For financial statement purposes, loss before taxes includes the following components (in thousands):</font></p> <p style="MARGIN-BOTTOM: 0px; FONT-SIZE: 12px; MARGIN-TOP: 0px"> &#xA0;</p> <table style="BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="92%" align="center" border="0"> <tr> <td width="66%"></td> <td valign="bottom" width="5%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="4%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="4%"></td> <td></td> <td></td> <td></td> </tr> <tr> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="10" align="center"><font style="FONT-FAMILY: Times New Roman" size="1"><b>Years Ended<br /> December&#xA0;31,</b></font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> </tr> <tr> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" align="center"><font style="FONT-FAMILY: Times New Roman" size="1"><b>2014</b></font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" align="center"><font style="FONT-FAMILY: Times New Roman" size="1"><b>2013</b></font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" align="center"><font style="FONT-FAMILY: Times New Roman" size="1"><b>2012</b></font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> </tr> <tr bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: Times New Roman" size="2">United States</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">(14,646</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">)&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">(33,717</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">)&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">(40,370</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">)&#xA0;</font></td> </tr> <tr> <td valign="top"> <p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: Times New Roman" size="2">Foreign</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" nowrap="nowrap" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">&#x2014;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" nowrap="nowrap" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">&#x2014;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" nowrap="nowrap" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">&#x2014;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> </tr> <tr bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-LEFT: 2em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: Times New Roman" size="2">Total</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">(14,646</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">)&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">(33,717</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">)&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">(40,370</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">)&#xA0;</font></td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td>&#xA0;</td> </tr> </table> </div></us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock> <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock contextRef="eol_PE151383--1410-K0012_STD_365_20141231_0" id="id_6895476_C6102E0C-DC12-402B-A52D-59B8621A1291_1_0"><div> <p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 0px; TEXT-INDENT: 4%" align="justify"><font style="FONT-FAMILY: Times New Roman" size="2">Activity under the two stock option plans was as follows:</font></p> <p style="MARGIN-BOTTOM: 0px; FONT-SIZE: 12px; MARGIN-TOP: 0px"> &#xA0;</p> <table style="BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="100%" align="center" border="0"> <tr> <td width="41%"></td> <td valign="bottom" width="6%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="6%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="6%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="6%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="6%"></td> <td></td> <td></td> <td></td> </tr> <tr> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" align="center"><font style="FONT-FAMILY: Times New Roman" size="1"><b>Shares<br /> Available&#xA0;for<br /> Grant&#xA0;of&#xA0;Option<br /> or Award</b></font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" align="center"><font style="FONT-FAMILY: Times New Roman" size="1"><b>Stock&#xA0;Options<br /> Outstanding</b></font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" align="center"><font style="FONT-FAMILY: Times New Roman" size="1"><b>Weighted<br /> Average&#xA0;Exercise<br /> Price per Share -<br /> Stock Options</b></font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" align="center"><font style="FONT-FAMILY: Times New Roman" size="1"><b>Weighted<br /> Average&#xA0;Remaining<br /> Contractual&#xA0;Life</b></font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" align="center"><font style="FONT-FAMILY: Times New Roman" size="1"><b>Aggregate<br /> Intrinsic<br /> Value</b></font><br /> <font style="FONT-FAMILY: Times New Roman" size="1"><b>(in&#xA0; thousands)</b></font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> </tr> <tr bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-LEFT: 2em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: Times New Roman" size="2">Balance at December&#xA0;31, 2011</font></p> </td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">585,476</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">1,598,408</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">21.93</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr> <td valign="top"> <p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: Times New Roman" size="2">Increase in authorized shares</font></p> </td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">416,667</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" nowrap="nowrap" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">&#x2014;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" nowrap="nowrap" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">&#x2014;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: Times New Roman" size="2">Options granted</font></p> </td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">(403,108</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">)&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">403,108</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">6.14</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr> <td valign="top"> <p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: Times New Roman" size="2">Options forfeited/expired</font></p> </td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">210,989</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">(210,989</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">)&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">17.00</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: Times New Roman" size="2">Restricted stock units forfeited</font></p> </td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">68,702</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" nowrap="nowrap" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">&#x2014;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" nowrap="nowrap" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">&#x2014;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">&#xA0;</td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">&#xA0;</td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr> <td valign="top"> <p style="MARGIN-LEFT: 2em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: Times New Roman" size="2">Balance at December&#xA0;31, 2012</font></p> </td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">878,726</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">1,790,527</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">18.96</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: Times New Roman" size="2">Increase in authorized shares</font></p> </td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">2,000,000</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" nowrap="nowrap" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">&#x2014;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" nowrap="nowrap" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">&#x2014;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr> <td valign="top"> <p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: Times New Roman" size="2">Options granted</font></p> </td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">(797,629</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">)&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">797,629</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">5.95</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: Times New Roman" size="2">Restricted stock units granted</font></p> </td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">(41,661</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">)&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" nowrap="nowrap" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">&#x2014;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" nowrap="nowrap" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">&#x2014;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr> <td valign="top"> <p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: Times New Roman" size="2">Options exercised</font></p> </td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" nowrap="nowrap" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">&#x2014;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">(21,397</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">)&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">5.32</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: Times New Roman" size="2">Options forfeited/expired</font></p> </td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">117,394</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">(117,394</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">)&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">12.55</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr> <td valign="top"> <p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: Times New Roman" size="2">Restricted stock units forfeited</font></p> </td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">4,999</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" nowrap="nowrap" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">&#x2014;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" nowrap="nowrap" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">&#x2014;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">&#xA0;</td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">&#xA0;</td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-LEFT: 2em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: Times New Roman" size="2">Balance at December&#xA0;31, 2013</font></p> </td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">2,161,829</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">2,449,365</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">15.15</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr> <td valign="top"> <p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: Times New Roman" size="2">Options granted</font></p> </td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">(944,831</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">)&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">944,831</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">8.80</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: Times New Roman" size="2">Restricted stock units granted</font></p> </td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">(43,500</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">)&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" nowrap="nowrap" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">&#x2014;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" nowrap="nowrap" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">&#x2014;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr> <td valign="top"> <p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: Times New Roman" size="2">Options exercised</font></p> </td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" nowrap="nowrap" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">&#x2014;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">(390</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">)&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">6.00</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: Times New Roman" size="2">Options forfeited/expired</font></p> </td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">95,980</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">(95,980</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">)&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">39.74</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr> <td valign="top"> <p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: Times New Roman" size="2">Restricted stock units forfeited</font></p> </td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">1,000</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" nowrap="nowrap" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">&#x2014;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" nowrap="nowrap" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">&#x2014;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">&#xA0;</td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">&#xA0;</td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-LEFT: 2em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: Times New Roman" size="2">Balance at December&#xA0;31, 2014</font></p> </td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">1,270,478</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">3,297,826</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">12.62</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">6.79</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">2,657</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">&#xA0;</td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">&#xA0;</td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr> <td valign="top"> <p style="MARGIN-LEFT: 2em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: Times New Roman" size="2">Exercisable at December&#xA0;31, 2014</font></p> </td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">2,140,754</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">15.17</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">5.76</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">1,553</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> </tr> <tr bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-LEFT: 2em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: Times New Roman" size="2">Vested and expected to vest as of December&#xA0;31, 2014</font></p> </td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">3,277,489</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">12.64</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">6.78</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">2,642</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> </tr> </table> </div></us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock> <us-gaap:SummaryOfValuationAllowanceTextBlock contextRef="eol_PE151383--1410-K0012_STD_365_20141231_0" id="id_6895476_8578C72B-0BD4-45D0-8411-A38B3403262F_1_0"><div> <p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 12px; TEXT-INDENT: 4%" align="justify"><font style="FONT-FAMILY: Times New Roman" size="2">The following are the Company&#x2019;s valuation and qualifying accounts (in thousands):</font></p> <p style="MARGIN-BOTTOM: 0px; FONT-SIZE: 12px; MARGIN-TOP: 0px"> &#xA0;</p> <table style="BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="100%" align="center" border="0"> <tr> <td width="47%"></td> <td valign="bottom" width="6%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="6%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="6%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="6%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="6%"></td> <td></td> <td></td> <td></td> </tr> <tr> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" align="center"><font style="FONT-FAMILY: Times New Roman" size="1"><b>Balance at<br /> Beginning&#xA0;of<br /> Period</b></font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" align="center"><font style="FONT-FAMILY: Times New Roman" size="1"><b>Charged&#xA0;to<br /> Expenses</b></font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" align="center"><font style="FONT-FAMILY: Times New Roman" size="1"><b>Charged&#xA0;to<br /> Other&#xA0;Accounts</b></font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" align="center"><font style="FONT-FAMILY: Times New Roman" size="1"><b>Deductions</b></font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" align="center"><font style="FONT-FAMILY: Times New Roman" size="1"><b>Balance at<br /> End&#xA0;of&#xA0;Period</b></font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> </tr> <tr bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: Times New Roman" size="2">Year Ended December&#xA0;31, 2012:</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr> <td valign="top"> <p style="MARGIN-LEFT: 2em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: Times New Roman" size="2">Deferred tax valuation allowance</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">169,107</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">21,086</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" nowrap="nowrap" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">&#x2014;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" nowrap="nowrap" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">&#x2014;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">190,193</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> </tr> <tr bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: Times New Roman" size="2">Year Ended December&#xA0;31, 2013:</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr> <td valign="top"> <p style="MARGIN-LEFT: 2em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: Times New Roman" size="2">Deferred tax valuation allowance</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">190,193</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">13,670</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" nowrap="nowrap" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">&#x2014;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" nowrap="nowrap" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">&#x2014;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">203,863</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> </tr> <tr bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: Times New Roman" size="2">Year Ended December&#xA0;31, 2014:</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr> <td valign="top"> <p style="MARGIN-LEFT: 2em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: Times New Roman" size="2">Deferred tax valuation allowance</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">203,863</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">1,037</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" nowrap="nowrap" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">&#x2014;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" nowrap="nowrap" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">&#x2014;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">204,900</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> </tr> </table> </div></us-gaap:SummaryOfValuationAllowanceTextBlock> <dei:EntityFilerCategory contextRef="eol_PE151383--1410-K0012_STD_365_20141231_0" id="id_6895476_719DD5F0-2E9A-450E-B7C0-E6D7E07576A8_1_400007">Accelerated Filer</dei:EntityFilerCategory> <dei:EntityVoluntaryFilers contextRef="eol_PE151383--1410-K0012_STD_365_20141231_0" id="id_6895476_719DD5F0-2E9A-450E-B7C0-E6D7E07576A8_1_400006">No</dei:EntityVoluntaryFilers> <us-gaap:CashFlowSupplementalDisclosuresTextBlock contextRef="eol_PE151383--1410-K0012_STD_365_20141231_0" id="id_6895476_AC644FBF-FB40-4BE4-ABE3-D1658327E91D_1_0"><div> <p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 18px"><font style="FONT-FAMILY: Times New Roman" size="2"><b>Note 3 &#x2014; Supplementary Cash Flow Data</b></font></p> <p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 6px; TEXT-INDENT: 4%" align="justify"><font style="FONT-FAMILY: Times New Roman" size="2">Supplemental cash flow information was as follows (in thousands):</font></p> <p style="MARGIN-BOTTOM: 0px; FONT-SIZE: 12px; MARGIN-TOP: 0px"> &#xA0;</p> <table style="BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="92%" align="center" border="0"> <tr> <td width="78%"></td> <td valign="bottom" width="6%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="6%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="5%"></td> <td></td> <td></td> <td></td> </tr> <tr> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="10" align="center"><font style="FONT-FAMILY: Times New Roman" size="1"><b>Years Ended<br /> December&#xA0;31,</b></font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> </tr> <tr> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" align="center"><font style="FONT-FAMILY: Times New Roman" size="1"><b>2014</b></font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" align="center"><font style="FONT-FAMILY: Times New Roman" size="1"><b>2013</b></font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" align="center"><font style="FONT-FAMILY: Times New Roman" size="1"><b>2012</b></font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> </tr> <tr bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: Times New Roman" size="2">Cash paid for interest</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td> <td valign="bottom" nowrap="nowrap" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">&#x2014;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td> <td valign="bottom" nowrap="nowrap" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">&#x2014;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">3</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> </tr> <tr> <td valign="top"> <p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: Times New Roman" size="2">Cash paid for income taxes</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">1</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">1</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">1</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> </tr> <tr bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: Times New Roman" size="2">Significant non-cash investing and financing activities:</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr> <td valign="top"> <p style="MARGIN-LEFT: 2em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: Times New Roman" size="2">Purchases of property and equipment through accounts payable</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">170</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">193</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">116</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> </tr> <tr bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-LEFT: 2em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: Times New Roman" size="2">Purchases of property and equipment through accrued liabilities</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">27</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">(2</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">)&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">37</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> </tr> <tr> <td valign="top"> <p style="MARGIN-LEFT: 2em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: Times New Roman" size="2">Purchases of property and equipment through trade in value of disposed property and equipment</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" nowrap="nowrap" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">&#x2014;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">81</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" nowrap="nowrap" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">&#x2014;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> </tr> </table> </div></us-gaap:CashFlowSupplementalDisclosuresTextBlock> <us-gaap:EffectiveIncomeTaxRateContinuingOperations contextRef="eol_PE151383--1410-K0012_STD_365_20141231_0" unitRef="pure" decimals="2" id="id_6895476_14EF385A-3844-4F78-AE65-D20D0D541C15_1_8">0.00</us-gaap:EffectiveIncomeTaxRateContinuingOperations> <us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits contextRef="eol_PE151383--1410-K0012_STD_365_20141231_0" unitRef="pure" decimals="2" id="id_6895476_14EF385A-3844-4F78-AE65-D20D0D541C15_1_3">-0.07</us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits> <us-gaap:NetCashProvidedByUsedInOperatingActivitiesContinuingOperations contextRef="eol_PE151383--1410-K0012_STD_365_20141231_0" unitRef="iso4217_USD" decimals="-3" id="id_6895476_84756BCF-71FA-4E32-A511-A3DCED215C30_1_15">-44843000</us-gaap:NetCashProvidedByUsedInOperatingActivitiesContinuingOperations> <us-gaap:RelatedPartyTransactionsDisclosureTextBlock contextRef="eol_PE151383--1410-K0012_STD_365_20141231_0" id="id_6895476_8649F9AD-B419-48EE-B59F-EAD8DFB32FF5_1_0"><div> <p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 18px"><font style="FONT-FAMILY: Times New Roman" size="2"><b>Note 7 &#x2014; Related Parties and Related Party Transactions</b></font></p> <!-- xbrl,body --> <p style="MARGIN-BOTTOM: 0px; MARGIN-LEFT: 2%; MARGIN-TOP: 6px"> <font style="FONT-FAMILY: Times New Roman" size="2"><b><i>Research and Development Arrangements</i></b></font></p> <p style="MARGIN-BOTTOM: 0px; MARGIN-LEFT: 2%; MARGIN-TOP: 6px"> <font style="FONT-FAMILY: Times New Roman" size="2"><i>Amgen Inc. (&#x201C;Amgen&#x201D;)</i></font></p> <p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 6px; TEXT-INDENT: 4%" align="justify"><font style="FONT-FAMILY: Times New Roman" size="2">In December 2006, the Company entered into a collaboration and option agreement with Amgen to discover, develop and commercialize novel small molecule therapeutics, including omecamtiv mecarbil, that activate cardiac muscle contractility for potential applications in the treatment of heart failure (the &#x201C;Amgen Agreement&#x201D;). The agreement granted Amgen an option to obtain an exclusive license worldwide, except Japan, to develop and commercialize omecamtiv mecarbil and other drug candidates arising from the collaboration. In May 2009, Amgen exercised its option. As a result, Amgen became responsible for the development and commercialization of omecamtiv mecarbil and related compounds at its expense worldwide (excluding Japan), subject to the Company&#x2019;s development and commercialization participation rights. Amgen reimburses the Company for certain research and development activities it performs under the collaboration.</font></p> <p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 12px; TEXT-INDENT: 4%" align="justify"><font style="FONT-FAMILY: Times New Roman" size="2">In June 2013, Cytokinetics and Amgen executed an amendment to the Amgen Agreement to include Japan, resulting in a worldwide collaboration (the &#x201C;Amgen Agreement Amendment&#x201D;). Under the terms of the Amgen Agreement Amendment, the Company received a non-refundable upfront license fee of $15.0 million in June 2013. Under the Amgen Agreement Amendment, the Company conducted a Phase I pharmacokinetic study intended to support inclusion of Japan in a potential Phase III clinical development program and potential global registration dossier for omecamtiv mecarbil. Amgen reimbursed the Company for the costs of this study. In addition, the Company is eligible to receive additional pre-commercialization milestone payments relating to the development of omecamtiv mecarbil and royalties on sales of omecamtiv mecarbil in Japan.</font></p> <p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 12px; TEXT-INDENT: 4%" align="justify"><font style="FONT-FAMILY: Times New Roman" size="2">In conjunction with the Amgen Agreement Amendment, the Company also entered into a common stock purchase agreement which provided for the sale of 1,404,100 shares of its common stock to Amgen at a price per share of $7.12 and an aggregate purchase price of $10.0 million, which was received in June 2013. The Company determined the fair value of the stock issued to Amgen to be $7.5 million. The excess of cash received over fair value of $2.5 million was initially deferred and allocated between the license and services based on their relative selling prices using best estimate of selling price. The allocated consideration was recognized as revenue as revenue criteria were satisfied, or as services were performed over approximately 12 months. Pursuant to this agreement, Amgen agreed to certain trading and other restrictions with respect to the Company&#x2019;s common stock.</font></p> <p style="MARGIN-BOTTOM: 0px; FONT-SIZE: 12px; MARGIN-TOP: 0px"> &#xA0;</p> <p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 0px; TEXT-INDENT: 4%" align="justify"><font style="FONT-FAMILY: Times New Roman" size="2">The Company determined that the license to the Japan territory granted under the Amgen Agreement Amendment was a separate, non-contingent deliverable under the amendment. The Company determined that the license has stand-alone value based on Amgen&#x2019;s internal product development capabilities since all relevant manufacturing know-how related to omecamtiv mecarbil was previously delivered to Amgen.</font></p> <p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 12px; TEXT-INDENT: 4%" align="justify"><font style="FONT-FAMILY: Times New Roman" size="2">In October 2013, the Company determined that the revenue recognition requirements under ASC 605-10 had been met and accordingly, recognized $17.2 million in license revenue attributable to the Amgen Agreement Amendment in the fourth quarter of 2013. In year ended December&#xA0;31, 2014, the Company recognized the remaining $0.3 million of the previously deferred consideration attributable to the Amgen Agreement Amendment as research and development revenues from related parties.</font></p> <p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 12px; TEXT-INDENT: 4%" align="justify"><font style="FONT-FAMILY: Times New Roman" size="2">Under the Amgen Agreement, as amended, the Company is eligible for additional development milestone payments which are based on various clinical milestones, including the initiation of certain clinical studies, the submission of a drug candidate to certain regulatory authorities for marketing approval and the receipt of such approvals, and which could total over $350.0 million. Additionally, up to $300.0 million in commercial milestones could be received provided certain sales targets are met. Due to the nature of drug development, including the inherent risk of development and approval of drug candidates by regulatory authorities, it is not possible to estimate if and when these milestone payments could become due. The achievement of each of these milestones is dependent solely upon the results of Amgen&#x2019;s development and commercialization activities and therefore none of these milestones was deemed to be substantive. During the period ended December&#xA0;31, 2014, zero dollars were recognized for milestones achieved under the Amgen Agreement.</font></p> <p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 12px; TEXT-INDENT: 4%" align="justify"><font style="FONT-FAMILY: Times New Roman" size="2">The Amgen Agreement also provides for the Company to receive increased royalties by co-funding Phase III development costs of omecamtiv mecarbil and other drug candidates under the collaboration. If the Company elects to co-fund such costs, it would be entitled to co-promote the co-funded drug in North America and participate in agreed commercialization activities in institutional care settings, at Amgen&#x2019;s expense.</font></p> <p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 12px; TEXT-INDENT: 4%" align="justify"><font style="FONT-FAMILY: Times New Roman" size="2">Pursuant to the Amgen Agreement, the Company has recognized research and development revenue from Amgen for reimbursements of internal costs of certain full-time employee equivalents, supporting a collaborative research program directed to the discovery of next-generation cardiac sarcomere activator compounds and of other costs related to that research program. These reimbursements were recorded as research and development revenues from related parties.</font></p> <p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 12px; TEXT-INDENT: 4%" align="justify"><font style="FONT-FAMILY: Times New Roman" size="2">Revenue from Amgen was as follows (in thousands):</font></p> <p style="MARGIN-BOTTOM: 0px; FONT-SIZE: 12px; MARGIN-TOP: 0px"> &#xA0;</p> <table style="BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="92%" align="center" border="0"> <!-- Begin Table Head --> <tr> <td width="72%"></td> <td valign="bottom" width="4%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="4%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="4%"></td> <td></td> <td></td> <td></td> </tr> <tr> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1px solid" valign="bottom" colspan="10" align="center"><font style="FONT-FAMILY: Times New Roman" size="1"><b>Years Ended December&#xA0;31,</b></font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> </tr> <tr> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1px solid" valign="bottom" colspan="2" align="center"><font style="FONT-FAMILY: Times New Roman" size="1"><b>2014</b></font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1px solid" valign="bottom" colspan="2" align="center"><font style="FONT-FAMILY: Times New Roman" size="1"><b>2013</b></font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1px solid" valign="bottom" colspan="2" align="center"><font style="FONT-FAMILY: Times New Roman" size="1"><b>2012</b></font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> </tr> <!-- End Table Head --><!-- Begin Table Body --> <tr bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: Times New Roman" size="2">License revenues from related parties</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td> <td valign="bottom" nowrap="nowrap" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">&#x2014;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">17,230</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td> <td valign="bottom" nowrap="nowrap" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">&#x2014;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> </tr> <tr> <td valign="top"> <p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: Times New Roman" size="2">Research and development revenues from related parties:</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-LEFT: 2em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: Times New Roman" size="2">Reimbursement of internal costs</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">4,260</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">2,019</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">4,174</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> </tr> <tr> <td valign="top"> <p style="MARGIN-LEFT: 2em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: Times New Roman" size="2">Reimbursement of other costs</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" nowrap="nowrap" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">&#x2014;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" nowrap="nowrap" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">&#x2014;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">3</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> </tr> <tr bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-LEFT: 2em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: Times New Roman" size="2">Allocated consideration</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">278</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" nowrap="nowrap" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">&#x2014;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" nowrap="nowrap" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">&#x2014;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> </tr> <tr> <td valign="top"> <p style="MARGIN-LEFT: 3em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: Times New Roman" size="2">Total revenues from Amgen</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">4,538</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">19,249</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">4,177</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p> </td> <td>&#xA0;</td> </tr> <!-- End Table Body --></table> <p style="MARGIN-BOTTOM: 0px; FONT-SIZE: 18px; MARGIN-TOP: 0px"> &#xA0;</p> <p style="MARGIN-BOTTOM: 0px; MARGIN-LEFT: 2%; MARGIN-TOP: 0px"> <font style="FONT-FAMILY: Times New Roman" size="2"><b><i>Astellas Pharma Inc. (&#x201C;Astellas&#x201D;)</i></b></font></p> <p style="MARGIN-BOTTOM: 0px; MARGIN-LEFT: 2%; MARGIN-TOP: 6px"> <font style="FONT-FAMILY: Times New Roman" size="2"><i>Original Astellas Agreement (Non-neuromuscular license)</i></font></p> <p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 6px; TEXT-INDENT: 4%" align="justify"><font style="FONT-FAMILY: Times New Roman" size="2">In June 2013, the Company entered into a license and collaboration agreement with Astellas (the &#x201C;Original Astellas Agreement&#x201D;). The primary objective of the collaboration with Astellas is to advance novel therapies for diseases and medical conditions associated with muscle weakness.</font></p> <p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 12px; TEXT-INDENT: 4%" align="justify"><font style="FONT-FAMILY: Times New Roman" size="2">Under the Original Astellas Agreement, the Company granted Astellas an exclusive license to co-develop and jointly commercialize CK-2127107, a fast skeletal troponin activator, for potential application in non-neuromuscular indications worldwide. The Company was primarily responsible for the conduct of Phase I clinical trials and certain Phase II readiness activities for CK-2127107 and Astellas was primarily responsible for the conduct of subsequent development and commercialization activities for CK-2127107.</font></p> <p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 12px; TEXT-INDENT: 4%" align="justify"><font style="FONT-FAMILY: Times New Roman" size="2">In July 2013, the Company received an upfront, non-refundable license fee of $16.0 million in connection with the execution of the Original Astellas Agreement. Under the agreement, the Company was eligible to potentially receive approximately $25.5 million in reimbursement of sponsored research and development activities during the initial two years of the collaboration. The agreement also provided for research and early and late stage development milestone payments based on various research and clinical milestones, including the initiation of certain clinical studies, the submission for approval of a drug candidate to certain regulatory authorities for marketing approval and the commercial launch of collaboration products, and royalties on sales of commercialized products.</font></p> <p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 12px; TEXT-INDENT: 4%" align="justify"><font style="FONT-FAMILY: Times New Roman" size="2">At the inception of the Original Astellas Agreement, the Company deferred revenue related to the Original Astellas Agreement in accordance with ASC 605-25. The Company evaluated whether the delivered elements under the arrangement have value on a stand-alone basis. Upfront, non-refundable licensing payments are assessed to determine whether or not the licensee is able to obtain stand-alone value from the license. Where this is not the case, the Company does not consider the license deliverable to be a separate unit of accounting, and the revenue for the license fee is deferred and recognized in conjunction with the other deliverables that constitute the combined unit of accounting.</font></p> <p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 12px; TEXT-INDENT: 4%" align="justify"><font style="FONT-FAMILY: Times New Roman" size="2">The Company determined that the license and the research and development services are a single unit of accounting as the license was determined to not have stand-alone value. Accordingly, the Company is recognizing this revenue using the proportional performance model over the initial research term of the Original Astellas Agreement. During the year ended December&#xA0;31, 2014, the Company recorded $9.8 million in license revenue based on the proportional performance model. As of December&#xA0;31, 2014, the Company has recognized $13.7 million of the $16.0 million upfront license fee as license revenue, and has $2.3 million of deferred license revenue under the Original Astellas Agreement.</font></p> <p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 12px; TEXT-INDENT: 4%" align="justify"><font style="FONT-FAMILY: Times New Roman" size="2">Pursuant to the Original Astellas Agreement, the Company has recognized research and development revenue from Astellas for reimbursements of internal costs of certain full-time employee equivalents, supporting collaborative research and development programs, and of other costs related to those programs. During the year ended December&#xA0;31, 2014, the Company recorded research and development revenue from Astellas of $8.9&#xA0;million related to the reimbursement of internal costs and $6.5 million related to the reimbursement of other costs.</font></p> <p style="MARGIN-BOTTOM: 0px; MARGIN-LEFT: 2%; MARGIN-TOP: 18px"> <font style="FONT-FAMILY: Times New Roman" size="2"><i>Amended Astellas Agreement (Expansion to include neuromuscular indications)</i></font></p> <p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 6px; TEXT-INDENT: 4%" align="justify"><font style="FONT-FAMILY: Times New Roman" size="2">On December&#xA0;22, 2014, the Company entered into an amended and restated license and collaboration agreement with Astellas (the &#x201C;Amended Astellas Agreement&#x201D;). This agreement superseded the Original Astellas Agreement. The Amended Astellas Agreement expanded the objective of the collaboration of advancing novel therapies for diseases and medical conditions associated with muscle weakness to include SMA and potentially other neuromuscular indications, in addition to the non-neuromuscular indications provided for in the Original Astellas Agreement. Under the terms of the Amended Astellas Agreement, we received a non-refundable upfront license fee of $30.0 million in January 2015. Concurrently, the Company received $15.0 million as a milestone payment relating to Astellas&#x2019; decision to advance CK-2127107 into Phase II clinical development. The Company is also eligible to potentially receive over $20.0 million in reimbursement of sponsored research and development activities during the next two years of the collaboration. Under the Amended Astellas Agreement, the Company plans to conduct the initial Phase II clinical trial of CK-2127107 in patients with SMA. In addition, the Company is entitled to receive additional pre-commercialization milestone payments related to the development of CK-2127107 in neuromuscular indications, and royalties on sales of CK-2127107 in neuromuscular indications.</font></p> <p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 12px; TEXT-INDENT: 4%" align="justify"><font style="FONT-FAMILY: Times New Roman" size="2">The Company determined that the license and the research and development services relating to the Amended Astellas Agreement are a single unit of accounting as the license was determined to not have stand-alone value. Accordingly, the Company is recognizing this revenue over the initial research term of the Amended Astellas Agreement using the proportional performance model. As of December&#xA0;31, 2014, the Company has recognized zero of the $30.0 million upfront license fee as license revenue and deferred the entire amount.</font></p> <p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 12px; TEXT-INDENT: 4%" align="justify"><font style="FONT-FAMILY: Times New Roman" size="2">The Company believes that each of the milestones related to research and early development under the Amended Astellas Agreement is substantive and can only be achieved with the Company&#x2019;s past and current performance and each milestone will result in additional payments to the Company. During the period ended December&#xA0;31, 2014, $17.0 million was recognized as milestone revenue for early development under this agreement. The Company is eligible to receive up to $2.0 million in research milestone payments for each future collaboration product candidate.</font></p> <p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 12px; TEXT-INDENT: 4%" align="justify"><font style="FONT-FAMILY: Times New Roman" size="2">The achievement of each of the late stage development milestones and the commercialization milestones are dependent solely upon the results of Astellas&#x2019; development activities and therefore these milestones were not deemed to be substantive.</font></p> <p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 12px; TEXT-INDENT: 4%" align="justify"><font style="FONT-FAMILY: Times New Roman" size="2">Under the Amended Astellas Agreement, additional research and early and late state development milestone payments which are based on various research and clinical milestones, including the initiation of certain clinical studies, the submission for approval of a drug candidate to certain regulatory authorities for marketing approval and the commercial launch of collaboration products could total over $600.0 million, including up to $95.0&#xA0;million relating to CK-2127107 in non-neuromuscular indications, and over $100.0 million related to CK-2127107 in each of SMA and other neuromuscular indications. Additionally, $200.0 million in commercial milestones could be received under the Amended Astellas Agreement provided certain sales targets are met. Due to the nature of drug development, including the inherent risk of development and approval of drug candidates by regulatory authorities, it is not possible to estimate if and when these milestone payments could become due.</font></p> <p style="MARGIN-BOTTOM: 0px; FONT-SIZE: 12px; MARGIN-TOP: 0px"> &#xA0;</p> <p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 12px; TEXT-INDENT: 4%" align="justify"><font style="FONT-FAMILY: Times New Roman" size="2">In the event Astellas commercializes any collaboration products, the Company will receive royalties on sales of such collaboration products, including royalties ranging from the high single digits to the high teens on sales of products containing CK-2127107. Cytokinetics also holds an option to co-fund certain development costs for CK-2127107 and other compounds in exchange for increased milestone payments and royalties; such royalties may increase under certain scenarios to exceed twenty percent. Under the Amended Astellas Agreement, Cytokinetics retains an option to co-promote collaboration products containing fast skeletal muscle activators for neuromuscular indications in the U.S., Canada and Europe, in addition to its option to co-promote other collaboration products in the U.S. and Canada as provided for in the Original Astellas Agreement. Astellas will reimburse Cytokinetics for certain expenses associated with its co-promotion activities. The Amended Astellas Agreement also provides for Cytokinetics to lead certain activities relating to the commercialization of collaboration products for neuromuscular indications in the U.S., Canada and Europe under particular scenarios.</font></p> <p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 12px; TEXT-INDENT: 4%" align="justify"><font style="FONT-FAMILY: Times New Roman" size="2">In conjunction with the Amended Astellas Agreement, the Company also entered into a common stock purchase agreement which provided for the sale of 2,040,816 shares of its common stock to Astellas at a price per share of $4.90 and an aggregate purchase price of $10.0 million which was received in December 2014. Pursuant to this agreement, Astellas agreed to certain trading and other restrictions with respect to the Company&#x2019;s common stock. The Company determined the fair value of the stock issued to Astellas to be $9.1 million. The excess of cash received over fair value of $0.9 million was deferred along with the license and research and development services. Allocated consideration will be recognized as revenue for the single unit of accounting above, as services are performed following the proportional performance model over the initial research term of the Amended Astellas Agreement.</font></p> <p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 12px; TEXT-INDENT: 4%" align="justify"><font style="FONT-FAMILY: Times New Roman" size="2">Following the common stock purchase, Astellas was determined to be a related party. As such, all revenue earned following the common stock purchase will be classified as related party revenue.</font></p> <p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 12px; TEXT-INDENT: 4%" align="justify"><font style="FONT-FAMILY: Times New Roman" size="2">Research and development revenue from Astellas was as follows (in thousands):</font></p> <p style="MARGIN-BOTTOM: 0px; FONT-SIZE: 12px; MARGIN-TOP: 0px"> &#xA0;</p> <table style="BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="92%" align="center" border="0"> <!-- Begin Table Head --> <tr> <td width="71%"></td> <td valign="bottom" width="9%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="9%"></td> <td></td> <td></td> <td></td> </tr> <tr> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1px solid" valign="bottom" colspan="2" align="center"><font style="FONT-FAMILY: Times New Roman" size="1"><b>Year Ended<br /> December&#xA0;31,<br /> 2014</b></font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1px solid" valign="bottom" colspan="2" align="center"><font style="FONT-FAMILY: Times New Roman" size="1"><b>Year Ended<br /> December&#xA0;31,<br /> 2013</b></font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> </tr> <!-- End Table Head --><!-- Begin Table Body --> <tr bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: Times New Roman" size="2">Research and development revenues with related parties:</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr> <td valign="top"> <p style="MARGIN-LEFT: 2em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: Times New Roman" size="2">Research and development milestone fees</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">15,000</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" nowrap="nowrap" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">&#x2014;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> </tr> <tr bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: Times New Roman" size="2">Research and development revenues:</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr> <td valign="top"> <p style="MARGIN-LEFT: 2em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: Times New Roman" size="2">Reimbursement of internal costs</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">8,939</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">3,285</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> </tr> <tr bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-LEFT: 2em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: Times New Roman" size="2">Reimbursement of other costs</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">6,452</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">3,130</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> </tr> <tr> <td valign="top"> <p style="MARGIN-LEFT: 2em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: Times New Roman" size="2">Research and development milestone fees</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">2,000</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" nowrap="nowrap" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">&#x2014;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> </tr> <tr bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-LEFT: 3em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: Times New Roman" size="2">Total research and development revenue from Astellas</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">32,391</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">6,415</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p> </td> <td>&#xA0;</td> </tr> <!-- End Table Body --></table> <p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 12px; TEXT-INDENT: 4%" align="justify"><font style="FONT-FAMILY: Times New Roman" size="2">At December&#xA0;31, 2014, the Company had $33.6 million of deferred revenue under the Amended Astellas Agreement, reflecting the unrecognized portion of the license revenue and prepayment on expenses expected to be incurred in the first quarter of 2015.</font></p> </div></us-gaap:RelatedPartyTransactionsDisclosureTextBlock> <us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock contextRef="eol_PE151383--1410-K0012_STD_365_20141231_0" id="id_6895476_D6491BAF-A8F6-42A6-B2CA-A3A25073E74E_1_0"><div> <p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 12px; TEXT-INDENT: 4%" align="justify"><font style="FONT-FAMILY: Times New Roman" size="2">The following table summarizes stock-based compensation related to stock options, restricted stock awards, restricted stock unit, and employee stock purchases (in thousands):</font></p> <p style="MARGIN-BOTTOM: 0px; FONT-SIZE: 12px; MARGIN-TOP: 0px"> &#xA0;</p> <table style="BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="92%" align="center" border="0"> <tr> <td width="73%"></td> <td valign="bottom" width="4%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="4%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="4%"></td> <td></td> <td></td> <td></td> </tr> <tr> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="10" align="center"><font style="FONT-FAMILY: Times New Roman" size="1"><b>Years Ended December&#xA0;31,</b></font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> </tr> <tr> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" align="center"><font style="FONT-FAMILY: Times New Roman" size="1"><b>2014</b></font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" align="center"><font style="FONT-FAMILY: Times New Roman" size="1"><b>2013</b></font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" align="center"><font style="FONT-FAMILY: Times New Roman" size="1"><b>2012</b></font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> </tr> <tr bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: Times New Roman" size="2">Research and development</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">1,361</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">1,538</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">1,801</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> </tr> <tr> <td valign="top"> <p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: Times New Roman" size="2">General and administrative</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">1,969</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">2,059</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">1,982</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> </tr> <tr bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: Times New Roman" size="2">Stock-based compensation included in operating expenses</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">3,330</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">3,597</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">3,783</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td>&#xA0;</td> </tr> </table> </div></us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock> <us-gaap:RevenueRecognitionPolicyTextBlock contextRef="eol_PE151383--1410-K0012_STD_365_20141231_0" id="id_6895476_A61449B7-A957-4366-AB0D-274390D30967_1_0"><div> <p style="MARGIN-BOTTOM: 0px; MARGIN-LEFT: 2%; MARGIN-TOP: 18px"> <font style="FONT-FAMILY: Times New Roman" size="2"><b><i>Revenue Recognition</i></b></font></p> <p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 6px; TEXT-INDENT: 4%" align="justify"><font style="FONT-FAMILY: Times New Roman" size="2">The accounting guidance for revenue recognition requires that the following criteria must be met before revenue can be recognized: (i)&#xA0;persuasive evidence of an arrangement exists; (ii)&#xA0;delivery has occurred or services have been rendered; (iii)&#xA0;the fee is fixed or determinable; and (iv)&#xA0;collectability is reasonably assured. Determination of whether persuasive evidence of an arrangement exists and whether delivery has occurred or services have been rendered are based on management&#x2019;s judgments regarding the fixed nature of the fee charged for research performed and milestones met, and the collectability of those fees. Should changes in conditions cause management to determine these criteria are not met for certain future transactions, revenue recognized for any reporting period could be adversely affected.</font></p> <p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 12px; TEXT-INDENT: 4%" align="justify"><font style="FONT-FAMILY: Times New Roman" size="2">Revenue under our license and collaboration arrangements is recognized based on the performance requirements of the contract. Research and development revenues, which are earned under agreements with third parties for agreed research and development activities, may include non-refundable license fees, research and development funding, cost reimbursements and contingent milestones and royalties. The Company&#x2019;s collaborations prior to January&#xA0;1, 2011 with multiple elements were evaluated and divided into separate units of accounting if certain criteria are met, including whether the delivered element has stand-alone value to the customer and whether there was vendor-specific objective and reliable evidence (&#x201C;VSOE&#x201D;) of the fair value of the undelivered items. The consideration the Company received was allocated among the separate units based on their respective fair values, and the applicable revenue recognition criteria were applied to each of the separate units. The consideration the Company received was combined and recognized as a single unit of accounting when criteria for separation were not met.&#xA0;On January&#xA0;1, 2011, ASC Topic 605-25, <i>Revenue Recognition &#x2014; Multiple-Element Arrangements</i> (&#x201C;ASC 605-25&#x201D;) on the recognition of revenues for agreements with multiple deliverables became effective and applies to any agreements the Company entered into on or after January&#xA0;1, 2011. Under this updated guidance, revenue is allocated to each element using a selling price hierarchy, where the selling price for an element is based on VSOE if available; third-party evidence (&#x201C;TPE&#x201D;), if available and VSOE is not available; or the best estimate of selling price, if neither VSOE nor TPE is available.</font></p> <p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 12px; TEXT-INDENT: 4%" align="justify"><font style="FONT-FAMILY: Times New Roman" size="2">Upfront, non-refundable licensing payments are assessed to determine whether or not the licensee is able to obtain stand-alone value from the license. Where the license does not have stand-alone value, non-refundable license fees are recognized as revenue as the Company performs under the applicable agreement. Where the level of effort is relatively consistent over the performance period, the Company recognizes total fixed or determined revenue on a straight-line basis over the estimated period of expected performance. Where the license has stand-alone value, the Company recognizes total license revenue at the time all revenue recognition criteria have been met.</font></p> <p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 12px; TEXT-INDENT: 4%" align="justify"><font style="FONT-FAMILY: Times New Roman" size="2">ASC Topic 605-28, <i>Revenue Recognition &#x2014; Milestone Method</i> (&#x201C;ASC 605-28&#x201D;), established the milestone method as an acceptable method of revenue recognition for certain contingent event-based payments under research and development arrangements. Under the milestone method, a payment that is contingent upon the achievement of a substantive milestone is recognized in its entirety in the period in which the milestone is achieved. A milestone is an event (i)&#xA0;that can be achieved based in whole or in part on either the Company&#x2019;s performance or on the occurrence of a specific outcome resulting from the Company&#x2019;s performance, (ii)&#xA0;for which there is substantive uncertainty at the date the arrangement is entered into that the event will be achieved, and (iii)&#xA0;that would result in additional payments being due to the Company. The determination that a milestone is substantive is judgmental and is made at the inception of the arrangement. Milestones are considered substantive when the consideration earned from the achievement of the milestone is (i)&#xA0;commensurate with either the Company&#x2019;s performance to achieve the milestone or the enhancement of value of the item delivered as a result of a specific outcome resulting from the Company&#x2019;s performance to achieve the milestone, (ii)&#xA0;relates solely to past performance and (iii)&#xA0;is reasonable relative to all deliverables and payment terms in the arrangement.</font></p> <p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 12px; TEXT-INDENT: 4%" align="justify"><font style="FONT-FAMILY: Times New Roman" size="2">Other contingent event-based payments received for which payment is either contingent solely upon the passage of time or the results of a collaborative partner&#x2019;s performance are not considered milestones under ASC 605-28. In accordance with ASC 605-25<i>,</i> such payments will be recognized as revenue when all of the following criteria are met: (i)&#xA0;persuasive evidence of an arrangement exists, (ii)&#xA0;delivery has occurred or services have been rendered, (iii)&#xA0;price is fixed or determinable, and (iv)&#xA0;collectability is reasonably assured.</font></p> <p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 12px; TEXT-INDENT: 4%" align="justify"><font style="FONT-FAMILY: Times New Roman" size="2">Prior to January&#xA0;1, 2011, the Company recognized and will continue to recognize milestone payments as revenue upon achievement of the milestone, provided the milestone payment was non-refundable, substantive effort and risk were involved in achieving the milestone and the amount of the milestone was reasonable in relation to the effort expended or risk associated with the achievement of the milestone. If these conditions were not met, the Company deferred the milestone payment and recognized it as revenue over the estimated period of performance under the contract as the Company completed its performance obligations. The Company has concluded that all of the future contingent milestone payments pursuant to its research and development arrangements entered into prior to January&#xA0;1, 2011 are not considered substantive as they are the results of a collaborative partner&#x2019;s performance. Therefore, they are not considered milestones under ASC 605-28.</font></p> <p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 12px; TEXT-INDENT: 4%" align="justify"><font style="FONT-FAMILY: Times New Roman" size="2">For collaborations and material modifications entered into after January&#xA0;1, 2011, the Company accounts for milestone payments under the provisions of ASC&#xA0;605-28. The Company considers an event to be a milestone if there is substantive uncertainty at the date the arrangement is entered into that the event will be achieved, if the event can only be achieved with the Company&#x2019;s performance, and if the achievement of the event results in payment to the Company. If the Company determines a milestone is substantive, the Company recognizes revenue when payment is earned and becomes payable. For a milestone to be considered substantive, it must be achieved with the Company&#x2019;s performance, be reasonable relative to the terms of the arrangement and be commensurate with the Company&#x2019;s effort to achieve the milestone or commensurate with the enhanced value of the delivered item(s) as a result of the milestone achievement. If the Company determines a milestone is not substantive, the Company defers the payment and recognizes revenue over the estimated period of performance as the Company completes its performance obligations.</font></p> <p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 12px; TEXT-INDENT: 4%" align="justify"><font style="FONT-FAMILY: Times New Roman" size="2">Research and development revenues and cost reimbursements are based upon negotiated rates for the Company&#x2019;s full-time employee equivalents (&#x201C;FTE&#x201D;) and actual out-of-pocket costs. FTE rates are negotiated rates that are based upon the Company&#x2019;s costs, and which the Company believes approximate fair value. Any amounts received in advance of performance are recorded as deferred revenue. None of the revenues recognized to date are refundable if the relevant research effort is not successful. In revenue arrangements in which both parties make payments to each other, the Company evaluates the payments in accordance with the accounting guidance for arrangements under which consideration is given by a vendor to a customer, including a reseller of the vendor&#x2019;s products, to determine whether payments made by us will be recognized as a reduction of revenue or as expense. In accordance with this guidance, revenue recognized by the Company may be reduced by payments made to the other party under the arrangement unless the Company receives a separate and identifiable benefit in exchange for the payments and the Company can reasonably estimate the fair value of the benefit received. The application of the accounting guidance for consideration given to a customer has had no material impact to the Company.</font></p> <p style="MARGIN-BOTTOM: 0px; FONT-SIZE: 12px; MARGIN-TOP: 0px"> &#xA0;</p> <p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 0px; TEXT-INDENT: 4%" align="justify"><font style="FONT-FAMILY: Times New Roman" size="2">Funds received from third parties under grant arrangements are recorded as revenue if the Company is deemed to be the principal participant in the grant arrangement as the activities under the grant are part of the Company&#x2019;s development program. If the Company is not the principal participant, the grant funds are recorded as a reduction to research and development expense. Grant funds received are not refundable and are recognized when the related qualified research and development costs are incurred and when there is reasonable assurance that the funds will be received. Funds received in advance are recorded as deferred revenue.</font></p> </div></us-gaap:RevenueRecognitionPolicyTextBlock> <us-gaap:ScheduleOfRentExpenseTableTextBlock contextRef="eol_PE151383--1410-K0012_STD_365_20141231_0" id="id_6895476_3116C55D-9ABD-4EB3-A288-BA56B6C99542_1_0"><div> <p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 18px; TEXT-INDENT: 4%" align="justify"><font style="FONT-FAMILY: Times New Roman" size="2">Rent expense was as follows (in thousands):</font></p> <p style="MARGIN-BOTTOM: 0px; FONT-SIZE: 12px; MARGIN-TOP: 0px"> &#xA0;</p> <table style="BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="92%" align="center" border="0"> <tr> <td width="73%"></td> <td valign="bottom" width="4%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="4%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="4%"></td> <td></td> <td></td> <td></td> </tr> <tr> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="10" align="center"><font style="FONT-FAMILY: Times New Roman" size="1"><b>Years Ended December&#xA0;31,</b></font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> </tr> <tr> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" align="center"><font style="FONT-FAMILY: Times New Roman" size="1"><b>2014</b></font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" align="center"><font style="FONT-FAMILY: Times New Roman" size="1"><b>2013</b></font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" align="center"><font style="FONT-FAMILY: Times New Roman" size="1"><b>2012</b></font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> </tr> <tr bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: Times New Roman" size="2">Rent expense</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">3,338</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">3,306</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">3,375</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td>&#xA0;</td> </tr> </table> </div></us-gaap:ScheduleOfRentExpenseTableTextBlock> <us-gaap:StockholdersEquityReverseStockSplit contextRef="eol_PE151383--1410-K0012_STD_365_20141231_0" id="id_6895476_F4F8A908-2CA8-4F3B-8B91-6AA61E4E25C3_1_1">As of the effective time of the reverse stock split, every six shares of the Company's issued and outstanding common stock were converted into one issued and outstanding share of common stock, without any change in par value per share.</us-gaap:StockholdersEquityReverseStockSplit> <us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes contextRef="eol_PE151383--1410-K0012_STD_365_20141231_0" unitRef="pure" decimals="2" id="id_6895476_14EF385A-3844-4F78-AE65-D20D0D541C15_1_1">-0.01</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes> <us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock contextRef="eol_PE151383--1410-K0012_STD_365_20141231_0" id="id_6895476_50F6179D-DF35-48F4-A796-933A49BFBF96_1_0"><div> <p style="margin-top:0px;margin-bottom:0px; text-indent:4%" align="justify"><font style="font-family:Times New Roman" size="2">Accrued liabilities were as follows (in thousands):</font></p> <p style="font-size:12px;margin-top:0px;margin-bottom:0px"> &#xA0;</p> <table cellspacing="0" cellpadding="0" width="92%" border="0" style="BORDER-COLLAPSE:COLLAPSE" align="center"> <tr> <td width="82%"></td> <td valign="bottom" width="4%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="4%"></td> <td></td> <td></td> <td></td> </tr> <tr> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom" colspan="6" align="center" style="border-bottom:1px solid #000000"><font style="font-family:Times New Roman" size="1"><b>December&#xA0;31,</b></font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> </tr> <tr> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom" colspan="2" align="center" style="border-bottom:1px solid #000000"><font style="font-family:Times New Roman" size="1"><b>2014</b></font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom" colspan="2" align="center" style="border-bottom:1px solid #000000"><font style="font-family:Times New Roman" size="1"><b>2013</b></font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> </tr> <tr bgcolor="#CCEEFF"> <td valign="top"> <p style="margin-left:1.00em; text-indent:-1.00em"><font style="font-family:Times New Roman" size="2">Accrued liabilities:</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr> <td valign="top"> <p style="margin-left:2.00em; text-indent:-1.00em"><font style="font-family:Times New Roman" size="2">Clinical and preclinical costs</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="font-family:Times New Roman" size="2">$</font></td> <td valign="bottom" align="right"><font style="font-family:Times New Roman" size="2">972</font></td> <td nowrap="nowrap" valign="bottom"><font style="font-family:Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="font-family:Times New Roman" size="2">$</font></td> <td valign="bottom" align="right"><font style="font-family:Times New Roman" size="2">4,975</font></td> <td nowrap="nowrap" valign="bottom"><font style="font-family:Times New Roman" size="2">&#xA0;&#xA0;</font></td> </tr> <tr bgcolor="#CCEEFF"> <td valign="top"> <p style="margin-left:2.00em; text-indent:-1.00em"><font style="font-family:Times New Roman" size="2">Consulting and professional fees</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="font-family:Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="font-family:Times New Roman" size="2">421</font></td> <td nowrap="nowrap" valign="bottom"><font style="font-family:Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="font-family:Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="font-family:Times New Roman" size="2">697</font></td> <td nowrap="nowrap" valign="bottom"><font style="font-family:Times New Roman" size="2">&#xA0;&#xA0;</font></td> </tr> <tr> <td valign="top"> <p style="margin-left:2.00em; text-indent:-1.00em"><font style="font-family:Times New Roman" size="2">Bonus</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="font-family:Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="font-family:Times New Roman" size="2">2,665</font></td> <td nowrap="nowrap" valign="bottom"><font style="font-family:Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="font-family:Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="font-family:Times New Roman" size="2">1,614</font></td> <td nowrap="nowrap" valign="bottom"><font style="font-family:Times New Roman" size="2">&#xA0;&#xA0;</font></td> </tr> <tr bgcolor="#CCEEFF"> <td valign="top"> <p style="margin-left:2.00em; text-indent:-1.00em"><font style="font-family:Times New Roman" size="2">Vacation pay</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="font-family:Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="font-family:Times New Roman" size="2">915</font></td> <td nowrap="nowrap" valign="bottom"><font style="font-family:Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="font-family:Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="font-family:Times New Roman" size="2">778</font></td> <td nowrap="nowrap" valign="bottom"><font style="font-family:Times New Roman" size="2">&#xA0;&#xA0;</font></td> </tr> <tr> <td valign="top"> <p style="margin-left:2.00em; text-indent:-1.00em"><font style="font-family:Times New Roman" size="2">Other payroll related</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="font-family:Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="font-family:Times New Roman" size="2">110</font></td> <td nowrap="nowrap" valign="bottom"><font style="font-family:Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="font-family:Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="font-family:Times New Roman" size="2">93</font></td> <td nowrap="nowrap" valign="bottom"><font style="font-family:Times New Roman" size="2">&#xA0;&#xA0;</font></td> </tr> <tr bgcolor="#CCEEFF"> <td valign="top"> <p style="margin-left:2.00em; text-indent:-1.00em"><font style="font-family:Times New Roman" size="2">Other accrued expenses</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="font-family:Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="font-family:Times New Roman" size="2">317</font></td> <td nowrap="nowrap" valign="bottom"><font style="font-family:Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="font-family:Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="font-family:Times New Roman" size="2">115</font></td> <td nowrap="nowrap" valign="bottom"><font style="font-family:Times New Roman" size="2">&#xA0;&#xA0;</font></td> </tr> <tr style="font-size:1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="border-top:1px solid #000000">&#xA0;</p> </td> <td valign="bottom"> <p style="border-top:1px solid #000000">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="border-top:1px solid #000000">&#xA0;</p> </td> <td valign="bottom"> <p style="border-top:1px solid #000000">&#xA0;</p> </td> <td>&#xA0;</td> </tr> <tr> <td valign="top"></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="font-family:Times New Roman" size="2">$</font></td> <td valign="bottom" align="right"><font style="font-family:Times New Roman" size="2">5,400</font></td> <td nowrap="nowrap" valign="bottom"><font style="font-family:Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="font-family:Times New Roman" size="2">$</font></td> <td valign="bottom" align="right"><font style="font-family:Times New Roman" size="2">8,272</font></td> <td nowrap="nowrap" valign="bottom"><font style="font-family:Times New Roman" size="2">&#xA0;&#xA0;</font></td> </tr> <tr style="font-size:1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="border-top:3px double #000000">&#xA0;</p> </td> <td valign="bottom"> <p style="border-top:3px double #000000">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="border-top:3px double #000000">&#xA0;</p> </td> <td valign="bottom"> <p style="border-top:3px double #000000">&#xA0;</p> </td> <td>&#xA0;</td> </tr> </table> </div></us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock> <us-gaap:ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock contextRef="eol_PE151383--1410-K0012_STD_365_20141231_0" id="id_6895476_6F22D9A7-F99D-43A5-ACAA-1B01A419E6A9_1_0"><div> <p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 6px; TEXT-INDENT: 4%" align="justify"><font style="FONT-FAMILY: Times New Roman" size="2">The amortized cost and fair value of cash equivalents and available for sale investments at December&#xA0;31, 2014 and 2013 were as follows (in thousands):</font></p> <p style="MARGIN-BOTTOM: 0px; FONT-SIZE: 12px; MARGIN-TOP: 0px"> &#xA0;</p> <table style="BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="100%" align="center" border="0"> <tr> <td width="45%"></td> <td valign="bottom" width="5%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="5%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="5%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="5%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="5%"></td> <td></td> <td></td> <td></td> </tr> <tr> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="18" align="center"><font style="FONT-FAMILY: Times New Roman" size="1"><b>December&#xA0;31, 2014</b></font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> </tr> <tr> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" align="center"><font style="FONT-FAMILY: Times New Roman" size="1"><b>Amortized<br /> Cost</b></font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" align="center"><font style="FONT-FAMILY: Times New Roman" size="1"><b>Unrealized<br /> Gains</b></font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" align="center"><font style="FONT-FAMILY: Times New Roman" size="1"><b>Unrealized<br /> Losses</b></font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" align="center"><font style="FONT-FAMILY: Times New Roman" size="1"><b>Fair<br /> Value</b></font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" align="center"><font style="FONT-FAMILY: Times New Roman" size="1"><b>Maturity<br /> Dates</b></font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> </tr> <tr bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: Times New Roman" size="2">Cash equivalents &#x2014; money market funds</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">16,932</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td> <td valign="bottom" nowrap="nowrap" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">&#x2014;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td> <td valign="bottom" nowrap="nowrap" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">&#x2014;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">16,932</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr> <td valign="top"> <p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: Times New Roman" size="2">Short-term investments &#x2014; U.S. Treasury securities</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">63,017</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">3</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">(7</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">)&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">63,013</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">1/2015&#xA0;&#x2014;&#xA0;12/2015</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: Times New Roman" size="2">Long-term investments &#x2014; U.S. Treasury securities</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td> <td valign="bottom" nowrap="nowrap" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">&#x2014;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td> <td valign="bottom" nowrap="nowrap" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">&#x2014;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td> <td valign="bottom" nowrap="nowrap" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">&#x2014;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td> <td valign="bottom" nowrap="nowrap" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">&#x2014;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> </table> <p style="MARGIN-BOTTOM: 0px; FONT-SIZE: 12px; MARGIN-TOP: 0px"> &#xA0;</p> <table style="BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="100%" align="center" border="0"> <tr> <td width="45%"></td> <td valign="bottom" width="5%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="5%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="5%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="5%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="5%"></td> <td></td> <td></td> <td></td> </tr> <tr> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="18" align="center"><font style="FONT-FAMILY: Times New Roman" size="1"><b>December&#xA0;31, 2013</b></font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> </tr> <tr> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" align="center"><font style="FONT-FAMILY: Times New Roman" size="1"><b>Amortized<br /> Cost</b></font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" align="center"><font style="FONT-FAMILY: Times New Roman" size="1"><b>Unrealized<br /> Gains</b></font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" align="center"><font style="FONT-FAMILY: Times New Roman" size="1"><b>Unrealized<br /> Losses</b></font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" align="center"><font style="FONT-FAMILY: Times New Roman" size="1"><b>Fair<br /> Value</b></font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" align="center"><font style="FONT-FAMILY: Times New Roman" size="1"><b>Maturity<br /> Dates</b></font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> </tr> <tr bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: Times New Roman" size="2">Cash equivalents &#x2014; money market funds</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">15,858</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td> <td valign="bottom" nowrap="nowrap" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">&#x2014;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td> <td valign="bottom" nowrap="nowrap" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">&#x2014;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">15,858</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr> <td valign="top"> <p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: Times New Roman" size="2">Short-term investments &#x2014; U.S. Treasury securities</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">57,564</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">7</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">(1</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">)&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">57,570</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">1/2014&#xA0;&#x2014;&#xA0;12/2014</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: Times New Roman" size="2">Long-term investments &#x2014; U.S. Treasury securities</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">2,502</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td> <td valign="bottom" nowrap="nowrap" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">&#x2014;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td> <td valign="bottom" nowrap="nowrap" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">&#x2014;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">2,502</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">1/2015</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> </table> </div></us-gaap:ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock> <us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock contextRef="eol_PE151383--1410-K0012_STD_365_20141231_0" id="id_6895476_573E3190-7F14-4F51-9261-29E7FA598940_1_0"><div> <p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 12px; TEXT-INDENT: 4%" align="justify"><font style="FONT-FAMILY: Times New Roman" size="2">The Company recorded the following income tax provision as follows (in thousands):</font></p> <p style="MARGIN-BOTTOM: 0px; FONT-SIZE: 12px; MARGIN-TOP: 0px"> &#xA0;</p> <table style="BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="92%" align="center" border="0"> <tr> <td width="67%"></td> <td valign="bottom" width="9%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="9%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="9%"></td> <td></td> <td></td> <td></td> </tr> <tr> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="10" align="center"><font style="FONT-FAMILY: Times New Roman" size="1"><b>Years Ended<br /> December&#xA0;31,</b></font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> </tr> <tr> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" align="center"><font style="FONT-FAMILY: Times New Roman" size="1"><b>2014</b></font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" align="center"><font style="FONT-FAMILY: Times New Roman" size="1"><b>2013</b></font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" align="center"><font style="FONT-FAMILY: Times New Roman" size="1"><b>2012</b></font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> </tr> <tr bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: Times New Roman" size="2">Current:</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr> <td valign="top"> <p style="MARGIN-LEFT: 2em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: Times New Roman" size="2">Federal</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td> <td valign="bottom" nowrap="nowrap" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">&#x2014;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td> <td valign="bottom" nowrap="nowrap" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">&#x2014;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td> <td valign="bottom" nowrap="nowrap" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">&#x2014;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> </tr> <tr bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-LEFT: 2em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: Times New Roman" size="2">State</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" nowrap="nowrap" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">&#x2014;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" nowrap="nowrap" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">&#x2014;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" nowrap="nowrap" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">&#x2014;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> </tr> <tr> <td valign="top"> <p style="MARGIN-LEFT: 3em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: Times New Roman" size="2">Total</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td> <td valign="bottom" nowrap="nowrap" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">&#x2014;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td> <td valign="bottom" nowrap="nowrap" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">&#x2014;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td> <td valign="bottom" nowrap="nowrap" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">&#x2014;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td>&#xA0;</td> </tr> <tr bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: Times New Roman" size="2">Deferred:</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr> <td valign="top"> <p style="MARGIN-LEFT: 2em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: Times New Roman" size="2">Federal</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td> <td valign="bottom" nowrap="nowrap" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">&#x2014;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td> <td valign="bottom" nowrap="nowrap" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">&#x2014;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td> <td valign="bottom" nowrap="nowrap" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">&#x2014;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> </tr> <tr bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-LEFT: 2em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: Times New Roman" size="2">State</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" nowrap="nowrap" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">&#x2014;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" nowrap="nowrap" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">&#x2014;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" nowrap="nowrap" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">&#x2014;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> </tr> <tr> <td valign="top"> <p style="MARGIN-LEFT: 3em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: Times New Roman" size="2">Total</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td> <td valign="bottom" nowrap="nowrap" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">&#x2014;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td> <td valign="bottom" nowrap="nowrap" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">&#x2014;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td> <td valign="bottom" nowrap="nowrap" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">&#x2014;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td>&#xA0;</td> </tr> </table> </div></us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock> <us-gaap:ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock contextRef="eol_PE151383--1410-K0012_STD_365_20141231_0" id="id_6895476_91D03DFC-F76F-4ED4-A31B-F4FF84222923_1_0"><div> <p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 6px; TEXT-INDENT: 4%" align="justify"><font style="FONT-FAMILY: Times New Roman" size="2">Components of Interest and Other, Net were as follows (in thousands):</font></p> <p style="MARGIN-BOTTOM: 0px; FONT-SIZE: 12px; MARGIN-TOP: 0px"> &#xA0;</p> <table style="BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="92%" align="center" border="0"> <tr> <td width="80%"></td> <td valign="bottom" width="4%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="4%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="4%"></td> <td></td> <td></td> <td></td> </tr> <tr> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="10" align="center"><font style="FONT-FAMILY: Times New Roman" size="1"><b>Years Ended<br /> December&#xA0;31,</b></font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> </tr> <tr> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" align="center"><font style="FONT-FAMILY: Times New Roman" size="1"><b>2014</b></font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" align="center"><font style="FONT-FAMILY: Times New Roman" size="1"><b>2013</b></font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" align="center"><font style="FONT-FAMILY: Times New Roman" size="1"><b>2012</b></font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> </tr> <tr bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: Times New Roman" size="2">Interest income and other income</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">108</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">98</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">89</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> </tr> <tr> <td valign="top"> <p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: Times New Roman" size="2">Interest expense and other expense</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" nowrap="nowrap" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">&#x2014;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">79</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">(2</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">)&#xA0;</font></td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> </tr> <tr bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-LEFT: 2em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: Times New Roman" size="2">Interest and Other, net</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">108</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">177</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">87</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td>&#xA0;</td> </tr> </table> </div></us-gaap:ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock> <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross contextRef="eol_PE151383--1410-K0012_STD_365_20141231_0" unitRef="shares" decimals="INF" id="id_6895476_550670F2-8019-4594-8D89-8D38F90A7B79_11001_14">944831</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross> <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod contextRef="eol_PE151383--1410-K0012_STD_365_20141231_0" unitRef="shares" decimals="INF" id="id_6895476_EAE02EAA-C88A-417D-A4E8-6DD5ADADA4AB_12001_14">944831</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod> <us-gaap:UseOfEstimates contextRef="eol_PE151383--1410-K0012_STD_365_20141231_0" id="id_6895476_156A7C5A-EE82-4FF8-A9AC-C1E171CF2F32_1_0"><div> <p style="MARGIN-BOTTOM: 0px; MARGIN-LEFT: 2%; MARGIN-TOP: 0px"> <font style="FONT-FAMILY: Times New Roman" size="2"><b><i>Use of Estimates</i></b></font></p> <p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 6px; TEXT-INDENT: 4%" align="justify"><font style="FONT-FAMILY: Times New Roman" size="2">The preparation of financial statements in conformity with accounting principles generally accepted in the United States requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosures of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.</font></p> </div></us-gaap:UseOfEstimates> <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted contextRef="eol_PE151383--1410-K0012_STD_365_20141231_0" unitRef="shares" decimals="-3" id="id_6895476_09173C79-2713-49DF-8107-C7F99AA4E397_1_3">35709000</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted> <dei:DocumentPeriodEndDate contextRef="eol_PE151383--1410-K0012_STD_365_20141231_0" id="id_6895476_BB2FF52D-3F86-4944-B60D-74EA496D7B67_1_2">2014-12-31</dei:DocumentPeriodEndDate> <us-gaap:CashAndCashEquivalentsPolicyTextBlock contextRef="eol_PE151383--1410-K0012_STD_365_20141231_0" id="id_6895476_21DC5BC2-2E34-410A-8565-3BFAE7BDD491_1_0"><div> <p style="MARGIN-BOTTOM: 0px; MARGIN-LEFT: 2%; MARGIN-TOP: 18px"> <font style="FONT-FAMILY: Times New Roman" size="2"><b><i>Cash and Cash Equivalents</i></b></font></p> <p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 6px; TEXT-INDENT: 4%" align="justify"><font style="FONT-FAMILY: Times New Roman" size="2">The Company considers all highly liquid investments with a maturity of three months or less at the time of purchase to be cash equivalents.</font></p> </div></us-gaap:CashAndCashEquivalentsPolicyTextBlock> <us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments contextRef="eol_PE151383--1410-K0012_STD_365_20141231_0" unitRef="pure" decimals="2" id="id_6895476_14EF385A-3844-4F78-AE65-D20D0D541C15_1_7">0.00</us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments> <us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock contextRef="eol_PE151383--1410-K0012_STD_365_20141231_0" id="id_6895476_EF6E96E3-BA79-4ACF-94B2-081B0A3C2EB2_1_0"><div> <p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 0px"><font style="FONT-FAMILY: Times New Roman" size="2"><b>Note 4 &#x2014; Cash Equivalents and Investments</b></font></p> <p style="MARGIN-BOTTOM: 0px; MARGIN-LEFT: 2%; MARGIN-TOP: 6px"> <font style="FONT-FAMILY: Times New Roman" size="2"><b><i>Cash Equivalents and Available for Sale Investments</i></b></font></p> <p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 6px; TEXT-INDENT: 4%" align="justify"><font style="FONT-FAMILY: Times New Roman" size="2">The amortized cost and fair value of cash equivalents and available for sale investments at December&#xA0;31, 2014 and 2013 were as follows (in thousands):</font></p> <p style="MARGIN-BOTTOM: 0px; FONT-SIZE: 12px; MARGIN-TOP: 0px"> &#xA0;</p> <table style="BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="100%" align="center" border="0"> <tr> <td width="45%"></td> <td valign="bottom" width="5%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="5%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="5%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="5%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="5%"></td> <td></td> <td></td> <td></td> </tr> <tr> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="18" align="center"><font style="FONT-FAMILY: Times New Roman" size="1"><b>December&#xA0;31, 2014</b></font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> </tr> <tr> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" align="center"><font style="FONT-FAMILY: Times New Roman" size="1"><b>Amortized<br /> Cost</b></font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" align="center"><font style="FONT-FAMILY: Times New Roman" size="1"><b>Unrealized<br /> Gains</b></font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" align="center"><font style="FONT-FAMILY: Times New Roman" size="1"><b>Unrealized<br /> Losses</b></font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" align="center"><font style="FONT-FAMILY: Times New Roman" size="1"><b>Fair<br /> Value</b></font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" align="center"><font style="FONT-FAMILY: Times New Roman" size="1"><b>Maturity<br /> Dates</b></font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> </tr> <tr bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: Times New Roman" size="2">Cash equivalents &#x2014; money market funds</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">16,932</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td> <td valign="bottom" nowrap="nowrap" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">&#x2014;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td> <td valign="bottom" nowrap="nowrap" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">&#x2014;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">16,932</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr> <td valign="top"> <p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: Times New Roman" size="2">Short-term investments &#x2014; U.S. Treasury securities</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">63,017</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">3</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">(7</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">)&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">63,013</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">1/2015&#xA0;&#x2014;&#xA0;12/2015</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: Times New Roman" size="2">Long-term investments &#x2014; U.S. Treasury securities</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td> <td valign="bottom" nowrap="nowrap" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">&#x2014;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td> <td valign="bottom" nowrap="nowrap" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">&#x2014;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td> <td valign="bottom" nowrap="nowrap" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">&#x2014;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td> <td valign="bottom" nowrap="nowrap" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">&#x2014;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> </table> <p style="MARGIN-BOTTOM: 0px; FONT-SIZE: 12px; MARGIN-TOP: 0px"> &#xA0;</p> <table style="BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="100%" align="center" border="0"> <tr> <td width="45%"></td> <td valign="bottom" width="5%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="5%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="5%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="5%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="5%"></td> <td></td> <td></td> <td></td> </tr> <tr> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="18" align="center"><font style="FONT-FAMILY: Times New Roman" size="1"><b>December&#xA0;31, 2013</b></font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> </tr> <tr> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" align="center"><font style="FONT-FAMILY: Times New Roman" size="1"><b>Amortized<br /> Cost</b></font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" align="center"><font style="FONT-FAMILY: Times New Roman" size="1"><b>Unrealized<br /> Gains</b></font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" align="center"><font style="FONT-FAMILY: Times New Roman" size="1"><b>Unrealized<br /> Losses</b></font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" align="center"><font style="FONT-FAMILY: Times New Roman" size="1"><b>Fair<br /> Value</b></font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" align="center"><font style="FONT-FAMILY: Times New Roman" size="1"><b>Maturity<br /> Dates</b></font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> </tr> <tr bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: Times New Roman" size="2">Cash equivalents &#x2014; money market funds</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">15,858</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td> <td valign="bottom" nowrap="nowrap" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">&#x2014;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td> <td valign="bottom" nowrap="nowrap" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">&#x2014;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">15,858</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr> <td valign="top"> <p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: Times New Roman" size="2">Short-term investments &#x2014; U.S. Treasury securities</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">57,564</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">7</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">(1</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">)&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">57,570</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">1/2014&#xA0;&#x2014;&#xA0;12/2014</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: Times New Roman" size="2">Long-term investments &#x2014; U.S. Treasury securities</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">2,502</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td> <td valign="bottom" nowrap="nowrap" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">&#x2014;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td> <td valign="bottom" nowrap="nowrap" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">&#x2014;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">2,502</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">1/2015</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> </table> <p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 12px; TEXT-INDENT: 4%" align="justify"><font style="FONT-FAMILY: Times New Roman" size="2">As of December&#xA0;31, 2014 and December&#xA0;31, 2013, the Company&#x2019;s U.S. Treasury securities classified as short-term investments had unrealized losses of approximately $7 and $1, respectively. The net unrealized loss at December&#xA0;31, 2014 was primarily caused by increases in short-term interest rates subsequent to the purchase dates of the related securities. The net unrealized gain at December&#xA0;31, 2013 was primarily caused by slight decreases in short-term interest rates subsequent to the purchase dates of the related securities. At December&#xA0;31, 2014 there were no investments that had been in a continuous unrealized loss position for 12 months or longer. The Company collected the contractual cash flows on its U.S.&#xA0;Treasury securities that matured from January&#xA0;1, 2015 through February&#xA0;27, 2015 and expects to be able to collect all contractual cash flows on the remaining maturities of its U.S.&#xA0;Treasury securities.</font></p> <p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 12px; TEXT-INDENT: 4%" align="justify"><font style="FONT-FAMILY: Times New Roman" size="2">Interest income was as follows (in thousands):</font></p> <p style="MARGIN-BOTTOM: 0px; FONT-SIZE: 12px; MARGIN-TOP: 0px"> &#xA0;</p> <table style="BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="92%" align="center" border="0"> <tr> <td width="81%"></td> <td valign="bottom" width="4%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="4%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="4%"></td> <td></td> <td></td> <td></td> </tr> <tr> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="10" align="center"><font style="FONT-FAMILY: Times New Roman" size="1"><b>Years Ended<br /> December&#xA0;31,</b></font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> </tr> <tr> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" align="center"><font style="FONT-FAMILY: Times New Roman" size="1"><b>2014</b></font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" align="center"><font style="FONT-FAMILY: Times New Roman" size="1"><b>2013</b></font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" align="center"><font style="FONT-FAMILY: Times New Roman" size="1"><b>2012</b></font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> </tr> <tr bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: Times New Roman" size="2">Interest income</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">101</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">96</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">83</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> </tr> </table> <p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 12px; TEXT-INDENT: 4%" align="justify"><font style="FONT-FAMILY: Times New Roman" size="2">The Company has revised the previously reported disclosure of interest income for the year ended December 2013. The correction had no effect upon the consolidated statement of comprehensive loss amounts.</font></p> </div></us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock> <us-gaap:OtherIncomeAndOtherExpenseDisclosureTextBlock contextRef="eol_PE151383--1410-K0012_STD_365_20141231_0" id="id_6895476_182B5531-E03E-420F-8C9B-47C033AAB822_1_0"><div> <p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 0px"><font style="FONT-FAMILY: Times New Roman" size="2"><b>Note 14 &#x2014; Interest and Other, Net</b></font></p> <p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 6px; TEXT-INDENT: 4%" align="justify"><font style="FONT-FAMILY: Times New Roman" size="2">Components of Interest and Other, Net were as follows (in thousands):</font></p> <p style="MARGIN-BOTTOM: 0px; FONT-SIZE: 12px; MARGIN-TOP: 0px"> &#xA0;</p> <table style="BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="92%" align="center" border="0"> <tr> <td width="80%"></td> <td valign="bottom" width="4%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="4%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="4%"></td> <td></td> <td></td> <td></td> </tr> <tr> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="10" align="center"><font style="FONT-FAMILY: Times New Roman" size="1"><b>Years Ended<br /> December&#xA0;31,</b></font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> </tr> <tr> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" align="center"><font style="FONT-FAMILY: Times New Roman" size="1"><b>2014</b></font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" align="center"><font style="FONT-FAMILY: Times New Roman" size="1"><b>2013</b></font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" align="center"><font style="FONT-FAMILY: Times New Roman" size="1"><b>2012</b></font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> </tr> <tr bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: Times New Roman" size="2">Interest income and other income</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">108</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">98</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">89</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> </tr> <tr> <td valign="top"> <p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: Times New Roman" size="2">Interest expense and other expense</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" nowrap="nowrap" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">&#x2014;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">79</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">(2</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">)&#xA0;</font></td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> </tr> <tr bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-LEFT: 2em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: Times New Roman" size="2">Interest and Other, net</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">108</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">177</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">87</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td>&#xA0;</td> </tr> </table> <p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 12px; TEXT-INDENT: 4%" align="justify"><font style="FONT-FAMILY: Times New Roman" size="2">Interest income and other income in all periods primarily consisted of interest income generated from the Company&#x2019;s cash, cash equivalents and investments.</font></p> <p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 12px; TEXT-INDENT: 4%" align="justify"><font style="FONT-FAMILY: Times New Roman" size="2">Interest expense and other expense in 2013 consisted solely of net gains realized upon disposal of equipment. Interest expense and other expense in 2012 primarily consisted of interest expense on borrowings under equipment financing lines.</font></p> </div></us-gaap:OtherIncomeAndOtherExpenseDisclosureTextBlock> <us-gaap:PreferredStockTextBlock contextRef="eol_PE151383--1410-K0012_STD_365_20141231_0" id="id_6895476_5DD2DE00-2290-41CA-A666-D7EB3F362AE4_1_0"><div> <p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 18px"><font style="FONT-FAMILY: Times New Roman" size="2"><b>Note 11 &#x2014; Convertible Preferred Stock</b></font></p> <!-- xbrl,body --> <p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 6px; TEXT-INDENT: 4%" align="justify"><font style="FONT-FAMILY: Times New Roman" size="2">As of December&#xA0;31, 2010 there were 10,000,000&#xA0;shares of preferred stock authorized and no shares outstanding.</font></p> <p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 12px; TEXT-INDENT: 4%" align="justify"><font style="FONT-FAMILY: Times New Roman" size="2">On April&#xA0;18, 2011, the Company entered into a securities purchase agreement (the &#x201C;Deerfield Agreement&#x201D;) with Deerfield Private Design Fund II, L.P., Deerfield Private Design International II, L.P., Deerfield Special Situations Fund, L.P., and Deerfield Special Situations Fund International Limited (collectively, &#x201C;Deerfield&#x201D;). On April&#xA0;20, 2011, pursuant to the Deerfield Agreement, the Company issued to Deerfield 8,070 shares of Series&#xA0;A convertible preferred stock (the &#x201C;Series A Preferred Stock&#x201D;) for a purchase price of $1,500.00 per share for net proceeds of approximately $9.3 million, as well as common stock and warrants that are discussed in Note 12&#xA0;&#x2014; Stockholders&#x2019; Equity.</font></p> <p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 12px; TEXT-INDENT: 4%" align="justify"><font style="FONT-FAMILY: Times New Roman" size="2">The fair value of the common stock into which the Series A Preferred Stock was convertible exceeded the allocated purchase price of the Series A Preferred Stock by $2.9 million on the date of issuance, resulting in a beneficial conversion feature. The Company recognized the beneficial conversion feature as a one-time, non-cash, deemed dividend to the holders of Series A Preferred Stock on the date of issuance, which is the date the stock first became convertible.</font></p> <p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 12px; TEXT-INDENT: 4%" align="justify"><font style="FONT-FAMILY: Times New Roman" size="2">On September&#xA0;26, 2012, all 8,070 shares of Series A Preferred Stock were converted into 1,345,000 shares of our common stock. The conversion was in accordance with the terms of the agreement with Deerfield under which the Series A Preferred Stock was issued in 2011.</font></p> <p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 12px; TEXT-INDENT: 4%" align="justify"><font style="FONT-FAMILY: Times New Roman" size="2">On June&#xA0;20, 2012, the Company entered into underwriting agreements for two separate, concurrent public offerings of the Company&#x2019;s securities (the &#x201C;June 2012 Public Offerings&#x201D;). On June&#xA0;25, 2012, pursuant to the underwriting agreements, in aggregate the Company issued to certain investors 23,026 shares of Series&#xA0;B convertible preferred stock (the &#x201C;Series B Preferred Stock&#x201D;) for a purchase price of $760.00 per share, for net proceeds of approximately $12.3 million.</font></p> <p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 12px; TEXT-INDENT: 4%" align="justify"><font style="FONT-FAMILY: Times New Roman" size="2">Each share of Series B Preferred Stock was convertible into common stock at any time at the holder&#x2019;s option. However, the holder was prohibited from converting the Series B Preferred Stock into shares of common stock if, as a result of such conversion, the holder and its affiliates would own more than 9.98% of the total number of shares of common stock then issued and outstanding. In the event of the Company&#x2019;s liquidation, dissolution, or winding up, holders of Series B Preferred Stock would receive a payment equal to $0.001 per share before any proceeds are distributed to the common stockholders. Shares of Series B Preferred Stock generally have no voting rights, except as required by law and except that the consent of holders of a majority of the outstanding Series B Preferred Stock is required to amend the terms of the Series B Preferred Stock. Holders of Series B Preferred Stock were not entitled to receive any dividends, unless and until specifically declared by the Company&#x2019;s board of directors. The Series B Preferred Stock ranked senior to the Company&#x2019;s common stock as to distributions of assets upon the Company&#x2019;s liquidation, dissolution or winding up, whether voluntarily or involuntarily. The Series B Preferred Stock may have ranked senior to, on parity with or junior to any class or series of the Company&#x2019;s capital stock created in the future depending upon the specific terms of such future stock issuance. As a result of the one-for-six reverse stock split effected in June 2013, the conversion ratio for Series&#xA0;B convertible preferred stock changed from 1,000 shares of common stock per share of Series B convertible preferred stock to 166.67 shares of common stock per share of Series B convertible preferred stock.</font></p> <p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 12px; TEXT-INDENT: 4%" align="justify"><font style="FONT-FAMILY: Times New Roman" size="2">The fair value of the common stock into which the Series B Preferred Stock is convertible exceeded the allocated purchase price of the Series B Preferred Stock by $1.3 million on the date of issuance, resulting in a beneficial conversion feature. The Company recognized the beneficial conversion feature as a one-time, non-cash, deemed dividend to the holders of Series B Preferred Stock on the date of issuance, which is the date the stock first became convertible.</font></p> <p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 12px; TEXT-INDENT: 4%" align="justify"><font style="FONT-FAMILY: Times New Roman" size="2">In the first quarter of 2013, 4,000 shares of Series B convertible preferred stock were converted into 666,667 shares of common stock. In the second quarter of 2013, 15,026 shares of Series B convertible preferred stock were converted into 2,504,334 shares of common stock. On July&#xA0;2, 2013, 4,000 shares of Series B convertible preferred stock, which represented all remaining shares of Series&#xA0;B convertible preferred stock, were converted into 666,681 shares of common stock. The conversions were in accordance with the terms of the original agreement under which the Series B convertible preferred stock was issued in 2012.</font></p> <p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 12px; TEXT-INDENT: 4%" align="justify"><font style="FONT-FAMILY: Times New Roman" size="2">As of December&#xA0;31, 2014 there were 10,000,000 shares of preferred stock authorized and no shares outstanding.</font></p> </div></us-gaap:PreferredStockTextBlock> <us-gaap:PropertyPlantAndEquipmentPolicyTextBlock contextRef="eol_PE151383--1410-K0012_STD_365_20141231_0" id="id_6895476_8E541330-1A4E-482A-AFD1-859761D4927F_1_0"><div> <p style="MARGIN-BOTTOM: 0px; MARGIN-LEFT: 2%; MARGIN-TOP: 18px"> <font style="FONT-FAMILY: Times New Roman" size="2"><b><i>Property and Equipment</i></b></font></p> <p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 6px; TEXT-INDENT: 4%" align="justify"><font style="FONT-FAMILY: Times New Roman" size="2">Property and equipment are stated at cost less accumulated depreciation and are depreciated on a straight-line basis over the estimated useful lives of the related assets, which are generally three years for computer equipment and software, five years for laboratory equipment and office equipment, and seven years for furniture and fixtures. Amortization of leasehold improvements is computed using the straight-line method over the shorter of the remaining lease term or the estimated useful life of the related assets, typically ranging from three to seven years. Upon sale or retirement of assets, the costs and related accumulated depreciation and amortization are removed from the balance sheet and the resulting gain or loss is reflected in operations. Maintenance and repairs are charged to operations as incurred.</font></p> </div></us-gaap:PropertyPlantAndEquipmentPolicyTextBlock> <us-gaap:QuarterlyFinancialInformationTextBlock contextRef="eol_PE151383--1410-K0012_STD_365_20141231_0" id="id_6895476_458BB275-B4B6-46FE-86E5-9A8B55CA17CB_1_0"><div> <p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 18px"><font style="FONT-FAMILY: Times New Roman" size="2"><b>Note 15 &#x2014; Quarterly Financial Data (Unaudited)</b></font></p> <p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 6px; TEXT-INDENT: 4%" align="justify"><font style="FONT-FAMILY: Times New Roman" size="2">Quarterly results were as follows (in thousands, except per share data):</font></p> <p style="MARGIN-BOTTOM: 0px; FONT-SIZE: 12px; MARGIN-TOP: 0px"> &#xA0;</p> <table style="BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="100%" align="center" border="0"> <tr> <td width="64%"></td> <td valign="bottom" width="4%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="4%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="4%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="4%"></td> <td></td> <td></td> <td></td> </tr> <tr> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" align="center"><font style="FONT-FAMILY: Times New Roman" size="1"><b>First<br /> Quarter</b></font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" align="center"><font style="FONT-FAMILY: Times New Roman" size="1"><b>Second<br /> Quarter</b></font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" align="center"><font style="FONT-FAMILY: Times New Roman" size="1"><b>Third<br /> Quarter</b></font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" align="center"><font style="FONT-FAMILY: Times New Roman" size="1"><b>Fourth<br /> Quarter</b></font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> </tr> <tr bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: Times New Roman" size="2"><b>2014</b></font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr> <td valign="top"> <p style="MARGIN-LEFT: 2em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: Times New Roman" size="2">Total revenues</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">7,979</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">7,788</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">9,415</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">21,758</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> </tr> <tr bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-LEFT: 2em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: Times New Roman" size="2">Net income (loss)</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">(8,744</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">)&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">(8,374</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">)&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">(5,971</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">)&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">8,443</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> </tr> <tr> <td valign="top"> <p style="MARGIN-LEFT: 2em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: Times New Roman" size="2">Net income (loss) allocable to common stockholders</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">(8,744</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">)&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">(8,374</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">)&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">(5,971</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">)&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">8,443</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> </tr> <tr bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-LEFT: 2em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: Times New Roman" size="2">Net income (loss) per share allocable to common stockholders &#x2014; basic and diluted</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">(0.27</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">)&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">(0.23</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">)&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">(0.16</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">)&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">0.23</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> </tr> <tr> <td valign="top"> <p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: Times New Roman" size="2"><b>2013</b></font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-LEFT: 2em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: Times New Roman" size="2">Total revenues</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">821</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">1,009</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">4,469</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">24,349</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> </tr> <tr> <td valign="top"> <p style="MARGIN-LEFT: 2em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: Times New Roman" size="2">Net income (loss)</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">(12,619</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">)&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">(15,041</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">)&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">(12,588</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">)&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">6,531</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> </tr> <tr bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-LEFT: 2em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: Times New Roman" size="2">Net income (loss) allocable to common stockholders</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">(12,619</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">)&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">(15,041</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">)&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">(12,588</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">)&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">6,531</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> </tr> <tr> <td valign="top"> <p style="MARGIN-LEFT: 2em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: Times New Roman" size="2">Net income (loss) per share allocable to common stockholders &#x2014; basic</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">(0.53</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">)&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">(0.58</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">)&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">(0.43</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">)&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">0.22</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> </tr> <tr bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-LEFT: 2em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: Times New Roman" size="2">Net income (loss) per share allocable to common stockholders &#x2014; diluted</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">(0.53</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">)&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">(0.58</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">)&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">(0.43</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">)&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">0.21</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> </tr> </table> </div></us-gaap:QuarterlyFinancialInformationTextBlock> <us-gaap:ResearchAndDevelopmentExpensePolicy contextRef="eol_PE151383--1410-K0012_STD_365_20141231_0" id="id_6895476_14C6FF31-4080-4958-82FF-AA8E4AACC6D0_1_0"><div> <p style="MARGIN-BOTTOM: 0px; MARGIN-LEFT: 2%; MARGIN-TOP: 18px"> <font style="FONT-FAMILY: Times New Roman" size="2"><b><i>Research and Development Expenditures</i></b></font></p> <p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 6px; TEXT-INDENT: 4%" align="justify"><font style="FONT-FAMILY: Times New Roman" size="2">Research and development costs are charged to operations as incurred. Research and development expenses consist primarily of clinical manufacturing costs, preclinical study expenses, consulting and other third party costs, employee compensation, supplies and materials, allocation of overhead and occupancy costs, facilities costs and depreciation of equipment.</font></p> </div></us-gaap:ResearchAndDevelopmentExpensePolicy> <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice contextRef="eol_PE151383--1410-K0012_STD_365_20141231_0" unitRef="iso4217_USD_per_shares" decimals="2" id="id_6895476_C3206D70-DEC9-4565-9145-8B70956A712D_11001_15">39.74</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice> <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="eol_PE151383--1410-K0012_STD_365_20141231_0" id="id_6895476_3C5D1DA4-14B7-4F1F-B924-42BFE68F3162_2001_1">P6Y9M15D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2> <us-gaap:StockholdersEquityNoteDisclosureTextBlock contextRef="eol_PE151383--1410-K0012_STD_365_20141231_0" id="id_6895476_CF77EA6A-ECFC-4F66-9CD7-3CF1DB62DEE4_1_0"><div> <p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 18px"><font style="FONT-FAMILY: Times New Roman" size="2"><b>Note 12 &#x2014; Stockholders&#x2019; Equity</b></font></p> <!-- xbrl,body --> <p style="MARGIN-BOTTOM: 0px; MARGIN-LEFT: 2%; MARGIN-TOP: 6px"> <font style="FONT-FAMILY: Times New Roman" size="2"><b><i>Accumulated Other Comprehensive Loss</i></b></font></p> <p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 6px; TEXT-INDENT: 4%" align="justify"><font style="FONT-FAMILY: Times New Roman" size="2">In 2014, the Company reclassified insignificant amounts of unrealized gains (losses) in investments out of accumulated other comprehensive income into net loss.</font></p> <p style="MARGIN-BOTTOM: 0px; MARGIN-LEFT: 2%; MARGIN-TOP: 18px"> <font style="FONT-FAMILY: Times New Roman" size="2"><b><i>Authorized Shares</i></b></font></p> <p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 6px; TEXT-INDENT: 4%" align="justify"><font style="FONT-FAMILY: Times New Roman" size="2">On May&#xA0;18, 2011, the stockholders approved an increase in the number of authorized shares of common stock from 170,000,000 to 245,000,000. The increase became effective in August 2011, when the Company filed the Certificate of Amendment of Amended and Restated Certificate of Incorporation with the Secretary of State of the State of Delaware. In June 2013, upon the stockholder approval of the one-for-six reverse stock split and the amendment to the Company&#x2019;s amended and restated certificate of incorporation, the number of authorized shares of common stock was reduced to 81,500,000 (See Note 1).</font></p> <p style="MARGIN-BOTTOM: 0px; MARGIN-LEFT: 2%; MARGIN-TOP: 18px"> <font style="FONT-FAMILY: Times New Roman" size="2"><b><i>Common Stock Outstanding</i></b></font></p> <p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 6px; TEXT-INDENT: 4%" align="justify"><font style="FONT-FAMILY: Times New Roman" size="2">On April&#xA0;20, 2011, pursuant to the Deerfield Agreement, the Company issued to Deerfield (i)&#xA0;883,333 shares of common stock for a purchase price of $9.00 per share, (ii)&#xA0;8,070 shares of Series A Preferred Stock for a purchase price of $1,500.00 per share, and (iii)&#xA0;warrants to purchase 1,114,168 shares of the Company&#x2019;s common stock at an initial exercise price of $9.90 per share, for aggregate gross proceeds of approximately $20.1&#xA0;million. After issuance costs of approximately $0.2 million, the net proceeds were approximately $19.9 million.</font></p> <p style="MARGIN-BOTTOM: 0px; FONT-SIZE: 12px; MARGIN-TOP: 0px"> &#xA0;</p> <p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 0px; TEXT-INDENT: 4%" align="justify"><font style="FONT-FAMILY: Times New Roman" size="2">The offering was made pursuant to a shelf registration statement that the Company filed with the SEC on November&#xA0;10, 2008, which became effective on November&#xA0;19, 2008 (File No.&#xA0;333-155259). The closing of the offering took place on April&#xA0;20, 2011.</font></p> <p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 12px; TEXT-INDENT: 4%" align="justify"><font style="FONT-FAMILY: Times New Roman" size="2">In accordance with the accounting guidance for valuing stock and warrants when preferred stock, common stock and warrants are issued in a single transaction and all are to be accounted for as equity, the Company allocated the gross purchase proceeds using the relative fair value method. The fair value of the common stock issued to Deerfield was calculated based on the closing price of the stock on the commitment date as quoted on The NASDAQ Global Market. The Series A Preferred Stock was valued based on the fair value of the Company&#x2019;s common stock on the commitment date times the conversion ratio of one share of preferred to one thousand shares of common stock. The fair value of the Series A Preferred Stock was determined to be essentially equivalent to the fair value of the common stock into which it is convertible, based on the preferred holders&#x2019; ability to immediately convert the Series A Preferred Stock to common stock and the fact that the liquidation preference of the Series A Preferred Stock is only $0.001 per share. The fair value of the warrants was determined using the Black-Scholes pricing model, as discussed above. The relative fair value ratio of each of the instruments issued was then applied to the total gross proceeds of $20.1 million, resulting in allocated purchase prices of $6.2 million for the common stock, $9.4 million for the Series A Preferred Stock and $4.5 million for the warrants.</font></p> <p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 12px; TEXT-INDENT: 4%" align="justify"><font style="FONT-FAMILY: Times New Roman" size="2">On September&#xA0;26, 2012, all 8,070 shares of Series A Convertible Preferred Stock were converted into 1,345,000 shares of our common stock. The conversion was in accordance with the terms of the original agreement under which the Series A Convertible Preferred Stock was issued in 2011.</font></p> <p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 12px; TEXT-INDENT: 4%" align="justify"><font style="FONT-FAMILY: Times New Roman" size="2">In June&#xA0;2011, the Company entered into an At-The-Market Issuance Sales Agreement (the &#x201C;MLV Agreement&#x201D;) with McNicoll, Lewis&#xA0;&amp; Vlak LLC (&#x201C;MLV&#x201D;), pursuant to which the Company sold, through December&#xA0;31, 2014, 2,397,278 shares of common stock through MLV for net proceeds of approximately $15.2&#xA0;million.</font></p> <p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 12px; TEXT-INDENT: 4%" align="justify"><font style="FONT-FAMILY: Times New Roman" size="2">On June&#xA0;25, 2012, pursuant to the June 2012 Public Offerings, in aggregate the Company issued to various investors (i)&#xA0;9,320,176 shares of common stock for a purchase price of $4.56 per share, (ii)&#xA0;23,026 shares of the Series B Preferred Stock for a purchase price of $760.00 per share, and (iii)&#xA0;warrants to purchase 7,894,704 shares of the Company&#x2019;s common stock at an exercise price of $5.28 per share, for aggregate gross proceeds of approximately $60.0 million. After issuance costs of approximately $4.0 million, the net proceeds from the June 2012 Public Offerings were approximately $56.0 million.</font></p> <p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 12px; TEXT-INDENT: 4%" align="justify"><font style="FONT-FAMILY: Times New Roman" size="2">The offerings were made pursuant to a shelf registration statement that the Company filed with the SEC on November&#xA0;25, 2011, which became effective on December&#xA0;8, 2011 (File No.&#xA0;333-178189) and a supplemental shelf registration statement on&#xA0;Form&#xA0;S-3MEF that the Company filed with the SEC on June&#xA0;20, 2012, which became effective on June&#xA0;20, 2012 (File&#xA0;No.&#xA0;333-182226). The closing of the offerings took place on June&#xA0;25, 2012.</font></p> <p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 12px; TEXT-INDENT: 4%" align="justify"><font style="FONT-FAMILY: Times New Roman" size="2">In accordance with the accounting guidance for valuing stock and warrants when stock is issued in conjunction with other securities, and the stock and other securities are to be accounted for as equity, the Company allocated the gross purchase proceeds using the relative fair value method. For accounting purposes, the June 2012 Public Offerings were considered to be one transaction. The fair value of the common stock issued in the June 2012 Public Offerings was calculated based on the closing price of the stock on the commitment date as quoted on The NASDAQ Global Market. The Series B Preferred Stock was valued based on the fair value of the Company&#x2019;s common stock on the commitment date times the conversion ratio of one share of preferred stock to one thousand shares of common stock. The fair value of the Series B Preferred Stock was determined to be essentially equivalent to the fair value of the common stock into which it is convertible, based on the preferred holders&#x2019; ability to immediately convert the Series B Preferred Stock to common stock and the fact that the liquidation preference of the Series B Preferred Stock is only $0.001 per share. The fair value of the warrants was determined using the Black-Scholes pricing model, as discussed above. The relative fair value ratio of each of the instruments issued was then applied to the total gross proceeds of $60.0 million, resulting in allocated purchase prices of $32.1 million for the common stock, $13.2 million for the Series B Preferred Stock, and $14.7 million for the warrants.</font></p> <p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 12px; TEXT-INDENT: 4%" align="justify"><font style="FONT-FAMILY: Times New Roman" size="2">In conjunction with the Amgen Agreement Amendment (see Note 7), in June 2013, Amgen purchased 1,404,100 shares of the Company&#x2019;s common stock at a price per share of $7.12 and an aggregate purchase price of $10.0 million, which was received in June 2013. Under the terms of this agreement, Amgen agreed to certain trading and other restrictions with respect to the Company&#x2019;s common stock. The Company determined the fair value of the stock issued to Amgen to be $7.5 million. The excess of cash received over fair value of $2.5 million was deferred and is being allocated between the license and services based on their relative selling prices using best estimate of selling price.</font></p> <p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 12px; TEXT-INDENT: 4%" align="justify"><font style="FONT-FAMILY: Times New Roman" size="2">In February 2014, the Company closed an underwritten public offering for the issuance and sale of 5,031,250 shares of its common stock. The gross public offering proceeds were approximately $40.3 million. The net proceeds from the sale of the shares were approximately $37.5 million, after deducting the underwriting discount and offering expenses.</font></p> <p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 12px; TEXT-INDENT: 4%" align="justify"><font style="FONT-FAMILY: Times New Roman" size="2">In December 2014, the Company also entered into a common stock purchase agreement which provided for the sale of 2,040,816 shares of its common stock to Astellas at a price per share of $4.90 and an aggregate purchase price of $10.0 million, which was received in December 2014.</font></p> <p style="MARGIN-BOTTOM: 0px; MARGIN-LEFT: 2%; MARGIN-TOP: 18px"> <font style="FONT-FAMILY: Times New Roman" size="2"><b><i>Warrants</i></b></font></p> <p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 6px; TEXT-INDENT: 4%" align="justify"><font style="FONT-FAMILY: Times New Roman" size="2">On April&#xA0;20, 2011, pursuant to the Deerfield Agreement, the Company issued to Deerfield warrants to purchase 1,114,168 shares of the Company&#x2019;s common stock at an initial exercise price of $9.90 per share, for aggregate gross proceeds of approximately $4.5 million. After issuance costs of approximately $0.1 million, the net proceeds were approximately $4.4 million. The warrants issued to Deerfield became exercisable on October&#xA0;20, 2011 and will remain exercisable until April&#xA0;20, 2015. The warrant holders are prohibited from exercising the warrants and obtaining shares of common stock if, as a result of such exercise, the holder and its affiliates would own more than 9.98% of the total number of shares of the Company&#x2019;s common stock then issued and outstanding. The Company valued the warrants as of the date of issuance at $5.8 million using the Black-Scholes option pricing model and the following assumptions: a contractual term of four years, a risk-free interest rate of 1.66%, volatility of 80%, and the fair value of the Company&#x2019;s common stock on the issuance date of $9.12 ($1.52 before adjustment for the Company&#x2019;s 2013 reverse stock split, see Note 1).</font></p> <p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 12px; TEXT-INDENT: 4%" align="justify"><font style="FONT-FAMILY: Times New Roman" size="2">On June&#xA0;25, 2012, pursuant to the June 2012 Public Offerings, the Company issued warrants to purchase 7,894,704 shares of the Company&#x2019;s common stock at an exercise price of $5.28 per share, for an aggregate gross proceeds of approximately $14.7 million. The warrant holders are prohibited from exercising the warrants and obtaining shares of common stock if, as a result of such exercise, the holder and its affiliates would own more than 9.98% of the total number of shares of the Company&#x2019;s common stock then issued and outstanding. The Company valued the warrants as of the date of issuance at $16.2 million using the Black-Scholes option pricing model and the following assumptions: a contractual term of five years, a risk-free interest rate of 0.73%, volatility of 76%, and the fair value of the Company&#x2019;s common stock on the issuance date of $3.78 ($0.63 before adjustment for the Company&#x2019;s 2013 reverse stock split, see Note 1).</font></p> <p style="MARGIN-BOTTOM: 0px; FONT-SIZE: 12px; MARGIN-TOP: 0px"> <font size="1">&#xA0;</font></p> <p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 0px; TEXT-INDENT: 4%" align="justify"><font style="FONT-FAMILY: Times New Roman" size="2">In February 2013, warrants to purchase 1,000 shares of the Company&#x2019;s common stock at an exercise price of $5.28 per share were cash exercised in accordance with the June 2012 Public Offerings underwriting agreements.</font></p> <p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 12px; TEXT-INDENT: 4%" align="justify"><font style="FONT-FAMILY: Times New Roman" size="2">In April 2013, the Company issued 358,460 shares of common stock related to cashless exercises of warrants in accordance with the June 2012 Public Offerings.</font></p> <p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 12px; TEXT-INDENT: 4%" align="justify"><font style="FONT-FAMILY: Times New Roman" size="2">Outstanding warrants as of December&#xA0;31, 2014 were as follows:</font></p> <p style="MARGIN-BOTTOM: 0px; FONT-SIZE: 12px; MARGIN-TOP: 0px"> &#xA0;</p> <table style="BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="92%" align="center" border="0"> <!-- Begin Table Head --> <tr> <td width="67%"></td> <td valign="bottom" width="4%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="4%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="4%"></td> <td></td> <td></td> <td></td> </tr> <tr> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1px solid" valign="bottom" colspan="2" align="center"><font style="FONT-FAMILY: Times New Roman" size="1"><b>Number<br /> of Shares</b></font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1px solid" valign="bottom" colspan="2" align="center"><font style="FONT-FAMILY: Times New Roman" size="1"><b>Exercise<br /> Price</b></font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1px solid" valign="bottom" colspan="2" align="center"><font style="FONT-FAMILY: Times New Roman" size="1"><b>Expiration<br /> Date</b></font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> </tr> <!-- End Table Head --><!-- Begin Table Body --> <tr bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: Times New Roman" size="2">Issued 4/20/2011</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">1,114,168</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">9.90</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">04/20/15</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> </tr> <tr> <td valign="top"> <p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: Times New Roman" size="2">Issued 6/25/2012</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">5,576,928</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">5.28</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">06/25/17</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> </tr> <!-- End Table Body --></table> <p style="MARGIN-BOTTOM: 0px; MARGIN-LEFT: 2%; MARGIN-TOP: 18px"> <font style="FONT-FAMILY: Times New Roman" size="2"><b><i>Stock Option Plans</i></b></font></p> <p style="MARGIN-BOTTOM: 0px; MARGIN-LEFT: 2%; MARGIN-TOP: 6px"> <font style="FONT-FAMILY: Times New Roman" size="2"><i>2004 Plan</i></font></p> <p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 6px; TEXT-INDENT: 4%" align="justify"><font style="FONT-FAMILY: Times New Roman" size="2">In January 2004, the Board of Directors adopted the 2004 Equity Incentive Plan (the &#x201C;2004 Plan&#x201D;), which was approved by the stockholders in February 2004. The 2004 Plan provides for the granting of incentive stock options, nonstatutory stock options, restricted stock, stock appreciation rights, stock performance units and stock performance shares to employees, directors and consultants. Under the 2004 Plan, options may be granted at prices not lower than 100% of the fair market value of the common stock on the date of grant for nonstatutory stock options and incentive stock options and may be granted for terms of up to ten years from the date of grant. Options granted to new employees generally vest 25% after one year and monthly thereafter over a period of four years. Options granted to existing employees generally vest monthly over a period of four years. At the May 2013 Annual Meeting of Stockholders, the number of shares of common stock authorized for issuance under the 2004 Plan was increased by 2,000,000. As of December&#xA0;31, 2014, there were 1,270,478 shares of common stock reserved for issuance under the 2004 Plan.</font></p> <p style="MARGIN-BOTTOM: 0px; MARGIN-LEFT: 2%; MARGIN-TOP: 18px"> <font style="FONT-FAMILY: Times New Roman" size="2"><i>1997 Plan</i></font></p> <p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 6px; TEXT-INDENT: 4%" align="justify"><font style="FONT-FAMILY: Times New Roman" size="2">In 1997, the Company adopted the 1997 Stock Option/Stock Issuance Plan (the &#x201C;1997 Plan&#x201D;). The Plan provides for the granting of stock options to employees and consultants of the Company. Options granted under the 1997 Plan may be either incentive stock options or nonstatutory stock options. Incentive stock options may be granted only to Company employees (including officers and directors who are also employees). Nonstatutory stock options may be granted to Company employees and consultants. Options under the Plan may be granted for terms of up to ten years from the date of grant as determined by the Board of Directors, provided, however, that (i)&#xA0;the exercise price of an incentive stock option and nonstatutory stock option shall not be less than 100% and 85% of the estimated fair market value of the shares on the date of grant, respectively, and (ii)&#xA0;with respect to any 10% stockholder, the exercise price of an incentive stock option or nonstatutory stock option shall not be less than 110% of the estimated fair market value of the shares on the date of grant and the term of the grant shall not exceed five years. Options may be exercisable immediately and are subject to repurchase options held by the Company which lapse over a maximum period of ten years at such times and under such conditions as determined by the Board of Directors. Options granted under the 1997 Plan generally vested over four or five years (generally 25% after one year and monthly thereafter). As of December&#xA0;31, 2014, the Company had reserved no&#xA0;shares of common stock for issuance related to options outstanding under the 1997 Plan, and there were no shares available for future grants under the 1997 Plan.</font></p> <p style="MARGIN-BOTTOM: 0px; FONT-SIZE: 18px; MARGIN-TOP: 0px"> &#xA0;</p> <p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 0px; TEXT-INDENT: 4%" align="justify"><font style="FONT-FAMILY: Times New Roman" size="2">Activity under the two stock option plans was as follows:</font></p> <p style="MARGIN-BOTTOM: 0px; FONT-SIZE: 12px; MARGIN-TOP: 0px"> &#xA0;</p> <table style="BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="100%" align="center" border="0"> <!-- Begin Table Head --> <tr> <td width="41%"></td> <td valign="bottom" width="6%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="6%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="6%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="6%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="6%"></td> <td></td> <td></td> <td></td> </tr> <tr> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1px solid" valign="bottom" colspan="2" align="center"><font style="FONT-FAMILY: Times New Roman" size="1"><b>Shares<br /> Available&#xA0;for<br /> Grant&#xA0;of&#xA0;Option<br /> or Award</b></font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1px solid" valign="bottom" colspan="2" align="center"><font style="FONT-FAMILY: Times New Roman" size="1"><b>Stock&#xA0;Options<br /> Outstanding</b></font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1px solid" valign="bottom" colspan="2" align="center"><font style="FONT-FAMILY: Times New Roman" size="1"><b>Weighted<br /> Average&#xA0;Exercise<br /> Price per Share -<br /> Stock Options</b></font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1px solid" valign="bottom" colspan="2" align="center"><font style="FONT-FAMILY: Times New Roman" size="1"><b>Weighted<br /> Average&#xA0;Remaining<br /> Contractual&#xA0;Life</b></font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1px solid" valign="bottom" colspan="2" align="center"><font style="FONT-FAMILY: Times New Roman" size="1"><b>Aggregate<br /> Intrinsic<br /> Value</b></font><br /> <font style="FONT-FAMILY: Times New Roman" size="1"><b>(in&#xA0; thousands)</b></font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> </tr> <!-- End Table Head --><!-- Begin Table Body --> <tr bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-LEFT: 2em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: Times New Roman" size="2">Balance at December&#xA0;31, 2011</font></p> </td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">585,476</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">1,598,408</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">21.93</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr> <td valign="top"> <p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: Times New Roman" size="2">Increase in authorized shares</font></p> </td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">416,667</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" nowrap="nowrap" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">&#x2014;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" nowrap="nowrap" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">&#x2014;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: Times New Roman" size="2">Options granted</font></p> </td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">(403,108</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">)&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">403,108</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">6.14</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr> <td valign="top"> <p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: Times New Roman" size="2">Options forfeited/expired</font></p> </td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">210,989</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">(210,989</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">)&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">17.00</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: Times New Roman" size="2">Restricted stock units forfeited</font></p> </td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">68,702</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" nowrap="nowrap" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">&#x2014;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" nowrap="nowrap" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">&#x2014;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">&#xA0;</td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">&#xA0;</td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr> <td valign="top"> <p style="MARGIN-LEFT: 2em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: Times New Roman" size="2">Balance at December&#xA0;31, 2012</font></p> </td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">878,726</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">1,790,527</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">18.96</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: Times New Roman" size="2">Increase in authorized shares</font></p> </td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">2,000,000</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" nowrap="nowrap" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">&#x2014;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" nowrap="nowrap" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">&#x2014;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr> <td valign="top"> <p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: Times New Roman" size="2">Options granted</font></p> </td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">(797,629</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">)&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">797,629</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">5.95</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: Times New Roman" size="2">Restricted stock units granted</font></p> </td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">(41,661</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">)&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" nowrap="nowrap" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">&#x2014;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" nowrap="nowrap" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">&#x2014;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr> <td valign="top"> <p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: Times New Roman" size="2">Options exercised</font></p> </td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" nowrap="nowrap" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">&#x2014;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">(21,397</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">)&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">5.32</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: Times New Roman" size="2">Options forfeited/expired</font></p> </td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">117,394</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">(117,394</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">)&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">12.55</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr> <td valign="top"> <p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: Times New Roman" size="2">Restricted stock units forfeited</font></p> </td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">4,999</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" nowrap="nowrap" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">&#x2014;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" nowrap="nowrap" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">&#x2014;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">&#xA0;</td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">&#xA0;</td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-LEFT: 2em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: Times New Roman" size="2">Balance at December&#xA0;31, 2013</font></p> </td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">2,161,829</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">2,449,365</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">15.15</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr> <td valign="top"> <p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: Times New Roman" size="2">Options granted</font></p> </td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">(944,831</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">)&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">944,831</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">8.80</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: Times New Roman" size="2">Restricted stock units granted</font></p> </td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">(43,500</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">)&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" nowrap="nowrap" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">&#x2014;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" nowrap="nowrap" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">&#x2014;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr> <td valign="top"> <p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: Times New Roman" size="2">Options exercised</font></p> </td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" nowrap="nowrap" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">&#x2014;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">(390</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">)&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">6.00</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: Times New Roman" size="2">Options forfeited/expired</font></p> </td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">95,980</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">(95,980</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">)&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">39.74</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr> <td valign="top"> <p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: Times New Roman" size="2">Restricted stock units forfeited</font></p> </td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">1,000</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" nowrap="nowrap" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">&#x2014;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" nowrap="nowrap" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">&#x2014;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">&#xA0;</td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">&#xA0;</td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-LEFT: 2em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: Times New Roman" size="2">Balance at December&#xA0;31, 2014</font></p> </td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">1,270,478</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">3,297,826</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">12.62</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">6.79</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">2,657</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">&#xA0;</td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">&#xA0;</td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr> <td valign="top"> <p style="MARGIN-LEFT: 2em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: Times New Roman" size="2">Exercisable at December&#xA0;31, 2014</font></p> </td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">2,140,754</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">15.17</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">5.76</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">1,553</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> </tr> <tr bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-LEFT: 2em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: Times New Roman" size="2">Vested and expected to vest as of December&#xA0;31, 2014</font></p> </td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">3,277,489</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">12.64</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">6.78</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">2,642</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> </tr> <!-- End Table Body --></table> <p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 12px; TEXT-INDENT: 4%" align="justify"><font style="FONT-FAMILY: Times New Roman" size="2">Total intrinsic value of stock options exercised was $1,000, $107,000, and zero during the years ended December&#xA0;31, 2014, 2013 and 2012, respectively. The intrinsic value is calculated as the difference between the market value as of December&#xA0;31, 2014 and the exercise price of shares. The market value as of December&#xA0;31, 2014 was $8.01 per share as reported by NASDAQ. The weighted average grant date fair value of stock options granted was $6.01, $3.85 and $3.89 per share during the years ended December&#xA0;31, 2014, 2013 and 2012, respectively.</font></p> <p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 12px; TEXT-INDENT: 4%" align="justify"><font style="FONT-FAMILY: Times New Roman" size="2">The number of option shares vested was 601,647, 457,465 and 348,693 in 2014, 2013 and 2012, respectively. The grant date fair value of option shares vested was $3.0 million, $2.3 million and $2.4 million in 2014, 2013 and 2012, respectively. The Company has revised the previously reported disclosures of option shares vested and grant date fair value of option shares vested for the years ended December 31, 2013 and December 31, 2012. The corrections had no effect upon the statements of comprehensive loss amounts.</font></p> <p style="MARGIN-BOTTOM: 0px; FONT-SIZE: 12px; MARGIN-TOP: 0px"> &#xA0;</p> <p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 0px; TEXT-INDENT: 4%" align="justify"><font style="FONT-FAMILY: Times New Roman" size="2">Restricted stock unit activity was as follows:</font></p> <p style="MARGIN-BOTTOM: 0px; FONT-SIZE: 12px; MARGIN-TOP: 0px"> &#xA0;</p> <table style="BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="92%" align="center" border="0"> <!-- Begin Table Head --> <tr> <td width="73%"></td> <td valign="bottom" width="8%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="7%"></td> <td></td> <td></td> <td></td> </tr> <tr> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1px solid" valign="bottom" colspan="2" align="center"><font style="FONT-FAMILY: Times New Roman" size="1"><b>Number&#xA0;of<br /> Shares</b></font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1px solid" valign="bottom" colspan="2" align="center"><font style="FONT-FAMILY: Times New Roman" size="1"><b>Weighted<br /> Average&#xA0;Award<br /> Date&#xA0;Fair&#xA0;Value<br /> per&#xA0;Share</b></font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> </tr> <!-- End Table Head --><!-- Begin Table Body --> <tr bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: Times New Roman" size="2">Restricted stock units outstanding at December&#xA0;31, 2011</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">517,535</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">6.78</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> </tr> <tr> <td valign="top"> <p style="MARGIN-LEFT: 2em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: Times New Roman" size="2">Restricted stock units vested</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">(231,935</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">)&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">6.78</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> </tr> <tr bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-LEFT: 2em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: Times New Roman" size="2">Restricted stock units forfeited</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">(68,702</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">)&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">6.78</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr> <td valign="top"> <p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: Times New Roman" size="2">Restricted stock units outstanding at December&#xA0;31, 2012</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">216,898</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">6.78</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> </tr> <tr bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-LEFT: 2em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: Times New Roman" size="2">Restricted stock units granted</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">41,661</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">6.00</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> </tr> <tr> <td valign="top"> <p style="MARGIN-LEFT: 2em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: Times New Roman" size="2">Restricted stock units vested</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">(211,897</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">)&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">6.78</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> </tr> <tr bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-LEFT: 2em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: Times New Roman" size="2">Restricted stock units forfeited</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">(4,999</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">)&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">6.78</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr> <td valign="top"> <p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: Times New Roman" size="2">Unvested restricted stock units outstanding at December&#xA0;31, 2013</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">41,663</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">6.00</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> </tr> <tr bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-LEFT: 2em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: Times New Roman" size="2">Restricted stock units granted</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">43,500</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">9.65</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> </tr> <tr> <td valign="top"> <p style="MARGIN-LEFT: 2em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: Times New Roman" size="2">Restricted stock units vested</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">(20,833</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">)&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">6.00</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> </tr> <tr bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-LEFT: 2em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: Times New Roman" size="2">Restricted stock units forfeited</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">(1,000</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">)&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">6.00</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr> <td valign="top"> <p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: Times New Roman" size="2">Unvested restricted stock units outstanding at December&#xA0;31, 2014</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">63,330</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">8.51</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <!-- End Table Body --></table> <p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 12px; TEXT-INDENT: 4%" align="justify"><font style="FONT-FAMILY: Times New Roman" size="2">The grant date fair value of restricted stock units vested during the years ended December&#xA0;31, 2014, 2013 and 2012 was $0.1 million, $1.4 million and $1.6 million, respectively. The Company measures compensation expense for restricted stock units at fair value on the grant date and recognizes the expense over the expected vesting period. The fair value for restricted stock units is based on the closing price of the Company&#x2019;s common stock on the grant date. Unvested restricted stock awards are subject to repurchase at no cost to the Company.</font></p> <p style="MARGIN-BOTTOM: 0px; MARGIN-LEFT: 2%; MARGIN-TOP: 18px"> <font style="FONT-FAMILY: Times New Roman" size="2"><b><i>Stock-Based Compensation</i></b></font></p> <p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 6px; TEXT-INDENT: 4%" align="justify"><font style="FONT-FAMILY: Times New Roman" size="2">The Company applies the accounting guidance for stock compensation, which establishes accounting for share-based payment awards made to employees, non-employees and directors, including employee stock options and employee stock purchases. Under this guidance, stock-based compensation cost is measured at the grant date based on the calculated fair value of the award, and is recognized as an expense on a straight-line basis over the employee&#x2019;s requisite service period, generally the vesting period of the award.</font></p> <p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 12px; TEXT-INDENT: 4%" align="justify"><font style="FONT-FAMILY: Times New Roman" size="2">The following table summarizes stock-based compensation related to stock options, restricted stock awards, restricted stock unit, and employee stock purchases (in thousands):</font></p> <p style="MARGIN-BOTTOM: 0px; FONT-SIZE: 12px; MARGIN-TOP: 0px"> &#xA0;</p> <table style="BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="92%" align="center" border="0"> <!-- Begin Table Head --> <tr> <td width="73%"></td> <td valign="bottom" width="4%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="4%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="4%"></td> <td></td> <td></td> <td></td> </tr> <tr> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1px solid" valign="bottom" colspan="10" align="center"><font style="FONT-FAMILY: Times New Roman" size="1"><b>Years Ended December&#xA0;31,</b></font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> </tr> <tr> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1px solid" valign="bottom" colspan="2" align="center"><font style="FONT-FAMILY: Times New Roman" size="1"><b>2014</b></font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1px solid" valign="bottom" colspan="2" align="center"><font style="FONT-FAMILY: Times New Roman" size="1"><b>2013</b></font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1px solid" valign="bottom" colspan="2" align="center"><font style="FONT-FAMILY: Times New Roman" size="1"><b>2012</b></font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> </tr> <!-- End Table Head --><!-- Begin Table Body --> <tr bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: Times New Roman" size="2">Research and development</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">1,361</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">1,538</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">1,801</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> </tr> <tr> <td valign="top"> <p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: Times New Roman" size="2">General and administrative</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">1,969</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">2,059</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">1,982</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> </tr> <tr bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: Times New Roman" size="2">Stock-based compensation included in operating expenses</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">3,330</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">3,597</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">3,783</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p> </td> <td>&#xA0;</td> </tr> <!-- End Table Body --></table> <p style="MARGIN-BOTTOM: 0px; MARGIN-LEFT: 2%; MARGIN-TOP: 18px"> <font style="FONT-FAMILY: Times New Roman" size="2"><i>Employee Stock-Based Compensation</i></font></p> <p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 6px; TEXT-INDENT: 4%" align="justify"><font style="FONT-FAMILY: Times New Roman" size="2">The Company uses the Black-Scholes option pricing model to determine the fair value of stock option grants to employees and directors and employee stock purchase plan shares. The key input assumptions used to estimate fair value of these awards include the exercise price of the award, the expected option term, the expected volatility of the Company&#x2019;s stock over the option&#x2019;s expected term, the risk-free interest rate over the option&#x2019;s expected term, and the Company&#x2019;s expected dividend yield, if any.</font></p> <p style="MARGIN-BOTTOM: 0px; FONT-SIZE: 12px; MARGIN-TOP: 0px"> &#xA0;</p> <p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 0px; TEXT-INDENT: 4%" align="justify"><font style="FONT-FAMILY: Times New Roman" size="2">The fair value of share-based payments was estimated on the date of grant using the Black-Scholes option pricing model based on the following weighted average assumptions:</font></p> <p style="MARGIN-BOTTOM: 0px; FONT-SIZE: 12px; MARGIN-TOP: 0px"> &#xA0;</p> <table style="BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="100%" align="center" border="0"> <!-- Begin Table Head --> <tr> <td width="46%"></td> <td valign="bottom" width="5%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="5%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="5%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="5%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="5%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="5%"></td> <td></td> <td></td> <td></td> </tr> <tr> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1px solid" valign="bottom" colspan="6" align="center"><font style="FONT-FAMILY: Times New Roman" size="1"><b>Year Ended<br /> December&#xA0;31, 2014</b></font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1px solid" valign="bottom" colspan="6" align="center"><font style="FONT-FAMILY: Times New Roman" size="1"><b>Year Ended<br /> December&#xA0;31, 2013</b></font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1px solid" valign="bottom" colspan="6" align="center"><font style="FONT-FAMILY: Times New Roman" size="1"><b>Year Ended<br /> December&#xA0;31, 2012</b></font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> </tr> <tr> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1px solid" valign="bottom" colspan="2" align="center"><font style="FONT-FAMILY: Times New Roman" size="1"><b>Employee<br /> Stock&#xA0;Options</b></font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1px solid" valign="bottom" colspan="2" align="center"><font style="FONT-FAMILY: Times New Roman" size="1"><b>ESPP</b></font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1px solid" valign="bottom" colspan="2" align="center"><font style="FONT-FAMILY: Times New Roman" size="1"><b>Employee<br /> Stock&#xA0;Options</b></font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1px solid" valign="bottom" colspan="2" align="center"><font style="FONT-FAMILY: Times New Roman" size="1"><b>ESPP</b></font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1px solid" valign="bottom" colspan="2" align="center"><font style="FONT-FAMILY: Times New Roman" size="1"><b>Employee<br /> Stock&#xA0;Options</b></font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1px solid" valign="bottom" colspan="2" align="center"><font style="FONT-FAMILY: Times New Roman" size="1"><b>ESPP</b></font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> </tr> <!-- End Table Head --><!-- Begin Table Body --> <tr bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: Times New Roman" size="2">Risk-free interest rate</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">1.9</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">%&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">0.2</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">%&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">1.1</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">%&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">0.2</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">%&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">1.1</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">%&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">0.2</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">%&#xA0;</font></td> </tr> <tr> <td valign="top"> <p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: Times New Roman" size="2">Volatility</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">77.1</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">%&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">86.0</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">%&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">73.2</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">%&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">74.6</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">%&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">71.1</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">%&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">72.0</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">%&#xA0;</font></td> </tr> <tr bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: Times New Roman" size="2">Expected term in years</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">6.30</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">1.25</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">6.20</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">1.25</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">6.13</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">1.25</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> </tr> <tr> <td valign="top"> <p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: Times New Roman" size="2">Expected dividend yield</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">0.0</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">%&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">0.0</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">%&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">0.0</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">%&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">0.0</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">%&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">0.0</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">%&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">0.0</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">%&#xA0;</font></td> </tr> <!-- End Table Body --></table> <p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 12px; TEXT-INDENT: 4%" align="justify"><font style="FONT-FAMILY: Times New Roman" size="2">The risk-free interest rate that the Company uses in the option pricing model is based on the U.S.&#xA0;Treasury zero-coupon issues with remaining terms similar to the expected terms of the options. The Company does not anticipate paying dividends in the foreseeable future and therefore uses an expected dividend yield of zero in the option pricing model. The Company is required to estimate forfeitures at the time of grant and revise those estimates in subsequent periods if actual forfeitures differ from those estimates. Historical data is used to estimate pre-vesting option forfeitures and record stock-based compensation expense only on those awards that are expected to vest.</font></p> <p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 12px; TEXT-INDENT: 4%" align="justify"><font style="FONT-FAMILY: Times New Roman" size="2">The Company uses its own historical exercise activity and extrapolates the life cycle of options outstanding to arrive at its estimated expected term for new option grants. The Company uses its own volatility history based on its stock&#x2019;s trading history for the period subsequent to the Company&#x2019;s initial public offering in April&#xA0;2004. The Company measures compensation expense for awards of restricted stock and restricted stock units at fair value on the date of grant and recognizes the expense over the expected vesting period. The fair value for restricted stock and restricted stock unit awards is based on the closing price of the Company&#x2019;s common stock on the date of grant.</font></p> <p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 12px; TEXT-INDENT: 4%" align="justify"><font style="FONT-FAMILY: Times New Roman" size="2">As of December&#xA0;31, 2014, there was $5.7&#xA0;million of unrecognized compensation cost related to unvested stock options, which is expected to be recognized over a weighted-average period of 2.52&#xA0;years and $0.3 million of unrecognized compensation cost related to unvested restricted stock units, which is expected to be recognized over a weighted-average period of 0.83&#xA0;years.</font></p> <p style="MARGIN-BOTTOM: 0px; MARGIN-LEFT: 2%; MARGIN-TOP: 18px"> <font style="FONT-FAMILY: Times New Roman" size="2"><i>Non-employee Stock-Based Compensation</i></font></p> <p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 6px; TEXT-INDENT: 4%" align="justify"><font style="FONT-FAMILY: Times New Roman" size="2">The Company records stock option grants to non-employees, excluding directors, at their fair value on the measurement date. The measurement of stock-based compensation is subject to adjustment as the underlying equity instruments vest.</font></p> <p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 12px; TEXT-INDENT: 4%" align="justify"><font style="FONT-FAMILY: Times New Roman" size="2">There were no stock option grants to non-employees in the years ended December&#xA0;31, 2014, 2013 or 2012. When terminating, if employees continue to provide service to the Company as consultants and their grants are permitted to continue to vest, the expense associated with the continued vesting of the related stock options is classified as non-employee stock compensation expense after the status change.</font></p> <p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 12px; TEXT-INDENT: 4%" align="justify"><font style="FONT-FAMILY: Times New Roman" size="2">In connection with services rendered by non-employees, the Company recorded stock-based compensation expense of $50,000, $104,000, and $56,000 in 2014, 2013 and 2012, respectively.</font></p> <p style="MARGIN-BOTTOM: 0px; FONT-SIZE: 18px; MARGIN-TOP: 0px"> &#xA0;</p> <p style="MARGIN-BOTTOM: 0px; MARGIN-LEFT: 2%; MARGIN-TOP: 0px"> <font style="FONT-FAMILY: Times New Roman" size="2"><b><i>ESPP</i></b></font></p> <p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 6px; TEXT-INDENT: 4%" align="justify"><font style="FONT-FAMILY: Times New Roman" size="2">In January 2004, the Board of Directors adopted the ESPP, which was approved by the stockholders in February 2004. Under the ESPP, statutory employees may purchase common stock of the Company up to a specified maximum amount through payroll deductions. The stock is purchased semi-annually at a price equal to 85% of the fair market value at certain plan-defined dates. The Company issued 19,726, 14,985 and 15,010 shares of common stock during 2014, 2013 and 2012, respectively, pursuant to the ESPP at an average price of $3.38, $3.66 and $4.32 per share, in 2014, 2013 and 2012, respectively. At December&#xA0;31, 2014 the Company had 170,170&#xA0;shares of common stock reserved for issuance under the ESPP.</font></p> </div></us-gaap:StockholdersEquityNoteDisclosureTextBlock> <dei:AmendmentFlag contextRef="eol_PE151383--1410-K0012_STD_365_20141231_0" id="id_6895476_BB2FF52D-3F86-4944-B60D-74EA496D7B67_1_1">false</dei:AmendmentFlag> <dei:CurrentFiscalYearEndDate contextRef="eol_PE151383--1410-K0012_STD_365_20141231_0" id="id_6895476_719DD5F0-2E9A-450E-B7C0-E6D7E07576A8_1_400003">--12-31</dei:CurrentFiscalYearEndDate> <dei:DocumentFiscalYearFocus contextRef="eol_PE151383--1410-K0012_STD_365_20141231_0" id="id_6895476_BB2FF52D-3F86-4944-B60D-74EA496D7B67_1_3">2014</dei:DocumentFiscalYearFocus> <us-gaap:IncomeTaxDisclosureTextBlock contextRef="eol_PE151383--1410-K0012_STD_365_20141231_0" id="id_6895476_4D8889F3-29AE-4B90-B8F8-9E25CF73A931_1_0"><div> <p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 18px"><font style="FONT-FAMILY: Times New Roman" size="2"><b>Note 13 &#x2014; Income Taxes</b></font></p> <p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 6px; TEXT-INDENT: 4%" align="justify"><font style="FONT-FAMILY: Times New Roman" size="2">The Company accounts for income taxes under the asset and liability method. Under this method, deferred tax assets and liabilities are determined based on the difference between the financial statement and tax basis of assets and liabilities using enacted tax rates in effect for the year in which the differences are expected to affect taxable income. Valuation allowances are established when necessary to reduce the deferred tax assets to the amounts expected to be realized. The Company did not record an income tax provision in the years ended December&#xA0;31, 2014, 2013, or 2012 because the Company had a net taxable loss in the period.</font></p> <p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 12px; TEXT-INDENT: 4%" align="justify"><font style="FONT-FAMILY: Times New Roman" size="2">For financial statement purposes, loss before taxes includes the following components (in thousands):</font></p> <p style="MARGIN-BOTTOM: 0px; FONT-SIZE: 12px; MARGIN-TOP: 0px"> &#xA0;</p> <table style="BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="92%" align="center" border="0"> <tr> <td width="66%"></td> <td valign="bottom" width="5%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="4%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="4%"></td> <td></td> <td></td> <td></td> </tr> <tr> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="10" align="center"><font style="FONT-FAMILY: Times New Roman" size="1"><b>Years Ended<br /> December&#xA0;31,</b></font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> </tr> <tr> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" align="center"><font style="FONT-FAMILY: Times New Roman" size="1"><b>2014</b></font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" align="center"><font style="FONT-FAMILY: Times New Roman" size="1"><b>2013</b></font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" align="center"><font style="FONT-FAMILY: Times New Roman" size="1"><b>2012</b></font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> </tr> <tr bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: Times New Roman" size="2">United States</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">(14,646</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">)&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">(33,717</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">)&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">(40,370</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">)&#xA0;</font></td> </tr> <tr> <td valign="top"> <p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: Times New Roman" size="2">Foreign</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" nowrap="nowrap" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">&#x2014;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" nowrap="nowrap" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">&#x2014;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" nowrap="nowrap" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">&#x2014;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> </tr> <tr bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-LEFT: 2em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: Times New Roman" size="2">Total</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">(14,646</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">)&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">(33,717</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">)&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">(40,370</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">)&#xA0;</font></td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td>&#xA0;</td> </tr> </table> <p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 12px; TEXT-INDENT: 4%" align="justify"><font style="FONT-FAMILY: Times New Roman" size="2">The Company recorded the following income tax provision as follows (in thousands):</font></p> <p style="MARGIN-BOTTOM: 0px; FONT-SIZE: 12px; MARGIN-TOP: 0px"> &#xA0;</p> <table style="BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="92%" align="center" border="0"> <tr> <td width="67%"></td> <td valign="bottom" width="9%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="9%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="9%"></td> <td></td> <td></td> <td></td> </tr> <tr> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="10" align="center"><font style="FONT-FAMILY: Times New Roman" size="1"><b>Years Ended<br /> December&#xA0;31,</b></font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> </tr> <tr> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" align="center"><font style="FONT-FAMILY: Times New Roman" size="1"><b>2014</b></font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" align="center"><font style="FONT-FAMILY: Times New Roman" size="1"><b>2013</b></font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" align="center"><font style="FONT-FAMILY: Times New Roman" size="1"><b>2012</b></font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> </tr> <tr bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: Times New Roman" size="2">Current:</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr> <td valign="top"> <p style="MARGIN-LEFT: 2em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: Times New Roman" size="2">Federal</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td> <td valign="bottom" nowrap="nowrap" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">&#x2014;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td> <td valign="bottom" nowrap="nowrap" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">&#x2014;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td> <td valign="bottom" nowrap="nowrap" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">&#x2014;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> </tr> <tr bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-LEFT: 2em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: Times New Roman" size="2">State</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" nowrap="nowrap" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">&#x2014;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" nowrap="nowrap" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">&#x2014;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" nowrap="nowrap" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">&#x2014;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> </tr> <tr> <td valign="top"> <p style="MARGIN-LEFT: 3em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: Times New Roman" size="2">Total</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td> <td valign="bottom" nowrap="nowrap" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">&#x2014;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td> <td valign="bottom" nowrap="nowrap" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">&#x2014;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td> <td valign="bottom" nowrap="nowrap" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">&#x2014;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td>&#xA0;</td> </tr> <tr bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: Times New Roman" size="2">Deferred:</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr> <td valign="top"> <p style="MARGIN-LEFT: 2em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: Times New Roman" size="2">Federal</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td> <td valign="bottom" nowrap="nowrap" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">&#x2014;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td> <td valign="bottom" nowrap="nowrap" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">&#x2014;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td> <td valign="bottom" nowrap="nowrap" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">&#x2014;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> </tr> <tr bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-LEFT: 2em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: Times New Roman" size="2">State</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" nowrap="nowrap" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">&#x2014;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" nowrap="nowrap" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">&#x2014;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" nowrap="nowrap" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">&#x2014;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> </tr> <tr> <td valign="top"> <p style="MARGIN-LEFT: 3em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: Times New Roman" size="2">Total</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td> <td valign="bottom" nowrap="nowrap" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">&#x2014;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td> <td valign="bottom" nowrap="nowrap" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">&#x2014;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td> <td valign="bottom" nowrap="nowrap" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">&#x2014;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td>&#xA0;</td> </tr> </table> <p style="MARGIN-BOTTOM: 0px; FONT-SIZE: 12px; MARGIN-TOP: 0px"> &#xA0;</p> <p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 0px; TEXT-INDENT: 4%" align="justify"><font style="FONT-FAMILY: Times New Roman" size="2">Deferred income taxes reflect the net tax effect of temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes. The significant components of the Company&#x2019;s deferred tax assets and liabilities were as follows (in thousands):</font></p> <p style="MARGIN-BOTTOM: 0px; FONT-SIZE: 12px; MARGIN-TOP: 0px"> &#xA0;</p> <table style="BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="92%" align="center" border="0"> <tr> <td width="64%"></td> <td valign="bottom" width="9%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="8%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="8%"></td> <td></td> <td></td> <td></td> </tr> <tr> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="10" align="center"><font style="FONT-FAMILY: Times New Roman" size="1"><b>As of December&#xA0;31,</b></font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> </tr> <tr> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" align="center"><font style="FONT-FAMILY: Times New Roman" size="1"><b>2014</b></font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" align="center"><font style="FONT-FAMILY: Times New Roman" size="1"><b>2013</b></font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" align="center"><font style="FONT-FAMILY: Times New Roman" size="1"><b>2012</b></font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> </tr> <tr bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: Times New Roman" size="2">Deferred tax assets:</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr> <td valign="top"> <p style="MARGIN-LEFT: 2em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: Times New Roman" size="2">Depreciation and amortization</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">780</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">918</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">1,024</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> </tr> <tr bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-LEFT: 2em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: Times New Roman" size="2">Capitalized R&amp;D</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">15,176</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">20,702</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">4,932</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> </tr> <tr> <td valign="top"> <p style="MARGIN-LEFT: 2em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: Times New Roman" size="2">Reserves and accruals</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">6,217</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">4,946</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">5,101</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> </tr> <tr bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-LEFT: 2em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: Times New Roman" size="2">Net operating losses</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">148,184</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">144,254</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">153,193</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> </tr> <tr> <td valign="top"> <p style="MARGIN-LEFT: 2em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: Times New Roman" size="2">Tax credits</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">34,543</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">33,043</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">25,943</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> </tr> <tr bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-LEFT: 3em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: Times New Roman" size="2">Total deferred tax assets</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">204,900</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">203,863</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">190,193</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> </tr> <tr> <td valign="top"> <p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: Times New Roman" size="2">Less: Valuation allowance</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">(204,900</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">)&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">(203,863</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">)&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">(190,193</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">)&#xA0;</font></td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> </tr> <tr bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: Times New Roman" size="2">Net deferred tax assets</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td> <td valign="bottom" nowrap="nowrap" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">&#x2014;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td> <td valign="bottom" nowrap="nowrap" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">&#x2014;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td> <td valign="bottom" nowrap="nowrap" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">&#x2014;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td>&#xA0;</td> </tr> </table> <p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 12px; TEXT-INDENT: 4%" align="justify"><font style="FONT-FAMILY: Times New Roman" size="2">Realization of deferred tax assets is dependent upon future earnings, if any, the timing and amount of which are uncertain. Based upon the weight of available evidence, which includes the Company&#x2019;s historical operating performance, reported cumulative net losses since inception and difficulty in accurately forecasting the Company&#x2019;s future results, the Company maintained a full valuation allowance on the net deferred tax assets as of December&#xA0;31, 2014, 2013 and 2013. The valuation allowance was determined pursuant to the accounting guidance for income taxes, which requires an assessment of both positive and negative evidence when determining whether it is more likely than not that deferred tax assets are recoverable. The Company intends to maintain a full valuation allowance on the U.S.&#xA0;deferred tax assets until sufficient positive evidence exists to support reversal of the valuation allowance. The valuation allowance increased by $1.0 million in 2014, $13.7 million in 2013 and $21.1 million in 2012.</font></p> <p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 12px; TEXT-INDENT: 4%" align="justify"><font style="FONT-FAMILY: Times New Roman" size="2">As a result of certain realization requirements of accounting guidance for stock compensation, the table of deferred tax assets and liabilities shown above does not include certain deferred tax assets at December&#xA0;31, 2014, 2013 and 2012 that arose directly from tax deductions related to equity compensation in excess of compensation recognized for financial reporting. Approximately $1.9 million of Federal and California net operating losses are related to tax stock option deductions in excess of book deductions. This amount will be credited to stockholders&#x2019; equity when it is realized.</font></p> <p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 12px; TEXT-INDENT: 4%" align="justify"><font style="FONT-FAMILY: Times New Roman" size="2">The following are the Company&#x2019;s valuation and qualifying accounts (in thousands):</font></p> <p style="MARGIN-BOTTOM: 0px; FONT-SIZE: 12px; MARGIN-TOP: 0px"> &#xA0;</p> <table style="BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="100%" align="center" border="0"> <tr> <td width="47%"></td> <td valign="bottom" width="6%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="6%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="6%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="6%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="6%"></td> <td></td> <td></td> <td></td> </tr> <tr> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" align="center"><font style="FONT-FAMILY: Times New Roman" size="1"><b>Balance at<br /> Beginning&#xA0;of<br /> Period</b></font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" align="center"><font style="FONT-FAMILY: Times New Roman" size="1"><b>Charged&#xA0;to<br /> Expenses</b></font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" align="center"><font style="FONT-FAMILY: Times New Roman" size="1"><b>Charged&#xA0;to<br /> Other&#xA0;Accounts</b></font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" align="center"><font style="FONT-FAMILY: Times New Roman" size="1"><b>Deductions</b></font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" align="center"><font style="FONT-FAMILY: Times New Roman" size="1"><b>Balance at<br /> End&#xA0;of&#xA0;Period</b></font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> </tr> <tr bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: Times New Roman" size="2">Year Ended December&#xA0;31, 2012:</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr> <td valign="top"> <p style="MARGIN-LEFT: 2em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: Times New Roman" size="2">Deferred tax valuation allowance</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">169,107</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">21,086</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" nowrap="nowrap" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">&#x2014;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" nowrap="nowrap" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">&#x2014;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">190,193</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> </tr> <tr bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: Times New Roman" size="2">Year Ended December&#xA0;31, 2013:</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr> <td valign="top"> <p style="MARGIN-LEFT: 2em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: Times New Roman" size="2">Deferred tax valuation allowance</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">190,193</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">13,670</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" nowrap="nowrap" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">&#x2014;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" nowrap="nowrap" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">&#x2014;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">203,863</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> </tr> <tr bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: Times New Roman" size="2">Year Ended December&#xA0;31, 2014:</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr> <td valign="top"> <p style="MARGIN-LEFT: 2em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: Times New Roman" size="2">Deferred tax valuation allowance</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">203,863</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">1,037</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" nowrap="nowrap" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">&#x2014;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" nowrap="nowrap" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">&#x2014;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">204,900</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> </tr> </table> <p style="MARGIN-BOTTOM: 0px; FONT-SIZE: 12px; MARGIN-TOP: 0px"> &#xA0;</p> <p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 0px; TEXT-INDENT: 4%" align="justify"><font style="FONT-FAMILY: Times New Roman" size="2">The following is a reconciliation of the statutory federal income tax rate to the Company&#x2019;s effective tax rate:</font></p> <p style="MARGIN-BOTTOM: 0px; FONT-SIZE: 12px; MARGIN-TOP: 0px"> &#xA0;</p> <table style="BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="92%" align="center" border="0"> <tr> <td width="81%"></td> <td valign="bottom" width="6%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="5%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="5%"></td> <td></td> <td></td> <td></td> </tr> <tr> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="10" align="center"><font style="FONT-FAMILY: Times New Roman" size="1"><b>Years Ended<br /> December&#xA0;31,</b></font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> </tr> <tr> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" align="center"><font style="FONT-FAMILY: Times New Roman" size="1"><b>2014</b></font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" align="center"><font style="FONT-FAMILY: Times New Roman" size="1"><b>2013</b></font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" align="center"><font style="FONT-FAMILY: Times New Roman" size="1"><b>2012</b></font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> </tr> <tr bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: Times New Roman" size="2">Tax at federal statutory tax rate</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">(34</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">)%&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">(34</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">)%&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">(34</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">)%&#xA0;</font></td> </tr> <tr> <td valign="top"> <p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: Times New Roman" size="2">State income tax, net of federal tax benefit</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">(1</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">)%&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">(4</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">)%&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">(6</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">)%&#xA0;</font></td> </tr> <tr bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: Times New Roman" size="2">State Apportionment</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">28</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">%&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">7</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">%&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">0</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">%&#xA0;</font></td> </tr> <tr> <td valign="top"> <p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: Times New Roman" size="2">Tax credits (net)</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">(7</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">)%&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">(14</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">)%&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">(19</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">)%&#xA0;</font></td> </tr> <tr bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: Times New Roman" size="2">Deferred tax assets (utilized) not benefited</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">7</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">%&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">41</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">%&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">56</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">%&#xA0;</font></td> </tr> <tr> <td valign="top"> <p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: Times New Roman" size="2">Stock-based compensation</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">5</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">%&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">2</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">%&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">0</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">%&#xA0;</font></td> </tr> <tr bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: Times New Roman" size="2">NOL Expiration</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">2</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">%&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">1</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">%&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">2</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">%&#xA0;</font></td> </tr> <tr> <td valign="top"> <p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: Times New Roman" size="2">Other</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">0</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">%&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">1</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">%&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">1</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">%&#xA0;</font></td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> </tr> <tr bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-LEFT: 2em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: Times New Roman" size="2">Total</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">0</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">%&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">0</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">%&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">0</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">%&#xA0;</font></td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td>&#xA0;</td> </tr> </table> <p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 12px; TEXT-INDENT: 4%" align="justify"><font style="FONT-FAMILY: Times New Roman" size="2">The Company had federal net operating loss carryforwards of approximately $386.8 million and apportioned state net operating loss carryforwards of approximately $285.7&#xA0;million before federal benefit at December&#xA0;31, 2014. If not utilized, the federal and state operating loss carryforwards will begin to expire in various amounts beginning 2020 and 2015, respectively. The net operating loss carryforwards include deductions for stock options.</font></p> <p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 12px; TEXT-INDENT: 4%" align="justify"><font style="FONT-FAMILY: Times New Roman" size="2">The Company had general business credit of approximately $30.8&#xA0;million and $13.3&#xA0;million for federal and state income tax purposes, respectively, at December&#xA0;31, 2014. Amounts are comprised of Research and Development Credits and Orphan Drug Credits. If not utilized, the federal carryforwards will expire in various amounts beginning in 2021. The California state credit can be carried forward indefinitely. Since its filing of its 2011 tax return, the Company has claimed the orphan drug credit. For qualifying expenses, the orphan drug credit offers an increased benefit relative to the research and development credit taken in years prior.</font></p> <p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 12px; TEXT-INDENT: 4%" align="justify"><font style="FONT-FAMILY: Times New Roman" size="2">As required by California state law, the Company apportions income to California based on a &#x201C;market-based&#x201D; sourcing approach. Accordingly, the Company&#x2019;s California apportionment formula is sensitive to changes in the source of the Company&#x2019;s mix of revenue. As a result of agreements in place in 2013, the Company adjusted deferred tax assets to reflect these changes.</font></p> <p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 12px; TEXT-INDENT: 4%" align="justify"><font style="FONT-FAMILY: Times New Roman" size="2">In general, under Section&#xA0;382 of the Internal Revenue Code (&#x201C;Section 382&#x201D;), a corporation that undergoes an &#x2018;ownership change&#x2019; is subject to limitations on its ability to utilize its pre-change net operating losses and tax credits to offset future taxable income. The Company has performed a section 382 analysis for the year ended December&#xA0;31, 2014 and has not experienced an ownership change since 2006. A portion of the Company&#x2019;s existing net operating losses and tax credits are subject to limitations arising from previous ownership changes. Future changes in the Company&#x2019;s stock ownership, some of which are outside of our control, could result in an ownership change under Section&#xA0;382 and result in additional limitations.</font></p> <p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 12px; TEXT-INDENT: 4%" align="justify"><font style="FONT-FAMILY: Times New Roman" size="2">Section&#xA0;59(e) of the Internal Revenue Code allows a Company to capitalize R&amp;D expenses. The Company elected to capitalize R&amp;D expenses on its 2012 and 2013 tax returns after completing a reverse stock split in the second quarter of 2013. For 2014, the Company anticipates foregoing the election in its 2014 tax return as they do not anticipate an ownership change under Section&#xA0;382.</font></p> <p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 12px; TEXT-INDENT: 4%" align="justify"><font style="FONT-FAMILY: Times New Roman" size="2">The Company follows the accounting guidance that prescribes a comprehensive model for how companies should recognize, measure, present, and disclose in their financial statements uncertain tax positions taken or expected to be taken on a tax return. Tax positions are initially recognized in the financial statements when it is more likely than not that the position will be sustained upon examination by the tax authorities. Such tax positions are initially and subsequently measured as the largest amount of tax benefit that is greater than 50% likely of being realized upon ultimate settlement with the tax authority assuming full knowledge of the position and relevant facts.</font></p> <p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 12px; TEXT-INDENT: 4%" align="justify"><font style="FONT-FAMILY: Times New Roman" size="2">The significant jurisdictions in which the Company files income tax returns are the United States and California. For jurisdictions in which tax filings are made, the Company is subject to income tax examination for all fiscal years since inception. The IRS&#x2019;s Large Business and International Division concluded its audit of the 2009 tax year with no material adjustments. However, in general, the statute of limitations for tax liabilities for all years remains open for the purpose of adjusting the amounts of the losses and credits carried forward from those years.</font></p> <p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 12px; TEXT-INDENT: 4%" align="justify"><font style="FONT-FAMILY: Times New Roman" size="2">The following is a tabular reconciliation of the total amounts of unrecognized tax benefits (&#x201C;UTBs&#x201D;) (in thousands):</font></p> <p style="MARGIN-BOTTOM: 0px; FONT-SIZE: 12px; MARGIN-TOP: 0px"> &#xA0;</p> <table style="BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="100%" align="center" border="0"> <tr> <td width="55%"></td> <td valign="bottom" width="10%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="10%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="10%"></td> <td></td> <td></td> <td></td> </tr> <tr> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" align="center"><font style="FONT-FAMILY: Times New Roman" size="1"><b>Federal<br /> and&#xA0;State<br /> Tax</b></font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" align="center"><font style="FONT-FAMILY: Times New Roman" size="1"><b>Federal&#xA0;Tax&#xA0;Benefit<br /> of&#xA0;State&#xA0;Income&#xA0;Tax<br /> UTBs</b></font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" align="center"><font style="FONT-FAMILY: Times New Roman" size="1"><b>Unrecognized&#xA0;Income&#xA0;Tax<br /> Benefits&#xA0;-&#xA0;Net of Federal<br /> Benefit of State UTBs</b></font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> </tr> <tr bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-LEFT: 2em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: Times New Roman" size="2">Unrecognized tax benefits balance at December&#xA0;31, 2012</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">5,340</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">1,158</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">4,182</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> </tr> <tr> <td valign="top"> <p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: Times New Roman" size="2">Addition for tax positions of prior years</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">24</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">8</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">16</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> </tr> <tr bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: Times New Roman" size="2">Addition for tax positions related to the current year</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">807</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">43</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">764</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> </tr> <tr> <td valign="top"> <p style="MARGIN-LEFT: 2em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: Times New Roman" size="2">Unrecognized tax benefits balance at December&#xA0;31, 2013</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">6,171</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">1,209</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">4,962</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> </tr> <tr bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: Times New Roman" size="2">Reductions for tax positions of prior years</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">(85</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">)&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">(29</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">)&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">(56</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">)&#xA0;</font></td> </tr> <tr> <td valign="top"> <p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: Times New Roman" size="2">Addition for tax positions related to the current year</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">188</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">10</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">178</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> </tr> <tr bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-LEFT: 2em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: Times New Roman" size="2">Unrecognized tax benefits balance at December&#xA0;31, 2014</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">6,274</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">1,190</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">5,084</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td>&#xA0;</td> </tr> </table> <p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 12px; TEXT-INDENT: 4%" align="justify"><font style="FONT-FAMILY: Times New Roman" size="2">Included in the balance of unrecognized tax benefits as of December&#xA0;31, 2014, 2013 and 2012 are $5.1 million, $5.0 million and $4.2 million of tax benefits, respectively, that, if recognized, would result in adjustments to other tax accounts, primarily deferred taxes.</font></p> <p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 12px; TEXT-INDENT: 4%" align="justify"><font style="FONT-FAMILY: Times New Roman" size="2">The Company recognizes interest accrued related to unrecognized tax benefits and penalties as income tax expense. Related to the unrecognized tax benefits noted above, the Company did not accrue any penalties or interest during 2014, 2013 or 2012. The Company does not expect its unrecognized tax benefit to change materially over the next twelve months.</font></p> </div></us-gaap:IncomeTaxDisclosureTextBlock> <us-gaap:InProcessResearchAndDevelopmentPolicy contextRef="eol_PE151383--1410-K0012_STD_365_20141231_0" id="id_6895476_300E19D8-ECC0-4264-BFF3-7E6A0F00E083_1_0"><div> <p style="MARGIN-BOTTOM: 0px; MARGIN-LEFT: 2%; MARGIN-TOP: 18px"> <font style="FONT-FAMILY: Times New Roman" size="2"><b><i>Preclinical Studies and Clinical Trial Accruals</i></b></font></p> <p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 6px; TEXT-INDENT: 4%" align="justify"><font style="FONT-FAMILY: Times New Roman" size="2">A substantial portion of the Company&#x2019;s preclinical studies and all of the Company&#x2019;s clinical trials have been performed by third-party contract research organizations (&#x201C;CROs&#x201D;) and other vendors. For preclinical studies, the significant factors used in estimating accruals include the percentage of work completed to date and contract milestones achieved. For clinical trial expenses, the significant factors used in estimating accruals include the number of patients enrolled, duration of enrollment and percentage of work completed to date. The Company monitors patient enrollment levels and related activities to the extent practicable through internal reviews, correspondence and status meetings with CROs, and review of contractual terms. The Company&#x2019;s estimates are dependent on the timeliness and accuracy of data provided by its CROs and other vendors. If the Company has incomplete or inaccurate data, it may under- or overestimate activity levels associated with various studies or trials at a given point in time. In this event, it could record adjustments to research and development expenses in future periods when the actual activity level becomes known. No material adjustments to preclinical study and clinical trial expenses have been recognized to date.</font></p> </div></us-gaap:InProcessResearchAndDevelopmentPolicy> <us-gaap:InvestmentIncomeTextBlock contextRef="eol_PE151383--1410-K0012_STD_365_20141231_0" id="id_6895476_B500390D-8813-4F7C-8372-AF9AFEF4C3BB_1_0"><div> <p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 12px; TEXT-INDENT: 4%" align="justify"><font style="FONT-FAMILY: Times New Roman" size="2">Interest income was as follows (in thousands):</font></p> <p style="MARGIN-BOTTOM: 0px; FONT-SIZE: 12px; MARGIN-TOP: 0px"> &#xA0;</p> <table style="BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="92%" align="center" border="0"> <tr> <td width="81%"></td> <td valign="bottom" width="4%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="4%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="4%"></td> <td></td> <td></td> <td></td> </tr> <tr> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="10" align="center"><font style="FONT-FAMILY: Times New Roman" size="1"><b>Years Ended<br /> December&#xA0;31,</b></font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> </tr> <tr> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" align="center"><font style="FONT-FAMILY: Times New Roman" size="1"><b>2014</b></font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" align="center"><font style="FONT-FAMILY: Times New Roman" size="1"><b>2013</b></font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" align="center"><font style="FONT-FAMILY: Times New Roman" size="1"><b>2012</b></font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> </tr> <tr bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: Times New Roman" size="2">Interest income</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">101</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">96</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">83</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> </tr> </table> </div></us-gaap:InvestmentIncomeTextBlock> <us-gaap:ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock contextRef="eol_PE151383--1410-K0012_STD_365_20141231_0" id="id_6895476_4030EFB3-1C3A-41D9-83E5-A868834757F7_1_0"><div> <p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 18px"><font style="FONT-FAMILY: Times New Roman" size="2"><b>Note&#xA0;8&#xA0;&#x2014; Other Research and Development Revenue Arrangements</b></font></p> <p style="MARGIN-BOTTOM: 0px; MARGIN-LEFT: 2%; MARGIN-TOP: 6px"> <font style="FONT-FAMILY: Times New Roman" size="2"><b><i>Grants</i></b></font></p> <p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 6px; TEXT-INDENT: 4%" align="justify"><font style="FONT-FAMILY: Times New Roman" size="2">In 2010, the National Institute of Neurological Disorders and Strokes (&#x201C;NINDS&#x201D;) awarded to the Company a $2.8&#xA0;million grant to support research and development of tirasemtiv directed to the potential treatment for myasthenia gravis for a period of up to three years. In September 2012, the NINDS awarded to us an additional $0.5 million under a separate grant. Management determined that the Company was the principal participant in the grant arrangements, and, accordingly, the Company recorded amounts earned under the arrangements as revenue. The grants were completed in June 2013.</font></p> <p style="MARGIN-BOTTOM: 0px; FONT-SIZE: 12px; MARGIN-TOP: 0px"> &#xA0;</p> <p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 0px; TEXT-INDENT: 4%" align="justify"><font style="FONT-FAMILY: Times New Roman" size="2">Total grant revenues were as follows (in thousands):</font></p> <p style="MARGIN-BOTTOM: 0px; FONT-SIZE: 12px; MARGIN-TOP: 0px"> &#xA0;</p> <table style="BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="92%" align="center" border="0"> <tr> <td width="79%"></td> <td valign="bottom" width="4%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="4%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="4%"></td> <td></td> <td></td> <td></td> </tr> <tr> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="10" align="center"><font style="FONT-FAMILY: Times New Roman" size="1"><b>Years Ended<br /> December&#xA0;31,</b></font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> </tr> <tr> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" align="center"><font style="FONT-FAMILY: Times New Roman" size="1"><b>2014</b></font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" align="center"><font style="FONT-FAMILY: Times New Roman" size="1"><b>2013</b></font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" align="center"><font style="FONT-FAMILY: Times New Roman" size="1"><b>2012</b></font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> </tr> <tr bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: Times New Roman" size="2">NINDS myasthenia gravis</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td> <td valign="bottom" nowrap="nowrap" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">&#x2014;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">69</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">1,308</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> </tr> <tr> <td valign="top"> <p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: Times New Roman" size="2">Other grant revenue</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">75</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">25</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" nowrap="nowrap" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">&#x2014;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> </tr> <tr bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-LEFT: 2em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: Times New Roman" size="2">Total grant revenue</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">75</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">94</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">1,308</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td>&#xA0;</td> </tr> </table> <p style="MARGIN-BOTTOM: 0px; MARGIN-LEFT: 2%; MARGIN-TOP: 18px"> <font style="FONT-FAMILY: Times New Roman" size="2"><b><i>Global Blood Therapeutics, Inc. (&#x201C;Global Blood&#x201D;)</i></b></font></p> <p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 6px; TEXT-INDENT: 4%" align="justify"><font style="FONT-FAMILY: Times New Roman" size="2">In October 2011, the Company entered into a collaboration agreement with Global Blood Therapeutics, Inc. (formerly called Global Blood Targeting, Inc.) (&#x201C;Global Blood&#x201D;). Under an agreed research plan, scientists from Global Blood and our FTEs conducted research focused on small molecule therapeutics that target the blood. The Company provided to Global Blood access to certain research facilities, FTEs and other resources at agreed reimbursement rates that approximated our costs. In April 2012, the Company extended this agreement through December 2012. The Company was the primary obligor in the collaboration arrangement, and accordingly, the Company recorded expense reimbursements from Global Blood as research and development revenue.</font></p> <p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 12px; TEXT-INDENT: 4%" align="justify"><font style="FONT-FAMILY: Times New Roman" size="2">Research and development revenue from Global Blood was as follows (in thousands):</font></p> <p style="MARGIN-BOTTOM: 0px; FONT-SIZE: 12px; MARGIN-TOP: 0px"> &#xA0;</p> <table style="BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="92%" align="center" border="0"> <tr> <td width="79%"></td> <td valign="bottom" width="4%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="4%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="4%"></td> <td></td> <td></td> <td></td> </tr> <tr> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="10" align="center"><font style="FONT-FAMILY: Times New Roman" size="1"><b>Years&#xA0;Ended&#xA0;December&#xA0;31,</b></font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> </tr> <tr> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" align="center"><font style="FONT-FAMILY: Times New Roman" size="1"><b>2014</b></font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" align="center"><font style="FONT-FAMILY: Times New Roman" size="1"><b>2013</b></font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" align="center"><font style="FONT-FAMILY: Times New Roman" size="1"><b>2012</b></font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> </tr> <tr bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: Times New Roman" size="2">Expense reimbursements from Global Blood</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td> <td valign="bottom" nowrap="nowrap" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">&#x2014;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">14</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">1,479</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td>&#xA0;</td> </tr> </table> <p style="MARGIN-BOTTOM: 0px; MARGIN-LEFT: 2%; MARGIN-TOP: 18px"> <font style="FONT-FAMILY: Times New Roman" size="2"><b><i>MyoKardia, Inc.</i></b></font></p> <p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 6px; TEXT-INDENT: 4%" align="justify"><font style="FONT-FAMILY: Times New Roman" size="2">In August 2012, the Company entered into a collaboration agreement with MyoKardia, Inc. Under an agreed research plan, scientists from MyoKardia and our FTEs conduct research focused on small molecule therapeutics that inhibit cardiac sarcomere proteins. The Company provided to MyoKardia access to certain research facilities, and continues to provide FTEs and other resources at agreed reimbursement rates that approximate our costs. The Company is the primary obligor in the collaboration arrangement, and accordingly, the Company records expense reimbursements from MyoKardia as research and development revenue. The research plan terminated as planned in August 2013.</font></p> <p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 12px; TEXT-INDENT: 4%" align="justify"><font style="FONT-FAMILY: Times New Roman" size="2">Research and development revenue from MyoKardia was as follows (in thousands):</font></p> <p style="MARGIN-BOTTOM: 0px; FONT-SIZE: 12px; MARGIN-TOP: 0px"> &#xA0;</p> <table style="BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="92%" align="center" border="0"> <tr> <td width="77%"></td> <td valign="bottom" width="4%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="4%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="4%"></td> <td></td> <td></td> <td></td> </tr> <tr> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="10" align="center"><font style="FONT-FAMILY: Times New Roman" size="1"><b>Years&#xA0;Ended&#xA0;December&#xA0;31,</b></font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> </tr> <tr> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" align="center"><font style="FONT-FAMILY: Times New Roman" size="1"><b>2014</b></font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" align="center"><font style="FONT-FAMILY: Times New Roman" size="1"><b>2013</b></font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" align="center"><font style="FONT-FAMILY: Times New Roman" size="1"><b>2012</b></font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> </tr> <tr bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: Times New Roman" size="2">Research and development milestone fees</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">100</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td> <td valign="bottom" nowrap="nowrap" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">&#x2014;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td> <td valign="bottom" nowrap="nowrap" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">&#x2014;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> </tr> <tr> <td valign="top"> <p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: Times New Roman" size="2">Expense reimbursements from MyoKardia</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" nowrap="nowrap" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">&#x2014;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">1,024</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">595</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> </tr> <tr bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: Times New Roman" size="2">Research and development revenue from Myokardia</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">100</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">1,024</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">595</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td>&#xA0;</td> </tr> </table> </div></us-gaap:ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock> <us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock contextRef="eol_PE151383--1410-K0012_STD_365_20141231_0" id="id_6895476_39293D4A-97F3-494B-BBB7-8613B6611486_1_0"><div> <p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 0px; TEXT-INDENT: 4%" align="justify"><font style="FONT-FAMILY: Times New Roman" size="2">The significant components of the Company&#x2019;s deferred tax assets and liabilities were as follows (in thousands):</font></p> <p style="MARGIN-BOTTOM: 0px; FONT-SIZE: 12px; MARGIN-TOP: 0px"> &#xA0;</p> <table style="BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="92%" align="center" border="0"> <tr> <td width="64%"></td> <td valign="bottom" width="9%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="8%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="8%"></td> <td></td> <td></td> <td></td> </tr> <tr> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="10" align="center"><font style="FONT-FAMILY: Times New Roman" size="1"><b>As of December&#xA0;31,</b></font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> </tr> <tr> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" align="center"><font style="FONT-FAMILY: Times New Roman" size="1"><b>2014</b></font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" align="center"><font style="FONT-FAMILY: Times New Roman" size="1"><b>2013</b></font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" align="center"><font style="FONT-FAMILY: Times New Roman" size="1"><b>2012</b></font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> </tr> <tr bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: Times New Roman" size="2">Deferred tax assets:</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr> <td valign="top"> <p style="MARGIN-LEFT: 2em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: Times New Roman" size="2">Depreciation and amortization</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">780</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">918</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">1,024</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> </tr> <tr bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-LEFT: 2em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: Times New Roman" size="2">Capitalized R&amp;D</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">15,176</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">20,702</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">4,932</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> </tr> <tr> <td valign="top"> <p style="MARGIN-LEFT: 2em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: Times New Roman" size="2">Reserves and accruals</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">6,217</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">4,946</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">5,101</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> </tr> <tr bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-LEFT: 2em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: Times New Roman" size="2">Net operating losses</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">148,184</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">144,254</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">153,193</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> </tr> <tr> <td valign="top"> <p style="MARGIN-LEFT: 2em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: Times New Roman" size="2">Tax credits</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">34,543</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">33,043</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">25,943</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> </tr> <tr bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-LEFT: 3em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: Times New Roman" size="2">Total deferred tax assets</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">204,900</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">203,863</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">190,193</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> </tr> <tr> <td valign="top"> <p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: Times New Roman" size="2">Less: Valuation allowance</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">(204,900</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">)&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">(203,863</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">)&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">(190,193</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">)&#xA0;</font></td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> </tr> <tr bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: Times New Roman" size="2">Net deferred tax assets</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td> <td valign="bottom" nowrap="nowrap" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">&#x2014;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td> <td valign="bottom" nowrap="nowrap" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">&#x2014;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td> <td valign="bottom" nowrap="nowrap" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">&#x2014;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td>&#xA0;</td> </tr> </table> </div></us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock> <us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock contextRef="eol_PE151383--1410-K0012_STD_365_20141231_0" id="id_6895476_E6F031F7-831D-4B9F-8196-D9ADAD75655A_1_0"><div> <p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 6px; TEXT-INDENT: 4%" align="justify"><font style="FONT-FAMILY: Times New Roman" size="2">The following is the calculation of basic and diluted net loss per share allocable to common stockholders (in thousands except per share data):</font></p> <p style="MARGIN-BOTTOM: 0px; FONT-SIZE: 12px; MARGIN-TOP: 0px"> &#xA0;</p> <table style="BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="92%" align="center" border="0"> <tr> <td width="66%"></td> <td valign="bottom" width="5%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="4%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="4%"></td> <td></td> <td></td> <td></td> </tr> <tr> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="10" align="center"><font style="FONT-FAMILY: Times New Roman" size="1"><b>Years Ended December&#xA0;31,</b></font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> </tr> <tr> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" align="center"><font style="FONT-FAMILY: Times New Roman" size="1"><b>2014</b></font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" align="center"><font style="FONT-FAMILY: Times New Roman" size="1"><b>2013</b></font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" align="center"><font style="FONT-FAMILY: Times New Roman" size="1"><b>2012</b></font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> </tr> <tr bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: Times New Roman" size="2">Net loss</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">(14,646</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">)&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">(33,717</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">)&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">(40,370</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">)&#xA0;</font></td> </tr> <tr> <td valign="top"> <p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: Times New Roman" size="2">Deemed dividend related to beneficial conversion feature of convertible preferred stock</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" nowrap="nowrap" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">&#x2014;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" nowrap="nowrap" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">&#x2014;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">(1,307</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">)&#xA0;</font></td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> </tr> <tr bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: Times New Roman" size="2">Net loss allocable to common stockholders</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">(14,646</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">)&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">(33,717</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">)&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">(41,677</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">)&#xA0;</font></td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td>&#xA0;</td> </tr> <tr> <td valign="top"> <p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: Times New Roman" size="2">Weighted-average shares used in computing net loss per share allocable to common stockholders&#xA0;&#x2014; basic and diluted</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">35,709</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">27,275</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">18,107</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td>&#xA0;</td> </tr> <tr bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: Times New Roman" size="2">Net loss per share allocable to common stockholders &#x2014; basic and&#xA0;diluted</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">(0.41</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">)&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">(1.24</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">)&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">(2.30</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">)&#xA0;</font></td> </tr> </table> </div></us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock> <us-gaap:ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock contextRef="eol_PE151383--1410-K0012_STD_365_20141231_0" id="id_6895476_2890B91E-E0F1-4320-B416-209153F4DF7F_1_0"><div> <p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 12px; TEXT-INDENT: 4%" align="justify"><font style="FONT-FAMILY: Times New Roman" size="2">As of December&#xA0;31, 2014, future minimum lease payments under noncancelable operating leases were as follows (in thousands):</font></p> <p style="MARGIN-BOTTOM: 0px; FONT-SIZE: 12px; MARGIN-TOP: 0px"> &#xA0;</p> <table style="BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="92%" align="center" border="0"> <tr> <td width="89%"></td> <td valign="bottom" width="5%"></td> <td></td> <td></td> <td></td> </tr> <tr bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: Times New Roman" size="2">2015</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">3,390</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> </tr> <tr> <td valign="top"> <p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: Times New Roman" size="2">2016</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">3,504</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> </tr> <tr bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: Times New Roman" size="2">2017</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">3,626</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> </tr> <tr> <td valign="top"> <p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: Times New Roman" size="2">2018</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">1,860</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> </tr> <tr bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: Times New Roman" size="2">2019</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" nowrap="nowrap" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">&#x2014;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> </tr> <tr> <td valign="top"> <p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: Times New Roman" size="2">Thereafter</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" nowrap="nowrap" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">&#x2014;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> </tr> <tr bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-LEFT: 2em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: Times New Roman" size="2">Total</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">12,380</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td>&#xA0;</td> </tr> </table> </div></us-gaap:ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock> <us-gaap:ScheduleOfQuarterlyFinancialInformationTableTextBlock contextRef="eol_PE151383--1410-K0012_STD_365_20141231_0" id="id_6895476_51D4D598-01EF-4AF9-B627-3D28A069601B_1_0"><div> <p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 6px; TEXT-INDENT: 4%" align="justify"><font style="FONT-FAMILY: Times New Roman" size="2">Quarterly results were as follows (in thousands, except per share data):</font></p> <p style="MARGIN-BOTTOM: 0px; FONT-SIZE: 12px; MARGIN-TOP: 0px"> &#xA0;</p> <table style="BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="100%" align="center" border="0"> <tr> <td width="64%"></td> <td valign="bottom" width="4%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="4%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="4%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="4%"></td> <td></td> <td></td> <td></td> </tr> <tr> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" align="center"><font style="FONT-FAMILY: Times New Roman" size="1"><b>First<br /> Quarter</b></font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" align="center"><font style="FONT-FAMILY: Times New Roman" size="1"><b>Second<br /> Quarter</b></font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" align="center"><font style="FONT-FAMILY: Times New Roman" size="1"><b>Third<br /> Quarter</b></font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" align="center"><font style="FONT-FAMILY: Times New Roman" size="1"><b>Fourth<br /> Quarter</b></font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> </tr> <tr bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: Times New Roman" size="2"><b>2014</b></font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr> <td valign="top"> <p style="MARGIN-LEFT: 2em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: Times New Roman" size="2">Total revenues</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">7,979</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">7,788</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">9,415</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">21,758</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> </tr> <tr bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-LEFT: 2em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: Times New Roman" size="2">Net income (loss)</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">(8,744</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">)&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">(8,374</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">)&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">(5,971</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">)&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">8,443</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> </tr> <tr> <td valign="top"> <p style="MARGIN-LEFT: 2em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: Times New Roman" size="2">Net income (loss) allocable to common stockholders</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">(8,744</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">)&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">(8,374</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">)&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">(5,971</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">)&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">8,443</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> </tr> <tr bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-LEFT: 2em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: Times New Roman" size="2">Net income (loss) per share allocable to common stockholders &#x2014; basic and diluted</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">(0.27</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">)&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">(0.23</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">)&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">(0.16</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">)&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">0.23</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> </tr> <tr> <td valign="top"> <p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: Times New Roman" size="2"><b>2013</b></font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-LEFT: 2em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: Times New Roman" size="2">Total revenues</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">821</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">1,009</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">4,469</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">24,349</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> </tr> <tr> <td valign="top"> <p style="MARGIN-LEFT: 2em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: Times New Roman" size="2">Net income (loss)</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">(12,619</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">)&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">(15,041</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">)&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">(12,588</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">)&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">6,531</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> </tr> <tr bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-LEFT: 2em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: Times New Roman" size="2">Net income (loss) allocable to common stockholders</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">(12,619</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">)&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">(15,041</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">)&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">(12,588</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">)&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">6,531</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> </tr> <tr> <td valign="top"> <p style="MARGIN-LEFT: 2em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: Times New Roman" size="2">Net income (loss) per share allocable to common stockholders &#x2014; basic</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">(0.53</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">)&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">(0.58</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">)&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">(0.43</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">)&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">0.22</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> </tr> <tr bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-LEFT: 2em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: Times New Roman" size="2">Net income (loss) per share allocable to common stockholders &#x2014; diluted</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">(0.53</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">)&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">(0.58</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">)&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">(0.43</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">)&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">0.21</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> </tr> </table> </div></us-gaap:ScheduleOfQuarterlyFinancialInformationTableTextBlock> <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1 contextRef="eol_PE151383--1410-K0012_STD_365_20141231_0" id="id_6895476_3C5D1DA4-14B7-4F1F-B924-42BFE68F3162_2001_2">P5Y9M4D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1> <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod contextRef="eol_PE151383--1410-K0012_STD_365_20141231_0" unitRef="shares" decimals="INF" id="id_6895476_EAE02EAA-C88A-417D-A4E8-6DD5ADADA4AB_12001_17">95980</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod> <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice contextRef="eol_PE151383--1410-K0012_STD_365_20141231_0" unitRef="iso4217_USD_per_shares" decimals="2" id="id_6895476_C3206D70-DEC9-4565-9145-8B70956A712D_11001_12">8.80</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice> <us-gaap:SupplementalBalanceSheetDisclosuresTextBlock contextRef="eol_PE151383--1410-K0012_STD_365_20141231_0" id="id_6895476_7FC1E3D4-C87C-4227-815F-B797CD6285EC_1_0"><div> <p style="margin-top:18px;margin-bottom:0px"><font style="font-family:Times New Roman" size="2"><b>Note 6 &#x2014; Balance Sheet Components</b></font></p> <p style="margin-top:6px;margin-bottom:0px; text-indent:4%" align="justify"><font style="font-family:Times New Roman" size="2">Property and equipment balances were as follows (in thousands):</font></p> <p style="font-size:12px;margin-top:0px;margin-bottom:0px"> &#xA0;</p> <table cellspacing="0" cellpadding="0" width="92%" border="0" style="BORDER-COLLAPSE:COLLAPSE" align="center"> <tr> <td width="77%"></td> <td valign="bottom" width="6%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="5%"></td> <td></td> <td></td> <td></td> </tr> <tr> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom" colspan="6" align="center" style="border-bottom:1px solid #000000"><font style="font-family:Times New Roman" size="1"><b>December&#xA0;31,</b></font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> </tr> <tr> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom" colspan="2" align="center" style="border-bottom:1px solid #000000"><font style="font-family:Times New Roman" size="1"><b>2014</b></font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom" colspan="2" align="center" style="border-bottom:1px solid #000000"><font style="font-family:Times New Roman" size="1"><b>2013</b></font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> </tr> <tr bgcolor="#CCEEFF"> <td valign="top"> <p style="margin-left:1.00em; text-indent:-1.00em"><font style="font-family:Times New Roman" size="2">Property and equipment, net:</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr> <td valign="top"> <p style="margin-left:2.00em; text-indent:-1.00em"><font style="font-family:Times New Roman" size="2">Laboratory equipment</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="font-family:Times New Roman" size="2">$</font></td> <td valign="bottom" align="right"><font style="font-family:Times New Roman" size="2">15,299</font></td> <td nowrap="nowrap" valign="bottom"><font style="font-family:Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="font-family:Times New Roman" size="2">$</font></td> <td valign="bottom" align="right"><font style="font-family:Times New Roman" size="2">15,317</font></td> <td nowrap="nowrap" valign="bottom"><font style="font-family:Times New Roman" size="2">&#xA0;&#xA0;</font></td> </tr> <tr bgcolor="#CCEEFF"> <td valign="top"> <p style="margin-left:2.00em; text-indent:-1.00em"><font style="font-family:Times New Roman" size="2">Computer equipment and software</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="font-family:Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="font-family:Times New Roman" size="2">2,418</font></td> <td nowrap="nowrap" valign="bottom"><font style="font-family:Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="font-family:Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="font-family:Times New Roman" size="2">2,549</font></td> <td nowrap="nowrap" valign="bottom"><font style="font-family:Times New Roman" size="2">&#xA0;&#xA0;</font></td> </tr> <tr> <td valign="top"> <p style="margin-left:2.00em; text-indent:-1.00em"><font style="font-family:Times New Roman" size="2">Office equipment, furniture and fixtures</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="font-family:Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="font-family:Times New Roman" size="2">913</font></td> <td nowrap="nowrap" valign="bottom"><font style="font-family:Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="font-family:Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="font-family:Times New Roman" size="2">1,050</font></td> <td nowrap="nowrap" valign="bottom"><font style="font-family:Times New Roman" size="2">&#xA0;&#xA0;</font></td> </tr> <tr bgcolor="#CCEEFF"> <td valign="top"> <p style="margin-left:2.00em; text-indent:-1.00em"><font style="font-family:Times New Roman" size="2">Leasehold improvements</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="font-family:Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="font-family:Times New Roman" size="2">3,334</font></td> <td nowrap="nowrap" valign="bottom"><font style="font-family:Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="font-family:Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="font-family:Times New Roman" size="2">3,297</font></td> <td nowrap="nowrap" valign="bottom"><font style="font-family:Times New Roman" size="2">&#xA0;&#xA0;</font></td> </tr> <tr style="font-size:1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="border-top:1px solid #000000">&#xA0;</p> </td> <td valign="bottom"> <p style="border-top:1px solid #000000">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="border-top:1px solid #000000">&#xA0;</p> </td> <td valign="bottom"> <p style="border-top:1px solid #000000">&#xA0;</p> </td> <td>&#xA0;</td> </tr> <tr> <td valign="top"></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="font-family:Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="font-family:Times New Roman" size="2">21,964</font></td> <td nowrap="nowrap" valign="bottom"><font style="font-family:Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="font-family:Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="font-family:Times New Roman" size="2">22,213</font></td> <td nowrap="nowrap" valign="bottom"><font style="font-family:Times New Roman" size="2">&#xA0;&#xA0;</font></td> </tr> <tr bgcolor="#CCEEFF"> <td valign="top"> <p style="margin-left:2.00em; text-indent:-1.00em"><font style="font-family:Times New Roman" size="2">Less: Accumulated depreciation and amortization</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="font-family:Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="font-family:Times New Roman" size="2">(20,327</font></td> <td nowrap="nowrap" valign="bottom"><font style="font-family:Times New Roman" size="2">)&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="font-family:Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="font-family:Times New Roman" size="2">(20,992</font></td> <td nowrap="nowrap" valign="bottom"><font style="font-family:Times New Roman" size="2">)&#xA0;</font></td> </tr> <tr style="font-size:1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="border-top:1px solid #000000">&#xA0;</p> </td> <td valign="bottom"> <p style="border-top:1px solid #000000">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="border-top:1px solid #000000">&#xA0;</p> </td> <td valign="bottom"> <p style="border-top:1px solid #000000">&#xA0;</p> </td> <td>&#xA0;</td> </tr> <tr> <td valign="top"></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="font-family:Times New Roman" size="2">$</font></td> <td valign="bottom" align="right"><font style="font-family:Times New Roman" size="2">1,637</font></td> <td nowrap="nowrap" valign="bottom"><font style="font-family:Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="font-family:Times New Roman" size="2">$</font></td> <td valign="bottom" align="right"><font style="font-family:Times New Roman" size="2">1,221</font></td> <td nowrap="nowrap" valign="bottom"><font style="font-family:Times New Roman" size="2">&#xA0;&#xA0;</font></td> </tr> <tr style="font-size:1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="border-top:3px double #000000">&#xA0;</p> </td> <td valign="bottom"> <p style="border-top:3px double #000000">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="border-top:3px double #000000">&#xA0;</p> </td> <td valign="bottom"> <p style="border-top:3px double #000000">&#xA0;</p> </td> <td>&#xA0;</td> </tr> </table> <p style="margin-top:12px;margin-bottom:0px; text-indent:4%" align="justify"><font style="font-family:Times New Roman" size="2">Depreciation expense was $0.5 million, $0.4 million and $0.6 million for the years ended December&#xA0;31, 2014, 2013 and 2012 respectively.</font></p> <p style="font-size:12px;margin-top:0px;margin-bottom:0px"> &#xA0;</p> <p style="margin-top:0px;margin-bottom:0px; text-indent:4%" align="justify"><font style="font-family:Times New Roman" size="2">Accrued liabilities were as follows (in thousands):</font></p> <p style="font-size:12px;margin-top:0px;margin-bottom:0px"> &#xA0;</p> <table cellspacing="0" cellpadding="0" width="92%" border="0" style="BORDER-COLLAPSE:COLLAPSE" align="center"> <tr> <td width="82%"></td> <td valign="bottom" width="4%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="4%"></td> <td></td> <td></td> <td></td> </tr> <tr> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom" colspan="6" align="center" style="border-bottom:1px solid #000000"><font style="font-family:Times New Roman" size="1"><b>December&#xA0;31,</b></font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> </tr> <tr> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom" colspan="2" align="center" style="border-bottom:1px solid #000000"><font style="font-family:Times New Roman" size="1"><b>2014</b></font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom" colspan="2" align="center" style="border-bottom:1px solid #000000"><font style="font-family:Times New Roman" size="1"><b>2013</b></font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> </tr> <tr bgcolor="#CCEEFF"> <td valign="top"> <p style="margin-left:1.00em; text-indent:-1.00em"><font style="font-family:Times New Roman" size="2">Accrued liabilities:</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr> <td valign="top"> <p style="margin-left:2.00em; text-indent:-1.00em"><font style="font-family:Times New Roman" size="2">Clinical and preclinical costs</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="font-family:Times New Roman" size="2">$</font></td> <td valign="bottom" align="right"><font style="font-family:Times New Roman" size="2">972</font></td> <td nowrap="nowrap" valign="bottom"><font style="font-family:Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="font-family:Times New Roman" size="2">$</font></td> <td valign="bottom" align="right"><font style="font-family:Times New Roman" size="2">4,975</font></td> <td nowrap="nowrap" valign="bottom"><font style="font-family:Times New Roman" size="2">&#xA0;&#xA0;</font></td> </tr> <tr bgcolor="#CCEEFF"> <td valign="top"> <p style="margin-left:2.00em; text-indent:-1.00em"><font style="font-family:Times New Roman" size="2">Consulting and professional fees</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="font-family:Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="font-family:Times New Roman" size="2">421</font></td> <td nowrap="nowrap" valign="bottom"><font style="font-family:Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="font-family:Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="font-family:Times New Roman" size="2">697</font></td> <td nowrap="nowrap" valign="bottom"><font style="font-family:Times New Roman" size="2">&#xA0;&#xA0;</font></td> </tr> <tr> <td valign="top"> <p style="margin-left:2.00em; text-indent:-1.00em"><font style="font-family:Times New Roman" size="2">Bonus</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="font-family:Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="font-family:Times New Roman" size="2">2,665</font></td> <td nowrap="nowrap" valign="bottom"><font style="font-family:Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="font-family:Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="font-family:Times New Roman" size="2">1,614</font></td> <td nowrap="nowrap" valign="bottom"><font style="font-family:Times New Roman" size="2">&#xA0;&#xA0;</font></td> </tr> <tr bgcolor="#CCEEFF"> <td valign="top"> <p style="margin-left:2.00em; text-indent:-1.00em"><font style="font-family:Times New Roman" size="2">Vacation pay</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="font-family:Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="font-family:Times New Roman" size="2">915</font></td> <td nowrap="nowrap" valign="bottom"><font style="font-family:Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="font-family:Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="font-family:Times New Roman" size="2">778</font></td> <td nowrap="nowrap" valign="bottom"><font style="font-family:Times New Roman" size="2">&#xA0;&#xA0;</font></td> </tr> <tr> <td valign="top"> <p style="margin-left:2.00em; text-indent:-1.00em"><font style="font-family:Times New Roman" size="2">Other payroll related</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="font-family:Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="font-family:Times New Roman" size="2">110</font></td> <td nowrap="nowrap" valign="bottom"><font style="font-family:Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="font-family:Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="font-family:Times New Roman" size="2">93</font></td> <td nowrap="nowrap" valign="bottom"><font style="font-family:Times New Roman" size="2">&#xA0;&#xA0;</font></td> </tr> <tr bgcolor="#CCEEFF"> <td valign="top"> <p style="margin-left:2.00em; text-indent:-1.00em"><font style="font-family:Times New Roman" size="2">Other accrued expenses</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="font-family:Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="font-family:Times New Roman" size="2">317</font></td> <td nowrap="nowrap" valign="bottom"><font style="font-family:Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="font-family:Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="font-family:Times New Roman" size="2">115</font></td> <td nowrap="nowrap" valign="bottom"><font style="font-family:Times New Roman" size="2">&#xA0;&#xA0;</font></td> </tr> <tr style="font-size:1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="border-top:1px solid #000000">&#xA0;</p> </td> <td valign="bottom"> <p style="border-top:1px solid #000000">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="border-top:1px solid #000000">&#xA0;</p> </td> <td valign="bottom"> <p style="border-top:1px solid #000000">&#xA0;</p> </td> <td>&#xA0;</td> </tr> <tr> <td valign="top"></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="font-family:Times New Roman" size="2">$</font></td> <td valign="bottom" align="right"><font style="font-family:Times New Roman" size="2">5,400</font></td> <td nowrap="nowrap" valign="bottom"><font style="font-family:Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="font-family:Times New Roman" size="2">$</font></td> <td valign="bottom" align="right"><font style="font-family:Times New Roman" size="2">8,272</font></td> <td nowrap="nowrap" valign="bottom"><font style="font-family:Times New Roman" size="2">&#xA0;&#xA0;</font></td> </tr> <tr style="font-size:1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="border-top:3px double #000000">&#xA0;</p> </td> <td valign="bottom"> <p style="border-top:3px double #000000">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="border-top:3px double #000000">&#xA0;</p> </td> <td valign="bottom"> <p style="border-top:3px double #000000">&#xA0;</p> </td> <td>&#xA0;</td> </tr> </table> <p style="margin-top:12px;margin-bottom:0px; text-indent:4%" align="justify"><font style="font-family:Times New Roman" size="2">Interest receivable on cash equivalents and investments of $109,000 and $215,000 is included in prepaid and other current assets at December&#xA0;31, 2014 and 2013, respectively.</font></p> </div></us-gaap:SupplementalBalanceSheetDisclosuresTextBlock> <dei:EntityCentralIndexKey contextRef="eol_PE151383--1410-K0012_STD_365_20141231_0" id="id_6895476_719DD5F0-2E9A-450E-B7C0-E6D7E07576A8_1_400002">0001061983</dei:EntityCentralIndexKey> <us-gaap:EarningsPerShareBasicAndDiluted contextRef="eol_PE151383--1410-K0012_STD_365_20141231_0" unitRef="iso4217_USD_per_shares" decimals="2" id="id_6895476_09173C79-2713-49DF-8107-C7F99AA4E397_1_4">-0.41</us-gaap:EarningsPerShareBasicAndDiluted> <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate contextRef="eol_PE151383--1410-K0012_STD_365_20141231_0" unitRef="pure" decimals="2" id="id_6895476_14EF385A-3844-4F78-AE65-D20D0D541C15_1_0">-0.34</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate> <us-gaap:FairValueDisclosuresTextBlock contextRef="eol_PE151383--1410-K0012_STD_365_20141231_0" id="id_6895476_B0DDABE6-CFC0-4132-A6A5-65DE277DCCDF_1_0"><div> <p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 0px"><font style="FONT-FAMILY: Times New Roman" size="2"><b>Note 5 &#x2014; Fair Value Measurements</b></font></p> <p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 6px; TEXT-INDENT: 4%" align="justify"><font style="FONT-FAMILY: Times New Roman" size="2">The Company adopted the fair value accounting guidance to value its financial assets and liabilities. Fair value is defined as the price that would be received for assets when sold or paid to transfer a liability in an orderly transaction between market participants at the measurement date (exit price). The Company utilizes market data or assumptions that the Company believes market participants would use in pricing the asset or liability, including assumptions about risk and the risks inherent in the inputs to the valuation technique. These inputs can be readily observable, market corroborated or generally unobservable.</font></p> <p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 12px; TEXT-INDENT: 4%" align="justify"><font style="FONT-FAMILY: Times New Roman" size="2">The Company primarily applies the market approach for recurring fair value measurements and endeavors to utilize the best information reasonably available. Accordingly, the Company utilizes valuation techniques that maximize the use of observable inputs and minimize the use of unobservable inputs to the extent possible, and considers the security issuers&#x2019; and the third-party insurers&#x2019; credit risk in its assessment of fair value.</font></p> <p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 12px; TEXT-INDENT: 4%" align="justify"><font style="FONT-FAMILY: Times New Roman" size="2">The Company classifies the determined fair value based on the observability of those inputs. Fair value accounting guidance establishes a fair value hierarchy that prioritizes the inputs used to measure fair value. The hierarchy gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (Level&#xA0;1 measurement) and the lowest priority to unobservable inputs (Level&#xA0;3 measurement). The three defined levels of the fair value hierarchy are as follows:</font></p> <p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 6px; TEXT-INDENT: 4%" align="justify"><font style="FONT-FAMILY: Times New Roman" size="2">Level&#xA0;1&#xA0;&#x2014; Observable inputs, such as quoted prices in active markets for identical assets or liabilities;</font></p> <p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 12px; TEXT-INDENT: 4%" align="justify"><font style="FONT-FAMILY: Times New Roman" size="2">Level&#xA0;2&#xA0;&#x2014; Inputs, other than the quoted prices in active markets, that are observable either directly or through corroboration with observable market data;&#xA0;and</font></p> <p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 12px; TEXT-INDENT: 4%" align="justify"><font style="FONT-FAMILY: Times New Roman" size="2">Level&#xA0;3&#xA0;&#x2014; Unobservable inputs, for which there is little or no market data for the assets or liabilities, such as internally-developed valuation models.</font></p> <p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 12px; TEXT-INDENT: 4%" align="justify"><font style="FONT-FAMILY: Times New Roman" size="2">Financial assets measured at fair value on a recurring basis as of December&#xA0;31, 2014 and 2013 are classified in the table below in one of the three categories described above (in thousands):</font></p> <p style="MARGIN-BOTTOM: 0px; FONT-SIZE: 12px; MARGIN-TOP: 0px"> &#xA0;</p> <table style="BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="92%" align="center" border="0"> <tr> <td width="56%"></td> <td valign="bottom" width="7%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="7%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="7%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="7%"></td> <td></td> <td></td> <td></td> </tr> <tr> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="14" align="center"><font style="FONT-FAMILY: Times New Roman" size="1"><b>December&#xA0;31, 2014</b></font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> </tr> <tr> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="10" align="center"><font style="FONT-FAMILY: Times New Roman" size="1"><b>Fair&#xA0;Value&#xA0;Measurements&#xA0;Using</b></font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" rowspan="2" colspan="2" align="center"><font style="FONT-FAMILY: Times New Roman" size="1"><b>Assets<br /> At&#xA0;Fair&#xA0;Value</b></font></td> <td valign="bottom" rowspan="2"><font size="1">&#xA0;</font></td> </tr> <tr> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" align="center"><font style="FONT-FAMILY: Times New Roman" size="1"><b>&#xA0;&#xA0;Level&#xA0;1&#xA0;&#xA0;</b></font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" align="center"><font style="FONT-FAMILY: Times New Roman" size="1"><b>&#xA0;&#xA0;Level&#xA0;2&#xA0;&#xA0;</b></font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" align="center"><font style="FONT-FAMILY: Times New Roman" size="1"><b>&#xA0;&#xA0;Level&#xA0;3&#xA0;&#xA0;</b></font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> </tr> <tr bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: Times New Roman" size="2">Money market funds</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">16,932</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td> <td valign="bottom" nowrap="nowrap" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">&#x2014;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td> <td valign="bottom" nowrap="nowrap" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">&#x2014;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">16,932</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> </tr> <tr> <td valign="top"> <p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: Times New Roman" size="2">U.S. Treasury securities</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">63,013</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" nowrap="nowrap" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">&#x2014;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" nowrap="nowrap" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">&#x2014;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">63,013</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> </tr> <tr bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-LEFT: 3em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: Times New Roman" size="2">Total</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">79,945</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td> <td valign="bottom" nowrap="nowrap" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">&#x2014;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td> <td valign="bottom" nowrap="nowrap" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">&#x2014;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">79,945</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td>&#xA0;</td> </tr> <tr> <td valign="top"> <p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: Times New Roman" size="2">Amounts included in:</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-LEFT: 2em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: Times New Roman" size="2">Cash and cash equivalents</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">16,932</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td> <td valign="bottom" nowrap="nowrap" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">&#x2014;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td> <td valign="bottom" nowrap="nowrap" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">&#x2014;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">16,932</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> </tr> <tr> <td valign="top"> <p style="MARGIN-LEFT: 2em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: Times New Roman" size="2">Short-term investments</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">63,013</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" nowrap="nowrap" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">&#x2014;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" nowrap="nowrap" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">&#x2014;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">63,013</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> </tr> <tr bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-LEFT: 2em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: Times New Roman" size="2">Long-term investments</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" nowrap="nowrap" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">&#x2014;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" nowrap="nowrap" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">&#x2014;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" nowrap="nowrap" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">&#x2014;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" nowrap="nowrap" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">&#x2014;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> </tr> <tr> <td valign="top"> <p style="MARGIN-LEFT: 3em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: Times New Roman" size="2">Total</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">79,945</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td> <td valign="bottom" nowrap="nowrap" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">&#x2014;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td> <td valign="bottom" nowrap="nowrap" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">&#x2014;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">79,945</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td>&#xA0;</td> </tr> </table> <p style="MARGIN-BOTTOM: 0px; FONT-SIZE: 12px; MARGIN-TOP: 0px"> &#xA0;</p> <table style="BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="92%" align="center" border="0"> <tr> <td width="56%"></td> <td valign="bottom" width="7%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="7%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="7%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="7%"></td> <td></td> <td></td> <td></td> </tr> <tr> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="14" align="center"><font style="FONT-FAMILY: Times New Roman" size="1"><b>December&#xA0;31, 2013</b></font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> </tr> <tr> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="10" align="center"><font style="FONT-FAMILY: Times New Roman" size="1"><b>Fair&#xA0;Value&#xA0;Measurements&#xA0;Using</b></font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" rowspan="2" colspan="2" align="center"><font style="FONT-FAMILY: Times New Roman" size="1"><b>Assets<br /> At&#xA0;Fair&#xA0;Value</b></font></td> <td valign="bottom" rowspan="2"><font size="1">&#xA0;</font></td> </tr> <tr> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" align="center"><font style="FONT-FAMILY: Times New Roman" size="1"><b>&#xA0;&#xA0;Level&#xA0;1&#xA0;&#xA0;</b></font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" align="center"><font style="FONT-FAMILY: Times New Roman" size="1"><b>&#xA0;&#xA0;Level&#xA0;2&#xA0;&#xA0;</b></font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" align="center"><font style="FONT-FAMILY: Times New Roman" size="1"><b>&#xA0;&#xA0;Level&#xA0;3&#xA0;&#xA0;</b></font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> </tr> <tr bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: Times New Roman" size="2">Money market funds</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">15,858</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td> <td valign="bottom" nowrap="nowrap" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">&#x2014;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td> <td valign="bottom" nowrap="nowrap" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">&#x2014;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">15,858</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> </tr> <tr> <td valign="top"> <p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: Times New Roman" size="2">U.S. Treasury securities</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">60,072</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" nowrap="nowrap" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">&#x2014;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" nowrap="nowrap" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">&#x2014;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">60,072</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> </tr> <tr bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-LEFT: 3em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: Times New Roman" size="2">Total</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">75,930</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td> <td valign="bottom" nowrap="nowrap" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">&#x2014;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td> <td valign="bottom" nowrap="nowrap" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">&#x2014;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">75,930</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td>&#xA0;</td> </tr> <tr> <td valign="top"> <p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: Times New Roman" size="2">Amounts included in:</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-LEFT: 2em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: Times New Roman" size="2">Cash and cash equivalents</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">15,858</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td> <td valign="bottom" nowrap="nowrap" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">&#x2014;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td> <td valign="bottom" nowrap="nowrap" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">&#x2014;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">15,858</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> </tr> <tr> <td valign="top"> <p style="MARGIN-LEFT: 2em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: Times New Roman" size="2">Short-term investments</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">57,570</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" nowrap="nowrap" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">&#x2014;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" nowrap="nowrap" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">&#x2014;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">57,570</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> </tr> <tr bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-LEFT: 2em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: Times New Roman" size="2">Long-term investments</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">2,502</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" nowrap="nowrap" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">&#x2014;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" nowrap="nowrap" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">&#x2014;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">2,502</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> </tr> <tr> <td valign="top"> <p style="MARGIN-LEFT: 3em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: Times New Roman" size="2">Total</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">75,930</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td> <td valign="bottom" nowrap="nowrap" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">&#x2014;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td> <td valign="bottom" nowrap="nowrap" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">&#x2014;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">75,930</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td>&#xA0;</td> </tr> </table> <p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 12px; TEXT-INDENT: 4%" align="justify"><font style="FONT-FAMILY: Times New Roman" size="2">The valuation technique used to measure fair value for the Company&#x2019;s Level&#xA0;1 assets is a market approach, using prices and other relevant information generated by market transactions involving identical assets. As of December&#xA0;31, 2014 and 2013, the Company had no financial assets measured at fair value on a recurring basis using significant Level 2 or Level&#xA0;3 inputs. The carrying amount of the Company&#x2019;s accounts receivable and accounts payable approximates fair value due to the short-term nature of these instruments.</font></p> </div></us-gaap:FairValueDisclosuresTextBlock> <us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock contextRef="eol_PE151383--1410-K0012_STD_365_20141231_0" id="id_6895476_83B21C03-2875-4861-99AE-A58E66F94F52_1_0"><div> <p style="MARGIN-BOTTOM: 0px; MARGIN-LEFT: 2%; MARGIN-TOP: 18px"> <font style="FONT-FAMILY: Times New Roman" size="2"><b><i>Impairment of Long-lived Assets</i></b></font></p> <p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 6px; TEXT-INDENT: 4%" align="justify"><font style="FONT-FAMILY: Times New Roman" size="2">In accordance with the accounting guidance for the impairment or disposal of long-lived assets, the Company reviews long-lived assets, including property and equipment, for impairment whenever events or changes in business circumstances indicate that the carrying amount of the assets may not be fully recoverable. Under the accounting guidance, an impairment loss would be recognized when estimated undiscounted future cash flows expected to result from the use of the asset and its eventual disposition are less than its carrying amount. Impairment, if any, is measured as the amount by which the carrying amount of a long-lived asset exceeds its fair value.</font></p> </div></us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock> <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock contextRef="eol_PE151383--1410-K0012_STD_365_20141231_0" id="id_6895476_680F6AF8-0FE4-437C-B19D-8D5C8F4C5814_1_0"><div> <p style="MARGIN-BOTTOM: 0px; MARGIN-LEFT: 2%; MARGIN-TOP: 0px"> <font style="FONT-FAMILY: Times New Roman" size="2"><b><i>Recent Accounting Pronouncements</i></b></font></p> <p style="MARGIN-BOTTOM: 0px; MARGIN-LEFT: 2%; MARGIN-TOP: 6px"> <font style="FONT-FAMILY: Times New Roman" size="2"><i>Recently Adopted Accounting Pronouncements</i></font></p> <p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 6px; TEXT-INDENT: 4%" align="justify"><font style="FONT-FAMILY: Times New Roman" size="2">In July 2013, the FASB issued ASU 2013-11, <i>Presentation of an Unrecognized Tax Benefit When a Net Operating Loss Carryforward, a Similar Tax Loss, or a Tax Credit Carryforward Exists</i>. ASU 2013-11 amends accounting guidance on the presentation of an unrecognized tax benefit when a net operating loss carryforward, a similar tax loss, or tax credit carryforward exists. This new guidance requires entities, if certain criteria are met, to present an unrecognized tax benefit, or portion of an unrecognized tax benefit, in the financial statements as a reduction to a deferred tax asset for a net operating loss carryforward, a similar tax loss, or a tax credit carryforward when such items exist in the same taxing jurisdiction. The Company adopted ASU 2013-11 effective January&#xA0;1, 2014 and the adoption of ASU 2013-11 did not have a material effect on its financial statements.</font></p> </div></us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock> <us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock contextRef="eol_PE151383--1410-K0012_STD_365_20141231_0" id="id_6895476_1A0543BE-A88F-4F2E-B86D-145A1E11B771_1_0"><div> <p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 12px"><font style="FONT-FAMILY: Times New Roman" size="2"><b>Note 1 &#x2014; Organization and Significant Accounting Policies</b></font></p> <!-- xbrl,body --> <p style="MARGIN-BOTTOM: 0px; MARGIN-LEFT: 2%; MARGIN-TOP: 6px"> <font style="FONT-FAMILY: Times New Roman" size="2"><b><i>Organization</i></b></font></p> <p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 6px; TEXT-INDENT: 4%" align="justify"><font style="FONT-FAMILY: Times New Roman" size="2">Cytokinetics, Incorporated (the &#x201C;Company&#x201D;, &#x201C;we&#x201D; or &#x201C;our&#x201D;) was incorporated under the laws of the state of Delaware on August&#xA0;5, 1997. The Company is a clinical stage biopharmaceutical company focused on the discovery and development of novel small molecule therapeutics that modulate muscle function for the potential treatment of serious diseases and medical conditions.</font></p> <p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 12px; TEXT-INDENT: 4%" align="justify"><font style="FONT-FAMILY: Times New Roman" size="2">The Company was in the development stage at December&#xA0;31, 2012, as defined in Financial Accounting Standards Board (&#x201C;FASB&#x201D;) Accounting Standards Codification (&#x201C;ASC&#x201D;) Topic 915, &#x201C;<i>Development Stage Entities</i>.&#x201D; During the year ended December&#xA0;31, 2013, the Company exited the development stage with the execution of the Amgen Agreement Amendment and the Original Astellas Agreement (See Note 7), from which the Company received significant revenues from its principal operations, indicative that the Company was no longer in the development stage.</font></p> <p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 12px; TEXT-INDENT: 4%" align="justify"><font style="FONT-FAMILY: Times New Roman" size="2">The Company&#x2019;s financial statements contemplate the conduct of the Company&#x2019;s operations in the normal course of business. The Company has incurred an accumulated deficit of $497.2 million since inception and there can be no assurance that the Company will attain profitability. The Company had a net loss of $14.6 million and net cash used in operations of $44.8 million for the year ended December&#xA0;31, 2014. Cash, cash equivalents and investments increased to $83.2 million at December&#xA0;31, 2014 from $80.2&#xA0;million at December&#xA0;31, 2013. The Company anticipates that it will continue to have operating losses and net cash outflows in future periods.</font></p> <p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 12px; TEXT-INDENT: 4%" align="justify"><font style="FONT-FAMILY: Times New Roman" size="2">The Company is subject to risks common to clinical stage biopharmaceutical companies including, but not limited to, development of new drug candidates, dependence on key personnel, and the ability to obtain additional capital as needed to fund its future plans. The Company&#x2019;s liquidity will be impaired if sufficient additional capital is not available on terms acceptable to the Company. To date, the Company has funded its operations primarily through sales of its common stock and convertible preferred stock, contract payments under its collaboration agreements, debt financing arrangements, government grants and interest income. Until it achieves profitable operations, the Company intends to continue to fund operations through payments from strategic collaborations, additional sales of equity securities, grants and debt financings. The Company has never generated revenues from commercial sales of its drugs and may not obtain regulatory approval for commercialization for at least several years, if ever. The Company&#x2019;s success is dependent on its ability to enter into new strategic collaborations and/or raise additional capital and to successfully develop and market one or more of its drug candidates. As a result, the Company may choose to raise additional capital through equity or debt financings to continue to fund its operations in the future. The Company cannot be certain that sufficient funds will be available from such a financing or through a collaborator when required or on satisfactory terms. Additionally, there can be no assurance that the Company&#x2019;s drug candidates will be accepted in the marketplace or that any future products can be developed or manufactured at an acceptable cost. These factors could have a material adverse effect on the Company&#x2019;s future financial results, financial position and cash flows.</font></p> <p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 12px; TEXT-INDENT: 4%" align="justify"><font style="FONT-FAMILY: Times New Roman" size="2">Based on the current status of its research and development plans, the Company believes that its existing cash, cash equivalents and investments at December&#xA0;31, 2014 will be sufficient to fund its cash requirements for at least the next 12&#xA0;months. If, at any time, the Company&#x2019;s prospects for financing its research and development programs decline, the Company may decide to reduce research and development expenses by delaying, discontinuing or reducing its funding of one or more of its research or development programs. Alternatively, the Company might raise funds through strategic collaborations, public or private financings or other arrangements. Such funding, if needed, may not be available on favorable terms, or at all. The financial statements do not include any adjustments that might result from the outcome of this uncertainty.</font></p> <p style="MARGIN-BOTTOM: 0px; FONT-SIZE: 18px; MARGIN-TOP: 0px"> &#xA0;</p> <p style="MARGIN-BOTTOM: 0px; MARGIN-LEFT: 2%; MARGIN-TOP: 0px"> <font style="FONT-FAMILY: Times New Roman" size="2"><b><i>Use of Estimates</i></b></font></p> <p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 6px; TEXT-INDENT: 4%" align="justify"><font style="FONT-FAMILY: Times New Roman" size="2">The preparation of financial statements in conformity with accounting principles generally accepted in the United States requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosures of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.</font></p> <p style="MARGIN-BOTTOM: 0px; MARGIN-LEFT: 2%; MARGIN-TOP: 18px"> <font style="FONT-FAMILY: Times New Roman" size="2"><b><i>Basis of Presentation</i></b></font></p> <p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 6px; TEXT-INDENT: 4%" align="justify"><font style="FONT-FAMILY: Times New Roman" size="2">The consolidated financial statements include the accounts of Cytokinetics and its wholly owned subsidiary. The financial statements include all adjustments (consisting only of normal recurring adjustments) that management believes are necessary for the fair presentation of the balances and results for the periods presented.</font></p> <p style="MARGIN-BOTTOM: 0px; MARGIN-LEFT: 2%; MARGIN-TOP: 18px"> <font style="FONT-FAMILY: Times New Roman" size="2"><b><i>Concentration of Credit Risk and Other Risks and Uncertainties</i></b></font></p> <p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 6px; TEXT-INDENT: 4%" align="justify"><font style="FONT-FAMILY: Times New Roman" size="2">Financial instruments that potentially subject the Company to concentrations of risk consist principally of cash and cash equivalents, investments and accounts receivable.</font></p> <p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 12px; TEXT-INDENT: 4%" align="justify"><font style="FONT-FAMILY: Times New Roman" size="2">The Company&#x2019;s cash, cash equivalents and investments are invested in deposits with three major financial institutions in the United States.&#xA0;Deposits in these banks may exceed the amount of insurance provided on such deposits. The Company has not experienced any realized losses on its deposits of cash, cash equivalents or investments.</font></p> <p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 12px; TEXT-INDENT: 4%" align="justify"><font style="FONT-FAMILY: Times New Roman" size="2">The economic turmoil in the United States in recent years, the extraordinary volatility in the stock markets and other current negative macroeconomic indicators could negatively impact the Company&#x2019;s ability to raise the funds necessary to support its business and may materially adversely affect its business, operating results and financial condition.</font></p> <p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 12px; TEXT-INDENT: 4%" align="justify"><font style="FONT-FAMILY: Times New Roman" size="2">The Company performs an ongoing credit evaluation of its strategic partners&#x2019; financial conditions and generally does not require collateral to secure accounts receivable from its strategic partners. The Company&#x2019;s exposure to credit risk associated with non-payment will be affected principally by conditions or occurrences within Amgen Inc. (&#x201C;Amgen&#x201D;) and Astellas Pharma Inc. (&#x201C;Astellas&#x201D;), its strategic partners. Approximately 10%, 63% and 55% of total revenues for the years ended December&#xA0;31, 2014, 2013 and 2012, respectively, were derived from Amgen. Accounts receivable due from Amgen were $1.6 million and zero at December&#xA0;31, 2014 and 2013, respectively. See also Note&#xA0;7, &#x201C;Related Party Transactions,&#x201D; regarding the collaboration agreement with Amgen. Approximately 69% and 34% of total revenues for the years ended December&#xA0;31, 2014 and 2013, respectively, were derived from Astellas. Accounts receivable due from Astellas were $45.0 million and zero at December&#xA0;31, 2014 and 2013, respectively. See also Note&#xA0;7, &#x201C;Related Party Transactions,&#x201D; regarding the collaboration agreement with Astellas.</font></p> <p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 12px; TEXT-INDENT: 4%" align="justify"><font style="FONT-FAMILY: Times New Roman" size="2">Drug candidates developed by the Company may require approvals or clearances from the U.S.&#xA0;Food and Drug Administration (&#x201C;FDA&#x201D;) or international regulatory agencies prior to commercialized sales. There can be no assurance that the Company&#x2019;s drug candidates will receive any of the required approvals or clearances. If the Company was to be denied approval or clearance or any such approval or clearance was to be delayed, it would have a material adverse impact on the Company.</font></p> <p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 12px; TEXT-INDENT: 4%" align="justify"><font style="FONT-FAMILY: Times New Roman" size="2">The Company&#x2019;s operations and employees are located in the United States. In the year ended December&#xA0;31, 2014, 31% of the Company&#x2019;s revenues were received from entities located in the United States and 69% were received from a Japanese entity. In the year ended December&#xA0;31, 2013, 66% of the Company&#x2019;s revenues were received from entities located in the United States and 34% were received from a Japanese entity. In the year ended December&#xA0;31, 2012, all of the Company&#x2019;s revenues were received from entities located in the United States or from United States affiliates of foreign corporations.</font></p> <p style="MARGIN-BOTTOM: 0px; MARGIN-LEFT: 2%; MARGIN-TOP: 18px"> <font style="FONT-FAMILY: Times New Roman" size="2"><b><i>Cash and Cash Equivalents</i></b></font></p> <p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 6px; TEXT-INDENT: 4%" align="justify"><font style="FONT-FAMILY: Times New Roman" size="2">The Company considers all highly liquid investments with a maturity of three months or less at the time of purchase to be cash equivalents.</font></p> <p style="MARGIN-BOTTOM: 0px; MARGIN-LEFT: 2%; MARGIN-TOP: 18px"> <font style="FONT-FAMILY: Times New Roman" size="2"><b><i>Investments</i></b></font></p> <p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 6px; TEXT-INDENT: 4%" align="justify"><font style="FONT-FAMILY: Times New Roman" size="2"><i>Available-for-sale investments.</i>&#xA0;&#xA0;&#xA0;&#xA0;The Company&#x2019;s investments consist of U.S.&#xA0;Treasury securities, money market funds, U.S.&#xA0;municipal and government agency bonds, and commercial paper. The Company designates all investments as available-for-sale and therefore reports them at fair value, based on quoted marked prices, with unrealized gains and losses recorded in accumulated other comprehensive loss. The cost of securities sold is based on the specific-identification method. Investments with original maturities greater than three months and remaining maturities of one year or less are classified as short-term investments. Investments with remaining maturities greater than one year are classified as long-term investments. The amortized cost of debt securities in this category is adjusted for amortization of premiums and accretion of discounts to maturity. Such amortization is included in interest income. Recognized gains and losses and declines in value judged to be other-than-temporary, if any, on available-for-sale securities are included in other income or expense. Interest and dividends on securities classified as available-for-sale are included in Interest and other, net.</font></p> <p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 12px; TEXT-INDENT: 4%" align="justify"><font style="FONT-FAMILY: Times New Roman" size="2"><i>Other-than-temporary impairment.</i>&#xA0;&#xA0;&#xA0;&#xA0;All of the Company&#x2019;s available-for-sale investments are subject to a periodic impairment review. The Company recognizes an impairment charge when a decline in the fair value of its investments below the cost basis is judged to be other-than-temporary. Factors considered by management in assessing whether an other-than-temporary impairment has occurred include: the nature of the investment; whether the decline in fair value is attributable to specific adverse conditions affecting the investment; the financial condition of the investee; the severity and the duration of the impairment; and whether the Company has the intent and ability to hold the investment to maturity. When the Company determines that an other-than-temporary impairment has occurred, the investment is written down to its market value at the end of the period in which it is determined that an other-than-temporary decline has occurred.</font></p> <p style="MARGIN-BOTTOM: 0px; MARGIN-LEFT: 2%; MARGIN-TOP: 18px"> <font style="FONT-FAMILY: Times New Roman" size="2"><b><i>Property and Equipment</i></b></font></p> <p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 6px; TEXT-INDENT: 4%" align="justify"><font style="FONT-FAMILY: Times New Roman" size="2">Property and equipment are stated at cost less accumulated depreciation and are depreciated on a straight-line basis over the estimated useful lives of the related assets, which are generally three years for computer equipment and software, five years for laboratory equipment and office equipment, and seven years for furniture and fixtures. Amortization of leasehold improvements is computed using the straight-line method over the shorter of the remaining lease term or the estimated useful life of the related assets, typically ranging from three to seven years. Upon sale or retirement of assets, the costs and related accumulated depreciation and amortization are removed from the balance sheet and the resulting gain or loss is reflected in operations. Maintenance and repairs are charged to operations as incurred.</font></p> <p style="MARGIN-BOTTOM: 0px; MARGIN-LEFT: 2%; MARGIN-TOP: 18px"> <font style="FONT-FAMILY: Times New Roman" size="2"><b><i>Impairment of Long-lived Assets</i></b></font></p> <p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 6px; TEXT-INDENT: 4%" align="justify"><font style="FONT-FAMILY: Times New Roman" size="2">In accordance with the accounting guidance for the impairment or disposal of long-lived assets, the Company reviews long-lived assets, including property and equipment, for impairment whenever events or changes in business circumstances indicate that the carrying amount of the assets may not be fully recoverable. Under the accounting guidance, an impairment loss would be recognized when estimated undiscounted future cash flows expected to result from the use of the asset and its eventual disposition are less than its carrying amount. Impairment, if any, is measured as the amount by which the carrying amount of a long-lived asset exceeds its fair value.</font></p> <p style="MARGIN-BOTTOM: 0px; MARGIN-LEFT: 2%; MARGIN-TOP: 18px"> <font style="FONT-FAMILY: Times New Roman" size="2"><b><i>Revenue Recognition</i></b></font></p> <p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 6px; TEXT-INDENT: 4%" align="justify"><font style="FONT-FAMILY: Times New Roman" size="2">The accounting guidance for revenue recognition requires that the following criteria must be met before revenue can be recognized: (i)&#xA0;persuasive evidence of an arrangement exists; (ii)&#xA0;delivery has occurred or services have been rendered; (iii)&#xA0;the fee is fixed or determinable; and (iv)&#xA0;collectability is reasonably assured. Determination of whether persuasive evidence of an arrangement exists and whether delivery has occurred or services have been rendered are based on management&#x2019;s judgments regarding the fixed nature of the fee charged for research performed and milestones met, and the collectability of those fees. Should changes in conditions cause management to determine these criteria are not met for certain future transactions, revenue recognized for any reporting period could be adversely affected.</font></p> <p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 12px; TEXT-INDENT: 4%" align="justify"><font style="FONT-FAMILY: Times New Roman" size="2">Revenue under our license and collaboration arrangements is recognized based on the performance requirements of the contract. Research and development revenues, which are earned under agreements with third parties for agreed research and development activities, may include non-refundable license fees, research and development funding, cost reimbursements and contingent milestones and royalties. The Company&#x2019;s collaborations prior to January&#xA0;1, 2011 with multiple elements were evaluated and divided into separate units of accounting if certain criteria are met, including whether the delivered element has stand-alone value to the customer and whether there was vendor-specific objective and reliable evidence (&#x201C;VSOE&#x201D;) of the fair value of the undelivered items. The consideration the Company received was allocated among the separate units based on their respective fair values, and the applicable revenue recognition criteria were applied to each of the separate units. The consideration the Company received was combined and recognized as a single unit of accounting when criteria for separation were not met.&#xA0;On January&#xA0;1, 2011, ASC Topic 605-25, <i>Revenue Recognition &#x2014; Multiple-Element Arrangements</i> (&#x201C;ASC 605-25&#x201D;) on the recognition of revenues for agreements with multiple deliverables became effective and applies to any agreements the Company entered into on or after January&#xA0;1, 2011. Under this updated guidance, revenue is allocated to each element using a selling price hierarchy, where the selling price for an element is based on VSOE if available; third-party evidence (&#x201C;TPE&#x201D;), if available and VSOE is not available; or the best estimate of selling price, if neither VSOE nor TPE is available.</font></p> <p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 12px; TEXT-INDENT: 4%" align="justify"><font style="FONT-FAMILY: Times New Roman" size="2">Upfront, non-refundable licensing payments are assessed to determine whether or not the licensee is able to obtain stand-alone value from the license. Where the license does not have stand-alone value, non-refundable license fees are recognized as revenue as the Company performs under the applicable agreement. Where the level of effort is relatively consistent over the performance period, the Company recognizes total fixed or determined revenue on a straight-line basis over the estimated period of expected performance. Where the license has stand-alone value, the Company recognizes total license revenue at the time all revenue recognition criteria have been met.</font></p> <p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 12px; TEXT-INDENT: 4%" align="justify"><font style="FONT-FAMILY: Times New Roman" size="2">ASC Topic 605-28, <i>Revenue Recognition &#x2014; Milestone Method</i> (&#x201C;ASC 605-28&#x201D;), established the milestone method as an acceptable method of revenue recognition for certain contingent event-based payments under research and development arrangements. Under the milestone method, a payment that is contingent upon the achievement of a substantive milestone is recognized in its entirety in the period in which the milestone is achieved. A milestone is an event (i)&#xA0;that can be achieved based in whole or in part on either the Company&#x2019;s performance or on the occurrence of a specific outcome resulting from the Company&#x2019;s performance, (ii)&#xA0;for which there is substantive uncertainty at the date the arrangement is entered into that the event will be achieved, and (iii)&#xA0;that would result in additional payments being due to the Company. The determination that a milestone is substantive is judgmental and is made at the inception of the arrangement. Milestones are considered substantive when the consideration earned from the achievement of the milestone is (i)&#xA0;commensurate with either the Company&#x2019;s performance to achieve the milestone or the enhancement of value of the item delivered as a result of a specific outcome resulting from the Company&#x2019;s performance to achieve the milestone, (ii)&#xA0;relates solely to past performance and (iii)&#xA0;is reasonable relative to all deliverables and payment terms in the arrangement.</font></p> <p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 12px; TEXT-INDENT: 4%" align="justify"><font style="FONT-FAMILY: Times New Roman" size="2">Other contingent event-based payments received for which payment is either contingent solely upon the passage of time or the results of a collaborative partner&#x2019;s performance are not considered milestones under ASC 605-28. In accordance with ASC 605-25<i>,</i> such payments will be recognized as revenue when all of the following criteria are met: (i)&#xA0;persuasive evidence of an arrangement exists, (ii)&#xA0;delivery has occurred or services have been rendered, (iii)&#xA0;price is fixed or determinable, and (iv)&#xA0;collectability is reasonably assured.</font></p> <p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 12px; TEXT-INDENT: 4%" align="justify"><font style="FONT-FAMILY: Times New Roman" size="2">Prior to January&#xA0;1, 2011, the Company recognized and will continue to recognize milestone payments as revenue upon achievement of the milestone, provided the milestone payment was non-refundable, substantive effort and risk were involved in achieving the milestone and the amount of the milestone was reasonable in relation to the effort expended or risk associated with the achievement of the milestone. If these conditions were not met, the Company deferred the milestone payment and recognized it as revenue over the estimated period of performance under the contract as the Company completed its performance obligations. The Company has concluded that all of the future contingent milestone payments pursuant to its research and development arrangements entered into prior to January&#xA0;1, 2011 are not considered substantive as they are the results of a collaborative partner&#x2019;s performance. Therefore, they are not considered milestones under ASC 605-28.</font></p> <p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 12px; TEXT-INDENT: 4%" align="justify"><font style="FONT-FAMILY: Times New Roman" size="2">For collaborations and material modifications entered into after January&#xA0;1, 2011, the Company accounts for milestone payments under the provisions of ASC&#xA0;605-28. The Company considers an event to be a milestone if there is substantive uncertainty at the date the arrangement is entered into that the event will be achieved, if the event can only be achieved with the Company&#x2019;s performance, and if the achievement of the event results in payment to the Company. If the Company determines a milestone is substantive, the Company recognizes revenue when payment is earned and becomes payable. For a milestone to be considered substantive, it must be achieved with the Company&#x2019;s performance, be reasonable relative to the terms of the arrangement and be commensurate with the Company&#x2019;s effort to achieve the milestone or commensurate with the enhanced value of the delivered item(s) as a result of the milestone achievement. If the Company determines a milestone is not substantive, the Company defers the payment and recognizes revenue over the estimated period of performance as the Company completes its performance obligations.</font></p> <p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 12px; TEXT-INDENT: 4%" align="justify"><font style="FONT-FAMILY: Times New Roman" size="2">Research and development revenues and cost reimbursements are based upon negotiated rates for the Company&#x2019;s full-time employee equivalents (&#x201C;FTE&#x201D;) and actual out-of-pocket costs. FTE rates are negotiated rates that are based upon the Company&#x2019;s costs, and which the Company believes approximate fair value. Any amounts received in advance of performance are recorded as deferred revenue. None of the revenues recognized to date are refundable if the relevant research effort is not successful. In revenue arrangements in which both parties make payments to each other, the Company evaluates the payments in accordance with the accounting guidance for arrangements under which consideration is given by a vendor to a customer, including a reseller of the vendor&#x2019;s products, to determine whether payments made by us will be recognized as a reduction of revenue or as expense. In accordance with this guidance, revenue recognized by the Company may be reduced by payments made to the other party under the arrangement unless the Company receives a separate and identifiable benefit in exchange for the payments and the Company can reasonably estimate the fair value of the benefit received. The application of the accounting guidance for consideration given to a customer has had no material impact to the Company.</font></p> <p style="MARGIN-BOTTOM: 0px; FONT-SIZE: 12px; MARGIN-TOP: 0px"> &#xA0;</p> <p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 0px; TEXT-INDENT: 4%" align="justify"><font style="FONT-FAMILY: Times New Roman" size="2">Funds received from third parties under grant arrangements are recorded as revenue if the Company is deemed to be the principal participant in the grant arrangement as the activities under the grant are part of the Company&#x2019;s development program. If the Company is not the principal participant, the grant funds are recorded as a reduction to research and development expense. Grant funds received are not refundable and are recognized when the related qualified research and development costs are incurred and when there is reasonable assurance that the funds will be received. Funds received in advance are recorded as deferred revenue.</font></p> <p style="MARGIN-BOTTOM: 0px; MARGIN-LEFT: 2%; MARGIN-TOP: 18px"> <font style="FONT-FAMILY: Times New Roman" size="2"><b><i>Preclinical Studies and Clinical Trial Accruals</i></b></font></p> <p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 6px; TEXT-INDENT: 4%" align="justify"><font style="FONT-FAMILY: Times New Roman" size="2">A substantial portion of the Company&#x2019;s preclinical studies and all of the Company&#x2019;s clinical trials have been performed by third-party contract research organizations (&#x201C;CROs&#x201D;) and other vendors. For preclinical studies, the significant factors used in estimating accruals include the percentage of work completed to date and contract milestones achieved. For clinical trial expenses, the significant factors used in estimating accruals include the number of patients enrolled, duration of enrollment and percentage of work completed to date. The Company monitors patient enrollment levels and related activities to the extent practicable through internal reviews, correspondence and status meetings with CROs, and review of contractual terms. The Company&#x2019;s estimates are dependent on the timeliness and accuracy of data provided by its CROs and other vendors. If the Company has incomplete or inaccurate data, it may under- or overestimate activity levels associated with various studies or trials at a given point in time. In this event, it could record adjustments to research and development expenses in future periods when the actual activity level becomes known. No material adjustments to preclinical study and clinical trial expenses have been recognized to date.</font></p> <p style="MARGIN-BOTTOM: 0px; MARGIN-LEFT: 2%; MARGIN-TOP: 18px"> <font style="FONT-FAMILY: Times New Roman" size="2"><b><i>Research and Development Expenditures</i></b></font></p> <p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 6px; TEXT-INDENT: 4%" align="justify"><font style="FONT-FAMILY: Times New Roman" size="2">Research and development costs are charged to operations as incurred. Research and development expenses consist primarily of clinical manufacturing costs, preclinical study expenses, consulting and other third party costs, employee compensation, supplies and materials, allocation of overhead and occupancy costs, facilities costs and depreciation of equipment.</font></p> <p style="MARGIN-BOTTOM: 0px; MARGIN-LEFT: 2%; MARGIN-TOP: 18px"> <font style="FONT-FAMILY: Times New Roman" size="2"><b><i>Retirement Plan</i></b></font></p> <p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 6px; TEXT-INDENT: 4%" align="justify"><font style="FONT-FAMILY: Times New Roman" size="2">The Company sponsors a 401(k) defined contribution plan covering all employees. There were no employer contributions to the plan from inception through December&#xA0;31, 2013. In 2014, employer contributions to the 401(k) plan were $336,000.</font></p> <p style="MARGIN-BOTTOM: 0px; MARGIN-LEFT: 2%; MARGIN-TOP: 18px"> <font style="FONT-FAMILY: Times New Roman" size="2"><b><i>Income Taxes</i></b></font></p> <p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 6px; TEXT-INDENT: 4%" align="justify"><font style="FONT-FAMILY: Times New Roman" size="2">The Company accounts for income taxes under the asset and liability method. Under this method, deferred tax assets and liabilities are determined based on the difference between the financial statement and tax basis of assets and liabilities using enacted tax rates in effect for the year in which the differences are expected to affect taxable income. Valuation allowances are established when necessary to reduce deferred tax assets to the amounts expected to be realized.</font></p> <p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 12px; TEXT-INDENT: 4%" align="justify"><font style="FONT-FAMILY: Times New Roman" size="2">The Company also follows the accounting guidance that defines the threshold for recognizing the benefits of tax return positions in the financial statements as &#x201C;more-likely-than-not&#x201D; to be sustained by the taxing authorities based solely on the technical merits of the position. If the recognition threshold is met, the tax benefit is measured and recognized as the largest amount of tax benefit that, in the Company&#x2019;s judgment, is greater than 50% likely to be realized.</font></p> <p style="MARGIN-BOTTOM: 0px; FONT-SIZE: 18px; MARGIN-TOP: 0px"> &#xA0;</p> <p style="MARGIN-BOTTOM: 0px; MARGIN-LEFT: 2%; MARGIN-TOP: 0px"> <font style="FONT-FAMILY: Times New Roman" size="2"><b><i>Comprehensive Loss</i></b></font></p> <p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 6px; TEXT-INDENT: 4%" align="justify"><font style="FONT-FAMILY: Times New Roman" size="2">The Company follows the accounting standards for the reporting and presentation of comprehensive income (loss) and its components. On January&#xA0;1, 2012, the Company adopted new accounting guidance and presents comprehensive income (loss) in a continuous statement of comprehensive income (loss) which replaced the statement of operations. Comprehensive loss includes all changes in stockholders&#x2019; equity during a period from non-owner sources. Comprehensive loss for each of the years ended December&#xA0;31, 2014, 2013, and 2012 was equal to net loss adjusted for unrealized gains and losses on investments.</font></p> <p style="MARGIN-BOTTOM: 0px; MARGIN-LEFT: 2%; MARGIN-TOP: 18px"> <font style="FONT-FAMILY: Times New Roman" size="2"><b><i>Segment Reporting</i></b></font></p> <p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 6px; TEXT-INDENT: 4%" align="justify"><font style="FONT-FAMILY: Times New Roman" size="2">The Company has determined that it operates in only one segment.</font></p> <p style="MARGIN-BOTTOM: 0px; MARGIN-LEFT: 2%; MARGIN-TOP: 18px"> <font style="FONT-FAMILY: Times New Roman" size="2"><b><i>Reverse Stock Split</i></b></font></p> <p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 6px; TEXT-INDENT: 4%" align="justify"><font style="FONT-FAMILY: Times New Roman" size="2">On&#xA0;June&#xA0;24, 2013, the Company effected a one-for-six reverse stock split of its common stock through an amendment to its amended and restated certificate of incorporation (the &#x201C;COI Amendment&#x201D;). As of the effective time of the reverse stock split, every six shares of the Company&#x2019;s issued and outstanding common stock were converted into one issued and outstanding share of common stock, without any change in par value per share. The reverse stock split affected all shares of the Company&#x2019;s common stock outstanding immediately prior to the effective time of the reverse stock split, as well as the number of shares of common stock available for issuance under the Company&#x2019;s equity incentive plans. In addition, the reverse stock split effected a reduction in the number of shares of common stock issuable upon the conversion of shares of preferred stock or upon the exercise of stock options or warrants outstanding immediately prior to the effectiveness of the reverse stock split. No fractional shares were issued as a result of the reverse stock split. Stockholders who would otherwise have been entitled to receive a fractional share received cash payments in lieu thereof. In addition, the COI Amendment reduced the number of authorized shares of common stock to 81.5&#xA0;million.</font></p> <p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 12px; TEXT-INDENT: 4%" align="justify"><font style="FONT-FAMILY: Times New Roman" size="2">As the par value per share of the Company&#x2019;s common stock remained unchanged at $0.001 per share, a total of $139,000 was reclassified from common stock to additional paid-in capital. All references to shares of common stock and per share data for all periods presented in the accompanying financial statements and notes thereto have been adjusted to reflect the reverse stock split on a retroactive basis.</font></p> <p style="MARGIN-BOTTOM: 0px; MARGIN-LEFT: 2%; MARGIN-TOP: 18px"> <font style="FONT-FAMILY: Times New Roman" size="2"><b><i>Stock-Based Compensation</i></b></font></p> <p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 6px; TEXT-INDENT: 4%" align="justify"><font style="FONT-FAMILY: Times New Roman" size="2">The Company accounts for stock-based payment awards made to employees and directors, including employee stock options and employee stock purchases by measuring the stock-based compensation cost at the grant date based on the calculated fair value of the award, and recognizing expense on a straight-line basis over the employee&#x2019;s requisite service period, generally the vesting period of the award. Stock compensation for non-employees is measured at the fair value of the award for each period until the award is fully vested.</font></p> <p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 12px; TEXT-INDENT: 4%" align="justify"><font style="FONT-FAMILY: Times New Roman" size="2">The Company reviews the valuation assumptions at each grant date and, as a result, from time to time it will likely change the valuation assumptions it uses to value stock based awards granted in future periods. The assumptions used in calculating the fair value of share-based payment awards represent management&#x2019;s best estimates at the time, but these estimates involve inherent uncertainties and the application of management judgment. As a result, if conditions change and the management uses different assumptions, the Company&#x2019;s stock-based compensation expense could be materially different in the future. In addition, the Company is required to estimate the expected forfeiture rate and recognize expense only for those shares expected to vest. If the actual forfeiture rate is materially different from management&#x2019;s estimate, stock-based compensation expense could be significantly different from what has been recorded in the current period.</font></p> <p style="MARGIN-BOTTOM: 0px; FONT-SIZE: 18px; MARGIN-TOP: 0px"> &#xA0;</p> <p style="MARGIN-BOTTOM: 0px; MARGIN-LEFT: 2%; MARGIN-TOP: 0px"> <font style="FONT-FAMILY: Times New Roman" size="2"><b><i>Recent Accounting Pronouncements</i></b></font></p> <p style="MARGIN-BOTTOM: 0px; MARGIN-LEFT: 2%; MARGIN-TOP: 6px"> <font style="FONT-FAMILY: Times New Roman" size="2"><i>Recently Adopted Accounting Pronouncements</i></font></p> <p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 6px; TEXT-INDENT: 4%" align="justify"><font style="FONT-FAMILY: Times New Roman" size="2">In July 2013, the FASB issued ASU 2013-11, <i>Presentation of an Unrecognized Tax Benefit When a Net Operating Loss Carryforward, a Similar Tax Loss, or a Tax Credit Carryforward Exists</i>. ASU 2013-11 amends accounting guidance on the presentation of an unrecognized tax benefit when a net operating loss carryforward, a similar tax loss, or tax credit carryforward exists. This new guidance requires entities, if certain criteria are met, to present an unrecognized tax benefit, or portion of an unrecognized tax benefit, in the financial statements as a reduction to a deferred tax asset for a net operating loss carryforward, a similar tax loss, or a tax credit carryforward when such items exist in the same taxing jurisdiction. The Company adopted ASU 2013-11 effective January&#xA0;1, 2014 and the adoption of ASU 2013-11 did not have a material effect on its financial statements.</font></p> <p style="MARGIN-BOTTOM: 0px; MARGIN-LEFT: 2%; MARGIN-TOP: 18px"> <font style="FONT-FAMILY: Times New Roman" size="2"><i>Accounting Pronouncements Not Yet Adopted</i></font></p> <p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 6px; TEXT-INDENT: 4%" align="justify"><font style="FONT-FAMILY: Times New Roman" size="2">In November 2014, the FASB issued ASU 2014-17, <i>Business Combinations (Topic 805) &#x2014; Pushdown Accounting (a consensus of the FASB Emerging Issues Task Force).</i> This guidance provides the option for an acquired entity to apply pushdown accounting in its separately issued financial statements when a change-in-control event occurs. This guidance is effective beginning November&#xA0;18, 2014, and is applicable to change-in-control events occurring after that date or applied to the most recent change-in-control event if financial statements have not yet been issued. The Company does not expect the adoption of ASU 2014-17 to have a material effect upon its financial statements.</font></p> <p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 12px; TEXT-INDENT: 4%" align="justify"><font style="FONT-FAMILY: Times New Roman" size="2">In August 2014, the FASB issued ASU 2014-15, <i>Presentation of Financial Statements &#x2014; Going Concern (Subtopic 205-40): Disclosure of Uncertainties about an Entity&#x2019;s Ability to Continue as a Going Concern.</i> ASU&#xA0;214-15 requires management to assess an entity&#x2019;s ability to continue as a going concern, and to provide related footnote disclosures in certain circumstances. ASU 2014-15 is effective for annual and interim reporting periods beginning on or after December&#xA0;15, 2016 and early adoption is permitted. The Company does not expect the adoption of ASU 2014-15 to have a material effect upon its financial statements.</font></p> <p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 12px; TEXT-INDENT: 4%" align="justify"><font style="FONT-FAMILY: Times New Roman" size="2">In May 2014, the FASB issued ASU 2014-09, <i>Revenue from Contracts with Customers (Topic 606)</i>, which supersedes the revenue recognition requirements in ASC 605, <i>Revenue Recognition</i>. ASU&#xA0;2014-09 stipulates that an entity should recognize revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. ASU&#xA0;2014-09 also requires additional disclosure about the nature, amount, timing and uncertainty of revenue and cash flows arising from customer contracts, including significant judgments and changes in judgments and assets recognized from costs incurred to obtain or fulfill a contract. ASU&#xA0;2014-09 is effective for annual and interim reporting periods beginning on or after December&#xA0;15, 2016, and early adoption is not permitted. ASU&#xA0;2014-09 permits the use of two transition methods, either retrospectively to each prior reporting period presented or as a cumulative-effect adjustment as of the date of adoption. The Company has not yet selected a transition method, and is currently evaluating the impact of the adoption of ASU&#xA0;2014-09 on its consolidated financial statements.</font></p> <p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 12px; TEXT-INDENT: 4%" align="justify"><font style="FONT-FAMILY: Times New Roman" size="2">In April 2014, the FASB issued ASU 2014-08, <i>Reporting Discontinued Operations and Disclosures of Disposals of Components of an Entity</i>. ASU 2014-08 changes the criteria for determining which disposals can be presented as discontinued operations and modifies related disclosure requirements. This new guidance is effective for the Company beginning January&#xA0;1, 2015. The Company does not expect the adoption of ASU 2014-08 to have a material effect upon its financial statements.</font></p> </div></us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock> <us-gaap:PensionAndOtherPostretirementPlansPolicy contextRef="eol_PE151383--1410-K0012_STD_365_20141231_0" id="id_6895476_E7561396-24A6-44AA-B65E-064AA9B8B09C_1_0"><div> <p style="MARGIN-BOTTOM: 0px; MARGIN-LEFT: 2%; MARGIN-TOP: 18px"> <font style="FONT-FAMILY: Times New Roman" size="2"><b><i>Retirement Plan</i></b></font></p> <p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 6px; TEXT-INDENT: 4%" align="justify"><font style="FONT-FAMILY: Times New Roman" size="2">The Company sponsors a 401(k) defined contribution plan covering all employees. There were no employer contributions to the plan from inception through December&#xA0;31, 2013. In 2014, employer contributions to the 401(k) plan were $336,000.</font></p> </div></us-gaap:PensionAndOtherPostretirementPlansPolicy> <us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock contextRef="eol_PE151383--1410-K0012_STD_365_20141231_0" id="id_6895476_4A7D9166-E53B-4FEC-B799-EB4DE34C1B28_1_0"><div> <p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 12px; TEXT-INDENT: 4%" align="justify"><font style="FONT-FAMILY: Times New Roman" size="2">Outstanding warrants as of December&#xA0;31, 2014 were as follows:</font></p> <p style="MARGIN-BOTTOM: 0px; FONT-SIZE: 12px; MARGIN-TOP: 0px"> &#xA0;</p> <table style="BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="92%" align="center" border="0"> <tr> <td width="67%"></td> <td valign="bottom" width="4%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="4%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="4%"></td> <td></td> <td></td> <td></td> </tr> <tr> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" align="center"><font style="FONT-FAMILY: Times New Roman" size="1"><b>Number<br /> of Shares</b></font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" align="center"><font style="FONT-FAMILY: Times New Roman" size="1"><b>Exercise<br /> Price</b></font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" align="center"><font style="FONT-FAMILY: Times New Roman" size="1"><b>Expiration<br /> Date</b></font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> </tr> <tr bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: Times New Roman" size="2">Issued 4/20/2011</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">1,114,168</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">9.90</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">04/20/15</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> </tr> <tr> <td valign="top"> <p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: Times New Roman" size="2">Issued 6/25/2012</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">5,576,928</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">5.28</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">06/25/17</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> </tr> </table> </div></us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock> <us-gaap:SegmentReportingPolicyPolicyTextBlock contextRef="eol_PE151383--1410-K0012_STD_365_20141231_0" id="id_6895476_B2A9BFEB-0FB5-43F5-BFF2-880FABDC804D_1_0"><div> <p style="MARGIN-BOTTOM: 0px; MARGIN-LEFT: 2%; MARGIN-TOP: 18px"> <font style="FONT-FAMILY: Times New Roman" size="2"><b><i>Segment Reporting</i></b></font></p> <p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 6px; TEXT-INDENT: 4%" align="justify"><font style="FONT-FAMILY: Times New Roman" size="2">The Company has determined that it operates in only one segment.</font></p> </div></us-gaap:SegmentReportingPolicyPolicyTextBlock> <dei:DocumentFiscalPeriodFocus contextRef="eol_PE151383--1410-K0012_STD_365_20141231_0" id="id_6895476_BB2FF52D-3F86-4944-B60D-74EA496D7B67_1_4">FY</dei:DocumentFiscalPeriodFocus> <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="eol_PE151383--1410-K0012_STD_365_20141231_0" unitRef="shares" decimals="-3" id="id_6895476_3E2C7E3E-7982-4F2C-A6E3-5C7781C1D9F7_1_5">10067000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount> <us-gaap:ConcentrationRiskCreditRisk contextRef="eol_PE151383--1410-K0012_STD_365_20141231_0" id="id_6895476_19E2707E-DEE9-4A02-B788-DBCEC1D86F2B_1_0"><div> <p style="MARGIN-BOTTOM: 0px; MARGIN-LEFT: 2%; MARGIN-TOP: 18px"> <font style="FONT-FAMILY: Times New Roman" size="2"><b><i>Concentration of Credit Risk and Other Risks and Uncertainties</i></b></font></p> <p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 6px; TEXT-INDENT: 4%" align="justify"><font style="FONT-FAMILY: Times New Roman" size="2">Financial instruments that potentially subject the Company to concentrations of risk consist principally of cash and cash equivalents, investments and accounts receivable.</font></p> <p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 12px; TEXT-INDENT: 4%" align="justify"><font style="FONT-FAMILY: Times New Roman" size="2">The Company&#x2019;s cash, cash equivalents and investments are invested in deposits with three major financial institutions in the United States.&#xA0;Deposits in these banks may exceed the amount of insurance provided on such deposits. The Company has not experienced any realized losses on its deposits of cash, cash equivalents or investments.</font></p> <p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 12px; TEXT-INDENT: 4%" align="justify"><font style="FONT-FAMILY: Times New Roman" size="2">The economic turmoil in the United States in recent years, the extraordinary volatility in the stock markets and other current negative macroeconomic indicators could negatively impact the Company&#x2019;s ability to raise the funds necessary to support its business and may materially adversely affect its business, operating results and financial condition.</font></p> <p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 12px; TEXT-INDENT: 4%" align="justify"><font style="FONT-FAMILY: Times New Roman" size="2">The Company performs an ongoing credit evaluation of its strategic partners&#x2019; financial conditions and generally does not require collateral to secure accounts receivable from its strategic partners. The Company&#x2019;s exposure to credit risk associated with non-payment will be affected principally by conditions or occurrences within Amgen Inc. (&#x201C;Amgen&#x201D;) and Astellas Pharma Inc. (&#x201C;Astellas&#x201D;), its strategic partners. Approximately 10%, 63% and 55% of total revenues for the years ended December&#xA0;31, 2014, 2013 and 2012, respectively, were derived from Amgen. Accounts receivable due from Amgen were $1.6 million and zero at December&#xA0;31, 2014 and 2013, respectively. See also Note&#xA0;7, &#x201C;Related Party Transactions,&#x201D; regarding the collaboration agreement with Amgen. Approximately 69% and 34% of total revenues for the years ended December&#xA0;31, 2014 and 2013, respectively, were derived from Astellas. Accounts receivable due from Astellas were $45.0 million and zero at December&#xA0;31, 2014 and 2013, respectively. See also Note&#xA0;7, &#x201C;Related Party Transactions,&#x201D; regarding the collaboration agreement with Astellas.</font></p> <p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 12px; TEXT-INDENT: 4%" align="justify"><font style="FONT-FAMILY: Times New Roman" size="2">Drug candidates developed by the Company may require approvals or clearances from the U.S.&#xA0;Food and Drug Administration (&#x201C;FDA&#x201D;) or international regulatory agencies prior to commercialized sales. There can be no assurance that the Company&#x2019;s drug candidates will receive any of the required approvals or clearances. If the Company was to be denied approval or clearance or any such approval or clearance was to be delayed, it would have a material adverse impact on the Company.</font></p> <p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 12px; TEXT-INDENT: 4%" align="justify"><font style="FONT-FAMILY: Times New Roman" size="2">The Company&#x2019;s operations and employees are located in the United States. In the year ended December&#xA0;31, 2014, 31% of the Company&#x2019;s revenues were received from entities located in the United States and 69% were received from a Japanese entity. In the year ended December&#xA0;31, 2013, 66% of the Company&#x2019;s revenues were received from entities located in the United States and 34% were received from a Japanese entity. In the year ended December&#xA0;31, 2012, all of the Company&#x2019;s revenues were received from entities located in the United States or from United States affiliates of foreign corporations.</font></p> </div></us-gaap:ConcentrationRiskCreditRisk> <us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost contextRef="eol_PE151383--1410-K0012_STD_365_20141231_0" unitRef="pure" decimals="2" id="id_6895476_14EF385A-3844-4F78-AE65-D20D0D541C15_1_5">0.05</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost> <us-gaap:NumberOfReportableSegments contextRef="eol_PE151383--1410-K0012_STD_365_20141231_0" unitRef="Segment" decimals="INF" id="id_6895476_603D6782-F8E1-4C09-8DA0-F407015C833A_1_0">1</us-gaap:NumberOfReportableSegments> <us-gaap:PropertyPlantAndEquipmentTextBlock contextRef="eol_PE151383--1410-K0012_STD_365_20141231_0" id="id_6895476_11245713-6384-477C-871E-037E14B80DB7_1_0"><div> <p style="margin-top:6px;margin-bottom:0px; text-indent:4%" align="justify"><font style="font-family:Times New Roman" size="2">Property and equipment balances were as follows (in thousands):</font></p> <p style="font-size:12px;margin-top:0px;margin-bottom:0px"> &#xA0;</p> <table cellspacing="0" cellpadding="0" width="92%" border="0" style="BORDER-COLLAPSE:COLLAPSE" align="center"> <tr> <td width="77%"></td> <td valign="bottom" width="6%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="5%"></td> <td></td> <td></td> <td></td> </tr> <tr> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom" colspan="6" align="center" style="border-bottom:1px solid #000000"><font style="font-family:Times New Roman" size="1"><b>December&#xA0;31,</b></font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> </tr> <tr> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom" colspan="2" align="center" style="border-bottom:1px solid #000000"><font style="font-family:Times New Roman" size="1"><b>2014</b></font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom" colspan="2" align="center" style="border-bottom:1px solid #000000"><font style="font-family:Times New Roman" size="1"><b>2013</b></font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> </tr> <tr bgcolor="#CCEEFF"> <td valign="top"> <p style="margin-left:1.00em; text-indent:-1.00em"><font style="font-family:Times New Roman" size="2">Property and equipment, net:</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr> <td valign="top"> <p style="margin-left:2.00em; text-indent:-1.00em"><font style="font-family:Times New Roman" size="2">Laboratory equipment</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="font-family:Times New Roman" size="2">$</font></td> <td valign="bottom" align="right"><font style="font-family:Times New Roman" size="2">15,299</font></td> <td nowrap="nowrap" valign="bottom"><font style="font-family:Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="font-family:Times New Roman" size="2">$</font></td> <td valign="bottom" align="right"><font style="font-family:Times New Roman" size="2">15,317</font></td> <td nowrap="nowrap" valign="bottom"><font style="font-family:Times New Roman" size="2">&#xA0;&#xA0;</font></td> </tr> <tr bgcolor="#CCEEFF"> <td valign="top"> <p style="margin-left:2.00em; text-indent:-1.00em"><font style="font-family:Times New Roman" size="2">Computer equipment and software</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="font-family:Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="font-family:Times New Roman" size="2">2,418</font></td> <td nowrap="nowrap" valign="bottom"><font style="font-family:Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="font-family:Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="font-family:Times New Roman" size="2">2,549</font></td> <td nowrap="nowrap" valign="bottom"><font style="font-family:Times New Roman" size="2">&#xA0;&#xA0;</font></td> </tr> <tr> <td valign="top"> <p style="margin-left:2.00em; text-indent:-1.00em"><font style="font-family:Times New Roman" size="2">Office equipment, furniture and fixtures</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="font-family:Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="font-family:Times New Roman" size="2">913</font></td> <td nowrap="nowrap" valign="bottom"><font style="font-family:Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="font-family:Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="font-family:Times New Roman" size="2">1,050</font></td> <td nowrap="nowrap" valign="bottom"><font style="font-family:Times New Roman" size="2">&#xA0;&#xA0;</font></td> </tr> <tr bgcolor="#CCEEFF"> <td valign="top"> <p style="margin-left:2.00em; text-indent:-1.00em"><font style="font-family:Times New Roman" size="2">Leasehold improvements</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="font-family:Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="font-family:Times New Roman" size="2">3,334</font></td> <td nowrap="nowrap" valign="bottom"><font style="font-family:Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="font-family:Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="font-family:Times New Roman" size="2">3,297</font></td> <td nowrap="nowrap" valign="bottom"><font style="font-family:Times New Roman" size="2">&#xA0;&#xA0;</font></td> </tr> <tr style="font-size:1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="border-top:1px solid #000000">&#xA0;</p> </td> <td valign="bottom"> <p style="border-top:1px solid #000000">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="border-top:1px solid #000000">&#xA0;</p> </td> <td valign="bottom"> <p style="border-top:1px solid #000000">&#xA0;</p> </td> <td>&#xA0;</td> </tr> <tr> <td valign="top"></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="font-family:Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="font-family:Times New Roman" size="2">21,964</font></td> <td nowrap="nowrap" valign="bottom"><font style="font-family:Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="font-family:Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="font-family:Times New Roman" size="2">22,213</font></td> <td nowrap="nowrap" valign="bottom"><font style="font-family:Times New Roman" size="2">&#xA0;&#xA0;</font></td> </tr> <tr bgcolor="#CCEEFF"> <td valign="top"> <p style="margin-left:2.00em; text-indent:-1.00em"><font style="font-family:Times New Roman" size="2">Less: Accumulated depreciation and amortization</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="font-family:Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="font-family:Times New Roman" size="2">(20,327</font></td> <td nowrap="nowrap" valign="bottom"><font style="font-family:Times New Roman" size="2">)&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="font-family:Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="font-family:Times New Roman" size="2">(20,992</font></td> <td nowrap="nowrap" valign="bottom"><font style="font-family:Times New Roman" size="2">)&#xA0;</font></td> </tr> <tr style="font-size:1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="border-top:1px solid #000000">&#xA0;</p> </td> <td valign="bottom"> <p style="border-top:1px solid #000000">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="border-top:1px solid #000000">&#xA0;</p> </td> <td valign="bottom"> <p style="border-top:1px solid #000000">&#xA0;</p> </td> <td>&#xA0;</td> </tr> <tr> <td valign="top"></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="font-family:Times New Roman" size="2">$</font></td> <td valign="bottom" align="right"><font style="font-family:Times New Roman" size="2">1,637</font></td> <td nowrap="nowrap" valign="bottom"><font style="font-family:Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="font-family:Times New Roman" size="2">$</font></td> <td valign="bottom" align="right"><font style="font-family:Times New Roman" size="2">1,221</font></td> <td nowrap="nowrap" valign="bottom"><font style="font-family:Times New Roman" size="2">&#xA0;&#xA0;</font></td> </tr> <tr style="font-size:1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="border-top:3px double #000000">&#xA0;</p> </td> <td valign="bottom"> <p style="border-top:3px double #000000">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="border-top:3px double #000000">&#xA0;</p> </td> <td valign="bottom"> <p style="border-top:3px double #000000">&#xA0;</p> </td> <td>&#xA0;</td> </tr> </table> </div></us-gaap:PropertyPlantAndEquipmentTextBlock> <us-gaap:ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock contextRef="eol_PE151383--1410-K0012_STD_365_20141231_0" id="id_6895476_5AE2BFA2-4D90-46A5-8EDB-76A843CDAC2F_1_0"><div> <p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 6px; TEXT-INDENT: 4%" align="justify"><font style="FONT-FAMILY: Times New Roman" size="2">Supplemental cash flow information was as follows (in thousands):</font></p> <p style="MARGIN-BOTTOM: 0px; FONT-SIZE: 12px; MARGIN-TOP: 0px"> &#xA0;</p> <table style="BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="92%" align="center" border="0"> <tr> <td width="78%"></td> <td valign="bottom" width="6%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="6%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="5%"></td> <td></td> <td></td> <td></td> </tr> <tr> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="10" align="center"><font style="FONT-FAMILY: Times New Roman" size="1"><b>Years Ended<br /> December&#xA0;31,</b></font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> </tr> <tr> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" align="center"><font style="FONT-FAMILY: Times New Roman" size="1"><b>2014</b></font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" align="center"><font style="FONT-FAMILY: Times New Roman" size="1"><b>2013</b></font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" align="center"><font style="FONT-FAMILY: Times New Roman" size="1"><b>2012</b></font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> </tr> <tr bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: Times New Roman" size="2">Cash paid for interest</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td> <td valign="bottom" nowrap="nowrap" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">&#x2014;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td> <td valign="bottom" nowrap="nowrap" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">&#x2014;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">3</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> </tr> <tr> <td valign="top"> <p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: Times New Roman" size="2">Cash paid for income taxes</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">1</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">1</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">1</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> </tr> <tr bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: Times New Roman" size="2">Significant non-cash investing and financing activities:</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr> <td valign="top"> <p style="MARGIN-LEFT: 2em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: Times New Roman" size="2">Purchases of property and equipment through accounts payable</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">170</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">193</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">116</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> </tr> <tr bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-LEFT: 2em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: Times New Roman" size="2">Purchases of property and equipment through accrued liabilities</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">27</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">(2</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">)&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">37</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> </tr> <tr> <td valign="top"> <p style="MARGIN-LEFT: 2em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: Times New Roman" size="2">Purchases of property and equipment through trade in value of disposed property and equipment</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" nowrap="nowrap" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">&#x2014;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">81</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" nowrap="nowrap" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">&#x2014;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> </tr> </table> </div></us-gaap:ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock> <us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock contextRef="eol_PE151383--1410-K0012_STD_365_20141231_0" id="id_6895476_7BC08E30-7AEA-4EC7-BBA7-C5ACE8D97269_1_0"><div> <p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 12px; TEXT-INDENT: 4%" align="justify"><font style="FONT-FAMILY: Times New Roman" size="2">The following is a tabular reconciliation of the total amounts of unrecognized tax benefits (&#x201C;UTBs&#x201D;) (in thousands):</font></p> <p style="MARGIN-BOTTOM: 0px; FONT-SIZE: 12px; MARGIN-TOP: 0px"> &#xA0;</p> <table style="BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="100%" align="center" border="0"> <tr> <td width="55%"></td> <td valign="bottom" width="10%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="10%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="10%"></td> <td></td> <td></td> <td></td> </tr> <tr> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" align="center"><font style="FONT-FAMILY: Times New Roman" size="1"><b>Federal<br /> and&#xA0;State<br /> Tax</b></font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" align="center"><font style="FONT-FAMILY: Times New Roman" size="1"><b>Federal&#xA0;Tax&#xA0;Benefit<br /> of&#xA0;State&#xA0;Income&#xA0;Tax<br /> UTBs</b></font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" align="center"><font style="FONT-FAMILY: Times New Roman" size="1"><b>Unrecognized&#xA0;Income&#xA0;Tax<br /> Benefits&#xA0;-&#xA0;Net of Federal<br /> Benefit of State UTBs</b></font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> </tr> <tr bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-LEFT: 2em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: Times New Roman" size="2">Unrecognized tax benefits balance at December&#xA0;31, 2012</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">5,340</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">1,158</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">4,182</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> </tr> <tr> <td valign="top"> <p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: Times New Roman" size="2">Addition for tax positions of prior years</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">24</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">8</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">16</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> </tr> <tr bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: Times New Roman" size="2">Addition for tax positions related to the current year</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">807</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">43</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">764</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> </tr> <tr> <td valign="top"> <p style="MARGIN-LEFT: 2em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: Times New Roman" size="2">Unrecognized tax benefits balance at December&#xA0;31, 2013</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">6,171</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">1,209</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">4,962</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> </tr> <tr bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: Times New Roman" size="2">Reductions for tax positions of prior years</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">(85</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">)&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">(29</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">)&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">(56</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">)&#xA0;</font></td> </tr> <tr> <td valign="top"> <p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: Times New Roman" size="2">Addition for tax positions related to the current year</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">188</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">10</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">178</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> </tr> <tr bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-LEFT: 2em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: Times New Roman" size="2">Unrecognized tax benefits balance at December&#xA0;31, 2014</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">6,274</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">1,190</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">5,084</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td>&#xA0;</td> </tr> </table> </div></us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock> <dei:EntityCurrentReportingStatus contextRef="eol_PE151383--1410-K0012_STD_365_20141231_0" id="id_6895476_719DD5F0-2E9A-450E-B7C0-E6D7E07576A8_1_400005">Yes</dei:EntityCurrentReportingStatus> <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures contextRef="eol_PE151383--1410-K0012_STD_365_20141231_0" unitRef="iso4217_USD" decimals="-3" id="id_6895476_58E9B802-84A6-48EC-8C22-C0DD0182E686_14008_66">-96000</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures> <us-gaap:RevenueFromGrants contextRef="eol_PE151383--1410-K0012_STD_365_20141231_0" unitRef="iso4217_USD" decimals="-3" id="id_6895476_FD977883-B531-4443-8A85-7DBADCAD1197_1_2">75000</us-gaap:RevenueFromGrants> <us-gaap:RepaymentsOfSecuredDebt contextRef="eol_PE151383--1410-K0012_STD_365_20141231_0" unitRef="iso4217_USD" decimals="-3" id="id_6895476_84756BCF-71FA-4E32-A511-A3DCED215C30_1_28">0</us-gaap:RepaymentsOfSecuredDebt> <us-gaap:PaymentsOfStockIssuanceCosts contextRef="eol_PE151383--1410-K0012_STD_365_20141231_0" unitRef="iso4217_USD" decimals="-3" id="id_6895476_58E9B802-84A6-48EC-8C22-C0DD0182E686_14008_82">2800000</us-gaap:PaymentsOfStockIssuanceCosts> <us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt contextRef="eol_PE151383--1410-K0012_STD_365_20141231_0" unitRef="iso4217_USD" decimals="-3" id="id_6895476_84756BCF-71FA-4E32-A511-A3DCED215C30_1_17">107043000</us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt> <us-gaap:IncreaseDecreaseInRestrictedCash contextRef="eol_PE151383--1410-K0012_STD_365_20141231_0" unitRef="iso4217_USD" decimals="-3" id="id_6895476_84756BCF-71FA-4E32-A511-A3DCED215C30_1_21">0</us-gaap:IncreaseDecreaseInRestrictedCash> <us-gaap:IncomeTaxesPaidNet contextRef="eol_PE151383--1410-K0012_STD_365_20141231_0" unitRef="iso4217_USD" decimals="-3" id="id_6895476_822093A4-C207-4594-84E4-6C13CA36E168_1_1">1000</us-gaap:IncomeTaxesPaidNet> <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign contextRef="eol_PE151383--1410-K0012_STD_365_20141231_0" unitRef="iso4217_USD" decimals="-3" id="id_6895476_7D9738C0-6CE1-4E3E-8312-71FD14F9FEB0_1_1">0</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign> <us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount contextRef="eol_PE151383--1410-K0012_STD_365_20141231_0" unitRef="iso4217_USD" decimals="-5" id="id_6895476_172A3583-D769-410E-B05B-9FA47EC31BD7_1_0">1000000</us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount> <us-gaap:OtherComprehensiveIncomeLossNetOfTax contextRef="eol_PE151383--1410-K0012_STD_365_20141231_0" unitRef="iso4217_USD" decimals="-3" id="id_6895476_58E9B802-84A6-48EC-8C22-C0DD0182E686_14008_84">-11000</us-gaap:OtherComprehensiveIncomeLossNetOfTax> <us-gaap:LicenseAndServicesRevenue contextRef="eol_PE151383--1410-K0012_STD_365_20141231_0" unitRef="iso4217_USD" decimals="-3" id="id_6895476_FF4E9404-B9B3-415C-99EC-66EC22E2B2E7_1_4">9836000</us-gaap:LicenseAndServicesRevenue> <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets contextRef="eol_PE151383--1410-K0012_STD_365_20141231_0" unitRef="iso4217_USD" decimals="-3" id="id_6895476_84756BCF-71FA-4E32-A511-A3DCED215C30_1_10">-274000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets> <us-gaap:GainLossOnSaleOfPropertyPlantEquipment contextRef="eol_PE151383--1410-K0012_STD_365_20141231_0" unitRef="iso4217_USD" decimals="-3" id="id_6895476_84756BCF-71FA-4E32-A511-A3DCED215C30_1_4">0</us-gaap:GainLossOnSaleOfPropertyPlantEquipment> <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan contextRef="eol_PE151383--1410-K0012_STD_365_20141231_0" unitRef="iso4217_USD" decimals="-3" id="id_6895476_58E9B802-84A6-48EC-8C22-C0DD0182E686_14008_63">67000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan> <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="eol_PE151383--1410-K0012_STD_365_20141231_0" unitRef="iso4217_USD" decimals="-3" id="id_6895476_58E9B802-84A6-48EC-8C22-C0DD0182E686_14008_60">2000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised> <us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax contextRef="eol_PE151383--1410-K0012_STD_365_20141231_0" unitRef="iso4217_USD" decimals="-3" id="id_6895476_FF4E9404-B9B3-415C-99EC-66EC22E2B2E7_1_21">-11000</us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax> <us-gaap:OperatingIncomeLoss contextRef="eol_PE151383--1410-K0012_STD_365_20141231_0" unitRef="iso4217_USD" decimals="-3" id="id_6895476_FF4E9404-B9B3-415C-99EC-66EC22E2B2E7_1_11">-14754000</us-gaap:OperatingIncomeLoss> <us-gaap:IncreaseDecreaseInDueFromRelatedPartiesCurrent contextRef="eol_PE151383--1410-K0012_STD_365_20141231_0" unitRef="iso4217_USD" decimals="-3" id="id_6895476_84756BCF-71FA-4E32-A511-A3DCED215C30_1_9">46641000</us-gaap:IncreaseDecreaseInDueFromRelatedPartiesCurrent> <us-gaap:ComprehensiveIncomeNetOfTax contextRef="eol_PE151383--1410-K0012_STD_365_20141231_0" unitRef="iso4217_USD" decimals="-3" id="id_6895476_FF4E9404-B9B3-415C-99EC-66EC22E2B2E7_1_22">-14657000</us-gaap:ComprehensiveIncomeNetOfTax> <us-gaap:NonoperatingIncomeExpense contextRef="eol_PE151383--1410-K0012_STD_365_20141231_0" unitRef="iso4217_USD" decimals="-3" id="id_6895476_73255E91-D164-4B6A-A45B-4757187E85BA_1_2">108000</us-gaap:NonoperatingIncomeExpense> <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments contextRef="eol_PE151383--1410-K0012_STD_365_20141231_0" unitRef="iso4217_USD" decimals="-3" id="id_6895476_7D9738C0-6CE1-4E3E-8312-71FD14F9FEB0_1_2">-14646000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments> <us-gaap:GainOnSaleOfInvestments contextRef="eol_PE151383--1410-K0012_STD_365_20141231_0" unitRef="iso4217_USD" decimals="-3" id="id_6895476_84756BCF-71FA-4E32-A511-A3DCED215C30_1_7">6000</us-gaap:GainOnSaleOfInvestments> <us-gaap:Revenues contextRef="eol_PE151383--1410-K0012_STD_365_20141231_0" unitRef="iso4217_USD" decimals="-3" id="id_6895476_FF4E9404-B9B3-415C-99EC-66EC22E2B2E7_1_5">46940000</us-gaap:Revenues> <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment contextRef="eol_PE151383--1410-K0012_STD_365_20141231_0" unitRef="iso4217_USD" decimals="-3" id="id_6895476_84756BCF-71FA-4E32-A511-A3DCED215C30_1_19">1104000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment> <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic contextRef="eol_PE151383--1410-K0012_STD_365_20141231_0" unitRef="iso4217_USD" decimals="-3" id="id_6895476_09173C79-2713-49DF-8107-C7F99AA4E397_1_2">-14646000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic> <us-gaap:NetIncomeLoss contextRef="eol_PE151383--1410-K0012_STD_365_20141231_0" unitRef="iso4217_USD" decimals="-3" id="id_6895476_58E9B802-84A6-48EC-8C22-C0DD0182E686_14008_85">-14646000</us-gaap:NetIncomeLoss> <us-gaap:InvestmentIncomeInterest contextRef="eol_PE151383--1410-K0012_STD_365_20141231_0" unitRef="iso4217_USD" decimals="-3" id="id_6895476_944F757B-AF2C-42F5-8AB2-26CA07F38C19_1_0">101000</us-gaap:InvestmentIncomeInterest> <us-gaap:InterestPaid contextRef="eol_PE151383--1410-K0012_STD_365_20141231_0" unitRef="iso4217_USD" decimals="-3" id="id_6895476_822093A4-C207-4594-84E4-6C13CA36E168_1_0">0</us-gaap:InterestPaid> <us-gaap:InterestAndOtherIncome contextRef="eol_PE151383--1410-K0012_STD_365_20141231_0" unitRef="iso4217_USD" decimals="-3" id="id_6895476_73255E91-D164-4B6A-A45B-4757187E85BA_1_0">108000</us-gaap:InterestAndOtherIncome> <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="eol_PE151383--1410-K0012_STD_365_20141231_0" unitRef="iso4217_USD" decimals="-3" id="id_6895476_58E9B802-84A6-48EC-8C22-C0DD0182E686_14008_83">3330000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue> <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic contextRef="eol_PE151383--1410-K0012_STD_365_20141231_0" unitRef="iso4217_USD" decimals="-3" id="id_6895476_7D9738C0-6CE1-4E3E-8312-71FD14F9FEB0_1_0">-14646000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic> <us-gaap:AllocatedShareBasedCompensationExpense contextRef="eol_PE151383--1410-K0012_STD_365_20141231_0" unitRef="iso4217_USD" decimals="-3" id="id_6895476_4ED78B6B-525C-4A06-A788-E5CE58B1F0CD_1_2">3330000</us-gaap:AllocatedShareBasedCompensationExpense> <us-gaap:DeferredIncomeTaxExpenseBenefit contextRef="eol_PE151383--1410-K0012_STD_365_20141231_0" unitRef="iso4217_USD" decimals="-3" id="id_6895476_313A5609-80D0-44B6-B522-EDB92ECD334E_1_7">0</us-gaap:DeferredIncomeTaxExpenseBenefit> <us-gaap:DepreciationDepletionAndAmortization contextRef="eol_PE151383--1410-K0012_STD_365_20141231_0" unitRef="iso4217_USD" decimals="-3" id="id_6895476_84756BCF-71FA-4E32-A511-A3DCED215C30_1_3">490000</us-gaap:DepreciationDepletionAndAmortization> <us-gaap:IncreaseDecreaseInDeferredRevenue contextRef="eol_PE151383--1410-K0012_STD_365_20141231_0" unitRef="iso4217_USD" decimals="-3" id="id_6895476_84756BCF-71FA-4E32-A511-A3DCED215C30_1_14">17399000</us-gaap:IncreaseDecreaseInDeferredRevenue> <us-gaap:InterestExpense contextRef="eol_PE151383--1410-K0012_STD_365_20141231_0" unitRef="iso4217_USD" decimals="-3" id="id_6895476_42B95EC7-417F-4E86-8649-AA2AAA9B2184_1_0">0</us-gaap:InterestExpense> <us-gaap:ProceedsFromIssuanceOfPreferredStockAndPreferenceStock contextRef="eol_PE151383--1410-K0012_STD_365_20141231_0" unitRef="iso4217_USD" decimals="-3" id="id_6895476_84756BCF-71FA-4E32-A511-A3DCED215C30_1_27">0</us-gaap:ProceedsFromIssuanceOfPreferredStockAndPreferenceStock> <us-gaap:ResearchAndDevelopmentExpense contextRef="eol_PE151383--1410-K0012_STD_365_20141231_0" unitRef="iso4217_USD" decimals="-3" id="id_6895476_FF4E9404-B9B3-415C-99EC-66EC22E2B2E7_1_7">44426000</us-gaap:ResearchAndDevelopmentExpense> <us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit contextRef="eol_PE151383--1410-K0012_STD_365_20141231_0" unitRef="iso4217_USD" decimals="-3" id="id_6895476_313A5609-80D0-44B6-B522-EDB92ECD334E_1_6">0</us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit> <us-gaap:RestructuringCharges contextRef="eol_PE151383--1410-K0012_STD_365_20141231_0" unitRef="iso4217_USD" decimals="-3" id="id_6895476_FF4E9404-B9B3-415C-99EC-66EC22E2B2E7_1_9">0</us-gaap:RestructuringCharges> <us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease contextRef="eol_PE151383--1410-K0012_STD_365_20141231_0" unitRef="iso4217_USD" decimals="-3" id="id_6895476_84756BCF-71FA-4E32-A511-A3DCED215C30_1_30">57000</us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease> <us-gaap:IncomeTaxExpenseBenefit contextRef="eol_PE151383--1410-K0012_STD_365_20141231_0" unitRef="iso4217_USD" decimals="-3" id="id_6895476_8E079FDA-A4BC-47E2-A9A9-72879770E667_1_0">0</us-gaap:IncomeTaxExpenseBenefit> <us-gaap:OperatingLeasesRentExpenseNet contextRef="eol_PE151383--1410-K0012_STD_365_20141231_0" unitRef="iso4217_USD" decimals="-3" id="id_6895476_BCDA57D7-0AE7-485E-8998-1C33E525DE09_1_0">3338000</us-gaap:OperatingLeasesRentExpenseNet> <us-gaap:CurrentFederalTaxExpenseBenefit contextRef="eol_PE151383--1410-K0012_STD_365_20141231_0" unitRef="iso4217_USD" decimals="-3" id="id_6895476_313A5609-80D0-44B6-B522-EDB92ECD334E_1_1">0</us-gaap:CurrentFederalTaxExpenseBenefit> <us-gaap:Depreciation contextRef="eol_PE151383--1410-K0012_STD_365_20141231_0" unitRef="iso4217_USD" decimals="-5" id="id_6895476_39F2804C-5F74-4B61-9FD9-4D6A1871D4BD_1_0">500000</us-gaap:Depreciation> <us-gaap:NetCashProvidedByUsedInFinancingActivitiesContinuingOperations contextRef="eol_PE151383--1410-K0012_STD_365_20141231_0" unitRef="iso4217_USD" decimals="-3" id="id_6895476_84756BCF-71FA-4E32-A511-A3DCED215C30_1_29">48949000</us-gaap:NetCashProvidedByUsedInFinancingActivitiesContinuingOperations> <us-gaap:ProceedsFromIssuanceOfCommonStock contextRef="eol_PE151383--1410-K0012_STD_365_20141231_0" unitRef="iso4217_USD" decimals="-3" id="id_6895476_84756BCF-71FA-4E32-A511-A3DCED215C30_1_24">48971000</us-gaap:ProceedsFromIssuanceOfCommonStock> <us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment contextRef="eol_PE151383--1410-K0012_STD_365_20141231_0" unitRef="iso4217_USD" decimals="-3" id="id_6895476_84756BCF-71FA-4E32-A511-A3DCED215C30_1_20">0</us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment> <us-gaap:CurrentStateAndLocalTaxExpenseBenefit contextRef="eol_PE151383--1410-K0012_STD_365_20141231_0" unitRef="iso4217_USD" decimals="-3" id="id_6895476_313A5609-80D0-44B6-B522-EDB92ECD334E_1_2">0</us-gaap:CurrentStateAndLocalTaxExpenseBenefit> <us-gaap:IncreaseDecreaseInAccruedLiabilities contextRef="eol_PE151383--1410-K0012_STD_365_20141231_0" unitRef="iso4217_USD" decimals="-3" id="id_6895476_84756BCF-71FA-4E32-A511-A3DCED215C30_1_12">-2865000</us-gaap:IncreaseDecreaseInAccruedLiabilities> <us-gaap:InterestAndDebtExpense contextRef="eol_PE151383--1410-K0012_STD_365_20141231_0" unitRef="iso4217_USD" decimals="-3" id="id_6895476_73255E91-D164-4B6A-A45B-4757187E85BA_1_1">0</us-gaap:InterestAndDebtExpense> <us-gaap:NetCashProvidedByUsedInInvestingActivitiesContinuingOperations contextRef="eol_PE151383--1410-K0012_STD_365_20141231_0" unitRef="iso4217_USD" decimals="-3" id="id_6895476_84756BCF-71FA-4E32-A511-A3DCED215C30_1_22">-4049000</us-gaap:NetCashProvidedByUsedInInvestingActivitiesContinuingOperations> <us-gaap:NoncashOrPartNoncashAcquisitionFixedAssetsAcquired1 contextRef="eol_PE151383--1410-K0012_STD_365_20141231_0" unitRef="iso4217_USD" decimals="-3" id="id_6895476_822093A4-C207-4594-84E4-6C13CA36E168_1_3">170000</us-gaap:NoncashOrPartNoncashAcquisitionFixedAssetsAcquired1> <us-gaap:CurrentIncomeTaxExpenseBenefit contextRef="eol_PE151383--1410-K0012_STD_365_20141231_0" unitRef="iso4217_USD" decimals="-3" id="id_6895476_313A5609-80D0-44B6-B522-EDB92ECD334E_1_3">0</us-gaap:CurrentIncomeTaxExpenseBenefit> <us-gaap:CostsAndExpenses contextRef="eol_PE151383--1410-K0012_STD_365_20141231_0" unitRef="iso4217_USD" decimals="-3" id="id_6895476_FF4E9404-B9B3-415C-99EC-66EC22E2B2E7_1_10">61694000</us-gaap:CostsAndExpenses> <us-gaap:RestructuringCostsAndAssetImpairmentCharges contextRef="eol_PE151383--1410-K0012_STD_365_20141231_0" unitRef="iso4217_USD" decimals="-3" id="id_6895476_84756BCF-71FA-4E32-A511-A3DCED215C30_1_5">0</us-gaap:RestructuringCostsAndAssetImpairmentCharges> <us-gaap:AdjustmentsToAdditionalPaidInCapitalStockSplit contextRef="eol_PE151383--1410-K0012_STD_365_20141231_0" unitRef="iso4217_USD" decimals="0" id="id_6895476_196715A1-F572-4BD3-B317-F78E4CBD8481_2_1">139000</us-gaap:AdjustmentsToAdditionalPaidInCapitalStockSplit> <us-gaap:GeneralAndAdministrativeExpense contextRef="eol_PE151383--1410-K0012_STD_365_20141231_0" unitRef="iso4217_USD" decimals="-3" id="id_6895476_FF4E9404-B9B3-415C-99EC-66EC22E2B2E7_1_8">17268000</us-gaap:GeneralAndAdministrativeExpense> <us-gaap:IncreaseDecreaseInDueToRelatedPartiesCurrent contextRef="eol_PE151383--1410-K0012_STD_365_20141231_0" unitRef="iso4217_USD" decimals="-3" id="id_6895476_84756BCF-71FA-4E32-A511-A3DCED215C30_1_13">0</us-gaap:IncreaseDecreaseInDueToRelatedPartiesCurrent> <us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities contextRef="eol_PE151383--1410-K0012_STD_365_20141231_0" unitRef="iso4217_USD" decimals="-3" id="id_6895476_84756BCF-71FA-4E32-A511-A3DCED215C30_1_18">104098000</us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities> <us-gaap:ShareBasedCompensation contextRef="eol_PE151383--1410-K0012_STD_365_20141231_0" unitRef="iso4217_USD" decimals="-3" id="id_6895476_84756BCF-71FA-4E32-A511-A3DCED215C30_1_6">3330000</us-gaap:ShareBasedCompensation> <us-gaap:DeferredFederalIncomeTaxExpenseBenefit contextRef="eol_PE151383--1410-K0012_STD_365_20141231_0" unitRef="iso4217_USD" decimals="-3" id="id_6895476_313A5609-80D0-44B6-B522-EDB92ECD334E_1_5">0</us-gaap:DeferredFederalIncomeTaxExpenseBenefit> <us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount contextRef="eol_PE151383--1410-K0012_STD_365_20141231_0" unitRef="iso4217_USD" decimals="0" id="id_6895476_415AD002-83D0-4FE9-B832-5E67DD6E4E77_2_0">336000</us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount> <us-gaap:IncreaseDecreaseInAccountsPayableTrade contextRef="eol_PE151383--1410-K0012_STD_365_20141231_0" unitRef="iso4217_USD" decimals="-3" id="id_6895476_84756BCF-71FA-4E32-A511-A3DCED215C30_1_11">-2178000</us-gaap:IncreaseDecreaseInAccountsPayableTrade> <us-gaap:OtherPreferredStockDividendsAndAdjustments contextRef="eol_PE151383--1410-K0012_STD_365_20141231_0" unitRef="iso4217_USD" decimals="-3" id="id_6895476_09173C79-2713-49DF-8107-C7F99AA4E397_1_1">0</us-gaap:OtherPreferredStockDividendsAndAdjustments> <cytk:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePrice contextRef="eol_PE151383--1410-K0012_STD_365_20141231_0" unitRef="iso4217_USD_per_shares" decimals="INF" id="id_6895476_58E9B802-84A6-48EC-8C22-C0DD0182E686_14008_62">6</cytk:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePrice> <cytk:IssuanceOfCommonStockEmployeeStockPurchasePlanPricePerShare contextRef="eol_PE151383--1410-K0012_STD_365_20141231_0" unitRef="iso4217_USD_per_shares" decimals="INF" id="id_6895476_58E9B802-84A6-48EC-8C22-C0DD0182E686_14008_65">3.38</cytk:IssuanceOfCommonStockEmployeeStockPurchasePlanPricePerShare> <cytk:NonCancelableLeaseExpirationYear contextRef="eol_PE151383--1410-K0012_STD_365_20141231_0" id="id_6895476_7D127D62-2F83-4FE6-AE3B-4ADD4C376019_1_0">2018</cytk:NonCancelableLeaseExpirationYear> <cytk:EffectiveIncomeTaxRateReconciliationNetOperatingLossExpiration contextRef="eol_PE151383--1410-K0012_STD_365_20141231_0" unitRef="pure" decimals="2" id="id_6895476_14EF385A-3844-4F78-AE65-D20D0D541C15_1_6">0.02</cytk:EffectiveIncomeTaxRateReconciliationNetOperatingLossExpiration> <cytk:ShareBasedCompensationArrangementByShareBasedPaymentSharesAvailableForGrantAwardOptionsExercisedInPeriodGross contextRef="eol_PE151383--1410-K0012_STD_365_20141231_0" unitRef="shares" decimals="0" id="id_6895476_550670F2-8019-4594-8D89-8D38F90A7B79_11001_16">0</cytk:ShareBasedCompensationArrangementByShareBasedPaymentSharesAvailableForGrantAwardOptionsExercisedInPeriodGross> <cytk:ProceedsFromDrawDownOfCommittedEquityFinancingFacilitiesAndAtMarketFacilityNetOfIssuanceCosts contextRef="eol_PE151383--1410-K0012_STD_365_20141231_0" unitRef="iso4217_USD" decimals="-3" id="id_6895476_84756BCF-71FA-4E32-A511-A3DCED215C30_1_25">0</cytk:ProceedsFromDrawDownOfCommittedEquityFinancingFacilitiesAndAtMarketFacilityNetOfIssuanceCosts> <cytk:NonCancelableLeaseAdditionalExtensionPeriod contextRef="eol_PE151383--1410-K0012_STD_365_20141231_0" id="id_6895476_7D127D62-2F83-4FE6-AE3B-4ADD4C376019_1_1">P3Y</cytk:NonCancelableLeaseAdditionalExtensionPeriod> <cytk:StockIssuedDuringPeriodValueSecuritiesPurchaseAgreement contextRef="eol_PE151383--1410-K0012_STD_365_20141231_0" unitRef="iso4217_USD" decimals="-3" id="id_6895476_58E9B802-84A6-48EC-8C22-C0DD0182E686_14008_79">37492000</cytk:StockIssuedDuringPeriodValueSecuritiesPurchaseAgreement> <cytk:PercentageOfIncomeTaxPositionsLikelyToBeRealized contextRef="eol_PE151383--1410-K0012_STD_365_20141231_0" unitRef="pure" decimals="2" id="id_6895476_6C1D653E-00AD-4593-907E-7F4BA9D3D863_1_0">0.50</cytk:PercentageOfIncomeTaxPositionsLikelyToBeRealized> <cytk:OtherResearchAndDevelopmentRevenueArrangementsRecognizedGrantRevenueTableTextBlock contextRef="eol_PE151383--1410-K0012_STD_365_20141231_0" id="id_6895476_7E3C0252-1D1E-4C8C-A2D4-C5D7BB1ABDE0_1_0"><div> <p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 0px; TEXT-INDENT: 4%" align="justify"><font style="FONT-FAMILY: Times New Roman" size="2">Total grant revenues were as follows (in thousands):</font></p> <p style="MARGIN-BOTTOM: 0px; FONT-SIZE: 12px; MARGIN-TOP: 0px"> &#xA0;</p> <table style="BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="92%" align="center" border="0"> <tr> <td width="79%"></td> <td valign="bottom" width="4%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="4%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="4%"></td> <td></td> <td></td> <td></td> </tr> <tr> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="10" align="center"><font style="FONT-FAMILY: Times New Roman" size="1"><b>Years Ended<br /> December&#xA0;31,</b></font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> </tr> <tr> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" align="center"><font style="FONT-FAMILY: Times New Roman" size="1"><b>2014</b></font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" align="center"><font style="FONT-FAMILY: Times New Roman" size="1"><b>2013</b></font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" align="center"><font style="FONT-FAMILY: Times New Roman" size="1"><b>2012</b></font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> </tr> <tr bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: Times New Roman" size="2">NINDS myasthenia gravis</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td> <td valign="bottom" nowrap="nowrap" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">&#x2014;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">69</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">1,308</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> </tr> <tr> <td valign="top"> <p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: Times New Roman" size="2">Other grant revenue</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">75</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">25</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" nowrap="nowrap" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">&#x2014;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> </tr> <tr bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-LEFT: 2em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: Times New Roman" size="2">Total grant revenue</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">75</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">94</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">1,308</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td>&#xA0;</td> </tr> </table> </div></cytk:OtherResearchAndDevelopmentRevenueArrangementsRecognizedGrantRevenueTableTextBlock> <cytk:ReverseStockSplitPolicyTextBlock contextRef="eol_PE151383--1410-K0012_STD_365_20141231_0" id="id_6895476_5CFDE11D-D0E9-4FFD-B001-C4326A522F66_1_0"><div> <p style="MARGIN-BOTTOM: 0px; MARGIN-LEFT: 2%; MARGIN-TOP: 18px"> <font style="FONT-FAMILY: Times New Roman" size="2"><b><i>Reverse Stock Split</i></b></font></p> <p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 6px; TEXT-INDENT: 4%" align="justify"><font style="FONT-FAMILY: Times New Roman" size="2">On&#xA0;June&#xA0;24, 2013, the Company effected a one-for-six reverse stock split of its common stock through an amendment to its amended and restated certificate of incorporation (the &#x201C;COI Amendment&#x201D;). As of the effective time of the reverse stock split, every six shares of the Company&#x2019;s issued and outstanding common stock were converted into one issued and outstanding share of common stock, without any change in par value per share. The reverse stock split affected all shares of the Company&#x2019;s common stock outstanding immediately prior to the effective time of the reverse stock split, as well as the number of shares of common stock available for issuance under the Company&#x2019;s equity incentive plans. In addition, the reverse stock split effected a reduction in the number of shares of common stock issuable upon the conversion of shares of preferred stock or upon the exercise of stock options or warrants outstanding immediately prior to the effectiveness of the reverse stock split. No fractional shares were issued as a result of the reverse stock split. Stockholders who would otherwise have been entitled to receive a fractional share received cash payments in lieu thereof. In addition, the COI Amendment reduced the number of authorized shares of common stock to 81.5&#xA0;million.</font></p> <p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 12px; TEXT-INDENT: 4%" align="justify"><font style="FONT-FAMILY: Times New Roman" size="2">As the par value per share of the Company&#x2019;s common stock remained unchanged at $0.001 per share, a total of $139,000 was reclassified from common stock to additional paid-in capital. All references to shares of common stock and per share data for all periods presented in the accompanying financial statements and notes thereto have been adjusted to reflect the reverse stock split on a retroactive basis.</font></p> </div></cytk:ReverseStockSplitPolicyTextBlock> <cytk:SharesAvailableForGrantOfOptionsOrAwardsOptionsForfeitedExpired contextRef="eol_PE151383--1410-K0012_STD_365_20141231_0" unitRef="shares" decimals="INF" id="id_6895476_550670F2-8019-4594-8D89-8D38F90A7B79_11001_17">95980</cytk:SharesAvailableForGrantOfOptionsOrAwardsOptionsForfeitedExpired> <cytk:AccountingPronouncementsNotYetAdoptedPolicyTextBlock contextRef="eol_PE151383--1410-K0012_STD_365_20141231_0" id="id_6895476_64FCF4BB-8E82-4A96-AF46-0D4FF02ECBB0_1_0"><div> <p style="MARGIN-BOTTOM: 0px; MARGIN-LEFT: 2%; MARGIN-TOP: 18px"> <font style="FONT-FAMILY: Times New Roman" size="2"><i>Accounting Pronouncements Not Yet Adopted</i></font></p> <p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 6px; TEXT-INDENT: 4%" align="justify"><font style="FONT-FAMILY: Times New Roman" size="2">In November 2014, the FASB issued ASU 2014-17, <i>Business Combinations (Topic 805) &#x2014; Pushdown Accounting (a consensus of the FASB Emerging Issues Task Force).</i> This guidance provides the option for an acquired entity to apply pushdown accounting in its separately issued financial statements when a change-in-control event occurs. This guidance is effective beginning November&#xA0;18, 2014, and is applicable to change-in-control events occurring after that date or applied to the most recent change-in-control event if financial statements have not yet been issued. The Company does not expect the adoption of ASU 2014-17 to have a material effect upon its financial statements.</font></p> <p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 12px; TEXT-INDENT: 4%" align="justify"><font style="FONT-FAMILY: Times New Roman" size="2">In August 2014, the FASB issued ASU 2014-15, <i>Presentation of Financial Statements &#x2014; Going Concern (Subtopic 205-40): Disclosure of Uncertainties about an Entity&#x2019;s Ability to Continue as a Going Concern.</i> ASU&#xA0;214-15 requires management to assess an entity&#x2019;s ability to continue as a going concern, and to provide related footnote disclosures in certain circumstances. ASU 2014-15 is effective for annual and interim reporting periods beginning on or after December&#xA0;15, 2016 and early adoption is permitted. The Company does not expect the adoption of ASU 2014-15 to have a material effect upon its financial statements.</font></p> <p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 12px; TEXT-INDENT: 4%" align="justify"><font style="FONT-FAMILY: Times New Roman" size="2">In May 2014, the FASB issued ASU 2014-09, <i>Revenue from Contracts with Customers (Topic 606)</i>, which supersedes the revenue recognition requirements in ASC 605, <i>Revenue Recognition</i>. ASU&#xA0;2014-09 stipulates that an entity should recognize revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. ASU&#xA0;2014-09 also requires additional disclosure about the nature, amount, timing and uncertainty of revenue and cash flows arising from customer contracts, including significant judgments and changes in judgments and assets recognized from costs incurred to obtain or fulfill a contract. ASU&#xA0;2014-09 is effective for annual and interim reporting periods beginning on or after December&#xA0;15, 2016, and early adoption is not permitted. ASU&#xA0;2014-09 permits the use of two transition methods, either retrospectively to each prior reporting period presented or as a cumulative-effect adjustment as of the date of adoption. The Company has not yet selected a transition method, and is currently evaluating the impact of the adoption of ASU&#xA0;2014-09 on its consolidated financial statements.</font></p> <p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 12px; TEXT-INDENT: 4%" align="justify"><font style="FONT-FAMILY: Times New Roman" size="2">In April 2014, the FASB issued ASU 2014-08, <i>Reporting Discontinued Operations and Disclosures of Disposals of Components of an Entity</i>. ASU 2014-08 changes the criteria for determining which disposals can be presented as discontinued operations and modifies related disclosure requirements. This new guidance is effective for the Company beginning January&#xA0;1, 2015. The Company does not expect the adoption of ASU 2014-08 to have a material effect upon its financial statements.</font></p> </div></cytk:AccountingPronouncementsNotYetAdoptedPolicyTextBlock> <cytk:ScheduleOfInterestExpenseTableTextBlock contextRef="eol_PE151383--1410-K0012_STD_365_20141231_0" id="id_6895476_1334E578-A4B2-48DF-AE11-5A08F52D25B7_1_0"><div> <p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 6px; TEXT-INDENT: 4%" align="justify"><font style="FONT-FAMILY: Times New Roman" size="2">Total interest expense incurred by the Company was as follows (in thousands):</font></p> <p style="MARGIN-BOTTOM: 0px; FONT-SIZE: 12px; MARGIN-TOP: 0px"> &#xA0;</p> <table style="BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="92%" align="center" border="0"> <tr> <td width="77%"></td> <td valign="bottom" width="6%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="6%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="6%"></td> <td></td> <td></td> <td></td> </tr> <tr> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="10" align="center"><font style="FONT-FAMILY: Times New Roman" size="1"><b>Years&#xA0;Ended&#xA0;December&#xA0;31,</b></font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> </tr> <tr> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" align="center"><font style="FONT-FAMILY: Times New Roman" size="1"><b>2014</b></font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" align="center"><font style="FONT-FAMILY: Times New Roman" size="1"><b>2013</b></font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" align="center"><font style="FONT-FAMILY: Times New Roman" size="1"><b>2012</b></font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> </tr> <tr bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: Times New Roman" size="2">Interest expense</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td> <td valign="bottom" nowrap="nowrap" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">&#x2014;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td> <td valign="bottom" nowrap="nowrap" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">&#x2014;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">3</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td>&#xA0;</td> </tr> </table> </div></cytk:ScheduleOfInterestExpenseTableTextBlock> <cytk:LicenseRevenuesFromRelatedParties contextRef="eol_PE151383--1410-K0012_STD_365_20141231_0" unitRef="iso4217_USD" decimals="-3" id="id_6895476_FF4E9404-B9B3-415C-99EC-66EC22E2B2E7_1_3">0</cytk:LicenseRevenuesFromRelatedParties> <cytk:OrganizationConsolidationAndPresentationOfFinancialStatementsPolicyTextBlock contextRef="eol_PE151383--1410-K0012_STD_365_20141231_0" id="id_6895476_6CF61D05-3DD8-470A-93CE-E2F3E45D35BD_1_0"><div> <p style="MARGIN-BOTTOM: 0px; MARGIN-LEFT: 2%; MARGIN-TOP: 6px"> <font style="FONT-FAMILY: Times New Roman" size="2"><b><i>Organization</i></b></font></p> <p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 6px; TEXT-INDENT: 4%" align="justify"><font style="FONT-FAMILY: Times New Roman" size="2">Cytokinetics, Incorporated (the &#x201C;Company&#x201D;, &#x201C;we&#x201D; or &#x201C;our&#x201D;) was incorporated under the laws of the state of Delaware on August&#xA0;5, 1997. The Company is a clinical stage biopharmaceutical company focused on the discovery and development of novel small molecule therapeutics that modulate muscle function for the potential treatment of serious diseases and medical conditions.</font></p> <p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 12px; TEXT-INDENT: 4%" align="justify"><font style="FONT-FAMILY: Times New Roman" size="2">The Company was in the development stage at December&#xA0;31, 2012, as defined in Financial Accounting Standards Board (&#x201C;FASB&#x201D;) Accounting Standards Codification (&#x201C;ASC&#x201D;) Topic 915, &#x201C;<i>Development Stage Entities</i>.&#x201D; During the year ended December&#xA0;31, 2013, the Company exited the development stage with the execution of the Amgen Agreement Amendment and the Original Astellas Agreement (See Note 7), from which the Company received significant revenues from its principal operations, indicative that the Company was no longer in the development stage.</font></p> <p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 12px; TEXT-INDENT: 4%" align="justify"><font style="FONT-FAMILY: Times New Roman" size="2">The Company&#x2019;s financial statements contemplate the conduct of the Company&#x2019;s operations in the normal course of business. The Company has incurred an accumulated deficit of $497.2 million since inception and there can be no assurance that the Company will attain profitability. The Company had a net loss of $14.6 million and net cash used in operations of $44.8 million for the year ended December&#xA0;31, 2014. Cash, cash equivalents and investments increased to $83.2 million at December&#xA0;31, 2014 from $80.2&#xA0;million at December&#xA0;31, 2013. The Company anticipates that it will continue to have operating losses and net cash outflows in future periods.</font></p> <p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 12px; TEXT-INDENT: 4%" align="justify"><font style="FONT-FAMILY: Times New Roman" size="2">The Company is subject to risks common to clinical stage biopharmaceutical companies including, but not limited to, development of new drug candidates, dependence on key personnel, and the ability to obtain additional capital as needed to fund its future plans. The Company&#x2019;s liquidity will be impaired if sufficient additional capital is not available on terms acceptable to the Company. To date, the Company has funded its operations primarily through sales of its common stock and convertible preferred stock, contract payments under its collaboration agreements, debt financing arrangements, government grants and interest income. Until it achieves profitable operations, the Company intends to continue to fund operations through payments from strategic collaborations, additional sales of equity securities, grants and debt financings. The Company has never generated revenues from commercial sales of its drugs and may not obtain regulatory approval for commercialization for at least several years, if ever. The Company&#x2019;s success is dependent on its ability to enter into new strategic collaborations and/or raise additional capital and to successfully develop and market one or more of its drug candidates. As a result, the Company may choose to raise additional capital through equity or debt financings to continue to fund its operations in the future. The Company cannot be certain that sufficient funds will be available from such a financing or through a collaborator when required or on satisfactory terms. Additionally, there can be no assurance that the Company&#x2019;s drug candidates will be accepted in the marketplace or that any future products can be developed or manufactured at an acceptable cost. These factors could have a material adverse effect on the Company&#x2019;s future financial results, financial position and cash flows.</font></p> <p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 12px; TEXT-INDENT: 4%" align="justify"><font style="FONT-FAMILY: Times New Roman" size="2">Based on the current status of its research and development plans, the Company believes that its existing cash, cash equivalents and investments at December&#xA0;31, 2014 will be sufficient to fund its cash requirements for at least the next 12&#xA0;months. If, at any time, the Company&#x2019;s prospects for financing its research and development programs decline, the Company may decide to reduce research and development expenses by delaying, discontinuing or reducing its funding of one or more of its research or development programs. Alternatively, the Company might raise funds through strategic collaborations, public or private financings or other arrangements. Such funding, if needed, may not be available on favorable terms, or at all. The financial statements do not include any adjustments that might result from the outcome of this uncertainty.</font></p> </div></cytk:OrganizationConsolidationAndPresentationOfFinancialStatementsPolicyTextBlock> <cytk:FractionalSharesFromReverseStockSplitShare contextRef="eol_PE151383--1410-K0012_STD_365_20141231_0" unitRef="shares" decimals="INF" id="id_6895476_D0CA187D-0E02-499F-9FB8-1A33B08D2A2F_1_400000">0</cytk:FractionalSharesFromReverseStockSplitShare> <cytk:CashRequirementsTerm contextRef="eol_PE151383--1410-K0012_STD_365_20141231_0" id="id_6895476_D90C30AC-3A97-4945-AA68-2DB3F2CE2480_1_0">P12M</cytk:CashRequirementsTerm> <cytk:EffectiveIncomeTaxRateReconciliationDeferredTaxAssetsUtilizedNotBenefited contextRef="eol_PE151383--1410-K0012_STD_365_20141231_0" unitRef="pure" decimals="2" id="id_6895476_14EF385A-3844-4F78-AE65-D20D0D541C15_1_4">0.07</cytk:EffectiveIncomeTaxRateReconciliationDeferredTaxAssetsUtilizedNotBenefited> <cytk:StockIssuedDuringPeriodValueExerciseOfWarrants contextRef="eol_PE151383--1410-K0012_STD_365_20141231_0" unitRef="iso4217_USD" decimals="-3" id="id_6895476_58E9B802-84A6-48EC-8C22-C0DD0182E686_14008_68">6000</cytk:StockIssuedDuringPeriodValueExerciseOfWarrants> <cytk:ResearchAndDevelopmentRevenuesFromRelatedParties contextRef="eol_PE151383--1410-K0012_STD_365_20141231_0" unitRef="iso4217_USD" decimals="-3" id="id_6895476_FF4E9404-B9B3-415C-99EC-66EC22E2B2E7_1_1">19538000</cytk:ResearchAndDevelopmentRevenuesFromRelatedParties> <cytk:ProceedsAndPaymentsFromStockBasedAwardAndWarrantsNetOfIssuanceCosts contextRef="eol_PE151383--1410-K0012_STD_365_20141231_0" unitRef="iso4217_USD" decimals="-3" id="id_6895476_84756BCF-71FA-4E32-A511-A3DCED215C30_1_26">22000</cytk:ProceedsAndPaymentsFromStockBasedAwardAndWarrantsNetOfIssuanceCosts> <cytk:ResearchAndDevelopmentGrantAndOtherRevenues contextRef="eol_PE151383--1410-K0012_STD_365_20141231_0" unitRef="iso4217_USD" decimals="-3" id="id_6895476_FF4E9404-B9B3-415C-99EC-66EC22E2B2E7_1_2">17566000</cytk:ResearchAndDevelopmentGrantAndOtherRevenues> <cytk:ResearchAndDevelopmentFederalTaxCreditCarryforwardsExpirationDateYear contextRef="eol_PE151383--1410-K0012_STD_365_20141231_0" id="id_6895476_D5276082-6BF3-412E-9245-B2B467B8A56E_1_2">2021</cytk:ResearchAndDevelopmentFederalTaxCreditCarryforwardsExpirationDateYear> <cytk:EffectiveIncomeTaxRateReconciliationStateApportionment contextRef="eol_PE151383--1410-K0012_STD_365_20141231_0" unitRef="pure" decimals="2" id="id_6895476_14EF385A-3844-4F78-AE65-D20D0D541C15_1_2">0.28</cytk:EffectiveIncomeTaxRateReconciliationStateApportionment> <cytk:NoncashOrPartNoncashAcquisitionFixedAssetsAcquiredTradeInValue contextRef="eol_PE151383--1410-K0012_STD_365_20141231_0" unitRef="iso4217_USD" decimals="-3" id="id_6895476_822093A4-C207-4594-84E4-6C13CA36E168_1_5">0</cytk:NoncashOrPartNoncashAcquisitionFixedAssetsAcquiredTradeInValue> <cytk:StockIssuedDuringPeriodValueNewIssuesToCollaborativePartner contextRef="eol_PE151383--1410-K0012_STD_365_20141231_0" unitRef="iso4217_USD" decimals="-3" id="id_6895476_58E9B802-84A6-48EC-8C22-C0DD0182E686_14008_75">9102000</cytk:StockIssuedDuringPeriodValueNewIssuesToCollaborativePartner> <cytk:IssuanceOfCommonStockToCollaborativePartnerForCashPerShare contextRef="eol_PE151383--1410-K0012_STD_365_20141231_0" unitRef="iso4217_USD_per_shares" decimals="INF" id="id_6895476_58E9B802-84A6-48EC-8C22-C0DD0182E686_14008_77">4.9</cytk:IssuanceOfCommonStockToCollaborativePartnerForCashPerShare> <cytk:IssuanceOfCommonStockToCollaborativePartnerIssuanceCosts contextRef="eol_PE151383--1410-K0012_STD_365_20141231_0" unitRef="iso4217_USD" decimals="-3" id="id_6895476_58E9B802-84A6-48EC-8C22-C0DD0182E686_14008_78">8000</cytk:IssuanceOfCommonStockToCollaborativePartnerIssuanceCosts> <cytk:IncreaseDecreaseInNoncashOrPartNoncashAcquisitionFixedAssetsAcquiredThroughAccruedLiabilities contextRef="eol_PE151383--1410-K0012_STD_365_20141231_0" unitRef="iso4217_USD" decimals="-3" id="id_6895476_822093A4-C207-4594-84E4-6C13CA36E168_1_4">27000</cytk:IncreaseDecreaseInNoncashOrPartNoncashAcquisitionFixedAssetsAcquiredThroughAccruedLiabilities> <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="eol_PE151383--1410-K0012_STD_365_20141231_0_1268687x1271212" unitRef="shares" decimals="-3" id="id_6895476_3E2C7E3E-7982-4F2C-A6E3-5C7781C1D9F7_1001_3">63000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount> <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="eol_PE151383--1410-K0012_STD_365_20141231_0_1268687x1273442" unitRef="shares" decimals="-3" id="id_6895476_3E2C7E3E-7982-4F2C-A6E3-5C7781C1D9F7_2001_1">6691000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount> <cytk:AvailableForSaleSecuritiesMaturityDate contextRef="eol_PE151383--1410-K0012_STD_365_20141231_0_1269523x1275948_1270365x1274813_1274212x1276380" id="id_6895476_5953821E-651A-43AE-83D1-8E91E00151B4_2002_6">2015-12</cytk:AvailableForSaleSecuritiesMaturityDate> <us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="eol_PE151383--1410-K0012_STD_365_20141231_0_1269523x1275948_1276136x1280724" id="id_6895476_0A2B8B9B-38B2-46FD-A118-E87D1AE00069_1001_3">P7Y</us-gaap:PropertyPlantAndEquipmentUsefulLife> <cytk:RelatedPartyTransactionCommercializationMilestonePaymentsReceivedByEntity contextRef="eol_PE151383--1410-K0012_STD_365_20141231_0_1269523x1275948_1279431x1424859" unitRef="iso4217_USD" decimals="-5" id="id_6895476_34DE31CB-E1F9-4ECD-8E18-6B236F60A418_1001_1">300000000</cytk:RelatedPartyTransactionCommercializationMilestonePaymentsReceivedByEntity> <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent contextRef="eol_PE151383--1410-K0012_STD_365_20141231_0_1269523x1277596_1270313x1275629_1280964x1294890" unitRef="pure" decimals="INF" id="id_6895476_58CB623A-E885-445D-B29D-69E6E82D9786_2001_1">1.00</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent> <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent contextRef="eol_PE151383--1410-K0012_STD_365_20141231_0_1269523x1277596_1270313x1555254_1280964x1294890" unitRef="pure" decimals="INF" id="id_6895476_58CB623A-E885-445D-B29D-69E6E82D9786_3001_2">0.85</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent> <cytk:AvailableForSaleSecuritiesMaturityDate contextRef="eol_PE151383--1410-K0012_STD_365_20141231_0_1269523x1277596_1270365x1274813_1274212x1276380" id="id_6895476_5953821E-651A-43AE-83D1-8E91E00151B4_3002_5">2015-01</cytk:AvailableForSaleSecuritiesMaturityDate> <us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="eol_PE151383--1410-K0012_STD_365_20141231_0_1269523x1277596_1276136x1280724" id="id_6895476_0A2B8B9B-38B2-46FD-A118-E87D1AE00069_2001_4">P3Y</us-gaap:PropertyPlantAndEquipmentUsefulLife> <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent contextRef="eol_PE151383--1410-K0012_STD_365_20141231_0_1269523x1277596_1280964x1294890" unitRef="pure" decimals="INF" id="id_6895476_58CB623A-E885-445D-B29D-69E6E82D9786_1001_4">1.10</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent> <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod contextRef="eol_PE151383--1410-K0012_STD_365_20141231_0_1270313x1271210" unitRef="shares" decimals="INF" id="id_6895476_9D5C22B2-CCEF-4AED-B18A-0ACE42E2B15B_9001_11">1000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod> <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue contextRef="eol_PE151383--1410-K0012_STD_365_20141231_0_1270313x1271210" unitRef="iso4217_USD_per_shares" decimals="2" id="id_6895476_4396C4E5-DD06-4003-A485-BA06C7D8368D_9001_9">9.65</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue> <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod contextRef="eol_PE151383--1410-K0012_STD_365_20141231_0_1270313x1271210" unitRef="shares" decimals="INF" id="id_6895476_9D5C22B2-CCEF-4AED-B18A-0ACE42E2B15B_9001_10">20833</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod> <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod contextRef="eol_PE151383--1410-K0012_STD_365_20141231_0_1270313x1271210" unitRef="shares" decimals="INF" id="id_6895476_9D5C22B2-CCEF-4AED-B18A-0ACE42E2B15B_9001_9">43500</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod> <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue contextRef="eol_PE151383--1410-K0012_STD_365_20141231_0_1270313x1271210" unitRef="iso4217_USD_per_shares" decimals="2" id="id_6895476_4396C4E5-DD06-4003-A485-BA06C7D8368D_9001_10">6.00</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue> <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue contextRef="eol_PE151383--1410-K0012_STD_365_20141231_0_1270313x1271210" unitRef="iso4217_USD_per_shares" decimals="2" id="id_6895476_4396C4E5-DD06-4003-A485-BA06C7D8368D_9001_11">6.00</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue> <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod contextRef="eol_PE151383--1410-K0012_STD_365_20141231_0_1270313x1271212" unitRef="shares" decimals="INF" id="id_6895476_550670F2-8019-4594-8D89-8D38F90A7B79_12001_18">1000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod> <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1 contextRef="eol_PE151383--1410-K0012_STD_365_20141231_0_1270313x1271212" id="id_6895476_5F253034-A3E2-4A92-8DC5-D01804806735_2_2">P9M29D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1> <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod contextRef="eol_PE151383--1410-K0012_STD_365_20141231_0_1270313x1271212" unitRef="shares" decimals="INF" id="id_6895476_EAE02EAA-C88A-417D-A4E8-6DD5ADADA4AB_13001_18">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod> <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross contextRef="eol_PE151383--1410-K0012_STD_365_20141231_0_1270313x1271212" unitRef="shares" decimals="INF" id="id_6895476_EAE02EAA-C88A-417D-A4E8-6DD5ADADA4AB_13001_15">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross> <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod contextRef="eol_PE151383--1410-K0012_STD_365_20141231_0_1270313x1271212" unitRef="shares" decimals="INF" id="id_6895476_550670F2-8019-4594-8D89-8D38F90A7B79_12001_15">43500</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod> <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue contextRef="eol_PE151383--1410-K0012_STD_365_20141231_0_1270313x1271212" unitRef="iso4217_USD" decimals="-5" id="id_6895476_25E57D28-4973-461D-96F3-FC38BA8FEA62_1001_0">100000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue> <cytk:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedInPeriodWeightedAverageExercisePrice contextRef="eol_PE151383--1410-K0012_STD_365_20141231_0_1270313x1271212" unitRef="iso4217_USD_per_shares" decimals="0" id="id_6895476_C3206D70-DEC9-4565-9145-8B70956A712D_12001_13">0</cytk:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedInPeriodWeightedAverageExercisePrice> <cytk:ShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentOtherThanOptionForfeituresInPeriodWeightedAverageExercisePrice contextRef="eol_PE151383--1410-K0012_STD_365_20141231_0_1270313x1271212" unitRef="iso4217_USD_per_shares" decimals="0" id="id_6895476_C3206D70-DEC9-4565-9145-8B70956A712D_12001_16">0</cytk:ShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentOtherThanOptionForfeituresInPeriodWeightedAverageExercisePrice> <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1 contextRef="eol_PE151383--1410-K0012_STD_365_20141231_0_1270313x1275629" id="id_6895476_5F253034-A3E2-4A92-8DC5-D01804806735_1_2">P2Y6M7D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1> <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate contextRef="eol_PE151383--1410-K0012_STD_365_20141231_0_1270313x1275629" unitRef="pure" decimals="3" id="id_6895476_A776E96A-A480-479E-9B5C-9A756B15D08A_1_3">0.000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate> <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="eol_PE151383--1410-K0012_STD_365_20141231_0_1270313x1275629" id="id_6895476_A776E96A-A480-479E-9B5C-9A756B15D08A_1_2">P6Y3M18D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1> <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate contextRef="eol_PE151383--1410-K0012_STD_365_20141231_0_1270313x1275629" unitRef="pure" decimals="3" id="id_6895476_A776E96A-A480-479E-9B5C-9A756B15D08A_1_0">0.019</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate> <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate contextRef="eol_PE151383--1410-K0012_STD_365_20141231_0_1270313x1275629" unitRef="pure" decimals="3" id="id_6895476_A776E96A-A480-479E-9B5C-9A756B15D08A_1_1">0.771</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate> <invest:InvestmentMaturityDateRangeStart1 contextRef="eol_PE151383--1410-K0012_STD_365_20141231_0_1270365x1274813" id="id_6895476_FC5D6B10-2950-4D77-93DA-2D46C596CBF7_1001_2">2015-01-01</invest:InvestmentMaturityDateRangeStart1> <invest:InvestmentMaturityDateRangeEnd1 contextRef="eol_PE151383--1410-K0012_STD_365_20141231_0_1270365x1274813" id="id_6895476_FC5D6B10-2950-4D77-93DA-2D46C596CBF7_1001_3">2015-02-27</invest:InvestmentMaturityDateRangeEnd1> <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate contextRef="eol_PE151383--1410-K0012_STD_365_20141231_0_1271382x1277228" unitRef="pure" decimals="3" id="id_6895476_A776E96A-A480-479E-9B5C-9A756B15D08A_2_3">0.000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate> <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="eol_PE151383--1410-K0012_STD_365_20141231_0_1271382x1277228" id="id_6895476_A776E96A-A480-479E-9B5C-9A756B15D08A_2_2">P1Y3M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1> <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate contextRef="eol_PE151383--1410-K0012_STD_365_20141231_0_1271382x1277228" unitRef="pure" decimals="3" id="id_6895476_A776E96A-A480-479E-9B5C-9A756B15D08A_2_0">0.002</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate> <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate contextRef="eol_PE151383--1410-K0012_STD_365_20141231_0_1271382x1277228" unitRef="pure" decimals="3" id="id_6895476_A776E96A-A480-479E-9B5C-9A756B15D08A_2_1">0.860</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate> <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="eol_PE151383--1410-K0012_STD_365_20141231_0_1271382x1277228" unitRef="shares" decimals="-3" id="id_6895476_3E2C7E3E-7982-4F2C-A6E3-5C7781C1D9F7_3001_4">15000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount> <cytk:IssuanceOfCommonStockToMlvAtPerShareUpperLimit contextRef="eol_PE151383--1410-K0012_STD_365_20141231_0_1271382x1511257" unitRef="iso4217_USD_per_shares" decimals="2" id="id_6895476_58E9B802-84A6-48EC-8C22-C0DD0182E686_15008_73">6.79</cytk:IssuanceOfCommonStockToMlvAtPerShareUpperLimit> <cytk:IssuanceOfCommonStockToMlvNetOfCommissionAndIssuanceCosts contextRef="eol_PE151383--1410-K0012_STD_365_20141231_0_1271382x1511257" unitRef="iso4217_USD" decimals="-3" id="id_6895476_58E9B802-84A6-48EC-8C22-C0DD0182E686_15008_74">74000</cytk:IssuanceOfCommonStockToMlvNetOfCommissionAndIssuanceCosts> <cytk:IssuanceOfCommonStockToMlvAtPerShareLowerLimit contextRef="eol_PE151383--1410-K0012_STD_365_20141231_0_1271382x1511257" unitRef="iso4217_USD_per_shares" decimals="2" id="id_6895476_58E9B802-84A6-48EC-8C22-C0DD0182E686_15008_72">6.64</cytk:IssuanceOfCommonStockToMlvAtPerShareLowerLimit> <cytk:ProceedsFromSalesOfCommonStockNet contextRef="eol_PE151383--1410-K0012_STD_365_20141231_0_1271382x1511257" unitRef="iso4217_USD" decimals="-5" id="id_6895476_8A8F0701-BBA5-4387-AD6C-5E09ADAEB480_1001_1">15200000</cytk:ProceedsFromSalesOfCommonStockNet> <cytk:StockIssuedDuringPeriodValueAtMarketIssuanceSalesAgreement contextRef="eol_PE151383--1410-K0012_STD_365_20141231_0_1271382x1511257" unitRef="iso4217_USD" decimals="-3" id="id_6895476_58E9B802-84A6-48EC-8C22-C0DD0182E686_15008_70">2376000</cytk:StockIssuedDuringPeriodValueAtMarketIssuanceSalesAgreement> <cytk:StockIssuedDuringPeriodSharesAtMarketIssuanceSalesAgreement contextRef="eol_PE151383--1410-K0012_STD_365_20141231_0_1271382x1511257_1276401x1270422" unitRef="shares" decimals="INF" id="id_6895476_58E9B802-84A6-48EC-8C22-C0DD0182E686_15001_71">364103</cytk:StockIssuedDuringPeriodSharesAtMarketIssuanceSalesAgreement> <cytk:StockIssuedDuringPeriodValueAtMarketIssuanceSalesAgreement contextRef="eol_PE151383--1410-K0012_STD_365_20141231_0_1271382x1511257_1276401x1273630" unitRef="iso4217_USD" decimals="-3" id="id_6895476_58E9B802-84A6-48EC-8C22-C0DD0182E686_15005_70">2376000</cytk:StockIssuedDuringPeriodValueAtMarketIssuanceSalesAgreement> <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="eol_PE151383--1410-K0012_STD_365_20141231_0_1272720x1275629" unitRef="shares" decimals="-3" id="id_6895476_3E2C7E3E-7982-4F2C-A6E3-5C7781C1D9F7_4001_0">3298000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount> <us-gaap:ReimbursementRevenue contextRef="eol_PE151383--1410-K0012_STD_365_20141231_0_1272896x1454595" unitRef="iso4217_USD" decimals="-3" id="id_6895476_097E51C1-D472-4642-91F0-D1638561D10B_1001_1">0</us-gaap:ReimbursementRevenue> <cytk:OtherResearchAndDevelopmentRevenueArrangementsReimbursementOfExpenseTableTextBlock contextRef="eol_PE151383--1410-K0012_STD_365_20141231_0_1272896x1454595" id="id_6895476_262EABF8-8FEF-46EE-9724-D546C19CEF98_1_0"><div> <p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 12px; TEXT-INDENT: 4%" align="justify"><font style="FONT-FAMILY: Times New Roman" size="2">Research and development revenue from MyoKardia was as follows (in thousands):</font></p> <p style="MARGIN-BOTTOM: 0px; FONT-SIZE: 12px; MARGIN-TOP: 0px"> &#xA0;</p> <table style="BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="92%" align="center" border="0"> <tr> <td width="77%"></td> <td valign="bottom" width="4%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="4%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="4%"></td> <td></td> <td></td> <td></td> </tr> <tr> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="10" align="center"><font style="FONT-FAMILY: Times New Roman" size="1"><b>Years&#xA0;Ended&#xA0;December&#xA0;31,</b></font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> </tr> <tr> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" align="center"><font style="FONT-FAMILY: Times New Roman" size="1"><b>2014</b></font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" align="center"><font style="FONT-FAMILY: Times New Roman" size="1"><b>2013</b></font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" align="center"><font style="FONT-FAMILY: Times New Roman" size="1"><b>2012</b></font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> </tr> <tr bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: Times New Roman" size="2">Research and development milestone fees</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">100</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td> <td valign="bottom" nowrap="nowrap" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">&#x2014;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td> <td valign="bottom" nowrap="nowrap" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">&#x2014;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> </tr> <tr> <td valign="top"> <p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: Times New Roman" size="2">Expense reimbursements from MyoKardia</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" nowrap="nowrap" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">&#x2014;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">1,024</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">595</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> </tr> <tr bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: Times New Roman" size="2">Research and development revenue from Myokardia</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">100</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">1,024</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">595</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td>&#xA0;</td> </tr> </table> </div></cytk:OtherResearchAndDevelopmentRevenueArrangementsReimbursementOfExpenseTableTextBlock> <cytk:ResearchAndDevelopmentRevenueFromCollaboration contextRef="eol_PE151383--1410-K0012_STD_365_20141231_0_1272896x1454595" unitRef="iso4217_USD" decimals="-3" id="id_6895476_097E51C1-D472-4642-91F0-D1638561D10B_1001_2">100000</cytk:ResearchAndDevelopmentRevenueFromCollaboration> <cytk:ResearchAndDevelopmentRevenue contextRef="eol_PE151383--1410-K0012_STD_365_20141231_0_1272896x1454595" unitRef="iso4217_USD" decimals="-3" id="id_6895476_097E51C1-D472-4642-91F0-D1638561D10B_1001_0">100000</cytk:ResearchAndDevelopmentRevenue> <us-gaap:RevenueFromGrants contextRef="eol_PE151383--1410-K0012_STD_365_20141231_0_1272896x1507815" unitRef="iso4217_USD" decimals="-3" id="id_6895476_FD977883-B531-4443-8A85-7DBADCAD1197_1001_0">0</us-gaap:RevenueFromGrants> <us-gaap:ReimbursementRevenue contextRef="eol_PE151383--1410-K0012_STD_365_20141231_0_1272896x1537165" unitRef="iso4217_USD" decimals="-3" id="id_6895476_C614CF06-9CB5-403B-B2F4-C612F97ACB77_1001_0">0</us-gaap:ReimbursementRevenue> <cytk:OtherResearchAndDevelopmentRevenueArrangementsReimbursementOfExpenseTableTextBlock contextRef="eol_PE151383--1410-K0012_STD_365_20141231_0_1272896x1537165" id="id_6895476_E9DB2652-8C11-4C9B-AB4A-F86D583C8589_1_0"><div> <p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 12px; TEXT-INDENT: 4%" align="justify"><font style="FONT-FAMILY: Times New Roman" size="2">Research and development revenue from Global Blood was as follows (in thousands):</font></p> <p style="MARGIN-BOTTOM: 0px; FONT-SIZE: 12px; MARGIN-TOP: 0px"> &#xA0;</p> <table style="BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="92%" align="center" border="0"> <tr> <td width="79%"></td> <td valign="bottom" width="4%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="4%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="4%"></td> <td></td> <td></td> <td></td> </tr> <tr> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="10" align="center"><font style="FONT-FAMILY: Times New Roman" size="1"><b>Years&#xA0;Ended&#xA0;December&#xA0;31,</b></font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> </tr> <tr> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" align="center"><font style="FONT-FAMILY: Times New Roman" size="1"><b>2014</b></font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" align="center"><font style="FONT-FAMILY: Times New Roman" size="1"><b>2013</b></font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" align="center"><font style="FONT-FAMILY: Times New Roman" size="1"><b>2012</b></font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> </tr> <tr bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: Times New Roman" size="2">Expense reimbursements from Global Blood</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td> <td valign="bottom" nowrap="nowrap" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">&#x2014;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">14</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">1,479</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td>&#xA0;</td> </tr> </table> </div></cytk:OtherResearchAndDevelopmentRevenueArrangementsReimbursementOfExpenseTableTextBlock> <us-gaap:RevenueFromGrants contextRef="eol_PE151383--1410-K0012_STD_365_20141231_0_1272896x1621940" unitRef="iso4217_USD" decimals="-3" id="id_6895476_FD977883-B531-4443-8A85-7DBADCAD1197_2001_1">75000</us-gaap:RevenueFromGrants> <us-gaap:ConcentrationRiskPercentage1 contextRef="eol_PE151383--1410-K0012_STD_365_20141231_0_1273333x1269843" unitRef="pure" decimals="2" id="id_6895476_C3137FA3-DA71-4E40-BD85-F7C46617CB80_1001_1">0.69</us-gaap:ConcentrationRiskPercentage1> <us-gaap:ConcentrationRiskPercentage1 contextRef="eol_PE151383--1410-K0012_STD_365_20141231_0_1273333x1271500" unitRef="pure" decimals="2" id="id_6895476_C3137FA3-DA71-4E40-BD85-F7C46617CB80_2001_0">0.31</us-gaap:ConcentrationRiskPercentage1> <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights contextRef="eol_PE151383--1410-K0012_STD_365_20141231_0_1273383x1358661_1280964x1403278" id="id_6895476_0AF6DB82-B080-4B35-841A-44AE3BB5C9C4_1001_3">Options granted to new employees generally vest 25% after one year and monthly thereafter over a period of four years.</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights> <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1 contextRef="eol_PE151383--1410-K0012_STD_365_20141231_0_1273383x1358661_1280964x1403278" id="id_6895476_0AF6DB82-B080-4B35-841A-44AE3BB5C9C4_1001_5">P4Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1> <cytk:PeriodFromPercentageOfStockOptionVested contextRef="eol_PE151383--1410-K0012_STD_365_20141231_0_1273383x1358661_1280964x1403278" id="id_6895476_0AF6DB82-B080-4B35-841A-44AE3BB5C9C4_1001_4">P1Y</cytk:PeriodFromPercentageOfStockOptionVested> <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights contextRef="eol_PE151383--1410-K0012_STD_365_20141231_0_1273383x1392833_1280964x1403278" id="id_6895476_0AF6DB82-B080-4B35-841A-44AE3BB5C9C4_2001_6">Options granted to existing employees generally vest monthly over a period of four years.</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights> <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1 contextRef="eol_PE151383--1410-K0012_STD_365_20141231_0_1273383x1392833_1280964x1403278" id="id_6895476_0AF6DB82-B080-4B35-841A-44AE3BB5C9C4_2001_7">P4Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1> <us-gaap:AllocatedShareBasedCompensationExpense contextRef="eol_PE151383--1410-K0012_STD_365_20141231_0_1274159x1269133" unitRef="iso4217_USD" decimals="-3" id="id_6895476_4ED78B6B-525C-4A06-A788-E5CE58B1F0CD_1001_1">1969000</us-gaap:AllocatedShareBasedCompensationExpense> <us-gaap:AllocatedShareBasedCompensationExpense contextRef="eol_PE151383--1410-K0012_STD_365_20141231_0_1274159x1269570" unitRef="iso4217_USD" decimals="-3" id="id_6895476_4ED78B6B-525C-4A06-A788-E5CE58B1F0CD_2001_0">1361000</us-gaap:AllocatedShareBasedCompensationExpense> <us-gaap:UnrealizedGainLossOnInvestments contextRef="eol_PE151383--1410-K0012_STD_365_20141231_0_1274212x1276380" unitRef="iso4217_USD" decimals="-3" id="id_6895476_FC5D6B10-2950-4D77-93DA-2D46C596CBF7_2001_0">-7000</us-gaap:UnrealizedGainLossOnInvestments> <us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned contextRef="eol_PE151383--1410-K0012_STD_365_20141231_0_1274544x1398741_1279431x1434297" unitRef="iso4217_USD" decimals="-5" id="id_6895476_F8E2956D-0212-47E3-95E1-66B87A6BD033_1001_1">30000000</us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned> <us-gaap:DeferredRevenueRevenueRecognized contextRef="eol_PE151383--1410-K0012_STD_365_20141231_0_1274544x1398741_1279431x1434297" unitRef="iso4217_USD" decimals="0" id="id_6895476_F8E2956D-0212-47E3-95E1-66B87A6BD033_1001_0">0</us-gaap:DeferredRevenueRevenueRecognized> <us-gaap:ProceedsFromIssuanceOfCommonStock contextRef="eol_PE151383--1410-K0012_STD_365_20141231_0_1274544x1398741_1279431x1434297" unitRef="iso4217_USD" decimals="-5" id="id_6895476_8F3077E6-41FF-4940-BA00-DABA022D23D7_1001_2">10000000</us-gaap:ProceedsFromIssuanceOfCommonStock> <cytk:FairValueOfCommonStockIssued contextRef="eol_PE151383--1410-K0012_STD_365_20141231_0_1274544x1398741_1279431x1434297" unitRef="iso4217_USD" decimals="-5" id="id_6895476_8F3077E6-41FF-4940-BA00-DABA022D23D7_1001_3">9100000</cytk:FairValueOfCommonStockIssued> <us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="eol_PE151383--1410-K0012_STD_365_20141231_0_1276136x1274094" id="id_6895476_0A2B8B9B-38B2-46FD-A118-E87D1AE00069_3001_2">P7Y</us-gaap:PropertyPlantAndEquipmentUsefulLife> <us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="eol_PE151383--1410-K0012_STD_365_20141231_0_1276136x1279264" id="id_6895476_0A2B8B9B-38B2-46FD-A118-E87D1AE00069_4001_1">P5Y</us-gaap:PropertyPlantAndEquipmentUsefulLife> <us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="eol_PE151383--1410-K0012_STD_365_20141231_0_1276136x1362982" id="id_6895476_0A2B8B9B-38B2-46FD-A118-E87D1AE00069_5001_0">P3Y</us-gaap:PropertyPlantAndEquipmentUsefulLife> <cytk:ExcessOfCommonStockFairValueOverAllocatedPurchasePriceOfPreferredStock contextRef="eol_PE151383--1410-K0012_STD_365_20141231_0_1276400x1269676" unitRef="iso4217_USD" decimals="-5" id="id_6895476_9D05859A-1643-40DB-84BF-0030A92FBDAE_1_0">2900000</cytk:ExcessOfCommonStockFairValueOverAllocatedPurchasePriceOfPreferredStock> <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="eol_PE151383--1410-K0012_STD_365_20141231_0_1276400x1281157" unitRef="shares" decimals="-3" id="id_6895476_3E2C7E3E-7982-4F2C-A6E3-5C7781C1D9F7_5001_2">0</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount> <cytk:ExcessOfCommonStockFairValueOverAllocatedPurchasePriceOfPreferredStock contextRef="eol_PE151383--1410-K0012_STD_365_20141231_0_1276400x1281157" unitRef="iso4217_USD" decimals="-5" id="id_6895476_99773C8E-7271-4D07-868F-1F24F1E8B022_1_0">1300000</cytk:ExcessOfCommonStockFairValueOverAllocatedPurchasePriceOfPreferredStock> <us-gaap:OtherComprehensiveIncomeLossNetOfTax contextRef="eol_PE151383--1410-K0012_STD_365_20141231_0_1276401x1268669" unitRef="iso4217_USD" decimals="-3" id="id_6895476_58E9B802-84A6-48EC-8C22-C0DD0182E686_14006_84">-11000</us-gaap:OtherComprehensiveIncomeLossNetOfTax> <us-gaap:NetIncomeLoss contextRef="eol_PE151383--1410-K0012_STD_365_20141231_0_1276401x1269588" unitRef="iso4217_USD" decimals="-3" id="id_6895476_58E9B802-84A6-48EC-8C22-C0DD0182E686_14007_85">-14646000</us-gaap:NetIncomeLoss> <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans contextRef="eol_PE151383--1410-K0012_STD_365_20141231_0_1276401x1270422" unitRef="shares" decimals="INF" id="id_6895476_58E9B802-84A6-48EC-8C22-C0DD0182E686_14001_64">19726</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans> <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures contextRef="eol_PE151383--1410-K0012_STD_365_20141231_0_1276401x1270422" unitRef="shares" decimals="INF" id="id_6895476_58E9B802-84A6-48EC-8C22-C0DD0182E686_14001_67">11704</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures> <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised contextRef="eol_PE151383--1410-K0012_STD_365_20141231_0_1276401x1270422" unitRef="shares" decimals="INF" id="id_6895476_58E9B802-84A6-48EC-8C22-C0DD0182E686_14001_61">390</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised> <cytk:StockIssuedDuringPeriodValueSecuritiesPurchaseAgreement contextRef="eol_PE151383--1410-K0012_STD_365_20141231_0_1276401x1270422" unitRef="iso4217_USD" decimals="-3" id="id_6895476_58E9B802-84A6-48EC-8C22-C0DD0182E686_14001_79">5000</cytk:StockIssuedDuringPeriodValueSecuritiesPurchaseAgreement> <cytk:StockIssuedDuringPeriodSharesExerciseOfWarrants contextRef="eol_PE151383--1410-K0012_STD_365_20141231_0_1276401x1270422" unitRef="shares" decimals="INF" id="id_6895476_58E9B802-84A6-48EC-8C22-C0DD0182E686_14001_69">510125</cytk:StockIssuedDuringPeriodSharesExerciseOfWarrants> <cytk:StockIssuedDuringPeriodValueExerciseOfWarrants contextRef="eol_PE151383--1410-K0012_STD_365_20141231_0_1276401x1270422" unitRef="iso4217_USD" decimals="-3" id="id_6895476_58E9B802-84A6-48EC-8C22-C0DD0182E686_14001_68">1000</cytk:StockIssuedDuringPeriodValueExerciseOfWarrants> <cytk:StockIssuedDuringPeriodValueNewIssuesToCollaborativePartner contextRef="eol_PE151383--1410-K0012_STD_365_20141231_0_1276401x1270422" unitRef="iso4217_USD" decimals="-3" id="id_6895476_58E9B802-84A6-48EC-8C22-C0DD0182E686_14001_75">2000</cytk:StockIssuedDuringPeriodValueNewIssuesToCollaborativePartner> <cytk:StockIssuedDuringPeriodSharesNewIssuesToCollaborativePartner contextRef="eol_PE151383--1410-K0012_STD_365_20141231_0_1276401x1270422" unitRef="shares" decimals="INF" id="id_6895476_58E9B802-84A6-48EC-8C22-C0DD0182E686_14001_76">2040816</cytk:StockIssuedDuringPeriodSharesNewIssuesToCollaborativePartner> <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures contextRef="eol_PE151383--1410-K0012_STD_365_20141231_0_1276401x1273630" unitRef="iso4217_USD" decimals="-3" id="id_6895476_58E9B802-84A6-48EC-8C22-C0DD0182E686_14005_66">-96000</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures> <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan contextRef="eol_PE151383--1410-K0012_STD_365_20141231_0_1276401x1273630" unitRef="iso4217_USD" decimals="-3" id="id_6895476_58E9B802-84A6-48EC-8C22-C0DD0182E686_14005_63">67000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan> <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="eol_PE151383--1410-K0012_STD_365_20141231_0_1276401x1273630" unitRef="iso4217_USD" decimals="-3" id="id_6895476_58E9B802-84A6-48EC-8C22-C0DD0182E686_14005_60">2000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised> <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="eol_PE151383--1410-K0012_STD_365_20141231_0_1276401x1273630" unitRef="iso4217_USD" decimals="-3" id="id_6895476_58E9B802-84A6-48EC-8C22-C0DD0182E686_14005_83">3330000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue> <cytk:StockIssuedDuringPeriodValueSecuritiesPurchaseAgreement contextRef="eol_PE151383--1410-K0012_STD_365_20141231_0_1276401x1273630" unitRef="iso4217_USD" decimals="-3" id="id_6895476_58E9B802-84A6-48EC-8C22-C0DD0182E686_14005_79">37487000</cytk:StockIssuedDuringPeriodValueSecuritiesPurchaseAgreement> <cytk:StockIssuedDuringPeriodValueExerciseOfWarrants contextRef="eol_PE151383--1410-K0012_STD_365_20141231_0_1276401x1273630" unitRef="iso4217_USD" decimals="-3" id="id_6895476_58E9B802-84A6-48EC-8C22-C0DD0182E686_14005_68">5000</cytk:StockIssuedDuringPeriodValueExerciseOfWarrants> <cytk:StockIssuedDuringPeriodValueNewIssuesToCollaborativePartner contextRef="eol_PE151383--1410-K0012_STD_365_20141231_0_1276401x1273630" unitRef="iso4217_USD" decimals="-3" id="id_6895476_58E9B802-84A6-48EC-8C22-C0DD0182E686_14005_75">9100000</cytk:StockIssuedDuringPeriodValueNewIssuesToCollaborativePartner> <us-gaap:ReimbursementRevenue contextRef="eol_PE151383--1410-K0012_STD_365_20141231_0_1278629x1344498_1279431x1434297" unitRef="iso4217_USD" decimals="-5" id="id_6895476_617189FC-1484-452E-8F04-6FAC2411A099_1001_0">8900000</us-gaap:ReimbursementRevenue> <us-gaap:ReimbursementRevenue contextRef="eol_PE151383--1410-K0012_STD_365_20141231_0_1278629x1361274_1279431x1434297" unitRef="iso4217_USD" decimals="-5" id="id_6895476_617189FC-1484-452E-8F04-6FAC2411A099_1002_0">6500000</us-gaap:ReimbursementRevenue> <us-gaap:ConcentrationRiskPercentage1 contextRef="eol_PE151383--1410-K0012_STD_365_20141231_0_1279431x1424859" unitRef="pure" decimals="2" id="id_6895476_D076CC70-CB7C-4170-BD50-2E3EFE86EE58_1001_0">0.10</us-gaap:ConcentrationRiskPercentage1> <us-gaap:ScheduleOfRelatedPartyTransactionsTableTextBlock contextRef="eol_PE151383--1410-K0012_STD_365_20141231_0_1279431x1424859" id="id_6895476_AF01382D-7DFA-425C-A42C-9F9D04A3A05C_1_0"><div> <p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 12px; TEXT-INDENT: 4%" align="justify"><font style="FONT-FAMILY: Times New Roman" size="2">Revenue from Amgen was as follows (in thousands):</font></p> <p style="MARGIN-BOTTOM: 0px; FONT-SIZE: 12px; MARGIN-TOP: 0px"> &#xA0;</p> <table style="BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="92%" align="center" border="0"> <tr> <td width="72%"></td> <td valign="bottom" width="4%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="4%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="4%"></td> <td></td> <td></td> <td></td> </tr> <tr> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="10" align="center"><font style="FONT-FAMILY: Times New Roman" size="1"><b>Years Ended December&#xA0;31,</b></font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> </tr> <tr> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" align="center"><font style="FONT-FAMILY: Times New Roman" size="1"><b>2014</b></font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" align="center"><font style="FONT-FAMILY: Times New Roman" size="1"><b>2013</b></font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" align="center"><font style="FONT-FAMILY: Times New Roman" size="1"><b>2012</b></font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> </tr> <tr bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: Times New Roman" size="2">License revenues from related parties</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td> <td valign="bottom" nowrap="nowrap" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">&#x2014;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">17,230</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td> <td valign="bottom" nowrap="nowrap" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">&#x2014;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> </tr> <tr> <td valign="top"> <p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: Times New Roman" size="2">Research and development revenues from related parties:</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-LEFT: 2em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: Times New Roman" size="2">Reimbursement of internal costs</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">4,260</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">2,019</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">4,174</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> </tr> <tr> <td valign="top"> <p style="MARGIN-LEFT: 2em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: Times New Roman" size="2">Reimbursement of other costs</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" nowrap="nowrap" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">&#x2014;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" nowrap="nowrap" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">&#x2014;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">3</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> </tr> <tr bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-LEFT: 2em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: Times New Roman" size="2">Allocated consideration</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">278</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" nowrap="nowrap" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">&#x2014;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" nowrap="nowrap" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">&#x2014;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> </tr> <tr> <td valign="top"> <p style="MARGIN-LEFT: 3em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: Times New Roman" size="2">Total revenues from Amgen</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">4,538</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">19,249</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">4,177</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td>&#xA0;</td> </tr> </table> </div></us-gaap:ScheduleOfRelatedPartyTransactionsTableTextBlock> <us-gaap:RevenueRecognitionMilestoneMethodRevenueRecognized contextRef="eol_PE151383--1410-K0012_STD_365_20141231_0_1279431x1424859" unitRef="iso4217_USD" decimals="INF" id="id_6895476_34DE31CB-E1F9-4ECD-8E18-6B236F60A418_2001_2">0</us-gaap:RevenueRecognitionMilestoneMethodRevenueRecognized> <us-gaap:LicenseAndServicesRevenue contextRef="eol_PE151383--1410-K0012_STD_365_20141231_0_1279431x1424859" unitRef="iso4217_USD" decimals="-3" id="id_6895476_DA0EFEFC-F120-4996-B278-29668E08DD78_1001_0">0</us-gaap:LicenseAndServicesRevenue> <us-gaap:RevenueFromRelatedParties contextRef="eol_PE151383--1410-K0012_STD_365_20141231_0_1279431x1424859" unitRef="iso4217_USD" decimals="-3" id="id_6895476_DA0EFEFC-F120-4996-B278-29668E08DD78_1001_4">278000</us-gaap:RevenueFromRelatedParties> <cytk:RelatedPartyResearchAndDevelopmentRevenue contextRef="eol_PE151383--1410-K0012_STD_365_20141231_0_1279431x1424859" unitRef="iso4217_USD" decimals="-3" id="id_6895476_DA0EFEFC-F120-4996-B278-29668E08DD78_1001_5">4538000</cytk:RelatedPartyResearchAndDevelopmentRevenue> <cytk:ResearchAndDevelopmentRevenuesFromRelatedParties contextRef="eol_PE151383--1410-K0012_STD_365_20141231_0_1279431x1424859" unitRef="iso4217_USD" decimals="-5" id="id_6895476_D20635B7-621E-4EE3-9E8D-D5D0621AE095_1002_1">300000</cytk:ResearchAndDevelopmentRevenuesFromRelatedParties> <cytk:FairValueOfCommonStockIssued contextRef="eol_PE151383--1410-K0012_STD_365_20141231_0_1279431x1424859" unitRef="iso4217_USD" decimals="-5" id="id_6895476_7F280FAF-8359-476C-AA21-F14004E0FF7E_1002_3">7500000</cytk:FairValueOfCommonStockIssued> <cytk:ReimbursementOfInternalResearchAndDevelopmentCost contextRef="eol_PE151383--1410-K0012_STD_365_20141231_0_1279431x1424859" unitRef="iso4217_USD" decimals="-3" id="id_6895476_DA0EFEFC-F120-4996-B278-29668E08DD78_1001_2">4260000</cytk:ReimbursementOfInternalResearchAndDevelopmentCost> <cytk:ReimbursementOfOtherResearchAndDevelopmentCost contextRef="eol_PE151383--1410-K0012_STD_365_20141231_0_1279431x1424859" unitRef="iso4217_USD" decimals="-3" id="id_6895476_DA0EFEFC-F120-4996-B278-29668E08DD78_1001_3">0</cytk:ReimbursementOfOtherResearchAndDevelopmentCost> <cytk:RelatedPartyTransactionPreCommercializationMilestonePaymentsReceivedByEntity contextRef="eol_PE151383--1410-K0012_STD_365_20141231_0_1279431x1424859" unitRef="iso4217_USD" decimals="-5" id="id_6895476_34DE31CB-E1F9-4ECD-8E18-6B236F60A418_2001_0">350000000</cytk:RelatedPartyTransactionPreCommercializationMilestonePaymentsReceivedByEntity> <us-gaap:ScheduleOfRelatedPartyTransactionsTableTextBlock contextRef="eol_PE151383--1410-K0012_STD_365_20141231_0_1279431x1434297" id="id_6895476_EFBC1AFB-949B-4E06-A6FD-8363B6C671F5_1_0"><div> <p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 12px; TEXT-INDENT: 4%" align="justify"><font style="FONT-FAMILY: Times New Roman" size="2">Research and development revenue from Astellas was as follows (in thousands):</font></p> <p style="MARGIN-BOTTOM: 0px; FONT-SIZE: 12px; MARGIN-TOP: 0px"> &#xA0;</p> <table style="BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="92%" align="center" border="0"> <tr> <td width="71%"></td> <td valign="bottom" width="9%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="9%"></td> <td></td> <td></td> <td></td> </tr> <tr> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" align="center"><font style="FONT-FAMILY: Times New Roman" size="1"><b>Year Ended<br /> December&#xA0;31,<br /> 2014</b></font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" align="center"><font style="FONT-FAMILY: Times New Roman" size="1"><b>Year Ended<br /> December&#xA0;31,<br /> 2013</b></font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> </tr> <tr bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: Times New Roman" size="2">Research and development revenues with related parties:</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr> <td valign="top"> <p style="MARGIN-LEFT: 2em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: Times New Roman" size="2">Research and development milestone fees</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">15,000</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" nowrap="nowrap" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">&#x2014;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> </tr> <tr bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: Times New Roman" size="2">Research and development revenues:</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr> <td valign="top"> <p style="MARGIN-LEFT: 2em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: Times New Roman" size="2">Reimbursement of internal costs</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">8,939</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">3,285</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> </tr> <tr bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-LEFT: 2em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: Times New Roman" size="2">Reimbursement of other costs</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">6,452</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">3,130</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> </tr> <tr> <td valign="top"> <p style="MARGIN-LEFT: 2em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: Times New Roman" size="2">Research and development milestone fees</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">2,000</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" nowrap="nowrap" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">&#x2014;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> </tr> <tr bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-LEFT: 3em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: Times New Roman" size="2">Total research and development revenue from Astellas</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">32,391</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">6,415</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td>&#xA0;</td> </tr> </table> </div></us-gaap:ScheduleOfRelatedPartyTransactionsTableTextBlock> <us-gaap:DeferredRevenueRevenueRecognized contextRef="eol_PE151383--1410-K0012_STD_365_20141231_0_1279431x1434297" unitRef="iso4217_USD" decimals="-5" id="id_6895476_029BFB08-6E6C-4557-8196-AF677A9BF516_1001_1">13700000</us-gaap:DeferredRevenueRevenueRecognized> <cytk:RelatedPartyResearchAndDevelopmentRevenue contextRef="eol_PE151383--1410-K0012_STD_365_20141231_0_1279431x1434297" unitRef="iso4217_USD" decimals="-3" id="id_6895476_CE89805E-4ADE-44CE-AB36-26227C885BB2_1_6">32391000</cytk:RelatedPartyResearchAndDevelopmentRevenue> <cytk:ResearchAndDevelopmentRevenue contextRef="eol_PE151383--1410-K0012_STD_365_20141231_0_1279431x1434297" unitRef="iso4217_USD" decimals="-5" id="id_6895476_15DFB880-F12A-494F-BE13-8D3CC55D7048_1001_1">2000000</cytk:ResearchAndDevelopmentRevenue> <cytk:ReimbursementOfInternalResearchAndDevelopmentCost contextRef="eol_PE151383--1410-K0012_STD_365_20141231_0_1279431x1434297" unitRef="iso4217_USD" decimals="-3" id="id_6895476_CE89805E-4ADE-44CE-AB36-26227C885BB2_1_3">8939000</cytk:ReimbursementOfInternalResearchAndDevelopmentCost> <cytk:ReimbursementOfOtherResearchAndDevelopmentCost contextRef="eol_PE151383--1410-K0012_STD_365_20141231_0_1279431x1434297" unitRef="iso4217_USD" decimals="-3" id="id_6895476_CE89805E-4ADE-44CE-AB36-26227C885BB2_1_4">6452000</cytk:ReimbursementOfOtherResearchAndDevelopmentCost> <cytk:ResearchAndDevelopmentRelatedPartyRevenue contextRef="eol_PE151383--1410-K0012_STD_365_20141231_0_1279431x1434297" unitRef="iso4217_USD" decimals="-3" id="id_6895476_CE89805E-4ADE-44CE-AB36-26227C885BB2_1_1">15000000</cytk:ResearchAndDevelopmentRelatedPartyRevenue> <us-gaap:LicenseAndServicesRevenue contextRef="eol_PE151383--1410-K0012_STD_365_20141231_0_1279431x1434297_1279908x1614534" unitRef="iso4217_USD" decimals="-5" id="id_6895476_029BFB08-6E6C-4557-8196-AF677A9BF516_2001_0">9800000</us-gaap:LicenseAndServicesRevenue> <us-gaap:RevenueRecognitionMilestoneMethodRevenueRecognized contextRef="eol_PE151383--1410-K0012_STD_365_20141231_0_1279431x1434297_1279908x1614633" unitRef="iso4217_USD" decimals="-5" id="id_6895476_15DFB880-F12A-494F-BE13-8D3CC55D7048_2001_0">17000000</us-gaap:RevenueRecognitionMilestoneMethodRevenueRecognized> <us-gaap:ValuationAllowancesAndReservesChargedToCostAndExpense contextRef="eol_PE151383--1410-K0012_STD_365_20141231_0_1279936x1276697" unitRef="iso4217_USD" decimals="-3" id="id_6895476_B444ABAD-A3F0-45D1-A8D2-D991236372AC_3_2">1037000</us-gaap:ValuationAllowancesAndReservesChargedToCostAndExpense> <us-gaap:ValuationAllowancesAndReservesChargedToOtherAccounts contextRef="eol_PE151383--1410-K0012_STD_365_20141231_0_1279936x1276697" unitRef="iso4217_USD" decimals="-3" id="id_6895476_B444ABAD-A3F0-45D1-A8D2-D991236372AC_3_3">0</us-gaap:ValuationAllowancesAndReservesChargedToOtherAccounts> <us-gaap:ValuationAllowancesAndReservesDeductions contextRef="eol_PE151383--1410-K0012_STD_365_20141231_0_1279936x1276697" unitRef="iso4217_USD" decimals="-3" id="id_6895476_B444ABAD-A3F0-45D1-A8D2-D991236372AC_3_4">0</us-gaap:ValuationAllowancesAndReservesDeductions> <cytk:WarrantExpirationDate contextRef="eol_PE151383--1410-K0012_STD_365_20141231_0_1280248x1351779" id="id_6895476_F7BC438C-6E3A-421D-B041-23B846FFE104_2002_3">2017-06-25</cytk:WarrantExpirationDate> <cytk:WarrantExpirationDate contextRef="eol_PE151383--1410-K0012_STD_365_20141231_0_1280248x1413008" id="id_6895476_F7BC438C-6E3A-421D-B041-23B846FFE104_2001_3">2015-04-20</cytk:WarrantExpirationDate> <us-gaap:IncomeTaxReconciliationTaxCredits contextRef="eol_PE151383--1410-K0012_STD_365_20141231_0_1280651x1276398" unitRef="iso4217_USD" decimals="-5" id="id_6895476_D5276082-6BF3-412E-9245-B2B467B8A56E_1001_1">13300000</us-gaap:IncomeTaxReconciliationTaxCredits> <cytk:OperatingLossCarryforwardsExpirationYear contextRef="eol_PE151383--1410-K0012_STD_365_20141231_0_1280651x1276398" id="id_6895476_0EF73AD1-38D5-4AA8-BDA2-BB195F3CE389_1001_3">2015</cytk:OperatingLossCarryforwardsExpirationYear> <cytk:FederalNetOperatingLossRelatesToStockOptionDeductions contextRef="eol_PE151383--1410-K0012_STD_365_20141231_0_1280651x1276398" unitRef="iso4217_USD" decimals="-5" id="id_6895476_901496F6-8F84-4A47-8EC5-7D68831C33FF_1001_0">1900000</cytk:FederalNetOperatingLossRelatesToStockOptionDeductions> <us-gaap:IncomeTaxReconciliationTaxCredits contextRef="eol_PE151383--1410-K0012_STD_365_20141231_0_1280651x1280458" unitRef="iso4217_USD" decimals="-5" id="id_6895476_D5276082-6BF3-412E-9245-B2B467B8A56E_2001_0">30800000</us-gaap:IncomeTaxReconciliationTaxCredits> <cytk:OperatingLossCarryforwardsExpirationYear contextRef="eol_PE151383--1410-K0012_STD_365_20141231_0_1280651x1280458" id="id_6895476_0EF73AD1-38D5-4AA8-BDA2-BB195F3CE389_2001_1">2020</cytk:OperatingLossCarryforwardsExpirationYear> <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions contextRef="eol_PE151383--1410-K0012_STD_365_20141231_0_1280651x1297583" unitRef="iso4217_USD" decimals="-3" id="id_6895476_7B98D2F9-CACB-495E-A3F9-A79C5892451D_7002_6">10000</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions> <us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions contextRef="eol_PE151383--1410-K0012_STD_365_20141231_0_1280651x1297583" unitRef="iso4217_USD" decimals="-3" id="id_6895476_7B98D2F9-CACB-495E-A3F9-A79C5892451D_7002_5">29000</us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions> <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions contextRef="eol_PE151383--1410-K0012_STD_365_20141231_0_1280651x1497867" unitRef="iso4217_USD" decimals="-3" id="id_6895476_7B98D2F9-CACB-495E-A3F9-A79C5892451D_7003_6">178000</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions> <us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions contextRef="eol_PE151383--1410-K0012_STD_365_20141231_0_1280651x1497867" unitRef="iso4217_USD" decimals="-3" id="id_6895476_7B98D2F9-CACB-495E-A3F9-A79C5892451D_7003_5">56000</us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions> <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions contextRef="eol_PE151383--1410-K0012_STD_365_20141231_0_1280651x1520580" unitRef="iso4217_USD" decimals="-3" id="id_6895476_7B98D2F9-CACB-495E-A3F9-A79C5892451D_7001_6">188000</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions> <us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions contextRef="eol_PE151383--1410-K0012_STD_365_20141231_0_1280651x1520580" unitRef="iso4217_USD" decimals="-3" id="id_6895476_7B98D2F9-CACB-495E-A3F9-A79C5892451D_7001_5">85000</us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions> <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent contextRef="eol_PE151383--1410-K0012_STD_365_20141231_0_1280964x1277228" unitRef="pure" decimals="INF" id="id_6895476_AA51EB59-4301-48A7-8417-F8ADFF1F04A4_1001_0">0.85</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent> <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans contextRef="eol_PE151383--1410-K0012_STD_365_20141231_0_1280964x1277228" unitRef="shares" decimals="INF" id="id_6895476_AA51EB59-4301-48A7-8417-F8ADFF1F04A4_1001_1">19726</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans> <cytk:EmployeeStockPurchasePlansAveragePricePerShare contextRef="eol_PE151383--1410-K0012_STD_365_20141231_0_1280964x1277228" unitRef="iso4217_USD_per_shares" decimals="2" id="id_6895476_AA51EB59-4301-48A7-8417-F8ADFF1F04A4_1001_2">3.38</cytk:EmployeeStockPurchasePlansAveragePricePerShare> <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue contextRef="eol_PE151383--1410-K0012_STD_365_20141231_0_1280964x1294890" unitRef="iso4217_USD_per_shares" decimals="2" id="id_6895476_945DE61A-5FF4-4863-A406-B144CAADCC72_1001_1">6.01</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue> <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights contextRef="eol_PE151383--1410-K0012_STD_365_20141231_0_1280964x1294890" id="id_6895476_58CB623A-E885-445D-B29D-69E6E82D9786_1_7">Options granted under the 1997 Plan generally vested over four or five years (generally 25% after one year and monthly thereafter).</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights> <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares contextRef="eol_PE151383--1410-K0012_STD_365_20141231_0_1280964x1294890" unitRef="shares" decimals="INF" id="id_6895476_945DE61A-5FF4-4863-A406-B144CAADCC72_1001_3">601647</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares> <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1 contextRef="eol_PE151383--1410-K0012_STD_365_20141231_0_1280964x1294890" unitRef="iso4217_USD" decimals="-5" id="id_6895476_945DE61A-5FF4-4863-A406-B144CAADCC72_1001_4">3000000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1> <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue contextRef="eol_PE151383--1410-K0012_STD_365_20141231_0_1280964x1294890" unitRef="iso4217_USD" decimals="0" id="id_6895476_945DE61A-5FF4-4863-A406-B144CAADCC72_1001_0">1000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue> <cytk:TermForStockOptionPlanForSpecifiedStockHolders contextRef="eol_PE151383--1410-K0012_STD_365_20141231_0_1280964x1294890" id="id_6895476_58CB623A-E885-445D-B29D-69E6E82D9786_1_5">P5Y</cytk:TermForStockOptionPlanForSpecifiedStockHolders> <cytk:SpecifiedStockholderOwnershipPercentage contextRef="eol_PE151383--1410-K0012_STD_365_20141231_0_1280964x1294890" unitRef="pure" decimals="2" id="id_6895476_58CB623A-E885-445D-B29D-69E6E82D9786_1_3">0.10</cytk:SpecifiedStockholderOwnershipPercentage> <cytk:TermForStockOptionPlan contextRef="eol_PE151383--1410-K0012_STD_365_20141231_0_1280964x1294890" id="id_6895476_58CB623A-E885-445D-B29D-69E6E82D9786_1_0">P10Y</cytk:TermForStockOptionPlan> <cytk:StockOptionsRepurchaseMaximumPeriod contextRef="eol_PE151383--1410-K0012_STD_365_20141231_0_1280964x1294890" id="id_6895476_58CB623A-E885-445D-B29D-69E6E82D9786_1_6">P10Y</cytk:StockOptionsRepurchaseMaximumPeriod> <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent contextRef="eol_PE151383--1410-K0012_STD_365_20141231_0_1280964x1403278" unitRef="pure" decimals="INF" id="id_6895476_0AF6DB82-B080-4B35-841A-44AE3BB5C9C4_1_0">1.00</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent> <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized contextRef="eol_PE151383--1410-K0012_STD_365_20141231_0_1280964x1403278" unitRef="shares" decimals="INF" id="id_6895476_0AF6DB82-B080-4B35-841A-44AE3BB5C9C4_1_8">2000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized> <cytk:TermToGrantNonstatutoryStockOptionsAndIncentiveStockOptions contextRef="eol_PE151383--1410-K0012_STD_365_20141231_0_1280964x1403278" id="id_6895476_0AF6DB82-B080-4B35-841A-44AE3BB5C9C4_1_1">P10Y</cytk:TermToGrantNonstatutoryStockOptionsAndIncentiveStockOptions> <cytk:PercentageOfOptionsGrantToNewEmployees contextRef="eol_PE151383--1410-K0012_STD_365_20141231_0_1280964x1403278" unitRef="pure" decimals="2" id="id_6895476_0AF6DB82-B080-4B35-841A-44AE3BB5C9C4_1_2">0.25</cytk:PercentageOfOptionsGrantToNewEmployees> <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross contextRef="eol_PE151383--1410-K0012_STD_365_20141231_0_1280964x1424733" unitRef="shares" decimals="INF" id="id_6895476_7DACACCF-F580-4FD5-9779-AA02BBB20B57_1001_0">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross> <us-gaap:AllocatedShareBasedCompensationExpense contextRef="eol_PE151383--1410-K0012_STD_365_20141231_0_1280964x1424733" unitRef="iso4217_USD" decimals="-3" id="id_6895476_D2960C5C-51C9-488D-A130-57FE536B4931_1001_0">50000</us-gaap:AllocatedShareBasedCompensationExpense> <us-gaap:ConcentrationRiskPercentage1 contextRef="eol_PE151383--1410-K0012_STD_365_20141231_0_1281318x1434297" unitRef="pure" decimals="2" id="id_6895476_B1D541CA-9025-4D78-9ABD-27AABA32983C_1001_0">0.69</us-gaap:ConcentrationRiskPercentage1> <us-gaap:EffectiveIncomeTaxRateContinuingOperations contextRef="eol_PE151383--1410-K0012_STD_366_20121231_0" unitRef="pure" decimals="2" id="id_6895476_14EF385A-3844-4F78-AE65-D20D0D541C15_3_8">0.00</us-gaap:EffectiveIncomeTaxRateContinuingOperations> <us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits contextRef="eol_PE151383--1410-K0012_STD_366_20121231_0" unitRef="pure" decimals="2" id="id_6895476_14EF385A-3844-4F78-AE65-D20D0D541C15_3_3">-0.19</us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits> <us-gaap:NetCashProvidedByUsedInOperatingActivitiesContinuingOperations contextRef="eol_PE151383--1410-K0012_STD_366_20121231_0" unitRef="iso4217_USD" decimals="-3" id="id_6895476_84756BCF-71FA-4E32-A511-A3DCED215C30_3_15">-33438000</us-gaap:NetCashProvidedByUsedInOperatingActivitiesContinuingOperations> <us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes contextRef="eol_PE151383--1410-K0012_STD_366_20121231_0" unitRef="pure" decimals="2" id="id_6895476_14EF385A-3844-4F78-AE65-D20D0D541C15_3_1">-0.06</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes> <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross contextRef="eol_PE151383--1410-K0012_STD_366_20121231_0" unitRef="shares" decimals="INF" id="id_6895476_550670F2-8019-4594-8D89-8D38F90A7B79_4001_3">403108</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross> <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod contextRef="eol_PE151383--1410-K0012_STD_366_20121231_0" unitRef="shares" decimals="INF" id="id_6895476_EAE02EAA-C88A-417D-A4E8-6DD5ADADA4AB_4001_3">403108</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod> <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized contextRef="eol_PE151383--1410-K0012_STD_366_20121231_0" unitRef="shares" decimals="INF" id="id_6895476_550670F2-8019-4594-8D89-8D38F90A7B79_4001_2">416667</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized> <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted contextRef="eol_PE151383--1410-K0012_STD_366_20121231_0" unitRef="shares" decimals="-3" id="id_6895476_09173C79-2713-49DF-8107-C7F99AA4E397_3_3">18107000</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted> <us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments contextRef="eol_PE151383--1410-K0012_STD_366_20121231_0" unitRef="pure" decimals="2" id="id_6895476_14EF385A-3844-4F78-AE65-D20D0D541C15_3_7">0.01</us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments> <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice contextRef="eol_PE151383--1410-K0012_STD_366_20121231_0" unitRef="iso4217_USD_per_shares" decimals="2" id="id_6895476_C3206D70-DEC9-4565-9145-8B70956A712D_4001_3">17.00</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice> <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod contextRef="eol_PE151383--1410-K0012_STD_366_20121231_0" unitRef="shares" decimals="INF" id="id_6895476_EAE02EAA-C88A-417D-A4E8-6DD5ADADA4AB_4001_4">210989</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod> <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice contextRef="eol_PE151383--1410-K0012_STD_366_20121231_0" unitRef="iso4217_USD_per_shares" decimals="2" id="id_6895476_C3206D70-DEC9-4565-9145-8B70956A712D_4001_2">6.14</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice> <us-gaap:EarningsPerShareBasicAndDiluted contextRef="eol_PE151383--1410-K0012_STD_366_20121231_0" unitRef="iso4217_USD_per_shares" decimals="2" id="id_6895476_09173C79-2713-49DF-8107-C7F99AA4E397_3_4">-2.30</us-gaap:EarningsPerShareBasicAndDiluted> <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate contextRef="eol_PE151383--1410-K0012_STD_366_20121231_0" unitRef="pure" decimals="2" id="id_6895476_14EF385A-3844-4F78-AE65-D20D0D541C15_3_0">-0.34</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate> <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="eol_PE151383--1410-K0012_STD_366_20121231_0" unitRef="shares" decimals="-3" id="id_6895476_3E2C7E3E-7982-4F2C-A6E3-5C7781C1D9F7_3_5">14866000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount> <us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost contextRef="eol_PE151383--1410-K0012_STD_366_20121231_0" unitRef="pure" decimals="2" id="id_6895476_14EF385A-3844-4F78-AE65-D20D0D541C15_3_5">0.00</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost> <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures contextRef="eol_PE151383--1410-K0012_STD_366_20121231_0" unitRef="iso4217_USD" decimals="-3" id="id_6895476_58E9B802-84A6-48EC-8C22-C0DD0182E686_4008_6">-401000</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures> <us-gaap:RevenueFromGrants contextRef="eol_PE151383--1410-K0012_STD_366_20121231_0" unitRef="iso4217_USD" decimals="-3" id="id_6895476_FD977883-B531-4443-8A85-7DBADCAD1197_3_2">1308000</us-gaap:RevenueFromGrants> <us-gaap:RepaymentsOfSecuredDebt contextRef="eol_PE151383--1410-K0012_STD_366_20121231_0" unitRef="iso4217_USD" decimals="-3" id="id_6895476_84756BCF-71FA-4E32-A511-A3DCED215C30_3_28">152000</us-gaap:RepaymentsOfSecuredDebt> <us-gaap:PaymentsOfStockIssuanceCosts contextRef="eol_PE151383--1410-K0012_STD_366_20121231_0" unitRef="iso4217_USD" decimals="-3" id="id_6895476_58E9B802-84A6-48EC-8C22-C0DD0182E686_4008_11">2139000</us-gaap:PaymentsOfStockIssuanceCosts> <us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt contextRef="eol_PE151383--1410-K0012_STD_366_20121231_0" unitRef="iso4217_USD" decimals="-3" id="id_6895476_84756BCF-71FA-4E32-A511-A3DCED215C30_3_17">92788000</us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt> <us-gaap:IncreaseDecreaseInRestrictedCash contextRef="eol_PE151383--1410-K0012_STD_366_20121231_0" unitRef="iso4217_USD" decimals="-3" id="id_6895476_84756BCF-71FA-4E32-A511-A3DCED215C30_3_21">-196000</us-gaap:IncreaseDecreaseInRestrictedCash> <us-gaap:IncomeTaxesPaidNet contextRef="eol_PE151383--1410-K0012_STD_366_20121231_0" unitRef="iso4217_USD" decimals="-3" id="id_6895476_822093A4-C207-4594-84E4-6C13CA36E168_3_1">1000</us-gaap:IncomeTaxesPaidNet> <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign contextRef="eol_PE151383--1410-K0012_STD_366_20121231_0" unitRef="iso4217_USD" decimals="-3" id="id_6895476_7D9738C0-6CE1-4E3E-8312-71FD14F9FEB0_3_1">0</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign> <us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount contextRef="eol_PE151383--1410-K0012_STD_366_20121231_0" unitRef="iso4217_USD" decimals="-5" id="id_6895476_172A3583-D769-410E-B05B-9FA47EC31BD7_3_0">21100000</us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount> <us-gaap:OtherComprehensiveIncomeLossNetOfTax contextRef="eol_PE151383--1410-K0012_STD_366_20121231_0" unitRef="iso4217_USD" decimals="-3" id="id_6895476_58E9B802-84A6-48EC-8C22-C0DD0182E686_4008_27">15000</us-gaap:OtherComprehensiveIncomeLossNetOfTax> <us-gaap:LicenseAndServicesRevenue contextRef="eol_PE151383--1410-K0012_STD_366_20121231_0" unitRef="iso4217_USD" decimals="-3" id="id_6895476_FF4E9404-B9B3-415C-99EC-66EC22E2B2E7_3_4">0</us-gaap:LicenseAndServicesRevenue> <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets contextRef="eol_PE151383--1410-K0012_STD_366_20121231_0" unitRef="iso4217_USD" decimals="-3" id="id_6895476_84756BCF-71FA-4E32-A511-A3DCED215C30_3_10">320000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets> <us-gaap:GainLossOnSaleOfPropertyPlantEquipment contextRef="eol_PE151383--1410-K0012_STD_366_20121231_0" unitRef="iso4217_USD" decimals="-3" id="id_6895476_84756BCF-71FA-4E32-A511-A3DCED215C30_3_4">2000</us-gaap:GainLossOnSaleOfPropertyPlantEquipment> <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan contextRef="eol_PE151383--1410-K0012_STD_366_20121231_0" unitRef="iso4217_USD" decimals="-3" id="id_6895476_58E9B802-84A6-48EC-8C22-C0DD0182E686_4008_3">65000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan> <us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax contextRef="eol_PE151383--1410-K0012_STD_366_20121231_0" unitRef="iso4217_USD" decimals="-3" id="id_6895476_FF4E9404-B9B3-415C-99EC-66EC22E2B2E7_3_21">15000</us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax> <us-gaap:OperatingIncomeLoss contextRef="eol_PE151383--1410-K0012_STD_366_20121231_0" unitRef="iso4217_USD" decimals="-3" id="id_6895476_FF4E9404-B9B3-415C-99EC-66EC22E2B2E7_3_11">-40457000</us-gaap:OperatingIncomeLoss> <us-gaap:IncreaseDecreaseInDueFromRelatedPartiesCurrent contextRef="eol_PE151383--1410-K0012_STD_366_20121231_0" unitRef="iso4217_USD" decimals="-3" id="id_6895476_84756BCF-71FA-4E32-A511-A3DCED215C30_3_9">-10000</us-gaap:IncreaseDecreaseInDueFromRelatedPartiesCurrent> <us-gaap:ComprehensiveIncomeNetOfTax contextRef="eol_PE151383--1410-K0012_STD_366_20121231_0" unitRef="iso4217_USD" decimals="-3" id="id_6895476_FF4E9404-B9B3-415C-99EC-66EC22E2B2E7_3_22">-40355000</us-gaap:ComprehensiveIncomeNetOfTax> <us-gaap:NonoperatingIncomeExpense contextRef="eol_PE151383--1410-K0012_STD_366_20121231_0" unitRef="iso4217_USD" decimals="-3" id="id_6895476_73255E91-D164-4B6A-A45B-4757187E85BA_3_2">87000</us-gaap:NonoperatingIncomeExpense> <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments contextRef="eol_PE151383--1410-K0012_STD_366_20121231_0" unitRef="iso4217_USD" decimals="-3" id="id_6895476_7D9738C0-6CE1-4E3E-8312-71FD14F9FEB0_3_2">-40370000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments> <us-gaap:GainOnSaleOfInvestments contextRef="eol_PE151383--1410-K0012_STD_366_20121231_0" unitRef="iso4217_USD" decimals="-3" id="id_6895476_84756BCF-71FA-4E32-A511-A3DCED215C30_3_7">0</us-gaap:GainOnSaleOfInvestments> <us-gaap:Revenues contextRef="eol_PE151383--1410-K0012_STD_366_20121231_0" unitRef="iso4217_USD" decimals="-3" id="id_6895476_FF4E9404-B9B3-415C-99EC-66EC22E2B2E7_3_5">7559000</us-gaap:Revenues> <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment contextRef="eol_PE151383--1410-K0012_STD_366_20121231_0" unitRef="iso4217_USD" decimals="-3" id="id_6895476_84756BCF-71FA-4E32-A511-A3DCED215C30_3_19">125000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment> <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic contextRef="eol_PE151383--1410-K0012_STD_366_20121231_0" unitRef="iso4217_USD" decimals="-3" id="id_6895476_09173C79-2713-49DF-8107-C7F99AA4E397_3_2">-41677000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic> <us-gaap:NetIncomeLoss contextRef="eol_PE151383--1410-K0012_STD_366_20121231_0" unitRef="iso4217_USD" decimals="-3" id="id_6895476_58E9B802-84A6-48EC-8C22-C0DD0182E686_4008_28">-40370000</us-gaap:NetIncomeLoss> <us-gaap:InvestmentIncomeInterest contextRef="eol_PE151383--1410-K0012_STD_366_20121231_0" unitRef="iso4217_USD" decimals="-3" id="id_6895476_944F757B-AF2C-42F5-8AB2-26CA07F38C19_3_0">83000</us-gaap:InvestmentIncomeInterest> <us-gaap:InterestPaid contextRef="eol_PE151383--1410-K0012_STD_366_20121231_0" unitRef="iso4217_USD" decimals="-3" id="id_6895476_822093A4-C207-4594-84E4-6C13CA36E168_3_0">3000</us-gaap:InterestPaid> <us-gaap:InterestAndOtherIncome contextRef="eol_PE151383--1410-K0012_STD_366_20121231_0" unitRef="iso4217_USD" decimals="-3" id="id_6895476_73255E91-D164-4B6A-A45B-4757187E85BA_3_0">89000</us-gaap:InterestAndOtherIncome> <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="eol_PE151383--1410-K0012_STD_366_20121231_0" unitRef="iso4217_USD" decimals="-3" id="id_6895476_58E9B802-84A6-48EC-8C22-C0DD0182E686_4008_26">3783000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue> <us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued contextRef="eol_PE151383--1410-K0012_STD_366_20121231_0" unitRef="iso4217_USD" decimals="-3" id="id_6895476_58E9B802-84A6-48EC-8C22-C0DD0182E686_4008_16">13761000</us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued> <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic contextRef="eol_PE151383--1410-K0012_STD_366_20121231_0" unitRef="iso4217_USD" decimals="-3" id="id_6895476_7D9738C0-6CE1-4E3E-8312-71FD14F9FEB0_3_0">-40370000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic> <us-gaap:AllocatedShareBasedCompensationExpense contextRef="eol_PE151383--1410-K0012_STD_366_20121231_0" unitRef="iso4217_USD" decimals="-3" id="id_6895476_4ED78B6B-525C-4A06-A788-E5CE58B1F0CD_3_2">3783000</us-gaap:AllocatedShareBasedCompensationExpense> <us-gaap:DeferredIncomeTaxExpenseBenefit contextRef="eol_PE151383--1410-K0012_STD_366_20121231_0" unitRef="iso4217_USD" decimals="-3" id="id_6895476_313A5609-80D0-44B6-B522-EDB92ECD334E_3_7">0</us-gaap:DeferredIncomeTaxExpenseBenefit> <us-gaap:DepreciationDepletionAndAmortization contextRef="eol_PE151383--1410-K0012_STD_366_20121231_0" unitRef="iso4217_USD" decimals="-3" id="id_6895476_84756BCF-71FA-4E32-A511-A3DCED215C30_3_3">591000</us-gaap:DepreciationDepletionAndAmortization> <us-gaap:IncreaseDecreaseInDeferredRevenue contextRef="eol_PE151383--1410-K0012_STD_366_20121231_0" unitRef="iso4217_USD" decimals="-3" id="id_6895476_84756BCF-71FA-4E32-A511-A3DCED215C30_3_14">0</us-gaap:IncreaseDecreaseInDeferredRevenue> <us-gaap:InterestExpense contextRef="eol_PE151383--1410-K0012_STD_366_20121231_0" unitRef="iso4217_USD" decimals="-3" id="id_6895476_42B95EC7-417F-4E86-8649-AA2AAA9B2184_3_0">3000</us-gaap:InterestExpense> <us-gaap:ProceedsFromIssuanceOfPreferredStockAndPreferenceStock contextRef="eol_PE151383--1410-K0012_STD_366_20121231_0" unitRef="iso4217_USD" decimals="-3" id="id_6895476_84756BCF-71FA-4E32-A511-A3DCED215C30_3_27">12318000</us-gaap:ProceedsFromIssuanceOfPreferredStockAndPreferenceStock> <us-gaap:ResearchAndDevelopmentExpense contextRef="eol_PE151383--1410-K0012_STD_366_20121231_0" unitRef="iso4217_USD" decimals="-3" id="id_6895476_FF4E9404-B9B3-415C-99EC-66EC22E2B2E7_3_7">35643000</us-gaap:ResearchAndDevelopmentExpense> <us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit contextRef="eol_PE151383--1410-K0012_STD_366_20121231_0" unitRef="iso4217_USD" decimals="-3" id="id_6895476_313A5609-80D0-44B6-B522-EDB92ECD334E_3_6">0</us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit> <us-gaap:RestructuringCharges contextRef="eol_PE151383--1410-K0012_STD_366_20121231_0" unitRef="iso4217_USD" decimals="-3" id="id_6895476_FF4E9404-B9B3-415C-99EC-66EC22E2B2E7_3_9">-56000</us-gaap:RestructuringCharges> <us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease contextRef="eol_PE151383--1410-K0012_STD_366_20121231_0" unitRef="iso4217_USD" decimals="-3" id="id_6895476_84756BCF-71FA-4E32-A511-A3DCED215C30_3_30">-3926000</us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease> <us-gaap:IncomeTaxExpenseBenefit contextRef="eol_PE151383--1410-K0012_STD_366_20121231_0" unitRef="iso4217_USD" decimals="-3" id="id_6895476_8E079FDA-A4BC-47E2-A9A9-72879770E667_3_0">0</us-gaap:IncomeTaxExpenseBenefit> <us-gaap:OperatingLeasesRentExpenseNet contextRef="eol_PE151383--1410-K0012_STD_366_20121231_0" unitRef="iso4217_USD" decimals="-3" id="id_6895476_BCDA57D7-0AE7-485E-8998-1C33E525DE09_3_0">3375000</us-gaap:OperatingLeasesRentExpenseNet> <us-gaap:CurrentFederalTaxExpenseBenefit contextRef="eol_PE151383--1410-K0012_STD_366_20121231_0" unitRef="iso4217_USD" decimals="-3" id="id_6895476_313A5609-80D0-44B6-B522-EDB92ECD334E_3_1">0</us-gaap:CurrentFederalTaxExpenseBenefit> <us-gaap:Depreciation contextRef="eol_PE151383--1410-K0012_STD_366_20121231_0" unitRef="iso4217_USD" decimals="-5" id="id_6895476_39F2804C-5F74-4B61-9FD9-4D6A1871D4BD_3_0">600000</us-gaap:Depreciation> <us-gaap:NetCashProvidedByUsedInFinancingActivitiesContinuingOperations contextRef="eol_PE151383--1410-K0012_STD_366_20121231_0" unitRef="iso4217_USD" decimals="-3" id="id_6895476_84756BCF-71FA-4E32-A511-A3DCED215C30_3_29">58327000</us-gaap:NetCashProvidedByUsedInFinancingActivitiesContinuingOperations> <us-gaap:ProceedsFromIssuanceOfCommonStock contextRef="eol_PE151383--1410-K0012_STD_366_20121231_0" unitRef="iso4217_USD" decimals="-3" id="id_6895476_84756BCF-71FA-4E32-A511-A3DCED215C30_3_24">43677000</us-gaap:ProceedsFromIssuanceOfCommonStock> <us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment contextRef="eol_PE151383--1410-K0012_STD_366_20121231_0" unitRef="iso4217_USD" decimals="-3" id="id_6895476_84756BCF-71FA-4E32-A511-A3DCED215C30_3_20">2000</us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment> <us-gaap:CurrentStateAndLocalTaxExpenseBenefit contextRef="eol_PE151383--1410-K0012_STD_366_20121231_0" unitRef="iso4217_USD" decimals="-3" id="id_6895476_313A5609-80D0-44B6-B522-EDB92ECD334E_3_2">0</us-gaap:CurrentStateAndLocalTaxExpenseBenefit> <us-gaap:IncreaseDecreaseInAccruedLiabilities contextRef="eol_PE151383--1410-K0012_STD_366_20121231_0" unitRef="iso4217_USD" decimals="-3" id="id_6895476_84756BCF-71FA-4E32-A511-A3DCED215C30_3_12">2098000</us-gaap:IncreaseDecreaseInAccruedLiabilities> <us-gaap:InterestAndDebtExpense contextRef="eol_PE151383--1410-K0012_STD_366_20121231_0" unitRef="iso4217_USD" decimals="-3" id="id_6895476_73255E91-D164-4B6A-A45B-4757187E85BA_3_1">2000</us-gaap:InterestAndDebtExpense> <us-gaap:NetCashProvidedByUsedInInvestingActivitiesContinuingOperations contextRef="eol_PE151383--1410-K0012_STD_366_20121231_0" unitRef="iso4217_USD" decimals="-3" id="id_6895476_84756BCF-71FA-4E32-A511-A3DCED215C30_3_22">-28815000</us-gaap:NetCashProvidedByUsedInInvestingActivitiesContinuingOperations> <us-gaap:NoncashOrPartNoncashAcquisitionFixedAssetsAcquired1 contextRef="eol_PE151383--1410-K0012_STD_366_20121231_0" unitRef="iso4217_USD" decimals="-3" id="id_6895476_822093A4-C207-4594-84E4-6C13CA36E168_3_3">116000</us-gaap:NoncashOrPartNoncashAcquisitionFixedAssetsAcquired1> <us-gaap:CurrentIncomeTaxExpenseBenefit contextRef="eol_PE151383--1410-K0012_STD_366_20121231_0" unitRef="iso4217_USD" decimals="-3" id="id_6895476_313A5609-80D0-44B6-B522-EDB92ECD334E_3_3">0</us-gaap:CurrentIncomeTaxExpenseBenefit> <us-gaap:CostsAndExpenses contextRef="eol_PE151383--1410-K0012_STD_366_20121231_0" unitRef="iso4217_USD" decimals="-3" id="id_6895476_FF4E9404-B9B3-415C-99EC-66EC22E2B2E7_3_10">48016000</us-gaap:CostsAndExpenses> <us-gaap:RestructuringCostsAndAssetImpairmentCharges contextRef="eol_PE151383--1410-K0012_STD_366_20121231_0" unitRef="iso4217_USD" decimals="-3" id="id_6895476_84756BCF-71FA-4E32-A511-A3DCED215C30_3_5">-56000</us-gaap:RestructuringCostsAndAssetImpairmentCharges> <us-gaap:GeneralAndAdministrativeExpense contextRef="eol_PE151383--1410-K0012_STD_366_20121231_0" unitRef="iso4217_USD" decimals="-3" id="id_6895476_FF4E9404-B9B3-415C-99EC-66EC22E2B2E7_3_8">12429000</us-gaap:GeneralAndAdministrativeExpense> <us-gaap:IncreaseDecreaseInDueToRelatedPartiesCurrent contextRef="eol_PE151383--1410-K0012_STD_366_20121231_0" unitRef="iso4217_USD" decimals="-3" id="id_6895476_84756BCF-71FA-4E32-A511-A3DCED215C30_3_13">138000</us-gaap:IncreaseDecreaseInDueToRelatedPartiesCurrent> <us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities contextRef="eol_PE151383--1410-K0012_STD_366_20121231_0" unitRef="iso4217_USD" decimals="-3" id="id_6895476_84756BCF-71FA-4E32-A511-A3DCED215C30_3_18">63900000</us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities> <us-gaap:ShareBasedCompensation contextRef="eol_PE151383--1410-K0012_STD_366_20121231_0" unitRef="iso4217_USD" decimals="-3" id="id_6895476_84756BCF-71FA-4E32-A511-A3DCED215C30_3_6">3783000</us-gaap:ShareBasedCompensation> <us-gaap:DeferredFederalIncomeTaxExpenseBenefit contextRef="eol_PE151383--1410-K0012_STD_366_20121231_0" unitRef="iso4217_USD" decimals="-3" id="id_6895476_313A5609-80D0-44B6-B522-EDB92ECD334E_3_5">0</us-gaap:DeferredFederalIncomeTaxExpenseBenefit> <us-gaap:IncreaseDecreaseInAccountsPayableTrade contextRef="eol_PE151383--1410-K0012_STD_366_20121231_0" unitRef="iso4217_USD" decimals="-3" id="id_6895476_84756BCF-71FA-4E32-A511-A3DCED215C30_3_11">690000</us-gaap:IncreaseDecreaseInAccountsPayableTrade> <us-gaap:OtherPreferredStockDividendsAndAdjustments contextRef="eol_PE151383--1410-K0012_STD_366_20121231_0" unitRef="iso4217_USD" decimals="-3" id="id_6895476_09173C79-2713-49DF-8107-C7F99AA4E397_3_1">1307000</us-gaap:OtherPreferredStockDividendsAndAdjustments> <cytk:IssuanceOfCommonStockEmployeeStockPurchasePlanPricePerShare contextRef="eol_PE151383--1410-K0012_STD_366_20121231_0" unitRef="iso4217_USD_per_shares" decimals="INF" id="id_6895476_58E9B802-84A6-48EC-8C22-C0DD0182E686_4008_5">4.32</cytk:IssuanceOfCommonStockEmployeeStockPurchasePlanPricePerShare> <cytk:EffectiveIncomeTaxRateReconciliationNetOperatingLossExpiration contextRef="eol_PE151383--1410-K0012_STD_366_20121231_0" unitRef="pure" decimals="2" id="id_6895476_14EF385A-3844-4F78-AE65-D20D0D541C15_3_6">0.02</cytk:EffectiveIncomeTaxRateReconciliationNetOperatingLossExpiration> <cytk:ProceedsFromDrawDownOfCommittedEquityFinancingFacilitiesAndAtMarketFacilityNetOfIssuanceCosts contextRef="eol_PE151383--1410-K0012_STD_366_20121231_0" unitRef="iso4217_USD" decimals="-3" id="id_6895476_84756BCF-71FA-4E32-A511-A3DCED215C30_3_25">2820000</cytk:ProceedsFromDrawDownOfCommittedEquityFinancingFacilitiesAndAtMarketFacilityNetOfIssuanceCosts> <cytk:StockIssuedDuringPeriodValueSecuritiesPurchaseAgreement contextRef="eol_PE151383--1410-K0012_STD_366_20121231_0" unitRef="iso4217_USD" decimals="-3" id="id_6895476_58E9B802-84A6-48EC-8C22-C0DD0182E686_4008_8">29916000</cytk:StockIssuedDuringPeriodValueSecuritiesPurchaseAgreement> <cytk:SharesAvailableForGrantOfOptionsOrAwardsOptionsForfeitedExpired contextRef="eol_PE151383--1410-K0012_STD_366_20121231_0" unitRef="shares" decimals="INF" id="id_6895476_550670F2-8019-4594-8D89-8D38F90A7B79_4001_4">210989</cytk:SharesAvailableForGrantOfOptionsOrAwardsOptionsForfeitedExpired> <cytk:LicenseRevenuesFromRelatedParties contextRef="eol_PE151383--1410-K0012_STD_366_20121231_0" unitRef="iso4217_USD" decimals="-3" id="id_6895476_FF4E9404-B9B3-415C-99EC-66EC22E2B2E7_3_3">0</cytk:LicenseRevenuesFromRelatedParties> <cytk:IssuanceCostOfWarrant contextRef="eol_PE151383--1410-K0012_STD_366_20121231_0" unitRef="iso4217_USD" decimals="-3" id="id_6895476_58E9B802-84A6-48EC-8C22-C0DD0182E686_4008_17">984000</cytk:IssuanceCostOfWarrant> <cytk:EffectiveIncomeTaxRateReconciliationDeferredTaxAssetsUtilizedNotBenefited contextRef="eol_PE151383--1410-K0012_STD_366_20121231_0" unitRef="pure" decimals="2" id="id_6895476_14EF385A-3844-4F78-AE65-D20D0D541C15_3_4">0.56</cytk:EffectiveIncomeTaxRateReconciliationDeferredTaxAssetsUtilizedNotBenefited> <cytk:ResearchAndDevelopmentRevenuesFromRelatedParties contextRef="eol_PE151383--1410-K0012_STD_366_20121231_0" unitRef="iso4217_USD" decimals="-3" id="id_6895476_FF4E9404-B9B3-415C-99EC-66EC22E2B2E7_3_1">4177000</cytk:ResearchAndDevelopmentRevenuesFromRelatedParties> <cytk:ProceedsAndPaymentsFromStockBasedAwardAndWarrantsNetOfIssuanceCosts contextRef="eol_PE151383--1410-K0012_STD_366_20121231_0" unitRef="iso4217_USD" decimals="-3" id="id_6895476_84756BCF-71FA-4E32-A511-A3DCED215C30_3_26">336000</cytk:ProceedsAndPaymentsFromStockBasedAwardAndWarrantsNetOfIssuanceCosts> <cytk:ResearchAndDevelopmentGrantAndOtherRevenues contextRef="eol_PE151383--1410-K0012_STD_366_20121231_0" unitRef="iso4217_USD" decimals="-3" id="id_6895476_FF4E9404-B9B3-415C-99EC-66EC22E2B2E7_3_2">3382000</cytk:ResearchAndDevelopmentGrantAndOtherRevenues> <cytk:EffectiveIncomeTaxRateReconciliationStateApportionment contextRef="eol_PE151383--1410-K0012_STD_366_20121231_0" unitRef="pure" decimals="2" id="id_6895476_14EF385A-3844-4F78-AE65-D20D0D541C15_3_2">0.00</cytk:EffectiveIncomeTaxRateReconciliationStateApportionment> <cytk:NoncashOrPartNoncashAcquisitionFixedAssetsAcquiredTradeInValue contextRef="eol_PE151383--1410-K0012_STD_366_20121231_0" unitRef="iso4217_USD" decimals="-3" id="id_6895476_822093A4-C207-4594-84E4-6C13CA36E168_3_5">0</cytk:NoncashOrPartNoncashAcquisitionFixedAssetsAcquiredTradeInValue> <cytk:AdjustmentsToAdditionalPaidInCapitalIssuanceOfConvertiblePreferredStock contextRef="eol_PE151383--1410-K0012_STD_366_20121231_0" unitRef="iso4217_USD" decimals="-3" id="id_6895476_58E9B802-84A6-48EC-8C22-C0DD0182E686_4008_12">12318000</cytk:AdjustmentsToAdditionalPaidInCapitalIssuanceOfConvertiblePreferredStock> <cytk:IncreaseDecreaseInNoncashOrPartNoncashAcquisitionFixedAssetsAcquiredThroughAccruedLiabilities contextRef="eol_PE151383--1410-K0012_STD_366_20121231_0" unitRef="iso4217_USD" decimals="-3" id="id_6895476_822093A4-C207-4594-84E4-6C13CA36E168_3_4">37000</cytk:IncreaseDecreaseInNoncashOrPartNoncashAcquisitionFixedAssetsAcquiredThroughAccruedLiabilities> <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="eol_PE151383--1410-K0012_STD_366_20121231_0_1268687x1271212" unitRef="shares" decimals="-3" id="id_6895476_3E2C7E3E-7982-4F2C-A6E3-5C7781C1D9F7_1003_3">217000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount> <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="eol_PE151383--1410-K0012_STD_366_20121231_0_1268687x1273442" unitRef="shares" decimals="-3" id="id_6895476_3E2C7E3E-7982-4F2C-A6E3-5C7781C1D9F7_2003_1">9009000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount> <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod contextRef="eol_PE151383--1410-K0012_STD_366_20121231_0_1270313x1271210" unitRef="shares" decimals="INF" id="id_6895476_9D5C22B2-CCEF-4AED-B18A-0ACE42E2B15B_4001_3">68702</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod> <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod contextRef="eol_PE151383--1410-K0012_STD_366_20121231_0_1270313x1271210" unitRef="shares" decimals="INF" id="id_6895476_9D5C22B2-CCEF-4AED-B18A-0ACE42E2B15B_4001_2">231935</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod> <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue contextRef="eol_PE151383--1410-K0012_STD_366_20121231_0_1270313x1271210" unitRef="iso4217_USD_per_shares" decimals="2" id="id_6895476_4396C4E5-DD06-4003-A485-BA06C7D8368D_4001_2">6.78</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue> <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue contextRef="eol_PE151383--1410-K0012_STD_366_20121231_0_1270313x1271210" unitRef="iso4217_USD_per_shares" decimals="2" id="id_6895476_4396C4E5-DD06-4003-A485-BA06C7D8368D_4001_3">6.78</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue> <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod contextRef="eol_PE151383--1410-K0012_STD_366_20121231_0_1270313x1271212" unitRef="shares" decimals="INF" id="id_6895476_550670F2-8019-4594-8D89-8D38F90A7B79_5001_5">68702</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod> <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod contextRef="eol_PE151383--1410-K0012_STD_366_20121231_0_1270313x1271212" unitRef="shares" decimals="INF" id="id_6895476_EAE02EAA-C88A-417D-A4E8-6DD5ADADA4AB_5001_5">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod> <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue contextRef="eol_PE151383--1410-K0012_STD_366_20121231_0_1270313x1271212" unitRef="iso4217_USD" decimals="-5" id="id_6895476_25E57D28-4973-461D-96F3-FC38BA8FEA62_1003_0">1600000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue> <cytk:ShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentOtherThanOptionForfeituresInPeriodWeightedAverageExercisePrice contextRef="eol_PE151383--1410-K0012_STD_366_20121231_0_1270313x1271212" unitRef="iso4217_USD_per_shares" decimals="0" id="id_6895476_C3206D70-DEC9-4565-9145-8B70956A712D_5001_4">0</cytk:ShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentOtherThanOptionForfeituresInPeriodWeightedAverageExercisePrice> <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate contextRef="eol_PE151383--1410-K0012_STD_366_20121231_0_1270313x1275629" unitRef="pure" decimals="3" id="id_6895476_A776E96A-A480-479E-9B5C-9A756B15D08A_5_3">0.000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate> <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="eol_PE151383--1410-K0012_STD_366_20121231_0_1270313x1275629" id="id_6895476_A776E96A-A480-479E-9B5C-9A756B15D08A_5_2">P6Y1M17D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1> <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate contextRef="eol_PE151383--1410-K0012_STD_366_20121231_0_1270313x1275629" unitRef="pure" decimals="3" id="id_6895476_A776E96A-A480-479E-9B5C-9A756B15D08A_5_0">0.011</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate> <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate contextRef="eol_PE151383--1410-K0012_STD_366_20121231_0_1270313x1275629" unitRef="pure" decimals="3" id="id_6895476_A776E96A-A480-479E-9B5C-9A756B15D08A_5_1">0.711</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate> <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate contextRef="eol_PE151383--1410-K0012_STD_366_20121231_0_1271382x1277228" unitRef="pure" decimals="3" id="id_6895476_A776E96A-A480-479E-9B5C-9A756B15D08A_6_3">0.000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate> <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="eol_PE151383--1410-K0012_STD_366_20121231_0_1271382x1277228" id="id_6895476_A776E96A-A480-479E-9B5C-9A756B15D08A_6_2">P1Y3M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1> <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate contextRef="eol_PE151383--1410-K0012_STD_366_20121231_0_1271382x1277228" unitRef="pure" decimals="3" id="id_6895476_A776E96A-A480-479E-9B5C-9A756B15D08A_6_0">0.002</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate> <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate contextRef="eol_PE151383--1410-K0012_STD_366_20121231_0_1271382x1277228" unitRef="pure" decimals="3" id="id_6895476_A776E96A-A480-479E-9B5C-9A756B15D08A_6_1">0.720</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate> <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="eol_PE151383--1410-K0012_STD_366_20121231_0_1271382x1277228" unitRef="shares" decimals="-3" id="id_6895476_3E2C7E3E-7982-4F2C-A6E3-5C7781C1D9F7_3003_4">11000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount> <cytk:IssuanceOfCommonStockToMlvAtPerShareUpperLimit contextRef="eol_PE151383--1410-K0012_STD_366_20121231_0_1271382x1511257" unitRef="iso4217_USD_per_shares" decimals="1" id="id_6895476_58E9B802-84A6-48EC-8C22-C0DD0182E686_5008_21">7.2</cytk:IssuanceOfCommonStockToMlvAtPerShareUpperLimit> <cytk:IssuanceOfCommonStockToMlvNetOfCommissionAndIssuanceCosts contextRef="eol_PE151383--1410-K0012_STD_366_20121231_0_1271382x1511257" unitRef="iso4217_USD" decimals="-3" id="id_6895476_58E9B802-84A6-48EC-8C22-C0DD0182E686_5008_22">89000</cytk:IssuanceOfCommonStockToMlvNetOfCommissionAndIssuanceCosts> <cytk:IssuanceOfCommonStockToMlvAtPerShareLowerLimit contextRef="eol_PE151383--1410-K0012_STD_366_20121231_0_1271382x1511257" unitRef="iso4217_USD_per_shares" decimals="1" id="id_6895476_58E9B802-84A6-48EC-8C22-C0DD0182E686_5008_20">6.3</cytk:IssuanceOfCommonStockToMlvAtPerShareLowerLimit> <cytk:StockIssuedDuringPeriodValueAtMarketIssuanceSalesAgreement contextRef="eol_PE151383--1410-K0012_STD_366_20121231_0_1271382x1511257" unitRef="iso4217_USD" decimals="-3" id="id_6895476_58E9B802-84A6-48EC-8C22-C0DD0182E686_5008_18">2820000</cytk:StockIssuedDuringPeriodValueAtMarketIssuanceSalesAgreement> <cytk:StockIssuedDuringPeriodSharesAtMarketIssuanceSalesAgreement contextRef="eol_PE151383--1410-K0012_STD_366_20121231_0_1271382x1511257_1276401x1270422" unitRef="shares" decimals="INF" id="id_6895476_58E9B802-84A6-48EC-8C22-C0DD0182E686_5001_19">432724</cytk:StockIssuedDuringPeriodSharesAtMarketIssuanceSalesAgreement> <cytk:StockIssuedDuringPeriodValueAtMarketIssuanceSalesAgreement contextRef="eol_PE151383--1410-K0012_STD_366_20121231_0_1271382x1511257_1276401x1270422" unitRef="iso4217_USD" decimals="-3" id="id_6895476_58E9B802-84A6-48EC-8C22-C0DD0182E686_5001_18">1000</cytk:StockIssuedDuringPeriodValueAtMarketIssuanceSalesAgreement> <cytk:StockIssuedDuringPeriodValueAtMarketIssuanceSalesAgreement contextRef="eol_PE151383--1410-K0012_STD_366_20121231_0_1271382x1511257_1276401x1273630" unitRef="iso4217_USD" decimals="-3" id="id_6895476_58E9B802-84A6-48EC-8C22-C0DD0182E686_5005_18">2819000</cytk:StockIssuedDuringPeriodValueAtMarketIssuanceSalesAgreement> <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="eol_PE151383--1410-K0012_STD_366_20121231_0_1272720x1275629" unitRef="shares" decimals="-3" id="id_6895476_3E2C7E3E-7982-4F2C-A6E3-5C7781C1D9F7_4003_0">1791000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount> <us-gaap:ReimbursementRevenue contextRef="eol_PE151383--1410-K0012_STD_366_20121231_0_1272896x1454595" unitRef="iso4217_USD" decimals="-3" id="id_6895476_097E51C1-D472-4642-91F0-D1638561D10B_1003_1">595000</us-gaap:ReimbursementRevenue> <cytk:ResearchAndDevelopmentRevenueFromCollaboration contextRef="eol_PE151383--1410-K0012_STD_366_20121231_0_1272896x1454595" unitRef="iso4217_USD" decimals="-3" id="id_6895476_097E51C1-D472-4642-91F0-D1638561D10B_1003_2">595000</cytk:ResearchAndDevelopmentRevenueFromCollaboration> <cytk:ResearchAndDevelopmentRevenue contextRef="eol_PE151383--1410-K0012_STD_366_20121231_0_1272896x1454595" unitRef="iso4217_USD" decimals="-3" id="id_6895476_097E51C1-D472-4642-91F0-D1638561D10B_1003_0">0</cytk:ResearchAndDevelopmentRevenue> <us-gaap:RevenueFromGrants contextRef="eol_PE151383--1410-K0012_STD_366_20121231_0_1272896x1507815" unitRef="iso4217_USD" decimals="-3" id="id_6895476_FD977883-B531-4443-8A85-7DBADCAD1197_1003_0">1308000</us-gaap:RevenueFromGrants> <us-gaap:ReimbursementRevenue contextRef="eol_PE151383--1410-K0012_STD_366_20121231_0_1272896x1537165" unitRef="iso4217_USD" decimals="-3" id="id_6895476_C614CF06-9CB5-403B-B2F4-C612F97ACB77_1003_0">1479000</us-gaap:ReimbursementRevenue> <us-gaap:RevenueFromGrants contextRef="eol_PE151383--1410-K0012_STD_366_20121231_0_1272896x1621940" unitRef="iso4217_USD" decimals="-3" id="id_6895476_FD977883-B531-4443-8A85-7DBADCAD1197_2003_1">0</us-gaap:RevenueFromGrants> <us-gaap:AllocatedShareBasedCompensationExpense contextRef="eol_PE151383--1410-K0012_STD_366_20121231_0_1274159x1269133" unitRef="iso4217_USD" decimals="-3" id="id_6895476_4ED78B6B-525C-4A06-A788-E5CE58B1F0CD_1003_1">1982000</us-gaap:AllocatedShareBasedCompensationExpense> <us-gaap:AllocatedShareBasedCompensationExpense contextRef="eol_PE151383--1410-K0012_STD_366_20121231_0_1274159x1269570" unitRef="iso4217_USD" decimals="-3" id="id_6895476_4ED78B6B-525C-4A06-A788-E5CE58B1F0CD_2003_0">1801000</us-gaap:AllocatedShareBasedCompensationExpense> <cytk:ConversionPricePerShareOfPreferredStockToCommonStock contextRef="eol_PE151383--1410-K0012_STD_366_20121231_0_1276400x1269676" unitRef="iso4217_USD_per_shares" decimals="INF" id="id_6895476_58E9B802-84A6-48EC-8C22-C0DD0182E686_6008_25">1000</cytk:ConversionPricePerShareOfPreferredStockToCommonStock> <us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities contextRef="eol_PE151383--1410-K0012_STD_366_20121231_0_1276400x1269676_1276401x1270422" unitRef="shares" decimals="INF" id="id_6895476_58E9B802-84A6-48EC-8C22-C0DD0182E686_6001_24">1345000</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities> <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities contextRef="eol_PE151383--1410-K0012_STD_366_20121231_0_1276400x1269676_1276401x1270422" unitRef="iso4217_USD" decimals="-3" id="id_6895476_58E9B802-84A6-48EC-8C22-C0DD0182E686_6001_23">1000</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities> <us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities contextRef="eol_PE151383--1410-K0012_STD_366_20121231_0_1276400x1269676_1276401x1272805" unitRef="shares" decimals="INF" id="id_6895476_58E9B802-84A6-48EC-8C22-C0DD0182E686_6003_24">-8070</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities> <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities contextRef="eol_PE151383--1410-K0012_STD_366_20121231_0_1276400x1269676_1276401x1273630" unitRef="iso4217_USD" decimals="-3" id="id_6895476_58E9B802-84A6-48EC-8C22-C0DD0182E686_6005_23">-1000</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities> <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="eol_PE151383--1410-K0012_STD_366_20121231_0_1276400x1281157" unitRef="shares" decimals="-3" id="id_6895476_3E2C7E3E-7982-4F2C-A6E3-5C7781C1D9F7_5003_2">3838000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount> <us-gaap:PaymentsOfStockIssuanceCosts contextRef="eol_PE151383--1410-K0012_STD_366_20121231_0_1276400x1281157" unitRef="iso4217_USD" decimals="-3" id="id_6895476_58E9B802-84A6-48EC-8C22-C0DD0182E686_7008_15">881000</us-gaap:PaymentsOfStockIssuanceCosts> <cytk:ConvertiblePreferredStockIssuancePrice contextRef="eol_PE151383--1410-K0012_STD_366_20121231_0_1276400x1281157" unitRef="iso4217_USD_per_shares" decimals="INF" id="id_6895476_58E9B802-84A6-48EC-8C22-C0DD0182E686_7008_14">760</cytk:ConvertiblePreferredStockIssuancePrice> <us-gaap:OtherComprehensiveIncomeLossNetOfTax contextRef="eol_PE151383--1410-K0012_STD_366_20121231_0_1276401x1268669" unitRef="iso4217_USD" decimals="-3" id="id_6895476_58E9B802-84A6-48EC-8C22-C0DD0182E686_4006_27">15000</us-gaap:OtherComprehensiveIncomeLossNetOfTax> <us-gaap:NetIncomeLoss contextRef="eol_PE151383--1410-K0012_STD_366_20121231_0_1276401x1269588" unitRef="iso4217_USD" decimals="-3" id="id_6895476_58E9B802-84A6-48EC-8C22-C0DD0182E686_4007_28">-40370000</us-gaap:NetIncomeLoss> <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans contextRef="eol_PE151383--1410-K0012_STD_366_20121231_0_1276401x1270422" unitRef="shares" decimals="INF" id="id_6895476_58E9B802-84A6-48EC-8C22-C0DD0182E686_4001_4">15010</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans> <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures contextRef="eol_PE151383--1410-K0012_STD_366_20121231_0_1276401x1270422" unitRef="shares" decimals="INF" id="id_6895476_58E9B802-84A6-48EC-8C22-C0DD0182E686_4001_7">144045</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures> <cytk:StockIssuedDuringPeriodValueSecuritiesPurchaseAgreement contextRef="eol_PE151383--1410-K0012_STD_366_20121231_0_1276401x1270422" unitRef="iso4217_USD" decimals="-3" id="id_6895476_58E9B802-84A6-48EC-8C22-C0DD0182E686_4001_8">9000</cytk:StockIssuedDuringPeriodValueSecuritiesPurchaseAgreement> <cytk:IssuanceOfConvertiblePreferredStockShares contextRef="eol_PE151383--1410-K0012_STD_366_20121231_0_1276401x1270422" unitRef="shares" decimals="INF" id="id_6895476_58E9B802-84A6-48EC-8C22-C0DD0182E686_4001_13">0</cytk:IssuanceOfConvertiblePreferredStockShares> <cytk:IssuanceOfConvertiblePreferredStockShares contextRef="eol_PE151383--1410-K0012_STD_366_20121231_0_1276401x1272805" unitRef="shares" decimals="INF" id="id_6895476_58E9B802-84A6-48EC-8C22-C0DD0182E686_4003_13">23026</cytk:IssuanceOfConvertiblePreferredStockShares> <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures contextRef="eol_PE151383--1410-K0012_STD_366_20121231_0_1276401x1273630" unitRef="iso4217_USD" decimals="-3" id="id_6895476_58E9B802-84A6-48EC-8C22-C0DD0182E686_4005_6">-401000</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures> <us-gaap:OtherComprehensiveIncomeLossNetOfTax contextRef="eol_PE151383--1410-K0012_STD_366_20121231_0_1276401x1273630" unitRef="iso4217_USD" decimals="-3" id="id_6895476_58E9B802-84A6-48EC-8C22-C0DD0182E686_4005_27">0</us-gaap:OtherComprehensiveIncomeLossNetOfTax> <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan contextRef="eol_PE151383--1410-K0012_STD_366_20121231_0_1276401x1273630" unitRef="iso4217_USD" decimals="-3" id="id_6895476_58E9B802-84A6-48EC-8C22-C0DD0182E686_4005_3">65000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan> <us-gaap:NetIncomeLoss contextRef="eol_PE151383--1410-K0012_STD_366_20121231_0_1276401x1273630" unitRef="iso4217_USD" decimals="-3" id="id_6895476_58E9B802-84A6-48EC-8C22-C0DD0182E686_4005_28">0</us-gaap:NetIncomeLoss> <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="eol_PE151383--1410-K0012_STD_366_20121231_0_1276401x1273630" unitRef="iso4217_USD" decimals="-3" id="id_6895476_58E9B802-84A6-48EC-8C22-C0DD0182E686_4005_26">3783000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue> <us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued contextRef="eol_PE151383--1410-K0012_STD_366_20121231_0_1276401x1273630" unitRef="iso4217_USD" decimals="-3" id="id_6895476_58E9B802-84A6-48EC-8C22-C0DD0182E686_4005_16">13761000</us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued> <cytk:StockIssuedDuringPeriodValueSecuritiesPurchaseAgreement contextRef="eol_PE151383--1410-K0012_STD_366_20121231_0_1276401x1273630" unitRef="iso4217_USD" decimals="-3" id="id_6895476_58E9B802-84A6-48EC-8C22-C0DD0182E686_4005_8">29907000</cytk:StockIssuedDuringPeriodValueSecuritiesPurchaseAgreement> <cytk:AdjustmentsToAdditionalPaidInCapitalIssuanceOfConvertiblePreferredStock contextRef="eol_PE151383--1410-K0012_STD_366_20121231_0_1276401x1273630" unitRef="iso4217_USD" decimals="-3" id="id_6895476_58E9B802-84A6-48EC-8C22-C0DD0182E686_4005_12">12318000</cytk:AdjustmentsToAdditionalPaidInCapitalIssuanceOfConvertiblePreferredStock> <us-gaap:ConcentrationRiskPercentage1 contextRef="eol_PE151383--1410-K0012_STD_366_20121231_0_1279431x1424859" unitRef="pure" decimals="2" id="id_6895476_D076CC70-CB7C-4170-BD50-2E3EFE86EE58_1003_0">0.55</us-gaap:ConcentrationRiskPercentage1> <us-gaap:LicenseAndServicesRevenue contextRef="eol_PE151383--1410-K0012_STD_366_20121231_0_1279431x1424859" unitRef="iso4217_USD" decimals="-3" id="id_6895476_DA0EFEFC-F120-4996-B278-29668E08DD78_1003_0">0</us-gaap:LicenseAndServicesRevenue> <us-gaap:RevenueFromRelatedParties contextRef="eol_PE151383--1410-K0012_STD_366_20121231_0_1279431x1424859" unitRef="iso4217_USD" decimals="-3" id="id_6895476_DA0EFEFC-F120-4996-B278-29668E08DD78_1003_4">0</us-gaap:RevenueFromRelatedParties> <cytk:RelatedPartyResearchAndDevelopmentRevenue contextRef="eol_PE151383--1410-K0012_STD_366_20121231_0_1279431x1424859" unitRef="iso4217_USD" decimals="-3" id="id_6895476_DA0EFEFC-F120-4996-B278-29668E08DD78_1003_5">4177000</cytk:RelatedPartyResearchAndDevelopmentRevenue> <cytk:ReimbursementOfInternalResearchAndDevelopmentCost contextRef="eol_PE151383--1410-K0012_STD_366_20121231_0_1279431x1424859" unitRef="iso4217_USD" decimals="-3" id="id_6895476_DA0EFEFC-F120-4996-B278-29668E08DD78_1003_2">4174000</cytk:ReimbursementOfInternalResearchAndDevelopmentCost> <cytk:ReimbursementOfOtherResearchAndDevelopmentCost contextRef="eol_PE151383--1410-K0012_STD_366_20121231_0_1279431x1424859" unitRef="iso4217_USD" decimals="-3" id="id_6895476_DA0EFEFC-F120-4996-B278-29668E08DD78_1003_3">3000</cytk:ReimbursementOfOtherResearchAndDevelopmentCost> <us-gaap:ValuationAllowancesAndReservesChargedToCostAndExpense contextRef="eol_PE151383--1410-K0012_STD_366_20121231_0_1279936x1276697" unitRef="iso4217_USD" decimals="-3" id="id_6895476_B444ABAD-A3F0-45D1-A8D2-D991236372AC_1_2">21086000</us-gaap:ValuationAllowancesAndReservesChargedToCostAndExpense> <us-gaap:ValuationAllowancesAndReservesChargedToOtherAccounts contextRef="eol_PE151383--1410-K0012_STD_366_20121231_0_1279936x1276697" unitRef="iso4217_USD" decimals="-3" id="id_6895476_B444ABAD-A3F0-45D1-A8D2-D991236372AC_1_3">0</us-gaap:ValuationAllowancesAndReservesChargedToOtherAccounts> <us-gaap:ValuationAllowancesAndReservesDeductions contextRef="eol_PE151383--1410-K0012_STD_366_20121231_0_1279936x1276697" unitRef="iso4217_USD" decimals="-3" id="id_6895476_B444ABAD-A3F0-45D1-A8D2-D991236372AC_1_4">0</us-gaap:ValuationAllowancesAndReservesDeductions> <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans contextRef="eol_PE151383--1410-K0012_STD_366_20121231_0_1280964x1277228" unitRef="shares" decimals="INF" id="id_6895476_AA51EB59-4301-48A7-8417-F8ADFF1F04A4_1003_1">15010</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans> <cytk:EmployeeStockPurchasePlansAveragePricePerShare contextRef="eol_PE151383--1410-K0012_STD_366_20121231_0_1280964x1277228" unitRef="iso4217_USD_per_shares" decimals="2" id="id_6895476_AA51EB59-4301-48A7-8417-F8ADFF1F04A4_1003_2">4.32</cytk:EmployeeStockPurchasePlansAveragePricePerShare> <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue contextRef="eol_PE151383--1410-K0012_STD_366_20121231_0_1280964x1294890" unitRef="iso4217_USD_per_shares" decimals="2" id="id_6895476_945DE61A-5FF4-4863-A406-B144CAADCC72_1003_1">3.89</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue> <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares contextRef="eol_PE151383--1410-K0012_STD_366_20121231_0_1280964x1294890" unitRef="shares" decimals="INF" id="id_6895476_945DE61A-5FF4-4863-A406-B144CAADCC72_1003_3">348693</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares> <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1 contextRef="eol_PE151383--1410-K0012_STD_366_20121231_0_1280964x1294890" unitRef="iso4217_USD" decimals="-5" id="id_6895476_945DE61A-5FF4-4863-A406-B144CAADCC72_1003_4">2400000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1> <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue contextRef="eol_PE151383--1410-K0012_STD_366_20121231_0_1280964x1294890" unitRef="iso4217_USD" decimals="0" id="id_6895476_945DE61A-5FF4-4863-A406-B144CAADCC72_1003_0">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue> <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross contextRef="eol_PE151383--1410-K0012_STD_366_20121231_0_1280964x1424733" unitRef="shares" decimals="INF" id="id_6895476_7DACACCF-F580-4FD5-9779-AA02BBB20B57_1003_0">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross> <us-gaap:AllocatedShareBasedCompensationExpense contextRef="eol_PE151383--1410-K0012_STD_366_20121231_0_1280964x1424733" unitRef="iso4217_USD" decimals="-3" id="id_6895476_D2960C5C-51C9-488D-A130-57FE536B4931_1003_0">56000</us-gaap:AllocatedShareBasedCompensationExpense> <us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare contextRef="eol_PE151383--1410-K0012_STD_90_20130331_0" unitRef="iso4217_USD_per_shares" decimals="2" id="id_6895476_6089C29F-80C3-42A5-8328-ED90E6D7FE11_1_4">-0.53</us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare> <us-gaap:IncomeLossFromContinuingOperationsPerBasicShare contextRef="eol_PE151383--1410-K0012_STD_90_20130331_0" unitRef="iso4217_USD_per_shares" decimals="2" id="id_6895476_6089C29F-80C3-42A5-8328-ED90E6D7FE11_1_3">-0.53</us-gaap:IncomeLossFromContinuingOperationsPerBasicShare> <us-gaap:SalesRevenueNet contextRef="eol_PE151383--1410-K0012_STD_90_20130331_0" unitRef="iso4217_USD" decimals="-3" id="id_6895476_6089C29F-80C3-42A5-8328-ED90E6D7FE11_1_0">821000</us-gaap:SalesRevenueNet> <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic contextRef="eol_PE151383--1410-K0012_STD_90_20130331_0" unitRef="iso4217_USD" decimals="-3" id="id_6895476_6089C29F-80C3-42A5-8328-ED90E6D7FE11_1_2">-12619000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic> <us-gaap:NetIncomeLoss contextRef="eol_PE151383--1410-K0012_STD_90_20130331_0" unitRef="iso4217_USD" decimals="-3" id="id_6895476_6089C29F-80C3-42A5-8328-ED90E6D7FE11_1_1">-12619000</us-gaap:NetIncomeLoss> <us-gaap:ConversionOfStockSharesConverted1 contextRef="eol_PE151383--1410-K0012_STD_90_20130331_0_1276400x1281157" unitRef="shares" decimals="INF" id="id_6895476_AFDDCC73-DDEC-4EF6-8B23-09AF6BA9ADD4_1001_0">4000</us-gaap:ConversionOfStockSharesConverted1> <us-gaap:ConversionOfStockSharesIssued1 contextRef="eol_PE151383--1410-K0012_STD_90_20130331_0_1276401x1270422" unitRef="shares" decimals="INF" id="id_6895476_AFDDCC73-DDEC-4EF6-8B23-09AF6BA9ADD4_2001_1">666667</us-gaap:ConversionOfStockSharesIssued1> <us-gaap:IncomeLossFromContinuingOperationsPerBasicAndDilutedShare contextRef="eol_PE151383--1410-K0012_STD_90_20140331_0" unitRef="iso4217_USD_per_shares" decimals="2" id="id_6895476_4BF77D0F-06CF-4C1C-B793-C2809F5E4DA5_1_3">-0.27</us-gaap:IncomeLossFromContinuingOperationsPerBasicAndDilutedShare> <us-gaap:SalesRevenueNet contextRef="eol_PE151383--1410-K0012_STD_90_20140331_0" unitRef="iso4217_USD" decimals="-3" id="id_6895476_4BF77D0F-06CF-4C1C-B793-C2809F5E4DA5_1_0">7979000</us-gaap:SalesRevenueNet> <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic contextRef="eol_PE151383--1410-K0012_STD_90_20140331_0" unitRef="iso4217_USD" decimals="-3" id="id_6895476_4BF77D0F-06CF-4C1C-B793-C2809F5E4DA5_1_2">-8744000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic> <us-gaap:NetIncomeLoss contextRef="eol_PE151383--1410-K0012_STD_90_20140331_0" unitRef="iso4217_USD" decimals="-3" id="id_6895476_4BF77D0F-06CF-4C1C-B793-C2809F5E4DA5_1_1">-8744000</us-gaap:NetIncomeLoss> <us-gaap:ProceedsFromIssuanceOfCommonStock contextRef="eol_PE151383--1410-K0012_STD_91_20120630_0" unitRef="iso4217_USD" decimals="-5" id="id_6895476_3FC5ED04-4EE6-46C9-A0D2-620382362F04_1_1">32100000</us-gaap:ProceedsFromIssuanceOfCommonStock> <us-gaap:ConversionOfStockSharesConverted1 contextRef="eol_PE151383--1410-K0012_STD_91_20120630_0_1276400x1281157" unitRef="shares" decimals="INF" id="id_6895476_3FC5ED04-4EE6-46C9-A0D2-620382362F04_1001_0">1000</us-gaap:ConversionOfStockSharesConverted1> <us-gaap:ProceedsFromIssuanceOfConvertiblePreferredStock contextRef="eol_PE151383--1410-K0012_STD_91_20120630_0_1276400x1281157" unitRef="iso4217_USD" decimals="-5" id="id_6895476_3FC5ED04-4EE6-46C9-A0D2-620382362F04_1001_2">13200000</us-gaap:ProceedsFromIssuanceOfConvertiblePreferredStock> <us-gaap:ProceedsFromIssuanceOfWarrants contextRef="eol_PE151383--1410-K0012_STD_91_20120630_0_1278975x1273442" unitRef="iso4217_USD" decimals="-5" id="id_6895476_3FC5ED04-4EE6-46C9-A0D2-620382362F04_2001_3">14700000</us-gaap:ProceedsFromIssuanceOfWarrants> <us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare contextRef="eol_PE151383--1410-K0012_STD_91_20130630_0" unitRef="iso4217_USD_per_shares" decimals="2" id="id_6895476_6089C29F-80C3-42A5-8328-ED90E6D7FE11_2_4">-0.58</us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare> <us-gaap:IncomeLossFromContinuingOperationsPerBasicShare contextRef="eol_PE151383--1410-K0012_STD_91_20130630_0" unitRef="iso4217_USD_per_shares" decimals="2" id="id_6895476_6089C29F-80C3-42A5-8328-ED90E6D7FE11_2_3">-0.58</us-gaap:IncomeLossFromContinuingOperationsPerBasicShare> <us-gaap:SalesRevenueNet contextRef="eol_PE151383--1410-K0012_STD_91_20130630_0" unitRef="iso4217_USD" decimals="-3" id="id_6895476_6089C29F-80C3-42A5-8328-ED90E6D7FE11_2_0">1009000</us-gaap:SalesRevenueNet> <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic contextRef="eol_PE151383--1410-K0012_STD_91_20130630_0" unitRef="iso4217_USD" decimals="-3" id="id_6895476_6089C29F-80C3-42A5-8328-ED90E6D7FE11_2_2">-15041000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic> <us-gaap:NetIncomeLoss contextRef="eol_PE151383--1410-K0012_STD_91_20130630_0" unitRef="iso4217_USD" decimals="-3" id="id_6895476_6089C29F-80C3-42A5-8328-ED90E6D7FE11_2_1">-15041000</us-gaap:NetIncomeLoss> <us-gaap:ConversionOfStockSharesConverted1 contextRef="eol_PE151383--1410-K0012_STD_91_20130630_0_1276400x1281157" unitRef="shares" decimals="INF" id="id_6895476_AFDDCC73-DDEC-4EF6-8B23-09AF6BA9ADD4_1002_0">15026</us-gaap:ConversionOfStockSharesConverted1> <us-gaap:ConversionOfStockSharesIssued1 contextRef="eol_PE151383--1410-K0012_STD_91_20130630_0_1276401x1270422" unitRef="shares" decimals="INF" id="id_6895476_AFDDCC73-DDEC-4EF6-8B23-09AF6BA9ADD4_2002_1">2504334</us-gaap:ConversionOfStockSharesIssued1> <us-gaap:IncomeLossFromContinuingOperationsPerBasicAndDilutedShare contextRef="eol_PE151383--1410-K0012_STD_91_20140630_0" unitRef="iso4217_USD_per_shares" decimals="2" id="id_6895476_4BF77D0F-06CF-4C1C-B793-C2809F5E4DA5_2_3">-0.23</us-gaap:IncomeLossFromContinuingOperationsPerBasicAndDilutedShare> <us-gaap:SalesRevenueNet contextRef="eol_PE151383--1410-K0012_STD_91_20140630_0" unitRef="iso4217_USD" decimals="-3" id="id_6895476_4BF77D0F-06CF-4C1C-B793-C2809F5E4DA5_2_0">7788000</us-gaap:SalesRevenueNet> <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic contextRef="eol_PE151383--1410-K0012_STD_91_20140630_0" unitRef="iso4217_USD" decimals="-3" id="id_6895476_4BF77D0F-06CF-4C1C-B793-C2809F5E4DA5_2_2">-8374000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic> <us-gaap:NetIncomeLoss contextRef="eol_PE151383--1410-K0012_STD_91_20140630_0" unitRef="iso4217_USD" decimals="-3" id="id_6895476_4BF77D0F-06CF-4C1C-B793-C2809F5E4DA5_2_1">-8374000</us-gaap:NetIncomeLoss> <us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare contextRef="eol_PE151383--1410-K0012_STD_92_20130930_0" unitRef="iso4217_USD_per_shares" decimals="2" id="id_6895476_6089C29F-80C3-42A5-8328-ED90E6D7FE11_3_4">-0.43</us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare> <us-gaap:IncomeLossFromContinuingOperationsPerBasicShare contextRef="eol_PE151383--1410-K0012_STD_92_20130930_0" unitRef="iso4217_USD_per_shares" decimals="2" id="id_6895476_6089C29F-80C3-42A5-8328-ED90E6D7FE11_3_3">-0.43</us-gaap:IncomeLossFromContinuingOperationsPerBasicShare> <us-gaap:SalesRevenueNet contextRef="eol_PE151383--1410-K0012_STD_92_20130930_0" unitRef="iso4217_USD" decimals="-3" id="id_6895476_6089C29F-80C3-42A5-8328-ED90E6D7FE11_3_0">4469000</us-gaap:SalesRevenueNet> <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic contextRef="eol_PE151383--1410-K0012_STD_92_20130930_0" unitRef="iso4217_USD" decimals="-3" id="id_6895476_6089C29F-80C3-42A5-8328-ED90E6D7FE11_3_2">-12588000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic> <us-gaap:NetIncomeLoss contextRef="eol_PE151383--1410-K0012_STD_92_20130930_0" unitRef="iso4217_USD" decimals="-3" id="id_6895476_6089C29F-80C3-42A5-8328-ED90E6D7FE11_3_1">-12588000</us-gaap:NetIncomeLoss> <us-gaap:IncomeLossFromContinuingOperationsPerBasicAndDilutedShare contextRef="eol_PE151383--1410-K0012_STD_92_20140930_0" unitRef="iso4217_USD_per_shares" decimals="2" id="id_6895476_4BF77D0F-06CF-4C1C-B793-C2809F5E4DA5_3_3">-0.16</us-gaap:IncomeLossFromContinuingOperationsPerBasicAndDilutedShare> <us-gaap:SalesRevenueNet contextRef="eol_PE151383--1410-K0012_STD_92_20140930_0" unitRef="iso4217_USD" decimals="-3" id="id_6895476_4BF77D0F-06CF-4C1C-B793-C2809F5E4DA5_3_0">9415000</us-gaap:SalesRevenueNet> <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic contextRef="eol_PE151383--1410-K0012_STD_92_20140930_0" unitRef="iso4217_USD" decimals="-3" id="id_6895476_4BF77D0F-06CF-4C1C-B793-C2809F5E4DA5_3_2">-5971000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic> <us-gaap:NetIncomeLoss contextRef="eol_PE151383--1410-K0012_STD_92_20140930_0" unitRef="iso4217_USD" decimals="-3" id="id_6895476_4BF77D0F-06CF-4C1C-B793-C2809F5E4DA5_3_1">-5971000</us-gaap:NetIncomeLoss> <us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare contextRef="eol_PE151383--1410-K0012_STD_92_20131231_0" unitRef="iso4217_USD_per_shares" decimals="2" id="id_6895476_6089C29F-80C3-42A5-8328-ED90E6D7FE11_4_4">0.21</us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare> <us-gaap:IncomeLossFromContinuingOperationsPerBasicShare contextRef="eol_PE151383--1410-K0012_STD_92_20131231_0" unitRef="iso4217_USD_per_shares" decimals="2" id="id_6895476_6089C29F-80C3-42A5-8328-ED90E6D7FE11_4_3">0.22</us-gaap:IncomeLossFromContinuingOperationsPerBasicShare> <us-gaap:SalesRevenueNet contextRef="eol_PE151383--1410-K0012_STD_92_20131231_0" unitRef="iso4217_USD" decimals="-3" id="id_6895476_6089C29F-80C3-42A5-8328-ED90E6D7FE11_4_0">24349000</us-gaap:SalesRevenueNet> <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic contextRef="eol_PE151383--1410-K0012_STD_92_20131231_0" unitRef="iso4217_USD" decimals="-3" id="id_6895476_6089C29F-80C3-42A5-8328-ED90E6D7FE11_4_2">6531000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic> <us-gaap:NetIncomeLoss contextRef="eol_PE151383--1410-K0012_STD_92_20131231_0" unitRef="iso4217_USD" decimals="-3" id="id_6895476_6089C29F-80C3-42A5-8328-ED90E6D7FE11_4_1">6531000</us-gaap:NetIncomeLoss> <us-gaap:LicenseAndServicesRevenue contextRef="eol_PE151383--1410-K0012_STD_92_20131231_0_1279431x1424859" unitRef="iso4217_USD" decimals="-5" id="id_6895476_D20635B7-621E-4EE3-9E8D-D5D0621AE095_1001_0">17200000</us-gaap:LicenseAndServicesRevenue> <us-gaap:IncomeLossFromContinuingOperationsPerBasicAndDilutedShare contextRef="eol_PE151383--1410-K0012_STD_92_20141231_0" unitRef="iso4217_USD_per_shares" decimals="2" id="id_6895476_4BF77D0F-06CF-4C1C-B793-C2809F5E4DA5_4_3">0.23</us-gaap:IncomeLossFromContinuingOperationsPerBasicAndDilutedShare> <us-gaap:SalesRevenueNet contextRef="eol_PE151383--1410-K0012_STD_92_20141231_0" unitRef="iso4217_USD" decimals="-3" id="id_6895476_4BF77D0F-06CF-4C1C-B793-C2809F5E4DA5_4_0">21758000</us-gaap:SalesRevenueNet> <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic contextRef="eol_PE151383--1410-K0012_STD_92_20141231_0" unitRef="iso4217_USD" decimals="-3" id="id_6895476_4BF77D0F-06CF-4C1C-B793-C2809F5E4DA5_4_2">8443000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic> <us-gaap:NetIncomeLoss contextRef="eol_PE151383--1410-K0012_STD_92_20141231_0" unitRef="iso4217_USD" decimals="-3" id="id_6895476_4BF77D0F-06CF-4C1C-B793-C2809F5E4DA5_4_1">8443000</us-gaap:NetIncomeLoss> <context id="eol_PE151383--1410-K0012_STD_92_20141231_0"> <entity> <identifier scheme="http://www.sec.gov/CIK">0001061983</identifier> </entity> <period> <startDate>2014-10-01</startDate> <endDate>2014-12-31</endDate> </period> </context> <context id="eol_PE151383--1410-K0012_STD_92_20131231_0_1279431x1424859"> <entity> <identifier scheme="http://www.sec.gov/CIK">0001061983</identifier> <segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">cytk:AmgenMember</xbrldi:explicitMember></segment> </entity> <period> <startDate>2013-10-01</startDate> <endDate>2013-12-31</endDate> </period> </context> <context id="eol_PE151383--1410-K0012_STD_92_20131231_0"> <entity> <identifier scheme="http://www.sec.gov/CIK">0001061983</identifier> </entity> <period> <startDate>2013-10-01</startDate> <endDate>2013-12-31</endDate> </period> </context> <context id="eol_PE151383--1410-K0012_STD_92_20140930_0"> <entity> <identifier scheme="http://www.sec.gov/CIK">0001061983</identifier> </entity> <period> <startDate>2014-07-01</startDate> <endDate>2014-09-30</endDate> </period> </context> <context id="eol_PE151383--1410-K0012_STD_92_20130930_0"> <entity> <identifier scheme="http://www.sec.gov/CIK">0001061983</identifier> </entity> <period> <startDate>2013-07-01</startDate> <endDate>2013-09-30</endDate> </period> </context> <context id="eol_PE151383--1410-K0012_STD_91_20140630_0"> <entity> <identifier scheme="http://www.sec.gov/CIK">0001061983</identifier> </entity> <period> <startDate>2014-04-01</startDate> <endDate>2014-06-30</endDate> </period> </context> <context id="eol_PE151383--1410-K0012_STD_91_20130630_0_1276401x1270422"> <entity> <identifier scheme="http://www.sec.gov/CIK">0001061983</identifier> <segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></segment> </entity> <period> <startDate>2013-04-01</startDate> <endDate>2013-06-30</endDate> </period> </context> <context id="eol_PE151383--1410-K0012_STD_91_20130630_0_1276400x1281157"> <entity> <identifier scheme="http://www.sec.gov/CIK">0001061983</identifier> <segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember></segment> </entity> <period> <startDate>2013-04-01</startDate> <endDate>2013-06-30</endDate> </period> </context> <context id="eol_PE151383--1410-K0012_STD_91_20130630_0"> <entity> <identifier scheme="http://www.sec.gov/CIK">0001061983</identifier> </entity> <period> <startDate>2013-04-01</startDate> <endDate>2013-06-30</endDate> </period> </context> <context id="eol_PE151383--1410-K0012_STD_91_20120630_0_1278975x1273442"> <entity> <identifier scheme="http://www.sec.gov/CIK">0001061983</identifier> <segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:WarrantMember</xbrldi:explicitMember></segment> </entity> <period> <startDate>2012-04-01</startDate> <endDate>2012-06-30</endDate> </period> </context> <context id="eol_PE151383--1410-K0012_STD_91_20120630_0_1276400x1281157"> <entity> <identifier scheme="http://www.sec.gov/CIK">0001061983</identifier> <segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember></segment> </entity> <period> <startDate>2012-04-01</startDate> <endDate>2012-06-30</endDate> </period> </context> <context id="eol_PE151383--1410-K0012_STD_91_20120630_0"> <entity> <identifier scheme="http://www.sec.gov/CIK">0001061983</identifier> </entity> <period> <startDate>2012-04-01</startDate> <endDate>2012-06-30</endDate> </period> </context> <context id="eol_PE151383--1410-K0012_STD_90_20140331_0"> <entity> <identifier scheme="http://www.sec.gov/CIK">0001061983</identifier> </entity> <period> <startDate>2014-01-01</startDate> <endDate>2014-03-31</endDate> </period> </context> <context id="eol_PE151383--1410-K0012_STD_90_20130331_0_1276401x1270422"> <entity> <identifier scheme="http://www.sec.gov/CIK">0001061983</identifier> <segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></segment> </entity> <period> <startDate>2013-01-01</startDate> <endDate>2013-03-31</endDate> </period> </context> <context id="eol_PE151383--1410-K0012_STD_90_20130331_0_1276400x1281157"> <entity> <identifier scheme="http://www.sec.gov/CIK">0001061983</identifier> <segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember></segment> </entity> <period> <startDate>2013-01-01</startDate> <endDate>2013-03-31</endDate> </period> </context> <context id="eol_PE151383--1410-K0012_STD_90_20130331_0"> <entity> <identifier scheme="http://www.sec.gov/CIK">0001061983</identifier> </entity> <period> <startDate>2013-01-01</startDate> <endDate>2013-03-31</endDate> </period> </context> <context id="eol_PE151383--1410-K0012_STD_366_20121231_0_1280964x1424733"> <entity> <identifier scheme="http://www.sec.gov/CIK">0001061983</identifier> <segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">cytk:NonEmployeeStockBasedCompensationMember</xbrldi:explicitMember></segment> </entity> <period> <startDate>2012-01-01</startDate> <endDate>2012-12-31</endDate> </period> </context> <context id="eol_PE151383--1410-K0012_STD_366_20121231_0_1280964x1294890"> <entity> <identifier scheme="http://www.sec.gov/CIK">0001061983</identifier> <segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">cytk:NineteenNinetySevenStockOptionPlanMember</xbrldi:explicitMember></segment> </entity> <period> <startDate>2012-01-01</startDate> <endDate>2012-12-31</endDate> </period> </context> <context id="eol_PE151383--1410-K0012_STD_366_20121231_0_1280964x1277228"> <entity> <identifier scheme="http://www.sec.gov/CIK">0001061983</identifier> <segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember></segment> </entity> <period> <startDate>2012-01-01</startDate> <endDate>2012-12-31</endDate> </period> </context> <context id="eol_PE151383--1410-K0012_STD_366_20121231_0_1279936x1276697"> <entity> <identifier scheme="http://www.sec.gov/CIK">0001061983</identifier> <segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">us-gaap:ValuationAllowanceOfDeferredTaxAssetsMember</xbrldi:explicitMember></segment> </entity> <period> <startDate>2012-01-01</startDate> <endDate>2012-12-31</endDate> </period> </context> <context id="eol_PE151383--1410-K0012_STD_366_20121231_0_1279431x1424859"> <entity> <identifier scheme="http://www.sec.gov/CIK">0001061983</identifier> <segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">cytk:AmgenMember</xbrldi:explicitMember></segment> </entity> <period> <startDate>2012-01-01</startDate> <endDate>2012-12-31</endDate> </period> </context> <context id="eol_PE151383--1410-K0012_STD_366_20121231_0_1276401x1273630"> <entity> <identifier scheme="http://www.sec.gov/CIK">0001061983</identifier> <segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></segment> </entity> <period> <startDate>2012-01-01</startDate> <endDate>2012-12-31</endDate> </period> </context> <context id="eol_PE151383--1410-K0012_STD_366_20121231_0_1276401x1272805"> <entity> <identifier scheme="http://www.sec.gov/CIK">0001061983</identifier> <segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember></segment> </entity> <period> <startDate>2012-01-01</startDate> <endDate>2012-12-31</endDate> </period> </context> <context id="eol_PE151383--1410-K0012_STD_366_20121231_0_1276401x1270422"> <entity> <identifier scheme="http://www.sec.gov/CIK">0001061983</identifier> <segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></segment> </entity> <period> <startDate>2012-01-01</startDate> <endDate>2012-12-31</endDate> </period> </context> <context id="eol_PE151383--1410-K0012_STD_366_20121231_0_1276401x1269588"> <entity> <identifier scheme="http://www.sec.gov/CIK">0001061983</identifier> <segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></segment> </entity> <period> <startDate>2012-01-01</startDate> <endDate>2012-12-31</endDate> </period> </context> <context id="eol_PE151383--1410-K0012_STD_366_20121231_0_1276401x1268669"> <entity> <identifier scheme="http://www.sec.gov/CIK">0001061983</identifier> <segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></segment> </entity> <period> <startDate>2012-01-01</startDate> <endDate>2012-12-31</endDate> </period> </context> <context id="eol_PE151383--1410-K0012_STD_366_20121231_0_1276400x1281157"> <entity> <identifier scheme="http://www.sec.gov/CIK">0001061983</identifier> <segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember></segment> </entity> <period> <startDate>2012-01-01</startDate> <endDate>2012-12-31</endDate> </period> </context> <context id="eol_PE151383--1410-K0012_STD_366_20121231_0_1276400x1269676_1276401x1273630"> <entity> <identifier scheme="http://www.sec.gov/CIK">0001061983</identifier> <segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></segment> </entity> <period> <startDate>2012-01-01</startDate> <endDate>2012-12-31</endDate> </period> </context> <context id="eol_PE151383--1410-K0012_STD_366_20121231_0_1276400x1269676_1276401x1272805"> <entity> <identifier scheme="http://www.sec.gov/CIK">0001061983</identifier> <segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember></segment> </entity> <period> <startDate>2012-01-01</startDate> <endDate>2012-12-31</endDate> </period> </context> <context id="eol_PE151383--1410-K0012_STD_366_20121231_0_1276400x1269676_1276401x1270422"> <entity> <identifier scheme="http://www.sec.gov/CIK">0001061983</identifier> <segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></segment> </entity> <period> <startDate>2012-01-01</startDate> <endDate>2012-12-31</endDate> </period> </context> <context id="eol_PE151383--1410-K0012_STD_366_20121231_0_1276400x1269676"> <entity> <identifier scheme="http://www.sec.gov/CIK">0001061983</identifier> <segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember></segment> </entity> <period> <startDate>2012-01-01</startDate> <endDate>2012-12-31</endDate> </period> </context> <context id="eol_PE151383--1410-K0012_STD_366_20121231_0_1274159x1269570"> <entity> <identifier scheme="http://www.sec.gov/CIK">0001061983</identifier> <segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></segment> </entity> <period> <startDate>2012-01-01</startDate> <endDate>2012-12-31</endDate> </period> </context> <context id="eol_PE151383--1410-K0012_STD_366_20121231_0_1274159x1269133"> <entity> <identifier scheme="http://www.sec.gov/CIK">0001061983</identifier> <segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></segment> </entity> <period> <startDate>2012-01-01</startDate> <endDate>2012-12-31</endDate> </period> </context> <context id="eol_PE151383--1410-K0012_STD_366_20121231_0_1272896x1621940"> <entity> <identifier scheme="http://www.sec.gov/CIK">0001061983</identifier> <segment><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">cytk:OtherGrantRevenueMember</xbrldi:explicitMember></segment> </entity> <period> <startDate>2012-01-01</startDate> <endDate>2012-12-31</endDate> </period> </context> <context id="eol_PE151383--1410-K0012_STD_366_20121231_0_1272896x1537165"> <entity> <identifier scheme="http://www.sec.gov/CIK">0001061983</identifier> <segment><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">cytk:GlobalBloodTherapeuticsMember</xbrldi:explicitMember></segment> </entity> <period> <startDate>2012-01-01</startDate> <endDate>2012-12-31</endDate> </period> </context> <context id="eol_PE151383--1410-K0012_STD_366_20121231_0_1272896x1507815"> <entity> <identifier scheme="http://www.sec.gov/CIK">0001061983</identifier> <segment><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">cytk:NindsMyastheniaGravisMember</xbrldi:explicitMember></segment> </entity> <period> <startDate>2012-01-01</startDate> <endDate>2012-12-31</endDate> </period> </context> <context id="eol_PE151383--1410-K0012_STD_366_20121231_0_1272896x1454595"> <entity> <identifier scheme="http://www.sec.gov/CIK">0001061983</identifier> <segment><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">cytk:MyokardiaMember</xbrldi:explicitMember></segment> </entity> <period> <startDate>2012-01-01</startDate> <endDate>2012-12-31</endDate> </period> </context> <context id="eol_PE151383--1410-K0012_STD_366_20121231_0_1272720x1275629"> <entity> <identifier scheme="http://www.sec.gov/CIK">0001061983</identifier> <segment><xbrldi:explicitMember dimension="us-gaap:OptionIndexedToIssuersEquityTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></segment> </entity> <period> <startDate>2012-01-01</startDate> <endDate>2012-12-31</endDate> </period> </context> <context id="eol_PE151383--1410-K0012_STD_366_20121231_0_1271382x1511257_1276401x1273630"> <entity> <identifier scheme="http://www.sec.gov/CIK">0001061983</identifier> <segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">cytk:MlvAgreementMember</xbrldi:explicitMember></segment> </entity> <period> <startDate>2012-01-01</startDate> <endDate>2012-12-31</endDate> </period> </context> <context id="eol_PE151383--1410-K0012_STD_366_20121231_0_1271382x1511257_1276401x1270422"> <entity> <identifier scheme="http://www.sec.gov/CIK">0001061983</identifier> <segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">cytk:MlvAgreementMember</xbrldi:explicitMember></segment> </entity> <period> <startDate>2012-01-01</startDate> <endDate>2012-12-31</endDate> </period> </context> <context id="eol_PE151383--1410-K0012_STD_366_20121231_0_1271382x1511257"> <entity> <identifier scheme="http://www.sec.gov/CIK">0001061983</identifier> <segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">cytk:MlvAgreementMember</xbrldi:explicitMember></segment> </entity> <period> <startDate>2012-01-01</startDate> <endDate>2012-12-31</endDate> </period> </context> <context id="eol_PE151383--1410-K0012_STD_366_20121231_0_1271382x1277228"> <entity> <identifier scheme="http://www.sec.gov/CIK">0001061983</identifier> <segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember></segment> </entity> <period> <startDate>2012-01-01</startDate> <endDate>2012-12-31</endDate> </period> </context> <context id="eol_PE151383--1410-K0012_STD_366_20121231_0_1270313x1275629"> <entity> <identifier scheme="http://www.sec.gov/CIK">0001061983</identifier> <segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></segment> </entity> <period> <startDate>2012-01-01</startDate> <endDate>2012-12-31</endDate> </period> </context> <context id="eol_PE151383--1410-K0012_STD_366_20121231_0_1270313x1271212"> <entity> <identifier scheme="http://www.sec.gov/CIK">0001061983</identifier> <segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></segment> </entity> <period> <startDate>2012-01-01</startDate> <endDate>2012-12-31</endDate> </period> </context> <context id="eol_PE151383--1410-K0012_STD_366_20121231_0_1270313x1271210"> <entity> <identifier scheme="http://www.sec.gov/CIK">0001061983</identifier> <segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember></segment> </entity> <period> <startDate>2012-01-01</startDate> <endDate>2012-12-31</endDate> </period> </context> <context id="eol_PE151383--1410-K0012_STD_366_20121231_0_1268687x1273442"> <entity> <identifier scheme="http://www.sec.gov/CIK">0001061983</identifier> <segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember></segment> </entity> <period> <startDate>2012-01-01</startDate> <endDate>2012-12-31</endDate> </period> </context> <context id="eol_PE151383--1410-K0012_STD_366_20121231_0_1268687x1271212"> <entity> <identifier scheme="http://www.sec.gov/CIK">0001061983</identifier> <segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></segment> </entity> <period> <startDate>2012-01-01</startDate> <endDate>2012-12-31</endDate> </period> </context> <context id="eol_PE151383--1410-K0012_STD_366_20121231_0"> <entity> <identifier scheme="http://www.sec.gov/CIK">0001061983</identifier> </entity> <period> <startDate>2012-01-01</startDate> <endDate>2012-12-31</endDate> </period> </context> <context id="eol_PE151383--1410-K0012_STD_365_20141231_0_1281318x1434297"> <entity> <identifier scheme="http://www.sec.gov/CIK">0001061983</identifier> <segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">cytk:AstellasMember</xbrldi:explicitMember></segment> </entity> <period> <startDate>2014-01-01</startDate> <endDate>2014-12-31</endDate> </period> </context> <context id="eol_PE151383--1410-K0012_STD_365_20141231_0_1280964x1424733"> <entity> <identifier scheme="http://www.sec.gov/CIK">0001061983</identifier> <segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">cytk:NonEmployeeStockBasedCompensationMember</xbrldi:explicitMember></segment> </entity> <period> <startDate>2014-01-01</startDate> <endDate>2014-12-31</endDate> </period> </context> <context id="eol_PE151383--1410-K0012_STD_365_20141231_0_1280964x1403278"> <entity> <identifier scheme="http://www.sec.gov/CIK">0001061983</identifier> <segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">cytk:TwoThousandAndFourPlanMember</xbrldi:explicitMember></segment> </entity> <period> <startDate>2014-01-01</startDate> <endDate>2014-12-31</endDate> </period> </context> <context id="eol_PE151383--1410-K0012_STD_365_20141231_0_1280964x1294890"> <entity> <identifier scheme="http://www.sec.gov/CIK">0001061983</identifier> <segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">cytk:NineteenNinetySevenStockOptionPlanMember</xbrldi:explicitMember></segment> </entity> <period> <startDate>2014-01-01</startDate> <endDate>2014-12-31</endDate> </period> </context> <context id="eol_PE151383--1410-K0012_STD_365_20141231_0_1280964x1277228"> <entity> <identifier scheme="http://www.sec.gov/CIK">0001061983</identifier> <segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember></segment> </entity> <period> <startDate>2014-01-01</startDate> <endDate>2014-12-31</endDate> </period> </context> <context id="eol_PE151383--1410-K0012_STD_365_20141231_0_1280651x1520580"> <entity> <identifier scheme="http://www.sec.gov/CIK">0001061983</identifier> <segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">cytk:FederalAndStateTaxMember</xbrldi:explicitMember></segment> </entity> <period> <startDate>2014-01-01</startDate> <endDate>2014-12-31</endDate> </period> </context> <context id="eol_PE151383--1410-K0012_STD_365_20141231_0_1280651x1497867"> <entity> <identifier scheme="http://www.sec.gov/CIK">0001061983</identifier> <segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">cytk:UnrecognizedIncomeTaxBenefitsNetOfFederalBenefitOfStateIncomeTaxUtbMember</xbrldi:explicitMember></segment> </entity> <period> <startDate>2014-01-01</startDate> <endDate>2014-12-31</endDate> </period> </context> <context id="eol_PE151383--1410-K0012_STD_365_20141231_0_1280651x1297583"> <entity> <identifier scheme="http://www.sec.gov/CIK">0001061983</identifier> <segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">cytk:FederalTaxBenefitOfStateIncomeTaxUtbMember</xbrldi:explicitMember></segment> </entity> <period> <startDate>2014-01-01</startDate> <endDate>2014-12-31</endDate> </period> </context> <context id="eol_PE151383--1410-K0012_STD_365_20141231_0_1280651x1280458"> <entity> <identifier scheme="http://www.sec.gov/CIK">0001061983</identifier> <segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember></segment> </entity> <period> <startDate>2014-01-01</startDate> <endDate>2014-12-31</endDate> </period> </context> <context id="eol_PE151383--1410-K0012_STD_365_20141231_0_1280651x1276398"> <entity> <identifier scheme="http://www.sec.gov/CIK">0001061983</identifier> <segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember></segment> </entity> <period> <startDate>2014-01-01</startDate> <endDate>2014-12-31</endDate> </period> </context> <context id="eol_PE151383--1410-K0012_STD_365_20141231_0_1280248x1413008"> <entity> <identifier scheme="http://www.sec.gov/CIK">0001061983</identifier> <segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">cytk:WarrantOneMember</xbrldi:explicitMember></segment> </entity> <period> <startDate>2014-01-01</startDate> <endDate>2014-12-31</endDate> </period> </context> <context id="eol_PE151383--1410-K0012_STD_365_20141231_0_1280248x1351779"> <entity> <identifier scheme="http://www.sec.gov/CIK">0001061983</identifier> <segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">cytk:WarrantTwoMember</xbrldi:explicitMember></segment> </entity> <period> <startDate>2014-01-01</startDate> <endDate>2014-12-31</endDate> </period> </context> <context id="eol_PE151383--1410-K0012_STD_365_20141231_0_1279936x1276697"> <entity> <identifier scheme="http://www.sec.gov/CIK">0001061983</identifier> <segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">us-gaap:ValuationAllowanceOfDeferredTaxAssetsMember</xbrldi:explicitMember></segment> </entity> <period> <startDate>2014-01-01</startDate> <endDate>2014-12-31</endDate> </period> </context> <context id="eol_PE151383--1410-K0012_STD_365_20141231_0_1279431x1434297_1279908x1614633"> <entity> <identifier scheme="http://www.sec.gov/CIK">0001061983</identifier> <segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">cytk:AstellasMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">cytk:EarlyDevelopmentMember</xbrldi:explicitMember></segment> </entity> <period> <startDate>2014-01-01</startDate> <endDate>2014-12-31</endDate> </period> </context> <context id="eol_PE151383--1410-K0012_STD_365_20141231_0_1279431x1434297_1279908x1614534"> <entity> <identifier scheme="http://www.sec.gov/CIK">0001061983</identifier> <segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">cytk:AstellasMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">cytk:ProportionalPerformanceModelMember</xbrldi:explicitMember></segment> </entity> <period> <startDate>2014-01-01</startDate> <endDate>2014-12-31</endDate> </period> </context> <context id="eol_PE151383--1410-K0012_STD_365_20141231_0_1279431x1434297"> <entity> <identifier scheme="http://www.sec.gov/CIK">0001061983</identifier> <segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">cytk:AstellasMember</xbrldi:explicitMember></segment> </entity> <period> <startDate>2014-01-01</startDate> <endDate>2014-12-31</endDate> </period> </context> <context id="eol_PE151383--1410-K0012_STD_365_20141231_0_1279431x1424859"> <entity> <identifier scheme="http://www.sec.gov/CIK">0001061983</identifier> <segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">cytk:AmgenMember</xbrldi:explicitMember></segment> </entity> <period> <startDate>2014-01-01</startDate> <endDate>2014-12-31</endDate> </period> </context> <context id="eol_PE151383--1410-K0012_STD_365_20141231_0_1278629x1361274_1279431x1434297"> <entity> <identifier scheme="http://www.sec.gov/CIK">0001061983</identifier> <segment><xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">cytk:OtherCostsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">cytk:AstellasMember</xbrldi:explicitMember></segment> </entity> <period> <startDate>2014-01-01</startDate> <endDate>2014-12-31</endDate> </period> </context> <context id="eol_PE151383--1410-K0012_STD_365_20141231_0_1278629x1344498_1279431x1434297"> <entity> <identifier scheme="http://www.sec.gov/CIK">0001061983</identifier> <segment><xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">cytk:InternalCostsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">cytk:AstellasMember</xbrldi:explicitMember></segment> </entity> <period> <startDate>2014-01-01</startDate> <endDate>2014-12-31</endDate> </period> </context> <context id="eol_PE151383--1410-K0012_STD_365_20141231_0_1276401x1273630"> <entity> <identifier scheme="http://www.sec.gov/CIK">0001061983</identifier> <segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></segment> </entity> <period> <startDate>2014-01-01</startDate> <endDate>2014-12-31</endDate> </period> </context> <context id="eol_PE151383--1410-K0012_STD_365_20141231_0_1276401x1270422"> <entity> <identifier scheme="http://www.sec.gov/CIK">0001061983</identifier> <segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></segment> </entity> <period> <startDate>2014-01-01</startDate> <endDate>2014-12-31</endDate> </period> </context> <context id="eol_PE151383--1410-K0012_STD_365_20141231_0_1276401x1269588"> <entity> <identifier scheme="http://www.sec.gov/CIK">0001061983</identifier> <segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></segment> </entity> <period> <startDate>2014-01-01</startDate> <endDate>2014-12-31</endDate> </period> </context> <context id="eol_PE151383--1410-K0012_STD_365_20141231_0_1276401x1268669"> <entity> <identifier scheme="http://www.sec.gov/CIK">0001061983</identifier> <segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></segment> </entity> <period> <startDate>2014-01-01</startDate> <endDate>2014-12-31</endDate> </period> </context> <context id="eol_PE151383--1410-K0012_STD_365_20141231_0_1276400x1281157"> <entity> <identifier scheme="http://www.sec.gov/CIK">0001061983</identifier> <segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember></segment> </entity> <period> <startDate>2014-01-01</startDate> <endDate>2014-12-31</endDate> </period> </context> <context id="eol_PE151383--1410-K0012_STD_365_20141231_0_1276400x1269676"> <entity> <identifier scheme="http://www.sec.gov/CIK">0001061983</identifier> <segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember></segment> </entity> <period> <startDate>2014-01-01</startDate> <endDate>2014-12-31</endDate> </period> </context> <context id="eol_PE151383--1410-K0012_STD_365_20141231_0_1276136x1362982"> <entity> <identifier scheme="http://www.sec.gov/CIK">0001061983</identifier> <segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">cytk:ComputerEquipmentAndSoftwareMember</xbrldi:explicitMember></segment> </entity> <period> <startDate>2014-01-01</startDate> <endDate>2014-12-31</endDate> </period> </context> <context id="eol_PE151383--1410-K0012_STD_365_20141231_0_1276136x1279264"> <entity> <identifier scheme="http://www.sec.gov/CIK">0001061983</identifier> <segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:OfficeEquipmentMember</xbrldi:explicitMember></segment> </entity> <period> <startDate>2014-01-01</startDate> <endDate>2014-12-31</endDate> </period> </context> <context id="eol_PE151383--1410-K0012_STD_365_20141231_0_1276136x1274094"> <entity> <identifier scheme="http://www.sec.gov/CIK">0001061983</identifier> <segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember></segment> </entity> <period> <startDate>2014-01-01</startDate> <endDate>2014-12-31</endDate> </period> </context> <context id="eol_PE151383--1410-K0012_STD_365_20141231_0_1274544x1398741_1279431x1434297"> <entity> <identifier scheme="http://www.sec.gov/CIK">0001061983</identifier> <segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">cytk:AmendedAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">cytk:AstellasMember</xbrldi:explicitMember></segment> </entity> <period> <startDate>2014-01-01</startDate> <endDate>2014-12-31</endDate> </period> </context> <context id="eol_PE151383--1410-K0012_STD_365_20141231_0_1274212x1276380"> <entity> <identifier scheme="http://www.sec.gov/CIK">0001061983</identifier> <segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember></segment> </entity> <period> <startDate>2014-01-01</startDate> <endDate>2014-12-31</endDate> </period> </context> <context id="eol_PE151383--1410-K0012_STD_365_20141231_0_1274159x1269570"> <entity> <identifier scheme="http://www.sec.gov/CIK">0001061983</identifier> <segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></segment> </entity> <period> <startDate>2014-01-01</startDate> <endDate>2014-12-31</endDate> </period> </context> <context id="eol_PE151383--1410-K0012_STD_365_20141231_0_1274159x1269133"> <entity> <identifier scheme="http://www.sec.gov/CIK">0001061983</identifier> <segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></segment> </entity> <period> <startDate>2014-01-01</startDate> <endDate>2014-12-31</endDate> </period> </context> <context id="eol_PE151383--1410-K0012_STD_365_20141231_0_1273383x1392833_1280964x1403278"> <entity> <identifier scheme="http://www.sec.gov/CIK">0001061983</identifier> <segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">cytk:TwoThousandAndFourPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TitleOfIndividualAxis">cytk:ExistingEmployeeMember</xbrldi:explicitMember></segment> </entity> <period> <startDate>2014-01-01</startDate> <endDate>2014-12-31</endDate> </period> </context> <context id="eol_PE151383--1410-K0012_STD_365_20141231_0_1273383x1358661_1280964x1403278"> <entity> <identifier scheme="http://www.sec.gov/CIK">0001061983</identifier> <segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">cytk:TwoThousandAndFourPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TitleOfIndividualAxis">cytk:NewEmployeeMember</xbrldi:explicitMember></segment> </entity> <period> <startDate>2014-01-01</startDate> <endDate>2014-12-31</endDate> </period> </context> <context id="eol_PE151383--1410-K0012_STD_365_20141231_0_1273333x1271500"> <entity> <identifier scheme="http://www.sec.gov/CIK">0001061983</identifier> <segment><xbrldi:explicitMember dimension="us-gaap:StatementGeographicalAxis">country:US</xbrldi:explicitMember></segment> </entity> <period> <startDate>2014-01-01</startDate> <endDate>2014-12-31</endDate> </period> </context> <context id="eol_PE151383--1410-K0012_STD_365_20141231_0_1273333x1269843"> <entity> <identifier scheme="http://www.sec.gov/CIK">0001061983</identifier> <segment><xbrldi:explicitMember dimension="us-gaap:StatementGeographicalAxis">country:JP</xbrldi:explicitMember></segment> </entity> <period> <startDate>2014-01-01</startDate> <endDate>2014-12-31</endDate> </period> </context> <context id="eol_PE151383--1410-K0012_STD_365_20141231_0_1272896x1621940"> <entity> <identifier scheme="http://www.sec.gov/CIK">0001061983</identifier> <segment><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">cytk:OtherGrantRevenueMember</xbrldi:explicitMember></segment> </entity> <period> <startDate>2014-01-01</startDate> <endDate>2014-12-31</endDate> </period> </context> <context id="eol_PE151383--1410-K0012_STD_365_20141231_0_1272896x1537165"> <entity> <identifier scheme="http://www.sec.gov/CIK">0001061983</identifier> <segment><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">cytk:GlobalBloodTherapeuticsMember</xbrldi:explicitMember></segment> </entity> <period> <startDate>2014-01-01</startDate> <endDate>2014-12-31</endDate> </period> </context> <context id="eol_PE151383--1410-K0012_STD_365_20141231_0_1272896x1507815"> <entity> <identifier scheme="http://www.sec.gov/CIK">0001061983</identifier> <segment><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">cytk:NindsMyastheniaGravisMember</xbrldi:explicitMember></segment> </entity> <period> <startDate>2014-01-01</startDate> <endDate>2014-12-31</endDate> </period> </context> <context id="eol_PE151383--1410-K0012_STD_365_20141231_0_1272896x1454595"> <entity> <identifier scheme="http://www.sec.gov/CIK">0001061983</identifier> <segment><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">cytk:MyokardiaMember</xbrldi:explicitMember></segment> </entity> <period> <startDate>2014-01-01</startDate> <endDate>2014-12-31</endDate> </period> </context> <context id="eol_PE151383--1410-K0012_STD_365_20141231_0_1272720x1275629"> <entity> <identifier scheme="http://www.sec.gov/CIK">0001061983</identifier> <segment><xbrldi:explicitMember dimension="us-gaap:OptionIndexedToIssuersEquityTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></segment> </entity> <period> <startDate>2014-01-01</startDate> <endDate>2014-12-31</endDate> </period> </context> <context id="eol_PE151383--1410-K0012_STD_365_20141231_0_1271382x1511257_1276401x1273630"> <entity> <identifier scheme="http://www.sec.gov/CIK">0001061983</identifier> <segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">cytk:MlvAgreementMember</xbrldi:explicitMember></segment> </entity> <period> <startDate>2014-01-01</startDate> <endDate>2014-12-31</endDate> </period> </context> <context id="eol_PE151383--1410-K0012_STD_365_20141231_0_1271382x1511257_1276401x1270422"> <entity> <identifier scheme="http://www.sec.gov/CIK">0001061983</identifier> <segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">cytk:MlvAgreementMember</xbrldi:explicitMember></segment> </entity> <period> <startDate>2014-01-01</startDate> <endDate>2014-12-31</endDate> </period> </context> <context id="eol_PE151383--1410-K0012_STD_365_20141231_0_1271382x1511257"> <entity> <identifier scheme="http://www.sec.gov/CIK">0001061983</identifier> <segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">cytk:MlvAgreementMember</xbrldi:explicitMember></segment> </entity> <period> <startDate>2014-01-01</startDate> <endDate>2014-12-31</endDate> </period> </context> <context id="eol_PE151383--1410-K0012_STD_365_20141231_0_1271382x1277228"> <entity> <identifier scheme="http://www.sec.gov/CIK">0001061983</identifier> <segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember></segment> </entity> <period> <startDate>2014-01-01</startDate> <endDate>2014-12-31</endDate> </period> </context> <context id="eol_PE151383--1410-K0012_STD_365_20141231_0_1270365x1274813"> <entity> <identifier scheme="http://www.sec.gov/CIK">0001061983</identifier> <segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember></segment> </entity> <period> <startDate>2014-01-01</startDate> <endDate>2014-12-31</endDate> </period> </context> <context id="eol_PE151383--1410-K0012_STD_365_20141231_0_1270313x1275629"> <entity> <identifier scheme="http://www.sec.gov/CIK">0001061983</identifier> <segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></segment> </entity> <period> <startDate>2014-01-01</startDate> <endDate>2014-12-31</endDate> </period> </context> <context id="eol_PE151383--1410-K0012_STD_365_20141231_0_1270313x1271212"> <entity> <identifier scheme="http://www.sec.gov/CIK">0001061983</identifier> <segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></segment> </entity> <period> <startDate>2014-01-01</startDate> <endDate>2014-12-31</endDate> </period> </context> <context id="eol_PE151383--1410-K0012_STD_365_20141231_0_1270313x1271210"> <entity> <identifier scheme="http://www.sec.gov/CIK">0001061983</identifier> <segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember></segment> </entity> <period> <startDate>2014-01-01</startDate> <endDate>2014-12-31</endDate> </period> </context> <context id="eol_PE151383--1410-K0012_STD_365_20141231_0_1269523x1277596_1280964x1294890"> <entity> <identifier scheme="http://www.sec.gov/CIK">0001061983</identifier> <segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">cytk:NineteenNinetySevenStockOptionPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MinimumMember</xbrldi:explicitMember></segment> </entity> <period> <startDate>2014-01-01</startDate> <endDate>2014-12-31</endDate> </period> </context> <context id="eol_PE151383--1410-K0012_STD_365_20141231_0_1269523x1277596_1276136x1280724"> <entity> <identifier scheme="http://www.sec.gov/CIK">0001061983</identifier> <segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdsAndLeaseholdImprovementsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MinimumMember</xbrldi:explicitMember></segment> </entity> <period> <startDate>2014-01-01</startDate> <endDate>2014-12-31</endDate> </period> </context> <context id="eol_PE151383--1410-K0012_STD_365_20141231_0_1269523x1277596_1270365x1274813_1274212x1276380"> <entity> <identifier scheme="http://www.sec.gov/CIK">0001061983</identifier> <segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MinimumMember</xbrldi:explicitMember></segment> </entity> <period> <startDate>2014-01-01</startDate> <endDate>2014-12-31</endDate> </period> </context> <context id="eol_PE151383--1410-K0012_STD_365_20141231_0_1269523x1277596_1270313x1555254_1280964x1294890"> <entity> <identifier scheme="http://www.sec.gov/CIK">0001061983</identifier> <segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">cytk:NonstatutoryStockOptionsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">cytk:NineteenNinetySevenStockOptionPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MinimumMember</xbrldi:explicitMember></segment> </entity> <period> <startDate>2014-01-01</startDate> <endDate>2014-12-31</endDate> </period> </context> <context id="eol_PE151383--1410-K0012_STD_365_20141231_0_1269523x1277596_1270313x1275629_1280964x1294890"> <entity> <identifier scheme="http://www.sec.gov/CIK">0001061983</identifier> <segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">cytk:NineteenNinetySevenStockOptionPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MinimumMember</xbrldi:explicitMember></segment> </entity> <period> <startDate>2014-01-01</startDate> <endDate>2014-12-31</endDate> </period> </context> <context id="eol_PE151383--1410-K0012_STD_365_20141231_0_1269523x1275948_1279431x1424859"> <entity> <identifier scheme="http://www.sec.gov/CIK">0001061983</identifier> <segment><xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">cytk:AmgenMember</xbrldi:explicitMember></segment> </entity> <period> <startDate>2014-01-01</startDate> <endDate>2014-12-31</endDate> </period> </context> <context id="eol_PE151383--1410-K0012_STD_365_20141231_0_1269523x1275948_1276136x1280724"> <entity> <identifier scheme="http://www.sec.gov/CIK">0001061983</identifier> <segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdsAndLeaseholdImprovementsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MaximumMember</xbrldi:explicitMember></segment> </entity> <period> <startDate>2014-01-01</startDate> <endDate>2014-12-31</endDate> </period> </context> <context id="eol_PE151383--1410-K0012_STD_365_20141231_0_1269523x1275948_1270365x1274813_1274212x1276380"> <entity> <identifier scheme="http://www.sec.gov/CIK">0001061983</identifier> <segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MaximumMember</xbrldi:explicitMember></segment> </entity> <period> <startDate>2014-01-01</startDate> <endDate>2014-12-31</endDate> </period> </context> <context id="eol_PE151383--1410-K0012_STD_365_20141231_0_1268687x1273442"> <entity> <identifier scheme="http://www.sec.gov/CIK">0001061983</identifier> <segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember></segment> </entity> <period> <startDate>2014-01-01</startDate> <endDate>2014-12-31</endDate> </period> </context> <context id="eol_PE151383--1410-K0012_STD_365_20141231_0_1268687x1271212"> <entity> <identifier scheme="http://www.sec.gov/CIK">0001061983</identifier> <segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></segment> </entity> <period> <startDate>2014-01-01</startDate> <endDate>2014-12-31</endDate> </period> </context> <context id="eol_PE151383--1410-K0012_STD_365_20141231_0"> <entity> <identifier scheme="http://www.sec.gov/CIK">0001061983</identifier> </entity> <period> <startDate>2014-01-01</startDate> <endDate>2014-12-31</endDate> </period> </context> <context id="eol_PE151383--1410-K0012_STD_365_20131231_0_1281318x1434297"> <entity> <identifier scheme="http://www.sec.gov/CIK">0001061983</identifier> <segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">cytk:AstellasMember</xbrldi:explicitMember></segment> </entity> <period> <startDate>2013-01-01</startDate> <endDate>2013-12-31</endDate> </period> </context> <context id="eol_PE151383--1410-K0012_STD_365_20131231_0_1280964x1424733"> <entity> <identifier scheme="http://www.sec.gov/CIK">0001061983</identifier> <segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">cytk:NonEmployeeStockBasedCompensationMember</xbrldi:explicitMember></segment> </entity> <period> <startDate>2013-01-01</startDate> <endDate>2013-12-31</endDate> </period> </context> <context id="eol_PE151383--1410-K0012_STD_365_20131231_0_1280964x1294890"> <entity> <identifier scheme="http://www.sec.gov/CIK">0001061983</identifier> <segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">cytk:NineteenNinetySevenStockOptionPlanMember</xbrldi:explicitMember></segment> </entity> <period> <startDate>2013-01-01</startDate> <endDate>2013-12-31</endDate> </period> </context> <context id="eol_PE151383--1410-K0012_STD_365_20131231_0_1280964x1277228"> <entity> <identifier scheme="http://www.sec.gov/CIK">0001061983</identifier> <segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember></segment> </entity> <period> <startDate>2013-01-01</startDate> <endDate>2013-12-31</endDate> </period> </context> <context id="eol_PE151383--1410-K0012_STD_365_20131231_0_1280651x1520580"> <entity> <identifier scheme="http://www.sec.gov/CIK">0001061983</identifier> <segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">cytk:FederalAndStateTaxMember</xbrldi:explicitMember></segment> </entity> <period> <startDate>2013-01-01</startDate> <endDate>2013-12-31</endDate> </period> </context> <context id="eol_PE151383--1410-K0012_STD_365_20131231_0_1280651x1497867"> <entity> <identifier scheme="http://www.sec.gov/CIK">0001061983</identifier> <segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">cytk:UnrecognizedIncomeTaxBenefitsNetOfFederalBenefitOfStateIncomeTaxUtbMember</xbrldi:explicitMember></segment> </entity> <period> <startDate>2013-01-01</startDate> <endDate>2013-12-31</endDate> </period> </context> <context id="eol_PE151383--1410-K0012_STD_365_20131231_0_1280651x1297583"> <entity> <identifier scheme="http://www.sec.gov/CIK">0001061983</identifier> <segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">cytk:FederalTaxBenefitOfStateIncomeTaxUtbMember</xbrldi:explicitMember></segment> </entity> <period> <startDate>2013-01-01</startDate> <endDate>2013-12-31</endDate> </period> </context> <context id="eol_PE151383--1410-K0012_STD_365_20131231_0_1279936x1276697"> <entity> <identifier scheme="http://www.sec.gov/CIK">0001061983</identifier> <segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">us-gaap:ValuationAllowanceOfDeferredTaxAssetsMember</xbrldi:explicitMember></segment> </entity> <period> <startDate>2013-01-01</startDate> <endDate>2013-12-31</endDate> </period> </context> <context id="eol_PE151383--1410-K0012_STD_365_20131231_0_1279431x1434297"> <entity> <identifier scheme="http://www.sec.gov/CIK">0001061983</identifier> <segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">cytk:AstellasMember</xbrldi:explicitMember></segment> </entity> <period> <startDate>2013-01-01</startDate> <endDate>2013-12-31</endDate> </period> </context> <context id="eol_PE151383--1410-K0012_STD_365_20131231_0_1279431x1424859"> <entity> <identifier scheme="http://www.sec.gov/CIK">0001061983</identifier> <segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">cytk:AmgenMember</xbrldi:explicitMember></segment> </entity> <period> <startDate>2013-01-01</startDate> <endDate>2013-12-31</endDate> </period> </context> <context id="eol_PE151383--1410-K0012_STD_365_20131231_0_1276401x1273630"> <entity> <identifier scheme="http://www.sec.gov/CIK">0001061983</identifier> <segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></segment> </entity> <period> <startDate>2013-01-01</startDate> <endDate>2013-12-31</endDate> </period> </context> <context id="eol_PE151383--1410-K0012_STD_365_20131231_0_1276401x1272805"> <entity> <identifier scheme="http://www.sec.gov/CIK">0001061983</identifier> <segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember></segment> </entity> <period> <startDate>2013-01-01</startDate> <endDate>2013-12-31</endDate> </period> </context> <context id="eol_PE151383--1410-K0012_STD_365_20131231_0_1276401x1270422"> <entity> <identifier scheme="http://www.sec.gov/CIK">0001061983</identifier> <segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></segment> </entity> <period> <startDate>2013-01-01</startDate> <endDate>2013-12-31</endDate> </period> </context> <context id="eol_PE151383--1410-K0012_STD_365_20131231_0_1276401x1269588"> <entity> <identifier scheme="http://www.sec.gov/CIK">0001061983</identifier> <segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></segment> </entity> <period> <startDate>2013-01-01</startDate> <endDate>2013-12-31</endDate> </period> </context> <context id="eol_PE151383--1410-K0012_STD_365_20131231_0_1276401x1268669"> <entity> <identifier scheme="http://www.sec.gov/CIK">0001061983</identifier> <segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></segment> </entity> <period> <startDate>2013-01-01</startDate> <endDate>2013-12-31</endDate> </period> </context> <context id="eol_PE151383--1410-K0012_STD_365_20131231_0_1276400x1281157_1276401x1273630"> <entity> <identifier scheme="http://www.sec.gov/CIK">0001061983</identifier> <segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></segment> </entity> <period> <startDate>2013-01-01</startDate> <endDate>2013-12-31</endDate> </period> </context> <context id="eol_PE151383--1410-K0012_STD_365_20131231_0_1276400x1281157_1276401x1272805"> <entity> <identifier scheme="http://www.sec.gov/CIK">0001061983</identifier> <segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember></segment> </entity> <period> <startDate>2013-01-01</startDate> <endDate>2013-12-31</endDate> </period> </context> <context id="eol_PE151383--1410-K0012_STD_365_20131231_0_1276400x1281157_1276401x1270422"> <entity> <identifier scheme="http://www.sec.gov/CIK">0001061983</identifier> <segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></segment> </entity> <period> <startDate>2013-01-01</startDate> <endDate>2013-12-31</endDate> </period> </context> <context id="eol_PE151383--1410-K0012_STD_365_20131231_0_1276400x1281157"> <entity> <identifier scheme="http://www.sec.gov/CIK">0001061983</identifier> <segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember></segment> </entity> <period> <startDate>2013-01-01</startDate> <endDate>2013-12-31</endDate> </period> </context> <context id="eol_PE151383--1410-K0012_STD_365_20131231_0_1274212x1276380"> <entity> <identifier scheme="http://www.sec.gov/CIK">0001061983</identifier> <segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember></segment> </entity> <period> <startDate>2013-01-01</startDate> <endDate>2013-12-31</endDate> </period> </context> <context id="eol_PE151383--1410-K0012_STD_365_20131231_0_1274159x1269570"> <entity> <identifier scheme="http://www.sec.gov/CIK">0001061983</identifier> <segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></segment> </entity> <period> <startDate>2013-01-01</startDate> <endDate>2013-12-31</endDate> </period> </context> <context id="eol_PE151383--1410-K0012_STD_365_20131231_0_1274159x1269133"> <entity> <identifier scheme="http://www.sec.gov/CIK">0001061983</identifier> <segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></segment> </entity> <period> <startDate>2013-01-01</startDate> <endDate>2013-12-31</endDate> </period> </context> <context id="eol_PE151383--1410-K0012_STD_365_20131231_0_1273333x1271500"> <entity> <identifier scheme="http://www.sec.gov/CIK">0001061983</identifier> <segment><xbrldi:explicitMember dimension="us-gaap:StatementGeographicalAxis">country:US</xbrldi:explicitMember></segment> </entity> <period> <startDate>2013-01-01</startDate> <endDate>2013-12-31</endDate> </period> </context> <context id="eol_PE151383--1410-K0012_STD_365_20131231_0_1273333x1269843"> <entity> <identifier scheme="http://www.sec.gov/CIK">0001061983</identifier> <segment><xbrldi:explicitMember dimension="us-gaap:StatementGeographicalAxis">country:JP</xbrldi:explicitMember></segment> </entity> <period> <startDate>2013-01-01</startDate> <endDate>2013-12-31</endDate> </period> </context> <context id="eol_PE151383--1410-K0012_STD_365_20131231_0_1272896x1621940"> <entity> <identifier scheme="http://www.sec.gov/CIK">0001061983</identifier> <segment><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">cytk:OtherGrantRevenueMember</xbrldi:explicitMember></segment> </entity> <period> <startDate>2013-01-01</startDate> <endDate>2013-12-31</endDate> </period> </context> <context id="eol_PE151383--1410-K0012_STD_365_20131231_0_1272896x1537165"> <entity> <identifier scheme="http://www.sec.gov/CIK">0001061983</identifier> <segment><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">cytk:GlobalBloodTherapeuticsMember</xbrldi:explicitMember></segment> </entity> <period> <startDate>2013-01-01</startDate> <endDate>2013-12-31</endDate> </period> </context> <context id="eol_PE151383--1410-K0012_STD_365_20131231_0_1272896x1507815"> <entity> <identifier scheme="http://www.sec.gov/CIK">0001061983</identifier> <segment><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">cytk:NindsMyastheniaGravisMember</xbrldi:explicitMember></segment> </entity> <period> <startDate>2013-01-01</startDate> <endDate>2013-12-31</endDate> </period> </context> <context id="eol_PE151383--1410-K0012_STD_365_20131231_0_1272896x1454595"> <entity> <identifier scheme="http://www.sec.gov/CIK">0001061983</identifier> <segment><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">cytk:MyokardiaMember</xbrldi:explicitMember></segment> </entity> <period> <startDate>2013-01-01</startDate> <endDate>2013-12-31</endDate> </period> </context> <context id="eol_PE151383--1410-K0012_STD_365_20131231_0_1272720x1275629"> <entity> <identifier scheme="http://www.sec.gov/CIK">0001061983</identifier> <segment><xbrldi:explicitMember dimension="us-gaap:OptionIndexedToIssuersEquityTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></segment> </entity> <period> <startDate>2013-01-01</startDate> <endDate>2013-12-31</endDate> </period> </context> <context id="eol_PE151383--1410-K0012_STD_365_20131231_0_1271382x1511257_1276401x1273630"> <entity> <identifier scheme="http://www.sec.gov/CIK">0001061983</identifier> <segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">cytk:MlvAgreementMember</xbrldi:explicitMember></segment> </entity> <period> <startDate>2013-01-01</startDate> <endDate>2013-12-31</endDate> </period> </context> <context id="eol_PE151383--1410-K0012_STD_365_20131231_0_1271382x1511257_1276401x1270422"> <entity> <identifier scheme="http://www.sec.gov/CIK">0001061983</identifier> <segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">cytk:MlvAgreementMember</xbrldi:explicitMember></segment> </entity> <period> <startDate>2013-01-01</startDate> <endDate>2013-12-31</endDate> </period> </context> <context id="eol_PE151383--1410-K0012_STD_365_20131231_0_1271382x1511257"> <entity> <identifier scheme="http://www.sec.gov/CIK">0001061983</identifier> <segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">cytk:MlvAgreementMember</xbrldi:explicitMember></segment> </entity> <period> <startDate>2013-01-01</startDate> <endDate>2013-12-31</endDate> </period> </context> <context id="eol_PE151383--1410-K0012_STD_365_20131231_0_1271382x1277228"> <entity> <identifier scheme="http://www.sec.gov/CIK">0001061983</identifier> <segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember></segment> </entity> <period> <startDate>2013-01-01</startDate> <endDate>2013-12-31</endDate> </period> </context> <context id="eol_PE151383--1410-K0012_STD_365_20131231_0_1270365x1274813_1274212x1435842"> <entity> <identifier scheme="http://www.sec.gov/CIK">0001061983</identifier> <segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">cytk:LongTermInvestmentMember</xbrldi:explicitMember></segment> </entity> <period> <startDate>2013-01-01</startDate> <endDate>2013-12-31</endDate> </period> </context> <context id="eol_PE151383--1410-K0012_STD_365_20131231_0_1270313x1275629"> <entity> <identifier scheme="http://www.sec.gov/CIK">0001061983</identifier> <segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></segment> </entity> <period> <startDate>2013-01-01</startDate> <endDate>2013-12-31</endDate> </period> </context> <context id="eol_PE151383--1410-K0012_STD_365_20131231_0_1270313x1271212"> <entity> <identifier scheme="http://www.sec.gov/CIK">0001061983</identifier> <segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></segment> </entity> <period> <startDate>2013-01-01</startDate> <endDate>2013-12-31</endDate> </period> </context> <context id="eol_PE151383--1410-K0012_STD_365_20131231_0_1270313x1271210"> <entity> <identifier scheme="http://www.sec.gov/CIK">0001061983</identifier> <segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember></segment> </entity> <period> <startDate>2013-01-01</startDate> <endDate>2013-12-31</endDate> </period> </context> <context id="eol_PE151383--1410-K0012_STD_365_20131231_0_1269523x1277596_1270365x1274813_1274212x1276380"> <entity> <identifier scheme="http://www.sec.gov/CIK">0001061983</identifier> <segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MinimumMember</xbrldi:explicitMember></segment> </entity> <period> <startDate>2013-01-01</startDate> <endDate>2013-12-31</endDate> </period> </context> <context id="eol_PE151383--1410-K0012_STD_365_20131231_0_1269523x1275948_1270365x1274813_1274212x1276380"> <entity> <identifier scheme="http://www.sec.gov/CIK">0001061983</identifier> <segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MaximumMember</xbrldi:explicitMember></segment> </entity> <period> <startDate>2013-01-01</startDate> <endDate>2013-12-31</endDate> </period> </context> <context id="eol_PE151383--1410-K0012_STD_365_20131231_0_1268687x1273442"> <entity> <identifier scheme="http://www.sec.gov/CIK">0001061983</identifier> <segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember></segment> </entity> <period> <startDate>2013-01-01</startDate> <endDate>2013-12-31</endDate> </period> </context> <context id="eol_PE151383--1410-K0012_STD_365_20131231_0_1268687x1271212"> <entity> <identifier scheme="http://www.sec.gov/CIK">0001061983</identifier> <segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></segment> </entity> <period> <startDate>2013-01-01</startDate> <endDate>2013-12-31</endDate> </period> </context> <context id="eol_PE151383--1410-K0012_STD_365_20131231_0"> <entity> <identifier scheme="http://www.sec.gov/CIK">0001061983</identifier> </entity> <period> <startDate>2013-01-01</startDate> <endDate>2013-12-31</endDate> </period> </context> <context id="eol_PE151383--1410-K0012_STD_365_20101231_0"> <entity> <identifier scheme="http://www.sec.gov/CIK">0001061983</identifier> </entity> <period> <startDate>2010-01-01</startDate> <endDate>2010-12-31</endDate> </period> </context> <context id="eol_PE151383--1410-K0012_STD_31_20150131_0_1271378x1273350_1274544x1398741_1279431x1434297"> <entity> <identifier scheme="http://www.sec.gov/CIK">0001061983</identifier> <segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">cytk:AmendedAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">cytk:AstellasMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></segment> </entity> <period> <startDate>2015-01-01</startDate> <endDate>2015-01-31</endDate> </period> </context> <context id="eol_PE151383--1410-K0012_STD_31_20130731_0_1279431x1434297"> <entity> <identifier scheme="http://www.sec.gov/CIK">0001061983</identifier> <segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">cytk:AstellasMember</xbrldi:explicitMember></segment> </entity> <period> <startDate>2013-07-01</startDate> <endDate>2013-07-31</endDate> </period> </context> <context id="eol_PE151383--1410-K0012_STD_30_20130630_0_1279431x1424859"> <entity> <identifier scheme="http://www.sec.gov/CIK">0001061983</identifier> <segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">cytk:AmgenMember</xbrldi:explicitMember></segment> </entity> <period> <startDate>2013-06-01</startDate> <endDate>2013-06-30</endDate> </period> </context> <context id="eol_PE151383--1410-K0012_STD_30_20130630_0_1276400x1281157"> <entity> <identifier scheme="http://www.sec.gov/CIK">0001061983</identifier> <segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember></segment> </entity> <period> <startDate>2013-06-01</startDate> <endDate>2013-06-30</endDate> </period> </context> <context id="eol_PE151383--1410-K0012_STD_30_20130630_0"> <entity> <identifier scheme="http://www.sec.gov/CIK">0001061983</identifier> </entity> <period> <startDate>2013-06-01</startDate> <endDate>2013-06-30</endDate> </period> </context> <context id="eol_PE151383--1410-K0012_STD_30_20120930_0"> <entity> <identifier scheme="http://www.sec.gov/CIK">0001061983</identifier> </entity> <period> <startDate>2012-09-01</startDate> <endDate>2012-09-30</endDate> </period> </context> <context id="eol_PE151383--1410-K0012_STD_30_20130430_0"> <entity> <identifier scheme="http://www.sec.gov/CIK">0001061983</identifier> </entity> <period> <startDate>2013-04-01</startDate> <endDate>2013-04-30</endDate> </period> </context> <context id="eol_PE151383--1410-K0012_STD_28_20140228_0_1271382x1382912"> <entity> <identifier scheme="http://www.sec.gov/CIK">0001061983</identifier> <segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">cytk:UnderwrittenPublicOfferingMember</xbrldi:explicitMember></segment> </entity> <period> <startDate>2014-02-01</startDate> <endDate>2014-02-28</endDate> </period> </context> <context id="eol_PE151383--1410-K0012_STD_1_20120926_0_1276401x1270422"> <entity> <identifier scheme="http://www.sec.gov/CIK">0001061983</identifier> <segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></segment> </entity> <period> <startDate>2012-09-26</startDate> <endDate>2012-09-26</endDate> </period> </context> <context id="eol_PE151383--1410-K0012_STD_1_20120926_0_1276400x1269676"> <entity> <identifier scheme="http://www.sec.gov/CIK">0001061983</identifier> <segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember></segment> </entity> <period> <startDate>2012-09-26</startDate> <endDate>2012-09-26</endDate> </period> </context> <context id="eol_PE151383--1410-K0012_STD_1_20120926_0_1271382x1559654_1276400x1269676"> <entity> <identifier scheme="http://www.sec.gov/CIK">0001061983</identifier> <segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">cytk:DeerfieldAgreementMember</xbrldi:explicitMember></segment> </entity> <period> <startDate>2012-09-26</startDate> <endDate>2012-09-26</endDate> </period> </context> <context id="eol_PE151383--1410-K0012_STD_1_20130702_0_1276401x1270422"> <entity> <identifier scheme="http://www.sec.gov/CIK">0001061983</identifier> <segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></segment> </entity> <period> <startDate>2013-07-02</startDate> <endDate>2013-07-02</endDate> </period> </context> <context id="eol_PE151383--1410-K0012_STD_1_20130702_0_1276400x1281157"> <entity> <identifier scheme="http://www.sec.gov/CIK">0001061983</identifier> <segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember></segment> </entity> <period> <startDate>2013-07-02</startDate> <endDate>2013-07-02</endDate> </period> </context> <context id="eol_PE151383--1410-K0012_STD_1_20130624_0"> <entity> <identifier scheme="http://www.sec.gov/CIK">0001061983</identifier> </entity> <period> <startDate>2013-06-24</startDate> <endDate>2013-06-24</endDate> </period> </context> <context id="eol_PE151383--1410-K0012_STD_1_20120625_0_1278975x1273442"> <entity> <identifier scheme="http://www.sec.gov/CIK">0001061983</identifier> <segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:WarrantMember</xbrldi:explicitMember></segment> </entity> <period> <startDate>2012-06-25</startDate> <endDate>2012-06-25</endDate> </period> </context> <context id="eol_PE151383--1410-K0012_STD_1_20120625_0_1276400x1281157"> <entity> <identifier scheme="http://www.sec.gov/CIK">0001061983</identifier> <segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember></segment> </entity> <period> <startDate>2012-06-25</startDate> <endDate>2012-06-25</endDate> </period> </context> <context id="eol_PE151383--1410-K0012_STD_1_20120625_0_1271382x1559654_1278975x1273442"> <entity> <identifier scheme="http://www.sec.gov/CIK">0001061983</identifier> <segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:WarrantMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">cytk:DeerfieldAgreementMember</xbrldi:explicitMember></segment> </entity> <period> <startDate>2012-06-25</startDate> <endDate>2012-06-25</endDate> </period> </context> <context id="eol_PE151383--1410-K0012_STD_1_20120625_0_1271382x1559654_1276400x1476082"> <entity> <identifier scheme="http://www.sec.gov/CIK">0001061983</identifier> <segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">cytk:BeforeReverseStockSplitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">cytk:DeerfieldAgreementMember</xbrldi:explicitMember></segment> </entity> <period> <startDate>2012-06-25</startDate> <endDate>2012-06-25</endDate> </period> </context> <context id="eol_PE151383--1410-K0012_STD_1_20120625_0_1271382x1559654_1276400x1388560"> <entity> <identifier scheme="http://www.sec.gov/CIK">0001061983</identifier> <segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">cytk:AfterReverseStockSplitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">cytk:DeerfieldAgreementMember</xbrldi:explicitMember></segment> </entity> <period> <startDate>2012-06-25</startDate> <endDate>2012-06-25</endDate> </period> </context> <context id="eol_PE151383--1410-K0012_STD_1_20120625_0"> <entity> <identifier scheme="http://www.sec.gov/CIK">0001061983</identifier> </entity> <period> <startDate>2012-06-25</startDate> <endDate>2012-06-25</endDate> </period> </context> <context id="eol_PE151383--1410-K0012_STD_1_20120620_0"> <entity> <identifier scheme="http://www.sec.gov/CIK">0001061983</identifier> </entity> <period> <startDate>2012-06-20</startDate> <endDate>2012-06-20</endDate> </period> </context> <context id="eol_PE151383--1410-K0012_STD_1_20110420_0_1276400x1269676"> <entity> <identifier scheme="http://www.sec.gov/CIK">0001061983</identifier> <segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember></segment> </entity> <period> <startDate>2011-04-20</startDate> <endDate>2011-04-20</endDate> </period> </context> <context id="eol_PE151383--1410-K0012_STD_1_20110420_0_1271382x1559654_1278975x1273442"> <entity> <identifier scheme="http://www.sec.gov/CIK">0001061983</identifier> <segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:WarrantMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">cytk:DeerfieldAgreementMember</xbrldi:explicitMember></segment> </entity> <period> <startDate>2011-04-20</startDate> <endDate>2011-04-20</endDate> </period> </context> <context id="eol_PE151383--1410-K0012_STD_1_20110420_0_1271382x1559654_1276401x1270422"> <entity> <identifier scheme="http://www.sec.gov/CIK">0001061983</identifier> <segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">cytk:DeerfieldAgreementMember</xbrldi:explicitMember></segment> </entity> <period> <startDate>2011-04-20</startDate> <endDate>2011-04-20</endDate> </period> </context> <context id="eol_PE151383--1410-K0012_STD_1_20110420_0_1271382x1559654_1276400x1476082_1278975x1273442"> <entity> <identifier scheme="http://www.sec.gov/CIK">0001061983</identifier> <segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:WarrantMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">cytk:BeforeReverseStockSplitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">cytk:DeerfieldAgreementMember</xbrldi:explicitMember></segment> </entity> <period> <startDate>2011-04-20</startDate> <endDate>2011-04-20</endDate> </period> </context> <context id="eol_PE151383--1410-K0012_STD_1_20110420_0_1271382x1559654_1276400x1388560_1278975x1273442"> <entity> <identifier scheme="http://www.sec.gov/CIK">0001061983</identifier> <segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:WarrantMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">cytk:AfterReverseStockSplitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">cytk:DeerfieldAgreementMember</xbrldi:explicitMember></segment> </entity> <period> <startDate>2011-04-20</startDate> <endDate>2011-04-20</endDate> </period> </context> <context id="eol_PE151383--1410-K0012_STD_1_20110420_0_1271382x1559654_1276400x1269676"> <entity> <identifier scheme="http://www.sec.gov/CIK">0001061983</identifier> <segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">cytk:DeerfieldAgreementMember</xbrldi:explicitMember></segment> </entity> <period> <startDate>2011-04-20</startDate> <endDate>2011-04-20</endDate> </period> </context> <context id="eol_PE151383--1410-K0012_STD_1_20110420_0_1271382x1559654"> <entity> <identifier scheme="http://www.sec.gov/CIK">0001061983</identifier> <segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">cytk:DeerfieldAgreementMember</xbrldi:explicitMember></segment> </entity> <period> <startDate>2011-04-20</startDate> <endDate>2011-04-20</endDate> </period> </context> <context id="eol_PE151383--1410-K0012_STD_1_20110420_0_1271382x1398639"> <entity> <identifier scheme="http://www.sec.gov/CIK">0001061983</identifier> <segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">cytk:DeerfieldMember</xbrldi:explicitMember></segment> </entity> <period> <startDate>2011-04-20</startDate> <endDate>2011-04-20</endDate> </period> </context> <context id="eol_PE151383--1410-K0012_STD_1_20110420_0"> <entity> <identifier scheme="http://www.sec.gov/CIK">0001061983</identifier> </entity> <period> <startDate>2011-04-20</startDate> <endDate>2011-04-20</endDate> </period> </context> <context id="eol_PE151383--1410-K0012_STD_1_20141222_0_1274544x1398741_1279431x1434297"> <entity> <identifier scheme="http://www.sec.gov/CIK">0001061983</identifier> <segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">cytk:AmendedAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">cytk:AstellasMember</xbrldi:explicitMember></segment> </entity> <period> <startDate>2014-12-22</startDate> <endDate>2014-12-22</endDate> </period> </context> <context id="eol_PE151383--1410-K0012_STD_1_20141222_0_1269523x1277596_1274544x1398741_1279431x1434297_1279908x1621939"> <entity> <identifier scheme="http://www.sec.gov/CIK">0001061983</identifier> <segment><xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">cytk:AmendedAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">cytk:AstellasMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">cytk:SmaAndOtherNeuromuscularIndicationsMember</xbrldi:explicitMember></segment> </entity> <period> <startDate>2014-12-22</startDate> <endDate>2014-12-22</endDate> </period> </context> <context id="eol_PE151383--1410-K0012_STD_1_20141222_0_1269523x1277596_1274544x1398741_1279431x1434297"> <entity> <identifier scheme="http://www.sec.gov/CIK">0001061983</identifier> <segment><xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">cytk:AmendedAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">cytk:AstellasMember</xbrldi:explicitMember></segment> </entity> <period> <startDate>2014-12-22</startDate> <endDate>2014-12-22</endDate> </period> </context> <context id="eol_PE151383--1410-K0012_STD_1_20141222_0_1269523x1275948_1274544x1398741_1279431x1434297_1279908x1621938"> <entity> <identifier scheme="http://www.sec.gov/CIK">0001061983</identifier> <segment><xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">cytk:AmendedAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">cytk:AstellasMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">cytk:NonNeuromuscularIndicationsMember</xbrldi:explicitMember></segment> </entity> <period> <startDate>2014-12-22</startDate> <endDate>2014-12-22</endDate> </period> </context> <context id="eol_PE151383--1410-K0012_STD_1_20141222_0_1269523x1275948_1274544x1398741_1279431x1434297_1279908x1479887"> <entity> <identifier scheme="http://www.sec.gov/CIK">0001061983</identifier> <segment><xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">cytk:AmendedAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">cytk:AstellasMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">cytk:CommercialMilestonesMember</xbrldi:explicitMember></segment> </entity> <period> <startDate>2014-12-22</startDate> <endDate>2014-12-22</endDate> </period> </context> <context id="eol_PE151383--1410-K0012_STD_0_20141231_0_1281318x1434297"> <entity> <identifier scheme="http://www.sec.gov/CIK">0001061983</identifier> <segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">cytk:AstellasMember</xbrldi:explicitMember></segment> </entity> <period> <instant>2014-12-31</instant> </period> </context> <context id="eol_PE151383--1410-K0012_STD_0_20141231_0_1280964x1403278"> <entity> <identifier scheme="http://www.sec.gov/CIK">0001061983</identifier> <segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">cytk:TwoThousandAndFourPlanMember</xbrldi:explicitMember></segment> </entity> <period> <instant>2014-12-31</instant> </period> </context> <context id="eol_PE151383--1410-K0012_STD_0_20141231_0_1280964x1294890"> <entity> <identifier scheme="http://www.sec.gov/CIK">0001061983</identifier> <segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">cytk:NineteenNinetySevenStockOptionPlanMember</xbrldi:explicitMember></segment> </entity> <period> <instant>2014-12-31</instant> </period> </context> <context id="eol_PE151383--1410-K0012_STD_0_20141231_0_1280964x1277228"> <entity> <identifier scheme="http://www.sec.gov/CIK">0001061983</identifier> <segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember></segment> </entity> <period> <instant>2014-12-31</instant> </period> </context> <context id="eol_PE151383--1410-K0012_STD_0_20141231_0_1280651x1520580"> <entity> <identifier scheme="http://www.sec.gov/CIK">0001061983</identifier> <segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">cytk:FederalAndStateTaxMember</xbrldi:explicitMember></segment> </entity> <period> <instant>2014-12-31</instant> </period> </context> <context id="eol_PE151383--1410-K0012_STD_0_20141231_0_1280651x1497867"> <entity> <identifier scheme="http://www.sec.gov/CIK">0001061983</identifier> <segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">cytk:UnrecognizedIncomeTaxBenefitsNetOfFederalBenefitOfStateIncomeTaxUtbMember</xbrldi:explicitMember></segment> </entity> <period> <instant>2014-12-31</instant> </period> </context> <context id="eol_PE151383--1410-K0012_STD_0_20141231_0_1280651x1297583"> <entity> <identifier scheme="http://www.sec.gov/CIK">0001061983</identifier> <segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">cytk:FederalTaxBenefitOfStateIncomeTaxUtbMember</xbrldi:explicitMember></segment> </entity> <period> <instant>2014-12-31</instant> </period> </context> <context id="eol_PE151383--1410-K0012_STD_0_20141231_0_1280651x1280458"> <entity> <identifier scheme="http://www.sec.gov/CIK">0001061983</identifier> <segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember></segment> </entity> <period> <instant>2014-12-31</instant> </period> </context> <context id="eol_PE151383--1410-K0012_STD_0_20141231_0_1280651x1276398"> <entity> <identifier scheme="http://www.sec.gov/CIK">0001061983</identifier> <segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember></segment> </entity> <period> <instant>2014-12-31</instant> </period> </context> <context id="eol_PE151383--1410-K0012_STD_0_20141231_0_1280248x1413008"> <entity> <identifier scheme="http://www.sec.gov/CIK">0001061983</identifier> <segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">cytk:WarrantOneMember</xbrldi:explicitMember></segment> </entity> <period> <instant>2014-12-31</instant> </period> </context> <context id="eol_PE151383--1410-K0012_STD_0_20141231_0_1280248x1351779"> <entity> <identifier scheme="http://www.sec.gov/CIK">0001061983</identifier> <segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">cytk:WarrantTwoMember</xbrldi:explicitMember></segment> </entity> <period> <instant>2014-12-31</instant> </period> </context> <context id="eol_PE151383--1410-K0012_STD_0_20141231_0_1279936x1276697"> <entity> <identifier scheme="http://www.sec.gov/CIK">0001061983</identifier> <segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">us-gaap:ValuationAllowanceOfDeferredTaxAssetsMember</xbrldi:explicitMember></segment> </entity> <period> <instant>2014-12-31</instant> </period> </context> <context id="eol_PE151383--1410-K0012_STD_0_20141231_0_1279431x1424859"> <entity> <identifier scheme="http://www.sec.gov/CIK">0001061983</identifier> <segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">cytk:AmgenMember</xbrldi:explicitMember></segment> </entity> <period> <instant>2014-12-31</instant> </period> </context> <context id="eol_PE151383--1410-K0012_STD_0_20141231_0_1277337x1486283_1279431x1434297"> <entity> <identifier scheme="http://www.sec.gov/CIK">0001061983</identifier> <segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">cytk:LicenseFeeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">cytk:AstellasMember</xbrldi:explicitMember></segment> </entity> <period> <instant>2014-12-31</instant> </period> </context> <context id="eol_PE151383--1410-K0012_STD_0_20141231_0_1277337x1317063_1279431x1424859"> <entity> <identifier scheme="http://www.sec.gov/CIK">0001061983</identifier> <segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">cytk:LicenseAndServicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">cytk:AmgenMember</xbrldi:explicitMember></segment> </entity> <period> <instant>2014-12-31</instant> </period> </context> <context id="eol_PE151383--1410-K0012_STD_0_20141231_0_1276401x1273630"> <entity> <identifier scheme="http://www.sec.gov/CIK">0001061983</identifier> <segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></segment> </entity> <period> <instant>2014-12-31</instant> </period> </context> <context id="eol_PE151383--1410-K0012_STD_0_20141231_0_1276401x1270422"> <entity> <identifier scheme="http://www.sec.gov/CIK">0001061983</identifier> <segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></segment> </entity> <period> <instant>2014-12-31</instant> </period> </context> <context id="eol_PE151383--1410-K0012_STD_0_20141231_0_1276401x1269588"> <entity> <identifier scheme="http://www.sec.gov/CIK">0001061983</identifier> <segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></segment> </entity> <period> <instant>2014-12-31</instant> </period> </context> <context id="eol_PE151383--1410-K0012_STD_0_20141231_0_1276401x1268669"> <entity> <identifier scheme="http://www.sec.gov/CIK">0001061983</identifier> <segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></segment> </entity> <period> <instant>2014-12-31</instant> </period> </context> <context id="eol_PE151383--1410-K0012_STD_0_20141231_0_1276400x1281157"> <entity> <identifier scheme="http://www.sec.gov/CIK">0001061983</identifier> <segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember></segment> </entity> <period> <instant>2014-12-31</instant> </period> </context> <context id="eol_PE151383--1410-K0012_STD_0_20141231_0_1276400x1270467"> <entity> <identifier scheme="http://www.sec.gov/CIK">0001061983</identifier> <segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember></segment> </entity> <period> <instant>2014-12-31</instant> </period> </context> <context id="eol_PE151383--1410-K0012_STD_0_20141231_0_1276400x1269676"> <entity> <identifier scheme="http://www.sec.gov/CIK">0001061983</identifier> <segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember></segment> </entity> <period> <instant>2014-12-31</instant> </period> </context> <context id="eol_PE151383--1410-K0012_STD_0_20141231_0_1276136x1457720"> <entity> <identifier scheme="http://www.sec.gov/CIK">0001061983</identifier> <segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">cytk:LaboratoryEquipmentMember</xbrldi:explicitMember></segment> </entity> <period> <instant>2014-12-31</instant> </period> </context> <context id="eol_PE151383--1410-K0012_STD_0_20141231_0_1276136x1362982"> <entity> <identifier scheme="http://www.sec.gov/CIK">0001061983</identifier> <segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">cytk:ComputerEquipmentAndSoftwareMember</xbrldi:explicitMember></segment> </entity> <period> <instant>2014-12-31</instant> </period> </context> <context id="eol_PE151383--1410-K0012_STD_0_20141231_0_1276136x1329743"> <entity> <identifier scheme="http://www.sec.gov/CIK">0001061983</identifier> <segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">cytk:OfficeEquipmentFurnitureAndFixturesMember</xbrldi:explicitMember></segment> </entity> <period> <instant>2014-12-31</instant> </period> </context> <context id="eol_PE151383--1410-K0012_STD_0_20141231_0_1276136x1280724"> <entity> <identifier scheme="http://www.sec.gov/CIK">0001061983</identifier> <segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdsAndLeaseholdImprovementsMember</xbrldi:explicitMember></segment> </entity> <period> <instant>2014-12-31</instant> </period> </context> <context id="eol_PE151383--1410-K0012_STD_0_20141231_0_1275672x1274022_1278604x1435842"> <entity> <identifier scheme="http://www.sec.gov/CIK">0001061983</identifier> <segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">cytk:LongTermInvestmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></segment> </entity> <period> <instant>2014-12-31</instant> </period> </context> <context id="eol_PE151383--1410-K0012_STD_0_20141231_0_1275672x1274022"> <entity> <identifier scheme="http://www.sec.gov/CIK">0001061983</identifier> <segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></segment> </entity> <period> <instant>2014-12-31</instant> </period> </context> <context id="eol_PE151383--1410-K0012_STD_0_20141231_0_1275669x1277587_1275672x1274022"> <entity> <identifier scheme="http://www.sec.gov/CIK">0001061983</identifier> <segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></segment> </entity> <period> <instant>2014-12-31</instant> </period> </context> <context id="eol_PE151383--1410-K0012_STD_0_20141231_0_1275669x1274813_1275672x1274022"> <entity> <identifier scheme="http://www.sec.gov/CIK">0001061983</identifier> <segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></segment> </entity> <period> <instant>2014-12-31</instant> </period> </context> <context id="eol_PE151383--1410-K0012_STD_0_20141231_0_1274607x1276380_1275672x1274022"> <entity> <identifier scheme="http://www.sec.gov/CIK">0001061983</identifier> <segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ScheduleOfFairValueOfSeparateAccountsByMajorCategoryOfInvestmentAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember></segment> </entity> <period> <instant>2014-12-31</instant> </period> </context> <context id="eol_PE151383--1410-K0012_STD_0_20141231_0_1274544x1398741_1279431x1434297"> <entity> <identifier scheme="http://www.sec.gov/CIK">0001061983</identifier> <segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">cytk:AmendedAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">cytk:AstellasMember</xbrldi:explicitMember></segment> </entity> <period> <instant>2014-12-31</instant> </period> </context> <context id="eol_PE151383--1410-K0012_STD_0_20141231_0_1274544x1398741_1277337x1486283_1279431x1434297"> <entity> <identifier scheme="http://www.sec.gov/CIK">0001061983</identifier> <segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">cytk:LicenseFeeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">cytk:AmendedAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">cytk:AstellasMember</xbrldi:explicitMember></segment> </entity> <period> <instant>2014-12-31</instant> </period> </context> <context id="eol_PE151383--1410-K0012_STD_0_20141231_0_1274544x1398741_1277337x1317063_1279431x1434297"> <entity> <identifier scheme="http://www.sec.gov/CIK">0001061983</identifier> <segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">cytk:LicenseAndServicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">cytk:AmendedAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">cytk:AstellasMember</xbrldi:explicitMember></segment> </entity> <period> <instant>2014-12-31</instant> </period> </context> <context id="eol_PE151383--1410-K0012_STD_0_20141231_0_1274212x1280237_1275672x1274022"> <entity> <identifier scheme="http://www.sec.gov/CIK">0001061983</identifier> <segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CashAndCashEquivalentsMember</xbrldi:explicitMember></segment> </entity> <period> <instant>2014-12-31</instant> </period> </context> <context id="eol_PE151383--1410-K0012_STD_0_20141231_0_1271382x1511257"> <entity> <identifier scheme="http://www.sec.gov/CIK">0001061983</identifier> <segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">cytk:MlvAgreementMember</xbrldi:explicitMember></segment> </entity> <period> <instant>2014-12-31</instant> </period> </context> <context id="eol_PE151383--1410-K0012_STD_0_20141231_0_1270365x1277587_1274212x1270374"> <entity> <identifier scheme="http://www.sec.gov/CIK">0001061983</identifier> <segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CashEquivalentsMember</xbrldi:explicitMember></segment> </entity> <period> <instant>2014-12-31</instant> </period> </context> <context id="eol_PE151383--1410-K0012_STD_0_20141231_0_1270365x1274813_1274212x1435842"> <entity> <identifier scheme="http://www.sec.gov/CIK">0001061983</identifier> <segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">cytk:LongTermInvestmentMember</xbrldi:explicitMember></segment> </entity> <period> <instant>2014-12-31</instant> </period> </context> <context id="eol_PE151383--1410-K0012_STD_0_20141231_0_1270365x1274813_1274212x1276380"> <entity> <identifier scheme="http://www.sec.gov/CIK">0001061983</identifier> <segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember></segment> </entity> <period> <instant>2014-12-31</instant> </period> </context> <context id="eol_PE151383--1410-K0012_STD_0_20141231_0_1270313x1275629"> <entity> <identifier scheme="http://www.sec.gov/CIK">0001061983</identifier> <segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></segment> </entity> <period> <instant>2014-12-31</instant> </period> </context> <context id="eol_PE151383--1410-K0012_STD_0_20141231_0_1270313x1271212"> <entity> <identifier scheme="http://www.sec.gov/CIK">0001061983</identifier> <segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></segment> </entity> <period> <instant>2014-12-31</instant> </period> </context> <context id="eol_PE151383--1410-K0012_STD_0_20141231_0_1270313x1271210"> <entity> <identifier scheme="http://www.sec.gov/CIK">0001061983</identifier> <segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember></segment> </entity> <period> <instant>2014-12-31</instant> </period> </context> <context id="eol_PE151383--1410-K0012_STD_0_20141231_0_1269038x1275680_1275672x1274022_1278604x1435842"> <entity> <identifier scheme="http://www.sec.gov/CIK">0001061983</identifier> <segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">cytk:LongTermInvestmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></segment> </entity> <period> <instant>2014-12-31</instant> </period> </context> <context id="eol_PE151383--1410-K0012_STD_0_20141231_0_1269038x1275680_1275672x1274022"> <entity> <identifier scheme="http://www.sec.gov/CIK">0001061983</identifier> <segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></segment> </entity> <period> <instant>2014-12-31</instant> </period> </context> <context id="eol_PE151383--1410-K0012_STD_0_20141231_0_1269038x1275680_1275669x1277587_1275672x1274022"> <entity> <identifier scheme="http://www.sec.gov/CIK">0001061983</identifier> <segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></segment> </entity> <period> <instant>2014-12-31</instant> </period> </context> <context id="eol_PE151383--1410-K0012_STD_0_20141231_0_1269038x1275680_1275669x1274813_1275672x1274022"> <entity> <identifier scheme="http://www.sec.gov/CIK">0001061983</identifier> <segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></segment> </entity> <period> <instant>2014-12-31</instant> </period> </context> <context id="eol_PE151383--1410-K0012_STD_0_20141231_0_1269038x1275680_1274607x1276380_1275672x1274022"> <entity> <identifier scheme="http://www.sec.gov/CIK">0001061983</identifier> <segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ScheduleOfFairValueOfSeparateAccountsByMajorCategoryOfInvestmentAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember></segment> </entity> <period> <instant>2014-12-31</instant> </period> </context> <context id="eol_PE151383--1410-K0012_STD_0_20141231_0_1269038x1275680_1274212x1280237_1275672x1274022"> <entity> <identifier scheme="http://www.sec.gov/CIK">0001061983</identifier> <segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CashAndCashEquivalentsMember</xbrldi:explicitMember></segment> </entity> <period> <instant>2014-12-31</instant> </period> </context> <context id="eol_PE151383--1410-K0012_STD_0_20141231_0_1269038x1275680"> <entity> <identifier scheme="http://www.sec.gov/CIK">0001061983</identifier> <segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></segment> </entity> <period> <instant>2014-12-31</instant> </period> </context> <context id="eol_PE151383--1410-K0012_STD_0_20141231_0_1269038x1272304_1275672x1274022_1278604x1435842"> <entity> <identifier scheme="http://www.sec.gov/CIK">0001061983</identifier> <segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">cytk:LongTermInvestmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></segment> </entity> <period> <instant>2014-12-31</instant> </period> </context> <context id="eol_PE151383--1410-K0012_STD_0_20141231_0_1269038x1272304_1275672x1274022"> <entity> <identifier scheme="http://www.sec.gov/CIK">0001061983</identifier> <segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></segment> </entity> <period> <instant>2014-12-31</instant> </period> </context> <context id="eol_PE151383--1410-K0012_STD_0_20141231_0_1269038x1272304_1275669x1277587_1275672x1274022"> <entity> <identifier scheme="http://www.sec.gov/CIK">0001061983</identifier> <segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></segment> </entity> <period> <instant>2014-12-31</instant> </period> </context> <context id="eol_PE151383--1410-K0012_STD_0_20141231_0_1269038x1272304_1275669x1274813_1275672x1274022"> <entity> <identifier scheme="http://www.sec.gov/CIK">0001061983</identifier> <segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></segment> </entity> <period> <instant>2014-12-31</instant> </period> </context> <context id="eol_PE151383--1410-K0012_STD_0_20141231_0_1269038x1272304_1274607x1276380_1275672x1274022"> <entity> <identifier scheme="http://www.sec.gov/CIK">0001061983</identifier> <segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ScheduleOfFairValueOfSeparateAccountsByMajorCategoryOfInvestmentAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember></segment> </entity> <period> <instant>2014-12-31</instant> </period> </context> <context id="eol_PE151383--1410-K0012_STD_0_20141231_0_1269038x1272304_1274212x1280237_1275672x1274022"> <entity> <identifier scheme="http://www.sec.gov/CIK">0001061983</identifier> <segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CashAndCashEquivalentsMember</xbrldi:explicitMember></segment> </entity> <period> <instant>2014-12-31</instant> </period> </context> <context id="eol_PE151383--1410-K0012_STD_0_20141231_0_1269038x1269048_1275672x1274022_1278604x1435842"> <entity> <identifier scheme="http://www.sec.gov/CIK">0001061983</identifier> <segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">cytk:LongTermInvestmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></segment> </entity> <period> <instant>2014-12-31</instant> </period> </context> <context id="eol_PE151383--1410-K0012_STD_0_20141231_0_1269038x1269048_1275672x1274022"> <entity> <identifier scheme="http://www.sec.gov/CIK">0001061983</identifier> <segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></segment> </entity> <period> <instant>2014-12-31</instant> </period> </context> <context id="eol_PE151383--1410-K0012_STD_0_20141231_0_1269038x1269048_1275669x1277587_1275672x1274022"> <entity> <identifier scheme="http://www.sec.gov/CIK">0001061983</identifier> <segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></segment> </entity> <period> <instant>2014-12-31</instant> </period> </context> <context id="eol_PE151383--1410-K0012_STD_0_20141231_0_1269038x1269048_1275669x1274813_1275672x1274022"> <entity> <identifier scheme="http://www.sec.gov/CIK">0001061983</identifier> <segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></segment> </entity> <period> <instant>2014-12-31</instant> </period> </context> <context id="eol_PE151383--1410-K0012_STD_0_20141231_0_1269038x1269048_1274607x1276380_1275672x1274022"> <entity> <identifier scheme="http://www.sec.gov/CIK">0001061983</identifier> <segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ScheduleOfFairValueOfSeparateAccountsByMajorCategoryOfInvestmentAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember></segment> </entity> <period> <instant>2014-12-31</instant> </period> </context> <context id="eol_PE151383--1410-K0012_STD_0_20141231_0_1269038x1269048_1274212x1280237_1275672x1274022"> <entity> <identifier scheme="http://www.sec.gov/CIK">0001061983</identifier> <segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CashAndCashEquivalentsMember</xbrldi:explicitMember></segment> </entity> <period> <instant>2014-12-31</instant> </period> </context> <context id="eol_PE151383--1410-K0012_STD_0_20141231_0_1269038x1269048"> <entity> <identifier scheme="http://www.sec.gov/CIK">0001061983</identifier> <segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></segment> </entity> <period> <instant>2014-12-31</instant> </period> </context> <context id="eol_PE151383--1410-K0012_STD_0_20141231_0"> <entity> <identifier scheme="http://www.sec.gov/CIK">0001061983</identifier> </entity> <period> <instant>2014-12-31</instant> </period> </context> <context id="eol_PE151383--1410-K0012_STD_0_20131231_0_1281318x1434297"> <entity> <identifier scheme="http://www.sec.gov/CIK">0001061983</identifier> <segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">cytk:AstellasMember</xbrldi:explicitMember></segment> </entity> <period> <instant>2013-12-31</instant> </period> </context> <context id="eol_PE151383--1410-K0012_STD_0_20131231_0_1280651x1520580"> <entity> <identifier scheme="http://www.sec.gov/CIK">0001061983</identifier> <segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">cytk:FederalAndStateTaxMember</xbrldi:explicitMember></segment> </entity> <period> <instant>2013-12-31</instant> </period> </context> <context id="eol_PE151383--1410-K0012_STD_0_20131231_0_1280651x1497867"> <entity> <identifier scheme="http://www.sec.gov/CIK">0001061983</identifier> <segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">cytk:UnrecognizedIncomeTaxBenefitsNetOfFederalBenefitOfStateIncomeTaxUtbMember</xbrldi:explicitMember></segment> </entity> <period> <instant>2013-12-31</instant> </period> </context> <context id="eol_PE151383--1410-K0012_STD_0_20131231_0_1280651x1297583"> <entity> <identifier scheme="http://www.sec.gov/CIK">0001061983</identifier> <segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">cytk:FederalTaxBenefitOfStateIncomeTaxUtbMember</xbrldi:explicitMember></segment> </entity> <period> <instant>2013-12-31</instant> </period> </context> <context id="eol_PE151383--1410-K0012_STD_0_20131231_0_1279936x1276697"> <entity> <identifier scheme="http://www.sec.gov/CIK">0001061983</identifier> <segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">us-gaap:ValuationAllowanceOfDeferredTaxAssetsMember</xbrldi:explicitMember></segment> </entity> <period> <instant>2013-12-31</instant> </period> </context> <context id="eol_PE151383--1410-K0012_STD_0_20131231_0_1279431x1424859"> <entity> <identifier scheme="http://www.sec.gov/CIK">0001061983</identifier> <segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">cytk:AmgenMember</xbrldi:explicitMember></segment> </entity> <period> <instant>2013-12-31</instant> </period> </context> <context id="eol_PE151383--1410-K0012_STD_0_20131231_0_1276401x1273630"> <entity> <identifier scheme="http://www.sec.gov/CIK">0001061983</identifier> <segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></segment> </entity> <period> <instant>2013-12-31</instant> </period> </context> <context id="eol_PE151383--1410-K0012_STD_0_20131231_0_1276401x1270422"> <entity> <identifier scheme="http://www.sec.gov/CIK">0001061983</identifier> <segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></segment> </entity> <period> <instant>2013-12-31</instant> </period> </context> <context id="eol_PE151383--1410-K0012_STD_0_20131231_0_1276401x1269588"> <entity> <identifier scheme="http://www.sec.gov/CIK">0001061983</identifier> <segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></segment> </entity> <period> <instant>2013-12-31</instant> </period> </context> <context id="eol_PE151383--1410-K0012_STD_0_20131231_0_1276401x1268669"> <entity> <identifier scheme="http://www.sec.gov/CIK">0001061983</identifier> <segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></segment> </entity> <period> <instant>2013-12-31</instant> </period> </context> <context id="eol_PE151383--1410-K0012_STD_0_20131231_0_1276400x1269676"> <entity> <identifier scheme="http://www.sec.gov/CIK">0001061983</identifier> <segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember></segment> </entity> <period> <instant>2013-12-31</instant> </period> </context> <context id="eol_PE151383--1410-K0012_STD_0_20131231_0_1276136x1457720"> <entity> <identifier scheme="http://www.sec.gov/CIK">0001061983</identifier> <segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">cytk:LaboratoryEquipmentMember</xbrldi:explicitMember></segment> </entity> <period> <instant>2013-12-31</instant> </period> </context> <context id="eol_PE151383--1410-K0012_STD_0_20131231_0_1276136x1362982"> <entity> <identifier scheme="http://www.sec.gov/CIK">0001061983</identifier> <segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">cytk:ComputerEquipmentAndSoftwareMember</xbrldi:explicitMember></segment> </entity> <period> <instant>2013-12-31</instant> </period> </context> <context id="eol_PE151383--1410-K0012_STD_0_20131231_0_1276136x1329743"> <entity> <identifier scheme="http://www.sec.gov/CIK">0001061983</identifier> <segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">cytk:OfficeEquipmentFurnitureAndFixturesMember</xbrldi:explicitMember></segment> </entity> <period> <instant>2013-12-31</instant> </period> </context> <context id="eol_PE151383--1410-K0012_STD_0_20131231_0_1276136x1280724"> <entity> <identifier scheme="http://www.sec.gov/CIK">0001061983</identifier> <segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdsAndLeaseholdImprovementsMember</xbrldi:explicitMember></segment> </entity> <period> <instant>2013-12-31</instant> </period> </context> <context id="eol_PE151383--1410-K0012_STD_0_20131231_0_1275672x1274022_1278604x1435842"> <entity> <identifier scheme="http://www.sec.gov/CIK">0001061983</identifier> <segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">cytk:LongTermInvestmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></segment> </entity> <period> <instant>2013-12-31</instant> </period> </context> <context id="eol_PE151383--1410-K0012_STD_0_20131231_0_1275672x1274022"> <entity> <identifier scheme="http://www.sec.gov/CIK">0001061983</identifier> <segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></segment> </entity> <period> <instant>2013-12-31</instant> </period> </context> <context id="eol_PE151383--1410-K0012_STD_0_20131231_0_1275669x1277587_1275672x1274022"> <entity> <identifier scheme="http://www.sec.gov/CIK">0001061983</identifier> <segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></segment> </entity> <period> <instant>2013-12-31</instant> </period> </context> <context id="eol_PE151383--1410-K0012_STD_0_20131231_0_1275669x1274813_1275672x1274022"> <entity> <identifier scheme="http://www.sec.gov/CIK">0001061983</identifier> <segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></segment> </entity> <period> <instant>2013-12-31</instant> </period> </context> <context id="eol_PE151383--1410-K0012_STD_0_20131231_0_1274607x1276380_1275672x1274022"> <entity> <identifier scheme="http://www.sec.gov/CIK">0001061983</identifier> <segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ScheduleOfFairValueOfSeparateAccountsByMajorCategoryOfInvestmentAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember></segment> </entity> <period> <instant>2013-12-31</instant> </period> </context> <context id="eol_PE151383--1410-K0012_STD_0_20131231_0_1274212x1280237_1275672x1274022"> <entity> <identifier scheme="http://www.sec.gov/CIK">0001061983</identifier> <segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CashAndCashEquivalentsMember</xbrldi:explicitMember></segment> </entity> <period> <instant>2013-12-31</instant> </period> </context> <context id="eol_PE151383--1410-K0012_STD_0_20131231_0_1270365x1277587_1274212x1270374"> <entity> <identifier scheme="http://www.sec.gov/CIK">0001061983</identifier> <segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CashEquivalentsMember</xbrldi:explicitMember></segment> </entity> <period> <instant>2013-12-31</instant> </period> </context> <context id="eol_PE151383--1410-K0012_STD_0_20131231_0_1270365x1274813_1274212x1435842"> <entity> <identifier scheme="http://www.sec.gov/CIK">0001061983</identifier> <segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">cytk:LongTermInvestmentMember</xbrldi:explicitMember></segment> </entity> <period> <instant>2013-12-31</instant> </period> </context> <context id="eol_PE151383--1410-K0012_STD_0_20131231_0_1270365x1274813_1274212x1276380"> <entity> <identifier scheme="http://www.sec.gov/CIK">0001061983</identifier> <segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember></segment> </entity> <period> <instant>2013-12-31</instant> </period> </context> <context id="eol_PE151383--1410-K0012_STD_0_20131231_0_1270313x1271210"> <entity> <identifier scheme="http://www.sec.gov/CIK">0001061983</identifier> <segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember></segment> </entity> <period> <instant>2013-12-31</instant> </period> </context> <context id="eol_PE151383--1410-K0012_STD_0_20131231_0_1269038x1275680_1275672x1274022_1278604x1435842"> <entity> <identifier scheme="http://www.sec.gov/CIK">0001061983</identifier> <segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">cytk:LongTermInvestmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></segment> </entity> <period> <instant>2013-12-31</instant> </period> </context> <context id="eol_PE151383--1410-K0012_STD_0_20131231_0_1269038x1275680_1275672x1274022"> <entity> <identifier scheme="http://www.sec.gov/CIK">0001061983</identifier> <segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></segment> </entity> <period> <instant>2013-12-31</instant> </period> </context> <context id="eol_PE151383--1410-K0012_STD_0_20131231_0_1269038x1275680_1275669x1277587_1275672x1274022"> <entity> <identifier scheme="http://www.sec.gov/CIK">0001061983</identifier> <segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></segment> </entity> <period> <instant>2013-12-31</instant> </period> </context> <context id="eol_PE151383--1410-K0012_STD_0_20131231_0_1269038x1275680_1275669x1274813_1275672x1274022"> <entity> <identifier scheme="http://www.sec.gov/CIK">0001061983</identifier> <segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></segment> </entity> <period> <instant>2013-12-31</instant> </period> </context> <context id="eol_PE151383--1410-K0012_STD_0_20131231_0_1269038x1275680_1274607x1276380_1275672x1274022"> <entity> <identifier scheme="http://www.sec.gov/CIK">0001061983</identifier> <segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ScheduleOfFairValueOfSeparateAccountsByMajorCategoryOfInvestmentAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember></segment> </entity> <period> <instant>2013-12-31</instant> </period> </context> <context id="eol_PE151383--1410-K0012_STD_0_20131231_0_1269038x1275680_1274212x1280237_1275672x1274022"> <entity> <identifier scheme="http://www.sec.gov/CIK">0001061983</identifier> <segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CashAndCashEquivalentsMember</xbrldi:explicitMember></segment> </entity> <period> <instant>2013-12-31</instant> </period> </context> <context id="eol_PE151383--1410-K0012_STD_0_20131231_0_1269038x1275680"> <entity> <identifier scheme="http://www.sec.gov/CIK">0001061983</identifier> <segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></segment> </entity> <period> <instant>2013-12-31</instant> </period> </context> <context id="eol_PE151383--1410-K0012_STD_0_20131231_0_1269038x1272304_1275672x1274022_1278604x1435842"> <entity> <identifier scheme="http://www.sec.gov/CIK">0001061983</identifier> <segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">cytk:LongTermInvestmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></segment> </entity> <period> <instant>2013-12-31</instant> </period> </context> <context id="eol_PE151383--1410-K0012_STD_0_20131231_0_1269038x1272304_1275672x1274022"> <entity> <identifier scheme="http://www.sec.gov/CIK">0001061983</identifier> <segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></segment> </entity> <period> <instant>2013-12-31</instant> </period> </context> <context id="eol_PE151383--1410-K0012_STD_0_20131231_0_1269038x1272304_1275669x1277587_1275672x1274022"> <entity> <identifier scheme="http://www.sec.gov/CIK">0001061983</identifier> <segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></segment> </entity> <period> <instant>2013-12-31</instant> </period> </context> <context id="eol_PE151383--1410-K0012_STD_0_20131231_0_1269038x1272304_1275669x1274813_1275672x1274022"> <entity> <identifier scheme="http://www.sec.gov/CIK">0001061983</identifier> <segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></segment> </entity> <period> <instant>2013-12-31</instant> </period> </context> <context id="eol_PE151383--1410-K0012_STD_0_20131231_0_1269038x1272304_1274607x1276380_1275672x1274022"> <entity> <identifier scheme="http://www.sec.gov/CIK">0001061983</identifier> <segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ScheduleOfFairValueOfSeparateAccountsByMajorCategoryOfInvestmentAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember></segment> </entity> <period> <instant>2013-12-31</instant> </period> </context> <context id="eol_PE151383--1410-K0012_STD_0_20131231_0_1269038x1272304_1274212x1280237_1275672x1274022"> <entity> <identifier scheme="http://www.sec.gov/CIK">0001061983</identifier> <segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CashAndCashEquivalentsMember</xbrldi:explicitMember></segment> </entity> <period> <instant>2013-12-31</instant> </period> </context> <context id="eol_PE151383--1410-K0012_STD_0_20131231_0_1269038x1269048_1275672x1274022_1278604x1435842"> <entity> <identifier scheme="http://www.sec.gov/CIK">0001061983</identifier> <segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">cytk:LongTermInvestmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></segment> </entity> <period> <instant>2013-12-31</instant> </period> </context> <context id="eol_PE151383--1410-K0012_STD_0_20131231_0_1269038x1269048_1275672x1274022"> <entity> <identifier scheme="http://www.sec.gov/CIK">0001061983</identifier> <segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></segment> </entity> <period> <instant>2013-12-31</instant> </period> </context> <context id="eol_PE151383--1410-K0012_STD_0_20131231_0_1269038x1269048_1275669x1277587_1275672x1274022"> <entity> <identifier scheme="http://www.sec.gov/CIK">0001061983</identifier> <segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></segment> </entity> <period> <instant>2013-12-31</instant> </period> </context> <context id="eol_PE151383--1410-K0012_STD_0_20131231_0_1269038x1269048_1275669x1274813_1275672x1274022"> <entity> <identifier scheme="http://www.sec.gov/CIK">0001061983</identifier> <segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></segment> </entity> <period> <instant>2013-12-31</instant> </period> </context> <context id="eol_PE151383--1410-K0012_STD_0_20131231_0_1269038x1269048_1274607x1276380_1275672x1274022"> <entity> <identifier scheme="http://www.sec.gov/CIK">0001061983</identifier> <segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ScheduleOfFairValueOfSeparateAccountsByMajorCategoryOfInvestmentAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember></segment> </entity> <period> <instant>2013-12-31</instant> </period> </context> <context id="eol_PE151383--1410-K0012_STD_0_20131231_0_1269038x1269048_1274212x1280237_1275672x1274022"> <entity> <identifier scheme="http://www.sec.gov/CIK">0001061983</identifier> <segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CashAndCashEquivalentsMember</xbrldi:explicitMember></segment> </entity> <period> <instant>2013-12-31</instant> </period> </context> <context id="eol_PE151383--1410-K0012_STD_0_20131231_0_1269038x1269048"> <entity> <identifier scheme="http://www.sec.gov/CIK">0001061983</identifier> <segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></segment> </entity> <period> <instant>2013-12-31</instant> </period> </context> <context id="eol_PE151383--1410-K0012_STD_0_20131231_0"> <entity> <identifier scheme="http://www.sec.gov/CIK">0001061983</identifier> </entity> <period> <instant>2013-12-31</instant> </period> </context> <context id="eol_PE151383--1410-K0012_STD_0_20121231_0_1280651x1520580"> <entity> <identifier scheme="http://www.sec.gov/CIK">0001061983</identifier> <segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">cytk:FederalAndStateTaxMember</xbrldi:explicitMember></segment> </entity> <period> <instant>2012-12-31</instant> </period> </context> <context id="eol_PE151383--1410-K0012_STD_0_20121231_0_1280651x1497867"> <entity> <identifier scheme="http://www.sec.gov/CIK">0001061983</identifier> <segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">cytk:UnrecognizedIncomeTaxBenefitsNetOfFederalBenefitOfStateIncomeTaxUtbMember</xbrldi:explicitMember></segment> </entity> <period> <instant>2012-12-31</instant> </period> </context> <context id="eol_PE151383--1410-K0012_STD_0_20121231_0_1280651x1297583"> <entity> <identifier scheme="http://www.sec.gov/CIK">0001061983</identifier> <segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">cytk:FederalTaxBenefitOfStateIncomeTaxUtbMember</xbrldi:explicitMember></segment> </entity> <period> <instant>2012-12-31</instant> </period> </context> <context id="eol_PE151383--1410-K0012_STD_0_20121231_0_1279936x1276697"> <entity> <identifier scheme="http://www.sec.gov/CIK">0001061983</identifier> <segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">us-gaap:ValuationAllowanceOfDeferredTaxAssetsMember</xbrldi:explicitMember></segment> </entity> <period> <instant>2012-12-31</instant> </period> </context> <context id="eol_PE151383--1410-K0012_STD_0_20121231_0_1276401x1273630"> <entity> <identifier scheme="http://www.sec.gov/CIK">0001061983</identifier> <segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></segment> </entity> <period> <instant>2012-12-31</instant> </period> </context> <context id="eol_PE151383--1410-K0012_STD_0_20121231_0_1276401x1272805"> <entity> <identifier scheme="http://www.sec.gov/CIK">0001061983</identifier> <segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember></segment> </entity> <period> <instant>2012-12-31</instant> </period> </context> <context id="eol_PE151383--1410-K0012_STD_0_20121231_0_1276401x1270422"> <entity> <identifier scheme="http://www.sec.gov/CIK">0001061983</identifier> <segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></segment> </entity> <period> <instant>2012-12-31</instant> </period> </context> <context id="eol_PE151383--1410-K0012_STD_0_20121231_0_1276401x1269588"> <entity> <identifier scheme="http://www.sec.gov/CIK">0001061983</identifier> <segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></segment> </entity> <period> <instant>2012-12-31</instant> </period> </context> <context id="eol_PE151383--1410-K0012_STD_0_20121231_0_1276401x1268669"> <entity> <identifier scheme="http://www.sec.gov/CIK">0001061983</identifier> <segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></segment> </entity> <period> <instant>2012-12-31</instant> </period> </context> <context id="eol_PE151383--1410-K0012_STD_0_20121231_0_1270313x1271210"> <entity> <identifier scheme="http://www.sec.gov/CIK">0001061983</identifier> <segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember></segment> </entity> <period> <instant>2012-12-31</instant> </period> </context> <context id="eol_PE151383--1410-K0012_STD_0_20121231_0"> <entity> <identifier scheme="http://www.sec.gov/CIK">0001061983</identifier> </entity> <period> <instant>2012-12-31</instant> </period> </context> <context id="eol_PE151383--1410-K0012_STD_0_20111231_0_1279936x1276697"> <entity> <identifier scheme="http://www.sec.gov/CIK">0001061983</identifier> <segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">us-gaap:ValuationAllowanceOfDeferredTaxAssetsMember</xbrldi:explicitMember></segment> </entity> <period> <instant>2011-12-31</instant> </period> </context> <context id="eol_PE151383--1410-K0012_STD_0_20111231_0_1276401x1273630"> <entity> <identifier scheme="http://www.sec.gov/CIK">0001061983</identifier> <segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></segment> </entity> <period> <instant>2011-12-31</instant> </period> </context> <context id="eol_PE151383--1410-K0012_STD_0_20111231_0_1276401x1272805"> <entity> <identifier scheme="http://www.sec.gov/CIK">0001061983</identifier> <segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember></segment> </entity> <period> <instant>2011-12-31</instant> </period> </context> <context id="eol_PE151383--1410-K0012_STD_0_20111231_0_1276401x1270422"> <entity> <identifier scheme="http://www.sec.gov/CIK">0001061983</identifier> <segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></segment> </entity> <period> <instant>2011-12-31</instant> </period> </context> <context id="eol_PE151383--1410-K0012_STD_0_20111231_0_1276401x1269588"> <entity> <identifier scheme="http://www.sec.gov/CIK">0001061983</identifier> <segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></segment> </entity> <period> <instant>2011-12-31</instant> </period> </context> <context id="eol_PE151383--1410-K0012_STD_0_20111231_0_1276401x1268669"> <entity> <identifier scheme="http://www.sec.gov/CIK">0001061983</identifier> <segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></segment> </entity> <period> <instant>2011-12-31</instant> </period> </context> <context id="eol_PE151383--1410-K0012_STD_0_20111231_0_1270313x1271210"> <entity> <identifier scheme="http://www.sec.gov/CIK">0001061983</identifier> <segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember></segment> </entity> <period> <instant>2011-12-31</instant> </period> </context> <context id="eol_PE151383--1410-K0012_STD_0_20111231_0"> <entity> <identifier scheme="http://www.sec.gov/CIK">0001061983</identifier> </entity> <period> <instant>2011-12-31</instant> </period> </context> <context id="eol_PE151383--1410-K0012_STD_0_20101231_0_1276400x1270467"> <entity> <identifier scheme="http://www.sec.gov/CIK">0001061983</identifier> <segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember></segment> </entity> <period> <instant>2010-12-31</instant> </period> </context> <context id="eol_PE151383--1410-K0012_STD_0_20140630_0"> <entity> <identifier scheme="http://www.sec.gov/CIK">0001061983</identifier> </entity> <period> <instant>2014-06-30</instant> </period> </context> <context id="eol_PE151383--1410-K0012_STD_0_20130630_0_1279431x1424859"> <entity> <identifier scheme="http://www.sec.gov/CIK">0001061983</identifier> <segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">cytk:AmgenMember</xbrldi:explicitMember></segment> </entity> <period> <instant>2013-06-30</instant> </period> </context> <context id="eol_PE151383--1410-K0012_STD_0_20120630_0_1276400x1281157"> <entity> <identifier scheme="http://www.sec.gov/CIK">0001061983</identifier> <segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember></segment> </entity> <period> <instant>2012-06-30</instant> </period> </context> <context id="eol_PE151383--1410-K0012_STD_0_20110831_0"> <entity> <identifier scheme="http://www.sec.gov/CIK">0001061983</identifier> </entity> <period> <instant>2011-08-31</instant> </period> </context> <context id="eol_PE151383--1410-K0012_STD_0_20120625_0_1278975x1273442"> <entity> <identifier scheme="http://www.sec.gov/CIK">0001061983</identifier> <segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:WarrantMember</xbrldi:explicitMember></segment> </entity> <period> <instant>2012-06-25</instant> </period> </context> <context id="eol_PE151383--1410-K0012_STD_0_20120625_0_1276400x1281157"> <entity> <identifier scheme="http://www.sec.gov/CIK">0001061983</identifier> <segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember></segment> </entity> <period> <instant>2012-06-25</instant> </period> </context> <context id="eol_PE151383--1410-K0012_STD_0_20120625_0_1271382x1559654_1278975x1273442"> <entity> <identifier scheme="http://www.sec.gov/CIK">0001061983</identifier> <segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:WarrantMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">cytk:DeerfieldAgreementMember</xbrldi:explicitMember></segment> </entity> <period> <instant>2012-06-25</instant> </period> </context> <context id="eol_PE151383--1410-K0012_STD_0_20120625_0_1271382x1559654"> <entity> <identifier scheme="http://www.sec.gov/CIK">0001061983</identifier> <segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">cytk:DeerfieldAgreementMember</xbrldi:explicitMember></segment> </entity> <period> <instant>2012-06-25</instant> </period> </context> <context id="eol_PE151383--1410-K0012_STD_0_20120625_0_1271382x1272538_1276400x1281157"> <entity> <identifier scheme="http://www.sec.gov/CIK">0001061983</identifier> <segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember></segment> </entity> <period> <instant>2012-06-25</instant> </period> </context> <context id="eol_PE151383--1410-K0012_STD_0_20120625_0"> <entity> <identifier scheme="http://www.sec.gov/CIK">0001061983</identifier> </entity> <period> <instant>2012-06-25</instant> </period> </context> <context id="eol_PE151383--1410-K0012_STD_0_20140228_0_1271382x1382912"> <entity> <identifier scheme="http://www.sec.gov/CIK">0001061983</identifier> <segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">cytk:UnderwrittenPublicOfferingMember</xbrldi:explicitMember></segment> </entity> <period> <instant>2014-02-28</instant> </period> </context> <context id="eol_PE151383--1410-K0012_STD_0_20130228_0_1278975x1376841"> <entity> <identifier scheme="http://www.sec.gov/CIK">0001061983</identifier> <segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">cytk:WarrantsToPurchaseCommonStockMember</xbrldi:explicitMember></segment> </entity> <period> <instant>2013-02-28</instant> </period> </context> <context id="eol_PE151383--1410-K0012_STD_0_20110420_0_1278975x1273442"> <entity> <identifier scheme="http://www.sec.gov/CIK">0001061983</identifier> <segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:WarrantMember</xbrldi:explicitMember></segment> </entity> <period> <instant>2011-04-20</instant> </period> </context> <context id="eol_PE151383--1410-K0012_STD_0_20110420_0_1276401x1270422"> <entity> <identifier scheme="http://www.sec.gov/CIK">0001061983</identifier> <segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></segment> </entity> <period> <instant>2011-04-20</instant> </period> </context> <context id="eol_PE151383--1410-K0012_STD_0_20110420_0_1276400x1269676"> <entity> <identifier scheme="http://www.sec.gov/CIK">0001061983</identifier> <segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember></segment> </entity> <period> <instant>2011-04-20</instant> </period> </context> <context id="eol_PE151383--1410-K0012_STD_0_20110420_0_1271382x1559654_1278975x1273442"> <entity> <identifier scheme="http://www.sec.gov/CIK">0001061983</identifier> <segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:WarrantMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">cytk:DeerfieldAgreementMember</xbrldi:explicitMember></segment> </entity> <period> <instant>2011-04-20</instant> </period> </context> <context id="eol_PE151383--1410-K0012_STD_0_20110420_0_1271382x1559654_1276400x1269676"> <entity> <identifier scheme="http://www.sec.gov/CIK">0001061983</identifier> <segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">cytk:DeerfieldAgreementMember</xbrldi:explicitMember></segment> </entity> <period> <instant>2011-04-20</instant> </period> </context> <context id="eol_PE151383--1410-K0012_STD_0_20110420_0_1271382x1559654"> <entity> <identifier scheme="http://www.sec.gov/CIK">0001061983</identifier> <segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">cytk:DeerfieldAgreementMember</xbrldi:explicitMember></segment> </entity> <period> <instant>2011-04-20</instant> </period> </context> <context id="eol_PE151383--1410-K0012_STD_0_20110420_0"> <entity> <identifier scheme="http://www.sec.gov/CIK">0001061983</identifier> </entity> <period> <instant>2011-04-20</instant> </period> </context> <context id="eol_PE151383--1410-K0012_STD_0_20150227_0"> <entity> <identifier scheme="http://www.sec.gov/CIK">0001061983</identifier> </entity> <period> <instant>2015-02-27</instant> </period> </context> <context id="eol_PE151383--1410-K0012_STD_0_20110518_0"> <entity> <identifier scheme="http://www.sec.gov/CIK">0001061983</identifier> </entity> <period> <instant>2011-05-18</instant> </period> </context> <unit id="shares"> <measure>shares</measure> </unit> <unit id="iso4217_USD"> <measure>iso4217:USD</measure> </unit> <unit id="iso4217_USD_per_shares"> <divide> <unitNumerator> <measure>iso4217:USD</measure> </unitNumerator> <unitDenominator> <measure>shares</measure> </unitDenominator> </divide> </unit> <unit id="pure"> <measure>pure</measure> </unit> <unit id="Financial_Institution"> <measure>cytk:Financial_Institution</measure> </unit> <unit id="PublicOffering"> <measure>cytk:PublicOffering</measure> </unit> <unit id="Segment"> <measure>cytk:Segment</measure> </unit> </xbrl> </XBRL> </TEXT> </DOCUMENT> <DOCUMENT> <TYPE>EX-101.SCH <SEQUENCE>8 <FILENAME>cytk-20141231.xsd <DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA <TEXT> <XBRL> <?xml version="1.0" encoding="US-ASCII"?> <!-- RR Donnelley Xcelerate Taxonomy Schema, based on XBRL 2.1 http://www.rrdonnelley.com/ --> <!-- Version: 6.22.4 --> <!-- Round: 10 --> <!-- Creation date: 2015-03-05T19:06:47Z --> <!-- Copyright (c) 2005-2013 R.R. Donnelley & Sons Company All Rights Reserved. --> <schema xmlns="http://www.w3.org/2001/XMLSchema" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:us-gaap="http://fasb.org/us-gaap/2014-01-31" xmlns:us-types="http://fasb.org/us-types/2014-01-31" xmlns:cytk="http://imetrix.edgar-online.com/20141231" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:num="http://www.xbrl.org/dtr/type/numeric" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:country="http://xbrl.sec.gov/country/2013-01-31" xmlns:currency="http://xbrl.sec.gov/currency/2014-01-31" xmlns:dei="http://xbrl.sec.gov/dei/2014-01-31" xmlns:exch="http://xbrl.sec.gov/exch/2014-01-31" xmlns:invest="http://xbrl.sec.gov/invest/2013-01-31" xmlns:naics="http://xbrl.sec.gov/naics/2011-01-31" xmlns:sic="http://xbrl.sec.gov/sic/2011-01-31" xmlns:stpr="http://xbrl.sec.gov/stpr/2011-01-31" targetNamespace="http://imetrix.edgar-online.com/20141231" elementFormDefault="qualified" attributeFormDefault="unqualified"> <annotation> <appinfo> <link:roleType roleURI="http://imetrix.edgar-online.com/taxonomy/role/DocumentandEntityInformation" id="DocumentandEntityInformation"> <link:definition>101 - Document - Document and Entity Information</link:definition> <link:usedOn>link:calculationLink</link:usedOn> <link:usedOn>link:presentationLink</link:usedOn> <link:usedOn>link:definitionLink</link:usedOn> </link:roleType> <link:roleType roleURI="http://imetrix.edgar-online.com/taxonomy/role/StatementOfFinancialPositionClassified" id="Role_StatementOfFinancialPositionClassified"> <link:definition>103 - Statement - Consolidated Balance Sheets</link:definition> <link:usedOn>link:calculationLink</link:usedOn> <link:usedOn>link:presentationLink</link:usedOn> <link:usedOn>link:definitionLink</link:usedOn> </link:roleType> <link:roleType roleURI="http://imetrix.edgar-online.com/taxonomy/role/StatementOfFinancialPositionClassifiedParenthetical" id="Role_StatementOfFinancialPositionClassifiedParen"> <link:definition>104 - Statement - Consolidated Balance Sheets (Parenthetical)</link:definition> <link:usedOn>link:calculationLink</link:usedOn> <link:usedOn>link:presentationLink</link:usedOn> <link:usedOn>link:definitionLink</link:usedOn> </link:roleType> <link:roleType roleURI="http://imetrix.edgar-online.com/taxonomy/role/StatementOfIncome" id="Role_StatementOfIncome"> <link:definition>105 - Statement - Consolidated Statements of Comprehensive Loss</link:definition> <link:usedOn>link:calculationLink</link:usedOn> <link:usedOn>link:presentationLink</link:usedOn> <link:usedOn>link:definitionLink</link:usedOn> </link:roleType> <link:roleType roleURI="http://imetrix.edgar-online.com/taxonomy/role/StatementOfShareholdersEquityAndOtherComprehensiveIncome" id="Role_StatementOfShareholdersEquityAndOtherComprehensiveIncome"> <link:definition>106 - Statement - Consolidated Statements of Stockholders' Equity</link:definition> <link:usedOn>link:calculationLink</link:usedOn> <link:usedOn>link:presentationLink</link:usedOn> <link:usedOn>link:definitionLink</link:usedOn> </link:roleType> <link:roleType roleURI="http://imetrix.edgar-online.com/taxonomy/role/StatementOfShareholdersEquityAndOtherComprehensiveIncomeParenthetical" id="Role_StatementOfShareholdersEquityAndOtherComprehensiveIncomeParen"> <link:definition>107 - Statement - Consolidated Statements of Stockholders' Equity (Parenthetical)</link:definition> <link:usedOn>link:calculationLink</link:usedOn> <link:usedOn>link:presentationLink</link:usedOn> <link:usedOn>link:definitionLink</link:usedOn> </link:roleType> <link:roleType roleURI="http://imetrix.edgar-online.com/taxonomy/role/StatementOfCashFlowsIndirect" id="Role_StatementOfCashFlowsIndirect"> <link:definition>108 - Statement - Consolidated Statements of Cash Flows</link:definition> <link:usedOn>link:calculationLink</link:usedOn> <link:usedOn>link:presentationLink</link:usedOn> <link:usedOn>link:definitionLink</link:usedOn> </link:roleType> <link:roleType roleURI="http://imetrix.edgar-online.com/taxonomy/role/NotesToFinancialStatementsOrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" id="Role_NotesToFinancialStatementsOrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock"> <link:definition>109 - Disclosure - Organization and Significant Accounting Policies</link:definition> <link:usedOn>link:calculationLink</link:usedOn> <link:usedOn>link:presentationLink</link:usedOn> <link:usedOn>link:definitionLink</link:usedOn> </link:roleType> <link:roleType roleURI="http://imetrix.edgar-online.com/taxonomy/role/NotesToFinancialStatementsEarningsPerShareTextBlock" id="Role_NotesToFinancialStatementsEarningsPerShareTextBlock"> <link:definition>110 - Disclosure - Net Loss Per Share</link:definition> <link:usedOn>link:calculationLink</link:usedOn> <link:usedOn>link:presentationLink</link:usedOn> <link:usedOn>link:definitionLink</link:usedOn> </link:roleType> <link:roleType roleURI="http://imetrix.edgar-online.com/taxonomy/role/NotesToFinancialStatementsCashFlowSupplementalDisclosuresTextBlock" id="Role_NotesToFinancialStatementsCashFlowSupplementalDisclosuresTextBlock"> <link:definition>111 - Disclosure - Supplementary Cash Flow Data</link:definition> <link:usedOn>link:calculationLink</link:usedOn> <link:usedOn>link:presentationLink</link:usedOn> <link:usedOn>link:definitionLink</link:usedOn> </link:roleType> <link:roleType roleURI="http://imetrix.edgar-online.com/taxonomy/role/NotesToFinancialStatementsInvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" id="Role_NotesToFinancialStatementsInvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock"> <link:definition>112 - Disclosure - Cash Equivalents and Investments</link:definition> <link:usedOn>link:calculationLink</link:usedOn> <link:usedOn>link:presentationLink</link:usedOn> <link:usedOn>link:definitionLink</link:usedOn> </link:roleType> <link:roleType roleURI="http://imetrix.edgar-online.com/taxonomy/role/NotesToFinancialStatementsFairValueDisclosuresTextBlock" id="Role_NotesToFinancialStatementsFairValueDisclosuresTextBlock"> <link:definition>113 - Disclosure - Fair Value Measurements</link:definition> <link:usedOn>link:calculationLink</link:usedOn> <link:usedOn>link:presentationLink</link:usedOn> <link:usedOn>link:definitionLink</link:usedOn> </link:roleType> <link:roleType roleURI="http://imetrix.edgar-online.com/taxonomy/role/NotesToFinancialStatementsSupplementalBalanceSheetDisclosuresTextBlock" id="Role_NotesToFinancialStatementsSupplementalBalanceSheetDisclosuresTextBlock"> <link:definition>114 - Disclosure - Balance Sheet Components</link:definition> <link:usedOn>link:calculationLink</link:usedOn> <link:usedOn>link:presentationLink</link:usedOn> <link:usedOn>link:definitionLink</link:usedOn> </link:roleType> <link:roleType roleURI="http://imetrix.edgar-online.com/taxonomy/role/NotesToFinancialStatementsRelatedPartyTransactionsDisclosureTextBlock" id="Role_NotesToFinancialStatementsRelatedPartyTransactionsDisclosureTextBlock"> <link:definition>115 - Disclosure - Related Parties and Related Party Transactions</link:definition> <link:usedOn>link:calculationLink</link:usedOn> <link:usedOn>link:presentationLink</link:usedOn> <link:usedOn>link:definitionLink</link:usedOn> </link:roleType> <link:roleType roleURI="http://imetrix.edgar-online.com/taxonomy/role/NotesToFinancialStatementsResearchDevelopmentAndComputerSoftwareDisclosureTextBlock" id="Role_NotesToFinancialStatementsResearchDevelopmentAndComputerSoftwareDisclosureTextBlock"> <link:definition>116 - Disclosure - Other Research and Development Revenue Arrangements</link:definition> <link:usedOn>link:calculationLink</link:usedOn> <link:usedOn>link:presentationLink</link:usedOn> <link:usedOn>link:definitionLink</link:usedOn> </link:roleType> <link:roleType roleURI="http://imetrix.edgar-online.com/taxonomy/role/NotesToFinancialStatementsDebtDisclosureTextBlock" id="Role_NotesToFinancialStatementsDebtDisclosureTextBlock"> <link:definition>117 - Disclosure - Debt</link:definition> <link:usedOn>link:calculationLink</link:usedOn> <link:usedOn>link:presentationLink</link:usedOn> <link:usedOn>link:definitionLink</link:usedOn> </link:roleType> <link:roleType roleURI="http://imetrix.edgar-online.com/taxonomy/role/NotesToFinancialStatementsCommitmentsAndContingenciesDisclosureTextBlock" id="Role_NotesToFinancialStatementsCommitmentsAndContingenciesDisclosureTextBlock"> <link:definition>118 - Disclosure - Commitments and Contingencies</link:definition> <link:usedOn>link:calculationLink</link:usedOn> <link:usedOn>link:presentationLink</link:usedOn> <link:usedOn>link:definitionLink</link:usedOn> </link:roleType> <link:roleType roleURI="http://imetrix.edgar-online.com/taxonomy/role/NotesToFinancialStatementsPreferredStockTextBlock" id="Role_NotesToFinancialStatementsPreferredStockTextBlock"> <link:definition>119 - Disclosure - Convertible Preferred Stock</link:definition> <link:usedOn>link:calculationLink</link:usedOn> <link:usedOn>link:presentationLink</link:usedOn> <link:usedOn>link:definitionLink</link:usedOn> </link:roleType> <link:roleType roleURI="http://imetrix.edgar-online.com/taxonomy/role/NotesToFinancialStatementsStockholdersEquityNoteDisclosureTextBlock" id="Role_NotesToFinancialStatementsStockholdersEquityNoteDisclosureTextBlock"> <link:definition>120 - Disclosure - Stockholders' Equity</link:definition> <link:usedOn>link:calculationLink</link:usedOn> <link:usedOn>link:presentationLink</link:usedOn> <link:usedOn>link:definitionLink</link:usedOn> </link:roleType> <link:roleType roleURI="http://imetrix.edgar-online.com/taxonomy/role/NotesToFinancialStatementsIncomeTaxDisclosureTextBlock" id="Role_NotesToFinancialStatementsIncomeTaxDisclosureTextBlock"> <link:definition>121 - Disclosure - Income Taxes</link:definition> <link:usedOn>link:calculationLink</link:usedOn> <link:usedOn>link:presentationLink</link:usedOn> <link:usedOn>link:definitionLink</link:usedOn> </link:roleType> <link:roleType roleURI="http://imetrix.edgar-online.com/taxonomy/role/NotesToFinancialStatementsOtherIncomeAndOtherExpenseDisclosureTextBlock" id="Role_NotesToFinancialStatementsOtherIncomeAndOtherExpenseDisclosureTextBlock"> <link:definition>122 - Disclosure - Interest and Other, Net</link:definition> <link:usedOn>link:calculationLink</link:usedOn> <link:usedOn>link:presentationLink</link:usedOn> <link:usedOn>link:definitionLink</link:usedOn> </link:roleType> <link:roleType roleURI="http://imetrix.edgar-online.com/taxonomy/role/NotesToFinancialStatementsQuarterlyFinancialInformationTextBlock" id="Role_NotesToFinancialStatementsQuarterlyFinancialInformationTextBlock"> <link:definition>123 - Disclosure - Quarterly Financial Data</link:definition> <link:usedOn>link:calculationLink</link:usedOn> <link:usedOn>link:presentationLink</link:usedOn> <link:usedOn>link:definitionLink</link:usedOn> </link:roleType> <link:roleType roleURI="http://imetrix.edgar-online.com/taxonomy/role/NotesToFinancialStatementsOrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlockPolicies" id="Role_NotesToFinancialStatementsOrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlockPolicies"> <link:definition>124 - Disclosure - Organization and Significant Accounting Policies (Policies)</link:definition> <link:usedOn>link:calculationLink</link:usedOn> <link:usedOn>link:presentationLink</link:usedOn> <link:usedOn>link:definitionLink</link:usedOn> </link:roleType> <link:roleType roleURI="http://imetrix.edgar-online.com/taxonomy/role/NotesToFinancialStatementsEarningsPerShareTextBlockTables" id="Role_NotesToFinancialStatementsEarningsPerShareTextBlockTables"> <link:definition>125 - Disclosure - Net Loss Per Share (Tables)</link:definition> <link:usedOn>link:calculationLink</link:usedOn> <link:usedOn>link:presentationLink</link:usedOn> <link:usedOn>link:definitionLink</link:usedOn> </link:roleType> <link:roleType roleURI="http://imetrix.edgar-online.com/taxonomy/role/NotesToFinancialStatementsCashFlowSupplementalDisclosuresTextBlockTables" id="Role_NotesToFinancialStatementsCashFlowSupplementalDisclosuresTextBlockTables"> <link:definition>126 - Disclosure - Supplementary Cash Flow Data (Tables)</link:definition> <link:usedOn>link:calculationLink</link:usedOn> <link:usedOn>link:presentationLink</link:usedOn> <link:usedOn>link:definitionLink</link:usedOn> </link:roleType> <link:roleType roleURI="http://imetrix.edgar-online.com/taxonomy/role/NotesToFinancialStatementsInvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlockTables" id="Role_NotesToFinancialStatementsInvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlockTables"> <link:definition>127 - Disclosure - Cash Equivalents and Investments (Tables)</link:definition> <link:usedOn>link:calculationLink</link:usedOn> <link:usedOn>link:presentationLink</link:usedOn> <link:usedOn>link:definitionLink</link:usedOn> </link:roleType> <link:roleType roleURI="http://imetrix.edgar-online.com/taxonomy/role/NotesToFinancialStatementsFairValueDisclosuresTextBlockTables" id="Role_NotesToFinancialStatementsFairValueDisclosuresTextBlockTables"> <link:definition>128 - Disclosure - Fair Value Measurements (Tables)</link:definition> <link:usedOn>link:calculationLink</link:usedOn> <link:usedOn>link:presentationLink</link:usedOn> <link:usedOn>link:definitionLink</link:usedOn> </link:roleType> <link:roleType roleURI="http://imetrix.edgar-online.com/taxonomy/role/NotesToFinancialStatementsSupplementalBalanceSheetDisclosuresTextBlockTables" id="Role_NotesToFinancialStatementsSupplementalBalanceSheetDisclosuresTextBlockTables"> <link:definition>129 - Disclosure - Balance Sheet Components (Tables)</link:definition> <link:usedOn>link:calculationLink</link:usedOn> <link:usedOn>link:presentationLink</link:usedOn> <link:usedOn>link:definitionLink</link:usedOn> </link:roleType> <link:roleType roleURI="http://imetrix.edgar-online.com/taxonomy/role/NotesToFinancialStatementsRelatedPartyTransactionsDisclosureTextBlockTables" id="Role_NotesToFinancialStatementsRelatedPartyTransactionsDisclosureTextBlockTables"> <link:definition>130 - Disclosure - Related Parties and Related Party Transactions (Tables)</link:definition> <link:usedOn>link:calculationLink</link:usedOn> <link:usedOn>link:presentationLink</link:usedOn> <link:usedOn>link:definitionLink</link:usedOn> </link:roleType> <link:roleType roleURI="http://imetrix.edgar-online.com/taxonomy/role/NotesToFinancialStatementsResearchDevelopmentAndComputerSoftwareDisclosureTextBlockTables" id="Role_NotesToFinancialStatementsResearchDevelopmentAndComputerSoftwareDisclosureTextBlockTables"> <link:definition>131 - Disclosure - Other Research and Development Revenue Arrangements (Tables)</link:definition> <link:usedOn>link:calculationLink</link:usedOn> <link:usedOn>link:presentationLink</link:usedOn> <link:usedOn>link:definitionLink</link:usedOn> </link:roleType> <link:roleType roleURI="http://imetrix.edgar-online.com/taxonomy/role/NotesToFinancialStatementsDebtDisclosureTextBlockTables" id="Role_NotesToFinancialStatementsDebtDisclosureTextBlockTables"> <link:definition>132 - Disclosure - Debt (Tables)</link:definition> <link:usedOn>link:calculationLink</link:usedOn> <link:usedOn>link:presentationLink</link:usedOn> <link:usedOn>link:definitionLink</link:usedOn> </link:roleType> <link:roleType roleURI="http://imetrix.edgar-online.com/taxonomy/role/NotesToFinancialStatementsCommitmentsAndContingenciesDisclosureTextBlockTables" id="Role_NotesToFinancialStatementsCommitmentsAndContingenciesDisclosureTextBlockTables"> <link:definition>133 - Disclosure - Commitments and Contingencies (Tables)</link:definition> <link:usedOn>link:calculationLink</link:usedOn> <link:usedOn>link:presentationLink</link:usedOn> <link:usedOn>link:definitionLink</link:usedOn> </link:roleType> <link:roleType roleURI="http://imetrix.edgar-online.com/taxonomy/role/NotesToFinancialStatementsStockholdersEquityNoteDisclosureTextBlockTables" id="Role_NotesToFinancialStatementsStockholdersEquityNoteDisclosureTextBlockTables"> <link:definition>134 - Disclosure - Stockholders' Equity (Tables)</link:definition> <link:usedOn>link:calculationLink</link:usedOn> <link:usedOn>link:presentationLink</link:usedOn> <link:usedOn>link:definitionLink</link:usedOn> </link:roleType> <link:roleType roleURI="http://imetrix.edgar-online.com/taxonomy/role/NotesToFinancialStatementsIncomeTaxDisclosureTextBlockTables" id="Role_NotesToFinancialStatementsIncomeTaxDisclosureTextBlockTables"> <link:definition>135 - Disclosure - Income Taxes (Tables)</link:definition> <link:usedOn>link:calculationLink</link:usedOn> <link:usedOn>link:presentationLink</link:usedOn> <link:usedOn>link:definitionLink</link:usedOn> </link:roleType> <link:roleType roleURI="http://imetrix.edgar-online.com/taxonomy/role/NotesToFinancialStatementsOtherIncomeAndOtherExpenseDisclosureTextBlockTables" id="Role_NotesToFinancialStatementsOtherIncomeAndOtherExpenseDisclosureTextBlockTables"> <link:definition>136 - Disclosure - Interest and Other, Net (Tables)</link:definition> <link:usedOn>link:calculationLink</link:usedOn> <link:usedOn>link:presentationLink</link:usedOn> <link:usedOn>link:definitionLink</link:usedOn> </link:roleType> <link:roleType roleURI="http://imetrix.edgar-online.com/taxonomy/role/NotesToFinancialStatementsQuarterlyFinancialInformationTextBlockTables" id="Role_NotesToFinancialStatementsQuarterlyFinancialInformationTextBlockTables"> <link:definition>137 - Disclosure - Quarterly Financial Data (Tables)</link:definition> <link:usedOn>link:calculationLink</link:usedOn> <link:usedOn>link:presentationLink</link:usedOn> <link:usedOn>link:definitionLink</link:usedOn> </link:roleType> <link:roleType roleURI="http://imetrix.edgar-online.com/taxonomy/role/DisclosureOrganizationAndSignificantAccountingPoliciesAdditionalInformation" id="DisclosureOrganizationAndSignificantAccountingPoliciesAdditionalInformation"> <link:definition>138 - Disclosure - Organization and Significant Accounting Policies - Additional Information (Detail)</link:definition> <link:usedOn>link:calculationLink</link:usedOn> <link:usedOn>link:presentationLink</link:usedOn> <link:usedOn>link:definitionLink</link:usedOn> </link:roleType> <link:roleType roleURI="http://imetrix.edgar-online.com/taxonomy/role/DisclosureNetLossPerShareCalculationOfBasicAndDilutedNetLossPerShareAllocableToCommonStockholders" id="DisclosureNetLossPerShareCalculationOfBasicAndDilutedNetLossPerShareAllocableToCommonStockholders"> <link:definition>139 - Disclosure - Net Loss Per Share - Calculation of Basic and Diluted Net Loss Per Share Allocable to Common Stockholders (Detail)</link:definition> <link:usedOn>link:calculationLink</link:usedOn> <link:usedOn>link:presentationLink</link:usedOn> <link:usedOn>link:definitionLink</link:usedOn> </link:roleType> <link:roleType roleURI="http://imetrix.edgar-online.com/taxonomy/role/DisclosureNetLossPerShareInstrumentsExcludedFromTheComputationOfDilutedNetLossPerCommonShare" id="DisclosureNetLossPerShareInstrumentsExcludedFromTheComputationOfDilutedNetLossPerCommonShare"> <link:definition>140 - Disclosure - Net Loss Per Share - Instruments Excluded from the Computation of Diluted Net Loss Per Common Share (Detail)</link:definition> <link:usedOn>link:calculationLink</link:usedOn> <link:usedOn>link:presentationLink</link:usedOn> <link:usedOn>link:definitionLink</link:usedOn> </link:roleType> <link:roleType roleURI="http://imetrix.edgar-online.com/taxonomy/role/DisclosureSupplementaryCashFlowDataSupplementalCashFlowInformation" id="DisclosureSupplementaryCashFlowDataSupplementalCashFlowInformation"> <link:definition>141 - Disclosure - Supplementary Cash Flow Data - Supplemental Cash Flow Information (Detail)</link:definition> <link:usedOn>link:calculationLink</link:usedOn> <link:usedOn>link:presentationLink</link:usedOn> <link:usedOn>link:definitionLink</link:usedOn> </link:roleType> <link:roleType roleURI="http://imetrix.edgar-online.com/taxonomy/role/DisclosureCashEquivalentsAndInvestmentsAmortizedCostAndFairValueOfCashEquivalentsAndAvailableForSaleInvestments" id="DisclosureCashEquivalentsAndInvestmentsAmortizedCostAndFairValueOfCashEquivalentsAndAvailableForSaleInvestments"> <link:definition>142 - Disclosure - Cash Equivalents and Investments - Amortized Cost and Fair Value of Cash Equivalents and Available for Sale Investments (Detail)</link:definition> <link:usedOn>link:calculationLink</link:usedOn> <link:usedOn>link:presentationLink</link:usedOn> <link:usedOn>link:definitionLink</link:usedOn> </link:roleType> <link:roleType roleURI="http://imetrix.edgar-online.com/taxonomy/role/DisclosureCashEquivalentsAndInvestmentsAdditionalInformation" id="DisclosureCashEquivalentsAndInvestmentsAdditionalInformation"> <link:definition>143 - Disclosure - Cash Equivalents and Investments - Additional Information (Detail)</link:definition> <link:usedOn>link:calculationLink</link:usedOn> <link:usedOn>link:presentationLink</link:usedOn> <link:usedOn>link:definitionLink</link:usedOn> </link:roleType> <link:roleType roleURI="http://imetrix.edgar-online.com/taxonomy/role/DisclosureCashEquivalentsAndInvestmentsSummaryOfInterestIncome" id="DisclosureCashEquivalentsAndInvestmentsSummaryOfInterestIncome"> <link:definition>144 - Disclosure - Cash Equivalents and Investments - Summary of Interest Income (Detail)</link:definition> <link:usedOn>link:calculationLink</link:usedOn> <link:usedOn>link:presentationLink</link:usedOn> <link:usedOn>link:definitionLink</link:usedOn> </link:roleType> <link:roleType roleURI="http://imetrix.edgar-online.com/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfFinancialAssetsMeasuredAtFairValueOnRecurringBasis" id="DisclosureFairValueMeasurementsSummaryOfFinancialAssetsMeasuredAtFairValueOnRecurringBasis"> <link:definition>145 - Disclosure - Fair Value Measurements - Summary of Financial Assets Measured at Fair Value on Recurring Basis (Detail)</link:definition> <link:usedOn>link:calculationLink</link:usedOn> <link:usedOn>link:presentationLink</link:usedOn> <link:usedOn>link:definitionLink</link:usedOn> </link:roleType> <link:roleType roleURI="http://imetrix.edgar-online.com/taxonomy/role/DisclosureFairValueMeasurementsAdditionalInformation" id="DisclosureFairValueMeasurementsAdditionalInformation"> <link:definition>146 - Disclosure - Fair Value Measurements - Additional Information (Detail)</link:definition> <link:usedOn>link:calculationLink</link:usedOn> <link:usedOn>link:presentationLink</link:usedOn> <link:usedOn>link:definitionLink</link:usedOn> </link:roleType> <link:roleType roleURI="http://imetrix.edgar-online.com/taxonomy/role/DisclosureBalanceSheetComponentsSummaryOfPropertyAndEquipmentBalances" id="DisclosureBalanceSheetComponentsSummaryOfPropertyAndEquipmentBalances"> <link:definition>147 - Disclosure - Balance Sheet Components - Summary of Property and Equipment Balances (Detail)</link:definition> <link:usedOn>link:calculationLink</link:usedOn> <link:usedOn>link:presentationLink</link:usedOn> <link:usedOn>link:definitionLink</link:usedOn> </link:roleType> <link:roleType roleURI="http://imetrix.edgar-online.com/taxonomy/role/DisclosureBalanceSheetComponentsAdditionalInformation" id="DisclosureBalanceSheetComponentsAdditionalInformation"> <link:definition>148 - Disclosure - Balance Sheet Components - Additional Information (Detail)</link:definition> <link:usedOn>link:calculationLink</link:usedOn> <link:usedOn>link:presentationLink</link:usedOn> <link:usedOn>link:definitionLink</link:usedOn> </link:roleType> <link:roleType roleURI="http://imetrix.edgar-online.com/taxonomy/role/DisclosureBalanceSheetComponentsSummaryOfAccruedLiabilities" id="DisclosureBalanceSheetComponentsSummaryOfAccruedLiabilities"> <link:definition>149 - Disclosure - Balance Sheet Components - Summary of Accrued Liabilities (Detail)</link:definition> <link:usedOn>link:calculationLink</link:usedOn> <link:usedOn>link:presentationLink</link:usedOn> <link:usedOn>link:definitionLink</link:usedOn> </link:roleType> <link:roleType roleURI="http://imetrix.edgar-online.com/taxonomy/role/DisclosureRelatedPartiesAndRelatedPartyTransactionsAdditionalInformation" id="DisclosureRelatedPartiesAndRelatedPartyTransactionsAdditionalInformation"> <link:definition>150 - Disclosure - Related Parties and Related Party Transactions - Additional Information (Detail)</link:definition> <link:usedOn>link:calculationLink</link:usedOn> <link:usedOn>link:presentationLink</link:usedOn> <link:usedOn>link:definitionLink</link:usedOn> </link:roleType> <link:roleType roleURI="http://imetrix.edgar-online.com/taxonomy/role/DisclosureRelatedPartiesAndRelatedPartyTransactionsRevenueFromRelatedParty" id="DisclosureRelatedPartiesAndRelatedPartyTransactionsRevenueFromRelatedParty"> <link:definition>151 - Disclosure - Related Parties and Related Party Transactions - Revenue from Related Party (Detail)</link:definition> <link:usedOn>link:calculationLink</link:usedOn> <link:usedOn>link:presentationLink</link:usedOn> <link:usedOn>link:definitionLink</link:usedOn> </link:roleType> <link:roleType roleURI="http://imetrix.edgar-online.com/taxonomy/role/DisclosureOtherResearchAndDevelopmentRevenueArrangementsAdditionalInformation" id="DisclosureOtherResearchAndDevelopmentRevenueArrangementsAdditionalInformation"> <link:definition>152 - Disclosure - Other Research and Development Revenue Arrangements - Additional Information (Detail)</link:definition> <link:usedOn>link:calculationLink</link:usedOn> <link:usedOn>link:presentationLink</link:usedOn> <link:usedOn>link:definitionLink</link:usedOn> </link:roleType> <link:roleType roleURI="http://imetrix.edgar-online.com/taxonomy/role/DisclosureOtherResearchAndDevelopmentRevenueArrangementsSummaryOfTotalGrantRevenues" id="DisclosureOtherResearchAndDevelopmentRevenueArrangementsSummaryOfTotalGrantRevenues"> <link:definition>153 - Disclosure - Other Research and Development Revenue Arrangements - Summary of Total Grant Revenues (Detail)</link:definition> <link:usedOn>link:calculationLink</link:usedOn> <link:usedOn>link:presentationLink</link:usedOn> <link:usedOn>link:definitionLink</link:usedOn> </link:roleType> <link:roleType roleURI="http://imetrix.edgar-online.com/taxonomy/role/DisclosureOtherResearchAndDevelopmentRevenueArrangementsSummaryOfReimbursedExpenses" id="DisclosureOtherResearchAndDevelopmentRevenueArrangementsSummaryOfReimbursedExpenses"> <link:definition>154 - Disclosure - Other Research and Development Revenue Arrangements - Summary of Reimbursed Expenses (Detail)</link:definition> <link:usedOn>link:calculationLink</link:usedOn> <link:usedOn>link:presentationLink</link:usedOn> <link:usedOn>link:definitionLink</link:usedOn> </link:roleType> <link:roleType roleURI="http://imetrix.edgar-online.com/taxonomy/role/DisclosureDebtAdditionalInformation" id="DisclosureDebtAdditionalInformation"> <link:definition>155 - Disclosure - Debt - Additional Information (Detail)</link:definition> <link:usedOn>link:calculationLink</link:usedOn> <link:usedOn>link:presentationLink</link:usedOn> <link:usedOn>link:definitionLink</link:usedOn> </link:roleType> <link:roleType roleURI="http://imetrix.edgar-online.com/taxonomy/role/DisclosureDebtSummaryOfTotalInterestExpenseIncurred" id="DisclosureDebtSummaryOfTotalInterestExpenseIncurred"> <link:definition>156 - Disclosure - Debt - Summary of Total Interest Expense Incurred (Detail)</link:definition> <link:usedOn>link:calculationLink</link:usedOn> <link:usedOn>link:presentationLink</link:usedOn> <link:usedOn>link:definitionLink</link:usedOn> </link:roleType> <link:roleType roleURI="http://imetrix.edgar-online.com/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformation" id="DisclosureCommitmentsAndContingenciesAdditionalInformation"> <link:definition>157 - Disclosure - Commitments and Contingencies - Additional Information (Detail)</link:definition> <link:usedOn>link:calculationLink</link:usedOn> <link:usedOn>link:presentationLink</link:usedOn> <link:usedOn>link:definitionLink</link:usedOn> </link:roleType> <link:roleType roleURI="http://imetrix.edgar-online.com/taxonomy/role/DisclosureCommitmentsAndContingenciesRentExpense" id="DisclosureCommitmentsAndContingenciesRentExpense"> <link:definition>158 - Disclosure - Commitments and Contingencies - Rent Expense (Detail)</link:definition> <link:usedOn>link:calculationLink</link:usedOn> <link:usedOn>link:presentationLink</link:usedOn> <link:usedOn>link:definitionLink</link:usedOn> </link:roleType> <link:roleType roleURI="http://imetrix.edgar-online.com/taxonomy/role/DisclosureCommitmentsAndContingenciesFutureMinimumLeasePaymentsUnderNoncancelableOperatingLeases" id="DisclosureCommitmentsAndContingenciesFutureMinimumLeasePaymentsUnderNoncancelableOperatingLeases"> <link:definition>159 - Disclosure - Commitments and Contingencies - Future Minimum Lease Payments under Noncancelable Operating Leases (Detail)</link:definition> <link:usedOn>link:calculationLink</link:usedOn> <link:usedOn>link:presentationLink</link:usedOn> <link:usedOn>link:definitionLink</link:usedOn> </link:roleType> <link:roleType roleURI="http://imetrix.edgar-online.com/taxonomy/role/DisclosureConvertiblePreferredStockAdditionalInformation" id="DisclosureConvertiblePreferredStockAdditionalInformation"> <link:definition>160 - Disclosure - Convertible Preferred Stock - Additional Information (Detail)</link:definition> <link:usedOn>link:calculationLink</link:usedOn> <link:usedOn>link:presentationLink</link:usedOn> <link:usedOn>link:definitionLink</link:usedOn> </link:roleType> <link:roleType roleURI="http://imetrix.edgar-online.com/taxonomy/role/DisclosureStockholdersEquityAdditionalInformation" id="DisclosureStockholdersEquityAdditionalInformation"> <link:definition>161 - Disclosure - Stockholders' Equity - Additional Information (Detail)</link:definition> <link:usedOn>link:calculationLink</link:usedOn> <link:usedOn>link:presentationLink</link:usedOn> <link:usedOn>link:definitionLink</link:usedOn> </link:roleType> <link:roleType roleURI="http://imetrix.edgar-online.com/taxonomy/role/DisclosureStockholdersEquityOutstandingWarrants" id="DisclosureStockholdersEquityOutstandingWarrants"> <link:definition>162 - Disclosure - Stockholders' Equity - Outstanding Warrants (Detail)</link:definition> <link:usedOn>link:calculationLink</link:usedOn> <link:usedOn>link:presentationLink</link:usedOn> <link:usedOn>link:definitionLink</link:usedOn> </link:roleType> <link:roleType roleURI="http://imetrix.edgar-online.com/taxonomy/role/DisclosureStockholdersEquitySummaryOfStockOptionActivity" id="DisclosureStockholdersEquitySummaryOfStockOptionActivity"> <link:definition>163 - Disclosure - Stockholders' Equity - Summary of Stock Option Activity (Detail)</link:definition> <link:usedOn>link:calculationLink</link:usedOn> <link:usedOn>link:presentationLink</link:usedOn> <link:usedOn>link:definitionLink</link:usedOn> </link:roleType> <link:roleType roleURI="http://imetrix.edgar-online.com/taxonomy/role/DisclosureStockholdersEquitySummaryOfRestrictedStockUnitActivity" id="DisclosureStockholdersEquitySummaryOfRestrictedStockUnitActivity"> <link:definition>164 - Disclosure - Stockholders' Equity - Summary of Restricted Stock Unit Activity (Detail)</link:definition> <link:usedOn>link:calculationLink</link:usedOn> <link:usedOn>link:presentationLink</link:usedOn> <link:usedOn>link:definitionLink</link:usedOn> </link:roleType> <link:roleType roleURI="http://imetrix.edgar-online.com/taxonomy/role/DisclosureStockholdersEquityStockBasedCompensationRelatedToStockOptionsRestrictedStockAwardsRestrictedStockUnitAndEmployeeStockPurchases" id="DisclosureStockholdersEquityStockBasedCompensationRelatedToStockOptionsRestrictedStockAwardsRestrictedStockUnitAndEmployeeStockPurchases"> <link:definition>165 - Disclosure - Stockholders' Equity - Stock-Based Compensation Related to Stock Options, Restricted Stock Awards, Restricted Stock Unit, and Employee Stock Purchases (Detail)</link:definition> <link:usedOn>link:calculationLink</link:usedOn> <link:usedOn>link:presentationLink</link:usedOn> <link:usedOn>link:definitionLink</link:usedOn> </link:roleType> <link:roleType roleURI="http://imetrix.edgar-online.com/taxonomy/role/DisclosureStockholdersEquityFairValueOfShareBasedPaymentsWasEstimatedOnDateOfGrantUsingBlackScholesOptionPricingModelBasedOnWeightedAverageAssumptions" id="DisclosureStockholdersEquityFairValueOfShareBasedPaymentsWasEstimatedOnDateOfGrantUsingBlackScholesOptionPricingModelBasedOnWeightedAverageAssumptions"> <link:definition>166 - Disclosure - Stockholders' Equity - Fair Value of Share-Based Payments was Estimated on Date of Grant Using Black-Scholes Option Pricing Model Based on Weighted Average Assumptions (Detail)</link:definition> <link:usedOn>link:calculationLink</link:usedOn> <link:usedOn>link:presentationLink</link:usedOn> <link:usedOn>link:definitionLink</link:usedOn> </link:roleType> <link:roleType roleURI="http://imetrix.edgar-online.com/taxonomy/role/DisclosureIncomeTaxesAdditionalInformation" id="DisclosureIncomeTaxesAdditionalInformation"> <link:definition>167 - Disclosure - Income Taxes - Additional Information (Detail)</link:definition> <link:usedOn>link:calculationLink</link:usedOn> <link:usedOn>link:presentationLink</link:usedOn> <link:usedOn>link:definitionLink</link:usedOn> </link:roleType> <link:roleType roleURI="http://imetrix.edgar-online.com/taxonomy/role/DisclosureIncomeTaxesScheduleOfComponentsOfIncomeBeforeTaxes" id="DisclosureIncomeTaxesScheduleOfComponentsOfIncomeBeforeTaxes"> <link:definition>168 - Disclosure - Income Taxes - Schedule of Components of Income Before Taxes (Detail)</link:definition> <link:usedOn>link:calculationLink</link:usedOn> <link:usedOn>link:presentationLink</link:usedOn> <link:usedOn>link:definitionLink</link:usedOn> </link:roleType> <link:roleType roleURI="http://imetrix.edgar-online.com/taxonomy/role/DisclosureIncomeTaxesCompanyRecordedIncomeTaxProvision" id="DisclosureIncomeTaxesCompanyRecordedIncomeTaxProvision"> <link:definition>169 - Disclosure - Income Taxes - Company Recorded Income Tax Provision (Detail)</link:definition> <link:usedOn>link:calculationLink</link:usedOn> <link:usedOn>link:presentationLink</link:usedOn> <link:usedOn>link:definitionLink</link:usedOn> </link:roleType> <link:roleType roleURI="http://imetrix.edgar-online.com/taxonomy/role/DisclosureIncomeTaxesCompanysDeferredTaxAssetsAndLiabilities" id="DisclosureIncomeTaxesCompanysDeferredTaxAssetsAndLiabilities"> <link:definition>170 - Disclosure - Income Taxes - Company's Deferred Tax Assets and Liabilities (Detail)</link:definition> <link:usedOn>link:calculationLink</link:usedOn> <link:usedOn>link:presentationLink</link:usedOn> <link:usedOn>link:definitionLink</link:usedOn> </link:roleType> <link:roleType roleURI="http://imetrix.edgar-online.com/taxonomy/role/DisclosureIncomeTaxesCompanysValuationAndQualifyingAccounts" id="DisclosureIncomeTaxesCompanysValuationAndQualifyingAccounts"> <link:definition>171 - Disclosure - Income Taxes - Company's Valuation and Qualifying Accounts (Detail)</link:definition> <link:usedOn>link:calculationLink</link:usedOn> <link:usedOn>link:presentationLink</link:usedOn> <link:usedOn>link:definitionLink</link:usedOn> </link:roleType> <link:roleType roleURI="http://imetrix.edgar-online.com/taxonomy/role/DisclosureIncomeTaxesReconciliationOfStatutoryFederalIncomeTaxRateToEffectiveTaxRate" id="DisclosureIncomeTaxesReconciliationOfStatutoryFederalIncomeTaxRateToEffectiveTaxRate"> <link:definition>172 - Disclosure - Income Taxes - Reconciliation of Statutory Federal Income Tax Rate to Effective Tax Rate (Detail)</link:definition> <link:usedOn>link:calculationLink</link:usedOn> <link:usedOn>link:presentationLink</link:usedOn> <link:usedOn>link:definitionLink</link:usedOn> </link:roleType> <link:roleType roleURI="http://imetrix.edgar-online.com/taxonomy/role/DisclosureIncomeTaxesReconciliationOfTotalAmountsOfUnrecognizedTaxBenefits" id="DisclosureIncomeTaxesReconciliationOfTotalAmountsOfUnrecognizedTaxBenefits"> <link:definition>173 - Disclosure - Income Taxes - Reconciliation of Total Amounts of Unrecognized Tax Benefits (Detail)</link:definition> <link:usedOn>link:calculationLink</link:usedOn> <link:usedOn>link:presentationLink</link:usedOn> <link:usedOn>link:definitionLink</link:usedOn> </link:roleType> <link:roleType roleURI="http://imetrix.edgar-online.com/taxonomy/role/DisclosureInterestAndOtherNetComponentsOfInterestAndOtherNet" id="DisclosureInterestAndOtherNetComponentsOfInterestAndOtherNet"> <link:definition>174 - Disclosure - Interest and Other, Net - Components of Interest and Other, Net (Detail)</link:definition> <link:usedOn>link:calculationLink</link:usedOn> <link:usedOn>link:presentationLink</link:usedOn> <link:usedOn>link:definitionLink</link:usedOn> </link:roleType> <link:roleType roleURI="http://imetrix.edgar-online.com/taxonomy/role/DisclosureQuarterlyFinancialDataSummaryOfQuarterlyResults" id="DisclosureQuarterlyFinancialDataSummaryOfQuarterlyResults"> <link:definition>175 - Disclosure - Quarterly Financial Data - Summary of Quarterly Results (Detail)</link:definition> <link:usedOn>link:calculationLink</link:usedOn> <link:usedOn>link:presentationLink</link:usedOn> <link:usedOn>link:definitionLink</link:usedOn> </link:roleType> <link:linkbaseRef xlink:type="simple" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:href="cytk-20141231_cal.xml" xlink:title="Calculation Links, all"/> <link:linkbaseRef xlink:type="simple" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:href="cytk-20141231_def.xml" xlink:title="Definition Links, all"/> <link:linkbaseRef xlink:type="simple" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:href="cytk-20141231_lab.xml" xlink:title="Label Links, all"/> <link:linkbaseRef xlink:type="simple" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:href="cytk-20141231_pre.xml" xlink:title="Presentation Links, all"/> </appinfo> </annotation> <import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/> <import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/> <import namespace="http://fasb.org/us-types/2014-01-31" schemaLocation="http://xbrl.fasb.org/us-gaap/2014/elts/us-types-2014-01-31.xsd"/> <import namespace="http://www.xbrl.org/dtr/type/non-numeric" schemaLocation="http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd"/> <import namespace="http://www.xbrl.org/dtr/type/numeric" schemaLocation="http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd"/> <import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd"/> <import namespace="http://fasb.org/us-gaap/2014-01-31" schemaLocation="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd"/> <import namespace="http://xbrl.sec.gov/country/2013-01-31" schemaLocation="http://xbrl.sec.gov/country/2013/country-2013-01-31.xsd"/> <import namespace="http://xbrl.sec.gov/currency/2014-01-31" schemaLocation="http://xbrl.sec.gov/currency/2014/currency-2014-01-31.xsd"/> <import namespace="http://xbrl.sec.gov/dei/2014-01-31" schemaLocation="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd"/> <import namespace="http://xbrl.sec.gov/exch/2014-01-31" schemaLocation="http://xbrl.sec.gov/exch/2014/exch-2014-01-31.xsd"/> <import namespace="http://xbrl.sec.gov/invest/2013-01-31" schemaLocation="http://xbrl.sec.gov/invest/2013/invest-2013-01-31.xsd"/> <import namespace="http://xbrl.sec.gov/naics/2011-01-31" schemaLocation="http://xbrl.sec.gov/naics/2011/naics-2011-01-31.xsd"/> <import namespace="http://xbrl.sec.gov/sic/2011-01-31" schemaLocation="http://xbrl.sec.gov/sic/2011/sic-2011-01-31.xsd"/> <import namespace="http://xbrl.sec.gov/stpr/2011-01-31" schemaLocation="http://xbrl.sec.gov/stpr/2011/stpr-2011-01-31.xsd"/> <element name="AccountingPronouncementsNotYetAdoptedPolicyTextBlock" id="cytk_AccountingPronouncementsNotYetAdoptedPolicyTextBlock" type="nonnum:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/> <element name="AccruedClinicalAndPreclinicalCostsCurrent" id="cytk_AccruedClinicalAndPreclinicalCostsCurrent" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item"/> <element name="AdjustmentsToAdditionalPaidInCapitalIssuanceOfConvertiblePreferredStock" id="cytk_AdjustmentsToAdditionalPaidInCapitalIssuanceOfConvertiblePreferredStock" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item"/> <element name="AfterReverseStockSplitMember" id="cytk_AfterReverseStockSplitMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/> <element name="AmendedAgreementMember" id="cytk_AmendedAgreementMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/> <element name="AmgenMember" id="cytk_AmgenMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/> <element name="AstellasMember" id="cytk_AstellasMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/> <element name="AvailableForSaleSecuritiesMaturityDate" id="cytk_AvailableForSaleSecuritiesMaturityDate" type="xbrli:gYearMonthItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/> <element name="BeforeReverseStockSplitMember" id="cytk_BeforeReverseStockSplitMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/> <element name="CashRequirementsTerm" id="cytk_CashRequirementsTerm" type="xbrli:durationItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/> <element name="CommercialMilestonesMember" id="cytk_CommercialMilestonesMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/> <element name="ComputerEquipmentAndSoftwareMember" id="cytk_ComputerEquipmentAndSoftwareMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/> <element name="ConversionPricePerShareOfPreferredStockToCommonStock" id="cytk_ConversionPricePerShareOfPreferredStockToCommonStock" type="num:perShareItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/> <element name="ConvertiblePreferredStockIssuancePrice" id="cytk_ConvertiblePreferredStockIssuancePrice" type="num:perShareItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/> <element name="DeerfieldAgreementMember" id="cytk_DeerfieldAgreementMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/> <element name="DeerfieldMember" id="cytk_DeerfieldMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/> <element name="DeferredTaxAssetsCapitalizedResearchAndDevelopment" id="cytk_DeferredTaxAssetsCapitalizedResearchAndDevelopment" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item"/> <element name="DeferredTaxAssetsDepreciationAndAmortization" id="cytk_DeferredTaxAssetsDepreciationAndAmortization" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item"/> <element name="DocumentAndEntityInformationAbstract" id="cytk_DocumentAndEntityInformationAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/> <element name="EarlyDevelopmentMember" id="cytk_EarlyDevelopmentMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/> <element name="EffectiveIncomeTaxRateReconciliationDeferredTaxAssetsUtilizedNotBenefited" id="cytk_EffectiveIncomeTaxRateReconciliationDeferredTaxAssetsUtilizedNotBenefited" type="num:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/> <element name="EffectiveIncomeTaxRateReconciliationNetOperatingLossExpiration" id="cytk_EffectiveIncomeTaxRateReconciliationNetOperatingLossExpiration" type="num:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/> <element name="EffectiveIncomeTaxRateReconciliationStateApportionment" id="cytk_EffectiveIncomeTaxRateReconciliationStateApportionment" type="num:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/> <element name="EmployeeStockPurchasePlansAveragePricePerShare" id="cytk_EmployeeStockPurchasePlansAveragePricePerShare" type="num:perShareItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/> <element name="EntitledPaymentPerShareDuringLiquidation" id="cytk_EntitledPaymentPerShareDuringLiquidation" type="num:perShareItemType" abstract="false" xbrli:periodType="instant" nillable="true" substitutionGroup="xbrli:item"/> <element name="ExcessOfCommonStockFairValueOverAllocatedPurchasePriceOfPreferredStock" id="cytk_ExcessOfCommonStockFairValueOverAllocatedPurchasePriceOfPreferredStock" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item"/> <element name="ExistingEmployeeMember" id="cytk_ExistingEmployeeMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/> <element name="FairValueOfCommonStockIssued" id="cytk_FairValueOfCommonStockIssued" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item"/> <element name="FairValuePerShareOfCommonStock" id="cytk_FairValuePerShareOfCommonStock" type="num:perShareItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/> <element name="FederalAndStateTaxMember" id="cytk_FederalAndStateTaxMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/> <element name="FederalNetOperatingLossRelatesToStockOptionDeductions" id="cytk_FederalNetOperatingLossRelatesToStockOptionDeductions" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item"/> <element name="FederalTaxBenefitOfStateIncomeTaxUtbMember" id="cytk_FederalTaxBenefitOfStateIncomeTaxUtbMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/> <element name="FractionalSharesFromReverseStockSplitShare" id="cytk_FractionalSharesFromReverseStockSplitShare" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/> <element name="GlobalBloodTherapeuticsMember" id="cytk_GlobalBloodTherapeuticsMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/> <element name="GrossProceedsFromIssuanceOfStock" id="cytk_GrossProceedsFromIssuanceOfStock" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item"/> <element name="IncreaseDecreaseInNoncashOrPartNoncashAcquisitionFixedAssetsAcquiredThroughAccruedLiabilities" id="cytk_IncreaseDecreaseInNoncashOrPartNoncashAcquisitionFixedAssetsAcquiredThroughAccruedLiabilities" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item"/> <element name="InternalCostsMember" id="cytk_InternalCostsMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/> <element name="IssuanceCostOfWarrant" id="cytk_IssuanceCostOfWarrant" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item"/> <element name="IssuanceOfCommonStockEmployeeStockPurchasePlanPricePerShare" id="cytk_IssuanceOfCommonStockEmployeeStockPurchasePlanPricePerShare" type="num:perShareItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/> <element name="IssuanceOfCommonStockToCollaborativePartnerForCashPerShare" id="cytk_IssuanceOfCommonStockToCollaborativePartnerForCashPerShare" type="num:perShareItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/> <element name="IssuanceOfCommonStockToCollaborativePartnerIssuanceCosts" id="cytk_IssuanceOfCommonStockToCollaborativePartnerIssuanceCosts" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item"/> <element name="IssuanceOfCommonStockToMlvAtPerShareLowerLimit" id="cytk_IssuanceOfCommonStockToMlvAtPerShareLowerLimit" type="num:perShareItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/> <element name="IssuanceOfCommonStockToMlvAtPerShareUpperLimit" id="cytk_IssuanceOfCommonStockToMlvAtPerShareUpperLimit" type="num:perShareItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/> <element name="IssuanceOfCommonStockToMlvNetOfCommissionAndIssuanceCosts" id="cytk_IssuanceOfCommonStockToMlvNetOfCommissionAndIssuanceCosts" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item"/> <element name="IssuanceOfCommonStockToRelatedPartyForCashPerShare" id="cytk_IssuanceOfCommonStockToRelatedPartyForCashPerShare" type="num:perShareItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/> <element name="IssuanceOfCommonStockToRelatedPartyIssuanceCosts" id="cytk_IssuanceOfCommonStockToRelatedPartyIssuanceCosts" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item"/> <element name="IssuanceOfConvertiblePreferredStockShares" id="cytk_IssuanceOfConvertiblePreferredStockShares" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/> <element name="LaboratoryEquipmentMember" id="cytk_LaboratoryEquipmentMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/> <element name="LicenseAndServicesMember" id="cytk_LicenseAndServicesMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/> <element name="LicenseFeeArrangementMember" id="cytk_LicenseFeeArrangementMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/> <element name="LicenseRevenuesFromRelatedParties" id="cytk_LicenseRevenuesFromRelatedParties" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item"/> <element name="LongTermInvestmentMember" id="cytk_LongTermInvestmentMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/> <element name="MilestonePaymentsReceivedUnderArrangements" id="cytk_MilestonePaymentsReceivedUnderArrangements" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item"/> <element name="MlvAgreementMember" id="cytk_MlvAgreementMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/> <element name="MyokardiaMember" id="cytk_MyokardiaMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/> <element name="NetProceedsFromIssuanceOfWarrants" id="cytk_NetProceedsFromIssuanceOfWarrants" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item"/> <element name="NewEmployeeMember" id="cytk_NewEmployeeMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/> <element name="NindsMyastheniaGravisMember" id="cytk_NindsMyastheniaGravisMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/> <element name="NineteenNinetySevenStockOptionPlanMember" id="cytk_NineteenNinetySevenStockOptionPlanMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/> <element name="NonCancelableLeaseAdditionalExtensionPeriod" id="cytk_NonCancelableLeaseAdditionalExtensionPeriod" type="xbrli:durationItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/> <element name="NonCancelableLeaseExpirationYear" id="cytk_NonCancelableLeaseExpirationYear" type="xbrli:gYearItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/> <element name="NoncashOrPartNoncashAcquisitionFixedAssetsAcquiredTradeInValue" id="cytk_NoncashOrPartNoncashAcquisitionFixedAssetsAcquiredTradeInValue" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item"/> <element name="NonEmployeeStockBasedCompensationMember" id="cytk_NonEmployeeStockBasedCompensationMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/> <element name="NonNeuromuscularIndicationsMember" id="cytk_NonNeuromuscularIndicationsMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/> <element name="NonstatutoryStockOptionsMember" id="cytk_NonstatutoryStockOptionsMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/> <element name="NumberOfConcurrentPublicOfferings" id="cytk_NumberOfConcurrentPublicOfferings" type="xbrli:integerItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/> <element name="NumberOfFinancialInstitutions" id="cytk_NumberOfFinancialInstitutions" type="xbrli:integerItemType" abstract="false" xbrli:periodType="instant" nillable="true" substitutionGroup="xbrli:item"/> <element name="NumberOfIssuedSharesOfCommonStockRelatedToCashlessExerciseOfWarrants" id="cytk_NumberOfIssuedSharesOfCommonStockRelatedToCashlessExerciseOfWarrants" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/> <element name="OfficeEquipmentFurnitureAndFixturesMember" id="cytk_OfficeEquipmentFurnitureAndFixturesMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/> <element name="OperatingLossCarryforwardsExpirationYear" id="cytk_OperatingLossCarryforwardsExpirationYear" type="xbrli:gYearItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/> <element name="OrganizationConsolidationAndPresentationOfFinancialStatementsPolicyTextBlock" id="cytk_OrganizationConsolidationAndPresentationOfFinancialStatementsPolicyTextBlock" type="nonnum:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/> <element name="OtherCostsMember" id="cytk_OtherCostsMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/> <element name="OtherGrantRevenueMember" id="cytk_OtherGrantRevenueMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/> <element name="OtherResearchAndDevelopmentRevenueArrangementsRecognizedGrantRevenueTableTextBlock" id="cytk_OtherResearchAndDevelopmentRevenueArrangementsRecognizedGrantRevenueTableTextBlock" type="nonnum:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/> <element name="OtherResearchAndDevelopmentRevenueArrangementsReimbursementOfExpenseTableTextBlock" id="cytk_OtherResearchAndDevelopmentRevenueArrangementsReimbursementOfExpenseTableTextBlock" type="nonnum:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/> <element name="PercentageLimitOnNumberOfSharesOfCommonStockExercisableByHolders" id="cytk_PercentageLimitOnNumberOfSharesOfCommonStockExercisableByHolders" type="num:percentItemType" abstract="false" xbrli:periodType="instant" nillable="true" substitutionGroup="xbrli:item"/> <element name="PercentageOfIncomeTaxPositionsLikelyToBeRealized" id="cytk_PercentageOfIncomeTaxPositionsLikelyToBeRealized" type="num:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/> <element name="PercentageOfOptionsGrantToNewEmployees" id="cytk_PercentageOfOptionsGrantToNewEmployees" type="num:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/> <element name="PeriodForPotentialTreatment" id="cytk_PeriodForPotentialTreatment" type="xbrli:durationItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/> <element name="PeriodFromPercentageOfStockOptionVested" id="cytk_PeriodFromPercentageOfStockOptionVested" type="xbrli:durationItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/> <element name="PotentialAmountsReceivableUnderCollaborationAgreement" id="cytk_PotentialAmountsReceivableUnderCollaborationAgreement" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item"/> <element name="PreferredStockConversionRatio" id="cytk_PreferredStockConversionRatio" type="xbrli:pureItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/> <element name="ProceedsAndPaymentsFromStockBasedAwardAndWarrantsNetOfIssuanceCosts" id="cytk_ProceedsAndPaymentsFromStockBasedAwardAndWarrantsNetOfIssuanceCosts" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item"/> <element name="ProceedsFromDrawDownOfCommittedEquityFinancingFacilitiesAndAtMarketFacilityNetOfIssuanceCosts" id="cytk_ProceedsFromDrawDownOfCommittedEquityFinancingFacilitiesAndAtMarketFacilityNetOfIssuanceCosts" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item"/> <element name="ProceedsFromIssuanceOfUnit" id="cytk_ProceedsFromIssuanceOfUnit" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item"/> <element name="ProceedsFromIssuanceOrSaleOfStockAndWarrant" id="cytk_ProceedsFromIssuanceOrSaleOfStockAndWarrant" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item"/> <element name="ProceedsFromSalesOfCommonStockNet" id="cytk_ProceedsFromSalesOfCommonStockNet" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item"/> <element name="PropertyPlantAndEquipmentUsefulLifeAndValuesAbstract" id="cytk_PropertyPlantAndEquipmentUsefulLifeAndValuesAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/> <element name="ProportionalPerformanceModelMember" id="cytk_ProportionalPerformanceModelMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/> <element name="ReimbursementOfInternalResearchAndDevelopmentCost" id="cytk_ReimbursementOfInternalResearchAndDevelopmentCost" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item"/> <element name="ReimbursementOfOtherResearchAndDevelopmentCost" id="cytk_ReimbursementOfOtherResearchAndDevelopmentCost" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item"/> <element name="RelatedPartyResearchAndDevelopmentRevenue" id="cytk_RelatedPartyResearchAndDevelopmentRevenue" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item"/> <element name="RelatedPartyTransactionCommercializationMilestonePaymentsReceivedByEntity" id="cytk_RelatedPartyTransactionCommercializationMilestonePaymentsReceivedByEntity" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item"/> <element name="RelatedPartyTransactionPreCommercializationMilestonePaymentsReceivedByEntity" id="cytk_RelatedPartyTransactionPreCommercializationMilestonePaymentsReceivedByEntity" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item"/> <element name="ResearchAndDevelopmentFederalTaxCreditCarryforwardsExpirationDateYear" id="cytk_ResearchAndDevelopmentFederalTaxCreditCarryforwardsExpirationDateYear" type="xbrli:gYearItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/> <element name="ResearchAndDevelopmentGrantAndOtherRevenues" id="cytk_ResearchAndDevelopmentGrantAndOtherRevenues" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item"/> <element name="ResearchAndDevelopmentRelatedPartyRevenue" id="cytk_ResearchAndDevelopmentRelatedPartyRevenue" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item"/> <element name="ResearchAndDevelopmentRevenue" id="cytk_ResearchAndDevelopmentRevenue" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item"/> <element name="ResearchAndDevelopmentRevenueFromCollaboration" id="cytk_ResearchAndDevelopmentRevenueFromCollaboration" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item"/> <element name="ResearchAndDevelopmentRevenuesFromRelatedParties" id="cytk_ResearchAndDevelopmentRevenuesFromRelatedParties" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item"/> <element name="ResearchCollaborationAndLicenseAgreementPeriod" id="cytk_ResearchCollaborationAndLicenseAgreementPeriod" type="xbrli:durationItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/> <element name="ResearchDevelopmentGrant" id="cytk_ResearchDevelopmentGrant" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item"/> <element name="ReverseStockSplitPolicyTextBlock" id="cytk_ReverseStockSplitPolicyTextBlock" type="nonnum:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/> <element name="ScheduleOfInterestExpenseTableTextBlock" id="cytk_ScheduleOfInterestExpenseTableTextBlock" type="nonnum:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/> <element name="ScheduleOfOtherRelatedPartyTransactionsLineItems" id="cytk_ScheduleOfOtherRelatedPartyTransactionsLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/> <element name="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedInPeriodWeightedAverageExercisePrice" id="cytk_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedInPeriodWeightedAverageExercisePrice" type="num:perShareItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/> <element name="ShareBasedCompensationArrangementByShareBasedPaymentSharesAvailableForGrantAwardOptionsExercisedInPeriodGross" id="cytk_ShareBasedCompensationArrangementByShareBasedPaymentSharesAvailableForGrantAwardOptionsExercisedInPeriodGross" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/> <element name="ShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentOtherThanOptionForfeituresInPeriodWeightedAverageExercisePrice" id="cytk_ShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentOtherThanOptionForfeituresInPeriodWeightedAverageExercisePrice" type="num:perShareItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/> <element name="ShareBasedCompensationLineItems" id="cytk_ShareBasedCompensationLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/> <element name="ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePrice" id="cytk_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePrice" type="num:perShareItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/> <element name="ShareBasedCompensationTable" id="cytk_ShareBasedCompensationTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem"/> <element name="SharesAvailableForGrantOfOptionsOrAwardsOptionsForfeitedExpired" id="cytk_SharesAvailableForGrantOfOptionsOrAwardsOptionsForfeitedExpired" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/> <element name="SmaAndOtherNeuromuscularIndicationsMember" id="cytk_SmaAndOtherNeuromuscularIndicationsMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/> <element name="SoftDollarArrangementsAbstract" id="cytk_SoftDollarArrangementsAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/> <element name="SpecifiedStockholderOwnershipPercentage" id="cytk_SpecifiedStockholderOwnershipPercentage" type="num:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/> <element name="StockIssuedDuringPeriodSharesAtMarketIssuanceSalesAgreement" id="cytk_StockIssuedDuringPeriodSharesAtMarketIssuanceSalesAgreement" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/> <element name="StockIssuedDuringPeriodSharesExerciseOfWarrants" id="cytk_StockIssuedDuringPeriodSharesExerciseOfWarrants" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/> <element name="StockIssuedDuringPeriodSharesNewIssuesToCollaborativePartner" id="cytk_StockIssuedDuringPeriodSharesNewIssuesToCollaborativePartner" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/> <element name="StockIssuedDuringPeriodSharesNewIssuesToRelatedParty" id="cytk_StockIssuedDuringPeriodSharesNewIssuesToRelatedParty" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/> <element name="StockIssuedDuringPeriodSharesSecuritiesPurchaseAgreement" id="cytk_StockIssuedDuringPeriodSharesSecuritiesPurchaseAgreement" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="instant" nillable="true" substitutionGroup="xbrli:item"/> <element name="StockIssuedDuringPeriodValueAtMarketIssuanceSalesAgreement" id="cytk_StockIssuedDuringPeriodValueAtMarketIssuanceSalesAgreement" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item"/> <element name="StockIssuedDuringPeriodValueExerciseOfWarrants" id="cytk_StockIssuedDuringPeriodValueExerciseOfWarrants" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item"/> <element name="StockIssuedDuringPeriodValueNewIssuesToCollaborativePartner" id="cytk_StockIssuedDuringPeriodValueNewIssuesToCollaborativePartner" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item"/> <element name="StockIssuedDuringPeriodValueNewIssuesToRelatedParty" id="cytk_StockIssuedDuringPeriodValueNewIssuesToRelatedParty" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item"/> <element name="StockIssuedDuringPeriodValueSecuritiesPurchaseAgreement" id="cytk_StockIssuedDuringPeriodValueSecuritiesPurchaseAgreement" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item"/> <element name="StockOptionsRepurchaseMaximumPeriod" id="cytk_StockOptionsRepurchaseMaximumPeriod" type="xbrli:durationItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/> <element name="SummaryOfSignificantAccountingPoliciesLineItems" id="cytk_SummaryOfSignificantAccountingPoliciesLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/> <element name="SummaryOfSignificantAccountingPoliciesTable" id="cytk_SummaryOfSignificantAccountingPoliciesTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem"/> <element name="TermForStockOptionPlan" id="cytk_TermForStockOptionPlan" type="xbrli:durationItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/> <element name="TermForStockOptionPlanForSpecifiedStockHolders" id="cytk_TermForStockOptionPlanForSpecifiedStockHolders" type="xbrli:durationItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/> <element name="TermToGrantNonstatutoryStockOptionsAndIncentiveStockOptions" id="cytk_TermToGrantNonstatutoryStockOptionsAndIncentiveStockOptions" type="xbrli:durationItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/> <element name="TwoThousandAndFourPlanMember" id="cytk_TwoThousandAndFourPlanMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/> <element name="UnderwrittenPublicOfferingMember" id="cytk_UnderwrittenPublicOfferingMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/> <element name="UnrecognizedIncomeTaxBenefitsNetOfFederalBenefitOfStateIncomeTaxUtbMember" id="cytk_UnrecognizedIncomeTaxBenefitsNetOfFederalBenefitOfStateIncomeTaxUtbMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/> <element name="WarrantExpirationDate" id="cytk_WarrantExpirationDate" type="xbrli:dateItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/> <element name="WarrantOneMember" id="cytk_WarrantOneMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/> <element name="WarrantsToPurchaseCommonStockMember" id="cytk_WarrantsToPurchaseCommonStockMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/> <element name="WarrantTwoMember" id="cytk_WarrantTwoMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/> </schema> </XBRL> </TEXT> </DOCUMENT> <DOCUMENT> <TYPE>EX-101.CAL <SEQUENCE>9 <FILENAME>cytk-20141231_cal.xml <DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE <TEXT> <XBRL> <?xml version="1.0" encoding="US-ASCII"?> <!-- RR Donnelley Xcelerate Taxonomy Calculation Linkbase, based on XBRL 2.1 http://www.rrdonnelley.com/ --> <!-- Version: 6.22.4 --> <!-- Round: 10 --> <!-- Creation date: 2015-03-05T19:06:47Z --> <!-- Copyright (c) 2005-2013 R.R. Donnelley & Sons Company All Rights Reserved. --> <linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"> <roleRef xlink:type="simple" xlink:href="cytk-20141231.xsd#DocumentandEntityInformation" roleURI="http://imetrix.edgar-online.com/taxonomy/role/DocumentandEntityInformation"/> <roleRef xlink:type="simple" xlink:href="cytk-20141231.xsd#Role_StatementOfFinancialPositionClassified" roleURI="http://imetrix.edgar-online.com/taxonomy/role/StatementOfFinancialPositionClassified"/> <roleRef xlink:type="simple" xlink:href="cytk-20141231.xsd#Role_StatementOfFinancialPositionClassifiedParen" roleURI="http://imetrix.edgar-online.com/taxonomy/role/StatementOfFinancialPositionClassifiedParenthetical"/> <roleRef xlink:type="simple" xlink:href="cytk-20141231.xsd#Role_StatementOfIncome" roleURI="http://imetrix.edgar-online.com/taxonomy/role/StatementOfIncome"/> <roleRef xlink:type="simple" xlink:href="cytk-20141231.xsd#Role_StatementOfShareholdersEquityAndOtherComprehensiveIncome" roleURI="http://imetrix.edgar-online.com/taxonomy/role/StatementOfShareholdersEquityAndOtherComprehensiveIncome"/> <roleRef xlink:type="simple" xlink:href="cytk-20141231.xsd#Role_StatementOfShareholdersEquityAndOtherComprehensiveIncomeParen" roleURI="http://imetrix.edgar-online.com/taxonomy/role/StatementOfShareholdersEquityAndOtherComprehensiveIncomeParenthetical"/> <roleRef xlink:type="simple" xlink:href="cytk-20141231.xsd#Role_StatementOfCashFlowsIndirect" roleURI="http://imetrix.edgar-online.com/taxonomy/role/StatementOfCashFlowsIndirect"/> <roleRef xlink:type="simple" xlink:href="cytk-20141231.xsd#DisclosureOrganizationAndSignificantAccountingPoliciesAdditionalInformation" roleURI="http://imetrix.edgar-online.com/taxonomy/role/DisclosureOrganizationAndSignificantAccountingPoliciesAdditionalInformation"/> <roleRef xlink:type="simple" xlink:href="cytk-20141231.xsd#DisclosureNetLossPerShareCalculationOfBasicAndDilutedNetLossPerShareAllocableToCommonStockholders" roleURI="http://imetrix.edgar-online.com/taxonomy/role/DisclosureNetLossPerShareCalculationOfBasicAndDilutedNetLossPerShareAllocableToCommonStockholders"/> <roleRef xlink:type="simple" xlink:href="cytk-20141231.xsd#DisclosureNetLossPerShareInstrumentsExcludedFromTheComputationOfDilutedNetLossPerCommonShare" roleURI="http://imetrix.edgar-online.com/taxonomy/role/DisclosureNetLossPerShareInstrumentsExcludedFromTheComputationOfDilutedNetLossPerCommonShare"/> <roleRef xlink:type="simple" xlink:href="cytk-20141231.xsd#DisclosureSupplementaryCashFlowDataSupplementalCashFlowInformation" roleURI="http://imetrix.edgar-online.com/taxonomy/role/DisclosureSupplementaryCashFlowDataSupplementalCashFlowInformation"/> <roleRef xlink:type="simple" xlink:href="cytk-20141231.xsd#DisclosureCashEquivalentsAndInvestmentsAmortizedCostAndFairValueOfCashEquivalentsAndAvailableForSaleInvestments" roleURI="http://imetrix.edgar-online.com/taxonomy/role/DisclosureCashEquivalentsAndInvestmentsAmortizedCostAndFairValueOfCashEquivalentsAndAvailableForSaleInvestments"/> <roleRef xlink:type="simple" xlink:href="cytk-20141231.xsd#DisclosureCashEquivalentsAndInvestmentsAdditionalInformation" roleURI="http://imetrix.edgar-online.com/taxonomy/role/DisclosureCashEquivalentsAndInvestmentsAdditionalInformation"/> <roleRef xlink:type="simple" xlink:href="cytk-20141231.xsd#DisclosureCashEquivalentsAndInvestmentsSummaryOfInterestIncome" roleURI="http://imetrix.edgar-online.com/taxonomy/role/DisclosureCashEquivalentsAndInvestmentsSummaryOfInterestIncome"/> <roleRef xlink:type="simple" xlink:href="cytk-20141231.xsd#DisclosureFairValueMeasurementsSummaryOfFinancialAssetsMeasuredAtFairValueOnRecurringBasis" roleURI="http://imetrix.edgar-online.com/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfFinancialAssetsMeasuredAtFairValueOnRecurringBasis"/> <roleRef xlink:type="simple" xlink:href="cytk-20141231.xsd#DisclosureFairValueMeasurementsAdditionalInformation" roleURI="http://imetrix.edgar-online.com/taxonomy/role/DisclosureFairValueMeasurementsAdditionalInformation"/> <roleRef xlink:type="simple" xlink:href="cytk-20141231.xsd#DisclosureBalanceSheetComponentsSummaryOfPropertyAndEquipmentBalances" roleURI="http://imetrix.edgar-online.com/taxonomy/role/DisclosureBalanceSheetComponentsSummaryOfPropertyAndEquipmentBalances"/> <roleRef xlink:type="simple" xlink:href="cytk-20141231.xsd#DisclosureBalanceSheetComponentsAdditionalInformation" roleURI="http://imetrix.edgar-online.com/taxonomy/role/DisclosureBalanceSheetComponentsAdditionalInformation"/> <roleRef xlink:type="simple" xlink:href="cytk-20141231.xsd#DisclosureBalanceSheetComponentsSummaryOfAccruedLiabilities" roleURI="http://imetrix.edgar-online.com/taxonomy/role/DisclosureBalanceSheetComponentsSummaryOfAccruedLiabilities"/> <roleRef xlink:type="simple" xlink:href="cytk-20141231.xsd#DisclosureRelatedPartiesAndRelatedPartyTransactionsAdditionalInformation" roleURI="http://imetrix.edgar-online.com/taxonomy/role/DisclosureRelatedPartiesAndRelatedPartyTransactionsAdditionalInformation"/> <roleRef xlink:type="simple" xlink:href="cytk-20141231.xsd#DisclosureRelatedPartiesAndRelatedPartyTransactionsRevenueFromRelatedParty" roleURI="http://imetrix.edgar-online.com/taxonomy/role/DisclosureRelatedPartiesAndRelatedPartyTransactionsRevenueFromRelatedParty"/> <roleRef xlink:type="simple" xlink:href="cytk-20141231.xsd#DisclosureOtherResearchAndDevelopmentRevenueArrangementsAdditionalInformation" roleURI="http://imetrix.edgar-online.com/taxonomy/role/DisclosureOtherResearchAndDevelopmentRevenueArrangementsAdditionalInformation"/> <roleRef xlink:type="simple" xlink:href="cytk-20141231.xsd#DisclosureOtherResearchAndDevelopmentRevenueArrangementsSummaryOfTotalGrantRevenues" roleURI="http://imetrix.edgar-online.com/taxonomy/role/DisclosureOtherResearchAndDevelopmentRevenueArrangementsSummaryOfTotalGrantRevenues"/> <roleRef xlink:type="simple" xlink:href="cytk-20141231.xsd#DisclosureOtherResearchAndDevelopmentRevenueArrangementsSummaryOfReimbursedExpenses" roleURI="http://imetrix.edgar-online.com/taxonomy/role/DisclosureOtherResearchAndDevelopmentRevenueArrangementsSummaryOfReimbursedExpenses"/> <roleRef xlink:type="simple" xlink:href="cytk-20141231.xsd#DisclosureDebtAdditionalInformation" roleURI="http://imetrix.edgar-online.com/taxonomy/role/DisclosureDebtAdditionalInformation"/> <roleRef xlink:type="simple" xlink:href="cytk-20141231.xsd#DisclosureDebtSummaryOfTotalInterestExpenseIncurred" roleURI="http://imetrix.edgar-online.com/taxonomy/role/DisclosureDebtSummaryOfTotalInterestExpenseIncurred"/> <roleRef xlink:type="simple" xlink:href="cytk-20141231.xsd#DisclosureCommitmentsAndContingenciesAdditionalInformation" roleURI="http://imetrix.edgar-online.com/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformation"/> <roleRef xlink:type="simple" xlink:href="cytk-20141231.xsd#DisclosureCommitmentsAndContingenciesRentExpense" roleURI="http://imetrix.edgar-online.com/taxonomy/role/DisclosureCommitmentsAndContingenciesRentExpense"/> <roleRef xlink:type="simple" xlink:href="cytk-20141231.xsd#DisclosureCommitmentsAndContingenciesFutureMinimumLeasePaymentsUnderNoncancelableOperatingLeases" roleURI="http://imetrix.edgar-online.com/taxonomy/role/DisclosureCommitmentsAndContingenciesFutureMinimumLeasePaymentsUnderNoncancelableOperatingLeases"/> <roleRef xlink:type="simple" xlink:href="cytk-20141231.xsd#DisclosureConvertiblePreferredStockAdditionalInformation" roleURI="http://imetrix.edgar-online.com/taxonomy/role/DisclosureConvertiblePreferredStockAdditionalInformation"/> <roleRef xlink:type="simple" xlink:href="cytk-20141231.xsd#DisclosureStockholdersEquityAdditionalInformation" roleURI="http://imetrix.edgar-online.com/taxonomy/role/DisclosureStockholdersEquityAdditionalInformation"/> <roleRef xlink:type="simple" xlink:href="cytk-20141231.xsd#DisclosureStockholdersEquityOutstandingWarrants" roleURI="http://imetrix.edgar-online.com/taxonomy/role/DisclosureStockholdersEquityOutstandingWarrants"/> <roleRef xlink:type="simple" xlink:href="cytk-20141231.xsd#DisclosureStockholdersEquitySummaryOfStockOptionActivity" roleURI="http://imetrix.edgar-online.com/taxonomy/role/DisclosureStockholdersEquitySummaryOfStockOptionActivity"/> <roleRef xlink:type="simple" xlink:href="cytk-20141231.xsd#DisclosureStockholdersEquitySummaryOfRestrictedStockUnitActivity" roleURI="http://imetrix.edgar-online.com/taxonomy/role/DisclosureStockholdersEquitySummaryOfRestrictedStockUnitActivity"/> <roleRef xlink:type="simple" xlink:href="cytk-20141231.xsd#DisclosureStockholdersEquityStockBasedCompensationRelatedToStockOptionsRestrictedStockAwardsRestrictedStockUnitAndEmployeeStockPurchases" roleURI="http://imetrix.edgar-online.com/taxonomy/role/DisclosureStockholdersEquityStockBasedCompensationRelatedToStockOptionsRestrictedStockAwardsRestrictedStockUnitAndEmployeeStockPurchases"/> <roleRef xlink:type="simple" xlink:href="cytk-20141231.xsd#DisclosureStockholdersEquityFairValueOfShareBasedPaymentsWasEstimatedOnDateOfGrantUsingBlackScholesOptionPricingModelBasedOnWeightedAverageAssumptions" roleURI="http://imetrix.edgar-online.com/taxonomy/role/DisclosureStockholdersEquityFairValueOfShareBasedPaymentsWasEstimatedOnDateOfGrantUsingBlackScholesOptionPricingModelBasedOnWeightedAverageAssumptions"/> <roleRef xlink:type="simple" xlink:href="cytk-20141231.xsd#DisclosureIncomeTaxesAdditionalInformation" roleURI="http://imetrix.edgar-online.com/taxonomy/role/DisclosureIncomeTaxesAdditionalInformation"/> <roleRef xlink:type="simple" xlink:href="cytk-20141231.xsd#DisclosureIncomeTaxesScheduleOfComponentsOfIncomeBeforeTaxes" roleURI="http://imetrix.edgar-online.com/taxonomy/role/DisclosureIncomeTaxesScheduleOfComponentsOfIncomeBeforeTaxes"/> <roleRef xlink:type="simple" xlink:href="cytk-20141231.xsd#DisclosureIncomeTaxesCompanyRecordedIncomeTaxProvision" roleURI="http://imetrix.edgar-online.com/taxonomy/role/DisclosureIncomeTaxesCompanyRecordedIncomeTaxProvision"/> <roleRef xlink:type="simple" xlink:href="cytk-20141231.xsd#DisclosureIncomeTaxesCompanysDeferredTaxAssetsAndLiabilities" roleURI="http://imetrix.edgar-online.com/taxonomy/role/DisclosureIncomeTaxesCompanysDeferredTaxAssetsAndLiabilities"/> <roleRef xlink:type="simple" xlink:href="cytk-20141231.xsd#DisclosureIncomeTaxesCompanysValuationAndQualifyingAccounts" roleURI="http://imetrix.edgar-online.com/taxonomy/role/DisclosureIncomeTaxesCompanysValuationAndQualifyingAccounts"/> <roleRef xlink:type="simple" xlink:href="cytk-20141231.xsd#DisclosureIncomeTaxesReconciliationOfStatutoryFederalIncomeTaxRateToEffectiveTaxRate" roleURI="http://imetrix.edgar-online.com/taxonomy/role/DisclosureIncomeTaxesReconciliationOfStatutoryFederalIncomeTaxRateToEffectiveTaxRate"/> <roleRef xlink:type="simple" xlink:href="cytk-20141231.xsd#DisclosureIncomeTaxesReconciliationOfTotalAmountsOfUnrecognizedTaxBenefits" roleURI="http://imetrix.edgar-online.com/taxonomy/role/DisclosureIncomeTaxesReconciliationOfTotalAmountsOfUnrecognizedTaxBenefits"/> <roleRef xlink:type="simple" xlink:href="cytk-20141231.xsd#DisclosureInterestAndOtherNetComponentsOfInterestAndOtherNet" roleURI="http://imetrix.edgar-online.com/taxonomy/role/DisclosureInterestAndOtherNetComponentsOfInterestAndOtherNet"/> <roleRef xlink:type="simple" xlink:href="cytk-20141231.xsd#DisclosureQuarterlyFinancialDataSummaryOfQuarterlyResults" roleURI="http://imetrix.edgar-online.com/taxonomy/role/DisclosureQuarterlyFinancialDataSummaryOfQuarterlyResults"/> <roleRef xlink:type="simple" xlink:href="cytk-20141231.xsd#Role_NotesToFinancialStatementsOrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" roleURI="http://imetrix.edgar-online.com/taxonomy/role/NotesToFinancialStatementsOrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock"/> <roleRef xlink:type="simple" xlink:href="cytk-20141231.xsd#Role_NotesToFinancialStatementsOrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlockPolicies" roleURI="http://imetrix.edgar-online.com/taxonomy/role/NotesToFinancialStatementsOrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlockPolicies"/> <roleRef xlink:type="simple" xlink:href="cytk-20141231.xsd#Role_NotesToFinancialStatementsEarningsPerShareTextBlock" roleURI="http://imetrix.edgar-online.com/taxonomy/role/NotesToFinancialStatementsEarningsPerShareTextBlock"/> <roleRef xlink:type="simple" xlink:href="cytk-20141231.xsd#Role_NotesToFinancialStatementsEarningsPerShareTextBlockTables" roleURI="http://imetrix.edgar-online.com/taxonomy/role/NotesToFinancialStatementsEarningsPerShareTextBlockTables"/> <roleRef xlink:type="simple" xlink:href="cytk-20141231.xsd#Role_NotesToFinancialStatementsCashFlowSupplementalDisclosuresTextBlock" roleURI="http://imetrix.edgar-online.com/taxonomy/role/NotesToFinancialStatementsCashFlowSupplementalDisclosuresTextBlock"/> <roleRef xlink:type="simple" xlink:href="cytk-20141231.xsd#Role_NotesToFinancialStatementsCashFlowSupplementalDisclosuresTextBlockTables" roleURI="http://imetrix.edgar-online.com/taxonomy/role/NotesToFinancialStatementsCashFlowSupplementalDisclosuresTextBlockTables"/> <roleRef xlink:type="simple" xlink:href="cytk-20141231.xsd#Role_NotesToFinancialStatementsInvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" roleURI="http://imetrix.edgar-online.com/taxonomy/role/NotesToFinancialStatementsInvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock"/> <roleRef xlink:type="simple" xlink:href="cytk-20141231.xsd#Role_NotesToFinancialStatementsInvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlockTables" roleURI="http://imetrix.edgar-online.com/taxonomy/role/NotesToFinancialStatementsInvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlockTables"/> <roleRef xlink:type="simple" xlink:href="cytk-20141231.xsd#Role_NotesToFinancialStatementsFairValueDisclosuresTextBlock" roleURI="http://imetrix.edgar-online.com/taxonomy/role/NotesToFinancialStatementsFairValueDisclosuresTextBlock"/> <roleRef xlink:type="simple" xlink:href="cytk-20141231.xsd#Role_NotesToFinancialStatementsFairValueDisclosuresTextBlockTables" roleURI="http://imetrix.edgar-online.com/taxonomy/role/NotesToFinancialStatementsFairValueDisclosuresTextBlockTables"/> <roleRef xlink:type="simple" xlink:href="cytk-20141231.xsd#Role_NotesToFinancialStatementsSupplementalBalanceSheetDisclosuresTextBlock" roleURI="http://imetrix.edgar-online.com/taxonomy/role/NotesToFinancialStatementsSupplementalBalanceSheetDisclosuresTextBlock"/> <roleRef xlink:type="simple" xlink:href="cytk-20141231.xsd#Role_NotesToFinancialStatementsSupplementalBalanceSheetDisclosuresTextBlockTables" roleURI="http://imetrix.edgar-online.com/taxonomy/role/NotesToFinancialStatementsSupplementalBalanceSheetDisclosuresTextBlockTables"/> <roleRef xlink:type="simple" xlink:href="cytk-20141231.xsd#Role_NotesToFinancialStatementsRelatedPartyTransactionsDisclosureTextBlock" roleURI="http://imetrix.edgar-online.com/taxonomy/role/NotesToFinancialStatementsRelatedPartyTransactionsDisclosureTextBlock"/> <roleRef xlink:type="simple" xlink:href="cytk-20141231.xsd#Role_NotesToFinancialStatementsRelatedPartyTransactionsDisclosureTextBlockTables" roleURI="http://imetrix.edgar-online.com/taxonomy/role/NotesToFinancialStatementsRelatedPartyTransactionsDisclosureTextBlockTables"/> <roleRef xlink:type="simple" xlink:href="cytk-20141231.xsd#Role_NotesToFinancialStatementsResearchDevelopmentAndComputerSoftwareDisclosureTextBlock" roleURI="http://imetrix.edgar-online.com/taxonomy/role/NotesToFinancialStatementsResearchDevelopmentAndComputerSoftwareDisclosureTextBlock"/> <roleRef xlink:type="simple" xlink:href="cytk-20141231.xsd#Role_NotesToFinancialStatementsResearchDevelopmentAndComputerSoftwareDisclosureTextBlockTables" roleURI="http://imetrix.edgar-online.com/taxonomy/role/NotesToFinancialStatementsResearchDevelopmentAndComputerSoftwareDisclosureTextBlockTables"/> <roleRef xlink:type="simple" xlink:href="cytk-20141231.xsd#Role_NotesToFinancialStatementsDebtDisclosureTextBlock" roleURI="http://imetrix.edgar-online.com/taxonomy/role/NotesToFinancialStatementsDebtDisclosureTextBlock"/> <roleRef xlink:type="simple" xlink:href="cytk-20141231.xsd#Role_NotesToFinancialStatementsDebtDisclosureTextBlockTables" roleURI="http://imetrix.edgar-online.com/taxonomy/role/NotesToFinancialStatementsDebtDisclosureTextBlockTables"/> <roleRef xlink:type="simple" xlink:href="cytk-20141231.xsd#Role_NotesToFinancialStatementsCommitmentsAndContingenciesDisclosureTextBlock" roleURI="http://imetrix.edgar-online.com/taxonomy/role/NotesToFinancialStatementsCommitmentsAndContingenciesDisclosureTextBlock"/> <roleRef xlink:type="simple" xlink:href="cytk-20141231.xsd#Role_NotesToFinancialStatementsCommitmentsAndContingenciesDisclosureTextBlockTables" roleURI="http://imetrix.edgar-online.com/taxonomy/role/NotesToFinancialStatementsCommitmentsAndContingenciesDisclosureTextBlockTables"/> <roleRef xlink:type="simple" xlink:href="cytk-20141231.xsd#Role_NotesToFinancialStatementsPreferredStockTextBlock" roleURI="http://imetrix.edgar-online.com/taxonomy/role/NotesToFinancialStatementsPreferredStockTextBlock"/> <roleRef xlink:type="simple" xlink:href="cytk-20141231.xsd#Role_NotesToFinancialStatementsStockholdersEquityNoteDisclosureTextBlock" roleURI="http://imetrix.edgar-online.com/taxonomy/role/NotesToFinancialStatementsStockholdersEquityNoteDisclosureTextBlock"/> <roleRef xlink:type="simple" xlink:href="cytk-20141231.xsd#Role_NotesToFinancialStatementsStockholdersEquityNoteDisclosureTextBlockTables" roleURI="http://imetrix.edgar-online.com/taxonomy/role/NotesToFinancialStatementsStockholdersEquityNoteDisclosureTextBlockTables"/> <roleRef xlink:type="simple" xlink:href="cytk-20141231.xsd#Role_NotesToFinancialStatementsIncomeTaxDisclosureTextBlock" roleURI="http://imetrix.edgar-online.com/taxonomy/role/NotesToFinancialStatementsIncomeTaxDisclosureTextBlock"/> <roleRef xlink:type="simple" xlink:href="cytk-20141231.xsd#Role_NotesToFinancialStatementsIncomeTaxDisclosureTextBlockTables" roleURI="http://imetrix.edgar-online.com/taxonomy/role/NotesToFinancialStatementsIncomeTaxDisclosureTextBlockTables"/> <roleRef xlink:type="simple" xlink:href="cytk-20141231.xsd#Role_NotesToFinancialStatementsOtherIncomeAndOtherExpenseDisclosureTextBlock" roleURI="http://imetrix.edgar-online.com/taxonomy/role/NotesToFinancialStatementsOtherIncomeAndOtherExpenseDisclosureTextBlock"/> <roleRef xlink:type="simple" xlink:href="cytk-20141231.xsd#Role_NotesToFinancialStatementsOtherIncomeAndOtherExpenseDisclosureTextBlockTables" roleURI="http://imetrix.edgar-online.com/taxonomy/role/NotesToFinancialStatementsOtherIncomeAndOtherExpenseDisclosureTextBlockTables"/> <roleRef xlink:type="simple" xlink:href="cytk-20141231.xsd#Role_NotesToFinancialStatementsQuarterlyFinancialInformationTextBlock" roleURI="http://imetrix.edgar-online.com/taxonomy/role/NotesToFinancialStatementsQuarterlyFinancialInformationTextBlock"/> <roleRef xlink:type="simple" xlink:href="cytk-20141231.xsd#Role_NotesToFinancialStatementsQuarterlyFinancialInformationTextBlockTables" roleURI="http://imetrix.edgar-online.com/taxonomy/role/NotesToFinancialStatementsQuarterlyFinancialInformationTextBlockTables"/> <calculationLink xlink:type="extended" xlink:role="http://imetrix.edgar-online.com/taxonomy/role/DocumentandEntityInformation"> </calculationLink> <calculationLink xlink:type="extended" xlink:role="http://imetrix.edgar-online.com/taxonomy/role/StatementOfFinancialPositionClassified"> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AccountsReceivableRelatedPartiesCurrent" xlink:label="us-gaap_AccountsReceivableRelatedPartiesCurrent"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="us-gaap_AdditionalPaidInCapital"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DeferredRentCreditCurrent" xlink:label="us-gaap_DeferredRentCreditCurrent"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DeferredRentCreditNoncurrent" xlink:label="us-gaap_DeferredRentCreditNoncurrent"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DeferredRevenueCurrent" xlink:label="us-gaap_DeferredRevenueCurrent"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DeferredRevenueNoncurrent" xlink:label="us-gaap_DeferredRevenueNoncurrent"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LongTermInvestments" xlink:label="us-gaap_LongTermInvestments"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OtherAssetsCurrent" xlink:label="us-gaap_OtherAssetsCurrent"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="us-gaap_OtherAssetsNoncurrent"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PreferredStockValue" xlink:label="us-gaap_PreferredStockValue"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity"/> <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_AssetsCurrent" order="1.0500" weight="1.00" priority="2" use="optional"/> <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" order="1.0600" weight="1.00" priority="2" use="optional"/> <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_LongTermInvestments" order="1.0700" weight="1.00" priority="2" use="optional"/> <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_OtherAssetsNoncurrent" order="1.0800" weight="1.00" priority="2" use="optional"/> <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="1.0100" weight="1.00" priority="2" use="optional"/> <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" order="1.0200" weight="1.00" priority="2" use="optional"/> <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AccountsReceivableRelatedPartiesCurrent" order="1.0300" weight="1.00" priority="2" use="optional"/> <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_OtherAssetsCurrent" order="1.0400" weight="1.00" priority="2" use="optional"/> <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_LiabilitiesCurrent" order="1.1300" weight="1.00" priority="2" use="optional"/> <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_DeferredRevenueNoncurrent" order="1.1400" weight="1.00" priority="2" use="optional"/> <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_DeferredRentCreditNoncurrent" order="1.1500" weight="1.00" priority="2" use="optional"/> <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_Liabilities" order="1.1600" weight="1.00" priority="2" use="optional"/> <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_StockholdersEquity" order="1.2100" weight="1.00" priority="2" use="optional"/> <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_AccountsPayableCurrent" order="1.0900" weight="1.00" priority="2" use="optional"/> <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_AccruedLiabilitiesCurrent" order="1.1000" weight="1.00" priority="2" use="optional"/> <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_DeferredRevenueCurrent" order="1.1100" weight="1.00" priority="2" use="optional"/> <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_DeferredRentCreditCurrent" order="1.1200" weight="1.00" priority="2" use="optional"/> <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_CommonStockValue" order="1.1700" weight="1.00" priority="2" use="optional"/> <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_AdditionalPaidInCapital" order="1.1800" weight="1.00" priority="2" use="optional"/> <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" order="1.1900" weight="1.00" priority="2" use="optional"/> <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" order="1.2000" weight="1.00" priority="2" use="optional"/> <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_PreferredStockValue" order="1.2200" weight="1.00" priority="2" use="optional"/> </calculationLink> <calculationLink xlink:type="extended" xlink:role="http://imetrix.edgar-online.com/taxonomy/role/StatementOfFinancialPositionClassifiedParenthetical"> </calculationLink> <calculationLink xlink:type="extended" xlink:role="http://imetrix.edgar-online.com/taxonomy/role/StatementOfIncome"> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CostsAndExpenses" xlink:label="us-gaap_CostsAndExpenses"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LicenseAndServicesRevenue" xlink:label="us-gaap_LicenseAndServicesRevenue"/> <loc xlink:type="locator" xlink:href="cytk-20141231.xsd#cytk_LicenseRevenuesFromRelatedParties" xlink:label="cytk_LicenseRevenuesFromRelatedParties"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="us-gaap_NonoperatingIncomeExpense"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:label="us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense"/> <loc xlink:type="locator" xlink:href="cytk-20141231.xsd#cytk_ResearchAndDevelopmentGrantAndOtherRevenues" xlink:label="cytk_ResearchAndDevelopmentGrantAndOtherRevenues"/> <loc xlink:type="locator" xlink:href="cytk-20141231.xsd#cytk_ResearchAndDevelopmentRevenuesFromRelatedParties" xlink:label="cytk_ResearchAndDevelopmentRevenuesFromRelatedParties"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RestructuringCharges" xlink:label="us-gaap_RestructuringCharges"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_Revenues" xlink:label="us-gaap_Revenues"/> <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="us-gaap_NetIncomeLoss" order="1.1400" weight="1.00" priority="2" use="optional"/> <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" order="1.1600" weight="1.00" priority="2" use="optional"/> <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CostsAndExpenses" xlink:to="us-gaap_ResearchAndDevelopmentExpense" order="1.0600" weight="1.00" priority="2" use="optional"/> <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CostsAndExpenses" xlink:to="us-gaap_GeneralAndAdministrativeExpense" order="1.0700" weight="1.00" priority="2" use="optional"/> <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CostsAndExpenses" xlink:to="us-gaap_RestructuringCharges" order="1.0800" weight="1.00" priority="2" use="optional"/> <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:to="us-gaap_OperatingIncomeLoss" order="1.1000" weight="1.00" priority="2" use="optional"/> <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:to="us-gaap_NonoperatingIncomeExpense" order="1.1100" weight="1.00" priority="2" use="optional"/> <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" order="1.1200" weight="1.00" priority="2" use="optional"/> <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_IncomeTaxExpenseBenefit" order="1.1300" weight="-1.00" priority="2" use="optional"/> <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_Revenues" order="1.0500" weight="1.00" priority="2" use="optional"/> <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_CostsAndExpenses" order="1.0900" weight="-1.00" priority="2" use="optional"/> <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Revenues" xlink:to="cytk_ResearchAndDevelopmentRevenuesFromRelatedParties" order="1.0100" weight="1.00" priority="2" use="optional"/> <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Revenues" xlink:to="cytk_ResearchAndDevelopmentGrantAndOtherRevenues" order="1.0200" weight="1.00" priority="2" use="optional"/> <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Revenues" xlink:to="cytk_LicenseRevenuesFromRelatedParties" order="1.0300" weight="1.00" priority="2" use="optional"/> <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Revenues" xlink:to="us-gaap_LicenseAndServicesRevenue" order="1.0400" weight="1.00" priority="2" use="optional"/> </calculationLink> <calculationLink xlink:type="extended" xlink:role="http://imetrix.edgar-online.com/taxonomy/role/StatementOfShareholdersEquityAndOtherComprehensiveIncome"> </calculationLink> <calculationLink xlink:type="extended" xlink:role="http://imetrix.edgar-online.com/taxonomy/role/StatementOfShareholdersEquityAndOtherComprehensiveIncomeParenthetical"> </calculationLink> <calculationLink xlink:type="extended" xlink:role="http://imetrix.edgar-online.com/taxonomy/role/StatementOfCashFlowsIndirect"> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:label="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="us-gaap_DepreciationDepletionAndAmortization"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:label="us-gaap_GainLossOnSaleOfPropertyPlantEquipment"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_GainOnSaleOfInvestments" xlink:label="us-gaap_GainOnSaleOfInvestments"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableTrade" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableTrade"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:label="us-gaap_IncreaseDecreaseInDeferredRevenue"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncreaseDecreaseInDueFromRelatedPartiesCurrent" xlink:label="us-gaap_IncreaseDecreaseInDueFromRelatedPartiesCurrent"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncreaseDecreaseInDueToRelatedPartiesCurrent" xlink:label="us-gaap_IncreaseDecreaseInDueToRelatedPartiesCurrent"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncreaseDecreaseInRestrictedCash" xlink:label="us-gaap_IncreaseDecreaseInRestrictedCash"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:label="us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/> <loc xlink:type="locator" xlink:href="cytk-20141231.xsd#cytk_ProceedsAndPaymentsFromStockBasedAwardAndWarrantsNetOfIssuanceCosts" xlink:label="cytk_ProceedsAndPaymentsFromStockBasedAwardAndWarrantsNetOfIssuanceCosts"/> <loc xlink:type="locator" xlink:href="cytk-20141231.xsd#cytk_ProceedsFromDrawDownOfCommittedEquityFinancingFacilitiesAndAtMarketFacilityNetOfIssuanceCosts" xlink:label="cytk_ProceedsFromDrawDownOfCommittedEquityFinancingFacilitiesAndAtMarketFacilityNetOfIssuanceCosts"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock" xlink:label="us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" xlink:label="us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:label="us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RepaymentsOfSecuredDebt" xlink:label="us-gaap_RepaymentsOfSecuredDebt"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RestructuringCostsAndAssetImpairmentCharges" xlink:label="us-gaap_RestructuringCostsAndAssetImpairmentCharges"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation"/> <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" order="1.1300" weight="1.00" priority="2" use="optional"/> <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" order="1.1900" weight="1.00" priority="2" use="optional"/> <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" order="1.2500" weight="1.00" priority="2" use="optional"/> <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" order="1.2000" weight="1.00" priority="2" use="optional"/> <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" xlink:to="cytk_ProceedsFromDrawDownOfCommittedEquityFinancingFacilitiesAndAtMarketFacilityNetOfIssuanceCosts" order="1.2100" weight="1.00" priority="2" use="optional"/> <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" xlink:to="cytk_ProceedsAndPaymentsFromStockBasedAwardAndWarrantsNetOfIssuanceCosts" order="1.2200" weight="-1.00" priority="2" use="optional"/> <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" xlink:to="us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock" order="1.2300" weight="1.00" priority="2" use="optional"/> <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" xlink:to="us-gaap_RepaymentsOfSecuredDebt" order="1.2400" weight="-1.00" priority="2" use="optional"/> <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" xlink:to="us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" order="1.1400" weight="-1.00" priority="2" use="optional"/> <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" xlink:to="us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" order="1.1500" weight="1.00" priority="2" use="optional"/> <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" order="1.1600" weight="-1.00" priority="2" use="optional"/> <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" xlink:to="us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" order="1.1700" weight="1.00" priority="2" use="optional"/> <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" xlink:to="us-gaap_IncreaseDecreaseInRestrictedCash" order="1.1800" weight="-1.00" priority="2" use="optional"/> <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="us-gaap_NetIncomeLoss" order="1.0100" weight="1.00" priority="2" use="optional"/> <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="us-gaap_DepreciationDepletionAndAmortization" order="1.0200" weight="1.00" priority="2" use="optional"/> <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="us-gaap_GainLossOnSaleOfPropertyPlantEquipment" order="1.0300" weight="-1.00" priority="2" use="optional"/> <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="us-gaap_RestructuringCostsAndAssetImpairmentCharges" order="1.0400" weight="1.00" priority="2" use="optional"/> <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="us-gaap_ShareBasedCompensation" order="1.0500" weight="1.00" priority="2" use="optional"/> <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="us-gaap_GainOnSaleOfInvestments" order="1.0600" weight="-1.00" priority="2" use="optional"/> <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="us-gaap_IncreaseDecreaseInDueFromRelatedPartiesCurrent" order="1.0700" weight="-1.00" priority="2" use="optional"/> <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" order="1.0800" weight="-1.00" priority="2" use="optional"/> <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayableTrade" order="1.0900" weight="1.00" priority="2" use="optional"/> <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilities" order="1.1000" weight="1.00" priority="2" use="optional"/> <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="us-gaap_IncreaseDecreaseInDueToRelatedPartiesCurrent" order="1.1100" weight="1.00" priority="2" use="optional"/> <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="us-gaap_IncreaseDecreaseInDeferredRevenue" order="1.1200" weight="1.00" priority="2" use="optional"/> </calculationLink> <calculationLink xlink:type="extended" xlink:role="http://imetrix.edgar-online.com/taxonomy/role/DisclosureOrganizationAndSignificantAccountingPoliciesAdditionalInformation"> </calculationLink> <calculationLink xlink:type="extended" xlink:role="http://imetrix.edgar-online.com/taxonomy/role/DisclosureNetLossPerShareCalculationOfBasicAndDilutedNetLossPerShareAllocableToCommonStockholders"> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OtherPreferredStockDividendsAndAdjustments" xlink:label="us-gaap_OtherPreferredStockDividendsAndAdjustments"/> <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:to="us-gaap_NetIncomeLoss" order="1.0100" weight="1.00" priority="2" use="optional"/> <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:to="us-gaap_OtherPreferredStockDividendsAndAdjustments" order="1.0200" weight="-1.00" priority="2" use="optional"/> </calculationLink> <calculationLink xlink:type="extended" xlink:role="http://imetrix.edgar-online.com/taxonomy/role/DisclosureNetLossPerShareInstrumentsExcludedFromTheComputationOfDilutedNetLossPerCommonShare"> </calculationLink> <calculationLink xlink:type="extended" xlink:role="http://imetrix.edgar-online.com/taxonomy/role/DisclosureSupplementaryCashFlowDataSupplementalCashFlowInformation"> </calculationLink> <calculationLink xlink:type="extended" xlink:role="http://imetrix.edgar-online.com/taxonomy/role/DisclosureCashEquivalentsAndInvestmentsAmortizedCostAndFairValueOfCashEquivalentsAndAvailableForSaleInvestments"> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AvailableForSaleSecurities" xlink:label="us-gaap_AvailableForSaleSecurities"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:label="us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:label="us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/> <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:to="us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" order="1.0100" weight="-1.00" priority="2" use="optional"/> <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:to="us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" order="1.0200" weight="1.00" priority="2" use="optional"/> <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:to="us-gaap_AvailableForSaleSecurities" order="1.0300" weight="1.00" priority="2" use="optional"/> </calculationLink> <calculationLink xlink:type="extended" xlink:role="http://imetrix.edgar-online.com/taxonomy/role/DisclosureCashEquivalentsAndInvestmentsAdditionalInformation"> </calculationLink> <calculationLink xlink:type="extended" xlink:role="http://imetrix.edgar-online.com/taxonomy/role/DisclosureCashEquivalentsAndInvestmentsSummaryOfInterestIncome"> </calculationLink> <calculationLink xlink:type="extended" xlink:role="http://imetrix.edgar-online.com/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfFinancialAssetsMeasuredAtFairValueOnRecurringBasis"> </calculationLink> <calculationLink xlink:type="extended" xlink:role="http://imetrix.edgar-online.com/taxonomy/role/DisclosureFairValueMeasurementsAdditionalInformation"> </calculationLink> <calculationLink xlink:type="extended" xlink:role="http://imetrix.edgar-online.com/taxonomy/role/DisclosureBalanceSheetComponentsSummaryOfPropertyAndEquipmentBalances"> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="us-gaap_PropertyPlantAndEquipmentGross"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet"/> <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentGross" order="1.0200" weight="1.00" priority="2" use="optional"/> <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" order="1.0300" weight="-1.00" priority="2" use="optional"/> </calculationLink> <calculationLink xlink:type="extended" xlink:role="http://imetrix.edgar-online.com/taxonomy/role/DisclosureBalanceSheetComponentsAdditionalInformation"> </calculationLink> <calculationLink xlink:type="extended" xlink:role="http://imetrix.edgar-online.com/taxonomy/role/DisclosureBalanceSheetComponentsSummaryOfAccruedLiabilities"> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AccruedBonusesCurrent" xlink:label="us-gaap_AccruedBonusesCurrent"/> <loc xlink:type="locator" xlink:href="cytk-20141231.xsd#cytk_AccruedClinicalAndPreclinicalCostsCurrent" xlink:label="cytk_AccruedClinicalAndPreclinicalCostsCurrent"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AccruedProfessionalFeesCurrent" xlink:label="us-gaap_AccruedProfessionalFeesCurrent"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AccruedVacationCurrent" xlink:label="us-gaap_AccruedVacationCurrent"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OtherEmployeeRelatedLiabilitiesCurrent" xlink:label="us-gaap_OtherEmployeeRelatedLiabilitiesCurrent"/> <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="cytk_AccruedClinicalAndPreclinicalCostsCurrent" order="1.0100" weight="1.00" priority="2" use="optional"/> <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="us-gaap_AccruedProfessionalFeesCurrent" order="1.0200" weight="1.00" priority="2" use="optional"/> <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="us-gaap_AccruedBonusesCurrent" order="1.0300" weight="1.00" priority="2" use="optional"/> <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="us-gaap_AccruedVacationCurrent" order="1.0400" weight="1.00" priority="2" use="optional"/> <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="us-gaap_OtherEmployeeRelatedLiabilitiesCurrent" order="1.0500" weight="1.00" priority="2" use="optional"/> <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrent" order="1.0600" weight="1.00" priority="2" use="optional"/> </calculationLink> <calculationLink xlink:type="extended" xlink:role="http://imetrix.edgar-online.com/taxonomy/role/DisclosureRelatedPartiesAndRelatedPartyTransactionsAdditionalInformation"> </calculationLink> <calculationLink xlink:type="extended" xlink:role="http://imetrix.edgar-online.com/taxonomy/role/DisclosureRelatedPartiesAndRelatedPartyTransactionsRevenueFromRelatedParty"> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LicenseAndServicesRevenue" xlink:label="us-gaap_LicenseAndServicesRevenue"/> <loc xlink:type="locator" xlink:href="cytk-20141231.xsd#cytk_ReimbursementOfInternalResearchAndDevelopmentCost" xlink:label="cytk_ReimbursementOfInternalResearchAndDevelopmentCost"/> <loc xlink:type="locator" xlink:href="cytk-20141231.xsd#cytk_ReimbursementOfOtherResearchAndDevelopmentCost" xlink:label="cytk_ReimbursementOfOtherResearchAndDevelopmentCost"/> <loc xlink:type="locator" xlink:href="cytk-20141231.xsd#cytk_RelatedPartyResearchAndDevelopmentRevenue" xlink:label="cytk_RelatedPartyResearchAndDevelopmentRevenue"/> <loc xlink:type="locator" xlink:href="cytk-20141231.xsd#cytk_ResearchAndDevelopmentRelatedPartyRevenue" xlink:label="cytk_ResearchAndDevelopmentRelatedPartyRevenue"/> <loc xlink:type="locator" xlink:href="cytk-20141231.xsd#cytk_ResearchAndDevelopmentRevenue" xlink:label="cytk_ResearchAndDevelopmentRevenue"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RevenueFromRelatedParties" xlink:label="us-gaap_RevenueFromRelatedParties"/> <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="cytk_RelatedPartyResearchAndDevelopmentRevenue" xlink:to="cytk_ResearchAndDevelopmentRelatedPartyRevenue" order="1.0100" weight="1.00" priority="2" use="optional"/> <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="cytk_RelatedPartyResearchAndDevelopmentRevenue" xlink:to="us-gaap_LicenseAndServicesRevenue" order="1.0200" weight="1.00" priority="2" use="optional"/> <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="cytk_RelatedPartyResearchAndDevelopmentRevenue" xlink:to="cytk_ReimbursementOfInternalResearchAndDevelopmentCost" order="1.0300" weight="1.00" priority="2" use="optional"/> <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="cytk_RelatedPartyResearchAndDevelopmentRevenue" xlink:to="cytk_ReimbursementOfOtherResearchAndDevelopmentCost" order="1.0400" weight="1.00" priority="2" use="optional"/> <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="cytk_RelatedPartyResearchAndDevelopmentRevenue" xlink:to="us-gaap_RevenueFromRelatedParties" order="1.0500" weight="1.00" priority="2" use="optional"/> <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="cytk_RelatedPartyResearchAndDevelopmentRevenue" xlink:to="cytk_ResearchAndDevelopmentRevenue" order="1.0600" weight="1.00" priority="2" use="optional"/> </calculationLink> <calculationLink xlink:type="extended" xlink:role="http://imetrix.edgar-online.com/taxonomy/role/DisclosureOtherResearchAndDevelopmentRevenueArrangementsAdditionalInformation"> </calculationLink> <calculationLink xlink:type="extended" xlink:role="http://imetrix.edgar-online.com/taxonomy/role/DisclosureOtherResearchAndDevelopmentRevenueArrangementsSummaryOfTotalGrantRevenues"> </calculationLink> <calculationLink xlink:type="extended" xlink:role="http://imetrix.edgar-online.com/taxonomy/role/DisclosureOtherResearchAndDevelopmentRevenueArrangementsSummaryOfReimbursedExpenses"> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ReimbursementRevenue" xlink:label="us-gaap_ReimbursementRevenue"/> <loc xlink:type="locator" xlink:href="cytk-20141231.xsd#cytk_ResearchAndDevelopmentRevenue" xlink:label="cytk_ResearchAndDevelopmentRevenue"/> <loc xlink:type="locator" xlink:href="cytk-20141231.xsd#cytk_ResearchAndDevelopmentRevenueFromCollaboration" xlink:label="cytk_ResearchAndDevelopmentRevenueFromCollaboration"/> <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="cytk_ResearchAndDevelopmentRevenueFromCollaboration" xlink:to="cytk_ResearchAndDevelopmentRevenue" order="1.0100" weight="1.00" priority="2" use="optional"/> <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="cytk_ResearchAndDevelopmentRevenueFromCollaboration" xlink:to="us-gaap_ReimbursementRevenue" order="1.0200" weight="1.00" priority="2" use="optional"/> </calculationLink> <calculationLink xlink:type="extended" xlink:role="http://imetrix.edgar-online.com/taxonomy/role/DisclosureDebtAdditionalInformation"> </calculationLink> <calculationLink xlink:type="extended" xlink:role="http://imetrix.edgar-online.com/taxonomy/role/DisclosureDebtSummaryOfTotalInterestExpenseIncurred"> </calculationLink> <calculationLink xlink:type="extended" xlink:role="http://imetrix.edgar-online.com/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformation"> </calculationLink> <calculationLink xlink:type="extended" xlink:role="http://imetrix.edgar-online.com/taxonomy/role/DisclosureCommitmentsAndContingenciesRentExpense"> </calculationLink> <calculationLink xlink:type="extended" xlink:role="http://imetrix.edgar-online.com/taxonomy/role/DisclosureCommitmentsAndContingenciesFutureMinimumLeasePaymentsUnderNoncancelableOperatingLeases"> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDue"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter"/> <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent" order="1.0100" weight="1.00" priority="2" use="optional"/> <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears" order="1.0200" weight="1.00" priority="2" use="optional"/> <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears" order="1.0300" weight="1.00" priority="2" use="optional"/> <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears" order="1.0400" weight="1.00" priority="2" use="optional"/> <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears" order="1.0500" weight="1.00" priority="2" use="optional"/> <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter" order="1.0600" weight="1.00" priority="2" use="optional"/> </calculationLink> <calculationLink xlink:type="extended" xlink:role="http://imetrix.edgar-online.com/taxonomy/role/DisclosureConvertiblePreferredStockAdditionalInformation"> </calculationLink> <calculationLink xlink:type="extended" xlink:role="http://imetrix.edgar-online.com/taxonomy/role/DisclosureStockholdersEquityAdditionalInformation"> </calculationLink> <calculationLink xlink:type="extended" xlink:role="http://imetrix.edgar-online.com/taxonomy/role/DisclosureStockholdersEquityOutstandingWarrants"> </calculationLink> <calculationLink xlink:type="extended" xlink:role="http://imetrix.edgar-online.com/taxonomy/role/DisclosureStockholdersEquitySummaryOfStockOptionActivity"> </calculationLink> <calculationLink xlink:type="extended" xlink:role="http://imetrix.edgar-online.com/taxonomy/role/DisclosureStockholdersEquitySummaryOfRestrictedStockUnitActivity"> </calculationLink> <calculationLink xlink:type="extended" xlink:role="http://imetrix.edgar-online.com/taxonomy/role/DisclosureStockholdersEquityStockBasedCompensationRelatedToStockOptionsRestrictedStockAwardsRestrictedStockUnitAndEmployeeStockPurchases"> </calculationLink> <calculationLink xlink:type="extended" xlink:role="http://imetrix.edgar-online.com/taxonomy/role/DisclosureStockholdersEquityFairValueOfShareBasedPaymentsWasEstimatedOnDateOfGrantUsingBlackScholesOptionPricingModelBasedOnWeightedAverageAssumptions"> </calculationLink> <calculationLink xlink:type="extended" xlink:role="http://imetrix.edgar-online.com/taxonomy/role/DisclosureIncomeTaxesAdditionalInformation"> </calculationLink> <calculationLink xlink:type="extended" xlink:role="http://imetrix.edgar-online.com/taxonomy/role/DisclosureIncomeTaxesScheduleOfComponentsOfIncomeBeforeTaxes"> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments"/> <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" order="1.0100" weight="1.00" priority="2" use="optional"/> <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" order="1.0200" weight="1.00" priority="2" use="optional"/> </calculationLink> <calculationLink xlink:type="extended" xlink:role="http://imetrix.edgar-online.com/taxonomy/role/DisclosureIncomeTaxesCompanyRecordedIncomeTaxProvision"> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CurrentFederalTaxExpenseBenefit" xlink:label="us-gaap_CurrentFederalTaxExpenseBenefit"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:label="us-gaap_CurrentIncomeTaxExpenseBenefit"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:label="us-gaap_CurrentStateAndLocalTaxExpenseBenefit"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:label="us-gaap_DeferredFederalIncomeTaxExpenseBenefit"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefit"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:label="us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit"/> <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:to="us-gaap_CurrentFederalTaxExpenseBenefit" order="1.0100" weight="1.00" priority="2" use="optional"/> <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:to="us-gaap_CurrentStateAndLocalTaxExpenseBenefit" order="1.0200" weight="1.00" priority="2" use="optional"/> <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:to="us-gaap_DeferredFederalIncomeTaxExpenseBenefit" order="1.0300" weight="1.00" priority="2" use="optional"/> <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:to="us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" order="1.0400" weight="1.00" priority="2" use="optional"/> </calculationLink> <calculationLink xlink:type="extended" xlink:role="http://imetrix.edgar-online.com/taxonomy/role/DisclosureIncomeTaxesCompanysDeferredTaxAssetsAndLiabilities"> <loc xlink:type="locator" xlink:href="cytk-20141231.xsd#cytk_DeferredTaxAssetsCapitalizedResearchAndDevelopment" xlink:label="cytk_DeferredTaxAssetsCapitalizedResearchAndDevelopment"/> <loc xlink:type="locator" xlink:href="cytk-20141231.xsd#cytk_DeferredTaxAssetsDepreciationAndAmortization" xlink:label="cytk_DeferredTaxAssetsDepreciationAndAmortization"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="us-gaap_DeferredTaxAssetsGross"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="us-gaap_DeferredTaxAssetsNet"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwards" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwards"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance"/> <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="cytk_DeferredTaxAssetsDepreciationAndAmortization" order="1.0100" weight="1.00" priority="2" use="optional"/> <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="cytk_DeferredTaxAssetsCapitalizedResearchAndDevelopment" order="1.0200" weight="1.00" priority="2" use="optional"/> <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals" order="1.0300" weight="1.00" priority="2" use="optional"/> <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" order="1.0400" weight="1.00" priority="2" use="optional"/> <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsTaxCreditCarryforwards" order="1.0500" weight="1.00" priority="2" use="optional"/> <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsNet" xlink:to="us-gaap_DeferredTaxAssetsGross" order="1.0600" weight="1.00" priority="2" use="optional"/> <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsNet" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance" order="1.0700" weight="-1.00" priority="2" use="optional"/> </calculationLink> <calculationLink xlink:type="extended" xlink:role="http://imetrix.edgar-online.com/taxonomy/role/DisclosureIncomeTaxesCompanysValuationAndQualifyingAccounts"> </calculationLink> <calculationLink xlink:type="extended" xlink:role="http://imetrix.edgar-online.com/taxonomy/role/DisclosureIncomeTaxesReconciliationOfStatutoryFederalIncomeTaxRateToEffectiveTaxRate"> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate"/> <loc xlink:type="locator" xlink:href="cytk-20141231.xsd#cytk_EffectiveIncomeTaxRateReconciliationDeferredTaxAssetsUtilizedNotBenefited" xlink:label="cytk_EffectiveIncomeTaxRateReconciliationDeferredTaxAssetsUtilizedNotBenefited"/> <loc xlink:type="locator" xlink:href="cytk-20141231.xsd#cytk_EffectiveIncomeTaxRateReconciliationNetOperatingLossExpiration" xlink:label="cytk_EffectiveIncomeTaxRateReconciliationNetOperatingLossExpiration"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes"/> <loc xlink:type="locator" xlink:href="cytk-20141231.xsd#cytk_EffectiveIncomeTaxRateReconciliationStateApportionment" xlink:label="cytk_EffectiveIncomeTaxRateReconciliationStateApportionment"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits"/> <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" order="1.0100" weight="1.00" priority="2" use="optional"/> <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" order="1.0200" weight="1.00" priority="2" use="optional"/> <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="cytk_EffectiveIncomeTaxRateReconciliationStateApportionment" order="1.0300" weight="1.00" priority="2" use="optional"/> <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits" order="1.0400" weight="1.00" priority="2" use="optional"/> <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="cytk_EffectiveIncomeTaxRateReconciliationDeferredTaxAssetsUtilizedNotBenefited" order="1.0500" weight="1.00" priority="2" use="optional"/> <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" order="1.0600" weight="1.00" priority="2" use="optional"/> <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="cytk_EffectiveIncomeTaxRateReconciliationNetOperatingLossExpiration" order="1.0700" weight="1.00" priority="2" use="optional"/> <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" order="1.0800" weight="1.00" priority="2" use="optional"/> </calculationLink> <calculationLink xlink:type="extended" xlink:role="http://imetrix.edgar-online.com/taxonomy/role/DisclosureIncomeTaxesReconciliationOfTotalAmountsOfUnrecognizedTaxBenefits"> </calculationLink> <calculationLink xlink:type="extended" xlink:role="http://imetrix.edgar-online.com/taxonomy/role/DisclosureInterestAndOtherNetComponentsOfInterestAndOtherNet"> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_InterestAndDebtExpense" xlink:label="us-gaap_InterestAndDebtExpense"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_InterestAndOtherIncome" xlink:label="us-gaap_InterestAndOtherIncome"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="us-gaap_NonoperatingIncomeExpense"/> <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="us-gaap_InterestAndOtherIncome" order="1.0100" weight="1.00" priority="2" use="optional"/> <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="us-gaap_InterestAndDebtExpense" order="1.0200" weight="-1.00" priority="2" use="optional"/> </calculationLink> <calculationLink xlink:type="extended" xlink:role="http://imetrix.edgar-online.com/taxonomy/role/DisclosureQuarterlyFinancialDataSummaryOfQuarterlyResults"> </calculationLink> <calculationLink xlink:type="extended" xlink:role="http://imetrix.edgar-online.com/taxonomy/role/NotesToFinancialStatementsOrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock"> </calculationLink> <calculationLink xlink:type="extended" xlink:role="http://imetrix.edgar-online.com/taxonomy/role/NotesToFinancialStatementsOrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlockPolicies"> </calculationLink> <calculationLink xlink:type="extended" xlink:role="http://imetrix.edgar-online.com/taxonomy/role/NotesToFinancialStatementsEarningsPerShareTextBlock"> </calculationLink> <calculationLink xlink:type="extended" xlink:role="http://imetrix.edgar-online.com/taxonomy/role/NotesToFinancialStatementsEarningsPerShareTextBlockTables"> </calculationLink> <calculationLink xlink:type="extended" xlink:role="http://imetrix.edgar-online.com/taxonomy/role/NotesToFinancialStatementsCashFlowSupplementalDisclosuresTextBlock"> </calculationLink> <calculationLink xlink:type="extended" xlink:role="http://imetrix.edgar-online.com/taxonomy/role/NotesToFinancialStatementsCashFlowSupplementalDisclosuresTextBlockTables"> </calculationLink> <calculationLink xlink:type="extended" xlink:role="http://imetrix.edgar-online.com/taxonomy/role/NotesToFinancialStatementsInvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock"> </calculationLink> <calculationLink xlink:type="extended" xlink:role="http://imetrix.edgar-online.com/taxonomy/role/NotesToFinancialStatementsInvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlockTables"> </calculationLink> <calculationLink xlink:type="extended" xlink:role="http://imetrix.edgar-online.com/taxonomy/role/NotesToFinancialStatementsFairValueDisclosuresTextBlock"> </calculationLink> <calculationLink xlink:type="extended" xlink:role="http://imetrix.edgar-online.com/taxonomy/role/NotesToFinancialStatementsFairValueDisclosuresTextBlockTables"> </calculationLink> <calculationLink xlink:type="extended" xlink:role="http://imetrix.edgar-online.com/taxonomy/role/NotesToFinancialStatementsSupplementalBalanceSheetDisclosuresTextBlock"> </calculationLink> <calculationLink xlink:type="extended" xlink:role="http://imetrix.edgar-online.com/taxonomy/role/NotesToFinancialStatementsSupplementalBalanceSheetDisclosuresTextBlockTables"> </calculationLink> <calculationLink xlink:type="extended" xlink:role="http://imetrix.edgar-online.com/taxonomy/role/NotesToFinancialStatementsRelatedPartyTransactionsDisclosureTextBlock"> </calculationLink> <calculationLink xlink:type="extended" xlink:role="http://imetrix.edgar-online.com/taxonomy/role/NotesToFinancialStatementsRelatedPartyTransactionsDisclosureTextBlockTables"> </calculationLink> <calculationLink xlink:type="extended" xlink:role="http://imetrix.edgar-online.com/taxonomy/role/NotesToFinancialStatementsResearchDevelopmentAndComputerSoftwareDisclosureTextBlock"> </calculationLink> <calculationLink xlink:type="extended" xlink:role="http://imetrix.edgar-online.com/taxonomy/role/NotesToFinancialStatementsResearchDevelopmentAndComputerSoftwareDisclosureTextBlockTables"> </calculationLink> <calculationLink xlink:type="extended" xlink:role="http://imetrix.edgar-online.com/taxonomy/role/NotesToFinancialStatementsDebtDisclosureTextBlock"> </calculationLink> <calculationLink xlink:type="extended" xlink:role="http://imetrix.edgar-online.com/taxonomy/role/NotesToFinancialStatementsDebtDisclosureTextBlockTables"> </calculationLink> <calculationLink xlink:type="extended" xlink:role="http://imetrix.edgar-online.com/taxonomy/role/NotesToFinancialStatementsCommitmentsAndContingenciesDisclosureTextBlock"> </calculationLink> <calculationLink xlink:type="extended" xlink:role="http://imetrix.edgar-online.com/taxonomy/role/NotesToFinancialStatementsCommitmentsAndContingenciesDisclosureTextBlockTables"> </calculationLink> <calculationLink xlink:type="extended" xlink:role="http://imetrix.edgar-online.com/taxonomy/role/NotesToFinancialStatementsPreferredStockTextBlock"> </calculationLink> <calculationLink xlink:type="extended" xlink:role="http://imetrix.edgar-online.com/taxonomy/role/NotesToFinancialStatementsStockholdersEquityNoteDisclosureTextBlock"> </calculationLink> <calculationLink xlink:type="extended" xlink:role="http://imetrix.edgar-online.com/taxonomy/role/NotesToFinancialStatementsStockholdersEquityNoteDisclosureTextBlockTables"> </calculationLink> <calculationLink xlink:type="extended" xlink:role="http://imetrix.edgar-online.com/taxonomy/role/NotesToFinancialStatementsIncomeTaxDisclosureTextBlock"> </calculationLink> <calculationLink xlink:type="extended" xlink:role="http://imetrix.edgar-online.com/taxonomy/role/NotesToFinancialStatementsIncomeTaxDisclosureTextBlockTables"> </calculationLink> <calculationLink xlink:type="extended" xlink:role="http://imetrix.edgar-online.com/taxonomy/role/NotesToFinancialStatementsOtherIncomeAndOtherExpenseDisclosureTextBlock"> </calculationLink> <calculationLink xlink:type="extended" xlink:role="http://imetrix.edgar-online.com/taxonomy/role/NotesToFinancialStatementsOtherIncomeAndOtherExpenseDisclosureTextBlockTables"> </calculationLink> <calculationLink xlink:type="extended" xlink:role="http://imetrix.edgar-online.com/taxonomy/role/NotesToFinancialStatementsQuarterlyFinancialInformationTextBlock"> </calculationLink> <calculationLink xlink:type="extended" xlink:role="http://imetrix.edgar-online.com/taxonomy/role/NotesToFinancialStatementsQuarterlyFinancialInformationTextBlockTables"> </calculationLink> </linkbase> </XBRL> </TEXT> </DOCUMENT> <DOCUMENT> <TYPE>EX-101.DEF <SEQUENCE>10 <FILENAME>cytk-20141231_def.xml <DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE <TEXT> <XBRL> <?xml version="1.0" encoding="US-ASCII"?> <!-- RR Donnelley Xcelerate Taxonomy Definition Linkbase, based on XBRL 2.1 http://www.rrdonnelley.com/ --> <!-- Version: 6.22.4 --> <!-- Round: 10 --> <!-- Creation date: 2015-03-05T19:06:47Z --> <!-- Copyright (c) 2005-2013 R.R. Donnelley & Sons Company All Rights Reserved. --> <linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"> <roleRef xlink:type="simple" xlink:href="cytk-20141231.xsd#DocumentandEntityInformation" roleURI="http://imetrix.edgar-online.com/taxonomy/role/DocumentandEntityInformation"/> <roleRef xlink:type="simple" xlink:href="cytk-20141231.xsd#Role_StatementOfFinancialPositionClassified" roleURI="http://imetrix.edgar-online.com/taxonomy/role/StatementOfFinancialPositionClassified"/> <roleRef xlink:type="simple" xlink:href="cytk-20141231.xsd#Role_StatementOfFinancialPositionClassifiedParen" roleURI="http://imetrix.edgar-online.com/taxonomy/role/StatementOfFinancialPositionClassifiedParenthetical"/> <roleRef xlink:type="simple" xlink:href="cytk-20141231.xsd#Role_StatementOfIncome" roleURI="http://imetrix.edgar-online.com/taxonomy/role/StatementOfIncome"/> <roleRef xlink:type="simple" xlink:href="cytk-20141231.xsd#Role_StatementOfShareholdersEquityAndOtherComprehensiveIncome" roleURI="http://imetrix.edgar-online.com/taxonomy/role/StatementOfShareholdersEquityAndOtherComprehensiveIncome"/> <roleRef xlink:type="simple" xlink:href="cytk-20141231.xsd#Role_StatementOfShareholdersEquityAndOtherComprehensiveIncomeParen" roleURI="http://imetrix.edgar-online.com/taxonomy/role/StatementOfShareholdersEquityAndOtherComprehensiveIncomeParenthetical"/> <roleRef xlink:type="simple" xlink:href="cytk-20141231.xsd#Role_StatementOfCashFlowsIndirect" roleURI="http://imetrix.edgar-online.com/taxonomy/role/StatementOfCashFlowsIndirect"/> <roleRef xlink:type="simple" xlink:href="cytk-20141231.xsd#DisclosureOrganizationAndSignificantAccountingPoliciesAdditionalInformation" roleURI="http://imetrix.edgar-online.com/taxonomy/role/DisclosureOrganizationAndSignificantAccountingPoliciesAdditionalInformation"/> <roleRef xlink:type="simple" xlink:href="cytk-20141231.xsd#DisclosureNetLossPerShareCalculationOfBasicAndDilutedNetLossPerShareAllocableToCommonStockholders" roleURI="http://imetrix.edgar-online.com/taxonomy/role/DisclosureNetLossPerShareCalculationOfBasicAndDilutedNetLossPerShareAllocableToCommonStockholders"/> <roleRef xlink:type="simple" xlink:href="cytk-20141231.xsd#DisclosureNetLossPerShareInstrumentsExcludedFromTheComputationOfDilutedNetLossPerCommonShare" roleURI="http://imetrix.edgar-online.com/taxonomy/role/DisclosureNetLossPerShareInstrumentsExcludedFromTheComputationOfDilutedNetLossPerCommonShare"/> <roleRef xlink:type="simple" xlink:href="cytk-20141231.xsd#DisclosureSupplementaryCashFlowDataSupplementalCashFlowInformation" roleURI="http://imetrix.edgar-online.com/taxonomy/role/DisclosureSupplementaryCashFlowDataSupplementalCashFlowInformation"/> <roleRef xlink:type="simple" xlink:href="cytk-20141231.xsd#DisclosureCashEquivalentsAndInvestmentsAmortizedCostAndFairValueOfCashEquivalentsAndAvailableForSaleInvestments" roleURI="http://imetrix.edgar-online.com/taxonomy/role/DisclosureCashEquivalentsAndInvestmentsAmortizedCostAndFairValueOfCashEquivalentsAndAvailableForSaleInvestments"/> <roleRef xlink:type="simple" xlink:href="cytk-20141231.xsd#DisclosureCashEquivalentsAndInvestmentsAdditionalInformation" roleURI="http://imetrix.edgar-online.com/taxonomy/role/DisclosureCashEquivalentsAndInvestmentsAdditionalInformation"/> <roleRef xlink:type="simple" xlink:href="cytk-20141231.xsd#DisclosureCashEquivalentsAndInvestmentsSummaryOfInterestIncome" roleURI="http://imetrix.edgar-online.com/taxonomy/role/DisclosureCashEquivalentsAndInvestmentsSummaryOfInterestIncome"/> <roleRef xlink:type="simple" xlink:href="cytk-20141231.xsd#DisclosureFairValueMeasurementsSummaryOfFinancialAssetsMeasuredAtFairValueOnRecurringBasis" roleURI="http://imetrix.edgar-online.com/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfFinancialAssetsMeasuredAtFairValueOnRecurringBasis"/> <roleRef xlink:type="simple" xlink:href="cytk-20141231.xsd#DisclosureFairValueMeasurementsAdditionalInformation" roleURI="http://imetrix.edgar-online.com/taxonomy/role/DisclosureFairValueMeasurementsAdditionalInformation"/> <roleRef xlink:type="simple" xlink:href="cytk-20141231.xsd#DisclosureBalanceSheetComponentsSummaryOfPropertyAndEquipmentBalances" roleURI="http://imetrix.edgar-online.com/taxonomy/role/DisclosureBalanceSheetComponentsSummaryOfPropertyAndEquipmentBalances"/> <roleRef xlink:type="simple" xlink:href="cytk-20141231.xsd#DisclosureBalanceSheetComponentsAdditionalInformation" roleURI="http://imetrix.edgar-online.com/taxonomy/role/DisclosureBalanceSheetComponentsAdditionalInformation"/> <roleRef xlink:type="simple" xlink:href="cytk-20141231.xsd#DisclosureBalanceSheetComponentsSummaryOfAccruedLiabilities" roleURI="http://imetrix.edgar-online.com/taxonomy/role/DisclosureBalanceSheetComponentsSummaryOfAccruedLiabilities"/> <roleRef xlink:type="simple" xlink:href="cytk-20141231.xsd#DisclosureRelatedPartiesAndRelatedPartyTransactionsAdditionalInformation" roleURI="http://imetrix.edgar-online.com/taxonomy/role/DisclosureRelatedPartiesAndRelatedPartyTransactionsAdditionalInformation"/> <roleRef xlink:type="simple" xlink:href="cytk-20141231.xsd#DisclosureRelatedPartiesAndRelatedPartyTransactionsRevenueFromRelatedParty" roleURI="http://imetrix.edgar-online.com/taxonomy/role/DisclosureRelatedPartiesAndRelatedPartyTransactionsRevenueFromRelatedParty"/> <roleRef xlink:type="simple" xlink:href="cytk-20141231.xsd#DisclosureOtherResearchAndDevelopmentRevenueArrangementsAdditionalInformation" roleURI="http://imetrix.edgar-online.com/taxonomy/role/DisclosureOtherResearchAndDevelopmentRevenueArrangementsAdditionalInformation"/> <roleRef xlink:type="simple" xlink:href="cytk-20141231.xsd#DisclosureOtherResearchAndDevelopmentRevenueArrangementsSummaryOfTotalGrantRevenues" roleURI="http://imetrix.edgar-online.com/taxonomy/role/DisclosureOtherResearchAndDevelopmentRevenueArrangementsSummaryOfTotalGrantRevenues"/> <roleRef xlink:type="simple" xlink:href="cytk-20141231.xsd#DisclosureOtherResearchAndDevelopmentRevenueArrangementsSummaryOfReimbursedExpenses" roleURI="http://imetrix.edgar-online.com/taxonomy/role/DisclosureOtherResearchAndDevelopmentRevenueArrangementsSummaryOfReimbursedExpenses"/> <roleRef xlink:type="simple" xlink:href="cytk-20141231.xsd#DisclosureDebtAdditionalInformation" roleURI="http://imetrix.edgar-online.com/taxonomy/role/DisclosureDebtAdditionalInformation"/> <roleRef xlink:type="simple" xlink:href="cytk-20141231.xsd#DisclosureDebtSummaryOfTotalInterestExpenseIncurred" roleURI="http://imetrix.edgar-online.com/taxonomy/role/DisclosureDebtSummaryOfTotalInterestExpenseIncurred"/> <roleRef xlink:type="simple" xlink:href="cytk-20141231.xsd#DisclosureCommitmentsAndContingenciesAdditionalInformation" roleURI="http://imetrix.edgar-online.com/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformation"/> <roleRef xlink:type="simple" xlink:href="cytk-20141231.xsd#DisclosureCommitmentsAndContingenciesRentExpense" roleURI="http://imetrix.edgar-online.com/taxonomy/role/DisclosureCommitmentsAndContingenciesRentExpense"/> <roleRef xlink:type="simple" xlink:href="cytk-20141231.xsd#DisclosureCommitmentsAndContingenciesFutureMinimumLeasePaymentsUnderNoncancelableOperatingLeases" roleURI="http://imetrix.edgar-online.com/taxonomy/role/DisclosureCommitmentsAndContingenciesFutureMinimumLeasePaymentsUnderNoncancelableOperatingLeases"/> <roleRef xlink:type="simple" xlink:href="cytk-20141231.xsd#DisclosureConvertiblePreferredStockAdditionalInformation" roleURI="http://imetrix.edgar-online.com/taxonomy/role/DisclosureConvertiblePreferredStockAdditionalInformation"/> <roleRef xlink:type="simple" xlink:href="cytk-20141231.xsd#DisclosureStockholdersEquityAdditionalInformation" roleURI="http://imetrix.edgar-online.com/taxonomy/role/DisclosureStockholdersEquityAdditionalInformation"/> <roleRef xlink:type="simple" xlink:href="cytk-20141231.xsd#DisclosureStockholdersEquityOutstandingWarrants" roleURI="http://imetrix.edgar-online.com/taxonomy/role/DisclosureStockholdersEquityOutstandingWarrants"/> <roleRef xlink:type="simple" xlink:href="cytk-20141231.xsd#DisclosureStockholdersEquitySummaryOfStockOptionActivity" roleURI="http://imetrix.edgar-online.com/taxonomy/role/DisclosureStockholdersEquitySummaryOfStockOptionActivity"/> <roleRef xlink:type="simple" xlink:href="cytk-20141231.xsd#DisclosureStockholdersEquitySummaryOfRestrictedStockUnitActivity" roleURI="http://imetrix.edgar-online.com/taxonomy/role/DisclosureStockholdersEquitySummaryOfRestrictedStockUnitActivity"/> <roleRef xlink:type="simple" xlink:href="cytk-20141231.xsd#DisclosureStockholdersEquityStockBasedCompensationRelatedToStockOptionsRestrictedStockAwardsRestrictedStockUnitAndEmployeeStockPurchases" roleURI="http://imetrix.edgar-online.com/taxonomy/role/DisclosureStockholdersEquityStockBasedCompensationRelatedToStockOptionsRestrictedStockAwardsRestrictedStockUnitAndEmployeeStockPurchases"/> <roleRef xlink:type="simple" xlink:href="cytk-20141231.xsd#DisclosureStockholdersEquityFairValueOfShareBasedPaymentsWasEstimatedOnDateOfGrantUsingBlackScholesOptionPricingModelBasedOnWeightedAverageAssumptions" roleURI="http://imetrix.edgar-online.com/taxonomy/role/DisclosureStockholdersEquityFairValueOfShareBasedPaymentsWasEstimatedOnDateOfGrantUsingBlackScholesOptionPricingModelBasedOnWeightedAverageAssumptions"/> <roleRef xlink:type="simple" xlink:href="cytk-20141231.xsd#DisclosureIncomeTaxesAdditionalInformation" roleURI="http://imetrix.edgar-online.com/taxonomy/role/DisclosureIncomeTaxesAdditionalInformation"/> <roleRef xlink:type="simple" xlink:href="cytk-20141231.xsd#DisclosureIncomeTaxesScheduleOfComponentsOfIncomeBeforeTaxes" roleURI="http://imetrix.edgar-online.com/taxonomy/role/DisclosureIncomeTaxesScheduleOfComponentsOfIncomeBeforeTaxes"/> <roleRef xlink:type="simple" xlink:href="cytk-20141231.xsd#DisclosureIncomeTaxesCompanyRecordedIncomeTaxProvision" roleURI="http://imetrix.edgar-online.com/taxonomy/role/DisclosureIncomeTaxesCompanyRecordedIncomeTaxProvision"/> <roleRef xlink:type="simple" xlink:href="cytk-20141231.xsd#DisclosureIncomeTaxesCompanysDeferredTaxAssetsAndLiabilities" roleURI="http://imetrix.edgar-online.com/taxonomy/role/DisclosureIncomeTaxesCompanysDeferredTaxAssetsAndLiabilities"/> <roleRef xlink:type="simple" xlink:href="cytk-20141231.xsd#DisclosureIncomeTaxesCompanysValuationAndQualifyingAccounts" roleURI="http://imetrix.edgar-online.com/taxonomy/role/DisclosureIncomeTaxesCompanysValuationAndQualifyingAccounts"/> <roleRef xlink:type="simple" xlink:href="cytk-20141231.xsd#DisclosureIncomeTaxesReconciliationOfStatutoryFederalIncomeTaxRateToEffectiveTaxRate" roleURI="http://imetrix.edgar-online.com/taxonomy/role/DisclosureIncomeTaxesReconciliationOfStatutoryFederalIncomeTaxRateToEffectiveTaxRate"/> <roleRef xlink:type="simple" xlink:href="cytk-20141231.xsd#DisclosureIncomeTaxesReconciliationOfTotalAmountsOfUnrecognizedTaxBenefits" roleURI="http://imetrix.edgar-online.com/taxonomy/role/DisclosureIncomeTaxesReconciliationOfTotalAmountsOfUnrecognizedTaxBenefits"/> <roleRef xlink:type="simple" xlink:href="cytk-20141231.xsd#DisclosureInterestAndOtherNetComponentsOfInterestAndOtherNet" roleURI="http://imetrix.edgar-online.com/taxonomy/role/DisclosureInterestAndOtherNetComponentsOfInterestAndOtherNet"/> <roleRef xlink:type="simple" xlink:href="cytk-20141231.xsd#DisclosureQuarterlyFinancialDataSummaryOfQuarterlyResults" roleURI="http://imetrix.edgar-online.com/taxonomy/role/DisclosureQuarterlyFinancialDataSummaryOfQuarterlyResults"/> <roleRef xlink:type="simple" xlink:href="cytk-20141231.xsd#Role_NotesToFinancialStatementsOrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" roleURI="http://imetrix.edgar-online.com/taxonomy/role/NotesToFinancialStatementsOrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock"/> <roleRef xlink:type="simple" xlink:href="cytk-20141231.xsd#Role_NotesToFinancialStatementsOrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlockPolicies" roleURI="http://imetrix.edgar-online.com/taxonomy/role/NotesToFinancialStatementsOrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlockPolicies"/> <roleRef xlink:type="simple" xlink:href="cytk-20141231.xsd#Role_NotesToFinancialStatementsEarningsPerShareTextBlock" roleURI="http://imetrix.edgar-online.com/taxonomy/role/NotesToFinancialStatementsEarningsPerShareTextBlock"/> <roleRef xlink:type="simple" xlink:href="cytk-20141231.xsd#Role_NotesToFinancialStatementsEarningsPerShareTextBlockTables" roleURI="http://imetrix.edgar-online.com/taxonomy/role/NotesToFinancialStatementsEarningsPerShareTextBlockTables"/> <roleRef xlink:type="simple" xlink:href="cytk-20141231.xsd#Role_NotesToFinancialStatementsCashFlowSupplementalDisclosuresTextBlock" roleURI="http://imetrix.edgar-online.com/taxonomy/role/NotesToFinancialStatementsCashFlowSupplementalDisclosuresTextBlock"/> <roleRef xlink:type="simple" xlink:href="cytk-20141231.xsd#Role_NotesToFinancialStatementsCashFlowSupplementalDisclosuresTextBlockTables" roleURI="http://imetrix.edgar-online.com/taxonomy/role/NotesToFinancialStatementsCashFlowSupplementalDisclosuresTextBlockTables"/> <roleRef xlink:type="simple" xlink:href="cytk-20141231.xsd#Role_NotesToFinancialStatementsInvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" roleURI="http://imetrix.edgar-online.com/taxonomy/role/NotesToFinancialStatementsInvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock"/> <roleRef xlink:type="simple" xlink:href="cytk-20141231.xsd#Role_NotesToFinancialStatementsInvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlockTables" roleURI="http://imetrix.edgar-online.com/taxonomy/role/NotesToFinancialStatementsInvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlockTables"/> <roleRef xlink:type="simple" xlink:href="cytk-20141231.xsd#Role_NotesToFinancialStatementsFairValueDisclosuresTextBlock" roleURI="http://imetrix.edgar-online.com/taxonomy/role/NotesToFinancialStatementsFairValueDisclosuresTextBlock"/> <roleRef xlink:type="simple" xlink:href="cytk-20141231.xsd#Role_NotesToFinancialStatementsFairValueDisclosuresTextBlockTables" roleURI="http://imetrix.edgar-online.com/taxonomy/role/NotesToFinancialStatementsFairValueDisclosuresTextBlockTables"/> <roleRef xlink:type="simple" xlink:href="cytk-20141231.xsd#Role_NotesToFinancialStatementsSupplementalBalanceSheetDisclosuresTextBlock" roleURI="http://imetrix.edgar-online.com/taxonomy/role/NotesToFinancialStatementsSupplementalBalanceSheetDisclosuresTextBlock"/> <roleRef xlink:type="simple" xlink:href="cytk-20141231.xsd#Role_NotesToFinancialStatementsSupplementalBalanceSheetDisclosuresTextBlockTables" roleURI="http://imetrix.edgar-online.com/taxonomy/role/NotesToFinancialStatementsSupplementalBalanceSheetDisclosuresTextBlockTables"/> <roleRef xlink:type="simple" xlink:href="cytk-20141231.xsd#Role_NotesToFinancialStatementsRelatedPartyTransactionsDisclosureTextBlock" roleURI="http://imetrix.edgar-online.com/taxonomy/role/NotesToFinancialStatementsRelatedPartyTransactionsDisclosureTextBlock"/> <roleRef xlink:type="simple" xlink:href="cytk-20141231.xsd#Role_NotesToFinancialStatementsRelatedPartyTransactionsDisclosureTextBlockTables" roleURI="http://imetrix.edgar-online.com/taxonomy/role/NotesToFinancialStatementsRelatedPartyTransactionsDisclosureTextBlockTables"/> <roleRef xlink:type="simple" xlink:href="cytk-20141231.xsd#Role_NotesToFinancialStatementsResearchDevelopmentAndComputerSoftwareDisclosureTextBlock" roleURI="http://imetrix.edgar-online.com/taxonomy/role/NotesToFinancialStatementsResearchDevelopmentAndComputerSoftwareDisclosureTextBlock"/> <roleRef xlink:type="simple" xlink:href="cytk-20141231.xsd#Role_NotesToFinancialStatementsResearchDevelopmentAndComputerSoftwareDisclosureTextBlockTables" roleURI="http://imetrix.edgar-online.com/taxonomy/role/NotesToFinancialStatementsResearchDevelopmentAndComputerSoftwareDisclosureTextBlockTables"/> <roleRef xlink:type="simple" xlink:href="cytk-20141231.xsd#Role_NotesToFinancialStatementsDebtDisclosureTextBlock" roleURI="http://imetrix.edgar-online.com/taxonomy/role/NotesToFinancialStatementsDebtDisclosureTextBlock"/> <roleRef xlink:type="simple" xlink:href="cytk-20141231.xsd#Role_NotesToFinancialStatementsDebtDisclosureTextBlockTables" roleURI="http://imetrix.edgar-online.com/taxonomy/role/NotesToFinancialStatementsDebtDisclosureTextBlockTables"/> <roleRef xlink:type="simple" xlink:href="cytk-20141231.xsd#Role_NotesToFinancialStatementsCommitmentsAndContingenciesDisclosureTextBlock" roleURI="http://imetrix.edgar-online.com/taxonomy/role/NotesToFinancialStatementsCommitmentsAndContingenciesDisclosureTextBlock"/> <roleRef xlink:type="simple" xlink:href="cytk-20141231.xsd#Role_NotesToFinancialStatementsCommitmentsAndContingenciesDisclosureTextBlockTables" roleURI="http://imetrix.edgar-online.com/taxonomy/role/NotesToFinancialStatementsCommitmentsAndContingenciesDisclosureTextBlockTables"/> <roleRef xlink:type="simple" xlink:href="cytk-20141231.xsd#Role_NotesToFinancialStatementsPreferredStockTextBlock" roleURI="http://imetrix.edgar-online.com/taxonomy/role/NotesToFinancialStatementsPreferredStockTextBlock"/> <roleRef xlink:type="simple" xlink:href="cytk-20141231.xsd#Role_NotesToFinancialStatementsStockholdersEquityNoteDisclosureTextBlock" roleURI="http://imetrix.edgar-online.com/taxonomy/role/NotesToFinancialStatementsStockholdersEquityNoteDisclosureTextBlock"/> <roleRef xlink:type="simple" xlink:href="cytk-20141231.xsd#Role_NotesToFinancialStatementsStockholdersEquityNoteDisclosureTextBlockTables" roleURI="http://imetrix.edgar-online.com/taxonomy/role/NotesToFinancialStatementsStockholdersEquityNoteDisclosureTextBlockTables"/> <roleRef xlink:type="simple" xlink:href="cytk-20141231.xsd#Role_NotesToFinancialStatementsIncomeTaxDisclosureTextBlock" roleURI="http://imetrix.edgar-online.com/taxonomy/role/NotesToFinancialStatementsIncomeTaxDisclosureTextBlock"/> <roleRef xlink:type="simple" xlink:href="cytk-20141231.xsd#Role_NotesToFinancialStatementsIncomeTaxDisclosureTextBlockTables" roleURI="http://imetrix.edgar-online.com/taxonomy/role/NotesToFinancialStatementsIncomeTaxDisclosureTextBlockTables"/> <roleRef xlink:type="simple" xlink:href="cytk-20141231.xsd#Role_NotesToFinancialStatementsOtherIncomeAndOtherExpenseDisclosureTextBlock" roleURI="http://imetrix.edgar-online.com/taxonomy/role/NotesToFinancialStatementsOtherIncomeAndOtherExpenseDisclosureTextBlock"/> <roleRef xlink:type="simple" xlink:href="cytk-20141231.xsd#Role_NotesToFinancialStatementsOtherIncomeAndOtherExpenseDisclosureTextBlockTables" roleURI="http://imetrix.edgar-online.com/taxonomy/role/NotesToFinancialStatementsOtherIncomeAndOtherExpenseDisclosureTextBlockTables"/> <roleRef xlink:type="simple" xlink:href="cytk-20141231.xsd#Role_NotesToFinancialStatementsQuarterlyFinancialInformationTextBlock" roleURI="http://imetrix.edgar-online.com/taxonomy/role/NotesToFinancialStatementsQuarterlyFinancialInformationTextBlock"/> <roleRef xlink:type="simple" xlink:href="cytk-20141231.xsd#Role_NotesToFinancialStatementsQuarterlyFinancialInformationTextBlockTables" roleURI="http://imetrix.edgar-online.com/taxonomy/role/NotesToFinancialStatementsQuarterlyFinancialInformationTextBlockTables"/> <arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" arcroleURI="http://xbrl.org/int/dim/arcrole/all"/> <arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default"/> <arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain"/> <arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member"/> <arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension"/> <definitionLink xlink:type="extended" xlink:role="http://imetrix.edgar-online.com/taxonomy/role/DocumentandEntityInformation"> </definitionLink> <definitionLink xlink:type="extended" xlink:role="http://imetrix.edgar-online.com/taxonomy/role/StatementOfFinancialPositionClassified"> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AccountsReceivableRelatedPartiesCurrent" xlink:label="us-gaap_AccountsReceivableRelatedPartiesCurrent"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="us-gaap_AdditionalPaidInCapital"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AssetsAbstract" xlink:label="us-gaap_AssetsAbstract"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="us-gaap_AssetsCurrentAbstract"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="us-gaap_CommitmentsAndContingencies"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DeferredRentCreditCurrent" xlink:label="us-gaap_DeferredRentCreditCurrent"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DeferredRentCreditNoncurrent" xlink:label="us-gaap_DeferredRentCreditNoncurrent"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DeferredRevenueCurrent" xlink:label="us-gaap_DeferredRevenueCurrent"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DeferredRevenueNoncurrent" xlink:label="us-gaap_DeferredRevenueNoncurrent"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LongTermInvestments" xlink:label="us-gaap_LongTermInvestments"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OtherAssetsCurrent" xlink:label="us-gaap_OtherAssetsCurrent"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="us-gaap_OtherAssetsNoncurrent"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PreferredStockValue" xlink:label="us-gaap_PreferredStockValue"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SeriesAPreferredStockMember" xlink:label="us-gaap_SeriesAPreferredStockMember"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="us-gaap_StockholdersEquityAbstract"/> <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsCurrentAbstract" order="1.0400" priority="2" use="optional"/> <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" order="1.0500" priority="2" use="optional"/> <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_LongTermInvestments" order="1.0600" priority="2" use="optional"/> <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_OtherAssetsNoncurrent" order="1.0700" priority="2" use="optional"/> <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_Assets" order="1.0800" priority="2" use="optional"/> <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="1.2200" priority="2" use="optional"/> <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" order="1.2300" priority="2" use="optional"/> <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AccountsReceivableRelatedPartiesCurrent" order="1.2400" priority="2" use="optional"/> <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_OtherAssetsCurrent" order="1.2500" priority="2" use="optional"/> <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrent" order="1.2600" priority="2" use="optional"/> <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_SeriesAPreferredStockMember" order="1.0100" priority="2" use="optional"/> <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract" order="1.0900" priority="2" use="optional"/> <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_DeferredRevenueNoncurrent" order="1.1000" priority="2" use="optional"/> <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_DeferredRentCreditNoncurrent" order="1.1100" priority="2" use="optional"/> <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_Liabilities" order="1.1200" priority="2" use="optional"/> <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_CommitmentsAndContingencies" order="1.1300" priority="2" use="optional"/> <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract" order="1.1400" priority="2" use="optional"/> <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity" order="1.1500" priority="2" use="optional"/> <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_AccountsPayableCurrent" order="1.2700" priority="2" use="optional"/> <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_AccruedLiabilitiesCurrent" order="1.2800" priority="2" use="optional"/> <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_DeferredRevenueCurrent" order="1.2900" priority="2" use="optional"/> <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_DeferredRentCreditCurrent" order="1.3000" priority="2" use="optional"/> <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrent" order="1.3100" priority="2" use="optional"/> <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="1.0000" priority="2" use="optional"/> <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" order="100.0000" xbrldt:closed="true" xbrldt:contextElement="segment" priority="2" use="optional"/> <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AssetsAbstract" order="1.0200" priority="2" use="optional"/> <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract" order="1.0300" priority="2" use="optional"/> <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="1.0000" priority="2" use="optional"/> <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_PreferredStockValue" order="1.1600" priority="2" use="optional"/> <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_CommonStockValue" order="1.1700" priority="2" use="optional"/> <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_AdditionalPaidInCapital" order="1.1800" priority="2" use="optional"/> <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" order="1.1900" priority="2" use="optional"/> <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" order="1.2000" priority="2" use="optional"/> <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquity" order="1.2100" priority="2" use="optional"/> </definitionLink> <definitionLink xlink:type="extended" xlink:role="http://imetrix.edgar-online.com/taxonomy/role/StatementOfFinancialPositionClassifiedParenthetical"> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain_2"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="us-gaap_PreferredStockSharesIssued"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="us-gaap_PreferredStockSharesOutstanding"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SeriesAPreferredStockMember" xlink:label="us-gaap_SeriesAPreferredStockMember"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/> <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_SeriesAPreferredStockMember" order="1.0100" priority="2" use="optional"/> <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="1.0000" priority="2" use="optional"/> <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain_2" order="1.0000" priority="2" use="optional"/> <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" order="100.0000" xbrldt:closed="true" xbrldt:contextElement="segment" priority="2" use="optional"/> <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare" order="1.0200" priority="2" use="optional"/> <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockSharesAuthorized" order="1.0300" priority="2" use="optional"/> <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockSharesIssued" order="1.0400" priority="2" use="optional"/> <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockSharesOutstanding" order="1.0500" priority="2" use="optional"/> <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" order="1.0600" priority="2" use="optional"/> <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesAuthorized" order="1.0700" priority="2" use="optional"/> <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesIssued" order="1.0800" priority="2" use="optional"/> <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesOutstanding" order="1.0900" priority="2" use="optional"/> <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="1.0000" priority="2" use="optional"/> </definitionLink> <definitionLink xlink:type="extended" xlink:role="http://imetrix.edgar-online.com/taxonomy/role/StatementOfIncome"> </definitionLink> <definitionLink xlink:type="extended" xlink:role="http://imetrix.edgar-online.com/taxonomy/role/StatementOfShareholdersEquityAndOtherComprehensiveIncome"> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember"/> <loc xlink:type="locator" xlink:href="cytk-20141231.xsd#cytk_AdjustmentsToAdditionalPaidInCapitalIssuanceOfConvertiblePreferredStock" xlink:label="cytk_AdjustmentsToAdditionalPaidInCapitalIssuanceOfConvertiblePreferredStock"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain_2"/> <loc xlink:type="locator" xlink:href="cytk-20141231.xsd#cytk_FractionalSharesFromReverseStockSplitShare" xlink:label="cytk_FractionalSharesFromReverseStockSplitShare"/> <loc xlink:type="locator" xlink:href="cytk-20141231.xsd#cytk_IssuanceOfConvertiblePreferredStockShares" xlink:label="cytk_IssuanceOfConvertiblePreferredStockShares"/> <loc xlink:type="locator" xlink:href="cytk-20141231.xsd#cytk_MlvAgreementMember" xlink:label="cytk_MlvAgreementMember"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTax"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PreferredStockMember" xlink:label="us-gaap_PreferredStockMember"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SeriesAPreferredStockMember" xlink:label="us-gaap_SeriesAPreferredStockMember"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SeriesBPreferredStockMember" xlink:label="us-gaap_SeriesBPreferredStockMember"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity"/> <loc xlink:type="locator" xlink:href="cytk-20141231.xsd#cytk_StockIssuedDuringPeriodSharesAtMarketIssuanceSalesAgreement" xlink:label="cytk_StockIssuedDuringPeriodSharesAtMarketIssuanceSalesAgreement"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:label="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans"/> <loc xlink:type="locator" xlink:href="cytk-20141231.xsd#cytk_StockIssuedDuringPeriodSharesExerciseOfWarrants" xlink:label="cytk_StockIssuedDuringPeriodSharesExerciseOfWarrants"/> <loc xlink:type="locator" xlink:href="cytk-20141231.xsd#cytk_StockIssuedDuringPeriodSharesNewIssuesToCollaborativePartner" xlink:label="cytk_StockIssuedDuringPeriodSharesNewIssuesToCollaborativePartner"/> <loc xlink:type="locator" xlink:href="cytk-20141231.xsd#cytk_StockIssuedDuringPeriodSharesNewIssuesToRelatedParty" xlink:label="cytk_StockIssuedDuringPeriodSharesNewIssuesToRelatedParty"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:label="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures"/> <loc xlink:type="locator" xlink:href="cytk-20141231.xsd#cytk_StockIssuedDuringPeriodSharesSecuritiesPurchaseAgreement" xlink:label="cytk_StockIssuedDuringPeriodSharesSecuritiesPurchaseAgreement"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/> <loc xlink:type="locator" xlink:href="cytk-20141231.xsd#cytk_StockIssuedDuringPeriodValueAtMarketIssuanceSalesAgreement" xlink:label="cytk_StockIssuedDuringPeriodValueAtMarketIssuanceSalesAgreement"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:label="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan"/> <loc xlink:type="locator" xlink:href="cytk-20141231.xsd#cytk_StockIssuedDuringPeriodValueExerciseOfWarrants" xlink:label="cytk_StockIssuedDuringPeriodValueExerciseOfWarrants"/> <loc xlink:type="locator" xlink:href="cytk-20141231.xsd#cytk_StockIssuedDuringPeriodValueNewIssuesToCollaborativePartner" xlink:label="cytk_StockIssuedDuringPeriodValueNewIssuesToCollaborativePartner"/> <loc xlink:type="locator" xlink:href="cytk-20141231.xsd#cytk_StockIssuedDuringPeriodValueNewIssuesToRelatedParty" xlink:label="cytk_StockIssuedDuringPeriodValueNewIssuesToRelatedParty"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" xlink:label="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures"/> <loc xlink:type="locator" xlink:href="cytk-20141231.xsd#cytk_StockIssuedDuringPeriodValueSecuritiesPurchaseAgreement" xlink:label="cytk_StockIssuedDuringPeriodValueSecuritiesPurchaseAgreement"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis"/> <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_SeriesAPreferredStockMember" order="1.0100" priority="2" use="optional"/> <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_SeriesBPreferredStockMember" order="1.0200" priority="2" use="optional"/> <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" order="1.3200" priority="2" use="optional"/> <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_PreferredStockMember" order="1.3300" priority="2" use="optional"/> <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AdditionalPaidInCapitalMember" order="1.3400" priority="2" use="optional"/> <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeMember" order="1.3500" priority="2" use="optional"/> <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_RetainedEarningsMember" order="1.3600" priority="2" use="optional"/> <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="cytk_MlvAgreementMember" order="1.3700" priority="2" use="optional"/> <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="1.0000" priority="2" use="optional"/> <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="1.0000" priority="2" use="optional"/> <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain_2" order="1.0000" priority="2" use="optional"/> <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" order="100.0000" xbrldt:closed="true" xbrldt:contextElement="segment" priority="2" use="optional"/> <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquity" order="1.0300" priority="2" use="optional"/> <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" order="1.0400" priority="2" use="optional"/> <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharesOutstanding" order="1.0500" priority="2" use="optional"/> <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" order="1.0600" priority="2" use="optional"/> <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" order="1.0700" priority="2" use="optional"/> <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" order="1.0800" priority="2" use="optional"/> <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" order="1.0900" priority="2" use="optional"/> <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" order="1.1000" priority="2" use="optional"/> <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="cytk_StockIssuedDuringPeriodValueNewIssuesToRelatedParty" order="1.1100" priority="2" use="optional"/> <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="cytk_StockIssuedDuringPeriodSharesNewIssuesToRelatedParty" order="1.1200" priority="2" use="optional"/> <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="cytk_StockIssuedDuringPeriodValueExerciseOfWarrants" order="1.1300" priority="2" use="optional"/> <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="cytk_StockIssuedDuringPeriodSharesExerciseOfWarrants" order="1.1400" priority="2" use="optional"/> <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="cytk_StockIssuedDuringPeriodValueAtMarketIssuanceSalesAgreement" order="1.1500" priority="2" use="optional"/> <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" order="1.1600" priority="2" use="optional"/> <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="cytk_StockIssuedDuringPeriodSharesAtMarketIssuanceSalesAgreement" order="1.1700" priority="2" use="optional"/> <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" order="1.1800" priority="2" use="optional"/> <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="cytk_StockIssuedDuringPeriodValueNewIssuesToCollaborativePartner" order="1.1900" priority="2" use="optional"/> <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="cytk_FractionalSharesFromReverseStockSplitShare" order="1.2000" priority="2" use="optional"/> <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="cytk_StockIssuedDuringPeriodSharesNewIssuesToCollaborativePartner" order="1.2100" priority="2" use="optional"/> <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="cytk_StockIssuedDuringPeriodValueSecuritiesPurchaseAgreement" order="1.2200" priority="2" use="optional"/> <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="cytk_StockIssuedDuringPeriodSharesSecuritiesPurchaseAgreement" order="1.2300" priority="2" use="optional"/> <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="cytk_AdjustmentsToAdditionalPaidInCapitalIssuanceOfConvertiblePreferredStock" order="1.2400" priority="2" use="optional"/> <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="cytk_IssuanceOfConvertiblePreferredStockShares" order="1.2500" priority="2" use="optional"/> <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" order="1.2600" priority="2" use="optional"/> <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" order="1.2700" priority="2" use="optional"/> <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OtherComprehensiveIncomeLossNetOfTax" order="1.2800" priority="2" use="optional"/> <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetIncomeLoss" order="1.2900" priority="2" use="optional"/> <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="1.0000" priority="2" use="optional"/> <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="2.0000" priority="2" use="optional"/> <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" order="3.0000" priority="2" use="optional"/> <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" order="1.0000" priority="2" use="optional"/> </definitionLink> <definitionLink xlink:type="extended" xlink:role="http://imetrix.edgar-online.com/taxonomy/role/StatementOfShareholdersEquityAndOtherComprehensiveIncomeParenthetical"> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/> <loc xlink:type="locator" xlink:href="cytk-20141231.xsd#cytk_ConversionPricePerShareOfPreferredStockToCommonStock" xlink:label="cytk_ConversionPricePerShareOfPreferredStockToCommonStock"/> <loc xlink:type="locator" xlink:href="cytk-20141231.xsd#cytk_ConvertiblePreferredStockIssuancePrice" xlink:label="cytk_ConvertiblePreferredStockIssuancePrice"/> <loc xlink:type="locator" xlink:href="cytk-20141231.xsd#cytk_IssuanceCostOfWarrant" xlink:label="cytk_IssuanceCostOfWarrant"/> <loc xlink:type="locator" xlink:href="cytk-20141231.xsd#cytk_IssuanceOfCommonStockEmployeeStockPurchasePlanPricePerShare" xlink:label="cytk_IssuanceOfCommonStockEmployeeStockPurchasePlanPricePerShare"/> <loc xlink:type="locator" xlink:href="cytk-20141231.xsd#cytk_IssuanceOfCommonStockToCollaborativePartnerForCashPerShare" xlink:label="cytk_IssuanceOfCommonStockToCollaborativePartnerForCashPerShare"/> <loc xlink:type="locator" xlink:href="cytk-20141231.xsd#cytk_IssuanceOfCommonStockToCollaborativePartnerIssuanceCosts" xlink:label="cytk_IssuanceOfCommonStockToCollaborativePartnerIssuanceCosts"/> <loc xlink:type="locator" xlink:href="cytk-20141231.xsd#cytk_IssuanceOfCommonStockToMlvAtPerShareLowerLimit" xlink:label="cytk_IssuanceOfCommonStockToMlvAtPerShareLowerLimit"/> <loc xlink:type="locator" xlink:href="cytk-20141231.xsd#cytk_IssuanceOfCommonStockToMlvAtPerShareUpperLimit" xlink:label="cytk_IssuanceOfCommonStockToMlvAtPerShareUpperLimit"/> <loc xlink:type="locator" xlink:href="cytk-20141231.xsd#cytk_IssuanceOfCommonStockToMlvNetOfCommissionAndIssuanceCosts" xlink:label="cytk_IssuanceOfCommonStockToMlvNetOfCommissionAndIssuanceCosts"/> <loc xlink:type="locator" xlink:href="cytk-20141231.xsd#cytk_IssuanceOfCommonStockToRelatedPartyForCashPerShare" xlink:label="cytk_IssuanceOfCommonStockToRelatedPartyForCashPerShare"/> <loc xlink:type="locator" xlink:href="cytk-20141231.xsd#cytk_IssuanceOfCommonStockToRelatedPartyIssuanceCosts" xlink:label="cytk_IssuanceOfCommonStockToRelatedPartyIssuanceCosts"/> <loc xlink:type="locator" xlink:href="cytk-20141231.xsd#cytk_MlvAgreementMember" xlink:label="cytk_MlvAgreementMember"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_2"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SeriesAPreferredStockMember" xlink:label="us-gaap_SeriesAPreferredStockMember"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SeriesBPreferredStockMember" xlink:label="us-gaap_SeriesBPreferredStockMember"/> <loc xlink:type="locator" xlink:href="cytk-20141231.xsd#cytk_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePrice" xlink:label="cytk_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePrice"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SharePrice" xlink:label="us-gaap_SharePrice"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis"/> <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_SeriesAPreferredStockMember" order="1.0100" priority="2" use="optional"/> <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_SeriesBPreferredStockMember" order="1.0200" priority="2" use="optional"/> <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="cytk_MlvAgreementMember" order="1.1900" priority="2" use="optional"/> <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="1.0000" priority="2" use="optional"/> <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" order="100.0000" xbrldt:closed="true" xbrldt:contextElement="segment" priority="2" use="optional"/> <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="cytk_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePrice" order="1.0300" priority="2" use="optional"/> <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" order="1.0400" priority="2" use="optional"/> <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="cytk_ConvertiblePreferredStockIssuancePrice" order="1.0500" priority="2" use="optional"/> <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" order="1.0600" priority="2" use="optional"/> <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="cytk_IssuanceOfCommonStockEmployeeStockPurchasePlanPricePerShare" order="1.0700" priority="2" use="optional"/> <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="cytk_IssuanceOfCommonStockToMlvAtPerShareLowerLimit" order="1.0800" priority="2" use="optional"/> <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="cytk_IssuanceOfCommonStockToRelatedPartyForCashPerShare" order="1.0900" priority="2" use="optional"/> <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="cytk_IssuanceOfCommonStockToMlvAtPerShareUpperLimit" order="1.1000" priority="2" use="optional"/> <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="cytk_IssuanceOfCommonStockToRelatedPartyIssuanceCosts" order="1.1100" priority="2" use="optional"/> <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="cytk_IssuanceOfCommonStockToMlvNetOfCommissionAndIssuanceCosts" order="1.1200" priority="2" use="optional"/> <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="cytk_ConversionPricePerShareOfPreferredStockToCommonStock" order="1.1300" priority="2" use="optional"/> <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="cytk_IssuanceOfCommonStockToCollaborativePartnerForCashPerShare" order="1.1400" priority="2" use="optional"/> <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="cytk_IssuanceOfCommonStockToCollaborativePartnerIssuanceCosts" order="1.1500" priority="2" use="optional"/> <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharePrice" order="1.1600" priority="2" use="optional"/> <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PaymentsOfStockIssuanceCosts" order="1.1700" priority="2" use="optional"/> <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="cytk_IssuanceCostOfWarrant" order="1.1800" priority="2" use="optional"/> <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" order="1.0000" priority="2" use="optional"/> <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="2.0000" priority="2" use="optional"/> <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" order="1.0000" priority="2" use="optional"/> <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_2" order="1.0000" priority="2" use="optional"/> </definitionLink> <definitionLink xlink:type="extended" xlink:role="http://imetrix.edgar-online.com/taxonomy/role/StatementOfCashFlowsIndirect"> </definitionLink> <definitionLink xlink:type="extended" xlink:role="http://imetrix.edgar-online.com/taxonomy/role/DisclosureOrganizationAndSignificantAccountingPoliciesAdditionalInformation"> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AccountsReceivableRelatedParties" xlink:label="us-gaap_AccountsReceivableRelatedParties"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalStockSplit" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockSplit"/> <loc xlink:type="locator" xlink:href="cytk-20141231.xsd#cytk_AmgenMember" xlink:label="cytk_AmgenMember"/> <loc xlink:type="locator" xlink:href="cytk-20141231.xsd#cytk_AstellasMember" xlink:label="cytk_AstellasMember"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:label="us-gaap_CashCashEquivalentsAndShortTermInvestments"/> <loc xlink:type="locator" xlink:href="cytk-20141231.xsd#cytk_CashRequirementsTerm" xlink:label="cytk_CashRequirementsTerm"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized"/> <loc xlink:type="locator" xlink:href="cytk-20141231.xsd#cytk_ComputerEquipmentAndSoftwareMember" xlink:label="cytk_ComputerEquipmentAndSoftwareMember"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ConcentrationRiskPercentage1" xlink:label="us-gaap_ConcentrationRiskPercentage1"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount" xlink:label="us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount"/> <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain"/> <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain_2"/> <loc xlink:type="locator" xlink:href="cytk-20141231.xsd#cytk_FractionalSharesFromReverseStockSplitShare" xlink:label="cytk_FractionalSharesFromReverseStockSplitShare"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="us-gaap_FurnitureAndFixturesMember"/> <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/country/2013/country-2013-01-31.xsd#country_JP" xlink:label="country_JP"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LeaseholdsAndLeaseholdImprovementsMember" xlink:label="us-gaap_LeaseholdsAndLeaseholdImprovementsMember"/> <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_MaximumMember" xlink:label="us-gaap_MaximumMember"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_MinimumMember" xlink:label="us-gaap_MinimumMember"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/> <loc xlink:type="locator" xlink:href="cytk-20141231.xsd#cytk_NumberOfFinancialInstitutions" xlink:label="cytk_NumberOfFinancialInstitutions"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NumberOfReportableSegments" xlink:label="us-gaap_NumberOfReportableSegments"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OfficeEquipmentMember" xlink:label="us-gaap_OfficeEquipmentMember"/> <loc xlink:type="locator" xlink:href="cytk-20141231.xsd#cytk_PercentageOfIncomeTaxPositionsLikelyToBeRealized" xlink:label="cytk_PercentageOfIncomeTaxPositionsLikelyToBeRealized"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RangeAxis" xlink:label="us-gaap_RangeAxis"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RangeMember" xlink:label="us-gaap_RangeMember"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain_2"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SegmentGeographicalDomain" xlink:label="us-gaap_SegmentGeographicalDomain"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SegmentGeographicalDomain" xlink:label="us-gaap_SegmentGeographicalDomain_2"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementGeographicalAxis" xlink:label="us-gaap_StatementGeographicalAxis"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:label="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockholdersEquityReverseStockSplit" xlink:label="us-gaap_StockholdersEquityReverseStockSplit"/> <loc xlink:type="locator" xlink:href="cytk-20141231.xsd#cytk_SummaryOfSignificantAccountingPoliciesLineItems" xlink:label="cytk_SummaryOfSignificantAccountingPoliciesLineItems"/> <loc xlink:type="locator" xlink:href="cytk-20141231.xsd#cytk_SummaryOfSignificantAccountingPoliciesTable" xlink:label="cytk_SummaryOfSignificantAccountingPoliciesTable"/> <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/country/2013/country-2013-01-31.xsd#country_US" xlink:label="country_US"/> <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_EntityDomain" xlink:to="cytk_AstellasMember" order="1.2000" priority="2" use="optional"/> <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="1.0000" priority="2" use="optional"/> <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain_2" order="1.0000" priority="2" use="optional"/> <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" order="1.0000" priority="2" use="optional"/> <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="cytk_ComputerEquipmentAndSoftwareMember" order="1.2200" priority="2" use="optional"/> <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_OfficeEquipmentMember" order="1.2500" priority="2" use="optional"/> <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_FurnitureAndFixturesMember" order="1.2700" priority="2" use="optional"/> <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_LeaseholdsAndLeaseholdImprovementsMember" order="1.2800" priority="2" use="optional"/> <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RangeAxis" xlink:to="us-gaap_RangeMember" order="1.0000" priority="2" use="optional"/> <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RangeMember" xlink:to="us-gaap_MaximumMember" order="1.2300" priority="2" use="optional"/> <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RangeMember" xlink:to="us-gaap_MinimumMember" order="1.2600" priority="2" use="optional"/> <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="cytk_AmgenMember" order="1.1900" priority="2" use="optional"/> <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" order="1.0000" priority="2" use="optional"/> <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain_2" order="1.0000" priority="2" use="optional"/> <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SegmentGeographicalDomain" xlink:to="country_US" order="1.2100" priority="2" use="optional"/> <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SegmentGeographicalDomain" xlink:to="country_JP" order="1.2400" priority="2" use="optional"/> <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementGeographicalAxis" xlink:to="us-gaap_SegmentGeographicalDomain" order="1.0000" priority="2" use="optional"/> <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementGeographicalAxis" xlink:to="us-gaap_SegmentGeographicalDomain_2" order="1.0000" priority="2" use="optional"/> <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="cytk_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="cytk_SummaryOfSignificantAccountingPoliciesTable" order="100.0000" xbrldt:closed="true" xbrldt:contextElement="segment" priority="2" use="optional"/> <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cytk_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" order="1.0100" priority="2" use="optional"/> <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cytk_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_NetIncomeLoss" order="1.0200" priority="2" use="optional"/> <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cytk_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" order="1.0300" priority="2" use="optional"/> <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cytk_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_CashCashEquivalentsAndShortTermInvestments" order="1.0400" priority="2" use="optional"/> <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cytk_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="cytk_CashRequirementsTerm" order="1.0500" priority="2" use="optional"/> <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cytk_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="cytk_NumberOfFinancialInstitutions" order="1.0600" priority="2" use="optional"/> <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cytk_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_ConcentrationRiskPercentage1" order="1.0700" priority="2" use="optional"/> <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cytk_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_AccountsReceivableRelatedParties" order="1.0800" priority="2" use="optional"/> <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cytk_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife" order="1.0900" priority="2" use="optional"/> <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cytk_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount" order="1.1000" priority="2" use="optional"/> <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cytk_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="cytk_PercentageOfIncomeTaxPositionsLikelyToBeRealized" order="1.1100" priority="2" use="optional"/> <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cytk_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_NumberOfReportableSegments" order="1.1200" priority="2" use="optional"/> <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cytk_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" order="1.1300" priority="2" use="optional"/> <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cytk_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_StockholdersEquityReverseStockSplit" order="1.1400" priority="2" use="optional"/> <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cytk_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="cytk_FractionalSharesFromReverseStockSplitShare" order="1.1500" priority="2" use="optional"/> <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cytk_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_CommonStockSharesAuthorized" order="1.1600" priority="2" use="optional"/> <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cytk_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" order="1.1700" priority="2" use="optional"/> <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cytk_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockSplit" order="1.1800" priority="2" use="optional"/> <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="cytk_SummaryOfSignificantAccountingPoliciesTable" xlink:to="us-gaap_RangeAxis" order="1.0000" priority="2" use="optional"/> <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="cytk_SummaryOfSignificantAccountingPoliciesTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" order="2.0000" priority="2" use="optional"/> <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="cytk_SummaryOfSignificantAccountingPoliciesTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" order="3.0000" priority="2" use="optional"/> <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="cytk_SummaryOfSignificantAccountingPoliciesTable" xlink:to="dei_LegalEntityAxis" order="4.0000" priority="2" use="optional"/> <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="cytk_SummaryOfSignificantAccountingPoliciesTable" xlink:to="us-gaap_StatementGeographicalAxis" order="5.0000" priority="2" use="optional"/> </definitionLink> <definitionLink xlink:type="extended" xlink:role="http://imetrix.edgar-online.com/taxonomy/role/DisclosureNetLossPerShareCalculationOfBasicAndDilutedNetLossPerShareAllocableToCommonStockholders"> </definitionLink> <definitionLink xlink:type="extended" xlink:role="http://imetrix.edgar-online.com/taxonomy/role/DisclosureNetLossPerShareInstrumentsExcludedFromTheComputationOfDilutedNetLossPerCommonShare"> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain_2"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EmployeeStockMember" xlink:label="us-gaap_EmployeeStockMember"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OptionIndexedToIssuersEquityTypeAxis" xlink:label="us-gaap_OptionIndexedToIssuersEquityTypeAxis"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OptionIndexedToIssuersEquityTypeDomain" xlink:label="us-gaap_OptionIndexedToIssuersEquityTypeDomain"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OptionIndexedToIssuersEquityTypeDomain" xlink:label="us-gaap_OptionIndexedToIssuersEquityTypeDomain_2"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SeriesBPreferredStockMember" xlink:label="us-gaap_SeriesBPreferredStockMember"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_WarrantMember" xlink:label="us-gaap_WarrantMember"/> <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain" order="1.0000" priority="2" use="optional"/> <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain_2" order="1.0000" priority="2" use="optional"/> <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" order="100.0000" xbrldt:closed="true" xbrldt:contextElement="segment" priority="2" use="optional"/> <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" order="1.0400" priority="2" use="optional"/> <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_WarrantMember" order="1.0500" priority="2" use="optional"/> <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_RestrictedStockUnitsRSUMember" order="1.0600" priority="2" use="optional"/> <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_SeriesBPreferredStockMember" order="1.0100" priority="2" use="optional"/> <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_OptionIndexedToIssuersEquityTypeAxis" xlink:to="us-gaap_OptionIndexedToIssuersEquityTypeDomain" order="1.0000" priority="2" use="optional"/> <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_OptionIndexedToIssuersEquityTypeAxis" xlink:to="us-gaap_OptionIndexedToIssuersEquityTypeDomain_2" order="1.0000" priority="2" use="optional"/> <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OptionIndexedToIssuersEquityTypeDomain" xlink:to="us-gaap_EmployeeStockOptionMember" order="1.0200" priority="2" use="optional"/> <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_EmployeeStockMember" order="1.0300" priority="2" use="optional"/> <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" order="1.0000" priority="2" use="optional"/> <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="2.0000" priority="2" use="optional"/> <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" order="3.0000" priority="2" use="optional"/> <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_OptionIndexedToIssuersEquityTypeAxis" order="4.0000" priority="2" use="optional"/> <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="1.0000" priority="2" use="optional"/> <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" order="1.0000" priority="2" use="optional"/> </definitionLink> <definitionLink xlink:type="extended" xlink:role="http://imetrix.edgar-online.com/taxonomy/role/DisclosureSupplementaryCashFlowDataSupplementalCashFlowInformation"> </definitionLink> <definitionLink xlink:type="extended" xlink:role="http://imetrix.edgar-online.com/taxonomy/role/DisclosureCashEquivalentsAndInvestmentsAmortizedCostAndFairValueOfCashEquivalentsAndAvailableForSaleInvestments"> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AvailableForSaleSecurities" xlink:label="us-gaap_AvailableForSaleSecurities"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:label="us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:label="us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/> <loc xlink:type="locator" xlink:href="cytk-20141231.xsd#cytk_AvailableForSaleSecuritiesMaturityDate" xlink:label="cytk_AvailableForSaleSecuritiesMaturityDate"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CashAndCashEquivalentsAxis" xlink:label="us-gaap_CashAndCashEquivalentsAxis"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CashAndCashEquivalentsLineItems" xlink:label="us-gaap_CashAndCashEquivalentsLineItems"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CashEquivalentsMember" xlink:label="us-gaap_CashEquivalentsMember"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_InvestmentTypeAxis" xlink:label="us-gaap_InvestmentTypeAxis"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_InvestmentTypeCategorizationMember" xlink:label="us-gaap_InvestmentTypeCategorizationMember"/> <loc xlink:type="locator" xlink:href="cytk-20141231.xsd#cytk_LongTermInvestmentMember" xlink:label="cytk_LongTermInvestmentMember"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_MaximumMember" xlink:label="us-gaap_MaximumMember"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_MinimumMember" xlink:label="us-gaap_MinimumMember"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_MoneyMarketFundsMember" xlink:label="us-gaap_MoneyMarketFundsMember"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RangeAxis" xlink:label="us-gaap_RangeAxis"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RangeMember" xlink:label="us-gaap_RangeMember"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RangeMember" xlink:label="us-gaap_RangeMember_2"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfCashAndCashEquivalentsTable" xlink:label="us-gaap_ScheduleOfCashAndCashEquivalentsTable"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShortTermInvestmentsMember" xlink:label="us-gaap_ShortTermInvestmentsMember"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_USTreasurySecuritiesMember" xlink:label="us-gaap_USTreasurySecuritiesMember"/> <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_CashAndCashEquivalentsAxis" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" order="1.0000" priority="2" use="optional"/> <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_CashAndCashEquivalentsLineItems" xlink:to="us-gaap_ScheduleOfCashAndCashEquivalentsTable" order="100.0000" xbrldt:closed="true" xbrldt:contextElement="segment" priority="2" use="optional"/> <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CashAndCashEquivalentsLineItems" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" order="1.0800" priority="2" use="optional"/> <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CashAndCashEquivalentsLineItems" xlink:to="us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" order="1.0900" priority="2" use="optional"/> <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CashAndCashEquivalentsLineItems" xlink:to="us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" order="1.1000" priority="2" use="optional"/> <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CashAndCashEquivalentsLineItems" xlink:to="us-gaap_AvailableForSaleSecurities" order="1.1100" priority="2" use="optional"/> <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CashAndCashEquivalentsLineItems" xlink:to="cytk_AvailableForSaleSecuritiesMaturityDate" order="1.1200" priority="2" use="optional"/> <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_InvestmentTypeAxis" xlink:to="us-gaap_InvestmentTypeCategorizationMember" order="1.0000" priority="2" use="optional"/> <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_InvestmentTypeCategorizationMember" xlink:to="us-gaap_CashEquivalentsMember" order="1.0300" priority="2" use="optional"/> <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_InvestmentTypeCategorizationMember" xlink:to="us-gaap_ShortTermInvestmentsMember" order="1.0400" priority="2" use="optional"/> <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_InvestmentTypeCategorizationMember" xlink:to="cytk_LongTermInvestmentMember" order="1.0500" priority="2" use="optional"/> <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_RangeAxis" xlink:to="us-gaap_RangeMember" order="1.0000" priority="2" use="optional"/> <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RangeAxis" xlink:to="us-gaap_RangeMember_2" order="1.0000" priority="2" use="optional"/> <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RangeMember" xlink:to="us-gaap_MinimumMember" order="1.0600" priority="2" use="optional"/> <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RangeMember" xlink:to="us-gaap_MaximumMember" order="1.0700" priority="2" use="optional"/> <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:to="us-gaap_MoneyMarketFundsMember" order="1.0100" priority="2" use="optional"/> <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:to="us-gaap_USTreasurySecuritiesMember" order="1.0200" priority="2" use="optional"/> <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfCashAndCashEquivalentsTable" xlink:to="us-gaap_RangeAxis" order="1.0000" priority="2" use="optional"/> <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfCashAndCashEquivalentsTable" xlink:to="us-gaap_InvestmentTypeAxis" order="2.0000" priority="2" use="optional"/> <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfCashAndCashEquivalentsTable" xlink:to="us-gaap_CashAndCashEquivalentsAxis" order="3.0000" priority="2" use="optional"/> </definitionLink> <definitionLink xlink:type="extended" xlink:role="http://imetrix.edgar-online.com/taxonomy/role/DisclosureCashEquivalentsAndInvestmentsAdditionalInformation"> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" xlink:label="us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CashAndCashEquivalentsAxis" xlink:label="us-gaap_CashAndCashEquivalentsAxis"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CashAndCashEquivalentsLineItems" xlink:label="us-gaap_CashAndCashEquivalentsLineItems"/> <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/invest/2013/invest-2013-01-31.xsd#invest_InvestmentMaturityDateRangeEnd1" xlink:label="invest_InvestmentMaturityDateRangeEnd1"/> <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/invest/2013/invest-2013-01-31.xsd#invest_InvestmentMaturityDateRangeStart1" xlink:label="invest_InvestmentMaturityDateRangeStart1"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_InvestmentTypeAxis" xlink:label="us-gaap_InvestmentTypeAxis"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_InvestmentTypeCategorizationMember" xlink:label="us-gaap_InvestmentTypeCategorizationMember"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_InvestmentTypeCategorizationMember" xlink:label="us-gaap_InvestmentTypeCategorizationMember_2"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_2"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfCashAndCashEquivalentsTable" xlink:label="us-gaap_ScheduleOfCashAndCashEquivalentsTable"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShortTermInvestmentsMember" xlink:label="us-gaap_ShortTermInvestmentsMember"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_UnrealizedGainLossOnInvestments" xlink:label="us-gaap_UnrealizedGainLossOnInvestments"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_USTreasurySecuritiesMember" xlink:label="us-gaap_USTreasurySecuritiesMember"/> <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_CashAndCashEquivalentsAxis" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" order="1.0000" priority="2" use="optional"/> <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_CashAndCashEquivalentsAxis" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_2" order="1.0000" priority="2" use="optional"/> <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_CashAndCashEquivalentsLineItems" xlink:to="us-gaap_ScheduleOfCashAndCashEquivalentsTable" order="100.0000" xbrldt:closed="true" xbrldt:contextElement="segment" priority="2" use="optional"/> <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CashAndCashEquivalentsLineItems" xlink:to="us-gaap_UnrealizedGainLossOnInvestments" order="1.0100" priority="2" use="optional"/> <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CashAndCashEquivalentsLineItems" xlink:to="us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" order="1.0200" priority="2" use="optional"/> <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CashAndCashEquivalentsLineItems" xlink:to="invest_InvestmentMaturityDateRangeStart1" order="1.0300" priority="2" use="optional"/> <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CashAndCashEquivalentsLineItems" xlink:to="invest_InvestmentMaturityDateRangeEnd1" order="1.0400" priority="2" use="optional"/> <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_InvestmentTypeAxis" xlink:to="us-gaap_InvestmentTypeCategorizationMember" order="1.0000" priority="2" use="optional"/> <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_InvestmentTypeAxis" xlink:to="us-gaap_InvestmentTypeCategorizationMember_2" order="1.0000" priority="2" use="optional"/> <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_InvestmentTypeCategorizationMember" xlink:to="us-gaap_ShortTermInvestmentsMember" order="1.0500" priority="2" use="optional"/> <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:to="us-gaap_USTreasurySecuritiesMember" order="1.0600" priority="2" use="optional"/> <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfCashAndCashEquivalentsTable" xlink:to="us-gaap_InvestmentTypeAxis" order="1.0000" priority="2" use="optional"/> <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfCashAndCashEquivalentsTable" xlink:to="us-gaap_CashAndCashEquivalentsAxis" order="2.0000" priority="2" use="optional"/> </definitionLink> <definitionLink xlink:type="extended" xlink:role="http://imetrix.edgar-online.com/taxonomy/role/DisclosureCashEquivalentsAndInvestmentsSummaryOfInterestIncome"> </definitionLink> <definitionLink xlink:type="extended" xlink:role="http://imetrix.edgar-online.com/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfFinancialAssetsMeasuredAtFairValueOnRecurringBasis"> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AssetsFairValueDisclosure" xlink:label="us-gaap_AssetsFairValueDisclosure"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_BalanceSheetLocationAxis" xlink:label="us-gaap_BalanceSheetLocationAxis"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="us-gaap_BalanceSheetLocationDomain"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="us-gaap_BalanceSheetLocationDomain_2"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CashAndCashEquivalentsMember" xlink:label="us-gaap_CashAndCashEquivalentsMember"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_2"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueByAssetClassAxis" xlink:label="us-gaap_FairValueByAssetClassAxis"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="us-gaap_FairValueInputsLevel1Member"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="us-gaap_FairValueInputsLevel2Member"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="us-gaap_FairValueInputsLevel3Member"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain_2"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:label="us-gaap_FairValueMeasurementsRecurringMember"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_InvestmentTypeAxis" xlink:label="us-gaap_InvestmentTypeAxis"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_InvestmentTypeCategorizationMember" xlink:label="us-gaap_InvestmentTypeCategorizationMember"/> <loc xlink:type="locator" xlink:href="cytk-20141231.xsd#cytk_LongTermInvestmentMember" xlink:label="cytk_LongTermInvestmentMember"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_MoneyMarketFundsMember" xlink:label="us-gaap_MoneyMarketFundsMember"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfFairValueOfSeparateAccountsByMajorCategoryOfInvestmentAxis" xlink:label="us-gaap_ScheduleOfFairValueOfSeparateAccountsByMajorCategoryOfInvestmentAxis"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfFairValueOfSeparateAccountsByMajorCategoryOfInvestmentCategoryDomain" xlink:label="us-gaap_ScheduleOfFairValueOfSeparateAccountsByMajorCategoryOfInvestmentCategoryDomain"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfFairValueOfSeparateAccountsByMajorCategoryOfInvestmentCategoryDomain" xlink:label="us-gaap_ScheduleOfFairValueOfSeparateAccountsByMajorCategoryOfInvestmentCategoryDomain_2"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShortTermInvestmentsMember" xlink:label="us-gaap_ShortTermInvestmentsMember"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_USTreasurySecuritiesMember" xlink:label="us-gaap_USTreasurySecuritiesMember"/> <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_BalanceSheetLocationAxis" xlink:to="us-gaap_BalanceSheetLocationDomain" order="1.0000" priority="2" use="optional"/> <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_BalanceSheetLocationAxis" xlink:to="us-gaap_BalanceSheetLocationDomain_2" order="1.0000" priority="2" use="optional"/> <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BalanceSheetLocationDomain" xlink:to="cytk_LongTermInvestmentMember" order="1.0200" priority="2" use="optional"/> <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" order="100.0000" xbrldt:closed="true" xbrldt:contextElement="segment" priority="2" use="optional"/> <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_AssetsFairValueDisclosure" order="1.0800" priority="2" use="optional"/> <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueByMeasurementFrequencyAxis" order="1.0000" priority="2" use="optional"/> <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_InvestmentTypeAxis" order="2.0000" priority="2" use="optional"/> <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis" order="3.0000" priority="2" use="optional"/> <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_ScheduleOfFairValueOfSeparateAccountsByMajorCategoryOfInvestmentAxis" order="4.0000" priority="2" use="optional"/> <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_BalanceSheetLocationAxis" order="5.0000" priority="2" use="optional"/> <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueByAssetClassAxis" order="6.0000" priority="2" use="optional"/> <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="us-gaap_MoneyMarketFundsMember" order="1.0600" priority="2" use="optional"/> <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="us-gaap_USTreasurySecuritiesMember" order="1.0700" priority="2" use="optional"/> <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_FairValueByAssetClassAxis" xlink:to="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" order="1.0000" priority="2" use="optional"/> <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FairValueByAssetClassAxis" xlink:to="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_2" order="1.0000" priority="2" use="optional"/> <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" order="1.0000" priority="2" use="optional"/> <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="us-gaap_FairValueMeasurementFrequencyDomain" order="1.0000" priority="2" use="optional"/> <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="us-gaap_FairValueMeasurementFrequencyDomain_2" order="1.0000" priority="2" use="optional"/> <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueMeasurementFrequencyDomain" xlink:to="us-gaap_FairValueMeasurementsRecurringMember" order="1.0900" priority="2" use="optional"/> <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel1Member" order="1.0300" priority="2" use="optional"/> <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel2Member" order="1.0400" priority="2" use="optional"/> <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel3Member" order="1.0500" priority="2" use="optional"/> <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_InvestmentTypeAxis" xlink:to="us-gaap_InvestmentTypeCategorizationMember" order="1.0000" priority="2" use="optional"/> <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_InvestmentTypeCategorizationMember" xlink:to="us-gaap_CashAndCashEquivalentsMember" order="1.0100" priority="2" use="optional"/> <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_ScheduleOfFairValueOfSeparateAccountsByMajorCategoryOfInvestmentAxis" xlink:to="us-gaap_ScheduleOfFairValueOfSeparateAccountsByMajorCategoryOfInvestmentCategoryDomain" order="1.0000" priority="2" use="optional"/> <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ScheduleOfFairValueOfSeparateAccountsByMajorCategoryOfInvestmentAxis" xlink:to="us-gaap_ScheduleOfFairValueOfSeparateAccountsByMajorCategoryOfInvestmentCategoryDomain_2" order="1.0000" priority="2" use="optional"/> <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ScheduleOfFairValueOfSeparateAccountsByMajorCategoryOfInvestmentCategoryDomain" xlink:to="us-gaap_ShortTermInvestmentsMember" order="1.1000" priority="2" use="optional"/> </definitionLink> <definitionLink xlink:type="extended" xlink:role="http://imetrix.edgar-online.com/taxonomy/role/DisclosureFairValueMeasurementsAdditionalInformation"> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AssetsFairValueDisclosureRecurring" xlink:label="us-gaap_AssetsFairValueDisclosureRecurring"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="us-gaap_FairValueInputsLevel2Member"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="us-gaap_FairValueInputsLevel3Member"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_2"/> <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" order="100.0000" xbrldt:closed="true" xbrldt:contextElement="segment" priority="2" use="optional"/> <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_AssetsFairValueDisclosureRecurring" order="1.0100" priority="2" use="optional"/> <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis" order="1.0000" priority="2" use="optional"/> <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" order="1.0000" priority="2" use="optional"/> <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_2" order="1.0000" priority="2" use="optional"/> <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel2Member" order="1.0200" priority="2" use="optional"/> <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel3Member" order="1.0300" priority="2" use="optional"/> </definitionLink> <definitionLink xlink:type="extended" xlink:role="http://imetrix.edgar-online.com/taxonomy/role/DisclosureBalanceSheetComponentsSummaryOfPropertyAndEquipmentBalances"> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/> <loc xlink:type="locator" xlink:href="cytk-20141231.xsd#cytk_ComputerEquipmentAndSoftwareMember" xlink:label="cytk_ComputerEquipmentAndSoftwareMember"/> <loc xlink:type="locator" xlink:href="cytk-20141231.xsd#cytk_LaboratoryEquipmentMember" xlink:label="cytk_LaboratoryEquipmentMember"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LeaseholdsAndLeaseholdImprovementsMember" xlink:label="us-gaap_LeaseholdsAndLeaseholdImprovementsMember"/> <loc xlink:type="locator" xlink:href="cytk-20141231.xsd#cytk_OfficeEquipmentFurnitureAndFixturesMember" xlink:label="cytk_OfficeEquipmentFurnitureAndFixturesMember"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="us-gaap_PropertyPlantAndEquipmentGross"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNetAbstract" xlink:label="us-gaap_PropertyPlantAndEquipmentNetAbstract"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain_2"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/> <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" order="1.0000" priority="2" use="optional"/> <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain_2" order="1.0000" priority="2" use="optional"/> <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" order="100.0000" xbrldt:closed="true" xbrldt:contextElement="segment" priority="2" use="optional"/> <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentNetAbstract" order="1.0800" priority="2" use="optional"/> <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentNetAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentGross" order="1.0100" priority="2" use="optional"/> <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentNetAbstract" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" order="1.0200" priority="2" use="optional"/> <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentNetAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" order="1.0300" priority="2" use="optional"/> <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="cytk_LaboratoryEquipmentMember" order="1.0400" priority="2" use="optional"/> <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="cytk_ComputerEquipmentAndSoftwareMember" order="1.0500" priority="2" use="optional"/> <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="cytk_OfficeEquipmentFurnitureAndFixturesMember" order="1.0600" priority="2" use="optional"/> <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_LeaseholdsAndLeaseholdImprovementsMember" order="1.0700" priority="2" use="optional"/> <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" order="1.0000" priority="2" use="optional"/> </definitionLink> <definitionLink xlink:type="extended" xlink:role="http://imetrix.edgar-online.com/taxonomy/role/DisclosureBalanceSheetComponentsAdditionalInformation"> </definitionLink> <definitionLink xlink:type="extended" xlink:role="http://imetrix.edgar-online.com/taxonomy/role/DisclosureBalanceSheetComponentsSummaryOfAccruedLiabilities"> </definitionLink> <definitionLink xlink:type="extended" xlink:role="http://imetrix.edgar-online.com/taxonomy/role/DisclosureRelatedPartiesAndRelatedPartyTransactionsAdditionalInformation"> <loc xlink:type="locator" xlink:href="cytk-20141231.xsd#cytk_AmendedAgreementMember" xlink:label="cytk_AmendedAgreementMember"/> <loc xlink:type="locator" xlink:href="cytk-20141231.xsd#cytk_AmgenMember" xlink:label="cytk_AmgenMember"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_2"/> <loc xlink:type="locator" xlink:href="cytk-20141231.xsd#cytk_AstellasMember" xlink:label="cytk_AstellasMember"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis" xlink:label="us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis"/> <loc xlink:type="locator" xlink:href="cytk-20141231.xsd#cytk_CommercialMilestonesMember" xlink:label="cytk_CommercialMilestonesMember"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DeferredRevenue" xlink:label="us-gaap_DeferredRevenue"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DeferredRevenueRevenueRecognized" xlink:label="us-gaap_DeferredRevenueRevenueRecognized"/> <loc xlink:type="locator" xlink:href="cytk-20141231.xsd#cytk_EarlyDevelopmentMember" xlink:label="cytk_EarlyDevelopmentMember"/> <loc xlink:type="locator" xlink:href="cytk-20141231.xsd#cytk_FairValueOfCommonStockIssued" xlink:label="cytk_FairValueOfCommonStockIssued"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_2"/> <loc xlink:type="locator" xlink:href="cytk-20141231.xsd#cytk_InternalCostsMember" xlink:label="cytk_InternalCostsMember"/> <loc xlink:type="locator" xlink:href="cytk-20141231.xsd#cytk_LicenseAndServicesMember" xlink:label="cytk_LicenseAndServicesMember"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LicenseAndServicesRevenue" xlink:label="us-gaap_LicenseAndServicesRevenue"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LicenseCosts" xlink:label="us-gaap_LicenseCosts"/> <loc xlink:type="locator" xlink:href="cytk-20141231.xsd#cytk_LicenseFeeArrangementMember" xlink:label="cytk_LicenseFeeArrangementMember"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_MaximumMember" xlink:label="us-gaap_MaximumMember"/> <loc xlink:type="locator" xlink:href="cytk-20141231.xsd#cytk_MilestonePaymentsReceivedUnderArrangements" xlink:label="cytk_MilestonePaymentsReceivedUnderArrangements"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_MinimumMember" xlink:label="us-gaap_MinimumMember"/> <loc xlink:type="locator" xlink:href="cytk-20141231.xsd#cytk_NonNeuromuscularIndicationsMember" xlink:label="cytk_NonNeuromuscularIndicationsMember"/> <loc xlink:type="locator" xlink:href="cytk-20141231.xsd#cytk_OtherCostsMember" xlink:label="cytk_OtherCostsMember"/> <loc xlink:type="locator" xlink:href="cytk-20141231.xsd#cytk_PotentialAmountsReceivableUnderCollaborationAgreement" xlink:label="cytk_PotentialAmountsReceivableUnderCollaborationAgreement"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ProjectMember" xlink:label="us-gaap_ProjectMember"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ProjectMember" xlink:label="us-gaap_ProjectMember_2"/> <loc xlink:type="locator" xlink:href="cytk-20141231.xsd#cytk_ProportionalPerformanceModelMember" xlink:label="cytk_ProportionalPerformanceModelMember"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RangeAxis" xlink:label="us-gaap_RangeAxis"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RangeMember" xlink:label="us-gaap_RangeMember"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ReimbursementRevenue" xlink:label="us-gaap_ReimbursementRevenue"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RelatedPartyTransactionAxis" xlink:label="us-gaap_RelatedPartyTransactionAxis"/> <loc xlink:type="locator" xlink:href="cytk-20141231.xsd#cytk_RelatedPartyTransactionCommercializationMilestonePaymentsReceivedByEntity" xlink:label="cytk_RelatedPartyTransactionCommercializationMilestonePaymentsReceivedByEntity"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RelatedPartyTransactionDomain" xlink:label="us-gaap_RelatedPartyTransactionDomain"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RelatedPartyTransactionDomain" xlink:label="us-gaap_RelatedPartyTransactionDomain_2"/> <loc xlink:type="locator" xlink:href="cytk-20141231.xsd#cytk_RelatedPartyTransactionPreCommercializationMilestonePaymentsReceivedByEntity" xlink:label="cytk_RelatedPartyTransactionPreCommercializationMilestonePaymentsReceivedByEntity"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned"/> <loc xlink:type="locator" xlink:href="cytk-20141231.xsd#cytk_ResearchAndDevelopmentRevenue" xlink:label="cytk_ResearchAndDevelopmentRevenue"/> <loc xlink:type="locator" xlink:href="cytk-20141231.xsd#cytk_ResearchAndDevelopmentRevenuesFromRelatedParties" xlink:label="cytk_ResearchAndDevelopmentRevenuesFromRelatedParties"/> <loc xlink:type="locator" xlink:href="cytk-20141231.xsd#cytk_ResearchCollaborationAndLicenseAgreementPeriod" xlink:label="cytk_ResearchCollaborationAndLicenseAgreementPeriod"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized" xlink:label="us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized"/> <loc xlink:type="locator" xlink:href="cytk-20141231.xsd#cytk_ScheduleOfOtherRelatedPartyTransactionsLineItems" xlink:label="cytk_ScheduleOfOtherRelatedPartyTransactionsLineItems"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SharePrice" xlink:label="us-gaap_SharePrice"/> <loc xlink:type="locator" xlink:href="cytk-20141231.xsd#cytk_SmaAndOtherNeuromuscularIndicationsMember" xlink:label="cytk_SmaAndOtherNeuromuscularIndicationsMember"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain_2"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis"/> <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="cytk_ProportionalPerformanceModelMember" order="1.2200" priority="2" use="optional"/> <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="cytk_EarlyDevelopmentMember" order="1.2900" priority="2" use="optional"/> <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="cytk_NonNeuromuscularIndicationsMember" order="1.3100" priority="2" use="optional"/> <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="cytk_CommercialMilestonesMember" order="1.3200" priority="2" use="optional"/> <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="cytk_SmaAndOtherNeuromuscularIndicationsMember" order="1.3300" priority="2" use="optional"/> <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis" xlink:to="us-gaap_ProjectMember" order="1.0000" priority="2" use="optional"/> <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis" xlink:to="us-gaap_ProjectMember_2" order="1.0000" priority="2" use="optional"/> <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" order="1.0000" priority="2" use="optional"/> <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_2" order="1.0000" priority="2" use="optional"/> <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="cytk_LicenseAndServicesMember" order="1.2000" priority="2" use="optional"/> <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="cytk_LicenseFeeArrangementMember" order="1.2700" priority="2" use="optional"/> <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ProjectMember" xlink:to="cytk_InternalCostsMember" order="1.2300" priority="2" use="optional"/> <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ProjectMember" xlink:to="cytk_OtherCostsMember" order="1.2800" priority="2" use="optional"/> <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RangeAxis" xlink:to="us-gaap_RangeMember" order="1.0000" priority="2" use="optional"/> <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RangeMember" xlink:to="us-gaap_MaximumMember" order="1.2100" priority="2" use="optional"/> <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RangeMember" xlink:to="us-gaap_MinimumMember" order="1.3000" priority="2" use="optional"/> <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="cytk_AmgenMember" order="1.1900" priority="2" use="optional"/> <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="cytk_AstellasMember" order="1.2600" priority="2" use="optional"/> <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="us-gaap_RelatedPartyTransactionDomain" order="1.0000" priority="2" use="optional"/> <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="us-gaap_RelatedPartyTransactionDomain_2" order="1.0000" priority="2" use="optional"/> <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionDomain" xlink:to="cytk_AmendedAgreementMember" order="1.2400" priority="2" use="optional"/> <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" order="1.0000" priority="2" use="optional"/> <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="cytk_ScheduleOfOtherRelatedPartyTransactionsLineItems" xlink:to="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" order="100.0000" xbrldt:closed="true" xbrldt:contextElement="segment" priority="2" use="optional"/> <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cytk_ScheduleOfOtherRelatedPartyTransactionsLineItems" xlink:to="us-gaap_LicenseCosts" order="1.0100" priority="2" use="optional"/> <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cytk_ScheduleOfOtherRelatedPartyTransactionsLineItems" xlink:to="us-gaap_CommonStockSharesIssued" order="1.0200" priority="2" use="optional"/> <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cytk_ScheduleOfOtherRelatedPartyTransactionsLineItems" xlink:to="us-gaap_SharePrice" order="1.0300" priority="2" use="optional"/> <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cytk_ScheduleOfOtherRelatedPartyTransactionsLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" order="1.0400" priority="2" use="optional"/> <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cytk_ScheduleOfOtherRelatedPartyTransactionsLineItems" xlink:to="cytk_FairValueOfCommonStockIssued" order="1.0500" priority="2" use="optional"/> <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cytk_ScheduleOfOtherRelatedPartyTransactionsLineItems" xlink:to="us-gaap_DeferredRevenue" order="1.0600" priority="2" use="optional"/> <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cytk_ScheduleOfOtherRelatedPartyTransactionsLineItems" xlink:to="us-gaap_LicenseAndServicesRevenue" order="1.0700" priority="2" use="optional"/> <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cytk_ScheduleOfOtherRelatedPartyTransactionsLineItems" xlink:to="cytk_ResearchAndDevelopmentRevenuesFromRelatedParties" order="1.0800" priority="2" use="optional"/> <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cytk_ScheduleOfOtherRelatedPartyTransactionsLineItems" xlink:to="cytk_RelatedPartyTransactionPreCommercializationMilestonePaymentsReceivedByEntity" order="1.0900" priority="2" use="optional"/> <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cytk_ScheduleOfOtherRelatedPartyTransactionsLineItems" xlink:to="cytk_RelatedPartyTransactionCommercializationMilestonePaymentsReceivedByEntity" order="1.1000" priority="2" use="optional"/> <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cytk_ScheduleOfOtherRelatedPartyTransactionsLineItems" xlink:to="us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized" order="1.1100" priority="2" use="optional"/> <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cytk_ScheduleOfOtherRelatedPartyTransactionsLineItems" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned" order="1.1200" priority="2" use="optional"/> <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cytk_ScheduleOfOtherRelatedPartyTransactionsLineItems" xlink:to="cytk_PotentialAmountsReceivableUnderCollaborationAgreement" order="1.1300" priority="2" use="optional"/> <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cytk_ScheduleOfOtherRelatedPartyTransactionsLineItems" xlink:to="cytk_ResearchCollaborationAndLicenseAgreementPeriod" order="1.1400" priority="2" use="optional"/> <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cytk_ScheduleOfOtherRelatedPartyTransactionsLineItems" xlink:to="us-gaap_DeferredRevenueRevenueRecognized" order="1.1500" priority="2" use="optional"/> <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cytk_ScheduleOfOtherRelatedPartyTransactionsLineItems" xlink:to="us-gaap_ReimbursementRevenue" order="1.1600" priority="2" use="optional"/> <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cytk_ScheduleOfOtherRelatedPartyTransactionsLineItems" xlink:to="cytk_MilestonePaymentsReceivedUnderArrangements" order="1.1700" priority="2" use="optional"/> <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cytk_ScheduleOfOtherRelatedPartyTransactionsLineItems" xlink:to="cytk_ResearchAndDevelopmentRevenue" order="1.1800" priority="2" use="optional"/> <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_TypeOfArrangementAxis" order="1.0000" priority="2" use="optional"/> <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_RangeAxis" order="2.0000" priority="2" use="optional"/> <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_RelatedPartyTransactionAxis" order="3.0000" priority="2" use="optional"/> <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis" order="4.0000" priority="2" use="optional"/> <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_SubsequentEventTypeAxis" order="5.0000" priority="2" use="optional"/> <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" order="6.0000" priority="2" use="optional"/> <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" order="7.0000" priority="2" use="optional"/> <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" order="1.0000" priority="2" use="optional"/> <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain_2" order="1.0000" priority="2" use="optional"/> <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventMember" order="1.2500" priority="2" use="optional"/> <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" order="1.0000" priority="2" use="optional"/> <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember_2" order="1.0000" priority="2" use="optional"/> </definitionLink> <definitionLink xlink:type="extended" xlink:role="http://imetrix.edgar-online.com/taxonomy/role/DisclosureRelatedPartiesAndRelatedPartyTransactionsRevenueFromRelatedParty"> <loc xlink:type="locator" xlink:href="cytk-20141231.xsd#cytk_AmgenMember" xlink:label="cytk_AmgenMember"/> <loc xlink:type="locator" xlink:href="cytk-20141231.xsd#cytk_AstellasMember" xlink:label="cytk_AstellasMember"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LicenseAndServicesRevenue" xlink:label="us-gaap_LicenseAndServicesRevenue"/> <loc xlink:type="locator" xlink:href="cytk-20141231.xsd#cytk_ReimbursementOfInternalResearchAndDevelopmentCost" xlink:label="cytk_ReimbursementOfInternalResearchAndDevelopmentCost"/> <loc xlink:type="locator" xlink:href="cytk-20141231.xsd#cytk_ReimbursementOfOtherResearchAndDevelopmentCost" xlink:label="cytk_ReimbursementOfOtherResearchAndDevelopmentCost"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain"/> <loc xlink:type="locator" xlink:href="cytk-20141231.xsd#cytk_RelatedPartyResearchAndDevelopmentRevenue" xlink:label="cytk_RelatedPartyResearchAndDevelopmentRevenue"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RelatedPartyTransactionDueFromToRelatedPartyAbstract" xlink:label="us-gaap_RelatedPartyTransactionDueFromToRelatedPartyAbstract"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ResearchAndDevelopmentAbstract" xlink:label="us-gaap_ResearchAndDevelopmentAbstract"/> <loc xlink:type="locator" xlink:href="cytk-20141231.xsd#cytk_ResearchAndDevelopmentRelatedPartyRevenue" xlink:label="cytk_ResearchAndDevelopmentRelatedPartyRevenue"/> <loc xlink:type="locator" xlink:href="cytk-20141231.xsd#cytk_ResearchAndDevelopmentRevenue" xlink:label="cytk_ResearchAndDevelopmentRevenue"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RevenueFromRelatedParties" xlink:label="us-gaap_RevenueFromRelatedParties"/> <loc xlink:type="locator" xlink:href="cytk-20141231.xsd#cytk_ScheduleOfOtherRelatedPartyTransactionsLineItems" xlink:label="cytk_ScheduleOfOtherRelatedPartyTransactionsLineItems"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable"/> <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="cytk_AmgenMember" order="1.0100" priority="2" use="optional"/> <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="cytk_AstellasMember" order="1.0200" priority="2" use="optional"/> <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionDueFromToRelatedPartyAbstract" xlink:to="cytk_ResearchAndDevelopmentRelatedPartyRevenue" order="1.0300" priority="2" use="optional"/> <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionDueFromToRelatedPartyAbstract" xlink:to="cytk_ReimbursementOfInternalResearchAndDevelopmentCost" order="1.0400" priority="2" use="optional"/> <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionDueFromToRelatedPartyAbstract" xlink:to="cytk_ReimbursementOfOtherResearchAndDevelopmentCost" order="1.0500" priority="2" use="optional"/> <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionDueFromToRelatedPartyAbstract" xlink:to="us-gaap_RevenueFromRelatedParties" order="1.0600" priority="2" use="optional"/> <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" order="1.0000" priority="2" use="optional"/> <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ResearchAndDevelopmentAbstract" xlink:to="cytk_ResearchAndDevelopmentRevenue" order="1.0900" priority="2" use="optional"/> <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="cytk_ScheduleOfOtherRelatedPartyTransactionsLineItems" xlink:to="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" order="100.0000" xbrldt:closed="true" xbrldt:contextElement="segment" priority="2" use="optional"/> <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cytk_ScheduleOfOtherRelatedPartyTransactionsLineItems" xlink:to="us-gaap_LicenseAndServicesRevenue" order="1.1000" priority="2" use="optional"/> <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cytk_ScheduleOfOtherRelatedPartyTransactionsLineItems" xlink:to="us-gaap_RelatedPartyTransactionDueFromToRelatedPartyAbstract" order="1.1100" priority="2" use="optional"/> <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cytk_ScheduleOfOtherRelatedPartyTransactionsLineItems" xlink:to="us-gaap_ResearchAndDevelopmentAbstract" order="1.1200" priority="2" use="optional"/> <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cytk_ScheduleOfOtherRelatedPartyTransactionsLineItems" xlink:to="cytk_RelatedPartyResearchAndDevelopmentRevenue" order="1.1300" priority="2" use="optional"/> <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" order="1.0000" priority="2" use="optional"/> </definitionLink> <definitionLink xlink:type="extended" xlink:role="http://imetrix.edgar-online.com/taxonomy/role/DisclosureOtherResearchAndDevelopmentRevenueArrangementsAdditionalInformation"> </definitionLink> <definitionLink xlink:type="extended" xlink:role="http://imetrix.edgar-online.com/taxonomy/role/DisclosureOtherResearchAndDevelopmentRevenueArrangementsSummaryOfTotalGrantRevenues"> <loc xlink:type="locator" xlink:href="cytk-20141231.xsd#cytk_NindsMyastheniaGravisMember" xlink:label="cytk_NindsMyastheniaGravisMember"/> <loc xlink:type="locator" xlink:href="cytk-20141231.xsd#cytk_OtherGrantRevenueMember" xlink:label="cytk_OtherGrantRevenueMember"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RevenueFromGrants" xlink:label="us-gaap_RevenueFromGrants"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable" xlink:label="us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable"/> <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" order="1.0000" priority="2" use="optional"/> <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable" order="100.0000" xbrldt:closed="true" xbrldt:contextElement="segment" priority="2" use="optional"/> <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="us-gaap_RevenueFromGrants" order="1.0100" priority="2" use="optional"/> <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:to="cytk_NindsMyastheniaGravisMember" order="1.0200" priority="2" use="optional"/> <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:to="cytk_OtherGrantRevenueMember" order="1.0300" priority="2" use="optional"/> <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" order="1.0000" priority="2" use="optional"/> </definitionLink> <definitionLink xlink:type="extended" xlink:role="http://imetrix.edgar-online.com/taxonomy/role/DisclosureOtherResearchAndDevelopmentRevenueArrangementsSummaryOfReimbursedExpenses"> <loc xlink:type="locator" xlink:href="cytk-20141231.xsd#cytk_GlobalBloodTherapeuticsMember" xlink:label="cytk_GlobalBloodTherapeuticsMember"/> <loc xlink:type="locator" xlink:href="cytk-20141231.xsd#cytk_MyokardiaMember" xlink:label="cytk_MyokardiaMember"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ReimbursementRevenue" xlink:label="us-gaap_ReimbursementRevenue"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_2"/> <loc xlink:type="locator" xlink:href="cytk-20141231.xsd#cytk_ResearchAndDevelopmentRevenue" xlink:label="cytk_ResearchAndDevelopmentRevenue"/> <loc xlink:type="locator" xlink:href="cytk-20141231.xsd#cytk_ResearchAndDevelopmentRevenueFromCollaboration" xlink:label="cytk_ResearchAndDevelopmentRevenueFromCollaboration"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable" xlink:label="us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable"/> <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" order="1.0000" priority="2" use="optional"/> <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_2" order="1.0000" priority="2" use="optional"/> <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable" order="100.0000" xbrldt:closed="true" xbrldt:contextElement="segment" priority="2" use="optional"/> <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="cytk_ResearchAndDevelopmentRevenue" order="1.0100" priority="2" use="optional"/> <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="us-gaap_ReimbursementRevenue" order="1.0200" priority="2" use="optional"/> <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="cytk_ResearchAndDevelopmentRevenueFromCollaboration" order="1.0300" priority="2" use="optional"/> <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:to="cytk_GlobalBloodTherapeuticsMember" order="1.0400" priority="2" use="optional"/> <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:to="cytk_MyokardiaMember" order="1.0500" priority="2" use="optional"/> <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" order="1.0000" priority="2" use="optional"/> </definitionLink> <definitionLink xlink:type="extended" xlink:role="http://imetrix.edgar-online.com/taxonomy/role/DisclosureDebtAdditionalInformation"> </definitionLink> <definitionLink xlink:type="extended" xlink:role="http://imetrix.edgar-online.com/taxonomy/role/DisclosureDebtSummaryOfTotalInterestExpenseIncurred"> </definitionLink> <definitionLink xlink:type="extended" xlink:role="http://imetrix.edgar-online.com/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformation"> </definitionLink> <definitionLink xlink:type="extended" xlink:role="http://imetrix.edgar-online.com/taxonomy/role/DisclosureCommitmentsAndContingenciesRentExpense"> </definitionLink> <definitionLink xlink:type="extended" xlink:role="http://imetrix.edgar-online.com/taxonomy/role/DisclosureCommitmentsAndContingenciesFutureMinimumLeasePaymentsUnderNoncancelableOperatingLeases"> </definitionLink> <definitionLink xlink:type="extended" xlink:role="http://imetrix.edgar-online.com/taxonomy/role/DisclosureConvertiblePreferredStockAdditionalInformation"> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ClassOfStockLineItems" xlink:label="us-gaap_ClassOfStockLineItems"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ConversionOfStockSharesConverted1" xlink:label="us-gaap_ConversionOfStockSharesConverted1"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ConversionOfStockSharesIssued1" xlink:label="us-gaap_ConversionOfStockSharesIssued1"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ConvertiblePreferredStockMember" xlink:label="us-gaap_ConvertiblePreferredStockMember"/> <loc xlink:type="locator" xlink:href="cytk-20141231.xsd#cytk_DeerfieldAgreementMember" xlink:label="cytk_DeerfieldAgreementMember"/> <loc xlink:type="locator" xlink:href="cytk-20141231.xsd#cytk_EntitledPaymentPerShareDuringLiquidation" xlink:label="cytk_EntitledPaymentPerShareDuringLiquidation"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/> <loc xlink:type="locator" xlink:href="cytk-20141231.xsd#cytk_ExcessOfCommonStockFairValueOverAllocatedPurchasePriceOfPreferredStock" xlink:label="cytk_ExcessOfCommonStockFairValueOverAllocatedPurchasePriceOfPreferredStock"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IPOMember" xlink:label="us-gaap_IPOMember"/> <loc xlink:type="locator" xlink:href="cytk-20141231.xsd#cytk_NumberOfConcurrentPublicOfferings" xlink:label="cytk_NumberOfConcurrentPublicOfferings"/> <loc xlink:type="locator" xlink:href="cytk-20141231.xsd#cytk_PercentageLimitOnNumberOfSharesOfCommonStockExercisableByHolders" xlink:label="cytk_PercentageLimitOnNumberOfSharesOfCommonStockExercisableByHolders"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="us-gaap_PreferredStockSharesIssued"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="us-gaap_PreferredStockSharesOutstanding"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock" xlink:label="us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="us-gaap_ScheduleOfStockByClassTable"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SeriesAPreferredStockMember" xlink:label="us-gaap_SeriesAPreferredStockMember"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SeriesBPreferredStockMember" xlink:label="us-gaap_SeriesBPreferredStockMember"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SharePrice" xlink:label="us-gaap_SharePrice"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockholdersEquityNoteChangesInCapitalStructureSubsequentChangesToNumberOfCommonShares" xlink:label="us-gaap_StockholdersEquityNoteChangesInCapitalStructureSubsequentChangesToNumberOfCommonShares"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockholdersEquityNoteStockSplit" xlink:label="us-gaap_StockholdersEquityNoteStockSplit"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:label="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis"/> <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_ConvertiblePreferredStockMember" order="1.1500" priority="2" use="optional"/> <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_SeriesAPreferredStockMember" order="1.1800" priority="2" use="optional"/> <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_SeriesBPreferredStockMember" order="1.2000" priority="2" use="optional"/> <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ScheduleOfStockByClassTable" order="100.0000" xbrldt:closed="true" xbrldt:contextElement="segment" priority="2" use="optional"/> <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_PreferredStockSharesAuthorized" order="1.0100" priority="2" use="optional"/> <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_PreferredStockSharesOutstanding" order="1.0200" priority="2" use="optional"/> <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_PreferredStockSharesIssued" order="1.0300" priority="2" use="optional"/> <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_SharePrice" order="1.0400" priority="2" use="optional"/> <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock" order="1.0500" priority="2" use="optional"/> <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="cytk_ExcessOfCommonStockFairValueOverAllocatedPurchasePriceOfPreferredStock" order="1.0600" priority="2" use="optional"/> <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ConversionOfStockSharesConverted1" order="1.0700" priority="2" use="optional"/> <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="cytk_NumberOfConcurrentPublicOfferings" order="1.0800" priority="2" use="optional"/> <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="cytk_PercentageLimitOnNumberOfSharesOfCommonStockExercisableByHolders" order="1.0900" priority="2" use="optional"/> <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="cytk_EntitledPaymentPerShareDuringLiquidation" order="1.1000" priority="2" use="optional"/> <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" order="1.1100" priority="2" use="optional"/> <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_StockholdersEquityNoteStockSplit" order="1.1200" priority="2" use="optional"/> <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_StockholdersEquityNoteChangesInCapitalStructureSubsequentChangesToNumberOfCommonShares" order="1.1300" priority="2" use="optional"/> <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ConversionOfStockSharesIssued1" order="1.1400" priority="2" use="optional"/> <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" order="1.1700" priority="2" use="optional"/> <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="cytk_DeerfieldAgreementMember" order="1.1600" priority="2" use="optional"/> <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_IPOMember" order="1.1900" priority="2" use="optional"/> <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="1.0000" priority="2" use="optional"/> <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" order="2.0000" priority="2" use="optional"/> <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="3.0000" priority="2" use="optional"/> <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="1.0000" priority="2" use="optional"/> <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="1.0000" priority="2" use="optional"/> <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" order="1.0000" priority="2" use="optional"/> </definitionLink> <definitionLink xlink:type="extended" xlink:role="http://imetrix.edgar-online.com/taxonomy/role/DisclosureStockholdersEquityAdditionalInformation"> <loc xlink:type="locator" xlink:href="cytk-20141231.xsd#cytk_AfterReverseStockSplitMember" xlink:label="cytk_AfterReverseStockSplitMember"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense"/> <loc xlink:type="locator" xlink:href="cytk-20141231.xsd#cytk_AmendedAgreementMember" xlink:label="cytk_AmendedAgreementMember"/> <loc xlink:type="locator" xlink:href="cytk-20141231.xsd#cytk_AmgenMember" xlink:label="cytk_AmgenMember"/> <loc xlink:type="locator" xlink:href="cytk-20141231.xsd#cytk_AstellasMember" xlink:label="cytk_AstellasMember"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis"/> <loc xlink:type="locator" xlink:href="cytk-20141231.xsd#cytk_BeforeReverseStockSplitMember" xlink:label="cytk_BeforeReverseStockSplitMember"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ConversionOfStockSharesConverted1" xlink:label="us-gaap_ConversionOfStockSharesConverted1"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ConversionOfStockSharesIssued1" xlink:label="us-gaap_ConversionOfStockSharesIssued1"/> <loc xlink:type="locator" xlink:href="cytk-20141231.xsd#cytk_DeerfieldAgreementMember" xlink:label="cytk_DeerfieldAgreementMember"/> <loc xlink:type="locator" xlink:href="cytk-20141231.xsd#cytk_DeerfieldMember" xlink:label="cytk_DeerfieldMember"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DeferredRevenue" xlink:label="us-gaap_DeferredRevenue"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EmployeeStockMember" xlink:label="us-gaap_EmployeeStockMember"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember"/> <loc xlink:type="locator" xlink:href="cytk-20141231.xsd#cytk_EmployeeStockPurchasePlansAveragePricePerShare" xlink:label="cytk_EmployeeStockPurchasePlansAveragePricePerShare"/> <loc xlink:type="locator" xlink:href="cytk-20141231.xsd#cytk_EntitledPaymentPerShareDuringLiquidation" xlink:label="cytk_EntitledPaymentPerShareDuringLiquidation"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EquityIssuancePerShareAmount" xlink:label="us-gaap_EquityIssuancePerShareAmount"/> <loc xlink:type="locator" xlink:href="cytk-20141231.xsd#cytk_ExistingEmployeeMember" xlink:label="cytk_ExistingEmployeeMember"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueAssumptionsExpectedTerm" xlink:label="us-gaap_FairValueAssumptionsExpectedTerm"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueAssumptionsExpectedVolatilityRate" xlink:label="us-gaap_FairValueAssumptionsExpectedVolatilityRate"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueAssumptionsRiskFreeInterestRate" xlink:label="us-gaap_FairValueAssumptionsRiskFreeInterestRate"/> <loc xlink:type="locator" xlink:href="cytk-20141231.xsd#cytk_FairValueOfCommonStockIssued" xlink:label="cytk_FairValueOfCommonStockIssued"/> <loc xlink:type="locator" xlink:href="cytk-20141231.xsd#cytk_FairValuePerShareOfCommonStock" xlink:label="cytk_FairValuePerShareOfCommonStock"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="us-gaap_FinancialInstrumentAxis"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/> <loc xlink:type="locator" xlink:href="cytk-20141231.xsd#cytk_GrossProceedsFromIssuanceOfStock" xlink:label="cytk_GrossProceedsFromIssuanceOfStock"/> <loc xlink:type="locator" xlink:href="cytk-20141231.xsd#cytk_IssuanceCostOfWarrant" xlink:label="cytk_IssuanceCostOfWarrant"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LiabilitiesFairValueDisclosure" xlink:label="us-gaap_LiabilitiesFairValueDisclosure"/> <loc xlink:type="locator" xlink:href="cytk-20141231.xsd#cytk_LicenseAndServicesMember" xlink:label="cytk_LicenseAndServicesMember"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_MinimumMember" xlink:label="us-gaap_MinimumMember"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners" xlink:label="us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners"/> <loc xlink:type="locator" xlink:href="cytk-20141231.xsd#cytk_MlvAgreementMember" xlink:label="cytk_MlvAgreementMember"/> <loc xlink:type="locator" xlink:href="cytk-20141231.xsd#cytk_NetProceedsFromIssuanceOfWarrants" xlink:label="cytk_NetProceedsFromIssuanceOfWarrants"/> <loc xlink:type="locator" xlink:href="cytk-20141231.xsd#cytk_NewEmployeeMember" xlink:label="cytk_NewEmployeeMember"/> <loc xlink:type="locator" xlink:href="cytk-20141231.xsd#cytk_NineteenNinetySevenStockOptionPlanMember" xlink:label="cytk_NineteenNinetySevenStockOptionPlanMember"/> <loc xlink:type="locator" xlink:href="cytk-20141231.xsd#cytk_NonEmployeeStockBasedCompensationMember" xlink:label="cytk_NonEmployeeStockBasedCompensationMember"/> <loc xlink:type="locator" xlink:href="cytk-20141231.xsd#cytk_NonstatutoryStockOptionsMember" xlink:label="cytk_NonstatutoryStockOptionsMember"/> <loc xlink:type="locator" xlink:href="cytk-20141231.xsd#cytk_NumberOfIssuedSharesOfCommonStockRelatedToCashlessExerciseOfWarrants" xlink:label="cytk_NumberOfIssuedSharesOfCommonStockRelatedToCashlessExerciseOfWarrants"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts"/> <loc xlink:type="locator" xlink:href="cytk-20141231.xsd#cytk_PercentageLimitOnNumberOfSharesOfCommonStockExercisableByHolders" xlink:label="cytk_PercentageLimitOnNumberOfSharesOfCommonStockExercisableByHolders"/> <loc xlink:type="locator" xlink:href="cytk-20141231.xsd#cytk_PercentageOfOptionsGrantToNewEmployees" xlink:label="cytk_PercentageOfOptionsGrantToNewEmployees"/> <loc xlink:type="locator" xlink:href="cytk-20141231.xsd#cytk_PeriodFromPercentageOfStockOptionVested" xlink:label="cytk_PeriodFromPercentageOfStockOptionVested"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain_2"/> <loc xlink:type="locator" xlink:href="cytk-20141231.xsd#cytk_PreferredStockConversionRatio" xlink:label="cytk_PreferredStockConversionRatio"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PreferredStockNoParValue" xlink:label="us-gaap_PreferredStockNoParValue"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="us-gaap_PreferredStockSharesIssued"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock" xlink:label="us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock"/> <loc xlink:type="locator" xlink:href="cytk-20141231.xsd#cytk_ProceedsFromIssuanceOfUnit" xlink:label="cytk_ProceedsFromIssuanceOfUnit"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ProceedsFromIssuanceOfWarrants" xlink:label="us-gaap_ProceedsFromIssuanceOfWarrants"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:label="us-gaap_ProceedsFromIssuanceOrSaleOfEquity"/> <loc xlink:type="locator" xlink:href="cytk-20141231.xsd#cytk_ProceedsFromIssuanceOrSaleOfStockAndWarrant" xlink:label="cytk_ProceedsFromIssuanceOrSaleOfStockAndWarrant"/> <loc xlink:type="locator" xlink:href="cytk-20141231.xsd#cytk_ProceedsFromSalesOfCommonStockNet" xlink:label="cytk_ProceedsFromSalesOfCommonStockNet"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RangeAxis" xlink:label="us-gaap_RangeAxis"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RangeMember" xlink:label="us-gaap_RangeMember"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RelatedPartyTransactionAxis" xlink:label="us-gaap_RelatedPartyTransactionAxis"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RelatedPartyTransactionDomain" xlink:label="us-gaap_RelatedPartyTransactionDomain"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SeriesAPreferredStockMember" xlink:label="us-gaap_SeriesAPreferredStockMember"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SeriesBPreferredStockMember" xlink:label="us-gaap_SeriesBPreferredStockMember"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_2"/> <loc xlink:type="locator" xlink:href="cytk-20141231.xsd#cytk_ShareBasedCompensationLineItems" xlink:label="cytk_ShareBasedCompensationLineItems"/> <loc xlink:type="locator" xlink:href="cytk-20141231.xsd#cytk_ShareBasedCompensationTable" xlink:label="cytk_ShareBasedCompensationTable"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SharePrice" xlink:label="us-gaap_SharePrice"/> <loc xlink:type="locator" xlink:href="cytk-20141231.xsd#cytk_SpecifiedStockholderOwnershipPercentage" xlink:label="cytk_SpecifiedStockholderOwnershipPercentage"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:label="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:label="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues"/> <loc xlink:type="locator" xlink:href="cytk-20141231.xsd#cytk_StockOptionsRepurchaseMaximumPeriod" xlink:label="cytk_StockOptionsRepurchaseMaximumPeriod"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis"/> <loc xlink:type="locator" xlink:href="cytk-20141231.xsd#cytk_TermForStockOptionPlan" xlink:label="cytk_TermForStockOptionPlan"/> <loc xlink:type="locator" xlink:href="cytk-20141231.xsd#cytk_TermForStockOptionPlanForSpecifiedStockHolders" xlink:label="cytk_TermForStockOptionPlanForSpecifiedStockHolders"/> <loc xlink:type="locator" xlink:href="cytk-20141231.xsd#cytk_TermToGrantNonstatutoryStockOptionsAndIncentiveStockOptions" xlink:label="cytk_TermToGrantNonstatutoryStockOptionsAndIncentiveStockOptions"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_TitleOfIndividualAxis" xlink:label="us-gaap_TitleOfIndividualAxis"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="us-gaap_TitleOfIndividualWithRelationshipToEntityDomain"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_2"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_2"/> <loc xlink:type="locator" xlink:href="cytk-20141231.xsd#cytk_TwoThousandAndFourPlanMember" xlink:label="cytk_TwoThousandAndFourPlanMember"/> <loc xlink:type="locator" xlink:href="cytk-20141231.xsd#cytk_UnderwrittenPublicOfferingMember" xlink:label="cytk_UnderwrittenPublicOfferingMember"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_WarrantMember" xlink:label="us-gaap_WarrantMember"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_WarrantsNotSettleableInCashFairValueDisclosure" xlink:label="us-gaap_WarrantsNotSettleableInCashFairValueDisclosure"/> <loc xlink:type="locator" xlink:href="cytk-20141231.xsd#cytk_WarrantsToPurchaseCommonStockMember" xlink:label="cytk_WarrantsToPurchaseCommonStockMember"/> <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="1.0000" priority="2" use="optional"/> <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_2" order="1.0000" priority="2" use="optional"/> <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_SeriesAPreferredStockMember" order="1.6300" priority="2" use="optional"/> <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_SeriesBPreferredStockMember" order="1.7300" priority="2" use="optional"/> <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="cytk_AfterReverseStockSplitMember" order="1.8000" priority="2" use="optional"/> <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="cytk_BeforeReverseStockSplitMember" order="1.8400" priority="2" use="optional"/> <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" order="1.6200" priority="2" use="optional"/> <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" order="1.0000" priority="2" use="optional"/> <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_2" order="1.0000" priority="2" use="optional"/> <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" order="1.0000" priority="2" use="optional"/> <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="cytk_LicenseAndServicesMember" order="1.6600" priority="2" use="optional"/> <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" order="1.0000" priority="2" use="optional"/> <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain_2" order="1.0000" priority="2" use="optional"/> <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="cytk_TwoThousandAndFourPlanMember" order="1.6900" priority="2" use="optional"/> <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="cytk_NineteenNinetySevenStockOptionPlanMember" order="1.7800" priority="2" use="optional"/> <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="cytk_NonEmployeeStockBasedCompensationMember" order="1.8200" priority="2" use="optional"/> <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="us-gaap_EmployeeStockMember" order="1.8500" priority="2" use="optional"/> <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RangeAxis" xlink:to="us-gaap_RangeMember" order="1.0000" priority="2" use="optional"/> <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RangeMember" xlink:to="us-gaap_MinimumMember" order="1.7000" priority="2" use="optional"/> <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="cytk_AmgenMember" order="1.6500" priority="2" use="optional"/> <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="cytk_AstellasMember" order="1.7400" priority="2" use="optional"/> <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="us-gaap_RelatedPartyTransactionDomain" order="1.0000" priority="2" use="optional"/> <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionDomain" xlink:to="cytk_AmendedAgreementMember" order="1.6700" priority="2" use="optional"/> <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" order="1.0000" priority="2" use="optional"/> <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="cytk_DeerfieldAgreementMember" order="1.6100" priority="2" use="optional"/> <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="cytk_DeerfieldMember" order="1.7200" priority="2" use="optional"/> <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="cytk_MlvAgreementMember" order="1.7900" priority="2" use="optional"/> <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="cytk_UnderwrittenPublicOfferingMember" order="1.8300" priority="2" use="optional"/> <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" order="1.7100" priority="2" use="optional"/> <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="cytk_NonstatutoryStockOptionsMember" order="1.7700" priority="2" use="optional"/> <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_RestrictedStockUnitsRSUMember" order="1.8100" priority="2" use="optional"/> <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="cytk_ShareBasedCompensationLineItems" xlink:to="cytk_ShareBasedCompensationTable" order="100.0000" xbrldt:closed="true" xbrldt:contextElement="segment" priority="2" use="optional"/> <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cytk_ShareBasedCompensationLineItems" xlink:to="us-gaap_CommonStockSharesAuthorized" order="1.0100" priority="2" use="optional"/> <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cytk_ShareBasedCompensationLineItems" xlink:to="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" order="1.0200" priority="2" use="optional"/> <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cytk_ShareBasedCompensationLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" order="1.0300" priority="2" use="optional"/> <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cytk_ShareBasedCompensationLineItems" xlink:to="us-gaap_EquityIssuancePerShareAmount" order="1.0400" priority="2" use="optional"/> <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cytk_ShareBasedCompensationLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" order="1.0500" priority="2" use="optional"/> <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cytk_ShareBasedCompensationLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" order="1.0600" priority="2" use="optional"/> <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cytk_ShareBasedCompensationLineItems" xlink:to="cytk_GrossProceedsFromIssuanceOfStock" order="1.0700" priority="2" use="optional"/> <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cytk_ShareBasedCompensationLineItems" xlink:to="cytk_IssuanceCostOfWarrant" order="1.0800" priority="2" use="optional"/> <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cytk_ShareBasedCompensationLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" order="1.0900" priority="2" use="optional"/> <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cytk_ShareBasedCompensationLineItems" xlink:to="cytk_EntitledPaymentPerShareDuringLiquidation" order="1.1000" priority="2" use="optional"/> <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cytk_ShareBasedCompensationLineItems" xlink:to="cytk_PreferredStockConversionRatio" order="1.1100" priority="2" use="optional"/> <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cytk_ShareBasedCompensationLineItems" xlink:to="us-gaap_ConversionOfStockSharesConverted1" order="1.1200" priority="2" use="optional"/> <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cytk_ShareBasedCompensationLineItems" xlink:to="us-gaap_ConversionOfStockSharesIssued1" order="1.1300" priority="2" use="optional"/> <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cytk_ShareBasedCompensationLineItems" xlink:to="us-gaap_PreferredStockSharesIssued" order="1.1400" priority="2" use="optional"/> <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cytk_ShareBasedCompensationLineItems" xlink:to="cytk_ProceedsFromSalesOfCommonStockNet" order="1.1500" priority="2" use="optional"/> <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cytk_ShareBasedCompensationLineItems" xlink:to="us-gaap_CommonStockSharesIssued" order="1.1600" priority="2" use="optional"/> <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cytk_ShareBasedCompensationLineItems" xlink:to="us-gaap_SharePrice" order="1.1700" priority="2" use="optional"/> <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cytk_ShareBasedCompensationLineItems" xlink:to="us-gaap_PreferredStockNoParValue" order="1.1800" priority="2" use="optional"/> <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cytk_ShareBasedCompensationLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOrSaleOfEquity" order="1.1900" priority="2" use="optional"/> <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cytk_ShareBasedCompensationLineItems" xlink:to="us-gaap_PaymentsOfStockIssuanceCosts" order="1.2000" priority="2" use="optional"/> <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cytk_ShareBasedCompensationLineItems" xlink:to="cytk_ProceedsFromIssuanceOrSaleOfStockAndWarrant" order="1.2100" priority="2" use="optional"/> <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cytk_ShareBasedCompensationLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock" order="1.2200" priority="2" use="optional"/> <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cytk_ShareBasedCompensationLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfWarrants" order="1.2300" priority="2" use="optional"/> <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cytk_ShareBasedCompensationLineItems" xlink:to="cytk_FairValueOfCommonStockIssued" order="1.2400" priority="2" use="optional"/> <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cytk_ShareBasedCompensationLineItems" xlink:to="us-gaap_DeferredRevenue" order="1.2500" priority="2" use="optional"/> <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cytk_ShareBasedCompensationLineItems" xlink:to="cytk_NetProceedsFromIssuanceOfWarrants" order="1.2600" priority="2" use="optional"/> <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cytk_ShareBasedCompensationLineItems" xlink:to="cytk_PercentageLimitOnNumberOfSharesOfCommonStockExercisableByHolders" order="1.2700" priority="2" use="optional"/> <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cytk_ShareBasedCompensationLineItems" xlink:to="us-gaap_WarrantsNotSettleableInCashFairValueDisclosure" order="1.2800" priority="2" use="optional"/> <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cytk_ShareBasedCompensationLineItems" xlink:to="us-gaap_FairValueAssumptionsRiskFreeInterestRate" order="1.2900" priority="2" use="optional"/> <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cytk_ShareBasedCompensationLineItems" xlink:to="us-gaap_FairValueAssumptionsExpectedVolatilityRate" order="1.3000" priority="2" use="optional"/> <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cytk_ShareBasedCompensationLineItems" xlink:to="cytk_FairValuePerShareOfCommonStock" order="1.3100" priority="2" use="optional"/> <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cytk_ShareBasedCompensationLineItems" xlink:to="cytk_ProceedsFromIssuanceOfUnit" order="1.3200" priority="2" use="optional"/> <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cytk_ShareBasedCompensationLineItems" xlink:to="us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners" order="1.3300" priority="2" use="optional"/> <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cytk_ShareBasedCompensationLineItems" xlink:to="us-gaap_LiabilitiesFairValueDisclosure" order="1.3400" priority="2" use="optional"/> <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cytk_ShareBasedCompensationLineItems" xlink:to="us-gaap_FairValueAssumptionsExpectedTerm" order="1.3500" priority="2" use="optional"/> <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cytk_ShareBasedCompensationLineItems" xlink:to="cytk_NumberOfIssuedSharesOfCommonStockRelatedToCashlessExerciseOfWarrants" order="1.3600" priority="2" use="optional"/> <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cytk_ShareBasedCompensationLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" order="1.3700" priority="2" use="optional"/> <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cytk_ShareBasedCompensationLineItems" xlink:to="cytk_TermToGrantNonstatutoryStockOptionsAndIncentiveStockOptions" order="1.3800" priority="2" use="optional"/> <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cytk_ShareBasedCompensationLineItems" xlink:to="cytk_PercentageOfOptionsGrantToNewEmployees" order="1.3900" priority="2" use="optional"/> <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cytk_ShareBasedCompensationLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights" order="1.4000" priority="2" use="optional"/> <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cytk_ShareBasedCompensationLineItems" xlink:to="cytk_PeriodFromPercentageOfStockOptionVested" order="1.4100" priority="2" use="optional"/> <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cytk_ShareBasedCompensationLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" order="1.4200" priority="2" use="optional"/> <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cytk_ShareBasedCompensationLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" order="1.4300" priority="2" use="optional"/> <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cytk_ShareBasedCompensationLineItems" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" order="1.4400" priority="2" use="optional"/> <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cytk_ShareBasedCompensationLineItems" xlink:to="cytk_TermForStockOptionPlan" order="1.4500" priority="2" use="optional"/> <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cytk_ShareBasedCompensationLineItems" xlink:to="cytk_SpecifiedStockholderOwnershipPercentage" order="1.4600" priority="2" use="optional"/> <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cytk_ShareBasedCompensationLineItems" xlink:to="cytk_TermForStockOptionPlanForSpecifiedStockHolders" order="1.4700" priority="2" use="optional"/> <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cytk_ShareBasedCompensationLineItems" xlink:to="cytk_StockOptionsRepurchaseMaximumPeriod" order="1.4800" priority="2" use="optional"/> <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cytk_ShareBasedCompensationLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" order="1.4900" priority="2" use="optional"/> <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cytk_ShareBasedCompensationLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" order="1.5000" priority="2" use="optional"/> <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cytk_ShareBasedCompensationLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" order="1.5100" priority="2" use="optional"/> <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cytk_ShareBasedCompensationLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" order="1.5200" priority="2" use="optional"/> <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cytk_ShareBasedCompensationLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" order="1.5300" priority="2" use="optional"/> <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cytk_ShareBasedCompensationLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" order="1.5400" priority="2" use="optional"/> <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cytk_ShareBasedCompensationLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" order="1.5500" priority="2" use="optional"/> <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cytk_ShareBasedCompensationLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" order="1.5600" priority="2" use="optional"/> <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cytk_ShareBasedCompensationLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" order="1.5700" priority="2" use="optional"/> <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cytk_ShareBasedCompensationLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" order="1.5800" priority="2" use="optional"/> <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cytk_ShareBasedCompensationLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" order="1.5900" priority="2" use="optional"/> <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cytk_ShareBasedCompensationLineItems" xlink:to="cytk_EmployeeStockPurchasePlansAveragePricePerShare" order="1.6000" priority="2" use="optional"/> <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="cytk_ShareBasedCompensationTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="1.0000" priority="2" use="optional"/> <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="cytk_ShareBasedCompensationTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" order="2.0000" priority="2" use="optional"/> <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="cytk_ShareBasedCompensationTable" xlink:to="us-gaap_RelatedPartyTransactionAxis" order="3.0000" priority="2" use="optional"/> <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="cytk_ShareBasedCompensationTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="4.0000" priority="2" use="optional"/> <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="cytk_ShareBasedCompensationTable" xlink:to="us-gaap_RangeAxis" order="5.0000" priority="2" use="optional"/> <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="cytk_ShareBasedCompensationTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" order="6.0000" priority="2" use="optional"/> <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="cytk_ShareBasedCompensationTable" xlink:to="us-gaap_PlanNameAxis" order="7.0000" priority="2" use="optional"/> <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="cytk_ShareBasedCompensationTable" xlink:to="us-gaap_FinancialInstrumentAxis" order="8.0000" priority="2" use="optional"/> <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="cytk_ShareBasedCompensationTable" xlink:to="us-gaap_AwardTypeAxis" order="9.0000" priority="2" use="optional"/> <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="cytk_ShareBasedCompensationTable" xlink:to="us-gaap_TitleOfIndividualAxis" order="10.0000" priority="2" use="optional"/> <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="cytk_ShareBasedCompensationTable" xlink:to="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" order="11.0000" priority="2" use="optional"/> <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="1.0000" priority="2" use="optional"/> <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="1.0000" priority="2" use="optional"/> <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" order="1.0000" priority="2" use="optional"/> <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_TitleOfIndividualAxis" xlink:to="us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" order="1.0000" priority="2" use="optional"/> <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_TitleOfIndividualAxis" xlink:to="us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_2" order="1.0000" priority="2" use="optional"/> <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="cytk_NewEmployeeMember" order="1.6800" priority="2" use="optional"/> <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="cytk_ExistingEmployeeMember" order="1.7600" priority="2" use="optional"/> <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_WarrantMember" order="1.6400" priority="2" use="optional"/> <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="cytk_WarrantsToPurchaseCommonStockMember" order="1.7500" priority="2" use="optional"/> </definitionLink> <definitionLink xlink:type="extended" xlink:role="http://imetrix.edgar-online.com/taxonomy/role/DisclosureStockholdersEquityOutstandingWarrants"> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain_2"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights"/> <loc xlink:type="locator" xlink:href="cytk-20141231.xsd#cytk_ShareBasedCompensationLineItems" xlink:label="cytk_ShareBasedCompensationLineItems"/> <loc xlink:type="locator" xlink:href="cytk-20141231.xsd#cytk_ShareBasedCompensationTable" xlink:label="cytk_ShareBasedCompensationTable"/> <loc xlink:type="locator" xlink:href="cytk-20141231.xsd#cytk_WarrantExpirationDate" xlink:label="cytk_WarrantExpirationDate"/> <loc xlink:type="locator" xlink:href="cytk-20141231.xsd#cytk_WarrantOneMember" xlink:label="cytk_WarrantOneMember"/> <loc xlink:type="locator" xlink:href="cytk-20141231.xsd#cytk_WarrantTwoMember" xlink:label="cytk_WarrantTwoMember"/> <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain" order="1.0000" priority="2" use="optional"/> <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain_2" order="1.0000" priority="2" use="optional"/> <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="cytk_WarrantOneMember" order="1.0100" priority="2" use="optional"/> <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="cytk_WarrantTwoMember" order="1.0200" priority="2" use="optional"/> <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="cytk_ShareBasedCompensationLineItems" xlink:to="cytk_ShareBasedCompensationTable" order="100.0000" xbrldt:closed="true" xbrldt:contextElement="segment" priority="2" use="optional"/> <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cytk_ShareBasedCompensationLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" order="1.0300" priority="2" use="optional"/> <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cytk_ShareBasedCompensationLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" order="1.0400" priority="2" use="optional"/> <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cytk_ShareBasedCompensationLineItems" xlink:to="cytk_WarrantExpirationDate" order="1.0500" priority="2" use="optional"/> <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="cytk_ShareBasedCompensationTable" xlink:to="us-gaap_ClassOfWarrantOrRightAxis" order="1.0000" priority="2" use="optional"/> </definitionLink> <definitionLink xlink:type="extended" xlink:role="http://imetrix.edgar-online.com/taxonomy/role/DisclosureStockholdersEquitySummaryOfStockOptionActivity"> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/> <loc xlink:type="locator" xlink:href="cytk-20141231.xsd#cytk_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedInPeriodWeightedAverageExercisePrice" xlink:label="cytk_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedInPeriodWeightedAverageExercisePrice"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod"/> <loc xlink:type="locator" xlink:href="cytk-20141231.xsd#cytk_ShareBasedCompensationArrangementByShareBasedPaymentSharesAvailableForGrantAwardOptionsExercisedInPeriodGross" xlink:label="cytk_ShareBasedCompensationArrangementByShareBasedPaymentSharesAvailableForGrantAwardOptionsExercisedInPeriodGross"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/> <loc xlink:type="locator" xlink:href="cytk-20141231.xsd#cytk_ShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentOtherThanOptionForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="cytk_ShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentOtherThanOptionForfeituresInPeriodWeightedAverageExercisePrice"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/> <loc xlink:type="locator" xlink:href="cytk-20141231.xsd#cytk_SharesAvailableForGrantOfOptionsOrAwardsOptionsForfeitedExpired" xlink:label="cytk_SharesAvailableForGrantOfOptionsOrAwardsOptionsForfeitedExpired"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/> <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="1.0000" priority="2" use="optional"/> <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" order="1.0100" priority="2" use="optional"/> <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_AwardTypeAxis" order="1.0000" priority="2" use="optional"/> <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="2.0000" priority="2" use="optional"/> <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="100.0000" xbrldt:closed="true" xbrldt:contextElement="segment" priority="2" use="optional"/> <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" order="1.0200" priority="2" use="optional"/> <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" order="1.0300" priority="2" use="optional"/> <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" order="1.0400" priority="2" use="optional"/> <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" order="1.0500" priority="2" use="optional"/> <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" order="1.0600" priority="2" use="optional"/> <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="cytk_ShareBasedCompensationArrangementByShareBasedPaymentSharesAvailableForGrantAwardOptionsExercisedInPeriodGross" order="1.0700" priority="2" use="optional"/> <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" order="1.0800" priority="2" use="optional"/> <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="cytk_SharesAvailableForGrantOfOptionsOrAwardsOptionsForfeitedExpired" order="1.0900" priority="2" use="optional"/> <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="cytk_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedInPeriodWeightedAverageExercisePrice" order="1.1000" priority="2" use="optional"/> <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="cytk_ShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentOtherThanOptionForfeituresInPeriodWeightedAverageExercisePrice" order="1.1200" priority="2" use="optional"/> <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" order="1.1300" priority="2" use="optional"/> <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" order="1.1400" priority="2" use="optional"/> <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" order="1.1500" priority="2" use="optional"/> <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" order="1.1600" priority="2" use="optional"/> <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" order="1.1800" priority="2" use="optional"/> <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" order="1.1900" priority="2" use="optional"/> <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" order="1.2000" priority="2" use="optional"/> <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" order="1.2100" priority="2" use="optional"/> <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" order="1.2200" priority="2" use="optional"/> <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" order="1.2300" priority="2" use="optional"/> <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" order="1.2500" priority="2" use="optional"/> <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" order="1.2600" priority="2" use="optional"/> <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" order="1.2700" priority="2" use="optional"/> <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" order="1.2800" priority="2" use="optional"/> <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" order="1.2900" priority="2" use="optional"/> <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" order="1.3000" priority="2" use="optional"/> <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" order="1.3100" priority="2" use="optional"/> <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" order="1.3200" priority="2" use="optional"/> <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_RestrictedStockUnitsRSUMember" order="1.3300" priority="2" use="optional"/> <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="1.0000" priority="2" use="optional"/> </definitionLink> <definitionLink xlink:type="extended" xlink:role="http://imetrix.edgar-online.com/taxonomy/role/DisclosureStockholdersEquitySummaryOfRestrictedStockUnitActivity"> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RestrictedStockMember" xlink:label="us-gaap_RestrictedStockMember"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/> <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="1.0000" priority="2" use="optional"/> <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_AwardTypeAxis" order="1.0000" priority="2" use="optional"/> <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="100.0000" xbrldt:closed="true" xbrldt:contextElement="segment" priority="2" use="optional"/> <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" order="1.0100" priority="2" use="optional"/> <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" order="1.0200" priority="2" use="optional"/> <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" order="1.0300" priority="2" use="optional"/> <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" order="1.0400" priority="2" use="optional"/> <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" order="1.0500" priority="2" use="optional"/> <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" order="1.0700" priority="2" use="optional"/> <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" order="1.0800" priority="2" use="optional"/> <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" order="1.0900" priority="2" use="optional"/> <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_RestrictedStockMember" order="1.1100" priority="2" use="optional"/> </definitionLink> <definitionLink xlink:type="extended" xlink:role="http://imetrix.edgar-online.com/taxonomy/role/DisclosureStockholdersEquityStockBasedCompensationRelatedToStockOptionsRestrictedStockAwardsRestrictedStockUnitAndEmployeeStockPurchases"> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain_2"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/> <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" order="100.0000" xbrldt:closed="true" xbrldt:contextElement="segment" priority="2" use="optional"/> <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" order="1.0300" priority="2" use="optional"/> <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" order="1.0000" priority="2" use="optional"/> <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain_2" order="1.0000" priority="2" use="optional"/> <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember" order="1.0100" priority="2" use="optional"/> <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember" order="1.0200" priority="2" use="optional"/> <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="us-gaap_IncomeStatementLocationAxis" order="1.0000" priority="2" use="optional"/> </definitionLink> <definitionLink xlink:type="extended" xlink:role="http://imetrix.edgar-online.com/taxonomy/role/DisclosureStockholdersEquityFairValueOfShareBasedPaymentsWasEstimatedOnDateOfGrantUsingBlackScholesOptionPricingModelBasedOnWeightedAverageAssumptions"> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsLineItems" xlink:label="us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsLineItems"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EmployeeStockMember" xlink:label="us-gaap_EmployeeStockMember"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfDeferredCompensationArrangementWithIndividualShareBasedPaymentsTable" xlink:label="us-gaap_ScheduleOfDeferredCompensationArrangementWithIndividualShareBasedPaymentsTable"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis"/> <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="1.0000" priority="2" use="optional"/> <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsLineItems" xlink:to="us-gaap_ScheduleOfDeferredCompensationArrangementWithIndividualShareBasedPaymentsTable" order="100.0000" xbrldt:closed="true" xbrldt:contextElement="segment" priority="2" use="optional"/> <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" order="1.0200" priority="2" use="optional"/> <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" order="1.0300" priority="2" use="optional"/> <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" order="1.0400" priority="2" use="optional"/> <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" order="1.0500" priority="2" use="optional"/> <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_EmployeeStockMember" order="1.0100" priority="2" use="optional"/> <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfDeferredCompensationArrangementWithIndividualShareBasedPaymentsTable" xlink:to="us-gaap_AwardTypeAxis" order="1.0000" priority="2" use="optional"/> <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfDeferredCompensationArrangementWithIndividualShareBasedPaymentsTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" order="2.0000" priority="2" use="optional"/> <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" order="1.0600" priority="2" use="optional"/> <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" order="1.0000" priority="2" use="optional"/> </definitionLink> <definitionLink xlink:type="extended" xlink:role="http://imetrix.edgar-online.com/taxonomy/role/DisclosureIncomeTaxesAdditionalInformation"> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DomesticCountryMember" xlink:label="us-gaap_DomesticCountryMember"/> <loc xlink:type="locator" xlink:href="cytk-20141231.xsd#cytk_FederalNetOperatingLossRelatesToStockOptionDeductions" xlink:label="cytk_FederalNetOperatingLossRelatesToStockOptionDeductions"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="us-gaap_IncomeTaxAuthorityAxis"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="us-gaap_IncomeTaxAuthorityDomain"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="us-gaap_IncomeTaxAuthorityDomain_2"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncomeTaxContingencyLineItems" xlink:label="us-gaap_IncomeTaxContingencyLineItems"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncomeTaxContingencyTable" xlink:label="us-gaap_IncomeTaxContingencyTable"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncomeTaxExaminationPenaltiesAndInterestAccrued" xlink:label="us-gaap_IncomeTaxExaminationPenaltiesAndInterestAccrued"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncomeTaxReconciliationTaxCredits" xlink:label="us-gaap_IncomeTaxReconciliationTaxCredits"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="us-gaap_OperatingLossCarryforwards"/> <loc xlink:type="locator" xlink:href="cytk-20141231.xsd#cytk_OperatingLossCarryforwardsExpirationYear" xlink:label="cytk_OperatingLossCarryforwardsExpirationYear"/> <loc xlink:type="locator" xlink:href="cytk-20141231.xsd#cytk_PercentageOfIncomeTaxPositionsLikelyToBeRealized" xlink:label="cytk_PercentageOfIncomeTaxPositionsLikelyToBeRealized"/> <loc xlink:type="locator" xlink:href="cytk-20141231.xsd#cytk_ResearchAndDevelopmentFederalTaxCreditCarryforwardsExpirationDateYear" xlink:label="cytk_ResearchAndDevelopmentFederalTaxCreditCarryforwardsExpirationDateYear"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StateAndLocalJurisdictionMember" xlink:label="us-gaap_StateAndLocalJurisdictionMember"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate" xlink:label="us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:label="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount"/> <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityDomain" order="1.0000" priority="2" use="optional"/> <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityDomain_2" order="1.0000" priority="2" use="optional"/> <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_DomesticCountryMember" order="1.1100" priority="2" use="optional"/> <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_StateAndLocalJurisdictionMember" order="1.1200" priority="2" use="optional"/> <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_IncomeTaxContingencyLineItems" xlink:to="us-gaap_IncomeTaxContingencyTable" order="100.0000" xbrldt:closed="true" xbrldt:contextElement="segment" priority="2" use="optional"/> <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxContingencyLineItems" xlink:to="us-gaap_IncomeTaxExpenseBenefit" order="1.0100" priority="2" use="optional"/> <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxContingencyLineItems" xlink:to="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" order="1.0200" priority="2" use="optional"/> <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxContingencyLineItems" xlink:to="cytk_FederalNetOperatingLossRelatesToStockOptionDeductions" order="1.0300" priority="2" use="optional"/> <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxContingencyLineItems" xlink:to="us-gaap_OperatingLossCarryforwards" order="1.0400" priority="2" use="optional"/> <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxContingencyLineItems" xlink:to="cytk_OperatingLossCarryforwardsExpirationYear" order="1.0500" priority="2" use="optional"/> <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxContingencyLineItems" xlink:to="us-gaap_IncomeTaxReconciliationTaxCredits" order="1.0600" priority="2" use="optional"/> <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxContingencyLineItems" xlink:to="cytk_ResearchAndDevelopmentFederalTaxCreditCarryforwardsExpirationDateYear" order="1.0700" priority="2" use="optional"/> <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxContingencyLineItems" xlink:to="cytk_PercentageOfIncomeTaxPositionsLikelyToBeRealized" order="1.0800" priority="2" use="optional"/> <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxContingencyLineItems" xlink:to="us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate" order="1.0900" priority="2" use="optional"/> <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxContingencyLineItems" xlink:to="us-gaap_IncomeTaxExaminationPenaltiesAndInterestAccrued" order="1.1000" priority="2" use="optional"/> <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_IncomeTaxContingencyTable" xlink:to="us-gaap_IncomeTaxAuthorityAxis" order="1.0000" priority="2" use="optional"/> </definitionLink> <definitionLink xlink:type="extended" xlink:role="http://imetrix.edgar-online.com/taxonomy/role/DisclosureIncomeTaxesScheduleOfComponentsOfIncomeBeforeTaxes"> </definitionLink> <definitionLink xlink:type="extended" xlink:role="http://imetrix.edgar-online.com/taxonomy/role/DisclosureIncomeTaxesCompanyRecordedIncomeTaxProvision"> </definitionLink> <definitionLink xlink:type="extended" xlink:role="http://imetrix.edgar-online.com/taxonomy/role/DisclosureIncomeTaxesCompanysDeferredTaxAssetsAndLiabilities"> </definitionLink> <definitionLink xlink:type="extended" xlink:role="http://imetrix.edgar-online.com/taxonomy/role/DisclosureIncomeTaxesCompanysValuationAndQualifyingAccounts"> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ValuationAllowanceOfDeferredTaxAssetsMember" xlink:label="us-gaap_ValuationAllowanceOfDeferredTaxAssetsMember"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ValuationAllowancesAndReservesBalance" xlink:label="us-gaap_ValuationAllowancesAndReservesBalance"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ValuationAllowancesAndReservesChargedToCostAndExpense" xlink:label="us-gaap_ValuationAllowancesAndReservesChargedToCostAndExpense"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ValuationAllowancesAndReservesChargedToOtherAccounts" xlink:label="us-gaap_ValuationAllowancesAndReservesChargedToOtherAccounts"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ValuationAllowancesAndReservesDeductions" xlink:label="us-gaap_ValuationAllowancesAndReservesDeductions"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ValuationAllowancesAndReservesDomain" xlink:label="us-gaap_ValuationAllowancesAndReservesDomain"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ValuationAllowancesAndReservesDomain" xlink:label="us-gaap_ValuationAllowancesAndReservesDomain_2"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ValuationAllowancesAndReservesTypeAxis" xlink:label="us-gaap_ValuationAllowancesAndReservesTypeAxis"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ValuationAndQualifyingAccountsDisclosureLineItems" xlink:label="us-gaap_ValuationAndQualifyingAccountsDisclosureLineItems"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ValuationAndQualifyingAccountsDisclosureTable" xlink:label="us-gaap_ValuationAndQualifyingAccountsDisclosureTable"/> <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ValuationAllowancesAndReservesDomain" xlink:to="us-gaap_ValuationAllowanceOfDeferredTaxAssetsMember" order="1.0600" priority="2" use="optional"/> <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_ValuationAllowancesAndReservesTypeAxis" xlink:to="us-gaap_ValuationAllowancesAndReservesDomain" order="1.0000" priority="2" use="optional"/> <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ValuationAllowancesAndReservesTypeAxis" xlink:to="us-gaap_ValuationAllowancesAndReservesDomain_2" order="1.0000" priority="2" use="optional"/> <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ValuationAndQualifyingAccountsDisclosureLineItems" xlink:to="us-gaap_ValuationAndQualifyingAccountsDisclosureTable" order="100.0000" xbrldt:closed="true" xbrldt:contextElement="segment" priority="2" use="optional"/> <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ValuationAndQualifyingAccountsDisclosureLineItems" xlink:to="us-gaap_ValuationAllowancesAndReservesBalance" order="1.0100" priority="2" use="optional"/> <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ValuationAndQualifyingAccountsDisclosureLineItems" xlink:to="us-gaap_ValuationAllowancesAndReservesChargedToCostAndExpense" order="1.0200" priority="2" use="optional"/> <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ValuationAndQualifyingAccountsDisclosureLineItems" xlink:to="us-gaap_ValuationAllowancesAndReservesChargedToOtherAccounts" order="1.0300" priority="2" use="optional"/> <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ValuationAndQualifyingAccountsDisclosureLineItems" xlink:to="us-gaap_ValuationAllowancesAndReservesDeductions" order="1.0400" priority="2" use="optional"/> <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ValuationAndQualifyingAccountsDisclosureTable" xlink:to="us-gaap_ValuationAllowancesAndReservesTypeAxis" order="1.0000" priority="2" use="optional"/> </definitionLink> <definitionLink xlink:type="extended" xlink:role="http://imetrix.edgar-online.com/taxonomy/role/DisclosureIncomeTaxesReconciliationOfStatutoryFederalIncomeTaxRateToEffectiveTaxRate"> </definitionLink> <definitionLink xlink:type="extended" xlink:role="http://imetrix.edgar-online.com/taxonomy/role/DisclosureIncomeTaxesReconciliationOfTotalAmountsOfUnrecognizedTaxBenefits"> <loc xlink:type="locator" xlink:href="cytk-20141231.xsd#cytk_FederalAndStateTaxMember" xlink:label="cytk_FederalAndStateTaxMember"/> <loc xlink:type="locator" xlink:href="cytk-20141231.xsd#cytk_FederalTaxBenefitOfStateIncomeTaxUtbMember" xlink:label="cytk_FederalTaxBenefitOfStateIncomeTaxUtbMember"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="us-gaap_IncomeTaxAuthorityAxis"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="us-gaap_IncomeTaxAuthorityDomain"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncomeTaxContingencyLineItems" xlink:label="us-gaap_IncomeTaxContingencyLineItems"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncomeTaxContingencyTable" xlink:label="us-gaap_IncomeTaxContingencyTable"/> <loc xlink:type="locator" xlink:href="cytk-20141231.xsd#cytk_UnrecognizedIncomeTaxBenefitsNetOfFederalBenefitOfStateIncomeTaxUtbMember" xlink:label="cytk_UnrecognizedIncomeTaxBenefitsNetOfFederalBenefitOfStateIncomeTaxUtbMember"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:label="us-gaap_UnrecognizedTaxBenefits"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" xlink:label="us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions"/> <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityDomain" order="1.0000" priority="2" use="optional"/> <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="cytk_FederalAndStateTaxMember" order="1.0600" priority="2" use="optional"/> <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="cytk_FederalTaxBenefitOfStateIncomeTaxUtbMember" order="1.0700" priority="2" use="optional"/> <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="cytk_UnrecognizedIncomeTaxBenefitsNetOfFederalBenefitOfStateIncomeTaxUtbMember" order="1.0800" priority="2" use="optional"/> <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_IncomeTaxContingencyLineItems" xlink:to="us-gaap_IncomeTaxContingencyTable" order="100.0000" xbrldt:closed="true" xbrldt:contextElement="segment" priority="2" use="optional"/> <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxContingencyLineItems" xlink:to="us-gaap_UnrecognizedTaxBenefits" order="1.0100" priority="2" use="optional"/> <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxContingencyLineItems" xlink:to="us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" order="1.0200" priority="2" use="optional"/> <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxContingencyLineItems" xlink:to="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" order="1.0300" priority="2" use="optional"/> <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxContingencyLineItems" xlink:to="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" order="1.0400" priority="2" use="optional"/> <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_IncomeTaxContingencyTable" xlink:to="us-gaap_IncomeTaxAuthorityAxis" order="1.0000" priority="2" use="optional"/> </definitionLink> <definitionLink xlink:type="extended" xlink:role="http://imetrix.edgar-online.com/taxonomy/role/DisclosureInterestAndOtherNetComponentsOfInterestAndOtherNet"> </definitionLink> <definitionLink xlink:type="extended" xlink:role="http://imetrix.edgar-online.com/taxonomy/role/DisclosureQuarterlyFinancialDataSummaryOfQuarterlyResults"> </definitionLink> <definitionLink xlink:type="extended" xlink:role="http://imetrix.edgar-online.com/taxonomy/role/NotesToFinancialStatementsOrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock"> </definitionLink> <definitionLink xlink:type="extended" xlink:role="http://imetrix.edgar-online.com/taxonomy/role/NotesToFinancialStatementsOrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlockPolicies"> </definitionLink> <definitionLink xlink:type="extended" xlink:role="http://imetrix.edgar-online.com/taxonomy/role/NotesToFinancialStatementsEarningsPerShareTextBlock"> </definitionLink> <definitionLink xlink:type="extended" xlink:role="http://imetrix.edgar-online.com/taxonomy/role/NotesToFinancialStatementsEarningsPerShareTextBlockTables"> </definitionLink> <definitionLink xlink:type="extended" xlink:role="http://imetrix.edgar-online.com/taxonomy/role/NotesToFinancialStatementsCashFlowSupplementalDisclosuresTextBlock"> </definitionLink> <definitionLink xlink:type="extended" xlink:role="http://imetrix.edgar-online.com/taxonomy/role/NotesToFinancialStatementsCashFlowSupplementalDisclosuresTextBlockTables"> </definitionLink> <definitionLink xlink:type="extended" xlink:role="http://imetrix.edgar-online.com/taxonomy/role/NotesToFinancialStatementsInvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock"> </definitionLink> <definitionLink xlink:type="extended" xlink:role="http://imetrix.edgar-online.com/taxonomy/role/NotesToFinancialStatementsInvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlockTables"> </definitionLink> <definitionLink xlink:type="extended" xlink:role="http://imetrix.edgar-online.com/taxonomy/role/NotesToFinancialStatementsFairValueDisclosuresTextBlock"> </definitionLink> <definitionLink xlink:type="extended" xlink:role="http://imetrix.edgar-online.com/taxonomy/role/NotesToFinancialStatementsFairValueDisclosuresTextBlockTables"> </definitionLink> <definitionLink xlink:type="extended" xlink:role="http://imetrix.edgar-online.com/taxonomy/role/NotesToFinancialStatementsSupplementalBalanceSheetDisclosuresTextBlock"> </definitionLink> <definitionLink xlink:type="extended" xlink:role="http://imetrix.edgar-online.com/taxonomy/role/NotesToFinancialStatementsSupplementalBalanceSheetDisclosuresTextBlockTables"> </definitionLink> <definitionLink xlink:type="extended" xlink:role="http://imetrix.edgar-online.com/taxonomy/role/NotesToFinancialStatementsRelatedPartyTransactionsDisclosureTextBlock"> </definitionLink> <definitionLink xlink:type="extended" xlink:role="http://imetrix.edgar-online.com/taxonomy/role/NotesToFinancialStatementsRelatedPartyTransactionsDisclosureTextBlockTables"> <loc xlink:type="locator" xlink:href="cytk-20141231.xsd#cytk_AmgenMember" xlink:label="cytk_AmgenMember"/> <loc xlink:type="locator" xlink:href="cytk-20141231.xsd#cytk_AstellasMember" xlink:label="cytk_AstellasMember"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/> <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="cytk_AstellasMember" order="1.0200" priority="2" use="optional"/> <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="cytk_AmgenMember" order="1.0300" priority="2" use="optional"/> <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" order="1.0000" priority="2" use="optional"/> <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" order="100.0000" xbrldt:closed="true" xbrldt:contextElement="segment" priority="2" use="optional"/> <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock" order="1.0100" priority="2" use="optional"/> <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" order="1.0000" priority="2" use="optional"/> </definitionLink> <definitionLink xlink:type="extended" xlink:role="http://imetrix.edgar-online.com/taxonomy/role/NotesToFinancialStatementsResearchDevelopmentAndComputerSoftwareDisclosureTextBlock"> </definitionLink> <definitionLink xlink:type="extended" xlink:role="http://imetrix.edgar-online.com/taxonomy/role/NotesToFinancialStatementsResearchDevelopmentAndComputerSoftwareDisclosureTextBlockTables"> <loc xlink:type="locator" xlink:href="cytk-20141231.xsd#cytk_GlobalBloodTherapeuticsMember" xlink:label="cytk_GlobalBloodTherapeuticsMember"/> <loc xlink:type="locator" xlink:href="cytk-20141231.xsd#cytk_MyokardiaMember" xlink:label="cytk_MyokardiaMember"/> <loc xlink:type="locator" xlink:href="cytk-20141231.xsd#cytk_OtherResearchAndDevelopmentRevenueArrangementsRecognizedGrantRevenueTableTextBlock" xlink:label="cytk_OtherResearchAndDevelopmentRevenueArrangementsRecognizedGrantRevenueTableTextBlock"/> <loc xlink:type="locator" xlink:href="cytk-20141231.xsd#cytk_OtherResearchAndDevelopmentRevenueArrangementsReimbursementOfExpenseTableTextBlock" xlink:label="cytk_OtherResearchAndDevelopmentRevenueArrangementsReimbursementOfExpenseTableTextBlock"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/> <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" order="1.0000" priority="2" use="optional"/> <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:to="cytk_GlobalBloodTherapeuticsMember" order="1.0300" priority="2" use="optional"/> <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:to="cytk_MyokardiaMember" order="1.0400" priority="2" use="optional"/> <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" order="100.0000" xbrldt:closed="true" xbrldt:contextElement="segment" priority="2" use="optional"/> <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="cytk_OtherResearchAndDevelopmentRevenueArrangementsRecognizedGrantRevenueTableTextBlock" order="1.0100" priority="2" use="optional"/> <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="cytk_OtherResearchAndDevelopmentRevenueArrangementsReimbursementOfExpenseTableTextBlock" order="1.0200" priority="2" use="optional"/> <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" order="1.0000" priority="2" use="optional"/> </definitionLink> <definitionLink xlink:type="extended" xlink:role="http://imetrix.edgar-online.com/taxonomy/role/NotesToFinancialStatementsDebtDisclosureTextBlock"> </definitionLink> <definitionLink xlink:type="extended" xlink:role="http://imetrix.edgar-online.com/taxonomy/role/NotesToFinancialStatementsDebtDisclosureTextBlockTables"> </definitionLink> <definitionLink xlink:type="extended" xlink:role="http://imetrix.edgar-online.com/taxonomy/role/NotesToFinancialStatementsCommitmentsAndContingenciesDisclosureTextBlock"> </definitionLink> <definitionLink xlink:type="extended" xlink:role="http://imetrix.edgar-online.com/taxonomy/role/NotesToFinancialStatementsCommitmentsAndContingenciesDisclosureTextBlockTables"> </definitionLink> <definitionLink xlink:type="extended" xlink:role="http://imetrix.edgar-online.com/taxonomy/role/NotesToFinancialStatementsPreferredStockTextBlock"> </definitionLink> <definitionLink xlink:type="extended" xlink:role="http://imetrix.edgar-online.com/taxonomy/role/NotesToFinancialStatementsStockholdersEquityNoteDisclosureTextBlock"> </definitionLink> <definitionLink xlink:type="extended" xlink:role="http://imetrix.edgar-online.com/taxonomy/role/NotesToFinancialStatementsStockholdersEquityNoteDisclosureTextBlockTables"> </definitionLink> <definitionLink xlink:type="extended" xlink:role="http://imetrix.edgar-online.com/taxonomy/role/NotesToFinancialStatementsIncomeTaxDisclosureTextBlock"> </definitionLink> <definitionLink xlink:type="extended" xlink:role="http://imetrix.edgar-online.com/taxonomy/role/NotesToFinancialStatementsIncomeTaxDisclosureTextBlockTables"> </definitionLink> <definitionLink xlink:type="extended" xlink:role="http://imetrix.edgar-online.com/taxonomy/role/NotesToFinancialStatementsOtherIncomeAndOtherExpenseDisclosureTextBlock"> </definitionLink> <definitionLink xlink:type="extended" xlink:role="http://imetrix.edgar-online.com/taxonomy/role/NotesToFinancialStatementsOtherIncomeAndOtherExpenseDisclosureTextBlockTables"> </definitionLink> <definitionLink xlink:type="extended" xlink:role="http://imetrix.edgar-online.com/taxonomy/role/NotesToFinancialStatementsQuarterlyFinancialInformationTextBlock"> </definitionLink> <definitionLink xlink:type="extended" xlink:role="http://imetrix.edgar-online.com/taxonomy/role/NotesToFinancialStatementsQuarterlyFinancialInformationTextBlockTables"> </definitionLink> </linkbase> </XBRL> </TEXT> </DOCUMENT> <DOCUMENT> <TYPE>EX-101.LAB <SEQUENCE>11 <FILENAME>cytk-20141231_lab.xml <DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE <TEXT> <XBRL> <?xml version="1.0" encoding="US-ASCII"?> <!-- RR Donnelley Xcelerate Taxonomy Labels Linkbase, based on XBRL 2.1 http://www.rrdonnelley.com/ --> <!-- Version: 6.22.4 --> <!-- Round: 10 --> <!-- Creation date: 2015-03-05T19:06:47Z --> <!-- Copyright (c) 2005-2013 R.R. Donnelley & Sons Company All Rights Reserved. --> <linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"> <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" roleURI="http://www.xbrl.org/2009/role/negatedLabel"/> <labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link"> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract"/> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountingPoliciesAbstract_lbl" xml:lang="en-US" id="id_6895476_1276885_1_1">Accounting Policies [Abstract]</label> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccountingPoliciesAbstract_lbl" xml:lang="en-US" id="id_6895476_1276885_2_1">Accounting Policies [Abstract]</label> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_AccountingPoliciesAbstract_lbl"/> <loc xlink:type="locator" xlink:href="cytk-20141231.xsd#cytk_AccountingPronouncementsNotYetAdoptedPolicyTextBlock" xlink:label="cytk_AccountingPronouncementsNotYetAdoptedPolicyTextBlock"/> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cytk_AccountingPronouncementsNotYetAdoptedPolicyTextBlock_lbl" xml:lang="en-US" id="id_6895476_1365615_3_1">Disclosure of accounting policy pertaining to new accounting pronouncements not yet adopted that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</label> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cytk_AccountingPronouncementsNotYetAdoptedPolicyTextBlock_lbl" xml:lang="en-US" id="id_6895476_1365615_1_1">Accounting Pronouncements Not Yet Adopted Policy [Text Block]</label> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cytk_AccountingPronouncementsNotYetAdoptedPolicyTextBlock_lbl" xml:lang="en-US" id="id_6895476_1365615_2_1">Accounting Pronouncements Not Yet Adopted</label> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cytk_AccountingPronouncementsNotYetAdoptedPolicyTextBlock" xlink:to="cytk_AccountingPronouncementsNotYetAdoptedPolicyTextBlock_lbl"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent"/> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsPayableCurrent_lbl" xml:lang="en-US" id="id_6895476_1282972_1_1">Accounts Payable, Current</label> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccountsPayableCurrent_lbl" xml:lang="en-US" id="id_6895476_1282972_2_1">Accounts payable</label> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableCurrent" xlink:to="us-gaap_AccountsPayableCurrent_lbl"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AccountsReceivableRelatedParties" xlink:label="us-gaap_AccountsReceivableRelatedParties"/> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsReceivableRelatedParties_lbl" xml:lang="en-US" id="id_6895476_1287293_1_1">Accounts Receivable, Related Parties</label> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccountsReceivableRelatedParties_lbl" xml:lang="en-US" id="id_6895476_1287293_2_1">Accounts receivable due</label> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsReceivableRelatedParties" xlink:to="us-gaap_AccountsReceivableRelatedParties_lbl"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AccountsReceivableRelatedPartiesCurrent" xlink:label="us-gaap_AccountsReceivableRelatedPartiesCurrent"/> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsReceivableRelatedPartiesCurrent_lbl" xml:lang="en-US" id="id_6895476_1286761_1_1">Accounts Receivable, Related Parties, Current</label> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccountsReceivableRelatedPartiesCurrent_lbl" xml:lang="en-US" id="id_6895476_1286761_2_1">Related party accounts receivable</label> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsReceivableRelatedPartiesCurrent" xlink:to="us-gaap_AccountsReceivableRelatedPartiesCurrent_lbl"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AccruedBonusesCurrent" xlink:label="us-gaap_AccruedBonusesCurrent"/> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccruedBonusesCurrent_lbl" xml:lang="en-US" id="id_6895476_1282530_1_1">Accrued Bonuses, Current</label> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccruedBonusesCurrent_lbl" xml:lang="en-US" id="id_6895476_1282530_2_1">Bonus</label> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedBonusesCurrent" xlink:to="us-gaap_AccruedBonusesCurrent_lbl"/> <loc xlink:type="locator" xlink:href="cytk-20141231.xsd#cytk_AccruedClinicalAndPreclinicalCostsCurrent" xlink:label="cytk_AccruedClinicalAndPreclinicalCostsCurrent"/> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cytk_AccruedClinicalAndPreclinicalCostsCurrent_lbl" xml:lang="en-US" id="id_6895476_1463046_3_1">Carrying value as of the balance sheet date of obligations incurred through that date and payable for clinical and preclinical costs. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</label> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cytk_AccruedClinicalAndPreclinicalCostsCurrent_lbl" xml:lang="en-US" id="id_6895476_1463046_1_1">Accrued Clinical And Preclinical Costs Current</label> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cytk_AccruedClinicalAndPreclinicalCostsCurrent_lbl" xml:lang="en-US" id="id_6895476_1463046_2_1">Clinical and preclinical costs</label> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cytk_AccruedClinicalAndPreclinicalCostsCurrent" xlink:to="cytk_AccruedClinicalAndPreclinicalCostsCurrent_lbl"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent"/> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccruedLiabilitiesCurrent_lbl" xml:lang="en-US" id="id_6895476_1283401_1_1">Accrued Liabilities, Current</label> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccruedLiabilitiesCurrent_lbl" xml:lang="en-US" id="id_6895476_1283401_2_1">Accrued liabilities</label> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_AccruedLiabilitiesCurrent_lbl" xml:lang="en-US" id="id_6895476_1283401_6_1">Total accrued liabilities</label> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="us-gaap_AccruedLiabilitiesCurrent_lbl"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AccruedLiabilitiesCurrentAbstract" xlink:label="us-gaap_AccruedLiabilitiesCurrentAbstract"/> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccruedLiabilitiesCurrentAbstract_lbl" xml:lang="en-US" id="id_6895476_1278549_1_1">Accrued Liabilities, Current [Abstract]</label> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccruedLiabilitiesCurrentAbstract_lbl" xml:lang="en-US" id="id_6895476_1278549_2_1">Accrued liabilities:</label> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedLiabilitiesCurrentAbstract" xlink:to="us-gaap_AccruedLiabilitiesCurrentAbstract_lbl"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AccruedProfessionalFeesCurrent" xlink:label="us-gaap_AccruedProfessionalFeesCurrent"/> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccruedProfessionalFeesCurrent_lbl" xml:lang="en-US" id="id_6895476_1283863_1_1">Accrued Professional Fees, Current</label> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccruedProfessionalFeesCurrent_lbl" xml:lang="en-US" id="id_6895476_1283863_2_1">Consulting and professional fees</label> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedProfessionalFeesCurrent" xlink:to="us-gaap_AccruedProfessionalFeesCurrent_lbl"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AccruedVacationCurrent" xlink:label="us-gaap_AccruedVacationCurrent"/> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccruedVacationCurrent_lbl" xml:lang="en-US" id="id_6895476_1282055_1_1">Accrued Vacation, Current</label> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccruedVacationCurrent_lbl" xml:lang="en-US" id="id_6895476_1282055_2_1">Vacation pay</label> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedVacationCurrent" xlink:to="us-gaap_AccruedVacationCurrent_lbl"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xml:lang="en-US" id="id_6895476_1282041_1_1">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment</label> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xml:lang="en-US" id="id_6895476_1282041_14_1">Less: Accumulated depreciation and amortization</label> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl" xml:lang="en-US" id="id_6895476_1282967_1_1">Accumulated Other Comprehensive Income (Loss), Net of Tax</label> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl" xml:lang="en-US" id="id_6895476_1282967_2_1">Accumulated other comprehensive income</label> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember"/> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember_lbl" xml:lang="en-US" id="id_6895476_1268669_1_1">Accumulated Other Comprehensive Income (Loss) [Member]</label> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember_lbl" xml:lang="en-US" id="id_6895476_1268669_2_1">Accumulated Other Comprehensive Income (Loss) [Member]</label> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeMember_lbl"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="us-gaap_AdditionalPaidInCapital"/> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdditionalPaidInCapital_lbl" xml:lang="en-US" id="id_6895476_1283855_1_1">Additional Paid in Capital</label> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AdditionalPaidInCapital_lbl" xml:lang="en-US" id="id_6895476_1283855_2_1">Additional paid-in capital</label> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapital" xlink:to="us-gaap_AdditionalPaidInCapital_lbl"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember"/> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdditionalPaidInCapitalMember_lbl" xml:lang="en-US" id="id_6895476_1273630_1_1">Additional Paid-in Capital [Member]</label> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AdditionalPaidInCapitalMember_lbl" xml:lang="en-US" id="id_6895476_1273630_2_1">Additional Paid-In Capital [Member]</label> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalMember" xlink:to="us-gaap_AdditionalPaidInCapitalMember_lbl"/> <loc xlink:type="locator" xlink:href="cytk-20141231.xsd#cytk_AdjustmentsToAdditionalPaidInCapitalIssuanceOfConvertiblePreferredStock" xlink:label="cytk_AdjustmentsToAdditionalPaidInCapitalIssuanceOfConvertiblePreferredStock"/> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cytk_AdjustmentsToAdditionalPaidInCapitalIssuanceOfConvertiblePreferredStock_lbl" xml:lang="en-US" id="id_6895476_1567017_3_1">Value of convertible preferred stock issued during the period.</label> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cytk_AdjustmentsToAdditionalPaidInCapitalIssuanceOfConvertiblePreferredStock_lbl" xml:lang="en-US" id="id_6895476_1567017_1_1">Adjustments To Additional Paid In Capital Issuance Of Convertible Preferred Stock</label> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cytk_AdjustmentsToAdditionalPaidInCapitalIssuanceOfConvertiblePreferredStock_lbl" xml:lang="en-US" id="id_6895476_1567017_2_1">Issuance of Series B convertible preferred stock pursuant to June 2012 public offerings at $760 per share, net of issuance costs of $881</label> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cytk_AdjustmentsToAdditionalPaidInCapitalIssuanceOfConvertiblePreferredStock" xlink:to="cytk_AdjustmentsToAdditionalPaidInCapitalIssuanceOfConvertiblePreferredStock_lbl"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl" xml:lang="en-US" id="id_6895476_1284706_1_1">Adjustments to Additional Paid in Capital, Share-based Compensation, Requisite Service Period Recognition</label> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl" xml:lang="en-US" id="id_6895476_1284706_2_1">Stock-based compensation</label> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalStockSplit" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockSplit"/> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockSplit_lbl" xml:lang="en-US" id="id_6895476_1288281_1_1">Adjustments to Additional Paid in Capital, Stock Split</label> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockSplit_lbl" xml:lang="en-US" id="id_6895476_1288281_2_1">Reclassification from common stock to additional paid-in capital</label> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockSplit" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockSplit_lbl"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued"/> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued_lbl" xml:lang="en-US" id="id_6895476_1284709_1_1">Adjustments to Additional Paid in Capital, Warrant Issued</label> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued_lbl" xml:lang="en-US" id="id_6895476_1284709_2_1">Issuance of warrants pursuant to June 2012 public offerings, net of issuance costs of $984</label> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued_lbl"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US" id="id_6895476_1278564_1_1">Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]</label> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US" id="id_6895476_1278564_2_1">Adjustments to reconcile net loss to net cash used in operating activities:</label> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl"/> <loc xlink:type="locator" xlink:href="cytk-20141231.xsd#cytk_AfterReverseStockSplitMember" xlink:label="cytk_AfterReverseStockSplitMember"/> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cytk_AfterReverseStockSplitMember_lbl" xml:lang="en-US" id="id_6895476_1388560_3_1">After Reverse Stock Split [Member]</label> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cytk_AfterReverseStockSplitMember_lbl" xml:lang="en-US" id="id_6895476_1388560_1_1">After Reverse Stock Split [Member]</label> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cytk_AfterReverseStockSplitMember_lbl" xml:lang="en-US" id="id_6895476_1388560_2_1">After Reverse Stock Split [Member]</label> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cytk_AfterReverseStockSplitMember" xlink:to="cytk_AfterReverseStockSplitMember_lbl"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense"/> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xml:lang="en-US" id="id_6895476_1285222_1_1">Allocated Share-based Compensation Expense</label> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xml:lang="en-US" id="id_6895476_1285222_2_1">Allocated stock-based compensation expense</label> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xml:lang="en-US" id="id_6895476_1285222_12_1">Stock-based compensation expense</label> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense_lbl"/> <loc xlink:type="locator" xlink:href="cytk-20141231.xsd#cytk_AmendedAgreementMember" xlink:label="cytk_AmendedAgreementMember"/> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cytk_AmendedAgreementMember_lbl" xml:lang="en-US" id="id_6895476_1398741_3_1">Amended Agreement [Member]</label> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cytk_AmendedAgreementMember_lbl" xml:lang="en-US" id="id_6895476_1398741_1_1">Amended Agreement [Member]</label> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cytk_AmendedAgreementMember_lbl" xml:lang="en-US" id="id_6895476_1398741_2_1">Amended Agreement [Member]</label> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cytk_AmendedAgreementMember" xlink:to="cytk_AmendedAgreementMember_lbl"/> <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag"/> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentFlag_lbl" xml:lang="en-US" id="id_6895476_1276506_1_1">Amendment Flag</label> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_AmendmentFlag_lbl" xml:lang="en-US" id="id_6895476_1276506_2_1">Amendment Flag</label> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl"/> <loc xlink:type="locator" xlink:href="cytk-20141231.xsd#cytk_AmgenMember" xlink:label="cytk_AmgenMember"/> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cytk_AmgenMember_lbl" xml:lang="en-US" id="id_6895476_1424859_3_1">Amgen.</label> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cytk_AmgenMember_lbl" xml:lang="en-US" id="id_6895476_1424859_1_1">Amgen [Member]</label> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cytk_AmgenMember_lbl" xml:lang="en-US" id="id_6895476_1424859_2_1">Amgen [Member]</label> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cytk_AmgenMember" xlink:to="cytk_AmgenMember_lbl"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xml:lang="en-US" id="id_6895476_1280165_1_1">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</label> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xml:lang="en-US" id="id_6895476_1280165_2_1">Total shares</label> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl" xml:lang="en-US" id="id_6895476_1268687_1_1">Antidilutive Securities [Axis]</label> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl" xml:lang="en-US" id="id_6895476_1268687_2_1">Antidilutive Securities [Axis]</label> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_lbl" xml:lang="en-US" id="id_6895476_1278584_1_1">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</label> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_lbl" xml:lang="en-US" id="id_6895476_1278584_2_1">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</label> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_lbl"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain"/> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain_lbl" xml:lang="en-US" id="id_6895476_1268688_1_1">Antidilutive Securities, Name [Domain]</label> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain_lbl" xml:lang="en-US" id="id_6895476_1268688_2_1">Antidilutive Securities, Name [Domain]</label> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain_lbl"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember"/> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_lbl" xml:lang="en-US" id="id_6895476_1275318_1_1">Arrangements and Non-arrangement Transactions [Domain]</label> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_lbl" xml:lang="en-US" id="id_6895476_1275318_2_1">Arrangements and Non-arrangement Transactions [Domain]</label> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember_lbl"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets"/> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Assets_lbl" xml:lang="en-US" id="id_6895476_1287793_1_1">Assets</label> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_Assets_lbl" xml:lang="en-US" id="id_6895476_1287793_6_1">Total assets</label> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Assets_lbl"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AssetsAbstract" xlink:label="us-gaap_AssetsAbstract"/> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsAbstract_lbl" xml:lang="en-US" id="id_6895476_1273668_1_1">Assets [Abstract]</label> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AssetsAbstract_lbl" xml:lang="en-US" id="id_6895476_1273668_2_1">ASSETS</label> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsAbstract_lbl"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent"/> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsCurrent_lbl" xml:lang="en-US" id="id_6895476_1288812_1_1">Assets, Current</label> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_AssetsCurrent_lbl" xml:lang="en-US" id="id_6895476_1288812_6_1">Total current assets</label> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AssetsCurrent_lbl"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="us-gaap_AssetsCurrentAbstract"/> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsCurrentAbstract_lbl" xml:lang="en-US" id="id_6895476_1276921_1_1">Assets, Current [Abstract]</label> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AssetsCurrentAbstract_lbl" xml:lang="en-US" id="id_6895476_1276921_2_1">Current assets:</label> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrentAbstract_lbl"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AssetsFairValueDisclosure" xlink:label="us-gaap_AssetsFairValueDisclosure"/> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsFairValueDisclosure_lbl" xml:lang="en-US" id="id_6895476_1285757_1_1">Assets, Fair Value Disclosure</label> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AssetsFairValueDisclosure_lbl" xml:lang="en-US" id="id_6895476_1285757_2_1">Assets at fair value</label> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsFairValueDisclosure" xlink:to="us-gaap_AssetsFairValueDisclosure_lbl"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AssetsFairValueDisclosureRecurring" xlink:label="us-gaap_AssetsFairValueDisclosureRecurring"/> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsFairValueDisclosureRecurring_lbl" xml:lang="en-US" id="id_6895476_1285755_1_1">Assets, Fair Value Disclosure, Recurring</label> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AssetsFairValueDisclosureRecurring_lbl" xml:lang="en-US" id="id_6895476_1285755_2_1">Financial assets measured at fair value on a recurring basis</label> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsFairValueDisclosureRecurring" xlink:to="us-gaap_AssetsFairValueDisclosureRecurring_lbl"/> <loc xlink:type="locator" xlink:href="cytk-20141231.xsd#cytk_AstellasMember" xlink:label="cytk_AstellasMember"/> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cytk_AstellasMember_lbl" xml:lang="en-US" id="id_6895476_1434297_3_1">Astellas [Member]</label> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cytk_AstellasMember_lbl" xml:lang="en-US" id="id_6895476_1434297_1_1">Astellas [Member]</label> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cytk_AstellasMember_lbl" xml:lang="en-US" id="id_6895476_1434297_2_1">Astellas [Member]</label> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cytk_AstellasMember" xlink:to="cytk_AstellasMember_lbl"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_lbl" xml:lang="en-US" id="id_6895476_1285758_1_1">Available-for-sale Debt Securities, Amortized Cost Basis</label> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_lbl" xml:lang="en-US" id="id_6895476_1285758_6_1">Amortized Cost</label> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_lbl"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AvailableForSaleSecurities" xlink:label="us-gaap_AvailableForSaleSecurities"/> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AvailableForSaleSecurities_lbl" xml:lang="en-US" id="id_6895476_1285760_1_1">Available-for-sale Securities</label> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AvailableForSaleSecurities_lbl" xml:lang="en-US" id="id_6895476_1285760_2_1">Fair Value</label> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleSecurities" xlink:to="us-gaap_AvailableForSaleSecurities_lbl"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:label="us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_lbl" xml:lang="en-US" id="id_6895476_1284698_1_1">Available-for-sale Securities, Accumulated Gross Unrealized Gain, before Tax</label> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_lbl" xml:lang="en-US" id="id_6895476_1284698_2_1">Unrealized Gains</label> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:to="us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_lbl"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:label="us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_lbl" xml:lang="en-US" id="id_6895476_1286779_1_1">Available-for-sale Securities, Accumulated Gross Unrealized Loss, before Tax</label> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_lbl" xml:lang="en-US" id="id_6895476_1286779_14_1">Unrealized Losses</label> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:to="us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_lbl"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" xlink:label="us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss"/> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss_lbl" xml:lang="en-US" id="id_6895476_1288312_1_1">Available-for-sale Securities, Continuous Unrealized Loss Position, 12 Months or Longer, Accumulated Loss</label> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss_lbl" xml:lang="en-US" id="id_6895476_1288312_2_1">Investments in continuous unrealized loss position for 12 months or longer</label> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" xlink:to="us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss_lbl"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent"/> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_lbl" xml:lang="en-US" id="id_6895476_1287808_1_1">Available-for-sale Securities, Debt Securities, Current</label> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_lbl" xml:lang="en-US" id="id_6895476_1287808_2_1">Short-term investments</label> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_lbl"/> <loc xlink:type="locator" xlink:href="cytk-20141231.xsd#cytk_AvailableForSaleSecuritiesMaturityDate" xlink:label="cytk_AvailableForSaleSecuritiesMaturityDate"/> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cytk_AvailableForSaleSecuritiesMaturityDate_lbl" xml:lang="en-US" id="id_6895476_1325378_3_1">Maturity dates for all available for sale securities outstanding at the balance sheet date.</label> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cytk_AvailableForSaleSecuritiesMaturityDate_lbl" xml:lang="en-US" id="id_6895476_1325378_1_1">Available For Sale Securities Maturity Date</label> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cytk_AvailableForSaleSecuritiesMaturityDate_lbl" xml:lang="en-US" id="id_6895476_1325378_2_1">Maturity Date</label> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cytk_AvailableForSaleSecuritiesMaturityDate" xlink:to="cytk_AvailableForSaleSecuritiesMaturityDate_lbl"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis"/> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AwardTypeAxis_lbl" xml:lang="en-US" id="id_6895476_1270313_1_1">Award Type [Axis]</label> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AwardTypeAxis_lbl" xml:lang="en-US" id="id_6895476_1270313_2_1">Award Type [Axis]</label> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_AwardTypeAxis_lbl"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_BalanceSheetLocationAxis" xlink:label="us-gaap_BalanceSheetLocationAxis"/> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BalanceSheetLocationAxis_lbl" xml:lang="en-US" id="id_6895476_1278604_1_1">Balance Sheet Location [Axis]</label> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_BalanceSheetLocationAxis_lbl" xml:lang="en-US" id="id_6895476_1278604_2_1">Balance Sheet Location [Axis]</label> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BalanceSheetLocationAxis" xlink:to="us-gaap_BalanceSheetLocationAxis_lbl"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="us-gaap_BalanceSheetLocationDomain"/> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BalanceSheetLocationDomain_lbl" xml:lang="en-US" id="id_6895476_1271969_1_1">Balance Sheet Location [Domain]</label> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_BalanceSheetLocationDomain_lbl" xml:lang="en-US" id="id_6895476_1271969_2_1">Balance Sheet Location [Domain]</label> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BalanceSheetLocationDomain" xlink:to="us-gaap_BalanceSheetLocationDomain_lbl"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl" xml:lang="en-US" id="id_6895476_1268714_1_1">Basis of Accounting, Policy [Policy Text Block]</label> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl" xml:lang="en-US" id="id_6895476_1268714_2_1">Basis of Presentation</label> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:to="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl"/> <loc xlink:type="locator" xlink:href="cytk-20141231.xsd#cytk_BeforeReverseStockSplitMember" xlink:label="cytk_BeforeReverseStockSplitMember"/> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cytk_BeforeReverseStockSplitMember_lbl" xml:lang="en-US" id="id_6895476_1476082_3_1">Before Reverse Stock Split [Member]</label> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cytk_BeforeReverseStockSplitMember_lbl" xml:lang="en-US" id="id_6895476_1476082_1_1">Before Reverse Stock Split [Member]</label> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cytk_BeforeReverseStockSplitMember_lbl" xml:lang="en-US" id="id_6895476_1476082_2_1">Before Adjustment Reverse Stock Split [Member]</label> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cytk_BeforeReverseStockSplitMember" xlink:to="cytk_BeforeReverseStockSplitMember_lbl"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis" xlink:label="us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis"/> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_lbl" xml:lang="en-US" id="id_6895476_1278629_1_1">Project [Axis]</label> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_lbl" xml:lang="en-US" id="id_6895476_1278629_2_1">Project [Axis]</label> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis" xlink:to="us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_lbl"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CashAndCashEquivalentsAbstract" xlink:label="us-gaap_CashAndCashEquivalentsAbstract"/> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsAbstract_lbl" xml:lang="en-US" id="id_6895476_1272011_1_1">Cash and Cash Equivalents [Abstract]</label> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CashAndCashEquivalentsAbstract_lbl" xml:lang="en-US" id="id_6895476_1272011_2_1">Cash and Cash Equivalents [Abstract]</label> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAbstract" xlink:to="us-gaap_CashAndCashEquivalentsAbstract_lbl"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue"/> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xml:lang="en-US" id="id_6895476_1285262_1_1">Cash and Cash Equivalents, at Carrying Value</label> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xml:lang="en-US" id="id_6895476_1285262_4_1">Cash and cash equivalents, end of period</label> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xml:lang="en-US" id="id_6895476_1285262_5_1">Cash and cash equivalents, beginning of period</label> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xml:lang="en-US" id="id_6895476_1285262_2_1">Cash and cash equivalents</label> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CashAndCashEquivalentsAxis" xlink:label="us-gaap_CashAndCashEquivalentsAxis"/> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsAxis_lbl" xml:lang="en-US" id="id_6895476_1270365_1_1">Cash and Cash Equivalents [Axis]</label> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CashAndCashEquivalentsAxis_lbl" xml:lang="en-US" id="id_6895476_1270365_2_1">Cash and Cash Equivalents [Axis]</label> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAxis" xlink:to="us-gaap_CashAndCashEquivalentsAxis_lbl"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CashAndCashEquivalentsLineItems" xlink:label="us-gaap_CashAndCashEquivalentsLineItems"/> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsLineItems_lbl" xml:lang="en-US" id="id_6895476_1275396_1_1">Cash and Cash Equivalents [Line Items]</label> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CashAndCashEquivalentsLineItems_lbl" xml:lang="en-US" id="id_6895476_1275396_2_1">Cash and Cash Equivalents [Line Items]</label> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsLineItems" xlink:to="us-gaap_CashAndCashEquivalentsLineItems_lbl"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CashAndCashEquivalentsMember" xlink:label="us-gaap_CashAndCashEquivalentsMember"/> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsMember_lbl" xml:lang="en-US" id="id_6895476_1280237_1_1">Cash and Cash Equivalents [Member]</label> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CashAndCashEquivalentsMember_lbl" xml:lang="en-US" id="id_6895476_1280237_2_1">Cash and Cash Equivalents [Member]</label> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsMember" xlink:to="us-gaap_CashAndCashEquivalentsMember_lbl"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:label="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease"/> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_lbl" xml:lang="en-US" id="id_6895476_1286290_1_1">Cash and Cash Equivalents, Period Increase (Decrease)</label> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_lbl" xml:lang="en-US" id="id_6895476_1286290_6_1">Net increase (decrease) in cash and cash equivalents</label> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:to="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_lbl"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock"/> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl" xml:lang="en-US" id="id_6895476_1275397_1_1">Cash and Cash Equivalents, Policy [Policy Text Block]</label> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl" xml:lang="en-US" id="id_6895476_1275397_2_1">Cash and Cash Equivalents</label> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:to="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:label="us-gaap_CashCashEquivalentsAndShortTermInvestments"/> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashCashEquivalentsAndShortTermInvestments_lbl" xml:lang="en-US" id="id_6895476_1287336_1_1">Cash, Cash Equivalents, and Short-term Investments</label> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CashCashEquivalentsAndShortTermInvestments_lbl" xml:lang="en-US" id="id_6895476_1287336_2_1">Cash, cash equivalents and investments</label> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:to="us-gaap_CashCashEquivalentsAndShortTermInvestments_lbl"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CashEquivalentsMember" xlink:label="us-gaap_CashEquivalentsMember"/> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashEquivalentsMember_lbl" xml:lang="en-US" id="id_6895476_1270374_1_1">Cash Equivalents [Member]</label> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CashEquivalentsMember_lbl" xml:lang="en-US" id="id_6895476_1270374_2_1">Cash Equivalents [Member]</label> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashEquivalentsMember" xlink:to="us-gaap_CashEquivalentsMember_lbl"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:label="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract"/> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_lbl" xml:lang="en-US" id="id_6895476_1270378_1_1">Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract]</label> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_lbl" xml:lang="en-US" id="id_6895476_1270378_2_1">Significant non-cash investing and financing activities:</label> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_lbl"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CashFlowSupplementalDisclosuresTextBlock" xlink:label="us-gaap_CashFlowSupplementalDisclosuresTextBlock"/> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashFlowSupplementalDisclosuresTextBlock_lbl" xml:lang="en-US" id="id_6895476_1272018_1_1">Cash Flow, Supplemental Disclosures [Text Block]</label> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CashFlowSupplementalDisclosuresTextBlock_lbl" xml:lang="en-US" id="id_6895476_1272018_2_1">Supplementary Cash Flow Data</label> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashFlowSupplementalDisclosuresTextBlock" xlink:to="us-gaap_CashFlowSupplementalDisclosuresTextBlock_lbl"/> <loc xlink:type="locator" xlink:href="cytk-20141231.xsd#cytk_CashRequirementsTerm" xlink:label="cytk_CashRequirementsTerm"/> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cytk_CashRequirementsTerm_lbl" xml:lang="en-US" id="id_6895476_1421263_3_1">The minimum period of time, subsequent to the current balance sheet date, for which the company believes existing cash, cash equivalents and investments will be sufficient to fund its cash requirements.</label> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cytk_CashRequirementsTerm_lbl" xml:lang="en-US" id="id_6895476_1421263_1_1">Cash Requirements Term</label> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cytk_CashRequirementsTerm_lbl" xml:lang="en-US" id="id_6895476_1421263_2_1">Cash requirements term</label> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cytk_CashRequirementsTerm" xlink:to="cytk_CashRequirementsTerm_lbl"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfStockDomain_lbl" xml:lang="en-US" id="id_6895476_1277017_1_1">Class of Stock [Domain]</label> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ClassOfStockDomain_lbl" xml:lang="en-US" id="id_6895476_1277017_2_1">Class of Stock [Domain]</label> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_ClassOfStockDomain_lbl"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ClassOfStockLineItems" xlink:label="us-gaap_ClassOfStockLineItems"/> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfStockLineItems_lbl" xml:lang="en-US" id="id_6895476_1268790_1_1">Class of Stock [Line Items]</label> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ClassOfStockLineItems_lbl" xml:lang="en-US" id="id_6895476_1268790_2_1">Class of Stock [Line Items]</label> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ClassOfStockLineItems_lbl"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis"/> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightAxis_lbl" xml:lang="en-US" id="id_6895476_1280248_1_1">Class of Warrant or Right [Axis]</label> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ClassOfWarrantOrRightAxis_lbl" xml:lang="en-US" id="id_6895476_1280248_2_1">Class of Warrant or Right [Axis]</label> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightAxis_lbl"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain"/> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightDomain_lbl" xml:lang="en-US" id="id_6895476_1272026_1_1">Class of Warrant or Right [Domain]</label> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ClassOfWarrantOrRightDomain_lbl" xml:lang="en-US" id="id_6895476_1272026_2_1">Class of Warrant or Right [Domain]</label> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="us-gaap_ClassOfWarrantOrRightDomain_lbl"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl" xml:lang="en-US" id="id_6895476_1275410_1_1">Class of Warrant or Right, Exercise Price of Warrants or Rights</label> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl" xml:lang="en-US" id="id_6895476_1275410_2_1">Exercise Price</label> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl" xml:lang="en-US" id="id_6895476_1275410_12_1">Warrants purchase upon exercise of common stock, exercise price</label> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights"/> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_lbl" xml:lang="en-US" id="id_6895476_1277021_1_1">Class of Warrant or Right, Number of Securities Called by Warrants or Rights</label> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_lbl" xml:lang="en-US" id="id_6895476_1277021_2_1">Number of Shares</label> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_lbl" xml:lang="en-US" id="id_6895476_1277021_12_1">Warrants purchase upon exercise of common stock</label> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_lbl"/> <loc xlink:type="locator" xlink:href="cytk-20141231.xsd#cytk_CommercialMilestonesMember" xlink:label="cytk_CommercialMilestonesMember"/> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cytk_CommercialMilestonesMember_lbl" xml:lang="en-US" id="id_6895476_1479887_3_1">Commercial Milestones [Member]</label> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cytk_CommercialMilestonesMember_lbl" xml:lang="en-US" id="id_6895476_1479887_1_1">Commercial Milestones [Member]</label> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cytk_CommercialMilestonesMember_lbl" xml:lang="en-US" id="id_6895476_1479887_2_1">Commercial Milestones [Member]</label> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cytk_CommercialMilestonesMember" xlink:to="cytk_CommercialMilestonesMember_lbl"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="us-gaap_CommitmentsAndContingencies"/> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingencies_lbl" xml:lang="en-US" id="id_6895476_1282923_1_1">Commitments and Contingencies</label> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommitmentsAndContingencies_lbl" xml:lang="en-US" id="id_6895476_1282923_2_1">Commitments and contingencies (Note 10)</label> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingencies" xlink:to="us-gaap_CommitmentsAndContingencies_lbl"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl" xml:lang="en-US" id="id_6895476_1272029_1_1">Commitments and Contingencies Disclosure [Abstract]</label> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl" xml:lang="en-US" id="id_6895476_1272029_2_1">Commitments and Contingencies Disclosure [Abstract]</label> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" xml:lang="en-US" id="id_6895476_1268805_1_1">Commitments and Contingencies Disclosure [Text Block]</label> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" xml:lang="en-US" id="id_6895476_1268805_2_1">Commitments and Contingencies</label> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl" xml:lang="en-US" id="id_6895476_1278673_1_1">Common Stock, Capital Shares Reserved for Future Issuance</label> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl" xml:lang="en-US" id="id_6895476_1278673_2_1">Shares of common stock reserved for issuance</label> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockMember_lbl" xml:lang="en-US" id="id_6895476_1270422_1_1">Common Stock [Member]</label> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockMember_lbl" xml:lang="en-US" id="id_6895476_1270422_2_1">Common Stock [Member]</label> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockMember" xlink:to="us-gaap_CommonStockMember_lbl"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare"/> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xml:lang="en-US" id="id_6895476_1278675_1_1">Common Stock, Par or Stated Value Per Share</label> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xml:lang="en-US" id="id_6895476_1278675_2_1">Common stock, par value</label> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_lbl"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized"/> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl" xml:lang="en-US" id="id_6895476_1270423_1_1">Common Stock, Shares Authorized</label> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl" xml:lang="en-US" id="id_6895476_1270423_2_1">Common stock, authorized</label> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl" xml:lang="en-US" id="id_6895476_1270423_12_1">Common stock, shares authorized</label> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesAuthorized" xlink:to="us-gaap_CommonStockSharesAuthorized_lbl"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued"/> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xml:lang="en-US" id="id_6895476_1268808_1_1">Common Stock, Shares, Issued</label> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xml:lang="en-US" id="id_6895476_1268808_2_1">Common stock, shares issued</label> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesIssued" xlink:to="us-gaap_CommonStockSharesIssued_lbl"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding"/> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xml:lang="en-US" id="id_6895476_1268809_1_1">Common Stock, Shares, Outstanding</label> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xml:lang="en-US" id="id_6895476_1268809_2_1">Common stock, shares outstanding</label> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesOutstanding" xlink:to="us-gaap_CommonStockSharesOutstanding_lbl"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue"/> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockValue_lbl" xml:lang="en-US" id="id_6895476_1282921_1_1">Common Stock, Value, Issued</label> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockValue_lbl" xml:lang="en-US" id="id_6895476_1282921_2_1">Common stock, $0.001 par value: Authorized: 81,500,000 shares: Issued and outstanding: 38,659,738 shares at December 31, 2014 and 30,681,624 shares at December 31, 2013</label> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockValue" xlink:to="us-gaap_CommonStockValue_lbl"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CompensationRelatedCostsPolicyTextBlock" xlink:label="us-gaap_CompensationRelatedCostsPolicyTextBlock"/> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CompensationRelatedCostsPolicyTextBlock_lbl" xml:lang="en-US" id="id_6895476_1270400_1_1">Compensation Related Costs, Policy [Policy Text Block]</label> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CompensationRelatedCostsPolicyTextBlock_lbl" xml:lang="en-US" id="id_6895476_1270400_2_1">Stock-Based Compensation</label> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CompensationRelatedCostsPolicyTextBlock" xlink:to="us-gaap_CompensationRelatedCostsPolicyTextBlock_lbl"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ComponentsOfDeferredTaxAssetsAbstract" xlink:label="us-gaap_ComponentsOfDeferredTaxAssetsAbstract"/> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ComponentsOfDeferredTaxAssetsAbstract_lbl" xml:lang="en-US" id="id_6895476_1268815_1_1">Components of Deferred Tax Assets [Abstract]</label> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ComponentsOfDeferredTaxAssetsAbstract_lbl" xml:lang="en-US" id="id_6895476_1268815_2_1">Deferred tax assets:</label> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAbstract" xlink:to="us-gaap_ComponentsOfDeferredTaxAssetsAbstract_lbl"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax"/> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax_lbl" xml:lang="en-US" id="id_6895476_1283349_1_1">Comprehensive Income (Loss), Net of Tax, Attributable to Parent</label> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax_lbl" xml:lang="en-US" id="id_6895476_1283349_6_1">Comprehensive loss</label> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="us-gaap_ComprehensiveIncomeNetOfTax_lbl"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:label="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock"/> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_lbl" xml:lang="en-US" id="id_6895476_1270405_1_1">Comprehensive Income, Policy [Policy Text Block]</label> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_lbl" xml:lang="en-US" id="id_6895476_1270405_2_1">Comprehensive Loss</label> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:to="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_lbl"/> <loc xlink:type="locator" xlink:href="cytk-20141231.xsd#cytk_ComputerEquipmentAndSoftwareMember" xlink:label="cytk_ComputerEquipmentAndSoftwareMember"/> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cytk_ComputerEquipmentAndSoftwareMember_lbl" xml:lang="en-US" id="id_6895476_1362982_3_1">Computer equipment and software.</label> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cytk_ComputerEquipmentAndSoftwareMember_lbl" xml:lang="en-US" id="id_6895476_1362982_1_1">Computer Equipment And Software [Member]</label> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cytk_ComputerEquipmentAndSoftwareMember_lbl" xml:lang="en-US" id="id_6895476_1362982_2_1">Computer Equipment and Software [Member]</label> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cytk_ComputerEquipmentAndSoftwareMember" xlink:to="cytk_ComputerEquipmentAndSoftwareMember_lbl"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ConcentrationRiskCreditRisk" xlink:label="us-gaap_ConcentrationRiskCreditRisk"/> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConcentrationRiskCreditRisk_lbl" xml:lang="en-US" id="id_6895476_1280278_1_1">Concentration Risk, Credit Risk, Policy [Policy Text Block]</label> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ConcentrationRiskCreditRisk_lbl" xml:lang="en-US" id="id_6895476_1280278_2_1">Concentration of Credit Risk and Other Risks and Uncertainties</label> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskCreditRisk" xlink:to="us-gaap_ConcentrationRiskCreditRisk_lbl"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ConcentrationRiskPercentage1" xlink:label="us-gaap_ConcentrationRiskPercentage1"/> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConcentrationRiskPercentage1_lbl" xml:lang="en-US" id="id_6895476_1273765_1_1">Concentration Risk, Percentage</label> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ConcentrationRiskPercentage1_lbl" xml:lang="en-US" id="id_6895476_1273765_2_1">Revenues derived</label> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskPercentage1" xlink:to="us-gaap_ConcentrationRiskPercentage1_lbl"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ConversionOfStockSharesConverted1" xlink:label="us-gaap_ConversionOfStockSharesConverted1"/> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConversionOfStockSharesConverted1_lbl" xml:lang="en-US" id="id_6895476_1277060_1_1">Conversion of Stock, Shares Converted</label> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ConversionOfStockSharesConverted1_lbl" xml:lang="en-US" id="id_6895476_1277060_2_1">Convertible preferred stock converted into common stock</label> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConversionOfStockSharesConverted1" xlink:to="us-gaap_ConversionOfStockSharesConverted1_lbl"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ConversionOfStockSharesIssued1" xlink:label="us-gaap_ConversionOfStockSharesIssued1"/> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConversionOfStockSharesIssued1_lbl" xml:lang="en-US" id="id_6895476_1277061_1_1">Conversion of Stock, Shares Issued</label> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ConversionOfStockSharesIssued1_lbl" xml:lang="en-US" id="id_6895476_1277061_2_1">Common stock issued pursuant to series A preferred stock conversion</label> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ConversionOfStockSharesIssued1_lbl" xml:lang="en-US" id="id_6895476_1277061_12_1">Common stock issued pursuant to series B preferred stock conversion</label> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConversionOfStockSharesIssued1" xlink:to="us-gaap_ConversionOfStockSharesIssued1_lbl"/> <loc xlink:type="locator" xlink:href="cytk-20141231.xsd#cytk_ConversionPricePerShareOfPreferredStockToCommonStock" xlink:label="cytk_ConversionPricePerShareOfPreferredStockToCommonStock"/> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cytk_ConversionPricePerShareOfPreferredStockToCommonStock_lbl" xml:lang="en-US" id="id_6895476_1535704_3_1">Conversion price per share of preferred stock to common stock.</label> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cytk_ConversionPricePerShareOfPreferredStockToCommonStock_lbl" xml:lang="en-US" id="id_6895476_1535704_1_1">Conversion Price Per Share Of Preferred Stock To Common Stock</label> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cytk_ConversionPricePerShareOfPreferredStockToCommonStock_lbl" xml:lang="en-US" id="id_6895476_1535704_2_1">Conversion Price of convertible preferred stock to common stock</label> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cytk_ConversionPricePerShareOfPreferredStockToCommonStock" xlink:to="cytk_ConversionPricePerShareOfPreferredStockToCommonStock_lbl"/> <loc xlink:type="locator" xlink:href="cytk-20141231.xsd#cytk_ConvertiblePreferredStockIssuancePrice" xlink:label="cytk_ConvertiblePreferredStockIssuancePrice"/> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cytk_ConvertiblePreferredStockIssuancePrice_lbl" xml:lang="en-US" id="id_6895476_1424732_3_1">Convertible preferred stock issuance price.</label> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cytk_ConvertiblePreferredStockIssuancePrice_lbl" xml:lang="en-US" id="id_6895476_1424732_1_1">Convertible Preferred Stock Issuance Price</label> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cytk_ConvertiblePreferredStockIssuancePrice_lbl" xml:lang="en-US" id="id_6895476_1424732_2_1">Issuance of convertible preferred stock at per share</label> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cytk_ConvertiblePreferredStockIssuancePrice" xlink:to="cytk_ConvertiblePreferredStockIssuancePrice_lbl"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ConvertiblePreferredStockMember" xlink:label="us-gaap_ConvertiblePreferredStockMember"/> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConvertiblePreferredStockMember_lbl" xml:lang="en-US" id="id_6895476_1270467_1_1">Convertible Preferred Stock [Member]</label> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ConvertiblePreferredStockMember_lbl" xml:lang="en-US" id="id_6895476_1270467_2_1">Convertible Preferred Stock [Member]</label> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConvertiblePreferredStockMember" xlink:to="us-gaap_ConvertiblePreferredStockMember_lbl"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CostsAndExpenses" xlink:label="us-gaap_CostsAndExpenses"/> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CostsAndExpenses_lbl" xml:lang="en-US" id="id_6895476_1287875_1_1">Costs and Expenses</label> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_CostsAndExpenses_lbl" xml:lang="en-US" id="id_6895476_1287875_6_1">Total operating expenses</label> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CostsAndExpenses" xlink:to="us-gaap_CostsAndExpenses_lbl"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CurrentFederalTaxExpenseBenefit" xlink:label="us-gaap_CurrentFederalTaxExpenseBenefit"/> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CurrentFederalTaxExpenseBenefit_lbl" xml:lang="en-US" id="id_6895476_1286842_1_1">Current Federal Tax Expense (Benefit)</label> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CurrentFederalTaxExpenseBenefit_lbl" xml:lang="en-US" id="id_6895476_1286842_2_1">Federal</label> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CurrentFederalTaxExpenseBenefit" xlink:to="us-gaap_CurrentFederalTaxExpenseBenefit_lbl"/> <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate"/> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xml:lang="en-US" id="id_6895476_1276508_1_1">Current Fiscal Year End Date</label> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xml:lang="en-US" id="id_6895476_1276508_2_1">Current Fiscal Year End Date</label> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CurrentFiscalYearEndDate" xlink:to="dei_CurrentFiscalYearEndDate_lbl"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:label="us-gaap_CurrentIncomeTaxExpenseBenefit"/> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CurrentIncomeTaxExpenseBenefit_lbl" xml:lang="en-US" id="id_6895476_1287874_1_1">Current Income Tax Expense (Benefit)</label> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_CurrentIncomeTaxExpenseBenefit_lbl" xml:lang="en-US" id="id_6895476_1287874_6_1">Total</label> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:to="us-gaap_CurrentIncomeTaxExpenseBenefit_lbl"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:label="us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract"/> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_lbl" xml:lang="en-US" id="id_6895476_1272082_1_1">Current Income Tax Expense (Benefit), Continuing Operations [Abstract]</label> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_lbl" xml:lang="en-US" id="id_6895476_1272082_2_1">Current:</label> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:to="us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_lbl"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:label="us-gaap_CurrentStateAndLocalTaxExpenseBenefit"/> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CurrentStateAndLocalTaxExpenseBenefit_lbl" xml:lang="en-US" id="id_6895476_1287373_1_1">Current State and Local Tax Expense (Benefit)</label> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CurrentStateAndLocalTaxExpenseBenefit_lbl" xml:lang="en-US" id="id_6895476_1287373_2_1">State</label> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:to="us-gaap_CurrentStateAndLocalTaxExpenseBenefit_lbl"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="us-gaap_DebtDisclosureAbstract"/> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtDisclosureAbstract_lbl" xml:lang="en-US" id="id_6895476_1278728_1_1">Debt Disclosure [Abstract]</label> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtDisclosureAbstract_lbl" xml:lang="en-US" id="id_6895476_1278728_2_1">Debt Disclosure [Abstract]</label> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="us-gaap_DebtDisclosureAbstract_lbl"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DebtDisclosureTextBlock" xlink:label="us-gaap_DebtDisclosureTextBlock"/> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtDisclosureTextBlock_lbl" xml:lang="en-US" id="id_6895476_1268864_1_1">Debt Disclosure [Text Block]</label> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtDisclosureTextBlock_lbl" xml:lang="en-US" id="id_6895476_1268864_2_1">Debt</label> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtDisclosureTextBlock" xlink:to="us-gaap_DebtDisclosureTextBlock_lbl"/> <loc xlink:type="locator" xlink:href="cytk-20141231.xsd#cytk_DeerfieldAgreementMember" xlink:label="cytk_DeerfieldAgreementMember"/> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cytk_DeerfieldAgreementMember_lbl" xml:lang="en-US" id="id_6895476_1559654_3_1">Deerfield Agreement [Member]</label> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cytk_DeerfieldAgreementMember_lbl" xml:lang="en-US" id="id_6895476_1559654_1_1">Deerfield Agreement [Member]</label> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cytk_DeerfieldAgreementMember_lbl" xml:lang="en-US" id="id_6895476_1559654_2_1">Deerfield Agreement [Member]</label> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cytk_DeerfieldAgreementMember" xlink:to="cytk_DeerfieldAgreementMember_lbl"/> <loc xlink:type="locator" xlink:href="cytk-20141231.xsd#cytk_DeerfieldMember" xlink:label="cytk_DeerfieldMember"/> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cytk_DeerfieldMember_lbl" xml:lang="en-US" id="id_6895476_1398639_3_1">Deerfield [Member]</label> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cytk_DeerfieldMember_lbl" xml:lang="en-US" id="id_6895476_1398639_1_1">Deerfield [Member]</label> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cytk_DeerfieldMember_lbl" xml:lang="en-US" id="id_6895476_1398639_2_1">Deerfield [Member]</label> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cytk_DeerfieldMember" xlink:to="cytk_DeerfieldMember_lbl"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsLineItems" xlink:label="us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsLineItems"/> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsLineItems_lbl" xml:lang="en-US" id="id_6895476_1273841_1_1">Deferred Compensation Arrangement with Individual, Share-based Payments [Line Items]</label> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsLineItems_lbl" xml:lang="en-US" id="id_6895476_1273841_2_1">Deferred Compensation Arrangement with Individual, Share-based Payments [Line Items]</label> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsLineItems" xlink:to="us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsLineItems_lbl"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract" xlink:label="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract"/> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract_lbl" xml:lang="en-US" id="id_6895476_1273828_1_1">Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]</label> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract_lbl" xml:lang="en-US" id="id_6895476_1273828_2_1">Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]</label> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract" xlink:to="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract_lbl"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:label="us-gaap_DeferredFederalIncomeTaxExpenseBenefit"/> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredFederalIncomeTaxExpenseBenefit_lbl" xml:lang="en-US" id="id_6895476_1288921_1_1">Deferred Federal Income Tax Expense (Benefit)</label> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredFederalIncomeTaxExpenseBenefit_lbl" xml:lang="en-US" id="id_6895476_1288921_2_1">Federal</label> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:to="us-gaap_DeferredFederalIncomeTaxExpenseBenefit_lbl"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefit"/> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefit_lbl" xml:lang="en-US" id="id_6895476_1285325_1_1">Deferred Income Tax Expense (Benefit)</label> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefit_lbl" xml:lang="en-US" id="id_6895476_1285325_6_1">Total</label> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:to="us-gaap_DeferredIncomeTaxExpenseBenefit_lbl"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract"/> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_lbl" xml:lang="en-US" id="id_6895476_1277108_1_1">Deferred Income Tax Expense (Benefit), Continuing Operations [Abstract]</label> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_lbl" xml:lang="en-US" id="id_6895476_1277108_2_1">Deferred:</label> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:to="us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_lbl"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DeferredRentCreditCurrent" xlink:label="us-gaap_DeferredRentCreditCurrent"/> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredRentCreditCurrent_lbl" xml:lang="en-US" id="id_6895476_1281966_1_1">Deferred Rent Credit, Current</label> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredRentCreditCurrent_lbl" xml:lang="en-US" id="id_6895476_1281966_2_1">Short-term portion of deferred rent</label> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredRentCreditCurrent" xlink:to="us-gaap_DeferredRentCreditCurrent_lbl"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DeferredRentCreditNoncurrent" xlink:label="us-gaap_DeferredRentCreditNoncurrent"/> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredRentCreditNoncurrent_lbl" xml:lang="en-US" id="id_6895476_1284640_1_1">Deferred Rent Credit, Noncurrent</label> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredRentCreditNoncurrent_lbl" xml:lang="en-US" id="id_6895476_1284640_2_1">Long-term portion of deferred rent</label> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredRentCreditNoncurrent" xlink:to="us-gaap_DeferredRentCreditNoncurrent_lbl"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DeferredRevenue" xlink:label="us-gaap_DeferredRevenue"/> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredRevenue_lbl" xml:lang="en-US" id="id_6895476_1284641_1_1">Deferred Revenue</label> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredRevenue_lbl" xml:lang="en-US" id="id_6895476_1284641_2_1">Deferred revenue</label> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredRevenue" xlink:to="us-gaap_DeferredRevenue_lbl"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DeferredRevenueCurrent" xlink:label="us-gaap_DeferredRevenueCurrent"/> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredRevenueCurrent_lbl" xml:lang="en-US" id="id_6895476_1284239_1_1">Deferred Revenue, Current</label> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredRevenueCurrent_lbl" xml:lang="en-US" id="id_6895476_1284239_2_1">Deferred revenue, current</label> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredRevenueCurrent" xlink:to="us-gaap_DeferredRevenueCurrent_lbl"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DeferredRevenueNoncurrent" xlink:label="us-gaap_DeferredRevenueNoncurrent"/> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredRevenueNoncurrent_lbl" xml:lang="en-US" id="id_6895476_1281965_1_1">Deferred Revenue, Noncurrent</label> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredRevenueNoncurrent_lbl" xml:lang="en-US" id="id_6895476_1281965_2_1">Deferred revenue, non-current</label> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredRevenueNoncurrent" xlink:to="us-gaap_DeferredRevenueNoncurrent_lbl"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DeferredRevenueRevenueRecognized" xlink:label="us-gaap_DeferredRevenueRevenueRecognized"/> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredRevenueRevenueRecognized_lbl" xml:lang="en-US" id="id_6895476_1285327_1_1">Deferred Revenue, Revenue Recognized</label> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredRevenueRevenueRecognized_lbl" xml:lang="en-US" id="id_6895476_1285327_2_1">Revenue recognized</label> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredRevenueRevenueRecognized" xlink:to="us-gaap_DeferredRevenueRevenueRecognized_lbl"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:label="us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit"/> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_lbl" xml:lang="en-US" id="id_6895476_1285842_1_1">Deferred State and Local Income Tax Expense (Benefit)</label> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_lbl" xml:lang="en-US" id="id_6895476_1285842_2_1">State</label> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:to="us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_lbl"/> <loc xlink:type="locator" xlink:href="cytk-20141231.xsd#cytk_DeferredTaxAssetsCapitalizedResearchAndDevelopment" xlink:label="cytk_DeferredTaxAssetsCapitalizedResearchAndDevelopment"/> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cytk_DeferredTaxAssetsCapitalizedResearchAndDevelopment_lbl" xml:lang="en-US" id="id_6895476_1452421_3_1">Deferred Tax Assets Capitalized Research And Development</label> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cytk_DeferredTaxAssetsCapitalizedResearchAndDevelopment_lbl" xml:lang="en-US" id="id_6895476_1452421_1_1">Deferred Tax Assets Capitalized Research And Development</label> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cytk_DeferredTaxAssetsCapitalizedResearchAndDevelopment_lbl" xml:lang="en-US" id="id_6895476_1452421_2_1">Capitalized R&D</label> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cytk_DeferredTaxAssetsCapitalizedResearchAndDevelopment" xlink:to="cytk_DeferredTaxAssetsCapitalizedResearchAndDevelopment_lbl"/> <loc xlink:type="locator" xlink:href="cytk-20141231.xsd#cytk_DeferredTaxAssetsDepreciationAndAmortization" xlink:label="cytk_DeferredTaxAssetsDepreciationAndAmortization"/> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cytk_DeferredTaxAssetsDepreciationAndAmortization_lbl" xml:lang="en-US" id="id_6895476_1548060_3_1">Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from depreciation and amortization.</label> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cytk_DeferredTaxAssetsDepreciationAndAmortization_lbl" xml:lang="en-US" id="id_6895476_1548060_1_1">Deferred Tax Assets Depreciation And Amortization</label> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cytk_DeferredTaxAssetsDepreciationAndAmortization_lbl" xml:lang="en-US" id="id_6895476_1548060_2_1">Depreciation and amortization</label> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cytk_DeferredTaxAssetsDepreciationAndAmortization" xlink:to="cytk_DeferredTaxAssetsDepreciationAndAmortization_lbl"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="us-gaap_DeferredTaxAssetsGross"/> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsGross_lbl" xml:lang="en-US" id="id_6895476_1285845_1_1">Deferred Tax Assets, Gross</label> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_DeferredTaxAssetsGross_lbl" xml:lang="en-US" id="id_6895476_1285845_6_1">Total deferred tax assets</label> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsGross_lbl"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="us-gaap_DeferredTaxAssetsNet"/> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsNet_lbl" xml:lang="en-US" id="id_6895476_1287895_1_1">Deferred Tax Assets, Net of Valuation Allowance</label> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_DeferredTaxAssetsNet_lbl" xml:lang="en-US" id="id_6895476_1287895_6_1">Net deferred tax assets</label> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsNet" xlink:to="us-gaap_DeferredTaxAssetsNet_lbl"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards"/> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl" xml:lang="en-US" id="id_6895476_1287389_1_1">Deferred Tax Assets, Operating Loss Carryforwards</label> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl" xml:lang="en-US" id="id_6895476_1287389_2_1">Net operating losses</label> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwards" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwards"/> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwards_lbl" xml:lang="en-US" id="id_6895476_1288395_1_1">Deferred Tax Assets, Tax Credit Carryforwards</label> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwards_lbl" xml:lang="en-US" id="id_6895476_1288395_2_1">Tax credits</label> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxCreditCarryforwards" xlink:to="us-gaap_DeferredTaxAssetsTaxCreditCarryforwards_lbl"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals"/> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals_lbl" xml:lang="en-US" id="id_6895476_1288929_1_1">Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals</label> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals_lbl" xml:lang="en-US" id="id_6895476_1288929_2_1">Reserves and accruals</label> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals_lbl"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance"/> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_lbl" xml:lang="en-US" id="id_6895476_1281963_1_1">Deferred Tax Assets, Valuation Allowance</label> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_lbl" xml:lang="en-US" id="id_6895476_1281963_14_1">Less: Valuation allowance</label> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance_lbl"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount" xlink:label="us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount"/> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount_lbl" xml:lang="en-US" id="id_6895476_1288941_1_1">Defined Contribution Plan, Employer Discretionary Contribution Amount</label> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount_lbl" xml:lang="en-US" id="id_6895476_1288941_2_1">Employer contributions under the plan</label> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount" xlink:to="us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount_lbl"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_Depreciation" xlink:label="us-gaap_Depreciation"/> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Depreciation_lbl" xml:lang="en-US" id="id_6895476_1286908_1_1">Depreciation</label> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_Depreciation_lbl" xml:lang="en-US" id="id_6895476_1286908_2_1">Depreciation expense</label> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Depreciation" xlink:to="us-gaap_Depreciation_lbl"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="us-gaap_DepreciationDepletionAndAmortization"/> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DepreciationDepletionAndAmortization_lbl" xml:lang="en-US" id="id_6895476_1285354_1_1">Depreciation, Depletion and Amortization</label> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DepreciationDepletionAndAmortization_lbl" xml:lang="en-US" id="id_6895476_1285354_2_1">Depreciation and amortization of property and equipment</label> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DepreciationDepletionAndAmortization" xlink:to="us-gaap_DepreciationDepletionAndAmortization_lbl"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_lbl" xml:lang="en-US" id="id_6895476_1273909_1_1">Disclosure of Compensation Related Costs, Share-based Payments [Abstract]</label> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_lbl" xml:lang="en-US" id="id_6895476_1273909_2_1">Disclosure of Compensation Related Costs, Share-based Payments [Abstract]</label> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_lbl"/> <loc xlink:type="locator" xlink:href="cytk-20141231.xsd#cytk_DocumentAndEntityInformationAbstract" xlink:label="cytk_DocumentAndEntityInformationAbstract"/> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cytk_DocumentAndEntityInformationAbstract_lbl" xml:lang="en-US" id="id_6895476_1430739_3_1">Document and entity information.</label> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cytk_DocumentAndEntityInformationAbstract_lbl" xml:lang="en-US" id="id_6895476_1430739_1_1">Document And Entity Information [Abstract]</label> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cytk_DocumentAndEntityInformationAbstract_lbl" xml:lang="en-US" id="id_6895476_1430739_2_1">Document And Entity Information [Abstract]</label> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cytk_DocumentAndEntityInformationAbstract" xlink:to="cytk_DocumentAndEntityInformationAbstract_lbl"/> <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus"/> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xml:lang="en-US" id="id_6895476_1279677_1_1">Document Fiscal Period Focus</label> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xml:lang="en-US" id="id_6895476_1279677_2_1">Document Fiscal Period Focus</label> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus_lbl"/> <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus"/> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalYearFocus_lbl" xml:lang="en-US" id="id_6895476_1276510_1_1">Document Fiscal Year Focus</label> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_DocumentFiscalYearFocus_lbl" xml:lang="en-US" id="id_6895476_1276510_2_1">Document Fiscal Year Focus</label> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus_lbl"/> <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate"/> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodEndDate_lbl" xml:lang="en-US" id="id_6895476_1274889_1_1">Document Period End Date</label> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_DocumentPeriodEndDate_lbl" xml:lang="en-US" id="id_6895476_1274889_2_1">Document Period End Date</label> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl"/> <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentType" xlink:label="dei_DocumentType"/> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentType_lbl" xml:lang="en-US" id="id_6895476_1269867_1_1">Document Type</label> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_DocumentType_lbl" xml:lang="en-US" id="id_6895476_1269867_2_1">Document Type</label> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DomesticCountryMember" xlink:label="us-gaap_DomesticCountryMember"/> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DomesticCountryMember_lbl" xml:lang="en-US" id="id_6895476_1280458_1_1">Domestic Tax Authority [Member]</label> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DomesticCountryMember_lbl" xml:lang="en-US" id="id_6895476_1280458_2_1">Domestic Tax Authority [Member]</label> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DomesticCountryMember" xlink:to="us-gaap_DomesticCountryMember_lbl"/> <loc xlink:type="locator" xlink:href="cytk-20141231.xsd#cytk_EarlyDevelopmentMember" xlink:label="cytk_EarlyDevelopmentMember"/> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cytk_EarlyDevelopmentMember_lbl" xml:lang="en-US" id="id_6895476_1614633_3_1">Early Development [Member]</label> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cytk_EarlyDevelopmentMember_lbl" xml:lang="en-US" id="id_6895476_1614633_1_1">Early Development [Member]</label> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cytk_EarlyDevelopmentMember_lbl" xml:lang="en-US" id="id_6895476_1614633_2_1">Early Development [Member]</label> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cytk_EarlyDevelopmentMember" xlink:to="cytk_EarlyDevelopmentMember_lbl"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract"/> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareAbstract_lbl" xml:lang="en-US" id="id_6895476_1275595_1_1">Earnings Per Share [Abstract]</label> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EarningsPerShareAbstract_lbl" xml:lang="en-US" id="id_6895476_1275595_2_1">Earnings Per Share [Abstract]</label> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_EarningsPerShareAbstract_lbl"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted" xlink:label="us-gaap_EarningsPerShareBasicAndDiluted"/> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareBasicAndDiluted_lbl" xml:lang="en-US" id="id_6895476_1278860_1_1">Earnings Per Share, Basic and Diluted</label> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EarningsPerShareBasicAndDiluted_lbl" xml:lang="en-US" id="id_6895476_1278860_2_1">Net loss per share allocable to common stockholders - basic and diluted</label> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareBasicAndDiluted" xlink:to="us-gaap_EarningsPerShareBasicAndDiluted_lbl"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EarningsPerShareTextBlock" xlink:label="us-gaap_EarningsPerShareTextBlock"/> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareTextBlock_lbl" xml:lang="en-US" id="id_6895476_1268989_1_1">Earnings Per Share [Text Block]</label> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EarningsPerShareTextBlock_lbl" xml:lang="en-US" id="id_6895476_1268989_2_1">Net Loss Per Share</label> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareTextBlock" xlink:to="us-gaap_EarningsPerShareTextBlock_lbl"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations"/> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations_lbl" xml:lang="en-US" id="id_6895476_1272229_1_1">Effective Income Tax Rate Reconciliation, Percent</label> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations_lbl" xml:lang="en-US" id="id_6895476_1272229_6_1">Total</label> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateContinuingOperations_lbl"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate"/> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl" xml:lang="en-US" id="id_6895476_1278867_1_1">Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent</label> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl" xml:lang="en-US" id="id_6895476_1278867_2_1">Tax at federal statutory tax rate</label> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl"/> <loc xlink:type="locator" xlink:href="cytk-20141231.xsd#cytk_EffectiveIncomeTaxRateReconciliationDeferredTaxAssetsUtilizedNotBenefited" xlink:label="cytk_EffectiveIncomeTaxRateReconciliationDeferredTaxAssetsUtilizedNotBenefited"/> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cytk_EffectiveIncomeTaxRateReconciliationDeferredTaxAssetsUtilizedNotBenefited_lbl" xml:lang="en-US" id="id_6895476_1438419_3_1">Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to deferred tax assets utilized not benefited.</label> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cytk_EffectiveIncomeTaxRateReconciliationDeferredTaxAssetsUtilizedNotBenefited_lbl" xml:lang="en-US" id="id_6895476_1438419_1_1">Effective Income Tax Rate Reconciliation Deferred Tax Assets Utilized Not Benefited</label> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cytk_EffectiveIncomeTaxRateReconciliationDeferredTaxAssetsUtilizedNotBenefited_lbl" xml:lang="en-US" id="id_6895476_1438419_2_1">Deferred tax assets (utilized) not benefited</label> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cytk_EffectiveIncomeTaxRateReconciliationDeferredTaxAssetsUtilizedNotBenefited" xlink:to="cytk_EffectiveIncomeTaxRateReconciliationDeferredTaxAssetsUtilizedNotBenefited_lbl"/> <loc xlink:type="locator" xlink:href="cytk-20141231.xsd#cytk_EffectiveIncomeTaxRateReconciliationNetOperatingLossExpiration" xlink:label="cytk_EffectiveIncomeTaxRateReconciliationNetOperatingLossExpiration"/> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cytk_EffectiveIncomeTaxRateReconciliationNetOperatingLossExpiration_lbl" xml:lang="en-US" id="id_6895476_1297509_3_1">Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to net operating loss expiration.</label> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cytk_EffectiveIncomeTaxRateReconciliationNetOperatingLossExpiration_lbl" xml:lang="en-US" id="id_6895476_1297509_1_1">Effective Income Tax Rate Reconciliation, Net Operating Loss Expiration</label> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cytk_EffectiveIncomeTaxRateReconciliationNetOperatingLossExpiration_lbl" xml:lang="en-US" id="id_6895476_1297509_2_1">NOL Expiration</label> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cytk_EffectiveIncomeTaxRateReconciliationNetOperatingLossExpiration" xlink:to="cytk_EffectiveIncomeTaxRateReconciliationNetOperatingLossExpiration_lbl"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost"/> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost_lbl" xml:lang="en-US" id="id_6895476_1280452_1_1">Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-based Compensation Cost, Percent</label> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost_lbl" xml:lang="en-US" id="id_6895476_1280452_2_1">Stock-based compensation</label> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost_lbl"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments"/> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_lbl" xml:lang="en-US" id="id_6895476_1275605_1_1">Effective Income Tax Rate Reconciliation, Other Adjustments, Percent</label> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_lbl" xml:lang="en-US" id="id_6895476_1275605_2_1">Other</label> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_lbl"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes"/> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_lbl" xml:lang="en-US" id="id_6895476_1273942_1_1">Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Percent</label> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_lbl" xml:lang="en-US" id="id_6895476_1273942_2_1">State income tax, net of federal tax benefit</label> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_lbl"/> <loc xlink:type="locator" xlink:href="cytk-20141231.xsd#cytk_EffectiveIncomeTaxRateReconciliationStateApportionment" xlink:label="cytk_EffectiveIncomeTaxRateReconciliationStateApportionment"/> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cytk_EffectiveIncomeTaxRateReconciliationStateApportionment_lbl" xml:lang="en-US" id="id_6895476_1554417_3_1">Effective Income Tax Rate Reconciliation State Apportionment</label> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cytk_EffectiveIncomeTaxRateReconciliationStateApportionment_lbl" xml:lang="en-US" id="id_6895476_1554417_1_1">Effective Income Tax Rate Reconciliation State Apportionment</label> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cytk_EffectiveIncomeTaxRateReconciliationStateApportionment_lbl" xml:lang="en-US" id="id_6895476_1554417_2_1">State Apportionment</label> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cytk_EffectiveIncomeTaxRateReconciliationStateApportionment" xlink:to="cytk_EffectiveIncomeTaxRateReconciliationStateApportionment_lbl"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits"/> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits_lbl" xml:lang="en-US" id="id_6895476_1272236_1_1">Effective Income Tax Rate Reconciliation, Tax Credit, Percent</label> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits_lbl" xml:lang="en-US" id="id_6895476_1272236_2_1">Tax credits (net)</label> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits_lbl"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_lbl" xml:lang="en-US" id="id_6895476_1270610_1_1">Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]</label> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_lbl" xml:lang="en-US" id="id_6895476_1270610_2_1">Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]</label> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_lbl"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl" xml:lang="en-US" id="id_6895476_1272251_1_1">Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized, Period for Recognition</label> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl" xml:lang="en-US" id="id_6895476_1272251_2_1">Weighted-average period</label> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions"/> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_lbl" xml:lang="en-US" id="id_6895476_1285370_1_1">Employee Service Share-based Compensation, Nonvested Awards, Compensation Not yet Recognized, Stock Options</label> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_lbl" xml:lang="en-US" id="id_6895476_1285370_2_1">Unrecognized compensation cost</label> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_lbl"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EmployeeStockMember" xlink:label="us-gaap_EmployeeStockMember"/> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeStockMember_lbl" xml:lang="en-US" id="id_6895476_1277228_1_1">Employee Stock [Member]</label> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EmployeeStockMember_lbl" xml:lang="en-US" id="id_6895476_1277228_2_1">ESPP [Member]</label> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeStockMember" xlink:to="us-gaap_EmployeeStockMember_lbl"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember"/> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeStockOptionMember_lbl" xml:lang="en-US" id="id_6895476_1275629_1_1">Employee Stock Option [Member]</label> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EmployeeStockOptionMember_lbl" xml:lang="en-US" id="id_6895476_1275629_2_1">Options [Member]</label> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeStockOptionMember" xlink:to="us-gaap_EmployeeStockOptionMember_lbl"/> <loc xlink:type="locator" xlink:href="cytk-20141231.xsd#cytk_EmployeeStockPurchasePlansAveragePricePerShare" xlink:label="cytk_EmployeeStockPurchasePlansAveragePricePerShare"/> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cytk_EmployeeStockPurchasePlansAveragePricePerShare_lbl" xml:lang="en-US" id="id_6895476_1315936_3_1">Weighted average selling price of common stock, pursuant to employee stock purchase plan.</label> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cytk_EmployeeStockPurchasePlansAveragePricePerShare_lbl" xml:lang="en-US" id="id_6895476_1315936_1_1">Employee Stock Purchase Plans Average Price Per Share</label> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cytk_EmployeeStockPurchasePlansAveragePricePerShare_lbl" xml:lang="en-US" id="id_6895476_1315936_2_1">Common stock average price per share</label> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cytk_EmployeeStockPurchasePlansAveragePricePerShare" xlink:to="cytk_EmployeeStockPurchasePlansAveragePricePerShare_lbl"/> <loc xlink:type="locator" xlink:href="cytk-20141231.xsd#cytk_EntitledPaymentPerShareDuringLiquidation" xlink:label="cytk_EntitledPaymentPerShareDuringLiquidation"/> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cytk_EntitledPaymentPerShareDuringLiquidation_lbl" xml:lang="en-US" id="id_6895476_1475291_3_1">Value of the difference between preference in liquidation and the par or stated values of the preferred shares.</label> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cytk_EntitledPaymentPerShareDuringLiquidation_lbl" xml:lang="en-US" id="id_6895476_1475291_1_1">Entitled Payment Per Share During Liquidation</label> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cytk_EntitledPaymentPerShareDuringLiquidation_lbl" xml:lang="en-US" id="id_6895476_1475291_2_1">Entitled payment per share during liquidation</label> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cytk_EntitledPaymentPerShareDuringLiquidation" xlink:to="cytk_EntitledPaymentPerShareDuringLiquidation_lbl"/> <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey"/> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCentralIndexKey_lbl" xml:lang="en-US" id="id_6895476_1278115_1_1">Entity Central Index Key</label> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityCentralIndexKey_lbl" xml:lang="en-US" id="id_6895476_1278115_2_1">Entity Central Index Key</label> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl"/> <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding"/> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xml:lang="en-US" id="id_6895476_1276513_1_1">Entity Common Stock, Shares Outstanding</label> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xml:lang="en-US" id="id_6895476_1276513_2_1">Entity Common Stock, Shares Outstanding</label> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCommonStockSharesOutstanding" xlink:to="dei_EntityCommonStockSharesOutstanding_lbl"/> <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus"/> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCurrentReportingStatus_lbl" xml:lang="en-US" id="id_6895476_1281311_1_1">Entity Current Reporting Status</label> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityCurrentReportingStatus_lbl" xml:lang="en-US" id="id_6895476_1281311_2_1">Entity Current Reporting Status</label> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCurrentReportingStatus" xlink:to="dei_EntityCurrentReportingStatus_lbl"/> <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain"/> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityDomain_lbl" xml:lang="en-US" id="id_6895476_1273139_1_1">Entity [Domain]</label> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityDomain_lbl" xml:lang="en-US" id="id_6895476_1273139_2_1">Entity [Domain]</label> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityDomain" xlink:to="dei_EntityDomain_lbl"/> <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory"/> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFilerCategory_lbl" xml:lang="en-US" id="id_6895476_1271511_1_1">Entity Filer Category</label> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityFilerCategory_lbl" xml:lang="en-US" id="id_6895476_1271511_2_1">Entity Filer Category</label> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFilerCategory" xlink:to="dei_EntityFilerCategory_lbl"/> <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityPublicFloat" xlink:label="dei_EntityPublicFloat"/> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityPublicFloat_lbl" xml:lang="en-US" id="id_6895476_1284726_1_1">Entity Public Float</label> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityPublicFloat_lbl" xml:lang="en-US" id="id_6895476_1284726_2_1">Entity Public Float</label> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPublicFloat" xlink:to="dei_EntityPublicFloat_lbl"/> <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName"/> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityRegistrantName_lbl" xml:lang="en-US" id="id_6895476_1269875_1_1">Entity Registrant Name</label> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityRegistrantName_lbl" xml:lang="en-US" id="id_6895476_1269875_2_1">Entity Registrant Name</label> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl"/> <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityVoluntaryFilers" xlink:label="dei_EntityVoluntaryFilers"/> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityVoluntaryFilers_lbl" xml:lang="en-US" id="id_6895476_1271521_1_1">Entity Voluntary Filers</label> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityVoluntaryFilers_lbl" xml:lang="en-US" id="id_6895476_1271521_2_1">Entity Voluntary Filers</label> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityVoluntaryFilers" xlink:to="dei_EntityVoluntaryFilers_lbl"/> <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="dei_EntityWellKnownSeasonedIssuer"/> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityWellKnownSeasonedIssuer_lbl" xml:lang="en-US" id="id_6895476_1269876_1_1">Entity Well-known Seasoned Issuer</label> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityWellKnownSeasonedIssuer_lbl" xml:lang="en-US" id="id_6895476_1269876_2_1">Entity Well-known Seasoned Issuer</label> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityWellKnownSeasonedIssuer" xlink:to="dei_EntityWellKnownSeasonedIssuer_lbl"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EquityAbstract" xlink:label="us-gaap_EquityAbstract"/> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EquityAbstract_lbl" xml:lang="en-US" id="id_6895476_1269012_1_1">Equity [Abstract]</label> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EquityAbstract_lbl" xml:lang="en-US" id="id_6895476_1269012_2_1">Equity [Abstract]</label> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_EquityAbstract_lbl"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EquityComponentDomain_lbl" xml:lang="en-US" id="id_6895476_1272258_1_1">Equity Component [Domain]</label> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EquityComponentDomain_lbl" xml:lang="en-US" id="id_6895476_1272258_2_1">Equity Component [Domain]</label> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_EquityComponentDomain_lbl"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EquityIssuancePerShareAmount" xlink:label="us-gaap_EquityIssuancePerShareAmount"/> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EquityIssuancePerShareAmount_lbl" xml:lang="en-US" id="id_6895476_1269016_1_1">Development Stage Entities, Equity Issuance, Per Share Amount</label> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EquityIssuancePerShareAmount_lbl" xml:lang="en-US" id="id_6895476_1269016_2_1">Common stock price per share</label> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityIssuancePerShareAmount" xlink:to="us-gaap_EquityIssuancePerShareAmount_lbl"/> <loc xlink:type="locator" xlink:href="cytk-20141231.xsd#cytk_ExcessOfCommonStockFairValueOverAllocatedPurchasePriceOfPreferredStock" xlink:label="cytk_ExcessOfCommonStockFairValueOverAllocatedPurchasePriceOfPreferredStock"/> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cytk_ExcessOfCommonStockFairValueOverAllocatedPurchasePriceOfPreferredStock_lbl" xml:lang="en-US" id="id_6895476_1353899_3_1">Excess of fair value of common stock into which preferred stock is convertible, over the purchase price of such preferred stock.</label> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cytk_ExcessOfCommonStockFairValueOverAllocatedPurchasePriceOfPreferredStock_lbl" xml:lang="en-US" id="id_6895476_1353899_1_1">Excess Of Common Stock Fair Value Over Allocated Purchase Price Of Preferred Stock</label> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cytk_ExcessOfCommonStockFairValueOverAllocatedPurchasePriceOfPreferredStock_lbl" xml:lang="en-US" id="id_6895476_1353899_2_1">Amount by which fair value of common stock exceeded the allocated purchase price</label> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cytk_ExcessOfCommonStockFairValueOverAllocatedPurchasePriceOfPreferredStock" xlink:to="cytk_ExcessOfCommonStockFairValueOverAllocatedPurchasePriceOfPreferredStock_lbl"/> <loc xlink:type="locator" xlink:href="cytk-20141231.xsd#cytk_ExistingEmployeeMember" xlink:label="cytk_ExistingEmployeeMember"/> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cytk_ExistingEmployeeMember_lbl" xml:lang="en-US" id="id_6895476_1392833_3_1">Existing employee.</label> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cytk_ExistingEmployeeMember_lbl" xml:lang="en-US" id="id_6895476_1392833_1_1">Existing Employee [Member]</label> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cytk_ExistingEmployeeMember_lbl" xml:lang="en-US" id="id_6895476_1392833_2_1">Existing Employee [Member]</label> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cytk_ExistingEmployeeMember" xlink:to="cytk_ExistingEmployeeMember_lbl"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_lbl" xml:lang="en-US" id="id_6895476_1280493_1_1">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</label> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_lbl" xml:lang="en-US" id="id_6895476_1280493_2_1">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</label> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_lbl"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_lbl" xml:lang="en-US" id="id_6895476_1277254_1_1">Fair Value Measurements, Recurring and Nonrecurring [Table]</label> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_lbl" xml:lang="en-US" id="id_6895476_1277254_2_1">Fair Value Measurements, Recurring and Nonrecurring [Table]</label> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_lbl"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock"/> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock_lbl" xml:lang="en-US" id="id_6895476_1270656_1_1">Fair Value, Assets Measured on Recurring Basis [Table Text Block]</label> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock_lbl" xml:lang="en-US" id="id_6895476_1270656_2_1">Summary of Financial Assets Measured at Fair Value on Recurring Basis</label> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" xlink:to="us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock_lbl"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain"/> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_lbl" xml:lang="en-US" id="id_6895476_1270657_1_1">Asset Class [Domain]</label> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_lbl" xml:lang="en-US" id="id_6895476_1270657_2_1">Asset Class [Domain]</label> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_lbl"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueAssumptionsExpectedTerm" xlink:label="us-gaap_FairValueAssumptionsExpectedTerm"/> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueAssumptionsExpectedTerm_lbl" xml:lang="en-US" id="id_6895476_1270658_1_1">Fair Value Assumptions, Expected Term</label> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueAssumptionsExpectedTerm_lbl" xml:lang="en-US" id="id_6895476_1270658_2_1">Contractual term</label> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssumptionsExpectedTerm" xlink:to="us-gaap_FairValueAssumptionsExpectedTerm_lbl"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueAssumptionsExpectedVolatilityRate" xlink:label="us-gaap_FairValueAssumptionsExpectedVolatilityRate"/> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueAssumptionsExpectedVolatilityRate_lbl" xml:lang="en-US" id="id_6895476_1273985_1_1">Fair Value Assumptions, Expected Volatility Rate</label> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueAssumptionsExpectedVolatilityRate_lbl" xml:lang="en-US" id="id_6895476_1273985_2_1">Volatility of warrants</label> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssumptionsExpectedVolatilityRate" xlink:to="us-gaap_FairValueAssumptionsExpectedVolatilityRate_lbl"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueAssumptionsRiskFreeInterestRate" xlink:label="us-gaap_FairValueAssumptionsRiskFreeInterestRate"/> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueAssumptionsRiskFreeInterestRate_lbl" xml:lang="en-US" id="id_6895476_1277268_1_1">Fair Value Assumptions, Risk Free Interest Rate</label> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueAssumptionsRiskFreeInterestRate_lbl" xml:lang="en-US" id="id_6895476_1277268_2_1">Risk-free interest rate</label> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssumptionsRiskFreeInterestRate" xlink:to="us-gaap_FairValueAssumptionsRiskFreeInterestRate_lbl"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueByAssetClassAxis" xlink:label="us-gaap_FairValueByAssetClassAxis"/> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueByAssetClassAxis_lbl" xml:lang="en-US" id="id_6895476_1275669_1_1">Asset Class [Axis]</label> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueByAssetClassAxis_lbl" xml:lang="en-US" id="id_6895476_1275669_2_1">Asset Class [Axis]</label> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueByAssetClassAxis" xlink:to="us-gaap_FairValueByAssetClassAxis_lbl"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis"/> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis_lbl" xml:lang="en-US" id="id_6895476_1269038_1_1">Fair Value, Hierarchy [Axis]</label> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis_lbl" xml:lang="en-US" id="id_6895476_1269038_2_1">Fair Value, Hierarchy [Axis]</label> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis_lbl"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis"/> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis_lbl" xml:lang="en-US" id="id_6895476_1275672_1_1">Measurement Frequency [Axis]</label> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis_lbl" xml:lang="en-US" id="id_6895476_1275672_2_1">Measurement Frequency [Axis]</label> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="us-gaap_FairValueByMeasurementFrequencyAxis_lbl"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract"/> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueDisclosuresAbstract_lbl" xml:lang="en-US" id="id_6895476_1274013_1_1">Fair Value Disclosures [Abstract]</label> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueDisclosuresAbstract_lbl" xml:lang="en-US" id="id_6895476_1274013_2_1">Fair Value Disclosures [Abstract]</label> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueDisclosuresAbstract_lbl"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueDisclosuresTextBlock" xlink:label="us-gaap_FairValueDisclosuresTextBlock"/> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueDisclosuresTextBlock_lbl" xml:lang="en-US" id="id_6895476_1278936_1_1">Fair Value Disclosures [Text Block]</label> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueDisclosuresTextBlock_lbl" xml:lang="en-US" id="id_6895476_1278936_2_1">Fair Value Measurements</label> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueDisclosuresTextBlock" xlink:to="us-gaap_FairValueDisclosuresTextBlock_lbl"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="us-gaap_FairValueInputsLevel1Member"/> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueInputsLevel1Member_lbl" xml:lang="en-US" id="id_6895476_1272304_1_1">Fair Value, Inputs, Level 1 [Member]</label> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueInputsLevel1Member_lbl" xml:lang="en-US" id="id_6895476_1272304_2_1">Fair Value Measurements Using Level 1 [Member]</label> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel1Member" xlink:to="us-gaap_FairValueInputsLevel1Member_lbl"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="us-gaap_FairValueInputsLevel2Member"/> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueInputsLevel2Member_lbl" xml:lang="en-US" id="id_6895476_1269048_1_1">Fair Value, Inputs, Level 2 [Member]</label> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueInputsLevel2Member_lbl" xml:lang="en-US" id="id_6895476_1269048_2_1">Fair Value Measurements Using Level 2 [Member]</label> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel2Member" xlink:to="us-gaap_FairValueInputsLevel2Member_lbl"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="us-gaap_FairValueInputsLevel3Member"/> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueInputsLevel3Member_lbl" xml:lang="en-US" id="id_6895476_1275680_1_1">Fair Value, Inputs, Level 3 [Member]</label> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueInputsLevel3Member_lbl" xml:lang="en-US" id="id_6895476_1275680_2_1">Fair Value Measurements Using Level 3 [Member]</label> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel3Member" xlink:to="us-gaap_FairValueInputsLevel3Member_lbl"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain"/> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain_lbl" xml:lang="en-US" id="id_6895476_1270690_1_1">Fair Value, Measurement Frequency [Domain]</label> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain_lbl" xml:lang="en-US" id="id_6895476_1270690_2_1">Fair Value, Measurement Frequency [Domain]</label> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementFrequencyDomain" xlink:to="us-gaap_FairValueMeasurementFrequencyDomain_lbl"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_lbl" xml:lang="en-US" id="id_6895476_1270691_1_1">Fair Value Hierarchy [Domain]</label> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_lbl" xml:lang="en-US" id="id_6895476_1270691_2_1">Fair Value Hierarchy [Domain]</label> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_lbl"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:label="us-gaap_FairValueMeasurementsRecurringMember"/> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueMeasurementsRecurringMember_lbl" xml:lang="en-US" id="id_6895476_1274022_1_1">Fair Value, Measurements, Recurring [Member]</label> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueMeasurementsRecurringMember_lbl" xml:lang="en-US" id="id_6895476_1274022_2_1">Fair Value, Measurements, Recurring [Member]</label> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementsRecurringMember" xlink:to="us-gaap_FairValueMeasurementsRecurringMember_lbl"/> <loc xlink:type="locator" xlink:href="cytk-20141231.xsd#cytk_FairValueOfCommonStockIssued" xlink:label="cytk_FairValueOfCommonStockIssued"/> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cytk_FairValueOfCommonStockIssued_lbl" xml:lang="en-US" id="id_6895476_1468043_3_1">Fair Value Of Common Stock Issued</label> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cytk_FairValueOfCommonStockIssued_lbl" xml:lang="en-US" id="id_6895476_1468043_1_1">Fair Value Of Common Stock Issued</label> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cytk_FairValueOfCommonStockIssued_lbl" xml:lang="en-US" id="id_6895476_1468043_2_1">Common stock fair value</label> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cytk_FairValueOfCommonStockIssued" xlink:to="cytk_FairValueOfCommonStockIssued_lbl"/> <loc xlink:type="locator" xlink:href="cytk-20141231.xsd#cytk_FairValuePerShareOfCommonStock" xlink:label="cytk_FairValuePerShareOfCommonStock"/> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cytk_FairValuePerShareOfCommonStock_lbl" xml:lang="en-US" id="id_6895476_1431300_3_1">"Fair value per share of common stock options granted.</label> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cytk_FairValuePerShareOfCommonStock_lbl" xml:lang="en-US" id="id_6895476_1431300_1_1">Fair Value Per Share Of Common Stock</label> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cytk_FairValuePerShareOfCommonStock_lbl" xml:lang="en-US" id="id_6895476_1431300_2_1">Fair value of common stock</label> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cytk_FairValuePerShareOfCommonStock" xlink:to="cytk_FairValuePerShareOfCommonStock_lbl"/> <loc xlink:type="locator" xlink:href="cytk-20141231.xsd#cytk_FederalAndStateTaxMember" xlink:label="cytk_FederalAndStateTaxMember"/> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cytk_FederalAndStateTaxMember_lbl" xml:lang="en-US" id="id_6895476_1520580_3_1">Federal And State Tax [Member]</label> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cytk_FederalAndStateTaxMember_lbl" xml:lang="en-US" id="id_6895476_1520580_1_1">Federal And State Tax [Member]</label> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cytk_FederalAndStateTaxMember_lbl" xml:lang="en-US" id="id_6895476_1520580_2_1">Federal and State Tax [Member]</label> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cytk_FederalAndStateTaxMember" xlink:to="cytk_FederalAndStateTaxMember_lbl"/> <loc xlink:type="locator" xlink:href="cytk-20141231.xsd#cytk_FederalNetOperatingLossRelatesToStockOptionDeductions" xlink:label="cytk_FederalNetOperatingLossRelatesToStockOptionDeductions"/> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cytk_FederalNetOperatingLossRelatesToStockOptionDeductions_lbl" xml:lang="en-US" id="id_6895476_1546753_3_1">Federal net operating loss relates to stock option deductions.</label> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cytk_FederalNetOperatingLossRelatesToStockOptionDeductions_lbl" xml:lang="en-US" id="id_6895476_1546753_1_1">Federal Net Operating Loss Relates To Stock Option Deductions</label> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cytk_FederalNetOperatingLossRelatesToStockOptionDeductions_lbl" xml:lang="en-US" id="id_6895476_1546753_2_1">Net operating loss related to tax stock option deductions</label> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cytk_FederalNetOperatingLossRelatesToStockOptionDeductions" xlink:to="cytk_FederalNetOperatingLossRelatesToStockOptionDeductions_lbl"/> <loc xlink:type="locator" xlink:href="cytk-20141231.xsd#cytk_FederalTaxBenefitOfStateIncomeTaxUtbMember" xlink:label="cytk_FederalTaxBenefitOfStateIncomeTaxUtbMember"/> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cytk_FederalTaxBenefitOfStateIncomeTaxUtbMember_lbl" xml:lang="en-US" id="id_6895476_1297583_3_1">Federal Tax Benefit Of State Income Tax Utb [Member]</label> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cytk_FederalTaxBenefitOfStateIncomeTaxUtbMember_lbl" xml:lang="en-US" id="id_6895476_1297583_1_1">Federal Tax Benefit Of State Income Tax Utb [Member]</label> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cytk_FederalTaxBenefitOfStateIncomeTaxUtbMember_lbl" xml:lang="en-US" id="id_6895476_1297583_2_1">Federal Tax Benefit of State Income Tax UTBs [Member]</label> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cytk_FederalTaxBenefitOfStateIncomeTaxUtbMember" xlink:to="cytk_FederalTaxBenefitOfStateIncomeTaxUtbMember_lbl"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="us-gaap_FinancialInstrumentAxis"/> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FinancialInstrumentAxis_lbl" xml:lang="en-US" id="id_6895476_1278975_1_1">Financial Instrument [Axis]</label> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FinancialInstrumentAxis_lbl" xml:lang="en-US" id="id_6895476_1278975_2_1">Financial Instrument [Axis]</label> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_FinancialInstrumentAxis_lbl"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_lbl" xml:lang="en-US" id="id_6895476_1277337_1_1">Finite-Lived Intangible Assets by Major Class [Axis]</label> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_lbl" xml:lang="en-US" id="id_6895476_1277337_2_1">Finite-Lived Intangible Assets by Major Class [Axis]</label> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_lbl"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_lbl" xml:lang="en-US" id="id_6895476_1272379_1_1">Finite-Lived Intangible Assets, Major Class Name [Domain]</label> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_lbl" xml:lang="en-US" id="id_6895476_1272379_2_1">Finite-Lived Intangible Assets, Major Class Name [Domain]</label> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_lbl"/> <loc xlink:type="locator" xlink:href="cytk-20141231.xsd#cytk_FractionalSharesFromReverseStockSplitShare" xlink:label="cytk_FractionalSharesFromReverseStockSplitShare"/> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cytk_FractionalSharesFromReverseStockSplitShare_lbl" xml:lang="en-US" id="id_6895476_1408014_3_1">Fractional Shares From Reverse Stock Split Share</label> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cytk_FractionalSharesFromReverseStockSplitShare_lbl" xml:lang="en-US" id="id_6895476_1408014_1_1">Fractional Shares From Reverse Stock Split Share</label> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cytk_FractionalSharesFromReverseStockSplitShare_lbl" xml:lang="en-US" id="id_6895476_1408014_2_1">Fractional shares settlement pursuant to reverse stock split</label> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cytk_FractionalSharesFromReverseStockSplitShare" xlink:to="cytk_FractionalSharesFromReverseStockSplitShare_lbl"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="us-gaap_FurnitureAndFixturesMember"/> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FurnitureAndFixturesMember_lbl" xml:lang="en-US" id="id_6895476_1274094_1_1">Furniture and Fixtures [Member]</label> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FurnitureAndFixturesMember_lbl" xml:lang="en-US" id="id_6895476_1274094_2_1">Furniture and Fixtures [Member]</label> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FurnitureAndFixturesMember" xlink:to="us-gaap_FurnitureAndFixturesMember_lbl"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:label="us-gaap_GainLossOnSaleOfPropertyPlantEquipment"/> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GainLossOnSaleOfPropertyPlantEquipment_lbl" xml:lang="en-US" id="id_6895476_1282816_1_1">Gain (Loss) on Disposition of Property Plant Equipment</label> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_GainLossOnSaleOfPropertyPlantEquipment_lbl" xml:lang="en-US" id="id_6895476_1282816_14_1">Gain on disposal of equipment</label> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:to="us-gaap_GainLossOnSaleOfPropertyPlantEquipment_lbl"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_GainOnSaleOfInvestments" xlink:label="us-gaap_GainOnSaleOfInvestments"/> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GainOnSaleOfInvestments_lbl" xml:lang="en-US" id="id_6895476_1284141_1_1">Gain on Sale of Investments</label> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_GainOnSaleOfInvestments_lbl" xml:lang="en-US" id="id_6895476_1284141_14_1">Gain on sale of investments</label> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GainOnSaleOfInvestments" xlink:to="us-gaap_GainOnSaleOfInvestments_lbl"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense"/> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl" xml:lang="en-US" id="id_6895476_1288487_1_1">General and Administrative Expense</label> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl" xml:lang="en-US" id="id_6895476_1288487_2_1">General and administrative</label> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpense" xlink:to="us-gaap_GeneralAndAdministrativeExpense_lbl"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember"/> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember_lbl" xml:lang="en-US" id="id_6895476_1269133_1_1">General and Administrative Expense [Member]</label> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember_lbl" xml:lang="en-US" id="id_6895476_1269133_2_1">General and Administrative [Member]</label> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpenseMember" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember_lbl"/> <loc xlink:type="locator" xlink:href="cytk-20141231.xsd#cytk_GlobalBloodTherapeuticsMember" xlink:label="cytk_GlobalBloodTherapeuticsMember"/> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cytk_GlobalBloodTherapeuticsMember_lbl" xml:lang="en-US" id="id_6895476_1537165_3_1">Global blood therapeutics.</label> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cytk_GlobalBloodTherapeuticsMember_lbl" xml:lang="en-US" id="id_6895476_1537165_1_1">Global Blood Therapeutics [Member]</label> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cytk_GlobalBloodTherapeuticsMember_lbl" xml:lang="en-US" id="id_6895476_1537165_2_1">Global Blood [Member]</label> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cytk_GlobalBloodTherapeuticsMember" xlink:to="cytk_GlobalBloodTherapeuticsMember_lbl"/> <loc xlink:type="locator" xlink:href="cytk-20141231.xsd#cytk_GrossProceedsFromIssuanceOfStock" xlink:label="cytk_GrossProceedsFromIssuanceOfStock"/> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cytk_GrossProceedsFromIssuanceOfStock_lbl" xml:lang="en-US" id="id_6895476_1532549_3_1">The cash inflow from the additional capital contribution to the entity.</label> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cytk_GrossProceedsFromIssuanceOfStock_lbl" xml:lang="en-US" id="id_6895476_1532549_1_1">Gross Proceeds From Issuance Of Stock</label> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cytk_GrossProceedsFromIssuanceOfStock_lbl" xml:lang="en-US" id="id_6895476_1532549_2_1">Gross proceeds from public offerings</label> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cytk_GrossProceedsFromIssuanceOfStock" xlink:to="cytk_GrossProceedsFromIssuanceOfStock_lbl"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:label="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock"/> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_lbl" xml:lang="en-US" id="id_6895476_1279053_1_1">Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block]</label> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_lbl" xml:lang="en-US" id="id_6895476_1279053_2_1">Impairment of Long-lived Assets</label> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:to="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_lbl"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic"/> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_lbl" xml:lang="en-US" id="id_6895476_1284997_1_1">Income (Loss) from Continuing Operations before Income Taxes, Domestic</label> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_lbl" xml:lang="en-US" id="id_6895476_1284997_2_1">United States</label> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_lbl"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign"/> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_lbl" xml:lang="en-US" id="id_6895476_1281842_1_1">Income (Loss) from Continuing Operations before Income Taxes, Foreign</label> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_lbl" xml:lang="en-US" id="id_6895476_1281842_2_1">Foreign</label> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_lbl"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments"/> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_lbl" xml:lang="en-US" id="id_6895476_1283677_1_1">Income (Loss) from Continuing Operations before Equity Method Investments, Income Taxes, Extraordinary Items, Noncontrolling Interest</label> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_lbl" xml:lang="en-US" id="id_6895476_1283677_6_1">Loss before income taxes</label> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_lbl"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsPerBasicAndDilutedShare" xlink:label="us-gaap_IncomeLossFromContinuingOperationsPerBasicAndDilutedShare"/> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeLossFromContinuingOperationsPerBasicAndDilutedShare_lbl" xml:lang="en-US" id="id_6895476_1270814_1_1">Income (Loss) from Continuing Operations, Per Basic and Diluted Share</label> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeLossFromContinuingOperationsPerBasicAndDilutedShare_lbl" xml:lang="en-US" id="id_6895476_1270814_2_1">Net income (loss) per share allocable to common stockholders - basic and diluted</label> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromContinuingOperationsPerBasicAndDilutedShare" xlink:to="us-gaap_IncomeLossFromContinuingOperationsPerBasicAndDilutedShare_lbl"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsPerBasicShare" xlink:label="us-gaap_IncomeLossFromContinuingOperationsPerBasicShare"/> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeLossFromContinuingOperationsPerBasicShare_lbl" xml:lang="en-US" id="id_6895476_1277410_1_1">Income (Loss) from Continuing Operations, Per Basic Share</label> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeLossFromContinuingOperationsPerBasicShare_lbl" xml:lang="en-US" id="id_6895476_1277410_2_1">Net income (loss) per share allocable to common stockholders - basic</label> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromContinuingOperationsPerBasicShare" xlink:to="us-gaap_IncomeLossFromContinuingOperationsPerBasicShare_lbl"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare" xlink:label="us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare"/> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare_lbl" xml:lang="en-US" id="id_6895476_1274160_1_1">Income (Loss) from Continuing Operations, Per Diluted Share</label> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare_lbl" xml:lang="en-US" id="id_6895476_1274160_2_1">Net income (loss) per share allocable to common stockholders - diluted</label> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare" xlink:to="us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare_lbl"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncomeStatementAbstract" xlink:label="us-gaap_IncomeStatementAbstract"/> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeStatementAbstract_lbl" xml:lang="en-US" id="id_6895476_1272476_1_1">Income Statement [Abstract]</label> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeStatementAbstract_lbl" xml:lang="en-US" id="id_6895476_1272476_2_1">Income Statement [Abstract]</label> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_IncomeStatementAbstract_lbl"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis"/> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeStatementLocationAxis_lbl" xml:lang="en-US" id="id_6895476_1274159_1_1">Income Statement Location [Axis]</label> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeStatementLocationAxis_lbl" xml:lang="en-US" id="id_6895476_1274159_2_1">Income Statement Location [Axis]</label> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationAxis_lbl"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain"/> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeStatementLocationDomain_lbl" xml:lang="en-US" id="id_6895476_1270824_1_1">Income Statement Location [Domain]</label> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeStatementLocationDomain_lbl" xml:lang="en-US" id="id_6895476_1270824_2_1">Income Statement Location [Domain]</label> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_IncomeStatementLocationDomain_lbl"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="us-gaap_IncomeTaxAuthorityAxis"/> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxAuthorityAxis_lbl" xml:lang="en-US" id="id_6895476_1280651_1_1">Income Tax Authority [Axis]</label> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeTaxAuthorityAxis_lbl" xml:lang="en-US" id="id_6895476_1280651_2_1">Income Tax Authority [Axis]</label> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityAxis_lbl"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="us-gaap_IncomeTaxAuthorityDomain"/> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxAuthorityDomain_lbl" xml:lang="en-US" id="id_6895476_1279066_1_1">Income Tax Authority [Domain]</label> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeTaxAuthorityDomain_lbl" xml:lang="en-US" id="id_6895476_1279066_2_1">Income Tax Authority [Domain]</label> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_IncomeTaxAuthorityDomain_lbl"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncomeTaxContingencyLineItems" xlink:label="us-gaap_IncomeTaxContingencyLineItems"/> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxContingencyLineItems_lbl" xml:lang="en-US" id="id_6895476_1275793_1_1">Income Tax Contingency [Line Items]</label> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeTaxContingencyLineItems_lbl" xml:lang="en-US" id="id_6895476_1275793_2_1">Income Tax Contingency [Line Items]</label> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxContingencyLineItems" xlink:to="us-gaap_IncomeTaxContingencyLineItems_lbl"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncomeTaxContingencyTable" xlink:label="us-gaap_IncomeTaxContingencyTable"/> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxContingencyTable_lbl" xml:lang="en-US" id="id_6895476_1279067_1_1">Income Tax Contingency [Table]</label> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeTaxContingencyTable_lbl" xml:lang="en-US" id="id_6895476_1279067_2_1">Income Tax Contingency [Table]</label> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxContingencyTable" xlink:to="us-gaap_IncomeTaxContingencyTable_lbl"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract"/> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxDisclosureAbstract_lbl" xml:lang="en-US" id="id_6895476_1272478_1_1">Income Tax Disclosure [Abstract]</label> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeTaxDisclosureAbstract_lbl" xml:lang="en-US" id="id_6895476_1272478_2_1">Income Tax Disclosure [Abstract]</label> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxDisclosureAbstract_lbl"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock"/> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock_lbl" xml:lang="en-US" id="id_6895476_1277417_1_1">Income Tax Disclosure [Text Block]</label> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock_lbl" xml:lang="en-US" id="id_6895476_1277417_2_1">Income Taxes</label> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock_lbl"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncomeTaxesPaidNet" xlink:label="us-gaap_IncomeTaxesPaidNet"/> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxesPaidNet_lbl" xml:lang="en-US" id="id_6895476_1281841_1_1">Income Taxes Paid, Net</label> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeTaxesPaidNet_lbl" xml:lang="en-US" id="id_6895476_1281841_2_1">Cash paid for income taxes</label> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxesPaidNet" xlink:to="us-gaap_IncomeTaxesPaidNet_lbl"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncomeTaxExaminationPenaltiesAndInterestAccrued" xlink:label="us-gaap_IncomeTaxExaminationPenaltiesAndInterestAccrued"/> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxExaminationPenaltiesAndInterestAccrued_lbl" xml:lang="en-US" id="id_6895476_1282793_1_1">Income Tax Examination, Penalties and Interest Accrued</label> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeTaxExaminationPenaltiesAndInterestAccrued_lbl" xml:lang="en-US" id="id_6895476_1282793_2_1">Unrecognized tax benefits not accrue any penalties</label> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxExaminationPenaltiesAndInterestAccrued" xlink:to="us-gaap_IncomeTaxExaminationPenaltiesAndInterestAccrued_lbl"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit"/> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxExpenseBenefit_lbl" xml:lang="en-US" id="id_6895476_1286481_1_1">Income Tax Expense (Benefit)</label> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeTaxExpenseBenefit_lbl" xml:lang="en-US" id="id_6895476_1286481_2_1">Provision for income tax</label> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncomeTaxExpenseBenefit_lbl" xml:lang="en-US" id="id_6895476_1286481_14_1">Income tax benefit</label> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxExpenseBenefit_lbl"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="us-gaap_IncomeTaxPolicyTextBlock"/> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxPolicyTextBlock_lbl" xml:lang="en-US" id="id_6895476_1270827_1_1">Income Tax, Policy [Policy Text Block]</label> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeTaxPolicyTextBlock_lbl" xml:lang="en-US" id="id_6895476_1270827_2_1">Income Taxes</label> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxPolicyTextBlock" xlink:to="us-gaap_IncomeTaxPolicyTextBlock_lbl"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncomeTaxReconciliationTaxCredits" xlink:label="us-gaap_IncomeTaxReconciliationTaxCredits"/> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxReconciliationTaxCredits_lbl" xml:lang="en-US" id="id_6895476_1283672_1_1">Effective Income Tax Rate Reconciliation, Tax Credit, Amount</label> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeTaxReconciliationTaxCredits_lbl" xml:lang="en-US" id="id_6895476_1283672_2_1">Credit carryforwards for federal and state</label> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationTaxCredits" xlink:to="us-gaap_IncomeTaxReconciliationTaxCredits_lbl"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableTrade" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableTrade"/> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableTrade_lbl" xml:lang="en-US" id="id_6895476_1289043_1_1">Increase (Decrease) in Accounts Payable, Trade</label> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableTrade_lbl" xml:lang="en-US" id="id_6895476_1289043_2_1">Accounts payable</label> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsPayableTrade" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayableTrade_lbl"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities"/> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities_lbl" xml:lang="en-US" id="id_6895476_1287513_1_1">Increase (Decrease) in Accrued Liabilities</label> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities_lbl" xml:lang="en-US" id="id_6895476_1287513_2_1">Accrued and other liabilities</label> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilities_lbl"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:label="us-gaap_IncreaseDecreaseInDeferredRevenue"/> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInDeferredRevenue_lbl" xml:lang="en-US" id="id_6895476_1285447_1_1">Increase (Decrease) in Deferred Revenue</label> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncreaseDecreaseInDeferredRevenue_lbl" xml:lang="en-US" id="id_6895476_1285447_2_1">Deferred revenue</label> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:to="us-gaap_IncreaseDecreaseInDeferredRevenue_lbl"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncreaseDecreaseInDueFromRelatedPartiesCurrent" xlink:label="us-gaap_IncreaseDecreaseInDueFromRelatedPartiesCurrent"/> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInDueFromRelatedPartiesCurrent_lbl" xml:lang="en-US" id="id_6895476_1283203_1_1">Increase (Decrease) in Due from Related Parties, Current</label> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInDueFromRelatedPartiesCurrent_lbl" xml:lang="en-US" id="id_6895476_1283203_14_1">Related party accounts receivable</label> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInDueFromRelatedPartiesCurrent" xlink:to="us-gaap_IncreaseDecreaseInDueFromRelatedPartiesCurrent_lbl"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncreaseDecreaseInDueToRelatedPartiesCurrent" xlink:label="us-gaap_IncreaseDecreaseInDueToRelatedPartiesCurrent"/> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInDueToRelatedPartiesCurrent_lbl" xml:lang="en-US" id="id_6895476_1288527_1_1">Increase (Decrease) in Due to Related Parties, Current</label> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncreaseDecreaseInDueToRelatedPartiesCurrent_lbl" xml:lang="en-US" id="id_6895476_1288527_2_1">Related party payables and accrued liabilities</label> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInDueToRelatedPartiesCurrent" xlink:to="us-gaap_IncreaseDecreaseInDueToRelatedPartiesCurrent_lbl"/> <loc xlink:type="locator" xlink:href="cytk-20141231.xsd#cytk_IncreaseDecreaseInNoncashOrPartNoncashAcquisitionFixedAssetsAcquiredThroughAccruedLiabilities" xlink:label="cytk_IncreaseDecreaseInNoncashOrPartNoncashAcquisitionFixedAssetsAcquiredThroughAccruedLiabilities"/> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cytk_IncreaseDecreaseInNoncashOrPartNoncashAcquisitionFixedAssetsAcquiredThroughAccruedLiabilities_lbl" xml:lang="en-US" id="id_6895476_1614703_3_1">Increase decrease in noncash or part noncash acquisition fixed assets acquired through accrued liabilities.</label> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cytk_IncreaseDecreaseInNoncashOrPartNoncashAcquisitionFixedAssetsAcquiredThroughAccruedLiabilities_lbl" xml:lang="en-US" id="id_6895476_1614703_1_1">Increase Decrease In Noncash Or Part Noncash Acquisition Fixed Assets Acquired Through Accrued Liabilities</label> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cytk_IncreaseDecreaseInNoncashOrPartNoncashAcquisitionFixedAssetsAcquiredThroughAccruedLiabilities_lbl" xml:lang="en-US" id="id_6895476_1614703_2_1">Purchases of property and equipment through accrued liabilities</label> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cytk_IncreaseDecreaseInNoncashOrPartNoncashAcquisitionFixedAssetsAcquiredThroughAccruedLiabilities" xlink:to="cytk_IncreaseDecreaseInNoncashOrPartNoncashAcquisitionFixedAssetsAcquiredThroughAccruedLiabilities_lbl"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xml:lang="en-US" id="id_6895476_1279090_1_1">Increase (Decrease) in Operating Capital [Abstract]</label> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xml:lang="en-US" id="id_6895476_1279090_2_1">Changes in operating assets and liabilities:</label> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl" xml:lang="en-US" id="id_6895476_1282768_1_1">Increase (Decrease) in Prepaid Expense and Other Assets</label> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl" xml:lang="en-US" id="id_6895476_1282768_14_1">Prepaid and other assets</label> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncreaseDecreaseInRestrictedCash" xlink:label="us-gaap_IncreaseDecreaseInRestrictedCash"/> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInRestrictedCash_lbl" xml:lang="en-US" id="id_6895476_1281825_1_1">Increase (Decrease) in Restricted Cash</label> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInRestrictedCash_lbl" xml:lang="en-US" id="id_6895476_1281825_14_1">Decrease in restricted cash</label> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInRestrictedCash" xlink:to="us-gaap_IncreaseDecreaseInRestrictedCash_lbl"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_InProcessResearchAndDevelopmentPolicy" xlink:label="us-gaap_InProcessResearchAndDevelopmentPolicy"/> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InProcessResearchAndDevelopmentPolicy_lbl" xml:lang="en-US" id="id_6895476_1277433_1_1">In Process Research and Development, Policy [Policy Text Block]</label> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InProcessResearchAndDevelopmentPolicy_lbl" xml:lang="en-US" id="id_6895476_1277433_2_1">Preclinical Studies and Clinical Trial Accruals</label> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InProcessResearchAndDevelopmentPolicy" xlink:to="us-gaap_InProcessResearchAndDevelopmentPolicy_lbl"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_InterestAndDebtExpense" xlink:label="us-gaap_InterestAndDebtExpense"/> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestAndDebtExpense_lbl" xml:lang="en-US" id="id_6895476_1287533_1_1">Interest and Debt Expense</label> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_InterestAndDebtExpense_lbl" xml:lang="en-US" id="id_6895476_1287533_14_1">Interest expense and other expense</label> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestAndDebtExpense" xlink:to="us-gaap_InterestAndDebtExpense_lbl"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_InterestAndOtherIncome" xlink:label="us-gaap_InterestAndOtherIncome"/> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestAndOtherIncome_lbl" xml:lang="en-US" id="id_6895476_1284530_1_1">Interest and Other Income</label> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InterestAndOtherIncome_lbl" xml:lang="en-US" id="id_6895476_1284530_2_1">Interest income and other income</label> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestAndOtherIncome" xlink:to="us-gaap_InterestAndOtherIncome_lbl"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_InterestExpense" xlink:label="us-gaap_InterestExpense"/> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestExpense_lbl" xml:lang="en-US" id="id_6895476_1285466_1_1">Interest Expense</label> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InterestExpense_lbl" xml:lang="en-US" id="id_6895476_1285466_2_1">Interest expense</label> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestExpense" xlink:to="us-gaap_InterestExpense_lbl"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_InterestPaid" xlink:label="us-gaap_InterestPaid"/> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestPaid_lbl" xml:lang="en-US" id="id_6895476_1284523_1_1">Interest Paid</label> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InterestPaid_lbl" xml:lang="en-US" id="id_6895476_1284523_2_1">Cash paid for interest</label> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestPaid" xlink:to="us-gaap_InterestPaid_lbl"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_InterestReceivable" xlink:label="us-gaap_InterestReceivable"/> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestReceivable_lbl" xml:lang="en-US" id="id_6895476_1288048_1_1">Interest Receivable</label> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InterestReceivable_lbl" xml:lang="en-US" id="id_6895476_1288048_2_1">Interest receivable on cash equivalents and investments</label> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestReceivable" xlink:to="us-gaap_InterestReceivable_lbl"/> <loc xlink:type="locator" xlink:href="cytk-20141231.xsd#cytk_InternalCostsMember" xlink:label="cytk_InternalCostsMember"/> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cytk_InternalCostsMember_lbl" xml:lang="en-US" id="id_6895476_1344498_3_1">Internal Costs [Member]</label> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cytk_InternalCostsMember_lbl" xml:lang="en-US" id="id_6895476_1344498_1_1">Internal Costs [Member]</label> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cytk_InternalCostsMember_lbl" xml:lang="en-US" id="id_6895476_1344498_2_1">Reimbursement of Internal Costs [Member]</label> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cytk_InternalCostsMember" xlink:to="cytk_InternalCostsMember_lbl"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_InvestmentIncomeInterest" xlink:label="us-gaap_InvestmentIncomeInterest"/> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InvestmentIncomeInterest_lbl" xml:lang="en-US" id="id_6895476_1284518_1_1">Investment Income, Interest</label> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InvestmentIncomeInterest_lbl" xml:lang="en-US" id="id_6895476_1284518_2_1">Interest income</label> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentIncomeInterest" xlink:to="us-gaap_InvestmentIncomeInterest_lbl"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_InvestmentIncomeTextBlock" xlink:label="us-gaap_InvestmentIncomeTextBlock"/> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InvestmentIncomeTextBlock_lbl" xml:lang="en-US" id="id_6895476_1277459_1_1">Investment Income [Table Text Block]</label> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InvestmentIncomeTextBlock_lbl" xml:lang="en-US" id="id_6895476_1277459_2_1">Summary of Interest Income</label> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentIncomeTextBlock" xlink:to="us-gaap_InvestmentIncomeTextBlock_lbl"/> <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/invest/2013/invest-2013-01-31.xsd#invest_InvestmentMaturityDateRangeEnd1" xlink:label="invest_InvestmentMaturityDateRangeEnd1"/> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="invest_InvestmentMaturityDateRangeEnd1_lbl" xml:lang="en-US" id="id_6895476_1278070_1_1">Investment Maturity Date Range End</label> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="invest_InvestmentMaturityDateRangeEnd1_lbl" xml:lang="en-US" id="id_6895476_1278070_2_1">U.S. Treasury securities maturity end date</label> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="invest_InvestmentMaturityDateRangeEnd1" xlink:to="invest_InvestmentMaturityDateRangeEnd1_lbl"/> <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/invest/2013/invest-2013-01-31.xsd#invest_InvestmentMaturityDateRangeStart1" xlink:label="invest_InvestmentMaturityDateRangeStart1"/> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="invest_InvestmentMaturityDateRangeStart1_lbl" xml:lang="en-US" id="id_6895476_1274849_1_1">Investment Maturity Date Range Start</label> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="invest_InvestmentMaturityDateRangeStart1_lbl" xml:lang="en-US" id="id_6895476_1274849_2_1">U.S. Treasury securities maturity start date</label> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="invest_InvestmentMaturityDateRangeStart1" xlink:to="invest_InvestmentMaturityDateRangeStart1_lbl"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_InvestmentPolicyTextBlock" xlink:label="us-gaap_InvestmentPolicyTextBlock"/> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InvestmentPolicyTextBlock_lbl" xml:lang="en-US" id="id_6895476_1270874_1_1">Investment, Policy [Policy Text Block]</label> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InvestmentPolicyTextBlock_lbl" xml:lang="en-US" id="id_6895476_1270874_2_1">Investments</label> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentPolicyTextBlock" xlink:to="us-gaap_InvestmentPolicyTextBlock_lbl"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:label="us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_lbl" xml:lang="en-US" id="id_6895476_1272531_1_1">Investments, Debt and Equity Securities [Abstract]</label> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_lbl" xml:lang="en-US" id="id_6895476_1272531_2_1">Investments, Debt and Equity Securities [Abstract]</label> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:to="us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_lbl"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:label="us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock"/> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_lbl" xml:lang="en-US" id="id_6895476_1275857_1_1">Investments in Debt and Marketable Equity Securities (and Certain Trading Assets) Disclosure [Text Block]</label> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_lbl" xml:lang="en-US" id="id_6895476_1275857_2_1">Cash Equivalents and Investments</label> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:to="us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_lbl"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_InvestmentTypeAxis" xlink:label="us-gaap_InvestmentTypeAxis"/> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InvestmentTypeAxis_lbl" xml:lang="en-US" id="id_6895476_1274212_1_1">Investment Type [Axis]</label> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InvestmentTypeAxis_lbl" xml:lang="en-US" id="id_6895476_1274212_2_1">Investment Type [Axis]</label> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentTypeAxis" xlink:to="us-gaap_InvestmentTypeAxis_lbl"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_InvestmentTypeCategorizationMember" xlink:label="us-gaap_InvestmentTypeCategorizationMember"/> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InvestmentTypeCategorizationMember_lbl" xml:lang="en-US" id="id_6895476_1270878_1_1">Investments [Domain]</label> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InvestmentTypeCategorizationMember_lbl" xml:lang="en-US" id="id_6895476_1270878_2_1">Investments [Domain]</label> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentTypeCategorizationMember" xlink:to="us-gaap_InvestmentTypeCategorizationMember_lbl"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IPOMember" xlink:label="us-gaap_IPOMember"/> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IPOMember_lbl" xml:lang="en-US" id="id_6895476_1272538_1_1">IPO [Member]</label> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IPOMember_lbl" xml:lang="en-US" id="id_6895476_1272538_2_1">IPO [Member]</label> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IPOMember" xlink:to="us-gaap_IPOMember_lbl"/> <loc xlink:type="locator" xlink:href="cytk-20141231.xsd#cytk_IssuanceCostOfWarrant" xlink:label="cytk_IssuanceCostOfWarrant"/> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cytk_IssuanceCostOfWarrant_lbl" xml:lang="en-US" id="id_6895476_1428533_3_1">Issuance cost of warrant.</label> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cytk_IssuanceCostOfWarrant_lbl" xml:lang="en-US" id="id_6895476_1428533_1_1">Issuance Cost Of Warrant</label> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cytk_IssuanceCostOfWarrant_lbl" xml:lang="en-US" id="id_6895476_1428533_2_1">Issuance of warrants, issuance costs</label> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="cytk_IssuanceCostOfWarrant_lbl" xml:lang="en-US" id="id_6895476_1428533_12_1">Warrants issuance cost</label> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cytk_IssuanceCostOfWarrant" xlink:to="cytk_IssuanceCostOfWarrant_lbl"/> <loc xlink:type="locator" xlink:href="cytk-20141231.xsd#cytk_IssuanceOfCommonStockEmployeeStockPurchasePlanPricePerShare" xlink:label="cytk_IssuanceOfCommonStockEmployeeStockPurchasePlanPricePerShare"/> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cytk_IssuanceOfCommonStockEmployeeStockPurchasePlanPricePerShare_lbl" xml:lang="en-US" id="id_6895476_1290420_3_1">Issuance of common stock employee stock purchase plan price per share.</label> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cytk_IssuanceOfCommonStockEmployeeStockPurchasePlanPricePerShare_lbl" xml:lang="en-US" id="id_6895476_1290420_1_1">Issuance Of Common Stock Employee Stock Purchase Plan Price Per Share</label> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cytk_IssuanceOfCommonStockEmployeeStockPurchasePlanPricePerShare_lbl" xml:lang="en-US" id="id_6895476_1290420_2_1">Issuance of common stock pursuant to ESPP, per share</label> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cytk_IssuanceOfCommonStockEmployeeStockPurchasePlanPricePerShare" xlink:to="cytk_IssuanceOfCommonStockEmployeeStockPurchasePlanPricePerShare_lbl"/> <loc xlink:type="locator" xlink:href="cytk-20141231.xsd#cytk_IssuanceOfCommonStockToCollaborativePartnerForCashPerShare" xlink:label="cytk_IssuanceOfCommonStockToCollaborativePartnerForCashPerShare"/> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cytk_IssuanceOfCommonStockToCollaborativePartnerForCashPerShare_lbl" xml:lang="en-US" id="id_6895476_1614460_3_1">Issuance Of Common Stock To Collaborative Partner For Cash Per Share</label> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cytk_IssuanceOfCommonStockToCollaborativePartnerForCashPerShare_lbl" xml:lang="en-US" id="id_6895476_1614460_1_1">Issuance Of Common Stock To Collaborative Partner For Cash Per Share</label> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cytk_IssuanceOfCommonStockToCollaborativePartnerForCashPerShare_lbl" xml:lang="en-US" id="id_6895476_1614460_2_1">Issuance of common stock to collaborative partner for cash per share</label> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cytk_IssuanceOfCommonStockToCollaborativePartnerForCashPerShare" xlink:to="cytk_IssuanceOfCommonStockToCollaborativePartnerForCashPerShare_lbl"/> <loc xlink:type="locator" xlink:href="cytk-20141231.xsd#cytk_IssuanceOfCommonStockToCollaborativePartnerIssuanceCosts" xlink:label="cytk_IssuanceOfCommonStockToCollaborativePartnerIssuanceCosts"/> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cytk_IssuanceOfCommonStockToCollaborativePartnerIssuanceCosts_lbl" xml:lang="en-US" id="id_6895476_1614462_3_1">Issuance Of Common Stock To Collaborative Partner Issuance Costs</label> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cytk_IssuanceOfCommonStockToCollaborativePartnerIssuanceCosts_lbl" xml:lang="en-US" id="id_6895476_1614462_1_1">Issuance Of Common Stock To Collaborative Partner Issuance Costs</label> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cytk_IssuanceOfCommonStockToCollaborativePartnerIssuanceCosts_lbl" xml:lang="en-US" id="id_6895476_1614462_2_1">Issuance of common stock to collaborative partner issuance costs</label> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cytk_IssuanceOfCommonStockToCollaborativePartnerIssuanceCosts" xlink:to="cytk_IssuanceOfCommonStockToCollaborativePartnerIssuanceCosts_lbl"/> <loc xlink:type="locator" xlink:href="cytk-20141231.xsd#cytk_IssuanceOfCommonStockToMlvAtPerShareLowerLimit" xlink:label="cytk_IssuanceOfCommonStockToMlvAtPerShareLowerLimit"/> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cytk_IssuanceOfCommonStockToMlvAtPerShareLowerLimit_lbl" xml:lang="en-US" id="id_6895476_1433577_3_1">Issuance of common stock to MLV at per share, lower limit.</label> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cytk_IssuanceOfCommonStockToMlvAtPerShareLowerLimit_lbl" xml:lang="en-US" id="id_6895476_1433577_1_1">Issuance Of Common Stock To Mlv At Per Share Lower Limit</label> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cytk_IssuanceOfCommonStockToMlvAtPerShareLowerLimit_lbl" xml:lang="en-US" id="id_6895476_1433577_2_1">Issuance of common stock to MLV at per share, lower limit</label> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cytk_IssuanceOfCommonStockToMlvAtPerShareLowerLimit" xlink:to="cytk_IssuanceOfCommonStockToMlvAtPerShareLowerLimit_lbl"/> <loc xlink:type="locator" xlink:href="cytk-20141231.xsd#cytk_IssuanceOfCommonStockToMlvAtPerShareUpperLimit" xlink:label="cytk_IssuanceOfCommonStockToMlvAtPerShareUpperLimit"/> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cytk_IssuanceOfCommonStockToMlvAtPerShareUpperLimit_lbl" xml:lang="en-US" id="id_6895476_1337212_3_1">Issuance of common stock to MLV at per share, upper limit.</label> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cytk_IssuanceOfCommonStockToMlvAtPerShareUpperLimit_lbl" xml:lang="en-US" id="id_6895476_1337212_1_1">Issuance Of Common Stock To Mlv At Per Share Upper Limit</label> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cytk_IssuanceOfCommonStockToMlvAtPerShareUpperLimit_lbl" xml:lang="en-US" id="id_6895476_1337212_2_1">Issuance of common stock to MLV at per share, upper limit</label> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cytk_IssuanceOfCommonStockToMlvAtPerShareUpperLimit" xlink:to="cytk_IssuanceOfCommonStockToMlvAtPerShareUpperLimit_lbl"/> <loc xlink:type="locator" xlink:href="cytk-20141231.xsd#cytk_IssuanceOfCommonStockToMlvNetOfCommissionAndIssuanceCosts" xlink:label="cytk_IssuanceOfCommonStockToMlvNetOfCommissionAndIssuanceCosts"/> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cytk_IssuanceOfCommonStockToMlvNetOfCommissionAndIssuanceCosts_lbl" xml:lang="en-US" id="id_6895476_1355181_3_1">Issuance Of Common Stock To Mlv Net Of Commission And Issuance Costs</label> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cytk_IssuanceOfCommonStockToMlvNetOfCommissionAndIssuanceCosts_lbl" xml:lang="en-US" id="id_6895476_1355181_1_1">Issuance Of Common Stock To Mlv Net Of Commission And Issuance Costs</label> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cytk_IssuanceOfCommonStockToMlvNetOfCommissionAndIssuanceCosts_lbl" xml:lang="en-US" id="id_6895476_1355181_2_1">Issuance of common stock to MLV, net of commission and issuance costs</label> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cytk_IssuanceOfCommonStockToMlvNetOfCommissionAndIssuanceCosts" xlink:to="cytk_IssuanceOfCommonStockToMlvNetOfCommissionAndIssuanceCosts_lbl"/> <loc xlink:type="locator" xlink:href="cytk-20141231.xsd#cytk_IssuanceOfCommonStockToRelatedPartyForCashPerShare" xlink:label="cytk_IssuanceOfCommonStockToRelatedPartyForCashPerShare"/> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cytk_IssuanceOfCommonStockToRelatedPartyForCashPerShare_lbl" xml:lang="en-US" id="id_6895476_1417893_3_1">Issuance of common stock to related party for cash per share.</label> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cytk_IssuanceOfCommonStockToRelatedPartyForCashPerShare_lbl" xml:lang="en-US" id="id_6895476_1417893_1_1">Issuance Of Common Stock To Related Party For Cash Per Share</label> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cytk_IssuanceOfCommonStockToRelatedPartyForCashPerShare_lbl" xml:lang="en-US" id="id_6895476_1417893_2_1">Issuance of common stock to related party for cash per share</label> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cytk_IssuanceOfCommonStockToRelatedPartyForCashPerShare" xlink:to="cytk_IssuanceOfCommonStockToRelatedPartyForCashPerShare_lbl"/> <loc xlink:type="locator" xlink:href="cytk-20141231.xsd#cytk_IssuanceOfCommonStockToRelatedPartyIssuanceCosts" xlink:label="cytk_IssuanceOfCommonStockToRelatedPartyIssuanceCosts"/> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cytk_IssuanceOfCommonStockToRelatedPartyIssuanceCosts_lbl" xml:lang="en-US" id="id_6895476_1435181_3_1">Issuance of common stock to related party, net of issuance costs.</label> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cytk_IssuanceOfCommonStockToRelatedPartyIssuanceCosts_lbl" xml:lang="en-US" id="id_6895476_1435181_1_1">Issuance Of Common Stock To Related Party Issuance Costs</label> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cytk_IssuanceOfCommonStockToRelatedPartyIssuanceCosts_lbl" xml:lang="en-US" id="id_6895476_1435181_2_1">Issuance of common stock to related party issuance costs</label> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cytk_IssuanceOfCommonStockToRelatedPartyIssuanceCosts" xlink:to="cytk_IssuanceOfCommonStockToRelatedPartyIssuanceCosts_lbl"/> <loc xlink:type="locator" xlink:href="cytk-20141231.xsd#cytk_IssuanceOfConvertiblePreferredStockShares" xlink:label="cytk_IssuanceOfConvertiblePreferredStockShares"/> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cytk_IssuanceOfConvertiblePreferredStockShares_lbl" xml:lang="en-US" id="id_6895476_1460975_3_1">Issuance of convertible preferred stock, shares.</label> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cytk_IssuanceOfConvertiblePreferredStockShares_lbl" xml:lang="en-US" id="id_6895476_1460975_1_1">Issuance Of Convertible Preferred Stock Shares</label> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cytk_IssuanceOfConvertiblePreferredStockShares_lbl" xml:lang="en-US" id="id_6895476_1460975_2_1">Issuance of convertible preferred stock, shares</label> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cytk_IssuanceOfConvertiblePreferredStockShares" xlink:to="cytk_IssuanceOfConvertiblePreferredStockShares_lbl"/> <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/country/2013/country-2013-01-31.xsd#country_JP" xlink:label="country_JP"/> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="country_JP_lbl" xml:lang="en-US" id="id_6895476_1269843_1_1">JAPAN</label> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="country_JP_lbl" xml:lang="en-US" id="id_6895476_1269843_2_1">Japanese [Member]</label> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="country_JP" xlink:to="country_JP_lbl"/> <loc xlink:type="locator" xlink:href="cytk-20141231.xsd#cytk_LaboratoryEquipmentMember" xlink:label="cytk_LaboratoryEquipmentMember"/> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cytk_LaboratoryEquipmentMember_lbl" xml:lang="en-US" id="id_6895476_1457720_3_1">Laboratory equipment.</label> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cytk_LaboratoryEquipmentMember_lbl" xml:lang="en-US" id="id_6895476_1457720_1_1">Laboratory Equipment [Member]</label> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cytk_LaboratoryEquipmentMember_lbl" xml:lang="en-US" id="id_6895476_1457720_2_1">Laboratory Equipment [Member]</label> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cytk_LaboratoryEquipmentMember" xlink:to="cytk_LaboratoryEquipmentMember_lbl"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LeaseholdsAndLeaseholdImprovementsMember" xlink:label="us-gaap_LeaseholdsAndLeaseholdImprovementsMember"/> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LeaseholdsAndLeaseholdImprovementsMember_lbl" xml:lang="en-US" id="id_6895476_1280724_1_1">Leaseholds and Leasehold Improvements [Member]</label> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LeaseholdsAndLeaseholdImprovementsMember_lbl" xml:lang="en-US" id="id_6895476_1280724_2_1">Leasehold Improvements [Member]</label> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseholdsAndLeaseholdImprovementsMember" xlink:to="us-gaap_LeaseholdsAndLeaseholdImprovementsMember_lbl"/> <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis"/> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_LegalEntityAxis_lbl" xml:lang="en-US" id="id_6895476_1281318_1_1">Legal Entity [Axis]</label> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_LegalEntityAxis_lbl" xml:lang="en-US" id="id_6895476_1281318_2_1">Legal Entity [Axis]</label> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LegalEntityAxis" xlink:to="dei_LegalEntityAxis_lbl"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities"/> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Liabilities_lbl" xml:lang="en-US" id="id_6895476_1284515_1_1">Liabilities</label> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_Liabilities_lbl" xml:lang="en-US" id="id_6895476_1284515_6_1">Total liabilities</label> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_Liabilities_lbl"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity"/> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xml:lang="en-US" id="id_6895476_1283630_1_1">Liabilities and Equity</label> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xml:lang="en-US" id="id_6895476_1283630_6_1">Total liabilities and stockholders' equity</label> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_lbl"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract"/> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xml:lang="en-US" id="id_6895476_1275871_1_1">Liabilities and Equity [Abstract]</label> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xml:lang="en-US" id="id_6895476_1275871_2_1">LIABILITIES AND STOCKHOLDERS' EQUITY</label> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent"/> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesCurrent_lbl" xml:lang="en-US" id="id_6895476_1282281_1_1">Liabilities, Current</label> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LiabilitiesCurrent_lbl" xml:lang="en-US" id="id_6895476_1282281_6_1">Total current liabilities</label> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_LiabilitiesCurrent_lbl"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract"/> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl" xml:lang="en-US" id="id_6895476_1272565_1_1">Liabilities, Current [Abstract]</label> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl" xml:lang="en-US" id="id_6895476_1272565_2_1">Current liabilities:</label> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract_lbl"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LiabilitiesFairValueDisclosure" xlink:label="us-gaap_LiabilitiesFairValueDisclosure"/> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesFairValueDisclosure_lbl" xml:lang="en-US" id="id_6895476_1284516_1_1">Financial and Nonfinancial Liabilities, Fair Value Disclosure</label> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LiabilitiesFairValueDisclosure_lbl" xml:lang="en-US" id="id_6895476_1284516_2_1">Fair value of warrants</label> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesFairValueDisclosure" xlink:to="us-gaap_LiabilitiesFairValueDisclosure_lbl"/> <loc xlink:type="locator" xlink:href="cytk-20141231.xsd#cytk_LicenseAndServicesMember" xlink:label="cytk_LicenseAndServicesMember"/> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cytk_LicenseAndServicesMember_lbl" xml:lang="en-US" id="id_6895476_1317063_3_1">License And Services [Member]</label> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cytk_LicenseAndServicesMember_lbl" xml:lang="en-US" id="id_6895476_1317063_1_1">License And Services [Member]</label> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cytk_LicenseAndServicesMember_lbl" xml:lang="en-US" id="id_6895476_1317063_2_1">License and Services [Member]</label> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cytk_LicenseAndServicesMember" xlink:to="cytk_LicenseAndServicesMember_lbl"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LicenseAndServicesRevenue" xlink:label="us-gaap_LicenseAndServicesRevenue"/> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LicenseAndServicesRevenue_lbl" xml:lang="en-US" id="id_6895476_1282734_1_1">License and Services Revenue</label> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/positiveLabel" xlink:label="us-gaap_LicenseAndServicesRevenue_lbl" xml:lang="en-US" id="id_6895476_1282734_32_1">License revenues from related parties</label> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LicenseAndServicesRevenue_lbl" xml:lang="en-US" id="id_6895476_1282734_2_1">License revenue</label> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_LicenseAndServicesRevenue_lbl" xml:lang="en-US" id="id_6895476_1282734_12_1">License revenues</label> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LicenseAndServicesRevenue" xlink:to="us-gaap_LicenseAndServicesRevenue_lbl"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LicenseCosts" xlink:label="us-gaap_LicenseCosts"/> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LicenseCosts_lbl" xml:lang="en-US" id="id_6895476_1289085_1_1">License Costs</label> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LicenseCosts_lbl" xml:lang="en-US" id="id_6895476_1289085_2_1">Non-refundable license fee</label> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LicenseCosts" xlink:to="us-gaap_LicenseCosts_lbl"/> <loc xlink:type="locator" xlink:href="cytk-20141231.xsd#cytk_LicenseFeeArrangementMember" xlink:label="cytk_LicenseFeeArrangementMember"/> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cytk_LicenseFeeArrangementMember_lbl" xml:lang="en-US" id="id_6895476_1486283_3_1">License Fee Arrangement [Member]</label> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cytk_LicenseFeeArrangementMember_lbl" xml:lang="en-US" id="id_6895476_1486283_1_1">License Fee Arrangement [Member]</label> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cytk_LicenseFeeArrangementMember_lbl" xml:lang="en-US" id="id_6895476_1486283_2_1">License Revenue [Member]</label> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cytk_LicenseFeeArrangementMember" xlink:to="cytk_LicenseFeeArrangementMember_lbl"/> <loc xlink:type="locator" xlink:href="cytk-20141231.xsd#cytk_LicenseRevenuesFromRelatedParties" xlink:label="cytk_LicenseRevenuesFromRelatedParties"/> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cytk_LicenseRevenuesFromRelatedParties_lbl" xml:lang="en-US" id="id_6895476_1371619_3_1">Revenues from license agreements with related parties.</label> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cytk_LicenseRevenuesFromRelatedParties_lbl" xml:lang="en-US" id="id_6895476_1371619_1_1">License Revenues From Related Parties</label> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cytk_LicenseRevenuesFromRelatedParties_lbl" xml:lang="en-US" id="id_6895476_1371619_2_1">License revenues from related parties</label> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cytk_LicenseRevenuesFromRelatedParties" xlink:to="cytk_LicenseRevenuesFromRelatedParties_lbl"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LineOfCredit" xlink:label="us-gaap_LineOfCredit"/> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LineOfCredit_lbl" xml:lang="en-US" id="id_6895476_1284503_1_1">Long-term Line of Credit</label> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LineOfCredit_lbl" xml:lang="en-US" id="id_6895476_1284503_2_1">Equipment loans outstanding</label> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LineOfCredit" xlink:to="us-gaap_LineOfCredit_lbl"/> <loc xlink:type="locator" xlink:href="cytk-20141231.xsd#cytk_LongTermInvestmentMember" xlink:label="cytk_LongTermInvestmentMember"/> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cytk_LongTermInvestmentMember_lbl" xml:lang="en-US" id="id_6895476_1435842_3_1">Long Term Investment [Member]</label> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cytk_LongTermInvestmentMember_lbl" xml:lang="en-US" id="id_6895476_1435842_1_1">Long Term Investment [Member]</label> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cytk_LongTermInvestmentMember_lbl" xml:lang="en-US" id="id_6895476_1435842_2_1">Long-term Investments [Member]</label> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cytk_LongTermInvestmentMember" xlink:to="cytk_LongTermInvestmentMember_lbl"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LongTermInvestments" xlink:label="us-gaap_LongTermInvestments"/> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LongTermInvestments_lbl" xml:lang="en-US" id="id_6895476_1287580_1_1">Long-term Investments</label> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LongTermInvestments_lbl" xml:lang="en-US" id="id_6895476_1287580_2_1">Long-term investments</label> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermInvestments" xlink:to="us-gaap_LongTermInvestments_lbl"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_MaximumMember" xlink:label="us-gaap_MaximumMember"/> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MaximumMember_lbl" xml:lang="en-US" id="id_6895476_1275948_1_1">Maximum [Member]</label> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_MaximumMember_lbl" xml:lang="en-US" id="id_6895476_1275948_2_1">Maximum [Member]</label> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MaximumMember" xlink:to="us-gaap_MaximumMember_lbl"/> <loc xlink:type="locator" xlink:href="cytk-20141231.xsd#cytk_MilestonePaymentsReceivedUnderArrangements" xlink:label="cytk_MilestonePaymentsReceivedUnderArrangements"/> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cytk_MilestonePaymentsReceivedUnderArrangements_lbl" xml:lang="en-US" id="id_6895476_1358883_3_1">Milestone Payments Received Under Arrangements</label> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cytk_MilestonePaymentsReceivedUnderArrangements_lbl" xml:lang="en-US" id="id_6895476_1358883_1_1">Milestone Payments Received Under Arrangements</label> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cytk_MilestonePaymentsReceivedUnderArrangements_lbl" xml:lang="en-US" id="id_6895476_1358883_2_1">Amount received as milestone payment</label> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cytk_MilestonePaymentsReceivedUnderArrangements" xlink:to="cytk_MilestonePaymentsReceivedUnderArrangements_lbl"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_MinimumMember" xlink:label="us-gaap_MinimumMember"/> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MinimumMember_lbl" xml:lang="en-US" id="id_6895476_1277596_1_1">Minimum [Member]</label> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_MinimumMember_lbl" xml:lang="en-US" id="id_6895476_1277596_2_1">Minimum [Member]</label> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MinimumMember" xlink:to="us-gaap_MinimumMember_lbl"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners" xlink:label="us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners"/> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners_lbl" xml:lang="en-US" id="id_6895476_1272649_1_1">Noncontrolling Interest, Ownership Percentage by Noncontrolling Owners</label> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners_lbl" xml:lang="en-US" id="id_6895476_1272649_2_1">Ownership percentage by affiliates and other holders after exercise of warrant</label> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners" xlink:to="us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners_lbl"/> <loc xlink:type="locator" xlink:href="cytk-20141231.xsd#cytk_MlvAgreementMember" xlink:label="cytk_MlvAgreementMember"/> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cytk_MlvAgreementMember_lbl" xml:lang="en-US" id="id_6895476_1511257_3_1">MLV agreement.</label> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cytk_MlvAgreementMember_lbl" xml:lang="en-US" id="id_6895476_1511257_1_1">Mlv Agreement [Member]</label> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cytk_MlvAgreementMember_lbl" xml:lang="en-US" id="id_6895476_1511257_2_1">MLV [Member]</label> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cytk_MlvAgreementMember" xlink:to="cytk_MlvAgreementMember_lbl"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_MoneyMarketFundsMember" xlink:label="us-gaap_MoneyMarketFundsMember"/> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MoneyMarketFundsMember_lbl" xml:lang="en-US" id="id_6895476_1277587_1_1">Money Market Funds [Member]</label> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_MoneyMarketFundsMember_lbl" xml:lang="en-US" id="id_6895476_1277587_2_1">Money Market Funds [Member]</label> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MoneyMarketFundsMember" xlink:to="us-gaap_MoneyMarketFundsMember_lbl"/> <loc xlink:type="locator" xlink:href="cytk-20141231.xsd#cytk_MyokardiaMember" xlink:label="cytk_MyokardiaMember"/> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cytk_MyokardiaMember_lbl" xml:lang="en-US" id="id_6895476_1454595_3_1">MyoKardia.</label> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cytk_MyokardiaMember_lbl" xml:lang="en-US" id="id_6895476_1454595_1_1">Myokardia [Member]</label> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cytk_MyokardiaMember_lbl" xml:lang="en-US" id="id_6895476_1454595_2_1">MyoKardia [Member]</label> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cytk_MyokardiaMember" xlink:to="cytk_MyokardiaMember_lbl"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations"/> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations_lbl" xml:lang="en-US" id="id_6895476_1287111_1_1">Net Cash Provided by (Used in) Financing Activities, Continuing Operations</label> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations_lbl" xml:lang="en-US" id="id_6895476_1287111_6_1">Net cash provided by financing activities</label> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations_lbl"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract"/> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_lbl" xml:lang="en-US" id="id_6895476_1269355_1_1">Net Cash Provided by (Used in) Financing Activities, Continuing Operations [Abstract]</label> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_lbl" xml:lang="en-US" id="id_6895476_1269355_2_1">Cash flows from financing activities:</label> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_lbl"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations"/> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations_lbl" xml:lang="en-US" id="id_6895476_1287595_1_1">Net Cash Provided by (Used in) Investing Activities, Continuing Operations</label> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations_lbl" xml:lang="en-US" id="id_6895476_1287595_6_1">Net cash used in investing activities</label> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations_lbl"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract"/> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_lbl" xml:lang="en-US" id="id_6895476_1277599_1_1">Net Cash Provided by (Used in) Investing Activities, Continuing Operations [Abstract]</label> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_lbl" xml:lang="en-US" id="id_6895476_1277599_2_1">Cash flows from investing activities:</label> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_lbl"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations"/> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_lbl" xml:lang="en-US" id="id_6895476_1272684_1_1">Net Cash Provided by (Used in) Operating Activities, Continuing Operations</label> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_lbl" xml:lang="en-US" id="id_6895476_1272684_2_1">Net cash (used in) operations</label> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_lbl" xml:lang="en-US" id="id_6895476_1272684_6_1">Net cash used in operating activities</label> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_lbl"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract"/> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_lbl" xml:lang="en-US" id="id_6895476_1269356_1_1">Net Cash Provided by (Used in) Operating Activities, Continuing Operations [Abstract]</label> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_lbl" xml:lang="en-US" id="id_6895476_1269356_2_1">Cash flows from operating activities:</label> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_lbl"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetIncomeLoss_lbl" xml:lang="en-US" id="id_6895476_1284477_1_1">Net Income (Loss) Attributable to Parent</label> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NetIncomeLoss_lbl" xml:lang="en-US" id="id_6895476_1284477_2_1">Net income (loss)</label> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetIncomeLoss_lbl" xml:lang="en-US" id="id_6895476_1284477_6_1">Net loss</label> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_NetIncomeLoss_lbl" xml:lang="en-US" id="id_6895476_1284477_12_1">Net loss</label> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_lbl"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic"/> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_lbl" xml:lang="en-US" id="id_6895476_1284476_1_1">Net Income (Loss) Available to Common Stockholders, Basic</label> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_lbl" xml:lang="en-US" id="id_6895476_1284476_2_1">Net income (loss) allocable to common stockholders</label> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_lbl" xml:lang="en-US" id="id_6895476_1284476_6_1">Net loss allocable to common stockholders</label> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_lbl" xml:lang="en-US" id="id_6895476_1284476_12_1">Net loss allocable to common stockholders</label> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:to="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_lbl"/> <loc xlink:type="locator" xlink:href="cytk-20141231.xsd#cytk_NetProceedsFromIssuanceOfWarrants" xlink:label="cytk_NetProceedsFromIssuanceOfWarrants"/> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cytk_NetProceedsFromIssuanceOfWarrants_lbl" xml:lang="en-US" id="id_6895476_1551737_3_1">The cash inflow from issuance of rights to purchase common shares at a predetermined price, net of issuance costs.</label> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cytk_NetProceedsFromIssuanceOfWarrants_lbl" xml:lang="en-US" id="id_6895476_1551737_1_1">Net Proceeds From Issuance Of Warrants</label> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cytk_NetProceedsFromIssuanceOfWarrants_lbl" xml:lang="en-US" id="id_6895476_1551737_2_1">Net proceeds from issuance of warrants</label> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cytk_NetProceedsFromIssuanceOfWarrants" xlink:to="cytk_NetProceedsFromIssuanceOfWarrants_lbl"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xml:lang="en-US" id="id_6895476_1279254_1_1">New Accounting Pronouncements, Policy [Policy Text Block]</label> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xml:lang="en-US" id="id_6895476_1279254_2_1">Recent Accounting Pronouncements</label> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl"/> <loc xlink:type="locator" xlink:href="cytk-20141231.xsd#cytk_NewEmployeeMember" xlink:label="cytk_NewEmployeeMember"/> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cytk_NewEmployeeMember_lbl" xml:lang="en-US" id="id_6895476_1358661_3_1">New employee.</label> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cytk_NewEmployeeMember_lbl" xml:lang="en-US" id="id_6895476_1358661_1_1">New Employee [Member]</label> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cytk_NewEmployeeMember_lbl" xml:lang="en-US" id="id_6895476_1358661_2_1">New Employee [Member]</label> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cytk_NewEmployeeMember" xlink:to="cytk_NewEmployeeMember_lbl"/> <loc xlink:type="locator" xlink:href="cytk-20141231.xsd#cytk_NindsMyastheniaGravisMember" xlink:label="cytk_NindsMyastheniaGravisMember"/> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cytk_NindsMyastheniaGravisMember_lbl" xml:lang="en-US" id="id_6895476_1507815_3_1">NINDS myasthenia gravis.</label> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cytk_NindsMyastheniaGravisMember_lbl" xml:lang="en-US" id="id_6895476_1507815_1_1">Ninds Myasthenia Gravis [Member]</label> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cytk_NindsMyastheniaGravisMember_lbl" xml:lang="en-US" id="id_6895476_1507815_2_1">NINDS Myasthenia Gravis [Member]</label> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cytk_NindsMyastheniaGravisMember" xlink:to="cytk_NindsMyastheniaGravisMember_lbl"/> <loc xlink:type="locator" xlink:href="cytk-20141231.xsd#cytk_NineteenNinetySevenStockOptionPlanMember" xlink:label="cytk_NineteenNinetySevenStockOptionPlanMember"/> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cytk_NineteenNinetySevenStockOptionPlanMember_lbl" xml:lang="en-US" id="id_6895476_1294890_3_1">Nineteen ninety seven stock option plan.</label> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cytk_NineteenNinetySevenStockOptionPlanMember_lbl" xml:lang="en-US" id="id_6895476_1294890_1_1">Nineteen Ninety Seven Stock Option Plan [Member]</label> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cytk_NineteenNinetySevenStockOptionPlanMember_lbl" xml:lang="en-US" id="id_6895476_1294890_2_1">1997 Plan [Member]</label> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cytk_NineteenNinetySevenStockOptionPlanMember" xlink:to="cytk_NineteenNinetySevenStockOptionPlanMember_lbl"/> <loc xlink:type="locator" xlink:href="cytk-20141231.xsd#cytk_NonCancelableLeaseAdditionalExtensionPeriod" xlink:label="cytk_NonCancelableLeaseAdditionalExtensionPeriod"/> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cytk_NonCancelableLeaseAdditionalExtensionPeriod_lbl" xml:lang="en-US" id="id_6895476_1322033_3_1">Non Cancelable Lease Additional Extension Period</label> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cytk_NonCancelableLeaseAdditionalExtensionPeriod_lbl" xml:lang="en-US" id="id_6895476_1322033_1_1">Non Cancelable Lease Additional Extension Period</label> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cytk_NonCancelableLeaseAdditionalExtensionPeriod_lbl" xml:lang="en-US" id="id_6895476_1322033_2_1">Non-cancelable operating lease additional extension period</label> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cytk_NonCancelableLeaseAdditionalExtensionPeriod" xlink:to="cytk_NonCancelableLeaseAdditionalExtensionPeriod_lbl"/> <loc xlink:type="locator" xlink:href="cytk-20141231.xsd#cytk_NonCancelableLeaseExpirationYear" xlink:label="cytk_NonCancelableLeaseExpirationYear"/> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cytk_NonCancelableLeaseExpirationYear_lbl" xml:lang="en-US" id="id_6895476_1295885_3_1">Date at which lease or a group of leases is set to expire in CCYY format.</label> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cytk_NonCancelableLeaseExpirationYear_lbl" xml:lang="en-US" id="id_6895476_1295885_1_1">Non Cancelable Lease Expiration Year</label> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cytk_NonCancelableLeaseExpirationYear_lbl" xml:lang="en-US" id="id_6895476_1295885_2_1">Non-cancelable operating lease expires</label> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cytk_NonCancelableLeaseExpirationYear" xlink:to="cytk_NonCancelableLeaseExpirationYear_lbl"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NoncashOrPartNoncashAcquisitionFixedAssetsAcquired1" xlink:label="us-gaap_NoncashOrPartNoncashAcquisitionFixedAssetsAcquired1"/> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NoncashOrPartNoncashAcquisitionFixedAssetsAcquired1_lbl" xml:lang="en-US" id="id_6895476_1287599_1_1">Noncash or Part Noncash Acquisition, Fixed Assets Acquired</label> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NoncashOrPartNoncashAcquisitionFixedAssetsAcquired1_lbl" xml:lang="en-US" id="id_6895476_1287599_2_1">Purchases of property and equipment through accounts payable</label> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NoncashOrPartNoncashAcquisitionFixedAssetsAcquired1" xlink:to="us-gaap_NoncashOrPartNoncashAcquisitionFixedAssetsAcquired1_lbl"/> <loc xlink:type="locator" xlink:href="cytk-20141231.xsd#cytk_NoncashOrPartNoncashAcquisitionFixedAssetsAcquiredTradeInValue" xlink:label="cytk_NoncashOrPartNoncashAcquisitionFixedAssetsAcquiredTradeInValue"/> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cytk_NoncashOrPartNoncashAcquisitionFixedAssetsAcquiredTradeInValue_lbl" xml:lang="en-US" id="id_6895476_1554826_3_1">The amount of fixed assets that an Entity acquires in a non-cash acquisition through trade in value of disposed property and equipment. Non-cash is defined as information about all investing and financing activities of an enterprise during a period that affect recognized assets or liabilities but that do not result in cash receipts or cash payments in the period.</label> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cytk_NoncashOrPartNoncashAcquisitionFixedAssetsAcquiredTradeInValue_lbl" xml:lang="en-US" id="id_6895476_1554826_1_1">Noncash Or Part Noncash Acquisition Fixed Assets Acquired Trade In Value</label> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cytk_NoncashOrPartNoncashAcquisitionFixedAssetsAcquiredTradeInValue_lbl" xml:lang="en-US" id="id_6895476_1554826_2_1">Purchases of property and equipment through trade in value of disposed property and equipment</label> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cytk_NoncashOrPartNoncashAcquisitionFixedAssetsAcquiredTradeInValue" xlink:to="cytk_NoncashOrPartNoncashAcquisitionFixedAssetsAcquiredTradeInValue_lbl"/> <loc xlink:type="locator" xlink:href="cytk-20141231.xsd#cytk_NonEmployeeStockBasedCompensationMember" xlink:label="cytk_NonEmployeeStockBasedCompensationMember"/> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cytk_NonEmployeeStockBasedCompensationMember_lbl" xml:lang="en-US" id="id_6895476_1424733_3_1">Non Employee Stock Based Compensation [Member]</label> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cytk_NonEmployeeStockBasedCompensationMember_lbl" xml:lang="en-US" id="id_6895476_1424733_1_1">Non Employee Stock Based Compensation [Member]</label> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cytk_NonEmployeeStockBasedCompensationMember_lbl" xml:lang="en-US" id="id_6895476_1424733_2_1">Non-employee Stock-Based Compensation [Member]</label> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cytk_NonEmployeeStockBasedCompensationMember" xlink:to="cytk_NonEmployeeStockBasedCompensationMember_lbl"/> <loc xlink:type="locator" xlink:href="cytk-20141231.xsd#cytk_NonNeuromuscularIndicationsMember" xlink:label="cytk_NonNeuromuscularIndicationsMember"/> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cytk_NonNeuromuscularIndicationsMember_lbl" xml:lang="en-US" id="id_6895476_1621938_3_1">Non- neuromuscular indications [Member]</label> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cytk_NonNeuromuscularIndicationsMember_lbl" xml:lang="en-US" id="id_6895476_1621938_1_1">Non- neuromuscular Indications [Member]</label> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cytk_NonNeuromuscularIndicationsMember_lbl" xml:lang="en-US" id="id_6895476_1621938_2_1">Non- neuromuscular Indications [Member]</label> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cytk_NonNeuromuscularIndicationsMember" xlink:to="cytk_NonNeuromuscularIndicationsMember_lbl"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="us-gaap_NonoperatingIncomeExpense"/> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NonoperatingIncomeExpense_lbl" xml:lang="en-US" id="id_6895476_1283571_1_1">Nonoperating Income (Expense)</label> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NonoperatingIncomeExpense_lbl" xml:lang="en-US" id="id_6895476_1283571_2_1">Interest and other, net</label> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NonoperatingIncomeExpense_lbl" xml:lang="en-US" id="id_6895476_1283571_6_1">Interest and Other, net</label> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="us-gaap_NonoperatingIncomeExpense_lbl"/> <loc xlink:type="locator" xlink:href="cytk-20141231.xsd#cytk_NonstatutoryStockOptionsMember" xlink:label="cytk_NonstatutoryStockOptionsMember"/> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cytk_NonstatutoryStockOptionsMember_lbl" xml:lang="en-US" id="id_6895476_1555254_3_1">Non statutory stock options.</label> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cytk_NonstatutoryStockOptionsMember_lbl" xml:lang="en-US" id="id_6895476_1555254_1_1">Nonstatutory Stock Options [Member]</label> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cytk_NonstatutoryStockOptionsMember_lbl" xml:lang="en-US" id="id_6895476_1555254_2_1">Non Statutory Stock Options [Member]</label> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cytk_NonstatutoryStockOptionsMember" xlink:to="cytk_NonstatutoryStockOptionsMember_lbl"/> <loc xlink:type="locator" xlink:href="cytk-20141231.xsd#cytk_NumberOfConcurrentPublicOfferings" xlink:label="cytk_NumberOfConcurrentPublicOfferings"/> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cytk_NumberOfConcurrentPublicOfferings_lbl" xml:lang="en-US" id="id_6895476_1552209_3_1">Number Of Concurrent Public Offerings</label> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cytk_NumberOfConcurrentPublicOfferings_lbl" xml:lang="en-US" id="id_6895476_1552209_1_1">Number Of Concurrent Public Offerings</label> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cytk_NumberOfConcurrentPublicOfferings_lbl" xml:lang="en-US" id="id_6895476_1552209_2_1">Number of concurrent public offerings</label> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cytk_NumberOfConcurrentPublicOfferings" xlink:to="cytk_NumberOfConcurrentPublicOfferings_lbl"/> <loc xlink:type="locator" xlink:href="cytk-20141231.xsd#cytk_NumberOfFinancialInstitutions" xlink:label="cytk_NumberOfFinancialInstitutions"/> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cytk_NumberOfFinancialInstitutions_lbl" xml:lang="en-US" id="id_6895476_1506661_3_1">Number of financial institutions.</label> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cytk_NumberOfFinancialInstitutions_lbl" xml:lang="en-US" id="id_6895476_1506661_1_1">Number Of Financial Institutions</label> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cytk_NumberOfFinancialInstitutions_lbl" xml:lang="en-US" id="id_6895476_1506661_2_1">Number of major financial institutions</label> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cytk_NumberOfFinancialInstitutions" xlink:to="cytk_NumberOfFinancialInstitutions_lbl"/> <loc xlink:type="locator" xlink:href="cytk-20141231.xsd#cytk_NumberOfIssuedSharesOfCommonStockRelatedToCashlessExerciseOfWarrants" xlink:label="cytk_NumberOfIssuedSharesOfCommonStockRelatedToCashlessExerciseOfWarrants"/> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cytk_NumberOfIssuedSharesOfCommonStockRelatedToCashlessExerciseOfWarrants_lbl" xml:lang="en-US" id="id_6895476_1374455_3_1">Number of issued shares of common stock related to cashless exercise of warrants.</label> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cytk_NumberOfIssuedSharesOfCommonStockRelatedToCashlessExerciseOfWarrants_lbl" xml:lang="en-US" id="id_6895476_1374455_1_1">Number Of Issued Shares Of Common Stock Related To Cashless Exercise Of Warrants</label> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cytk_NumberOfIssuedSharesOfCommonStockRelatedToCashlessExerciseOfWarrants_lbl" xml:lang="en-US" id="id_6895476_1374455_2_1">Number of issued shares of common stock related to cashless exercise of warrants</label> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cytk_NumberOfIssuedSharesOfCommonStockRelatedToCashlessExerciseOfWarrants" xlink:to="cytk_NumberOfIssuedSharesOfCommonStockRelatedToCashlessExerciseOfWarrants_lbl"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NumberOfReportableSegments" xlink:label="us-gaap_NumberOfReportableSegments"/> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NumberOfReportableSegments_lbl" xml:lang="en-US" id="id_6895476_1280895_1_1">Number of Reportable Segments</label> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NumberOfReportableSegments_lbl" xml:lang="en-US" id="id_6895476_1280895_2_1">Number of reporting segment</label> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NumberOfReportableSegments" xlink:to="us-gaap_NumberOfReportableSegments_lbl"/> <loc xlink:type="locator" xlink:href="cytk-20141231.xsd#cytk_OfficeEquipmentFurnitureAndFixturesMember" xlink:label="cytk_OfficeEquipmentFurnitureAndFixturesMember"/> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cytk_OfficeEquipmentFurnitureAndFixturesMember_lbl" xml:lang="en-US" id="id_6895476_1329743_3_1">Office equipment, furniture and fixtures.</label> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cytk_OfficeEquipmentFurnitureAndFixturesMember_lbl" xml:lang="en-US" id="id_6895476_1329743_1_1">Office Equipment Furniture And Fixtures [Member]</label> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cytk_OfficeEquipmentFurnitureAndFixturesMember_lbl" xml:lang="en-US" id="id_6895476_1329743_2_1">Office Equipment, Furniture and Fixtures [Member]</label> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cytk_OfficeEquipmentFurnitureAndFixturesMember" xlink:to="cytk_OfficeEquipmentFurnitureAndFixturesMember_lbl"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OfficeEquipmentMember" xlink:label="us-gaap_OfficeEquipmentMember"/> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OfficeEquipmentMember_lbl" xml:lang="en-US" id="id_6895476_1279264_1_1">Office Equipment [Member]</label> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OfficeEquipmentMember_lbl" xml:lang="en-US" id="id_6895476_1279264_2_1">Laboratory Equipment and Office Equipment [Member]</label> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OfficeEquipmentMember" xlink:to="us-gaap_OfficeEquipmentMember_lbl"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="us-gaap_OperatingExpensesAbstract"/> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingExpensesAbstract_lbl" xml:lang="en-US" id="id_6895476_1279274_1_1">Operating Expenses [Abstract]</label> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingExpensesAbstract_lbl" xml:lang="en-US" id="id_6895476_1279274_2_1">Operating expenses:</label> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OperatingExpensesAbstract_lbl"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss"/> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingIncomeLoss_lbl" xml:lang="en-US" id="id_6895476_1283121_1_1">Operating Income (Loss)</label> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_OperatingIncomeLoss_lbl" xml:lang="en-US" id="id_6895476_1283121_6_1">Operating loss</label> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss_lbl"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDue"/> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDue_lbl" xml:lang="en-US" id="id_6895476_1283561_1_1">Operating Leases, Future Minimum Payments Due</label> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDue_lbl" xml:lang="en-US" id="id_6895476_1283561_6_1">Total</label> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDue_lbl"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent"/> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent_lbl" xml:lang="en-US" id="id_6895476_1284896_1_1">Operating Leases, Future Minimum Payments Due, Next Twelve Months</label> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent_lbl" xml:lang="en-US" id="id_6895476_1284896_2_1">2015</label> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent_lbl"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears"/> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears_lbl" xml:lang="en-US" id="id_6895476_1283562_1_1">Operating Leases, Future Minimum Payments, Due in Five Years</label> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears_lbl" xml:lang="en-US" id="id_6895476_1283562_2_1">2019</label> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears_lbl"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears"/> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears_lbl" xml:lang="en-US" id="id_6895476_1283125_1_1">Operating Leases, Future Minimum Payments, Due in Four Years</label> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears_lbl" xml:lang="en-US" id="id_6895476_1283125_2_1">2018</label> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears_lbl"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears"/> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears_lbl" xml:lang="en-US" id="id_6895476_1283564_1_1">Operating Leases, Future Minimum Payments, Due in Three Years</label> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears_lbl" xml:lang="en-US" id="id_6895476_1283564_2_1">2017</label> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears_lbl"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears"/> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears_lbl" xml:lang="en-US" id="id_6895476_1284469_1_1">Operating Leases, Future Minimum Payments, Due in Two Years</label> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears_lbl" xml:lang="en-US" id="id_6895476_1284469_2_1">2016</label> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears_lbl"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter"/> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter_lbl" xml:lang="en-US" id="id_6895476_1282235_1_1">Operating Leases, Future Minimum Payments, Due Thereafter</label> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter_lbl" xml:lang="en-US" id="id_6895476_1282235_2_1">Thereafter</label> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter_lbl"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OperatingLeasesRentExpenseNet" xlink:label="us-gaap_OperatingLeasesRentExpenseNet"/> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeasesRentExpenseNet_lbl" xml:lang="en-US" id="id_6895476_1286571_1_1">Operating Leases, Rent Expense, Net</label> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeasesRentExpenseNet_lbl" xml:lang="en-US" id="id_6895476_1286571_2_1">Rent expense</label> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasesRentExpenseNet" xlink:to="us-gaap_OperatingLeasesRentExpenseNet_lbl"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="us-gaap_OperatingLossCarryforwards"/> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLossCarryforwards_lbl" xml:lang="en-US" id="id_6895476_1288124_1_1">Operating Loss Carryforwards</label> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLossCarryforwards_lbl" xml:lang="en-US" id="id_6895476_1288124_2_1">Net operating loss carryforwards</label> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLossCarryforwards" xlink:to="us-gaap_OperatingLossCarryforwards_lbl"/> <loc xlink:type="locator" xlink:href="cytk-20141231.xsd#cytk_OperatingLossCarryforwardsExpirationYear" xlink:label="cytk_OperatingLossCarryforwardsExpirationYear"/> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cytk_OperatingLossCarryforwardsExpirationYear_lbl" xml:lang="en-US" id="id_6895476_1521077_3_1">The expiration date for operating loss carry forwards expressed in years, CCYY.</label> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cytk_OperatingLossCarryforwardsExpirationYear_lbl" xml:lang="en-US" id="id_6895476_1521077_1_1">Operating Loss Carryforwards Expiration Year</label> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cytk_OperatingLossCarryforwardsExpirationYear_lbl" xml:lang="en-US" id="id_6895476_1521077_2_1">Net operating loss carryforwards expiration</label> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cytk_OperatingLossCarryforwardsExpirationYear" xlink:to="cytk_OperatingLossCarryforwardsExpirationYear_lbl"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OptionIndexedToIssuersEquityTypeAxis" xlink:label="us-gaap_OptionIndexedToIssuersEquityTypeAxis"/> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OptionIndexedToIssuersEquityTypeAxis_lbl" xml:lang="en-US" id="id_6895476_1272720_1_1">Option Indexed to Issuer's Equity, Type [Axis]</label> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OptionIndexedToIssuersEquityTypeAxis_lbl" xml:lang="en-US" id="id_6895476_1272720_2_1">Option Indexed to Issuer's Equity, Type [Axis]</label> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OptionIndexedToIssuersEquityTypeAxis" xlink:to="us-gaap_OptionIndexedToIssuersEquityTypeAxis_lbl"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OptionIndexedToIssuersEquityTypeDomain" xlink:label="us-gaap_OptionIndexedToIssuersEquityTypeDomain"/> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OptionIndexedToIssuersEquityTypeDomain_lbl" xml:lang="en-US" id="id_6895476_1276019_1_1">Option Indexed to Issuer's Equity, Type [Domain]</label> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OptionIndexedToIssuersEquityTypeDomain_lbl" xml:lang="en-US" id="id_6895476_1276019_2_1">Option Indexed to Issuer's Equity, Type [Domain]</label> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OptionIndexedToIssuersEquityTypeDomain" xlink:to="us-gaap_OptionIndexedToIssuersEquityTypeDomain_lbl"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl" xml:lang="en-US" id="id_6895476_1276020_1_1">Organization, Consolidation and Presentation of Financial Statements [Abstract]</label> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl" xml:lang="en-US" id="id_6895476_1276020_2_1">Organization, Consolidation and Presentation of Financial Statements [Abstract]</label> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock"/> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock_lbl" xml:lang="en-US" id="id_6895476_1279280_1_1">Organization, Consolidation and Presentation of Financial Statements Disclosure and Significant Accounting Policies [Text Block]</label> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock_lbl" xml:lang="en-US" id="id_6895476_1279280_2_1">Organization and Significant Accounting Policies</label> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock_lbl"/> <loc xlink:type="locator" xlink:href="cytk-20141231.xsd#cytk_OrganizationConsolidationAndPresentationOfFinancialStatementsPolicyTextBlock" xlink:label="cytk_OrganizationConsolidationAndPresentationOfFinancialStatementsPolicyTextBlock"/> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cytk_OrganizationConsolidationAndPresentationOfFinancialStatementsPolicyTextBlock_lbl" xml:lang="en-US" id="id_6895476_1382051_3_1">The disclosure for organization and consolidation of financial statements.</label> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cytk_OrganizationConsolidationAndPresentationOfFinancialStatementsPolicyTextBlock_lbl" xml:lang="en-US" id="id_6895476_1382051_1_1">Organization Consolidation And Presentation Of Financial Statements Policy [Text Block]</label> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cytk_OrganizationConsolidationAndPresentationOfFinancialStatementsPolicyTextBlock_lbl" xml:lang="en-US" id="id_6895476_1382051_2_1">Organization</label> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cytk_OrganizationConsolidationAndPresentationOfFinancialStatementsPolicyTextBlock" xlink:to="cytk_OrganizationConsolidationAndPresentationOfFinancialStatementsPolicyTextBlock_lbl"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent"/> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent_lbl" xml:lang="en-US" id="id_6895476_1283556_1_1">Other Accrued Liabilities, Current</label> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent_lbl" xml:lang="en-US" id="id_6895476_1283556_2_1">Other accrued expenses</label> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAccruedLiabilitiesCurrent" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrent_lbl"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OtherAssetsCurrent" xlink:label="us-gaap_OtherAssetsCurrent"/> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherAssetsCurrent_lbl" xml:lang="en-US" id="id_6895476_1288617_1_1">Other Assets, Current</label> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherAssetsCurrent_lbl" xml:lang="en-US" id="id_6895476_1288617_2_1">Prepaid and other current assets</label> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAssetsCurrent" xlink:to="us-gaap_OtherAssetsCurrent_lbl"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="us-gaap_OtherAssetsNoncurrent"/> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherAssetsNoncurrent_lbl" xml:lang="en-US" id="id_6895476_1288618_1_1">Other Assets, Noncurrent</label> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherAssetsNoncurrent_lbl" xml:lang="en-US" id="id_6895476_1288618_2_1">Other assets</label> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAssetsNoncurrent" xlink:to="us-gaap_OtherAssetsNoncurrent_lbl"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:label="us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax"/> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_lbl" xml:lang="en-US" id="id_6895476_1283113_1_1">Other Comprehensive Income (Loss), Available-for-sale Securities Adjustment, Net of Tax</label> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_lbl" xml:lang="en-US" id="id_6895476_1283113_2_1">Unrealized gains (losses) on available-for-sale securities, net</label> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:to="us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_lbl"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTax"/> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTax_lbl" xml:lang="en-US" id="id_6895476_1282225_1_1">Other Comprehensive Income (Loss), Net of Tax</label> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTax_lbl" xml:lang="en-US" id="id_6895476_1282225_2_1">Other comprehensive income (loss)</label> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:to="us-gaap_OtherComprehensiveIncomeLossNetOfTax_lbl"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract"/> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_lbl" xml:lang="en-US" id="id_6895476_1272731_1_1">Other Comprehensive Income (Loss), Net of Tax [Abstract]</label> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_lbl" xml:lang="en-US" id="id_6895476_1272731_2_1">Other comprehensive gain (loss):</label> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:to="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_lbl"/> <loc xlink:type="locator" xlink:href="cytk-20141231.xsd#cytk_OtherCostsMember" xlink:label="cytk_OtherCostsMember"/> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cytk_OtherCostsMember_lbl" xml:lang="en-US" id="id_6895476_1361274_3_1">Other Costs [Member]</label> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cytk_OtherCostsMember_lbl" xml:lang="en-US" id="id_6895476_1361274_1_1">Other Costs [Member]</label> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cytk_OtherCostsMember_lbl" xml:lang="en-US" id="id_6895476_1361274_2_1">Reimbursement of Other Costs [Member]</label> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cytk_OtherCostsMember" xlink:to="cytk_OtherCostsMember_lbl"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OtherEmployeeRelatedLiabilitiesCurrent" xlink:label="us-gaap_OtherEmployeeRelatedLiabilitiesCurrent"/> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherEmployeeRelatedLiabilitiesCurrent_lbl" xml:lang="en-US" id="id_6895476_1284457_1_1">Other Employee Related Liabilities, Current</label> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherEmployeeRelatedLiabilitiesCurrent_lbl" xml:lang="en-US" id="id_6895476_1284457_2_1">Other payroll related</label> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherEmployeeRelatedLiabilitiesCurrent" xlink:to="us-gaap_OtherEmployeeRelatedLiabilitiesCurrent_lbl"/> <loc xlink:type="locator" xlink:href="cytk-20141231.xsd#cytk_OtherGrantRevenueMember" xlink:label="cytk_OtherGrantRevenueMember"/> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cytk_OtherGrantRevenueMember_lbl" xml:lang="en-US" id="id_6895476_1621940_3_1">Other grant revenue [Member]</label> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cytk_OtherGrantRevenueMember_lbl" xml:lang="en-US" id="id_6895476_1621940_1_1">Other Grant Revenue [Member]</label> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cytk_OtherGrantRevenueMember_lbl" xml:lang="en-US" id="id_6895476_1621940_2_1">Other Grant Revenue [Member]</label> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cytk_OtherGrantRevenueMember" xlink:to="cytk_OtherGrantRevenueMember_lbl"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OtherIncomeAndExpensesAbstract" xlink:label="us-gaap_OtherIncomeAndExpensesAbstract"/> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherIncomeAndExpensesAbstract_lbl" xml:lang="en-US" id="id_6895476_1272740_1_1">Other Income and Expenses [Abstract]</label> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherIncomeAndExpensesAbstract_lbl" xml:lang="en-US" id="id_6895476_1272740_2_1">Other Income and Expenses [Abstract]</label> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherIncomeAndExpensesAbstract" xlink:to="us-gaap_OtherIncomeAndExpensesAbstract_lbl"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OtherIncomeAndOtherExpenseDisclosureTextBlock" xlink:label="us-gaap_OtherIncomeAndOtherExpenseDisclosureTextBlock"/> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherIncomeAndOtherExpenseDisclosureTextBlock_lbl" xml:lang="en-US" id="id_6895476_1276035_1_1">Other Income and Other Expense Disclosure [Text Block]</label> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherIncomeAndOtherExpenseDisclosureTextBlock_lbl" xml:lang="en-US" id="id_6895476_1276035_2_1">Interest and Other, Net</label> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherIncomeAndOtherExpenseDisclosureTextBlock" xlink:to="us-gaap_OtherIncomeAndOtherExpenseDisclosureTextBlock_lbl"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OtherPreferredStockDividendsAndAdjustments" xlink:label="us-gaap_OtherPreferredStockDividendsAndAdjustments"/> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherPreferredStockDividendsAndAdjustments_lbl" xml:lang="en-US" id="id_6895476_1289152_1_1">Other Preferred Stock Dividends and Adjustments</label> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_OtherPreferredStockDividendsAndAdjustments_lbl" xml:lang="en-US" id="id_6895476_1289152_14_1">Deemed dividend related to beneficial conversion feature of convertible preferred stock</label> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherPreferredStockDividendsAndAdjustments" xlink:to="us-gaap_OtherPreferredStockDividendsAndAdjustments_lbl"/> <loc xlink:type="locator" xlink:href="cytk-20141231.xsd#cytk_OtherResearchAndDevelopmentRevenueArrangementsRecognizedGrantRevenueTableTextBlock" xlink:label="cytk_OtherResearchAndDevelopmentRevenueArrangementsRecognizedGrantRevenueTableTextBlock"/> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cytk_OtherResearchAndDevelopmentRevenueArrangementsRecognizedGrantRevenueTableTextBlock_lbl" xml:lang="en-US" id="id_6895476_1342594_3_1">Total revenue recognized relating to grants awarded for research and development activities.</label> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cytk_OtherResearchAndDevelopmentRevenueArrangementsRecognizedGrantRevenueTableTextBlock_lbl" xml:lang="en-US" id="id_6895476_1342594_1_1">Other Research And Development Revenue Arrangements Recognized Grant Revenue Table [Text Block]</label> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cytk_OtherResearchAndDevelopmentRevenueArrangementsRecognizedGrantRevenueTableTextBlock_lbl" xml:lang="en-US" id="id_6895476_1342594_2_1">Summary of Total Grant Revenues</label> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cytk_OtherResearchAndDevelopmentRevenueArrangementsRecognizedGrantRevenueTableTextBlock" xlink:to="cytk_OtherResearchAndDevelopmentRevenueArrangementsRecognizedGrantRevenueTableTextBlock_lbl"/> <loc xlink:type="locator" xlink:href="cytk-20141231.xsd#cytk_OtherResearchAndDevelopmentRevenueArrangementsReimbursementOfExpenseTableTextBlock" xlink:label="cytk_OtherResearchAndDevelopmentRevenueArrangementsReimbursementOfExpenseTableTextBlock"/> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cytk_OtherResearchAndDevelopmentRevenueArrangementsReimbursementOfExpenseTableTextBlock_lbl" xml:lang="en-US" id="id_6895476_1292123_3_1">Revenues related to reimbursement of facilities and personnel costs pursuant to research and development collaboration agreements.</label> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cytk_OtherResearchAndDevelopmentRevenueArrangementsReimbursementOfExpenseTableTextBlock_lbl" xml:lang="en-US" id="id_6895476_1292123_1_1">Other Research And Development Revenue Arrangements Reimbursement Of Expense Table [Text Block]</label> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cytk_OtherResearchAndDevelopmentRevenueArrangementsReimbursementOfExpenseTableTextBlock_lbl" xml:lang="en-US" id="id_6895476_1292123_2_1">Summary of Reimbursed Expenses</label> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cytk_OtherResearchAndDevelopmentRevenueArrangementsReimbursementOfExpenseTableTextBlock" xlink:to="cytk_OtherResearchAndDevelopmentRevenueArrangementsReimbursementOfExpenseTableTextBlock_lbl"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="us-gaap_PayablesAndAccrualsAbstract"/> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PayablesAndAccrualsAbstract_lbl" xml:lang="en-US" id="id_6895476_1269445_1_1">Payables and Accruals [Abstract]</label> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PayablesAndAccrualsAbstract_lbl" xml:lang="en-US" id="id_6895476_1269445_2_1">Payables and Accruals [Abstract]</label> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="us-gaap_PayablesAndAccrualsAbstract_lbl"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts"/> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts_lbl" xml:lang="en-US" id="id_6895476_1281683_1_1">Payments of Stock Issuance Costs</label> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts_lbl" xml:lang="en-US" id="id_6895476_1281683_2_1">Issuance cost of common stock, value</label> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts_lbl" xml:lang="en-US" id="id_6895476_1281683_12_1">Stock issuance costs</label> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsOfStockIssuanceCosts" xlink:to="us-gaap_PaymentsOfStockIssuanceCosts_lbl"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:label="us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt"/> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_lbl" xml:lang="en-US" id="id_6895476_1281686_1_1">Payments to Acquire Available-for-sale Securities, Debt</label> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_lbl" xml:lang="en-US" id="id_6895476_1281686_14_1">Purchases of investments</label> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:to="us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_lbl"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xml:lang="en-US" id="id_6895476_1284434_1_1">Payments to Acquire Property, Plant, and Equipment</label> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xml:lang="en-US" id="id_6895476_1284434_14_1">Purchases of property and equipment</label> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PensionAndOtherPostretirementPlansPolicy" xlink:label="us-gaap_PensionAndOtherPostretirementPlansPolicy"/> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PensionAndOtherPostretirementPlansPolicy_lbl" xml:lang="en-US" id="id_6895476_1279333_1_1">Pension and Other Postretirement Plans, Policy [Policy Text Block]</label> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PensionAndOtherPostretirementPlansPolicy_lbl" xml:lang="en-US" id="id_6895476_1279333_2_1">Retirement Plan</label> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PensionAndOtherPostretirementPlansPolicy" xlink:to="us-gaap_PensionAndOtherPostretirementPlansPolicy_lbl"/> <loc xlink:type="locator" xlink:href="cytk-20141231.xsd#cytk_PercentageLimitOnNumberOfSharesOfCommonStockExercisableByHolders" xlink:label="cytk_PercentageLimitOnNumberOfSharesOfCommonStockExercisableByHolders"/> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cytk_PercentageLimitOnNumberOfSharesOfCommonStockExercisableByHolders_lbl" xml:lang="en-US" id="id_6895476_1535599_3_1">Maximum amount of common shares a holder of preferred stock may own, expressed as a percentage of total number of shares of common stock outstanding issued and outstanding. This limitation will prohibit conversion of preferred stock to common stock if, as a result, the holders ownership percentage would exceed the specified limit.</label> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cytk_PercentageLimitOnNumberOfSharesOfCommonStockExercisableByHolders_lbl" xml:lang="en-US" id="id_6895476_1535599_1_1">Percentage Limit On Number Of Shares Of Common Stock Exercisable By Holders</label> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cytk_PercentageLimitOnNumberOfSharesOfCommonStockExercisableByHolders_lbl" xml:lang="en-US" id="id_6895476_1535599_2_1">Percentage limit on number of shares of common stock exercisable by holders</label> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cytk_PercentageLimitOnNumberOfSharesOfCommonStockExercisableByHolders" xlink:to="cytk_PercentageLimitOnNumberOfSharesOfCommonStockExercisableByHolders_lbl"/> <loc xlink:type="locator" xlink:href="cytk-20141231.xsd#cytk_PercentageOfIncomeTaxPositionsLikelyToBeRealized" xlink:label="cytk_PercentageOfIncomeTaxPositionsLikelyToBeRealized"/> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cytk_PercentageOfIncomeTaxPositionsLikelyToBeRealized_lbl" xml:lang="en-US" id="id_6895476_1335404_3_1">The minimum likelihood, expressed as a percentage, that will trigger recognition of a tax benefit.</label> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cytk_PercentageOfIncomeTaxPositionsLikelyToBeRealized_lbl" xml:lang="en-US" id="id_6895476_1335404_1_1">Percentage Of Income Tax Positions Likely To Be Realized</label> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cytk_PercentageOfIncomeTaxPositionsLikelyToBeRealized_lbl" xml:lang="en-US" id="id_6895476_1335404_2_1">Percentage of income tax likely to be realized</label> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cytk_PercentageOfIncomeTaxPositionsLikelyToBeRealized" xlink:to="cytk_PercentageOfIncomeTaxPositionsLikelyToBeRealized_lbl"/> <loc xlink:type="locator" xlink:href="cytk-20141231.xsd#cytk_PercentageOfOptionsGrantToNewEmployees" xlink:label="cytk_PercentageOfOptionsGrantToNewEmployees"/> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cytk_PercentageOfOptionsGrantToNewEmployees_lbl" xml:lang="en-US" id="id_6895476_1313263_3_1">Vesting percentage realized upon one-year anniversary of grant date.</label> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cytk_PercentageOfOptionsGrantToNewEmployees_lbl" xml:lang="en-US" id="id_6895476_1313263_1_1">Percentage Of Options Grant To New Employees</label> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cytk_PercentageOfOptionsGrantToNewEmployees_lbl" xml:lang="en-US" id="id_6895476_1313263_2_1">Percentage of options grant to new employees</label> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cytk_PercentageOfOptionsGrantToNewEmployees" xlink:to="cytk_PercentageOfOptionsGrantToNewEmployees_lbl"/> <loc xlink:type="locator" xlink:href="cytk-20141231.xsd#cytk_PeriodForPotentialTreatment" xlink:label="cytk_PeriodForPotentialTreatment"/> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cytk_PeriodForPotentialTreatment_lbl" xml:lang="en-US" id="id_6895476_1508496_3_1">Describes the term of the grant to support research and development activities.</label> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cytk_PeriodForPotentialTreatment_lbl" xml:lang="en-US" id="id_6895476_1508496_1_1">Period For Potential Treatment</label> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cytk_PeriodForPotentialTreatment_lbl" xml:lang="en-US" id="id_6895476_1508496_2_1">Potential treatment of myasthenia gravis term</label> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cytk_PeriodForPotentialTreatment" xlink:to="cytk_PeriodForPotentialTreatment_lbl"/> <loc xlink:type="locator" xlink:href="cytk-20141231.xsd#cytk_PeriodFromPercentageOfStockOptionVested" xlink:label="cytk_PeriodFromPercentageOfStockOptionVested"/> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cytk_PeriodFromPercentageOfStockOptionVested_lbl" xml:lang="en-US" id="id_6895476_1509969_3_1">Initial stock option vesting period.</label> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cytk_PeriodFromPercentageOfStockOptionVested_lbl" xml:lang="en-US" id="id_6895476_1509969_1_1">Period From Percentage Of Stock Option Vested</label> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cytk_PeriodFromPercentageOfStockOptionVested_lbl" xml:lang="en-US" id="id_6895476_1509969_2_1">Period from percentage of stock option vested</label> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cytk_PeriodFromPercentageOfStockOptionVested" xlink:to="cytk_PeriodFromPercentageOfStockOptionVested_lbl"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis"/> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PlanNameAxis_lbl" xml:lang="en-US" id="id_6895476_1280964_1_1">Plan Name [Axis]</label> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PlanNameAxis_lbl" xml:lang="en-US" id="id_6895476_1280964_2_1">Plan Name [Axis]</label> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameAxis_lbl"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain"/> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PlanNameDomain_lbl" xml:lang="en-US" id="id_6895476_1279330_1_1">Plan Name [Domain]</label> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PlanNameDomain_lbl" xml:lang="en-US" id="id_6895476_1279330_2_1">Plan Name [Domain]</label> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PlanNameDomain" xlink:to="us-gaap_PlanNameDomain_lbl"/> <loc xlink:type="locator" xlink:href="cytk-20141231.xsd#cytk_PotentialAmountsReceivableUnderCollaborationAgreement" xlink:label="cytk_PotentialAmountsReceivableUnderCollaborationAgreement"/> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cytk_PotentialAmountsReceivableUnderCollaborationAgreement_lbl" xml:lang="en-US" id="id_6895476_1512077_3_1">Potential Amounts Receivable Under Collaboration Agreement</label> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cytk_PotentialAmountsReceivableUnderCollaborationAgreement_lbl" xml:lang="en-US" id="id_6895476_1512077_1_1">Potential Amounts Receivable Under Collaboration Agreement</label> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cytk_PotentialAmountsReceivableUnderCollaborationAgreement_lbl" xml:lang="en-US" id="id_6895476_1512077_2_1">Potential amount receivable under collaboration agreement</label> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cytk_PotentialAmountsReceivableUnderCollaborationAgreement" xlink:to="cytk_PotentialAmountsReceivableUnderCollaborationAgreement_lbl"/> <loc xlink:type="locator" xlink:href="cytk-20141231.xsd#cytk_PreferredStockConversionRatio" xlink:label="cytk_PreferredStockConversionRatio"/> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cytk_PreferredStockConversionRatio_lbl" xml:lang="en-US" id="id_6895476_1520217_3_1">The ratio of the number common shares issuable upon conversion for each share of convertible preferred stock that is converted.</label> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cytk_PreferredStockConversionRatio_lbl" xml:lang="en-US" id="id_6895476_1520217_1_1">Preferred Stock Conversion Ratio</label> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cytk_PreferredStockConversionRatio_lbl" xml:lang="en-US" id="id_6895476_1520217_2_1">Preferred Stock converted into common stock, ratio</label> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cytk_PreferredStockConversionRatio" xlink:to="cytk_PreferredStockConversionRatio_lbl"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PreferredStockMember" xlink:label="us-gaap_PreferredStockMember"/> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockMember_lbl" xml:lang="en-US" id="id_6895476_1272805_1_1">Preferred Stock [Member]</label> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PreferredStockMember_lbl" xml:lang="en-US" id="id_6895476_1272805_2_1">Preferred Stock [Member]</label> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockMember" xlink:to="us-gaap_PreferredStockMember_lbl"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PreferredStockNoParValue" xlink:label="us-gaap_PreferredStockNoParValue"/> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockNoParValue_lbl" xml:lang="en-US" id="id_6895476_1269471_1_1">Preferred Stock, No Par Value</label> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PreferredStockNoParValue_lbl" xml:lang="en-US" id="id_6895476_1269471_2_1">Issue of series B convertible preferred stock share price</label> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockNoParValue" xlink:to="us-gaap_PreferredStockNoParValue_lbl"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare"/> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" xml:lang="en-US" id="id_6895476_1280976_1_1">Preferred Stock, Par or Stated Value Per Share</label> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" xml:lang="en-US" id="id_6895476_1280976_2_1">Preferred stock, par value</label> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare_lbl"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized"/> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockSharesAuthorized_lbl" xml:lang="en-US" id="id_6895476_1279344_1_1">Preferred Stock, Shares Authorized</label> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PreferredStockSharesAuthorized_lbl" xml:lang="en-US" id="id_6895476_1279344_2_1">Preferred stock authorized number of shares</label> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_PreferredStockSharesAuthorized_lbl" xml:lang="en-US" id="id_6895476_1279344_12_1">Preferred stock, shares authorized</label> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesAuthorized" xlink:to="us-gaap_PreferredStockSharesAuthorized_lbl"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="us-gaap_PreferredStockSharesIssued"/> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockSharesIssued_lbl" xml:lang="en-US" id="id_6895476_1280980_1_1">Preferred Stock, Shares Issued</label> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PreferredStockSharesIssued_lbl" xml:lang="en-US" id="id_6895476_1280980_2_1">Convertible preferred stock, issued shares</label> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesIssued" xlink:to="us-gaap_PreferredStockSharesIssued_lbl"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="us-gaap_PreferredStockSharesOutstanding"/> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockSharesOutstanding_lbl" xml:lang="en-US" id="id_6895476_1276106_1_1">Preferred Stock, Shares Outstanding</label> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PreferredStockSharesOutstanding_lbl" xml:lang="en-US" id="id_6895476_1276106_2_1">Convertible preferred stock, outstanding shares</label> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_PreferredStockSharesOutstanding_lbl" xml:lang="en-US" id="id_6895476_1276106_12_1">Preferred stock outstanding number of shares</label> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesOutstanding" xlink:to="us-gaap_PreferredStockSharesOutstanding_lbl"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PreferredStockTextBlock" xlink:label="us-gaap_PreferredStockTextBlock"/> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockTextBlock_lbl" xml:lang="en-US" id="id_6895476_1276108_1_1">Preferred Stock [Text Block]</label> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PreferredStockTextBlock_lbl" xml:lang="en-US" id="id_6895476_1276108_2_1">Convertible Preferred Stock</label> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockTextBlock" xlink:to="us-gaap_PreferredStockTextBlock_lbl"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PreferredStockValue" xlink:label="us-gaap_PreferredStockValue"/> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockValue_lbl" xml:lang="en-US" id="id_6895476_1282154_1_1">Preferred Stock, Value, Issued</label> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PreferredStockValue_lbl" xml:lang="en-US" id="id_6895476_1282154_2_1">Preferred stock, value</label> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockValue" xlink:to="us-gaap_PreferredStockValue_lbl"/> <loc xlink:type="locator" xlink:href="cytk-20141231.xsd#cytk_ProceedsAndPaymentsFromStockBasedAwardAndWarrantsNetOfIssuanceCosts" xlink:label="cytk_ProceedsAndPaymentsFromStockBasedAwardAndWarrantsNetOfIssuanceCosts"/> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cytk_ProceedsAndPaymentsFromStockBasedAwardAndWarrantsNetOfIssuanceCosts_lbl" xml:lang="en-US" id="id_6895476_1464748_3_1">Proceeds and (Payments) from Stock Based Award and Warrants Net of Issuance Costs</label> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cytk_ProceedsAndPaymentsFromStockBasedAwardAndWarrantsNetOfIssuanceCosts_lbl" xml:lang="en-US" id="id_6895476_1464748_1_1">Proceeds and (Payments) from Stock Based Award and Warrants Net of Issuance Costs</label> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="cytk_ProceedsAndPaymentsFromStockBasedAwardAndWarrantsNetOfIssuanceCosts_lbl" xml:lang="en-US" id="id_6895476_1464748_14_1">Payments from stock based award activities and warrants, net</label> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cytk_ProceedsAndPaymentsFromStockBasedAwardAndWarrantsNetOfIssuanceCosts" xlink:to="cytk_ProceedsAndPaymentsFromStockBasedAwardAndWarrantsNetOfIssuanceCosts_lbl"/> <loc xlink:type="locator" xlink:href="cytk-20141231.xsd#cytk_ProceedsFromDrawDownOfCommittedEquityFinancingFacilitiesAndAtMarketFacilityNetOfIssuanceCosts" xlink:label="cytk_ProceedsFromDrawDownOfCommittedEquityFinancingFacilitiesAndAtMarketFacilityNetOfIssuanceCosts"/> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cytk_ProceedsFromDrawDownOfCommittedEquityFinancingFacilitiesAndAtMarketFacilityNetOfIssuanceCosts_lbl" xml:lang="en-US" id="id_6895476_1311783_3_1">Cash proceeds, net of commission and issuance costs, from sales of common stock through draw downs of committed equity facilities and sales of common stock through at-the-market issuance sales agreements.</label> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cytk_ProceedsFromDrawDownOfCommittedEquityFinancingFacilitiesAndAtMarketFacilityNetOfIssuanceCosts_lbl" xml:lang="en-US" id="id_6895476_1311783_1_1">Proceeds From Draw Down Of Committed Equity Financing Facilities And At Market Facility Net Of Issuance Costs</label> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cytk_ProceedsFromDrawDownOfCommittedEquityFinancingFacilitiesAndAtMarketFacilityNetOfIssuanceCosts_lbl" xml:lang="en-US" id="id_6895476_1311783_2_1">Proceeds from draw down of committed equity financing facilities and at-the-market facility, net of commission and issuance costs</label> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cytk_ProceedsFromDrawDownOfCommittedEquityFinancingFacilitiesAndAtMarketFacilityNetOfIssuanceCosts" xlink:to="cytk_ProceedsFromDrawDownOfCommittedEquityFinancingFacilitiesAndAtMarketFacilityNetOfIssuanceCosts_lbl"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock"/> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xml:lang="en-US" id="id_6895476_1287188_1_1">Proceeds from Issuance of Common Stock</label> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xml:lang="en-US" id="id_6895476_1287188_2_1">Aggregate purchase price</label> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xml:lang="en-US" id="id_6895476_1287188_12_1">Proceeds from public offerings of common stock, net of issuance costs</label> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock" xlink:label="us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock"/> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock_lbl" xml:lang="en-US" id="id_6895476_1287673_1_1">Proceeds from Issuance of Convertible Preferred Stock</label> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock_lbl" xml:lang="en-US" id="id_6895476_1287673_2_1">Allocated purchase price</label> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock" xlink:to="us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock_lbl"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock" xlink:label="us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock"/> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock_lbl" xml:lang="en-US" id="id_6895476_1285617_1_1">Proceeds from Issuance of Preferred Stock and Preference Stock</label> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock_lbl" xml:lang="en-US" id="id_6895476_1285617_2_1">Convertible preferred stock, net proceeds</label> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock_lbl" xml:lang="en-US" id="id_6895476_1285617_12_1">Proceeds from issuance of preferred stock, net of issuance costs</label> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock" xlink:to="us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock_lbl"/> <loc xlink:type="locator" xlink:href="cytk-20141231.xsd#cytk_ProceedsFromIssuanceOfUnit" xlink:label="cytk_ProceedsFromIssuanceOfUnit"/> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cytk_ProceedsFromIssuanceOfUnit_lbl" xml:lang="en-US" id="id_6895476_1497866_3_1">The proceeds from sale of warrants to purchase common stock.</label> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cytk_ProceedsFromIssuanceOfUnit_lbl" xml:lang="en-US" id="id_6895476_1497866_1_1">Proceeds From Issuance Of Unit</label> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cytk_ProceedsFromIssuanceOfUnit_lbl" xml:lang="en-US" id="id_6895476_1497866_2_1">Gross proceeds of the offering</label> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cytk_ProceedsFromIssuanceOfUnit" xlink:to="cytk_ProceedsFromIssuanceOfUnit_lbl"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ProceedsFromIssuanceOfWarrants" xlink:label="us-gaap_ProceedsFromIssuanceOfWarrants"/> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromIssuanceOfWarrants_lbl" xml:lang="en-US" id="id_6895476_1285620_1_1">Proceeds from Issuance of Warrants</label> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProceedsFromIssuanceOfWarrants_lbl" xml:lang="en-US" id="id_6895476_1285620_2_1">Warrants, valued</label> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfWarrants" xlink:to="us-gaap_ProceedsFromIssuanceOfWarrants_lbl"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:label="us-gaap_ProceedsFromIssuanceOrSaleOfEquity"/> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromIssuanceOrSaleOfEquity_lbl" xml:lang="en-US" id="id_6895476_1287667_1_1">Proceeds from Issuance or Sale of Equity</label> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProceedsFromIssuanceOrSaleOfEquity_lbl" xml:lang="en-US" id="id_6895476_1287667_2_1">Aggregate gross proceeds from issuance</label> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:to="us-gaap_ProceedsFromIssuanceOrSaleOfEquity_lbl"/> <loc xlink:type="locator" xlink:href="cytk-20141231.xsd#cytk_ProceedsFromIssuanceOrSaleOfStockAndWarrant" xlink:label="cytk_ProceedsFromIssuanceOrSaleOfStockAndWarrant"/> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cytk_ProceedsFromIssuanceOrSaleOfStockAndWarrant_lbl" xml:lang="en-US" id="id_6895476_1328282_3_1">Cash inflows from the additional contributions to the entity and from issuances of rights to purchase common stock at a predetermined price.</label> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cytk_ProceedsFromIssuanceOrSaleOfStockAndWarrant_lbl" xml:lang="en-US" id="id_6895476_1328282_1_1">Proceeds From Issuance Or Sale Of Stock And Warrant</label> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cytk_ProceedsFromIssuanceOrSaleOfStockAndWarrant_lbl" xml:lang="en-US" id="id_6895476_1328282_2_1">Net proceeds from issue of stock and warrant to public</label> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cytk_ProceedsFromIssuanceOrSaleOfStockAndWarrant" xlink:to="cytk_ProceedsFromIssuanceOrSaleOfStockAndWarrant_lbl"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" xlink:label="us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities"/> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_lbl" xml:lang="en-US" id="id_6895476_1288695_1_1">Proceeds from Sale and Maturity of Available-for-sale Securities</label> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_lbl" xml:lang="en-US" id="id_6895476_1288695_2_1">Proceeds from sales and maturities of investments</label> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" xlink:to="us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_lbl"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:label="us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment"/> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_lbl" xml:lang="en-US" id="id_6895476_1287211_1_1">Proceeds from Sale of Property, Plant, and Equipment</label> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_lbl" xml:lang="en-US" id="id_6895476_1287211_2_1">Proceeds from sales of property and equipment</label> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:to="us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_lbl"/> <loc xlink:type="locator" xlink:href="cytk-20141231.xsd#cytk_ProceedsFromSalesOfCommonStockNet" xlink:label="cytk_ProceedsFromSalesOfCommonStockNet"/> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cytk_ProceedsFromSalesOfCommonStockNet_lbl" xml:lang="en-US" id="id_6895476_1495936_3_1">The cash inflow from the additional capital contribution to the entity, net of issuance costs.</label> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cytk_ProceedsFromSalesOfCommonStockNet_lbl" xml:lang="en-US" id="id_6895476_1495936_1_1">Proceeds From Sales Of Common Stock Net</label> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cytk_ProceedsFromSalesOfCommonStockNet_lbl" xml:lang="en-US" id="id_6895476_1495936_2_1">Net proceeds from sales of common stock</label> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cytk_ProceedsFromSalesOfCommonStockNet" xlink:to="cytk_ProceedsFromSalesOfCommonStockNet_lbl"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ProjectMember" xlink:label="us-gaap_ProjectMember"/> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProjectMember_lbl" xml:lang="en-US" id="id_6895476_1277737_1_1">Project [Domain]</label> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProjectMember_lbl" xml:lang="en-US" id="id_6895476_1277737_2_1">Project [Domain]</label> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProjectMember" xlink:to="us-gaap_ProjectMember_lbl"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis"/> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis_lbl" xml:lang="en-US" id="id_6895476_1276136_1_1">Property, Plant and Equipment, Type [Axis]</label> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis_lbl" xml:lang="en-US" id="id_6895476_1276136_2_1">Property, Plant and Equipment, Type [Axis]</label> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis_lbl"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="us-gaap_PropertyPlantAndEquipmentGross"/> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_lbl" xml:lang="en-US" id="id_6895476_1287207_1_1">Property, Plant and Equipment, Gross</label> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_lbl" xml:lang="en-US" id="id_6895476_1287207_2_1">Property and equipment, gross</label> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentGross" xlink:to="us-gaap_PropertyPlantAndEquipmentGross_lbl"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems"/> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems_lbl" xml:lang="en-US" id="id_6895476_1269502_1_1">Property, Plant and Equipment [Line Items]</label> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems_lbl" xml:lang="en-US" id="id_6895476_1269502_2_1">Property, Plant and Equipment [Line Items]</label> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentLineItems_lbl"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet"/> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xml:lang="en-US" id="id_6895476_1285626_1_1">Property, Plant and Equipment, Net</label> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xml:lang="en-US" id="id_6895476_1285626_2_1">Property and equipment, net</label> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xml:lang="en-US" id="id_6895476_1285626_6_1">Property and equipment, net</label> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_lbl"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNetAbstract" xlink:label="us-gaap_PropertyPlantAndEquipmentNetAbstract"/> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentNetAbstract_lbl" xml:lang="en-US" id="id_6895476_1276139_1_1">Property, Plant and Equipment, Net [Abstract]</label> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentNetAbstract_lbl" xml:lang="en-US" id="id_6895476_1276139_2_1">Property and equipment, net:</label> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentNetAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentNetAbstract_lbl"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock"/> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl" xml:lang="en-US" id="id_6895476_1276143_1_1">Property, Plant and Equipment, Policy [Policy Text Block]</label> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl" xml:lang="en-US" id="id_6895476_1276143_2_1">Property and Equipment</label> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock"/> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl" xml:lang="en-US" id="id_6895476_1281009_1_1">Property, Plant and Equipment [Table Text Block]</label> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl" xml:lang="en-US" id="id_6895476_1281009_2_1">Summary of Property and Equipment Balances</label> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain"/> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain_lbl" xml:lang="en-US" id="id_6895476_1274491_1_1">Property, Plant and Equipment, Type [Domain]</label> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain_lbl" xml:lang="en-US" id="id_6895476_1274491_2_1">Property, Plant and Equipment, Type [Domain]</label> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain_lbl"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife"/> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl" xml:lang="en-US" id="id_6895476_1276144_1_1">Property, Plant and Equipment, Useful Life</label> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl" xml:lang="en-US" id="id_6895476_1276144_2_1">Property and equipment estimated useful lives</label> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl"/> <loc xlink:type="locator" xlink:href="cytk-20141231.xsd#cytk_PropertyPlantAndEquipmentUsefulLifeAndValuesAbstract" xlink:label="cytk_PropertyPlantAndEquipmentUsefulLifeAndValuesAbstract"/> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cytk_PropertyPlantAndEquipmentUsefulLifeAndValuesAbstract_lbl" xml:lang="en-US" id="id_6895476_1468839_3_1">Property Plant and Equipment Useful Life and Values [Abstract]</label> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cytk_PropertyPlantAndEquipmentUsefulLifeAndValuesAbstract_lbl" xml:lang="en-US" id="id_6895476_1468839_1_1">Property Plant and Equipment Useful Life and Values [Abstract]</label> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cytk_PropertyPlantAndEquipmentUsefulLifeAndValuesAbstract_lbl" xml:lang="en-US" id="id_6895476_1468839_2_1">Property Plant and Equipment Useful Life and Values [Abstract]</label> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cytk_PropertyPlantAndEquipmentUsefulLifeAndValuesAbstract" xlink:to="cytk_PropertyPlantAndEquipmentUsefulLifeAndValuesAbstract_lbl"/> <loc xlink:type="locator" xlink:href="cytk-20141231.xsd#cytk_ProportionalPerformanceModelMember" xlink:label="cytk_ProportionalPerformanceModelMember"/> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cytk_ProportionalPerformanceModelMember_lbl" xml:lang="en-US" id="id_6895476_1614534_3_1">Proportional Performance Model [Member]</label> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cytk_ProportionalPerformanceModelMember_lbl" xml:lang="en-US" id="id_6895476_1614534_1_1">Proportional Performance Model [Member]</label> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cytk_ProportionalPerformanceModelMember_lbl" xml:lang="en-US" id="id_6895476_1614534_2_1">Proportional Performance Model [Member]</label> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cytk_ProportionalPerformanceModelMember" xlink:to="cytk_ProportionalPerformanceModelMember_lbl"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_QuarterlyFinancialInformationDisclosureAbstract" xlink:label="us-gaap_QuarterlyFinancialInformationDisclosureAbstract"/> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_QuarterlyFinancialInformationDisclosureAbstract_lbl" xml:lang="en-US" id="id_6895476_1277772_1_1">Quarterly Financial Information Disclosure [Abstract]</label> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_QuarterlyFinancialInformationDisclosureAbstract_lbl" xml:lang="en-US" id="id_6895476_1277772_2_1">Quarterly Financial Information Disclosure [Abstract]</label> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_QuarterlyFinancialInformationDisclosureAbstract" xlink:to="us-gaap_QuarterlyFinancialInformationDisclosureAbstract_lbl"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_QuarterlyFinancialInformationTextBlock" xlink:label="us-gaap_QuarterlyFinancialInformationTextBlock"/> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_QuarterlyFinancialInformationTextBlock_lbl" xml:lang="en-US" id="id_6895476_1276165_1_1">Quarterly Financial Information [Text Block]</label> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_QuarterlyFinancialInformationTextBlock_lbl" xml:lang="en-US" id="id_6895476_1276165_2_1">Quarterly Financial Data</label> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_QuarterlyFinancialInformationTextBlock" xlink:to="us-gaap_QuarterlyFinancialInformationTextBlock_lbl"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RangeAxis" xlink:label="us-gaap_RangeAxis"/> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RangeAxis_lbl" xml:lang="en-US" id="id_6895476_1269523_1_1">Range [Axis]</label> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RangeAxis_lbl" xml:lang="en-US" id="id_6895476_1269523_2_1">Range [Axis]</label> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RangeAxis" xlink:to="us-gaap_RangeAxis_lbl"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RangeMember" xlink:label="us-gaap_RangeMember"/> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RangeMember_lbl" xml:lang="en-US" id="id_6895476_1279402_1_1">Range [Domain]</label> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RangeMember_lbl" xml:lang="en-US" id="id_6895476_1279402_2_1">Range [Domain]</label> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RangeMember" xlink:to="us-gaap_RangeMember_lbl"/> <loc xlink:type="locator" xlink:href="cytk-20141231.xsd#cytk_ReimbursementOfInternalResearchAndDevelopmentCost" xlink:label="cytk_ReimbursementOfInternalResearchAndDevelopmentCost"/> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cytk_ReimbursementOfInternalResearchAndDevelopmentCost_lbl" xml:lang="en-US" id="id_6895476_1600136_3_1">Reimbursement of internal research and development cost.</label> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cytk_ReimbursementOfInternalResearchAndDevelopmentCost_lbl" xml:lang="en-US" id="id_6895476_1600136_1_1">Reimbursement Of Internal Research And Development Cost</label> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cytk_ReimbursementOfInternalResearchAndDevelopmentCost_lbl" xml:lang="en-US" id="id_6895476_1600136_2_1">Reimbursement of internal costs</label> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cytk_ReimbursementOfInternalResearchAndDevelopmentCost" xlink:to="cytk_ReimbursementOfInternalResearchAndDevelopmentCost_lbl"/> <loc xlink:type="locator" xlink:href="cytk-20141231.xsd#cytk_ReimbursementOfOtherResearchAndDevelopmentCost" xlink:label="cytk_ReimbursementOfOtherResearchAndDevelopmentCost"/> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cytk_ReimbursementOfOtherResearchAndDevelopmentCost_lbl" xml:lang="en-US" id="id_6895476_1600137_3_1">Reimbursement Of Other Research And Development Cost</label> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cytk_ReimbursementOfOtherResearchAndDevelopmentCost_lbl" xml:lang="en-US" id="id_6895476_1600137_1_1">Reimbursement Of Other Research And Development Cost</label> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cytk_ReimbursementOfOtherResearchAndDevelopmentCost_lbl" xml:lang="en-US" id="id_6895476_1600137_2_1">Reimbursement of other costs</label> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cytk_ReimbursementOfOtherResearchAndDevelopmentCost" xlink:to="cytk_ReimbursementOfOtherResearchAndDevelopmentCost_lbl"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ReimbursementRevenue" xlink:label="us-gaap_ReimbursementRevenue"/> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ReimbursementRevenue_lbl" xml:lang="en-US" id="id_6895476_1283930_1_1">Reimbursement Revenue</label> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ReimbursementRevenue_lbl" xml:lang="en-US" id="id_6895476_1283930_2_1">Expense reimbursements</label> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ReimbursementRevenue_lbl" xml:lang="en-US" id="id_6895476_1283930_12_1">Reimbursement costs</label> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ReimbursementRevenue" xlink:to="us-gaap_ReimbursementRevenue_lbl"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain"/> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyDomain_lbl" xml:lang="en-US" id="id_6895476_1279455_1_1">Related Party [Domain]</label> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RelatedPartyDomain_lbl" xml:lang="en-US" id="id_6895476_1279455_2_1">Related Party [Domain]</label> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="us-gaap_RelatedPartyDomain_lbl"/> <loc xlink:type="locator" xlink:href="cytk-20141231.xsd#cytk_RelatedPartyResearchAndDevelopmentRevenue" xlink:label="cytk_RelatedPartyResearchAndDevelopmentRevenue"/> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cytk_RelatedPartyResearchAndDevelopmentRevenue_lbl" xml:lang="en-US" id="id_6895476_1299320_3_1">Revenues from research and development agreements with related parties.</label> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cytk_RelatedPartyResearchAndDevelopmentRevenue_lbl" xml:lang="en-US" id="id_6895476_1299320_1_1">Related Party Research And Development Revenue</label> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="cytk_RelatedPartyResearchAndDevelopmentRevenue_lbl" xml:lang="en-US" id="id_6895476_1299320_6_1">Total research and development revenue</label> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cytk_RelatedPartyResearchAndDevelopmentRevenue" xlink:to="cytk_RelatedPartyResearchAndDevelopmentRevenue_lbl"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RelatedPartyTransactionAxis" xlink:label="us-gaap_RelatedPartyTransactionAxis"/> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionAxis_lbl" xml:lang="en-US" id="id_6895476_1274544_1_1">Related Party Transaction [Axis]</label> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RelatedPartyTransactionAxis_lbl" xml:lang="en-US" id="id_6895476_1274544_2_1">Related Party Transaction [Axis]</label> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="us-gaap_RelatedPartyTransactionAxis_lbl"/> <loc xlink:type="locator" xlink:href="cytk-20141231.xsd#cytk_RelatedPartyTransactionCommercializationMilestonePaymentsReceivedByEntity" xlink:label="cytk_RelatedPartyTransactionCommercializationMilestonePaymentsReceivedByEntity"/> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cytk_RelatedPartyTransactionCommercializationMilestonePaymentsReceivedByEntity_lbl" xml:lang="en-US" id="id_6895476_1614515_3_1">Related party transaction commercialization milestone payments received by entity.</label> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cytk_RelatedPartyTransactionCommercializationMilestonePaymentsReceivedByEntity_lbl" xml:lang="en-US" id="id_6895476_1614515_1_1">Related Party Transaction Commercialization Milestone Payments Received By Entity</label> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cytk_RelatedPartyTransactionCommercializationMilestonePaymentsReceivedByEntity_lbl" xml:lang="en-US" id="id_6895476_1614515_2_1">Commercialization milestone payments eligible to receive</label> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cytk_RelatedPartyTransactionCommercializationMilestonePaymentsReceivedByEntity" xlink:to="cytk_RelatedPartyTransactionCommercializationMilestonePaymentsReceivedByEntity_lbl"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RelatedPartyTransactionDomain" xlink:label="us-gaap_RelatedPartyTransactionDomain"/> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionDomain_lbl" xml:lang="en-US" id="id_6895476_1281057_1_1">Related Party Transaction [Domain]</label> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RelatedPartyTransactionDomain_lbl" xml:lang="en-US" id="id_6895476_1281057_2_1">Related Party Transaction [Domain]</label> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionDomain" xlink:to="us-gaap_RelatedPartyTransactionDomain_lbl"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RelatedPartyTransactionDueFromToRelatedPartyAbstract" xlink:label="us-gaap_RelatedPartyTransactionDueFromToRelatedPartyAbstract"/> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionDueFromToRelatedPartyAbstract_lbl" xml:lang="en-US" id="id_6895476_1281068_1_1">Related Party Transaction, Due from (to) Related Party [Abstract]</label> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RelatedPartyTransactionDueFromToRelatedPartyAbstract_lbl" xml:lang="en-US" id="id_6895476_1281068_2_1">Research and development revenues from related parties:</label> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionDueFromToRelatedPartyAbstract" xlink:to="us-gaap_RelatedPartyTransactionDueFromToRelatedPartyAbstract_lbl"/> <loc xlink:type="locator" xlink:href="cytk-20141231.xsd#cytk_RelatedPartyTransactionPreCommercializationMilestonePaymentsReceivedByEntity" xlink:label="cytk_RelatedPartyTransactionPreCommercializationMilestonePaymentsReceivedByEntity"/> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cytk_RelatedPartyTransactionPreCommercializationMilestonePaymentsReceivedByEntity_lbl" xml:lang="en-US" id="id_6895476_1614514_3_1">Related party transaction pre commercialization milestone payments received by entity.</label> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cytk_RelatedPartyTransactionPreCommercializationMilestonePaymentsReceivedByEntity_lbl" xml:lang="en-US" id="id_6895476_1614514_1_1">Related Party Transaction Pre Commercialization Milestone Payments Received By Entity</label> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cytk_RelatedPartyTransactionPreCommercializationMilestonePaymentsReceivedByEntity_lbl" xml:lang="en-US" id="id_6895476_1614514_2_1">Pre-commercialization milestone payments eligible to receive</label> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cytk_RelatedPartyTransactionPreCommercializationMilestonePaymentsReceivedByEntity" xlink:to="cytk_RelatedPartyTransactionPreCommercializationMilestonePaymentsReceivedByEntity_lbl"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="us-gaap_RelatedPartyTransactionsAbstract"/> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionsAbstract_lbl" xml:lang="en-US" id="id_6895476_1276208_1_1">Related Party Transactions [Abstract]</label> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RelatedPartyTransactionsAbstract_lbl" xml:lang="en-US" id="id_6895476_1276208_2_1">Related Party Transactions [Abstract]</label> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsAbstract" xlink:to="us-gaap_RelatedPartyTransactionsAbstract_lbl"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_lbl" xml:lang="en-US" id="id_6895476_1279431_1_1">Related Party [Axis]</label> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_lbl" xml:lang="en-US" id="id_6895476_1279431_2_1">Related Party [Axis]</label> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_lbl"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock"/> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl" xml:lang="en-US" id="id_6895476_1272898_1_1">Related Party Transactions Disclosure [Text Block]</label> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl" xml:lang="en-US" id="id_6895476_1272898_2_1">Related Parties and Related Party Transactions</label> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:to="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RepaymentsOfSecuredDebt" xlink:label="us-gaap_RepaymentsOfSecuredDebt"/> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RepaymentsOfSecuredDebt_lbl" xml:lang="en-US" id="id_6895476_1281633_1_1">Repayments of Secured Debt</label> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_RepaymentsOfSecuredDebt_lbl" xml:lang="en-US" id="id_6895476_1281633_14_1">Repayment of equipment financing lines</label> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RepaymentsOfSecuredDebt" xlink:to="us-gaap_RepaymentsOfSecuredDebt_lbl"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ResearchAndDevelopmentAbstract" xlink:label="us-gaap_ResearchAndDevelopmentAbstract"/> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentAbstract_lbl" xml:lang="en-US" id="id_6895476_1271204_1_1">Research and Development [Abstract]</label> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ResearchAndDevelopmentAbstract_lbl" xml:lang="en-US" id="id_6895476_1271204_2_1">Research and development revenues:</label> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentAbstract" xlink:to="us-gaap_ResearchAndDevelopmentAbstract_lbl"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis"/> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_lbl" xml:lang="en-US" id="id_6895476_1272896_1_1">Research and Development Arrangement, Contract to Perform for Others, Type [Axis]</label> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_lbl" xml:lang="en-US" id="id_6895476_1272896_2_1">Research and Development Arrangement, Contract to Perform for Others, Type [Axis]</label> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_lbl"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned"/> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned_lbl" xml:lang="en-US" id="id_6895476_1283461_1_1">Research and Development Arrangement, Contract to Perform for Others, Compensation Earned</label> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned_lbl" xml:lang="en-US" id="id_6895476_1283461_2_1">Upfront payment received</label> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned_lbl"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems"/> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_lbl" xml:lang="en-US" id="id_6895476_1271205_1_1">Research and Development Arrangement, Contract to Perform for Others [Line Items]</label> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_lbl" xml:lang="en-US" id="id_6895476_1271205_2_1">Research and Development Arrangement, Contract to Perform for Others [Line Items]</label> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_lbl"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain"/> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_lbl" xml:lang="en-US" id="id_6895476_1281064_1_1">Research and Development Arrangement, Contract to Perform for Others, Type [Domain]</label> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_lbl" xml:lang="en-US" id="id_6895476_1281064_2_1">Research and Development Arrangement, Contract to Perform for Others, Type [Domain]</label> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_lbl"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense"/> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xml:lang="en-US" id="id_6895476_1285664_1_1">Research and Development Expense</label> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xml:lang="en-US" id="id_6895476_1285664_2_1">Research and development</label> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpense" xlink:to="us-gaap_ResearchAndDevelopmentExpense_lbl"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember"/> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember_lbl" xml:lang="en-US" id="id_6895476_1269570_1_1">Research and Development Expense [Member]</label> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember_lbl" xml:lang="en-US" id="id_6895476_1269570_2_1">Research and Development [Member]</label> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpenseMember" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember_lbl"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy"/> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl" xml:lang="en-US" id="id_6895476_1276218_1_1">Research and Development Expense, Policy [Policy Text Block]</label> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl" xml:lang="en-US" id="id_6895476_1276218_2_1">Research and Development Expenditures</label> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl"/> <loc xlink:type="locator" xlink:href="cytk-20141231.xsd#cytk_ResearchAndDevelopmentFederalTaxCreditCarryforwardsExpirationDateYear" xlink:label="cytk_ResearchAndDevelopmentFederalTaxCreditCarryforwardsExpirationDateYear"/> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cytk_ResearchAndDevelopmentFederalTaxCreditCarryforwardsExpirationDateYear_lbl" xml:lang="en-US" id="id_6895476_1475231_3_1">The earliest date at which certain federal carry forwards will expire.</label> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cytk_ResearchAndDevelopmentFederalTaxCreditCarryforwardsExpirationDateYear_lbl" xml:lang="en-US" id="id_6895476_1475231_1_1">Research And Development Federal Tax Credit Carryforwards Expiration Date Year</label> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cytk_ResearchAndDevelopmentFederalTaxCreditCarryforwardsExpirationDateYear_lbl" xml:lang="en-US" id="id_6895476_1475231_2_1">Research and development credits and orphan drug credits, federal carryforwards will expire</label> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cytk_ResearchAndDevelopmentFederalTaxCreditCarryforwardsExpirationDateYear" xlink:to="cytk_ResearchAndDevelopmentFederalTaxCreditCarryforwardsExpirationDateYear_lbl"/> <loc xlink:type="locator" xlink:href="cytk-20141231.xsd#cytk_ResearchAndDevelopmentGrantAndOtherRevenues" xlink:label="cytk_ResearchAndDevelopmentGrantAndOtherRevenues"/> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cytk_ResearchAndDevelopmentGrantAndOtherRevenues_lbl" xml:lang="en-US" id="id_6895476_1472443_3_1">Revenues from research and development agreements, grants for research and development activities and other sources.</label> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cytk_ResearchAndDevelopmentGrantAndOtherRevenues_lbl" xml:lang="en-US" id="id_6895476_1472443_1_1">Research And Development Grant And Other Revenues</label> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cytk_ResearchAndDevelopmentGrantAndOtherRevenues_lbl" xml:lang="en-US" id="id_6895476_1472443_2_1">Research and development, grant and other revenues</label> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cytk_ResearchAndDevelopmentGrantAndOtherRevenues" xlink:to="cytk_ResearchAndDevelopmentGrantAndOtherRevenues_lbl"/> <loc xlink:type="locator" xlink:href="cytk-20141231.xsd#cytk_ResearchAndDevelopmentRelatedPartyRevenue" xlink:label="cytk_ResearchAndDevelopmentRelatedPartyRevenue"/> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cytk_ResearchAndDevelopmentRelatedPartyRevenue_lbl" xml:lang="en-US" id="id_6895476_1622335_3_1">Research and development related party revenue.</label> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cytk_ResearchAndDevelopmentRelatedPartyRevenue_lbl" xml:lang="en-US" id="id_6895476_1622335_1_1">Research And Development Related Party Revenue</label> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cytk_ResearchAndDevelopmentRelatedPartyRevenue_lbl" xml:lang="en-US" id="id_6895476_1622335_2_1">Research and development milestone fees</label> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cytk_ResearchAndDevelopmentRelatedPartyRevenue" xlink:to="cytk_ResearchAndDevelopmentRelatedPartyRevenue_lbl"/> <loc xlink:type="locator" xlink:href="cytk-20141231.xsd#cytk_ResearchAndDevelopmentRevenue" xlink:label="cytk_ResearchAndDevelopmentRevenue"/> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cytk_ResearchAndDevelopmentRevenue_lbl" xml:lang="en-US" id="id_6895476_1383444_3_1">Research And Development Revenue</label> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cytk_ResearchAndDevelopmentRevenue_lbl" xml:lang="en-US" id="id_6895476_1383444_1_1">Research And Development Revenue</label> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cytk_ResearchAndDevelopmentRevenue_lbl" xml:lang="en-US" id="id_6895476_1383444_2_1">Research and development milestone fees</label> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="cytk_ResearchAndDevelopmentRevenue_lbl" xml:lang="en-US" id="id_6895476_1383444_12_1">Research milestone payments</label> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cytk_ResearchAndDevelopmentRevenue" xlink:to="cytk_ResearchAndDevelopmentRevenue_lbl"/> <loc xlink:type="locator" xlink:href="cytk-20141231.xsd#cytk_ResearchAndDevelopmentRevenueFromCollaboration" xlink:label="cytk_ResearchAndDevelopmentRevenueFromCollaboration"/> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cytk_ResearchAndDevelopmentRevenueFromCollaboration_lbl" xml:lang="en-US" id="id_6895476_1352628_3_1">Research and development revenue from collaboration.</label> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cytk_ResearchAndDevelopmentRevenueFromCollaboration_lbl" xml:lang="en-US" id="id_6895476_1352628_1_1">Research and Development Revenue from Collaboration</label> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="cytk_ResearchAndDevelopmentRevenueFromCollaboration_lbl" xml:lang="en-US" id="id_6895476_1352628_6_1">Research and development revenue from Myokardia</label> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cytk_ResearchAndDevelopmentRevenueFromCollaboration" xlink:to="cytk_ResearchAndDevelopmentRevenueFromCollaboration_lbl"/> <loc xlink:type="locator" xlink:href="cytk-20141231.xsd#cytk_ResearchAndDevelopmentRevenuesFromRelatedParties" xlink:label="cytk_ResearchAndDevelopmentRevenuesFromRelatedParties"/> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cytk_ResearchAndDevelopmentRevenuesFromRelatedParties_lbl" xml:lang="en-US" id="id_6895476_1461375_3_1">Research and development revenues from related parties.</label> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cytk_ResearchAndDevelopmentRevenuesFromRelatedParties_lbl" xml:lang="en-US" id="id_6895476_1461375_1_1">Research And Development Revenues From Related Parties</label> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cytk_ResearchAndDevelopmentRevenuesFromRelatedParties_lbl" xml:lang="en-US" id="id_6895476_1461375_2_1">Research and development revenue</label> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="cytk_ResearchAndDevelopmentRevenuesFromRelatedParties_lbl" xml:lang="en-US" id="id_6895476_1461375_12_1">Research and development revenues from related parties</label> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cytk_ResearchAndDevelopmentRevenuesFromRelatedParties" xlink:to="cytk_ResearchAndDevelopmentRevenuesFromRelatedParties_lbl"/> <loc xlink:type="locator" xlink:href="cytk-20141231.xsd#cytk_ResearchCollaborationAndLicenseAgreementPeriod" xlink:label="cytk_ResearchCollaborationAndLicenseAgreementPeriod"/> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cytk_ResearchCollaborationAndLicenseAgreementPeriod_lbl" xml:lang="en-US" id="id_6895476_1362022_3_1">Research Collaboration And License Agreement Period</label> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cytk_ResearchCollaborationAndLicenseAgreementPeriod_lbl" xml:lang="en-US" id="id_6895476_1362022_1_1">Research Collaboration And License Agreement Period</label> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cytk_ResearchCollaborationAndLicenseAgreementPeriod_lbl" xml:lang="en-US" id="id_6895476_1362022_2_1">Collaboration agreement term</label> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cytk_ResearchCollaborationAndLicenseAgreementPeriod" xlink:to="cytk_ResearchCollaborationAndLicenseAgreementPeriod_lbl"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock" xlink:label="us-gaap_ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock"/> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock_lbl" xml:lang="en-US" id="id_6895476_1277816_1_1">Research, Development, and Computer Software Disclosure [Text Block]</label> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock_lbl" xml:lang="en-US" id="id_6895476_1277816_2_1">Other Research and Development Revenue Arrangements</label> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock" xlink:to="us-gaap_ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock_lbl"/> <loc xlink:type="locator" xlink:href="cytk-20141231.xsd#cytk_ResearchDevelopmentGrant" xlink:label="cytk_ResearchDevelopmentGrant"/> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cytk_ResearchDevelopmentGrant_lbl" xml:lang="en-US" id="id_6895476_1475460_3_1">Governmental, corporate or foundation grants awarded to fund research and development activities.</label> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cytk_ResearchDevelopmentGrant_lbl" xml:lang="en-US" id="id_6895476_1475460_1_1">Research Development Grant</label> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cytk_ResearchDevelopmentGrant_lbl" xml:lang="en-US" id="id_6895476_1475460_2_1">Grant to support research and development</label> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cytk_ResearchDevelopmentGrant" xlink:to="cytk_ResearchDevelopmentGrant_lbl"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember"/> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_lbl" xml:lang="en-US" id="id_6895476_1277823_1_1">Cash and Cash Equivalents [Domain]</label> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_lbl" xml:lang="en-US" id="id_6895476_1277823_2_1">Cash and Cash Equivalents [Domain]</label> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_lbl"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RestrictedStockMember" xlink:label="us-gaap_RestrictedStockMember"/> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RestrictedStockMember_lbl" xml:lang="en-US" id="id_6895476_1271210_1_1">Restricted Stock [Member]</label> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RestrictedStockMember_lbl" xml:lang="en-US" id="id_6895476_1271210_2_1">Restricted Stock [Member]</label> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedStockMember" xlink:to="us-gaap_RestrictedStockMember_lbl"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember"/> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RestrictedStockUnitsRSUMember_lbl" xml:lang="en-US" id="id_6895476_1271212_1_1">Restricted Stock Units (RSUs) [Member]</label> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RestrictedStockUnitsRSUMember_lbl" xml:lang="en-US" id="id_6895476_1271212_2_1">Restricted Stock Units [Member]</label> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedStockUnitsRSUMember" xlink:to="us-gaap_RestrictedStockUnitsRSUMember_lbl"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RestructuringCharges" xlink:label="us-gaap_RestructuringCharges"/> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RestructuringCharges_lbl" xml:lang="en-US" id="id_6895476_1286183_1_1">Restructuring Charges</label> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RestructuringCharges_lbl" xml:lang="en-US" id="id_6895476_1286183_2_1">Restructuring reversals</label> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestructuringCharges" xlink:to="us-gaap_RestructuringCharges_lbl"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RestructuringCostsAndAssetImpairmentCharges" xlink:label="us-gaap_RestructuringCostsAndAssetImpairmentCharges"/> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RestructuringCostsAndAssetImpairmentCharges_lbl" xml:lang="en-US" id="id_6895476_1288236_1_1">Restructuring Costs and Asset Impairment Charges</label> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RestructuringCostsAndAssetImpairmentCharges_lbl" xml:lang="en-US" id="id_6895476_1288236_2_1">Non-cash restructuring expenses, net of reversals</label> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestructuringCostsAndAssetImpairmentCharges" xlink:to="us-gaap_RestructuringCostsAndAssetImpairmentCharges_lbl"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit"/> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xml:lang="en-US" id="id_6895476_1283021_1_1">Retained Earnings (Accumulated Deficit)</label> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xml:lang="en-US" id="id_6895476_1283021_2_1">Accumulated deficit</label> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xml:lang="en-US" id="id_6895476_1283021_12_1">Accumulated deficit incurred</label> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_lbl"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember"/> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RetainedEarningsMember_lbl" xml:lang="en-US" id="id_6895476_1269588_1_1">Retained Earnings [Member]</label> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RetainedEarningsMember_lbl" xml:lang="en-US" id="id_6895476_1269588_2_1">Accumulated Deficit [Member]</label> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsMember" xlink:to="us-gaap_RetainedEarningsMember_lbl"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RevenueFromGrants" xlink:label="us-gaap_RevenueFromGrants"/> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RevenueFromGrants_lbl" xml:lang="en-US" id="id_6895476_1281624_1_1">Revenue from Grants</label> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RevenueFromGrants_lbl" xml:lang="en-US" id="id_6895476_1281624_2_1">Total grant revenue</label> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueFromGrants" xlink:to="us-gaap_RevenueFromGrants_lbl"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RevenueFromRelatedParties" xlink:label="us-gaap_RevenueFromRelatedParties"/> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RevenueFromRelatedParties_lbl" xml:lang="en-US" id="id_6895476_1284377_1_1">Revenue from Related Parties</label> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RevenueFromRelatedParties_lbl" xml:lang="en-US" id="id_6895476_1284377_2_1">Allocated consideration</label> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueFromRelatedParties" xlink:to="us-gaap_RevenueFromRelatedParties_lbl"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized" xlink:label="us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized"/> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized_lbl" xml:lang="en-US" id="id_6895476_1282115_1_1">Revenue Recognition, Milestone Method, Revenue Recognized</label> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized_lbl" xml:lang="en-US" id="id_6895476_1282115_2_1">Amount recognized for milestones achieved</label> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized" xlink:to="us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized_lbl"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RevenueRecognitionPolicyTextBlock" xlink:label="us-gaap_RevenueRecognitionPolicyTextBlock"/> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RevenueRecognitionPolicyTextBlock_lbl" xml:lang="en-US" id="id_6895476_1272964_1_1">Revenue Recognition, Policy [Policy Text Block]</label> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RevenueRecognitionPolicyTextBlock_lbl" xml:lang="en-US" id="id_6895476_1272964_2_1">Revenue Recognition</label> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueRecognitionPolicyTextBlock" xlink:to="us-gaap_RevenueRecognitionPolicyTextBlock_lbl"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_Revenues" xlink:label="us-gaap_Revenues"/> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Revenues_lbl" xml:lang="en-US" id="id_6895476_1284373_1_1">Revenues</label> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_Revenues_lbl" xml:lang="en-US" id="id_6895476_1284373_6_1">Total revenues</label> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Revenues" xlink:to="us-gaap_Revenues_lbl"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RevenuesAbstract" xlink:label="us-gaap_RevenuesAbstract"/> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RevenuesAbstract_lbl" xml:lang="en-US" id="id_6895476_1271283_1_1">Revenues [Abstract]</label> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RevenuesAbstract_lbl" xml:lang="en-US" id="id_6895476_1271283_2_1">Revenues:</label> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenuesAbstract" xlink:to="us-gaap_RevenuesAbstract_lbl"/> <loc xlink:type="locator" xlink:href="cytk-20141231.xsd#cytk_ReverseStockSplitPolicyTextBlock" xlink:label="cytk_ReverseStockSplitPolicyTextBlock"/> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cytk_ReverseStockSplitPolicyTextBlock_lbl" xml:lang="en-US" id="id_6895476_1359295_3_1">Reverse Stock Split Policy [Text Block]</label> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cytk_ReverseStockSplitPolicyTextBlock_lbl" xml:lang="en-US" id="id_6895476_1359295_1_1">Reverse Stock Split Policy [Text Block]</label> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cytk_ReverseStockSplitPolicyTextBlock_lbl" xml:lang="en-US" id="id_6895476_1359295_2_1">Reverse Stock Split</label> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cytk_ReverseStockSplitPolicyTextBlock" xlink:to="cytk_ReverseStockSplitPolicyTextBlock_lbl"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain"/> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_lbl" xml:lang="en-US" id="id_6895476_1279494_1_1">Sale of Stock [Domain]</label> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_lbl" xml:lang="en-US" id="id_6895476_1279494_2_1">Sale of Stock [Domain]</label> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_lbl"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SalesRevenueNet" xlink:label="us-gaap_SalesRevenueNet"/> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SalesRevenueNet_lbl" xml:lang="en-US" id="id_6895476_1282578_1_1">Revenue, Net</label> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SalesRevenueNet_lbl" xml:lang="en-US" id="id_6895476_1282578_2_1">Total revenues</label> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SalesRevenueNet" xlink:to="us-gaap_SalesRevenueNet_lbl"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock"/> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_lbl" xml:lang="en-US" id="id_6895476_1274583_1_1">Schedule of Accrued Liabilities [Table Text Block]</label> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_lbl" xml:lang="en-US" id="id_6895476_1274583_2_1">Summary of Accrued Liabilities</label> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:to="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_lbl"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_lbl" xml:lang="en-US" id="id_6895476_1269612_1_1">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]</label> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_lbl" xml:lang="en-US" id="id_6895476_1269612_2_1">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]</label> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_lbl"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"/> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl" xml:lang="en-US" id="id_6895476_1271235_1_1">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]</label> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl" xml:lang="en-US" id="id_6895476_1271235_2_1">Instruments Excluded from the Computation of Diluted Net Loss Per Common Share</label> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfCashAndCashEquivalentsTable" xlink:label="us-gaap_ScheduleOfCashAndCashEquivalentsTable"/> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfCashAndCashEquivalentsTable_lbl" xml:lang="en-US" id="id_6895476_1271242_1_1">Schedule of Cash and Cash Equivalents [Table]</label> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfCashAndCashEquivalentsTable_lbl" xml:lang="en-US" id="id_6895476_1271242_2_1">Schedule of Cash and Cash Equivalents [Table]</label> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfCashAndCashEquivalentsTable" xlink:to="us-gaap_ScheduleOfCashAndCashEquivalentsTable_lbl"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock" xlink:label="us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock"/> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock_lbl" xml:lang="en-US" id="id_6895476_1274594_1_1">Cash, Cash Equivalents and Investments [Table Text Block]</label> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock_lbl" xml:lang="en-US" id="id_6895476_1274594_2_1">Amortized Cost and Fair Value of Cash Equivalents and Available for Sale Investments</label> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock" xlink:to="us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock_lbl"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock" xlink:label="us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock"/> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock_lbl" xml:lang="en-US" id="id_6895476_1281103_1_1">Schedule of Cash Flow, Supplemental Disclosures [Table Text Block]</label> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock_lbl" xml:lang="en-US" id="id_6895476_1281103_2_1">Supplemental Cash Flow Information</label> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock" xlink:to="us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock_lbl"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:label="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock"/> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_lbl" xml:lang="en-US" id="id_6895476_1274600_1_1">Schedule of Components of Income Tax Expense (Benefit) [Table Text Block]</label> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_lbl" xml:lang="en-US" id="id_6895476_1274600_2_1">Company Recorded Income Tax Provision</label> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:to="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_lbl"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfDeferredCompensationArrangementWithIndividualShareBasedPaymentsTable" xlink:label="us-gaap_ScheduleOfDeferredCompensationArrangementWithIndividualShareBasedPaymentsTable"/> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfDeferredCompensationArrangementWithIndividualShareBasedPaymentsTable_lbl" xml:lang="en-US" id="id_6895476_1271248_1_1">Schedule of Deferred Compensation Arrangement with Individual, Share-based Payments [Table]</label> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfDeferredCompensationArrangementWithIndividualShareBasedPaymentsTable_lbl" xml:lang="en-US" id="id_6895476_1271248_2_1">Schedule of Deferred Compensation Arrangement with Individual, Share-based Payments [Table]</label> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfDeferredCompensationArrangementWithIndividualShareBasedPaymentsTable" xlink:to="us-gaap_ScheduleOfDeferredCompensationArrangementWithIndividualShareBasedPaymentsTable_lbl"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock"/> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl" xml:lang="en-US" id="id_6895476_1277849_1_1">Schedule of Deferred Tax Assets and Liabilities [Table Text Block]</label> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl" xml:lang="en-US" id="id_6895476_1277849_2_1">Company's Deferred Tax Assets and Liabilities</label> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:to="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock"/> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_lbl" xml:lang="en-US" id="id_6895476_1277853_1_1">Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]</label> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_lbl" xml:lang="en-US" id="id_6895476_1277853_2_1">Calculation of Basic and Diluted Net Loss Per Share Allocable to Common Stockholders</label> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:to="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_lbl"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock"/> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl" xml:lang="en-US" id="id_6895476_1269624_1_1">Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]</label> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl" xml:lang="en-US" id="id_6895476_1269624_2_1">Reconciliation of Statutory Federal Income Tax Rate to Effective Tax Rate</label> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:to="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_lbl" xml:lang="en-US" id="id_6895476_1276285_1_1">Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table]</label> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_lbl" xml:lang="en-US" id="id_6895476_1276285_2_1">Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table]</label> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_lbl"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock"/> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_lbl" xml:lang="en-US" id="id_6895476_1272939_1_1">Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table Text Block]</label> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_lbl" xml:lang="en-US" id="id_6895476_1272939_2_1">Stock-Based Compensation Related to Stock Options, Restricted Stock Awards, Restricted Stock Unit, and Employee Stock Purchases</label> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_lbl"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfFairValueOfSeparateAccountsByMajorCategoryOfInvestmentAxis" xlink:label="us-gaap_ScheduleOfFairValueOfSeparateAccountsByMajorCategoryOfInvestmentAxis"/> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfFairValueOfSeparateAccountsByMajorCategoryOfInvestmentAxis_lbl" xml:lang="en-US" id="id_6895476_1274607_1_1">Schedule of Fair Value of Separate Accounts by Major Category of Investment [Axis]</label> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfFairValueOfSeparateAccountsByMajorCategoryOfInvestmentAxis_lbl" xml:lang="en-US" id="id_6895476_1274607_2_1">Schedule of Fair Value of Separate Accounts by Major Category of Investment [Axis]</label> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfFairValueOfSeparateAccountsByMajorCategoryOfInvestmentAxis" xlink:to="us-gaap_ScheduleOfFairValueOfSeparateAccountsByMajorCategoryOfInvestmentAxis_lbl"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfFairValueOfSeparateAccountsByMajorCategoryOfInvestmentCategoryDomain" xlink:label="us-gaap_ScheduleOfFairValueOfSeparateAccountsByMajorCategoryOfInvestmentCategoryDomain"/> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfFairValueOfSeparateAccountsByMajorCategoryOfInvestmentCategoryDomain_lbl" xml:lang="en-US" id="id_6895476_1269630_1_1">Schedule of Fair Value of Separate Accounts by Major Category of Investment, Category [Domain]</label> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfFairValueOfSeparateAccountsByMajorCategoryOfInvestmentCategoryDomain_lbl" xml:lang="en-US" id="id_6895476_1269630_2_1">Schedule of Fair Value of Separate Accounts by Major Category of Investment, Category [Domain]</label> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfFairValueOfSeparateAccountsByMajorCategoryOfInvestmentCategoryDomain" xlink:to="us-gaap_ScheduleOfFairValueOfSeparateAccountsByMajorCategoryOfInvestmentCategoryDomain_lbl"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock" xlink:label="us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock"/> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock_lbl" xml:lang="en-US" id="id_6895476_1277866_1_1">Schedule of Future Minimum Rental Payments for Operating Leases [Table Text Block]</label> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock_lbl" xml:lang="en-US" id="id_6895476_1277866_2_1">Future Minimum Lease Payments under Noncancelable Operating Leases</label> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock" xlink:to="us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock_lbl"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" xlink:label="us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock"/> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock_lbl" xml:lang="en-US" id="id_6895476_1271257_1_1">Schedule of Income before Income Tax, Domestic and Foreign [Table Text Block]</label> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock_lbl" xml:lang="en-US" id="id_6895476_1271257_2_1">Schedule of Components of Income Before Taxes</label> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" xlink:to="us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock_lbl"/> <loc xlink:type="locator" xlink:href="cytk-20141231.xsd#cytk_ScheduleOfInterestExpenseTableTextBlock" xlink:label="cytk_ScheduleOfInterestExpenseTableTextBlock"/> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cytk_ScheduleOfInterestExpenseTableTextBlock_lbl" xml:lang="en-US" id="id_6895476_1371045_3_1">The total of all interest expense incurred.</label> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cytk_ScheduleOfInterestExpenseTableTextBlock_lbl" xml:lang="en-US" id="id_6895476_1371045_1_1">Schedule Of Interest Expense Table [Text Block]</label> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cytk_ScheduleOfInterestExpenseTableTextBlock_lbl" xml:lang="en-US" id="id_6895476_1371045_2_1">Summary of Total Interest Expense Incurred</label> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cytk_ScheduleOfInterestExpenseTableTextBlock" xlink:to="cytk_ScheduleOfInterestExpenseTableTextBlock_lbl"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock" xlink:label="us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock"/> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock_lbl" xml:lang="en-US" id="id_6895476_1274636_1_1">Schedule of Other Nonoperating Income (Expense) [Table Text Block]</label> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock_lbl" xml:lang="en-US" id="id_6895476_1274636_2_1">Components of Interest and Other, Net</label> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock" xlink:to="us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock_lbl"/> <loc xlink:type="locator" xlink:href="cytk-20141231.xsd#cytk_ScheduleOfOtherRelatedPartyTransactionsLineItems" xlink:label="cytk_ScheduleOfOtherRelatedPartyTransactionsLineItems"/> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cytk_ScheduleOfOtherRelatedPartyTransactionsLineItems_lbl" xml:lang="en-US" id="id_6895476_1391750_3_1">Schedule of Other Related Party Transactions [Line Items]</label> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cytk_ScheduleOfOtherRelatedPartyTransactionsLineItems_lbl" xml:lang="en-US" id="id_6895476_1391750_1_1">Schedule of Other Related Party Transactions [Line Items]</label> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cytk_ScheduleOfOtherRelatedPartyTransactionsLineItems_lbl" xml:lang="en-US" id="id_6895476_1391750_2_1">Schedule of Other Related Party Transactions [Line Items]</label> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cytk_ScheduleOfOtherRelatedPartyTransactionsLineItems" xlink:to="cytk_ScheduleOfOtherRelatedPartyTransactionsLineItems_lbl"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_lbl" xml:lang="en-US" id="id_6895476_1272974_1_1">Property, Plant and Equipment [Table]</label> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_lbl" xml:lang="en-US" id="id_6895476_1272974_2_1">Property, Plant and Equipment [Table]</label> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_lbl"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock" xlink:label="us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock"/> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock_lbl" xml:lang="en-US" id="id_6895476_1277899_1_1">Schedule of Quarterly Financial Information [Table Text Block]</label> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock_lbl" xml:lang="en-US" id="id_6895476_1277899_2_1">Summary of Quarterly Results</label> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock" xlink:to="us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock_lbl"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable"/> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_lbl" xml:lang="en-US" id="id_6895476_1272980_1_1">Schedule of Related Party Transactions, by Related Party [Table]</label> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_lbl" xml:lang="en-US" id="id_6895476_1272980_2_1">Schedule of Related Party Transactions, by Related Party [Table]</label> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_lbl"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock"/> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock_lbl" xml:lang="en-US" id="id_6895476_1274645_1_1">Schedule of Related Party Transactions [Table Text Block]</label> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock_lbl" xml:lang="en-US" id="id_6895476_1274645_2_1">Revenue from Related Party</label> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock" xlink:to="us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock_lbl"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfRentExpenseTableTextBlock" xlink:label="us-gaap_ScheduleOfRentExpenseTableTextBlock"/> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfRentExpenseTableTextBlock_lbl" xml:lang="en-US" id="id_6895476_1272981_1_1">Schedule of Rent Expense [Table Text Block]</label> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfRentExpenseTableTextBlock_lbl" xml:lang="en-US" id="id_6895476_1272981_2_1">Rent Expense</label> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfRentExpenseTableTextBlock" xlink:to="us-gaap_ScheduleOfRentExpenseTableTextBlock_lbl"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable" xlink:label="us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable"/> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_lbl" xml:lang="en-US" id="id_6895476_1281128_1_1">Schedule of Research and Development Arrangement, Contract to Perform for Others [Table]</label> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_lbl" xml:lang="en-US" id="id_6895476_1281128_2_1">Schedule of Research and Development Arrangement, Contract to Perform for Others [Table]</label> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable" xlink:to="us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_lbl"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl" xml:lang="en-US" id="id_6895476_1271276_1_1">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</label> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl" xml:lang="en-US" id="id_6895476_1271276_2_1">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</label> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock"/> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock_lbl" xml:lang="en-US" id="id_6895476_1269649_1_1">Schedule of Share-based Compensation, Restricted Stock Units Award Activity [Table Text Block]</label> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock_lbl" xml:lang="en-US" id="id_6895476_1269649_2_1">Summary of Restricted Stock Unit Activity</label> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock_lbl"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" xml:lang="en-US" id="id_6895476_1271278_1_1">Schedule of Share-based Compensation, Stock Options, Activity [Table Text Block]</label> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" xml:lang="en-US" id="id_6895476_1271278_2_1">Summary of Stock Option Activity</label> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl" xml:lang="en-US" id="id_6895476_1269652_1_1">Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]</label> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl" xml:lang="en-US" id="id_6895476_1269652_2_1">Fair Value of Share-Based Payments was Estimated on Date of Grant Using Black-Scholes Option Pricing Model Based on Weighted Average Assumptions</label> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="us-gaap_ScheduleOfStockByClassTable"/> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfStockByClassTable_lbl" xml:lang="en-US" id="id_6895476_1281133_1_1">Schedule of Stock by Class [Table]</label> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfStockByClassTable_lbl" xml:lang="en-US" id="id_6895476_1281133_2_1">Schedule of Stock by Class [Table]</label> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_ScheduleOfStockByClassTable_lbl"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:label="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock"/> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_lbl" xml:lang="en-US" id="id_6895476_1279540_1_1">Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block]</label> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_lbl" xml:lang="en-US" id="id_6895476_1279540_2_1">Outstanding Warrants</label> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:to="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_lbl"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" xlink:label="us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock"/> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock_lbl" xml:lang="en-US" id="id_6895476_1281137_1_1">Schedule of Unrecognized Tax Benefits Roll Forward [Table Text Block]</label> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock_lbl" xml:lang="en-US" id="id_6895476_1281137_2_1">Reconciliation of Total Amounts of Unrecognized Tax Benefits</label> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" xlink:to="us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock_lbl"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SegmentGeographicalDomain" xlink:label="us-gaap_SegmentGeographicalDomain"/> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SegmentGeographicalDomain_lbl" xml:lang="en-US" id="id_6895476_1276336_1_1">Geographical [Domain]</label> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SegmentGeographicalDomain_lbl" xml:lang="en-US" id="id_6895476_1276336_2_1">Geographical [Domain]</label> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SegmentGeographicalDomain" xlink:to="us-gaap_SegmentGeographicalDomain_lbl"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock"/> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock_lbl" xml:lang="en-US" id="id_6895476_1279551_1_1">Segment Reporting, Policy [Policy Text Block]</label> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock_lbl" xml:lang="en-US" id="id_6895476_1279551_2_1">Segment Reporting</label> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:to="us-gaap_SegmentReportingPolicyPolicyTextBlock_lbl"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SeriesAPreferredStockMember" xlink:label="us-gaap_SeriesAPreferredStockMember"/> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SeriesAPreferredStockMember_lbl" xml:lang="en-US" id="id_6895476_1269676_1_1">Series A Preferred Stock [Member]</label> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SeriesAPreferredStockMember_lbl" xml:lang="en-US" id="id_6895476_1269676_2_1">Series A Convertible Preferred Stock [Member]</label> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SeriesAPreferredStockMember" xlink:to="us-gaap_SeriesAPreferredStockMember_lbl"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SeriesBPreferredStockMember" xlink:label="us-gaap_SeriesBPreferredStockMember"/> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SeriesBPreferredStockMember_lbl" xml:lang="en-US" id="id_6895476_1281157_1_1">Series B Preferred Stock [Member]</label> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SeriesBPreferredStockMember_lbl" xml:lang="en-US" id="id_6895476_1281157_2_1">Series B Convertible Preferred Stock [Member]</label> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SeriesBPreferredStockMember" xlink:to="us-gaap_SeriesBPreferredStockMember_lbl"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation"/> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensation_lbl" xml:lang="en-US" id="id_6895476_1288753_1_1">Share-based Compensation</label> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensation_lbl" xml:lang="en-US" id="id_6895476_1288753_2_1">Stock-based compensation</label> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensation" xlink:to="us-gaap_ShareBasedCompensation_lbl"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_lbl" xml:lang="en-US" id="id_6895476_1277943_1_1">Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period</label> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_lbl" xml:lang="en-US" id="id_6895476_1277943_2_1">Vesting period of options</label> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_lbl"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights"/> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights_lbl" xml:lang="en-US" id="id_6895476_1273019_1_1">Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights</label> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights_lbl" xml:lang="en-US" id="id_6895476_1273019_2_1">Award vesting right</label> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights_lbl"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_lbl" xml:lang="en-US" id="id_6895476_1269684_1_1">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period</label> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_lbl" xml:lang="en-US" id="id_6895476_1269684_2_1">Shares Available for Grant of Option or Award, Restricted stock units forfeited</label> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_lbl" xml:lang="en-US" id="id_6895476_1269684_14_1">Restricted stock units forfeited, Number of Shares</label> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_lbl"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US" id="id_6895476_1276373_1_1">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value</label> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US" id="id_6895476_1276373_2_1">Restricted stock units forfeited, Weighted Average Award Date Fair Value per Share</label> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_lbl"/> <loc xlink:type="locator" xlink:href="cytk-20141231.xsd#cytk_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedInPeriodWeightedAverageExercisePrice" xlink:label="cytk_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedInPeriodWeightedAverageExercisePrice"/> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cytk_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US" id="id_6895476_1340728_3_1">The weighted average exercise price per share of restricted stock awards granted. This per share amount should always be zero as restricted stock grants are awarded to recipients on the grant date and do not have an exercise feature.</label> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cytk_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US" id="id_6895476_1340728_1_1">Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Granted In Period Weighted Average Exercise Price</label> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cytk_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US" id="id_6895476_1340728_2_1">Weighted Average Exercise Price per Share - Stock Options, Restricted stock units granted</label> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cytk_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedInPeriodWeightedAverageExercisePrice" xlink:to="cytk_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedInPeriodWeightedAverageExercisePrice_lbl"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_lbl" xml:lang="en-US" id="id_6895476_1274705_1_1">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period</label> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_lbl" xml:lang="en-US" id="id_6895476_1274705_2_1">Restricted stock units granted, Number of Shares</label> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_lbl" xml:lang="en-US" id="id_6895476_1274705_14_1">Shares Available for Grant of Option or Award, Restricted stock units granted</label> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_lbl"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US" id="id_6895476_1273023_1_1">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value</label> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US" id="id_6895476_1273023_2_1">Restricted stock units granted, Weighted Average Award Date Fair Value per Share</label> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl" xml:lang="en-US" id="id_6895476_1279571_1_1">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number</label> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl" xml:lang="en-US" id="id_6895476_1279571_4_1">Unvested restricted stock units outstanding, Number of Shares, Ending Balance</label> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl" xml:lang="en-US" id="id_6895476_1279571_5_1">Restricted stock units outstanding, Number of Shares, Beginning Balance</label> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US" id="id_6895476_1269687_1_1">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value</label> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US" id="id_6895476_1269687_4_1">Unvested restricted stock units outstanding, Weighted Average Award Date Fair Value per Share, Ending Balance</label> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US" id="id_6895476_1269687_5_1">Restricted stock units outstanding, Weighted Average Award Date Fair Value per Share, Beginning Balance</label> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_lbl" xml:lang="en-US" id="id_6895476_1273025_1_1">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period</label> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_lbl" xml:lang="en-US" id="id_6895476_1273025_14_1">Restricted stock units vested, Number of Shares</label> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_lbl"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue"/> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_lbl" xml:lang="en-US" id="id_6895476_1285692_1_1">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Fair Value</label> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_lbl" xml:lang="en-US" id="id_6895476_1285692_2_1">Share based compensation, vested restricted stock units, grant date fair value</label> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_lbl"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US" id="id_6895476_1276353_1_1">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value</label> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US" id="id_6895476_1276353_2_1">Restricted stock units vested, Weighted Average Award Date Fair Value per Share</label> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_lbl"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" xml:lang="en-US" id="id_6895476_1273029_1_1">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate</label> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" xml:lang="en-US" id="id_6895476_1273029_2_1">Expected dividend yield</label> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" xml:lang="en-US" id="id_6895476_1273030_1_1">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term</label> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" xml:lang="en-US" id="id_6895476_1273030_2_1">Expected term in years</label> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl" xml:lang="en-US" id="id_6895476_1279587_1_1">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate</label> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl" xml:lang="en-US" id="id_6895476_1279587_2_1">Volatility</label> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl" xml:lang="en-US" id="id_6895476_1274709_1_1">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate</label> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl" xml:lang="en-US" id="id_6895476_1274709_2_1">Risk-free interest rate</label> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" xml:lang="en-US" id="id_6895476_1269692_1_1">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</label> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" xml:lang="en-US" id="id_6895476_1269692_2_1">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</label> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized"/> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_lbl" xml:lang="en-US" id="id_6895476_1274711_1_1">Share-based Compensation Arrangement by Share-based Payment Award, Number of Additional Shares Authorized</label> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_lbl" xml:lang="en-US" id="id_6895476_1274711_2_1">Increased in number of shares of common stock</label> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_lbl" xml:lang="en-US" id="id_6895476_1274711_12_1">Shares Available for Grant of Option or Award, Increase in authorized shares</label> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_lbl"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_lbl" xml:lang="en-US" id="id_6895476_1281179_1_1">Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant</label> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_lbl" xml:lang="en-US" id="id_6895476_1281179_4_1">Shares Available for Grant of Option or Award, Ending Balance</label> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_lbl" xml:lang="en-US" id="id_6895476_1281179_5_1">Shares Available for Grant of Option or Award, Beginning Balance</label> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_lbl" xml:lang="en-US" id="id_6895476_1281179_2_1">Shares available for future grants under the 1997 Plan</label> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_lbl"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl" xml:lang="en-US" id="id_6895476_1287262_1_1">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Intrinsic Value</label> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl" xml:lang="en-US" id="id_6895476_1287262_2_1">Aggregate Intrinsic Value, Exercisable at December 31, 2014</label> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl" xml:lang="en-US" id="id_6895476_1273034_1_1">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number</label> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl" xml:lang="en-US" id="id_6895476_1273034_2_1">Stock Options Outstanding, Exercisable</label> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl" xml:lang="en-US" id="id_6895476_1273035_1_1">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price</label> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl" xml:lang="en-US" id="id_6895476_1273035_2_1">Weighted Average Exercise Price per Share - Stock Options, Exercisable</label> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl" xml:lang="en-US" id="id_6895476_1277951_1_1">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term</label> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl" xml:lang="en-US" id="id_6895476_1277951_2_1">Weighted Average Remaining Contractual Life, Exercisable at December 31, 2014</label> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue"/> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_lbl" xml:lang="en-US" id="id_6895476_1288760_1_1">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value</label> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_lbl" xml:lang="en-US" id="id_6895476_1288760_2_1">Share based compensation, options exercised, total intrinsic value</label> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_lbl"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod"/> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_lbl" xml:lang="en-US" id="id_6895476_1277952_1_1">Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period</label> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_lbl" xml:lang="en-US" id="id_6895476_1277952_14_1">Stock Options Outstanding, Options forfeited/expired</label> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_lbl"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice"/> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US" id="id_6895476_1276360_1_1">Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price</label> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US" id="id_6895476_1276360_2_1">Weighted Average Exercise Price per Share - Stock Options, Options forfeited/expired</label> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_lbl"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl" xml:lang="en-US" id="id_6895476_1273037_1_1">Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period</label> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl" xml:lang="en-US" id="id_6895476_1273037_2_1">Stock Options Outstanding, Options Forfeited</label> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xml:lang="en-US" id="id_6895476_1274685_1_1">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross</label> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xml:lang="en-US" id="id_6895476_1274685_2_1">Stock option grants to non-employees</label> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xml:lang="en-US" id="id_6895476_1274685_14_1">Shares Available for Grant of Option or Award, Options granted</label> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US" id="id_6895476_1271328_1_1">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value</label> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US" id="id_6895476_1271328_2_1">Weighted-average grant date fair value of options granted</label> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl" xml:lang="en-US" id="id_6895476_1285691_1_1">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value</label> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl" xml:lang="en-US" id="id_6895476_1285691_2_1">Aggregate Intrinsic Value</label> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xml:lang="en-US" id="id_6895476_1281183_1_1">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number</label> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xml:lang="en-US" id="id_6895476_1281183_4_1">Stock Options Outstanding, Ending Balance</label> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xml:lang="en-US" id="id_6895476_1281183_5_1">Stock Options Outstanding, Beginning Balance</label> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xml:lang="en-US" id="id_6895476_1271330_1_1">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price</label> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xml:lang="en-US" id="id_6895476_1271330_4_1">Weighted Average Exercise Price per Share - Stock Options, Ending Balance</label> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xml:lang="en-US" id="id_6895476_1271330_5_1">Weighted Average Exercise Price per Share - Stock Options, Beginning Balance</label> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl" xml:lang="en-US" id="id_6895476_1276363_1_1">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term</label> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl" xml:lang="en-US" id="id_6895476_1276363_2_1">Weighted Average Remaining Contractual Life</label> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue"/> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_lbl" xml:lang="en-US" id="id_6895476_1286207_1_1">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Aggregate Intrinsic Value</label> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_lbl" xml:lang="en-US" id="id_6895476_1286207_2_1">Aggregate Intrinsic Value, Vested and expected to vest as of December 31, 2014</label> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_lbl"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber"/> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_lbl" xml:lang="en-US" id="id_6895476_1269697_1_1">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number</label> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_lbl" xml:lang="en-US" id="id_6895476_1269697_2_1">Stock Options Outstanding, Vested and expected to vest</label> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_lbl"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice"/> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_lbl" xml:lang="en-US" id="id_6895476_1277958_1_1">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price</label> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_lbl" xml:lang="en-US" id="id_6895476_1277958_2_1">Weighted Average Exercise Price per Share - Stock Options, Vested and expected to vest, Outstanding</label> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_lbl"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1"/> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_lbl" xml:lang="en-US" id="id_6895476_1269698_1_1">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term</label> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_lbl" xml:lang="en-US" id="id_6895476_1269698_2_1">Weighted Average Remaining Contractual Life, Vested and expected to vest as of December 31, 2014</label> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_lbl"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1"/> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_lbl" xml:lang="en-US" id="id_6895476_1281600_1_1">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value</label> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_lbl" xml:lang="en-US" id="id_6895476_1281600_2_1">Grant date fair value of option shares vested</label> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_lbl"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares"/> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_lbl" xml:lang="en-US" id="id_6895476_1274692_1_1">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested, Number of Shares</label> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_lbl" xml:lang="en-US" id="id_6895476_1274692_2_1">Number of option shares vested</label> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_lbl"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent"/> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_lbl" xml:lang="en-US" id="id_6895476_1274694_1_1">Share-based Compensation Arrangement by Share-based Payment Award, Purchase Price of Common Stock, Percent</label> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_lbl" xml:lang="en-US" id="id_6895476_1274694_2_1">Option grant prices as percentage of the fair market value of the common stock</label> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_lbl"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod"/> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod_lbl" xml:lang="en-US" id="id_6895476_1274695_1_1">Share-based Compensation Arrangement by Share-based Payment Award, Shares Issued in Period</label> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod_lbl" xml:lang="en-US" id="id_6895476_1274695_2_1">Stock Options Outstanding, Options granted</label> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod_lbl"/> <loc xlink:type="locator" xlink:href="cytk-20141231.xsd#cytk_ShareBasedCompensationArrangementByShareBasedPaymentSharesAvailableForGrantAwardOptionsExercisedInPeriodGross" xlink:label="cytk_ShareBasedCompensationArrangementByShareBasedPaymentSharesAvailableForGrantAwardOptionsExercisedInPeriodGross"/> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cytk_ShareBasedCompensationArrangementByShareBasedPaymentSharesAvailableForGrantAwardOptionsExercisedInPeriodGross_lbl" xml:lang="en-US" id="id_6895476_1301903_3_1">The effect of stock options exercised upon shares available for grant of options or awards. Typically, the numerical effect of options exercised upon shares available for grant is nil.</label> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cytk_ShareBasedCompensationArrangementByShareBasedPaymentSharesAvailableForGrantAwardOptionsExercisedInPeriodGross_lbl" xml:lang="en-US" id="id_6895476_1301903_1_1">Share Based Compensation Arrangement By Share Based Payment Shares Available For Grant Award Options Exercised In Period Gross</label> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cytk_ShareBasedCompensationArrangementByShareBasedPaymentSharesAvailableForGrantAwardOptionsExercisedInPeriodGross_lbl" xml:lang="en-US" id="id_6895476_1301903_2_1">Shares Available for Grant of Option or Award, Options exercised</label> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cytk_ShareBasedCompensationArrangementByShareBasedPaymentSharesAvailableForGrantAwardOptionsExercisedInPeriodGross" xlink:to="cytk_ShareBasedCompensationArrangementByShareBasedPaymentSharesAvailableForGrantAwardOptionsExercisedInPeriodGross_lbl"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_lbl" xml:lang="en-US" id="id_6895476_1274697_1_1">Equity Award [Domain]</label> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_lbl" xml:lang="en-US" id="id_6895476_1274697_2_1">Equity Award [Domain]</label> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_lbl"/> <loc xlink:type="locator" xlink:href="cytk-20141231.xsd#cytk_ShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentOtherThanOptionForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="cytk_ShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentOtherThanOptionForfeituresInPeriodWeightedAverageExercisePrice"/> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cytk_ShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentOtherThanOptionForfeituresInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US" id="id_6895476_1500336_3_1">The weighted average exercise price per share of restricted stock awards forfeited. This per share amount should always be zero as restricted stock grants are awarded to recipients on the grant date and do not have an exercise feature or an exercise price.</label> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cytk_ShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentOtherThanOptionForfeituresInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US" id="id_6895476_1500336_1_1">Share Based Compensation Arrangements By Share Based Payment Award Equity Instrument Other Than Option Forfeitures In Period Weighted Average Exercise Price</label> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cytk_ShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentOtherThanOptionForfeituresInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US" id="id_6895476_1500336_2_1">Weighted Average Exercise Price per Share - Stock Options, Restricted stock units forfeited</label> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cytk_ShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentOtherThanOptionForfeituresInPeriodWeightedAverageExercisePrice" xlink:to="cytk_ShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentOtherThanOptionForfeituresInPeriodWeightedAverageExercisePrice_lbl"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US" id="id_6895476_1269701_1_1">Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price</label> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US" id="id_6895476_1269701_2_1">Weighted Average Exercise Price per Share - Stock Options, Options exercised</label> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US" id="id_6895476_1277960_1_1">Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price</label> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US" id="id_6895476_1277960_2_1">Weighted Average Exercise Price per Share - Stock Options, Options granted</label> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl"/> <loc xlink:type="locator" xlink:href="cytk-20141231.xsd#cytk_ShareBasedCompensationLineItems" xlink:label="cytk_ShareBasedCompensationLineItems"/> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cytk_ShareBasedCompensationLineItems_lbl" xml:lang="en-US" id="id_6895476_1338457_3_1">Share Based Compensation [Line Items]</label> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cytk_ShareBasedCompensationLineItems_lbl" xml:lang="en-US" id="id_6895476_1338457_1_1">Share Based Compensation [Line Items]</label> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cytk_ShareBasedCompensationLineItems_lbl" xml:lang="en-US" id="id_6895476_1338457_2_1">Share Based Compensation [Line Items]</label> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cytk_ShareBasedCompensationLineItems" xlink:to="cytk_ShareBasedCompensationLineItems_lbl"/> <loc xlink:type="locator" xlink:href="cytk-20141231.xsd#cytk_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePrice" xlink:label="cytk_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePrice"/> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cytk_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePrice_lbl" xml:lang="en-US" id="id_6895476_1290360_3_1">Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price</label> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cytk_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePrice_lbl" xml:lang="en-US" id="id_6895476_1290360_1_1">Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price</label> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cytk_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePrice_lbl" xml:lang="en-US" id="id_6895476_1290360_2_1">Issuance of common stock upon exercise of stock options for cash per share</label> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cytk_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePrice" xlink:to="cytk_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePrice_lbl"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit"/> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_lbl" xml:lang="en-US" id="id_6895476_1277965_1_1">Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, Lower Range Limit</label> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_lbl" xml:lang="en-US" id="id_6895476_1277965_2_1">Issuance of common stock upon exercise of stock options for cash per share, lower limit</label> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_lbl"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit"/> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_lbl" xml:lang="en-US" id="id_6895476_1273047_1_1">Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, Upper Range Limit</label> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_lbl" xml:lang="en-US" id="id_6895476_1273047_2_1">Issuance of common stock upon exercise of stock options for cash per share, upper limit</label> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_lbl"/> <loc xlink:type="locator" xlink:href="cytk-20141231.xsd#cytk_ShareBasedCompensationTable" xlink:label="cytk_ShareBasedCompensationTable"/> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cytk_ShareBasedCompensationTable_lbl" xml:lang="en-US" id="id_6895476_1409911_3_1">Share Based Compensation [Table]</label> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cytk_ShareBasedCompensationTable_lbl" xml:lang="en-US" id="id_6895476_1409911_1_1">Share Based Compensation [Table]</label> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cytk_ShareBasedCompensationTable_lbl" xml:lang="en-US" id="id_6895476_1409911_2_1">Share Based Compensation [Table]</label> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cytk_ShareBasedCompensationTable" xlink:to="cytk_ShareBasedCompensationTable_lbl"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SharePrice" xlink:label="us-gaap_SharePrice"/> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharePrice_lbl" xml:lang="en-US" id="id_6895476_1273051_1_1">Share Price</label> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/positiveLabel" xlink:label="us-gaap_SharePrice_lbl" xml:lang="en-US" id="id_6895476_1273051_32_1">Per share price of common stock</label> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharePrice_lbl" xml:lang="en-US" id="id_6895476_1273051_2_1">Convertible preferred stock, purchase price</label> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_SharePrice_lbl" xml:lang="en-US" id="id_6895476_1273051_12_1">Issuance of common stock at per share</label> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharePrice" xlink:to="us-gaap_SharePrice_lbl"/> <loc xlink:type="locator" xlink:href="cytk-20141231.xsd#cytk_SharesAvailableForGrantOfOptionsOrAwardsOptionsForfeitedExpired" xlink:label="cytk_SharesAvailableForGrantOfOptionsOrAwardsOptionsForfeitedExpired"/> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cytk_SharesAvailableForGrantOfOptionsOrAwardsOptionsForfeitedExpired_lbl" xml:lang="en-US" id="id_6895476_1363229_3_1">The effect of stock options forfeited or expired upon shares available for grant of options or awards. Typically, shares available for grant will increase to the extent that outstanding options are forfeited or expire.</label> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cytk_SharesAvailableForGrantOfOptionsOrAwardsOptionsForfeitedExpired_lbl" xml:lang="en-US" id="id_6895476_1363229_1_1">Shares Available For Grant Of Options Or Awards Options Forfeited Expired</label> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cytk_SharesAvailableForGrantOfOptionsOrAwardsOptionsForfeitedExpired_lbl" xml:lang="en-US" id="id_6895476_1363229_2_1">Shares Available for Grant of Option or Award, Options forfeited/expired</label> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cytk_SharesAvailableForGrantOfOptionsOrAwardsOptionsForfeitedExpired" xlink:to="cytk_SharesAvailableForGrantOfOptionsOrAwardsOptionsForfeitedExpired_lbl"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding"/> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharesOutstanding_lbl" xml:lang="en-US" id="id_6895476_1279581_1_1">Shares, Outstanding</label> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_SharesOutstanding_lbl" xml:lang="en-US" id="id_6895476_1279581_4_1">Ending Balance, shares</label> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_SharesOutstanding_lbl" xml:lang="en-US" id="id_6895476_1279581_5_1">Beginning Balance, shares</label> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesOutstanding" xlink:to="us-gaap_SharesOutstanding_lbl"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShortTermInvestmentsMember" xlink:label="us-gaap_ShortTermInvestmentsMember"/> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShortTermInvestmentsMember_lbl" xml:lang="en-US" id="id_6895476_1276380_1_1">Short-term Investments [Member]</label> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShortTermInvestmentsMember_lbl" xml:lang="en-US" id="id_6895476_1276380_2_1">Short-term Investments [Member]</label> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShortTermInvestmentsMember" xlink:to="us-gaap_ShortTermInvestmentsMember_lbl"/> <loc xlink:type="locator" xlink:href="cytk-20141231.xsd#cytk_SmaAndOtherNeuromuscularIndicationsMember" xlink:label="cytk_SmaAndOtherNeuromuscularIndicationsMember"/> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cytk_SmaAndOtherNeuromuscularIndicationsMember_lbl" xml:lang="en-US" id="id_6895476_1621939_3_1">SMA and other neuromuscular indications [Member]</label> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cytk_SmaAndOtherNeuromuscularIndicationsMember_lbl" xml:lang="en-US" id="id_6895476_1621939_1_1">SMA and Other Neuromuscular Indications [Member]</label> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cytk_SmaAndOtherNeuromuscularIndicationsMember_lbl" xml:lang="en-US" id="id_6895476_1621939_2_1">SMA and Other Neuromuscular Indications [Member]</label> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cytk_SmaAndOtherNeuromuscularIndicationsMember" xlink:to="cytk_SmaAndOtherNeuromuscularIndicationsMember_lbl"/> <loc xlink:type="locator" xlink:href="cytk-20141231.xsd#cytk_SoftDollarArrangementsAbstract" xlink:label="cytk_SoftDollarArrangementsAbstract"/> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cytk_SoftDollarArrangementsAbstract_lbl" xml:lang="en-US" id="id_6895476_1423225_3_1">Soft dollar arrangements [Abstract]</label> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cytk_SoftDollarArrangementsAbstract_lbl" xml:lang="en-US" id="id_6895476_1423225_1_1">Soft Dollar Arrangements [Abstract]</label> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cytk_SoftDollarArrangementsAbstract_lbl" xml:lang="en-US" id="id_6895476_1423225_2_1">Soft Dollar Arrangements [Abstract]</label> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cytk_SoftDollarArrangementsAbstract" xlink:to="cytk_SoftDollarArrangementsAbstract_lbl"/> <loc xlink:type="locator" xlink:href="cytk-20141231.xsd#cytk_SpecifiedStockholderOwnershipPercentage" xlink:label="cytk_SpecifiedStockholderOwnershipPercentage"/> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cytk_SpecifiedStockholderOwnershipPercentage_lbl" xml:lang="en-US" id="id_6895476_1409375_3_1">The minimum ownership percentage, with respect to all common stock issued and outstanding, that will trigger limitations upon terms of stock option grants.</label> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cytk_SpecifiedStockholderOwnershipPercentage_lbl" xml:lang="en-US" id="id_6895476_1409375_1_1">Specified Stockholder Ownership Percentage</label> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cytk_SpecifiedStockholderOwnershipPercentage_lbl" xml:lang="en-US" id="id_6895476_1409375_2_1">Percentage of stockholder</label> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cytk_SpecifiedStockholderOwnershipPercentage" xlink:to="cytk_SpecifiedStockholderOwnershipPercentage_lbl"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StateAndLocalJurisdictionMember" xlink:label="us-gaap_StateAndLocalJurisdictionMember"/> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StateAndLocalJurisdictionMember_lbl" xml:lang="en-US" id="id_6895476_1276398_1_1">State and Local Jurisdiction [Member]</label> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StateAndLocalJurisdictionMember_lbl" xml:lang="en-US" id="id_6895476_1276398_2_1">Federal and State Tax [Member]</label> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StateAndLocalJurisdictionMember" xlink:to="us-gaap_StateAndLocalJurisdictionMember_lbl"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementClassOfStockAxis_lbl" xml:lang="en-US" id="id_6895476_1276400_1_1">Class of Stock [Axis]</label> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StatementClassOfStockAxis_lbl" xml:lang="en-US" id="id_6895476_1276400_2_1">Class of Stock [Axis]</label> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_StatementClassOfStockAxis_lbl"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementEquityComponentsAxis_lbl" xml:lang="en-US" id="id_6895476_1276401_1_1">Equity Components [Axis]</label> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StatementEquityComponentsAxis_lbl" xml:lang="en-US" id="id_6895476_1276401_2_1">Equity Components [Axis]</label> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_StatementEquityComponentsAxis_lbl"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementGeographicalAxis" xlink:label="us-gaap_StatementGeographicalAxis"/> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementGeographicalAxis_lbl" xml:lang="en-US" id="id_6895476_1273333_1_1">Geographical [Axis]</label> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StatementGeographicalAxis_lbl" xml:lang="en-US" id="id_6895476_1273333_2_1">Geographical [Axis]</label> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementGeographicalAxis" xlink:to="us-gaap_StatementGeographicalAxis_lbl"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementLineItems_lbl" xml:lang="en-US" id="id_6895476_1279599_1_1">Statement [Line Items]</label> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StatementLineItems_lbl" xml:lang="en-US" id="id_6895476_1279599_2_1">Statement [Line Items]</label> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementLineItems_lbl"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="us-gaap_StatementOfCashFlowsAbstract"/> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfCashFlowsAbstract_lbl" xml:lang="en-US" id="id_6895476_1281214_1_1">Statement of Cash Flows [Abstract]</label> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StatementOfCashFlowsAbstract_lbl" xml:lang="en-US" id="id_6895476_1281214_2_1">Statement of Cash Flows [Abstract]</label> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_StatementOfCashFlowsAbstract_lbl"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract"/> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfFinancialPositionAbstract_lbl" xml:lang="en-US" id="id_6895476_1271363_1_1">Statement of Financial Position [Abstract]</label> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StatementOfFinancialPositionAbstract_lbl" xml:lang="en-US" id="id_6895476_1271363_2_1">Statement of Financial Position [Abstract]</label> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StatementOfFinancialPositionAbstract_lbl"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract"/> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract_lbl" xml:lang="en-US" id="id_6895476_1281215_1_1">Statement of Stockholders' Equity [Abstract]</label> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract_lbl" xml:lang="en-US" id="id_6895476_1281215_2_1">Statement of Stockholders' Equity [Abstract]</label> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_StatementOfStockholdersEquityAbstract_lbl"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementTable_lbl" xml:lang="en-US" id="id_6895476_1274733_1_1">Statement [Table]</label> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StatementTable_lbl" xml:lang="en-US" id="id_6895476_1274733_2_1">Statement [Table]</label> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementTable_lbl"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity"/> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquity_lbl" xml:lang="en-US" id="id_6895476_1283431_1_1">Stockholders' Equity Attributable to Parent</label> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_StockholdersEquity_lbl" xml:lang="en-US" id="id_6895476_1283431_4_1">Ending Balance</label> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_StockholdersEquity_lbl" xml:lang="en-US" id="id_6895476_1283431_5_1">Beginning Balance</label> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_StockholdersEquity_lbl" xml:lang="en-US" id="id_6895476_1283431_6_1">Total stockholders' equity</label> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_lbl"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="us-gaap_StockholdersEquityAbstract"/> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityAbstract_lbl" xml:lang="en-US" id="id_6895476_1276413_1_1">Stockholders' Equity Attributable to Parent [Abstract]</label> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockholdersEquityAbstract_lbl" xml:lang="en-US" id="id_6895476_1276413_2_1">Stockholders' equity:</label> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract_lbl"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockholdersEquityNoteChangesInCapitalStructureSubsequentChangesToNumberOfCommonShares" xlink:label="us-gaap_StockholdersEquityNoteChangesInCapitalStructureSubsequentChangesToNumberOfCommonShares"/> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityNoteChangesInCapitalStructureSubsequentChangesToNumberOfCommonShares_lbl" xml:lang="en-US" id="id_6895476_1271366_1_1">Stockholders' Equity Note, Changes in Capital Structure, Subsequent Changes to Number of Common Shares</label> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockholdersEquityNoteChangesInCapitalStructureSubsequentChangesToNumberOfCommonShares_lbl" xml:lang="en-US" id="id_6895476_1271366_2_1">Preferred stock after stock split</label> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityNoteChangesInCapitalStructureSubsequentChangesToNumberOfCommonShares" xlink:to="us-gaap_StockholdersEquityNoteChangesInCapitalStructureSubsequentChangesToNumberOfCommonShares_lbl"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock"/> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" xml:lang="en-US" id="id_6895476_1276414_1_1">Stockholders' Equity Note Disclosure [Text Block]</label> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" xml:lang="en-US" id="id_6895476_1276414_2_1">Stockholders' Equity</label> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockholdersEquityNoteStockSplit" xlink:label="us-gaap_StockholdersEquityNoteStockSplit"/> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityNoteStockSplit_lbl" xml:lang="en-US" id="id_6895476_1273336_1_1">Stockholders' Equity Note, Stock Split</label> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockholdersEquityNoteStockSplit_lbl" xml:lang="en-US" id="id_6895476_1273336_2_1">Stock split description</label> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityNoteStockSplit" xlink:to="us-gaap_StockholdersEquityNoteStockSplit_lbl"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:label="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1"/> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_lbl" xml:lang="en-US" id="id_6895476_1273337_1_1">Stockholders' Equity Note, Stock Split, Conversion Ratio</label> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_lbl" xml:lang="en-US" id="id_6895476_1273337_2_1">Reverse stock split, conversion ratio</label> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:to="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_lbl"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockholdersEquityReverseStockSplit" xlink:label="us-gaap_StockholdersEquityReverseStockSplit"/> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityReverseStockSplit_lbl" xml:lang="en-US" id="id_6895476_1273339_1_1">Stockholders' Equity, Reverse Stock Split</label> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockholdersEquityReverseStockSplit_lbl" xml:lang="en-US" id="id_6895476_1273339_2_1">Reverse stock split, description</label> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityReverseStockSplit" xlink:to="us-gaap_StockholdersEquityReverseStockSplit_lbl"/> <loc xlink:type="locator" xlink:href="cytk-20141231.xsd#cytk_StockIssuedDuringPeriodSharesAtMarketIssuanceSalesAgreement" xlink:label="cytk_StockIssuedDuringPeriodSharesAtMarketIssuanceSalesAgreement"/> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cytk_StockIssuedDuringPeriodSharesAtMarketIssuanceSalesAgreement_lbl" xml:lang="en-US" id="id_6895476_1484583_3_1">Shares of common stock issued during the period relating to at-the-market issuance sales agreements</label> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cytk_StockIssuedDuringPeriodSharesAtMarketIssuanceSalesAgreement_lbl" xml:lang="en-US" id="id_6895476_1484583_1_1">Stock Issued During Period Shares At Market Issuance Sales Agreement</label> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cytk_StockIssuedDuringPeriodSharesAtMarketIssuanceSalesAgreement_lbl" xml:lang="en-US" id="id_6895476_1484583_2_1">Issuance of common stock to MLV, shares</label> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cytk_StockIssuedDuringPeriodSharesAtMarketIssuanceSalesAgreement" xlink:to="cytk_StockIssuedDuringPeriodSharesAtMarketIssuanceSalesAgreement_lbl"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities"/> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_lbl" xml:lang="en-US" id="id_6895476_1279601_1_1">Stock Issued During Period, Shares, Conversion of Convertible Securities</label> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_lbl" xml:lang="en-US" id="id_6895476_1279601_2_1">Conversion of convertible preferred stock to common stock at $1,000 per share</label> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:to="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_lbl"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:label="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans"/> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_lbl" xml:lang="en-US" id="id_6895476_1274738_1_1">Stock Issued During Period, Shares, Employee Stock Purchase Plans</label> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_lbl" xml:lang="en-US" id="id_6895476_1274738_2_1">Common stock shares issued</label> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_lbl" xml:lang="en-US" id="id_6895476_1274738_12_1">Issuance of common stock pursuant to ESPP, shares</label> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:to="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_lbl"/> <loc xlink:type="locator" xlink:href="cytk-20141231.xsd#cytk_StockIssuedDuringPeriodSharesExerciseOfWarrants" xlink:label="cytk_StockIssuedDuringPeriodSharesExerciseOfWarrants"/> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cytk_StockIssuedDuringPeriodSharesExerciseOfWarrants_lbl" xml:lang="en-US" id="id_6895476_1436764_3_1">Shares of common stock issued upon cashless exercises of warrants.</label> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cytk_StockIssuedDuringPeriodSharesExerciseOfWarrants_lbl" xml:lang="en-US" id="id_6895476_1436764_1_1">Stock Issued During Period Shares Exercise Of Warrants</label> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cytk_StockIssuedDuringPeriodSharesExerciseOfWarrants_lbl" xml:lang="en-US" id="id_6895476_1436764_2_1">Issuance of common stock upon exercise of warrants, shares</label> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cytk_StockIssuedDuringPeriodSharesExerciseOfWarrants" xlink:to="cytk_StockIssuedDuringPeriodSharesExerciseOfWarrants_lbl"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues"/> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xml:lang="en-US" id="id_6895476_1274739_1_1">Stock Issued During Period, Shares, New Issues</label> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xml:lang="en-US" id="id_6895476_1274739_2_1">Convertible preferred stock, issued shares</label> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl"/> <loc xlink:type="locator" xlink:href="cytk-20141231.xsd#cytk_StockIssuedDuringPeriodSharesNewIssuesToCollaborativePartner" xlink:label="cytk_StockIssuedDuringPeriodSharesNewIssuesToCollaborativePartner"/> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cytk_StockIssuedDuringPeriodSharesNewIssuesToCollaborativePartner_lbl" xml:lang="en-US" id="id_6895476_1614457_3_1">Stock Issued During Period Shares New Issues To Collaborative Partner</label> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cytk_StockIssuedDuringPeriodSharesNewIssuesToCollaborativePartner_lbl" xml:lang="en-US" id="id_6895476_1614457_1_1">Stock Issued During Period Shares New Issues To Collaborative Partner</label> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cytk_StockIssuedDuringPeriodSharesNewIssuesToCollaborativePartner_lbl" xml:lang="en-US" id="id_6895476_1614457_2_1">Issuance of common stock to collaborative partner, shares</label> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cytk_StockIssuedDuringPeriodSharesNewIssuesToCollaborativePartner" xlink:to="cytk_StockIssuedDuringPeriodSharesNewIssuesToCollaborativePartner_lbl"/> <loc xlink:type="locator" xlink:href="cytk-20141231.xsd#cytk_StockIssuedDuringPeriodSharesNewIssuesToRelatedParty" xlink:label="cytk_StockIssuedDuringPeriodSharesNewIssuesToRelatedParty"/> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cytk_StockIssuedDuringPeriodSharesNewIssuesToRelatedParty_lbl" xml:lang="en-US" id="id_6895476_1530796_3_1">Stock issued during period shares new issues to related party.</label> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cytk_StockIssuedDuringPeriodSharesNewIssuesToRelatedParty_lbl" xml:lang="en-US" id="id_6895476_1530796_1_1">Stock Issued During Period Shares New Issues To Related Party</label> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cytk_StockIssuedDuringPeriodSharesNewIssuesToRelatedParty_lbl" xml:lang="en-US" id="id_6895476_1530796_2_1">Issuance of common stock to related party, shares</label> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cytk_StockIssuedDuringPeriodSharesNewIssuesToRelatedParty" xlink:to="cytk_StockIssuedDuringPeriodSharesNewIssuesToRelatedParty_lbl"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:label="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures"/> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_lbl" xml:lang="en-US" id="id_6895476_1281223_1_1">Stock Issued During Period, Shares, Restricted Stock Award, Net of Forfeitures</label> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_lbl" xml:lang="en-US" id="id_6895476_1281223_2_1">Issuance of common stock upon exercise of restricted stock units, shares</label> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:to="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_lbl"/> <loc xlink:type="locator" xlink:href="cytk-20141231.xsd#cytk_StockIssuedDuringPeriodSharesSecuritiesPurchaseAgreement" xlink:label="cytk_StockIssuedDuringPeriodSharesSecuritiesPurchaseAgreement"/> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cytk_StockIssuedDuringPeriodSharesSecuritiesPurchaseAgreement_lbl" xml:lang="en-US" id="id_6895476_1399732_3_1">Shares of common stock issued during period pursuant to securities purchase agreements.</label> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cytk_StockIssuedDuringPeriodSharesSecuritiesPurchaseAgreement_lbl" xml:lang="en-US" id="id_6895476_1399732_1_1">Stock Issued During Period Shares Securities Purchase Agreement</label> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cytk_StockIssuedDuringPeriodSharesSecuritiesPurchaseAgreement_lbl" xml:lang="en-US" id="id_6895476_1399732_2_1">Issuance of common stock, shares</label> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cytk_StockIssuedDuringPeriodSharesSecuritiesPurchaseAgreement" xlink:to="cytk_StockIssuedDuringPeriodSharesSecuritiesPurchaseAgreement_lbl"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xml:lang="en-US" id="id_6895476_1281224_1_1">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period</label> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xml:lang="en-US" id="id_6895476_1281224_2_1">Issuance of common stock upon exercise of stock options for cash, shares</label> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xml:lang="en-US" id="id_6895476_1281224_14_1">Stock Options Outstanding, Options exercised</label> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl"/> <loc xlink:type="locator" xlink:href="cytk-20141231.xsd#cytk_StockIssuedDuringPeriodValueAtMarketIssuanceSalesAgreement" xlink:label="cytk_StockIssuedDuringPeriodValueAtMarketIssuanceSalesAgreement"/> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cytk_StockIssuedDuringPeriodValueAtMarketIssuanceSalesAgreement_lbl" xml:lang="en-US" id="id_6895476_1516788_3_1">Value of common stock issued during the period relating to at-the-market issuance sales agreements.</label> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cytk_StockIssuedDuringPeriodValueAtMarketIssuanceSalesAgreement_lbl" xml:lang="en-US" id="id_6895476_1516788_1_1">Stock Issued During Period Value At Market Issuance Sales Agreement</label> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cytk_StockIssuedDuringPeriodValueAtMarketIssuanceSalesAgreement_lbl" xml:lang="en-US" id="id_6895476_1516788_2_1">Issuance of common stock to MLV at $6.30-$7.20, $6.50-$6.79 and $6.64-$6.79 per share, net of commission and issuance costs of $89, $232 and $74</label> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cytk_StockIssuedDuringPeriodValueAtMarketIssuanceSalesAgreement" xlink:to="cytk_StockIssuedDuringPeriodValueAtMarketIssuanceSalesAgreement_lbl"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities"/> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_lbl" xml:lang="en-US" id="id_6895476_1284348_1_1">Stock Issued During Period, Value, Conversion of Convertible Securities</label> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_lbl" xml:lang="en-US" id="id_6895476_1284348_2_1">Conversion of preferred stock to common stock, value</label> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:to="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_lbl"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:label="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan"/> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_lbl" xml:lang="en-US" id="id_6895476_1283000_1_1">Stock Issued During Period, Value, Employee Stock Purchase Plan</label> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_lbl" xml:lang="en-US" id="id_6895476_1283000_2_1">Issuance of common stock pursuant to ESPP at a weighted price of $4.32, $3.66 and $3.38 per share in 2012, 2013 and 2014 respectively</label> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:to="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_lbl"/> <loc xlink:type="locator" xlink:href="cytk-20141231.xsd#cytk_StockIssuedDuringPeriodValueExerciseOfWarrants" xlink:label="cytk_StockIssuedDuringPeriodValueExerciseOfWarrants"/> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cytk_StockIssuedDuringPeriodValueExerciseOfWarrants_lbl" xml:lang="en-US" id="id_6895476_1454389_3_1">Stock Issued During Period Value Exercise Of Warrants</label> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cytk_StockIssuedDuringPeriodValueExerciseOfWarrants_lbl" xml:lang="en-US" id="id_6895476_1454389_1_1">Stock Issued During Period Value Exercise Of Warrants</label> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cytk_StockIssuedDuringPeriodValueExerciseOfWarrants_lbl" xml:lang="en-US" id="id_6895476_1454389_2_1">Issuance of common stock upon exercise of warrants, value</label> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cytk_StockIssuedDuringPeriodValueExerciseOfWarrants" xlink:to="cytk_StockIssuedDuringPeriodValueExerciseOfWarrants_lbl"/> <loc xlink:type="locator" xlink:href="cytk-20141231.xsd#cytk_StockIssuedDuringPeriodValueNewIssuesToCollaborativePartner" xlink:label="cytk_StockIssuedDuringPeriodValueNewIssuesToCollaborativePartner"/> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cytk_StockIssuedDuringPeriodValueNewIssuesToCollaborativePartner_lbl" xml:lang="en-US" id="id_6895476_1614455_3_1">Stock Issued During Period Value New Issues To Collaborative Partner</label> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cytk_StockIssuedDuringPeriodValueNewIssuesToCollaborativePartner_lbl" xml:lang="en-US" id="id_6895476_1614455_1_1">Stock Issued During Period Value New Issues To Collaborative Partner</label> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cytk_StockIssuedDuringPeriodValueNewIssuesToCollaborativePartner_lbl" xml:lang="en-US" id="id_6895476_1614455_2_1">Issuance of common stock to collaborative partner for $4.90 per share, net of issuance costs of $8</label> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cytk_StockIssuedDuringPeriodValueNewIssuesToCollaborativePartner" xlink:to="cytk_StockIssuedDuringPeriodValueNewIssuesToCollaborativePartner_lbl"/> <loc xlink:type="locator" xlink:href="cytk-20141231.xsd#cytk_StockIssuedDuringPeriodValueNewIssuesToRelatedParty" xlink:label="cytk_StockIssuedDuringPeriodValueNewIssuesToRelatedParty"/> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cytk_StockIssuedDuringPeriodValueNewIssuesToRelatedParty_lbl" xml:lang="en-US" id="id_6895476_1306121_3_1">Stock issued during period value new issues to related party.</label> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cytk_StockIssuedDuringPeriodValueNewIssuesToRelatedParty_lbl" xml:lang="en-US" id="id_6895476_1306121_1_1">Stock Issued During Period Value New Issues To Related Party</label> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cytk_StockIssuedDuringPeriodValueNewIssuesToRelatedParty_lbl" xml:lang="en-US" id="id_6895476_1306121_2_1">Issuance of common stock to related party for $7.12 per share, net of issuance costs of $21</label> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cytk_StockIssuedDuringPeriodValueNewIssuesToRelatedParty" xlink:to="cytk_StockIssuedDuringPeriodValueNewIssuesToRelatedParty_lbl"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" xlink:label="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures"/> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures_lbl" xml:lang="en-US" id="id_6895476_1281593_1_1">Stock Issued During Period, Value, Restricted Stock Award, Net of Forfeitures</label> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures_lbl" xml:lang="en-US" id="id_6895476_1281593_2_1">Issuance of common stock upon exercise of restricted stock units, value</label> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" xlink:to="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures_lbl"/> <loc xlink:type="locator" xlink:href="cytk-20141231.xsd#cytk_StockIssuedDuringPeriodValueSecuritiesPurchaseAgreement" xlink:label="cytk_StockIssuedDuringPeriodValueSecuritiesPurchaseAgreement"/> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cytk_StockIssuedDuringPeriodValueSecuritiesPurchaseAgreement_lbl" xml:lang="en-US" id="id_6895476_1333757_3_1">Value of common stock issued during period pursuant to securities purchase agreements.</label> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cytk_StockIssuedDuringPeriodValueSecuritiesPurchaseAgreement_lbl" xml:lang="en-US" id="id_6895476_1333757_1_1">Stock Issued During Period Value Securities Purchase Agreement</label> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cytk_StockIssuedDuringPeriodValueSecuritiesPurchaseAgreement_lbl" xml:lang="en-US" id="id_6895476_1333757_2_1">Issuance of common stock pursuant to June 2012 and February 2014 public offerings at $4.56 and $8.00 per share, net of issuance costs of $2,139 and $2,800 respectively</label> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cytk_StockIssuedDuringPeriodValueSecuritiesPurchaseAgreement" xlink:to="cytk_StockIssuedDuringPeriodValueSecuritiesPurchaseAgreement_lbl"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_lbl" xml:lang="en-US" id="id_6895476_1283001_1_1">Stock Issued During Period, Value, Stock Options Exercised</label> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_lbl" xml:lang="en-US" id="id_6895476_1283001_2_1">Issuance of common stock upon exercise of stock options for cash at $4.02-$11.10 and $6.00 per share in 2013 and 2014 respectively</label> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_lbl"/> <loc xlink:type="locator" xlink:href="cytk-20141231.xsd#cytk_StockOptionsRepurchaseMaximumPeriod" xlink:label="cytk_StockOptionsRepurchaseMaximumPeriod"/> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cytk_StockOptionsRepurchaseMaximumPeriod_lbl" xml:lang="en-US" id="id_6895476_1552025_3_1">Maximum period during which stock options may be repurchased by the entity.</label> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cytk_StockOptionsRepurchaseMaximumPeriod_lbl" xml:lang="en-US" id="id_6895476_1552025_1_1">Stock Options Repurchase Maximum Period</label> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cytk_StockOptionsRepurchaseMaximumPeriod_lbl" xml:lang="en-US" id="id_6895476_1552025_2_1">Stock option repurchase maximum period</label> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cytk_StockOptionsRepurchaseMaximumPeriod" xlink:to="cytk_StockOptionsRepurchaseMaximumPeriod_lbl"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember"/> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventMember_lbl" xml:lang="en-US" id="id_6895476_1273350_1_1">Subsequent Event [Member]</label> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SubsequentEventMember_lbl" xml:lang="en-US" id="id_6895476_1273350_2_1">Subsequent Events [Member]</label> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventMember" xlink:to="us-gaap_SubsequentEventMember_lbl"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis"/> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventTypeAxis_lbl" xml:lang="en-US" id="id_6895476_1271378_1_1">Subsequent Event Type [Axis]</label> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SubsequentEventTypeAxis_lbl" xml:lang="en-US" id="id_6895476_1271378_2_1">Subsequent Event Type [Axis]</label> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeAxis_lbl"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain"/> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventTypeDomain_lbl" xml:lang="en-US" id="id_6895476_1276407_1_1">Subsequent Event Type [Domain]</label> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SubsequentEventTypeDomain_lbl" xml:lang="en-US" id="id_6895476_1276407_2_1">Subsequent Event Type [Domain]</label> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventTypeDomain_lbl"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis"/> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsidiarySaleOfStockAxis_lbl" xml:lang="en-US" id="id_6895476_1271382_1_1">Sale of Stock [Axis]</label> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SubsidiarySaleOfStockAxis_lbl" xml:lang="en-US" id="id_6895476_1271382_2_1">Sale of Stock [Axis]</label> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SubsidiarySaleOfStockAxis_lbl"/> <loc xlink:type="locator" xlink:href="cytk-20141231.xsd#cytk_SummaryOfSignificantAccountingPoliciesLineItems" xlink:label="cytk_SummaryOfSignificantAccountingPoliciesLineItems"/> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cytk_SummaryOfSignificantAccountingPoliciesLineItems_lbl" xml:lang="en-US" id="id_6895476_1556063_3_1">Summary Of Significant Accounting Policies [Line Items]</label> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cytk_SummaryOfSignificantAccountingPoliciesLineItems_lbl" xml:lang="en-US" id="id_6895476_1556063_1_1">Summary Of Significant Accounting Policies [Line Items]</label> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cytk_SummaryOfSignificantAccountingPoliciesLineItems_lbl" xml:lang="en-US" id="id_6895476_1556063_2_1">Summary Of Significant Accounting Policies [Line Items]</label> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cytk_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="cytk_SummaryOfSignificantAccountingPoliciesLineItems_lbl"/> <loc xlink:type="locator" xlink:href="cytk-20141231.xsd#cytk_SummaryOfSignificantAccountingPoliciesTable" xlink:label="cytk_SummaryOfSignificantAccountingPoliciesTable"/> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cytk_SummaryOfSignificantAccountingPoliciesTable_lbl" xml:lang="en-US" id="id_6895476_1394184_3_1">Summary Of Significant Accounting Policies [Table]</label> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cytk_SummaryOfSignificantAccountingPoliciesTable_lbl" xml:lang="en-US" id="id_6895476_1394184_1_1">Summary Of Significant Accounting Policies [Table]</label> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cytk_SummaryOfSignificantAccountingPoliciesTable_lbl" xml:lang="en-US" id="id_6895476_1394184_2_1">Summary Of Significant Accounting Policies [Table]</label> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cytk_SummaryOfSignificantAccountingPoliciesTable" xlink:to="cytk_SummaryOfSignificantAccountingPoliciesTable_lbl"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SummaryOfValuationAllowanceTextBlock" xlink:label="us-gaap_SummaryOfValuationAllowanceTextBlock"/> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SummaryOfValuationAllowanceTextBlock_lbl" xml:lang="en-US" id="id_6895476_1271384_1_1">Summary of Valuation Allowance [Table Text Block]</label> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SummaryOfValuationAllowanceTextBlock_lbl" xml:lang="en-US" id="id_6895476_1271384_2_1">Company's Valuation and Qualifying Accounts</label> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SummaryOfValuationAllowanceTextBlock" xlink:to="us-gaap_SummaryOfValuationAllowanceTextBlock_lbl"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SupplementalBalanceSheetDisclosuresTextBlock" xlink:label="us-gaap_SupplementalBalanceSheetDisclosuresTextBlock"/> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SupplementalBalanceSheetDisclosuresTextBlock_lbl" xml:lang="en-US" id="id_6895476_1278021_1_1">Supplemental Balance Sheet Disclosures [Text Block]</label> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SupplementalBalanceSheetDisclosuresTextBlock_lbl" xml:lang="en-US" id="id_6895476_1278021_2_1">Balance Sheet Components</label> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SupplementalBalanceSheetDisclosuresTextBlock" xlink:to="us-gaap_SupplementalBalanceSheetDisclosuresTextBlock_lbl"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SupplementalCashFlowElementsAbstract" xlink:label="us-gaap_SupplementalCashFlowElementsAbstract"/> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SupplementalCashFlowElementsAbstract_lbl" xml:lang="en-US" id="id_6895476_1281237_1_1">Supplemental Cash Flow Elements [Abstract]</label> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SupplementalCashFlowElementsAbstract_lbl" xml:lang="en-US" id="id_6895476_1281237_2_1">Supplemental Cash Flow Elements [Abstract]</label> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SupplementalCashFlowElementsAbstract" xlink:to="us-gaap_SupplementalCashFlowElementsAbstract_lbl"/> <loc xlink:type="locator" xlink:href="cytk-20141231.xsd#cytk_TermForStockOptionPlan" xlink:label="cytk_TermForStockOptionPlan"/> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cytk_TermForStockOptionPlan_lbl" xml:lang="en-US" id="id_6895476_1456806_3_1">The maximum contractual term of stock option grants.</label> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cytk_TermForStockOptionPlan_lbl" xml:lang="en-US" id="id_6895476_1456806_1_1">Term For Stock Option Plan</label> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cytk_TermForStockOptionPlan_lbl" xml:lang="en-US" id="id_6895476_1456806_2_1">Term for stock option Plan</label> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cytk_TermForStockOptionPlan" xlink:to="cytk_TermForStockOptionPlan_lbl"/> <loc xlink:type="locator" xlink:href="cytk-20141231.xsd#cytk_TermForStockOptionPlanForSpecifiedStockHolders" xlink:label="cytk_TermForStockOptionPlanForSpecifiedStockHolders"/> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cytk_TermForStockOptionPlanForSpecifiedStockHolders_lbl" xml:lang="en-US" id="id_6895476_1376322_3_1">The maximum contractual term of stock option grants awarded to 10% stockholders.</label> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cytk_TermForStockOptionPlanForSpecifiedStockHolders_lbl" xml:lang="en-US" id="id_6895476_1376322_1_1">Term For Stock Option Plan For Specified Stock Holders</label> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cytk_TermForStockOptionPlanForSpecifiedStockHolders_lbl" xml:lang="en-US" id="id_6895476_1376322_2_1">Term of grant</label> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cytk_TermForStockOptionPlanForSpecifiedStockHolders" xlink:to="cytk_TermForStockOptionPlanForSpecifiedStockHolders_lbl"/> <loc xlink:type="locator" xlink:href="cytk-20141231.xsd#cytk_TermToGrantNonstatutoryStockOptionsAndIncentiveStockOptions" xlink:label="cytk_TermToGrantNonstatutoryStockOptionsAndIncentiveStockOptions"/> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cytk_TermToGrantNonstatutoryStockOptionsAndIncentiveStockOptions_lbl" xml:lang="en-US" id="id_6895476_1299207_3_1">The maximum contractual term of stock option grants.</label> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cytk_TermToGrantNonstatutoryStockOptionsAndIncentiveStockOptions_lbl" xml:lang="en-US" id="id_6895476_1299207_1_1">Term To Grant Nonstatutory Stock Options And Incentive Stock Options</label> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cytk_TermToGrantNonstatutoryStockOptionsAndIncentiveStockOptions_lbl" xml:lang="en-US" id="id_6895476_1299207_2_1">Term to grant nonstatutory stock options and incentive stock options</label> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cytk_TermToGrantNonstatutoryStockOptionsAndIncentiveStockOptions" xlink:to="cytk_TermToGrantNonstatutoryStockOptionsAndIncentiveStockOptions_lbl"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_TitleOfIndividualAxis" xlink:label="us-gaap_TitleOfIndividualAxis"/> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TitleOfIndividualAxis_lbl" xml:lang="en-US" id="id_6895476_1273383_1_1">Title of Individual [Axis]</label> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_TitleOfIndividualAxis_lbl" xml:lang="en-US" id="id_6895476_1273383_2_1">Title of Individual [Axis]</label> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TitleOfIndividualAxis" xlink:to="us-gaap_TitleOfIndividualAxis_lbl"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="us-gaap_TitleOfIndividualWithRelationshipToEntityDomain"/> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_lbl" xml:lang="en-US" id="id_6895476_1276433_1_1">Relationship to Entity [Domain]</label> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_lbl" xml:lang="en-US" id="id_6895476_1276433_2_1">Relationship to Entity [Domain]</label> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_lbl"/> <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol"/> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_TradingSymbol_lbl" xml:lang="en-US" id="id_6895476_1269880_1_1">Trading Symbol</label> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_TradingSymbol_lbl" xml:lang="en-US" id="id_6895476_1269880_2_1">Trading Symbol</label> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_lbl" xml:lang="en-US" id="id_6895476_1279916_1_1">Financial Instruments [Domain]</label> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_lbl" xml:lang="en-US" id="id_6895476_1279916_2_1">Financial Instruments [Domain]</label> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_lbl"/> <loc xlink:type="locator" xlink:href="cytk-20141231.xsd#cytk_TwoThousandAndFourPlanMember" xlink:label="cytk_TwoThousandAndFourPlanMember"/> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cytk_TwoThousandAndFourPlanMember_lbl" xml:lang="en-US" id="id_6895476_1403278_3_1">Two thousand and four plan.</label> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cytk_TwoThousandAndFourPlanMember_lbl" xml:lang="en-US" id="id_6895476_1403278_1_1">Two Thousand And Four Plan [Member]</label> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cytk_TwoThousandAndFourPlanMember_lbl" xml:lang="en-US" id="id_6895476_1403278_2_1">2004 Plan [Member]</label> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cytk_TwoThousandAndFourPlanMember" xlink:to="cytk_TwoThousandAndFourPlanMember_lbl"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis"/> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TypeOfArrangementAxis_lbl" xml:lang="en-US" id="id_6895476_1279908_1_1">Type of Arrangement and Non-arrangement Transactions [Axis]</label> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_TypeOfArrangementAxis_lbl" xml:lang="en-US" id="id_6895476_1279908_2_1">Type of Arrangement and Non-arrangement Transactions [Axis]</label> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_TypeOfArrangementAxis_lbl"/> <loc xlink:type="locator" xlink:href="cytk-20141231.xsd#cytk_UnderwrittenPublicOfferingMember" xlink:label="cytk_UnderwrittenPublicOfferingMember"/> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cytk_UnderwrittenPublicOfferingMember_lbl" xml:lang="en-US" id="id_6895476_1382912_3_1">Underwritten Public Offering [Member]</label> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cytk_UnderwrittenPublicOfferingMember_lbl" xml:lang="en-US" id="id_6895476_1382912_1_1">Underwritten Public Offering [Member]</label> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cytk_UnderwrittenPublicOfferingMember_lbl" xml:lang="en-US" id="id_6895476_1382912_2_1">Underwritten Public Offering [Member]</label> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cytk_UnderwrittenPublicOfferingMember" xlink:to="cytk_UnderwrittenPublicOfferingMember_lbl"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_UnrealizedGainLossOnInvestments" xlink:label="us-gaap_UnrealizedGainLossOnInvestments"/> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_UnrealizedGainLossOnInvestments_lbl" xml:lang="en-US" id="id_6895476_1282544_1_1">Unrealized Gain (Loss) on Investments</label> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_UnrealizedGainLossOnInvestments_lbl" xml:lang="en-US" id="id_6895476_1282544_2_1">Unrealized Gain (loss)</label> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UnrealizedGainLossOnInvestments" xlink:to="us-gaap_UnrealizedGainLossOnInvestments_lbl"/> <loc xlink:type="locator" xlink:href="cytk-20141231.xsd#cytk_UnrecognizedIncomeTaxBenefitsNetOfFederalBenefitOfStateIncomeTaxUtbMember" xlink:label="cytk_UnrecognizedIncomeTaxBenefitsNetOfFederalBenefitOfStateIncomeTaxUtbMember"/> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cytk_UnrecognizedIncomeTaxBenefitsNetOfFederalBenefitOfStateIncomeTaxUtbMember_lbl" xml:lang="en-US" id="id_6895476_1497867_3_1">Unrecognized Income Tax Benefits Net Of Federal Benefit Of State Income Tax Utb [Member]</label> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cytk_UnrecognizedIncomeTaxBenefitsNetOfFederalBenefitOfStateIncomeTaxUtbMember_lbl" xml:lang="en-US" id="id_6895476_1497867_1_1">Unrecognized Income Tax Benefits Net Of Federal Benefit Of State Income Tax Utb [Member]</label> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cytk_UnrecognizedIncomeTaxBenefitsNetOfFederalBenefitOfStateIncomeTaxUtbMember_lbl" xml:lang="en-US" id="id_6895476_1497867_2_1">Unrecognized Income Tax Benefits - Net of Federal Benefit of State UTBs [Member]</label> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cytk_UnrecognizedIncomeTaxBenefitsNetOfFederalBenefitOfStateIncomeTaxUtbMember" xlink:to="cytk_UnrecognizedIncomeTaxBenefitsNetOfFederalBenefitOfStateIncomeTaxUtbMember_lbl"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:label="us-gaap_UnrecognizedTaxBenefits"/> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_UnrecognizedTaxBenefits_lbl" xml:lang="en-US" id="id_6895476_1284319_1_1">Unrecognized Tax Benefits</label> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_UnrecognizedTaxBenefits_lbl" xml:lang="en-US" id="id_6895476_1284319_4_1">Unrecognized tax benefits, Ending Balance</label> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_UnrecognizedTaxBenefits_lbl" xml:lang="en-US" id="id_6895476_1284319_5_1">Unrecognized tax benefits, Beginning Balance</label> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UnrecognizedTaxBenefits" xlink:to="us-gaap_UnrecognizedTaxBenefits_lbl"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" xlink:label="us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions"/> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions_lbl" xml:lang="en-US" id="id_6895476_1289283_1_1">Unrecognized Tax Benefits, Decrease Resulting from Prior Period Tax Positions</label> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions_lbl" xml:lang="en-US" id="id_6895476_1289283_14_1">Reductions for tax positions of prior years</label> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" xlink:to="us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions_lbl"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions"/> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_lbl" xml:lang="en-US" id="id_6895476_1283872_1_1">Unrecognized Tax Benefits, Increase Resulting from Current Period Tax Positions</label> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_lbl" xml:lang="en-US" id="id_6895476_1283872_2_1">Addition for tax positions related to the current year</label> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:to="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_lbl"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions"/> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions_lbl" xml:lang="en-US" id="id_6895476_1281565_1_1">Unrecognized Tax Benefits, Increase Resulting from Prior Period Tax Positions</label> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions_lbl" xml:lang="en-US" id="id_6895476_1281565_2_1">Addition for tax positions of prior years</label> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" xlink:to="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions_lbl"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate" xlink:label="us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate"/> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate_lbl" xml:lang="en-US" id="id_6895476_1282545_1_1">Unrecognized Tax Benefits that Would Impact Effective Tax Rate</label> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate_lbl" xml:lang="en-US" id="id_6895476_1282545_2_1">Unrecognized tax benefits</label> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate" xlink:to="us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate_lbl"/> <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/country/2013/country-2013-01-31.xsd#country_US" xlink:label="country_US"/> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="country_US_lbl" xml:lang="en-US" id="id_6895476_1271500_1_1">UNITED STATES</label> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="country_US_lbl" xml:lang="en-US" id="id_6895476_1271500_2_1">United States [Member]</label> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="country_US" xlink:to="country_US_lbl"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_UseOfEstimates" xlink:label="us-gaap_UseOfEstimates"/> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_UseOfEstimates_lbl" xml:lang="en-US" id="id_6895476_1274809_1_1">Use of Estimates, Policy [Policy Text Block]</label> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_UseOfEstimates_lbl" xml:lang="en-US" id="id_6895476_1274809_2_1">Use of Estimates</label> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UseOfEstimates" xlink:to="us-gaap_UseOfEstimates_lbl"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_USTreasurySecuritiesMember" xlink:label="us-gaap_USTreasurySecuritiesMember"/> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_USTreasurySecuritiesMember_lbl" xml:lang="en-US" id="id_6895476_1274813_1_1">US Treasury Securities [Member]</label> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_USTreasurySecuritiesMember_lbl" xml:lang="en-US" id="id_6895476_1274813_2_1">U.S. Treasury Securities [Member]</label> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_USTreasurySecuritiesMember" xlink:to="us-gaap_USTreasurySecuritiesMember_lbl"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:label="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount"/> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_lbl" xml:lang="en-US" id="id_6895476_1282061_1_1">Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount</label> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_lbl" xml:lang="en-US" id="id_6895476_1282061_2_1">Increase and decrease valuation allowance</label> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:to="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_lbl"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ValuationAllowanceOfDeferredTaxAssetsMember" xlink:label="us-gaap_ValuationAllowanceOfDeferredTaxAssetsMember"/> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ValuationAllowanceOfDeferredTaxAssetsMember_lbl" xml:lang="en-US" id="id_6895476_1276697_1_1">Valuation Allowance of Deferred Tax Assets [Member]</label> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ValuationAllowanceOfDeferredTaxAssetsMember_lbl" xml:lang="en-US" id="id_6895476_1276697_2_1">Deferred Tax Valuation Allowance [Member]</label> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ValuationAllowanceOfDeferredTaxAssetsMember" xlink:to="us-gaap_ValuationAllowanceOfDeferredTaxAssetsMember_lbl"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ValuationAllowancesAndReservesBalance" xlink:label="us-gaap_ValuationAllowancesAndReservesBalance"/> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ValuationAllowancesAndReservesBalance_lbl" xml:lang="en-US" id="id_6895476_1284723_1_1">Valuation Allowances and Reserves, Balance</label> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ValuationAllowancesAndReservesBalance_lbl" xml:lang="en-US" id="id_6895476_1284723_4_1">Balance at End of Period</label> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ValuationAllowancesAndReservesBalance_lbl" xml:lang="en-US" id="id_6895476_1284723_5_1">Balance at Beginning of Period</label> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ValuationAllowancesAndReservesBalance" xlink:to="us-gaap_ValuationAllowancesAndReservesBalance_lbl"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ValuationAllowancesAndReservesChargedToCostAndExpense" xlink:label="us-gaap_ValuationAllowancesAndReservesChargedToCostAndExpense"/> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ValuationAllowancesAndReservesChargedToCostAndExpense_lbl" xml:lang="en-US" id="id_6895476_1282539_1_1">Valuation Allowances and Reserves, Charged to Cost and Expense</label> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ValuationAllowancesAndReservesChargedToCostAndExpense_lbl" xml:lang="en-US" id="id_6895476_1282539_2_1">Charged to Expenses</label> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ValuationAllowancesAndReservesChargedToCostAndExpense" xlink:to="us-gaap_ValuationAllowancesAndReservesChargedToCostAndExpense_lbl"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ValuationAllowancesAndReservesChargedToOtherAccounts" xlink:label="us-gaap_ValuationAllowancesAndReservesChargedToOtherAccounts"/> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ValuationAllowancesAndReservesChargedToOtherAccounts_lbl" xml:lang="en-US" id="id_6895476_1282540_1_1">Valuation Allowances and Reserves, Charged to Other Accounts</label> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ValuationAllowancesAndReservesChargedToOtherAccounts_lbl" xml:lang="en-US" id="id_6895476_1282540_2_1">Charged to Other Accounts</label> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ValuationAllowancesAndReservesChargedToOtherAccounts" xlink:to="us-gaap_ValuationAllowancesAndReservesChargedToOtherAccounts_lbl"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ValuationAllowancesAndReservesDeductions" xlink:label="us-gaap_ValuationAllowancesAndReservesDeductions"/> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ValuationAllowancesAndReservesDeductions_lbl" xml:lang="en-US" id="id_6895476_1289287_1_1">Valuation Allowances and Reserves, Deductions</label> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_ValuationAllowancesAndReservesDeductions_lbl" xml:lang="en-US" id="id_6895476_1289287_14_1">Deductions</label> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ValuationAllowancesAndReservesDeductions" xlink:to="us-gaap_ValuationAllowancesAndReservesDeductions_lbl"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ValuationAllowancesAndReservesDomain" xlink:label="us-gaap_ValuationAllowancesAndReservesDomain"/> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ValuationAllowancesAndReservesDomain_lbl" xml:lang="en-US" id="id_6895476_1275094_1_1">Valuation Allowances and Reserves [Domain]</label> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ValuationAllowancesAndReservesDomain_lbl" xml:lang="en-US" id="id_6895476_1275094_2_1">Valuation Allowances and Reserves [Domain]</label> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ValuationAllowancesAndReservesDomain" xlink:to="us-gaap_ValuationAllowancesAndReservesDomain_lbl"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ValuationAllowancesAndReservesTypeAxis" xlink:label="us-gaap_ValuationAllowancesAndReservesTypeAxis"/> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ValuationAllowancesAndReservesTypeAxis_lbl" xml:lang="en-US" id="id_6895476_1279936_1_1">Valuation Allowances and Reserves Type [Axis]</label> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ValuationAllowancesAndReservesTypeAxis_lbl" xml:lang="en-US" id="id_6895476_1279936_2_1">Valuation Allowances and Reserves Type [Axis]</label> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ValuationAllowancesAndReservesTypeAxis" xlink:to="us-gaap_ValuationAllowancesAndReservesTypeAxis_lbl"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ValuationAndQualifyingAccountsDisclosureLineItems" xlink:label="us-gaap_ValuationAndQualifyingAccountsDisclosureLineItems"/> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ValuationAndQualifyingAccountsDisclosureLineItems_lbl" xml:lang="en-US" id="id_6895476_1271714_1_1">Valuation and Qualifying Accounts Disclosure [Line Items]</label> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ValuationAndQualifyingAccountsDisclosureLineItems_lbl" xml:lang="en-US" id="id_6895476_1271714_2_1">Valuation and Qualifying Accounts Disclosure [Line Items]</label> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ValuationAndQualifyingAccountsDisclosureLineItems" xlink:to="us-gaap_ValuationAndQualifyingAccountsDisclosureLineItems_lbl"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ValuationAndQualifyingAccountsDisclosureTable" xlink:label="us-gaap_ValuationAndQualifyingAccountsDisclosureTable"/> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ValuationAndQualifyingAccountsDisclosureTable_lbl" xml:lang="en-US" id="id_6895476_1281534_1_1">Valuation and Qualifying Accounts Disclosure [Table]</label> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ValuationAndQualifyingAccountsDisclosureTable_lbl" xml:lang="en-US" id="id_6895476_1281534_2_1">Valuation and Qualifying Accounts Disclosure [Table]</label> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ValuationAndQualifyingAccountsDisclosureTable" xlink:to="us-gaap_ValuationAndQualifyingAccountsDisclosureTable_lbl"/> <loc xlink:type="locator" xlink:href="cytk-20141231.xsd#cytk_WarrantExpirationDate" xlink:label="cytk_WarrantExpirationDate"/> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cytk_WarrantExpirationDate_lbl" xml:lang="en-US" id="id_6895476_1447172_3_1">The expiration date for warrants or rights outstanding.</label> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cytk_WarrantExpirationDate_lbl" xml:lang="en-US" id="id_6895476_1447172_1_1">Warrant Expiration Date</label> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cytk_WarrantExpirationDate_lbl" xml:lang="en-US" id="id_6895476_1447172_2_1">Expiration Date</label> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cytk_WarrantExpirationDate" xlink:to="cytk_WarrantExpirationDate_lbl"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_WarrantMember" xlink:label="us-gaap_WarrantMember"/> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WarrantMember_lbl" xml:lang="en-US" id="id_6895476_1273442_1_1">Warrant [Member]</label> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_WarrantMember_lbl" xml:lang="en-US" id="id_6895476_1273442_2_1">Warrants to Purchase Common Stock [Member]</label> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantMember" xlink:to="us-gaap_WarrantMember_lbl"/> <loc xlink:type="locator" xlink:href="cytk-20141231.xsd#cytk_WarrantOneMember" xlink:label="cytk_WarrantOneMember"/> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cytk_WarrantOneMember_lbl" xml:lang="en-US" id="id_6895476_1413008_3_1">Warrant one.</label> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cytk_WarrantOneMember_lbl" xml:lang="en-US" id="id_6895476_1413008_1_1">Warrant One [Member]</label> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cytk_WarrantOneMember_lbl" xml:lang="en-US" id="id_6895476_1413008_2_1">Issued 4/20/2011 [Member]</label> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cytk_WarrantOneMember" xlink:to="cytk_WarrantOneMember_lbl"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_WarrantsNotSettleableInCashFairValueDisclosure" xlink:label="us-gaap_WarrantsNotSettleableInCashFairValueDisclosure"/> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WarrantsNotSettleableInCashFairValueDisclosure_lbl" xml:lang="en-US" id="id_6895476_1284312_1_1">Warrants Not Settleable in Cash, Fair Value Disclosure</label> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_WarrantsNotSettleableInCashFairValueDisclosure_lbl" xml:lang="en-US" id="id_6895476_1284312_2_1">Warrants, valued</label> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantsNotSettleableInCashFairValueDisclosure" xlink:to="us-gaap_WarrantsNotSettleableInCashFairValueDisclosure_lbl"/> <loc xlink:type="locator" xlink:href="cytk-20141231.xsd#cytk_WarrantsToPurchaseCommonStockMember" xlink:label="cytk_WarrantsToPurchaseCommonStockMember"/> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cytk_WarrantsToPurchaseCommonStockMember_lbl" xml:lang="en-US" id="id_6895476_1376841_3_1">Warrants to Purchase Common Stock [Member]</label> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cytk_WarrantsToPurchaseCommonStockMember_lbl" xml:lang="en-US" id="id_6895476_1376841_1_1">Warrants To Purchase Common Stock [Member]</label> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cytk_WarrantsToPurchaseCommonStockMember_lbl" xml:lang="en-US" id="id_6895476_1376841_2_1">Warrants to Purchase Common Stock [Member]</label> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cytk_WarrantsToPurchaseCommonStockMember" xlink:to="cytk_WarrantsToPurchaseCommonStockMember_lbl"/> <loc xlink:type="locator" xlink:href="cytk-20141231.xsd#cytk_WarrantTwoMember" xlink:label="cytk_WarrantTwoMember"/> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cytk_WarrantTwoMember_lbl" xml:lang="en-US" id="id_6895476_1351779_3_1">Warrant two.</label> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cytk_WarrantTwoMember_lbl" xml:lang="en-US" id="id_6895476_1351779_1_1">Warrant Two [Member]</label> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cytk_WarrantTwoMember_lbl" xml:lang="en-US" id="id_6895476_1351779_2_1">Issued 6/25/2012 [Member]</label> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cytk_WarrantTwoMember" xlink:to="cytk_WarrantTwoMember_lbl"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:label="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted"/> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_lbl" xml:lang="en-US" id="id_6895476_1274823_1_1">Weighted Average Number of Shares Outstanding, Basic and Diluted</label> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_lbl" xml:lang="en-US" id="id_6895476_1274823_2_1">Weighted-average number of shares used in computing net loss per share allocable to common stockholders - basic and diluted</label> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_lbl" xml:lang="en-US" id="id_6895476_1274823_12_1">Weighted-average shares used in computing net loss per share allocable to common stockholders - basic and diluted</label> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:to="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_lbl"/> </labelLink> </linkbase> </XBRL> </TEXT> </DOCUMENT> <DOCUMENT> <TYPE>EX-101.PRE <SEQUENCE>12 <FILENAME>cytk-20141231_pre.xml <DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE <TEXT> <XBRL> <?xml version="1.0" encoding="US-ASCII"?> <!-- RR Donnelley Xcelerate Taxonomy Presentation Linkbase, based on XBRL 2.1 http://www.rrdonnelley.com/ --> <!-- Version: 6.22.4 --> <!-- Round: 10 --> <!-- Creation date: 2015-03-05T19:06:47Z --> <!-- Copyright (c) 2005-2013 R.R. Donnelley & Sons Company All Rights Reserved. --> <linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"> <roleRef xlink:type="simple" xlink:href="cytk-20141231.xsd#DocumentandEntityInformation" roleURI="http://imetrix.edgar-online.com/taxonomy/role/DocumentandEntityInformation"/> <roleRef xlink:type="simple" xlink:href="cytk-20141231.xsd#Role_StatementOfFinancialPositionClassified" roleURI="http://imetrix.edgar-online.com/taxonomy/role/StatementOfFinancialPositionClassified"/> <roleRef xlink:type="simple" xlink:href="cytk-20141231.xsd#Role_StatementOfFinancialPositionClassifiedParen" roleURI="http://imetrix.edgar-online.com/taxonomy/role/StatementOfFinancialPositionClassifiedParenthetical"/> <roleRef xlink:type="simple" xlink:href="cytk-20141231.xsd#Role_StatementOfIncome" roleURI="http://imetrix.edgar-online.com/taxonomy/role/StatementOfIncome"/> <roleRef xlink:type="simple" xlink:href="cytk-20141231.xsd#Role_StatementOfShareholdersEquityAndOtherComprehensiveIncome" roleURI="http://imetrix.edgar-online.com/taxonomy/role/StatementOfShareholdersEquityAndOtherComprehensiveIncome"/> <roleRef xlink:type="simple" xlink:href="cytk-20141231.xsd#Role_StatementOfShareholdersEquityAndOtherComprehensiveIncomeParen" roleURI="http://imetrix.edgar-online.com/taxonomy/role/StatementOfShareholdersEquityAndOtherComprehensiveIncomeParenthetical"/> <roleRef xlink:type="simple" xlink:href="cytk-20141231.xsd#Role_StatementOfCashFlowsIndirect" roleURI="http://imetrix.edgar-online.com/taxonomy/role/StatementOfCashFlowsIndirect"/> <roleRef xlink:type="simple" xlink:href="cytk-20141231.xsd#DisclosureOrganizationAndSignificantAccountingPoliciesAdditionalInformation" roleURI="http://imetrix.edgar-online.com/taxonomy/role/DisclosureOrganizationAndSignificantAccountingPoliciesAdditionalInformation"/> <roleRef xlink:type="simple" xlink:href="cytk-20141231.xsd#DisclosureNetLossPerShareCalculationOfBasicAndDilutedNetLossPerShareAllocableToCommonStockholders" roleURI="http://imetrix.edgar-online.com/taxonomy/role/DisclosureNetLossPerShareCalculationOfBasicAndDilutedNetLossPerShareAllocableToCommonStockholders"/> <roleRef xlink:type="simple" xlink:href="cytk-20141231.xsd#DisclosureNetLossPerShareInstrumentsExcludedFromTheComputationOfDilutedNetLossPerCommonShare" roleURI="http://imetrix.edgar-online.com/taxonomy/role/DisclosureNetLossPerShareInstrumentsExcludedFromTheComputationOfDilutedNetLossPerCommonShare"/> <roleRef xlink:type="simple" xlink:href="cytk-20141231.xsd#DisclosureSupplementaryCashFlowDataSupplementalCashFlowInformation" roleURI="http://imetrix.edgar-online.com/taxonomy/role/DisclosureSupplementaryCashFlowDataSupplementalCashFlowInformation"/> <roleRef xlink:type="simple" xlink:href="cytk-20141231.xsd#DisclosureCashEquivalentsAndInvestmentsAmortizedCostAndFairValueOfCashEquivalentsAndAvailableForSaleInvestments" roleURI="http://imetrix.edgar-online.com/taxonomy/role/DisclosureCashEquivalentsAndInvestmentsAmortizedCostAndFairValueOfCashEquivalentsAndAvailableForSaleInvestments"/> <roleRef xlink:type="simple" xlink:href="cytk-20141231.xsd#DisclosureCashEquivalentsAndInvestmentsAdditionalInformation" roleURI="http://imetrix.edgar-online.com/taxonomy/role/DisclosureCashEquivalentsAndInvestmentsAdditionalInformation"/> <roleRef xlink:type="simple" xlink:href="cytk-20141231.xsd#DisclosureCashEquivalentsAndInvestmentsSummaryOfInterestIncome" roleURI="http://imetrix.edgar-online.com/taxonomy/role/DisclosureCashEquivalentsAndInvestmentsSummaryOfInterestIncome"/> <roleRef xlink:type="simple" xlink:href="cytk-20141231.xsd#DisclosureFairValueMeasurementsSummaryOfFinancialAssetsMeasuredAtFairValueOnRecurringBasis" roleURI="http://imetrix.edgar-online.com/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfFinancialAssetsMeasuredAtFairValueOnRecurringBasis"/> <roleRef xlink:type="simple" xlink:href="cytk-20141231.xsd#DisclosureFairValueMeasurementsAdditionalInformation" roleURI="http://imetrix.edgar-online.com/taxonomy/role/DisclosureFairValueMeasurementsAdditionalInformation"/> <roleRef xlink:type="simple" xlink:href="cytk-20141231.xsd#DisclosureBalanceSheetComponentsSummaryOfPropertyAndEquipmentBalances" roleURI="http://imetrix.edgar-online.com/taxonomy/role/DisclosureBalanceSheetComponentsSummaryOfPropertyAndEquipmentBalances"/> <roleRef xlink:type="simple" xlink:href="cytk-20141231.xsd#DisclosureBalanceSheetComponentsAdditionalInformation" roleURI="http://imetrix.edgar-online.com/taxonomy/role/DisclosureBalanceSheetComponentsAdditionalInformation"/> <roleRef xlink:type="simple" xlink:href="cytk-20141231.xsd#DisclosureBalanceSheetComponentsSummaryOfAccruedLiabilities" roleURI="http://imetrix.edgar-online.com/taxonomy/role/DisclosureBalanceSheetComponentsSummaryOfAccruedLiabilities"/> <roleRef xlink:type="simple" xlink:href="cytk-20141231.xsd#DisclosureRelatedPartiesAndRelatedPartyTransactionsAdditionalInformation" roleURI="http://imetrix.edgar-online.com/taxonomy/role/DisclosureRelatedPartiesAndRelatedPartyTransactionsAdditionalInformation"/> <roleRef xlink:type="simple" xlink:href="cytk-20141231.xsd#DisclosureRelatedPartiesAndRelatedPartyTransactionsRevenueFromRelatedParty" roleURI="http://imetrix.edgar-online.com/taxonomy/role/DisclosureRelatedPartiesAndRelatedPartyTransactionsRevenueFromRelatedParty"/> <roleRef xlink:type="simple" xlink:href="cytk-20141231.xsd#DisclosureOtherResearchAndDevelopmentRevenueArrangementsAdditionalInformation" roleURI="http://imetrix.edgar-online.com/taxonomy/role/DisclosureOtherResearchAndDevelopmentRevenueArrangementsAdditionalInformation"/> <roleRef xlink:type="simple" xlink:href="cytk-20141231.xsd#DisclosureOtherResearchAndDevelopmentRevenueArrangementsSummaryOfTotalGrantRevenues" roleURI="http://imetrix.edgar-online.com/taxonomy/role/DisclosureOtherResearchAndDevelopmentRevenueArrangementsSummaryOfTotalGrantRevenues"/> <roleRef xlink:type="simple" xlink:href="cytk-20141231.xsd#DisclosureOtherResearchAndDevelopmentRevenueArrangementsSummaryOfReimbursedExpenses" roleURI="http://imetrix.edgar-online.com/taxonomy/role/DisclosureOtherResearchAndDevelopmentRevenueArrangementsSummaryOfReimbursedExpenses"/> <roleRef xlink:type="simple" xlink:href="cytk-20141231.xsd#DisclosureDebtAdditionalInformation" roleURI="http://imetrix.edgar-online.com/taxonomy/role/DisclosureDebtAdditionalInformation"/> <roleRef xlink:type="simple" xlink:href="cytk-20141231.xsd#DisclosureDebtSummaryOfTotalInterestExpenseIncurred" roleURI="http://imetrix.edgar-online.com/taxonomy/role/DisclosureDebtSummaryOfTotalInterestExpenseIncurred"/> <roleRef xlink:type="simple" xlink:href="cytk-20141231.xsd#DisclosureCommitmentsAndContingenciesAdditionalInformation" roleURI="http://imetrix.edgar-online.com/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformation"/> <roleRef xlink:type="simple" xlink:href="cytk-20141231.xsd#DisclosureCommitmentsAndContingenciesRentExpense" roleURI="http://imetrix.edgar-online.com/taxonomy/role/DisclosureCommitmentsAndContingenciesRentExpense"/> <roleRef xlink:type="simple" xlink:href="cytk-20141231.xsd#DisclosureCommitmentsAndContingenciesFutureMinimumLeasePaymentsUnderNoncancelableOperatingLeases" roleURI="http://imetrix.edgar-online.com/taxonomy/role/DisclosureCommitmentsAndContingenciesFutureMinimumLeasePaymentsUnderNoncancelableOperatingLeases"/> <roleRef xlink:type="simple" xlink:href="cytk-20141231.xsd#DisclosureConvertiblePreferredStockAdditionalInformation" roleURI="http://imetrix.edgar-online.com/taxonomy/role/DisclosureConvertiblePreferredStockAdditionalInformation"/> <roleRef xlink:type="simple" xlink:href="cytk-20141231.xsd#DisclosureStockholdersEquityAdditionalInformation" roleURI="http://imetrix.edgar-online.com/taxonomy/role/DisclosureStockholdersEquityAdditionalInformation"/> <roleRef xlink:type="simple" xlink:href="cytk-20141231.xsd#DisclosureStockholdersEquityOutstandingWarrants" roleURI="http://imetrix.edgar-online.com/taxonomy/role/DisclosureStockholdersEquityOutstandingWarrants"/> <roleRef xlink:type="simple" xlink:href="cytk-20141231.xsd#DisclosureStockholdersEquitySummaryOfStockOptionActivity" roleURI="http://imetrix.edgar-online.com/taxonomy/role/DisclosureStockholdersEquitySummaryOfStockOptionActivity"/> <roleRef xlink:type="simple" xlink:href="cytk-20141231.xsd#DisclosureStockholdersEquitySummaryOfRestrictedStockUnitActivity" roleURI="http://imetrix.edgar-online.com/taxonomy/role/DisclosureStockholdersEquitySummaryOfRestrictedStockUnitActivity"/> <roleRef xlink:type="simple" xlink:href="cytk-20141231.xsd#DisclosureStockholdersEquityStockBasedCompensationRelatedToStockOptionsRestrictedStockAwardsRestrictedStockUnitAndEmployeeStockPurchases" roleURI="http://imetrix.edgar-online.com/taxonomy/role/DisclosureStockholdersEquityStockBasedCompensationRelatedToStockOptionsRestrictedStockAwardsRestrictedStockUnitAndEmployeeStockPurchases"/> <roleRef xlink:type="simple" xlink:href="cytk-20141231.xsd#DisclosureStockholdersEquityFairValueOfShareBasedPaymentsWasEstimatedOnDateOfGrantUsingBlackScholesOptionPricingModelBasedOnWeightedAverageAssumptions" roleURI="http://imetrix.edgar-online.com/taxonomy/role/DisclosureStockholdersEquityFairValueOfShareBasedPaymentsWasEstimatedOnDateOfGrantUsingBlackScholesOptionPricingModelBasedOnWeightedAverageAssumptions"/> <roleRef xlink:type="simple" xlink:href="cytk-20141231.xsd#DisclosureIncomeTaxesAdditionalInformation" roleURI="http://imetrix.edgar-online.com/taxonomy/role/DisclosureIncomeTaxesAdditionalInformation"/> <roleRef xlink:type="simple" xlink:href="cytk-20141231.xsd#DisclosureIncomeTaxesScheduleOfComponentsOfIncomeBeforeTaxes" roleURI="http://imetrix.edgar-online.com/taxonomy/role/DisclosureIncomeTaxesScheduleOfComponentsOfIncomeBeforeTaxes"/> <roleRef xlink:type="simple" xlink:href="cytk-20141231.xsd#DisclosureIncomeTaxesCompanyRecordedIncomeTaxProvision" roleURI="http://imetrix.edgar-online.com/taxonomy/role/DisclosureIncomeTaxesCompanyRecordedIncomeTaxProvision"/> <roleRef xlink:type="simple" xlink:href="cytk-20141231.xsd#DisclosureIncomeTaxesCompanysDeferredTaxAssetsAndLiabilities" roleURI="http://imetrix.edgar-online.com/taxonomy/role/DisclosureIncomeTaxesCompanysDeferredTaxAssetsAndLiabilities"/> <roleRef xlink:type="simple" xlink:href="cytk-20141231.xsd#DisclosureIncomeTaxesCompanysValuationAndQualifyingAccounts" roleURI="http://imetrix.edgar-online.com/taxonomy/role/DisclosureIncomeTaxesCompanysValuationAndQualifyingAccounts"/> <roleRef xlink:type="simple" xlink:href="cytk-20141231.xsd#DisclosureIncomeTaxesReconciliationOfStatutoryFederalIncomeTaxRateToEffectiveTaxRate" roleURI="http://imetrix.edgar-online.com/taxonomy/role/DisclosureIncomeTaxesReconciliationOfStatutoryFederalIncomeTaxRateToEffectiveTaxRate"/> <roleRef xlink:type="simple" xlink:href="cytk-20141231.xsd#DisclosureIncomeTaxesReconciliationOfTotalAmountsOfUnrecognizedTaxBenefits" roleURI="http://imetrix.edgar-online.com/taxonomy/role/DisclosureIncomeTaxesReconciliationOfTotalAmountsOfUnrecognizedTaxBenefits"/> <roleRef xlink:type="simple" xlink:href="cytk-20141231.xsd#DisclosureInterestAndOtherNetComponentsOfInterestAndOtherNet" roleURI="http://imetrix.edgar-online.com/taxonomy/role/DisclosureInterestAndOtherNetComponentsOfInterestAndOtherNet"/> <roleRef xlink:type="simple" xlink:href="cytk-20141231.xsd#DisclosureQuarterlyFinancialDataSummaryOfQuarterlyResults" roleURI="http://imetrix.edgar-online.com/taxonomy/role/DisclosureQuarterlyFinancialDataSummaryOfQuarterlyResults"/> <roleRef xlink:type="simple" xlink:href="cytk-20141231.xsd#Role_NotesToFinancialStatementsOrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" roleURI="http://imetrix.edgar-online.com/taxonomy/role/NotesToFinancialStatementsOrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock"/> <roleRef xlink:type="simple" xlink:href="cytk-20141231.xsd#Role_NotesToFinancialStatementsOrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlockPolicies" roleURI="http://imetrix.edgar-online.com/taxonomy/role/NotesToFinancialStatementsOrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlockPolicies"/> <roleRef xlink:type="simple" xlink:href="cytk-20141231.xsd#Role_NotesToFinancialStatementsEarningsPerShareTextBlock" roleURI="http://imetrix.edgar-online.com/taxonomy/role/NotesToFinancialStatementsEarningsPerShareTextBlock"/> <roleRef xlink:type="simple" xlink:href="cytk-20141231.xsd#Role_NotesToFinancialStatementsEarningsPerShareTextBlockTables" roleURI="http://imetrix.edgar-online.com/taxonomy/role/NotesToFinancialStatementsEarningsPerShareTextBlockTables"/> <roleRef xlink:type="simple" xlink:href="cytk-20141231.xsd#Role_NotesToFinancialStatementsCashFlowSupplementalDisclosuresTextBlock" roleURI="http://imetrix.edgar-online.com/taxonomy/role/NotesToFinancialStatementsCashFlowSupplementalDisclosuresTextBlock"/> <roleRef xlink:type="simple" xlink:href="cytk-20141231.xsd#Role_NotesToFinancialStatementsCashFlowSupplementalDisclosuresTextBlockTables" roleURI="http://imetrix.edgar-online.com/taxonomy/role/NotesToFinancialStatementsCashFlowSupplementalDisclosuresTextBlockTables"/> <roleRef xlink:type="simple" xlink:href="cytk-20141231.xsd#Role_NotesToFinancialStatementsInvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" roleURI="http://imetrix.edgar-online.com/taxonomy/role/NotesToFinancialStatementsInvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock"/> <roleRef xlink:type="simple" xlink:href="cytk-20141231.xsd#Role_NotesToFinancialStatementsInvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlockTables" roleURI="http://imetrix.edgar-online.com/taxonomy/role/NotesToFinancialStatementsInvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlockTables"/> <roleRef xlink:type="simple" xlink:href="cytk-20141231.xsd#Role_NotesToFinancialStatementsFairValueDisclosuresTextBlock" roleURI="http://imetrix.edgar-online.com/taxonomy/role/NotesToFinancialStatementsFairValueDisclosuresTextBlock"/> <roleRef xlink:type="simple" xlink:href="cytk-20141231.xsd#Role_NotesToFinancialStatementsFairValueDisclosuresTextBlockTables" roleURI="http://imetrix.edgar-online.com/taxonomy/role/NotesToFinancialStatementsFairValueDisclosuresTextBlockTables"/> <roleRef xlink:type="simple" xlink:href="cytk-20141231.xsd#Role_NotesToFinancialStatementsSupplementalBalanceSheetDisclosuresTextBlock" roleURI="http://imetrix.edgar-online.com/taxonomy/role/NotesToFinancialStatementsSupplementalBalanceSheetDisclosuresTextBlock"/> <roleRef xlink:type="simple" xlink:href="cytk-20141231.xsd#Role_NotesToFinancialStatementsSupplementalBalanceSheetDisclosuresTextBlockTables" roleURI="http://imetrix.edgar-online.com/taxonomy/role/NotesToFinancialStatementsSupplementalBalanceSheetDisclosuresTextBlockTables"/> <roleRef xlink:type="simple" xlink:href="cytk-20141231.xsd#Role_NotesToFinancialStatementsRelatedPartyTransactionsDisclosureTextBlock" roleURI="http://imetrix.edgar-online.com/taxonomy/role/NotesToFinancialStatementsRelatedPartyTransactionsDisclosureTextBlock"/> <roleRef xlink:type="simple" xlink:href="cytk-20141231.xsd#Role_NotesToFinancialStatementsRelatedPartyTransactionsDisclosureTextBlockTables" roleURI="http://imetrix.edgar-online.com/taxonomy/role/NotesToFinancialStatementsRelatedPartyTransactionsDisclosureTextBlockTables"/> <roleRef xlink:type="simple" xlink:href="cytk-20141231.xsd#Role_NotesToFinancialStatementsResearchDevelopmentAndComputerSoftwareDisclosureTextBlock" roleURI="http://imetrix.edgar-online.com/taxonomy/role/NotesToFinancialStatementsResearchDevelopmentAndComputerSoftwareDisclosureTextBlock"/> <roleRef xlink:type="simple" xlink:href="cytk-20141231.xsd#Role_NotesToFinancialStatementsResearchDevelopmentAndComputerSoftwareDisclosureTextBlockTables" roleURI="http://imetrix.edgar-online.com/taxonomy/role/NotesToFinancialStatementsResearchDevelopmentAndComputerSoftwareDisclosureTextBlockTables"/> <roleRef xlink:type="simple" xlink:href="cytk-20141231.xsd#Role_NotesToFinancialStatementsDebtDisclosureTextBlock" roleURI="http://imetrix.edgar-online.com/taxonomy/role/NotesToFinancialStatementsDebtDisclosureTextBlock"/> <roleRef xlink:type="simple" xlink:href="cytk-20141231.xsd#Role_NotesToFinancialStatementsDebtDisclosureTextBlockTables" roleURI="http://imetrix.edgar-online.com/taxonomy/role/NotesToFinancialStatementsDebtDisclosureTextBlockTables"/> <roleRef xlink:type="simple" xlink:href="cytk-20141231.xsd#Role_NotesToFinancialStatementsCommitmentsAndContingenciesDisclosureTextBlock" roleURI="http://imetrix.edgar-online.com/taxonomy/role/NotesToFinancialStatementsCommitmentsAndContingenciesDisclosureTextBlock"/> <roleRef xlink:type="simple" xlink:href="cytk-20141231.xsd#Role_NotesToFinancialStatementsCommitmentsAndContingenciesDisclosureTextBlockTables" roleURI="http://imetrix.edgar-online.com/taxonomy/role/NotesToFinancialStatementsCommitmentsAndContingenciesDisclosureTextBlockTables"/> <roleRef xlink:type="simple" xlink:href="cytk-20141231.xsd#Role_NotesToFinancialStatementsPreferredStockTextBlock" roleURI="http://imetrix.edgar-online.com/taxonomy/role/NotesToFinancialStatementsPreferredStockTextBlock"/> <roleRef xlink:type="simple" xlink:href="cytk-20141231.xsd#Role_NotesToFinancialStatementsStockholdersEquityNoteDisclosureTextBlock" roleURI="http://imetrix.edgar-online.com/taxonomy/role/NotesToFinancialStatementsStockholdersEquityNoteDisclosureTextBlock"/> <roleRef xlink:type="simple" xlink:href="cytk-20141231.xsd#Role_NotesToFinancialStatementsStockholdersEquityNoteDisclosureTextBlockTables" roleURI="http://imetrix.edgar-online.com/taxonomy/role/NotesToFinancialStatementsStockholdersEquityNoteDisclosureTextBlockTables"/> <roleRef xlink:type="simple" xlink:href="cytk-20141231.xsd#Role_NotesToFinancialStatementsIncomeTaxDisclosureTextBlock" roleURI="http://imetrix.edgar-online.com/taxonomy/role/NotesToFinancialStatementsIncomeTaxDisclosureTextBlock"/> <roleRef xlink:type="simple" xlink:href="cytk-20141231.xsd#Role_NotesToFinancialStatementsIncomeTaxDisclosureTextBlockTables" roleURI="http://imetrix.edgar-online.com/taxonomy/role/NotesToFinancialStatementsIncomeTaxDisclosureTextBlockTables"/> <roleRef xlink:type="simple" xlink:href="cytk-20141231.xsd#Role_NotesToFinancialStatementsOtherIncomeAndOtherExpenseDisclosureTextBlock" roleURI="http://imetrix.edgar-online.com/taxonomy/role/NotesToFinancialStatementsOtherIncomeAndOtherExpenseDisclosureTextBlock"/> <roleRef xlink:type="simple" xlink:href="cytk-20141231.xsd#Role_NotesToFinancialStatementsOtherIncomeAndOtherExpenseDisclosureTextBlockTables" roleURI="http://imetrix.edgar-online.com/taxonomy/role/NotesToFinancialStatementsOtherIncomeAndOtherExpenseDisclosureTextBlockTables"/> <roleRef xlink:type="simple" xlink:href="cytk-20141231.xsd#Role_NotesToFinancialStatementsQuarterlyFinancialInformationTextBlock" roleURI="http://imetrix.edgar-online.com/taxonomy/role/NotesToFinancialStatementsQuarterlyFinancialInformationTextBlock"/> <roleRef xlink:type="simple" xlink:href="cytk-20141231.xsd#Role_NotesToFinancialStatementsQuarterlyFinancialInformationTextBlockTables" roleURI="http://imetrix.edgar-online.com/taxonomy/role/NotesToFinancialStatementsQuarterlyFinancialInformationTextBlockTables"/> <presentationLink xlink:type="extended" xlink:role="http://imetrix.edgar-online.com/taxonomy/role/DocumentandEntityInformation"> <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag"/> <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate"/> <loc xlink:type="locator" xlink:href="cytk-20141231.xsd#cytk_DocumentAndEntityInformationAbstract" xlink:label="cytk_DocumentAndEntityInformationAbstract"/> <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus"/> <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus"/> <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate"/> <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentType" xlink:label="dei_DocumentType"/> <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey"/> <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding"/> <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus"/> <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory"/> <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityPublicFloat" xlink:label="dei_EntityPublicFloat"/> <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName"/> <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityVoluntaryFilers" xlink:label="dei_EntityVoluntaryFilers"/> <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="dei_EntityWellKnownSeasonedIssuer"/> <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol"/> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cytk_DocumentAndEntityInformationAbstract" xlink:to="dei_DocumentType" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cytk_DocumentAndEntityInformationAbstract" xlink:to="dei_AmendmentFlag" order="1.0200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cytk_DocumentAndEntityInformationAbstract" xlink:to="dei_DocumentPeriodEndDate" order="1.0300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cytk_DocumentAndEntityInformationAbstract" xlink:to="dei_DocumentFiscalYearFocus" order="1.0400" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cytk_DocumentAndEntityInformationAbstract" xlink:to="dei_DocumentFiscalPeriodFocus" order="1.0500" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cytk_DocumentAndEntityInformationAbstract" xlink:to="dei_TradingSymbol" order="1.0600" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cytk_DocumentAndEntityInformationAbstract" xlink:to="dei_EntityRegistrantName" order="1.0700" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cytk_DocumentAndEntityInformationAbstract" xlink:to="dei_EntityCentralIndexKey" order="1.0800" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cytk_DocumentAndEntityInformationAbstract" xlink:to="dei_CurrentFiscalYearEndDate" order="1.0900" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cytk_DocumentAndEntityInformationAbstract" xlink:to="dei_EntityWellKnownSeasonedIssuer" order="1.1000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cytk_DocumentAndEntityInformationAbstract" xlink:to="dei_EntityCurrentReportingStatus" order="1.1100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cytk_DocumentAndEntityInformationAbstract" xlink:to="dei_EntityVoluntaryFilers" order="1.1200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cytk_DocumentAndEntityInformationAbstract" xlink:to="dei_EntityFilerCategory" order="1.1300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cytk_DocumentAndEntityInformationAbstract" xlink:to="dei_EntityCommonStockSharesOutstanding" order="1.1400" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cytk_DocumentAndEntityInformationAbstract" xlink:to="dei_EntityPublicFloat" order="1.1500" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/> </presentationLink> <presentationLink xlink:type="extended" xlink:role="http://imetrix.edgar-online.com/taxonomy/role/StatementOfFinancialPositionClassified" xlink:title="104000 - Statement - Statement of Financial Position, Classified"> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AccountsReceivableRelatedPartiesCurrent" xlink:label="us-gaap_AccountsReceivableRelatedPartiesCurrent"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="us-gaap_AdditionalPaidInCapital"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AssetsAbstract" xlink:label="us-gaap_AssetsAbstract"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="us-gaap_AssetsCurrentAbstract"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="us-gaap_CommitmentsAndContingencies"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DeferredRentCreditCurrent" xlink:label="us-gaap_DeferredRentCreditCurrent"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DeferredRentCreditNoncurrent" xlink:label="us-gaap_DeferredRentCreditNoncurrent"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DeferredRevenueCurrent" xlink:label="us-gaap_DeferredRevenueCurrent"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DeferredRevenueNoncurrent" xlink:label="us-gaap_DeferredRevenueNoncurrent"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LongTermInvestments" xlink:label="us-gaap_LongTermInvestments"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OtherAssetsCurrent" xlink:label="us-gaap_OtherAssetsCurrent"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="us-gaap_OtherAssetsNoncurrent"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PreferredStockValue" xlink:label="us-gaap_PreferredStockValue"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SeriesAPreferredStockMember" xlink:label="us-gaap_SeriesAPreferredStockMember"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="us-gaap_StockholdersEquityAbstract"/> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsCurrentAbstract" order="1.0400" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" order="1.0500" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_LongTermInvestments" order="1.0600" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_OtherAssetsNoncurrent" order="1.0700" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_Assets" order="1.0800" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" use="optional"/> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="1.2200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" order="1.2300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AccountsReceivableRelatedPartiesCurrent" order="1.2400" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_OtherAssetsCurrent" order="1.2500" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrent" order="1.2600" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" use="optional"/> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_SeriesAPreferredStockMember" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract" order="1.0900" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_DeferredRevenueNoncurrent" order="1.1000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_DeferredRentCreditNoncurrent" order="1.1100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_Liabilities" order="1.1200" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" use="optional"/> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_CommitmentsAndContingencies" order="1.1300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract" order="1.1400" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity" order="1.1500" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" use="optional"/> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_AccountsPayableCurrent" order="1.2700" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_AccruedLiabilitiesCurrent" order="1.2800" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_DeferredRevenueCurrent" order="1.2900" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_DeferredRentCreditCurrent" order="1.3000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrent" order="1.3100" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" use="optional"/> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AssetsAbstract" order="1.0200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract" order="1.0300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StatementTable" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="10.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="100.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_PreferredStockValue" order="1.1600" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_CommonStockValue" order="1.1700" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_AdditionalPaidInCapital" order="1.1800" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" order="1.1900" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" order="1.2000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquity" order="1.2100" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" use="optional"/> </presentationLink> <presentationLink xlink:type="extended" xlink:role="http://imetrix.edgar-online.com/taxonomy/role/StatementOfFinancialPositionClassifiedParenthetical"> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="us-gaap_PreferredStockSharesIssued"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="us-gaap_PreferredStockSharesOutstanding"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SeriesAPreferredStockMember" xlink:label="us-gaap_SeriesAPreferredStockMember"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_SeriesAPreferredStockMember" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare" order="1.0200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockSharesAuthorized" order="1.0300" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" use="optional"/> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockSharesIssued" order="1.0400" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockSharesOutstanding" order="1.0500" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" order="1.0600" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesAuthorized" order="1.0700" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" use="optional"/> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesIssued" order="1.0800" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesOutstanding" order="1.0900" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StatementTable" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="100.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/> </presentationLink> <presentationLink xlink:type="extended" xlink:role="http://imetrix.edgar-online.com/taxonomy/role/StatementOfIncome" xlink:title="124000 - Statement - Statement of Income (Including Gross Margin)"> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CostsAndExpenses" xlink:label="us-gaap_CostsAndExpenses"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted" xlink:label="us-gaap_EarningsPerShareBasicAndDiluted"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncomeStatementAbstract" xlink:label="us-gaap_IncomeStatementAbstract"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LicenseAndServicesRevenue" xlink:label="us-gaap_LicenseAndServicesRevenue"/> <loc xlink:type="locator" xlink:href="cytk-20141231.xsd#cytk_LicenseRevenuesFromRelatedParties" xlink:label="cytk_LicenseRevenuesFromRelatedParties"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="us-gaap_NonoperatingIncomeExpense"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="us-gaap_OperatingExpensesAbstract"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:label="us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OtherPreferredStockDividendsAndAdjustments" xlink:label="us-gaap_OtherPreferredStockDividendsAndAdjustments"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense"/> <loc xlink:type="locator" xlink:href="cytk-20141231.xsd#cytk_ResearchAndDevelopmentGrantAndOtherRevenues" xlink:label="cytk_ResearchAndDevelopmentGrantAndOtherRevenues"/> <loc xlink:type="locator" xlink:href="cytk-20141231.xsd#cytk_ResearchAndDevelopmentRevenuesFromRelatedParties" xlink:label="cytk_ResearchAndDevelopmentRevenuesFromRelatedParties"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RestructuringCharges" xlink:label="us-gaap_RestructuringCharges"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_Revenues" xlink:label="us-gaap_Revenues"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RevenuesAbstract" xlink:label="us-gaap_RevenuesAbstract"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:label="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted"/> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_RevenuesAbstract" order="1.1100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_OperatingExpensesAbstract" order="1.1200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_OperatingIncomeLoss" order="1.1300" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" use="optional"/> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_NonoperatingIncomeExpense" order="1.1400" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" order="1.1500" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" use="optional"/> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_IncomeTaxExpenseBenefit" order="1.1600" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="2" use="optional"/> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_NetIncomeLoss" order="1.1700" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" use="optional"/> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_OtherPreferredStockDividendsAndAdjustments" order="1.1800" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="2" use="optional"/> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" order="1.1900" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" use="optional"/> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_EarningsPerShareBasicAndDiluted" order="1.2000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" order="1.2100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" order="1.2200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_ComprehensiveIncomeNetOfTax" order="1.2300" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" use="optional"/> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpense" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_GeneralAndAdministrativeExpense" order="1.0200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_RestructuringCharges" order="1.0300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_CostsAndExpenses" order="1.0400" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" use="optional"/> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:to="us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" order="1.1000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RevenuesAbstract" xlink:to="cytk_ResearchAndDevelopmentRevenuesFromRelatedParties" order="1.0500" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" use="optional"/> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RevenuesAbstract" xlink:to="cytk_ResearchAndDevelopmentGrantAndOtherRevenues" order="1.0600" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RevenuesAbstract" xlink:to="cytk_LicenseRevenuesFromRelatedParties" order="1.0700" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RevenuesAbstract" xlink:to="us-gaap_LicenseAndServicesRevenue" order="1.0800" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" use="optional"/> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RevenuesAbstract" xlink:to="us-gaap_Revenues" order="1.0900" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" use="optional"/> </presentationLink> <presentationLink xlink:type="extended" xlink:role="http://imetrix.edgar-online.com/taxonomy/role/StatementOfShareholdersEquityAndOtherComprehensiveIncome" xlink:title="148600 - Statement - Statement of Shareholders' Equity"> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember"/> <loc xlink:type="locator" xlink:href="cytk-20141231.xsd#cytk_AdjustmentsToAdditionalPaidInCapitalIssuanceOfConvertiblePreferredStock" xlink:label="cytk_AdjustmentsToAdditionalPaidInCapitalIssuanceOfConvertiblePreferredStock"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/> <loc xlink:type="locator" xlink:href="cytk-20141231.xsd#cytk_FractionalSharesFromReverseStockSplitShare" xlink:label="cytk_FractionalSharesFromReverseStockSplitShare"/> <loc xlink:type="locator" xlink:href="cytk-20141231.xsd#cytk_IssuanceOfConvertiblePreferredStockShares" xlink:label="cytk_IssuanceOfConvertiblePreferredStockShares"/> <loc xlink:type="locator" xlink:href="cytk-20141231.xsd#cytk_MlvAgreementMember" xlink:label="cytk_MlvAgreementMember"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTax"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PreferredStockMember" xlink:label="us-gaap_PreferredStockMember"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SeriesAPreferredStockMember" xlink:label="us-gaap_SeriesAPreferredStockMember"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SeriesBPreferredStockMember" xlink:label="us-gaap_SeriesBPreferredStockMember"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding_2"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity_2"/> <loc xlink:type="locator" xlink:href="cytk-20141231.xsd#cytk_StockIssuedDuringPeriodSharesAtMarketIssuanceSalesAgreement" xlink:label="cytk_StockIssuedDuringPeriodSharesAtMarketIssuanceSalesAgreement"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:label="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans"/> <loc xlink:type="locator" xlink:href="cytk-20141231.xsd#cytk_StockIssuedDuringPeriodSharesExerciseOfWarrants" xlink:label="cytk_StockIssuedDuringPeriodSharesExerciseOfWarrants"/> <loc xlink:type="locator" xlink:href="cytk-20141231.xsd#cytk_StockIssuedDuringPeriodSharesNewIssuesToCollaborativePartner" xlink:label="cytk_StockIssuedDuringPeriodSharesNewIssuesToCollaborativePartner"/> <loc xlink:type="locator" xlink:href="cytk-20141231.xsd#cytk_StockIssuedDuringPeriodSharesNewIssuesToRelatedParty" xlink:label="cytk_StockIssuedDuringPeriodSharesNewIssuesToRelatedParty"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:label="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures"/> <loc xlink:type="locator" xlink:href="cytk-20141231.xsd#cytk_StockIssuedDuringPeriodSharesSecuritiesPurchaseAgreement" xlink:label="cytk_StockIssuedDuringPeriodSharesSecuritiesPurchaseAgreement"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/> <loc xlink:type="locator" xlink:href="cytk-20141231.xsd#cytk_StockIssuedDuringPeriodValueAtMarketIssuanceSalesAgreement" xlink:label="cytk_StockIssuedDuringPeriodValueAtMarketIssuanceSalesAgreement"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:label="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan"/> <loc xlink:type="locator" xlink:href="cytk-20141231.xsd#cytk_StockIssuedDuringPeriodValueExerciseOfWarrants" xlink:label="cytk_StockIssuedDuringPeriodValueExerciseOfWarrants"/> <loc xlink:type="locator" xlink:href="cytk-20141231.xsd#cytk_StockIssuedDuringPeriodValueNewIssuesToCollaborativePartner" xlink:label="cytk_StockIssuedDuringPeriodValueNewIssuesToCollaborativePartner"/> <loc xlink:type="locator" xlink:href="cytk-20141231.xsd#cytk_StockIssuedDuringPeriodValueNewIssuesToRelatedParty" xlink:label="cytk_StockIssuedDuringPeriodValueNewIssuesToRelatedParty"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" xlink:label="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures"/> <loc xlink:type="locator" xlink:href="cytk-20141231.xsd#cytk_StockIssuedDuringPeriodValueSecuritiesPurchaseAgreement" xlink:label="cytk_StockIssuedDuringPeriodValueSecuritiesPurchaseAgreement"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis"/> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_SeriesAPreferredStockMember" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_SeriesBPreferredStockMember" order="1.0200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" order="1.3200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_PreferredStockMember" order="1.3300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AdditionalPaidInCapitalMember" order="1.3400" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeMember" order="1.3500" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_RetainedEarningsMember" order="1.3600" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="cytk_MlvAgreementMember" order="1.3700" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquity" order="1.0300" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" priority="2" use="optional"/> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" order="1.0400" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharesOutstanding" order="1.0500" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" priority="2" use="optional"/> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" order="1.0600" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" order="1.0700" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" order="1.0800" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" use="optional"/> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" order="1.0900" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" order="1.1000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="cytk_StockIssuedDuringPeriodValueNewIssuesToRelatedParty" order="1.1100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="cytk_StockIssuedDuringPeriodSharesNewIssuesToRelatedParty" order="1.1200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="cytk_StockIssuedDuringPeriodValueExerciseOfWarrants" order="1.1300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="cytk_StockIssuedDuringPeriodSharesExerciseOfWarrants" order="1.1400" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="cytk_StockIssuedDuringPeriodValueAtMarketIssuanceSalesAgreement" order="1.1500" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" order="1.1600" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="cytk_StockIssuedDuringPeriodSharesAtMarketIssuanceSalesAgreement" order="1.1700" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" order="1.1800" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="cytk_StockIssuedDuringPeriodValueNewIssuesToCollaborativePartner" order="1.1900" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="cytk_FractionalSharesFromReverseStockSplitShare" order="1.2000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="cytk_StockIssuedDuringPeriodSharesNewIssuesToCollaborativePartner" order="1.2100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="cytk_StockIssuedDuringPeriodValueSecuritiesPurchaseAgreement" order="1.2200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="cytk_StockIssuedDuringPeriodSharesSecuritiesPurchaseAgreement" order="1.2300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="cytk_AdjustmentsToAdditionalPaidInCapitalIssuanceOfConvertiblePreferredStock" order="1.2400" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="cytk_IssuanceOfConvertiblePreferredStockShares" order="1.2500" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" order="1.2600" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" order="1.2700" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OtherComprehensiveIncomeLossNetOfTax" order="1.2800" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetIncomeLoss" order="1.2900" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" use="optional"/> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquity_2" order="1.3000" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" priority="2" use="optional"/> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharesOutstanding_2" order="1.3100" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" priority="2" use="optional"/> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_StatementTable" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="10.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="11.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" order="12.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="100.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/> </presentationLink> <presentationLink xlink:type="extended" xlink:role="http://imetrix.edgar-online.com/taxonomy/role/StatementOfShareholdersEquityAndOtherComprehensiveIncomeParenthetical"> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/> <loc xlink:type="locator" xlink:href="cytk-20141231.xsd#cytk_ConversionPricePerShareOfPreferredStockToCommonStock" xlink:label="cytk_ConversionPricePerShareOfPreferredStockToCommonStock"/> <loc xlink:type="locator" xlink:href="cytk-20141231.xsd#cytk_ConvertiblePreferredStockIssuancePrice" xlink:label="cytk_ConvertiblePreferredStockIssuancePrice"/> <loc xlink:type="locator" xlink:href="cytk-20141231.xsd#cytk_IssuanceCostOfWarrant" xlink:label="cytk_IssuanceCostOfWarrant"/> <loc xlink:type="locator" xlink:href="cytk-20141231.xsd#cytk_IssuanceOfCommonStockEmployeeStockPurchasePlanPricePerShare" xlink:label="cytk_IssuanceOfCommonStockEmployeeStockPurchasePlanPricePerShare"/> <loc xlink:type="locator" xlink:href="cytk-20141231.xsd#cytk_IssuanceOfCommonStockToCollaborativePartnerForCashPerShare" xlink:label="cytk_IssuanceOfCommonStockToCollaborativePartnerForCashPerShare"/> <loc xlink:type="locator" xlink:href="cytk-20141231.xsd#cytk_IssuanceOfCommonStockToCollaborativePartnerIssuanceCosts" xlink:label="cytk_IssuanceOfCommonStockToCollaborativePartnerIssuanceCosts"/> <loc xlink:type="locator" xlink:href="cytk-20141231.xsd#cytk_IssuanceOfCommonStockToMlvAtPerShareLowerLimit" xlink:label="cytk_IssuanceOfCommonStockToMlvAtPerShareLowerLimit"/> <loc xlink:type="locator" xlink:href="cytk-20141231.xsd#cytk_IssuanceOfCommonStockToMlvAtPerShareUpperLimit" xlink:label="cytk_IssuanceOfCommonStockToMlvAtPerShareUpperLimit"/> <loc xlink:type="locator" xlink:href="cytk-20141231.xsd#cytk_IssuanceOfCommonStockToMlvNetOfCommissionAndIssuanceCosts" xlink:label="cytk_IssuanceOfCommonStockToMlvNetOfCommissionAndIssuanceCosts"/> <loc xlink:type="locator" xlink:href="cytk-20141231.xsd#cytk_IssuanceOfCommonStockToRelatedPartyForCashPerShare" xlink:label="cytk_IssuanceOfCommonStockToRelatedPartyForCashPerShare"/> <loc xlink:type="locator" xlink:href="cytk-20141231.xsd#cytk_IssuanceOfCommonStockToRelatedPartyIssuanceCosts" xlink:label="cytk_IssuanceOfCommonStockToRelatedPartyIssuanceCosts"/> <loc xlink:type="locator" xlink:href="cytk-20141231.xsd#cytk_MlvAgreementMember" xlink:label="cytk_MlvAgreementMember"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SeriesAPreferredStockMember" xlink:label="us-gaap_SeriesAPreferredStockMember"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SeriesBPreferredStockMember" xlink:label="us-gaap_SeriesBPreferredStockMember"/> <loc xlink:type="locator" xlink:href="cytk-20141231.xsd#cytk_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePrice" xlink:label="cytk_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePrice"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SharePrice" xlink:label="us-gaap_SharePrice"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis"/> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_SeriesAPreferredStockMember" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_SeriesBPreferredStockMember" order="1.0200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="cytk_MlvAgreementMember" order="1.1900" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="cytk_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePrice" order="1.0300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" order="1.0400" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="cytk_ConvertiblePreferredStockIssuancePrice" order="1.0500" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" order="1.0600" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="cytk_IssuanceOfCommonStockEmployeeStockPurchasePlanPricePerShare" order="1.0700" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="cytk_IssuanceOfCommonStockToMlvAtPerShareLowerLimit" order="1.0800" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="cytk_IssuanceOfCommonStockToRelatedPartyForCashPerShare" order="1.0900" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="cytk_IssuanceOfCommonStockToMlvAtPerShareUpperLimit" order="1.1000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="cytk_IssuanceOfCommonStockToRelatedPartyIssuanceCosts" order="1.1100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="cytk_IssuanceOfCommonStockToMlvNetOfCommissionAndIssuanceCosts" order="1.1200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="cytk_ConversionPricePerShareOfPreferredStockToCommonStock" order="1.1300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="cytk_IssuanceOfCommonStockToCollaborativePartnerForCashPerShare" order="1.1400" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="cytk_IssuanceOfCommonStockToCollaborativePartnerIssuanceCosts" order="1.1500" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharePrice" order="1.1600" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" use="optional"/> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PaymentsOfStockIssuanceCosts" order="1.1700" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" use="optional"/> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="cytk_IssuanceCostOfWarrant" order="1.1800" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_StatementTable" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="2.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="100.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/> </presentationLink> <presentationLink xlink:type="extended" xlink:role="http://imetrix.edgar-online.com/taxonomy/role/StatementOfCashFlowsIndirect" xlink:title="152200 - Statement - Statement of Cash Flows"> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_2"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:label="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="us-gaap_DepreciationDepletionAndAmortization"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:label="us-gaap_GainLossOnSaleOfPropertyPlantEquipment"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_GainOnSaleOfInvestments" xlink:label="us-gaap_GainOnSaleOfInvestments"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableTrade" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableTrade"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:label="us-gaap_IncreaseDecreaseInDeferredRevenue"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncreaseDecreaseInDueFromRelatedPartiesCurrent" xlink:label="us-gaap_IncreaseDecreaseInDueFromRelatedPartiesCurrent"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncreaseDecreaseInDueToRelatedPartiesCurrent" xlink:label="us-gaap_IncreaseDecreaseInDueToRelatedPartiesCurrent"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncreaseDecreaseInRestrictedCash" xlink:label="us-gaap_IncreaseDecreaseInRestrictedCash"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:label="us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/> <loc xlink:type="locator" xlink:href="cytk-20141231.xsd#cytk_ProceedsAndPaymentsFromStockBasedAwardAndWarrantsNetOfIssuanceCosts" xlink:label="cytk_ProceedsAndPaymentsFromStockBasedAwardAndWarrantsNetOfIssuanceCosts"/> <loc xlink:type="locator" xlink:href="cytk-20141231.xsd#cytk_ProceedsFromDrawDownOfCommittedEquityFinancingFacilitiesAndAtMarketFacilityNetOfIssuanceCosts" xlink:label="cytk_ProceedsFromDrawDownOfCommittedEquityFinancingFacilitiesAndAtMarketFacilityNetOfIssuanceCosts"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock" xlink:label="us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" xlink:label="us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:label="us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RepaymentsOfSecuredDebt" xlink:label="us-gaap_RepaymentsOfSecuredDebt"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RestructuringCostsAndAssetImpairmentCharges" xlink:label="us-gaap_RestructuringCostsAndAssetImpairmentCharges"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="us-gaap_StatementOfCashFlowsAbstract"/> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_DepreciationDepletionAndAmortization" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_GainLossOnSaleOfPropertyPlantEquipment" order="1.0200" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="2" use="optional"/> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_RestructuringCostsAndAssetImpairmentCharges" order="1.0300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_ShareBasedCompensation" order="1.0400" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_GainOnSaleOfInvestments" order="1.0500" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="2" use="optional"/> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInDueFromRelatedPartiesCurrent" order="1.0600" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="2" use="optional"/> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" order="1.0700" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="2" use="optional"/> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayableTrade" order="1.0800" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilities" order="1.0900" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInDueToRelatedPartiesCurrent" order="1.1000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInDeferredRevenue" order="1.1100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" order="1.1200" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" use="optional"/> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:to="cytk_ProceedsFromDrawDownOfCommittedEquityFinancingFacilitiesAndAtMarketFacilityNetOfIssuanceCosts" order="1.1300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:to="cytk_ProceedsAndPaymentsFromStockBasedAwardAndWarrantsNetOfIssuanceCosts" order="1.1400" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="2" use="optional"/> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:to="us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock" order="1.1500" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" use="optional"/> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:to="us-gaap_RepaymentsOfSecuredDebt" order="1.1600" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="2" use="optional"/> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" order="1.1700" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" use="optional"/> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" xlink:to="us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" order="1.1800" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="2" use="optional"/> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" xlink:to="us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" order="1.1900" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" order="1.2000" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="2" use="optional"/> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" xlink:to="us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" order="1.2100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" xlink:to="us-gaap_IncreaseDecreaseInRestrictedCash" order="1.2200" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="2" use="optional"/> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" order="1.2300" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" use="optional"/> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:to="us-gaap_NetIncomeLoss" order="1.2400" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" use="optional"/> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" order="1.2500" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" order="1.2600" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" order="1.2700" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" use="optional"/> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" order="1.2800" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" order="1.2900" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" order="1.3000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" order="1.3100" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" use="optional"/> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="1.3200" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" priority="2" use="optional"/> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_2" order="1.3300" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" priority="2" use="optional"/> </presentationLink> <presentationLink xlink:type="extended" xlink:role="http://imetrix.edgar-online.com/taxonomy/role/DisclosureOrganizationAndSignificantAccountingPoliciesAdditionalInformation"> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AccountsReceivableRelatedParties" xlink:label="us-gaap_AccountsReceivableRelatedParties"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalStockSplit" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockSplit"/> <loc xlink:type="locator" xlink:href="cytk-20141231.xsd#cytk_AmgenMember" xlink:label="cytk_AmgenMember"/> <loc xlink:type="locator" xlink:href="cytk-20141231.xsd#cytk_AstellasMember" xlink:label="cytk_AstellasMember"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:label="us-gaap_CashCashEquivalentsAndShortTermInvestments"/> <loc xlink:type="locator" xlink:href="cytk-20141231.xsd#cytk_CashRequirementsTerm" xlink:label="cytk_CashRequirementsTerm"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized"/> <loc xlink:type="locator" xlink:href="cytk-20141231.xsd#cytk_ComputerEquipmentAndSoftwareMember" xlink:label="cytk_ComputerEquipmentAndSoftwareMember"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ConcentrationRiskPercentage1" xlink:label="us-gaap_ConcentrationRiskPercentage1"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount" xlink:label="us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount"/> <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain"/> <loc xlink:type="locator" xlink:href="cytk-20141231.xsd#cytk_FractionalSharesFromReverseStockSplitShare" xlink:label="cytk_FractionalSharesFromReverseStockSplitShare"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="us-gaap_FurnitureAndFixturesMember"/> <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/country/2013/country-2013-01-31.xsd#country_JP" xlink:label="country_JP"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LeaseholdsAndLeaseholdImprovementsMember" xlink:label="us-gaap_LeaseholdsAndLeaseholdImprovementsMember"/> <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_MaximumMember" xlink:label="us-gaap_MaximumMember"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_MinimumMember" xlink:label="us-gaap_MinimumMember"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/> <loc xlink:type="locator" xlink:href="cytk-20141231.xsd#cytk_NumberOfFinancialInstitutions" xlink:label="cytk_NumberOfFinancialInstitutions"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NumberOfReportableSegments" xlink:label="us-gaap_NumberOfReportableSegments"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OfficeEquipmentMember" xlink:label="us-gaap_OfficeEquipmentMember"/> <loc xlink:type="locator" xlink:href="cytk-20141231.xsd#cytk_PercentageOfIncomeTaxPositionsLikelyToBeRealized" xlink:label="cytk_PercentageOfIncomeTaxPositionsLikelyToBeRealized"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RangeAxis" xlink:label="us-gaap_RangeAxis"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RangeMember" xlink:label="us-gaap_RangeMember"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SegmentGeographicalDomain" xlink:label="us-gaap_SegmentGeographicalDomain"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementGeographicalAxis" xlink:label="us-gaap_StatementGeographicalAxis"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:label="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockholdersEquityReverseStockSplit" xlink:label="us-gaap_StockholdersEquityReverseStockSplit"/> <loc xlink:type="locator" xlink:href="cytk-20141231.xsd#cytk_SummaryOfSignificantAccountingPoliciesLineItems" xlink:label="cytk_SummaryOfSignificantAccountingPoliciesLineItems"/> <loc xlink:type="locator" xlink:href="cytk-20141231.xsd#cytk_SummaryOfSignificantAccountingPoliciesTable" xlink:label="cytk_SummaryOfSignificantAccountingPoliciesTable"/> <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/country/2013/country-2013-01-31.xsd#country_US" xlink:label="country_US"/> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="cytk_SummaryOfSignificantAccountingPoliciesTable" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_EntityDomain" xlink:to="cytk_AstellasMember" order="1.2000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="cytk_ComputerEquipmentAndSoftwareMember" order="1.2200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_OfficeEquipmentMember" order="1.2500" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_FurnitureAndFixturesMember" order="1.2700" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_LeaseholdsAndLeaseholdImprovementsMember" order="1.2800" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RangeAxis" xlink:to="us-gaap_RangeMember" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RangeMember" xlink:to="us-gaap_MaximumMember" order="1.2300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RangeMember" xlink:to="us-gaap_MinimumMember" order="1.2600" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="cytk_AmgenMember" order="1.1900" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentGeographicalDomain" xlink:to="country_US" order="1.2100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentGeographicalDomain" xlink:to="country_JP" order="1.2400" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementGeographicalAxis" xlink:to="us-gaap_SegmentGeographicalDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cytk_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" use="optional"/> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cytk_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_NetIncomeLoss" order="1.0200" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" use="optional"/> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cytk_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" order="1.0300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cytk_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_CashCashEquivalentsAndShortTermInvestments" order="1.0400" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cytk_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="cytk_CashRequirementsTerm" order="1.0500" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cytk_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="cytk_NumberOfFinancialInstitutions" order="1.0600" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cytk_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_ConcentrationRiskPercentage1" order="1.0700" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cytk_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_AccountsReceivableRelatedParties" order="1.0800" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cytk_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife" order="1.0900" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cytk_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount" order="1.1000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cytk_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="cytk_PercentageOfIncomeTaxPositionsLikelyToBeRealized" order="1.1100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cytk_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_NumberOfReportableSegments" order="1.1200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cytk_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" order="1.1300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cytk_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_StockholdersEquityReverseStockSplit" order="1.1400" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cytk_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="cytk_FractionalSharesFromReverseStockSplitShare" order="1.1500" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cytk_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_CommonStockSharesAuthorized" order="1.1600" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cytk_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" order="1.1700" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cytk_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockSplit" order="1.1800" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cytk_SummaryOfSignificantAccountingPoliciesTable" xlink:to="us-gaap_RangeAxis" order="10.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cytk_SummaryOfSignificantAccountingPoliciesTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" order="11.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cytk_SummaryOfSignificantAccountingPoliciesTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" order="12.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cytk_SummaryOfSignificantAccountingPoliciesTable" xlink:to="dei_LegalEntityAxis" order="13.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cytk_SummaryOfSignificantAccountingPoliciesTable" xlink:to="us-gaap_StatementGeographicalAxis" order="14.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cytk_SummaryOfSignificantAccountingPoliciesTable" xlink:to="cytk_SummaryOfSignificantAccountingPoliciesLineItems" order="100.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/> </presentationLink> <presentationLink xlink:type="extended" xlink:role="http://imetrix.edgar-online.com/taxonomy/role/DisclosureNetLossPerShareCalculationOfBasicAndDilutedNetLossPerShareAllocableToCommonStockholders"> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted" xlink:label="us-gaap_EarningsPerShareBasicAndDiluted"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OtherPreferredStockDividendsAndAdjustments" xlink:label="us-gaap_OtherPreferredStockDividendsAndAdjustments"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:label="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted"/> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_NetIncomeLoss" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" use="optional"/> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_OtherPreferredStockDividendsAndAdjustments" order="1.0200" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="2" use="optional"/> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" order="1.0300" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" use="optional"/> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" order="1.0400" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" use="optional"/> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_EarningsPerShareBasicAndDiluted" order="1.0500" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/> </presentationLink> <presentationLink xlink:type="extended" xlink:role="http://imetrix.edgar-online.com/taxonomy/role/DisclosureNetLossPerShareInstrumentsExcludedFromTheComputationOfDilutedNetLossPerCommonShare"> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EmployeeStockMember" xlink:label="us-gaap_EmployeeStockMember"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OptionIndexedToIssuersEquityTypeAxis" xlink:label="us-gaap_OptionIndexedToIssuersEquityTypeAxis"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OptionIndexedToIssuersEquityTypeDomain" xlink:label="us-gaap_OptionIndexedToIssuersEquityTypeDomain"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SeriesBPreferredStockMember" xlink:label="us-gaap_SeriesBPreferredStockMember"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_WarrantMember" xlink:label="us-gaap_WarrantMember"/> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" order="1.0400" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_WarrantMember" order="1.0500" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_RestrictedStockUnitsRSUMember" order="1.0600" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_SeriesBPreferredStockMember" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OptionIndexedToIssuersEquityTypeAxis" xlink:to="us-gaap_OptionIndexedToIssuersEquityTypeDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OptionIndexedToIssuersEquityTypeDomain" xlink:to="us-gaap_EmployeeStockOptionMember" order="1.0200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_EmployeeStockMember" order="1.0300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" order="10.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="11.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" order="12.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_OptionIndexedToIssuersEquityTypeAxis" order="13.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" order="100.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/> </presentationLink> <presentationLink xlink:type="extended" xlink:role="http://imetrix.edgar-online.com/taxonomy/role/DisclosureSupplementaryCashFlowDataSupplementalCashFlowInformation"> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:label="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncomeTaxesPaidNet" xlink:label="us-gaap_IncomeTaxesPaidNet"/> <loc xlink:type="locator" xlink:href="cytk-20141231.xsd#cytk_IncreaseDecreaseInNoncashOrPartNoncashAcquisitionFixedAssetsAcquiredThroughAccruedLiabilities" xlink:label="cytk_IncreaseDecreaseInNoncashOrPartNoncashAcquisitionFixedAssetsAcquiredThroughAccruedLiabilities"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_InterestPaid" xlink:label="us-gaap_InterestPaid"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NoncashOrPartNoncashAcquisitionFixedAssetsAcquired1" xlink:label="us-gaap_NoncashOrPartNoncashAcquisitionFixedAssetsAcquired1"/> <loc xlink:type="locator" xlink:href="cytk-20141231.xsd#cytk_NoncashOrPartNoncashAcquisitionFixedAssetsAcquiredTradeInValue" xlink:label="cytk_NoncashOrPartNoncashAcquisitionFixedAssetsAcquiredTradeInValue"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SupplementalCashFlowElementsAbstract" xlink:label="us-gaap_SupplementalCashFlowElementsAbstract"/> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="us-gaap_NoncashOrPartNoncashAcquisitionFixedAssetsAcquired1" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="cytk_IncreaseDecreaseInNoncashOrPartNoncashAcquisitionFixedAssetsAcquiredThroughAccruedLiabilities" order="1.0200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="cytk_NoncashOrPartNoncashAcquisitionFixedAssetsAcquiredTradeInValue" order="1.0300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SupplementalCashFlowElementsAbstract" xlink:to="us-gaap_InterestPaid" order="1.0400" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SupplementalCashFlowElementsAbstract" xlink:to="us-gaap_IncomeTaxesPaidNet" order="1.0500" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SupplementalCashFlowElementsAbstract" xlink:to="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" order="1.0600" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/> </presentationLink> <presentationLink xlink:type="extended" xlink:role="http://imetrix.edgar-online.com/taxonomy/role/DisclosureCashEquivalentsAndInvestmentsAmortizedCostAndFairValueOfCashEquivalentsAndAvailableForSaleInvestments"> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AvailableForSaleSecurities" xlink:label="us-gaap_AvailableForSaleSecurities"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:label="us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:label="us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/> <loc xlink:type="locator" xlink:href="cytk-20141231.xsd#cytk_AvailableForSaleSecuritiesMaturityDate" xlink:label="cytk_AvailableForSaleSecuritiesMaturityDate"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CashAndCashEquivalentsAbstract" xlink:label="us-gaap_CashAndCashEquivalentsAbstract"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CashAndCashEquivalentsAxis" xlink:label="us-gaap_CashAndCashEquivalentsAxis"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CashAndCashEquivalentsLineItems" xlink:label="us-gaap_CashAndCashEquivalentsLineItems"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CashEquivalentsMember" xlink:label="us-gaap_CashEquivalentsMember"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_InvestmentTypeAxis" xlink:label="us-gaap_InvestmentTypeAxis"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_InvestmentTypeCategorizationMember" xlink:label="us-gaap_InvestmentTypeCategorizationMember"/> <loc xlink:type="locator" xlink:href="cytk-20141231.xsd#cytk_LongTermInvestmentMember" xlink:label="cytk_LongTermInvestmentMember"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_MaximumMember" xlink:label="us-gaap_MaximumMember"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_MinimumMember" xlink:label="us-gaap_MinimumMember"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_MoneyMarketFundsMember" xlink:label="us-gaap_MoneyMarketFundsMember"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RangeAxis" xlink:label="us-gaap_RangeAxis"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RangeMember" xlink:label="us-gaap_RangeMember"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfCashAndCashEquivalentsTable" xlink:label="us-gaap_ScheduleOfCashAndCashEquivalentsTable"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShortTermInvestmentsMember" xlink:label="us-gaap_ShortTermInvestmentsMember"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_USTreasurySecuritiesMember" xlink:label="us-gaap_USTreasurySecuritiesMember"/> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashAndCashEquivalentsAbstract" xlink:to="us-gaap_ScheduleOfCashAndCashEquivalentsTable" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashAndCashEquivalentsAxis" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashAndCashEquivalentsLineItems" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" order="1.0800" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" use="optional"/> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashAndCashEquivalentsLineItems" xlink:to="us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" order="1.0900" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashAndCashEquivalentsLineItems" xlink:to="us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" order="1.1000" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="2" use="optional"/> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashAndCashEquivalentsLineItems" xlink:to="us-gaap_AvailableForSaleSecurities" order="1.1100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashAndCashEquivalentsLineItems" xlink:to="cytk_AvailableForSaleSecuritiesMaturityDate" order="1.1200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentTypeAxis" xlink:to="us-gaap_InvestmentTypeCategorizationMember" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentTypeCategorizationMember" xlink:to="us-gaap_CashEquivalentsMember" order="1.0300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentTypeCategorizationMember" xlink:to="us-gaap_ShortTermInvestmentsMember" order="1.0400" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentTypeCategorizationMember" xlink:to="cytk_LongTermInvestmentMember" order="1.0500" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RangeAxis" xlink:to="us-gaap_RangeMember" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RangeMember" xlink:to="us-gaap_MinimumMember" order="1.0600" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RangeMember" xlink:to="us-gaap_MaximumMember" order="1.0700" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:to="us-gaap_MoneyMarketFundsMember" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:to="us-gaap_USTreasurySecuritiesMember" order="1.0200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCashAndCashEquivalentsTable" xlink:to="us-gaap_RangeAxis" order="10.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCashAndCashEquivalentsTable" xlink:to="us-gaap_InvestmentTypeAxis" order="11.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCashAndCashEquivalentsTable" xlink:to="us-gaap_CashAndCashEquivalentsAxis" order="12.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCashAndCashEquivalentsTable" xlink:to="us-gaap_CashAndCashEquivalentsLineItems" order="100.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/> </presentationLink> <presentationLink xlink:type="extended" xlink:role="http://imetrix.edgar-online.com/taxonomy/role/DisclosureCashEquivalentsAndInvestmentsAdditionalInformation"> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" xlink:label="us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CashAndCashEquivalentsAbstract" xlink:label="us-gaap_CashAndCashEquivalentsAbstract"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CashAndCashEquivalentsAxis" xlink:label="us-gaap_CashAndCashEquivalentsAxis"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CashAndCashEquivalentsLineItems" xlink:label="us-gaap_CashAndCashEquivalentsLineItems"/> <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/invest/2013/invest-2013-01-31.xsd#invest_InvestmentMaturityDateRangeEnd1" xlink:label="invest_InvestmentMaturityDateRangeEnd1"/> <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/invest/2013/invest-2013-01-31.xsd#invest_InvestmentMaturityDateRangeStart1" xlink:label="invest_InvestmentMaturityDateRangeStart1"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_InvestmentTypeAxis" xlink:label="us-gaap_InvestmentTypeAxis"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_InvestmentTypeCategorizationMember" xlink:label="us-gaap_InvestmentTypeCategorizationMember"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfCashAndCashEquivalentsTable" xlink:label="us-gaap_ScheduleOfCashAndCashEquivalentsTable"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShortTermInvestmentsMember" xlink:label="us-gaap_ShortTermInvestmentsMember"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_UnrealizedGainLossOnInvestments" xlink:label="us-gaap_UnrealizedGainLossOnInvestments"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_USTreasurySecuritiesMember" xlink:label="us-gaap_USTreasurySecuritiesMember"/> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashAndCashEquivalentsAbstract" xlink:to="us-gaap_ScheduleOfCashAndCashEquivalentsTable" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashAndCashEquivalentsAxis" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashAndCashEquivalentsLineItems" xlink:to="us-gaap_UnrealizedGainLossOnInvestments" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashAndCashEquivalentsLineItems" xlink:to="us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" order="1.0200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashAndCashEquivalentsLineItems" xlink:to="invest_InvestmentMaturityDateRangeStart1" order="1.0300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashAndCashEquivalentsLineItems" xlink:to="invest_InvestmentMaturityDateRangeEnd1" order="1.0400" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentTypeAxis" xlink:to="us-gaap_InvestmentTypeCategorizationMember" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentTypeCategorizationMember" xlink:to="us-gaap_ShortTermInvestmentsMember" order="1.0500" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:to="us-gaap_USTreasurySecuritiesMember" order="1.0600" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCashAndCashEquivalentsTable" xlink:to="us-gaap_InvestmentTypeAxis" order="10.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCashAndCashEquivalentsTable" xlink:to="us-gaap_CashAndCashEquivalentsAxis" order="11.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCashAndCashEquivalentsTable" xlink:to="us-gaap_CashAndCashEquivalentsLineItems" order="100.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/> </presentationLink> <presentationLink xlink:type="extended" xlink:role="http://imetrix.edgar-online.com/taxonomy/role/DisclosureCashEquivalentsAndInvestmentsSummaryOfInterestIncome"> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CashAndCashEquivalentsAbstract" xlink:label="us-gaap_CashAndCashEquivalentsAbstract"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_InvestmentIncomeInterest" xlink:label="us-gaap_InvestmentIncomeInterest"/> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashAndCashEquivalentsAbstract" xlink:to="us-gaap_InvestmentIncomeInterest" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/> </presentationLink> <presentationLink xlink:type="extended" xlink:role="http://imetrix.edgar-online.com/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfFinancialAssetsMeasuredAtFairValueOnRecurringBasis"> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AssetsFairValueDisclosure" xlink:label="us-gaap_AssetsFairValueDisclosure"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_BalanceSheetLocationAxis" xlink:label="us-gaap_BalanceSheetLocationAxis"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="us-gaap_BalanceSheetLocationDomain"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CashAndCashEquivalentsMember" xlink:label="us-gaap_CashAndCashEquivalentsMember"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueByAssetClassAxis" xlink:label="us-gaap_FairValueByAssetClassAxis"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="us-gaap_FairValueInputsLevel1Member"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="us-gaap_FairValueInputsLevel2Member"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="us-gaap_FairValueInputsLevel3Member"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:label="us-gaap_FairValueMeasurementsRecurringMember"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_InvestmentTypeAxis" xlink:label="us-gaap_InvestmentTypeAxis"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_InvestmentTypeCategorizationMember" xlink:label="us-gaap_InvestmentTypeCategorizationMember"/> <loc xlink:type="locator" xlink:href="cytk-20141231.xsd#cytk_LongTermInvestmentMember" xlink:label="cytk_LongTermInvestmentMember"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_MoneyMarketFundsMember" xlink:label="us-gaap_MoneyMarketFundsMember"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfFairValueOfSeparateAccountsByMajorCategoryOfInvestmentAxis" xlink:label="us-gaap_ScheduleOfFairValueOfSeparateAccountsByMajorCategoryOfInvestmentAxis"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfFairValueOfSeparateAccountsByMajorCategoryOfInvestmentCategoryDomain" xlink:label="us-gaap_ScheduleOfFairValueOfSeparateAccountsByMajorCategoryOfInvestmentCategoryDomain"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShortTermInvestmentsMember" xlink:label="us-gaap_ShortTermInvestmentsMember"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_USTreasurySecuritiesMember" xlink:label="us-gaap_USTreasurySecuritiesMember"/> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BalanceSheetLocationAxis" xlink:to="us-gaap_BalanceSheetLocationDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BalanceSheetLocationDomain" xlink:to="cytk_LongTermInvestmentMember" order="1.0200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_AssetsFairValueDisclosure" order="1.0800" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueByMeasurementFrequencyAxis" order="10.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_InvestmentTypeAxis" order="11.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis" order="12.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_ScheduleOfFairValueOfSeparateAccountsByMajorCategoryOfInvestmentAxis" order="13.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_BalanceSheetLocationAxis" order="14.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueByAssetClassAxis" order="15.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" order="100.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="us-gaap_MoneyMarketFundsMember" order="1.0600" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="us-gaap_USTreasurySecuritiesMember" order="1.0700" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByAssetClassAxis" xlink:to="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="us-gaap_FairValueMeasurementFrequencyDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementFrequencyDomain" xlink:to="us-gaap_FairValueMeasurementsRecurringMember" order="1.0900" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel1Member" order="1.0300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel2Member" order="1.0400" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel3Member" order="1.0500" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentTypeAxis" xlink:to="us-gaap_InvestmentTypeCategorizationMember" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentTypeCategorizationMember" xlink:to="us-gaap_CashAndCashEquivalentsMember" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfFairValueOfSeparateAccountsByMajorCategoryOfInvestmentAxis" xlink:to="us-gaap_ScheduleOfFairValueOfSeparateAccountsByMajorCategoryOfInvestmentCategoryDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfFairValueOfSeparateAccountsByMajorCategoryOfInvestmentCategoryDomain" xlink:to="us-gaap_ShortTermInvestmentsMember" order="1.1000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/> </presentationLink> <presentationLink xlink:type="extended" xlink:role="http://imetrix.edgar-online.com/taxonomy/role/DisclosureFairValueMeasurementsAdditionalInformation"> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AssetsFairValueDisclosureRecurring" xlink:label="us-gaap_AssetsFairValueDisclosureRecurring"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="us-gaap_FairValueInputsLevel2Member"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="us-gaap_FairValueInputsLevel3Member"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_AssetsFairValueDisclosureRecurring" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis" order="10.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" order="100.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel2Member" order="1.0200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel3Member" order="1.0300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/> </presentationLink> <presentationLink xlink:type="extended" xlink:role="http://imetrix.edgar-online.com/taxonomy/role/DisclosureBalanceSheetComponentsSummaryOfPropertyAndEquipmentBalances"> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/> <loc xlink:type="locator" xlink:href="cytk-20141231.xsd#cytk_ComputerEquipmentAndSoftwareMember" xlink:label="cytk_ComputerEquipmentAndSoftwareMember"/> <loc xlink:type="locator" xlink:href="cytk-20141231.xsd#cytk_LaboratoryEquipmentMember" xlink:label="cytk_LaboratoryEquipmentMember"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LeaseholdsAndLeaseholdImprovementsMember" xlink:label="us-gaap_LeaseholdsAndLeaseholdImprovementsMember"/> <loc xlink:type="locator" xlink:href="cytk-20141231.xsd#cytk_OfficeEquipmentFurnitureAndFixturesMember" xlink:label="cytk_OfficeEquipmentFurnitureAndFixturesMember"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="us-gaap_PropertyPlantAndEquipmentGross"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNetAbstract" xlink:label="us-gaap_PropertyPlantAndEquipmentNetAbstract"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain"/> <loc xlink:type="locator" xlink:href="cytk-20141231.xsd#cytk_PropertyPlantAndEquipmentUsefulLifeAndValuesAbstract" xlink:label="cytk_PropertyPlantAndEquipmentUsefulLifeAndValuesAbstract"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentNetAbstract" order="1.0800" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentNetAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentGross" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentNetAbstract" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" order="1.0200" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="2" use="optional"/> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentNetAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" order="1.0300" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" use="optional"/> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="cytk_LaboratoryEquipmentMember" order="1.0400" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="cytk_ComputerEquipmentAndSoftwareMember" order="1.0500" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="cytk_OfficeEquipmentFurnitureAndFixturesMember" order="1.0600" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_LeaseholdsAndLeaseholdImprovementsMember" order="1.0700" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cytk_PropertyPlantAndEquipmentUsefulLifeAndValuesAbstract" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" order="10.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_PropertyPlantAndEquipmentLineItems" order="100.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/> </presentationLink> <presentationLink xlink:type="extended" xlink:role="http://imetrix.edgar-online.com/taxonomy/role/DisclosureBalanceSheetComponentsAdditionalInformation"> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract" xlink:label="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_Depreciation" xlink:label="us-gaap_Depreciation"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_InterestReceivable" xlink:label="us-gaap_InterestReceivable"/> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract" xlink:to="us-gaap_Depreciation" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract" xlink:to="us-gaap_InterestReceivable" order="1.0200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/> </presentationLink> <presentationLink xlink:type="extended" xlink:role="http://imetrix.edgar-online.com/taxonomy/role/DisclosureBalanceSheetComponentsSummaryOfAccruedLiabilities"> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AccruedBonusesCurrent" xlink:label="us-gaap_AccruedBonusesCurrent"/> <loc xlink:type="locator" xlink:href="cytk-20141231.xsd#cytk_AccruedClinicalAndPreclinicalCostsCurrent" xlink:label="cytk_AccruedClinicalAndPreclinicalCostsCurrent"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AccruedLiabilitiesCurrentAbstract" xlink:label="us-gaap_AccruedLiabilitiesCurrentAbstract"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AccruedProfessionalFeesCurrent" xlink:label="us-gaap_AccruedProfessionalFeesCurrent"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AccruedVacationCurrent" xlink:label="us-gaap_AccruedVacationCurrent"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OtherEmployeeRelatedLiabilitiesCurrent" xlink:label="us-gaap_OtherEmployeeRelatedLiabilitiesCurrent"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="us-gaap_PayablesAndAccrualsAbstract"/> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccruedLiabilitiesCurrentAbstract" xlink:to="cytk_AccruedClinicalAndPreclinicalCostsCurrent" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccruedLiabilitiesCurrentAbstract" xlink:to="us-gaap_AccruedProfessionalFeesCurrent" order="1.0200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccruedLiabilitiesCurrentAbstract" xlink:to="us-gaap_AccruedBonusesCurrent" order="1.0300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccruedLiabilitiesCurrentAbstract" xlink:to="us-gaap_AccruedVacationCurrent" order="1.0400" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccruedLiabilitiesCurrentAbstract" xlink:to="us-gaap_OtherEmployeeRelatedLiabilitiesCurrent" order="1.0500" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccruedLiabilitiesCurrentAbstract" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrent" order="1.0600" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccruedLiabilitiesCurrentAbstract" xlink:to="us-gaap_AccruedLiabilitiesCurrent" order="1.0700" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" use="optional"/> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="us-gaap_AccruedLiabilitiesCurrentAbstract" order="1.0800" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/> </presentationLink> <presentationLink xlink:type="extended" xlink:role="http://imetrix.edgar-online.com/taxonomy/role/DisclosureRelatedPartiesAndRelatedPartyTransactionsAdditionalInformation"> <loc xlink:type="locator" xlink:href="cytk-20141231.xsd#cytk_AmendedAgreementMember" xlink:label="cytk_AmendedAgreementMember"/> <loc xlink:type="locator" xlink:href="cytk-20141231.xsd#cytk_AmgenMember" xlink:label="cytk_AmgenMember"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember"/> <loc xlink:type="locator" xlink:href="cytk-20141231.xsd#cytk_AstellasMember" xlink:label="cytk_AstellasMember"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis" xlink:label="us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis"/> <loc xlink:type="locator" xlink:href="cytk-20141231.xsd#cytk_CommercialMilestonesMember" xlink:label="cytk_CommercialMilestonesMember"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DeferredRevenue" xlink:label="us-gaap_DeferredRevenue"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DeferredRevenueRevenueRecognized" xlink:label="us-gaap_DeferredRevenueRevenueRecognized"/> <loc xlink:type="locator" xlink:href="cytk-20141231.xsd#cytk_EarlyDevelopmentMember" xlink:label="cytk_EarlyDevelopmentMember"/> <loc xlink:type="locator" xlink:href="cytk-20141231.xsd#cytk_FairValueOfCommonStockIssued" xlink:label="cytk_FairValueOfCommonStockIssued"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/> <loc xlink:type="locator" xlink:href="cytk-20141231.xsd#cytk_InternalCostsMember" xlink:label="cytk_InternalCostsMember"/> <loc xlink:type="locator" xlink:href="cytk-20141231.xsd#cytk_LicenseAndServicesMember" xlink:label="cytk_LicenseAndServicesMember"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LicenseAndServicesRevenue" xlink:label="us-gaap_LicenseAndServicesRevenue"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LicenseCosts" xlink:label="us-gaap_LicenseCosts"/> <loc xlink:type="locator" xlink:href="cytk-20141231.xsd#cytk_LicenseFeeArrangementMember" xlink:label="cytk_LicenseFeeArrangementMember"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_MaximumMember" xlink:label="us-gaap_MaximumMember"/> <loc xlink:type="locator" xlink:href="cytk-20141231.xsd#cytk_MilestonePaymentsReceivedUnderArrangements" xlink:label="cytk_MilestonePaymentsReceivedUnderArrangements"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_MinimumMember" xlink:label="us-gaap_MinimumMember"/> <loc xlink:type="locator" xlink:href="cytk-20141231.xsd#cytk_NonNeuromuscularIndicationsMember" xlink:label="cytk_NonNeuromuscularIndicationsMember"/> <loc xlink:type="locator" xlink:href="cytk-20141231.xsd#cytk_OtherCostsMember" xlink:label="cytk_OtherCostsMember"/> <loc xlink:type="locator" xlink:href="cytk-20141231.xsd#cytk_PotentialAmountsReceivableUnderCollaborationAgreement" xlink:label="cytk_PotentialAmountsReceivableUnderCollaborationAgreement"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ProjectMember" xlink:label="us-gaap_ProjectMember"/> <loc xlink:type="locator" xlink:href="cytk-20141231.xsd#cytk_ProportionalPerformanceModelMember" xlink:label="cytk_ProportionalPerformanceModelMember"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RangeAxis" xlink:label="us-gaap_RangeAxis"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RangeMember" xlink:label="us-gaap_RangeMember"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ReimbursementRevenue" xlink:label="us-gaap_ReimbursementRevenue"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RelatedPartyTransactionAxis" xlink:label="us-gaap_RelatedPartyTransactionAxis"/> <loc xlink:type="locator" xlink:href="cytk-20141231.xsd#cytk_RelatedPartyTransactionCommercializationMilestonePaymentsReceivedByEntity" xlink:label="cytk_RelatedPartyTransactionCommercializationMilestonePaymentsReceivedByEntity"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RelatedPartyTransactionDomain" xlink:label="us-gaap_RelatedPartyTransactionDomain"/> <loc xlink:type="locator" xlink:href="cytk-20141231.xsd#cytk_RelatedPartyTransactionPreCommercializationMilestonePaymentsReceivedByEntity" xlink:label="cytk_RelatedPartyTransactionPreCommercializationMilestonePaymentsReceivedByEntity"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="us-gaap_RelatedPartyTransactionsAbstract"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned"/> <loc xlink:type="locator" xlink:href="cytk-20141231.xsd#cytk_ResearchAndDevelopmentRevenue" xlink:label="cytk_ResearchAndDevelopmentRevenue"/> <loc xlink:type="locator" xlink:href="cytk-20141231.xsd#cytk_ResearchAndDevelopmentRevenuesFromRelatedParties" xlink:label="cytk_ResearchAndDevelopmentRevenuesFromRelatedParties"/> <loc xlink:type="locator" xlink:href="cytk-20141231.xsd#cytk_ResearchCollaborationAndLicenseAgreementPeriod" xlink:label="cytk_ResearchCollaborationAndLicenseAgreementPeriod"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized" xlink:label="us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized"/> <loc xlink:type="locator" xlink:href="cytk-20141231.xsd#cytk_ScheduleOfOtherRelatedPartyTransactionsLineItems" xlink:label="cytk_ScheduleOfOtherRelatedPartyTransactionsLineItems"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SharePrice" xlink:label="us-gaap_SharePrice"/> <loc xlink:type="locator" xlink:href="cytk-20141231.xsd#cytk_SmaAndOtherNeuromuscularIndicationsMember" xlink:label="cytk_SmaAndOtherNeuromuscularIndicationsMember"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis"/> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="cytk_ProportionalPerformanceModelMember" order="1.2200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="cytk_EarlyDevelopmentMember" order="1.2900" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="cytk_NonNeuromuscularIndicationsMember" order="1.3100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="cytk_CommercialMilestonesMember" order="1.3200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="cytk_SmaAndOtherNeuromuscularIndicationsMember" order="1.3300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis" xlink:to="us-gaap_ProjectMember" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="cytk_LicenseAndServicesMember" order="1.2000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="cytk_LicenseFeeArrangementMember" order="1.2700" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ProjectMember" xlink:to="cytk_InternalCostsMember" order="1.2300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ProjectMember" xlink:to="cytk_OtherCostsMember" order="1.2800" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RangeAxis" xlink:to="us-gaap_RangeMember" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RangeMember" xlink:to="us-gaap_MaximumMember" order="1.2100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RangeMember" xlink:to="us-gaap_MinimumMember" order="1.3000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="cytk_AmgenMember" order="1.1900" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="cytk_AstellasMember" order="1.2600" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="us-gaap_RelatedPartyTransactionDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionDomain" xlink:to="cytk_AmendedAgreementMember" order="1.2400" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsAbstract" xlink:to="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cytk_ScheduleOfOtherRelatedPartyTransactionsLineItems" xlink:to="us-gaap_LicenseCosts" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cytk_ScheduleOfOtherRelatedPartyTransactionsLineItems" xlink:to="us-gaap_CommonStockSharesIssued" order="1.0200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cytk_ScheduleOfOtherRelatedPartyTransactionsLineItems" xlink:to="us-gaap_SharePrice" order="1.0300" preferredLabel="http://www.xbrl.org/2003/role/positiveLabel" priority="2" use="optional"/> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cytk_ScheduleOfOtherRelatedPartyTransactionsLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" order="1.0400" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cytk_ScheduleOfOtherRelatedPartyTransactionsLineItems" xlink:to="cytk_FairValueOfCommonStockIssued" order="1.0500" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cytk_ScheduleOfOtherRelatedPartyTransactionsLineItems" xlink:to="us-gaap_DeferredRevenue" order="1.0600" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cytk_ScheduleOfOtherRelatedPartyTransactionsLineItems" xlink:to="us-gaap_LicenseAndServicesRevenue" order="1.0700" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cytk_ScheduleOfOtherRelatedPartyTransactionsLineItems" xlink:to="cytk_ResearchAndDevelopmentRevenuesFromRelatedParties" order="1.0800" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cytk_ScheduleOfOtherRelatedPartyTransactionsLineItems" xlink:to="cytk_RelatedPartyTransactionPreCommercializationMilestonePaymentsReceivedByEntity" order="1.0900" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cytk_ScheduleOfOtherRelatedPartyTransactionsLineItems" xlink:to="cytk_RelatedPartyTransactionCommercializationMilestonePaymentsReceivedByEntity" order="1.1000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cytk_ScheduleOfOtherRelatedPartyTransactionsLineItems" xlink:to="us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized" order="1.1100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cytk_ScheduleOfOtherRelatedPartyTransactionsLineItems" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned" order="1.1200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cytk_ScheduleOfOtherRelatedPartyTransactionsLineItems" xlink:to="cytk_PotentialAmountsReceivableUnderCollaborationAgreement" order="1.1300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cytk_ScheduleOfOtherRelatedPartyTransactionsLineItems" xlink:to="cytk_ResearchCollaborationAndLicenseAgreementPeriod" order="1.1400" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cytk_ScheduleOfOtherRelatedPartyTransactionsLineItems" xlink:to="us-gaap_DeferredRevenueRevenueRecognized" order="1.1500" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cytk_ScheduleOfOtherRelatedPartyTransactionsLineItems" xlink:to="us-gaap_ReimbursementRevenue" order="1.1600" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" use="optional"/> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cytk_ScheduleOfOtherRelatedPartyTransactionsLineItems" xlink:to="cytk_MilestonePaymentsReceivedUnderArrangements" order="1.1700" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cytk_ScheduleOfOtherRelatedPartyTransactionsLineItems" xlink:to="cytk_ResearchAndDevelopmentRevenue" order="1.1800" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" use="optional"/> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_TypeOfArrangementAxis" order="10.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_RangeAxis" order="11.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_RelatedPartyTransactionAxis" order="12.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis" order="13.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_SubsequentEventTypeAxis" order="14.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" order="15.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" order="16.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="cytk_ScheduleOfOtherRelatedPartyTransactionsLineItems" order="100.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventMember" order="1.2500" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/> </presentationLink> <presentationLink xlink:type="extended" xlink:role="http://imetrix.edgar-online.com/taxonomy/role/DisclosureRelatedPartiesAndRelatedPartyTransactionsRevenueFromRelatedParty"> <loc xlink:type="locator" xlink:href="cytk-20141231.xsd#cytk_AmgenMember" xlink:label="cytk_AmgenMember"/> <loc xlink:type="locator" xlink:href="cytk-20141231.xsd#cytk_AstellasMember" xlink:label="cytk_AstellasMember"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LicenseAndServicesRevenue" xlink:label="us-gaap_LicenseAndServicesRevenue"/> <loc xlink:type="locator" xlink:href="cytk-20141231.xsd#cytk_ReimbursementOfInternalResearchAndDevelopmentCost" xlink:label="cytk_ReimbursementOfInternalResearchAndDevelopmentCost"/> <loc xlink:type="locator" xlink:href="cytk-20141231.xsd#cytk_ReimbursementOfOtherResearchAndDevelopmentCost" xlink:label="cytk_ReimbursementOfOtherResearchAndDevelopmentCost"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain"/> <loc xlink:type="locator" xlink:href="cytk-20141231.xsd#cytk_RelatedPartyResearchAndDevelopmentRevenue" xlink:label="cytk_RelatedPartyResearchAndDevelopmentRevenue"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RelatedPartyTransactionDueFromToRelatedPartyAbstract" xlink:label="us-gaap_RelatedPartyTransactionDueFromToRelatedPartyAbstract"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="us-gaap_RelatedPartyTransactionsAbstract"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ResearchAndDevelopmentAbstract" xlink:label="us-gaap_ResearchAndDevelopmentAbstract"/> <loc xlink:type="locator" xlink:href="cytk-20141231.xsd#cytk_ResearchAndDevelopmentRelatedPartyRevenue" xlink:label="cytk_ResearchAndDevelopmentRelatedPartyRevenue"/> <loc xlink:type="locator" xlink:href="cytk-20141231.xsd#cytk_ResearchAndDevelopmentRevenue" xlink:label="cytk_ResearchAndDevelopmentRevenue"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RevenueFromRelatedParties" xlink:label="us-gaap_RevenueFromRelatedParties"/> <loc xlink:type="locator" xlink:href="cytk-20141231.xsd#cytk_ScheduleOfOtherRelatedPartyTransactionsLineItems" xlink:label="cytk_ScheduleOfOtherRelatedPartyTransactionsLineItems"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable"/> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="cytk_AmgenMember" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="cytk_AstellasMember" order="1.0200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionDueFromToRelatedPartyAbstract" xlink:to="cytk_ResearchAndDevelopmentRelatedPartyRevenue" order="1.0300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionDueFromToRelatedPartyAbstract" xlink:to="cytk_ReimbursementOfInternalResearchAndDevelopmentCost" order="1.0400" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionDueFromToRelatedPartyAbstract" xlink:to="cytk_ReimbursementOfOtherResearchAndDevelopmentCost" order="1.0500" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionDueFromToRelatedPartyAbstract" xlink:to="us-gaap_RevenueFromRelatedParties" order="1.0600" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsAbstract" xlink:to="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentAbstract" xlink:to="cytk_ReimbursementOfInternalResearchAndDevelopmentCost" order="1.0700" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentAbstract" xlink:to="cytk_ReimbursementOfOtherResearchAndDevelopmentCost" order="1.0800" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentAbstract" xlink:to="cytk_ResearchAndDevelopmentRevenue" order="1.0900" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cytk_ScheduleOfOtherRelatedPartyTransactionsLineItems" xlink:to="us-gaap_LicenseAndServicesRevenue" order="1.1000" preferredLabel="http://www.xbrl.org/2003/role/positiveLabel" priority="2" use="optional"/> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cytk_ScheduleOfOtherRelatedPartyTransactionsLineItems" xlink:to="us-gaap_RelatedPartyTransactionDueFromToRelatedPartyAbstract" order="1.1100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cytk_ScheduleOfOtherRelatedPartyTransactionsLineItems" xlink:to="us-gaap_ResearchAndDevelopmentAbstract" order="1.1200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cytk_ScheduleOfOtherRelatedPartyTransactionsLineItems" xlink:to="cytk_RelatedPartyResearchAndDevelopmentRevenue" order="1.1300" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" use="optional"/> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" order="10.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="cytk_ScheduleOfOtherRelatedPartyTransactionsLineItems" order="100.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/> </presentationLink> <presentationLink xlink:type="extended" xlink:role="http://imetrix.edgar-online.com/taxonomy/role/DisclosureOtherResearchAndDevelopmentRevenueArrangementsAdditionalInformation"> <loc xlink:type="locator" xlink:href="cytk-20141231.xsd#cytk_PeriodForPotentialTreatment" xlink:label="cytk_PeriodForPotentialTreatment"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ResearchAndDevelopmentAbstract" xlink:label="us-gaap_ResearchAndDevelopmentAbstract"/> <loc xlink:type="locator" xlink:href="cytk-20141231.xsd#cytk_ResearchDevelopmentGrant" xlink:label="cytk_ResearchDevelopmentGrant"/> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentAbstract" xlink:to="cytk_ResearchDevelopmentGrant" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentAbstract" xlink:to="cytk_PeriodForPotentialTreatment" order="1.0200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/> </presentationLink> <presentationLink xlink:type="extended" xlink:role="http://imetrix.edgar-online.com/taxonomy/role/DisclosureOtherResearchAndDevelopmentRevenueArrangementsSummaryOfTotalGrantRevenues"> <loc xlink:type="locator" xlink:href="cytk-20141231.xsd#cytk_NindsMyastheniaGravisMember" xlink:label="cytk_NindsMyastheniaGravisMember"/> <loc xlink:type="locator" xlink:href="cytk-20141231.xsd#cytk_OtherGrantRevenueMember" xlink:label="cytk_OtherGrantRevenueMember"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RevenueFromGrants" xlink:label="us-gaap_RevenueFromGrants"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable" xlink:label="us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable"/> <loc xlink:type="locator" xlink:href="cytk-20141231.xsd#cytk_SoftDollarArrangementsAbstract" xlink:label="cytk_SoftDollarArrangementsAbstract"/> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="us-gaap_RevenueFromGrants" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:to="cytk_NindsMyastheniaGravisMember" order="1.0200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:to="cytk_OtherGrantRevenueMember" order="1.0300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" order="10.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" order="100.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cytk_SoftDollarArrangementsAbstract" xlink:to="us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/> </presentationLink> <presentationLink xlink:type="extended" xlink:role="http://imetrix.edgar-online.com/taxonomy/role/DisclosureOtherResearchAndDevelopmentRevenueArrangementsSummaryOfReimbursedExpenses"> <loc xlink:type="locator" xlink:href="cytk-20141231.xsd#cytk_GlobalBloodTherapeuticsMember" xlink:label="cytk_GlobalBloodTherapeuticsMember"/> <loc xlink:type="locator" xlink:href="cytk-20141231.xsd#cytk_MyokardiaMember" xlink:label="cytk_MyokardiaMember"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ReimbursementRevenue" xlink:label="us-gaap_ReimbursementRevenue"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain"/> <loc xlink:type="locator" xlink:href="cytk-20141231.xsd#cytk_ResearchAndDevelopmentRevenue" xlink:label="cytk_ResearchAndDevelopmentRevenue"/> <loc xlink:type="locator" xlink:href="cytk-20141231.xsd#cytk_ResearchAndDevelopmentRevenueFromCollaboration" xlink:label="cytk_ResearchAndDevelopmentRevenueFromCollaboration"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable" xlink:label="us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable"/> <loc xlink:type="locator" xlink:href="cytk-20141231.xsd#cytk_SoftDollarArrangementsAbstract" xlink:label="cytk_SoftDollarArrangementsAbstract"/> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="cytk_ResearchAndDevelopmentRevenue" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="us-gaap_ReimbursementRevenue" order="1.0200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="cytk_ResearchAndDevelopmentRevenueFromCollaboration" order="1.0300" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" use="optional"/> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:to="cytk_GlobalBloodTherapeuticsMember" order="1.0400" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:to="cytk_MyokardiaMember" order="1.0500" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" order="10.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" order="100.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cytk_SoftDollarArrangementsAbstract" xlink:to="us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/> </presentationLink> <presentationLink xlink:type="extended" xlink:role="http://imetrix.edgar-online.com/taxonomy/role/DisclosureDebtAdditionalInformation"> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="us-gaap_DebtDisclosureAbstract"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LineOfCredit" xlink:label="us-gaap_LineOfCredit"/> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="us-gaap_LineOfCredit" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/> </presentationLink> <presentationLink xlink:type="extended" xlink:role="http://imetrix.edgar-online.com/taxonomy/role/DisclosureDebtSummaryOfTotalInterestExpenseIncurred"> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="us-gaap_DebtDisclosureAbstract"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_InterestExpense" xlink:label="us-gaap_InterestExpense"/> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="us-gaap_InterestExpense" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/> </presentationLink> <presentationLink xlink:type="extended" xlink:role="http://imetrix.edgar-online.com/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformation"> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/> <loc xlink:type="locator" xlink:href="cytk-20141231.xsd#cytk_NonCancelableLeaseAdditionalExtensionPeriod" xlink:label="cytk_NonCancelableLeaseAdditionalExtensionPeriod"/> <loc xlink:type="locator" xlink:href="cytk-20141231.xsd#cytk_NonCancelableLeaseExpirationYear" xlink:label="cytk_NonCancelableLeaseExpirationYear"/> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="cytk_NonCancelableLeaseExpirationYear" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="cytk_NonCancelableLeaseAdditionalExtensionPeriod" order="1.0200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/> </presentationLink> <presentationLink xlink:type="extended" xlink:role="http://imetrix.edgar-online.com/taxonomy/role/DisclosureCommitmentsAndContingenciesRentExpense"> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OperatingLeasesRentExpenseNet" xlink:label="us-gaap_OperatingLeasesRentExpenseNet"/> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_OperatingLeasesRentExpenseNet" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/> </presentationLink> <presentationLink xlink:type="extended" xlink:role="http://imetrix.edgar-online.com/taxonomy/role/DisclosureCommitmentsAndContingenciesFutureMinimumLeasePaymentsUnderNoncancelableOperatingLeases"> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDue"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter"/> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears" order="1.0200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears" order="1.0300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears" order="1.0400" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears" order="1.0500" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter" order="1.0600" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDue" order="1.0700" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" use="optional"/> </presentationLink> <presentationLink xlink:type="extended" xlink:role="http://imetrix.edgar-online.com/taxonomy/role/DisclosureConvertiblePreferredStockAdditionalInformation"> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ClassOfStockLineItems" xlink:label="us-gaap_ClassOfStockLineItems"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ConversionOfStockSharesConverted1" xlink:label="us-gaap_ConversionOfStockSharesConverted1"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ConversionOfStockSharesIssued1" xlink:label="us-gaap_ConversionOfStockSharesIssued1"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ConvertiblePreferredStockMember" xlink:label="us-gaap_ConvertiblePreferredStockMember"/> <loc xlink:type="locator" xlink:href="cytk-20141231.xsd#cytk_DeerfieldAgreementMember" xlink:label="cytk_DeerfieldAgreementMember"/> <loc xlink:type="locator" xlink:href="cytk-20141231.xsd#cytk_EntitledPaymentPerShareDuringLiquidation" xlink:label="cytk_EntitledPaymentPerShareDuringLiquidation"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EquityAbstract" xlink:label="us-gaap_EquityAbstract"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/> <loc xlink:type="locator" xlink:href="cytk-20141231.xsd#cytk_ExcessOfCommonStockFairValueOverAllocatedPurchasePriceOfPreferredStock" xlink:label="cytk_ExcessOfCommonStockFairValueOverAllocatedPurchasePriceOfPreferredStock"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IPOMember" xlink:label="us-gaap_IPOMember"/> <loc xlink:type="locator" xlink:href="cytk-20141231.xsd#cytk_NumberOfConcurrentPublicOfferings" xlink:label="cytk_NumberOfConcurrentPublicOfferings"/> <loc xlink:type="locator" xlink:href="cytk-20141231.xsd#cytk_PercentageLimitOnNumberOfSharesOfCommonStockExercisableByHolders" xlink:label="cytk_PercentageLimitOnNumberOfSharesOfCommonStockExercisableByHolders"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="us-gaap_PreferredStockSharesIssued"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="us-gaap_PreferredStockSharesOutstanding"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock" xlink:label="us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="us-gaap_ScheduleOfStockByClassTable"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SeriesAPreferredStockMember" xlink:label="us-gaap_SeriesAPreferredStockMember"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SeriesBPreferredStockMember" xlink:label="us-gaap_SeriesBPreferredStockMember"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SharePrice" xlink:label="us-gaap_SharePrice"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockholdersEquityNoteChangesInCapitalStructureSubsequentChangesToNumberOfCommonShares" xlink:label="us-gaap_StockholdersEquityNoteChangesInCapitalStructureSubsequentChangesToNumberOfCommonShares"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockholdersEquityNoteStockSplit" xlink:label="us-gaap_StockholdersEquityNoteStockSplit"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:label="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis"/> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_ConvertiblePreferredStockMember" order="1.1500" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_SeriesAPreferredStockMember" order="1.1800" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_SeriesBPreferredStockMember" order="1.2000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_PreferredStockSharesAuthorized" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_PreferredStockSharesOutstanding" order="1.0200" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" use="optional"/> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_PreferredStockSharesIssued" order="1.0300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_SharePrice" order="1.0400" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock" order="1.0500" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="cytk_ExcessOfCommonStockFairValueOverAllocatedPurchasePriceOfPreferredStock" order="1.0600" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ConversionOfStockSharesConverted1" order="1.0700" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="cytk_NumberOfConcurrentPublicOfferings" order="1.0800" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="cytk_PercentageLimitOnNumberOfSharesOfCommonStockExercisableByHolders" order="1.0900" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="cytk_EntitledPaymentPerShareDuringLiquidation" order="1.1000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" order="1.1100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_StockholdersEquityNoteStockSplit" order="1.1200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_StockholdersEquityNoteChangesInCapitalStructureSubsequentChangesToNumberOfCommonShares" order="1.1300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ConversionOfStockSharesIssued1" order="1.1400" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" use="optional"/> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_ScheduleOfStockByClassTable" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" order="1.1700" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="cytk_DeerfieldAgreementMember" order="1.1600" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_IPOMember" order="1.1900" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="10.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" order="11.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="12.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_ClassOfStockLineItems" order="100.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/> </presentationLink> <presentationLink xlink:type="extended" xlink:role="http://imetrix.edgar-online.com/taxonomy/role/DisclosureStockholdersEquityAdditionalInformation"> <loc xlink:type="locator" xlink:href="cytk-20141231.xsd#cytk_AfterReverseStockSplitMember" xlink:label="cytk_AfterReverseStockSplitMember"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense"/> <loc xlink:type="locator" xlink:href="cytk-20141231.xsd#cytk_AmendedAgreementMember" xlink:label="cytk_AmendedAgreementMember"/> <loc xlink:type="locator" xlink:href="cytk-20141231.xsd#cytk_AmgenMember" xlink:label="cytk_AmgenMember"/> <loc xlink:type="locator" xlink:href="cytk-20141231.xsd#cytk_AstellasMember" xlink:label="cytk_AstellasMember"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis"/> <loc xlink:type="locator" xlink:href="cytk-20141231.xsd#cytk_BeforeReverseStockSplitMember" xlink:label="cytk_BeforeReverseStockSplitMember"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ConversionOfStockSharesConverted1" xlink:label="us-gaap_ConversionOfStockSharesConverted1"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ConversionOfStockSharesIssued1" xlink:label="us-gaap_ConversionOfStockSharesIssued1"/> <loc xlink:type="locator" xlink:href="cytk-20141231.xsd#cytk_DeerfieldAgreementMember" xlink:label="cytk_DeerfieldAgreementMember"/> <loc xlink:type="locator" xlink:href="cytk-20141231.xsd#cytk_DeerfieldMember" xlink:label="cytk_DeerfieldMember"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DeferredRevenue" xlink:label="us-gaap_DeferredRevenue"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EmployeeStockMember" xlink:label="us-gaap_EmployeeStockMember"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember"/> <loc xlink:type="locator" xlink:href="cytk-20141231.xsd#cytk_EmployeeStockPurchasePlansAveragePricePerShare" xlink:label="cytk_EmployeeStockPurchasePlansAveragePricePerShare"/> <loc xlink:type="locator" xlink:href="cytk-20141231.xsd#cytk_EntitledPaymentPerShareDuringLiquidation" xlink:label="cytk_EntitledPaymentPerShareDuringLiquidation"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EquityIssuancePerShareAmount" xlink:label="us-gaap_EquityIssuancePerShareAmount"/> <loc xlink:type="locator" xlink:href="cytk-20141231.xsd#cytk_ExistingEmployeeMember" xlink:label="cytk_ExistingEmployeeMember"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueAssumptionsExpectedTerm" xlink:label="us-gaap_FairValueAssumptionsExpectedTerm"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueAssumptionsExpectedVolatilityRate" xlink:label="us-gaap_FairValueAssumptionsExpectedVolatilityRate"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueAssumptionsRiskFreeInterestRate" xlink:label="us-gaap_FairValueAssumptionsRiskFreeInterestRate"/> <loc xlink:type="locator" xlink:href="cytk-20141231.xsd#cytk_FairValueOfCommonStockIssued" xlink:label="cytk_FairValueOfCommonStockIssued"/> <loc xlink:type="locator" xlink:href="cytk-20141231.xsd#cytk_FairValuePerShareOfCommonStock" xlink:label="cytk_FairValuePerShareOfCommonStock"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="us-gaap_FinancialInstrumentAxis"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/> <loc xlink:type="locator" xlink:href="cytk-20141231.xsd#cytk_GrossProceedsFromIssuanceOfStock" xlink:label="cytk_GrossProceedsFromIssuanceOfStock"/> <loc xlink:type="locator" xlink:href="cytk-20141231.xsd#cytk_IssuanceCostOfWarrant" xlink:label="cytk_IssuanceCostOfWarrant"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LiabilitiesFairValueDisclosure" xlink:label="us-gaap_LiabilitiesFairValueDisclosure"/> <loc xlink:type="locator" xlink:href="cytk-20141231.xsd#cytk_LicenseAndServicesMember" xlink:label="cytk_LicenseAndServicesMember"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_MinimumMember" xlink:label="us-gaap_MinimumMember"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners" xlink:label="us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners"/> <loc xlink:type="locator" xlink:href="cytk-20141231.xsd#cytk_MlvAgreementMember" xlink:label="cytk_MlvAgreementMember"/> <loc xlink:type="locator" xlink:href="cytk-20141231.xsd#cytk_NetProceedsFromIssuanceOfWarrants" xlink:label="cytk_NetProceedsFromIssuanceOfWarrants"/> <loc xlink:type="locator" xlink:href="cytk-20141231.xsd#cytk_NewEmployeeMember" xlink:label="cytk_NewEmployeeMember"/> <loc xlink:type="locator" xlink:href="cytk-20141231.xsd#cytk_NineteenNinetySevenStockOptionPlanMember" xlink:label="cytk_NineteenNinetySevenStockOptionPlanMember"/> <loc xlink:type="locator" xlink:href="cytk-20141231.xsd#cytk_NonEmployeeStockBasedCompensationMember" xlink:label="cytk_NonEmployeeStockBasedCompensationMember"/> <loc xlink:type="locator" xlink:href="cytk-20141231.xsd#cytk_NonstatutoryStockOptionsMember" xlink:label="cytk_NonstatutoryStockOptionsMember"/> <loc xlink:type="locator" xlink:href="cytk-20141231.xsd#cytk_NumberOfIssuedSharesOfCommonStockRelatedToCashlessExerciseOfWarrants" xlink:label="cytk_NumberOfIssuedSharesOfCommonStockRelatedToCashlessExerciseOfWarrants"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts"/> <loc xlink:type="locator" xlink:href="cytk-20141231.xsd#cytk_PercentageLimitOnNumberOfSharesOfCommonStockExercisableByHolders" xlink:label="cytk_PercentageLimitOnNumberOfSharesOfCommonStockExercisableByHolders"/> <loc xlink:type="locator" xlink:href="cytk-20141231.xsd#cytk_PercentageOfOptionsGrantToNewEmployees" xlink:label="cytk_PercentageOfOptionsGrantToNewEmployees"/> <loc xlink:type="locator" xlink:href="cytk-20141231.xsd#cytk_PeriodFromPercentageOfStockOptionVested" xlink:label="cytk_PeriodFromPercentageOfStockOptionVested"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain"/> <loc xlink:type="locator" xlink:href="cytk-20141231.xsd#cytk_PreferredStockConversionRatio" xlink:label="cytk_PreferredStockConversionRatio"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PreferredStockNoParValue" xlink:label="us-gaap_PreferredStockNoParValue"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="us-gaap_PreferredStockSharesIssued"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock" xlink:label="us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock"/> <loc xlink:type="locator" xlink:href="cytk-20141231.xsd#cytk_ProceedsFromIssuanceOfUnit" xlink:label="cytk_ProceedsFromIssuanceOfUnit"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ProceedsFromIssuanceOfWarrants" xlink:label="us-gaap_ProceedsFromIssuanceOfWarrants"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:label="us-gaap_ProceedsFromIssuanceOrSaleOfEquity"/> <loc xlink:type="locator" xlink:href="cytk-20141231.xsd#cytk_ProceedsFromIssuanceOrSaleOfStockAndWarrant" xlink:label="cytk_ProceedsFromIssuanceOrSaleOfStockAndWarrant"/> <loc xlink:type="locator" xlink:href="cytk-20141231.xsd#cytk_ProceedsFromSalesOfCommonStockNet" xlink:label="cytk_ProceedsFromSalesOfCommonStockNet"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RangeAxis" xlink:label="us-gaap_RangeAxis"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RangeMember" xlink:label="us-gaap_RangeMember"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RelatedPartyTransactionAxis" xlink:label="us-gaap_RelatedPartyTransactionAxis"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RelatedPartyTransactionDomain" xlink:label="us-gaap_RelatedPartyTransactionDomain"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SeriesAPreferredStockMember" xlink:label="us-gaap_SeriesAPreferredStockMember"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SeriesBPreferredStockMember" xlink:label="us-gaap_SeriesBPreferredStockMember"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/> <loc xlink:type="locator" xlink:href="cytk-20141231.xsd#cytk_ShareBasedCompensationLineItems" xlink:label="cytk_ShareBasedCompensationLineItems"/> <loc xlink:type="locator" xlink:href="cytk-20141231.xsd#cytk_ShareBasedCompensationTable" xlink:label="cytk_ShareBasedCompensationTable"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SharePrice" xlink:label="us-gaap_SharePrice"/> <loc xlink:type="locator" xlink:href="cytk-20141231.xsd#cytk_SpecifiedStockholderOwnershipPercentage" xlink:label="cytk_SpecifiedStockholderOwnershipPercentage"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:label="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:label="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues"/> <loc xlink:type="locator" xlink:href="cytk-20141231.xsd#cytk_StockOptionsRepurchaseMaximumPeriod" xlink:label="cytk_StockOptionsRepurchaseMaximumPeriod"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis"/> <loc xlink:type="locator" xlink:href="cytk-20141231.xsd#cytk_TermForStockOptionPlan" xlink:label="cytk_TermForStockOptionPlan"/> <loc xlink:type="locator" xlink:href="cytk-20141231.xsd#cytk_TermForStockOptionPlanForSpecifiedStockHolders" xlink:label="cytk_TermForStockOptionPlanForSpecifiedStockHolders"/> <loc xlink:type="locator" xlink:href="cytk-20141231.xsd#cytk_TermToGrantNonstatutoryStockOptionsAndIncentiveStockOptions" xlink:label="cytk_TermToGrantNonstatutoryStockOptionsAndIncentiveStockOptions"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_TitleOfIndividualAxis" xlink:label="us-gaap_TitleOfIndividualAxis"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="us-gaap_TitleOfIndividualWithRelationshipToEntityDomain"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/> <loc xlink:type="locator" xlink:href="cytk-20141231.xsd#cytk_TwoThousandAndFourPlanMember" xlink:label="cytk_TwoThousandAndFourPlanMember"/> <loc xlink:type="locator" xlink:href="cytk-20141231.xsd#cytk_UnderwrittenPublicOfferingMember" xlink:label="cytk_UnderwrittenPublicOfferingMember"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_WarrantMember" xlink:label="us-gaap_WarrantMember"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_WarrantsNotSettleableInCashFairValueDisclosure" xlink:label="us-gaap_WarrantsNotSettleableInCashFairValueDisclosure"/> <loc xlink:type="locator" xlink:href="cytk-20141231.xsd#cytk_WarrantsToPurchaseCommonStockMember" xlink:label="cytk_WarrantsToPurchaseCommonStockMember"/> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_SeriesAPreferredStockMember" order="1.6300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_SeriesBPreferredStockMember" order="1.7300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="cytk_AfterReverseStockSplitMember" order="1.8000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="cytk_BeforeReverseStockSplitMember" order="1.8400" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="cytk_ShareBasedCompensationTable" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" order="1.6200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="cytk_LicenseAndServicesMember" order="1.6600" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain" xlink:to="cytk_TwoThousandAndFourPlanMember" order="1.6900" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain" xlink:to="cytk_NineteenNinetySevenStockOptionPlanMember" order="1.7800" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain" xlink:to="cytk_NonEmployeeStockBasedCompensationMember" order="1.8200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain" xlink:to="us-gaap_EmployeeStockMember" order="1.8500" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RangeAxis" xlink:to="us-gaap_RangeMember" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RangeMember" xlink:to="us-gaap_MinimumMember" order="1.7000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="cytk_AmgenMember" order="1.6500" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="cytk_AstellasMember" order="1.7400" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="us-gaap_RelatedPartyTransactionDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionDomain" xlink:to="cytk_AmendedAgreementMember" order="1.6700" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="cytk_DeerfieldAgreementMember" order="1.6100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="cytk_DeerfieldMember" order="1.7200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="cytk_MlvAgreementMember" order="1.7900" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="cytk_UnderwrittenPublicOfferingMember" order="1.8300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" order="1.7100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="cytk_NonstatutoryStockOptionsMember" order="1.7700" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_RestrictedStockUnitsRSUMember" order="1.8100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cytk_ShareBasedCompensationLineItems" xlink:to="us-gaap_CommonStockSharesAuthorized" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cytk_ShareBasedCompensationLineItems" xlink:to="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" order="1.0200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cytk_ShareBasedCompensationLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" order="1.0300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cytk_ShareBasedCompensationLineItems" xlink:to="us-gaap_EquityIssuancePerShareAmount" order="1.0400" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cytk_ShareBasedCompensationLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" order="1.0500" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" use="optional"/> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cytk_ShareBasedCompensationLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" order="1.0600" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" use="optional"/> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cytk_ShareBasedCompensationLineItems" xlink:to="cytk_GrossProceedsFromIssuanceOfStock" order="1.0700" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cytk_ShareBasedCompensationLineItems" xlink:to="cytk_IssuanceCostOfWarrant" order="1.0800" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" use="optional"/> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cytk_ShareBasedCompensationLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" order="1.0900" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cytk_ShareBasedCompensationLineItems" xlink:to="cytk_EntitledPaymentPerShareDuringLiquidation" order="1.1000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cytk_ShareBasedCompensationLineItems" xlink:to="cytk_PreferredStockConversionRatio" order="1.1100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cytk_ShareBasedCompensationLineItems" xlink:to="us-gaap_ConversionOfStockSharesConverted1" order="1.1200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cytk_ShareBasedCompensationLineItems" xlink:to="us-gaap_ConversionOfStockSharesIssued1" order="1.1300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cytk_ShareBasedCompensationLineItems" xlink:to="us-gaap_PreferredStockSharesIssued" order="1.1400" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cytk_ShareBasedCompensationLineItems" xlink:to="cytk_ProceedsFromSalesOfCommonStockNet" order="1.1500" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cytk_ShareBasedCompensationLineItems" xlink:to="us-gaap_CommonStockSharesIssued" order="1.1600" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cytk_ShareBasedCompensationLineItems" xlink:to="us-gaap_SharePrice" order="1.1700" preferredLabel="http://www.xbrl.org/2003/role/positiveLabel" priority="2" use="optional"/> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cytk_ShareBasedCompensationLineItems" xlink:to="us-gaap_PreferredStockNoParValue" order="1.1800" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cytk_ShareBasedCompensationLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOrSaleOfEquity" order="1.1900" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cytk_ShareBasedCompensationLineItems" xlink:to="us-gaap_PaymentsOfStockIssuanceCosts" order="1.2000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cytk_ShareBasedCompensationLineItems" xlink:to="cytk_ProceedsFromIssuanceOrSaleOfStockAndWarrant" order="1.2100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cytk_ShareBasedCompensationLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock" order="1.2200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cytk_ShareBasedCompensationLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfWarrants" order="1.2300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cytk_ShareBasedCompensationLineItems" xlink:to="cytk_FairValueOfCommonStockIssued" order="1.2400" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cytk_ShareBasedCompensationLineItems" xlink:to="us-gaap_DeferredRevenue" order="1.2500" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cytk_ShareBasedCompensationLineItems" xlink:to="cytk_NetProceedsFromIssuanceOfWarrants" order="1.2600" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cytk_ShareBasedCompensationLineItems" xlink:to="cytk_PercentageLimitOnNumberOfSharesOfCommonStockExercisableByHolders" order="1.2700" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cytk_ShareBasedCompensationLineItems" xlink:to="us-gaap_WarrantsNotSettleableInCashFairValueDisclosure" order="1.2800" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cytk_ShareBasedCompensationLineItems" xlink:to="us-gaap_FairValueAssumptionsRiskFreeInterestRate" order="1.2900" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cytk_ShareBasedCompensationLineItems" xlink:to="us-gaap_FairValueAssumptionsExpectedVolatilityRate" order="1.3000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cytk_ShareBasedCompensationLineItems" xlink:to="cytk_FairValuePerShareOfCommonStock" order="1.3100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cytk_ShareBasedCompensationLineItems" xlink:to="cytk_ProceedsFromIssuanceOfUnit" order="1.3200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cytk_ShareBasedCompensationLineItems" xlink:to="us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners" order="1.3300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cytk_ShareBasedCompensationLineItems" xlink:to="us-gaap_LiabilitiesFairValueDisclosure" order="1.3400" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cytk_ShareBasedCompensationLineItems" xlink:to="us-gaap_FairValueAssumptionsExpectedTerm" order="1.3500" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cytk_ShareBasedCompensationLineItems" xlink:to="cytk_NumberOfIssuedSharesOfCommonStockRelatedToCashlessExerciseOfWarrants" order="1.3600" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cytk_ShareBasedCompensationLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" order="1.3700" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cytk_ShareBasedCompensationLineItems" xlink:to="cytk_TermToGrantNonstatutoryStockOptionsAndIncentiveStockOptions" order="1.3800" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cytk_ShareBasedCompensationLineItems" xlink:to="cytk_PercentageOfOptionsGrantToNewEmployees" order="1.3900" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cytk_ShareBasedCompensationLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights" order="1.4000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cytk_ShareBasedCompensationLineItems" xlink:to="cytk_PeriodFromPercentageOfStockOptionVested" order="1.4100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cytk_ShareBasedCompensationLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" order="1.4200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cytk_ShareBasedCompensationLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" order="1.4300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cytk_ShareBasedCompensationLineItems" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" order="1.4400" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cytk_ShareBasedCompensationLineItems" xlink:to="cytk_TermForStockOptionPlan" order="1.4500" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cytk_ShareBasedCompensationLineItems" xlink:to="cytk_SpecifiedStockholderOwnershipPercentage" order="1.4600" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cytk_ShareBasedCompensationLineItems" xlink:to="cytk_TermForStockOptionPlanForSpecifiedStockHolders" order="1.4700" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cytk_ShareBasedCompensationLineItems" xlink:to="cytk_StockOptionsRepurchaseMaximumPeriod" order="1.4800" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cytk_ShareBasedCompensationLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" order="1.4900" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cytk_ShareBasedCompensationLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" order="1.5000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cytk_ShareBasedCompensationLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" order="1.5100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cytk_ShareBasedCompensationLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" order="1.5200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cytk_ShareBasedCompensationLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" order="1.5300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cytk_ShareBasedCompensationLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" order="1.5400" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cytk_ShareBasedCompensationLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" order="1.5500" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cytk_ShareBasedCompensationLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" order="1.5600" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cytk_ShareBasedCompensationLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" order="1.5700" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cytk_ShareBasedCompensationLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" order="1.5800" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cytk_ShareBasedCompensationLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" order="1.5900" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cytk_ShareBasedCompensationLineItems" xlink:to="cytk_EmployeeStockPurchasePlansAveragePricePerShare" order="1.6000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cytk_ShareBasedCompensationTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="10.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cytk_ShareBasedCompensationTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" order="11.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cytk_ShareBasedCompensationTable" xlink:to="us-gaap_RelatedPartyTransactionAxis" order="12.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cytk_ShareBasedCompensationTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="13.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cytk_ShareBasedCompensationTable" xlink:to="us-gaap_RangeAxis" order="14.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cytk_ShareBasedCompensationTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" order="15.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cytk_ShareBasedCompensationTable" xlink:to="us-gaap_PlanNameAxis" order="16.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cytk_ShareBasedCompensationTable" xlink:to="us-gaap_FinancialInstrumentAxis" order="17.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cytk_ShareBasedCompensationTable" xlink:to="us-gaap_AwardTypeAxis" order="18.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cytk_ShareBasedCompensationTable" xlink:to="us-gaap_TitleOfIndividualAxis" order="19.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cytk_ShareBasedCompensationTable" xlink:to="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" order="20.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cytk_ShareBasedCompensationTable" xlink:to="cytk_ShareBasedCompensationLineItems" order="100.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TitleOfIndividualAxis" xlink:to="us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="cytk_NewEmployeeMember" order="1.6800" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="cytk_ExistingEmployeeMember" order="1.7600" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_WarrantMember" order="1.6400" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="cytk_WarrantsToPurchaseCommonStockMember" order="1.7500" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/> </presentationLink> <presentationLink xlink:type="extended" xlink:role="http://imetrix.edgar-online.com/taxonomy/role/DisclosureStockholdersEquityOutstandingWarrants"> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/> <loc xlink:type="locator" xlink:href="cytk-20141231.xsd#cytk_ShareBasedCompensationLineItems" xlink:label="cytk_ShareBasedCompensationLineItems"/> <loc xlink:type="locator" xlink:href="cytk-20141231.xsd#cytk_ShareBasedCompensationTable" xlink:label="cytk_ShareBasedCompensationTable"/> <loc xlink:type="locator" xlink:href="cytk-20141231.xsd#cytk_WarrantExpirationDate" xlink:label="cytk_WarrantExpirationDate"/> <loc xlink:type="locator" xlink:href="cytk-20141231.xsd#cytk_WarrantOneMember" xlink:label="cytk_WarrantOneMember"/> <loc xlink:type="locator" xlink:href="cytk-20141231.xsd#cytk_WarrantTwoMember" xlink:label="cytk_WarrantTwoMember"/> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="cytk_WarrantOneMember" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="cytk_WarrantTwoMember" order="1.0200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="cytk_ShareBasedCompensationTable" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cytk_ShareBasedCompensationLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" order="1.0300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cytk_ShareBasedCompensationLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" order="1.0400" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cytk_ShareBasedCompensationLineItems" xlink:to="cytk_WarrantExpirationDate" order="1.0500" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cytk_ShareBasedCompensationTable" xlink:to="us-gaap_ClassOfWarrantOrRightAxis" order="10.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cytk_ShareBasedCompensationTable" xlink:to="cytk_ShareBasedCompensationLineItems" order="100.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/> </presentationLink> <presentationLink xlink:type="extended" xlink:role="http://imetrix.edgar-online.com/taxonomy/role/DisclosureStockholdersEquitySummaryOfStockOptionActivity"> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/> <loc xlink:type="locator" xlink:href="cytk-20141231.xsd#cytk_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedInPeriodWeightedAverageExercisePrice" xlink:label="cytk_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedInPeriodWeightedAverageExercisePrice"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_2"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_2"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_2"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod"/> <loc xlink:type="locator" xlink:href="cytk-20141231.xsd#cytk_ShareBasedCompensationArrangementByShareBasedPaymentSharesAvailableForGrantAwardOptionsExercisedInPeriodGross" xlink:label="cytk_ShareBasedCompensationArrangementByShareBasedPaymentSharesAvailableForGrantAwardOptionsExercisedInPeriodGross"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/> <loc xlink:type="locator" xlink:href="cytk-20141231.xsd#cytk_ShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentOtherThanOptionForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="cytk_ShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentOtherThanOptionForfeituresInPeriodWeightedAverageExercisePrice"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/> <loc xlink:type="locator" xlink:href="cytk-20141231.xsd#cytk_SharesAvailableForGrantOfOptionsOrAwardsOptionsForfeitedExpired" xlink:label="cytk_SharesAvailableForGrantOfOptionsOrAwardsOptionsForfeitedExpired"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_AwardTypeAxis" order="10.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="11.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="100.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" order="1.0200" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" priority="2" use="optional"/> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" order="1.0300" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="2" use="optional"/> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" order="1.0400" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" use="optional"/> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" order="1.0500" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" order="1.0600" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="2" use="optional"/> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="cytk_ShareBasedCompensationArrangementByShareBasedPaymentSharesAvailableForGrantAwardOptionsExercisedInPeriodGross" order="1.0700" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" order="1.0800" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="cytk_SharesAvailableForGrantOfOptionsOrAwardsOptionsForfeitedExpired" order="1.0900" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="cytk_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedInPeriodWeightedAverageExercisePrice" order="1.1000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_2" order="1.1100" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" priority="2" use="optional"/> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="cytk_ShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentOtherThanOptionForfeituresInPeriodWeightedAverageExercisePrice" order="1.1200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" order="1.1300" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" priority="2" use="optional"/> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" order="1.1400" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" order="1.1500" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="2" use="optional"/> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" order="1.1600" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="2" use="optional"/> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_2" order="1.1700" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" priority="2" use="optional"/> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" order="1.1800" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" priority="2" use="optional"/> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" order="1.1900" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" order="1.2000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" order="1.2100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" order="1.2200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" order="1.2300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_2" order="1.2400" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" priority="2" use="optional"/> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" order="1.2500" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" order="1.2600" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" order="1.2700" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" order="1.2800" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" order="1.2900" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" order="1.3000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" order="1.3100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" order="1.3200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_RestrictedStockUnitsRSUMember" order="1.3300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/> </presentationLink> <presentationLink xlink:type="extended" xlink:role="http://imetrix.edgar-online.com/taxonomy/role/DisclosureStockholdersEquitySummaryOfRestrictedStockUnitActivity"> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RestrictedStockMember" xlink:label="us-gaap_RestrictedStockMember"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_2"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_2"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_AwardTypeAxis" order="10.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="100.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" priority="2" use="optional"/> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" order="1.0200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" order="1.0300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" order="1.0400" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="2" use="optional"/> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" order="1.0500" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="2" use="optional"/> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_2" order="1.0600" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" priority="2" use="optional"/> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" order="1.0700" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" priority="2" use="optional"/> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" order="1.0800" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" order="1.0900" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_2" order="1.1000" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" priority="2" use="optional"/> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_RestrictedStockMember" order="1.1100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/> </presentationLink> <presentationLink xlink:type="extended" xlink:role="http://imetrix.edgar-online.com/taxonomy/role/DisclosureStockholdersEquityStockBasedCompensationRelatedToStockOptionsRestrictedStockAwardsRestrictedStockUnitAndEmployeeStockPurchases"> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" order="1.0300" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" use="optional"/> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember" order="1.0200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="us-gaap_IncomeStatementLocationAxis" order="10.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" order="100.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/> </presentationLink> <presentationLink xlink:type="extended" xlink:role="http://imetrix.edgar-online.com/taxonomy/role/DisclosureStockholdersEquityFairValueOfShareBasedPaymentsWasEstimatedOnDateOfGrantUsingBlackScholesOptionPricingModelBasedOnWeightedAverageAssumptions"> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsLineItems" xlink:label="us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsLineItems"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EmployeeStockMember" xlink:label="us-gaap_EmployeeStockMember"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfDeferredCompensationArrangementWithIndividualShareBasedPaymentsTable" xlink:label="us-gaap_ScheduleOfDeferredCompensationArrangementWithIndividualShareBasedPaymentsTable"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis"/> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" order="1.0200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" order="1.0300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" order="1.0400" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" order="1.0500" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfDeferredCompensationArrangementWithIndividualShareBasedPaymentsTable" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_EmployeeStockMember" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfDeferredCompensationArrangementWithIndividualShareBasedPaymentsTable" xlink:to="us-gaap_AwardTypeAxis" order="10.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfDeferredCompensationArrangementWithIndividualShareBasedPaymentsTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" order="11.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfDeferredCompensationArrangementWithIndividualShareBasedPaymentsTable" xlink:to="us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsLineItems" order="100.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" order="1.0600" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/> </presentationLink> <presentationLink xlink:type="extended" xlink:role="http://imetrix.edgar-online.com/taxonomy/role/DisclosureIncomeTaxesAdditionalInformation"> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DomesticCountryMember" xlink:label="us-gaap_DomesticCountryMember"/> <loc xlink:type="locator" xlink:href="cytk-20141231.xsd#cytk_FederalNetOperatingLossRelatesToStockOptionDeductions" xlink:label="cytk_FederalNetOperatingLossRelatesToStockOptionDeductions"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="us-gaap_IncomeTaxAuthorityAxis"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="us-gaap_IncomeTaxAuthorityDomain"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncomeTaxContingencyLineItems" xlink:label="us-gaap_IncomeTaxContingencyLineItems"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncomeTaxContingencyTable" xlink:label="us-gaap_IncomeTaxContingencyTable"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncomeTaxExaminationPenaltiesAndInterestAccrued" xlink:label="us-gaap_IncomeTaxExaminationPenaltiesAndInterestAccrued"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncomeTaxReconciliationTaxCredits" xlink:label="us-gaap_IncomeTaxReconciliationTaxCredits"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="us-gaap_OperatingLossCarryforwards"/> <loc xlink:type="locator" xlink:href="cytk-20141231.xsd#cytk_OperatingLossCarryforwardsExpirationYear" xlink:label="cytk_OperatingLossCarryforwardsExpirationYear"/> <loc xlink:type="locator" xlink:href="cytk-20141231.xsd#cytk_PercentageOfIncomeTaxPositionsLikelyToBeRealized" xlink:label="cytk_PercentageOfIncomeTaxPositionsLikelyToBeRealized"/> <loc xlink:type="locator" xlink:href="cytk-20141231.xsd#cytk_ResearchAndDevelopmentFederalTaxCreditCarryforwardsExpirationDateYear" xlink:label="cytk_ResearchAndDevelopmentFederalTaxCreditCarryforwardsExpirationDateYear"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StateAndLocalJurisdictionMember" xlink:label="us-gaap_StateAndLocalJurisdictionMember"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate" xlink:label="us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:label="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount"/> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_DomesticCountryMember" order="1.1100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_StateAndLocalJurisdictionMember" order="1.1200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxContingencyLineItems" xlink:to="us-gaap_IncomeTaxExpenseBenefit" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxContingencyLineItems" xlink:to="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" order="1.0200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxContingencyLineItems" xlink:to="cytk_FederalNetOperatingLossRelatesToStockOptionDeductions" order="1.0300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxContingencyLineItems" xlink:to="us-gaap_OperatingLossCarryforwards" order="1.0400" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxContingencyLineItems" xlink:to="cytk_OperatingLossCarryforwardsExpirationYear" order="1.0500" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxContingencyLineItems" xlink:to="us-gaap_IncomeTaxReconciliationTaxCredits" order="1.0600" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxContingencyLineItems" xlink:to="cytk_ResearchAndDevelopmentFederalTaxCreditCarryforwardsExpirationDateYear" order="1.0700" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxContingencyLineItems" xlink:to="cytk_PercentageOfIncomeTaxPositionsLikelyToBeRealized" order="1.0800" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxContingencyLineItems" xlink:to="us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate" order="1.0900" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxContingencyLineItems" xlink:to="us-gaap_IncomeTaxExaminationPenaltiesAndInterestAccrued" order="1.1000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxContingencyTable" xlink:to="us-gaap_IncomeTaxAuthorityAxis" order="10.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxContingencyTable" xlink:to="us-gaap_IncomeTaxContingencyLineItems" order="100.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxContingencyTable" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/> </presentationLink> <presentationLink xlink:type="extended" xlink:role="http://imetrix.edgar-online.com/taxonomy/role/DisclosureIncomeTaxesScheduleOfComponentsOfIncomeBeforeTaxes"> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract"/> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" order="1.0200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" order="1.0300" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" use="optional"/> </presentationLink> <presentationLink xlink:type="extended" xlink:role="http://imetrix.edgar-online.com/taxonomy/role/DisclosureIncomeTaxesCompanyRecordedIncomeTaxProvision"> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CurrentFederalTaxExpenseBenefit" xlink:label="us-gaap_CurrentFederalTaxExpenseBenefit"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:label="us-gaap_CurrentIncomeTaxExpenseBenefit"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:label="us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:label="us-gaap_CurrentStateAndLocalTaxExpenseBenefit"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:label="us-gaap_DeferredFederalIncomeTaxExpenseBenefit"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefit"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:label="us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract"/> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:to="us-gaap_CurrentFederalTaxExpenseBenefit" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:to="us-gaap_CurrentStateAndLocalTaxExpenseBenefit" order="1.0200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:to="us-gaap_CurrentIncomeTaxExpenseBenefit" order="1.0300" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" use="optional"/> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:to="us-gaap_DeferredFederalIncomeTaxExpenseBenefit" order="1.0400" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:to="us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" order="1.0500" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:to="us-gaap_DeferredIncomeTaxExpenseBenefit" order="1.0600" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" use="optional"/> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract" order="1.0700" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" order="1.0800" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/> </presentationLink> <presentationLink xlink:type="extended" xlink:role="http://imetrix.edgar-online.com/taxonomy/role/DisclosureIncomeTaxesCompanysDeferredTaxAssetsAndLiabilities"> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ComponentsOfDeferredTaxAssetsAbstract" xlink:label="us-gaap_ComponentsOfDeferredTaxAssetsAbstract"/> <loc xlink:type="locator" xlink:href="cytk-20141231.xsd#cytk_DeferredTaxAssetsCapitalizedResearchAndDevelopment" xlink:label="cytk_DeferredTaxAssetsCapitalizedResearchAndDevelopment"/> <loc xlink:type="locator" xlink:href="cytk-20141231.xsd#cytk_DeferredTaxAssetsDepreciationAndAmortization" xlink:label="cytk_DeferredTaxAssetsDepreciationAndAmortization"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="us-gaap_DeferredTaxAssetsGross"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="us-gaap_DeferredTaxAssetsNet"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwards" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwards"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract"/> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAbstract" xlink:to="cytk_DeferredTaxAssetsDepreciationAndAmortization" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAbstract" xlink:to="cytk_DeferredTaxAssetsCapitalizedResearchAndDevelopment" order="1.0200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAbstract" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals" order="1.0300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAbstract" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" order="1.0400" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAbstract" xlink:to="us-gaap_DeferredTaxAssetsTaxCreditCarryforwards" order="1.0500" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAbstract" xlink:to="us-gaap_DeferredTaxAssetsGross" order="1.0600" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" use="optional"/> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAbstract" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance" order="1.0700" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="2" use="optional"/> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAbstract" xlink:to="us-gaap_DeferredTaxAssetsNet" order="1.0800" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" use="optional"/> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_ComponentsOfDeferredTaxAssetsAbstract" order="1.0900" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/> </presentationLink> <presentationLink xlink:type="extended" xlink:role="http://imetrix.edgar-online.com/taxonomy/role/DisclosureIncomeTaxesCompanysValuationAndQualifyingAccounts"> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ValuationAllowanceOfDeferredTaxAssetsMember" xlink:label="us-gaap_ValuationAllowanceOfDeferredTaxAssetsMember"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ValuationAllowancesAndReservesBalance" xlink:label="us-gaap_ValuationAllowancesAndReservesBalance"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ValuationAllowancesAndReservesBalance" xlink:label="us-gaap_ValuationAllowancesAndReservesBalance_2"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ValuationAllowancesAndReservesChargedToCostAndExpense" xlink:label="us-gaap_ValuationAllowancesAndReservesChargedToCostAndExpense"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ValuationAllowancesAndReservesChargedToOtherAccounts" xlink:label="us-gaap_ValuationAllowancesAndReservesChargedToOtherAccounts"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ValuationAllowancesAndReservesDeductions" xlink:label="us-gaap_ValuationAllowancesAndReservesDeductions"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ValuationAllowancesAndReservesDomain" xlink:label="us-gaap_ValuationAllowancesAndReservesDomain"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ValuationAllowancesAndReservesTypeAxis" xlink:label="us-gaap_ValuationAllowancesAndReservesTypeAxis"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ValuationAndQualifyingAccountsDisclosureLineItems" xlink:label="us-gaap_ValuationAndQualifyingAccountsDisclosureLineItems"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ValuationAndQualifyingAccountsDisclosureTable" xlink:label="us-gaap_ValuationAndQualifyingAccountsDisclosureTable"/> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_ValuationAndQualifyingAccountsDisclosureTable" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ValuationAllowancesAndReservesDomain" xlink:to="us-gaap_ValuationAllowanceOfDeferredTaxAssetsMember" order="1.0600" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ValuationAllowancesAndReservesTypeAxis" xlink:to="us-gaap_ValuationAllowancesAndReservesDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ValuationAndQualifyingAccountsDisclosureLineItems" xlink:to="us-gaap_ValuationAllowancesAndReservesBalance" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" priority="2" use="optional"/> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ValuationAndQualifyingAccountsDisclosureLineItems" xlink:to="us-gaap_ValuationAllowancesAndReservesChargedToCostAndExpense" order="1.0200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ValuationAndQualifyingAccountsDisclosureLineItems" xlink:to="us-gaap_ValuationAllowancesAndReservesChargedToOtherAccounts" order="1.0300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ValuationAndQualifyingAccountsDisclosureLineItems" xlink:to="us-gaap_ValuationAllowancesAndReservesDeductions" order="1.0400" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="2" use="optional"/> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ValuationAndQualifyingAccountsDisclosureLineItems" xlink:to="us-gaap_ValuationAllowancesAndReservesBalance_2" order="1.0500" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" priority="2" use="optional"/> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ValuationAndQualifyingAccountsDisclosureTable" xlink:to="us-gaap_ValuationAllowancesAndReservesTypeAxis" order="10.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ValuationAndQualifyingAccountsDisclosureTable" xlink:to="us-gaap_ValuationAndQualifyingAccountsDisclosureLineItems" order="100.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/> </presentationLink> <presentationLink xlink:type="extended" xlink:role="http://imetrix.edgar-online.com/taxonomy/role/DisclosureIncomeTaxesReconciliationOfStatutoryFederalIncomeTaxRateToEffectiveTaxRate"> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate"/> <loc xlink:type="locator" xlink:href="cytk-20141231.xsd#cytk_EffectiveIncomeTaxRateReconciliationDeferredTaxAssetsUtilizedNotBenefited" xlink:label="cytk_EffectiveIncomeTaxRateReconciliationDeferredTaxAssetsUtilizedNotBenefited"/> <loc xlink:type="locator" xlink:href="cytk-20141231.xsd#cytk_EffectiveIncomeTaxRateReconciliationNetOperatingLossExpiration" xlink:label="cytk_EffectiveIncomeTaxRateReconciliationNetOperatingLossExpiration"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes"/> <loc xlink:type="locator" xlink:href="cytk-20141231.xsd#cytk_EffectiveIncomeTaxRateReconciliationStateApportionment" xlink:label="cytk_EffectiveIncomeTaxRateReconciliationStateApportionment"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract"/> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" order="1.0200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="cytk_EffectiveIncomeTaxRateReconciliationStateApportionment" order="1.0300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits" order="1.0400" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="cytk_EffectiveIncomeTaxRateReconciliationDeferredTaxAssetsUtilizedNotBenefited" order="1.0500" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" order="1.0600" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="cytk_EffectiveIncomeTaxRateReconciliationNetOperatingLossExpiration" order="1.0700" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" order="1.0800" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateContinuingOperations" order="1.0900" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" use="optional"/> </presentationLink> <presentationLink xlink:type="extended" xlink:role="http://imetrix.edgar-online.com/taxonomy/role/DisclosureIncomeTaxesReconciliationOfTotalAmountsOfUnrecognizedTaxBenefits"> <loc xlink:type="locator" xlink:href="cytk-20141231.xsd#cytk_FederalAndStateTaxMember" xlink:label="cytk_FederalAndStateTaxMember"/> <loc xlink:type="locator" xlink:href="cytk-20141231.xsd#cytk_FederalTaxBenefitOfStateIncomeTaxUtbMember" xlink:label="cytk_FederalTaxBenefitOfStateIncomeTaxUtbMember"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="us-gaap_IncomeTaxAuthorityAxis"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="us-gaap_IncomeTaxAuthorityDomain"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncomeTaxContingencyLineItems" xlink:label="us-gaap_IncomeTaxContingencyLineItems"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncomeTaxContingencyTable" xlink:label="us-gaap_IncomeTaxContingencyTable"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract"/> <loc xlink:type="locator" xlink:href="cytk-20141231.xsd#cytk_UnrecognizedIncomeTaxBenefitsNetOfFederalBenefitOfStateIncomeTaxUtbMember" xlink:label="cytk_UnrecognizedIncomeTaxBenefitsNetOfFederalBenefitOfStateIncomeTaxUtbMember"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:label="us-gaap_UnrecognizedTaxBenefits"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:label="us-gaap_UnrecognizedTaxBenefits_2"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" xlink:label="us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions"/> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="cytk_FederalAndStateTaxMember" order="1.0600" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="cytk_FederalTaxBenefitOfStateIncomeTaxUtbMember" order="1.0700" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="cytk_UnrecognizedIncomeTaxBenefitsNetOfFederalBenefitOfStateIncomeTaxUtbMember" order="1.0800" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxContingencyLineItems" xlink:to="us-gaap_UnrecognizedTaxBenefits" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" priority="2" use="optional"/> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxContingencyLineItems" xlink:to="us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" order="1.0200" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="2" use="optional"/> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxContingencyLineItems" xlink:to="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" order="1.0300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxContingencyLineItems" xlink:to="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" order="1.0400" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxContingencyLineItems" xlink:to="us-gaap_UnrecognizedTaxBenefits_2" order="1.0500" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" priority="2" use="optional"/> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxContingencyTable" xlink:to="us-gaap_IncomeTaxAuthorityAxis" order="10.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxContingencyTable" xlink:to="us-gaap_IncomeTaxContingencyLineItems" order="100.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxContingencyTable" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/> </presentationLink> <presentationLink xlink:type="extended" xlink:role="http://imetrix.edgar-online.com/taxonomy/role/DisclosureInterestAndOtherNetComponentsOfInterestAndOtherNet"> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_InterestAndDebtExpense" xlink:label="us-gaap_InterestAndDebtExpense"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_InterestAndOtherIncome" xlink:label="us-gaap_InterestAndOtherIncome"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="us-gaap_NonoperatingIncomeExpense"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OtherIncomeAndExpensesAbstract" xlink:label="us-gaap_OtherIncomeAndExpensesAbstract"/> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherIncomeAndExpensesAbstract" xlink:to="us-gaap_InterestAndOtherIncome" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherIncomeAndExpensesAbstract" xlink:to="us-gaap_InterestAndDebtExpense" order="1.0200" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="2" use="optional"/> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherIncomeAndExpensesAbstract" xlink:to="us-gaap_NonoperatingIncomeExpense" order="1.0300" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" use="optional"/> </presentationLink> <presentationLink xlink:type="extended" xlink:role="http://imetrix.edgar-online.com/taxonomy/role/DisclosureQuarterlyFinancialDataSummaryOfQuarterlyResults"> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsPerBasicAndDilutedShare" xlink:label="us-gaap_IncomeLossFromContinuingOperationsPerBasicAndDilutedShare"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsPerBasicShare" xlink:label="us-gaap_IncomeLossFromContinuingOperationsPerBasicShare"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare" xlink:label="us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_QuarterlyFinancialInformationDisclosureAbstract" xlink:label="us-gaap_QuarterlyFinancialInformationDisclosureAbstract"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SalesRevenueNet" xlink:label="us-gaap_SalesRevenueNet"/> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_QuarterlyFinancialInformationDisclosureAbstract" xlink:to="us-gaap_SalesRevenueNet" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_QuarterlyFinancialInformationDisclosureAbstract" xlink:to="us-gaap_NetIncomeLoss" order="1.0200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_QuarterlyFinancialInformationDisclosureAbstract" xlink:to="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" order="1.0300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_QuarterlyFinancialInformationDisclosureAbstract" xlink:to="us-gaap_IncomeLossFromContinuingOperationsPerBasicShare" order="1.0400" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_QuarterlyFinancialInformationDisclosureAbstract" xlink:to="us-gaap_IncomeLossFromContinuingOperationsPerBasicAndDilutedShare" order="1.0500" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_QuarterlyFinancialInformationDisclosureAbstract" xlink:to="us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare" order="1.0600" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/> </presentationLink> <presentationLink xlink:type="extended" xlink:role="http://imetrix.edgar-online.com/taxonomy/role/NotesToFinancialStatementsOrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock"> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock"/> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/> </presentationLink> <presentationLink xlink:type="extended" xlink:role="http://imetrix.edgar-online.com/taxonomy/role/NotesToFinancialStatementsOrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlockPolicies"> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract"/> <loc xlink:type="locator" xlink:href="cytk-20141231.xsd#cytk_AccountingPronouncementsNotYetAdoptedPolicyTextBlock" xlink:label="cytk_AccountingPronouncementsNotYetAdoptedPolicyTextBlock"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CompensationRelatedCostsPolicyTextBlock" xlink:label="us-gaap_CompensationRelatedCostsPolicyTextBlock"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:label="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ConcentrationRiskCreditRisk" xlink:label="us-gaap_ConcentrationRiskCreditRisk"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:label="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="us-gaap_IncomeTaxPolicyTextBlock"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_InProcessResearchAndDevelopmentPolicy" xlink:label="us-gaap_InProcessResearchAndDevelopmentPolicy"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_InvestmentPolicyTextBlock" xlink:label="us-gaap_InvestmentPolicyTextBlock"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/> <loc xlink:type="locator" xlink:href="cytk-20141231.xsd#cytk_OrganizationConsolidationAndPresentationOfFinancialStatementsPolicyTextBlock" xlink:label="cytk_OrganizationConsolidationAndPresentationOfFinancialStatementsPolicyTextBlock"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PensionAndOtherPostretirementPlansPolicy" xlink:label="us-gaap_PensionAndOtherPostretirementPlansPolicy"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RevenueRecognitionPolicyTextBlock" xlink:label="us-gaap_RevenueRecognitionPolicyTextBlock"/> <loc xlink:type="locator" xlink:href="cytk-20141231.xsd#cytk_ReverseStockSplitPolicyTextBlock" xlink:label="cytk_ReverseStockSplitPolicyTextBlock"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_UseOfEstimates" xlink:label="us-gaap_UseOfEstimates"/> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="cytk_OrganizationConsolidationAndPresentationOfFinancialStatementsPolicyTextBlock" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_UseOfEstimates" order="1.0200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" order="1.0300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ConcentrationRiskCreditRisk" order="1.0400" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_CashAndCashEquivalentsPolicyTextBlock" order="1.0500" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_InvestmentPolicyTextBlock" order="1.0600" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" order="1.0700" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" order="1.0800" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_RevenueRecognitionPolicyTextBlock" order="1.0900" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_InProcessResearchAndDevelopmentPolicy" order="1.1000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy" order="1.1100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_PensionAndOtherPostretirementPlansPolicy" order="1.1200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_IncomeTaxPolicyTextBlock" order="1.1300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" order="1.1400" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_SegmentReportingPolicyPolicyTextBlock" order="1.1500" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="cytk_ReverseStockSplitPolicyTextBlock" order="1.1600" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_CompensationRelatedCostsPolicyTextBlock" order="1.1700" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" order="1.1800" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="cytk_AccountingPronouncementsNotYetAdoptedPolicyTextBlock" order="1.1900" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/> </presentationLink> <presentationLink xlink:type="extended" xlink:role="http://imetrix.edgar-online.com/taxonomy/role/NotesToFinancialStatementsEarningsPerShareTextBlock"> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EarningsPerShareTextBlock" xlink:label="us-gaap_EarningsPerShareTextBlock"/> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_EarningsPerShareTextBlock" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/> </presentationLink> <presentationLink xlink:type="extended" xlink:role="http://imetrix.edgar-online.com/taxonomy/role/NotesToFinancialStatementsEarningsPerShareTextBlockTables"> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock"/> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" order="1.0200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/> </presentationLink> <presentationLink xlink:type="extended" xlink:role="http://imetrix.edgar-online.com/taxonomy/role/NotesToFinancialStatementsCashFlowSupplementalDisclosuresTextBlock"> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CashFlowSupplementalDisclosuresTextBlock" xlink:label="us-gaap_CashFlowSupplementalDisclosuresTextBlock"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SupplementalCashFlowElementsAbstract" xlink:label="us-gaap_SupplementalCashFlowElementsAbstract"/> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SupplementalCashFlowElementsAbstract" xlink:to="us-gaap_CashFlowSupplementalDisclosuresTextBlock" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/> </presentationLink> <presentationLink xlink:type="extended" xlink:role="http://imetrix.edgar-online.com/taxonomy/role/NotesToFinancialStatementsCashFlowSupplementalDisclosuresTextBlockTables"> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock" xlink:label="us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SupplementalCashFlowElementsAbstract" xlink:label="us-gaap_SupplementalCashFlowElementsAbstract"/> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SupplementalCashFlowElementsAbstract" xlink:to="us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/> </presentationLink> <presentationLink xlink:type="extended" xlink:role="http://imetrix.edgar-online.com/taxonomy/role/NotesToFinancialStatementsInvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock"> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:label="us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:label="us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock"/> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:to="us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/> </presentationLink> <presentationLink xlink:type="extended" xlink:role="http://imetrix.edgar-online.com/taxonomy/role/NotesToFinancialStatementsInvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlockTables"> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_InvestmentIncomeTextBlock" xlink:label="us-gaap_InvestmentIncomeTextBlock"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:label="us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock" xlink:label="us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock"/> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:to="us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:to="us-gaap_InvestmentIncomeTextBlock" order="1.0200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/> </presentationLink> <presentationLink xlink:type="extended" xlink:role="http://imetrix.edgar-online.com/taxonomy/role/NotesToFinancialStatementsFairValueDisclosuresTextBlock"> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueDisclosuresTextBlock" xlink:label="us-gaap_FairValueDisclosuresTextBlock"/> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueDisclosuresTextBlock" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/> </presentationLink> <presentationLink xlink:type="extended" xlink:role="http://imetrix.edgar-online.com/taxonomy/role/NotesToFinancialStatementsFairValueDisclosuresTextBlockTables"> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract"/> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/> </presentationLink> <presentationLink xlink:type="extended" xlink:role="http://imetrix.edgar-online.com/taxonomy/role/NotesToFinancialStatementsSupplementalBalanceSheetDisclosuresTextBlock"> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SupplementalBalanceSheetDisclosuresTextBlock" xlink:label="us-gaap_SupplementalBalanceSheetDisclosuresTextBlock"/> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_SupplementalBalanceSheetDisclosuresTextBlock" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/> </presentationLink> <presentationLink xlink:type="extended" xlink:role="http://imetrix.edgar-online.com/taxonomy/role/NotesToFinancialStatementsSupplementalBalanceSheetDisclosuresTextBlockTables"> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock"/> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentTextBlock" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" order="1.0200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/> </presentationLink> <presentationLink xlink:type="extended" xlink:role="http://imetrix.edgar-online.com/taxonomy/role/NotesToFinancialStatementsRelatedPartyTransactionsDisclosureTextBlock"> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="us-gaap_RelatedPartyTransactionsAbstract"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock"/> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsAbstract" xlink:to="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/> </presentationLink> <presentationLink xlink:type="extended" xlink:role="http://imetrix.edgar-online.com/taxonomy/role/NotesToFinancialStatementsRelatedPartyTransactionsDisclosureTextBlockTables"> <loc xlink:type="locator" xlink:href="cytk-20141231.xsd#cytk_AmgenMember" xlink:label="cytk_AmgenMember"/> <loc xlink:type="locator" xlink:href="cytk-20141231.xsd#cytk_AstellasMember" xlink:label="cytk_AstellasMember"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="us-gaap_RelatedPartyTransactionsAbstract"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="cytk_AstellasMember" order="1.0200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="cytk_AmgenMember" order="1.0300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsAbstract" xlink:to="us-gaap_StatementTable" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" order="2.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="100.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/> </presentationLink> <presentationLink xlink:type="extended" xlink:role="http://imetrix.edgar-online.com/taxonomy/role/NotesToFinancialStatementsResearchDevelopmentAndComputerSoftwareDisclosureTextBlock"> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ResearchAndDevelopmentAbstract" xlink:label="us-gaap_ResearchAndDevelopmentAbstract"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock" xlink:label="us-gaap_ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock"/> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentAbstract" xlink:to="us-gaap_ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/> </presentationLink> <presentationLink xlink:type="extended" xlink:role="http://imetrix.edgar-online.com/taxonomy/role/NotesToFinancialStatementsResearchDevelopmentAndComputerSoftwareDisclosureTextBlockTables"> <loc xlink:type="locator" xlink:href="cytk-20141231.xsd#cytk_GlobalBloodTherapeuticsMember" xlink:label="cytk_GlobalBloodTherapeuticsMember"/> <loc xlink:type="locator" xlink:href="cytk-20141231.xsd#cytk_MyokardiaMember" xlink:label="cytk_MyokardiaMember"/> <loc xlink:type="locator" xlink:href="cytk-20141231.xsd#cytk_OtherResearchAndDevelopmentRevenueArrangementsRecognizedGrantRevenueTableTextBlock" xlink:label="cytk_OtherResearchAndDevelopmentRevenueArrangementsRecognizedGrantRevenueTableTextBlock"/> <loc xlink:type="locator" xlink:href="cytk-20141231.xsd#cytk_OtherResearchAndDevelopmentRevenueArrangementsReimbursementOfExpenseTableTextBlock" xlink:label="cytk_OtherResearchAndDevelopmentRevenueArrangementsReimbursementOfExpenseTableTextBlock"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ResearchAndDevelopmentAbstract" xlink:label="us-gaap_ResearchAndDevelopmentAbstract"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentAbstract" xlink:to="us-gaap_StatementTable" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:to="cytk_GlobalBloodTherapeuticsMember" order="1.0300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:to="cytk_MyokardiaMember" order="1.0400" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="cytk_OtherResearchAndDevelopmentRevenueArrangementsRecognizedGrantRevenueTableTextBlock" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="cytk_OtherResearchAndDevelopmentRevenueArrangementsReimbursementOfExpenseTableTextBlock" order="1.0200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="100.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/> </presentationLink> <presentationLink xlink:type="extended" xlink:role="http://imetrix.edgar-online.com/taxonomy/role/NotesToFinancialStatementsDebtDisclosureTextBlock"> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="us-gaap_DebtDisclosureAbstract"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DebtDisclosureTextBlock" xlink:label="us-gaap_DebtDisclosureTextBlock"/> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="us-gaap_DebtDisclosureTextBlock" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/> </presentationLink> <presentationLink xlink:type="extended" xlink:role="http://imetrix.edgar-online.com/taxonomy/role/NotesToFinancialStatementsDebtDisclosureTextBlockTables"> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="us-gaap_DebtDisclosureAbstract"/> <loc xlink:type="locator" xlink:href="cytk-20141231.xsd#cytk_ScheduleOfInterestExpenseTableTextBlock" xlink:label="cytk_ScheduleOfInterestExpenseTableTextBlock"/> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="cytk_ScheduleOfInterestExpenseTableTextBlock" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/> </presentationLink> <presentationLink xlink:type="extended" xlink:role="http://imetrix.edgar-online.com/taxonomy/role/NotesToFinancialStatementsCommitmentsAndContingenciesDisclosureTextBlock"> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/> </presentationLink> <presentationLink xlink:type="extended" xlink:role="http://imetrix.edgar-online.com/taxonomy/role/NotesToFinancialStatementsCommitmentsAndContingenciesDisclosureTextBlockTables"> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock" xlink:label="us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfRentExpenseTableTextBlock" xlink:label="us-gaap_ScheduleOfRentExpenseTableTextBlock"/> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_ScheduleOfRentExpenseTableTextBlock" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock" order="1.0200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/> </presentationLink> <presentationLink xlink:type="extended" xlink:role="http://imetrix.edgar-online.com/taxonomy/role/NotesToFinancialStatementsPreferredStockTextBlock"> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EquityAbstract" xlink:label="us-gaap_EquityAbstract"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PreferredStockTextBlock" xlink:label="us-gaap_PreferredStockTextBlock"/> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_PreferredStockTextBlock" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/> </presentationLink> <presentationLink xlink:type="extended" xlink:role="http://imetrix.edgar-online.com/taxonomy/role/NotesToFinancialStatementsStockholdersEquityNoteDisclosureTextBlock"> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EquityAbstract" xlink:label="us-gaap_EquityAbstract"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock"/> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/> </presentationLink> <presentationLink xlink:type="extended" xlink:role="http://imetrix.edgar-online.com/taxonomy/role/NotesToFinancialStatementsStockholdersEquityNoteDisclosureTextBlockTables"> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EquityAbstract" xlink:label="us-gaap_EquityAbstract"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:label="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock"/> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" order="1.0200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" order="1.0300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" order="1.0400" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" order="1.0500" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/> </presentationLink> <presentationLink xlink:type="extended" xlink:role="http://imetrix.edgar-online.com/taxonomy/role/NotesToFinancialStatementsIncomeTaxDisclosureTextBlock"> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock"/> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/> </presentationLink> <presentationLink xlink:type="extended" xlink:role="http://imetrix.edgar-online.com/taxonomy/role/NotesToFinancialStatementsIncomeTaxDisclosureTextBlockTables"> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:label="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" xlink:label="us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" xlink:label="us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SummaryOfValuationAllowanceTextBlock" xlink:label="us-gaap_SummaryOfValuationAllowanceTextBlock"/> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" order="1.0200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" order="1.0300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_SummaryOfValuationAllowanceTextBlock" order="1.0400" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" order="1.0500" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" order="1.0600" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/> </presentationLink> <presentationLink xlink:type="extended" xlink:role="http://imetrix.edgar-online.com/taxonomy/role/NotesToFinancialStatementsOtherIncomeAndOtherExpenseDisclosureTextBlock"> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OtherIncomeAndExpensesAbstract" xlink:label="us-gaap_OtherIncomeAndExpensesAbstract"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OtherIncomeAndOtherExpenseDisclosureTextBlock" xlink:label="us-gaap_OtherIncomeAndOtherExpenseDisclosureTextBlock"/> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherIncomeAndExpensesAbstract" xlink:to="us-gaap_OtherIncomeAndOtherExpenseDisclosureTextBlock" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/> </presentationLink> <presentationLink xlink:type="extended" xlink:role="http://imetrix.edgar-online.com/taxonomy/role/NotesToFinancialStatementsOtherIncomeAndOtherExpenseDisclosureTextBlockTables"> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OtherIncomeAndExpensesAbstract" xlink:label="us-gaap_OtherIncomeAndExpensesAbstract"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock" xlink:label="us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock"/> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherIncomeAndExpensesAbstract" xlink:to="us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/> </presentationLink> <presentationLink xlink:type="extended" xlink:role="http://imetrix.edgar-online.com/taxonomy/role/NotesToFinancialStatementsQuarterlyFinancialInformationTextBlock"> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_QuarterlyFinancialInformationDisclosureAbstract" xlink:label="us-gaap_QuarterlyFinancialInformationDisclosureAbstract"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_QuarterlyFinancialInformationTextBlock" xlink:label="us-gaap_QuarterlyFinancialInformationTextBlock"/> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_QuarterlyFinancialInformationDisclosureAbstract" xlink:to="us-gaap_QuarterlyFinancialInformationTextBlock" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/> </presentationLink> <presentationLink xlink:type="extended" xlink:role="http://imetrix.edgar-online.com/taxonomy/role/NotesToFinancialStatementsQuarterlyFinancialInformationTextBlockTables"> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_QuarterlyFinancialInformationDisclosureAbstract" xlink:label="us-gaap_QuarterlyFinancialInformationDisclosureAbstract"/> <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock" xlink:label="us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock"/> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_QuarterlyFinancialInformationDisclosureAbstract" xlink:to="us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/> </presentationLink> </linkbase> </XBRL> </TEXT> </DOCUMENT> <DOCUMENT> <TYPE>GRAPHIC <SEQUENCE>13 <FILENAME>g828167ex10_40pg136.jpg <DESCRIPTION>GRAPHIC <TEXT> begin 644 g828167ex10_40pg136.jpg M_]C_X``02D9)1@`!`@``9`!D``#_[``11'5C:WD``0`$````9```_^X`#D%D M;V)E`&3``````?_;`(0``0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$! M`0$!`0$!`0$!`0$!`0("`@("`@("`@("`P,#`P,#`P,#`P$!`0$!`0$"`0$" M`@(!`@(#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,# M`P,#`P,#`P,#_\``$0@`B@*(`P$1``(1`0,1`?_$`-T``0`"`00#`0`````` M```````("0H!`@8'`P0%"P$!```'`0$!``````````````$"!`4&!P@#"0H0 M```%!`$"`P0""@H.!@L!``$"`P0%`!$&!P@A$C$3"4%1(A1A%?!Q@9'!,D(C M%CBAL5)RM7:V%W@*8K(S)"5UQ=4W=X<8&3G1-$2TEUCA\:)#H[-5-F:6)R@1 M``(!`P(#!`4(!P4'`P4````!`A$#!`4&(3$205%A!W&!(C(3D;%"4G,4-@BA MP6*"PC,)\'(C%371X?&BLB1TDN)30V,T9!?_V@`,`P$``A$#$0`_`,_B@%`* M`4`H!0"@-OM&]^OL'J4+7L/W;4!!?>WJ,\0^.N8GP'9FU&K?,4416?PN.Q<C MDSF'N:R:$P,.@Y2C79_Q@05.57Q^&L/UG>VV]%RW@:CDQ^\T;Z(QZI+P:5>/ MZ?06#4-SZ/I=WX.7=2FGQ7<=,_\`&7X#6'_^HSU@*(B(8+DMA`M[B%V-_95J MCYI;,<4WD7$Z?_'<7Z*%N>^=NUX7I4\(_P"XG[J#;>#;UUWC.UM;R2\OA68, MS/H61<M'#!5TU(NJW,=1F[(5=O91,WB`"-9GIVI8>J84-2T]N6-<I1T:JGVT M?%<S)\+*LYV-'+QG6U.*:?*J?'D=I%\`^T'O_#UJY42X+D5/%\^9K0"@%`*` M4`H!0"@%`*`4`H!0"@%`*`4`H!0"@%`*`4`H!0"@%`*`4`H!0"@%`*`4`H!0 M"@%`*`4`H!0"@%`*`4`H!0"@%`*`4`H!0"@%`*`4`H!0"@%`*`4`H!0"@%`* M`\0]!$1Z=?9[A$;#8>@>%Q&@(\R_+SBIC\I(P<[R2T7#3<,\<1\M$2NT\*8R M<6_:J&1=,7[%U-I.FCMLL42J)J%*<A@L(`-`?/\`]]/A_P#^:3C[_P"+^!!^ MQ]?=*"J-?]]/A_\`^:3C[_XOX%_GZA"J/&/-/A[<?_\`4O'W_P`7<!_SY0B; M3\U.'B9#*'Y2\?"D(43G,;<&!``%L`B8P_7MAZ"%@M0=/@5Q>H+ZMN#:2Q\F M`\:Y[&]D;9RB,(Z2R^*>,Y["L"BWI1\B67>,E5F4W-N2'[FK4IS)DZ'4$2_# M6J-^^84-!E+2]':N:O)-2D_<L+M<N^7AV&"[HW?:TGJP<!J6I-<:^[!?KEX= MABBY=EF3Y[E$[F^<3LCE689,[6D9[()9P+B4D7JHF$55E3%.`$3*?\VD2Q2% MZ!TKF_*R;V=>EDY$G/)N2<I2?-M\W7Q9IB[D3R;COW9=<YNKD^+;?-^LXZ)2 MV-\``/:'A:P=3>%K@'NJEXJ$EZ3S9G&^E?\`J#\<P]V(NOX:D:ZZ\N_P7@?9 M?Q&_]H_AW%^R?SEAE9N9*N0H1%`*`4`H!0"@%`*`4`H!0"@%`*`4`H!0"@%` M*`4`H!0"@%`*`4!M$0N`"'CX#XA]J].)!R4>9IW@'0?&U_$/#WVN'2I>56N+ M(\U7L-U[^%$ZOD0[#0!Z=>G6WVZF;2YA<5P-;A[PIR5>PB+A[P^_4*I<&*HU MJ(%`*`]&3D6,1'/I:2<I,XZ,:.7[]VN<"(MF;1`Z[E=4P]"D21()A^@*`A+Q M;Y./>2&T=UJ1HE::^PL8.(PQB=,H.Y)%8SHSW(WJH@8Y1?JI623`;%3`/;0$ MZ*`4`H!0"@%`*`4`H!0"@%`*`4`H!0"@%`*`4`H!0"@%`*`4`H!0"@%`*`TZ MW^BW[-`?C@^H>P9&Y_<U#G:I',/)K;8B8QC]QA'*GPB(C>UQ&H%;"G0O00^! M@Q``#Y)'I_9'_P"FA-1&I8]B-_[U0`.O2YO:(^V_6U!1&XL8T.JBBBP\Y=TL MDV;M6Z*SER[<.%"(-FS5LB(JO%UW"@%323_.'4'M#J-`9(6A/2<QGA_I7#.4 M?.3#F<QOO:[8LCQKXGSB9E(_#8@I2K&V_O5B!P)(O(T%4U(V`.7R".A+\QYA MB'(&`>86\%MC2_@6)*>K7UTVE]1/G/\`<Y&&;RW*]!P''#I_F=U=,/7SE^[R M.2'$QU%E5`)YBZQEE133(BF90QKCY:212)I)E$;%(4`*4O0``*Y4O7+MV[*Y M?GUWI2;E+ZS?-^LT!.<[LW<N?S).K]+YFGT^%>9*:#^5^]#\-2_0EZ_UD#.- M]+#]0?CG_%%U_#<E777EW^"\'[+^(Z!VE^'\;[-_.6&5FYDBY"A$4`H!0"@% M`*`4`H!0"@%`*`4`H!0"@%`*`4`H!0"@%`*`4`H#8?NL';[^O6W3P_8O>HJG M:23KV<B(G(7B4RY!@NJINW?NJGAF_DMU]4;!<XN@@8H6!<62;=9%90;=>[H- M4&=@O+X1NW;;ISBZ&W/+?S>O^72E"WHFW]6LN:E_W^&K\^]Q4FU1=U.2*>=U M^BWRT42>R6B/4AWFZ?>2HHA$;6R*85!=4.X2-BS$"X(*93W_`!CI"`5@FH;$ MU6\NK!UG.A/NDXN/JX5H=W>7OY^?*3%G;QO,#RLVW]W5$[F#9MIKO;A=BUZD MREC?VD?6TX=E<3&29_R"F,4CQ,93--<9Q,YKC0(ICW%5<I,#+2#4O9\1A50` MI0\1\:QK+PM]Z'6;R;]ZV^U*,_E1WEY<[\_IW^?<X86)IFWL76YJKQ\[%AAS MDW]1UC&3[/9G5]B(Z87ZRGJ/8*8B#'D=D4X1LIV*L\PAXJ=L9$>PZ"X/&I7` M&`P6-<P&`:MV/N?=%B;5C,^++M4K<:1?<^XW!N#\@WY4MV8T;EK;EC%ZHUZL M2=R%4^-8TFT_2JT)P:V_K)',K%1;I;%U_JG9#0H@"BA&,EB\@H4!^,PJL'*[ M;NM[.SQJ\VO,#<>/)+,Q<:];[XRE&3^7V30&[_Z3GDEJO7=VOJNLZ7<E&D(2 ME"_;B^^77%2IX5+(]3_UF7C].JMVNX-'[%P0_E$^;E\8<1V6QA5/_>>2R!1G M)"F0W7P$UA]M7_%\R--?LY>/D6&^;HI17[T6U\O(Y+WI_23\V]+MN_L?6]*U M91J_ASC/'N=/9[4TX-^"9:QI+U8N`V^1;-<.Y#X=%33A,B@X]G+@^&RZ`*=" MD5+-D;,^[NZ=%C=:RG3=SZ%JSZ,+(MRNKG%NC7RG&/F#^3S\QWEHW+<6V,^> M'%-N]C1^\VZ=];74UZ'%,L"AIV&R%DE)P,Q&3D8N4#H2$0_:R3%<H@`@9%VR M5604*8!Z=IK#5ZC/JHXM./>G4YNRL3,P+[Q<^U=L9,><+D)0FNSC&:37R'V. MX*G3KQ7(\/25C>IMNUUA&KHG5D"]%K.[1762EE4CF!=MB$:8AY$`$@@8A)-P M8B`F"P]O<'MJ)&E54AGZ7&<H8SO'),,<J$10S[$2BR`X@4#RF.KBN5)/V"H= MHJ:P>T`H0,@:@%`*`4`H!0"@%`*`4`H!0"@%`*`4`H!0"@%`*`4`H!0"@%`* M`4`H!0"@-`\/NC^V-`?CF^H=^OYS4_I,[;_E4^J!6P]Q>@AY0F-HG(D0ZBAN MU,G<8QOC$``I?,,;M)U`?A$H?NC#0&?#Z`7H8ZUU[JG`N=G,S`VTUN>?>QNS M=*X3DZ8A%Z?PUG'OU(.>G(9<?DW>5S[=^$BH5R4X,02;]@`H01KSE.,8.;_E MI-R_=J4=^Y&VI2;I;BJO]9#;G-R)DN3_`">V7LY=RJICB,RYQ#`F9C"H2,P_ M&W"S./%L0``J:DD=(SE4X``'45KCC>.M7=Q:[DYLO_QF^BU_=@^'R]ISCN+5 M7J>L7<R7\J,I1AXQKP(C_>^X%@^][*QUNKJRR*M./,5`B:#^5^]#\-2_0EZ_ MUD#.-]+#]0?CG_%%U_#<E777EW^"\'[+^(Z!VE^'\;[-_.6&5FYDBY"A$4`H M!0"@%`*`4`H!0"@%`*`4`H!0"@%`*`4`H!0"@%`*`4`H!0"@I3D*`]=1N15- M1%0B:B*I#)G24(4Z9TS@)3$4(<!*8ABC80$+6HVVJ5H$YQFIP;C.+JFG2C7: MNY]S14_S*]&[AMR[2D9QWAY=2[0=`=1#8VMD6\0Z<O#@`)GGX0"%B)M`!N`@ M8A#@!A$#7K%M9V=HVM)SN0^%E\U<A[,J^*7"2[T^9V)Y%_GF\]_(N=K`P=0E MJ^TXR7_8YKE=@EPXV[K?Q+3_`+K<?V3#NYV>D[R=X,/WTWD,*IL;3OG'&/VU MA[)RYBT$3'[4$,GC0!1YCCOM$`$5;H&$!$#^`5JS5]OZIMQ2O7T[^&O_`*L> MQ=E8KEZ4?=G\MOYVO*#\PMBWIF-?6D;]E!.>GY,DI3G3C]VN-J-Z%>5*27:F M5@7^$HA8;]0$HB8M@Z^-P*(^(>'B%617;=^"NP58-<'7@_5R9V6TXOVN+[N< M5XU[Z\.78:&[3!8Q2F#WB`#[;^P`OX=/=4)6+5ZDIJ-5R:X?*3<'!VY)2MRY MIT:IZ.1WSJCE%R)T5((R6H-U;%P%=$$@32A,C?$9!Y1@$J?R#E5PS%(;6$HD ML(=/"JS%S-2TY1_R[)NV8Q?%5ZD_E[#5V]_)/RF\Q\>>-O;0-,S[5R*3Z[$% M.J[KD5&?_,6V:4_K#O.G6XLF6PBX#NV);B0BI<EA1@9Q5(+`IW34(9,55[!< M#'2'KXUDN'OG7\1=&7"SE1;X-)PE_L.'M_?TL?R^[KC.]M2]J6@9\I5_PKBO MV5QK2-J[7I5.'"7!<CX^Z/7$UGR5VPOD^S-=Y7K[ZNB&..L$X=ZCDL0S(VN= M^JD4!0=]KET;O-<`'X0K8>%N2QDXL;N19=JZWQ7/]/+Y#YB>8G]/W?FVM:S= M.VCJN%K&+8OR4)2A\"Y)17)OJ<6Z]G?Q.YM$\[-!L,YPW/\`!-OXXVF\9FF< MJWC)Q5:!?+H$.!'K)1)V0$Q,Y:F.40[K5=[6I8%Y>Q=5?'@<P[D\@O./:7'6 M-!SI64Z=5B'QTO\`T<3,PUONC6FTL3Q_+\.SC$YR-R&)8RK88W(HEX9,KQ`B MID5"(.U#I*HJ&$@E$+@);55JY:E[LHOT,UMD[=W!A2<<O`S+4US4[-R+7IK' MAPXG/W4_"L2%5>RT6S3,8I04<R#1$@F.-BD*914H&.8?``ZC4>J*?2VNKN*& M&'FW)-6K-V27-J+HEX\.'K/J@8#=0\!\!]X5,U0IJM2Z6N)NJ!$4`H!0"@%` M*`4`H!0"@%`*`4`H!0"@%`*`4`H!0"@%`*`4`H!0&@>'W1_;&@/QS?4._7\Y MJ?TF=M_RJ?5`K8>XO00\H3%DWI(<*W_/3GOH_1JI'J>#1DPEM+;,DS`Z2L?K M_`7C66<H%<IA9NXR"5!JP2./4"KB)>H#45WGG=G14/U+^6V6(ZEXG[SRA@4B M2>+:CR=O&)"`"5(3PAH5@0.[Q[#.2![*Q_=&9]QV_F9'U<:?Z>!8-=RONFCY M.4^4+,_T\#`";@8J"0'MWB0#'L``'<I^<-8`Z`'<:N,:4MQ7@<WOW4>:H$!0 M&@_E?O0_#4OT)>O]9`SC?2P_4'XY_P`477\-R5==>7?X+P?LOXCH':7X?QOL MW\Y896;F2+D*$10"@%`*`4`H!0"@%`*`4`H!0"@%`*`4`H!0"@%`*`4`H!0" M@%`*`4`H#00OT'WW^W]`_10'QYN#B,ABGT#.QK"9AI5LLRDHF59H/XU^S6() M%FCQDY34;KH*E&PE,40J1V[;3C))VY+BGQ7R'MAYN;I>7:S],NW,?/L34[=R MVW"<)1XIQE&C37>F8F'JE>@T@R:93R!X1Q*H^01U.9IH-$>[O1*=1T^D]:&[ M2F[T2]QC1AQN)0_,F'\2M:;AV1&"GJ&AQHZN4[7T7W]"2X.G96GAS/M#^3?^ MI%>M7L;RP_,%D=6/=C&SBZO-NL6J1A#-3?+L5])<72YP]HQ.7K-TQ=N&;YFY MCW;5=5L[9/&ZK5TR=H'%-=JY;K%*LDX15*('((`8HA6MXWE<BY13BE+I=?HR M^JUS/MYCY./F8UK-PVIX-Z"E;E&CC*+55*,DVI)KCP[&>J/C80Z`/@/_`*J] M6N%&5'-G@<N?E6SIT:UFK==;KX6*F80OU]](0=W(MV%R<D46H9RTS3\G4IM* M%BS.7'E[KI7TLBRHJ9<RJIKW54.H:_XPF4.8PCT\+UM>W;Z+<8=B2X=A\Z[E M^65=N9$V^J=R4GV<92;^0V`:PWM?KW!;X1`;![0Z^RI96+<J]2X,AU/E]%.M M/]_,D!I_9&88^FK"0F79/`*)&%ZR/#Y!+1O<B;N\Y$@-7:(!Y1Q[K!X`-8+N M?286KD<RW<O6K37&EV<8IKAR3HO$W]Y+7-OZOCY&TM;P,2_>ZW>M.Y8MSE.+ M3^)%2E%R?2ZNE>1E!^B3PFWGRCV9`<EMZ9;LAYQ[UA+I2F)1F1Y3D:[+96=1 M2Y58U%NR>NCHOL;@7?YUTJ("FLH0J0#^,-5NQM"R-3SHZQDW<K[ECMJW6[.E MQ\G))OC%>)Q+_4*\]_+3REVCE>3OEQ@:5_\`T;6;"AE7+./9K@XLO>4Y*-8Y M%Q44.U1K)HS8RE$+B(B(CXW_``>%;J;J?`Z$'%U;JV;J@>@H!0"@%`*`4`H! M0"@%`*`4`H!0"@%`*`4`H!0"@%`*`4`H!0"@-`\/NC^V-`?CF^H=^OYS4_I, M[;_E4^J!6P]Q>@AY0F,X#^I[:2CACN8W(UZQ35EE)K!M-X_(&+^<:1D?&*Y= MD"#<P@/1Z]EFO?\`2@%1137^:,ICU'(5W/<(.2K%CWF<%UG*NBID\3IL';"1 M6N'[DJ#,]8AOJRKVTLZ':K+E^DQK=$>O;^4O_LOYS!!2$!11$/`4DQ_]@M<> MQEU14N]'/<ET^SW'DJ8E%`:#^5^]#\-2_0EZ_P!9`SC?2P_4'XY_Q1=?PW)5 MUUY=_@O!^R_B.@=I?A_&^S?SEAE9N9(N0H1%`*`4`H!0"@%`*`4`H!0"@%`* M`4`H!0"@%`*`4`H!0"@%`*`4`H!0"@%`*`]=8G>(!<2^'4.HAUO?K<.@A4T. MF%7VGG.O7%TK#C7Q3[#&=]:[TCX?;..Y%RVX\0L3!;-Q*.=S6V,/0.UB(S84 M`P1,N\R1IWG08L\MB6J9CG_%!\F6P_G`"^M]Z;5CF/\`SG2DHY]M>W#E"Y#Z M3IRZHKC%TXOF?6+^GS^=O4O+S5\7R6\SKN1F;(SLB-O`OOJN7,*_<]B-N5*S MECS;2257;?&G3RPL"B'0P`(E$;E`W0;?3[>E:PC/XD7TU/T&1X4X-Q_4<4SA MV#3''W6PNS(,RE&X#^>-^<M;J-BA5WT.S]YU-4^@J^NAK3S<U):9L/*3?MY, MK=E+OZFG)?(1[]AO$.P;"%O=X#;Q\!K8ZEU<3B9)T=>$H\_U&]-,ZJB**:9E ME5S]B*213G564,(%*0A"`8QA,/0`"XB(U+.?2OVGR)9SA:BIW)*,*.3JZ<%S MJWP2\66W<)^`4U+Y5A&W>044[@]914W$S*^OESJMLDS6!*[3._;NR$.DM#13 MIK<3F,(**$Z``7O57;T)YW^I)/$5'T=LO[>!Q!YW?G5PO+_+OZ'Y17G?WUCP M<9947U8^+\14?1+C&]=H^,:.,>WBC]+75T7@T3KO"6&MH:)@<!;XY$?HE#0; M9%I$QL(HR259-F;=N`)D(FF>QA&XF-<1$1$1K*[5JS:M1LV(J%F*2BDJ42Y? MV^4^56M:SJ^X-6R-<U[(O9>K95YW+MVY)RG.<G5N3?'GR7)*B2221V%4Y;Q0 M"@%`*`4`H!0"@%`*`4`H!0'0V\\SWCA45'R>F=3P^V5@%P,U#O<L1Q:213(4 M@MQBS.D%6SQ181$!*8Q>VU`5(!ZOFT#[<@]12G'1MAV0N<]B,)R!G-Y0#A]" M.'TBBR7[DD$2D5.F503%$+E,`=*`O7E59)&*D5X=JW?2Z3!TK&LG2XM6SM^1 M`YFC9=R!3B@BLN!2F/8>T!O0%/7(3U'^2'&AQ'--I\2VT(C-NG3*"R)KG[65 MQZ8<M$BK+(M'#9L51-8B)@.)%``>WPO0$U.#_)'(.56DD-KY#C#+$W3S))Z( M;Q3!X=\B5K$/#-4UC.#%+W**=MS!;H-`3"H!0"@%`*`4`H!0"@%`:!X?=']L M:`_'-]0[]?SFI_29VW_*I]4"MA[B]!#RA,?H)?U0.8CU^&7)>`25*,K%<E%' MSU$MO,*UE<$QI1BH;H/PG!`Y0^U42EO>^966=8G'9[A67X/+%(I&Y=C<YC3\ MI@`0!M-1J\>J>WCW$(X[OMU29^/:S,2YAY%/@W82B_12GSE+D6OO%J=I\IPE M'Y3\\_9FOIS4>Q\ZU;DC<S2>P+*YG%WZ+A,4S",:]739N@O^.@Y;>6H0?:`U MQ+GX=W3LZ]@7_P"=9NRA+TQ;1S1F8KPLFYAOG:G*/R.APG[_`-T+#]T/?5*4 MPH#0?ROWH?AJ7Z$O7^L@9QOI8?J#\<_XHNOX;DJZZ\N_P7@_9?Q'0.TOP_C? M9OYRPRLW,D7(4(B@%`*`4`H!0"@%`*`4`H!0"@%`*`4`H!0"@%`*`4`H!0"@ M%`*`4`H!0"@%`>NNH1,IC',!2E*)Q&X!VE+<QC"(V`H`4/$>@!48Q;?'W?UD MDI-*B4JM<.GBWRX)=O8877KD^JTKM?()?B)QVRI8FL<:>"VV]F<"Z,E^GF1M M%0#]$8Y^@<IE,:A%T[.A*($=.`[1$2$ZZ>WKN2>H79:'I<G&U;<?BW$W[3KQ MM1:[&N<ERY'WJ_IU?DMM;/P['GKYK83>Y\A*6F8=R*?W>U*/#+N1:_G33]A2 M]V/%<6F8RG4!^^%P]MOH]P5AC48QX))4_M\A]A.*Y<6CJ[9SRS>*9@/]U75= MJ7]@)$[+_?\`OUE.V;2C<N7WP73P;Y<?$YT\_P#4(PP-/TJ+I*Y<E=EQH_83 M7#]1R#2'&C;_`"`E4V6`XRZ4BBKIED<ID0,TQV.2,;XU7<DL0$5#$*`V21`Z M@VM8!K-;5G)R6[6/"JIS?!+Q7><&^9OG7L#RHTYY.Z<ZF;T]4,6VU=R;R[G% M>ZGXTH7N<:N"6K-!`UR":(TV%L@"E4-/2C0J\)!*E^(2X[%."G2*JD(V!=4I ME/:%7_`TNWB)7+\OB75RJN1\M/.K\U6]_-6Y?TK1YW=)V9<]W'M.EVZNZ]=Y MI4X]$:+Q)PG'S^\5SBH)P$#B<>_O(<HE'XKC?M*(].@>X`J[)/G](Y;A)071 M+V,;M2JW.7?VM5[7VOBS)!].G.ULUXQ8FU>+"L^PQ[*8>N)ANH"48Y,=GWW$ M1M\LL4`^@*<>WF3-M\7P?<3KH0%`*`4`H!0"@%`<%V9L7%=38)D^Q,UEFD-C M>*1#R6D7CQ8B*8D:HG43;)=WQ*NG:A032(6YC',``%`<7X_[8)O/3>`;<1B% M(%OGL$G/MHE98%UF;5PX7(V(JJ4`*90Z"13#;P$UJ`[BH!0"@%`*`Q.-^12! MO5A<,2B!$G>]==+F$2`?M46,Q.H(@/0;CUH#+'H"E+UN$B&TEJ542B*B6S#> M68.@@!XHY3A<?"X4!WSZ1K,6O"C!E!()!>Y)FSNXC<3^9D#H.^WY-^V@+-*` M4`H!0"@%`*`4`H!0&@>'W1_;&@/QS?4._7\YJ?TF=M_RJ?5`K8>XO00\H3&8 M-_5#.0$'BN_>47&V7=D;2>UL)Q39N')+/!(1Z^P%P]A<C8MVBGYL[P8Z8;KB M)?B%-,1]E11X7H]J,^\/#[/P]:%/R,5KUQ^*L[C&SHKE9C;$'6%9JSBL2SXS M)H1,<<RN,(#>'EY#Y=(/-:9`S`$A64&X+IB4P]2USGYN[;O8^I6]PXW#&R(] M%U]D91]U_O(T]YAZ1<AE0UFU_+N)6Y>E?VYE!H]!'H(=?`0L/W@Z!6G*Q?&" MI'L-=NE>'(4!H/Y7[T/PU+]"7K_60,XWTL/U!^.?\477\-R5==>7?X+P?LOX MCH':7X?QOLW\Y896;F2+D*$10"@%`*`4`H!0"@%`*`4`H!0"@%`*`4`H!0"@ M%`*`4`H!0"@%`*`4`H!0&TQRE_&&WTV&WW_91NE*]KH0;2XMI&/MZZGJ1*\7 M]5!QUU'-_+[SW)"."2\HR5`'NN]=/0.T>29!()CMYS)1$[9G<`$B1550ZE*- M81O'7Y:;C?<<%UU2]&B_9C])^$J5IXGTG_IW_E2?G-O=^9^\L=ORWT"_"48S MC[&9FUK"U^U:M/IN7N%'[$&^+,%,1,8QS&.=0YC&4.HJ;N44.>YC*'.(B)SJ M'N(F'J(CUK3UGX=N*Z.KU\ZUXU??6O$_2#;MPM15FTE&W&*25*))+A3LI3DD M=N:4T+N'D7FS'7FE-?9)L'+'RB0?5\%'K.$6:*IRD^<EWH%^2BV*-Q,=58Y" M%*`C51C8V7J61]TTZ#G?Y/A[,6_K/DO14P3S%\T-A^4^W;VZ/,'5,72](LP; MZKTE&4VDVH6K?&=V<N48PC)MM+M+-O\`A+1.GMEA'<DY]GF.68W&PR[W`,5< MJ_HM$2+YL1^:,FIP2D7E'39-4"KI(`"(CX&,%ZV[M[:TM/QD]3FKMY\>E*B7 M_`^"'YHOZB.K>8VX[NG^3F/>TW;V/9=M9F1TO(NM.CG9M\5:5SOG[278F3GB M8F)@8MI!0$5'04&P0(@QAX=HDQ8-DR6*!$T$0(41[?$QA$P^(C>LQC"%OA;5 M(GS-U#4=2U;.GJVJW[N3JF0W*[<G.4Y.3?:Y/G_=21/[BQP=F.2V!9/G"^4N ML(9,I0(?$%S1Y'S6==LD_P#"CET"@@H#!HN8$B&2ZB:_N&IBD.M]W\-]Y:'* M[DL@@BY+B21NX<NQ8B[Z,13Z`)Y-H)!=QP=?%0O;<!ZT!8QZ2TFHO@&U8P#D M.V:9BQ=(=INX`%Y&@*MNWX+=R?LH"VQ15-)-154Y$DTB'5445,"::::8=QU# MG/8I"$*%Q$>@!0%2&WO4.V;F6=SNIN#6FG>\IO&7)X_*-E.4W(:^A)-,0(HT M8NT"^5)JME+E4.8Y$@$!`+^-`14V/R^]6#1<?^F&T]1X<WQ%LH!Y&1:8R=_# M,TC'`0+(R,4[65C4S`;M!0]P`?&@+"N!G/B$YB14_!S&.$PC:6&-VKN>@4'/ MSL1*1CPYDV\WC[I3M<':^:`%534*!TSC[0&@+`Y:6C(&,?S,P^;1D3%,W,A( MOW:A46K-DT2,LX<N%36*FDDD03"(^Z@*EL9YS;WY;;1RK7G##"\2B,$P=<4, MDW;M/YY>-5.)U$FY8+&XT/-<`^.0QD`4,!S$+W&`I1O0'DY`9;ZF?';`)O:K M?*]';=QK%69Y')86/PF4A9UI&)?$YDFI2.!([0:E&ZI2CWE(`FL(`-`3=U5M M?8VQN+F$;@C,1AYO966:_CLF;8BVE1B(1],/TQ,FR)+.R&,T:"40-WF*(A[` MH#'I]3'(>:D@KB1.3)<7P[!LB7EU<-UW@$W]:PR;J';HJNWL\O8KF4D$$78> M6=7\V4?Q2W"@+$.).PN=D5QHTW'ZVX_ZCRC"6N%1R>+Y!.;,<Q$K+1?<L9%X M_C4VJI&3A41$#$`P@%J`MLP!]F<GAF.2&PX2,QK-W48@MDT%#2)I6*C)0PG^ M8:,)(Y2&=MTPM92P"-Z`AMRTYZX9QPFX366+8Z_VUO;+E&K;&M:X\X3(=!:1 M5(WCE\B>?G/JYN[5-^;3`HJG+<P!8!&@/+#8UZ@V80">03>SM,ZIGI!L5TVP M6,PEYE[2$,L0#DCY6??.FZSMTV`>U0R).SO`;7"@(:N?4BWKQAW:32O,_7^+ MNXU55DLVV?K;YMLW7@7RQD6V2EA'MR.8](]OF4TS`N@(#<OA0%UD'-1>10T7 M/0KYM)Q$RP:R49(LU`5:OF3Q`CALY04*(@9-5$X"%`8K^^?^;9_MOUQ_:LJ` MRM:`I6];;_0=JK_67_DPU`2+]*#]2367^,LO_E&^H"P/),C@L0@9?)\FE64' MC\$P<2<O+R*Y&S)@Q:IF47<.%U!*0A$RA[^H]`ZT!3AD?J`<K-]3$HTX-<=7 M.2X#%O%F*>W,Y;.&\3/JH'%(SB#:*&;M!9*"413.H<QSE"]@"@(YY]SY]2WC M9*1CS?6I,-2Q^0<@BW5<0;AC"R"EN[Y)ODL4NNW;OCEOVD,%S"'2]J`N&X?< ML,.Y=:P'/,<8.<?F8F0-"9?BC]5-9W`322*:WED<)?`[8.T%`405"URB(#80 M$``[TV=LK#M08)D>QL^F$(/%<7CU)"3?K#<W:6Q46S9(/C</':QBII)EN8YS M`%`5CZDY4\O>:KG(\@XXXK@&F--0,LXA&.>;1;OLCR3)GS80\\D?`1PD9-P1 M`P"<1.8I!'M$>ZX4!P?DCO7U'^(D?!YIE;[2>VM=2F01.//Y:&QF4@GD$]EG MJ+1F660*H84V[H3B!%B7*"E@'QH"YJ&<N7L1%/'B9$7;N-8N722?<":3E=JD MJNF0#@!P(14X@%^M@ZT!]*@%`:!X?=']L:`_'-]0[]?SFI_29VW_`"J?5`K8 M>XO00\H3$D.(')W..&?)K3?)W7PK*Y!J7+F<TYBDU3)%R7$W`BQS#%G!B_\` M9YR`673L-_SIDS>RB)9QZE0_7PXV\A-:<K-&ZTY`Z@G6N0X!L_%X_)(9ZW.1 M19J+M`HO8>01((F;2D.^\QLZ1/8R2R9@&HE&U1T[CG.R=>X?M?",FUSGL*TR M'$<NB74--1+TA3(KLW:8D%0IA`11<H*6.DJ6QDSE`Q>H50Y^%CZCB7,3+CUX MUR+BX]_CZBFRL6QG6)XF0JPG$PFN>?`[8/"K/EDUTG^2:7R-ZM_-]L`B)S)E M25,8Z.,90HB'EL<A8%$$R*'LFY3#N)<1,6N3MX;.R=J973<]O2)2K:N]R^C! M^*7`T'N';F1H-ZC]K&FWT7/JQ[(>I$"1"PB'N^U^"X5A[;?%\S'4J*BXHT'\ MK]Z'X:E^A+U_K!G&^EA^H/QS_BBZ_AN2KKKR[_!>#]E_$=`[2_#^-]F_G+#* MS<R1<A0B*`4`H!0"@%`*`4`H!0"@%`*`4`H!0"@%`*`4`H!0"@%`*`4`H!0" M@%`*`Z9Y!;HQ+CSIO8NZ,W=$;8WKK%Y/)'X&.1,[M1FW,+&.0%02E,YDGHD1 M3`!N)CA5-F9-K"Q+F9?=+-N+D_49CY>;&UGS*WQI>Q-!@YZIJF9;QX45>E3D ME*X^=%;C6;\%Q/S).2.^\]Y3;RV!O'/7#A_E6Q\E7>LXY/S')8N-75\B`QF, M;!W&*WC(\$FZ1"%N80'IW&$1YPR=3R-0RIZIEU=^]<;C%*K2Y1BESY*K2[S] M='E-Y:;;\DO+/2]BZ`H6=*TO$5N5R7LJY.BED9%WDG*[)2DYOE[M4D75>GIZ M">U>0[:)VCRA<3.F=2.RHOHO#R(';['S!FH`*D540<I@7%8M<H@`'5*+@Q37 M*4/&LST+9&=JDHYFI2=G"?'X2]^?I?9ZF?/C\T7]2W9WEY/(V5Y*PLZYNI=4 M)Y4GU86--/CTT=;TXNJHO8X4J9A&@.,6AN)6`DP[26OX#`\;CV@.))RT;D4F MY@[-$557^03BX'?RCLY2"8QE3B!>O:`!TK:VG:9@Z3CK&T^VK=M?+ZWS?I;/ MAEYG>;?F+YQ[@EN3S%U3*U+492]E7)MVK4>R%FU[MN*[EV=IC2;>S)38.U=D M9JHH*@9)F4V];&OWB,>1ZJVC@)^Z`K5`"A;V!5>:Y2[>UGGTYJK(=V;'QO6^ M,D/\W.O$PD7Y2B9&%A$C$4E)=P(%$"E:M>[R_P!TJ(![Z$3*KUMK['=5X/C> MO\4:@T@L8C$(YD2P`JL*877=N#!^.Y>+F,HH;VF,-`<R<-T'2*S=RBDX;KIF M27073(JBLD<O:=)5-0IB*)G*-A*("`A0'46L-%:\T[+YO*:^B?J!'/I5O-S4 M.V4_P0A)HH^0=>+:=H%8)N2B)CID^#O&X`%`<EVC@#+:>OLMUY)S$[`1V7PS MN#>RV,OS1<ZS:O2>4N>.?D*8[=91(1+<`O81"@/E:=T[KW0NOH'6VMH-ICV+ MX\T(W232*0'+Y<"A\Q)RSL2@J_DGJESJK*")C&'QM0'L;'?8-+89EF-9-+XT MHPF<<FHY['2<G&$*Z1<1[A(Z1F[E<.\>MP"W00`:`QJ?2`($=S0R6/9J&!DG M@6:,B%*8#$6:LIQ,K6Y@``.4@%`0&PW&@+V^?T%F&1<0-Y16#%=*3JN(+K?+ M,0.9X\C&SE!S,LVQ$OSAU%XU)4.T+B(7"@*-/2@YBZUX]R^7:TVBZ1QS&]BO MXV4@\T63LPBIMFW^06AI]4`$[-NJ`AY:@_`D<!*:U`9-`GQ38N*.T$'47E&) M93$NF"Z[!TWD(R4BY1JHV<ID<MSJHJ)K-UA#H-PO0'BP+"<=UOAV.8'B30[# M&L4BFT-",SJG7%K'-"B5NAYR@B=0$B=+CUL%`43^NA_U3CZ/2P*[!\0O_P!@ MB?#PH"T/T_QOPRX[CX7US%C_`/%<T!WMN;8C+4FJL_V6_`IF^%8M+SP)'-VD M7<,VBAF;<P^Y=V)"?=H#%CX-[.DYGE?DW(W8>O\`8FZLK;LIK+2,,(APGI*, MR3(E_(8.W*"ITR,V$;&K&1;`'1,P`(6&@+SU^?T^EVBEPWY1+W`>X2X>S3[1 MO>QN]X'B'6]`54^H2XW%S%R'7&0X5Q.WABZ^&1,W$2ZN30")%9)I*+HKMD6H M,SK"8J"A#"(&'\JU`7.>GI`['Q;B3JC'-J0\E`95"QSV/")EP$LBRAT)!P6' M1=$,(F3.5D)?A'J`6"@*'M\_\VS_`&WZX_M65`96M`4K>MM_H.U5_K+_`,F& MH"1?I0?J2:R_QEE_\HWU`2JY!:`P[DCA#;7>?/\`(6^*?I!$S<O&0$HI%DR- M")7\\(*:,D43.X1Z;HNC<`.`=:`[6QW'<?PR!C,;QN+CL?QV#9I,(N*C6Z+& M/8,D"=B2""*8%33*0I>H^(CU'K0$,/4)-@&4\1-YPDS*8V^>M<->2\2R5DXX M[]":BU$G4<Y9("N9R5TFNET[`[K"(>`T!7%Z&#EP=+D.@90PH'6P%T*9A&WS M*C"3*=2P_BB8O0?M4!)[UE8;+Y/BJP>P";QQ`0.P8"4S=!F513_`I2.$6SMV MFD`W9,I%5,Z@F#M*%A]E`1J]*#FOJ?#-=(<;]DS,?A,U'STO*87D,LLFT@LF M93KCYU1DK)J&(@WEVKE0Q0!00!4@@(&$>E`7@;"U_A&YL%E,)S%BVR'$,E0: M&<(I.`%-P5LZ0D&+IH[0$P`=%RW(H0Y!'J%`<[;H)M6Z#9*X)-T4D$P$;B": M)"IDN(]1'M+0'FH!0&@>'W1_;&@/QS?4._7\YJ?TF=M_RJ?5`K8>XO00\H3& MH>(?;#]N@+O_`$@_6OW/Z8F0DUU*1Y]D\4<RSN.R+/\`!U3G6R'!DET7C/)< M@UH<YP10>R'FMG;ID</*<&:"!+**"<8IH\KEMOB?II:'WQJ3DWJG#MUZ0S2' MV#K7.HI"4@,@AW!5TC)KID,JQ?MQ,"\?*QROYMTU6*1=!4!*8`H4K5'0Y'L; M6^#[9P^<U]L3&HO+<1R)F9G+0<NU37:N$E0,4%"`H`G0=)&'N35(('(8+E$! M"K?J&!A:EBRP<VVKF/-<4^7J?9(ILO$L9F/+&OV^JS/GZS&OW_Z$6S&F<NG? M&K.<6D-=20JN6L'L60?L9[&#F.)@BDY1BS=IS<>4@@5(ZI"*D*7XA,/6M$ZS MY/YZSG=T*[;EB-.D+O."[(KT=[-6:CY>9*O/_*96_N[=:3[%7D=&CZ%_,\0$ M/K[3`C:Y1_229'KV"7Q^IK^VK,_*'=3BJ/$7#ZTN'R<"WR\O-;IPG8]"<J>H MR3^$>F,NX]<7]2Z<SM:(<99A,$K&S"T$NLZBCN%)!TZ*+1=PF@HH3RUPN(E* M-_96^=IZ7E:+M_&TG,Z?C6[<E+I;I5/LKQIQ-IZ!IUW3=)L8-]KXL%QIRKQK M2O$EF7J`#]'V>/6LF+PG55-:$10"@%`*`4`H!0"@%`*`4`H!0"@%`*`4`H!0 M"@%`*`4`H!0"@%`*`4`H#8<W:6]KW&WW_?;V4[4O$<>2Y_VYF,M_6#MO;&S_ M`/F!X"Z2BY/)\[W?.)Y7D&-0155Y*0C(EX#;'8YR1$#>2P5DBJ.EU#V3(DW$ MQQ``&M9>86H7[RQMM:?6>H9DZN"[;<6NIONBJJK\3ZQ?TR]E[5VY>W#^93S` MO6</;6W;#Q[&1>I&$+MV#E>G"3YS5MJW&*74Y373Q)">F9Z)6I>)T=`[9WHR MB=I<BCMT'I`=IED,*UJ\.4%19XTP<D\F4F&9C=AY%<@W,`^44H?$-[V]L[`T MCIR\E1NZETJK^C#]F*\._FS5_P";;\_N^O/3,R]H;!NW]&\K5<E!1@W#)S8K M@IY$TZQMOFK,6E]=MU1?#Y`6L)A'K>XVZ"'NM:P![+5F$H*33?-<CYUN*?.E M?U]Y&3F3LLFJ^.VQ9XBY49.2AUL8A?C`ASRF0)G8)`F-[B8B2AS]/W-3$QB\ MQ<>^D'49#1+1S)2TJZ;1L9&,4S+NY&1>*%330;)$`5#'56.`_P!CU$:`R3.% M/%1CQWP<9.?10=[1R]JU<Y2_``.$0V$/-;XU'G-^*V9";\\(6\Q6X^`!0$W/ M"@%`*`BOS!Y18[Q,T])[(F&(S<RX<I0>'8T18J"D]D;PB@M4%51^)%@U*05' M!R@(E3"P=1"@*I>-.&<I?4A2FMK[NWGF&NM)(3#J(A,#U4X'%T<C<LQ_OU%! M\D'S/U2P$WDG74,9=96_;V@%`3P=^FQQ%Q[&9UT;7LGD,@U@Y-<DEE.:99-/ M5'39BNJFX46<RP@"HJD`PB!0#Z*`IL](,I"<T)Q),`!)#`<U;I%`;@5)"712 M2*'[TA0#WC:]`942A"J$,F<"G3.42G(8H&*<I@$#$.4URF(8HV$!#J%`5"\J M/20U3N&2E\XU!)EU-G,HHL\D(HC87>"S[]7N455=19!!:)<.5`^-1L/9<>X2 M4!306>YD^FSL]MCYY.7QLAUA?-L><O5I_5>?1;=7M7^0!P)D4!53"WYL$7#< M37[;!>@,H[BWR!@>3>E\3VW!-#1AII!5G.0IU06/"9%&F!O+QHJ_C*IHN.J9 MAZF3,%^M`4_>N@<OR_'Q.X=QC["-VW^*P,(D`-]J_2@+1?3_``[>&?'</&VN M8K_YKF@/D^HLR?/^%N_$(\BIW!<0*X$$N[N%NWE8]=T/P_%V`W(;N^B@*7/1 M2RQI%<@L_P`776326R_6S=S'E,8"F<&@GZ*ZJ"8&&YCD06%2P7N4!'V4!D]` M/4>GV>VX>R@-:`4!BE;Y_P";9_MOUQ_:LJ`RM:`I6];;_0=JK_67_DPU`2+] M*#]2367^,LO_`)1/J`\OJ$\YV_$##X:/QB-8S^ULX2?#C4?)J"$1"1K$H%>9 M)-$2'SEF[=0X%11"WG*=!$`"@(J<;^*.[^8&'PV\>7N^]HKP67E&6Q;5.%S: MF'0Y()14P(N97ZI*DLW3>D+=)!,>X$A`QC7&@.?<N>!W%W5/%G=&98EKI1+* M\9PF0E(6?D\ER67D6<BCY14W@GD)5=-8Y0.-P.42C?PH"/'H8CW'Y$F$;CWZ M_N(^(]S&3->_A81O0%_<Q#Q601;^$G(YE+1$JU58R,;(-TW3)ZT7()%6[ENL M4R:J9RCX"'[-`4=\G?1HQ;)5)3*>-N0-\-D5CJO3:WR85G.(N7%_-\F$E"E5 M?P9CJ7$A3%42)X7`*`K:U/RJY7<`MF'U_FYLB6@,?=(%RC4>;.U9&-5A#J_' M)89++>:HT[T`,=LJDH9`XAVF`/"@,LK7N<P6S,&Q38&,K"O`Y?!1T_%J&L"@ M-9%L1P5)4`Z%60$PD.'L,4:`YC0"@/&`_%8`Z=;B/O[A$?P6^@:`_*]YQ^EQ MZCF;\U.6>:8?PIWQD>)97O[9D_C601F--W$;-PLAD;MQ&RC!<SY,RS1ZV4`Y M#"4+E'PIQ*J,K?2JTK0BT/I(^J$`B'^XCR%Z?_BS3_.=*,]E.U0U_P"$AZH7 M_D2Y"_\`ZJU_SE2@^)9-W_"1]3\H7-P1Y##[[8BW_;"1ZTXGFYVZ\T6[^D*W M]8OTP]Y-)%WPBY?97Q=S!P8NWM,P$%$*(+.5^U%#-L;CIMR[;,Y^*(`J*%9G M9*/4P%,ZOLIZ3RG\*G#F?H>8'F+38&'8[FC*'R;'FV1Q;:43@\PA7..9/$E< MD*H,?.0SH3+QTDV$>Q1+N,'>`V$0ZT/`YH'4`^U]GOH#6@%`*`4`H!0"@%`* M`4`H!0"@%`*`4`H!0"@%`*`4`H!0"@%`*`4`H!0"@%`*`4!XE1$"#8+C[/#Q M]_6HQ5627)N$7**JZ<N_B1/P?BCA<+R7V?RLR<2Y7M;,XR&P_$Y*12*L37&O M81GY)<;QLIRV:K3#XZKEZN0`.H8X$OV@(#;EI>+'4I:I**>8X*"EVQBJ\(]U M:\6N=%4VYK'G'N34_*O2_)W`:Q-F:?>NY%ZW;;3S<N[*KOY*^F[:2A;BZQBE M5*M"692@4+!?[HWJX=M34J5%0W4(E('J7[)E]A;+P+CO@S9]/OX=1&9EX6'1 M.]=2&23!01AX\R"("``Q9F\TQSV(F*O6PA0$G>%G!N-TJ@QV3LMNUF-LNFMV M;01(ZCL(;N"C=NQ$0$BTR=,UEW`?BC<I+>-`614`H!0"@*._6]Q>?D-5Z<RY MFW<K8YBV;R[;(7")3'1CSSL8@A$NG(%`2IIG7:F3`YK`4QNH]:`]_P!*3EGI MN,T#&:3S3,,?PG-L'E9LS=ID#Q"(0R*%EI!620E8YVY,1JY434<&26*!^\#% M`;#>@)8\A^8.&/(>6TMQ]FHK;.^,\AI6(@X3%7*<O$8@R<L5DY+,,WF&8JL8 M2%B&(J*`)S^8JH4I2AUH"E#TBEFD'S2>QDG),TWI\$S*(1,JNFF$I*-9%$'9 M6@J'**ZBBA#&`I;F$`]M`9*'(+-YK6VD-IY_CGRIIS#L)G<ABRNT_-:G?13- M1TDFNE^6FH8G:(7]M`?,XU[K@>0>E-?;5@7K-U^D^/1[N8;-%2&-%3WRQ22T M8Z0`PG;+-GQ#AV&L/;8?`:`K:]:'*-;(<?\`&\7EG,4XV@\SJ%?87'I'37GF MK-`ROUTZ312[GB3)PV,5(Q>VRIA``N(4!W_Z6FG,LT[Q3Q]OFK)W$SN;3<KG M`PCTIDW,3&S/D_5:#A`X`9NZ6:I`J<@@`AWA[;T!`WUS6KDZW'IP5(X-SDSY MD5<0LC\VJA$&31[["'FB2YNWH(E`;>%`3V]/C=NJE.%VJ%76=XQ$A@&)_468 M)3$U'QJ\"_B%5S.R/TG:R*B*8I'*<AA+8Y3!VB(T!)[%<XUCRLU5EGZ,KOIO M`,G3R3"%I)Y%/(UO,-_)4CG4E#E?$1.^BEO.[FSD@`18"]Q>E`8FV3XKM_T\ M>4<4X,R7:RN!Y&I)X3+.4EDH/8.$*K'2^62=V!%8KZ*4%NY(`]R*G40Z7H#* M#X[<W]`\C,683&.YO"0&2?*)&GL'R:2:0^0P;_L+\RW40>K)$>-@4OY2R(G* MH3XNE`<QV]RRT+I2#4E\NV%`NGRQ?+A,4QI\VR/+LFD5#`FUB<?@8I5R]?OW MBQ@(0O:4H"-Q$`H#NS'LB1GL7ALI79/\>0EH=E+J1^0)$CY*)(]:INOE99!0 MXE:.VQ5+*%$WPF#K0&)UNO8.'R'J@N<W:3L>OB3/>N#I.)])RDK'%3BUV;-^ MX!T0WD_+MG!#%,>XEL%[T!EOM'C20;I/&#ML]:+E!1!TT72<METQ\#I+HF.D MH0;]!*(A0%'_`*V^58Z&L-28E]<,%,D5SUS*?4R3I`\@G&LXO^^'CAL4XJMT M+J%`ICE`#&Z!>@)$>D9EF/S'#G#H)A+,%YK')_+F,U%)ND32#!92<=.41<-` M.*Z2:Z"I3$,(6,'@-`5F>MGB&0M][:^RUTBX+C&2:X6QZ(D![Q9EFHR1<KO6 M`J6!)LX.DZ35[;]QRA<`Z4!:[PJYFZ%S_06NXYWL#$L1RW#\5B<:R?%9^59P MKV->0K5..\]$CY1`CEB]30*JFHF(@-Q`;"%`1]Y_<G8C=6FMLZ4XYR++/!A< M97R+=6P(M45L*P/#(E4CQU#C.ELSD,LGE4B(HLT3',4AC"8:`C_Z&LI&%D^0 M<89\T2DGJ>#/FD8HLFF]59(M9)-5=%N)@4610.H4IC%+8HB`#0%LO-/?4KQL MTDKM:**U5"(S7"(^71<H>?YN/2TX@SG`0)W`(.DXXYU"&]@DH"2F+Y/`YKCT M1E6,2;29@9U@UDXN28KIKMW+1VB1=(Y5$C'*!@(I8Q1ZE-<!H#'N]:.4PO+] MC:/P7"4FF1[F*G,,I"+@$R2$T,3*&20AX>03:=ZPG7D>\Z:9[>6%S#8HT!=9 MQ1UK,:@XZ:AUSD)A&=QG#(QK,$[A-\O(KE,]=M.X1^+Y-9R*5_["@)"T`H!0 M"@%`*`4`H!0"@%`*`4`H!0"@%`*`4`H!0"@%`*`4`H!0"@%`*`4`H!0"@%`* M`4`H!0"@%`*`4`H!0&E@#I8+>ZP>RGCV@UH#PKE4.BJ5%3REC)J%25[0.":@ ME,":@D$0*<"&$!L(A>UJ`Z)U5QUU]JR9G\Q:M%<AV+ET@ZE<IS^?$KR?DW;Q M0RAT&QS@*47'(@($310*0`(``(C:@._*`4`H!0"@.,YCAN+Y_C4QA^9P<=DF M,S[-1A+PTH@#ED^:JA8R:J8V$#`/4IRB!R&`!`0$*`J_R#T:N(,U++/VB6PH M!@JN*X047E!ABT+GN*;;YUHZ=HI]OP@'F"(>-`32T5Q)T-QPQ>5Q;4^"L,>1 MGVBC/()DQCO,CG$E$CHF"2F5^]R8@$.-B$[$P'KVWH#JB$]-GAQCRI'D5J1% MK,)NE7R.0(Y'D[>>;/5E#J'=M9-K+H+MEQ.<1`2=H6&WA0$AU]'88]U+/:5D M5\BD\+R.,E(>1^LYY](30QTL)A7;DF79EW@%3`;)B8QA*'2@(48IZ6&G==J. MPUEMGD)KMD],4SB+Q79*[*.5$``.Y1J+$Z1UC!T%00[K>V@.W]<^GUQMP#+4 M=@O<<F]F;`;G25;9EM;(I'-Y9FJB/<F=J225^00,0PB);(B!1ZA;QH";1;6` M`"P`````%@``Z6#H'0+4!T1R&XX:LY.8,;`=J0RLE&).R2,1(,7!V,S`2J91 M3))1#],!,W7\LPE.!@,10@V$!H"&&L/2*XGZ\FR3DNRRW8YT7!'*$1F<\JOC MXJI*=Z)WD0P*S;RBB(@'_6!.0;=2T!9W'1L?$,6D9%,6D;',$$FK%@Q;I-&; M-LB0$TD&S9`A$D$4R%``*4```"@.L-OZ,U1OO&S8IMG"8?,(<ICJM"2")BO8 MUPH40%S&R#<R3UBX#H(BF<`,(!W`-`5UR?HP<2'LB+]H]VA$)=XF(R89?9-$ MHC<4D5CL#NBI#[A.(_30$H=&<`N+G'V5;Y+A&NFS[,6O5KF67.W&39"U$0$! M,R=2)E$&)_[)%,IP'J`T!W)N/0>O][LXV+V(7)'D-&F<&&'A\HF<>CI'YHI2 M*%E4X5TS5?IE*3X2G/8+^%`1]+Z:/",&WRO\P^.B02&)WC(Y"*UC#<QA5&5[ MA.8>HB/6]`=MZNXJZFTPUR./UNCEF.Q62PRL&ZB/TSR*3C	O`SB%;2S]Z M$2^(!_A51$@E"U@H#JI3TX.(+]\O+9'JX^8S;HO:[F\NRC*9Z4=`(]WYQV\F M#&`@&Z@4MBA[J`]J']/'BKBTPAD6"8))Z^G6Z[=R23PO,,J@UE#-CD423<I( MRQVKM"Q`*)%"'#MZ4!(3;ND-8[VPI?7^U<58Y;C2W8HFV?\`F%=LG:20I(R$ M>_0.DZ9/TRB-CIG"_@:X"(4!70?T7N("TH1^N?9*[(BO>6&5RPOR0)6M\MY@ M,"NP0'W`I?Z:`G)$\4-"X_I:;X^X]@$7`:NR..5C9V#B#+LW$NBX[/F5Y&4( MI]8.W;CL^)4Z@FL(@%@Z4!U7!^G3Q&Q447&(ZQ4Q&7;MQ;(9!C64Y5$SR278 M``7ZP:3!3J!<H#VF`Q1'Q"@.X=Q\;M<[WU(CIC8?Z026()*P[CS$)A=M,JN8 M,W<P<.)/L.LLJ!Q[CB8+J#XWH"*&*^F'K'!F2D/A6[.26+8VL<YE,<A]GN6L M2"2EN]!!N#&S1,;>"?;0'?6E>$O'30\XOF&&82,CG3HQU76?9A)/\MR]=10! M!17ZVEE5S(K&`;"=,I3VZ7M0$M*`4`H!0"@%`*`4`H",/*SE-K'B%JV2VKL] MZX,S!P2+QW&XSRSSF5Y`NFHHVAXE%0Q2B<Y$Q,LJ>R2"8"8UQL`X]N+<>G[9 MP):AJ,Z0Y1A]:7=ZRT:QK&)HF*\W-G_@\HQ^M+TE1>.<[O56Y#1Y<\X\\0,5 MAM:OC**8^]RYP(O)5A<?)=)O)B;A"O@.7\MNV*D;Q*<0K6=C>?F)K-M9.BZ7 M;CAOC&4F^,>Q^U)*M.XPRWN'>>I0^+IN#;ABODY<Z=GTEQIX$Y.%.]^;>P\K MS_%N8&B(/4#/%X6&?8[E4491)EDTA(/7B+J.06-,RT6N9H@W*<P$,0P=]99M M76=W9V7>Q-T84,;'C"+C<K[TN'#M7Z>POV@9^OY%Z]:UNRK48Q73)+@_1Z?2 M65$43.0AR'*<AB%,4Q![RF*(7`Q3EN4Q1#V@(UL!.JJ99P[.*/"+EL*ID!<( M>;VB)DO,)YH$ZCW"EW]P!;VVJ#E;3XTJ0ZCQ#)QX"("^9A;IU<M[]/?=6]ZA M\6"X5%8^!N3?,ES`1%VV5./Y"3A-0W3^Q(H(TZX2X"J1H[?LF*0+/WC5DD8> MT%';A-ND(A^2!ECD+W_:O47*$%[7"(;BE6?!&YH\:O4BKLG*#I`1$H*MED5T M1.'B'F)&,'=U]XU!3BU5>Z15&DX^[V&]5PW0*!EU442F-VE,LJ4@";PL`J6" M].M>)&OB;_,)V>9W@!`*!A/W$[+6O<3C\-K>[I4>M$#P)/6;@3)H.6ZY@`!. M1%=)4Y2F^$!$J8B(%^FH=4.VA"M#R$<MCJF1(N@=4HCWI$63,J3KU[TP'N+; MZ:=5OP(U-JCMHB8I%G*")SC8A%54R&.)O#L*<X&&_L`*=5OPH0ZCV.XH!U'\ M7Q'KX>SWB-.N/9R(\SP)N&ZQE"I+)*'2'XR)J)G.0?:50A1[BB'M`:1N*3Z> MTC6G:;5GC1`P%6<MD3#X%6622,(>\"G.%_O5%N%:.E27JAVTJ;"OV*ABID>- M%#G^$I2N4!.81ZCVD(?N->WLJ'5;\!7NY&Y1\R1,*:KILB<``135613/VB-@ M&QE`&GQ;?(5AX5-GUE'=P`#YF(].@.D.XUPZ`!?,ZWJ'Q8"J]1YU'"")>]59 M)$HVL=90A""(];%$R@!?K4>J"75WD>9YBJ$,4IBF`Q3``E,7J42CX"40N`@/ MT5,FFJKD#TW<C'QY0._>LV*9QL0[MTBV*<1_<BL<@"/[-2RG&"K.5$0;C'BS MS(.$'*956RZ2Z1P`2JHK%5(/3H(&(8Q3`/V^M3)IJJXID4ZJJY'A=OV4>3SG M[QHR3,/:4[QPDV3,8/805SIE$1^W4LI1A[\DEZB#Z8\6;V[IJ[2*LU71<(G` M>U9!1)9,;_C=JJ9C)CVB'7J-%<B^*=414J\F>Y4X%`*`4`H!0"@%`*`4`H!0 M"@%`*`4`H!0"@%`?(G9Z)QF*>3DZ]2CHF/2\Y\^7[O):H@-C++"0IC%2+[1M M8`ZC0'#<(W#J_93ATUU_G..9BHR3%5X;'9%&41:E`Q2"5PX:B=!)4#'`.P3= MP>Z@.R:`4`N'[-ONT!U7N7;F.:-U[/[,S!I-.<6QAJ=_/+P3#ZR=1T<D'<L^ M5:E.DH9NB'4PEN(!0'$)KD]IO%\(U=L/*\I#&\<W&^QV+P-629.Q<2LIE*": M\/'G0:(N#-G#@BA;]]BE'Q&@)`@(!T$P=;VZ];V[A_8H#=</?[;?=]WVZ`TN M'OH#PN%TVJ*SE8W8@W2.LJ8"F,)4TRB8YNTH"8>TH7Z=:`ZLQS?&G<OGOT6Q M;8N+Y!DA5#)+P,3))/)9F<G<!ROV*5UV`D$@@/G`2PA0'L;=W/K?1&)$SC:F M2M\5QA2:B,>))N&[IP0TM.NRL8MH"3-!POW.7)P+?M[2^(B`4!V8W71=((N6 MYP40<HIN$5"W[5$EB`HF<+^PY37^[0'$M@9HQUWA\_F\LRDG\1C,:ZF)5*(; ME=OTXYBB==ZY2;"HF*X-D"&,8I1O8*`^+I[:^*[PUQC&T\'4>JXKE[(TC"JR M+463M1H"RB!3JMC&,9(3'2$0`>MJ`[),JD42%,H0IE!$J93&*4QQ*%S`0!$! M,(!UZ>R@-PB%AN/O^CZ!^X%`1GQGE9K7-,Z:X9B3;*,C8N<JFL&+G<7"*KX* M&7X\T6=2\']>=X%469E0,052D%$50[`,(A0$F0^W>_X.GA[+4`$0#Q&W_I\/ MOT!\Z6EF$%&O)>5<%:1S!$SAVY.!C$00(%SJ'`A3&["!U$0`;!0'`,-W3JC8 MDDM#X)G^,Y=(MDSJNVN/R2$FHR*G^,#WY83E9J@/Y"@E/]%`>'9&[=9:DE,# MAMA90TQZ2V=DQ,0PAJX1=+&F\@40.X(P2%L@L5$QDB"/<IVD^F@..;7Y#X-J M6<A,0D49W)\ZR**EY^(P;$8P9C(W6/P1!5EYP[8#HI-HYB`"7O4.7O.(%*`F MZ4!VMA^31^9XMC^612;Q&-R*)93#%&1;G9OTFS]$BZ23QJK^<;N2`>QR#U*8 M+4!R2X>^@%`*`4`H!0"@%`*`QJ_5C+_/'Z@G#+CS,KK/,.67QEW+095#HH*G MRG+UT990X7,DJNZAH8B=Q#X4[^^M">9'5JN]M+T*?M8OL.4?[\Z/_E1JG>=< M[<V#IC_DOH4OWIMO_E,D.,BV4+&L(B):MH^,BV;=A'L6J1$6S1FT2*@W;H)) ME*1--)(@``````!6^+5N%FW&U:5+<4DEW)<#:=N$;4%;@J0BDEZ$1WY=:5#D M#QWVGJ])202FYG&WKO$W49*+PKYGEL6BH_QU9I(M3%4;F/)I$2.(]#)J&`>E M6/<^E?YQH63A/^;*#=NG#_$BJP^61;=;P9:CI=[$@Z79P?3SYHJ0]*;F3^B' M%+>F#;WRE5ME?$]3(I-XVR?YE2:0Q$P.A9,W2SAU\U)JM,E068E)VIG`QTR` M/Q%-6L/+?=$\3;V=@:O/_N],ZI.OU'6E?W^!A6S]=5C1LG'U&?\`CX;;:_8_ MXGC](?`-A[Q?\AN9.V)3*'4MM?*9#'L`=OYAXG&)PI),DC/NXB#4,NS9I@]0 M1:)G()B^6W[0]HC-Y:8>9J]S/W/GSOM9-UJW2?!J2_Q*+LXOI([)Q\K.N96M M9S]N]*2AW<:UHOD(/^HOP,><-]2--MPFZ-NS[Z?V(G"*1TOGKERQ01FB2<B) MVZ3"+BETS(J)%``%4Q``/Q:Q3>NSI;7TV.I1S,F4KM_IZ?B<JO@O5R+#NK;D M]'QHY=B_?77=I17*))ON[B<_'WB!CW#/"HCG=DFY=ESS3%-*2F7N<:R7+CS6 M..I'*L:;&8L_J4L8R<N!&4<HHI`+H#%[NIK]0R[0-L0VQAV]WY&7D3MQQ'.4 M+DNN*E.-8I+V>";IS+]INC6]$Q5N/(R+[4,92I.75'KFN[T\B*7%KBOR']4A MSE/(WDQM;9$/KB4E)%A@C/&,K2QUHHNT<*)+H06-*1,DP:X]%GL@"@&(94X& M'XO&L8VYM[7/,+XFL[@R;UO3^I_"49]*J^:2Z71+L573O9:=&TG5=V.>I:O> MO1L=34.F?2J=E$N2IV'&=O89R'](7D+K+,,-V9FDYQYS:>9L'R&39"?*HV5C M4';8N40V00WRD2V;2S:,<"Y8J)`!@L-E0,%J\=1P]=\L];Q\K%NRGHMZ:C6< MG.M.$^KNI"CC0I\S'U/9>J69V+KEI]V:B^IU=*]M>WO)R^NIEKI[Q5TCDN(S MLHR:3^RXB19OH22>QBCN/D,;</&PJ*M%4E#MU"J@/:8;=:RWS>R'=VUAY&+) M_"GD0<6FTVG!M>)D/F!>^)I6-=MM]$[U4TZ<'$Z>Y[<H]E[/A-"\!^*D[(S> MR\WQ##D]L#BYW!9-DBM"1CAM!/,J;.CEB6Z"9C.I80+W(I=@'.`B)!MV\=?U M'/C@[+VW-2S[UN#O.->J#:5$Y=B^OVI%%N+6,O,L8VW=&;>3.,/B>"HJEN/! MWAU!<0];NX,TO/91G63/!?9?E629*]R5\Y!$YRQ<8S=.D6R+:.C4#@4J::)` M,?N,/<(WK9>T]L8^V=/=KXD[F3-UG.<NJ3[DV^WCS1F>W]"LZ'ANW5N[)U;; M;X^LK&X:2\PZ]9?F=&N9N9<Q;6&S`[2+=RKUQ&M3!.XP7N;1RJQVJ':`C82E M`0`:P#:MZ]+S3U6U.JBE/A5T5''D8KH3D]\ZA&KZ:2[?&)'SUW)#+$N1^BXW M%YG*63AWJB76(QQJ9E&2JSA#)7BXK)-8]=(57J*20F[NTQ_+#W5C_F_+(AKN M';L7KT+T\:J4>"]FYX<RT^8UW*6I688[:4;,I</3X%C/I,<ZW?*37<KKS8LX MU=;=U>Q@FJR8M#-'N28LC$,(X<E%4[I<TFY^NFS@KE4I$P`QB")0[JSSRVW= M/<.)+"S_`/4+"27>[:C2K\>NIE.S=P2U?'GAY+IEV>FG]WIX$<?2/E9I[S#] M0-I(34S)-F69*$9-9*6>R+9H7]-,I+VM4G*ZB;8`*4`[4R@`!8*LGEG=OW-R MZVY-M=:I5O\`^2YR+9LR?5K6I.K<?B.E:_69USZJN+2&S?44XG:A/EN6XS!; M'Q>)QB57Q?('L.Z01D,GG/.>-2)&.U%\":(`!CI&Z51^8EJYF[ZTO3)7;T,> M[!5^'.C]Z?84.\[<LK<V'@?%NQMW(PJER]_P)N:?](O7>G]JX+M.,W9OZ;?X M-D!)YI$Y#GZ,C"2"B**J";:38$AFWS2"A5+F`#%L-97IWEK@:5J-O4;>3EW; MEMKIC<N<.'9[KJ9#A[*QL'.AEVK^0U%]LW3Y#A?/ST[4]KY'N/DR3;>S\:=1 MFN5I=#&8#,?JO'07PC%E!3+]5DB'"Y"._D;J]JX"H8;@):I-Y[(GJ-W,UY95 M^%U6.I1C<HE\.W2B]D\=R[;CE3R-5E>OJ4;2<4KE%P[EV%9_IV<!'O,+3Q=R MSNZ=N0+Z%V*XA4XZ&SQ=NQ4;X\:-D$U%V\A&2ZIU%E%.TX`J`&*(VM6"['V? M=W-I2U6]F9/QHY-$E=X/H?TO8^4Q?;>WIZ]@1SI9&0I*_P!+_P`3ZCXEC?KE MO96`XAPWU1,2D6X;Y]@+,SN-D7D:[43(QRU,P'<LE$5A*?L`1#\4:S;S=E>M M[9MJ+:E\>";3[NKM5.9DWF%-VM&]EOA.'&O'Z7:B6\]O]OQN].;&=UR+PBDK MC>A,*4@S2::TD,IETGCL:Q@6SE/YA)9X+J4<E$_<H'<4#"(^_)\C6(Z%LRUJ MEZ=)V\2'37MFX*A>9ZG'2]JPU&3X0QXM5^LXJGZ2GGB3P0W;ZA&,ON2?+;<6 MUVD5G#IVYP5OCV:!&"X9)KF1^<1QY>'=LXN#*L4Z;0J9B@)"@8">!AU;MK9V ML;VQI:[N7*R(+(7L*%RCIS22Z>$?68/HFWM2W%!ZIK%Z]&,_=2G14?<NPNZX M;\9E>'6G<LU^OEN0YNR+EF2Y=%R6231Y^72BUF:`MH]1Q\E'=GDE9B!42%[0 MO8#5MO:^B2VQIL\-WG=I<E.-9.3Z:<%V?VY&P="TEZ#B7+*DY^VW&KJVJ<*^ M)0AQ.U7,^JMO3?65\C]Z[`8QV)2RK?$L)P[-4\:<-&;F0D$F2<7BZ[5X!(*) M9M2D.HB:_G!903#UK3&VM*N>8VJYU[7<N^HVY-6X1GTTC5T2BN21K?1L"YO# M/RI:KE7E&VZ1A&=%%5?"B[C(5XA\7XGB5K*2U9!93EF71"F8SF21TEF4P6;F MR-I;R?+8J.R-&:94&H)V(F!1[0]HUNS;6W(;<P'I]J[=NVW>E-2FZN":I1/M M2[#9FB:1:T?%EAPE)VOBMIMU;4EPJ^\EM64%Y%`*`4`H!0"@%`*`4`H!0"@% M`*`4`H!0"@%`>H^12<,WB"Z::R*S99-5-8A5$CD.D<IB*$,`@<@E'J`^(#0% M7?I-L6+'26UP:,T&O;R'VFC^:22(84DI@I42"8@`)TTP-8@7$`#H%`=G;EY! MYNZY-0'&S7["=3:,==.=DYY,XPFP7R=VV=/#1D'!X^$D(-D$P7(=9VN`]Y0` M"A[:`^9B^P^1>(:;V(ZY#Y9BNHSQ>P48G`-F9"FR?3DOK^26#Y,'F/,0^55S M[O,#9!$A3E64^.PT!U;J3E!L#"-U;\PG/,SR'9^LL`T6ANR`E\GQ)MB>:M/( M5<%D(@S5H@B#Y@[!,/(5,4!#]B@.L-G9%OG>WIV[0Y%2FRV\2&>X+DF1DUFS MB(Y7%HS7BSM9JGC)GJJ0OUIT\43O,\[@,"YK!T"@.:[IS[--8<:>"TOAS^$1 M;SV2Z,PZ4A)[&8K(&:C288LB*R+%21064C)=JF(E262L8!->X6H#N'=>Q-Z1 MW-/3NC<(V4WQ[!]JZ\S'(YI)WCD9(OX1?&C=I%8!VHD)S.7`"%BK")"]1\*` MX_IW>N\<3S;FOJW+I=7=SWCO!PF5:]?_`%4TA\BR`L_CDA,)XS)MXU,B#E5% MRU*F14H=QP$?;:@.CE^0O(/(=%\>MJ:WW,WR3;FXL^Q^"R_5,;C<7()P\?+R M:B611<=%BD=[`.,":E-YSAT4GF"4>\;C0%U+=)1)N@@LL=R=)!-)5PH4A3N# MD3*0ZQR$`"%,J8!,(````CTZ4!57Q!C8QKSW]08[6/9MCEF-=&`R+=$ABF6C MGIEA3,0H"GYY@N8`M<>HT!VSZD&?9CJ_CZ&>83)0A)"'S[`(QU#Y'CL5D\+) M(3N31\>?YAG)H+@@];)K"=!4MC$/UZ4!Z>Z=YYPPY&\?]%ADA-4Z]V'@<WED M[LA1LT34G\AC$4",,"A)!\0(Z*=+)G%<Y@$%1+8"A:@.O-:YUNK.,`YO);`R MY?-=<X,RSO#-6Y82"8P[7*XQKB[M=]))N6Z*8RB\>X4%L9PF(H*"%P$1O0$4 M<%S/?FB?3PT%OK"=J(-&.//<0BRZS-C<<YQR<QG(LP+"KLI.151-)DE2IKF4 M!=,0*4PV#H-Z`F#MV2SF:Y]<78"-V)/X_C^0:@SW+38VS29K1S%^R^JTUC&1 M5*)7JLB@<4S**@84BE^"UZ`LCG&;Q[`R3%A*+1+U9BNDA+-T4%UVBX)F#YHB M"Q!;J*`<+B4P6H"D;C3N"9XS>GOM/=2#A;*W$)L?9,9C&)R#1FA%-LLD=@O( M9G-.G:0"[!NX>N_.=%N%B@8I:`D1N#;.]^,.*<>]R3>??SGP6=9=A6([=Q)W M%L�`S]-+Y68P==JD59DI"/E@(1$XB59'J;XJ`]1]E_*C8G+W>''G!-W1F' M8AAF%:^S^/G7F&Q,GD$<&1NA57@&A#)E1<-72113.LK^<3)82]:`M*00/\@B MV?"F\5!HFB[.9,ODN52)%(N<4C`8H$64`1[1#P&@*I?2S8L6P\O3-6+1N8O) M[-D2J(-TD3^24P=B!3D(!B($$?A)>P#>P4!VKS8V#FVO=B\2S8O*0BD3G>\H MO"YN)G,9AYTK9L>.=O59.$?/6RSN'EQ*@"/F)F*(%,/6@.L<S@9YQZJ^!%;Y MC(,5'/&S(I%JHE'L%?DXM'+"@OCY2J)B0[1V8ICF5-=8!L`#0'@;;_Y";^_W M@)+2L?D<0AKG.IO6FIVL"T@U(IWD>)))B^E=@'DOSP,9=\MY8()AV)MQ`WXU M`61ZED-@2NM<*D-K0L?CVR'6/L%,TAHET#V,8Y`"78_38.2@`*-CJE[R]`L! MK>R@.Q*`4`H!0"@%`*`4!C3>L2PGM'\PN*/+IO$N9'%H)Q!Q\HJD411)+X;D M2LPI&K&_N95Y3'I!4$.X;F.00#K6A?-"%[1]RZ=NI*N);E"$_P"]&?4H_O)U M-6;UC/3]=Q-:?\B-$_W7U%^FI][ZGW=AD+GFN,YQW(8*<CVK],S27:"\8BX3 M*=1E),3+`[CGS501(JFH0HE,40$*W'IVLZ=JN-'*P+UN=N<5*G6JJJK1KL:- MBX6HX>H68W[%RW)-)TJJKA6C.8QN=87+S[O%8G+,<E,DCFB;^0@8V88/I=BR M56%!)V\9-%E7#5`[A,2`8Y0`1"JNWEXU^^\:U.U*[&-7%.K7_`]X9&/.;MPN M)S7T5V>!BP>K!QG8XES9P)K@4\OBL;S+6@XO-8U@91%FA,FRB/BIB1<MTCE3 M>M)%0$7H)"``5Z4QO"N=/,C0HX^[K$<2ZK,-4Z/B17)-OI;\>IFG]Z:5\'7X M*PJ6,[I4_2GQ,H;4.K\4TMK3"M682P3CL9PC'HZ`BFZ9"%$R;-NFFL[5[/[J MY>+]RJIQN)CF$:Z'TS!M:5@6<"PJ6;=N,4O0J?V9MW"P[6#BV\6S_+MP45ZE M2I3_`.OI^J!B'^N&!]W_`-&F_=TK6/G0J;8M?^3'_ID83YB<=&MO_P#87S2. MU>86(9!FOI)R$5C:*[J09:-UO/K,FI#JK.XR";04A*)@0O50J3)(RI@]@)C5 MQW1BW\ORV^'C_P`Y8MM_N]**K7+%S(V3T6O>5BW+]"/;]'#<6`9OPKUKA$-- MQ9<MUHC+0&68\9X@E)M%?K1T]:RAF1U/F3QTDT=%4(MV@3N$2^RH>6&JX>;M M*QAV9+[Y9A*$H=OLNCE_O/78^;8R]!MPK_BVY.,O2N9$/UWMFXAE^%Z;XZ8F M_C\HVS/;#3E4<>A7",E+1#=PS-!QR;M!IYRC5U,R$D4B*)NU0Y4A/;M"]8WY MO9]G(Q\/0\:2N:C._5+PZ53_`)BR>863C7[.-I5IJ>9.\FH]W'D>GZRF-/L& MX)\4\4EOCDL5R3#(.1$#"(`[C\)^3=``#85#@JD/;U\0KS\T+$L/9FG6)KIG M;E"#7<W!*GJ)-[V[EK;N'9O+IN*D6NY]"31&+CC.2?I2<IX1UNV`:Y5J'D5A M^.+P>\3QIEYJ%8R:#=\=5"04$ZC<L2\>E1FFH#W&2`BY;D"U6#0[ESRYW%&6 MJV8?Y7FVX-7GSBYI4DO&-:3CVQXEGTF[+:.L6WJ5I_<,F"Z;G.C=/=\?K1[> M:,J_&\FQW+HAI/8M-Q>0PC\#"TEHAVW?L'/8?L4*DY;'41.*9R=AB_C$,`@/ M6NC;%['RK?QL5QE:?&JXI^*-QV+MN_;Z[4NJ/>NWQ,?7A=_SI>:O6_\`@3,. MM^Z_^'<7_*L%_O5I?:M'YJZKT\J3^>)K70&WO[46^?0_G@>[ZD1"*^J1Z?"* MJ95$5UHINLF<@'3507R^1262.F8!`Z:R0F(:X"%AJ.^8U\Q=%BN,IQZ9+]ES M8W3%/=FG-\;4DHO_`-;(_<R.-.1>F%R,USS-X\%?+:RF<YDT\WQXIC$CX$<@ MF%WCW#%^P3%1Q6=@5?):G/?R7C<IA\2U8MTZ#D^7VNX^ZM(=V>G2N3ZX=BZW MQA+]F5:)]Z+;KFEW=HZO9U_3VYXURY)2CW5;X>OW?4=N^BME4;G7)OF_G$,D MNA$9H_B,IC4'0`5RT9SN29%((-5P#H"J)%NT;>ZKMY5Y4<[<&JYMOJ^'=Z9J MO.DKC?'QXE=L2]'(U7.R(JD9OJ2[JNIQOU6\&+L[U(.(FNSS\MB)<TQF*QTV M40+DK6:@BOLGG1"3BW!QLV>H^78I_;7AYE8L=0WWI>!*5R#G!4G#G'VIGGO+ M&65NG`QI35KJIQC[WOOF6#:*],MEI+;^&;33Y:\@,^/B$@\=%P[+LL;/H"<, MZCW;'R)5H0"F<$0%R"A0]@DK,M&\OO\`*]0L9\M3S<G[O*3Z)S73Q[*=R\3( M]-VE#`S+64LR_=^')^S-\/%+T$Z^3?ZN>]!Z==1;"\/#_P"U9/PK,M?_`-"S M/_$N_P#0S(-7:>DY+7+[O<_Z2KST%OU,Y[_7%EG_`'&$K7_D]^%9_P#DW/F1 MBWEW_HLOMYGSO7G_`%1V'^LO!_\`NF8U+YO_`(7C]O'^(\O,3_1?WX?QGQ_4 M%Q2>RGT@-=K0:#ARGC&(Z/RB;3;D64.6$CHALV=+BFB-Q29JO4U#B/P]A1JE MWO8O7_+&Q*U[ENS9G+]V*_VGGN;'G?V1;C#E&U:E^A$R?3+WEK3:7#[2\;BV M0099S`L*B<,RS&@?-&\K"3$`@#%R=S'"HFNFV?\`E`LDMVB10A[@(C>LJV%K M&#J.V,:UBRMN[9M0C.->*<4JM^OB7[:NHX>=HEB-JXOC6H1C)=TDN*)]1LW` MSA'81$M%3"3!PI&R(QK]K()M'B1;K,7@M5%4T'"::@=Z9[&`!ZA68PNV;\92 MA*W<A[LJ->BC,D^)&YU134XUHUXE)7)CTBM.Y!(9?R`X[;CEN/F6I_6^5NUX MJ<(.O2RA//?OW!7C5XU?8TD[>%$510<^4D)C""=^E:GW'Y9:?>=_6=$R;N)F MNLI4G['5'BZ4HXNOC1=QK_5]F8MRY=U+3;WP,E5FZ<D^?9\QRST9^3^YN0.K M=I8QN.>7SAWJ7*HR`@,_>74?S,=(,UEACY&2["?6KB..AWD7,'F&;K$`XWJL M\K-PZKKF!DV-4NO(N8UR,8W&TW./&K;256FN+*C8FK9VIX=ZSF7%=G8E2,_2 MBZFMK&=B@%`*`4`H!0"@%`*`4`H!0"@%`*`4`H!0"@/A9(PEY.$?L(*9_1Z4 M=(&1:S/R*$F,>8_0RY6+HY&[@Y2WL!QL`]:`@YJ?A/F.C<9F\4U=R9S6!BY_ M(9O*GWSF%8A,+C/Y`J9>3>D6=`!B$45,(D3"Q4QM;PH#7)N"+>0=:GSC%=SY MWB.\M414A"H;=;M8Z0?YE%2SYS(R,;F$`\,,7(L5W3M02$O9(IA*7I0'-]K\ M497<FN<8QO--P9&]SW#-AP>S\9V"E`PK=",R;'S][%#]$2`,,M#=@B4R!Q$! M$1-<#4!\^"X=%0W)D>ZLPVG/YU.Y]KH-9;!@I:!B&F.3N-74/\K&LVABG@$T MU#W*5$3#XW&XT!UZAP`5;:3ROC.WWMFZ&B)L\K]1XVG$Q!LDQIC)O#R!8!'* MSB9[(0+)R<1(BJ6YB?`(@%`<RV!PL'8VL--:ME]LS[2*TG-8OD&-RS+'H896 M2DL,\LN.GEO.,*!D&Z*0%63*%E_$1"@.;Y+QD?Y1O_7/(9YLV3;Y/K7&Y'%8 MJ#;8]$A!/XN;`/KWY\#'^:^8?GZIG*/][^!;T!UCE&E)7CX^Y1\H(3(,TV3E M.QL*4<3FNX*$C&CI^OCL4[CL<0Q5RV,=\S=QR3P3F$.XRW9W#UL%`0#USB6X M<6U'ADSQMY-3.7[,=(Q#MAJYUIF"14)(2[Q-W/0V990[BVLPS9L!<*$<.W!Q M.8R8B("(A0%\L>27/!LB22K=*>/%-B2"S9/S6B4L+0@.U6Z1A*"C<CP3"4HV MN4``:`@]C/"[+,+V;M+;F)\C<OALQW$\8/<U4##,5>QBRL20Z4:G&L'(B2/1 M:)'$MBC\=Q$W4:`;`X226T]4Y'K#8&^,SGAR_84;L/(\H-!0;:35=P2T>X@8 M2*9D,9A#PT<O&D,)$@NK<U[7H"-_*)C(Y#R1TSK;*-IY3J1MK36<A-0^UW.! M,<FP[.\EFU"Q:T0WA'3.0@8R;BF#0IU%CV4`J@%3&@.T=$87R%S1'?&L\MVN M]R[1<SBS#&]>;)DM?0F+3RDE+(.VN7MH;'FJ35DO!MF"Q2H.#%*`K&[@`;4! MS:1X'L)/C#C7%1;;.2$P3&).)>LYDD##?I&LU@I8DW%QZZXF\BR$D0#&6`.] M0GPB`>-`<RS?B;,99M#2^XX_<$WC.?:DQ26P=>08XW#/&658Y-*HG?%<QSL_ MDQ<@=-N4H*HB/:-Q`/90$MI!A(KPCF.CY4S*248"U;S"[5)Z=!P*7E@^.T4$ MB+A0#?$)1$"B/T4!#;77!K"<0T3L+CGE>63FQM:;`?3THNUF&3"*E8>1R1\M M*23J.DHP04*JG**@NV&P"@8H`%^MP/?0XA'G66I<:VKLV9V3@VE)>,GL0QY[ M$1\4M+RN/MOE<8<YE(LCF5G`@4@`2D$"E75*"A^H6H#DN(\9GF)\C,WY&I[( MDW\YL2"A\6R7&5H&*2A!Q_'3J*0;6/72,+QJ[:&.(G6N(J^T`H"3,RVD7<8] M:Q$F6&DET#ILI0S1&0!BN8+%<_).1!!SY=[]AA`!]HT!!+5?"7+=*ESG^;?D MKFD,IL/+)/-\F,\PK$I9-?)I4>YV\;I.K?+(7_%1*;M*'2@/=RCA&\R^#TS& M3>\<P>RFF,Z>;,C,E=04*ZD\AS1XX=*&>S*:R@H%C46[LR)&B5B`0`&]PH#L M&0XQ/9+DCC?)A;9LJEE&.8:M@*6/(X_$_4#O%WCOY^0;K&.<717SEX(G*X`> MY(/A`+4!PIIPRD<%VYG.T=%[JRK4K':<@,SL7`D8.&RG%)6>5)V.<AAVTU<T M%+N2C\1TKAW=?9:@)K0[%6,BX^/7D'DJNS:(-UI*0,0[U^JD0I3NG1B%*05U MC`)C6``N-`?2H!0"@%`*`4`H!0'5FW].ZWWO@LWK;:V*1V88=.D*5[%22=P3 M63$1;/F3DEEX^0:G&Z:Z1@4(/M`.E6W5-,PM6Q)8.H05S%GS7<4F9A8NH8\L M3+@IVI=A3I*>@YH@LJ[>8-O#=^#1;Q4RGU-'R\8[20`YQ.**3Q=F5RH0H#8! M,8QQ#Q$1ZUJR]Y.:)\1RPLG*QX-\%'IHEV)>'IXF#/R[T^,G]WR+UN->$5]' MPY]A,SAOZ<&FN&&1Y)FV%9-L#,<VRR%3@)R>S2:*\!>-1>B^(FA'HI(MT#%6 M#\?J(UE>U=CZ;M?(GF8]V_>S)QZ92F^#7?2E/TE^T/;&%H5Z63:G*=^4:-OM M??Z6<GY,\$]><H-LZ3V[EV6Y?`S6C9-O)0$=CZK%*-E56\RWFB)RQ7#19<4C M.FY0'RSEN2JC<.S\#<&H8NH9%R[&_BR4H*/N\'5)GKJNW;&K9MC.O7+D;ECD MERYDYTP`"@`>`6`/M``!^"LR7RF0_*1"YG<.\)YK:SC=6Y[DN38M$1F3M,I1 MD,548IR!W;)L[:D;J"_;.4A043=#>Q>[Z:Q?=6U\3=6##!R;ERU&W<4ZPYEE MUK1;.N8\<:[<G&,95X$A\.P:)Q'`,;UTF)Y6$QW%HW$2&DRI+'DHR.C4XP?G MDNTJ*IG34GYT.WM&X]+=*O&-AV<;`MX'M7<6-E6_:XMI*GM>GM+A8Q+=G"C@ MIN5F$%'CVI*G$J2V9Z(W''+,SE<RUIGVTM&JSCEPXDH'!)E'ZA`SE4ZZZ4:W M>(G5C&AU#W!),_ED#H4`"M:ZAY3:-E94K^GY.5B*4VY1AR=75I>'RF'9VP=+ MR[[R+%V]:DY-^R^%6=R\7/2EXW\:,S;[/%?*]N;-9*&6B,PV4]2E%85P8G8+ MV*C4D46;>0!,.TK@Y3*D_)$*NVW_`"XT#0\C[]%3R,U.JG>;;B_V:_H*[2-G M:5I5_P"]-.]EUJIRXM/OY\SO#F?PNP7FW@>-8!G^493B\7C.4)Y2U=XHHQ3> M.7A&:K,J"PO6KE/R`25$?A"]_`:O.Z=JX&Z\6WBZA<N*W:N*:Z>74OG7`N.N M:':UW&A8O7)Q4+G5P7<?=WOQ`U-R*T.RT%L9F[>P4+%1;+&\E;BW)E&-R4&T M19LIR(?&1,1!\HDCVK%$/+6*<Q1"UJFU?:FG:[HL=%S_`&\6$4E/Z<9+A5>) MZY^AX6H8$=.R$YVXQ2C)\XT5*^GD<+X9<*(?A9"Y#B6%;9V-FN$S;LLDAB>< M+QKQAC\N:XO)."5;,F[EJ:1*)?/2`XI&.'=;NJFVMM.WM2W.S8R[]["E]"YR M4N]/G0I=`T"WH$)6<>_>NVI=DN2_N^'<-4<%->ZGY5;8Y:0N69?(9GMQK*-) MO'9)5B?&XY.5>Q[Q7ZM(BT(\N56.*`=ZA@`/&FG;2Q-/W'?W,K]V>1?JG%^Z MG+GT^'<1P]NXN#JU[5[4[GQ+S;<>SBZ_H[#?O;@WK_?7(C2'(S),MRZ'RG1J MC13'X2&68$@);Y255EB!+E7:*N1$ZZHD$2'+\(5/JNTL+5]:P];R;EV.5BOV M%'W>#ZJ,EU';N-J.IV-0O3O?<I3DZ=Y)'<NI,+WKK3,-3[!C22>)YK#N(F M31[2_,MQ5`1:R+%4Y5"H248Z`BZ"EA[%"%$>E7S4]-Q]7P+FGY:4L>ZFFOXE M\Y=]0P;&HXLL/)XVY?H\2(?"GTZ]8\(9K/)S7^:9OE;C/XV%C)$F7K1ZQ&:$ M(X>KH*-?D6;8154,\-?NN-8OM+8^F[1O7[^!>NW/CPC&DO=73V1\/6670-KX M>WKD_NURXW-<NP^-S!]-+5_,C8^*[.S+8&P\-G,2QG]&(]+#7;!FB*`2+J1! MZ91RS6<)O2*N1`IB&"P5Y[HV)@;JS8:AF7<BQ>MPZ5\/]1Y:UM7"UW*MYF3= MNJ[;ATJG]D=6:=](366G-J8+M6,WWOS(9+`YY*>9PF0961W"22Z*"J?RTBW! M`HJM3E5N("/C5MTKRSP=)U+'U*.=EW;F/)R4;ES@Z]Z*'"V/BX&9#+A?ON4. MQMTJ6C9]AS+8>"YC@DFX=,H[,L:FL8?.F/E_-M6L]'N(UPNU\PBB0+)HNC"` MB4;#6Q,S'MYF'=P[W"U=@XRZ>+XKB9EE6(W[,[#_`)=R#B_6J$>N&_$/"N%N MJWFJ<$R+)<IB'N4264GD<K59JR8/))%L@HAYC)NU1\A,K0O;<HFJR[7VSB[4 MT]Z=I[D[<IN7'GQ[_$M6A:'CZ!A/!Q6W;<W)^E\SU^8_#W".:.M4]89WDV38 MO$HY!$9`5_BJC,D@9U#I2B+=$QGS=PAY1RRJG=\/=T#K7ENO;>-NC`_R[)N3 MM1C.,JPY\_\`W#6]#M:]CQQK]RY&VI=5%R.\\8UCC6/ZJ@=/O&X9+B<+A<?@ M3AK.H-W83,&RBTX<Y)1$"`@N+UJD'FV`I1$>@`-7JUIUBUI\=-NIWL.-E6_: MYM)4X^+*^WA8]C3XX$D[F*H*WQ[4E3B5(9EZ&''.4R>0R'6VS-O:@92:JRJ^ M.8I--UXQL554RAF\>J^;G>MVI`,)2)BH8"%Z5K+,\H]$NWI3P,G*Q+<I-N$7 MP=>[EP,*O^7>D.[UXMR[9JZT3X*I8+Q$XAX'PWUM+:UP3(,OR9G/Y&]RF9F< MRD224DZF'S5!HY52%-%-%LV%)L6R8`(=U9KMC;&#M7">!@SNSC.YUR<N+;:I M\YD^B:)C:+BO#LRE/XDI.3?-ME>$WZ(.MIR>G'3GDMR`2Q?))Z5FY7#D9EB6 M+6&6?JOWC),?E_@;=R@D+<HB!?`:PJ7E%@7,B=W[]FJQ.;E*VKCIQ=6EQY&, MW-@8MR_.]+(O.S.3;BGP5>Q<>1:5QXXXZHXOZW8:LU!CP0>-LEE7KU=RL=[+ M3LLX(4'DQ.22UUWK]SV@`F&Q2@':4"@`5L+0=!T[;^G1TW3(../%NJD_:DY> M\V^\RS2=*P='PXX>GQZ;";<D^<NKFV_$D!5]+H*`4`H!0"@%`*`4`H!0"@%` M*`4`H!0"@%`*`4`H!8*`TL'N^P:`UH#2P?9X_?\`&@-?L\:`?9X_@\*`T$`& MX"%P'Q`>H?>H#UD6+)L8QV[-JW.<1$YT6Z21CB;J(F,F0HF$1\;T![5`*`T$ M`'W_`'Q^SK0'KKLVCH"`Z:MW()CW)_,(IK=@^\GF%-VC]J@/,5-,A2D(0I"$ M"Q"$`"E*`>``4+`%K4!NL'T]/I'_`*:`U``#PH!XT`^SQH!8/=0&EOLN/V!0 M&M`*`4`H!0"@%`*`4`H!0"@%`*`4`I1`4`H!0"@%`*`4`H!0"@%`+!0"@%`* M`4H!0"@%`*`4`H!0"E$!0"@%`*`4`H!0"@%`*`4`H!0"@%`*`4`H!0"@%`*` M4`H!0"@%`*`4`H!0"@%`*`4`H!0"@%`*`4`H!0"@%`*`4`H!0"@%`*`4`H!0 M"@%`*`4`H!0"@%`*`4`H!0"@%`*`4`H!0"@%`*`4`H!0"@%`*`4`H!0"@%`* M`4`H!0"@%`*`4`H!0"@%`*`4`H!0"@%`*`4`H!0"@%`*`4`H!0"@%`*`4`H! /0"@%`*`4`H!0"@%`?__9 ` end </TEXT> </DOCUMENT> <DOCUMENT> <TYPE>GRAPHIC <SEQUENCE>14 <FILENAME>g828167g88o03.jpg <DESCRIPTION>GRAPHIC <TEXT> begin 644 g828167g88o03.jpg M_]C_X``02D9)1@`!`0(!>@%Z``#_X5BV:'1T<#HO+VYS+F%D;V)E+F-O;2]X M87`O,2XP+P`\/WAP86-K970@8F5G:6X](N^[OR(@:60](E<U33!-<$-E:&E( M>G)E4WI.5&-Z:V,Y9"(_/CQX.GAM<&UE=&$@>&UL;G,Z>#TB861O8F4Z;G,Z M;65T82\B('@Z>&UP=&L](D%D;V)E(%A-4"!#;W)E(#4N,RUC,#$Q(#8V+C$T M-38V,2P@,C`Q,B\P,B\P-BTQ-#HU-CHR-R`@("`@("`@(CX*("`@/')D9CI2 M1$8@>&UL;G,Z<F1F/2)H='1P.B\O=W=W+G<S+F]R9R\Q.3DY+S`R+S(R+7)D M9BUS>6YT87@M;G,C(CX*("`@("`@/')D9CI$97-C<FEP=&EO;B!R9&8Z86)O M=70](B(*("`@("`@("`@("`@>&UL;G,Z>&UP/2)H='1P.B\O;G,N861O8F4N M8V]M+WAA<"\Q+C`O(@H@("`@("`@("`@("!X;6QN<SIX;7!'26UG/2)H='1P M.B\O;G,N861O8F4N8V]M+WAA<"\Q+C`O9R]I;6<O(CX*("`@("`@("`@/'AM M<#I-;V1I9GE$871E/C(P,34M,#(M,CA4,3(Z-3<Z-#`K,#4Z,S`\+WAM<#I- M;V1I9GE$871E/@H@("`@("`@("`\>&UP.D-R96%T941A=&4^,C`Q-2TP,BTR M.%0Q,CHU-SHT,"LP-3HS,#PO>&UP.D-R96%T941A=&4^"B`@("`@("`@(#QX M;7`Z365T861A=&%$871E/C(P,34M,#(M,CA4,3(Z-3<Z-#`K,#4Z,S`\+WAM M<#I-971A9&%T841A=&4^"B`@("`@("`@(#QX;7`Z0W)E871O<E1O;VP^061O M8F4@26QL=7-T<F%T;W(@0U,V("A7:6YD;W=S*3PO>&UP.D-R96%T;W)4;V]L M/@H@("`@("`@("`\>&UP.E1H=6UB;F%I;',^"B`@("`@("`@("`@(#QR9&8Z M06QT/@H@("`@("`@("`@("`@("`\<F1F.FQI(')D9CIP87)S951Y<&4](E)E M<V]U<F-E(CX*("`@("`@("`@("`@("`@("`@/'AM<$=);6<Z=VED=&@^,C4V M/"]X;7!'26UG.G=I9'1H/@H@("`@("`@("`@("`@("`@("`\>&UP1TEM9SIH M96EG:'0^,3(X/"]X;7!'26UG.FAE:6=H=#X*("`@("`@("`@("`@("`@("`@ M/'AM<$=);6<Z9F]R;6%T/DI014<\+WAM<$=);6<Z9F]R;6%T/@H@("`@("`@ M("`@("`@("`@("`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`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`K4T5F.6-69#E1,6XO<39F.&M) M+W=#=4MU*V]A>B\Q9%`X06MH2"]!1GA6,S%$5V8K<G`O=T%K22\V-'$W-FAR M4#A!)B-X03LQ9%`K4T5F.6-69#E1,6XO04MU;B]*0U`K=4MU*V]A>B]W0EA4 M+VMH2"]81EAF54Y:+S9U;B]*0U`K=4MU*V]A>B\Q9%`K4T5F.6-6)B-X03MD M.5$Q;B]Q-F8X:TDO=T-U2W4K;V%Z+S%D4#A!:VA(+T%&>%8S,4179BMR<"]W M06M)+S8T<3<V:')0.$$Q9%`K4T5F.6-69#E1,6XO)B-X03M!2W5N+TI#4"MU M2W4K;V%Z+W="6%0O:VA(+UA&56]U4$U&:F)A,T9O5G@U;W1O=%IN-"MJ<#=P M14HR-4-Q.%5R53%P:7%B+U5.6B\V)B-X03MU;B]*0U`X07)I<48Q5DYC<W1, M=DQX3E-$=F)14U1+:E%*46U.0W=";V9B1E4X>%9,=DU'=5%A2G!R86A00DQC M46\X84]S2'`X;$5J)B-X03MH3U(Y4C1X>%5T=E$Q.7-64U11=GI*,&96.5A8 M4VMS<C9Z=D=:,#188U-21EA2<&=&9$))>G%85S)D,35,.6UH,G%-5E)M:F$Y M;V-&)B-X03MT4$10<4YR1DUL-65H-#-M:E9G9G)C=7A"3E)I<5`X03A3*UA0 M*W)R6B\X05-21B]Z5FER=CA3*UA0.$%Q-C)F+U-21B]W03%9<3<O)B-X03M! M0DPU8R\V=71N+S!K4F8X,5EQ-R]%=FQZ+W$V,F8X03!K4F8X,5EQ-R]%=FQZ M+W$V,F8O045K4F8X,5EQ-R]%=FQZ+T%+=71N+S!K)B-X03M29CA!3E=+=2]W M05,K6%`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`O<$EI M+W=#87-#<&0U:3AX)B-X03ME6#,X=C9M:6%N84TW5VLV<7%Z>&MK;4YG04%' M>%9K5TMQ1C-95TXT<V$S9'9&8W)%-GEX3$MI=49K6#=,<GE";W=R<V-654Q0 M44Y#)B-X03MS<%5M<SE/=&)A84Y$2$A*1$1(1WEO>D9I<6Q60D-L:514>'A6 M6F](*SA-=B]-6F4O=T156DQI<5DT<3=&6%EQ-T9867$W1EA9<3=&)B-X03M8 M67$W1EA9<3=&6%EQ-T9867$W1EA9<3=&6%EQ-T98;68U>69M;G(S:V5B4TE. M13!983%.<4,S1#-%43E1=$5S2FE#3GAI1$=J;5)T)B-X03MZ-%EQ>D<S:CAZ M86A"1DQC6$U/;'AY2W)M2S!8,35H558O=G`Q.4UE-#E(-F-64D9V-6(P:4M: M3&E323-L,TAU;#%D=3%X27`X54UP)B-X03MB,"]K;$)I<5HT<3=&6%EQ-T95 M=3AY+SAO-7%V+TU(8V8X;6UX5DUC5E-B>EIP97$V;G!)=$Y-;DYR8W1.135U M4E!.03!A231::41$)B-X03LX5#%!-#A#47!",T]+<V(X<&55=E!U;39X83-7 M<C8Q.6)S;V]64V$S*W,S13-*9VMI=CA!1$MQ<3-Q4TUS=DTW<E1G4&AW<6YU M:E$V)B-X03LT8F%C=UAD<6M*=DPS9VHR,&IS0CEB;#9S2C!"+W=#0D="568V M2&U0+VQU<R]W1'!%;"\W2V-69#9(;5`O;'5S+W=$<$5L+S=+8U9D)B-X03LV M2&U0+VQU<R]W1'!%;"\W2V-69#9(;5`O;'5S+W=$<$5L+S=+8U9D-DAM4"]L M=7,O=T1P16PO-TMC5F0V2&U0+VQU<R]W1'!%;"\W)B-X03M+8U9D-DAM4"]L M=7,O=T1P16PO-TMC5F0V2&U0+VQU<R]W1'!%;"\W2V-69#9(;5`O;'5S+W=$ M<$5L+S=+8U9D-DAM4"]L=7,O=T1P)B-X03M%;"\W2V-69#9(;5`O;'5S+W=$ M<$5L+S=+8U9D-DAM4"]L=7,O=T1P16PO-TMC5F0V2&U0+VQU<R]W1'!%;"\W M2V-69#9(;5`O;'5S)B-X03LO=T1P16PO-TMC5F0V2&U0+VQU<R]W1'!%;"\W M2V-69#9(;5`O;'5S+W=$<$5L+S=+8U9D-DAM4"]L=7,O=T1P16PO-TMC5F0V M2&U0)B-X03LO;'5S+W=$<$5L+S=+8U9D-DAM4"]L=7,O=T1P16PO-TMC5E%' M;UAF;5-#5T\P=')Q>G5,*UE6:F@K<7EH5E%':&QK8C9Y94M$-WED)B-X03MH M:%9V5&1#,75X33!O,4,Q;74W<'5D,61Y5VMH:VM),E5B6$E#;V<R5E)S4&U3 M4T92,V]E62\X06QU<R\K:U-8+W-P>%8S;V59+SA!)B-X03ML=7,O*VM36"]S M<'A6,V]E62\X06QU<R\K:U-8+W-P>%8S;V59+SA!;'5S+RMK4U@O<W!X5C-O M95DO.$%L=7,O*VM36"]S<'A6,V]E)B-X03M9+SA!;'5S+RMK4U@O<W!X5DQV M355(;4%E6#E43#-T;WEF5DHK45<Q:T)).4YQ,$IU1%0W<U9E8F9L.35J.#`S M=FYE=VDQ1CE465,X)B-X03LP5S)M3397,&5N2F)Y3D1E4T-206MR,W1W0WDO M1GI13'A!-&AS2W96<G988DA3=$YA.3%+5C!G1GA*15I&:FML-"]V6$,X:$5R M;%9!)B-X03M89&IS0C%/0E5*;W9N-WEL<E8Q2&$V6F8K=DY,-F=I2'!427)' M2C5),T-S-DMP4$M#4VTK+T5K8D1&5F91-RMX:G,U:VMU66MD8GDY)B-X03M$ M2WIQ0U`X05,U96]*>%9-4#!N<'8O3%A$+WE-6"MU2W4O4V5M+SA!3%A$+T%- M:D8O<FER=C!N<'8O3%A$+WE-6"MU2W4O4V5M+SA!)B-X03M,6$0O04UJ1B]R M:7)V,&YP=B],6$0O>4U8*W5+=2]396TO.$%,6$0O04UJ1B]R:7)V,&YP=B], M6$0O>4U8*W5+=2]396TO.$%,6$0O)B-X03M!36I&+W)I<G8P;G!V+TQ81"]Y M35@K=4MU+U-E;2\X04Q81"]!36I&+W)I<G8P;G!V+TQ81"]Y35@K=4MU+U-E M;2\X04Q81"]!36I&)B-X03LO<FER=C!N<'8O3%A$+WE-6"MU2W4O4V5M+SA! M3%A$+T%-:D8O<FER=C!N<'8O3%A$+WE-6"MU2W4O4V5M+SA!3%A$+T%-:D8O M<FER)B-X03MV,&YP=B],6$0O>4U8*W5+=2]396TO.$%,6$0O04UJ1B]R:7%" M,4QZ2%I1;$QA,&YG;G8U+W=#-FI-:3A%6'9*2U%F:%)F=E!167%U)B-X03LP M,#966DDW3F925#-5-34S5C`W<'EK8G`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`O271F-EEQ-SE'86(O=T%S:U`X07E,6"MM2W4O4FUM+SAS M:U`O271F-EEQ-SE'86(O=T%S:U`X07E,6"MM2W4O)B-X03M2;6TO.'-K4"]) M=&8V67$W.4=A8B]W07-K4#A!>4Q8*VU+=2]2;6TO.'-K4"])=&8V67$W.4=A M8B]W07-K4#A!>4Q8*VU+=2]2;6TO)B-X03LX<VM0+TET9C99<3<Y1V%B+W=! M<VM0.$%Y3%@K;4MU+U)M;2\X<VM0+TET9C99<3<Y1V%B+W=!<VM0.$%Y3%@K M;4MU+U)M;2\X<VM0)B-X03LO271F-EEQ-SE'86(O=T%S:U`X07E,6"MM2W4O M4FUM+SAS:U`O271F-EEQ-SE'86(O=T%S:U`X07E,6"MM2W4O4FUM+SAS:U`O M271F)B-X03LV67%L,G!.<#!->5=&;EI7."MQ5$QZ:FA+3'A22S`Y85EG9D-G M4#!S9&@W2W$R;F583DUS-&TU45)Z,TUP-3-&>3AA8VYB-55O<6IO)B-X03MQ M:EE$1E58*VI.3B\U6DEF*U)A+S!X5C,V33`S+VQK:"]W0U)A+S!X5C,V33`S M+VQK:"\U1G(O5$989F]Z5&8K5U-(+T%*1G(O5$98)B-X03MF;WI49BM74T@O M:U=V.4U69"MJ3DXO-5I)9CA!:U=V.4U69"MJ3DXO-5I)9BM282\P>%8S-DTP M,R]L:V@O=T-282\P>%9,=DUE;F%E)B-X03MV;#=61U<Q:$1#,&Y)26I51452 M3C=9<7AM,'104'$K6F9,:F5A8GI26FQJ;&XY1G)+>G99-3)F-FY+2%):,FMK M:5AL.6]Q>7)Y0S=B)B-X03MR:7%D95EM.'=R;T)/9TQ/,F]F6%=&3%E7:%E2 M;31F,4,T=D=336]&,TE69W@V07)8:T95;SAP9CAR5R]41G(O04EG<"MJ4%)8 M-GAY)B-X03LK<58U.$I057(V2'AC=E<T8T]0=RMN.7(T.$MP-V\P,G5#,FY% M1G!A=D-,>3DT3SEZ26I%9E<U97%I0G=0*T-/0E5F-B]M4"]!2EEB)B-X03M0 M+W!,;"\W2G-69#8O;5`O04I98E`O<$QL+S=*<U9D-B]M4"]!2EEB4"]P3&PO M-TIS5F0V+VU0+T%*66)0+W!,;"\W2G-69#8O;5`O)B-X03M!2EEB4"]P3&PO M-TIS5F0V+VU0+T%*66)0+W!,;"\W2G-69#8O;5`O04I98E`O<$QL+S=*<U9D M-B]M4"]!2EEB4"]P3&PO-TIS5F0V)B-X03LO;5`O04I98E`O<$QL+S=*<U9D M-B]M4"]!2EEB4"]P3&PO-TIS5F0V+VU0+T%*66)0+W!,;"\W2G-69#8O;5`O M04I98E`O<$QL+S=*)B-X03MS5F0V+VU0+T%*66)0+W!,;"\W2G-69#8O;5`O M04I98E`O<$QL+S=*<U9D-B]M4"]!2EEB4"]P3&PO-TIS5F0V+VU0+T%*66)0 M+W!,)B-X03ML+S=*<U93,U5T9#AX=S-%96Y796XR8S)Q6$-L;S`K=%-S:TUE M-#EE9B]2,7!'1S)!<E9J<W9C:%9F<$9H<G5N4E`X039,83-&-6-.)B-X03LV M;#5E4UAC;G%44U5P53!T<4)13FQ58DM.:&EQ4#EF>D@O>7<R9CA!,&QY+SEK M,DMU.69Z2"]Y=S)F.$$P;'DO.6LR2V]454YC,4A4)B-X03ML9V4O:7-,6F)M M6DQA0G!,,E)1.#!N,D5&8F)Q,4U643=E8DI!>%)4<'-S<6UH:&AV<$IP2RM( M<'@R>E`K1T97=CA395E:1%,Q,$DS)B-X03M*+V%(<7I7.4LK.3%B5S10,%EQ M<G<V:C4P;5AL*V<W4T0O275.45E0+W=!:W)A6F8K1W=+;W50>D5C:V8W:6]K M4%I'=4,T*U1S:%@W)B-X03LP=W%K5&56+WI,+W@S66594G$Y=DQP5G!B4S)S M;6M44T@Y-$II1V1V56AT-%9"-4I'4E=-+UHY.$-S=SEF>D@O04US3FXO,&QY M+SA!)B-X03M:3FEQ6&59<"]-0CAV-FU(<W)252MQ5#AI=#%)4T(V8E9O1&)I M=C,T<3@T+TPV>'5)+TYM:WIZ87$Y,W`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`Q168P96EF;FEQ5&59+WET M.'%E6D)A;E=X9#-K;&Y*-C!-:EA5-FM3-V9%07)")B-X03M6-F1&04AT:7), M55)54E5504MO055!04%!97=X5G9&6%EQ-T9867$W1E5U.'DO.$%+3V%R+W=! M=V1X+WEA8D98;5AK2'E.<BMK96),)B-X03M05UHO2WEA6F589G)F<"]75C%M M4SEK;CE72FYB;F%T16M9-5A!42]U>CA0=4U696QV<$9N<4YP2$1F4G,V45AV M,75*43=X+W993&MZ)B-X03M1<V5"6&M!>6AU2BM%.7=C5E5,1'E:-6-S9%-8 M53=E,6(Y24M#4')-:S`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`O;S%N)B-X03MQ3C-P;'1O6#%U M25-0<#8R2TQD=W-E<5-09%(P0D(V:C!F:S%-5E1E,#AH*U0W6G59,&TS;6QQ M1#9T=V=N8T5F>6U8;'<K4S!'0E5B)B-X03LO:')Y-2\Q87)0.$$V4C1V*V%C M5F0O:')Y-2\Q87)0+T%+4C1V*V%C5F0O:')Y-2\Q87)0+W!(:2]W0V%C5F0O M:')Y-2]W0E=Q>B\V)B-X03M2-'8K86-69"]H<GDU+S%A<E`X0392-'8K86-6 M9"]H<GDU+S%A<E`O04M2-'8K86-69"]H<GDU+S%A<E`O<$AI+W=#86-69"]H M<GDU)B-X03LO=T)7<7HO-E(T=BMA8U9D+VAR>34O,6%R4#A!-E(T=BMA8U93 M-WI&-60X=G`U9C%.,#!Y,%8Q=$HR5FQG:D)"16)%145,:7))<U93)B-X03MR M>DAQ3W!71G1A4V%F8FTU;&UV8E,S;6E%56MT25HU;&IL9CDS.6HP,%EV>F(T M4E1F1E=,*U5V3G9N,U5T671B6%8Y1BMQ5U5S2W9.)B-X03MC9E9R:4AI>%-2 M;BM+5FU69E1K5EEU0C-A=DUF1&A64&1(=DY54S)N5TQ4+T%&67AE6'9'5#%K M5V\K='DY:4YS0V\W-B]R4"]!1F$O)B-X03LK4SAF.4U6959E679Z6B].1W<O M3D-0>7AP,VQI1S8P<&UH54\V>D(R.5-)3S,K;&AV45=J3C%-6G`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`X03%A+RM3.&8Y359D.68Q;B]! M2W1F+TIE4"MM2W4K=C9Z+W="5W8O:W9(+U1&6&98.5HO-G1F+TIE)B-X03M0 M*VU+=2MV-GHO,6$O=T1K=D@O5$989E@Y6B\V=&8X07E8:B]!2UEQ-S8O<E`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`P M4$ER1692:F@U<UII6$553553<68X05-P3FQO=3E33U<K2V]V4G1'<S5R8656 M-4QO33DU96MH3'4U:E@O9758;W%3)B-X03M+;RMG67%J+T%.05=0*R]B>B]P M3G90.$%Q<FER=C!"62]W0R]B>B]P3G90*W%U2W4O449J+W8R."]W0VLR."\V M<31Q-SE!5U`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`X*V]8;74K;EHR>3@U<%)Q9'DY1C9#:7!->D5K;6=! M1E1G5E9G=G9).#A%)B-X03MC.$]U<DI$2V]E3U)D5VU)6E-+9VHY+VA694IF M3$QF,TXQ9C-1,RM+,75.4G5"='0Q:&1X:7)I3DMB84-(5TIN,RM(,4Y2:2\T M860T)B-X03ML+TA&6&965S=A6'$Y9#9C=%)O2RLY3#!N.$U663,U,G0O>D9T M;V1.8GET<%`Q;'!B>4Y,-5HY5W93>5%%+T5307E+<6YU-G-X6"M5)B-X03LY M;%=39F]45FYP*S=%2&EF,'!Q33%4-%4O8S1Q-R]$3W)':"]34$5N<79055=P M-V-V<GDQ*V1-5F0O:&)5,C)F5EA6935I92M6=F],)B-X03LS:VDO.$QI<G8X M1U-.=2MU-F]R9456>7ER.7HK;V9X>'15;6LO2RLO8GIR<"MV9C1P,5HY3W1, M95='8E,U3&@V4T\U1E`S:49+265R)B-X03M#;&%Q=2M"5U=F;T-X+S,W968X M05-B968Y5F-64S=Z1F]6:VYL+U4S16PR4W1P3U%'=DQT:'1',U5'56<O5&ER M27-69&EQ45A'<C8K)B-X03MN;D\S,'5/>#4V3$IB<DI,92MN2CA-:#EB;"LK M<C9F=VU/3F5&3U(U,39$1E945#=J57)+2V%".4MU6E`Y2G5P1FMJ93$T<VMT M>$I))B-X03MJ1&Q/<F)Q=S9J1E56*VQB-R]Q>EAN+T(R9CA!,E59<7!.<C%Y M=#%(86Y33'HQ<%5E5D8U5VTV>&Q&63$K<V5-:31Q<2]P5RLO=T-R)B-X03M. M968X2%HO.6Q'2W4O4W0Y+W="5V$X+S1/>B\W2TU69"ML8C<O<7I8;B]",F8O M6E)I<G8P<F9F.5=A."\T3WHO04]Y:D962TA8<FUA)B-X03M394]04TQW=&)U M27!2>71"4FEI>54O,V\O;&M'2W%V-E9V=BMR3F5F.$A:+SEL1TMU+U-T.2\Q M6G)Z+V<W4#A!-TM-5F0K;&(W+W%Z)B-X03M8;B]",F8X03)567$W.4LS,R]6 M;790.$%G-U`O04Q+3595<F)8<FTU:DUK5VM8:DMR>5)%.')19D9%-6IC8C-( M6FQ/2W%V-E9V=CA!)B-X03MQ>EAN+T(R9B]:4FER=C!R9F8X059M=E`K1',O M*WEJ1EAF<%<K+S9S,34O=V1N+S)567%L4&UH3DXQ8E%R>3$Q+W=!=5A&-7!F M<$\Q)B-X03MZ2$EB43!24GE,2U9U3U-S2U9"53$X3592=6Y39F\R>&=S3E`X M=C-&<EI7>4-/0S-I3FUQ26\V04%81TMO;CE+,S,O5FUV4"M$<R\K)B-X03MY M:D989G!7*R]W0W).968X2%HO.6Q'2W4O4W0Y+W="5V$X+S1/>B\W2TU657`Y M975)4%0Y6%-,=V5Q-GA*.%9O87,S46)81TMQ=C96)B-X03MV=CA!<7I8;B]" M,F8O6E)I<G8P<F9F.$%6;790*T1S+RMY:D989G!7*R\V<S$U+W=D;B\R55EQ M-SE+,S,O5FUV4"M$<R]W1'-O>%93)B-X03MB6')L8G%/,4]K6&YR4V\X<4QY M=$XQ:DM+>'(Y63A:1GA65B]3=#DO,5IR>B]G-U`O<V]X5D(V>&1A;F5A4F97 M:U=J,UEL=4QE5TM-)B-X03MS.6]">61#;W(K+S963TMP-VER<U9D:7)I0U%1 M1%%N=4]O*R]&6&Y&;$PK8D5Z5VM.,49E5S-Q5U9V.$%P0S5P<$Q#3S533G!* M=E%6)B-X03M866QP2&I74#1W52]E5DA$:%5L5FM$9FY"*VE:;S=Q2V1T46=! M:VIU<F8X05)G96-,67A2*VEG:TIJ:F%3.&0U5TQI:6A#05=(14UQ)B-X03MH M6&LO4%)%-7AX;6(K.7!'-3`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`X<E-F;4HY63!X9DU%4C0P,4ID5&10<79P)B-X03LX;&YJ3FDV*VUF M531T1'I!;TLO>F=(07)-<U99:C4P8GIY3&@Q.'5P8VU"<D-8:3ET.5%Q=#<V M.$EG22MU16)#37E-.61I;V]+4%1&)B-X03M506\O335R-DM6>$UB5U=A,6%E M,6(Y2&Q)-'!R,VYC24-0:EE15V(K;7@U5DQ,5D]683164RMZ;"]/4UA5:$I0 M1&-7.6TW1C592E`P)B-X03M7>4IZ.4YI:U1X=3!H5D%:56HU:FQY0W-Z1E=) M5E9K6&MU5'IQ,#AV*TDT-VA!8DMX;TIV<5!P:3A%4DXS-E@Q5FUK-#@R569V M2VEQ)B-X03MK<65*1T)75C1Q=UA78FXX>5E:-VE45')3-7522'%5<'1)461/ M155L:71R1WE#67E/:V=2<FYM:3A32D%0:6%O041+;T]#3#@R-$LR)B-X03MK M,&MT-T<P;#%B>#9K>39C:W%X=3%O<T8R,%-H135X<3$P>4E!43-&95DS07A6 M4G-(+T]-2&YC4C-$46@P6DEP=C!8-GAI3B]"5DI$)B-X03M#4D@V<3)H;C5& M4T9)0SAF:G=Q>DAY=79M4E4Q3DYB6G!!=#E,*VI*6E!116I76E9$2'I&=4%G M;WAD4BLP44%4=F=63WE#45%$46YU)B-X03M/;RLO1EAN1G!,*V)%<5<X3GA& M95<P:VQL82]83&MJ4U=33S54.35D96EQ=7I&<$)(-EDU07!Y:W%/05-P2W%B M3BMC2#%F,#-J;F%7)B-X03M$5#1*1W594#!92&UV1FIL:FUH:D5P2U(K;S=1 M>DU70E)E1$)3,G=+<71P<VXU>'$X4FUI4UIJ3D]#3',R:TU15#!B9W=M6#9S M6C5&)B-X03M4,5!Q*S!F2G$X-FYJ431Q>DAY<61F4&QZ5'8X47%Q83,V0T15 M06I+-BMS0CA2<6EO;2]5.%)19'$Y8T-P<&ER<U9D:7%7:GI&<')-)B-X03LT M4F)Q5#`U2&E::W,W<#$U>$]9,T%:66EP;WEK5D)P:7)F-F9S9CA!9E8U+S!H M6&XO5DQ&6&9P*W@O,S%E9CA!4T9E9CE5<U9D*VXW)B-X03M(+V96-2\P:%AN M+U9,1EAF<"MX+S,Q968Y258U+W="57-69"MN-T@O04@Q968Y258U+S%3>%8S M-F9S9CDY6&XO045H6&XO5DQ&6&9P)B-X03LK>"\S,65F.4E6-2\Q4WA6,S9F M<V8Y.5AN+U-&968X059,1EAF<"MX+W=".5AN+U-&968Y57-69"MN-T@O9E8U M+W="258U+S%3>%8S)B-X03LV9G-F.3E8;B]31F5F.55S5F0K;C=(+V96-2\P M:%AN+T%&4WA6,S9F<V8X0696-2\P:%AN+U9,1EAF<"MX+S,Q968X05-&968Y M57-6)B-X03MD*VXW2"]F5C4O,&A8;B]63$989G`K>"\S,65F.4E6-2]W0E5S M5F0K;C=(+T%(,65F.4E6-2\Q4WA6,S9F<V8Y.5AN+T%%:%AN+U9,)B-X03M& M6&9P*W@O,S%E9CE)5C4O,5-X5C,V9G-F.3E8;B]31F5F.$%63$989G`K>"]W M0CE8;B]31F5F.55S5F0K;C=(+V96-2]W0DE6-2\Q)B-X03M3>%8S-F9S9CDY M6&XO4T9E9CE5<U9D*VXW2"]F5C4O,&A8;B]!1E-X5C,V9G-F.$%F5C4O,&A8 M;B]63$989G`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`R2#)$5#,V67%X>CAV<E0X,4E.3V%(>FQD-F9*8W!/>G).8G!*)B-X03M+ M,&M4<UA+;'552V]5<GA8-$1T5$95;70O2C,U<C)F;W1B-B]$3UER<4LV94\V M=6)L*V-56DMV6DTU:F(T2%=E4G96-&-Q<$=#<F)V)B-X03MH5E(P<GE**V%& M9S!Z3')G:VUA24I$4&,V:F8S5D<Y1S1I<DI$2V=H6G55<TUP6D93<&IP>%=V M3$96,7(U62].<%`X05$W;E9/5C%*)B-X03M:,TU),75'-60T561B2DQA,D0R M<V=3:G9/<'5M;%)72W-3;38W-$9297(K6'9Z93E.-"],=7(R=6Y1;4]4,&]B M:35E.5I*5T964'(S)B-X03M6;E!)-F@Y>E@Y:SA11G!Y2W%&=')(.#<W*WEU M1VDQ;3%S-W%/4SAG06UH5E(V:4M9-$I)*U9P=D-82$I4=G1V5G$X1DMO=E10 M3%`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`R<3AG M5F8O6CPO>&UP1TEM9SII;6%G93X*("`@("`@("`@("`@("`@/"]R9&8Z;&D^ M"B`@("`@("`@("`@(#PO<F1F.D%L=#X*("`@("`@("`@/"]X;7`Z5&AU;6)N M86EL<SX*("`@("`@/"]R9&8Z1&5S8W)I<'1I;VX^"B`@("`@(#QR9&8Z1&5S M8W)I<'1I;VX@<F1F.F%B;W5T/2(B"B`@("`@("`@("`@('AM;&YS.F1C/2)H M='1P.B\O<'5R;"YO<F<O9&,O96QE;65N=',O,2XQ+R(^"B`@("`@("`@(#QD M8SIF;W)M870^87!P;&EC871I;VXO<&]S='-C<FEP=#PO9&,Z9F]R;6%T/@H@ M("`@("`@("`\9&,Z=&ET;&4^"B`@("`@("`@("`@(#QR9&8Z06QT/@H@("`@ M("`@("`@("`@("`\<F1F.FQI('AM;#IL86YG/2)X+61E9F%U;'0B/F<T,W4U M-#PO<F1F.FQI/@H@("`@("`@("`@("`\+W)D9CI!;'0^"B`@("`@("`@(#PO M9&,Z=&ET;&4^"B`@("`@(#PO<F1F.D1E<V-R:7!T:6]N/@H@("`@("`\<F1F M.D1E<V-R:7!T:6]N(')D9CIA8F]U=#TB(@H@("`@("`@("`@("!X;6QN<SIX M;7!-33TB:'1T<#HO+VYS+F%D;V)E+F-O;2]X87`O,2XP+VUM+R(*("`@("`@ M("`@("`@>&UL;G,Z<W12968](FAT='`Z+R]N<RYA9&]B92YC;VTO>&%P+S$N M,"]S5'EP92]297-O=7)C95)E9B,B"B`@("`@("`@("`@('AM;&YS.G-T179T M/2)H='1P.B\O;G,N861O8F4N8V]M+WAA<"\Q+C`O<U1Y<&4O4F5S;W5R8V5% M=F5N=",B/@H@("`@("`@("`\>&UP34TZ1&]C=6UE;G1)1#YX;7`N9&ED.C5" M14)#0CA!1D9"144T,3$Y,44P030Y-3=&-T0W-$9$/"]X;7!-33I$;V-U;65N M=$E$/@H@("`@("`@("`\>&UP34TZ26YS=&%N8V5)1#YX;7`N:6ED.C5"14)# M0CA!1D9"144T,3$Y,44P030Y-3=&-T0W-$9$/"]X;7!-33I);G-T86YC94E$ M/@H@("`@("`@("`\>&UP34TZ3W)I9VEN86Q$;V-U;65N=$E$/G5U:60Z86-A M-#<U-C4M9&$T82TT8F1B+3@R96(M8SAE,CEA-3(Y938V/"]X;7!-33I/<FEG M:6YA;$1O8W5M96YT240^"B`@("`@("`@(#QX;7!-33I296YD:71I;VY#;&%S M<SYD969A=6QT/"]X;7!-33I296YD:71I;VY#;&%S<SX*("`@("`@("`@/'AM M<$U-.D1E<FEV961&<F]M(')D9CIP87)S951Y<&4](E)E<V]U<F-E(CX*("`@ M("`@("`@("`@/'-T4F5F.FEN<W1A;F-E240^=75I9#HS,68Y,V0Q92TS,C)C M+30U-#(M86%B."UA,#=B,F$P-61D-S@\+W-T4F5F.FEN<W1A;F-E240^"B`@ M("`@("`@("`@(#QS=%)E9CID;V-U;65N=$E$/GAM<"YD:60Z,$)%038P04)" M13E&13,Q,4)%,S4X.$9!-D$U,D,W1D,\+W-T4F5F.F1O8W5M96YT240^"B`@ M("`@("`@("`@(#QS=%)E9CIO<FEG:6YA;$1O8W5M96YT240^=75I9#IA8V$T M-S4V-2UD831A+31B9&(M.#)E8BUC.&4R.6$U,CEE-C8\+W-T4F5F.F]R:6=I M;F%L1&]C=6UE;G1)1#X*("`@("`@("`@("`@/'-T4F5F.G)E;F1I=&EO;D-L M87-S/F1E9F%U;'0\+W-T4F5F.G)E;F1I=&EO;D-L87-S/@H@("`@("`@("`\ M+WAM<$U-.D1E<FEV961&<F]M/@H@("`@("`@("`\>&UP34TZ2&ES=&]R>3X* M("`@("`@("`@("`@/')D9CI397$^"B`@("`@("`@("`@("`@(#QR9&8Z;&D@ M<F1F.G!A<G-E5'EP93TB4F5S;W5R8V4B/@H@("`@("`@("`@("`@("`@("`\ M<W1%=G0Z86-T:6]N/G-A=F5D/"]S=$5V=#IA8W1I;VX^"B`@("`@("`@("`@ M("`@("`@(#QS=$5V=#II;G-T86YC94E$/GAM<"YI:60Z.40V-C@Y1C0U-S8X M13$Q,4(Q,#,Y1#5&,D1#1$%%0C<\+W-T179T.FEN<W1A;F-E240^"B`@("`@ M("`@("`@("`@("`@(#QS=$5V=#IW:&5N/C(P,3(M,#,M,#=4,#@Z,3DZ,#@M M,#4Z,#`\+W-T179T.G=H96X^"B`@("`@("`@("`@("`@("`@(#QS=$5V=#IS M;V9T=V%R94%G96YT/D%D;V)E($EL;'5S=')A=&]R($-3-3PO<W1%=G0Z<V]F M='=A<F5!9V5N=#X*("`@("`@("`@("`@("`@("`@/'-T179T.F-H86YG960^ M+SPO<W1%=G0Z8VAA;F=E9#X*("`@("`@("`@("`@("`@/"]R9&8Z;&D^"B`@ M("`@("`@("`@("`@(#QR9&8Z;&D@<F1F.G!A<G-E5'EP93TB4F5S;W5R8V4B M/@H@("`@("`@("`@("`@("`@("`\<W1%=G0Z86-T:6]N/G-A=F5D/"]S=$5V M=#IA8W1I;VX^"B`@("`@("`@("`@("`@("`@(#QS=$5V=#II;G-T86YC94E$ M/GAM<"YI:60Z-4)%0D-".$%&1D)%130Q,3DQ13!!-#DU-T8W1#<T1D0\+W-T M179T.FEN<W1A;F-E240^"B`@("`@("`@("`@("`@("`@(#QS=$5V=#IW:&5N M/C(P,34M,#(M,CA4,3(Z-3<Z-#`K,#4Z,S`\+W-T179T.G=H96X^"B`@("`@ M("`@("`@("`@("`@(#QS=$5V=#IS;V9T=V%R94%G96YT/D%D;V)E($EL;'5S M=')A=&]R($-3-B`H5VEN9&]W<RD\+W-T179T.G-O9G1W87)E06=E;G0^"B`@ M("`@("`@("`@("`@("`@(#QS=$5V=#IC:&%N9V5D/B\\+W-T179T.F-H86YG M960^"B`@("`@("`@("`@("`@(#PO<F1F.FQI/@H@("`@("`@("`@("`\+W)D M9CI397$^"B`@("`@("`@(#PO>&UP34TZ2&ES=&]R>3X*("`@("`@/"]R9&8Z M1&5S8W)I<'1I;VX^"B`@("`@(#QR9&8Z1&5S8W)I<'1I;VX@<F1F.F%B;W5T M/2(B"B`@("`@("`@("`@('AM;&YS.G!D9CTB:'1T<#HO+VYS+F%D;V)E+F-O M;2]P9&8O,2XS+R(^"B`@("`@("`@(#QP9&8Z4')O9'5C97(^061O8F4@4$1& M(&QI8G)A<GD@,3`N,#$\+W!D9CI0<F]D=6-E<CX*("`@("`@/"]R9&8Z1&5S M8W)I<'1I;VX^"B`@("`@(#QR9&8Z1&5S8W)I<'1I;VX@<F1F.F%B;W5T/2(B M"B`@("`@("`@("`@('AM;&YS.GAM<%109STB:'1T<#HO+VYS+F%D;V)E+F-O M;2]X87`O,2XP+W0O<&<O(@H@("`@("`@("`@("!X;6QN<SIS=$1I;3TB:'1T M<#HO+VYS+F%D;V)E+F-O;2]X87`O,2XP+W-4>7!E+T1I;65N<VEO;G,C(@H@ M("`@("`@("`@("!X;6QN<SIS=$9N=#TB:'1T<#HO+VYS+F%D;V)E+F-O;2]X M87`O,2XP+W-4>7!E+T9O;G0C(@H@("`@("`@("`@("!X;6QN<SIX;7!'/2)H M='1P.B\O;G,N861O8F4N8V]M+WAA<"\Q+C`O9R\B/@H@("`@("`@("`\>&UP M5%!G.DY086=E<SXQ/"]X;7!44&<Z3E!A9V5S/@H@("`@("`@("`\>&UP5%!G M.DAA<U9I<VEB;&54<F%N<W!A<F5N8WD^1F%L<V4\+WAM<%109SI(87-6:7-I M8FQE5')A;G-P87)E;F-Y/@H@("`@("`@("`\>&UP5%!G.DAA<U9I<VEB;&5/ M=F5R<')I;G0^5')U93PO>&UP5%!G.DAA<U9I<VEB;&5/=F5R<')I;G0^"B`@ M("`@("`@(#QX;7!44&<Z36%X4&%G95-I>F4@<F1F.G!A<G-E5'EP93TB4F5S M;W5R8V4B/@H@("`@("`@("`@("`\<W1$:6TZ=SXV,3(N,#`P,#`P/"]S=$1I M;3IW/@H@("`@("`@("`@("`\<W1$:6TZ:#XW.3(N,#`P,#`P/"]S=$1I;3IH M/@H@("`@("`@("`@("`\<W1$:6TZ=6YI=#Y0;VEN=',\+W-T1&EM.G5N:70^ M"B`@("`@("`@(#PO>&UP5%!G.DUA>%!A9V53:7IE/@H@("`@("`@("`\>&UP M5%!G.D9O;G1S/@H@("`@("`@("`@("`\<F1F.D)A9SX*("`@("`@("`@("`@ M("`@/')D9CIL:2!R9&8Z<&%R<V54>7!E/2)297-O=7)C92(^"B`@("`@("`@ M("`@("`@("`@(#QS=$9N=#IF;VYT3F%M93Y4:6UE<RU2;VUA;CPO<W1&;G0Z M9F]N=$YA;64^"B`@("`@("`@("`@("`@("`@(#QS=$9N=#IF;VYT1F%M:6QY M/E1I;65S/"]S=$9N=#IF;VYT1F%M:6QY/@H@("`@("`@("`@("`@("`@("`\ M<W1&;G0Z9F]N=$9A8V4^4F]M86X\+W-T1FYT.F9O;G1&86-E/@H@("`@("`@ M("`@("`@("`@("`\<W1&;G0Z9F]N=%1Y<&4^5'EP92`Q/"]S=$9N=#IF;VYT M5'EP93X*("`@("`@("`@("`@("`@("`@/'-T1FYT.G9E<G-I;VY3=')I;F<^ M,#`Q+C`P-SPO<W1&;G0Z=F5R<VEO;E-T<FEN9SX*("`@("`@("`@("`@("`@ M("`@/'-T1FYT.F-O;7!O<VET93Y&86QS93PO<W1&;G0Z8V]M<&]S:71E/@H@ M("`@("`@("`@("`@("`@("`\<W1&;G0Z9F]N=$9I;&5.86UE/E1)4E]?7U\N M4$9".R!425)?7U]?+E!&33PO<W1&;G0Z9F]N=$9I;&5.86UE/@H@("`@("`@ M("`@("`@("`\+W)D9CIL:3X*("`@("`@("`@("`@("`@/')D9CIL:2!R9&8Z M<&%R<V54>7!E/2)297-O=7)C92(^"B`@("`@("`@("`@("`@("`@(#QS=$9N M=#IF;VYT3F%M93Y4:6UE<RU";VQD/"]S=$9N=#IF;VYT3F%M93X*("`@("`@ M("`@("`@("`@("`@/'-T1FYT.F9O;G1&86UI;'D^5&EM97,\+W-T1FYT.F9O M;G1&86UI;'D^"B`@("`@("`@("`@("`@("`@(#QS=$9N=#IF;VYT1F%C93Y" M;VQD/"]S=$9N=#IF;VYT1F%C93X*("`@("`@("`@("`@("`@("`@/'-T1FYT M.F9O;G14>7!E/E1Y<&4@,3PO<W1&;G0Z9F]N=%1Y<&4^"B`@("`@("`@("`@ M("`@("`@(#QS=$9N=#IV97)S:6]N4W1R:6YG/C`P,2XP,#<\+W-T1FYT.G9E M<G-I;VY3=')I;F<^"B`@("`@("`@("`@("`@("`@(#QS=$9N=#IC;VUP;W-I M=&4^1F%L<V4\+W-T1FYT.F-O;7!O<VET93X*("`@("`@("`@("`@("`@("`@ M/'-T1FYT.F9O;G1&:6QE3F%M93Y424)?7U]?+E!&0CL@5$E"7U]?7RY01DT\ M+W-T1FYT.F9O;G1&:6QE3F%M93X*("`@("`@("`@("`@("`@/"]R9&8Z;&D^ M"B`@("`@("`@("`@(#PO<F1F.D)A9SX*("`@("`@("`@/"]X;7!44&<Z1F]N M=',^"B`@("`@("`@(#QX;7!44&<Z4&QA=&5.86UE<SX*("`@("`@("`@("`@ M/')D9CI397$^"B`@("`@("`@("`@("`@(#QR9&8Z;&D^0FQA8VL\+W)D9CIL M:3X*("`@("`@("`@("`@/"]R9&8Z4V5Q/@H@("`@("`@("`\+WAM<%109SI0 M;&%T94YA;65S/@H@("`@("`@("`\>&UP5%!G.E-W871C:$=R;W5P<SX*("`@ M("`@("`@("`@/')D9CI397$^"B`@("`@("`@("`@("`@(#QR9&8Z;&D@<F1F M.G!A<G-E5'EP93TB4F5S;W5R8V4B/@H@("`@("`@("`@("`@("`@("`\>&UP M1SIG<F]U<$YA;64^1&5F875L="!3=V%T8V@@1W)O=7`\+WAM<$<Z9W)O=7!. M86UE/@H@("`@("`@("`@("`@("`@("`\>&UP1SIG<F]U<%1Y<&4^,#PO>&UP M1SIG<F]U<%1Y<&4^"B`@("`@("`@("`@("`@(#PO<F1F.FQI/@H@("`@("`@ M("`@("`\+W)D9CI397$^"B`@("`@("`@(#PO>&UP5%!G.E-W871C:$=R;W5P M<SX*("`@("`@/"]R9&8Z1&5S8W)I<'1I;VX^"B`@(#PO<F1F.E)$1CX*/"]X M.GAM<&UE=&$^"B`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`*("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@(`H@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@"B`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`*("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@(`H@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@"B`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`*("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@(`H@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@"B`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`*("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@(`H@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@"B`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`*("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@(`H@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@"B`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`*("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@(`H@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@"B`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`*("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@(`H@("`@("`@("`@("`@("`@("`@("`@("`@("`*/#]X<&%C:V5T(&5N M9#TB=R(_/O_;`$,``0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$! M`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`?_;`$,!`0$!`0$!`0$! M`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$! M`0$!`0$!`0$!`?_``!$(`2L"5`,!$0`"$0$#$0'_Q``?``$``00#`0$!```` M````````!P4&"`D$"@L#`0+_Q`!=$```!00``04,!@<%!@$)!@<#!`4&!P`! M`@@)$1(96)@3%!87&"%769?6U]@5&B(QEM4*(S)!57B9.#E"M+@D,S11=;<E M)B<I-C=$4V%W4F)Q<J:U-4-4DZ6VTO_$`!D!`0$!`0$!```````````````! M`@0#!?_$`#T1``(!`04%!@4#`P0"`@,````!`A$2(5%2T3%!D9*A`Q-A<8'2 M,F*QP>(B<O!"LN&"HL+Q(U-#8W.#D__:``P#`0`"$0,1`#\`[_%`*`4!0W,Y M$1G-]8=+D/AI:$@IYE35#PF`PU@"A4.X@EPRY8,8T;,"<E@BI(F`.=.F<PBA M,N.9&""S`U%JVXVP!5YRJP%8^DME<=F^^J^M,:@DD9OJ!Z'(VF&"HQF9Y=_B M"!*R4Y9$*MT=\$PE18R<+52I"6".)0DOM%%+I:H-47"+;\:-\-QR69MQ,3QW M45M###R4$I18LJ;!&5V8DQNLG)V.2*V#`^ILM,E`P**+5/L)/<^"_N0B(BXI MDV9RF4&+`Q<2A-1=1P\$*TJ*7E=XMR7#]+\;S-G2.;7+L+K0PY,>@1'%Y76) M/CYWF4PI=/3%ATPO++YAEQ.1-3KB#63D]T+#!..(DG8#CAIY94")A#C!@8BY MC+5'P:\FJKHRQY?XE&E,$22Y(ADV:PTJ1V=@CY.UL(4?2H_#+9%<".3<*,27 MCC`8[H2TE44$!23%L%(/G@%2R0IIBD(4P)J)(8<51;O2(WZ8#AY^G)>]@FQ_ MPBH+$L.JU'3`<//TY+WL$V/^$5!8EAU6HZ8#AY^G)>]@FQ_PBH+$L.JU'3`< M//TY+WL$V/\`A%06)8=5J.F`X>?IR7O8)L?\(J"Q+#JM1TP'#S].2][!-C_A M%06)8=5J.F`X>?IR7O8)L?\`"*@L2PZK4=,!P\_3DO>P38_X14%B6'5:CI@. M'GZ<E[V";'_"*@L2PZK4=,!P\_3DO>P38_X14%B6'5:CI@.'GZ<E[V";'_"* M@L2PZK4=,!P\_3DO>P38_P"$5!8EAU6HZ8#AY^G)>]@FQ_PBH+$L.JU'3`</ M/TY+WL$V/^$5!8EAU6HZ8#AY^G)>]@FQ_P`(J"Q+#JM1TP'#S].2][!-C_A% M06)8=5J.F`X>?IR7O8)L?\(J"Q+#JM1TP'#S].2][!-C_A%06)8=5J.F`X>? MIR7O8)L?\(J"Q+#JM1TP'#S].2][!-C_`(14%B6'5:CI@.'GZ<E[V";'_"*@ ML2PZK4=,!P\_3DO>P38_X14%B6'5:CI@.'GZ<E[V";'_``BH+$L.JU'3`<// MTY+WL$V/^$5!8EAU6HZ8#AY^G)>]@FQ_PBH+$L.JU'3`<//TY+WL$V/^$5!8 MEAU6HZ8#AY^G)>]@FQ_PBH+$L.JU'3`<//TY+WL$V/\`A%06)8=5J.F`X>?I MR7O8)L?\(J"Q+#JM1TP'#S].2][!-C_A%06)8=5J.F`X>?IR7O8)L?\`"*@L M2PZK4=,!P\_3DO>P38_X14%B6'5:CI@.'GZ<E[V";'_"*@L2PZK4=,!P\_3D MO>P38_X14%B6'5:CI@.'GZ<E[V";'_"*@L2PZK4=,!P\_3DO>P38_P"$5!8E MAU6HZ8#AY^G)>]@FQ_PBH+$L.JU'3`<//TY+WL$V/^$5!8EAU6HZ8#AY^G)> M]@FQ_P`(J"Q+#JM1TP'#S].2][!-C_A%06)8=5J.F`X>?IR7O8)L?\(J"Q+# MJM1TP'#S].2][!-C_A%06)8=5J.F`X>?IR7O8)L?\(J"Q+#JM1TP'#S].2][ M!-C_`(14%B6'5:CI@.'GZ<E[V";'_"*@L2PZK4=,!P\_3DO>P38_X14%B6'5 M:CI@.'GZ<E[V";'_``BH+$L.JU'3`<//TY+WL$V/^$5!8EAU6HZ8#AY^G)>] M@FQ_PBH+$L.JU'3`<//TY+WL$V/^$5!8EAU6HZ8#AY^G)>]@FQ_PBH+$L.JU M'3`<//TY+WL$V/\`A%06)8=5J.F`X>?IR7O8)L?\(J"Q+#JM1TP'#S].2][! M-C_A%06)8=5J.F`X>?IR7O8)L?\`"*@L2PZK4=,!P\_3DO>P38_X14%B6'5: MCI@.'GZ<E[V";'_"*@L2PZK4=,!P\_3DO>P38_X14%B6'5:CI@.'GZ<E[V"; M'_"*@L2PZK4=,!P\_3DO>P38_P"$5!8EAU6HZ8#AY^G)>]@FQ_PBH+$L.JU' M3`<//TY+WL$V/^$5!8EAU6HZ8#AY^G)>]@FQ_P`(J"Q+#JM1TP'#S].2][!- MC_A%06)8=5J.F`X>?IR7O8)L?\(J"Q+#JM1TP'#S].2][!-C_A%06)8=5J5] M$XLG#D6P#(V6V\5M@4H;N3&3)'-+45+_`#[%BQO$P$VY+1VFOF$T4$V%8NKE MTT5*,CX&BI<X*:(G02\JL5Q)9E@_K]#8?5(*`4!;SL:+3?K<5F>^6PWGHTE\ MK<BNM9V(J:XFXM$KYX"W)JR(L%CB8I%;B!AB7+G"HP5\P\,[X<['&]@,)$WA MHZFM=7DMQQY':%%SDD*48DF!.6XX9\=-`U&KPA4BQR[-!CW!%910$BUS*BQ0 M%YTM5?P<*0Y55SO7O\'O!Q#D01JU+'<U?XUU^A>R=I:P$5UDI10W.[$N;`I, MDF5%66L`VR97'$M2NRVU';M05E'-H`S=$9H3+848(;?12R<6.)8<41^;-*ZH M>3UPPX1*\-E/6NO%D\0S$;/@B,&?$S#!/!MAFIHA(H8536!Y95CQX\:5UYQK MQX,`J$><+G<"BJ.)P'02I0`VLJAXR"4*A"X`!B-U=3"#3+^V=Q;/YH=?O]". MLE#4MD/VO^^1LMH9%`*`4`H!0"@%`*`4`H!0"@%`*`4`H!0"@%`*`4`H!0"@ M%`*`4`H!0"@%`*`4`H!0"@%`*`4`H!0"@%`*`4`H!0"@%`*`4`H!0"@%`*`4 M`H!0%L*+V9B0<&3U9W-A+4"_<^[D5%?2B1P#NH6`P7=BQDV$,'W0$0,4/GX8 M\\(3`3'EPRQO<"J)*VC+Q;,XAJZ8LE`QLBPAI)/E5$L&8PP#%S`S')BC!8C8 M!C!"9!996SQP%#SOC;'/&]P*G0"@%`*`\V_]*5_O2#/\O,0_YEWT.OL?@]6> MDA0Y!0"@%`*`4`H#6EIE_;.XMG\T.OW^A'62AJ6R'[7_`'R-EM#(H!0"@%`* M`4`H!0"@%`*`4`H!0"@%`*`4`H!0"@%`*`4`H!0"@%`*`4`H!0"@%`*`4`H! M0"@%`*`4`H!0"@%`*`4`H!0"@%`*`4`H!0"@%`8ASUOKJ%K0J@->79U9J3(! MW*P:3$K:$4)%F=<'SPOF"`AP['9%TR8JY#^;$,0FUA2_.RQYXV&-[Y6%46]B MNQV+B[CS+^.C*($T<4W:&3"K%DZ-BCGRAD0HSIC99V/)&3BB;K]%*,6-N%EJ M8PJJWL5T!.#7T<DK8E5:Z$J)@ZHG)A\8PG%1U]FJ0BO/9?O>\[>OZ(S_`';$ MR?SLR5_V.URH>/;_`!K]J^K.TO0\10"@%`>;?^E*_P!Z09_EYB'_`#+OH=?8 M_!ZL])"AR"@%`<<T:*D2ID\>,ER9(F7&-'#AH8,N5*E2X>0Q@R9,#98!`%P` ML,Q1AA<\0P@\<L\\L<<;WL!#K8V0U]>K,?4C-*;HI<3`B_)6M)+U27ZV#C68 M%D%'"<2P*\UT)3R36R73VZ.7<1DRLF"9?!OF2RW86Z69`-B"T>#O.*V]G=<W MFQ4J3F9.D3O..EY>.M5`>[0?K:=#6<+E3"9U04T!O+:"HJ">NK"6GIBJ?4TY M)'.&DXDDJYLZ$`72E`0L%&KFFGMV$QHZPD.%(2U]`5$Y<0EQ.)*Z*M(YXLII M"PDJ18(XG*B6I$A1R:@G'R8P)LD=*##%C184(<`40(3'*XAKCTR_MG<6S^:' M7[_0CK)0U+9#]K_OD;+:&10"@%`*`4`H!0"@%`*`4`H!0"@%`*`4`H!0"@%` M*`4`H!0"@%`*`4`H!0"@%`*`4`H!0"@%`*`4`H!0"@%`*`4`H!0"@%`*`4`H M!0&(<];Z:A:T*H#8EZ=68CO\[E8-)B9MB*$B3.N#9X7S!!0X=CLBZ9,5LA_- MB&(2:PH'.RQYXV&-^=851;V*['8N+N,>O*RWAG7_`&?53197C9M&_L%IIWX= M5H11P\;?:R.I.O;$!?D\+H>85\,BI)YE8=S'$SL$,<)\P7,(6B6V7I&_JZ+U M3?D/(*G2:O\`:MU=YIGDA)-_:.PEK%@+I[!=RYC[1Q#5#L?K:QL&\TO[BO.< M,Z!E3I;'/(=%!N/<((6TE\,4O%_J?6[H9>0+J;K/JZE#I&OD&1G$H)W&]E90 M9S43$]QN$3+.PN9EU.W(`5TNL\():V8J@Y%A4/#98XY"F,[XX\@RVWM=3^GQ MJ3JG)KH4WO).LNODA/1;[S^F7>^(8CAV.A7^CD\JDI_TFOKS;/JQ_O!+(DDT MGWT;%[U3R94F!S"Y<$/`*O%\20HVB6*H:0C37B",X^BELGE4==.MV-F8W&,A M'%PT4(D#2R:2&PFI:>853)%,320ZB*7S.#%$\B6$&R!*`8!B5KM)!H!0"@%` M>;?^E*_WI!G^7F(?\R[Z'7V/P>K/20H<@H!0%L/9::+;9KK<,@'D5,8B$W%M M7>:DY,BV+>(-5.33)M?.+N1VV1/%'+)0)H92N:QR+V)X#=VM</G6H#4-DFQZ MY';NL/.VP+.(Z[;"+^H;MC;;*)G7C#9H-]"&G,F-V#DR4$YUN)L*9B,Q(MC! MXHCA)&REUT.9Q4%S!*6!FQ<4;O\`TT3JJ_I:;NQIXU?`MN,3$P-2>].GIL%) M9M^PQ%RKQ!HB9^P+[*M]K^&H"N8AP[KY(,A'D@F@LW%P*4>,F<V.DR"32F\B M2`7)!N1(!$\8A+)2!T:E1;;+:PVU2VW5:>VY7/89M<-9NNMKZ81.G.XBHI9D MXL3`Y6PE*Q4P0/I,7O.;Y(=\-I(Z:<P"-I=DR)5QE$04DR`7,)0!<).&+%Q" MV0.`DG5\-F-%7J8%QHC;R*>]_%1%U8D755F-,/8?7\-R$I]AV69'<)MP^0_K M;EB:1%./INB].((UDVY0'(B>2E$[<Z&8,64+`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`V9?WLX52,_CV5@TF)VYJ[M1(<SK@V>'=`04*'8\VM=,F*^0UN;B'F1:PP' M.SQYXV%K\ZAI13V0EYVDEQ<*$?Q?L3^D%SBZ2MH]@C3MA1*)S>Z2KM/!$XZ_ MJ)_&V=LA!&_#1':Z3YBN'D6O80I=\-"/\QQ\L2XX9/'$8<$&NS6URKA%I];* M7"I5YDX>O&$V`<V1V5.)##9N-QNZ8FH&C^*9PA*-#Y<?*UQTY8<$'SO'$W.! M+%PM<`4@NRZ?+#`998"A96SRY04H+9!^;DJ]8M+AZDOP+I#O=JZE#I&OF?"1 MB8([C>RNHM#2_88@Y'$)EG87,TZG=GMJ,Z78>%$M;,90<BPJGAL[8Y"F,[XV MO81R3VJ;_P!:]AD+X*<8;T[<-WLL[,?-W0E899<R]@\%.,-Z=N&[V6=F/F[H M*PRRYE[!X*<8;T[<-WLL[,?-W05AEES+V#P4XPWIVX;O99V8^;N@K#++F7L' M@IQAO3MPW>RSLQ\W=!6&67,O8/!3C#>G;AN]EG9CYNZ"L,LN9>P>"G&&].W# M=[+.S'S=T%899<R]@\%.,-Z=N&[V6=F/F[H*PRRYE[!X*<8;T[<-WLL[,?-W M05AEES+V'0Z_2(B.P"=Q$#!?95SQ`[9)\2,99W5H09#RC]D?0&0[F^BBUD!] M/V1UVRN#G8W=0.W<=R9G',O8N0*W"$N*.KLJ6+JI5>UU^R^AZ>=#C%`*`4`H M!0"@-:6F7]L[BV?S0Z_?Z$=9*&I;(?M?]\C9;0R*`4`H!0"@%`*`4`H!0"@% M`*`4`H!0"@%`*`4`H!0"@%`*`4`H!0"@%`*`4`H!0"@%`*`4`H!0"@%`*`4` MH!0"@%`=?Q?_`$FGA2-E>6VXJR-+`:HWU=21%(,*%W@,$&?2C@Q`Y@$-@%S! M0\3``F.`N/V1,;6RQ\U[4/3NIY>JU,VTOB[</E2B2-)?OL(WRY*7T<1;CR-B MZ:M.2>7,3P/GTW#%-@9E$'/*YH8<VG#X`6+M48+/#($3(7'`7'*AFQ*K5-FW M93CLZE&\K3=^=?\`9]4]%5F.6V;^P6FG?=TV@Y%#QM]NYY)U]8P#\GE>"S"O MAD6)/(E#V8XF?<ACI3F"YABTBMLJ^$57JZ+ZGYY!<[S7_M6ZF\\S2(DF_M'H M2U?"$T]@VY<Q]HXAJB@PEM9V%>:7>W(4ODOSH`6.EK"9#HP-Q\@@Q+27PQ2\ M7^I^W_;7Q,O($U+UFU=2QTG7R#(SB8,]CE974F@U4PBY7$)F)W40RZG>(",Z MG8>%$M8090<BRJGAL\<<A#&=\<>01MO:V_/[&0U""@%`*`4`H!0"@%`*`4`H M#S;_`-*5_O2#/\O,0_YEWT.OL?@]6>DA0Y!0"@%`*`4`H#6EIE_;.XMG\T.O MW^A'62AJ6R'[7_?(V6T,B@%`*`4`H!0"@%`*`4`H!0"@%`*`4`H!0"@%`*`4 M`H!0"@%`*`4`H!0"@%`*`4`H!0"@%`*`4`H!0"@%`*`4`H"TWX_&7%S+=$BR M*Z$1E,1E(B@Y'8['(H%TI";Z$E%\S2@J*B@:S#`+%2P`>6>>>>7+E?FAAXYB M9X89`>4.O\)[B2R\X'#*L=:6SZY&!)#@7'RR7$&R#J<"OM-TJIM:;RV6)*^2 M>I@%%9*.%3Y2QPD6&S+&`A+A8VSM0[%."23DJJY^AZ&7!1U(3-6N'_KPD.V` MFU#.P9UE*-IG&$8[?;TDJZ_F[W`*7\.UT@2P65LYBDV2K%[JJ@<[B1#)`@WP M!!"#P'-VDK4G?55N_P`&W*A@4`H!0"@%`*`4`H!0"@%`*`4`H#S;_P!*5_O2 M#/\`+S$/^9=]#K['X/5GI(4.04`H"G+!A2*)*H:1TX)85RR>='2DD<_BE@*: MB"6$$))XRGF7-XIP)PSB$7%/9%#5BF`F1BY8?N?<LP-:9+>U[I8DBM!S-F)7 M*^TK:R&=4HY7XM?I]?CQ>>TP(Z$XEHLZ,3R>`X$-:A%O''"M/E&!L-@Y0D$L MF))]OK:DJ)[8&K.S;L;O6Y?6O3QVE=;V\2T[9XSU%26\VB&P:'*,R,QXJ2A= M5-,=+8T1Q9#4N%I,34,N<*KA[PW0]CX+12[3&<!6S96G*\<[NES@,4N$[0I= M7=NQO;5.C\Z>)E-K%.A#9*#F3,1)%S;1APW<R*XFSF?LK8ME\Q^\'!'4A-P! M7L43_I@F@/IIN)((K%TY-S529,!0S34_,SD3`$:HZ?SPZ&%.ICQ:+;W4XLY9 MQ.EN()DQLYK\.`76EM,2QQP+:*:S!W&!"/&@!!`K"8Y8=TPQRPY^.6/+RVO: MA9;(?M?]\C8IXTXQ]([#_%[?_,:&1XTXQ]([#_%[?_,:`>-.,?2.P_Q>W_S& M@'C3C'TCL/\`%[?_`#&@'C3C'TCL/\7M_P#,:`>-.,?2.P_Q>W_S&@'C3C'T MCL/\7M_\QH!XTXQ]([#_`!>W_P`QH!XTXQ]([#_%[?\`S&@'C3C'TCL/\7M_ M\QH!XTXQ]([#_%[?_,:`>-.,?2.P_P`7M_\`,:`>-.,?2.P_Q>W_`,QH!XTX MQ]([#_%[?_,:`>-.,?2.P_Q>W_S&@'C3C'TCL/\`%[?_`#&@'C3C'TCL/\7M M_P#,:`>-.,?2.P_Q>W_S&@'C3C'TCL/\7M_\QH!XTXQ]([#_`!>W_P`QH!XT MXQ]([#_%[?\`S&@'C3C'TCL/\7M_\QH!XTXQ]([#_%[?_,:`>-.,?2.P_P`7 MM_\`,:`>-.,?2.P_Q>W_`,QH!XTXQ]([#_%[?_,:`>-.,?2.P_Q>W_S&@'C3 MC'TCL/\`%[?_`#&@'C3C'TCL/\7M_P#,:`>-.,?2.P_Q>W_S&@'C3C'TCL/\ M7M_\QH!XTXQ]([#_`!>W_P`QH!XTXQ]([#_%[?\`S&@'C3C'TCL/\7M_\QH! MXTXQ]([#_%[?_,:`>-.,?2.P_P`7M_\`,:`>-.,?2.P_Q>W_`,QH!XTXQ]([ M#_%[?_,:`>-.,?2.P_Q>W_S&@'C3C'TCL/\`%[?_`#&@'C3C'TCL/\7M_P#, M:`>-.,?2.P_Q>W_S&@'C3C'TCL/\7M_\QH!XTXQ]([#_`!>W_P`QH!XTXQ]( M[#_%[?\`S&@'C3C'TCL/\7M_\QH!XTXQ]([#_%[?_,:`MUW;`08PFLX7L\I@ MC1N--IHRBX7&O*;U;P">D(J25%.J*@;%^D+WQ!+%01!<K88YB9\WF!X9B98X M7#;<C5"QU)*XF3W;4\;!KB&P]&6.O$75K5J\\%](1W!L0O)!G$XW-CMFFP>. MAF"K**F0@%J$H*6P.;GS24A2,1$/9H2`2&ZV4TKV]KP\%]WZ77FX"TIQA;S6 MD9AVM;S6M9WM[S?_`.0H8'C3C'TCL/\`%[?_`#&@'C3C'TCL/\7M_P#,:`>- M.,?2.P_Q>W_S&@'C3C'TCL/\7M_\QH!XTXQ]([#_`!>W_P`QH!XTXQ]([#_% M[?\`S&@'C3C'TCL/\7M_\QH!XTXQ]([#_%[?_,:`>-.,?2.P_P`7M_\`,:`> M-.,?2.P_Q>W_`,QH!XTXQ]([#_%[?_,:`>-.,?2.P_Q>W_S&@'C3C'TCL/\` M%[?_`#&@'C3C'TCL/\7M_P#,:`>-.,?2.P_Q>W_S&@'C3C'TCL/\7M_\QH#S ME_TG];17!Q/3*@@JZ6MD/)^B4'OU(/E%(IW8,R[>Z!=\DQ1@>ZA\['GA\_GX M<['G6MRVH=?8_!ZL]*2AR"@%`4)T>$W@TX?`JR%=X_0BIX*6=%U#%M7<?>0_ MT+9PY)-LE3%$NH][65,DW'(]B2N/<ICD/8/&X&O!WZ)&'X^5?8(4O'\=3H>? M&I4D`-UFBJ2I'!ETZK.&3U+OEQN`1MM9<75R3FG,S[C56>V;0+J#:;!-A#@H MCB$:&9%9&K5U-U_G^I*N_P`*_P#9_+<T=<[1V''W'3%=HJ<]N&3YG=#R;AY0 M6DYCG8\E:)H-B%-CY)=8#?45LJ<9R9K'"3CLY33.,!+JL6?9+%`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`0((0>/)CC:^0HXN09< MN&*.*$'F%J;N4I-^;-=NOG#`U3W2E5N;6O/1&`=?=26AD9.:R0`3@&/F"_)\ MP/`9``3[LR23FVGJI5DJ9(3OJ)H"5LK%1$XP`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`@ MR*X\AUC6@R+UJS/C%G(#';-EA2'=&*@J60VV034WZ0/8EBV)LYWMWP8L`#84 M3*P>'(.KLFW"K;;J]MYZ-KAV6@EJ3.V==W#);?3)O>:*&Y&M&0MSPKK7&Z(< M,I_T^0(%R8W=$4`Z3-%CBK<3$B1&`$P.C@7M0XZ.E:78[C'PEQ0^'\H[+9Z? MD=IXQ,[$X.`5H^+\,TK]S$>0(V145E`/+))LPC+V#4,,TG)G%W2(YK+6&:)] M%?2V&1.PU8E9M4NQ_E_J9M*#E04I9;[>454H46W5FIAMU-&SOB:5\T8C=25< M2>%K7L)<B1M<T/RWQYH7GMRW\U#)7*`4`H!0&M+3+^V=Q;/YH=?O]".LE#4M MD/VO^^1LMH9%`*`4`H!0"@%`*`4`H!0"@%`*`4`H!0"@%`*`4`H!0"@%`*`4 M`H!0"@%`*`4`H!0"@%`*`4`H!0"@%`*`LN1I&8D0L1V2?)[L0V+'S%0SSD=S MN<AX%-1$%$30;C&SY\V->V.&&&-K8!!86S,&C&814J$,9&!!S!7W+:S5O'L< M/OB4/EJ[$;'-1;8VEC(6R#OU:U3=Y`9-7)I6TP;$VVME]GFV;QQS#3`\\05F M$X-6`LRZ*#F2?+^)C.(1+2$L;K8JDZR=S:W>"?U?HL7M\H8%`*`4`H!0"@%` M*`4`H!0"@%`*`4`H!0"@/-O_`$I7^](,_P`O,0_YEWT.OL?@]6=N_B)2=N#K M0XIFD;5#3-];,27/$#LV*(ME6.3#>4CT*/%K*LDY`$)":I[/%PYL5*-OT*1V MXH(8!])77+DNM]W"MHJ4158X.>*B[I2HDZM8[#7%JYHPF\.3AU#13+VM\D3I MO3M\K!.B1WHQ(*>TUDX,<KO6BR0T'4[YL;+5<3?;9'6["X,H*^24Z##L-OT! MQ++)+*I<ZF+P8U)VYU32C'9>E5+!.FW^;#L12O\`VBM4?^H35_VU$H>:V/R^ MZ,G*$%`*`4!K2TR_MG<6S^:'7[_0CK)0U+9#]K_OD;+:&10"@%`*`4`H!0"@ M%`*`4`H!0"@%`*`4`H!0"@%`*`4`H!0"@%`*`4`H!0"@%`*`4`H!0"@%`*`4 M`H!0%D23)+"AUA.V491=J&Q(\8B&><CN=SD/!)R*@HJ<%<4T=.FA;_\`Y0BY M<+$4T=-"@$R8!@V8``$!)MT5[9J]CF-G]Q('VT]D-E&FNL+3MC+9%WZJZF/` MB(FK<KK2:-B:;>S.T+<,VY;7PSL$L0M""L&(5:H&9-Z/<L8=(Q!.2!MM15%? M+?+#PC]WZ(V\T,"@%`*`4`H!0"@%`*`4`H!0"@%`*`4`H!0"@/-O_2E?[T@S M_+S$/^9=]#K['X/5G:VXF+&WVV0V);<(ZD[R,O1QE1!#C*F)Y+A]1$+.Z4GK M*+ZE1K-5"R!*!XF[LQI)T-JIE3#'.@I:@==881Q%<N1,.R*/"#BE64;5;EX4 M_P"S6*EOWBI\1%^-EO[03+$VE&FFI$GH#3G1WM!P8&%C<^5H%?A1LO11:2*3 M%0W$YH^D&0FP;Q;J,43V['10!:+%RA*4'(AEB!4:_1'X?U2EL65-75\:._[; M3L\2O_:*U1_ZA-7_`&U$H>2V/R^Z,@'.B`N5NKC>,J2NCE5M+/)1M30%,9%6 MR10\7$+&ATE9+<TXCG\2X@EBJJ0$`4$X6^)Q/-%#H(!D(0U6-;3]64F]N4W= M;9"(P-$VQP,4E8B0EA.=,C,?/)DV-XSM*""PP)'8:R09VP::OH\;*H[5>+5& M6$QL!2FB*(N3R1%E1&J[*WM<?!5OV;;Z[:4(!UZR7%"8=1-99#BEA,=DM-?X M@R;+K381MT."$)9F^%1(1;D?.I*`D!077`IH"RPY0D-V$62]51R#M%VMPV1L M=45*-TU:!%>]UK\/FDTZUI=@MU5YT-A'#==CP>>FT6*SV4U1;4T];F)G(JZM MG#2FKK\?1[.$DL&*EY15CP@QY:-K<8MIHJHRX=,&3BWD;^EC1HT8."&!!);; MO#C15Z[#`:-)HV5C/>_BHI<):9N?95#4-A]?SZNYT.;X8BX!OJUM'];2]D$9 M*DQ?2%11&R)A`*'T@G@BD+8&L2UQ.^`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`N4*`8#'5` MZ,7($"YDZ9+EQ`44W12JW\K,#,GSQ`-ZI+B[8B7N&3)RYJ*TTQJR3KKK`K[" M:^L3PCD3+',^1FC9)NOMSI"VXE5N7[U-Q+&RJWDYOM3,;%V+117<F9`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`PX9A@U6UZ>%X1C(C>/5E_,62#EDLL.YKD5OPDCM M15&]<)3R%'Q#(6-=_%;E<KF0\+"A<X=794L7.M[.ZOOOP/\`5;B1[&)^P&R# MGEH$RVH48T.M-NQLYT1JE"8#:?4L/586E<PIM1R&%(PJB2*GD20((I($@&BF M<Q`S69_#(L.>/:2BJ*FVM?1+[&MR5_T?KA"Z<9,:6%R>Y;B5^)$@,=1B#QA2 MXR5/!W20E.Y#.-9KI3(LQ4M>?`BPLX$4X\CMP8-1#(FQCG?:>$!F>`&EVG:2 MNVXW;O/<=B.5_P"T5JC_`-0FK_MJ)0\EL?E]T3^Z&RWWJVUYGNM))K[7=*.H MM]Q(2D%W=.64-8*"D%5*4"][VQ,$5$B..4.%L^4,P6&%!$QR#SRQN(8SM_0[ M3AI):DD-'7&*VD45EAIN$Z(U6T7;:E].L0X>4&:LE%E%R(K"<IMHXJ*1A'.I MQXJ8)YGS?<A+8F!;9"VGB_6_;MVDUJ<.Q@K(*`VC3+10DAJ*IQ=:P:8"(BG& MRNJ199(JRVWU=&%(*Z*LK1%QN,@NJJ:>+'UP@XG`25C!PJN*@1L0O-OM]":: M$C-=KHJ4W&TW$H@AM]OH2>5245#14HJ$12TA(2R(0!).34XD`"4(D2@`)8J6 M"#``#P#PQQL!KITR_MG<6S^:'7[_`$(ZR4-2V0_:_P"^1LMH9%`*`4`H!0"@ M%`*`4`H!0"@%`*`4`H!0"@%`*`4`H!0"@%`*`4`H!0"@%`*`4`H!0"@%`*`4 M`H!0%A2C*,>0I'KOE>6'>AL*.6$B&W$[G<XSF!%(1$@EC:XI@P-E;+,4443( M,J1(E0QSZD?'+)R<6-'C1<N*"3;HKVS6/&472%Q$9`:6S>T306F%JHQ%LD\- M2-1'>3$(K+S5R&?=V[LYM&WAKW#%<N>-\%6'884\1T^.2(Y=S.LN;?)@()$& MZJ*I%UD]LL/"/W>_=<;=:&!0"@%`*`4`H!0"@%`*`4`H!0"@%`*`4`H!0"@% M`>;?^E*_WI!G^7F(?\R[Z'7V/P>K.XWQ1D/B[N!O(R9PW'9!#0;!XL7*2$L+ M2?F;V%3<S!P4%04(YL]+&(D,)11'SL.*5/AD'CF>#QLWE`,QD%S!SPL?UIO# M#UI>:4]9^%'J*K['R8^-X]O)RV(V/CJ+X-F!"D#8(S(L)NYJR89D*8;N#-'B MB0E`-_/)!80C'C$=(",*3@9BD"[`<B9`9-<2$``-OM)42BE%5:HJ/"YO%WX, M[0LK_P!HK5'_`*A-7_;42AY+8_+[HR<H04`H!0&M+3+^V=Q;/YH=?O\`0CK) M0U+9#]K_`+Y&RVAD4`H!0"@%`*`4`H!0"@%`*`4`H!0"@%`*`4`H!0"@%`*` M4`H!0"@%`*`4`H!0"@%`*`4`H!0"@(_E25([A".WA+4M/!$84<,)$-N%W.YP MF[$TI&2B=K<\47/DS%,&#`N81-.3B81A155$P43$PH;4#98L*"3;HKVS6=%T M62)Q"9":.T6TS/6V#K`Q%HF[]1M/W@3N35W&K$LKBM[9S:)OB7S"'>HP>6*E M$,.J-C*;%A`<!Q.,$Y(!G_P0;;44XK;LE+ZI>&+W[-FW;C0P*`4`H!0"@%`* M`4`H!0"@%`*`4`H!0"@%`*`4`H!0'FW_`*4K_>D&?Y>8A_S+OH=?8_!ZL](R MPH5Q<P+"AW'##"%$!MGC<4,(;(7`$7,.U^?B&+F`/B%GE:V(F0(N.-[W#SM8 M<AK@XD33D]3C1NNYNQWKS-T:,E[1VL21%,T,9R'':21PG\AX*,J0Y)R`]$K! MD/F.B`]G05*G6HIB*(2(*(FN%'/!8$%<:CMVM8-?1^#,AY7_`+16J/\`U":O M^VHE"+8_+[HR`<K@(-1O+;E5,#PJ>@I9U5-`)9`TJJAH(D!F/<HE))`(<^JJ MAN^%BR:ED0!SJB=%`)E`13`X8>0AA>B[^QP./)#<>\7S5$DJ1L]H689J&)`1 MX^%?KL5=BULZW(1/L918<DOB-7`AOY81W&4P5;R"3!:5FFZS3^Q:A%`4#00U M9?FL56EVW=6ZN'E4O(CN;&:LO)["1&\^EB73DER)%1R'"A=H`OI!<D6M%'?S MN.+IE1>1%D$FX79;LCYQ$%[!XCE%(G)C!+E><I+MR)4++\*4K7=?=Y[:K9N) MSB&5F;.$:M"5V`=,'FF]$JRFF9'B@B>IDA0C`Y!515I.%O<9,7F^L$SZ$OI8 MM\A4U93CQ$3++,OE>XSLN9@SIE_;.XMG\T.OW^A'62AJ6R'[7_?(V6T,B@%` M*`4`H!0"@%`*`4`H!0"@%`*`4`H!0"@%`*`4`H!0"@%`*`4`H!0"@%`*`4`H M!0"@%`*`CV5Y7CF#(Y>$N2X\$5@QPPD4TX':[7`:L43$A,*6M:^>=[8YCFC9 MH?,$DF)A$$RIJZF9*):64.*)PL6%!)MT5[9K2BN)Y'X@,BM#:C:UGKD?ZX,% M;*N[4'3MW%N]%-25">5Q$#9S:)`SOF`:D8P%EBHQ-$2AWRF1`G&`EI<#.R&; M&%1!JJ2HMK^*7V7AB]^S9MVWT,B@%`*`4`H!0"@%`*`4`H!0"@%`<4Z>))A0 M<^I'"J>1*AY#&CITP"4*%@<+<N8HYD?,,$$/&WGRS$SQQQMY[WM0&&<E\2'0 M*(!\R,A[DZW("Q@)W*[;#EUEK;NS%Y>;8(%GM]65708$OG^KQP`2!,LA+V#Q MM?.]L;C2A)[(O@R(>E8@)RWYL(1!NELI^[$[#.G,\7;68E_V,,'[)S1C2/<L M1;<EPC5G9WD):_.Q,WQME?$+#WN*\Y*O"M3KZ<<[CA;)P^WXD@Z.->I?U!DQ M<>\=S[@MRX\H@.O5;CB-WB.L(2,H,2()&D0PV$5W2"UT\)8`=+A3\W"WVTX6 MUFDGTM641`AZ]GV:=6VFJ-75WKQ2W5.U9I]LTQ]R=9(6V:CP3"S:EYCI;F^C MK&,#0S<7[=T3G<T#P^%L<!%-G.PBM-A2SPM8,0\DCB!7R!S#RR'C)66U@Z&2 M=""@%`*`\V_]*5_O2#/\O,0_YEWT.OL?@]6=K?B#Z1\3_8#;G*4-)=V2NHD8 M!:XQ*PG&4-AGEG%]OQNR;L"X3Y@-%*I:H$FY-UO/-MAYJ@N)<14LLX%`\A\4 MD2P`\(R@E24;3JWT6AK[<NBW&+:CO:#/F'C,1A).*BM--S*FN:NL)[)=\Q,- M(>"6,XVZ@E%9.2CIH%<)D3Z,&+:X24<.Y_11X\6!',"!C5KLWL[.GCMIXG9! ME?\`M%:H_P#4)J_[:B4/);'Y?=$_.E64T)M.!;16PK/9824924DIG()QOIZV MZ5$D3&,$V^DGW6LMUL$E%7,!AD"9IPKR,C%QQ\!5)3)%,!3`8AJ'6(KG2<!V M]+*UJ;*\2R\P]G]<-BWEC)S[UK/#2@@1P.NLHQ%$4^*&=Y;(%D6+8X=KQ<B% M:1E>/2SC?Y[%1+!6.OMT&VH-52NJG5-75NKO=4NFX_ME:IS$SMX%G?,XREI0 M*/R4]AB*E$Z:K-/)W-B,WW`.H$4,5ZC%C3D*MLTM*KCTU+J*JCD7$*KIR!+" M'93*@'&RY"J:#?Z5'!+BG)T_W=/$S?T;A=U0!K&PHY?6)8!YYKDJ2(ZDPF=! M4BK>7YJEY^S.JM,NHELLBB@$T#K_`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`!%N(FP(W82,87G6['!NB\RR:E)P%\`\?-@D"&3IXZ9% M`3TE)3P#2JLJIHFE)1,XHG"I44$VW11BV_`P@@?A?/G=?,U-6U4^;^M+7WPF M:SVU*UTDW8]SJ\K(`K5,#'FWL),PJP1/$6M)+@N8Q4F7&B8FAFHO112]W"K' MWD9.!(XTY6;DH[*2=+K]R\/'?Y4-DG1H)77EXEO;(>?Y70S:^6/`=&@E=>7B M6]LAY_E=!:^6/`=&@E=>7B6]LAY_E=!:^6/`=&@E=>7B6]LAY_E=!:^6/`=& M@E=>7B6]LAY_E=!:^6/`=&@E=>7B6]LAY_E=!:^6/`=&@E=>7B6]LAY_E=!: M^6/`=&@E=>7B6]LAY_E=!:^6/`M=8T'CMO.%H--<XA7$227/(!Q8(,AOG]V' M465W6<;R*:<:Z`@IXB=B94LT="(FE52[V#$Q)D@KC#WPQRPYP6OECP+HZ-!* MZ\O$M[9#S_*Z"U\L>!07'P^F$SDP9;=W$(XA[51B_P#Q"NX]WW&AI@'FOE^N M/J9,J4"^S:]_MBX^:U[_`'6H+7RQX&#[W<?#28"C=$5^-;MLMN&V66%VM'&_ MCFEYV]UPOR9%_!.*$EZ./OGE^XK]%]\9<MN:'?EMRC7ZLB]53JZ8ED_2$;.? MSPB[?TC"?2PWV4]9:*I-<8M51ROYL,RSLV9)00@9EKY<G/,8G<L0\+\_FY6Y MML@ICW:X/Z5'DN\1E\<@,=LC?6,`37_"KVT7&-"1<B0>7G#'/M#7B+]@S8V5 M\>2XA/!S%!PKWOAEGS\;VH*QWV?],:_5K^;CEDN$EQ4GH<+C._BZ2E!:4$)B M**CQ*^-BYI6C.'+]LF*\9.EJ/4O'&UOV#@$=`9\MKWR*WME;'!_/Y_/06HY* M^=%T2^YF+'W"0>:(0S"DOBI\4V3CPY?(N9L3V9O':-]O#FY#$RS:;(SE)#VO M>]PQ,7@)W.W):UKY6Y]Q'-;H17I7ZLB&0/T<[1*6C^"G*\D[G2DH8#V,V-R3 MLVYGX-D/CES^Z"Y.M*5^[97RY>?87GVSM>]L[96O>UQ5VLEL45Y12)DC7@G: MWPP`&6AZ=MT(H+A!]R#`C:?[L8$,+DYO<\`VPT4O#'#F^;FVM:U[>;DH1S;V MI/S7^27NC02NO+Q+>V0\_P`KH2U\L>!A_,GZ.=H9L.^#<ESJ^MNI<D`\03DL MV\9`V$4G0X1DU)`[V3$_)356\9,V)D0.7`L6QSQ!"YPF6.%LA,\LAI=K)*BH MEY$T0QP6H%UT904;P1LQOU$C``4U!9`9S"VK<S<;@"JJY!9J1\!)3D8$F`8/ MY@AB&A`@L+CBXW%$YPF6>60CFY.K46_(ECHT$KKR\2WMD//\KH2U\L>`Z-!* MZ\O$M[9#S_*Z"U\L>`Z-!*Z\O$M[9#S_`"N@M?+'@.C02NO+Q+>V0\_RN@M? M+'@=#G](BAL""^(@98Q>2YCE<.T(QDL>%<YR$HR8^;Y*`[FQNFW<RF`7-71R M?>ULD]/[GW,ID.9OAE?NU^0=797PPO>P[U6WW&&TCT,GD*!=KI`6(Q7%>(F1 M+S25RK%D%]D7(E.QY2BS#Z;8!A-)QYI!IO'(V#-#"J@P&*D"X0,"8=KIQK(0 M<T82DJQ5;Z;4L,7XFMS:3C+<&3=>/4:%24LB29)QZ2(Q5X,('H'F5*4D>8DM M_-PVQU1#=#FCM*(-<3)6"`(+*AFKIP)MMFU=).B&2)\P3,#4>S[2+K3SO6S? MOP-Z$K_VBM4?^H35_P!M1*'FMC\ONC)RA!0"@%`:TM,O[9W%L_FAU^_T(ZR4 M-2V0_:_[Y&RVAD4`H!0"@%`*`4`H!0"@%`*`4`H!0"@%`*`4`H!0"@%`*`4` MH!0"@%`*`4`H!0"@%`*`MEZ/)JQTSG7(+Z7DUJLEC-M;>#P<ZR8Q)I#=:[:3 M#*RO+JJ;S^P53DE*)FCYTQG]D$L`*)EYL;T!KL4N,]PK$M./J9C>S7H<!.)& MCXP":]0%91&"*`"&!`B"6F@FE%2.B8!Y8%4]/*F3IP>X9<J`,.(&'D-]W/*R MRX?B:1-^9#96W.U[35&3`#)5";TTTT\=`0>)HN;PPR%;VS^S"/CF.24Y>420 MV*A%L8FLCJ-"*2<#4#MCTE'#I]%$;LJBV[)/[+PQ>_9LV[;:&10"@%`*`4`H M"-Y2F.)(.:YE[S/)\?Q,SBG.L8=$D/!OLI!#SPPOG<'Z5<:@G$\S&6-OU9<, M;(<6]\<0P\\LL;7!)O8J^1@1?B<(,J7N1TEUIV,W.,#W[D1?S49GB8USL-C] MH00QL'/.;":JV1""O8;(U&2;)0PN&8=B9,UF*'AD-6:?$U'J^"X7T.D1Q-^( M]Q'9IX@[$F9O1XXHC7])W(Y&A#Y*%4UWR>R4=Q!K1PC(3G(.YY1RFHTA&'>` M``TEA7&8A=E.9L(*:`40E)%,C'%<=$(P46FT[5[K<_!4K=3B=S.%-,$?:&(8 MTFI_;X\1V6&[+#);CXP;I^=2^MZ>$6<B6641V^LM#6%CP>>1S:8*.*DK:$;4 MS`Q%1*G"0HG."OC8>#=&THQVO=:\-]:DVMSA)\.)O*@*Z=U,C21E\#SAK\ZW M<>Q"[W3EMEW;-8G==D51$'Y]K"=VS,Y"6$M;/'*V5K7L);EBTL%<N"H9P,B- M(XC-.LCQO'[)CY(MCCA9+9#40FHG6PP_8QL102!`M;'#_#CW+DQ_=:U#-:[2 M]J`4`H!0"@%`*`4`H!0"@%`*`\V_]*5_O2#/\O,0_P"9=]#K['X/5G:DXM4Y M:L0-)C2$&X=I'B3[R2O&22AL.'2L.I4KJS7AV/74]#Q5VKQXU'TDJS(:>;PD M%SEP;(3<',/%4+#%30I(JW<U,@/"%7_78CC6E[PO5=F-QKGUEVCAEU2FR(BX M@?`4;.@J9*3P;34BS9A)UC)-5G-^3U5;(X1^DJSP58:9Y]@+9YSX)9-O.U&= MA\8HX327BHI"2DY'%DH-23I6/:VZ7M5PVNE75?;$[-$K_P!HK5'_`*A-7_;4 M2AY+8_+[HR<H04`H!0&M+3+^V=Q;/YH=?O\`0CK)0U+9#]K_`+Y&RVAD4`H! M0"@%`*`4`H!0"@%`*`4`H!0"@%`*`4`H!0"@%`*`4`H!0"@%`*`4`H!0"@.. M;-E2!4P=/&2Y,F4!$,FC9L8,N5+%P<+B##F#`V6`0((0>.68@HF>.`>&-\LL MK8VO>@,!)!XI.BS#<)ACIT[),R26!RAXQ5K0@.S9F2<SO.N&&FF&G!2&_3Z, M=%%M8/'%Q61P`\LL<C!@$/*V=#5B5*THL71+BZ&"&_VV>V4R:)[HE(UX>TI1 M]$JCJCL*5=LK;6R5'L*KB:T1(D=N+F5VE"+1,RY)JZNET7(V,WT-ZDXR`45. MY4LI*:4%8UD`-124H_J3=I7)-[UO=%PK]CS`>]#7_P#3&/\`^R)__P`T.P]J MR(?_`&31?_\`3ME?_P"M)E#YY(E`*`4`H"'YFV"@K75LYO*>IAC2'&OC87N: MU)+T;[.)'!`<;99%4W)=/DLU4_ESL<`4]-P-'C`N88)<N(*)AAD*DWL3?DJF M#_22*DM_[+I'J#L;M4&8_P"`E!=;ODP:X#!X^84V%+L^%FTN.<@$)?&V)N+X MTD8,T'804EWSCW'NXMFGQ-+J^"^[7T'B.XED\_:G+;&.=3&8;^R:C321C!NZ M11$\;]9F44ME]@D=6"**`5KV+B'F+`K2,896OF25L>3NHP5BMB;>,KERK[R? MD21%O#+TTC)T%I'4(LSFV8@.:)G-^S;G<NQTM7.8YV$N>37;+RFZQ&F-?*UK M6+L<HV$X'"UPRY$$/+/'(+3V5HL%<N"V^IGO:UL;6QQM:UK6M:UK6Y+6M;S6 MM:UO-:UK>:UK?=0R?M`*`4`H!0"@%`*`4`H!0"@%`*`4`H!0'FW_`*4K_>D& M?Y>8A_S+OH=?8_!ZL[<V^&]I#A;;`']AIGU\DZ2-9I[CJ-F*LS?#:.BN)T1% M(D8KTA9D67("0N*S<*8L!UI<@%UQDJ%G(2%*.@)_%2Z6L&E4#$N.>,;:HFK2 MJZ/>J+88DX\<B!>)D(<TFTHU\V#E60IS3A&8Z'D_60VFI%D',!>SP3'7,;T6 M2CN<ZH$-'R88'<;63PT8I9==R>AHB<ME5H\G`F!KNW#]4FE392]OP7W-XDK_ M`-HK5'_J$U?]M1*'FMC\ONC)O*U[VO:U^;>]KVMER6OR7Y/-?DOYK\E_/R7\ MUZ$-7T;R7M;)&J6T1F.E@22)W:^UFTT-QTI*BI'D<JI%BQ[L:XH[3!$E9&CA M?CLB\FC&269,-!1=4;N5O*KS3D@9[I"RFG%BPPTTE)84B\=L4\4[WMH[MQ$< M#[(2'([VU8UU,2!L8E.-X#;FK>Q1^<BD'E9S:[OU@-1(S,H<NMPK';2B$1NY MK\WMU^-]X1\V@\W:SVZ@F3"P9)NAQ$C(-*C=%_32C=+ZNM[;W4==CW&<VBTS M.Z?-8&#(C]%`-O4-<E6.G2KEB)9,`<BY"LP/V&%%WAII(,`@GV>1E@9NFY%. M``32>2Q<LG%P"08`.`C5'=@GQ2=/2IK9C3=B`M8=[^*BUI;,RV`L.+8?7]P) M>,>:V;'S6G73<='];4Z]SRY"T42`B)!WOHH-:R4K*)%5N!W,Y8E<H.`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`A,[YAAC2[)[W%>J;^M.I"G2/[`3%]J0]K#^H3?&\^3 M:U=X5/$'G62,2X_^\+#3)L3K<F,DL<+A_J\#2?KJ+C8>^8H0N5L`<[A8I_37 MSG%=$_NS[E3_``BG*:+JNR3LXBFZRZ7&",!&-MM<.)-)C1"&#SL+EWI"Z3KH MTH#(@B#8V%N7)Q6`%AE;D#QQQR$MF%)[E&/[7%/C6UU,_(_XD?#AB9O%VC%; M-F2,VH4YO>K9C_AL[K,UO%N;C;#'O=&;FKB:F@\W"UL+=S+8\F-K8V\UN2A' M";VW^<HZE\=+AI5_$-G.P+OI\M="=W+!<T=1TN&E7\0V<[`N^GRUT'=RP7-' M4=+AI5_$-G.P+OI\M=!W<L%S1U'2X:5?Q#9SL"[Z?+70=W+!<T=2-'[QV>&1 M%0Z85E":)1C<TM<[Z&+/W4#<MGCJW,SL'G]&`N&`$X0_S,[VPR[UQ%YN=[8W MY+WM:@79S>Q)^4HZD"3=QZH^;9TBB:Y:@[B3T,KAA"D)*<&N\]Q3!Y4J:!L( M743ZW>('Q,1HK;GX"=S0H-5.^0;VN`9Y,\<["KLV]KBO"J;^M.I`OEPOF=OU MFQN\D_:]M,U]DY$NA/#*WN1%O(M;[>)92V:G+5YY/DR)GG?N1D\P8TB8[<(. M]RA@J(-S@A;#6R*?C*4?HI7>K9+\-2GP8(/<V$A-Z*-AWM+U[A#&IRF[1SB* MSU-YP[AE<3,]XU)@@!YO%,%''RR,"ED%42$W`2]K%R(`>`8>`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`D:9[TQ3T)H*0F36 M.8*&2L@CF@HWRFW1;$MK?VIZ;=I@YIZ@\:/AUOYH8[E%M5-A-19$?;59LDNS M7-M,MBOB#E)^+I%I-F25!):T.039TLY,=*VE`/JX[<>!]%;1L\X`#Z2G(ANX MHU+NY)N-J+\;T^K^IO5E?^T5JC_U":O^VHE#S6Q^7W1DW?SVO;EO;EM]]N3E MM_\`.W+:]N6W_P`[7M_SM>A#%9IZJI\?LES,Q@3/-3,$=DZO+8%4=B.<C`=R MW=LAOA5D![H.(2U%JLU1V4XUU:4L#:(HM@\:*IX^!9+5"`A8J."+6^K5;J;] MRHM^XJ(VJD<XG&8XT52=;9D5CNZ1GRFRDCF6Z.]U%PRZ1&(26*O_`$\VEIJJ MR:[</HH0=!&:^*&C9M5F`MA.0R320"A`*XW[K_#9_/,E6)HM9L)QPT8KC]/& M36BRTK!+2@31L=04#.68PQU15E=2,Y9FE5=7%4T>6EU6-9Y&E184#R@9RR', MB7N)MO9@MIE_;.XMG\T.OW^A'62AJ6R'[7_?(V6T,B@%`*`4`H!0"@%`*`4` MH!0"@%`*`4`H!0"@%`*`4`H!0"@(4V"V,A/5:,U28]@I!2(PC)&4$A+5'<N` M*9A.)J"\?"3$@L($D$%(]?,\?&"+!7P*9X6SSM<3+##ERL*DVZ)59AU%G&-X M9LV2*SHFBS;F/7E(L@+Q)LLUJIJ8]PCZ\O*(G<B*:4$/M4H3P&,"?9PR,F@` MK7_:$QM0KA-*KBTD9<39M)K;K:F?3$_SS$<-DL@;CEO&/(#8:9Q1PMRVM@D) MBPI%5-9,"7QRQ!*))0X:'SM?`$$3/[-")-[$WY*IAYTG3;D;_9M1]6-O-N!# M/ZI+=S1A\Y"T*F3/FO>XDT;,GH=:9U/#M]H11:&+PQRQR"$+`&0A@Q+BV:;7 M%>M7P56/_2V31]UM0-&6L>_YW?&Y<V)X&/\`\K>(2&T92&__`#2.GE+Y?^_6 M"_7A^A8R_P!JV>KV^0Z,9NR-_M.W&U.WFVXAG]:J-!UR^;A2%3)C]V(<,:S$ M8=:IY.#M]D-.>`KPQRQR%#,CF0A1,+A:IL45Z5?%UZ&8,):M:UZV)GT1K_`L M1PV2R!L`9O',?MAIG5'#S7RS5U1(32JHM&!+XXY#&U8X<-#YVMF,,)E;EH1M MO:V_-D]4(*`4`H!0&IUX\9[1J,MOYPU#E65D"/'!",>L-V'WBMJ-S"*ZW>ZC MABR]%333DHJ>55]^-5'56"J_0""$L+BUFY'`GE4<N,Q5G,8;4).*DE5-M<-_ MEM7H7%Y>,^31_LVF.B,TOY*-?9)33M,/Y'4)W+F?LDEQ-2GVC+VQ+N2\L?\` M;+8HT$E2YPK8/$%8!N8Q%#$LI?%)+P7ZGT=.H\E/>J<_U^T>]:A%C;-_;,PW MH*S0(<(A8X_9P)J6P\D9R%-RQCEA?*QH\RL(>&&SRN(7+$KX@X@!6*V1KXRO MZ*BXUTG>"^'WIUKHN9O.,H*:5I+,9XC*$R/O-6E>;54U;&UA#2C,<H*+ND@P M(/G;NHH-G*&4L)>W<BP6&`>&`CDW<W=AL7!7&9-""@%`*`4`H!0"@%`*`4`H M!0"@%`*`4`H!0"@%`*`4`H#S;_TI7^](,_R\Q#_F7?0Z^Q^#U9VLN(-J1Q:) MCV^'DGA_[<,35B,!-;8=8[RN\TXNMYOI^-B3]BUX2R<1$C60,RSW1>^S M=Q$G!0NX"P.&!ZZ<)D4>7\Z,\(N"5)1<G5[VJ*B\3#4_P^OTAPQ=*O*?$FB* M8XT*.9HJD@16B-\HA+#^9B.Z4=6<K72U3Q%MW$`^JHY(V6*ABKR.`;&RP)F% M$H"8$&QE^^G'_"+:[+(UXU;IZ5.QN_V4XEZ9(!=Z84#&06&<DT5S&LC98$0E M@Y&3FC)%PBPHN!@YWPH7L#G8J&+<#']:-;`/[54\\?%?=,G&A!0"@%`:TM,O M[9W%L_FAU^_T(ZR4-2V0_:_[Y&RVAD4`H!0"@%`*`4`H!0"@%`*`4`H#"7<7 MB+Z::!^+ORMYF!B/QK^%G@!W5B2<]O"#P'\&_"GF^+AE._Z-^BO"]N\OTQ]' M]^?2-OH_OOO4[WL-1A*5;*K3;>EM\V17J'Q?N'QO1(!:)=:9V&>\I#-%1?!E MBGHREEIJ2:@(XJ:75QCJPZ6.D-',PFF58@7&+$'&=$'S&OF1[[!#$%P%E"4; MVJ*M*U1LNH8/X$$#"PS%%SP"##QOGF()ECAAACC;ERRSSRO;''&UO/>][VM: MWWWH"&77LCKLP^Z^',]PLS.X\O=O"N4F,W>Y<W]KNOTPND^Y\WD\_/Y.3]]" MT;V)F-+GXK/#1:`F0"QOAJD,:QRYF1)O3>P7>?L)R\G<OH]I+:V=[MR^:P/< M.ZWOYK8<OFH6Q+*^%/J6;TOFA!S[+5DV29)'R\Q<")]7]J)2[[R_PXEC;#A= M?3\^?_@$R.8!9<MN03SVY0L2P7JTOJQTG+74_.RM+N),^P\_.7,$=*I,8I0U MC?\`9S`.3-XL2O<\_P#"(*,$'R?:OE;'ST%GYHKUK]*GYY<FTCB\\=\*+<@\ M%?\`9,RA(>F\0@VM^[,0NH[)N-7PPOYK\W!+%,6M]Y>U[7QL%E;YQ]+3_P"- M.I^^4%Q05[]4W>''#+0[K_NSTK[XI!?O;E^ZYE*B[7N2NZ\G^/$LLWY.2]L, M\^6UZ"D<S](ZR1^]]\8Q:\^*#PTXXQ$\]L1G3M#,@I:U_NL)B"TH-",YX6_: ML&.!AE>U[8B6M?G4'Z/FZ+[OZFG;CM09Q.'OPZ)'#DV7H-F%&S?,5"#P;K%J M#*28Z5@Q@]4W(LHDGDX-@9270"*`-:RD?!!9!BQTJ!F",:3P\LA\1OLW!25S M6V]R5%<_!;3J(<+G4B6)+W\UF;3KB.?4I@E-AFRRI3<K31I38*@Q\P!RPK@2 MU.0FF"BK<=+A%//%<SPX2XA+:65/@#V'*=\`BW'O.2LN^-6KMCKZ/:>G-"7# M]TKUV4_"*(=:HJ;;RR&L9'D=1;@3SE4Z9QY.0PHRL^1'+(ZF/SK6SN*H.@R) MD)RBWRN)EEE<<KE)[6_+=PV&5ZNM(Z`1%4UU63$1-`MRCJ"N?*II$&W)>_** M;."@@!VY+7ORYB6\UKT,F*#\XA6AD7]VPD'<_5EI&2_.[HFK,\Q@66+WPY>= M@$B^$V2L8$QY+VN&`2$SM?S<WEO:AJS)[(RX,@^_%]T&4>4-ARH^YE-Y^8H4 M@?739";._P#._FQP)J$9Q,YD7/G_`.`013"`R\W(+Y[<H6);U3S:7U:H.DB5 MUS[$;<//B12`*+YB8Q_7IN0LFBY9?[O,P9V*DV(CA(OE]]Q1$W,3#&]KW`OY M^0+/S17%_1,>4]Q'7']EF\+\HUL!O,7-SQNK#31[ACE^P,<3X9;&PABW-M>V M0A4(QW7[P^Z8Y>>P4COEP3?"M.M!W7C%N;SXE.&U#8(_W6%.[,["J!$//]V> M(1/6\@9-!8W\]L!N]KB6\V0@?WA^CYGP7N'DT\2=R?;=_$U;;.L-YQB4#Z1Q M<W>]+9?M`DE.;'[/V8O,MRXAF3*9;*_FRR`M?S4%8Y:^<G]J?8='(Z5[];)G M$9XCK[,"^<V"B3<PX/2Q,K_MXDRVO<1Q8I$`<O/S<`EH04/E^P/;DMR!:PC% M>E?JV4)T<(?3E1;3B'.QZ]YR?UT)7R;PVS^T^U<L-I6<]D\Q=#P=I9V2F["0 M"&.J=ZX+(R4V#!H,AD9$+$#1C'`',+;\%Y1BOL=;#6C]&EXE.K&SL7[41MLA MI\GOB,9#+/LDEDS4N)*"I%!3(X;C9PA(C$V(9!LN=O*"NU#Q,B&'WLAJA@`G MW++`++`>S[6,HV6I4=U;F_,[S8=\[X87%QPP$OAC<3`/.XF&.=[6Y^.`F086 M0F&.7+;'/((.^5K6RN'A>_-L.<_N@%`*`4`H!0"@%`*`4`H!0"@%`*`4`H!0 M"@%`*`4`H!0"@%`>;?\`I2O]Z09_EYB'_,N^AU]C\'JSTD*'(*`4!^996QM? M+*]L<<;7RRRRO:UL;6MRWO>]_-:UK>>][^:UJ`B8E/,,*;)7)(2I-9JNPVXZ M5%CJSK1ULFK(H+U2G0&R#K/+'$X0S@I.C%["@LTNWTSOQ6/.T8!M$2AE:&"( MYA1_SC]+_(^0D]Q$&A)3AQ>I`R37'0ML=(3R))7470H/9L!+1ATLPLRR">9> M`CM:I1MN,\Z6U9"^FFVGM];/K9$@323XY<*/^?SQ1(K;<C?>+>0W:TUM)<K7 M<R2GKS=<2$H%55$7416*!'DM72%,B*.34$U1)#@FR1TJ,*7,EQ0Q@1,\,\<K M@:[-,O[9W%L_FAU^_P!".LE#4MD/VO\`OD;+:&10"@%`8?S?Q`=)=:GK:-Y^ MVCA:(7[='(."S2?KX1V\NW1%00T$G*ED\\.&/<D=$)&\"X_-Y@N1<6V-[WPO M0THR:JDVB\=?=P-7=KK.W+6N>8QFZS#N@V>=XX=2:YK-F[H^F;MZRS=/%%[R MNLV;RY]']UYO?/T4=[GR]PSY!'&4=J:J9'T(?P((&"'F**)@$$'C?,003+'` M/##&W+EEGGE>V..-K>>^65[6M;SWO0$!O;;'5F-.[>,?9:`(_P"]^=W?PVF2 M.FKW#F_M=U^G7&0[GS?\7/Y.3]]"T;V)F(#UXTO"I8%Q;+F]<`J%P>6V5F0Z M19,OE>W[@;1P1==S%[_=C8#NE\[\EL;7O>U#2[.;_I?JJ?4B`7CS:$+'+:)@ M=HM@,[^8#"&-0]A%[OO+]V)09QL1J%A^=?DMAGB/W+/EM?$2^-[94'=RWV5Y MR6I3!>,')#E_5Q'PC>*@[\\_^&/2!`;>A5!.<O\`NQ2ZH\'P9,6+9^:]AQTP M'DQOR\R]K4+86^</1M_14ZE,%WLXPKQ^Q&W!5$;!(7_<.&:-Y(.0>YVO^S<V MS49)%7L.2U[99V#.Y7MY\+?:MRT)9AOGPB_O0I@SP_2,7U]A`A_A:064'_:$ MD-]S](JV2PO_`/"&8EQT88QA;_XJ<*7SRMR?8M?EH7_Q8S?DDOJ4P;5_](!? M5N:Y^)OJM"08_F'#A?4](D'O;#+]O$H/*R63-9\VU[VPSR'`&^Z]A<,OM6"O M9K^B3\Y4^B.MI^D"\/[B!,C+4X[*.T4\<2577_'G<#-&UPQ::-#GT=XH+F<2 M"'&R@\BA7P_R/@]TR/W3NZ8LH*Q/`Q;`S8N/7LI1_51*.S?6NW'#[F-G`5X? MDU2=O6(W95)[M:J-8&%G^J^,V(CTDZY.DTHDU5H!E6F-(G@\!G=&60S)@P>0 M01P1E(5-*C8YVL2ORC7:R2C=9=ZN='CN.[&O<'Z%W6GAISLVIXDSH!##[GG= MP;^;#*=A[>?ER%*F'3DG\[+EOSK!$P\+\O[%J'/;^6'*C%]W_HUG#I?N>0KP M7=K7*)GES\A'#L:YW%G?*_\`BRR<">J7RRY?/RY<O+?[^6W+:A5VLELLKR2. M:T_T<'A^L*X>3'6IZ:HP7)W,VF.>+Q5#EMR<W(124H?/J`^=N;;DS',BY_?> M^5[WO>@?:2>W[ZF2S7X3+68N%@F)NUOZR0\<>;@&V)<BI-PPQMR\F..&,%B8 M\VUK\G-O:]N2UK<G)]XEO&,7YIZEX]'0],+7L7XF/$O+_NM_YVH#.7MYK6^] M2UG/7O\`=]^5\KWO>][WH+7R0X/7Z'[T>LJ!_P#"\4KB1@WY>7&PSJU+/8V\ M_+R7L=U$&RRM^[SY?=;SWO;EM<2TLD>#U^FA^>03L`#;_8N*UOR'>WW=_)>F M*E^[DMR]UU)"OEY_/?EOY_\`\;<M!:62/&?N'D0[7@?\#Q9]Q0^3[N_XIT=4 M_P!]OO[MJP%SO-;]_P!_+R_\[7"TLD>,_<?OD;;M!?\`"<6_9*WW>8_K?HH? MY?O^_DUP+7OR\MONO:_);S7M?DO8+4<BXRV\3&7<EF;]ZGZQS'/B3Q+=@I47 MX]:!L\T(X0M.-2W"O/E[*`I=&9S:`(M.%_I;$DI.103@UQ2))YJZ&@_2:X,! MF631;4-1LR:5E*N^KNQVOIU.KQP053?17W$?,*S9(V_>LT>;>+[NDE\23'T8 MHC>%7-@@\#KC+K+O=\OP9(:>TBCT(9N9'/*+:P;AI5<H[.)GS0Q8H1L2'MVE MFRFE%V:))M[/)->&)W'NBUBA=^S*NRO$"FHKG_Q*6]]X)Z;*$<O_`(N^&[#+ MHBE!Y,ONRQ`30<.;>^&...'V:'/:>Y17E%?5U94TGA#<-5-/!*:AI_%+\4@; M\N*C,)=>G`]G?EY;W'-S$MODP9OE>W+G<P(+?._GSYU[WH+<LS7E=]#*]AZR M:VQ9W'Q8Z]P?'/>W-[W\`XG8;0[AS/V>X^#Z`G]RYO\`AYG-Y/W4(VWM;?FR M<+6Y/-;S6MYK6M^ZA!0"@%`*`4`H!0"@%`*`4`H!0"@%`*`4`H!0"@%`*`4` MH!0"@%`*`4`H!0"@%`*`\V_]*5_O2#/\O,0_YEWT.OL?@]6>DA0Y!0"@/R][ M6M>][VM:UN6][^:UK6^^][_NM:@-"#?0'"L0J6<Z47.G&K&O&ZE&9Y,+%2XX M][P^/MK)@Z2^S!0/#(0RS4(\Z&3+0KAP#$22K.;P[W#-71TS,^&/1TK_`/KC M3SL+_*Z']1PU7<V^(ZO[6.`0=(U0>,[[8)3,<2CSRK/(NA:U8T.8J;)HR@/S M2"6UWJ[M<=AVJVW6:$+(:VK'"7T.H'1I'1;K`G]*2VT7K?)^MSB_3P-AG#A9 MKQ8NG47(CY2U5"5SZ[,;S2D!<)FDQ9;S$D:<9)D*,&\J)!X,$\B'D&-G0TT@ MT@GBY8\ABDLD@X5*F20I<,23J^'%))]3`.-&!N4[M[^*@<UKV4AF$VP5V'U_ M+.!#DO65;G%45UZ^C^MHN*JGKJ9/L1A(Y#%/S*D[I`B.IB7,`"G/I*V)BQ4$ M:=FS"J;=E[&E=:EX/Q,L/$GQ6NOYJC_3Y=OSJT,UAEES+V#Q)\5KK^:H_P!/ MEV_.K05AEES+V#Q)\5KK^:H_T^7;\ZM!6&67,O8/$GQ6NOYJC_3Y=OSJT%89 M9<R]AT)/TCQM3HUN(F$E["RFQIBD#Q!QD9L[X[B<_#3>LA#*CSLFI5V<HR/* M1BY\D*&<$,JWA18,]B9!PQ32ERU\QQU=E2Q=B]KK]E]"M\#N&>*W+;7V]OPQ M=B6!!PK?$@J\SHKOS22"X_[*@<R>+WP37%:+)`#3!FY]'O:RB']-,T$U]/$, MQC"GD5!LGB=HX*S;3>VE-VRM;UX8FTI8T[XVQ$X+EMELYQ/!TX:][F<H*;&, MYQN8#MR]VN(AZR<0Z+).%+Y>?N1;*+,30F-OL$@KWQMD/.UV>Z,/5T_N@UP? MF4Y.U,TP45(FG3MOI`C4>`X^`1I-XA&EO$6CE2Q4.7EN"HVVKWX0&:(-CE:] MQ<R`PQ+EME?NM^;ER!66Z,O]$H.[_3`VE05PIFJXDX):@&8."W))`$,,4%Q, M_A=L*6L@@[\G<Q@W%?<IU&,+9^;FC8G[7S\WV[T,.>/><_XF>3/TKWWCVP=F M!M)H,Q[`VM8&S/X7PC9L%:UN2U@[(NX!+N=K6\UN;R<EONH9K%[5)_ZU["2_ M$GQ6NOYJC_3Y=OSJT%899<R]@\2?%:Z_FJ/]/EV_.K05AEES+V#Q)\5KK^:H M_P!/EV_.K05AEES+V#Q)\5KK^:H_T^7;\ZM!6&67,O8/$GQ6NOYJC_3Y=OSJ MT%899<R]@\2?%:Z_FJ/]/EV_.K05AEES+V#Q)\5KK^:H_P!/EV_.K05AEES+ MV#Q)\5KK^:H_T^7;\ZM!6&67,O8/$GQ6NOYJC_3Y=OSJT%899<R]@\2?%:Z_ MFJ/]/EV_.K05AEES+V#Q)\5KK^:H_P!/EV_.K05AEES+V#Q)\5KK^:H_T^7; M\ZM!6&67,O8/$GQ6NOYJC_3Y=OSJT%899<R]@\2?%:Z_FJ/]/EV_.K05AEES M+V#Q)\5KK^:H_P!/EV_.K05AEES+V#Q)\5KK^:H_T^7;\ZM!6&67,O8/$GQ6 MNOYJC_3Y=OSJT%899<R]@\2?%:Z_FJ/]/EV_.K05AEES+V#Q)\5KK^:H_P!/ MEV_.K05AEES+V#Q)\5KK^:H_T^7;\ZM!6&67,O8/$GQ6NOYJC_3Y=OSJT%89 M9<R]@\2?%:Z_FJ/]/EV_.K05AEES+V#Q)\5KK^:H_P!/EV_.K05AEES+V#Q) M\5KK^:H_T^7;\ZM!6&67,O8/$GQ6NOYJC_3Y=OSJT%899<R]@\2?%:Z_FJ/] M/EV_.K05AEES+V#Q)\5KK^:H_P!/EV_.K05AEES+V#Q)\5KK^:H_T^7;\ZM! M6&67,O8/$GQ6NOYJC_3Y=OSJT%899<R]@\2?%:Z_FJ/]/EV_.K05AEES+V#Q M)\5KK^:H_P!/EV_.K05AEES+V#Q)\5KK^:H_T^7;\ZM!6&67,O8/$GQ6NOYJ MC_3Y=OSJT%899<R]@\2?%:Z_FJ/]/EV_.K05AEES+V#Q)\5KK^:H_P!/EV_. MK05AEES+V#Q)\5KK^:H_T^7;\ZM!6&67,O8/$GQ6NOYJC_3Y=OSJT%899<R] M@\2?%:Z_FJ/]/EV_.K05AEES+V#Q)\5KK^:H_P!/EV_.K05AEES+V#Q)\5KK M^:H_T^7;\ZM!6&67,O8/$GQ6NOYJC_3Y=OSJT%899<R]@\2?%:Z_FJ/]/EV_ M.K05AEES+V#Q)\5KK^:H_P!/EV_.K05AEES+V#Q)\5KK^:H_T^7;\ZM!6&67 M,O8/$GQ6NOYJC_3Y=OSJT%899<R]@\2?%:Z_FJ/]/EV_.K05AEES+V#Q)\5K MK^:H_P!/EV_.K05AEES+V#Q)\5KK^:H_T^7;\ZM!6&67,O8/$GQ6NOYJC_3Y M=OSJT%899<R]@\2?%:Z_FJ/]/EV_.K05AEES+V#Q)\5KK^:H_P!/EV_.K05A MEES+V#Q)\5KK^:H_T^7;\ZM!6&67,O8/$GQ6NOYJC_3Y=OSJT%899<R]@\2? M%:Z_FJ/]/EV_.K05AEES+V#Q)\5KK^:H_P!/EV_.K05AEES+V#Q)\5KK^:H_ MT^7;\ZM!6&67,O8=#K](B;DY-;B(&$O824V-,$@^)&,C%WA'D4GX;;UT08=S M634NS.49&E$Q8\1RP-9&53PHN&>L.%CBG%.X7N,.KLJ6+E15>UU^R/3SH<8H M!0"@%`*`4!K2TR_MG<6S^:'7[_0CK)0U+9#]K_OD;+:&10"@%`?`0L6%RYXI M<`7+DM;G"!!YY<EONMRY8WOR6Y;\EN6@/Z#`!!Y>X@A!<[DYW<P\`^=R<O)R M\VUN7DY;\G+]W+?_`)T!]:`X*FEIBT1,I:PG$59,.AW!.)RF4+GR)L'+]H(R M4-!BEQP\OWABAYXW_?:@,'Y$X8/#VE%2^G75I]!)9S]TR%\,F0QTV+WS8;/E MY1[/F,L6@[L3%N6]\![+5A@[WO<//&]#2E)?U/RK5<"..C*1FARY0!N;OYK\ M&6^TDH*/LHKS:QTS/'SA`AL[:I%GE/\`H['+D[H1*C$NZ8\N/=\.7EH+>,8O M_33^V@\3?%4CO]:Q=UM<-@2F/V;(FRVJ9]BK@@>/W7RD'7:3VJCA&A/-CF/X MH!RX?VL\2(G.L'@%8X->3K]5]QY0_$QCWE!DOAY1]+Y4K]HTY-3]MVFH&#@& M/GS&)L'8]D0(:!&QPM?*Q+!ZJ0HN?ZD$03*V.0@4CNE3S3^U?IZ(=*;$;5_] MOFO&\>LH6'V#"O*^I<H.9GEAK?M!CR'`9&:H_!PMY[]]#.8(KB%;NP@P87+E M8+#W.+\I)='1]":HKXB6B$V#AD(PV]UX=*V()W'P6#E5H)3S"&Y>;W$TR5Q4 M3':3%MGRAW#-(P.=A+9!WQMGCEC81QDMJ?G2[CL,QPA0APPQ@1`Q@1<,1`A0 ML\1`Q`\[6RP$#SPO?'/#/&]LL<L;WQRM>U[7O:]"']WO:UKWO>UK6M>][WOR M6M:WGO>][^:UK6^^]`49NN1NN]$37,TEY%=#;6BV)U'<#=5"*VB*Q/.^6.!M M-5DT<R0/%L\L<K8CE3`H65\<K6SO>UZ`K5`*`4`H!0"@%`*`4`H!0"@%`*`4 M`H!0"@%`*`4`H!0"@%`*`4`H!0"@%`*`4`H!0"@%`*`4`H!0"@%`*`4`H!0" M@%`>;?\`I2O]Z09_EYB'_,N^AU]C\'JSTD*'(*`4`H!0"@%`:TM,O[9W%L_F MAU^_T(ZR4-2V0_:_[Y&RVAD4`H!0"@%`*`4`H!0"@%`*`A65-;-=IT`$*S7` MT-2\`*'W+,.38Q93ZMW.V/-QQQNYT13RPYEO]WEA?'(.]K7POC>UKV%3:V-K MR,-Q>$;I0BBYGH;;,LZOK%\\A`%35C8B=8&+E<L\KY96":+$D!.CX4+++SY` M'6@;+Y8\H>05PLLP\A;<M]'YI/JU7J:U.*UH?Q.473V2$32/>W9J<&X>1CY> M4H"EK&)G#*KOCZX08JL0B28FC%K*DL=5Q+`&"JRQ51?4#S_;IQ01B*J:4[AM MQTC<)0M*U%+Q5=OBFZ4\EM-?7Z/*A<8/7'7A7?*5``<V:=O125!X]@9^RNF0 M],*2O8'2XJI)4-!R"BYMDNQ%\;%53U-KNMQ,Y/<Z_B$[6^9(!?2JDZ!KM7"3 M5]&MK2JO7?=X5P?AV*;<5*&&/R%]I87VNTU,A_JC*O/$".I2C'$UAYC&`4X0 MK>6X:P)A<F0N)]5?"0'<MS!AL"^0F(5#RLO<XOR?V='T,U8?V)@+8-'^GX)F MR*9C1[`X#BJ$92`U7N`5PSY+6L>\'%11S("XY7L&*7.X@#@B\H(P>`N.6%A& MFMJ:\U0F2A!0"@%`*`4`H!0"@%`*`4`H!0"@%`*`4`H!0"@%`*`4`H!0"@%` M*`4`H!0"@%`*`4`H!0"@%`*`4`H!0"@%`*`\V_\`2E?[T@S_`"\Q#_F7?0Z^ MQ^#U9Z2%#D%`*`4!!6RTJN.%(0?LDM!D.:172@)Y$)OM5I,IZ2(J&51:6$]! M*JIEF1VF+#W7F^V,E.[G=1%KIQE=%;*.K8I0>1^Y;&XJVF&L/[M.R7@=7V:T M7G!SY?>R);85X^';.9TG)["8K!UV$:[==Z6KQR^'$W))"DPE(C^9+-76LZ%) ME'&X.:<HB@F]_-L--6!6J-[:*BW5J_%56YLRZU5G8/92!V1+]T4-MJBV,[VV MZF\`=S4B:$_(T?+EC"0DA.4A"Y,9224Y\LYPE$A1')DC!Y,"*&S!,H,,(7#$ M:HZ?R^]&"&L\QQ%&V[?%A3)$E2-V"I']EM?CY!/>CX;#6/'2-M%]:"]SA0HN M*A$<R5L.$*!<P"'F#W8,0/G\_#+&PTTVH43^%_WR,^O*IU@ZQ\"^V"/?>*AF MCP?!CRJ=8.L?`OM@CWWBH*/!\&/*IU@ZQ\"^V"/?>*@H\'P8\JG6#K'P+[8( M]]XJ"CP?!CRJ=8.L?`OM@CWWBH*/!\&/*IU@ZQ\"^V"/?>*@H\'P8\JG6#K' MP+[8(]]XJ"CP?!CRJ=8.L?`OM@CWWBH*/!\&/*IU@ZQ\"^V"/?>*@H\'P8\J MG6#K'P+[8(]]XJ"CP?!CRJ=8.L?`OM@CWWBH*/!\&/*IU@ZQ\"^V"/?>*@H\ M'P8\JG6#K'P+[8(]]XJ"CP?!CRJ=8.L?`OM@CWWBH*/!\&/*IU@ZQ\"^V"/? M>*@H\'P8\JG6#K'P+[8(]]XJ"CP?!CRJ=7^L?`OM@CWWBH*/!\&+[4ZOW\U] MCX%O:_FO:\P1[Y__`-14%'@^#,*9?@W@]3JK^$\C$-+S+WL+F8#DAHR%'\92 MJ`8SY>4<M*D9.IGR(6&QOEEF&*`Y@\PQ,LA`[XYY997&DYK9:IA2[@[B&_%6 MS(S_`%NK?&D>,:EP_L%V-/TS0EN5&0)8/SEB(8<R*(<SDR8/)B%;%+G)/%L6 MPP`"%!QME?,+WMAZI.+Z7=!Y=.X41>9Y'^&WN&@@_JK+&OVVB'K7)@P87_O8 MD8SJK/F.S1LP':U[E@9\1BW?.0E\;E@,0\,@LIYH^<:]53^TK"#QW]#B*L1; M,^*\BZJ.8^+8F5"F5HEEME'E#'_?EDV7X06I>B$P$%S<A<3)M[I^.1;F#"!@ M9"6"L'=RW7^6CH^AL":^ZNG3V1"3D:&UNN#D05##NA-61IMC8^2&MR6YV%AB M[ESQP&"O?F#EQ.8.7$M<(<,,3'+&PS9>#X,N#RJ=8.L?`OM@CWWBH*/!\&/* MIU@ZQ\"^V"/?>*@H\'P8\JG6#K'P+[8(]]XJ"CP?!CRJ=8.L?`OM@CWWBH*/ M!\&/*IU@ZQ\"^V"/?>*@H\'P8\JG6#K'P+[8(]]XJ"CP?!CRJ=8.L?`OM@CW MWBH*/!\&/*IU@ZQ\"^V"/?>*@H\'P8\JG6#K'P+[8(]]XJ"CP?!CRJ=8.L?` MOM@CWWBH*/!\&/*IU@ZQ\"^V"/?>*@H\'P8\JG6#K'P+[8(]]XJ"CP?!CRJ= M8.L?`OM@CWWBH*/!\&/*IU@ZQ\"^V"/?>*@H\'P8\JG6#K'P+[8(]]XJ"CP? M!CRJ=8.L?`OM@CWWBH*/!\&/*IU@ZQ\"^V"/?>*@H\'P8\JG6#K'P+[8(]]X MJ"CP?!CRJ=8.L?`OM@CWWBH*/!\&/*IU@ZQ\"^V"/?>*@H\'P8\JG6#K'P+[ M8(]]XJ"CP?!CRJ=8.L?`OM@CWWBH*/!\&/*IU@ZQ\"^V"/?>*@H\'P8\JG6# MK'P+[8(]]XJ"CP?!CRJ=8.L?`OM@CWWBH*/!\&/*IU@ZQ\"^V"/?>*@H\'P8 M\JG6#K'P+[8(]]XJ"CP?!CRJ=8.L?`OM@CWWBH*/!\&/*IU@ZQ\"^V"/?>*@ MH\'P8\JG6#K'P+[8(]]XJ"CP?!CRJ=8.L?`OM@CWWBH*/!\&/*IU@ZQ\"^V" M/?>*@H\'P8\JG6#K'P+[8(]]XJ"CP?!CRJ=8.L?`OM@CWWBH*/!\&/*IU@ZQ M\"^V"/?>*@H\'P8\JG6#K'P+[8(]]XJ"CP?!CRJ=8.L?`OM@CWWBH*/!\&1C M+'$,T;A!NISKDS:V"V^A*KH;C.(FR\BMQP"BKKI40TU+"S(ML\KJ!=/"$S$. MK*V8*A(K=12B@O+Z@FHR<>/`"J,GLB\=A)UMJM7[^>VR$"WM?SVO:8(]\_\` M^HJ$H\'P8\JG6#K'P+[8(]]XJ"CP?!CRJ=8.L?`OM@CWWBH*/!\&/*IU@ZQ\ M"^V"/?>*@H\'P8\JG6#K'P+[8(]]XJ"CP?!GG@_I,[X9<@\3$RX&$[VN]T&\ M!Q02^FV@X$ERI'?I8PZ[F2GTDC&SI/OHO84*XY?NW=0K"!W$PQY^/*.KL?@] M6>EQ0Y!0"@%`6#(H,HC(A*\2*+!3W&`OHQA2#D5%<*PB*C6#,_\`E"DDAFRO MH9]!7SA._P#X,XAP'(G)ID/_`&YKJP0WZ@/,Q%3=+LV=)#%GEF.!!$F1M/W8 MUXN?%323J4RG<F[.EVEX;MDH73C2@I-G%'58PB1:35J]E\RLC,M9!528)][F M5Q"&J[MUWC2G"NU\3(+6>#$S6Z$F5#R:LBN01N>$BPON48CBE9.9[/QVKTA2 M"Y@TG`T?Q1R[A?+J<2R41[*"C]$E3P*==1/W+7.#"-U=36_`&MNNLU[Q<5Q< MF6`X6EM:2-DM?TI)6)-BQC/U43$N^C6M)RZ:G*#J0E4V2(7-CCFKDRPP1>Y@ M84>X?=1,\KC3DTH4;7Z=S:_KD9Q>0+HIU*]2^SE#WN;0EN>:7,]1Y`NBG4KU M+[.4/>YM!;GFES/4>0+HIU*]2^SE#WN;06YYI<SU'D"Z*=2O4OLY0][FT%N> M:7,]1Y`NBG4KU+[.4/>YM!;GFES/4>0+HIU*]2^SE#WN;06YYI<SU'D"Z*=2 MO4OLY0][FT%N>:7,]1Y`NBG4KU+[.4/>YM!;GFES/4>0+HIU*]2^SE#WN;06 MYYI<SU'D"Z*=2O4OLY0][FT%N>:7,]1Y`NBG4KU+[.4/>YM!;GFES/4>0+HI MU*]2^SE#WN;06YYI<SU'D"Z*=2O4OLY0][FT%N>:7,]1Y`NBG4KU+[.4/>YM M!;GFES/4>0+HIU*]2^SE#WN;06YYI<SU'D"Z*=2O4OLY0][FT%N>:7,]1Y`N MBG4KU+[.4/>YM!;GFES/4>0+HIU*]2^SE#WN;06YYI<SU'D"Z*=2O4OLY0][ MFT%N>:7,]1Y`NBG4KU+[.4/>YM!;GFES/4>0+HIU*]2^SE#WN;06YYI<SU'D M"Z*=2O4OLY0][FT%N>:7,]2(9<X27#.G!&^@W_I#KKWO8(0$-08\=H\4.0$( M3EO<,!VQ6$S'0#ACE?+,/`-7QP"$RSS#QQRSSOD"G-?U/C7ZF$E^`=!4:WN- MJ](Q&/B^'F!8^Q.N&N&Y<;A@A^<N3#$EJ/R$VE"H7F"O9/G0H+WOA@$$(%;' M*^8UWCW])2B^CIT/SR2YTB+DQ>W"@X5&X"$%^K^G-=6;'VNDD"!`_>:%BR?& M"[8_,FC.%K7L7`V!3"_?%Q.2Y<&P>&06J_\`R3CYMM<4T^A_6,O\)MEWL6V? MX;"=IB;QO8(51V+X>C.+1SWQA?FF,0IPBME2C"'>P%^7.YP[(9`*X%PQ<\0K MB6#L'_D>R;?E-_1M/IU,VHK@?A.3H@".J%84X>LMML`OWT97(VC+7)[)9,#F M\_+,\<;B&H@$>YVM?NV!O,','+'+`7'#/#+&PCE-;937FV0;JB<X+N[2[,;; MUK@G2Z1EB#'B,SGP3(ZY1"7S$OAR!E7:VK&&;A=S,!6/!J"8BO1)L.AJIY*/ M6)&12UR9DX*WVD:5E)555^IZF:'D"Z*=2O4OLY0][FT,VYYI<SU'D"Z*=2O4 MOLY0][FT%N>:7,]1Y`NBG4KU+[.4/>YM!;GFES/4>0+HIU*]2^SE#WN;06YY MI<SU'D"Z*=2O4OLY0][FT%N>:7,]1Y`NBG4KU+[.4/>YM!;GFES/4>0+HIU* M]2^SE#WN;06YYI<SU'D"Z*=2O4OLY0][FT%N>:7,]1Y`NBG4KU+[.4/>YM!; MGFES/4>0+HIU*]2^SE#WN;06YYI<SU'D"Z*=2O4OLY0][FT%N>:7,]1Y`NBG M4KU+[.4/>YM!;GFES/4>0+HIU*]2^SE#WN;06YYI<SU'D"Z*=2O4OLY0][FT M%N>:7,]1Y`NBG4KU+[.4/>YM!;GFES/4>0+HIU*]2^SE#WN;06YYI<SU'D"Z M*=2O4OLY0][FT%N>:7,]1Y`NBG4KU+[.4/>YM!;GFES/4>0+HIU*]2^SE#WN M;06YYI<SU%]!M$[6O>^EFI=K6\][WURAVUK6M]][W\#:"W/-+F>I$+O@?A-1 M]W7P]AGAVLCN'.[OX7QWK6VNX\W]KNOTRCDNY\W_`!<_DY/WT+:F]DI\6=;3 M;_C+\(6`MO6-"D/\/_4&?8);2\82-C)M:L$0X:#`N8PR)XA058LUL$=[XM`Y MEBIKRV=,W079@6'0&F;"P%!=M#UC#M'%MSDGN3;ZWW&VU/V;_1[UH@24F]'F MHSK*J!0N=*>!FC*B]!Q`#06(P-KE&G`*R:P&OAG:V9;,'$P$)S@A0L!<<L+/ MYL_E/4\__+C+F_R<SQV<&4_]EG:#'Y%$OYL`V+P=)Y5>ZW_=8$8YJFFEAK9> M;FYACY!WY?-G0?\`DWSIY]HE_P`JCPYX?1S_`-7^"3/CAY?V/_11-IG]T_Y> M>3&VQK!<[]W?'<>3E^US;<M!^O\`]G^]OZ"YG7=4^PT?T>&6587+_=B.35SA MWQ\2SY?NYPSJG@J<!_\`O=V3@[X_OMR\MK!62_\`E_W3?T0\7IM0\Z+^CEP\ M1PR_W6;Z<W#C;_+C?[LA@FDIR(8!\WGRP[CF)CY[<R][<EPJ_P#VOTM_>@\0 M<N*GV$G@)\-%O<_]DR^IRAK'N/\`RN,09.E+NY_)_BQ!4;__`"RRH+7_`-L_ M1/[R0\BO9Q5^V!PR.!6RPL_V0U0N]'V<!Y?_`(H*;IZR"@M\;??W-0QME>U_ M/C;DO06OG[1]/^3_`)O'1V;0*7FRUPX$+/QS\V60&B#^D$4&U^7EN'F._8X" M%SQ_PW$`PQROY\L+6^S06_F[1_ZZ?9CHE9J6?UBN[>%>TN=^T58O!WCI0YG+ MR<M@3[VV(6>3F^>V-Q4T;E^_*W[J#O/_`,G_`/1^W^5'0L+1_P#_`(OL)KVG M<[]KP%X5G#^1.;;]]@;O2,)*OA_]VXMQ[V_?SOWAWC^;GE]FC1'QB?T=K9'O MR,9@U-6E#9HXHG$*,GY'Z;$T"0JNM@RMK^99O/A&;,#1]$D;F67B;5\2;Y5E M!O!KS1*@EW*MKBDSBZD99@].S[57J5V^M9/TO;?6GA7;V*>'/P<=>-3=2HUA MN?XK@'9*7$L)06WI(+V@Z+'*(26'"8LI&V:V%Y<963I5V<UC`@I%#478=/+9 MZV1DWCBB)`R4UD`><NTDY-IR2W)-K[_0SC\@713J5ZE]G*'O<VAFW/-+F>H\ M@713J5ZE]G*'O<V@MSS2YGJ/(%T4ZE>I?9RA[W-H+<\TN9ZCR!=%.I7J7V<H M>]S:"W/-+F>IY]'Z2C%L91!Q)S+0B6.6)%S3M`\5JEFO'31;[);ME(Z8=6)U M1LB-I/3$VQXWB`!8T;[V[X,6!"L*)G8/#D'5V3;A5MMU>V\],NAQB@%`*`4` MH!0&M+3+^V=Q;/YH=?O]".LE#4MD/VO^^1LMH9%`*`4`H!0"@%`*`4`H!0"@ M%`*`4`H!0"@%`*`4`H!0"@/R]K96OCE:V6.5KVRQO:U[7M>W)>U[7\U[7MYK MVOYKVH#5]NSPC=.-S(W?Z$/%;%AF8W2B'BC?V,BEBMEJRJVU@;D$!,J2ZA$T MA1>#=/9XY)SG:ZXHY%EUOGE5-`.)1LX$J%1J,Y1:OJL'LX'79X1_Z.EMM`&P MDJRW/6PLCZP7CTRXHWBM?U;>;0L\9=3U'$IF:?!A1=K3?3:)Q4>(7*Y$6B\& M48<ZFX0K&E-+:AAJ$1ED>T^UBTDE7>[2V>'GXI[/.[L;^11M^B_89O%EVL!` MQ_8+R#"VE$A\ZW^&PYOR<&PHY\G^*X)TOEE_SM0\;2WPCQDO^1^^3;Q+TWSH MW$W8JMS?/AC(6A;!6>Z<EO-B.(PIGC#]O_%F"$%S>6]\0_-;&@K'+PEJF/`K MB_H?ZLAL/P]'^#C]PCHU7V"8A\;D^[E';6U3H(@7R_Q<B88MC>_V;7M;DN'Z M,)<R?_%#Z5XQB7Y\F)PU'KAAY\K`RIM!&HP]K??8+`:()3"!SR^[&PA@3#&] M_M"7M;EH/T?-P3^Z'CUXJ"+^K6>'MKB[>9^V<C[?H^6[KR??W!-?FJ+9Y.7[ M\>[JP?\`RRO;[Z"D,S]8Z28OMUOFF?:7^$_+!X+#SC"Q[M=J(YN3&U_/D``[ MI(C8X8\WGQPQ+8"9?_8MY^0*1SKU4OLF?G2&2<F?JW=PPN(TA#8?[X1$96ML MAD,>3[^Y#L+9Q>/&.3S_`.[2_M6Y+X<Z]^2P65GC_N7UBOYZG[?B@,(A]IU: MB\2-GA8^<<RH:'3VY29:UOOR'.QRW'N4QPM_]O`?/"_)]G++EMRA9\8\R7UH M.EVT:*?9<CNG%B#X^88O(.FVY#)[VO;[[#FW%`I!-QYO^++$[GACY^=E:@L2 M\/247]&<@IQAN&(8'P+&]U(3;ID3]DL]ETZP3%K_`+[9@O9-0!`KV_Q6$QPO MC?S9<EZ"Q+*WY*OT-5D=_I1VESOW<=,`N!/-LO67F@-N.]K5@R9"15M\$#)W M!55'6V<R&!UK1>XN<5)-%T#9B'T\0G@L.],24=P#B,X;?8RLUW[X[Z:^!M*Z M83AWF_\`U8GE4D?*_F"QB"$=@YC[YRO^SB5SBV*G<$8Y]^2V&00F0=^6U[YV MQ\]#%B6%/-I?5BW%`8:M]I@ZC<1N2`,_^&/(FCTT,Y,.6O\`LYEE68DF,4W+ M#+EM]L0T'ACR_;OAR7Y`L^,>9/Z5'ES;0.2__FVX4NY2@%^XW*C^T\ALMR?N M$S+JNR+B6[!7\U^3%&S-6QORY%+96OC8*+-'T4G]J=1X^N*2X_U+;X>4"L3N MO^[49>WN#S[VY?NN:18HUPD/NG)]^=BR_GR<G)A<3EYU@I',_&D=9+Z#F\8Y M;^\;AH1I;/[^:6VCF[,O:_[[7R,P!@:RP_=RXE<<[V\]L;7H/T?,^$?</)_X MH;A_7.3B+PHR>Z^<1/B'1!-"[UY?OL5697V$DSNW)R\F&1E"\W):^>`G+>U! M6&5^LM(H>0ILJY//)7%7W65<;_>5C!H:@0P3Y/WAV$;^M2NLXA?NYUEKONUO M_>^6W+06EDCQD]_[O0=%W'"M]B0-K.(K)I?/_B2#BWGG9JI1RU_VK&4B(W%& MJ7?'+SVYH10+'&U[V#MA06L%%?Z4_K4_;<'KAT&>2[DUZ$D7*_G$REZ7YVF6 MX][^?*YFTJ2<\,3//ORWSL-CGCERWM>W)YJ"W+'@DOHB7&?PW>'LP>Y9,_1W M4M",`\WF*!77N*A%;[/[-\U@RU1U06^-_/:XIS.]K\M[7Y;WO06I/;*3]68+ M;.\`#A^;0[/Q;LNX6#BQQ6@:!%DZ*X](IC9C>=2R.3Q#:Q=YHZ87*8HXR8:` M*!+1YM8D##N;X.2$M<[.Y94*#2[2235?*NU>1NM24E*04I-0D)-3T5$14\FD MHZ.DDRZ<EI*6G%PR:>FIJ>3#!*$2!$H""5)DRH(1<L7"#!!#P#PQQL/,J%`* M`4`H!0"@%`*`4`H!0"@%`*`4!YM_Z4K_`'I!G^7F(?\`,N^AU]C\'JSTD*'( M*`4`H!0'Y?*V-N7*]L;6^^][VM;SWY+>>_F\]_-_^-`?M`:TM,O[9W%L_FAU M^_T(ZR4-2V0_:_[Y&RVAD4`H!0"@%`*`4`H!0"@%`*`4`H!0"@%`*`4`H!0" M@%`*`4`H!0"@%`*`4`H!0"@%`*`X*DF)JR2,IBNGD55..!"`&T]2*`'B1H`7 M#(,4$R5-!B@#A"!Y98"!BAY89X998Y6OC>]J`T%Q=^CD:%QAO.O[@%$,9;9- MAR+JCC6%62R0\41S)^1TT;5W26Q%&&$7FV6%L0/,B/U(EBA,Y5R4!L1%9-"; M"2V!Z=[*S9Z[Z8?S=U[`5#S%`*`4`H!0"@%`*`4`H!0"@%`*`4`H!0"@%`*` M4`H!0"@%`*`\V_\`2E?[T@S_`"\Q#_F7?0Z^Q^#U9Z2%#D%`*`4`H#7QL:7' M=6[NCL;NY,*+D,KK"V]=:PWULH`I-==EYI(<-)<;E5A+/!#)JF<(L!Y3@K(Q M$Z"9M:Y)15@`L!T8,P$-*Y.FVJX7UZT*UPTEQT.#2V)#KK.'U(0FK2\W6DI* M9D<Z<4XI:4W20U854LSYG,4PH@J$0(S'.%%,88<12)C`'LQQ\C%Q<PE2TZ>' M&E_!U,=L4#>+6[:O=%_1%J8RMC(XV=DF*90;CCSV:;40*C:R9VNT4PPKMI:; M3DC]P#CG?IB.3RP74")\0@,EJB?A;*QS`X"`+^EJ-9--*GPUWMXK$DCRE.)3 MZL5G]O&./A%04AG?)^0\I3B4^K%9_;QCCX14%(9WR?D/*4XE/JQ6?V\8X^$5 M!2&=\GY#RE.)3ZL5G]O&./A%04AG?)^1$\Z[^[WZYPY),[2=PT&^0CV*&BL/ M=XG$K=^/U=1+("$6R-J`Q)+*Q#WP?,8`X97#+`_K!<OLX^>A5&#:2FZMT^#' M_42J%LQQ)Q@PQ<.&,T+X"X8"8<N^$<6OS<\;98\MO%%YK\E[>;]U"4AG?)^1 M_?E*<2GU8K/[>,<?"*@I#.^3\AY2G$I]6*S^WC''PBH*0SOD_(>4IQ*?5BL_ MMXQQ\(J"D,[Y/R'E*<2GU8K/[>,<?"*@I#.^3\AY2G$I]6*S^WC''PBH*0SO MD_(>4IQ*?5BL_MXQQ\(J"D,[Y/R'E*<2GU8K/[>,<?"*@I#.^3\AY2G$I]6* MS^WC''PBH*0SOD_(>4IQ*?5BL_MXQQ\(J"D,[Y/R'E*<2GU8K/[>,<?"*@I# M.^3\B(X'X@.]NQ\0,.<8OX:+?/L"2$6S@:YQ5W?C]'41TW(V9)6S-IAJ(N^" M8O=R@UNY"_:YML<ONRM0KC!.EM\GY$N>4IQ*?5BL_MXQQ\(J$I#.^3\AY2G$ MI]6*S^WC''PBH*0SOD_(>4IQ*?5BL_MXQQ\(J"D,[Y/R'E*<2GU8K/[>,<?" M*@I#.^3\AY2G$I]6*S^WC''PBH*0SOD_(>4IQ*?5BL_MXQQ\(J"D,[Y/R'E* M<2GU8K/[>,<?"*@I#.^3\AY2G$I]6*S^WC''PBH*0SOD_(>4IQ*?5BL_MXQQ M\(J"D,[Y/R'E*<2GU8K/[>,<?"*@I#.^3\B(XLX@.]LR*4O)3(X:+?-'(/EQ M8A)_8G]WX_3L";]0VJS7FH%$[,>(N133\$-]MX4-2+_[.*8&,E\?UA42A7&" MI^MWJOP?D2YY2G$I]6*S^WC''PBH2D,[Y/R'E*<2GU8K/[>,<?"*@I#.^3\A MY2G$I]6*S^WC''PBH*0SOD_(>4IQ*?5BL_MXQQ\(J"D,[Y/R'E*<2GU8K/[> M,<?"*@I#.^3\AY2G$I]6*S^WC''PBH*0SOD_(>4IQ*?5BL_MXQQ\(J"D,[Y/ MR'E*<2GU8K/[>,<?"*@I#.^3\AY2G$I]6*S^WC''PBH*0SOD_(>4IQ*?5BL_ MMXQQ\(J"D,[Y/R(C)\0+>P].[AUQ+\-%OWD]L1*T)K5B&6[\?XI0;#?#P>S& M0#8*Q>(>]1E`9P1\Y`3";A^O+%@"IH3]6;#H6S"E;;HVU\&%/F\42YY2G$I] M6*S^WC''PBH2D,[Y/R'E*<2GU8K/[>,<?"*@I#.^3\AY2G$I]6*S^WC''PBH M*0SOD_(>4IQ*?5BL_MXQQ\(J"D,[Y/R'E*<2GU8K/[>,<?"*@I#.^3\AY2G$ MI]6*S^WC''PBH*0SOD_(>4IQ*?5BL_MXQQ\(J"D,[Y/R'E*<2GU8K/[>,<?" M*@I#.^3\AY2G$I]6*S^WC''PBH*0SOD_(>4IQ*?5BL_MXQQ\(J"D,[Y/R(C> MO$!WM8$G0M$3CX:+?`>D^J3Z2HY*EMWX_-D3IR.66=?SGQ4SX<1=Q2L`&ZGF M1BHAGS'#..)4+]9G:A;,*-VW=\GY$N>4IQ*?5BL_MXQQ\(J$I#.^3\AY2G$I M]6*S^WC''PBH*0SOD_(>4IQ*?5BL_MXQQ\(J"D,[Y/R'E*<2GU8K/[>,<?"* M@I#.^3\AY2G$I]6*S^WC''PBH*0SOD_(>4IQ*?5BL_MXQQ\(J"D,[Y/R'E*< M2GU8K/[>,<?"*@I#.^3\AY2G$I]6*S^WC''PBH*0SOD_(>4IQ*?5BL_MXQQ\ M(J"D,[Y/R'E*<2GU8K/[>,<?"*@I#.^3\B))LX@.]NOS)+2#)'#1;Y)MFWU& M$<@CIF[\?JIJ[GEZ1VO%;*`R*%HA[KB5-.]X(A8\<O\`JD\F*.>'_4E\Z%48 M/^M[&_@P57_5@B6_*4XE/JQ6?V\8X^$5"4AG?)^0\I3B4^K%9_;QCCX14%(9 MWR?D/*4XE/JQ6?V\8X^$5!2&=\GY#RE.)3ZL5G]O&./A%04AG?)^0\I3B4^K M%9_;QCCX14%(9WR?D==KB8<%SB3<4;9PWL^/'D!ZU?\`D,THZ"CMX3Z<D14' M#:6"@9\)`W`R8MLDXDU(5;$*!)XP81\L*FCB#89`#E11)?NIQ_PSTCVD8*RJ MRWUI3I>=U.J>`H!0"@%`6J[6,RWZ1*)CW:;<=Z>GG[*I`FY45.6RY!3Q)'4V MRB2"42YC$H>^C5)23KFR]@Q\D]1/DLA+E3AD(4"MI:6F(:8G(B(G$$=&1R)1 M+24A+)ET],2TQ/+AE""<G$"@8)4D1)%0@BQ0H6""+EBX08((>`>&.-@.?0"@ M/GD,%B(&#D*'B,+B)D$%EGC803$+F=UR#PO?G9XA]TP[I?&U[8<_#G<G.MR@ M<,LK)1PZH)I-33S2BDW+8JJ>6.%ASJ9<X%<<I90*A"9#DKF@;7&+6,AAW'"M M<0+G86Y:`X]W"@8F"17)<1\32D=4$U.+74R5C"@HI.8H:H0)`W'[H:.IN8`V M"@5`Q$')Y@BXF`P[AYVL!'<[0Y'^Q412-`4H`FSS$EQFKK-=J8F*HJ.KG6VK M`8$5:R>H%;V-DQ,<#0(??A>U\BX@X/GMD)A;($Z--;5>O0D$9=;R5A8`VN)! M&Q<\10KXG%,D7R#53H``R<E9]V'PO92/%ARPQ0EER&C00X(H(6>`N&60'+,* MJ64/$$PVI)Y525>^?HM/,'"X)Y2[R"L,<[P*""8CG.]`<L13/>X8G<`KV$%Y MF%[7H!BJI>:F*BX*2?FL`$PU`=)Q.%\E,$@,+D`">%(6$N:#)BC89@AF<PK` MYBX9!XYWSQO:P`BK)2ID>P3%-/4<TPZ*FJ6!$X6-Y)ZB!CAD.0/8EQ!+E#H. M(@>0I4>P8X>.>%\P[6RMR@5"@%`*`^8@P0-L<AA0PL<A`@<<A,\0[9"C"8A` MA8WRO:UQ!1<\`PL+?:$$RQPQM?+*UK@</-62@E(!%$4T\-8-%1CQ9)S.%L%( MP2+YX!&#@!#(2QH8J`()@&,8#"R!"SSPPSSQRRM:X''/N%`2L3.:HN(Z;@2S M(AG,SZF2)XE!%,2X*;@9R,#AV`S4!<<@B.(M\+FQ+7P`L)E:]J`JF8P05PL1 M10P\AA.X@VSSQPN*+S,Q.Y!6RO:X@G<PQ,^9CRY<P//+DYN.5[`0K"T615JW M#[*A%A&L6]'T6M<4F@%7(X<3A]/;94Z,9,'5)44A0QQBI<T?RQ'4#-\0@KB! M!B"8WYMKBMU=2632ZB$2)53.K*4333PA($BH&E`H7(G!5++#%."*FQ1L`#`A M_(0/$E@")GD:RSPL!;.^6/*(5',8(/(+`04,/,P)<(##//''(87$(0?(,+'* M]KB"6`!&&OAA;+*P00@E[<S#*]@.'BJI>:F(BX*2?DL@DPU$9)Q.%\E,)/%% MR`"/"$+"7-8$Q!\<@0S605@,Q<<@\<[YVO:@*A0"@%`?,88(N$*..*&```'F M,,,-GB&$"$'C?,0443.^.`88>&-\\\\[VQQQM?+*]K6O>@.&>5DI+R(X*:FG MIV:F="34W`\<+%,E!1'MED`0(XF!`[FSHV.&=PBH%A!Q+897P#O;&_(!_1M4 M3$_*^!]1(DL[$CRG?$V;+ELK)R9WM924+XC"87L23[G"G?QOD[@4[Z+=W$#[ MN%S@!=3332>$KE5`B92ARN)X!3+FP!D\8EF'W7`X$=#$R+"%<@OUN)C`6X60 M?V[9WQ\]`13&<.QO"2K*B@T<3"8H3],:U,;QQ5EG,W],2.M,MK-I2S1`3>6/ M>A:[6CA)&Q1R5L@P<4Y14+8\F9G/$*U]+B3"[A;YI($<!5<1S*""$:'%6RZF M2&2`@".0N!T812#'R)8!$\P1L#0F0UL"^00N(M\+AY6L!S0CY$8F`H@G2@J> M9!`,%CP1D$0F8`-6PN6&`-89W`%!,V$#N`('GE@-83"X>67/QY0/OF,$'D#@ M(*&'F8$N"!AGGCCD.+B$*/<(''*]KB"6``&&OAA;+*P0(HE[<P/.]@/I0"@% M`*`IIY91TQ.,*ZDJIJ>DE>=WTJ'CQ4HG%N:-WMEWP='%#+`\TQ_L^7=!<>0; M]5?[?V:`Y`QTF7P+B#FRH&!L8$L5S&'"#P,F#/\`PX!?+//&PPQC_P#DA!WR MS%_P8Y4!\4Y62E@(8=(4T]5`+FS!`P,G'2QX(`\3S[D;)#"%A!<`C943]68+ MYWQ&`S^P+ACEYJ`B<"(HR2YK7]G\<A`'^Z(C94,*B\.N7LWAF`SWD\WLV"X! M$02R<"=NXY%<`F2H'GW8\";)%+WRP+@6N+6ZFY-OC31$L$U9*4#"@4(*:>>- M))C$HJEB9PL9,)AO,+$?`JH`@B9B$C&8.>`V()G$,3(++$2V-\,K7N($U62U MDM<ZCJ2>JD[#&"US::<+GBUC!07,`T!<<J(*%88L.'F"8"Y_/!%PS#$QQSQO M:P'S.+:*G$RR@H*Z60('!BA<H>.*!0J3-#J&6.!`$L9'%P!'&.YYX8%`PL\L MS.6>.(..=\K6N!5*`4`H!0'Q[Y+\AB_=P>0GE?$W?NN'(5RL`&9OB8OSN0#* MQ88(Q>PO-O8`4,7_`'>>.5P*>`O(9E'NXBRRDF&_8F.H770%$F*CV(%L1,S) MZZF&-D2L3+X!"YCF>[]Q"Q#$R$SQMAE>P'V+JR4</*"644T\TII/>WTJG%SI M8<\F=^AW&)_2!0(3(P3[[!QR%+=\AA]W#QOF%S\;7O0$7O*&(]D23X<EM?!. M&GKKVK/I08!@FK"ER28HR*R#3'<^*PG@WN"HW';"J)B5`.<G>8HP)T*W.YE[ MA7:L=I))1P(!\T6(D5M(.G3B4"NDRA12)I#,98X%UDL7!&S%'2A\\\,`5 M$+#(H+EGCC@-E?*UK@?<JK)9XVH$"2DGG#R0*"`JDRIPN8-I@Q@&Q@N"H%P1 M,QB0HX%[#@AF<`LQ0;V$PMEA?G4!_9A23BI,VH&CY(LGD,#(AX\8-``DR09/ MG]]YFS(@F();`KW,3OG(;/"P',S[K?'FY<@'V*FBIXL7.DC(!PF;`",E#948 M,P6-%A\,10#!<<++,(8`8/+$0(4//(,3#+'/#*^-[7H#[T`H!0'S[L%W6P'= M0^[W#N-8'GX]UN%CECAD+8/EY]P\<\L<+YVMS;998XWORWM:@.&15DI4R.X) MBFGJ.:8=%35+$B<+&\D]1`QPR'('<2X@ERAT'$0/(4J/8,</'/"^8=K98\H' M'!<*`9-$2)=<1S!U3)C*":3!4R0II0(%L\0S!XB7P'R%-DP!,L0QC(&`@(6> M6.&>>.5[6H".)JAB/=@F<#&\C`'#Z$0>T5R7B22U49*/A.*)Y(;DHL0X*.5R M[XL1">3'2QS)?*U@%0J3.IXE\@A![6%3IP:XJCZ,D?-PH`0Y0J(N(X9D^H&4 MDB7S4R6`YQ5)XYYG$PH%D/80PH%<`Q,C),'',R!CAGD*'C;&]["'(R5DO%3P M1,E)/Q6126:D&D9'"]E,1/#&L7$/X$+B=]9DL!\L0,S6(5P,1LK!Y9VSO;&@ M.988+(7,#$4/(8+`,40&V>-Q0PQKBX@B9AVOS\,!<@1L0\\K6QSN$+;&][AY M<@'\A&2XPA@($<$44H+B`;""%P$$*C9@!&<`3&&.5\@1<RQ@`QB&);'/(`8( M6UKAB897`^U`*`4`H!0"@%`*`4`H!0&O*3$]/`XI&GJD"2)A*:AI?OF5/GPR MX.!XZ5399T'S32QLUCA8<P7(9J*CF2!&SS#*YGCN0&.&1H>^8TO@?[H_29C^ MXRNJ<%S^Y=KHRSC-L9:Z:^[',R1"K(5&X5E#:>3%`XTWX?;#CLGB^$DGK\>& MXK=>9M<<8#@6U*3W^K%$U1"5D!\%3H*K5G;6E*[MU?!7\+\&6ML5K>+&.F\6 M*N<=Q/+,WPJZX&FJ>U!0/#$9@7W:4G1(G.0RT$N<FF+RBS'E*<T*+V/-TN'B M6+N;-=5VN2$P6G+9R)`J=6[VDTTO!4I?X)&4*Y@AHO%-;CA,X):7>_#SE8VO M+0N!4IEDGI&P</9AF%4_E8/+(HFEKF<@Q#0MPB@.0]\;AX9"<HG]'^K[&+B] M%4#3'J4X'M/#.BYTS'O:'+DD18CS=9%P*M,O,*623XN<0F#DM<1BFHB@)*@A M%D-Z(H91TD1V&C(R!<1WJ33;2D*FT[FTHT3IUXMNGGN1C_+15Q)$,\43)(>! MN29-BMDZ*H.HDDFSX2PY707;40Q@<@)V-98`&,Y'#3WV]%E0P3/HQH8!?>1A M8+`#G1,<K7%6V.'ZK7A>ZKEIMNV>)5ADN4'/#$,F&XNG&?MV^>+GM\P7`\R@ M0@CJ0DU3>.W#+.]\<S(,^H-%HZH-IAKS<3C`V:79ILB.5<E?D2&Z=+OY]Q<G MX6(_2+_NK]/`G[2UM2HWMLHO82@R41D@:V\/%#@G9\PRG.2=+*=<UX/:,3T+ M7!54\B1R-J)!GH$VO5)).@,C(+?:\JDSCK:Z$6>S?4'"(Z4?C*JNW4=?JN&T MW24,"@%`:\]^4]/'<6A*B8)$QE!/W]AP)//#%P1#A+`ZR94Q.ADS.>%QB^)O M``+$SB#GA8?`$.PMLK!X\@U'^K]K+-V/B76IZ;%PVH`G(L:$\1K.<=3J_)F5 M51MIDIMYM-U..DD.*4AR'!P7,:#ELIFFL4>-R9C!O81FHN=?5BH2RI-$N\`3 M:3VT::2W>?IM\_4LY-B!.VBUQGZ4@VU"3PDS;5>F)]0F!/R?=Q1Z0BPNW4F% M(;=0:%B34S0B.KPVSF;(HQI-3\C"&I2JY[`F\0'&K!K05HUMHJ)T=-M[5?.O M`LS(\0=31X##US9:BS%4]+C8`*(KH5;.IWMI)/<,_;@P8;Q]YF"9)0<6.0J< MF#G5D8JGYN,8D16CR:5-WP+EA?\`V+PW;/CB3&=)P=)[XVCV'V*26LZ(C:4@ M-#6V.$!Z%4E::#LQ@[%Q$'+A=M."^2`O+JMLG*DCL+!'4P1R@[CAYA+N5P%) MM))M)$V42VWOC_A+B8NZTQ*SH]GN#(.=:NPW7`2)J9OH\D!G)ZTDNB'XX=4H M[-1F]'G$**9P&'012,&P3*K?BEJ""8EABD9''1=((I#=7EE-"%;JF]]8W[VD MG1XWM5>ZM#XZY"NY<1^`FZY/#/'9)/QA*@"@X'(#F(\U%!&U$<QE!&<!\]A] M+"JBJB8(BLNXGQ.^AUH8<RHX7/W$RL#VS2V5_P"7_=/`X31,/*S9@9V"!C8[ M)JG&UG]NO(QCCE9QF&5A*>QK76$$T+R=^FV>GZ2MMJGD8D:R%3K,EM,I9"PO M@EHQL$+K\+$<=M%_RKU-^E#`H!0&O/BSIZ>H\-#>3!1)$SP976:6U$K@<+@F M<"ZB0:"F93SP&(V&>(1PD;#",$S.%L1BYC`,8#/`7#'*PU#XX_N7U*3Q$H>U MZFF.'+&,CD(K,3'+\<N..(><\FC(61B'+BY"64YM9IM='`-,T[&RFNHCO/+; M3.(2ZZ'(W8[:V"Q@J8MD4B$6TZWTWTW^'KZ^3/[9B(P]@IGFA]KPC6D^.(J9 ML9:O1$,^SY-::#Y>9]*;LYR4Y!3-@S24ZTMZK;A@)O&\<"*F%=Y0P<,%"8RH MGE\2H;$MSO?V\\>)@@[V@::_"CVCC1X1ZS6LK13M6]R>(+)$&/Q0?6%S;AMR M1DX8:3E-,3Q&:S$DW()QGI;/`"''8JPW%YK"K"R>33BL=&E\:\EY_#2_^7[= MYL-F1.8TS;.Y-F3ATNT)ZIP4KRC)?A"?!(-`5[S@.M--"\(CQD4%/Q3&G"+` MFQ.?R0JB73C['G`D`M!W1E80(X,;%XMW>G^:<#`(2.H]9<BQ<J0V(PVQ`FPG M$V@U]/Z#8\$0D]I,)B(VL\C-R*'$]&&@9!HS*6IHVBC&-GD.E&$U*,FU\-C) M:XF8/Y/=((0UN==JBU5XVE6GE%OKX''D<H9,:K;3%CI$L,QV9QI-=RD%BBE@ M12:*WQ]\=-L7^$U!<\,L$\N4FQ=G-OF<$W(+`J/DNHMK!@V,E;"[&J;>[=?6 M+^U/J9];6)Z??<GA>*N1(G=5#GS8)/"4;EP;G\$\;2;8TR.2#-WP[XQ)BF2Y M8<8OB)8$08``7/"^80>6,>[S^S,+9+R^Z-AE4@H!0''.$RB@4,D#Y8N=(G0! M2IPF;!#,%394P'D$.6,EQL<PAP!PLL@Q@1<,@Q`\LL,\<L<KVN!IPU*2->1. M%SJ&9V!:#$?K2(,/!*9\</\`)M=5:KL>BP;<1%%2"+:>66+/.K]TP)5+IZJL MX!)[2;X[F75%01F\47%4G%>E6^Y&Y?$Z/UX?S_)S8(C)HE`=0M53#];<B1KJ M'!;VFN6'&@.L159:6Z'0`]H,B5E)SFN<P&$8+61U?9DBW!CQLHH-SQ,LXR8" M)+"7?)*I&_B>RMRNW;6_/X?.K+\@"-"T?[#<0>-U.((J:[,>C"@F4&Z+%);$ MI&:LRE]K2I&Q!I.UBCH*4BD92218K45AV+Z=90)N]GN=A%1@4P!M$2HP-W1= M76]7[=SX7W>-7O(>UEQO(VD/!FUS!$$R+/C736&<I$#!RYHX<6:P0Y%+[`,8 M"7MECE8WL&LZ\(1\F-C<!1;ZROEQL1@<1BPPLOBF_&2XMKZ5(,VSCN&F@SMO MIMU'4X]C@=(TX?D".0G%"RC)CWFBUI$;CMF.5%\!NFL'&OK$)1PU7V0;$H*F M9]X*BR_)04<5`(D01UMQ@GL3S57A==3SN\+D9,28B$"DW\1QDM)%1<8,SX:, M+++B;R>GD?`<I+.-MLT)*%))H(7T/@N&8?:T>%%?`N#<;!JMJ,N^,0R(*%?( M%LCC:?JOT^NVOA>_$K+A8NO3[X?VLC=FMG11(;H>6I+$CV(&I,8B#DUPW.Z8 M::X2@X0[N'`<JVBZ&"`GJ3F?J<6%<;=02691L7,+RR00E\2]2;551WM>9L6@ M)OI[0@Z(&8EOT24R3(C5E,@.2AE`%6,OP1F-Y/;!EVG5(N:/`G5!>-)0RDH& M0SAK$0Z8'R[X&ORB9#+VO=X8$MT`H!0&J?6]`B/`CQ1TV42C73H@([[.9<>Q M%9P)D6>,CIFMFI+E52[D)7PP(**$K'BXEG(BG03!%SE3B@D*Y11*JIPH9&GL MAC9_Y2_B(<:L:QLDM%?UVB8VR$=K[S[L$9`482CT^@C-F$==T)AM5U2LVSK< M;8XJ:UT^<FYKZX`7NDD"Q-/1Y(V5448"QH8N(KGQ:[W?2+2=][OI?X5N\([- MQ/R='R='_$=B1[,V,XNP8DGZV[`,X@^HR.C%'V,N$WY#K]>KGG/$)*$)R6E* MRTGI"4SG::<`RRR7<MNP)5R73DKB&$03;%W[&MN%'2F&^JWJF%\"Q\JG&IJ_ MNU'L<B8-EY3/Q$]B]=8U%00029AMN":Y33&*<>*.5`#Q!MG_W-*QT/`+* MV*8R5,:X(]\+@B"O;'!13OV7;O79ZDDR7`FL2=/D!@0P6AV.IAUN?UW8M/GZ M3;:5)BCBM0\ZHQC#6;)QCF@'<X$YXW>[`ODQ3AU21&[&C,:B-9*3AUR-A\1* MNCK?7=NV[:+"^_'U(+TZR6\+<&)11[&QGP_]/YY/[3BF0[XKB\<-L2)G/+BI M(P=\,!CC@(;9K*<&HF5G#,\F.QTN8H'F`87%D,T-27QX*2IQ=.FSP,E-&&6R M7!J9(;.66RPE=(#WHXBA-I,UZ%BO@$<6TK?+9;P32CK?N`,04D]+%+`'4U(Q M3#MB(R834DLH"HI*>;*#,MJ_;#^R)*G#51EAH:OA1ROLU"92O&,U;(,=2),L M^;/QJIJ1">9"4E=8B<,^GIAM!C$575CY!G,<<KE>.$Q.QCW`ZJ!M?!4.!+;Z M+;MV+;XXO?M,^J&10"@-<J8@I1CBB3J6#!^C!''P]X$#65%'$ND*X^8T][+I M>*A]*D+@'@U(J1"!`(J5A[&R6!4M8L,'8L%;`7<O-_2)B^<!A"&7+LK/^GAF M&V&LR3!T::TPG'\6BM1+*2Q."M*"FQV+-SG9S6$"Q4F\B2!+\>LA#?A]/^E5 M-M!NA:&4#C,5&(J*(U>Z)[G5UK<J5IZWNGWJ2!.VO#-A-6T15XEBZ-':A0!L M3KA%SN60U`<KL03)+#8):YLH9`<I-*4S0C?8Z&_DJ2)499P\F!.:/$MRJ0@A M(EFK9KHB?Q)O:GY5V[/'=X\5=Z8]V="&[_$WEQ?+`I[:8>F&E$G/(5-*`X'# MY=JJ6^2JJ&L@P<,<U!8,)2,`2+7$[H:,W!(D\+Y6P`#L&V,5OM272/\`GJ07 M*VJ<*J^LC`AR;;Q:B;?RNA)LA.*57>IMXHXX$>SKE$Q-LUR]&SF6Q@5)E&&K M)[O>1N/<6X8(J+M=8+5;ZB8LU$-65&F+6CJOA6[<[J)/;M6WPJ6$LJCI46E+ M+[3A>_=@\>-O!J0RE0#*PRV)'9V3X&;:*E$36/.-A,Q3T1<;@4U$N3SP3LV" MXG4N7QL"I*9H4+KL+#XT=/\`=3U,K6$OGXRVCXISL8L?GWHY"7DI*J>SFFG` MY*3D<JG#YHK@9,ER^1<8R'B8,!*3@-`6-*]T<F=&(E%(^&5(F!'?&%^.WS.# MPX72.I3)Q%40XV9>3U'/:"/'2L+\I-;)N'%%<5M*=2"ZX";+75%(%&5#JL6. MN)/:1#*R2@,]8;I9'L62\29`J++9#9\.[]TOYYIFUVA@4`H!0"@%`*`4`H!0 M"@+5-L5DJ#J3'T?9S5.O9%(F4M'>)MO)!EU)*:<SQ$-IR8X1BF:L0(FL\,,S M)0J;"+CYX8Y"AY7QM>P$<I>L>MB&IF%M%U[@](638F(II72XG82>IF1<5$JK MXB&#Y1`"-#"8JQ$DJ8YB"Y964294[:_?)<(7`6KQ9>YF,(T./8*2S<>,8U(X M":41@9`,M)`'>P*00,	%*"=8J?DNAII(T<-F2A'`_8J7,&C`P(6`@XN60A M^JT91LO+AMSKD?,=:<I]NGF@><*LTT%17#K34P\P5)KFU8X0&/F6ZH`BB!'D M08QFFFPQ,\#!83'/*UPKJ4)[05"$E?0MI&AN*G_9MDLDUNV>T>M%U?0*=GW' MGD$7Z=2#_P!%DL^]R_.*D>X`9=P!Y0[]RPYH5:V.A7<HQC;(VV5#*/6/D?91 M%/3&:=R::#<VTDU)M:R4GMDS<AW9!(IEK6LGE$K,H7)6M:Q8,.@KUVG,#83% M"<QQZA,MIA/)1+"$U!VAMQ'P<QXH,5($12IQ>Q)V53184DEIA00`<WF%F53B M!?+&X1,O@&%=VXJ#=;#::"9@BM-O(;71@QS1H-);J2014S`T>'S-'3.!!-+E MBN(YPR((8-#8A6$,#B9C"Y9B9Y97`KE`*`4!:KF8K)>@B(*\6<U78*VE0-<; M@CF;R0O"("T#C?`)81,U0H:R2E0+#++`-0(W`-X8WOCB-:U[VH"RE37N`EMY M7D9:@^(%>0;J!%7N^U2-&6?>5U5,P+AIJG=SFT45;NH)X9,I@1.]_=\E,"I? M$N*'8`*V(M7LJZ%65X9A]P%F437HIC9;*1J6N3CDJKL5KJ19@%,DTNC9%64` M<2Q@FJ6R2"A5*N`A8D`KII8N1OCWJ"&%B)5X[=OB5]>8K(=2BWU=SLUJN-6: M1W-2:JHO-Y(6%%LJ(@61?,^WSJ@3,&48[F!GF#F:312P^0660=Q+X97QN%2@ MN&&XA=S9"9;LBJ-W.S@%T^Z`&FX6,V%IL@N95/*JFJ.()!4DLREAKJDI+JXH M'U?`K90.'EE5-F#`AA1."#!5XG&!@^%B[336$7B"+@&,C'#JBD,P%@-,)II2 M@I8'0E$\FMW!)Q1R)Q0#4E$,Z:*DPAS6"@=P'S$Q-#V$"KQ+F56&QEY<;KG7 M&8U%ERL_(?-I.%5;J0HKC7S-!]Q,YMU6.$QCZ)D8"_5#Y)A@M<8/[`E\L?-0 M'Z$Q60`Z3#Y`9S5!>QL#(L:>`3>2`W29+9EB1+,N8<&!.RL,!D334XID$(;R M#R+$"0%\;A%0,`PKNW%U4`H!0%ONEI-5\H9YL/5LM]X-I3PQ#4F\Z45-<"&H M!X9XB8!GDE6+&R!O#`3''/'$P7$QQSQQRM:V5K7H"P7CKY`DACI1F0(0B%\F M4)+"0T,P\8U9CF'1D0`048!'2A5I%.B)R6",,,*$GE,@2@8@HN>`-LA,KW%J MUL;*PJ0[$:VTQV$M19'*NQC*UX1F68J,ALJ#3,.'Z6^G_IX=NFTP5'%6OIW_ M`,:^E!">1[Z6_P#$N[]^?KJ$J51:CF/7(UPF.XF(S5YE`7*7!:"TUT14:X-R M`V)@C<)OGB(Z2'<D8QQ'*7P*6N6&QQ%!YF=K94%=^\_A0C:.E9+<R&J,%E*2 M(],"0;Q1U!JH1Q+=F":G$$=.P<R>8("%%[!/2$I+2R6*H":L53DT@1`L&6)E MP@P+>;D#P<ST%<:K2AJ*6LV'.,3,.1N-R.V@B(+A,)V>(J>.N(Z8CE4]6&(B MX8"$Q3Y<QF5SQQS`RPRQM>P5>)6E&+(Q6&RF,M6CEAJC.1#1,\C--1:#?.ME M(.IQGOQ/-IB"93Q4L@:(F[W-$S!4J$*5,W[N!G@+]J@*@KL)BN!6;:^O,MIK M:ZS1A3#06E=N(ZDK-4P.#<L,.VU(X3&.(8PQ>]RXHJ6,5S$!O<+/*^%[XT!= ME`*`4!\#14L>+&"1TN`<)FP!2ILH:!#,%C18</((<N8`%QS"&`&"SR#%"$PR M#$#RRPSQOC>]K@1.IZ]P&M-5%8JS!\0*S(;9H8^W6<IQHRS[503QG#,,P<16 M\:114A+-#AB"8#&"),`87`3/'//+'+*UQ:O;5U*TC1!$K<059JMZ+HZ0FNO( M&+476VC,EM):"M-;'Z9YK:5D<BF`)ZB@8^$3@YJ.<+C)UOIU9Y"W_B9WNXE7 MB<]!C6.6LTQ&&V&`R6XQA2N9$5F(+50DAIB$A"H1',F(W4\@71\RN9$``GF7 MR)W"R*@A%[X7!#PPL!_;?CF/6G@FAM5ALQLAHJ",U4<-OM=$1L$EL�!X=N M)N*<1+8D$$<Z5+'!D<K8)/$-%P#&9?(4(//$*EJLK7Z!8U5#BY',(Q$P%M03 M#**?6&5&S-:JH>1C@Q8R<23B@A(I`V93#9@F3',D!ALRHXQ4L**%EF`%EB+5 MO:V7$GQ;&22V5=E)<<L1-9J_B)BNM)/:+?)ME;Q%(E4P7%702Z>&E*6(B:1) M)XECA0:V9$F5*9<H!<$/`2I;3CUZ@)XI;:1'=!T/NI%9A(=-9Z0XXT9:XEM1 M.,][W,D&T04T4T40B1BY0K<<JEA%0!>]B_=`\NXA\T6KQ9)Z.CI#>24M`0$M M.0T)$3R20BHJ.1+)B2D)2<7#)IZ8EII((`F03R!0$$J2)%`0BQ4N$&``%@%A MCC80J-`*`4!&9F%8;.)#M;YR)8S-(+^4@EE]HAEAM8=(>JP`.6-`*KM314K( MDXU($R2)F`CRP"<-!CE"PV`MA``LL`J\3^63"<,QH,"8CF)(Q8!@M]+V+CLE MA-5JC`6<&*'@O6!%0DHAF%]-X-AM8J_,RQ^DL6\AXG.[622%BX5;VLJK+C"- M(WLJ6CR/&,PK+9XTIK5F6TD!K65U(\<,J!U05+(:>1[_`#QQ0.&SQHV;[J8, M'#1DR,)F,.+GD!\D>*8N;HP!AOQLP4,P6=)U\EAT=G-U,&+O522E="47@`*2 M3@,PG2?1%]>1CK@#RQ5C24MJZ>.;$**1P$8*Z%!Q@"!\'OXS,(3B/&2+JF2Y M>0<8W9N+WNM9VO;-8\*[(UE[Z4SMEE;)0[_[[RME>UQK\MZ%J\7Q+P1V$QF\ MJ+:X@,QIH:VYLQ1'&L([=1TQ4<`@YPVH#YK:@2)@&U7,90/GCPN1\8>XAPZ; M,YWN,9&SS$J6J8@B#SC9R91N&HI-,W-QA/#)I&(\:([9R=P!W)2`=.2"*CY) M5W&"HYYGPENY2ZF&=RR-8&K#Y7$N%7B2603R"41*)B62*)J:0+A%"*>0+`DR M)(J!A8,`L4*%\`P"Q<$/''`($$/`,/#&V.&-L;6M0'+H!0"@+-&CJ/C+B5'> M88C-,.Q<1/!I;=`S81!7$L-SFBX>#ZHMYD<E)01.8.-A]%&S(Q#FC"X]PY!, M[7"NI9+6UOUW8Q_!49,"PNSU,,R1.!J+6BUCM\_@;3#%CB::P-I*$4,8F4\W M:QHB/82PI0Q:PY?(,6W.H6K>ULN\C&$:I;S69'3(\8R=(;BL4LX'X1:2`4>: M[8@G8I!&RRZ"Z>&N*=B23ABF%+'3P_>R=CB2!YA:U@K"5W;CY'(IBY04W$MJ M$;,$\LO`F03W:KG&<W3*FZ2"4-8RF$7$?&3LS:V33C&.(Y`LIBF@28UK"E\` M\[6RH*O$H3X@"").6@7))4*1)(3B+D0$P!>?$;LYV+0":5&,&"R>"J+R,H'@ MR)<P;-#@%,!\0`1C)@4,/',83+(6K6QLO$1B,<5T@/@5FM41ZE0,2I9X"-Y( MS=)8M@5-D<"P#@R)W5@0,21\\3Q!#-XAXE3ILO;&P1@;#,0)+%9*"X'`[$)G M-5%=3LR+9.ERI+>2$YP.7(GA8,IDX%DF4!45G(J':P9:ZB9,W`PM;$+FXVY* M`K!%&1TPVLJ":DIJ>?<1\!5<!TB1*E#:ZJ%DI.0BRDLF0`@QE,^71$=(1@#A MW,<P$E)2<G!B8E")8$("I4`H!0"@%`*`4`H!0"@%`*`4`H!0"@%`*`4`H!0" M@%`*`4`H!0"@%`*`4`H!0"@%`*`4`H!0"@%`*`4`H!0"@%`*`4`H!0"@%`*` M4`H!0"@%`*`4`H!0"@%`*`4`H!0"@%`*`4`H!0"@%`*`4`H!0"@%`*`UUWDS M=.5)ZV@8<*NO5YCL+7^16#'*?C*,0RN_G<OFW1`,1S(HJYQ7:<[QVC%RX)V3 M!T<D1!;]A`RJ6$,.;,##9WM+\5P_R:HDH[6VJ[:;VL'@7?X-\2OTRZ-=F>?/ MFSI?BN#U)=@^*T'@WQ*_3+HUV9Y\^;.E^*X/478/BM!X-\2OTRZ-=F>?/FSI M?BN#U%V#XK0>#?$K],NC79GGSYLZ7XK@]1=@^*T'@WQ*_3+HUV9Y\^;.E^*X M/478/BM!X-\2OTRZ-=F>?/FSI?BN#U%V#XK0>#?$K],NC79GGSYLZ7XK@]1= M@^*T'@WQ*_3+HUV9Y\^;.E^*X/478/BM!X-\2OTRZ-=F>?/FSI?BN#U%V#XK M0>#?$K],NC79GGSYLZ7XK@]1=@^*T'@WQ*_3+HUV9Y\^;.E^*X/478/BM!X- M\2OTRZ-=F>?/FSI?BN#U%V#XK0>#?$K],NC79GGSYLZ7XK@]1=@^*T'@WQ*_ M3+HUV9Y\^;.E^*X/478/BM!X-\2OTRZ-=F>?/FSI?BN#U%V#XK0>#?$K],NC M79GGSYLZ7XK@]1=@^*T'@WQ*_3+HUV9Y\^;.E^*X/478/BM!X-\2OTRZ-=F> M?/FSI?BN#U%V#XK0>#?$K],NC79GGSYLZ7XK@]1=@^*T'@WQ*_3+HUV9Y\^; M.E^*X/478/BM!X-\2OTRZ-=F>?/FSI?BN#U%V#XK0>#?$K],NC79GGSYLZ7X MK@]1=@^*T'@WQ*_3+HUV9Y\^;.E^*X/478/BM!X-\2OTRZ-=F>?/FSI?BN#U M%V#XK0>#?$K],NC79GGSYLZ7XK@]1=@^*T'@WQ*_3+HUV9Y\^;.E^*X/478/ MBM!X-\2OTRZ-=F>?/FSI?BN#U%V#XK0>#?$K],NC79GGSYLZ7XK@]1=@^*T' M@WQ*_3+HUV9Y\^;.E^*X/478/BM!X-\2OTRZ-=F>?/FSI?BN#U%V#XK0>#?$ MK],NC79GGSYLZ7XK@]1=@^*T'@WQ*_3+HUV9Y\^;.E^*X/478/BM!X-\2OTR MZ-=F>?/FSI?BN#U%V#XK0>#?$K],NC79GGSYLZ7XK@]1=@^*T'@WQ*_3+HUV M9Y\^;.E^*X/478/BM!X-\2OTRZ-=F>?/FSI?BN#U%V#XK0>#?$K],NC79GGS MYLZ7XK@]1=@^*T'@WQ*_3+HUV9Y\^;.E^*X/478/BM!X-\2OTRZ-=F>?/FSI M?BN#U%V#XK0>#?$K],NC79GGSYLZ7XK@]1=@^*T'@WQ*_3+HUV9Y\^;.E^*X M/478/BM!X-\2OTRZ-=F>?/FSI?BN#U%V#XK0>#?$K],NC79GGSYLZ7XK@]1= M@^*T'@WQ*_3+HUV9Y\^;.E^*X/478/BM!X-\2OTRZ-=F>?/FSI?BN#U%V#XK M0>#?$K],NC79GGSYLZ7XK@]1=@^*T'@WQ*_3+HUV9Y\^;.E^*X/478/BM!X- M\2OTRZ-=F>?/FSI?BN#U%V#XK0>#?$K],NC79GGSYLZ7XK@]1=@^*T'@WQ*_ M3+HUV9Y\^;.E^*X/478/BM!X-\2OTRZ-=F>?/FSI?BN#U%V#XK0>#?$K],NC M79GGSYLZ7XK@]1=@^*T'@WQ*_3+HUV9Y\^;.E^*X/478/BM!X-\2OTRZ-=F> M?/FSI?BN#U%V#XK0>#?$K],NC79GGSYLZ7XK@]1=@^*T'@WQ*_3+HUV9Y\^; M.E^*X/478/BM!X-\2OTRZ-=F>?/FSI?BN#U%V#XK0>#?$K],NC79GGSYLZ7X MK@]1=@^*T'@WQ*_3+HUV9Y\^;.E^*X/478/BM!X-\2OTRZ-=F>?/FSI?BN#U M%V#XK0>#?$K],NC79GGSYLZ7XK@]1=@^*T'@WQ*_3+HUV9Y\^;.E^*X/478/ MBM!X-\2OTRZ-=F>?/FSI?BN#U%V#XK0>#?$K],NC79GGSYLZ7XK@]1=@^*T' M@WQ*_3+HUV9Y\^;.E^*X/478/BM!X-\2OTRZ-=F>?/FSI?BN#U%V#XK0TP;Y M\83>/02<PH*=K7U1E53,,EOOD-SMR/Y>9)`,FX#:P1"2\T=3FQV&,S)05$'& M$.XJ>`0P9H(/$H%D!F(-?/\`G5FXQ4E6]>JT.T)0\Q0"@%`*`4`H#!K5[^TQ MQ*/YFX?_`-#&J-#4MD/VO^^1'ACC`<-LH8'*F-J&>&.6&%+CA^#4BY<P8'/( M,3#G8,W+#+FYXY8\[#++&_)RXWO;DO06)8=5J=97BO\`Z3H]6].+0C'AQK"3 MFQ(F=R8O2;*KI:PIHA,RHF"<XY&*.@+Y0BK)49AXYC$7,X,`T1VN)5QY&N?0 M$=)!5W4/:'8U59;7L2W>/^,/'9O4U-X_G#ZV*@QG2:]Y1+08_5`ODGON*W6B MO%6/-%V$`P;*I)/7T)KG4EQ-\QD,$?0%LL(7'.)1HM]*)J.L!J"22'E+LY1= M-OCCQ,]F'OSJS+L8S9*T,2:3E5N0"SE%ZR*$V4EP%#Z:G$F^XG(7+@EW$DHO M?1Q4(M59Q(X%[BAW&*WP'$!Y^'.&;+5$]Y;$(//:N583@;8@PXXW#RE5O,.5 MWC"B2R3!DLBQF^D`LZBS(8#\.O)--FY,0$U62B:F\W4".SGB=(*V"6S6`"KI MQY"!I5:]*_>GVOIXGP5>(!'PT9Q;)K"CV1'XG2FKZSIY!*"LSVVJ-O#9B9<X M80"3J`<+K)W2W8VG"FN,LXVK:PPZ2MHUT%<.HN>9X\F"V;VG=2OK15N\]SV% M$GG?)HM6')*<L;YGBCE'CS:TQ`[X=+=+JT9R%*.K33?BT]FF3"2W,5<`@B<9 MCMYFR?TV4;*<[4%FN1<:2LM))<F;/@HUZ5QHZ7]47L3VJ35YG:]NP@>6B*+* M4JQ]'9)W)[3070T924W,R5M4/DVF=+/8F=0&S=>(&2H;]-IYDM<X@&":.EK: M4J%UJPE-O@J\'_/Y<49N<1>`ETIDHJ1!_,=+.MD!S--4?24VD%.?``LU)VO` MR<A&\7<<!2E`G,*XVFB9%>^311\L'*DN,HK&FI9274\6RZT_F/TON^I;JIQ` M6FO&3*"SV;(R0"8U_P!K)<49`/H;2508^-:R/%G1\X`<FCB]BV,C%Q5=Z$U] M#5&8OJ#2=Z)DWS;9<BNC+Z@LMP+/1Q7G:KX>&_\`P3<V-JF2MDT6Z8CR,]B` M%VJBOA\--@F%)!9#G<D,ILXDRCU1T=25G(W\#;"6VLJCGD])7FPD*+W:;<.. M3Z74,@`1&J?SQI_/(DV$IH:,_1^DR<P<3@[,<()$ZVEH8TW5%/<B2HHJ2MEE ME"5&LO.-'44VV*K]%&LPE+OD@O):TCGBQ8XFCAT#5'1[?7[F'<D;B+D*[5;% M-20Q^_H$A34O7R?K$FJT;*,@6<,P3).<5K);,WFN``JZ&DEXI1%1/3B:866+ M&5E8YYQ2"!($<!5&J6+<EX7)/#Q)<3-TX]60W.EI;$EM1DEFJ4ND''"Z8VV\ MK2@4!A$@PU-\J1%.2G:=;3B*X$96BL1"*-ETK*VX#4B-M*2T@=9LLIZ2)9\J M77[KZT^CX%1.[EQ&25BA*Y)[#(QV5<X)+O`-O``-VTU>".3O`C(V`>5";H2W M`:#QR;`9Y5;9%K@/^UF&?<)-TB!)F84?2OILK_//80H4XF<3*34;3T2X<V24 MD%Y0&K;2-44JP6K8VOZ_-U$B=?<DEIB>8D``X9(H9"8VO@*W,`?#97/$EY.; M+87#I,F"HBV75JJN=/6_P\/(E@+>:"SN"(K(QAS.%C.A_G(F;$EHB41.,A?E M$JR#;]!8I$QDK@KP*DI)R<H(B:L*2`0:([T*79>;C!<AI/3C@E']Z;Z8_P`O M\"VDKB!1(?CJ/Y;46+-35C>32$?KK1>+K9"<DH:@UY1'BPJQW'@>LY3((N"V M8E=,Q":Y/(W(`99KOE3%9^"2WK'SHMG;>KJ[\*U^A1<>(E%R8V7BX'BS'JVS MS:?VS#226>&>82H[GFW]4Y"QC:4'FU4NSR)8+6)5?-(H:<R4L<](*\(X4HDU M6PY#/?G>PEE]$^-_\>SQ.0\-P15>8M5&I#P`BU'DG;1/6!),>BDWP?H8P.VM M3)]G`9`:9T=R)[A3G&A.Z.&VF+IHZRSJ-SBSK;%U$DOI9D`,5*YM[HU7,E]V M9CR-(K+B1C.B2Y%7RS78S+23"ZYW"<!.&"J0DE.;WP<&`(%C9T7`/G8_JRQ8 M<;*][6P#ROYJ&5?<MK,!NF(X:W6K9_X8D?W+H:L2PZK4UYS]^DI:21-MGKS" M#-<J?)$-/?Z5PV!G1-*.4FGPN,J7NG,(,LDGDHDH+ERZJ"*J2+;$A>Z"T3B< MH(]UA4R-)0`TNRDXMX;%CCO_`.S85AQB^&F)AB('M:S<P\\<<\,\&U(V6&>& M5K98Y8Y8LR^.6.6-[7QRM>]KVO:]K\E#-B6'5$JO_9K"5=17A/&E,@L!V+(M ML4R-'4[T!RG8]..P)V)[6$(.M'M=M.GZ%#430A52'31"B@7#Q[\(7-]SQ+F0 M2OH_6FW97Q+6UOVU<&Q,@,9!&)@Q@YVPR)I0]GM?EY/`4GQ%D\Q<X(23"Z&$ MZ`3P`)MD+"-*1YVM-R%4@VGR0S#C#=B$H)!4PL)AP&J+'91[FK_7:O2\X>O& MZ:O-TG[,QD52F2>76FW4*9M9BJ$Y@!BTHP&["*LT&NLKZG84S@EN$W*#"<BD MOE^]R@C69,BQ=@IIV)\T*:/@XT2=]^V[8_\`K9BZX&'9OB$S;AIYM',1!Y,E M.V$UP@INNJ3=>I,AEQ,"2X/G*PYHRXT%WL\V\KY/"$7:3OD#$ST;*L*4422` M?42TC/VY\2Z*+9_4EN=:-.YI+<Z;<<*[$9^#3=*<6;60WKS)QAGOMH[$L>65 MJ.'NUVVI,]TM)Y0P6:JVX6P^D<RY7,C.%#=#7=(RDW74@^#`J&IMP=`6$%5N MNIZT6$HG%O>J56*>'D0FPN(RC'#VZIQ[D&Z8;T!10<VMAW!C+("PI27JL1:[ ME)773&5AQPPGJ,^(O=ZN=2[@D<T)HR1$Q52(8GS@YP\#C='QNO5+[M3EG-G) MUC&,],ITDXVQW$A[0RCK]&,B1RV6Z<308R/;/W)HT=G(Z=8JR=47$"QWFOMA M!?(CK(&<7LCF%=X-\*._H\!IG`HFY);JM-^&VOHKO&ZK)>7)ND-_;B.C5*-U M5'8:/$T#L";)0?I]`Q<SE5S\NO*0&I'C)9"<H'B:$DE"`$5NQ?>KD5D]RY&0 M5!O("(02S@BBLE!*75Q;2]*5^J![:HO!+9?*=L8J%76\(3:X\JSN\HD:(J6R M(VA-W25)2-%DA.9O+[Q5W"2!'8;`65UXI#6//Y50;-!UK!DN"CCMX15"E=F^ MY5WNZZ[S\#XC[Y1UD[AF0C1G-#E71'Y+\6(>*,A,?`FZ9+A%&NZ7NS$0ZM2& MD`A&[,\$^Z49>7;HK,5228<1PG-@[;E&X:"SY+?Z/>4$IQ((%4L4-624&551 MAJJ/K(XU*3RC13<62TFWM^&4P@APN:YMR%72&D.13/DD=:,HK86KLLT9P/O` M-$;^(JT&\19\M]WEM\.OE>5U2XA&NZ&A(;M<"@XT!DO:.G#+$8OA83T@HT)- MCUJNMGM)==#<7;KV91"2R`\@LAP#FY&NQ0`V0X?#<03!L-]W*;>%LOSV*[%_ MREV^[>JVU,V[R5$-W<Z,VZ]W`$W->#4O$(G";S33SBV$!+:5&@;B+2<(^3+? MS3A3BVFCXD4\DJ$3S5&Q=R`KK@I@@BG02KX7T_B)F1=N8I7IB2H0(8.`9X*: MPY&H..4";ZPD(+X:#1!>SC9KFS;[B5U9!/IR+<\#9PGT<-@GE](4&JFO`XY> M\4HZ)9=*F/[NW&7(DV@VM:TDB9*$'0/!6HTCI!)H-"R@_<W)LE*,WQFH`'C6 M:X"&LHZ2=C!MCI9-.3"BF#9>6A#0RK@6(@@BTN36UN2\+DG]RZG;O(V#D>27 MC'C9>0,WM!M;'&+1BXD)M'5UJ*6NI5!+/%P.D$@_RK35&JG++[C;O?%LOX^I M.0J]4L-$`''*K^*&%F]5V.E_G_'M/[B+>E@/$G#+/4\%9S2F^6NRD]RXLLF@ MF49)E==@1)G@RU%).%<P;@;1-5;"@%DD.Y82"\9EU]32&.I/PD\#Q9&%!QI5 M[J_>GE]_"A/6O6P[.V59QI]L)$>:4WB:D(WS(CS1R2"?`=B6'B"\F@82PU90 M/E')'+@L<9+\(G"Y<)#?"0O-C`R<4D%7#)"-4N?\PXG!V%VQUYU32VVL[!R< MDQHF.\^>3&V:54]?4<54\F%P31\N"&@)"L,'D6+F`!,\S`8(=["XXXYY97YM M`DWL-;FU''"TNC+7";)"@F>XWD"9&;'#H<,9LAP-B3?H1TO),31C"&B*G<$5 MN#=Y'SF`8`_<EU)SYF5^:?+W_66&HP;:3N3=^PZ]^I_Z5KM%*.R<*QW/D7ZJ MQW##QD!!09+?#>:\R?3;6:1XSW-564OOB4W(#WX3!^V#W5!5L.=]Y(;]FAZR M[&*BVG*NZ]:':.QXPW#7RRMCCM4S[Y97MC:W@S(]N6][\EK>=F<GW_\`.AXV M)8=5J7AN%L9-D!.6'WE%S+3Y6B<HW)%D389C)B0HGY2,1"S3<=)2H\87N1.! M!J[O9.,AX/928R@FJ`[[:S;5F\V!4YVFTBQX$DZU=-B6%;]O#;NWW%41MH>_ M(JGV7T.0(]D!HEGLRD#7!P%^]T-FN$O+D5PLY(I!<+F"4S@)Y-67[+Y1/4G4 M#BEER#3#+'!TL(TGJ1PZ)38L=O%Z$.8[LRB\]%(TV58+$4%UY%7H@,/:1`C% MLCRJZ8>,,9YGX[V;58_CY-/8JLAFV`[&^M9-U.(!+"D?9XY=[$6R[02X#>6! M7&DFJTWJMU=ZOV+Z5NJMI3T;:Z5'\YM%DJ+9PA.0F3M0O;28G959D>JB@BJ3 M6BY$<CQC7-)03[X`/-=X)B<33F=+2$M'3@P3L2G$"53FD:P^C2`4^+:J4I7Q M]+_#9B24T]Q'B20-OV;)R>P"DT:K2@T8D(+J2,I-F*I.6IL9$>N^`EW(JO+" MXJQ^`N')1;K8?R&H.5RXM4XE*ZV5<2DBFB68(..RG]2KXW-I_2[$CI(W_<[S MUKT_=#526@2G?9O81%U'=A4[WTOLB()K9Y"2S>PIHV0359,/N1+:%H2DD-@I MEEY%N[1CK)/C*1=%4QS%PHJN^Y*J\4Z4];U7`R*8LW/A#W`<^HT@'$UXAF-? M$C8J.)!(HX;?6LD4"0#4:OEF/E,)F!D0TI)2T9:ZXUW(@E$$NJHR\HHB@W@C M[4S<#F$I=7QI]S"(GOU-J3,+O9JH?9JJ00^),W].D](6(G>S5;1J*'"VHR6S M3E,[`#KY:+$66T"SX5CB(T5,8=0DX=&1V"U&2&ZW@D*(8TXJBVNL;6U7;=U* MTN7E?>9J,[;MJG#SC:05GM*,B@/[94JE,1KL=#;CK`:.O;O;J`]\@"2P^`T9 M;3F4I/Y@,XNO_3A!9?*NY4@XEM4$,=0Q3Q++]+K_`#_Z?#C:#.XCD)/8VY3Z M.35LV`%C"0,8/XRLLI&2YD49QB+.<6X1:Y=T.AO"-W(K'(9I:-YOX9JX@70W M$5.V(G"2<75A*-7;_6Z^E_J2BS-Q8YDE-;2A'[6E9T8+A:,QG`"E,`V<4XNO M+;G4F>U,I%;_`'^`N%2Y%:1E8T\#C:).1,9C43Q'\Z%%)8)M.=)P*;;U=7UI MMI_+]QBS!W$I0Q8)1WC/[7>R>]RD5&Y;5U!J,Q,P;3W:A28\8?5U:.T4)YK# M@#":SF6&PGJZ4YPDE5.%U4LKMGPI2Q;J%"N-]%_U=6_KL,F$'=2.W*H'&FBL MJ4#TK)BM,26K0P$E-'.0TX*"K,.\@*^>6+VR9)])*VE:*K)0J,\U,VL#2*VR M9(EF>P7"R,)3Q5,=V_UW/<1!'.^38>$L/>Q1P)KTA]Y,/3%QZPA--OC)[O?B MOLZE36N?1@N;B62!<<?-`C0-SY_3.#2#:Z&F.#Z:##'(&,\A:>C54_2FM"]% M_B'P&WV\L+8I.05!0:*7,"U(C.36ZFYN^-TR!)$:\6RT;=2>;<!(B.$TW8\4 M+FY-53<UG$@&K.II_3K;S+J@X677=NOW.NSC_AWW$OM?9QD.E].2-"[?>R6] MVE+*9$*X@+2>@E#A9668ARF]+=07<7(:P-,,^Q@S%RCB+YB9&'"24VR`1$6D MI3*%!*75\*]:<:F.,Q;@KL$;1S&A/LQ@9UZAS1XCM4XB+<:F"E(6"B%)KO9C MAP)J`RZ2***$GMQK_3@**&G!+(RED;Q!5C0%RJ1<5*JKOM4)>3-Q&,YU5S,! M!;$@DIC09`>47CQ>J(;8%=Q)?:$6L"8CSC&`"?)=JG&>%'LM18Y+&\7J3-B" MOQO-0T"F/`R9120E-_A7K3ZUX,A#6#B%,Z2X;U"-/[,98F.<(=UI6)%#8*:E MB(#1EB=(*;$N%D90;@SD%>2,A*V"^0$)+)=&6VLVP'.UP'2Z$O$X(:"%<:.6 M";VX)T\OOX&5L![&-'8E/="FS6X^4,!E.-88[L!>J.F(9Y`D%LK2JANIA*!` MLN*9L-R-D5-*GE2^`(B(*F+Z"<25E3L;,!E!&J?7T=YTTOTBS^\$3_\`Z`1O M_P#OS[H>D-GK]D=ZVAY"@%`*`4`H!0KW]ICB3_P`S</\`^AC5&AJ6R'[7 M_?(SEH9.OEQ2_P!'VU^XC,OL*=V^Z<X"DZ[D1"<[KS802I\.7HZ*6P"."B)^ M68!-/E9-(@`IK?>YD(\6,)N6)%T):X"F(GT</2':.":VI[*[GCJNJ-T.NVNT M.ZIPZRH'@=E)C"C-A)F":AH:;A?(487*_=5!:6E`7G'5QQKAW(927EY2&,** MLHF!S9L?,3/S##;;;;JV2^I)R>L)Y](5B1522U0D:3E)./`!&B*@GG@,RQPD M<*CXY@F2IHN*(`8`&PS"&!$S#$QRPRO:XAC'%NMF.OC'2&5%LBRPO1_&Z,,2 MB>$G8ZV@"ST!,1B(V#,CP!_%HY%EG)EH-\":.D!NMZO+)-12Y--/@K:.G@)% MQ6ZNKVO:UI6GT(O8VF#>58=<;?>*<>B%WR7LDC[=+J=%SM)ND.-Y70I9;DQ( M*:U%QYM`\A*27@ZVN56G@GCLK%L+;J<\@JB4DD;.+`U@_GW*W?C14V4KYTZ; MZ4*DL\/N$EQF+D=&UJ0\&*=,["*;4;(*LV,B,8.#:!)>Z)+SBC\P:9YE3*J" MLG2A*!5$*.0^YT)J%)"<*:W4=.2@&^00PM/Z?[=GT7`^K9T)C%G$FVB-M_RT MEM%H3DVMAVPR`5)@Y-5`D=%0S:6N#(I(6.LS:0WY!5E)9?#X;B8>*)9I^+R^ MXT`%NC+:F"9"T^E*EH'.&E"IYNM]NC/^:P[-!EJ+3:"V2<C+3'"UU,?81K[/ MHD@(ZDFQ\4[D^6?+S*:JRVS!@$RVOH]'#2%YLKI,ZIXG@M.M;OXJ4O\`!DEN MK3)LO<VE+3JF";5IW%X9FV"7(\C2G&UEA],:>LV$.[[+Z8#&`;/0E%,.1LU# MK7O'#88B4FF"IZQU)5"ZJI`&1*TW+:GOVJM-_BS^6#I<THP<C@6V-+DZMU)> M3<:*8]V0FNIIE&H[7<QHP;D/-J5SF19B@NE#D(JP6<STA1LS'.V&.XA&JAGW M(R5<Z3[OF%:^FQ]:>576^OU*Q'^J:-$CV*NF,7R[6LG+\G.Z6)C;!,HQ$YLR M^YG/%:+&MA7"VVXQ4%+23@!]MM^01UQIV;BBJO`DKG')BX[.8SFG!6N[P6VZ M_P#B+?ES1V.)F?<QR`YGU*::J3?#<:P6[$YOJ#$+(Y%BQ2_7;)#4Q;X:G'ZN MHE%>SF?;M$4E%04E2QTDLYE+%P<2"5D0%4FDE@V]^])8^"*8;T/8N,DG)A;, MMSDPY0/R-(S]-/)H+<>`'1TJ6V[%+:D2,#"8M1FMMTY'3C+0C&"EB$=1C+U0 M7`U"*\V'JB*>0Q@02MU-V'JW7JR[<=,HI!75M4)JKX*(ZW+P,_YLK)71U1K$ M)M+M$!I`R22^GF\K./-8QS)I[OS25%Q*#3,/\C@\33='5S:H,?"KIZ4KOI@8 MZ^0J=1)!UPCAKN.1">N4-Z&RSI\HN<%?CW%^*Z&Z5[7XHU6VKC&&IWQWKX"1 M`L$%AVM)%;SC)JYEN&$U0Q&,K1]/%KM>]RK]77#>3NGZ,0HAYFR+<%=;<9>< MF#30C1JEFV[=BM.5Q6,(Q,'LVB"BV#ZL5,EBXGA.4;IY:464`^,;.K%L?2.0 MN0@EI_:M]6MM-I8"]PXHK7&-%$>ARI.B,WH?@5GZ[M[!,7(Y''465'SF8;O9 M2JKXKL7K1$N[D1=C9HF#*PV"+;*NHJF`ICW3',F%R90J+:VW*]UXUP\RX<-# M64ENX@_69,L\1\\4F0IT?:2NM-8C*XQ%.V7=**_)QCC(DXXJ<*4JL!]OQN(+ MTR"72"J[VLOHZ<,QW>V2A,N3#"UNHJ.G2Y/_`**DDZ,1NWY';;_0I`E]-36A M/JMLRW8VR<#45V,G2\Z(K>\/O=>L<<+(6)&-%'RU9$=YYR(YV0#*=X5K)QTH MP".KF#)@82KIYJC\JIKZ(S5H0XQP(P.4-`E#5R)H8L.$6.V!#,7)F!`LL`35 MBXWZD>Y<2^(M@1?U8M\.9G]G*]`=6>0_T4?5:67X\9.D;;K;MW/V0'*LN]XN M=8/Q(84UYQN`^.IJZH<$M&F.'=39TR*+W,+`,`''+$$`(($,,/$>J[:2224: M+P>IV&-3X`%U9U]C77VTHOV8DR*T$-IMM[R;FB#/8=JIXHF#<1%<XWTM&3SX M;82;E6\DF_H\(YDBIJ<$?%.'`1CI@>;=6W1*NY;"1Y3CLK*K)4V.><3D:I14 M-(QH59:=V_BM@9(BTGKI8,MDYV^YTC$(<VF@!&N[)`XF1;(7``0N+EB-@(G3 M^8D0OK4>*GK(SVF,H*YF#,$A0(NZY.J3H_/I2*ZU*/UE72EHF;%R/HBPCYNY MJFTXT&T7(,D#&D0HN*I7`,8+!(LDBU=*;JUIX_Y*,_M+XK?+TCQ_$59XQHX8 MZBZ5X<)#12(SF5@X&#,2(WD=T(SDS*LPR<%P3S31:[E:OT*;0PFXZ$%.52`. M-@Q"X@5=&L6G?BMY9$H\/R,)I2Y=+R;(TONEPS-"2#KPY7V*<C)+=J;$R&Y5 M5WB-Q!R0XN3&[@,N.%8-*"PLKC>75GG8`!)1]*!QS#$%4J4HE<ZTO\L:]215 M[4QL.Q6<SO=DERTXI,6(O=T/->43:HR$]V1,QG]DFC/,M%*8WV$C,)KKSE-H MJ&:6'@892J[3UT)")F%O-+1$H@3$KX+&G_=X=.G4/.F1XHDK,J=05"*H_DJ* M?!MM)C'2F=(L:2RE-I+>;%DU$\#1\G`US>3/;2F21TTXA$TY522QDJ%@'W0# M,*N_QO\`7%$"(>ETA-25861A7LDRWJ#`@;56H0AZ0U<^@O&$7ZRDI1;#5<&3 MK1V@XC6P*4T6JJ#$8\2),5F\I,]5*DW.LN%^.TB@N-O"U5'=23VM;'7PW>GE M<C)Q]:V-=VR^BSXWG@_8IEY-8PD7JKSCLRT<Q7G&UEL9SI[*>:`_V<_&HL)R M`Y3:@NME5#02;I;AM8<!=&<!),<;@(*8E;J;56N_;Z4+->6ET7OT^^E!S.*1 M%#.8(B3X,G@N(MH>92<HT3%UZ+I-OOT`=LC63\0+27)2"7,1WDQ!B35?*JVB M&11)2FF6;@5:]'5>#\."X(X:=I/':2\4A\)[XD\NLH<R39.2<'8ZQ,R`3RG= MDJ+"=I?(N)'^>8B"EHBH<%;)#(:YDFH98#JI]9`#P+6"OT2]$8\0QP_RS#D! M[,9:/O<[K8WHQT>8,;)"FMQ^>$?P6H!95,-O"2,DYKE7-;%(6"S*,=S11VPF MN\-'5"3F(G$@Z9(*XM>-6^--AD&UM'(F9B4S4)O+\@%$:+FZ[67$"6.H-0^2 MBEB/IYM-WNIC-<`^SC.*PV50LR6\Q;E9`\-39..2YYGD#I4@M+62@(Y-_P`W MJY/T\"Q3'#8@*[45&0DK4C-AJ*$./Z$R2$VC[)3$MLMN0I<'FT^I--/\`QB2 M"H-]]"@YLU#*%[1ZV6ZGIK3(,BS=)`IUA;3\[ZU>-*?S>37&VL"1%TBN]^-^ M5IB-I3Z<F;]<T7JBTS;QN>D\ZW$UM."1PB:4Q4EVDE9T@)N"RNM(D\`(JS=9 MDTZTZ/4UP9A*`(C=?YNP_EY9$FZ.1Q*CZFM_KS[E1.5)Y9,&L!XIZ&?80"01 M;^O+_<LE1UBW0U*/510)'`7*\71=9,J"DJ_2A!8$*9!@]Y)0I`*W)45U<=ZH M]^%.!;BSP]XP4G2Z'PG29-+6>+S59W%<K@;JO'>)A5:6QQ)@EY.C8R068S64 M7-FFCD8,5;03.27=\-M80^[I+R+EE-8**`MIW;+J=*T\=[\/#87/%6E+5A16 M5C<;3'.K=0%]):(:XQ`U]@FF@IO5CQFV(D;\I"`FXV&72CQP9S*:(2PC)J\1 MB]SJS?)K;FCM74C"D8/"-UV_?%NGE5OQ\22(/UJ8VOBM(1^/5AX!)4F*#<<+ MB:2NII:@VL'PC-A+:BY(:>&&B%5@%Z2.41$I6DM3-+)PJ['46,.P<@7<"NN* M"F#;=*[OY_UAY&0U"$);)00U-H(#E[7=]*;A1F;,[!<<=N56:9E-)N9/1G,G MBIQXVAFEA+6TLNI@@C99E13Z0HE<!;8W&*#8\N%Q4W%IK:KS1IK-^C'Z.ZKS M_$>QC"F/:Q;><-/A%?K:27<[HB.-A05D(QWR5*KA5&A9#51TX7/[)@,@L)QG M+'S!F@K_`&J'H^UE)--1H_!ZG8XH>1'2S')99DQD2?=S.9/4&,VWHURS<(7; MG@RN)KZ,M8ZK9KN!]N'G#D:*FV:@F$P5&<*,&#D7&P-`G`3(P>8>'\WZD&LC M2J$HT'32T>D59HLQ/FY_;`YQBF>#P\>GY"D5H&V>MW'1U9NJ)\BW"(*HMKC? M;2$K)"4BKRP,.5!^CDQO)B,+:;VWW)5\$<1`TS:#,>$BO*/I0F"/!I)FU/GY M2;K24(\*LY%?@$490VM8(+948W4T[P?>+4P(*#K1UW!=P/O)*3WH3&3W'B:/ MF@KLJDZ*G6N/\5Q:J5H#&3;6XM=+1D66VDZXKD+8&6"+C1QXN,&W3).S9I8- MRR[78FKL6++=$-*HBZ?P2TMN(C;;J(#<`(@C!XEPN:+:VW*^F.[9O)%;>H48 M-<^AJA)3>"@H`2LXYO?IUP'6^X#<TRFY&&9C6[JE0TK-HT8/^#S/'"1F<@-, M5GM9IIZ4W4M#0R:,V&ZFI8E=/)5K1>I98VA$,"*$L*)=8?J9E)TZ,C9E')I" M@U4M/AJ>&$V&\TDJ2(=*D6>!9!5%9';"8"\4MRY.YM/7$=?*NA$5$YV.DBLA M5W>"IYK!_P`^B/S6/7^7X\D22Y0V)<C'F*7'0G$6(DSL@YJ+85CL/MA>6UYC M,'"'<&R&U(T`2CKG751T&FZ^G<:>[F&P6U8T"2+MY`:HK:=RN6VGCY[_`+<6 MZ49X?$4JH[]*.20)><[)E#9=O;8OR-%54CXJSG)++0/Q^L-/(Z9;\;HCUQ:C M?7(L8*R7;!=X`D5(ZW0,%^ZP1.JA,\%IW8I43OK1UKO\7Y;MQ<Z+I)';:>6$ MD-M]2D@R,7>\]/$D]B"@QLU<D2V346RNRFQ,"9Y@'&\<9*DY60R',EE51$4' M`CK3111RCCL7^D"I\2O"ZZ_=L>WQ98E^&["*0"1`CAX2W$`;:$@U2CGQ>KS/ M[I%[IU^8)R)F0[VD,]&(\AE!64HI4E*.GHDOP1Z,MV-M24[J35NL*1]6,BVG MOH]M?&KK?ZWJE"5TG4Q#0)6"F!#F"<TMQJ[9:S<E-.`=+6&;\VBLE4<"TU7' M(),XR#1Y(<"0H.=8PYT3J<9(RDWQ"3'649282.CM<@)7=1:;OMOKCMO(<%X: MD-#,]"9.4A3/9);T/K<)$1L5>.K'\F@OS"V9M4#)@:\8W`$7,G4TD9/!.8%@ MB83?"&*?1UU$P(JW%M.M:+;7I0DA/TECM%DA1F%OOF44&45!\RR],'JG*#&S M42!2;&]&R!(+%+)Z@P#R`99"D)#T8.$J45T=37TYR,M*4"KBP"%42AX+6ZBI M==Y5O\[WQ+83N';`:`:3S+6./UJXM9-UJ3HV+HRP@7"BS+5(H[TN+%!GC*C6 M4SQT^,B/YZ(#SN^3;R*.U&<BH34B=^[VSQ$M>6^OC7_K=0A>8=*G\:DUB&(I M,JR>UDW&3W@I/TDIZ[GGF?F:89"3'J_W)(B/.^K\XH(3<,8M9FX-93A]*;KE M0;)YYNXHX+<*(/>HJE<Z[Z8W);E22\=M:]3)R,88<@VQKYV+DMFM=N/8O&C> M@1NKK5=JBLWDEG-QR+KNN_W0W!$9*2VJ?&4%\0DUF_8RY%IK$SCO3QW2J)BP M2M@(W=15I6M'_-/(ILW:/QM/3PEMY.Y[R@EFIHUM,ZK.U);*@QRB.7BXXO++ MC-9HEE9@K2J3<HRDX%B]U8VJGP,`#MP@D\/O<KD`"=+O&IQS>C;"SE5:G!'D MR86O*RW*RO+`[P0E&.^^"YMS0E$\`NYF`I"Q&JNW##%=3"@Z+15-.4T906B3 MG:1!RMYP(BED,((%ITINI3JW]6RFP;H2P-<Q6L6BB6YW;[60([B./5IBY.5C MFFN_L8)923',5N]W9YQUBY"[P;S';;2:ZJ.RW"SV^_$5HH"?(S==Q4`V$=%< MF]M-]^%75]6_*I+4-:QLJ#'D^GHRW&^13<GI+3\8J.M*2";0GG(#7*&4XU-B MR6)MM..^-YZI(A!)?SB(J!))<Q!OMO`PWP1D)/&!$;KMW;/!8>1TX/TBS^\$ M3_\`Z`1O_P#OS[H>D-GK]D=ZVAY"@%`*`4`H!0'GW<9GBJ[[Z'\4_<",M4IZ M$BECNP_!#[<"'A&<.O6R@ZS.LD--\=5^D9%CUW*Q6^:0@))3O(D?+IV/>G=\ M2F)D<R,,.J$(RA%R57>MK7]3P9K0^L:<9GKE#>P'5SX)4-=UV>7K+4?6-.,S MURAO8#JY\$J#NNSR]9:CZQIQF>N4-[`=7/@E0=UV>7K+4?6-.,SURAO8#JY\ M$J#NNSR]9:CZQIQF>N4-[`=7/@E0=UV>7K+4?6-.,SURAO8#JY\$J#NNSR]9 M:CZQIQF>N4-[`=7/@E0=UV>7K+4?6-.,SURAO8#JY\$J#NNSR]9:CZQIQF>N M4-[`=7/@E0=UV>7K+4?6-.,SURAO8#JY\$J#NNSR]9:CZQIQF>N4-[`=7/@E M0=UV>7K+4?6-.,SURAO8#JY\$J#NNSR]9:CZQIQF>N4-[`=7/@E0=UV>7K+4 M?6-.,SURAO8#JY\$J#NNSR]9:CZQIQF>N4-[`=7/@E0=UV>7K+4?6-.,SURA MO8#JY\$J#NNSR]9:CZQIQF>N4-[`=7/@E0=UV>7K+4?6-.,SURAO8#JY\$J# MNNSR]9:CZQIQF>N4-[`=7/@E0=UV>7K+4?6-.,SURAO8#JY\$J#NNSR]9:CZ MQIQF>N4-[`=7/@E0=UV>7K+4?6-.,SURAO8#JY\$J#NNSR]9:CZQIQF>N4-[ M`=7/@E0=UV>7K+4?6-.,SURAO8#JY\$J#NNSR]9:CZQIQF>N4-[`=7/@E0=U MV>7K+4?6-.,SURAO8#JY\$J#NNSR]9:CZQIQF>N4-[`=7/@E0=UV>7K+4?6- M.,SURAO8#JY\$J#NNSR]9:CZQIQF>N4-[`=7/@E0=UV>7K+4?6-.,SURAO8# MJY\$J#NNSR]9:CZQIQF>N4-[`=7/@E0=UV>7K+4?6-.,SURAO8#JY\$J#NNS MR]9:CZQIQF>N4-[`=7/@E0=UV>7K+4?6-.,SURAO8#JY\$J#NNSR]9:CZQIQ MF>N4-[`=7/@E0=UV>7K+4?6-.,SURAO8#JY\$J#NNSR]9:CZQIQF>N4-[`=7 M/@E0=UV>7K+4?6-.,SURAO8#JY\$J#NNSR]9:CZQIQF>N4-[`=7/@E0=UV>7 MK+4?6-.,SURAO8#JY\$J#NNSR]9:CZQIQF>N4-[`=7/@E0=UV>7K+4?6-.,S MURAO8#JY\$J#NNSR]9:CZQIQF>N4-[`=7/@E0=UV>7K+4?6-.,SURAO8#JY\ M$J#NNSR]9:CZQIQF>N4-[`=7/@E0=UV>7K+4?6-.,SURAO8#JY\$J#NNSR]9 M:CZQIQF>N4-[`=7/@E0=UV>7K+4?6-.,SURAO8#JY\$J#NNSR]9:CZQIQF>N M4-[`=7/@E0=UV>7K+4?6-.,SURAO8#JY\$J#NNSR]9:CZQIQF>N4-[`=7/@E M0=UV>7K+4?6-.,SURAO8#JY\$J#NNSR]9:CZQIQF>N4-[`=7/@E0=UV>7K+4 M?6-.,SURAO8#JY\$J#NNSR]9:CZQIQF>N4-[`=7/@E0=UV>7K+4?6-.,SURA MO8#JY\$J#NNSR]9:CZQIQF>N4-[`=7/@E0=UV>7K+4?6-.,SURAO8#JY\$J# MNNSR]9:CZQIQF>N4-[`=7/@E0=UV>7K+4?6-.,SURAO8#JY\$J#NNSR]9:CZ MQIQF>N4-[`=7/@E0=UV>7K+4?6-.,SURAO8#JY\$J#NNSR]9:CZQIQF>N4-[ M`=7/@E0=UV>7K+4?6-.,SURAO8#JY\$J#NNSR]9:CZQIQF>N4-[`=7/@E0=U MV>7K+4?6-.,SURAO8#JY\$J#NNSR]9:E@+&X>QV\"H=F7:*1LI0DDGF`R2SD MR:;'9MPVPB%"ZBEI?T1'[9:B%G8J<7%0;OS-+R4!N^NYF#0H0)?`(9E%1=(J 'BV[W]3__V3\_ ` end </TEXT> </DOCUMENT> <DOCUMENT> <TYPE>XML <SEQUENCE>15 <FILENAME>R39.htm <DESCRIPTION>IDEA: XBRL DOCUMENT <TEXT> <html> <head> <META http-equiv="Content-Type" content="text/html; charset=us-ascii"> <title></title> <link rel="stylesheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript"> function toggleNextSibling (e) { if (e.nextSibling.style.display=='none') { e.nextSibling.style.display='block'; } else { e.nextSibling.style.display='none'; } }</script></head> <body><span style="display: none;">v2.4.1.9</span><table class="report" border="0" cellspacing="2" id="ID0EUGAG"> <tr> <th class="tl" colspan="1" rowspan="2"> <div style="width: 200px;"><strong>Net Loss Per Share - Instruments Excluded from the Computation of Diluted Net Loss Per Common Share (Detail)<br>In Thousands, unless otherwise specified</strong></div> </th> <th class="th" colspan="3">12 Months Ended</th> </tr> <tr> <th class="th"> <div>Dec. 31, 2014</div> </th> <th class="th"> <div>Dec. 31, 2013</div> </th> <th class="th"> <div>Dec. 31, 2012</div> </th> </tr> <tr class="re"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> </tr> <tr class="ro"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Total shares</a></td> <td class="nump"><a title="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" onclick="toggleNextSibling(this);">10,067</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</span><span></span></td> <td class="nump"><a title="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" onclick="toggleNextSibling(this);">10,197</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</span><span></span></td> <td class="nump"><a title="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" onclick="toggleNextSibling(this);">14,866</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</span><span></span></td> </tr> <tr class="rh"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OptionIndexedToIssuersEquityTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Options [Member]</a></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> </tr> <tr class="ro"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> </tr> <tr class="re"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Total shares</a></td> <td class="nump"><a title="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount[us-gaap_OptionIndexedToIssuersEquityTypeAxis=us-gaap_EmployeeStockOptionMember]" onclick="toggleNextSibling(this);">3,298</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount<br>/ us-gaap_OptionIndexedToIssuersEquityTypeAxis<br>= us-gaap_EmployeeStockOptionMember</span><span></span></td> <td class="nump"><a title="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount[us-gaap_OptionIndexedToIssuersEquityTypeAxis=us-gaap_EmployeeStockOptionMember]" onclick="toggleNextSibling(this);">2,449</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount<br>/ us-gaap_OptionIndexedToIssuersEquityTypeAxis<br>= us-gaap_EmployeeStockOptionMember</span><span></span></td> <td class="nump"><a title="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount[us-gaap_OptionIndexedToIssuersEquityTypeAxis=us-gaap_EmployeeStockOptionMember]" onclick="toggleNextSibling(this);">1,791</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount<br>/ us-gaap_OptionIndexedToIssuersEquityTypeAxis<br>= us-gaap_EmployeeStockOptionMember</span><span></span></td> </tr> <tr class="rh"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember', window );">Warrants to Purchase Common Stock [Member]</a></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> </tr> <tr class="re"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> </tr> <tr class="ro"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Total shares</a></td> <td class="nump"><a title="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount[us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember]" onclick="toggleNextSibling(this);">6,691</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount<br>/ us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis<br>= us-gaap_WarrantMember</span><span></span></td> <td class="nump"><a title="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount[us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember]" onclick="toggleNextSibling(this);">7,692</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount<br>/ us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis<br>= us-gaap_WarrantMember</span><span></span></td> <td class="nump"><a title="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount[us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember]" onclick="toggleNextSibling(this);">9,009</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount<br>/ us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis<br>= us-gaap_WarrantMember</span><span></span></td> </tr> <tr class="rh"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted Stock Units [Member]</a></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> </tr> <tr class="ro"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> </tr> <tr class="re"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Total shares</a></td> <td class="nump"><a title="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount[us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockUnitsRSUMember]" onclick="toggleNextSibling(this);">63</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount<br>/ us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis<br>= us-gaap_RestrictedStockUnitsRSUMember</span><span></span></td> <td class="nump"><a title="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount[us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockUnitsRSUMember]" onclick="toggleNextSibling(this);">42</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount<br>/ us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis<br>= us-gaap_RestrictedStockUnitsRSUMember</span><span></span></td> <td class="nump"><a title="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount[us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockUnitsRSUMember]" onclick="toggleNextSibling(this);">217</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount<br>/ us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis<br>= us-gaap_RestrictedStockUnitsRSUMember</span><span></span></td> </tr> <tr class="rh"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember', window );">Series B Convertible Preferred Stock [Member]</a></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> </tr> <tr class="re"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> </tr> <tr class="ro"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Total shares</a></td> <td class="nump"><a title="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount[us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember]" onclick="toggleNextSibling(this);">0</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount<br>/ us-gaap_StatementClassOfStockAxis<br>= us-gaap_SeriesBPreferredStockMember</span><span></span></td> <td class="nump"><a title="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount[us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember]" onclick="toggleNextSibling(this);">0</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount<br>/ us-gaap_StatementClassOfStockAxis<br>= us-gaap_SeriesBPreferredStockMember</span><span></span></td> <td class="nump"><a title="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount[us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember]" onclick="toggleNextSibling(this);">3,838</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount<br>/ us-gaap_StatementClassOfStockAxis<br>= us-gaap_SeriesBPreferredStockMember</span><span></span></td> </tr> <tr class="rh"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_EmployeeStockMember', window );">ESPP [Member]</a></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> </tr> <tr class="ro"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> </tr> <tr class="re"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Total shares</a></td> <td class="nump"><a title="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount[us-gaap_SubsidiarySaleOfStockAxis=us-gaap_EmployeeStockMember]" onclick="toggleNextSibling(this);">15</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount<br>/ us-gaap_SubsidiarySaleOfStockAxis<br>= us-gaap_EmployeeStockMember</span><span></span></td> <td class="nump"><a title="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount[us-gaap_SubsidiarySaleOfStockAxis=us-gaap_EmployeeStockMember]" onclick="toggleNextSibling(this);">14</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount<br>/ us-gaap_SubsidiarySaleOfStockAxis<br>= us-gaap_EmployeeStockMember</span><span></span></td> <td class="nump"><a title="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount[us-gaap_SubsidiarySaleOfStockAxis=us-gaap_EmployeeStockMember]" onclick="toggleNextSibling(this);">11</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount<br>/ us-gaap_SubsidiarySaleOfStockAxis<br>= us-gaap_EmployeeStockMember</span><span></span></td> </tr> </table> <div style="display: none;"> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"> <tr> <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td> </tr> <tr> <td> <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div> <p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p> </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"> <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 260<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -Subparagraph (c)<br><br> -URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Antidilution<br><br> -URI http://asc.fasb.org/extlink&oid=6505113<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Diluted Earnings Per Share<br><br> -URI http://asc.fasb.org/extlink&oid=6510752<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Contingent Stock Agreement<br><br> -URI http://asc.fasb.org/extlink&oid=6508534<br><br><br><br></p> </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"> <table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:sharesItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table> </div> </div> </td> </tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"> <tr> <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td> </tr> <tr> <td> <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div> <table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:stringItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table> </div> </div> </td> </tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockUnitsRSUMember"> <tr> <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td> </tr> <tr> <td> <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div> <table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockUnitsRSUMember</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td></td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td></td> </tr> <tr> <td><strong> Period Type:</strong></td> <td></td> </tr> </table> </div> </div> </td> </tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember"> <tr> <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td> </tr> <tr> <td> <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div> <table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td></td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td></td> </tr> <tr> <td><strong> Period Type:</strong></td> <td></td> </tr> </table> </div> </div> </td> </tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OptionIndexedToIssuersEquityTypeAxis=us-gaap_EmployeeStockOptionMember"> <tr> <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td> </tr> <tr> <td> <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div> <table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_OptionIndexedToIssuersEquityTypeAxis=us-gaap_EmployeeStockOptionMember</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td></td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td></td> </tr> <tr> <td><strong> Period Type:</strong></td> <td></td> </tr> </table> </div> </div> </td> </tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember"> <tr> <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td> </tr> <tr> <td> <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div> <table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td></td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td></td> </tr> <tr> <td><strong> Period Type:</strong></td> <td></td> </tr> </table> </div> </div> </td> </tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_EmployeeStockMember"> <tr> <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td> </tr> <tr> <td> <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div> <table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_EmployeeStockMember</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td></td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td></td> </tr> <tr> <td><strong> Period Type:</strong></td> <td></td> </tr> </table> </div> </div> </td> </tr> </table> </div> </body> </html> </TEXT> </DOCUMENT> <DOCUMENT> <TYPE>XML <SEQUENCE>16 <FILENAME>R54.htm <DESCRIPTION>IDEA: XBRL DOCUMENT <TEXT> <html> <head> <META http-equiv="Content-Type" content="text/html; charset=us-ascii"> <title></title> <link rel="stylesheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript"> function toggleNextSibling (e) { if (e.nextSibling.style.display=='none') { e.nextSibling.style.display='block'; } else { e.nextSibling.style.display='none'; } }</script></head> <body><span style="display: none;">v2.4.1.9</span><table class="report" border="0" cellspacing="2" id="ID0E5G"> <tr> <th class="tl" colspan="1" rowspan="1"> <div style="width: 200px;"><strong>Debt - Additional Information (Detail) (USD $)<br></strong></div> </th> <th class="th"> <div>Dec. 31, 2014</div> </th> <th class="th"> <div>Dec. 31, 2011</div> </th> </tr> <tr class="re"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> </tr> <tr class="ro"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCredit', window );">Equipment loans outstanding</a></td> <td class="nump"><a title="us-gaap_LineOfCredit" onclick="toggleNextSibling(this);">$ 0</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_LineOfCredit</span><span></span></td> <td class="nump"><a title="us-gaap_LineOfCredit" onclick="toggleNextSibling(this);">$ 152,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_LineOfCredit</span><span></span></td> </tr> </table> <div style="display: none;"> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract"> <tr> <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td> </tr> <tr> <td> <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div> <table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:stringItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table> </div> </div> </td> </tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCredit"> <tr> <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td> </tr> <tr> <td> <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div> <p>The carrying value as of the balance sheet date of the current and noncurrent portions of long-term obligations drawn from a line of credit, which is a bank's commitment to make loans up to a specific amount. Examples of items that might be included in the application of this element may consist of letters of credit, standby letters of credit, and revolving credit arrangements, under which borrowings can be made up to a maximum amount as of any point in time conditional on satisfaction of specified terms before, as of and after the date of drawdowns on the line. Includes short-term obligations that would normally be classified as current liabilities but for which (a) postbalance sheet date issuance of a long term obligation to refinance the short term obligation on a long term basis, or (b) the enterprise has entered into a financing agreement that clearly permits the enterprise to refinance the short-term obligation on a long term basis and the following conditions are met (1) the agreement does not expire within 1 year and is not cancelable by the lender except for violation of an objectively determinable provision, (2) no violation exists at the BS date, and (3) the lender has entered into the financing agreement is expected to be financially capable of honoring the agreement.</p> </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"> <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 942<br><br> -SubTopic 210<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.9-03.16)<br><br> -URI http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 19, 20, 22<br><br> -Article 5<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 944<br><br> -SubTopic 210<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.7-03.16)<br><br> -URI http://asc.fasb.org/extlink&oid=6879938&loc=d3e572229-122910<br><br><br><br></p> </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"> <table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_LineOfCredit</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:monetaryItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>credit</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>instant</td> </tr> </table> </div> </div> </td> </tr> </table> </div> </body> </html> </TEXT> </DOCUMENT> <DOCUMENT> <TYPE>XML <SEQUENCE>17 <FILENAME>R48.htm <DESCRIPTION>IDEA: XBRL DOCUMENT <TEXT> <html> <head> <META http-equiv="Content-Type" content="text/html; charset=us-ascii"> <title></title> <link rel="stylesheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript"> function toggleNextSibling (e) { if (e.nextSibling.style.display=='none') { e.nextSibling.style.display='block'; } else { e.nextSibling.style.display='none'; } }</script></head> <body><span style="display: none;">v2.4.1.9</span><table class="report" border="0" cellspacing="2" id="ID0EALAC"> <tr> <th class="tl" colspan="1" rowspan="1"> <div style="width: 200px;"><strong>Balance Sheet Components - Summary of Accrued Liabilities (Detail) (USD $)<br>In Thousands, unless otherwise specified</strong></div> </th> <th class="th"> <div>Dec. 31, 2014</div> </th> <th class="th"> <div>Dec. 31, 2013</div> </th> </tr> <tr class="re"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrentAbstract', window );"><strong>Accrued liabilities:</strong></a></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> </tr> <tr class="ro"> <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cytk_AccruedClinicalAndPreclinicalCostsCurrent', window );">Clinical and preclinical costs</a></td> <td class="nump"><a title="cytk_AccruedClinicalAndPreclinicalCostsCurrent" onclick="toggleNextSibling(this);">$ 972</a><span style="display:none;white-space:normal;text-align:left;">cytk_AccruedClinicalAndPreclinicalCostsCurrent</span><span></span></td> <td class="nump"><a title="cytk_AccruedClinicalAndPreclinicalCostsCurrent" onclick="toggleNextSibling(this);">$ 4,975</a><span style="display:none;white-space:normal;text-align:left;">cytk_AccruedClinicalAndPreclinicalCostsCurrent</span><span></span></td> </tr> <tr class="re"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedProfessionalFeesCurrent', window );">Consulting and professional fees</a></td> <td class="nump"><a title="us-gaap_AccruedProfessionalFeesCurrent" onclick="toggleNextSibling(this);">421</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_AccruedProfessionalFeesCurrent</span><span></span></td> <td class="nump"><a title="us-gaap_AccruedProfessionalFeesCurrent" onclick="toggleNextSibling(this);">697</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_AccruedProfessionalFeesCurrent</span><span></span></td> </tr> <tr class="ro"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedBonusesCurrent', window );">Bonus</a></td> <td class="nump"><a title="us-gaap_AccruedBonusesCurrent" onclick="toggleNextSibling(this);">2,665</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_AccruedBonusesCurrent</span><span></span></td> <td class="nump"><a title="us-gaap_AccruedBonusesCurrent" onclick="toggleNextSibling(this);">1,614</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_AccruedBonusesCurrent</span><span></span></td> </tr> <tr class="re"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedVacationCurrent', window );">Vacation pay</a></td> <td class="nump"><a title="us-gaap_AccruedVacationCurrent" onclick="toggleNextSibling(this);">915</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_AccruedVacationCurrent</span><span></span></td> <td class="nump"><a title="us-gaap_AccruedVacationCurrent" onclick="toggleNextSibling(this);">778</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_AccruedVacationCurrent</span><span></span></td> </tr> <tr class="ro"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherEmployeeRelatedLiabilitiesCurrent', window );">Other payroll related</a></td> <td class="nump"><a title="us-gaap_OtherEmployeeRelatedLiabilitiesCurrent" onclick="toggleNextSibling(this);">110</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_OtherEmployeeRelatedLiabilitiesCurrent</span><span></span></td> <td class="nump"><a title="us-gaap_OtherEmployeeRelatedLiabilitiesCurrent" onclick="toggleNextSibling(this);">93</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_OtherEmployeeRelatedLiabilitiesCurrent</span><span></span></td> </tr> <tr class="re"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAccruedLiabilitiesCurrent', window );">Other accrued expenses</a></td> <td class="nump"><a title="us-gaap_OtherAccruedLiabilitiesCurrent" onclick="toggleNextSibling(this);">317</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_OtherAccruedLiabilitiesCurrent</span><span></span></td> <td class="nump"><a title="us-gaap_OtherAccruedLiabilitiesCurrent" onclick="toggleNextSibling(this);">115</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_OtherAccruedLiabilitiesCurrent</span><span></span></td> </tr> <tr class="rou"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Total accrued liabilities</a></td> <td class="nump"><a title="us-gaap_AccruedLiabilitiesCurrent" onclick="toggleNextSibling(this);">$ 5,400</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_AccruedLiabilitiesCurrent</span><span></span></td> <td class="nump"><a title="us-gaap_AccruedLiabilitiesCurrent" onclick="toggleNextSibling(this);">$ 8,272</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_AccruedLiabilitiesCurrent</span><span></span></td> </tr> </table> <div style="display: none;"> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cytk_AccruedClinicalAndPreclinicalCostsCurrent"> <tr> <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td> </tr> <tr> <td> <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div> <p>Carrying value as of the balance sheet date of obligations incurred through that date and payable for clinical and preclinical costs. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p> </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"> <p>No definition available.</p> </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"> <table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">cytk_AccruedClinicalAndPreclinicalCostsCurrent</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>cytk_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:monetaryItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>credit</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>instant</td> </tr> </table> </div> </div> </td> </tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedBonusesCurrent"> <tr> <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td> </tr> <tr> <td> <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div> <p>Carrying value as of the balance sheet date of obligations incurred and payable for incentive compensation awarded to employees and directors or earned by them based on the terms of one or more relevant arrangements. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p> </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"> <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 20<br><br> -Article 5<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Current Liabilities<br><br> -URI http://asc.fasb.org/extlink&oid=6509677<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 8<br><br> -URI http://asc.fasb.org/extlink&oid=28358313&loc=d3e6935-107765<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.20)<br><br> -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 6<br><br> -URI http://asc.fasb.org/extlink&oid=28358313&loc=d3e6911-107765<br><br><br><br></p> </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"> <table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_AccruedBonusesCurrent</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:monetaryItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>credit</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>instant</td> </tr> </table> </div> </div> </td> </tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent"> <tr> <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td> </tr> <tr> <td> <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div> <p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p> </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"> <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 20<br><br> -Article 5<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.20)<br><br> -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682<br><br><br><br></p> </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"> <table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:monetaryItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>credit</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>instant</td> </tr> </table> </div> </div> </td> </tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrentAbstract"> <tr> <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td> </tr> <tr> <td> <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div> <table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrentAbstract</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:stringItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table> </div> </div> </td> </tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedProfessionalFeesCurrent"> <tr> <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td> </tr> <tr> <td> <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div> <p>Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p> </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"> <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 20<br><br> -Article 5<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Current Liabilities<br><br> -URI http://asc.fasb.org/extlink&oid=6509677<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 8<br><br> -URI http://asc.fasb.org/extlink&oid=28358313&loc=d3e6935-107765<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.20)<br><br> -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 6<br><br> -URI http://asc.fasb.org/extlink&oid=28358313&loc=d3e6911-107765<br><br><br><br></p> </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"> <table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_AccruedProfessionalFeesCurrent</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:monetaryItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>credit</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>instant</td> </tr> </table> </div> </div> </td> </tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedVacationCurrent"> <tr> <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td> </tr> <tr> <td> <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div> <p>Carrying value as of the balance sheet date of obligations incurred and payable for unused vacation time owed to employees based on the entity's vacation benefit given to its employees. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p> </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"> <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 20<br><br> -Article 5<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.20)<br><br> -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 6<br><br> -URI http://asc.fasb.org/extlink&oid=28358313&loc=d3e6911-107765<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 710<br><br> -SubTopic 10<br><br> -Section 25<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&oid=6409733&loc=d3e19396-108361<br><br><br><br></p> </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"> <table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_AccruedVacationCurrent</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:monetaryItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>credit</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>instant</td> </tr> </table> </div> </div> </td> </tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAccruedLiabilitiesCurrent"> <tr> <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td> </tr> <tr> <td> <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div> <p>Carrying value as of the balance sheet date of obligations incurred through that date and payable arising from transactions not otherwise specified in the taxonomy. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p> </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"> <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 20<br><br> -Article 5<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Current Liabilities<br><br> -URI http://asc.fasb.org/extlink&oid=6509677<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 8<br><br> -URI http://asc.fasb.org/extlink&oid=28358313&loc=d3e6935-107765<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.20)<br><br> -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 6<br><br> -URI http://asc.fasb.org/extlink&oid=28358313&loc=d3e6911-107765<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 9<br><br> -URI http://asc.fasb.org/extlink&oid=28358313&loc=d3e7018-107765<br><br><br><br></p> </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"> <table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_OtherAccruedLiabilitiesCurrent</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:monetaryItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>credit</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>instant</td> </tr> </table> </div> </div> </td> </tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherEmployeeRelatedLiabilitiesCurrent"> <tr> <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td> </tr> <tr> <td> <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div> <p>Carrying value as of the balance sheet date of obligations incurred through that date and payable for employer-related costs not otherwise specified in the taxonomy. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p> </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"> <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 20<br><br> -Article 5<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.20)<br><br> -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682<br><br><br><br></p> </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"> <table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_OtherEmployeeRelatedLiabilitiesCurrent</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:monetaryItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>credit</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>instant</td> </tr> </table> </div> </div> </td> </tr> </table> </div> </body> </html> </TEXT> </DOCUMENT> <DOCUMENT> <TYPE>ZIP <SEQUENCE>18 <FILENAME>0001193125-15-081081-xbrl.zip <DESCRIPTION>IDEA: XBRL DOCUMENT <TEXT> begin 644 0001193125-15-081081-xbrl.zip M4$L#!!0````(`'N#9D;,W=[NS,(!`#B3&``1`!P`8WET:RTR,#$T,3(S,2YX M;6Q55`D``]D;^E39&_I4=7@+``$$)0X```0Y`0``[%U;;^-(=GX/D/^@^"%( M@)1=]XLQW0M>)XW,=AONV9E!7@RV1-O$RI27I+OM_?4Y14JV+I1%42)-[V87 M\+1-4N+W59W[J:J?_O1X-QU]C[,\F:4?3L@I/AG%Z7@V2=*;#R</.8KR<9*< MC/(B2B?1=);&'TZ>XOSD3Q__]5]^^C>$1I>7(W^6IO%T&C^-_AC'TSB+BGCT M*;5/C&.X.'ZXB]/BOT;?HCR>C&;IZ`_W\I<1/26CT6U1W)^?G?WX\>,TRR:+ MCSD=S^[.1@@MON*WZNW.1R-Y2NDI7[IT.7M()^<C@I?^YF5Q5,#]HPF\R/F( M8B(09@B+7XDYQ_*<J_]=OGMV_Y0E-[?%Z#_&_PDW8X'@"3:Z/+T\74+V[Z.O MLS2'N^_NH_1IY$RGHTO[5#ZZC/,X^QY/3N<?^O@MFXZ`U#3_<+*$S_[Y=);= MG,%7L+-D3L])=>>YO3I]Y?YIDO[5\O=\O_W#ROT_6'DW,<:<E5<7MR;YC%.B M7GN9ZH[GS\Z3ND^&6\G9'W_^Y>OX-KZ+T#H"F"HW473__.1UE'\KGYM?@.<) M1Y@@1A:/3.*7+RK?*(_'IS>S[V=PH>;V\5/Q`CFYBXLL>3R-)S=1AF8I(([+ M>6.?(_3E*?CZXND^SFM?K+Q2\U7V;2;%ZLO-.1!GU<656Y/:6V5U:[*X-2_N MLWK`]HI]#;*&&&9WD3W5/S._:!]C:X\]9!G(\+;GYE=K8,>/X]OZA^R5F@?2 M*!GG]4^4EVHP)>GW."_JGZFNU2#*D_$6XI)QS7>D\0V(_F3KE#=GV6P:G\UO M>W[JX:[^B4F1G=F9<@9WQ%DR?GX`M,/N9V8I6GONH<A>>36X>@)Z9#0J-<GT M/"_E[3*^'I5B?6X_]<-)GMS=3ZWPE7^+LK%%U$R!E$_<9O'UAQ,K4F@A,:>/ M^:2%?FFNNLXJ6'.%<`ZZ]&Z6?BUFX[]^O8VR.'<>BMM9EOP=K,1XEA;Q8W%I M7S*>3:\N`B((TPPA>%>,_@=T$;WZ^JM_A:_L\&-!]!58KH<TJ9[)RP\\&4WB M<7(736&.?OH<GHP2F!/)Y$IJ([B25XJ&,O`I1T)1C#B1!CG&U8AZ@?&Q(Z6C MY16!#_Y(%*[^]]-9@]>O<((6.P_2(BF>-F[]\E"4!A6,[)Y0!:94M8%*C.^+ M$",:&`=Q@0/D*@^C0/HJP$HHP'I%KX3%J$\^,BT5UX;^=-8,18783J?SG[-9 MGE]DLW$<3_(PF]U]RO,':RF^7)?/[CVVG.(5P'-S=?67K_XR:B0V0,/TDPY7 M'+DD4(A+)T"&$?B!:>A*2KD4],K:M2MV\A&^:S["C6"LS>5IE.=?KG^/LBQ* MBR]9Z1L$CW$V3O+X`F0_?KZ8SZ_FI!T35X0JN(D^$B&,%+R>F:O[.+MJ-C5" MZI`0,Q_YH<<0=Y5"VF`-[^!YCJ(BE-JS$X-<D9./YM0LRT`;V`V8^_QP]RW. M@.D8K%52)''N1>"&3=RG]4\[.H?'YLPJ#P*O(O4.VIIC7A*V"Z`:G.OH)OXE MN4N*+^GSIU02>KTDM/-QB;Y-8_?IOV?3";C51Z?O_B&+CT>>./F(3[$Q>BZ4 MA\)=G7KE0^4L/0X-]G?),7XD5!JIY,&2"3QA3%V%J&"@OWQ?(X<+:Z2$8*$, M)?7U%9E+)I@&X&I).%_@K<*^`-,?@P\X65+E5KFU,+O[TG!LV"!<&JLES-NQ M#49?V]^U40+H48QS>O`L4;[DKL,-PLHQX,7X+M(!#1#Q/.XXC'B<\"LY%Z=_ M3/W]"J?'YI!WI<\7'[:X^GE6?(V+8AI;#?8I]:+\-HR2[+=H^A#[23Z>SG+0 MM7W.R1W>5B.U7G(H3SX*O>9.[P=[R026SBGP>A$]V3P3F(A2['T@/;WY)?G; M0S*ITD&MF6JMTUD[CY3-59M5YV1N^9JB[-P1;T;(,1QSME!9?'^_O'L"B)45 M^$L[66E$`)_K&TD'1\#!RJ(1`6*N++@8=F3&("C7R\0P)34G!UMVHHP)")!$ M*86@'4N*#-%@E8(@Y(8+37S^[/^)4[K+)`W9LN_F\-B<V<AL-:-S3#.^D2UI MY6+S%U8J>PT_#-G?OV&!5B[G!+D@90C^`2ZU(S52QH?O]CEEOEME0H`5@1FA MXK54U[)+W86FV0V[N:9I#AV$B&-V@*HYRI!3F+*B189/&ZVHPRE21('[Y;N` MT^4>\K'O!8PS^$KV//$-@V]2LN$0'QPP;V)JIQ";8[1C>2KD[FBX7RW7_>"" MOP`*E(-KTI%B.W02O`@UA:"`Z26'4A,BU,&31$IJN&02.=(%"^!(CHQA`OD& M^SQ4#C:JS/K"#^!*-DN:_#E)9\#2TR=`#.]0?/F1QEE^F]R_I*3<I\^SU%*2 MS:93\,JK6PXE:6>&C==H/,$];<#P<5\B[@F*W-#12+N:2"=TPD`XE6_%7O)K M!P-=Y>N7)/J63,MI=7C4NH64HSBBC<AZCOR?7?%F.%]+O'V>7435_>W9.*K< M--(QBVK)NMQLP]91ZG$W!T?4%<SJ"C`H%'Q4.<Q<XQ(?1\TM-IH3BT#]G4<@ MNSELZFLWT"AJ[HAU:ZN/66+7C'158J>6"3J/\O<IL7>9`(3IP/"!:G8S`<A" M3P0^YH@'`4P.Z0$?V*<(#`M8-B9IB'DE4/R0!.!Q0Q+V0H7AC#P23KD69O_) M$%*-00"09L(@^(L'H1@E*(2`#_,`AZ$*GK.?\#=XE:91Z,'>Z6Z,+:LSC3&# MA5&GA&[W15]:,2X>ODV3<3B=1<7>D74)LY6KU*B'A%EG"6-C>V:>\W:U;[[; M-6C?)H-M0].*\(*2E?O[![;=R;C"1\*G`G$C7*2EU,BEOA]J7_G,-<\!YXXZ MY$:[S&LWMU;4_2.?Y]%65??KF&IDUK7=P;:]-D[S4I$YUK#=Q%;9N4\OM\SU MG_,CRB9?[NV-R\3^'ELK&$^<[W$&D<J*N[&OQ:N(W$L!T`T:/09VQ%<8^0&H M>BZD0(9P`<Z`PD9(1Q'J/T\@2DX-6Y/_[GDYTF"LMF(XWZ-D:DMXX2S[V7HH M![/?;-H*@:7"(44:$\NWX4C[VL`/ID.#'>6J%X$5VCYS!,)W8.]LNE??VQ.U M@1-@&C@.\K0&]4^4CQP>:"3!*#@^_)\[[E(WBM$<ZTXF<X5ZC52K9FZK+I\` MG*'BZ9CBOF(8-YTZH0/P:3%,.H@@$=>!A[1'*?*P[V.B:2!M'RG&NDQ+:J+T MBJ[<?/?U7$H*L9('RC0Y7(RVH,(;H,!!9=A(#)Y*"))$*4-&@`X+0M<XKN#8 M9\&\.5;0M9S(R_NNN:-1?NND$_L?"_1[-(51SIW"@RCF"4:V33KDD('37`GI M>B&$MR%,Z8!1Y`A"D,,@O/4I$1[#\Y2'G=-:,[8:H#3!<R3IKV:&75>3E0MJ M\B_%;9S]>ANE<PGY/"O;Y^/)FK(O59`?%?%S@JH=P]:EP(PPZU(02@ZUC)P9 MZ?%`()`1$!J,&:@3+9#K8.DI7S.I7RRC/%7'T"5'Y+#W43U$U[\R=,UTO_$% M*#075)H7A(@[@8]<`E8`.U[`:4!=(EYTOR!*,-'K<'5I$I8:/D"/RRTAX9%, MA+0$LKW,0Q<XC="Z4YS*X@2IUX+@_=`>&!EN@EWOXFGH:#8$2FR5B92Y!*'6 M9&)[2-C!F#9M5FH_II7CM^?D/?YP4HU%9\/)['"N]AR_P5`RR;KU5$7IJ0HI M%=UK.*UIK+3[=#K[83LE<O"/YDMD<S>:EFN"6^,WADF+'[3PED3L#OPNYQ"E M.!"YL!!#>.B#KZ=]BGQCX%LD4]3QGK-Q1!J"U0K^1OC>0W:#]I?=6)2'B#XU MQPBV#\YN],57:SW#RE`1-VUA&4C*9I.B(Z9LV+P55"NMZ#]=RJ8MM8U2-@MJ MB3)8T'4?I;N4C3_/$/\:/3IY'A?YIG(]II#NL`P<3)W+0P<1CVG$?8V1*P5' M,G1\[DH28C>L'``%5!F8JJN.3@,TJ_#_DF;Q>':3VGPX/.3&:7R=%#E$-\7O MLX?IY-/=?30N@NOK>%PDWV.XY=)NK-$5(S7E'M\XVA$:@3(/$.<2)-3Q)!)< M$I\KS465NF8V!\37&V/:P5NEZ%,ZGMW92\%C=)>D)9L7<1I-;04<[.ZB1\D9 MC[,6/21-N:F3+-\HB*<]'X6:@M("P4$F<%SDAM(E(3<4]/PS.4NT[`GIR*[D M(0+2W')1<_(1W"8M]G(=N\@-'H*W46ZP'.$R-\C-FJO8(C>XH4/*_N-!*D'9 M3`F6`':`_')OMPRR70QP;\G.]2RS9F28R&T;H&`[D6]'M8..S_'ACE<7N/6* M'JM[[1W`X!]536#X8PS1"@4_=,<0UP/:S<+B;\&C=:KB1?0(RJ+4^O#Z@R2% MV<PN)CLYV0UOJ7EKXP.\Z#XIHJEU&^R343:V6M2/O\?3V;WU,`?)#04/R*ZI M>%XYLC^NUTCQXWOPII+*G00>[V99D?R]55=;+W18@X@I?X6.5Q"]^WH9?;MZ MV:)S\/_K9>WJ9;N'[HCULL5@40*/]3M<G=3+:-_U,F;K93;:(/LU5'2!M-N* M&;,5,XL4XG"M=;\ELTVT'9;,2J%@MA^<*6X7??97:-F-\_BC2LI1G9O*70-: MFM+R8M7Z7#5_7\19,IM4Y+PL$+AX``\#%(1SD\5Q>[^IQT$W2\M2#T+:^>SO MKL+(2D<;;ZPU>H.IWVV-D=D:HYWZ@FA#]ZL9=U%DI'T7&1<KSFNR*"V*C%NR MK:U)T%@*.PN,$IJU(D&Y!C"'!GF.Y]K^\<#289"CC"=@R+D@9?:X7%E'B-!- MLL>]@.9&:=ENY)N"+B,D#K(P&-""8AB"3D%7O6&,-ZH3=+*,J645C1/A>"34 M"((!D&<*09?Q#4'$D5*'FCB"LRM:IH$9EII(NKR>K\FJI2-N$-LU2-H(Y%9+ M=;P5B5T#M7L+$K%6U=JY(G'871^;G'76]5$NF2?E2H!3<HQFT$/:/I:&[2+* MOF1?"[OQ=YF76"RD[(')`V:C]93FJT'WP-3A,K..I8_R0Q>5K=[[3D>=;8QZ M,UB#[`]J.V4:]0=5ZH:5R33PJ\P_6X=06W(;=0B]D,LY!$?=:/-^6H1>E>`C MU3^H;1&RZ_GE@2U"BP<NX^]Q^A#;77?*PSL.E[P]0#=35417.U#7`MYX_VTP MTV)>4!TL3`DC2[>`7'O[59#.>/QP]S"UJGJY]@7_GL8U1;"+;`;FI'BZ@&"_ M@&LV#]*F_'D()X0PG[AV'^X@]!#'#D..)"[RA!L8Z?F".APXL91@8U99.1;< M#1)M5]1OT;A\JO]IXG.A.*4AXE((L$5V5;SK!4@)&1K0I*`!P&R7F["M+?*L M?_6MFV8-5P*L;@-[O)JQWGSSVH%S9^E#_A;@&HX;LTW_A-<-W.JKOT$K9W/X M[5LY:;7]Y[MKY6S,S2&MG/28K9Q+T5N;%H,>!)W:8X#(MNQ'34W?7DV*LNYL M^QX!#WAU<3H&-HZ+[C%/SM-D^N&D`%Y;PR,;!U(MV:RR<&Y=VBR^!:\69G4U MVK:9[W-<?+F&81_>D#%>-M[6F^$FD#;XL&?,Y>"WV\!GN"8)U#93V*PCKWGY M58"7<1$E:3P)HBR%N9JO."W7R7CO[1;Z&&-AFP`T%69UI'=CJ;7([\+E@&FM MJ=IP,.O?_\B5T3Z&U)Z'P3G?;ZEE*<]#&,6&OI4LRWPK$%^'L-4W!NOR+H85 M/&7-B-;;/.5:'&M2.H%X$OR*:'H1)1-['$K913I`L+8[F-E=+5>EM/[]:U41 MQ(#7<9Z7=X?Q@&<R/?DHS8:=?07"JUF=X:I=NV:7JRT=WZMO7Z.:@KO[Z>PI MCB_CT@B]!Q5E#YMAFQIJ)Y*MFFIX@TIM;Y%67&Y32KM2<X-.0MI^(KXK/;<M M#=G%`K0^1K0\NG2M?Z;%XK.M*;C]%R3U@-HNPJ64K)4'MR/H8*%=/Z4$V:R4 M4+/0;A$!7<;C&&8`!$%S!78198/V]WF5@]J,Y78@:3B?^Q[KAFETN^8,9C1K M-J5KQML*^[K`@X=Y.\N*7^/L[E/9^E^F9WK,/`JPKRIT`Z0E&%W0S=+N(*L0 M"QTG"#4-70/.HTV\:KR^A+PYH+Y6F/8C\K;W`:)!P5\7^:8K3'^9I3=]38#6 M,J_MBDN\MH_DYHNO:;B2A^&!L5NW;$9^U=NN(5CJ*O@*4_REJ]V/OQ5+V_T/ M55?;L$\)M2JX>Z(Z^H+H?L1TWP71BWK`BQ7K"M;F9J[:9]0`+.1XRD<\T`II MZAB$N6+<]=S0]=G\&(:U',WF6_>QS+N?$023RQ@^QC+O*I-5+?0=JJC:<%[B MN@S<\GMOQ37DP,\N`:1J&[)M`=_`QPL\?V48JS,BS11G%UL-]".8S"ZG7\M1 M#'^K@7ZX*>-]A8^UU\`\<^E-DS091U.X[R*+Q_/?O%G^%@+2,%UGU]`8)5Z( M:(REG[T6^ID/P(*9KW\^<*N%ZO::8^PNK<>6M5Z+<F671V.FRV72F#=8)EU[ M%!DX)LJ`FG1X>;P\9LCEFB#%%0VHHQV":]LT=J-JR,)QP-L5A@#9'G\)$2]3 M]G<!@VU7'-IC;]L)#%-<!MQ!`58.XIYKD($)@@+/$Y[K*15ZJCKRTC3CIG]* M)%;EHDNP=_U14IWLUW"^],Z)D-*4'&C"^N.$;\8VPZ-$"=VCY(AY3_=`*>F# M@LK4T'?`07E^H\3\D7`F=*-385MR(DM.R+`X410BVC<U,N5.#D1H41>Y#(*9 MM[(UI+0U-?FRP5#S9B:'6),#`K7>Y34X9GJW/*2L=0Y8G'HS0*0T0$J4/1J# MIZ)7.U0MM=ZHH!S*S/$"/Z"FR?82K0,_.@^%!QGXE>#?U":SH05^+Y2\E3%F M@PO\GCEY,RN\OLOO\"CIW?RRH05^2Y3T9'?9X`*_6@YZ-;BL9>`WA*U86]/? M^W:V8A$8G*ZLC!@`A^]C.]O=0W?$[6P7@\6)E,<XQ?JPW6RW]Z`LK8PJN^CL M\M:J6/9SE*1N?#W+XM;+^RJJI5@VWW.OKW1QVNVH:`33E`1("@)*B3D!TLPG M2`>&!/`:@KC<FF]ABX.J82M.0QI>9W6UGV=>6K(CG1<PGDG+ZO(;DTC*'(WD MKQ*Y"WG3V?@N&>+[=7T=+IFVQ?%]2R:K-K0Z3#)7:!BXOCO`"6O*JKQ:\TO_ ML91=+PS6IHW>B:[KA2#>@*!WH^IZ88P=+)3#UG.+',3">F"(&3NEE/^CZ;DW M8)#4%E$&J^C>@"'>A*$!:[HWH*Q;37?T]-G;U1_XP'H"WJ[LP(?6`_!VU08^ ML)K_VQ49^,!J_/W5%OC0:OIO5U+@!]7PNUCN7!X'0\K34#1(:3MKVFCY\V+= M*Z-K&ZOLLP"Z6PKLJ_%V9Z$T6P$^7_A"RB5:PZ1`4J/;"4$C"MAB?8O@9J`4 M<*'`7'5'`5^<B",8.402-C?*/_A(D?GA4+ALO)5*=K/W?[7&:;7FO@/.;NR' M'!?3)VRY$W;=Z3&K]QU8XMT"]<BK&RNXXA6X=576(VWZUM\!E=JFPX1>+\IU M?CYE#=!NSZ?4]GQ*"[1N:\JNSZ?<1-OA487:5KF%J3L%J>M#^G;C//ZHDG)4 MU_8!?H/YV_%QA-J6Z"S2FCT,=^[1N&-WHO;8#6?V/#K*M6BBI#9WW_&QDO_' MW;4NMVTLZ5?1`YQ1S?WR9ZL&&&`W6XGM2GS.J?Q2,1)DLXY,9DDJE[??'EPH M$+Q@`!`@9%<JED6*0G_3T]/=T]U?'"N,XDC%GMT#H\@)#!X(2])$RR01^F3I M;(M(X_,QUE&8BH\Q1^'$L*V;\3&^@3`1'R.KQ@_1QC3E":D)CX0>FX\QKP7F MOI=<WHR/\4CHL?D8]T3Q1)'N0H]F\C1\K7VVA=.@S7YL\B+B!">Q1093@;A3 M&AD;.?!&+=@`".(UBX>;O.L04O(Q2=1(04BI);ACK,8N/S4AY=A"TB`ASWME M`QFL_I57(/IX_*_?LT?X\O/:?VLHGU=?U(+XO/R.)YX!X;\858KK:["E=81C M+%;0L;7M>V0%/<9L-%90D[>JY<-;[R6],2OHT%]:?K0_*V:[Q_.);APKT8Q3 MKRGW:+"^9R77!?6M&@7WCDH^%6"]LRH0<&#]H.%$T@V\1MBW[6?4>]8[4QC7 M*^[W87B-S<1\+3T-]`!FQ\0\LL<S4R;FJ5?]NV)B[JLR04S,-2ND,%=->_[= M,S%/X-5Y='TY@J;R'5,Q7]S"5QJ/2`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`OY6#4R-N3W$\AK6<[U(8V&Y8G M)[F?P/*#@G-ZY+5.2W(_A9OB6?%\&\4\2.XG6%@O,,''1WI'EOMP8_?G>J8V MW-<_"LQ[VO!2K*8%7V4?GXNKARGS1#Q)RHY2D!K2=,F1$;%"21L9&X(<[ MECPTF;'J#WOV()K?EO4U;1R;QL+5'KGM1FO6EW?&-R*0EENM<[=W@=H[O6T* MW)'8$[*:7E[W22/EV<-]OJ]!(EXPN<)'SC6]Z6_QFD2\0;($ML)WIU2>0&KO M2DH6V/1^Q*Y\Q?*''U:[S7*U73Y.K1XF(5%J>8Q2:[1O5&-(IW"""^OB2#L6 M&1J71"C^,D@TVFS'0J"E$*3/7(5I:C]D6.W'B0$*(Y5,UBIX[9<OF^P+>%KO M0-ORJ\>&BWPSA+IUHLTV\/`-AU(V.(X#I1EQX,D$-2K"MR281N*TRW237*]^ M:U>]W]KKZ`]5B\QR]U'?2"#8\>X;!8)C!ZKI<:R>?OFZWNP^9YMO/^0#^',7 M;,**`0'AK$JC!&D),2[8)8DBZA1BJ;5)JBG$/)X>&JR69K39JA4L4,NI]^:6 M@G[F/MCS>N,1GN=1Z*NXN2::7SX*STO5"!#7JR]3*4!O$WO(973BD4_-DIN? M&'Y>Y(D<:_&XH5-8#R?;SO94A#TK&2:'QJZC5"T;=^+8)WB''FKKJ<=N5BT5 M)3QOOL)88N%C2CX'^@AB(1LKAWBB%=+4&H2Y8CR*HS1RK`CG26.0Q/%3AVIP M4;3SNGYM3,_]M-[FV7="?X)W?-U^W/B=GE]15C4&/X[H!YW*QJ6Q<#*"#Z5& M8#^#0"'#G$74<1D+<(6BM.*##1P@/%#XEBT!7Y35TK,_Q\!Y9%PTRDL"!3IU M%9^_?;;FT.?JJ3AU_UY_[K-RS3G1:7QL?N(:HOGDI\[HV:Z7+QM@$`:1$R=U MV.D$7U3?\X'Q:IM5<X9\E;Z_@(-'G.7.]$<W;=2*]!.O@.CQ[]U_CC^@O%OU M]L__Y&+SZ).B+OLC>UE/W9,1CDT>PA%5!/L]!:NA4E[$QB_+U?)Q\0+O^[3) M'LM_>;*"^=X^PH%GRNOS;J+4Q*_:`=/E:K%Z7"Y>/$?<<O>:1[:#1=Y_ZD/M M8UL)\K",++,8Z5C'GB`/(T-)A*145EH6,VGQODZ;E;)?E./2)JAW\32:=V:I M_K#HJJREZBS0R$S5_(A;%/[F`9,R>S-5GZC6OQ53]1GA;\<48<H9V+<;!'\) MDIM01GA7@C8J\.:#R6VX(P@I!X7/&I-I623(J9EV,\)D"@R4AT"^`PBFXY4@ M^4A/,2],%&4Y\<?M3IFB/4,:=E/JF4O(W.RP*<:"'B=A9P/-[<Z</)![#]!, M?_3D3OZ<-]1D)U">!8(H@(MW@,2T!U%S),%03*X7]`$H(=.6>P=]U0Z99="7 M"W_3XYC-+>A[@^1FYS";6]"WQ^1V!S";6]!WA,GT)R^;6]!7PV2B(Y?-+>@[ M"<&T9RWK=];V+NLL&OM\!GOSFA?7Y+=YG[\N5F7)V8=U7GB3/36&A>8C_-QB ME^V?K3?\"C/"/-R$DJ$35SDS,N:)0,[Y/@4`%`YX+5!DL8R5TTQJ5Q#D>`)+ M?2]JHR'G`.+DRSID6.*%M0L;GFB<B"F-*(KC)/7W+PY%1%N$;9QP<,,B(J*W MU9*,L6N4,G<%YW!-JH:[7[+-'\O'[/13[#\A_X7;S^N=OQ9[>]U?D7U8[W[- M?$5-.0<I[[<MG^`JZQ%BJDZ5:5+!,./(LH3"FAB*M(MA0V&B,==8*B8*(CC? MB->H!9@$G'>Y'D+2?F10H>M1#-I2MU^0/GSJ_[U8KOIRRA^`77#*5RYNQ2GO MPX!1.>7S:XW0\L=`&"ZC>EA#65Z]^F7=[F!]EX,T]F8@DB)/IRX"V29YJ#:^ M2X1.)WG/RCA\9_HZQ/>],UF3QW,P##.W=P/BE%!4CR+Z[\O838+@Y2+BN5JY M2:#A@<HU<_,V"59L\$:<MVVK4G/5B8&9XJ-"2KXWVW8#!$_?*L[6Q-T`(1Z" MT(PMW0T@&]72G:+&&<(.ZK&!-P$V@OAFD,ZY,6UUBA4F*(JL`%RT0M;)&(D$ M&^ML$D'L7UQ0>K(X9A2MD[:<%V?L9/KMKB/YH.J@QO"P`?(+SO\BS&C%?=Y2 M*<84_!NB6LEJ].#]N7)URK!2B42<I"GBAF.?WL;(6?B+4D>94X5F>!*%,V,T M2C$GQ8!K2?5U,$AU0HV0#F'0-L15XB=G)01)&6EE9>0P8P4&M,I2!J-P59;@ M4VB<D3[0+H2L/JOL`N98DQK=4!"-\%#RP0XR]Z/_"L<`'!%^;YJW!B<8[D93 M_<&JGL@X!4.G4:HP1SR%HS+R8@LL4V-E0J1*WII4F.RBZF.8_YN57O"9E4#> ML.*"SZSD\8:%%GQF)8[3U5?PF94TWK"L@O<KJQAC1I,77!(F<Q=9T7Y!4]C, MIM(%9(SUG]HT+@2>#I&S\2"@9=QH&H9P1@A(:G0_[0]"@)4^,.5$SQ0"+I2B M(\XNVV>D!#5F``;'$75M]N(`$.#Y\HXCJ>1(=,"Y#J@#"]@BSOC)D:G$EJUB MGPJ!#M\WL+[MC*C7GF.1BRLNB'MRUNRX6@TAB^P>XR88&[`-"4H3GQ,4D?15 M?#%2)G)$JY0)@?<]ZM=4ZJ%TWA-*COL2?.>]_,EJM]R][.OB*MYK]^H[&'Y< M@AU\&C"8H`:#)D1T"_B/U1_+1$1&&J2T8HA+/X;:B@0ESH]LX3J1/M2NU*'@ M^^XD90T8>,\CO'7Q)?MQ^6VY^[@Z9+'^^%S+H-3&,49__T_!E'%UP'X'K[1- M:\(!PCE`QN@2H:'BCL,`5<)!O-'4$#GVNUC0B8DTIDAS*Q&`$",=4XIB['SM M'$W@H_,(43YH><1RU\9^,H:H1NB`$19#1%6EJ,=<;ZWR7O5H((6!/`B``\GL M0T4E#QH\'J:E,(HUZ>S/GPHCK&M3T!'6E>3KVN#6/+>D^<;/7RP\G\(<@B58 MKI\*=-[NTCZ];AZ_+K:9_;+)LOZ#FB9==E\'BQFAHAI<TU?6\36#2=:S_"T4 M#Y%KQ@GZH[8-?[6$^)G[+\JUZ%<1K5*J<6I3I)DP"+X3PVE'"4H)F'">X#15 MR0,MJR6IN,D%V-4OO#`U41IAC60"\G(A%-+$@'>82J4LO":(+()]/_:]69=_ M^1*@97QY?Q0&+[7#L+JQPBB.%$@-.H0B)S"$^RQ)$RV31.B'MS[V8][*BX(= MPN"CHZ*%Y.5E_>=B]9A/MZL&W46+%_^M`5B8/.>GP)T)T8#C+1]QSFUD';(L MQ7[T.$%6.XJ<,?!;)%/4Q@^T;"$[0:`0)%_C)O1EL04?\-\+WU2S^[CYV7<O ME6Y@<8FV?W%;OKKM.8W](:\8X!HLA2!*G5&7#G>$J8IBSB!TD@F#2(H2AR+, M":(LTERF$%]A_E!-)!+WM.8B]!([`+F];_TV(';Q`N%)]'?STZZ.X;4Q@^T& M)DB:5MC"99Z!ZG&?)C[C@H^@>GEBUAQ<3[]_U3O"\-J8>4M/X-?(L53OVAP! M.392D.)6W(2$>"?._R15S(+-9]H)Q*W5<!):BJ*(&)&R.&':O"7[]5$C6"A% MP(C":\S%B,+SJ@1"YR/W^PCO*P6K!K?/B[^B;)4]+P=MB4)RHX3N=\NE(@-G M?&I0;.,(XG:1^./?(*M,[)UZ+HA[$-XB>QXNTB!A.R//)$)SH[3LY^F$"LV\ MT`(WV#%N*;2@6/1L:`H5.F=<D_X2O;/0M5Q>.;>X"(%+'_`I76\*GCX?*P_R M=C4VDN?U'I1V/PNL%22)?&S',('@UD*L`[X_2K5U:4I2S&M7NQ`3P'\G*]S" MA+QZ[5LEO.':=)MG<+)''CS]1!*+1)IR`$.R@H,Q(IS'UCH(C^B^TE'?X^9` M@Q.U;M/K01.*T*1/'$D*[D"B-9A]``)%U#@D32(339VW,(79/V3AN(8*]!DL M<)@[KQ>HYX,>9H^B.4!Q+!ANK(L<,ZJZVR1L4^DB#3X'UA!]1TQXFP2>*K<) MBR(1F[@LMC">_4%A7B_''ZB1HV5H-&%$#\I+1<0)3F*+#*;"DZ9H9&SD$%76 M1I91HUF\S]!PT;RP#$O1%%=5ZQUHV'+Q8K\U?N2?JZ=L$Z]?0,W6FT)+NZ>K M28D,I0_%3"!!B\$-IIPC?:&NM\CO8(^D,EKW0](XX522^(U)8\03$H&NR13% M"7><:I58*O=1(\7[N]_^X+PW<"4EAO6+((+`K=34B.\!6P!7CE*0'H1EU8$@ MOP]%#0&SH:C],MY!X%;M<.3*X%84)H=O7#W]""[DJG8Q5MR?]4:U124;B##C M(-:'&""2L40\E<9GABR*B8&HR\5:D71?W/")_EIBT4V6FVG8];=G.%[D[1RY MD@)5[HOOX=VGXSIB0S"GN"?':$HMA(?,(9?F4UT51(ZP(^'WQ+%55*12QP^U MK5.*??*QZRIQ4%85^W%)FRU`\+,'8K!XS0J?$P50F$G+%8>@+U&(2YL@PTCB M?:X4?'O*I2A9>NK53Q>?^JC`]S'+GK;I9OVM`N.@]J>?D&]-L*#?LJ=%5$[R MR'*#L+(&<>(BI!.:(!+'W%I&8D[XGHN1F.:U5ZMHXZCOQ**K-UZV((W^D.U. M`U.EQH=*+>#`%"'-#7TW<=G<P'E=[%:Q3I1TG"L,^9#]F;]T)2@&USP'*<,^ M$815L]:C5<X0DW!H4PK>+_A&!B]>Q4ZT8A6N1J!%&%/?&R`8&$WG-+)<&&2- M$"R5J:1./Q17<,URB7ZRU[;7OK.H*CF]JC%M@L2T%C)_71N53V=@_%Q'5?`D MU:!=2,N$A[DGM-R"ET6_&48@$M;T%A@5?<B^7/M>=`%I/\*Q&%=:JF'U`X6# M=E646FH5@U$),E15=[:Y/QA7>4'6FYON_M6+X8B`FFC-X,\PX[W7+PLO?BNF M='KFSL==]O2O]0LX@"^`,SB"'=*I;0B=V5=-[[;G+MJG^>]U35_"Y6S'Y^?E M]C\IA#1[KNM;H,,'H*-R]Y](>1F?4W).87':#_3K6IA]DD1@W-/(O,5,'Y]K M'37%MT'%.A0<!:(1>!D1%`^6KN`AJW&K2"<86^,]K?.GU]]>EH\?G\'M`4/4 MU;Q2+!NA[^'GM8DM)35<,HFLC"SB5G)D#!/(&>QXJBPVBA;\];3!U7I6@H;/ M6]QB;4MHZD%4'UE%SRR&-EI1RRE2Q+?SN`@\UXC'R&$7)XPS^+6>MAKV.S]J M`+L@08!_GT_2^OC<M;Q]*HGE6SZYQ5D_$.0@DW/^S95;WR_NGT!\./Z$/,S7 MA8LSEN==RMT6G0RT^"P1/-:&(L.=1#P6%$6IU4A'FDB;VC01=I\$8O=*WS0: M:<6DB$:FP*2*T/"]9#V"CTL.UN=L\^UZP!PZ2'U$K:C*/HE?PSQ$+\!$?G.P MX!W\YG!0<L]0M?B%-_2;AZ-S[#>'HR.+M+EB0_WF25)F-:S:6ZQ;SITPAZH< MHDZ.NHH&I\E.?\`_09#^H+2G=]KNST(4IYH3#):\]3S.!6KK)?RPWA7P_/([ M;+W&94W7.(,!'+SC'5/*4VU]8$EC$):G#&*JR!`DK94DX0D5,7N@10,YD>I2 M(^%E6<8-L1A6F%[<'H$UJ*GSI94,.9?X>_A4`AR4(6QL"IO%6.?RJQ?F$>%] M0JR6MQ<9GV'B]\]8!8E?T=A)^*-)*P"E1..N/\6&RA%N7X1RL8Q-C*CC`G&A M"8H,,XA$$8VT3;&0O(@]"6L,7+N./EP#D4$($)5R/T8/=,`IQ$WDYU"2"*5I MP@2-19S&=%^'<7C_=,L=<2A^_QT1)/Z^%350!TYNB2M>QE.=5YM@"E_4KZ0U M-3WIP5BB5<1YKOT$P1<0JEJID3(.'L!QRERT3STQU>R^[G(;7R5O"I!.#"0I M2T4_K^/%]NM+MMU6C7)]KK$9+NPG9X<IJC#M8"E)F:1P<!H'_^-:HXBF"9(* M;*=)3&J3I#`/?MJAQ(W\U!`13]1ON>R/[&5=3C+KE,HH4(`]P_J6X'"K(YDP MA2RQ#OP(!2>'\'>OC,0VBB-L(E<@(>J>T[E'[^8W=5]N60C:%$(Q14QLD&]` MA^4T"?)U64@FE,4F8M;QN"BXL=N[Q1VLVNO+[F[]?+?[FMVM5QEZ7F_0=OD7 MO.*W?7:WS??MW39_R.SY.8^T[I:KN_]]765W_DG^D?_LX]Y.W.555G?P07>_ M9!M?Y!V5K^Z6O[UD=W>_5WYV^>&/7WUA_M/=,VRM._(/@/:NT%W_7(^Y2I7O M_#W;%"_Y5_8??O#IS0_?K>^(E/=2=?G,QA,W/O,^W(6<RGEN*$4'[SE08:[M M/9_^Z3C7A.T/JZK78+=Y??3=!;^\_K;-_N\5]E;YEL_KMPQY;G.*Q>T'V&"? M.PS$ZEHG5\<V((=",9IK=BOD^EX(C>"<'$$PS628.@R]G)/J[64E<<?;H>M+ M39FR+)4<G`UI_2P@@XP?A6R5XTJD?A).]#8S\*@%IR[&H8#5F6Q73[5CN=8! M!DJRVRP>=Y_7G[(-G%3?TO4F)]/=UEO&DL5FU66@(JLBV<88F?XET4HI(ZBS M*)8I^.X$@C?M1(J,M)0G.K*ZCI!L(G15'"8HMV\!L#<X]#W4U]]2>WQ!O3AP M:P<4U,]B%PJ`<L]FI'2>6&5BG,8%S1)+'7%(&.([G5V,C'40<,=6NT0XB+G? M&CV..5W&VJ4_+2'NVH%37]VM%VN8/>4K6/O\+H?`C,$E]4.B(P+7C46E\"CA MHEMUO&`T3VI3'1Z-5I-3P:Z!"NVW^.=-MMAU-%8-$?L]/JS8)_;KVT37<\_5 ML<U]>Z[!^V-U85BD(L"[+G[IOS,_32=[LN`Y+KYD!V.+.F/"+BU[\!UYS"B6 M3F'D$O".N9`"@?X+I".%C9!6$>H\5T917''/:(?^]ZOBTZC`RS,$L,5^6$&4 M[=GJ_&VC-V#+U>MR]:4<:-.)F?XLKNTWS80G*=/"(J:YIR!2H(()0.DH=CCO M_R;PV45YYD&E7;`8(>)[\OG5X_)EF?\(?#/>9$^=AK:,#P$$I@@B?-Z&P3E9 M#G'XD/T_>]?ZVS:2Y/\580Z[N/O0'O:[>P9[`)^#`$D<9#R+FT^!;-$);V3) M)\E)O'_]=36I!RE*:DHD)<UL`B2V1%&L7U=7U[L6X/<S=LG7;`2-JWXSG/9F MLFIGY,.-\\Y6W;"&>_L:94P-$80)DC@Q1DA,"?(YQD9416$<$<Q#,'P^86X` MDK(RB^(T.EW$6K45NCVYK$V7;U:8`#$O;<B/L,U_>S;?8G^R[;%[$6)'M[_5 MGJ<^41@LBF^J76`Z`J3YMOUU85X",V'Z,!ROKFOD<^I\$V.[B;V&FW@792TU MERD.%:N&K$Z4AO-7=D+GR(7<$])+#!=Z&`Y3S8PAI+3YAZI$>[X,I%X=IE)+ M070+[61V$]X2LINAN.7]>\,T]F./Q+XQ+I7RH<-MA'QC5"(11=R/S%_F!^UC M6D=RRTV0_)$YS\Q'EJUNCAFMT1N_KLIGV^Q_M!N!,M05M;#4/FFC3SW,Q'X` MXS8;ORPZ0K'F8/<TEC24&F;/4`AO)DAA3Z)0)EK[AE>IEKGB0R21Y:CW<90U M/U2L%>^/_O=EOFAJB'=^F!15.<W.DBI![9XAQCA\3#.(@D`'Z/C[<U9H4G\* M0\[VW[KAO+VCYR2\>EZZ"SRXL.W8*ZEF/2Y)R[Z.LO9QU?L#QD'<Z";;HSUP M.C35WDZ_79NI1F$XM7?0Y=0.()53=3B;0/W;L@2D?>7B&"9VU#6,B8OP#=FT MS_:3TURC\!=):E"&A('AXF4QG;V6+KXD!<.SUBIM:*T>(+#2?W*RR$8`I;GG MNIMZ_/UA_#)*1Q`N!WY]6>2ZRV-U-9I6#I^FL-*8A#*F,9):$0,;"9$O8HIX M**4RF$4Z`2;BD`&`M2RWHVR#T.;<]GYJMO3HY<'F24$=SF2>ULL"B-)?$O-Q MJ]V29KS7C%RGO@^V6.=C.E\8\;=8EIY88RQ=W#YN:`N].D4;G`7&ND>"U,QD M.X'6:AS9SOX!)OZE:6[LZ5`DD3;;S]P[X#9OF%&D?,61C`(_"OT(8RO:H1L/ MJX1U*X]=I>IY7?(,.]9@E=ZW?/RWX_LFY2[5.YZ\OB+];NH__-]+9D3,1CME MJ/-=2ZE+)1M+<%RQZ@SR9H2543&R998:61&E^?]O)NOM`(&$2X2!E$?5'B)A MB^"E._G#,(.-WB^)!#+"?89"8K2QW)'&8H9$B&GH4Q%CH7*_>3FW</NQZ\B" MH1SYT;H=VPG2Q^DLW;B/X0YC7S282]L"^3*"$9*A9^B-,:QPC)2Y'RQXA%FB MDSCP<O*W:#^&MD-CR9;#W,QG_/D\+1)8WTQ:4[/<\RNP)#[EYMZ1%-"(Q8M1 MX/$`Z<1G,@XI#B*9JZB85B?2-"6L,J<&/&2@*LS2+T9;6"D<`+@]!\U-+O2L MYS""%9=WB@LYM=FGQLCY-9U]-;_,&P\M;.-83UAL#FR&`AT8B\T(.Z2U(5V( MV!`?DX#$A<5FE,GR`,J=!!R2]1]FYN3,1DMN*11(<Y_<:PJ<<YFQ;[#45"7T M?1QY98A^&6838)3;2=[YX\-L:H3,XA4<`PO(A7\^*BNI!T@8J`8E/-QH<;<) MXJ?G\?0US2LJEA->X687*APHA\EZSF;`3O+<$=KP)*V\2"T[@-I#Q[J2:R9U M-Z'-_2#9K9.N8S-G.6P<Q2[HG$U.FB;T[A@;M[[9)0("H0A$J:K8F#5/?^@0 MBG*3M#RM),Q[C%VBI-4'K(]]]&Q-[*GRSD7O`6*77)+RN;N'BDH.WG0R+;-' M<2+W:X)0PGFL,8JP8(@%PH=FQ@$RBR^QDK'B@9^[3[`LNS1W/O_)IMB[;#*= M02?%HB&.45'*=\G+\-ZEBR]3\\[7M+WH?.NV6\$D6-;8K[V`LJW1+36@<R'G M*%AD2;#L>/!:3^1%GA`<2DL$4W4^R!W=(E<NK)*N"F'I2U:]L3D1."/[G7([ M*=K*4ZY1(NZF&Z63166N#<SU"H=C3+%>`#0D;`\J%ZI0<WF8[NI!L=S5^15+ M0=<K@9JQQ)Q\`?(AO,=(PI'R`X*("'U/)D;@8YW[G;2H2/3ZIZ_2F+\*3LM+ M=+1Z%65N_;3U="R=!SG-EZBXP$I5'2-USUZ)2Z\SY(S(6J5;`A#KBG\(+-Y7 M`XL?4R/)YMDB+7Q/N<WX,9^A"Q=8\_%2-RT<4KP:NNX8BY/5Q<C\,%_T+/T= MU3^O+?5O262%3\?CZ0/85?51[G,8%"R.I`I$@#@QFA#S/8%\J12*>1AS%>#$ M"Z/\6-SF-"=JR@@LO9DKJ(JKBD'5O9).,?6Y\#127N0A9F02"KC9:'$4:!*' M$:4LWE)L#Q!0I=;8E@]YLH/Y>9P6M?'^T]38U?^RKU^B3@@):;2<@^!"RD%? M28'=.0(4KMHPE$T)*,7=[YROD%)_W)YE/Y-`\SB$_@0R,70J@91@&OJ?^+ZO M`X(5VZDYU&[9KKO9]AAZ+V_E4]K6[F\V<(Z%=[1K85B`SN<O'VJ9L%>`UU>Y M7;XT%[72W(6:K84O6D@912`T!^#GR_1CZ$JNT?935[RZPSFP`?P'1O[7X1@T MR5P5K(K!2]SC%!H*$E[I;=6`J!T)-V?D;!5[4B<1&$R!4=%D;"C7OD:2**FE M]&(A9(U(=V#B5;SC+5`^_[C>]'UG%@5AY',92>3Y,,E&<:.?:ZT0#BF-S7I& ML5<8\D8O$?5!FSHB*LR=QS&*C.>KD%?E9*(#!.S6/GO-!J(:^J^Q$/%$6EL? M(\._&K%(^,;6QQ%;=EMAE5R@S4=V:H&09!-S;%]E"P0"!6K0(=:E!8(CG=WU MZ.L/%L@%J2HH#3OR;5Y>DSYRZ2YY8O/D=@)P@*):D5=2<*Y"\)$ZP;>?C$/V MI__P,'M)1V^SX3W,-<EZUMA<35#K:ZF4`+@0L]/G"XG3%QRLAER,2O97_<,[ MG0BY9_\Z3P0(/IFGT"XG@B.=6TD,#^9>MS-(["A^L2&^N77P)MGW=)1G%A:! MOT:M;'N+>T#;7TVKZ0U-*:L5E)>@\#M*2%HG(9WT?MOC-:^7AFLNTG"%+%G! MJI'IZI/O,\J+2^VJOWEZ'F:SI[S-<^^VNN/^YWML];W$5))&S)(;ZP"N'CUE MD\S<9@B5>!?LE5*VUZ0NK_4!.APR\^ZF5Y.7AZF5_=XAO_-.HO9KP`;$=T-@ MI<7K[>/N],Z+1`8:'BG&V%Z%V)%`E\8#EPB"J(F_U3]]O;NV\!A<T>G&:QVU M^^G8HCV;`#B3Q2R[?UFV2"A2Y6=1-C>[RD;'9Z^;%W5=/U7;N!]S/_(@Z$\! ME"36*%"&%W@L9!2)F,52%G,C2J"<0*"#M61;57\8OMIDI]EP=)$>7]M61O!J M?H\+.345`.7P3Y2!SCT9V:.WU;Y2K2>NE1V%[K1LM#*N]:SLK"RQ'4:6'0^N MH<V*A(G`0A3]D4\@=@,RIS8'Z6+MHY["Z*9EEZ)+ZN`@EOW)6J!K`Z!C&CP5 MC6XV#G%;\5_74WG4?0?,[7;<[OT$<2ZP^T=B<P7VU$6]3[_9=^8EI;+!Q/=> M\]V8M^$:/I:V'6-GH]GP6S3]-LG%0;8PE^<9^BO/>S)\*!QM($`7[X:S/])% M\>*KK1E9BI2FDV#Z<S#Q-3MV2GQ5`&RS\.UCP;^W,\O-\W)#MS3OY7:134(W M^]BU0>(&6$4M]++.8+L2ZQ*-=_#&R7PH=`'(03(.*1WE+6L`LQ[0/G6-[7.T M@9PB1D[=8+)/T]A+83-XSB=V&D`"?6'QFD.:DM50Y:IVD)C_!I/L_Y6.WD\7 MA:W8BFAI3?MBH'VQ)MJ7$XF.:L!)\U)[92.6CPMU./Z=!J26$]ZN2^S"D"FO MB!4=152-)@3ICD7MEW6L`;Y6'[4'F'EWB>65Z#O0845Z5&T,XCJ=TH-\E.OH M1;W*)1<YPCEEKC_$0K7T-)3(>>3^^1FRQ:>3EC(O6A._Q!J_LH'XW:9G<V)U MXV"D=4>].4.UD6/$U1@.:N/X/HW`3?5FRT]WQ*V_S*8OG[^<.[O##4CH64LV M]*`NZ;^@YJV?,#&'N)(PVPZ3TLSY]IJY&@;-:U?*<<0.FKE>#):4L6ZPA&FQ MH&)(H3M#T^Z`W;&Z93PO.J'1,F"E.:&`E=F2"F8H>N82^)TI3.V,1<./\+LP M>L*V;JHY503'2'!L-`WJ0^%@A)%167%LOI3C@`%8'!RHYGL96ME];I2=!0J# MA>@&"@I0\`**E3NY"13[PYL.HP%RU]6;":1/Y'U506^Y^S*<5!TPIPY+R"'$ MM)!JS9U..N)&'PN,J1/&"6)^'*$`*Q]Y?A@ST-,P#SZ)8C(-T[J-F3_-X>EK M7?;.#[!O`I<DPVQVDIZT9]6.\0LQJD7(8J-31IZQ7CV/(I\IC@+?$Z&,%!4J MRM?0;`MQ<SB"?P8H^UKA?Z;SZ]IV(-0Q5EKVL6AE=,ZSZZY@3<PV8EB(@Z,- MVP?G/-ODSR<(!0A"J?K?4Q<C"#>Z\__YEE?VM[Q-<+QV]7*_H7=T3%/9F":Y M?OURFR7.O@!.P]%6"]"&9K@;A(N=/]LCRKI5D+L;17L>I:U+`:/_8DK;W70Q M'+=]A!,'S_1V.3;A,9<148AI21$3.$):)!0E(56!KY+8%R3WG4+=:;4D^SR` MG9A!V(!/=BJ'K4QS=%O`'3K8M@O.:;JC*G2P4Q(/6P>PR8+NG#-9?:#*\]0< M>G^J-6V43=H3B"U)U]7&]^?SEZ=E9NMS"F.0EHGKIPQ<W%PS+HC>$T3>#ICX M4HI8V^IEY2$F=8QT`"%U'[(0,(\\Y7^BMA[SIAW9Z0I'#?I;;1VWO^Z^R=?= MI;.GHXN`MV$_#EJC''\0OY-W9BM4T.V$W`Z9^F,V_R.9I:N&LY?.U%Y>%M"& MWN8*1P\BY9_3\7!A<Y<O'7\HZ[F1].!PX%8!Z3,FN2,&R2A7K"8)UR4&*4#[ M,5_"SQ2`[.,P,Y?92*TD1+7/=^S?AYD+[,=!"X<9_IV^^_=)UBM'YR?9X3'K M?]63K&O\\Y.,B3.<9)>2MK4+X_;2MBBX<5CAQNDN:6M'^<:[\5=_L?S0;\_& M`GZ;/1W?7F"-&,>8<-E'`0\DN:I/G-H0EMY?K;*#7"><;%JYK;:;SS/;2;N5 M;'HWR-JHQRB`,KQ&*#E8V'.8XH;<]7;Z[9S<A4\"C0!W\0;,M:;6L:)G6:*Y MO#GHO'/_LSF?3DF][YV[;,&ODFX5/_MI/@Q<4<;9"W+PNV`>AL/`8^2(R(LK MBO@3S^M5/:[H?A1=`+@H_MN#8@?\B"T_XGZ8\4PH4D$[K.$#[/AR5XOV@+P8 M_<[\]6J\0>WI=ZP(TQ'&=-=%#A_3[.G^939/-\H(3P)':?$=,\ZXYD=VPI$Q M-TB@B$F#D&`$:9QXT%Z4*BYPA+T@#V2"Q/-(60>N(\>U)#3';SP>WD]/Z]S2 M,PYD`X<CJ'2%YTK0V`B?[26G=DHE@//+2;71:VJY9W;T<=0FD3;BP'Q7P"E& MC#&*E*\XDE'@1Z$?8:SEBEJA*SN@0DD?^YU3B<5QM(8"LS#Q!-)AP!'S:(`" MDC!D7B>)EGX82%E.7'#9[1VNJR!8LR,K=EW6=5F417B3=0VGYMB<+/(M#6XJ M(_3AA>'G]"1?*#5_OD-1D6*T45%N2#&5B4]1Y$L8QL8\%$2&UD2&3`@L0Z-( MK.2X=T/99O_7W;3T2K6$7IWM4TV6<LHV*FM.=;<3YFQX!G-M5QU3>A2G.TV< M6ZX^\7A%SSEBZ%R/H'#9Y1B^I:CC5)T,RF^363JT#4-@5C/T;[N=M#!B>KN* M\!AA&/)(!.9;B.8>8I&42-/(1R1B(N1:A,&R0A4&-I9G_1R@Z\(,!F-W@<&@ M,"YY4]HS&'BA!G;H##;2Z6LZ`Y]>J4MB=91::5IR!YAUV#\28]M\1I6L_V/( MK@2$]KEAUK<'QR#\O,CNV^C57(6P)U<4!@<*@QZ<BDJA-A-*3H+!"5+K2;@$ M1-MVJ.2HBGR2TD%(W6"X="8ERN/=,2FU3(H(]8CXB_!HQTX_#$X_X%'4&9/: M'%8XM6;I%Z/JK%KWP/%OXTYWP^\G(@=(&7*$[@XIH^F:*P$H7-9I7,C;&HZS MOJ0-RC57JE/*C:HB:Z=OETAI()MV]G)N`X\.3TH-(IT*\&AHQ1U%T&YB&R!F M)XYDD$21S[Z%5`O+7ALYX=>`G;;CT_BFW^!DNAO`:-^L=F>^!MP(-#N@I5X' MC>D\3^/I_C0NBQ0THB9NX:O#7:B3V?`!,!R.<UCS1HUP^N6[^=?G<98W`K\" M'F(:="=5`.-.FFMTOKU.I7V"PNWT%B8.,,PN$EW!Z6]3M8X0M@Y\\S1.$.W= M5!>@''1GH6@P4&AYB/F?1S'H&C?MCIN[3G`NH=4Q6&QC5L#UR:NNP<&.X)PB MJ:S^T-?6Z]8'H,$%0)71#41EL.VIM+LCN5,27@M\9D-R[@S>3G+=$>O,D.D# M+9OTZ.YPVF/,K.(FZZ%9=U-_-,IRU?;#,!N]F83#YVQ1Z+E;E3P?T[Q_;_IK M.ON:QPK,]T)#Z<\3>Y>3FT3TB"SG-;,(N\;F_&9E#\CF\XV8:LNR[&?D0]\@ MG3X"HNL4$<VH08,1IOB^FN#M%)'(DR(,I8?"0(;0R`A21+B'2$SC)%8BCKE: MI[+="'I,BD@QG,>?C(H=-V\AUVL'R>X,$/F>(3$)48*)AYC6`@5$*D2T$"KV M5!3)->GK<4,'B=J9\]7.@(^>:6>5"=$[J"GE;:Y%0V<YG#TBP&'T.V&EL2>. M%)90V<@.O'VT-9OFN*K_.)0G70DZ9'LF3$-"=X-43/^X<H3H9@YP$_K.M*<H M(_JX.JLP5MI8P3%B?F3^86&,_(`*1`0A,E2*!P')YWX*AOGU[:?.D3&L0HGB M5[J9.H?'G$44;T[].V8_+8\RT-?RZN_Q>/H-ZGQ@0A-\>O8UG8?&<OB<CB"5 M:@Z#B%K(V-2:"INC*(Y$*6",^8$?(9\F1N3P""-?101%6IMO$502/\PG"V$J M9%E;.8K:HP"SB[`<?7T->-&2AG,,E4UPBM+1BXU0704VK`$V:\JVTWZM:?TO M.SJPF!0X7\XA`K_WRQ@F.H-6^<&84K.B/>/P^X=I/H+H%*R4)SA8BEIR=5SZ MN`RT@2;1*/3#P!SU1DX9U#3RI0ZY,JHAQU%>)F>VGMI*#3Z5]A/0#%]F,R/\ MKA9/F*Q$CP=T)_F7R*!,2R6.V\RN@-JN=EC\13BT%T`IS*MB?Q$6Y<3C1]97 MN"**K4%Y`J!7Q:*]`$KA4)*=LVC_R0_*TX(Y]3:J"[WZ/L=QP#4R)PQ&3/D2 M*88E2I0?)0E./.:S=6EWBXF1^<#/G1<5+6]+%1X=@'1,.R-WR,PFIK:>\`AB MNYP:T.7DDR72FBE]ZN03;33R6&`?\21A!FD!DT\\@0)LC&/?C\)0DA5STIL2 M;_8+6$LM%$L-VM^_/-VGL]O'?#]UL"1N$L)]$4!/Y9*)ZC*TC$076"\7>K6@ MI\2A'+;`@<D![IC;-F!UDP,Z@*1=D;0,$LY+@PC>3!;F))EG#SW(H?WMX=W7 MP#8GDMM+T#$XESQ7ID"?$29+U>IN(D=&OM'GP@0E'!I;)A%'6DJCU?D>"8*` M>`&7FYU%>ILKTWE!^R[<&D1DB!9>R$/$,4PU4"I"/J8>XC*).14!TQ1OL&VE M7>41]>P=!?.5^5G5N-,/!_,#;.?+^TA[A$,1NT+:#R)$I.\'/B5:T7`CF']< MEPN#33:_?2Q\GZ#[3L?9PVO^[YTA.1@?4VW-EH/0MR8M>0$)9&SL'*H0\Q*. M`B9\1!2EQL:)%8G\3_#!__[[>/'S*/OZ]\^+G\T#PV_/@_GB=9S^XX=W_L=? MWKQ'P>W=W>V[GP;>\_>?!\5K;^/D[J<!^=OJA;O;#S\-L'K^_L/&G1X--<N; M);?O[U#BOWOS]O>?!G?9D]%0WJ??!A^G3\/)#X.YL:E@;>##\,G[Y0\9_&#! M&TP?S6T_&'$```/@\/Z/V?+*'U>?^1&^=_7+<T/2+"4"7KB+_^<.O7D?Q>\- MK>QO/PR&X^SSY!\_0`95]OBZ>MCCR+S[8C?^W'#`"+;0X#&;#"</V7!L[F5> MR+L[9!-;[3]8F*N'R_"`12)\74S_R";I(GN8#X:3T<"8HH-O7Z;C\>M@^FUB M;CA_N9]GHVPX>[T9P+>MOL!\NN8KAN/Q8+A.#QO\)SQ=-@=F'4PG<-?'P60Z M>[*?GT&!)]APFQ_Y+_.8P\7`D#K,Y>?@/AUGZ5<#`IACD_0AG<_-XPP>IS-S M#Z#IT6@+@^>-185O@3?NAV/K*K>DS:QE/8?/V3>?K<"=FWL4'TU'-_M7_L>" MQ]=[UVU'5F77TU.6T^I/C*BSGTL-IND\RN8/X^G<2)OV=S/S,*<A"Q"GL5$M ML%9(B2A`E`N?>A$CA+)3=G-Y\[:P<]]/%^D`>W\?/CW__!_??>_GXB>@$1YL M`T>[OB4DV]S,]7)*=".F-JBZ?M$$Y_AP\CH86]?6_[-WM;^-VTC_>X']'XB] M%M@%I-2R9=F^WA7PZR'/M;N+S;9%[TM!6W3,JRRY>DGB^^N?&5*R+<=)-HD= MO62`HAO;?)T9S@R'G!]A5<[Q):9HQ>'_R#*\#:K.B,'4NB)D'.;A![XYPU6K M7G!@`2Q3KM2':D0K!W&SDK@]E3X#:>@:[%K&"V@12N/R1[400*%80!^XU'55 M7/A0AF\NK,)OH1#F6O`PU09:QZGBV(@(EQ%HAP"?+5#5,1H']5;:C8,907/L M,N1NHK1O-..>GAGTJD44Y[\5W-X/4589==1,A#&7_LXDA?9V(CV0M+Y6E3IH M&*DQ9.7T`")P'C!68'J@RD'I*4-W)<+MW%')Z0D>28!PH9]:@C[O3O2:PRI' MY8WGGV!7@&KQ(D@B(';T_N_/F)4:S\7Y?\8PJ>;^-!L[BWRKA_;;CY6DIGT, M/GX>C3^;PX\__=3_=`&MSA!D<16!`PDR[:'P`Z/5Y@\_KU`<T\_7THT7_WS; M:VXIB8Z@"-^R:1#"`L%2N_V&NQ_<K'ZG]=V&\M_';K[,5=KP-(CC8+GIT[Z[ MRK&^?XU=?Y]G47COJ/*K12T$2W^9%[V<G#\PTZ]I\Q&MYV4\6T=_4[&@!K-6 M-TRYHF]O$1P6`4@^?($O4^=E^ZE*PLI;T-]!BT=L#';$A?&.P$W$^-UV<BW+ MN,^,'H&.][=)HK`O"LT320(ZB(6R^G73OD6T+XSVS5*I.#:]A$D'X+;\;3@< MCR>3MX<'$`>KW5_VW36]_[+$<L_A-.&K([J8]_N0+RQE][;^V%E^^^C^,@$- M<5OQS-Y;1JO5??P(_.`ZY*M_OM7_/C>H<'PF$(MS+&XXQ.*:L[C3KAZ+;YFD MW4[377\^D'<WV[Z*O7<-\2OJ[IN_U,50@8C,OVB!?^$&R=03ATSS8PW6:7L\ M4)PH2!0L%07S^N%[%<F[QQ6].Q[:/'T\M(\1],.1#0R#VP:;)PB3PI;2E\MD MF8:]LV`U3$E'V?W`OSO`'K%K`4WD0ZWJG(V"K3E13NMW>X\/MK9?.NQ8_HT8 M/N!-&["3N6Z]1O5=MQ**[($]3UU$]AD='U=VVPV[^K);"07<(6D^N30[S0K& M22J@B0\$&$EVCRJ[EM%U:N!%5$(3]\HLS2=CZ7,'<DQIW[UK6!X*U45A?UF( M4/`Y;+9)T$G0*;Q_X/K``9$Y163UR1T>*/YR=K=Y$J6$V6YEUD?/FUZQ,2BK M:;2Z=7`?*ZY@Z.RFP!2TVQDJE<WN./=5<D$0NM+'9*Q9@%B`>#XU32+IBR@R M5($L`V3)UUDB!<Q&^JY8^G(N9US#N4"]*V@&3Z&B6;!*<RA4^D4<L"OANT$( M+7K0+OX!363=L!4/8U^$.@<H0&PX]17"_*JLD%!$*S&+L9TTW0)J+WD,K4.+ M.F\-^C6@Q1C43<P\N928S!$'T&$012KQ3$8J@RV)T]2R-W<D=TS!KYTML%"4 MP+_\,A0Z0\Y@48I5C".9BHP:>%EYN@9"8BK'5"RX-\^RU](.#/QQ'@9+&&PL M/`\FDV`.2H@G=_%:D7..670Z6V[F<0ED6W)78,/Q0H9N1I$S=K[-?\DQ"%I9 M\(BI`S"8._04['-I9S*:LI@KZ,H0QA-H\D,CFXR6N?I99_RDS!$I%DFDDWBN MI><!=_Y*H(D\20W&EP&26W$39N!?HCAM1X33$DL8$'2%^)D;OGJ23Z6GW\Y, MTPC7BGN*%HBPLTD.E*'*7TPB)&_*&\;QE'0S)V,[?BBS&7XN-P=Z`&+A.#;U MH`DEB[HN##I*0CQO-=CU0H)0X)AF*C\GH];NL%-9@T8TSY&*4UBZF@<Y(MQB MP![YH8W####4QWD0+F$0N2+;YA0]L_9F,IPE2Z`79E/>-7^02(0AW,Q&BV8Z M>3V\W5<M&2A"$8(D;\H?)!6.XB%B;4FU)[-(@0WQ4/QC)B.URE>PLO&14:2H M*U#58.X4KH@EOU&GYZL@!EG7F:Y<O_T-9!4W*Y6@F9ZE0P60K?V5LM,G<Q/L MXXW.5,UTRT)&0&25#;M"U*Q;+:2K.$TEPTSTOQ)<(7,^2],=<RR!^E>!=Z56 M+E,:2*WX6>+Q6VWG:'+&+E!/W3<!%%>D&.BL*)G^5^M2I4,UG3R%VN#Q1*6M M_;S-VTTI/=,@5AXLQ&O,X(4Y:X63*F&]4,&`>$`7#G+!\1<18A(S=]7[<4S, MY]AOH*W.;@[R*H7$,C;YO=!^>J=!6180'!XMV%S=9=A7WD=+AWN!ZQ^@NK.[ M'^EUCUT#.Y<><)\SCU]'B8PQ$5M<9GJ$)V[B*9;XL$(5=XP=4X4IQOAXGY(K M7US"J`4N64UN)#((D^(;<WG,=W.SM6G6J94@!-('"?)8C,S;3V$$<8B$^!.7 M*VAW$:/;X/(EM`1BTT<Q@!+P'U?CT7[2>J/%WWR3,A@EG#/4_`:(ES:C^'2P MLE]3(7QM^N1M4=FFJS\ZS_MQ.=OY?.^1F,:G3.RV)DV[W1B/S4:K-S'M,6*6 M#!I-LVF/1\/.L..TG?(E=F_]^MZ="=Y(N(KZQGW0ZAZLTH:37Z4Y_XK[.PG0 MJ:"J!;MQM+2?]:\Q2Q_54>ODOCM@EI&NV!3Y0%FL31]>@*A_X,2BU4"G=V/$ M8-FIW.%KY0!]:[6;!NS=\H8^%"LNM3D*!5K]U"/>-+;I"'5.-ATPKE.U9G]& M9'`<8U.KF8#-DU`Y>',8A09WX%=<JEMI;[ZY-3344T`Z&1]!9[_LMD]!QXL( MR3+>236I[-Y/!<K49@1GM<G0AJT46GI7[SJV<I//W(;Y4.[V@4.9+'>[\_CK MA$YQ"=1U[IH2=E\V=WL[%Y7$O?U(N=SE%PW*Y:XE[2F7FW*YM8HK_[VI\SV' M]'Z_LDY72YYPM$LW2DJ2$TR20))0_>L=K>JQEVYVE/=F!U&0*%@T!1^X773[ MC.B.<Y[\8="8AQ@WC[(75XY_'-1O.,-&O^N876?<-NU^<VSV>[9E3GJMWKBC M7A%X_G%0X\@POTVVZRM`G9C]%$08+`9",46I^W9#98V4(SSTC/DBUH?D*YB+ M>HP`3V>#&4^O'\R"Y3+PH740@T7@N7@F+B-U[V&Y2F(=40=&277*LFGMP3:F MZ_36P77ZD@SC^BD9YJNW3=2M*_7LQJ:Z?O5EYU`'K\.H9Y9V(+//V$AZ:EPX M%NE#97'?!/5,#DPQ-\%+F"`>(NF3?CP>\[SM'0QOK2[F0+=X<R0WW)U+7+GC M*-59B@BLKHPE?CI;W"6&<J80>[&0P:YYJ)YA,'`9`I%B=35D%8JY4$<:JEAZ MKR<EDHRB1$UP<Q'D\(VP[`4F=I&VD;W"Q/`9)O9N6WKXP_CBTZ?MY]$/[PVD M#%^MO'7&@A@O,27A>C.DI8@7&7"Q/F/!HC)2I6?<PSL@&2;Z5,FCON>SX2"T M\5CIS)W@0'UQ,Q.K>*<%O"9`)SO>[LF.<\^!16%`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`-UN/3\^\I\JQOG^-75-.WHNE9U)"9OF9 M3PF9M:0])6120J96<>4/Z7S4("KHIZXR])+\0>?]OF25=W@E.=]H&<W>@4?. MRWZ\0;Q^RL&E8=MT2/TZ>&T9G5[18=<C'%N6S6+]E@)ZD<DJ3K0=PZFB:!.O MGS",#O"Z2;Q^%;SN&8TJWJ&KWK;K0H3XR.E@%VH`1K$'2\G>\2@KH<`+<F<) M[\MLYBCMO/2KAD2"1(*,YC'B-]U6!>,W9=_G?=Z#<GZ#,,\RKG%*<4GDV:G@ MDQ_$Z"<,PZ9MW>M@=+/P;/+7L:G;>SX@!SJ'=[W4(P!DODX<=J>\L%?"Z*)O M/A.C7XC1%3QJJ%OR7WWPMHA^1+\BZ7?$N$OS%%[LER#F7HJ30<[JJ4U;PV@X M%=R<$;.?QFRK1\Q^)<RVC:Y3-$`C.:ZU0@P@"A(%BZ;@HQ]/OO-=Y/SSR1>S MA7`33WR<CU7&J[P2Y^K]V2_\YC./Q6<Q"_R9]*1*Q/V"W1[_A>5AJ]'IV`/+ M[(^:$]-NM7IF=]`=FL-AOV>W>V-[W&T=XX7E%\YQCAAG88Y^^,H)1J2CF,=) M'(1K-A>N"+D'DTF?_8WY#0N!\'CMZ,XG<$7&*RP.=;$"91^KE9O6[UJ/SSZ^ MYSW98WU_5]<%ODM[\JXI`?7%LH]W'H=5WX7L^W3LE)=<?K&@O.3'M5EJBE<Q M&[G:%*<<Y$=ZJ^!I\CCS0+<^*8PD<T+O=RDI7'6$1R>*/DU__UW12H7X2GPE MOIZ`KV6_:GX18YQC&_<P%+2;PGK+C!(:(OUN;$RVZ-2R7?1]'U)9)V%KA306 ML?7KV5KT(><S#%'Y]T;*-$&W_=4J"#%RCU"E9(%.G3!1=#X?::I3(%D04^O' MU*)!LNNS"\(PW"P4KHP1G_H=;(%*C3!1"^E]5[1.(I_X-#M8VNO4DZ]%HR/5 M>K,SRM"/,-K&HTAH2Y3$TH-2[GL@99Q%X>K\7%!)I+UHVT0J[!2@#T4'5XFK M)^!JN^@@7'VV01<(-F1.>21<Z!P?_Q%^I"[-DL$YM1171HA)-7U]+)686C^F M5C?J5OY=T(>//['QS4J&9'1(/Y%^>M(P:)-30Z969Z66?8_S,5Z(D"P+.4FD MA,BR$%,KQ-2ZP7/4!]?K0?J581)$M5I0[:1!C=.ARI''21XG.2?$5&)JA9A: M-X^S3F!<+^D]$=V(;H\&?WL.JMM=^'`*16Z`]S.&.Y<SML]%J0L<O^!34?UK M'KI][%7&ZQ-!QO7&'6LP=FRS,VD[IMV&%@;VJ&T.QBUG,NK:3KLYJ0)DW/YS M6^JQ+<93XK%K'C'X3X/*103QIM9G6K_3>CS$6[<XG+4.X:S5!5#K0Y*'4@OF MZJ<MVMK%%L9]NIE?N1SX&K/G-X$[A5L0>/TK$?)+L9VCLE-[A4:(>K0I,>%R MA\V_<B\1>^57NW*@V%XHUZMW[>:@`<3\@R")HYC[:#40INH@@"$##^'`(0*% MMXY[/]3J&.U6T;=$3\"/<G'[VT*9[)QUBLZ^?P(/ROZJRYW:[0I^H%RJDTOU M.]@]&KW"==?[FJJLDG"Y'KJK_*>)=VJS>1#.!26'OH1"<[I&IU'TE4S29Z3/ M'M9G%3^QJL^]E>/3[_3ERGZ7^]EQBP,ZG&SE<1,7+,?H]BJH28G;K]=H5G<3 M<!ERG[8`IQ=TVS(<I^BK\Z357DJK-8J^LT9A65)A1P_+6A:X9D4C75$8@SRR M.GMD%)9],85F&[U>X2"5I,Y(G5%4EJ*RIRM7]JCL+[[VX%FX9Q-A*,HJ?G5X MMD4V\R7B&`?(7':-2LQ^M7&,"N\%*#K[0EJM9;2K*.K$["<,HW?F%'VUD**S MI,*.'IUM&-U6T9X913/((:NS0T;!V1?39Y;1*%S829V1.GM8G5%PEH*S3R[W M>H*S!Y[Y(YMY7'W:,EJM"FK4:C&[V)3?[EF[@M<(ZV8SZP1457VK^2APK:-` M8CV,M_6)KY?"CU4;JLF/*^PG^I5[B>JQ'T7)4G]W(KBMKM5V6L-^RVQ;]LBT MVR/'[/6[CMF>-'K==A=:;/2J`+?U92'8G,L012,1+)BS",FLWYUC*TWH2,%N M`1?EDJ./$O@L7@B8C0L?L8XZ2V%)A&X*_,(&'I_]:0+K`@^Z#A0GV`ID``LL M`U=X3'<0^-`*UM"`7OCS=0I6P[B&I\$'6#-FU@OORVHTG@?X93N/!_QJ%P?X M15U3UT?KFL#=4H)OT,.<$Z&'_2YXR,:^>PL_[('=Z'0SUV.3M9`VZ\2@%C&H MW`QJ%LH@TJW[DG$J9,;Q<N4%:[$/HJ@V-=L9IML;6K0ORIJ+3Y^(XK08B#6T M&&@Q$&M*M!@J"&HLHS_->2@$D\@)$<4PAA"AI6_-E,XMC_NDY%G169CT;M,) MV-HX*QKRD-AZDM5:]`$TL956*[&55NLK9FN55FO9KSC^&G@\EIZ,U^3IGUAL M.QU21W7D:]<Y*_K>*?'U%.NU52$[0WS]>K[:9P[QM89\)7>_GGQM5LB^5B_T M/[Y9"979%(MPR21>^%T+'D:T'SAUQM+9Z\E7>I4,MLZ:%01;(08_8@4W:077 MF<&T@FO.8.?L$&XF,;@V#*[F"B[[J<%FS^#**^D*W\5-@Q0>00.=_NRK:(^# M8AS$5F(KL9782FPEMA);B:TG.SYX(K;+T^%7]J!=L,7I/EI,/PRY?RFPA\%Z M6V2WTZP_!9[6]]ULN_`EP*\^;C'3?DNQ1/H:2N2S6'+IP_=#(%#(9W'"O2\B M7%I'@X5I#=LC:]2WH=J@8]H3:V(.>DW;M)N#R=CI3EJ6TX3Z#>N/UML?/SF_ M]WZVK-$.M4M#D0.<NH7KLS.N*!W8+?E(!S:^$>%,1B(Z]S^)4`;NWCBRWS^% M<B:>S@T$S5.U9!383:OSQR\7HS]6(OQ#@=I$;YDK9G+)O4@E!^WQ;MAJ-IQ1 MIV&.QL.>:;>=MMFS[+;9'70:O;;3[UC-T1^6A<RS[+<_(L#F'N=>C$*:.ZZ0 M?Q\%LP2;^K)>/8-N>Y08#)J32;LY,EN3KF/:/=LV!TYC9';L<=_N`8T&3D># M&V&K__A^?R#;X8W]6,;KS^)21C%B!'W@R^,-LV/U1J/VI&$VQ[T^,*PQ-@>= M8<,<PPC'C4Z[X_2[,$P;$\:LMS\.?__R\=_G'\9?SH<7[/S#4(_[T`CWQ_^; M\+Q_@Z;V+P2/`E^XYZ#@1%C(1$#R/@2[0[]C<-LY?`DYKOR+]7(:>(6,N:&( MGPI*;CAY-9,'#?,0:VH81''T*?#D;'T"$*]AIS,<.@.S-QEW05MW8`Y6LV%V M!LW^9-ANVX.>\QP0KQ1%^[L\UI35S:/Q/='Y\=)L1/Q#XA_*%)M*O[!=2BK# M+C?^P*;2W7&TKP8H<UX&H`QGP_TUX[-9D"`<V3P(-5!J'J>,<52H$5MR5[`X M@-F(-(LV8F#^F"M#L(I!&!E,^C,O4;"J61'=8`I6ILKOU$]_7"7A;`$]1FRZ M9DM8;TF809[M#F>V0WUH9`8RC.BM6$PCI2G<M`P!37T_X]XL41*_!\>F@=;4 MQ`PU"9A"<.G+_ZFQWV`_`AOA#/47F@S3D[YJ748L`..1-I%-)?4585GT?HB@ MM;\2&4D83B3"*S2^*V5]#'8I?#`\GK=6XT.@6N@1VM&_IT/3`SO3:<FY>2L> M^8%O;ED@$>5=4PWAW31!;LU6-ZFJ"SY;9/T!WZ6W2PUHCLT3')\&T3T[DDQK M<+B7$^I07$EQ'6DJ9Q[T+N@=4DI10LG.FQ1U#T0!Y`%^1/#@Q(L--@^#)8NA M6Q!]_:^,V;7T/.;)/P70"407G)&4AH>[DHCB!^.&%C1/M-QK44U75_IP$K0A M@<M)#-Q,F12=,9S9;H,)5H1RF7QGRP79GH[B+M3!K+]0K&"*^`70D6MO*B?$ MT,X41&`#4!AELH5$,-@T49]@F6P+2/\J\*XP&WDA0J&HFO@S$<;@#<<R51=* M&%<KL#V:4##,[0C8?Q/W$O\X8WTH#@UD?)!S-%"NU`1(B9ZUM].`(K0KY_-L M!#MT,U3A5$3R*_8N19,I`Z5P$L\%FC"<;"C5(MYTA-Q0'%"<.V/G(`&N'JV1 MRD8FFC+5#[A<02(R\JGJ(CNB29]M0"D(4\%4Q-!:2NSH*!@%KNIX$<!'[9%O MFT&)@PY@/!N=IW8CM]J7T>%IH?BC?CDL(YO!&P\24)-/"14L6IC$'`3`CV]U MQJX7(&=@#J"@\-6,0U=+NY[`+`E58;TX'M!/M[?>7^D-W7:A0K&`>O)*G/LP M/Z'+G\J'ZC>:S?YX,C!;+0OVN</FQ.QV8.O0[%N#;G-B-SO#T?%]J,9I7*@< M]=A/0135QWG2"*O:SJ2.%"IC%1A0>E:O38'Z-@A38X]J*]6^&QTXRQ%)*AEC M[SP@UGM5'G'KL0SL1<!7.X-6/OKL_[B?\'"]#52E.&<Y10>*"-PO6$(^3&<[ M1FCA,I$N!P6].Z#HWI%(=(E0R*6?!`G:")AIK#7O`Y.X7DBPMD`&C\^$FR[F M7.T`EK2B!UB\O,Q@"ZESB58$C*\V`)&^^:ITSR+P7!%&N_J)H9J-0<-HAY)G M7H_2,^A%P?X./+DH``=4*)H>Z';C,J6.E+IFRP3BSAU&FH-F<&5K2$#M72)/ M--KO7ZA\02O[(M;-<Q>%4FM\L):A`%']G_(#+L%J:I.)!?^?O2?;;=Q8]OT" M^0?"N`%F`%+#G>),,H`V7P0G.1Z,G03GR:"IEL2$)A4N7L[7WZHFM8[DL;61 M3=5#)C9-=G<M75M756/'WP@U+(A<'OG82?*]1HBMBKY+,"DP!,DZL(8L_:TT M-*]`>*(D!KQVT28^O`@<V*[;Z_8UI=-17<7L]$S%M=NF8IN:V]4,2P4O<^]> MT*<P2R^#"#89*%8T10"%*\;ZLJ$><;.SQ&KI:GBXQX#SMG<%G3&8(8'JE_P0 M)@'=.M>8$H]&<[T+@@H?@@29\7(VP>8Q8(BQ<9R@@0;;RT^".US;'7@YTKN@ M:"4->QVF2=\WJU6TJ^_7*=K:H5.T4UWW8)KZ*%-37\_U%F&:>:0>82_IVY<L MR:,?PA(/?,,#ZI%X``V2!2C<-%G\6IHGW$!://T=KU"HE#_J2[`$O)=97[^C M]_@K;$C^ZZ+Y8B=;`+J)N+O3;1DXVN.'W^/'8I--\/S*'EBXY.ANA9FV>!WI MI1.]A**7<6;T$J\"_#?PXY^E>R_YF^$QQR@'__Q;()M2R%'M%8::+;M&U6UE M3E9RMD<"Z$$!WH'F:_,?D@<6@66S:L00)Q`G",,))/=/3^.Z5Z+^WKIN23<) M#]8\XP$>GGH$F"+27`NF)G45MB&KYU,]7Q<%=L"%D"8CEB"6J`E+D$JHD96S M,FF9:+":T;:=@*\B]+8EON+;=1NKC`KRW(=O0X(;F..M9M!1)]SP.N&/\$?X M:PC^CAH--X[A4=[$F1<VUWFL-@SBN+)K"MB02VP'@8*>Q`G$":)S`LE]<@SW MM?,,L/.&<7X7LE-9EKO/6$_3G#!(&"0,'L]!W,,=/,H!8^>^:&E1U@P69?7? M*5ZJAYU0U7L$%4%UBO>.&EK2CR%+>EXZX466/OP`TV-1,:R*EY@((%!$=#Q$ MS;NA,`.%&8@3B!-([I^7W#^@.W04$^9Z$B>9@E<%<D=HWD.DN?8+I=8();0H MM8Y8@EBB+ABJ*TN02JB1C5/_P,VO<306S.@AH5?[?4`L02Q!+$$L02Q!+''6 M64G-27<G_!'^"'_BXN^`X7<J3A'MS$C4)&6Q+40Z(29.($X0G1-([I,;N*]5 MUZ2T=L(@89`P*#H&OW,=.UU2LUTYGL%U+><Y-5U>4"*\TDMJBK2/NSE4AT;@ MVRQ/X@&ZI$8,@M$E-;3'!;Q$@RZI$8M>=$F-6/2B2VKHDAH*B,^+YRRY;;7? MOH2J`^)T_$7'7\0)Q`DD]\]+[M>]AQ1=4E-=C9PJJXZ`?0#$5F`'7`AI,F() M8HF:L`2IA!I9.:*G>S6G:H#P1_@C_(F+/[JDIF:60L7YX);L&JIX!H+8#@(% M/8D3B!-$YP22^^08[FOG-:F"@#!(&"0,BH[!NA\PTB4U];)^""J"Z@2A);JD MIAF.AZAY-Q1FH#`#<0)Q`LG]\Y+[=$E-W?BX)JDUEB-;CH`15+'5%Z76$4L0 M2S2/)4@EU,C&J7_@1L!+:AK!X;ILJ0*F$Y."(P5'+$$L42^6((U0(Y-'\#RB MYB2H$_X(?X0_<?%'U\J<\2F/J&G%8GL#=*9+G$"<(#HGD-PG-W!?JZY)B>B$ M0<(@85!T#'[G6ID/P^`!?_WI0YXJ8\^;?L0^\7]@=_BBHWS9]G]X%7W%3G)) M$(V[7AJD-^PIZX:Q__=G&$GZ:?;U+Y$?W[,;[^D+^+;^\_PMR0<=`+]\9:.? M+U@<WGX9:)9FM`U%T4Q-5?ZEJII^>WW3OS5LZQ8M%DTWM%OU0@J&/U\$PUN[ M[5JF8]]:/:UGJVY/,36[JYB.V5-<_$=SW;:J75JF[;BW^.%G!*^$;HN7NW*' MSNJAZ8^K=^AH[54MM*."#&==HN&'`'\HT`6#`L;*#GW!7)_-7]WN*;\&(@Z` MC0]67'ES<4'/7WF:!:/G?1W["9-Z\?W4BYXES_>+*J%1G&"E$``I90BBE$=# MED@9O.LA?V'V/\`2!MY=$`;9LW3/LDD\;$F_E^\%:?E(EH9LQ!)@11RI^#I= M^SR`";R$P9MX-AU$\.Z=E\*_<<2G'`8C&()%/I/N6/;(&'\,`XR"R(O\P`L! M;"_CEUSPN@2<Z0[978I'2U.N3)CC%1@P!HL\/RM7E\`@6"(E,9C0SS@:<`'/ MS$-\2(^3P)^L+2F%,7#Q[&G*BH%BR2L^AR'Y]4P%)EL2[D\O"P`J+PSC1P^_ MQF]Q%2EN\2"=P`"/$P`P8O#'U$N><3S`7NZSC9B$OQ:X\,H"K^5UW#'X%+CE MOVS8.A!'%A=5G9`EPS0&.B"^TH+_"AX%XDGC/!@B$N&YER%V@'60'/A:-DE8 M.HG#(2=BPOQX'`7_Q:_PKW<L@K<SSA^<\"S+DTB:QFF`]$EY?@1_<P.+`<U2 M:>&D]3[=QPE3PN!O%CXKL)1(B>)L\?<^XK@@1@KH\0K^?BY6Z3WADKP<MDK1 M[K/D_#0.8;1R`^#WS)]$@0_+N&?);.$PP&S%+>F7XD$)*>>R!0X"A`@VI#R; M=88!B6_40E?P+3+#%/Y:(#STDC&PYYS%9CB;C8#(EV?H*LFV@-[]E$I_Y<,Q M(DXNUC$&GLRXE/`BR5)_E`K4O8UAO]6`VW38NJ:;I;T<2]5UW4Z[X[JF8KMN M1S&[E[K2Z;;["CSM][M]Q^HZEDBJ;C5-2%@]-X>H\^`%(<IE!22#DGHA^V$E M&ZJU!.<FBW7#3S=;.']U8.0PT$E\`V&_WZ7OR\:_2VU_9>E^PW4&\MJ']SD( MA6`*8@'W[CA^8$E4:,$QZ*9GZ2[F'Q7J%K8'"`\NRZ;>E"4M:5G0#ED*V.8* M$+33RKH]KN.^05NA:B>@!N$);MQIG&1<9MQ+((]'8)&B89TSN1!J,`@(I7_R M&+43AVLH39/`1V`?@VP"1L9L\TMC$).ESHY!T:5<+B6SNF54`OE]'GHX4HQ+ M0."F"0/-F08/C']4@.?'!<(7F(41TD(FKEH9*>C-8!3X2C`$J/&G0E?/3)NE MG0!#\`6#S!Z#?@"A[&7EZ*O2#24P0TIFD[04K_<`66%Y+'T$"P1J%W8&J*L0 M5#\W*OP0U#PLI9#&Z9:BA96U%2N;S[-U:3`?C,)G_':F<)8HN#H-(A240))Q M&I6HA5&&["Y;PG"A#`"_@$$VCH&OX6=OB/N8%?JX'*1`,!\"B'<?Y/<%EH"\ MH)&+OX&IE996*2B($IKGEG2=@RFV/`[B9%'?CFL(\(H86/W<`/NZ4&[?,%BQ M1X;,#]&*P,\Y[W+E-;>F.*\5.AYL`>!W,-!`JX&1&<'_^1HV[),ES""JEY=8 M,&]I:L<)6H)@OT4I0YJ6J\=%@II`MARFR*U+XZV0;<LN79MR95P^/UX8&+%, M)!-Q+LVO-E`$.0&$6I`@V^X@SCL@_TK[:HM4WX#F%8&9H*UW]Q=W`L`=D$#: M!O$P\)?6!:,D["%@CZMB>&Y_(4<NO2[Y$[3#"N?`F_'IDITZE[:X](!W>E@L MZ(Z!_<S?XYNV\(V"M&3NN7VZB;U;TB4X2'%2JB]P[PKS%4@"2H8O+>!\C[L( M?2I<(N=J+]HXX#)0$Y`UL8\!BE*R<S;]R%<:X59G,T(LH/DTGX`[8@4B$`V( M`ABD0`)*G"Q+@KN\N"(7`)P)>!!%H"=3Q$4T+.S]TF,KW8,5Z?IIS0V8?[2Z M,L:*%U/V@`8Z\F"I'J5AGG@K'\SA_\3?609GQ@:3POCF*\EF;NW,V098N%6_ MBI=5\?CG9.XE+S1\Z5ZGA</T.OJ@UBXI)*_/"$A^A.E@@=(P?HQP!<AYA<U2 M$L++RF4P%#>EU\*WP\*C+OR0)?>_7!_.O6F%,Z(OL\\._L(63V#58;CVP2?/ M0W8UZH!5,`S"/`,+XWHN@@=/A6B]3.)[Q#3P&Q+[:C3P$E3`Z1>67,/>98?W M-!QW8!D#PU6,GNLJI@[?=AW'4`9=;="SU.YE;Z#NXVF<U.$O?'S<@:"8LR0O MC1G&0RNE]AH!CDLI-D=T:8$@7>`-4&-<H2.+<8,7U25BGX=<_)DHF/TE`W+@ M5@)Q@"9V&>XIV#-%FR3%:^9`WC'?RU.,*C`0LV5TZ#'.81-.O`>,)S`N`Y<X M1'K')7.<I[!UT_??:;5S9O>$.\;;[PE_X9-#/3_'J>D2UQ+AQ[^H>>-EW2_% M4@Z`N9?').*O$_]8-XRB&J^4U.>->X-P7QGN]5J)N/K?8WLU+7Q2L%.G>0)^ M/W=5T6#%T"6:K-]Q=03.QZM)>98AZZZ`77>(UCN5XIFF2[0^"UIKLN-JXM&Z M[LV%__22Q"M/:$AE5</:MFR+R-I$ZUWJ!H#6`E:/$ZUW6(8KJZJ`YHEX;M<U M2_!$O8O',P\LR8([GADT3699EUR/2>^\=/9&D1:P?);POLYJCGJIU'[7$$L0 M2Y#2/$3\IFT(&+^INY_WE:59$O#J`J[N8`5Y%%`#P>,[=X9XS$R$WF$9)KEU MYT%H77/$H[2`3AWF?F&J:YKS#*B$%44#6?Q#42<VN/[RA=37L</NEGB\3H3> MA=`F$?H\""W@44/3NM8TI_DAX8_P5R7^ZGY;%6^^6=0Q4*SEZ*I-E55;0.>, MB+T;L367B'TFQ#;EMFV+1^RF&:Y-:M1&&"0,5HW!-S<+/'Q-\[::Z:(I4Y=W MB)DW:.K#_](L\#O1\!*>`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`TN\\=+N&SSA=<0I6WOO"]X)S"]PX]M84M;^SHDO+=&<*%LWRGZ=73^\]F(/ MID\\/\N]</'RK\&($1E/2<;.>)RPL9>M[[Q?@#I!E`;^VO,_\";/%TBT].H! M5O<NB!9H_N%_E@J4*N42\4YYNAXX@SY>P?K#EO(-";SF#9U\#GT.M!^Q!*TV MM]J6;#I5'P.=+/?E+&FLR9;;EDU5P%[#1.4W].ILN6?3@'?7,:MZ3SQ8ZIY4 M_4OD)PQO<`HBR<O!^DK@CT-8QZD:4)VED#$U6[;/I^]4;<#<=R&4($N,0(S0 M6&7=)%C$*R:>784\QE.9(NQ(IL<Q$M\,6:O<B3UV5N-9TK8>I*V]$A&:QG;K M?/KNUU.S-@F6NH<G2IO@!TQN2T8,NXU\8$_3("'[X&CQ3U5VVP)>0DLT?KT- M6`\BDPUXC%,JIZ567=92^]U+!D)SPPCK]Y86MY8N6Q!D.1S',VG+CGHV5UK6 M!LQ]%T*A;&($8H3&*O`FP5)A$?0KOU@W=YK="X6P5B76*GN/5EJ/B&N%>>0; MS'SRH0Y@-[4=<*)TRB-O,HTUV7%5V=(I_:_15&ZW7-K'=30*A(1%O#@L9997 M(79T&7P7_(]$SXG!W'<A%'XC1B!&:*P";Q(L@F2-42;Y<;.('->1;9VRB!I( MVWJ0MO8J0V@:6RW7(@*337"N`8JMB6)D-AS5;#`UV;8W-"(Z:ZN!O%'2/,0( MQ`AD@AS.!*F;P;$H9F-E,]0:VA@D?TC^-,C8U#79<*O.M*B;L=D(TEHM@XI- MR'8XV_`%E<:?6N)HF@/*A+IO-)G&[^I!9+(8CK%_]99%)QYD,IQ)N($*X2N2 M,Z;LNG1T3O$EBB\1(Q`CU$1;-PD6JH,_[82[X8"P=AJL5?8>K;2N`=<**^,W MW!U$3M5!"MLT6Y/;E)/<<"J;IBL;-H7ICD+E_ZV4N)K5THBP=;0/A(2E[O%7 MJD([R8&=:YIRVZ!\\@;2MAZDK;W*$)K&[5:;>E6032!"5(&JT)HC=MZ9AFQ5 MWB6G;E8#G<F1YB%&($8@$^1P)DC=#`ZJ0B/Y(Y[\$=O8-%RR-!M(5YNN6B/# MX8QC%U2"=FJ)XUJR2_'21I/X72UH3/;"$4AKN"VGZLK"VF]>,AB:$FF@`K2* MY(Q&%P!0:(E"2\0(Q`CUT=9-@H4*T$X[X6XX(*R=!FN5O4<KK6NXM<("M`T! M!G*J#N)4Z8XJFTZ;S*@&4]F0==>1VW0%[W&H7'$!FMZRJ6=HD[>OW7*H0+B! M.U>7;:OJ+LX[$+89?K(!#M@PSN]"=BJ7;_<93^7S$=[JZM?12FM]TG@4SWA0 M9#)[P/CB>L=-"C\+;43JLF:JLF-1JD8#+4EL0B*@)2D"86NR?:V60]&;)NY< MV;(V=%>K.V'%.V?X@Z68L^5%0XD]31E/X,IBZ0$>PV*\5(I'9&`)N8%K(J$- M67<<V6Q3J*Z)8EIOV60Y-WG[VBTZ!&WBSM5EVQ3P>&S5P/J0811H^<$P>,!? M?_J0I\K8\Z8?K_T)&^8ANQI=3[R$=;V4#7OQ_91%J8<%;=>8K%[6MG7\+'@( MLN<;'/6&/67=$/[X&<:6?IJ/E]_?>\GSU>@/+\SY")TPC!\Q5V/^A>3#^N&7 MKVST\P6+P]LO`\W2C+:A*)JIJ<J_5%73;Z]O^K>&;=VB':7IAG:K7DC!\.>+ M8'AKMUW+=.S;MN6T>X[>5=1NWU1,JZ\J;5/3E([1[AJF:NBV?GF+'WY&X$O8 MM]B0W:N;FZO?/DKJ].F35#[C\61-QR<K=J7YXYS7_LK3+!@][TGIFPF31C$B M*HC&$M!!RN`)TL&+GA=IJ^ZG%#FNP"NW2?_)81VC9_@*K5'?C_,H2Z5W000# MQ'D*KZ3O/[YLA;Z(B.7#&7T=,^K2<<WVZ#KGP;5`?>_JUU\[7ZYA5##_0V^: ML@O)9V&83CT?8/GY0BU^GWK#X>SWQV"834`JJ>H"^SX#1DHNI+LX&;($7UMQ M+U;W:CF`Z?SX:JMU]HV]_9-#/:>ISV7JUQT@G$PO;Q[S#:.O;NV9^/@V8_4; MA,/>APT?H1!<V]"[2E-M_N4=_K!($N2/$NE#N?(N&P=1!))E`6<\6GOG"TN" MN*C*NIO#7B^3JL&DZX$U,F;#!3!9O$:?P1,:*2PE"M650E=@Q"P%Q3JE>4($ MJX9@?3#T?6[($P5JIH\&T7!%$\U_KH$2$J\5RW^8ER!*V?"E[`?].W[1B;E6 MH#@]0450$50BYXCUV8@E"1YE>D^+B!*&D&;!.A%DHXAQ9<UV94T]FZ2;\R2R MKLEJ^VSR;JCK!'6=()8@EB!-L$'=NZJLN92I5QNOWR"OGZ`BJ`BJ([Q'7C^9 M`0TS`XC(;R"R(=O.V;0:)1>/7#QB"6()T@0;XK^J(;=M`=5]4[U^D[Q^@HJ@ M(JB.\!YY_60&-,P,("*_Z7X1@](YR,-;6A9Y>,02Q!+GI@ATU91=$:^:>GO- M^"MJO(NJ\"$+/@ZB+,B>+X.0)3TO8^,X>3Y8`;BCN?V^=:DJ^L#M**:E#I2N MTU.5@=UW!JIC.7:G?:O=FECYX5Q\[O@^@V5XV,2'+^BG#UM6N+[\/^(PCS(` MFK^55@*`??'YW_'RBM<6M5J(W_/2R250Y3J?3D-VS^#%L!^D?ABG><+2PQ?C M=WJV:5YV+Y7+KJDJ9G=@*IWNP%#ZFFVU#=T9N%I__V+\=EESOL<."<MJG'_' M&9,,:5E"PW*6\`6,BEB4$(U2W\L\OAWNYKMHJ\OT:G#LX[<66*:_Y",X(P0G MB$9Q<E\T$GCT4NQD530@X-T#`(ZF]@]P]?W:!SAM:A_PNJDM*J0_=>&BIAZI M<A'#[&D19^?/%J6+&V/N+PG*`^#T+?8,L<7QZEGG+0ZK(O5YX]X@W%>&>[U6 M(J[^Y[3<D)YZP1`OO(;I`Z0'2[.7;<LF!:AVB$Y07*HF<2GB!.($\2.4`IY$ M'O!P_?AJ#92:']\S#)YX3V5CJIJJMH,1LDI^UL3C9Z(ST9GHW!PZB^>(7</\ MP2CP/?@XBB,%CP2X/X976O#NPQ$HLR#R(I__5O1\#EA**;0$E4!0U3TM\TN> M^!,O9?P&F6D23UF2/>/F@Z6P?_)@BD=V4C9)XGP\6;3VGGK/_'Q>@+THMBZB M2KYSH335Y9X+I34!>W*)=V7:FS5;DK.A%`;>71!R2Y.4V[%3%2EA_3P(_:[J M*XS>$WV/&M$7<",WRS'+$F_(I"#BE74,/QD&Z31.0:-M^[;.ZHUJ,FJ_?TA0 M[K",MH"Q9=K[M/?W+=5Y;17(:NW(8#1B&/=GO_`#[1OOZ:N7L1XL*XCR(!I? M3;&(!F^2V;UZ)(^"XJLI+.1"&C(_N/?"E"?MK566:.;@TFA;'<5HFZ9B7CIM MI3.P+:6OJWVU;YE:3[-NM=OVQ6>UI:H+X%\/QO^S]Z[-;1O)_O![5^D[X/AQ MJIPJD`'`>[*;*DJ4]OB<)/;?<G;KO'*!P%#$&@087"1K/_W3W3.X$J0HB10! M:'8W69$$YM+=T]W3T_/K?:;_F<%<+=BBTBOPY47`;">J%0EZ;W_M``U&#]%@ MVUR*=/B#12@_GP+_UK&9?7[_)[@U'SQ!-N]FFIX-'4DTG-#O&_KHZY_7LSQY M.KW-2J#]T6!X?G'5&>E7TT[_LF=TI@.J!#J[N)P9^N"BIP%]]`$0J-\?]WM: M7E">-]$BT3XS%^^7?3+!\_L2F%YH\II+V:H[0AW487]R-9G..N=]?=+ICR\O M.^>#R57G<CH;SZ[.>\;5U:!^5Z]&A:M7BB`<#`MI![2FDTCQ+7UWK^0)2@IO MGNK)K0[U?W4ZRO=YX*ISW[Y7.IU'SEWL-'[8N+B5WYX\DQSXAX-_?&8A,V'[ M`<WBY&?LEKD^WW!,`YC[#:EP/G4GG>T>1*C!3&F\T]4-\Q3015UH[WW&_PO^ M2_;%[)<?2[-\UMQ>ZK;=!R^]$*,8FC94\X5\%4I"!V%VO,A73'YW;>YS-2)V MB?Z:?[@)&/%:N7.BI<+)!B_!YM+R;UF@@CHDV2`Y`<V^8H'EP%3^@^EG'CSB M*B%H2U=9^2ZS8I<J"H//PN+(L4(54]7<&._&*6`5+',%"D[!/X*YXZJ8P;8T M(W[X#\M/@>]MQ[2450Q*C)'>"O!'UX%%B9EO:UC0H!E-%R477`W'$D:`*A%# MYP$S(YH/[)"7(..1LC`=%[2A\AY_WY`$:&>:T*`@%5T%BR5G]+F!98$*@I/( M]!(*`K'\>63274;XEGV'^89@!Q48&]:-5.[\P+7O0-^K^"-;1\K_F,`EE<B< M$1=>+Y"W@E[$`Q_IJ]A!?`/4\FS'!KJ!"@N<D!=G7@3^BDA1X'H7UH+RNWF/ MPC)1Q238=^P-0PCH7O#Y=)5IB#-1P&N+W2AY=(YC8?CE&JCMX$U)9`?V8^>4 MQ^8\N,P!,[9,)Q!Z%]Y9^[%GPU0B3!.!`3%>>#,CH/*>J$O21#3\457">/YO M<#R0F#`8>+.RF'5IC!4C7*,ML)QU`EI$>X"P*Z8?,&<UCP,,UN37&9+`8@%R M'TE#*E70H-!C:M9A7@K8<[P2&X+[8;-`C+K(K`/IH9>H*`YB]3^QQPCR7E4N M[B/_F^,Q7/M$Z%30K!BY#`L$Q,BS>6C+I_7/Q$/I,D1><K7!DJ7"A1'Y#I0V M,XDH4V[+(L^U/4VZ+RWV/Y$98CR@/%<4E:L:7-I`4>4&H(UAU<,422]ZG8`M M@,%TISA>PZ*$5Q.-L&`4P'NG#[J:LG)<%T?NY`B)1NO/1#KV'0$H2ZR[B4-0 M/F%@$1KYH*R79K`RK80KP.`8O!.\%8-W+)'4(6S9?-"31/)0K%:B.Q$;6DF5 M+F]7^?#A@V*YC@?*URT(^CKP04VNB/-Y37WC^G-X-&`W3A@)3ME^&#HP0UQ# MF[I!+#Q<B,G2LS>6'M=R821XY81\=J3K\$(V]J,*GB;OP4,,Y)\T&$Q>L"U] M'$:Y#EAG0S]`*\`H%D8^L&AMWI-[Q)472B77/@5:Y%4>OEU0>OZ]Z9(^`$*$ MILMCP!4:DJP*\:)A.@&$\=^Q9_%K_^A9["_(:'W<T-]T8E8KI%:$&YJUB)WG M_9>E`\IW+;96:`B%A"!]D;RZVM?ZJJYI2@AK@I.<;ZMS#4-7PL!'7/0#6+.H MLOE+M&Q'7=T@-J(VNX$!W*#KD@Z)OT+K&[;(7'!PA:MBB(B"D&J+PJHGCR,1 M5)NA&H)5:PL)!C\FR*+_-#,:LA.&,5_)J?<V9SC*0=(S-8PG`^!^A#1OPF=( M!X&.7JGY=T;V.HZ8,C<=7,XN#DT@_1$17-ABD@F?L^B.,>Z'):H.GPA9<`L? ML8VYB>O8IV>@.[Y^8/F%#'J"=42T`\N(O@RT%T8*)HNND+[^`MXO/"<\M+1_ M"ST36^R6$S+[-QY()@PS)%URRSR8(/W$_[0"!^CL@$T!80-9B9QPX3!;54!Z MX+%D[/0SR@,WW@G1P`4-_.\T0*`+B`5(4K0$M^$3:*S8](1?`DHG%5142$+$ M\"MB7.)#X"%/DAK+_3R\N@ASY3XN+21TP<#A0:'P\\NFZ/#DA?HYJN,`N!I[ MJR;M^)JI>H'Q34A>;`5IN16$QT!(_``U4[(+B!^VSASN!"0(7$N0#U7X!19% M=F[P`1LL$4@1]Q'2!E,'J:`/R*7</N`ERFH$<M,Q7311?"$GRRT1N:*,T-58 M;O%\]!P*YLN"J2=Y,D!"JB;MNK2&7':+D@W$C1?@VL8!BNPWS[_K+/V[U*'' M?=&F0>.J!$SLK>/'(>D2HD%.@37,TGVT(I_OPM$!CAX0,*%VB(ZDFTA7!7AF M&_"8BY"$Z?6%,M0&'5T#WJ)N!2%;L62'A6FZ`:H*]U[-:[EW^JAKY%W*1#ZR M?LT(%,H\YF@W0LZWR[#85B_\.`#=\U<,NR1RD\%$<),%%+A':&SN3FX'QBZ; M^-R@.5U6H`!1D-YIW5XZ`V'H"O+";0]Y_GE]_[AY"7.0;=D*PB^H%?+-="+1 M:QXN;))\;MU$J&C<2-.@K=OB(`LG*N<;YXE4X0]S!P?]I)SFN34#Y%VV8TA? M+(2'<`S<Q4@B!L(J(J>35]&_=_`]<G_B^0J<'_&T68J)Y.PJL?HF!BXB)IP9 M1TL_X(H-I[<R@V^,WTA!:PZ:D^2!2R5X2.M(^!XQSDT\`D/`A_B$+3]V47\A M\A6Y!>]Z`RW;VN%N;IK2$%=LO,;1O>MI6G$#F&T[<D3BS:/SQ#*7+?%S4]>! M[R(B,[AA44@L`&W1568QRT(CGAG%W(<E4N68N<D(<#YH)3CA-S[]<@@E)5;2 M7"X:-;_/$1QU3D9R%4,@(&.>#]M%W`**Y9KZ><Y"4)9[DK2-K1`U3O,YP\,F MQ8X39]!:.C#.9`/&X#,?/;64)ZJ#0:$URC^N*]]%_RU><\]4A!M"_FJ%Y7PX MG)0+^7"-C=X<`W%CZ`0D'GQQ2.@OV+@\;>'#@X"C34</&65HQBTM*41P67U[ M#Z7['Q;XL-5V7815$CYL3O62_&<C$.3;<&_R0=(FJ;\O%3:`]I9B^83I)C'1 M?EE(@'8\5L!(D64;]CD&6CH8VD%>9/&0@N\D8A)H)Q\3Q-T>$%0^+(H!?A>V M`"&I.#X8KIVH8UQAT,"=6""XCW8B5VPT_`Y,?86G8CQX0B_#;S044"-_^`$= M`X!\6:8X'<I"HY2`)K8M.V6>=*[C`0^C6)@."W52R"+4M*@]HZJ%)4*^39*Q MXDZOPM#F^;8L;$KW<$&X!\+;1%E-HV%<"Y*,I7Y\&@M+C,(B=MT.Z%40@M7: M]>\9H^Q`T-KXMDI&C8)_9/WR,G?+LJ$E43T;7%1+N/9<2)-3HGOLU&/?HPZ, M,W'(DK.<$!J!91"PY)@'@^9)M%^(&$:_:$GP*>3V$.0YEX="RCYD^>B@<$"P M&R1P8-.>_V$7+SDQ:;"3]WE35#:1-B7.)I[/G[,;(,47&L%_,]A7%8[IMR%Q M&H]'XNR?#@ZSS5V_#LC%X&;^7E/AOS_6!HSS3`)P-D0:)`9G6\G_*F$XZT/^ M.B%QHB\#>GG3DZER=,XW\A&;@!_S6S%RS6.Q_/PA[ZCO]F7;=-%!HCDV]\K+ MBW/^H`@EJM&3("5RM3=VM=<=W//SEB!5EK%2?1(ID=+DK!HTJ^8AS'S.1Y<I M7U"$VNF`)HQJ[7T>3,V>TOGHJ\90^AZO@]>&JND3R>M7P>N^JH_ZS>-UW3%E M-@P6G:HVP5I)4(C:"[\4"2D2TO;)\BB-V+I-DVM!9Z5$\3H;P5:(MS$:-T_` MI6V3MDV*A!2)1YK!?*<B*[((8_/,&.JV(>[Q;MGDBKP*2M2L3*JHD)K'6L9C M]UGQN*2BI&(MJ7C`4%'O&`[R%[JN5LZNX7<R6NLBGS:3HJ\.>M(W;C6+]8EJ M].4A1JMYC&<7+<##;X'SV@/C;?OQW&4OZ#$\O=/:.EZ2CJ>>4BWIN"OG/)=4 MSA\M083O?8MP?#Q4H6J@6>TXD+K3,&*N2[@BGPASC]!G2]BSXIGLNTWXV;35 M^H/L?@1KZO!LJ&1FN8OV[__PO8['8MA8Q*$5NV:0H-$T%7$W!W2Y`VTW!WUV M5H:G+,/M)E3;@*U,2*ODQ&H73NTZ<%8FWL,F-%2\OBV@<XK]8Z]Y;CF$(6#: MMR8"/'$X7X[?FZ"CV$[(J$@-YJ:NF(TP+/Q(A0.:X#WCT+<<RDNE20GLWCMF M?O-8V*B;U!E<S@;]M]WH%X!@>:)6H@!S\(4\F/*_?1`8]_ZLC/M[\;\=0S=& MNC9209H69@@3^<9<AMOU*/#7ON=XV55Z%;ETEL?HS,$B(UR#M[$*'<].89-3 M)%4$&,FCH^$-<BY4CGM?B?LK\$91T`0,QED.J2<*8"Q<:A(T@@0L`UI#F#N$ M(LQ!1O!I9)/G\+$)3?<>SAEA4R%R"OLKYB!KC\!J*0^B2<)+"LJ]KU!0&3:M MEV#1JB6,6IC0!CKML`Q.Y'FLA.C)@7TY`M/9FX=63C<':FM6+B=H`SF=1VA- M!=M-)U*"77QG#')@E4X!-#;)@R)Y\5%+;T6$R,0`&K`SK!V!>ZE$=SY!G865 MJK4$%W[VI@`T8POPCES7\)=+);L4S.E'\+X;5DK^KX`]2@$T$U2M0IO)ZLN_ MNQ_(UB;$EF!G#F2+L,!RJ$_'0-S*5B=*I!E[!.!4LF("KU!@<%6"Z9:UJIV^ MU*0E/8T$QQ`V/H>']Y!U.GN3`R$46*T)H$P!6V5G4V=O".Z'H`;)/^`^BP`F MA$57,!@,(2>Y%[!DA.4B,&)2@$?F%A`.20MDQ2:4I7F;X%;Z''<Z#V@)@N^$ MH$"JU9=07@0-FRP5D\"NP#L!0\/GFP(RID,$840@LAR2)D.?*,$03(']-Z$U M4YA]\5Y7^1<B?'&P5X%O1@(-"W:#)S[C#R2)*04HSSPJ*,<!RT!$H1$L6D.K MCU=JARFK.;PZ@03C%YM<\&GEL!,Y]'Z*`^9L06P6.%79B$("Y.$.($=W2I"D M5G-"NMP<7I,6W+[XL!G!MX+^I\C!B'ME(H3J#<&\ELF#.#VYIH4%S'?NDZS0 M\MB0PZXRS4.!%N7,R<"FN/)W,MQC#K',P35]@H#R^4Y.(!S3@E_YP'H.:9BW MA.FL<8QEG52Y&>SFP>OVPPL]*^*VIZ!.[R;=\0Z$TP+$-$XG-[O-N6&U"YS` M`[BE.9H6$;S`2^IU1V6XTJ+K)#RNDH<%S91&SI<QMO_.*$*@YM9M>;;Q/CN6 M)JW`,IS:WANQI8!T35FS)[1:TBQW_3?PU1Z%KG;VIH"OED=7VX*MMGGC4T"< M">=F%S":3V#S_.G\`H-&'@_)FRVPH%@;ZF'*X69AW)UD'22B&Z25M@0S-]SR M$G&QOW?#G#.?S5>H@XT6<M0Y@)A71\W2BF2'"9M-.>SNEJC9Y7=@1R@J"R5E M4`H;>/++TBU\(X-I'[T*N32,*KDL1M>\!+0X]6'`)**$Y"WS_C&W+,8LBL7P M-;/)EXV06Q[2_XQP%!G6*!%PUCLWP1R5M-A3/KR'*)BFES3U0$0/?0D*W_'J M3_N&\'8$\'#S6`SAY27Q^O=IL;P+;&+Y&MPAHRIM)`0$<J(,=@:FN"+,MLX" MAWS/X$)2P.<LJ2^TC:TJS#$7'MD,BFPKW=,K(3?_C^G%&'\%`8%]T87O67&` M`,K@E&TZ,KRW8OD?JA6PL>%/*\QP';IY?C#YA>I5)OHBB>3FPFBT;I+06SY" MEU/LQ9T<BC858*F.PG`K2W$8#G9ME&BQ1_"EPK;DHG"YX`N"BFY$7LIA]6ZA M6-)V7A<#36L7]"R/R_)`9M[%36.5Q8`F#B"C+=\@8\DP#CZ*Z@761['^T`:X M>@;'FZ/D0_6'ME8?RIO74OFA@A`H6Y>:*C8OU46)=C127.--<C*/L<TKUX+: M+HA)9&+O/6'UCA":V'=/N&5'2)HIMR?<;Z.WTW15;RNW;KS.ML!*5O@!I8T7 M`9NGZJ"HCZN4]N9^2VB@=&M%\6P@/V[75\B(IDKT'!0W3)&':A(,?)I>#NJ] MX%E7!*;S,A[OH5U1&81YQ'KNB6&=3,^]IRA6`BZ?1I>J*A>A8L8C+WJ;V]"" M]/`1PE`SA7@';!>0_3SZGU>FB;(L%DOJ;@/3?T`@L;Z*EJ^+52PQE0WJ+"LV MA>[+=IKF_<BR&<;MI+M9JTY4CS#*5E?P,#^&=/I\$/#K(J8:$)4!=;2K23"_ M:<)?7?F!:]$'SU?"BO.'#</+(WEIT0AT^K>6C=CFJ6TY;1*]BP(1FX4A&)6- MB`K5(6C3D=6':!"[]G/6<HNX9'XW3\ZBHN_S<&4:/"5^X`QM^PG:V9M]S]!V MG:#Q@^H=9VA[G:"=O=EUAO;@"5I:6R9?O&:8+TN3G[M0/!/8MVP$>\[>%#R@ MDMNX:ZLG`EVWA%/Q3B_4Q,G%NXHM)NL[V8XF.!=;>^F62O#`KJ6X;2F<&&Z4 MWRD4W]EN#PN^T.-K](@*/5PT'ENCIZ(0\]XU>K94Z*&\DGUJ]&RMT'/V)E^C MYQE*ZB4+$;Y0M@8YG+=4ERS1?X4S:[1*]\6%R\,BXO`[[QT+'X@["-4[.:P0 MLY&0EK66"5?V.A[.XC?I8>?2N<$VQ,;%!M\D<ZWP-]@H@(M=Z#:G:KR(UW@K MIMB4BD9CY&'INW98K+&>U+G)$@PV*^Z@9BPE$"7AX:2XN$.Y64L\=#Y[(R)+ M29&?"ADNY!?\PHOL9.19F?=G694@H1;2Q0Z;#;0O1!^LO(IJ[`Y:O4>'T\HB M5GL$J0H4"ABV7R0/\34M[;-5UR<,*&65\7`?ZHLDJXS3<GO:F`C'_=F][L+H M3,^T3:%R+N&5-=L(^&4%YDMEB!(&50MYOB-B1M)7N#,\N.4,,LLFXZM%A*F* MY.7G0`D714&BS2Q'7CE83*.819:4V]T5`=@H0E48`Y#(9::=&T<N.E8.-&RZ MK"+]I5((]N<KKM*4LX*O0L9Y12AZ.Q7S)GF@VPM4[QL\/$J%:D/5^IHZUH</ M5:A.,TTISZRR2'6_.]&>4*1Z2XWJ9$],V^#-ZL8XBHQ2V?`>+G#,@P_5)8[W M+W`L%EQE2&^OPMF9^R:J9T^Z>J%Z]B-J9Z,7JW4GA2A!5C';]6'ZJ<#E`XU[ M!!E!A6VK=HT:C?NHE16O4U';'G*<PU340LUKLU3RFI>3VB_`EP83T]W2GN'$ M9J8M7!5(4ZD)<@MC(YY+;C*LY#S`\SW%2-'E4+'T<LI*(*%79H;8O&QJGT0N M+.@V=+"R.:^*ENLFDY(F$7P;9O:6'(5B0328D"R)YCZG))K^^))HD]/5)3MZ MU[(2U0O6XL&R9+PJ&7T5*#^)P6^M4)9[1I:Q:C3O3EL#Z]458=JG,H5PV65E MBM<PJ_H#8&\5V"R\MV#UKAOV/!*<&`!GH&J:K-@@T1YSPVH+VF,;S+6TS"V= M5?TMLZRE]`0E>$!M/%8G/0E-]SIXW5.-\:!YO&Y>G8'F5MQIA9P/U?[`:)Z< M2UX_2:?I3:Q#7'_'[-6'3&HBX(8,G9QTPL\=B`R=;/7CFH\UW*KB!)**QRCQ M<-#=RE&+/FS--*O,GFFOX3_M64G/4'L3O7G:7?+X41M4O0V!F.8;\):!LTLZ MUASD_@1@H?MC*=C*NUZO.\RAS)$C4,(*W>?BOPI/+UR$*!*`$OA:+@U=Y(BG ME[$K0!C6`4OP;NCV3WKI!O^PHN3&,]ZTB@-^X8(G]CM!&"E_Q680(98G3H'P M=[;[*_Q_])7MW.*7?_LI#CLWIKG^^3-/8?J$.=%?`M,+37XG8>:$ENN'<<"^ ML._1N>M;WWZ%1I2_)2]>6TMFQR[[N+@4.'#7/(/^&F]CG./=,B0\3(ER]44* M/_SU<?$YI=,G`B&XP*!QV@W=V((/G]GB[V^9[W[]=*D/]-ZXU^GH?5WK_*^F MZ<;7ZR^SK[WAX"NR63=Z^E?MK>+8?W_KV%^'X\F@/QI^G0W[$_U\>M69CJ^& MG;XQ'7;.C8MI9]J;&@-MU+L<]2^_XHN_(FD$9>HHXW@3(Y?XSM.FXQ7"@N-] M24I^[W`$2"M'\B)4#D^1Y[?10C6]?\)L\8MY9P9VU0]X:P*O11$&A6!U*>$^ ME(GEW&$H*OXD;;SW^+3Q_NG2QMO<]>O(6/__-/K/7BG/NG;$G.>0)SV?[4AT MKDE6LQ2%XV6_O];+!S6A_6DO#[QNVANU4G'-2N4LQFAW>Y0R4O?DS'6U-Y3! MV):S6!9@;CV+QUH#5_$!DX2.8H[^P3P6<(PY#(#8*\=SPHA7,VBO0:I)7I"N M3H8R<?MU\-I0M8'D]>O@-:SK<0.3E]MR-KRY,ZZ0C4.>9SZ[PXK')?TD_6I# MO^:%6:ZWG!B>O4DJWM!IL[\FH#7O)CV;;J_3>^*<.+77Q$L>DL6/8?%@,I(L M;C>+1^->\UC<-L_VY5+UGM]C/7TS24%)P6WZ82,==#.G\&BI@<4,Q,\\F5*\ M@N]_`O?>NC]\)N%TJ/?[D_-19SH9C#K]WG#8F9YKLXXQZO<FVJRG38:CYV02 M'KL`:WH`3053!=V@U1SIB)-9/=4M1]9UK:S*:R&EJ,XWL6,3*#,"0"<YMT$V M6?C[K]@)LKKN42'#T@J<"*3/Q!(!$:;@KAC^'Y4I2EK#&E]S7O`JD=B?E??. MC]E"PM*HL1EB:0J&V.<>AQY'9/(`2TPD54\=D'"DZ7LG_[:H/L\KP/F62`&& MZ:0XU50&;\X8S@8SEIDM6LDW0Q-C#"N;+)SOO(4$@QG7\2_B;..]<YM["U,D MF04+W7&=2-3/,T,?W[C'F@`Q=-959DD[&?S^W9)198/'S#TIJB(0))XR\:S$ M$4^E!ODP;TH5;!$^_=^Q?9-4D;PQ@[2H#"<-+T.3I&POJ+"UM<2Z-;80))&< MD&VW9K&@.R(F:%"0ZX\4(<F2DAGU>F2_L*M=+*K'#RW)0$8)<=5K+C$-6 MF`GF\*;HV:+^3"JHIBB5A8**0\WJA8C*9U$NM5LM+XG_B`GR0JU)[6Y>((ZF M(4H!F?8MEOM%&5@L*$6]6=C9^?1^/PYV54_.I#3D)>ERI$H$+2FCET+`"ZV2 M%E'GH.@>T-Z*NJ1N=Z-W`V>RBET"\#P6Q5+22@-A@J/O!"GP*.<>KSNPH\AZ M5DY#Q2HN69WM0OW??`%)G@^^[=HDO@&2HA+J2[F(/"<JZ>-"=;*D\EM:4*90 M_Z^X7@M,P>(G#@+Z(VZ\J#R<J2Q^XT/GQ%G%T/(:IL+<A&983(Z!:Q438*N8 MB\-KJ5`EBY`!,;%:!.:[AZ4R`4ZNW%ENS>$"984258D"Y(5I29-!!V(8I-(V M"I>>I95L+9!S?\6"O$;D%?((R1UDQ/:##E:)<!:.E:N1+4K90G_$P%3EOL_( M>?'+/Z\_7F:?9[_\F&JZ<J4(:`O%+AD]S'<EN%0LOU!9X/F.*C"8:<4&<^4+ M+5NB<'X9.4%2_@*G@P."-FA(8:I0L:X7B";-L,JFIXQ!7I^]X8_S6S3YNHC% M46R9UMF;RHEAL'1.Q0MXZ8I\$<QR85M:;ZD`4=&P=(0+,F<T#BICP3+UW<U$ M^J.W0]!597I]H7SQUR`(0VW0,0:J4O;P\OX=:N0<N(+RNU@BG4LAF].<RLN< MP:((09?0#N^N)$I)+<B,'T#O%"TYU4^9!L.UDRQ3(6O(VA`KIYDK$&(R,4E) M5<Y,JA$D2M%DK>7%L%"<!@<!_2[PGE0%'<_HXI2>U=$&/R=>VR2UB0>9V4JJ M#YX(M9"ILS?ITN8E@$$(F.N2]:12,TL'9@7*\QXU.^-5+HN/G+T1IC=MR<DM M#5RS5'?NUG1<[J^1XN]0#8MTH:,#E^?3ET_%E:X6VB""\I:IWEV^=3^I7C(' M;9V5OL-":OE14X,><TA#45,>O`G=<F.9-M@D_^!/7C]9K3:'-/6T0!I62PY# M%H9)'9/,,TOT-E:<\@N%M;D,B:J"_IS72\NL0:+QLKISXKVN\J]4=A+;;/N, M\ZY<##MI9<LTN%6G"1355WHS,2SI/^'@A+EKD3E%G*OBFQLD^@A<!<(J!G>2 M[R!<RIMR[[FZ#2.Z^9@4W\[[4=SS5#<5,1]O*.IV;FQH<G<XT8>#=S%9"P.[ M'1=9`\L*!I)VF4BWG=1"Q@JZXN[EV9O\B*HX4&G+RP6S-L:\<1&42P@,A.7+ MW62O%DU;MO4A4]&<Q54R5N/=QJIDJG*EG7^'Q>7;.^R3:+^D_N!]$%<G7(KB M6/EJT2MJDDPX5IRSV)K?'Q3?9V:LP)+B+BOGZ%)M2W&VFBH,OG9VN>8YZYL9 MI'R%43X<%0N?B5O#5.B<]&VN^[0L<ZDTM%FH4IXU6][<@$Y"YXR7A,>]?[K- MP17B)*72BF/C2E]4.N\JT\)/9-NHX.?[8F0"1L^C*.FK:'>(<-2/C_7AJ,HA M6CM<TL+@;"V/EENRT!2\*V@AP@A)%$+)7.@XHC*MO(9UONAGIGBV=J&60C8H M$BEU`D&5/-5C3T@,T%4L?%[]&-F5BXLX8<&/H?B4>)X3,JEOE="-^\@;H1]X MYX[V[GQZ=+I?629^SG#J=E:1-RT8_X7V,;DX3S(8L\CC_#2=+-`BZC,[6#74 M3K0=SS)@Z_P%^=STN]F"YX8J\<[Q1G+6#8\V><DF.^>_)Z7"$C-:6@GE]>^$ M1<&DRI)>&-,F@;:3#XA=T5:0B\I[+*T248R.>4M\+AG.;59`C^H;PV8KMW.D MC05GWUZB*UIY2'2W#E+="$3R2^1A4O8=7EQC&=5\8Q7")]2*"!JRU/I3QR"\ M!8^?T!`2I<;0UW"275A>+AID[CZ*^JZ[K4*ZM4PU!XJ2(`0J`:?<C&!"JN2! M%:%YP_?MZ$*D[CN7"A[&R(=1;ADI4R^]B5LA&R*8R.U*LO)R44YNS#);VU4^ MD.'T`QYTIS53V"HFIE[-&6ZJ*IQ5JJ^JY)@:7EKH(#9G;]*8Q6:P7E06WRL* M3S&HBEAT6:4_&(R&AC;#T6IY-?#-X+88O/KT&'R#EL0G$;S;$=$HQ9-20<!H MF..ZJ:/#[53Z1&4)ZTQX<+%D[DFE%5"SNLI%E9TL1A[4*NZHU(+1$QL=B@MA M97J*Z3C>K>_R8K+I")(SAZR3-+ZUPFC1QN!$YSEEZ@AH#U%7FHP*[Y[R]&PN M8C2,K(`SVLND`.LN6L!J7B3'"]EY1!*B2B*>>5:E`#K5M"N%RAQR=S/V[-R. MY=52NO\4<H!1=;%=38>"R8PNBZB;HE+SP?V_X7'D<N'<)07VDKQ'[MVX;JII M^`%*52@[T]8A0J&DQ8$=TNU;8OUY3Q\WR/F`U?JA-9(>]&2:N>1C<H+<TX,\ M(K?-$-#H=YL"HE1`!Y]JUNQ&_[ML0X,TU)4?E$\<Z'S/)/OB8H5?]+S$3R4/ M?6N4L4*WB;@P#XM62E,6:R'%%%*/P$(@;-9V8GUSQR<YFYW;=W$<J8+'ODCW M*"6?^HE[E'2'@B*]98_".Q4_X\[/]\"4Y1Y)%=1>FR_:6"RVZ3/J)><(T2[R M/CE(+>QQN+[;K*,=4@AIVS9GB[DJ.BTE?XYO3'#@<X;.>XB_4IQ40>'+<XAX M5G3!"IT[49J=\#3RD;-5Z9]30(K<\'17DN<\'[ZRN4W:NO'@QHF?<VW=&E6W M)S9+=GF;5#R=>A_^6-XIE4QL)B#([^(NJ<#Q(K]1U6WC^9F`C@N%)UYA[?:P M<MRE+;C?U28M+)LT?#-GU!JD:!\\!Q>'QQ6'RG2RQ[=1M`GRV(T?D7^C!+1- M34J^5PKB(G;=#FZ44$LE4&9X:`_21>T7HHE77TKGI700944QV`+8?7?\16?M M6]\8WRF%&+B#5\0XR%"6!\=]BS17)=G&;5NOU*@J3H.3J%LB%W-8`4"N$*/Q M@?^=A`H/D]+#W*XR15NSXJ8FW6M2".C6%+&PTKY/Q`(#F^^_RM"(7>4/6JT+ MX5H(;N6\.WX8@DN8'S&DQP].\H[+;DUBM9"![(2`NY>P+X1]50BLHGUE&B@O M9&0D8<BY'RW3)(B5^:U@1-.#7S1U176=9`(4UFZ8N.G%G6RT([>L,*HD58,/ MK1B3@NG=`/D]90XL$2?YI`[30_]\%H')#1>#'6"04)N_4U+H@6_'%LI((3DH M2Z9*9T;A-^@[WK;51MV);15/;D$Q<V]=7`"JW.K3P>GF@6D^8^:^I'$Q^X2& M`%W2[Z61"BM$G"/^WHN<A&##',4>Z.NP;(Q1UNE,/CGMYUML#`"``N-I$G/F ML07849`F]IVG8:7J(]M(BLU9SL$RO?Q6/#TCK4RE2#M)UE^R^1!G:(48Z!8A M*TH2%R,4'1Q+DC&">QC$-_7\S%]U8,36AKOS##MQ`&C&O>V0]@+^/@A4/@C' MX\7YM"HN<3>!6=JW5:C*-$V@Z$PZJ$39*@5SY2X]K'1G334`J2?\X$7)4<M& M=XE'D*5O%?;"R?-,'),LMMN_O*T%W0%OKA+W-[<?%GY/8:CY@:JY82Z(AIOD MR*L3BM5LL?BI7OD'-H?VJ\B49+^9LR1DA8OGU\E!`$^"(H/[%UAI6.@[$N*X M>:6F4HA=KB62YOC^*.<E4]B-Q\^3`QD^WIQ.Y:L<6BF)5\[N)J,OF]FSM&#I M`ZNT"L;W@5SX;>"]GX$2EYP)A/Y\^.3YGJX/+P:#66<R/9]U^I?GO<[4&(\[ MY]/!\'QX,8&GC.?#\(Y?PFW-!):RP<Q0Q*$E_FTE@(_$OZU;UQ+T5.+?2E&0 M^+>OB?82_U;BWW(55W]@EKR+^<`60*(T/`-K1<*AMIW%VE"RN.4L'LD*<P\_ M)W$NBEMBB10B*5AC"CX#:V5K)+<4^D7LOZ7O8HK0Y5^Q$]UC[#@(&?UPO7:= MZ&"AWZO^U7@ZT<8=XV(Z[O2O>N>=\?E$[PRGTZ%^V;\T!A>]K_I7_>VOT_3" M?';ODV<T9V?-,$9%%!X+<9@J)OD$]Z"288^#R#+AQN''V@]_P0O\82SR;OPX MHDM;E#GLKU:^ES1)&8XP<6@RRBZ0LFTO4X?8GVB%&E$5.A&%YPA+09PI\@LL MXEAPS0+^;C?'PX=94N3A94*C#QZF$7TQOW\V(PK^>Y;C.G10>!W!5U//_LVW M3#=]CH5/9RY>;*:WUG'`WBHVLYR5Z8:T@2PQ7N]?7O7&@VFG-^[W@?&C<6=Z M.1QT9H8VTV:#OGZA#SCC.UI7TS-2/&=FVXXXII85``M_<W@NM</"(YUT#+2K MH3Z:S#JSJ]Z@TQ]?]3O3T638F?1ZT_[D_.K\:C)\\*1C908WCM>!/>C/>!X@ M/G(%1=\H.-:.X^%1]L]['G+@WYV%N7+<^Y]WW]/CM%+<C%A\93S[K(.&@%W] M3,<:#TUS[V..QQQB9*<6VTY'DC^J0B*[3SG&ACSE:'-\>6OX;+AQ."9DBTM; M(M-I)"[Q(IZZ4$M1-GFR<#+.;P1.7Y;S[3]7J#'E3WNJ<.C(MC"_+EM$/^M= M3</8=M[-Z/`O#^);0-\Y[^(!]Z$>`;)3/=?D63VOME->((UC">2%ZWB.)>ZH MKP-FB<]G(I^[":+YI(D?(W2[=^>3T1[57TIQVH/.OJ&1^69PMZ].]HG+UXR_ MQ[2GQU-?OI=`/W`%YB]8&!*T!XP'<9Y:J\">XT0>4-:-/6HNUDS2)9L?/8KA M/G4[:L;F!GA?Y[X72PUU7-$UU.&P>=98,OK1H]#5H0@&-8G1C72[_FF*:WMK M\UZJK^-N%76IO%X!FT>C/?(Q:\;F!CA8'\7MZ?O`)_`L<352ZJSC6F)]CT*. M-1-FR>;'FZ8]"OW5C,N-]+:X$C/3HZ.F5J)MF'CW].;%/"2;GV"LFN=@;TNA MISYY@EE=,^A%=@(FO6U)33AL[O(A^ZMX7%+O2'G?#VTG&J[[3GI`.5#[FO30 MV\O?L6HT,,&@'48MNQ?S0GKY^1W6RJRUD'[/N-#TT+V-;?<]+LQPB?]<9L"> M4\^^7OI!](4%JP_>+0LCPG$[TCV0X95AS";34>=J,IEU^KWIH#.]F$X[^KFF M3_OZY'(XG3P;\>JEJBJOL!PL@JP1'BLFFA1!#BV@=`%#E6.H9=7FJ-BA2;#U M*>$16KHR<1W1LOO4"^;80CN'N7S2#*`M7=.>A[35'SS^#LJ.5P[UO>SZM73= MMJL?!\`7&Q\)7:=2?9Y12=/3W@J1,O#@;94#B<`TL<WT3:#\)`9^`9;ZI"+P MBGGRIQ<P:'B3*?\P'2^47*D95W[SP^0PJ5EL:3`SKF#_4&+#/W$WT4`NM((? MOYM1'#C1?8DG,ZR/4"M/HO[X?1?ES;"8*Q4RAN&L?(]A]8/@&Q/8Z9LDJ/<Y M=E/PP?2A.NGM$0<N#^'4`&$O?J?ZH!-^`L_+@?@#RD!^\4E)D)+PNB1!:ONV M<K9I5_\ER.7+]5CQN*2@I&"S*%B+6320;H]_]\5M0743I]NQ4UI`!RLGYL^G MLV-?<AF5/[O77>4+5@*+$7"461@P<9J7A=X4?V[84[5],M"E/]=<'N]Q@4:R MM[GL?7_JY?NCW%\?5A_+!7MD'A_U3M`C@BD_@=,SV*`'#YZEW^H&?ZQQ,B&C M$Z]IAR,I*"DHHQ.UH%L#HA/USS#XS?=N6AFND,>/=768I"1(29"2("7AY4,F MDO_MXK],7)#;LOIL+R0%)05E:*`6=*M]:&`#N$!>+=_AG;R"F\ZRZQ?N6EXK M+M\'.\75\GJ5O9,R(*^6OQZ>R*OEC>**O%K^\LR05\OKQ0]YM5Q>+=^C]68E M0^H#=3S8HV+):X_9R],;*0E2$MHH"5+;MY6S\H16GH[5YY1'4E!24)[0UH)N MM3^AE5?+Y>Y]G]X'(W4PW*-4LO3GFLOC4U\]ENP]*GO?ZR?FK[Q:?EA]/-JC M()=<L`>:X"F935?+^QOTJ+Q:WD`;+:,3KVF'(RDH*2BC$[6@6P.B$_7/,&CM MU?(FN\>&.M`DL+$\87YE)\Q2$J0D2&7?:L;*4(B$SY/[RYKODR0%)05EC*,6 M=*M]C&/CCOQ/HK3]WWZ*P\Z-::Y_OK:6S(Y=]G&!UQGPG\OL1L/4LREEX@L+ M5A^R",07;/4+^QZ=N[[U[5=H6_E;17O^:NU[^/S'Q0?/\E?LB_G]\ON:>2$[ M9QY;.%&Q(<4"$P<?/K/%W]\RW_WZZ5(?Z+UQK]/1^[K6^5]-TXVOUU]F7WO# MP5=TN76CIW_5WBJ._?>WCOUU.)X,^J/AU\&H=]G3)UIG=*7W._VK@=Z9&$.] M8TPN1U?3P60\Z6M?\<5?D2:")%NB.P44@3QH`(<1*$1\^MF%_G_'8>0L[I_I M#'Q9,@7):'KW2L`L!`>PE0B^7/BNZ]\YWHWB$&65R/RNK`/_U@D=WU-,#!+Q M9T+EO>/!.WX<FIX=_OCSIC.QWG?Z]0-1F!C/PU`8CAZ/H3`YW97^-G<M;Y*7 MKP#JVI'N`/X?,X-0N?3LC1NRE3@#-+UY.M&7#2=(L7BIFZ'I`?^I6/VZ:7]: M'(_737NC5BJN_N>2%W$0``\>\"7K$9(\U7-R5G6;U0%O)QC'6%57#/8MIEOG M126/\NIZ""`E04J"E`0I"2_F6![%!%Y'9L1>CP$\X$"DU$N1D"(A14**Q.M, MFLDB:!4B<XQS]R=W6/&XI)^D7VWH=\`P4>\8/O(7/Y)!(FGT7I\?)"5!2H*4 M!.D(RPQ424%)P9>B8/.R$V9LP8*`V3(]0<ZJ0;.2Z0G2RVRMERDE04J"E`0I M"3(]H4'"+@\>I?Z3(B%%0HK$Z6UCPZ.R[3D>EO23])/I"3(]06X(I1\D)4%* M@I0$Z0B_TJ-A24%)P5-3\#F`9X\%*-N&=/8Q6K+@#]_SURPP(\>[X:V)IHX$ M<C;19UIO=G71N1H-KSK]RUF_,^WIYYVK_M75N&\8QL3H/1OD;'A\C+.,"XJ_ M4#X@L@<+(\7T;(7HJL*+D7('WRIFF`<U@[E(6+-J6+.Q]GA8L_[IL,7:W+7$ MKQ($E[!F4BPDK-FKH[V$-9.P9ES%U3]Q.'4^!:@N^J`^^J`P%/[5;B^S'EFJ M+Q:S.F",2M?&C^__U*$IR>#]>Y](_K::O^-)\_A[P)/4XYHCQ@-)!7LDOJNS M09)I1K5?`LU2<<\1@0.R?-1`72<9_81AO#]UY;<?7^TQ:7ORM23])/U.2;_F MW;*I.`.$07@LJK.SV^3-FXR^M)W!HY%D<)L9/&X@?]OFLK8IJTI24%+PU!1\ M1F;?8Q+R2DE]2S-@YV;(;,Q+@Z?A==^;!H'IW3`L?GI^GSWRR;S'KZ9W9F!_ M7..#X3_@P2C\X'UB@>/;_PC\,'QZQE_L.?RM$+L,WRHVLYR5Z89_?_OACZO- MLJ<#;3C2KHS.6-,GG?Y@TN^,9^,)_*LWOIIHT]'Y:/)5UZ&[KWK_[:^3?G_< MTW/D._S4#T1;^C;\$(8QLY/V7XRJE]-+S;B<3CL7X_&TT]='L\ZT?SGN#&>S MP70&_^U/S[_JQL&I6C7I(CW_#$'4+\,(!A^Q9XA9:<+Z8#@=70RFG<O+L='! M;-+.=#*]Z%SHE_I(O[@RKGK&<Q)+Q<[QA^UYED_W0ER1_(!_./@'T$CQ%]!H M2B?2'4[J.&S)CM@[>?2%LV6Q(O`Z8&LS(#G"E-F%XYF>Y9@NM`83I`K-BN.A M/"S\8.5$]\J=$RUA,J9E^;&'^A#:<."=M0L]W3`/<9W<>_R=K2-F*U0QF"E_ MPDJ!3X1Z@16%`_97[(!0*C`LDTNO$OGPZ1M36"J'N&LW06Q77"U`2R9LY1<+ M9D5G;ZA=&+\?8,OF"L=#B;_P!HOXRZYCSAW7B1S1F.V$ENN',?9,O$1)ATE@ M]]M>BZ@C&P:$C5/)Y(1,T$".4/CFMC$%[)9YL1B%.'`+%3L&VMT4ID(4I17: M5:96%`,O8+"Q&^&JC%V<`LP_4!:!O\*DY9#A"5Y"L>X#<8T-0U=<^$6E\"^& MVPEF3V^!J3?LCQCS'C\N2)M\C".8N8?9QJ!N'&OJV3/'C7'6Q]"FG=Z&;M$F M^JAW,9ITC)'>Z_0GLZO.6-=&G8O1U60R!;W:FXQ`M_3>_MH;C+0).!C9K)\V M,TX=FSD_SWPK1IYS57H)3Z!T'$IKGI\;5U<#8];I78V',+-^OW,^U&:=4?]R MVI\,9Z/S(<[,>/LK-M+1C0Y:B:WC*C(5R[+#E$K5V3_YKF/='_YF@:'/+@;G M%T;'N.SUP>)IT\YX,!QT>N=7T\O1^6S6G^B'-P#Z^#@6`(F&"QB:I3]S!&R^ M*4B*PP/K0\=F`:@JUU66L%!`G;L.3!65^2VH&J[MT!`H)DP&-`>H,3`-I!T# MQI05#&():B]0P"BD&A1T#&G0=1Q82W!14-_/8=4`)5&%9;1\M!+;2Z:+R^"2 MC(ASR]+;.I]AJ7QF,'L+-#]91'+]IS:2F$_Y^9H-YL[R>LW8=)GZEU>],;A, MO3&L^_[5"%RF2U@Q,T.;:;-!7[_0![!B1F]_U;IYE?:4"15)\B%C[@=OQN81 MD/1W,_C&:+N$A(WNKYF%O`:[B/1F060ZWI?`1&4Y)?,Y2PWLX97)Y=7P<C*\ M['7.IZ#V^].+J\ZD?VYTM+%^KDU[%\;E^;.\R8+S>`"]\8</1J&?W/6AM`[2 M&^A"9F)*'D&.]H?4']7J<7@\[5@QM>FMZ;ATIPE<2.4:?MF8;:/U)CAYX+7] MAQP?<="T,)T`@R`QZ3M4<'GU)BR(6:!+B'3)JU=0FI573124(^H%,^*AG8KK M;*V]S*9KVO-NL_4'C[_-MN.50WTONWXM7<O+6AMW^,9'NK52J3YAY">_Q25E MX*4N+DT3VTS?9)<X+\!2GU0$7C%/_O0"!@UO,N4?L)?8Z?U*KIR`*[_YL*]K M(EL:S(PKV#^4V/!/W$TTD`NMX,?O(L)5XLDL/0.JBR=1_WNQ%^7-<#XZ@L%$ MWV/WRHK"3LHBABWL)@EDIN9!$OF&ZJ1WZEL)#<CEDWA^4A*D)+11$J2V;RMG MG]_Z<9^3^<KUS165%)04K#T%:S&+!M+M\>^^N"VH;N)T._;KI1]$G8@%J_SY M=';LR_,:_NQ>=Y4O`3/#.+A7PC1-9-,`R]W[(?RY84_5]`;>U)(\WK_WGF1O MF]G[_M3+=W]($+F_WDL?RP5[9![7!,Q'_PF<GL$&/7CP+/U6-_ACC9,)&9UX M33L<24%)01F=J`7=&A"=J'^&P6^^=]/*<(4\?JRKPR0E04J"E`0I"2\?,I'\ M;Q?_9>*"W);59WLA*2@I*$,#M:!;[4,#&Z!Z\FKY#N_D%=QTEEV_<-?R6G'Y M/M@IKI:?MDBEE(&7NA,HKY;7CR?R:GFCN"*OEK\\,^35\GKQ0UXMEU?+]VB] M6<F0^D`=#V0=('EZ(T]OI"2\2DF0VKZMG)4GM/)TK#ZG/)*"DH+RA+86=*O] M":V\6BYW[_OT/ABI@V%?^G-MYO&IKQY+]AZ5O>_U$_-77BT_K#X>:7+!'I?' MSPG>'3*8\A.5)RC3H_)J>0-MM(Q.O*8=CJ2@I*",3M2";@V(3M0_PZ"U5\N; M[!X;ZD"3P,;RA/F5G3!+29"2()5]JQDK0R$2/D_N+VN^3Y(4E!24,8Y:T*WV M,8['W9'/7XGGE^2/6\Q^&F*U^@>*SF_]N:<JT9*=X07(U=KT[C-/?/)+N#4H MHEBN&8;.PF$VUK`/TX00:"@78U&6IJW$Z3TRQ:6;8SA<<[T._._.RHR8>Z^\ M&]$@W]%EW("%:V9%SBW\`ITOF>*QJ-R*8D:[IGQG8GQG'4`'@0,=6&8<PIOS M>QB=A=.!43A>;MSP"?X/QJT$>(4'7@[C><C^BF$:2N0CC91U'%A+>%6Q\1&< M!7X;,!<^VCGBI(.&5G+#OC&AQUW#[N&PJP:-HW'1,U-LML_H-\>.Q-A[]--= MI(66X+V`*7?X+\\OL#M:POR0YW/&/!RBJ5@@TXX7^W&8HP4T0DQ<^R'TZ7O* MP@]@K>!5GV@)8PO@9^^&!9R20C()&P($`T;+9X1-!Z85Q:8+M`J7RL+U[^!M MZ#GBHIL-OTJ&<;30S`JO<D&CB\!?*?]C>K$9W&<O\FD/X.'`CV^6RA6;!\4G MC!%_!)I"(6;?47I#)/R<*01V`7^*L</*=W>,F\\K8"L0%<>[X4/C@P5^;9\5 M"DC&P$T_=UU7W?4AD5M8EOZ*T0*`_RV`6DB2]P[2!&0'"!O^^/,S)E8_X)*) M\3S<DK'^>-R2_NE@--K<M41O*%^[U;4CW;O]/V8&H7+IV1NWTBM-%DUOGD[T M94-X4BQ>ZC9VFE1S*E:_;MJ?%COG==/>J)6*JW\N0,GCW.U2-ODTX,272[53 MIS*W_KCGM`R>#"5_V\S?<0.+HC4I:IL/;"W-4`G8K1/RT):RQ@]^'+KW\/7: M#S#D93NAY?IA'##%7U"4M1@YP0@:OGL/&R2%X?XHW1%1;)&'TBP_"#"VZGO0 M!`;J/%]ABP5&IN(U#T!A>(K\&1X7C.#_,+B'`2CH"(:V9%[HW#**X&',:^7' M7O10U.DGV[G%CW_[*0X[-Z:Y_OE#%C?\X,W8/)IZ]N\$\H-LN_PK=J+[ZS2H M!3]>L"`R'>]+8&(H91J&+`IG*56^L._1N>M;WWZ%'I6_);U\Q&#E!R(1-$&? M+K^O80:LXE6*S,&'SVSQ][?,=[]^NM0'>F_<ZW3TOJYU_E<#?^OK]9?9U]YP M\!4W';K1T[_"7M>Q__[6L;\.QY-!?S3\JH^-\\&@IW<NM=YEIV]H5YWQQ>2\ MTQ]=:+W>='H^-HRO^.*O2!M!FL=*:1*U>L822_S(/_R(*7J_F!"9>$HBKDFT M4Z&IG3")3XHT#H^_W'"I^1X%J4&04R>P.#$>TR[&'RG>+2.0!;V?1"`U&8&L M2=<RU"0CD%(L9`3RM=)>1B!E!)*KN,9%(,D']=$'I5V=#$H>,R@IX>Y:S>") MY&^K^3N>-(^_=0?S2LT1XW&Q@CT2W]79(!V-P<\=B+P?UTP55Y-K5*,&ZCK) MZ*>`?IWZ8N3^H%]MNR*7[9PKY.$8MVR>W&'%XY)^DGZUH=]1PS#&4?W>[`P0 M!N&)X\V:.KM-WKS)Z$O;&3R2\+2M9O"X@?QMF\LJ;X9+"DH*'LMQK7?.Z-:3 MP^0+O''MNLJ:!8YOYZZ2G]%EZ=`),:43;Q*7&KIA'@LHWY,N04=9;FH!#@"; M,<.ERF\MYTLVXDAR%\$;>05Y(_Z=?@-DI>OY&0UA#X6X!92)B^@$>+<?<WA- M?M6?<FEM)US[H>DBP9%6:R1-5ZGJ#UJIZM'(@P%4\B]YGO)YYWX0^'>.=X-7 M[6UL+>E563B>Z6$^H.(ZWH-7Q#>3=1^51EO,P/T4L`4+`F9?1_#;X7-M![.9 M,;O4M(YA3+1.7[^8=J;#X;`S&UV>]ZYZ0V-ZV7]VKJT^/G2RK5XN<WKAP_H) M(@=3/%.:*40TXLF6!(L\W_ZKTU&^SP-7G?OVO=+I/&6F+Y"+^P!@B98'F-`U M%?0__I,]%R[-@"`ZH)5U2JD0*:68<;3T`UJ$N(X]7^%/*WX<A1%\!6N@2=KI MHZ=,00FX.4"*,5%)5_-J6J&D'H9*./(5,X<&<99#_C!O`L:3^=_CNYD`7OPR M8RQ8.,RUE6GR4/;S[)<?E3LG6IYACF/RW*<`M#](\HR%,%_E"E2.\N&#JOS6 M_=15MSX'39`"]$R\A`#*L>J5ZS6S'/CMVHEB>BZDYL6#9V\$HLT#CY<Z^LU9 M.1%!C[P78!R$,*-6DZ$P^:ZRR09#$VS@!`YC,P.*J2!FD5M.&,9XU\,O4'2L M:B,ME=>%<@UFG(59EU/4F:F.*$D^SJO,5-Z`,MW0)P7.XLT1,Q,2F*;%^.)Z MIZL#3>N"_P4>!1\8/8T6;QWX%F-V%9C/I-N#]U>.ZP+E5<RGOV/@E<#_@_U8 M@6442Q58=&<&@9DBQV#[>,\E#D,296B%*TMCPZ/E5Q1H-DO?!6,7YCT5A5\? M:=)"Q]LY"],)T$..60+/4R`8K>V[I6,MZ;>$NS";$G\)1B4O*^P[\DK<+@(/ MT;?(V4MX?O:&<SWI=9O<('[2.Z,[27@K(&L(48A+#`HV.!I,112GV(W0XR`8 MH#EXF`N'EBD?6$BP/XRP=^ANTED*007O6OZ-1TH<F]_Y+HJ5"0-AG0C(2R%< MW^MP-]7&M8=7IVX=FWEVLCR%P&1++#]3:(#/-3>WXLPX!YPP^QG_X"Q:.`%= MF)DSRURQ/`^:)(N@[:[9.BJ99V-(&L]0:8]1K:RJI1$-N2!%8J)TM=<?H%G/ M->''@1!X:(3HF5Q:2YF.@HWR9%E^8",[R"X1`Q`'*X&U0A.1VCIZ(M.RW#7> M7$;E84,;U!M7U=PAUQO&Q?^)/;9ALHP=G@,1YPX]!^\F3\20WR^\`W>*K4W< M*JK(%G`R`B3Q&G;FC@7$!P+2_B-E0R6J7`Z#:\-FX9#YWN<3-0IM?$R:W33* MI0D.D@F6+/+9F\+,<O-229QNX/--LI(WC+1B\9N'9PFVG0_*P^BIFC'<8:W/ MJZUU(MI;K?7Y8ZQU7G._&PV+MEK=QUCK1MY:-TF^+TU8P=PIR?3/!O4V;"'* M.<5#\JX(G@+>*VA!\._,2!3EUE^C+]E5_MN_8[=X9Y"+%G]4@/?Y2V?NI)&4 MI&.0N9RNV1@D25;DYZ2I:/@7*C=SW*CB[V$,D\\48VDH%([!L,QBX;@.X?W= M^3$H/__.4U9^@()N>LJD.QG_D!C]R(],%\UG3'>&L8_JT<##7K(X*%:2VUF! MSWU&`($*$(A?&MX63%)<!YPTF]QS%=V^T'=C_L''U,,[AYI4XK5:8;$K^$P3 M!->!X>5D$U>&>4\&@/V%2'M`WG>X/O2<,SMG"R0&\CY=(O`]O`OCB0)G'D<L M=1OR1!`#ZBK790-X7F$`>7C-=?&F]RV!)M[Z)!-T*`,Z"/VS=:30-7`@"E<3 MX&RYYIW`%*3?R4E.KF@+\N9(8RHK\]^P^8WN,_V;8\YVTCE9OSA9\%P\.[.I MW+/;);ZX(G8P*'6I!&1DA#;'B5S>6\HQ8$+BJ0%)8L]E(0\LQO`T2B;"@CK@ M"!(E;6:Y9L`Q/;>*V-PW`PJ8V0Y>>P>]W85VONR8B@+;D6^$A^DY:/'\G<'0 M@@XAR,=4;F@;BDRA>^K9[?HM36U;#(B%F5\)=TM&@<);^-V+>&C0YS='<E]U M=\]Q90I)+$P6%ZZOHM\+%AZ%B!PGZ/_?<4(+0N%$Y%?\.N3-[S;UEKEV0*\( M&B%X*7<!B1:+F#QXFZU9,D,_T1\)LS._CE2>>$7H1>&3=Y5I03N*)G!3`.N[ M$SK?$5X!Y#-Y,5R[3B2`#_AP$K<CA</-.9T!LH5LZ9XV/MV1@XWV;A);H)?< MW8+T9#JIJ$IVM(\,T8?#[G"THU%<-ALF<D>C37(`GKQEKM+1SB%VS)M+#7?, M>K?7NAUSE7I_Q3OF#T*AX604<#=@HTLN%-<H_=+*WW-]5^V;A\.A.LRO^)(9 M0@^,4Q<D`ABX,19]4-RW(/?VT`N5@\&J+GVUU^LG6F9#!8E-FIN'2U:KJ;+G M0!)I"AC\@$X0>J$NN@<9;/*C-V5ITRS(='^1YF-]ZQ2+,8HP:66/.`684>?& MP>AT%J[(Q2>$'=N//_E8!;R(^^`FK:`'4>PK#X4*XG/@LR#^O^KST"V'FN63 M3Q\L<'3_R34]1#>Z3(YC/_FN8]T?_BAT?#GHZ[V>UM&G_<M.?VQ,.].KF=X9 M#R:CH3[K3XS1U7..0D4V[@];SD9%2\\\'L4_'/PC(9\X[TFI1QQQ4G;M<2Y: MI\//9%9\7Y<>T)ODU)*/`7L\RP<SPO<_EA6O8L+HQUTI*CTPZ[0SP`9,[C[S M+S$W`#T'V(&8N+'LX%F_,C=#L+P^*`[AV3*8QHJ>CD.VB%W8>]QN%@3@^Y9$ MVV(_Z2Z6U!*H*\(:XY%!1`:+HT+*`0XO]!?1'8]$X18O?1XW/.;<!\?:#^Y+ M[_B+!3I6Z9<J;PGC"84&%G'@.=R?@=\7SG?\&ZL7K'Q0D?_A-())N5@O`1T8 MQ5G!)O]6Q#,=L8%;QYP228BF2+P5[+9\.Z4>+[G`S6D9JY_Z(>VN""BV"D(O M6(G.*-R"TM']6NQM85MV@TV*9!PD-0:',A)TE3]Q/QF:+N.[OX!%L,--<-K2 M%LDPA2(_)^7L`R*5IQ_R'=J%^>=2@^:F2R8M7#*6H(/Q*24.+)6ZH"H.8<BC M"PLWW6JA_/-C6MR,_VYB,HM'#?)1KL&EIS`,;I^"&QXER%Y2J+2'PV//]J,S M6?95RD55_O^X&^7>7_%$&M/]X($8KFA(AU?D_<'X_-P8#3KG_?-AIS^\NNR, MAY>#SF0Z/A\,+J;ZZ.*\ACDM@W).2THV):6;,C,C4WG_IV?&-L9)?VRB$L_F MQ64^K$*.RW#CT@!??D,.^R"S98!RNJ8]#U%NN`,H[37"NKW.KB5JV4NA-UUA MO((^92AV0K?M4LLU!=1J,".N*5HC.7%Z3GQ9.H%D1`T8<>7'0;2L(2>:ASB7 MTO0AE,KZ770^U7/'6*AR+J]Q+@?$_SH*#L(7S/NA\W$O9F$3=$(3KTZ/U,GK M`71Z78P=C5\-KL5K8NQ$[>L#R=CV,=;0U=&@@4NV>1!+6%*%WS"'OM_C8="/ M[?4OZH(F.%9'_?Z)I7M_1,$FJ*OZ<+8WDIQM(V<'L#LX=;U,R=EC(&:I_7[C M"RG6+V:1.1;"K1`IVG,7/0V\L;=Y5T=Z'M+SD%I,>AZ2L]+S>`6<;8GGT:0@ M1^*+I'?Y8#"I7[+%*RF6W,5<;4L`PMF.BZG)[75;3AL%?*]UC5/#V;9+\9V> MGZ?6=Y*?!^6G/I3\;`T_:[`\3QL(.7IFU\X:N/5S&F0&D9Q+L^?2O+V*S/5Z MD:VW<>J(BLP;.0);$;]'IO"UD+%]M3^4C&TA8XV^VNLWD+/-.7Z5>5TO)<OO M=4,=ZJ<6YG9%1&K#VH&J]4_M,TK6'FG5#DY^/T"R]@BL':J#WJG7["L]8)7) M7B>7?NF.M)BUTAUI+6NE.])2UK;$':F_\_',[*[V>B8GSQ<9G#K!H%V*[?3\ ME(:J5?P\>3ZRY.=!\[F,YKL;38Q^/-T!D2GET@61*DZZ(*^7G](%:1$_P05I M?,3C)X)@SW^Q4;%@O]H#Q7H%GUG(S,!:3CU[QFZ9ZU.)@\OO:^:%C%<Z.%BQ M`KU_,;RZZNF=OC;6.OW)8-P9&U=7G>ET?-F?3B\NAC.M.55G$LJ=\;H6.>HI M1#Z;:H[P`Z;&%J%))DE3M'-3%-5"]JR]H6QMAW%)HYIZH1-B!6)G):I54LDR MU_&PV(D"0XL7I@4TQ;HAU+V*A9S2!\(HMN_3]K!:'38IZHQ0O1BJAQDA;#,6 MKHSNDU;8:NWZ]XPJ`N+;-`5L((S7:Q<K:N'K6*`E@#45JDF9/U$W!FN^+)DI M:MQ:5KR&Q9<T#JW`J!V7%['.:JP4JJE`(VD5FT?7*=EC!1>7/%6B/3=#9E_D MYCL-L)@,588YO\\>^<1+XT[OS,#^2%6-PRL_6#`NW%@6Y?O:$4S_X'T""OGV MOQCJ;&9/@3#F#;O\S@++@;%0'<0G*Y/8<_A;3NCW#7WT]<_KV5<0N*^\5M=; M+/0*HN.&A#1=4CT7/4,;SD9:9W9Y,>GT!\-!9Z+W!YWQ^4B;#(;3D6[,ONHZ M=/Y5'[S]M3?ICOH9B4]*L0KFS1\>RGS+4#YF%<U*G7Y."A1=`(<"7&FF^X4% M*^-@^K]W,9CILVD?7CL?=?I7^E7G?&+T.WWC_.IR.`;+,#3@?>3!VU\_#?]O M\KL^F)6X\+)3+]$^MU_&:D#1/5:SF3FA!?MM8.[AR_M<7(U&E]/AM'-Y<74! M%!L..Y.+V:C3N[C29^=#8W9YV:]A>1^C7-XG3[GLI\DO"B?COI;QOSH=Y?L\ M<-6Y#ZJ^TSF(?S`\CGLPS8IG*1_)\J#4!FP)@HLESG[SPX;[!A\\JK>HYJM5 M8WU9+/OL+!RJX15"?U2)&SHP5WZ,!=7(KL=>P&`T6'(1:X"%/&;%PA^Q\)?C MW;(PXN77_)A7*LN1DPSY&2_*EA%4Q+ZH$*?'(BHI=H"ZEB_K5$ZS2I2\8'RS M1>2CI_QNYDJZZF.JT:FK65W?)/YHKJGF'GI1R,J`BN0Y29%O+\9BGR0(&86V M%+/F-;1'6>G/R(=6C/X@^8(78DT[$06%>9%O+DG*-+X!`HBQWH&(%4N7*PO' M%164+[#.*DHXKV4\!:FUD_)Z]$$4%04W+1*5]$JO?`#!#=8^=PFR\J_7#,87 MF<$]E:>-Q,-\&.G'&7--K)M(U7QSI<G3*O(Y&@L2@ZN\=^'SI&"?F<Z*UWD^ MVU+$W<Q-.!`35JSB=)W\=-4G\!<+V,*F(K9HTP$-C'5U(%C]_AK<>&Z$?FS< MXK^@62;F4LGY*XW7`E/8UKF9'C"T1`^LXP"+?R>"!0+-`K`=KJU,DT+'B8PD M:T\4+X87LH??.[EXV7C<4WN]WH;\X(Z.:P@?%D-:HCTKT/YNT@492H]-5&BV MT*ZJC;2S-YOUN:<;U=RW]``OOR-A+?6#ZP7ZRG<&JQH<6S"`,,^T'5W5P>#J MPW%A%#GB%)=C8=F8$5>ML!,%%<#$%N/L36'ZD\*P:!8WP(<;7+LW`1;I!!6" M!>^%&2>5\IV*E\*._9VA=?5L"J*4?5>9+K`4:E+F7>R"J][7NH8BWN(F`@UY MVB,OG9A_@^@)HTY>>LZ2)WE^7I7$O1>==OQ%AR;.!Y-&X1)4F2O39H7E9F)= M5G<!NO3&P6*VJ(]IB0!IN:Y?FE%AY7&KEUFHRPNL(_P'ELHME.+6-5RSL),; M)V6!-VQL]7L3E=Y2WE\YE+/]A]_-?H4EW=$'`V,P^5&44@<7#V>7E$A/9AOY M_C=E[9HHU3BC+<JG247//U27B,?OP*>F2KJQPW_$10M&/J;Z]KCR18`R52CD MSFQ4M"_JBOSS_``Y+1F/<@-MXTDR_![";CDM".RZ%!$$V9JG8\-ZP*A&,![( M:+=7W#"(6)KPIH2.R?2F6/IIV>6S-[P\,<K0PG3X5)DHO\S%(O>UD(S\W+*I M%`P(KA#+="VQQ:`8@B)\J$3.<EH\=:W29Z`+A[8L6*^5*KS^%?NBTC:.ZH_I M]6SZ_Y1_N/[<=,^PG''PC45\Q%O-"(Z*9E(:$4X1VBA,\F$+4#U4G`V)'O_- M0R\0.4H*@>*;'A.5:.%#)C<8[_7H;5&]=HN_MHTIR:2AA:IIVPPK9#L>[VF. M1;)#&+)#=:]1D*"Q@D.ZF^U\7\B5$3BV3BBF&CES%RP=41<:$23*9ED5M##G M&,^]QZZ=U8K9#K=>HL'$1=_&TU+^1>IC8W`[5;G0@.O\A4N:5A<?#_.L#>IM M-(\EW#UN&='+T#-[OHT1F6(HD!TWZ6FQ\W/0IM\ZUQ:0@X6T$/"7E6\S5T59 MMYW0BD.44',.:IVZVK)44[EB)O!"C,'QP`+%2<%U6IYWI#(B5%8FA>'MQ$>, M")QDPQWA[D?J/U#W2?P?U5:J:(IN&7]UF'D>I*\X#_*,4M$_ZI<?VLX(#L[X MKM\=;+R34+Q)%@B<^&NVCDH6VQB2+37H3$0A![G"/:;M8KK:-I<[^G5B]9") M`3[K:H]OV+/F<'G&085NR2DM%&&GVE:B7*-$)=Y"X-PX'LB1F>PSE-C#73+7 M$076Y@:_15MEUK&!G@7&#?+N41*?24PT5>M,&`-[B&G4`;)WN`6#.7U('/MK M$[5#NG%3WF,KF>J\^.7WW_Z9_9S],/OE1^(3FD7K#P?+B:O*;^S."4O'YOB/ M\D_7_*;\]MN%\K[4=*'!;&MY1G?_,K8FTPI!M>-$`S^^68(K8)5DNZ>K/,") MOJS:FXQ48S3>%I1(FL$9XC(O;%RJMCKZH&ML;I4:)#@?-P1GD.B"\J8^"4P9 MRJ=X[CH63.>C<-9#E=9KNLFLWNC?FH$#3H8(#/L!KN/"EG^B]L"MUT?#K4'! M[1MRT-##[9M^HZ=JQK"TVQ::X3S3!6G49FML832LV/73/![>]X_4\:2OCK1^ M<1S;PG`5^_YDOY\;$`C@&(>3Q!(>W.^711@GE.Z\<9]5O<TOO];/WDHW^12& M$!U1_+9*;#*AV1(*&`QS`VK04LKOU<7<7G"W#NN6=NL\U+UMM[ZI'T4L?\=F M?336QY,?^=Z0)U/04#%98_=<?"]KZ<H/5MFGZT[O]\NKAR:+JY%/MVS;$A6U M?:(;;W#B&'R>V2^;TQT;AC'<'9L@ES8?GMBB0YLDO0>/383)1B;SJL#%^W?L M6=D)27(&&#(K#BBY1DUW4MF^BJ?\9,]4A2=PZT@!BJ>')PI;I5WAB2OL**,+ M-+3V,5E)R.Q#"H]RI&P6I'MBW)KGHC"HA!^.@.3(^I!Q?E18I!`4$3&2QX5% M\D&1;`M]_JBP2&'>>QG(+1&<-"C",\GV#8N$R2:?>"-"(X5P_2."(U4.QN.# M([GVL_W/8X,C@DQDJ)\7'!&3@Y8V.;M7<"0?&DG'4Q$<V6Q>!$=RH9&$,X\, MCA0"DD\)CA351!K+>T1PI!P:$2MN:W`D[ZVI6T(C2,V*X$C/R.(J:1"C%!O1 M>UT#7M\2'ME@!=?6[_1^=U01=VEB@.1#A95""DQ7-\"G;%.<90B\#Y/#ZM&/ M*J7+YH_P^7L).VQ%5_M:7]7S$9%'[0&$GD[W'WQ3T@6]3_X9KJ3,]Z_8O^@% M^>'*@A_%6\RY)7N2,V&]KO(GA5/2T`L?+ZS`-."2S)&^$"*,R0(F6J;`M(N) MNYA/`(/AZ<5$7?AFS:R'<A(VU6UBV_-:=(N6+!A,Z(</F.M<(%X:VN,-L^^P M8KB.-\,E!2`%;3!'N*1=WAFYR"#7+F*!X)R!3G,&!#A[DW-!YBRZ8SP7!72@ MA0F^]'#(@EM:K'E-[02ICB$_"3I*C'5RGC('DH+IB&@+A6,J/-6PQ7?%YD&, MZ3*;26GHJ?#,(@KQW8$S&-':$OY.>G*8:*UT#TO4!5N*Q!FH6D]7C4%^`3I1 M6`H3<TE('$7RXM+F'SC)[FO=7E&@"E&D=%^<#(C^YD/!!C=C3+V<A(+"I>VY MC9DS4>*LIO3@HH:6"IU3ONR282<Y]0T3B&3'6B$0IAOZI;!F^9`PU8!9?)CK M/,RA<FQQK)EGAZ%J?4T=ZTFPB&L1D)!2I!"T2`C\<6');]7+?<S$X(ZCZ1U" M+Q>(T;C,J'\)?T#F03V0!]7(K*%^WH[N%43DIYOZHW*%L)]^0;WF',U*8B;1 M(3YINCP/=/EH17XQ?I:$B'0>RX`>8/'AC8+"J[CG=[<(P*`T'B7-B@THRK!T MY@YE4J`)$(TF*CS+TR!UX<\C?I=A6R3<6="FQ!1;`#+[,>B,A+>)F"5)H^B, M8.N+!6SL@))`6S\&ZOAW'NQQ,)ZR!`D!(1C_D+FD?!>2974^5NQP;Y-E:I`U MRK(ABUZ<"`0429'SCNTD[S2UZ1'&OL>I[[7ME-M?IQO,W(XNVY+ZX)?=D8\* M+:_X'9.?R9"DETC(\^4RO\"SRWMF!ABH4@(G_-99P,)&Z\/0M<6M'XU3[PZ' M/ZC*K8^^&VVEX<NQ]H,J8F65@8Z]PQR"J$2(A#*P@C&\^4[O#@P0^@4RU;11 MYY'9R[9EE9V@LU^5/*PJX4%S<9MWL%6AK/<ZW<FV'\\\W4'9+>EE[S$'/+@[ MS_;T?-D]7D/EU2RMY,=K*#1<!1WU>`T%3>1UU-,UU-F;G(YZJH;"M9QV5JFA M]'Q&RA85A8*R%@E"3U51J*RYDE(6&([:1T5IW5&OH**XQ(Y0;SU/10G;LZFB M>MW1&%24UAWV:JBB]LX==A\)RE#7[.+2?KNG;O,\M2?'J_8ZLQ;G(F:8Z09[ M6P+0SH.._$8XV_(U;<M+WJ5@2(7UZ0W&:G^H;>C=5*51P(B[P4A3%Z-9"5WI M^<Q?WJ"Q6+K;S[":1,O<W9NR5[D]44AL.D+R]E#SAC^?]CX"088D?9Q__#R[ M_-RY^/C;;]-/U]`JIEF9ZY"]52SFNN':1`OR][<:_[PV;3OY?.?8T?+O;R=& M1F:+HB=OE3F(``OPJ=(]W7-V`S+RA4;PWXB.4+BN6\9O%3T,1S^DC'L0GT6\ MT]_^RJ&^?XU=[X>W^V*`0\^&CRNN@F2E!3?S]YH*__U1T=??,270L=]NT!Q6 M"BP/CX`EBO+_5"VCEZ[-DQM*'P/E)S%P3*#-[@!OB76='`FJW8Q)D#A*K"%@ M#LF6$[(E@5`I,68&[LM)^5)4FV@(+V%#M&$&JZSD^0:HQ8%A1X]26/H#=RW[ M/QG:3Q@#W>WQ-!DSM";X_6DT__&C.#6B7;/X?5K,0CQ5D1Q^%2M:(^6I#YK' M[@,6Y3BF<1K^9`S0.%7@D$OC=%!1'JB#T5"=&-(XM=HX81A6<OA5K&B-E*<^ M:AZ[=VW%<GLM_F@)7+E^*5#7(B^-@UDJGUS3.U(ZU)%A$FF\AJ;U,8X"LRA- MHA&97'AIVO3$Z9<FD@O/?3.PZ83`"9B%MU05T_;7R=TA?%#@7<*,/G@8$<$# M5Z3!YDUI>IK(4[S4G.7WI8!Y\_NS'"!)<B[O%$[HM#X_DDZ;3=(8P]S9Z0T> M<XA+:TXZ/G$TRP^/55C5'M[3BV%^]Z7?SMZD2=H9KHPXT%OGX(Y)+87)3VL6 M$$@Y='CVAE!^>9K`QJ_)L57DIXC-T(B=$9ORGP3H,]T>R*6@IQ-7D^$J*_,> MT[AIUGB$'XGD:&C$\Q$_\H[>!5KIFI;F#="Y]HKN*>VX8I6>9"<'V-0+OQF^ ME8`\DR$A?'HHE_^U-&;B79)<'Z\I+85Y_`R?4C&J1M$5.B1,FR'$S+N,JLH- M\UA`EXGPOC5FMPU^$/G#>*T)V^?#@=6SA*<P09^)WS'3W42^.3ZM!DQ\@A9H M3)5=L^].2&*WK?^D&XR)5[6>M#WEMX-^-_F9M#+U/,S!^ITQ(=5G121:D398 MD0)2/(S.$`F!WOD$JGA3O`0"!8>6Q+6):<$)[.14Y#_NP!K@I.0GB;IJC#2U MOQ5T@*\W%MP*2=@UK@:D_)(-T">34;,-`\Z@E&V>LP+X:X+O2$OAI\2PIR@: MU0:!7MPP"%RK;RATL>SS"KVH2_(ZE%9R3FUN)&ILKMI,P-)A):J).>)F[A8+ MHNQ4@=W,,&[HOY+NHXM\,(\4I22=SWOHVHUM?J7!7RQ`J0<"=3\U%G=+GU+7 M^$V`Y%6@YQ\;8TNSK#:&4-E[B9K=U&<+<V3+4VP?98XI!<GUCZ))*5Y+G-]O M<470."<W%U1E";8--*G*KU06D#2B):M(O.&@O)6,H0EOY2BJ+M<E@PI3I802 MD8U'1A7?'0]2XYK<1;*WF]E$%58:6#6Y$P;#=.]37,T\O$;IXACPCL;R0]Y[ MXLMW-Q6*LZ0E]U@B*+JNY7*F'S/Y*D$@]R>Y;I>\P7_+^L<K:MA#FNJ7+6XN MCCB07-9Z_@XOW1.$-1/&\W\+\@4LS?5*ULB2N3@0(8G)^N!^*^6;)$9\97YW M5O$J9\PSW\5$IX-2/ODU;.R:KQ[Z$M:7[22%1G;(/]K:9`7LI\6*G@?'A*.[ M>^AGP`+-"*>\SY[=[1YQM@@'Z4?A!CSD!*246YIV:N9)R+(7=F#=I+Y`+J5+ M<`BGE$MOJJ!"FL69>"*>GXB>>6LZKLF!L+"?18QE+3A)PZJV#I56.6X^).L4 M]1(F]&=DBN[\HJ98X[Z>[^]:FT>&FO_(B61]_?&)9,/397/)KMO6=2/2YQYL ML]9)0%ER7"X!:)K8IVR:8*9*#_T#K57V@+_(_N8^0NEYL'-42&A7E+6F&5\- M9S&:QC)SRBPOUTF0#'HY!B6%M#96(=75RJ:Y*X^2[JC18E8ZI=_S@9(FIL&^ M#N:FY=-*#^:JJ64/_^8LFI@YVVQ.3I,[GR4.?0`&89$NJ_3]/S'HL(-+N4</ M,+KW3@[N\2P#E`]_/*F@U#F5USA&MM2YZ8KKI[O.*%X@P_=YO&YHHL5@/%#[ MH^'CQW#J/`O)XT?D;@\F8[6OO9KDJ5?)94/O3GJ2P[O;/-5SS9M+[9.LLVJ= MN5R)LP1K2KH+1U$R?7VH#H<-3,M\&1X?;9K/'<@A92!+!>G7B$)2$*0@U%`0 M3OU<\^92=CSJ?QFYE.$A78^CN![O^UI/U4^^B?VQI@JFT;RM!VMK;T0:S>-A M5^]+!DLOX76$)SZF68\+/U@P1"G]B2%^C/0/CA;_U-3)>")53(MY_+X>3)8^ MX#%.J49=[=5@S]33J+9I+LT+(WPNW6+FMY+S'H3T'(ZS,QFK(ZT"I4>J'AG* MEH(@!>'T%*J7()SZN>;-9<,9R0N#N"57!#1XY@B*!-GCC;*[(S**Z;I>93IQ M13>/=4:.W>?3*"%I]Y*T.]ES<J3UB+Z>,*?\!8`Y7^5^:CR"#94A<\K;S&-= M'4TT=6#(5,!6<WG<G<AU7$>GH)%S:5Y,5F:9GT+MI."%4O6\\#2?.Q`9BI." M(`6AM0:\37-I2`:9S"H_;D;1:#)2AX;,*&HA;^O!VMJ;C$;S>-"=-+""59OL M:)OFTKP`Q=:D,>DV'-5MZ.OJ<%@!2O2JO0:Y&Y661PJ"%`3I@AS.!:F;PY%= M;$LJ5=30QY#Z1^J?%CF;AJ[V)J?.M*B;L]D*U@ZZ/7GQ1/H.KS9\(:_)O[3& MT?41&!.)Q-%F'K^O!Y.EQW",]6MT!_+$0[H,KR3<("_%GTC/]-7)1!Z=R_B2 MC"])09""4!-KW::YR#OQI^CS:920M'M)VIWL.3G2N@9?3WA+OJ*FD-Q@'>22 MFS[4U;',3VXYE_O]B=H;RI#=4;C\[J3,U0==73*VCOY!(^=2]UBLO)'V(H=W MDWY?'?=D;GD+>5L/UM;>9#2:Q^/N6.)62)^@"5$%>2.M/6KG?;^G#DZ.F%,W MKT&>STG+(P5!"H)T00[G@M3-X9`WTJ3^:9[^:;:SV9M(3[.%?!W*$FS2<7C% ML0MY'>VE-<YDH$YDO+35+'Y?"QY+?^$(K.U-NJ-3WS*L_>*5#D-;(@WR,MJ) M](PNBP'(T)(,+4E!D()0'VO=IKG(RVBGZ/-IE)"T>TG:G>PY.=*ZAEY/>!FM M(M@@-U@'V6`9(TWMC\;2I6HQEWNJ,1FI8UF:]SA</O%E-*,[E%BB;5Z^P^Y( M7A9NX<HUU.'@U.C.3V!L:_;,/=B#V7X\=]D+;OR>WNE+[?PD]>J]QY,CK?4) MY%%VR9<\P]D$P6_N3KE-8>E&.Y2&JO<U=320*1PM]"H1G*2!7F43&%N3Y3OH MCF0DIXTK5QT,*E#7ZL[8YITY_).%F,ME>K;"OJ\9)79%OG(+7\-@S%#Q%]+! M:N0"KHF&[JG&:*3VQS)LUT8U;72'TG-N\_(==N6!:!M7KJ$.^PT\*BLZ6/_5 MZ2B7X+E\H6#0N6_?*YU.]B)^N\.K.O_XY<O'WW]6M/7W7Q3Q'059=0._*7A: M_1]2ZO\[#B-G<?_,N7_Q(]-5'"\*'"]T+"1TS-#9XEGUOL`93*_S*W?@B[VC M)'`5YO-.UT;T-WEN_V&!K]@Q-'6C1$NFW#,S@'<]&][;[KQA.PAN3$W`'X:J M!"Q$']"Y9>Y]5_D"395'Z(2*9;I6[)KD-F+F/_9H.XL%"QAFK\Q9=,>81U^O MS.`;B\2K.YQ)/I(^C03?2Z:MK`/'XF19FC`X/J;-5G=&`3GIQEU-5]8LX"WA M:P%;^P'.8GZO_#&]GDW_7Q?:P0[N&*XPG-\M"\P;QG&;%!OFK"Q,)]C&+0'O M!*U0ET/H4E7>];KC`<T,_YKDQE#-L9US47=R;+<[7B_YATE[,4X2R<@)*)A, MFP\A\4.@X+`_4I7^`)S((=$1IM/KC]7AI`?2N0=5B*4E#D(;*0^W=@[\TI25 MX[KP,_#1Z/:23V(8\%4__6K_L5SXJ[7IW2M+6CX!NZ4%CF*PQ@]^'+KWF73: M3FBY?ACCX+:,%G=JT-]6*:V<X<(/,M&#%HKJ0DF@SZGE\K<&GXCE!P%.#65_ M:>(P/%]AH`FL2(G7/M<!800#6C$OHN%;,/>`+1FHE%NFP+RP:W/EQ_#[<^0W M?^)JE`5:RYW!;C\FVWM]:,=?'I77K!03Q<B)[DDZX7\+WW7]N_#GT]*-[&SI ML/+BXV^_33]=0ZL6C-%<A^RM8C'7#=>F!3KO[V\U_GEMVG;R^<ZQH^7?WTZ, MC)@6B`T+WBIS/[!9@$^5K/\YNX%UQ^W_?S/3%O9_R^&5Z&'4^V'O?7WRSGC[ M*X?Z?EO7HV-WO=^)WXLYTM5M/J+UHB@FXEZ9<;Y!<Q!7D%$/UV%)")^ZH/7T MS3G^\4=<M.S^@GX*E)_$)*Y)2]/$YND4Z[75:3>'_B6\OQ)?IMP7S*8YO3.# M\D,SL'79$U=@A;-/_T1S7'I^G1<%XOQ)&;]K>Y53KU7:-[?[.D[X^V6O,_MQ M!(Z+A\9),:/M'GD%D/6A0^"O/`(UT$?JH/=J:DR\SG!4,\.,=4^5VJK=^!90 MJJXC2_5[`ZS$Y.2ZZ]BX/Z^<R^W07?5/5:@#],PK%_7WP[$ZTDY];B3UF=1G M#^NSE[N*(\$8#G&II-U7(>H9O:C0Y-)B'C;/0A^JXTD#]:GD]NLUG<W="KQ8 M@:U7+NA]71T.7TT1QU?.[&:61)#!62G5NX.SN@ZNV:GO!\I@AO3(VNR1R>#L MBRFTOCJ9G/J:E51G4IT]K,YD;%;&9EL>F_W3$WGV0<DRPE#(-NX=I*VX!R\M MY^&C&0V$&Y#,?K71C`;O"&2,]H6T6D\=-%'4);.?,(Q)=WCJ-$,9HY4J[.`Q M6DT=]T[MF<F8AG3(VNR0R1#MB^FS.E1QE.I,JK.'U9D,T<H0K0S1[AFB?0$@ MS->N57MJK]=`O=HL9I_V$O"X.VA@2F$++>=KJV=2>]O99*##3?`UI``')BL; M7F%V4U2SQV,:%M'7$"@+FGFG=?4<D)N>0VTC7#Z].\Q^WL!K@P82Q+85,SD0 M&\*8,2\T"5<-@;.]D!&BVI894:&2_-PY-EJ.,#B0@%G^C0?$"P4*(F_7OV4$ MU09-I!C=2"(DS9H%CF]S.+9<^]N'`HTXH3(W$7).C`+AY:BM!&PQRD#J!(F! MF)-?:-HK!)(33M+&++K*5I]*,1$N!R@1,"6,Y_]&C+C(/T/\NW4<6$L8$+I8 MG@^=A/A3?A0'0#84@94?2BM@7%3-3[0:KH`.PC\<_.,:I]PY)RI?Y&2%ANZD MDTA?.@!JX_!EUG*R%,SUVG6$H)J6A0!^*$,WL6-3$5N4P$1.\JM%5>Z6CK54 M0#Q`;3GA$MK(O4^O(0Y2AXOHVKQ'[$!H1,C/RK092@=;K5W_GK%0!9GQ.NE' M6DBV@[B$?@`_.I[EQNC`X^H1#RE%V$X"OR_^E(ADB!)MT_)SZ.Q23$_ESXE! M%K0!B2\L,:$K;)3J=)6@3L/57EQ_&:!J43T2;7':'.;5X7"10D<@^BI\G6D) M4&8PJL!$3ZSC.A[U`@/)JP\QR^*J#MA?L1,Z,*R0!;>H`[A6494;YK'`=-U[ M&HK0.6=OQ.^%(38-?)1C)Y)UX?B%\6IE!J1[M[(V8,0EF!((8$&&U&WZKN(' M5,.(>+M+[)3W#LJ&'X?P5/BC1'@\/L)C_W0(CVWN6H)+9C1/H0MU[4C8A?]' M7O+E+ASI78['`4CYN,VRE`;O>$"6:6#R5-Q^]>3O2?*?DOQ&C73=ZP!3!?,# M>SN.CF^S6^;Z:]R^[79?9<3\J;WK:D_>PF\[BP>]!E[YDBQ^#(O'6@-7<=V/ M]__!@U?"&IGVRO$<C(]A:+^]!JDFY_6Z.AF>^BYRZ]5637AMJ-I`\OIU\!K6 M]?C4^*\R24.F-YY\1I**;:7B46]V',73O=YR8(FY'G3\#=\[GN*O&7J_WDUR M9ARVUPT^[8Y.)JN^`A8/3HX=)UE\9!:/QJ>^>RI]79F07(<I23JVF(['3C8_ M=NXM)=1>BE0Z:&W/[-O&Y=S&H4BX/7=-F."UM?1=^$:4]\;T;73N5[[-7)Y; M;;.(!2M,!8V6NTK7\^34L)!7FYSB)JFTN_(5E;5K)O7%>2[Z-W8/6XYU3)F[ M81BO1*YM3*7.?4S_=5:;%P)@F"%+4GW%WB5-?6>!Y6!?^31UD1Z;I,M3FJ68 M$TZ]^`NT<NN[(`HN%M'>E>@NB",R9T6+A4?.<LGX64^!$W[K+`(@D(.Y##!+ M)<!9/JXEI/36H:7/VLZM8S-X]-YA+M#`62"MGY<L?X!DT3J54?^R*?6;N>4A ME5-/!#+)RCX3F=KP#K_?$(?)590]5E^2WPVM1(5DXSM17%@Q>3GA_.)H5Y:O MKFG'3O/M#Q^?YCLX7:ZM[%IV+?.JM[1^D%S"X1'3JGE6-7V5J_>^&Q%@7NUK MUC3S\[7QJ(G9N:^-1W5*X95*]J@)V\D&OB0:M)G/)OF1^\IRZ;XT=ZX_?9)$ METM"<D<N";DD)'=JNB1>WZ6KC8@SC`%CSIN$:DMN3UU28;NG3GK^X=2ZJ(UL MU;JGSF^6;#W*:CWU%2O)5KE:)5OE:GW%;&W2:JW[]=9_IIDLTM,_LMB.1E(= MM9&OXV'WU+<T)%^/L5Y[#;(SDJ_[\[7?'4J^MI"OTMUO)U^-!MG7YEW[O<QG MC2L.)AL32K[<#QQ9KH?=UW.[]U4R6.\:#:RF*QG\B!5LR!7<9@;+%=QR!@^[ M>@/OYDL&MWP%U_W4X+)\>Q0W#7A_5&X:CG[V=6J/0\8X)%LE6R5;)5LE6R5; M)5LE6X]V?-#P@KW;8&RBI2AF64`D<KP<M`U,J0B%4JXV^V?WNIM1]4M`93+O ME?^PP.]8?KR&QYPPC!GBXMPYT5()V,IT/`)?8<$JA,&N'-<,DA*Q!>R<,$'U M$749N]!('D')]F&\GA\IIA?!(-<XJ;5YCXTG&Z)T/@L?)LX8\@I:6<11'+`$ MFB=@^"N?OJC!68')@X/!>8D6H94JL)AN882.J,<9%'&2<`1^L&!.1/6'!1O@ MMQQ"#2\A?(L82='2AW\G+X?\<"B,YR$TS>!17L`3OE\HIA7%IEMHW786"Q8H MB\!?\9;@Y;2MKO+?3ACY,`-XRS8C$X>\`>NT#E@GJ5&<"D9A!J+><2#*8E;5 MV\Q*F[KW"9B.G^%#D31B/>%,!'PJ4MJT6J3%U12!$-]YRC*C<@I]96)=:L2N MXMA<['L$*@[S``4NF.LLF&+=6RY)15+?UH^C,((W:`GY0+'`N:5BR[P<=(9\ M5%A*5(K7@T$7(,**PIH,&"4;AIP#U^*CO\^6/DXKS%W2$VA6,`$:EWB>"PG- M1=28S0EML29TL1U0$)$#I%K'<]>Q<#PHPM@RK+TIK#<WTSF&IO6+\ZBLZWWV MIE#96PA=5=5R+LM;JFT#G3<+?Q>AI1ZH_7WVIJCHGE#[^^S-]D&F<&L/E`47 MPWBP,'CE')NT)*?$Y5U%YLD"$&S8NT%WE#V15)4G8L5>KE;S9HEH44P8I3I. MBJ87:PJC`:1:V4Y84'%SEJ\"3=!R9@HLUDF`Q;ATT$I0C.[`R$9)20(D#^^T M;D_)!KU]R&=OM@^Z6O+5S;&?O7GLZ#DAM>ZX5QI]`PK"$\[D'[G2Y&?M!:;D MACQ4MF!*%@JTJZ1715'V?*5V[M.`&MM4ET(_(UH?J97$K<M_GT!:5CD2((1@ M1_X-/7%<3--&&M!K)M>W,59Y=\D11.\K0O1*$.N8`P0VT*E`_83_\OR]N)(X MO;2ZD$,(TK-3!R*`D@*F!D%ZNLJ_EHPC;CH>E1@0<)19^Q9,Q/&`I=#S.O#1 M34[+S1<-.[($G@YC-\*A"M/%14.,'IV^-786"664;QV9I>:-Z!E!D/J60ZJ+ M]A1DW\0[F4$5>X=$R16T,30"4F2YT)*S<!#`,2Q04#Q=Z;^:BXC#?Z(3'IE1 M#`TM3>^&-4FF/J#=\CQ80S@UHJ+@'^Y8</D`4>;WI<4N9EU4%&P?GW\!ME53 M-4U#A?%.U_KT-S=;@R%^0)G-R2+^@L*(SX--0IL#?JY[,#S4\?'P4*MMD78H M4S0OV*04HR$S./-FF1X0Q?\QO=B$_07Z\GRQG_O@Q9+CEB$6V[!X&<?2Q5D+ MGP3]*EB]YAKU$!=:?()$<NF[(,FD#J_8/$C[Z"I_HHAG325+F78YF9I;F?<9 M*G+1*R[`#2OQ6I@B!265JY25^=U9Q2O%7/DQ[G>6@1_?+#%`$?@N;+:9'5L\ MK$'6C[?KH&I*NH2%Q59.Q_2`.BYLFG&#+!QX,&LFPD(KX\$/R6#(TJ[,X!M# MU`AN<N$5BP61"11`5.>.S1:.AZ$-OODOQBI"5)_Z1!T90Z0(K,7)>$`K41^H MFJX)3&CLKT`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`<V114#ZORB<5+@M,;^SG;A3 M=36J><5N6A9:H)"K*)J:$N'$,C6%+C6+A-IV'7/.XWXK%BTQ)I582_"9^5<J MF*\%"RBL;7[G;X>EUQW&7?NT;(%=C$CQN#1#=3EGT1UC25@=+!0H48S_H4WF M^T':-$!/T()#2CCKLM`AX;K3CL?D`19X)Q!!<X5!A[!I3&*2N#O"KWEHHS@D MVJB4@M$F?QV:I',@3LFN\D\PM-S;-1$7'O4_39P'8^%1)USB3@7W5.!PLS!$ M-P3:"]`#X,4<JJC)#22.8\79MQ$U`HGY#[.+5MQV;#H2$=%X4Y2-$SSGF[60 M=M&Y+>+#&T1NS7MJLD>$`5AF'+*RY00'Q6,9C4#-A-EYB0AQ-FB;=`73K1)' M\&+6?H@[(IKAG!\@\44E"EV$9^5J`;@S\CT*0;PGFOAQ"/(;_MBN4@$38\]* M`5OJ``R;50>@W^*N7P=B\O^GT7_V@EK4M2.":8?[HVGO\DE>&)91BL7Q$#@; M6GN@+;1O8DV!MM"^7K4"ZG]__$_/P;W!-?JH+;XT?MHBLN]A*S3LGQJVY,?Z MJ)`V\;;74T?ZJ:M`2]X>A;=]3>V-3IU_O#]OZW[Q\,H/&`RASF;F:)='GSN0 M0\IU/FI='PK558-)D9`B(46B+A1Z\E8LWZF(?!=S:[8+T5["MFV(>[Q;ML3Y MXN^;^^H*D3EDM?EG=UCQN*2?I%]MZ'?4((UQ#+_YBQ^9;IV]YD9O\F1PIKV\ ME<&9]O*VX<&9ICND/;#/MA_/7?92'L'3>ZRG2R4I*"FX33_4'Q]BXSI/,6VM M,GO0Q/0V_HS,9JL,TB?9;*/'9[--3I=2UN:N9=J2S&:38B&SV5XK[64VF\QF MXRJN_MELXA[>`[YD/6(NIWI.SJINLSI@VLY1CA^N&.Q;ZGT`<=B@WA,"F_(< MOB8A;2D)4A*D)-1;$IIW`D_W(UZ/`909:5+_29&0(B%%XO2VL>%I`NW)&Y3T MD_0[)?T.&";JO<HL5;DAK*O1DY(@)4%*@I2$-CO";<I5E!24%#PU!9N7G3`3 M<)TR/4'.JD&SDND)TLMLK9<I)4%*@I0$*0DR/:%!PBX/'J7^DR(A14**Q.EM M8\.CLNTY'I;TD_23Z0DR/4%N"*4?)"5!2H*4!.D(O]*C84E!2<%34_`Y<%X' MP+/:&RY,.SY:6)+W4*PB&["%2X51ERPI_IF46L7*Y&RU]@,SN(?YY.JKYFN^ M*I89!/>(-9:4.MU:X/7L#95OS6IR!@Q:C_#=I"8GKQ6+-6U%8W&8E.=.ROH2 MEIEX7%1?!RHY"\?"RN2Y.IW%,N^9G9O\@B/94@.W4)#V#N8+O^6QTG``$BVM MN.H3M+0=)2TW'(?30Y:-6]RUA,42!#\^6MH4%<V9Q$9K@A!(;+16TEYBHTEL M-*[BFI-]C&XG],X=3YF*+&?5H%G5/15YQM8!@PUF1GHWK;(4;S?_05TU8 M;"\663Y@)'DT/G49B`8<)329P1-]+!G<9@;KJF;TF\?BYF4*7YAK)X)1_(>A M<?I,,\5_9NVU3<\Y?CVDB`]4?73J,F.M5V,U8;:AJ2/-D,Q^%<SNJY->`WE= M]\W49Q:RX):?S.%&RK*"V'1#::B.+,Y#U3AYR42INEY,=9V\]*GD]<OP&OQ/ M36\>KYNWQ_J#18J_9H&)"2;0O>N'(9-VZ^@;K/Y8U<<-C")(;C^)VWW5&$AN MOQ)N#WJJ/NDUC]MUWV1],;\K5L!L)Y(&ZMA"W.NK@WX#95@R^RG,[JF:9/8K M8;8Q@'UT`YG=MDM,[;E-+>DGZ7=*^ATUZG*\^_V%RS5G29:C]&R/?MS95R>: M3,)Z+=SNJ>-A`]T=R>VGA%XFVJL/O1PE(?\W%H8_*_\TW9B2@]%:X65/T[-J M#>78"J%^7P^+]:-474?F<ATLE>3R<;E<#PNU/Y=EU*6NNUY)/TF_UD9=CN+$ M8JY+XV(N$E6MKGLV*0E2$J0D2$EHL[O<)I0[24%)P5-3\#E(BWGH.PZ&=UPH MQ,\,FN-@$(@26`4%Z(3P]9IY-H,.XC4\N(BC.$``0F8&GN/=A*KB+!33NU<) M9C!R5@2"Z-D"NQ!;OELZUE(Q`Z;$GL6"R'2\+K1P;B*J(;6*K]XQM"Z$FWAK M.BZA^K%;QT:L156TX7B6&]LP)7@!6J@"-5263ACY@6.9;I;XKL`?"S]8F=06 M!URD2\=6O(I=>.26XS[R['B@$CR'G;%U@IY!P(^.%;O1/?R`%\!B:)JYB`D) M+3/+#*FC;5B+@G#0=PAMA&K^06AB!31!N@!!3'C4=5&T8X'=D43B%4$I;]L^ M!U$:@7Z5(&P*6ESZ=X_F@W]PX,C;JJB_<F<B[R,6K&A4ZS@(8X26C'R.3&E9 MR%Z<\DWLV/0*T`&:R`-K)GP+V%^Q$]#U.1IJ&*X8EPU8N4ME[8<.\8#?KO/8 M#6=)PGYHA7GI:+!/^`)&$2A.A#*Z`@8HKO,-V`&#,W$BGH]HGF94C7!)C+#\ M6Q`/$#-.!L$,&'\$`H_@F##5A"][<.7/[G4WHWC2[=F;?,=(,5<)8Q0E!RF0 MSCR=*OL.\AMBWV&\1CF%%@(&(PU1H#F89\4H2JS,?N`<"1@MMOF]\D[O:LK* M<5U\"B;&Q>(=",.H]#67DW>&WM510@N_&=W=>^I:*;HI<%PL/*2@4$'P3:;_ MA("N$LC43+QA0GD!A]Y]ZQL!K#(OI)>%YB.%5:U'<6&50%7#I7\'7)J##((I M@B]08(5Z2T>X99%'>Z]P@Z\!,_!#Z`8F:$5<8P7^BL9G,SNV<!*(@0N*$/OR M%20&Z+G\))'O[+L%*Y<#/19^P[5TXR&.PS9HVZXR7:\#_[NS(J6)4CC)"160 M351.I9%?`&.@(<\Q2==E:ESH9[Y^:;A\F>)4.&-\KK%S\\H/'-2-_RWW(ZX: MA]C#C=4=C$>9,Y&%SHE![2Y]%X87YE5Z0B723:2':*6:A&?1I.6!BH-C^Y+I M!MIN-6(Y_0)L^BM&/MWS12)6#,$#MQ8<6->TYZ$#]T>/1P<>G@ZB5W;=MJXE M'*X@^-%A0<]-EYP&,Z*O`N4G,?)S=N-XZ,5F\_07I6<^L<#Q;9KQ/)W[H<DL M6;>%=1=+,[AA=C:9R"_QY_([>C_B(K7D4`TY]!'WA]GO4^&>2(:=AF&SU.>6 M'*B9/;KT[((E2O^N@1%J7A+"_S$S0)+2UG3K/MV08-=R5G)6<E9'>*[N,`]Y M\/_JPX<FZ,87R\4XY/69X435-8FGUVHF&[JJC26.WNDF_-R!R&PK*1)2)&HB M$DVV!/6XBW2(+,N6[/I[<M<O9R5G)6=UA.?DKE^Z`2US`R23'\'DGCH<G1I" MH@$\EEL\*1)2).I"H;J*1),M03UP9N2N/\O)E[M^.2LY*SFK(SPG=_W2#6B9 M&R"9_*A2U3V9SB%W>+EAR1V>%`DI$J_-$-0#0OC9F_['`:8<X'[PWA>QM9>^ MA^UPT`++]RS'=5*4%KR:'49F%$=^<*\L^*7YLSSJAH*X)`E,1^4M;K98,(M0 M)SBN`+[0KGO:$^-YU[3'>J.N:0]:W+6\L%R^(*9K1[HAAN',D,<SZ;OLBEAE M;).F-T\G>FB:/L9N2+$XWKU!]!Y/RNHCM5EKBO<DQ5^8XD:MU%G]S[ZP6*\9 M)1YHYI.>O4F=T-TN99,W>\_9[Q]PU_>^=^J:XS_^<&JE(ODJ^2KY>@2^UKUD MV76$<8XL[J%RK$`$)TR,$AJB.?/8PHFD+3JV;.O-$6VILO9G:X,TEF3K_FP] M]07Q9QBB^N^-R#1!MU,"<'9\#W&%I04Z]AG8^,0R+375$;AZZO06R=0C,/74 M!]7MV05A&(ZCE2/\^'O8`OTH#<VQG:=3ZR3I$Q]G!ROW.NWDZZ0Y?&W>9F=6 M6>_D?1PY5`GC1ZIL(J)P/+%`&B?I+TL5]IAA]$\=7)5</0)7!Z<.PK5G&W2- M19HZ<RQR=E8L3B4-SK&EN#%"+%73_K%4R=3V,;6Y4;?Z[X+^^/@;%@5R`FET MI'Z2^NE)PY";G!8RM3DKM>Y['%[13%H6Z21))20MBV1J<YBZL9W)]R4N3N>N M2>]DV5ZLW:;-]WBW;-?$;2VZR[UY5:M"'!YKCX[:8<7CCZ-?'28AJ=8*JATU MJ'$4]+8O?F2ZTN.4'J=T3B13)5,;Q-2V>9P],,JV'\]=]E)NP--[K)/W).DF MZ?8<B+4\DA?']CH^!IK`+%.6IIW>Y*6KO6N&IVO>C>+Z8:A89A#<+_S@S@SL MD-_[-=?KP/_NK,R(N??*N]YXV!TK*\=U$3S-]&Q\@%_(8C8A5K!BP]!$9=/E MAHWQH#O*2)[T,&?P#M[[2D8MLAX1)V,[.GQ7^;"@',DD8U)%Y+9<*SAP/MB= M%+B#44"/-XZ'X&\,SR*Q%?AX:P:.'X>*N?)C+PKY0QXV8VB&1NW#0`:J$K!P MS9'AW/NN@KP`\D`;._MU/,N-;:;8S(XMI&VHP&\P8M_Z1N_2=]W=VXA:"^$- ML)'8&8>.QY``=.%B0S!@+N]Z6G>\*1E(XG=ZK]O;_`EIM<'ILP*@WSH.UG[( MPB*#U`?$"MJ8"H:;`:.<J,`)0?!AV)]9R,S`6E*/,P;-^6N\HZA<\*LD^#V\ M_S%8+TU/F07Q3?)+M;2F,RB(!K1`0LEE<;<DPH\@C#J7N@M@)S3B.28TP45? MD-PR<9E1-PY,1?0$;]NPT#PG(L&]!MI!=]#^`L9(RQKFC)^!,#J'IV%1''AJ M'B,16`V<=4V0#)N^]_GL;9@]M,`'T%6N@%]_Q3C`>QPWS(UYQ)O2*YF0+%B` M!.4\#1CFJ*6:(6"NR9$8.5YCD&>,G6,,;^T,P76^,0_)=4]H;<!3/VC2XIJ& M,,F_8@<SQN?W.58+1KOF79$MJ<X.<ZO"S[](:7\*+K,$8A+X?/'+R@R^L8@G M!6;?SWY10C\.+"X7M'Y-:]E5II;E!X@CB2MK*W1FKE<S?[D7U;4?K&+71.#. M$$3"2=AJ@43<,-23'+P3.V<"RA->J^QFY7S')P(0`"]F,#@.!AK&+M<Z-P%C MV"VUNG9-2VAZ1`XK4<]&MC$4IHTT?1Q=P!8N:!1\)\1&Q&B;)%$?O$1#JTH, MBB!0KAD9HIQ2'!L)>.H'Q`WS0%5]YL0%2MDX\?=YT1$-*/!>7G)^!)T+BA2T M,4_S@09!!U.?-SX3BSQ[8?R+?P?C"I?.6M`USV42E'C^;Z*^K[C.RHE,;C^A M97Z?SYR#`HON\7>A;TF-K0/6X0U6.$8T#EM`NXJK@=@`*")@NK*(0?.172'( M5;Z@A-K-*4)H$@6:TFEA:6;T@,9-]SYTN)5'BJ(B4ABB1NXP1]@,C`J;1NN! M:A,T..AI<,H\I4PGX"^J<$/3AB#\BEAH7(]OA[7][H1$A3UI@E9Q"P/`3(7X M[B+P5TCM6[):Z2ASZT2YXO0LK?+*`9)+E+6BHG%#;0:3NELZJ/2A(3^.0L>F M+T%3@+1Y4>"#9%M^[-J)#G`\+FL;=-LA_TB`W.LVT`">(?#@W-2;M/`WICF8 MO&<_[ESHO.X(,#C3O*2CS340@-;79VH._YFEQKVX/!@J3%2D/LK![C?%4L8E M8"2.=B_G@<!(%C#,,YZS[C*26),4?Q`R(3'A&I1`:C\0$MI&%R2`%W&RV"3Y M)=`*+K62`?`BQW+68%IIQ;(;'[O`)V@>N*J==(S]LS>YP8&9P`?O85]*BS9K MJG+-DNQ!`U72UR2QRO.:XW$3&103/`3P6I%\-[%C8_$:;@!`0816X,P9EROR MM-D2?0#P`%8@=2[IRJ5_1[^9G@-/ADNQH"W_QH/>564%KB&H$E0+V"*8=Y6[ M@4YH@1)C0@(<V"\X'O3N"-A%X0G$,)X@,O$A4G.P97"X-N,N(XP`I5*(+GK1 MXGOTFS*F@ZR77C?)=X</L';NLP';B416CN8.YH\^281F;@5R!TKF&VZ>(W20 M49J(=/A^TE.R@P6E'.(\H(=X35J??3=7T`D]-+^GE\B+B:.E'\"[N$*O8U"@ MM%O*#YS<HF3HM+V*YR&XGS!&^$)0W!:"#KYG`#H\$ML34B1$B\1;IR'#?,#] M,G'QT5P&V@_)W."%.4/Y@-]I<Y1,`)0N[1%A]4:12R2"V4;+C:G<HVL6K\CV MQ$"-;YY_YS+[AF6V+R475^@NNX5UJ2Q,*VJ4\L95%D)[SL*Q<`+_CL'FVHZ( M((!H<9.85V6PFR,+BQY+05%Q&<5'_\0]H*T0``^W^9G'SO=NA7ZXURQZ@N;X M?I$WMS)M5E2E18<MVZ"7)!37.L@;-!9:L"CX/HT[-/@OBH=PB_+A\W7!0X"& M?D,15,Z32`/.0!@R;JV5F7,+O@ET@Y4!,/!BD_(V8[[91+HLR7.:T(S(.2-1 M\WP%13#`A<IW!;12N\I_^W=H;E08';R=NM)9I0%R1O+N$7E^T+CK<`?5X;8% M9PTM\`D';`5K.$1'S$M=11')H#T,#2&Q14E`(-T6Y;RVQ%\K;_K).8-E$W(7 MM''27ZKU$)ESV#X&6VH^1'@4GY")*X/8R^GB'-1A6-S+_/GE/"QL8I3WQ&B@ M7!P"?<,?VU7[0=>TYQ5_&.RH:;!QOI=V>KH2#.WN6P+]"XH?'03]BL=PZ7-6 M^@$T1#8]LJNE!\!=I(G.TRG7*]?@B6W6GT_I9)`#Z8?S#.\VQR1_469B^O$# M^3'%UHHODP61+'Y!%O^9,^V/X91@?I@]T\G^_(/@D97J92[>Q`<XL/+)F=Z\ M=,D_MSEDN(4T70H8[#JSJ[@JU994R]-6QQNHO?ZI<[>.P(0Z9.:=NOZM/C@U MZJMD[#$`CU1]?.J;HT]@;-VOD$[%J4\:P4F#I3RD0-D$/)K27EM4DV1BX]1H MDRU57#5AKS1+;>:N?FKHM@,8I_J#ZNPT5Y0ZQ\\R,4!NQ4&`QVIHO*3M.K9R MTTX-,RK5VU'=[YYD;XO9.QHVT/=LVY6V]EQLEW``DFJG`E%XALM:RS.`"L,K M?=>#&K^AJH].#1TDW9OCG@H8VJE+?D@.'_=X8#)LP?%`_2,PGXN7>LN9Y?+( MX$7%_OWXU&#[/TIM=@2V&J>V5I*MQV#KR>N[[,_61A]<RY.`$_K:8WG0V6K^ MRKRY5K-WU,#E*T\"ZAJ=E3%M234)IWRLLX&*0]NV>+.GS38>JL:H@2?B3?!S M3GX_8"(=V!8R=J!JXP:NV+9YKFV"R7U)+TS23=*M2;#,'U*H&0[YE'BK.U%( M3('*O-V?Y1DO"2Z:0;`[[P9=/<%L5O&3!DT4<'3[72/]@D,TI7V6$7(1L$E5 MG`4%B9-1JLI=&4LO@\,AI$0LM,=AF3CD5\@QN9R5&3CN?0%*LUE0F7EHLY0@ M"*D4L8"`KRPKB)F=CZCG^7OVIL1A8,>:>:9+"$!FF`<M%@AX7>5S(3H/36R7 M&,_'!\VY?UM"7K(=FR/0T?C.$)7B/M>S'V13L..`(UNGX@6_HG050/R@"1L1 M.Q,L2BLB%*5M0\MP7%,,)8)[AH%R8"./?8>'[IA+B&]>M'Q(+'ZRG5O\^+>? MXK!S8YKKG_GM_B_F]QG'>XL#]@5:/7=]Z]NO\);RM^S)3X%OL3!,8)RGGIT# M<?X$NVWKGI`CX?W/;/'WM\QWOWZZU`=Z;]SK=/2^KG7^5P.:?+W^,OO:&PZ^ M(KETHZ=_U=XJCOWWMX[]=3B>#/JCX=>>IEWJD]FX<WEQH77ZQK#?.;^ZZG5& ME\.I=@4_:N/>5WSQ5YR7F-8CA%]LN'\HK89QT0]ZHHOF"D`%_,/!/SX!@UW' M<Q"9ZSJ*;2>!"4N^_(+,A4ZG*&JFRY,:G)2':6L'6/'#%T!;)L"[")$;86X" M1W4GBNHZ(]`9@F]G)$),LUUOIG2-D(2ALC1A,<P9X0"F<+(<O\\)[,[:#"(N MI8%I11GRM1_<F+``S>1TKP!F=?'Y8PG,"D?&%?8M\VP_"#G,6VX:R210B4<E MU#F$S8-WE#CDQ@TT"`+U$0JG$(`4X)YK+Y@)8GV8-QRWU0^^)="=7,?9'![3 MSF:V0MBZR/<8(?I:2P>6JLU'6219"4Q\VSC/WNPQ4L6+T>92A@X\1::->8'O MNF``4?O%08HOQK\G4$*NT1^>(:++YXT)Z#R'!B@ZR[?IHFH*$[A"M`5$![#1 M'#E.'-N"KL*GUT@SF#1B@D7+P(]OEERY(_@=(O&R.^*DY0=HZWW/9A0W$]#Y M<:BL&,&HAASV#B5&%9WCR]PG29@3(^U9L"I"O!;E6E":<5A`FZT1ZQCA(3TA M4/`S<S.\/F`'$-<B.$B@E0E3\F\=F\L^6AD<4B:WT$@JN1\*RXO0DLFD$O&Y MF>.MPR=L6D6`S95Y3U;59D$'GT&CE(PYH?-]RH4P]"V'##*11R#RYY8Z'K#S M!6R"/"@WX$IYH#F`!^3].8@6_0'=0`=(<TLHI0C,CRZ5<+,"N^Q1;86U3W%R MH6F.3,V7F./;'$-4(*\2HXIS`=6"!C,DC$ROJ_R1X1NB?!4'4%8''`QTR_(C MS84Q6=!=>;S31/8?;]GWL-=E$W_+^/"%6Y!X`@<SZ^<#3>M-M%EG/-9[G?[5 MZ*(S[HV,SO1J,KVZO.I?],[/GV/67W!O(CP_X7S>F>2*)LB][VG+TDZHPXGQ M/*3#L?YXI,/^Z<`&V]RUA#DL8ZOIVI'`U?Z/\&DOL6`!?9>!H%5&*G:Y_4>/ MVDNQ>"G(O?1\]52L?MVT[TG:GXSV1JU47/TOQ90\S@>V`S(KX\FIIZ_FFN;K M9/#DU/<C)'^/BQ+40!29!TYEJX([6R(UQ8!.$OK)Q7VFGHV!OAB,R;6_B.[, M@%4<_1PLX-/7>MKEU7FOHU_TIIV^/IMTQKW+06<Z'H['O?YH,+H:/3_@DQS; M/(-IB6?RAY^'*1]O,!/GB@/\2-'_K25-D_)?TR#``SP*">YR>!Y[E%-]?C4\ MSO'5/V`.4<//I#Y0G4J-'W+\D=2U^>!!VTFQF3]8'(`/>$/!65@4%--*JM)> M1X'_C96JG/P!P\T5TZ&3(:P2DUT+2PNB01/OC*HJO3=(7'P\C*FVY_:P-:^S MXP1FR%:1<ZO83I`6UN(UFO`LPZ'(,C-).]#-M=6]&<+OO+`M='<KRBB:(N9- M"15KWDK`DKHV&&Z_9NN(8A-TEIV4B*99YR>*M77SQ?V4=UIWD&9+\.J`6,YQ M;0:\S##-N:O\;GHF7QLP3SP0H?);:8FNA'9WHE#6.@#7UUE3I!W/\:@LG)?6 MJ..$-',+CDY@5,JGR!=9/7M32$>@622E@&#J5`*,QDRG`+GV,,*;5$<51U'4 M::C<,5'LF)]7P8C^)_88+Y+WC#5R@.#OWFM0>X%$$"HGQ/DDZ"A()T/G>X7. M1Q,9.J])US)&*D/G4BQDZ/RUTEZ&SF7HG*NX^H?.^8:E8ANTV[D\;0SNL$&I M)\3D2OT?,D:7CZ6<F#`R&GO<2ZZG!IF2_#WR7=>>U@(PC[I9+!Y=IDC)V9LD M5E)G:W4P#IY2F$>G!CILO;*J":,-R>C335@ZHO)B?]MA@B3])/U.2;_FP53E MS@9?@\=[VEV;='3;S=])`U&*)']?7=2EZ?YJFX"!)`4E!4]-P0.`4[TLKLL_ M7'].Z8CGKN_;F!`(>I7%D6.%JO+!L[K%=-'BXX6\49IPDY-K/UJ1+Q)%]2*, M$IU^4U)DY"LF3YJ;^QP(!.9BW@2,YX`2-`2GT0Z"$J)+X-XKEHFP(M!"\14S MN"$D#O[\CU4<J*!_5_D34SYQ/!X?DITEXJY=TU.5T$*,$2>,0F41^*MBMP2L M$0?*U9=+A+6P?`]+&.4;6?@6X;WXGA*N$-5FY;O,B@EP))LE9;^>(>(53H/# MGF$'!:20#-L#*%H<AH6(#_`UCH$%D>EXN1&8EN,2^HE*X\RAV,`S,'J+<?@- MFC[MPIS5/`Y"SIZ`T$@H.]=<PPB^$]8'G[;E`UDH97BZ#ARWD"Z<R@%"K="@ M$<0C8WN"MY(D<U7B9N5R@%=F<*_X<Y!?@B;AU3?R0I7/V55%^G8Y!W@S`UC@ M<!0GS5E=EC%*`]Z2I)WD!Q]H\;X$EL7G!^92(>X<[@(F([-V"QYMT<#*K-VZ M=2W3,U\V:S>;"T_?33_*S-WZBX;,W&TE[67FKLS<Y2JN_IF[EWL[Y;L]SC:E M4LA47GGHL#>!#WGH(`^5VLU?M3]J8+:V/%2J;T!?4E!2\-04;-RATN_W_O^: M@>V8_`2#1MWDDZ%I?`--94<"3SP8*I&%G]=L/:V!]\OG-6D#A<.:Y*BFZJ`& M&WG@J`8&OW3F"$5.35M*"&WX*\8AQ0,_8HX7;C^\R8TI.;E)SFWH_*7BY"9! M^7<(/8-0QJF]TI$.?[U\J+/7D4[N1.>L"+CO['\(@PPL'<,\=`@3)F<PY:.G M30;N<0`CAEX0"X6#S-"Q%;2!7WD<KB43TF<!MM3SZ"8C7!&F'&8DSVW<[><V M(WEN4Y.N97!>GMO(<YO3QZ_EN8T\MWF-M)?G-H?Q2\_>9(7)E`5CM49@>1X) M3@UC_FHJD,MS.7DN)R6AK9)0=Z26W1D*:>2ESG9.(CW4?A4TR_5YC@@<]$!; M,V3.PNO@]6#2P"OM;4M=:`]^AJ2?I-\IZ=>JB$_Y+/);[3WB%]_^R<B/9+!T M:R6+I3=;'V^V34F0DH*2@J>FX*.+7#ZY>F6Q".:UM61V[+*/BQE;L"!@]A?S M^S0,611"<[\YYESD5G[!$1V^!&9O8DQZL_ZT,QE=]3K]2?^\<WY^/NJ,AWKO M?#C4]?YX^.P2F"]1O6W)X/.-YRP<"RNX8;D[WZ-HM[_(IW-FH=;)+R'L!3C1 ME<C\#K,RB?"T2W`STLLJ<(_(2QSN2+?;EJ&W`X+B4-]OZWK<XJYE\MF+Y25. M0UX`568@UE\(9`9B*VDO,Q!E!B)7<?6/1\^JW,X'_,AZ!*Q.]9R<5=UF=<#< MIZ-@]L_8.F"6(T`7.<[BR@\BYS_T51,66Q.CPZ.Q/.%I-8,G>@/!W26#6W^$ MU[RJ,A?FVHE@%/\A/.//-%/\9]9>VU23A#Q]H.JC8?-D7#+["<,P-'6D&9+9 MKX+9?772:R"OZ[Z9PM/.X):%&6!]$)MNBR](UD2<AZJACYHGSI+73U-=?>F3 MO`Y>@_^IZ<WC=?/V6'^P2/'7#&&_O!OHWO7#L,T7^VLBWWI_K.KC!D81)+>? MQ.V^:@PDMU\)MP<]59_TFL?MNF^ROIC?%2M@MA-)`W5L(>[UU4&_@3(LF?T4 M9O=433+[E3#;&,`^NH',;ML-I?;<=Y;TD_0[)?V.&G7I'<63]2/3K;Y<(SW; MHQ]W]M6)O&;_:KC=4\?#!KH[DMM/";U,M%<?>CE*0OYO+`Q_5OYING%:'P2O M>IJ>Q:3!.K)0OZ^'Q?I1JJXC<[D.EDIR^;A<KH>%VI_+,NI2UUVOI)^D7VNC M+D=Q8C'7I7$Q%PEN7]<]FY0$*0E2$J0DM-E=;A.$G:2@I."I*?AH&,4GXA]N M`U&\-`//\6["3RRX7IH!.S=#QX*&9HX;1]CV44`4+X=76D^_&G7&/7W6Z9]/ MKCIC?3+LS";3V70V&@P'@^FS011?H!XZ@BARC$.@85)/VS)=*W8YC(:_4.9( M48ZCSFFJ>+#MP+1ZF-":@45`NE/XW")D0BP:[J]6\'88`=&7OFNSH(2AJ+#O M%EM'^#ZTPENPS<B4V(I\G2?8BL/'8RL.6EQX^81=2U@]0?`7JOFL4*GG,XFP MV`11D`B+K:2]1%B4"(M<Q34C%HY.Z6[_L<DGOJ<%B7JO]]7AR:^KM_4T_\2\ M[?74T<EA)R1OC\+;OJ;V1LW)M:I[XN",L17#6,BM8S//5@+FFA@4B7P8RYQY M;.%8CNEBJ.F6!2$&41;,C.*`83"%?QLY&&58!R(`AA$0C)34V73)JLRU/ZJ1 M(B%%HM&&LC8IC6I/:XXSU+83VO8DE$GZ2?J=DG[-#>(43A-A&!7GB75VEAN] M7Y1QGO;R5L9YVLO;OJX.1\WA;=O<UC8E=4D*2@J>FH)UCP/_BZ'29G;'O&6! M><-X$AOFQ,4ALQ7'HXK$,:+0I@ESN]/EDC!PXN"6A85B4)OI>.UUA&L2#^H- MU)$V.;%AE<&_EV&V,5*-T4`R^U4P6Q^K^LDCO?)23JO\%DE!2<%34[#!@=_4 M0SY[\_"5DDW'&-_R[(PVK?>13QQTTKK]4U<UD>'$XQP#=$]>$U1R]BB<-;J] MIJ8#/NI^Z:.NAFZ[7WH58^K>[X[GK.+59^9%IOO)O%_!'^&5'WQ,"@W]QLRP M?&7U8+=-C?%$.Y_HEYU+[4KO]'N&UCGOZ\..H4WT0>^J/[L:73W[MBF_,7G< MZZ;3$',@*R]T*3A_55D0N945I[?B(EF5M2`XQM8\,/P@BYZ%2(TN.0=IM2?^ M>*C<,0RPA>)F*]T\A5?3NZ?RCBE?X>+]\:2&=TR;Y\&"_%:$C:2;>9`(K-J; MG-ID'2!,4T.1K<CS:(O(UB3&V%,'VJD=Z4.$&)N@@"M"N5*:#RS-0^/4N6'M MU,1C*;O'/NU1Q\,6>!&-T,05Q^7UD69Y<:EQ0E\W$?^R9`$S%[#9EH(N!5T> MY<O;,X]32L<I)XQ%V.JLCYXWO=/&H'1#[8W;X#XV7,&T-T_C48=;SSB7VG;4 M]?]B,P"'QKV_<CS30Q"+#]["#U:$!'JDHZV!/NO/!I-Q1],OKSK]Z=6D<SXT M1IW>S!A/M>%DJ.GG30!236FG!"R,W:CR$"H[@E)?"?ZIKFG/!$#=@>NY[7"J MS2BDK[-K";@I"'YTX,$K)P@C^A0H/XE!"]U&,YFG<SHT^4[29GT9<<W`Q-J2 M$Z?GQ)>E$TA&U(`15WX<1,L:<J)Y$?J4I@\!+-<O=G"JYXZQ4.5<7N-<#GBV M<;PP(NQC;YD7,XFS<Z1XXDB=C%[-I>+7Q=C1N"*90S*VZ8R=J/VJ%%_)V*8S MUM#5T:"!2[9Y)Y1XS=/Q+'^%USO?XX7/']OK7]0D[>W]6!WU3YV!?.RK?*^5 ML[V1Y&P;.3N`W4';+U:_2LZ.U7Z_UWQ7H[Z.A7`K,O`(&$PU?(3T/*3G(;68 M]#PD9Z7G\0HXVQ+/HTE!CL07>2:H%4):P9L2R^JXFD_K&J?&@FR7XCL]/T^M M[R0_#\K/*K@*R<^&\K,&R[.%%U/QS3G^\5#Y]OHY#3*#2,ZEV7-IWEY%YGJ] MR-;;.'5$1>:-'.-*L*J]GKH@KXFQ?;4_E(QM(6.-OMKK-Y"SS3E^E7E=+R7+ M[W5#'58!;<F(2/-9.U"UUA=6>*6L-=3!R>\'2-8>@;5#==`[]9I]I0>L,MGK MY-(OW9$6LU:Z(ZUEK71'6LK:EK@C]7<^GIG=U5[/Y.3Y(H-3)QBT2[&=GI_2 M4+6*GR?/1Y;\/&@^E]%\=Z.)T8^G.R`RI5RZ(%+%21?D]?)3NB`MXB>X((V/ M>#RJ"L`C(/M+J/_H+LS-D-D7_FK-O)#>F`:!Z=TPK")P?I\](@H+3._,P/ZX MQ@?#R^\LL)P0>_@70\XQ>WK+`O.&?68KT\&ZVQ<PX<"THMATO[!@I1^L9D#O M8C#39],^O'8^ZO2O]*O.^<3H=_K&^=7E<'S5TX<&O*_I7XVWOWX:_-_D]_XL M1[R7GWD%Z<\?'L#YE@%<^<&".5C](9QZ]N7WM1-0"^$'[Q,+'-]^.J%CS^%O MD3<9OE5L9CDKTPW__O;#'U<;C+B<7FK&Y73:N1B/IYV^/IIUIOW+<6<XFPVF M,_AO?WK^52=.Z*.WOTX&D[%68L0QZ?!(LH</]/</>#)*&R_Q7D@%^Q0X%CL` M`YS0[QOZZ.N?U[.OX-Y_W62(L<&.BYZA#6<CK3.[O)AT^H/AH#/1^X/.^'RD M30;#Z4@W9E]UG=@!*V/<?10W#D>>$E_B]=JE'DSWW'2QK/OUDK%HYH06;&^0 MO8<O.S*ZNM`O>[,^2.[H`A2',>J,]0'HD=%D=#$;&N/!Y<6#94=69G#C>!W8 M"?ZLC]???Q&?N5GY.:FW438E^'=G8:X<]_[G_6[R_.%'3!D6-VZ"4C`D(I:" M3/,]9!.9C'EJ:;;NZJJF,:R:Q2\*DKSC>#8T__.>E5/VGN6GP`?YCN[QCK/" M_HJ=-8J",N?SJRRC@F?\22&5O>NET("PXY^I-$INTMI6UF$;12.^62IEST(H M$^.'?.&39%3E"BO)'U4(ZEM.1$0'H]'C"Z4,3U<R9"!+ACPK*I*A[0\WZNL( MV>+2ELAT"MR?0/D_==F60/EGS&*K.0NRN?1T=9<..OJ6YM5P?J/.PLMR_J'2 M`2??N[:9\CNO]K[X$GMNT%R87Y<MHI_UKJ9AV#SO='3XE\?P-%08B\>B!]R( M>H3`ZW@1M^ZS>EXZ25XPC6,)YF\FJ`TS\H-[Z#X5S"8(Y).F>XP0X=Z=ZP/5 MF.R1I%JN5WU(`KS8S;Y7RN">O@>,4\T8?$R+>C3%A4&'&-R?W+Z=(Y6%_B*Z M,P/66AUVU!3/O4=AJ'U]C^/(FHFZ9/03&#W8Y]9RS1C=`-?KXV*!\?IL-Z`L MXL"C0P7,I8&-PL+Y3D<,4I4=5<(G^A[G\#63;\GFQWMGJC;0&L?H1CIGOS$S M9)CT![T[JW7@W_)C/*G(CBKA/;77VP,8O682+AG]!$8;DQ;L,S>/1W.'GSMY MMQ>/MXUPCW?+6E/$UNFXO3JPOOVL]M3]53PNJ7<PZCUNHR&UWR%VI+HZ&4H[ M]QHX;:A&`S=G#?79P_!G96I9\2IVS8A1U0>V#ICE4#H>123,E1]$SG_H"^G, M'U7VWQN:VMNG*,0QA?_8%P1>/8<GDSWN+=:#P])]KZ4#*JDGW?=&'(ZKPU[S M8A:2O_OSU]CG`ES-^-L.H]8#-6G[,=X)>!F]_/P.:V766DB_!RYV5EXD,E[^ M"LXLO\-DW_'R%U/NS%!YIW4'"KSOP@\J?NHGGV@C"E\,82K)5PL_4*(E4^Z9 M&80*@[':2N7M``4SQ^G?/6H'_C"@G8"%:V9%SBUS[[N;*N.%;O54,:6RK>/R M9&I900P$=!US[KA.Y%1?A9(7H;+5+SH8&X^_"-4_W46HHW?]:J[#R(M0KY7S MI[^.(R]"R8M0ASYE.-I%*.%;0-\Y[T)>@&KIK!J0A7OA.IYCF2[M!G`O(C[# M8"P_;''*VDF#19/1B8\]9"CPB-SMJY/1H''\;>2I_87OA;$;P497*#!_P<+0 M\3W28`LF+P\<6]8;&/26;'[T*(8MR+>MH?HZ][U8:JAC7^`;#IMGC26CGW+" MKC<O+;:1;M<_38L?6:W->ZF^CGP[4RJO5\#FT:AY:`(-<+`^1DL6H)8*?->E M@V[*[98ZZ[B66&_>16/)YL>;)GDUY065F)D>'8D\(;EQ/*YX-Q'+2K+Y"<:J M>0YV.])V6W>;0E)/WD5IP@'E0.UKTD-O+W_'JM'`!(-V&+46WJ60]'L5=U$^ M8!8I"R,E8!9S;NEF@>\IEADN":41R(H@9I1HX7BW\"2!FBG^`B;R3M<F*M". MWTXQ]`%]<$(LE^K&>!_%\3"_;&V"`X'/^+2IM>(@@$:@`3,,&38>[;BXDEQ9 MZ:F/N;%24<3M$76/>,4DFSD_7WJ1$]U?,"PPYGX`'GS_7W9_N+)(^F0V&UQI M'>-R,NWT!]IEYWQTH74NA[/1I38:C(;3\5?]:Q\%U'C[*_Q;UX;Z9-S[VT]; M!U>L]G1I!E@A+?S$@J2:E&--/7O&"]&>J'*6-M%'O8O1I&.,]%ZG/YE==<:Z M-NI<C*XFD^FT?]F;C'#>;W_M:-V^GC'Q@>F4YKY8<&GY0-5[OYC?/YL1^\Q@ MSI;C\OM7T^B*@5(PW>O(C&+$A"\\?`#ZK$&R=E-#[U]>]<:#::<W[O<[_:O1 MN#.]'`XZ,T.;:;-!7[_0![PX%E"CU\]1X_D3+%+LRG2"?YINS(Y:#.Q<F\VF MYY?#SL45R'I?[QF=Z7`ZZ`P'LTMC-)I=7,RN'BP&)NH^GW_\\N7C[S\KI"C% M=U\^?J(O*C7C(RI+NOEZ8(-B/3"D%`R)B*7\SDPD50;W.$]UTE8%M?=$L$98 ML:;UGC9@_YE^63(J:&9Z]XII^VM4#'BS<`&31,,*4S0MRX\]RKF[B1T;M2<6 MO*8?848.:/%%4A(S5>M>X3Y=EX@FV@,C83-X`WHR0^P,&EE3+;]H">;@SH]= M6YDS89;@*;SM*-J]6S(/=Z5@3_"8!VQ+Y,/KH`2]<(%!T[37>S1`IJ>0X7?O M^2.F1:?8<Q;=,6@(#.XWAL9H;0:18SEKT^,F"2FPRCBKV*@/WK/O3L1'^F-7 MR1$.&H@CZ/,_0&;>)+Y@*GS8\8H7[>.SBW+TGC/786!7X7WQ6F$<G!!QR+@I M=?"Z'[U/M,#6T[EB915N>"DS,M>I.?=CL/!.^(UX@J_C![338(]Q;G2SD1CI MK6/H%EB+3R&O^)E_Q*REY_P5,YHT#8<>M$R/L\FTP=>`!OQYR`+R(]1D0I8? M!#Z5W&#$LAOFH4*BQV,O>V'?2Z@/K1CRHUYPR0!;8*8P?<4$%P-OCI+H\,G# M5X%O6DL28)!F\'V`/3"EW.+*21E?-7B9U[SU`V*$$"MJ=`X.&'$I+3J+I`]] M#^@'W=^:CDN41$PK$'KHR;U7"_*6""FT4L%=(:`K\[NS2OI$X?,7.<8FO.>U M!U:.M_%LGJLED0(#@@*W]L/0(2'AK8!M"1U8I)QV(=*)EB](,7R9J=[)+ZD( M1TLGL#NX6NZ))$C"TJ-6P&Q'2#Z(.&HI7#=A2`L:!KK@:IS8T%3QLUR8D[-( MY,YFX-&O2+/F1(RJZZ)GSY=YPAZN)($0T=)/%W5!45<H?CR-"G%#XX2@"D#= MYOI9.K"T`VMYSP4)EH8/C"2MB(,3L@!B@DP'D1"BGVN":]6LG1M0__SEI7.S MQ*V*:/2>J_W8,^W_G[UW;6[;R!9%OZ?*_P'7)ZE*J@@%[T>R)U4@`<[UG"16 M6?9,S?WB@DA0PH0$N`'0LN;7W[56=P,-D)0HB91(&6>?FE@2T.BU>O5Z/Q"I M`-[_KG+\#W'GDE@_:4?\*I9T!5,THUCQ"Y,F.1*`7/;]X^_`C^>-(:++]_.G MFOSF^<VFS:P3?G<]L[4>`[>Z+I)$2$3<#[Y2LH-)-N,W;A6G[UJ-?@3:1A>] M:SX%IF&][R)RH)0KX*,`,SMGH3$\^J3WI:$]QX7O(,W8@K1W'%/,T(8K2!>^ M?3&(6780-F#7%6E*(N`DI66F*<BM"N0+-9PH\M75-7%L(=51@MS`H_*KD@HD MN4G@[IPNSLTM./^T?N<'1(`WURG0*Z*0-*L2:*^JT+]2*%G>4A)%*X^:4&4R MK>F>#@Z8>X:ZDSK%W>7+9"K)\44^!;9Q2H)LW#4:.&^<H@8N\3UL@=*H3RC. MTI*A!'CD#LXC(NU:4DZYPJN06PX6`2T\O\%?YEDBN"[CR1/06J^`PR=HL)23 M(KW$O5WF<'<>.QIY$]X)8Q?O_K](H'V3+8L+W=<69$M_#RPAG\?+,GG[H,8A MG6+SIH_('4$[,7'XCFG'VYISW#%3>5^_[S_]K)]^;3TQVM=+7&$>0U#J</E: M7*UIX:!;FWKL/(:#[M(0!7;^XNTR>AI8HP'M0#2`AEL#"GDGFQ];;LKZMY]* M8/PO2A_'>V`%6%:B[\KV'BQ[.KN`%"#ZL5!^YA`$50/HIL-]_+G)P/5W?/]W M_%!DL@F>>TUJ`7-_Q8_QO-:M^?Z\COF\UCT!K_N\]EU`P6W;WZ/Q1S!WL7RB MY610]2W%$[N[%?X`._ZV">W-5F"?KP-YW)43NT-[B+S#W;^N.P/?W"'SL+N% M3B;BTS9Q`JFE^P7X$6?>3?W<(PW(#M&>$GI*Z"FAY_O'>L9/JV`_O.[RZ>SB M3/E8D+,&,QMX,D1Z>K6?CSK&ER1IQQQHN\S>.S:2/FT!ML>-])*L)XF>)(Z$ M)'J1<$1:3NNC/-'@6"OKN%>0<A_678(;B..IE6%[_>"&QWO\]?CK\?=*\'=0 M;[AY"(OR8U[%\]=K/+ZL&\3U![ZU0S>98U,03MM`Z)V>/27TE'#JE-#S_=XP M?*J>U[3R>"[-\O%?/$[5O,=@C\$>@X<S$)]@#AXDP!@LL**WZ=+S!NO*^GF$ M/50]5"\,U4%=2\8A>,D(&X5AD25V#(//2SW#3H&AG*+A<:IY-[V;H7<S])30 M4T+/][\MOK]'<^@@*LS%=5Y4*C9-(D.H[G'Z>O67/K7FI)A6GUK7DT1/$L>" MH6,EB5XD')&.<_R.F]_S[.K$E)Z>Z1W]/>A)HB>)GB1ZDNA)HB>);SHKZ?6D MN_?XZ_'7X^]T\;=']WM?G')J,:-335(^;0VQCQ#WE-!3PJE30L_W>S/PJ5K= M:TIK[S'88[#'X*EC<->YU/V0FC7A^`V,:_DV/]T/+^`(?]$A-2SMX[*&:M\( M?)CFV=-`/Z3F-`ZL'U+3W_$3'*+1#ZDYK?/JA]2<UGGU0VKZ(36]0[PNGK,' MGNT]?`LO[1#OPU]]^*NGA)X2>K[_;?']8^\AU0^I>;D:.6V@N2?8!^"T!=@> M-])+LIXD>I(X$I+H1<(1:3FGGN[U>JH&>OSU^.OQ=[KXZX?4')FF\,+YX/;` M-[734Q!.VT#HG9X])?24<.J4T//]WC!\JI[WFBH(>@SV&.PQ>.H8//8`8S^D MYKBTGQZJ'JIG<"WU0VI>A^%QJGDWO9NA=S/TE-!30L_WORV^WP^I.38Z/I+4 M&ML=V.X)>E!/6WSUJ74]2?0D\?I(HA<)1Z3C'+_CY@2'U+P*"C<&MG:"Z<2] M@.L%7$\2/4D<%TGT$N&(5)X3SR-Z/0GJ/?YZ_/7X.UW\]6-EON$HSZFF%9^V M-=#'='M*Z"GAU"FAY_N]&?A4K>XU):+W&.PQV&/PU#'XE+$R\A09-E>F90Q: MS8B7_ZS**IW=/M4TO$X0@:NX2O-,J9+)=9;^[RI15F4R5:I<6;`1!,HL3@MZ M$/Z9%TIUG0`THWRQC+/;1N?Q?RV5;FMS):8V^4I:*C%O\*O$RV61QY/K`7PG MS:Y@J6613F"7F)B>P^*%4B3SY$L,(*49?'#!]G>59$D15["U2ZE9<%7$61E/ M\`FLD?F2S[_`HDHZ3;(JG<1SOH,S)2B5?*;<,7;#H@W@_(T!@B@`5*[C*<AM M999F<39)ZQ4%=J9*7!&&8!6&(]AK#"!,5D6!6[F,2P"?8`7L7V7I#/8%L!&N M%$/)\<UNSVH`9;G";>,93>*BN,778ZH%0CBD#;9.`):*)Q-6,01;2-(O-&<( M(:M_OXQOV2_Q(+ZF@%Y`?G/&L,04H(#SQX^4=;Z=DL454@/[>IG`%LNJ6%$@ M^NP>!\,T_8(__L_/JU*]BN/E+S@=X9_XM3`M)_,<$5E^3+Y6PWD^^>LW>$WY M'_'H.X`R+?`S[PMX>IF7\?S]#"/BOZ=?DBD;Q'">S]/);;V",H&MP`\?DMG? MWB;Y_/-YI-NZZ9FJJENZIOY?3=.-SQ<?P\^F8W_&P]<-4_^LO07"^=O;=/K9 M\7S;<IW/GCDT])%FJH;GVJKE.;KJ^T&D!K87.<[8M\:V\1E?_`WAY&`^X*[S MG($?.I??:RMAC]0/YZ)).OPCQ7\TJ,13I*2".>)0::99_)S6)UB_N_U@=V9G MSN&YV;N,2+R8PC5-E)NTNB8"YF2/U^=JE;(_<BZFI#4^`![XW923%V)GWF"' M7?@V5RB2+VER4TJ/X=7C#[):/?PDW+!E4E2W=`.QW&:)7QO0#IJO*S?7P-R^ M),@)X#]X2>'OD^LXNTJ0JRF7R#Z2LE0F:3%9+<H*P<"_3(&75'!9KX$),;Z\ MA5D(IA7?`C.KE$M`PFH^1S@F.7P8&<*9\BF;TAZVX&T`4,B[AGM;*C?Y:C[% M]7`EX&[_)4P@0$H"Q[H@CKV"C9:T'OPP6Q$?P1HD93;/`8G)UV4RJ9C0`4:P MFE,;^")?T$Y`'+6@(%RF``RA:@7'Q<XM)3$1P])S0!6!@?N%!SLX.5.:BP"' M-8,%;P<HHQJ67G)L<B2"Q+FY3B>,HC9@.%XC%X!IDB13W`;NH&&O#V:5C^%_ M;0X*%R:H3_.\R#/XYX1-%F+O'8I[.IXV=H*QIVKCR%(MTQVI0]T/52^T1][8 M&MF>;NV?>VJ'89X?D@EC%`TNE38R#\,_-P/I[`M(";8Y-C`.IOD2K^*N4)Z* M;/C'"KA=H]V-@XLA7/ERA:!>?**_J+H^4&J<G`,G`GB9\IG/D!EDP"$;-J=\ MC+\J0V#<L[12_H4,+X;O5\K[)>JIB+C?D4&.D%T`O[^)BRFJFK%RD2[2>5S0 M^_C(`+E]3#^.@/O`:O([2O0U+66TG^&&F<Z*6P8VE&33<J.@0[4>@%VV00%` MX/65#$H%W[[DH-PP4#(`):]!(5X_D4%18EBDY*#@^W,!"OXP88#(;P!+1$!0 MIP5>FR4W\'Z]TP*%(VQ30;T=VV<38YZ`[(Q!_DV*%%30-";NODB`:X.DX%"Q M@]DUH"3IL#?K:H[!`_7#*$-8H^R!J*T;W*!10KY^N)LQ>RN'':3)+BH)$ M'GZ4L?X9'>?]^).Q!PO,&U+8AD$ZFG(%@@CPL2@91OFF\32`%/!=_.!_5D5: M@GJ`>V5FA%!=8G'#&[)7DMD,)##($UCE'W&VBHM;R8P;-/8126%<@.-37F2: M3DFYN(Z_)$0=*/P+Q");'LF1A.$&[#Y8+#Y4J+5%XOOB*@8"H!LQ`M,1(\/T M0Y!-Y8O_?C86F[VH]]K8+/#T16/22?O!;Z>22;,WD:H'FFV90[!`/&^L6F,C M4H>>$\(J=J!'NCYT7?TI(K5V/CS5.2WDYY\YZ*>ZTEBI%FY'QC_1E83&ENCA MB-Q5H/X_JJI\O2SF@\M\>JNHZG')VK9"(>/@M$VOT6V5_P4&2I5.@(.]R\`* M`Y9+FO^/R#":PQ_]NN:U"']%J2@_<I/(?T6.*/\U7Q7RGW]2;F+JCM)\<X5F M#&>)\_BF%-8#<1OF!8)?HR@!X@M65X"#AMG9`T7W?;?%,E&)1^8_F:<9.95@ MI:M$N4SSY75<+.))LF+.I@EGL;-\0DZT7'!F,G_`SF*&X!2]/?E2&.)9CIZ@ M<A'/Y\HBGR>3U1Q-.A`=2UJX)/L.^6D^7<T1AL4*.!":<!F31<*@7<)E@XL# M.ZF*)*[$!TK@POFJ9/L`&X<[VQ;)E.\:S#/RH-W#A8_.>RE$&B,!0H&,6W9, M8!K?X?8S!BC808X#_4YQD9KARWP(F'\V!0E<*L,<_@.O_BC3)&J3;:+<^.XH MGQ*/0UQWEP@N1NT5/N;+=*+X.A"D_%S-/D()T`L$%%:,N/(D*8NMJQ2NR"6) M>+I-0/$`Q1&`WH@=IBMS9X#`,^@;9*9OQ'/M<DF^`@D+!8'1?["X`LTEN"H2 M$J'P,WR:_B64BO=%>@68!ZR753*?PYDT3_]XD>`B)$K<GP;,-=`8Y(U/!AV> ML#_9S5J@EV"%'DYXB5OC2\#")%VBHX<I:$#Z`^%-@15J?TJ+P+*<K'SRD&PC MMA.]0&TO_D;MEQ28Q7+.W$WD:0*VL9K<Z8Z6\"M0EJ%#'WG.JB"_#FK?W+O5 M5E.O&5M?%>20(>?>:D'L;TK7=9+2I[^W@%D;R!S3^1QI#M::H'-ZDBQK[0*9 M*3IN,G14P3F"GKXJR.Z0/&?U6<-"P#3(\%@6.=@%\64Z3ZO;[OZF7,LGW9X@ M^5ZWSIQZ)_AE_#MYND@>P(H21FCWUIE7OS#+A?=ME]MIG2G8T&?`UI=Z^>"' MW[0*Q1`=.*.(N=B^]\PSH]GE%O9(GQ!^N.\][4P:?+K+NV97A,88D8%;A^$& M0CO:FHAK)*TT8S$'LAW:9A.75AG%>PC6?%4QQR'@DWL3ERCBIB<KP$"]*%>7 M_T$C"7V@:?D7WKC%@MF9;;T#;\P6S2--RL;Y/("+59%!-@<[D[E7D:%WM0_8 MW;187>'UF*(5A+;W-%DB]7$?PE_)+2*XS+,LF9,/0UB"[&+@'O-+NC#QE*D2 MN*5X"5<'XV7PC63*:`^'>R(/1L+B)S>/L_;5;[.0>0J4/<6O$+%<"K<]7B>\ M<^5JALR`9,GZQ]'3`!B(O\1@:6/4BR*=Q8+\)<`A\'=XYW*9A\%N<@4QT8T$ MEK3_A+F?FYO,8IB+N$CG@(OK(E]=78,Q/D_HCI,'FIUE6:$M2!VX<KB=196R MSR\+[D=@3PSH2A0Q4,,ROF4WF"FU;"T0CY=Y(=2(6,A).K?+2O!O]%`7!<80 M^!^O4`/-Z-ROX/<2HP",).1(@'U2'*!*YW@]X\EU"M12UGQPGK1$9IMQXCKH MB4**E:XT';G$]@2"!&B"QY05JN]7H/2T((3/2.=:8Q7Y7=6>N#:0P.I@8H-L M$0&7)J[<4A7HR)*"B4'Y*/&N</V9!5,P=L2(OTBN4$#EJ.9C<!7X,:GFS5+" MY"47$5Q,X,D5P8`QF#FQ?>;YPE_<<2G*%5!O28%U<571O<+U&^E:TK1E/)F< M+OHV'",\/\.>BA@,!*2I#=<XHPO,O\RB1YR5<&Q0>#_/$A;27N0L6"QP)O$7 MBL;'/-33OF.(T\EUGI=(.K`*;6C3=@05,3J@Z%W[Q-G[:X38OKFUPX]X49M( M8+_L=('E"$<DR2V)X]"LXIHQ-5R&$30ZZM`/UEQ(LM/8QF/I".#7Y-KC7M`I M/D>G6<(VRQDP`J0IXEN`NQH9\]O!/:I-6W]OTU#G4!HHB#$R;85=<':TP*A1 M'!0,"63F<@Y>Y*@(EF(7G"H(#'H[6R$((EF"Z7*<]P(2RHKP7F*B"0**'`YC MBNMNQ'@*MP*>:]R)6X'C6ZM5620E(C>X7HU^VT0->5-$%I`\)2UB&#>.!H6T M96:+5*N:8Z$_,RXFUUW?`PH>%+[M&WB9S!G/YSH:]S(C]4YJ=?/-=UV%LZ5N MWJE3"D)KRV[Y?M))\+O`%I3Y)3,CDJ^X?UU62@%_UW`_WLT&"B?0"C`WV$XD M0+@E1IY+KGDW]_0NM.%K(&@6R'I1,TNZ<A!Y&/PIG28LH`V7(]F^&@:_,U1R M+V]).9O'MZ2\D<N(F!=G'+20V!SBBGX_XQQ7\%LN`NK/$6-<WSNPD3G<JHSL M7<Y')%U]@4G2G/DR'E>K-5NE]')U.8=?$R9!'?J"EJ+$CI&E47:7K)2<*1?( M)#DT)/F8KCB@>U\G*[3TMUG\):>,!<816<P$#GP^9PQ<OO22!3O-:37>2%EA MH1"\A.S/1.X<;N(4PF.`F`&+`U4C9NMB.E?&)0)8A4]@%G+>M=?E'G(<>WN" MXM'%R3\)LS[BZ1\GGE?TD050EW%1QT\W.D@P3)E3OB*S5:KK)AF/I0*1TPDU M2:9RH@+5D;6@>9.A1K&FDF06#XO"MF)V9R@S,_XKJ=-K&/M%N;]8"@T;KP,) M24Z_L/^\P)5CWDX<0Z$L)0A?GJ=,94SY8M,F*X^=)>-$5V1D;7F-\>4I=[%7 MV^^A,!XW[:E6P2E?2G#&*;DM6Z`01LGF!TXVH2P@+M^Y]C!-`?Y"9!'EI-76 M&-N#@'_>S+TA)9'24<CAR=._69,Z^(J989OO%>/74E(:QX0<=JJ3PFZN<[Q8 M^0VZ\\O599E.T[BXO5,RU"(!'7^22/@1=\=UGSS#56?<?TE74V3X2J_\Q,5( M<UMK=0KC35F"MA-L1W+U46I8-T,#_W`9SUF:'X(FB+N.]#!_%_,=X*O)].2( M>I1GF';4\%6>_?(A+9F3Y#WI"Q_(&\9<%9]JN9N>NEQIXDQ2(C4CGSJ,!R17 MNP4E%5U8M@WV&/-$O'&2;6(<C&PGVUN_#]JJNYPJWJ20GY))M-5K,MGJ+F^C MH$AJ]SD3S=.$+,52Q+B*)($[_A^XB[/6*:;52G8K$,%*`OVLT>-"L2)[LL3K MGOW%$G19ZBAC>"0:T<,TPP]PRQY=2^F4F7WD9!#[V^#E(@\&2M(B17?N5&&1 M,G1%P0_<O\X3<VHP.<%LM/4P<[E!UJG110+W(U^`F5*MBD6.7LX-BI="OCR\ M7<(CQPX3;,XBS@LP59"%?\GG</?(T<878>Y=YBV1ZUFX60XK9,D5BS`NXDF1 MUYOAH<?&]R&>@\N+WNY))T;5)FO)W<<L-N;10JNM$3CDNENBZL3=[W5.N7!E M"C<+JJ7,T8+_8JX6)`KQ`IIF381&""9<I;D,=4K!J=&'N#L`'ZKR"!?<CJN< MW!],/"5-S11SL)`R(:QBL!,JT.Y+^8@V(89AK+$$ICDI_&BA<J6?&=@5.8;Q M]%#?2#:6]Y"2NVTC=WB1@2V0DD\>>P8<RI`W5,F0PW[Q2A#+R_),Y?[ZQD]( MI`%/R**&G!@2D&CU3QC]3Q+&/^&RL'2`=]GDK),$@;]OI4'P8%.=%'!.8:]- MK_(G6F\/B'!KG*"V5&,E:,J?8-^Z]L-`<<P?Z&NV_0,I8=@Z18H*U+5OQ!3N M#<^R**BH*C,&>%66+,MR?HN7Z`8]MU.X<YBS0&=(\)^)Y)'6&6--5O,,O4L! MYTZ\^;])D=_C?JO+W)A/M-[2F7*1H`Y<YI1IT;SIMC-0/B0L"'\.J,33_BB5 MX`U:Z28%<+%B*C).6OZB)FHE3&4!>^M8')^=B&G=<2+L/)`_WW,B4H5?ZRQ: M)R'"48*@[CL.09FTQO>6?:9)R0@//9+V@<!"CSB2[0="![[KD30(."$6'G9B M&DTHXO)V+<XD^*R(U2$)8;1N#N3$+*^Z!NG3V86DO(WS?$IG1I\+IHLT2\NJ M#LBV4\/"H)W71?H3=[U21$N.&L(5P'179*E(VTS/;X*':-)B+))X^LX9+3N$ M?7CJ%"F'W/P4L2CDP`)!;?2@JWTM2PI$"86`LA1U3?YB!['DL,UN>8!,1$I; M3\A+S>-;YA#&A!$I-+0>&.*Z4CLP=$KTNU542R%+<HTMEO/\-N%NA7D^B5L! MN[;5`=)R]Z2B@6+J/S2)>QLW4S-@XGEUVAW=%E&_<<^F"`KD[AN6B)5_Q/!1 M-(IHM5L!`1>]]Z<M*HXC8-A6)OT(&-:\LT(R/00&"0)882L,F)8ZG]^96]>" M@#FD'@H#WCEZFOT6Y0T_G=D,;`KVR`SE;`)$KH@<ZSVE"C^SMXE[0)"H\9]1 M9_C=R3J26CD+Z/T!1:8DZKE.KZY!B6(95"T7!PEX'EO'[!G.]<FO06%4I(PY M68?,]8215'QFN2HFUS%E9U!>Q)I_X.3HXEVGG_[)TD$-42""I2I<7!45AC?? MK?ML&)R;6KML^-<VN=1>N'8^`J&T-::/!956W[:RM8#2$JF5!WDL!IT7%ZLL M9:G:9"XW&6RD*H&]F=-+[%Y+*5O+>-E)H`)%`O/"&7N;S]L>/^+F:VAK<H>1 M`_+($Y6&+T37#U;4/<`N'\0_0?7XWU6.');@FO+F)@-VX[#TD.MQ5W'*93GW MP6%18B$&_+:RG;D3"<`HDNL$,/PEH9=X=Y"\Y$4>`K/H!LA!2TI+MBVA#Z%E M@6GQ*NN.(BH1L*#R&N-HTDU`ZQ0WG(NL?,XG4*!<86D)%=C$69MGL$#%`B!C MX3KI)9ZG0,*O9BVHP8*!4<)66-%]N66Z5VMO;&?U=[9N#;XG%(;U+\W%1(WV M9SXRGVM1T1EQU%):QF4E89@)TQ0]RE5RA9H[U@=1&`CE+ZJW;!&I>A@.;Y&N M%K6'O4B$"TGT1BA9:)<Q9)X9(:_SALJ0Q"!HW,-:YN:'IK)UC<#8'>$Y*P0" MZU?SG]7TBB7G`D,G6E,1?RJF^X.T+VZ;'@DLWW3]GDB8053+6V3$R_;'<D-X M6!?/E.^>A9S1I8T^2W1J-^NUCFW++>U\LK4N?7]`KM?JE"R!IDQPPXD@)=1M M(1[!SH.[5<O-:.Z$2.2$]9C'(]&5+?=485U2VFRX+KXN.^U$0*\HL(R(E9]S M.GU3U]I(7:AX7IN\H4LP\V^X3P-.GC5=@O_/B/O-=W>0]YDRKO,.F?8D>DS5 M0=PT8SY1X%K(<6"++),IV[B@#!3&8+@#E'%V(M-?6`Z;W%!)@N;7^@.LQH@0 M0;4.<ILIY#A55:27*Y9(B2YBSN!K>UCV-K,*;^;X:7'77SLE[_5+[9TE"7N0 M<I59ZK7(Y)BNBE;DNH'_5WI&!D<.3HF=5*(03(ID7*,$:^.ES1ZIXT([\6Z: M($<G[L9S5'<Y'Y3:_(0&W2\"DF_@<[!!99K?4#%&2FUT*->9'43M;DF0W<RD M\#R>&2M32RN6JLWW-Q7[PV]OVJ$X=)E\3DZS/N?-CSBE1*+]T6FKV><;6SHQ MCEB1O@8G2TR(*3F-(D?2%]0`#*P(YW!,CF?^2Z:JQ12PP$1$E6B`\3+4?`6= M-7V5RF2VFBO8=ZAL_'9,:Q3-J!@!XG?J8!-EGJ#>Q@(9O$1AN4+528((ME?F MLPHKI3%I^HOT_!NLK.:IZ[>==W+,Z4WD;E>T$GHK6@O,5D66$@=DL<.O^&]T MM[=5)TKZ38@=P+TM``\\::=D&C]N>\K[Z[$@K(P\IMO6V&,:)OR[=G`U>B1] MAU)*%1Y7V(#H6=+!\YNF[5=UN\1:+.RJ%6=7N"3W'R.J*8)7H^!,^;1$/0?E M*B$#M4&6[-RDY@UJ>294:WZR]Y"4C+^8[)9%7ON%I,PB0$:25!(?9[%<ZB"# MQ0ZHI^>LR`0LH#D+]K5*&#%"\4=,#)P69+M$YLJU>Q+II%O*#DQF-IXH5^N; MZ/5-]/HF>D?=1._XF,8'YJN'5;F%_CJR=[?Q!1Z:$.1,-%6GLDMU:;-\#K3+ M<FMXAZ_%JJ2;!8(;_L/];FPU%NUDD0Y^2WY1?DQ_:NQ:+%)>Q>0@2\B=,$EX MTR^IZ(3W(4.<_IC*;T\3I+WBMJ5U(Q,ID^(+M2BFN.-E0I5Z&1F*?!5Y&0(L M(0,-E!JV@M#\D47\RCTQ/Z9?I+<P%`_W5UA`)'/C,L<W;EET%V2E$HIU&K^2 M,*X>`KMLE9$*\7#`B4<(]R+Y^H2UW(Y2H0'.%+9VZ@%#3=L$GE&;#Z$T,$+B M94P\'RMA<?=%"MRIRM'0HVYP7($AA;"%1EH8BTEA:2PVNB9&*PD%R4*>Q*LR M:4&"K+2VV7B:9JL5'4J!!>_XQA.3W]2%[7)KZD'W2OQ7^`E)#+8K&@@,+A"Z MF7A[49B>S8G%V1XO7L]7H%`".65EPFO@6]DG4ED84^XE5+7\V)P6Y+Z!["U. M1J)X_HS8[9:R.Q$]E0TD>#(3_:/>R(7U0A-*BREED*4\^8B>F-Y58(GG_T7$ M.^+;NM0`$^I`J89/D?-&H`7)=-!:[TV[84-=*4<69I&DBTMLI-+D;DN5.LTM MX3I^D=_&<]S+'3F!G;IP*1%E2U]`G2%G@9;#$D!)Y@)G&!7GR9+LWB(L*<M< MIHKTDE55(7WPK&-)H&QI_X@7-*ED];#M+"-.!A_@VR"6AJK>5(WG&($0/<YY MQX<)T'F^(%]>RT]5L!04H)$I^C^%8RTGER?+E)D2B6(-U%QBN:WDGW]>O(\Z MV3^S#<Y,QKJ0[,3NJ;VCB.\PIR3OTK^IW]$-\XS/1:@?="IA#+<Q+%^CM)"2 MS5JNQ;)FJ)B<`Z1)$&Z2Z?7!\!0$>IRIH$F,Q:>S#;O8`I;DQY,!0Q/_DEQF MS+BL60*UXT2K?\[6Y3U:&P(B];G>X8S$65W%1\3)V;<4;GR?W4'H`R6X&/&^ M7(YFJX8MM8L5K$[2[]Y\UVI[J/S!KX@:<=H,));7*(-K?<%@'?:Y#BEEW&AO MSD.NH*OY4\/!\.Z(:\II#8\6O><3;!U:=P%E?@0Z3`I*\08^S6HR&5*+"7&E M<W(;Q#/TL6S`XQOJN:9S*XG7TBY9]5=C(0E22TN)J#E-H77'T<=\/D`$R7S. M*RSA`EZG`!4P3TSKI'O,*%!Z!$4TB=YZ)3E2BG>6[!D1`?F5,7YU2<F5XJ*_ MZ>3Y?3QOW_1!:PU"*%NYTY#F5Z5.*[[$F)6P]UA(5]HU+XY.B4/14AF\"9]E MPK)>\)3T@T]+,%#1?MPH#@ETT?\&Y3.+P!`MD%@4FIG@VX`/Q"T>.!>HC(9X M>(1W:9&D01U,J>UD_AZ%%SCM"-F,&?I-?]L-JVP!@TEU[HF3V9<@\]I07BL^ MJ#M9RHRXOH:M3=(T$6*!<(NIRJ-D#D-61<(S,\AK)7RALA[%-,]N)P,I5L=2 MK]<,FJ9M#KFNWWQWI_-:\F;P"`EV\N&."XR1-SO:=`(;97FW=<':GL7;-;JE MC*9X7J>3-Z^V15MC^BQ.*X+<$5;>W<*J(ZJ$ZH@.7G*AWR&?^/H=]@?O`[FF MY34O95M(2W*O?%QVFL$(;_ULH[;1MK(D19=\6"KCX)V&67>IYJT^%)_JJU9O ME&\'.W6+VA?6$Z5L?WZUY**8M\NJO?A4?UQAW[LO\K)=XR9E#C;,R2F2IIJL M&T-L[XTQ??9!K(%O_8ED&R*E[1ZAW?.<<?$JRIV8]R;$VNF$):B3F8-7F@N< MK5FHTI5E_E^.BZ;JAZ.B5J%Y*XTFV""8[YLMZ<;2)P8=E\V,.B=Q[!0<*S+6 MI48=K18%=%R27R0M6WH,<WRRYQDBF^Y(#&],1UYS_<0B1;UVP;:;XM7D>9D@ MZ-*DI:;W'-DQDI]';"9NG[$,9MHX6GBJ''IBXZD4G6XZ8@H_<`/^67/A>>"F MR820/B-\TM6:_LXMYUJ,=FY"]_[#YEJ$28E[5-Y:\:C#/637EA6DHK(O=FZ) M".1EUS'O#H_;$887]T*BL259CG'3FVPGTGUS1X^M738Y6'-$LD!?B5E\*+MQ MU@'V/9(7VT!\G*UPIV%22W_Z,!!O2^/']VNF1OT0ZSQ]F2Y.2-R]YUF2=TN% M)DE><`XD)8X(9`)I=QE^"#63AZ,HL=TQDC4E10OU753"$LU(;I0OB:@ZW$X; MW)G(Y(JX>9*7DPFS1M92-4$W4M<R%86H'TB"F^IM:E0(CK99*65I6',JW9EM M<];S<1P[>>')![7!%]UEZ?<ZHV&A=7?TH'L;F#&XS0<_>+P/_H2NQ#EWWMWA MT>CXDVI"0&]82J<O=U"LGY!8;&.A-<2#EZ513S9*@4'3Q:#-LNLRXYC50\L6 MU:`E]+BA0WXA;'U!/ATV`Y+$>+T#$7-H/E+[MUKQW>;O[.,2,Z6.`/-83'XA MH<(^3^FL4T9BM(VF=OK-=W((?3LN1"%=.V-/N*B$QU,^*C%W9@ON.JZRE-3= MYGCN-,=DMB1/4JA;TL9M]P^FX,P32@VIVDPM!_7_BB>*H%8C&9;7Y-@3.;M, MNVER4D5P>X,KN^'6)=:B`)]A89H[&_;)FCX:R++#:GG?':D#/0UG[NB8#"&W M]&"31K-)$+SY[EY1P$L[,?`Y:)9=^_Y=LN&$.-284L^ZG6B;PLZ%-#%A34/? MZF7<P-OJM@DH]S=24^-K(<94BJXZS6`&6%M(7RE\(LELR>YBZ<8MC7U6VR@= MG?J1-HJ<L++-1F$?Y7^>4%$$-FEH'JD9U$[&%QD6LVW\C+XB*4)D1=Z*0&K+ MQND4#DN)N[%,W!U<;1%7;:6EH\\QPP0W?IF@\E[/OSU3QC1KJ_D8G5E;!6M] M/*WJ[(3'H8^4K8WZ.3FD2`VOK1+YY-GVE74S::OAP803BW-M-8TVK\>-I6G7 M3&I'IWXL?^I:2AT1VQ`(GG?;2FJ=>/N\D=5M.W/R^L[PHC%-?(.TVT'*,96V MI7YO%FEE5Z3AFY)0.R%&>V\<G`>/-P25*;+'S"@R@K+D*J]8MG+!9D?G=_B' M,$-.14,)N12O6F_UDVIW2_C8B9>R8BE*4`/K6\UGZC*?L'I!2HR%6_PQXOM@ M'?8ZFV.Z19VK(LRX;?>5%AWP:'!WP$S3RZ]I4H+!I"8O30E0UBSD=B',M19/ MO\3<%]:Q^[@O$$O_^"0BIMGQ@SE3_J3;*I*.^6G)(PPI&()7F(48ZO!#6B<J MLVGJM7[41`B8>MGT=">[LG:4MS(RA!OR,J^NZR0(;$0J"]$Z\(NBKLVN129` MZ^Z60DW?/>>TM2N1JL&VUO9)`7A7*69<7\*1\$@^*U8207\YBR!F@BL!"U!D MA_-WUGI&4[/S03LYJ$FFJB$C]QM\>[7-U):G24HN;\H'CTNY3FX#@A"ZM8"I MG#%SV^&XF'U"6\!VU%3@U-XIET*L7F_)>_M(`2A)'*TR*FW8D(M`,7D1[>?3 M)7BQ*9&DF#$*U)1\96E834O+VI#DQIFD8,69;(K7,=*-J13U1\3]$\8'CZ&U M?*!;B*Q-28R,D'1P+R)C!&T8'`*4Y8V^*IJUM=6=)\@)N4.T<;@.T6*Y@^O[ MU)6NW:FBG5;%*(X&>;2O^CJKK-,$VLHD%5HEB[JDE:GTO$49M\"HICP3HU/7 M/R<T@B9]JV4+B^<3'B:YHTO'AN;K0OV5[&&N][2V*F]T(&V3=?9;1T=G..U] M#>?/E+_C<F]XX7US*,+>E"2)J%22^,M-4WXGZE+^%Z0TJ]3=^FU>S,(*=L5H MKSK7O;:/)"UYO;%19^A&?<MAE0YY27)7[+XK9M_4G6!.+J?\O$CJP5`7%4@Q MKL2-Q"\_%JS3<3"9%'`T)UZ:$C16`4WN*&0^OF6\0XT@RDMH4'1?:YT:KQ6B M4$I_;N)."6\IUF0&U0XR:?9",^&U["8,C3Z\+]=U729^F>)1,A-5`D,`(>8R MRH,.Q?`4,6B."TG2;3@!R+VT&238XY0',V[RXB_)F5?E7*?D.:4$63NCM`X^ MDQ>GA;*Z=_O@SGVR\.@].U6R%;9((M49GB)AD&0%^NJI*YA<?<Q^7UN%NT"( M?..CK"?E64H;Y!^3UZ0LFU8QWALYQ;?V#'^M&+O'/[&D'3$^@[=^FXO:IP$9 M,@5F8N9\X!I52[(!+HLDJ6AX!BE]2#$#_G%\N6G-7W`3B4\(^KB-KJ61`:SN M5)X<)9)BYDU;6*PTA+4ICQYP%3<^>Z!]M(UQ2PW=8B*4H-R.AX=/<^3(9SD& M;/6*O%TQ<Z_$M=*I4B[!%VKDP)0]CN?;^A0Z/4J_Q&+*K;CJJ%BR"TS1<Z;& M+?.4"_YTD?"N7"FO@Z)-4.Y]+5O;,T+N%ZO24$)VQ;!->Q,VYP?5AJ5V3?V5 MY3<96GRU1HGTU=Y`EQVPLK@MUX\X%YKO+%8FV8R,]D]-Y@DWQAN6T"[/P(TH M#D,%Q2<NZ;;Z:AKM:9?"VNVU#S5U2,WB^?1"QE($,36CNRCLRWPCZP18,WON M/.7)$8T\:U3\6[%*[0M"G@!O$P@#<D;PO&,Y$%`.1"8P9_3(&:Z3F'EV,4H, M7&8B%B>?S$1,)FD*J%NETGR&X')/>0[/?0_J<O'S>?P**@F%G$`Q6*+TC15+ MTW_\ZZ=Z-#?).>QV@H>'<\N(V+`7"9(:*'1U3TS1'94'4,4?BM820EB_84/0 M>`_M.D=*R.N[QMN"Z*".F8UG<_,G!"3T'=8FV#2=@:9I)T=W[ZB/$VI,\==3 M9[,RV;7"@[Q9584@RAXP43<-L(C)1[=U\S2IH$&DC39!^OBK-#9)>CVM-;$Z MF[I5Z<:&&)%6>)E4-TEM<F^8E,/<9O`EGG*]=<`3E4U0&#QF]>+P3B'&'O#1 MBG)G[78&:K,EL@&PQ$LJ/.?C`F!)GC7!VI+]L^Z8CUS\AH^U*7@SDSI-F+2D MUL@"/CQO$R;KZRO<[?(^6*2-.NV=4I2F19+8]9OE7`E?U+JODGPBC$.60H6_ M!@6(VJ6P`EJF\XD4&.X;9;62>/`)"/>L'H3)%`CF9=DTC`FT>-F&Q9F#ZCS] M*YG?L@Y&65[)-NT;T7>K!/3$C+Y9'V[X-O'M%5P5WNF-43Y/MZNC-%4RN>;* M"+:=JHL\Q8YK2T/.%&]P0$F1=?H,70_A@I9;%:R5EN'3<]2Q:#ZOE"8DK8#( M'PAT;;2W1$[N@.VCU9[0UGY0&.KV2+"O<:#@J-7X\O>\?$5R9\O]IB*7N)@V ML=6Z1IQ;/MV!8>WNH%R"_8C-17ZJ6WW@,WE&Y0ZPROML6^J,T4F=F>8THA#G M1S=[1'(67$C:4'GG3M`A*Q(*A:DNQ-<]0#`)!&C`*<2BVK_UMM262&G3#.MB MQ#Q*K/EKTP&`5LDG?R&WZ(YMX;.EV?C!NLDA4Q4Q,1&'S!7`L58%=L/G[OS. M9_$`Y5K8>V>'O/E.FAXRJ,>'4"UL\K\K-@PF2WCGF%;3T::]+)Y.M_\GAD3W M.KCI>57/B^2*%^Y\$'?A]?"!ZWB].R"6-!-),\V,#2"DG+62H>+DCA#+S@KJ ML7%!D[(NP-`_\6Z`[[/F\OYCE4DC6HSZ"K>R(,30I!C/DC573;_R*!2V[&0S MQ$K$C.ASBFE:V"R._E*/CP=6"D0P%>EU;/P3_:I6:'@_0LPN9%F4K'5J)O7Q M5W[$W;7B$N_?8<Q(K-T*49PI0:V`-<7BHC>\2%"IP4!214`&Z%W%YM_I5Z6\ MCHNF6>%&K2DMRU4=&,Q7%4E#YH"2$$&&-,@26+EJJL^3[6_3E[F8J9=AC;GA M,>K$PC,26/E;W2IBB4P>7V:>]4TG5<_"0N'2`G%[HI$$B[S-=+%(IBD;?U0G M)_,LS_M1+A!.`XEPG&G9#J'@D=3;:^VAJ54G&[C$U.I."OCFF`(3DBE-HZ1B M%YPIS[)6>-W;0-ZG$+@<<]*%:,+77*=N`C_=/=>+T#YQTW5]#B.)DNM%S8L@ MF+D1R7&.X8KZK>0K-HYG3=+XWY?U!+,;R@Q`VZ,Y)S24MIQ4<TX42-E^3*@R M_`E&7L&Z!,4UZ;!*!D[(ZTF6&R_9&6.J7(_!6DY>B4@NV)N4ZJ=%V0P>5347 MR6/U])^UK32Q=.HT)V5M@>V2K%C$/I\A(&OG#8RD82-UWE'[7+G]QS26+80) M2/7T,[OAK'RXUBD9]H'(>A.I2C5/N3L.+>'AC>A52AV*&*>B7K/?:V>:IC<K M8KTRJWR'I;_731\]C75%B]1/G?38+JI;M:KI5,7V._$RA>6`^<_9X&/A`**F MIENX"8N^<A@I=DC)>[2"B(K5HXO%A4?S@M!`M94;'1#$UK.<YQ$6";:*KLFZ MUH;)=40M2[?=O3??L5Z[L$*1QXRKDN?LY+0JNO;JD+PG(RF8<MJ*U5;O+)UA MNZQ3B6_(6.9YC(T_/A'C[('N,:8O)WS6`:@VNV<$UOFCF'I34E]X\AHU[8:; M[<BAK#<L05D4=+#4+<JH:'EX)_%\PL=\;.H)18`-6OXIVCL+N.W6+9J#TAT> M!6*[3*M$E%76'4":D:0L!;;DUGY3(48W%3?&14X+;CHC-(Z;(^`^..%KJ[:D M;=*2C;W,OX?>AKF,#:KII+:K;#[S*8D!F:A%\UO"<N,?!Z&_$*18,4Q<\3P] MD8\SD'6"`4^B1(40U0_\;\I+@;A[D6NU#(>;/Y5B-R7&T-F9,+IGI,IO%VU# MY.SP$CW.R?G@%&E!D84DZ+MN^RB/,!#ZV>;;7"1</FSK+?FFTS*I-:QJH%RN MZ*<RD1[@U:'P7Y0=A-6F^DH$G8D8V[G"4D](X=,E6XAGC=,Y8,,ZJ9LD0[I8 M3UJ`$"W"**PRL\;;8+LNL(W1"&;P1NH:*8URKC]4^_7IY-;U\S>M;%0Q_9$R M^N5TZSK*`A=UEK#^[5*V=U,AW/"H^2UW8V(C3JXOR,$:O,=23BQ/D>FN3PTM M-H#%6S!LZS\J-C^X%X%UXL]E*V%M[6.@6L>LKV"=55-,:QT&CX&-^^:7HW?G M=YU`$T;V0>/O/B_R+%_Q#AT'<N]O!M+9%Y`2;#1@(>!>\UVA/`FE#'C&/U9P M(1J_UCBX&`I+-;CX1']1L?A63E.6(Q44OU`^95*X[6/\51GRF-J_V/2?/Y-* M>5_/F,>8CS+"CN'`%$@CPE64BQ0L0;"H\'U\9$"M!^G'$9MF+K^C1-1NHD'[ M&6Z8>=MQR\QW5FX,LXK6'YV@"^6@K&10Y/`@'V2$KOJ\!H6<]A,9%-8TC8." M[\\%*/@#'\LNO\'[9J#,Q;*!Y$8.Q=1=MA,^_W.PK9$JCXKF`BIV,-N@H0U) M2=<;'B7.R1^^)X;<*56(Y73\.L3/#,8=\"=C#Y,K&E+8AD$Z&NJ&0HU6&48; M!E[&BSI"_1]0]<MI.F&QYI95(FYX0_:-Y^?-UC:B5J-C3/.Z(9.\R#2=-GT& M^9!.5E[$LS-RUC!L$W9/P'IE,RKE0&*;,>*H<^7?<.J<A9XHH_P3)]6@FXM% M\[8P2TO578E9#OF,"J:,7?(&8*7R(VODYVGV3^U&?>>K\IHF4TERYD>*L998 MV4W#K6;-QZ-%4M!DFG>XBQ)X9?D7IN]/DI^D,7*,L]0\A2=]BP033K2\A6H\ MX8HB,1S*94#=^19L9KXSN:<SS3"$(Q8U@O-;@8^-K(*S4*9+JVFF4GI=CCXD MUM*`^@,)5EAO."TE5_EE`@#S@93B3*0[Z8FQU[QIFM1H$T#9^F71FH@"PS.> MU,$-?$1,TPB9M']65\T5G[5%.3#`J#=B@?@`,H1;FHF0L$&0B+7.@%/1H)0I MU]MX#)(<\Y)TQZAS]D).\0,RF&<SM^$6!JLK;-EPWQVT[U18QC4>+II3:5W# MO^=("*,<;<E,^?%B=5G1A34T6[6TGWZ!1<*TG(!HXN,./K6MSDL6@5(BND1M M"R:HA^(15^#=F$B*MCXK7V"`3(I$$H2U:O"F.^*`M=6EWB4;/B_-Y)O('T>M M(V=1.?H\;QJ>"W91EP7.\KQ"ARW-.648X(D7M5HB#^0YDX^E?949R\E6K,7A M&S8ZL$@72G>"0MG<^E9'ZO6$"SAYI@(Z;+I07,QOFTN34O>'!0X`O/NN<=:X M^;;9BG!2;[]K;S;F=)[:;?LCOKWOJFG^ACZTW(8?\5(F4>_$*ZUK\>=HSD\- MD8O)#>4*&\XETT2T4;YC^DP=O>+MDM;W\F;+B)ZSSIUBL`"6TN5J+G6:$)<( M)\TU=43,)2(V1IT#`"#NK<(Y(3->X`:(2-%!<94C%5.,LA["@C>P1@FF4F4B M,9$^S0,>I8B"-@7L;R@-L\GAY3MDI%OR],,Z)+A>FY^3=TELJ=[0%I10XFIM MAS3Q)/1@-CR0L3R*!M(,F`&'98#>.U$](G=&(DY<MZ;(IO+LJQAT]+J3;%V@ M+RKC9+<_V5I-,6(SG896;.;"M/_`4H[?M+KV\NA92?3$:YF;)N.`IMEJ/D,O M;-P:2+(197=PN74>)P70'L#EB,<-&B:'YI[$YI"52:QNXR[9WQE]B7EB-]0J M%RDXE6:)8WT/:Z1)X34Q98*ENC+O/L7+UV&28H((3TG=.FC8(;RO<J;95,3A M$W6P9,H37`1<;8Z-#CNA1)7)7"0=-'M_\UW3\)GI@MR1-Z^;EP@O-F_S(`(7 M#=??=L!<H<);F<]3-N^@YO=OOCM=CA_`0<[OY?GMWN/-F:-.Q'6*J?#WB!YP MH:0M`*)#/E:0?AC5F:S,OFDTIS:_%I^O;S:Q1GDDB$BZ8_MA+'):?XKWRFYH M$M/TY#WGK3TC!5'#NJ2LM1^)Y<DRJ/'>R&9+*\>GTU9)NNQ;/`MVM\OBS@8! M8*A643;X&YYB$/P\3;_@C__S\ZI4K^)X^<M[J2I^5%\(^"'(IK+N_7Y6Z]V- MVMU0!3Q]T7#RQOP]A_4F<`(?DZ_5<)Y/_OH-=J+\C_CZ.2;GTK>H8?`Y,/!F M]BK6TI6T`"OGAR4^)+._O4WR^>?S2+=UTS-55;=T3?V_FJ8;GR\^AI]-Q_Z, M6-0-4_^LO572Z=_>IM//CN?;ENM\CES;T4W?40TK<%3+"@)UZ-B1JCGP3W_H M#35_]!E?_`W1Q;%U1.Z:OO#PVRL\7+^TNUZ;]F6[F%PGT]4\>3^3<],BRAC\ M$TS"?_'$NO?%!\Q@:.[LWFZ?%;BAKSN.&MGF4+7&T4@=NKZO1D,KC$QKI`\- M[RFW[_G:FTLIHG4^(M-^MI**Q0Z=,K]XI<DO>XI&/K(7%1OSP;\Q?/\AC#ZH MH_>__QZ<7\"JU`EV629OE4DRGY>@8P&T?WNKL9^7:$KPGV_2:77]M[>^T:!Y M0KU1WRJ7&(TM\"GYNX7\PU2\[[@_U,?R<S5M/_.%+WR95V!/U-^TMK^RK]]_ MBY_^N7U$Q9V[:E\ENB4Z^V6;]%IT?@^DNZSY@-7;-"[NT?_1Z/\I^O*K0HK/ MVS6$PR4`RL_PWG=(^[$,1&_+\C\I^Y9^+)2?^:Z!C5Q09L9=<GP/&.Q/9<NI M1#P!O7,NYSC&H#^3ESJ395K4N;32J81@CKSHH72YI7)Y!=C(0>S]G]$HBL;C MMYLW4.5+^2]=<<]L"3U9=+09%7[U5%\!\PE8/QO:S]B>_1X%]'E)\,[5'VPT M/?[#@HP+U(:?N`U]H(.)H#O>PW>1Y3=%O/S;6_;?_:'C:%C.7L_[^Q<]9O_, MU_H3_B9NM$;,4[=/[[AW4^Y?7#@Y/QLV"B>C%TX')F5[8+O.P#=ZX?2JA9-] MUI_P-W*C-6*>NGMZQ]T63C^3BU+^Q9HO_-%>[8YSG'7QJ..AS('._G?_CO"A M$?C#<314M?'05BUS;*O#\=A0/4\;!\-PY&E6>#IAJ+X9S`.;P6R@XEW(CU'L M-$E_"?/)"I\?I^4DGI]3LL88?E?NCT*'QGAL&Z%JCCU'M7S+4H>.%JJN%066 M[X3NT'&!0JVWOXW__3\_W[FG]D4+LBJ=IO,51M4ODLF*]9N+OK+I@^,B7R#F M5R+J',4%1ME+6(]<H@'+L7HTF*LL96^QTK>W<+:3=!'/R[^]5<TU+)B1,7(C M,U)=WS-4:VR,U,")3-4>N:ZGC_30'R,6[+>_Z9KFN)JF-4>Z%T#;N*/<4LQ> MPE<^I.5?K+(&_[6W@]?]R'`U-U+#*/)5*]`,=>AZGAH.1Q$`[#EC8W@ZK*F% M,4I6804HA#),;&&#BO%'D3322@8^;3[6I$JG65D5*]ZV'%G8,L>N^*Q\LUQ= M_D=DI`BV1_G-$QE[%-TL.*F)1M5L.`JUJF8I@"(7$*/AS5RQ@=SL3#2SE^=R MT0S`/2'VF6O'.TU"`/8!0X4\5XWE#DHH*-@4>%8UCT)DFE`3S5*,E"H2K!S^ M#Z8NMDXQK7A605T@]0E8&JQ!:3GE6:-IA6)%]F2)[0BROTJ:/95\G22)/'67 M19W23,QWJ6<+Y+PV2^QO8QX?GO97S!E,:%8AJZAGS>_DAG=5V8#)"6:P@5K8 M0()]-L=[5KI(X'[DBW2B5*MBD:=S47_7.B<VPQAO%VM"**J^@847<5Y,X<R+ M6^5+CKF6;/YUUG2X@",L_A+=A%E3=YX="2MDR16;9+F()T5>;R;-IEA"CTDU MK#)=/(=5/WQ0UO:^4E+=01%C]Z*J'OW3:A&,_>)IFATE`U[R`BK>/?Y6KAF/ MI]0%!O_%\MJ0*,0+F$S3E!F*$::X2G,9ZO+^4Z,/<7?X[!JJ]<@S7K[!Q)/( M<&4RBR$3.XM4R14<)9]:W&Z/N0$Q#&--"Q',0'SS'1\G1=F/+,FCPK_3Z:&: MDFSBS3PQ:LM&[AIR\G7)\BTQ7YX!AS+DS7=K$T.P34D];ES,SA7]R&11<\FG M_`H@<30)FTQ/;9!P,:PI6`#@RKML<M:>]$._;_71>\.:N`;`B0$9I7(.ZM<B MWO0J?Z+U]H"5T`F<O/E.PDK03*:$?>O:#P/%,7^@K]GV#Y2Q3*VAZD&2/,L4 M%KFW,ZG4E[1N2XJS!YOT;KQ$E'($!G$SX(W@/Q,5BJTSGO+B#XX[?!>6^%X_ M<Q3>Y8N^]-^DR+&YQQV93GQ#)FY!WM*9<@%BC6H2T#9OWL2R2PG3'WB^[CF? M?/@1\\)9,[1R(*,?5K^*BZE(!6]-KU;BJR)).#U5*&,$[*UC<7QV(J9UQXFP M\T#^?,^)-*"WSZ)U$I@!1GCF!'7?<0C*9%F#EGVFO?GNT4?2/A!8Z!%'LOU` MZ,!W/9(&`2?$PL-B=86YZ%.J'*AG"C;=U.49GX+/THQ:8.J4(H_SN8"<6.-] M/G41U(.S"TEY&^<Y:QQ*GPNFF!5?5G4%47M.;QBT9Y>1_D2CK7CS.#@2K-K( M04C'<`4P([MNDDC,=+'`A!>NL96@AM7ILSSK/LLW#/_;IBU,.R@B=E[W-<QN MF]:)K%SYS7<-@MKH61M=A8V768G4-,FPJ%>\V$$L%:Q@)C'JKN*9]A/R4O/X MELTOPU81I!YU2P2YOE)7F[0:S9\2_6X5U>WR";EK6X'MLR=QTQMPS>I@D[OX MB(K[I9:I_W!/1]::`1//:\\H%=TT[MD408'<?<,2L?*/&#Y*_:BH5D5`P$7O M?3``&W4<`<-&"-Y\]Q@8VA!PS00ETT-@D"#`]*AM,!B#>T<OMB!X\]UC8*#B M.WR:_1;E#3^=V0QL"O;(#.5L`D2N2-V0'U[,<H=_K.U(BT1=#QNA\S'^^@$V M@J6FV80V!>__B2,`J2\*"..(=:4BSQPU=Y1[.XZPH<#3/9)+4)-E?Z2Q[INS MHK'IV8%J>I:E6F/74X/(L=70T$(MM"U]I-O,':F=:7:#E_V#VT8G2V)]/V/N M:U1>N#_["?[H&BU\*1DS[_X<K^'&T<S0<3U#'7N1KEHCS5>],-#4L:6YFFZ/ M/-,,F-]2;Q"S?>.=.J4"F6-UB[4559!-(S&K;/^A(5TW+-O53=6!0U8MUQVI MGJM'JF:ZD6X-/2T<NO?Z7Q<Q-A91JWSY"[H9^8\LQO<+21W<JYK2P,E?=A0Q M^&]U%H/>>?O+G1)&8(N)$8$JY3*>,Y6'UT'4\S9^3-G$RWQ5PAOE3[N61="& M\,._D-R4@-8V`;US1<1#ZAV:`H=MA13B'YO28K?DX/`/N(\HB'!>KBK![JL2 MGI1YT*10.VMU-)RV&+4)FJZSL45^]F.O;2?3>J/&<%?\X]DSK%_MR:\ESS_O MR:-<>M&#_I8Q;Q[5%7MJ$0,7O_-D5OVBGVD:9HK*2H?*?GD(36-`49#J'C7B M.-+,7NJY4X;J:0G,,F$:AR+,WYG+,R]N>6B3"/,4"/)1X!XBL77GC^OVP/#] M^W?026W<*P).-+'U9`[8W"67]<@.^)`2]6",B^6D)85DM[.TJ#*?53=QD;Q: M'G;0U.V==V$,+'V'+/TC(_7^H!]QT+9U>D+K!%2O][,93M!IK`%EMBHRFEW! MXRFS]"O^5/:L[*`4[G.+]I3HNS_FAVMG`\W>H>CYR`[Z))6SWY.X3+#""1,5 M%IC3($TOZ1G9H2C<')BF=7(4WA_T(P[:\%^!G;D>'FT7USS1'[=MASN\V^6: MW+>.(=LMCO7ML=J7_MZ&QWOL[0U[#S,T>NZW#XM4'_A.+^>^A9,V!L8)&F<G MJK.7Y2^8W\\:YU,&Y!2'J4Y2GA*/U9`++/O^;S,INE?F#T7[/QK:P#1>6,O[ MJ>=NASUAW]_0-NHX3[A7WX]2`>VQUZOO)Q$<'SCFZ?DL^O/=_7P-8T-_WB,_ MW]<AU$Q@D]-\A34!S\.7G_[!HQ)KKQ!_#^Y/=W_IT+8I+:.XO![/\YN+U7(Y MIT!//)?F<'W$3^^__L@.(F,X#@S5"GU-M9S`5KTH'*JN$WB6.0J#D3%^\HR6 M9^A])&.MF4ZHI!GVW&"6-Q8`[Z$,Z=N8SN)Z)U6,U-=!G4Y-QM-G3NC:@89. M_)O:L$18&DN_DZ9.]$521T\6AQI%\OK+I(X:]R];*/5MX]XX*A9W_)-V4(E7 MEG$ZQ0X7;[YC?7F2\JA+@?;;!/P1WI.N,^->;\J#6Y(C!W]IQ)R`VZRGA)X2 MMCL03V7PQ0Z9#L=VO,<^HZ<EUG!@<K[`ZHHJ_GIZ914G-]UCAW#`L=%S?\[] M.??G_'K.^?0,L0OX?CI+)S&\C*VF>=MYUF<>F]5*W<7Q)^R71]T-^S8B/50G M!-4>-4?C$/?P?%5,KN.2=?U<2OU[WDB-4G#^1;ZZNFY:T2_C6PJUGL!=/&U9 MY/8#;+^1D_9/T"[N3_HQ)ZT[IW?2!]4PCT.R%3CF>)ZRV3II[S@Y^$78I>SC MV.Y!?]"/V,:/.U1_'/2@3ZO`Y^3.=Y>,]V.[R*_+,*N*>)K@P`?8^"K!5Z9I MN<Q+FM6U^=UC%F\'HXZG;J2/>/:,\@G;\$[0M]S?_?[N/[7JXI%5%-M*,3YE M13+)KS*`8OHQ_CI,LF265N6'?#X?Y\5-7$P/5(WA#D>:%YF:Z@91H%K1R%6' MP\!51W8PBKS0=PW'?W(UQG--'6.%%AA=24LE5N`45_.XP*%2TAPB,8^*S6%D MPXEI:MY,64FG@*D&RB4_A_8XO$\?A^T1G:^\LD/7M*>5=MAW5"QL*W+0M9<K ML'C=W^[3^)\KG7F<3''R,?W<%'8`AVC`HUEUG0=``!"@ES7(^\;NBZQY_.=4 M`X,G4/_`A7'GD/)9]Q#K']D0O/9J[9=)@O1'_(Q'+"M8#SDIH8DUSZC-/_], M*E0;-E]S_B8^0/3Q\H=^>A&/3]L4,M@*G_9WYU3J#5[:XW$)/0TU+YOQ;`], MZYN)XW]+!ZL/='N'\1#]P9[:P5H#W7OIH-4KK%,(P%HFKP*6*:"$6N8E_8*[ M%)9%"G_`>=E]]/W@T?<=>LL>&WV?`N,ZDN/MQ=)K/MT^A>S%Q5614/]@I<K) M03Y9%05&Y%%X];+KT,Q-.\&,DYZ][:Y^?S.YT-_D\;J[S#4XMO/=UD-3CD`> M:Q--[F*FH.BZ?WD#93RU">1>/[CA\8?A[QB`Z+'V*K!V[&FC3XT!;!"\O>ZZ M5^'G#'3WFTD#_"9/6!\8V@ZSA/L3/MD3M@:^\PK"`\?O@?F03%<3\K@('PSL MH?;"]"&#YR7['SW[A8G^T(5<W^:Q&B\MK?IC/<2QVB\=)'C\U*UCDT-]).!( MB5SW^D#GJS[?/F_N51^O>X+7MX\$'*MWMO=I]UA[J4C`ZZ\/V!"T?2W:[,MF M&SL#PSW!B/@IZ#DO7A_@]PKL*SQ8>Z!Y)WAC7YOFV@P8?2YUXO%?/"8MK,=; MC[<G-'%Y:/\5UL=EFJ2_1%F55K<CYB']D"SS`IN]8\7OJMQ?EQ;=#T-[K*E& MY`>J96N1.G1'FAHYH1MIKHVS<S_KGRU$L/WVMW\GY?_\?-_F.JUH*H#J75FN MDFFX*N"A\Z1(\^D_L?G:AZ2LBG12)5-Z*D!T_)E4[V>`FEF25MCFYO&@KK*4 MO966N67H[N=/%^%;99I,TD4\+__V5C771PA[D3_T-$/UK,!1+2\:J=[(,-21 M%H::[AF1XSF?=<"&]]EQWOZF^@[@13KV)\+:QMR'Y$N2K9)QD2_^7L382OPY M43$.?=?U8.VA;>JJ95FFZ@6>K;KA,`A'0:CKO@N48;S]S;5;2%C;=A>J97R+ MS8S*][.+9`)@3\/DLGI6V#S+M9WA:*RZ^AA[$YF&&MBZK@9F.(I"0[='IH:P M>6]_:P&V<>=M\,Z;1P0QH+$XRLMG/K\'D+('AVAXQ$2EZ=]W`+(9Y(]Y,/G? M55HDP9<XG2-7`]*^B.<)(8OZ!!_K2>ONV]]TS=4L<R,.=H2LC99WV:1(XC() M$_;?=UG#`F@(U1'BP=!;%'\?"&L`YXOD(P[2.H]39&[/"Z)A:+X96.K(T%P0 M9;X%I!]9JC/2S5%@.I'NH"C3\:2U-I"=;6\"Z_>\+)&EC0"B-%L!;W^_3`KJ M^U4.DUE>)-(Z0!T):##/"KX+_-KT0'0[HTC'$XY4S]0-//!0M\;^.!IJ#/PU MV!\#6QM'*.'H^0#[I"&?")-9`LH!ZCQ!62;5Z#K.KF"=@-JB'1`S]AIF=-<( M3!O6#EW'5V%YT'$T>ZCZX\!RHY&I#T.7=:+3M0X3?"A<;:R\KZZ38I0OED5R MG61E^B5I\$VB'Q8Y6IE@@7JCMV_*+O"T,?![.H$'DR";7B3%%_BAY-K!\ZHR M8ROR+<U2A_[0!`*P1ZKO`^R.$P'TD3$T(B0`@-CWS+9&MQ6`^WC]>9'@D$%! M+M'7)5^'D$BD\[SZP*Z2$*Z!:KA6ET4^`KPVBOX>IQD2ROL,!>?[V3GOM7P^ M!QTQJKLT'R%*K!;+W`V.W6V@:+&<Y[=)0L^(3M:XV+%R!L=\^YOC[FSW;(5O M=Q31W]XO21Y%7Y-BDF*S[F-%#UP@8V?L;`1M=RFR71\-IMC]%$GQ123-CBP7 M]<V'2)F'P-O!(M-HLJMFL6-$B$X(`;[49L`;=G^?``J9"?Z!)=R=QP5BB3ML MCI'+^F]_LQS'6M/-'P!6&R4;2.BHKX)!)^_8;=9Z!Q1M</_,L[Q-)5PH/Z\5 M8AJV'?FZ&NJ.I5I#)U`#"W1MH`%7]]S(LX<!\QKIFM<"=.O^GVR-_9%F.3") MVW?8]A'L5]!2VJN@U*YN_TBJZQS^@E,UR>H_1O.-$XGE;#!AGP4IZTJ=4(1> M"G,[\A<7M)86TK;L?:,/]BAEA8T<T[>T3=[7^UQT+:T5SOZH%7`=9`,H"=;= MOKFM('7X9%)MT"<^YL!H%WE&^MAU/I\F13F,RW3RK/C0?-TU1ZX/!I@.!^^' M8]73-5<=N6/?#P)`D/"Y;V`"#P3L#JP<JVKMV?<#WI46XEZS)P2W>U8(?<L: M@_@;JL'8&*F6,;95+Q@:JN&,`LT=`]?7?>%_ZJH_F[??!9+]%KV7Q^AQU3HN MQV:WF^$07@0&\S&J+]JZ^K)Y\VT`&QL%N18ODXGGB(EWV2A>IE4\O[B.B^02 M5-TI:GZ@_Y#\_H"CJ,JT2K@7BEF0'UAD&1\@8_)H[ZWY]C?3--N"ZM#(>++: M&,(_RNJ9)<".:J"V+S50`-DAU/D\GZ!]10<P[![`2Q@65A2ZWM`9JK8!ZI`5 M:(X:N)ZG1O8HLKVA/M9&(1.-ZY2V$S1M#`C'9HTJ_I3HO?Z<H)NZ&=B.YJN> M%FJJ!5Q)'=IPTZ)PZ!O1*#1-*V(*K@3T/0!TH04;<\*FV,"_YPF%/+)IL,"\ MCO^RZ39'J!@"7['\]F'O`LJ]KA..NY>(5>RJ$EL@@ES3]^]SE[1!V2QP7^0^ M&T/?QJ%0ENZ.`4[/43W'\M4@,((@\(>&[EE;=8>-5Q;T_TF23(GWB6P%=,]S M#+"LFVS*?I'`'^DWQWBX1OLJ/PZPKAU;)G$QN8;G0B"%>4Z6T4L<_([&+:#` MLBS#Z1BW=T"QF8'3A`QX_G<0`?,3XN;.1FZ^"S1K!U\5JTE%@8<1","KXW1F M^)U4J_5==[R[<8ED@/]!0_]+/$=-DJF"739XC'?<!,[6=?4^`*0MF3<O2-=> MI+G^.$2#:0@*FAL!W'[@JZ[AN;[K:I'CN!L8^@XD7`<_?D?(RP_-E7_N%*/A M*`QL-W15+8A`<GDV:.>^[ZGZR#0C4$S#2..6/"BAWN8(SB8@.J3-HAE\^,]) M<*MV5M$]`&S7/9\U+<CTQX:G62/5'KMDZ^LJT*^O6J$3@*VOA]8P9(=I:]MU MS#4W&EY?D-A?TFDR'=Y^*E$%'Z<9"&TX_&!2I5\H7KG).CM&/F5@7,[S+;_K M<GL"G+OH;9+7\BC18A%:W+:_[EY0MD.^(9GDV-WRAK953;T'FHW\KJ7;G`37 M,S9QO;O!N,_T#":38I5,?T_CRW1.%^@83U['"(3A.?8]UN<Z-%L]OI@_?<0! MZV[:[*9][R0*F$O_-$4!GCIH\CN)@AWA7,MAF,!:[PO,Z^`_4'2/-9`:IU^3 M*<LMY#&_J7Z,`0\3?3-:-[OAH9!M9)+'H.GOR!W-3=QQ)X6?:DQ07K!GCM)> MQ3Q91V?A=SE;I[WSNVQQ_BB=^KO%,DX+%(TO8:+O>/_M.TST.X%Y1!0,E:6+ MY?R0E+U>#*G[CJO;@:Z.;=<`61":ZM#4777L>I$U&H:>Y0$7I`H2TW]X,*N& MJ9-#`U<`S"3$WG219BF@%7CCEQ=)W]J1^#UD<(;3MG#O@6.'?,6/^<ED*^KF M/852V\&YVP8`]/T1XZ6J;M_/MJ>['B5.D"PT2_.]K4;1`R#LI(=O#-T=(Q:< M#1'(S;O?[+#F7I,3$O3V1E?UW7"LP9YFB)RL*M++%2(';49>.E"$:0G7BEAJ M<2L_=.ABLG41`2PQ"#7,>C`1)>/(5X<>4((=.6X8.I$5N2Z("/(`.AVGT5-@ MW,%NQ,?*\_B6LKZ*>'J4;F_*;X<5N\DSN\"SH2RB'00+4S1!LBEI(HU$/L84 MOK8]N3LL#`>3V^JO+4R%?EL&J^HZ+[#GQ*<,KJ%498(T5U>:G!?I9,]D\AE, MN\\E;4+&U+L_QT\JJ@'3T_F?G_<*MX3*C;ZZK85+]/8YK(Z?/`GL`8<VSTR/ M(_`)T$HX`R-VA*N0]*:@!G#XE)GU_T[B8G\M2D+=<$/'4(TQO`PLUU&#R!RJ M5A"&ULAT'4VD3\(B`L;[=B<!$LUF"?HHFK2H#Z"T83I9-DGGS,N/)1=U`"<O MRV:Q/9S_<E4D\FD;ZX:)%8U-SPY4T[,L0('K`0H<6PT-$,RA;>DCW>8QXS/- MX"AX&ESW,IJ@*+#R&;G2\+9YA*=E\^LH:7?4"X2ZGG3+W=YE+,;Y]V(_N<?K M]V>=J&Q;<UQM#+<'J(=[<D(/-)W0],:^%KA#%XA*AX]]UEDH_OE1(1V!K$.' M17P3YC<9N[YI!08&J]6HHR_C>,+=K2@\JC_BXJ^DXK^\I>JAEVM+LJNOT6Z0 M?E#@[^1HC24??:VP!"OGY_/<S`W4A7/SWUMYV]9]RK?XKBK4VNH2G#^X*I+D MV0-/#Y!IK@\RS;5\5FK[%`CE:P;7$'X37U%)$.>:YV)\P>_I7\G\]F,^!"8: MSZDS[',P?V>DAXYM1JJF!2&R*E/U-3=2W;$U#/S0##W'Y(D59W9]9QX(B80$ M4D8W9UKQ+$*)WY4?ZNYFQ-7X$^V>9ON[+9$YT@S;4/50CU1KY(W4P`@M=62' M[G"H!\,PXMG1V):-=V7;TCQX^/[CQ_=__*)HRZ^_*OQWU$Z.?M'J)VS]4#?$ M1$4\G=T^L1WEQ[R*Y\H5(DPI1(7930+:9(S#F[#72*G\F&8*:+.K,@8KX*=? M[FXH?"=T<LM*8P.X=8>][1WSJ.5=I_G>Z/WOOP?G%[#J!+8<+TL@9.!*\W(9 M(R,FL8L_+V-@3_SGFW1:7?_MK6\T*$4Z38JWRF5>@,J.3[7Z;K9;`_+W7?^' MG9MKBG>L[:_LZ_??XJ=W&T?S;+UQG]PKNTWCXAZMMTA?0SA<`J!\^(6N=6G[ ML=Q"K]^\Q'^@X5(J$5BV4_I=H?S,][ZQ#SF!=UD#^KP]C'NRZ)*%<2"JJ+O- MO]11?]NX-WO<OQCNC:-B<<<_(O1/6.M"6=S&)>CX61K##D`)_9(>]3C0_7:" M?T0O_,[W]]D;GZ,%6?A+(^;99A]\FU,0G)>>&]J?[X''EYC:*YC/=FP2BYQ1 MS%/RYCOA*SEF:;6W$WQ)8G9?>G;UJV=61W+01G_0+P=PKXCVLYI>^^3''G\] M_EX2?Z<W>52*#7X+&N_+6FV]HONZS]<_P<&3_?E^<UZ74]=77].LQQZ#/09? M&H,[SQL]4,*>E`V(?R_*I"E>/0<U?7*[_]P^>S0.(UT/U5"+?-4:CT-U".^J M(\LTG,`VC+'C/"6WCZOL/[2SWW2OS6<?*0+F/":-_TCQ'QQML"IK84.HH[-+ M:\:])6Z]<UJ?#(=S^*3%]UE#LO]894GSDV$-%,R$&"A`B0IFQL?9K9)0_4$R M56(ESQ)UEA=JF7[E-@W@!G:`F"FIRCN?*2EEHF-!"O]+=5WDJZMK)<Z4&$AW M2NG(58X/PBKT*UP]FRK8BP,+;95)4@"D*79[I26S25XL<UZI\2/NKG%TC7X= MO7\'"P5B[>9/X:\_G2E!B4O@.XFHI%`J0)#X;0L,6(<`&2CXVUM`'!BTE/@O M'N=H:3[B_UHJ*64K(PRP0+ZJ`(P,<R7;B*#,4+AGL#("F6:`!$#I]K?IR_AA M>9F!<I-B/FFEX.E,:&X=K*4LXP(YX`J)=9D4[.4SY6,71'Y2<7VL\WD;1'A_ M(Y`M6.1MIHM%,DWAK.:WRK)(\P)/ERVT`\H%PF-,G86]P'_QF6R%B7#P!AY) MO;W6'F)1BZ$`41(6,9U>66')V%V`)%1I@%0%U()[6V)1V9GR#@B49^`/Y'WB M#B3,21>B2*:K"1$E)?E*NU[;<[T([1,WO5KF["5&$ICMWWYQ*2H)!<X+6*1^ M*^'%)O0.^SNK0H'GE)NX8*.&I7."E[>=5'-.65*6=QS3&2SR9Z[,BGC""A7$ M=HFV!2&7A)IR-:_NO&1GBCS-0+FYSI6;?#6?*CE*PAN$[3J&X[E,DDS!HZKF ML'J5$^^9)'AR\=I6Q)^`B>!P5C'J%P]HGB8KW$V1Y#,$9.V\@9$T;(0=+GZP M=:YQ79JXG3`!J9Y^9C><=9'.Y_"5LSU)"9;]?5@Q$;!K6'.5AJ?<R0EE/-`Y M+6(LEX9+R3@54$>E?*^=@4K0K`B7'W"&_C)8^GO=]`>HE]W$)3OI>5R6(`W@ MW5F1+]90'==5,PK.,E3AI">L50<P__F<UN`==4M\?ALW`0'4P#B-JYC82DPK M+*D$I<0K66+VVU1<^'@R86A`1CACQ4M(BBC'&.$QMI[E55(RXH,M-&0=4TTP MD35N<PZW<-O=0^&0T<VJBCQF7/4R+M/R'K+JJ)GW:8+=BL'UDK?W,U[O]KZ@ MZK>2_\@GH-,826Q]=)`:P(TUM`^H`G3?_N;;OM>J!'P\B!*R>*D[UBL5>0;_ MG#`"^#.O_IU4P12X<S(]E-;M6./1V!H.52_R#-4*?$<-QI:C:B%HX)H1C8;# M)U74'%KK)FVZP2"LUT8B")U*`30J'(\=%?PD%&\0-W_F7RB_']5LB\F<<7`Q M%((SN/A$?U%U=Z#4:!FNRA3%,E-G+H'',#'_X\=\F4X43[-_DM1AZU?E?%5> M3_.;3&D0JOP8(ZT![RI7N!!GX?3Q:)$45_@,U=R5RL>X_$L!0I\D/YTU>`9% M,BV5JU4Z)25KR?K$X5JX$%,]&,,$'L5[GS&A?4M,>KE$G4/L+&YVEJ)JA$9# MF8"P8;H)Q\=&?GISC6R3*[[`[%6\0T6.7!IM8%`Y)I-549YU-@S_;I31RP0` MSABAB3-II+7N#?@!H4R`%W'S8(R@T@:@;/URR3Z-)8N@7E>DA(*TFY(54[!5 M&*='E"WRLB)EA0)$:XMR8-+99BR0!`&AHMS"I4!)@D@DK#&57UAOTQQ.%)]+ MOBZ%;(FG_+B`"B228YH5+1PK"_A2@=]D2&-J)Y[2IMV<DEX#MS!87<%2]]Y! M6[J#YTSNQQQM`-BXQL-%<RJM:_CW'`EAE`/U%6"U7JPN*[JPAF:KEO;3+[`( M=HN9Y^6**56?\,D*]"7J#!5?,AM/B>@2M=6L@!IQWK(CXPT9$Z9XMSXK7V"` M3++U"4*@/[JI>(T!4S'S+=%]+4NT!&*N>'<^']>?)PE6?QR6N<J9W4N?9S<( MGN+L`KY'G;2`4>05JD3*M,9`R3@!1X$R28O):H&V"ZAM9_*QM*\R8SG9"@Z" M:5HI%B>D"_C4$D>%P&:$\E;?>M2C\#6ZH^LU5W#RL`Y\S:'M)W$!+*F^-/!U M6)#5K-]YUSAKW'S;;$6H@=OO&BSP"F[;'_'M?5=-\Z6K)J:UH*[/B1M-O)+< M'LH(MI4OT%SDXL_1G)\:(A^`>$@GUTJY6J*2.V4Z=Q.`1X8KQDL)XJ_MP^!B M!,O9ZWN!]Z6Q5,W7SCIWBL$"6$J7*Z3SD@F`^A*!;8'V+;-JF/>VWAB0PS0! M@!B+!I"S<L8L3K@["YJ4?94C%9,7H.13[.D&UB@!&,C)1MVTZ-/<I"B%GZ%, MI[QE*U)GSK%%'@"V0T:ZM.YETAC=L'+RE?N:\,:!#4Q^$;&E>D-;4`*J>UXS M&\EB@R4:#L!9'MG;V%D.[4*"98#>(Y*J&5F2G$O>,DXL,(A_))M_1G77<9&6 M9)21S<AQ1.R*R&F`_I_YBCM&2J!Y<C@"XOZSFE[5IAL7S(3;]A]B:O,JGV5M MGY9$3Z@*,'&?7Q)+`S3-5O-9BDZN>B/HB-B(LCNXW#J/DTS4!W`YXG&#ALFA M.U9B<\C*)%:W<9?L[XR^5LP95=V@4"(*9O=L0<-G`>-@.6$:.!FPY9*!-B<I MDL1`ALPCM0Z39'4C/"CD0#3@#8/W5<XTX[JY%CY1>S*GW(4LX&IS[.NXK)6H M,ID+MUZS=Y2+M/M:%YRP[H^P[03](M1RAZ!/8<E)[?"2N/ZV`^8*%=Y*3)EB M<E'P>W(7GBC'#^`@Y_?R?*_%9YLS1YV(ZQ131>JDC?@/)6T!$`T_+O,2>`O^ M@&>:9X@N9M\TFE.;7XO/US>;6&.1D@RFBS9-*J1J;A\P%CFM/P4\`EEC0Y-` M0U-YSWEKSTA!^13=5V6M_4@L3Y9!W&3)`+&2V=+RHC/>VQ!P<]G_$0-W*&ZE M^TW7VR:";SSANQL$@*%:12'U<'\&0<<C]1C/B>REFEPGTQ4;_]R:*W:@[B4Z M]LNTL7>7-314RPO':A#INFH'FC>VC="PA^Z3NY<\@S^"92BF8I1NPOL4UX+K M\K9%:C?(>.NV)@!/W]ADOKVQB?OPQB;.RW47><V?[CM8/&]CDP86UN&D_K%O M;G+\I-$W-WF5N.^;F_3-31B+._[F)N\Z"ND]IL0KJBGM>YJ<;O5%3PD])9Q^ M'8YY>L?;U^`<;_U#C\$>@R^-P8?5X.SH2Y:\S[^G$_P[CQ13<_OVN+!C'/QF M-EWY[]V_W%*\N(JS]+\4W!C582N<G)!-Y0R9][,Z.Z9)CCE8ZN-H[.BA9JMF M&'JJY6J!ZINC2(V,L1E9=FC:8OXWGO>^4A^=P]0;R1@F\CS9,J/1;97_E69) ME4[*@?*NKN!)IAL*>+J9Y.&O@\;=3X_<)/)?,0XL_S5?%?*??Z)@12I_4RX* MF<<W=8T#Q:PHE@A$?T/9[2)!K.$J]D#1?=]MQ8XQTX@BT?,T2R<L^G65*)=I MOKR.BT4\2585_9[GARNS?++"+`Y6OL$3'W*J,L+0YK2I]L/M9/`76'.!U3F+ M?)Y,5IA\>)V`CD4+L]02%ERD7!-EL2HG6`JSRB9U+B9E\.<5IG'`3JHBB2OQ M@1)#ZY0+"OO`X1,LPHKU(6S7&<O1.*G@\\=.O(HGZ<NX9<<45YM[;;^AO"^# MJI&F;-(;+M(D^TDIM1=85X.YX<HPA_]@1$RF28QZMXERX[LC"@Y/1$Y.:XG@ M8M1>@:4\^92:*#U7LP^I9!0_<85D1D%PX.,-.SEK724V8X/P=(OSGE@YWD;L ML.K`-]^UZP._IA6ODEG',^5L\6JER4K$F!G]!XNK!.Y:/:&DJ;RAI$%XZ3W8 M-"G6=01EE<SG<";-TS]>)+C(GYA$Z/XT8*DW33J3V%U=#21G^-2S&GB.&8:Q MEX"%2;K$&I0Z?H\Y0E,Z&RQ@PWRJ;D`TRY5YGETEF).UC=A.]`*U,SXW)B&3 M"%\LB?VP,T6VL6JR8#8N)>5'B*JY'!@F\IQ502E$L-`E3WI?S]>IX].4:,X3 M@3"I`J[KA)6@?F\!LS:0.;*Z*P"1<BG@?UB>`R<P+,=DV1P99;RN"LJY$"<M M94W<4-)616E<RR*?I15/@>WN#].'0.@!55`='2SQO6Z=.?5.\,OX=TI4(WF` MB6$-1FCWUIE7OS"C?+]=;Z=UIN`4]P%;'W-+0"&7RI!2&N<N,A[9E$9*4?O> M,\^,9I=;V"-]`I:AR_:]IYT9:S5N=[YK=D4HW,84;UV=*PD'2+BNTXI%#DHN MYIL1:KFT`DPBT2&L^:IB>7^`S]D*LP=%1MR)WC]4+\K5Y7\H22=7BK3\JRZO MPZS/EMZ!-V:+YI%2\B)/=1S`Q:HH_6>>+AC?SI&A=[4/V-VT6%WA]9A2:AKP MPFFR1.K#&P);^"NY1027>98E\P$=)6/:4FXXSWN4"O1X81Z*URQ)IHSV0&69 MBGQG?G*L('<K-YJG0-E3_`H1RR7+OJ.2DY0*AE<S9`8D2]8_SE,;F_)AQ&A2 M+$KD)\`A\'=OOA-U&GP#L)N<L@G;U?'(D7#_"4$@W618`$3*(BY2S'#D)?`E M7,9R8Y$\I9JRTO"4?;Y3_3NH,T:;FE:FU+*U0#Q>YG5J;RSD))W;927X-^;0 M2DTD!LH5:J`9G?L5JQB6LN@Q"I/2U*DSY1/<QSE>SWARG0*UE#4?G"<MD=EF MG+A.-BU;E0+BR"6V)Q`D0!,\AH:/)U>@]+0@A,](YUICE15VX_G78\(&$E@= M3&R0+1G61L+[5S0#':]'2U6@(\.J:_FCB'Z\*UQ_CF^1N&`-3OQ%<H4"*D<U M?XEE$/`NJN;-4MS<8SF^<#&!)U<$PQ<<O$QL'S61&;4DN.-2E"N@WA*;$=17 M%2ZSJ*Z2KB5%.%G[`;SHVW",\/R,";EQ2KG>FZXQJ^[@7YZMYD#KG)5P;.#4 M/FIR0&)LD;-*%X$SB;]0HP91-MZ^8XC3R76>EPDO_L8-;=J.H")>X$^IG*T3 M9^^O$6+[Y@JMA/&B-I'`?MGI`LL1E2HDMR2.@TN6-6.2FA000:]`0<5\RN9" MDIW&6V1(1X!5_%CJQC-$*?>9M1&`;98S8`1(4\2W`'<U,N:W@WM4F[;^WJ:A MSJ$T4!!CK,N>\2CI:(%13Q(&0<P:4@@.7N2H"-;ILIPJ"`QZ.ULA"*N"580S M78[S7LJ@)[S#,3-`D<-A9X#U=-1XR@JE>5HJ;XZP68=E6Y-SK!FYP?5J]-LE MGZ[7J2<X)2V"QI8*5/"$==+;5S7'*GB?H:[O`04/"M_V#;Q,YHSG<QVM1*NO M)&UL4JN;\&I'X6RIFW?JE(+0VK);OI]T$JV*'9E?,C,B^8K[UV6E%/!WC:T] M9@.%$R@V(AEL)Y(E+TTHN>;=W-.[T(:O@:!9(.M%S2SIRD'D8>BYG2:LTA]; M2VQ?C:<^E,KE+2EG\_B6E+<FSYPS#EI(;`YQ1;^?<8XK^"T7`?7GB#&N[QW; M)<"MRF)6E]%"$AE35]<59[Z,Q]5JS58IO5Q=SN'7A$E0A[Z@I2BQ8V1I5!(B M*R5GR@4R20X-23ZF*P[HWI-\;7-6%)[Q%_@J5>@B1QPHC#B`'S(&OKFP0IGF MM!K3CQ.BCUB:.$_DSN%F_4RXQX!JGE<5JD;,UDU+N3#I8?GO^W2K2][Z<=T9 MA34Y8*[]3O.'?0T_WZU10ZB-`MUS0U6+-$.U?'^L^N.AI^J!:0XU+S0"8_Q9 M_VQ14*B)4>P.B00^VL$?)'[Q$>AB;T&'T-=&IA:,5#/P70#$LM4@<#S5"(?F MV!A%AN7Q?@OGNO$'!V/3CAXXP#SD-@'\,:#ZLT^@E6/IV9]Y-02E=48VW1'- M,K=HEKG[@%GF.X&XXT!D,9#[_>Q?HB'2D<Y!=KRWOSF[S4!>!ZK5Y^^._H$G M$IW4W_ZF^[;I->AX*%0;1JXC+^7&)3Y/""8]B?J[P%\%,D]DL+KS]C=#&IJ] M!S#OI2(V[SZ;\D:5W#`^0@(R@(``B\Y]!+01H'O1,$ZPAGH._&D$;"JM1H#1 M6U`6J4\0]05B?`SH$0LB]B=S;,-U-,]0G>$8@3<BU3=`\`R-H>6X0R^PG8@! M;VB&?B?@#P3A@4**E)-@226=>;:GZ?-[DT@&2B3#>X!$6H='0LB?\"#(]?<% MLA[^0X#];Y@5.4Z_PMTC.1;PKC@?BW@*GR->_KRL!1B&;P:6.C(TE[?)LB)+ M=4:Z.0I,)](=#Q!D-XK7TX#;44B#$<LZ#WW,1XWY\"7!;V;)$^[/826V"WCR M=<W836C?`Z2$*L&3W\]&Y""F53>_-<X+U"GA,_M2XR5,?5XFQ><=^Z\]`&ON MV]^L,Y]C[/&P/@YA+R?6'X(B4`4EW>>QX,D8XI&^,&'_?9<]XF(S6S^83`J@ M[]]3YD]^;@UR1Q8&5H?A2B@\)/P,SZM2O8KCY2]!5J73=+["4[FHHQ#15_(O M3%$E0X?*2ACT45Q@]7XIR#I@O5L>B=+/N@%DY+E?=</5#=VXTS[?@%TS,D9N M9$:JZV,703!DU<")3-4>N:X'XC/TQZ!>81M%$ZP5DQ"\5\"/%)>F91T&EP:U MI`1<.B!)#H1-UF)!:G!Y$<^E-?_`3CMI=8NZWE-PY=N&B;B"*PDW$&X?/((_ M6YYNXL]PP0W\V0&[;IT[HKEGZ)'JV#H8/680J9X9ZBHP33V"C]KZT$)D&9_1 M[(&?5=T0S2-V@JQ-6&`L@7"K;L_G3/^/X(J37ORI3&:K^>_I;*^H<'33@9\] MS36L-="UP!AZ8,Z`UHK=))QQJ`:Z[JF1YX9Z`,!KCE_?N7/WWPV-[`!%RY:I M#>3;C]C?AKG41MTPY!_I/"FK/$N$&?F!9U`-;UD[E7UBQK=,_:MN&99G^SO( M`WO]EEEA9.JCH1KI8Q^LY5$(-`/8<X:&Z8P=+;!TCV$/;IFI\?]7VT9[0DF; MNN@&7J+-C7<TR4KFRVT\W,/;YA&^)%GGYRLPU."7YT7:$?=PKR=/,*-DU`/N M'78_=784C@'T!<3I.Q;\#`?CWV5V;5;_1D/',`.@6<]6+<L.P2;U0]7Q(R?R MC-!W0;<1K$X_D_G<X7!UNF=BV[9A6\]Q)B:>"=G#GOU\9_+,`JE![KX%DHD" MR>8"2=./7R`)5#Q=(-%M!BW[W'R,0#JI6WGP6ZAS7.IG^DMQQN']WQEVOQ-1 MDLV[K*R*%4E%\J)^O(ZS;J_T=QESA#SA4&IQ!6;-P\..?FB#K0W4/!I%8]4* M(C@&W0M4+1A%%KJ-=7OXV2<!A1)*6Y-0SX.?YSH8<GN7XJO_2C"^#>8NIIM= M)?1'Y%#C."V>Y*.\X]CN=S.MNW<MTW=&5F2K8:@YJJ5IIAJ`WJ@.`\T9N:%G M.E[(#M%_^YM_YG0EVC&@\KE.^)])>6+W3D,QZIGF<QQ:&SLO<^M.X$S@&EFF M_3R\L(V<E[DFKX\1XJURUNVM8\#E,RLAV#'V%9ZO_GSG^Q!$GKJ&>;>S]_$3 MB)@/Q#L:%3-:+.?Y;0(F*C5OW[R//W-*XN49)"5UC97_CL$FUJFW&4G*/@9? ME]KFZ_L[G"[RQX9M:J:E!F9$PX_@&,(1W!]-]S3+@Y,Q83UT=)S[?X#YU6#^ M>1&PIVNQ?B%?G/RC(-*,*`C4D0>JA*6[(;"LR%.=,+2#$/[/"H:?=5.0_SYH M?SL6]HOFMF;R]P+K.D\!S?9>T;P!"R>M-Q^6P]O?F.9,+''?:I3QJ("084>V M&QJ>:OFNJ5J.'JJ^,S;5\<CTAH$WC@+'8!XWC8GAE]".V_CJ#EP\')ELU<]% M2C'Y#`][?EO4X'47_,@T-"=T-36,1GCA'%OU=<M6O:&K^;83P#="<>&D?D9' M@<*''&FYZX8Z^]D@^5[9J3H/.-5GPN*IZ\\8[7V<_DR!PG/CW\X?[JDKT#7G M#<IRM6"7.Z)I*,DT3'%.73;]\+3H8P?A6X-&ZWE#@>LZD>\$:/-KJN7ZD>H/ M,<\]P+H`W0XU+^`=W,[V([QV1<>>8G=W?0XKH@Y'YSNB%NG<^;?YA^Z%>PC' MW0ON`8GZ0UK^-2Z21/0R/':BUHBH=?]`1+T)'<_`4OZ9XZ0R;+YP[/C7$?^N MJQ^8J;01PDZ`58K_\JXN&)>3)3[@URZJN*B>R!R:#)#UTJ*1'0(J--7P;4!1 MZ+JJ;X:!:H26,[)]9S04N:]&G?%!21^[[GQ7.*-L>@Q0F@)*0S7<7:#$?9^0 M@(;'*/W'-0QO_W?)Z`7T+FA_'&I10.L@H'OI_*P4S:2S9O32^67P3]+9<P[- M439)YV.IR-B&X_U59)@B&<\^:#W&EJ*N/^9?@DJ\]&FY3(K?L4W?TS%FZ[IA MNT\,3.]6PV93#1L6")VY]]3Y;0%W)SQ1_3K^,BW+E%JE[*6X;S>4[:78CR$* M:,VU[JWVNQ_@!Q+7[_G-Z1*7@<3E6`\@K@;<#:TAJ%$"MO-KK?!G<F#4W!/) M\`)OK+E@9`R'@:U:IN>J0>B,5#O2_"`,HB&UF!%5%;8A5[;<"]F.I=D!J/G8 MYDV@F-9J>C"?RAW#Y$+3W;&]RMTPWX\XHK?R>3!'R?R6IJ-(U"SC$5'-7;&H M?W:Q@LJ!W9EW(W$7^(^*_&0DFHYYR/IN0*1]`'(\&O4,_D_;X*#:GWIF\<BM M:?C>H<N//R3IXA([DB.B>7>8)R''\YVONF5;MF\_BL8TWXULP(0:6BY6YEB& MZNMC30UUQ_1L1P]U;5A+!`DWFP"1I[JP[C=W=%B2XVRMQ0"1^QRUOHZE;G3? M,:)@./94;XS)RTX$EI)K6&IH6\Y(]T?1V/>>/'K].3IT?MC6^9'W&V;-8O^X MS?\O6&MIW`]?/_3P=>OE)J"_YD_W$[;[X>O]\/67'T+=#U_OAZ]_B[COAZ_O M1R^E]M^\"XHR2_@TL2.=ROXT%+SL!&8PWQ[^_9>>P=P/6^^'K?>4T%/"P]7[ MEY-TW'&E%+(_JYX(67M>CEG.'>R,^UMPJOSPY4A@GSK00#.L_JR_B;.V??OT M3GK-KI,_REWI[?GPVT]OIU/>ML4=WNU*5FZGDW=_W4C?0!D/E7<'_>"&QWO\ M]?@[&OR]*H]/-Q;YU]%KQ,]N_O6>G_Z`>[6V/^)>FST>;=8$X3[-5Y?SY+G4 MB<=_\3CUL1Z#/0:W\8>?*=E+_D5GF.W>LPEWG6[)DCRE^<,GDJQI-(V('@'D MKM@Y$61H#T%&-U^WQM#?GS3KM0'9UEQ/?QS(X]!W70^^-;1-7;4LRU2]P+-5 M-QP&X2@(==UW:Y!;R;H=*)XC*=DV7=UY')PC1[=&8\U1_='05BW-'*I#8VRI M\'MC[+O!:.AN@?/DDI(%EKI=^?QP:#BVH7HC'4YZY`_58&@%ZMAS0MLS1Y[M M^:\H*?GO\_PRGBN`TWS*\Y(!&)Z9W.<E,QVZ+=)%7K+?YR4?R:?[Y-,^+[G/ M2W[Y_,P^+[G/2_X6<=_G)>\S6TM62>_6.%]3PE:?K=@'.79&\#[C6'T0ZW6? M[\!R_=,[XCZ,=;PAA!Z#/09?&H/'$<8Z8+#",73?>ESWFIV"%6*"M]MNC7=/ MP&*49V@]L6`5]GCD4VCCJ^1)C41-^']?<5JO9YEW=%M<;S0V,G73'0>F&@8N MP!I9FCH,`=:Q.[(<1W='0ZFOEG;F2-VH[X+E6:%VL9/0_J$V1)CFS-0?`_6C M^U'2_^",E#2[^H`JS).N@PF/?=5-VP/`F@'.EF8:[GK/62T8.^'0,]2AALTW MAZ:M>A;._+:"R!P.[9$_LNJ.R'P2B'+%1H$H5:YDH,`D?`H"_"')DB*>SV\5 M!1LE*X;]@Q+/JJ10L'#V%K@)!5<6`-PU/(1,)N%__P+_$RM+-N4HGRFS?%70 M&^79'CI^KF/X`$?'VE8]D<`/<G;VV]_.K7_O&8\<7+FC()M:`:RPN2/O9]3> MBY$.FP-TA`BRJ*>R:!^X&QC'?/E]PS/-_>"'N**S\?(G7U/:]D8.0`Q`W/2U MZ_UMW^]]'X][\/M=-YJ;@S(7P_EO_H1P5#X!199N^Z39Z*;Y*&W.BD+7&SI# MU3;LD6H%FJ,&H-VID3V*;&^HC[51V'0.]1V_W4EO)P!?#"FV^S@5=R>D"`5( M-QW]R4CYE(%LG^,PH[_':?9[7I;OLV9^PI.8',!,;;`=TWNDPK_+'`B!#=5M MX>(>N+IVSB832KJ(H%V":CFI/N9PW69YL1CG!1E?90O!<9$]36Y:MF4AX_&` ME/!GWS)U8#RF9?B/Z\\[]B)`GA.J&AR&:KF1J?IVI*N.,_3<P!F&&G(X?LM, M9MZVS*8](J:-\S"9)4613+EE5O]'S-9Z.32NSX/;'8OM]+'[8&QC1.Z'O+%= M]%%1EC<V-=>-'-72QV/5\M%6"S0-3#?XCV&$AAFZG=11F;+N!5926.M!`*T' M6"O:$\4)F&E^*X7T+AC7R`04M.KV?`X:'EQ,G!U(U_)3F<Q6\]_3V9-DF`-B MA2;S:+ZU0=<QAM[0'ZJF-\04V7&H!KH.\LES0SV(`!S'9],)</R)^^_6>=^W MZQ<!TS><1X)I<:YY;A\]F*9C^-ZZNV4G,&W.UL[-QX!)M!U]G21EN[M[0^Y@ M<M1ZR_D*9$W,IUB^GYT7G'\^F?LY<%BDF#FN\ZB;[8>:[=E^H.J.9:J6%@Y! MR1^.54TSM<`WQL,PB%CZK.'+UWH_H!]9`VV.34_76VWQ]]=`V^8<Y("S38Z& M)KM8?`!-^JYKCCQ`I8'>TE!S5<_QQJH^-JRQ'GE#$#F?N:5P:)HDG0]/H$BN M0>N#0WJ73?)%@HHWS03Y&']](K*P];WC.8Y_P-;W<"0@Q2VP)O2V:;4+?&V, MP&^;1_8!NF][WF%!=S][-H)N.9;3@KX%2\=E<]=\A7KP+CY44Q/(C'T@Y)"S M)$BV.SAAR7<-1_+8/`[:!Z`,+*X*KEO%;QEY>HC`I!G0)X$\%Y"GPV=V1-XN M<#\`C9(;N!2SL9]D*SP;WM`.][4=L;81S!WGEC125-#J7H:6;$'4`=B5_MGU MW_YF:SM-*+D#VEVGY0@$OY_]*RZ>'`Y_-H)"'.FP#WN7B3CK,.Y(3<^"G(,0 MD>,Q_\0.1/1H[/R9W-!?RH^Y5!?[)3F/BRI+BE-!E6OCO-V=4'4/Q+O>N>=' MW-XO(%B<@#1+\W1GEQNX$^+N$0YT`L^E21QX&I6%TZ@<P*'JMY72I\*^.R:W M*G8G@SX<=.GNC+VM\.Z.LH/I7\^"+DVPN4>#VO'83+'VF0)/'_-@.DWQX7A^ M'J?3=]DH7J95/-\\'?I#\K^KM$PKT%^*+V"%L^_R"`(E.>`63@6Q'M"A:9KM M2,"AD7,<ZO!SH!?58=.U//<95.(#*GW/<L6]G2V'8U;ZGH6J[&ZLZLEZWZ'Z MA'B.X7_53<NR<,+>'@)ZCN[JGC\>P:<]2[5L(U*]L6:ISC@8&9:N!YKOUX%? MS^_$.+=W#SDP`AR,WSTK`@Q$@&,_&`&'2D'F@!N69_L/2D$.-=<9C5Q-'0W= MD6KI+J8@VYIJ1&8TCCPGBFRO"?6?Z=JC4I`GU\ET-0>6\B&9DZ<=;L?M1V`N M93PA16)_76':F.A`&XPU'#(;JFXX#E0+DXX"RQBI_M@/-2LP`\T>G4A7&*GY M2["X2K+.-,J^YPLK.&O7OXB>+T;?\^5(/MTW]GC>GB\*M7J!_?8]7HZ?%/H> M+Z\2]WV/E[['"V-QQ]_CY?=TPGN\D,)9=W<IF"*O+$&33X][\F3?X.58NT/T M#4`>T`#$'1AF/XRBO^TG>]N/??CD_4-WF/3KRKY[?"O'P?)>ZKD>JF.#ZJ`Z MJ'&8BRFYU;%,.T6C((OGL)5)7E9'K7WNC<V^I/)A#0RGUSV^C;,V!II^@IWF M^K-^U+W6W1-L'+E'3?)Y!%:.Y32G(*WZZ>5'3_P]2?0DT<N^IQ^Y>7KG?'JF M6UU;2\(O*]-IPO*%CED(O@KR-ESO]`B\EVV];.M)HB>)!XK!$V\JWZ1$;""9 M0_3S?O0'-SS>XZ_'W]'@;X^.(?,0ZO#'O(KG:[DTE+_]>A7BE\V;L`:VV6O" MK_J(=7]@6'W(XE6?,48JW-,[XM>FJKZFV3,]!GL,OC0&=YY_]-A2RHT#CJ26 M`7^D\Z2L\BSY(ZFN\^E>VU)O*4K=4HV[J>V,:861J8^&:J2/?=6*1J'J1;JG M.D/#=,:.%EBZQSJBM[MG/AS.-IYXUGN037FKA7(/Q<H/0\>&(O8PT*)Q-!ZI M8]W05,OW'75HN)YJ^([C19H7AJZWJ2WW5FBV3K^2:"M]6M><9P3:>OL;_&'; M&*PV2%)+`_D>W3E;[$308+_]S0*3IVE?L#.`+:3<\5SYHB2R7K0?&IICVD-7 M=0P]`BZ![>HC+U1#.]3@5T&D^38KVJ^;_M>H>1B8S]"D_<G8<,>&IXV#L>J9 M-O!,UQFI06#H0#B6IEF1-AZ[$<.&R<?&/:`I.\=::[#>.YZ-N1F9H[Q\4D.9 M9[PY($,LPVF1QP,!W8ZD.T87GA"&3)(KCX!O"[^5]);S(D&:P]XSH*3]-VX) M;3X,".36)$F_)-/A;915:77[HA=M=^4$Q+%IUR,A]HZ%%V^VP?NM=/`3C8<C M/1@/5=_RAX`?'.Z#/?<]TS&'SLAQ];%](LTV-A>&"$<N[\)15LE\'I>=1AP` M4-^*8X,S7K3BT!_>BL-_N7X8!_]TWP3AN8K!L1T&ZX9!ORJ4G_G.MW;&D)[I M.RB<[L&];/N%TVL!L$M=Y$U:7?=UD=\(5,=??K&58!="EU9FR7%WK7@:"EXX M(&L/0$@\?`LO':WK<PW[7,-O05SWDOF50G7\DKFOY'\$$]PC-_8&OMFG2GT; M9VT.#,\^O;,^O2JWTZWW?A5T[@PLVS@].N_/^E$\33_%+GC'KYA]\RZ3(R%P MHW>=O"C`3]U([SK9JL>=>.[[ZRF3Z_&WWS+#O5HH!RT\;*0\[.'>5);7*^Q? M-CYB&@/3UT^/H_=G_""C5'\-SI<3%]JOJ5BHQ^!^!??!RZW"9)841=)4&^V_ MN.KQHPXUPQ^.AYJG.I$S4BW;=E5/]QTU&#NN&\#?;-UA6=_ZV]]TT^W,.KP/ MMA>JL-D5'^M9\*/(\SW-CE0K".%_K%&D!D/340W',-R1Y]G#H?%9_^R\_<TT M3!H0>JCZFA<E"]T.QT//T[`8(%`MWQJKPT@W52\T1R/;#EW-\FJR,#HY[;L" M__SU(P>G"Q,'HIK^B1:/'!P]UMO?',LVMJ+G(?4CFZE,OH0GPTV0M=H[7:(U M\)ZO8I6P0#_[FO=5=W3+-JW#R1Q1,N-['9'SL#K6YRUR7L>18YJ'8\`"1[JK M=9#TU-)GK/^CLB-LW7D39X!E0#A29?$E*4?7<7&53''8=5G![Z.O2QH/]A0$ M^J:#L[T=YY%7;6A95C`,0C4PQQH05:BK@1<::NC[\!7'=(U@]-G$ZCY=,]T6 MLAX%[*/P1?PMF$SRU1.GQC\7NLQ6"?ECH'P(GD+0LID^?0JXL1Z`FP8R28;] M*R[`A*B`H%+6#C<$[OX$R#W-L(#KF+;NNNM3K\?N<&29W@BXKHE3K_50'6J6 MKAKFT+.<\3C2-0LY"E4$P[JNJH&@LKE`VKC7P\-BZ::F>8^&1>>PV*IFJ89V M/RSB--]EDWR1?(R_(H/,)ND\I0?A%R.P=M(G75Y/<VR="-3TO<>5NMOPLN89 MJC,<FRJL'*F^8=GJT!A:CCOT`MN))*/-[`B'>X&3SO7]DEHU9U>_YV4Y`L3= MSO+B)BZF98,^*L79&SZZRD(T=LT`KJ#IA3;H48&G#L/`4(=#W;?'YB@R/;\N M2\:CYH>\Z\;E8OX$^U+/_TRJULM,ZRH_YE0'_WY)%+,/3O5T0O!A.=\9.ZHW M]BQ`C@6:5#2R53=T/,_41Z8Y'M>]0'2_5>7_&&"?_Y)XFF4?\)+4A=E:5\T\ MTDO"\?&82V+4YGK-"1]V201J/F5%K38"/H9)ELP`(8"Q(HE+U,?+U1Q7Q=89 MHU51@.ERGA1ICD^?YV6ZKXOCN[:WBWJ]+N+=H0\2?>RKHV`T!/4:3#00]KX: MN/[(]I!.]/"SB\+0086Q11G[`7\GE(;)IC7/8:WB9!%J`P7ZNR#T0<`?)X5: MONLYCU-"=T6H213:Z7CT>DGT63`*)&H[WPB)VH9F>]I!$4KN<MW[5DCT63`* M).K9!R;1"S#HDTMX=SK*%^CT8/8M&D]7Y+`=WC:/\+8T`6H/YZMB<@V_A*], MVEVDX)/8!N!)2/8="Y5FUS!DQ7"Y*I+[&@D&@:U'0^R'96JZ:GD!J,L6&+IC M+PC'8WVL@0;=M,X[\VPI!'@P7'1PWO3:"E<%G!8[)%J[C!;+>7Z;).QUL?`\ M?B+5;D9H29_<'TK1%/5=PY%P^CA8)<5[^T/!%]!LKQC685E:\P!(DJ[V9]"E M/Z\CS7@"R@PP3,Y,CROK#P-VPU4>WD^^PR[Y,@NP_#LZ3(`YLQ/Z5X*I,<F4 M?Y?^B#Z4NG/<'C#M6YZ_A8GNC&G?LL/(T0/5'H_!//8<4PTLS5&'NF6-@B`< MC5RC)D[G3-,[]_WY$+:GTZ+_^6=2(IO_@)_<!V/@)]'!K>V-AHYA!FKD>6!R M`J;!LO9#U?$C)_*,$/6TS_IG]^UO'"/*%4*=3.%(ITFA5->)HON^JR`%*\H5 MB*LBGL]OE2^P?7@J!U0ILWQ5*#G\-_V2*+=@B);*C\V3AOV#$L\J>`[K$O#/ M5+B@`(.MKN'OZ(9.Z(&?SO9PLNO(W9.XY`CZ)P'^YPJ;U[R?,2YX@(NT&U_? M_>J8<'4TW;'</0C+.S!Q"%R+ZUE?0_VPC.L^;][..+=$!U-MWTA?1\E^!4GT M%;L:@CHJ/D0YR>^R"N1_F4Z>07K(A[#.UG8_`XTYAO8G,G9!C:3[?$R*Q3@O M)#\M<E+\S1+@FZ7)E/[T_^9S8+<O+@?`7CFW_\TUF8=M78*Y_?=K^OO[&Y`' MY76ZY/HTR-<#$%#7O%A7-G9$!$94SW3A@-T1H'N/_:6/%R[#N:[=?;[R.39_ M`;MTR779/^*OZ6*U8,3_TA`Y+8AVV/#IV,Z69AKN0VUG+1@[X=`SU*'F::HU M-&VT6@)`8!"9PZ$]\D<6(P3];"]BZ:&&\V.YKU`S@NF4G"#QG"D<P:JZSHLG M)@9MP_AN2MB../>D%,QG0$>'&7W,R9SY$VY&%5>K*B]NY=L29*!3X'&!"B__ M?G](?1S2]#6.]4A`)'0T#/O]3+8#/^9_)C?"?-\CY`^03CMB!0=HG-5)'[O! M<TA/P]^+O-P'P@S+;27B[7;_W#`8!:/16!W;B+1Q:*N^Z_IJ$&C&<#@TM*'M M;AJU<0`<M)%<#]3>_*6GY^-MP]L#VLD;OJ.-[)%JZR,?%&DO5`/=U%3;'4>V MZ0PM'SXE<&>WF==NX+51,LKI<K*8]8>T_*LAWB=9=;JI>QMR@.^_<4,]M"U] M%*B^9H">$;J>Z@?#4#7<(!@&IN%[YDAR-CM^`_]=L+2ACF:S9((<J4E7`+S! M^U6:K=+LB@?X'\AO,?M6-Q@.'@2S;D5CT[,#U?0LL)[&`',0.;8:&EJH$3IT M^[.)`DMK*0F[@[$+^/M(1SDT"L`,4,$.\._#P=W9)^+=/Y-J%)?7YT7^)9WB M2(!/)9KR=7I'@`NGV([W0*2Q.U_P+-=VAL!377T,XB<R#36P=5T-S'`4A89N MCTP-\*.#P:B:IF6VHX9/`_3AQ',!F@"FFO\._&A>/_<P&7YH4M*)E#3G8:2T M#;*CDN9;4+>;]+9MS7&UL:%ZF@X2R/8MU0L]'U/HO;&O!>[0]3];W(4)*I6N M><\HPA_]`::.L["96/_9<!H%D69$0:"./`]NK^Z"5+<B3W7"T`Y"^#\K&.X? MIYM`/DKK[YGH%4<4Z8[C=%WNA[3WQ(<ZH:R6D_[]J@+3*</I(/"==(+52^E\ M51T(B1NDB^;KKCD"%=UP=5.U_'"L>KKFJB-W[/L!D*KINTSZZOC[EFQY'&0/ MERFL/&**4VEHD,\QR1*7-#/]8:*D"]!^1<@X+V9)6JT**JAH\E*W!5>%&YW\ M1OM5;78./(],0W-"5U/#"(T?&Q#MZQ:8W$-7\VTG<'4CK-FD[JX[S%X*7\]\ M=$<HMW!^I*[YGO^,)_)`K)=/R3TXK>MA8%Z&;CW@+/:'G`YGCXL,N'\I\FOV M+^`>@\D=Y1T0M6J<F;+%?3<X#Y=J0<4K2BZ$\[3U\#$).8T,)M-ZF)2[!\". M@PZ,SRFB$IW%R615D$T:?9W,5V"V4DHKD.^J8O)SUCV-8(&UD\^E-)F1,7(C M,U)=WS,`;<9(#9S(5.V1ZWJ`L]`?(Q&!1:Y;GM-.C-X+H`^GMC]SG/R$54F7 M\X3[`S>SAH>V1C@T\=F[^;Z>`NY.&:643O`A*2M@=16//S.#(*G>SR21]:S> M(=N+_*&G@0UD!8YJ>=%(]4:&H8ZT,-1TSX@<ST')X&%\5K6T3@;&$T'=.@F; M"8UGQ<0X].'VP=I#V]15R[),U0L\+.T;!N$H"'6=.#O6L[/BM8WSKMG&NW`M M^0A1,&[PR@*VDLM]7)*]>P$-#SMC&/\_>]?6I#:2K/_*AM_55MU5&[,3(2%I MPN>,W8X9^T3LTP8&M:VS-/0*VG;/K]^Z2"`)`8601-$P\V";!EKY9596WK-& M7>/C5VG\N'E+(1.R)5N>#EL%&LC6/("JK5'[Z&BF^-/"G_SG.16J]?LXG<FQ M5+(28SPK:6=;N0V$]\DAJS6*'$G85HNJZGXHNB#>S3=Z0`:2;80!RH`NX+3> MCKJ7D!V=N<GRXSB5>FY80B%T.?*Q,X+"%M61+!QAAXX`&OF(1H!Z.G`-FGMN MUX_=1);L5=6&Q7:$/T@>%EE2^AXA(\+$/ZH^ZF3RF5#=R!NY@MX(2#Y'CH<` ME&P/`8YY'`6N)G^+]C:T'9JP4<QH$Y_QE\MD-?HF?:5W\\Z,S".FVC#H(R*^ M.V14.'[`C9S`)8'#8Q^S:(1`$#)MH$,`:A4MQQ)6A47%J*2AE"7?A*VT-K<D MX,H,$%]BZ<4`63X>:H.%"34]3(8ZW:B)<<2QBYV`![(GGXP<S@7EE$:"]@@& M,&);DU4,!SYM:\B/F3`5TFDA)KG=++Y'!RRER-B9^Y0#">#6.((6U%41^FV< MSJ6$W,_EM7G_\#%;".6R>I'%F:M(W*UZ"+2%B&!=X;:!PXP4<T=H9V^5I3I! M-ET08]]G)W7F.G*WT;4)_)]%CQJJ%`B.4J+'D%L#L2A%V'R9C7A(;T/XSYA4 M<V`-3W](RX;:TRS-)I35%[IAVT9=PJ5U?4BY[B.J7G>V)4!6GP.H^(Y(]2SL MH:)6:;28+ZHRTJ+8\'0+&T%"(@Z<$%#LX(#ZCH^%'2DD@`&/11X)?!T<\:KR MO?/Q3W8TWJ?SA=`0+VK":Z(F!5:_1=Y*JQ<]??'=7'8Y=I7][=PSR66$-4U$ M&@24;;NEN.C/A9RA<F$5RW7'@S>&&:V\)<B;7QDAO"FZ>"C\5+'(9-K39OL2 MB$L!0+(_[K23HJU:S`8[0HX/73>PZ#ZOI<JY#0J'8;I0G7]`&:O77AY#V!Y4 M+#6J9;2Y0>]5'KU^3Q2'6K^CT'.#$L@QCL6]%SB^S-QA&!/'\P/H0#KR718+ M?0^X#JIXJ*;0FY^^3J-^54;D;(PBNKH7NDS6YH&;22F<9$VVC9:+9!9OI*KZ M[+6L\Z8&2VBM=4&?!.+=?#1^2E=Y==]6/]X?B5!FRW25Y"$6[3R6QD<?W9@] MY+F5VQA83;C[QN)XY/.QL]I'MQ1*0-66#PJ.QK)"W<G6="C^LEP-?#L:6L=N M5]9Q063?O5TG`X.CD'D!#1P"A:&(?9<Z/O,\)R*CB'@!B-U1J,V&[6/8HI6K M"&FNH<K?E8\T&Y1T!)!/J,L=SPU=!PN%[01$')TH##B,1B%".-JR^P\04*=6 M>-X37><A_CY+5(YC/O4?%]DJ_4N];J/-C-[\2GA53YB0<C"<5-TH9"/E`-<S M=_MI:#9"SG*08<!)-&*R`C86!'K4\2B6#:W0]WT>0.#A?295XW$5?M$D2:9* M[Q4%"C(BGX.@RVWF4_U"(GZH7K&1L2K3)GY+K0"A%7UU)[]IG\LY1,#0\Q=( M($(QJKG^>ZAHUN'-;6;V*W3:J-!-J-EB_"I[GJQ42D9OR+`RTB.CXK69MTV/ M7HM]CY=2%N0?,ACR?3R3)J*VE^M:T<;SCJ0IASBLTGT,53O*;LXHWU[D,AZ' MTJT,A*W&(D$Z][G#H,<X8VY$:5YBT51XLT^4-\/B\WFRZZ,_='U1,`I]PD+F MN'XD[C*/"$.=<\^1"P\B8:.&D9M'/!!BI#G!U41$3;IUNB>O^KX(K54M*3I` MP&XS=-":(,1CN=5@Y)"8J8@(<(3\<@>'U`<>`R$.0LU,NK5\<O/(1OWP<3H7 ME_=%]L-#H:")A^!62/8$.DW,N%)PUTI8A"F.43U2?9"4W90WE)/8GKR`;KTZ MY@B"&E5>Q<RY",4'FQ3??C(..:+^9)(])]/?T_&7=*;.D(W,!U`RGWL'ZAFV MB=D9&9=%U!;G]$%=V)L?W>@^T`F0R[P/9(X.>EZMINDT0K=*/2;BN^XS6?Z2 M_T.E0O6R@#C]F4QUF6&>()T>-6AIJ/R0[+`&M%X%<BQEC7K2!GO?4$&B)@5I M9/:K7I/-WDLKO5=9,8L]M\;F^I/O\\SSMRJNOWM\&J>96CI\!H?=4`&00P[[ M7HIJ!39ZI+I\]_0QG:=+-7KL^UE*NPPY+AO#(*XMDCI`AT$EXZ?%Q=0Q`JG8 MT*&+?S=-^VU@@>'[L92DU<O]P^YJ6"N!$;)!$:\YBRT)-!G-8",(32GQYJ=O MCMOF08,+NN%(8\1V/QT&/H!:8OQQ_*)JG;+QU,I`IJSFIOQ047,3-0T=`-7, M1IA*2W(^57=)IT.+.B];4\MN:T.=S"DJS?%MC!GL;*)HO6.H]1R0QNEAQC4> MXJ#@.P3S&;\GT%I>Q&0RQ*"V:G8S",>F^0Q4S6<HT#F-KO)HZ-+U$V;C'^'B MQUQ#GJ[$U:SKH-=QNW@\R=UT*:.K]^/LW\DJ?_%%%>:?KZ/=U$&5>SX]6-HX MW"L$]>4".SJA-A=[(=7^URQ)!@_MF9]6.=R=\]RS.86^,D)ZPE_)Z%%S(M9# MON\S-1YC69U?E>C1559.1"Q-[>J"PA)6>?=I4?6^W15DHW>DO7VSYV^X]^2) MNG_(*_HL/1=J6(2'-\>B\>&/O*+J'>7+SROQH[^2Z8?%*C<9.Q'_SFXK68ET M1^@1MY41B278FFL^+NLX`#DO-<\1M2*JX2*7%3]YAXAR*:525KZ5WA4WG^82 MN+R0ZUHZC(ANW]8GT'E0BI1.+@K:;>Z#DI6MR(.'!*B1GB-5D$Y:/3W)BLG% MO"/#I#-]`XOI92?04P+D^$"\<EK?G:$=P3#;0#8W[VG$E5`R*;\ONW'S[TFF M)L55_5Y;+W)8+KKLDN"R9;,5#&G!G6_9XOGKMW/GA<WD4&Z(+%UXO=)OT>A+ M(4U"L#PF5S7+UWH9A0E<5YG8@F%]S\*T!DR$<3]@0@FF,-"XZ_*^T6P]R%G' M)M[-97Y-S^.3-_RG;^-YW8$\=;*UP)RY"*!<@%LL[@V)T+.!T+2C*':P'X5. M`#S?<?U1A*5%`\AF0X-@K@QUG0&?H1A3W6I[`5R1]3P(<$2&8$L5G?/PI--E M\H9,:S-J&R-.1S@2)G'H"HM&J"W'QQYQ`M^E(Q9ZB'KEH>6LB\4G74,YL#H4 M7L?R];$7#<?>8W"\]*MNOWG1.CQ,),O(*[CJMD7B[`PPVJI1,*"?%2?GO;O4 MAO:N-1DT\`NWVR@@B0@+H>=@SI"#*0@=3F/DQ"/D!;X71SZ%VG.1*YKKK13G M`:R>DFJUUZ/^!+4':)"5/C:BF/%PQVVTO:3<:$,*R3-?;CGI90&&'9W%M9CX MR^7SHY8F6;XC1UX7-1RGK!8ILXQ0R/?$2[=]6Y\Q&G%5HRY7`S,>.3R0T6-? MAML!"5W/_Q=1B;B[;DZ:*1P=[:'?]^ODMNS6M=[;L+>#5EC9'^D_P7MQZW2P M;?X@N3T*M=SP&V?)>OZ2[4+MZB5QH">A;H)C`)7R?XO9>*6J2VS'7W9YWK'> M\&\&Y(*4NG@;E/@S"+WN\:<WI6X">SMHI5('_T3O;QI]4(G6&KT3__A5:O2^ M\=<:'?:M4?9I]'-GFG9AW.$&.^G\8MD-V%>>:7=!]:?%^]EW?U5\Z/.3<`1_ M3Q_;=U)L$",`0,*.\C=!NW0]4<,6A:RRN[W5XSN)-4))U1&IJN#E4H\/ZZ1X MR@RP+JH:-$QP/<'S-'J/E*S?%S\N5K+DB(\[=(1D;8@U+/\NZLB++Y>]7LN3 M*\`'%BW9WU:MK&]/\F'<\DKJ08"3_Z;8!?(:<#%LD1$P!!&HB=\800;Q?@Q- MR+=*^/9@V+TP`B6,8!A)/!.(B*(>2^`$B"0_T8!WAZ,U5IWXWVV(A71GU>$B MI<%X;W;=IL$^??SRG"V34K7X2>!XG/X$F&#"2<O&2!81@8038B80HA@Z',2N M'*&"/$)!"-Q`)WV`G-9:G1721(UIX;^&;S8;?UF<UL(W,`QP`T,+(DW1N1`P MW$WJ:"\Y/:U%WE!+7'&>VU%KM"9YG?8\>E-R'^>=(`9H.VI'%.!1[%*'CP(B MAY`'3@!C[(C78<R9/PI8B5K,ZIM;=AWX'GE+(>"XQQ781?VH.5?[';`N*<>` M<''I40X0ZF_@>J'7`?>J$[':S%P?$!3">IQ"#POA]VJ[X8\!1:E$W58@7?)* MTWM]\G-E_\TI^`A[TU7X4$:'F09`E==-*@9\&ZJ-UFQJ1VKS]96^C=,'RM01 M',:5I*K<4\84$39:QVF(@OGB4AL`[=@ETJ"B^G+PDU"P742AYY+>1%2/274\ MEUV+@/;KLU/ILTL!=7J3T+/[[3FR'@"5>&9W?CO)W3'Q.%[??GO1P'S_L&91 M)_F$'2!U+&Y,!7W%->UY57G;1]:6(=/0'UE\X.3"Q\,X=&VZ:$R$5F.T:KD< M(M-\X_6I6WQ+^D@\,>7]"8A`G^K=)>8+KG=L]^UB2V.9<$X\KU?"68NMC7NO MOIVCK[K`HT=3M!B#(V0`F%[SNVD]`C`U=325Y05Z$XXL0E#25:H:O@#HY/'! M<B&Z(78F9)]O*-5PUKH"SU/]N]T-J#)H[M=<N`#!`J5A3,9TG0N+_OP0E:>1 M6$#D0MH.#Q-#>RAUU*^+@:6+0=7%9NYCF*ND@>V?(<""U16,Q]L^^Y#=>5%> M"#BR9=4H/K6?VGZ-Q4&DQ*M(R1XCT=9=RD,#=D6[E0>&MM-=R^<V,@?`2T]" M=5F7AN:91VL-+7$]C]K:+-X0[YZO=-&$+/X7?)$OC+\F)W68<(P$5!ABC^QK MK-H>[A"ZC(Y&S'5&`1O)1G77"4+B.C!"41QY-(J(MZF)N",E)W`?+56J\TFK M_GR:*[=E!R4#.T@VEX[0=P6)\<B)`70=S#EU`L@\!W)*O<CUPI!YY7*0@]3L MK!CH9@[HP$3C794#.P>`EG[PTEL5T(`(D.WAJ(8$5D`IE9;</ZA&'Z%&FC\N M`]07`@Y4X.`R.$<2NAND?$KHA2.$BEWA+4BLJA)Y;>LNI]EL\4->.'+XK/QT M]CU9ZL5%4UEXH':]=5"1PCFB\N:EE+=+WP088S_P0\='L4")A,#QO1`Z(>?B MMU#$H#_ZEQ[I!5RONJRI%;6M`%-,*'9_7`)>U5UE;:@\!J<PF3Y/3MKS-R0V M^`AL-I2=.__AN9QBH^:^IOBB[Q,0!80[&+E`&+@^$Z8N8$[L^6$<@]C%/MY4 MPW68_]!#CG>^*9]]TLG^EST@M9EF9@X9K&R#.8[8;B=;Z5K-(<8"%DAS[/%3 MY\9Q<50C"GR'Q#$62%,Y-\X5UR7`>.3[H7`[X%HXT9W<4'$FP#J:(5"9Z_3A M^?%+DMT_G)R!V,42P_&:QDR0YHKX.4<=3!C8@T0?6!>,7C/T%%_:X`@<&#AF MCKE<SH*;!H[U`$FW*JD8:[6LS"\31K^X29;I9``]M'],F#D/W$X'\)G@TN?E M\%MV6LHA!UXX2*Q2H6^F;5CHC_S1*'9B(H<ZQ"%Q.&/<\7T7!D$`W8"P/E!O MP&#@(OY=N!WA6`H/TAV1D4.`'&SG><+@!<AU"(LC@FB`N?A5!7:U_;9M^AHV MZ1U=.;B]]%J@&<IRP_QKS='AK@0'N>CH_7W;5@1U/3Z"/'8\=X0<#'WB>`AZ M3A1R-Z*A``<`;?T[[ATI75Y'T]<"'H%T.K$?'-0.G`UU-8TEVVKS2->'Y(AP MC`'I!PZ)(<'BA'BP5AY0?>@]"=OU;K1**\>WQ6R:9$N%B844RZ7W`%+`=Y?Z M'::KDRSV8"2#PR1O)5_6E>:E"IH\=9-,C[`:*T0>517>Z,;'H31(D!.&T<C! M44P=+X#(<;D?T\#G?A@JGU0)-JYM<C]`DQ$$.@QP(OWM2\:,Z(>J9.S-KU3^ MQPXBD)/45JG+D.P)=Q_N1+WC(&8L=&/'I<*FPB,P<@+&D3.2YD9,(ASZ9*W> M(6NCWFMT=JKH]X)PJ*71C'1Q'ABO-?.>4],/0++4]![#V!)%/P#%X"#%M::6 MTCK=QF%)1]`(E)GO4N0:T;@=#$#QB$2A*WS0**(.IL*V]]T0.A2ZR(.(PMC% MFD:D+)9*&\LA0OJ[W\ITGWR_F6&0WV_@E/MM%V(G5Z>8`M*U8.1;4P""AK)A M5(;2_.%B7^4)J'B<D8:E6!VC`O-E(P`S(U0*PH9S@($VC_:HC6Y]/%@XP-X% M.,##@X/:@=.]`WR8]"Y\(YCK42OLHJ%(5AXP<3$XOV$T%,G@,,D]6PBH(PO! MU`/6DDU4G\RY7>`&`/IW@173H>`Y0MA>'QAHSZ`+#6_D(Q0:'K8*<?;D`Q\& MH0OW2)T(.0S*&ET_`,G*!T;,`A]X*(K!08J',VZA5GQ\*/L-Y<8MOH3LSO#@ MH';@=&_<'B:]"[-'Y3\QIE88MT.1K-,[I*;ESZ+QAB(9'"9Y>,,&:G7?Q>DV M4OS%Z0;4(L/F,`A=W'GJG'-<F]QRSG,^`,GRG!/.+/!AAZ(8'*1X:,-&U_0, M<7=C5;1^!\'%V#5#8J.6B4%HB5FSC_(N+CPLU1W$"%MDU_1/LUP(3Y`MZFX` M@L$A@COOG*V0UJ(%;CM'$\J$#PF80R&(9*(&.3SR0B<DH2M>\B.7DTTZC]4S M5X;]L\.9<YTH-:/KKE!J-H6I#F/0Q46OU1M@Q(HXU5`TRU57&"-+U-L`!(-# M!.?M8_K!U2\YXL'5A\7'$W%(5B_YO\2_Y3+05?J0)MG?EI-OR6/RCS??5JNG MO[]]^^/'C[ME,KG[NOC^=O3N?\7A$U_M4L`]<00W'RN^^&WEFW]Y4N7DF]^S M7(TSU3GTJWPH1SRI*TRWS:OK-R;BJ&[>!AT$Y%=/2V_ZY6WIRW]YFP/2"IU= MJKUOM"0@R5<U-N27GU^RV33]>_+S:99.TM7[1+;\_&V:/LH)4XOY/]YLY@AL M6N@_9>/Y<JS[,(.7\D_\G^GRS:]Z#,?CUV2NO^^7MXV_YE?!@OPY6K`1F;$1 M#<5&NX3<&G0*3]0J=+#C,B,5X'('N7W*CHWH(#-T4)_H5-(S5J$CA`*;R0[M M%YU=&6PKKX\_5P(#^9GH/\_BJ623TV(N1S3I&V.3#U_;4KU>'48L1`.S<%.% M83<+1[/QLIC07F6?\`O39!E4*QBOB)%V:2IKT-E59VJEF,?I?#R?I++W=[G* MGE7':D7(\Z+4'L4:FC$.#LFXFWYZ!8RT2S_9@$ZE%<8J="0T9G8FZLV#V]LL M:+<2L,3.-&$A&IB%-SU^Z8RT2U-9@,Z!L1Y6RKF<0?9A_)B48J8?%O/*N+*M M@2#]VBHF7(0]1@P/3!.Z&"ZF\V25)'/UY\N?,DFFN*EGWL@/7"D;]1C`"V!C M\6KE,%X9TZKS/ZUDVOY9H9]>GFKLW'[__4.8FQ"?QC_]Y3)9+:^.S;?4XZO@ M8V7I@I5\-/3-=JQLN%9^JOUEE\S/(:-M]K+Q%C*Y>![JU:^7S,,_DM58."73 M8L/TM3)2+2^^9$;ZD\GSX[,R?G:M!;Q"WMX"FZ^)DY131B_,LCW$6?\HSMXL MZT'EZP(L;;OEZZ:VFL3J`BQ_N\7JNCV/M4Q=E0R].DYB0+CV(9FE1HQV&];\ M_%TN)I"Q\IH'V;3Y+M]3<+4\!;;FF(UX^ELR3[+Q3+#4GSZF\W2I5L-^3ZZ4 MJ]#C]">@$'!LZ4EM/H2EK2NR&S4;3U:?%A^3[&&1/<:+3,4)EL'+)BVF<B7J M9;6&)>_FO$YV$\0`M=3Z[Y+=O\T67\:S8+983#^)-XR?DN=5.KFZ0&#.=)=Y MX`J8_B&=3Y?O7\9+\>-Y.A:G_7MZI2S'!!-^!2Q__[+X]SB;IN.K8S.#TF-B MA$)+0_RZ#.S=?)K\E%M^U:S7;*E=X.V:E4H)DO[HM;%4O`T*90T`E$OH+BH> MW$<\UOPIGK\L4Z$"LA<YK:/BFFL=,?ON?\T2]:`WF;J88%U7P;*;''4L1Y;* MS8U[![AG<UWR'N[=BI2EOD8`V6WNJ76W-[MN#^_D:Q?%.^&HK;)TLLI3&9_G MZ6KYQY^?KYA_EMKA9OR[,KY1CWK,[AD,OOB.J1R9F'Y/_DPFSYEPDY)E]',R M>YXF4SUO\?'I>:62&?</13GCQR33>[1?FK_@#',<[.6^Q5IW".[?=+AE7<16 MP$-*4RMEXR)`P/L),,+0MAZX:9+^_??DZW@6J:<I=S\M5\EL-NXSP&\\FV)( M7MTZOE\1%UT$F:4N>0,7/_U8?/JV>%Z.YU-_/HT7SUG/7=X6L^[6K/\ZV&AQ M4.R\S?IV,HT2\!,0Z!+/TK.G2]%DF_WSZMLBJ]HL<3+-2]!4FD.\ZSH9B#GS MJ&66IA$#/\^S9++X.D__2J;K-P;)/'D0?M6'9'7_D+,X?TU&L@6FZ[=^7GVY M3HX+QX)XEMJK)D=VP^8;2PN6>BXFEEZ=NUA:_#P4/UVNTLEH\3Q?92]7RD!& M$;]0!JHS*.Y16>H]^Y_G+%U.T\E5.I(0R]`-0*YK*2OSCID\#GV?_9%^_;8J M:=CB!_,^:[(MYATB@#%+L[J&O/OT8W%EO+N-#;L2-NNQ82HRKMGNBB-+`::V M1E^/'R-F%D@W?@`I6?</I7KNTN^*QMGLI53U?1.G7)P(PC=Q.EJ</F:+IT66 MUQ;K7@&IM]XOIDF?XQZL%ZWK$J77RLK;K,H+YZ-'(1?V/94]U)=Q1//6#!G> M'"V6*V'Z?YX_98OO@J%"U299O4+%?Y3J]R]E-@8O^7M>[C/QM_]/)F55G<_O M6AXT(6_JI"<QQ!AS[]K%\)U`,1/6PDT2SR&)5][2]FKY>47M9*^5A[>IKZ^% MD;>IKZ^2M[>IKZ^)D[=1=Y?/22`S0$@X5YZEQD_A",E"PI4_GTJUJ\+N6W-4 M=*=)DJW?(4O4%@^K'^/L^G0MT)F]_[9WKDV-ZT@8_D74D>7[U*FMXG*RRREN M-8'=CU,F48AW@STKVP'VUZ]D)R8AX<1D(J<E]1<(B3#8SRNIU6IUQS0`ZI/O MQ+7-PS*9I"/6-K&5ID=B$V@.*F'<EA67L2^#]%6^LL[0]7S/$P-O'(6>HX<_ MZQ,'T9I_7#PZ-NZ:H@)=4P<7%75H$Q('-[)\SHI2_M+FL#"<YKR\9_SYO9%] M!#'UL+E,,?6P051=T4Q.X#1R7;L.0W:/>DE+F0?I,ANG\W1<">VL!%&)EV6: M/2U/@EDJ'S\*`@?E\V7YW+`7>Y7C-JE\?`+41&@GDK^S_(DG/Z?IJ(77G%7Y M]C"T#E@01Q[0^;\#L#_O[`&&506L&E"QJH#:J@*0H6-5`=N08U4!TS%C50'3 MD&)5`:VSP6NE*8O"0%%'!]814-T@O1WT("=0`U15`"1!(MZJ8V,B!ZAW[3PI MI$4OO\F1>RXP;@S:#\-[SI*B$I3;),CVD<3Z$+JS`YRI'$I]".C\@*ZHCEX? M`B*W(/9IS2WTX\#>O+[='6S2D;8NH.LT2Y^K9\N%LPPQCDA(30@QOA+&%)OF ML[%,%]7^</E<'\#N$EF(DOIE2:U:YGI$IRJRU(\5'8L:/H"&I5WD^S[U/3WF MUP]VTK)RA7C(957F0K7O,^O!](-S.F#Q-@MJ+<6[_P(;I:NG='TA3DVRAVUA ME[QV8(?YR90J!Q<R!QR,.@G:>$GA0D;GA8R=&L;"L3T5C@5-'_!V3!_T<7,' M6.%8.(_'Q<*Q.UBYW5BYO;+"PK'F4(3LB()6?10R1L#!<\>M/@H3&E8?-0$@ M5A^UC3A6'S4'*59>LP2SKEG]CII;#S)*R#N2T/8+07*T_.RHL3R%F03T5']' MGKTE(@>-T:+CMZ8RQ"HLIH#$*BQ&LFVKL&AF#QVV*@O:8[WJ2P/[#+:^K+</ MM\I*`WL1MJSLME>Q()D1).%'Y`(J?`&3(!:^,)<I%KXPB"KFG]<3&.:?UP48 MYI^W:D#%_/-J\\]#AH[YYVU#COGG3<>,^>=-0XKYY[7.&ZZ5IC38T+`U_SQX M'0'5#=+;00_R$3I`^>=!$MR>',9S_0AJX@V(R6'J@>`JSY[6M\'L$Q.FP->= M'>"<*U!2X$/G!W11=_04^!"Y8=IIH[*U*4]_"EK#F''0!`TKSS@(4L.8<;"G MC(.@Z0.V?ON@C[8TL(R#<!X/@?AX2+?'0U0^'D<^'5_J9^D3#:-Z(G'])HS4 M][Q7QXVCT'.T3JJQEGI!/$DV[NKW/GHZCR^YB]E_*[E+--]NC*TW4#@R^MVT M73=3JFV7A)@0YA?GN+#3("Z:J2))&I*!>('Y8/;&&'3#&)RXI!^,>`;,`)"P M;"HP3X>2&-[3H2<D[O!TZF:*M>/!>SI"%%XW[7BJG@Z-ZO3QA(H7*S$*XDL, M=6F_*\+D0=C:_$6LUTN6W56/XFJW$S%2BN6]PD%2<*2=<MV+9C12@M)9C`(T MP"1+^PY5-.@T5,EF_1`D]5FN(`R`$]QEKISV9JX`Y+B(VO/CH*XK:B_7@XWQ M%XQQ<8^SSCX5$Q3EDI!0'-OW=BG03BX%V:P?@K@4U9=C0#V`JXG@A'J=5J*R MF;J)+Z!^(_(H#GW8N\2#-$NR49K,+K.BY%5]`J[G'5Y:`_$[3"]-LQZXX>!D M!L>/AJ<U_5%;0Q.Z@IJ1P0L#$@%5T%^,##71,S;).9/9)WC11+`/Q2514$<5 ME!M%?@`TV'&7H$XG)>.HIR/H"9;]#>GA@-OJ:.Z:='LX:K8ZZH?C$(\2]*[N M/0(X<B]J-\>V60\<T<C5:@[10$$6>E=12^JTU"Z8<'3"!9LA@FX6;"AH7#": MH6<+EP&H*`6*`JH@)-B!H!M'@0LTO+\S07O`P7)P07DXGD/I(L0$C]+I?1#* MD^<PZ<YHE[:9>DEMI%_Y*XG5/\<D:I+;0QU8]TY+8K&H._\#\D#H[60EI?3* MWQH^)Z=94ZCSAE4\?ZZ*435+^&4V3IO"+-BW=!N^L2_A!+&>V^@+$P30E*A[ MY_RQ6-0'F2!N\@PGAOW[E!?&4:311(%]JH<^)3<$&9>^\.MTQHHRSW8F9=.\ M,Y%%9UKDY(@<UXE@6E%CEGZ[8D_)[(_ZOU%N2J29H"):+P'(7!K+]Q0"('$@ M1B^/N#0$.N/?S9+L)GE>359]_Y+?3_.J2+*Q6+0,\HK+1@;QH&)NB8$&8&[A M<9-FK&0LJ[^_#64IN95DU*:Q`5PP8)U-#S4"CD4B\(6-Y5/B0\W)VE2WO4]> M3ZMRFO/U&63`QHNJMO5FHFAE$!4O#J,`V&3>B<I#QMDH?\K2_[%QV_",96R2 MEL4-*V\G"VZ+]^2VCZ#7-GTH'PW"*`PR/P):L[9+YWIG9SBGB'@^T.GH,T[+ MSR_$IT69CLZ;0L,F40D#-]:42MU;Q-PD*[+/_JQX6HS3T>&KBAR+#_7DBM-Q M"0'*9Q%7M`B#N^7?TZ?IJM=@^4%VX&K-1P7B^DX8`MV4[`A$K$I-`!+&L1O4 M(U@`S2>S!/+/9%;5KN?3V2Q_2;(1*\1X)2OH\CDK-O/>;K:_G5PL8O/D.%@4 M;&=5`DW88694N'!"UPT%G"B@D:O'%O(@S=*27:5SN2(2C^<I?9RQIKN<O5TG M_\YY/3:NUI%+1^(B;,#8BLL;NC-?)_FX3D@"5X^^OK=\I&=$C.7BA\,5B[%W MW+&\9+9>D"PZY:@5F"#V(Z`+QHY@OK,R23,V7E;7,8I.)%8K6M,Y'8VJYZJ> MB>HH3-F.LZF\VGSANS0%&"8S`X]'3$-0]W`ZX#G/LSGCI;0VS45DWQ%)3?`X MTGWF^6%(@5K;=SP7]UV^R6B!4BRUY,3T4U[C[.UC5?CD,>=)F?.WMHU!C-R` MQE#SYG5GU%1.9+QM(1?/^:1\2;@A%D,#B\:A!W0_NCNLV\DD';'V\T$E3/&R MXM+A,4A?Y2M#S/*:&8U(2($>PN[$;-GXBB4%F^:SL=QG:'^X%!9Z/J\G.C.H M^4%8E[J6!6CJ9"(!D<&AKA]!329RELSD=LYPRE@I]ZL_1)5?Y=G3>O'I0[D3 M!TG*Y;82.WN[KNMJUS(8\+J\XNC#CGK;>*5I\5V6L3U\'1P`TH$I%23VD5@0 M-P<<HU`[@O4FPLKF07MN)<_8VW7"_\/$W)J-#[9[@.+9+AXO<EQCQ/,PO.<U ML;?W$N,H(#4"\@(2-F%R$<X?>Z>"$@]A7,D$-.W?NYT,V<^$RPB^T4B&5;8[ MK>*M)[&0OYV\&T,?7#+3G)?KUI(99JV&1_>-.R^IIU(P8@</_AHDY(W8(1.% MW%_L$*I8M8JI0VLO(G7U6Z)",1+?K;E-O^9Y4DQ%?Y'?I/]SGLR,,?H6:4`= MAX*-,]B11/)Z-E>4`/1(2(@;^*L>IT7W%N^'0#<)MO>/?EQ.N_JM:1UVJ8ZE M2ZE1!^3-AR[J4.E3VJ:0_;8]=%9(XT-"A7QU##'6W4-<ITG0%5"@(:&G+PD? M;Q)9R]/1Y$XQ"H@C^JM60+Z+?L'34;D(3WL0*]+B^_#!-"A`!\]N4$R`$<3$ MC9HA:W,W!`,QNJZXVY?_$#>3\-'T[8K-V>R31?=E]K,JB[J%B[M\_>L:IHY1 M3EK)"4-84-DF*QOC:U#=YJE;Z^`?F^2%D4B*.X+.&YS8$7"W=9NP[16N7JRH M2SQT-O5N93KZC7[ZZQJFCE%.6LD)G4VH;).5C<XF5+=YZK;3V:2AO-#9I+@C M6.EL,KDCV.UL$M^;"ISHP.BU1U']>I3^NH:I8Y235G)"!P8JVV1EHP,#U6V> MNNUT8&@H+W1@*.X(5CHP3.X(Z,``6E*D#^'"9Z6<#:1[=M]+<HK7$<SL0&.6 M?KMB3\GLC_J_Z3/QC=LC`*QO#Y<*UK<W`B/6MP?.">L0Z\P.?&U28/5`^X2# M]4`U@H3U0&&"P7J@H.E@/5!]@&$U0\!XL)JA)HRPFJ%.L+":H7;,L)JA7M0P M+!C@UK!^TH$I%23VD1@&MZ)X?E$\&#^*`MI+0%J':$()!M,X*K)7K>D<!0E% M:X`"#_O4#E;@T:T"SS'4@15X?D4A?5?@.;Y"L`+/?F.(L28*UA:!`P-KBQSW MF*2&R6[UUS5,':.<M)(3.I11V28K&[W=J&[SU*VU*]XF>>&^@.*.H/,^`78$ MW+3`VB+ZLL+:(D>Q,C5,=JN_KF'J&.6DE9S0V83*-EG9Z&Q"=9NG;CN=31K* M"YU-BCN"E<XFDSN"W<XFK"UR',M%PV2W^NL:IHY13EK)"1T8J&R3E8T.#%2W M>>JVTX&AH;S0@:&X(UCIP#"Y(Z`#`VAZ4MBU1?IB!:FVB/)[IEC:XNM4:.]4 ML+2%$1BQM`5P3EC:0F-V6#U!(TAB2/2UAM132O%CL,'*%C#!8&4+T'2PLH4F MP#`+#A`8D%PMRN_9P56&*KTZ/;+#589&D'"5`9<-KC)@@L%5!F@ZN,K0!!BN M,H#`@+3*4'[/9*.`HYAHH6X==BC@>)YG<\;+]''&>K*%B&I$'A%+!UBR]$Y( M<.(2A;$5S3UC!?*]`E\4PZ'O<!9C1N0XOKYC1E/T]:RW'1K%>!P2P9O&2*36 M04@"ZC>2C.*P3FWO>E`/]@W2+,E&:3*[%$^#5YO!NO]*N!A&=IWG^T4)4K\7 M'#A"@,8C&M%7Q_?CP/>LZCW=Y5$]%NDX3?C;,)'1^"ORJ"?S"\:XN*?9^/2) MLUI'Q@D#IA"L!D-#ZKN1U0/L(8321C/>W6HO#D@&G_)[EL=YHM4.(;[$#M`I M:]=(]9"-&7_A:5FR[*YZ%%>[G8A^H/*LHEC!TQ,:J5S!MX`:F\(-@\AS8`+Z MU*:H\2P,BN(^OZOX:)H4K(^M'%<U(8=XE.":J?L2UCNA2I?M+0[<\H0+AM1; MGD$8``>SR]8Z[2U4H#\\N)C5:,UT3&%8VX]1*-V%`E08]H&!M+!5?L^^6#>% ML.[9KU<BH4K.OA/!NF?!V3]QOK3ZJK*TN>%BFG!6M'?SW"3'^%OS]N^_+7]N M+B%_Z\/OIT7N42?\\3"\V+C(XK-OXK.O7>F'^,=_?/C/QNE</*/W^Y>_=R., M$)Z4^?L@U>6O-\]F^^_7E[U@6?XLC)U/+KSMV;Q?<_.7?_]MY7_?>NL_Q64V MGIY\L\-C:ZVR'](L2\M*;N=O7*PYZ;RM:8<_L>[FV7[M]38=+CIL1O+M5UM\ M^,EEFNE!O/@_4$L#!!0````(`'N#9D;>2R9%'QD``$!J`0`5`!P`8WET:RTR M,#$T,3(S,5]C86PN>&UL550)``/9&_I4V1OZ5'5X"P`!!"4.```$.0$``.U= MZV_C.)+_OL#^#[XL<+@#+DFG>V9VIS&]"^<U")"T/8XS/7=?%FR)3G0M4SY* M2N+]ZZ^*>LNB7I9,,C-?.FV)C_H52\5BL5C\Z1^O:W?R3+GO>.S3T=G)NZ,) M999G.^SQT]'#_?'T_N+FYN@??__SGW[ZM^/CR6(QN?08HZY+MY/?+.I23@(Z M69)7CWGK[>2"N%;HD@!:F]PZ[-M7XM/_FN"_]@0>_7:^N)V\/SF;3)Z"8//Q M]/3EY>6$<SMI\L3RUJ>3X^.DNU\CPCY.?CAY__[DN]R;A1<R^^/D[%WNV06G M4<\VT/1Q\O[=V??'[SX<O_M^>?;CQW<_?/SNK_^3+^UMMMQY?`HF_V'])Q1^ M]_TQU/@P69PL3G(@_WUR[S$?2J\WA&TG4]>=++"6/UE0G_)G:I_$C;HQW@FP ME/F?CG(07[]R]\3CCZ?0S8?3I.#1G_\TB0I_?/6=0H67#TGQL]/?[F[OK2>Z M)L<.\P/"K$)%;*RJZMF//_YX*MY&I7WGHR]:N?4LP:46!$ZD)?#7<5+L&!\= MG[T__G!V\NK;1W_'#G_BGDL7=#41-'P,MAOZZ<AWUAN7'L7/GCA=?3JRML$W MY/QW9^^C^G^Y]*QP31E`M:]8X`3;&[;R^%I0?33!=A\6-RGYSIH&W'D]H?8C MX<<>@Z:ID*,@%LI3K'%:V^CIOB0OH.8_[P.0.^QCMKIV&`R40]RYYSO8Q85+ M?-]9.=3NC:!E\X?$,B><]A^2#GT$3S1P+.(.C^X&M-V:#H$A;FEP"N^?@`-/ MGFN#,KSZOQ!$=\KL&7"$HU*"5Y3YSC,=#DBW#M7B'4P"N_<ZGDQ>$/_IVO5> M_!MF.YQ:P1``=QO=F^Y+Q[=<SP\YG?%'PIQ_"6T*?+MW'AE\O!9AP=2R8*H. MP)Z8>ZYC.=2?VK;XQ(D[B%X?D(8!&?*9!K>>[\\I%X*5LXMFJW/B.Q90>.FX M84#M4E&P,&"&_NK2I0>2M_;8?>!9WV+)'(!-8U$V'O-NP.SA8O+VKUXM-[2I M?<V]]?*)XJ<9!C'Q.T3'1&(3P_-M"*(&9-E]N('RPL#AV^13OR0!R;UPD^?# M?G>]NQX0/C:/6ON9N#@B(,(W[)GZ@1B?Z=KC@?,O:E]X?@"OKHG#?R5N2".E M6*PW?2:.BT)^[?%[>)IK9P!>'8;.@S%V)$W>H]-#0;X/UVL0<[3V`LKAZ9YF MUY[=#@@[E;8[2O!WL=_40)_Z/@W\N(P]#3(A90MJA9S#+(O3R!!?R^`DC<VN ML3Z(#IT-"/&<N.AMN'^B-,!)S6,%_L^YMZ%<V,DHMQLD*JXRQ.#OT_OH3!AK MH+OT=KB1!ON9A]2^=<A7QP5*#C&^%7T."'A!P>05O@5L&60H]V"[Y(3YQ$(F MCS;0>Q*@@A4+^DQ92-'*S1<Y)#-D)`RYDL4E/[IV";>><"D$7;J>4"]Q[U,. M%#V.J_"'H$(94])O>.F!Y?\SO$A*#:$WAJ-%/8,6U%E_#;E/[:O7#66^2@95 MT#(@@R[IUV"LCT7>]L``BL*4F.(QN\`B!U-S#_]^G[Z&7/9XZ[43+[$8+$&% MOXRR,3UVG;L\#-P%/(P9/2[(?$>'@78=!E#@SF'..ES?PF*"SLE6E'Q@-N6? M/6:A428<"[,-;NY"55%N$._'.(0-RCI8<X,5`KW,H3#%CTQX.<?[!#IU.*3' M,.>\C3<\1L+8MJ=1P<W"`#?/,;#A"\'Y;Q!_7KM^1@663A3BU6PCMC_`7'YV M!K'-.W9X&*A@W0`**XB_E0?F!(>!7-?QN-#QR3G&T>!:&68,\<G$BZ"EEQL* MOT3C](5PN_Q0$,[L*R#+V]*HOWD(]N)`FEXQ@%&'(N>6%]LX`E0R6WTA_I4? M.&M$-6.7\&>V$JN.!Q^]D"ZQOMU;T!SU([!SP`0O[CR;NJ*A&?M",;Z(VE.8 M&,@CG?I^N(X8,\K`*(0SX#!%_O`E>1W/6FWL8APX&/MEARYN`J5>LB38Y)Q" M[U&Q80&V[70<R'&PW8):'K>IG;Z9<^_9\0<?S>;N1H7I7\9V'SR,MC)`L0WK M:^W1Z;B04>$D@1J_A,1U5EM0&W&<QDB(&_H<!S`*%2QP7">.!\"`G##P^/:: M@@I&_1$778!N77I7JQ5%>R)Y,BPG]B7F,"P2#H_I6HS*;/7`.+Q_9+@O#L7/ M*:,K9V@1Z4?"H.R(_#M)S-GG_)Y(MNN;>ST(`SIW.B!D^`0Y=.!NTWW<*&8D MMK33UV#XA>X@`]ZUQV'B^CY[`?677MIG&I+GYP/6+L`>\ES'3A34'#B/@3.1 M/%94SF`UQ;HMZ6MP[H+9UYN%&D%X:V.2/'@#8Y-"&7N,K@AG0$`:BC>F@,O[ M4H9RB3[0,02FJ<>Q$2<Q@OFXP4P.1]5CK;O6A0>C"4%'`L;F1RX&[H:)C3YF MWQ'^C0;8?^Q:PB`O)PX=N*`\(`Y;<H(NV&AID]$_I@R-1JJI/!Y-1D<F>&Q^ MIQZW`RFW^OZ4HAU-1-KT.C;RO`K-1[L=:-@[=:\3+T83BAY$C,T76:3;8::L M+KUKQ(G1!*0[#>-S)8KCR@5QB=`)/&($9KJW"E[`4C^4M/2E15LNC2A)^U$T M-L?0:CJ,U,AZ4H1PM!&O[V_T=:,\M.HPP]R1`+WX,=YJN@\98_.F&&@VIE#( M>AK=VMR)<L"RA_D0VO>M#1?&,[@[4C"^IR/>\CN41ZBF.Y581_3,-'8Z^@X. M[E5&="0[EW&,]6$&O5O_6G%C-+'H0\78G-G=#<[%<HTI("T[U@/_:"+1J?N8 M%U:6J^06D!=X`C4HL_'X3?04NQ\T1UA$PFF)AL,0UC+UER`&R`'.%4C`M"V! MQXL"$U,@\KJMB/]5)'<+_>-'0C:G*$BGU`W\Y(D0K>-W9W&.M[_$C_^9A$_- MR1:'Z@*/);$@Z<DE7ZG[Z:BA\*E"NA?4HLXS4E,\A-H.2%-M1<A*!Z<;L4C* M*Z(^7(>"E[+D6YA(YS.%3P',##FF3JTH09K&$,^)8]^P"[)Q`N+*$$E**Z%< M[)_)"(U>JJ.K0=H+991064K<DVU4BF.?Z:\&'!U;48$40PG0ZU%*;!-<$,XQ M]%;LSTGPM:NK!%66^JP60+F8"EJ3(&\\:'H!?YV@7JKDY?6@'H^!=@20JZ(6 M@SAYWY;]A<(:T-V!\>7R*J@OG)ZHI'?WJ(,R"C'`<L=/UDQV=37%6.KE6Q,; M\]9CCTO*UX74?M4$5Y140;$P8MN8-Q4%%=/;J#FJRZJ@NKA;43>Y5Y540W&4 M!&WN$K&_G&9"$P=$)*375%&!84$Q-(_:2?1Q;NT&DXIC.3(D+2JJP--:E]=I M[YQ#:<J+I!-N)0W"?PO>I-T\_7&)4Q\/N6!KQTY`UTG]%??6.RNWI#-/MFB: MX"E)+BZ+^/[=NZ/)BSC@*W[#KPUW/%AZ;#\=O3^:A#X0YVVBA:NNZ.H_H@SL M#V\!;.7<EV'\ZUO`*)E],I1_,PUE:=+/@VVYR,[`G[TA\)U]*1D;WK\E-K1U M9F?P/[PA^%76<8;T.W.05BQ;"[J[8IV5XCPS:$0;<-;X'C*X;V=8Z]U<&6*# MC*VVW@V)=.=1&V1U]4%=52H%_]Z@N5KN!*J:J<K;Q9FZ_O$-0I;MQV92_NZM MH9;YO3/(;TZV:S9;,M0&F9WM%-CN=E@&UJ#59#NPTCW[#+-!:\N6F+M&9&2\ M,$B7M^-%&U]E-GL;I-3;P:]TD&=X^^@VK0/JBM?\:4)O?/./FLB'\I??$(=5 M5T--[(8O#N)DV?8E9)>*J:#U9\HP)QM>]66O'>;X`2:]?J9I9O)*TIMJJ4"2 M31)X<4=T""H$]1GG\?:8'Z64S"5DNW.8T!NY'&3%5B(E=4>#)\]NWL<])`7J M.`QTQ\,<IZBKY<9N:36Q`Q:2@.MERI_A1W+'BS2$0%:^&_6[X?+X)&D^N2*D M=-',;CA)RTHJ.`N*-A-8"3>+9910"9-<DLX_(J5>O\G+*XES*))2P^FJDLHB M,R0FO'PW96K_;QCIMX8)?[#FU40B5-V94R^/]74&T4G578@LW,EAJNQZI5WM MU*7ZB/1V4ZF=VU`D+P$/K2#$"R8OG@A_E%J4E475T%PI*3NOE:Y&6RPT\LO2 MTDQGY!Y11\C#J7$C=UIDZ[BBKZ96FQL9U],&=^.ZT<AHGY8C7J&/C0S[4;!D M+JB7*KO6R-TJQ8RL6=X8N1-6N:C,`SXHOXW<5FO)P@IGCB36YUAOO#5KY*+R M3@Q3(\.+6Z+<G<8DD0^:#VIY&8$8>R[^C(Q,[8A?LE@W,AI5"KV%[]3(^-,J MP"W<U_M%H*K?9Q17`!1O[632"`!=-D<[$:WE]FZ2?]^_8;;#J14HV>FM/%0P MIR"U:)MQO'?WDD9_97NH79I0<\(9Y,&*;GR"_[M4*!58-:\]T%;1M2D2;*VJ M*MDS)@Y#TV/&T/$S6Q6.-J7GFF1;Q^TJJ\*5D-6\VRLKK6AGMB#J-ZP4`HMW M$LB^H9:5M<%5BG/M@JI<50],I2C6UH#*]31!$])=HZS^/'G'1K3!N?3V1BEK M0@^,<TXWQ+$308O7DXFQ4YNAJ6=C>N#.KH%&RZ(UPE(U1?$8V+>X5!;,Q?/M M@X]WS<;AAW@1J;A''"6MPFLF#^#8IU&-^!!-U`/SH6VC&O$A=20-R8>VC?X1 MIR3-M!%?B+[TIA:8PIS6'SV6X.C:BA9(I?D1VH*4-S!(O`DT;U%JHULUZ1HM M%!&C+NZ@G[X0;L/;+X2C'RXZJG#C^R%>`"0\LE4A*$,T.R@^[/V2DY=+[X6) M>]G73@`36N3F2#7^-;&R,XC3(+H6+7ZX[89\G`X5Y<E)$2741(CBHTLR46ZL MIP^:XN&,Z(Y7>$#QDJO.$!L;4XT;E:6X]0]W^X/M;"77I"V`=VE-!^0EYTP; MI=RA!35Q:9M8R<Y6@MEXHDHZC\I*JX\"C/?WQ)KI9@VK*HYD=@D.K&]!248K M=*J+*0^=Z+`TK/.-2@JK#1[JX<XN!1CN9:H;F:1C)*:U7N<9>8QT)*:U=A)D MAS$-BIT8QC-22NG69.\9>4QW.$X=8F5A9!Z3D5B\U^)4<L1:\QBA0WW6S0N? MC'\&S;_#LT]J8V?\^<Y\^>KH2"[(5U<GG^2HR>^/<7U7YD9F-SN`X-4L[R4' M=G[W,E?K$S$R)]'P/&O>3Y4D,C)3NCKNI;4Y4VA2D/+P7&D7,V=D6//PS&H; MC"<)BO[=?7*='*E&YO<=GF<RUZR19VC&^00KXT8EIW]_=]]<UR!!R=GA/_C6 M,B!/<ACY#_Y)PJ*-S`M\(';M1%L;>4#[0#I-&A!LZC'L\9E6CGW?[[2UHI-5 MV?WR,_Y(6+Q&P?-ZSB-S5HZ%KH)(]0"/YI[K6")12I+G5Y<;P#,<,/:XJIA3 M+HR_BZSCV0HL0<?"HZ>.&X*LEXI.70P20.7JY;;"XM-R*HZ9F1'Z6:`@=696 M\5"POPV.%JTH2PY7W$ZY=%##,+&!E:4/DF:Y:]^`:OW99TC?H(-H7S9T$1F) M7ZBM\:N;YKUAZ*\0V*Y>+3>$?G#EM'RBN!8/@U@G[^CBF+O8A"93RGVXV;CB M_#'AV^0`\B4)2.Z%FSS7;T8LWWW&\EEB8M<D.DA$:IEKXG"1N3PZ:EVL5]ZJ MROL,%.CC,CG%2\T*R/`#E6GESLVHF'LZQ^]J%J);DW4ONR3@9PXJX(&!A>TB MQ]$]%:5#DF=4W;]=4[B!ZG$,;A3;57N57<\/NMV=AZT%36*L:.Z%4L6\DEP: MN;LU+N_V3>RCN06AL3.@EO![%`R^Q:V/*+.>!KEZ,M)30^R.$OQ=)#F]E27R MG,=E[&F0V6]L@0*(FX61R&H,2V<1.B<NQE'>/U$:X,+%8X6!2':M\_$T<14U M-G'^RJ7F:(2NYZ0&:U[1,;%J:L2,)C\95E=)*QSB1O9N*+"*TJFW#9A6U]'' M@VBD_=&5"<-]Y7M&UVBJG@V>4"IV+M5,(TC%N<=@U!O2`U67'>1L?]ST!93$ M)(31X04K_B5BH*I)ZUA9B0M`?N]M'9<KRBND'A3+BOJ^^-*N:4L(LDH*<?Q* M+/'IMZ*_7%C95E17$6JHI`S'U7KC>EM*XQ"$;GB:*ZOU+#2-47H4KH.N,W(W MK14GVNH7(ZV\/APHS\!&IHCN`WQ')1L9TMP)>5ME:&3T<G=.U-38[W8BY4N` M8JP=:/K<@^V2$^832X2BZ;R.:0TBCI`KA4UO52QK-+M.=4&=]=>0^^G5U0'E M,-;5ER2@"5"US.G>R!BTQU<W[$%X4PL#49T)8.U='-4$MZT\ZD61>2)J:&U; M>?Q++;O0IRXA=+6:D@=8R,LKF6?[B7?CQ305PF;4ZJ,_6UK,&4:M0O86D,YS ME5%KE6'9TS@=&K6:V?\CJE&N1JUF1M*R._K$R&5-C=#'$*>8Q.E1_TW_;DC2 MO9NE%Q!77&:67HIE-)Y4J647\BDQS'*JM7Z]5EG4?`.W#TW1_:(ND.3Q^-1[ M1R)W6U"I<OM`[:YWS;%H^_*C_JO:SZ)5KN<P;E/G>47$E19FBR3V,%:P-PQC M]J`[/>B-<EVNX]C)Z+#L(V6ZGP&M(7M!LTONM2?V.@R@P)W#G'6XOL5SQTDF MM`?HGW_VF(6A)"+J.#W<+,HIF:A+)!2H3PB_E,[=;6LKV:9N1UO#=G6W1C3& MB6DVG^E_PPPD/>G:O2&]\7HA'P9OVI#6>)?0ZS`#G&M);\0OWC!XDW8T1KN$ MU2`E*[`\]D.;:T>/V^7;33R%G>:.FMVHI<+A^)/_?HSRBA^413FE:I1O_)!, MRLVT1OG(#\JCS/HRRGM^.![E9SC#O>JP(GRF/'!@C5=*Y:_Q"CR?'"6Z)\,L M:F=AX`>$V2!HR<T3VM*:.I3$JYD0WSC#V59_HK,,VZ+0`W,"_8E/KR?)IY6- MMP677FX<_!(\<9U)^:'`S.PD\E,\FX?<>LH<.1HR(9<I)DNSFZC@+\2_\@-G MC0R9L4OX,UN)C;$''P\DN\3Z=F]!<]2/^#0'=L"+.\^FKFAHQKX(/4WM*6@_ M\DBG/LPL$4\U84ET7'Q)7O5VAN;(!)93.W2CNY[B@V<8RH$%TA0.:GR'6:*M M:/=B-RUC1&`.S27\!V1,EE%NGQ857>;>E=YK^.D\RJX:W*-!0_"#W2>,MV03 M1>1WR+<2::H[&CQY=B'!]5`,ZTV!4OM;`:M+R53[?^M&.F#,8WBJ6@S?$<Y! MPCF/L.V"6HC)3M^(-,%^.F$?5NO%CL5K"EPF+E`3;TZ>4T97CFPKJ:F6"OT= MTY2RM0L0626%..X#,%KAH[N%GKJ.2T-=%:B2=-6QR'0;I9:55>+J!TA')`7A MZ0>K51-J+P)NI2SR<UBCHC32,.C-AR;U9.0F3,N/N7CE5CN]9N1^RQ[\:*=% M]MMAT="X\Q/\\#!*C8<\Z)M+1Q)WN]/'!=DX090-LSHPLRKVMD<K@T0-[_2; MSR"U<UE="[KKZJN<2%,"Z]*[20IK0;<\G5ME42UHSO;G@(T7A/,M+"R%T[LM ME)H6M$`(_[F`WT[0"YVDMB[(2O=SH1[BS]&-]IB-@;A=@+9H3`O<N(L1:2_7 M]5XPHK8MR(J:6A@,U:HO/0[1;0HPTK#NRXD64[G1IK6<'_NJ!:,M[!YLJ9OI MC(Q<VD]$*N=$(Z.3ZNRP6B[L9*#M$V]D&NBJR7//:U!U7%=F,)G]"R@\9[45 M%PE&MW+JM]6/NQS,@E6OZ!=C@T@0@D&U+3M*%B2@2^]JM:(8=9,\4;$5DM)0 MH*WNAL:2>=:A`15V9S5YQ8&:)@[.=+P*A3L![];R(+Z%-H3L:)"'P!'VUF<O MB!U3V?>0=SP,U_C!L((2+9@)8#\Y\M/8>[:HJTQ_]E##A98(88TMR.J+V2LR MA8W8D:[\BI(?-EXFV:LI73%7NZNEN;?V:O)@7W]$P6:#BVF/R?S`/5O2=233 MI<`^8Y=K1*E5W-TDR=O*@TSX1GI?QN>;7&$8Z9[IQ["]-)&1_IKQ!2NOOXQT MXXPL2BW-=R,]/^-+5U=;V$A?TL@26+>HDGB>WB*_]EM29(SZF^&1'V5/ETBK M-%T+O]QLA?>46MXC0PT%Q6,-I8_#+@WN%D/T.7\E5'8Q9>ZUFK,Y*1F8P"I) MGU1MWDL*JSE14F1??+]G(]WYPBKHADG"2Q1<1$8]R^7EE:JU1AC%(PK58V7D M\J<O\L+7)5G'&+.)\DM(."!SM^E=M9<D(.FYW_3U@OJAJU@C@^U*_:674BK6 M2V*FG/%'PN)0")B1?<]U[&0?:`[#!F7B>:>B<L8,S![NP"RT<BR\@C':-@+I MF$-[F.EM"2C.0:5\^X,-@@W)`TW9<44X`[+].>7">M=]^*3T+C%UH*Y<QMN[ MKUWOY3[<;%SQ"'1(*DO:?S-MR==Z#'(G"V^82*_*[#O"O]$`J8[3(:0WW6," M2\H#XK`E)Y@\(PXO2U'K/F9CP=5ZC--,#@9]7+4T:\WMO#K(WP5L$/.[0-!Z M+&17EIFCL#H@T'PDHF#;7*2MR(:\WH2P2KCW5L$+V"TFC4M//%J/$LZ(YHR! MA%JM.7PASP9N#N.[@=!Z/(HI]W1G_&Z6+BQKCN"TIE]KF4DW)\QA?!W)6O,Z MYRQ.7,>Q!]4<YG?"H/5H[/I\<_GP=!^&=L0W\?^G4R3M*_$I_/A_4$L#!!0` M```(`'N#9D9L+SLG:D4``%/S!``5`!P`8WET:RTR,#$T,3(S,5]D968N>&UL M550)``/9&_I4V1OZ5'5X"P`!!"4.```$.0$``.U]:W/DN)'@]XW8_Z#KC;C8 MB[A^SXSM"<]NZ#FK#;5*EM0>[WV9H(HHB6X6609)M<J__@"019!%``188"5` MU0=[U$4\,A.O?.>?__-E&1\](YQ%:?++FX_O/KPY0LD\#:/D\9<W7^_>'M^= M7EZ^^<__^-=_^?/_>OOVZ/;VZ"Q-$A3':'WTMSF*$0YR='0?O*1)NEP?G:%% ME$0Y&>SH*DJ^/009^K]']/_#(_+3WTYNKXX^O?MX=/24YZN?W[___OW[.XS# MS8COYNGR_=';MYO9_EK"]?/13^\^?7KW0^/+;5HDX<]''S\T?CO%*&`SAP2D MGX\^??CXX]L/G]]^^/'^XY]^_O#3SS_\X?\U6Z>K-8X>G_*C?Y__']+XPX]O M28_/1[?O;M\U</S?1W=IDI'6RU60K(^.X_CHEO;*CFY1AO`S"M]5@\85OD>$ MHDGVRYL&BB\/.'Z7XL?W9)K/[S<-W_SKOQR5C7]^R:)6A^^?-\T_OO_;EZN[ M^1-:!F^C),N#9-[J2`<3=?WXIS_]Z3W[VFQ-X`CSNGD3K!_?EQ_+UEGT<\;F MO$KGC*8:Z!Q)6]!_O=TT>TM_>OOQT]O/']^]9.&;_Z`3_AFG,;I%BR,&\<_Y M>H5^>9-%RU6,WE2_/6&T^.7-?)U_H^OTP\=/9?]_.TOGQ1(EA##A>9)'^?HR M6:1XR:!^<T3'_7I[68,?+5&.HY=W*'P,\-LT(4,CMNOR:@>_ISW>*P=]ORO( MMZ3G[W<YV:5TCMGB(DK(LD9!?)-F[.R<QD&618L(A8,QT!Q^G[C<!!@-7Q*# M.?(GE$?S(+:/W26Y&I?(!@[52-8AO'LB%'A*XY!<G>?_*,C6/4["&:$(IE<8 M^822+'I&]A`QFQ`67VL[T'S6\?;D:9`]7<3I]^PR"2.,YKD-!+N#[@SW693- MXS0K,)KAQR")_LEN4T*WN^@Q(8=W'B3Y\7Q.'O:<,!\W:1S-(Y0=AR$[XD%L MY5ZW"(-%@ERC_"K-LAN$V<8Z#>)Y$;-99HN3((OF!,*S*"YR%&XU)?P(>:$? M8G2?DIVW3).[/)U_JW:F!3*-!=EXQ+LD3!)FCW=V_C*/BQ"%%SA=WC\A>C2+ MO`*^`W0%)!W"/MUL`&619'?%BK1G#`Y>;X[Z69`'C0_QYG>[YV[PU!;1I\/3 M6_LYB.F*D"U\F3RC+&?K<[Q,<1[]$X6G:9:33Q=!A/\:Q`4J+\5VO^/G((KI M)K](\1WYM3&.!5KM!\Z]$7:DFWS`I/M"^:Y8+LDVI]Q>CC#Y=4>V:\=I+:)= M[[8O**#_;L];,^C'68;RK&H3'N=\DR:W:%Y@3%Y9^HS8."W601J;7&,="(/) M+*)X$L14-W'WA%!.'[4T:='_!J<KA!F?3/?MB@)5=;&Q^+O,/CH1QEIHD]GV MM]*$?\8%"J^BX"&*"23[6%_!G!81OD6$Y66Z!3HRV4.-'];W.$BR8$Z)/-I" M[P@`!"ENT3-*"D2YW&:3?1)#!H)-29:*_%01'.#Y$Q6%R)1QRJZ7:O9C3"!Z M'/?"MP$%&%'J,WR?$L[_5_)AT\K&O6$/%G@"W:)H^5#@#(7G+RN49)`$$L!B MD4!GZ"$?Z[#(Q[:,0'LS;5CQBER$(R>LY@[Z_2%SV11[TN4RJD2LA(B@3%^& MDC$U=L93[@?=6_)C1>AQD6Q.M!_4+HJ<-/@2)=&R6%X180+=!&O6\FL2(GR= M)G/*E#'%PFQ%+<&D*VMG1?LQ#F!624=D;L*%D%EN2&-$#QG3<HYW!(PFM*DQ M;"AO*X/'2#CJSC0J<K,BIZ9VZ@7Q6T#?/ROZ/+UY1D6L?BC8I]F*F3\(N_P< M6>'-#2?<#ZJ$NR%8S//JK'Q-HGP_**LF'A=U^LL)];JALC)Y,=B1J82@^[2Q M%-D6C,??`QQN_\@`3\)S`E:Z1N5\-P7A%RW=],`(C+H4#;4\,^,PI#:OU6]! M=I[ET9)B-4O.R']F"R9U?,VH%C(.YM_NYF0XE)7(WA"<R(<O:8AB-M`L^0U1 M;R04'I.'(7A$QUE6+$O"C+(P@.A87*92'WX?O(S'K?9.,0XZU%,L+&)J!*JU M9!MGDQ-$9B^;V450=])Q4*Y<\V[1/,4A"NLO-SA]CC+KJ]D_W:AH9F<5WT=^ M+$T9Y&*SJVL=,.FX*-,+9^.H\9<BB*/%FEP;E9_&2!CWS#D.PG13$0$GCBI_ M`.J04^0I7E\@<@73^Z-J>DONUOOT?+%`E)_8_&*7$KL"LQ\2,87'\9*MRFSQ M-<'D^V-"[>*D^0E*T"*RO46&@6"5'*5^9^-S=MVTB7"K;^.S%0(83VH197($ M,9D@7M=VW-)GI.*TZ\^$\2MB*PMN.J,=O[[K-$?9?5K/6;OD94V'M5/"#Z5Q M%&XNJ!M">>HX4^Y'06>.5I^OVSUZR4]BPO8-)J%#*$QM338_3&!M:E3&7J/S M`"<$@-H5;\P-+I\+#,M[J@,=8\/TS3@VQAL?P:;?(-^'H]YCVE.[0H/1-H$A M`&/3H^$#=YDP0U\2?@GP-Y33^2O5$G7RBBK7@5.$\R!*[G%`5;"E:,/A'W,/ MC0:JKS0>;8^.#/#8]*XU;GNZW-3S@6([VA;1F75LS)M7:-/;;4_+;C2]2[08 M;5,,`&)LNL@\W?;S9)G,[A`E1ML@YC",3Y72CZOAQ,5<)VB($6'3TT7^G7#J M^]HM0V%QEDHC[J3=(!J;8I1KVL^ND<T$A.%H*ZZ>;W2Y4>Y:M9]E-@3`+7J, M)TT/`6-LVK0=S<;<%+*91N<V.UX.M.U^#H+^W,Y083R&VQ""\34=E<EO7QHA MQ720N(ZHF>F=='0+#K55EG!L+)>5C_5^%MUL?J>H,=JV&`+%V)3I6H,;OEQC M;A#-B=W`?[0M831]10LB4.F20Y*Y;),3C:8L^Y%1*8CC-T?5P$T$ZUY1DK\/ MH^7[JLU[VF%$>,A4---0FKP-T2(HXMP,NF[W_<":+H,H&0QJV7M,2-D,;Y=H M^8"P(9BMKB/"^$2&P//B`;VM*6,&J6B`"MZP3N)X12!KP4R.&DI"&K=6_DJ' MLII<KX3@?1N$O8"EF3&/P4*@(1=."P2:[2A/L7`YV2(L@NR!K421O7T,@M5[ M>O^^1W&>;7YA-_+;#Q^KU(C_5OW\^\;K\"98TQONE$;S)?EFICAX0/$O;WH: MOP>$^Q;-4?1,H6G';NLATM<;"+.M?`.]N$C:`T%?+`M&2UG..II_ZAJ1HT"X M<SE.1J.`8%J[WM\$47B9G`:K*`]B&4:2UB"0,[.S#-#R(QQ<QP]9CH.Y=+NW M&\'!V7,J6VW`H=0BZG9;$*BWLHEQ[PD6BU[_JX?ZAJ-`8$K]FZ@J=BO;5GX: M8$SC`9C3@`0_O;X@6%%NIHK(/*MX<3$*W88@\,KUXC+`%3V@,*@R8"JWS'8S M"%@WL3XTW\`I^6^4J\^QO+T;T--L`(8(-+K`XL`2L.B2O]78`;@-"+_='@+Z M5A"=$-YNQ!L8A-3/OF,NZ0=;W,U%7'J8(>WNP+BISZXC\F`7#'WJN\"/7J7) MXSW"RU;V73'@@I80$#.!64=$$30$AK?W5A>WA8"Z[5"@8KQ$+6$@+O.4WL0! M<P&KDY6R&$X)Z(HN$#C<(NH]C\)-@%!#3T2K`\TC&28:'2'PN4.8OC+M+?*E ML@T($5'U`,%@H]ENRG/'+Y'LEI2W!X7^BFR.2_)G+]B\(2B\S!S9!VO9"`9. M3?[1$8[1F$?4X0JY3>D8MS$)\'PS;F4R,[7^5;T7.%U*5:.;*=,^/=\1S3:" M686V'SY\>'.TPE&*"4J_O/GTYJC("'#IJM1=.XV<^H'C./[H,8Y"=I2C]I/' MJ$GX0([<'SQ&;F-RX=C\T7%L)-):$RE-#7:-\Z=/_N-L;)_@V'^>`/:Z5G>. MM>LOB@;6(HF:(^CZ<Z*SK#+<W'U/Y':F)F)*^8K?Q1^=1=-4E=GB%12J-X[[ MGR:)N\)<4*-.5GW:J(NL5!S[R6_Z)K+N<AZ[(*LT7G/DW64\=D%>U9KC[B[[ M86F72ZQUG`+N\B?]MB$1[[GMJ<JY%7<%1&-,91Z@'%EWY4<S9&4."1Q3+S@4 M(TP[SB\ULI^]X$DTD%5NWL]0O$<G3$2$:*])H_4$"^00SEP#K28+)5*BUK%W MM%_6MI5A@\^'#Q5&9<#(SS1>#H6_O,DQ,WY6/Q(N!+WDYV5ZFU_>9.AQR5;? MR4VM1Y!M_1Y?8'?Y2CW,])D0CC,0.RF,2E)BWC*2"3=X]X2#GUVMI37A%86> M"IP]=%?%8RX+M=U@.8[N,H9F.$I#3CBJ[K*%AJB:QA%Q$KC++YJ10,?9A7/) M4[FNE,+L)SW&T>$8SYN`\L)/*(_F!-Q#@,:8\/[^"3H@@ZSV#+.-$;)':9/0 M6H:"1D]@C!@0V7&1/Y$C^$]^8N28='HX@<%EEA7ZT%>MG8"\4==/%_QF%WAG M6<-#H=D9'B_-H]'3R14\E`=$T<$5^/N/25^O@T/PP2%XT@[!!Z>-W73(F[1( MTU0B[T593EAT>$P/ZG*[2F5==F\Z:O0^1A!<>3XJIAM6T8<P@N%8MAA*'Z() M]%#5TE;X$&%@C*[JF+IL,1B$9O>,NFPI&(2BY(`"F0/<-%=":\9+RXT;F1C9 MKFG;)1*IL0DH-V.?#4RI&M#O[U#^/#5&RCYF6'3S%--?R!1_+ZK(NOM4,A^] M3&G-)EJ4/GE&.(_(R6WS#%L(6!T:9K7Z86<'ZB$@0@[=:62;L;2KMXB<K2S* M$9'KGZ,YY2JB-+PM"UG3!JKD":-/ZRHM?PLP#I)<J84U'\<S`QZTP45Y%W7; M04!;/EQUM70E@<5MO83:V+0KN>TO<%E8K;I%L@O"FE%/9)RADK-<Q5$NLDZ9 M]K8"K<;C4`(B`E:_LQ58O\3/QX\8,5Y+>(YDK2#VXS7*N4^19!^VVX!E2AJ6 M4-G9+,H&EBYG3%S;CEE*J"6-08Q%08RJ]_4Z6)(_&Y4EE5>P1L>#L70X!B?& M&(A[@&"@:6QWQ+P^#>/T%DN4Z6`@[',PL1]R;IGGW))P?&S<4M`\*S`YXJ7( M7:G9\R\!_H;R#1=*GY2L9OU$K.$NPX'17P9OR7)3)7"+_>;Y8E1K-7Q0Y^AP MOES%Z1J5XM%-@>=/089HPJY!!%",-OZ./G]!>!YEA!NJ="Q"J<MTB/'AOD;? MV:?L/CU-8P)KBH.<"`0TA4\BEM)V&F^OKIN^"26L<YT[1+<IR',WSBOT[ M_A[@D$EQ%RE>H"@ONBH`>^..OY[\`MN<Z>$/A6HLY]:5?9PQBUU]-\B4OP,& M&G/EF#;=VB.O,YI#J\?`M?S$:X[I&A6D3_(`[.5CC;Z3=WK<92.,#K6]IUUK MN'WB,_!A5P[CVMFQ_ZSK#SOZ6MIYU'N'<FU-+3SIBG%`L"T>LBB,`KQNJ(55 M&BAI^T,@@D-H2I30/OAH*ZW)$I?!#GZ?)X!?SQ)^=M?Y7!O%'J\QCJN[+NCZ MN.K[_W&\W?5'U\9;9E_E2#KLA:YM8Z482STE.*I0GNBO)%6::3B?RO361%:R MV5W"5V===T+W$-PWP>`^97X>[\/;!HARTXEZFW2<VQ#%^W3"W@:J;*<3$#?8 M*CV=@+G=58_@077[V0Z&Q'"XCH2:&,/U[SY4D1B.>X]7@0]5)79<>)'YRX=Z M$KNNN1IO7_F[G>WV/A23V/T-U##@^Y$V>;<SH+\9)LT3&NT&7UG#W3T*_$B[ MW$L#DSA`/W(N6V-^>M9=,R6S7T3H]UCPH:CIKIM`DP!>LX/6TCWX4/%4@QX& M(<8^E$#5K.]BGI#!AQJI]I#?+;.'#Q7:]&AE6(K"X2)M>OANQ<6#UV0;(ZF6 MV,0);K?<:_ZP3Y-`4^Z86*'YV76S>Y]K90M=#4\3W]+#&:5D>T6E5"3^UEQ' M<8/+]Y<1<+9H,VQ4AJL='[=`'#Z.10P$3.:&#V4`R6'N[6DU[\YIFN6U:E@$ ME+BA]=P_]2)(#9>M=51!.F2X\?`1:QLN4GP:9$_&Z.B-MF]LFGND-U&3T5AC M8D*=%/,-S:[2[PA?1<M(>0@T1]@;U%]7JQVA;HPP,M1,F&#EW3-Z+9-7<.BV MT1AL3%R:IM/AYU@URKZ@'[H`\C%>7YZUFV#-%`T5+Z0BJ5:70Q8MI_$!*L!W MR`NV"P:RV$YZV9YLJP"W<^A_)<(@;GA3,B>ZC5>%E)>W-C98!C0+P-\&R6/) M%Y5_"1B5O4SI/0T9E[9?&FY/"49#T1$3-#CDWAL,?4=??LA:=X@F/T233R>: MW'8$)YACU"N)X#P$^-GT![+&Y4\H)G!4!M__\$$C0\Z$`@I'E5G\#SW<W6KE M?_3A((N*_Q&'@PT"_@<8#K)&3224T-R(,I$XPAWL>!,))ASFB3*1D,)=7!DF M$ETXW/]A0K&%#06L_X&">B9;_X,!50Y>X`%^>_6./?@Z.Y)K#-H+>!K>ST.R MCT'[/U/>X").OV>721AA-,\!*V6?11G5>1:$B\./01+]D^DW"`=[%STFT2*: MDROR>#Y/BR2G<8-I',VI?:,.(+I,%BE>LDY`Q;,I:-DMFJ/HF5X7#3E$GHV_ MMQN$D4PK1*L.4Y9A9C:(%:>1X^4C2N1>:<W/=N;+<D0X3G%%1E$+B-6DAYS^ MCP8X/)-KC,8<D5/UE.+\'N'E)9&DJG62K*3!`':<],E<+-8/HW+[D$E$M!6V M`Z$PET'(L9UA=L.60=T2YU.3GL`8;6N8^S'I]+`4NK%<%3G"=!>NZ'K3/9@N M\N]D,OGYT^@%0U_"_2<Y+N-:H^P;66WZ0_"(/DH)K.@"@<,9Y0>H-8(`%3T4 M&VM#I6W']#W'B%WZ>-UL=+RD+YX$RQT''4Z'#,W?/:;/A/.)2A*0/[8Q)S_] M?D[8CWPM=%3M?'8*FHF7,+>SIR\*G+"$>^2:N(A>6.H]I1^LHL/NJ\]80[RF MX'_>_(-"_KD!>?7S[_]]LTUN_@&"DE<HR%AH)>45ZG]<+E<X?2Z?:R5=M;N/ M?\:NT&,0ER=)X"@F:@%![R_!2[0LEDJBMMN`0$DDR%XH6VT@H+Q&.=.:D[T6 M$:GV9/TU0T1HF:T0?7V3QV-RA3VS1#7T"8J2@OQ6?4REE45W'!2(#LUT##*T M&FVLO##7!5WYV>(B2H)D'E'1/B-GJQ!15Z,#".4JB&[1BDA)`4OD]JB2L10= M(."?+1;1'-5,L_*\BMM:V0F<Q9TMREUV'[S<I!G3)617T3<4K^_3$W2+@E@@ MFPP;`R10#:?DJ.=KRNM2$:6FYLGZGLRM<%#6Z>D41A0J99R73D^G,"(7^:*( MKZ*%3,K7Z0F!$7,`4^PM_AT,.N7-TVP!`F'#TT2YI04-/8,7*+2R"4C#XI*= MK)M?5%M8?P`8_-JEIQHEN*@F9"[5KFMTA`DD94S+KRA]Q,'JB6;*4<?T2MM[ M#3U4(/+&LM>$2"?DK=,>!OKM2C_7:=[0"G&?KULJ$\GTI,;#N(%K1PFFC5ZW MIYT`[&*Y#/!ZME#:7Z\DX8F#AM@CW*(P1>/N^]7P?;V3:/C(A_U[.\FTSSS3 M[99M%#Z-M=H=1J'JHSAU\77<S<40'R>*Y^DY[A@(R^UJM1H2*3P)^AT,#43K MAL-TO_74AQSCAKCWZ+-\2"D]$&.5)<N'!,D#T=8W.\%G3=:Z[#HZFE;EXJ:* MQ(>K2Z#3:>*S9<3R(>=_'T9M@Y</:=SE6B+.VS7][%S*/*#R<S;7);6+A'>I M`G_B]*X0RXB[P2IJ!&+TJ7/8?FY(5UX4F3%!BCJ%P!<*,2QY+E->M;.^2*D` MOS/-$J'LA*X31[&3$647_1%/#6*BQYE@%I5=B6AB8G`Y'90M.LAJBSB8&LHB MRCOY,;F<4\<6C4RB(US.G6/ESA5'7KB<0\<*VCT.9R[GQK%V#)0!"2YGQK%% M@?X`/I<3Y=BB@I:3D\MI<VP18M?H%I=S[%BY-,U],UW.OF.-Y5(X_KJ<>\<6 M_N9.'"XGY1F/*@)W#Y=3\UBY,085O78P38\]GDL19.MR1I\1"""/FW8YY8\U MWM,PX8+[B8*&NF)UK)N^I`RR@;"68PMX6J']K+V!S0J\VNJH%!'Z<54H_S!- ME#5L)!4!?G0ZTQ)/:72-<JIVWKQJIT$\IRIX,O%L<1)DT9R<]K,H+LC&WFIZ M'%-G4D*@5B[+BI=T(EW3%L!4=X8+]I:=O\SC@LQ#&;W[)U3ZH%58=["ML&./ M/D3.([(E0PI3]$Q$MGF!F5Z\B4$+_(TUI5XF55(+.V.#9(+:#?*3M7@`14S" MF#-Z2,$.VVB77%<#?>_'I`W-KZ<,N^GM-B%<@"*)]E=JW`Z\K13_RIA144MP MB,M:#?IPM]J#Y`=@`%P2)N(%A?<IS6=;J[9Z`M:UNKJ(D_(<:':>*%Y@T<&$ MU8SF>97M_2MA=[/;NZ_JF'%E'Y!8P*D5^)T_H;"@H.W(G"A+"=J=!";:&*[H M[J'$YBBE(/<(?94T7KE?VFU@W7OW($FV-.J][#BX2EG/3]@QNKGI<#R6L-U2 M1EI^UB;HLKR/9;"DIW/9E=-4I=`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`?T/Y19&$ZLM`TOA0@L/#$APF M$(*[J8E?4?&OFEYL`X:$=0H3@Z;GZZ7J"X*5($V0VH-+W@$"_J]W]X3]SPJ\ M;C#8*O@5'4`54_U,N=AZ/.1`@NOJI.XOFJR]V*M%>2XG[*PR@&CF"B>74P=9 M),0`;8[+N83V3)DMS8[+&81&H8S;&8(&H&RD!(//#J3UTLK5%\U%UE$:@+^C M&HNMK_S8SBFI9!S<RW2T&\(J/M@'3TLSK'NT3O`^EYKY\#VJ+&&U5(8OGG(# M2TLX[/,ZL/R'@UE';>IV6B20Z#'A77WW3PN5=@+<X7.`*Y6&YLO;]%<[8ROB M*WUT3#1$6Z6X,G47=-J_J$YJUW&+<L7EHLJ!GQ9;(ODFI^W'3^1RSI^R&::\ M'\(-0;XL*2#4F(XWGSO.`P?GAZ&8;.K`1NRDE&5@R[^WJ\"6OS:NR:;V@#T5 MYTFX71-9LY,;\-_E`<[-,:BZP;M&'%PY)H3/P50,9])WBP9`.^%@,'?28-XR M8U$V;):T2@2)K>8]O0ZF_UWTF*_*]N^:.X03NM2#0P2P3;?W6O1!?6G5EKVS M,@%<P6F78OKBGP]64JN(EW([O)E4[[6=DOU_KPX/3KR4P!X`[B8A@K%=`5EJ M0:TY4S9B:5ASM(U9+EMSZKH>EX2QQ>37L@"@$V'N=>3Z%W;^4!O@NL3K<98A M>H!9F_`XYP'OR2T]L3A*'DOG70@C%0.N!HDC)S,R2=M#J!9.@IC0&-T](5K< M8\Y>#H5R7-K<%=B529@5'3R''ZKT@+EZUSD5=GT2RX-)8+N*@H<HKMB`\LYI M7#2DP75*Y,3FO=-GE+0[AZ]44JG![8WO`'4$\#(`OR;I0X8P*UA]F:R*G'Q. MR0L71^PHGZQ9=Y9S2'D/C#;=@7:#IP.Z@6MTFA`I'G!Y>V#HZS__*T*82`%/ MZROTC&(]5%2=@?%J<+87&/VC0,E\K8>4M"<H1NPP9(R\'Y4/O:J'*QA\,L;@ MDV,8?#;&X+,+&(CVMMZUK>@Y.8R@WY2F5-Z]8HVQDX_A#)8U$Z!WK%1=X9VL M#DYN^OA,+E^1ISEVN#JWD=7R#JT"3-:X*D><$=XH^'N*JV5GJLT-R54U@6P, M[2---K^I"Y39G>1`)ZU)H!P6?7?MFXQ#7)_^O6FQ4NF+P0UV>@9Z.^CZ8I[O M5_`;A:@#.1=)/?9&T9PW=X!%I?.$?0!'7P:%A1,\5Y*VGX!U`X9PHZKT?>`W MEANT\CMX>%_;2*D.]Z<VR:CDLB,K@I<M<8.8<LZL(M"/KYQ`"DM;1:&?7.9% MQS:SFB5&<3?MS3[II.=X"I501T^`[35`*QAZB\0%9Z[TY%\GJ.6&^&Q*+PT' M`2'Q](Q8+M%#\[CU>1;T4:-CIG2)!GI[PC()W#@8!F]4O]&Y]TAT+)X^)/D= M9*$6DD+DSN)#5-LH%/C4I8"[>4!'H<#G+@7@$X,>,OP:NPOT!_JXDZQ1[^&W M:1BWJ439-IK"[R.]ZJA>D-,7AF0<R[MQS*IF\GT7@][<R;DH,_;4C*+$Q*[1 MT8'P@D-XSR&\9SAUIAJF<'")A\?@]3E;CXEET['NX`YS<(?9ASM,@T,"ERJ= MLYGJ.#0X(31J:M]?CSD"WCSCBQB\+Z6LNUGF]J64U5/,`POZ39>:TW2Y2I-6 M>IL;G)([.E^3&Y7J)5>45E47F$0V/*WA&5J1&[ZT'Y._8\2V4!)6Y3+9[QOP M;PC$>1,'F7[`UO!6`KOH>A0YPO6P9(J[=)%_#["X1+5N+SMA9\%#BFGK=3V3 M(NY,VAB"T[\B!Q\]I7'(6(G-/RZ7*YP^H_Y`$^WN5N@\6RRB.:K)=E%@<C&0 MDTOFOHA>Z%]B:`T[0ZR#]/R<K'MB0W5Z.H41*\UJBDS9R2D\^M2,&AV=PN<: MR=X"91?7<#A^R'(<S(?@4G=U"B=ZBI6:%IV>D\,(O':$'$:M\A$]W6$%9X/7 MJ"D-:"TXO&2H)2N/1P(GQ&.I6E3_N1/;T?N.Q815F<-(I_>6@4?N[8*_X%76 MHD#%*8)K9T?$W9X4[X.^R?H.83RK#PZ@!KP0#S*7JQ5\\/@<@K*.G@?>UW,< MW`VT&SY$9AF2P%PA!1YR-2#IO9[0H'7U-?E04W;224V[PJ?.27AKRP!YPPG3 MVC3$.@'U+6)LQ4V`*4ADZS1^6-_C(,G(:TO`L.',*%'8'B\9/L>/&"&U5ES2 MTHK:^'CYB,3YZ3J?(50*QQC36D7+JA;$-5D(_DMSG92:>--17@VFQHHBV2[* M<A3'@<+"L-4")L/_*LK+DFBG:99GL\77A+V<8?6.D)O@_&4>%^2L79`WJBE; MG*PW;\T,D[_^CN:J]'QCS&3+5+@DSW(4Q%^B&&4YN:P5:Z9H#;)^!)PTN<O3 M^;>[)\+S9I=95O`'87L-)*TA(#]#"X0Q(H_,,TH*F?YSNY4#D-;_F:>/"=W. M>J!WNUG9O><!CM=GU(TB[;$C2UI:@:(1%M+88\*]V-\>Q(&5LECH*B+7T662 MD\<A(NQUZ3*WB6OIR[QO,()C&'+HKH.EVM!B.LJKP=06U\"J>!'.FKV1\L,L M:F;'-26:$\F4ZA#N$'XF_U``(6T+XIC2`4;]LLC;`T+/EE,-<-G$YEI?(-1@ MD7N76]@<)`=V\!(MBZ4Z]76KC16JU7S?3;#>I%A`])KX2@12W!0V1$0TZ`U" M4W+K]=*TU<8*38E,=HT*PO47V;R(`WR9A%&9HTQQ_?1WLN-$EC\AW',==]I8 MF?DFS<E&H`42ERS"MMPJ5/''-LMI2H1'IO&G^LF-(D0$WK"!@%Q`Y@B%&94` M*3M(U6@M'E'N`-+3#P@;*JLJ3U.[C1=0VN)UJ%!/A7RJ2;Q!F*D2R;I]24,4 MR\^:1B\(*K+ZX0KY@'\'@TZYPLT6(!"B:/E0X(S=/6K63=@4!F:N(%<*$X*& MT/`V%)^J7:OH8>4.D$S`U6R;_"\RONED?4Z>MGPMNBKL#>[0:FEOM&Z?26!A MZ_613'*#T:B;;]CX#JU<=K)N?C&_/$0#P."7(1JN=IR$#;5H0P0[31/F872? M5GS&18H9IY]1HRZ1A=GBG0<XD2J![<YA:=^+0!*_N!H=QH>),?5MX[0QF*(Q MK$+>EJ%HE'6I7MI(4V1UHU2H"S<<`>:D-&T7K1OK"\J?TE#7)C)@("NKQ!UJ MV-F274Q7D@B=86/`AAOH7;YZL0<F8\'4NPHPNL'DP,A0X0WL[*=E0$XHVP?F M>BO]SB"T+!XREFHV/W^6J8/5;1V`NB<$4M;:$<C5!>JD[;V&'B@\BP(P6S3X M,<6N$;>%<Y@=Z!U5^P_KJ-]J1]%/[@8)[$H'F0L%Q]W=3-F[XJYA>*G)\-G= M:)I=R:#R`>/X3_<(&/`SG!Q0P3-Z(:DC>C9NN=LWC2?@<9IZP:H0Q'$BC%4W M$9BY.U@KRY&I!Y)+=%'E`]LK6=S8,!I)L8;YF_&P/:G+%>=`)H^]V`F)$P"J M2I96W%K7?%ZC)_3GXV@Y'8"J0*OK%,-Q@@HXU[K".F;ZY@75LI+[</4(S/JM M0GUM#SF^1.YR\GT8M?W3.#/J\!I)G03JT]0*../E#MP5.W5PV@I_XIL/*@19 MC_73\)%H71EJ\S;\):)W*UI$VA>V3<LQH7%$Q9&I?%M#)5;898$5MGS9>CNS MLSL9B7:R](F3$QD9T2:8J<@:2=OQ#2XGZ+&&LC0TT^7$._;.4,,DZW*^'6L( M:WBNNYR$9V<Z:,2!NIR(Q]H^Z,0UNYQ[Q_;]+HJ^`T^[,_JN-_=><SD[GRV: MV/2N=;EH\:CTVHE8FO42O2+6+BZ)G#`39CLM>S5SFDV06=TERI(39H),[2#7 M9DZ1";*W$O9.><M,F,L51^MQU"?(ZAH'_W-JO$K&MTD`("YW0,+-`6[SS7,A M\2<%5Y;NGQ(-0VN%_:?7A+W*H%+1X_,KHL<H#F<5'7]X1724QCE4M/CQ%='" MQ*95D>>G5T0>(V>]BCY_<,%.K;+.]\3Y]!P59VR7>D9;&\CZ8HWO#2128-NU MQ4-)7GJ;6!ETU"KV8>K6#[_26AM[+`(,V>R^)%VOI*HM:\+:4MKUD1*>^YP: M&RJAI#310$/C,EML_(K%(CCEL45D-1]D#-@K;<,.@/>-`)TN9=QD4!H);08D M^=#M#$W;IJ]>>1_>IRV&7UW/<]!0#N$\]?0[?:NG[#1J,IKF`3%.EM/M['\R M'ZO)97J3_/2W/Z2*\315C)/Q"\*8#`<=5FW$9#CHB6KCZ>\U5`FN=)>=52W3 MQ%B@<-F!=4S:]`HL+GNVVB*,QGL-[^KZ6H-AM-9?A]\VMNU#>60>PG\\\!(Q M<0^?MK?JD+OW-?NK"HC@'H]JW_5;VZ,*B#GUPLKOB^U'P596*]ZR?SE;[M@, MC[H,\GV:!_&OY$,=*F/%F'4=)6'V91UD!*HD"L@$SY&JBI"BN;WZ04TT>\H( M"9HZI)[5B2-H5AHWT>(:CNT9560:0ZM#>T:3WGRQ=L8&5FNS$ZVASJ[:02N# MAU-<4T.\XP3`N@.+UZ*EN"VG7-LZ<OD85Z=,7-]UZTY0AA^;_()[S@]KB<5' MBZ=35O&>?EA;QB"+E`4&-[8,DF?M/)"6+O_FJS)I^;>6&VOC3'C^0N.5+<F- MO\;I0Q"?Q&D:WA.X@A4J\FBND!S5':S(CE_6Z;<`AU$@AV*[R:%VXT&^/<BW MCM!DTO*MXU2Q5R?2LWIYE!5OY6PP!K([PD$G`:V34.>L/2@E)J_;<2*2[Z#= MF9S<KC),:[H`35+-TZ/U4N:_F::&9^!.$?`CX'H?,%58CY;!#P_;,0C3476` M^]0>=(.`NL$S])"[Z_%"H6O[L3#W>93EE4KR,ID7-$V<$]#2)*)1OJR"Z.EV MB<C62>8TX-Q9$BN`OB4_5G1V'=2+(B<-JJHU5RC(ZL1Q+&'<=9K,::+PF![^ M&;EN`MJ5M<L<02UYIMF9"'@WN$I]R')Z*S;.?K4$+(G-;,&`4BJ5!`TAM!I- M,/I4IN*V(%#S;.[*BN#==C#0TEU+'^R*>&4!AFHSH_"C%/J^?@YA4V;5-T1E MTPD.#\%=TK.CU+VLZ%//$.&<(A1WZ_MT-:?2ME8@.:=)O&/JU<R>"<+1L84[ M*S!]&*)_%%$HU>EJ]X58_7,R?;ZF*:;3A`"GO*K%;>W0]V6.Z)W:N*AXT0JR MT8YC-AHA8D%X;OI>TQHFLT5[[PFI;V=DB+6YO)DISR#_;F4-K@LZ%J54R263 MK5H\Q-%\MB"$(%M5&%/?W\D*;.30S,G8P2.ZB@A3-TLV\Y;W9VMYSU]H:OZ, M\FXGZ_]*8\+0"4'?>4R(/='>EB6DQT7^1*3&?W+N<FNC]'1R!8]-01IM'*H. MKL`_*_(L#Y*0;'L#))J]8#`154C:$BN2L/R!B$](=-7N.!B('3.@JB$V/ZV# M/%M(JPUNVR?[.\+:91EH)VLFIN@96KL]0#`@+P:YF`RX4%4/.`Q.C#$0]P#! MH%$@3@PP;P`"7TYX-:9>;0CA"I\O>7M0Z+=8Z4P'`V$?&"P(#9]*)J@$ZCK- MT>D3U7QGETF55/PNQ\6<JMEX6MBJR7W*N4;&8;%W4(K^*).Y0[>2%5C%D2RY M6F\W%W'ABHY;*MS*]"'&PX#@2O94%$8!7C>>?M6)E;:'LP[*];'MXJ@]NB"7 MJ^B8H:ID-L!+I%A&4\*1\,S<KODM*=7Q8D<D`=<[8<\B;0+U*0Q\<!?:"=F6 M5.Z#*]!.V':+^KKKRJ-_R(55J]UUQ3%8P6&Z%W`G'!M$L*KXA\]Q9W%;:!A* M72[?;+8#-,P.+M=E-D-V=SL&>(8_>T=?VZ;J<C(Z\\?,6')V.>&<=?3=3BUG M"=W==67@*>?V\-[5KC0NES#6<J1H(]OQV7*Y)*VYN:R^X.7N.RY7)!Z&L,!G M@R,)]%(/\)27F@[;=YK4!@,>"3<:SG(=L(]U=,W666RM`J^7JUFNL<]BV+J< M!4I5\#UMB*?*MMC$5?)B^8)NGU&FM9,U[G+/(G&ZC*4%WW]98<!%3C,"41ZM MP:DKR@2JVD-8\&HM$F,L3X*,UKM>TE`51J1-U(K8G*?9V4X)QB7;(AK^SI*6 MEJ`X%)[L[J'O`0Y[,@RUVUBAS0DB9QD9'#YU!^C8&H]B@7YC16WS&;Z-'I_R M2ANWT3]7'[/J:R8-^!@TEC-8U^I)-"_(:QBA[#2(8Q2>K+>!-L'?8%3@J*J- M?H;I(VC(+WY&X46*RP#"C<E&AKOQ.(<8,@-H-9W?53V<P$#I]BYK[5#$VR%^ M;V#\GO-1;_7H&@``W@EGE2E8G>)RNQ5(M-UR%:=KA*IR2V*!XIKN,<+OAHR; MS%@>@^9W6MON.LW_!^6W:)X^)O0FNT%$7*4/2O43;2?;PWL&8E)T9F=^QA0! M,HYG/W.#4K675Q"U!(>X))T^W*WV=J)<F\/7#BUQD&3'Y%4)'DN!8&,(%UVW MAB,<8I^5NV//L<\VH=Z(#!N*'B_3(I%%$"B[6(K?CC*:(V6S/^4,@Z0E!"5K M1[-C0IEE>;%2;=Z<W,OW""\EU.SMYAHN?TUC<LABL@5N@US&'AD,X`I^MU'V M[8*PO9LD3X;8";M;.0W<@['ISR64\_K;VX5H<_A;,REA$O<`V0-10NZOB-HW MLAP7+-^:7!<K:PT$>92CJ^@9A62W!<DCC;`A6Q'EV<GZ2_#W%#,]F1H;[1$< MPY!#1VUORE?6=!0K9^-7G&:9V!-;>CIZ^UB!;#,HE09J':H(''%#B'UP%04/ M]*6@2=8V-P@W6DJ6O:>3%5IV:QW+>11I6PB*5EGJE')+NPT0E,Q<OGE,9]\3 MA+.G:,4]GD_6-*\>S8J9QF3^Q[*)'*.!X]FI\!(_:VC?!*WL9.)!N?ANV9A' M1,#T=[($V_=^)K_;R,[<48)RA!+VW_4=5>0U)'4J!BL+RNKUM0-IFK1$]8X" M2`&H9E=;<&9YD!>D_;JI7U*"I^IA-1-5R0$+0B.J&M/WZ6F0/<4HRS86U9XC M8F-<D!P]57;2BKMH/O>R"U39Y9"32Q.SV:+:WJQ,WGW:N-AZX%?VM`4E5;>3 MN[XY:^-,_I5IF"5@:G4%V>OD*J8LOD(8:C6!A%$IS&PU\@1.6_69V@&:6T%- MPCVI[`"?X^TZO0E*T41&1UES>-A]S*\G8F7E.BO]?BYA(\FV8HB;;!1+YU@T MZ=>DDZZHK[4[=)>PB)J=G,$#EU[MI7''!)=VQ_%V"6YZYB>A0G]ETMTZO'2: M-F=)1.D^*,6=(/;&+8T3554]K;^#0:?4735;@$!8RGSDM<[7/>4O.PVAX6V$ ML2CKWLI[.(2!-O'=R+<J@2@[63>_F"^+:``8_+(<1]3\RZXW^H9GMW=?U6=9 MV>>0Y?>0(W<R.7([:ME&Z:^3-6]2Z>&8GQ_[/ZI:B9+'4@4CS8MI<PIO::2, M++$Y@U<4JKRY:J^&C%65NW\*DDKC6"KO+I-R_9EO:6U6M4W,W8#QBNX;532/ ML]6,0!ES1B\I6&'Q'$2LPMI%BG\52(:C3^<5[68;E[S2()6U3M1E0MBN)(OF MHYQQDZE]I"G;#356S+5G)!**9O*?8K\A^HJBL')!9Q_/B``SVJ,S$`HP2C_T MX_@@P;']?-:X*/G&,:;SEW;M5V!4NFU-Y17-MO*K-A2;E8G8-N7Z)W3R9LR4 M8@7+_9"$6G;74:8ZT,QX*EL6;S%L5Y)BLEI=1H1+5!BJM_FT*A+)Z+5"\V@1 M57JF,L62P/U42#O-KH?*28.AGV#E)%7N7PEBAL.`X5IZD)3AGB5/6?)&\CA6 M%<H#1G,.\VOTG7T:A"CO;.>F:_COWJ)51;@OP0L-)BCG%=YR&MTF4J=I%^K2 M6-"+%&]YF8L(*FDY(A3TE]9;I?#)-1S!&M3W*9/A90[GA(^[3.B#&CTWX_6E M*`P=#F(GW].@^=GB,@FCYR@L@EBQB\5MG8#ZMRA_8K9L2DC"`=VG+!^`VLW" M=)17@ZFQG&()5VKW7I"378?#T5BKA2"\-J/B52;^I":$S2D.-.J=PI;$>_\] MO7]*BRQ(0@+515I@=0R6LKT5B+XFY`WZCJ,\1TF[C(P<JMX^$#NJ\G94^D6T MVP!"F1'QXP[EY#:C6@):U2)[TH_^-1S$RC[9S'F?;L2%OC2(VMW&SXJ-%D$1 MU_K8=EIL89;:3BTUZ\HZ3Y*&@U"'W+8.T&>_=5-_\J,JS:YU4__@*YH::=UK M)/_HZY;5R9_-L9QX::&?H(IIZ;U;/;E]FEC:9;;A;V:MEPN(/FZ\7;H4,LVQ MU*2:<0(C>++TWQP#LS+5EZ<\:0Z_5Z`J>.G=*Z)H\E8%7C\963.TW#C%_=M5 M[`)0[T:UNH'O2'<+H_8@J)_?AG.@[E;$[4-6-T4.9]'<K0<JQ[5FXD3)DSEJ M4'6\M6Z;3HAI$[%6A*</MXP@)+6)SU:^-7[2',9(&L+*9;UF22=^5;I;/EX' MIZVR47RIH&0YO=/4'\#;.E_J:%DO3IQ.P&]CJXIKH/%="U4E=Y?E5<0%RU;; MIR4>ISSP3^X6/-\%X>Z%Y2YG,P!/4?),CJJ[W/D`5/OMC9S%<U=7/*8#MY0' M;I?CX/O#X2,_,IFT,G)R0CE<*WY/^ZDG104_>D![*HCC-H%,X@3J':'TW]_@ M^.%#Q1U08,+\9VHM1^$O;W+,PN^J'],D1R_Y><P6X9<W&7I<LL@>IW:1*9$$ MUH]N8#;GH=R[7X8B;.Y-SJG@'L.Q$Q4TO*TY[NX]Q$-Q5]<"XAB[9]L<?,AW MK5++B>*>[L,J4?H+%G-20-EP[)%"LY('1]D][FD0RI(2(1Q/]^P#0W>Y1DI8 MCK9[4N:@Y=6OO5>C_M$])=$@U'L22'-\I\/0:118YFA/AX/KJ\3,<9X.YZ;* MS\WQ]9]OT\VVRW&>$%LFJ_3.D?6?\1*%Z7/\_.>RQ`>V60R`8SMQ7FLKX3C' MVW]FJ\9;66BGQOC39'@L@[3M'/OI<%S&A1DX$:;#?_552>`X^\]_M6O;"NOS M<G3]9[\V2WQ6[6(:!Y&T'JU/_O-;NC43.<[^LUV6*K!QDDR'4S,-2N4TF`[_ MIE\NG6,_'2[.H)8]Q__S1'BZOE+O'&'_V;C>"E4<V>FP:SN46N;D\)^3VY"C MK^(XQWDZ[)SJ@J.YCII83X6_LU(3F)/%?Q:PI7D;*>4OIY?__.'NB<4X-?SG M%(T*'7/$I\,DVJP?PPGTPT2X2.WBTAQS_]E)JUNC+O#$*30='G3,DC8-@DV' M2VT\KJ?!*LHW>-^B#.%G%%ZD^*+("<.ZD6":9/"?<54F1.6(3H17U<X@SC'W MGQT=E&V6$V`B_*562F6.M?]\I+47H7H'ND7!.+4.S*=9&;":<C_ZSY7:HIQQ MZ2I.Q(DQN-8K*W%*38S1':5^%Z?6=+C<P8=SQYJFG);^L\J=8-DR\Y9XA&OJ MJ4(IPZB8,;HTOU/'I>LT_Q^4WZ)Y^IA0`4NBT_K1?^9[=-)5ISC%U4^T7>LH M^\_&C_/.5D4U.:'\9_?KG,(Q2SQ=V20Z?:E9)LE:=]2$F/ZA-7XX,?SGZ<M` M'2FR%6O)C"P;DWPSQ0D0:_Y$>N)Y\8#>UFEMM,G0JAW7W@_2&F/@26Q&0=@D MV4]%@4^O@@(ME#]/"^6>6G05TC],"^E&#L`*P1^GA:"B>EB%\$_30KB=0[;" M\0_3PE&:-KM"]X_30G>KOD6%Y)^FA:2D.%J="6=:V!JE-=_0P/7TU;VU:`79 M+5I%'L"Y24,\555KNPE=.J4>?$&WKP!GZ[W5R+;G$MZJ+//*>HW*NZNO<*!+ M%%"L_%@$\"5S_<""D(WHI=K=KIL$U3U]D2VTS\DNH;Y24MS_X)Y"=<R:CX(P MINYV<,_$,39)]$OV\8VC9\WX\WM.I"LR7?EC^[<6Y=!+SK)3;\!KT8Y<E3F. M7MZA\#'`;].$M$#OYNGR?1Z\I$FZ7+]GE.31"=T,?K,BSPB7%Q+"U5[K`(4= MA1G%%$6(Y>TARE(*H6EO*QWXJQ[>8P!4.'A@5CI]['K'<@9KDP2%^O@;C&JE M:*JF3:19,+6ORXAPM23J?IC*YC:+RYZ_K"+,QCYCD:9=2,0-;<(P2[8JG0BF MYVULSGS_/>V=F;>!%=]Z7[O>9)N>B6NV$/9%/--X3K?YS,;)<3EW]`X8-DXH M>%[H0Z9T\'S!PY(H3\=W<><DRN[)Y8,.D81[`<^;/8IU1?$0FKYKSJD2[HKE M,L#K5M3F\3R/GFGV/@#):,LX*91SVFU`Y+>N4DDLD77:04"K+`V^!;&X+034 M/75;A-"K^T!@<3=_0F'!C%B#Z]V(A%3[XX-09[10@(L4+U#4B`:0T6^/$(RH MQ[`!,'/&YN!N13VUF!Q]C<F^`9O6+F[[Q^]]"V]-[Q5M91I'BP-[10^=G`IV M":4QHY<4E,8@CT,^V71@M-LAT+&17[0=ABPSZ8PXH5=[KXM.N3UL;SKI/)Y3 MRX"9V??LGI_C+=QN$148H^3QE":6#.9Y$<0TW\<>#K@V)#[NY4J:*.A3D(1< M[S8:<Z@][R2I"7!?[`:3YZNPOUWL];X5QDN/0C'13#Y2K.$JMYWX9A2ZR>?S MG'JC\IO=>3RG%L#[H3N[C_RF'#<9E_=I)'YS""0^[N4RE4[)B)09PU/Z4X/= M/GY\Q.@QR-%>[M7A\$R(^ONZCK6GGR9M`2[O'8'R\4XW1GG?J@6+`'IU3DJ% M<YFP9RRY3#@'F'U4HF(7Y=(,5<(7``!.[BRIIP'WW$G"368)I3O**%/M9Y]) M(=LVNVY9706Z"NNF^'W!YM?NE*7-'8,?L`N$EW16)MG="Y$-(+!W9W2O^;JL MR@R7:2:W/8B8,KACH+<R),C.T4EXL;W6RCXP6"C2&C;3I]8OMQ0UXX%`XX*$ M+KI&64$'\0<^A!`I/6TEE3Z<"2#J]9T?S:>U/SN5PQDA]T(5O6R"<%DC.Z%9 M]OWW6N2P1^L)1GR-3/O1_.?``PS]HZFQ!['+07F.TMBH&IF#`7Z.DG5("`=X M?*%_9-;*M/_!W0Q:=LD)H2+F5':OGH';FU;H(,;)Z6[*N[$V[2ZZ(TXW]ZHI M.';81XB7JZG_T5WM!03U]V8EX0MP$"YV=@+DQ#Q($3M9U3DA7YW<,$!]SJEU M8/\'<U*R\!%.W-<B#.S=[Y>3^+6PKB,&/G)BOA9^%L3R7I/YTVMA7/?OQ,MI M[&[N0$>WLJ&S#J?T00JPS$'H$OX@,0Q^^G1)?.".;=_4NI1_E:SS#C[V@P*[ M.+E?I4)]!W(/RMO`R?TJI98=R&TSQ(6OPD'<&2R>;X<JUD3]_"J%&SLW22>3 M$Z?J09RQPHCH1-URHGLLV>P0.-0N-ZU,'<M)!26+.%T7TMT<U8)U/>2J-LRC M;)(_^9`W66-\)V.O7G'>9$\H3!5I6]P_4\O30@H7081'2:9A%[AIK<LAU_*^ MD'-OVYO"-ZW5N4Z39R9XC)-4QGC^B5+7O6UO`-JTUJ24L\'N^JWIITQ;]S:] M*7Q>K4Y'._5*JA[XDG'F$*__VB*W78MG/T1J^Z@8=RPTLR,Q@">OF""1Y:'; M'EMXG*:Q!K-ZB)\?7QH[!-,?@ND]);.)LN<0%PXOW+_":'+'C$C3B$L?QW&E MX[#R48^[=L^#@_[2H=\MB@/FX]0,]]PB09G40.3XD83GRU6<KE$YWTV!YT]D MA@S$$R1F@Z-0O%&H-U>2R52=FIU!*H=O*(SP<S1'DF-0PD_^HAXZ\_0QH3F1 MRAOX-,WRK$\I:7L6"$K]BA)RP\5D5QZ'2W+,R'XEP#ZC:O647C=Z?2&PNDS( M.4>U(]I5M0(*?R=5#X<P4*J`U7TF@<7O,%5IR#V.R+/[1+;Z&7I&<;IB_HT: M9T2G)ZR?FIU;3,]GS>9<^]8SC_2FB)7.5A=EP@KH/2R*+H\$KV'C5C6T"(HX M%Y-,XVULHM]SA8/;A?1LB3:1_OV3"VCWGPVMQW=+BNM_Y7RPF!ACKLD%@ULR M!IB&1WC>-4[*,*.Q<_)_K>YIFH$K-4GV6Y"=9WFTI&_#+*':H=F"*8J^9E'R M>!('\V]D&<@456Y#&G1-/GQ)0Q2S@6;)EIKI.,N*9:E..,2%R*`\0PN$L52C M]5N4/UTF8?0<A465\;BU:GU"O;7A0?4>O1$SHI;@$)?G1!_N5GL0*2I@'B(4 M%JH@G2WNR4;)@GFOD*O1$58JW/$8Z(F#5B9QTJ]/IE:O'Y3&5;^)F3VCB)+G M[):\)+;=(+7G]:HBIPJK42IL]D\XF=WXUS0FP\2$"=KW?MR:V7N*WD;9MPN, M:.0[PBC+]T5/X;Q.4M,7+^A]TJQXR*(P"O"ZP2JHZLQ)VQ]\N%WR5K8MO8C5 MQW:XMPGKC4==AO$?#W!%U)1(+.-XX!7Z#A!Y)+;<!U=9[S9P6X#TPDU66W_2 MRA<DTG*!VR4&Z.9M*EE<CMURB#0*OAJ\&*E##IT*M2Q\\36]+&1]`E1K5VC< M0YX9LTK#W'WP@C)>`/(R6:1XR?8,A(&)D)*PL-'\-"V2'*^5BGYQ6ROE["]0 M2*V]URB?D7N)4"-YO$JSK'3KS5INO6?D.IJ7!KDVF#L,!.>(1W9#5?PS7_?Z M0G8:NP&WAN^@H+G'L`.Y/-;@T)2^9&.C9+[NLYVJ^[B"A<HV)6\/"OWY2[", M$G9OWR!RC^<1JV:P40H<S^>X0+)\,*:C`&/*/&Y.4$(>RKP?HU9K4,BIWTPR MC^*($9AN(<*^1GGO69'V@\"F]8Z=!ABO"</`0EDD:"@Z6'FKY>/S4A[_@X)M M+L*LKQ5(;XB(0YCMX)&PC_7BWJ098[VRJ^@;BM?WZ0FZ14%<%M_N0FP\AA7( MQ7Y_%7-3;T@)`:G?DVP![`P,8GZA#FT$;.K/%O]W@:,LC.:]SBE]O2`P^9K@ MVJ&/D+RZ*K/[IR#_+2WB\'*Y(G+.^6*!:$9B=B')[9,#!X/`FRK):M_&[T$R M1QN5`F6QL@SEIT]4:+Y,CI=4Q)!@;#R,"\[=,CZ_Z[@IXD[!U44F+MV[H.J7 M([=<D&CB*A&Q32-Q74>S]WX&+YLLM0!K"5;"[=N5829LH1U.IFT1`MPR,`:V MYL^;#S9C;3+LHL?SP:YKO!]4@IL/QE:SE=>7"GVP@@Z_ZN0Z!W@KC>TUMR2E M^I"]R(PPYHH''Y('&1^*H8*N#WE\=F&&]#3'G%]VW4>@5Z6O%OV\C$QL&'.Y MB\1I75AK<^Y/$+GYRF9O'`.;`ALD:_I@$=*'_)["Z7.4U?9HYP#.MMEJ>GJN MHN"!.@I&SM(YX_)!$OZE(!?_8DW."CGN5!@`B2[M2BS<RZ<FKE*]:C*"&RI' MNEDHWX*?4782Q/0G;=Q$?=W#BDB9^)'F0J-AXE4!2'G*L&%C.8PU2R%8GZJ= MD&X/Y1[.4E<8X^X.XJ9RS-#J.D&<@!Q/U*#UI"?0[`R+E^A%YH]YAZ^7HJ@[ MCLO8JIQQS,:`D\Y,SJ%:AZO@B.`5.GH62+/CJR:'B(SP!CLMZ^2X9'#"<BFU M<`V^Z<1DT+I`)FP)LTQ.I6SB@ZUL#_202C4^&-'V29\M^<<'T]H>R".V-@(9 MW[05JX-8-GVB#(]'<T>[UK:WT8BA("\(![VNS%#<,!?DZ#[M&!L<1^<^S8.X M]!?(9@N)0<5,=Z@.P2';@WGRD.&%FC]U6YO!0!S!<E4YF;[F#[VPZ?1V(P3E M$/9S")QQ.7!&<DJ;=U$]U>9&H@Y`B^HD#CG$]@9WR,';S(/;)<C/T!PC6A&% M<`Y%3#?3!>%3;BB74&:D;;HWF*%I-K1#-"%[30#X:8$QD5MWI8KIX,[3Q<I> M,1O:<U=X!]1)ECS$>]A+>#6J?32U>%>O_-[Z$+?(#H#[PAT"!=QP%/1#^6D+ M6T,FRP>]IRW2&/(4/N@\QR6-@@WU1_OY.MU**R_@)&2*?/)RMIU*.Y^=T&#^ MI0@P@2Q>7T1)D,RC(#X+\N"N6"X#O)XMZL_E)H5TT;Q.62!2#6==)R6;X<>` MG"ZF>"4[+DOC*-PHWV\(T:E#?ZF4%73FI*`<;D2.Z2*:!TE>Z>K)[KTAX\TC M,C?!XH2(9=\.1*"U5JL?G"3&>8`3`G1&KE&6P<WMI9-"R^Y,-RE\&F1/%W'Z M_:Y8K4K>EMP<]2YR_*SH`N\P_2]9C?GJSS/T0!^6+P'^AG(*<U5Q&<T+'%51 M*J<(YX2UN<=!2"V1S!^J88=T>KW&0M;A]:USTWISJ)00.TSIYB50^>[</2&4 M>T-X$P0<7H>J$OP-83C7C92AWEQ2!O`W5V%'8][QDDA7<G-<\[,5X^%QEJ,X M#L3!1:(6,"6F^5(HC=V"AM#P-K?.R;KY1>%N8#``;"DT&:#L1/#S+<;2>!BP M;&>L?&>/GX*@(2B\RC)S[49PRC?YR:[M&=LWE`_J5AVTFA<]O)Y4RY9J?J^U M2RAWB0)N695:F.3GOI-KJW':)FQ+TB2(\=,`;EG2K\`@O%IE6[SO@'BA#U>Q MQV7*F4:^&2JHI\M5D2-\ER[R[P%&_C#[`[&QR/K_&J</1.*+TS2\?T(X6*$B MC^8*SES=P8IX\&6=?@MP&`5R*+:;V$EM3&TJXJQ&M^3/I$#-NAZ\+#NK,5ZU M4/*@8\T"@GVT?"APQOXU6U3Q./:QUY@%1M@28=``G1HM,;F([],;A&F-CXL4 M,]S)M=P3,FUG;,^H0N'ND;)MC'T0YOP2YC0E!(N'L<U96=G/X/*&EO!H\>C6 M\F8/=P$O@4(1IL/B@/OE'&12.S+I:)PDN,@*0QH=-A-<.V=5FK?RF'DNZ%/[ MO"]BO`16AZVDI^ER&96N$$SAL/&OC)`WAE(S%!Q>BQM<)1ABR='=)CH#\2F- MR=62E0XSM*TO6T8;>H=W2^WG[`O150`[3&?VH):P;YRM*][#%\(;8>#P2G1] MRQLU<]U>`CW0>VC_Y_<4LH<@0^0?_Q]02P,$%`````@`>X-F1B<SJ[D2L@`` M"LL)`!4`'`!C>71K+3(P,30Q,C,Q7VQA8BYX;6Q55`D``]D;^E39&_I4=7@+ M``$$)0X```0Y`0``U%WK;^,XDO^^P/X/==G!7@]@)Y;\#F9FD:2[%SED.D&2 MGIV[QJ$ARW3,'5GRB'(ZOK_^^-#3UH.R99']I=NQR7JI?L4B521_^L?;RH%7 MY!/LN3^?&>>],T"N[<VQ^_+SV>>G[M73S>WMV3]^^>M??OJ/;A<>'^&]Y[K( M<=`6?K>1@WPK0/!LO7FNM]K"G35##H$[[/XQLPCJ`/MW#IX+OU\_WH%Y;@`L M@V!]>7'Q[=NW<]^?1]3.;6]U`=UNQ.DW(=,EC,Y-\WR0^N71V[CS2S!ZJ>]N M?&0%M#G,J3B78/:,8;?7[_:&S\;TLC>Z'(S_)]W:6V]]_+(,X)W](VW<&W9I MCSX\GC^>I_3[.SQY+J&M5VO+W<*5X\`CZT7@$1'DOZ+Y>4C4"?4%:DV7_'R6 M4O%MYCOGGO]R0=GT+Z*&9W_]"XC&EV\$9SI\ZT?-C8O??[U[LI=H976Q2P++ MM3,=&;&\KL9T.KW@OXK6!%\23N7.L[F5)`2$PA;LKV[4K,N^ZAIFMV^<OY'Y MV2^,X4^^YZ!'M``NPV6P7:.?SPA>K1UT%GZW]-$B7PK']R]8_PL7O=!G.6<< MIHR#,6(<_A9^S1WM#%C+SX^WA0I-,[1$IPLAI,/^8(Z:$1.]!<B=HWDD*.M> M8BY.G5N:$V5D/3M#T&$V]_Q<Q3FMA45FG."&=%\L:TT)&X,+Y`0D^H8YYZ#; M,T(C_RW\^NN5;5,H!!2J#YZ#;8S(U8P$OF4'$3>NX\]G$ATN8OE9EXP&/B+> MQK=1+9.(QU-3BJ_.C'5:.;0+BS_([7Y^.@,\__D,S[^.)M/A8#SZ:ICCT60R M_&I\-<Y^28A!1`V^1/3^]R<A2+.Z!30RH;L6%#0/4_#*SWJ@Y=N1H/1CA89A MBPO;H\%F'70S#W+A>RLI;XKX>])&N:B%'WL;_,%189@A)M@W:1X^'8\V5(45 M<@/RR0O^&P57<V]-@P!GOWVF0+^FM/_8>8:'TVD807//WC"F/&`W):2D__5' MPY$Q_-IG_O<>$]OQR,9'X"W`2KQQS4G#&OF!A5WV3>"!B[YEVF0D`]<+8(L" ML(1P$"RM`%;6%NC80!V!_HUH]A'@8/N?!!;8I0,>MASPT=KS&;USN'5M9S-' MA"86FP"P(.G@%>;DO`[\N;$H@046`QT3F1-]6R.;-?%\*EZPH40%R_.31(B\ MZ-?2,]L+BMDG0!D!Y00A*Q%2MO"%<0/.KN68V9)9]D)IJ5E41-6C`Q@+ML=9 MLUX,;C2'(0_6UIHYZ&;C^U36\H%UMW'[N<N.!++#^L2<CLT,1`F$E#H0TE*: MLAREEYG1:RTH:9"@%/A63G*2I[Y*4#PB&^%7)M$C<M@$YL&BXR`B%0^QL)L" MH!3)(NU:8W/:WX%,0K,#(54(R:I%3S/*9G'DQS1AOM$"3E5>F0>L4LOH"#&Y M@:BJMT:`JQO21^.1(8\[38:O1I7G.(ST7%-"VVAJDT:ESHB4&/%D+*8(G_X& MS:\]=T,DT)C3MEWL[0L@GSP-^[T8:8P.A(34@^I8K3B$.`'%,"GVI1U0%&C< MU/(4(W]#6V+;<J[<^0.-(^%?-QX)"OR\9F<%"U%RDDGZSF#4[PU&8O7IQO+] M+9NPOUK.!H%%HA6=F>6PUR%`EHC.V]E;'_:+-W/P"Q>4`'9MQI:M,OG>YF4I M5IMX2\N=1_,36'@^1,**'Q+AP6;2G\-GPE>7:-1?."A<I[*%3L"7II*5)@=; M,^Q@%D+A'4W8X!L.EIC^["+8(LMG*U#A5ZRYZ_DKRL=;L_=H3$][:U.A\`(< MSWU!_H_M+U"=XEEFHEM$'"AU2)$'3E]-S#NE\CP(WI2ZF,H%IWHA*;W*5,-8 M"E.(NP214FE$3OOV4XE](:0'WOZ@9V0!ER*F1TIQK'9F6KM4Q#V-4EY@.2TH M-6)*/3-F;)HAHUK+^5,QD')RJ`)K:!4'JM^65_33(2[4?K4\&0ZFU?%!AY?H M32I<%#(NM016Q8MT"<,H!-J#[RT08<5;EO,128ZZ19W:AUB!)/+!?#+J9_&5 MI@B,I!ZC<".*BN26SK<V#I^_B/0VI>\":3%X53AE#L#*S*,07;]9HK1!"E6[ MC=M'TXX$\LM'O>$PBZ*(DA[@.4HO#IJ(`EN)T``@!7Z5`XP\U14!8K/:\$7K M]XA-J3$7BWYV$/M`IZ17*[8Z\W_\>XIG5JNT?:!/**"_??AS@]>K4@@U0[Y= MT#4B<PUW'B23S8@UI'EW(.;.!X<T_PY$$M!/3(8.;Q*+T2S"\VJ!M3+C@-GQ MCHXYEY"VYCPE`K>/E>*M.'(T"L"=6-/<(U`<G>Z#)?+9+@(?+9%+\"NZ=6UO MA>X\0CZAX'[Q;+U5>Z(4%36Q1D:T&K5$H_%^2.$L(,,#!!-XQ]C\V`'*B:W" M4U[*,H/3&<3<-8C'#6)G#((Y$TU"0AVO+T"^M!DU!?BO:#5#_N'N$O;7"]1" M*%GO'4U&H^D!<(8O@H^ZU:=3V&$/Q<?902-49UV])IY3IE2"Y/D<!WR>_V#A M^:U[8ZUQ8!6Z1D'K-E&:+T*-E9MX<AU3`D:*CB`0$E.$NR8T,W<T6U-27:J9 M7:Q9:T@J=[4,;DI,H1%*RL>XTC[J$5,OAH_[H[A2*XN;;H(;U0-7<XKNPH@K M>BNGJ&(\E8Q&E?9IIM1K_N\-"?BVFV>O@.<M(1M6PW2_N/'<5SI[Q3,'/5"J MB)4M/05%FQ,;(MUZF5@S<DOZ\'`T[AEC443V&Z\=HU-#.R'*:G`$52",+&#* MFBVV;'R^E7&)V,Y&[,W;+L!28:4PI,6<X=F#W<P@!?R(/]PO("4!Q"(`ET%% M!9<*Z_$X&=N$NMD3=1Q$X+K4W]8;G_4(6%WA?VU<Q,ZL,.FW,P?;E`AM2_V0 M@!7`#^-1CSDCD*7EHPZX8IT#1QQY!1G[YH?)Q%!72=9LQ$OJS!I\I&K2IFKY MG]B#Y2>EL,D1G1GQ(/J(_MQ@@@-$_>D5V^B!QZ-'9'LO+J?"XUIA'G!BMJTF M;Z?517IV,1CW1OO!,M@/EDDZV`$N65><@Y.6C>VA":6#4#P0\D%*0%59I$X6 MYP&6HS@THYUBJ#;[;`?;V02VA4>C;:!D3O"T=G#A2]MZ1'0+8K%DT@"9F!.C M?DCB&0AGI'%\.=`8X;8]V[$(20X"8<!E<6-%/XL$C-K(TG2-Z!`@U(X16?/J MBOA_6;Y/L^1;/CL[PINR=#3#?4:X.F/CM#;T0U8@>.F+_B-,LC<?^R9H$<DY M5]D,:SH9Z!X:<A%3-SKLFU]Y@&")BFMC!WU"0?(:^-F[L<CRP?=>\1S-K[=L MJ]ZM>Q_MI[NR`_S*BZ2KBOU/P4I5F&E(_AH5]J-!;B2*!>'%&=D7F_1G)@]$ M`L%L"^_X3DOL_@BQ6)#(I7Y/@G(CFSE&]F,CL[CE4"'$26P!36:H?3?"I*D] MIE8LA-K=#R=$=V&\:_*I-?.F8$'=[A&Q(WA1DI/EOE6K;M_ZFGZ),+('M$VH M8_?$0CTG!R&]]"SEM"_5BA?C&U//4*A>Q9)Y8SJ:A^O8S@JU!-*29><JLRC) MAQQ.',WY`L_U[@+/AS?VL7!%6*YSFSF+E$32R?_0-*/#]2+"A8NO$!)7E$>< M0'$SJS@I6"[E1Z&>2G&*EIG7ONI&Z0)QF<:MI3JU@)M)7N3MU4PZLN+'GU^] M^(B?&EJ2B.2W;#T%R15#=N2:3L8#(TP^!"&(*:E*.AI0R%"@4$6:T8!69GVM MVDDL2C&3I!3%)C@\F2#(/G_Q7B_F"(L\@G[831_H5X(YX_K1L5YV'M#^[RTD M`7M,Y<_&'\9O8:/^P`BTZ]5'RF_*R7]J_RUT#>:U^2HV-,R\(+=L;$E^;G]` MB7G+GO-D#B;#:32*T-YMUXP=*K$12ZQV:#A0?%-._);&@#V'3@7^K()*IHYN M@.?8V03X%3TA>^/SY:P/;_PZA?E'J@A+*S<"%O>+#Y;/KG0@#\CGB>?5BIT6 M6I33-T*[S8EG$P)+SU%ZQBC:;9'B"PECB#B+M]0IWNR=4\2=%0>)^6P'A`2* M)J_M&\],CL;B-9!J#Q1I$DF9J5YCAOT.`\SU-I_`U1LN/.[^A!R_GV!4ID:- MS8F3<7F(^L+HJ7KMIHN%S,,L])U$)AD(-ABO*A_+=QC%[K"+;@.T.E'(2LA_ M/_$IEKG&B^[)H-%\";XP(8!+\7V&L`.-6!JOFC;B=Q+E]B#:8$C+/B9]XM<G M:X7>>RL+[RYX2'=3'F\26>H,V9/2.-(!1A6^"+I:189#U2U#O(2Z:C&\[Z;5 MV-PQE!+,L5+)%W''WI4[_^2Y5O+-,_U$6,&5YY+RK?(UJ;2)R'JB28]1P[X1 M`33%@1]Q1GET4TP@S44U8$]I#;-9:[2&Y\,@D('W`695@G9"4%"8WXL?V\0F MYRA_P=PXODV/=U1T8OX!0J>/QR\4O35_SSA!QHT3U=1Y9U6M>[91Z]Y:N_2Y M/QI-TEZKOA#\"#U$B']Z^O#\I-Z%2^NF]Y54Y](5QUUGVK3NT'4/@9Y,##/M MSR<^TEHN'!^D1"HJ1Q=BZ1*=RPZRWE-8N6-+A6R5]X_D"2!?\C(UC5R'UR22 M'Z67N`(AX_UJ]]64^54A##2)\Q\M[/-S"-YC8CL>V?B%]>R%[5N'18X0\A7, MX^$X"PU&#<2950D]E>@X6CTSE;I9`2R8@OQ"1_4P*?&W?:@4&4(KN#RRM3&V MD;GN,TTZZ@"@6)HZKC:40!([=R<DK1FH#E29H^LC=BW7QO'L&%;(8C3G6<`! MNT*`[1@5C&!F$:Q!KB;CQE)PS)JPF5)5$B#'L?)7;_-:M%ZPFF$O6T+9'YC3 M\'S$B("J#0]'R&^T)W]%$>L12IC22K13RIKK\$DUZ[ZF2L:_5PL[[`;GCY[_ M9#GH/9H%J2(2<3<(VRQ%@FL6Y(J"<5TR;8Z--66K,VQ$ZVD1B^["\[N$,@'& M)?/6,&;$+VB&ZZ(AHX6%BI,:9"3*R=/**AT9#W3PS#AYB,%T0',BI*0KI#HH M1&@B10W7BX\'V,=B0D]1JMJ0?B)%C;-QG6"U[VEE`-HQ@%Y02=VT\4_?(^2S MZR/+80#_IX7=:T3="I5<-74T72V`)RFL_)%BHVGQ6)D9)E/7NG#.D+`&QKL# M,\Y=X0U5[5J-HW['"&HGFTU!1RY$U#'J]Q))V&E)IX@D6;J:1Y*,L-*8&(W' MT^,C">-]NDA2XX[,ENTVV`DFC);BC6!-P>?8:+)O5KVBR8WG!MC=>)L=F1\\ MPL^>-,Q?:8LEN??O//<%^2E-6;/:#G@L/RVBSY%*R+_&[\>U".51*1%H-QQ! M)%,'#!.$6.#Y(`3+QC/67K?DIU53B]-IW5<4G>#(#IU.3+M)3,M/<ER',@!] M)LRZJ]BZ#I=%SP#8$.+E`F,3CT^O@)E=IJDH?:I)18O@EBN:?#WHI"<W)=M; MRCQIF=7A`:@!<X@CT):>'W2I("L:5>((HV>(*/5Q.>`7FZV9%W^%C'^U`O9I M^Y[&D-R707(]6W]1*"66[)E<YK`_GH@7B%%WF-/^A`]5EN.`%?'CWW!TDF3_ MH;<)2&"Y<WXB<<!O7)M9#C]OG2P1"CBQMD_2.8&%LH$**&5XR@8JB.W'J*MX M>7D"M<V,8Q0IULX+S5I`3EYTREM%2?KPS?+GSY1+V1$9F39M#OUIQM+EE+V^ M$>U.8?V!$5![\L3A:IC2:K0V%N<Y3&:DW=-6A5]?BT'@B8T!=YZXOJ?$Q0N; MM^CM13+([]8?]<(C#T)2P&E!1$PI")K1SCQ(N[:P4>5T:9B4VD,7Q)1N]R_I MH!@U]?:\CXWI:%J.&Z5;A9O2L!0[&FS_K7;`*OPHWL+/BU_N%U>VS<Y0HS.2 M!\_!]E;\^XS>@FMG_S;NFIU;19:,1/(G2XR->'2BA-GY,`GI#@BR\"7\G]$' MSD`9ZIK7WLQH_T#ECB;::G%7QVVS&)2V42-K*>+U5(UK;LH[M+UR4BJ-;+'O M>-2;F&+!1-#3Z*:;!A4T5"I8OL[1H)9F2LOD@BD]+[Z1`E^\[%%M)!4C='@O M852M2F/79W?M>Z]H_N"SF\UVS^D*:ULYHJ^W89OMO4\__1O90<F$\A2<6AS[ M3R!^C8F>&:;C86^E\U;EEC#E+-%6MG!""*53BU.974W4(<LK=\[^^_#G!K]: M#C^>J'RO?D6G5F-!F232SDR-$^[>YQ=VLA.I^(<43>7[^)M4U3Q&U?;0+..: M66!6FD@CC`4WEN]OZ<R$[QBH]]1W^JI'7%:@&K>;C<P*X'78N].(>O'NBJ.5 MID$9>_,/;FE-Z`FT'V2TYQ?:HK3VB'Y+9^1"O!-J_A18?M"R[L,*W6?H!;OL M`-H36^#0X'N,[F:I[AH&WOQX)1%_<ZRD41@NFR<5=E`?<.N]KHWN9RD;\U7. M8YI1L3*M43]!J7)!"3CI-UVXJ[@4H*J7<C3=U3Y]?MB?CBHA=:?Z4/Y&M:U" M5X6V:C&VYZ+50+M3?M9]OEREAVR7=E&.LWH'1D]Z9G]<"3(EB^W-JUF%+H5+ M['7<L1I6RI?9\X1ZX'.+6]?VD470>R3^K_70"T@HQUR^7/)[$\UIKW*&+GA` MQ`3>16Q^5'.,RNDLP8]0^80"P+&N\TA7OM'I^YG0E?M\-9!+S*D1L*4*7.3Z MJH?R804>+'VK&D?U*W(Y@0G*QU@-$5I=YB)O)568W)V^NG.^B>L9^:O4)M$2 M)Y`DT#(ZY:22W^+6[Z?FDYV\57#JLJGM;[?EV]_:P><IC&`F1M@=0[D---GW M5]^U=V%;PWBJL%MGUJE\NGGP!&S<ZX\'J?%1K^GED6J9M=5J$T'2\TB])I`? M'>_;)ZHA_2B@BMT7BM_PB&+ZV0[PJ]C!&Q_<*U%3<139EM%VC*QU/'B2`B;C MV8&0*\1L^;`0,X:$<^I,;"W*-]JSF=@LCU]<O,"VY0;@>FZ76PUGK+:(K6;% MO)5>[=`4NG;CQ]&F5QEJGC;KM<.OB;.<1#PB,ZN5ZJX@=%3)5*>>:3]$I*FG M@@`=][28UC9O`('WA*2_A=@<;&NZI0.F9=TX#[M2YFID(P?C^,@F';ZXJI'E MXSO/LKA=V]LV\H20+?,W#7/4%[LUGI<(5MC%J\TJ++-A!3<!7J$.D,V,4`ZL M]C_P^"$6T3U8^X=9=/@Y&-^6V%Z*EMYJ;;E;H`)C1*,NH#<L!A];:H('W[#C MT-Y4B`4=R'`HQ&+#FM&?>7\_I7_+IVD<;_XD<J7I`".D8/O(\?HDTXWT8X&@ M0)]6=H>4(3K>%%*HNI*!W[$(N5_PO2FE^YQS&K8YF.]QEQZUQCTC6I)F1%BX M$3N*U.YG/E8CLZ9&K0W!A0Z5&6SSM5>-@+NJ\J+<MHIP<%>WN&8T&<=O6'<< MYTYY_=#QBN4BHD(Q%:C8<[(B8-RI+PL2TOR+7Q\>W/N/^&59NM^OL'W[&-D7 MHD:9S&"R@Y.0&CLLE--36\7:C(;FH1JVC)IB]\M!3H%1M$&/3)*5VT,U@FHF M*6;/'%5B2(<,['@MJW"D3U96YHJ56-(C3\O*].$-^38FZ,''-HI_).&OQ*CS MZ"MIJ49@E8#R)2H#8S</W/7:#D3<@+-+M2%Q(U7U`*<W#H=TU@(GT?45^3-/ MN;8&5S=^O&NJQ9(5'&[6G@LHL@+U`-M;K>A7A&6GG>27=9%]E(8WV=A0&?BD MC*U-2/RT82^MZ10B.<W9<APTO][N"E['X6I051TFY46ML>)B&I4!4_#E<\_D M.&+!&F9;O:/GJ6S&`TO*,$O+/]']>X=&TI-YRR$Q5;L86C^85$;3F@9OYDT; MM3&SN.7\BAU$3>VBDCNH2UJW_M:M4!3I([:FDTEX-W5"#!)JB@Y):THQ0Y%B M%6^W&M+./$R[=MYU56(J>>-5;@XEJ1,5"8M7OZRHG5][\X)<N_B6W+(>;:8\ MQ6)(K_Z94[.?(">D)G8JI.DIRD^:4M#,4]!.TX-WG[P`@='+W3S6VL!;[8J9 M0;7"/IJA2;XLM18-/1!W1/&DV8O.]RO%H%:%I:<S1"Y6#S2$!KB5K!:M;4]M ML5U9(%J/B&[H/N"DZTEO6!?>ZBM&3VB+:H1KC^7R\M'ZME.%9L_EY07AX:)B M3>81$>2_HOE'S_^X":BHMX1L6,UEB:O4H],RIFL)5^,LVG$J<_9<46;"-E%R M-N$"%T2,>)&J8`41+W70/J%)PBL3N?([:UK@IXV!2ZS0)M@/PL`NWNL;5#'D MR[=6[K53`]FZ>P\'IKD/2=7;*8]3QZREC@+<E&RAS-5<L=\_6/Z]_Q2P:XKY MR9`/R.=HK7YZA3W58*-(G#K1>I@W@%'"[,64("W.OF5G[8@!33F&FE$[C:KP M%?::JOU:=-"O`EQ5.6H!TDKMHQA[8EB\V@1+SV<'V5<_[;T>:K"V*T:=$)Z; M)(;Y44)1.:Z.4S$'3]9I=9-YR=O8`\Q1CX@G6*ZE@K!1A+&"<)%K&"W"!$N6 MY4-$V%IE>!`BU%D*F12'A@X(<IK$A4-T*P8-+E1-&6"RWE8*EI0MM`#*?7+C MN^SC3'=1"9F4''5\:UJ&FQ1-3<!SL);%"/+*E50&HQQ?+,72KFD4`ZKT4I3= M9FJ`4^_2!W,:5RMFP,*I:#/&'*!3#C1^Z)WW>D8RC[M,I=>7,#$ZPUZOT^OU M0@Q=AMKSMP\I/%U"?](9#:>=<7\29WD!O$<V7\.`OM$!YDF\7[_7&5'*(W-0 MTK2O"42+K]#(>Q2*H+A&+N$U<(_(89-8?MF9Y(&JDKW;!:Z,2#6F([U>C.>8 M,H2D@=/6\%354UA!O&=@/MN]M@A7/N&B&'%UG'@'B-*&4H5/SV4O-N\7[]$" M^3Z:/UMO5X2@ZOO[I/JVC,U*@6HD;$:RFAK29>^_(LI`28.@K4/U3M.:<S3& MN@945XM34WNN6QUWW<6AG('^O[VW;XX;5\Y'OPKJ5N[-;M5X,\-YS_U+MNR- M$MM2;.W92KENI:@9C,0LAYQ#<F3/^?07;WPG2(`$`8SS2ZK.6A+9Z&[VTV@` MC6Y3*(S@"W(4WBN\"W;A$7Z&R?T!<=CRP7EO:$8<APWAZ&\^7^3+OYP:H.3` M+Q_#./YU`G"U?(0^1'D";I(D\I[.B?OD0US)Z<'%E:0,-0E0I8)5704^$MTT MW#KLL@JR-E58`BTZ]XI'H$*OFP5=(T\RT=>2CT`[HT_U"G#J"OAH'_Y:C;<# MC'PEJ;J(=3JCCX>++)]PLARN11X>DN_(.[=>R.IZR\#%K`Z6!"UKOG*V&R>[ MH$6(DD*%A"K9;X@97=TE!Q6+."N)F%$%-[C=`*-K^-*64GD=CKRNJ+RZKG$) M(K)XG4M$46:F<B1M@")ULICVXK_>H2#>2_"_N!,%_PVM$S:7#8FB3ED-\R(U M@(E,`"7(?K!ONE8DOE,7'ZT("K(3^-TG+S`B/](\]#_0\U'B>D%B/`^]TW[+ M$WB[VJR`X`.,\"_<9\@MQ]/VBDD0%O@0#A3GZZP%<@,*<XJ6`*VWB`1I7^`K M#,XP!GL8H1C2\/%^M^&U@J>J"D/H>47?$''$BD#2(U/ZZP3N6R#4\9Y>'+4S M(U%*8Y4=?:0TL^J>649=1M@8IE2*Z^3B)A[>O4)K-+;%2B]4[%+"`$U8H3T% M1$1-MP)"`=U9A$1Z?BP)P_0E\QADG,A8Y*P;@&93"M0)6DLP8%EKN'P/OL5# M>@+$:*K#:;P<7,:<D\C!FA!*?E7XT664\592&89]4@7$`@ZIJ$)%.V'I.*2L M7)JQ?W]X2!5)1G\,"WD:S;L6/>CHWRV39U+06I?SY7JZ2/?/,A=%2A+B#B,T M10>[K*J%5J9.[;MK8ZNDZK5I'<_L4@^X/X!L+';+[#$$Q90Q(YMP8ZO%:50+ MN;3*#[DL"+,&>XW"_EU/'2MT?$3-Y?'2B[*$*;YM=+YIQKEUL27<W&:QGCM% M=]9LD.D]:NKHC/@NM1+/JA)7?5-*>\1JO"*N2:W4Q!EEDG4X(3?))S3#'D@4 MOA6?(Z0\<XN]!O8Z;LRWOZ5]N<=E1>*8>[7NQJ+IR_4*9:WMMLC(JG<9TVF> M]75,NY+,("TF%7+>_\!)KRW5%BN/:<52>6SQKO*;_')]S$H<I41,99X-$86D MFSWB,4"(9AZ7]%.$+0+IPT.S$94!T""Z$8NG32P_P#U2H?_H_F`<O84!/'C< MS.F.MW3BH9T589M:;19IG,?Z>C*2)$V:$06_,+*--3DU3"XJA263"R-E%"]B M)EB"CX`>^J,IAKO?GL/7?]E#CP()_:.*'_2KC`LOWKG^?T$W>A_L;]VDNCQL M?50#4MK&%PY'5LOL;G@*#T(+8&(`4</ME34O?-0)YO01;&Q\B)@8!D6G&@S. M*S1O4W):X;VD?U;A<"(3J"S*J&&7`C3.*9U1F$)1\YC,@@FEP_8:YI,V'=@' M(EK&\XS"WGL:_X9!YXVW_@2M`5\;EQ)UG3>..#`G(!\4Y*.:OS6G25'%Z='L M];G!@!!'?:?Z#'H$4DT-+1\_HI%D%VT=[^K'>3M#XA/0/*M^RR!-")-]#D+: MPH6<2M'9[7-#P6HO`VT`HX!&3.#N%CXEPLTB.`]K1%8S!^(%*=<.6^QA0C9U M>5`AF",OF"[TM)M9$2XMBC"/CZY+J;RGC2&D3]N`U8(#$>/W593(EJ'$'CRT M7A=M$UI):L@MA-'!@_[^YCF"$"==\.^$<I_5G?[!8T0T*VFY72U9_EI&"F2T M#+7G4R/4S(A0[5D<:B1S^DBF)3^C"T-91D:K(M3"60#%IL$K=\%WNUG-MU7, M&D9J'PEF&B40A&4?,1QQ,?1BL`MZAG,QTBI'Q0ID-[@'[S/Q!W]ZR<M=L/=> MO?V9M3<A1=<>W`OI<_31"^!=`H^\'`YEY+4&K6IX%K]+N5G,4ARRO*-2E;_" MX.`[&AWDP[/K-V^>2"6\E`7P#3,!"!?&HF,32G1T*E%?>*X6HN5X7N%G,NN_ MXB1F79APX=>'")Y<;W\3[,E%?UK!36)O:1A5(]ZJ%ZL2^,IWJS)\D:JCA4$G M@`T[*=188,4/K=K?TJBSJD\:16?Z?=$@N#6[H/X?PZ3G8>E1<CD8@B\;\"/M M'`D?EFRR`N29Z:>9?OJ3,T3]@4K9;<G[DS/3)F`*:,4D_OH!SR+$#36WY=Q9 M5J!F7_Z34F'M2(`2-,`F2%T9EGKD0`VA:`\&E23WK&?3:N1\C6E0VE15"IB- M)D(I@(4$^JU,A4IY_H*6^[2R'$LAZ;"2^O,&4%UC0GB:F6U7JPIF,3%611!! ME-(SB\2!XK&&W6&4O$%#'L$)_8N5]MFG0O.$U(U`KODUX:M9+W:@YS.261)` MA5>,8BCG0]C.%JO%M`U&.4E;D-172`*FCV'P?$U8JAMC.YPJRC&+*%)ULO.[ MTJ>,X(8,+6-%U0T31L(T-'K(4=[SC/ARZ+?]DMDTFWLNL`46+AINE1XV9^^R MD<C"R7,0RF9O39#57ZY&&$Q`RY1G"`]"055-#Q:@0R*<JCYO#B,]8@P4L%?W M^#*8V!-$#9*.`Y8@#-[8!QC1R*E)(Q;`)OO/+GP.BMWBVS]M_35S(*KQ(K.% MO.9AB?T#Y&2MP-1`88MUVA&RVD0SA">N0;;`JEDI)M%5NE;5[UQ*B(0!U(GP M)6Z46168#('56X3V'A*KUX0==PK[&'$3.H7UHRC!O-*ELY!!\@7&$"G@!3%S MBWR%'Y).197/VY>*_C1U619%RU`NG84S2S/9&1P+36L+XX!T(-*PJS"4[GSW M<54QLTX578GSX^J#%B8HRO[_N,?3_WMK,+F^+^@+^?>]=#:.S[J%)Q25>33[ M-MC?'/'N\3_$74';^\;]5`MSHA>N%AO<%(5X*/3Z.4C`$SR$$8H7?*)WMM/^ MZOIG^@/^_7=<4C8N[<!G[:F!6VD-O(?[\XX6_TS@\11&;G0!>^^`7H2$#+8^ M]%0N"HE5W((PF@LPCZ=GKOLKCD#<7G$,&_R>,A6PO8B6KVV/[Q-P'GROUZ4Q MDZNIC,G?HS#NNF!4>=C`"JG,@<P*H+JSET-N`@@QLRE[0P0KE(^M>V&C]6/; MK:QI8=.@!RO@\1EV;2J4'C4)#32^1*F[;1LP$"D\M_\MF_-OTCG?$K1(RTJP M@L6R'2D%@VO%2:H!*U!RGU:OQMW:W[E1=$$1Y'<WV@O/+"T43&**SY9$9:M- M]1"V"+5L!-+I'I3&,+L7IUP)3HK!O-BYCRB:+77>PY9;<=FA+"O@BO[!4OCZ M0)7SMDF8-K,D?J=HWCH;XG^S#M<VPE.%\`2:6,X=H607(MO-M16-+;JQ!8GI M[]@F/MX?BUXA[JQPL]M%9]>7`:8`,<,X[>90YBI@V\R*_YW]@0TW`>F`9-,A M'=(>)*M6#SN=+LCLMLAL$N+B..A"O*`.K7``V1(K6V&)&DO#FR:A76=')D-I MWH+CT5>A6RIN`)_=!.ZE$#M8Z@5);8=Q_*\%.=TV.8UAE&^JK8#DJ,@0^KP` M%T,(Z`$%[M")OM+[X\D/+S#"]0\BB'_K1I?B0_1<A&\30XCJQ>P`3B7FG4*R M/1X0%(D!/.0$I(."TJCE)^FXQN9F;;HB<W2FD%V!6@S.P1[]+GF!X(1(&?8' M"L!3<15#=6S&B^3'.ESK*3RB%>'YN.*=M+;Y%>K\=5.PZRM`_521-=(SBYFZ MJ9014!'7M#VC?_NP.U-"ZE5#]L_C1R*[-R^QFY.=@(PP74(:.Z8?3^CN$WI\ M.G2*\#YN<B%_A'\_>]P4+1-PZ[)D'@Q;-6@$GEE5KOM#L9+@%^CCY0JI[$6* M!SX5BP=V51`91E0GI`=Q*EY-;CM-]Y+RLG#(R$ME+MF8:9VYYL*6IBN):-27 M,[J^M'D.)2`K^93AWT%-/B3+*<2=>H/$2RYWP2&,CG1%WNPDQ-_3GO\HP)1H M^NU\NLYJC#.R="8CA(&74]:=?*A<R%E)2)Q<2`F#`F5CCFLDF9WA,NM).93` M9YYJ**JN\3L(IZS0OJT/,/+"_0?TN^JI5?NSFGH(<QD0GO>VJ_6Z@B?6;)=2 M`X2<_B;"BB1S^D@V-DZ$S"QM(]RN"-UXP'V,Q="0/VD$"]GP$EVG9]-F))"V MTU;@H*=4C2AHETH_!FJFU8R`L@KTV3]%'K^=?/-SFFV_-+BPC2PVFVI,Q5RD MN2;R"B1R9"72:?.-YE2U^+KP^NS]$9%M^2[DSYJM&X\IW#%ONUE5`QO\OCE+ MEN?>$>)>I]46C:)JK)E\1C85PR.,$V_W#I^D19?&!F+MS^K<`FQB0'A'>[I8 MIL=;C`[-+CDG+V&$%X1FNG(I%,[I*9RVS;4V8ROMF7%UH60K[+T;^9?"I6-^ MVSS.D[JWNYK9$#2.U6RQFL_I!A<A5+Q(;ZB9G@J!9@8$:M^\4B&5(R^5ENVI M=LQD&U(M*C`QO2%V`B]XCE%`2/;8.T[#N(]KG.1X/`C'\,ME>HDA)85C>'KH M8OQ42HUT3B_I=$US7497G.E:]6$#8MZZL;?#-3H\_YQP2]AUO640/Q56A`UM MLTFK--0-;0((57),Q.C:`:=!PF;7\O!E/'!"PL8$5;3^!ZOAL0N/QS``<1+N M_GH)_3WB$+P!3YDZ]GQUF,(?QX3;8-BD1QO06&L;WV$/^?,&$5AN8"^RBM]L MTXVU)B>/Z0%"T)))K*>`&=[(A=],0)N@4[.W-M"4U6`$+H<#W"7>*\PJXGUQ M$]C4\H7W9<4)Z`24,%?"#M]QTBMS&?%B-4A,GY1G#7:>G^8[HN^\&ZWV6E?E MA[%T8$>7,WG#+0%13C?V(+-L83<):X*(BUN>$2.7TL-2AB%'V3B6I=B5B>K6 MLB!WDZR%:#9Z]:6174'G]*M;A=FE>*2<`U-.G"D'UX^)#)>550BO;L<BKVDU MN[8"S-0N'?Z1>*3:Y.<P855Q:VM8Q<2U[PVKXEPXK6ZSF+%\2>8&W&>2\HLO MI^75',$33+Y#&(`(XCY-<`\\ZD4P7F!:;?J)59NF&9?HM[O.)]&?3GA1!IXN MP#V=_`NN'T/&3D\^ZA@M$,10C?%*]A1!_#/[TR]XT?LKK4"YRUM#AGEKR'HU MRUH!*7!F>@5!B,MG,LUJSALU9!%2$PUHN.$-4AX`8@)D7)C8R#>CP7)SCH)9 M_9+:U:]EPS)W&J#:%^<'"$I5KVWB0<OX4L&G]S].7C3(9[=0M'&*X;,K&FMM MU\OI_YE70A#4"J-A9IDR+9Q*5'UYR84*WCBKU,S+1[9TSE"E*KIS>/^Q0V)K MIH)N[RCE_SO4:.O^QN<PR"N@LYI$Z6D#O@B6WPW#E\(&+'XE![)L]T..>YD, M*4?:QQ19R4N'%>\OENXY8H:N8'-D3`VS-COA[B^FH%V!G.U;)/T0*KMCTD/] MMKJT>Q0?13?[_SG'";FV.L`H:Z0L<TM5_L0S5E;3I:SC(8.!PFA7X%6&*8CX M#4+"=B?!LWE9-]"H+UN!WMQO#`X!/)>D9<#G\2E1(F$A'7GP._7!:_`%:G26 MM^PK++0G=(%\R%;C>+'-%O&VNXXN%,FZD%8U:]O[HER<\&X,^HG7_:\G)1OW MNNILBC8^6BX6LS5+Q1?=*:<`*`UGWR;04)7('1[H4LGP'9^A>BFXP$YQK=GN MX3L$J6T>CNYL#9&R$O-#@J("$<O"H)PSB02K^4HV\'G,>BQ<09C35R?5+@O@ M%Q33-'9<MBEZJ1NX;+Q2T9<1)-.BLO`KC%Z]'6??Y2;K>'E_R#N?TUOEI M1R^`=PD\<J&N>!2=OD`MZ\+`F*[2,B+<[=6;*$(T(+D0]W1I*B,';G!?CTE] M5Q9\PQP!PI*IK'&3BG6,*5:;!QL'V"47-\(7M-8'?@Z#5Q@G<$^^?$Q2I*M[ MTY_#Y+]@4I7R0QBQ7^'G9D/@H(X)VSRH,LDD(H\E*\>?,@@8A]P#+7("1MFD M#B!N\@`X6^L"$Y`S.DFKQAS""!28M=CQ&OH>Q"__";WG%S3T&_<51CCIY40( M6^]-E;L(:6>K]JO]5+Z8G,'>GTB.D6Y@E,;^&3QO42")$NKKJ6J'V^1K"7.` M<?>3N=C^BB>>]8\@RDB5,A'0#['9XP*=N-?B5VN?RJ@[Q<RT5K-J>M*$J\J' M%XX<4.BPJ3H6X@/,5K`:+!(MZ_'UX<&*:E4MIM2(IXK4QJV?0E$<`Z7G32&A MR(1$`DEVF;F,!TK-)ECTEX\FR%#W:A\^FHR-BY*:$M0<51>'>$"?\07-:KB/ M6'Q#EU4/$9KOTF(%C0=Z<A2T'TU+L2=H7?/9<CM?T2/I=!T*TG5H#'T?9]>? M,&&<<[$K5'^9@-,YBL]ND.!;"S!%'OD;_A-ACW2KTWUI840]-7F9=`C2T3`& M;!!`1FDOZS'V`?6(BB#NZ%W!'#*CH<:2E0\R=U+=RQ_D)]3RRE/CQG`?!S_K M!),.<'N.\&T'[^]G;\_W$*+O:G==@HR)WI=<+YWMC#HMW%:V[9K8*8+IK[P` M^/E8)+N.--1T(Q!&Y%87\GVOF%Z<$J1OX^N8Q)ACW:YL%+U1)\9(9R<\>84E M2AX4Z)MP7J.([I1$/S'1\UIG>RJZWRZZ'O\EZ0ARSR6CN?$+H]/&-.\0)Q%. M4MS#'_\!+Y4OSG].4ZGTQL'%JX3,9LL"JBZ`$0*$$D"D])=/5R"1(RN1CI+J MK>:4UE;G"Z_-WDEH1(('@K[X_IR@&2;8(PSROU;;2WJ1T,*)3`^5>1D6-%[\ M2I</E#`H4#:&$F72.@.EU8@@`0.MP*E+2]JP=48169!\(04`T."D\E!39Z76 MQ_7BJ9$'X1,-M.J:E9%$Z8&,(*W69:#1DCKYG)[R:<1,J^%5T,+7B"Z<W(9' MUZNNQVI_UHH#.J;X-:!9VK62V<4W2D#S5NXP_AU!_O79<=DPRG9;D%"7G7[P M?!B]0ZOOYS#BKPS*3VFUVM+0PA]_MJPX;4(&I'1,F?``81PI8?39<Z,!E<VZ M+K4NZWXX/_G>[H,?NM5[<<W/:+7LPL#"D_5B[:Q*=DV)`$+%E%7W%L21$$2? M13<83=F>J_+JLN8O\-G#+2J"Y+-[;&ITU_B85ILNCRW1.FY=WL3)Z0!,R)1E M#Q''D1-'GWTWFU'9Q!L$UV7E?PO]<Y"X$9TV^$O+ZG-:[;PRN,14[I3CDHP0 MG=2-+2('">1("J3/UCG&5#;V)MEU6?N?T/?_(PB_!U^A&X<!W-_%\;F6--3] MO%;KYS`AXQ_+40PF^.8O3!&D)`&E:0H/2D1T>HNH#R$=!EA&2IM6C"3=_?V, MN.KJ+%=^2&=Z76ED<=N9SM*B-82`^<YQ`^1PA.70ECS7:#2EC+FZO.:L&^=^ M(Z@%2>.68ONSVFV]PH#,A:Q-R>0S0H:V'16*Y4B+I1<)'`.K`Z))"^9P@:<> M-\C3P&Z.N&-QZV?DO*(=)<U\R/A5%CX5V]1^)36[R3SMX4)ES.+2L2:%)",Z MGDE`J=!`/0W2@O1'&1NM(ZQ%+6H2''_L8!S?'PK'R1]<+R)Y?/>O,&(7Z.$^ M2[K$&KT_/*2I>.25RI=525E[<J02MD73=Y?SS9:5V:<#DUIZ:#R:^5C-\@9> MD(3@^XNW>RDF0](_Q;BD/>*05+*=@!#]DV9-9MG?:>)X?*Z_KSN7TH":9P4U MWQ]*&2$`#PYH]BH>'F3C%Q+*B?K0BQD/]%T3Z9@&M$><*W4_N"P)-<(64X6( M1[B'-*O7S=19MD9S^9Q*_5Z>[:GNPRAR[UZ,\QW2_/G&"VAM3^IWOTULB%KJ MUMG,YZD[I82RNS#:'=QP068E0;*++F9NT"F3RI&72I-+:,-*`>)<%9A8^F3N MA39?PO5G/??)\TG,_PFZ\1EYE?O@"]R=(YQRCA[X'.*+^/1'W%N[LX":VC$T M+JZ4,B[1>F'+L)M'%9.TK1JI(ITS`5(N`)HX,S[(4T5.2(O[V(*Z:08UZIC0 MJ*[5X2@P+BXGU7^X:_5VC[BWUXCF3>E?F9<C3$L4B%@NJAXNQ1WKD-&"O&]D ML"MV8#V4Y8R@K&OR3270J?9+^?>PP"<U\$R9A#^2MWY]LZPW&7,>II,WB7*H MRQ4W5&J>R-F\3;XYP",",J0=[D2Q9FBAV//QB+-GP@/XX`5NL/-<OZ8BW"D^ M]RYUA5GD/X0!TN(FQ/1LL3?X(PB?8AB]8BN^"T[GI%R;^^V%O/[.=^.X]91W MM.'L\R[2,LA@C36]("0`H6'XF-D.I3@R2K',G_2&6`^_T^\SF/9/YR.M8/6> MM61^A-%1P!P;7S/D+YIXD3'Q36T94R`Z`2E9@.F:=P3#I65'Y`')8SKCAET< MP4R`N<T>>:#DJL0V</TM])$O\'$JO9N([#]T$+`$<&6N)%K*;9:"T,M'($UJ M[$/A$!40/!8D1$'^=Q<W@$BL"=G%#%D4GPW*L@6I7[SXKP\11!,X,@<8)Y(X M;7S=,$J;>)+8N%IU3(^8/,#T03J`91`=+C\!*";SYH#E]%(Y(XZ<)A':9L!= M^.1JRB@ZBX'SS0^O\X"R]KP)_%69D"@MN]HVK$,Q#=.KT&$RU9>17)FTXX=G M8HV`:52#881D__PW#T9(`R^7CS@)6`PN;2^;P4X+1Q+9P//:S#4!&4%;(*5, MU-K1N(BH!I`F8*H<V'6IRC`&"\=Y:!+]^QD&NXL8`+EOFD$?CQT)?[]F5]4* MI$!&RQ;HJ9'3Z2.G`=QUF2<'=*U*,HJX6R_>^2%F+NZXZ]GZB@F,-?`A;'2+ MZ:R6608*!(W?"U4G935A0EQ*[?AJ,<9&8/%T8PNBA#,5&M\QC"GYD_9-UDJ` M9V[V9!D,%[0M$<DV-(EE!'!U8A1/Y!0P)D'JK+7M3]L;)K!49T/\<O-\6DL+ MG`!*<`((23`SW`!(F9QM0`)_Q*1FOX#$VO'%-\Q&=''49`NV'&EL.79@RY&S M.;3.7S1L:92QY5B(K5YR"F.K76*3V'+DL.58B*VY-+;F=F!K+MW2;3/MPM;< M0FSUDE,86^T2F\367`Y;<UNPU;2?(I;=V?*F":SQV9'(1MHV8(ZSEV9')J8J MJ6N[]?)2:T=?M^DVHK!#9;:@,:X?+TCCDD_#,$*YC,E8[:RV0U(X8K(.GHI$ MKDZ58B*;Q&:G(7>AM%USUN`UR[X6"U';7C6-S@H_$KODCM,Z@9;N%5H2O"H3 MO&T.%1;<*%(Y)MP)T":U*:D5DXU6*E]#ZKGN*]^U^WG==6/:F!%M2HE61PM6 M/:;@]*N5HBA-O<5DU$E7G<4U2M=>64:=B/4J@`<WK5)EK+B,"+BR$C.=NE"+ M][2V8&FTUF_4_(8QS#>R(VHT\]E\.J6H_[\^9(92Z$);+6P6TH19\(RS].%> M<UTIE4)7G4%>#[3B%DSZ`P5RYL$"_;:5+VK>*;0BL.X6^"I1XQC@'H7^_DVP MQVWRX*/[@U\VCONL=F?`84304I;.=+EA;H"1`H@6:70(`:(V;@3-A[L2L6:& MQ.J`N!+9G*)LKK!L>@#>@:0<VFVJ4`GJSS"Y1U.;BRO8?0QCM)KPT7CQ8TA\ MR#V9VF[A_KPC<US+5Y,D9,@=R'$I:GB+U7HY+_N*`"8H,&`C`1\-!2(Z%DC" M4N``]MEXND.'\752<C1H()"-!/!0@(T%'D.VWJ##@7P\<WYH3+T0)_699R-[ M;",)<E@<.S'MO_HYC:ISZZ%?E9X/^=2W,(`'+[D_$"=[%Z`@$+O:/Y*GS@!' MY&U#/DZ`-=&]M>UZN:DX-CR/,O)X54`G5SH"^1L:PVQHI%S\F57B"[DNY3IP M>#H(FW3P^#:V)M:2@'G508EJT<@I2%KYZRZ(DXCXA;;[19RG=9YU-+,@D:R< M-@#-BY[EI,Q>(U(AFM-#-&WG%>W&5CJB:-&%(9QX"?SHO<+]'9HZ@V?<#(/6 M;GI[^>3^3QAUWB67H*`73Z)LB1<XF,_7&<80]3>$/,CIIV4&GRZ`#&'#C?2Q M]."HU(-&I,J:>P6]4LJT#-$YA[@G<7O&CB05.Y#=Q)K$+87U5@3=DY)-XX%, M9_2,J1`!F$LJQ`*LMP%!$.]<S:I9@^-+CF@9Z_KDX"+^@"3[`E^Q)9#5_]>3 M[R7D3XVK'/&WM:_!A5D3/;*:;I#VV!H\(TZ/Y6*`R0-&G^V@D1'HWS6OOT<2 M?6:-Z!UK[Y'D=RKRQU1^!-+$ISG"IW.$NP(F>-LP8AJA6X<Q'M/<$EP:Y?D2 M7$Z91@*1<X2\YSF"-\'^@_<#_RMN3S_DOZ`SO.!R(9%QMTUAF1(C)VTI.=/9 MA8HD='I*J"T`Z#3`TES?KA43"/H=Q11XY_\^^.KZI.L=/@Y)+@_HZR2XWRGI M6\OYRH(O:T26&$?"38Z<3=K$%Q,&OV#2O^)2_K=>?`ICCQP*A;C])!T&D'%` M-I!:\&VI_`%\Q@=4;?`;10V+3`_X)(PH`$V%2'K8)JXN),H9<A&5$LHRA="4 MM;O@%<8)R3EN^?)-3VO&8`,+PM:V0"N5`NAPPANBA0VM0,TDLH8+5X)2S*3S MVJ73":06>ZLBAZ<,(U"!`4O9N=D?T;H:%_))T,H:%SH.8E[AX*ZW=$*GG15A M*]LL-FP7F5$DD5.9)F!$S02(2B5UJI*Z)9I&T21FDB54":C&0G2UKKO$WK4' M:;(5,F9I:^!NO!E>F8T@>`U^%<%M6*A)&:\$&E7GA/[NAT^N_]8/P_WC"QKX M!,^)MVO>U!!X0??>:RLWHOEY\_5LM:3;K90>>,($<=?ZC*+F/$V%<LT*<A&" MH$C19.:20B&=FI#&DY&$D)5M?G;K0@W<([3P1`O.'81[LL&*;Y2Y2!"<[L2Y M\M7YCG;0=S`D;#K.<K&EN$<Z!SLW?D&+HH,??@?X.V+\H\AN[[%-^)U[\A+\ M7]PZR7LZD\T8G+6+'D/L>LE%MY-0J@?J)S!)D-*D!RXI59K\:.8JF%I1G5S4 M4RHJ^>*G\Y/O[=#B^`#Q]6IS6=>B.,W]AXB"3$3Q=\>3ZT48S_?1+=O$NS]\ M#(-G<@9-3YX?0J3V2U?1V5ZD-,;X??@3/I[83M.[%?DP((S`;6%C%`_%,AK2 M-`8Z'/C&_FN\C.WX.G*J.F)Z\0MZ,;DR&`*(XD*AMR:->`&21HUWO;%OPLT' MO>",/"R[#1(&\5MX"*,\W1KB)IDP1C$0SY`&4-3I$_JS*;['N]VRW3>6D<_. MC<B4E@\)\C'!$QFTD,$/D:](!S;D&71IBCB(/W`6%+LH:M8=#$=&R2L,U.*5 M.(</Z$?OF9?I.8"@W:Z!<2EL[[/-PE'A&=BX5^,8>NF)YG[P);78(U3@,-`A M%+5W)?[@DQ>$$5J!IZT+;X)]F0H^5T\NGV#R$NZ[3[5U<F"WQ^DKEC#TYJMU MS^"%C@SHT,6S^DG%>[W_D41N&.V]P(TNX"Z!1_3+SPB(>",G]'U,/I5O'!<7 M)JZOV,7I^3`K_&'(M7VF=(]J-L$L7)F3'.HC!GK501_,3C?\`*.W;NSMD"BW MGG]&`753_OYP>E:Y2`Z3XF5E-VF"NZC#FY"J7&10<MS)AC61]:Y935G-#.9V M?O&)JO+";*Z/`8#O[21AJ:#72^COD1#@#7C*]+:G?-CMMCHP)>>$VCZ"W2Y% MC2.QV'W(H6&]F$W[.XVK<!0]%*+,/5R'2U#@"*X`_JHB":LCB%Y3XF*VZN4$ MKB5>Z*\4%8[@6J(#)5&!1=$`V8(G14/:N_CRGM8.[1H+XK?/R7\+`,Y(&>_: MJT0TIX=H>K'%-;8Z@IIU80%./N*1$(Y;"MBTO6$.+T4V)/S[<LO!3$K/:#$: M93(V@T=`1D,(:C+#%A35%&,1DEK+QK2_8QY-LEV--LZB$T]&:[\HE+,+4Q:4 M=!$R20%<&6[1E&UTWYR3%[+/W3D]U1[6CJ4J!\)G(]/5<E8"$:Z!F9&R8#X: M)IG30S*]>.$96ATHC9JP`R$"TT[#XT91(NF$M]/5J@TG%LPS0Z5KP8HULPO? MZ-KQ8LN<0C<QGG'GT(]>`,D)?M=';7S'!'::&!%OU[S>SFL`*E`$WS!-FM-@ M&D;#!:UB2490[8AJ,\I&6''U8PNV'O$&J<17IL\;QA1A0L9EK]OQ1.A9!*4> M\K7"B"^?20253*\+/;E*C"+GUHMW?HB;<@KM7#>_80(]=39DMGDW-?SD]"S9 MQE8@8Q5#PC)J1Q'?#!MQQ%&,)4CJO`+8]HI9+,E?5ULO9O7)J&AHYF_K*1.S M@B<;DD?;#:\#/+9<J2.Z?'"]_6?8.?WD#YI`2C:ZS*V,VBX;C`$F,\&=Q0QC MHJ=`M#<QKC5P0J^#0QA9EE3=9%*-:"@KP"@&WO]PCUY`-L(?8.#ZB0=CDF#- M<JUWNZC>PKPO%1/H$6--O,)FT[Y"80R<.,1&(:FSZ3B`#608>F-H@UT+C>`N M?`Z\?^".?$@G3[0;5`R",`$NH8L4<@&G=%@K\"IG_HU@EE"I8:23.EBL2U>W MH92>-H/<(@O"-KE:;.I'3&E)MU\8M5^-X["_;`1O#U'XZL7X++8\#YHJMZKF MJRT*GZW@1"QQ%4WXX;B$F@Z,0E^P2@SO<1/@[UO)9(KFI"KZ+2SFHD1,.Y>& M(A58VL0WBI0O$(OJ^1Z9S_'N:03W7L=UY[;W3&"'QXS,#596_>#]X0!WI#9H M83+]@GN8E@>9T/UR,LX$W!S#L^J:^M+04J,%NN@D;X*=&T47--U^=R-<]PS- MNP?6Y15'^C%.++("@5U&W`C%5G49PF0$W1C>0OK?NP"%TMBNT.+Y@@\R'B-W MWW+J)O*R7G0*<"1LG-OI(E^'$H+@EY3TKR@>!"EUP,@CA.(!C(%2N?`$F9F4 M)TK',/XD#+8"0E'U6(-$O*C]Z+E/R&/@%:_,AZ^^:AJ%%7Z$S7"]G'5B$-,& M!>(6X6^0V"GZB'QX^@MQT6?@MTMJ%(H<B^T$8I.>[(#A+3S`"$W3N-E;<!:? M"ZOO&05@A1EA,UPN%NM6]*6$`:-L"_0&"4QPETD6\24S!S6.5;;CK$DIEH#L M#&E#11_O@3VX$78"[\Z(66Z[-4DB9N'7PIGX4LF9ML^$:!1ZVYJ-`]A`$\"& M,KAO.9Y"R'9F*O')Q7WGW#1@C>`.>J_VQ:PBYMX!Y2X%6H/KQW`PJGDD3&.: MPY=XNZ:ETS&[GDE)`#UX'C#9*E*%4X<R6W+2<UZ7A<+6!L#=YMZ)ZC9%*FFR M41\5%QMTXY?["`_)?KC9_?WLT9:>'[P?:<%N\EL40#R^1.'Y^:5SA:IA0-WM M/4:51A`NJ]EBC::^><ES[!E#V&\$E`M<@1_#*/O9S=D"!\P7<`EC]`\XV$TH M:TU0T]P_Q")%EUUTRA"X"P#C`MQ'Q#EG/Q?8`H0O5MH?I)P!QIKY[0O;E$U/ MWI%X+XB/&#=(.*7]A/$<D+77;3-58YU1M#C7K*W*^%_-CBB2%0<*GM_1)D?= M-QI$"1B-('E<2=RGV4Y;X\=L!,"&L.$*Q"A:H$>(+^A)Y#-P)^%,\G2&"TH> MXE_M"AR[++P];&Q5H1T0?H@@3BA.=Z!8\LY-L+_'6]K4)0F;C!`QH]`6X5`B M`72U:84Y&RU+P,.V3@9J:2AD9M]G!+TL:*8>U4!^2.*:;Z4T"`3MB!?6HQWH M_P*10_)VR%SPU0)A:ZF\9A3195XD+E4XRU;LYG0!)FP/5`<)O*`G*/F*-,K% MW''$-(?+9O-L1V"#>LQ@C;15C&/$#T1*>,'%M.$K]$.R2**Y?]QO+O*N5M0) M,"1QLV^>+=T!(PQ2RK14?4[;QO15Y<I@2>UPA\;S=F@U\#4Y[]-+-._27SY& M'OI?LB!T?<,SJ(1QE^$JJCLSF,UZ;-S"IX1-WEPS:'Q8*RJ;.)#(9,EAR*YI M4>P])6G`:F[24R#9HB0:+(3@-!"%?!GUX:C-X,K`X6K$,%)(8$L3:;N_9O%A M,T@I<"#>_W$YGS8@A:[D*"U34]%PN9R27.PN58X2CRN>`9`TV!H')%5UF`2) MV#QB<`*1]:_+15Z?C]G-*!.&+`QZR>$T31,VV+O`;&#+-(`O]'=\&_*(`=O& MXTHX1*<:$N'WS5JUO`2-M2+XC0IU&W;16IJL.A/8I$E_R3+4.CY/X4$#YIV/ M+I[1,UUL*D;^I34=3Y^I]Y6F[,/SY$(0!F17BQQ.O[H^;HQ(8ALO;Y1H`R+J MQM:$BXIV%"4=(=J!Z[\+XR3^!(]/,*I\(^YC^A-\:CP(6LE\L5AL-VE:#J4" M"!GPC1(:9RNI)85FH"@SW:)T9:D,E(<E&'K'IS,:AV21A`<@(:"F)!(N6`JI M'\VJ,#.7I5Z.KH121\+UPIS'M<YKS3Q(!$"S#!XI*;9&GXS<KKE[EE,A6]-Z MW>P<UFYDY9FL10,V(*2[2@CO>8,8Z5-;,>^.5`$)*_5KPS&+$BD)7+Z>CT?< MQ#V=4S!R^/MVII#3436D31W]L1/#W6_/X>N_T(@8(V?._HTQ,R]@AOZVP,@G M-SF3>O]N`K_@!*_WP7Y6^9J"+VE`CQ@GPL:UF:ZG-0BE),$M*1*"B0)$52^` MQA"45KG[[>MOX!$?LY\1EI#A8*KXE/*8B@UQNVQ#A4#DS!-#2T)1=N#K:^)& MB3S"V&M68(SR(M[B;K.H3U1-*"-T;<-9'V$%D19CTA9CK6RJ8F@KJ,ML+"A: M,8[WO)%8L'\QM?6B"C$;DVZ4R.F4Y32\^==A;\WAGSU5XS(MXHR$FV#__N]G M!.>OF;?JO`TB3,`(H+JX$N\,L9S/J@B+)S31!F]&TP%`/H(%ET'&44(5?@.4 MH!^EHF;>#%LA11K&,2Y$0IC\Y$9_P03O`]38#?;O8)2X7H"K<GG!,TUIEVG% M,=)P9GR$4AG$VYYMENN:1Z%5?QB<<G8:D/4+22NE/`'&%+N1\JMMG41LT'1^ MGOZ^<HYH72@Q#H8Y+DW])S'K`!_14*W]AVL/&G$ZZ>CB"TMGYM16T9B*X9;# MPP1RY`32C\6J.36CJ"2\>?M_AU;CSV'D_8.<PS=F!$B\:`P?3=S(+!5K9XBQ M\;;#:L6KAN*6]!T6-44^EKBJ,8*MA_MV"&5_UXF4=%"9Q5L*B(=[0XDF`[EW M1+C79N=5LRB9<TE`-5E><7QV$5<X*>7^\*<;16ZMT%O+@]HSO9JX$/S<"V># M;__07"]&!^P0(7SX^YV2TETP:;@XLY(XF!"X/P!&RD3"UW"1G))(^<>))\`K M?K=QJBZ]PN@I'%?`&9&0O1J7A3*7PM;F"?(D-J[T2MW1_>%=>#R&P=<$K?_> M'T]^>(&0_)"6F7I`BGZ(O!U\@-'7%S>J)F,/)F?*M?7@572^VTX7SK3B`!&\ M=F0\$.,Q`&0CLA]/;$QP0J3!"8\*3C`",1[7D+<<74-EGXK<*1T/D#%`.B+[ M,1T3X$$!&16@80$9UZ`#'EU+-3==LB-D./@O"2Z&^O[KP\,D-QOC+FZ`=ZDY MPKYJ'L]=/H;O0A^I(,0%IEXA+BL7P.A#&.%]2FEO*4;-"F<IQ*IX9</%JNHK MJY[@,02E$0$;$J`Q26F8D1V!G*<<03WMCM*T>GKXR1%TU.XFD7?<E71T8CK" M5_/(!25+W::4EVGWFN)*U^TTB]%N<Z'DOK0L=I@E1F5LW>GK+DO+UW%6=2I< MY0#%]'24&A2CS$D.T$Y/%]F]&6";>VST)WV<8UW98[K&3_[K39(ZXH_A=QA] M](ZU7ME]*%CB!CGLB>[JS.?+];IC78VL^-/'OP$WR2?T"?#Q4,#'8]FPEE:D MB$YGAT8!-TD>_0$R$B!#V>/DE.BBT[6U&H5M/JW#$71YLC:-:O-??YQ.`_U7 M@8*-_BMG3_2F]7R-LR9Z^*\S'LI:_]57$?+^BXQDM?_JJXL>_JM@%%;[K[HC MD/)?%8V.[+\^PX3^$@6]R#?<!/N^:U,!8O9XM0Y.16UYN9QM9MVK4XQK-&+Z M)SHFN,'9G/:M4%5K1\CK&=-.7P^H5$4BSG`"`IBD?V,Z(G6%K%ZLBGL8`1\I MHO,QW66A&]NE_[%'&Q5+'&0+BZ*KE-EZLZWFQ#08=E3J\%??F[8C^E.FCTY? M6&SO>+'Z/$.93CJ=7Y>-V.;S!-Q$E[/K4JXN+]<W%N33L-##]9FX%_.&R*_+ M=K,IO#QGV^?C!FA$TL/9&N$ITH:D;[,[ENMT##)>34/D%KS"*/&>?/@0L=Y( MA`_B13N=6?O+)KU8*V>BYKF:;M?+)O>540>GE#RUU@F=;$UZ*X62-[BI7/*, M//-:=`##SDFA\`U>J?.S6^&,A!#=Z(6ZM3>\WM(N/`=)=*$%E]@/U8I+[-?_ M_>\/U>^=_T'#O9Q\--'4S-5VLV#KEW^_>;CYK!D-/?DEEO[O[LD-8`S-5G.M M?7ABIV6YE$R!'^F9?AA=WJ?]D?E5EOD/ZY[BN)R(^K;E>ITFH>>T\A[1FN<M M1>+,*N)DQ$S67E8DF]-+-BV33B>&LDFF71<F+H!^Q$T)7T)_CRLA9#_<'4]1 M^$KJ7#<779=^7>/U45&>A,L:3]<.JT"6DR:[Z=F/H$C=\/W3<<1W2N*+RZOK MQJJL'1<OM$II;'CDMX<>Q2?Z1Q66Z%>(G6?7?Q\D7G)I*/;1](0&<#4,*][9 M=9Z6/"<4`"5AI+;'8#$<"3'&MOT68\'FS9/5R#3CN4^>3RKN\-Q6X0F=DT4^ MK$R9>[8G4'A['#L.$]=O=?9]V5]A]A\Q>>"W"Z'-@]=-I.2D*Y(:MF(T4Y`] M`3Q3(&=#RTIU?Z3FU\S8>R,OPE8T7Z4])PLD"Y42C>-!@7C-("%"Q@72_TS6 MC<TB&T!/JVER(,57EHTXZRC<*ORZ1;B3KE>ZW*QG;?@S7J-U'(EI_'5W\_;N MX]WCW?NOX.;S+?CZ>/_N/_[M_N/M^R]?_QF\_\\_[A[_RV8PME5DE5*;87"^ M.T<1K!7J:7G0#.#8Z,*^WW$V=6A-`"-C?&+K)4YA*MO1]RV,^RKVQ(%%47X[ M`"`^'U5?,`J('C6R5_6%3P8,FV:<01+2<KIUE/RK73`1G$6:5&$8-A]<+_J; MZY]A7F:W^Y,VO60&/@V<R"R^66OR#U[@!CL/.60<M'T.@T/VBQ*Z\&B`#%<H M?6T<8(-U0$!&9'LELA4*K%D"LQ8KY4"-IQ0U)[7>#O=2QT$AC%[1#RWM<+G/ M:C^GY3`B>N-AMIZN6&(X(T6N>J3$#+7'52/5S(Q4':>U2D1SBJ*YHJ+I.:SM M@%%^5MNF"3,3:)6A+_`5!F?^W,E[7NNTR6%"?/FRGB_*6"D9%",W"E1.8>SA M<A?M<Z(2`><ER$241`RPX9;2?D<[:>B>^Y7(V22F[@*JJFVS\=.9#6(Z/$4Y M?FG3@D%'UW2-I/$1_>Y,)KG?V6RGFV79@QFXOS!<`F+F:)WR!GWJ<[`GO7M\ M)M`!&NU4W&0Q#3:N^/H`H_H!PAN\<'F&'=F3+8\;BLN;>!%-R]NLG$TE-$?D M0(&>V>A\N&PS8[()Q>C#!2Q-7,SK6Q.AM\&J&J1S5:$2YTQ!\0?$:N%R4CVE M1?`E0YCG<R2ZQEO/5K,M1?Z74J":S@;N<P19;N!W+WFI!K"ZDZO5RCUK`$T, M,-72;47M@?H8L@Y;E.CT%MW@K/J,#AV9"7P#?/\H@OM:6;#&1[0&OOFX$AN] MTW06#8/G-\ATCP`3PIN]E)2I&+BO,`00^=4#/W2#&(3G)$[<`'</-!L$UZVG M'`17I%8S.:(O^X@^;*%O.C\"YCVK?2KD,")^7WNS8*7J,"F`:15Z;9H*?)5( M-3,C5<>\ID0TI^R*2MWEC$>]'3C*IZ\V51B9M6H,<7=M&I[4.8?5AQ?V_NOE M9EJ=RCJ:ZVJ8QX8*5`&$9T>WX!:#*LUG'.E-8."3^\,[GH^M=^7*SVBT^]+` MXNF6VP6[M</>-WRO;8`4CJ@4NBR\T5R*MET75DFP]LGS$53"`#ZX%P*8+W`' MO5>X_R/8PZBPA=*XI2'QMNZ`3IPUX5J+FTVZO9D1!REUD)('A'YQ8U!S6<ZQ M!)]9(GA[6#B6],1AW!QQO040I1*[,3AF"CG1`8V%B_)(S@)(2:49F4Z]H'LZ M+3VC<SHM#BP\$:&9:)6B*K!A.NTOA2,JA;;IM,E<2M-I35A#5AU&7G*Y"]#7 M01"\_QZ@K_3BG1X@^KIH=GN&;R^?D;AAD"#1T?C/]!'^)^Q)3R]:^C$IGK.] M6K!=^3(9D`XY`=F@(!\5/%U`Y07ZF#$\ZM`3P6ZNCE-)'>[AX/F>F["+9&'R M@J9X=OL(_1$Q!N`/](87%_-U#2-_&*0J7F+`)U`3H/NO-^GA&7\?M>$I[0%W MC05!.US.9LZ2M2DB71M2*II/!8<*0*=RW((CI6)R?W2H-$[Z.8SO@_(1D`>P MS<(:F=)1&'WYY$9_P>3#.=BW%TOB/*QS,F[D0"+ZVZ2&CPD!2@D04J;#6062 M.3TDTS;1M1I::1;C:T+-%'4)_W*CO>>VS$^51[1/3N7QA0O-+99;5N864?@/ M0D'WK#2$\QGCG%(P.AT-$<,I?0`+9J1F@\^GHP9A3<Q%GV%"2O]'X:NWA_NW MES]BN+\+V#W#X/EFEWBO]$HH"F"]X(SC5[0`(##BK3$'$M4XMPWC5/S<;#9C MQ0%P%R+:;X,-B9=0O^!1@1?\"K*!03[R!.1C@WQP,R4%="ILE2J,-N,H*.R0 MJ<G-QC,YT:I!47%"5J#GZW,G'241%!&_&O<B6XA@M9TOEZK=C/$"#29T2(LY M8/T=_/`[2UYM<CI&JSNH!9LZ[V.\:@2'?9KSH3BH$25JWNL(<BJ1#+05\S;9 MP%<6U(RBL')0<Z8Z8DE4U@<TD@@2<"DR.KX^5](OH)$E?C6N1;JR$D+,5K6+ ML36@&56'C0%-D].Q,:#I"39UWL?6@(9QJ#:@$25JWNL(<BIQUKU9"'F;;&!3 M`4U/%S.*PIQ20//+.552:&=0-XH.FH.Z,#,3JX,Z22\BX%9E='Q][K1?4"=+ M_&K<:Y\=EI5J-VMK4#>J#AN#NB:G8V-0UQ-LZKR/#4'=7;`+C_!C&+?$:(5G M]/J$?&#QZ\Z+]3J'-B4`?L$D?@4W21)Y3^>$E`!*0ESO8+3"V`)H[2M=%NYX M3#H?2V<LQ.DK1A:Q8/9-U5(;8F1.EP`:_5L=QA4W59'2N+>Y>74]'P/Q,2RT MSV9)NV_=V-N)?#$!*J8\5C=K,N:VXOJT=!CLT(IMZ-E($T#&LL#)J59(LQL$ MKH]-F"FDV(F>C62!GU2MB9(G-:,`65>K'!W.8!T8\=;B;I#KSP55J22)$@V, M8MT=A'M2?RAO/OXGJX'>E%77_9+N1,M.CD2ST)>S]9Q="GA\@73OQ0OP6HCM M;Q?ZST?>\TL28X,\(8%>W!AFEDD:M`,W`2[N3+^'N*J!%^`J59&W@Q,0(+M& M%#)J.UP04G.*IV*=9=-92I26(DO)@OL#^+.EKOYX<]<8PF;.Z90*6[,.DTT$ MY*"=)9"**<E,I/G]9D?:SJ/U-N(Q0/_<T;O!#Z'O[2[T?Q_AC^0M8N,O[HPE M249KK"G'F_!N\M999D<0WT$^!B@/,@%T`/"-_1>/!,A0QO:_QM2(0\M&XOMT M?*68#2OZV7PYKNBA0D6!Q??WQY,?7B#DW\^H/Z0_<*AP(%Z?8;6:T4`!PPHR M(MKG\$'L9UXA)6+RKL9`61PI633-P!P,%&;<)IG5`-##=ZXN;IR\P,!S?X_< M5Z^E4T_;X]I!R>=%-$R;KC<S=H7J\]WGVZ_@F)$#SX2>;J2JDHEB%E,#.3E` MZ1F%KRH!G?RCR0FH!]/=L,K1W:$253A'RTL8D/]>ON)BPF2_X/Z$X?6`--X* M>K%W#7@`(<9$0[[M8K.=,G?`2(.`T`8Q)D[WDD!(R(,3(J;?/8P@\*PD,*4- M"'&ZI0PH>8#I&_8=(TA/',ELNUUWRZ?+=4@AM>A'Q-6CQJF$P3N\]"?;D!^A M&\.;_=[#H[G^^Q\)#&(\,(R\<-_X/25>U^Y:Q'D3#4`=9SIG)?H0=9"3!X0^ MR`<`V0B`#J'9RXPE^\P:V3L<S5@*R'H2[7(%Y&DS/E&%FZL"9JHX<56AQR?) M`SUW2Y+*',DSO?]Q\FC^S7]!MSG,Z7K'O`\J,R0\SRTW&[;*N743B`\<OK]X MNQ=F<&$$\&HG/)_PAC3Y70Q0$!W#!)]:0#PFQ%FE[][]UW^!0Q@=7=W5C]1J M@N^&<JH`D[7"]0R15,3?T.]K\`!"$*HM#J5!14:.'Y"D;OQR'^'&+.R'F]W? MSUY,W-T'[P?<W\0(5C'Y;03W,]Z>=@]*.@\AY-F3N:I8*(^(#U:1?\+C@/3G MPD@30,8"=#"0CF;H(&)LK1`T/[!#Y!@[ZU.$T8Q6:[C^(<SZO"0OR)L_OP"7 M;NK'N/PO!HO1<XK^X"@=5?14LJJH0G+PQ\C=P[N`=%GGN/LA%`U$)`/8%3X\ M7VR<59Y=X=+"ULC<#P3L+@5[\H(3)P+P/D@\C``Z8(P#%1<$9,Z+7^BO*7<9 M+!+,$W[N%7.%">^]^!3&)/&B"5"_@<\I/107[>&!)&FX>"P:#F'J[E-X3G`& M4O%V(Z+25+P!CXE8A[ARYRG"]4GWYX@\PB)])MWA`'>DI'?X''C_R&5'+M'W MW"?/I]2>S@E]81\BR?$+\=G'"7(T,X64!#_1UVA!F[0\NH>5`MF8^F,Z;;94 MFD_N^?-)\W0"R,#@+@!D:#-1H39=2<\RTG`R&6HJ\-_%0'3H5U$U+:7'@V3# M[RWZ</MWX?&$UM;$-[5L[0N^:F"B$>%+M%*?LU@7M]ZRLU^ZO4V(@R)U0QW1 M1I%Z9HG4G1Y.O>C9\A>61'\C*;HNWR0#XJ(3$E:<*F_S&9X1X^=X=_;=Z"[8 M>SMZL:W5SW2\9,##M',D:&HK9[:=;S+?\@8$1:IH6LS(FG,J*@6=<02]TR5H MIQ]1*:TS4%I=KD,,D46G(:`E0WMHV08EO>OP_@=V9=75<_?S>O?#FID0WM^9 M+]>S#%KY#FUZYXN1&^FRI\#&E@KQ");29A5YQPYRS<'0[2PU@JUJ@MVW"J9Q MRZT=2Y6-M19=J(H<8C0AG]'SET)F0GO8T/:&@9BAA1WA9?82)Y9GBY&,8BF[ M2'OBH4+14C^62U9,(S(='B@3,XT-D'3R<NH*#`0`5XP*NI2CQ@^<,;W[PSO$ M_CG"M1@>SD^^M[L_'"#>!6V^3=CYDG9OT,61L#DYSG3+'`*AB6_!Y50!)0LR MNIH]@UHQ9V;%['`/:F5U"K*&![#+93U16<,V6?6X"%$LYEY"2$=*'06K_NSZ M=\A!><A!-=06%'C!E(-HY$8XVWV5WR#*+.F04@1>@:3ND$&=>!6GD%$$19(& M_8$"$2N^X.C^3QAQOJ-Q9]"*MYHCX"M'J1/`]XSA_BNY,X^]3U;RX`OTW03N M'T-<DLN'<?R>-7WL*$^@@JXIES*$:=&4U?5BL5Q6/8]'!DY+%Y!)+:^R`2(Z M.JF^P<9O:L%IRE/ITUK%H=&!`1V9ACUYQ1[`1@>/(4C'!RD#I@LB:-><,X:] M&?>H*IQ7S?$._BA&-G@9\U_@*8Q(2;ZO\+G4^;VZ2<=_0><6+Y<+X;W"Z69; M=@S(0'-R(*5G:(]7D7P5^$:$'-[*CBDYH_NAG:97VA!MUXB2V`:MF;P=?)\F MQGPX1P$*H")X$^P_>#_POUHV1\5?UAVE"',F?'MFNUZP_`U*.T\FFH!#2IZE MV]$!-(<8(XD\*XB<$0<9=8#(@Y2^R7W5D<1WFL2?%.1W1>77,MM+PSF;TN7T M9V+>KG#8VCFZ^5F-LW4C`Q*%?U8+#O+,=HU6(!9!%!HCC%QR8I&+1LXM9>35 M-6VW6EYQQN:KQPA@TM-4=H[:5;V?_[Q.X/"8D+"R=0J>+(TA)6:\5KXB\9RR M>)`1,UKLOM/<2DAIU8-1M'06IF]ZT@1">M0/G\^<614;I;+.9M)@!HNT*HMD MNBYZBRTU@L""&ND9+^0^:_SAC$.^3U[@'<_'!W9;Y[9VA4SV;1,P:6=)(M%J M58,.)8V7`V0MP*B#E#RX'>NNCC"@5`I/0/:(A[8"6V*&VH@W`:U8C,%W]-![ MV*=/B=B'2,:9>!GVS7;5`Y@3\!D7CGW\#OU7]$08)"^&=C['U`L)%)&Y+:\` MLA6[[H'<HHHL!C#N)OX*<:6(SA!3G)!]0"YP)S/1.))@GF`TX]N?>#12-<5N M'/=62XKE[15@N<'$>^"YJBJ[,8TL2@VF,T)68CKE3F:%MNR-:33:=6"ZGUI2 M3&^N`]-5$^^'Z9*JK,;T(QI5S41=H&0CJG/V9.:DVCZK**S)<%>!Z[Z*28&] MO@I@U^V\%[(KRK(;VM]#-<!.Z5@):\:<1$^SU;8WJ+^'UP'I7DI)`;VZ#D!7 MK+L?G(N*LAC,CR\P@NXAX:<#2-.Q#\PY<\)VZSCS?H%W/I;54.ZK$H<5=FN1 MT3)`URV\!Z`KZK(`T%\09^P`^#,4W-"NO&,.J&5&A"UPE15:J(,2DTQS%?#^ MM*$6X0H%9=W+D%@L1\$BL#5;7PNP&A1A%D1A'+]SH^AR"*/O;K3OCF5K+QB! M3Y4+89/:S)SZDA.WW2V1,PV:8>)E+3L+9;*QB+LN$?6CB&=^S1!J5(N:)';N M&-TU]X7?U9["+LB8Z"509S9=%SH&P[S0_!Z7Y$?$&RT.I*/B-Y"@N&X=6NM= M\+I@0@KRZ\YS'T4OG4[%@LK\XT@NY&\*YF(NMUT2Y7EJNXS>S$SHF(6[8`]_ MX#MSY%9=%.,TXN3RB`:_^>'QIW:!5[5.\MW\"*>ZHO^?IL@DP&-T\6U+2OF? M8T!I3P"F#KYA^L92>U6+[J@175]@(&[&Y1!!4'$V8O,V/+I>=0*7?-DB?%*. MA,UT-9UM)1%*1[`4HWW$ET-IB_BVX+1LTC)(+:C/"%:C9S?P_D$F]'=A$(>^ MMR<_W`3[!V1/:;A=J!B"*Z?1/N-=EV.4T-:)=!4,2R`AFZH+XTY`:61RPZLX M-KZ@G9?:R8<W?TU'O_(<3<K3YF54@K'DA)1]FZOS4;=>O$.+,WHM]ZOW''@' M;^<&R0UMLX26.`^(WLZ#\2/\D;Q%8OPUAH'W8>-:/%\/V22N[FU4.LF<5?). M@5F0<PM2=L$WS#`@'%^C5QW]P]0<L(A6K];##G`ERIQQWT^J9M-X".>$KPO/ MR:JGKWWS62'SH@4W-LYT.<LWJ/>Y=R-[TU5@[DI.LU22,LY8T;TW;4QMM5FE M,JG<5">5>\ZD0KDP.%D85F1M%C"WWSV"@\KWQ%4KV$@LC9L<H,DB.L/]Q[P; M8<?]R/:7=,:IK9Q(I!LOT_N/F"!@%$&!)`HQ*5%#<9]"09U<4)<)FE:_,!J+ M"9EB*7+J5HHY3)&>@2(X*CVH'3O%T<6S+%:S=0DOA(H5$.DO#^V9&<&3Z^WS MSC8@K?9.N[::!TB37=5!45.#82!\S@K-=W^]PK-FX)`S(&-!FR9$Y*2,@Z*O M5,7IPB8,U$V*`X.*X,:0@!LZ1O`%3;3>*\SKU=R\NIZ/2Y-^"*.O+JY0BK@E M$]G-_G_.<8+CQ<\PN3\\NC_:OK(*\KKQIH!GB<NBLWD1HJ6QRR6<)B#CX`U: M.;^)75+;-V4"Y%R0%&.\=$:<&$2X=CT2I_!'$$'7)SW-GUTOB,$O..T)QK\" MO,%0UV"<#6^\K9IJ0-9<CZHO8INW&N");/,RTI;O.-DM_&X/8K-?Z"=Y(1#8 ME23WF.0^K_R=#:CNB]BK0.,#C+QPCWX?X5L6MY#^MRL?8SAARY#<SJU$YN!\ MU@/GYE,N-*N(ZQ!P-,#<@=EZJLJ@(^LM!-2LY@B.\A(G;3T&JL]H/PJK,"!Z MG+":X4*]\R(0X\14"_9A0LRT"M%Q,C1($G8=T3L^G=$@I,`X<G^BHNDY]N&` M(C^Z:=*`L;G]_?'DAQ<(6<<?N6.8[I=US]&='$D4C5B6MIE3REFS+<O.9Q1+ M7IA>3^X%\>&GO;*,SZG")EN;-\5TI&YN_!UWROH"7V%PAAU39,.C1F;*.A^" M=K-R9MO%M#AA/F-2R&H(+9,3YU"9"EZ`D`)?=,@D,(\.%<SI(YB^690/G_)D MRE&#L3F51N0WP5ZT<4?[2[KG4"XG$@NT,FK8JA6?:]K3R4.AJ,X04;7.G9VF M69LSVU5D'F-T8J>\Y0FIG?GS4C2,(;"#,8D;*O,E!Y`LNJ5C%'/2+<@W'T\7 M!+%W`6(!QDFN!V[1'C,@%;1M/F9%=&8,P@^(($1A]YZTG+WU7KT]#/8Q8CL_ MCN+>FQ<GH!N\0EP)+\:VLZ531&Y&G;5^SN@3(RZ,H!:R6RI\`)_)PLF$#A98 M";<0'I'L>T:QV+_Y"0;PX)%\:`2T5^1<<)[T`;JD4!YI_(Q_FWBX5^XI4R/I M`VT<\E)8J.%=7-WJUK9?8`R1E"]HD%L4>OLA:9G'HO`;W"/ZF68;?X&[\#G` M!_7%./T1GT.W7\!0/XJ1%;52$42W2Q?.<LMVKTG'GVP9'F6#4.S@RU`(/&2M MCGP(+JN"_H1O;$2,;^)8]CGG`,5^R,+PKHGNZQF&U5EPPRD7Y&)&@8]L!5WD M!.2L5-;9A!OCES4,JY7$8E_/QZ,;7<AI)C'8DJ*,I/V-[.O*>QCJ]6_$U1=. M9NX/+/!4[^H%1K'=U7>+(!H>;1WTR:BK3]%2#(NBZFG9P=VQ36_BV4_(-X1! M`''4A`_03NC9,X8>>9<S!>Q"WZ<M@,EUON<(FKFO9UCI`R:$XD>Y/V3K[ZN< M$%2KM3HA9"/D>VI7,Q^(.\3>\X&@^DVL\Q_<"V:$K$3P52G7[]H+;WM#XTJ^ MA0U16UYM%PNVZ992HVMT1L_X#K@R&9V^,NI:8@N887%-W:480T@B<+\_D#4^ M+MWE(KE)'@G_^_)?T8LE+A_">T"SU6:>@8E.HFAFH'M@*46:`F0,3(J$I%O3 MJ4@X**.;5\<C"K7(;M4$O+K^2*V)7V'T%.H2=49G>O(1O:+$1J]YB4"MXB[: M]6'27SR&-[N_G[T(\B]_W,*GEME8BHH!KR+(FHQAKBJ.!JV$V!CM5[,F`(]D M:N-]7(60W?<'Q/8+[J2`/9(7O,*6LP;=:)4T]"8`RVC."DP_1+CH=W)Y\''5 MI6"/*WF2=8*HB?`)F$0RERN)%,;Y@@_BE/X$D!$F-%LC'<0:_*I20QVZ)T:9 M"`[;!#>&XD[3;@5PN^J,8!=?UB#E>>B)'0H.(I@@5C%7F$U6E8=G'**OZ\2M M($_B9?SF\S3&IZ0+"2IEZ@2X:+Y-JUVQ_QK/6!E')>S60TEXHV"5M.425&4T MI.0(XP&BKQPD[C/\Z!V]Y#[X?,8IHBA:?W&1$=P?WI&E%8G=W_]`#WLQGOK? M7OXM]/>PUF!4#4W=QQ-#&1;M23)?+K=;>ACQR?U!6A.Z1UP,LKB&)4,"%[P0 MVG1"*J5C@*-[`>'W8%)H6N/B-TZ9&/BMA!P4!D02_#,C7%DM@_"<Q`GR)/BH M&Z\R(:NPD__Z-_#XXL7`QZJA1QK?/=_'T^2+]^0EQ7R2!F919%$:SSM,*+>( MF;./P@MDZ$S6&$N%_O/BG8JR?`_//JZ#M8/XS`8]'9_@SCMXZ"?"D^9C%;W& MPAQ^I@PR)K@/`!T5GX[0<?&_Z,ALWZ<P-GA[`6QT`P<F>A7F5!1&3`17O>A$ M`BPH[.F2VJ2QLQ15GCD[.5'R'11/.O<'FHV)[^6&L8>]2_S1^POZE\?P+?S" M:IBT6Y4@#7.3BAB#HFDA\^5BNL@KR1Y9CUL?$_1>PG#?,B]@;^LFU'\GD??\ M#*,TYRDM-.N"Q/W!T@7-N=8Q5%9UI<AALDQO7"$@&P;0<<!C"-[B^XQT**-^ M<PQM5/TDV;,BVL#?WZ<Z((FC(&K1@697*.<O&ER?A"J5NSK:8"8FF4F/X6?X M/;UQV1%%M[YITJWQV1*UQ=G<6;'TG+_!F.1;%B*_K(;5^82=4P#?X,Z,*#X- M/!QQL@0(>I,2]WDTZ*Y4J:+!23'2+.</N25$/;MP;3:@4R=W@SL*F=ST^R)7 M%""Y89O<VIU1-Z(;75"'TE0Y'B_<?PBCAS!!XWJN_XC@E#3L?W<^;L#%\'@1 M70M,-XOMBOJ56QCO(N\)!?QX[8@L^TA6Q^C?F6'%Y],IC!(+D[J5J2+U*X@: M0.1`1@]D!,UX$C7B4?>1R92D5/"G/E[<&'WNP'/Q%W_U8F($)OU'%S"+3J-5 M/RH]!>*PZ*/(,I`Z*CPS<Q=A0J\:\B!=?`G;V':[8OMV=WBE1+IPD,TSVACQ M-0]=T+!F7(1:64ON`I$&Y9"$[C"QMI"4OCGOH59RIR`Y1FUE5[7VW<TNBV2` M6_4J0GHS<AJ(OM-G]]C6&;KTB,Y3O<*XP@?-T^TJW7U`3P+\OM%>SOV%<$2% MT';8UF`JI0.UJJ@F[;FUFW+E(0,V+=D>>#N?3VM6;;3_\1!!JI9M02?C9K-I MLN[>G8EY$6$:;=Z0TTE\JPYZK_@PX(]@C\OS%>XWW:37FQIGZ%Z$M$>+?;@4 MC2IFSG2]IK%COCYA`X%\)$"&`J6Q0#:8YHAR?'W,+-1'1[`YOE(JBUB6&A#E M.CD3G7"N%YH+0X=XBSPH[:U?-2ZO5"3B79;2\`4/V&@/K2]H=V%MW(A:H3-U M9NO\9)'H.MTK8Z?GY205<BN!&";>GR_6%0DC`-W="WVPH[P(/9/TXO09J'T% MK4YY,]:IJE2%)J<("$D3WDN=B$Z3B-FG`UY0R?B94$,RYYY$D)V[H4Y%&5E! ME+AJ+);:^JC.U43#^.+U`C?393.&S!0352=4(VI,%A(5,:W26H.G`O-X^!P^ MN-'?\*4_H<]7>-P8+G(>)"X3KV>-V,"M[``B!_XVVKU'28#TE2Z[W$FW6F&$ MRW"\;8T=:(!QBKQ=H^1F4%0W2#Z2*KHRCR;$SGU$VB'O"5L/,"()@D)?GONR M,:3Q.)+8^%RO.+C#H$.1+J5.X8</2FA&K@U`5"-\9>YB4=T)"<^]:6T&=UVF MRT=AJZ+,8Y)FZ-Z<DY<P:DB(%7S)&`:KG$ALS2X6'.RQK/><J`UX&R9H$\Z` MFQ&K9;`;*W&@\N,V.Y?T%DSKUS7C9'A8Y#N71@W9XE1(N"7C4-@+AIT)Y4)B M'MM,VQT))6B/$^DC(,'2.WZT/$EO>/']ATE,E4VQ"T\%!=F"I?O\TIS$ERZ^ M91A5!5;$*\;/IKSX.+V9EE.U!U^]1>T&6?%*I7TS=?]OW!B?%(45"5!,.I@& M?'9YF:JVS+N:KN8=O*>-N98>32AFTPUG&]A\$0,5LM5\2$5.>X#3VDZC31?F M@2*^(VQX,UAJIW3CS):\-3$A-+$HE.TA6?-ZT+*-)L&]W;[;NMP<A1#70,"5 M-].:/CB)EPSUUHWA_@8W*$!__=.-2,<"TO*XK1BF,K+Z\QT&\RQHEHO58KW8 ML`0N-BJY'_1+.O"O-$^<3E!D<$!&)T^EXZ?-R#54XVS)<]"LM-D5**V[!)DA MW2U*!=J(MFC$_42TY5)M91?3B.*^L\$G(##3J4NUGRKD9:C1OU)'C#FXC=SO MM^'W@);/\!)D1+B>6G+YX`5H:+1N^)"U%,`EDY-/;O073-@O+W(N>IP!33GO M4:01OG8\6V_8S?-W;OR"RQD1I@ATTMHP7IP56BM7X)TP0+I^0R&9Y"4*S\\O M8(]D`WLD7/8(D8_4%$PNU583[;3<Y$WR`M\<B?0Y,_0E8RTF+/J2Y;F&W%G# M'`',4EH;B:J?<@4RMD#.%^E/<9,`REKZAPN9A^ZU3-Y=:7S6Z-LIZ9N@(;/W M9G//]%TQ_+)ILS]>Q'!H?(X;=0JHS7[C?7<SR_5<JI2C4A4J[AJSZSVM2_D. M9H27O^O9IAHR$UAE7B<L5W@SM<!7*B]Q(S?/:`+#\3?NKT0*\?(SNO1LFZO] MI@V^\G1^\KT=^J0'&"'(UB;^S/V9]W?2<"UOB(BHTB;ODVW*EO=R)$V%1\4" MS\1A3=RF5^MJN-7@IZ3VMLVY+27*H$[,)\:*Q.QV8J8AVV'C(@!N4YP]<"XS MAS</R"\@^J,\JCN)&0=W%X?"9KU<Y9>9>!BOGLWAZ#P?SSZPJU5.=QH`GL#3 M706[(AG%9M(0WG@%.VE4S!5$-J*^H]M;"NE;^<YD/OX?@==\/9__M,D]P3(K MHMOFV_5FM<IOKYY*]DAZ$2&;2S?(<=6W;)HNQMT&-]"&B-VP^Y6YZOL#P`0- M;U<-D8XXF-^C,([SS\KN):<+*"LV@IH1U[B+TZ`.>Z*F]`Q%:E+)7C(>!:6< M2$QCSK0KVDF)VA31]!.4H.G/[*20I%88SJ\7,<+N:;:D#FO01'JDW1_H'JW, MYRV_:!I5)6XDEL>KCG5$!+ZRN9F2M@A?`T2N;&L^E^>N4HAL'?(:#;83?75E MC1?0LK'2:)KA7C@"X;QN1<C;S)OHT9RS0?]?.-3V@H,??F<&A\,E=[\G->]= M']^J3B+OZ4R+;*-X&/\=E^!AG>]*1DKBK<A[?FD)G8&;X&83:)D#<8%=+\!; M87@'S(:86H5>6X-LYL>RXJ@W>1Z3+9&W"AT0Q_:YL+.1VTFA/FHA%XF:"S[L ML"M$;_<A[3%[BR)-AQV8,\32)S?!/5DO]P=^MU:!J5"&FJ$`18)%X2E\L]HN MFZ(6@G!LV^EHV.);FQZ;CV9&TT_#KA_+1D(*.M+A/+N:(0_#"2\$DM6P#2X" M[TE*=D>6H�%;2P)1[!.[,9%_[DX$-?A^2^D%>F!R[,[>R4+&_G;;#NTJ+R M)0X>M-R)#\5:70%>\TLFES.-'`GO^2ZW\\)&_BY?R#2O8]R3EU36,^7E#.?$ MR>"R1(%^&A8CA&JM#^CGYIL`&A<@"J3E+#L:<Z:M6&>T`KEQ=<'7DJ&`X7_@ M+NDH-5E\1N^DGP\L?/-VO9[G>Y'X?=/EZOM+X8A*H7'>K9M+96:M"&O(JIMG M\[>71S1V6\,1@3?U(J"+'8D;Z87II!C8EN/:"<"4S38N42VU,UQJC0@3-=T* M[H149A4:R5&_K`W0EVS`(.%$8I4U70O!CY"U#'@]1"UAKKQRG-"#,BMA5K)) M(83ENK$*7!^]`-XE\"@-L/Q%&T"6<2->8G@Y=02`!KYATH#0MFV>ZRET]S37 M*;1Q_-7,5@B#9859A</ZQH[0*S9@3WSY3E*.Q*)+[?L4ZL5LG=HX%1F&RQ<F MKJ]'OE4/^8P[CLJ^B[!6;',6-T]Q$KF[/DXC>]42YY'R([-8VXHZ$;168^1M MF[U[2][E5_[55N!5;584@"4U607$A]#W=I?N&HR"K]L`R`I/$J:YF`N!D@X` MOK'_6E#"<0Q-U$':>B1L')X<2Q:":).BK()I;X#:!4UI4]S,IE.1F1)\>R2- M^^S%8D_1"0J_GH]'-[H4<S4JXK]U?9+6:B4R^V'29C2BD=N;7PN\:04>,W:$ MYX;%8CN3.%TQ?2*I5F[Q\Q4[SC!%S5<,D&6E687(/V)X./L?O0._0'+WFS8@ M,F=')EI;""&2T@:8N&5X["MURT(2P#CQCJ1^R9G*[7NOEDZ0=>L5`F1%:ZJ2 M][H&0[\EA:!CS@Y.?SH&4ORDF12N>KO9S+=9F65JH$V!:P&4Y"]TM+$W?=JR M^D96R<Q2E73F_XVL%V<<O>C*%.SM-8K)@_U4K,SQA1'-P7V`T2&,CGA%]2G< M0[\Q:U#T+1-.K9TE0;M$,^QROLA=6$H4%*@"0G;<;M:MODJEI#/3DG:[()7B M.@/%U>99Q&!9\B,">C*Q?OG/LQNAC^RGM6U=_RX@_&%N;[UXYX?Q.8(=1V.R M5#2N:R19D\@27K-<EVP$D`T!"F.`?!#C!V>C*L-1J@Q=2Z">`"@NA_IHU3JL M=^WG"[YL"[+['#&MEF*`-M\B;0S1N?"]=1/76H2V[N1+J,D$'K^@K])V(R+_ MNT9498-*)$`Z[)2:O&OT_D)/[AT1[G79>\TLBB9=%M"8U;;>6BL^H=MR)>]Z M;1=IQC+[^D9/AWI+X(A)H-6"^3?5JF(JV2WY`KWCTQDI&&]%W!_N`J1MM-SZ M`F.(.'^Y"?:W\!7Z(=F_P5TYFA:T\D1T[Z5(<RBZ`I].9^F=\-(8M+H('05$ M;!BRV;?/!R+7O37?]AY9$[.Z)G!_HE03Z3"D"E5A(-*XR,!6S,C:<-KMPFRG MH-[0SS9H^FEO#+]UG[S`:)#3ZJ)@V&-UL"=CENLF=X5`2H8P@%!15Z54!<U^ MRI0*I)R44CTT>ZB0Z,$J]R2(<)YO$E&:D65!D<TOB*F`VQJ\\5&="X6&\85S M(.?;^;0)=(R.H87#8(D(?-[_.,$@ABC,*Y`SUEE#P6=J<`K&6V&T`:6T2N*) M;P;=/DY<>G"CY-*:9]KPH%9D5T>76$<OERFN"1%`J)C>$1@HD",GD#X,\,RI MC(!&X16%W3GMYMFT>0Z3?%E_L"W(F:@9;;=S9YK&V>1-5AB,NQ60MTH&W[WD M!3U(K>^$>/*@[IIP(RFDP5%P@^U1(P/>U>0QA2>7E!_QR'PKB/A":PJZ)?%= MB+=EE&9Z,GZ,W"!V=]@?M)TDM;QA:'JNL"%^ZV&9YI:7X5>@9_8$2I6,#5.W MF(PF)G&.&?)F\R;%*)_6"X/@DH\PP@?`WC_(W/G)\V&<A`%\<"]DKOH"=]![ MA?NWE_>DHFF7.QU&W&18,(ASB7R^V3(-&_+Y_P*2@@GOJL.#8SH^>IHR@"82 MR@%XNK!BLP8C"(VZZW!QM>%!-CY(&0`I!^#M!5`>C&SZ&=$?ZQXJ8&'0]YY) M?]$D3*W-BK!%B?]J#&N&?P:+PA[A[8CZ.^9#'[DU_68V7:X[@Q]K-BP&RMD5 M`%FVC\$U28$@R/`E5AY79XC+9C^&Q;]W9(+W(F4!#MOXDS#;U:8#GA.`AJ([ M*+\DX:^@LC=G.#]\?.TP4+?O&F1;3*6=(Z,UF(9`1,0!=&IXS.710P1'72'U MHV_)(JD7\S*QZJ)KG72*X'6OE32HL",H0AQ<_Y))@QK9#3SX1LC>KF#E-,BU M=2V>^G\0BZ(\7M$$X=?,1V^R]]N=]<J9=D5JYJ[WCR-M^W+*]*5]62,5B*F& M7,D?%W%O+Z4P3_K<IHF`!2BL<R61K#"?-69?V'>2,UC,IIP,6P]S6DQ5!($< M5=F$Q?Q^;M<-6!D*%J"Q@2UA.W4VV^[IL7B5V_B-V-&T4$.KQQKP\C5C(XY; MS%P$R#PUFD%RN@"Y/Y#&OW!_"Y_XX6OSTUH1VLB"^,;9:IY>L,THX>1V1@M@ M8FI1MZ5"!?`96T,[[E3(MB@)AV7+J^8=Z-WMX!F@\<V6R^NPO#*0^'HQ`YJF M3*;.I5_K2UHAU,:)L$>?.=-LJZBP!5W,UC._Z%,GJ=AFN^%]=1&[+".K4T$6 M`2R*\&5G>CLG(!P^AJP$U(<P(I=YXL[6F&IHFX>K',,R<=JJ`]6%H2<@'1QO M6[+A`?H?>FDNMJ`+IP'UU5W%6.HS[%GZ`5+``?7X.E?FI]Z%1WP_C&QSOW>C M`.[5VV_#&-?AM^J,B]]56ZQF*OU7D15`>;DZ/S94G<2?_7%"+@%I+UU7I.>C M5^J6^/A3Y)XX2K\R-_6QH_VJ$M+7X90^RG8SQ>N&I3I?9$&G5_W:4Q9*6=,R M5B48%;FJC\;;S@Y@OK-;CQK:U^&CY#O?X$S"KFV<'BL6PWG3VA6H?,EG14*V M0E`J<E46="EJYIZ5^Y"RR/0=X[Z%,2+17KG39S"2-CF`7E*V;OO:A\Z*&7:C MKJ@4Z]#47AE5X$U;D"57AW2U7:ZG8O@RU+%B-*';YU&3_2IZ&*PP^@SWK6CE MC3;/[?/]V9NV8)"R(Y'G.=N(8="^EM'*]=`.2T)X[R7GR'1*@;`="T.SH"U% MMX::!OL`]S!R_4?WQ[L((DV^<Z/H@@+?[VZTCQ$G7D3[7[@)_"_T>N6S*R2L M_YZ0`JY%.[&ME^A3T`M"CR\0H#=]#\8)V",ZP$W`]Q</6?<.1@E:7X`#90+L M\.`@'1U\]WP?0,P#U'XA2+NNROZO6HR)#0W0V(`.#DJC@WQXW/@"`LR`D2M` MVA77GBVR(P/2U,<P.KVX`=A'Y^?T]Y.R[369GL&K00K]5^%.D*HO-**3_CVB MG0M9U5B:\"-N;\VOV^%P&WD3MGAGL9CW+&LW`<]XZ)CL@/&?WR7>JY=E"]-" MQ%0Y^FO@C:2_=E=+!B"_3:M1TS&L\:8*--#J,YFA%+Y_U*("@ZZPU4MT.#R^ M$D=T:^4:?2UU.D5?ML.E-7`F>GW7<>;SK.`6-^&S>,.<V:(5OFBPX.V>J%JH MTT"E[C&%;P_<\GO;!VB=YVD!<H??X6EM5*\C[6GL\BXRMC7?S!>+1<6CZ"QM M*^U">DC7Y39L<Q0]1!SJ'`9+VE+I7_GG+`M;KUAAG?>3\W@ZO1PN1_0N])%` M8=3/T=0I6.4':^R)VMK263F;SE"+C$'7E+OB*);$6RI4T'[2\*6H@M(H1BJA MCZ>&E;@E?+J$?[G1WC/23W<`YL4\4[,>QW=5,1ZX$`]Z,EM<+32L<E<-#(IN M5:QF\W7WVK"E\IY-/FNP'H1BOAC@84#EWK]MD>!@70A=$+4O*AQN`P/*4-KI MNEM\H)CSYNE4J?LNS0Z(C8_>#A]8WZ1[ZP\P\L+JK;(^%$RY;C'V1..+E3-U MG(KC+HU`W!<;`V2#`#J*&:<]A@9F-FE`S%^/H096TKXH?78J!1!;1^.N20[? M-<<DH323.6?%!/!@CR_-G9'VOX:'Y+L;09F"4GWI&<A/DV92.%MKO9E5KN]/ MBB'9A$S/Z8`@'=&V\E-:M$0\0*6W+V_=7;B;8$6&6V_4-.6]]=.STEBF>@;: M-AO4GC45GU09$<\06JQ8&\#?0Q2[!V0T?P)V873"#AN",`*'\!SLZ<3$4B1< MG/>"8N<D!`?T-Y%T"4.+S6&:*4<HM2P(@X'(,+F(PZ&)'.@3QN<3^M@)]RL: MCS]XF*Q%&HU:,113))&W0XNN=VZ,5V;X/^__?O9>71][[N;?=ETRZ4]2;V31 MFT^):=-A>4J8#@TE\#\*%,W?_-2D!J>_&C0&"X/A4(D7ABG7K$_XFJ#011#L MQ6>-H+C`@$3!A%D^>3(Z@!`R?TMLJ%B.M%CZ4=9@8,WPJ6K!`ES\$7A)_.7K M'S+XJ+QC#B=E1F0,R^'@A5`$OR":\:]V@6>(K,T@HK):"*5FFVR!5(-NC$'K MO$O.D1<\OWMQH^?:&6KKH[J!5!E?^'[\:K:9%_"3D@&,CD&X#)+(J4N$S["B MV/5-[_UPS:H&BB8-F,="&"<QBA!OXA@F=\>3ZT6DVH<$1-HI&$-.*UO"YH?6 M%:M&0&'R9)U!!@#Y"#9A3:$."`0_A\&;'5Y7125E0'HO-YZ``)+JYA:"4\C. M^9CMUJ09*.-KL7#_WHT"Q&5\L]N=CV=RQGT+#][.XU<^[WQ1*W"[N!$OCCEU MLBNRE"A(J8)?"G0!(_RK*9BJE9B@LRC>GE+1G=LRVA?E"0B\8'>.(M,U3T5A M6'8P0CJRP:]T+$$;'S;H/Z2KW&PV/)]A>J$Y7+`:<IAQ6;*\;#.T-K087U!F M*<'D@(4?*E>?TXJ+RN`2;6N<[/90(;^;4C&%A4'"$!@\XB1Z=FNY)?M3G_5S MC*AL^$UR&[;YUFST[N?-8*!71JVS6<S7ZP8L&,V=5BP=G2-\8CM()&2ZL8?K M?/!NLQ@`"#_W5TP7!@'S!>["Y\`K=4_^!).7<%]^X!\M#2>D">F'F`1WPM;I MS&;+,O8*HTP*#<[I0!-0>>P?YEI#C*L3BMAC>*9M'Q@-4K(ENQ8:`W?WXD'C M#2'Z@J`!W++ZM`/UM&!==[ILUWM&,5UA1KS]TG:U:(&P?74:E0KN<`2W"Y$< M`VT'8)->#.*M(PHU$71*16'S$DA&BB=YEXB',;[*UU8F*T#Q#*+!C(W'A'%G M:]+*8P:LMT=3SDW%BBUH-SI$EJ+W-MU'M-ELFFQ[0*]0[IT`?)X'24;'UY/O M)>T1C=@[^N\(M#,D7!5AZVR7>6U%1))E[1"B64`S=B33A.`1Y)R9EK/K&H!* M81V.L`83_\6`5[@`(*`/$_/>5]>']P?"UV?WB/[Y&+E!C*_%A$%KKRB!%S7. MC=W<",\PV\66+8PP4=+PGF;0&DW75RV@(R>@KOE4W!R+,ZR@<DSA*V81P&?( M"RNK3VE&3F%H\>VNY7I3"BHG`+UN#AR]97#L6B5Q#*9J[E5QC=CV[@7NSQAZ M-[M==(;[CY[[Y/GD.N6C^^1WWD27(*`3$<)<";O<Q3)=@:7$L=MEY$&!/HK; M\`CF]]O&4@*==\['HQM=.#HPBCYIDRX!4TYIAC$;)-[>\\^)]PJ_PMTY(FR^ M_['SSWNXIT75\/UVLG"[/Z0)'@\P^OKB1I#(TVT\*@8Q@WT%G(MG!*W2^S4E M_U!@`>0\@)2)M,9AQ@9^*4N1>L!5*S`KS*>8=R3:->H8T*@!3Z40R!QOINK+ M7;?'$X]F5`UTE9Y/.C"8.6DI_?&P:E5$943!Q!G>!?CV!"G.4U%D\@*KRKS% M/**_HS4&^!C&5*GHF2/Z,^'DY_!_@A&=RH]FU@\V5Q\0"^C:WC7BK5H8DL#' MHB'\:BE984=`I4ST6IS42W3]R!<PY&8P=VG./#XKK"%FO[Z$4?((H^-=\`KC MY)AQ+!Z7]"9L#-E]N)78D$AW^O$PD[JQ8P04AK$PE-"CHS2K,4I(-B.^=4ET M\\'U(O`WUS_G3J.JOIM7U_.)UG`.)#EP*#!ECQL9@C>^C^G]:<P[H`]^^/WK M^73R(:VYEQ<W[.-UQ*D9<S7"+(I?<)E-&W9]"4SP8!-0'*Y06-161S.2AMB6 M<$$5F8J0KT!NXVC\PL-`:/`=A)Q*#7L%M+X)`^RP[@]WP2X\PD?W!^O]_18& M\.`ELIY!FJ(9[R#+IOCLNII.&SQ$-A[^B8Y(.D>S,<$O;-1?;704XRJ+%2,_ MGMS@0A*W29W7@HX>HO#5B^WQ%WU!P_$9O;1KUF_<P@/$I0`P[XA/6F4]KQ+] MIY>\W`5[[]7;GUV?;):\=6-\2^R21T>=9J=D$"/>107G,LO]3=WAI"R`(@_% M2M[@.^("Y&Q,Z/[?FR?,"4A9L65?1+]&:QLH&C2JWY>I!'*S>U/VY>SP>,@W MD\I$,6DJT3<W1HZ:41\FQ*)$]>#%ML59X=F>CD9V&NS.HAE10\60Z)]C$?W8 MY4ZD4-+N-\2U:]9!5$^'D!?S=K@_%CUQDW00<M2,.`@I%B7,?]FPP5(_`YX` M,A[M6<(.->US$2/JB)5@]W>XUA`[W:VKI'3.2P_/:?$)K*@DS(Y^<9[U2^CO MD6AV>))><&KV)/(?P;`G.1P@[F$"L]7@%S<AUX&#'?)^Y&O+NA-YDF9\BC2? M$MEC:9VEDF-)!RSN-^`Q07E0&WW+R+IB-[1*6B`72]SDC#!P`1\@+ESCUS2' MW$JNUO2WEGB5WM#BN)9^W\"P?SF>_/`"X5<8O7H[F*^Y2DLT6J*()+[DE3YH MVSQ2HE5L#T?E6&8\DCH!A.?WE;-I2)Y+.0&,E=+N0I&;"<CYP2_F'+%FEJRD MLB5;.\8T7-OAT:EA`[Y//>PY3E'Q!_TIO*5XJ*9XO&OVFCT*`<T;MI=&PK55 MP:!)A5-'BI>0;][6=)I5;T1A(;V4?'_"OX]Q!;E*,Y8;W..QZ0^XMPGMWII_ M2_*'!Z33%S2F+:O6<9S%J'[6HL@4)Y^1W+/[PU=X<G$ST)O=#E?>B]]>/KG_ M$T;OT*^>T>(#'Y6FR58W/SQ>12HEI(UXT/[\RAR^K^O.LIP`F(X-TL'!TP60 MX4$Z/DUH2#D`WS`/QOVA+O758LCQU*??FPV'8[/C&OAQKM%'I;]KK[^B=I`K M\EMESB7VJ>8-N58#(3C)?V^X/HQ!I:KV:X)*O18?UPQGE=ZNX>,9]GOGY!S! M3U[@'<_'+R2S-<W1^!!&]R=2PSQX_@AQ-"YY/#&$MADOUY]AB5.^U:K!N9&1 M`1L:T+'SY")\(R,;'M#Q+5RN:M,?\6,5G1&JN<K.P1Y&X#-R&B[R&_1B2U6% MEOBJX1#DN*B!G\.L9Z)G+V\ALOW\'`;Y3>1)R3DO$@%ZS[)'IOVH&O%&O5B5 MR(9<-BP3V:'?$QFT<`0X`>G`]#H9'=I"%Z1!:?4[N$VW`"@+6'>V^)E!@&KV M,/VUK:2J;I$19"-H5)9@W^H4I%[576-7D"_1JJSKV73!2NT^ON`S?!Q6("-U M?1]X;("T^VC6"?`WO>5V1Q&Y[-GN,2R9M.G5'.JZ#%??'47V:N4V6C*QIH`[ M@XT?^\`W*]$KHS2S,<Q]\@(C%(.&::Q%G:2(EQI(S$C$(L.AQ(;LO&'!1(8" MQ;'2B?<7-IR-5^[&4U"66EX,1!C@<<1&1N86?M4?C/1!1G,,(JU3Q:$'&;_0 M+^U2*&D<?_0">)?`8_4DJQ\-<\&(&(.BT]1VMEY.:512QW2Q+>`%%,<!W_!( M@`REN27`N)K@>#>3FA`-6\901VV!-5@=FL,9.9?0$-=(:-5L@/,08;>;7![0 M=TW0@@^74#EAGR*61]KQNI$@IITGB12:-4M,3PE.`"%)\UU2HK:D:ZJ4VADD MM?Y81,R(FZ,/`;V91>A_GI'_@)%_^>`%;K#S7+]0J45R!2)#RPAV)1B4.'#8 M-B0?9B.!;*AB"1P+UQZCZ::ZW9"KY@N,S[XMM<-Z`*$9\K**-(M_7A3Q]E+Z MB]!T+4/+"/XE&)28TC8-$3H_&)W@I(GRGRV9XT?33BU@5Z4=_5ZB!UR:O82L MLNWT$I(!@B`9JWQ#[UVWVBE#J^%;&!&,H9%2NV92KKRD$KM!+A,%2"C/-+0# MH6-1F3<-`9C#CLQD-6O";)`?BMF(4B5B,V#FHMH"Q0[KY*&O32FF`1=#I`M< MMOP6.4(_)/L!A>)8[\*`M!=^#!]@A%<..!L+[_@)WKX>/(`A^`[C6J)4K=-0 M.2\=GM91R1DHEGJ;@)0'?*V-<4&3+PD?]@3R.E79$-V/JTH37D@-9'G.2L'G M,NO3.+<0<Q'0NJ96Y8_<^Q1S:4/I&_%H`YF6R#I<-V1`\&X[%U%(+G`TE*ND M5W)M<6=:]5CS9N/J4;\O4P359E>FXE/9Z,GRJ^GD`CJ^F!X3MF]P'2"/;=2( M+YW4C&*15Y-D7>):6E/E4'XEA\8:`C'#8<J+A:LX`UJMGLLTJB[3F<W.JR<Z M95Q8GR]AHR,CW+-2'$I]EP!AB]Q5-[<R44/#<I+OH2K54*[.)ZE67=4-%?5S M%=Y''%(R#D=0S;;XF&(H5V0=7X&F,6`<GX^G/H=&2@8Q['OZ<RXQIR\;6E]R M%R4U1Y2Q`@J\6.V5="F5WB8N5T(@:GU;;O'PW8W!^SCQCN0\"RGR%M=*0$__ M'N$,MS]B?`OAK>_N_GJ#Q$%BQZF;>T"A!?[CIW"/E$G)HE__";WG%TSKYA5& M[C,L?AG;/.)P!]#E'0=^;L.>$C/\]O+.=V/!7?SZ&V9\6)4-B<WA>4--=^IU MGBZ`4+1FBVF8E/5-(V$I#6"69XH<`#:JQ@(TL<+U.*,VN7P.$_BGB_>9DO@^ M^H+]ID3U35EZYI`HSJ1P%([^T9#`5ASMGP$=#^`!)R`=$H01H(/:&":,J2V" M]_MS$B=NL,<3=TK7(H3+PZ,%_Y**-.L=_@BBK.3EH_N#==.+OX2^_R&,LLUF M<?<@3="(?Y#E4F:*:R@%4AR.U/M/!P1X1,"&M-`SC*LG3O\$>L?^YDC+IK6I MSPX7TA=#S3ZDE\J-.!'XC-<8O\/P.7)/+][.]=MK-W*?U^D">$R(%\:?IW?H MBT1,%T)4(Y8C)98VI'496@E(K9HPB),O\!1&^$[]0^A[NPO]W\YY5>A=_?AI M9T@B0%RF2:24+L@(3P`E"KZQ_YJ?%=6+[C2*;@'6Q(RU`7<"VC&#P<B#\<U# MQ%HFDD#]$SP^P8C[M?EO:,4;EPV)C=DLYXE0`S<@H\=V7[Y1DL:0I4A(IR3D MNS!XA<@8<4PM([`^K'4:91EA[5HRAZNWTKAJ?D,[KAK9D%C#9&4?J<F]M1)7 M"H1T2D)>!ZY:C;*.*[Z6C."J\9R;]YF;']:)ID8.A&ULL\XZVG)200SA1X%8 MA<X_5*Q=AUC:4-)J8B6`\-5@#S8*>;.\M%GR/W_#]511>$K:^\RD/GS/(8SC ML!_?XH4KMHL.]!;3OUNSOR<L^91QPEJ*V01^';HD+B-5P8EV50L/(+0@F6$$ MZ'5[F@$ZOUK_1$^*QC1--L*U>2?*MC"@YM/9=B3G1#FY8N?41Y7$-U$]O#(] M1)C,U7NE,N"4.Z6"KJ_*)]%3[+L@3B)2WS0F=RD?7]R`991]"*,#]!*XOPNH MXU5ML3TXN`:?)B^6Q%;89J',Y[%LE@*CK(1H@EC-,V(S;H$77&?8-O8'<;(/ M$H.;5]?SR5D_OL5-4UYQ;5::X8I^Q91?N&84D^V5,[FA=4@Y4:OB+55Q`)]Q M4NY5*GFVH"D%[6J;@,]GO+V392=?9U#=WS<KF=YZ?LN?<OH[(QM*,]!9`CI! M-<YJS[K;F0*3&',_TZ0I)+%$:L1:W0:'W'R*!9G4[S;0&8-<F<CO6ORD\^T( MW](1FR3J5TK(NJ>B=KQ#0S_X3SV)2'DXK?.+N(&HZ58QFCR$ZWRVK,CT_@>, M=EX,\?VGZE1B$6/:^VK8(+5H3X;%=.UL\A9BWU,'XS('`QE1<,)4B6>),?,X M4(VJ_LK%4L3@F;+Y&WA\\>+"*R[)GT4_A&<?C>!_=R\Q>(+@'S`*@1O7Z3W3 MBPKD74P:_2$)T6,[[^21>0K-<TA%]#FPQUX0%ZW:AR`($_""9$`_YR(<H(NA MJ;L!VO690QY9L-N,W,CB+8LLP-MZ9,$/+!X+@05@4J#'V"J]/LNEHI";EIJC MBFO]AB2BZ-!D'BB`-]4+Q9Q@A&';7!L6&[Y$,:BPAZN?<"U+I(^-[>-6AO\I MUJ-EF<3+/Z^G2]TK3LKJS[M].^13M"T8F8\6VU.\[LW90=:\4+?_;7!:-.6% M]:RH&S[PSSS%V;=C*\O?3SA)JMOKFT\=[?NVU5GT?^OF[:C?5&@Z_C^[MP,< MGHGI9HP]7-OGH\_X*D6,A*;!HW:85L?_*>:3BE`25S+7,]WS1<9KNGX892*@ M2<3O`T/KAD$?A*P;_F`$ZKO6U.N'>7V9^D(,?0Q:>>:MBP8<:4N3JOAKXD;) M%2IYV3*C=NCV+7SV@J!#O=<_D7(\M9Z)LNG;_J03H7UK,@G6?J[I4UG4CG/S MU@9G5H-+,%MF7L7?4GY2EEV._2^;M!5_'^'Y7/ZS_&^;[RU;,TM:S,\5)?R- M2&[LA+(R_$\QVY=EDMF'TWY"25D=ZX32A@.V01^C[>I#>8_A9[_WT.PF]/CG MAD_X,_M@4JO3W-JLE9F?T#^7)12N1+)<;1W3WGKR$Y]VJ?M(^2U!0)5?+!<S M`:T+KDDQ-?>`E?W*4_;/YN.;W9`)C]_P\7]F_V_?=ITL?S_A+*'RNE1792X= M$\?_SA2*4;]I6PH%=]OT?V4&14]_9V+N^0FWA#+6"PVKWO\X06RTM]ZKMX?! M_@L2434ZA<>]ANE#5!B9#0=U594*KJ3`'YHN&(<@91%@'J_,RX^C>N*],_WL M4_U</.A?9U:T+,R5>%>I;V/,:SYU2_8D(]DCC(ZM=2_'&5"WGQQ%"@F4SJ?Z M'"3FS:!?M$#598>(V#[B]<,%NI'Y+>Y1`5QSA.-]C)\F;OQ;Z",R/HJL=4>. ME9&O/78LBR.1<:@P&ZC3.>9,_FSQXQ#UTQK#&0'C3E(/QD</&QL^R=6[S2]> M_->'",*[`)DYC!-=3K-QW&MUF4W"R%R@'7^YC3D$F$60\OBS^,OANJ>[I8C, MFP-6D)<J*.(HZ"I=9QO.1W.<W&]S56[SHQ?`NP0>E1=LSPE?@^/+N)5(5E66 MF`"^X>$!&=]4OR7-BG/T*,YZ;U:#GQ)W5?XH5^6/:)K?_>%FO_?P*ZY/T_UN MSLE+&.'.PJHM6&#$:_!@W6)(!`XS=;=)\[S-G#.6P@ERWJ[,ZZE6-G&'=\$N M@D2%7@""3&TQU17ZURX\'I'NR8'W*`I[A=%3>"4JF_6I2I^J&&O8S09F*K[* M"43<7RJ9602_XE5..4R2U)0^A!$QI+&`P!ONFB8;C@P2+3K7ZK8'JC<$FKS" M%=Z45*KK/J7,?H+;C$IUN.RA0Z&KAU<0\"A18''F=DL*/)QQX>6TGO,YV),4 M2PAFV^T:/"#:5SU'=TPP2B?HM@]U50DA]^DQ!:E@BV6Y"Y+("V)O1W;DE">$ M=`]X#0DAG5((0W;MK-3=P+G/#SDSQG!8SE@SG@YM@:IIG\+GYXA<YZSJIJ0Y MX";@%NY(PV\PGTT`!I]Q%SDJRI5DC8A]L:M:Q-1%&J<N&W><:UBV\)B7R=A2 MUY^PV1>.6$MMO/!0C6+SAO-9TX?[8L6/`GGC3FX,C"H)`%L_Q96[-(F^0KI' MOT[WIZ"-",&NNH(:S4[1JDXO5G^'H>U<?CX?*]J@Q<1GO?*5>$6^+_#H>GB3 MZUV(PFEWEYQ=?Y0[&P,XN<ZUNZAXPKYBO5VJ.^(5]-D9UZ#`]C7>`-'U?9I] M>;,:/WJ'_SU[`[)^9Z1-`ZFO?L6A-XQ+)4+*>R7C!D?M0U]?T-TJC_`^X6:] M4G='K^J]8:D'B#U;LU8IOZ/84<BV+]*6HDB1"1X2YU\S=5YO@:,>SF&$^+K[ M8UZCQRTTAKX)]N]_G+R(4!BMMZ'PN%?D:SN%D0G#1CC[*O!'^A`7.+SB$J$C M*7_1L2F<_O)`QX7[?X%XS"OML2?K!E0Z5K$O]U-Z50,;R\-X^IF\L9+-S]5\ MC)!8R%/_I-O3&K_;T$WK_YUS@.Z-[>$&<>5SA[X8_,JC[AYEX.?JZFHT>N]K M;0ZN2KE=N17I+S^D+O0G<9V:`N:K#Y'+#4U_C\)8^8WPEI&NR,TUL"]^<6VU M&2%3HMZXF7!UG8YNL'H+CH[NPJ:W"9(0!&'P!AY/?GB!S=?]KF	@!]KD$ ME,X/K$GU-<\.+:Y.Y>S`^T[7/SMHKYS?DXNKG57454R?S9V-CAGGIZQSK^/; ME+8^WKA,>XW=4+!?#G]6-ZRW.OV`+WN-[KNPTM.2O,$?[XI<,E<(F;9((R39 ME9;M/T5ZAB)-MU^<NV97V8E?E4ZQ_6M<N?L;]5)<?9SK='=R=[<VL]E&7:>E M9C<WXJ6X<8MWJ%%N5P[$3U"A0XVBEAV*^CDZ@'>YM9%F@RN_1UB0Q$"ZA^CH MUSEC*$D%F,T5=AYIGD=,)&KHGF#4?8O%T+N$/^.TI$Z]RX'J_5DG,]UY+3(? M]QHO;/+EX]U8<D:Z,=>'DRNZL-E#/)D\N;$763_]A<W1OX_LA4WC#MN,5U%Y M';/O-[W&%0QMF4MS+VF'LQ#_JG`C-=O]U++-WY^?*UKE]!92>.=BY4Q'2'YD MO<A9UCKK+AB27U<NZDMMF=M_FJ#I@W65Z2OH'Q;TCSN4`Y>4<[?O=KY)WZ0R MHA]F`C_1U*#KY$-X^.MW_+UWJ''C&]U^7M<ABBFG/O!C="7%M_CPG]!7:SE/ MD/J0/Z<G-G#Z,)"IG\IK*]G`Q:UH3?KRG_+&J<YO-_3*:<O44/I4/_<\H7NK M7H&%7.,.OK38NBLQ*F3PBO;[U4DM$[;:->_\;&<$IKZI?*W':]Q@LN+#C'$, MH=ALKG>22B]39)<FQIUR&H:[N@FD+H-XTN-J.D+*%/,LA>M=5ESA,JYHXJ-_ M;[^:E;9K?24C7K_#Y>-9O?OD?)_K=8;E9FRCVG9EJ*MS@F7^)2ZT;T<HT$A9 MJG<4O6;G-T3!Q/'ERO@Y/5TS6-5[N88/<54>[@$9^(O+ME3N#^](4W*R.X:\ M]PZV-TP>9\!K\':=4LA`4ET3LI0MMN.)T$TYH_N=$\"8NS+/IUC9Q/_=%ZK) M@!,F'.-U]HD2Q*MUI#S<K):$A4<W^@LF>72(_["CFHTQ'U?I+X6AK\1KBGW$ MJSHCI#[_+H[/>;2K^C"E<8QK.,%K8EP&I^I*:U%.`&7E:DL'#M>G:-'`:ZY& MT@9))4=7W,\@Y[EVE^0OXH]F#O-&^#>]V*(<U7J#-S59V+=5!#3`@&(_M@]W M9\P0X=FX=(+@G$]GV^G\O^<8G(\HK("'`]R1JFUQH>Q=H?D(.)_RY9I;*OCV MG!9\2U]"OW,QH_%OX/%R\G:N[U\F)'H)D*8B_(O"@/)#>3$(//^W45QITZQD M^U?,IRSPMGW*>LNF+/9<.F6QN2JOX_<AJ^-'>,V<=,8MN$LG-!.%(FW_(,Z` MXH@9#$S,A.:F`SQ-&OJL5D;_,2\4(/^#W"J\"?8/R!@_NT=X&^*#P+ZQ7Y^A M;%H+].!?)H1E^=;O_W[VD@OSA]\HF?_/TFA^=(TX4AJQ)GX?`"JI,+ZO_O5$ M\USNZ`>]"^(D(A'M/0K9HL<7-Z`^M*%4N40:LEV\6;<&T"2X(,R72++Y*E\> M?$^3BM+BHFF40C<Q29(K"=AQ:(-82=!O\>-T,4$7`WEG%;0L>/'BPDON,3RC ML"A^"<\^&L/_[EYB\`3!/V`4XOW1&D56CIN\BXG3M*4([KR3AY4)4&B%UQN% M&J@XQVF/RW<GX`5)@7[.A3A`%VN0+%R"BFRV+3.L-!3A%4C,6X+0681-*;D0 M@$@!L!AIR%SLR)&O0JQ*9K_B+SDTI_U+%:KGP$L*V+=W5:-Y6A1?\.BTD^M: M"U76=J.VXE/+Q%6LG_I()IZQO)Y*%#:.!S6@MFIRN(;OHJJ9GM'-++/^1<V" ML?>GODI'WEI+7XL7E^#@FERXN%@2-R!EFJ4*^V^!MB`_A?,>ZXNH\MS7<!RO MWITH==J2GWC$S;^/7@#O$GB4.'S/7[%CJRSC1_0D;KY9+-=T!XN[,?$-4P6$ M[#A;^9+;/#V%;-]]&5W(/ML@/25U!DEJ<)^AAL".Y7]9/R.Z!G9T>DY>PLC[ M!]S_$>QA1.8$ZL7P*47<%GJII6V'LY%G7'22WDYQK_)VKY0F#F3#`S)^::8& MA`4=H9"D"QM;=>V^SB[5]7&,8^N/>%"<2(B+?>/3FF)".<V\RLX_:ME@.(-E MY\8O^=&-96ZVOS?K\,<]/XL]JW!Y`;[@./=C^!U&]%_>T6N]EC/6D,;7V6KD MD%G&=62A3QK\W)GCYR;5M1_A:`((=_0'0/BS:1UM0N.*'>,$^$3#/D^W9E?1 M:MU!][)9X1>]>I_ZQ^FDVZ=6A[Q6GUJ10QCA\^FBHVRJ"I]*N/O)?.H@C2OW MJ6>BX9_+IW+<P6@^M>F+CKC!\(@SLL77/_1Q.[8!""^"%K^8;K>S6==^(Z%H MQ59C#]DZMAE'E*W/0KJ'@!V[BWP!#:YX2_#J6,3F*C$60W4>WIHY6Y4[:)M/ MER4TC-CW+XR]Q'OMGNY["#`GYOZ0)>&>TN(-724&-$4P/40B$KT+@U<8)1Z^ M<G5"]@NC*$U&G(!36JKB--HW0X,_A>/(-VL/J-S$[,8<'^FU8&:,8\_Z!;#[ M0]KA*2('LS'[\4.:C?K^Q\E#UL&=50:0-!+"].=7]!QN-7><;?>]X2S?%^?4 M0SK$\"O$+>]^]WP?>,$N@AC=24C2_^&/!.>8)"\(&6%>="`;!;N]!DY-I/SK M^G*SQJNI^7W?^T->IH'=38VSWV1#`S:VJ6A/E[:&7.3-#.M?(%]9^B+'X=ZQ M'%T._`3&(M!BM[^VZ;GTG.YXM#BX<(BP76Z*86G<V4-@>'@JW):ZOT"D@72Y M"W0Z$1CO!MU?*M*WN=9\N4TPK<%;$TAJ,5Q->C.8#J,$%[V^"W`129*7]PFV MMBGCOJ`5Y3PN)+K%;K)T"$3L#9HVCZ!`#GRC!(U=4E<CH=-30GUXZ3+`,G!: MM:)F,71T;X(]N0SV&9X1L^=X=_;=Z`XA=4?6#\T(D7Q9^P)'E#-!^UHYL^V< M+66^?KHA%X1#<MLT*))'BXJ,_KB0XB\0QI%\5I2<WK,MD0=WNB3OB/C'$=]1 M);Z>&%X6U'FT+J4^-1XH/"2WH8\&*:;+WSS%I$M%XS=N?T.[KVEE1_14P4%K MR"5S,(@@V!.*P"U>B_F6$M7M4Q1*.,LDI!3+%W]&EK##=R@4TQD@IAX?(02[ MW#%TZT:--SC!G7?PX)Z<3;^$_AY&]]\#]-U>O--#5OJX\?,)OJK=/XCQ)7[\ M.%\O\TW5HQ=XQ_,1A"G%0H'H"?CN)2^X(@KN$80W.EW?+Q\#>+3D+(EGBI56 MR38HV2=-(N_Y.4VD8#,<V9S%$79<W<UEU59T[XJ.H6+JJ5+*H$`:9+1!3MR$ MPQI#[/2DKU!D/,[)F_-7<HXA=UP2.C*R)X$PA2M\?41#^/]^CKP815H82>T; M$QUOZ=R=:&=%8@&?=1I,TAI,A"8H$C6]4:%26(*T#Q`9)!(2BTL%?W1_V+%9 M(6:9I1T+`?48`QF>I-_Y;AS?'X@ON/GA<5LD<9_7#:PF)L2M;)%V:R,D2%\A M,E=_PV1,0FBX6(Z46%HQTV9H-;1P-6$4)[1:%,X'"P,2Z`M@I?$=$WAI8D3& MN&:E(JXY'3M@,UPZ1U8Z[>AI,[]&!'&58A1%O\,0+8=.+S@E101!M>=-H*?* MA'C6&?H_BIPB"3M`,TPH1T(H[5CA&5DC3AKU8!0C'SGE1EH>-(&*CY(U*/#1 M_79;6,^0`D;FRFNH$LB1$T@[&FKFU`B#CP,J9BBV__O#.S=^^>"'WWEG'D*O MF,!$`Q_B_8V=V:**#MP+$-_A(A2-'06H%]/I+Z9V_+288R.2>,HQC*D/7N`& M.\_U'\BEB#`0QQ;_53,8X_(C[+AQ@FH#UC+"(*5L$^84B5W'GK38!C#8:;X< M++8KS3`F"QOP,5VOB8.RY5TSJ.0S)#,W+!M@6:3\SVF1>XN`J4KR.C)[2&X` MF]UFS`%GA^*,HK/IXC7G(1-XD[F?ZZP7ZWEMOC-RXUB%'-4%E[F+Q>U&TVCT MAB\1UP#'_3ZU![5:>75T84<Z7\S36QQ-OO,F22+OZ9R0BTA)"![<"([46EWL M=L=`21NN=QB]UC%0G.9['>.XJ#!Q_3%E69%\)#Q*,5L$F2(DQ,SZ*YX;*/NL M1@78X;<Z`V4[HN.A@>%ZM9C-I?V9!<&Q&L&=NN`4/?]J%WS:XUT+@]PJ2Y_# M!+Y[P5FL\5WPSCUYR&U]3:+S#O<_^GI^BI':\;$\?>0Q_'S&V2OWAW<D<Y+> M9Q.V!26#&86Q"@ED=FU6+2X`\S(!;"C<^8'Q`S*&)B!G*7L0.0O*%=E]I0FP M7\>[%]K#9>A7,DWT+!<]`>XAP55!R+_CDV^X=-JHR&UW6\J^ASTN[]:+=WX8 M(_X?X8_D+1K_+RGS;'K?N&-J8$IFUEUT^!J0TT=K;S0"($-8$VDH44%#X/'> MPK"]PX:[\<Q3E#T0);_]BOVNE`447C,.R)P7F22;[CF?IGA^Y<U)IL#75]P< M<W2>!7L8[R*/7**Q#W9UN^Q&6T4S-H*,EG^+D<J_X)M-LYY?OD;&(A!6>9.Q MTK4,*%%4G@T%R%AVPG280@ALOT!,`1;#Y`G8Y=)'/.EM`3'/[F5`W:A'.T#. MOD^/R;3^IE$HU]B1,=8M'[VX]38U80MGU8%"\Q%J[0S+M==V/#8K2LTU;$SS MCMP-OCU'7O!,^Q*R8F[))S?Z"R9I;=&OKH]^^1Q!<N97^<Z#R6F_KMV?5]&+ MMIO%<C,OE/^.:]59V;7L/6&`E*>D9U(@@C[B'/\N!&[R!OWES9%P1%XAE5YC MS!-P4Z;&V>%J\F-ZU9<[-T"'`W0\U@LV:]&0`#HFR$KADE%!-JR)B]NZE-1> M`QC9T*>/?S-92$Z5L\FO>P_4K+$`AL=S'F;AO<6L6O57N$./)E[[041_HKK# MGMZ<BE]?6$UG74XC;>Q26LN0$X.\3'@^M,&`29.Z"C724U7L^!73L3^IUAC_ MI]ED.IU:4FI<"<YJ,=FP;V&=PWE_//GA!=*P\H&5P"?M8?H89`LU6UP,GT69 M3+V-N&])!V2+KW1(VB_*0J>B2D',FQ0<!*O13J-=8PT6M!A'>R1V.D?X+Z1& MT_NO#P]6%/<=YB6$_62'BL=?SZ9MK^X/?Y)R>TG5T_4B8=6ZM<Z?Z#IBOEJO M%B)K55(3#/=@0S%UG+5J(X]_9V/JK@HVID8$EY]9\[_[`T@'LFW!.505DIW[ M4FNP>]W)=PIB:TV.4JT+]S[#[^1/O:*[_&5;@KF,(YGI>2L>NR'Z]`D;`[6> MPG=WPF(NWO*8I&;*PB%(67'C1QS9>(_A.UQ4]2G$1X:O\,&-DH!3:WT(/:MB MD0YF10MSSQ:+Y9H%)IW3<`Y;\!B"TK"`C6M1;*)40X*!BBD-#8A;E*JI<Z=\ M5U+)B8YA=PPCZ&;$`AH1;6OUG%_P41C<X_&K%_OZT['54Q:9%#3LY7RZWJZ* M'K)\JLA.%-D>3(#P[U'\(V./Z'#$S"\V+=N4J*272V3#$6?8F!AKB2OLKY9. M%UBRBJMQ?4U^0MKEU;1JW4+N"XR3R-LEK-(UZ:KW&>*B(+2EWKGCTM(@NK8L M_T28E2A3X72F&>0KPWQHMJ_/6CRBX4G9F9P!"U>.ZO4FN2D4Y=IC3P2>V2TB MY:`37HT*?XSQPZW\L#+=F.^?Y]5&RZJPJX51T8ZPV^UZ[DAD>+%8K'@,%&=< MY(W(\Z0NFV(R9?H2C,OR\?*S4VNSN90II]6AVAV,"7@1L8"L2YG6!67DCZRU M<7HB4.T@/X"0+6%7(W<R\<*BT(OXS1/ZKGM2F1P&,7'AQ>Y9X.D"BL\]N!?R MZW)'[4EV\D9NB5-F+0R\%&A.,M*BOP[SQN/DT':<-LE;JJ(`/N/%DTDES1;Y MW)+UK"\VO$I_F:K*2`?VX3Y%.,CDZW3,J/)OKG^&RNX/B%"S)+(48%5TLV:V M6F\V-+8D5$>]/&!'G*E<>UV1)E7L-=T=4*XBD:L#),-W]=M\^N:?UK\YTPG^ M88E^6/VVWI*.5NA?JP7[.<L!GH"`[HE@BLCR\`2/'\Z,<!?&"5DQ_=-FBV@Z M<X<26R]LBV\E_%E7A"OZ`2V*<0G+BB\H"-(T'_F*,2H<I2SF"X$48C+H%=Y. M&$-9#9<3.BXD3,`KYL/"R$X.20)!GH3";7,HW'S@'B;'IV6)`^$R*%Y^<YHV M^1-P'&U7#^QS&(J4(Y=ZCV,:%WR'WO,+.>N,//K2/RU^FSLH&IG_MEK1<&3^ MVWR31S5XFP%9.WH$_>^</(&-/^V^[+U"WWP]I;Z0$_4X[5]L])7EH$Q^'@6; M5I#]4[67B_EFVYDN1]<]VI+6>ZT#A^I`;.UG=^*^$D7TSMLW%D4-<`!"RR\E M2?L]_):Z?&`A<C9Y-(5)G$M!]W8MR<#J]2/F^JXJ%5B]DOIE`I.3%!0C;J<- M&UU-.UM6^D]%&</"'T6G9^V9+]Q*QE)/VB,'=#Y=S9Q99[8PF?KM3Q96IY`^ M+M/25&%U2I'+%*:N<?W;S!%SC<[,=M_8)Z6X4_NV[<.I3R@6)VO)[IS:M-CE M5B"=F&W476DV\4A:4Y1,;/7NO^)48KDO,7H<IB:1N).43?&8@LS/^7R=WG$5 M2?6XTBQBM=H2"]BN)(=8K6K$#T+^_1Q`<II!SC$^P*?H[$87>J!Q.C_YW@Z] M?H"8T9@D@2Q^6[)3D<UO4\$EL#.9S5F:B#/9H+=,'Y6H\&)"8>`5Y3%3?H>G M,;?0L238&Y9E.I^*E)=DT5TY#_5]6\JIV5!.@4Z4I"<S'S-UWOS3;/;;;)HF MEQ5=#3N`O;*CUZ'9O!V?25U@Q\A_@6D<\<G]X1W/1\H&=T[K>,U(P-;.DVB: MY-*9.NS(@;V?!F`L'/O^XNU>*@9]="_@"2++3(?>X_L,.$<7<>V9V3Y3J8Y9 M/<T^IPM2/9FXCC&.O(4V/O03%SXM^MA%LS`;T8C!MQR]""C*2*22==][_XK^ MYQ/$G?=XDUOCLSHCCB8&)#I:+-/DKKRI)2$$OE%2ICK1#1?+:1(K;I5+VX3= M9F&E29FK!@N`\8C&N_GA<3=I.4^;`T?*@D0?T_6&`P],"WS#U.Q`2#_9&C'2 M)9LAE%3-K04G)658@I3;\.AZW!QC[O-FT4*9D.CV.5VWXH72LP<Q?>1KPTR+ M?`914S:]#MP45&(*.=[><Z,+OIMT?Z`'"^VS3//SFI'3R(2$-]ZD]2D0!;Q1 M08-^TS.,`JD<&:ETHJ35S*HHX2M"S1;(^7A$]!%M[SGP#M[.#9*;W2X\!_A" M[4/H>SL/QA^]`-XE\-B<=BY)0OO6B!Q_PNODU725-CNC(^"4ZL(8(!\$I*.` M;W@<0`8:!UW\+9$QU3"S30T=VR5CZL)1K`L]>RG]_$"^K])#HQH=V*/[Y,/^ MED!?M]-Q$=Z$2RXM9IN%O-,B8UCIKWI(+^VK1I1>A9OJH0)I%\57@47>J01R M2<^4*]',XH/QB$^]B#^X\?WP.SY9?(0_DK=HZ+^XP;+`JUJ7)-W\R,3Q%;RB M4#XC##+*S$`!'@&0(8PM751+GS87.[G!Y9_C@O#X-/@_SZ[O'2X8J\RDS984 ME3#C\CI'4&MFL'DZ^22%Q?7?NCZI7O("87+KQ3L_C'&J83=&)4AHQ:HX7\)6 MNYEFMPL*Y`&C#\@`H#`"PJYYU(ZE!X+>LN@8RV'`:V"M#ZKR5EV&K*3*3$/W MG1N_?$!.Y3W]17SS%">1NZMFZ4J]:@BJ/'XD*@?.UPT0Q70!)@Q2RN!;2ML" M9*H1VQDNM@F,=IDO#YNM2E.R`'^$T?%#&!42*QIJVK0]J7M9W<R&<(F!U6;* MFH\\ON2I,.AS$KVB@`P@JSY64_[`LXE.D2I$)7X"$\*7<TH9G@:JZRB3RLFD MPJF8I2_%DTK+2K<=3=FBMD4%(X(:_^8$=V@1S2[>_%OH[]&G$O](7`IV.`$> M>Z*[*^O5W'%Z.P?@XGM,<(\O*LRF_S=]Y(5R8(7C4*.>#H="?YL.P_[.!K+& MV:C11.Z$D$$0&[#,[W0!OL,?M6I)F9]Z#'_'JOL<!C'"^QF]>BEF>=X$^SLD M>X#3Y8N_YWWLON1,>+">O(I&S-NM,UU?4ZRC11^Y_WH,`1D/%`>L7()!8X)L MT/+?#'DS+4K*71N:S(@]@*"HI/+M`5(E.5-2Z6]&/>)`UU)RCT/4;F+SY-%+ M<,[)7;#W7KT]PGI+,E3SLQJW1QH9D$C;WK`4!D('^[.<DM%4*`5R.?)RZ=K@ M:#6QXHX&7PU6(.-/+WDA94\P8%^\TV/XGEQZ:DV]E:5B$DWMK$FDL<X9SHK$ M2(%:0LYPGNZH8CL]Q3:&13&C;D6I@/[ZXS>&N]^>P]=_V4./0A?]HXI8]*O_ M?HQ<W`GGZ^7X%%:_?/WO&E!6&U34D%;;S8;=FF+O`TI`+UP&\N^(\3^VW7-- M`UMTLXA&YAH4,\8']"E0?/@51J_>#O%T?_C@!6ZP\US_#D63$5DHQCB)/F[^ M4_M$I'((G;.40KZ%??EV.V-;XADQ4*!F>@8SIA*GGTJTS6XCP*@T]:E6O)K= ML>_AXTMXCM'R&O'U`=D;WI5KO%?<_;SV_:T69D3/>J9S9\U:BB%R(&'TR'[# M`5$$)_2^[GTJ97+-4KE2>F2S"5.D&^EF;E(K%I(X%C3LHELF/=M"`IC*]WVZ MU&`DI$`#W!\*G4?;-G8:G]4YR3<Q(#$U35.8X&N2X:'4<!4CYG,8O'$+OR.. MW-W1;4FC.S_#!7=&$%S;A-UFI*69EZLG)5/H'\$>1M\C+TE@\$`*Q-VS^G#\ M:;3S'=U3:1=#HJ>6&V<[8\?;19*`T@0IT7$G'N[$JE;*F5DIVZ=7M:(Z@T35 M,NN*PC";>84T9&+V_2.(H.M[_X#[WU&L_S&,X_O@+GB%<4*6`)S9H.LMC3-R M!RO"V9C.<K%(4992!)@D^`43_16$`2C0-3,+*Q76:136Q\*:G&H%+;(XZ8JH M1='T&\%=^!S@H>Z"77B$C^Z/MS"`!R^):<5GB(#N^NQW^(Z\F\#LT3^2I[9Y M6A5Q_1.Z(LY%UV+;]6:U3F?^?&Q`*0)$$J3#DU+N]P?`.$A_3ZX98B:*[R`^ MC`4+1C0XNSH-=@4B1M3H"*GQ3=95H*+(,%7D'X]OS19F&\?)%:(@E9_'5+B4 M2E#@O66Z;GI:<WC4P()$"^C9ML%-%`U[%)S36I[O@WU7.#18N$5-N`0)]\1H M30#B`:\YV*VR$85%MAXEHXN[[!#W+7SV@J!#8IVQ8`O<JC$@3SD6>8I;N$.Q M:@SC+S`^^_C*_P<D\0/Z_A$M]XJ>?0ACKRDG6"EI\SY(BE]A(]\Z:?(<UV%- M0#HTR(8&V/``&3SM8(%?R<97B_LM55H`GW%OJAZ8'U-W"YH:M#_O\N+PV$>< M4GHX8#D135V@VWP+PK"#Z(4R`6\BKW:+7`\*HQJ8?W>.(K2V&^I\9(F;=S^2 M'(MW8]BLG4X'E`Y>=4!L>`TN2&;+2;?VR'KJ9K\G[S;XG[3M81*2DOX[IC3L MC2QT1CUQ)^".^GP$ZQV2DEA(CK2MSFCH?#Y;KI:]79&N6&@41Z1$<UUNR/HP MJ!?`>ON=*PF#'E_<Y,_P[._OCB=WE[P_'&CO(O3(%S2KR%E?%S'SGJ6#0YDC MHRY?@B9C-P%D,$!'`]EPY$$\H%7.0ZERZKO`Q9T5"]V#(!($'(*('H=?K2`5 MY:(+]@#S]`<,_GD!_.S7_XV_4_E\(/^#!E#FHXF7UUM.V6V*/S[?/;Z_!5\? M;Q[??]5\BM*3;V;['FVDC#ZYX7.,FA60,XBR<$;FI!C>']['B7?$.N(YJ_)# M.N>0TLC")K#83--#`MI=,",QH45;+^`;^Z_QXGI#1'2:1#3JV!O-J>2PZ^(: ML?NOCSAB/$>7O"=K:T.QEA=TXH'+A83AS-+]Z*\@I5;LBVRVP9@J"2DT?OOZ MF[2,VK#2:8(EW+3KQ02&ZM5H;^$!1A&)Q&[B&";O7G#6\5UP<\0S'>>+2Y/1 MB#=9WL0#].F*58%M*->,SX/H*&250L8I[(O\DN[Z_SH!=%@S4!U7.;1_<"HS M3LG?IX=DKWF1YW1DDT#NBX,BO'OIT@[0WQ^JK+;/I#(4C$*=RY9X98/5=LU% M.0[:ZC@W/?^.I@:"YY*\C87J+9B8>YAX.Y3;-6@'BO'-W"\PAM$KC%FBC;"% M-+UK%+D-#(DG):V=.1>SM!172GJB(0FK(^-L!-D7Q9KL;H+SS;"K&K%WMV"Z MV0BR+BNRYLEFK1*;\T0M,&WW03Q5V>=]4*`3/2-7&;X+XP3]_OV/$PSB?MZ( M1\L:[\1A4&*C?[X5]E9L,)RF@(<C?V4#VA)L*-<-[0^3"\Z(&-TE&V3_XC!O MTY_%L+]/7F"4MNL99CAE4O:!OL2?S.'>M`_FR6BMC9"L0?P`Q50!WRVU9;!O MM/\>J*_KT#[0WV99O;WLI?"Z->#.>9))<^9O$U0!G=,WE0(^DOP+ND'0)IT= M2*T;K3@Z*]JQ$)%MI?"$7K4'B7)UVI;3[4(0A8;+V*D7VQDNMB78Y):@$U:: M?9C$-7Q:BE`)OFP-+E..)*HUS5>BR"3UG$P6IAI#=D%X=LAN!T*KQBR.T9+N MS*(TV.>M9=,0.V_M^+':!IYK(J)TC&!7D#GQQ+SUK#;!<KKT%AJ@@F]X)$"& M,@[I453B*%>)?J1+`J(9]#+:M1G_I4;K/6V)TK`0]WDG>+%[*_->F">C6`[W M'IKH`76^)FQ#><GL^R`\5ZB2XEA_DOJ=R?L?)R\BP]_6K].T/*B[:%4C%Z)U M?Q9H*BET5H09$;#'A7SP7;'OE'X,T+\C[_D%_^N<Q(E+ZHEHKO*L0%CB51@= MD!,"M]HO]:B2B'@'`4FT5%UJ14]608DOM8D)FG'3FGY6?D;C!%L:6+Q'U6)1 M,76S^6$#I'`*4L3X:.8!<?>"$SK?A<<CLG?:_<^&%+!&0RI.:74UJ)RR[@/( M+\M8>\;01)4Q(.KD9O/IE'4;2&TY#*"9B:<G\R4@(AHF:PL.DX2F5\?Q&>[! M`HV)G>S,?*T_'@"J$TY9:H-S3?PY3+[")/$A#E[O@G=N_/+!]2(<\\(\M&WW MIJ)$],]6@IS)E'PK3V<Q0".`?`C@!0`/,@%X&)(C#`OK(:.3WBC**,V*$W*W M`1I-.NQGV`V3HXRZ5,Z>\6.81A8TL"!Q1>>$VOJ:H3FVC2?Q7NJ;Q:PT[?8, MOD:?E-5)6_8PCT:D%9J]U8E\!=&U+$BKDWZGLE1ZD<?O8:?+R)\QY!\R!D1M M93E;K[?E&#SY'IJ)P7LR7XK!<7LO\RCN*4DQ!E_]B[/$P:=C#4)K`*C"L2RU MD1@<XGU,N+]YA9'[##^?,3?WAZ\O;@3O\[W-MV[L[6Z"_:WGG]'3O""O'S&= M,7DO#B7NS:<WG]*!`!L)T*%(87@\6`P*P^%;4&A`<IC!AC04I6M0CU-4SQN7 MJ2?(U!-3]9QCI#RTDMF%Q].9E+`+8`)P*Q-P0@^2I\CEY1U9\Z#9>D<GZ1C/ M:"^AOT?"@C?@*=/L?D3-(BF>0O.ZG34KUX1*M:VU!CFPTIJK_P>B'HRIX2,B MC'Y&/Z%_(%U!],/_#U!+`P04````"`![@V9&^7]N>49?``!16P<`%0`<`&-Y M=&LM,C`Q-#$R,S%?<')E+GAM;%54"0`#V1OZ5-D;^E1U>`L``00E#@``!#D! M``#M?5ESXSBVYOM$S'_PU(V8)6)R<U95WZKHG@EYR^L9V_*UE56WYZ6")B&) MG12IYN*TZM</`.X45A(D*)`OW5DR`)[S83L[_OJ_WW;>V2L((S?P__;#I_<? M?S@#OATXKK_YVP]?G]\MGB]O;W_XW__K/_^GO_Z7=^_.GI[.K@+?!YX'#F?_ M80,/A%8,SE;66^`'N\/98P@BX,=6#(<[NW/];R]6!/[G&?I?YPS^]!\73W=G MY^\_G9UMXWC_ZX</W[]_?Q^&3C[F>SO8?3A[]R[_WF\I9;^>_?S^_/S]CY6_ M/`6)[_QZ]NECY;?+$*1?=B!1OYZ=?_STT[N/G]]]_&GUZ9=?/_[\ZX]_^7_5 MUL'^$+J;;7SVW^W_`1M__.D=[/'Y[.G]T_L*E__U[#GP(]AZM[?\P]G"\\Z> M4*_H[`GR&KX"YWTVJ)?Q>P8Q]:.__5!A\>TE]-X'X>8#_,SG#WG#'_[S?SI+ M&__Z%KFU#M\_Y\T_??B/^[MG>PMVUCO7CV++MVL=T6"DKI]^^>67#_BO:>O( M_37"H]P%-D9)@,`S:@OT7^_R9N_03^\^G;_[_.G]6^3\\+_0!_\:!AYX`NLS M3,.O\6$/_O9#Y.[V'O@A^VT;@O7??K`/\3>$_(^?SM/^_W(5V,D.+2/?N?9C M-S[<^NL@W&&J?SA#XWY]NBW(=W<@#MVW]\#96.&[P(=#`[R.XFQ5?D`]/C`' M_="5Y"?8\X]GN/`!^L9R?>/Z<*)<RWL,(A=]XM*SHLA=N\!IS8'@\$/R\FB% MH/V42'PCWH+8M2U//7>W\+C;`14\9",II_!Y"Q'8!IX##\/K?R9PZ2Y\9PD1 M"=&A!/\$_,A]!>H8D?N@7GZ5K4#YK_:W)B^M:'OC!=^C6]]Q0V#'*A@\'K0S MW5=N9'M!E(1@&6XLW_T3GZ80MV=WX\/-:UM^O+!M>%7'4*!X##S7=D&T<!R\ MQ2U/R;FND`:%@#R`^"Z(HD<0XH5U:7EVXN&O+-<75N3:D,(KUTMBX#2:0@D# MWM`O'E@%<.7M`O\Y#NQOV<I4`%-?E/4'WBT4>T)\>4?7;[:7.,"Y"8/=:@O0 MUDSBC/@CHC,BT1#J<5-!E$+(GI,];(\%G/"0;_4K*[8J?_#RW]7NN]:?5L@^ M&AZ=VJ^6AV8$+N%;_Q5$,9Z?Q2X(8_=/X%P&40S_=&.YX6^6EX#T4*SW6[Q: MKH<6^4T0/L-?*^,HP&H8.@<#MJ>3O,5'AV+Y.=GMX#)'TEX,H+8;=Q2[.GY6 M(=O%:KL'%OKO^G<+`7T112".LC;.(BX7J?\$["0,X2V+KA$5NT4Y27W#U=>& MD/B80A8O+`]9&YZW`,3H4@O\&OZ/8;`'(9:3T;K=(Z*R+BHFO\O7>P>AKXF6 M^=IP,PWEYS`!SIUKO;@>I&2(^25\4R'#3P"*O-BV@$:&:ZCRPV$56GYDV0CD MWB:Z(P$ZH'@"K\!/`))RJTV&!(-&@DI-%JG\R+1KA?86J4+PDUZ`CY?LZXL0 M4K3I]\!7084V4(H]O`J@Y/\%_B%OI>+<4$>+?H">@+M[2<((.-=O>^!'.@$B MT*(0H"OP$O>U6>AC*V:@OIAR43R#"TKD4-3L8-]O\RV5:D^PV[F9BN5#%13; MRX#?I\5.^I/#L/L$?\R`[I?)ZH>&8>TFB6&#>]=W=\GN#BH3X-$ZX)9??0>$ M#X%O(Z$,&Q:6>^3=A5UQ.R76CWX(4PH=U+FA%`*_\@@;`[3)L)6SORT@]4&5 M%L.*\39S>/3$H^B7>F5NF<3(>8XB&WZWT/VGQ)XG]IU>&2LN"ORGY1Z[/Z"X M_.HJD<TE/S@,JU"Z@5S8<;97OOIN/`S+K`_WRSKZY0+%T2!=&=X8>,MD2M`J MJ$Q%U*!Q\=T*G>:/F'#?N89D!0>0?N\Q@?*BHI->,P.]3D7%+(_=.)BI_+;Z MW8JNH]C=(:Z6_A7\O^4::QU?(V2%]"S[V[,-AP-1RNPCY`G^X3YP@(<'6OJ_ M`Q1?!)P%O!BL#5A$4;)+@>EE8C2RHW":4GOXRGKK3UKE?J(?=E#LEY-XR`E4 M6,GR8),+`+^>-E/+H.A'^V$Y"[9[`G80.L`I_O(8!J]NI'PV^9_KE<WH*I/[ MX(^I*P,>;&IMK2T^VB_+Z,#)`S7^/;$\=WV`QT86I]$3QYQO]L,P6E10P?'< M+!X`!>0D<1`>;@`\@M'YD35]@F?K*KA>KP&2)_)?U"+1E9AA(,(&C\4.S\IR M_=4/X=\W/O*+P^87P`=K5_42:4>"4CA2^TX><_90]8F47M_*GY4`(/U1A2S# M+1C"#WB'PH^;QHQDDG;Q9RCX)9Z2"9?]HIJXOH<@!M$J*+Y9A.1%U8"U2R@/ M!9[KY`=4-9*^XNHN.Y=L\6+=5N`MOO"@V-<:PA&Q8-J<Y#\8,#<%*WW/T;45 M^I"`(A2OSP5._Y8V+E?(!MK'@N%]L6^.\QC!:MQ@N0Y[/<>$/ST6#'I;!)($ M](U')0;NUL>./M^YM\)O($;?STQ+*,C+S4('+D$86ZZ_"BUD@DU5FY+^/M=0 M;Z2>*L:]K=&>">X;[\+B-M#AQOZ>5FY[6R(B7^V;\^H16HUV&VC:I3X_)BQZ M6Q0MB.@;%UJDVS!7ELS71X1$;PM$GH;^44GCN"I!7#AT`J4803$]6,??H:0^ MU&II2\MH4>IQ)76CJ&_$D-0TS*JA?4D3A[W-./M[O>N-]-"J8:99DH!QX=&? M-MV&C+ZQJ0>:];DH:%_J7=H\BG)`;8?9".+?'@T*_0G<DA3T;^G(7'Y#6808 MG]/):X^6&>Y'>_?@(%]E2D?NN<QBK(>9=+GOCPJ-WI9%&RKZ1N;8&UR)Y>IS M@0A^>!S\][8DI#Z?8;&O>"WO(.LU4&`7X#LH_R;]%7U?:9$P3`.D`M)5^S`J MBA('87TZLN_BJFD1L-]O@M</#G`_H!E"_\!3]>[CIZQFVK_`G_Y8P$\[Z/,W MGK7)A_.L%^#][8?COW_HG9Y+E&,$OP:WJ.7]':JSU[YSA8.2CDBC-I6C\G@1 MHU_^R*=E09B6Q4L4AQ8JD50C2KQ?_SCF9*3H/(+0#9P;^%M$`)+>=F@ZT2R* M45FV'([&%!GZ@B2W&XZ^%1R601;^<__4I*O^$GX01_<YX.W_@@.!+'*[P>@K MBTGAN(.HDD-#)Y;5:3#*TV/O">Q1Y1Y_@P,J21N&V7PH:F]<#X27<!]L@I"^ M"NJMAJ+M,7GQ7/O&"ZSF24YN,Q1=3V#CHHO"CQ^L'6E'$YL-1=UO@9?@LEMX MTN@+K]EN*/I^!Y[W?_W@N_\,K"CP@7,;10D(J732VO=/;Q8:\'S8O00>@;[Z MWPMZJA+I(JS39H5V/A#\9TT</2ZHF[7XL,>5)=_96]<K)-EU&.QD))J<BH!P MYYRA%(<0EWK^]/'C#V?[W$)WE_)*)1!3!P7V"."6J*<;A)""O_UP_L-9$D'F M@GV:$W-:\#2D[A*?\QD?AL15XO1YQHDI/9=(_3@CQ=&'2JQ^FK$BW$LE/C_/ M^-"EM!*FO\PP,13!$J=_G7%BF[Q*J'Z9H1*0\`N\H)@YX\6U&)1PS6(Y0W&M MX#2+YU2C306E63@7M1E60)OE=(K5K8)1W_+Y7S\TO7T#^0!%7_')ONO&Z!.? MD&[W\>S=6=&[]N]@?5:,=98/]C_/*L.U-G"MK>@%XYQ$[S:6M4^M7,"+H_R7 MIKDK^_F/O/+!HW5`7M;L9FK8OCB-VQOFNM/]!&S@OB)JZO5CQ1CA]=;$6:/F M,9<72GM-U">[!&-)>S<'O8'Q`.#.6EEO=)ZD1M'":5'^Y]%RG5O_TMJ[L=4T M&_-::Z$<I[[1"$W_J(\NBB^?TD@?G9Q=66NCG4HA4)MMM5#=>-&DS.#$]7"+ M_^*@+SF*#DY1CC4*!V^\^!%?6F&(:A+AQ$4*?V)]M7"%I)FL*N15L+-<G\;" M<4,M]-)C\VF$,WKHXB#39YA+IME,!ZUYO3%4\_@2_K\;L_<QO?TXJ$<5B249 MJ'31RP,N`B\*?ZWQ".B6`+[97@?UM4)^1'J/J^YIHQ#5^CE*V>"33>XV1EXX MPI!P=\V\L??N2/3!8S+$T1^#/'H7^)L5"'>U%P#)A!-:ZJ`8*\PB*@JAH69Z MN:<ZN:T.JNM)C2S!B]12#\7I6VF/GI5:@/,'TW`=20KIC"XZ>'@"J((/</(B M914[$;SP7=NE<2+040<_SR!$MTQ]B=R#W<M1>*1(#RT<Y.;MJCZW>'-IIR2] MO5;J[^#BN(7_Y))=-M1*+\$MP;E7A;IJY0FG>?&H3QOIH5-0)AZ)%"PM]XI( MN@-Z+-E68>2>Y%@Z30VY%`>&?>6;&F8IC@]1N#<UNE(<%HI$;FH\I>Q!TS5B M$I65/P4D*/IZ%1!!'T:!U[E9\5K2>$E[MTKDS(KADD=.--ZC1,SD6U\`,9(= MJ`3'Y"M?9#G1<&ESYX__0*=[9:N@,*T1IJ8,MG4:U.1(AI';U)0!%;@QG'JF M9@ZHA8WDAS8UB4#Q1NV:13#^0[\+4,RP&%,3"U0`QVIM:FZ!XIU)B3_HEG5P M4MM50A]JQNV7DJR91AIIE&BQ]"509F6]M@.*%A96HF2\]"J%TE'X8@'49^/E M50&@F!ON<QNY=/SG-]<37I.O"`IYJ2F:N83HSO9CRPQ)?S;3=BR&BKAH96I) MGC8A$'7!O!YF,)G=5@NK(")R?&#EX'R<T:GNRP(6@W&14=J(09"EGF:F_US> MD%+/SBGQ,5-#D\.'FD5;PF2F?B8)DVQ:=0F?F8J;''PB<<.EJCL?[>1HQQ*A MOC6XD=?]>,1@;T'LVI#D.<M6)D<58K<,,<P.OA#S=\9I#`CTU,Q16D5HD<1; MN*C_+-<?G9.C'J/@`!=M$Z8^:ST*RNFEXH6ZZ,\?DMP4@IWU\R6X-3B=QL(' M<X,P.HR%?OXVX?6:<Z3F'*DY1^K$<J3F>,-QJF.SNTB!8T14CIK=2"+262?G MT2L(7P)S<<JE/]/3"MLC1"ZD:VAVH1A,0H8/TS,.I:%B'4PMG"8&'4Q4HXVI MCSATA(=R))GJ$YE#(P8+C9C!T149,0;G4.IR+=#)ZK^?\^J_I]W._CO\?R]! MA]+9ES"(HK-[*]RX_O_0XDHZ]B1SBG.S>NAQ!T0X2R5[3)Y>M[713`>MN0,Z M%_XNK,BU(5%7KI?$5-LRKY<.3KX`'X26!ZE8.#O7QR]OQ7!!9/!2..'UTL%) M&3YQ`T_"--<I@7`O]R#$ATET`=9!F"UUN,I!=._Z^(RZ]>')!2)46Z4^2NHR MOP=0@G7XI0.'I$`?PL5)R+'"TEKKHQPBGBW0"[A^U]0J<[36>@IOVH@$%"T, MPE?X'U&6VT&AG=Y>CGKTT`RFZ=-Y1A%^>B8;/AL3K]!Z`8<&68*=="`++[MR MJU'0K+?13F51=V055%2D++P'WR8B?`B,HH53***E!Z6_28EEWT'T]EK*G^:D MY'()YW2DM]=*/7='D%IJ*S=+"9^DE^=9./](TAN4(QPK&WYLV.2$I2_UPM]# M8$7@"J3_SUNTW0?6AD?=TGWEOKH.U"0C+,+FLT9=].(#Z"FG&P$KM%$)KRMX MQWH!+@[(/CW9?93("N1/?`G3(H88TUPD($D-,MU[I%=.U)$>0]-ZB</$CN&I MY6\NH2:ZH6K;Q*9Z:":NE*,_ZZ2-<WH>-=-!Z^_`W6SA^EN\PGM\`QX2%*:Q M7&-[1,7*+F;0:#F83KLH1X>M9QLTI]7TFCP2X##D75.?]>V"4E6N[E9W9_P9 M]!+X,'0^TZOL2*`TJ&73]/H\TK@3K(;M<F-_23'RP08)@,:@U+"C=<N+-6K] MR.B=[?)DI["D1(R>G=)D3R*N2`(]KG/2]!19":S:JD/=<FB-@E"%M='TRO(2 M<#(#.;K5D1__Y<KUHM3U<Z;9T_3,$RFLN&$>IB=6R*XL@H'4]))<4A`=1VMU M2Z@X@;-)F5=-]/:4\V.:7FJ=9F5':+;TWW1*;CD)M:$E:!0GG>D9+ERT!,*? M3']>BX610-!:IP27D]]RQ][,;LDLIU:,">O5]>)5/K426C,L_\=__9D=EE\= M_;^=9>6N-/A8!:J\,0M?B/?7X4&FE/IC<\3LHR1ZHV)-7064[Z$L.\NWP7)] M&?CP,(E=*%S5#;2DH`Y50^N9+3[M>-^\0$'502L-+C-\%CP!N($B-P;9&9[* MMD_`#C8^'H7U6GKOGQTKEK];(9*=F#6&Y,?1DH]SNL7IF&?1<3LM&43X=D(+ M/_#A0F`"3&ZKY-2\01(*7GUIHFTJT;XB,31-O]U[;DRJ82;;6PFU`H=L2@B) M6/'.2FB]]UX7FQ!@X82X'FFMM&<9C#870JQD+I%XH:[Z"[PQ#Z[1%$)KEN%E M4DUIK*7\EN6![)YZL';PGRMXQ4;I$<8\@`4ZSB7UVG-P(<T!N8<6#@1+,HZD M"&-;:O\XGTLNMJ>^(<!%(AP0^\R%(Z4*1_)KI=,K1S+ZGESIR$'I/"XX3Z'U MJ.&)T2M])E(T!3QRJNA?88]S:O+(JF?%]U;X#<2Y]H)$D:A0&4@J19?AM,T` MC=Y458N@G%53VTI/*&NVV@\Z.ARN=WLO.(!4K7Y,0GMK1>#1@U)H&P`8H_6_ MHJ_?0&B[$92B,QL745N7':)_NA_`=_RG",6A>I#6(`VA09X_GZS==QIO4(XJ M7LSF`=A^G-'M(AS7X]IQIC8LOENA@[7_FR!<`S=.CDU'ZL;M?S[+`RS?T^TO M"M98HYM7_,<E=G<69P/-^-YBH#YG#GLSE%WR(J.-:/8PN8JO>,$QQX8"]4IN MP3U]K-Y7<J?+G39"[U2KN]J%AAN2GY87.W.8L>T=]=>Z^+"]SZ6:2YT[U-CF M5,&5SAA'"[?)2^0ZKA4>*NX$EB60VGY^$F34`8`R$%%<'Z9G8S"C'RB5P(^P M^3QQ;#A+Y[.962K"\'#B%$N<S*PO(8Z3>+1JB9F9CX$(8T:+@"@!,C-!0CR" MHDB9(,5!E3"9F2,Q/PHF"A#+,UZK:4#>F9/!Z<CW+OS(=YMDU7UJ$HVAMF\, M/G)ZYOPZ&"5<J%/*Y#36%=,G87H*9?<=R;"$FYY;J6#9L0(%S,^][+[ZQ&S) MDWF"K/U"E`32T*(%;"#;.W),KT3;'C=.:(OIQ6D[+CB2_[9;O5J3(:,'M)E> MO;;C,N,%O'0K0GOJ\"F*FFE7I=84$+N'5G>K9'OJ^*D*SVY7V-84%+N''G4J M;6L&?C))ZJ;7ME4H&'/6FZ&5;3ON5V8XENEE;+LN/D'P)JMF**MA5&(Y6?5# MHE9(B=:4M8T6U8U*X*:H8<@`UZW$5HGSE#41L?(O)593U#?R5K1'6<Y-?1^C M;:3$'^?5<*06.D/JT[[V1_[Z2DN'?QV>%AK!J<$C4C2BOJ+J=1DF$Y%4JT-! M1(0<VY4#]'%&B!`>F*,SY?5#SY/)T3F?,#J$<[S84N;N*5[N5`TB@2#EX8[I MDRN[_8AG8PMBUX9,&%UXEI*.67HU'L-4*TO?`UO7S0>U]^@:)+8?1R$'!)-' M;A7!!-%IYO946LX5O253.,])1)$;*B\I6TP"-8BN-H\L2ML,UQ\_9%O_31!> M6M%6FAVQT8;FIKI&N/5_I<;JDQ.4'1/GF-T%WT%XY^Y<YB80'&$PJK_N]QVI MKHS0,]783(1^="-T+*-7D5LN&X'!^N2E&M36?A^S1AF*^K830!]C>N6['ZT# M-C]GLA`+4J$N<W'FN3BSWN+,M$(IV7O&=3=*%LZ5Q%NHBOT)G*]0=0HK^3<X M_2&/TJ1*OLK&UE;860'Q3Y:_2:6(]%^$:WV03YX\AEBF&1;#YB>U84C:8H0& M<T'QUM0?.7%H9)<-YU+<DRO%/1><F@M.S06G>BE<8GHP]ERXI'T$K#(=Q?0' MYR5B4GI3;:9=Z$/*6=2I],?)0S6,ECCM\B#=/7+3KA#2RM/4J2J(T9`QG2S3 M+@'2RCLX%_MHX1";*WUT\>?.Y3Y:1C/-13\ZA=+,]3\ZQ.[,U3^:KI1.I3P, MRM]A!SIT*MAA`$JLH,K)E.&8$W@&2,"8,#C<W)TY.65.3IF34\234Y#@?.,% MWZ-;WW%#4#FEW1@-_.DG5$WE[-U9T:?V[V!]AD8XPT/H2%>II?^CW'W?=CU0 M2\"&4B_2#L+@U86X71R^1L"Y]9=[@*1@?[.`L_^*RZ)P8B)Z^92.T`1$(U36 MT?^A&_H5;@J4(!I?0G'E`,G,ZAX001#K:R17TB^.]\E76JP"KKP06!&X`NG_ M2[%'&4('CU<`GGFVBT\\^&\/Q*D]:;$+PMC]$_].X4VHJPZ>OL#;!)T)2S^] M=>"I`,^!^(#\)C@[>T]X15"RLRZ^<K)N_5>0'8D,1DBM=5#>7.JW_L*V@P1M M!>N`I"HH#3BT/238>31\A0D465SKQ?58S_@*=1T'3U>9'(9J#_K4DYS?;R3< M)"`MI%BX'B#2ETD8TL\$R4%&PV?-P=*.2]H0X^"QD.^R<E,<.5)B@''P]QB" MO>4Z^4:Z?D.!%R!/8E]$$:`>_RT'&P??Y2,*2'(2YK#130<O4"DA*2(WKF]! MI:6JB%P&/EQX"?PM6X2!3YO+CH.>'@Z<?:QH\!'AD@IHBM>'Z*"GAT.[]2$[ M^(AP(1@RNJ\/T4%/#X=VZT-V<$VX5`L<TMBKM-&9F+T*%C94F4.P>+5<#^EJ M-T&(5-*R(O(5>*%-D^PHH^"T9B^`PA7/WB`Q@))48CB\#8`3P9'S3R--!EOF M<7@O?K$*_C5_U`7'&G&K%:@85BE_Z.M7H?7]*OCN9[%2,10,4\=H(2G<6':F M:R/#5?8P1O;C08[S?CZH94U7.")&L]"6,K??>+BI!X&A58M_`.@]%&D6N8/I MYAL=EI"L>RM&Y^5AN::?I`*,RXPV!LX;1ER10UEB!!T</D%-OH@(0F`#AW&/ MTEKKH1P*3XD=XS<2\!&'SD%D>[C=[2TWQ"$&6RO<4%>BS`CC*:=`88;26'/2 M>N&:%L]5/^ZB,S2A3]]T-:I!S'MF>A[V4&B+^O7:)77_DN+M@PTR=\^(2Y_6 MIJ?M#@4Z[0(Q/65WR&.$Z$9OE^A[2N>&O`>M"IRL+[5=4N^4\13S][5+]ITR MKN1H$],S@'M`\2BVQ?1TX!Y.3&I4ANEYPLJQ;,8EF9XSK-:I7DLPXYM\.Z44 MGT26F7IXA_!(F)ZQW/.L=/*#M4MW/B5);.@CA^^7Z90E/=%SB.LW:)=H/2]D M%2%_G=*WXP"*32>)?,M0+U):O'"82;ML<`.6N0JPV_J332\>.N#Z9OBQRZ=N M993'>6E+!PR40$]*R50`,S_.O\365,]=?^AVC2POL6^C1YZL&-(RHECHT?$6 M?KI35E`40-F/#["<$3,+:_4W'S(FVQ)E,VOX]GJ`=$KZ*)$W4X,4"4U3AR=I M19OI(%2$J[3P4N)JID:H"%=IVU2!ZV<S'8BRN,H5<"G1:Z/8F7>*"I;U*6%K MX1?<X[F`E(7Q!,'[X[P*7PNU*X7OVA=6>K45/KMR(]L+HB0$RW!C^5EL-$3H MV=WX[MJUD9TEC=*!Z#P&GFLC$=YQW)3^6W\=A+LT$E)'L;-CTC@ER^@==`3W MYP%04*4"<#&^>*`>@\+F@MY-"R]5';%<(8^6"P_U3"O!OL+GO4=]@5)R$"6I MB8O=!OCT1Y6K?U;SO2@&GF=%C$_66^@JLM8\)>&IL`W">`7"';_.E<0`2E!% MWWH"V!R?+A_X$1*VQ'9:$"ZC>."V78;X*G/P!41Y.UVFIV:.F@\0\3DYZJ%F M502[?0)%Z,)1@-9@L(Z_PX_1]Y]`+SWX^C8D)M4OGMSH&YQM](.U`9^H`#.Z MZ"ELN(:2B(,4IM!]21!9R)F3/:@4(GDDQ.E:5GBH-EKLT(U'X;+CH.UQB(#] M?A.\?G"`FT(`_]'D'/[TQS44.>(#\=WXHS\K6?<W85K#%]Z6>%^EZ0#HX0U0 M7I^D,T:VMXXU=).$OAM#F15NRQOW#?V+?)D*=.@^]U@4"P^(_,_Y?R#*/U<H MSW[^X_\\-N$N_Z`#R3ND8J/:].AN+O[C=K</@]?T>F3B*MR]_QUV!S:6E^XC MPIO"I!8Z\+ZWWMQ=LF."6F^CA4K7YU-9:W-ZI8@H;)UF2:9>2P]1;IB'!,W\ M<IU90Y$I(()[*R&A*]!!"W(914]@#[42I$8_@PU+IV%TT$'_<KUV;5`(J<S] M2FZKIK1/(5*BQ$VTRE;6VV,08=T]NG._`>^P"B[`$[`\@B[0;@Q-!4S(T4<7 MAQ7\-N,M>Y&>H^((44445V5ZCHHC>)"O$^_.7=.T:I&>6DJSH/=X&6NK_+LV MZI@G3[6%GM(VY6.6S"5-:*B;WLIK+-'%H?H7UH(0'T`/?[&%M/5K"RIE_B9: MV':R2S!A2(^WJ;9A@8Y:"O2D(L`7$&Q":[]U;<MC+C-Z>ZWEA:KT,!87O;T> MZIMOJST$<<5&43XV^H0D=)J53'J8<?!Z9)(19N^XIQ))\#G9[:SPL%PSO8=W MS<<"JX*@[!`#TEU[9TR>YK3[L/:FK\\4>Q/\@]::,ER_;9$0*C4WICX(2+,A M%R@U?8KMTDY.`PB*J0]A<8R3J2NBA4[:2*WA*WZ3Q>Y8^ZT\7\YW*+9+ES$6 M-XZYRO0L@)9HL9Q<W0++C85,W)ME>@3YD<VH5FV@:K(Q_8PGV*>J6#0<<MV2 M[4X?C;KCS_3,(;IEL)2KJ[&!IF?,RUL>ZT5,CM$T_73AVO[P0JHHXZ9GJ4L! M@J)A.F7EG@(@//MJK<0P'3U3=U(7NV']].%[%3H5?!]U!K@J%&DI\U(5VR<& MF)H48<.*LZO"5R8-P=1"[%VQ9*1'M"NM/A'(.!%N[<JHFX^=6+9"NV+ITT&/ MGQEH:IET50@*18*96B==%8A=TW5,K9VNY(*1#YPUM9*Z,G&<$='=J5#Z!+"3 MCZ4RM<1Y?X@2(K;:U2HW'T3I-,9.!<@-!E(H.[M=H?%)@D=/UN]6,=Q\$&4K MA+0K"VX4GK68TR,G?NI'R&'Z.&'?`!4GH?BX',$I>U?H*TW"*YP#>3X#60)) MC%G-D?H\(T42G*E.TQRW'V?<&K*R]`5=W!L#7!PC*'#W`&+DU<S%M4O+LY%_ M&'YXN;ZP(M>&M\.5ZR7P1<77@H.0,]4!E4Y,!,L=-1]BYW<A<$LHO>49OK M2&-J$M.`7I"%9B\3"R_T0&7Q'@QI)6-,1?@0&$5+.03T&&_]H;(K%[GE?1P0 M7-$^*$Q*#*"#O]^!N]G"Q;YX!:&U`;FM$^^'91)'L>4[<(^(;:B6@^D,I>*= M>D*!+*9%_K0!1V:CM`L!.J6G7UHO*Y'#M%M\S_B+5\N`U_;\ZA378]SFY<I/ MP\7TC$^H1Q$Z88*/KNLWVTO@=Y#+8+4%:=Y>)NX?B?G9_L5F7!VEDZ&*YB": MW-?*$WU5#FKD'RT75FU,-6-K*2C=C?*+`WD`1G&+/K]X@@@>&?/5PG77LHA# MG]@\6#MVW2MN-RV%@3TK0D\'8TF.13VAX1AL`"=EOTA#GU+_,[/P%:FE=HJ7 M^`H7I[O67HM6CPFXA2+#&W!6`7J2O`BGX%3=$^HZ1IZ8>UBPLY[27OF[H7CM M?/7=.'IZ_LHN#\?LHZ70$GYJ%E.#SO7ENN+U8E?VXG?4PH^]!4Z"2.MX89,* M(/7T$3V%W$)(Z$7=,,)<NZP>6HNY5>]YD6)N1^VU4)^\1'#E6.&ALI%8U%/; M:['.6B'<[>PBO/4V6@MP]:];U2)_N,*VJ?FM?:EB?'2ES0>FYL_):GPUFV5] M5YN:+]<%(H[09VJ:'%_WKF?V,V2+3MZI$X!(QKRM6E@U_5Z148]K/D!!%73J M^-&W-,.LTJENP@F`)JXA4P$[ALJL'*)^E>_:B4E7FXR-#!\07;I*;6S4^'#H M]JJ&&AN,/MS\B$D7QL:RG\Q&N-,3U:VYI!K-REE+W".H9Z;+M%Q#:NV"$Y#E MA@-L!"%%S\E^[^'UA6I:6-'VQ@N^7UFQ5?F#E_]^ZZ^#<(?)TA$XE)/Q$/@V M_&=:#@N5'4,UHW'5HFH)LI)'CL.]\[`Z#/!%!0T0H8S2!T#CCM!0R2LB<-P0 M%9V^`NG_W_H9?LL0I<AE_[&PX>V9EOBX<>&MNH@B$$?X5[BC5MLP2#:PD1TF M<'^YUHOKN6F]GQHO`WQ0SQS"TP*N-30OU-FK--&24"&-,>W9H38CJ7F[4WZ9 MA)8#UQ=.>"<MQ8XCZG$W'A_GU^D/1Z_1''D>!;IJ-4HKNA=JL>]MUKWIIFV5 M0`]QB9ANF50^'UV/2N/MFQ*G:/4TJ=_TIKN>VZ-T+-.:[H-NBU7WK3^<JWH$ M:NYQ5>5*,>7%+@AC5!GJ,HA0U90;RPWQ@;9<'_<K\N!N@A!9$ZI%F74$]C?( MN0(O<<4T7.4,Y4Y1DQMDA]&2Q-`@LB10D*M*AW'17ZG?_R4,HNBK'V95,+]8 MKG\!U@&RIKY)LRDZ[JF@@1+8^D"C/JX2K9-.QKT5HW\=KB`A).U2L*>6U!LD M#_I.\U3DV]<8G4;$!SWZEM%A//3?<3+8>+UT<5(AAAE03&ZKQW*77_J<I!Q" M0_WT7L+C8X-J85K<["B!CDI.R[O`W]2?N""2Q6ZK`]G&DWI$$.MMM%!9?^J. M3&6MC18J`Q\<[JWP&XAO$M]A'P:4QEH2P9KO3S:3OHJ_:Z..G916::$WD8Y\ M0Y%_%<RS:S&DWK0U,FEBV6BLOEJX(CQ=Q,XQHW?00?_7YQ6R2R?AH2*$L^AG M=-!M*.;+[>3(=.9Z-#VXA*\HD)-#VAQDT\3R2&FI!8I)6[>ZO1,T_A)4"D!L M878R]>&@@5%MF*_:/1=T2M7FE.)J[H-`+>"2LC&:^A@0WQQ3=R_RC2"FW\'B MAJ"FLY$IL)CI[6\'%DOG,=WS+X<8Q_)GNNO_R&QT].+)5$XE@HFJBD7#>FEZ MCCT/C;K%V=2G954:!VOP48S,IL=NJL:191HS/>Y2RE@[M7>L.H-$DN8GE'TL MB1;+0CFAG&`EJ-U-]KD@=GQD\7BAY@1`NKT#O<;M^DF0-*QM^?O2G\[AO1]O MHV6(]`T05FQTC/=L^OO>>(*&YN"M<=!_9.4;+'@K`O;[3?#ZP<4['O'Q.?LW MXN!SA8/TU\H%734S8MGFVC_*_Q/L-`[ZGV,KC.4YR+KI#^V:0]'FX)4Y>&4. M7L$:>LV;B\2.I5_-5J%$L'!ZS6$X<QC.6(";PW"&\<ES3Q+3C:=*XQ@ZZZJF MFU<ET!:7Z$UW5BL%+57CIN6MGL-&]$1"&.K<U^)N,],AWHLG:?:[M?$D&7O" MS9ZD(3Q)S\EN9X6'Y3HOB).6?-%53-($;TB);HIECBS7BMIH/C[9E5TJB,;U M<*KH"#9;4:GF'LL&H+[)LD)`EI>6[,K:.(NX+'#C/R%I(LP>(M=3P0835Y!4 M,D=SRE+;Z]A^%Y8',0;/6X">U[;374-WPE";CX5VYI./C`[C<:1R2TB,RG52 MK..LK)Y?K6"8[]C*-H4-'@(_K.U:GNM8[3=.%266$TK=^"-`AT`O)O"K'[Q$ M('Q%=-[Z^R2&?P[@_>"Y>"-?''!W7$*>>0KT]CFMV%7I81S@]/::J2_^^6\N M"*'HM3W<@5?@B;'"ZJR9KXID<Q."?R;`MP]B3%%[:N6HE%=XR@:SBU8>\':. M\!+YQ+QN63W&PL&Y-`?G(^/@LS0'G\?``6E_BET\C)YCX2@Z/E*E>:./,1HN MBRM?;`FRNNH/1IN#Y\3Y,:Z.VXG6'BOMUI6JQ<]@;X5PCA>VC1Z[CJ`L9/TC M"+-IQ^;7''+6B_,JACY%3/+?F`>VXH_,`8[3#0ODV1"KAF^6S<[T*`2^O5*J MJH"9P5.]&!1K@6UT>WVWXEO3P);J2!:R>1@?O=`KQ)/,+!YJT3(-D,9G(O>* MLAHAW_B'BWN=`[J0EN/ZXXQKMQ.DZ8#)@?UI!K8+L&H$0?-?VN[;C2I7A<C, M4-XA,18+F3:S:A;7K<TX*11.BND6"3G_.Q%S,9_1A(#D.?QY*![Y$B>#'2.T M0+5@,)&\8PE?-7=S'[E*32^JWLHM3H21%&]B>CYG+^B='Z-G9FIG+^A]GDKR MXIP8VW\]=9$"%&864U`9LJ#22MIT^YN^=OL)DY!.`)=Z_,2D/*WQE-6D>70+ MD54V%:OL.()\B#FG9LZIF3,K#,]#F*/X1Q`-/DS,NWZWQ8!!594KV'2]8%2! M*E/Q<LX^YW',QNQ`FIT@8X>V9TNTX?'8/5NB^_:"C,"*4@W!NPQV^\"OE;MY M#(,]".,#W*K(JKI'2&==]!2V*>NV7@$(DYW&2<!_>P`O0-_)7K#&O^?D/T** MXRH/-..+JN&5)/ZA^4C@@BJ&A9]X#M;Q=[A!Z"F``KW4I"5:+T&(6A^*+S'R M$JF-=2A:=_#8`-O`<_`=E?_'[6X?!J^`G[(EW%T)SLOUVK5!`=M-$OIN#'<N M_/:-^X;^1:96LK..>:#NGXL#)W=8I.>H.,*OELLRDW8:%1\\&ZY`QU'Q\P!H M=P&SR]AXX)@;A;J.BB>TBYF&+I&>2LY?ZH>^1F"=>'?N&IVF6)JD67W;CZ,W MU9N.L=#C,YSN.C4(B9NGJC<(+5?3=5?QNT$(NMKI97JVJ\P9+H1>)E>8;L=N MBYLZ?;&=3>67%&$?;/!3(T9BS):MNEE3@MCR3A2U8PFFK*1`5YU-#R)M`Y>( M'<3T\-$VN$E8#DS/D9.$3]Y09&KR6V<5B!Q-RM,L3)>A974LH?NVJKL8[W/O M!4%-?O+1^H%&$TY[E6%_&43HG:>]&Z=O_#V&8&^Y#IS#9;P%8>IX+KGBF,6Z MCJK#.E-58ZAL59KH*:F9OASR!&S@OC)L182&.L\41:NL>M34I\MT-;T'`$EK M:;CXAM&>S(6'?F';80*JD3::_/*(BHO`ARA&ETD8,IWLA+9*;/79T)>PI6M; M'EQO<.79V7^EBY)(FF1G'6?J\3P+H4QH/RKJ.3<TOY]&;J`8N091A,^+&R`X M(;1.&OGXS4I+;PG1WVRL@^[T$I'<$)Q.VOBXWNV]X`#`$TB?HY;BA]]9BU?7 M.J"+&AE-,."6Q\N'8?70*=`(GUN%T4WB"C)=&I0"3_1L-3VVM0MH3?'+]'H> M7;`ZNO1,][RT`DOTAC+=_=(>/(:88KK3I<OV9./5QL=R`JYDOM@DA)2.<)H1 M&$JRX^G1"A$6$,3*#X=5:/D1Q`22H<*J3;,_[#`_BTT(`#L@GM)2C15DMP'D MIXN._JQ%ZPSA7&RR>ATX!<PJ?ZG.$S,(7W84-<A&,?`\BQ%PWVBAYPG?PNZ* M]8WE^JN/'=9.YO>"N^/ZS?82N/YNX`%4#8"Z..2^L64(__4/8+->,^KC2ZHR M9W8@1,]TW[OP0(T#GY4DP6BM9?X@.8'_'`?VM^<MO#2BVRA*RD.R.0>4UGI\ M4^GU\@1>@9_0G#[-5B.@M/@_.]CX:#F+D7[<3<GJO;9"[W"%<A(#3EH5I:42 M*BH%K"IKC+@6^>VUE--P?3<&=RX\CFZA!.)O7"A<I:ZGO`(7[V%BB1%&QF%) MW8.U8V=2R(ZB9'5AMYZ?6<3H"YS43$WVHFL#/T)A2\\@?(7_P2""VE9+[N(1 M,>S3EMY>(_5X.MD$ITU4SO4-`!6AD3O=Q.9:GM&TWMQ=LF._GEEKHP2U0A:" M:FE>;!F@0^(K5%S"JOA-`E&BMQ9,X9G'Q;361@FF4$MY``F4A)/(3CPKO/4= M-S5#,HX??B<U><;(6L4YCH_:J,FP"V*X$*#X#?6#I%@JR!2"%\ME`!4J'#"/ M3#&YPDPBK]U`FO(>;0"<"&E%2$1"$1XUN8GF)^/VT\0-TM^8NZG>1EEF)E(H MD27G$838E`/QN`\<X-'7L$`O'1@^H0.1(8N6?]=&'7-^JRVT4`C<W4L21GA/ MLT4B8E,]-)<&2J:(3FBHF]Z*B8VU:AD]E)P!E`^4)IV\<#A-'KDX7,,K(SZ0 MC@IU@X]HMH07VG&?/F?L,02]3EJ[\4<T;[P0&FZW,?%R<:C^1?X`(0V@A[\( MH%IC4+VNF.$JZLUEX&/T5T$F:]P$(9:B(Q3+"_5,O!"OK="G&AW5?D/1'B:1 M1+YU!3KT3Q,6F.L.0FDR26,HI;RNGZ#JB:GI)M=4X.RZ`='V*CF"GIU2M977 M3M][$&\#1]0&WV(@);-4)ISAO44[F.XH!9+:C:&W_HO8X2M6#$9F+"U<(^?9 M8P@W#(V5LH&:];2S\GP8>9N0>&<M6"8O$7[0+;Y^I9E:V6U'0#6G`AVM]4@H M9TKY]/8ZJ$>?7ZXK\@P#=7);K4%N[:)9BGAQ$2-6$<9U;FC,<T<,:0[S$C<S M7X/LBIN`.Z*`\+.A.0H=(61%&I78S=N6A)V$!%1":68F0X\Q>XW"%U5'C>E5 M5EI$`-6JQ,N&UTP83U:\45GWC!IT4][4,W(,Y,@A+"5X9M6>8KJ7"VB(D60E M)&;>%VQ(CD,Y2CS,K*MZY#VOGN,UY[7I9S3!4U_%HA%,5JX+,\5['AKU,+!2 MRC1T;5#C#<KT]6KN4/F>L)GZLP@>C8R?<L.8F;,I$.)1.UK9,0;&'[8B(1:5 MO47.#BS7E)F9YZ(!#>12H5).J(DN.$8\!6VWFKY%._EL:S6`:RD+IM9L4087 M-7O1U,(MRI"K>J`[56[9!Y$;NZ^FXR400V]J39?.&`ID>)I:TD79^CO*=C:U MGHOJJY24NVAT_?S..U4^MM'4AY14X:DR!KW$VBPS2:]8=P+ZTZRK4!0\^2#; M$M19HZ&`JC3&O\1[UH..3XN6N<`EJ&;Y^]2*#Z()!B6:L]HD(OHS3]59>Z*< MJJ1\W1*V%BK4*PA?`F.!DR[*46(YJU22*E45O!;ZTZ@7HI(TG^I.IL3O3^@% MLHX`5H)7<M",<\>H!XWEJ,YA/)]AY,#82^!Q#O_G&7X._-2<LQS"'V<(VQT$ M1)=XCNI/,ZH<5*5"YW-8?YYAI<#:4F8=\A%23<BRDVXY9Z7I02S"";X,G(ZC MS,RR2`BE$=?>39!-6QMN=9W2*PJ9JMQP/AX4O:/0TPL&IUS77U?E7VK5FHH! M;[G.TW#(=A6D6Y!@E1^D#]JSZ[@#X;P1=-?>ZK>ZH$"EMQ85HT0[Z\:V&OB= MGH>KH*9ZM*K;QAYJ1#S/=>E.IRX=;Z:8G7JMTE;=[-)5Y(X[GWZ5.Z55U[C5 M[_CMYQIJ)UI#;:1Y=<0\0\.2*E3D&1J6+:%"@.+Z<`F7B>E/X2K"4UJE,S7# MHD]<N>JFJ:D7JD`5D&Y,S<68<VH'@W+.J:4C)J)=JKE6S(I=4X.@Q`5B5O9/ M:_C$8OWF_)WV>7MM4G(FDJC<3MR9\W+:Y>40`#1+A5:?EB<<"]U&=PYBRQLG MD*,(13,WLF<",5,CB-=@R(+9!J[%NSB.FW)PZ^-2\^@_E(1LI+EC-T%89/"M M0F#%U*<Z&<UGAQG!"57YP!<XGY2@!$K;$Y35C_DUWTL@!11SPPWG/CBY(_`Y MV>VL\+!<KY!D@M=67DA#R4'XX/I.='^P(DB5[UKP`Z\NZW5G1G-U[SI7V>0\ M[TQH.J(#623K_N+`>;M'S=@GA@K-J:YTZ!/#A/M2DIJQ-4=^X!TM$/&1M=,= M+]$><<$@BHX?4!,)$ZSC*U2.H9:T39$W17J,4')I=U8K*KTRI?00E;<"Q;^: MGR$3%<+;72;E0ULLF=#\4)\^(*6*M:9'^JB_*A6=N-6C?%+6S5'-@B9+J`X7 MB)`(10N`Z3IIDTH*;&EA*<(6G.LW5`=/D87EBQ>\6-Z%%P3."M)E[4$2NS;# MQL+NH$2>OS\$WZS0<2TZ%<TF>K1"4M4MBF)(:'IB^OUL"9HM02=L"1IC7E(; MFI`"6:L]*4WD\0BSE6JV4LU6JE,0UONR4LF%=L[F*CG+'[,ZZVRI4K1""3=C M-_O5^*/M^C$'<G1"\]/4^@#U2*DU/3%MM%:]V;8ZAEF8;:NS;56Y;?4*O,0* MPG+5:+B(F)(T3O@KI;&>VF@^>L4.KA&71FVMB<[CC8UQ/>^JRM5PNLQ(=D4] M4A.GC8(HSEP)M[Z=(.[G72).=P-""L'-5J>Q5XYXF]1V0:^IN7%Z2?L.NF!= M>-GZ-BKA.9:[A4&C\&:2&T.)#?0A\"_1T[(>DDWN@!6!$M%K-(D1_&?^<M*Q M052F>T_TPBWAIM:%OT/!3(S(1A^=9T"K=5.&7G'A,-U&J!H_QO*?5-H)`]<G M^&-^$<TG;4]<+O<`;6-_@U=E%?,'0..*W><D=ZD@'+,XE()YD\2PP;WKN[MD MAZ'*GU+#3ZC!X\XNCKL&I/-6'F@KU^8HGYXK:J22:.\1<W:)=-FCI-Z6@XR8 MSUO_QGT%2.ZB!1^U&&C<_`9)J(;?8J!1\[N"7U4SP961QLWQ]T`-O_DX(^86 M^5:!M8Z/(ES;CV.2T,4]WF==4PV@U5UG>E3*@)A6SF[3TZB&0[4B`9@>AC(@ MJ*48:7I0RE"@5N]VT\LG#X5IUTJV,N%\H["[^*_HS>`7#SSFC#['@?UM/$XH M]&KI<HV)8N9[$!KJD,NK9-QQ\G;(;;50#;=7X&-"B/EP]'9ZJ$6K%ODQ,O"> MM_``B;+%#)Q/5.IY_4;$S6T4)=*LY)WT\4$X2S@KBMU+B8OU"H!P[0+/66R@ MP(S.>GK6)[6M$DJNX<45>Z@@)KYR'D&()^XJ"='5Y/XS<1UJPI5P7QVS?PT_ MSWTZK]%('YWP'-L'/@21>:60VZI9!V\V0&=_Y4"]L=SP-\M+P!)NB(6'1X.3 MG83V%CD]0M<&RW5]CQ!7B9J1M80[/2Z99T7Y=S6!%PD:"R&5AJ;!+96\>*Z] M7$,@X)8BOF;&[Z2$-KBY;20#;L"="P7?I9]_-SWG:]-[_08;NQ%R@%T<_BWP MH/Q*)+WSF#K61'U9II0NDG@+1>L_03.`1[#36/A(;VL)'K(.8Z%_F<11;/D. M7/823%1[Z>$DL`%P(I3*A0!%WN/F\0=US/0'J&("TE';<3`MR=`6"O;'WW^P M=O"?U:<-6->@0$>]R=V8M(L#5J?$LK6/>VCA`-X8\&"2D)99/?1Q<"'-`;F' M%@[0F81%(!K!90,M],505L-).!5C`:-`"KV]5NH;HG0DP@&QCQXN((;;5`A* MB7H(8G"Y1?E1T:U_:>W=V/*>XS"QD57Q.7F)P#\3-`=IDU502HU8PL+W()7] M7CXV'MQ246#O41-_N-W&R$MID'E"2CC-;B,]C!9>X9IR'=<*#Y6KG[5CJ>VU MN@RHEN.J7X!KM2H?TS'46R4$$U-4*2$R\_4Z&8@HLE`!T;E9R<=";H\J2CQ] MWOB`FRY`U13N3F$T\,Q["8S&*C>N&!\7(PI25=,Q/JY%?.6T,P89'\/"`U"I M%\/XZ!71Y2C@V3;]I66QE2?@NS']364QH+H[DDQ];5GRJ!-VW'=Z8=D$O-J; M3$Q]0EDY=.8^EJP(JN[&V6Z/*!L$,"\^K02JA2YQ$GHH.;:)7$R-X(LTO4XP M,Z2JOI*.HDS+Q6.F-"ON="\D#7JP8@F6F6J2'%B$J+$2(#-%58&0A_K52/4= M3Z@FJ1A4=)=7#I6QYW?;547VZ>=PG<]PL>0L<^O1"D>NT%":ROL*0L$Q59`H M@I;Q./'"$6JGDX`,,:ERQ<?ZL8+</DK4^@(EHZ*7$B!$I;&"GFO#;*\C\J5P M6&`=]\**@(.V&X`K"('$KL,JV%E)?L!BAY>(0#X3I:4B*C;`9WVZ_+.:[T4Q M\.!-P?ADO866-?3="AW.,W;U-DJPN0!P+P.)S<?NH#MW]H1R?7^W4*G\>!D^ MN9MMG#E1<E=G]L<H^VM$3>AL-=9HN"Z\2L!.X(WH@NC2\CS@7!R:1,OP+S&J MYJSIW,R,3:/H087P%3@W09C6&<@C"VB\2X\SYXA+4"N8-,;J,0H.F.EBM-8C MRFB?\_-;YN>//JN]&%V``(UGPE6FY['?46ZVTD)I^9+WNJI#/`$/*1B7011' M>$6]("TCKU_#>]BBVZ!:LO5W>R\X`/`,[T$H`I$5JP>TUZ#<[V"I.L*/CU3_ MCAA[".*_@_@)V,'&1R=Z6@`=7JS93Z@=;2\/3(11...S;XF-(C3);YAO:T65 M*S.16FJG.(5.G.Y:>S55,JK#%S&DGN5'"WB[6IM4,<ICL4C7CN0(<XT7YNH8 MN':*2JISU2E'=+$+$FK];F871?5?W`A5H\O7)UUPHK34@601V[V`R.S2@Q59 M-6UX+J]`N*.@R>TV-EY^"Z!`Y'IP"3Q!P:@%5XT!QL+?DQM]NX'B?_[TEB1W MQ.Y*=D.9-%`-1R;JN_SV:BG*-W_M2TR:R#VTK`'7A^>7B_P\4(9/\*N>=)LT MK;4FRMT8W+FOP(&KS?(W*#\7+D401Q>'>^L?08CMA6QNA$<8&8<E=<B#R;QE M94=1LC>^A$$4D1.GJ+N#VT<)9?F@2!LH;,DD<L@-]3R$:KV@FP*]=).?(*6B M3IEV3B<E6-Y!N=B/P,)W,L6,X76CMM6!:%;4EZFWU-MHHA*'#N27Z?*[#\)H MZ^[+A)V+`WK<"+V]''CP^YNT"9VCEN,I62WWWJN`%9+02DTE/Q"3SY;<340B MAM])$6W?^4+^<2,UWW9]$`/@X_\_/".#9D531VHP@R31OJH>P:RIZD<&(`:A M@EU5T1G%5IS`]H>J?8E)'JN'TDJ6J01,R.S+3+RKX-**MAZ(HMRSS-DB*L;5 M4N,O,UYGTD7UNJ<=H,PN<TU/0<Z6ZVQY?T&3OPHJ!QN'?F9/550B<SL\ZZM? MK>S)W["%F4*F4%<M:QT>Q4C$9RA#M28Z:60J,XU&:N:\5FF@D7%*G&EF!_V5 M5Q^"1RL5^&DHTIKKI_T4J]Z2!$2Z)4B\WYBXH51`D^2--HJB?4SZZ%?_J(@@ MK_5X<*<(7H*=1L-'F$;<IRX3&5[J'?M;)6$U:\!W&%8AF>[*Z46?J<MKQZ]B M"W;2L3:>4#(]0P0I_ZZ-.J9%J-I""X6I)@5OZ_C`E)((#7736TFQ8:T`1H\1 M<2`,_CBJH%,HBBX.U;_(3PMI`#W\17'H(J<J/M[0'1X]/7]E[V5FG[GV_ERY MWIC*]4?&S@423S;8PGYQ*)MDUBT</8?_!QDL7'^3&C:HU:I5?N)D,6+FK:C\ MPDDAE,5(%;$"T3+>@G"UM?S,CI>:Q&[]=/YQQ&;AK%0-9C=B3@KWW,!;9O$* MYK?T^<631##CXM5R/603OPG"+P3-L/?/G11VRSS0+77S1+4==>M#L<N/7+N7 M/2[SZ5/$%*^&@BL<,-,3A*0OG3YBOP-TBP(G"^S&?[R""DQOETY+*K0A_<+G M\87"8_WZ+'AARHU]?.YTL:O?`KWBUOC426'6*!1>,6QFCE?5R/$_.,J3,6*J M%;BRA.\(>5U[^902ZSB9LCO*H^I"77JDB_3P(+>Y62_>T?#:`]M=NYG%)"U% M1`A/)&(GV'5^F:\U]0:^S,<J,4YA3'(8;;RFL1!I.F`J':6W/#W/D<5RB]%& MQ_D#^([_U(K1LK.:DZX2W_D$]AEP]]8;"C9/OTL\Y02Z&?(.8!=T4:[@31`V MHI!)@%):]D@%^J5V5S%B-B5'4$;U*L#:*"T@&4IQMSZZ4-W7:CXWE86VP^E8 MR2N45+U<W_J.^^HZB>4Q5C&Y[2BH_MV-M]@KBX"$$M`JP/GB[(`!V5&T<(J\ MFFNXVHL4(I2?LB:D)$9(X8C(?V+#H/(3:O;D]V"U#9+(\AU(TTV0A.R,#&9[ M)11]]>&)\SUTXQCX]?>4Z%1Q^^A83UF4%M.?6V^CD<H("IO/((:[%.F$Z,F2 M:"N>"R@YB))UDG]S%>3"(:\XG'`WG86&B94[CYY05&Z6,;U^L\H7AG\V_S&> MKB\,_V6*$`F4GRX`^M<I;C.1&L$E0F:^"JNFJEZ!)M,.;/JAKN31IY_-?+N. M4W>EBHY:Q<?T1=>B+$P5;.F:*Q/&DU6$IC@!Z35"RBUNYE-EI*3;VKOB$Y/Q MR:[F8J&P31WE8C'SV38...)5.DH9W\PGK7E`B18)*059,P4,.DZ%>$8J/5O" M\I.1L!SE(%81J:4`FGX<$_(=JU@T2F25QXJA:%!S*TO30?4EH_(^,G2?".#1 M>&FI7")FF@8$TEEKAPD[=]3XXT4D=;:RM\AOE97;S,RWG^53<VE+;"KKJI_7 MLG_^-(-%?H2E<JR;*2BWP(A4R;*$R4P%M05,_%"!4MLPTR'59XP^596KO\E1 MKDM#C[B>(18JZ5F";*:8,M0ZYE3R*(\+L]:R3"H+Q6]VG.!="H(S6.WR`$H$ MS9)\.B$H$&-?XF;6K=X6-_;K0B5:9IE-6A]J7=\.+@%M89J#1\!+,`E(^8]0 MET"V<-`:!:3@FR8E8&:)@:W@HCRT4F+4PC]IU*(J/'7\`L(E:&89%UHMK&OA MMQ,+V#Z990MM!1NGS'F)U:PNI+H5]X'R$K)9/V!`5KR"7N(UZP7IP4^O?%]B M-6VM0+0&=HF76?YX9::AXX5E5M1E:Z-&I=1)B4T+^7T?1"Y*9#8+'OK+(B58 M9@4:*A7C&R\?E)A-6XXO,&.^P56@=3Z+[W+O5I3(S<(\2\6FOFI3`CB+]G0` MR^=I2KRF+=K7G_DF/E5>0C5MR;[(N,SX1RFG?DVP.)^V*"_Z;&V)U[0E>D4/ M:)9P3MN(W[8"28G?K!?@!,H<I`7<N[NL@IL;?;L)`<A?XGZRXAIRLW9`0^[Z M;0]0?-!O`2I.Y4$F&]A]GG6%$KC<-T)S)WV>MGK`?3:R!&I6`[*D,,Q&?FX1 MZNQ>'!X"WP[\&)+@H4(%N$D5RFEK"#F4=Z[U@LXO%T3L:_3SK";P+@-4:K** MV*PW_)&+O:G621!^L]RA58`$.0]$Q:,I1-7B\[15BR'>+"BQGK;>T;T6;8GD MM#60AD*\7%=?HUD%#^![GC=2`VU6/H12'F2>!2S`_7'63O[(7NR!`U379F4+ MIT_45%&;MIJB=$D6KWF6Z,ZZ32=T15Y;+,&>M9]&>,JEM7?C'+,G2'GX"IR; M(+Q)8J@(Y1IY%<)I*T3,=PY*D&8=2/Q1H1*U::LYK1ZO*,&;]1:QUUU*Q*:M MGRB[>:FO])9(STI-)Z2EWO0M4/]IVMJ.*M2EW[`M)V!6G#J9[9C/LY8HSPJ4 M.I1)#PB72,_:4Z<#)<M$+ZN"+^,M"%=;RR?.`3[=B>?*M%6PH[([:65K\@@/ M*,H4H8IG(,*85O^.@IT?@OCO('X"=K#QD<&`8L_^:=I*7>^P9R=/$&8_H7:U MXV?:ZF$_\@Q.JZ^"/&TULGAHRL.O;66^VZ.^R/7M1[4S>58F.SV!6P(Y;5TQ MS;&G`I6I'=B1G8>750MI3D;EJSWF7E^!U$>_<Y@^FE:=M0U.,K5O<^",*VNK M$+@Z4N<S4MP7['.L/L]8U5Y&R''Y<<:%^<)YCM-/,T[-YXYR:'Z>H6$\]I:C M])<9I:.G=7-L_G7&AOHX?8[1+S-&DB__9<B=3UH2%U,-"Z7%.*P$-#9"Z!+A M#5WC']U@R]$$$RWYZ5?C<:++B@3!4N!%!=,!H]QK`A?@[VZ\Q8HP,AELW?TJ MN$9U(2?S#HXT((UCOQ+]?_P:CEFF9%607<.UB4*HJ;C]Q2S_4#\/4!_O[2S? M['@9FN5E[AM.O$;SW+U5D%OM68^K_Z5OA_)?/U0!AD+EM_3GYJ\UW,%;C%^# MRYFK(>_N0!RZ;^^!L['"=X$/6X#W=K#[$%MO@1_L#BF592KM\;L/RR2.H'[@ M0-B+5,=\/7A!?0U@)UQ0O)"YA5`5I&!PUE;T@A'*IA<B]>G'#\"+H_R7=^B7 M=Q\_O?O\Z?U;Y/P+LRI[]?[STNG@M_\P%NKKBU*$_JS':#C@5\47YXT[UFBX MEGE>09Q_B5%U(%$>$3@AMU!],_<*+D)X%+`6+5[@$0R%=`H0'0>5PP&=^)B[ M3^<9;S+.WHQRH2X]TE6S2O!I2ILKH2=;A==O>S?$8U_A4C+'E)`;JJ1AZ3>> M8B9\OFRC\LNK[P'WRV4;G7(3][[D/GDR%=U0X&YN"HR5!6CJPV$=T*EL$E,? M!5-[*W*LR]F9;^H^','35W.@O)*'K\RR0+0*!:1(29U>63M-C*B>1X9D,D?\ MC=+/.$J[U'.RVUGAH58+96''[BMZ.T"#@MP(R"#JN_4V6@P:Q_9-LHGBJ-UL M=&AC=%"#`\5!3&2/W%8'U9SWJ8G4L_OHX.+9W@(GP<YG7B8/]5UODM5&_?A: MT.DMN?(F"-?`K>17TO`;D((>#7LJ",:I8B6YC=SWFB0O;D(<FC"S5G$]>V_P M)=SX_$EA2S/!*QSXI/`0J9RF%BB!+YXD@M0*./W`1_O<C%WKS_UQK@^]#D4[ M*F^HU,L`T3SE/7[PI%;?,3OI`E&][*C?.7&T)$3!H;]^XONXP=L30.JVZV\N MT:,.EATGEH=J!`ZPP84I.<6UG.EB";H,?*<TK_<F6@M_UT@T-9P7W6@Z\5D8 M;A6?]+HEUL+I!3'2ETX1L4KT;K/P9"^XT;]WXNCU*F\>?V=&2^([.K5!-7QH MN&]%OSXCV]/73]2&0>>.IG&<]Z3[M*'D%%=S6F8T%8K3%]P"]%-%]5ML-B'8 M6#$8Y(YO3X]!Z`]UV0E_WDQL-1S?'8DZQ3-=FN6AS5P*"3RI?9*Z/]("G7W9 M"(C?T!;I0''XD-Y5<%B&``T$C')E46.&REA$W\FKD3$#RWKYU##KC$I9,X"B M$3]!L)LI#ZH9BK;36IVT)U3ZD`?4$G&2.#,?31D$9`D*U)T9Q\=\\>SK,DQ+ MX3=C`;%CXBC41LF06E:.2*VJYEPS^^CA@E'&O/H\1'%S4UF3'DAG^B$QYT#J M\8%6XH&IF8@Y:NJR.GL((C<=?&:N`^55U*DD8RO/11"H*&M<+MX@8`K64C=V M%_<+;EM3Q]VDZK0J0$DA]N+/C[:I%;%/Y;38"N-Y5OI,8&E7-.&7=)9\[!1R MYAE2G/;1J00#5+%?@ODPZSU[T=0:$".=(J'G\S[*U*"=[B&FPYM3SI%93QR. M>[L08Y++J3"SU'5?FZ6+>;G$W*P'%D=V0/606%_,W*=9K]2O5_YQ7IV1%F;! M5+.\]N<+7Y];O9Q`,\M(CFQ+T>/YRXEH43)QMM&H#`(KI\*LLHL]3T(+3W&) MM(SB/EUM<<"<WW)J9D5>Z]50%[-::.R3%+,&SW<JIZB%)C_?WYTFB5"\I)R. M6<E7.!$JHQV+*3J?M?GA]HIXTE4Y/X:&_(QS"TD&9I>S-"OP(Q*@12?-K/<1 MQCUIXMGCE0EJ80*8!6XULISH'IJ=_F,2'T1GS<PW:GN<M1?^J"_2)Q^CLD0Y M57.8P'!3U:H`8CE5<QC!<%.E,K>_G,'97J%%(FS6=RDFY/-LG=!R^AV5<2YG M9+9':!?X1$HDE1,V4=-$APH1U2GDO/93PFRH,4$DD;J*%R7/<;CTSG&_ZD98 M3O/K;O-[::U>'I-Y<6Q^:4Q@_%'6.%&9JT/&;T`*C$08.2(:RB9VQ:(W<F\L M-^RE:*5:XLR:E_EULJ&8&]^REZ7/K-EY"/Q7K#/V4[Q5^OLSNCU^_]3JPXOS M-[YC18*T>4Y&-R?&[934,*A-PFE\WF1LQ[?L9>D[J=DY,J>K@K4<>)1XG$H] MX[D:I"F6_;D:I*EUY.:*AW-1OK%Y8T=6Q^I(D^]48G7.(!O(D-NIEN*\C;0; M6UN669PG<"@[0KN*BW/B^:!>W'85%^=)&M(PW[(6XYS$-`Z#<<<ZC;-`.!+; MYUSC<603*!<R,U>+'-?L27G<NE6,-.4*["<,_2C\O$T)2`/"JM$O1^AG%NQ5 M4"U\U@`P+5-+BL;VG>O=W@L.(/W>8Q+:6_B%2$MXMH<'!PYYF:&L$#^B>2`% M.\\!W?H"NHN5!L)7UP:4PR2=1_@OE#Y@!QL?O8Z02D"8*9[/5/57="#U!?CP MIO'@[EPX.]=WT:3%[BO(5C$S%%ZLKPZN;GUXWH$BQ^8NFP%&,@:KQX@X8'JH MV7TT)58`>.=OX1*Y`J_`"_:(,)&U)=)3;]*%FMTOEH"A\ENF^L:5SH?I?O*> M+LB:MUQ0QNKDNCB)QX@$;J,J<)RCW_2E*73S-50X_B5C^E.?TJ@)"G[&>X;[ MO,\%=O7D0HEZAEGYQ39DC-$H;4&%Z;$:!I:+9K];T744NSMTSR]]9*E<KK'1 M\FOD^IL+S[*_P:F'G\A>+D(%T^`?[@,'>'B@I=\P>2ZB*-FEIJ4Y<9]JY\F6 M(,4V^KL;;V]]QWUUG21[_[$V:SS#AK+A9QO8"&Q@W)(&I);:*4[/"W&Z:^VU M6`8L'"F+:$$NA^5Z!3=,!&>?9[81Z*C7TM'Q.!`S<2CYR"A34&B.JN)BK5QY M>3VJ*\0HO-:?X.FB.F-'^+O:T'SA<_4BPU56CI`.8S\?-&8U_A;`6\[UH#`X M]'IL?/GD$7URHV\W(4!5Y0`4ZN.A\"1^=Y1HGDK"WI"8)2^1Z[A6>*B("@S] MA-Y^3C<TSK*B6A54$O`D?O29;E\\F>FAW?6F9Y;T/D$]";/M,DKF>1E(96N7 M2W)"T].C)U^-O<'TBU_<WD3TCQ"C70UUCO9CRII+`_2)*$/IR=$U=VOWCJZZ MVW6NP:`J%8'A_NB4]'@*$/,L'+630>#BFU19_#2T9&6]@6CA.&Y*WJV_#L(= M_KP./SJ<"*CCN_9ED/AQ>&#Z\<AMY2QM]B'^AFGY=)Y1@G[YXP8X*,KI`<3+ M/4`!3O[F+HBB5$J-:IDL5_#(M=.X@SJ9'0;2%SD.5\,BB;=X[7+#WH\:CX-N M@6!W0G.MM*,WL.#2`+Y]X`59L/N,A0N6\Y;>7BOUY<'(">I@]=#*P?6;M7-] M?'8_`GB6QRY^D3>WG"YL.TS*RX/&E>`HFCG%T:87P`=KESM/C=9:*4=Q@[[M M>BX&&&T"*%ZX,7>W4_OIX*9VEUU:87B`0@/.X*2PP>B@Y+ZFCU\^1_UW8#4E M";F^2BA]!*&-Y+L-%$"+R7T,(BQ^007I&_`.J^`"/`'+0]&E)(JEQU!".3E> M/A-PB@5)`1"%>-(F0,W`6CRL*"P;DHVBLKW_DX1NY+@V-_Z,UTL')U_]L`AH MAI!G1V6TVEKQ[T'B.;>[/;S>KM=K@%['P@<2/02AY6`Z^$96^2*V^[OEVR`W M<2`1,8I`?+E%^OJMO]@A-8/"L?0P^G,^:)+^<?(!2;8VW4K.TRIJ1C&RSCI< M+8CQ0\0]*$NPS/3G"VEZQ*W7%'5-=[I((R5_A)L>/"(,81=;E^D!'M+KD*44 MF1YU(;?BQ+4UT\,AVE\+=#N"Z4X?N;6F2&OM5'[2.%#EC1BFUWV4WLAM%6[3 M2S!V$93%K-^=RB">*(*<\@+'M@#C(Y':H41>E.;'L@@XR7AX#1Y>.:X(BS(V M"T4#!3Z*_\DOSPL`18^TF8Z8BY0()(O?P$E/IRR!LY:)Z?!&3PFL<).;O)A> MJW8CZO/.2=%[`__3W;"C#%H->"+\W[L^WG[%]8INVNHH:160>P"O%?@75*88 MQ[RI`ZPU!09%&9S*5=#R<)F,K;,W+(MC:C(VS]Z@;'_B=3.5!K'EG:;,@R0= MRS\@4Q5$P"DM!6'PZD::(DPODS"L68"$8HEXO73<*1E-<D%1G$[CXX.T-SE7 M9X<!-?)?\Y%*3B>GK\Y:8]F6D5NE@IUU\M6.H1/BI,7&ZS*B3@1JVZ?=Q`H- M,6L>742\[O=$50+DR@&F*Q^]P,F[Q$Q70WH!52`6J&_%0F\Q!T5PBHHDID=K M]`2KV"UJ>DA'3^`*X-DFW&/\9X"D8:?+`3R9(`\Q*#NMY.$"/D9I\XJ:,:@H M%.'.M5Y0B2Q7CY^OZG@\)H]C4A'JJR3/Z&CX2VOOQFD@$3F:BY14U&*4?JB_ M`G`AVFF8'GHU8Q>$L?MGFF`O0C>KOTZ=N2#P2QA$O(KPC<:CH/L!\'3Z6M-1 MT"R=>"DSPB@X)(=DBG)'Z3T6SO+?LHL4G4/A*XY2P]%IEB?#J,!@H^#[.#]# ME$E"S]F"ULDZ(2,!%-&^<E>:\68S-1@*"#7&V\IDD>QZM)J>LJ0.T"GG,BE= MED19QG03F#H$,]W"=!N7.L!(PE8[L]8O*7H^V*#"O%/!#RN%W6Q7XU]NLB95 M,72'RTP:I\6OW'J^\^]0X'#7!WB!0ND#)9UK#.Q7KKAH+<]"6(+,8CLR(XR# M0R2SYN+KA>4Q%&:QOD9R]<?Y"/FZW%KA!BZK`)6QA[\7;Y6WX),VUHBY7L9; M$!;G72>FZT.-CV=JT5?I[B/DC54^5:CK^'CBO,PKV%DO7R2IHKRF[SAE8^7' M&3.WK/*R<F.<D!PN"8[I)=ID3C%VO2B&3&EZ,16Y8Y,-(PG^Z2Q"R>-9',I" M6N[D6=D#""`*T0OCR2-*E=--][@,B6U#&S#=]S(`M.3J>S).F%.RZ0YWLOYQ MWM$EDYZMU[XAB%++X(@*"\87#U*(I/#B'K+(T+@,[/52A^@))RM.H`)Z:.9Q MH`IIJ^"H9IH&/;:@H48;*6*:HL1*#*!#3R>35Y^H19Y;5\Q7K;$4XW(C*PGD M%2'D2&W\BIY`_A,X#T&<1<F37W!0-_A@O#;K`Y=5,MLRR!AQK&OZ(4`G')+" MX,&>J0WD=_Z0:M%AB4M^:*QXI4J`\X^$7?VIU5!CY9F<!@>Z\$X=<K#=GU*P MWZ-(S\"G)5VT'&FL,[GBO<XD.<@<O#R@M5R)B&)Z,',/F-*//].M:X)@=CIS M33>C];`@5\3:^&;&+JM>@H(*CND!S3VL2EE-PG1'I.J5RU)7YSQ_Z>5ZK,A- MYD6'+B"2+7[=(J5/MQYHTY"[0JRDCW)%RS7E10PY\RW[/7<HEF*A"@Y/#!IF MMU7YLGS)8&K/+F'Z&K]P:1/I/8ZWV.<WY.<WY.<WY%L:6;J<,]73M/A8?J8B MX6B=G25MCB%U@X_HK6/*3-%:GRSEFE(G*-1<`3L$4.6!PD&4>&@KHU+JCTBP M><1A%:O*RV)RC,H-/2),X#XA$)Y5-NN*BNS@H\=%R5J1&WH4>LG\>G>GIZDY M>L%D["V"$`DI+),QK/!`4RA]3<;.TO'ES*G$QZO"2U+P:N>\.Z6`8U7`2DHI MD_'H]0(K0RB>C*^O([!3"7_GFICF=W%;HS2_BSN_BROE$RJ>T,..12@17]9> MQ3WZLY[R.0495^`E9E?SH#368XVNPY>N.C[=U<8ZZ'Z`:R5WV:=DL"&GM]=! M?06],J645U:=TTGGT2;&3_UT(Z\[TX,H.R%5.UG,5[+DL6*<"I-Z5_7?$RN$ MJ\8[W+B^Y=NNY5U9L?6<['96>%BNBS^GZM%('Y*'>MJ%%;DV6OBNE\#EBF/> MF$[2-N.-\Q'UG%HU/(^<4U7SJWU>H?19$DH316IMM%.Y>+5<#^D5J,3%;H=" MR0/[VS;PX'D9X<4CPH?`*#HX/3X(;_UU$.[2@&71``S9471P^FQYR-SU"OP$ MT%\K:;;2>;VWG)OJ?7_$M.GBHP+,&D>4Z8DVJA$3.2Y--],KP%1:`#+=0C\H MID<BM>E).4.A2T.U[[@0;3KG0Q"#:!44L.+0!)SUL0PWEI^]]`/1B@+/=?(R M-H\5LI9K0N?*E/C.L[OQW;5K6WZ<5;V!L#_"\6P7?AMR<0'EJF\ZE-AC<CB2 M)*.#%CODT'-$L6P.38;.HXB_9JJGSO`S-)P(/1]:W_(?IG5X4=(0*N.'<+82 MWTYQA=/U=Q`O'+A\@(,_?:"=*.W'T7'\(EDL6JX;N![8+$IVUL'7I16A!^K0 M_UW_,W%?H98.X1=C2ZRO%JXJ>=9/P$/^$Y1N+<J78&]=G(5@"\DK<E)E5J)P M=SV\P>WOQZF(_N1&W]+Z#NA?5';H/;18T'=[RPW1";:$^D6T#R++6Z[O`G]S M!_%VTEH+8C/5:BBM27*"?-&:ZZ$=7CLVB"+R6YTIB51&1/KJX>H5I/G\HE-" M:Z_'X_&=)A7(G'32PRB1BSH)I0+RDM+Q=<SN([IZ,+DX9.`1WJLAB-T04_CH M67[$W'3"W;7P%J*(AOB`Z,#UYZ%0M!??AL+==?!&/N2RD`WFE(GTU,,1]D4] MI;'3:-.(31._GY*3!'T&*NC89?&\]US.(A+KH\7;"39HPI\`+G@FISB)]=62 MRAJ!Y?HZBMT=/%VI2:GU1N,W9?5PAYGNYI6S$3:7C>DN73ET1(TLICMMY5!C MJLVF^V(EH1*S=IGN8I4#C:%.FIY-+P>4N/QO>D*]Y`)K934S/8%>#D,!;6:X MA]Q/`3!!TU\!VB<S,QUE5YF`%:"$;);X90Q>)6ZS+L!R*Y0XS=*_C$.PQ&U6 M!83-4B5H4U8%!"V2)5BS.B`1A%#"-FL#;?Q_)7Y3U@0ZQ&65`/:M&8PPCO#: M"GV(%PH)Q['@6J.4F\1PPORHS;4\O44%4HSX<<3\\F:@]C@`G>-)A^92<<%% M<;1$T)[RQGJVM\!)/+!<+^#1[J"\%2CK/P,[@0L#W@;7;[:7P,E,DUUV^R3W MS\GNR!X^I!>O)EV-C"J\',5!D1OM5`ZQUFB9[MEM!Z*Z+3J<;WB$5PART=UX MP??G9+_W\$^65R9MZ$TE$Z:-?*`(=]=R=E:(R@F]3G_@Y9P(==6YH65X:WJ- MQ>9[TE*?*$SZA,#RE.;1*B<8R(TV;^MQ;.O6JV'2N[R,!H'_1%7NH(!X;X7? M0(Q00B$/\:&4>U"P#0ACR_57H>5`02=UYI?@:KW(*[QDG!S1SWON27@`O8D@ MBN>*BX;:S^DM!2R[1LBQ4ZIG8#Z$>H!5GVA2<I0YOH7W6K.]YH/&R(.T+BHT MPD=1!8%M$,8K$.XJ?+20(5L-?+J'HPI433="J;I^CDZ525N7;BPW_,WR$C`6 MDQ*)(,Z1R>RBXY!D@RK.Q#B.-I$9J6XU#O>3%M>8V.B3N0JR4GGP'EB(,F?I M/Z'#-82"(DY($E[#HL.,97,J.6!.:6L*S_.D=VO5"G9A>?#/X'D+0#R6N[)3 M?BKOX0XE8^NV\')GC6_IY0ZA];4)E2N@II%(@3B?$H)0Z;OBY[-"JE!)ZQ(E M8PGX6=AVF,`=Z%HOKH?58TDS#'<`(\\]D05ANJ6EOTM%8G5.VBJ3)4D\6G`E MKD++CR"@D(JQ>`MIY'&N"6XW/<6/Q*&68VML_CO16:NGN4J@,VDI4`*I-D(@ MK?KP;@/\>[![`6%C=1[]64VUXR@&GF=%C$_66^C>TE?!SG)]@9V;-=1-KZG' MZ<6A^I?TJ6DIK@@#Z!6P:81*BMF"PVCA-3_<[IJ/KC>Y.6ZHE=[:<]XT6M-& M8[F0Z^=4F<78.&]-KY(F`DGURC.]_ED;F:VY#89[>'U<&-&O')J$FZ\XTQ&C M'^QD;5WTJC/=,$*^8$3T)=):S-`Z-WZ54=$BK<-\#7W\V#\NHU0CT[I2E:)2 M*&@3)\J!\#E8Q]\A\*.Q`Y&*8''5%F8GG26]Y4%GLR@_GMY[5&0V24706N`V M<5M12]P46HZ^>,&+Y<%1`V>U!:&U!TGLV@S##KN#$NO2_2'X9H6.:]&I:#91 M\U8%JD='7OY9-<E%""_S33Y[N++DG\#Y`G_,6S#5_KZ^HH5[=_>2P/V'JY2N MLXJ'ZKD7^,IX7G\XW2NO05(Y!>BM6$3=*G@$(7IU]B8(\1Q"678%J6.:\%2, M?6*H(+HYQF858\]V0!/M@+*"U_1,/`I/*WX97^D-/^,O<2X6EER."&J^;;</ M4(]D:-/?O6`;,WN3[R=CZU0'JXCB8+J#2\2$K.2N,_U*FJW++0Q/*'%V)+;C M.BD<!9K26(=R08-0A/!QV'G9R%=W$)7725MO*:CH2^T8?BM1+(FEQ_C6A[,, MHEC8/"C:==P;1PZ%2>^BRV"W<]-R#MCW@4NU`Q_5=!_)#25$(6>WR8VAXSZ3 MG(<.;(YC$[>:U<9C%E*`S;M<&"Q]5^@T]GIY,]TD,23FWO7=7;)[0HO#>[0. M:8D*J$WN`7I#U=_<`2N23ASL,K;ND&Y?2&*1Z7G29YT0-*9;PA2BV&G;33HC M\C'G%C^ZI?=E&EQVC/=L1KV1GMQV,F1D@FFMM;X[0$2ZGJY-X7'24A<&8QMX M$((HQ1"U'8E:=2K;1QQ$6H"!:/]Q;S$)'.9-)X*3QJ>?3F7KE0_Q[/9><`#@ M&82O+JJKDS[&`YSJDY(+#]."*U*4SMM'`!=1^LZDQ,-&BK^G%STR^4\`3JUK MQ]FE^=5WH6#[W0J=A1V[KW#N)74?-5\9(U*8\N4^S;A3"8[`P&/!(]-/\-15 MR49E!-/=$$7);M\F]5G)1S3C1#ST?[>0MSZ.EN&3N]G*G#^RXXU<=&B/D^E& M!2GP6A].ID?3=$=1^C(T/2I1!E+ETIGIL8KMUFN7*[A$]*?IJ619J7_K;22F M#P(]W-=`Z#WT/&_"0%28A7'(+P*S47]!@L7ZI$T?+&AT/B1TZKNM\BP,O%`# M'V&-HHHR*C-_W`7PP=J-95_9D1Y1+P)7V8:"5*;%ZQ=^A^*V<J-IMH&MUP`) MHZ"8IB>X\9`H!;>AY^(-+_M^M_R0>C%(Z;P`ZR`L:;Z"_Q?%^&'N&_B[NY&% MH=VH>I'XZH>%$`VIS;9J]!1X'B07B8B2($@/J*>F_VYGA8?ENI1YH5KQ'=5: MY]?R%^AZ0G)(YTUANFFE-9XM+EG3#2RML92\KDVWJLCB*'3<F6XM:;WXVDA, MPQE*3@Q,>8&CA/+GZ>G".!,S!1L>>?B_LBMD)$:H.H$9;=P77MB==(B$<D"+ ML,4;0^N;'$*S5MW!DOA,VH`EA97&-YP,V;KEY8*)>X!SE(<^IX2V"\*7&NRT M-G-;Q":]J_\]L4+(@W<H_G;KHWH)J?RG\PYF4B9LKI8=1<=6%YR#%@R.8RNW MG,GJWA:%:-[+7)#T7<W3V='E5<2>$[F[6V:L$]_O+0'4O/W_^@$Q\F)%`/[' M_P=02P,$%`````@`>X-F1A,N"I?[&@``"#0!`!$`'`!C>71K+3(P,30Q,C,Q M+GAS9%54"0`#V1OZ5-D;^E1U>`L``00E#@``!#D!``#M7=USVSB2?]^J_1]X M?KB=K1I9=IQD-JG);#G^F'65'7ME9V;V7J9@$I)PH4`-`-K6_O6'!D`2%$B( ME&2;VN-+8I'H1C?ZAZ_N!OCCWY]F<?"`&2<)_;1WN'^P%V`:)A&ADT][7V\' MQ[<G%Q=[?__ISW_Z\;\&@V`T"DX32G$<XT7P6XACS)#`P1UZ2F@R6P2WX13/ MT/?!/>(X"A(:_/9Y=!F\V3\,@JD0\X_#X>/CXSYC4<9D/TQFPV`PR"KX18OR M,7B__^;-_EOKS2A):?0Q.#RPGITPC(0L'D12BH_!FX/#=X.#H\'!N[O##Q\/ MWG]\^\/_V*63^8*1R50$WX5_E84/W@TDQ5$PVA_M6VK]=W";4"Y+S^:(+H+C M.`Y&0,6#$>:8/>!HWS#E2MM`-B'EG_8L!1^/]A,V&<HJ#H>_75WJ5MG[\Y\" M7?;CTSV+28D"GF0T1T-"N4`TQ!9)3.@W#P6\AD:W*W%(C%B''SY\&*JW5NF4 M#R8(S?/R8\3O56GS0E9S^'9P<#@X.BQ3B<4<\THR]:::+ER(0C0RPX*1IWT< M31`;)%1*AA4N@/3P38F02C.EL^J&B`0;0IU#66@@2V%&0IMT-9U#`V4BD9/9 M;?YNJ%_:6DF("K8H%^<XW)\D#T/S$I0Z<MLC94SVNSI2\[:Z+2-,JLGDBVH* M_!1.JTG@334-H0^8BVHJ_:Y:,XI(R*O)U"N@.G2H.`FK:>2+&@HQ9S4D\LTR MC4!L@L47-,-\CD+<$HIRV)MA*LX3-CO%8Y3&LEW^2%%,Q@1'>P$2DL=]*G"I M0$J+(C\!EQ\1I8E0XY?Z#4_F<T+'B?DI'T`G_<B2&-])?`;PQ]?1Q6IIA1F/ MAT`Q/$W"%.1%-#JC@HC%A:R#S53->P&)/NUY2^329/)$>$PH47(?'AP&@R`C MM_^4K`+-*["8_3A<YK#,/)43QS7]2?T=HCA,8T5X*7\;8E/"1SAG<J2F8@W* M0K)Z.O,T,\N6K74KQ5;PNAZ?$RIG`8+BFX0KF4YBQ+E!&=AM)`E^;TC@-^.1 MM%W.*("YDO(D)C"O1L%G%,-L%-Q.,1:\M^&6;'B#Y*@NIE@0V4BM#:JH5UCU M;7.K!M^5Q/EK;^4V5KZ0:^89KK:A>>>WU#N?I?(7/$C&:F'*\!133AYP<)GP MOD>VLM7M5`)]FL21W&J<_9'*&>J81M<2^*S4LCZ3MF/AM_S[YI:_%4GXS53[ MET!7W-O^V6S?8'QNSV\%&G[8#`W]*+X).DX0GY['R2._H!%A.!351G>+^6WZ MMQ9CNV0=*-Z]Y59:[DLB,+]+\C52T937;((H^;?2JFAM^4/VSAM+8VN!51"? M$A[&"4\9EJ5OR83*Y5:(J#@.U1:>T,F-Y!<263=^$I]CV0LMG'1(*#\J/\!N M+><J?]CRJ>V;54U0U!-D%?4(W0"A9XA1V9C\!C,UA[2#4CVUU^;@.RW;_`L6 M:@492$Z!8M5;=0.K9C/#;3J?:Q\1BHOV;CE>-&;FM_GALLTM?FQ1S#C!*1*H MM_X&UK]0;E#SYRF^%W*HOD+L&Q;H/L9Z@7:+PY1)^3&7+T\P$XC0.X8@WG+, M.;8'^G9H>;;*_>AZLXPNA2>H[@'%:E4#,XDE7(^P#1!VC@C[!<4I7GM0\7/P MV_IHV=;`+%#<@BN,X&%OXDU-;(_VQD.G''1K6[P50S\`WBX#H.1"5(ZIA/8( MV!`!(QS#SE!NY,5"CLZ4HQ`$77MF:,//;_]WR_8WK`/@+6<5-=;;SQ:!76&/ MBHU0P3%BX?04/^`XF<,SF,1EETN%W`4D8_$H5^_K8V1=[G[$O'<VF>`;"[+J M%&"L.N6+!TSE='+,)&XF_72R,6Q@);@N*.IH_2;_8=GDP*:WX2:[RF0V(WKU MK#JE<L-@"CZ8=4W;DJ7?XG]S]@`%=]7#2_Q[*&P`A1N&QY@Q'"GG?SN;U]'Z MC>NX":4Q'^36D<A=99"SU,&(WK2;+/RM<([>KD/9=3MX<VY>\[]Q/(9]#'+K M7B.(#=ZAI_4]/QX&?NLZOD'-"_)Y^X%ZLP@4K'-U:V81X;.G.:9\[1[=CJ/? M[H[7[H+*93[F.FU/\?X>8@,]!#:`P#]3N0/&+%[D[ZQ$R':V;\C*;W3'?9=S M#7*V?1!@UT+/V8-.AJ!SX?S(=/R*;4/1P7?97WW&R[-$I>\@B-0,8ZMX^*'@ MN!C="'7PG>;4F_HE0M4M+-^2I1\(CN?0%[;N(='E^'4+"#VS"'[(.9[+5;'L M'G;/'M1N@9TF?/P`<!R9-0'NWNXO'>EN`8,UV/I1X7A`ZZ+>/2Q>./S=`A7M MN7I!<>3X1=N%PGNHO&I,O!5P-JO##R/'`;M&?+S'TC,&REL@Q<_!CP/'(0O, M>L.^?/2\S79W'<9^&#@N6F\DO<?'B\9=VZQ!6_+TH\)QCU:?_.O!\+S!V%9N MC)5L_"9WW*!V8+8W]8M':%O8?AV^?C`XKM"::&V/BY<+V[8`1"N&?B0X'LJZ M$&X/A1;7(^4-:H<=5\4XCZ-(25VRIKE-:8L,_7AP'):M`Z>#H*C7OJ@I^.X4 M"T3Z&P1:`4@.PA"KS$*?)T5K7(\_(TY""8)3$J<"1TM%CV,Y"$"7O4M@S9]0 M>XVW#*OGJL8/-L</6A&:A9A)+@Q<:*#$T6X,+5`552Y5())`RU5:X_9@W`(8 M+R@7+-4A^J<P3B,<G;-D=C?%VIEE\./@QN`$6*S`X39J\$+P;8/SZVIYE,L1 M9(($8RE)()=*@24+`+02EAD&=;I!#[[VX"M%Z[/$`%B9V.&9[+EG!EV;CQ]( MK0[%EU_'UMM^PMP0)M"45H!=SEM6>/UXEC!!_HVCDX2#TST/\.HK>,ITQP^R M\6$..4_8K7QJ\5G&U,M4Z@=@ZW/SL%++1`M`-E7`"E!GMP<M\\AE#"16`Y"R MG,+0PW;;L&VR,UB#@Q]0KNNX`:#ZI?_+0.(VG<WDO`)W06K/C7VYX(8\_+!P M?,<-8&%J@A$E]S09_V,/C36@D4\A=@Y1;L[<<:.3UTR9Z%@4,P\=0<H;DQMW MV$XY\]G6^?LAY?BFZ[*D2D@J_%-:CJQH%"!1FL9HD$NC=H_]%+4]T#6:FEI0 M^H'B^*WK@=+/1-NSO)WT5B2GY>/!#4OFF*F+2F$:4'DEAL09639AY<>&X\FN M3:HKC2)9C?IZ^:S.C+@?*K8(F$9C11M2/R`<5[8'$/UH\6*CQ7$8LA1'EP3= MDU@EW;<<(RH8^('0/-VV-#*8>@*KHAX0ZP#"RI351RSJ4F<;#1`;<O-"Y=VF M2;C]2/(JP#%)K!`;L(NL#9TZ?G[P."[@UN#)DG%5:*%<L@?0.N%WR&3)4I\A MA%DD/INFMM.>FP7@M\#2#R/'D;M.!G<_$+T>CO*5RETB4/RS?)&5<I8ZVV/L MQY3CRUT/4];J2(D0*!FRTOWRZ"7!-<)D=I\R*;-)!MP6N"H8^\'E7K:P*;@* M$8),AAY;ZV!+'7AN,JW5%_3;WG'=JF,F_>RS;2.6A_XLB&(ZQP55W_.,JHS: MC-!O9,?M:HSL3`=Y<,?P#[(*>L.O%0&L/P_4+"3<EMX/`_<V`^]9HGX0>"$L MC.1#T^%:(,"F\MN]W6VL:AM+BR&@M_9VK7V>"EG@2HHZ2V>7&'%\@Q:JY%<: M8?8EH2$X-U6"SO4<OJ8N254Y-VWI>6KQHZGB^E<_FK0H@9$E4)4$F31!"N($ M)7F"7"!=N%\[KHG!_%K>\D6_#>>>5M1>S+QWW+*>*X/[>6>K*'`/GC8R?U,R MO]W=I-JJ<ZJ]P9_7X->IX/`A=SF@_HI@S^XFP#8C\AO;\7O6&-OB'&2L>U-O MQ]3Y;E&]NIZ#G,>A(`_$C::TI/8;WW%0UAC?VG+JT5[7$F35]$#8,A!&<CO/ M2"C,[/U5BKP&('Q<_,!H=E7!DO<PJ\Q@!*KK$;)MA,"3SW)YK:XNDEL]I:$) M6MXEUA#`EZQ__(A8M/Q008)&9[-YG"RPKN\F9>&T:N/RRM+X$>NX1.L0"X\' M2N;`%CH/_(JD-,;Q[UUD:^$K7H`"W^N<-J.#>9%KT?>#[?0#ZSB/.MVG#)IM M3W]%_(P+,@-[7M-3^=_U6,7,OG+(C8Y1^.TVE.PPUS:^D4:4+ZZ2",>*T37] M%9/)5)(?RPT/FN!CSM.9QL/J7O&*LOG[B'L7;W4?*9]&4CJ8'I,[`!X1#W(] M(-D;-('2.C:IE`F4-@.C3K9F,`H%2J-`LY6/,Z4"HU5@J=5WFG4Z37YY34._ M]<KR?G`Y?NK253?];O&93"M[%X[2&(XUYAF5<+8("GS&LIUU,8^QFW+PF]]Q M5R^9/ZM%G6\L<C_5V2154%>5W8S4HV(C5$`+([H8X3!A$8[R-S<L>2#<W_E7 MT_J1X+B:EY!@^`=9!=;[(*^C1\!V$,!/C9M6/M0'MN0"VY,%O@8'+QI^<)S( MU6CX"P^R>A00S.$R6$KWF>#;1P4L[K+;C/Z9HIB,%W#MOKY8J`DH5C#P8\+[ MN;(2)O)J%!**BK([D'I$;(H(&(5I*/N7N=4%[CM+1<(6YUCN"F`!:(J.Y`+_ M+CD;CS&X=+(G'JALRMF/H8I/GY4P5*Y=>RY-_8$1P)YXH$;8^N=2%$][A&T7 M82IIZ7BFNN_U^"ME\OV$PGT8LOAG3*46WB%H/7Y^-#F.\)5HTJE7IEIX8%>L MP)-5W0-H/0#II+;L[LTO]JFTXO($Z[4+F=8<_"!QG.)U]W<.G!U.S3V?/3#: M`\.]AE-?(V5B'OGK$>9I[`XD;<G]D'"\SK47>99B)44I4\W_)RC`/_>(XQ$> M!T_JB9"%/NUQ,IO'<D&AGR$6`GV.D\?'Q_W'H_V$38:''SY\&*I2P[D^1RZW M!L.,;<;`H7ZZ9[&B?W-P<*11M=1^1JJ,PY3A\:>]<"&^#=X<'+X]?'-T^+ND MV'^:Q5D100348E^6"(SX]P&*X[UA=S4OF[&!XI*@0O'3G,V.Z!VC>QPW5%F6 MK5#Y$CCLB+;+W;R!TI*D0FG[HZ)5NO\X1/,YH>-$_9:_*$UT:?U`JIXP$5`T MPWR.0I_@A$*>22CUY.$4S]!E$BI&'A+X-<CH!O!H</AF<'2X_\0C(V(;"8J6 M;B=!1M=6@C'B]XI5R@<`%3X$:PP.#B6#6AE4_3;E!*&Y(AQB.:'DO`8%K_;- M$0DV!"Y#FM`!36>8D;!9J]B47S0A-,L':);#]YM(LIX4ZXE@&_F=^A6)QJC( M"*#2=ZV!D)MS<QS`D[8P4&PY#O<GR<-0N5K8`K@>-1&GBB[[,2B8K"$('&NA MX:)QPU02YK\V:I0(D]9B9#3PQT:5XZ=PVKKVG$C]M5']1%TTUQH0%IGY>R,X M4$1"-5@>MA&BH-)_#@H&[47@)&PM0$8#?VQ6N9BS]K5G1.JOFOJQOB17"?!I MS[KDGLD]62IG694%\"41_\+B.$KF<%=#$I-P47S$7NV[8&WQ^WKD>M$DIP\Y M=G\4V?,+@6>PI]@+T#T7#(7BT]X8Q6I9)+4D'^5RB231G2*.4F8BW93$ZI#" MISW!4IC84TE-1`IO?V9).O^TI\F)Y%_;"'`QS8F<Y8G<!>@OK8?F%USDRD_4 ML"+*FC>ET>IJ(68)Q7!_<2ME]?I'9*_N]6T[4A"&(R*VTP31_Z;F>LF[I(CG MWR`27=`3-"=PUI'S%"J&:'+-602[@;;%<>/F*[#RC.TW%G`T7.K`==K0[3PF MX@K/[C&S&\5;K-0OHF2&"*U25`OYW'U"_AWAZ'C"L'KLJE)3H%M*3#"MD-QZ MVBEQN<"2"7<E7GK1*:&7+M@NOOU]A03\M3C-@TE:F88$=K^?_`LC=I50,7V] M64)GL:SNXRO*=<EV<-/P"/^1$G/-YQUF,TN3ZM>V73)I7L\J<-@1,W#&7I%8 MKCKE!.'V'U^A3MG#?+,VOS83ODADOE];I=3*PMU2#J9X;A)?<?9)$KBCU)[P M2Y^]*:F[#KEI`*G]//L$RBM"M6:-DRV#E&*.RJL)NJ3D*<9L3'#L63G4%^D2 M7',IZ^7OIMA+*5UFJ0VQZ^JKBTJ:M2=^MMU-A.^WM#AWU#K%<[E9(UF6D_EJ MAY4Z7=T:7K)=:(<D3,U$<28W[6)A96L?&P%M_1L5M_6&,S-T\FK8/T,L7EC@ M='IN78$N=>`\3:F41%7.4G&0^540U4F_),+DIF27%VF]M\>S-->$4NS7FVJ: M:/4%B^(VC83SLZ<Y8<L=?5-&.]8FZKNGQW-P0\I?2U/`N@RZU`95APQOY&C* MS0&DT@+2UKTE89?676J$CO/#:)F0IRF,R)=$[A$B!_:-2394-)_9MJ'G4X@Y M5P=:LE5^<2A/6DE_J!*\SIG]P&;+NP2[%;;$<"?<E&=/A,,(EB'=G2%K"G1I MAK2_]U88#?9$I4G/7^SYS+6]]5JN0;'9K=X;KRK8I8'*9&B#LP*F$3G!.""L M+](I&&HIEQ<&^K`Y+QV1/\51JN\D=[5L2[\3P-6J%4G:^HA`L:;X*N[KK-Z( MJ%,X8/J^>12KGL7U)?=+WM_EI48;HM(.2Y5^O=[[<YQ(O'R.$\E]*LTUQY(Z M=#VN*\IUR7ZR&.<W+`DQCI0=BJCD\CB[NN@NQ'IEAV)PC=\IUO]?4'7;'Y]> M,_@T@OEQ',H%(%=1VW/RA"-S0#!4X0!I5%G79%KW[1G56L]<SRX,A.IX`#4) M`4XGJ7S;I:Z1P1L$O!Z;N\%L!:K?[\12V,X]R)=*M3O`NBWC1ERZM"RK5`2" M*<`Y@8H>,/1:BMEYPB`RV+0U&C+9T<:PNP!?KRF66.S$N%:MW57\<)S[$2Z3 M1\PNR8Q4C1A-"7<`%279O\[GZREM$^Z&TK!Q40\)YSH@TK(O-.&QPYW!_M!5 MZR'32[P#^+#E;PD+#^FNH:$F?*^W?#4ML8*F2YO!2SV3)6R1YZ`X:UQ/F2ZM M="_EPHQR#"XGS![D#W>U7E^D@XJ<8_M;1'6Z5)?JH#K9![&6/B!8WF\V*+L3 M.Y/+A$X@U>Y"':.HME]MD2X9+T^VR^X6'.$0RW5OI#YY8'^MRE*M#=$NS`>P MRJM-A:IZV2D++I)OB$4$N9(OO^F2V')96>VE*U^WKA1I4'8G1HTO^+$VJE?Q MKE/F(C3B5PO$Q113@GYFZ(&X\Z^W5,?4P0)CJOY?W,)T9,5RP`]4I5M#DDXI MFM"3_",QZLLPQ3F?LR<A)V,07M5NZ]J&RNYZKY]L[HI>I`'!"06OELM%;=74 M^897U:NM7YZA"%]0%70N:[T1H]T8:1-:\O`ZMZ2[W;LI1<=Z]Q><RBDQY7`# M"KN@$=&G3RO&YM5E.Z8:SZZ,LV^RK]++6[!32J4@DW(AZ%/PXB:]CTEX/1YC MR.@J+7I6E[6[(J$"3_!K#E!&WOSFI0N:LZC2JZ;<ICIM,Y$M$U4G)&GW3LD3 MEG]K`9Q_<D_$SY[@#!.O6<9NA5V7O$L2BW)#GWN-SE-&"7RX[IA&<AZ!O]S^ MVH*F2UVWE`!T(JVQ&"=,?8FB=GW1G*1#ZXQK-D'4G)B00P]/8I-BJH_/Y_<0 M61U8I0"I[7[]+03;95L"1@=N)U"W"E8G$+BO.H5JD$Y]-,*XY*KEKRK1.34: M?_5]E-\4:NMU!S)40O<9F'<2P"UT-)^JAU_78_/5VZTU8!/F76O`&WVB`DVP M"A!?TVRRKYCFS:P.-7Y>_$-__\5JKLU9E8*/K0]Z;',%5>B2?=,"/F60Z*TF MOR3?<+RX2S[C$=8G&"N;H2GI9FH_$QRNQV8_HH:#N\3R\U4;W4_0+1TEX_.$ MW21"/I4S]AW#2"P=5O*6ZI;KR(@JM\BV-:P]Y2^8BV6,-J/HF**9*<P%VCI\ M`TQ5`,=*@)+KLRSV8:N]'OU.>([*(?WB1H,1U&RW@;^<K>L\?<WLCRQR`@MM M$ZX#P!9.+O4]/?DVVV*JA)^ZA)"M<-L1(!01IU.&'D^31VH2H83LT^9C<WJS M0B?G*#19SW#J7%PA]@T+\W#1J$6?J9Y=B+]6!_?@<XXU[;1<:.<`E2N@KE<R M4T;1:U:I74>U:\8&-<H+VOQ+`H[R-65WQ?2R2K&`**&ZJR'S?GWE>)S&EV0, M[B\58.$5MSRL1UYR%+[NK0^@@#Z)CF*Y4E)75,@V5A^A=#P.30IWR?FPM&'- M3HQ4;WAA5+9T78-V)P"_I)?'`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`0?.WC M%/9\I6/1%3&^506[-*S-<4C&Q*2^3%76X?4CE9NB*9D7B5"V<DTI.I3>9EU% MJZ];UG.JZ8@F\R*+R*O@=%6JU$9<.M5G?8IXC[VTIMP9M;_@1_6*5U\:UK0- M5K+9Q0:QM\]K-$29?&<:H/A06G:G8.M!P<MBPX;89FIWC1(J"V73X;$1DYWP M*_H47&?4K"7<^=;8>#!MQN4_J9W:C;%^ZIUOEXV&WM4<=J=]S!9PA.=&BROT M1&;IS(E)-2K=K4#4;3J;R8:_'M^2"94[BA"<DL4'KB$0(\U7Z3=J2]FE#5<C MV1UW21NJ3KI/X/HT^`)MV9%EJ5A7H%N@K982GI2VQ>Y)P+:$W5/[+E%NJKH[ M.N`R60K;?#E#V\^7VF!M+AUKD,?D;IJD'%$X('.>I*SRHBE_L2XYMY2;^9'! M.15:OIS$46IUT6XIQO)CW/G94_/)$WVBR23WM?AVRA9Y=JFIS`ZDG,]HJ5WS MOM0S0<U7ZY5&P&OJWGW@ONI@R\N5?+9<M<[&U.GB+]U!]>1H6*>+]>H5!?]Q MR,,IGB'YY_\!4$L!`AX#%`````@`>X-F1LS=WN[,P@$`.),8`!$`&``````` M`0```*2!`````&-Y=&LM,C`Q-#$R,S$N>&UL550%``/9&_I4=7@+``$$)0X` M``0Y`0``4$L!`AX#%`````@`>X-F1MY+)D4?&0``0&H!`!4`&````````0`` M`*2!%\,!`&-Y=&LM,C`Q-#$R,S%?8V%L+GAM;%54!0`#V1OZ5'5X"P`!!"4. M```$.0$``%!+`0(>`Q0````(`'N#9D9L+SLG:D4``%/S!``5`!@```````$` M``"D@87<`0!C>71K+3(P,30Q,C,Q7V1E9BYX;6Q55`4``]D;^E1U>`L``00E M#@``!#D!``!02P$"'@,4````"`![@V9&)S.KN1*R```*RPD`%0`8```````! M````I($^(@(`8WET:RTR,#$T,3(S,5]L86(N>&UL550%``/9&_I4=7@+``$$ M)0X```0Y`0``4$L!`AX#%`````@`>X-F1OE_;GE&7P``45L'`!4`&``````` M`0```*2!G]0"`&-Y=&LM,C`Q-#$R,S%?<')E+GAM;%54!0`#V1OZ5'5X"P`! M!"4.```$.0$``%!+`0(>`Q0````(`'N#9D83+@J7^QH```@T`0`1`!@````` M``$```"D@30T`P!C>71K+3(P,30Q,C,Q+GAS9%54!0`#V1OZ5'5X"P`!!"4. =```$.0$``%!+!08`````!@`&`!H"``!Z3P,````` ` end </TEXT> </DOCUMENT> <DOCUMENT> <TYPE>EXCEL <SEQUENCE>19 <FILENAME>Financial_Report.xlsx <DESCRIPTION>IDEA: XBRL DOCUMENT <TEXT> begin 644 Financial_Report.xlsx M4$L#!!0`!@`(````(0#08QCQ:0(``!DL```3``@"6T-O;G1E;G1?5'EP97-= M+GAM;""B!`(HH``"```````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M``````````````````````````````````````#,VM%NVC`4!N#[27N'*+<3 M,;$3IYL(O>BVRZW2N@?PD@.)2.S(=CMX^SFA157%0&A(^V]`D/B<GPA]5__B M=MMWT1-9UQI=QFDRCR/2E:E;O2[CGP]?9S=QY+S2M>J,IC+>D8MOE^_?+1YV M`[DHG-:NC!OOAT^,N:JA7KG$#*3#E96QO?+AHUVS054;M2;&YW/)*J,]:3_S MXXQXN?A,*_78^>C+-GR]3V*I<W%TM[]QW%7&:ABZME(^)&5/NGZS9?:\(0DG MIWM<TP[N0X@1LZ,;QBM_7_!\[GMX-+:M*;I7UG]3?8C!MAW[;>SFES&;Y/20 M(RG-:M565)OJL0]/('&#)56[ALCW73*])[UJ]4ON$_NGFQV;WM(K!QE_WS3X MPAP<)(<`R9&!Y,A!<DB0'`5(CAN0'!]!<J1SE"`HHJ8HI*8HIJ8HJ*8HJJ8H MK*8HKJ8HL*8HLG(463F*K!Q%5HXB*T>1E:/(RE%DY2BR<A19.8JL`D56@2*K M0)%5H,@J4&05*+(*%%D%BJP"15:!(FN&(FN&(FN&(FN&(FN&(FN&(FN&(FN& M(FN&(FN&(FN.(FN.(FN.(FN.(FN.(FN.(FN.(FN.(FN.(FN.(JM$D56BR"I1 M9)4HLDH4626*K!)%5HDBJT215:+(6J#(6J#(6J#(6J#(6OPO67TH/A*;7O_] MWS&-.=.\<W[7D;MR6V8_]-SF1EFJ?W@;*J)7#_!Z]ID<E>JJNR9T):_\$`YS M3^T/!<Y[:P87JJR6+@_PTE4=3\^&,(BL;^G05CW6^CQL##78RQ>^J9W26+2M MJ3ZRFTW%WN4?````__\#`%!+`P04``8`"````"$`M54P(_4```!,`@``"P`( M`E]R96QS+RYR96QS(*($`BB@``(````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M`````````````````````````````````````````````````(R2ST[#,`S& M[TB\0^3[ZFY("*&ENTQ(NR%4'L`D[A^UC:,D0/?VA`."2F/;T?;GSS];WN[F M:50?'&(O3L.Z*$&Q,V)[UVIXK9]6#Z!B(F=I%,<:CAQA5]W>;%]XI)2;8M?[ MJ+*+BQJZE/PC8C0=3Q0+\>QRI9$P4<IA:-&3&:AEW)3E/8:_'E`M/-7!:@@' M>P>J/OH\^;*W-$UO>"_F?6*73HQ`GA,[RW;E0V8+J<_;J)I"RTF#%?.<TQ') M^R)C`YXFVEQ/]/^V.'$B2XG02.#S/-^*<T#KZX$NGVBI^+W./.*GA.%-9/AA MP<4/5%\```#__P,`4$L#!!0`!@`(````(0#\];X%WP(``/HK```:``@!>&PO M7W)E;',O=V]R:V)O;VLN>&UL+G)E;',@H@0!**```0`````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M``````````````````````"\FLUJVT`<Q.^%OH/8>RWO=U(BY]!2R+5-'V"1 MUY:)+1GM]L-OW\4D4@/MY"+F$M":K/]X9^8WK'UW__MTK'[&,1V&OA%RM195 M[-MA>^CWC?C^^.7#C:A2#OTV'(<^-N(2D[C?O']W]S4>0R[_E+K#.55EESXU MHLOY_+&N4]O%4TBKX1S[\LIN&$\AE\=Q7Y]#^Q3VL5;KM:O'O_<0FU=[5@_; M1HP/6^5$]7@YE[=^>_-AMSNT\?/0_CC%/O_C/>I?P_B4NAASV32,^Y@;,2VE M^OJ*<JLRLZC_,XYDCR/1.$:1QS$*CN/9XW@TCM/D<9R&XQ0O4:7L;M`XDNTL M"9TEV<Z2T%G*D`]+&718FFUT#8VNV4;7T.BF8(OJ++-&AV4L>QR+QK'L&+0P M!BT[!BV,0<>.00=CT+-SQ\/<82L9"MFQ$>$@(N0MV>;R%ME<LI4CH7(4FU@* M$DNQB:4@L32;6!H22[-]KJ'1#9M8!A++L(EE(+$LFU@6$LNQ<\?!W''L5'8P ME?VBN9.Z,,;MMSR6^YE4Z/-\A_%J&3&"+62L8S;.+<2Y9P/+0V"Q(Q`FH&1_ M-A)^-G)14TTW@+.AIJ7G2T$)8:[8]%20GIHN':@=S0X=#5/'L.EI(#TM&U<6 MXLJQG>6PL]@U6<&:;-C$,I!8EMV\+&Y>;$@X"`G/UHZ'VO&+0B*7;]CBS*OK M8WW]"Q7#UB\<AAW$,(?EHL<S]8?YB*:EETH!&:[8#%>0X8K-<`49KMG2T5`[ MALUP`QENV0RWD.&2G<,2YK!F9Z"&(6C8##>0X9;-<`L9[MC:<5`[C@T)!R'A MV9#P$!)^44BTX=A^ZL*AGQ$Z+:$K+KJ?T#!L,$`N2+9<))2+7%0N4[V:Y3(M MO30NW"G89Z7A86FVCC7F`CN(+0QBRPYBBX-XT3Z:\N58?F8YW^Y?GU',L`L? M['N>7;`\+%CL0@/[C&*'C)I"IG[UB]W-'P```/__`P!02P,$%``&``@````A M`$%QTHF<!0``/!8```\```!X;"]W;W)K8F]O:RYX;6R4F%MOHT84Q]\K]3M8 MO'?-S3A>)5GELE$MM;OI.LT^HHD9QZ/`0(<AB?OI>Q@:^,-@E#PE!YN_S^5W MSEQ.O[QFZ>R9JU+D\LSQ/KG.C,MMG@CY>.;\?7?SVXDS*S63"4MSR<^<`R^= M+^>__G+ZDJNGASQ_FI&`+,^<O=;%Y_F\W.YYQLI/><$E?;++5<8TF>IQ7A:* MLZ3<<ZZS=.Z[;C3/F)!.H_!9O4<CW^W$EE_GVRKC4C<BBJ=,D_OE7A2E<WZZ M$RF_;R*:L:+XQC+R^S5U9BDK]==$:)Z<.0LR\Q?>>Z"JXK(2*7VZ"MS`F9^W M0=ZJ6<)WK$KU'87WID[Y\D/?C^IOUJFX%_RE[%ZJS=GK3R&3_*7^*J7VT%H! M.?!B/OHI$KVGSUW7;9_]SL7C7K\])/DYZ)L,TN^8OS-IPGO+2$R5BK]*+?0A M7LLF^R*G$M997U-DGC-3GP7]H]:)5SN.*E>4Q#P5":,4Q9<L97++XTW]:@D2 M2W*SU?`_H!'?,I`)0,4D^Z@G&TT.U?4NXWP77^49J(2@$D[ZTE?9:,S*,@*9 MQ<=D**-M=E'&8/'>F%@OP>#,<NC,=_7(I/C7$&^JO1&/4E!7,*GC"_!EN029 MDZ',-Z[C/_*RC&^YHA(SQ?%5:OJVPJOAJYNJ*%)3#Z8.\14K]_$-]5)\S336 M=[D"$<\=JICWOOY3B6>6FM+6Y*[E,[4DE1J<.:&^:9WQ+&9OF%#Q/4LK'O_) M65FIAA04H`IU`A:P/<YKN@H:=,0:*OBH8,'ZHQY`U#&W3&G!2U.5[AGJ(/.> MA>MWO:=B_.`E9VJ[-S+7_)FG>5'#CSI(O6?Q>LT?>M_&?O5&L,PR4>><VJNN M`0T!3=.?5@&*!7\4X?8L+NDU6D:T>$AY?*OXCBM%*:$VVSZA"$+I652:K^_S M-*'Q'==PZ`.^C%AZ%I=K6K<R'M^QU[[?R"$-X<',6TO-%4%G8F\J0+T!O[I" M_GR+O[\JJCI7Z2&^$9(&IF#IL!-6"*!O`3C=T?1N.UY6R*%O<6CW-"6#ZH%5 M7"&"OH7@5&_'=^@*(NA;"$YW=R\FI+-92W%H'FGOD<`03]_"\UB7-T(8&!+J M6X1V?3W6Z[W`D%;?HG6ZV7M""'!@`5QWNYT.VD[`S`HL;&G.'>_Z&/+AN>1+ M.SX#B]Z1EAWS!LD-+'*Q=<?>1F@#"]KQ%A[306AI!S88!<=:N5'JY02A#:R1 M.MW1E(JVHST7L0TL;$=:^HJEVZK9\8)0@+21,0AM1&<M2ZTJ,_=1IP>;1>WD M?-B`3HCXD3'P9WH^8(9"Q(^,#PD1-VVJ0T20C`\)$3B=$-(86BP?FUB;*LN8 M`AW/Q5$36E@?$[I(Z`PC0"A$&LD81'9T]!F/0,=S$:+0POJHD/$(A,)>8!;4 M1W6,0SCZ/!=Q#"VLIZ=Q#Z.>D,7UM!!BM$"PR1@D>WJLHT<+!)N,#PGU/$*P M%Q;8TQXAV`L$FXR!1V:A:>#+)>URNO.EC*\YE'^!8Y:,,9VF&P[U@>XNUT:M MV8>A#G*]L+B>7L(0HP4.63(&#DT+]6J&8"\LL*>%L&8>'8BZ575A@3VQFXXO M$LB11R<B$++`'EN>NQJ"4(0.D3'(T9C.]TJ;JZ'Z#J>=CA'Z0\8[=#H64`>I MCBRJQ_SI=+#X$5)-QGL<JD\MEZSDF.D(J2;C'3K=!,?`D.K(HKJW%>HJ]7^W MH0Y"'5E0]W0VVSU/*CJ9-?<G!=Y]1,@T&8.X>CH$>,'D@<ZHVUPE=+Y#?W#Q MB"RBQW1*FAO-01%T/*]7>8OH<:'Z!J"^$P&A)1)-QE1@=4!T=DM%<Z^2[U`' MB5Y:1/?\L720Q"4&1H;ET-A)].U&`AU"HI<6T4>WL:8_4`>)7AJBYZ:/Z7)Q M2[M,NO6L_YAKPW`1-6??^=O%[_E_````__\#`%!+`P04``8`"````"$`80LW MU&D%```O%0``&````'AL+W=O<FMS:&5E=',O<VAE970T+GAM;)18VVZC2!!] M7VG_`?$>0T-SB^*,!E!V1]J15JN]/!/<ME&,L8!<YN^WFL*FJWP9D@?'IDZ7 M3UVZCKL?OGS4.^M-M5W5[)>V6+BVI?9ELZKVFZ7]S]]/=[%M=7VQ7Q6[9J^6 M]@_5V5\>?_WEX;UI7[JM4KT%'O;=TM[V_>'><;IRJ^JB6S0'M0?+NFGKHH>/ M[<;I#JTJ5L.B>N=XKALZ=5'M;?1PW\[QT:S75:GRIGRMU;Y')ZW:%3WP[[;5 MH3MZJ\LY[NJB?7D]W)5-?0`7S]6NZG\,3FVK+N^_;?9-6SSO(.X/(8ORZ'OX M<.:^KLJVZ9IUOP!W#A(]CSEQ$@<\/3ZL*HA`I]UJU7II?Q7WN1?8SN/#D*!_ M*_7>&>^M;MN\_]96JS^JO8)L0YUT!9Z;YD5#OZWT(UCLG*U^&BKP9VNMU+IX MW?5_->^_JVJS[:'<`42D`[M?_<A55T)&P<T":93-#@C`JU57NC4@(\7'\/^] M6O7;I>V'BR!R?0%PZUEU_5.E7=I6^=KU3?T?@H0F=7+BC4XDL!_MWL*+`Q&$ M/_?B(*,AP+SHB\>'MGFWH&O@.[M#H7M0W(/G8V3(XQ3KM5"!GG;R57L9?$$4 M'=3G[3$2#\X;I+0<(2E"$MLZ03R*R(X(';3VFAL/'*![X@R9X)Q]J.GE:API MZD6,(B.0GD-\1O$"@L69GT.BR0L)PZ=AW*:OP=`V1OHB2<FE")%#T^C\9?Q! M;CP@3*#PGT^H7K2T(=Q30:.`,4)(/#2$2`(_IO;,M'NN2*@Y-\U21-')3,C# M#OH\>;V(D0]/[H?N2Q$2(ODH")D],^U1("=VV+RFV??CJ=<(^9"2O]T#&LQ( MLV]-$2('TBX-*$/;,2#/9_;\\EI"-_H,70UF=%D#I`A!2DGL\Q2;9C\.IAQB MBM',@R6$M0(;X^UV?C68$68MF2($"<LPD2R'F6GWW5"R@'/3'@7!Y)ZPABDY MG[4&T\D0,U8I0HS)P!_DQ@/"1,!<G4]E0-,,QFP^IB-F3*&4'B\Z!20R8-'D M!.`'H;PR7X76C]G%']",.VNX=,2<ME#(RIM10.`FS$-.`9[TKG2`T#(RGSN* MCCF+XRDI.,X&CTN;[Y;!F-TRYL1X%TSUHIVBQ64^8Y0BPICKF4`,9CL4L-O8 M0*,`&<BS;)L>9.R*:]RUTLSGCKI$N'/E$XA![G="@D!P\@0!"L'#RZD/Z<I@ MFO8T]5IKYM-'92+TI[R,S8(8;!;AGK4Y,1O"C'-9_S2&D82KXVNDM=S,)XWB M1$A/CD?2IL!!SD/)PLH$0?A^))B/G"*DZT?3]*$YU^(SGSY*%:'/DIJ*RW(V M;M`;QOS*2LI7*\]\OJA3A.\TJ<9TFUIV.=T$<3'=!'$KW5J@#/KZG"*AS6X+ MND!9,\-(IGJ.81RE3Y]:F#$;'5P<FOEH/.YQWYV:B:3>8QJJN<\XK^A55(\2 MKJ6#YZ5]9'"AXRGB4@DH0HK0V,XT#":G,\/`0QPI`1O3J8>8:/C5>N<N)(LS MHP"Q\-@PS2D`CL4)^9NV&HT(6/&F"G]^D-2K6&&XV'J(P<+X<-)GFR<C`"_R M^-$I)P`1BZO-]2G9]5`0X?5T:..RDXX8X]?BV9/<?$)3RI1T9I.<*VK"%=5# M#&[%.W'6(C?-.5DM)M^4O-8M8\C<'B[ZTH7W`1.<=,3@"5C/2$/"<;!3!&Q0 M;VK6`:$OMO3WC#Y@1@:</MY;X;5.K=J-RM1NUUEE\ZKOI`1LJ]-3O"]+X;YL MN%QR3@:XKCH4&_6]:#?5OK-V:@U+W44$7][BA1=^Z)O#<(ORW/1P436\W<+% MI(+[!G<!X'73],</^DKM=-7Y^#\```#__P,`4$L#!!0`!@`(````(0!8L_#( M/@(``-T$```9````>&PO=V]R:W-H965T<R]S:&5E=#4T+GAM;(R4VXZ;,!"& M[ROU'2S?+P9R6(@"JTVBM"NU4E7U<.T8$ZQ@C&SG]/8=VTF:-%6;&\#XG\_S MSPQ,7PZR13NNC5!=@9,HQHAW3%6B6Q?X^[?E4X:1L;2K:*LZ7N`C-_BE?/]N MNE=Z8QK.+0)"9PK<6-M/"#&LX9*:2/6\@YU::4DM+/6:F%YS6OD@V9(TCL=$ M4M'A0)CH1QBJK@7C"\6VDG<V0#1OJ87\32-Z<Z9)]@A.4KW9]D],R1X0*]$* M>_10C"2;O*T[I>FJ!=^'9$C9F>T7=W@IF%9&U38"'`F)WGO.24Z`5$XK`0Y< MV9'F=8%?D\E\@$DY]?7Y(?C>7#TCTZC]!RVJ3Z+C4&QHDVO`2JF-D[Y5[A4$ MD[OHI6_`%XTJ7M-M:[^J_4<NUHV%;H_`D/,UJ8X+;A@4%#!1.G(DIEI(`*Y( M"C<94!!Z\/>]J&Q3X,$X&CW'@P3D:,6-70J'Q(AMC57R9Q`E)U2`I"?(`+(_ M[:=1FHV2T?C_%!(R\@87U-)RJM4>P=#`F::G;@23"9"=LP'4Y^_.P)*+>75! M/A34!KJQ*[/\>4IV4$)VTLSN-8-;Q?Q>D>7914,@P4N6X/TZRW]GY\3@`J-+ M=L/TC[-G03/T!7:6YE<O;DX&S.,G.W&!`74Y.<OSBR-?NUG09+YJ\>T>C+"+ M#WO)"+[QWX*05)C0T,">KOEGJM>B,ZCE-1P91\\P3CK,9UA8U?M&K92%N?*/ M#?Q&.%B.(Q#72MGSPGT!EQ]3^0L``/__`P!02P,$%``&``@````A`";@6!6( M`@``%@8``!D```!X;"]W;W)K<VAE971S+W-H965T-34N>&ULC%1;;]L@&'V? MM/^`>*^QG7L4IVIC=:NT2M.TRS/!V$8UQ@+2)/]^'Y"XN71=7VSS<3@^Y[NP MN-W)!KUP;81J,YQ$,4:\9:H0;97A7S\?;J88&4O;@C:JY1G><X-OEY\_+;9* M/YN:<XN`H349KJWMYH085G-)3:0ZWL).J;2D%I:Z(J;3G!;^D&Q(&L=C(JEH M<6"8ZX]PJ+(4C.>*;21O;2#1O*$6])M:=.;()ME'Z"35SYONABG9`<5:-,+N M/2E&DLT?JU9INF[`]RX94G;D]HLK>BF85D:5-@(Z$H1>>YZ1&0&FY:(0X,"E M'6E>9O@NF>=#3)8+GY_?@F_-R3<RM=I^T:+X)EH.R88RN0*LE7IVT,?"A>`P MN3K]X`OP7:."EW33V!]J^Y6+JK90[1$8<K[FQ3[GAD%"@29*1XZ)J08$P!-) MX3H#$D)W_KT5A:TS/!A'HTD\2`".UMS8!^$H,6(;8Y7\$T#)@2J0I`>2(:@_ M[*=1.ATEH_'_64A0Y`WFU-+E0JLM@J:!?YJ.NA9,YL!\=!9T]%[_914\.I([ MQ^*YP(6!\KPL9W&\("^04W;`W`?,#*,>DYXC5D>$2Z"CS4\"!/3VHB$5EZ(' M4-2WRW'4Z`Z=:QQ<2GP#<B'Q#41R#LFO(9-!#SFS,3BW\;Y\!X:^.4G?,'WE M]?FZ#Q@_"#ZPN@SD)X$S*5#ZTXR^+\6!,PP^^TH.TVEO,4@)F*GOA8LTK][9 M@REVW.'<J[V@-<QG:%_)=<57O&D,8FKC9B^!?_71<"W<P[7@AXCT&S"6':WX M$]65:`UJ>`E'XV@"<ZC#8(>%59UOEK6R,)#^LX;[ET-;QA&`2Z7L<>&NCOY& M7_X%``#__P,`4$L#!!0`!@`(````(0`;(N[8>P(``-$%```9````>&PO=V]R M:W-H965T<R]S:&5E=#4V+GAM;)Q4RV[;,!"\%^@_$+Q'E.17;%@.D@9I"[1` M4?1QIJF51$04!9*.D[_ODHP9Y]'"Z$42I>'LS'!7ZXM[U9,[,%;JH:)%EE," M@]"U'-J*_OQQ<W9.B75\J'FO!ZCH`UAZL7G_;KW7YM9V`(X@PV`KVCDWKABS MH@/%;:9'&/!+HXWB#I>F978TP.NP2?6LS/,Y4UP.-#*LS"D<NFFD@&LM=@H& M%TD,]-RA?MO)T1[8E#B%3G%SNQO/A%8C4FQE+]U#(*5$B=7G=M"&;WOT?5], MN3APA\4K>B6%T58W+D,Z%H6^]KQD2X9,FW4MT8&/G1AH*GI9K*YFE&W6(9]? M$O;VZ)G83N\_&EE_D0-@V'A,_@"V6M]ZZ.?:O\+-[-7NFW``WPRIH>&[WGW7 M^T\@V\[A:<_0D/>UJA^NP0H,%&FR,L@0ND<!>"5*^L[`0/A]N.]E[;J*3N;9 M;)%/"H23+5AW(STE)6)GG5:_(ZCPHA))^4B"]T>28IY-R]GB_`06%A4%@]?< M\<W:Z#W!IL&:=N2^!8L5,A^<11W)Z]^LHCQ/<NE9*KJD!%U8/)Z[S3(OUNP. M,Q6/F*N(P6O"E`G!4$V2A#*.);T=\J&R!_O*/BDOY2J^."XS>;O,Y'D9[WR" MG?'O<GX3XHY,3"=YXH\*(F8:.NK8U_1_"OI-%453*;5E_I1;+!@QTY![F1?G M2<^S6+'3CF,]S:_?]++\4YZQ?,2@B"1Q,9^_T!!'*W:>`M/"!^A[2X3>^;$I M4'IZFR;ZL@P1I@\X42-OX2LWK1PLZ:'!K7FVP/HFSF1<.#V&OMYJA[,4'CO\ M=0)V1YXAN-':'19^ZM//>/,'``#__P,`4$L#!!0`!@`(````(0`%^U4[CP(` M`"<&```9````>&PO=V]R:W-H965T<R]S:&5E=#4W+GAM;)Q46V_;(!A]G[3_ M@'BOL>/<%:=J8G6KM$G3M,LSP=A&-<8"TK3_?A^0>'&3;=5>$@/G.YSS75C= M/LL&/7%MA&HSG$0Q1KQEJA!ME>'OW^YOYA@92]N"-JKE&7[A!M^NW[];'91^ M-#7G%@%#:S)<6]LM"3&LYI*:2'6\A9-2:4DM+'5%3*<Y+7R0;,@HCJ=$4M'B MP+#4;^%092D8SQ7;2][:0*)Y0RWH-[7HS(E-LK?02:H?]]T-4[(#BIUHA'WQ MI!A)MGRH6J7IK@'?S\F8LA.W7US02\&T,JJT$="1(/32\X(L"#"M5X4`!R[M M2/,RPW?),A]CLE[Y_/P0_&#.OI&IU>&#%L4GT7)(-I3)%6"GU*.#/A1N"X+) M1?2]+\`7C0I>TGUCOZK#1RZJVD*U)V#(^5H6+SDW#!(*--%HXIB8:D``_"(I M7&=`0NBS_S^(PM893J?19!:G"<#1CAM[+QPE1FQOK)(_`R@Y4@62T9%D#.J/ MYZ-H-)\DD^F_64A0Y`WFU-+U2JL#@J:!.TU'70LF2V`^.0LZ>J]_L@H>'<F= M8_%<X,)`>9[6BWB\(D^04W;$;`)F@5&/&0T1VQ/")=#1YF<;!/3VHB$5KT6G M4-3KY3AI=$%#C6D\%+"Y`ADBME<0R1"27T)F:0\9V$C_QX8+@OXY2^/XPD?` M^('PB=R^WLC/-@:2H`7.,_OWC#IPAL%O7]%Q.NFM^ILW`3/W/9&FZ7QXO!T> MQ]/A,<RTN^$4/?M-'D2'@0W]++FN^)8WC4%,[=TP)G!IOQO>B0V\$WZJ2'\` M<]K1BG^FNA*M00TO(32.9C"8.DQZ6%C5^>[9*0L3ZC]K>)`Y]&D<`;A4RIX6 M[BWIG_CU+P```/__`P!02P,$%``&``@````A`.*NFA+5`@``[`<``!D```!X M;"]W;W)K<VAE971S+W-H965T-3@N>&ULG%7+;MLP$+P7Z#\0O$=OR99A.X@; MI`W0`D71QYF6*(F(*`HD'2=_WR7I*++<.$DOEJF=G=D=DJOEY0-OT3V5BHEN MA4,OP(AVA2A95Z_PKY\W%W.,E"9=25K1T15^I`I?KC]^6.Z%O%,-I1H!0Z=6 MN-&Z7_B^*AK*B?)$3SN(5$)RHF$I:U_UDI+2)O'6CX(@\SEA'78,"_D6#E%5 MK*#7HMAQVFE'(FE+--2O&M:K)S9>O(6.$WFWZR\*P7N@V+*6Z4=+BA$O%K=U M)R39MM#W0YB0XHG;+D[H.2ND4*+2'M#YKM#3GG,_]X%IO2P9=&!L1Y)6*WP5 M+C9A@/WUTAKTF]&]&OU'JA'[SY*57UE'P6W8)[,#6R'N#/2V-*\@V3_)OK$[ M\%VBDE9DU^H?8O^%LKK1L-TI=&0:6Y2/UU05X"C0>%%JF`K10@'PBS@S1P,< M(0_VN6>E;E8XSKQT%L0AP-&6*GW##"5&Q4YIP?\X4'B@<B31@02>!Y(P\J)Y M&J;9ZRR^J\@V>$TT62^EV",X-:"I>F+.8+@`9M-9!O[\NS-HR>1<F22;"F@% MVW&_SH-TZ=^#A<4!LW&8'*,!$P\('\2'"D!U6D'\:@4FZ;B".!CH;9$;!\GM MQH[UXO_1,TFP:Z-NDA-!ATE.!)-CP?/6&O`*1];4*`BGKKKPW(;C.'_N^<A2 M.%1C2\\K&O!(,9O8Z,*94TR#9`@?*6;O433@D>)LH'0;Y\('Q2QZ+NA(<?8> M10,>*<XGBB[L%,-Y]H*K9IJ/KLIY5PUXI)A/%%TXL:Z^(`=7Y^UR!FSDGF]; M$D]]=9BSFC!$WR%JT<>J^;31`\:=V#"*Y]-NW=!U,XE36=-/M&T5*L3.#-00 M'!K>NF&_@6$?V4LV!]J2FWXBL6:=02RM(#;P9G%WIIK5;:-';H;$5&J:L M_=O`5Y7"3`L\`%="Z*>%^1X,W^GU7P```/__`P!02P,$%``&``@````A`%G. M>$*V#````$D``!D```!X;"]W;W)K<VAE971S+W-H965T-3DN>&ULG-Q;<^(X M%L#Q]ZW:[T#QW@$;<H%*LC7@^W5K:R_/-"$)-4E(`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`:G;9^;O$VX\*]<N^ M^:>'A1X$9BOL@7'A#?N?R:O7#A#]RWYCSAXA7CM$]"]M\\O/[QA]4)D7HWYI M^SE_U_3,<;<[C(/9=G9_NU[][*BY465X\S[3,ZTWUL_1'L#F<-L?TK\ZHM51 MJ'OY37=SUU6C1AVL&S4-_7$_ZE_=]OY04\>\B9DPYGHP<&.F;8P^O'7'@0'U M_[[CZ\'0;12VC0XQOAL1M1%MM[&$I(5#']BXM(UI>\E:L!M=ND^=MS%MHZ(% MNY%(0]G&M(TJ`^I_*PWBF>HV1C7JJ;V[W\5J]#N[^/C<W.Y)':WW9/O4DQ;L MIQ:[=FIB[,T;]:_=1`3'^A$Q(6-$9J(C$9[[1#%#KD4O"4-&_9';37HDQNN[ M,1ECK@?B->5'8H9B?!:,&7GB996,N1F*;:Z.Q<AA<B3FYF;_NIR1HV:\3XP< M'>V,'`E3`^XP.3RU.>!EHU!")"&6D$A()602<@F%A%)"):&VP$FCFOD_D48= MK99!UJ$^\L1XF9B8X?X@G4H()(02(@FQA$1"*B&3D$LH))02*@FU!4X:U=G) M2:,^50W4`N/C^4RWNNNJ0;^?.4>>F`XF)L9*IX1`0FC@:G>J\_KFW_X@VHWD MZ'1(++M-)*02,@FYA$)"*:&24%O@I/SJ2RG7K63*Q3E[8F*LE$L()(0&;G8I M%[-&)(-C`]>[X.'%Y>7(_B=.7XELG4K().02"@FE@?.VH)*M:PN</:**A"\< M!+J5W"/BO#`Q,=8>D1!("`V8/2).C=$'C\7V8YX_\&[4\>,>/(E\KE1")B&7 M4$@H)502:@N<M.OK%?8R^>,Y1T?+=(LQ-S$Q5KI;T(MG,=\'[6/MHBR4$$F( M)2024@F9A%Q"(:&44$FH+7`RJFJ%3V141[L9O;Z4`]C$#'>'?/_"N[INIF7S M0RRGIFUTF]*@!9W_D\W#-KIM'DF()2024@F9A%Q"(:&44$FH+7!V@"[2G3VP M*_T&ZE3P\>#>M7/WQ<@3B]Y)$V0-;TBP%_O4+";V<!^T3S0DAB20%))!<D@! M*2$5I+;%3;DNT<Z?1O1U$#'JO;Z8&B9-D)UIT^P@`6)"2`2)(0DDA620'%)` M2D@%J6UQTZI+FD^DU51`'Z^P]<4CE?M#$J>0`!)"(D@,22`I)(/DD`)20BI( M;8N;5EW/V&D];\&MKY.)43OR1*$Z:8+L])IF!PD0$T(B2`Q)&C%K]2OU[T:< M"U(GPAL,+[$>R9P0_[(_',C+4+D3HI_G2LR*11-Q>(TEI(+4MK@[2%=*]@XZ M,7&;PLHIA7RQ[IKHRY1BW$L)$!-"(D@,22`I)(/DD`)20BI(;8N;5ET-?2*M MIG@Z,9U8%=:N.ISJBZU.H@-("(D@,22!I)`,DD,*2`FI(+4M;EIU26.G54\G MZKVI4\L-4PFYHU8<P!//*I>:]$H)$!-"(D@,22`I)(/DD**12U,ACBY&-^$W M<7(OT:J"U+:X"=?%C)WP$].#J7W<1(L-FGA6@=0D6DJ`F!`206)(`DDA&22' M%)`24D%J6]RTZHKF$VDU!=")Z<&JDIJT2@D\*2$D@L20!))",D@.*2`EI(+4 MMKAIU76*G=8S5QNFO'%&+:[O>58-U*172H"8L)$/K_&A50Q)("DD@^20`E)" M*DC=R"]>A;,+_&,5X>DKK+MFHB#TY276)NBP])E"`DBXEUU1[EXBBO8/MJ5A M#$D@*22#Y)`"4D(J2+T7=_/=I,N:\+QQ[[,VO))KN2;&SCE*0\2$D`@20Q)( M"LD@.:2`E)`*4MOB9E=-#,ZL\O$YT-?AI]Y\:8+LM)IF!PD0$T(B2`Q)("DD M@^20`E)"*DAMBYM67:Q]?K+V38WG3-:<*4S0(9G3IME!`DBX%_=0V\WVT4</ MQOL'VVDD@:20#))#"D@)J2"U+6[29;EWYDS!LN]*EN.^K/&FD``2[N5HSMLN MCSP8[UL><MZ&MY(B)H/DD`)20BI(;8N;<UVER8%^NFC1G]N2UT!\^198$W08 MUE-(``D;,>=S?[2[N"U/C+*TC-%-`DDA&22'%)`24D%J6]Q\'RL2SUB"'"L2 MY?L#OBP)IY``$D(B2`Q)(&DC9K_=]*_%R3I#BQQ2.'WH=YW='5^B106I;7%3 M+\O%,Z>78V6C?+/+ET7B%!)`0D@$B2$))(5DD!Q2-&+*<R_\)E:T)5I4D-H6 M-]FZF/O"O&)J0/<$*JXR3GQ9*$XA`22$1)`8DD!22`;)(06DA%20VA8WO;*8 M/+'L,]7@QS6Z+TO&*22`A)`($D,22`K)(#FD@)20"E+;XJ153\08M:=GYUTS MMT#$"J2)L4Z&D``20B)(#$D@*22#Y)"BD5]-Z25:5)#:%C?77ZL+!ZP+1YY< M>31!=K)1&"(FA$20&))`4D@&R2%%(^;#)IYZAT:<^]"B@M2VN,G6!9R<CO6N M^7C>&)BZSYF./;GL:(+L9)MF!PD0$T(B2`Q)("DD@^20HA$SLD>#(XO,$HTJ M2&V+F^^OU8^#8_4C\HWZL6EFYUO&A(B)(#$D@:2-F,P=?RL1C7)(`2DA%:2V MQ<VWKJZ^,+Y-46:/;Z\OUD&3@:S<II``$D(B2`Q)("DD@^20`E)"*DAMBYM> M626>F#9,?:;&H/695/E.B_X@CO/^X!020$)(!(DA"22%9)`<4D!*2`6I;7'3 M^K5B<,!BD,L-U()-*WN2D#$A8B)(#$D@*22#Y)`"4C9B)AM_T/=%W56A26V+ MF^ROE7^#(^4?3X$H_YIF=K9E3(B8"!)#$D@*R2`YI("4C313NTJW_N>N0BJT MJFUQ$_ZU$G!PK`3$`@\E8-/,3KB,"9N89HEU[/5%Z":&))`4DD%R2`$I(16D MML7-MZP)S[N^,3!EGWT.'/E8<Z`V;)K9^38QS?#!T`G1(H+$D*01T^L0O:9H MD3DMU$):3AJY$\`N"W190BJG#UZIJNT6SEX:'BLQ3U]PW35S2\R1+S\ET@0= M]LD4$D#"1C[ZG$:$5C$D@:20#))#"D@)J2"U+6["OU9G#H_4F7(D39H@.^&H M,Q$3-O*K"V\16L20!))",D@.*2`EI&KD5]M;VRW<U.LZT%Z5?[QL')JRT9V) MQ.>E)TV0G7+3["#!/D:_->-=75W(#RJ&^XCVW9@($D,22`K)(#FD@)20"E+; MXJ99%WMVFL^;^(>F1G33+=\X:X(.R9U"`D@(B2`Q)(&DD`R20PI(":D@M2UN M>F5M>6(4FW+QX^)GB)H2$D!"2`2)(0DDA620'%)`2D@%J6UQTRIKRC-'K2D; MG5&+ZW_Z?.K6EI``$D(B2`Q)("DD@^20`E(V8I:KU_+3+Q4:Z!NA[%^VR;6Y MKXFY(<+K8OVTF"Y>7C:=^>J'OF>)^NC4_>V>S0U52G^LO@FLID7AE3]67PBF MU_Y8?2^8'OMC];UE>N*/U=>7Z:D_5M]BIF?^6'V9F9[[8_6=9GKAC]57F^GJ M1C&_'?.)-Y[N[K8B7F_HC=5-%-A/XHW5?1+HF3=6MT*@%]Y8W>V`/O''DV/; M$_CCX)B'_EA]4YS]1/Y8?6%<>6__`M3]9]YG3XMRMGY:OFTZ+XM'M:_[%]=J M=*S-'6S,']O5^^[^&-]76W7GF=VOS^I.0PMU6XK^A0I^7*VV[1_Z"?;W+KK_ M/P```/__`P!02P,$%``&``@````A`!]-V=;$,```9T,!`!D```!X;"]W;W)K M<VAE971S+W-H965T-C`N>&ULG-U=<R+7O;;Q\Z?J^0ZN.<^,$`B!R\ZN+4%W M`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`4Z?Z7XZ2V\E.ZPYW$H> M0/][O'OWT[MTH^*PT6G-;;IB<UAQN-FMPRZ`_C?Z/';GRL-&\1K[-E2'-8?/ M5!\@WLB^@.:PYK!1&R`\GPS?S,ZA=]A'\$Z/D./#1`>8Y&%R_CGP\&@85@^/ MAL,]>0B@&X^^+_/TN_O(-8O9,EVSXIKE9)*N67/-_?0^79-QS7)JMY-SS6)F MW_*":ZSDYLP*^T1;+KFW6]EQR7)JC\[RS)H;^_Y59]9,;#>MN0;?O^;,FIG= MGY9K%LM%VJ'CFON9[2]]6',W?SJJZ-QE8=^_/6]D&1U7DH>QGM^2A_%PM)OJ MR?SYA_.PE=9%C]ZE'W(>PIK9\2'_Z+!R6#MD#KE#X;!QV#KL'$J'RJ%V:!Q: MA\ZA=]A'D"31J4*2Y/D4P^J?WZCXZ4!R9P^JA[`F2N&P<E@[9`ZY0Q$@/"H7 MD[N;X9_TT;VYO&3K-[MS*!TJA]JA<6@=N@#ASM_.PIVW>]_':R;W3U^??X7[ MZ(:3J#J!>T'48;5'M2/M0U@S>SH(W+R=S`]W*-PO.R0\'E8?GH!6#NL##*<J M%V\O.ZP^W%[N4#AL'+8..X?2H7*H'1J'UJ%SZ!WV$201=?J<1+SN8#ELE<9< M^JG60U@3[:$!PN/Q?K&<W=_8L\#*-UD[9`ZY0^&P<=@Z[!Q*A\JA=F@<6H?. MH7?81Y`TTJ5)TNCYH^>PVMO8:=A#6!.U<5@%6#SMBK<WDZ<],#WRK7V;S"%W M*!PV#EN'G4/I4#G4#HU#Z]`Y]`[[")(XNMY[09QAM<>Q\]:'L":*X[`*$/:D MLVE\B\PA=R@<-@[;`.&S+A<S/!7N?(O2H7*H'1J'UJ%SZ!WV$22I=.7Z@E3# MZC35XLY.?Q_"FBB5P\IA[9`YY`'"]WEZ>ZYO$2^9+9;WPZ)T[]S$2^[#LW^Z M8ANOF$WG]\.S;;ID%Y:<OK[2H7*H'1J'UJ%SZ!WV$21%AQE=DO2ZIZ^GS=*V MRZF?88Z+3E_\(V1UE.$,8[+^DUW2K8\?/YQ39)`<4D`VD"UD!RDA%:2&-)`6 MTD%ZR#Z6--HP?XC'4<\_GPV#5-L1YW[('-?$K<)6X]%JJJ>P>WL27&&C-22# MY)!BE'&'7<SOEO?^8-JD:X;KV_FMG?UL<<L[2`FI(#6D@;20#M)#]K&D28?+ M\Q<D#5?S\16>QNOIL>=AF'>K>]PTR'T8$KR]NUO&_R"O;[_&+6:0'%*,$DZ% M[""QP?+M*-?=R1VV+R$5I(8TD!;207K(/I:T\'!I'Q>^\D@;)@)QZ>74!E8/ MPTL35CI(V*7F3R>?_MRTPE9K2`;)(05D`]E"=I`24D%J2`-I(1VDA^QC2<,- ME^]QN`M'VW"UGP2;V6G!P_#2CP4+$H(-IX;Z)]V?5]AH#<D@.:08)7RJV\69 M3[7!1MMTH\ETB?NWPT8EI(+4D`;20CI(#]G'DA8=KN7CHE?NBF$$D);%03>: M$SR]-O,XO&"GUN';?3?NBY[6MUJ/6YT.WADDAQ20#60+V4%*2`6I(0VDA720 M'K*/)0TW7.![N)F^=Q=VR3`72,/YE<CP.JCMDBXKK%E#LE%"[NG=8C:W_3C' M-@5D`]E"=I`24D%J2`-I(1VDA^QC2;,-E_Z>[?(+"L,KRBJ29K,+A(=QT6D_ M>82L(&M(!LDA!60SRG@H?3J26NUMLF0VF<_]W'N'FRTA%:2&-)`6TD%ZR#Z6 MM.,P%WA%QS!.2#O:N?O#\+*_[7XN*ZQ90S)(#BE&"=4FMQJCWN.T-'SR,>QD M/EG<VDG7-KF5Q?WB_M9.H'?XS"6D@M20!M*.$N[>W>)NYM=F';;I(7I?V.E[ MGH8>Q@5QZ`O'US!=2`/[2Q/#VR8LL,L*:]:0#))#BE'"MV<YFRW\9>M-LN)^ M>3]GWG#OPFW,]':T&WN,[/!Y2T@%J2$-I(5TD!ZRCR7)>?NZ(<_39G[\M<?X MP[@H.OY"5I`U)(/DD&*4D&0ZG0['V_1$:I,NT2`!2[;IDOO%<#/IK>SPJ4M( M!:DA#:2%=)`>LH\E+?NR2=`M)T'W]SX*&A?%1<-F)UEAS1J207)(`=E`MI`= MI(14D!K20%I(!^DA^UC2/#HD)L?1ZRXT;H?-+KV58EQTBO((64'6D`R20PK( M!K*%["`EI(+4D`;20CI(#]G'DF;RT<SS3W>W9T8R,^Q%&,F,FYV"K2!K2`;) M(<4HX]E`>,T_/:)ML-$6LH.4D`I20QI("^D@/60?2]KK91.9VW,3&7LR?Q@7 MG>H\0E:0-22#Y)#B**?WYRS]37R;XZ+#*Q];R`Y20BI(#6D@+:2#])!]+&FQ M8;YQ_0GE\,9[N_*[O[?S[X=Q45S,IR@KK%E#,D@.*2`;R!:R@Y20"E)#&D@+ MZ2`]9!]+FN?<7.7R!?IM&)#H2'=\GQG?\C<NBC-AKH(U:T@&R2$%9`/90G:0 M$E)!:D@#:2$=I(?L8TDSG9NC7!Y_W9Z9H]S9*>_#N"C.%#8[R0IKUI`,DD.* M4<+SU;F7YS?IBC`.3Y_1MNF2,%9-E^SPF4M(!:DA#:2%=)`>LH\E#3M<B+_@ M\!BNV]/K;9R`1!?W81!]Z[*"K"$9)(<4HXP79L-EF3V\-MAF"]E!2D@%J2$- MI(5TD!ZRCR7--8P&7I`K3!+27#C_\&'(XZW+"K*&9)`<4APE.F[[J\>;XZ+3 M^8??H1W6E)`*4D,:2`OI(#UD'TM2;'@N>T&QI^4^^?"!UKCH='Q\A*P@:T@& MR2'%49[>B)L>YC;/?7![_.`AXPY20BI(#6D@+:2#])!]+&DT'VY<=_4\/3?D M\-UM7!3'PY`#:]:0#))#"L@&LH7L("6D@M20!M)".D@/V<>29GK=D&-ZS9!C M7!1G"IN=9(4U:T@&R2$%9`/90G:0$E)!:D@#:2$=I(?L8TDS^9#CRKWIS+`# M[U2?8M@Q2C@C./]>=6RTAF20'%)`-I`M9`<I(16DAC20%M)!>L@^EK2;#SNN M['9FZ(%WWT[#HM/.]#A*>//5G7X<.'VN66&+-22#Y)`"LH%L(3M(":D@-:2! MM)`.TD/VL:317C;OF'+>L9SZ*RWCHC@6YAWCFK#;C3^QE!9<XV8R2`XI(!O( M%K*#E)`*4D,:2`OI(#UD'TO:RP<@ST^`IV&"D9S1W_D[$\9%<2\,/K!F#<D@ M^2CC];-^#(@77`6VVD"VD!VDA%20&M)`6D@'Z2'[6-)@/@JY$.S<",3?@C#U M@<?C*,]]HU?8:@W)(#FD@&P@6\@.4D(J2`UI("VD@_20?2QI,!]Q7/DTQE'' MO;]9XV'J@XU'R`JRAF20'%)`-I`M9`<I(16DAC20%M)!>L@^EC33<(T?CS:N MS!1&`\]/@J<^/WB$K"!K2`;)(05D`]E"=I`24D%J2`-I(1VDA^QC23+-?)YQ M7::GS6RN@9/Y<5'TO`590=:0#))#"L@&LH7L("6D@M20!M)".D@/V8\R/DW$ MP\\TVNOF&3/.,Y8XDQ\7Q=$PS\":-22#Y)`"LH%L(3M(":D@-:2!M)`.TD/V MHYRYTDFC^73C^1.-61A/I&>&/CD<%\6QPF8G66'-&I)!<D@!V4"VD!VDA%20 M&M)`6D@'Z2'[6-(\KYMJS,+`XOGGJW'1*<HC9`590S)(#BD@&\@6LH.4D`I2 M0QI("^D@/60?2YKIW!#C\BN7LW-##+\N'A?%F7RLL<*:-22#Y)!BE+MPU+"? M_=A@_1:R@Y20"E)#&D@+Z2`]9!]+FLQ'&%>>8IP99=SY:Y-#^?2]P)`59`W) M(#FD.$K\8I>-M3;'18=72;:0':2$5)`:TD!:2`?I(?M8TG(^S+BRW+FAAK_I M9N8CC$?("K*&9)`<4HPR[FS#KP]-1UD;;+*%["`EI(+4D`;20CI(#]G'DE;S MB<:5U<Y,-F8^BIIAL@%90=:0#))#BE'"R;!^&2]G4QMLM(7L("6D@M20!M)" M.D@/V<>2=GO=8&/&P<;2?U+L85P4/[7YJ&.%-6M(!LDAQ2CC1<S9'XK!1EO( M#E)"*D@-:2`MI(/TD'TL:;?733IF88B1G.#/[43@85P4=_/9QPIKUI`,DD,* MR`:RA>P@):2"U)`&TD(Z2`_9QY)DNGO=I.-ILTMOH1\719D@*\@:DD%R2`'9 M0+:0':2$5)`:TD!:2`?I(?M8TDSG9AMSM7O^<OGNS&QC[C^9.RZ*,V&V@35K M2`;)(<51HK/%N3V=;HZ+CF>+D!VDA%20&M)`6D@'Z2'[6-)RP^CAY1/?NS"Q M2(^#_HK*N"@N%S8[R0IKUI`,DD.*H\3E_(SQN.A4SN_0#FM*2`6I(0VDA720 M'K*/)2WGLX\+^UJ8>:3%_&+Z+BPZ]7F$K"!K2`;)(<51XF)VJ;@Y+CH5\[NX MPYH24D%J2`-I(1VDA^QC28N=&X,,[W^[4.[,&&1NE[`/=S[T>(2L(&M(!LDA M!60#V4)VD!)206I(`VDA':2'[&-),[UN]'$7IAIZ>#[SXQ#CHG@'\V'("FO6 MD`R20PK(!K*%["`EI(+4D`;20CI(#]G'DF8Z-^<8IB(7]J8S<PZ><V#.H5^M MG<ZL5I`U)(/DD.(HT>-F;H.7S7'1Z3CH=VB'-26D@M20!M)".D@/V<>2EO-9 MQX5B9V8<<SQS8<:AP9$7<UEC30;)(<51XF)XYO)/MCUN=FBX@Y20"E)#&D@+ MZ2`]9!]+6LRG'!>*G9ENW-O/A#S<^2SC$;*"K"$9)(<4D`UD"]E!2D@%J2$- MI(5TD!ZRCR7-\[IAQEV82EQXQO+1Q>.XV>DY;`590S)(#BD@&\@6LH.4D`I2 M0QI("^D@/60?2Y)IN"!.KK6>WXN>EJ=OU^!O>1P7G6(\0E:0-22#Y)!BE/#J MU^+MC<V]-MAB"]E!2D@%J2$-I(5TD!ZRCR6-];J1QOR:D<:X*(Z&D0;6K"$9 M)(<41XF>K.Y1SC_]]KC9\<D*4D(J2`UI("VD@_20?2QIN>&:_N4CC7D8!:07 MR/ZD-2Z*RX7-3K+"FC4D@^20XBCG?NKK^,%#GRUD!RDA%:2&-)`6TD%ZR#Z6 MM-AP31\7NW!@#".`I-2]CPWG8=&IRR-D!5E#,D@.*8X2[6/^%U<VQT6G8GX7 M=UA30BI(#6D@+:2#])!]+&DQ'V5<*'9FA.%_O^EACA$&9`590S)(#BE&T0GO M^+=-[+5E;+&%["`EI(+4D`;20CI(#]G'DL;R@<:%6&$BD>Y>/MN=^]CB$;*" MK"$9)(<41SGM7O<^`-L<%YUV+[^+.ZPI(16DAC20%M)!>L@^EK38<'$?'Q"O M>S?`/,P$TG(V!'\8%\4'1A\EK+!F#<D@.:0XRJG<D@=&__3;XV:'ECM(":D@ M-:2!M)`.TD/VL:3EALO^5Y0+TX*DG/^1MX>YCQ0>(2O(&I)!<DAQE+,G'WY' MML?EIV*^IL2:"E)#&D@+Z2`]9!]+6LQG&U?N:^=F'#Z5FF/&`5E!UI`,DD.* M4<Z\#?WI]W]L[.-G?C7B\3;/--\=/W@H7$(J2`UI("VD@_20?2QIS]<-0^9A MSI'L@?CEB..B^-CIXY$5UJPA&22'%*.$,Y3YF:OM\)G#QZ=O%W:<WR;;Z^,V M4M[A,Y:0"E)#&D@+Z2`]9!]+$O3^96.3I^7IV&2)GQD;%T4A(2O(&I)!<D@Q M2M@QYS>3N?^VP$VR8G9W/YM[S&3%=+:8+^U="3M\WA)206I(`VDA':2'[&-) M<YX;K%Q^%?3^S&`%OQ1N7!1G]<G&"FO6D`R20XI10M:G7T:+7WN4++D-:](+ MC6VZY-RONMKA4Y>0"E)#&D@+Z2`]9!]+6E8'SU><^]P/F]D.N_#!R[@H+ALV M.\D*:]:0#))#"L@&LH7L("6D@M20!M)".D@/V<>29O)IRW4G//=A6J'_?>;U M[7'1*<HC9`590S)(#BD@&\@6LH.4D`I20QI("^D@/60?2YKI92.6^S,C%O]3 MW`_CHCB/#UU66+.&9)`<4ASES-GDYKD/;I_[X.[XP>-Y**2"U)`&TD(Z2`_9 MQY+V\ZG+E;O9F>G+S*\K[GVT\0A90=:0#))#BE'"\]S37T%.G\(VR8+)#?^P MY399\?0W<-*;V.&SEI`*4D,:2`OI(#UD'TL:U0<SSX_2[CF0N>=3F\\_'L?- M3KOI"K*&9)`<4D`VD"UD!RDA%:2&-)`6TD%ZR#Z6-,\P='CY].4^S"HN/+7Y M0.-QW"S.Y&O66)-!<D@!V4"VD!VDA%20&M)`6D@'Z2'[6-),YT8NE]^Z=7]F MY'*'0R-&+N-F<29?L\::#))#BE&.KR+X-?@&FVPA.T@)J2`UI(&TD`[20_:Q MI-5>-UBY/S-8P8\ZC8M.C1XA*\@:DD%R2#'*."B[UU\VM8N-#;;90G:0$E)! M:D@#:2$=I(?L8TFR+5XV/GE:[E=C]GZ!AW%1E`NR@JPA&22'%*.,N9;X.TN; M=,%LZ7OA-EUPI[_&;J<?^*0EI(+4D`;20CI(#]G'DK;TV<GSIQ^+,S.3A;]0 M/BZ*6V)F@C5K2`;)(<4HAYDE_LRO?=S?Y;E-/CY[.[6O98?/6$(J2`UI("VD M@_20?2QI2!^57`AY9D1R:X_BAX4/1!XA*\@:DD%R2`'90+:0':2$5)`:TD!: M2`?I(?M8TCRO&Y$LKAF1C(OB_2UL=I(5UJPA&22'%)`-9`O904I(!:DA#:2% M=)`>LH\ES>0CDNLNL1=G1B7X/5CCHE.41\AJE/&I:3+1WW>TG\M98Z,,DD,* MR`:RA>P@):2"U)`&TD(Z2`_9QY)V>]UH9'%F-()?A34NBKOYL&0UK@E/0\NW M]LK8&C>107)(`=E`MI`=I(14D!K20%I(!^DA^UC29C[YN')?XP1DN;#7KAX6 MF(!`5J.$?6UV[H62-3;*(#FD@&P@6\@.4D(J2`UI("VD@_20?2QIMW,CD<O7 MVHLPR=`IQ6G:?XO+`!]W/(Z;G?:^U2CC-;)VML7Z3W;:ML96&22'%)`-9`O9 M04I(!:DA#:2%=)`>LH\E#7=N2'+Y==+%F2')PM^]-RXZ97H<Y;E,*VRUAF20 M'%)`-I`M9`<I(16DAC20%M)!>L@^EC3<N3G)%7O<F3F)7\H^+,*B.)S+"FO6 MD`R20PK(!K*%["`EI(+4D`;20CI(#]G'DF1:^ESDNB>TI\TN_6J1<5&4";*" MK"$9)(<4D`UD"]E!2D@%J2$-I(5TD!ZRCR7-Y"./*S.=&7W@''_I@XY'R&J4 MY\[QL5$&R2$%9`/90G:0$E)!:D@#:2$=I(?L8TF[^83CRFYG)ATXQU]BT@%9 MC?+OSO&Q00;)(05D`]E"=I`24D%J2`-I(1VDA^QC29OYV./YJ=0RS"V2<T3\ M'81Q47PHQ+AC7!/VL;O%F5\:M\;-9)`<4D`VD"UD!RDA%:2&-)`6TD%ZR#Z6 MM)?//R[TXMSC#J^?+<.BN%>0\=3P_NWX7K?PN_UN;B;K/]GUW&J\C7&+R=OY MG.?\^#P9)(<4D`UD"]E!2D@%J2$-I(5TD!ZRCR4-ZH.1"T'/#$06_H+HTL<? MCZ.,>6[>WMLF*U_@0RW<9`;)(05D`]E"=I`24D%J2`-I(1VDA^QC2=OY@.1" MNW.#$?LE$@]+#$9&&4]'YN$W;*8O9ZVPU1J207)(`=E`MI`=I(14D!K20%I( M!^DA^UC28#X9N1#LS$1D87O&PQ(3D:.<!BGXX;75<='A36UK2`;)(05D`]E" M=I`24D%J2`-I(1VDA^QC28OY2.1"L7.C$!OV/BS#HOCYSF6%-6M(!LDA!60# MV4)VD!)206I(`VDA':2'[&-)\YP;?%R>6"W#!$-GA:=1X]0G5N.B.!,&'UBS MAF20'%)`-I`M9`<I(16DAC20%M)!>L@^EB23_N2VO4ON^=THK+>WA$S]J>JP M*BI$6ATH/'^=>_9:'Y:<;B@CY:2"M"%M23M22:I(-:DAM:2.U)/V"5E"GXI< M2LAQR`*7U9,;S$-(2AA6C:<@R^6YR[7#HB2BW[HB.BFBDR(Z*:*3(CHIHI,B M.BFBDR(Z*:*3(CHIHI,B1F01?41R*2)G([KU].3O87*#X0A)$7V5]CLG[7=. M2N:D9$Y*YJ1D3DKFI&1.2N:D9$Y*YJ1D3DKFI&1.2A:1)?,)R753K<E-F'D\ M_QQW6'7::1Y)2A=NZ[1*Z9R4SDGIG)3.2>F<E,Y)Z9R4SDGIG)3.2>F<E,Y) MZ9R4SDGI(K)T/BRY-AVG)O[K&;7386I"4CE?I7).*N>D<DXJ%VA\(IWJ?9'^ M0ZY*Z9LII9-2.BFEDU(Z*:634CHII9-2.BFEDU)&9"E]3')MRC/SDJ6_C6YR M@X$)22U]E5HZJ:636CJI9:#Q&?7NW&F18OIVBNFDF$Z*Z:283HKII)A.BNFD MF$Z*Z:28$5E,GYM<&_/,`&7)9T-,4"8W3HKII)A.BNFDF$Z*Z:1T3DKGI'1. M2N>D=$Y*YZ1T3DKGI'1.2N>D=!%9.I^@7)LN3$ETJ'[FBF]R@UD*2>E\E=(Y M*9V3TCDIG9/2.2F=D](Y*9V3TCDIG9/2.2F=D](Y*9V3TD5DZ5XV2IG<G)FE MX&^4'U:=3DT>24KF`Q8E<U(R)R5S4C(G)7-2,B<E"Q2.N;.;<S^<KXB^G2(Z M*:*3(CHIHI,B.BFBDR)&9!%]X'+I`B*,3'1V>]SOSET%^F!%$9T4T4D1G131 M21&=%-%)$9T4T4D1`X6(T_NGGTZUYW-%].T4T4D1G13121&=%-%)$9T4,:(T MXN2%TYBG]>DT9HYAS+@HWA%!JPEH3<I(.:D@;4A;TNY`H>'=S71R>X>$N*/5 M8;/35UB3&E)+ZD@]:9^0)1PN\5_^8Z>321@-Q/OC<FEOCGPXK#I]I8\DM8S& M#$^_\$DMG=3222V=U-))+9W4TDDMG4J2TODJI7-2.B>E<^I(2N>KE"XB2S=< MZK\F71@17#B%F81523HGI7-2.B>E<U(Z)Z5S4CHGI7-2.B>E<U(Z)Z5S4CHG MI7-2.B>E<U*ZB"S=<*GOZ2Z_SW(R"2,"W>[Q67")MT$<5B7IPH8G4CHGI7-2 M.B>E<U*Z0,=W36C\&_]CES;JZC>AKD[JZJ2N3NKJI*Y.ZNJDKD[JZJ2N3NH: MD74=KON]Z^67D?3C-]HN?6)<^J_)TM$TFBH\'2=U-'525R=U=5)7)W5U4E<G MI7-2.B>E<U(Z)Z5S4CHGI7-2.B>E<U(Z)Z6+R-(-5_FO21>F`WI(G'9)O`0X MF40SA$,Z)Z5S4CHGI7-2.B>E<U(Z)Z5S4CHGI7-2.B>E<U(Z)Z5S4CHGI7-2 MNH@LW7"5[^FN.9J&Z<"EHVDT0SBD<U(Z)Z5S4CHGI7-2ND"'HVGZ*HDR^A;* MZ*2,3LKHI(Q.RNBDC$[*Z*2,3LKHI(P16<;ABO\U&<.D(,FX]!?A)Y-HGG#( MZ*2,3LKHI(Q.RNBDC$Y*YZ1T3DKGI'1.2N>D=$Y*YZ1T3DKGI'1.2A>1I1NN M\SW=-<][83YPZ>`931$.Z9R4SDGIG)3.2>F<E,Y)Z9R4SDGIG)3.2>F<E,Y) MZ9R4SDGIG)3.2>DBLG3#U;VGN^;@&:8"R5YWYE0TFAT<TCDIG9/2.2F=D](Y M*5V@XSM$_>>05-(W4DDGE71222>5=%)))Y5T4DDGE71222>5C"@M>?O":<S3 M^O2D4R\?I\\V#Y-QU>G*X9&T(JU)&2DG%:0-:4O:D4I21:I)#:DE=:2>M$_( MD@T7][[S77'<O`U#@0O'S7%5DBZ:)CSMCTKGI'1.2N>D=$Y*YZ1T3DKGI'1. M2N>D=$Y*YZ1T3DKGI'1.2N>D=!%9.AWYDG07!MBWP_IT;UOR58AQ59(L;'@B M)0L4YHYGWTBMAKZ9&CJIH9,:.JFADQHZJ:&3&CJIH9,:.JFADQHZJ:&3&CJI M8436<+B0?\WN-VQG+9?V>Z]UY`RK3N%TY'122R>E<U(Z)Z5S4CHGI7-2.B>E M<U*Z0.-C;#Z?+VR*HY3QDLET-KR&D3Y]J&V\1N/QV=0OCA4[7J//-/<7!10_ M+#E]+Q7?2?&=%#\BBS^,`N+XEW;@,#K0@^ETH>_?$T6/!@SC"0](T7V5HCLI MNI.B.REZH!!J<N:7C-F*,[]ES%:<^35CAQ6G`'J$^'W1(\))#P`G]7927R?U M=5)?)_6-R/H.\X*X[Y6O\-^&.4/2>6D_9J3.T33BT-E)G9W4V4F=G=3929V= MM',[:>=VTL[MI'1.2N>D=$Y*YZ1T3DKGI'1.2A>1I1MF!*])%V8+VN5/NZ@? M;I0NFD`<TCDIG9/2.2F=D](Y*9V3TCDIG9/2.2F=D](Y*9V3TCDIG9/2.2F= MD])%9.F&&<%KTH790KS7\:V*M]$`XE#.2>4"A0/B8C'5/^FSDDKZ5BKII)). M*NFDDDXJZ:223BKII)).*NFDDDXJZ:223BKII)(16<EA9!"7O/3\&$8,<<'E M$J_NWT:#B$-")R4,M'CZ$W?V8T^JYQNHGI/J.:F>D^HYJ9Z3ZCFIGI/J.:F> MD^HYJ9Z3ZCFIGI/J163UAC'!2^J%L4)<[_[&]AL=.J/APZ&>D^HY*9F3DCDI MF9.2.2F9DY(Y*9F3DCDIF9.2.2F9DY(Y*9F3DCDI641ILN&Z/TEVY0G+TW:7 M?JW+9%QU.H%[)*U(:U)&RDD%:4/:DG:DDE21:E)#:DD=J2?M$[)TPYC@!7O; M-(P5XKWMS+O9QE5)LF@>\;0#*IF3D@4:+PG&5^+3YT!%].T4T4D1G13121&= M%-%)$9T4T4D1G13121&=%-%)$9T4,2*+J!POBCBL3Z<`?N'Z,)F&14E#)S5T M4L-`8\/9S4SOJ4!"WTP)G93020F=E-!)"9V4T$D)G90PT#/W74U],S5U4E,G M-752TXBLZ7#Y_Y(=,XP+='O'*PC^X?K)-!HJC$^#($7U58IZH.$/R]R_G=BT M73OE8<'AI^E5U$E%G534246=5-1)19U4U$E%#W3^CBOG8<'ACBNGDW(Z*:>3 M<D9D.8>K_9?D#-.!-">NY:?1#.&0TTDYG93320&=%-!)`0.%'>3L>W]5U#=3 M42<5=5)1)Q5U4E$G-7120R<U=%)#)S6,R!H.E_UQPVM/<\*X(&UIUP8ZWD9# MA4-+)[5T4DLGM7122R>U=%(Z)Z5S4CHGI7-2.B>E<U(Z)Z5S4CHGI7-2NH@L MW7#9_YIT85R@W?IX5%UR+C.-A@J'=$Y*YZ1T3DKGI'1.2N>D=$Y*YZ1T3DKG MI'1.2N>D=$Y*YZ1T3DKGI'016;KA.C].=^%J?AKF`O'>AM\0KKTMFAX<DCDI MF9.2.2F9DY(Y*5F@<.34ZPG#/^EID1KZ9FKHI(9.:NBDADYJZ*2&3FKHI(9. M:NBDAA%9P^%J/VYX[9$S3`GBELNE__J?R32:)1Q:.JFEDUHZJ:636CJII9/2 M.2F=D](Y*9V3TCDIG9/2.2F=D](Y*9V3TD5DZ8:K_M>D"]."2T?.:*9P2.>D M=$Y*YZ1T3DKGI'1.2N>D=$Y*YZ1T3DKGI'1.2N>D=$Y*YZ1T3DH749INYF.9 M"T?.I_7I9>&9:_MQ57Q="%I-0&M21LI)Q8'&B[*S0X'-8='I;FU).U))JD@U MJ2&UI([4D_8)6<3AJC_>_RY%#%."^)#):_M9-$H8=SN0&OHJ-7120R<U=%+# M0..SG_Y>Y6)B5S-*Z)LIH9,2.BFADQ(Z*:&3$CHIH9,2.BFADQ)&9`D5XT4) MA_6^']I[&!XFL[#J](!_)*FAKU)#)S5T4D,G-0P4?KOO[&WX'43C[GAS8^]; M5DZ_!>5T4DXGY7123B?E=%).)^5T4DXGY712SH@LYW"1_Y(],@P%='O':X@% MWV\Z"ZN2G$[*Z:2<3LKII)Q.RADH[)++\(-/?D**S=30;TD-G=3020V=U-!) M#9W4T$D-G=3020TCLH;#1?Y+&H:A0-SPS$7%+!H='`ZK3FKHI(9.:NBDADYJ M&"@TG$[G3WLC(OIVBNBDB$Z*Z*2(3HKHI(A.BNBDB$Z*Z*2($5G$X7(_CCA< M55SQ!O!AB1U?ETO,8\95R0X9S1>>^BJFDV(Z*::38CHIII..H4Y*YZ1T3DKG MI'1.2N>D=$Y*YZ1T3DKGI'016;KA<M_37?'VX5D8$VB_/AY+S\QCQE5)NFB^ M<$CGI'1.2N>D=$Y*YZ1T3DKGI'1.2N>D=$Y*YZ1T3DKGI'1.2N>D=!%9NN$J M/T[WS\GL_8<??_G7ZN.W#Q]_5Y>;MWJ#U)]_>OHV_^=D%J8"EPZ=T>S@<.AT MTM[FI&1.2N:D9$Y*%FA\^CM_X/2ME-!)"9V4T$D)G93020F=E-!)"9V4T$D) M([*$P]5^G/#*<<PL3`GBE/BCPI-Q4;+S1=.%P\[GI)).*NFDDDXJZ:2=STGE MG%3.2>6<5,Y)Y9Q4SDGEG%3.2>6<5"XB*S=<[+^F7!@27#IN1J.$PT[HI)W0 M2>F<E,Y)Z9R4SDGIG)3.2>F<E,Y)Z9R4SDGIG)3.2>F<E,Y)Z2)*T]V]<!KS MM#Z]"CSSKK1Q5;RW@5:3D<*[TO3_;/"\/BPXW4Q&RDD%:4/:DG:DDE21:E)# M:DD=J2?M$[*`PP5^O.]=>.*["P.!^&AYYN=FQE6G[_SC!*2`X;;&)ZNS?XCQ ML.9T2VH8S22>=F@U=%)#)S5T4D,G-7120R<U=%)#)S5T4D,G-7120R<UC,@: MJD;2\,IGOKMA.]L9;VV`]3`95YT*J&78\$1J&2B,4?B'7+0S^C8*Z:203@KI MI)!."NFDD$X*Z:203@KII)!."NFDD$X*Z:20$5G(X=(^WAFO#1E&`KK=TP7$ M+7X`ZBZL.E532">%#!1VRF%^DEYX*Z1OHY!."NFDD$X*Z:203@KII)!."ADH MW/'%S;W=<67U;93525F=E-5)69V4-2++.ESLOR9K&!+$6?DF_+MHDC">WH!4 MU5>IHY,Z.JFCDSH>:'CSD7V7E?29CZKNX:.']R6IKI/J.JFNDWHZJ:>3>CJI MIY-Z.JEG1-9SF`!XSV$L<.FY,TP.XI[+6[PE_RZ:+QR".BFHDX(Z*:B3@CHI MJ),J.BF=D](Y*9V3TCDIG9/2.2F=D](Y*9V3TD5DZ88)@*>[8D1S%R8'VL5/ M1UB^969<E1QAHY'#4TVE<U(Z)Z5S4CHGI7-2.B>E<U(Z)Z5S4CHGI7-2.B>E M<U(Z)Z5S4KJ(+-UPY?^:=&%B$.]U9XZBT5CAL-,YJ5R@?_<4HXZ^C3HZJ:.3 M.CJIHY,Z.JFCDSHZJ:.3.CJIHY,Z.JFCDSHZJ6-$UG&8`[RF8Y@?Q!V79TYR MHBG#(:230CHIG9/2.2F=D](Y*9V3TCDIG9/2.2E=H/%\[/Q/=6,SM?1;4DLG MM7122R>UC,A:#H.!U[0,`X6XY9E],IHZ'%(Z*66@9_9)WT9AG13626&=%-9) M89T4UDEAG1362?NDDSHZJ:.3.CJIHY,Z1I1VG+]PC/.T/KUR//.^_'%5_'0( M6DU&^O=C'&R3';8YW7).*D@;TI:T(Y6DBE23&E)+ZD@]:9^0!1R&`Z_8$>=A MJ!#OB/K#)^DEW\-D7'7Z=C^2%#(:4#SMKVN2TODJI7-2.B>E<U(Z)Z5S4CHG MI7-2.B>E<U(Z)Z5S4CHGI8O(TNF;_ZITPW87?\YP'E8EZ9R4SDGIG)3.2>F< ME,Y)Z9R4SDGIG)3.2>F<E,Y)Z9R4SDGIG)3.2>DBLG3#)?]K]KHP*M#MGJXF M.'B;1P.%\?D/I'2^2NF<E,Y)Z0+]NXF=0CZ_0%G]1I7525F=E-5)69V4U4E9 MG93525F=E-5)62.RK,.5_VNRAHE!FA5CN'DT5SAD=5)6)V4--)X)8C*GR+Z- M(C^_C2+[-LKJI*Q.RNJDK('"'1S&^>GSB"+[-HH<;Z/7*7PW4/-X!6]5CP"_ M53T"G/0(<-(C(")[!`P#A-<\`L+@(7X$\+QV'DTG#@^`0.$[=SO%=T&/!]]( MCP<G/0*<]`AP4G,G-7=2<R<U=U)S)U5V4F4G97522">%=%)()X7\'\[N=:F) M+`J@\*M0_#?8.I-`2JD2`1&Y>'F"C#9H#4ZL$,O7=YV<;MB]=JJ2T5^RJCL* MGWWHLY-(2((LXX0_@:QCB`B99^%'S3A,*WK*FNKM[,2O)`#2IP#I!*03D$Y` M.@'I!*03D$Y`.@'I!*03D$Y`.@'I!*03D"$)LLP3(N2&6>NXSA\BX,%?6I#P M"U.*WL\),B?(G"!S@LP),B?(G""KJ=O4[N=_>A#Z+`B=('2"T`E")PB=('2" MT`G"D$18Q@C_A[".'2(A7XCTDO%QF$[TADX8.F'HA*$3AC5UV]/GZWZB'JH^ M#U4G5)U0=$+1"44G%)U0=$+1"44G%)U0#$F*98@0%;=\?>JX#A^BYL&SC!E& M%#VF$YA.8#J!Z02F$W0U,:\L3V<=C`[V3Y[H_P$`T^>!Z02F$YA.8#J!Z02F M$YA.8#J!Z01F2$/,B><^6S[AO#IO./_ATM27[:CI#HN;SY2.\U$G.9WF]":G MLYS>YG2>T[N<+G*ZS.DJI^N<WN?T(:>/.7T:)-F5B8(OQ"V>RIK4202[G\?- M9WXJJSMJ0!=&&*MK$SHGZ)R@<X+."3HGZ)R@<X+."3HGZ)R@<X+."3HGZ)R@ M<X(N)-&Q"@[H-MS,3,KQZ7)+8[KNL(%9/;,N;L]'_L&^"-8#'L]!T`E!)P2= M$'1"T`E!)P2=$'1"T`E!)P2=$'1"T`E!)P1#DF`9'OCB*X/J39)UZ,#C/EQ\ M+)QZEQD+9YA-=-\&4\+.1V'GA)T3=D[8.6'GA)T3=D[8.6'GA)T3=D[8.6'G MA)T3=B')KFS[;;?-PEG'!3SN@]V:MVE,PE"AIW."S@DZ)^B<H'."S@DZ)^B< MH'."S@DZ)^B<H'."S@DZ)^B<H`M)=&6C'^DV76YU,*#++2^<87[0FSEA5E-_ MH\B/?HB_=/.#IQ\!3R<\G?!TPM,)3R<\G?!TPM,)3R<\G?!TPM,)3R<\0Y)G MV>]'SRTW$Y,Z)Y!K&K5VASU^<WO=I(1K&#JL]+%SPLX).R?LG+!SPLX).R?L MG+!SPLX).R?LG+!SPLX)NY!D5S;ZMMMF&:T#@DW+:!@C])>D$W1.T#E!YP2= M$W1.T#E!YP2=$W1.T#E!YP2=$W1.T#E!YP1=2*(KN_M(MVD9K=,`76YY&0U# M@]ZLIKIF/AV-=0Z"/@=!)P2=$'1"T`E!)P2=$'1"T`E!)P2=$'1"T`E!)P2= M$`Q)@F5+'P7+PKG-_6<=!4@RO>9_$B8&O:03=D[8.6'GA)T3=D[8.6'GA)T3 M=D[8.6'GA)T3=D[8.6'GA%U(0[O]/QRZK,[;^(1_=U3\GI?2<9/224ZG.;W) MZ2RGMSF=Y_0NIXN<+G.ZRNDZI_<Y?<CI8TZ?!DET94L?+[L-"^=^'0'H<M,B M>-1TAPW,PO!@=05B5E-=2YO1W^F.,ST,@GX8!)T0=$+0"4$G!)T0=$+0"4$G M!)T0=$+0"4$G!$.J@GOW7]MV>3Q;S@Y??&\7M^WK]N[N?N?S_&=Y<W=YHN6A M[BS:FY>[KYKIJV>[O$U!_:B9'C=K^DDS/5W7SYKI^;I^T4POU_6K9GJ]ZGL/ M?_#]X8L?L]OV<K:X_?;?_<Y=>\-?^>FHW%8OOMV6E;]^L)S_>+G+9_[/?+F< M?U_]]FL[^](NR@$<?#.?+_L/^,3V?LT7_ZZ^+(>_`0``__\#`%!+`P04``8` M"````"$`2B_6O#X#``#S"0``&0```'AL+W=O<FMS:&5E=',O<VAE970U,RYX M;6R45LMNVS`0O!?H/PBZ1R\_9=@.8@MI`S1`4?1QIB7*(B*)`DG'R=]W2=HJ M23EQ>K&MW=GQ["REU?+VI:F]9\PXH>W*CX/(]W";TX*T^Y7_Z^?]S=SWN$!M M@6K:XI7_BKE_N_[\:7FD[(E7&`L/&%J^\BLAND48\KS"#>(![7`+F9*R!@FX M9/N0=PRC0A4U=9A$T31L$&E]S;!@'^&@94ERG-'\T.!6:!*&:R1`/Z](Q\]L M3?X1N@:QIT-WD].F`XH=J8EX5:2^U^2+AWU+&=K5T/=+/$;YF5M=#.@;DC/* M:2D"H`NUT&'/:9B&P+1>%@0ZD+9[#)<K_RY>9''DA^NE,N@WP4=N_/9X18]? M&"F^D1:#VS`G.8$=I4\2^E#($!2'@^I[-8'OS"MPB0ZU^$&/7S'95P+&/8&. M9&.+XC7#/`='@29()I(IIS4(@$^O(?)H@"/H17T?22&JE3^:!I-9-(H![NTP M%_=$4OI>?N""-G\T*#Y1:9+D1#(&]:=\$B3S23R97F<)M2+58(8$6B\9/7IP M:N`_>8?D&8P7P'SN3.OH>WVK5>A1DMQ)%L4%77"8S_-ZGDZ6X3-XFI\P&XU) M?:_')#9B>T9(`R5M9@1"T-N+!BM<T2,8ZN5QG#7*(EOC*+(%;"Y`;,3V`B*V M(=D0,AOU$*N-D=W&^_(E>.4#>6_?+)KVO,JOC<:,U;&1!F[=0&8$+"DP>M?1 M\9L'_.RH+(*C;$B:I\Y,-QIC2'(#F1&P),'?FY+>=T>";7?FJ>N.QLS5\70F MOS5S\=BV-;.3L[1/6WJG_Z-7@FV]LVC>\^II:HQAG1O(C(`E969+D3?U]6G* MHFO3U!A#DAO(C(`E2:Y"YSES_9:51;9+H_2?^]HEC1FKJ<:1.U<SZ^2RRSE+ M-3RM3-7OGT$)MM4.SZ#&:+6.GJW.34^=).XI-$LGQM/5$@Q;T%(L1W_=9U5E M2Q\GSG-M<P+I^V?HM),>R+?R0_UZ]^K5U&"VQUM<U]S+Z4'NU1A,Z:-ZYV_D MSE=;NT_`RNW0'C\BMB<M]VI<0FD4S.#^97IIZPM!.[4(=E3`LE4_*WBYPO#$ MC`(`EY2*\X5\+>A?U]9_`0``__\#`%!+`P04``8`"````"$`P_<["C8#``## M"0``&0```'AL+W=O<FMS:&5E=',O<VAE970U,BYX;6R,5MMNXC`0?5]I_\'* M>W/AFB"@*D3=K;255JN]/)O$(5:3.+)-:?]^QS:D=BB7EY:,SQS.G!EGF-^_ MU15Z)5Q0UBR\R`\]1)J,Y;39+KP_OQ_O8@\)B9L<5ZPA"^^=".]^^?7+?,_X MBR@)D0@8&K'P2BG;61"(K"0U%CYK20,G!>,UEO#(MX%H.<&Y3JJK8!"&DZ#& MM/$,PXS?PL&*@F8D9=FN)HTT))Q46()^4=)6'-GJ[!:Z&O.777N7L;H%B@VM MJ'S7I!ZJL]G3MF$<;RJH^RT:X>S(K1].Z&N:<298(7V@"XS0TYJ3(`F`:3G/ M*52@;$><%`OO(9JE4>@%R[DVZ"\E>V%]1J)D^V^<YC]H0\!MZ)/JP(:Q%P5] MRE4(DH.3[$?=@9\<Y:3`NTK^8OOOA&Y+">T>0T6JL%G^GA*1@:-`XP_&BBEC M%0B`OZBF:C3`$?RF_^]I+LN%-YSXXVDXC`".-D3(1ZHH/93MA&3U/P.*#E2& M9'`@&8'ZP_G`'\3C:#RYSA(81;K`%$N\G'.V1S`U\)VBQ6H&HQDP'RLS.KI: MSY4*-2J2!\6BN:`*`?UY7<9)-`]>P=/L@%D93.*A#C-P$>LC0AFH:%,K$(#> M3C18T1<]A*9^WHZC1I7D:AR&KH#5)Q`7L?X$T:LS/85,AQV+4\;PM(S1V:DZ MEJ&28'XL&^.D9^3*8$9Z?)21ZWX@M0*.)!@!V]G+CBKPPH-ZNXZ.HIX;*X.) M]4Q,QYT/NK]K^S`9N8>I?1@-P[@[=@2#7[<+5F!7<)Q\]$9K6AF,Y5T_D%H! M1\K$E:*NTO5VJJ1K[3082U(_D%H!1]+4E72YG0KLNG/:3H,9Z7;V;L_:/ILD M7;O,53:'$YUXOIMJ85IOH\MZ%=C5&_>':&4PEG7]0&H%'.O@165+N:V;*NE: M-PW&DM0/I%;`D00KSM%TV1Z-=OTY[><!=.9^.J>#WNU5&U=5:W(_AL%(-KO4 MK)J:\"U9DZH2*&,[M2<CF(,N:G;X2NUPO86[`UBA+=Z29\RWM!&H(@6DAOX4 M+B`W2]@\2-;J%_N&25B>^F,)/Y8(O/E"'\`%8_+XH-9\]_-K^1\``/__`P!0 M2P,$%``&``@````A`%SLON*!`@``7P8``!D```!X;"]W;W)K<VAE971S+W-H M965T-3$N>&ULE%5=;]HP%'V?M/]@^;UQ`H$$1*A:JFZ55FF:]O%L'(=8Q'%D MF]+^^UW;D/+5B;W@.#GWY-QS;LSL]E4VZ(5K(U1;X"2*,>(M4Z5H5P7^]?/Q M)L?(6-J6M%$M+_`;-_AV_OG3;*OTVM2<6P0,K2EP;6TW)<2PFDMJ(M7Q%IY4 M2DMJ8:M7Q'2:T](7R88,XGA,)!4M#@Q3?0V'JBK!^(-B&\E;&T@T;Z@%_:86 MG=FS278-G:1ZO>ENF)(=4"Q%(^R;)\5(LNG3JE6:+AOH^S5)*=MS^\T9O11, M*Z,J&P$="4+/>YZ0"0&F^:P4T(&S'6E>%?@NF2Y&F,QGWI_?@F_-P34RM=I^ MT:+\)EH.9D-,+H"E4FL'?2K=+2@F9]6//H#O&I6\HIO&_E#;KURL:@MICZ`A MU]>T?'O@AH&A0!,-O`RF&A``OT@*-QE@"'WUZU:4MB[P<!R-LGB8`!PMN;&/ MPE%BQ#;&*ODG@!(GJB<9[$A@W9$DHR@=C++\?UB&.Q98]RSCJUE(Z,O;]$`M MG<^TVB(8/5!N.NH&.9D"L_,G_=`?Z,G5W+DB7PIH`YF^S/-\-",O$`3;8>[/ M,=DP/<8LSC&#'D%`8*\2G#M4>3F]O3H'/E4W[GE]!_>7,-DQ9G$)D_>8(WW@ MW/7Z'!CF"*/>O30^<>8^8%(_1L[RQ<&-HS>GQV]V^0WA*_FW0ZZHP-!?KR#/ M)WUGP:&`R7RZ<722[N+PZ2#ZP!68HT-7KM/FBDZT3>(3;0%SX,[^QGM#V?@] M\F!8."/"\'=TQ9^I7HG6H(978$,<94"BPPD1-E9U?HR6RL*7[2]K.,@YQ`&& M8%0I9?<;=P;U?PWSOP```/__`P!02P,$%``&``@````A`('Y6*L)"```+BL` M`!D```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`[%BN2"UOO?WS.FTQD5$PS"V(Y4U:=10#B7Z<LY*TA M,I)^5_^_%?OVM''#9!8OYJ$OY,Y+WK1?"CFEZV2O35N5_X'(UU/!)(&>)!31 MZ_Y@%BQC/T[LLW@0D5K@Y[1-GY_JZLT1=XVX9G--Y3WHK\7,<F6+P96))<DQ MG^0@-52H&V''M^?E?/'D?1,IS+1F"YJ5Z]PT(57L#`K_)O%$?+<@Q=)YD*$P MT9S^+D@YB`89SF_3JW5L0;)2:98+VZ$&$H#(#`\@LF9)#A).HPPLYTL6`6BB M>P2H@400T0C&ER[%&U<LYI;[Y7S%K@R:I7)OL5I%,>W?D?YXA7)'XA)9P)D9 MCTN*65P^]P0T*".H@5PYH5>6=Z[=$SG(Y@EH4`2H@42PH!&,KUV*V=I[GH`F M49[XR2H,F">D/U[&][N)Q"4?.ZBFQ^.28AX7]P0T*".H@5Q9E#N^\C1/Y""; M)Z!!$:`&$H$ON(!#&%^\4O/5\TK1(K`E">=^#V3RFAM7"^;SQ=TW&AN#K24V MX".I8O\.2""8#R*4&-Q"KR[AAFZ+:>;X@,1QBFD1C@*&J18:A00<BL*2`\`A MR4&O:OR.F?)!Q&[=G>X$;X)X/F3-N_CJFP#+[HJM%N&DP#!#4AA%)UH#9+18 M@_"I;IF=W+B(N]40!2.JQ1J@HL4:$(V4#A;$"[$GNB&/WC:,M3)#]BV`;X"N M?[\#=`F!"/N$6F@4C*P3?0):6GQ"2-4^H18:!:.LQ2<@I<4G$(%/IMV`3P3# MVX&`X7=:AM0HAF%.V:T6(9]P"\E0P$`[,0I@Z;A/:FI=/>`3;J%12`9.1ET@ MU2P'/=1I$?ADVB%0P?`6(9#,1+%-S)`<Q6+THUO%0CVIJ6F&8%B?.`&C[L0H M`*,6GQ!KM4^HA?K$Z#M>3_*[%L]!WR<0#7-/SZ(%PUN&@#%Y8H8,;/;9!G^K MIJ8^P3"#3P;ZVO?:`6#4XA-BK?8)M5"?&'TM/@$^Q[D7=(PU;1UT)W@TO'4( M&(XG6F3`LI_P4@(11AYJ(<F1#\/W%[0:9=M[:Q&*`K?0*!AXQRT*`;CC%FG1 M<"D1P<@6(F0XEC[)A5AB-	Y^\ZU-2DE'`+S9!DX;O!&P)!QTM)B[!/,*Q? MT"$#KR4'0$Z+3QU>3:6DKB<31#MI9AB&I]51:,"Q?_]>#(\D+<*9@6&&S#P$ MW!#(:?$'X150IX<9HF#`M?@#Q+3XTV&56J`#,7=2?QA^)_ICP+#/OV&''8;E MJU/U(@ZWT"@>HFT(V+3X@]BJHT`M)(J(T7;<'Z5FVZ;>ED&+>(E`(`.=-";& MWFG^1`8&!_<O8>KR6RU"]8-;:!0&RMJW"A%0=MP?+<)1P+!^_402?(BR%G^D MVNH/B`;\,7?2S##F3O3'P-Z`OP6*.O;>Z@>WT"@>HJQT4&1(K!*]4>:4U2+L MSQ!E(T99BS\`SG&^J2G[CQA=/QUZ*?QH9AASI3_V_4%D8&_`7S%H$<Y,!USY MLQ/^J2-ZB+)JE-6?'F7U,$/],,I:_`%,6OSI6$HMT/Z8.TEF8L;<:?6C1K': M#OBK.BU"_N`6&L5#E(V!LN/UHT4X"AC6]R>6X)O,-Z5F.>@]?[3(S+>!3IH9 MR4`4TT1_@)SDW@GX*X481#@SJ(5&\1!E8P"HF'2$;UJ$HT#<I5$PRH[73PR8 M)#GH^].QU%0_>@9N'HV),7>B/P;V!OQ50MSA]?;\P2TT"@-E[?N#&'!I\0<Q M%;"BAQGJAU'6X@^`T^)/1U>C/^9.FAG&W(G^&-@;\/<(<8?7NS^HA421/$19 M-<KV_-$B5#^XA4;!*#ON3P*8'/='BWB)P(TRT$EC$O-COEEBDFK&W("_-TA` MA#."6NC5)?#>3=<$,#E>-UJ$HX!A_;I)&%TM.0`\BB4AJO+O?FK*[L=3TRMM M*AA^I9TPYDZK'S6*^\1WMEJ$,]31F._?DH<HJT99ZZ='63W,X!.CK,4G`*?% M)Q#!>SBC3T0PXA-C[T2?#`P.>O=2A]D;YQ+40NOI(=HF@$U+/2&V:KR@%A+% M@M%VW">E9O=J;Y^@16;.#732F!A[I_FS,#`8G1E2>=AJ$:HCW$*CD"!\-^\6 M@,]Q?[0(1P'#^G4D#A62*"S^`#;'ZTA-N7'AX!5[T2(/,<JG!N^$S,#Q1#B] M5^;U,=_EYW/C9-6K/'H8B'>KMU8X%KGUU]M`'BUC[3MQ7%*U>[<.<5KQFA[S M/]+Z6%P:YYP?Q)3SF3P*6,-Y1_C05E=UINZE:L4Y1?7G29Q+S<7AN?E,B`]5 MU78?)!IO)UV?_P<``/__`P!02P,$%``&``@````A`.YJ&@.%`@``!0<``!D` M``!X;"]W;W)K<VAE971S+W-H965T-#4N>&ULE)5;;]L@%,??)^T[(-YK?,FM M49RJ3=6MTBI-TR[/!.,8Q1@+R*7??@>3M+YD2O?B&#CGG]_Y'\"+NZ,LT9YK M(U25XB@(,>(54YFH-BG^]?/I9H:1L;3*:*DJGN)7;O#=\O.GQ4'IK2DXMP@4 M*I/BPMIZ3HAA!9?4!*KF%:SD2DMJ8:@WQ-2:TZQ)DB6)PW!")!45]@IS_1$- ME>>"\4?%=I)7UHMH7E(+_*80M3FK2?81.4GU=E??,"5KD%B+4MC71A0CR>;/ MFTIINBZA[F,THNRLW0P&\E(PK8S*;0!RQ(,.:[XEMP24EHM,0`7.=J1YGN+[ M:+Z:8K)<-/[\%OQ@6N_(%.KP18OLFZ@XF`UM<@U8*[5UH<^9FX)D,LA^:AKP M7:.,YW17VA_J\)6+36&AVV,HR-4USUX?N6%@*,@$\=@I,54"`#R1%&YG@"'T MV/P>1&:+%">38#P-DPC"T9H;^R2<)$9L9ZR2?WQ0=)+R(O%))`'ZTWH<Q+-Q M-)Y<5R&>J"GPD5JZ7&AU0+!IX#]-3=T6C.:@["I+P)_+E4%)+N?>)36I$&V@ M&_OE+(D69`\6LE/,PS`FZ4:L+D2\BQ#@>X.$TO\?TB6E&)[OD-&TB_#@8T:- MSZZR56NB0P#6]`E&_]P`9YM<$MC9)@AG/0(?TR)H370(1D."ZXUR23T/DKA' MX&-F31O#[MKJ\EJ'"USH.W.=RR7UN.(^EX]I.=.:Z!!,A@37>^.2KO7&Q[0( M6A,=@NF0X+H'+JGGP:`W/N9R;RZO>2Y_D_F#7M,-?Z%Z(RJ#2I[#:0B#*7BI M_3WF!U;5S8%>*POW3_-:P.>&PYD(`PC.E;+G@;LIWSY@R[\```#__P,`4$L# M!!0`!@`(````(0"-"$.FUP,``$@-```9````>&PO=V]R:W-H965T<R]S:&5E M=#0V+GAM;)176V_B.!1^7VG_0Y3WDC@72!!0#:FZ.]*.-%KMS#R;Q(#5)(YB M4]I_O\=V&FS3X?+2PO'G<[YSR9?#XO&MJ;U7TG/*VJ6/)J'OD;9D%6UW2__' M?\\/F>]Q@=L*UZPE2_^=</]Q]><?BR/K7_B>$.&!AY8O_;T0W3P(>+DG#>83 MUI$63K:L;["`K_TNX%U/<*4N-740A>$T:#!M?>UAWM_B@VVWM"1/K#PTI!7: M24]J+(`_W]..?WAKREO<-;A_.70/)6LZ<+&A-17ORJGO->7\ZZYE/=[4D/<; M2G#YX5M].7/?T+)GG&W%!-P%FNAYSGF0!^!IM:@H9"#+[O5DN_2_H'F!,C]8 M+52!?E)RY,9GC^_9\:^>5O_0ED"UH4^R`QO&7B3T:R5-<#DXN_VL.O"]]RJR MQ8=:_,N.?Q.ZVPMH=PH9R<3FU?L3X254%-Q,HE1Z*ED-!."OUU`Y&E`1_*;^ M'VDE]DL_GD[261@C@'L;PL4SE2Y]KSQPP9I?&H0&5]I)-#B)@?UP'DVB+$7I M]+J70#-2"3YA@5>+GAT]F!J(R3LL9Q#-P;/,+/EM9I"2O/-%7E)7`<VA':^K M+(X7P2N4L!PP:XW)?6_$.(CB$P0:G03`;R0)J;LD8VCBY^7_("DOV23C<'2O M\EAK2*[*+!,K#(-%`"IC$K@<6(*APV;F2>1$UICD%-DP6)&3>R)+\-*'),:: M9W'B1-:83'4M0OG4.2^L\RA"IZY9O&!&S(K(N;G>$GG)YA<G,X>?QDP5OX<H MC",'4#B`/#_5UF(XM1E>[ID$.\PRAYB&:&)H&KNTK&.HVWC;(C6[AY0$VZ2R M.!W]ZA'6&&.0#(,56;Z+C`?]<CDD^-H(:XP1V3!8D4$#;H\LP6[.SHBN-6;H M1!KEN5V3PCZ/T:E5%B\$$F(2NVV&U2V;X<Q]B-8#R"B.:;%9.`I\N3%(B^9E M<1E`9G1]35GLZ%+Q;AX+I/7QLL`,(-V>*$'.<U38YVERZI[-3"JBP>S&[F@= MM1E.[?E8(T-LU5-4F!:;Q5WZB[1X7NF.!IG=,2QV=$=EK\S&N;R>R[]<6^`! M2Y2^YH:Z#X4PU16%Z>F-:1.[2US1N;IFKGZN!Y!9%GWMDZ&]2T615L0K33%D M<ZB$8;%SOTM)82V]+F@#2+^4X]A]9\O=5CH9SJ/<%32]N.J]KB']CA2DKKE7 MLH-<2B/H]6C5"_,:S6'Y@475L1>P2"M[,![`'MOA'?F&^QUMN5>3+;@,)S,8 ME%YOPOJ+8)W:MC9,P`:K/N[A%PN!M2J<`'C+F/CX(G?M\3?0ZG\```#__P,` M4$L#!!0`!@`(````(0#L08?<M0(``-X&```9````>&PO=V]R:W-H965T<R]S M:&5E=#0W+GAM;(Q576^;,!1]G[3_8/F]&,A'2112-4'=)FW2-.WCV3$&K&*, M;*=I__VN<6&0=%OR0/#U\?$Y]]J7S=VSK-$3UT:H)L51$&+$&Z9RT90I_O'] MX2;!R%C:Y+16#4_Q"S?X;OO^W>:D]*.I.+<(&!J3XLK:=DV(8167U`2JY0W, M%$I+:F&H2V):S6G>+9(UB<-P2205#?8,:WT-ARH*P7BFV%'RQGH2S6MJ0;^I M1&MZ-LFNH9-4/Q[;&Z9D"Q0'40O[TI%B)-GZ4]DH30\U^'Z.YI3UW-W@@EX* MII51A0V`CGBAEYY79$6`:;O)!3AP:4>:%RF^C];9`I/MILO/3\%/9O2.3*5. M'[3(/XN&0[*A3*X`!Z4>'?13[D*PF%RL?N@*\%6CG!?T6-MOZO21B[*R4.T% M&'*^UOE+Q@V#A`)-$'<RF*I!`#R1%.YD0$+H<_=_$KFM4CQ;!HO;<!8!'!VX ML0_"46+$CL8J^<N#(B=J((E?2>:@_G4^#N)D$2V6_V<A7E%G,*.6;C=:G1`< M&MC3M-0=P6@-S+TSKV/P^C>K(,^1W#N6%*\P`A<&RO.T36;)ACQ!3MDK9G>) MB:>(?8]PKAUM-@H0T#N(AE2,1;]=AEZ;`SMM/>O.!X![$#L[$_(&(II"LDO( M[1^6B=C95*S+\`Q.X+]%NT6`&VE,9JNIA)W'S`=C^_-`-@I,)$&AK\^?`Z<8 M_`[I2N;AF12/2;K*+T+WFP+V8\#\#4`V!BRG@(ETN"]CZ==ETRTZMW!6T)W' M>`M1N+JT,`;$D7,Y]0@-R.W2U<-+]OW$7S?)=<GWO*X-8NKH>D4,V1JB0QN[ MCUT]S^([:&]=,R##!+27EI;\"]6E:`RJ>0&487`+(K1O4'Y@5=M=\H.RT%BZ MUPJ^(QRN5Q@`N%#*]@/8F`Q?INUO````__\#`%!+`P04``8`"````"$`_D][ M<R@#```P"0``&0```'AL+W=O<FMS:&5E=',O<VAE970T."YX;6R4EEMOFS`4 MQ]\G[3M8O!<PX1*B)%5+U:W2)DW3+L\.F&`5,+*=IOWV.[93;JVZY"4)/G__ M^9WCR\GZ^KFIT1,5DO%VXV#7=Q!M<UZP=K]Q?O^ZOUHZ2"K2%J3F+=TX+U0Z MU]O/G]9'+AYE1:E"X-#*C5,IU:T\3^85;8AT>4=;B)1<-$3!H]A[LA.4%&92 M4WN![\=>0UCK6(>5.,>#ER7+Z1W/#PUME341M"8*^&7%.OGJUN3GV#5$/!ZZ MJYPW'5CL6,W4BS%U4).O'O8M%V170][/."3YJ[=Y>&/?L%QPR4OE@IUG0=_F MG'JI!T[;=<$@`UUV)&BY<6[P*L.^XVW7ID!_&#W*T6\D*W[\(ECQC;44J@WK MI%=@Q_FCECX4>@@F>V]FWYL5^"%004MRJ-5/?OQ*V;Y2L-P19*036Q4O=U3F M4%&P<8-(.^6\!@#X1`W36P,J0I[-]Y$5JMHXB]B-$G^!08YV5*I[IBT=E!^D MXLU?*\(G*VL2G$P60'^*!VZPC'`4_]_%LT0FP3NBR'8M^!'!KH%WRH[H/8A7 MX*PS6T!]WL\,4M)S;O0D,Q74$I;C:;L,@[7W!"7,3YI;JTD=U&L64T7VC@+W M$@_X>DA(_7)(/6D*N?![>Y/'K96DILPZL6PT,`&`RHP!/JZ.%D,5QYE'\^I8 M33B\>30P>7-XR9NU>.-`$D/-HUG5;ZUF:58M369<V3@:IDG4%VP"!9OV_')H M\1PJ['WM0EA-:*#"8-@%)IJ-HW&:]',G3/$E3%H\9QIRM4Q6$QNF((YGX6P< MQC$>,II0)9=0:?&<*NZSM5168RN5XCG4.)HDRW[NA$EWI=&1_W@S:_&<:5@! MRV0UE@GCV2'+QM%TV(T3)+@FSD?2XCG2D*I%LAJ+M,`SX&P<Q:,B3IB@H5P` M9=13JF4X9&NI3B)[^*+0GY=J$E\&H]-IR6R#LO=W0\6>9K2N)<KY03>?`+9J M/VH;XRU>P24'#6DVGD'#-.->'X!^U9$]_4[$GK42U;0$2]]-X/`)V_'L@^*= MN55W7$&G,C\K^&="X?KT71"7G*O7!]U3^_\ZVW\```#__P,`4$L#!!0`!@`( M````(0`;SYI)$P\``")?```9````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`1ZM^S M[R->BVFK$:_%MM6(>5Q;3:]\Q;ZM1LP3=C7-BJJWS'[SU!NVV#SMJV>W%9KJ M9BOL>C.)4$^^;\6X+][FE#7B#50M%9WR/2J6C,0LNJUD5$YC6-,3W\FR9-P? MEM.XMAKQK7Q;S;B<)[35/.YKB@U5'R.*#;5;1\<W6#.J7F_Y]AD\[+_!=O^> MQ)K^?J-.)502E`0MP4BP$IP$+R%D4+2B+UIQO`5-]:?;NM/[770H-M4DEF0= MB##<'F=ZX^'@<=03FZXJ2AZ&X\ZP*]:<DM-J">;T)%:.<1*\A)#/^MCK/G1& MA_VW:&1]OBGVJ>.-;*K+1M9G*+$OQ9JLDQ'&\8A=%E>R6$48;8O[=X/!8_[K M\!ZVNZV6HXT$*\%)\!)"A).OH.AB?=Z]H(M-M>RB.`5-8DUL6J_;>6A^E;V; MYB7]\>.H*2I+JKQDU!]P$I57]'O#T0B3Z%ARV*!&@I7@)'@)(8.BDZ.+.ME4 MRTZ*<\(DUAQ>_C1"7-F/X]X0[[C**WKC09WJ16/5;M(FA8BOZ=W7=F=((\%* M<!*\A)!!T:_F4B;/5L?7;U,M^R4.69-8D_4K0NQ7YW'0&Z,=55Y2'VP>4:'R MBGZG;3>3W]=(L!*<!"\A9%"TK4Z1%[2MJ2[;5E\CE$MM$FNRMDFH)"@)6H*1 M8"4X"5Y"R*!H0:=.X$4/SHL3VV&G\D0JRKH!J2`*HB$&8B$.XB$AE[(M34P^ M?T4UUS-BWQ@/1/R=I**\'7'802K4*(A.DI;B]G`NCTP&HRS$03PDY%(VJ$FL M%S0H!MRCX:L3:P[=F$(JB(+H)*D__8=^?4HLEZG!(`MQ$`\)N93M:2+K!>V) M"3=O#R-5)XO!V^0SA500!=%)8K89W75$Z#`882$.XB$AE[(Y32Z]H#DQQI;- M$2]ZTI'A=PJI(`JBDZ2=ISZ#-;_DWB._E\4\#N(A(9>R04WZO*!!,:R6#1(I M>=+<$:L/4?GJBA+?ZB@>1\IW6F&0@FB(@5B(@WA(R*7L3Y,;+^A/C)EE?^29 MNY-ET;2Z=M(2[ZI4GO:34;?'_43MIVR90.^_N`^(<LJ67<]BE(-X2,BE;&03 M*"]H9,R?92-E<NQD(34U,DKLU;918D55&*,@&F(@%N(@'A)R*=O3!,>\/6>& MHY@WRS;)6PV=+)2F-D5);4KG=71*#E.82$,,Q$(<Q$-"+F6GFGQY1:=B+"T[ M)6ZP3#I9=DV=VDG+PJI0KB`:8B`6XB`>$G(I.M2]+FAOAY57'>/!X<[@MA^3 M5)0=VR$51$$TQ$`LQ$$\).12MD4&[?.66#<FYSH1[6_FC7$_,Q7E;4'@1HV" M:(B!6(B#>$C(I6Q+O22*]73\BK[;E)=[26<HUU$JRML1A\4C3K<U`6"0@FB( M@5B(@WA(R*7LSV7YNLM\/7J0MRQ34=X?F;@KU"B(AAB(A3B(AX1<RG;(1'WF M*HI!]L0JDFEWVI52011$0PS$0AS$0T(N95LNR]'-CUC%*AH/Q0EXDHKRO40F MZPHU"J(A!F*3I)#9W**L?Y41W6&4AX1<R@;)('WF?M,2J(=83KOXO`NXTZZ4 M"J(@&F(@-LGN0-9V)',8Y2$AE[)1EP7E;DM0'LI+UE24[TDR.E>H41`-,1"[ ME^Q\.1270&Y?M-MB'A)R*3O4!-,\`9XX8\4<6R2_H;R4Z,JP.TV25D2O^3F% M7!$51BF(AAB(A3B(AX1<R@;)B'RB02W1>"AO*79W07BWQ:9)TDK8MD<<,2H, M4A`-,1`+<1`/";D4_6D^"U+L0.<=B[;#RN@S'LJ;'ZDH6VJ0"J(@&F(@%N(@ M'A)R*=MR74#NG1.04U'>%@1DU"B(AAB(A3B(AX1<RK9<%I![YP3D5)2WHPC( MK;<N,$A!-,1`+,1!/"3D4O9'!N0S5Q.#\AB?DNC)6#R%5!`%T1`#L1`'\9"0 M2]F6ZX)R[YR@G(KRW0=!&34*HB$&8B$.XB$AE[(MEP7E7EM0EI>;J2AO1QP6 MSTWCYL?#.'=CD()HB(%8B(-X2,BE[,]U.;G7EI/ES9M4E/<).1DU"J(A!F(A M#N(A(9>R+3(5GWF0B3'W^&5G3V;A*:2"*(B&&(B%.(B'A%S*MEP6A7MM41BK M"5$X#8NK:=AVR5.EDL.NI2`:8B`6XB`>$G(I^R.3\)F[34LB'HEP.^DA$4,J MB()HB(%8B(-X2,BE:$O_N@"\'7;JHQBIZ+`G3"$51$$TQ$`LQ$$\).12MD4& MX./73?V88/,+2P285)-W(X[:73;U'^J/<98W6BH,4A`-,1`+<1`/";F4[;DL M"/<9A/E)@U24]R<.VWT>,IZ[X]5E_;NX;J\P7D$TQ$`LQ$$\).12MDIFXA-[ M4DL6'LB;.'UDX21Q5XH?V43,P2@%T1`#L1`'\9"02]D@F8Y/-"C&VWRIC0=B MV4SZ,@-/D\0&/;9]J+7"(`71$`.Q$`?QD)!+V9_+8G*?,9D_E4E%^5K+8W)O M^\E4[D"QYC!*81X-,1`+<1`/";F4#9(Y^<0.U):/Y1F]+]/P-$G<@>)%.1LD M1RG,HR$&8B$.XB$AE[)!UR7F?@S#Q4K##?=4=-@GII`*HB`:8B`6XI+LSJ#Q MW%">0CU&A5S*1EV6H?MM&1K':F3H-.S0L@JB(!IB(!;B]G+D%KS?%^UNZ(9< MR@[)%'UBK;6D9]QP[R,][Z7MHQ;[+^Y>K8)HB(%8B(-X2,BEZ,R@+4@WQZSC M'=H.$W>21_*G6JGHL,=,(15$033$0"S$03PDY%*V10;I\RZ[!C$:'[]:3T5Y M6^*P@U2H41`-,1`+<1`/";F4;6FB[?D_N!K$))P?BGE23T6'-S]-DD+/]NA8 M'APKC%$0#3$0"W$0#PFYE.V1H;G9:\Y83"WA>20/R`.$9T@%41`-,1`+<1`/ M";F4;9%1^<S%%-/PB<6$R#R04D$41$,,Q$(<Q$-"+F5;FEQZP6**,?;$8I)9 M=SJ(<C0`IIK#$E00#3$0"W$0#PFYE`V2"?G,Y=22E.7_>YX,9.:=0BJ(@FB( M@5B(@WA(R*5LRW6Y>!!S\8GE%(L.>\(T#3M(!5$0#3$0"W$0#PFYE&VY+`4/ MVE*PO)Y*18<W/X54$`71$`.Q$`?Q28XMYI"/*ALD0_"9A^&6,#P2=[$F`X1A M2`51$`TQ$`MQ$)\D-JJ3/A]>AHB0CRH:-6S+Q,V'#HYGXNTPF8GEIU!24;9' M02J(@FB(@5B(@WA(R*5LRW69>'A.)DY%>5N0B5&C(!IB(!;B(!X2<BG;(C/Q M><MJR&P\SAXY$#^LGHKRML1AY1%`'+8J#%,0#3$0"W$0#PFYE)UJ(FP>>,X[ MGP]C\LV#SW@D_XM(*LH[%8<=I$*-@FB(@5B(@WA(R*5LRW7Q>'A./$Y%AR9, M(15$033$0"S$03PDY%*V1<;C,]<58_(8M_^&B,F0"J(@&F(@%N*2Q#6</JDL M;\IZ#`NYE)UJR\EGG*_:<K+\6?H0.1E2011$0PS$0AS$0T(N95NNR\G#<W)R M*LK7E4S.%6H41$,,Q$(<Q$-"+F5;+LO)PY:</!"?AIZDHKP=<5C<QQ^;!V#( M/;S"(`71$`.Q$`?QD)!+V9_K8O*P+2;+SR^EHKQ/,CA7J%$0#3$0"W$0#PFY M%&T971>*M\-.?>(B%65M@500!=$0`[$0!_&0D$O9ENM"\2BFVR+3#.2Q-Q7E M;8G#TF5-_$2_#'\8I2`:8B`6XB`>$G(I&]4$5QG^FFN-XQ=5HYAWBT:-Q5N> MI**\47'802K4*(B&&(B%.(B'A%S*MK1EXM/G[E$,M_7O1_Y/9RHZ-&$*J2`* MHB$&8B$.XB$AE[(MUV7B4<S$Q=Z"\)>*\K;$80>I4*,@&F(@%N*2I!-CZYT) MCU$AE[)1;2GYC&75DI+'\N=W(Z1D2`51$`TQ$`MQ$`\)N91MN2X2CV+:/;&L M$(G3L'S_D34*-1IB(!;B(!X2<BG;<ETD'L5L>V)9R0`\3</RML@:A1H-,1`+ M<4GBLFH>/[?]5=[Q\Q@6<BD[)5-R<_5YQKIJ2<MC^:.\42PZ]&4*J2`*HB$& M8B$.XB$AE[(MUX7C44RY)]:5C,+3-.S0J`JB(!IB(!;B(!X2<BG:4C^RF^'F M]%E\.TS<,<;I*A4=FC"%5!`%T1`#L1"7)#Y6<_<)39&_/(8USS#?/T$I=BH^ MDCP^Y?IUOOHVG\Y?7M8W3\L?S>/&N_7C2_>Z?Q3Z+]WF^;K"IYT/:OL\\?O] M%^HGE+_/OLW_/EM]6[RM;U[F7^LI'^Z:L\,J/N,\_F.S?-\^6_O+<E,_FWS[ MU^_UL^CG]0.K'^[JXJ_+Y6;WC_H;W^^?;O_Y?P```/__`P!02P,$%``&``@` M```A`,+TZ.]E!0``^!4``!D```!X;"]W;W)K<VAE971S+W-H965T-3`N>&UL MG%C;CJ-&$'V/E']`O*]Q<S'8LKU:&R99*9&B*)=G!K=M-(:V@!G/_GVJ*<Q4 M-;Y-7G;6U:?*YU07?7#/O[X7!^M-5G6NRH4M1F/;DF6F-GFY6]A___7T);*M MNDG+37I0I5S8/V1M?UW^_-/\I*J7>B]E8T&%LE[8^Z8YSARGSO:R2.N1.LH2 M5K:J*M(&/E8[ISY6,MVT2<7!<<?CB5.D>6ECA5GU2`VUW>:9C%7V6LBRP2*5 M/*0-\*_W^;$^5RNR1\H5:?7R>OR2J>(()9[S0][\:(O:5I'-ON]*5:7/!]#] M+OPT.]=N/PS*%WE6J5IMFQ&4<Y#H4//4F3I0:3G?Y*!`M]VJY'9A?Q.SQ`UL M9SEO&_1/+D\U^;]5[]7IERK?_):7$KH-^Z1WX%FI%PW]OM$A2'8&V4_M#OQ1 M61NY35\/S9_J]*O,=_L&MCL`15K8;/,CEG4&'84R(Z21J0,0@'^M(M>C`1U) MW]N_IWS3[!>V-QD%X=@3`+>>9=T\Y;JD;66O=:.*?Q$D-*F^B-L5@;]=$1&, M?#<(H\]4\;HJ\+WG*N[(C0(13.YS<5!7VZ8X;=+EO%(G"V8/F-?'5$^RF$'E M<W]03=^Q:PT#D;K(-UVEK06]J&&7WY91Y,V=-]B9K,.LAIC0"SAFC9BI;?5U M7(Z(SPC=7_W5"0DXH*D7!LTVA7DP/I<W_JQ#)W$=WI@36%V`"`Y97X!P1'P! M811)AI#PHZ-,*0S&YY7J)!AFTNDH,*4BQF]G6?=Z;09B,Y"0`./H<XZW=T&# M%S8TH)^",.0-7"&$4,-`U,[>-/(F'!_392\*C*E*Z/)'%Y@">#AHEV\KT&!# MP?AC]]K!72&&2#`#L1E(2(!QFW!N^B&^/^LZZ=X$((9P-`.Q&4A(@'$,.<?; M_=-@HW_F!"!DTFZX",%6^8ZO<=UOUXVUV,@UG_'D<BZ3HU\0C'/S?LMU$F^Y M%_J<]PHQI.5F(#8#"0DPCG".4HZW6Z[!O.5>:!S/*\00;AC`3?#=B=EGNNR. MQ91+3>BR+T@GF`H!I_;C,EJTJ<,X#58=B`CI(]J[3!FW%A.V^/&,<PG:I,BT MW-X)@99&SS]O<`!V("H!TW#BW3#BS8[[A`L*DRN+7(1VI,=%H'^!'_2'N&\^ MHRN!("K"C,0#3$(CG*%VG\<9HE?!%_8,AQ,OB*&UQ_:ZBUR=>;9^8>C9^HVI MUY;TN!8T,*YE,/4(HMT^1R[,1"QN+"9L\=K4:[LB$AZS)?UV;AQ$460>DAV( M2L&T;EL";S#^=%U,7=\\C+J270%!'C@^8]K?B*@[CS*Z(=V7<&R\Z:T$L<QN MQLQ(/,`D-,(9:O<B#!]L.WH>?5Z'WB3.QGA^^UX/(O$@DM`(9ZJ-Z_-,T>YH M3[VIL9LK03RQZRE&<']%,#8/HWB0DM`()ZZ=BQ"_,P3H<XSPP%H%@NA$4WN, MIIXA,>XR4)`'/P3Y@9_0BHR]^RE#;='W#+4#$?9=!-E-?/.-.V;KGAB\@M&* MG/VGO-1%4Z1C/;2A#D39G[WT/.CQ`)/0"&<(._WX=+@:;?;7V,M5!Z(,,0W[ M>V$ZNHRKTT$K<O;:\1Z>;1?]D<^V:3P=B++'M.O30=<O30>NMQ4Y>VU:A/UC MAY^+5L=4#(Z4#D158!JJ@%\@YGOC(".A$<[[?WFEOO<Q9F?HE1V(\L8T_+'L MN=[4<*2X2T'`Q!?&..H;._V]I/UX`8<W2X6L=G(M#X?:RM2KOEP3\"NLC^+% MWQHN_MI;,J=?@'NW8[J3OZ?5+B]KZR"WD#H>A?!E%=[<X8=&'=L[FF?5P(U; M^]\]W+!*N*$8CP"\5:HY?X#GU^GO;)?_`0``__\#`%!+`P04``8`"````"$` MDK.%V'L#```J"P``&0```'AL+W=O<FMS:&5E=',O<VAE970V,2YX;6R45EUO MFS`4?9^T_X#\7L`)"2$*J=I4W29MTC3MX]D!)[$*&-E.T_[[7=M`#;1I^A*" M.3X^]]S+Y:ZNG\K">Z1",EZE"/LA\FB5\9Q5^Q3]^7U_M4">5*3*2<$KFJ)G M*M'U^O.GU8F+!WF@5'G`4,D4'92JET$@LP,MB?1Y32MXLN.B)`INQ3Z0M:`D M-YO*(IB$X3PH":N095B*2SCX;L<R>L>S8TDK94D$+8@"_?+`:MFRE=DE="41 M#\?Z*N-E#11;5C#U;$B15V;+;_N*"[(M(.XG')&LY38W(_J298)+OE,^T`56 MZ#CF)$@"8%JO<@81:-L]07<INL'+#8Y0L%X9@_XR>I+.?T\>^.F+8/EW5E%P M&_*D,[#E_$%#O^5Z"38'H]WW)@,_A9?3'3D6ZA<_?:5L?U"0[AE$I`-;YL]W M5&;@*-#XDYEFRG@!`N#7*YDN#7"$/)GKB>7JD*+IW)_%X10#W-M2J>Z9ID1> M=I2*E_\L"#=4EF32D,"U(<%S/YK,XL5'6*8-"UQ;%B`\+R&PX1AW[H@BZY7@ M)P]*#@3+FN@"QDL@;&VQ071&O>43&*1);C1+BA+D@042DONXQF$8KX)'R$C6 M@&XM"'X[T*2/V+0(G4C0UXF$\%R1K^>LU:+!6HO.H19W:Q?<<Z>#<\>(191T MF)X4\,B5HOV:0C&>EZ0W`<Z)/)E&';]5:3'F#3`+&V>AIR#J*SA_L@:G".+K M/(?$+`9'6Y!SM%V8FT3&BR2*PQ>U/2U0^JX;Y[5H\$C+B\W6!@MRM#@+O:/G M_:,O2X3>]%XB+,91X"ST%,1]!>>#U^!1\,-$6)#U'6,<X?D`L;$((ZZG17^F MG-?XO!8-'FK!X:`H+"@V-9#X@S1M[-.Q#F@!E^O0X)$./-!A03.C(YJ`*?WG M&_M\K`3#6WFY%(,>:1GTI]L&Y=2&N])+"-:]S,G(9?5I=KU7H`W(56$;YRLF MZ,[FJ#A?%]CVP7>Z18.R53J;Q?-D,JS2!O**'MW4+M=C6V!?SZA0L4792IWY M8S%O-5(8-SXBYK56BH?5:CA3U)9K,@3H&4<7O6.-'5GL1[FD8D\WM"BDE_&C M'D<P%'ZWVHU*-Q,S['0/8%*IR9[^(&+/*ND5=`=;0S^&YBGLK&-O%*_-)W_+ M%<PHYN\!9E(*G\G0!_".<]7>Z(]P-^6N_P,``/__`P!02P,$%``&``@````A M`'8S1MT.!P``#A\``!D```!X;"]W;W)K<VAE971S+W-H965T-C(N>&ULG%G; M;N,V$'TOT'\0]!Y9I.Y!G,5*Q+8%6J`H>GE6;#D6UK8,2=GL_GV'',HB1XIO M>7`L\LSXS'`X1Q*?/GW?[YQO5=O5S6'I,L]WG>JP:M;UX77I_O/WEX?4=;J^ M/*S+77.HENZ/JG,_/?_\T]-[TW[MME75.^#AT"W=;=\?'Q>+;K6M]F7G-<?J M`#.;IMV7/5RVKXONV%;E6AGM=PON^_%B7]8'%ST\MM?X:#:;>E6)9O6VKPX] M.FFK7=D#_VY;'[O!VWYUC;M]V7Y].SZLFOT17+S4N[K_H9RZSG[U^-OKH6G+ MEQW$_9V%Y6KPK2XF[O?UJFVZ9M-[X&Z!1*<Q9XML`9Z>G]8U1"#3[K359NE^ M9H\BR-S%\Y-*T+]U]=X9WYUNV[S_TM;KW^M#!=F&=9(K\-(T7R7TM[4<`N/% MQ/J+6H$_6V==;<JW7?]7\_YK5;]N>UCN""*2@3VN?XBJ6T%&P8W'(^EIU>R` M`'PZ^UJ6!F2D_*[^O]?K?KMT@]B+$C]@`'=>JJ[_4DN7KK-ZZ_IF_Q^"F':% M3KAV`O^U$QY<;0Q(Q2`\&3/N\31B47R9P@+#4=D195\^/[7-NP,E!X2[8RD+ MF#V"YR$M&,0I41_E"1(DG7R67I0O2$$'B_OMF?DL>%I\@Q59:5".H,QU3B!N M(XH!(=,O_0IC8`&$3ZPA@91U`"4QOY@#26DT(1G:%/(IB(11S""8[41,(<GH MQ0H$%I4&$GY8E4,@T@CJST@D9#NR.>0("E7]R5P6=$`8`Q8G*`/*Z7)RI='2 MA<!/BPN<8L()0;$J$,YBEO+,1A0F(DW2A!,7P@1$:10F(\`*`I)X>Q#2:!)$ M8E/,$60D%@=T5+[ZLTV$B0A9',>C3XMT?`]I:30AG=H,<@0AQX<L#-.`U&QA M(9(LB>G:"`L10N?SQU^QPDCN"4,:3<(@Y9$C*%0%Y-LA%F?FQ#`G%<+L(U+= M2?>[7.K2B#+EA$V.($QX%F4IF2_,><:2(".-2)@`SOPL'7-AA0#]]/80I-$D M!%(1.8(P!,83/TS&]5;MN3`1L_M9F`BRGZTH&'3OV\-05I,XB*KD&J4W:!AF M04R:96%!6)+Y$1^WJ)8BR7#IZG3`BH8?E3^3JG5S52FK22RC;"@6N4;INIK; MQQ9B=A];B'/[F$D=NST05#];"C@I[USY'M+Y,+=#;,3L'K$A_,PN85+L;@\% M)9*$0HHG5[Z'4`*>)2E5K<*"\+D2%!:$EJ"]5Z0&DE@NWS0P5$X2RZB>NKX0 ME>`]7.31VXI"N]&`U,N(!V$!./.RL83M**0H&E&<OW>3M^K3CD7V:*Y1>J>S MT$\B4G>%AHSR+<P1FZ$4/(.AO#>^K`X,99+DF73.7*,PC:F7XFW#\$GB*BQT MY&6D`H4U'WML#-H.2,K@[0&A>)*`1C72A8,H3'W`DR0T!$M!"F:HL!H1YHC- M5*H?87I%B:-FVDP#HKPY0U2J2IQ4;Z$G<5TB+R!:(O2\*A^;L52ZVQFC/A+& M5(@9HI!4D'G)N+XZLR8`G@JC28$@`&-F8WE9(?"[-%A94=VB><LU2K<-[L4D ML84-F#8>80.LQF-'<9?Z<GS2)`LQMBXL<HW240#),9.X$!I@=!=SQ.8)OW5[ MP7!I-<DVJ8=<H\9L$T"A`29/=#PM;/F&@O*\W`65U80G*<M<HT!SC*?&@.[) M$^KT6L`<L9-ZES3R.6D,R-KF&D7(DL9>G%`C6?0^DUFB@%)?+C<Y^:YG6@&T M'6N4338DK;`XH4:RZ'V&+!'#\W+-YT0PI'U-H[`K\3@B&2_TO%FEZ'>&WEW2 MQN>D+22M*=>HX<X_(EVAT/,F34/I[/J\2]?XG*Z%A$:N44,V:1B%GC=IHM^9 M;$JY,,3LPF*CN-B]<Y)$!(V_7G`Z(LP1*VVRWYA\KMLIRNKR>S)\KC.(:;MQ M1)@C-K&[Q":8$YN0].A<H_!EQT.0T<VKY[$L'S@+,K)_Q,D#?>T1$.TYO[X* M;??R)*$-1X/&I!63$6&.V&F<T9C+G3#`IS/X--2#/K#D&F420[MQ1)@8FYCL MW<9&N.X1(,".;V^(D(J?1NGU"X/(GZPP^AD0\.*0=%"A?:A0;.(SVB*K^,)* MSVE+2/0X#Q"E^R$\LY`7<=9\F&6D5(0U'Z>)/_8*.P8B.5<F?TYZ&)'I/!B$ M1)Y53`(X,RE.EI--=9<$!;,21'9RKE'S+S[/38H/)NU$WZ5*P:PJ31*-*%2E M2:+/3`KM?Z:VB3I=J09S*A62VLSA"%+>77U`]\RD/+R<L\1$X[$D'KSMJ_:U M*JK=KG-6S9L\<F3P*'H:Q>/0'(Y#U=GAXC0!IY''\K7ZHVQ?ZT/G[*H-F/I> M`KNQQ?-,O.B;HSKE>FEZ.(=47[=P[ES!&9#O`7C3-/UP(6OX=)+]_#\```#_ M_P,`4$L#!!0`!@`(````(0`P#%*KZ@,``'`-```9````>&PO=V]R:W-H965T M<R]S:&5E=#8S+GAM;)Q7VVZC2!!]'VG_`?$>H,'<+-NC8)2=D6:EU6HOSQBW M;12@$8WCY.^GBL*7;LPDV9?$[CIU.*>ZFBXOOKY6I?'"6UF(>FDRRS$-7N=B M6]3[I?G/WT\/D6G(+JNW62EJOC3?N#2_KG[[LCB)]ED>..\,8*CETCQT73.W M;9D?>)5)2S2\ALA.M%76P==V;\NFY=FV3ZI*VW6<P*ZRHC:)8=Y^A$/L=D7. M4Y$?*UYW1-+R,NM`OSP4C3RS5?E'Z*JL?3XV#[FH&J#8%&71O?6DIE'E\^_[ M6K39I@3?KVR6Y6?N_LN(OBKR5DBQZRR@LTGHV'-LQS8PK1;;`AQ@V8V6[Y;F M(YNG;&;:JT5?H'\+?I(WGPUY$*??VV+[HZ@Y5!OV"7=@(\0S0K]O<0F2[5'V M4[\#?[;&EN^R8]G])4[?>+$_=+#=/CA"8_/M6\IE#A4%&LOUD2D7)0B`OT95 M8&M`1;+7_O^IV':'I>D%EA\Z'@.XL>&R>RJ0TC3RH^Q$]1^!V$!%).Y`,@/U M0]RUW,AG?O`^BTV*>H-IUF6K12M.!G0-/%,V&?8@FP,S.O.@/J3CXG7**GA$ MDD=D69JQ:4"ZA/UY63''=Q;V"Q0U'T#)&.2JB/49@15$WO1FP0;!%]50BUO5 M]_?A+`[!*.[,FM`"<%_4>IJ0.PBF0M(Q)+RR*&*]SXA%\-($\HLVJ*3V[(1` M?</W=5KK"^G-@J(%MOBV<+C=L\E&/A<0DZ`M%$W,5^N1$.A&D[Z0WBPHFN#Y MNB9LP5]O*B:-ZJ3U4T*@H&_(&0N"ZP91V6[C+@NB.%)-I;<`GX6^=W6M6`C^ MCP5,&EG0)"8$&BQXOJ,=JK42!XM:JZ04[[=%41R.%;_?")@T4CQ3:Y80*.R+ M'EO!M6)4<PI'?3A04U.*C<7B/7KG)?7K#L&DD5A-34(@*N^#ZT2>5O^U"F`L MBD--M(KP6#S5)/!Z_+P+3!JYT.J6$&APP9Q1DRCQ61S'F@4E'D2A<SU(2M,P M.):ZA?>[IL\:>=#*F`PH,A%XGJ=WN@*X<YI3!:`=9]4&7BM:/WW`!EU&VJM9 M>V,DC%!W^WL]!.EL!%:H):?3<54_WCV?UT\WEJ9?:X6$$6I"/P6G]4_&5?UX M.WU>/]UIJOY`ZY*$$6I"/P6G]4_&5?UXDVGZ@W=O+!A0QT=9?U\G`XHD1I9^ M]:^'^%U_.`/C(^[X(_TTX-+\5_%VS]>\+*61BR,.KRZ\DR^KE\'ZT<7!25M/ M<.#&=?L2@'FWR?;\CZS=%[4T2KX#2L<*X0IM:6*F+YUH^JES(SJ8=/N/!_AE MPV'<<RP`[X3HSE_P`9??2JN?````__\#`%!+`P04``8`"````"$`R6V_LM`" M``!Z!P``&0```'AL+W=O<FMS:&5E=',O<VAE970W,RYX;6R45=MNHS`0?5]I M_\'R>S$D@5P44C5!W:VTE5:KO3P[QH!5P,AVFO;O=XP3"J3M=E\2\)PYG#,S M#.OKIZI$CUQI(>L8!YZ/$:^93$6=Q_C7S]NK!4;:T#JEI:QYC)^YQM>;SY_6 M1ZD>=,&Y0<!0ZQ@7QC0K0C0K>$6U)QM>0R23JJ(&;E5.=*,X3=NDJB03WX]( M146-'<-*?81#9IE@/)'L4/':.!+%2VI`ORY$H\]L%?L(7475PZ&Y8K)J@&(O M2F&>6U*,*K:ZRVNIZ+X$WT_!C+(S=WMS05\)IJ26F?&`CCBAEYZ79$F`:;-. M!3BP94>*9S&^"59)A,EFW=;GM^!'W;M&NI#'+TJDWT3-H=C0)MN`O90/%GJ7 MVB-()A?9MVT#OBN4\HP>2O-#'K]RD1<&NAV"(>MKE3XG7#,H*-!XD]`R,5F" M`/A%E;"3`06A3^W_4:2FB/$T\L*Y/PT`CO9<FUMA*3%B!VUD]<>!@A.5(YF< M2&:@_A2?>)-%&(31OUF(4]0:3*BAF[621P1#`\_4#;4C&*R`^>S,Z>B\OF45 M/%J2&\O2<H$+#>UYW`2!/UF31R@J.X&V#K3$J`.-$+LSPE;0\B:]`P*".]50 MB['J*73U]7Z<1=JDH<BI/Y+X"F2(V+V""(:0Y!(RGW:0@8WIT,;[\BT8!J=7 MOB@</7KK,+-V;FP!=^.#I'<PD`*][U?T?2D6'&/PV74R"F>=Q;9U6X=9N&'P M%\/HKA]=CH))/[A8=ID#O?#>?%RO!8_UAAVOT^LPLU;O:"QV_=C\19";T7[P MZF6B!VJC_U%KP6.UT4BMP[Q5W4%T/A_FPJ*T_"YW\1)T@MT.="NBXBKG.UZ6 M&C%YL/LM@/)TIV[U;F'UMHN*=`%8?0W-^3U5N:@U*GD&J;XWATHIMSS=C9%- M^S[NI8&EUUX6\(WC,+B^!^!,2G.^L>NY^VIN_@(``/__`P!02P,$%``&``@` M```A`%66**?8!```BA(``!D```!X;"]W;W)K<VAE971S+W-H965T-S0N>&UL MG%A=DZHX$'W?JOT/%._*-U%+O745\7.KMK;VXYG!J-0`L8`99_[][1"%I&'O MS-QY&/2<DS;=IY,`TV]O6:J]TJ),6#[3K:&I:S2/V3')SS/]G[_#P4C7RBK* MCU'*<CK3WVFI?YO__MOTQHKG\D)II4&$O)SIEZJZ3@RCC"\TB\HAN](<F!,K MLJB"K\79**\%C8[UH"PU;-/TC2Q*<EU$F!2?B<%.IR2F`8M?,II7(DA!TZB" M^9>7Y%H^HF7Q9\)E4?'\<AW$++M"B*<D3:KW.JBN9?%D>\Y9$3VED/>;Y4;Q M(W;]I1,^2^*"E>Q4#2&<(2;:S7ELC`V(-)\>$\B`EUTKZ&FF?[<FA[%NS*=U M??Y-Z*V4/FOEA=W617(\)#F%8H--W(`GQIZY='OD$`PV.J/#VH`_"^U(3]%+ M6OW%;AN:G"\5N.U!0CROR?$]H&4,!84P0]OCD6*6P@3@OY8EO#.@(-%;?;TE MQ^HRTQU_Z!'3L4"N/=&R"A,>4M?BE[)BV7]"9-U#B2#V/8@#L[_S]M`>>9;G M?R&*>X\"UR;*IZ<`DZWS@&LS^,MY^/<@1`[RY3Q@9=53@6LSE4_G,;X/AFLS M^,MY6-!&PE5PI@WSV4P,T2-URP51%<VG!;MIL(RA"\IKQ#<%:V)!Z$>SB=9H MVN__N@_:CD?YSL/4P:"Q2E@QKW/+,IVI\0I]'M]%"R&",C0BXGBJ9OG0\+;F MD0,,K#`08F"-@0T&MAC8/8!V:K8ZL?U#\9C800(,*&9342ABIZ(.N->_?!\% MY*/4`A(T@T57@@J\["J(,U;S"+H:9,&JJR"NJ48)NQK'4B7KKH2X2+/IT3A$ MC;/MT;BH-+NN!I5FWZ-`DSET):2-HE@,F^(O6,Q'P5XLM;_OH[HNA,:MMV+> M_DL,!!A882#$P!H#&PQL,;##P!X#!PE0:@-;O5*;G[<]5\]TJ'R[):"&70C) MJ-Y4;(MX([4_EC(_=BW4S8%,$S)"HU<*/2;HQT.9MEW'1?Q:YEW71_1&IBW3 M1/16ID<VZL>=8-M>V&/@(`&*!W!B?L$#KE8]\'U4IH70^+4)(]=MUT6]22]E M>N"-"4HE4/B10US5PY7*$Q?QH<S[7F>KD>D!W.5@ES>JP#/Q1K15!;9O(:MV MJL#U75]-8:\('(=8:!\[*`+7=$B[]A7SX(Y%,8^?R!^?'WP4,K%S@`B-6$D] M)LITGXD*WV.BRG=-E/D>$V6ZUT15T&.B*N@Q417TF*@(^DQ4!*[ED]9EQ42X MW?P%$_DHU42XBT)K82%$[;:PQ$"`@14&0@&0>CG#4P0Z3M<R/3"'>+EO$.^1 ML?*'EL86R]'NL1-\F]$>`P<)4,K,GWCQW:L+"^WGAPX?U2DS.C<60M24",UY M*=-0(@OE'"#>1N-7F&_[J-Y10\&W-5EC8(.!+09V&-ACX"`!2EWA'KU3UX_W M(#ZJ4U=4F(40M8DM,1!@8(6!4`"--^BT6<MT7_LB_J/VQ7)DY4[P;49[#,#+ M`EZ86B'*+)[]Q8-81HLS7=(T+;68O?#G>AO698.*5PX+:P(/+?#L@?`=O(JH M<:,AX%7`-3K3/Z+BG.2EEM(3A#2'!)9%(5XFB"\5N]8/'$^L@I<`]<<+O/.A M<-=I#D%\8JQZ?($?-IJW2/,?````__\#`%!+`P04``8`"````"$`^V*E;90& M``"G&P``$P```'AL+W1H96UE+W1H96UE,2YX;6SL64]OVS84OP_8=R!T;VTG MMAL'=8K8L9NM31O$;H<>:9F66%.B0-))?1O:XX`!P[IAEP&[[3!L*]`"NW2? M)EN'K0/Z%?9(2K(8RTO2!AO6U8=$(G]\_]_C(W7UVH.(H4,B).5QVZM=KGJ( MQ#X?TSAH>W>&_4L;'I(*QV/,>$S:WIQ([]K6^^]=Q9LJ)!%!L#Z6F[CMA4HE MFY6*]&$8R\L\(3',3;B(L()7$53&`A\!W8A5UJK59B7"-/90C",@>WLRH3Y! M0TW2V\J(]QB\QDKJ`9^)@29-G!4&.Y[6-$+.99<)=(A9VP,^8WXT)`^4AQB6 M"B;:7M7\O,K6U0K>3!<QM6)M85W?_-)UZ8+Q=,WP%,$H9UKKUUM7=G+Z!L#4 M,J[7ZW5[M9R>`6#?!TVM+$6:]?Y&K9/1+(#LXS+M;K51K;OX`OWU)9E;G4ZG MT4IEL40-R#[6E_`;U69]>\W!&Y#%-Y;P]<YVM]MT\`9D\<TE?/]*JUEW\084 M,AI/E]#:H?U^2CV'3#C;+85O`'RCFL(7*(B&/+HTBPF/U:I8B_!]+OH`T$"& M%8V1FB=D@GV(XBZ.1H)BS0!O$ER8L4.^7!K2O)#T!4U4V_LPP9`1"WJOGG__ MZOE3].KYD^.'SXX?_G3\Z-'QPQ\M+6?A+HZ#XL*7WW[VY]<?HS^>?O/R\1?E M>%G$__K#)[_\_'DY$#)H(=&++Y_\]NS)BZ\^_?V[QR7P;8%'1?B01D2B6^0( M'?`(=#.&<24G(W&^%<,04V<%#H%V">F>"AW@K3EF9;@.<8UW5T#Q*`->G]UW M9!V$8J9H"><;8>0`]SAG'2Y*#7!#\RI8>#B+@W+F8E;$'6!\6,:[BV/'M;U9 M`E4S"TK']MV0.&+N,QPK')"8**3G^)20$NWN4>K8=8_Z@DL^4>@>11U,2TTR MI",GD!:+=FD$?IF7Z0RN=FRS=Q=U."O3>H<<NDA(",Q*A!\2YICQ.IXI')61 M'.*(%0U^$ZNP3,C!7/A%7$\J\'1`&$>],9&R;,UM`?H6G'X#0[TJ=?L>FT<N M4B@Z+:-Y$W->1.[P:3?$45*&'=`X+&(_D%,(48SVN2J#[W$W0_0[^`''*]U] MEQ+'W:<7@CLT<$1:!(B>F8D27UXGW(G?P9Q-,#%5!DJZ4ZDC&O]=V684ZK;E M\*YLM[UMV,3*DF?W1+%>A?L/EN@=/(OW"63%\A;UKD*_J]#>6U^A5^7RQ=?E M12F&*JT;$MMKF\X[6MEX3RAC`S5GY*8TO;>$#6C<AT&]SAPZ27X02T)XU)D, M#!Q<(+!9@P17'U$5#D*<0-]>\S210*:D`XD2+N&\:(9+:6L\]/[*GC8;^AQB M*X?$:H^/[?"Z'LZ.&SD9(U5@SK09HW5-X*S,UJ^D1$&WUV%6TT*=F5O-B&:* MHL,M5UF;V)S+P>2Y:C"86Q,Z&P3]$%BY"<=^S1K..YB1L;:[]5'F%N.%BW21 M#/&8I#[2>B_[J&:<E,7*DB):#QL,^NQXBM4*W%J:[!MP.XN3BNSJ*]AEWGL3 M+V41O/`24#N9CBPN)B>+T5';:S76&A[R<=+V)G!4AL<H`:]+W4QB%L!]DZ^$ M#?M3D]ED^<*;K4PQ-PEJ</MA[;ZDL%,'$B'5#I:A#0TSE88`BS4G*_]:`\QZ M40J45*.S2;&^`<'PKTD!=G1=2R83XJNBLPLCVG;V-2VE?*:(&(3C(S1B,W&` MP?TZ5$&?,95PXV$J@GZ!ZSEM;3/E%N<TZ8J78@9GQS%+0IR66YVB629;N"E( MN0SFK2`>Z%8JNU'N_*J8E+\@58IA_#]31>\G<`6Q/M8>\.%V6&"D,Z7M<:%" M#E4H":G?%]`XF-H!T0)7O#`-005WU.:_((?ZO\TY2\.D-9PDU0$-D*"P'ZE0 M$+(/9<E$WRG$:NG>94FRE)")J(*X,K%BC\@A84-=`YMZ;_=0"*%NJDE:!@SN M9/RY[VD&C0+=Y!3SS:ED^=YK<^"?[GQL,H-2;ATV#4UF_US$O#U8[*IVO5F> M[;U%1?3$HLVJ9UD!S`I;02M-^]<4X9Q;K:U82QJO-3+AP(O+&L-@WA`E<)&$ M]!_8_ZCPF?W@H3?4(3^`VHK@^X4F!F$#47W)-AY(%T@[.(+&R0[:8-*DK&G3 MUDE;+=NL+[C3S?F>,+:6["S^/J>Q\^;,9>?DXD4:.[6P8VL[MM+4X-F3*0I# MD^P@8QQCOI05/V;QT7UP]`Y\-I@Q)4TPP:<J@:&''I@\@.2W',W2K;\```#_ M_P,`4$L#!!0`!@`(````(0"J?/YDH`L```9G```-````>&PO<W1Y;&5S+GAM M;-1=>V_CQA'_OT"^`\%KBP2(+8FB+,FQ')QDLSG@Z@0Y!RW0%`4E439K/E22 MNK-3]+MW9OF:E41R::VT3H2<)4H[\YOW[G!)7GW_['O:9R>*W3"8Z+WSKJXY MP2)<NL'#1/_EWCH;Z5J<V,'2]L+`F>@O3JQ_?_W5'Z[BY,5S/CTZ3J(!B2"> MZ(])LK[L=.+%H^/;\7FX=@+X9A5&OIW`Q^BA$Z\CQU[&.,CW.D:W>]'Q;3?0 M4PJ7_D*$B&]'3YOUV2+TUW;BSEW/35X8+5WS%Y<?'H(PLN<>0'WNF?8BI\T^ M[)#WW444QN$J.0=RG7"U<A?.+LIQ9]P!2M=7P<:W_"36%N$F2":Z41S2TF\^ M+"?ZA:ZE(L_")8#X\W\V8?+='],_[[Y]]Z[[KV^^^\?/SO*?OWZ]^]VOW^B= MG`VA"3:HIWG>K24+7Z>4.YD$UU>K,"""#$%-J*W+IR#\$ECX'3@#B(<_N[Z* M?],^VQX<Z2&\1>B%D9:`E4$^=B2P?2?]Q<SVW'GDXL]6MN]Z+^EA`P\PQ\A^ MY[M@)CS823F<EL\<T>0RC1`&)U,?CU"9?!#)QH/U,MG_WB,3QVO0S.L0_7&\ MF!3U<DGCM>L7.SH\A%=A*\(G>IA/=,N"'-+K=E&MU&!'8C:>=8'?R9A=#$XF M6=_J6T.IDG&^N&LW9-BW9*JR@:'U?GAS,G7*9U8E79:&3Q4!&'!RM>A"Z-;$ M]]#"URG\Y,0%[3@68U2YI,]"K\R-]Z[OQ-J=\T7[.?3M`!5+BQK[-5>3.<<[ M#GG.!>2S.#+YPGE-5&:=[N5,CL:G83,\WYVL;/G28?)0QQ)@UMIQ"[L<2U\L M3&*(']?SBC5!W\19,QRYOH+E2>)$@04?M.S]_<L:YLP!K*005"?]7<.O'R+[ MI6<P8X@-B$//72**AQF;J6<SI=G%K36[97P),E$4%40M:S8\`M';Z7@F'^EL MS&*G(U%\PX*79*3O!_B23-2"_V;2=)K52I;Q9*BSH*<E+JZLN^?#\7@\ZEV, M1J.QV>^9)E/R//-H-U@ZSPXNMJ6I:1?!`!",^Z/QA0%`NN:(L3HI@CX`&`X& MHT%O;)CP/TN_QT<@6Z<#7;55"0)%5B4(%%F5+>XDQBKTN13'*D&@R*H$@2*K M#F65B2S_02-0L54)`D56)0@4696U)"7&*O2/%5N5(%!D58)`D56E33ZS6!TK MMRI!H,BJ!,&IK9HOJV:WMQ9K4.W.S*KGQVPE!VO'>1@MX>1;?D:IAZO']-CU ME>>L$E@E1N[#(_Y-PC7\.P^3!$Y575\M7?LA#&P/WG;R$?G?FI%P,@_.VTWT MY-%=/`$SKE^1XDU9'(M#D8E,G.&;0[,[-`?&1;J(DL3:=Y;NQM^5KN"]UU=` MC:C;9L&)#H."2>8.9;^R@U;(S"<X@IF:65IP`/A$[A*"(V3(6/;N164D(\1D M)`,$920C1&6$T-D77+DFE^$&SB-O&]BR1MUNVB85Y5-/D`#?XS'[09`QN_IL M'+)'HXUCVLH*^64G-J8&OMB,=8^D#2-VY6P8L$?*AA&B,O)^DUN7(UZT$S`] M[T&RI6_NYZ^#`8S2@3F>K228Y2<\?9.>P!%.=_O%;21/I`8*[<I5+L.6FG9E MD,&DC20YL,8Q=4;,ZC64_X7C>9^P(/]]5<P!H-5U??6\(ML_8$\.[H_`W27X M%OK)V=NTWJ<?0,=5@XS*09J]7GLO=QM_[D06VZC#6+"CV+<N/TW91*7\_-YS M'P+?8<TZ/27S4Q0FSB)A&XG869PJ//T*/+V,D`B>0_B;%?Q!3\+Z.(0_-(/V M&A'THI0_.)<P?YG^@%NF,J<&$U"GKL,C$P$L^7,$8`05"'"+5Z8#<$\5"&`I ME2,`!RT1`)P:KS@D#GHDFX$/E"R!_[%80H[)I>18'E'*JO0+_&NDM+CT>Y": M2;X%1R_5#!]J`!S$LBK%JDHQQ.P0::4*X$.-"BRHNG)*7J\JYRM3"$FZ@*'4 M"*2!.HW(\TJ2<X%G":!>(U.)\Q#B%)B*5$,`.$H@$$/T%-7?'L6@J`)3;U!4 M@BD$K@:?,":H);@*J0@#X%$2%>4\H<=5C!.J@4!0E2&)-QBJ4B3%H"I'EJ8P M5*5(`D%5AJ264)4B*095.9*80E6*)!!`(THR)+6$JA1),:C*D:4I^JI2)(&@ M*D,22_2/G"([M&V:-E%)_W0P?E7_5'M>-392>U6+)K![/CQ=/:4K1[`%6TN1 MI31>5&?GO5/M,8S<WV"1B1?7+:"9ZD0Z7HR9N`MZY$MDK^^=9UB*IN>=GE?5 MO5Y`DO<WMIV11UB)J>0/S75=:\-<NGX.P'*X(AHE9XOZQL;\EF?PS>U&#VD$ M@<T=U1@@^RO'@*&I6@_H<QD&Z:$@/U7TH&"*Y0H+A,+DTY#-&GV5Z`=7$\J8 MXXKN=\2\[M0>E%IEDAC@$>J8DZXV^!(W`^8KW1&\5]AYCU%EC9KF^M$EIZ'3 MWUZ'UG&W6.>X,8?0-(>;1.A\:&<^HN&%(&EJ@ACI",Z+FF"+`6V5[(C%FKAS MJ590:6VP'-N`;PD+=2:V?ZCE=):4B5>9K29Q4S-(25]45IF!<U2@J5&:8O<$ M$%HM<PS9R\`V,5/)'&[.LK74X`O?-#MSUIB"Y:"!B4E=.9"'ABR`Q!UE_RJ, M5UAE[::A]HJT`M?R[I\VX4E(*3JC`/.V0BNK5B($9:M#6&'IAM0L8FK!.DOU M^@K#4_=L`,U[XJOA*<VLXE4HW1,L.'VKKY:50=O&_Y6NC*F7U,O*.XD4R0V, M,9@`[]E@6AOX4IA3R8\='S*=4^F"K+*:-!232HO1)">W>,B:H!R,D"S'N`@[ MW12*;7C)6X7BRXRW4\O>3/_N[20*=LN[VB8$37"<X\F(5?&,U@Q4;6?OY#U- MN.RR;-S_;J*Q"G6]9XFD$*':\)H),#GC\';BMOFDJO3Y(*U@XG%;`92>AA0_ M[23-#_(Y0GFN-C_2..5F%P!D51"\5FSBN1]XI<LV@\#%;EZ*A3L[^U$(SLBI M^7-EB:F/;7V`S0[DTC'^PK%B:X2&]_R#>Q1W_Z2=:>\7R*:8?Z$_SS>N!S>% MP(D^;EM9;&*X]GF:'LPV&M31*MH[N&*@M""5MJ55-!4,W,I$<$$J;DL+V*<- MBCY(2VC!576M:8%C9+3@':4%7M(6%PS):/&Z'PCJWMQG1[8ED^@+1!;!16F5 M=@3-$1G[(');6J4=P7"4%HC<EE9I1T!(:)G`I"VMTHY@!4H+W*TMK<*.)I;9 M4O<#0=U?[+4C[ZNX?TH$%Z55VI'WU;Z@KU):I1UY7T61V^(J[0A4B;Y,^*(M MK=*.?)XP!?,$E;&T(Z_[@:#NMS,J[_&&H,>G5$K;P3NB(YPBB>@HI5):C??R MOJ"7IU1*>_'^;0KZ=TJEM!30(Q*9\(6X1(6-^KQV34'M3NUEGG5YA\$Z(P(# M;G"ZV'CPE($0GU'`]@=BBX`(A+O!A2@].HLG;0:7>Q>$^'C`,BI"Z/9Y[=F! MG831BX9[`@MRO-$'@N3^$H:%CG@*>)Y)!-`/\$0'>%B$!GI)-<3[,$Y(VY`I M8H%7#_9+VI"!T2D:WO]P`=Z&#(Q.R?!)%>=/(F0^!.M-82$^EV+I%B'QT0V> MG"7O.;R&L?LH0NG.V2217?@?'U*&H&+N\"8!!0T^1:1W;L[O:)#-/^_@G@"Y M$G&A0F('9_\BP'_<)$2-[$J]LNYBIT*$R+V;P+U<\B#F<0`L(1(A[-,M2&QE M%$$:?[.C`*.%"]TM'ZV0J-SU#+/_Y7-YPPBF]P2?><)N)5&L!T"]2V=E;[SD MOOARHI?O_\KND@3.E/WJ)_=SF#`2$[U\_Q%O/P51#*>2(-U\C.&61O!7VT3N M1/_O[70XOKFUC+-1=SHZ,_O.X&P\F-Z<#<S9].;&&G>-[NQ_H#)\0,PE/&'D M@`>PL`?%P+[GGGD9>_"8EB@3-@/_J3PVT<F'%#Z[YPS`ADU"N1"=N'B`S?7_ M`0``__\#`%!+`P04``8`"````"$`P6*Q*%6B``#@/@(`%````'AL+W-H87)E M9%-T<FEN9W,N>&ULS)WK;AS'M>^_'^"\0T-0<"2`I$G=+#FV-FA=`B6V)8A4 M@B#8'X8S37+BX?1D>D8T\RD/D2\;.`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`9]6RM_C#\;CD9?XZ\6$VC/*LNKA`=X]6U?C''=?+NGB]7AG<0/V&U]ZL M3V;3<?%R5HU6W4>>H>G5;(IV,_>WH]EH/BX9&=BIMV#$\7FUKD$60.+ZB)"K M_/T>'6$G1G7-U%_U_CRJSPW*QOI'^;?U]/UH5LY7/7X?G;.1NZMR>5%,Y^_+ M>B4-[3WUMIS9@A>C);@X&ANHUL6R')<,?#+KB?F;9;D832=&@H%?,6X1W*7W MN%HA[=N?>;,$]VU^L$%+6HC6G6)>]G;INVI^]LE%O18H%\[`87J&_Q95;S8= MG4QGT]6T[/,?"961J8O%Z&J(/_Q]N4:"LC&Z)#PO3TMT?`*7WY?S=;D3V=-] M,-M"TTHDOCHM)LWK\QY_VNR^$1'S:KX;]JE+2,/UF]&Q97YI\-1ETL49$XGB MXD#`]>+.#]6J+`[V>V;YXX>/'[K4&0J<5[,)J/-_3'Y65WV]<<2H'3%N[^_M M[Q^PA\L"]5F77Q6'ZQ4*,_U[.?FJ>'RP\W!_?V=_?[^H9?+KKQQ.@]0W,/-5 M<?_QSJ.'3W:^O/\X/%J,5@7Z75Z<((+1K-L*L=2/&/G1O0=;'NW!P>%D@B!6 M<Y1(>K<[G1?CT6**4G79@.2M+]:NSD$SJPN<I_-R7D_?EZ#`N.J;K?PM)&LZ MGFZ0*>-<A\M=$ESZLEVWA5_GS2.<`_;]L`"&<2E74Z"G`&N"IM@6%W_YWMC: M\UB:Y\+VVIYVB=L*\&_89GRT<C7%][B["?&^$.I$2)_Z["0]_LWV>V.SCX>)+N3-S8R<]-^KWN>M\ZSO>-R=NR MQLL=NT&?\-2L,M-7!,M0%Z?+ZH*?&B.-EO2''QYEIS@S;U6!CP-"'+8[PG?3 M,2!1WFS:[DO=01T,-DWY&HL_,D>S_(F@KQXPM9NXTYWH=^6<L6:&-:/)Q71N M;OH*S.L^R8BKY7J\6B_EX8JT93V:]1CJE,LG:5/8':Y9PPQ)Z_[UU1SGBPF- M+N/_!H\&(3TI"4@C1!>KT4_]77YE\*V_\?0<I.[A]`_EJA@BY'F)@DR*R?3] M=$*DEL1I5861QE.Y:`:\BN6+TQ+7'W)0*/^MP_&BK>3=]<;IB]%L5HWE&Q7, M@,V1IVZP$*S'QA=AN*O\)X<H=HN348TK+]F>3&=KG/;NL'\JIV?G_'YWQ#:/ MSLIBOC:CS*H"N*UKV"*#"FJL31;Q.(V%Q2]+BCNDFJ8!IS.2&,4=[=?=GK/R M;D[.8R9GI-!C@)B>*^N[!:P<O1]-9V+O+C*SB_R2>RAQW,Q?'12Q-BH.B4C+ M-K8A]4@>4[+[+_#."11N`JI'*6O2W2'3L^XOE8ZYT\_'?/_='S?:?]:7HL&- M#P4/X]M_T\,P=FR<)//6WLA;(XOTS+VUS:]D;IO+27N[@M[?^4Z2<JU1B"_D MQFU\]EL2&?.Y$#"&N>ZSIC3407=/>F_L1!7ZU)M*0U@D;5C20$&Q6"_UEY4P MXL71FS?RFT?%9=#98K'$)`F`;C_8NW]OI[A]?^_1(]-V_H6SW>@G6D3FC$?X M[WU[0HDT0$X).1F!62_+<&VBXC*[_-@XP'J!@I8_E<NQ4H*0+P/`4I13,`A4 MHG)5[WC4\<L/Z\!V[7'AO?0*UM]^M'=_?_?VEWOWR"?RPT-^>+3WY1-G^:.] M1P_"SXGQAC1N(HCD:C,<0F/^Z3L^KFK"9&WAXR>,>>_^/1_LRP==^D`?66*9 M'A[OF)FN$;DI[WR-FW:R/?46:]<EPYAV8#%B8DEW71O%)!=^LKBE2;!QAX3O M<JTDF@GQPO-5U2EA$/I:VZ0/]AX&37A,$-MH0MJ0@1VXMW-P/^SEO9W'O/5S MU&,3#_-E)I3=QLKAY0\N]LM'UUSAX\<]U,KIVD+.=99U.5K*E2;KD\%6LW-= MTK=MQ9/'/?DWF[*+0P-*R$G`'<;QK.9=>1IR(SRJ#XY$]P7RQEM@OA>GM!^/ M?)'0;0UOVGS.,+Z'A@Z!U4*+([:IEN0RE,X$?Q[L[=_;O7UPL'>P'S$G%VZY M:;\`P%^3HKCT+C\WKA20R8.T*UL;:$KM)Z'#-J&X]PGAS9C:G>K&M/9X$(7[ MILBZ9:!A._12]2:VGF@C>."DN%<S"]];FN61&7ZM?$\J:^1BNUO1EM6NC/;2 M:.W'(\\^^=JV#1]7,]SP2C$BV342-BO"4-_X!WM/K@M;W77=>,:XENY`[15W M5]K#H/;C<=!/OH;]W)2+,53K!0[72[1MY$)/YC9`2M*Z+EM^N9%WB!0OV?'9 ME$3VYYQFO=!J;C9-;J?D7N\T.'1M4KM(TP#VS;G;&VO:<A-O0M-FO3-C\K-H M&Q[S9]*(.=M(A"E%QT?>MO@&F[<3@QY&%_I-#)VV^#Q=;W8;"=N&V;;4C9J& M+(2H(['IY^G2X$`_1UM\H&2@\<$V1S1=5FU!P&=R;B@V7V[,0ML3I_:$97J; MG*,LY?L-)<C)7]>AG*M]I%9;434C#92R5_Q6_S9]B$FN:PW]O"3Z(ATH*VUN MV.A"[0!_]U]8<*9Q5"HFU$NEVBY/?J?<%B-,IO6B(D.EL&[CPS^H[BA.6:R< MLK,Q+9QV96.Z-LYFJ3!FVE+N?G8^HL98RYO,^&&5=EM15KKJ)>7>]"K?PU7D M6`%NTN[9J%U.M>OOH:9,G`=W1S>O)'='5TKVDT+0?:DKD\Y.Q1%;9/+-FC(& M`8P%_%LV@%+_N"PGH;"A'?/%TNX5,IB2E6T#Y!,M!AL'N@L:FO/:HDSD0RZ6 M9`XBDR5SQ-7N/#UN#W&N^U*7VZ?3.?FR3W&[Q<5N]"D."L)00/..D@9M-R%M M-DV6H\MBHI:B,-ITI226M!CM;Z@\'0$]AE,NM+2<G)>[%Z/EC\A>^.-5HN!& MR/IF=.6%/8-&=_0\2!YA%J4@$2)MZL94@GU=-K<7EQAA8A"+S#=A%GU23ET+ MVC*^S*;S?@TG20B"JV+,I#C)>=DLJ$N^7B32=TF\,PDR>5=":?HMO+!_:'\V M-`29I`T]N$,9*&:$Q1!R3=6D2\&6MTLFW_C>Z^79:!X-B&8_FI[-Z9,<*_<+ M5*J91M+^AMXKM7YTYQUXI-C<N_B#M8T4__K'/XM_=^+\_2Y1SZY6U8]L,-T" MY'*5H5_2&&.-5'<0?^;_O\_(XXSF5__ZQ__;T8^7)?\J2'CP[VJ]Y(>[Q>5( MABA[=TU/X++0`+,1/@,\U;_I::,7AA^>4P9&R/GWG':5,WR`CQ\>[A0'3YY\ MN5<<\V28$_>25/H8"50S@]ZG^'4RK1848BY&XY)2EWZ/+HI"O'IZ+!%%1M5T MV.QQA2_I)CXO2D/"G+\PX@4EON*BFE%V4I6/;JO1PH:M^0&?\**:6"-*<;&N MQSQQNIY;X&\1A"99L$_L.U2LD&EK`](*:XG>NA8-PMQ@&LI)H)=LEF6.]MK[ ML52;;[Y^9ZRO)BNJ.R,@#TRW1I*/'T*##M4#]D+M+VJ=1*E>.@I#7R9_U,7H M95YBO+ZMA#]WV,N7AT??VF8./O>,9FB)NKE3>OSPZ)D]?5PM*%X^.6#[^*TO MAV7H_]_PG^D7M"'_744"^JKW;_$3`0K"`^LN:*0^T&^6+^F8\D>.IQ?PZH?R MLGA;78SF^NOIZ&(ZNPHCZ!=?V,"T0V<,84%(Q@OU1"?-RZCX3!3L21.>8^W1 M>LG"E1I]P1`XW]N8^SOV2!3L\J>IC)#>R@73-_9RNCJW/U%_&2/CR'/0H,,+ M^LJ*P[.E"N&"'?[K#<L")(WV>CD%`;7=]8IF6H2A>?K.45D6!BQ?WMWQAHS+ M\RE-&WHQ4N8-D]!69_`6>Q_\)>H^*FMAW!=,%-Q/:R^?(M@2$M)(IC[YP)+E M>46J`;]U*=$<7'S0"#8O:V$_;NC[US_^"Y<K"34,BTTSQ`[\<Z$&$QN:GR?X MX)%U87WV?D-RI&.N/GTA"5EQ@ZB3=2V[5[?Q",=00*<^4:PV@456\@P]9YKO M]@.`[%Z!X*KM'DZJ`U?_L7RQV7@6#_YA.S!98@L>^)K$/,_U&<<PI*]6"D4P MM_1+>%/G59<V2&HB)Y%Q\&#O4:)"$@+0#[K12F(;W0_V'J<7E-76'FT3ZP=[ ME(7K<QH_%?=D-ML6F7F_6KX9?<2THI!V/^//$)`]<%&[_7A_[]['#Y&30T_> M;[,!:XSY72`%`<*I'U^*@Y*/*4VJFO^<3HHHN"BO]R08R8E#=&]Y.`O73]?6 M1>+^1-T![39B8['J]<E?*=A:1#NM?ZRC"\N\US1E:B"$7[.UBAXX->L5(D(_ MA_)S0HUJIX4:[-P<R)PLUV>2J(FU?M=ZA@(,C3((%5+X8WDECZBNYO-RAID( M@!%D2=16)R9CHZ91,S1HRJ;,"79L;ME`3`L8$-E"AWE;3TS)9IQCF6+GKIS] MB/D4,SV5YDPQD.M3U?8%8@/SP44M.#6(F$FG`1P[2E_]`@60M:Y,/(-B(P65 MFMUH0I;01CB3QHI@S0K)F>:#8#CWLBVK\V6U/CLO/(B#FWIRG,4=QBSD!V=B ML($(\4>X5!-0,[6[^IH3F+.14GJ=;1A%\+8-.B&T:.(DE>;.#-GYXYE\E[G! MO'6_N0\QC;U8R`=-L'O%.Z1ZQCQPYGR*210T.T;`HF:Y;:YH%%K]Q<)<+6QG MFW<28]*B0OPB!_$,LY\E&PW^LYU,O`QQ5M[8DRUG4N8<:$L16BJQ@PL%5D\M M;&QBVQ)ID]2B`'2G"<5RJ4+PN497)DI!MI?EF?PY#FP4HX5B%]ZTZET:*'KX M^BUP,\-]6^'.006/"@K9&N17OV@!C\E\O48\Z8)#?J/R88#F)@:9HB'U9@)A MOQ179W&&&"JQ^P(REB/U8&3,36HI':[0)9OU=#U#F(,[82(;@E>.T<AA)P'& M_[IT=[!B#W<!XT%:8#WCN$*N0!<P<'Q>55#`5!M)B3H4MIOI.EL[*&L=E0Q. M@>-*B[O"-2$"*#)&"64*S4YF,"+AK1/6--#A,KO&S1EEN@:!D60BC%0`X]>7 M--W""<!+4,4O9,'Q:6IR`"8X[-T%DGJ88')&6N#Z]MP$I</_AFR#-X&5^T>^ M@S@UPG"1C$A:J!,LTI+X9"R,&9DC$3;?Z<:!7HMF&B`G$F4>R=!332W&8C;6 M5R;,6\\F;AQ'!8DL@AB$?C1!UGFJI'E#_I13%@#65A,,0>.6N2"A*<VO2)]: MS&.":=Z"F=>>,?W6F@?").$4AT6.:\_(L5A&1P^UH<A_[C[#)QURS,7WI)PY M*AKK)&^XWK4%ZB+B&H[+D,_Q(&U8)H"H1S*-ML`@1&X/6G@B"N?E3ZOB0,X- MMN,<@7IUBE7V[5T1![7686P&KZP5#(N&+#1V0ZO:S)-E!=YB.<FU*)73&I9- M%F*,R>"8=I=(DYJG-_`W9K*5[)D0PU^9>V)QMOE6"H2@#'E;6^)/A(DE]OM3 M)*>'0VDJ7FOM9*`:-9LAAG.+*8*>)=M^H;;8`$FN_5&E-R$JQ</0B+14!/,> M$6_XB'RA[%+DPIID@B7>*XX$'F$=!O[N"^T8]P(J-7B#Z)Z.WI-$,1]%6+&C M@;6SLYF#6J,56?PRP1B`<.[W`?<D-$9Y?<32$;YB@VEWD"5)N*KR!3S2P?20 MHW",7%WUU.L=BHP->($*2,%[6:ICQENH/H!)"H'G(+7@$YX#<HA+*@^/B!5P MB3FP$!TJ)^ZF6Y;)P:?!MG<T$/(3L;M\]:`L-4R=$\R;WX-&78Q^!'DBM:;Q M"I4N0N>-`Z(#DU@!Y91YA'<7?KB-M7IQPU[-ZA<.'J2(</Y!2`,7]X6@F+T: M+*5H%S6-_$QG=Y(?@#+;S.A=#]&37!@]E%1JTN01_"4IC4<<*`$HS@20B7V. M.$U&YA19-?O&D2\A=.13;]M!500#9KR1QG&Z59O[=>>DN/8>%M3I\.B&G5=@ M`E[P=-AR&SE/)1ISI?V7M$VP]63?V1,"HYJ(@*;`+6J0Y%]!;R;_=T190.YJ MKC&5Q+.HG90%$;GXE;UPUXUE)DW)%"CS."=S5M?J3Q26:BVGQ"82_<2>N,$G M?H36_<FX!?&M$!/&%\M)C_7/J&G"\4:?GH&/^.MOB0V-3]X,IQ]]BG=)?5,N MJSG-_S*E/NBF7RW7;EQ,#5(J$N:D&)2%!4L='+"&%MNUI:@(K!4D>E+'V6M& M3$)J_\B">T"06"A6;O5$$@1/'PG[>HR0>.5>PW7M+[OETSETX%C+E9"K9VDR M<F&@Q%_9Q49<Q9OIRE)GBJ1M?UMPL_?Q`Q5B'\?_COJ<C.9L@4RB3E$QFXFX M`8ED@4%#BD:!@Q4]Y!K*.$2:VCZKQ2]`NG2<0X%L*XP"ULF#^)&(D'=@%*TG M#J*Y-O"&16:<'^2P:NC5!<$9?M]%I=!P8/GZI78*H`LAC9:*0[(<54O,M?3B M?34#):B(7<4AO'#E+JF+JEO+Z*7-RS.ST[!PO*P2(2$I6"TC<,7GD#*E!)0J MZ8A&%BMYQ*$'W,0WBHMUJ.F1`.^-?3%C9SJE38P.+-,$%U;_<ELA?L<7,,_L M#Y0#(%&])=.-.,%2-!;$'.1XU"\&D3T49W!USBJ-1\Y+NE[J'*=AK@D2DS<> M2NBWJW'QAJ9T1C=6=%)AJ^0H!(.)\I)>P$?"/H@CPL(,F!M];'*W_;E;<FN^ M)C)K=M%0PQ=A4(%=K-16@2B;_NFL=2P@6IJ-",UYS!,YGN`R)C:"/'A:Y$YU M000X;$,ADI[>?C4?[UE)PGZT*H.V(R6TWUCU1\6J\%C(=.M)D&F0N9C0!5K[ MDSD]B,'!_F]VBD?W?V/"\O#A;PSK[8!_LLX1X4U!-J7U'[1/:U!^08+2<8T= MCH&P&1.T_SWL,$MMBY)%-V<IOZ"@F)"<;)[Q=V\?=%*X?R^79(L'2C\/;"UJ M+6X3@?\*0G(XL++<_\</7,)"J2;V:]#&B(8?DWFJT41DO-Y168-$"94AB;!4 MKPF0Y1.F%):+0%Q1B\&/GCAO[S_X^;S=L*!!K@89^!1C8U'$]N7V@X=[^RG= M+1G['\C<N+"NL_:\G>V-T1-BAJ9E>&KV+&)%S'F9`E+/Q,LW_0L^9%F\VSO" M-+ZLN-Y&_+!)#K.3J.R^%0N?'YI>FCT*\9EU0^?Y-3#+KD``!7@.;")("=DZ M.Q!H&3M#'G3D.I40`Z;!S(FC'%*.=<5Z:OEAR:Q#<@G^=M:L>+O%)]6G(!+\ M(F7.[4?I18%5XI5^T"QF]N/0[2?R@8B1RXE`J;C<FEL)=A#V9ENWS=H8+[)4 MK79+U:_JJ@1/Y>'JZ*I@>LC^LWB?:6MM9X=K'UQ[.^8Y8:2I46!^P#=\"BO" M;IW?A$L0,3#`J/C]:#&B]H9#HK$(%JY!+*#WZ-%G)%8X]HL1JRH]X4V0U-PG M_O<YBWR:-K?<79ED7#GDP9Q^3!O'$Q7!>[>'4+\G;,]4T9-8V3]>;&['.6ZD M0R:>$(]TH2WPG'0%QM8K00AB$S-XPD`N&F$O]L=889Z\)<.D4'8K68BWE0_3 M,S2#6W->4%1YR7G1L;>&5\V4;?RDOKQZ>M@_?YS1&`;[_&T$N@E&_Y?QT;0[ MH\7Y2B$"'CA$'ZN8NL9-SPLK9!(I\H6LO[G+.^'QBS4M-%:NUXYFI252+?/Q M57&"AULCE?RQ06F*6?BT+=\0;%1?@`F21#BG$?Q,6;#F1+>&!-,X<:_R@Z<V M5)DM+^3%6-`MYYB\I'?$`8%_6]-4,_%UF!.)BXC15[BW[IXGU_`AC`*'"%X< M\8A'MUXAHU=\8<J#BZT-'PL2(,`F`4*>B@ZWXHUW$6]@*37#7)3D7B;"J(YT M<P>/=V($(5=1E]H?K+,\OO`W$WBM8\G-@;0ZX7-EKT":\J8&U$DK9##I[:CM MFCY59^O!.[(&J!J<HT56FDU&I#V+>C=Z=U8Y&T-[-=R/#+7Z3\95LT-P559) M-Z99<Y<E>'A)SG:_0[N\F*XMGL(8TT-,EQK2`4,LX[S6*48,=L20D*=MC<)T M(9]D=K!7/'V+R-#$UUQ/D(F3_AERYI9#,"DM_KJ>G$&O.PH6_M(F.IK#E8L% M.=\EI2"J@W@(1)5XRGV$R3@B!N?D>33-;RR92RN1WR>B741HR+>8?D["[1<@ M.=D'A7MN;]M;-3!S=[K6J#:W=;<VN)<Z<`PM7TN+.XL-)7TEH9K7A)CJ_?I, M75<1+@^'+>C`PEL@!<]3<HQ`*J18R9=X=X+EG;'"T_*R#7Q"%Q,5!>3YPQBD M)<UG5C8<18EA7\V3:_!-<JO8-">&C&1U:<^9TH`W$MCZTT*V5[PD6/.,BAM< M9!*_/\MV0H!RV&`$>`)QVCU1/B2S^7*4M`JAN73&<KU?&8V@OE(+K(.QLG7\ M-@VOWP>5$0.RQ;,H.IB64UI98N]&!-28G)&-\RP+SUJ6)D:?#<M^ZTQ-.=#T M2INJLO0'K6PO]T*Z;,21P(L@8HNPCA3M^6_MF<@G_2VX9=:%8,^J9\)5,$M/ MZ5A@AQ]M4/J3RLGY>),29>9N'\R!5R]NMB=>OVM8(GFY!`(@SKO<@2;)6?`" M'+6"&T7/1V24,I($>>R2MP`2H3!0HDUKXJ5-\A(W.1>6!@`2;JR>OLG/-<B' MM%NAVKY8YRGEF?WN*`&6U52`?_K69*C=*<R,.TE3-#,_Y\-+Z9=HA5#8LFTJ MG>VJ`FH7[B#D5+5M8V+59%*LZY(F"OQ5M=$$.5]2YY0WX@4AW!#KF!1I34[. M+;DGBF3)`'"NX6'X;"VPOJY.5VI[5EF<_K/F^7#Z5D:Q_0;W)>CVD/1+]]`D MUO/L]=/UDE*:=%-R?CK]2?_&O3GL''E2+TMI`@O6$1-[IY'V/1`L#D2E4Y*P M89E[.0W/S-]@@8E)T7.Q.0I)N'QXR?T`>T\3BG2YN[JBG1C'DB0YK5"B):0F MY"HAV=G2:7U:R`+JVB"FDG>`<R,5A:BX6R)`@B/0EH,5]G*K`.5<TSXS*KP* MX:T&#`4AG"[N5+6!]5M/'8MDNQ`)DN1DBKOXOC28AUB\B=GWBN]Q]]!;:_MT M^M0@!ZW,ZF;%/(WF%;EZ8++UGP9]:TI#KQ*8B0-VTZ4D69E37<#:5;I7*`9) MR.7$I@_%%$2HJ>*>T;]G?Y1,:XF9B>0W>&'DB$<6QYIGZ+/EK(\8Z@:UAB,X MD.W'W,2(;8@DJ!30.A-YS9[-+$-K36'2`C:6O\*K>!@N)O6+\71)"`!\6((K MU"!4M0Q8.*;&K_Z%4"F.DNS4@Y[>-G:BLH.)(^8?P+#"%CUWDX`=`]R2CN;T MFA1X]H?1DAM!_ER6(=,.K%]M26')FO?W6(#K;:AR!DV&T`(7M:@:I7"K1;_) MI(R`L4B58]^KT("#=!F.RG$U6]'A!0YG$J7&G460+RSF-#`T><#77J-O.!Y- M'WEG+%/&WKZ'`AO"#)&-F]`3Z;=:`%GQX*?+='?%^!BY'-@%BRA"-B4RW2Q_ MZC-(DG!*`:6ZE"B,L:/817J?UM@:=@O8XW\00&V<DQ(2E<T^?E7<F=[]^`'1 MY;H@NY\4[Y$8$=P6$*%E35LGZZ:$7?^65_0./30H**B?VU$)-,='W@/\M?=B MG90("I42A*Z<V+MZ60IY"BJR+T`^FR*5#+Z%Q-0]FCO3]SRK_#W2$_T6PR1= MK\US.$=J/:=PS:$%X3;.5721HCMTD[69[,47?\X"#?U2Z-UXM)834?@EC!>H MY@4*YT#;0Q5S(HH*0]`:;QMC.?RLFP0%NO26HX1$O9)OFA_U._&VPS.S=&JR M8%AL*S<:JU<N0Y[DBRK$E48VI,MRQ:VQQ@G^FF1-8#^GGB=9$YFQOS%``&:X MJ<PD*6S$ST-GJRHO=,)90.J^G7?S(<7=ZF>O24'QG;YC\%6]H-'PFUL+L6KY MOKSU-"H@35RR]FO=WD#9&/K%IDY9J)'S8/92<)VV4XP-[#?+$K31M]18+,9[ M+_4>:K^A$2THH[)"R1UC;]5DXI2F$E5J$YARSFE!K4MI&+'9GI!+L&$*%</\ MV+KW>850B*V:[V+0F<8"F<@.2875W88[$U/WF'FQ9%\O3M;T5/JZG97JH,.E M1!`:@=1?EM75:":R6_&H:4.+_W8FAX4A:[^G\Y-4Q,</_C&&`\^=<:7R:KK` M6^)B>I_8$MJA-AVTP;,+"@S,VX)C>+]^UYO!6>,=D.:(HMJ295.BQJI'*-#. M!SA@JD""`9]L-'=;XAN4?IN<EF`:"`J3"E'8:M:2WYD?@L*HQ@(>3W1OI'^N M8LSQ!1V[D&=M;`-;;8<2&JMP]<>CUR^\<N51;&-[H@&5_!@J0R760)V^QX8& M'F<[-HJZQK?1#?,\+9IP74/9!=N(*NK!VKOI(A=S7:#C"`$,]>+,$")*6H/> MIL:$C-E*H@D*RF\HG5AO>VD/0PH,+#D/$-?4IN!&"R(R."%F<JC,4$=KU<&F M,^2)W+([W8UPF&^3:).^!1J4P3-2`^11;7P][PGL3L'Y0@YTZ&SAH_V'N_<> M[A1N^)5<^OQG"R/LO?6DCW%:1W&_#RJT^R+<]72885Z/P,^3`!L&:F^8@&G. M+I=Q3SSDX@+$1NQL4#"`@?+K"2."$DCN=*GOF.^$A`;PJ&`N:Y:"54$T0]Q< M.P`T>2V.)^R]D/>47_6V7"=99&-6YW@GZX4Z+"E4A`A$R.KN%W]L="R*>403 MCUZ12TX^FB&T"V0X%D-B=GQ.2A:Q!#Q<*?-'S"#@C(==99*DI4(,2^F^#Y?5 M*K6$,:'K1;%*"UV.WQBXN,\<GS=-]E$ZIYI^*VZ(F!,<D!0)2&E;"[#AYB7; M`WML(/H>"^:2ZY?2G8/IEW<+PF?[`,60U3(6Q?-*<D,4_/#_AA^-OQ(1G$FE MM"(X6#US/@V:V(EPPJ:/YJFY(+RU5_PI;4,TGZFKR4[F]<8@,3VT`'?&S&%L M0U.4%E!*Y$:H#IZ'.J1=U%KPFB2X12!R9Q$NIQ^LTTR>)UD$M`#7&5=%/:FR MVBF=E+LW[HFU6^X3I5(=?5*DY[VS`7$!:,RULU<^F<0GQ8H9+:U%!1].8<<` MKW.6]:B-.Q8I#.&T56C1S$1Y>+%MI&QW+9S!2^A$>YN=T(XM>/P_Q!9$-ZWX MWDJ`_X/@_['@GX]]L;=\)H@TE;L2R;%4K$'14MDDQ:?-D<KP^\9*L)WFQ-LV M"B63RP>L!']5R+P*EWZFDX*N89N]Z\QN-LA/S)28ZJ3@!\4CE6@RL@;D*3X( M4Z^5`92XAL./LF12`'2&7G/\2G,'FT%Y.PFT;)+E'WB'S"%8SL\:*^A12HWK M=ZTAPF1$S(>=/V!"Q`S/"!B](5T07PEVQ<;FU@D9`/XM4Z)$=<#X3/_,S<^T M6"^$)3?]DV'%R0\.QT%@OMP5O-"$P`$(NZ/NA'R$-CAE<K`'L"OGXYJ<AIV] M4X[.#8$=A+`-:#94K\&$QNRG3(LS)[6)^H%5VJ/DZY(1\:P&(WNVS.D7?[*C MCTG`3DJM3"V3(5H(:W/O-EJOZ*XS*%F=)%R=A?%C3"R`QZ*&WUR,..00EDDX M$\[N(UR=Y9+&C>.B3G#-C`+V!:W+N6<NL=Z-?W?:0MB:MJ@CR7JA1;<EF_#* M$772-@K.+'5[#=&!3V%P6T(S*KNN:<HY^4#N$PDZY)6CL%Y%0EGX9MY_V!]7 MMY\O?-J_0;JB5'K6'E%$8;"Y/+[0F=Q<*S(!8N?4&F.Y+67MW%;;)%BGEENK MMV+O,N)*IP&RUMW=!.NIJB5#]=2JX3D4#:(@8..Q8:-9<4+H#'N6X5E88H(U M%EKK9A/M@K5`^4XYYZU$E1]>E6<N*.&L=%?#33#EO47A0SB3`$1_2';6PH?' M:CF076A5!]*?'R:>_`JAV$YOLE\UK+(^SP0Z$;HR(X(J1%?(-%P^4%":@<2R M\`'+]C-RQE$;@@3?*&=L[UJ2V@(B1*_G<\J+CT!\[8QQVIJD&ZKEAF[?;A)J M@Q?LF87>#1V)PXV81ET%91N>FZILPTR.?,;3.FTLC8JHM$T[NMAIX79P_`46 M=@+"LA?4WZN9DCZR3F;'9(W:$^@-0Y-T@JC]=TV<014C.5K)OGL"+$QM?4!J M;`.H!P]AV"QN32-ZMZ9"G<UL*>W<-%GD:9CVYG"536E7W+1&B?PW`YGV!Q9@ M6YL-27$0WJ>=M@!C/1^-5N28W<1@`D"[/(-A-&,,U[!RI"NM;DK"/W^WPJW5 M62/UK;8N#%-$PW#6M2+NR^YG"AFJ:HT#F3`P+HYY2,S&[WFH/`78#N=TL[I. MQ^%)'>]='1B"X=Q'<`;@70$3XL3-@=[8X<V6MJ<^U@V0WW6ZJ2J_1.@Z>68) M-EUWJI3I\K3F9K`.&X83/6U1"Z4[S\D/[$8C):;&^K2&V3V,T<</T5@=MX0F M=2!';QQM.L&5RY"$W#7LA<E`8<[_S^;A^H0A.E!,8$=8155P@MV+RZ2_:\$= MG,,X`X#GOG44&,`DXEO`DN0>.Q0D)8N>,FF^%H=:C&GO6=+]1NO-],49Y=IX M,4:2<D($J5O=^*N,#*UK2%0^E6]/YIAD.T+NBX((=0#;P>OS"LYFT)I[@6*Q M.WO!2F=J;,C&JQ#<<:^[&Q.0&=+#5IBZ-O)K2C,T2'"R)Z'2$6AHEQSN\'DD MD"#>QQ+=B6;T;/LCM%]C/P4"+=9FB\(Q!O(=?N,VFL7S\/_O[%_T<JX-\!O0 MW(O^F]"\"S]O-Z%O(`<V(6.#5374V[.XYB-PZ+3BGD99$T5-#C@9!TS?U.NQ M:YYV/$N3'R_PHT_'7D#2M-0(U5S!_0N[U>GN@D\\4,.U=B.D_/A%F$A@WIO= M35.;Q"XU-I+K?8K*TSZ?Q(M-[!"2'VS,*DCD)I24#[<@H+$>A\A=F;RWTFO' M'(M**;9UT+-UR0<(C-[C]"`%NB"PB?L)"["V?O^6&:^L0AH@"QVDTDAN)-G3 M)J/JDADO,;+@(TI;IIT6GCDC3NAB!5"\FFM71`2A54XUE+[@YK*-6['2V1)S M&[4;ZF@G@F627Q?+$%XR:3(=,7!RHB*">5P/")X1D'$M#]L0:I46A?*-9"]K M@FWQCC?7=:H69/@#AWF5ZJ9;@7#+#ZO)^PC`7*TQ`GW(6##=6D5OO)X3W]'0 MX!X01?<%J0C'-)''PF,@N^DVM[6W&\.TG%XQ)MM\ILW$U_JG;'I=*(,-X.JY M6&BPO`H+T>/6C&P;"=5-3K[A,+\-K4J-6QB$60"9"IO2QG@PPPH2X<N2\L\Y MS&_]8;9[FC61HK=RJF68D]F@MA,\6'NF7RF.4P1Z2`<>2VR\7AMYK.$W25); M8%Q:8`PA?9`0*X^?C[BWT8XYN,.E5KCQ2J*0D=[)I:^>OH2=PNR8?]#75ZUN M9=Q6$X3S.WQ8M>$X;.T@0123H,C!D9#K-/'O<4(*>RUJ<'S#K:"FG#IQA,:S M!_IC;RI)G?.'-*T?8FB$(#[M*8VH%6%R4XN!^X)ZUA`B!2X;:7.`\+GLP%1O M];+"46=8:$(OR4Y.05*?W]&P0R=/F_]F`R`DPT4S(('50453BM`<%O3F;Y@7 M/^.S<5XS$D8UK+?&4+.(<2@F@`=)J!'&_D6C3FL&&68K,&'M-62VHRLB/6/1 M->-OD,1XC?/1BGLM$4`QX%G\Y;$%$X?Z4L#`=VP/&\<%>[M0GY-#F#8VEXE% M-D^=S9,%@?GCB2:.)NB$<%.?"OZ)8U=>\$5I/5A-.U)E%X/S?0RZ3)Z]?<UU M#ER,K24ZQCF<$ZW*^QV@T@4QOW,W7LJV5D%6,.9H)'L$H!B;@@$)NL=%B*1N M0[KPLEKJ7I<80".YEJH706D%R:%D+X)K[?2UV1(M0_WOT]A\N':!E81:18Q+ M-2=2!9ADAS/\MY;,$,GLQB?7UDX$T'TSM0,R8:(PCXV((U*RV1HX*EK3[16! ME<M0E`A?V)>^PD>`PSVA:MKF2C*K=7)."+[@-B$.%*.\[U,C4WU:88@O:!%G MRT(;F@3#'3I`E5<%:W$[Y$E:8-):B"%=-$2.S9QN*#61E8RD`')8=;"!;G/- MC'3`20YU,CB;3@$M)L`PP\IHB(HAT>Q$ALJE@"E!AKQ4Y6-3=-#`'IS1*6VH MO6NU*=I9([408KC.`>#`\,[=(>^Y?E67I$=%13."'EJYQ@WB@GM4W(2P2G,- MK4/$PETCP-L<T7M<5YS;SA=E-N1N`EJ;\Q<:+9$Q3L2P4?'`3O#NVZM(X>R/ M<RZUDE/<I$(ZDW>U'#^0W=F@6QGT:"G!(`2U[5GWMWE4]%S<#9];?R$GCE-4 M:W:AB\&MEW+3U9B0V"[+O!L.'10;1TDL-;=&!9ITP:ZD/`(]7;'A5DHAF4VM M%&UC'B0-NH&)A="-8E?KQCJF^.=PVK@R:L*@I9IJ=[C]@)^;#T\JE2N'+)B; MF+62$GJG7K`C"FK/2SPMFP(%6A`CI:&!XOAID,`K"$F'C,(0Z<3"P&ZEHREO MN*&RNR_'C0WC"X'DMW2N;U0\V#^X\^-=Q6'6?V<PH?-SFDX77;).B#9S@*\? M5X^%83RL?LCNQC\HB8?A"@-8F"3HL(&L]HBFAQ)GO$3Q.<ZCOC.>/BYPW]1/ MWW--W-XP;*#=1C=";M^__TB?F.WQYI6?=CT>^E!\SAB`QR_T4R7-4`G<TTMY MW*!S+K:#\9X_3D1:IT/38H`S%#L+DM.B+]&K]0EHU/;'ETUHX&3*D!''Y"?" M_?X]:_0_*5>7:M(72YMKHV0"O)RJ8>U[]_$:O@W3>0,;)X+\I`=T>:Y"YM\O MKM+R-8N=!^?736*@(8=E0+8T*!X8";=>08(%1\Z_O>*/Z58J:<.ET@+AW:QS MQ/"P=>N6.<3B"RDC5;DS_@$<HB[F'7(:3BPE9Q>?]:2@M=.ZJ<A+9S$\L*V7 MI,<0E$DP$:X:_I".X'$HC99\<2A"J-X1/2%4L\RQJ*7=@S-S.))^)ZV9`3TW ML'<PI-9]2;H]F:-+/U*"]D/0Q!7X>'(76%E-Q,9AKN@NFFR::JYIM`D'M%UX M0HE711XF7)7C<_^X"7W.LLU`I7X?*4L!35B1:7^S5I=F]\M,OC@:Q?<!K'TA MG=5!]B(_H"_$7#,=6@:DPQ$>30M?8D@K]BH]8;3D#G-LD^"/G=L,'N[_!LT1 M>P)+B#F&-UOC+4NLK!V6^8Y#<ML0<8,DP.[P"9.H$<VMF=(V9JCE#<=`04:A MF30`R!V=S7(O7;S7,^2X\$KWBM>]IF0N;='.!&[@:?#U7_BI"[P#.+4D-"/" M1]XT.UQ6$5\]36OWAB)JR&QN(=M5GV7K=FBT$.(:Q.'=QH+SD8;6.'XPT:MD MR#?F(SO'0G)J_*,TB7PPWJ<E0&GXP3LW@8[5/#,:JIOJ;D_:NSD;`GH,SJ0= MRMO1_>"K?-B!#Z5@6_P.,S&0?]VSOGJ,J]QC_QJ@D>_.%B-H]&W7@J!IS6GI M_C4W1Z4=*,*OL;!R?K9-&.429^;`4$B][_B.EE-F+_UN4C*EM0_<P[JWN&NZ M3OO(/@E\A'/2^\;7Z_G'#_HF]\</]Q([<MES6\#:1TQ7^ETK4Z&:CVP[Z!\; M%IX$T28B0C[T&>)HX$=('@&1?T`&WNI!^X5&-M0P><)GI>W+;SRQ!+"T)UT< M5*3O1+U^U7R/1M$O*>B$9TZQ&E2\C\51;H!@/`L6P;4VK*?F9@4,DK"I43P+ MB/39LT`DR7?#`@DGVM*LTOP.](KAK(2L`RW*8&]XUR;37/D@?NL,4\`/O$%/ M([+)9+="`8>==SH]:AM847,=HA1M\YKR>5522*N:4D?BUMR5H#55EL61&S`5 MN;TDO1S1OXG#&WI:\Z>V<E.O])4Y"_1ZNR'/U]HG%:-;$Q+N*5#P2L4&O]+! ML7.(.YDL-XDV6*P%?I),(XRB(@<&@D'U#5>96'O9K`[P/W5OQ75`H!'?X3-+ M?$,"E=0;IB'QP^X\Q8%])?00PQMMB47C07('EFV!XZGE%O*OB)O,1@%%&5%I MQ3Y1!08'.LKP&G>P"MV3%B==:E5-4DO;PU?*L17VL56E^9BC2P:3AJRQ'3]. MV7(VA4!JK9U9EM7IP/X^RR&`83SYW][)D7M$NG*GV9V6[$'<XX.]A^FK/ST$ M!58TYH`21D8]P]RAL885K;']^B/FIM)OV@S2K8K;^WO[^P>R;$X3T2$L4F\^ M.WC[X/X3A2YFAV!-<^^2F<#6\)`>)9Z7.<P_V85KX7,=X"$::'*HH,%BL`TL M,.<A4N-)')DY`4A,4RS<P6$I05GDA-BJA83#CBR8CM>JF;6%$-N(1C*G)AIV M7X$Q>4#D0%&3S-6RLMR(E5FG`Y95@KG[K85,VA`</G/'MAG85IAGNMAN+"_L M@YFAU`6I*>PU@S6ACWNLK)]\5_4`B17QD8YJB\6=/\7;Y3C]H\!1]ZMI`,E: M3HK8'->"M9`3O;*'O(Q`9BP6GB,FC6;C]8Q?XZSHDO%69ZTM*.8$/?%C5'O^ MPWG=OHN#.`+GNRG#A[R'";N=IR6HD?MA1\B#O/`Y(?N$CJXRT'IT5YFF<6F* M:F.T<+;9,+"U3$F?G+W(,2(F!=)B$:L*Z]^P.#,AYO^%V=;`$,X<9-B$&LHO M61!5O</)[>]K(8]*N?HBFO`U^R0`Q-ADV6ZPUW"XP5,N8+%ZF%IJ$2)S27#C MK`(28AA'ARW3\#R9>5-BWT\3D9`A"%)J)+B&MI.,[BRH%!,_9!"S_%Q^8K(2 M!:_-4X.+88T@#G!$(!\9/Z!@(G&B,$_;K>07/'!9U9K]RV+L`T:B>2"T-J)! M`@ERKTU35$RCV=:UZYS-I*F5WOR_:,+02$MUQQN>`G^EA1HM>]VX&I,9Z%;# MI%8`9FO;J)8A?8AZZI0^`7K,_"'_S=@!.7UOANR9`ZH$-%TG*]`)S#3*4XH# M%3FEHQN%L*1-\*!#*C?F,]%G*)`V^1<;`OZG01A=2I#"_I"#[HXMY6,W5;1J M+<C$NN&E\2A22RK4`-G3$"WM[G$KJT/UQ[]4[D614+B70HGWQ@Q9#5*%$ZCC M7L0NV+_%M^"OA\U1X3><4"2UYP</>JD`?QXB#D.\?<TW-Y\F>T5DOV9`CS(E M?"_Y]&D,"PZ/WME?=@\X.^_$J\G]\Q\Y?N/:FQ(6!&?ON.PRE0*.2<]\&]([ M?U*)8L1W4E?%:_C,.T"Y$BG<U<JM-D@+7JL@KSCBDX&D>@J]K0=V5*09V8_A M,Q3Y&\4+NYZDM^S/TW'_%(!HN.V1)_C42$;*]@4[&@`N9Y$"_\2B/(-E64O_ M'&;(@\`B2QS8!349B^K`(KVM!XQ%^B'<W9\_CQKK_A;!-RJHU$^B,=TK8TXV M2.F(YP>FVK=]D(`&RCC&$@";K=ZT#B/&$A,>T&Q]-,)9NAXOI8-@JUN_K)-! M=Q6&D$BKM8RT(=//YQI>\P:^V7;860J[4\'Y&#W76H?+>5-2_%=\KIJ/R"IO MYU92KJ,=,(\`D,E,$P%W.JT?&/R:G=)K(1S,Q8VO9%IKB+G`M*,&.(UY=MBM M=,B0'QTP#4S(CCULA"5=NE_\&4T-`-8&Q*TP]0,^G@HP`B3R0!N@ZL'N`3?Z M]W3V,WYY^5N5*51M9FM.PG5!-#X<VW4-C_<?WB5?_L_BS;H^GY`<S+'^CF4Z M2<R2+X].IZ'O"]+?=MW;*V5V:@"*S]*\K$@IWFW8'5'X\\#1AGL53-.3EH=2 MNON?0;#`$J0-X"(-(F_8`,"RX.H%(V<3&9%!&ZHJ\8K]:SP5HOXA@?.2-*RS MB)6(<M=J>155/SMM:B=!(R@E4@&H1CU.^%[GW*X6CD+%Y3`<I';)DA?&XZ%U M3?D4T&G#;.R;^@L\&6PW.7@M!OTQVR*W$"8P@/EU"H^`:-G\#0/*,1Q<M6GF M'.VY0GO,UW`>M6$AW1S@/I3-:KGYMLY+2T34!G6W7-`-%'ZKWOHG[3^IM;_R MG29=!^-E,A-'L4ZI0M<_B]_9EVN>Z;-5U,CN'*U/5J;9][B(Y<'^W:^*Y^FK M:=+A=WI.Q2^[6FETXME2_QB[9V`.3_PS0K"?457G4!L:;DAKIO]F/<<VD&X_ M0$X>(K"FRG*R8R@EV9&)M!Z;H.+F7L<[U?B[M+)97/@`D+/1`WR>"0#"%#,T M1M6+:H6,4TU-3+5J9.!I^QK#Y#`9E2T%=Q#BVJ>963YK49I>,$VH:J2\48,$ M\BA`+M/AIM9_@%B""H]L&(YQ`$U)G9@1=Y,O_BE*;YV[NKX6/ORUM/![&I,^ M83CWG_RZAO.M\!KAMS!-JJ`$<&P-6Q.>8063(7VT_^ANSZK_FJ8O7JY&!XT* M5MS\;^"JC*`6$1QO\ZV"PJB[SJ0W'!7^[^'N6X\(1-BOQ#^/9(`/_+3=_2<$ MVM.%)?S$,8)EO(/@%-"BH(1$"EKXEW,3:*"A"+_7>&R7_N&<"U]!C`O2^/IJ M@]K34-F0VK/<4VP5-[;+"_'#IC8MJ6;=^NC;!CC9ESD\>F*ZIG,DT.8&U$8E M86*_5*T`5Z730:];$'O$U++#O324<S9+B#<X5;BOD)OC%C8"D48^K2TQ& M,""_I,D^64-CY)?^E-V.2B>AW5SL*?F@2@;(IF)Y/CC+;:14%<9(XYE_99R, M?0[^!XN-K)L^-N;Y/':Q,)EF;[N&I^$.)/:(A"9?7`&,$Q$=!GU>]'9[TX=O MN5,9A+O1"U+KOW=I(0EG_ODE;IPNH/2;8[USBL@VW%Q`#2%\DIA*$H8"#GB> MU\Z`=VU/C'>1*=D=.0#A(QV\O>N^*K8F-G#JB5!`LY0Z_XZ&J&U[E(K2NN0F M<G&6-ST1BG;I=I[`]Y"B@N#X73YD36(8CE:$6>-LHJ+%J!`;2J.V?BJU\6A2 MH+C=;Z2Z._NDS?K5KS^*'H3<ON#A3&+>2:=QI3J-2VB;QH]V-;3]H`#>VVK$ M23#J!6[2ZNI7Q6;CZN[^XZ3CVN[6_82QK4.XX]`(4H5%A$M\%IZO07Z1./[: M<*-IM3%N^)EH[&7T\O0PN27+#;MO::92<HP\MO)(/5P0I3$'TCAOG7S'P[9* M7-L=@R,H[2\4%*V>*B.I-&/Q!MMUI/8-W^7F./D+#@;#XNR)XB^')RIPC5?_ MV7WX!SG&]RPH^?3(%!JY+7(.!9;F`\V\F!LZ?6-4F[6(A"8GA;YC9)0;^^VD MVD0?6)$8I+'(LG.KYY81J!=JFR[YJM:Y1AG1=**#&$T#@Y>V-(]UJ(3.EJRE M(/17:1A(5^H<I9H93:(C=*S]FTNCI5X+"UC+SEM%&2ZCD:&4P)1J"V@1FIO/ MO`W"2U[_G[USVX[CR,[TJ]0%-`.M!:(!%([=5Q!)M6F+AR$H]?(E#D42$@C` M*$!J^DU\AV?!D_G[]XX=$1F960`H<=P>SUIJF\C*C,..?3Y%2I98052G74(G MI!I;\JF]@B:9LB@LG1O@7)\*FA!4\D#Z2.(D<P>-3'V#^'#*R?-(]CZP6.4; MDL\0`[/)&R5&JP3G^<&;-]X%C;,Q/XPV+NA>JQC*;LZR3R-!^!T_E88MH(3> MS=$X][XJ\GIL%'Y2'<UCSV39_+2D^K%=E5TJ[UIGGM`587?X[9];4OA79/D< MSGD"=A5C;;J>VN,4`EMJOUS&=[B]N=T^IBMX^VAY.EW96=_I/=Y<6YGNK+6/ M<16TCY;75Z9K`]^OKVSO]![_+1'+DR"6=/(Y$FHDV:'#`J3[*/+N5IZ,WGFU M"Q97>>SQ=0:FA[MC0COR\MKJYGKOX?KJQF;OX<;JM`?<!ANKJ[XM10BDT1WL MN`^\KM/H%0:60R.#^%G3]/U<41X%T8!S(RS_+/V.:`<K!9%?R69(S*2ZW])\ M=>1,P443-^F@?!^Y%R+T:W/?FUD2"1J9.XF"6WC^+1*V8&\/^N``=HNL_HY1 M+5EPD#4M(_+3[X"=H0.86D*RTPL1OFT8(*P1YV*[4A.0F!O!ZD);8'0!7BRL M_>2=924YI;2_':C2Q>H-='WW4]V-^+WNEWH&0UGP[EGUZO/H#'Z/3)Z:3/[B M";/AAE@#S8B]R%EK_;/5ET&U"+A!:C;9QYF*(;:;LZTK^<K"6>8*XSSN>XL# M!:6'ZE`.N/'0TE]Q8BL)QI;O.<5B3Y):R8&MOPA=>3%SCX>'E#*M&+,>RE(G M13Z73GAIM8DY-]?#H+EM2KOZ1XYUI739JK"E'6YYHWWRF`G0WDZPGLY+9I/K MSLPYO,UV,CNQYP"!5!IT$;<I7I0;%=OWJY]6$(='<K&<3#0``#TH=^+=@\:; MAL:/G7SP_?U?4WMHP[D#74I4+;)=O]@[O@[4(.5!>@Z9L*B3'69H)LRH@=)- MS.7V'<%=:I?[WG`V=9BIV3T&''Q34R\*@Y,]D,;Z0[4;V8]-M#\\Q3?2/E,^ M@]>$M+_\E?!!CSW^@"'1KV+\'ABUG_^D"T3;AR_3W;+M<]AA?U0[TQK6DO)H MZLUUJNU8W`)R==V[$=.P2M>T<JUZZ)H9)]LAEGN*T?J?."O27UD"0;H-^ZO] MRFYW4K5PY_2UZ(?.VSO;:3O'<D]_L95M=E;64V?VW0'0U@YN&A+V)^WG=(UM MH+F+%$_J$.C5+4/)%(YGIMPAV^5WN(05>9L<'#]+.[:>)9)\4&O2!0QG7#4M MRI2]U8RAM+G>XC=-9)4R5].*S(3$6M/),S-,L;-2S@QB365]ZL8$TL'QI%%( MYF>%!2O`UZVGH1B4VSX'%VKWC@TM%,*'Z(<6.J>/WD=5TGWU]>X/`I#=D2]G M.BT]3FI.9AYLG:9'?I7OE/PM*I)JCR?JY8S[4C,$Z5Y_Y-QU"1NWJC27&*N? M7:J-!+H:5NX'Q<Z,Y_J%6\G+-WK=,N<%K-%=\.HD1;QURO#*U<7-!_2PV1$- M&W0CRP:Y&B)O0[^NQ[TX&&QU9IN/K\WQ(J[=LV5X"Q5P78'LT74GKV115E]8 MKV:0,OD8'J>'-5^W3.0=`'Z:,GCDJ,5_;\$,+1^+XE<U`(`>W5<,'"M/F3;2 M+"UL$JM^I7*)#X(J!=6IDP4)B0183*=,S7.2C9(K/@!K<=WF+"FQ";1`EA7% MB68;>E"BG]\N260EM#,ZP%LFM,G@%@+5:\^R&W!^G]=KRX1(]>VB*6H@F]<: MN`C`[XL^4>6>Y`P1>`ZJ!:&\;N)#BG9(HZHT1CJ#E-%PCWCQK;E"_2QU4:61 M1'W7G762,:),HWHBF.ITH4W3T<7YY*I7N.LPSVC=V/'E*+=4,6A[1;HU9!G5 MUNF*4^I`KNUR<U,</8"64M--I18KG2R3N8>71?UO*4RK`8:_2W6J"O9?J7\; MKU-6IP!%R<ZV?6F;@<I'T7UM:`T.`%G(<']-&:XG@X$Q):XFLIR(VK-63^BA M,6_VRCEH:OTA>9*RLLTZT@R8_68<ZQT=9PKP66$QLL4V:TNQ%Y,K&^F$<4Y$ M#0%T]:LXCVZYLOV+>BZ.N,M:CDS@4`H';L[+ZSTN4H.T2!I+*0*V6EP:WP0Q M_68,*Z#3E$M4X6IU>&X)B-(/?U5;!)`EG9<->2196MN0DKIQK=VO22,G\(8Q M=267[AEWP&@I<8SY[`<`IT4;@T=I`#_LNQ06*V`(^(M8"%GVWJQ!%N\F41\- M9M!RY7'PZ)08$WW,M%.6F>1]2@[S<ES-I-^L`\83X;Y(1:$%_SUEK1KJ@",B M;:'=?&ZT`(<K@%YXAKG.R9<2X1%PH@S0[8<04/%D'V;R%'?'T`[[&&)&G"1H MJ,LJ6'`]1[Z^A_$X#W#+"NI%L8)#(@#S&@+9A#O5`$[M912UE?%//Z+["('2 MD!:_O#G/E5#_=H-C7!8L/,,4.3/M`X]E1-&)0GUX=&.M`1E8\ZQBFI/E'XCO MGZ'&Q\)T"EYQKL7CZ.@O(.!HIIT1;8PR[8SB&U,S`.O%8-T'4J<=`WZ'_Y?] MJS=$,0%[3HI8L'M07V?^D`"MABK0+@/\`>#Y2RLKT^0;/OD+XVVD0`,J^2(1 M!P+:/1.+PL$3;;."9(I8>X68&)\&=.6L,#SS0ND:K.K#2BK\Y>X6ZAM9\]37 M_&/%(S/(A"DYW8)U(3ZI^J824\NPWGY%\H2*8[*BQ:<"?=.,Z$%%-XK4R@=4 M+5R,""0MKGH$7G+^TO")7!#CUQ7)1(5?\&;YT<5&I""%OI6[PKAE9^X%P3SS M#<L<T7F)KM6"0[Y(.))JL!-^.NX>(VD^0-,0&3E&!&6/V`H"D"C4/3[`[]%( M[FY_D@YS=_NRTL'N;G]4.DA[5/O6Y*7W]/KNMAJI_?GN]NZV$$4_:E+]#MXN M_!T<Z?_^\EXOPYA%W*X49\R-)V"EZ,#I>8^\WW$@!4VN0TM0+1MR98A_&I_3 M.2:A:5F/`9!@>T*/5L`3$+2<G,1`);B<DC%GO15L+;E=S1##)6"7B*Y2^L2` M?Z7EOE2IENDBX.]#S:[83U9!<MH6YOT8:O"]U<E$!A/"U=!T`L\T<0#GU%9( MHO6[01%$4(,U"49+-4)U-L(1W/)SBK']X67V9B"(BF)>W8=3N1TZ]^*:+DA\ M]L:LE1Z+^.Z0$"JJ_(%=;J[%@9]@58MLKZNNARO@1AA4XJ%:\AO\''R7(U*% M]53IQO?X9[?-"'KHBMX,>]33;>UJ@-"1?/<QE^'AN(F.ZSM:8/P`NT)AOB#N M(B>BN?+;=P1*POD$S.(-@]/\XOTUT?&>^_+U^_>RJ/++U*S2LLCK"P5?;O"0 MYZ%W+C_([V2-D,AFHO&?!80&WIK/_RR]^(8;'TW3[[0S,YQSUZX=8+N7Y0U" MPAL]SZ4>[^WU0@G/5)IZ3`<+X4;4&LK+0-W]EKKRG_'#BO[:C+\,-#S8S@]" M+CZD>8Q]C43:P*]0.??:7;#]-B[R6"09&**''$^C]9V@*DC$W]9+KEV4*"E= MV^7O7[Q'>0=`L"E=,MR^_]W%^4WOX4^'"%5!&W[1?O`:7FY-H]5W$P#9\0^_ M!-LQ`*4SZTV3?3]L*M@5DPX&+FK?'N)_:9WD:W55T":7-L@ZUQ^($9Q0'MHV MVYFK<PGCZ1T7'=)(X"HA=M!:%N@CC6^WW>/;E(+_)O41URSUL\^X[\O=VXN^ M[KYYGVMGQ[A:/5/45=?/NF/V9Z\:6]8-(/>K3L[M1_N?$+*$I8Y7_;98_:D< MF?:]%^<9JGC5UK:[PA/PPTBEW:$NR"E[=N;<3_AF)^7U=ODZ3;_:PB?G$WGX MU+R`AJ^RC2XN[:-C7;E`%Q;SVZ,3\\MD_DGI29^X]HN2>#/`KPXO9]CLQ_/: M;T+<ENMIB;IB'2%C<:R$":!0K)P_/*6!SK$NDCAF((QL-`M^1`GW8NS+2(&* M&B@1C]E\IL#B5;#XFD0V72*YK`^1>P;WS<V/?'?['[#%)%:]_9%TK0*%:`;@ MK\JUY7`")"EMF&>6V&%]T>*>31KYGIW\ALI#UJVG"OWSX>4A[%*@'`5@'R85 M$9U<W=`KB:,Z]2A#)WE:&^Z<J=7%>S&%ZB5\^=$R!S20T6L[,36LU/O[BT=^ M=;#XL%P;L@2"DZ?5FU]">%.C0%8;1C9RE6B7;RY1>D]0/W$$L90L7@)L\OQ% M*Q"#'!=C$G?15>$1=)%DCFXQ]R\JNQN-P5XI?C)GZT9;^6)W=S"D@6W'4=`C MM4BW$=MY=&83MKH+7Y[*V15PXDHZ-F?&;WLJ`T2KEF'F!D<?^WQ]\0L>`=&* MS92/[=A2"D$UZ_1EP`>3=.K^2L9A02<Q8RYK!D#&3I-H@CD?TF@HH6878<:( MHNT.]F/>&0R%G2:CL%W&/FNT%F5=-N0B1Y:BY62020BD3#>^N20K"AD1%(34 MU-A+ZUNK:UF=8`,97*4[:!\(([/#0E1*;=._L<S#%Y-+,A<_'1X'W*D"42-; M&>H6J`"<5-)<$K5TL$:/*H,MC]A(84-IS!<O2N/<&E=0[&`GG^QDRT<?SBY0 M=A'I'RA25U<`&/*)W(L@D(BN3TL]O'7?8HVWS@\H>O?S04+;OA9WR\`[_L%H MG4VG@^HT1J*5)I2;&;XO-;<CE]8BQ$SYTS*9$HK6,.!(^QLRB%Q=?#[DXE/\ M"0!`*1*V]H&7A03"[)X1]$+==<]_IO;$@&@W;`Z1R`AV6/%+3TY6O>ERF+>( M!_</26.'UZ/><UZ:T3(\V.KZRN;:YLHZ.E)*D^29^)W`J%U:+BM0<NJ1_\L= MEU5BJ6A@9Q6E6,Q6#.`#XHI;U*JHLYGJ3BRTQ`IBB4(PJ>R9[+H$](ZE!M94 MKF+MH+).68'MR1:;"I[SFOG'T4PKS":!F\V2>F24\ZWIE7D!TB&:P9<VRL<6 M\L8C'XG-D6ELF_?>SX`Y0DE:5O`+O9%+K'!]\1H0Y@W"?29WE!_=N:$=+FV> MCB,Y<_F?M=K1BCMO^790:<@E%^<`PZJ*K`3<*#`R4'MI6/7/7+%@MNP<NIF_ MI]K:NWJHG-QZ/B53-XD0+5^@ZB9`Y!CY*H7ZY<([H@K(BU!C0MK;`W,/A12# MO5B*O&`53AW/^3;%R0@FV5Y!NPD]S'U48VV/^-Z-X1)879]3X@G./Q$A],^5 M`1YZ%N(@"<Y1B>(IAX`-F<Z1^"WST@YA.9`O^M499WWE4B4/EP6G'^@@VC=+ M5>2;^,;YR9-#\A'<`U<U";,%&F#"K0OQ7DC`A(IG<IH^<AXV%&L#X7`/2$$& M)]V=1K5RU5I=#>J??,3G&KH2\!K@@<*[RQ*(+S>1!6'VS@?F^/KX^B(UIIAV MQ7*'^!,4HF8/TA5ZN]XDQP;=^(S-^U'%_;+K:Q2DI+P/LO.=7=41O#2.4N>6 MUG=6R?9P%X*$:!!QS'EX[4W/[0P3QHSC`P,(P][3S)8H`#UG:1UJ19B>7,#. M!S(/BB>\"XIJF1K46P]*F.'7()*3UIQX8N<(WH/,/0;QN)T8TQC1-!-L<!PJ M>SS0P_1:.OBVBN6/&?$;N!&QA%=(.Q,'TA:#%.`A60.0(*O+/]UD,7P>$/@N M!15'R(PW;HG(;I/\6<<*U/S.[@V_)"Z\+4'1H*2X0#J^5FP`RFI#":,93L<H M$M.*[Q&2\I&)MZ3FE:9;:&/NIS:?[J5$-]J7.*(?-RX1"CLD!2QBEEY@>KWB M&_7V9*G5I)CTTG2K$KRH9ZE_*G1.Z/KF4NM:FM)'/PMG(;W8J1O/0BL$$#Q& MJD'J?99%9M8N8FNN'%VK%SBZA,`.P5%X1$Y(HI7B.C8`50I8;8([\%-F@H6> MV7;UKM-P@$B_=:!M#1>'P<PLZ,M>X$F2EUN0K"U+6;J'.#R]_3[>[0R"HD<& M*``4L=*4%(%7G:BH.TAU3%6+ZGH4W``*3%T*SY$)Y`VIU#6G$B'EL(E,/REL MO-UZ.:#3?W=EUV+);NTEC,&"H<6\C)F(CW57(4;=N7!+V8/(%*Q&DCR>T3=) M>C)4X`4;%'!+C^R[QU8F_SZ[PG<@OPUY!J9)5*S*T+H@45P,5-FA#1OH,8QW MK*%Y!SE%4_^$?AXYUTJ#7W">"4?!9L]$I$8^:_$$A(XOGLB^TQ:+:51#V7RI M.L4!$2<`NY+2HAU#)AVA=7ET>D[#S7`78-.K[,,6XC1MDQJ&YIPG4"2WV.5= MMOQ)18S:;?J40[%E0+>O,`8_RBPFQ>#0T+@X%\3-7!,;\HQ4Z,-KY'\P*XXQ M\Q+C[9)^>BTM1MR&UE/NZ?N/[![IG5E7!^R=7Y>]>QY?;KLVZM$(&6QBQC%" MV)6=)"[\.;.L]>13#`:U^$).>7+,HC8.#("S*Q(-/2^+,S!CV6/_@#^QMG!$ M6E^!<])QGJ08I.SF<!G.\=6`4D#40"XQP#S9Z23,`N<X7CV6E1SBU"8!]NTR M3&F$LALH9#*,^S?S=\+>&M,?)[W?PN!RRQ$_`S$2_GM@#<#;,7_5PG7T@B!O M9Z>?CC`T3.,3S+IGWBH=O=<K$+?O[@];5.UK7CK57;4!I'UQGR:T(!(ERN;0 MJ1SFZ8<AG_EK'($T5#HC%)V^+HZTY5<4#9W/;N`%.*#1)90C1$NL^6S(]9[= M4EVB@['4;O?0<X4=%=Z#N=EZ2W[W6$_TZ5^PTN*VQA&`;J/\0#E*9?!R9,[$ M,HTQE]EY><?(2;`^[I=U'[XHX_!2!HM('Y)3>!+\8]GJ:J_,*?G2S"@06LXO M%"B$2&WHY+#_;7;XBQK.]=C6CYE_+]A5%XYA'N95#WK=G=,GLK/5_JQ[R!#\ MM2A'@OW+DXWUC9WU-=*ZE;6&_3_G#I29>H?3&P.?M[BX("C.00P7(!2'G65' MID@=[ZFVK(LFIT#&?T=0A[>U:W:Z_:;34CXG7*/G9Q=\94IR@DEV%I4X[EL3 M%B5U.>0K8\G&E^^EDC;:0-FT029#\E%+J6H?:N[F^!SJ[("VU%U`#R->]+J[ MAI*1M6`./+F(W>"O7,=!5=EEO-TJVN?<A-3U"1(*P:<NF9%(9`$JUI[F3*== M_!00L_$$&F9LL=.UQOR-*V=I8ZMR>X%''=&B51E.H%RJ\="(35@=<=6)(/G/ M)M?T@?'`^Q`;<(3,^^DH>^[)[$Q+^(.]Z*"QJM!4[,K*&@<&%/B>-=@9\>N9 MAL(V<YS)M&/O?[R=6/@)X,#A3/*AJA!J+HL"(P*>N^58]&)0+GNWRS!64AB? M].ACWWUH<AYY^#$=Z`*D[>)G;AJ;)"DHI6/,6M6"@4RC-4>.91BY\#AX.MFF ML2`XW,G*C[NZ92G[-=>2/L4[!8^M?4?ZT>J^/[B"81U-E.>&X((!=YQOELT( M)7J8:(0'2*/,80@IU$J8Y#_;9W9RY<6!)N>T(-(R$@^Q+,_P.J4`;]\%F.OW MTU>KD[_)BF8@A"G_Q:"XOG%/:OA@9[G%2[B1Z\D#4#'_$>O/;DY,.6QJ(3-G M<6/.3L<L#1^G*L2O=J/4$[>#DV]*Y%M9C7`=UM$/F"2SJ_A1%1A%*]:BS60) MTTB-9`%N?VD]#'Y7`V&&4D3>O8Y%P]8KU@I]1R,L;Q[><CM>.50_$)WNKT#* M<CVP.'3&`.;@4BJ.WC"N=\!X<&K/I8:)`^1T`X!"-COQ@+Z'$_0VA*R0H5MV MR:-OU&,9ON46B.#4F2\*,#ID#;*`)CN>@T<Z-\U46=I;W<W.3-`@1&AL)7/N M^W<#L,R/,N2SJ"'7V)]<T+*ZDY>0MKRT7HONH9`PI]BLU:E`HQ-(ZGAH,]-K MOJB\(HM@W%H8K;6]X-LNT3<[SX<M7*\E:`#?+>^P`$33'=W`H-TUQ$SZ)$WP M$<9W);!JT[M=5S+%DR3CJ"JSCJ55@D0]!N/MWXVCCX03ZUK:7=W+%Q!U5]:8 M[@)8`T+M>FF[TLDZ.QOXOH)"C]U9B!G^EK7LRJY\_O=+]>9#PL&$(E=CU(+H M&9NOSROWX`;W&Q+E2'W&@TEUK4XDJ;O[37L#JJ3WLK0@"NV[0@0)WH@D-I9B MV*+CFPM3%"Y9!L';0Y43G4B=LR\@&U<FQH=7GA#+30/=8^5RPF[4BD]_!;.V M/KV#E_L&W%KM=_08/5<YXG.(16.)5RZV):&LDF;`U_<*B6)H2ZX8W]`WXP`F M9T"(GBX2>W".SK2);*2*:F$F"N)3FBE[`FA;R)=GZF;YP,HI2PAO=BAT3L\F M=$F8R$Z=_X"%<@U<(J=P8U3&+F1^$2;T<&).5X<5[LKO?9\Y9^'YI8UFZQU. M+2[SQ5:<?)OWFG#EA!<=:BV&N7>4'$E`@C)G#@;]&'I(]B)DV\Q<#=I'!Z*< M"=$TY?J8.0#ZWY-95/G7TZ%GW,=$NWQ49I'(W\FE%IZ])2Z@/+&\88.LN\O1 M(7K\_AU`#.Y;:YE?KMZ:]$G8OIAH+0*(H<#+_RB:L-%&C5A9EM<*[CC*ILP< MC0#36Z!*?Z'R:;$T,$83$)BMW$4/TSF-V6?U4J-`#"1&I"*AA>AQ!&/!O9], MJBI\65A>)QZ102>L=2],C?<E&+8`G/"T*NYHJU=)N5UK)2O30ZK)?:OM)%RV M[)9+^4=-2TAI_+5!XXO"_U'XM5W(QJIU!68EXT3GD2&8Z#?-TM$4[XV#*GFD MQ-%EUH5!!F/@K[*0K$^C08\#KM95>I*@%@+!N%(\?Z-:!=O,QU3FS]N5"F\' MG>Z3ZZI;8+@QXIS;/8@^XV'O>QUR"#101\=ZG%,.PD>;5\M+X._#(N8=X6O5 M`)894GDCTX0I.L[4351<WA+9WZ.A\=;X>IB@JU)6\GDXAK;.2UR8-15E,!0< M79#4TAD[B\H\!H:2J_7&O@'[%V:X_$.Y,<$=):;462_;=49+O>=$(7ND;C?F M6!)HC9A=%$%Q\]Z5+1)I*Z*K[+/N>,%30RN_1Q-O\W70Z>IIH.U"-H6[#&7J M/(@79RT^0C?_8]-Y6AI_X2:-8M]D/X3_HP#?^KW8E=XCCO9*<J&86I*EAUZ& ME3W+\!KDQ1T*+A]36&;7767_KWI1A.)U0BC9LTVT#/OE>D:X6*[L[/!/O-ZZ MDNKV'=%#05YLI4X%B,P0%86*@5>%1Y'-$@A4,S)/9Q#G*,,:^P]O121!@-;D M:-O="1;?+"D\F8\57B@>FL'P%T^CR7^33Z>""<\`2KZU6-J<@#DQS@NS.)03 M+N7]-\Z7"[;(?>,?=7!M7(-I:F.XPD"]!WM@`;R6N#-\J#)Y`NC=H&^*6.>0 MK\>]1]5_J34Z9)7XLS*N&SKQ1*#G9`M<XO+G]Q!%LE5*M94;7CG!*`YE*&Y4 M3V(G&/,H\_>1CH!,3(DJ4E9'%]V$-'%N43NJ`$HGMN_5"VD#,KJ+T+_7>]-/ M)^N@.X`Z(WB=UU!&[IC^`GS-$SPS#V5^Y-"UK2\]R83-GM]E*2`9H7M*&MP+ M_.H'4Q8A=<VPOD+YR<;*&EW`=[D6ZI[RD^"U!&.&*U`V5_>\Z!=&].`*E)0N MFU1T;RH&942@P!R7]Q0RY(7))6EV?V#H'UG+T(EA=LSW!Q7"Q")!8(PI0BOT M#?(\<2>)Q]3"K*WNQ<=6YY"-3)4@<,>%^MP(:VKO;4<=K87!/,7*T'"&LZU< M2K+HK@E5&TZ:;(%KX0C-#!6MJF*1&9$L1$[,\]5"$89Q+3#F'Q@7&R>H'DU^ MCZ)P\5O,+JXA86R%3%',1;5,G%\_1`AD5!I[9@YS<0%ZC>[+EC[^R*9-P?!$ M/<Q+A3.[NQV<+X.\:KEC-FPU"5/:L+W]O!U+!,DGIMJ`SH88^X$Y@__*)ORN M@E8QNV_:Y`:L`47NV$`VX4A,MV@<0[T2[IV]-U$D#8Y,-PBL=L^D7`2C&BL5 M4;W+TG1:M;M`"F6"C5D>8A2H2-=N_0I45:?4G*J;2$9>V)KT8P(I9Y>TXG3G MBM3-++WUC^.4Y@$NHZ3)A7,2JL7[TRM<.]V"F:T>TKUFTJM)YQ2>@9_T`#"K M_ZWCZF11#X/1CQ>WDKF[W4T-S7[_$OZ*\M[OAX/0)DBQYO':5Z9*X*=ZD=,< M`/DKI8">77RPK,=GIW/K;>DNE0.2!7_!DZ>K2UZ]>/7L0/&OR:&N\79AI>-Z MZG7J,!+BT^PGB0:O>),^&/7%5V/$K7,_O2*7Q-HEM`G1.>9D=Z1XQP/I/)\^ M'\Z9__ST4%/1O]74?,2[W5,C9'(SW=MY69Z8.?$/2#'*%Q@37M0>;'/UQFY, M]PX=%Y#536&2UE3EKECZYNKD9;F8LR-E4PY(0$I\6+.2SGI^?'K)Z*Z`\4\, M0S0(_6A#3JKL(6PV*('_,Y:Z(8KR/.W4<2LQ[4*@]6B2:8G"7(K;A*GR`L[. MI0TB+%:34W][E.-\R%>:QDH#/)PK.^A[A]FR*R?2SE3M*P.K:5_YJ]>B?W?& MI852BJK.'2^B`4G]SE!.-215%1K2JENG%4>+P5?G0W=5]A(R-C6GGFAP,6`Y M.?YD)9*/K#L/NQ]8>13\=,52P;\U(JW?\%BU^Q5-JS4-,Q.AXF14*APKS*7; MX[WLKA[`C#)J#B??OWMN!KV\N"PC#_'^@GL>>2"=8[PI"O`1_MMR#59'@K[C M7(`M&WRPB^X2CJW,FL>A%Y?9#X_5*L5*YVR%DA-N</(.Z^9+E9D8U+7J.M5? MA;4I0E%5(/,]VS47@[&*?2C4KKY+;"*6:TU2C05V"I/9G?=N#,$JWKO1W6E% M^RF5G:8$<+-$]0W"E+8Y1OP/H/TD&KO;'3Q<D?]B!:)'[V_O^6``A[3?AS,# MJ6CSN]OGRH&XNPTPFG[2DO)S1#^U"O=NM/WNY>>+?['&.TXW[<]0=[DHNSWV M1Q!W,PWW49^@9#R8#O/G@T183NXQ)$B3YM,C<BS[1420W_4,?U,756NBK-;S M,(H4,<H=I9NGS3F61G-F\OM)M:94&'EFP*@!XL>E4N0/)*]<J#:(=!6('D!: M9I)G`A0SGBAT3+&.6"P4HT<RN6`,!2&G7TB296V/H\=%1);';$GH85R"SW\Q M.FP_?\;%.4//N'@P7U=YGUI-EIQN'1D:2@2>V/KB'F*8&;DE8NK)B8.BE>'/ M<8]>GE)88X8S2F>':4D`)`TA-7R47EK&/;M0LDI]>6$H:^`Q#?FXA`)4('L( M3Q=!FXX?1Q817>B$[:6(OQZJ3%.6?Z);B4"IE];L2>+)&`S=?NGCR%"Z(MCZ M5N'D*)?ZM(MB#][0NX>.+XQ%8G0ES&D/TG4TRTPD3R\,.5:4##>*:K6A$+2/ MP]8\>1*"[>2,RBWQGJ`O#O0T>FJ@!/6Z""Y\^>&X.%DG1"A<7#C>@I6V/[VK MP(,[665K%]Z4<WYY>,RIL;%R\GYRGNA&_/T85X^:G:6;8<%G&P*8HR@!-5(\ MK+\<B,&%OJ:EPIA*2SA7?.R(_$,98A)JN2$`OZ%G/K&<;;?$'&O3/):F%Z)` M'ZMOHAE`J;>2/.ZR?4ZX,0#N-T?U]3U5:)&R-NP+T5.HAF57"0$:@99=#N+/ M6%KI+>FOJL6X.E37M"=&=E:-4?QUOOJTG_9$WM9C/0YCZT_;8?<MG[''3DB% M35D6UMG_YE,ZPIR,X4=.IN7X>3_:2`/IJ+M[CX1J5[F0AN"U.C:[Y4!UFX38 M2935D1VIEH#*E:[UI$!;(`=%AK-/?L&=Z@P,=^"P/TOR8HS9,E\PT]0)_ MX@E7,:P`#2(Z^D=,8<;U.1FZ]H$;"&9O@^J&X>"\O$@6NDHYYEQ<P\@,`F.B M[Z=964<WNF=/#=Q@(J#F]063V65@6.E^SSO<5YMK4?4(V'D%E??<B/1CQ@\/ MMB;'@955+O@@Q`%B'LT^'IZ1D=X9U3HK69!6G-3NY=$U07P-BMK-"^_5=\&+ MCO##G@*C3X<GM"\1>SV]PI_FW4479#4JJ1_$+M9L<R!%$B8P*G+FOAM=B6'Z M7X(FB[<(H;&I]-LL796;C+`4M[/N.S7\,'MP:7](=AUKM^8!`"M68_*"EG.Z M90J!$JR@ONW`F)M02\=D,.`\YL#6@4K_+&6,WX!A_,LC"E+`\EZ`=JR<-_+" MN])85QYYS#:^<W3S+UGN_`8'W3&Q!,^[T7JLX>C@D@.A_(P![`674-`4+2?5 M.VT0EOXRH+LUZ?Z%LCN=6:S>Q$!`\_CTBI;,*B/"IA[;-]AG:5X!^G0!B)4% M&3;@4RIW&'E3@S.H*=TY\[M!%!B12I,KD+'D%V@]_78MV4EG*/?ID#M5X*?% MX5A:HB,J_*+T4(6PA#,.#LRH=BZB:;&"8!CX"JQ=#VB'`@HJM2M.E"I@Z3MJ MOK@IA_)M-?DP"-;'P->_TGG>+03C+T;37LC?CES09W5RH+X_XR^(4WPV1@<_ M(JDR6I(&=.SR*5:*YP>X5A[/!-^<"F_N5&/V2FE)')6-H6EXJE5[OSNY[:JC MB*M[(5!!H;3#C]O4HN.GB80D\TU`X+K1];+IHK0.QQQ05+.F;G':KB!Z3W(^ M5AB9A[_-N;U3H3#:5\*'WE\=WIS<Z#90@?#FV%@LLB9S>-F\ZN)K!W8^^P#9 MSJ`:L7+M1F<DOD/%KBYTHC<:%[);F,$%6/)AYYP[2T_O4AQPGL]FM%']8%=! MXEC[S&"?&(?S0&F((LVXF4[SBTL"=YTLTBX25R=BFJHT=;EC-09B^T>D]?`N M\@)+H7L&5EMC&G0/HF@"G)]?H?Z&<(]W"SM0,+)5&I[#YQ%3BZVXR?JZM:1^ MQ+CL'MCV5*8U;0*#QKJ9$`S!E-+_[FY+U@"<*2W8HZ>II9::N8GR`%&\R[U6 M:ID'^'L0>)U,2R[607LNIE]8,QUQJN@!M.+-EB)86X1J;E?[;$;/W=,9J8G[ MH3=8%,94E_+CFRMO*OULILL?)M_#IR8O7JQ,?EA]0PK/Z'MF,N%S0+"@0`Q] M<(!N1/_KR0&M?.R]N0T>(PLZ9?21E_%0HTCD:7Y(&M2RO)UH7C3R4.4,0:8\ MDCNO"T!IX9\`"JCF-XJ3).Z:/RGPZ=)RZ>A97MU=6=NI>Y8>$#.:X7C<E\\J M8W&+%%$?YF]/]G6;1(WF=BYF$94;,^'THGXU^EW94M[EF@)4CDU&[+K6$]&I MS#'#WLH=C>>?9(M<\HG0EN).5)[_?US'^G4(!.4L`NB4;KG.^$MNK#@<,GZE M?D_KZ0HC(THEWL%O,:;2%<4]?'XG]EMN\6`38@:=F5%Z+I)&H]_&(&-NC!JT MGBHG+9JOX*ZI^6BF@PRVA:.BSA)S+`DEB<FJ?[A`;E>8F\[E3$\L$U`<PN#. M9]QC(;3V11GK>T\_]9LKNI:]8TU!L]EF]*4N_%+GPB5]Y[,G]%I%TU.UFR22 M>LK#Y*5<J;Z-PTJXFXY`:QV%W.B>7(]$&@A$MF7]P]F7![Z/O,MY!??>$4-A M.1[*-:`TU9=/"$P#RX:)I(_VSE?3+.S2<&)]9;KIMR<$X\2(L>!*R5%Q2%<G M(.-9!V013E,<C<MI7_"/4N#7..$*7;MVYI#15Z-0M9FX2M&6:YQE"#2*?`(5 MYSV+@@$V[V]BYJ!87IU'I-6EI/1R9;=)0X)'H-0?<_CP$+XSZM>B$^J9EZ.2 M$<%](AR[08M<&X`[67R`S#33NK?B-%N>.;)<S^O,_9>KM1@IB5I+',YOSI"I MMS%=6=NH4_`<ZG>WWSV&FW[W.&ZZL]WEI=[$Z!YF2C`N<]/>>3^7C6[(6M%C M;U4]3F;8WN&)BCFB\8H'*/XH,#JAVXG&K03_Q"5[2!J75?Z[C8TLL#`-T#;K M+Z@7Q*HPNK\N6T>AM<Z*3M^;[(A;$+2_E!LN82?FUUF&Q(D,RT.,5^PS14J] MD^#%;^B%:@>)-GD^V5O=V_U&8VE=UQ=RXYW??%(#7HU/ES*^XU^=E?`JC0&= M\#1-Y:\V7X2&4K[-H!_E#'M(ET/8>FG:-;\XLQ9'Y@XA"TY*&4D?*PG<-GOB M`'UX^8Y@[\K;A&U'>A&^4S8"HI/QL;:V7DGK(V^%J;/-`CO)6>_FZP2B+=1[ M3DP>PRN#9'11R2I&\)MQA-KYZX7Q%+_0(5^V`9^\DI-7N4X(0<P44U,E56GN M:KJ^+X,(J<.R$C4R.WZ^@%E9BT&]5YU"L,P^P)`T>4[`<X@5`$/0T=>L>6QK MJY-_<GU#*#'VDDL2.=E8=6Y8F<\(P(<$G=-V]ERN/MOW#6^?48F,IHI81W;Q M(A<:<3@&'BWRJ6<I&0D>71!XTCJRL\,ET>BR4*Q^82A@*;,]">]ZQ/J\I07P M"OCI6`&V&B:J50]$E5NTUM^/8;9<4C5B1]<A+'_VC)>(G9HCH7IPSUYD`QIR MM9N"BG0SD^&%B5T&_AD?A._8RE)H/\A6S$N&NBP(MJ"E&;B"84D-4<F$7*5A M1MY(O^)HB-PG6DW:31Q=P27C3\G1[3I-:'-FY-:LS#`8I0O-^\G\].]@J9A: MJ$+S2Y)$DD_!EQ("=.I,K](_['8*T\H=%>X38<=67I(8];K=%37"]XK.7Z-_ M\':%9"ZS+>';!876M[=7MW?&6.FCA^Q)O'?0Q1?I]X/,H=[,EZCW_4&EWJ\7 MB1T^E/_&ZGU_CU]7O7\1_IM^'BS8O]E@;.9_]5&V>&E.E/2"T1.(NKV]O;(] MBJE9L*/,TI.AR<=E';IF;4"!G"S6'X<6LH&-O;DRG6Z.$,WJ!(/GGV_./J/5 MFW+\A5`(+SXQ>+0<A!60D,E4`O&%#SR(E:@Q":QQ"*Z[ZZ.;$0'[)]+AY!Q@ MC(<84$A_W)F'>!+"IY1R6GNFTSUG((.M-J,V>DQFW^1$SR>W*='!:FW)Q2=7 M;;5%O"]RR=6>CO^=_!RM-S*Y1LS96+]?/"/M%W1/RS=4>F*JA'D);OQ`6+#] M!E+$M&X:&:':2*:BM1@IU?>V>NS!@*=D>;N![L0\MN1C>]SQ6YUUYP9#CS]B M/^?E>;P3_:1:'D%-=9PWBT$6DT;KG]L-%Z5?6=M&5US;#4%)+P\AI*ZOTX17 M*)O>HU*TH76F`DK6+(E=3(7J8`O5L,)2RV*&T/I.]MQ*O]IP]X)8F&L\>8+D M]IAA%IMO45`J*52DXZ!%^1IT:E)LW-VO53V5!ULZI'N0K!3'W/.([:C+D=WR M-KI,-1^\`+17E[IU%8+T\+*&/9BQ>?/42_Q?I]'ME_CC&:D9NG'5N&6EHF1] ML8+LI&[^J5'D<UJD_FC)>L^4=ML/$-2#!`%3B^U'.RS+\=7"R.'K`D2HD_?G M^M-C#E)N%Y1RXB:LYV*R:SY1DT++![1R=$K\MH>+K%+(8,0Y>5T\\`,H:;E= MV6?#8;>^C^(LROYTWT<@0^)G+*^\NGSZ+;4:NU-$R[1B4<<=)$4QQHPD[Y@8 MBF4@)L?O7L?IN\(-OS;:H`MZP+OV"(<R5CX'S?B:H#B$B>_$JM97UN%!Z]N[ MU2Y:/.CLRIP94!"N+<1%7+"(MAIN;;P`E4O;W3"E@O+#%;REF,M@?^/?IK_4 M>JX90;57CDEVW"+<E)G>_VJM7*^3D+#VHIM,:>999YU1>-C#KW<BH>1%,R>, M!;]JS"%:\W%V]A[DK6ZQR\$P2"DY>@*)G*-D[^7!\Z?27E]13"@'"4S3?(IK M2K+Z>(K?J<>SNF_O25E9VYTL?T]@DF%628F>3I^L;VUM;.U]F_RHL'$Y0("6 M3C3OY_KBXA=EDPH;<X`JXBD]4""FAMRO>B8KF_$_R`>CD*804\UL]="8DV%? M1COCLD@=G).RP^V-E8YGI/N^7"E%EP#@C,MFB::>SU4JS>*%W5*S]"KT>01# M\W4QOI$)*2L66NQ2-)^D^((`DU`R*"*[<DIW4ZOSDU>H,HZX@>9C5"U4CQ.P M.R0SQ$#$^'!,*#HOKMII/WJ<#B[3E%;I`&7/^D/#>^*B._H9[-]N".C@Q#BW M:,6K_8-G^_\G2B=([OQ%%^:\XU/7/@?8BE9DK8B;U?0WEW#:9$1GHR.KD^/3 MHQ)%-YVX:0VX=)&,B7DA:D$/CE._`.2;N8YY6!/P/?67N'"7.<O#9`Y(@]L( ME1U^AO=$^`(8^%L8)6#W1^]LVK2F%'LA"<`*8_`W6-R;1`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`(:[L$ M<D(#[\4M1<2)0K]KHY&N7Q1%.@OKI7XD4L2\2`G?6=G=VUS96:N]5)H[G7A? MT+H2/J!\<U"[]<8,`CF`VV=XC5*L&&I6BA^J>V^6;P9T;S/5M9EQ''"?3[.4 MK:HQ>H]\(<BLSR8OUU?7T#<<N\U=,*:A%Z]6RO?J*>@[N^N[>Y3,2W&U0GB_ M(`)3:J$]<7%^=_L]U;]WMP=/IB^??P\%/\C`""87@?]QXZ+[IJ_[[K98%KL; M&QO;BRT+A;EJTR(-F;A"[Q#_8,O"%624EL+ZT:%^YJZ2XGIQYU?)H7#[6-CI M7^M8VG?^*XT+CCPL&FDA*![DO,;5H`*O7(A]III]QW9QLZL]J+FF3Q?K:4R/ MZ[#0`LS[:!BA^U]IT/09]#^80>,8A@+Z^\V:X;U6*C>S_/<Q:_J[^0/-FO[@ M_Q/-FEJN/\JLF6X4>\@T'G&!FD%@UW"O2=_V&5.;G.,NK6]6=Z%(2=&XHZ8- MDJ+'RO6!7Q19=/#BG5\F(]Z]QSOHTUAOP2R)[_E78<2=3-97-HD1TFJU\C%H M](7:EUFO6/0Y=1?GQ=+.:BJ?Q6PH+L^8*7VB%]<K/2L\?F)7*;/%$B3RBNN& MD55J#7B<@W6Q*7M@5NXQ'@B2^>4ML\R*(MF(3Y*'8D(1U4GMU7@2]6Z+]NWR M(D&E-O#U4=])$O+8<BJA:`>[<R8@M57TS'=\_YB6<1OE8W/.Y@Y4VB1@.:)U M`5F7V<EW-*,#9XKPU&WDYG&S4NVDH?HK>QSFY%:;W)5SFTP=<Z<>69WR'*=6 MBMITWAK2<KZ?'5W=J"JC'^^3JP_Y#+[D%,QK5MID@F;*DS3.]5-S5<*"303+ MI^LK&ULU_BI;KR93/[OP=';23$'+E&P^Y";?K"Z!]T$ZMF+6[F,QPH7DJAL: M;EH=/*S`G/LGBO^8)UD?9S@(\'((R<UL^G)V8.=BWM82A4^$!CX`Z__W^DV. ML8X.$'H8^;=4&-!"#P?2UPF6!5^7]RTSPW^XP%/E;'M$V*GR%@I[.\0Q1`"; MQ0GHY)2!DS1M8%3"C!$%^OOLBBM?O%(_=YLJ04TCCU0QJ[K3",O9!Y`/N9#= MD]WJS)W38Q5&:=.-DY-!U*@-YN6:0#F*[L+#WOG)6)YQ>"[<7^#.<-O$'Y=E MK,6.2G!^',\Z?E>^C(!(=^?F\=6C-O%,V=U+6]5%<V.N[]1`H>,!M_UK5.]> M:2(,=O_)[K^<_QEW`3J0E1):/C(YMF+^[U5#8;WL8*<3ZIE_>?*>?@OR7N+% MI``:5[E)B?75[>UO5D@?/B,5@0Q(R_7=7>.13M+F[57VC,(O!7JR.`I`J!7L MQF29)+VM#<0PBAT1N9.?;^:E2Y]FJL=%)DZ1N+T,397"CR<`P*ND'T$"R;O0 M=9IJDM"?-@9\CM4BPEV0$;MF4E_9,5=KB??ZYFJ5^?^3[U<C7RYD+-;,_P7Z M55CY(?2[MKHS[='OCDCZCZ1?KJ@DJ8"(W_;TJ](OFEJM%6.5#=)?FT)=T>T7 M.\63<TR%X2&&S-X:RG(8YR%=/34;8OVT.79JLE<**=NL=A"<9[JUN[*Y76OO MM>;NUHC[\%0[:#4.L7"31!ER"/[';:*G&E:I5.5`L$L1-*%3ECA3<MNKJ$U- MI_OMCU]9\4^K9C+6@16^M#\\=RUGUCY_(^NK??A<O8DLJ:[]Y1D"KWWVPE-2 M-_^TL<9_Z^LCOV__:6-+OV^TOQ]8!^W7)HHG;VC$ULOF)!MGTWYI/^7\R^V` M^!D,`[Z+@I-G5.P<TP0"6_X$I4#'C.BRP9Y;X@J5TL=$),4E-&\.,^;Y/&+H M?GVY$"R,HBX0),MK+#/#(_\2#*G(;FW3Y4@>2\J?"E)3G2)?6W]5J2*<&JE^ M:25NVKL2,[>R5F4^W5@SB^:W\#:P(/L%L6ZPU#)51VZ^^2AF\I_PJ:`XT`F! ME"+*3;!DQ>'ZOR6=$WF=6[!06%L`RD=H3&INH$;(M1<E;Y@2%U>OK!,"+E/; M+VM%D;.`GK<(`;OQ\Q!R.:=[U]HW`H9`:SX/FG:26^.*8OS0H=^D*X6*Y!UK MY?*B&G@$;+;A$7#;;ZK9J59K#K0HNDI-CE%P3:QXT:"6VUD!B>]IY[%EX'@^ M^ZW`<E)JS[B\[7JRL?5-,MCEP+9^7CH7\C"O/Y*OP@PD)9M!;W<7$7>E")6N MN@"K**F#T\[^3FF4D"R?8SMW3+)PY/UK.Q5RD(W73O;/SZ4IOYS-;'#Q':%> MHH44JKRO/K'*11:4L\9K;@J;+R.3^:(X-<`@GP[T9TWZ/"%Y?X2)VC+0DLU6 MQ(M#3O/F>-P>:L)GQ>#WK:7'V=?W]G;&^)-^ZTJFFAG9EP:YA#)_\C_$4XU& M.WPIS^.UQ^_`._M](6=QV@Y2K`G:L+VBXJ"P9$'TT:F<2UY)T/8,7Z=R28?9 MF,K8QBE22=B#W"\&#RJRC"EVD!98H?0R$WOK,#9!1CDE:;:[PK%^^T@5);C@ MCJKHAT7,]=4XIV@XP>#,(M,*A@5H!5AV1LU87\!55.I8A:&2".I+.ZRU=*./ M:G-SW3-<UQ([Q*U"Q7$^K'.'^PZ?G8%Q].SDCB1%])PB4EBFJ4^%DPLTNS"V MQ-'A<^;6A<!D#`_Q]O!T>")FAZ=:9$6>=*2U^I=H<,_M;MWLJC%87_NF%LY. M@(_9]2*$'=VT9OU#-FN[TT$I)!%#NG`K`/>R/\HIPL@IN)>0+6W8/%5U^J-@ M)UJH&DY16Q4YNL$J2,'.BDY0G*M"9X>7<_P>N!5PBT2KJB*1Y&1W\0C.66FI M)ZEJ6J>*J(<_(=%=I50/Q.RRP>`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`,VXM,EL+3H60 M[N%U;XS</=MIJ%BA78TZGXNQ01J/J>&=LA!V_%]:@]T0?G*CQD-FUKATG.GB MA8&%>*VT+5[^DJ[FXUX%(A"=51&8K_+#V*%8^\FIJJRL'*&.TG<4KS%@9`TD MME=412=L7\?#QI)\6-I=[?1WX1$ZQ\65C@E5UFMJDNL]<6)ZHAOK=6;A)G8W M%:)[$J$4V'1DN))-NC1=W=VRO>A?>U5*R1]T&BT%O`/NI4;SPIU:#K&)L(_= M:GG;+&Y[$\-P<VL'_Z0O<;JYN[*]-T413P%V>347HH'M>`@PHQ,#AIR$#'BJ M%DT.I8T20GW$.D(]5#]+PDTT_G5?&VZH7T\1,K@P\F$K[8#$C!N4(]'AX$I% M,X_;FU0<X?P094W(X'"OA<8-PH^GZ<H8*FWE+31U5+H;>I37-)<>,KD"T19^ MW*GR9D?H0'X55$^3&A0^N).3?G6/^N2>7NE"+;)EW6%0$WJ&KY;$9FRMN]N? MJ!SLZ0UH[*0\2SEK!QY<,+LNQ<`/4PU&QG%":"==WN"<]J9;O>?;NZ3O]X3N MR-CWK;$W#AK#.B4"??FYN;*WUQ/I/U(98U1\-:Q0W#=]7\)29;$[[3\V.=*" MXO?.WI=QD,PHH8UL,0'@2QFHB\E.*1@A[<W(6',V1$`]'@R)O^`WG_`&&B,1 M,7)!D7N\4PJ3^?%&]H`244L2]S=4@!"C@!U<?#BW:\+%66)4LR;C@2D6`H@D MNUO`+L.JT<6:1I:A?+JZAG&P.#5MMA^32\[OLFRYX<?0T^X1A$6-FOV`!)ZG M&O`HY$L3]]B99%R<`*$&:O]<WQ@K6W8I71]1Y%8!.'2Z4ZHS6%DI>A;$3&8^ M<>A$M[BT!ZM&J1V9WORS.+AU>MGS5UTKD!V&R09PV</4O!]?1RPD>4.JT`:' M%=78*="2EE?OS`'(JPDU+=HA;"FGU!QYJ5.N<"9YD6S#;N(S9$9(!M6B"TH2 MFV3="Z[4B-T9$EECN3E6%%D@5[^JM8!C[DH5&="2NW@M8:VGMJ9!G"BY-3I5 MN9<^H1\:`1D*#(&K\GATE#FC^J[%YJ<_\(-,.0=2;+,]1#R%(O$P=WM7O![( MIS&T/'<KH\WP??_"DY8]/T]N98^%//G.2%N4$JRI_:"F)+5X-P!W"WF3?M3- M9@+YLR?8ONFB3@U)1SQ5#V44=X3/!+((_<W!X[0()6BYO\QTU<`EO6]HI7.3 M$JC(WI7&QQ1P0DO=[2X(O,%AF,@WP=36W;<N,HJ%SS99;PD.<H@VOW2SKO1] M8DZ&[`D6\E7J)Q_&?BF&81YS-,7K_L_%0]JY\PPGT8KXLWJ+PY'D</\\3$2= M1+$!+NCNM@!T+G_O.,M3-K76\P!LZHB@0L2_M698=>`]"@JM.F<P]/2L((Z6 M!IX?O'G3/GL[G&K7OO;-W6W[Z*><@M?^\CS[`>13AY[-5!A]JWMD[6OO@.P8 MLO2J!XVRC0$%_IDQ+97!RO,MK;Y6`WY</:#GR#O%.F^N/IOWX`FIVI<(?,5( MX1,IYI$\AJF1XYQ.[[3A#/&=L:^J:X@%)&).A#(YN6#,<X(X.%WI&W"IM$:$ MKE88<*#TS[4DA#/$/#,.GYS*"?<I<5=.HFTW22?3CV*(B6&_Y(CY0Q9`Q%E- MK,Y$7^J_VN$Q[@PT!1#M1=BN0(,F<&FK=;DYRH_4`F3V9)LA^C&G(05I%TG^ M\12Z/*;S_IET1SD:;6SWHT2LOS,.C5;MGA'U094=?JBS!`!=9GAY-7L2PC3Q ML7I\7R8&:/)-#@DB':8NX+00J"E^6D?BJ(9QTNS*D=/+%A8QR&$"K(Z6ZOA# MHV&_+L6VD7ER-E"U0"XCX_Y>45<24V=XHB?'GX^]3L*WU341.2NRX16>XG24 M:E*85EFHB!%@6'I$@HT=7H.AG<56'#^N><D\3/,8SS<>'Q4Z\9IF$IZD8%6% M`BQ6/]2B(_HPM04C(&[.^(XTGP#J_19).C.0M&<4."(,.JH'#98NSP\T^FHV MR^CR`@_!_7P.`N87F3.=3?40>-]\+SUIXZE?BH&A&9,EOI,[*H@;J*5?LN44 MK"_ZF&OK_TG;V2W'=2-W_%7.A5-+5XFR2.HS%ZFB1<GA1K(44?)6:BN5XL>( MGEV*5,UP;"N5BSQ&+G+A9_&CY$GR^W<#.#@`SGR05-6NUSL\`!K=C?Y&([-! M%]%_RDTHJK`\[\G^>L:U6Z#9O"$=&K7F=@Q>!E8##*Y6T>DA9$8Y4E2"I@;I M-P2S8B%+:]P1O`_N/]T+\%9TH&IB.UG;1V8^;V;N"G.SLW!68Q303[X4&!4' M:7[P3ZX[E'<DLQ6+WV0^I02YL>E**AQ#:[XGAG*%DO\*/8S&+6$+G;/4>%9C M#W.)KRTA>F'JT3M@H1LYM:$]SIC@%7=.^(<RM'D.=6334=^V(IK)RH+O+4B, M6%.JX'[W%^NVB%#5V[;H;[,U(Z&L?1*_+JRA5Z@224[@4`+*Q<SJ6LQ)8.]@ M.\`K?0-OTRI+06T&\W6:6SCHS70I+HS'*Y4D\FUJU!9'G"57$ZH(P?%$YGA" M.P-1W\`3^'(F"3@=G.ZH-+UR3A-;32#36"OIBJD/[2KLI8>!'<QTC9$\RAG4 MLV1%OB[,J8FC_'>VYK-1YHI`L=5O'GF3366+K#VP>['?/'IL71K1,Q`UDEC2 M5S0NXF&E9<H>-BZ)E0D>988%HS^+-WROCK6^M$]L692Y?DC%!#Y17WC9,YXJ M4E*%"43JVXT&DD<$>H4EX0S\/N_4&@M,POMPL3</]NF,VF@<8;OA2!F)'W+G M&7@E+@<M)I^FVSSPC&%')@*Q0?VDZI[5CPR[#=[-RI1,F`SS6M?IV<#/Y,6W MN1++<YJ$F&0+E::JW<C=>7;OB9YW@7C/0OY);9=W1NO00S!U);GKFSA"N6V) M&%!(E_G>Q%][]_?HE<+_/'YL!YBF5WN[.K7NTMOE[95K4O'2*`-X.&![94S4 M,I;_CE:ZR&U85E^IG32.),PRZ=X?_[;)*\![UE[XT#OO,K9^</A]=F9#Y-$+ MLXE.:,%K#<HJ7Q!?%"+K#/9O*,8NA9'_X3G_24\0??1&C,PCT:>W"/+!"IE* M@*8H#G(E]P!'4K?]\WPI%^6"F548#P!0?60YOVXSN<2JAW<%EVZOF2<4$EW1 M.);&T3%WHT<"H`?'P<ZM(-XM06!J0G,)'7_W.V6</!RON^*_JIPDC$TQ7S2! MM!7REAZ!NL+-043"TJ_6>*N%PZ"C8KOF'(X3J0UOW#P\DV>\VRW?UD4S^&)O MD<;(`8KR[4$J-JRMKJ-N[0D4R6**'D_U-F-U%G@#&G:).+'D8)C?S<&*SU^B MP5O418B%KC0V2;CVQ\1&.1E%_(O@[N,V[(U(`6XMK:MMT=&PYP<"I_#"T;48 MH50D0$0`Z++\.3\X2=D-`6BB%W7M(*Z$ZOF"3.SE=15B>CE!`1]?E``9].6/ M!^'\59/$/V0\``*)7.AI/$-D(%S,_DH]H<9H,@V#YN<@+ZDXQ<\U<S`RYO@Q MU"'K">U9<4L>!4+[>8:@<2K8*Y2D9UP;/@X:#S)9&VTB&1GQ!3GS/(<="#:: M.]PZ4J58,AMU?6KMUP[9&#%,Z+AT:M#E,]P4KJP()+9/F\__-!%23OC<WSVQ M=NGOK-??0?G).U<V+G41\/2(N*A8_$?.:!_5UP&KC\%[!"6W#JA4K89[@5`# MIR4PKY!O_]B2B.6'6[O8@<\:=56[E,4]?=S($C]#YSZK?M?&UH#KG<E+E])P M2V.$;&Y_049A,HM`AI@?.D+%BIB_'LQV,YCXFY@Y$'#!&.9U/2)U1[\P;YUR MOW-O,?5;=[?9U-<OH2Z4IZGT?E__BC-RI9=W.5MGP:N>G`A:SIK==)+)'$J- M0J]^!:5TT)WFZGZ,TM$_O&!'\.NL3VDA3`$L4A06XDEI:Q[+K$A]3_F6!RP@ M!U.'@85K$!^MYC@?4XZ+Z:J.P(6.),"7I%"+'AQ,,-J*?Z"/]@SQ^A<7#*WY M9=]G5@?Z9?#`9Y:%C<E."\_U,ET=TIRBX8$JG3$S.N;SV+S_A#YOO.Q,CM&B M?V"3QWG9*5B/1'7='R$1TV`,@$XL#X*%6%(*)5],_ZYVO7:EX!(5;H'.)EKX M6-I(%C"IQZ$!H.OZEX0:,!XB#=:@@`?A6XO!UGH`:R'^F.I<I)VFS=FM*UMQ MOO@LU@,Z8*.1B\@GKFG09IQH8+^_^$2U1"KA$FNZ`:].44]BS43XV?GAF]V= MK,^4#VB^')(_\Q3.*6#+I'(F#?3V)L!L8XQ7W`.3)HIYSR`<S$!D8`NII1J: M<W4%MCJ!I'UZ`CQ(`B1WK#E1RUG)ZK_,;@L1<\70/:`$EWF['<1][U&R_0L. M_9E8)T1Z\FT)S5EOI6S#QHP6B'7=W=#XN%5RLWD%W<4*9$T]\\4DP=RQ(_T< M(B!V+J=N5_9"+L@OR=8,5,S#88@IV]$`Y!.UE.S_*`;DZ+GE0?P#$74"LDW[ M.1*,M.&2'Q9%1(K9\7YNDPU>ZK;W`R-5$)?",SL22`RYYM./;E5Y:<A*R[&O M*2X7_UX/BDM?M<KHWMI=RG+(<PKCSB=G?_Q^?57^Z84G8RJ#X(WD%^\:!W#+ M80<I4E'^Y<4EZ^BN0QN4?Y-#QC?0H)+\NPU3*O,],YQ&-ZQ<?-GL>]7LR[Y^ M6'T])+IXRT[&Y:D]=:E7!H(XE#_K=YP_NIG/V>*HF2/N;5:"ZY?K_?[1&7&\ MU',-`']0[B1,VB\31Y38V-JKBN2^;>29S>O(8*0$2<8DUW'#2IK?WR^^KI:H M5MAZ7'[C\R,A9`5?74KFEI^\9X5@F79;K%[=XMC:J1?:J2H:#QJABBU>^D3L M3\Z^-<\Y[*.^;?'CFU<=AV&D68`=APKJWB7A942D8\"7H0^;#56#+6#.KGE5 MB#U=\_'(QE!@[CU]G+4#,ILSXHN3(E*[D3<4EQ3*XZPMF7;WZ2!_%%SN"&?` MA9BJ.HM<^3_\:!B+^'/%%\<*1`=K*4A!\"*Q3._811>IFMBI.WJ&)U&H80+L M/HBV'SU[,#_334DW*E9B-VK67AF8V>>J/"1WJZ"%3G<XCT;+<)^N.U&L2<^% M.GOJ6*@E0:;K]L@M]2DZX47V"]FFT`?=%J_1ELF$/C"2[]:20BVZ['MIM@7= MI,(IWH!'`$R.XC&O"!GZ#C#2+JX^FQG[W)T^^_W-[+/Z$QS,%N==^'T%J8=, M9A0E6,6-I>6$A,K0<L>)EFE]YYJ`SE-`D5Y6<IU-!%9F8LPAY:PQF>]W1^"* MQ0@"Z5EACA1[U?_#_-GQZ-^$ZH9+9]">B)9BH8@"DP?B\OJ4]GVF??OB][N7 M!#`RW:P0'/F=X.O4`U@7=60^`A!%*]:>A)=1C'DEKR`(=TC9$^,L(T;8^?7Q MW]5;+%XOA8I7LXHKB4BDIW.Y65)AD9>_AKN&-UW**A@*<Q@XV;`4F3TFK/R_ MGAKPM"'W\+LY3<).A6!C<9ZUQK##`)B=\9LN*@N/`;\6@\DF3@L;PT''3[Q8 M(^>'%U."[P1B/%EE@5K-9>M9D4LY\R>>8X7*\C1(\0&&JUNYHOJ][Z,C#)+) M,)=7#+$W@#(T%8,%6N8U`&71,NSG`%Y%AL/+6$ZJUX,)W76\RR9=1O+RZ:X` M$OQ<49S,]#;B.X<:5&'?;X'G\'7'Q]Z&13W:TFMH#$8"V[SG*EZ"2__OO_\' MEP%>^WGZ.4`E$U7H7)S\S<)[5WB4)"S-G4&CP$J<B.R-F""V[>?/%.WXWERU M#W23K<@9R50PB('5E24(00#^.(B(O^\9`6E)?LH#%."9;)>C1IME*\<77Q3+ MAR$,1PI)=Y.V^??0Y).FN\0_UF%$)G#RF13;JD!'B'/05.,QW-$%KH^DR)DT M=0VI%4=CZS+F1W!,_2^ZX-R=*U!JUX$JP.:(%7^NN&#V'*:@B^*>J,'6486/ M^OB2;E\0,]*/:MVG_#(Y0KV#M>`N.])%1P'F;^&FP:/22]F@,[^N#K-F7%3Q M?>+R1\^V)M]&Y+;YW%(C.J5AGY*#X5%GK*\NQ#:-K)*Q02UX0+>;*&0M0;UT M3.1R<WNU(9WW3`&PNO65.676"V_F(AM=P0JERTG\DHK5H\Z@S<0/419F00-P M=<\>G]>$KA;X-R_$2?OIZPF-G2?G5V(&S6/0RP%@WJ"7'F9@$5#29X3<50MR M#<528>)ZQ*OHDA^_F(D0(*THA@D7N'5^.IN>B.$MKMX_.>IEFSJ?1"GL;\>7 M2ND1M'!&"]5&]^(U`/7D0+==4A0A&H0[<&8,`(-*6*C7P"N"MTS5>XPEA4L- M,1YE4KL$5X.LKO,>>0"+(/P.?V>8A&F04OU@'=90V4;00T&S$*<(!&Y"DCGX MXX$Y83.NDZ('\P4;LG2YQ7HGOQU[:0J41SEKB(1HN#=^#1(Q71:88_HU3@8! M!D`+A7WI'KOH+UL8UW14P9Y3@1(C&=(U3!=-=Z,N\I77>'$1)&-AJ4</_B&& M&_G<NUS'6(8'OI$=7MN.C+_VET7Z4I9\$Y08J#3>Q)["O'^_O/KU8G)VGI1V MW)?Q`C;0Y!?8FRJF4SIIM?RE_*7:OW&+>'X66XQ#LSY+&X6(GD/L31DVSFNH MF'J.16%\D/<S('JCQ$_RV"I,YN:D3Z:;.$/;8:AMHSG%L)SP.CAJ&_.1JZ!P MO/0;9\<-UAB#=UEW^.[(C*97(FCW??0KQ`!!HLJB8(X#*NPMC8MTLACAF>OV M!3([RF#TWC-C!%.H5H5$+9;";S,=O+[."Q[\Y]@X!PP'M\8WJN.YP+&$23(M MX+J:;<;J`$F#N$W?G[]6C=6!O9Q4>_!B-)LO'\5C]/'$NE`LQOG8MYO"V.F% M^1^ZA2ND:0LV.:G/$D,H28D3+$Y=3Q/:RIB,/^2603*HH\Q.%($Y#+8/[[^? MRU);E76&>%P[E7=>\?KQ;^5/+ST\\,?O[X]_^^/W[]UO*#]2Y,PF_./W0S/@ M[?/R*\%7_995ABX='%;F;;%M'N[Q4$^`K9PS?"J:&E#=JH5SX:0*VO'>&]6E MBOU@DR3^BZ+%XB7F'SDWE$`N&9@'DF$]\EXS)3G$5.4L'S+TK;^+*EWY+@5& M-]['UM/ZOG#=B&/K415@NQGH54`-?E-&`FGCYE&D'L0?/RW8-OR]#E.460II M/8J9LS;H_+\^]R,I2$57WU%7P@(9=.*G9#X,!$E\'6-_D*[ME3ZIO-(T3AVE M4:6X-$@?-"2S!CN)66$KW>M#[^8.(IJ[9(_WL$]42FE-:28DKJEGY>7!7<9Q M2Y#&;A&=QVAA660#!1>"$/>[=WV^1F)S?+9+>]#5TDM#!1:KA=@NL*$<J5M, MJZ*W$O!UR1Y_E94]M-+3U1JWU4PKC8%EIKR5IB:M!)*ML%R[N>0.1L=K&Q<$ M3*QI8XUQ4XJ&6K!E\==['=*J)(S]!0V*T:\MGBF(:U&<[J_[)[I(>GK][^68 M'\$8!8VALBY2<.DRHGVH1((U1V#SHFCH&8WR%45+:1KLA0B^<ZG_4,*=O@], M8OOU`>&7T1'"3$`B?O#H9R.`2"3(RI%+?D4`NS\V*%O\>_ENH&4:3T.8QJT- M_3&]_Q'.D%E":E.,0\L_L]=T.0^`ZB\XFNM0'<756!"XYAOVT/$8IM+O`*DP MP/DQ5>Z<5:^Q<YL81P:-@_'$-TJ06NA4_1P#?XSB/*Q&,6H2)OVZ.5;B#/(7 M:-%Q]2L64BS,3"M&]PG?DEAG0Q+]J[NK;.9E<K0.N*Y5TK3UW>$EAAQ6HIS5 M@]2\9.5)>60GI36A%NZV/EP>RS@EQS(.!%)2=23+CXC=CJ!P18SF=;UV$^W; M*A?V<CJ;5UP<`"QA((J!FU_^2GJX[KCVDE#+]<_EI[*1`D=OR7JM=KE%5X^' M#\MA_+KWI/Z5%E)/JB94U1+A62+=/5=0)*LR#RGK<K5ZAAZ'BLV<6@"O/9>1 M5T6WIW;XSJ87N`45QK8>W-^M6XOP8V4$\>5.9:5L4>__N,[9;:F:_&&%$'W] MZ&G5/.UN=EGB#G@?M3;QJ%J?+Q]67]X:J!&$OYF=$XL)%2N2BD=9=:0"\PO= M4CGOWE[Q6I4LB:WX;Q6'"L17ZNOSEH-UI#XYW=9[<43-S/C/IWA2)B.07A2W M!;8X<+:0$B[GVL\9#!&O*Q%'"KB-,*NLJ8'_)IL`_SE?N.)'D]R63=V`LP<: M&,]=97$KI<MA=@7JA5W7*E78XCHAJ(F6B(-61Z(CRJC":Z[4X3Z7^GM)67GG MLG2$*MF@BVQ,)M!+IK:)7Z17ZEVO'MJE0`_)C3$`^465J[+EY^J@(L9[J9O\ M/ZGQDK1C<^;]5.NH6,&1WAS+%BN!.[)^&J:/DX(]-".H_#);^K6WR%D.?39S MKQ_W_=I"F("$PO5@2Y<8V_(-=9C$[_,2B%B-<_0S3<+-#XA5Z:/D4K\0V]_; MF3+DE%X*D:*'YV3#E-52&?P<<?,I7DT]K\,1+P&+3L);0MCF2[!&_MN7[GW_ MD"L"8@3<?2RX"^ZC=7]]/?ET,IE5%G-,:9D=-UB@A,B?[QN;QZWU=WEN-$]4 MQV7V9T!]/EF;TEZ^_(,:K;)]RQE6J/KAX@J/MOO^XHIF\V/P9=A_-YE^.EF0 M.NA=BG*OK[]<_0L%'92RC<UW,#FA5_4(UK/%?`/I*+QP'X839"&+2A5+O$SM MK20_UL_MOB+FMJN!D?7>*?81IBZW$G)6KPFG?UI\XO%YKO!T;X^_.`D\H<1% M6?+UI_BE,DO>P-4(08Z,?5SA.Y?_?S+&YPR,H>)-UH[M+T0#(60]82\S;.[0 M9IX4-7EWFON66\K0"\/%!CP^5&'C\8$C=X#3R<**RB$@CE`ML&^5/HT_:&7/ MG+P8M-CA]2E*-\!ZM>],`B)\37F'?CR)/JJ$?A'ZU>")8=RK8(BO_4A\L+SE ML'W*&R\/?\OE0='P-;EJ#D>\N!4["'>A+Q\)^/DB=,@I\>QR6ZD9F2`CO'=T M^C.1,6^P`/<.?.E3^;[?>\<-FZ5<00,4O4!*4XS`@>R7[!"O'BX?&?2G.=&I M4$7(Y-I(O,&V1*[*0,E3%8"8@2QK)<!DCFP>.U+")"Z01]`WO(L2I@=ZJ5TW M-J1`\'%B*6FP`"M^$9:&$7#%;KTB,<1Y<P2^$ZO`T2_L\ILJ6(0F_5IBM)[8 MQ18&`Y:H!0(_Y%%4S1,BR!602=1I4R$P(<-RC'^$CY7QEQ+@<8]UC$M[$=./ MY6S+<RTGW]@ZW^YBI!HUE!ENW=;!A+SB!=F&#T<'W3>5\?Z`T\GC*1QQ%4Z4 M<.PL_>O>TK_R;M7];I=$MZ(EY<3VQST:`+?^F&RK_Y"Q3'<9^0OE#$>3S_>[ M,$/E"+\^GO%';V=:_3$?60&6CZS^>#0YE\XJ0=E?G*?5*F<S:HHWB-<5+M9? M7Q&4Z0ZY1S>OC"0.Y$)E3_C."B<C6"UNH*1#137QND6^MA:R,*:7W\;K6P34 M2N!E<*\.E+5&$>.R;D.NQHED?2J_XN:G!V#+/WBO5BF13\=_PZ3OD^GJ$!$H M7H$:E%HH6)F>&%_$()?DIJZ=ETOAE.K1%%K3:[FI!T.OD1[QTDQH4.+ANG)T M#VA_!7'>Y@+9AD4QB"IJ<(IFEG&505.5R#<'<5>5@@K3H24\^R8)M=>LJ#LT M<]*OLQ80^NT+*H?;#O(9TQ2]'K!V6;@NR,N\,^MI%AKRX)KO1TPXO42N(S4I M'+.[_.586THHSR<AC\(#."S!4E]"\1DST41K%OJ&)_>["LT"K5S_N0PHC)P% M\ZAI8L7]:!*\C;G=]+1`@_D5.1322,=]E=+GX^G9-D"$BJ(2Y<,J@#%C/'H& M'$ZU<JJ@^O,Q5@:NR:@U'S4N)#R=3'\Q,_BL;D8,%F@J2*"E]_:$^:.KC]=8 MA>/3#SQ%G5OW%+%=K5B#%T?F$R[;<2KH25*B8*^=''U%7@BNOH*YAM"\L;>% MLA_'L/:H/?%+RC"LJ9AQY,OI;]1EP+9CLSQIS_+ZF$M#^!MQ6/=?[DTH;M0= M4MM,QLAE5_RBW'?T6.+?-Y^A$<_:5JEM'HRZDRC82D4?K>[4<"G(@J`BK#H+ M@8JY?HGZV#04MFU]%9:&>)NHN-MH6$)"2<A]@ID6")4)2LR>XB`+:0P#<'ZV M4O#M1;BZF\4UEVEH=WK&N32ZGI(^T1^3I9_BF8E12^@K!U`B:7PA:W426;:< M*XOUU0'";6K*4OQP)!28<#QF438C>%FXKL-6_0I1P,WABBCB5&,#4T.)[:=G M%%\2D1C'KFU/(K?:YS+F&.ZX)(H\FY`N_.$8"VC)WQ5HKP5T[\:70X_0DM?; M,LYP"]1N:BCQV+LN\!+)"TTTL\,1\5-.^>KJ\OQN9WR-"\F)_&*AA7(Y/(1' MVP\JN[HAF[_"7EG\86OQ6K5\G<4?;=</P1I,]<\5/XI)<YK?V$?,)Y&=Y`W, M:)=BA2.!<5UCV%UVK#3%Z9/US_T8%`HQU[HP:E/>&S+KO)?D))Z=A>;7A*NM MYU3)2*O'3L#862,XL8*VU4+#X]RU$[MKT"OZCEC1*:81PE.K_/HE8FJT=*67 M(CQ8:B\&N+"06D@IA^2<QVC7VHF/3$+W*]T;+*689DR61/%SKVM'+O(YVH&W M.+5%+?N)=2X(-V-GYVF9;JGX#G$W51^3K?I%V:J2ZAOHD.42M)RXWVC<D)/% M(Z^O\.XNNIU1XV&ST9OIPHWG'A[!-73-QBM\3=2"G`TEP3K@[]Z*=/WHNR?= M8.ZO0KK!"G=/NL'T7X%T>[<B73_Z[DDWF/NKD&ZPPMV3;C#]AJ1;HOM&4M"K M1T"B=0[SN!R^LR5ZIBX5Q9TMT2._7&(,!S>V+7MS(N2V/KGE8744'Y.R)=+( M/8Q>9:N`IW*31BLI!@;,(!+6QZUBS41FI;3MCL'X%$GC49@9KEF)KV:(+%HV MY<=EV.P>KNA&@3!+EJ\?WEJ"KQMFDU(V5-4]I*ZS#G3WR*9.%&KU!+47:P2[ M;:URT8/)9^@?6M^%<M<2@\E*YLL81(5S3E4')5)AN)$+\+J&:>\.E],L04QF M"3=*:%8RCR<UCT/Q39;#+4'(ZV#6*+ZY\?G+$W'5M9D_+RY28FNOA)![&>3W MZ+,L?[3\([V5T\CJYHEG!FG`P<AJS3R9'RMZ/.VE.J2BYFB9S4[B)Y3Y4CM] M:MF?/`E00IQ>!TX-D55S?5J9^:_X38VZE6FA?4`Y#;$Z+@!Q,5->1MZ:8>1[ M')%M&@40<K*(/\66-OO'235S"!5:_F.)&\(IXQ&43Y](>W%;+U9XTB^$V(_2 M-?2#=O=A<C$]GX8:8#\NU9)$K4B^L]5T^55^?9J+<W3Z\Q0\5-F.8:$6NC-B M35@Y\M>TYJ/&TX?/I&Q8-X"J]3G,]2ION6I!8)>,]W$"-)YZ$`K]3^E\[4D* M5:6GS@XET9ZW/[/W8LIO=]O)AI#_R7!5#DR<D?`7-UAIC:ID+L-@7&A,B:32 M,E%9^3>3B;K[:3(Y(9TIJV5JD$.9FLVE-^\J4*OE_,QNOM8^:ZC\9I_KQI:6 MV0C2S49GZ%R+(6\\^RIB+9WXJ']XYP6R)HOXKT.[_NS:V=%-L(KQ2GHW,F;# MDUP.D$RZ"T'3".8N1<U*SI61YLUJ8'PT@5U-4:<?KT6+AV<=1)(&XCY,7DFZ MR6C)=S)JB]G5I\5<6;\9!Y)[Z99EZD4@@#21?YLST1.G>QW%_]==\>CUOND] MEP$_KK7K4!2:X_16DF!CPRF>T;K\>$UKCM3T1BH_6C79J)R[(CR#.N4;VW>' MER+^!>H/<WQQB15`^0>5(K-?Z>S5OQY1'NR\1JHRT<SR"]55U8/U7A5*CG.> M.KIF&\TLHG+)7IM?DXRR/)45"'TYG@.O>GKRH@KEF$VM?#.<9L9\J\I[)?V3 M2I<6R6F8T0XG"%M&5T4M\>NBR/(C!C,'<DG5UX^'/QX<=:][%(!=H2">EA*' MC@8G0>2CY=^.;B$.S[8R)W6;H2RI_KZ(?27&8O'Y+!;`R[*HC`JK;+\QR^?L M6:4->X?_XNJ8>YI9N5.)S`!%MN,5E?0K=R^)/%Y:OW+#)8#2+5G1?-8LT2KL M\9%II%<A=\6HK#"*>]1JL(;E3%46=W/+]5=M)[\3<&O<W/X2P1H@J%COVIPB MW*B/$Q57=EZ-OY(X8^40[NQZI6LE2=\N>-;YE+@/^+T\+_%K[O<#][#WRC^: MA-;C.2TGFG?W\,U]T>H(/%=YG$2K[VR9_.FQX&YG7W7772YTF4?3>"%1"1]2 M+R'S<T*F36.O\YSJ/D+;Q5XZ5-5)E&Z=3B9G-6LGF,A1V^T6>9&&8P!U)%># M'`O>O&MYY67>^%O%EKC3VQB6VZJLG.$&%]6?H433:B4[V&`B4NUY&P7@T_<Z M6U87:@H!QUBAGN^581_#72B:#+?>=^P!K%#)!2E.O9S(B95**8W6Z\R-UMYY M_/C^XR=9H>CMIEQ:Q1E+1^GNDYKKSR.<!<\$G`AC):<=3%"J>C"XX3N6W^(* MQ&I@:TNDN'+)R4+78-?AI4\+T)Q\H9?9!;&%BH]RKNW/C7/7F`[NOW.29=JH M`JO<2G#P`,A;6^7!\FH#.BXPHKC6+VRKA!>\W^P41@8UUH9I<FR58+X@0D,; M,%;SP%-^079AMR(OID1F*;MHD#:<B'W94.E$]$@;(A<?:B-6&`JET-_/Z6#2 MH-Q).IYK`G/X]LVHH6:0!T9*%]ANK&-,W(_>IIB<H`MXWZP5I^6)NO3'6L78 M76Z_M_6<NF.,`2^.7*8R4IECXJ[0T$YQ`B1^<;A*)/^@+$H2\*$?Y@H)GI94 M*;HN$<*0=0>'DFV"D&WQ,!V!M-$2MCY$;+F>`LJX>#GJ,`>JW/Z]=BV):F6C MDG,<6)6]1CN#RN&@WMLNI7(`7<>5*_>7%VPTS0!3^7]^8KL9MRXE#W22R928 MCYA>-V;)L%`E\2A%4MF@8;`25^5.2^".');C7^(S-@HMAY:P.'H*=WD,5S)K MY]FS)]W;QNT.EP"#!Y&UC<O\6=1R96\HH`T;+ELOFXZDEP8WT$!A?R):#%=5 M7+>MZ!!0[AZ'NS+=$VK0OE3(-GR%U^_RI>$@(OML!E,_WD-U'EFH2EAY2=U< M5EG;DJP!3VKX-;#=9\W5TQ%;[U2KUTHX[\TD2IPNL'_E6112`!XT>VO$3J9A MX4/CCE%Q&RZD.BH,(G(7UEHX6@-A"5.BW*Y7';!5>8F-M79^8$J&>J_J6KC. MIX?WJ$$,=R*=$LZ?,>VH)56'/OA;.2=O8%I[PO+WS(`!LCBQKRS&G_S:\0S; MQ=672>WYA2/'N'PW8ISZP<ERW1K'J-L?62W=-!ZS<>RV<GJY=C8]__FZG-S) MHTZCL*H+HL%&8FM)XK!B]F[WT3\$=:V,EO!D84=C8;Z!7L@E:]=K3<%XQA2K MDIOY[/RC&AZW&S^"6GUD<4`&9)R14RH<MW(+.S9I^>M/0*LK%?WZ@6+EAP_; MU&YB_<5O-,72K"M1W\!KZEB=N*1$;L3B)JA+\GG%">Q)W)#M!2#P@8%@%)-N MT)DQRG5;H=4HM%Z;%;ZM7!$[MM(Z`_*VM`R<47*#VVXE&6U*N,P8N?SCD76) M=@;@T"5)&A_N=2:I1ID11KT+^!C*_<!*2=1267%]=4V^@ZMY&-9JK=,L5*WT MDDN/0D/HL,05PKDL0>OMB["I8%^X0BJ__J&EA_I5HG'2'JR@5>18CUN$-@7/ M<RT\)H+X"*X.=`Y`NDE4`CGX<OA0,.1Q&,LQ;6/-[%!P.&8\O8D-VB4<(G?A MS/%.K#68)1`@(\]B]='E#$(OZ=9^^A*F98X0@COJ7VFMMXO@!8:].YN.H?*G M*VQ%`*02HU^],E9>9H5;XRC`C[+`.&T'FD']?A-CT-2HGU/A8\&MTXSF)78^ MJ#C@5VZ<$-]D_XK!=3$(-RK!&CG*U6)OK4$0Y(W=]AT/[*\[#^>$XQ&M#R?E MJKD'/!\\!813&9+A(83"8W8/JA62:;+2AO[Y`"POX1D]@OMECR'6&D\@E^RP MV6BFWJB:Y5#WHW584F@K>)X69RYQ:M()3#<JCWJ_):F.]G=F^2A_HX"D\\#1 M9[U-$(_1AI08GN9E!VO_MDL#V<UET_?>YF4_M>;E-LF=(>%.)[_5-HVB=>SH M3:/-T<J41Z_"W3DHCX8Q[UGW\+O=!_R')Y$B"Y4?OHC^WML6ZY+V"X^?-:_X MA54>?[?[2*N,5SB/;#U+T>4B+S5A6HD&LN3O:4LP1^/B,8=.?H81.<['&V7. M9:^%F`(BK`\19(E4/>E@LX?O0J^ESEVE9=$UIQ*=D_*HB5M62!B7]+IN9S/= MHT-.>,^1[DO6+KTDVX;SQ8B/>C9DN:"YQ7)N.7=44R/&YH:0QMFBK52%&&XX M'_["QXG:T7[GZ=7;SON"8B!<N3'RF,L0]Y*=\'5(.SXV3CB&ZM4C5Z-A?([E M6X[>2>H.-I0LECXPVJD8(5_D=B@)JRC'4_+Q+2"Z.:(5.<#CDPN@8.1I"(O( M._H*\(V>DCO8^TI6N<4:7XV5O@X[+"'JO2X[W2LI_&ZB%[HE.'(?ZM7T8\6\ MCT/()`5X=QZU`[P3!>;@N-B4;WR)>_1YQ&6=SBTAFCWP.=IQ*[1YZ1(0#V\/ MPQ)<*K2+-HP/1XR"5>-FIPE7G_>AECI$5GYJ70$>_7!SE"V9Z@YV/A"<.>?! MAL$3'14)&RI."LP::8D8ZBTY_6XF3R*GFCY7&.U]OXP*OAQ["S&U&0[N?J'E M^*A=B<R>SD!WIE'OF99A77T8/86Q^_NC`TK$9Q_.C7Z6V,HK]WB\(U7^.`>M M80R,3!MLHGK*-<%*XRLRNG5_H$2<>=0F0GI[9LWY90%,"/66.UYS>&*%U3-\ MH.3"C)!9^PAGQ2KU9$B\I9;M"/8'<VZ*P9L3/2)UTQ4W1_IM5]B(*)LNMHIH M)@$:XD*GLA6/C[7X1)D'&J?1NM@.![YWQA>]O%G>TWBE=V\BX38NN6JX,T]> MEYN6EFT;Y!O4%;#I_@9!7D<>96C)9S_P=-6,J+G<@_VS3YB">HW(LLIC0T9H METDB3";'E%?\A*`$KZI@3KU(?0(),)L(X^L?+*-SMPV@$S'++6=7BS-2Y$$5 M>ZE0EVM^F9Z14KC7"K$L+[?W)&ZW-]*U--J+\>_=SM.FO1B_B]U/U0FI5=(1 MO^/A,A5?=#OMRH_0\8>.QV0V;EPCUL]B/@.^`QW=ORQE8RY1A=<BT1J$?(C\ MVC.D)6E25$CL>#;QHB#+/7JYF"H.?U4^K!PXX/OL:DAZO%$3UF^E(R8^^GN' MU"O-9E^`CBP;/=NR]^/+I0:E.VK_&E]_6_M#?U^W\=Q9.<,!:.*XG%JOZWWO M4TJZ;.Q@*H>5E>ZK_&VPJW+Z5=\K7A""K>70Y]2S8[T-IK?*XXA.X5O%*Q6E M7@9\ZP/EE[R1]P9;RFK,A/VY&7)7WB?^++UK6`+<,ZVQ?GXW7!*9Z@_5B2&* MPH<A2.]'956+K&)R3;BR$7P23V/E_NU)UVL4?_/)94J&LP:!&GW<LZF3(`5+ M60-X99?LD"9&'3/<UYZ@I.9J*/-&$$NN1<7^#,0>^@@W7/#6*GC*99\3G3XG MLH$50AY"U^NK?'7VB5^ABMUXR[FRE;%OQ7GM-0LV>'=7;?,3'4O`5B[H=Y>\ M:-R.S$`BBA=B._VTQAB/#T;J-$=9NH8!OF3L<H<A2J`,4J'?A5&_>WM%-K%P MB:7!ZMF@M/5M>X&*>>-RX2_]4GJE=G3^U']$<M(X"<\(^4[/WT)<78>G/8?? MK1)9_<,!?=\<K+%CQ<+[%GW]5RA8>QAOU;R"<>KZW9L5FELZM](C:>^E#[R% MWK\EKN]B3C-PK7%OW?WAEO-7LWXWGU__T_\+````__\#`%!+`P04``8`"``` M`"$`,6GWP=T"```>"0``&````'AL+W=O<FMS:&5E=',O<VAE970S+GAM;)R6 M76^;,!2&[R?M/R#?EX\0((E"JD+7K5(G3=,^KATPP2I@9#M-^^]W;*=I33Z6 M-!<$X_>\?LZQL9E?/[>-\T2XH*Q+4>#ZR"%=P4K:K5+T^]?=U00Y0N*NQ`WK M2(I>B$#7B\^?YAO&'T5-B'3`H1,IJJ7L9YXGBIJT6+BL)QWT5(RW6$*3KSS1 M<X)+'=0VWLCW8Z_%M$/&8<;/\6!510MRRXIU2SII3#AIL`1^4=->O+JUQ3EV M+>:/Z_ZJ8&T/%DO:4/FB39'3%K/[5<<X7C:0]W,PQL6KMV[LV;>TX$RP2KI@ MYQG0_9RGWM0#I\6\I)"!*KO#296BFV"6!S[R%G-=H#^4;,2[>T?4;/.5T_*! M=@2J#?.D9F#)V*.2WI?J$01[>]%W>@9^<*<D%5XW\B?;?"-T54N8[@@R4HG- MRI=;(@JH*-BXHT@Y%:P!`+@Z+55+`RJ"G_7_AI:R3E$8NU'BAP'(G241\HXJ M2^04:R%9^]>(@JV5,1EM34*@W_:/W-$D"J+X_RZ>(=()WF*)%W/.-@ZL&AA3 M]%BMP6`&SBJS$.IS.#-(2<7<J"`="FH!T_&TB$=S[PDJ6&PEV;XDM!7Y`46P MDWB`MV.$S-\SGF93XA3!]8UM,')F)(D&#[Y<#;KSH]T6%!3K?"@E'D"-=[GJ MFF9&$ALHW_QL27Y28L&-+X%3X@%<9(^<&<G1BAWMMJ!@J9]?,24>0,4#*",Q M%9L$D2Z9+<E/2BRX^!(X)1[`)?;(F9$8N'`21],DG-B2W)+X\22(1V^+PH)+ M+H%3X@'<8.3,2$["69*3<.J0NW@'44$#2-\N3V8D8[T'JETG?_?`JL[T(P`J M:``P'0`8R5B_D0.X_'"?A04'T@<*HZ-LL&0P>+;5'"8[TFG0S`EG#H`>K\AW MS%>T$TY#*M@N?3>!%X:;\\TT).OU1K]D$LXE?5O#=PB!^?!=$%>,R=>&.D%W M7S:+?P```/__`P!02P,$%``&``@````A`$FYBO1X!0``$Q8``!@```!X;"]W M;W)K<VAE971S+W-H965T,BYX;6R46%UOJS@0?5]I_P/BO0$;3$+4].I"=7>O MM"NM5OOQ3(F3H(80`;UM__V.&1?;0]N%E[2Q#^/C,\.Q,[=?7NJS]T.V7=5< M=CY;A;XG+V6SKR['G?_W7]]N-K[7]<5E7YR;B]SYK[+SO]S]_-/M<],^=B<I M>P\B7+J=?^K[ZS8(NO(DZZ);-5=Y@9E#T]9%#U_;8]!=6UGLAX?J<\##,`GJ MHKKX&&';SHG1'`Y5*>^;\JF6EQZ#M/)<],"_.U77[BU:7<X)5Q?MX]/UIFSJ M*X1XJ,Y5_SH$];VZW'X_7IJV>#C#OE]87)1OL8<OD_!U5;9-UQSZ%80+D.AT MSVF0!A#I[G9?P0Z4[%XK#SO_*]OF$?>#N]M!H'\J^=Q9_WO=J7G^I:WVOU47 M"6I#GE0&'IKF44&_[]40/!Q,GOXV9."/UMO+0_%T[O]LGG^5U?'40[H%[$AM M;+M_O9=="8I"F!47*E+9G($`?'IUI4H#%"E>AK_/U;X_[?PH68EU&#&`>P^R MZ[]5*J3OE4]=W]3_(HCI4!B$ZR`1L-?S?,4W@HGD_Z,$R&C8X'W1%W>W;?/L M0=7`FMVU4#7(MA#Y_1W!5A3VJP(/CP#9#M+PXXZGM\$/4*[4D`PAJ>^-D,A% MY.\@V`@)@-;(#79L<U.J1Y"[SSFJAUR.43B&'[:1(20=U%7[RJT!AP`(8A/X M?&$%!H+VSCE9&"&Q6=@:<!:.ERRLP#L?]F`D)YIG"-E@RD+.A$LL=^>9V(SS M#BTHUOEZ*#"A%8]A,1$(209:210R0CNWY\4:7ICQ>8=6LH26`A-:1(T,(4@K M3I(X&9<=:.<X'P^TS;,.I?422@I,*)$E,X0@)3"--6'D3"?A!Z34<33[75=@ M0HJLFB%$DXH8B\Q[C$+9@'4:11^4%;C%?%X*3'B9L%A6"-&\DHC0SIUIS@UI M)X,,G&8^JP%-:$VL447<^5@WII11*AT`27,1&NMP62WS:_1:VQIBLG#&$(.L MX%Y!*LN99MQHZ=)2#CJ[M!CZK4/+9`%SJ#%OQ<73A&0Y=Q";B&T,P.6F3'8^ M-[1D^!S=-#:YT-PLV];9LT;<Q1<Y.9M:>4P\,=.8-V$2(ESNS$?KT%2A2VR1 MEZO+#GGK8FKF&H/$1#RM)-O--WQM5'6)+7)S-K7SV+B?3I?MYVP=TGSF.HB6 M-%Z'1E.7VB)79U-;IR=)IC'Z*#&*Z*K""/K5-+,NJ46NSJ:V'IMW6NMEVS:/ M-H((FNL@J!=/0-'1-%QJBXR=39T]-J^TIN9X=R*LBXJ6S`$(JP@=9GR1N0]H MU]QC\UHA,XW!7,6IJ2#DY4P+JP)=6HO<G4_=71#[SC0&4Q6'J94J30R#Z%QN MUE:)NM2(P\^\C$^=7A!I,HX8L+[1<86I=<WR4XQ+5%GQ;+OG:-SP:1:GCJLQ MUK7='G$7)W:O5%J#[WW^RX%/;5^85TK7%V*POB)2?;F.H&>-PBZY19:O?E,2 MRZ=&D&D,%H_8I+:IZ\39IB_@./K(6SFQ_9GU-;5_0:_.0^2W:]<-T35W9HT3 MNL(M\GT^]7UZ7\\T!H6[B=,UI^=\3B`;+M*/Z"TZ`?CT!*`NFFD,TDMYF$Q4 MLX\($<<?&AHY`69F=7H2"%+Q&7>,/GKG?N@@/KD?JI:";1CS.`Y/N6="0LU7 M8RSCL$><$HL6.?^`=GL-@KJ6QMB+H]4/(^[BQ-L_=RMHM%%CH)?03&.PX4!D M49TZ%8!.(B7LP6&+JI;M4>;R?.Z\LGE2_34.O[G'4>S]96P+#1WHN9'Q''J" MPW@P3D!+[EH<Y>]%>ZPNG7>6!P@9KI1!M]C4PR]]<QTZ2`]-#\VXX=\3-%\E MM(K"%8`/3=._?5%MP[&=>_<?````__\#`%!+`P04``8`"````"$`H[(\SF0$ M``"A$```&0```'AL+W=O<FMS:&5E=',O<VAE970W,BYX;6R<6%V/VC@4?:^T M_R'*^Y`X)"$@H"H9S6ZE5JJJW?8Y)`:B26(4FV'FW^_U1Q+;88;""Q#?X^MS M/WQBL_S\6E?."VYI29J5BR:^Z^`F)T79[%?N?_\^/22N0UG6%%E%&KQRWS!U M/Z__^K0\D_:9'C!F#GAHZ,H],'9<>![-#[C.Z(0<<0.6'6GKC,%CN_?HL<59 M(2;5E1?X?NS56=FXTL.B_1,?9+<K<_Q(\E.-&R:=M+C*&/"GA_)(.V]U_B?N MZJQ]/AT?<E(?P<6VK$KV)IRZ3ITOONX;TF;;"N)^16&6=[[%P\A]7>8MH63' M)N#.DT3',<^]N0>>ULNBA`AXVIT6[U;N%[1(@ZGKK9<B0;]*?*;:;X<>R/GO MMBR^E0V&;$.=>`6VA#QSZ->"#\%D;S3[253@1^L4>)>=*O:3G/_!Y?[`H-P1 M1,0#6Q1OCYCFD%%P,PDB[BDG%1"`3Z<N>6M`1K)7\7TN"W98N=-X$LW\*0*X ML\64/97<I>OD)\I(_5N"D'(EG03*R138*WLP"9((1?%U+YYD)`)\S%BV7K;D M[$#7P)KTF/$>1`OPW$4F>?2QOA<JQ,B=?.%>A"^(@D)]7M;(G\^6W@LD-5>@ MC03-7:<'!28B[1"\%L"O)PFAVR2G4,3+Z>\X\4DFIZEOKK>Y`#$1Z04$ZB$& M1TB>SO%C;AR\<L%YGPKD)V'O6"1U(T&A:`*>Y50;,)8.;UF:@Z'_C*5G]M(2 MI"VM#1A+0_OJ4?/VN5X9/LF.?IY8T4M0(IHI1K,AZR(YJ6Z.IN%068->?`\] M/LFD%X=3BYW$A(+=0Q*9UK2SVGT\,^E\W",<;-,8PI0M(C%:G;H!O@6#H:I& M4OA;R=KRUVO&)]ELK)IL)$8F!25605/=FOB#.!C<0!UNY\8GF=Q`?>9F3382 M%,M^"NR.3PVSWFX&/02J<SL_,<LBB'R[E@JE%5,?,6E8JOUQ(R$IJU>VO$+I MR\MY8L1<GJOBS1V$I)::HC?:]@HEZX0"WRIC:MI1-'2929%KY>T4I<+J%,=; M'TF0VOO!B&!GMC<_NDFF!=KLF5A3.;G]%4BO62?47`#>R\U=HLW/.]8NBT-; M`11(28#5X:EAU235K-Q=FHW&HGU!`Q1*-1>:CPA*+Q>:SZ1HZ3A_ZX60GBO; M<"SH"/FC#'8*SD^1XJV/M!&3AB7D5Y:7^@O=J9TY;!G<H$ZEA^6U$7/YN[0: M713KH5-58^MR',[CT4'1L*-DL!L4@[OD6LRRMYY]`%`@I0)1;+YMTMYLJT!P MDW0+M$W%ZMJ-`FDJT(^(D_C`S4S.72H>C%5\+`,*I&1@9E4W-<RS^)UC"ESH M[I!P,<O,V`4A4"AYNHQ&1V]^F>1B)^U&_\D4RINBO$C5N-WC%%<5=7)RXK=` M!(>,?E3>4#=P0Q77.:\WP`7QF.WQ]ZS=EPUU*KR#J?YD!D+2RBNF?&#D**XQ M6\+@:BA^'N"O``PW`G\"X!TAK'O@W=;_N;#^'P``__\#`%!+`P04``8`"``` M`"$`=<7!-:8#``!7#```&0```'AL+W=O<FMS:&5E=',O<VAE970W,2YX;6R4 M5]MNXC`0?5]I_R'*>W.#A(*`JB3;W4J[TFJUEV>3&+":Q)%M2OOW.XYSLT,I MY:$0^\S).3.3>+J\>RERZQDS3FBYLGW'LRU<IC0CY7YE__G]<'-K6UR@,D,Y M+?'*?L7<OEM__K0\4?;$#Q@+"QA*OK(/0E0+U^7I`1>(.[3")>SL*"N0@$NV M=WG%,,KJH")W`\^+W`*1TE8,"W8-!]WM2(H3FAX+7`I%PG".!.CG!U+QEJU( MKZ$K$'LZ5C<I+2J@V)*<B->:U+:*=/&X+RE#VQQ\O_A3E+;<]<6(OB`IHYSN MA`-TKA(Z]CQWYRXPK9<9`0<R[1;#NY5][R\2/[#=];).T%^"3WSPV^('>OK* M2/:=E!BR#762%=A2^B2ACYE<@F!W%/U05^`GLS*\0\=<_**G;YCL#P+*'8(C M:6R1O2:8IY!1H'&"4#*E-`<!\-<JB&P-R`AZJ;]/)!.'E3V)G'#F37R`6UO, MQ0.1E+:5'KF@Q3\%\ALJ11(T)%-0W^P'3G`;^F'T/HNK%-4&$R30>LGHR8*N M@7OR"LD>]!?`+)U-(#]*1^?U+:O@49+<2Y:5/;<M".=0G^>U[\VCI?L,24T; MT&8,"G1$W")D!B5O,EAP07"G&G(Q5'V^#JTX"9;B6M:-6@#N3NW$$'(&X>N0 M9`R9]2R:V,E'Q$HPE&"@+8SF^JTW"C/M#,7F0C)8T*1`A:_/FP2O;/#9I2GR M/4.*PH2SNN8WGC.9ZH#X/4!R`:!)AP=E*+UMU,NEET&FA;Y*=8]M%*:WX!F5 MCD<`PV,R`O2=KUF(=`N7I4NP*;WG5=(5II$.[YY;3_L83F,-/G,TK.?-OMP8 MSV.B!?2EUTS-/F)*@DU3,[UC-@K3UN,*F;$>X3G^5+=F%#09X?L'3+,FC^\S M[\;+=9-!AL6@3YVJF\(T%J]QJ`5XSM1T9.R'D9Z`L$NQY@_>UT-_EWU)L.[+ M#XP&VRA,UX]>?]_:=VSNF_VF[Y\7[</I=+WJ&JW+C@(C>YL&U.LV=,4C@,&0 MC``]@Y9Q7QYH@Y:ZG/(:;8KOF54O-:!6?)<TE7%CUS%?;LD%@*Y<GG?7*U>G MX_#LF/</62-<8=X2?FE7#GNR&T>Q2K*:X]284V"VQS'.<VZE]"AGM`#.JFZU MFQ_OZ_'16-_(N5(>LVZW`6-=A?;X!V)[4G(KQSN@])P9G`%,#8;J0M"J'JZV M5,!`5_\\P`"/8:KQ'`#O*!7MA;Q!]R_!^C\```#__P,`4$L#!!0`!@`(```` M(0"+9P"J*0,``)$)```9````>&PO=V]R:W-H965T<R]S:&5E=#<P+GAM;)Q6 M76^;,!1]G[3_@'@OGPD)49*J">I6:9.F:1_/#IA@%3"RG:;]][NV`\7`LG8O M2?`]/C[WW&MNUK?/56D]8<8)K3>V[WBVA>N49J0^;NR?/^YOEK;%!:HS5-(: M;^P7S.W;[<</ZS-EC[S`6%C`4/.-70C1K%R7IP6N$'=H@VN(Y)152,`C.[J\ M81AE:E-5NH'G16Z%2&UKAA5["P?-<Y+BA*:G"M="DS!<(@'Z>4$:WK)5Z5OH M*L0>3\U-2JL&*`ZD).)%D=I6E:X>CC5EZ%!"WL_^#*4MMWH8T5<D99337#A` MYVJAXYQC-W:!:;O."&0@;;<8SC?VG;]*8MO=KI4_OP@^\]YOBQ?T_(F1[`NI M,9@-99(%.%#Z**$/F5R"S>YH][TJP#=F93A'IU)\I^?/F!P+`=6>0T(RKU7V MDF">@J%`XP1SR932$@3`IU41V1E@"'I6WV>2B6)CAY$S7WBA#W#K@+FX)Y+2 MMM(3%[3ZK4'^A4J3!!>2&:B_Q`,G6,[]>?1O%E<K4@DF2*#MFM&S!4T#9_(& MR1;T5\#<9J9U=+G^+57(49+<21;%!5EP*,_3UO>6\=I]`E/3"VBG0;%M=:#` M1.Q;A'10\B:]!1<$=ZK!BZ'J$*HZ78]6I-QDB@P]4\!N`F(B]A,(WX0D8\@B M["!&&N'_I"$W;6PXI+/1]^)A(AHT4PTDG=P/%Y+>@J$)FN#]ULI-T-2FIH$O M.PWJ:1HN)+T%0Q-<DKZFZV66X)$_@T[;:=!2M6K@A<OHM4*J\_9]@!][?CP` M)`8@BGUO,5WCZ#W:)7BD?7#R3H.BRS4+7\_5RHUP&"T&K9'TXP%<TVA:]^(] MNB5XI'O6$2MA.PV:*=T#4?LKL60Z9C2(G+.]M]CU!I%@4VSD#3W6F&FM5V+) M=,S0"B_`MVN58%,K7/;YP%@-:IMY%GM#=TW`N-MA=LIC-,.@V[5V/1KUY*@P M.^(]+DMNI?0DQYX/->U6]43>P416\\OM`C`1&W3$7Q$[DII;)<YAJ^<LX"8Q M/5/U@Z"->DT?J(!9J'X6\-<'PVO,<P"<4RK:!SFUNS]3VS\```#__P,`4$L# M!!0`!@`(````(0`$CUZN/`,``-P)```9````>&PO=V]R:W-H965T<R]S:&5E M=#8T+GAM;(Q6VX[:,!!]K]1_B/R^N1`2+@)6"]&V*[525?7R;!*'6)O$D6V6 MW;_O.(9@)Q1X`3(^<W+FC.UA\?A>E<X;X8*R>HD"UT<.J5.6T7JW1+]_/3], MD2,DKC-<LIHLT0<1Z''U^=/BP/BK*`B1#C#48HD**9NYYXFT(!46+FM(#2LY MXQ66\,AWGF@XP5F;5)7>R/=CK\*T1IIASN_A8'E.4Y*P=%^16FH23DHL0;\H M:"-.;%5Z#UV%^>N^>4A9U0#%EI94?K2DR*G2^<NN9AQO2ZC[/1CC],3=/@SH M*YIR)E@N7:#SM-!AS3-OY@'3:I%1J$#9[G"2+]%3,$\"'WFK16O0'TH.POCM MB((=OG":?:,U`;>A3ZH#6\9>%?0E4R%(]@;9SVT'?G`G(SG>E_(G.WPE=%=( M:'<$%:G"YME'0D0*C@*-.XH44\I*$`"?3D75U@!'\'O[?:"9+)8HC-UHXH<! MP)TM$?*9*DKDI'LA6?57@X(CE289'4G&H/ZX/G)'TRB(XMLLGE;4%IA@B5<+ MS@X.[!IXIVBPVH/!')A/E6D=7:W_*Q5J5"1/BJ7E@BH$].=M%?CQ:.&]@:GI M$;36H!ER.E`/L3DAE(.*-S$"'@CN5(,7?=4A=/5R/TXB59(M,O1[$B]`;,3F M`B*P(<D0,@D[B%5&."PCOEF&2H(-9-@(7I]?T!JWUJ!QNX&4DYM^(#$"EB;8 M!*:UURU5X"6"@KN6@I9Q5ZS6HD'3=EN$8=_SC;4<S29V=F(M3Z;G0BW5<(SN M5ZW``]61_=ZU!AD.]@.)$;"TQ+86=:1N=U4EW>RJ!AF:^H'$"%B:)K:FZUU5 MX($__:YJ4*P/>QCW#L'&6H["J>UN8BU/_7.VI5K-3^-RNJY:@0>J8_N]:PTR M'.P'$B-@:8%[R]1R7U=5TLVN:I"AJ1](C("E"6:>)>JZ02UZX%"_KT>4/J[! M+)[9#FZL]9$?]=;5'%8UG_*GYSM>2]=#5L^@BO`=V9"R%$[*]FJ`!K"?NJ@> M[FLUW-OQW"W`;&WPCGS'?$=KX90DAU3?G<")Y'HZZP?)FO;"WS()4[7]6<"_ M*`(7HN\".&=,GA[4_._^EZW^`0``__\#`%!+`P04``8`"````"$`?-6=,L\# M``"/#0``&0```'AL+W=O<FMS:&5E=',O<VAE970V-2YX;6R45VUOVC`0_CYI M_R'*]R9Q>$E!P%3(NDW:I&G:R^>0&(B:Q)%M2OOO=Q>38#NT3?D`Y/S<PW-W M]OE8?'HJ"^>1<I&S:ND2+W`=6J4LRZO]TOWS^_[FUG6$3*HL*5A%E^XS%>ZG MU<</BQ/C#^)`J72`H1)+]R!E/?=]D1YHF0B/U;2"E1WC92+AD>]]47.:9(U3 M6?AA$$S],LDK5S',^1`.MMOE*8U9>BQI)14)IT4B0;\XY+5HV<IT"%V9\(=C M?9.RL@:*;5[D\KDA=9TRG7_;5XPGVP+B?B+C)&VYFX<>?9FGG`FVDQ[0^4IH M/^:9/_.!:;7(<H@`T^YPNENZ=V0>D['KKQ9-@O[F]"2T[XXXL-,7GF??\XI" MMJ%.6($M8P\(_9:A"9S]GO=]4X&?W,GH+CD6\A<[?:7Y_B"AW!.("`.;9\\Q M%2ED%&B\<(),*2M``+P[98Y;`S*2/#6?ISR3AZ4[FGJ3*!@1@#M;*N1]CI2N MDQZ%9.4_!2)G*D42GDE&H%ZMA_!UH//X[`R?K7/HD7$P?5N`KX)I<A,G,EDM M.#LYL.%`KJ@3W+YD#KR8E"FD5H70I>FE+$%ZD.0.69;NS'7`74!I'U<DF$8+ M_Q'JD9Y!ZSXH-!&;%H')1]Y8,_@@N%,-:=157R]A*P[!**YE72L#<'=J1Y:0 M*PAB0N(^)+JP&&*AP,/%(GCI`GFG+;H-S)]>*TQS5)HT;6Q#K!D,*5!A70I6 M>_SB$6CSATZPV35)4-Q;2Y,":9IL0ZP9#$WP^[JFUVN)8#,]D\G4DJ(PDZC9 MA^'GFTM95+;>6(]?7C=T3]^C&\&V;CN%"G/6'7BW5EP;:ST:6X#8!ER.ER$\ M>H]P!-O"9U;"%0;JV^U9V"`6:#,$%+\!,L+`>UGK7*_O&P1;84SM8Z4P;?[- M&#>O+<8O+!IRH3D.EXM@4VX4V>U48;039QMBS6!((=#@=2W#VD#C]68?.*,T M63U+K%M,8=CO!]>4J-M![Y7]9G`&G:M*O-GGF\NQ4/W`A@0S\]7SB-_C80:( MM\;P`-4=8P9H=PVB0.VV]:*(!/JK%ZV-'Q$C7(L_[O$3,S^7;6E&BE?0\$C5 MA65&:G60-6EO-;W/1-8IWEQ'V;?W==0E5V8L>'4-CT5==$8LO5X#@RZ>\+9J M5K-Y=16'Y*N^2K.:?]6,5U*^IQM:%,))V1%GVQ`NQ<[:S=UW(0Y'EGV-\SC: M_6X!QN$ZV=,?"=_GE7`*N@/*P(O@QN1JH%8/DM7-9+EE$@;AYNL!_OA0&.D" M#\`[QF3[@#_0_95:_0<``/__`P!02P,$%``&``@````A`'@S0W9Y!```<A`` M`!D```!X;"]W;W)K<VAE971S+W-H965T-C8N>&ULG)A=CZLV$(;O*_4_(.Y/ MP.0[2G*T8&U[I!ZIJOIQ3<!)T`*.,-GL_ON./4!L0Q-.]V(W&;\>GAF//7BW M7S^*W'EGE<AXN7/)Q'<=5B8\S<K3SOWKS]<O*]<1=5RF<<Y+MG,_F7"_[G_^ M:7OCU9LX,U8[X*$4._=<UY>-YXGDS(I83/B%E3!RY%41U_"U.GGB4K$X59.* MW`M\?^$5<5:ZZ&%3C?'!C\<L890GUX*5-3JI6![7P"_.V46TWHIDC+LBKMZN MER\)+R[@XI#E6?VIG+I.D6R^G4I>Q8<<XOX@LSAI?:LO/?=%EE1<\&,]`7<> M@O9C7GMK#SSMMVD&$<BT.Q4[[MP7LJ&![WK[K4K0WQF[">VS(\[\]DN5I;]E M)8-LPSK)%3AP_B:EWU)I@LE>;_:K6H'?*R=EQ_B:UW_PVZ\L.YUK6.XY1"0# MVZ2?E(D$,@IN)L%<>DIX#@#PVRDR61J0D?A#_;UE:7W>N=/%9+[TIP3DSH&) M^C63+ETGN8J:%_^@B#2NT$G0.)D!?3,>3(+5G,P7S[UX2*0"I'$=[[<5OSE0 M-?!,<8EE#9(->&XC0XXNUO\*%6*43EZDEYV[=AV(0L#ZO.^)OYQNO7=(:M*( MPKXH,!51JY`9E'ZI9O``N*.&7.C4P^O0PDFQA&N]AF@`WQVMA1H-*(C)2OL2 M+6`#=OHCL%(,Y:&Q029GYK-#%,VZB"+;0#6#P0)+/#YQ4KQS(=`N3\`RMUA0 MM%*+[IMCT8,Q.CQFP,+>T&%E;4YA[SY>;3FI![TPP4(4+9I*]>6/J8@,Q70Y M(*&Z)"#$E!B!+/J!S&#VXT#DI%X@2Q,S1-%,!1+X@56D43O<EC[5#`;ALD_X M/-5RDDFXG%L[*43-?(GU,;&J)\+A>R53S6``RE:JG5./4R?%)A@4[LI*'8JP M!N;6ZJG3)S(4:GFM*J&Z8@9-&7ZZIQCX<#3J^.-*64[JA;'N'J`@0Q1A!=P? MC@$\&*/#8P8T@<VF4S].NE+;N"L+*6Q4]Q6/>A:J6TP@V0]&5P'![O'D+&U4 M.A#.NUNHKC&!9!<8#X0]PSQ05]:>#0FJL#"GJ\7*+"M<V4:D,^(T93$992_0 M&,?5'L$.8K%:#3ML5-WY8ZUVU(UW!Y!N,3%E0_AQ3&PC%J9]"!%4-2GUAS.* M&CVCFL5$E2>_AOID7V"?L!#MEBY?)V&SWQ\?]2Q4MYA`\E@?#X1-X-F^T%I% M4W.VA1+-8@+)8UP#&EES>/A;F;):1DA0U33O]>#NT+J(8J?-I('=(8]PC?3) M6N*!;Q'V=K#>%N`-?>CM(2(HNB\XU2UF-N59K3&.S":>\!9K;P?K?2#PB97M MB+3C]QVL60Q,N(']#TPUJ]<V[!W<J/`UDTRG0ZO>:+2,ZA9$Q2L>WH`*5IU8 MQ/)<.`F_RNM;`&\IG;6[6KX$\D7;LH=PY53W,Z\;@!O?)3ZQ[W%URDKAY.P( M+OW)$G9VA7=&_%+SB[IW'7@-=SWU\0QW>P87'G\"XB/G=?L%'NQU_RW8_PL` M`/__`P!02P,$%``&``@````A`'VP&KK-`@``C`<``!D```!X;"]W;W)K<VAE M971S+W-H965T-C<N>&ULE%7;CMHP%'ROU'^P_+ZYD`L7`:N%:-N56JFJ>GDV MB9-8F\21;9;=O^^Q#5D,E-(72.SQ9&;.R<G\_K5MT`L5DO%N@4,OP(AV.2]8 M5RWPSQ^/=Q.,I")=01K>T05^HQ+?+S]^F.^X>)8UI0H!0R<7N%:JG_F^S&O: M$NGQGG:P4W+1$@6WHO)E+R@IS*&V\4=!D/HM81VV##-Q"P<O2Y;3C.?;EG;* MD@C:$`7Z9<UZ>6!K\UOH6B*>M_U=SML>*#:L8>K-D&+4YK.GJN.";!KP_1K& M)#]PFYLS^I;E@DM>*@_H?"OTW//4G_K`M)P7#!SHV)&@Y0(_A+,LQ?YR;O+Y MQ>A.'ETC6?/=)\&*+ZRC$#:421=@P_FSACX5>@D.^V>G'TT!O@E4T))L&_6= M[SY35M4*JIV`(>UK5KQE5.80*-!XHT0SY;P!`?"+6J8[`P(AK^9_QPI5+W"4 M>LDXB$*`HPV5ZI%I2HSRK52\_6U!X9[*DHSV)#&HW^^/O-$D"9/TWRR^560, M9D21Y5SP'8*F@6?*GN@6#&?`?'!F=0Q>_V85/&J2!\UBN,"%A/*\+,-@DL[] M%P@UWX-6%C3%:`"-7,3Z@-`):M[L:,$'P8-JR.)4=015O5R/@TA]R!49!:Z` MU06(BUA?0(0N)#N'C*,!XMB(7!O7Y6LP-,Y1?$DZ'7A-7BN+B4W?Z`#7IPO9 MT8(C!6I_G.AU*1J\P.!SJ&1R9-%*L9B):8:[,$[CDW98.X`H&H=CUTSF`.(@ M&K]7RY$.K]#MTC7X5'KL/GAE,;&1_OY,8VM]92^[O.=H3?]'JP:[6B<G&:TL MY$K*#N!2R@[@4LIV*MJAT5)1T35M&HEROM43+X24AE4[C%<PC,WH\H<-&(8] MJ>A7(BK62=30$HX&WA@2$W:<VAO%>_.&;KB",6@N:_CJ46CEP`-PR;DZW.B! M/7Q'EW\```#__P,`4$L#!!0`!@`(````(0#'YC\;$@,```(*```9````>&PO M=V]R:W-H965T<R]S:&5E=#8X+GAM;)16RV[;,!"\%^@_$+Q'#[]M6`YB"VD# M-$!1]'&F)<HB(HD"2<?)WW=)VH(HJZISL2WN<#P[N]1R??]6%NB5"LEX%>'0 M"S"B5<)35ATB_.OGX]T"(ZE(E9*"5S3"[U3B^\WG3^L3%R\RIU0A8*ADA'.E MZI7ORR2G)9$>KVD%D8R+DBAX%`=?UH*2U&PJ"W\4!#._)*S"EF$E;N'@6<82 M&O/D6-)*61)!"Z)`O\Q9+2]L97(+74G$R[&^2WA9`\6>%4R]&U*,RF3U=*BX M(/L"\GX+)R2Y<)N'*_J2)8)+GBD/Z'PK]#KGI;_T@6FS3AEDH&U'@F81?@A7 M<1A@?[,V!OUF]"1;OY',^>F+8.DW5E%P&^JD*[#G_$5#GU*]!)O]J]V/I@+? M!4II1HZ%^L%/7RD[Y`K*/86,=&*K]#VF,@%'@<8;3353P@L0`)^H9+HUP!'R M9KY/+%5YA,<S;SH/QB'`T9Y*]<@T)4;)42I>_K&@\$QE249GD@FH/\='WF@Q M#:>S_[/X5I%),":*;-:"GQ!T#?RGK(GNP7`%S)?,K(XFUW^E"CEJD@?-8K@@ M"PGU>=V$P6*^]E_!U.0,VEK0$J,&-'(1NPM".ZAYX]:"#X(;U>!%5_48JMI? MCXM(O<D5.0Y<`=L>B(O8]2!"%Q)?0^;C!N*D,7;3&):OP=`X+?NF\UG#:_S: M6LS$](TV<-==B%L+CA2H?=O182D:'&'(LZGD=-ZMML4L3#-T;-X-Q.+^F*,5 MSLSM6C6XJW71L<UB)KU:!V)Q?\S1.ON(5@UVM2Z7':D6TB]U(!;WQQRI\X]( MU>!N-W:U6DRK&[L+<6O!D:('9^NM--R-&NRZ=MV-%M-OVT`L[H\Y6N&%=KM6 M#>YJ[7:CQ?1K'8C%_3%'*PS)#X@U:%?M53^>,?WG?"BH![;VHKO3ZK6CV$ZJ MDHH#W=&BD"CA1SUF0SBIS:J]`FSU%<`,\28`$[@F!_I,Q(%5$A4T@ZV!-X=3 M*^P,MP^*UV8L[+F"V6M^YG#7HO#^##P`9YRKRX.^)32WM\U?````__\#`%!+ M`P04``8`"````"$``ABB@9(#```["P``&0```'AL+W=O<FMS:&5E=',O<VAE M970V.2YX;6R45EUOFS`4?9^T_X!X;\!\)!`EF490MTF;-$W[>';`2:P"1K;3 MM/]^UW9*L--FV4L;?(\/Y]Q[L>_BPU/;>(^$"\JZI8\FH>^1KF(U[79+_]?/ M^[O,]X3$78T;UI&E_TR$_V'U_MWBR/B#V!,B/6#HQ-+?2]G/@T!4>])B,6$] MZ2"R9;S%$A[Y+A`])[C6F]HFB,)P&K28=KYAF/-;.-AV2RM2LNK0DDX:$DX: M+$&_V-->O+"UU2UT+>8/A_ZN8FT/%!O:4/FL27VOK>9?=AWC>-.`[R>4X.J% M6S]<T+>TXDRPK9P`76"$7GK.@SP`IM6BIN!`I=WC9+OT/Z)YB9`?K!8Z0;\I M.8K1;T_LV?$3I_57VA'(-M1)56##V(."?JG5$FP.+G;?ZPI\YUY-MOC0R!_L M^)G0W5Y"N5-PI(S-Z^>2B`HR"C23*%5,%6M``/SU6JI:`S*"G_3_(ZWE?NG' MTTDZ"V,$<&]#A+RGBM+WJH.0K/UC0-K10!*=2!)0?XI'DRA+43K]-TM@%&F# M)99XM>#LZ$'7P#M%CU4/HCDP*V?)F\[`DMKS46W26P$MH!R/*Q1FV2)XA!Q6 M)U!A0+GO#:#81JQ?02`;4EY"9F>6`#P,1B`]KI$8"OUZB5Z,J$VVD3BT%10& MDNNJ*O-K=Z$<+5B*8EO1=24*#&TQRE::18X4@TG.4MR%<K1@28'*CI-S78H" M+WUP-10NS<Y)UQU0&$RF:S_+G)RMQ]$<.8U1CJ,HC)+!I249FO!VR0KL2C[S M&LD&,S7MFJ+9='BOCJ_'\2B<A4[VRW$\R>-SV)(]_1_9"NS*3FU9A<$8V=,( MS>SP>AQ.\L0Q58[#*0K/GY<E>O8_HA78%>V\MC"84ZZ3#&5.,=8V((E2!U!: M@#1&^;D#+>GJBAV=7]<[6X%=Z4Y""X,QTN,D3<[O-6UBQ>/0C9?C>)3FH[BE M&\[%VW4KL*O;^:H*@S&ZHS#)0_>CM`%Q-G6<E6,`RL,W4X[@6+U=NT:[XG.[ MBXL3R*B_>U6^"WG%@`VY:D'=*S>W#8P6%_D?]:,Y7DX@<R2ZN;\65).+HG=W MFG8Q,XFYLEO"=V1-FD9X%3NH>2.&TVQ8-;-0@>9P9\$,XJROT1RNKLOU$F8G MO1X,&V!TZ?&.?,-\1SOA-60+KPHG,S@!N1E^S(-DO;X\-TS"T*)_[F%()7!+ MAA,`;QF3+P]JO!K&WM5?````__\#`%!+`P04``8`"````"$`;`2PIB($```& M#P``&````'AL+W=O<FMS:&5E=',O<VAE970Q+GAM;)27VXZC.!"&[T?:=T#< M!S`Y1TE&`ZAW1YJ11K.G:P(F00T887>G^^VW"G.PS:B7W"2A^/WG<Y5=AN/G MM[*P7FG#<U:=;.)XMD6KA*5Y=3W9?__UM-C9%A=QE<8%J^C)?J?<_GS^[=/Q MSIIG?J-46.!0\9-]$Z(^N"Y/;K2,N<-J6L&=C#5E+."RN;J\;FB<MH/*PO4] M;^.6<5[9TN'0S/%@698G-&+)2TDK(4T:6L0"^/DMKWGO5B9S[,JX>7ZI%PDK M:["XY$4NWEM3VRJ3P]=KQ9KX4L"\W\@J3GKO]F)B7^9)PSC+A`-VK@2=SGGO M[EUP.A_3'&:`:;<:FIWL+^00D9WMGH]M@O[)Z9TKORU^8_??FSS]EE<4L@UU M$O'E3UK01-`4*F=;6)$+8\\X]"N$/#1S)VY/;45^-%9*L_BE$#_9_0^:7V\" M3-8P0YSH(7V/*$\@PV#C^&MT2E@!0/!IE3DN%<A0_";_.$_%[60O-\YZZRT) MR*T+Y>(I1TO;2EZX8.6_4D0Z*VGB=R;P?>_N;QU_MR;KS0,NR\X%OGL7_W&7 M5><"WX/+_TW$E4EI<QS%(CX?&W:W8"'#M'D=X[8@!S#$Y"ZA9+].+F05QWS! M0>U04'-8(:]G[^B^0@V33A%,%;ZN"'L%%@Q-(R7@`MQ`""E_G!`'Z81$__]@ MJECJBG"J6.F*:*I8#PIM#E#PQ^>`@Z`:L'_Z+&\&]S9E@52LVI6*.0S-0*0$ M-"`HM0KT<;E1?+)AL@/(U@"1"O@<%#M=$?:*H=Q*0".#/3F?#,4ZV5[_WT`J M)-GE5TLU[!4#F1+0R#:/D*%8)R/F'I&2=0NU@D/&6%VAO#]6-U("&MCV$3`4 M&V#FUI"250OF>\3DZF\/"5,"&A>>R$IO^7B1H=C@,EI&("7J*B/FGNTE`YL2 MT-CVC["AV&`SDA)(B<8V]H)VMX:]9&!3`AH;@08\/W&MVJ`S&T6GT?",/1P. MFH%/C>B`V*MG5Y;(SJ[V#V*TAZ#3R#5'O`W9[\S2#I*13QJW.T3GP\8\GT^V M<8W/;"-$:I`O.R\6Q%\L8==D>/0MB"$.!_%(V@^'B$Z*#7H^J6SG*JEO=A72 MM_RQ%_O&!@\'S0C8CYH`PIIY`!#5^EKTS5U,I$9=B_ZDUKUF!%0B>@:Q7<_/ MH&SN6@;-K8P/ES`)#7"2P5XS`BH1'1#;]GQ`V>0U0*.1!*0_")02&SL^'#0C M8#]J4F+LWPK@S&=`V?4U4*.E!$0Y&60/["*;]FQ9[C;;U6YO+)!(':5G$INY M`OKQ@0+O*).U.&D[RO'0`9H1?-=!GVV+3+8K9RR'I)-O+O*INHZO]'O<7/.* M6P7-X''(<[:P,AKYWB(O!*O;9],+$_"^T?Z\P?LFA2<XSP%QQICH+[!8PQOL M^3\```#__P,`4$L#!!0`!@`(````(0"Q)LSXC0(``!H&```9````>&PO=V]R M:W-H965T<R]S:&5E=#0S+GAM;(Q476_:,!1]G[3_8/F]<4(*!42H"E&W2JLT M3?MX-HZ36,1Q9)O2_OM=VQ`18%U?DM@^]^2<^^'%_:MLT`O71J@VPTD48\1; MI@K15AG^]?/Q9HJ1L;0M:*-:GN$W;O#]\O.GQ5[IK:DYMP@86I/AVMIN3HAA M-9?41*KC+9R42DMJ8:DK8CK-:>	$-&<3PADHH6!X:Y_@B'*DO!>*[83O+6 M!A+-&VI!OZE%9XYLDGV$3E*]W74W3,D.*#:B$?;-DV(DV?RI:I6FFP9\OR:W ME!VY_>*"7@JFE5&EC8".!*&7GF=D1H!IN2@$.'!I1YJ7&7Y(YODM)LN%S\]O MP??FY!N96NV_:%%\$RV'9$.97`$V2FT=]*EP6Q!,+J(??0&^:U3PDNX:^T/M MOW)1U1:J/09#SM>\>,NY89!0H(E&8\?$5`,"X(FD<)T!":&O_KT7A:TSG$ZB M\5V<)@!'&V[LHW"4&+&=L4K^":#D0!5(1@>26U!_.!]%H^DX&4_^ST*"(F\P MIY8N%UKM$30-_--TU+5@,@?FH[.@H_?Z+ZO@T9$\.!;/!2X,E.=E.8W'"_(" M.64'S"I@9ACUF-$0L3XB7`(=;7ZR04!O+QI2<2XZA:)>+\=1HPL::DSCH8#5 M%<@0L;Z"2(:0_!)RE_:0@8UT:.-]^0X,?7.2OFD\Z7E]OE8!XP?!;ZS/-_*3 MC8$4*/UI1M^7XL`9!I]])=/D7$K`3'TO)/%9CM:GI[.S4!AD1Q]"I^>I"S,: M6EAR7?$U;QJ#F-JY^4O@?_UNN!I6<#7X02+]`8QF1RO^3'4E6H,:7D)H'-W! M+.HPW&%A5><;9J,L#*7_K.$.YM":<03@4BE[7+CKH[_5EW\!``#__P,`4$L# M!!0`!@`(````(0!K91J2E`0``)42```9````>&PO=V]R:W-H965T<R]S:&5E M=#0Q+GAM;)18V8[J.!!]'VG^(<I[$QP(FX"K2UH]<Z6YTF@TRW,(!J).8A2' MIOOOI^S*8A=AR0O=V,=5Q[4<8R^_?6:I\\$+F8A\Y;+!T'5X'HM=DA]6[C]_ MO[W,7$>64;Z+4I'SE?O%I?MM_>LORXLHWN61\](!"[E<N<>R/"T\3\9'GD5R M($X\AYF]*+*HA*_%P9.G@D<[O2A+/7\XG'A9E.0N6E@4S]@0^WT2\U<1GS.> MEVBDX&E4`G]Y3$ZRMI;%SYC+HN+]?'J)178"$]LD3<HO;=1ULGCQXY"+(MJF ML.]/-H[BVK;^<F4^2^)"2+$O!V#.0Z+7>YY[<P\LK9>[!':@PNX4?+]RO[-% MZ$]=;[W4`?HWX1=I_._(H[C\5B2[/Y*<0[0A3RH#6R'>%?3'3@W!8N]J]9O. MP)^%L^/[Z)R6?XG+[SPY'$M(=P`[4AM;[+Y>N8PAHF!FX`?*4BQ2(`"?3I:H MTH"(1)_Z[R79E<>5.YH,@NEPQ`#N;+DLWQ)ETG7BLRQ%]A^"6&4*C?B5D1&P MK^;]@3\+6#!Y;,5#1GJ#KU$9K9>%N#A0->!3GB)5@VP!ENN=(8]FK[>V"GM4 M1KXK*]H6[$)"?C[6TYF_]#X@IG&%V2!F[CH-AB#"&J%2`?0:CK!SRG$$.>R. M?DU)+;(IC8:$40?$1H0="-9`+(X0N_X<U:*5"TZ:D$QGH\:^#NT&,6-="BK6 MH3%@,1C;#.Y'1X&A"BW/8^(9,89G8\#R##5L[OV^9P6F>PZ(9\1,="&QR7Q$ M"\6:#V;!K%EO\9KTX:7`E->DL8NY0,Q8\R+%%';/67RF??@H,.4S)7P0T\VG M>\[BHXXGH_?OYTV!*9\V[A@?Q-S.FS5_.V^@$28OI4F/^UTMHOSF)%Z(,2K: M&+`BPT!>3`KW0Z/1C[JI`AG.S1';.Q'E!]Y1-FT5H1W%$(2IF8R&C)12:`&" M:3!IU<#FIB3QZ:)A**`V-]I5%0C+F,A?:$VVI&U.2A*?YX0":G-J+6,ELUIE MU5GV0F9#>_;&B<!Z";)&T_JE_56!VBQ>10LE&@&0Q6FK4G;$B&0_UV+J)P_M ML7GKH8H<@LPZ-T9L%KT$FJ'"WC^S*I#IO19F^JN"]9)CC:;YN>JR;M'5@0DK M"Y@;/QBVAYH=E%ZJS+ID^:K!$-1]3E06Z*3-B2CR`T'JDF+20AM62Z]J,%)# MX8U)BY/?2Z(UFJ:/ME<%HJ'`]%63C]+G]])NC2:TYJV>8$=5(*.FFQ'CA^/\ M1CWY1+!5JX^A(^_G4*^BQ(C:;"J020SU7H_8V>HET3ZJ[_U6KT"F=US6X;V7 M%/LHHM8!<9T4!,%G^]O=2$%5,UV@&P>KNL.9A]B3>4)MM;E26=*F(>OM'<(< ML?/42Y+]9R2Y`IG>;TDRW.&M&#RH451;>^]7S5-+LIDG(I#J[4`=;'8R6\7" M".'K`%Z>,UX<>,C35#JQ.*N;/X-+03.*KQ(;>)705WBOF8!'@5-TX#^CXI#D MTDGY'I8.!U/(8H'/"OBE%"=]=]V*$IX#]+]'>/[A</\;#@"\%Z*LOZASK7E0 M6O\/``#__P,`4$L#!!0`!@`(````(0`3<SV:$0T``(I$```9````>&PO=V]R M:W-H965T<R]S:&5E=#$U+GAM;*R<VV[C.!*&[Q?8=S!\/[$E.2<CR:!CG4]8 M+&9WK]V.DQ@=QX'M/LS;;U%DB8=?4ML]<Q,G'XL_J6*18M%2[G[_L7T;?5OO M#YO=^_W8NYB.1^OWU>YI\_YR/_[/'_%O-^/1X;A\?UJ^[=[7]^,_UX?Q[P__ M_,?=]]W^R^%UO3Z.2.']<#]^/1X_YI/)8?6ZWBX/%[N/]3N5/._VV^61_MR_ M3`X?^_7RJ:FT?9OXT^G59+O<O(^EPGQ_BL;N^7FS6H>[U=?M^OTH1?;KM^61 M^G]XW7P<6&V[.D5NN]Q_^?KQVVJW_2")SYNWS?'/1G0\VJ[FV<O[;K_\_$;7 M_<.;+5>LW?P!\MO-:K\[[)Z/%R0WD1W%:[Z=W$Y(Z>'N:4-7(-P^VJ^?[\>? MO'D=W(XG#W>-@_Z[67\_&+^/#J^[[\E^\U1NWM?D;1HG,0*?=[LOPC1[$H@J M3Z!VW(S`O_:CI_7S\NO;\=^[[^EZ\_)ZI.&^I"L2%S9_^C-<'U;D49*Y\"^% MTFKW1AV@GZ/M1H0&>63YXW[L4\.;I^/K_3BXNKB\G@8>F8\^KP_'>",DQZ/5 MU\-QM_V?-/*4E!0)E`A]*A'/NYCYE]<WC<I`S9FJ29]<,]#-#U2DSC7]ID]5 MT;^Z\&;3*]'M@7I7JAY]GM?@M:I(GUSQQ&NDJ=9TE3ZYYFG7>*LJTJ>J&%Q> M7'O3V^!Z^"(]"J.F2?'+>6UZ'!#B%ZYZXH5Z%$2R61U-WFF7ZG$(B5_.O%B. M(>_4()K(.=!,J7!Y7#[<[7??1[1.T24?/I9BU?/F0HTGDXRG=GKUS2Z:5D+E MDY"Y'].HT<0YT)+P[6$V#>XFWV@:KY3-(]KXML6"+<2<%;*A"R(7Q"Y(7)"Z M('-![H+"!:4+*A?4!IB0:UO_4EC\'?X5,L*_[)E'!MKACKL7;,%50A=$+HA= MD+@@=4'F@MP%A0M*%U0NJ`U@.9,FBN7,[A6?8U)8T]INQ>3,CKA'97/=.G8! M)`02`8F!)$!2(!F0'$@!I`12`:E-8KF0IO@9+A36M#+0#6!@7DNC@-9ZP^C2 M=O2B-6K#$4@$)`:2`$F!9$!R(`60$D@%I#:)Y5:Z.9WA5F'=N)6=\2C)S';T ME>/#UHBKA4`B(#&0!$@*)`.2`RF`E$`J(+5)+!_2_L3RH;@5^9<79'_FS4@( MV>Z5A#:E9HA>.^YMC5KW`HF`Q$`2("F0#$@.I`!2`JF`U":QW$NQ9;EW>/$4 MUK8/)9DU>_/F[KP`$@*)@,1`$B`ID`Q(#J0`4@*I@-0FL1PF\D5S:S3L,&%M M.TP2)^ANG*!KC=J@`Q(!B8$D0%(@&9`<2`&D!%(!J4UB^9!FW!D^%-:V#R4Q M@PY(""0"$@-)@*1`,B`YD`)(":0"4IO$<IA(7\[P6&-NNTRAF=[2``F!1$!B M(`F0%$@&)`=2`"F!5$!JD]@N$WOOTR>JR/*<*%-HYAL^DU:$]"WCTLE70JY' MNZUVZ^/?.!OQ2%OQ'(\1)8A21!FB'%&!J$14(:H9-8ZPG2SVY*:39:)X(=+R MX^MF]>5Q1RX@IW6LD@$EA"I-E#M[VE"R*QY%!DW#8?D>4*BL`BK1GKYVQB/2 M5BP?(TH0I8@R1#FB`E&)J$)4*R0OV_:TV+O_=4_+#,#RM$(WK?,7XNA!S`5: MOUNW8I1+HT`,X[<'?^HY252D5,A`N[T59I2<TE:JI51;SF3*M`$+YUJ84:%1 M_W656DJUY813I0U8N-;"A.QA$[F!.6P=$X$.ZMJ9(%,):WP4HGM#.QBSZ:VS M81"'-#1D/DVUU@J'3!G11VOD7SI[CTA)!6(*\[&-?^5X/.8&32VWP82-AGJ5 MLI$UB=U>96PEP^W*N?Z<BX>Z4[#14'=*-AKL3J6L@ED3_5XP=;Q8LTQ/A^P@ M$<F/&22_MHH*%>>F+Y$X"6Z'<N9-W=A1%8>GNS+2-\-(G*Z+F+MN?'#MY/:Q M*A9SHVT<(^2$ME-6TFUG=MN^TW;.-8;:+MAHZ+I+-M*K6,5M4T[57AA,D%I7 MU%;&Y=L!(-(S,P!^LDK(;,Y:)23RS56\19T=4$>IRDB?(48>H)B15D\TZE=/ MV4BK9XAR1EJ]T*A?O60CK5XAJADUZK;718YG>OW7IIW,%*W!4,FCN<[,/,^= M=M+J)TNV,AI<C2)JO)F)<G'$F:B*>]:B)A(2UC`[;<1K8Y2RT6!W,K:2W;EU M-@8Y%P]UIV"CH>Z4;#38G4I9#:S5P_ZQ@T8DM4-!\\?NHV_':][HA8RS6$MD M3>$6]4^#4&S32"K01S`1HE@A0SW1J%\]1:D,4:ZE>$]4:-2O7J)4A:C64K"] M$AFS.1H_63AE@DT!P=U\]%3.32'0+N8SS]GS+;055PP118AB1`FB%%&&*$=4 M("H158AJ"UD![KM'#6)5#&[$E^;GGK@V4G:0*V0??WG.YG*AK5IW(XH0Q8@2 M1"FB#%&.J$!4(JH0U1:RW4T+W!D1+.X6SKJAD.-29]%=:"OM4JE%%1E%:!4C M2A"EB#)$.:("48FH0E1;R'8IW0[.<:DP=Z)4(O.`T0<4(HH0Q8@21"FB#%&. MJ$!4(JH0U1:R_2>R]-,755\E]<:BJI!QV`@D!!(!B8$D0%(@&9`<2`&D!%(! MJ4UBNXSV,I;+?FDKZ0L5)Q(5TGOC!5O1;;^]8[D;M5`962=C,\])DR)MQ2M` MC"A!E"+*$.6("D0EH@I1K1!M!:BKMN]%"FF&ZZ_Y7B6B9A2WN2E[9R%N@F*$ MAGTOC?I/QI2*>3*FA;FM1*/^<4ZU5,_)F#9@X5P+,RHTZF^KU%(])V/:@(5K M+4S('C:19O[U89/)JKFC\Q6R#LP\]UMS927N(@.S2*7"9J:"!V9*ZB<'9MR@ MJ>5.VX2-AGJ5LA'=D=JN0Z\RMI))F'LZFW/Q4'<*-AKJ3LE&@]VIE!4G8;-K MYP2O9IF>#MFQ(Q*VH=@Y+0FCDRM8;U4J:*ZW+=+N=@<N5%)F$H8H5LA,PC3J M5T]1*D.4:RF>?H5&_>HE2E6(:BT%,UDDH.9H#"=A=/7@=8GL!UT\]TD,59&L M^/I"1!&B&%&"*$64(<H1%8A*1!6BVD)V@+MY[5](PC#G]25R,@;G!'NAK;2[ MVXJ,(K2*$26(4D09HAQ1@:A$5"&J+62YFZ;M.1'<F-O[-(4<ESIKW$);L?]" M1!&B&%&"*$64(<H1%8A*1!6BVD*V2T5R>?JB$`ASQZ42F4F8LC)0B"A"%"-* M$*6(,D0YH@)1B:A"5%O(]I_(-\_PGTQ/S7V0V/N32XTD#$@()`(2`TF`I$`R M(#F0`D@)I`)2F\1VF9NW_E(B0+MRB$2%C$T!6PTF`LI(=+C=J&$2IJUX48@1 M)8A21!FB'%&!J$14(:H5ZDC":%]GA^NO^5ZH.*N`0J;O6Z3="ANRID-T<"FW MOQV/)V@#[?96F%&BK`83OE1+]21AVH"%<RW,J-"H_[I*+=63A&D#%JZU,"%[ MRHA4]8Q51J6_>@?V*+(>,62T,VAC/+B%&Y^T&LZVE)0XF&JE(*^)V$KE-5/G MV^R8RVDL6Q4W.A(V&DIL4C8RE:`_F;(2'VU[\&UPWJ7E]JI@HZ%>E6PTV*M* M68F/_E[575I&K^Q0^5OR]0#S=87$24';U9GO#.N"*PXON$I=?UD?L3J5M.HP M/#&KTT+?6AF.D-^0LM%0%U(V,IY54(CN]6+*>E/?.9O/N<Y0ZP4;#;5>LI%N MO5*(TC?1^N6M<P98<Y6>QNT8<//NX4POP/Q:(<I\>'5::-3O^Y"-C.\J$,6, MM'JB4;]ZRD9:/4.4,]+JA4;]ZB4;:?4*4<VH4;>]3D-N+=+BWDHO>38SYN2' M+,6;..Z]52%S[9[Y[G,*JN)/UFXI];.U6UGUKMVJW%S;<!HJHZ%5,N5.#]Y+ M,F5%]\>^F7E"APIN:ZA#)1L-=JAB*^F@CLDZW!\[;$2R;M[;W2W9:8=D(J5U MXT8B:Q*WJ'\BA$J*DD:>_!&B6"%#/=&H7SU%J0Q1KJ6X#X5&_>HE2E6(Q`ON MPEFR[W(TY`OK\NW:[7K_LEZLW]X.H]7NJW@9G>[`#W<MEF_*/P;B5?GFQ7*W MY'9.[PA0QUWN40%MP3I*_.E<?/O<54*MT*3N*O&II+F%N.WX-U32K%!.";W= M_ZFS!C72W08)=;4=T*5W\$^S^2=R;D=G9W-Z_ZZ#7\[IG;(.?C6GEZ$Z^/6< MWOGIX'3%71=,W[#-Q?=46"/T+^<1K<U80M_6S+/.$OINA=2ZZH1!,!>I&*J% MP6P>T=*%)920S+/.$DH?2*VKSJ-/(40G9*CV&%`(R3GK#/JCY\W%D_I89T$E MB\X2>CMB+MXQP#KT-#^5=*G1"P@415TEH1?,Q8/FJ$;/C,_%8^%80D]X4SM- MR:2](/I/$!_+EW6UW+]LW@^CM_4S3<YI\Q[#7OXO"?G'43W=]7EWI/\!07D/ MO1M/__-C3:^E3\4[B<^[W9'_H*8G[7\1>?@_````__\#`%!+`P04``8`"``` M`"$`.G+$X`<&``!H&0``&0```'AL+W=O<FMS:&5E=',O<VAE970Q-BYX;6RL MF=MNJS@4AN]'FG=`W.\0R+$HR5;3A#-H--HS<TT)25!#B(">WGXO8\QAK33* MGIF;TGXL_[9_>QG;77S_2$_26YP7279>RNI@*$OQ.<IVR?FPE/_Z87R;RU)1 MAN==>,K.\5+^C`OY^^KWWQ;O6?Y2'..XE$#A7"SE8UE>=$4IHF.<AL4@N\1G M>+//\C0LX<_\H!27/`YW5:'TI&C#X51)P^0L<P4]OT<CV^^3*-YDT6L:GTLN MDL>GL(3V%\?D4@BU-+I'+@WSE]?+MRA++R#QG)R2\K,2E:4TTNW#.<O#YQ/T M^T,=AY'0KOX@\FD2Y5F1[<L!R"F\H;3/#\J#`DJKQ2Z!'C#;I3S>+^5'50_4 MD:RL%I5!?R?Q>]'Y72J.V;N9)SLO.<?@-HP3&X'G+'MAH?:.(2BLD-)&-0)_ MY-(NWH>OI_+/[-V*D\.QA.&>0(]8Q_3=YR8N(G`49`;:A"E%V0D:`#^E-&%3 M`QP)/ZKG>[(KCTM9&P_&VF0V5R%>>HZ+TDB8IBQ%KT69I?_P*+76XBI:K0+/ M6F4T'4QFPU$E<J/@J"X(S[J@.AS,)Y/Q=#Z#ZF^4'-<EX2E*:O>5!-VJR_`4 M)1_N*SFM2\)3E+RSSEE=$IZBY)W]A$2M6@M/4?+..A_JDO`4)>_LIPK3D,\* M-A_K`;^S5K694?"+*'MG7U4QC]2[1U7A\[E*CTU8AJM%GKU+L.9`[<4E9"N8 MJC,YD1A\2C6I\E6F0(HPE4<FLY3!0LB!`M+[;376M(7R!BD9U3%K&H,BGD0$ MRS\FN\%@BX&!@8F!A8&-@8.!BX&'@8]!T`$*6-OX"T/U?_C+9)B_PIFU`*WA MH[[=3R)"%-E@L,7`P,#$P,+`QL#!P,7`P\#'(.B`GIFP_/7,O+YZBSG)HI<R M_.S,2632NHZ9-<8^$;(A9$N(08A)B$6(38A#B$N(1XA/2-`E/0LAQ7_!0A8- M*P,LQQT/4=:N>=`(5MY.T!C-QB:HF8Z$;`DQ"#$)L0BQ"7$(<0GQ"/$)";JD M9RM\)'NVLF54FPR:;_/="RD3JAP7/JTY&?77U@FRMPD2Q3:$;`DQ"#$)L0BQ M"7$(<0GQ"/$)";JD9R_L)'KVWDY\%MWWD)-Q?QY/D8=-4.,A(5M"#$),0BQ" M;$(<0EQ"/$)\0H(NZ7D(G?\%#UETWT-.T#R<(0^;H,9#0K:$&(28A%B$V(0X MA+B$>(3XA`1=TO.0'0>[NZ7;\Y!%]SWD9%R=5:H=SA,A&T*VA!B$F(18A-B$ M.(2XA'B$^(0$7=(S#%:M7S",1?<-XV3<?IXQV&"PQ<#`P,3`PL#&P,'`Q<## MP,<@Z(">1^P8T3.)[\$'[&17'I/H99W!UP0VF%=FVPCVVO4.G*GTS:N$`<U; M^UK4?JPGZ(.^J8-&L`UKO^@J^N1LVRB1ZP9%)D46139%#D4N11Y%/D5!C;@1 M?>_9OKV;T?_.>[[[AWV2L&+-SG=L.+K>-ZBUE7K/@T9L8-]6VE!%&ZEM+0P! MHBZ#UF6VZ.NZK%:JK@OMCNTV0-3EM,("N2WZNBZOE:KK0I/.;P.$<-`*`^H/ M&SLA_/=AX^>,WK#5"'*UG?K:''WEV`$<!E>#L6JBZ$C60;!G;(*T"9+:UE(C MENOBZ*Q-T4`8HL*N%J[0%$&W6F6)H*X2:95]5ZN<:UJX5:X(NM4J3P2!9:T+ MV"M?1/'<0!X%XFVW9YW6].</.Q_=FC\_LLM72R[<]S5K+C]F]2801UHW[QO4 M=J[3L/JF@P>-VJW!%NY#V2SK(*-&'76S15^K6U3*ILAII40*NBWZ6MVC4CY% M['JW2IK*&3X:_+J6WT>E<7Z(G^+3J9"B[)5=Q<)UU&K18'Y/O)[H<$J`YF$^ MU6'G>X7/=-C-7>%S'38ME,.W3V=?D&MO5)TMOO0-K*,Z6RKI&UCU0.W:&[CO M?M2NE%BS>_!K7-/A5H36L![I<-:G_'&L/X+A],5ZK,,I%KC2.`CWW)?P$/MA M?DC.A72*]V#^L-I^Y/RFG/]1UCGQG)5PP5VEQQ'^HQ'#1=V0G73W65:*/U@% MS?](5C\!``#__P,`4$L#!!0`!@`(````(0"W-\Y$V0@``/<I```9````>&PO M=V]R:W-H965T<R]S:&5E=#$W+GAM;*R:77/B.A*&[[=J_P/%_0G8!I)024Y- MP%]@4UM;9W>O"3@)-8`I[$QF_OUV6Y(MZ04'9O=F/'G<:DEOM^26\<.?/W?; MSH_L6&SR_6/7N>EW.]E^E:\W^[?'[K_^"OZXZW:*<KE?+[?Y/GOL_LJ*[I]/ M?__;PV=^_%Z\9UG9(0_[XK'[7I:'<:]7K-ZSW;*XR0_9GNZ\YL?=LJ0_CV^] MXG#,ENNJT6[;<_O]46^WW.R[PL/X>(F/_/5UL\JF^>ICE^U+X>28;9<EC;]X MWQP*Y6VWNL3=;GG\_G'X8Y7O#N3B9;/=E+\JI]W.;C6.W_;Y<?FRI7G_=`;+ ME?)=_0'N=YO5,2_RU_*&W/7$0''.][W['GEZ>EAO:`8L>^>8O3YVOSGCA7O7 M[3T]5`+]>Y-]%MK_.\5[_AD>-^MDL\](;8H31^`ES[^S:;QF1(U[T#JH(O"/ M8V>=O2X_MN4_\\\HV[R]EQ3N(<V()S9>_YIFQ8H4)3<W[I`]K?(M#8#^[>PV MG!JDR/)G=?W<K,OWQZXWNAG>]CV'S#LO65$&&W;9[:P^BC+?_4<8.=*5<.)* M)W0]X:2EH2<;TE4V=/HW=\/A8'1W2]VWM!S(EG15+=W+6I+?:L9TO6ZP(]F0 MKE=V>2M;TE6UO'":M$RKP=)5M;QPFO>R)5W5-+W+!'(H"45.<#;*>%_8JU/G M$_U'M;UPKHY*(_Z/:GMIORJ3G":5O$OGJW+)N3B9>F(558MRNBR73P_'_+-# M.QW-NC@L>=]TQNQ.+4>1R?4"/;<^:6&REV_LYK%+H:.E5]"F\N-IX-X_]'[0 M1K"2-L]HXYH6$V7!JY[=3FW@VR"P06B#R`:Q#68VF-L@L4%J@X4&>B1MK2]E MQO]#7W;#^BIEGA5H!/<L,96%:C*U@6^#P`:A#2(;Q#:8V6!N@\0&J0T6&C#$ MI*4"8GJTYD\_.U1N<BMZ2NBYZ?5-L9ZES6TM\`3(%(@/)``2`HF`Q$!F0.9` M$B`ID(5.#"EIJ1M2MDO(UK1#T..@97T+(X]V_L;(<TRA)[51G99`?"`!D!!( M!"0&,@,R!Y(`28$L=&+(2L_H*V1EZTI6)<:S(`-#:,_>)FLCU6P*Q`<2``F! M1$!B(#,@<R`)D!3(0B>&AE2N&!KR(\D=WI#]E0\E=F3**XAG/*<\>^.LC6IY M@?A``B`AD`A(#&0&9`XD`9("6>C$D)=RRY"W?>6SM:FA():&`VN9UT:UAD!\ M(`&0$$@$)`8R`S('D@!)@2QT8FC(AU&]:FK7D*U-#0495">EJM*9`)D"\8$$ M0$(@$9`8R`S('$@")`6RT(DA&*VX*P1C:U,P00;-X]D&4QOX-@AL$-H@LD%L M@YD-YC9(;)#:8*$!0R,^QA@BB5K\A@^6Y?MF]?TYIYV0"LT3V>91S2TK<?9B MBE<Y)E2=ZD6Z-:AY6`^MY\Q4&GE4CM5/='=X:RYUO[%2:SU`%"**$,6(9HCF MB!)$*:*%1$((4WNNW_45_7O:BU,`U4E*BF<^7W(X=.UKU,B*V@LCCP/[X\GM M.]8.ZTO'9*#Z"K"OL$'G^XH:5[(OZXD8-P:JKUGC6*%Y@\[WE32N9%]6TJ6- M@7*\:!P3,L/&)X7_/6SBO&&$32):JW7J#[RAF?H3/O=3<%V*56V%D91&=*F- MW.&=Z<J7KKQ!%6_/\RR#0/5%I6?MQNXK5$9M`XJ44>N`8GM`_9$YXIERTS:@ MN3)J&U"BC%H'E-H#NK6BL5!NS@S(3!P^&+4ESE_YX=Q>2^\9Z\U6G*^,S!%( MO$*5FVV-SH=NRN^!*)?H.*ORWD<42*1Y#QMTWGN$KF)$L\:5&L.\0>>])^@J M1;1H7,$RYO.4'HT33SA==3:W'G$"656IE;(3?L'%&C?O4::(?$0!HA!1A"A& M-$,T1Y0@2A$M#&0F.!^OKI!4G,:,1!9(+U+Y/3WIIZ$I(A]1@"A$%"&*$<T0 MS1$EB%)$"P.9^O'YZ0K]Q''+T$\@K69U;#(%X@,)=&(.D8\G5PQ1G&:,(4IT MKXH,:TN=D#$'_(L'G#1JW;Y]Z:I^P-U;K^`"U1>MT5,/.'/J?-"X8NKB7&), M7:!J5ZGJ*]@K9!NZG!I.M;-/J:RK=B)7V[0%\ASQ(!_VK<(M4&UHOS_EV)PG MGQ6NF*<X6ACSE*@.L56^3QQA\$6(I9$^3X%4/$>N)6"@'%\23]<^^K0_`"IS M\P$@41-/JWZ:J#:M\51&VCPEDO%T[D9VWJHVE\235;XBGI6Y-4_V0*B.I_4K MRT2V:8^G,FHV)U\BC[;X.BW=D742")J&C956A1K)Z]*&8$SVM\Y4E1=+`W;, M[P2UH0X\.[%5P_:`"U=4FJB*QY?M7-JLVX2H&S969X7@TN[R5>R*2E!?Q1)I M9=^D02<'(/8G9=04/#ZB0*'JC&J&D`LF?>2_%T)1=AD3$FB@GPON(96%T1>I M+(TH'DVXX'CE"BNY6SFN=P?+6/JA2^WG;$"Y#FJ3Y;+3`R<PKV7M=8%$1J"% M%:&3`Y.!%D;ZZ4&ZTE!@>#<#S:6)/J,O-F!1R1@CE\4-%0.U?@/[%#OA5453 MIA\XU'J;(O(1!8A"1!&B&-$,T1Q1@BA%M#"0*2F71;JDO'9NZ5N5JW_'<$6! M9:@MD'7>@0546S5J`_*E>^U4%"`*$46(8D0S1'-$":(4T<)`IMI<=NEJ?Y'` M;&XM/8%,20?6-C'A94@--;&FB'Q$`:(0480H1C1#-$>4($H1\;=>S82$I.+; M+?&9R"X[OF63;+LM.JO\@[_+JDJ/&HN/QI[=$7TU-N)%#7=NZ4ZUW.'.G?K2 MS+XS'-.O@R=\42<G^Z`N3O9`'53/--N_,QCST?E$#PYU38="O$,OP\?\2OG4 M'6?,;V/Q#KU8'?.[4[Q#KT')VZD[]/G=MZKZA#'3P$YX>G9)Q%/<&]./_]CS MMP'Y/RD*:5))TJM[IL_N#LNW+%T>WS;[HK/-7BG\_>KWB*/X<$_\4<IW92]Y M21_<48;09T3T@65&7_#T>;M[S?-2_4$CZM6?;#[]%P``__\#`%!+`P04``8` M"````"$`A??R`1<#``!D"0``&0```'AL+W=O<FMS:&5E=',O<VAE970Q."YX M;6R4EM]OFS`0Q]\G[7^P_%X,A"1-%%*UJ[I5VJ1IVH]G!TRP"AC93M/^][O# MA`22IND+A,O=]W-W-F<6-R]E09Z%-E)5,0T\GQ)1)2J5U3JF?WX_7%U38BRO M4EZH2L3T51AZL_S\:;%5^LGD0E@""I6):6YM/6?,)+DHN?%4+2KX)U.ZY!8> M]9J96@N>-D%EP4+?G["2RXHZA;F^1$-EF4S$O4HVI:BL$]&BX!;R-[FLS4ZM M3"Z1*[E^VM17B2IKD%C)0MK71I22,ID_KBNE^:J`NE^"B"<[[>;A2+Z4B59& M9=8#.>82/:YYQF8,E):+5$(%V':B11;3VV!^%XPH6RZ:!OV58FL.?A.3J^U7 M+=/OLA+0;5@G7(&54D_H^IBB"8+94?1#LP(_-4E%QC>%_:6VWX1<YQ:6>PP5 M86'S]/5>F`0Z"C)>.$:E1!60`%Q)*7%K0$?X2W/?RM3F,0TG7A#Y$_`F*V'L M@T1%2I*-L:K\YWR"5LEIA*T&W%N-T<0;3_U1\+X(<_DTY=USRY<+K;8$]@P@ M3<UQ!P9S$#Y=#Q2"OK?H'-,9)9"K@45X7D91L&#/T+BD];ES/G#M?,+.@P&T M(P/M<C(Z(QD[BZG<.<,A9G0:,_H(!IUC"M<N^2C:I^_(SB=JMLMA/=%'0.@, M+9_V2,-6MDZP60_2>:-,V$:'W<3].8*%.K^>&-1DT;6UM4!W#Y#1Z<Y.CI%A M,/5`XCP5X_K4UM*GCD]3H67#0H,(]L%Y)D;UF:VESYR<9N(4/WA)L+DS6)7S M2`SJ(UM+'SD]C82U&R(O*!.C^LS6TF=>GV8&4-,0&ODS#Y;G?*E-8)^[,_7! MLS?`.#0&#;Z@V@##!MC6U,.._3>PX'6$G8'QG6HQ;(!M37#;OS?C_?O<&WQP M3AUAWW]7FZ@!U8VBH$_=SRM'=6>:&_JET&OQ112%(8G:X'D5PACOK-U9>AOB M>!O:H_FM.V-9]P^<<35?BQ]<KV5E2"$RT/2]*0P![4Y)]V!5#;G#4:<L'&_- MSQR^9@2,<A\G1J:4W3T`F77?1\O_````__\#`%!+`P04``8`"````"$`[<SQ MMMXS``"2,P$`&0```'AL+W=O<FMS:&5E=',O<VAE970Q.2YX;6RLW5MSVT:Z M[O'[7;6_@\OW2Q8E48=4DE43D2#`\UF'.X_C3%P3QRG;,YGY]ON!T"^Z^_V3 ME.B==3'V^N5%-P@\W0`:E/S]__[GXV^O_OW^\Y</GW[_X77GY/3UJ_>_O_OT M\X??__'#Z\VZ^)_KUZ^^?'W[^\]O?_OT^_L?7O_W_9?7__OC__T_W__YZ?,_ MO_SZ_OW75VKA]R\_O/[UZ]<_OGOSYLN[7]]_?/OEY-,?[W_7?_GET^>/;[_J M__W\CS=?_OC\_NW/3QM]_.W-V>GIY9N/;S_\_KIIX;O/+VGCTR^_?'CWOO?I MW;\^OO_]:]/(Y_>_O?VJ_?_RZX<_OEAK']^]I+F/;S__\U]__,^[3Q__4!-_ M__#;AZ__?6KT]:N/[[ZK_O'[I\]O__Z;/O=_.A=OWUG;3_\/FO_XX=WG3U\^ M_?+U1,V]:7:4G_GFS<T;M?3C]S]_T">H#_NKS^]_^>'UWSK?/7;.NZ_?_/C] MTQ':?GC_YY?D[Z^^_/KIS\'G#S^//_S^7H=;)ZH^!7__].F?=6GU<TW:^`VV M+IY.P?SSJY_?__+V7[]]77[ZLWS_X1^_?M7Y[NHCU9_LNY__VWO_Y9T.J9HY M.7O:C7>??M,.Z']???Q09T.'Y.U_GO[\\\//7W_5WVY.SJZ[G>ZEZE_]_?V7 MK\6'NLW7K][]Z\O73Q_O0E6]5VTK9Z$5_1E:.;\\Z5Z=GG>.:.0\-*(_0R.7 MR9X<Z/TB;*@_PX97+]M0'_#IP^M/V^U.W.T#/5Z&#?5GV+#3.;GN=B\NKZ_4 MV($MK\*6^O.X#ZD1^[2O^O.X#WD3-M2?QWW(CL+89*-.93CM+_R8G397^LMQ M'[1C8:K_<MQ'[5B$ZK_8ASU[T1GM6(CJOQS[82U'G9B'-/\'XM"Q/-1_L6ZO M7K;'EHA.C,1+4]BQ4-1_L0.5C-@#>WQFJ:C_$C9]X7`[LU#4?[$/F\XVA[JU M5)S%5+STTYY9+,[BN7WA^:FGKZ<Q4/_%=OEEY^?,)HGZ+[;IX>'SIIF<G^;Z MWMNO;W_\_O.G/U_I"JKC]>6/M_7UN/-=W9S-\LT!:^?]?=.^9NJZE;_5S?SP M6J=<$_H77:S^_>-%]_S[-__6]>5=J/F)-6=YQ:U5U!>`NMF>A[Z'PL/`0^FA M\C#T,/(P]C#Q,/4P\S#WL/"P]+#RL/:P\;#U<.?AWL.#A\<$WB@F;58T/OZ* MK-3-U%FQL_R300R/B\ZM5=@F/0]]#X6'@8?20^5AZ&'D8>QAXF'J8>9A[F'A M8>EAY6'M8>-AZ^'.P[V'!P^/"63!T"R8!6/W+:+-%77U#Z_UOW&NN'`SP4^A MYJH-R2VD!^E#"L@`4D(JR!`R@HPA$\@4,H/,(0O($K*"K"$;R!9R![F'/$`> M4\FBH>OB$=&HJW4ETAU+S`:N(TW1N>Y-DJ(+=REIB]HI`]*'%)`!I(14D"%D M!!E#)I`I9`:90Q:0)60%64,VD"WD#G(/>8`\II+%1?="1\2EKGZ*BYWDGQJY MR`/4==EHBVRS'J0/*2`#2`FI($/("#*&3"!3R`PRARP@2\@*LH9L(%O('>0> M\@!Y3"7+ANY.C\A&79UGHY'S_";UTF6C+6JS`>E#"L@`4D(JR!`R@HPA$\@4 M,H/,(0O($K*"K"$;R!9R![F'/$`>4\FRH0%_1#;JZCP;C;AYX\IEHRUJLP'I M0PK(`%)"*L@0,H*,(1/(%#*#S"$+R!*R@JPA&\@6<@>YASQ`'E/)LJ$;A2.R M45?GV6C$S1O7+AMM49L-2!]20`:0$E)!AI`19`R90*:0&60.64"6D!5D#=E` MMI`[R#WD`?*82I8-70R.R$9=G6>C$3=OW+ALM$5M-B!]2`$90$I(!1E"1I`Q M9`*90F:0.60!64)6D#5D`]E"[B#WD`?(8RI9-NI5ZB/"\52>IR-0/G5<GKIX MQ*HV'Z0^J2`-2"6I(@U)(]*8-"%-23/2G+0@+4DKTIJT(6U)=Z1[T@/I,:,\ M-O7R6;JD>G@UI'Z?X2:50!=/[^>>%D)O23U2GU20!J225)&&I!%I3)J0IJ09 M:4Y:D):D%6E-VI"VI#O2/>F!])A1GI%Z)>V(C#0+;UH7L1GBI_H5EF+CII:. MGUK:*MNP%S<TZI,*TH!4DBK2D#0BC4D3TI0T(\U)"]*2M"*M21O2EG1'NB<] MD!XSRF-3+[.EL:G?UIQ?U^_?PYOAE[^P:5;LLDB%13Q=$./"VJ5;F;VM7X`V MP;/\]$A]4D$:D$I211J21J0Q:4*:DF:D.6E!6I)6I#5I0]J2[DCWI`>2OBB2 MG+0\4O527!JI9ZY6S<I=%INPF)?'QK_!J5]^^]B`^JPJ2`-22:I(0]*(-"9- M2%/2C#0G+4A+THJT)FU(6](=Z9[T0'K,*(]-O4IW1&R:1;TL-@VY"YA?QJ^_ M<.1C`^JSJB`-2"6I(@U)(]*8-"%-23/2G+0@+4DKTIJT(6U)=Z1[T@/I,:,\ M-O4"WA&Q:=;[LMBT2X#I1<JO\-=?E_&Q`?5959`&I))4D8:D$6E,FI"FI!EI M3EJ0EJ05:4W:D+:D.](]Z8'TF%$>FWIM[XC8-$N!66P:<K.-7_S7%H@-J,^J M@C0@E:2*-"2-2&/2A#0ES4ASTH*T)*U(:]*&M"7=D>Y)#Z3'C/+8U,M^:6S^ M/VZ7FQ5$]65WO3_57XYKYIAT)O+O#&*5;=@C]4D%:4`J215I2!J1QJ0):4J: MD>:D!6E)6I'6I`UI2[HCW9,>2(\9Y9&J5PM]I,ZZ)[HG.?8;<\VZ8Y:HAMPD MY=\TU%^L]-<V4)]5!6E`*DD5:4@:D<:D"6E*FI'FI`5I25J1UJ0-:4NZ(]V3 M'DB/&66)JK_LFB7J\`/84WF^RAS(Q<:_A(A5[41$ZI,*TH!4DBK2D#0BC4D3 MTI0T(\U)"]*2M"*M21O2EG1'NB<]D!XSRF-SW"IS_;UH31KI;!,HC\V5?SD1 MJV)LFK:TH5&?505I0"I)%6E(&I'&I`EI2IJ1YJ0%:4E:D=:D#6E+NB/=DQY( MCQGEL3ENX;G^2KR/34/Y*\\KO_`<-E259:1'ZI,*TH!4DBK2D#0BC4D3TI0T M(\U)"]*2M"*M21O2EG1'NB<]D!XSRF-3KQ_^);<]]4],^$2UBY/)C?257W<. M&R:S3H_4)Q6D`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`S4(_5)!6E`*DD5 M:4@:D<:D"6E*FI'FI`5I25J1UJ0-:4NZ(]V3'DB/&649.3]NU?BI/%_^"W01 M[W4A/4@?4D`&D!)208:0$60,F4"FJ>2'[+@5TW.NF`9*'@9N(\7K>M<M7?2L M2.L<\8MU5^Y-83]6V91=&,4'DD&DV);OL+2BO$/W1J"*5=;AT"AV.(JTO\.Q M%64=7KM%P4FLL@ZG1D\=YJ?+KU0VOYGBI/XM.%]__?#NGS]]TL'42=IQ43W7 M;Z!H?B_%.1<P`V5G,:QIQH_="U7U'\DY<^_B^K'*/E'!Y@>D,FZ8-'_M%M^K M6&7-#]G6B#2.&Z;-NUQ.8I4U/\W:RL]'O4KW\JO2>5WN9IQ`NA+%0WKM5V7" MAO42=EOE`]ZSHGC"^H'.+YY^^TBGT[GH7+K35=AF6OC9V_;`B@[M0&E%:3S. MNJZ_RJKJ//[[QYL3-P*']M\/[<_(B@[MS]B*X@&9!.J>-;^.Y4Q')/]V^-0V MVM-]?OKKQ;(C3G]=[DY_0_7#>7OP+Z[=/MWJ_#UMJ/O7MHJG/Q3%3]L/VVD^ MJ0]UMWMU>7/F3D=A;:>SE&][8$6'=J"THF=.?_C$5\T^Z3>'Y2=@:,T<VJ&1 M%1W:H;$5Q2,R"=1MPG=Q=M-Q\_'4-MK3?7[^ZX6P(\Y_LVZ6WI3J=]759S9_ M<73M'X%CE<U)/5*?5)`&I))4D8:D$6E,FI"FI!EI3EJ0EJ05:4W:D+:D.](] MZ8'TF%$>FWK5ZXC8-(MD66P:ZNJ&MYT0+J[](_!Y6Q5C`^JSJB`-2"6I(@U) M(]*8-"%-23/2G+0@+4DKTIJT(6U)=Z1[T@/I,:,\-O6J5QJ;^N;OF[YF==ZL MGV6):I?4TD2YV_';L&'ZOI'4)Q6D`:DD5:0A:40:DR:D*6E&FI,6I"5I15J3 M-J0MZ8YT3WH@/6:4)ZI>$$L3M>.Q0;<F[7-#7>[N7QIR$Y&[I-_6OY9(&ZHJ M3D2@/JL*TH!4DBK2D#0BC4D3TI0T(\U)"]*2M"*M21O2EG1'NB<]D!XSRF-3 M+YNEL?GVKQ#77[3RD6JH_B_)M<T])=R&#;.9J-W04M9G54$:D$I211J21J0Q M:4*:DF:D.6E!6I)6I#5I0]J2[DCWI`?28T99I+0JRTAUKI\6-G9,2G$MXVG# M?$X*U.VTL\TMJ4?JDPK2@%22*M*0-"*-21/2E#0CS4D+TI*T(JU)&]*6=$>Z M)SV0'C/*TZ+'_FP"VA&1Y+IU49>[C#14!S).,C=NJ>DV;*@JFU%ZI#ZI(`U( M):DB#4DCTI@T(4U),]*<M"`M22O2FK0A;4EWI'O2`^DQHSPV]8IF>MUZ)C9U MN8M-0TJF!>)62Z9U54(]4I]4D`:DDE21AJ01:4R:D*:D&6E.6I"6I!5I3=J0 MMJ0[TCWI@?2849Z1>CWVB(S4Y2XC#27OD"Z\]"!]2`$90$I(!1E"1I`Q9`*9 M0F:0.60!64)6D#5D`]FFDI_">H7QB%,8UDWCM[)_NFA(*8G#'-2S*IW=Y!KB MUA/[L<K:*HQB\P-2:90W[Y8&JUAES0^-8O,CTM@H;]X]\$]BE34_-8K-STAS MHX/-+V*5-;\TBLVO2&NCM/GNJ7MMLHE5UOS6Z*GY/#;'+>9><#$W4!:;L+X; M/TW/JM)=O[AQKZ'ZL<IVO3"*;0U(I5'>O%L:K&*5-3\TBLV/2&.CO'GWP#^) M5=;\U"@V/R/-C=+FNZ=N3"UBE36_-(K-KTAKH[QY][IE$ZNL^:W14_-Y;.H5 MU2-FFV8!-EUZNV@HBPVH9U7IKE_<N,3W8Y7M>F$4C\R`5!J=MU->11H:Q;9& MI+%1OJON"7X2JVQ7IT:Q^1EI;I0VWSUU`V@1JZSYI5%L?D5:&Z7-GW-J"6<H M'J^M;?C4?)Z172NWG>Z1K^WKET3^7J.A+#J@7MBP?HV=7*A<ZONQR@Y8$2AI M?D`JN6%%&G+#$6D<-XR[VCUUSV636&6[.F5;,]*<&RY(2VZX(JWCANFNNNOS M)E;9KFZSMO*<U(NB1\PES1IJ-I<T5#\#M:>Z>^IF_]N+IDI?)["=ZAG%L=$/ MI!>B3V^/K[L7_DN6A6VEFZ/8G1N)`RN*O95&L;<J[ZW3O;F^.'67E:%M=JB[ MD17%[L9&L;N)4?,B^*QSXJ?2J54<ZFQF1;&SN5%\1ER0EJ2546QK;13;VI"V M&>6!JI=$VT!I_#_SQ-NLH&:!:BC[@D+WU-TFWEZ$#:^30`6*Q[P?JL+7$?15 ME,M+UU!A#:63+[Z-8$6QM](H3L=5H/H+[&TVSR[=!7,8-XQ5OL.1%<4.QT:Q MP\F+.IS&#?=W.+.BV.$\4'RL7$"6D!4;6J-H`]FFD@6J?M%S1*">RO/'8R/% MHSTM73_2;T-5.D,9)8$RRM)RZFXT"JM*!_*9_X6S`ZN*HZ\TBCU6@<*<>*%_ M<<_O^M"V2KM#HJPH]C8VBKU-C)I)ZO($7U:R@D-]S:PH]C4WBO/*@K0DK8QB M6VNCV-:&M,THCU2VF/OL'*5E?7\7%"B?HSKNIN'6-HQCJF<4#WD_4)BCSCJG M-]?(4]B#+'7^HF=-Q]Y*H]A;%:C^:8DX&/Q7DH:V8=HA`CRRJMCCV"CV.(D] MUA?UCIM_I[9%VI4/[\R*8D_S0,GL!%E"5FQHC:(-9)M*'J5Z+3:]W'W3UV/U MY4`D+%`V:77<.;\-&V:35K.A?HC<[K3ZH2I,(?H7+/VC2V'M'!K5`RN*([$T MBF>ALLZT#-$&C!?!N&&L\F=]9$6QP[%1['#RH@ZG<</]'<ZL*'8X-XISS8*T M)*V,8EMKH]C6AK3-*`^;QD@6ML/W5OK*(5+5D'[HQ<)Q&ZH2ZAG%EU!]4F$4 MVQJ02J/85D4:&L6V1J0Q:4*:DF:D.6E!6I)6I#5I0]IFE)]7#;MCSFM=[FYQ M&JJ_R=4.NF['W7G>=L.&\2CWC-+9(K35?(7W^NKZZLP]S16VU:$Y>V!%L;?2 M*/96!0I7O\[5S6GWS%TBAK;9H>Y&5A2[&QO%[B:!=/E[NAA=G]RXSS:UC0YU M-K.BV-D\4)R8%I`E9,6&UBC:0+:IY%'*EI1U*7AFBN"2<C=0=N'!XU>HRBX\ MS8;9A:>A<.'1OQQ>_U_^Y>O"6E+J8G3==6Y@17$R+8WB`:\"U5^#;9O:<>D) M^WFHPY&U'CL<&\4.)R_J<!HWC+OEKW4S*XH=SHWBY6)!6I)61K&MM5%L:T/: M9I3GJEY\3.]SGLE5LU:9/M9W&\IOF?VCS&VHTF_^LPM4SRB.XKZUE=_$NN7% MPC9,1S)N8@=6%7LLC6*/5:`P35W=7%V>N9OTH6V5=N=/\\B*8F]CH]C;)%"8 MI;HG-VZ-;VK;'.IK9D6QKWF@&.$%9`E9L:$UBC:0;2IYF.H%XR/"U*PO9V$* ME$U2'7>4;KM-539)!8H'NV]5V;'LN,M"857IK+$C3.BQC!M:HJM`S\U3H:VT M1^8)'8[9X>1%'4[CAH?F*70XM^WBW+(@+4DKHW2>"LW'MC96%6F;41ZM;#W[ M^>L?U[.[8:4ZO8AT_5/K;:C*YJG05ER?ZUM;Z6T9+DB%M94%$%?`T'H<S*5M M%[-<68<ZBNT5L-OQB]JV8=HALCRRJMCCV"CV.(D]/BW9GYR['9_:-FEG/L8S M*XI]S0.E4U5S"*(L4;-B0VL4;2#;5/(\:88Y9JJJR]VM>:!\JG)W0;?=IBJ; MJ@+%@]T/5>%^JM.Y.K_!12]L=6C6&+"WTBCV5AEE9ZZ#R]Z.#G>$"9]O;,W' M'B=&S>ICY^RDZZ;TJ54<^G@S*XKSRMPH3B(+TI*T,HIMK8UB6QO2-J,L4Y=^ M1?N;UHR>6LFC%BB_Q<*:D6T8QUK/*)Z*?B![<W)SX\Y[8=MDZ7"#?V!%L:_2 M*$Z35:!GWIO$#9.YS74XLJ+8X=@H=CAY48?3N.'^#F=6%#N<!XKSU`*RA*S8 MT!I%&\@VE3QEQRUR7W*1.U"R,G1+ZAG%!9X^J3"*AVE`*HUB6Q5I:!3;&I'& MI`EI2IJ1YJ0%:4E:D=:D#6F;47Y>Z_7=E]\\7S;+P>G-<Z#\C?V9OR*%JO2* M9)1.$TWS]H3?N>Q<^P>CPC8[-&</K"C.LZ51[*X*9-U=Z.M(E^X2,;3-#G4W MLJ+8W=A(GZB]=\+O$IA85;A$=4_\4\?4*@[U/[.BV/_<*%Y6%J0E:644VUH; MQ;8VI&U&><@TJQ\3LKK<78L:RJ]%>-R_#!O&H=PSBF>]'RA_9W7FOJ)7V(9J M,IX_O'2UJMAC:11[K`*%J]_-Q<7UN>MN:%NEW?G[VI$5Q=[&1K&W2:#PN']] M<MTLE-G_NN70J;5PJ.>9%<6>YX'2ZU)S^*,L4;-B0VL4;2#;5/)H:5P<$ZVZ MW$4KD&XIVQ/=]</P]K*IRN:O0/'0]ZTJ/Y;NKJ*P*FW?]HA[W(%5Q7%8&L4C M7`5ZYN$_;AA[9+KP$<=Q.UMMF+RHPVG<<'^',RN*GW!N%&>:!6E)6AG%MM9& ML:T-:9M1'JUZ9;>]-.JA^_`BY66S$)Q=&L/:\.&'?]LPCJV>4;S)[`<Z?%=; MQ`WW'_>!%<4.2Z.8Y<HZS![^S]Q+H*%MF"8>61Y95>QQ;!1[G,0>ZX=_MV0V MM0W2GGR&9U84.YH'BF-F`5E"5FQHC:(-9)M*'J9ZO?J(,#7+VUF8`N7S%.ZS MFJILG@H4CW3_LJ%PXW.C[RJZ=HI04?]BYG:.\D=[8$5QT)5&L;/**#]Q;J5A M:%5IASN"A(\WM@UCCQ.CYJ[J_.;DRO4VM8JT-__Q9E84/][<*,XI"]*2M#** M;:V-8EL;TC:C/%+UXF8:J6][\&^62+.D-93?;/'!/VP8AUKO,E`\%?U`]D*6 M+^QLFSP=^5N]@17%ODJC.$56@0Y/D<.XX?YDCZPH=C@VBAU.7M3A-&ZXO\.9 M%<4.YX'2B:LYOE&6J%FQH36*-I!M*GG*ZF72-&7/7`7#PG+RPVB7#64/_J"> M5<6']3ZI,(J':4`JC6);%6EH%-L:D<:D"6E*FI'FI`5I25J1UJ0-:9M1?E[K M)=3TO'[;[-$LQ&:S1T-N/<`]5M]>-E79=2I0.GLT9"O49U>G%U?N]4-A+1V: MR@=6%*??TBAV5P4*W9V?W5Q=^R^K#&VS0]V-K"AV-S9Z9CT@'(-VR=K_2]U3 M:^=0_S,KBOW/C>+'71@UG5V>7+E%V:45'.IK946QK[71P<^Z"56V^G+9=4^F M6VMF3_=9G*^R57#=)?@XKS_]H>>^YV[BGYK)GP\#I=,7J1=(OZ?6GI3ZI((; M#D@E-ZQ(0VXX(HU)$]*4-"/-20O2DK0BK4D;TC:C_'QGZ]$ZWX<O2U=<CPZ4 M?\G-#_=;VS!>)'J!XE6X#RD@`S94&L4A604*MTMGG8O3JZZ[=QW:9H?NF$96 M%/=[;'1P5$Y"E7VE32N2;EA.K9U#_<^L*/8_-XH?=Y%WII\G=`]]2]OF4%\K M*XI]K8T.?M9-J+*;TV[7/=UNK9D]W>>)5%^XH#:_W>Z9;-8;NCFG(7<-=2?B M]JJI2J^A1NDT%*HB%:P:&,59O#2*YZL*U%X@KZXN_$\7#&VS/;/VTV]P'EE1 M[&YLI-UMGSBY8&Y5\0+IAL?4*@[U/[.BV/_<*'[<A5%[@73W'DLK.-37RHIB M7VNC@Y]U$ZK:"^2%6TC<6C-[NL_CJ0QG\7PFE'6Y"V5#V:\<ZOK??GM[U5;9 MA;!'ZI,*TH!4DBK2D#0BC4D3TI0T(\U)"]*2M"*M21O2EG1'NB<]D!XSRF.C M;!T3F[K<Q:8A%QMWJWE[U5;%V(#ZK"I(`U))JDA#TH@T)DU(4]*,-"<M2$O2 MBK0F;4A;TAWIGO1`>LPHC\UQ:^?UK__WL6DH^;54MZ$JH1ZI3RI(`U))JDA# MTH@T)DU(4]*,-"<M2$O2BK0F;4A;TAWIGO1`>LPHSTB]EINN0#QS16J6?M.E MAJN&\JGEW"UEW\:J.+6T&QKU6560!J225)&&I!%I3)J0IJ09:4Y:D):D%6E- MVI"VI#O2/>F!])A1'IMZ$?2(V(0UZ61!\BHLH\8[XEM2C]0G%:0!J215I"%I M1!J3)J0I:4::DQ:D)6E%6I,VI"WICG1/>B`]9I1GY+A%ZRLN6@>*#_FWD!ZD M#RD@`T@)J2##5/*/6J\8'C$<F@7&;!9M*/DE.;=7+<5G,?]ZK&=%NN%O']BZ M_HLM_5AE4VUA%)^T!I&2MMSC3FE%:8<7-^ZIN(I5UN'0Z*G#[.A=^V7#P]>@ MI_+\]C90>O1(/:-\U]V7@/JQRG:],$J.%:DT2IOO^N_.5['*FA\:[3@RZ0); M1X?IF2/#!;;KAK(C`^I957RMUB<51NEA0%NE5>6'P2WJ5+$J'H:TK3P@]>J) M#:_Z,/AUY1?]@U77S1I,.NH"94>GJ4JH%ZKTFZ]L7_ND@FT-2&7<,!ECYV[Y MI(I5UN,P:RL_.CK2.#HO6?.ZKC=T`RF0IIYD.O'OC<*&6O-*JMQ$T;.B]*@U MK8>U%/T$3O?<-5W85GKLC#O@FAY8T:'^2RLZN+Q36=6^U:6A%>S9H?Q,U`_+ M:4Z?&:[-LW46R(;R]?!SMR![>QTVU!5S[T'J65%Z_)OM\B]=GKNYN[`-=;+: MUO$ED(%5'=J'THKB/E2!PM*VWG>YY;RA;9-VGUSV\@.>/N%^^\3`!]_K\."; M)0S?O@A5SXR#IJGT9ZAMN^PCGKL#45B53MJA\Q":S_;4#9C2FDK/0]AN?_!# M0=K]WO.0/D6^X#K%I\CKAM(7?)'BYT]VX&D-NV=%\5L&?5)A%%].#"+M;[V, M138/5Z1A1GD^T\<DR^>+IF8^,%TWE'\AZ-POX84J_1#C_H_5LZ(8AWZ@]IW7 MY?4-\ACV*4NM2]K`FC[4?VE%L?\JT(%IX7#O^6%7[\?,PW6YNPXVE+_[P?>1 MKYNJ9\9_*(H?MA^V"]?!^E?8N9O0PEK>,_B>LC^PHL-#']U7MET8^OG7O(;V M7_=TG1_H^A'EB`M>\T237?`:>NZ"%S;49VFG0DX%H2@]T`WE%[P+MS957(<- MTV#ON."]8!]*:RKN0Q7H0+)W=)]\N.R`WZ2/2C:A'/T[8)]:R0,?R`7>C>[; M4'4X\%84CT'?*#W"W0L?>JM*D\?S8%4'4V]%<1\JH[T7/"M(N]]['M3[$<&_ MJ<O=`6\HO>"%*M&!E%M1<L$C%4;)!2_2_M;+6-1>\$C#C/)\[GI2>\D%[X8/ M9X'R"YY__7IK&QX^:*'U&(=^V"Y<\.HYV#VB%M9R%EHW(@96=*C[THIB]U4@ MFQ7<'&P;[.DZ/^0J.B:*=;F+8D-N[+LGL]N;INJ9L1^*XB?MA^WL8G>.7\1< M6,M[!EYSL;.BP\,>W5>V73/L;T[PLX56L*?W_%BKZ)AC79>[8]W0,]>[F[#A MH53UK"@]ULUV[GJ'8(?6=;#:J^F.>?8%^U!R'ZI`^Y*]H^^]DVS]!)+>77S3 MLL]-\QR3WG0$<H%W0_LV5#T3^/"4E)Z$0.GA[5ZX)9["6M?Q.'020EN'4X]] MJ*SUW;=X]E_3OO>>A.,>[6[X:!<HN]*U3WOQPR<[T#S:V7;IE2YL%ZFPJO1* M]X+62VY7D889Y5-!_3QBX:Q_VJ$.Y]GER=/EZM</[_[YHC7)F_!4D[P8"^0N M>YB-PX:'9XA0E(:SH7#9NSP_]V]J"]NE++YN;`RLZ%#WI14=7H&SS]O\^K[K MDZZ[+1Q:,WMV*#\KVB&<E?3^^&7?0+ZIFW$3=T-9BELZE.*F*/U.<F@]H2)0 MTOH@TO[6RU@4[]?:O3(:9E7Y\:J?/=(4'UZQO`F/*FE<&\I?_U_X%<NPH:IL MIWJD/JD@#4@EJ2(-22/2F#0A34DSTIRT("U)*]*:M"%M27>D>](#Z3&C+#:= MT_0YM)[]#N>FJ<\'E%G]#UG$*R#N[Y.R-CH[K+_#BATVV&'E#JMVV'"'C7;8 M>(=-=MATA\UVV'R'+7;8<H>M=MAZAVUVV':'W>VP^QWVL,,><W.)JI^'7SX3 M=4Z;Y^?TML[,S47N_<9M4I8DJFDNF:"4*)@2!5.B8$H43(F"*5$P)0JF1,&4 M*)@2!5.B8$H43(F"*5$P)0JF1,&4*)@2!5.B8$H43(F"*5&IN42E:Q$OF:.X M!-$Y;<PERJV,*U%M69(HF!(%4Z)@2A1,B8(I43`E"J9$P90HF!(%4Z)@2A1, MB8(I43`E"J9$P90HF!(%4Z)@2A1,B8(I43`E*C67*-V"'C5'U?7^JM=8\OU9 MQ0?6VV&*#^H4'YCB`U-\8(H/3/&!*3XPQ0>F^,`4'YCB`U-\8(H/3/&!*3XP MQ0>F^,`4'YCB`U-\8(H/3/%)S<6G7OLXYA(7UDJ2N^W.:6/)5^)("H^O4G8\ M*3J>E!Q/"HXGY<:38N-)J?&DT'A29CPI,@FY(UBO=*1'\)M6A#JGS8))?N\0 M+*XC:%RV%N]0L4QA5=D_C'?F?XY6)Z!I+/D6D<X`3*<`IG,`TTF`Z2S`=!I@ M.@\PG0B8SD1CS:_$=:>B7F3Y"TY%LU:3GXI@V:EH[>"I:*K.FV6OLU/_3QWI M++05=J7666C;-M-9:&U_?SHO;6OU+\M1?VZI56>IK;"V=9;:MLUTEEK;WY_. M6]M:Z,^MR^@LMA76MLYBV[;,G<5Z.2@]B\\]QX45I6Q*"J:%@/8Y[MHMXF@L M-56'5U/;*EV#V[;P\X<ZBTUCX9U"YQSOSZWB\*_.::MT$]EVYP>XSG+8]8,[ MI5.=[U37?Z%')SXTI/EM;W>*0J@ZM%.*PDMV2GG(=^K:_RNX2L?AG7)YJ1>7 MTKQ\XP3<K%'EHSZL6VG*:0_.M<NW8A2VU!]ME3]CNOZ%JF3AT\Q^SOCFTGUU M1O-`V$I7\+UM:V9XP1XH,]@#!:0Q^X[-:=?M@0+R@CU00%ZP!PH(]D!IR/:@ M<^./K])P>`]<&HY;/=0_@Z;T^/OAQI*53YWDUO:?")WD4!77%#4QP'1:V]9L M2M1);&U_#SJ):$TG$:;3UK9F/>@DM;:_!YTDM*:3!--I:5O#%%Y_"P1#\N@7 M$9VG9MRY,5/G<4!<N-3>VJ;/3.VA,7T/,C:V8VH/96%JW_%^HNWNT"PZ:*L. MS:)E6W5PIRHKLYWJ^I]W&%K%P>O-J*TZM%/CMNK@3DVLS';JZMK=?$RM8M]. MY8.YHYU"CHY_==)Y:L<'J6Y;K\?2.[I0)XMYX$P>JI)W)7WK(;'"+.E!$6A[ MW=^#(M!4):WI?,-TAMO6XB"/MK\'G4^TII,'T^E*>W`G1UG(3LXS]VF=NMZ? MA,;J?T,SCN:N^S*<1G-;9I^SM\-T%E"GLP#368#IF,-TS&$ZYC"-(9B.,$Q' M&*8C#)OML/D.6^RPY0Y;[;#U#MOLL.T.N]MA]SOL88<]YN825:]3I'=RSR6J M6=?(;MDZC>6KH_[]K1+5EB6)@BE1,"4*ID3!E"B8$@53HF!*%$R)@BE1,"4* MID3!E"B8$@53HF!*%$R)@BE1,"4*ID3!E"B8$@53HE)SB:J7;8Y)5+/,DR>J ML6QUM`/3A`13?&"*#TSQ@2D^,,4'IOC`%!^8X@-3?&"*#TSQ@2D^,,4'IOC` M%!^8X@-3?&"*#TSQ@2D^,,4'IOBDYN)3KS4=$Y^P-I4N170:<Q,2'B)C63(A MM9N:*5$P)0JF1,&4*)@2!5.B8$H43(F"*5$P)0JF1,&4*)@2!5.B8$H43(F" M*5$P)0JF1,&4*)@2!5.B4G.)JM>]CDE46"?+$M58/B'!-"'!%!^8X@-3?&"* M#TSQ@2D^,,4'IOC`%!^8X@-3?&"*#TSQ@2D^,,4'IOC`%!^8X@-3?&"*#TSQ M@2D^J;GXU`MCQ\2G64C+KV>-I:]K]-_K6_-("H\G9<>3HN-)R?&DX'A2;CPI M-IZ4&D\*C2=EQI,BXTF)\:3`>%)>/"DNGI063PJ+)V7%DZ+B24GQI*!X4DX\ M*28)N934"V;'I"0LL&633&/)SYS?=NJ?X*MCHB>6^+3FKF1*3JC275E;=>Y7 M)Y2FMLPN;HH33'F"*5`P)0JF2`6+:Z[*%$RA:K<]L,L*6EMFNZRDP10UF+(& M4]A@2ENPN,N*&TQY:[<]L,O*8%MFNZP0PI1"F&((4PYA"F*PIUUV2:S7"-,D M?MO:?*=9:E3B[5/\U`F6![2I2TQQ;"Q_%>K_.6[%L2VS+A1'F.((4QQABB-, M<6PLV3W%$:8XMMLFY[;C7E\ICFV9[;+B"%,<88HC3'&$*8Z-);NL.,(4QW;; MN,OXM:F*8UMFNZPXPA1'F.((4QQABF-CS2[G<3SSZ]+/+#`\U;LEJV#)$;GM M1$L^/29&J]+S1CLQ=OUO\>VWC<6K<=%:MQT`@QU6MI9WX;ZH7R5E=AJ&K<6) M9[3#QJWE7;@?)9DD9=;%M+7X*68[;-Y:WH7[%(NDS+I8MA8_Q6J'K5O+NW"? M8I.461?;UN*GN-MA]ZWE7;A/\9"461>/K>V84>LW&G_!C/K4C$]VL]:;)QO6 MZX1MLQGUPO_;X<IQLVGVY9)@21?*,;I0CK&M0@M3:+&M0@M3:-MMX]##+BNT M;9F="X46S2FT,(46VRJA,"44VRJA,"6TW?;`+BNA;9GMLA**YI10F!**;15' MF.*8;NMFU'KU.KW`/S>C-JO=V96\?OU6OQC0O)W,B_['-3JAK-Z96,9)MFDL M_=4F[9;-5W`Z)^YMH:;7L%$^5-V7M)744!9_8;.2BOZ4U&!-?Z<G;B<5VY?T MIR2C/R49_2FV67^=$WVG/?T_=^.@2+^D>Z4<W2OEZ%XIS[K'QU7D7]*?1@'Z MTRA`?XI\UM]S'U?#X27=:X2@>XT0=*\1DG6/CZOA\DQ_;@35J]?'C*!FM3L? M08WE/Y_7Q5?"S\*FNE\_-()"5;R$:BX/'30_$'=U=7*J?ZDY_I^[;FI`A3;T M1^S)?_]0`RJ4Q7>P&E#!8O<:4(V%G]^]=E.#QE/81G_L[T[C*93%[C2>@L7N M-)X:"]U=G?L!K!$4MM(?^SO4"`IEL4.-H&"Q0XV@QJS#BY-N/+;ZFSN\&E"A M#?VQOWL-J%`6N]>`"A:[UX!JS+KO'#Z[&E"A#?VQOWL-J%`6N]>`"A:[UX!J MS+IWLZ7&4]A&?^SLSHTG3>)'C:>ZWM\)!<NO2.ZR<=NIO\2@39^[(H6J^)$U MGH*%GX4^<5^3T``*!?HC?F9W9#1^0E5V00H6N]/X"687P#-W%ZH1%"KTQ][^ M-(!"5>Q/`RA8[$\#*)A]/+?C&C^A0'_L[4[#)U3%[C1\@L7N-'R"[?MX&C"A M0G_L[4_C)53%_C1>@L7^-%Z"V<?S7['5"`D5^F-O?QH@H2KVIP$2+/:G`1)L MW^?3$`D5^F-7?VZ$U*\GCKGB-*\S\BM.8_D5Q_\KR!HA8=-GKCBA*GYFC9#0 M07/%<=\(T?@(F^R;$YI?T-&6Q2E(%QCTI@%RJ#>-CI?TIN$1RF)O&A[H3</C M4&\:'"_I3:,#O6ETH#>-CD.]:6B\I#>-#?2FL8'>-#8.]::!\9+>-#+0FT8& M>M/(.-2;AL4SO;EQ4;]W2<?%TZ]/Z)ZHD7?_^O+UT\?R_8=_/"U@/ONSQ?6/ M]N&BTEC^(MA_2UQ#IBVS![K>#M,`09U&!4S7")B&`$Q#`*;<PQ1RF$(.4\AA M2C9,,88IQC#%&*;LPA14F((*4U!A2B=,480IBC!%$:;\I>;"5K^]^8O"UKP( MRN?GQES8W'5886O+DK#!%#:8P@93V&`*&TQA@REL,(4-IK#!%#:8P@93V&`* M&TQA@REL,(4-IK#!%#:8P@93V&`*&TQA@RELJ;FPU6]HTK`]MTK3O-')$]68 M2Y2[<56BVK(D43`E"J9$P90HF!(%4Z)@2A1,B8(I43`E"J9$P90HF!(%4Z)@ M2A1,B8(I43`E"J9$P90HF!(%4Z)@2E1J+E'U2Y9C$M6\E,D3U5C^Y=]+]["K M1+5E2:)@2A1,B8(I43`E"J9$P90HF!(%4Z)@2A1,B8(I43`E"J9$P90HF!(% M4Z)@2A1,B8(I43`E"J9$P92HU/)$Z<ON1R7JJ=X]MP=S<Y1[V+WMQ+*8*%I_ M1UVQPP8[K-QAU0X;[K#1#AOOL,D.F^ZPV0Z;[[#%#EONL-4.6^^PS0[;[K"[ M'7:_PQYVV&-N+E'U:XLCYBC]$!QNVH.Y1+D%2"6JV51E2:)@2A1,B8(I43`E M"J9$P90HF!(%4Z)@2A1,B8(I43`E"J9$P90HF!(%4Z)@2A1,B8(I43`E"J9$ MP92HU%RBZI7]8Q+5O`G(KGKU:U,]&KI$N7=-2E1;EB0*ID3!E"B8$@53HF!* M%$R)@BE1,"4*ID3!E"B8$@53HF!*%$R)@BE1,"4*ID3!E"B8$@53HF!*%$R) M2LTEJE[;3A/UM+YP?5+_ZW@[;M+K%<"GI:V_=?0+!3A;-=:-"XH*$JRWPQ0D MU"E(,`4)IB#!%"28@@13D&`*$DQ!@BE(,`4)IB#!%"28@@13D&`*$DQ!@BE( M,`4)IB#!%"28@I2:"U*]`IP&:4=ZM!P6X].L&.=34V/9;[_K=GG[U)8E4Q-, MB8(I43`E"J9$P90HF!(%4Z)@2A1,B8(I43`E"J9$P90HF!(%4Z)@2A1,B8(I M43`E"J9$P90HF!*5FDM4O7B:)NK;ET//PSIL^OW-8.XZB'?6L2P)6]-<<K>E ML/T_NLYMMXT;"*"_8N0'S-6N;T1JP+K8DBPY=N+F76W73E$G"F0%^?V<6:%! MD3E](9(Y'G)V.*2]O.PD&<&69`1;DA%L24:P)1G!EF0$6Y(1;$E&L"49P99D M!%N2$6Q)1K`E&<&69`1;DA%L24:P)1G!EF0$6Y(1;$E&L"49P?9?V2'8CE\_ M]?U^NMEO+M]^[G?/_:1_>7D]^G/[[0L;6<UI8<;Z*3_:]4^_O1GS%UJELN&7 M7&:C8,-.4F9ML"&A7&9=L.',968GP8;S?HDUIS!N;!"=B8V"L0:L["S8,""R MWGFP81<ILXM@PWM&8FV!\2)K[97P"]^14Q9^X2-AQIK0XXZRLM#C]J6R\"=7 MZY2%/[DD)>R,*DDZ;H0*R2MMA.KX>\D('4#"6".XGS2A0BYP,%^9%=*BTZI. M2X>UVE\MM1WFJ5][JZ.S#E>X$B&\^0Z\6-#1&8>SD[_J1*AYI(VPVN-LA-4> M92.L]AAK\;6/A!8+2"$@5H]X4LX^&^%).3UAA"?E')41(H03(4:($#;"C6`U M?_P(:2),5:>)('6=&-;ZI$T,:HV0)H:T1DB#KSGZ*+:AHAH1H/;S30Q_]7,3 M$Z;Z>1C>ZN<F!K?YF>DG&M)^NVKJE=>&AMD<W6QR&K>VK[IZ]3\S,1VI_4@W M:B_2B=J',3&(1:RCEDIA3\%Z:JDLH)KO84TPTV-]M50*8ZRSEDIAC/764EE@ M-<;:<ZDL-ILML":8Z;$672J%,=:D2Z4PQMITJ2Q&&V,]NE0*8\1C#`F/_-`; MNQ[[`:526)W38&P$V+/#FF"FQSY!J13&V"\HE<(8^P:ELE%@;!F,PAA[!J52 M&(O+:/A3YXJX&13,1G_<',/7RN(&&;&K+&Z2$4O:7ESK"6;M<0'KG#Y2-@E& M87I<R#K'9]H>["*8Z2U#C\)87.K#G\I(@5PCP7&>7\D*#+$^(",NQ.8E,D;7 M2'N;:^/;7R>,+;Y.J>R4V..;AYG%!QMY9F7Q<<6HT_3&'/)F_/#1^UPG+"9\ MOD.=V<>NJQ]YP\]DS+.-]=E(^UTG2LCU72.3=ZZ-S-8U\E8;82"JW\EJ##'O MDAJ\1C;C7!L9PFLD-<Z$M.`UDGYG\AX?O%<??(!\4/((^;VSWS"/W0G$^OVQ M.X58[SUV9Q#KA3O:N5/R#O).R3WD06V[Q[8'M>T>VQ[4MGML>]!VYM2VT-KF MU+;0VN;4MM#:EEB]5'(+N56R@JSU25?8ME;;5MBV5MM6V+;6=NYXQ;SSMT@L M&*O.!#)1,H7,U.HI5L_4ZBE6S]3J*5;/M)UKVKE6<@.Y43*'+-2V.3Y8Z%OV MO&5^5.\LT5DJN87<*EE!UMK.BG;6JC-&9ZQD`IDHF4)FVLZ4=F:J<XW.M9(; MR,V!'/]\&7N]?/MU\]RO-[OGO[^\'KWT3RQBE&$Q?W<X.GCXSW[[E<6--T=_ M;/<<*QS^^:G?_-7OXJ=9)'G:;O?__H?IZ_C[=O?/L%!R^0,``/__`P!02P,$ M%``&``@````A`*I0VR*[)```F-D``!D```!X;"]W;W)K<VAE971S+W-H965T M,C`N>&ULK)U;<]NXLK;O=]7^#ZG<[\22+-E236;71.+YH+.^:T_B3%R3Q"G; MLV:M?[\;(IH-]$M"DK^Y&6<>O.@&T0`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`^B_;[X_F+%! M77+W[^/?OQ\^OWS]\'9T]>YZ.+ZY'9#^S>_WSR_Q@['Y]LVGOYY?'K__OT8U ML+8:*T-KA?ZRE<F[\<W5Z!(C(VN$_EHCM^^&M^/!>&):$O!^;2O27UMQ0/T8 MJ$#FC@=-?SN:&Z@XL17I+WN:OAM<7YUJX8VM1W\O.S2:I\>6TE]V&#ZTJ:U` M?R\[---ES4@P8]`&^:R#&[1CB/YQV>$->."8?[#3\`$.>)B8?UQXB#Q0!LY( M.>\0><28J77A(?*8&<B@&3F3(S#:!CQLS#^X=\;.[`S5Y9$S.'OH#'CLF']< M=I!#'CSF']S2<!R'/&K,/VR5T9D'-^1A8_X1=/>^6>Z.J^?B[N7NUU^>'O]^ M0^<D<OK\\\Z<X08S8X77S:9+VY6T;R&E%=18^<V8^?"6^HN6R&=:_O_UZW`T M_.7]OVC%_F0U'SLTOF+."K,\&[,+#2(-8@T2#5(-,@UR#0H-2@TJ#6H-EAJL M-%AKL-%@J\%.@[T&!P>\IQ"W<:;0_A-Q-F9,G#E"'QE(X$<JJ*S@*@L-(@UB M#1(-4@TR#7(-"@U*#2H-:@V6&JPT6&NPT6"KP4Z#O08'!WA!I97?"VKW9H?G MJ%'3ML:9H^/)U`_61ZNY:0,\![(`$@&)@21`4B`9D!Q(`:0$4@&I@2R!K("L M@6R`;('L@.R!'%SBA93.R!>$U*AIY:;38F#=;40C.O^U(MJ2^H&?MZ)VF@*) M@,1`$B`ID`Q(#J0`4@*I@-1`ED!60-9`-D"V0'9`]D`.+O'"3-LG+\SFM#L< MOR-\X8G7&#J.`([;QX:,W'/Q^&:@PMV*N-H"2`0D!I(`28%D0'(@!9`22`6D M!K($L@*R!K(!L@6R`[('<G")%V[:\GKA#B_41NW'M"$JIFI_-6]%;4R!1$!B M(`F0%$@&)`=2`"F!5$!J($L@*R!K(!L@6R`[('L@!Y=X,:5%]X*8&K4?TX9< M'],:Q]WN',@"2`0D!I(`28%D0'(@!9`22`6D!K($L@*R!K(!L@6R`[('<G") M%T`Z(5X00*/V`]B0:]DJ:;#0(-(@UB#1(-4@TR#7H-"@U*#2H':`UT=T%KF@ MCXS:[Z.&7`^EDUKB[$;42K:P&MHDM3N6X:VZKHA:$2]W,9`$2`HD`Y(#*8"4 M0"H@M27'@_=ZU>28O&YMKKK?W=`)Y.7KPZ<_/S[2@=.E7,=Y8D17U_::VUCQ MN_MH^,-;M[\1+2P:T66%].^-"D(DJK:#$26(4D09HAQ1@:A$5"&J+6H.V^]I M<SV,^8U+>[JYJJ9]-G?%1Y/L,YU_VZ*Y(.G6L>K5A16-3!@I27(UN/9W9I$( MV%<LAADE@OI]I6+*^E)3*!,!&\[%,*-"4+^O4DQ97^K`*Q&PX5H,$_+#9JYX MW;!U3`1*AK<SH;E`]N)C$<W!=HR/;U0'S$VZE:(XI&"*2K5\P2+2MJ+A^%;' MS9KR%JVQNKZ.V19=&(BMB;H82U@5:E;*HF"S,E9YS9JHRX&<5<%F%:P*-:MD M4;!9%:O\9JF>KUG5URQ_S)`M;\R\;E$U5M2BVB!S\Z6-V?A&S=NY2<,W"X*C M4@>T8-&H734BBX:TSVRM#R=JH,92451Z;4E81"?SUI06I2R2)F1G-2&7BOW6 M"Q:%FE"R2)I0G=6$6BIV-L$?#N;:^X(EQ,A5W!LT=)?X%G4VP":MK4BRI)&Y MT6+6&4$Q([&>".JWGK)(3&6(<D9BO1#4;[UDD5BO$-6,CM;]7C>7P&ZOOVX2 M-A?2WGK>H&MW[9FJU75N[DJ9;G9%>@(L6!1<H")6T:QNY](0EW/KD,(K*ES. MSVA6R@Z#S<I8Y34+E_-SFE6PK5!OE2P*-JMBE=\LM?K5K.KK+7\DF0OOT$C: M/?ZD^=JY1W:W!LWUNS>4&N3-ZQ9)'''@-**17+%'YEXF#3@'Q18YUA-!_=93 M-)4ARL44[Z(*0?W62S15(:K%%&S(S%6T&XT3&[+FHMOK]0:I'-;8WT7-J<:Q M0V7]62"*$,6($D0IH@Q1CJA`5"*J$-6(EHA6B-:(-HBVB':(]H@.'O(GGLD% M7!#J)G5`]GA$?C2WVFE6N*DM1`M$$:(848(H190ARA$5B$I$%:(:T1+1"M$: MT0;1%M$.T1[1P4-^7$TZXH*X-MD++ZXVH=%&>FZ>D#"1;LD"2`0D!I(`28%D M0'(@!9`22`6D=HG79>8IC@NZ["CW]Y`6N0D90?WK]8)%W@D54F"BXKD7(TH0 MI8@R1#FB`E&)J$)4,\)DF-FM>9W\JBWCT8KJ>V/83X99E1..A44GDF&BDIYN MS%-%1@FJ4D09HAQ1@:A$5"&J+>I(AIGG>_Z!GC965$];)%<;\Z,O4H4N!!=6 MU)\,$P'W<2R&&26"^F=4*J9ZDF$B8,.Y&&94".KW58JIGF28"-AP+88)^:L0 M+0)>V,)[KZ&1J_A81*MU>YDROIFHO9>M:,:/J-0>?L$B9Q.,*$:4,`I93UDD MUC-$.:*"4<AZR2*Q7B&J/>0'PES%GW\&'387_>X9U*(1739(%]_<Z$#8BN&Y M8T7>&0*RDM;AB>P2M]2UI2]_$A:%6I6RR+4$N=+LK%;E7;9TJPH6A5I5LBC8 MJNJL5M5=MIQ6^0/&7(>[`^9UI[;F:MX;1PWRLB'TJ+H>1S8-$)H4"Y/6I.6" M#HN7HLBB$96THQ13DE)15$Y'''-A"8M"34A9)$W(SFI"+A7[FU"P*-2$DD72 MA.JL)M12L;,)_G`PV0)W.)Q8R)OD@A?W!CG)A;F9VB9^H0FP8)%<5D>(8D9R M&D\$=1[>,<@IB\1ZABAG)-8+0?W62Q:)]0I1S0A3DD.=NGC=),2,QM$P[2_= MLRJD)*WHQ#[(&@^N3Y$U98XT-"T[;.&TM*+0H$FYZ<%696>U*N^RI5M5L"C4 MJI)%P5959[6J[K+EM,J?O-0J;_+J871>/M+,4[T[:Y`WJ5LDH78:UMQGL*:< MY&.$*+;(L9X(ZK>>HJD,42ZF^.Q1".JW7J*I"E$MIF!/;!(/%RRE39["6THM M<F?O^$;?4:`[-L?5-73R6+!(]I41HAA1PBAD/6616,\0Y8@*1B'K)8O$>H6H M]I`W+6CT71*(H]R_.+'HQ)Z8*]+$:!<_F!$L"JX-D56=6$>[;&F'"8M"K4I9 M%&Q5=E:K\BY;NE4%BT*M*ED4;%5U5JOJ+EM.J_P!0\/1F[EZ'3WKV:>1L:+& M48-.[(EMQ?!%+HMD-QA9=&)/+!7[1VG"HM"\3%DD3<C.:D(N%?N;4+`HU(22 M1=*$ZJPFU%*QLPG^<-`YJ?">V*3I=-P;1.<*/@7-K<J</@*+A:TG^\J(ZPF* M&8GU1%"_]91%8BI#E#,2ZX6@?NLEB\1ZA:AFA'MBRKC]$Y/06%&3L$'A/?'1 M.]4+A\<:IS]M#"&3$%E3I];R#EO.^M1<JI[3JI1%P59E9[4J[[*E6U6P*-17 M)8N"K:K.:E7=9<MIE3]Y=4),K^7G[8E'F"BSR)O4C>K$I&Y$=$+BQ2"RIAP4 MH_5$D`PWY[";"UTTE2'*Q12WH1#4;[U$4Q6B6DSI/;$Y-WEGUA-+:9/X<??$ M1PO^C5M$"T01HAA1@BA%E"'*$16(2D05HAK1$M$*T1K1!M$6T0[1'M'!0_XL M,QF>\Z]US$9:K\H-\I^]N%5/G<YM15+QN%T@BA#%B!)$*:(,48ZH0%0BJA#5 MB):(5HC6B#:(MHAVB/:(#A[R0VWR,A>$VJ9QG&<O1@URG[U`M$`4(8H1)8A2 M1!FB'%&!J$14(:H1+1&M$*T1;1!M$>T0[1$=/.3'E4[?E\35R-7&JD&R%Y^; M'_222,@"2`0D!I(`28%D0'(@!9`22`6D=HG?92;SXDX%O;<X[SK19GG<&6*1 M[+GG9F$T_4T]VNXU]<E_845F4RVB6_4D?20J7D1C1`FB%%&&*$=4("H158AJ MB^BH]4Z"5H]_H.^/5OQ1S,CI>T%.M^J[SE9$>U-[0UT]?1^)H.UV,<PH$=3O M*Q53/0\*B(`-YV*842&HWU<IIGH>%!`!&Z[%,"%ORIC4AS=EPAO`HUS%I\FA MF`>BG#&NHC&W%<,Y%!8Y.W%$,:*$42@WD;)(K&>(<D0%HY#UDD5BO4)4>\@/ MA$DMN&O7B4`TF0AW)TY/[Y@5R>P4G$"H7X7,K2J\;K'(7;?P0MJJZ(Z(&8DW M>G,8LQ7W$E,OD0F+0NMHRJ)@>S*_/=.!NK>=LY50>PH6A=I3LBC8GLJJ*+5E M^F=P-50K4,UF>AKDCP\273(^C%Q-U`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`O.:$:N3JA-NC:&SVW:H,Y-\54\<0Z:T4RQB);SZZSPZOKZ95*M,9L MNF>=L5/L#/\I6Q+_F?8_NM4_)L^Y5LA_P:+P.@O'7_G^!].KCG76UNKQ[T\R MDYIQ]T^O6V=M@L=)`YE;E":^=#J3D]VM?O['JDY<85GK$H6(K=.<%^M3&`BV MHKO:#.'GP^>T(661M"'K;H/:X^1<,=B&@E44.3D>M2LO621MJ+K;H"K67+&O M#=Z(&.OD5/CB^BCW%P"+W&574/_Q+5@D2U>$*&8D"V,BJ-]ZRB*QGB'*&8GU M0E"_]9)%8KU"5#/"97=,Z\#__SP\6E'!,(8)T520D:6W9G-;,;P:L\A=5S#3 M857F?EOK$)]N[[(%^0X6A=;(E$7!5F5GM2KOLJ5;5;`HU*J21<%656>UJNZR MY;3*G[TFL15:S\][9&!LS*B!U"!O5K=(0NTT['BB75A3SO,!$:+8(L=Z(JC? M>HJF,D2YF.+KM4)0O_42356(:C&E,\9C6G$A&J][#ZFQI`+2('.;H9UHM.56 M/U(Y-H$RG;(P+1!%B&)$":(4488H1U0@*A%5B&I$2T0K1&M$&T1;1#M$>T0' M#_ESDA:!?V@4&$MJ%#1(C0*=OAJW*IX`"T01HAA1@BA%E"'*$16(2D05HAK1 M$M$*T1K1!M$6T0[1'M'!0_XH,(D==V4^L:]J\D#N38MQ@U2H=0)+5!+JMB*C M"%4QH@11BBA#E",J$)6(*D0UHB6B%:(UH@VB+:(=HCVB@X?\4.ODU8E08Y9J MW""Z%\D1FR-:((H0Q8@21"FB#%&.J$!4(JH0U8B6B%:(UH@VB+:(=HCVB`X> M\N-Z649JC!DIB^2ADCF0!9`(2`PD`9("R8#D0`H@)9`*2`UD"60%9`UD`V0+ M9`=D#^3@$C^$)C=RP2K<I%*\5;A!=#]2IF:+G)V8N@A?C*W(O0@?3U7B.1(5 M6X\9B<-$4+_#E$6NPXE.EF6B8H<Y(W%8".IW6+(HZ+`2%3NL&8G#I:!^ARL6 M^0Y5QGTM*G:X820.MX+Z'>Y8Y#J$&.Y%Q0X/C(X._0%I<E07#$B;TG(R;>,& M>0,2T()5?M-55C82%3<]9B1]E2!*&;GF)_J&7R8J-I\S$O,%HI*1;UY-L4I4 M;+YF).:7B%:,Y(V9:T0;1F)KBVC'R&^JNBS;BXJ;>F!T-.^-D8E.R;TJ27NT MXE\\6.0.'40+B_PG\_0OL2-1\1'%:"M!E&+%#%&.%0M$)5:L$-58<8EHA177 MB#98<8MHAQ7WB`Y>17\$Z/1@>$<YL4D_9Y5@1"M#FRV87.GK1*L*YP%9))O3 M"%&,*&$4RIRE+!+K&:(<4<$H9+UDD5BO$-6(EHQ"UE<L$NMK1!M$6T8AZSL6 MB?4]HH.'_$&D<X,G!A'F`"<-\FZ>3Z[T%:A5A6_JL(@LMN,1D\GLT#X6-ID. MKM2.*69#[GJKDY`)BV@/UGK3HI1%P29E?I.&@ZM;=?PYVPFUJ&!1J$4EB^2\ M5%D4_D5>+17[CW?)HE`35BR2)JS/:L)&*O8W8<NB4!-V+`K&96]5_`1AQXW1 M`QOJ"8P_64ATP;YL8N3JY&J1O^*JX3NW%4^LN(TI>LD?GULCKB<H1I0P"JTK M*8O$5(8H1U0P"EDO6236*T0UHB6CD/45B\3Z&M$&T991R/J.16)]C^C@(7\0 MZ<SOB147T[L3F[BE?%"[<'6LN+9B:!HMK"GSTO_65,>*:QW:%;=C&L5LB`9E M:T@OI@F+0DU*611L4F95/+-'$_UUO9SMA%I4L"C4HI)%LMQ5%IU:<6T(0DU8 MLO50$U8LDB:LSVK"1BKVQV7+HE`3=BP*QF5O538NPRM\%.;`AGIZQ9\LER7( M)Y@@9^2ON.H:=VY5)U;<QKJWX@**V92L#PFCT+J2LDCJ98AR1`6CD/6216*] M0E0C6C(*65^Q2*RO$6T0;1F%K.]8)-;WB`X>\@?19:GW":;>+3JUQ[450]-H MP=:#TRABA\V*VS6-8C;4,XV:)]I8%&I2RJ)@DS*_28.KD=JUY&PFU*""1:$& ME2R2U:ZRZ-2":R,0:L*2K8>:L&*1-&%]5A,V4C&TX)XQ4G9L*1B6O56U"RX^ M^WA@0SV]XL^5RVYG3/!VAD7N;2I$"T01HAA1@BA%E"'*$16(2D05HAK1$M$* MT1K1!M$6T0[1'M'!0WY<:;1?<NEBY.K2I4'>G>;)E7YX<]*J^*ID@2A"%"-* M$*6(,D0YH@)1B:A"5"-:(EHA6B/:(-HBVB':(SIXR`^U2?2??_=@8N0JU`WR MIC"@A:WHJ")$,:($48HH0Y0C*A"5B"I$-:(EHA6B-:(-HBVB':(]HH.'O+C> MZ(Q_^,+Q*/?C:I%SIQG(`D@$)`:2`$F!9$!R(`60$D@%I':)WV6TK[Q@*MP8 MN>JR!KEW0ZR*4/\9?L$B]YR+WU,5%:^6,:($48HH0Y0C*A"5B"I$-2.\$W5# M'>%U\JON1!VMJ+XWAOV/25B5$XZ%1=Z=J"%\6554TM.->:K(*$%5BBA#E",J M$)6(*D2U1<TQ^L.91M,_T-/&BNIIB^0)]_E-BT*CO!'UOR/"6B$!]W$LAADE MB%*I:-_2H.[@9R)@,SF:*1"54M%:UG>,1<"6:\^,'Q*3XCG_9'MC,T+.33A& M=()M,V>3@?K9RMRJP@D*%LF(CAA1H!SKZ@<I,:NH=8Y*=4S"JD$;S)21>,P8 M!3WFK`IZ+%@E'DM&XK%B%/18LZK/HQ_6R_).YB/2>DK9S!#]<;I4C>(Y5Z1= M<ZO2:=,%B^20(XO,R[3;>J.!"EC,%?V.4:J$53+Y4T;B,>OR.-%?4LZY8M!C MP2KQ6#(2CU6W1W5WNN:*?1[]L)KK[@MFJ[U,=V>K1?YL57?[YC>-ZL1LM2(Y MY(CKV7?NJ"QES,7N$!Z/51XF895,FI21N,H8-:Z4C9Q+@YX*5HFGDI%XJA@U MGM3"5G-IGR<_?I=E)VXP.V&1]Q/$B7X!PYPKAJ>EM2Z'&K%U;UI>01AMQ;XA MVZ3NI`U\&DH9B<>LR^,$WMS"%8,>"U:YTQ*.L>KVJ/(`-=OJ\^B'U20-+IB6 M38[!?0#SQB)O6@[56)M;U8EIV9ARW^/`]3KG2LRE?2/8AM.:E;F2<D4WG%;5 M>+I6Y^F<:P1=%:P25R4C<54Q:ER-U1)6<W&?*S^`)CMP00"-7.U`&^3-R\$0 M3I>V(O52>]K#TZ45R;%&-]9Z\Z8E=0J);:GYTK58Q66U]2WS$3QEOB=UJLW/ M\E2PRIV'X*GR/:FA7K.-OF/RPG=[66;A*/?#QXB:V78AO=A&_>[,JL+SCT5. M^!@U0U5U:LRE?2.UF7^LDDF1,A)/&:/&DVI_SJ5!3P6KQ%/)2#Q5C#J/J>;2 M/D]^^'26XU47X+>8_+#(FY23H>K_.5<,3DH620]$;+V9E&H`QURA;P#;J-I& MRU1)N:)XRGQ/$%5K(^BI8+/BJ60DGJJ@IYHK]'GRHZK3*N%TWVV3S7!/BA8Y MOY^="Y)Y"@LHB^3GH1&BF)%T2((H922V,D0Y([%5("H9B:T*4<WH:,OO4>IW M[RSUNGEBK*C5KT'>6Z3TL]#SVT9T8O&S(AE2$==K%@J8)K9"WT)AITGKNSUW ML5GQE#'J])1S:=!3P2IW\8-CJEC5Z:GFTCY/?E!)%0SJ>3]NOS5F5%0;Y$V? M%H6F3R-R?]QNK3LHMLBQGB!*L6*&*,>*!:(2*U:(:J^BW].7Y41N,2=BD7\+ M$39YHN+!ND`4(8H1)8A21!FB'%&!J$14(:H1+1&M$*T1;1!M$>T0[1$=/.2' MVJ0FW/V\62E?]8Z"6YLO<5(H%JE1H'X,,Q>5C(+&%E5D%*$J1I0@2A%EB')$ M!:(2486H1K1$M$*T1K1!M$6T0[1'=/"0/PK,Q;\["D[L0&RNP`UU@U2HU?77 M_+95<5P7B")$,:($48HH0Y0C*A"5B"I$-:(EHA6B-:(-HBVB':(]HH.'_%"; MO(,;ZM=/^":#X>U#&Z1&@4HXS&];E8P"0!&J8D0)HA11ABA'5"`J$56(:D1+ M1"M$:T0;1%M$.T1[1`</^:/`9!G<47!BPMNDA#OA&Z1"K;++\]M6):$&%*$J M1I0@2A%EB')$!:(2486H1K1$M$*T1K1!M$6T0[1'=/"0%^JI3OF\>L(?+?D[ M9XO4*%!I\+FHVE&`*$(4(TH0I8@R1#FB`E&)J$)4(UHB6B%:(]H@VB+:(=HC M.GC('P5=F:-7[?.FF#VR2(T"=:-@+BH9!8TMJL@H0E6,*$&4(LH0Y8@*1"6B M"E&-:(EHA6B-:(-HBVB':(_HX"%_%%R6:9IBILDB/]0CE:N8BXKCND`4(8H1 M)8A21!FB'%&!J$14(:H1+1&M$*T1;1!M$>T0[1$=/.2'VN1BSC_#3YO4C;N9 ML\AYZG..:($H0A0C2A"EB#)$.:("48FH0E0C6B):(5HCVB#:(MHAVB,Z>,B/ MJ\DY71#7)D7EQ;5!SK.A4TT60"(@,9`$2`HD`Y(#*8"40"H@M4O\+KLLG37% M=)9%SL.(<T&!!"&+:'*U-\O&-VJ3'(F*5\N8D>1L$T0I(]?\9*1NI6:B8O,Y M(S%?("H9^>;5U5PE*C9?,SJ:]T.ATTWAZXXIYI0L\D+1J!RT8)7?='4_*!(5 M-SUF)#V3($H9^>958BL3%9O/&8GY`E')R#>OADTE*C9?,^KH>)WA>=4=D2DF M?BQR.G^.:&&1]^CN1'_Z)1(5'U&,MA)$J524>389J>Q3)BHVGZ.M`E$I%5WS MZBJG$A6;KSU;_D0P"0]W&9>KLA-3HLF4>`MZ@[R;4I,1;+\;5?BNU-2*:./7 M+ECX*W&KLF_A'X^NU?XO9C-T7FG-Z)N/"8OD!E+**.@^\]T/!F,5B9S-A-P7 M+!+W):.@^\IW?SVX5;?):S;3X]X?!R8;XHZ#$]%ODB=>]!ODW[K7$9E/;46* M;V]$%BR2U2FRR'ZY3'^7*^8:[DJ%@6Y]\\1(N9YXRGQ/$%)K(^2H8*MR<[ED M)(XJW]%`G<]JKM'CR8O>X*HSN3)Y=XS&UX=/?Y[U'<W&C)]9:1D=>!NQB7Y. M;,ZR\+1N5=(-4<N:6[.W\&J=5M`SCIL;SJU*YE':,G&7M:QQI[\-D[?E(6]% MJQ)O9<O$6]6RQMO-1)V;ZU;0XTZ%66=/PK.4OG5%LUK'LV'.;6`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`: MPVM%-F8O%B?#&UQ2K2$:A:VACKG5-HHC2M$[IPD4T$;&7^>DSZ;YCZM3>,]H M`@4<FD`!/Z<)-`:\)HRO].=!:42$FZ#&R*ETSGG/0M+[-#L6VX;YD[-E_2&B MR=FHG(<?:7("H\G96N-0TN0$1N&%NA1+8!0]J$NQ`D:Q@KH4&&`4"K>NZGA: MGKR3W*FMC-'KLUG#_'MHUVI5IEG8RKB7J(>!40\#HQX&1CT,C'H8&/4P,.IA M8-3#P*B'@5$/`Z,>!K;L8*L.MNY@FPZV[6"[#K;O8`>?J1%@,A'NI<JI$6`S M%\ZS,X.KAJD1H#-VCLP9`6U59C0"@-$(`$8C`!B-`&`T`H#1"`!&(P`8C0!@ M-`*`T0@`1B,`&(T`8#0"@-$(`$8C`!B-`&`T`H#1"'!9,P+>/W^]OW]9W+W< M_?K+]_NG/^[G]]^^/;_Y]/C7#SIOF8R"P]\\W7_Y\/8CC:39<3A1M-HZ;=G4 ME!VW,KKLEJK1XUL=M6ZI$CWMTU$RO9J9)T"Z2@94<KPHT'ZF0RHY[H2A9$0E MQ[<YZ)+)S<R\?ZK#SX1:3:\KZBJA5M,+;SI*;L=T/./.D@F53#I+J`7TB&.' MM1'5H>O^KA*J,^JL,Z8CI>]W==097U/)\4:I[H,QM9H^`=15AUI`'Y'I*J&" M+DX5.O74X,[V#JB@R0#K5@W,8.OL_Q&UES[*B*VBNWPS<P^OJV1")5TMHQLB M5-+5-KKU-S-W/=#:;X/9;YWCC(9FY\BD@=FIIV!UQ>JWZ]EO/7.)@M@50[JC M.C,WD["M=&-U9FZ;=I5,J*2K3^@>%)5T6:.[K3-SHPFMT4W7F;G?A"4?J>1C M9PG=>)Z9.VQ89T$EYEYR5\F$2KI:33?FJ*3+&MV"GIF[;VCMX\U@]I%>78,E M<RJ9=Y;06Y)FYEU#6(?>ZD,E7=;H140S\XJ<KCJC641O:L$2>IO,S+PP!DOH M;3#DIZMD,[Z=F0\Y8!WZ+,S,?,\!2^A;,#/SI9>NDBF5=*UT]!F(F?GN`]:A M#\30$M!50E_5F9EOYF`=^B@*E73YH<]@S,QW+[`.?6IG9CY_@27TQ9V9^0H& MEM!G=F;FRQ=80M\AFIDO>F`)?7QH9CXMU%4RI9*N5M.'0&;FRQ]8A[Y(-#,? M`,$2^C#1S'P'!$L6(^J=YK%"M48NKJ]F4?-,DRI)J23K+"FII.HL^4@M^-C9 M@CF5S#M+Z%M0,_.EIXY64TS-1W@Z2JAWS#=6L(0^$#4SGUK!DH_#J]E'NH;' MDCF5S#M+%E12-:\]5KVS&-(,[JQ34YVZLV0Q',ZBYO4*REI*)5EG24DE56?) MQ^F,ME-=AS.=T=521\&"!D%G;P[H*#MKU-,9;4V[3`T&LVC0U9DIE62=)265 M5$W)^_;XGW_]Y>?='_?5W=,?#S^>WWR[_T)[QZMWYN4V3P]_F%1/\S\OCS]I M3_GVS>^/+R^/WX___'I_]_G^R0A(_.7Q\87_AR+\_N_'IS^/^]-?_T\````` M__\#`%!+`P04``8`"````"$`U"NCAA\#``!;"0``&0```'AL+W=O<FMS:&5E M=',O<VAE970T,BYX;6R45LENVS`0O1?H/Q"\1YMWPW(0.T@;H`6*HLN9EBB+ MB"0*)!TG?]\9T58I*8W=BRT-']^\6<C1ZO:E+,@S5UK(*J:A%U#"JT2FHMK' M].>/AYLY)=JP*F6%K'A,7[FFM^N/'U9'J9YTSKDAP%#IF.;&U$O?UTG.2Z8] M6?,*5C*I2F;@5>U]72O.TF936?A1$$S]DHF*6H:ENH9#9IE(^+U,#B6OC"51 MO&`&].M<U/K,5B;7T)5,/1WJFT26-5#L1"',:T-*29DL'_>55&Q70-POX9@E M9^[F94!?BD1)+3/C`9UOA0YC7O@+'YC6JU1`!)AVHG@6T[MPN0U#ZJ]738)^ M"7[4SC/1N3Q^4B+](BH.V88Z805V4CXA]#%%$VSV![L?F@I\4R3E&3L4YKL\ M?N9BGQLH]P0BPL"6Z>L]UPED%&B\:(),B2Q``/R24F!K0$;82_-_%*G)8SJ: M>I-9,`H!3G9<FP>!E)0D!VUD^=N"FHA:DNA$,@+UI_7(B^:3<#*]S.);14V` M]\RP]4K)(X&N`9^Z9MB#X1*8SY%9'6VL_PH58D22.V2)Z8(2B$)#?9[7L\5\ MY3]#3I,39C/$1%W$]HS`4H"\5B-$[FI\.^MG*0A&*5@%U+:Q!N!NM8UZ?M]` MA"VDHP0R=+T2!$.E'<>S^;CEM>(L9MRJW3J&CN=QUS/6:01]_'XN<%-,(;PV M]-EBT5-@,?.F:$%W;6O7&G4=,="TUZ<!P5T1\Z#G:&,Q3AH<0\?S]'\\(_A2 M`2S&\>P8.IYG7<_7%0`W]6/_VUJV!2QFTA1@#!?[I%<$NSXL`@Z7WLF]W!&X MJ2^H=PPW%M,*FO;6MW9]*`B.OROH_=9$<%]([UQN+,:IC6/HU":$DW"]ZP9] MJ2].(,>Y:^EZQWO+J<3[@<.<&D;>OQ9.('LJ;V9!_\#@M$.6$R!T`5:;G67V MJB^YVO,M+PI-$GG`.15!M[76=H;>17@/]>P;G*UH]]L%&&TUV_.O3.U%I4G! M,Z`,O!D<6F6'HWTQLFX&S$X:&&K-8PX?,1QNY<`#<":E.;^@@_:S:/T'``#_ M_P,`4$L#!!0`!@`(````(0"`6>_=KA$``/UC```9````>&PO=V]R:W-H965T M<R]S:&5E=#$T+GAM;*R=76\;NQ&&[POT/QB^KRUI)=D6DA2QM-\?*(K3]MJQ ME40XMF58RLDY_[[#)6?)F7>UDHW<Q,[#X9#[<LCE4*OUAW_^^?1X]L?Z=;?9 M/G\\'U^,SL_6S_?;A\WSMX_G__DM^<?U^=EN?_?\</>X?5Y_//]KO3O_YZ>_ M_^W#S^WK[[OOZ_7^C#P\[SZ>?]_O7Q:7E[O[[^NGN]W%]F7]3"5?MZ]/=WOZ M[^NWR]W+Z_KNH:WT]'@Y&8WFET]WF^=SZV'Q>HJ/[=>OF_OU:GO_XVG]O+=. M7M>/=WOJ_^[[YF7'WI[N3W'W=/?Z^X^7?]QOGU[(Q9?-XV;_5^OT_.SI?I%_ M>]Z^WGUYI.O^<SR]NV??[7_`_=/F_G6[VW[=7Y"[2]M1O.:;RYM+\O3IP\.& MKL#(?O:Z_OKQ_/-XT<RC\\M/'UJ!_KM9_]P%OY_MOF]_IJ^;AVKSO":U:9S, M"'S9;G\WIOF#053Y$FHG[0C\Z_7L8?WU[L?C_M_;G]EZ\^W[GH9[1E=D+FSQ M\-=JO;LG1<G-Q61F/-UO'ZD#]._9T\:$!BER]^?'\PDUO'G8?_]X'LTO9E>C M:$SF9U_6NWVR,2[/S^Y_[/;;I_]9H[%S99U$S@G]=$[&HXOQ=#0W/@;J35T] M^LGUJ!\#%<A=VUOZV=/;@8IS5Y%^GM;2E:M`/[G"29=$\ZKM(?WD>L.7=.,J MT,^W7=*88J5MROQR6EMC'FWS"U<YZ;+&=!&V,1\HA@U(/N:H,+_PI8TOKL:C MF^AJ."[&'!CF%^YG;VN7-IS;V;&ZV]]]^O"Z_7E&2PY=X.[ESBQ@XX7QPO/" M=KB;*8<F"LT0X^6S<?/QG,:&YL".9O<?GZ+YZ,/E'S0C[YW-+=I,I,62+<ST M,VY7&L0:)!JD&F0:Y!H4&I0:5!K4&C0!N"1I.WUI-'Z%OL:-T9>5N640"*[$ M9`NNLM(@UB#1(-4@TR#7H-"@U*#2H-:@"8`0DR:($+-_\>:8--:T3(N8'$N1 M;IW-52?L$L@*2`PD`9("R8#D0`H@)9`*2`VD"8F0D*;X&R0TUK0RT.(^,*^M M440K>6"DIW9GU(4CD!A(`B0%D@')@11`2B`5D!I($Q(A*ZW3;Y#56+>RLABW MEDRET)$,UF5GQ-560&(@"9`42`8D!U(`*8%40&H@34B$AK3G>(.&QEIJ:,F, M[O)!'$Z5AIU1IR&0&$@")`62`<F!%$!*(!60&D@3$J$A!9#0T-S.9W1O>N/M MW+B1XEH2R3O\3(G;&77B`HF!)$!2(!F0'$@!I`12`:F!-"$1XII<4.^5HFN3 M+[Q57^-)ZFN)TG>N].V,.GV!Q$`2("F0#$@.I`!2`JF`U$":D`A]*;A^D;[& MD]37$J7OE=*W,^KT!1(#28"D0#(@.9`"2`FD`E(#:4(B]#4)D!!X>/_4FDL5 M'9JVN7:[15\B6B&*$26(4D09HAQ1@:A$5"&J$34"2?W,)E\O`)/9Q=OGO\DK M58`ZI"+T6D6HM^I"%%&,*$&4(LH0Y8@*1"6B"E&-J!%(JFVR@%^CMLTG:!O+ MHMV:G)P&0*E]H]7NK+CBRE=D%"-*$*6(,D0YH@)1B:A"5"-J!))JFXQ!J_V. MG8,YQ-"1[9(16I?\QNQ*G0XL744:$19VA2A&E"!*$66(<D0%HA)1A:A&U`@D MM39IA-;Z?>N(34A$9+L<1:JM\MZE.>JQ\>_5!A2C58(H190ARA$5B$I$%:(: M42.05-LD'+]&;9NZ"+4MDNO(E4Y^S4&S5AM0C%8)HA11ABA'5"`J$56(:D2- M0%)MDYJ$:A_98]A,1DAJD9)4Y\+CSLH',*`8K1)$*:(,48ZH0%0BJA#5B!J! MI*0F(7F#I#9_$9):)+9M@%94PT1I8!4C2A"EB#)$.:("48FH0E0C:@22^IF$ MXPWZV?R$_'%DW8XMFG9D"60%)`:2`$F!9$!R(`60$D@%I`;2A$1*9G*(4#+[ ML<"%^3QB_WUS__OMEF[EM(GMF=T1'?^[#P5L)B*4=.@ZD+)#?GLP4ROH:FR- M(MJ0=7N(R4SE;[&WXJ%+$*6(,D0YH@)1B:A"5"-J'*(1H*X*[2<Z2WN7]JT7 MF;PQ"K3WR,L*VCNCR`SL'Y\FH[$Z4XN]02>[=\PH]>AP6YEWY=I2ZW[N#=AQ MX1TS*CTZW%;E7;FV5-#5WH`=-]XQ(3EL.CGLF1IT4L1S8X(9(",*]2[&KU2( M+YV1^=$9X8A9YQ/:T75&DYG*)6/G*C)SFC^UF\R5X`DW&/K2#:9L--2KC(WD M'%:]RKE7TS;:QE>32&4*!?L9ZE')1D,]JM@H]`0ZU=RC09V:/E^!3C)63%ZI MEU>;`!R)&IN0ABOJQ")S"-F-8G2EINC269D%O[,*>F<_;75&_C87`TF`I*>X MSJ!:#J0`4I[BNH)J-9`F)'(D=-I[1'_,;B<63<-`H\_MU4F"LS)!,J"_=46= MY?4F=O4B.QNF$_VA>L*.PQ#6`YNRT5#K&1OYUG/9.JW\ZH"DX#I#K9=L--1Z MQ4:^]5JV/AWKH&ZXSH'6Y4"3D9AR1P;:F*O;IT4191G=$$97^HC>K+FFXO!$ M<T;M\T[MW(M=O4GHO6<Q[BKZ/N!HG]"%C/OINY"?U(7"5SS<A9*-AE2HV"@< M<MOUR56[^*M;4<,5:)IT(Q!<O1QO6@_%>+]O%V6\J#"P2,UWN$U;JR/SW1EY M`6*SC%.#%-GMGN1*W1T3+B>=^B1H8REEHZ$)E[&17^USAX8W!(6O>+@+)1L- M=:%B(]^%^J0N-+YB;Q=D()A3@?!>>V3BVT,$<8>U:!+NFSO4VP%W.W5&_D0S M-M/;#*]'"2/O/?7HL/>,C;RK'%'!R'LO/3KLO6(C[[U&U#!JO4O5S5E"J/K[ MII\]D1"#X0XIPDURI*?)DA:0$U9A9S2X'XV=JVC<SLCI+((IZ=P<6)7<E#RA M0QGW>K!#N>S0^&8RA;OR"3TJN;'A)?H4B6K9([I1J]6PX;8.2"0CASHT&#F_ M;5]H1>X]>J!UH<NOC!NU<ELDYG&'#L^%%54PKB+_H6>,*'$H\)YZ=-A[AJYR M1(5WQ5O#TJ/#WBMT52-JO"O(:LVY"\SCZ_8@J&<A]6<_M,2!_A;1ATI\#4MG M%:`5HAA1@BA%E"'*$16(2D05HAI1(Y"(:PH?J62/?$'\MN8R?AV2#XE=J<F_ M]%:L\@I1C"A!E"+*$.6("D0EH@I1C:@12$I*JX`(SB.2&G,EJ47RF;%K=>"P MI+7?5"0K+RF@&*T21"FB#%&.J$!4(JH0U8@:@:2DYC0AG.]')+6'#^$-VAS1 MFM52W*"O]>>/WLI+VE5D%*-5@BA%E"'*$16(2D05HAI1(Y"4U&3UH:1F*_2N M3WOI!!8"V"*EMCK(7+J*9,72KA#%B!)$*:(,48ZH0%0BJA#5B!J!I-HF@]1J MO^\A/3IT`;DM4G*K/'7I*@JYNXH\`C%:)8A21!FB'%&!J$14(:H1-0))N4V^ M^HODMJFO6$LL4G+KLTV3K]H5A[5=(8H1)8A21!FB'%&!J$14(:H1-0))N4W^ M^(ODMJFHD-LB);<^RC0'8%IN0#%:)8A21!FB'%&!J$14(:H1-0))N4WZH^5^ MW]+M$JG@0^7((J6V/D_T5CZXNXJ,8K1*$*6(,D0YH@)1B:A"5"-J!))JFSPK M5/O(WL.F92*`+5+;.96-+LTW5?1V#E",5@FB%%&&*$=4("H158AJ1(U`4M*^ M]&T>M>G;&[\28.*45!-R6Z0B6)V/+%U%^L'AND(4(TH0I8@R1#FB`E&)J$)4 M(VH$$G+3HS,R@M^]U6L]2;4=,JUW1[_1M4[_O%6G-J(848(H190ARA$5B$I$ M%:(:42.05-OD8.%Z\7ZU;387QK8YW[=WN4#M&YT9>BNO=E>148Q6":(4488H M1U0@*A%5B&I$C4!2[;=EAE/,#!V2`7RC,T-OQ?JM$,6($D0IH@Q1CJA`5"*J M$-6(&H&DI'V9X3N>N9YB7NB0TEKGA=[*:]TEE(QBM$H0I8@R1#FB`E&)J$)4 M(VH$DEKKO'!X<S'%W,\A6H]8F26B%:(848(H190ARA$5B$I$%:(:42.0U*\O MT7M/K&*6-^WRMW"IU4FUMV+Y5XAB1`FB%%&&*$=4("H158AJ1(U`4FN33ND; MV_O.,*8V,Q-WMBY9"^762;6K2`N(E[NKR"A&JP11BBA#E",J$)6(*D0UHD8@ M*;?.\HXL#9C*F2-YW"SHQ-E;L7XK1#&B!%&**$.4(RH0E8@J1#6B1B`IJ<FG MP@@^(JE-OT246J1N8#H[GG967E)`,5HEB%)$&:(<48&H1%0AJA$U`DE)=2IW M1%),UZ86B1L8H!5:Q8@21"FB#%&.J$!4(JH0U8@:@81^YE#@#2'9FLL$S"'_ MM,H2R`I(#"0!D@+)@.1`BI#(2]6)T7"HF+NXRNP=HJTKSZNE1_ZV$3Q\91]Y M82/:1/H<]48=P,3>BKTGC'R#J4?>EVXP8Z/!!G-OQ0T6C-H&I7IO2W1FF.@X M)-2S5@%:L578]8G^ZECLK;CK":-0*W"?L=6@^]Q;L?N"48\RY$M,H7<]U#,S M7M3,LBA09^FL`K1RB#YI._`]!&_`%Y.@FQ11YBL>^-:!-V#/A7`C`TBG&OY< MXLA$Q*1CYA"MT\&$TD=LSFKX:4,V\OE+C"A!E#*B9:+K`TY$VU'Z?@0KE',] MCPJ!I&@ZOS@B%:81,Y=&T"ZUZV9TH\_'G-7P\[EL1+.J<P7?"XBY0?MDV'@V M&JGCH83]A'-0*Y>R$>U;NL:T4<9&P>.Z#IEG\+IZ\,1PX2MZJ\"['`.SP3]] MUS:S^4"X:V,4ANM4R[)T5D?"U7H/`BKF>CZ@$D0IH^%P!>\YU_/>"X&D5&_+ M&6:8,SAD/GSJA@^_-\`5AX)CQ4;^AA"S=QN;US>1F@<)UQD.3=?MH=8S]N1; MSV7KT>1:I4(%USG0NI3:;.C?$)7&7-U>+#)GFX'4.I>86:LC4>F,_,7&KAY] M1FYN'O-I,+O:35'"CFF%[)K71BD;A7W41AD;^=9SV7HTAF]+<9T#K4NI33H0 M2OV^&[Q-*L2Z8)$,=ER;7472^*!0JYDS\AK$#M%33?;VK1><A.L<"#?[B"X; M#;6>L5&X#ML.'5N'7;</=$$,P_QMJ4IK+B/>(7JND^_&2X\&Q&4C?^H3(TH8 M>>^I1X>]9VSDO>>("D;X4/F<)@>$YV3>OH#K]&\EMUZ47,8Q??,]'/KI2'\R MX2H.+Q!L-+QU<%9NS8@FD?X8)&$_!Z:M#5DV&EPTV&BP1[GLT7PZUDLVNSG0 M(1G`)AT96D=.>X9[;MRHD;)(!':'#H?>RKFB9TEY0L2($H<"[ZE'A[UGZ"I' M5'A7U`>I%ZT*0J_AS2^])QMTL4@<ETU'^O,>5S$\U$44(TH0I8@R1#FB`E&) MJ$)4(S)O##=*V`NRDMHW@-MW'#^M7[^ME^O'Q]W9_?:'>;LW[>@^?>BP??7X M[72V,*?Q-"I0,J>2>6_)%96T3_-`G6LJ:1<O*+FADG;QTR7SB-]^KDLBJF,O M3Y=,1^2MC6<HH7>ITV:G[WHF5-+>.:$.]8`^/>NK,Z62]M!+UXFH#CV)V5,G MHCJTN/65D-;T?%M?"6E-&X2^$M*:'AOJ*R&MZ>F7GI(Q>:-7JO25D#>[-]'7 M,R&MZ0'^GCH1:6W7#ETG(JUIX]%7A[2FLXJ>DC%YH[?,]960-WHC6E\)>:.W M=_65T"C0NZ;Z2F@4Z+U(?24T"O0.GYX2,]A]G"KTVI/,O2J3R+TC1@/6.UXD M?9_R=`JX,"<VV%,Z^EN8@[V^D@F5]&E%!SU4TN>-S@,7YD@'O=$?)OC<Y^O6 M#%6/_2T-5*^]F2P]]I^GB\^TC&'#],Z3A7ES2$_)9+0P+]W`$GI_QL*\(@-+ MZ&T7"_-""RRYI4N_[;UT.O-=F(,XK+.B$G.,VU<RH9(^`>C\CDKZO-'I[\*< MU)&WRVY^T1]?>+G[MJ[O7K]MGG=GC^NOM'R/VB?77NV?;[#_V;NO@WW9[NG/ M+M!N@=YA3W]F8TVOCQ^9-S-^W6[W_!_30/>'.S[]7P````#__P,`4$L#!!0` M!@`(````(0#/\)YH#`L``",U```9````>&PO=V]R:W-H965T<R]S:&5E=#$S M+GAM;*R;W7/B.!+`WZ_J_@>*]PWX`PA4DJW!WZZ[JJNKW;UGAC@)-8!3F$QF M_OMM66K+W8T-OMV78?)S?TBMEM02^.'7'X?]Z'MQJG;E\7'LW$W'H^*X+9]W MQ]?'\>^_Q;_<CT?5>7-\WNS+8_$X_EE4XU^?_OF/A\_R]*UZ*XKS""P<J\?Q MV_G\OII,JNU;<=A4=^5[<80G+^7IL#G#GZ?72?5^*C;/M=)A/W>_GDL-D= MQ]K"ZG2+C?+E9;<MPG+[<2B.9VWD5.PW9VA_];9[K]#:87N+N</F].WC_9=M M>7@'$U]W^]WY9VUT/#IL5]GKL3QMONZAWS\<?[-%V_4?POQAMSV55?ERO@-S M$]U0V>?E9#D!2T\/SSOH@0K[Z%2\/(Z_.*O<NQ]/GA[J`/VQ*SZKUO]'U5OY MF9QVS__:'0N(-HR3&H&O9?E-B6;/"H'R1&C']0C\YS1Z+EXV'_OS?\O/M-B] MOIUAN&?0(]6QU?//L*BV$%$P<^?.E*5MN8<&P+^CPTZE!D1D\^-Q[(+CW?/Y M[7'LS>]FBZGG@/CH:U&=XYTR.1YM/ZIS>?B?%G*,*6W$,T;@TQCQ[Q;.=.DM MP$:/GF_TX-/HS>Y\=[:XKYWW*(+9NM7P:12=Y6V:<Z,)GT83_M?C:6'DX7-0 MUV!^U2V$SV%=6QI%^!S8-0>2I_:I_M/7N8G.@3JEPLUY\_1P*C]',$]AE*OW MC9KUSDH9P632\6G2JRN[(*V4E2_*S.,8.@")4\&4^/[D>?</D^^0QELCLY8R M+I4(4$+EK#(;<A!Q$'.0<)!RD'&0M\`$PM+$!B;(WQ$;94;%!GNU1M`*%@L$ M2J!*R$'$0<Q!PD'*0<9!W@(D$##)12!\F(B75QS,":4%:PO)B27MZ-K(+)K@ M!(*$@D2"Q((D@J2"9(+D;4)"`.L5"4%_UY4TS"A807KF@Q:"G:(EY$]I@()& MJ$D%02)!8D$205)!,D'R-B'A@,$?$`XE78<#.['6Q",+AN^POC="J!8*$@D2 M"Y((D@J2"9*W">D[[!X#^JZD:=\U\>M-OE[F`D%"02)!8D$205)!,D'R-B$= MA?0=T%$E33NJB6_G-@<A!Q$',0<)!RD'&0=Y"Y#^J8)8[GUWJH(YO^VVW]:E M+H,NS'4/]CB]\RDCM-N&U!6@'M^&V)D^8WM?J&4\6(*;)<-=,*&H$<(9$0N2 M")(*D@F2:^+4C29!@BGZUX.DC-`@&=(*4D-L`$20M(RGHO_]R9TZ/ETQHN9Y M$Y_&*I*D(=U^TL:.\>-1/UGS'*WFC54@)'ZJJ"(!O)!-4'=C.M7B-%2(P$63 M&I[/4B,P4BX4,XV4B!\*V;4GDBB6*$'49SU%(6L]DR@GB(9*%6+M"7DE5+IN M@UT61V'M:.3!DM8$P?/9Z`5&"I+=2LE0&>MD0LY831NA0Z?.2&?F+EF%$Z,S MJ"R:)G%G"0KUM2A%H=X69;Q%GK.@R9NCG8X6T2%1)>&`(5'B+'LU\B&<3?\] MGTW<P-%25[+7"+G-@$=&S_/UBN`[;(!B-`R53.->AO\&[RE:LMXSYGWFL\'/ M4:?#.PVUJCT'A%J7JB3[-6+9/Z/#'SA&L2_70A2RG8T,<A=UJ)<.FU4QJH#Y MGDC?X#Q%2]9Y9I!GYMETQNKD''4ZO--(J[*V'6E]Z!VX\3NZ."8#H!'+]3D? M`"UU)=>-D(U!9!R:7/<\CTVBV`BXH-HS`C=X3]&2]9XQ[^Y2+"O&<(=W.@*J MN&Z/P)657M?B)-0:N:T"0MV!P>(#J+O[(0K9XW@D48S(6D\LZK:>HI"UGDF4 M(Y+%EJ-J\0%QT:4[B8M&=N""VB:LR?UA,9:L7F3TS)1SG>5<Y)M1ZIAS=>V; MW.(^12'K/F/N79<O.#DJ=;BG":?.`.W`JBGOSM4%Z8!:'P(MMC=SN*#;&YL; M@5&\,N6U*=<&(4*]=A<]7^QQ1K$]\]PY6R$3M-5N*=\)4Q2R;<@0T3:(G>Y* M&^AH0"Z2T;@R_94XJRHT(M._0=T3-%2S0*T1=H)&$L6(VM/_!NLIZEGKF40Y MH@O37YTB>)8ZLZ$;DSF+M.MBC>RH!HX1@FYU[A4A"D%YU`BYL@;6IG!OGGLL M^V,TT\X@GGD)"O4U*$6AW@9E1@H;!$L'W8%S--/1()*K+C^_\6+AM_(=<O/: M96AMAN:P0>T<ML@&G$<J-$*>/69%$L76%)Z.$HNZK:?25"91;DWQ\ZY:XT@. M]\_M6IS%15F`BV-(JR;K/%[P!481I+!_H4211+%$B42I1)E$.4$T;=21HCV5 MKX1!GT!@K<7>K&$?4&%HWQ-*%$H4211+E$B42I1)E!-$^PSS:4B?E3@;>HW8 MT+/I&[B-%`8KE"B2*)8HD2B5*),H)XB&017"`X9>U\UDZ#4B0R]0J.I\FB"1 M1+%$B42I1)E$.4&TSZKV'M!G7:J3/FO4NBU6M9GJ7S,E0D$B06)!$D%203)! M\C:A7555;[NK?$.XZ=K8-;5S>\(;9*N.`*7Z-L70"%VY.K92.&EBB1*)4HDR MB7*#H+8!\S1>JC+\Z_'2]27)&(/:\6J0W3KD_JF%NF^1X8I#)1X(V%`UAA$E M1DI5<\TVQ7VEUE3'3;(50,.Y-2Q"";Y(**]L*DJ<+;`&T;V5WR6K(S0HJMVM MLVLA"K7+$*-G42RE$D1]UE,4LJ8RB7*":-:IHK2==5="I6M8DEX:T=NT&;OU M"N`D4<<8>MX3*B/46[9&QA0,O\J5)?_R)T97L/MUNDI0J*\]*0KUMB<S4J:, M]I<+=I.8HYF.!I'Q@&IUR'C4XC1U#:*7:S-V)Q$8J?[412%['HH0Z:^6?'YD MB/$Y[+G=P4>AWLQ&(>L\0Z2=S\75&C[O<$X#K:KGVQ,?1I>O$0:QQ&>#'Z!B M7Z*%*&3[&J%U?9/KSN?,<(PZ'5FE;Y50J,][BD+6>T:].W/^#6*..AW>::A5 MA3X@U+J@;Z\Q:L]6)4X[8;P9OS`V4E=R6IN"ZAPWD@CU=%HM'1%IH]*15B;2 M1JC=1+'-H2?K/$.DG2\6[-(JQ^<=SFF@832&!%J)L\5#(Y;3[*(B@!W_^F*. M0K:OD4%FY78<=O46HPJ8[UD\;G">HB7K/*/.EVR#RE&CPS>-,PP&B?/_5=K" M%Q0B_!JQ/&<I$1C%*WFN39$\-TBGFOC",T:[(-83?F.D/\^%\PR-:^<.GV0Y M/N]P3N,_[!3ER5.405`7X2H06-3=^Q"%[&U*)%&,R%I/+.JVGJ*0M9Y)E".2 M1P@U;?^&O)1'KMHP%+JM:#6'L.[^A$9-?;O;))2\%S52L*.H>F[F3\6R8'QU M3$VS_M[0H/2F!F6T0??BYT4YFNEH$,U5=2)J;WY\K;CM7M0S!ZO6.=@@DL-: M2I7[3<#Y)A0:/2B6,/<CB6)I/;&HVWHJ3642Y=84/[NIWWF*>+FS.YC#`W]K M75MBVYLR+JY,V7<T@5%L7YE*%$D42Y1(E$J42:3>C#!-;2*DWW30/TL_%*?7 M(BCV^VJT+3_46PQP6?_TT&#]BL7:N\=W+-@3>/GB2SV=&5_#2QGU&PR<NROX MV3,TA7,/'%S@7_S5%^C"!05_!3^7O<!G*_@IZ04^7\$O+R]P%UH*6^"E)ZJM MEQH;WJ_@)WU2(URNX"=QDJ?+%?R$37*X2EJIRYU+3Q:K".H;^02N.$#GTI.U M"S&$:U*ILW8A6'"9"$\F3=SA%97WS6OQ[\WI=7>L1OOB!09_6G_W==(ON>@_ MSN;[EJ_E&5Y.@?R`EQ;@9:0"WA>8JMGT4I9G_$,Y:%YO>OH3``#__P,`4$L# M!!0`!@`(````(0!BF=14/Q(``&QG```9````>&PO=V]R:W-H965T<R]S:&5E M=#$R+GAM;*R=6W/;2)*%WS=B_X-"[V.)%TD6P_9$6P0($'?$[,RS+-.VHB71 M(:K;W?]^LU"5R*HZ0!'R^*5I?3QUD$`6LBY$D^_^^=?CP\F?N^?#_?[I_>GL MS?GIR>[I;O_Y_NGK^]/_^U?\C[>G)X>7VZ?/MP_[I]W[T[]WA]-_?OC?_WGW M8__\^^';;O=R0@Y/A_>GWUY>OJ_.S@YWWW:/MX<W^^^[)WKGR_[Y\?:%_GS^ M>G;X_KR[_=PU>GPXFY^?7YX]WMX_G6J'U?,4C_V7+_=WN_7^[H_'W=.+-GG> M/=R^4/R';_??#^SV>#?%[O'V^?<_OO_C;O_XG2P^W3_<O_S=F9Z>/-ZMTJ]/ M^^?;3P]TWG_-EK=W[-W]`?:/]W?/^\/^R\L;LCO3@>(Y7Y]=GY'3AW>?[^D, MU&4_>=Y]>7_ZVVS5+B]/SSZ\ZR[0O^]W/P[6OT\.W_8_-L_WG_/[IQU=;<J3 MRL"G_?YW)4T_*T2-SZ!UW&6@?C[YO/MR^\?#2[O_D>SNOWY[H71?T!FI$UM] M_GN].]S1%26;-_,+Y72W?Z``Z+\GC_>J:]`5N?VK>_UQ__GEV_O3Q?F;V?+\ MDM0GGW:'E_A>.9Z>W/UQ>-D__D=K9L9)>\R-![VRQ^6;BZOSQ4R9!!HN3$-Z M-0UG\_[@@79+TXY>N=WRS7)^<?7VV!$IGNYTZ?5UH5Z:AO3ZRD->F9;TRBTG MG23=H5VH],KM)I[DM6E)KZ;E?-(19]3[=&=0W=!D>N(Q9WU'HG]PVVE'Y>XS MD_XSFWI4[D$SZ4(3SY7[T.SUG4C=7_HZ23>:UG%GW(W4/_@J33U7[D@SZ4F+ M:??9C/N2^L>TPY[I.M&5G?7MR^V'=\_['R=4RRF]A^^W:F28K90=%QQ]N_8E M:*P"4>E1+K\IF_>GU$.INARH;/[Y83%[^^[L3RIU=T;S$35S5W'#"E77E.W: M!Y$/8A]L?)#X(/7!U@>9#W(?%#XH?5#YH/9!XX/6`F>4GCY'="/]BAPI&Y4C MOKH?&5A)\Q+""FZR]D'D@]@'&Q\D/DA]L/5!YH/<!X4/2A]4/JA]T/B@M8"3 M$*I.3D*&1V>^-Y2:QF'GWKAV+_1'H[GJDW,#9`TD`A(#V0!)@*1`MD`R(#F0 M`D@)I`)2`VF`M#9Q4D'E_A6I4&JJ=%1Q`W5*BQ94#$4T/W<3=M.+^EL#2`0D M!K(!D@!)@6R!9$!R(`60$D@%I`;2`&EMXJ2'1E0G/6IXF5^\(?S*`489=9GC MZ_U1DX4SYLQG7IIZ$3=;`XF`Q$`V0!(@*9`MD`Q(#J0`4@*I@-1`&B"M39PT MT?3EUZ1)&;EITL1+DS_P]Z(^34`B(#&0#9`$2`ID"R0#D@,I@)1`*B`UD`9( M:Q,G352W?DV:E)&;)DV\-"V\NZD7]6D"$@&)@6R`)$!2(%L@&9`<2`&D!%(! MJ8$T0%J;.&FBD<-)4WAZH-1N+C3Q<K'T<M&+^EP`B8#$0#9`$B`ID"V0#$@. MI`!2`JF`U$`:(*U-G%S0\/"*7"BUFPM-O%Q<>+GH17TN@$1`8B`;(`F0%,@6 M2`8D!U(`*8%40&H@#9#6)DXNU(;$*Y+1R=UL&.2EX])+AZCZ?""*$,6(-H@2 M1"FB+:(,48ZH0%0BJA#5B!I$K8/<]*CUI[T7$*Y;:HO(NUD,\M)SY:='-R25 MI`=0)%ZLBA%M$"6(4D1;1!FB'%&!J$14(:H1-8A:![GI4:O15Z1'+UYIK</7 M[Z/:D:.,+;LMZ&Z#Y0;1&E&$*$:T090@2A%M$66(<D0%HA)1A:A&U"!J'>3F M0JU'7Y$+O7QU<J'1LL_.C=KS5-GIR1I(!"0&L@&2`$F!;(%D0'(@!9`22`6D M!M(`:6WB7GJUUK0OO=ZQ?'-%BYN7;_=WOW_<TQJ3ZLE`]5K0SJ39K]0K5B<C M!KWM$W"C-I-5B:/91;\5<.&M7=9&M*";JQ?-K[TQ*1(5WXXQH@VB!%&*:(LH M0Y0C*A"5B"I$-:(&46L074$Z;3>/:C'ZW^=1+VF=/!IDY[%'DB+,HQ8MZ#;L M\[B8>YO8D?JP@+H$J22/@#:H2A"EB+:(,D0YH@)1:9"^]EVWKP3).?H7HC:B M)75^ZT)X.Y:-J/A"M(SFF&RUI/WODZT7QDZR#;*3W2,)WS_'M?K`1J=11(N% MMWL4B8K/,3;(NJ@;0>+E'S`1*Q$M%EXM247%!]R*.Z-,D'CY!\S%2D2+A;>B M+T3%[J6X,ZH$B9=_P)JM[#JX6'C[IHVHV+TU:#G0;=02V^XV`S6=/I/NB[I> MD3O]PR!:DTA?7OAK:6JA>L.<1HU>Y9_?FD7V^<TOH#YHJ\6R^Q!L=GGMYSAF M'_OV\@^V85$HHH1%MA-$E!K5@JI4?W+S2Z\C;(>\_*@R%H6BRED4C*J8%%4Y MY.5'5;$H%%7-HF#V&HYJ-'LM^]AG9T7D#G%J5\+NOC\W5=%[&W1@OF,^J@F) MZJ]V2A<+?U?"J-1+GW@K5/,)JW'O;KX.1:;=8M9UX<O%^<SK+#$[VT.E[[QA M4>CP"8MD.$T-FE.%[L,>Z*\F[E`(&;N'0LA9)"$4DT(HI:$$ZE^%BD6A$&H6 M21(:@\:3T'*CD2O@]D2U)V/WQ".%5&_A.%U.H[D]T/9H_/S7,R.2Q7Z$*&8D M[AM!X^X)B\0]1;1E).Z9H''WG$7B7B`J&8E[)6C<O6:1N#>(6D:=NY/3N;^; M]E/5I7-Q-]D,6MI=]MJ;_MT847C(9%&PZ$9&98;,J^OKI5?)8O89*;I=V=JP M*#0,)"RRG7#(Y(CL^HHE:,C+O_\S%H6BRED4C*J8%%4YY.5'5;$H%%7-HF#V M&HY*#YD#V6O9QSX[*R*W4U-$3J'R._6_]M_'5O?63%!U2QH@[0)FD%W`!(W? MIFLC6LBF680H%BL>I#>"QMT3M$H1;<6*W3-!X^XY6A6(2K%B]TK0N'N-5@VB M5JS(W<TU=2PGU^%!::[D7DXU\N9!WM;+#3>TZYG5__0\R(AD]RT"$@/93+%. MH%D*9`LDFV*=0[,"2`FDFF)=0[,&2&L3-[4T*7E-:I7<2ZU&2[M"^:O7F[D6 MJ2[63Q4QLT84+&.1L0JLV_A@(V7,#$(3(DJ&G`8&(6UU9-TVY.5?@HQ%H>N4 ML\@^/XBJ,*IP5.60EQ]5Q:)05#6+@MEK.*KQ=1O[V&=G1>3V7A*]IO<JN==[ M-5K8:QC8=9B;=N&Z9$2R-(A,N_&E0<S.U(-&[XL-BT*'3U@DBZ/4H"/K,VDX M'D+&HE`(.8LDA&)2"*4T'`^A8E$HA)I%DH3&H/$DM-QH)`ENCU-;R/;ZS)_V M3/I00XV#?D?4R"VC,)?7HB-EU(CL$5*C<"V(353J<@0ZXX00$G'BB4IJ4#B$ MK30<#R%C4:@<Y2R2JU!,"J&4AN,A5"P*A5"S2$)H)H702L/!$-P.J?;'[0YY M9&ZFM].=^;9&SGR[1X,!F(F8$<FR.%*EAOKU7%#,2!;=&T'C[@F+Q"I%M&4D M[IF@<?><1>)>("H9B7LE:-R]9I&X-XA:1@,;!FIKVL[ISQ49LZ-N;4?.-5K2 M5D]_A^.&@6D7*K1KXZ0^>.^=8`X2&96IO0-+SIA]1FJOF:M-B"@9<H*(4J-2 MUU[BACWV(2]K#M)%E;$H=)UR%MGG!U$5DZ(JA[S\J"H6A:*J613,7F-4X]EK MV<<^.RLBMU!11,%./7'#0-EX<SB-G`+6(TFS%9@I8%KD;!@`BLFVJVE2!#:" MQMT3([+<4T1;L>*1,A,T[IZC58&H%"MVKP2-N]=HU2!JQ0HV#-1>LEW`C@Q* M>NO9&90TLI^`HE%%)<)":T01HAC1!E&"*$6T190ARA$5B$I$%:(:48.H=9!S MWU$'?$TN.KE[?QDDTY@;(&L@$9`8R`9(`B0%L@62`<F!%$!*(!60&D@#I+6) M>^EI>NC<!C\UCE/]]2L>(ZE)-X+&[^NU$3E/0"UF_L,4HN*J$2/:($H0I8BV MB#)$.:("48FH0E0C:A"U!M&G=7XY4]?K%^11N7AWED%V'GL4RJ,6'7D"J@O; M?0(*T091@BA%M$64(<H1%8A*@_2U[T;G2M#XA:B-Z,@34*+B#MTRZC8*W)N6 M)C._(-G*Q4NV07:R>S1^CFN59;)RDPU/0(F*SS$VR+JH&T'C!TS$2D3X!)2H M^(!;<6>4"1(O?R*6BY6(\`DH4;%[*>Z,*D'BY1^P9BNZC?I5`#X!)2IV;PT: M>`**]J/=;A.>\G1RKW^8#42:YEA!^4]`F8;A+2`6V><'JX[(J.A%?0W`[.*M M_XQ4S#[!'2$6A?9"$A;93A!1:E1'-HF&O/P49RP*196S*!A5,2FJ<LC+CZIB M42BJFD7![#4<U6CV6O:QS\Z*R*UZ:EO/GK'_W%1%;P[:$WF52ZI>:DO+ZM7> M<P,W1J6>E.E55JAZO<8BV=R-#**A6W7AR_/S*^]!S9@;41$===ZP*'3XA$6R MO9T:=&0W01J.AY"Q*!1"SB()H9@40BD-QT.H6!0*H6:1)*$Q:#P)+3<:28+; M$]4>HMT3CQ12O>7H=#FS"VD/M#T:/_^U^A!(=579MHL0Q8S$?2-HW#UAD;BG MB+:,Q#T3-.Z>LTC<"T0E(W&O!(V[URP2]P91RZAS=W.J-O#LG/Y<=3';@-:& MYD*C\!-01G1DR-1.ZH/ROD[``!49*ZJLJMY<75S[CTW'?+"1HMM5L@V+0L-` MPB+;"2)*.2*[ON(34$->?GW-6!2**F=1,*IB4E3ED)<?5<6B4%0UBX+9:SBJ MT>RU[&.?G161VZFI3@8[];0-3?7U)?Y*02/:7^.)YXU1J2VWOGM:@9D!4K>C M_0AN%YEV%HK%BE4;0>/N"5JEB+9BQ>Z9H''W'*T*1*58L7LE:-R]1JL&42M6 MY.[F6NT]V@7LR*"DMRJ=04DC;Q[D/P&E_H=<U1G":=8BV8^+3#,A,9#-%.L$ MFJ5`MD"R*=8Y-"N`E$"J*=8U-&N`M#9Q4DO[R:]);2=W%VX&N1_=>T_BWQA1 M>!!B4;",149E!J&A=1O[C)0Q/0BQ*%18$Q;93C@(<43A06C(RZ]A&8M"4>4L M"D953(JJ'/+RHZI8%(JJ9E$P>PU'-;YN8Q_[[*R(W-Y+$;VB,*D^Z@TV!JG) M6S^RP!-0W"Y8EU@D2X.(S?7Z[.**OIS4_8Z!F!N-+`U,5S5AAPZ?B!./#:E! M1]9GTE"N@'6]NQ`R%H5"R%EDK<\FA5!*P_$0*A:%0JA9)$EH##+KLX$DM-QH M)`ENCZ/N[?2XGYK+TPX:=$2-5"S2$?TGH$R[(V54.]%<GGM"9-J9FCF_./?W M"=AXY*8S_=`8VR'Z/241)SYZRD<_4A^->RB$C-U#(>0LD@E!,2F$4AI*#OP3 MK%@4"J%FD>2@X1!TY<,<M-QFY`*XW9#ZJM,-PS.RI9)[P[9&]BS;J,*S;!;) M8CA"%#.2.?Q&T/C%35@D[BFB+2-QSP2-N^<L$O<"4<E(W"M!X^XUB\2]0=0R MZMS=G%+BG9S^7&E1+EZJ-0H_]Z0^1#HZ]V81W:I]D8+Y4&14IN(.;1.PSTC% M->5F0D3)D!-$E!K5L9'0'#`45<8'#`U#.8ML)XBJF!15.>2%16G"M:K9*9B] MQJC&L]>RCWUV5D1NIZ:B'^S4T[8)ELK&Z]4:.06L1](]K<"Z;K4V5M:>0(0H M-LARWP@:=T_0*D6T%2L>)#-!X^XY6A6(2K%B]TK0N'N-5@VB5JS(W<VUVD&V MMPE4`?NI;U&EGRZ`=&ND%K)]Z5DL_._L,@U)Q:>^1A0ABA%M$"6(4D1;1!FB M'%&!J$14(:H1-8C4#T*HJZHOCLZ<_H$'_4WKC[OGK[N;W</#X>1N_X?Z\09Z M3.##NQ[K7Y;X>+UJNZOK\]GYJJ4O;:/K#N_0CU'0]X4-O3.G=[HYDM]F3H?1 M'T7X[RPO^:<MO'?H-R]^&_12AQ\Z.AU\4+]8M=T2QO=?KGZC2SAP&DN*:(A? MK-KNQR\\HX]T!H,^5ZNVV]WW]6]7;3==\#@]T+12C_)@1.O%?*4>-,%WZ)D1 M:C/\SH+>&3IQ>ER$KLC0._1TQBH:?(<>HUBE@^_0\PX4VZ#;;+E27\Z$4:]G M%ROUU4'X#GT+$+49?N>2WAFZSO0%0-0CAMZA[]M9J6_3P>/0%^.LU-?>X#OT M#3846_?.69\@^JV3[[=?=\7M\]?[I\/)P^X+W4[GW9=_/>M?2]%_O)C_3?C3 M_H5^YH0&./IE`_I5FQW]J,"Y^O;I+_O]"_]!AS[K?R?GP_\+````__\#`%!+ M`P04``8`"````"$`R?_P.JD1``!-:```&````'AL+W=O<FMS:&5E=',O<VAE M970U+GAM;*3=77/;.):`X?NMVO_@\KUC4:1D*Y5D:OC]3=;6SNRUXRB)JVTK M93N=[G\_I`!"P'D92\G>='<>'+`A'(#D(17[W3_^>K@_^W/[]'RW>WQ_[KU9 MG)]M'V]WG^X>O[P__]?_IA?7YV?/+S>/GV[N=X_;]^=_;Y_/__'AO__KW8_= MTQ_/7[?;E[/A"(_/[\^_OKQ\>WMY^7S[=?MP\_QF]VW[.+1\WCT]W+P,?WSZ M<OG\[6E[\VG?Z>'^<KE8K"\?;NX>S]41WCZ=<HS=Y\]WM]MX=_O]8?OXH@[R MM+V_>1G&__SU[MOS=+2'VU,.]W#S],?W;Q>WNX=OPR$^WMW?O?R]/^CYV</M MV^++X^[IYN/]\+G_\H*;V^G8^S_@\`]WMT^[Y]WGES?#X2[50/F9-Y>;R^%( M']Y]NAL^P3CM9T_;S^_/_^F][=?^^>6'=_L)^O?=]L>S]=]GSU]W/[*GNT_U MW>-VF.TA3V,&/NYV?XRAQ:>1ALZ7Z)WN,]`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`AWF+AQD0GQ,0GQ"1S M,6(-IXQ9B^%D#/$6OCOD7,5L]A>*<1<6["2/6S($QZWF8L3XZKD8\3$;QLCA MM`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`N=`ZSGIJG M83826@F=A-X"9^Z'&@=S'PSGH]=OH,9><N[%5294,=92EQ`KT$L]"!:!.!$E MLD<J(9.02R@DE!(J";6$1D(KH9/06^#,]_AP`A-^_)R^[R9G7%2;H0ZRIER+ MFN+E]5)<[V+T2(R,:U'LE]0T3BLQ@^20`E)"*DBM91JZ)^X@&O1H(1VDM\7- MRUC2_OI):'Q:A)T@EG&H@^R\J&X'B1&30%(C,[G)3..4FQQ20$I(!:DAC9'] M"4NLDM:T3B/I(+TM;A[&HN\W\J!J1:<V\,13B]!308=9CR`Q)-&B%F+@+Z^6 M8M^EZ)-!<D@!*2$5I(8TD!;207I;W`2,M9I,P/$KPOC<$QM!W+"'.LA.@.IV MD!@Q"235HJ\<?K!:R"<_&3KED,(YS`7+@1)=*D@-:2`MI(/TMK@)&<LUF9#Q M(?_KEVA/57GNCA#5<*B#]$EVLY%;)M(!=G[4<=4]E3@I)PA/(1DDAQ20$E)I M,6-?B-56HTL#:2$=I+?%S<Q8M]F9.9(15>:Y&1$S&(ZO#89]=)CP"!)K49]\ MXR\7WI4XU27HE$(R2`XI("6D@M20!M)".DAOBSOS8^5FS_SX9.*$NRA5\#D9 MD/=$X?A^9,B`/KDL?4]LFD@''%(40Q)("LD@.:2`E)!*RT\'7*-+`VDA':2W MQ4W'6-G)=!POF#U5$+KI$'<3H0XZS'8$B8V,]R/B'C<QC=/M2`K)(+D6?7;Q M%TNQPPIT*2$5I(8TD!;207I;W%2,A9Y,Q0F7;U4?NJF0U;2G@O1"\Z_6(E>1 M#CCD*H8DD!2207)(`2DAE9:?#KA&EP;20CI(;XN;CK$.M--QY!*ARD8W#;*P M]E20^E3^U;5HCW2[G06K&E6/3A&30C)(#BD@):32\K/QUNC10%I(!^EM<9*P ME#7WZTG8AXM:6][SASI(W09YHN*+3.MTSHDA"22%9)`<4D!*2&5DY@19F\9I ML`VDA71&]L6HF(#>M`['=',AZ^PCN6!]?2UOF98J1JVOX?&9+Q_K1SK"VA&0 M!))",D@.*2`EI#(RFP[Y;*`QX5."6D@'Z;7,3HN;DN%T\POGJ.48+K>'R'^H M@]3__&HQO&-R7W-'.L!.B3JNVE%ROR6(3R$9)(<4D!)2:5WG7FZ4XQ=;H MTT!:2&=DOV7$;66O6Z=\!=?7UX=;&3=ALD0_LH=F2G-Y.Q,N92$>06(M:H1+ M_RI8;CQQCY"@5PK)(+DX,N^VT*6$5)`:TD!:2`?I;7$S,5>;'Z]#EC.U^5*4 MKZ$.TE<83SQTBDSS=%*((0DDA620'%)`2DAE9+^XY7!KTSP-MX&TD`[2V^*F M0A;C8TEX_,9W_*8CSF9B:X8ZZ'"RBB"Q%KTY/%]^52Y!EQ2207)(`2DA%:2& M-)`6TD%Z6]SY_[V2?#E3DLMWGJ$.4EMAA4N).L0A.[&)GQ9;`DDA&22'%)`2 M4AD9=X(<;6U:I[$UD!;207I;W$3\7C&^G"G&/5'@A3KH,-41)-:B-H(7;.2E M/T&7%))!<B,S]TR%:9PFM814D!K20%I(!^EM<5,Q5XP??RZRG"G&Y84VU$%J M3URLY2U*9-JG*8DA"22%9)`<4D!*2&5DS!_'6YOV:;P-I(5TD-X6-QFR%#_Q M`C%3DLOOB85+66!'D%B+WA?^8N6+2WJ"/BDD@^1&9C>&'%AIPJ=YKB`UI(&T MD`[2V^+D8MP#3LEQ6B[VW63I(<M!':3F^6IX-R0J#]U^.(?%1L89E#>TIG&: MKQ2207)(`2DAE99IZ(&X#ZG1HX&TD`[2V^+F15;G8U[&Z-<K#)]5NN>+>0]U MT&'>(TBL9;IV+`)\I3M!IQ2207(C<YO$-$XI+B$5I(8TD!;207I;W&3(NOS$ M9,S4Y[Z\D/MVL2UOJ$SC-!\Q)(&DD`R20PI(":F,C,D3@ZU-XS38!M)".DAO MBYL&66V?F(:9JML7)Y?01]4-B;6H/>&O-H'\OGV"/BDD@^1&9K>$'%AIPJ=Y MKB`UI(&TD`[2V^+FXO?J[?'O;\DB3U:HH0ZRST^JVW0ZOA85>HP>B9%Q3L6> M2TWC-(,9)(<4D!)206HM9NCB[56#'BVD@_2VN'F9*[Y/N&[,%-_R67KHJR`[ M+U)BQ"20%)(9&;,E;L9RTSAEJX"4D`I20QI(:V0<R(4826=:IY'TMKAYF"O" M3\C#7!$NEDSHRS([@L201(N^HGM7BY5\7Y6B4P;)(06DA%20&M)`6D@'Z6UQ M,S!7?1]_#.7/5=_B?!/J('LGJ&X'B1&30%)(ID5?8ZZ'5[O7XNR5HU,!*9W# M7"SYUKQ"GQK20%I(!^EM<3/R>T6X/U.$^^(]0*B##O,?06(C^\V]%/?TB6F> M=G<*R2`YI("4D`I20QI("^D@O2WN[,NJ^T@E,5-MRT<;H:^"]&I=R2>MD6X_ M9"6&))`4DD%R2`$I(966GXVW1H\&TD(Z2&^+DX1`EMNO)V$?+LML<54*=9!^ M_B2?%$:F>5K6,22!I)`,DD,*2`FI(#6D@;20SLA^-\N/W9OFX6.[*9"5]9$4 ML*+&>^]`Q:AE=>'[5YZX8$0ZPMH(D`220C)(#BD@):2"U)`&TD(Z2*]E=B[< M/,BB^D@>YHII;`45I/[GJR`(1)D7!5.U?=@,DXS+2%;G">)32`;)(06DA%1: M]."'[T[(OR55HT\#:2&=D?$3BH79ZT:=KN!Z:9_$W7S)ZOM(ON:J;O'((`QD M<1M!8BUJA/YBN!]:XSL)Z)5",D@.*2`EI(+4D`;20CI(;XL[];]7;`<SQ39> M;NL@=?7`=E%'L$];4A)S@&E+I9`,DD,*2`FIC(Q+60RV-HW30!I("^D@O2UN M&N9JZ^,5Q1@AGWG(F\]0!QUF.H+$1O:GJHUXK)N8YNGSIY`,DD,*2`FI(#6D M@;20#M+;XL[^7$5]_!L>P5Q%+:8NU$%J$ZS%.3(RK=/$QI`$DD(R2`XI("6D M,C*N`SG:VK1.HVT@+:2#]+:XB9@KK(\_V@CF"FM1VX8ZR-X&**QUC+H@>)LK M^0VJ!`=)(1DDAQ20$E)!:D@#:2$=I+?%G?_?*Z.#F3(:[[)UD*XE-N+)4V2: MI[450Q)("LD@.:2`E)#*R+@3+N1P:],\#;>!M)`.TMOBID+6U*>]/0UF:FN\ MR=9!]E90W0X2ZQB]%89G>N*&.,%!4D@&R2$%I(14D!K20%I(!^EM<>9_)<OI MT]X([;N)LEK>^H<Z2%\3Q*MKTSBMK-C(N!3%:2TQC5-X"LD@.:2`E)#*R#@0 M<<-=F\9I(`VDA720WA8W([*Z/C$CK+(]O*-;J:##^H\@L1:U(X8?IS/\%$@W M=0GZI)`,DD,*2`FI(#6D@;20#M+;XB9@K&?MO^<R)N#X;=)*E<'#/X=P]2,& M/;R8TT%V`E0W-=W#%Y'%!2-&CP220C)(#BD@):2"U%I^-MX&/5I(!^EM<9,A M:^83=\-,[2S_0G"X0NT,B2&)%C4!_GKX6H=XDIZB3P;)(06DA%20&M)`6D@' MZ6UQ$S!7.8\EQNL/+U8SE;,OUG:H@]14;KR%J$<CW7[8+;&1\=0LPA/3.)V: M4T@&R2$%I(146LS013U4HT<#:2$=I+?%S<M<*7V\AEC-E-)X%:2#U(5;?++( M-$ZS'$,22`K)(#FD@)20"E)#&D@+Z2"]+>[<SQ72)\S]3"'MBU(Y7*F@PYJ/ M(+$6?0Y>##_V3I[;$G1*(1DDAQ20$E)!:D@#:2$=I+?%S<!<!7W\!TFLYBIH M\18SU$'Z!'\5;,1Y)M(!AQ3%1F;N&!/3.&V8%))!<D@!*2&5%C-V^3V?&ET: M2`OI(+TM;F9D;7WD.C%74\NOP:Y4T&'"(TBL17WRU?Z'EXLS5X).*22#Y)`" M4D(J2`UI("VD@_2VN#,O2^DC,S]30N/U]$H%Z?7DRR_"1KK]D)D8DD!22`;) M(06DA%1:?C;>&CT:2`OI(+TM3A+&.L$I'EY/PCY<U-'RW4RH@_0C)?F>-C+- MT_DEAB20%))!<D@!*2$5I(8TD!;2&1E/JA?R8_>F>?C8;@ID`7TD!2R<\7IZ MK6+4LKKP@G4@;F4C'6%M!$@"22$9)(<4D!)206I(`VDA':37,CL7;AYD'7TD M#S/ULR^OS6L5I'Z^\&:Y6(O'=9$.L/-@=_'%I25!?`K)(#FD@)202HL:_&KX MJ]CXX<CHTT!:2.<<5W[ELA>MP]/^X%"PN@F3M?:1A,W4V')^P^$7GXRO[@[Y MB""Q%GW2OEX/+]!EXA/T2B$9)(<4D!)206I(`VDA'63\-3!F-M34J]_JHG[! MQ</VZ<LVVM[?/Y_=[KZ/O['%&WZHL5'UVV1R[^WP,]3'<YYI&'Z9R[>;+]OF MYNG+W>/SV?WV\]!U\6:\'7Y2OPY&_>%E]VW_>P@^[EZ&7^.R_\^OPZ_MV0X_ M-7[Q9@C^O-N]3'\8_P?F%P%]^(\`````__\#`%!+`P04``8`"````"$`7*C; M"^,$``"H$@``&````'AL+W=O<FMS:&5E=',O<VAE970V+GAM;)R8W8_B-A#` MWROU?XCR?DD<"`$$G"Z)MCVIE:JJ=WW.!@/1)C%*LLON?]^Q)Q_VA#N@/.S" M>&;XS8<]P9O/[V5AO?&ZR46UM9GCV1:O,K'/J^/6_O;/TZ>E;35M6NW30E1\ M:W_PQOZ\^_67S474+\V)\]8"#U6SM4]M>UZ[;I.=>)DVCCCS"E8.HB[3%C[6 M1[<YUSS=*Z.R<'W/6[AEFE<V>EC7]_@0AT.>\41DKR6O6G12\R)M@;\YY>>F M]U9F][@KT_KE]?PI$^497#SG1=Y^**>V56;KK\=*U.ES`7&_LWF:];[5AXG[ M,L]JT8A#ZX`[%T&G,:_<E0N>=IM]#A'(M%LU/VSM+VR=^#/;W6U4@K[G_-)H M[ZWF)"Z_U?G^C[SBD&VHDZS`LQ`O4O7K7HK`V)U8/ZD*_%5;>WY(7XOV;W'Y MG>?'4POE#B`B&=AZ_Y'P)H.,@AO'#Z2G3!0``'^M,I>M`1E)W]7_2[YO3UM[ MMG""T)LQ4+>>>=,^Y=*E;66O32O*?U&)=:[0B=\YF0-]M^X[_C)@P>*V%Q>) M5(!)VJ:[32TN%G0-?&=S3F4/LC5X[B-#CB'6'X4*,4HG7Z07Y0NB:*`^;SLV M]S;N&^0TZW0BU%G9UJ#CFQIQKR$3*-TFFL`%W@$:4D&A9U#4Z^7H&:61R1@2 M@&BJ,B.(5S28J9),5<+1BQ'&;!K&_(==U8<AC;8V?,F01C8G"!'J+%4A%B9> MC&MSU5HJR9K`H(-NH$F^32>-*!W-,NJ,!#$*0H4[=SRVTE^$/]&L#5Q(W..X MTHCBCL5231BACH:+`L1ES"')3S1]`W`Q!;S=M-*(`L[-BD:H@SPS9[8TEV-S M>4'SJ2_/G=E8+`,^_#_PTHC"!R9=A#I:=E&`T80.&WGP2-#T#4`Y:LDY=CN[ MTH@"DOQ$J*,!H@`WET^+KVD;>'#L/8XGC2A>2/*'.OW>67G&BW1*C,IC+(DF M,'`9G*:/\RHK"DS:,>J4YFJWD\5X6!Q'@"39VHK91)3#0:OXSP]_AJ/$/#97 M))>=$I9V@H8>M.1UZGWN@T`_ME9C'YG8<CS<CXW#Q,`.)H,5E18JH_[2(^LQ MPW6=W+!@LS$1)JL<#?>SXB`Q6<G^B)@V;=2&CB>29)#(YXC5<FQB$TX.`@U. M/KG<WO$,QX<.N2#YBCJ=,5_Q1)+H$A-+'O^/8^'0T+%80(Z^2#YQ]ENARQV5 M))T.MC"#PV!H<9-2GOJ/4^*L,"@].BX9*NG9HY)$US&YY/'^.!<.!8,KF'!I MDZ/+'I4D#"68O5!K#!-2'O*/0^)H,"$G)=;F1P>)DBL%5>L)TRQ,2GFV:Y0W MSD><!";=V#SJNR*FC8N.CDJ204=NWN5RW/\&G$_FR\_AE#:9*][H&>$Z):WO M)I)$EY@\9)C<=YCX5X9*,!Y7'1<JX918.`NR'G=.^G7R?)20Y;&K37XHG%[L M._FE%<EK0``B'Y5ZOG"<%=@"-]838SUTQHXW`R"CYLX`KHV<<?!V!4"E;E-/ MTJ^O^MKCKS*6MPHR16B\'&-'>+PPP-_3):^//.9%T5B9>)67`0P&\B#%BXH( M+BK4KWIW6(![@G-ZY'^F]3&O&JO@!S#UG!".]AIO&O!#*\[JU^NS:.&&0+T] MP8T0A]_)G@/*!R':_H.\RQCNF';_`0``__\#`%!+`P04``8`"````"$`UNQT MSK,&``!%'```&````'AL+W=O<FMS:&5E=',O<VAE970W+GAM;)Q9VV[C-A!] M+]!_$/1N6R1U#>(LUB*V+=`"1='+LV++MK"V94C*9O?O2VIHDS.2'24ONS'G M<'SFPCFR^/CI^_'@?2N;MJI/2Y_-`]\K3^MZ4YUV2_^?O[_,4M]KN^*T*0[U MJ5SZ/\K6__3T\T^/KW7SM=V79><I#Z=VZ>^[[ORP6+3K?7DLVGE]+D_*LJV; M8]&IC\UNT9Z;LMCTFXZ'!0^">'$LJI,/'AZ:*3[J[;9:E[)>OQS+4P=.FO)0 M=(I_NZ_.[<7;<3W%W;%HOKZ<9^OZ>%8NGJM#U?WHG?K><?WPV^Y4-\7S0<7] MG87%^N*[_S!P?ZS63=W6VVZNW"V`Z##F;)$ME*>GQTVE(M!I]YIRN_0_LP<I M(G_Q]-@GZ-^J?&V=O[UV7[_^TE2;WZM3J;*MZJ0K\%S77S7TMXU>4IL7@]U? M^@K\V7B;<EN\'+J_ZM=?RVJW[U2Y(Q61#NQA\T.6[5IE5+F9\Y[&NCXH`NI? M[UCIUE`9*;[W_[]6FVZ_]$4\CY)`,`7WGLNV^U)IE[ZW?FF[^O@?@)@F=77" MC9-0L3=V/N=IQ*+X;2\+8-0'*(NN>'ILZE=/=8WZSO9<Z!YD#\KS)3+@<8WU M5JB*GG;R67OI?:DH6E6?;T\L2AX7WU1.UP:S`DSF>U<,QXC\@M!1:[?265@H MOE?2*A64M%!%'2_'A:/>A#F*`!-8C4`P(A]!,`R10T@BKA`4AL!AW*>OP:IO MG/2Q*+WZ[?.U`DS8MXU.8$X7I+.`J*C2NQF]3T6#E[Z*\UK)-"-,`)+VK3!C M81S&&)`C@!`)(^TB$2`,1&*+A9BK`^0RUPW\=B_H3329-`3`.,FD"])90)3B MCU#2FW!266Q#AOH")NRS&F;$FB.KL#T'9\FU1IEM6L0\P<SOMX$&4\;6+S`& M##"F?%W;+"'IE\AJ)P6BJ_65#*^W:Z\W4=K6/]`&S#CM.S;IVF:1[7G$6HU` ME_7])&LP8<M):5>`B?NV$().M1R9HXP>-&1.4NL<D69JODYGW:,)[=AZAB0; M$&1Y9I/56W-D):TC;Q@Q8ZT>[^X.!IJ#YFP<XN&U,B!G-@Q6I+N">6F!<'C= MKS\#.7&'K8@H'<!``\S".`[),<R-E]&&ELC(;*HQ:ZT<TUF#SKBL63R@?1$C M_;S`$Y+DG+GFE!&MD\@\$_P6;ZTCTWF#ZKB\PT';`L9DF[.$,,N9"U!AD\Z6 MQ@[%B)TQCA.NU64Z<=`BESB+R1>O]".K&B87YBFM2(X`(J*#1B([#S(;.::N MM<:A/DV3&2@4#H$,JY4!C39RCHPS%MF6Z$>*1'8F;K'7RN.P?^-\@DYAUM:S MF70`@L2S1&1$['*&`#$/R`&6!D#CQFG7ZC.=.&@5)DYXK1B`+I,E3.EIR#$B M28;G%+D0(KR9=RU$T^F#;*D9<7T(9<XCHLD[@-PY35<D<U90.OF[%*]'$\5+ M2!57!F32R8(D&.030Y(L%&0N2HS(>)+:=L,!?$@`.0@@ZHN$/A\9D&GH('1' M`<@W0B1I&`["@.\!%['(`GM:<12*R?2VX!I-RT`GN`%=RL`"PBTW`#AMLR@D MX4ML5S_BKX*,J6L%<SIZVASDH'NX`(3ARH#H/#"Y=Y63D>@EVFHCP\S?I9I\ MJ)HLL3F!LVA`-QB#AU&C1#M99E4-4WZ77NHW)H,^L9X-9:2781"2\9@;+Y=& MBA@!2`S@:<IL6C![(IGW18>#5.+A1Z72@)SA-UB1[@KF0T1P8NN.B"%]/%IQ M5^O"-*-3,D>`)!S(.+*'(DYLY#@&HH<ZAOCMUT0CNDA_G*XX@$;[-;]GE,8( M+</36X^M7*O2^T<':!D:':F=JZ:K+X*G'[MGW$X`,SS`#`35*THK+KU=]LR6 M/H0^$\(>&I1\_3O\_0'TN\CX3JF*&M!X\N\9I3%";(P+YV$%D_^0<HH1Y4Q) M>E<&=(,\>!@U2K13/=U:SY@[T<MI)U>,Z*;S*@`ZQX`@?>KD#N8A`K`P=)Y, MH'D0($H%OW%TQ8>4L]]%NX<JIP%!CNE+ZMQ8(<2(1Z3W)++/1,9OM3\1T(E5 M&!'2U"J&J0*`@*+ZI4#?`N?"!3#UGM`FV50!`=+4>5>(6XE(ZL0@1J0UM6DR M00`(7A#S@#NZV`-R=9VC!?H"&$2I[WLL`$<)0<!M#EQV',MF5^;EX=!ZZ_I% MW]0P];;LN@JW2"MUB]1?N2RN!G6)<RYVY1]%LZM.K7<HMVIK,$_4=S=P#00? MNOK<7RT\UYVZONG_W*OKNE*]@P_F"KRMZ^[R05\T72\`G_X'``#__P,`4$L# M!!0`!@`(````(0!+#HX:%`<``*<C```8````>&PO=V]R:W-H965T<R]S:&5E M=#@N>&ULE)K;CMLV$(;O"_0=!-W',JF##UAOL&F0-D`+%$4/UUI9MH58EB%I ML\G;=SBBM>*08S$WFYC+F9__D/Q,:?GP_EM]#KZ6;5<UEUTH%LLP*"]%LZ\N MQUWXS]^?WJW#H.OSRSX_-Y=R%WXON_#]X\\_/;PV[9?N5)9]`!DNW2X\]?UU M&T5=<2KKO%LTU_("OSDT;9WW\+$]1MVU+?,]!M7G2"Z7653GU24<,FQ;GQS- MX5`5Y<>F>*G+2S\D:<MSWL/XNU-U[6[9ZL(G79VW7UZN[XJFOD**Y^I<]=\Q M:1C4Q?;S\=*T^?,9?'\325[<<N,'*WU=%6W3-8=^`>FB8:"VYTVTB2#3X\.^ M`@>J[$%;'G;AD]A^6(DP>GS``OU;E:_=Y/]!=VI>?VVK_>_5I81JPSRI&7AN MFB^JZ^>]:H+@R(K^A#/P9QOLRT/^<N[_:EY_*ZOCJ8?I3L&1,K;=?_]8=@54 M%-(L9*HR%<T9!@`_@[I22P,JDG_;A1*$JWU_VH5QMDA7RUA`]^"Y[/I/E4H9 M!L5+US?U?T,G=!0-N7!H'_,^?WQHF]<`YAMZ=]=<K1ZQA<2W,0T9QE%R@X31 MJ21/*LLNW(0!Z'=0V:^/8KUZB+Y"-0K=Y\/0!WZ.?>38(X+1C$."84R'Y"[/ M35EU5LJJ7&HH'X:&J4SLEHE_1$9UAGI/!B_6ZS'OH#ST27`-3/TDII`JL<S4 M%#,S?[.FXF!:5H8HK:KN!(MQ+*M8;\:1&84%1?_"JLZH/E96MTQ+*S9+MU1F M2N&R$NEBUK.*,U5U"TSKF\&-<*M"J:8&476U\2BU"C1E=8LIRRQ8!6BZAS80 M>7_EJBA34[>8FLSJA;U&-9/E9@'5NJ^JXDQ5W6*J)NX""UAG5%9FZ_EYQ4!3 M]]9D"J>,L*('K?%ZL7(OJ!@0I,&DXHBN;K(WJH"A3$7N5Q)[D]0J`3296R1C M+!$`X6I-('1&=L`,8&'<F$(WF95\(X4!`4%P-*,V0NA-33>9)M]@:*HI:-!Y M\P&!^F*D$Z>;3)L,ZX2#0!(V]8Q=FS^8B,PI')R8.740*$L\MH<-(,5]58"I M6[EDP"=<"%I*;G_`=\^X06P,83)+F6&?<(!(^"G;*,)DEC)#0.E@49RX@3`Q MC&&@,=D_MR:SU`P"I<('7=%I[%%JC"3**IEEF&&@A/%9RO/?,QA&9%4F2Y;A ME"2<NK^#L#=1TWB:`D,N&3Q)@B=%Q53X5-<F%>:R;#*D4N>Q:75G;-IXP@2@ M9MID\"0=>(K3E8]/&U&8#)1A3.,920H&40J"4Y^JP'(#Q9LQ;!,*,UFR#*$D M(=2,FDTE3$#+*Q@J20>59`+K<$;61A)F`EF##8)!4DR0=%\->T/J"8EN3<8: M$@R)8@4/0B*Y3#S6$$82997,\LF0*"8DFO&I:3/UJ9M,GPR`8@(@7+%IZN-3 MDV>JK)O,^61@%#M@Y'7*QD!28,TG4YB!44Q@A);]IM8&$R:SII8!4^P`DY]E MFTN8BPI+ADNQ@TLB@Q<<<YL6`TFM76<GR9`I)F12M8Z7F<_RLBF%R2S+#*5B M!Z7\O@0PDGC6[#+6EV1`E1!0*<_)DGV>FAR?,-)4OC69R@RTU`/.%%KWT8&] MB9H&56:_9X$!3%,K4V+^?)2H,**AFTQ'#`S5UPJ5G7_2P"BBJM%D0%$R4$P< M:(K7L<>[#HPDRBXV20:*ZH@]]3LS@S:/,`$,P/3)D#!Q\$CX/$!B(+&I$65. M*P/"A/!HQJ9]/,($U&;,T"]Q0&BU\IE-FT&8"X0-FS%#OX0P:,:F?4#"!)9- MAGBI@SMB_IT'AIES>6LR33*X2PETD`P>LAHUD^,#9K)JR[`NA<%-=PK*LI!] M>VF%<<2N2@5-]DNKE.#G_@1B;Y+:A9V8@5WJP(X'8S&,R+J8$S.T2W^(.=B; MJ&D,&<R)&<*E#N9XO;''0"+L8D[,P"[](>9@;Z*F,63:9`B7.I@3;V"\,TO( M)@YF@I$8FS%A4)<2XN"ND&L/UF$D,>PZ]20,ZS)"G_L^L;>I=FLRRILPK,L4 M/<CCF=>!%@.)L,IE%9BA7>;`CL<3/H8164T=<UX9VF4$1+ZTPSBBJY%DTRXC M_)F90LV8"<`Q`:B94\C0+B/849:\0("!Q),F$/P#688_DLJ$X5WF))#'WUDP MD`B[")0PZ,L(@?P=VP<@S`5C,1TSZ,L<,/)[F8&1Q+)&E+EN&0QF#AYY*MNG M(4P&@S&44X:$*\(C56R_,SQ&FIYO3:8R0T*XYF"SR>LE-D8291><4DK%X5K$ M</>@+MMC^4MY/G=!T;RH*P\2_B`QMH[7,9ZD>LBC[<GV:;BF$8V_@6L2U_Q8 M_I&WQ^K2!>?R`#F7^`C?#A<MA@]]<X6QPV6)IH<+$OC?$UR(*>'BP%*]:3@T M37_[`,K1>,7F\7\```#__P,`4$L#!!0`!@`(````(0!81(%0D@L``,XX```8 M````>&PO=V]R:W-H965T<R]S:&5E=#DN>&ULK)M;<^(Z$L??MVJ_`\7[`6SN M5))3$WR_U=;6V=UGAC@)-8!3P)S,?/MM66K+ZL8*F7->QID?K7_+K59+%OCN M]Q^'?>_/\G3>5<?[OC,8]7OE<5L][8XO]_W__!'\MNCWSI?-\6FSKX[E??]G M>>[__O#/?]R]5Z=OY]>RO/1`X7B^[[]>+F^KX?"\?2T/F_.@>BN/\,ES=3IL M+O#?T\OP_'8J-T]UH\-^Z(Y&L^%ALSOVI<+J=(M&]?R\VY9>M?U^*(\7*7(J M]YL+]/_\NGL[H]IA>XO<87/Z]OWMMVUU>`.)K[O][O*S%NWW#MM5_'*L3INO M>[CO'\YDLT7M^C],_K#;GJIS]7P9@-Q0=I3?\W*X'(+2P]W3#NY`A+UW*I_O M^U^<53$>]8</=W6`_KLKW\^MOWOGU^H]/.V>LMVQA&C#.(D1^%I5WX1I_"00 M-!ZRUD$]`O\Z]9[*Y\WW_>7?U7M4[EY>+S#<4[@C<6.KIY]>>=Y"1$%FX$Z% MTK;:0P?@W]YA)U(#(K+Y45_?=T^7U_N^.^_WOI;G2[`34OW>]OOY4AW^)S]T ME(1L[*K&<%6-Q[/!=#X:.^#K5I&Q$H&K$ED,YLYH.9Z#AL7Y1+6#JVKGC`83 M=SI?U-XM+4&WOF>X8K>G`W<Q=:8ST6]+RYEJ"5?TZ0R<R>BC=A#2VB-</W6/ M,$OK=G!%?S?>XU*UA.LG[]&!')0I(9)1#?M-=^DTR01_?.H^'<PD\0?ZO/%. M'4P@\<=G[Q63R&EED>U>AW+ZU+/1VUPV#W>GZKT')0[N^/RV$07360DQG(<R MF9J9V34Q848*E2]"YKX/@P9S[PS5Y,\'=SJ^&_X)%6"K;!ZOV)@6:[00TUW( M>A3X%`04A!1$%,04)!2D%&04Y!04+3"$T#;QA;SX.^(K9$1\,3*/"'3`2;C7 M:(%-/`I\"@(*0@HB"F(*$@I2"C(*<@J*%C"""1/%".;UQ0)S4EC?]^'?5DY. MS(Q[5#;S)K!K1CQ&?$8"1D)&(D9B1A)&4D8R1G)&BC8Q0@A3_!,A%-90&:#\ MMV)($NU1&HVAUK>,IF:@UXU1DXZ,^(P$C(2,1(S$C"2,I(QDC.2,%&UBA!66 M7R.LHHR.%V+KHI;EFRNI4*I#CH%ZE&1L%M<9B6]CA,T\1GQ&`D9"1B)&8D82 M1E)&,D9R1HHV,>(+&Q<COO:9+ZS-&$HRJ?>D]=*R9L1CQ&<D8"1D)&(D9B1A M)&4D8R1GI&@3(V`P93\1,&%M!DR2B:Z+%'@4^!0$%(041!3$%"04I!1D%.04 M%"U@Q$@\2_*]ST#LWR^ON^VWQPIF,2SL5Y)M#'L<N?,1(F;H%%GHV#5$5\BI M:TY@3]J,8>EK5=&Y:>0W1CC+`T9"1B)&8D821E)&,D9R1@I)G/KFC6!#^?KK MP18B9K`5:06[(3J0+-C29BQ&$7:J(X=L"_SF\R;.C2J2L"'=?J)&1_DA2V?< M?(ZJ2:.*)&U(MY^LT5%^2'+ES>>H6C2J0(QQ$H]1QD!=R7Y8UC#]:W-S2!"! MBR:5%TLSD]?*R(7IU1BQ84(C<U(L3"D?K6#/TTBY4^(P0"M8PK75;&1JA6AE MZU:$1M9NQ6AE=&OFF`X3M+)V*T4K6[<R-+)V*T<KLULD80JTZNJ6F3+0+2-E MZMV/&/Z;JZAX!"<S6R&QA6H&;$G&:XWMH.PT1CR-E/BXJ<@^BL/ZV;1S9V1Z M!JC>CA55#]'(UH4(C707XINZD.B&NJ.T"RD:V;J0H9';1"''+L`"V8H"*88% M-FQ'P6W-'#,7(/N,7/B@?`AS4CXD<ELE79RN@!4@W4\:!`^-]$.RSU&`2*N' M&G6K1VBDU6..$D1:/=6H6SU#(ZV><U0@JM7-J,/8&%&7QSB?W,J(@R@Z&`JU M:_F2U+"U:O=!+9=*+@RESK4IJ^7*"BXM*U;+E557=:IW9N$MW8K0R-JM&*V, M;O%:?DNW4M2RUW(E9>U6CE)FM\BC=X%67=$R,PFLK)GT1_4&\_7JIKB]+1`R M9%Y+9,SK!NG1YO-:&LDO(^J1]<5!):BW4*!02SW4J%L]XE(Q1XF6P@U4JE&W M>L:E<HX*+<4V8^*!F#ZBU"<!MZ^L\ID:SG"PZX_B>Q913MLKJSNC)PK*"K;R MW3?HH9%>5'R%QDZ]N1[#URIL^JHNM=.6#GN(RC;W$1II]['IWIV[<S(?$FQD M<Y^BD<U]AD;:?6ZZ=Q;.B#S#%=BHP[TY&\7S/1U_9ZKK^HVS41X3&#D@46N^ MK)T&V09<&K6FGJ_:M5"@I3#I0HVZU2,N%7.4:"E43S7J5L^X5,Y1H:78;!0' M"70TW.D`TOF#78X\@3#BKU![875G)%?6XN15S%3;6N&AD76M\-&JG7;NC*R_ M`5I!@=7K;VNOIU;6&[H5H92U6S%:F=TB%2-!*VNW4K2R12M#(VNW<K0RNC4G M3Q\%6G5URYS+4$J,[/D@9X0Y64$E,D^"YVPWUECA[/!$#1?KI=Y>^AP%'(4< M11S%'"4<I1QE'.4<%08R0PJSYS,A%>8DI!*U#X8=ACR.?(X"CD*.(HYBCA*. M4HXRCG*."@,9\7,_=]93FYOQ4ZAU3LR(QXC/2,!(R$C$2,Q(PDC*2,9(SDC1 M)F;(H+@8*?=+3UJBH)-,1*0?'=<:Z6),]TF>,C(/CN?D/,?75E@4`HY"CB*. M8HX2CE*.,HYRC@J%8-;3]5<\._X-L1<J)(L5:L>^0;;82Z/N<^2ZQU!X];%/ MH)"\/;F<:M3M*])2'6?)V@"'.-'"B%*-NGUE6JKC/%D;H'"AA=FPP2)J#)M] MX7.%.1D?A:`RZUW)G)S6K55#D3^-%9\N4@IZBSWW5;OQ1#ZPN$NZ*4+A]C)/ MA4,TLGF/T$A[CTWO[F1"]S[8QN8]12.;]PR-M/?<].[,Z=E.@6TZO)NU$8P^ M,]#"G`RT1.:3Z9P<2*Y=U1!V-9:!5D;Z9GW53CV9SF;T9@,4AASI%`[1R.8] M0B/M/3:]SV=+4J,3;&/SGJ*1S7N&1MI[;GI?CNA#>8%M.KR;`RT>X'_E04@, M+!URA<RY39[9UZKA!W-;2L&=Z+DMT1@NS8CR<WY4AY1IK/@$5^JV*19I)>Q" MK)"]"XENV-V%%(UL7<C0J#WX*@JJPBW&I,(5V*8C`.;@BQ.`]N!_4,[E@0$\ M*F%$'EUUT&`,RIR>/RDKL?OO'!0/C?3-^J@^K\LY^TX'6W3DN5J15:=MOB-4 MTKYCT_>$S7`E:_.=HJS-=X9&VG=N^G8=<I908),.Y^88BP?\]AC_VBY7G7&T MAUXA<[:3KJ[%3[FA3'PPVY61#H&/[>3W^@XI(@%^W)'E:NAO\!VADO8=(U*^ MR9J5X,<VWRD:V><WN^\<VRG?Y$2@P(\[?)LC#VEGC/P'LUN8DS5<HO;)(OQ= MCR=<+%-9&;4.*;"=1@$BO54/->I6C]!(2\4<)8BT>JI1MWJ&1EH]YZA`=.7) M1IPY_/7Y)E3(8$@TAL+31-Z=D_*_=E5#^_@H(YWSOFJG-E0.O$%#9G*`RAU% M1TVY&]Q'J*3=Q]2]LR3N$VQD<Y^BD>WN,S32[G/B?K*@7Z$4V*C#O3'QX/C< MG@*W'?77,F8.*`39AROP6B.=%G3#XRDCN&`[GZ-`2Z%5J%&W>L2E8HX2+87J MJ4;=ZAF7RCD2+SBIN@3J<C3D"TOR%8E#>7HIU^5^?^YMJ^_B9238C#S<-;AY M4^I+G16$/\(;5/5K1Y2[*_B!.SBD?`QO7%WA7R:K+]#1*PTF*_A!\A4^7<$/ M::_PV0I^+WJ%.POH:9T=M$O.$CZIBQKYQ%NLX,=_7,M;KN#'<YQ'RQ7\V(WS M;+F"'Z=Q#L=:*W$X=.T3=^7+QW?2)S@B6<57/X$##5"K@SYL&L';9&^;ES+? MG%YVQW-O7S[#`(_JK]9.\GTT^9^+^L+[:W6!]\D@!^`E&7AOL(3W4T;BJY_G MJKK@?Z"[P^9-Q(?_`P``__\#`%!+`P04``8`"````"$`W?JV_U0'``"2(``` M&0```'AL+W=O<FMS:&5E=',O<VAE970Q,"YX;6RLFMMNHT@0AN]7VG>P?#^Q MP2>"XJSB(V!`J]4>KHF-8S2VL8!,9MY^JVF*IJL<)L[NS=CY7%W5_5?U">;A MM^^G8^=;G.5)>IYVC;M^MQ.?M^DN.;],NW_]N?IB=3MY$9UWT3$]Q]/NCSCO M_O;XZR\/;VGV-3_$<=$!#^=\VCT4Q<7N]?+M(3Y%^5UZB<_PRS[-3E$!?V8O MO?R2Q=&N;'0Z]LQ^?]P[1<FY*SW8V4=\I/M]LHT7Z?;U%)\+Z22+CU$!_<\/ MR25';Z?M1]R=HNSKZ^7+-CU=P,5S<DR*'Z73;N>TM=V7<YI%ST<8]W=C&&W1 M=_D'<W]*MEF:I_OB#MSU9$?YF.][]SWP]/BP2V`$0O9.%N^GW2?##HUQM_?X M4`KT=Q*_Y8WOG?R0OJVS9.<GYQC4ACR)##RGZ5=AZNX$@L8]UGI59N#WK+.+ M]]'KL?@C?7/BY.500+I',"(Q,'OW8Q'G6U`4W-R9(^%IFQZA`_!OYY2(T@!% MHN_3K@F!DUUQF'8'X[O1I#\PP+SS'.?%*A$NNYWM:UZDIW^DD5&YDDX&E1/X MK)P8-_L85C[@L_9AC4;#L37Y>$?`LAP-?.)H;N[(N/(!GY_OR*1R`I^UDUM5 MA2E:#@8^:Q\W*W)?.8'/3RMB0%66/1%?*B]0+Q\L#@-+3'RI!W*K&`8$E'U0 ME6K<W2R'@:4JOGQ>$"Q6XS/5VI-3L)S1BZB('A^R]*T#RR3HDU\BL>@:MO", M<UG.O'IVOS>Y858++T_"S;0+"8=YF\.*].W1G-P_]+[!*K*M;&97;'2+.5J( M)4.X75"PI&!%P9H"AP*7`H^"#04^!0$%80/T0-I:7ZB<_T-?X4;HB\K,$"C! M!T1,M,`F"PJ6%*PH6%/@4.!2X%&PH<"G(*`@;`!-3)@_3,P!K`_7-QZL3=$* MMIAF;5I]7:Q993.I!9XSLF!DR<B*D34C#B,N(QXC&T9\1@)&PB;1I(2IKDG9 M+J&PAA4"=I:6^2V-!K!U*"/+T(6>UT9U63*R9&3%R)H1AQ&7$8^1#2,^(P$C M89-HLL(AX`99A74I*XHQDV2@+:26232LC;#9@I$E(RM&UHPXC+B,>(QL&/$9 M"1@)FT33$`Y!-V@HK'4-)1F69]AR&YDSLF!DR<B*D34C#B,N(QXC&T9\1@)& MPB;1!(-I>8-@PEH73)*A6OLH6%"PI&!%P9H"AP*7`H^"#04^!0$%80-H&HF[ M9_.<T[[>"6M=(TF&IA*I)FJY&Y&9NJAL8!5N+(EDHU[61CB=5XRL&7$8<1GQ M&-DPXC,2,!)6I!R\IBJL4YJJ\O1X)VY/Q2'9?IVE,&XX&EU1>P"G1'EV%$YT ML25IBLW(0I(!'!64M!.B_[(VJJ5E9,V(PXC+B,?(AA&?D8"14!(Y5$U:<>_Y M[]J67G1Q$5FJE!528K):KHP&(G%PO.\;0WU;6BJ#6FWE&-%:H?=C.<I5%8O, M&5<9H&-/.4:T4>C]6+YR5<4B110H`W0<*L>`]+2)B\#'%QIQ/R7%CP@J0U6V M1<2>5U8FM*^M>,JD=Q..*[61.;)HWJ350$S:^O8V)HJO,%PVX1J.V7CEH MU/3$>N565NV]\J[YHKW:H%%;KWPTTA84JE6`5G(2$(U"_+4YLD9O]$(1EYP; M"D7>B>`(CD4X$X\GH';$,S.5-VND9W=>61FPAM=6C3Y5]^S*N]K>ENA]4DYW M<HQ?H=?FSD:]KM&H+;2#1BJTVQK:PP9MH3=HU!;:1R,5.F@-'6*#=T+K^04C M+;]B;S1'=Y"M*[LA)!&W0_&4B"X)%=*7A#'-M+3ZR9)0&:G3\;(*:"JTXFB- MJ&T2.6BD7+D<>1QM$+5Y]]%(>0\X"C6DIP3FY>=2(AJ2752B`1S*ZVEE6A.: MDJIA6QDNQ&,WX5V5X;)"9C7Y)N1QQ0J;0#+KZ'SZ?2"X@YY4<)<$OR>KG(=- MVH)OT*AMY#X:J>`!"6Z0(@^QR3O!]7S#7/M<OD5#DF^)ALT"-2VRE<[%6Q!H M^),I6!FI42^Q776V(F6TPI\AH2WI_D!L!SVIV"ZBIJ*F11[>>FC5[((Y)G6Y M0:NF2K0N?312?0@05=LJ&7^(/S>#-]SJ21?7Y.:^*M;=@27>1/ULX947;&V+ ME4B?Y?=DU'-XUU:62UNM+]!H4&_@RPJ9T+Q.J\D/7I7W9GX:@R\W\#5Z;^N" M@T9*>!>[(!<:^K3.PQ9ML3=HU!;;1R,U_`!CMPY?O,@LQ7VG"S+W\E6E?+%Q MBK.7>!X?CWEGF[Z*UY#@XO&AQO4[TJ=2!\)GXMVI2!'EI@V/I:_P@0T/63E_ M&MI/$)?_,!O:\/CP"A_9\$CL"A_;\.3G"K?L6?D^@'1T;MGS:WQAV7"SYWX6 M]S9<2SD/+1LNIYPOC+XMKGK\%[BUV>)BQG^!.Y8MKE'P2Z_N+KP1OD0O<1!E M+\DY[QSC/:2J7SX[R.0[9?E'D5X@A?#J+RW@77#Y]0#O_F-X/]07IZE]FA;X MAPA0_V^"QW\!``#__P,`4$L#!!0`!@`(````(0!I&?`6;!$``,5=```9```` M>&PO=V]R:W-H965T<R]S:&5E=#$Q+GAM;*R<VW+;.!*&[[=JW\'E^[5UL'Q@ M)9F*#CR3DJC#7BNVDJAB6RY)F<R\_39$M`#T3]%2=FYBYT/C1Y/=`$&`QH<_ M_GIYOOASN=FNUJ\?+YM7C<N+Y>OC^FGU^NWCY6SJ_^?^\F*[6[P^+9[7K\N/ MEW\OMY=_?/KWOS[\6F]^;+\OE[L+4GC=?KS\OMN]>=?7V\?ORY?%]FK]MGRE MDJ_KS<MB1__=?+O>OFV6BZ=]I9?GZU:C<7O]LEB]7I8*WN84C?77KZO'97_] M^/-E^;HK13;+Y\6._-]^7[UM6>WE\12YE\7FQ\^W_SRN7]Y(XLOJ>;7[>R]Z M>?'RZ$7?7M>;Q9=GNNZ_FC>+1];>_P?D7U:/F_5V_75W17+7I:-XS0_7#]>D M].G#TXJN0-WVB\WRZ\?+STUOWKZ[O/[T87^#YJOEKZWU^\7V^_I7L%D]I:O7 M)=UMBI.*P)?U^H<RC9X4HLK74-O?1V"TN7A:?EW\?-X5ZU_A<O7M^X["W:$K M4A?F/?W=7VX?Z8Z2S%6KHY0>U\_D`/U[\;)2J4%W9/'7Q\L6-;QZVGW_>-F^ MO>K<-=I-,K_XLMSN_)62O+QX_+G=K5_^6QHUM50ITM8B]%.+W%_==SHWM_=W M)%)3\497I)^Z8K-YU;KO-#NWJOF:FE2Z]YM^LM_U%6YU!?IY9E-WNB;]/._J MJ(_M?:2?9S;YH&O23ZY)K=?<CB8ESKXM]0M7.?%6-CD'U"_G76&3TJ9LUN3/ MJ1%L<M:H7]CE=ZZ2\Z5I)4SKJGG3>"]=5)<H';42QDKTNEO+F=,\/W6:G#OJ M%WV-[?H\;7+6J%_XMIP:2<Z;IDF<$WMBBQ.H99+`'@EJ;E"+DT#]<IK'U^4H MM!_4^HO=XM.'S?K7!3TIJ/'MVT(]=YJ>DN/AK&S^,,`=&]]H8%,JGY7,QTNZ M"31T;6E0_O-3ZZ'YX?I/&D@?M4VWPL:UZ+&%&C65;%^"@02^!($$H021!+$$ MB02I!)D$N01#"482C"4H))A(,)5@)L'<`M<4XD.<*;3_1)R5C(HS1ZC+P`2^ M+8+*%ERE+\%``E^"0()0@DB"6()$@E2"3()<@J$$(PG&$A023"282C"38&X! M)Z@TCD-0VS2N5,]%N*^J6C3K</IJRPU:5]OLYU'[KM@#T@<R`.(#"8"$0"(@ M,9`$2`HD`Y(#&0(9`1D#*8!,@$R!S(#,;>*$EIZW3FCK0ZJL:02G9U[-^%L: MM>DI9QG)WGHP.G17(`,@/I``2`@D`A(#28"D0#(@.9`AD!&0,9`"R`3(%,@, MR-PF3IAI:G)&F)7U/LP<G&Y);MS`W[B=N7<PXFI](`,@/I``2`@D`A(#28"D M0#(@.9`AD!&0,9`"R`3(%,@,R-PF3DQIUGI&3)6U&].2M-W)5$?$]&!TB"F0 M`1`?2``D!!(!B8$D0%(@&9`<R!#(",@82`%D`F0*9`9D;A,GIM3!SHBILG9C M6I*;_=)"^3P%T@<R`.(#"8"$0"(@,9`$2`HD`Y(#&0(9`1D#*8!,@$R!S(#, M;>($D)YZ9P106;L!+,G-8>+;DZ`OP4`"7X)`@E""2()8@D2"5(),@ER"H00C M"<82%!),))A*,)-@;@$G5C3R.;$JWTFOU-+6[OOJ\4=W72Z05<R)VO3N6;Z1 M*A$WA)K<FQ@>B)D1=<1,N%_:M&D*;LV:;MW1>'`PXM'8!Q(`"8%$0&(@"9`4 M2`8D!S($,@(R!E(`F0"9`ID!F9>$EESHCCG!5^MI3O0KHDQ+E1SFO;D;9XUN M6B;0!IDH0J39B"9K5JCO1*B-U2'6C,KE7K5P$1ADM&2#(1NY#3ZX#4;&BAN, M&9D&$X..-YBR46V#F;'B!G-&IL$AHA$C6[[=$!UJ;*Q8OF!DY"<&';^>*1NY M#8KI[\Q8<8-S1OL4<=-/+:#@@MB9@X]:V!6CCT9.5I96%NIK*S'<W+LI,3!6 M?$4^R@>(0E/1W-5VH^'*1\:*Y6/42A"EIJ(M+]8!,V/%\CEJ#1&-3$5;7KS! MCHT5RQ>H-4$T-15M>3'QGADKEI\[6FXVJ96;_S^;RO4?>KWG)KMJ'T`E&`VC MA[&JW1"/I9ZV4BO,!RLY"O79R'G"=2#ER@;;-_O%W>;M0UOT:Y]U[,XH&PO8 MJ,ZCD(ULI9;T*-)6:G7_<'&M6Y$-<966]"IAHSJO4C:J]2H[R:N\2DMZ-62C M<NM//59&C&IC-68?CL:J8!W[6F3[$S:JNRM3-C)O-C-$<P>Y/42M@-7UD.GZ MC?+\O35-M:4E!]P2M:SYGK8B9%)&7G9?&]$Z*O>V`2+?2+%58-!Q]1"E(D2Q MD6+UQ*#CZBE*98AR(\7J0T0CK#A&5&#%B4''/9T:(_9AAFCN(#=O*'4A;UJW M:L_]C)<$M:TITZ9$>QW>RVHWQ"RPQQ7K,TFKU_;6@99J-_<CZVV[T12-^=P8 M)?1AI)-I&[!1G4<A&]5Z%&FKUMW>(QA1]575>9-P0W7>I&Q4ZTUFO#%7WVZ( MYU/.6K97K5LQLQFRE1D31HQJG1AK*RM(XK84K&,[((,T8:.ZVS)E(_/^,M.( M(F+?`_&F,.>*1UQP^X]:OOP'QETE(UZ_2N2,NP=DW)?WIJ^^&"`I9]P%Y&LK M2STPZ+AZB.H1HMA(\:B4&'1</46I#%%NI%A]B&B$%<>("JPX,>BXIU-CQ#[, M$,T=Y.:-6B*5>7/^N%LNM#HS6HV<&6U3=.">^B2$DN2=&:TVHH'J,%["_'&@ MI>KGCSXW:&O)U`W8J&ZF%+*1K01>12=Y%5=I2:\2-JKS*F6C6J^RD[S*J[2D M5T,VLF>UI\1K?)(/!<O;UR-]F+!1W9V9LI&9!\X0S1WD]A2U%BU[2K-C5A). MG-F62]I.5RF1-0;VJ'C?+^H>+'UMY(RP93T+^4:*1XC`(-.AY$T-43U"%!LI M5D\,.JZ>HE2&*#=2K#Y$-,**8T0%5IP8=-S3J3%B'V:(Y@YR\X9BZ.3-.PN@ MREP\@4MD[S:I;]O(RD)]1`-$/J(`48@H0A0C2A"EB#)$.:(AHA&B,:("T031 M%-$,T=Q!;ES5DK<]'KP35[U";B_ZE,C:A%+K/RJLAU?5/I`!$!](`"0$$@&) M@21`4B`9D!S($,@(R!A(`60"9`ID!F1N$R>$ZIM-)X2_M3.U5W%[+"/S7M(S MZ/A8T]=&SG)QNRD67`?&BD<D'U&`*$04(8H1)8A21!FB'-$0T0C1&%&!:()H MBFB&:*X1]6ZZA6Y.T"3"R8GZ;JUFKF*XULC:!N@95!?\4NK&GNJT'L3BP8"E MS!CA,S+;+8%!QQL,V<AM4+R%1L:*LRUF9!I,##K>8,I&M0UFQHH;S!F9!H>( M1HQL>=RO,E8L7S`R\A.#CE_/E(W<!N5^E;'B!N>,<+]*?;/MI-_O#4E*10Q) M)7*R$E!_WSR]M%.)>=5Z$(LS`V/%5^1K9,D'B$)3T<CC?I6Q8OD8M1)$J:EH MRXOA,S-6+)^CUA#1R%2TY<7"T=A8L7R!6A-$4U/1EI?[5<:*Y>>.ECN8T=+1 M/Y!-2D5DDT8T7SGD">Y7M4HKE>T'*_F>T6<C)^7D[M!`6_%^5>=>6OBL8W=& MV5C`1G4>A6QD*^&;/7M$:UJ'B\/]JBHMZ57"1G5>I6Q4ZU5VDE=YE9;T:LA& MUIL]H]I8C=D'O5^%L2I8Q[X6V?Z$C>KNRI2-K+=Z1','N3V$7*CM(:>]U;>4 MC.@B);+?ZK45(9,R\K+[VLAZA1\@\HT4#P.!0<?50Y2*$,5&BM43@XZKIRB5 M(<J-%*L/$8VPXAA1@14G!AWW=&J,V(<9HKF#W+Q12]GVVY]Z3I^];JIVI63: ME.B=_2JN6)])6KVVMPZTE-X*Z=QU;L4$QN?&:#0_C'0R;0,VJO,H9*-:CR)M MI?>KQ`0X9HTZ;Q(VJO,F9:-:;S+CC;EZ^N->]QN;G+5LKW"_BJW,>^&(4:T3 M8VUE@G0G5M(+UK$=D$&:L%'=;9FRD;5?I9&[7]44,Y\Y5SSB@MM_U!JQ[#_G MKZ:VRJ5F6GWC;MS5R!EW]8)TW67W=3UGW"WK6<A']<`@DR#RSH>H'B&*C11? M3F+0<?44I3)$N9%B]2&B$58<(RJPXL2@XYY.C1'[,$,T=Y";-VJ!6^;-^>-N MN4SNI(U&SHP6]JM4#Z`!^YT9K3:J[=(#+:5GM*V._+#2Y[;J)DD!&]5-DD(V MLI4J)K2EV_4;:'&5ELSVA(WJO$K9J-:K3%O5>Y57:4FOAFQD3VA/"=68?2@G MM!BJ@I7M2Y'-3]BH[J9,V<@>?$L?;V[WGV_<T/D@XIUPSI6.-.]V(!H$H0/] MQL"K9,2$MT3.P'M`QX>$OIH.DY0UR@X0^1I9ZH%!Q]5#E(H0Q4:*AZ7$H./J M*4IEB'(CQ>I#1".L.$948,6)0<<]G1HC]F&&:.X@-V_4U@0,O)TKFF.>>;9` MJ]SD<`;?$CE_(]=NBGEH3U<D*[Z$/J(!(A]1@"A$%"&*$26(4D09HAS1$-$( MT1A1@6B":(IHAFCN("<+J).Z65"_.KXW=T<)C42HQ8C6,U:'4",:(/(1!8A" M1!&B&%&"*$64(<H1#1&-$(T1%8@FB*:(9HCF#G)#3<\II\._$VIE+D)=(FN3 MND<O,,K*0GU$`T0^H@!1B"A"%"-*$*6(,D0YHB&B$:(QH@+1!-$4T0S1W$%N M7&E:>DY<E;F(:XG,#E1/[1>HL)J!&<@`B`\D`!("B8#$0!(@*9`,2&X3]Y;1 M&^TYMTR9BUM6(FM[I-<^H.-/[3X;D>UAZ:5U+UZ\!\:*1TL?48`H1!0ABA$E MB%)$&:*<$>Y\T8N0>Y-_:^=KKR+NO1*FY#13ZIZVLE!?(Y4#YD[?B66>@;$R M=[J4IXJ,`K0*$46(8D0)HA11ABC7J+Q&-YW5NJ"<RMFO`"?]0:YZ(Y-9KI%9 MWNJQ%<WQ#[=5OAGUM1'EQOZDJ8:<^0V,`=]CWP@S"@PZWE9HI'1;HC-%QH"% M8R/,*#'H>%NID=)MB73*C`$+YT:8D!LVN63VS@,9E\;:&KEK'/*OS+15_1H' M&SG=1>[)#=BJ#&RS(;9B?2X_\N*Z_\OO@(UHZG`TA4(VJO4G8JO2GP=QY3$7 MU[F3L%&=.RD;U;J3L57ICAS6<RX^XHZ;'&J1P.[3[R1'N:9@OX/1(9NJ/XN) MN5A][QDKSM@^H@$B'U&`*$04(8H1)8A21!FB'-$0T0C1&%&!:()HBFB&2)UY MJL-Q&`?*,TS+X_Y>EIMOR][R^7E[\;C^J<XGO57K0P=<'I[:;=_QZ:FRY-:C MTU%(6G*JL%],E[QY[ZF/(2MJM!X\]<984=)N4.O[G5FIUE:GNN[7X40)/0L\ M-=RC&HW<GAJ<L83&64\-I5A"A\=^WC^712M=:KZJ]6Z++J5"I]LF=ROXYQOO M,P4*&^[>>'1(5`7O>'30$'+ZE,B;T8A;5=*BDBJGZ"LB\K:JI-MN>UUZ_J,: MS3H]-?O!$IIJTDVLNDB:&E%)51V:S7EJGH%J],66I[ZJP1+Z<,M3']=@"7V_ MY8TK[P%]>4,E577HTRU/?5Z#:O0%EZ>^LL$2^N[-4U^U596TJ*2J#GWRYJF/ MD+`.??GFJ6^1L(0^=_/4QVQ5)2TJJ:K3I3K=RA+ZAM#K59;TJ41]%HCMT.=< M5%+5#GTSZ*EOMK`.?3KHJ4^WL*1H-CSUI_=80J<[>.HO\+&$CG3PU($-5264 M\95UZ#0'ZIU5:O1]+/6%*C4Z+\-3)QA@.W1(AJ>.P*@JH?A4UJ'S,3QUA@'6 MH6,R/'64`9;0:1F>.@NCJH3RNK)._\&CHU2P1I>TNI4U>E32JRSI4\F@LGTZ MA()*JGSVJ8XZ:0(]H`-//'7@!);0*2>>.L.DJH3Z564=.N#$4T=.4)WKPTA, MAVB_+;XML\7FV^IU>_&\_$H/L<;^SVDVY3'<Y7]V^@_&OZQW='PVO=K1H;9T M7/J2_GZ^H5:?OZ[7._Z/:N!P`/NG_PD```#__P,`4$L#!!0`!@`(````(0`% M^S)#+PH``(HP```9````>&PO=V]R:W-H965T<R]S:&5E=#(R+GAM;*R;77/B M.A*&[[=J_P/%_0F8#V-<24X-W\8VMJG=/=<,<1)J`*>`R<S\^].RU9+5[3@P M>VX&>-)Z6W*W6[+DN?_SYV'?>$]/YUUV?&A:=^UF(SUNLZ?=\>6A^=__S/YP MFHWS97-\VNRS8_K0_)6>FW\^_OM?]S^RT[?S:YI>&J!P/#\T7R^7-[?5.F]? MT\/F?)>]I4?XRW-V.FPN\//TTCJ_G=+-4][HL&]UVFV[==CLCLU"P3U=HY$] M/^^VZ23;?C^DQTLA<DKWFPOT__RZ>SNCVF%[C=QA<_KV_>V/;79X`XFON_WN M\BL7;38.6]=[.6:GS=<]C/NGU=ML43O_P>0/N^TI.V?/ESN0:Q4=Y6,>MH8M M4'J\?]K!",1E;YS2YX?F%\M==]K-UN-]?H'^MTM_G$O?&^?7[,?\M'L*=L<4 MKC;$243@:Y9]$Z;>DT#0N,5:S_((Q*?&4_J\^;Z_K+,?BW3W\GJ!</=A1&)@ M[M.O27K>PA4%F;M.7RAMLSUT`/YM''8B->"*;'X^-#O@>/=T>7UH=NV[_J#= MM<"\\34]7V8[(=EL;+^?+]GAK\+(DE*%2%>*P*<4L6[6Z$D-^%0:3K_?LYW! M]1T!RWPT\"E%[+N.T[?Z]@VCL:4(?$H1N#A77@FXK?(.P.?OCV(H1>#S]T=A M02KE71%?;AZ'!4,N6NO$L.YNCH>%F2&^_!]CP>2P='9<'Q,+`RJ^_'Y4K`%> M$O@B9?IW`ZL][-Z0H19FB/AR<V=:Q=V;%X/)YK)YO#]E/QI08>'^/+]M1+VV M7*&,9:"X:55A^*@N0$$0*E^$S$,3\@YN^3,4L_='NS^\;[U#`=I*FQ&WZ9@6 M8[00U4;(3BB84C"C8$[!@@*/@B4%/@4!!2$%*PHB"F(*$@K6)=""\*@80<;^ M$S$2,B)&>'5'"'30NB0@:(%-)A1,*9A1,*=@08%'P9("GX*`@I""%041!3$% M"07K$C`"`C6)!:0+U;)Z[L1[1+2"6;)\C]AM\X*/I,U`!6G,R(21*2,S1N:, M+!CQ&%DRXC,2,!(RLF(D8B1F)&%D729&2*"^&R&I#X6PAHH'];BF7A5&72B* MVLBVS("-E9&Z11B9,C)C9,[(@A&/D24C/B,!(R$C*T8B1F)&$D;696*$!]95 M-X1'6.?AP8LZ*DC7F&!L.GTH(VPV863*R(R1.2,+1CQ&EHSXC`2,A(RL&(D8 MB1E)&%F7B1$+6,S<$`MA;<:B(+W\\2*?IL>,3!B9,C)C9,[(@A&/D24C/B,! M(R$C*T8B1F)&$D;696)<>"@W-UQX86U>^(+T]-Q`P82"*04S"N84+"CP*%A2 MX%,04!!2L*(@HB"F(*%@70+&=8:*?<-U%M;F=2Y(KZ,OM")Z*NB3ZC.1-C!# ME:8+LJ":*B,L43,EC63.R$*U*DOWS9G(4T8HM&1"/B.!:E66MDWI4!FA](H) M18S$JE59>F!*)\H(I==E(2.L4/R-L!:/*G?B&>KRNMM^&V5PX6$-73'U=^&1 MI'A0$2)FM`M2CC8CDX)T83U8BFW/',I4&>%09DQHSLA"M:J1]I012B^9D,]( MH%K52(?*"*573"AB)%:M:J039832Z[*0$5NQUV`$MR*(L!.#4<S-S3!*U._E M3Y^=MD7",Y8&'<@0%41V$Z.1GMRF',TXFB,J]K?$P^L"D=;R.%IRY"/26@$B MK15RM.(H0J2U8D1:*^%H;2`S5N(YM;QG\$FLBL=:6&QC&HRL`G5AIE2A&)#M M@K$T$IL2RHC'2XJ7[\Q.WR%W)OJS\MP8#*FO&?HJ%V_J:XY&CAK(`E&M>X^X M'SBD?TN4J7/OHY%V'R"J=1^:[H<]B\P<*Y2I<Q^AD78?(ZIUGYCN.]:`AF>- M.A_X-Y,/G-V2?,*<%(H"]2!S5%[9-@G)6.QC0L-/JH4TTBN%*;8KC\6V26[/ MT`J>EU0?.G0S8(Y6^MY=(-(>/42&QP'96%BB5:U''ZVTQP"1]A@B,CV2)^,5 M6M5ZC-!*>XP1:8^)1-VBN#N]'EE7K;%-V5GI!C93"/IMI)!82'3Z=[".^*22 MB88DF0ID5#)[0):&8[&)+1K6ES)II(<]E>TZL-!5:5*13+(A?"BKBF12?<`R MO,!N:8]>I4>>3-=X]%%>5XP`D?885GMDR72-QPCEM<<8D?:82-0M9H.J9*IP M]F$R0<:Q9.HZXLSLLVP2+4DV%<@L30.2ZV-QEO%Y:9)&4*%T4M#*.T4I&+"R ML@=DY31#*Y!45A4)IKJE$^R:3G@H;W:"3%)+M*KMA(]6NIP$B&JO1(A69B?( M@]`*K6H[$:&5[D2,J+83"5J)QY7W1SAX):%?HT'9_X>9*3:`;EBF"7.2C@7J MBW7W^R,LJ4EWQN*\^/.Z5ACI;8NI;*;)C)&YEM;91(4\UFS)B,^%`F84,K)B M).)",3-*&%F7B3D-B7VB&^)3;"L9RVBYTU1>R="E[5B<77Y>+:11;7I.4:I( M3Z=#BO0,__Y!=N8/X',TTC?'`E&M=T]:R36`U6Z31=429>K<^VBDW0>(:MV' MIOM>CZ[I5BA3YSY"(^T^1E3K/C'==WK='AG^&G4^\&_FGM@ZNR'WBITV(_<* M9"Y\^"I:-JQ?^$@C/45/P5.>M/"A9AQ[0/:.9M)*S.?*JF)>4GW0E81Y]*H] MDJ>"Y54>?;32RY``D1YC6.V11'6%#6O'&*&5]A@CTAX3B>3"Q^YWR0V\QC9E M9Q].+V*?KIQ"5Z^B14,RT12(K'O8*KJP^N213!KI84_%LEM4P/*H*I))6I5O MGXID4GW0R<0\>M4>63)=X]%'+5TQ`D1ZC"$B<XPLF:[Q&*&6]A@CTAX3B60Y MKDJF"F<?)I/8&/RM9"IV%"%Q,1XC2VX[PI2FJH+MD.?AL;02HU!6I=[)UT^D M>FUIGDHI\RG-(??6#!V6(U217]*COI$7V+"V$UYU)\@MM$2MVD[X:*4[$2"J M[418W0FR:ERA5FTG(K32G8@1U78BT9V0BVAR$=8H4_9?"KTQ4<(;F+^7F'E# ML\I)9%8YASQLC:55?95#H]HK,46K\D!MEIAH55_XT$H7A06BVDYX:&5V@L1D MB5:UG?#12G<B0%3;B1"MS$[0Q$2KVDY$:*4[$2.J[42"5NKICI0(\;IO/E&5 M_;/$+%[H+=[A.Z2GEW2<[O?GQC;[+E[6S<](%"[>)![U7'@Q`^HCY7T77A*H MX+8+9]B<KQP7SH8XCQP73H@XCQTWR>]>XC<>NDF5_=IQX8"(Z\";T%_RB8?H MC.`-Z3P(E'?@S>D*G5'7A?>'*O1[H)\?AA"AA>/"J2IOL!BZ<"+'^=)QX5R. M<]]QX72.\\!QX6BU@@]=.);C?.2XHRH^=MQQ%9\X+APX<YW)T(7#2LYGC@M' MEIS/'1<.+H&WU`6"-\'?-B]IN#F][([GQCY]AN1KYV>QI^)=\N+')7N#(@AO M06<7>`<\__H*[_RG<#[6%ANNSUEVP1_"@?I?!(]_`P``__\#`%!+`P04``8` M"````"$`)<D`.F,'``#D(```&0```'AL+W=O<FMS:&5E=',O<VAE970R,2YX M;6RLFMMRHS@0AN^W:M_!Y?NQ#3Z&2C(5&W.&VMJ:W;TF-HZIV,8%))EY^VTA MA%"WS<2S>S/$'[]:4JO5Z##W7[\?#[WW)"_2[/30UP:C?B\Y;;)M>GIYZ/_U MS?JRZ/>*,CYMXT-V2A[Z/Y*B__7Q]]_N/[+\M=@G2=D#"Z?BH;\OR[,Q'!:; M?7*,BT%V3D[P9I?EQ[B$G_G+L#CG2;RM"AT/0WTTF@V/<7KJ<PM&_AD;V6Z7 M;A(SV[P=DU/)C>3)(2ZA_<4^/1?"VG'S&7/'.']].W_99,<SF'A.#VGYHS+: M[QTWAOMRRO+X^0#]_JY-XHVP7?T@YH_I)L^*;%<.P-R0-Y3V^6YX-P1+C_?; M%'K`W-[+D]U#_TDS(FW>'S[>5P[Z.TT^BM;?O6*??=AYN@W24P+>AG%B(_"< M9:],ZFX9@L)#4MJJ1N"/O+=-=O';H?PS^W"2]&5?PG!/H4>L8\;VAYD4&_`H MF!GH4V9IDQV@`?!O[YBRT`"/Q-^KYT>Z+?</_?%T,)V/QAK(>\])45HI,]GO M;=Z*,CO^PT5:;8H;T6LC\!1&9M)(1\%Q71">=<'98#&=3F:+.=3>47!2%X1G M71`"ND,/UJINPK/6:]//U32K2\+S4S7-:ST\;^L2=*!J(CP_5=%=K8?GC5W2 M(,KXH+-PXP/:[3ZM"1/XX[9N:2(XV!^?JTQ$A2;#0M,'VF0T8S'9,<J:"`OV M1UT7N(>6&/)94$TJ,R[CQ_L\^^A!IH+N%>>8Y3W-8$;$=.(FF@EV;7[!Q&)6 MGIB9ASY4#5.G@*3P_CB;CNZ'[S"1-[5F236ZJE@)!9NUS*R)P1H#"P,;`P<# M%P,/`Q^#`(,0@Z@%AN#:QK\0`_^'?YD9YE_AF:4`TN%CY$RA$$5,#-886!C8 M&#@8N!AX&/@8!!B$&$0MH#@3IH?BS,LY7\0D4T-V5V)24YVTK#75]ZH*N14A M)B%K0BQ";$(<0EQ"/$)\0@)"0D*B-E%<"%/\!A<R-60&2.T=\YJ+QI!06R(\ MM1M1$XZ$K`FQ"+$)<0AQ"?$(\0D)"`D)B=I$<2NDZ1O<RM256X4SEIR,U02* M9W0C$L5,0M:$6(38A#B$N(1XA/B$!(2$A$1MHO@0%APW^)"I51]R,JF6CWPN M$V(2LB;$(L0FQ"'$)<0CQ"<D("0D)&H3Q6$P+6]P&%.K#N-DTGQ45AB8&*PQ ML#"P,7`P<#'P,/`Q"#`(,8A:0/$19*4;?,34JH\XF>C220V1Z6Z*LIU9:R`+ M-RE17Z#IO&Y$8CI;A-B$.(2XA'B$^(0$A(2$1#6I.J]X%?*4XE6^:ARP/4RY M3S>ORPSZ#4NB"Q_H,:P.^9J1&5&=S4G;V828G(QAB2!=.T?^7S>BQK6$V(0X MA+B$>(3XA`2$A(1$G/"N*JYE>Y7_[MO*BNI<@18RE"62SB2Q7(O&;.#>'_61 M-E'74&LI:+PM#0MD2W2]+D>:JNM"<\:5`F'8DX8%\B6Z7E<@3=5UH2`*I4`8 MCJ1A0.JPL0U`>R-U(?1A,R=BG^TO4?`+!)'11/9LBIR]JE4ZE&]4=,BX=5V9 M)-,%'K=:Q0=6&Z'WEJ@*%CU7J[*%J*L]CA!UML<5*MZ>.]0<3[SN:HXO1%W- M"82HLSFA4/'F+.Y4[T7B]97FJ,$!-2G!\4OYDITGX)CAB)T2-$,TFT[5IJY$ M04CGC8K&3&U]W*2'=5U.AP5(4TZ?H2EI">OMCQVV;@M15Q,<(9(?6U<T85XE MGSD:!$^4Z*K;%Z*NN@,ADG6'LNY6]VD<-'YKJ6;R[$,-!+8ONR%+,#G*XASI M[2S>(-D"/``F.UH"4[H\0EA39`DDK=L27;?N")&T[E+D"22M^Q)=MQX(D;0> M4A0)5%E7O<ZV;6VO_]KT8U;08'`T:6>;V72&IQ]7_21EUR*()CG7:,JN55=3 M=OT>'HT5'`HV.^9CH=!N-18Y0M39'E>HZO;,YVK7/?&^JSV^$'6U)Q"BSO:$ M0E7G;-2<2+R^TAPU:-@^M2MHOF5GB(:+:]SVAYYO=_F-2+7N7;+;"N9_.0U6 M$ET?-[,6C>4&=TV1)4V)58LMT77K#C7E4N1)4\*Z+]%UZP$U%5(425-D><4V MP>W1^,GRBN^9%:]SA(Y84(2LM$8E^F=2M*;(HLBFR*'(I<BCR*<HH"BD*%*0 M&N!LR]QV*<N*.MR%B?N#SQ_^\\VWXFV.D+?1DF[%#A9A)H!*>IN@-559%-D4 M.12Y%'D4^10%%(44L8M/V2'N;7Z1R>]<CDG^DJR2PZ'H;;(W=DFI+6!AT^#F M!O6I6H8@OF0WJ\Q3F.L&G)A?X&,#SH$I?YH83]!0^F(Y,>"$\P*?&G!J=X'/ M##B<NL`U>`&!=^G-7-P.XTXLC&45!HBO%L;J$C<7!AQ8T!K,.P-VVY1'"P/V MW)2;VLA@.UCZ!C:C!MMOTC>P=338[A#>#)OFPAWS.7Y)PCA_24]%[Y#L8'A' MU9%(SF^I^8^R_FP\9R7<+E=?D#W\;X($KKM&;.[MLJP4/U@%S?]/>/P7``#_ M_P,`4$L#!!0`!@`(````(0!"FFUF/0L``#0W```9````>&PO=V]R:W-H965T M<R]S:&5E=#(T+GAM;*R;6W/B.A+'W[=JOP/%^PG8W*DDIQ)\O]76UMG=9T*< MA!K`*2!S^?:G9:LEJQLK9&I?ALG/_^Z66VI)%OCVSY_[7>][>3QMJ\-=W[D9 M]GOE85,];P^O=_W__!7\,>_W3N?UX7F]JP[E7?]7>>K_>?_/?]S^J([?3F]E M>>Z!A\/IKO]V/K\O!X/3YJW<KT\WU7MY@"LOU7&_/L.?Q]?!Z?U8KI]KH_UN MX`Z'T\%^O3WT&P_+XS4^JI>7[:;TJLW'OCR<&R?'<K<^0_M/;]OW$WK;;ZYQ MMU\?OWV\_[&I]N_@XFF[VYY_U4[[O?UF&;\>JN/Z:0?W_=,9KS?HN_Z#N=]O M-\?J5+V<;\#=H&DHO^?%8#$`3_>WSUNX`Y'VWK%\N>L_.,O"7?0'][=U@OZ[ M+7^<6O_OG=ZJ'^%Q^YQM#R5D&_I)],!357T3TOA9(#`>,.N@[H%_'7O/Y<OZ M8W?^=_4C*K>O;V?H[@G<D;BQY?,OKSQM(*/@YL:="$^;:@<-@'][^ZT8&I"1 M]<^[O@N!M\_GM[O^:'HSF0U'#LA[3^7I'&R%RWYO\W$Z5_O_-2)'NFJ<C*03 M^)1.QC<S9[@8S<"'Q6XL[>!3VDUT;(L=>*T;#9_2SEE8`TVE`7RJ0//)9#R= M?]+"F32$SR_=&917W4+X5`%55BUW!K=1V\'G=7?FP(BI+<1_5*BK[LW!OA?_ M^=+=.3!:FJ!ZV%S7<PX.%?&?*^\01XG3'B:V.QPT8[PN&6]]7M_?'JL?/9B' MX#Y/[VLQJSE+X0V+I>D053Y=U0-E([P\"#=W?>@B*(P3E/SW^^E\>COX#F6Z MD9I'KG%-Q0H5HB:%6X\"GX*`@I""B(*8@H2"E(*,@IR"H@4&D%J57Q@-_X_\ M"C<BOYB91P0ZX2.23%2@B4>!3T%`04A!1$%,04)!2D%&04Y!T0)&,J%`C&1> MGM%Q3`HUS-VM,>E.QF:2'J5FIA*[8L1CQ&<D8"1D)&(D9B1A)&4D8R1GI&@3 M(X50XE](H5##S`!3?:NN9R2'C6AD%O_<%*V42`U'1GQ&`D9"1B)&8D821E)& M,D9R1HHV,=(*R^X7TBK4=5HQ&8\-&=<;FWKJ6S'B,>(S$C`2,A(Q$C.2,)(R MDC&2,U*TB9$PV'9\(6%";2:L(6-=MQ1X%/@4!!2$%$04Q!0D%*049!3D%!0M M8.0(RL[(4;,VWXC]V?EMN_GV6#7;T`O3X`C6X&9E%D[,U$DRU[E31)?YA*S- M7J,9P=2LI@)W0J8"7XEP8`>,A(Q$C,2,)(RDC&2,Y(P4#7'JFS>2+9[^^$;H MB\D63LQD2])*MB(ZD2S9C68D>O'[O3MTR++EJ^LJS\HKDE"1[CB1\B/CD#U$ MK*ZCUT1Y19(JTATG4WYD'#*X<G4=O1;**Q"CGV"9,?KIPN"'QS0<_4)M=H@D M[=5JOB"+5:-Q84^GQCKK(JDQZX&L>KX4P6JL'+D3$BV0(EA;M&@Z-)L47M&D MZ)HFQ9>:-'7,:,DU34JO:%)V39/RBTTB0Z3XI$G&&!$/?L8@$3-GO4&Y>MJL M79@C1R)Q"*`Z:D'Z:85V,'Z5B(T=%(W4%.RC<U@+E)T[)?48:$.MHMY#%-F: M$*%(-R&^J@F)-NQN0HHB6Q,R%+DJ"SDV`6;I5A;([%>@H5%6K8HQQX)X,FM/ M[/8)0SSXDQE#(K<UAVNDVTG[P4.1?FKS.0H0:>^A1MW>(Q1I[S%'"2+M/=6H MVWN&(NT]YZA`5'LWLRX>X=I9_ZV]BSA4H9TA$4P':H0LR/2UDG;V"1Q%]AD< M5<988U,XJNQS.*ILZTJ$(FNS8E09S6+3.*JLS4I196M6AB)KLW)4F<V:F*M+ M@:JN9IDC"7Q91])?U3O,TY\>4`DW9#YOD%'7"NG1Q>NZ$8WTPYHOCN[`>PL% M$K6\AQIU>X^XJYBC1+O"'5.J4;?WC+O*.2JT*[K[$D>$K#>^N+(*%Z0G&F2L MK.Z4G!^NZMA@:%M4/!3I1<67:.34N^D1G#G3'1@:02^J285V>X@B6_@(13I\ M;(9W9^Z,U$."1K;P*8ILX3,4Z?"Y&=Z9.T/RT%:@44=XLQK%`[UM7K^R&IMS M`3A8PN'[*+ZA@6'1JI>51MW=XDE1J_1\C@+M"@.&&G5[C[BKF*-$NT+OJ4;= MWC/N*N>HT*Y8-8J3`]H;+GSM\.ELV!PY&/F7J+VPNE,R5E9.H_ID994BZUKA MHZOVL'.GY`DJ0%776E$?<H2HLBUA$8JLS8I193:+S!@)JJS-2E%E:U:&(FNS M<E09S9J1IX\"55W-,FM9G(5<'CU?_?9'GJJTM^U3^E3]*(Z1Q2)IC+`9V[LI M%=:2IPT1^1P%'(4<11S%'"4<I1QE'.4<%08R.P#F<J,#/GDT$7*R<#:H?6XL MED=0M9#'D<]1P%'(4<11S%'"4<I1QE'.46$@,W_B3*`]@#_)GY"3_#6H=8PL MOC47Z5,+D\>(STC`2,A(Q$C,2,)(RDC&2,Y(T29&RMQ+)R/.Y(O'G+47,Y.( M](/F2J/N)="3(O-<>48.?WRMPAD@X"CD*.(HYBCA*.4HXRCGJ)`(1BU=K<6B M:0S7WWHFKKV0W`O'@-JY5\B6^T;4?<PL8X%`IUTY1A1BBV#BZ=P]1]I5QU&S M%J#C1#M&E&K4'2O3KCJ.F[4`'1?:,2"S9&!A-KK-/LNX0D[Z1R*86E2"W!DY MVUM)0]$0I:(/(1Z*]`;?EV@T;AYOW`7=0J%->U-`'8<HLD6/4*2CQV9T=SRF M.R6TL45/462+GJ%(1\_-Z,Z,G@05:-,1W>QHV%M]I:.%G'1T@\SGV!DYOERY MTM!6+QZ*],WZ$LGGV.F4WFR`-N"_<P2%*+)%CU"DH\=F]-ET0>;H!&ULT5,4 MV:)G*-+1<S/Z8D@?X0NTZ8AN=C2,!J.CQ41\S6.3*PQ)ETMDUC9YPE])PT]J MNW$%6IR5?&DW@@<ZU:/\6P'T#O9*Q0M<>K>56*0]81/BJYJ0:,/N)J0HLC4A M0U&[\YNFXPPW'Y$9KD";C@28G2_.&:[?-(I:IEW>(%+E]+0*#6TCW4.1OEE? M(G=63^?L&R"TZ!CGS>,PBFRQ(Q3IV+$9>\PJ7.;"%CM%M[;8&8IT[-R,[3KD MY*%`DX[@9A^+`XAV'__>3DN>B+0.J5R)S&HG35U)U2?5K@Y)L-1\M&N^]G?( M)!+@Y8Y1+KM>NK756(2>=/IC1#(V6;,2O&R+G:+(%CM#D8Z=(Y*QR8E`@9<[ M8IL]+TX/VCW_R6:M.6R`1W3LA$<H/%'P[7-(C;HG-P]%^ALSGZ,`D=ZJAQIU M>X]0I+W''"6(M/=4HV[O&8JT]YRC`M&%)QLH=B/KOU=OP@M971LT@D&M5C9W M1J;_%?15;0@?2D77/P]%>MSY$LD-E0-O:9!*#M"H8]*1)7=%^`@]Z?`Q#>\L M2/@$C6SA4Q39[CY#D0Z?D_#C.?W"I4"CCO!FX8ESDW;AT2%PW1<#\%X(&P,- M@L9@C:ZD2K3/TN&-7?N+`6G70H%VA=Y#C;J]1]Q5S%&B7:'W5*-N[QEWE7,D M7J+14U73&\U+,<TO_/?E\;5<E;O=J;>I/L0++W!"<'^K,+Z-,UL^@"=H(+D" M![9+<7IYZ<H<KM0=0FS@W9Z'>HP1_@CO_-0OR%#NPKM`ER*,EO`;9A[Y8;Q\ M@$-N?N%QO(1?YU[@DR7\")5S;[:$7P=>X/,E_+J.\VB^A%_#<9[-E_#K-<[A M8&LICH<N77&6/NP-^!4X)%G&%Z_`D09XJVT&*H/PSM+[^K7,U\?7[>'4VY4O MT,7#^BCOV+SUU/QQEE^0/U5G>%L)1@&\Y0%OIY7P@L50?%7T4E5G_`,:-5#O MN]W_#0``__\#`%!+`P04``8`"````"$`_=+V4;P'```I)0``&0```'AL+W=O M<FMS:&5E=',O<VAE970R,RYX;6R<FEMOVS84Q]\'[#L(>J\MDI)\09PB7=&M MP`H,PR[/BBW'0FW+D)2F_?8[I"B2AY>(V4L04^?V/R1_HF7=O?]^.2??ZJYO MVNLN)8LL3>KKOCTTUZ==^O=?G]ZMTZ0?JNNA.K?7>I?^J/OT_?W//]V]M-W7 M_E370P(1KOTN/0W#;;M<]OM3?:GZ17NKKW#EV':7:H"/W=.ROW5U=1!.E_.2 M9EFYO%3--1TC;+N8&.WQV.SKC^W^^5)?AS%(5Y^K`>KO3\VMGZ)=]C'A+E7W M]?GV;M]>;A#BL3DWPP\1-$TN^^WGIVO;58]GT/V=Y-5^BBT^..$OS;YK^_8X M+"#<<BS4U;Q9;I80Z?[NT(`"WO:DJX^[](%L/Y2K='E_)QKT3U._],;_27]J M7W[MFL/OS;6&;L,\\1EX;-NOW/3S@0^!\]+Q_B1FX(\N.=3'ZOD\_-F^_%8W M3Z<!IKL`15S8]O#C8]WOH:,09D$+'FG?GJ$`^)M<&KXTH"/5]UU*(7%S&$Z[ ME)6+8I4Q`N;)8]T/GQH>,DWVS_W07OX=C8@H:HPE2OM8#=7]7=>^)##?8-W? M*KYZR!8"3S6-$525H2*A.A[D@4?9I9LT@?P]=/;;?;DN[I;?H!M[:?-AM(&_ MRH8JBR54HTJ",LR2_.V9,G-CGIFWBY?R81PPTS!_&O:6--P8^FT43]9K%7?, M/-KDHMVFGOPMB;@QS,7*S+3)K$S2R!1)#"/435@:9C?%!)-B$5QW4V.YGRA$ M=5:.0(/5#)(-4:6AK*4GZVK#UW5@N4]IN2-.*T=PVL#2@;8Y8C?@^?H:XEXX MIQS!.0/KB./9VD%YMEE`V:]GY7XXJQS!67-_@V&OV5EIN9Z?5NZ'L\H1G%5O M7C2M!*!GIGU=H;`6R<P54RI!X[:9K/!JUE:X`+`R"Q#+.8?!F4JX&Y9-Y!#6 MO5+%X;1@9::=R<:M'=TV+HBT@CJ,_:2M<`$6K:*W,1FI!$!1^W@:PLHW`>46 MO7AB"MMCI@,>C,%I0Z60,^_AF&F%.\#Q8^VS,I]?\/P.:T^]AV0T"Y",^%"6 MT<5J%F7"TUIT'IC1+``S?A.P%9.XS"[11#`HQIQTF@601CQ,8_F\8!=I(I*3 M-L`TXH$:*5A,JUVLB6!.Y@#7J,4UL;WF;QS"#<_P-(3['*`9Y0PRUO3KFTI8 MBVP:!Q)+G'\DU$RNF%=I4E#/(*(#K+DA$PX6CI9S'<AH>X!FU>#:C7$', M5*Z))95+*ZQ<6V'E'JZQ8A4C7;%-$97*(=@A"N64:-SAS)P^5L_I!B+,]("[ M61V70SAM@&/4XMA,-@DJ`(FA2(-*=EQ:H8X3;85U>W!&<YBSF4I<EO'[C[/2 M2(!EU&+93#:%,%.WYI74+:VP;FV%=7NH1K,\9J6Y5*-R".&%!*C&+*J]+EU8 MVW@AFERC],D*2]=62#H#*V>I%T6$=.&)5_LTA*5K_.','K!%G<J9I)AQ7IJ& M<.(`V)@%-G%>BIIMX6E)ED3#F0-$8QZBQ4EV@29B02TH,0T`C7F`1DIX-#&W MM86CI5@B#2<.((U92..]9ED9L[P4WA3#13!'<H!ES,.RN+N'\+0T^W!&`SAC M%LZXYCQ;QVA6:-.:Y1#N=H!CS.+8#$U<=HD`(+UTGY!8H.*BR/SQ*^=NN)?3 M$%84X"/_WNC@"2;C=67"2V0U;A%4$W#DY&2%.&E8(5KE4*Y="%NSB,<EPM-J M`0\&0[@%`4[R^Z^9>4:ZY!'T2)\*J":AE"ZML'1MA:5[J$5BGD_E+K6F(:P\ M@$O^=>8-RB67D'*F@2B52RNDW+#"RCWT6JUBYMR%5RZ'D'(6P&;.>6,<0&?F MG%O;RYUI+DKET@HKUU98N8=A9/XA3NX";!K"N@/HS"V`"<I$I'5))B+96XP% MN%E8<'N]W<+::;<&V-CNR0JW6UNA=A=@9<YW)%V%FZA$W2^F(=QNC3Z<%JS, MM#.ZN;6C6U-+ZI966+>VP@58;..Z:1FQP0J%.:U<#F'E`:85%M-FE"N0&5!E MFEI2N;3"RK455FZQC2MG&V#$3"4*<EJW'$*Z<\T]G-9#-$+7,1UWD5;XD)8' MD%:\"6G"VEYKN8:5[+@/:885ENY#6LP9N'"A-@WAG@>@5GB@%O$T0;A9FUMR M#J<-0*U\$]2$M=-PC:NQX9,56N*YMD(-+SU0B]K<PA$KGX9@K>MC31[`6@G] M,;$V4B7BEQ?A:"7FL6`(MSR`L_+_XDPX.MW7[)+=EX3#3=!6N/L6X403HK[E MEHIVBC'3$.Y"`&TE!Y)Q>'E#9HDRXYN]"&;WOPC0K?30+>Z0+CRMF??1K0C0 M#5Y*<#3'/1<7GE9FB374[4+#;YSG\26&\4V!2]T]U;_4YW.?[-MG_H("/.2^ MOU/#\NV),ML^P!J':76N,+@BVFY?R8OM`YQ=/3[Y"JZ(G_5MGP+RP$'$XU-0 MN,*\5W*XXLU30!Z`H2<:A:K']S#L"F@)5[QZZ!JN>*,QJ!J^G'KRY`2N>/N6 M0P7PG<;C`RY^C^V#-SN![/"#IR\2]`Q^$/1=@9[!1'NN4)Y>Y%^JUL"+*K?J MJ?Y2=4_-M4_.]1'6228>2W3CJR[CAZ&]P7J$UU7:`5Y1$?^>X)6D&E[=R/@3 MHV/;#M,'2+U4+SG=_P<``/__`P!02P,$%``&``@````A`-N-++FP!@``C!P` M`!D```!X;"]W;W)K<VAE971S+W-H965T,S4N>&ULK)EMCZ)($,??7W+?P?A^ M151$B;H9'WA0,)?+WMUK!G$D(V*`F=G]]EM-4PUT*>MD[\W@_*C^=W5U5=,- MLZ_?XW/G/4RS*+G,NVJOW^V$ER`Y1)>7>?>?;^:72;>3Y?[EX)^32SCO_@BS M[M?%GW_,/I+T-3N%8=X!A4LV[Y[R_&HH2A:<PMC/>LDUO,"=8Y+&?@[_IB]* M=DU#_U`TBL_*H-\?*[$?7;I<P4@?T4B.QR@(UTGP%H>7G(NDX=G/P?_L%%TS M5(N#1^1B/WU]NWX)DO@*$L_1.<I_%*+=3AP8SLLE2?WG,XS[NSKR`]0N_B'R M<12D298<\Q[(*=Q1.N:I,E5`:3$[1#`"%O9.&A[GW2?5V*NCKK*8%0'Z-PH_ MLMKO3G9*/JPT.KC1)81HPSRQ&7A.DE=FZAP8@L8*:6T6,_!7VCF$1__MG/^= M?-AA]'+*8;HU&!$;F''XL0ZS`"(*,KV!QI2"Y`P.P-].'+'4@(CXWXOK1W3( M3_/N<-P;#31]HH)]YSG,<C-BFMU.\);E2?P?MU)++:XR*%7@BBHPDI8&P[(! M7,L&:D_3^\.BTY9VH[(=7$6[B::-QA,=O&UI"'>+<<(5/7RHPW'9#JZ?ZU`O M&\)5-'QDA%"8A:-P%>T>&N&T;`C73XU0A9GB*<"2KYS=WD-=JB)[X(=H^L@H M5<P8]J-L";]:)E#%E&$_<(#M+3!9H/ZPQ<T^%%X318FM_=Q?S-+DHP/K%HPJ MN_IL%50-)H+%Q=T4Y7:OVJ#,F,H3DYEW85Z@CC)8(MX7^F`R4]ZAK(/29DEM M!DV+%5JP&F:R:QEL9&#*P)*!+0-'!EL9[&3@RL"3P;X&%`BMB"_,QO\17R;# MXHN162*H`CZ4@HD6V&0M@XT,3!E8,K!EX,A@*X.=#%P9>#+8UT`CF%`6C6#> M?@)@3C)K6.MK.3G6U&:0EJ6-+@*[(F1-R(80DQ"+$)L0AY`M(3M"7$(\0O9U MT@@AE/@G0LBL866`!;Y6UU,IAMQH6"_^L29GHS`2Z4C(AA"3$(L0FQ"'D"TA M.T)<0CQ"]G72""L\<S\15F9=A!6#L>1D5&R$BJ5O1<B:D`TA)B$6(38A#B%; M0G:$N(1XA.SKI!$PV&Q\(F#,NADP3HI=)X^7#-8RV,C`E($E`UL&C@RV,MC) MP)6!)X-]#31B!&7WB1@QZV:,.!D-JL5-D*J>->DAO"YM8`41-3^82.6\$4:8 MP28A%B$V(0XA6T)VA+B$>(3L2U(,OA%5=BRD.YX>VUSGIRAX72;\+'#CX3*$ MG0W?[S"19K`YJ0>;D#4G0WB\5:'5I?AOA)$(+2$6(38A#B%;0G:$N(1XA.PY MX4-MA!8>`;\?6B;2#&U))E4>"U(%DN0QMQFR.7M?#/KJJ/G8VHC[(LY"%8DE MR/U^;*%3]B.5BB/NH^I6J"+9"7*_'U?HE/U(>>.)^ZBZ%ZI`&O/$SD.-B;J1 MZW`TQF0OS)M3@@BZ$*D\UJ00KTJK`6R.A169)S1J5(4F'1XV:,6G4^U+]TV\ M#T_HNUU9:-3FCXU&K?XX:,7]F4KN;/%VFSL[-&ISQT6C5G<\M.+N3*0MVAYO MWW&GF1SL*//;"R0[-TME7"+VSD5,T5C3FF6YPH:PR`@KFC.E^E`L"1M4AX>I M:#<82\5HHGK]Z2:K6VC4YH*-1M73U4$7='X`EB9ABRW:^MZA45O?+AI5?7M5 MW[7ATSP0<:M9C?MB"IJ)`"G72(1?K!+,7%HE.!K45F[V,@2L`%4>R!.P1J/J MO+NAR$14J5L5NJ]NHU&E[E"T152I[RIT7]U%HTK=HVB/J%!O1IT=W7Z__)B* M-!D<C2`%1(&,M;&8>[Z-9J^>V/S4K>C\E$8PET)J0)?LTNKNDEW>O[,H%?Y8 MC_ACHU&K/PY:E?[H>G/H6[S?YL\.C=KBXZ)1JS\>6I5KMN3.'F_?<:>9- MFC3?DBMDPR_?XC$9*6LX:I2P0-7LTQ3A1L/J1+MAKQ=!O8;,$M74K0K=5[>I ME$/1MI+"+=&N0O?572KE4<0^>1254BMA_@F#OU^-P_0E7(7G<]8)DC?V>0*^ M62QF`HMO)T_%*B[Q)?NFPAYN,A\8\';L!A\:\,Z'\J>1\02.TAO+D0%O,VYP MS8!#^PVN&\MBI))#*]U8W>)KW8!#&=593PPX45"^UPTX5U"^GAJP4Z?<GAJP MLZ;<G1JP$P:N"$?A6]#5?PD]/WV)+EGG'!YA,OK%@2_E7Y/X/WE9(\])#A^! MBG(YP5>_$%Y$]WNP:3DF28[_L`[$=\3%3P```/__`P!02P,$%``&``@````A M`+?XGCKI"0``TRX``!D```!X;"]W;W)K<VAE971S+W-H965T,S8N>&ULK)I; M<^(Z$L??MVJ_`\7["9B+35Q)3@UW@P&;VLLS0YR$&L`I8"[GVY^6I=:EVW%@ M=E\"_-+ZMZ1NM67+#W_^.NQK/[+3>9<?'^O>7;->RX[;_'EW?'VL__M?XS]Z M]=KYLCD^;_;Y,7NL_Y6=ZW\^_?,?#S_ST[?S6Y9=:J!P/#_6WRZ7][#1.&_? MLL/F?)>_9T?XSTM^.FPN\//TVCB_G[+-<]'HL&^TFDV_<=CLCG6I$)ZNT<A? M7G;;;)AOOQ^RXT6*G++]Y@+]/[_MWL^H=MA>(W?8G+Y]?_]CFQ_>0>+K;K^[ M_%6(UFN';1B]'O/3YNL>QOW+ZVRVJ%W\8/*'W?:4G_.7RQW(-61'^9CO&_<- M4'IZ>-[!",2TUT[9RV/]BQ>NO?MZX^FAF*#_[+*?9^M[[?R6_YR<=L_Q[IC! M;$.<1`2^YODW81H]"P2-&ZSUN(A`<JH]9R^;[_O+.O\YS7:O;Q<(=Q=&)`86 M/O\US,Y;F%&0N6MUA=(VWT,'X&_ML!.I`3.R^?58;X'CW?/E[;'>]N^Z0;/M M@7GM:W:^C'="LE[;?C]?\L-_I9&GI*1(6XG`IQ+Q;M;H*`WXU!J];K?C]X+K M.P*6Q6C@4XGX=ZU>U^OZ-XS&5R+PJ41@<JZ<"5A610?@\_='<:]$X//W1^%! M*A5=$5]N'H<'0Y:M36)X=S?'P\/,$%_^A[%@<G@F.ZZ/B8<!%5]^/RI>@%," M7Y1,]R[PFO?M&S+4PPP17V[N3$.NWJ(8##>7S=/#*?]9@PH+Z_/\OA'UV@N% M,I8!N6AU8?BH+D!!$"I?A,QC'?(.EOP9BMF/IZ#=?&C\@`*T539];M-R+09H M(:J-D!U2,*)@3,&$@BD%$04S"N84Q!0L*%A2L*(@H2"E8&V!!H1'QP@R]O\1 M(R$C8H2SVT=@@M8F`4$+;#*D8$3!F(()!5,*(@IF%,PIB"E84+"D8$5!0D%* MP=H"3D"@)K&`M*%:EE\[<8V(5G"5M-:([],UHFP"':0!(T-&1HR,&9DP,F4D M8F3&R)R1F)$%(TM&5HPDC*2,K&WBA`3JNQ.2ZE`(:ZAX4(^M>N6YR=^71FV[ MJ/D^+5G:2"\11D:,C!F9,#)E)&)DQLB<D9B1!2-+1E:,)(RDC*QMXH0']E4W MA$=8%^'!2>U+TBFVM,6E8<#(D)$1(V-&)HQ,&8D8F3$R9R1F9,'(DI$5(PDC M*2-KFS@3#SN7&R9>6+L3+TG'U",*AA2,*!A3,*%@2D%$P8R".04Q!0L*EA2L M*$@H2"E86\"99R@E-\RSL';G69).RTRT)J9&=4GU&2H;J(JZCOD^N8B/M!&N MIK&61C)A9*I;V=)=MT1&V@B%9DQHSDBL6]G2OBN]T$8HO61"*T82W<J6#ESI M5!NA]-H6<L(*.V(GK')[?"?V[9>WW?9;/Y?WN"67FS9L@^7F6(BXT9;$CC8C M0TG:L`>Q8MMQAS+21CB4,1.:,#+5K2JD(VV$TC,F-&<DUJTJI!?:"*673&C% M2*);54BGV@BEU[:0$UNXL#NQ+8DAW/QC$(6U&T1)NIWB=J?5]$AL!O+_+=C5 MZP"R!:QLS'5MQ,B8D8E6QD%.F4W$R(R1.=.)F<V"D24C*Z:3,)N4D;5-G,"( M!P\W1*8P=T.C4!NJM9[[X-Y=.P-L!PFBC5B`T,A>AJUNSY4:H3]/WOK>4U]C ME+$K-?4U0:.>O@A,$56ZCXC[H$?Z-T.9*O=S-#+N8T25[A>N^_N.1RX32Y2I M<K]"(^,^053I/G7=M[R`AF>-.A_X=Y-/W(7;3T2JRX(G;]KA5@+78E^ACKWP M?9^$9*"LJLL#&IEMP0B1/1;?)[D]1BO8D.O<;M&[S0E:R8>RXHG+%)'Q&"%R M/`;DSG6&5I4>YVAE/,:(C,<%(M<CN3];HE6EQQ5:&8\)(N,Q5:@MBWFOTR&; MJ#6VL9U9"]A-(<A7)X7$KJ'5O8--PR?))!J22B:14\G\@.P#!^*IJVA87<J4 MD1GV2+5KP?Y'ITE),JF&=CA*DDGW`5?"%+ME/$:E'GDR7>-QCO*F8L2(C,=% MN4>63-=X7*&\\9@@,AY3A=KR:E"63"7./DPFF'663.V>.)3Y+)M$2Y)-$KFE M*2"Y/A#/W*'A)Z5)&<%0=.J47!B5%7QH*S\@.Z4Q.K075TF"Z6Z9!+NF$Q'* MNYT@%ZD96E5V8HY6IIS$B"IG8H%6;B?(7<\2K2H[L4(KTXD$464G4K02]R8_ MGN!DCX1^C0:V_P\S$XR<S/RDN`ESDHX2=<4N^\<3;*%)=P;BV.;SNB:-S#.* MD6IFR)B1B9$VV42%(M9LQLB<"\7,:,'(DI$5%TJ84<K(VB;N94@\%+IA)R/, M27PD<LH%W=H.Q*'QY]5"&56FYPBE9'KV6J1(C_'_$"==3:SL+.ZV)VAD%L<4 M4:7W2%FI/8#7;))-U0QEJMS/T<BXCQ%5NE^X[CL=NJ=;HDR5^Q4:&?<)HDKW MJ>N^U6EWR/#7J/.!?S?WQ'.R&W)//E9S=M$2N1L?OHM6#:LW/LK(7*)'XD17 M)*VS\0G(@Z*QLA)%4>=;R75)]\%4$N8Q*O=([@IF5WF<HY79AL2(S!@7Y1Y) M5)?8L'*,*[0R'A-$QF.JD-KX^-TV6<!K;&,[LQ:PFT+BH9R=0E?OHN73/">9 M)'(*6<DN6EI]LN]11F;8(_!4)),]*I\GD[*RET]),ND^F&1B'J-RCRR9KO$X M1RU3,6)$9HP+1.X863)=XW&%6L9C@LAX3!52Y;@LF4J<?9A,XBG@;R63:$BN MBA*YE:E'[H<'XEY,-(0/73NLWJGW&Y1196D>*2FW6/7(VAJC0SM")?FENV7R MZYI.1.6=(#>BLZLZ,4<K4TUB1)4SL2CO!-DU+E&K<B96:&4ZD2"J[$1J.J$V MT602UBAC^[="[U8Y\13TMQ)3/CZ%58*![,/K@B+EW"K7(S=;`V7U2953#V<K M9V*$4O9`?9Z82NN3PJ>L3%&8HGQE)R*T<CM!8C)#J\I.S-'*=")&5-F)!5JY MG6")><U,K%#+=")!5-F)%*WTW1TI$>)]TN)"94\"2TSYQJA\2>R0G5ZS0;;? MGVO;_+MX&[0EGI!I+%]5[7="./F'-*2\&\+!-.?+((0#'\Y700C'/IPG09@6 M:4[TDUZ8EMFO@Q!.?;@.O%+[I;C`$)V^>-6VQ+[?"N$5(*[3;X?P(@KG7SKA M%YAB_H]I$,)1:0GOA7#,QODL".&PC?-Y$,*1&^=Q$,)Y:0GOA7#6QGD_"/ME M?!"$@S(^#$(X1>8ZPUX()Y"<CX,0SB$YGP0AG$8";^@(P"O%[YO7;+$YO>Z. MY]H^>X$D:Q8'K"?Y4K+\<<G?X6(*K]/F%WB9N/CZ!B^/9_#,NBD>K+[D^05_ M"`?Z=?2GOP$``/__`P!02P,$%``&``@````A`&P6%^TA#@``<%,``!D```!X M;"]W;W)K<VAE971S+W-H965T,S<N>&ULG-Q;<]I(MX#A^UVU_X/+][$-$F!3 M2;X:T/E<N_;AFM@DH<8V+D,F,__^ZZ:%U+U>;1M\X\/#ZD9:W6IIR5B?__7W MT^/%7^O7W6;[_.5R='5S>;%^OM\^;)Y_?+G\G_^./MU>7NSVJ^>'U>/V>?WE M\I_U[O)?7__S/S[_WK[^N?NY7N\O5`_/NR^7/_?[E_GU]>[^Y_IIM;O:OJR? MU2O?MZ]/J[WZ]?7']>[E=;UZ.#1Z>KP>W]Q,KY]6F^=+T\/\]90^MM^_;^[7 MP?;^U]/Z>6\Z>5T_KO9J^W<_-R^[8V]/]Z=T][1Z_?/7RZ?[[=.+ZN+;YG&S M_^?0Z>7%T_T\_?&\?5U]>U3[_??(7]T?^S[\@NZ?-O>OV]WV^_Y*=7=M-I3[ M?'=]=ZUZ^OKY8:/V0*?]XG7]_<OE'Z-YX]]=7G_]?$C0_V[6OW?6SQ>[G]O? M\>OFH=@\KU6VU3CI$?BVW?ZI0],'3:KQ-5I'AQ%H7B\>UM]7OQ[W_[7]G:PW M/W[NU7!/U![I'9L__!.L=_<JHZJ;J_%$]W2_?50;H+Y>/&WTU%`96?U]^/Y[ M\[#_^>72FUY-9C?>2(5??%OO]M%&=WEY<?]KM]\^_9\)&K5=F4[&;2>>VOKV M]<F5/Y[,;L_IQ6][4=^/O=R=WXO:ZL,.J>_'7L97X]O):#(]8X^F;2_J>]?+ MR>F8M8W5]Z[QV3E5!^AA/]3W8R?>U6QT<^?-3A^8N[83]?W8R0>2,5*STDP2 M/3W;`59C?N+L&'5S3/W0-3\[(:/C+-,_M-U\8*Z.U"0U.V/-UO,S.SK.5OU# MOU-G3S1]K)K-<2;LV0?/Z#AC]0_'[1E=C?R;$Z;]M5D4#FM,L-JOOGY^W?Z^ M4`NW&K#=RTJ?!D9SW?%Q=3%K0;?>_'_+C5IG="]_Z&Z^7*I)J%:2G5HC__HZ M\\:?K_]2Z]I]&[,P,>JK%>.Y,<NA&-^-"8;>:^+&A,<8O1SJ#8PDQ!(2":F$ M3$(NH3A"OXLB">4QXKAAE83:@%E^]:8W%ERK4>N&3ATDSM`-GQ".(Z2C]0@= MWWAQA'Y;9][43>-R*&;FQ@0F1FUD-ZQB4,.A7N[<7B+&B"&-&3'S;]Q>$L9X M(S<D9<C,%S'90(PG=CL?B/'%8!<FYHW4E.Q%;G#%D)E(<#T0XHNCIC$QD]O# MP:G6C-M^IYU9I=;,,V:5CG9FE82EA,"`G929=^L.4B@;11)B"8F$5$(F(9=0 M&'`VS1>Y+F6C2D(MH3&@4J^./2?7ZL1R1JYUM)-K"4L)@8%^+0EE1"0AEI!( M2"5D$G()A0$GL7+,2]FHDE!+:`P,)%:=:9W$ZK.:IRYMWEXB=2L59ZUD,U^L M0@L3XW?+Z%)"("&4$$F()2024@F9A%Q"(:&44$FH)306.!-772@X^7T[KSKZ MRZ5:@+HSQ,P79YJ%B;'R*B$P8-:O3_[=;.Q[-S?B!!#*5I&$6$+B]GL[GMS- MT&\J6V42<@F%V^_P]I9NT/";5[+K6D)C@3-.JCXY8YQTM#M.M^(TO3`AUC!) M"`Q,#Z>96W]HC.R(3RK;(Z0[<D)N/76BER,=NR$SGR&)'3*=>'R?U([XI"K9 MVUN\4>;&3&Y\]I.[,>/IZ`[]%&Z,/_6GB"F=&,^;C3@5*R?&O_%TB#@,:A/3 M#U-C@3-!]$TB^_+_[0-91[L39.:+ZZ*%B>G?>BDAD!!*B"3$$A()J81,0BZA M,&!FZB??OQV8JZ43,YN-.#\J)\3S?(\QM7SOQ@)G/%0%Y8S':2<NW4J.B[BD M6I@8:UPD!`;:(]=3=_DPKT+9)I(02TB<7F^&>DUEFTQ"+J%P>AW<UM()&7SC M2G9;2V@L<,9)WS!Q!NKM`^<0+D=(KJUMD#5$D``20B)(#$D@*22#Y)"B$^O< M/A&K4=D%'6O/"E)#&EO<W*OKR'-RK\-%[B=]\7.X/;#0=[!4D)U[*4$7HV]O MB+(@[%X\[F,$B2$))(5DD!Q2=#*P:67WXG'3*D@-:6QQTZ\KR=//&?I>'M(O M"N5%&V2GWS3K)4!,"(D@,22!I)`,DD.*5LQZZ7D#9_.NC1X5<5!4W8O'4:DA MC2WN&.B2TAZ#T\X3^LXHQD+,Y$4;U&=^"0D@(22"Q)`$DD(R2`XI6IG,#I>= M-U>B:BO1HH+4D,86-_VZ\+33_\[J;^I4IP":B/LS"WV76:Q`4@+$A)`($D,2 M2`K)(#FDZ$1/<+&DEMV+QPE>06I(8XN;<UV+GI%S4[JZ.1?38J%OS1]R?CA` MKT;3P[7TX<)'?Q%[M#PO/.C"CPD((1$DAB20%))!<D@!*2$5I(8TMKA#I,M0 M>X@.?TRX44E^Y_@PY:L[5O(&@?[CA#@^I`2("2$1)(8DD!2207)(T8E]=20* MIK(+.DZ3"E)#&EO<0="EGAR$]^]]C4R%:(_!R,.IP2HC#]=-R[99?[((("$D M@L20!))",D@.*3H9.`F7W8M][N4NUHAI;'%SK\LZ._?OS'M3!=HYGTUDW3:R M2L4VYU*"-J8MW4:3PPHF;JFCGP@20Y(3>D[1*H/DD.*$GLL38BKT7#NMQK[) MAKC\:IR@PVT6G;0N9^ZPZBKPC&$U1:,]K%.<>:S"LAU5*<'(B+FF&86?Q-$8 MMJ_WQUX$B2').[VF:)%!<DCQ3J_E.Z]7Z+&&-+8XXS.6Q?AI5\.'9K(PE$5Y M&]0G>0D)("$D@L20!))",D@.*5HQR\'(X[W($FTJ2`UI;'$'X+R*?#Q0D4_[ M8\]4Y&V0G7A4Y(@)(1$DAB20%))!<D@!*2$5I(8TMKB)5HN*LQ*=.--UL_?^ MLC4V07;"I02("2$1)(8DD!2207)(`2DA%:2&-+:X"9>%]MMG]/%`@3T59<2B M#;(3;9KU$B`FA$20&))`4D@&R2%%*UV!+3^E4,J`J;A^K]!G#6EL<8?AO()[ M/%!P3^4]IS:H3_H2$D!"2`2)(0DDA620'%)`2D@%J2&-+6ZB995]X@)C"FDU MC:T_\<IK'OWA3+>"@P20$!)!8D@"22$9)(<4D!)206I(8XN;<%DSO[/`#)3* M7&!D8;P<2PD@(22"Q)`$DD(R2`XI6ND6F*FX$"ME@"=NH%7HLX8TMKC#(*OF M=X:!U?),WBY:C&4IN80$D!`206)(`DDA&22'%)`24D%J2&.+FVA9(I^XP)B: M]YT%1A;&R[&4`!)"(D@,22`I)(/DD`)20BI(#6EL<1.NJ\C3B]>Q*3K5E5^_ MDG.!D;7JLFW6GTP#2`B)(#$D@:20#))#BE;>6&#,3G4!7&#D7M=XE\869QCT M';@SAN$0+FK3J;@!L&B#^J0O(4$KIA8<OA<2HE4$B2%))P,WUM+NQ>.-M0R2 M0XI6WMK8LFLU\+95]^+Q;6M(8XL[1.=5L=Y`%7N#(9(UZ[)MU@]:``DA$22& M))`4DD%R2`$I(16DAC2VN(G6=:6]))UV#O!,.?KV.:`-ZM.[A`20$!)!8D@" M22$9)(<4D!)206I(8XN;<%U?V@E_^^K&T^%R\9%5;!MD)]HTZR5`3`B)(#$D M@:20#))#BE:Z)5[L4RE?ERMN)0,F[<WEPPUW]45<D];8A,86=XS.*W&]H1(7 MJX\)ZD=DV3;K)6C%?*YVI#_%8-T&/]R*"]$H@L20Q.E8W-U+$9Y!<DCA=#FX MK:43(MZU0H\UI+'%':"/E<:>J7K="RHQ3Q9M4#\L2T@`"2$1)(8DD!2207)( M`2DA%:2&-+:X"9>E\8FG"5/KOG.:D`7QTI,20$)(!(DA"22%9)`<4D!*2`6I M(8TM;L)E$7QBP@>*8?S!RT,Q#`D@(22"Q)`$DD(R2`XI.K%K(7%?L^R"CI>< M%:2&-+:X8_"Q^M@SA:Z[RHA/&BS:('N507V,F!`206)(`DDA&22'%)`24D%J M2&.+FW!=U=G71B=.>E,,OK/*R(IQZ4D)("$D@L20!))",D@.*2`EI(+4D,86 M)^&^K(1/2_BAF;PHE;>8VR!KAD,"2`B)(#$D@:20#))#BD[L549\"J3L@KI5 M!E)#&EO<,3BOU/4'2EUY@W;1!MFYE\5O@)@0$D%B2`))(1DDAQ20$E)!:DAC MBYOHCY6Z_BFE;AMD)]PTZR5`3`B)(#$D@:20#))#"D@)J2`UI+'%3;@N0L]? MSGU3N[KG3ZPN)JA/[[)MUDL`"2$1)(8DD!2207)(T8FUNLQ$751V0?WJ(G>U M1DQCBSL&LI0]<84?*&EGHD1?^"AI(0$DA$20&))`4D@&R2$%I(14D!K2V.(F M_&.EJ6]*4S74_;U^_,-S&]1/\24D@(20"!)#$D@*R2`YI("4D`I20QI;W(1_ MK#3U38WYSBHC"]%EVZP?@@`20B)(#$D@*22#Y)"B$VLF<961.U9US8[K3@UI M;'''X&/5JC]0K<[D9T/:H#[C2T@`"2$1)(8DD!2207)(`2DA%:2&-+:X"?]8 M:>J;&O.=5486HLNV63\$`22$1)`8DD!22`;)(06DA%20&M+8XB;\8Z6I>A@= M;]_C6D86HLNVF9UP&1,B)H+$D`220C)(#BDZL589^3FSL@LZKBD5I(;H!_AU MGTTR8V">QV>>E?6T?OVQ7JX?'W<7]]M?^EE[ZM\OOG[NV#P(,!O/U:-0U-L* MS\=S]404>CF>JX>>T*OQ7#W[A%Z/Y^H1*/1FK!Y`..#JP81_#'DPFJLG5[&? M8C173Z.B+\;SQ5`_R_%\.>3A>*Z>,\-^HO%</6Z&'H_GZJDS]&0\5P^?H:?C MN7H&C?+K+M'J>8<OJQ_K<O7Z8_.\NWA<?U=C='.EGZ/W:IZ8:'[9;U\.CSS[ MMMVK)QT>?ORIGFRY5H_94O\T>'GQ?;O='W_1;]`]*_/KOP$``/__`P!02P,$ M%``&``@````A`!+O!N%^!```M!```!D```!X;"]W;W)K<VAE971S+W-H965T M,S@N>&ULE%C;CJI(%'V?9/Z!\"[WFT8].8IXG60R.6?F&;%4TD`9H-ONOY]= ME""UH;NU'QI9>]5RU[[4Q?&/]S21WDA>Q#2;R+JBR1+)(GJ(L]-$_OTK&'BR M5)1A=@@3FI&)_$$*^<?TSS_&5YJ_%&="2@D4LF(BG\OR,E+5(CJ3-"P4>B$9 M6(XT3\,27O.36EQR$AZJ06FB&IKFJ&D89S)7&.6/:-#C,8Z(3Z/7E&0E%\E) M$I;@?W&.+T6MED:/R*5A_O)Z&40TO8#$/D[B\J,2E:4T&JU/&<W#?0+S?M>M M,*JUJY>.?!I'.2WHL51`3N6.=N<\5(<J*$W'AQAFP,(NY>0XD7_JHYTGJ]-Q M%9]_8W(M6I^EXDRORSP^[.*,0+`A32P!>TI?&'5]8!`,5CNC@RH!?^?2@1S# MUZ3\AUY7)#Z=2\BV#1-B\QH=/GQ21!!0D%$,FRE%-`$'X+^4QJPR("#A>_6\ MQH?R/)%-1[%=S=2!+NU)408QDY2EZ+4H:?H?)^DW*2YBW$1,\/YF-Q3#LW7; M>4+%NJG`LU%YV`5PMIH'/)O!3\_#N8FX;9&GYP&=5;D"S\:5A^<QO`V&9S/X MZ7GH4$8\JY"9N\RC,U%YC50EYX=E.!WG]"I!&T,5%)>0+0KZ2`?INMAX:33E M]UGU0=DQE9],IA*#PBJ@8]ZFKFN.U3<H\^C&F7$.1.'.,6V1,Z\YK*J9L(^! M!08"#"PQL,+`&@.;&KB[9HB.;6M&[=BN!:@0RR:@$,-.0$U(7G_WUO%CHU#\ MD`>S+@4%>-YEN.90G(??Y:`4++H,U])$E:#+,761LNQ27`MQ5CT<TQ5UUCT< M"X5FT^6@T&Q[&,B979?2JF`AQ;`F"BG^.K6,#4MPJ^P-VQ(G.>,<JUJ!6=G/ M,>!C8(&!``-+#*PPL,;`!@-;#.Q:@!`36.&?B`EC3V2(>+,4>*A09YSB56N) M9UDHH?.V>6`/791-7[![IHLBOA#MKH7L0=ONV)WJ;IL'L*]ZGIC1E4BP-5S[ M:Y%@.#H*P$8D6([EB%^Q%0BFZ>JH=78"P=),]][&0NY@@Q5RQ_8`"\"OZYJ- M$G,XO.M7B_>,4UIEC0$?`PL,!!A88F"%@34&-C7`]B7DX_8+VX[;G*H&/3T@$/IZ0"!8NN-^DD,X'W9RZ'R[;;-18@Y=O-+,.*?5!!CP M,;#`0("!)096&%AC8,,!7LPF7`?0>K-MVPW7<-&Y8->VZY[^63.P2R@^4'[? M#&R4&,@AVN1GG-**(P9\#"PP$&!@B8$5!M88V'#`Y8N"IN"%?2O8=<5`.PO< M'-E4;^/A3C44_N[["%]B^"V1']E3DI_(G"1)(47TE=T`#?"B0?GE=*:/X'P+ MQU2$;^#26N%J8X!+XR4\D;_"_!1GA920(TAJB@O+7LZOG?REI)?J;+JG)5P7 MJX]G^'6`P$%%4X!\I+2L7^"+U>;WANG_````__\#`%!+`P04``8`"````"$` M-PM&Z4P$``![#P``&0```'AL+W=O<FMS:&5E=',O<VAE970S.2YX;6R,5UV/ MJD@0?=]D_P/A_0J-"&+4FRN=V;W)WF2SV8]GQ%;)`&V`&6?^_5;1(-6-5WR9 MT:K3Y:DZW=5=ZZ\?16Z]BZK.9+FQV<RU+5&F\I"5IXW]S]\O7Y:V53=)>4AR M68J-_2EJ^^OVUU_65UF]UF<A&@LBE/7&/C?-9>4X=7H615+/Y$64X#G*JD@: M^%J=G/I2B>30+BIRQW/=P"F2K+15A%7U3`QY/&:IX#)]*T39J""5R),&^-?G M[%+WT8KTF7!%4KV^7;ZDLKA`B'V69\UG&]2VBG3U_53**MGGD/<'\Y.TC]U^ M&84OLK22M3PV,PCG**+CG",G<B#2=GW((`,LNU6)X\;^QE:<1;:S7;<%^C<3 MUYI\MNJSO/Y698<_LE)`M4$G5&`OY2M"OQ_0!(N=T>J75H$_*^L@CLE;WOPE MK[^+['1N0.X%9(2)K0Z?7-0I5!3"S+P%1DIE#@3@KU5DN#6@(LE'^_^:'9KS MQIX'LT7HSAG`K;VHFY<,0]I6^E8WLOA/@5@72@7QNB`^L._\WLQ;+M@BF([B M*$9M@CQIDNVZDE<+=@W\9GU)<`^R%43N,U,\;KG^+%7($8-\PRAM+,BB!GW> MMV&X6#OO4-.TP^P4)K*M&\;3$7&/P`)B6$X,#O"]D892F*3G(.I].7J.N$CG M.'=U`KL[$!T1WT$P'<+'D'!^@VAIS,=I^#_=57T:N`CV#REC&`:W^&W==@KC MM]L'"QF;!DX,&B78`K2RCRN*X(T-^0Z*ADN#BL($[9Y@T+5"W1_K?A89?J[Y M_64PI*KQAK(]SQO!.N\P-'YWIS"DA*:!$X-&)="IX(F:5A473:FJ,(22:>#$ MH%$*=4J/546P7AUOI*K"*%7G7F2('E.WY_N1KCFG;A9&PP'22./E:72FZ4.. MBW3RX8B\PI`ZF@9.#!HE:%XFI6EI<=&4M`I#*)D&3@P:)09]CW)ZK&V+UNLS M%K<#*76#@.C3=I=8\X=!9+1QKODCUQWDUYEC=R<"3S!7=P%M-F$X1%9]CRD0 MJ>/(PJE%YX.-F_!Y[N`RU>X?]^,.1'FI98.%4XS."WLUX351)]79:9WN*-RW M?[RI@^%VZO2E7G^D+O5Z;.B;.FGLVX0T%G/Z]#+5[2EYYAKT=AUH*%T\LG!J MT7EAUS9X31]A?.M-GN$.1'F1*Z(M+:<8G1>V;L)K0F35Z&F=[HC<WP8HLO'2 MB=D#)^^<77M?SH?VKG/&/OX\9]7U*>=P:=#:,06B-30MG&)T/MBV"9\G#[!J M]K"K;Z^8\8.*D1NA.R2FA5.,S@M[-^$UH:WJ]+1.=[3MKP/4EADO[1A&(=RN MOGIT^<;MJWO-RU?-0&I$*$1U$K'(\]I*Y1O.-PQ"WJQJ]MKA[-5.3S<'C#Z7 MY"1^)-4I*VLK%T=8ZLY".`Z5&I[4ET9>V@?Y7C8P]+0?SS#D"GBQNC,`'Z5L M^B\XGMW&YNW_````__\#`%!+`P04``8`"````"$`@/]%D1T#``"#"0``&0`` M`'AL+W=O<FMS:&5E=',O<VAE970T,"YX;6R<5MMNHS`0?5]I_\'R>R%`[DI2 M-4'=K;255JN]/#M@P"I@9#M-^_<[MA,"3II6?4F"Y\S).3.VA\7M2U6B9RHD MX_42!]X`(UHG/&5UOL1_?M_?3#&2BM0I*7E-E_B52GR[^OIEL>?B21:4*@0, MM5SB0JEF[OLR*6A%I,<;6D,DXZ(B"AY%[LM&4)*:I*KTP\%@[%>$U=@RS,5' M.'B6L83&/-E5M%:61-"2*-`O"];((UN5?(2N(N)IU]PDO&J`8LM*IEX-*495 M,G_(:R[(M@3?+\&0)$=N\W!&7[%$<,DSY0&=;X6>>Y[Y,Q^85HN4@0-==B1H MML1WP3R>87^U,/7YR^A>=GXC6?#]-\'2'ZRF4&QHDV[`EO,G#7U(]1(D^V?9 M]Z8!/P5*:49VI?K%]]\IRPL%W1Z!(>UKGK[&5"904*#QPI%F2G@)`N`354SO M#"@(>3'?>Y:J8HFCL3>:#*(`X&A+I;IGFA*C9"<5K_Y94'"@LB3A@60(Z@_Q MT`NGHV`T?I_%MXJ,P9@HLEH(OD>P:>`_94/T%@SFP'QT9G6T7M^R"AXUR9UF M,5S@0D)[GE>3:;#PGZ&FR0&SMI@91BTF[",V1X0NH*:-.PL^Z&U%0RE<T1$T M]7([CAIU4E]C-.@+6%^`]!&;"PC'9WP.F40M2\]&]!D;.@GV3[>,4]>'Q0S- M]M&%W+@+<6>A)PFV0+>RURNJP4L,?D\=G0Y;JZ:%:XN9FCWAR-Q<B<7=V!OE M@Z/S<:T:[&H=.5HM9FBT.EW=7(G%EV.]NH[[6O4Q>W_'ZB2WU6-'L\5T6NTN MQ)V%GJ3)9R3I)+>,$T>2Q1S*.'&;WHO.3JVU)[X7#4YF>\KU5'7NK/>+J9-< MY5-'N<58Y:%C:],-WCA75]P-1J?,GFRX^ES90]@ZU\^83G)DSYR2KBWF\AGK MQMPK&4:F)G<3K6@[#.VLJ*C(Z8:6I40)W^E!%\`A:5?M#%[###83RV\#,`,; MDM-'(G)62U32#%('W@1<"SM%[8/BC;F9MUS!]#,_"WC9H7!U#3P`9YRKXX.> MT^WKT^H_````__\#`%!+`P04``8`"````"$`HJ_YFP4C``#'O0``&0```'AL M+W=O<FMS:&5E=',O<VAE970S,RYX;6RLG5MSVT:RQ]]/U?D.+K\?6:1XD5A) MMBP2(`#>K[J\*;8<JV);*4G9['[[TT/,GSW3?Q`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`/G_N^\/+C2D1^[^]?/[ICA^^/SR]>?W9YV3=O?TK"'B[WZ] M?WY)'YS)]^\^_?G\\OC]JA1J>%.ED3-O1'YZ(XVC;;2\#?GI;31/6LUV]WS7 MD!KGTLS='<A/.#\]Z39.+\ZZ@FH4.UY1?GI%:?\;[[CK=>4GG!Y]QS(%=PV7 MG\?=\857E)]P_K8[;DAX[5RZ7XZ^YP9BQ?T"QT??=4,BK6R#AESS3>/50)BY M7^!?C-0,<0-1Y7XY_H81(0T-$7?O=0X1&`V-C/9)\[S=:'?<A*I313PT-"#> M'I!-#*W[!7?ZM@G4Q+BZ7[SJQ4FC=?I:BYL82O<+?+YY"KGNV`6"^\5KMX(6 MOW$F-C%([I>W-N)#F05W275P]W+WRT]/CW^]DY5*>N#YCSNW[C5ZSB#2:3EN M^P1[*+]*8G56/CHS/[^7^2FI\UD6A7_^TFVT?OKP3TGDG[S,)<LT8XD^)%S6 M=F8'%B06I!8,+<@LR"TH+!A9,+9@8L'4@ID%<PL6%BPM6%FPMF!CP=:"*PNN M+;BQX#8`'R1,]K$B0?_?B!5GQL4*1OD20(/GS`0&)*`RL""Q(+5@:$%F06Y! M8<'(@K$%$PNF%LPLF%NPL&!IP<J"M04;"[867%EP;<&-!;<!B`)#LG84&-5[ M,>0*)RV[KB!7M%HF$UQZF>X^2/I$!D02(BF1(9&,2$ZD(#(B,B8R(3(E,B,R M)[(@LB2R(K(FLB&R)7)%Y)K(#9';D$2A(=N0(T+#2<M*)%N)8!UIQ\G@LA0Z M"Q>;5K<3"_7W0ON4020ADA(9$LF(Y$0*(B,B8R(3(E,B,R)S(@LB2R(K(FLB M&R);(E=$KHG<$+D-210NLC,Z(ER<]"Y<,,B7)6GMCI"[+42?R(!(0B0E,B22 M$<F)%$1&1,9$)D2F1&9$YD061)9$5D361#9$MD2NB%P3N2%R&Y(H$&0K>D0@ M..DX$$K2TO7#@H$%B06I!4,+,@MR"PH+1A:,+9A8,`U`U$>2)H_H(R<=]U%) M6DWMI#W1_-LV2_/`RTC&W^?H5K<;I]]D+X29F>Y-@PSW1`U99]G>CLJTNA>Q MLWPO!-/%WC3(:$_4D'4VWMM1F=9Y(W8VV0O!]'1O6D@T/G*LC<:G/%N=N"K- MR]>'3[]?/I:%IHKMTIF<H<J3E3,2#UM)PF$C,BC)F6S8@D$ZCV\EV0OA5E(R M-"22[;4"T^>GL>E\+P33!1D:$1GOM4+3)OXF>R&8GH:&H@&0+4(T`!4=+6=Q M]+23CGO:DVBG<6[/)J60*R7LN]I&UL#+Z$Q+2G+6VIV5&XU&J]$QPY-Z)5DK M#QH>OL%YMG>N=IIMXRSW0B[N_OG+Q8F98L4;VC)Z0UO&^[9@\"8E:3=WCEM- MZ8DXE*;UKJ/Q=E6^(P9\)QZ/N$>N0K/O]-:Y:5(?BA)X>RD:<P@%@^[166-W ML^UVMW/1-`.10BW,K];V$$)U#<@@%"8!'G@OU>R6;9+27=S_!<S4-6@$H;H& MC2&D/3+QJ%W&7:MYT3#Y=@JE`^[C\7>5B[":53_A76FSG/$ZC-V&.4E<>JGX MO'%A$EY?I1#9`T8)HY31D%'&*&=4,!HQ&C.:,)HRFC&:,UHP6C):,5HSVC#: M,KIB=,WHAM%MA.)(<J6.(R*IK(S(P16C?^G*_A)<X5&$T8!1PBAE-&24,<H9 M%8Q&C,:,)HRFC&:,YHP6C):,5HS6C#:,MHRN&%TSNF%T&Z$X1B0E'1,C3MRL M-B4*3BGN28^+FGT<#8@D1%(B0R(9D9Q(061$9$QD0F1*9$9D3F1!9$ED161- M9$-D&Y)X"%TAXHAI7M8MHFE>HG`W[AZ]N3'496X`)*.[WS"T+LQ2EZ@4LD@* MI+:&C#*@V+RIF^4J!?,%D)H?,1H#Q>;-D6^B4C`_!5+S,T9SH%KS"Y6"^260 MFE\Q6@.%YMNG9A>_42F8WP+MS,=AX\H61X1-6>6(PJ9$08STW4L,-FP\"IO> MNC`'H@2*9_NDD0)ISPP994"Q>;/_R54*/5,`J?D1HS%0;-YL+R<J!?-3(#4_ M8S0'"LVW3\V<6J@4S"^!U/R*T1HH-F].`AN5@ODMT,Y\'#:ND'-$V)1UGRAL M?"E(F]YWC^IMV'@4-KUU82(^@6(8-F1K""GUF`&I8LZH`%+%$:,Q4-Q4<_J< MJ!1Z>0JDYF>,YD"A^?:IF4`+E8+Y)9":7S%:`X7FSSBU[(<#YK=0W)F/8\15 MD_8Q(GO(7='HXD0R`3V2?WL126+(!4D42F'9JBR5>ZD@*0T\B@M)%V86)"J% M.TS9UI!1QHHYHX(51XS&JJAK;/O4G-,F*H6F3MG6C-&<%1>,EJRX8K16Q;"I M9KW>J!2:NHULQ7'CBF!AW+QR]'7B)B!*U(H*6:=F->B[=W5$4<I=:-0`2.=* MXI$O;[7/V_2`+H66;);V6R*N<Y"W#'KJ+8^]-=H7YZU3L\P44*MS-X*0WMP8 M2-U-@,J:1;-Q8E/K%!)USF804F=S('U\M6"T9+0"4EMK(+6U8;2-4!Q0KNYV M1$"593H)4,3%9<-7[B1UZ0B?FFUCWTM)0Z`X`-(^3SSRE3,IEG8ZQE`*K3`9 M<T#Y9JJW3/70@-PC]S[4ON7-CEE`"U54*>MP!"%U.`;2]7/R)H=353SL<`8A M=3CW2`^5"R)+(BLVM":A#9%M2**`<N_I'1%0._$X0P')&.Z'I6UG>M]+A1D* M*`@HH"A:3LW&(X54.)&;';.F#"&ELR\#4H^Y1SXGMN2%8]OT`EJA.XHH"*FW M,9!ZFP"52:HC;S?&9=TI!.I\S2"DON9`FE<6C):,5D!J:PVDMC:,MA&*0RJJ M]\IFJ7[1<\]HS*+G453O;S?,`/>AJ'-J`*1=GGCD<U137L@^IWCR+8BBSFQ' MAS"MWC(@]99[)'7[8#+8ZGD!Q=`A!?`(4NIQ#*0>)^K1/2-JF/P[A4;HR@;O M#$+J:>Y1D)V(+(FLV-":A#9$MB&)0\F5:\/E[F\]K'7O!=L(\RA*6@TSYGVO M*,W#(C0`TA%(//(II'/>M4>9%$IULWH((766`>DHY'`6+M^\"*IB$(;F[D80 M4H=C('4X>9/#J2H>=CB#D#J<`VFN63!:,EH!J:TUD-K:,-I&*`XVF2-1L+V2 MMYRX60I+U-1YU&\2&@#IN[8)HQ1(;0T994!J*V=4`*FM$:,QHPFC*:,9HSFC M!:,EHQ6C-:,-HVV$XG&5:7?,N#IQ,ZXE.@MWGNV&V7GVFUY1>WD`%&8+;ZM\ MVGS>/>\VS6DNA9:$CNZHS.P=0DB]94#J+??(KWZ-[L5INVF6B`)J=>Y&$%)W M8R!U-_'(/[9NG)]<F'N;0JG.V0Q"ZFSND2:F!9$ED14;6I/0AL@V)'$HN=)O MN!Z]DB*<N`DECZ*%AXY?;N<CBM'"XY'V=N*E_,(CGWAT_\4;RA26).IJ8HG< M9:J'I2^'.Q'>FZI8>KRM.H<C6-?L/0;2$9Z\R>%4%;59O,.A.YQ#3Y>+!:,E MHQ60-GX-I+8VC+81BN/*%2./B*NR=AD>Z]VIV$5,.#@5IS"OJ!-KX!7E@2H& M.H&M>!-KCBHI%,.93)O8(:348P:D'G./?)KJ7G0[3;-)+Z`5NK/#/(*0>AL# MJ;>)1_N7:RY,C6\*G3I?,PBIK[E'&L(+(DLB*S:T)J$-D6U(XF!R->0C@JDL M.4?!Y%&4I!JFE_KND&.3E$?:V0FDHKZTK_.DD`JS1D4PD<=,%1&^N4=GX52H MR%/>5NB1XXD<CMGAY$T.IZI8EZ?(X1QZFEL6C):,5D!AGO+FU=8&4HJV$8I# MRU5^CPBMLE`<A9:O'8>#T[:GUK[LH'<+I\ZM`9#6YQ*/W$0XO""EJJA2=J"' M$%*'&9#&<@Z'THM[A^V&+6I#,8QXBN41I-3C&$@]3M2C.]VW3\[,-G`*G="9 MO;L9A-37W*,P595]KF1),BLVM":A#9%M2.)XD@QS3#PY<;.?\BA.5687U&^6 M4M%^RB/M[,1+^?U4H]$]L\_44ABJRQI#".G$RX#46PX4C5R#ECW?S-!A13#1 M_8UA7CU.@,KJ8Z-YTC8I?0J)T!M'$SF;0T^3R(+1DM$*2+MJ#:2V-HRV$8IB MZLQ6M/]6S6AG)0XUC^(M%M6,H*AS;0"D0Y%XA"<G%Q=FW%/H1-%A)O\00NHK M`](TF7M4GR8+50QRFW$X@I`Z'`.IP\F;'$Y5\;##&834X=PCS5,+(DLB*S:T M)J$-D6U(XB@[KL@M`VTSET>2&[%SZ3,:`&F!)V&4`JFM(:,,2&WEC`H@M35B M-&8T831E-&,T9[1@M&2T8K1FM&&TC5`\KK;B7'_"=Z]@F!7)H_B)?=.N2%XJ M7)&`PC11FL<)O]%IG-N#40JUNIP]A)#FV0Q(W>4>P5U+7D_JF"6B@%J=NQ&$ MU-T82.YHOW>BSSU,(.67J/:)/75,(5'G?P8A]3\'TF5EP6C):`6DMM9`:FO# M:!NA.,@DJ^NV1[:OKP29$S=K48GBM<@^N>R?>46=R@,@'?7$([?KWX],NVE> MV4NA*";W4K01&4)*/69`ZC'W2&;A[G--K=;YF7%70"MT9W<B(PBIMS&0>IMX M)/?GO)V?G)>%,OS?E$.GL%#G>08A]3SW*%R7RNY7LB29%1M:D]"&R#8D<6C) MO#@FM)RX"2V/9)>W'VCYWJ"XKMB7'.$4H_SED79]`JFX+\VN(H64Z.\]5H06 M><Q4$4MH[M$KAW]55(\<7>1PK'IP.'F3PZDJ'G8X@Y!FFCF09IH%HR6C%9#: M6@.IK0VC;83BT'(UU/WA__6LY<1-:)4HSEIT^'=CYQ1U;@V`=).9>%2_JTU5 M\7"_#R&D#C,@C>4<#N,T:1X"%5`,(YYB>00I]3@&4H\3]>@2EWV2`H70DXWA M&834T=PCS4H+(DLB*S:T)J$-D6U(XF!RE>@C@LF)FV#R*,Y3M,\JI:(\Y9'V M=.*>[(EYB?W=@B3O*AH[J9=P3X;V.<KV]A!".NDR('66`\4#9\KK!:1"AQ6! M1+<WAJ)ZG`"5NZJSBY.N\3:%1.C-WMX,0GI[<R#-*0M&2T8K(+6U!E);&T;; M",4AY8J;84C]O8._LV(BK40F;9E5K'_F%76J#8!T*!*/_-:GP0_LH!-'1[SZ M#B&DOC(@39&Y1_4ILE#%PY$]@I`Z'`.IP\F;'$Y5\;##&834X=RC,'&57:YD M23(K-K0FH0V1;4CB*'-ETC#*7MF[^TIV\`;N68FB@S^A`:3TL)XP2H&TFX:, M,B"UE3,J@-36B-&8T831E-&,T9S1@M&2T8K1FM&&T39"\;BZJF8XKG\O>Y2U MT?")A_N(NB044P^@_70I%:U3'H79HT1^G6HTNZ>MKGG\D'I_KZQ4Y"Z#GKK+ M/?+NSIH7W7/[LDH!M;J58P0AS?9CH%?J`;Z=^Y)UQZ3=*>S4^9]!2/W/@?1V M%T"EL\Z)_4J;)03J?*T@I+[60+7WNO%2OK>;G;8YF6YAYH#[*)SE$^[UX;Q^ M_$-6N==*#SLS\6KH49B^&`T\DOHI3DH)HY05AXPR5LP9%:PX8C1F-&$T931C M-&>T8+1DM&*T9K1AM(U0/-Y1/5IVA?7+DLM&9I?CD=M?!3M<<^KH0U$7B8%' MN@HG1%(B0S:4`>F4S#WRVZ6F?!MPMVWVK@74ZG9,(PAIN\=`M;-RXJ5\]:@A M%4DS+:>P4^=_!B'U/P?2VUW$SMHG]@L4E]"I\[6"D/I:`]7>Z\9+87/:;IO3 M[19F#KB/(U)\T8+:;+O/3+X2FT[1Y)P2.?=!;)J!Z,M'))UBN(8"A6G(2RE* M66H(I%D\`]+QRCW:+Y#=;LM^NJ"`VH&LO?N0YPA"ZFX,),W=WS,7S"&E"Z29 M'E-(U/F?04C]SX'T=A=`^P72[#V6$*CSM8*0^EH#U=[KQDOM%TC[_;1;F#G@ M/@Y/B>$H/%\)2B>^"TH=C:Y-!9>M4LHMU/LQ:Y^96D)?I;`V#A@EC%)&0T89 MHYQ1P6C$:,QHPFC*:,9HSFC!:,EHQ6C-:,-HR^B*T36C&T:W$8HC2<+MF$AR MXB:]E4A6=P1$OT5HP"AAE#(:,LH8Y8P*1B-&8T831E-&,T9S1@M&2T8K1FM& M&T9;1E>,KAG=,+J-4!PCKJ8=GBY?R3:^!!Y4#5HETEU6G\B`2$(D)3(DDA') MB10AB6_5E22/N-6R@AF>F%LEDFRNTV&/@L1JCH(#Z$6[$_MD,5$I6$^!U.%0 MT6&'&81"AZT+LRW)50H."Z"=P[CW7$GKB-[S1<<P4'Q13&^FWR(T`(J;;I[" M)BJ%IJ=`:G[(*`,*S;?MRXNY2L%\`531,\<5WEI<>/,HBJM2*D`#2&E=,V&4 M`H7=0+8R2,7=8';5N4II-X2VX@!Q%1$$B/L:QK]5IVJ5=95HUI4HZ(J^EPK0 MP"-YMP%M31BEK#ADE*EB,,?.S/XU5REX+");4>^TP[('>N<MAXZ=8KPJ`\6; M.5NX\U)RZ`ANPF8F"`6]YI'?S,HKT.TS8SJ%EFP%=#=I3`\A5.<_@U#M_CJ' MU*'M?0&!`PV*1\)5&,(XK5_QVD[<]'^)XH+$F2U(0%$FS,%.&D`H[/_2>OS6 MRYG)W2D4PPE,3^&&D*IK0P8A;4/ND:\M2,'1G*<*Z(3N@\=R<8>[<VW8X7\K M,<A7_M(XE"@^?--[KU[QE7E0FI+/X&(N)]"+;O',=$0*J3#R*L;!FY>A/1@+ M&4QI&W*@PX'O#8?N#XZ#W$DT#J\$OA,W@5^BL,(J7\7KI`0=OK,!A/0Q3\(H M!=+JT%#18>N9"F'L<D9%A.+XE,Z+^L7%YYM2LU,T/52B^(GLF7F'NM_VBO6= MYH4T'!*OMR\Z=LXO*!Z]E@S+P4@;OL5_!B'UGWM4DQ;JO<?='IX\W(KX2CCR MR:/M3Q[1K*(7PKS4*_._-!7-_Q+Y==!]AY#9A*:P+#==T]?><M1(LU9FL!3V MM=?S4S]^SEY`X8#KN*/#<\\;.IK//>T2O;;@><7ZJ/9">J>)MQXO>"U3FTJ] ME/MNUGUG5R3:-[0A@REM0ZYMV+W15+'@><.A^X.)-CPJ8:\G!?KC_I)#FT]0 M'KVVX)6*KP2\%](^2+QU]WT%^QYNMRCHO6(8>17C\(8V9'"H;<B!#B]X%>X/ MCH-$8I387\DP3MRD\Q)%"]X>!;UDYO.@[87"!8]0"JEPP7N#]8SU<D9%A.*$ M4'52>]."QX>S=HGB!<_6O_M>RGU]G(86=9JWKN&0>#V_X+D<;(ZH*2Q'06LL M#R%4YSZ#D+K//<)Z9W.P;^\!UU&7=^SQKSX4=^)Q*'IDYKXYF?6]5/W<AY#> M:>(1%KLS^B;,%$KAO`\FWNYIT1!"M8L=A-1]#E1.^XL3^G`'!`YXC_M:O!\Q M[3M.W/1UB5Y9[Z!8%U4#".G-)AZ9]<X&-A3#Z.(\"ZFZ-F00TC;DVH:*-W@+ M*(2^@[&.>]N=0/[CTUVG/,>$91^/3,";J=WW4J\$O#\E:0<DT(MNL65*/"FD MPK"K&`1OOC[JJ0TYK%=O\7`U]'UP$.0VHD%X);TX<1/R)0I7NLX>U21M"`4K M':,4*%CI%!VVGJG0_FC'J(A0')S2>5&_[(YV'?>GWH_XFUH=9\5T5XG,LD?9 MV"O6S<X!K(?!6>KY9:]S=F:?U*90DB$ZN*`.(53G/H.0A.?>$CW-S[V47PG/ M3]IF6UC`S($&Q:/BCC9(&>XE8%L0>MLK8)WRA!3E#']HTCCK>ZGZ`H47"E\* M8Y2J*43C4)'V7C!)=ZMBID+0RQD5$8K[RYT]POYZ97;[HXKLE/<CVK5?!G'9 M*:7B-P):IIS05RDT?<`H890R&C+*&.6,"D8C1F-&$T931C-&<T8+1DM&*T9K M1AM&6T97C*X9W3"ZC5`<2>[T=$0DE8>M:(:5*'PCH$-HP"AAE#(:,LH8Y8P* M1B-&8T831E-&,T9S1@M&2T8K1FM&&T9;1E>,KAG=,+J-4!PCLEP<$R-.W"R. M)0K>".A8,B"2$$F)#(ED1'(B!9$1D3&1"9%I2.(N<R?!<%K9!>U-?[JSX\^3 MP2-SH'`]\U+2H_OL;E><@==S'_3>"S7M:]N)2B&YIXR&C#)&.:."T8C1F-&$ MT=2C\J.74=]WPY-UU6;B37V_LQ)',5#0]XJT6ZGOO9!\$-H=K9JG]JNT$Q78 M=[L:!AHJ.NPK4U/>ESE%YBH`PX4:!AHI.NQKK*:\+W,4FZ@`#$_5L*!XV,)# MNANV^CU-EP_I0#(?]C%N__QNWPO5'P\A%,\6LQ5*O)0OD33.Z'$`S,CF?=\@ M&QU#"-6>%2%4VZ#<-*AMGTT6,%/7H!&$ZAHTAE!M@R:F0>?VKRM-8>9`@^(` M$5__>4[M.BMF7I<H.KJ=FUCN0Z\VRT(H.+EYA!?5+SKFT5\*G0/GI+*,!J$Z M[QF$U'L>>V^>MHWW`CIUWD<0JO,^AI!ZG\3>&Q>V4Z?0.>`]'GX1BH;_E?S@ MQ,TXERBL:'3WZ/`,'4`HJ&@P2H%T=1@J.FP]@Y!:SQD50&I]I.BP]3&$U/J$ MT11H9SWN=5=XL!N9YK'UDJZS8@;#HS!9MULF//M>\95L79IR7Y>^3[-4L$B\ M*9^M*RHH\"76]F8X6WM?=<DQ@Z7:!N6F06W[-F8!,W4-&D&HKD%C"-4V:&(: MU+5_J7P*,P<:%`?.?Z>DXYZ0VLCADHZ7JB_I>*&PI,,H55/8LPP5'0Z,C$WE MC`HU!>LC18>MC]G4A-%43='FZKB"4;>R8&0FYZ67B@M&=L;T50JW/&"4,$H9 M#1EEC')&!:,1HS&C":,IHQFC.:,%HR6C%:,UHPVC+:,K1M>,;AC=1BB>U\<5 MC+I<,/(H+!@Q&C!*&*6,AHPR1CFC@M&(T9C1A-&4T8S1G-&"T9+1BM&:T8;1 MEM$5HVM&-XQN(Q3'B&P4HTW#*ULU)VYV!R4*"D9=2P9$$B(ID2&1C$A.I"`R M(C(F,B$R)3(C,B>R(+(DLB*R)K(ALB5R1>2:R`V1VY#$H>"*4^'^\950\+6L MH.+5+5'P9G]?T>$E<P`AV>'OMW-G=H^5J!16IY31D%'&*&=4`.FA:,1H#%3; MU(E*H:E31C-&<T8+1DL@;>J*T1JHMJD;E4)3MXRN&%TSNF%T"[1K:A1NY_^5 MVM_.2IR0/`JCD-'`H[C*:O^P3*)2Z)V4T9!1QBAG5'@4-'7$:*R*P?2P?_YM MHE)HZI31C-&<T8+1TJ.@J2M&:U74IM('_C<JA:9N&5TQNF9TP^C6H[*I<<S) MT>N(%'?NQ$UPE2CHAKZ7$A3<LZE)#2`4G<?LETXD*H6.28':^P\W#!EE0+%Y M\TI#KE(P7P!I*ADQ&@/%YLT+-Q.5@ODID+9^QF@.%)LWK5^H%,PO@;3U*T9K MH-B\:?U&I6!^"Z2MOV)T#12;-ZV_42F8OP6JR(T22U&<_JUG4N?.B@G?$D7A M2VC@%:/<V+)_SR91*=Q1ZE%@?L@H8\6<4<&*(T9C5=3)1TV=J!2:.F5;,T9S M5EPP6K+BBM%:%6N:NE$I-'7+MJX87;/B#:/;2#'.C:Z^^O;MW[D3-\'E450G M;-N/UGG%^CHAA'1B)T#EHSGY2]SQ&[TIKL?3T'ST;@@I_9J0#$A]Y4"EK],3 MD\T+7*_U-8*4^AH#J:\)$.[+?7MC\)]Y5VL*\5K7,TBIZSF0NEX`';C-):[7 M^EI!2GVM@=37!NAMM[F%>*WK*TBIZVL@=7T#=.`V;W']D*]XFHC4,=/$B9MI M4J+H&5:[;9Y8]L^]HIRE]V<B6[`;0$AO-O'(O^S7[9Z<RI\!T?_,JI?"0GA( M:-N7#8:0TD<:&9"ZSF/7YV;B%]"H=36"E+H:`ZFK2>RJ>V9GZ!0ZM<YFD%)G M<R!UMC#.6B=M[4_YS73I$A9J7:\@I:[70.IZ8UPWZD=S"PNUKJ\@I:ZO@=3U MC7%M4N`M-`ZYBB>-?<)07UHXYR<)0/':8M:`OI=Z96WQ#R7T7A/HE1FB<V+> MQ$AQ7>;DP<DXA)`FHPQ(7>5`R(--LU$L(%#G:P0A]34&4E\3(-R6&<,IKM>Y MFD%(7<V!U-4"Z-!M+2%0YVL%(?6U!E)?&R#<EOV;N5L(U/FZ@I#ZN@927S=` MA^[K%@('?,73X+A'.^?[1SO8"EYZ%*\='?-QRSX4Z]<.;UUO-H'U\F]:&*LI MK!Z:\>7K#Y#2Y)(!J:>\UE,!A5I/(TBIIS&0>IK4>II"H=;3#%+J:0ZDGA:U MGI90J/6T@I1Z6@.IITVMIRT4:CU=04H]70.IIYM:3[=0..2I#/X/SU_O[U\& M=R]WO_ST_?[IM_O^_;=OS^\^/?[Y0Y)IH]&6=^WV_-W3_9>?WW_L=GH?Q;K$ MO;DB3S)[[I%7U96N7-E5HZU.H]F[+?\4K;GRL776^RCO[E=8DRONV]FJKK3D MRNYQA[76D5;+@]T*';GBWNRNNB*MEO=Y^8J4!WKNN,97/C9Z'ZOXI2CLLIEI MUZ7<?J6\W&+5'7YL]3[*)Y_9\:6[\RK>[MU6W?;'AK2T+`;8)LF5VT958Z6` MTW.G9_8N=9R>J])476G*E2H=*>'TW/F9=:22TW/':+XB!9V>.SKS%:F#]5R5 MJ^I*4ZY4Z4@)K.>*#:PCE;">JSGP%2F(]5R=@:](Q:OGR@U\12KM$BZ5HR8Z MEY4Z4KKL]2NO2+VRYZJ1[$>*0W*EJ@52JNRY"A#K2,6RYPI!?$4*ESU7_.$K M4IGLN1H07Y$"9<^5@OB*/)WIN><E%5?.3Z5'JWI''J9(CU9=D6<J$HE55^31 M2L\][&`_4@"7V*G2N12=R\HK\HQ,1J%*1QZ,]=RC*O8CCR^DWZITY#F6]%O5 M%7F<)?U6=46^6*WGOC:-_<AWC<F5W1IA9K!\SY9<J6J;?`]=SWV9%EN35]M[ M[@7QBBO=TYY[MYJOR&O2T@=55^2EYIY[;YEUMHU6;UM^\,6T^E+:=EG9MKY< M<5]-QM;D&P![[OO]JJYTY4I5O\GWO<F5JGZ3[SJ3*U5^Y`L#>^X[SMB/?&]@ MSWW5&5^1+PN44:AJVU+Z8%G9!RNYLJJ\LI8KFT95AE\WVG*E*L>O&QVY4M6" M=:,K5ZIZ9RI^II579G)E5GEE+E<6E6V;2]L6E6V;2]L6E6V;2]L6E7XRL997 M6LO$6EYI+1-K>:6U0EI=5%X9R951Y96Q7)E4WNE8VC:I;-M8VC:I;-M8VC:I M]#/MRL)4$5.7XO^R4J,O5_J55P9R):EL\T#:G%2V>2!M3BK;/)`V)Y5^4O&3 M5EX9RI5AY95,KN25;<MDV*KB,Y.D5]4S15=2:T6/C;J26"OX6+J^RO[X7#8+ M%?*775DB*GB_*PM$!1](-U79'TCRJ9)/N[)`5]@9=F5Y=OS#/ET^__+3'W>_ MW4_NGGY[^/'\[MO]%]FKG^Z^!>?IX3?W.*K\QXO_@P^_/KZ\/'Z7[;Q\(/C^ M[O/]DQ.00LN7Q\<7_,,Y^.OQZ??=>>"7_Q<```#__P,`4$L#!!0`!@`(```` M(0#[]LS:RR```#F[```9````>&PO=V]R:W-H965T<R]S:&5E=#,T+GAM;*R= M6U/<R+*V[W?$_@\$]]O0YZ;#]@[3.I\X\UTS&-O$&.,`9F:M?[^S6I7*JGRE MZF[6=V/PH[<R4W5(E5+=XN/__NOIY\'?#R^OC\^_/AV./AP?'CS\NG_^^OCK M^Z?#F^OD?Y:'!Z]O=[^^WOU\_O7PZ?#?#Z^'__OYO__KXS_/+W^^_GAX>#L@ M"[]>/QW^>'O[O3HZ>KW_\?!T]_KA^??#+SKR[?GEZ>Z-_OOR_>CU]\O#W==- MHZ>?1^/CX_G1T]WCK\/6PNIE%QO/W[X]WC]$S_=_/3W\>FN-O#S\O'NC^%]_ M//Y^96M/][N8>[I[^?.OW_]S__STFTS\\?CS\>W?&Z.'!T_WJ_S[K^>7NS]^ MTGG_:S2]NV?;F_^`^:?'^Y?GU^=O;Q_(W%$;*)[SR=')$5GZ_/'K(YV!Z?:# MEX=OGPZ_C%:W)]/#H\\?-QUT^_CPSZOS^\'KC^=_TI?'K]7CKP?J;1HG,P)_ M/#__::3Y5X.H\1&T3C8C</YR\/7AV]U?/]\NG__)'AZ__WBCX9[1&9D36WW] M=_3P>D\]2F8^C&?&TOWS3PJ`_CUX>C13@WKD[E^?#L?D^/'KVX]/AY/YA]GB M>#(B^<$?#Z]OR:,Q>7AP_]?KV_/3_VM%(VNJ-3*Q1NBG-3+:V\;4VJ"?UL;X MPW@Y&\WF)I"`<SJZ.0/Z:1LNQ7F@W=RVHY^VW43:[7CB"VN#?K[[Q&DE;N*G MGUT<T_%LL=R,0.`$3FQ#^LG.)[MUV8BFV<:G^:5SNN^HCWCNF%\X@KV[<$0S MKXU%IN!TQ]/@>3=R)M[BPTZ=-^+Y9GYY?Q?PY#-+[OU=P--H)/-H_&$YFTWG MRP49WG$RCG@FF5^Z8/8WP_-JY$RLO8=US%/,_&*#V7%!CWE>F5]LTY,/H^GQ MMDPPYJED?MF[`X[:S+A)M-'=V]WGCR_/_QS0U8NB>/U]9ZZ%HY6QS"FV79I= MTAW*N91LC94OQLRG0^I32J>O=*'X^_-B?/SQZ&]*[O=6<XJ:L:]8L\)D<F,V MTB#6(-$@U2#3(->@T*#4H-*@UJ#1X$R#<PTN-+C4X$J#:PUN-+AUP!$-<3?. M-+3_/\;9F#'CS"-TRD`&?J(&E17<)-(@UB#1(-4@TR#7H-"@U*#2H-:@T>!, M@W,-+C2XU.!*@VL-;C2X=8`WJ'1E\`:U?U_$:]2H:0?DK-'9_,0?K%.K670# MO`82`8F!)$!2(!F0'$@!I`12`:F!-$#.@)P#N0!R">0*R#60&R"W+O&&E"[8 M>PRI45/FIBNKDW=':DQ;T<1-SK.%3KV=J%NF0&(@"9`42`8D!U(`*8%40&H@ M#9`S(.=`+H!<`KD"<@WD!LBM2[QAIHW/'L-LU)MAYL$Y;<ET<_NTN52N@41` M8B`)D!1(!B0'4@`I@51`:B`-D#,@YT`N@%P"N0)R#>0&R*U+O`&D&ZL]!M"H M_0%LR>;>N1T_#2(-8@T2#5(-,@UR#0H-2@TJ#6H-&@=X?41I:8\^,FJ_CUHR M'<O%J".2[V8JDT560QFVRXGCI=J4Q)V(5U0")`62`<F!%$!*(!60&DACR>;D MO5ZE^Q^O5]L=^P=S+_7VX_'^S]/GMJ31LQF8T,Z\W:\;(WYGM\3M;"!12R:T M'9&NU5>2N!-U70LD!9(!R8$40$H@%9`:2-.2]E2]KJ5+Y'_>M<:(W[66+&4> M=T0Z$N9QJYF8,?O[\_AX-/4OZW%WO.OGSBJ3M"/#?K+.CO6CEDK>'6>K16>5 M2=F183]59\?Z4>NV[HZSU::S2L0;)U/9\0:J9ZY388TG^T;N#PDC<M%-Y=E" MG?K:JLRMNJA4W!&+O%4Q6ZK18I67EF9J^YVPBO8-G</Q7-U(IZP*A96Q*!A6 MSBHOK+G:01:L"H95LBH45L6B8%@UJ_RP5,\WK!H*RY\SYLX8*QU[YDU3#52K MVR)3R.W&;+90JW7-#2GWB$J=4,2B29<I8K9.U]BNW7BN)FHB#46E$TK*HE`( M&8LDA'RG$`II.!Q"R:)0"!6+)(1ZIQ`::=@;@C\=:`)ZTV%+"C%RE4):-';2 MNBGWDHI0;P"VIF5%4D2)N9V@A)%83P4-6\]8)*9R1`4CL5X*&K9>L4BLUX@: M1AOK?J_3@O9Z_5V;%U,1UX/1HJF;>TY4=EW;=EO2>6O)U$)EP6$ZMRKZX:B4 MPX0=#B6HS81(6>7&KA=OQJ)@6#FKO+`PG=O@@V&5;"L45L6B8%@UJ_RP5/9K M6#44EC^32!6<2=?/OVF];JU;&S-J7;?(6]<=DM'6(Q299RUD:B+WY#&BQ"+' M>BIHV'J&IG)$A9CB350I:-AZA:9J1(V8@@V9N4]V+ZY;LFE[6ZWJ5FH^G)K' M3J9#_3W:S-]8K47%IQPABA$EB%)$&:(<48&H1%0AJA$UB,X0G2.Z0'2)Z`K1 M-:(;1+<>\M>B*0#L,?IMO8!>?L=&1+"+)VUH@B1#&B!%&**$.4(RH0E8@J M1#6B!M$9HG-$%X@N$5TAND9T@^C60_ZXFAH$CZM9_%M6=5NR\,;55C&ZD5Z; M-4^+6@I?$9`82`(D!9(!R8$40$H@%9`:2.,2O\MHZ[=/EQFYNORTR"W$F$?> MIL_<BRQ>?JS(N\9"W8M-R=XZ090BRA#EB`I$):(*48VH8805,//LWNOD]^TB M;7G!34,M\OH>4+1Q3]<E=SC&4`83%6>Y!%&**$.4(RH0E8@J1#6BQJ*>@ICY M?,-_WM,;*_XL9R0W(&M!PQN5R(J&JV(BZ+I=##-*!0W[RL340&5,!&RX$,., M2D'#OBHQ-5`=$P$;;L0P(2\+F3L<;]C"B7LC5^-C+!"BV=_=W\P6<[7WL@W- M#U&I;5S$(KFVQX@21"FCD/6,16(]1U0@*AF%K%<L$NLUHL9#_D!0CMAG((Q< M#42+)F[]9[98Z(&P#>D:$!@(*_*N$'!G:VY\*8:QZQ`+3E9E;MD&':8L"D65 ML<BU--91Y3M%5?39TA?*DD6AJ"H6!:.J=XJJZ;/E1.5/&'+H39AW7=K&QHJ: M1RWR"B3T,4P]CUJ5F="#PQI9ZV/9P\463=P::,^DL=9I)SEH/67KH1`R%DD( M^4XA%-)P.(221:$0*A9)"/5.(332L#<$?SJ8FL+N.W`:$ACW%CGUAK55A:N4 M+))*7XPH8227\510[^EM2EX9B\1ZCJA@)-9+0</6*Q:)]1I1PPBKE*:4[_7Z M^Q9A5^3@*_;IQC!MY-VK*E0IK<AL?P=72<0B6E&="+)F;%7;<KD-U+7EY*>V M2,D.0U%E+'(M053Y3E$5?;9T5"6+0E%5+`I&5>\45=-GRXG*7[RFJ.$N7CV- M=BM1FM'3R;Q%WJ+ND$P()[#VT8,UY98H$246.=930</6,S25(RK$%"^+4M"P M]0I-U8@:,05[XOV*&6,L9C!R5^]LH6K^:ZO:<@EMK=,.GCLAYG:"$D0IH]"E M*6.1F,H1%8A*1B'K%8O$>HVH\9"_+&BQ>LMBR\V)D:N]3(NV[8EM0_K1I4A< M$584S`VQN53NL"?NL:4=IM94,+MG+`I&E>\45=%G2T=5LBC45Q6+@E'5.T75 M]-ERHO(GC"G!A/+H3I]X&ALK:AZU:-N>N%5M6=!6)+O!V#K<MB?N&@[/TM2: M"H:0L4A"R'<*H9"&PR&4+`JGANYD.*W5.X70L/6!.P-O.M#5RY\.X?RQD?OC M;A'-00YS+6BX#R(6R;XR1I0P$NNIH&'K&8O$>HZH8"362T'#UBL6B?4:4<,( M]\03&OC_?!%NK*C!,(:W[8FY72@_12P*YJ?8JLQ&H;LLX*UJGRTG/[5[8A:% MHLI8%(PJWRFJHL^6CJID42BJBD7!J.J=HFKZ;#E1^8O75)="N7RW/;&IO:MD M;I&WJ&TI*]03D6U',Y^308PH0>NI()E(SFFW-[IH*D=4B"F.H10T;+U"4S6B M1DR1=7\T:/B[T3!EJBVIU,@WJU=B6HS59]%.J39O5-YC^\58?QY.5'S*$:(8 M48(H190ARA$5B$I$%:(:48/H#-$YH@M$EXBN$%TCND%TZR%_]-WBT@ZCC\6E M28O<KZ$@BA#%B!)$*:(,48ZH0%0BJA#5B!I$9XC.$5T@ND1TA>@:T0VB6P_Y MX^J6KW885ZQ3F3VKN29W*7$-)`(2`TF`I$`R(#F0`D@)I`)2`VE<XG>9J9[P M9<ETF2[5['2+86Y(]57)(MFNK5D5OBJU[4SJ[G8ILZ7Z7'9L39&*DVB"*$64 M(<H1%8A*1!6B&E%C$=WWPD7(+<R\O^^Q7C.QR.W[#CG=JA]8VG:4..VS6'7M MBD4@W=X99I2*^V%?F9@:>,8L`C9<B&%&I:!A7Y68&GC&+`(VW(AA0OZ2H?GK M+9DM>P<C5SM_B^BFT9GC:C36DU85O/>-6.1NXFP[00FJ4D:AV]J,16(J1U0@ M*AF%K%<L$NLUHL9#_D"8FVXW=VT9B/8>G3[!Q(-\:K9J9L=&.<<9"+6O6UM5 ML'(5L<C-6_`$(+8JJA&:F;A8JB^X)&S%O3O16^N4133.$K6:/1F+@O'D?CPG M(_58M&`KH7A*%H7BJ5@4C*>V*KJQ,OTS.M:[YX;-#`3DS0_:G>TS/S9R?Z%: MY-?)EBHKKJTJO%!9)%>LV"+:SVQ.=C;2'S-)N-%`=:B]&6=1:*UE+!+WN>]^ M?+PX5G.HX$8A]R6+0NXK%HG[VG<_/9DH[PVW&?#N#S5YWR,5F`%5.=DBE0KT M9ZZY86BJ1RR2DXW9>CNOY^.1^AQ+PFT&YK4=:1MVR'O&EL1[[GN?GDS5QYD* M;A/R7K(HY+UBD7BO?>^ST;':S#7<9L"[/]"4/_89:"-7:[I%QJEDSZ7JD;7Y MR"DUW+*FK4A.-K;M>$U/ER.=+A(V/3"O[5#OX#]C2^(_U_[IK5DJ717<*N2_ M9)'72VJ%5BP2_[7R/YN,3M3EM.%6`_[]X:8YX0WWNVY/IL:*F@4M4LM=K<HU M-PQ-^8A%T@NQ1?8R-IG.IJH3$FXT,.?M)+!QA]QG;$G<Y\K]Y%B[+[A1R'W) MHI#[BD7BOO;=CV<GVGW#C0;<^U.`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`,M1/8YD(;65/NTV9$B46.]530L/4,3>6("C'% M^XA2T+#U"DW5B!HQI2O&L_T*41OY9OE*3(NQ*D6<6I4IB'4+;':B[V-%Q:<< M(8H1)8A21!FB'%&!J$14(:H1-8C.$)TCND!TB>@*T36B&T2W'O+6XHPRA)?3 MPU?2C=Q/WA9108P'<8TH0A0C2A"EB#)$.:("48FH0E0C:A"=(3I'=('H$M$5 MHFM$-XAN/>2/JRG1[+Y#FK45'??Q@T7.TV8@$9`82`(D!9(!R8$40$H@%9`: M2`/D#,@YD`L@ET"N@%P#N0%RZQ)_"&DKO,\0&KE:FBVBFI8LS0XYB5EO<F=6 M1#^<[*WJ3[&HV'K"2!RF@AQ;RF'&(M?A7-\SYZ)BAP4C<5@*&G98L2CHL!85 M.VP8B<,S0<,.SUGD.U2%MPM1L<-+1N+P2M"PPVL6N0YG)VH,;T3%#F\9;1SZ M$Y(VBMZ$W.S;3C[0+GK/]]+/C"4U5UODS55`D6UH2G3.S%1UFUA4?%8)(^G& M%%'&R#4_UX\$<E&Q^8*1F"\158Q\\VHQU*)B\PTC,7^&Z)R1O$7B`M$E([%U MA>B:D1^JJM;?B(I#O66T,>]/'U/R<2])>MN_TZ=Y9L:*FCHM\J8.H,@V]#^[ MH[_F%XN*SRBQR#&?(LJP88ZHP(8EH@H;UH@:;'B&Z!P;7B"ZQ(97B*ZQX0VB M6Z^A/P-T(6_+9A,K=C.+W/N*^;&Z^UA;5;A2P"+9M\:($D0IH]"]=<8BL9XC M*A"5C$+6*Q:)]1I1@^B,4<CZ.8O$^@6B2T17C$+6KUDDUF\0W7K(GT2F`N>F MD2V3J"W8>3O;%GF/U^;'<'-J&U)!22XU*E=',RNB[7,G@L).;%7\P9'YR>A8 M78@3-N3F6UVF2%D4"BEC43"DW`]I/#K6#YD+MA.*J&11****17)=JBT*?]VC MD8;2N[I3SE@4"N&<11+"Q4XA7$K#X1"N6!0*X9I%P7&YL2J>*CV/3F[9T,#` M^(N%0MIGL1BYNKA:Y&=<-7W7LU:U)>-:D:S\F-L)2A"EC$)Y)6.1F,H1%8A* M1B'K%8O$>HVH073&*&3]G$5B_0+1):(K1B'KURP2ZS>(;CWD3R)30MTCXQJY MFD0MVI9Q;4.:)ETRU<L]FEE1<!G%5A581@D;&EA&[1-8%H5"RE@4#"E7(4WF M"_4HL&`[H8A*%H4BJE@DZ:ZV:%O&M;T;"N&,K8=".&>1A'"Q4PB7TG!X%ERQ M*!3"-8N"XW)C57:JC(_Q8?DM&QKH%6^QS/<KIV_D_F)A1$/1+8/YL;K'75M5 M...R2%9^C"A!E#(*Y96,16(]1U0@*AF%K%<L$NLUH@;1&:.0]7,6B?4+1)>( MKAB%K%^S2*S?(+KUD#^)R/H>&7=NY&H2M6A+QN6&H644L2BXC&*K"BRCA`T- M+*,VX[(H%%+&HF!(N1_2Z'BB=BT%FPD%5+(H%%#%(LEVM45;$JXTE,6NKWEG M+`J%<,XB">%BIQ`NI>%P"%<L"H5PS:+@L-Q853=3\--1MVQH8&#\M4+>]EDK M1KY9*W*VB[&Z^3N=MRKO^>7\6'\R2%1<+(H0Q8@21"FB#%&.J$!4(JH0U8@: M1&>(SA%=(+I$=(7H&M$-HEL/^:-/4V2?T3=RE2E;Y#Z_G`.*$,6($D0IH@Q1 MCJA`5"*J$-6(&D1GB,X172"Z1'2%Z!K1#:);#_GCJI\UA*L\<WR@8)'S_!)( M!"0&D@!)@61`<B`%D!)(!:0&TKC$[S)=7]_295A(GT/5?"U(TJ6^/D4LHF73 M[5CQC[N)BK-E@BA%E"'*$16(2D05HAI1PP@?8LQU"?M=#S$V5E0::BO;SE.& MM54Y*++(>XB!+[D6E?1T:][Y3G**J@Q1CJA`5"*J$-6(&HO:<_2GLRFMNE6' M]_6T+=`Z'_V<=X5=[IVU()G`.,O;=L-?0+962,"&$S',*$6424/[%6#U7#@7 M`9LIT$R)J)*&UK(J8-<B8,N-9\8?$MK]>4.R)<,8N9KE%GGWMB-5"%G/6]66 M>ULKDN>8,;=S\]!\I#[MG+"*+AE=MIJ/5,>DK!IU@YDQ$H\YHZ#'@E5!CR6K MQ&/%2#S6C((>&U8->?2'U11]W)6V95AMC<A=4BWR/D@_'ZE9O)[;AC1P7<?C M*K,B.>78MC/O+NS:3?2`)6S=[Q@8UBX&GN\9-Q2/>9_'N?Y3CP4W#'HL626? MUJX8B<>ZWZ-ZL-EPPR&/WK`N]JM$;>3^:F5$?=9U_'RD[I765A5>K2R24XX9 MV1<ZJ`)7PH?=*3R;J5OXE%6R:#)&XBIGU+I2-@H^&O14LDH\58S$4\VH]:02 M6\-'ASSYX[=?$6B!12"+U+)4I[_FAL%ER2(YU9BM>\M2URD3;C@T9=NJ#ZMD MD62,Q&/>YW$.KP7@AD&/):O$8\5(/-;]'E4=H.&&0Q[]8=VO7K'HZA6<L$X9 M><MRK.;:VJJV+,O6NOOE-6[7NU82/CHT@^UP6K.R5C)N*)V;,VH]3=5UNN## M05<EJ\15Q4A<U8Q:5S.5PAH^/.3*'T`:YCTNEPLC5WFU1=ZZ'.DWMJVY87A= M6NMRKK%M9U_CH2XA"5NE=EU.[TFKUJRLCHP;BJ?<]Z0NM04W"'HJ626>*D;B MJ?8]J:G><(,A3_[PT2#O,WQ&KH;/(G_]J>F[7K2J+>O/BN148V[73E75J0D? MI7:AX>M\<]+(N*%XRAFUGE3\!1\->BI9Y2X_.*>:5;WGU/#1(4_^\.DJQ[MN M"\V?9=>CVB)O4<['JO_7W#"\**UUZ>O8MK.+4DW@A*T.36";5:U962H9-Q1/ MN>\)1M7:"'HJV:QXJAB)ISKHJ>$&0Y[\4=5EE?`MR**M9K@?ZK+(^7+66I"S M5M2`1BR2+T7&B!)&TB$IHHR1V,H1%8S$5HFH8B2V:D0-HXTMOT=-M<*]J7O? M.FEK'EY'M\A[18G^&.UZT8JV)#\KDBD5<[LV4<`RL0V&$H5=)IUO27[@*0]Z M*OAHT%/)*C?Y@:>:5;WGU/#1(4_^H%+:"0[J;M^<7!@SZIK6(F_Y="BT?%J1 M^\U):]U!B46.]111A@US1`4V+!%5V+!&U'@-_9XV=0)W^6Q)2$:^Z5'IJ\58 MW6F=+EJ5_U1QHF;Y6E0\?R-$,:($48HH0Y0C*A"5B"I$-:(&T1FB<T07B"X1 M72&Z1G2#Z-9#WN@O]RN=;.3^>K+(?:J(*$(4(TH0I8@R1#FB`E&)J$)4(VH0 MG2$Z1W2!Z!+1%:)K1#>(;CWDCZM;4MG^IW.76%*QR'FJ""0"$@-)@*1`,B`Y MD`)(":0"4@-I7.)WF5NNV*'+L%RQ;)'S&&LM2-(E5()9Y&T@]=]8C$7%V3)A M)/N*%%'&R#4_GZB:=2XJ-E\P$O,EHHJ1;UX5'FI1L?F&T<:\/Q1DJ[LF[3`4 M1JZR4HN\H0`4+2VB']T]YGRB[B1B47'H"2/IF111QL@WK[Y:EHN*S1>,Q'R) MJ&+DFU>7XEI4;+YAU-/QM#GS.OY=>^FEL:+&HT7>>`"*;$/OH>]<OY$R%A6? M46*18SY%E$E#=[A5W2@7%9LOT%:)J)*&KGE5[:]%Q>8;SY:_$,Q-+&_.S$(P MXS&>F2^BAK=I2WOWZSRZLLB[G9E/5(5W;57A^QD64;[KU@U^&<BJ[,O!9I.I MVO\E;(;.JS.CDV/*(KGUR!@%W>>^^]%(_TW7@LV$W)<L$O<5HZ#[VG<_'2W5 M_7C#9@;<^_/`K1KLD!"Q:K!LD5_TT2.RMJKP&\!8)-DI9NOM"Y7UZX(3;N%F M*AQH&[14"S)N)YYRWY-:7`4W"#DJ622.*D;BJ/8=Z6>!#;<8\.2/GKE5AE4\ M_[`9C!^/]W_N]'W@97O#[58H&'GU6?UX86U56Y8TW,['W*Z]G5_"-_GX^,`$ M;FL4+)+UDS&2SLX9M:[TBRH+/ASR5+)(/%6,Q%/-J/6TF*NK<</'!USYXVI* M`NZX;LG);07!&\"N\L`7@_6R0\-),6*1U,QB1`DCF>@IHHR1V,H1%8S$5HFH M8B2V:D0-HXTMOT?=8L1>U[NN+,$=>;JT-0A**]W593Y567AM55LRGK4N\RAF MZ_95TJ.%VC4F;'@@0=C580U+KV;<3GSEOJ_16'\\N^`V(5\EB\17Q4A\U;ZO MZ<E<=5C#;09\><-YXE87ME^V-G)_W\B(^LD91'7OLK:J<(9CD9QLS,@]E_E4 MI82$56Y*P!=7LDK23\9(/.:,?(]J"UJP*NBQ9)5XK!B)QYJ1[U'=GC6L&O+H M#ZLN+FQVI?M>STZPYF"1VJ2HE;7FAI0HNSFA=Q,1BZ0G8K;>;E)&^B6X"3=Q M>TK;35DDJRAC)*YRY4IM?`MN$?)4LD@\58S$4ZT\+=2.J.$F`Z[\<37UB]VO M9R=&KI9KBYSR]]JJ"(5&R[:3ZT;,[00EC*1'4D09(VF8(RH8B:T24<5(;-6( M&D8;6WZ/4K=[/?J^E6*LJ(YND7\S-U7W_NN35K4E+UH1#4&WG/!FSIJR-W/S M\0*RI#7C9A!</5U`?)G..,:@^]QW/Z(W+7\\^IO^(M#]YX^;*VG!9D+N2Q:Y M&7.7LZ]]][-C_=<$&K8\X-Z?%"2"23&:?3#/D=_,[<!NS[9.C!DU*UKD+;\. MR>CJ88FL*>=!5HPHL<BQGB+*L&&.J,"&):(*&]:(&J]AV]-'KS\>'MZBN[>[ MSQ^?'EZ^/ZP??OY\/;A__NL7S7&ZV#GXX.7AVZ?#+XN3U1>R1/.R:]`>H8=9 M*_,$I>?(\GAE:O!XY,OL>/6%OMN'1^B%H2OSELJ^(R,ZTM?FRWR\^D)/\'K: MT!'SG;&^(Q,ZLOF`OCZ?&;GI:?%E-%M]:;\VH5O0D=M17YO3T9R.S/NL32:K M+_0NUI[(Z(CYJY!]1Z9TI&\,J,B\,B5D;$-54#K29XWJ<72DSQI5GE>FZ(;6 MOHQ67_J\G-+0](W,*75_K]Z<8I_]Z>H+[8/1\2F=>1^G>O[*E#*Q!97U5Z9H MWW=D0D?ZW%,%E([T6:-:_\J4.=$:E?Q7IMJ)1T[IR&GO$7KLL5KW'HGHB'F2 M@=:H&$]'^J*FLC`=Z8N`'H"L3.T7K9W.9ZM3^LH-'J$O>JW,%X[P"'V[:V6^ M(]5W9$Y'^MK0%ZA6YJL]?6T6JYB^88)'Z%LP*_-%%SQ"WV(A/WU'Z.V(*_/N M,FQ#+TE<F5>8X1%Z,^+*O/>P[\B4CO3U&[WYC([T6:/7)5+>Z#M"[YA<F3=( MHA]Z#R`=Z?-#;WZC(WW6Z,63*_/&-[1&[Y]<F1>_X1%ZZ>3*O.P-C]!;.5?F M)79XA%[%N3(OVNP[0JND-VIZ]QT=Z;-&[^=<F7?>H35Z3>?*O/H.CT03FE7T MWH*^(S1WZ$\?XA'Z@XVKO/<(_7E%LM;7YI0B..V-8$U'UKU'(CIBWGN*$="; M*>E(WYC2BP?I2-^9TNM25^;M@FCM=+1<G8[Z+A-K.K+N/1+1D9H*-F@M&IW0 MD3YK#;5I>H]$X^-5/.Z[(&=T).\]4M&1NO?(Z8)28D]DZP4EQ!X>T:#UC5E$ MI]BG;Q9TY>JS<[**^\X[.UGE?;RBCMKPH^Y:__KYX^^[[P_UW<OWQU^O!S\? MOM%6Z7BS*WUY_&YN7-K_O#W_IEWGX<$?SV]OST^;7W\\W'U]>#$"VL)^>WY^ MX__0$!W]\_SRYV8[]OG_!````/__`P!02P,$%``&``@````A`%)9?JTN!0`` MR!0``!D```!X;"]W;W)K<VAE971S+W-H965T,S$N>&ULK)A=DZ(X%(;OMVK_ M`\7]B""V-J5.M1\(BM;6UNSN-8U1J19B`=WV_/L](2%`CNUH[=YTVH>3-\F; MDP0R^OZ9G+0/DN4Q3<>ZV>GJ&DDCNHO3PUC_ZX?[;:AK>1&FN_!$4S+6?Y)< M_S[Y_;?1A69O^9&00@.%-!_KQZ(X.X:11T>2A'F'GDD*3_8T2\("?F8'(S]G M)-R5E9*3876[3T82QJG.%9SL'@VZW\<1F=/H/2%IP44R<@H+Z']^C,]YI99$ M]\@E8?;V?OX6T>0,$J_Q*2Y^EJ*ZED2.?TAI%KZ>8-R?IAU&E7;Y`\DG<931 MG.Z+#L@9O*-XS,_&LP%*D]$NAA$PV[6,[,?ZB^ELS:YN3$:E07_'Y)(W_M?R M([TLLW@7Q"D!MV&>V`R\4OK&0OT=0U#90+7=<@;^R+0=V8?OI^)/>O%(?#@6 M,-U]&!$;F+/[.2=Y!(Z"3,?J,Z6(GJ`#\%=+8I8:X$CX69:7>%<<QWKOJ=,? M='LFA&NO)"_<F$GJ6O2>%S3YAP>90HJ+6$($2B%BV1UKV#?[3TSE1LV>J`EE M5;-N_48]6]2#LNKVS7:@%^4PH13Q]EWM/(EZ4-[5SD#$0_G0>&`YEOV#\JYV MGD4\E`^-!U)1S#?+-#'A-YTS98;`/P^-R:S2POS%+!D\)\L4GX=%.!EE]*+! MO@$MYN>0[4*FPT2JY.:)(=/]JVR'-&<J+TQFK(-5D,@Y+-&/R:#[/#(^8%E% M(F:*8ZQVQ*R*8&N(R<Y5L%"!JX*E"CP5^"I8J6"M@D`%&Q5L&\``:Z6_,$'_ MA[],AOE;.3.M0&UX3S&SBJBJS%6P4(&K@J4*/!7X*EBI8*V"0`4;%6P;H&4F M;&$M,Z_OP%5.LFC8:QLY:5N*25,1,Y#&SA"9([)`Q$5DB8B'B(_("I$U(@$B M&T2V3=*R$);X`Q:R:-@98*NMU[79;2?:E`?UFHO?M@;MH)D,DNF(R`(1%Y$E M(AXB/B(K1-:(!(AL$-DV2<M6./0>L)5%E[969DPYL<L7D7+KFR$R1V2!B(O( M$A$/$1^1%2)K1`)$-HALFZ1E&)SV#QC&HMN&<6+7ZU8%<Q4L5."J8*D"3P6^ M"E8J6*L@4,%&!=L&:'D$RZ[E$3^;.P,PM3C&T=N4\M?&*]M@#\Y@?C(SD;9U M@@QK[R2IEWE?.9OG/*8'6[/<"FRSWU[E"QE4);:+R!(1#Q$?D14B:T0"1#:( M;#DQR\&WS&9?:_A%Z$&SF4C;;$$:9DM2&XG,YC$]-HL?$ZMKVHK/\KGT6:I6 M9"G)U^UX4D>THQR/OGQ>J:ZD:D76DGS=3B!U1#M*<FWD\TIU*U6!M.8)CIG_ M/D],I#U/@K0/L6';]AD/LN!=3ZX!-'4B!DX*&6/U%:$%#^JQA5R]+UM/BOGN M%26UM>4=/?*NZ*`>^??T:'5%2>W1^HX>!2*FN9>@'FU$$%\#BC?;VSUI)0S[ M'KN9,3_H&7+AEU\X3*:=,Z7R6+<:B[M&]<RJ%LU%4*\^[1<8N;54M2B6-?I: MW<-2/D:K6JI27]?H:_4`2VTP8M<QS"SN#)\-?KW"OST3DAW(C)Q.N1;1=W9U M`I_`DY'$_%YGVG?@_0&ZI_#YP(&-_0H?.HMR*I1X;^C`1H;C@Z$#&P_F<)_T M8EWA4W;/=(U;#GRQ8)UISX'W<,Q?;.<%#,(/IK8#;YC`#3D"N$<ZAP>R";-# MG.;:B>S!K&YY*F7\)HK_*$0.O](";I#*=#["C2&!C^AN![:9/:5%]8,U(.\@ M)_\"``#__P,`4$L#!!0`!@`(````(0"'G>^B$P<``"$?```9````>&PO=V]R M:W-H965T<R]S:&5E=#(U+GAM;*R96W.J2!#'W[=JOX/%^U'!&U+1K7@%!6IK M:R_/1#%24;&`G)SS[;>'H0?H-B1F]R68'SW=,__NF6'@X;<?YU/K>YBD47R9 M:'J[J[7"RR[>1Y?GB?;7GZMOIM9*L^"R#T[Q)9QH/\-4^VWZZR\/;W'RDA[# M,&N!ATLZT8Y9=K4ZG71W#,]!VHZOX07N'.+D'&3P;_+<2:])&.SS1N=3Q^AV MAYUS$%TTZ<%*/N,C/ARB7;B(=Z_G\))))TEX"C+H?WJ,KBEZ.^\^X^X<)"^O MUV^[^'P%%T_1*<I^YDZUUGEG.<^7.`F>3C#N'WH_V*'O_!_F_ASMDCB-#UD; MW'5D1_F8QYUQ!SQ-'_81C$#(WDK"PT1[U"U?'VB=Z4,NT-]1^)96?K?28_RV M3J*]&UU"4!OR)#+P%,<OPM39"P2-.ZSU*L_`[TEK'QZ"UU/V1_QFA]'S,8-T M#V!$8F#6_N<B3'>@*+AI&WDW=O$).@!_6^=(E`8H$OR8:`8$CO;9<:+UANW! MJ-O3P;SU%*;9*A(NM=;N-<WB\S_22!>=4DYZA1.X%D[TNWWT"Q]P53[,P:`_ M-$>?[PA8YJ.!*X[F[HX,"Q]P_7I'1H43N"HG]ZH*4S0?#%R5C[L5&1=.X/IE M172HRKPGXD?A!>KED\6A8XF)'VH@]XJA0T#9A[)2]?;=<NA8JN+'UP7!8M6_ M4JT=.07S&;T(LF#ZD,1O+5@F09_T&HA%5[>$9YS+<N:IV?W>Y(8)*;P\"C<3 M#1(.\S:%%>G[=#CN/G2^PRJR*VQFW,:H6\S10LQSX79!P9*"%05K"FP*'`HV M%&PI<"GP*/`KH`/2*GVA<OX/?84;H2\J,T-0"MXC8J(%-EE0L*1@1<&:`IL" MAX(-!5L*7`H\"OP*J(D)\X>)V8/UX?;&@[4I6L$64ZE-PZ2U6=B,E,!S1A:, M+!E9,;)FQ&;$863#R)81EQ&/$;]*:E+"5*])V2RAL(85`G:6ROS6ZP4WDT:] MZB)@F'2**R-5EHPL&5DQLF;$9L1A9,/(EA&7$8\1OTIJLL)#P!VR"NM<5A1C M)DD_?_[*E\`Y(PM&EHRL&%DS8C/B,+)A9,N(RXC'B%\E-<'@B><.P81U73!) M^N6\I6!!P9*"%05K"FP*'`HV%&PI<"GP*/`KH*813+L[-!+6=8TDZ1NE2(J4 M\WE`9NJBL($51,UYPR2;S%(9806O&%DS8C/B,+)A9,N(RXC'B%^0?/`U5<5I ME#_YM,63?W:,=B^S6)Y!;JR,/7C"D<\]PDE=;$FJ8C.RD*0'VUPI[8CHOU1& M2EI&UHS8C#B,;!C9,N(RXC'B2R*'6I,6MH#_+JUP4I>V(&99QXJ40K(ZEC8] MD;/O4Z.K]^O;UE+=5SHKKTC6BKP?QU9^BCADJCCJ/GK=**](MHJ\'\=5?HHX MI&X\=1^]^LHKD%J>Q-FJEJ@;M0Y'<BSVW+R>$D00HBQEDT@\+ZP,>$A65BQ/ M:`1[JS(R!B;)5F'5$[,4CQK&D&B]NN6+!ERC45.O;#1J[)7SJ5YM;OFBO=JB M45.O7#2JK2!4*P^M9.D3C7R\6QU9I3?U0A''F^IB^4&A"'-2*!*)%SQEWLQ! M/;MS<5P7#6%E45:5/A6'PL*HW,^613MCE$]R\F"Z0J_5K8QZ7:-14V@;C<K0 M3F/H#39H"KU%HZ;0+AJ5H;W&T#XV>"=T/;_BQ%7-KW@-8`S:D*T/,BV/:G`R MP-5F)MZ:B!S6EX0AS;2T^F!)*(S*Q^%EX=THT8JC-2*HE'?KR$:CTI7#T8:C M+:(F[RX:E=X]COP:JJ<$\O:UE(B&9/))U(,'3"6'88YH2HJ&366X$.^PA/>R M#)<%PLDW(F?K%3:!EBHZGWZ?"&ZCIS*X0X*/R2JWP29-P;=HU#1R%XW*X!X) MKI,B][').\'K^19GRB]-0=&0Y%NB?K5`#9-LI7/QN@\:?C`%"Z-RU$ML5SQ1 MD3):X6UHV)#N3\2VT5,9VT%45=0PQ_5*WJ!5M0O&D-3E%JVJ*M&Z=-&H[(.' MJ-A6R?A]O%T-7G%;3SHLL"SI/5-\-OEHX14M2=8EJL]R^A9V+C[4B(9-M;Y` MHYY:UI<%,FIK"'_P*KQ7\U,9?+Z!K]%[4Q=L-"J%=[`+<I<WR3:_P19-L;=H MU!3;1:-R^![&;AR^^.J6B_M.%V3NY7<U^1;^'";/X3P\G=+6+GX5W\S`Q?1! M8?5![S'7@?"9^-`G4D2Y8<$[U!N\9\$;0<X?^]8CQ.4W9GT+WG7=X`,+7NG< MX"-KEA_/2(?F(VM^BR]&%AS9N9^%:<%YDW-_9,&ID_/%V()S'.?VV()S%^?N MV()S$O".ZBA\H+P&SZ$7),_1)6V=P@,DHYN_#DCD)T[Y3Q9?(4GP)2K.X--D M_O,(GZ)#^%S1%<]+ASC.\!\10'W<GOX+``#__P,`4$L#!!0`!@`(````(0"/ M:^A!11```+55```9````>&PO=V]R:W-H965T<R]S:&5E=#(V+GAM;*R<6W/: MR!:%WT_5^0\NOX^-P,98%6<J7'1!%^Z<9V*3A!K;N(!,9O[]V8UZJ[OW$@K. MS$MP/JU>O:6^J"^2/OS^U\OSQ9_KW7ZS?7VX]*X:EQ?KU\?MT^;UZ\/E8A[\ MUKF\V!]6KT^KY^WK^N'R[_7^\O>/__W/AQ_;W1_[;^OUX8(<7O</E]\.AS?_ M^GK_^&W]LMI?;=_6KW3DRW;WLCK0?W=?K_=ON_7JZ9CHY?FZV6BTKU]6F]?+ MPL'?G>.Q_?)E\[CN;Q^_OZQ?#X7);OV\.E#\^V^;MSV[O3R>8_>RVOWQ_>VW MQ^W+&UE\WCQO#G\?32\O7A[]^.OK=K?Z_$SG_9=WLWID[^-_P/YE\[C;[K=? M#E=D=UT$BN=\?WU_34X?/SQMZ`S49;_8K;\\7'[R_&6K=7G]\</Q`BTWZQ][ MZ^^+_;?MCW"W>4HWKVNZVE1.J@0^;[=_*&G\I!`EOH;4P;$$QKN+I_67U??G MPW3[(UIOOGX[4''?TAFI$_.?_NZO]X]T1<GFJGFKG!ZWSQ0`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`U%7%9 MSE2T_T8Y*QM5SEQ"70:FX%MNL?=8P4GZ$@PD""0()8@DB"482I!(D$J029!+ M,))@+,%$@JD$,PGF$BPD6%K`*53J[Z%06]3_5(]1N*VJ5#0:L=IJ$]JJUMR5 M!=T#T@<R`!(`"8%$0&(@0R`)D!1(!B0',@(R!C(!,@4R`S('L@"RM(E3M'1# M=HJVODB5FGIPNC]:_:]HB-U"U+([Z>;]K6BMI:ALKD`&0`(@(9`(2`QD""0! MD@+)@.1`1D#&0"9`ID!F0.9`%D"6-G&*F89/[RAFI3X6,Q=.MR`WQZG,\9;9 M`](',@`2``F!1$!B($,@"9`42`8D!S(",@8R`3(%,@,R![(`LK2)4X`TB'U' M`2JU6X`%N3']K`1]"082!!*$$D02Q!(,)4@D2"7(),@E&$DPEF`BP52"F01S M"182+"W@E!5UCTY9%6/=*S5A.7S;//[1W183\HJ^MD5CVF*DJTS<(M2D8\JP M)*8[OA5CW7ZA:=&MO>RRF_=MMS<>E")N\`&0$$@$)`8R!)(`28%D0'(@(R!C M(!,@4R`S(',@"R#+@M"$CZZ84_@T!70*OZ*0:76$2UFIW5(NR$W3E'))3`E" M*6L-]?]6*=^)4BY%92EK4JPKJ9E06!)C)#.+2A^C:=[?NYG%I8@S&Y;63)*2 M&".965KZ&`UDEI4BMLY+:R8C(.,RE;%N-43[F90B-IJ"T:PDQDB>Q[ST,9I6 MX\:]:(M2Q)DM-3E6!Z>>T?#*J6>_U,DH$[?Z%<2N?D#Z!1%=2L<]E4$IXE,) MP"@$$I6I[*O4<*WC4L360S!*@*1E*MO:<ZVS4L36.1B-@(S+5+:U&!9/2A%; M3\%H!F1>IK*MQ6!Z48K8>FD;.=5&K3#^\WIS='$K#B/*N>R"6@UQH^EIE5J! M*E6RJ?19Y-RS;F4%TZK6S7$9R&O?MT33#=C'[A5E9B&+ZB**6&0[-65$,4>D M[O.\/-5LBWHPK/*2424LJHLJ95%M5-E94>557C*J$8N*S0-UOQ@SJBVK"<=P MLJRF[&.?B\Q_QJ*ZJS)GD9FK+!`M'>2V$'*O;2'S[1M5_9^M?JB%>=&W:M2T M1G`&F2HC3[NO1;3BPNU[@"@P5JP*#3KM'J%5C&AHK-@],>BT>XI6&:+<6+'[ M"-$8$TX033'AS*#3D<Z-B&-8(%HZR*TW:O5,+G$WVVK7[AW#?K4](ZM-@8X^ MW*VT&F)PU^.$-&`H.Q^L2=J=?DH1]&,#;=7RB@7V5L,3F06<&2TKE3XRLY!% M=1%%+*J-*-:JYMTQ(NA1]5G519-P1G71I"RJC28ST9BS;S7$_2EG+SNJ9EN, M94:L,GW"F%%M$!.ML@I)7)8I^]@!R$*:L:CNLLQ99"8E"XVH1.QK("8!2TYX M(@2W_9`(VH]'&XS<?L[L=Y6-&)H4R.EW2V3"E]>FK_8YR<KI=P$%6F6YAP:= M=H_0/48T-%;<*R4&G79/T2I#E!LK=A\A&F/"":(I)IP9=#K2N1%Q#`M$2P>Y M]8:&#%!OWM_O*A=1;31R1K2>:,`]M:5-"7\RHM4B^BG[RXI^MU"U:L>/`6=H M>\FJ&[*H;J04L<AV@JABK:J/:ECE):-*6%075<JBVJBRLZ+*J[QD5",6V:/: MHB2:M3%,SHIARO:VEXQAQJ*Z*S-GD1D'+A`M'>2V%*I8T%)^H8=5-J*I%,CJ M`WOJT0W5+NIN+'TM<GK8(IV%`F/%/41HD&E0\J)&Z!XC&AHK=D\,.NV>HE6& M*#=6[#Y"-,:$$T133#@SZ'2D<R/B&!:(E@YRZXU:Z+9'MO5KFNJ!&UD_]%*Y MJ;D]K;*VE/J(!H@"1"&B"%&,:(@H090BRA#EB$:(QH@FB*:(9HCFB!:(E@YR MRU4M8K^C7/6:M]FL[ZJ=8"IJ:UL)2!_(`$@`)`02`8F!#($D0%(@&9`<R`C( M&,@$R!3(#,@<R`+(TB9N$5+WZA3A+RT#J^?69(O5R,Q+>JRJ[]&+=,[B<,L3 MRZP#;44J[I$"1"&B"%&,:(@H090BRA#EB$:(QH@FB*:(9HCFB!:(EAK1#UU" MMTZHQ=]W-.MBK9BJ&)=%5SV5J)JU*9Z>0:=O-'T6V4.=YKU8/!@8%6<8,+(V MH@PZG6'$(C=#,0N-C8HS'#(R&28&G<XP95%MAIE1<88Y(Y/A"-&8D6V/6U)& MQ?931L9^9M#I\YFSR,U0;DL9%6>X9(0;4^K!5*?Z_5*7='1Q!YD:V;4245\C MIP-JWHO%F8%1\1D%Z!4BBDQ"<U5;#3$IC(V*[8?HE2!*34+;7G2?F5&Q?8Y> M(T1CD]"V%PM'$Z-B^REZS1#-34+;7NY6&17;+QTOIS-3\^I_H38I%U&;-')F M][!?=<S^9[-[%M4NV`VTBO>K;CMR_RA@'[LQRDE-R**ZF6+$(ML)9_8<$<VX MS*H$[%=5><FH$A;5196RJ#:J[*RH\BHO&=6(1=;,GE%M64TX!KU?A64U91_[ M7&3^,Q;5794YB\S<:(%HZ2"WA="IU+:0\]9-U4/YLHD4R)[5:U7]K%Z+K"G\ M`%%@K+@;"`TR%5)>U`BM8D1#8\7NB4&GW5.TRA#EQHK=1XC&F'"":(H)9P:= MCG1N1!S#`M'206Z]44O9]C!1W:??O6[:+!;$[=&C1C_9K^*$M;,)%M6VUH%6 MZ:V0V[O;MAC`!.Q#P98]G:Q8(8OJ(HI85!M1K%5ZOTH,@(?L41=-PJ*Z:%(6 MU4:3F6C,V=/K@>ZC+SE[V5'A?A6KS+QPS*@VB(E6F4*Z$X.F*?O8`<A"FK&H M[K+,663F+PN-W/TJ3XQ\EISP1`AN^Z&N']K/^U=3U1JS['<+Y/2[)3)%**]- M7ULY_6Z1SD*!5EGNH4&GW2-TCQ$-C17W2HE!I]U3M,H0Y<:*W4>(QIAP@FB* M"6<&G8YT;D0<PP+1TD%NO5$+W/^\WRV6R9U^5R-G1`O[5:I;IOJFQA,GN\(^ MBVJ;]$"K](BV>2N?G0S8ABKAR;Q"%M4%%+'(=JH8T!;G]I.MJBHOV982%M5% ME;*H-JI,J^JCRJN\9%0C%MD#6EV>M44UX1B*`2T6U92=[5.1V<]85'=1YBRR M.]\BQIOV\?&-&_K"@)@3+CG1B>S=!B2W(^0"PYD#7MRF:!;(ZAI[!IVNPGTM MLGK9`:+`6'''$1ITVCU"JQC1T%BQ>V+0:?<4K3)$N;%B]Q&B,2:<()IBPIE! MIR.=&Q''L$"T=)!;;]ZWW:&&"L6-V<34OA<CRZY6.6^[M3Q1O7M&Q:'W$0T0 M!8A"1!&B&-$048(H190ARA&-$(T131!-$<T0S1$M$"T=Y)8^C1B=VV[])J:: MX<IA68&L'<N>5EFHCVB`*$`4(HH0Q8B&B!)$*:(,48YHA&B,:()HBFB&:(YH M@6CI(+=<U5Z%/9SZ2;D66QO.N*E`UB9F4Y(^D`&0`$@()`(2`QD"28"D0#(@ MN4V<2T;WJ?=<LJ/<73S5R%Z*-\ATEW(`T6>1/;]J=L0L;&!4W%L&B$)$$:(8 MT1!1@BA%E"'*&>$V"$UTW8LL1REGO05X=!'77AF[FW-:915'7R-W&^1.S/D' M1F6N=&%O;<V&J(H0Q8B&B!)$*:(,4:Y1<8YN=::AK],#_-J55B[B2FMDUCIZ MZGHJ5=WR0U^+Z*M1Z@,ES88G!@T#(S"7O31F%)Z35V2L=%ZB,<5&P,9#8\PH M,>ATZTV-E<Y+5*?,"-@X-\:$W&*C3J`L-O706GW'35<3RD<CZJW+Z67+DZ\< MZ83U$UX642F45C"_'+"J*%BO(?;E`CY^8A9S?+$W9%'=)"IB46T\,:N*>.1; MO4,^7!=.PJ*Z<%(6U8:3L:H(1W;K.1\^$4Y1.8KOI!6?#GI9[[ZN>^OGY_W% MX_:[^@9:6UF76'^@K7GG?R)OJE_B"`W.?34BK#K2H2/'=BW24./U5?O$--34 M?-6:\`@U#%_5?3Q"'X_[5,6[]%&YXQQ>Y-YM4E@5/MT6?82N@G^Z(?]VQ8'N MC4\?@\"`NK<^?6,`.3T(X"]H3[_B2+/A+VA_%H_0,P`4;=61;JOA=ZG#QC0] M.M*K/$)C`[J(56YT+Z,C56YT^_75C0'SH><M?+4GCD?HL0M?;8WC$7KZPI]4 M7@/:-_?5KCBFH0<O?+4YCD?H^0M?[9'C$7IJQ5?/I%0<H7S4LP-XA!Y8\=4C M!'B$GEOQU9,$>(0>5O'5HR@51R@?]1`!'J%'?_QNY1%Z`LCO51ZAQWY\]5`/ MNM'#&+YZU`*/T!,_OGKB`H^$=$0]>(%'IAU_6I7+K./3B[.HGW=\>J&Z@E-5 MK](OJ4^HXGV/C(KGK&1S]=K4CJO:7]+QZ15DS#OM^/2R>@6GHJK2YQV?WD!& M_:CCTWO(R,<=?U+E/Z:J7:7OW_GT<0/TZ7;\;I6^U_%[5;S?\0=5^?:I:E3I M@XY/[X-COF''I[?"D4<=G[XH4,&I*57IAQV?7@HG_7599/31S+?5UW6VVGW= MO.XOGM=?Z(;2.+Y>M"L^NUG\YZ!?[_R\/=#G,FFL1Q^KH\^CKNEMU\85+61^ MV6X/_!^50?G!U8__%P```/__`P!02P,$%``&``@````A`'XQ,V51$```1ED` M`!D```!X;"]W;W)K<VAE971S+W-H965T,C<N>&ULK)S;<MLX$H;OMVK?P>7[ MM2U1/DB59"JV2)'BF36[>ZW8<JR*;;DD93+S]ML@T6R@FX1HS]Z,G$\_?C;1 M8`.$./STVY\OSR=_K'?[S?;U\^GH[.+T9/UZOWW8O'[_?/KOWX-_W9R>[`^K MUX?5\_9U_?GTK_7^]+<O__S'IU_;W8_]TWI].`&'U_WGTZ?#X6UV?KZ_?UJ_ MK/9GV[?U*WSSN-V]K`[PS]WW\_W;;KUZJ!N]/)^/+RZNSE]6F]?3QF&V&^*Q M?7S<W*_GV_N?+^O70V.R6S^O#A#__FGSMD>WE_LA=B^KW8^?;_^ZW[Z\@<6W MS?/F\%=M>GKR<C^+OK]N=ZMOSW#>?XXFJWOTKO\A[%\V][OM?OMX.`.[\R90 M><[3\^DY.'WY]+"!,U#=?K);/WX^_3J:5=[-Z?F73W4'_6>S_K4W_C[9/VU_ M+7:;AV3SNH;>ACRI#'S;;G\H:?2@$#0^%ZV#.@/%[N1A_;CZ^7RHMK_"]>;[ MTP'2?0EGI$YL]O#7?+V_AQX%F[/QI7*ZWSY#`/#?DY>-&AK0(ZL_Z\]?FX?# MT^=3[^KL\OK"&X'\Y-MZ?P@VRO+TY/[G_K!]^6\C&FFKQF2L3>"SP\31T-,- MX1,;TL$=[2:Z'7SJ=I.S\<WEZ/)*1>UH"-_6IPN?NN'(.YN,+Z]OZO-UM+S2 M+>'S?8>\U@WA\UWG"%=H'2I\ON^`4]T0/G7#J[/KT<74NW;WS0@&7S,6U"AL M\CRP6T?M,((_WG66(QP[ZH]W'A1'SXB&S\`SQ?$S>O<`4M=6TTDTA+Q!8W:$ M(TC]\<XSQ3$THD$T=-R.<!RI/P8=]KPI$77%F:\.JR^?=MM?)U#&(;?[MY6: M%$8SY8:UIKEJVNK35WR@ZBB7K\KF\RF,3J@K>ZB8?WRYFEY^.O\#JMR]UMQ* MS=A6W*%"E31E.^?`YR#@8,%!R$'$P9*#F(.$@Y2#C(.<@X*#DH/*`.>0GC9' M<!7]/W*D;%2.L'=O$5#2/)805&"3.0<^!P$'"PY"#B(.EAS$'"0<I!QD'.0< M%!R4'%0&L!("M<E*2/?$C->&4L,4;%P;WFAJ=_2MUERWR;D39"Z(+T@@R$*0 M4)!(D*4@L2")(*D@F2"Y((4@I2"52:Q40+&W4J'JU_CRK)T5!U<P901%$(JQ M4<*N6)H:D6?6.6]\;8ON6E%[U0CB"Q((LA`D%"029"E(+$@B2"I()D@N2"%( M*4AE$BMSD"(K<^Z+2*GK]&"GWC9D4B^EZ]GB3I"Y(+X@@2`+04)!(D&6@L2" M)(*D@F2"Y((4@I2"5":Q.AZ6*N_H>*6V.[XA$RI5',PY\#D(.%AP$'(0<;#D M(.8@X2#E(.,@YZ#@H.2@,H#5SU!*K'YNEE9G:L5^>-K<_[C=-C=A'0/?@R54 ML[!2)G;W:U+??S;COB54NB[9TFK>:#R8T=KR-IZR\N:W(KS(`D$6@H2"1((L M!8D%201)!<D$R04I!"D%J1H""UXX4RMIL`3^^TE3)G;2-#&2UA)*B$A:H_%@ M\FN3YHUO[.G&;T5MT@19"!(*$@FR%"06)!$D%21K2-/9]8C-6T(GQD^^:#03 MF#^,DV?KIK(5X<E7FHQ%9F'2_ON9529V9C4Q,ML2"IR?W+S1V)GU1BRSK0A/ M+FBMD2Q:TG^PL/4AC>>Q`A&U(K1>MM9(XI:0$3^SI/4AC>>Q^XJT%:%UUEHC MR5M"1OQ@A?8QJYKG7=C=6+8BM*X:,I%C1&V76(.DHS;#;A06YUIN#P=$<`@: MMM[$#NE.J\9PQ]>J^,G-462>W?B27_Y:Y4WJN^[1U91G-D`?\TKB!UN@R!51 MB"+32404841JGL/=@/$5&P+++B\>58PB5U0)BIQ1I8.BRKJ\>%0YBEQ1%2AR M9J_$J'JS5Z&/>79&1-;DI;;LK.'[H25'[<)&M3)6-U9&2CV/;?#<84,HP6WB MC5#KTC]'47WQU<C7R!LU&T?>Q8@-E@`;F3,A=UZ@R'7X$$5>NWR--!K#.JX- MNV.\-EV@]B5;%0\A1G=7"`F**(1T4`@9->P/(4>1*X0"192$4J/^)%38J*<' M[)$(P]X:B4<*J9*S(=>@L3&QJNUD-0I=IS9'$>US^1(%B,A]0:B_=T,4D7LD MT1(1N<>$^MT3%)%[*E&&B-QS0OWN!8K(O92H0E2[VSF%Q%LY_5AU42XLU0V: MF'F=LI7>G;KP5/)=17>.(A@H[44J)BA?J_24>3V=3E@E"]"GI^C696N!(E=$ M(8I,)Q%1A!&9];6C!.DN,+UD"1K03\F@J-)!465=7CRJ'$6NOBI0Y,Q>B5$U M4V9']BKTZ>DG>U"#R#FH?]^^P6@]^ON'LF&CND%6`6L1#4_>57/U^Q58>;2Q MY4L4:&2X+PCUNX?2*I)H25:X9HX)];LGTBJ5*",K=,\)];L7TJJ4J"(K<+=S M#9>7E>LCDY*2LYPVB*V#V#;*G?H]434TZYE,<R.B;31?-R,2"+(88AV*9I$@ M2T'B(=:):)8*D@F2#[$N1+-2D,HD=FK5)ISY.^:1U#9[=K#;CR/P5OV""TF; MF!6*W[?>:=&12:AQ&CO+F*^M7/=MV@?J03N9\6&T&!)1B"+3J6,2:H[GP<!L MC]<Q"0V(*L8#FIW)0T]0Y(PJU2IW5%F7%S]@CB)75`6*G-DK,2K'?9N[G^S1 MJ[8CWS%Z]>ZE.7KU%B<<M,V=W'5H=SU)Q#MIKGX!4\6+;@U\C?IO#0)L!&N/ M]O#<>8$B5UD,440W1Y%&Q^[/=-RN$&)T=X60H(A"2`>%D%'#_E[(4>0*H4`1 M):'4J#\)%3;JZ0%[Q,'AK1'WL;6\<F$S9(/L,BK6\HWH2!G5(IH/?36CPO'< MM2#0JK%95^1@'!!"2$XX342#0EA2P_Z1$*/(58X2%%$OI(-"R*AA?P@YBEPA M%"BB$,I!(534L#,$>T"J/=EWE,!F"Q>&/&;F=M0@8T5\1Z@S`+TAI=O1;;&/ M[0@%B.BF>T&HWSU$$5E%$BT1D7M,J-\]01&YIQ)EB,@])]3O7J"(W$N)*D1R MPV#,=],_5&1J%[O(:#2!S+73C=@PP'9PH;<B7@;F*'+.]KY6Z=K;<<L9H$]/ M[6TV#%#DBBA$D>DDUVI:=61.[/+B71"CR!55@B)G5.F@J+(N+QY5CB)75`6* MG-DKM:H_>Q7ZF&=G1&05*C5I686*#^IA&P:U#1O5RKG>WL2:=J=5[AU/+3(W M#"0*R`K=%X3ZKY!06D42+<D*W6-"_>Z)M$HERL@*W7-"_>Z%M"HEJL@*W.U< MP\"R<NV^JU1W?&PYI)'YE))$<XE\B0*)%A*%$D42+26*)4HD2B7*),HE*B0J M):HL9.<"+L[WY$+)V?75(%K&W(TYF0OB"Q((LA`D%"029"E(+$@B2"I()D@N M2"%(*4AE$KOK825M=3TO>8.>9%+K<9X1C6AA<H<J5]V?:Y'U-),WXH]/D`JK M1B#10J)0HDBBI42Q1(E$J4291+E$A42E1)5&L/@6Y4QM.9IK[(_E4>]N&DMO MM1^J4FOFL47]]7FNV]F/P8@'G$A%>6S<H2&BA52%$D42+26*)4HD2B7*-#(Z M(B?4WQ&%%AUYV(E4>-85HGJCP+YHU?[3WT]VLXMEWF>I-2=/=HOZSW&NV]G) M%L\\D0K/,9`'7!#J/V!(5B22SSV1"@^X)'=$,2'R,E:(]?H^(2L2R6>?2(7N M&;DCR@F1%S]@@5;F^E<^_T0J=*\TZG@":JRVT<QA<V3)HW?=S&*@D7ESYHF] MR/HXQW[.19%Y?N)>R-<JW$F_O.'/2`7HX]P10I%K+R1$D>DD(HHP(JA2[:VG MW$GO\N(ICE'DBBI!D3.J=%!469<7CRI'D2NJ`D7.[)48E=Y)E]FKT,<\.R,B MN^K!NL$:OA^;XI0+6SPV2-7;-J7R"2AUH];41E(9H38;3BBBS5U?(]S<O;BX M9H]G!M@(5JSM\;GS`D401:\H1!'-G9%&JBJT[3K&JSXY5P@QNKM"2%!$(:2# M0LBH(07*>R%'D2N$`D64A%*C_B14V*BG!^R1J+85WU%(FUU(:Z)M$!P4Z_;= MN$7]YS]'$6W;^1(%B,A]0:C?/401N4<2+1&1>TRHWSU!$;FG$F6(R#TGU.]> MH(C<2XDJ1+6[E5/88K%S^J'J4KO8U44C]Q-06J2V*]JKE`_^.8J<1=?7*GP" MZG+*'YH.T*>GZ#8;FBAR112BR'224R9&9-9768*ZO'@7Q"AR196@R!E5.BBJ MK,N+1Y6CR!55@2)G]DJ,2C\!);-7H8]Y=D9$]J"&B*Q"Q0?UL`U-*)M\SM3( M+&"$7&.XL8*3P,+GZW8&"L@*50M"_>ZAM(HD6I(5NL>$^MT3:95*E)$5NN>$ M^MT+:55*5)$5N-NYAH%EY=J]NE<;+&P=I!%;!_$GH+"A:PJ>:Q'MQ_F"!((L MAEB'HEDDR%*0>(AU(IJE@F2"Y$.L"]&L%*0RB9U:M9<Y?+VA;L-Y:AMD_W3/ MGL2_T^V.3$*-D]K,;6<J4?)];>6X;\.#]90Q/0GI@[D*:]CE)"**,*(CDY`^ MH"NJ&`_HBBI!D>DDHDH'195U>1DEO^ZK'$6NJ`H4.;-78E3]]VWH8YZ=$9$] M>D'TGM&KY&P)U2#/O(<1NPXPUNIV[KJD171KX.MV4%C5JTTNK^%E2O;_T16@ M,XR-=L@;)ZN'ZH##A^2$<T.DT9'[,VK8'T*,(E</)"@R[L\&A9!1P_X0<A2Y M0BA01$DH->I/0H6->I)@CSBXR*T1QY<]@W[44(\B\8'8(+N,\B>@=+LC9;1Q M@C**(\'7[>!$U4`<7U[P?0(TAI'F&(?:V%4&0G+"HT=X=&C>FG<LTK6[*X08 MW5TA)"BB)4(Z*(2,&E*@_&K,4>0*H4`1Y:#$$/IR4&&;G@ZPAZ':.G_'M*UW MVHW]5E7Q8`A:J^P6]9_^'-O1S;`O48"(;K47A/K=0Q21>R31$A&YQX3ZW1,4 MD7LJ48:(W'-"_>X%BLB]E*A"U+%-P/?0/U9:Y-:ZUR#W<T]:I!Z^:R]2/O;G M*'+.\;Y6Z8I[+6\T`_3IJ;AZVM-GXHHH['(2:Z%(JX[-A/J`KJAB/*`KJ@1% MII.(*AT45=;EQ1.3H\@558$B9_9*K>K/7H4^YMD9$=F%"B*R"A4?U`.W"90- M6[DUR"I@+7*-X49D[`GX\%9.Y6Z@0"/#?4&HWSV45I%$2[+"23(FU.^>2*M4 MHHRLT#TGU.]>2*M2(O4*4YHXFEPWKR1M7A#XLMY]7]^MGY_W)_?;G^IUH_!D MP9=/+6[?A?JUGAL9OX5WI-8O%.5\/*LZ]1Z\4U6M<YC^ZV3V%0*57]Q.9E6] M+F`-;B]G5?U25,['ZLA=AX;'26;J00IY#'A`8:9^YI??P"_VT*;[FROXYJJC M#?Q8#Q%T?0._C<_\SF_@1^Q9U/D-_-H,L76Z7<_*>GW`>F!^,X.7LW2<R\VL M[.3365E/@<RGNIE577P^G?E=/)S.X.TB\KC)=`8O`@%^WAX`WF+[MOJ^3E>[ M[YO7_<GS^A&&W47]RJ1=\Q[<YA\'_3]E?ML>X/VU4$[@Q97PON(UO#/R0KW[ M[7&[/>`_U`':-R!_^9\`````__\#`%!+`P04``8`"````"$`[GXK?F,'```[ M(0``&0```'AL+W=O<FMS:&5E=',O<VAE970S,BYX;6RLFEF3HD@0@-\W8O^# MX?NH@">A3K0"WL;&QNSN,XW8$JUB`'W,O]\LZH#*5!MW]F5H/[*R*H^JRBIF M^/WS=*R]ATD:Q>=1W6BTZK7P',2[Z/PRJO_UP_O6K]?2S#_O_&-\#D?UGV%: M_S[^_;?A1YR\IH<PS&J@X9R.ZH<LN]C-9AH<PI.?-N)+>(8W^S@Y^1G\3%Z: MZ24)_5W>Z'1LFJU6MWGRHW.=:["3*CKB_3X*0B<.WD[A.>-*DO#H9S#^]!!= M4JGM%%11=_*3U[?+MR`^74#%<W2,LI^YTGKM%-B+EW.<^,]'L/O3:/N!U)W_ M(.I/49#$:;S/&J"NR0=*;1XT!TW0-![N(K"`N;V6A/M1_<FPMZ99;XZ'N8/^ MCL*/M/1W+3W$'[,DVJVC<PC>ACBQ"#S'\2L37>P8@L9-TMK+(_!'4MN%>__M MF/T9?\S#Z.600;@[8!$SS-[]=,(T`(^"FH;989J"^`@#@']KIXBE!GC$_\R? M']$N.XSJ5K?1Z;4L`\1KSV&:>1%36:\%;VD6G_[A0H90Q9680@D\A1*S7RBY MT]`2#>$I>Z_4KBW:P5.T:S>,=JO+QGRG.WB;&PM/T<RPJK3KBG;P?*2[GF@& MSX>L@[F9#Q.>CW0W$,W@*:TSJEAG0-+Q'	Q^-;R9V&2A[XXR$+#9DQ[(^' MNI098Q0I8U2S4N:,42UIFGRBY//.\3-_/$SBCQHL9F!K>O'9TFC83)><<3SO MU!R\-05A[C$M3TS-J`ZQ@MF5PKKQ/NX9QK#Y#G,]$#(3*F/J$E,IP28V4^M@ MX&+@83##8([!`H,E!BL,UAAL,-B60!-<J_P+&?%_^)>I8?Z5GIE(4#C<0LZ4 M$K*)@X&+@8?!#(,Y!@L,EABL,%ACL,%@6P*:,V&6$&=:,,VO;P\R-UDKV`A* MN=FV6KJS)D*FIQP\)<0AQ"7$(V1&R)R0!2%+0E:$K`G9$+(M$\V5,-4U5]YW M(9.&%0*6_M+\1K-WPH6L\B+0MMJZHZ=*2*4E(2XA'B$S0N:$+`A9$K(B9$W( MAI!MF6ANA;WX`;<RZ=RMTAD33MIYE90O@5-"'$)<0CQ"9H3,"5D0LB1D1<B: MD`TAVS+1'`9%R`,.8]*ZPSAI%_,6`P<#%P,/@QD&<PP6&"PQ6&&PQF"#P;8$ M-!_!M--\Q/?H1@^<FAVBX'42\YKVRARV8"_F.S13HKM.D'[A.T6*:=Y!L]SA M,A8LT6HI,#L]?9:[2D@FMD?(C)`Y(0M"EH2L"%D3LB%DRXF1&Z\YFQTE:4'T MH+.9$MW9@I2<K4CA2.)L+F.Q*+Z/S9:!5E-7O5=^5EHEF2ERNY^YTB/Z0;7$ M0KV76I=*JR0K16[WLU9Z1#\HN3;JO=2Z55J!:'&";>;7X\24Z'$21-_$.GIZ M3[F0"36?F@,D=$)&GR=]79'+A:QV'E_+LM![3RB![>9F1[,*@YE7&<P"#:;5 MU0>[K#"8587!K*L,9H,&TT,AV-X?C)8I[$1X-U5^Q!=(@J_*R%R-GBP"F:59 M7:#;(7.$$)2N,L]=BKQ"E92:%>BV]CE5M:!H6:B2VE<%NJU]355M*-H6JO"\ M9<=L+1I7=BVX^)#;5BZ>>[T84\]`Z]-$2*':$R7PM)"2)CL4N11Y%,THFE.T MH&A)T8JB-44;BK8:TG.>':'*V]@77N8G+BCPI6<F["X#UL9R*4J10Y%+D4?1 MC*(Y10N*EA2M*%I3M*%HJR'=?^S@](#_^#E+\Q]'I<J47?(PCRH?.X2XA'AE MH@^1'4(>&"(_LVA#%&@@RPNTR$[9A1",^/Y&)X7N[W1"2FUU`W0"]Z0:Z/+: M7J>;SHX3#YC.3Q^:Z1SE"TU>69&U0K2!^N/:<,3UE!#*;\1SY++;:G"99?`M MO=-")9LG!%A8KRG6[60G@@?LY`<(S4Z!5(A1I3XUN,`7(19"93LYDO'LFLB! MGE1<*9ZL&I=V@N(O%BM1NY<7*XZ*<*)":@H^86&!>O^JUT4XA5#93(Y$.(U^ MEZ2M:%,IG*R8K6ZF*'W+9@JDHCG02[0IL^_K"2N$BH7(%>TL2%Z5E&87[;*> MU%XII*Q`*]GZG\ZL!J_RM(06A5]YI&V+9+5H")8J>TB%+K5;:D%V!3(A!U6[ M*WX0VJO$W"P7GU^F=BZMUY@"E6O,`A6C)-9)H>+.V*7(DXB>@]F*\,L!S)4@ M>YA>V`7AH5P\P'DLVMU?E:30_8U'2(F%RC"M/I["4D^5M(:/GW>]4NTHD6M! M;N'EEA9FA0I/T3!SH?)10F@O(4\@KIUO,?P;+/\6=`J3EW`:'H]I+8C?V/=5 MV(W'0X7YQ]])QX9[/"@0$7\R#/L)>J!OH"ZW69%Z[8T);ZZU<7HV7-?0%D[? MANL.RN=]&ZXG*%_W;;A.H!P^83]=ZW?"AGI%?@(#O2IOV7"[?D5_VWZ"TP]] M,6G;<&\,O*G\!Y^N+_Y+N/&3E^B<UH[A'ES?RN^:$O[QF__(Q`'U.<[@HS5$ M![[3P7]2".$36:L!*^$^CC/Y@W6@_MO#^%\```#__P,`4$L#!!0`!@`(```` M(0`+M43-E`L``(HZ```9````>&PO=V]R:W-H965T<R]S:&5E=#,P+GAM;*R; MVW+B2!*&[S=BWX'@?@P2&&S"]H1!YU-L;,SN7M-8MHDVX`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`<#C;?3N?#[G_2R%%24F2B1.BG$G&T1D^[J6I' M/^MV-]?7T]G-G#KO:4A7*Z_I)WM]48<SU8Y^?J[#N6I(/^N&=91Z'*5I5CE* M/^MV%]WAK6I(/U7#_H@XE#E53^(_G^O*X1P0_ZF;7G)W#F6-[%2GCW-UT?TY MG#/B/Y?=(6>+<VFZC&2N5U/'6Y_7#W?'PX\!K4=TGZ?WM5C=G(50XTDC![*> M1EVSB*:/4'D4,O=#&B&:(">:^M\?YN/IW>@[3=>-LEFBC6M:K-A"S$TAZ]G` MMT%@@]`&D0UB&R0V2&V0V2"W0=$`(PIM'5_*AK\COD)&Q)<CLV2@`SZQ@LD6 MW,2S@6^#P`:A#2(;Q#9(;)#:(+-!;H.B`8Q@TOPP@MF^LG-."FM*:UJG&DEY M;49I*8TFS<R=CF],HU5M5,<2B`\D`!("B8#$0!(@*9`,2`ZD:!(CK#3M/Q%6 M85V%E8.QE&1:[<[5O%T!\8#X0`(@(9`(2`PD`9("R8#D0(HF,0)&^\\G`B:L MS8!),JUG\\H&G@U\&P0V"&T0V2"V06*#U`:9#7(;%`U@Q(C.%9^(D;`V8R3) MM#HORJ2JB9[/U]8.XBD;2O5ZSKLWULKHUT:<P0&0$$@$)`:2`$F!9$!R((4B MU<T;4:7%S(BJW*ZOQ!GQ_+K=?%T>Y`FU966<T+8L-VLA8@9;DF:P@7B2T`&^ M$=JY%7^_-JI#"R0$$@&)@21`4B`9D!Q((8F\52.TH@S$D]`G0RM$S-`J<J,G M>TUT("&/I<U$C-GW!W?L6&<IO[Y>Q[E691+6I+N?J-91_5A3):ZOLVI2JS)) M:]+=3U;KJ'ZLO,GKZZQ:U*I$C'&BK=H8IY94IWJ-<UU8FP.BB+GCWUH[OC1R MZ517KR,P1LJ&=HG:QKVVC@Z^-)J(^<DG8W=F13EH4;)["R_P*%(VQA2U/8J5 MD4RMF77CR06NI!>XDEWB2BZ-)M,JRYV)?>XJ^ITQLD+4>D9:_-+*6*F8Z:*0 M>`10C^#4&5OYP@TI:VLK>P@]-M)[FL_J\RH$<^MT&G"+YGYFRX9LU-=WQ$:Z M[]CLV[7Z3KA%7]\I&_7UG;'1I%X#<^Z;-KHZ7C`O"MU06S5NWTP`48$UU^_^ M=4$4^-;"H)#;6*HU:G5`%:E2RM75F<_M-`H8:?50HV[UB(VT5(PH8:354XVZ MU3,VTNHYHH)1I6Y&791JS:C_VK23!1^5:KS\+\7S%!J?:7,%GCJ./>VD5?\Z MK:1<LM6Y9B^+/EO)=1%GHNJIN=HW4K'*A)`UFD[;1A$;];H3LY5TY];:_Q.^ MW.=.RD9][F1LU.M.KJRZEVJ6Z7#(3!I1B?8ES1^'=UJ$/WSF)&2LQ5HB8PK7 M2(^^/2:>>/)&4A-=POJ(`H4:ZJ%&W>H12L6($BW%DR#5J%L]0ZD<4:&E[/.4 M>.IGC,8'"Z<PKQZ2UY-I/IZ9\W)9:5(\]81>(?(0^8@"1"&B"%&,*$&4(LH0 MY8@*`YGY+6KB9GY_$%%A7N6Q'N7Y>&Z'5%J93ZKLNF`EWG>(1-;KN8?(1Q0@ M"A%%B&)$":(4488H1U08R(RR*)(_$6594QM[C"JS]:Q?.8`\1#ZB`%&(*$(4 M(TH0I8@R1#FBPD!F_$0E_(GXR<+9B)^JI>M=>R4>ME+ZZ2=;'A`?2``D!!(! MB8$D0%(@&9`<2-$D9LA$4=H,V:^==H2*M6\II(]O*Z=&>E7`?4L:&0]EIHYU MDO>5E'SW6IU4`D0AH@A1C"A!E"+*$.6("H7H!VQ3HAC\_V,O2TH:8=YDEXY" MS=C7J"_VTJC[&8T2)@/N*\"^0HVZ^XJT5,=S&FW`?25:F%&J47=?F9;J>%:C M#5BXT,*$C"GC_BUU>:5B3AE&-`KU063J6`>1E;+J+Q#8J'EVQ2<YRNJ#1SEM M6O:T#=FH[V`>L5'OP3QF*UDGV.>!A"\W;\UV)V6C/G<R-NIU)U=67"=,Y];S MI8)E.APR<X<<ZIWRE]4)8O"M]5:AQDE^I9'.)SM2GC)JU@F(`BW%$R34J%L] M0JD84:*E6#W5J%L]0ZD<4:&E8";3R!NCT7^J%>4V1;V9+G/[`=]2&37K!$0> M(A]1@"A$%"&*$26(4D09HAQ182`SOT75V=S2/HBH+%+%Z:1>\;!.<%4I:ZZ+ MUC1<:2M.(@^1CRA`%"**$,6($D0IH@Q1CJ@PD!EE4;!^(LK"W-IJ)&J^X'8! M>8A\1`&B$%&$*$:4($H198AR1(6!S/A]KIH5#\KM^$FDJX*5,M+$`^(#"8"$ M0"(@,9`$2`HD`Y(#*9K$#)E=FOY2G>!BQ<JH<5;52*\*N&])J0_J!"75K!,0 MA8@B1#&B!%&**$.4(RH4:JD37%&"-J?[K\5>%K+-.J$2IH6A&7ME1558O2)C M[*51=YV@A)MU`O85:M3=5Z2E.NH$;<#K?J*%&:4:=?>5::F..D$;L'"AA0F9 M4T94LLUA^V`O5-5QHXZCPURU\#0WOLDM;'S22AQS>H9,&34/+RT%@;)21^^Q M]4XP4`Z)E;6SJY"-^OR)V*BI!/[$RJJ_0$G:M.R<3=FHSZN,C7J]RB_RJFC3 M:GAEIHHHO)NI\FLS7*A8^[Q$8EFO!VSJ6L.ZHO=\54,:_=JJX:I\)\A&NO;W M%1(K5]T.7GD&NJ&VLM5#-NIS(6*CQAM?A2:.?.$^=NW72MR&SI"UCW;O*1OU M]9ZQD>X]5XC6`+%@7-]:CZD*;M+1N9$#5(&9.="_7%3FYF`K1(G'J]-*H^Z[ M]]A(/V'W$06,M'JH4;=ZQ$9:/4:4,-+JJ4;=ZAD;:?4<4<&H4C>C+BII>^:Y M,_$YQ2?^_(S2SYYYC&AJU7DW=>VWO<JJ?^UFH_ZUFZVZUFZ^WES;[(D0LE'? M*AFQ4:\_L;+BYR8X,UFFSZ&4C?H<RMBHUZ&<K62`<++R]0Y_S+2AKB!MG&O] MIW67/<<1IU=KQ5;(F,322FPH=2K9(^>I=I3I//E]1`&JAQIUJT<H%2-*M!3[ MD&K4K9ZA5(Y(?&@E@B4C(T=#?C@EO_[8E<>7<E6^O9T&F\,W\5$4Q>+AKL;R MBRUZC[L0[SG)0>O*HW.]>*2)B%>6=$6\M6N[,J,KL[8KKKL0STFPS:,[63S2 MO>"5)5T157_;%?*:3EUXA;Y`>VS5HB_36N]%N-6F0T[1"W7L8$D^M7+RJ,TA MS[E9B-<@J.0YMPN?'JOC%7H9L(A;K]"C>U)K:^.YLX4HHU#-<^<+G[9DO$+% MQ")NO4)'?U)K:[.<+99M?#5;K-JX1VZU>D4=M-D7E$%MW+M9T)_$MMS#S8+^ MA!5Y1F&7VUN=U_0EX/OZI<S7QY?M_C1X*Y]I4HRK->HHOR64OYS5WZ9\.9SI M&T`Z4]`W4_3-9TF?*XVO:!]\/AS._`MU/*J_(GWX"P``__\#`%!+`P04``8` M"````"$`OP7&2U`*```D,0``&0```'AL+W=O<FMS:&5E=',O<VAE970R."YX M;6RL6UMOX[82?B_0_V#XO;%U\15)BEAWH04.#MJ>9\=6$F-M*["4S>Z_[U#D MB.2,)=O!>5FO/WW\AAS.#"]6[G__<=@/OA>G:E<>'X;.W7@X*(Z;<KL[OCX, M__XK_FT^'%3U^KA=[\MC\3#\653#WQ]__>7^LSQ]J]Z*HAZ`PK%Z&+[5]?MR M-*HV;\5A7=V5[\41GKR4I\.ZAJ^GUU'U?BK6VZ;183]RQ^/IZ+#>'8=287FZ M1J-\>=EMBK#<?!R*8RU%3L5^74/_J[?=>X5JA\TU<H?UZ=O'^V^;\O`.$L^[ M_:[^V8@.!X?-,GL]EJ?U\Q[&_</QUQO4;KXP^<-N<RJK\J6^`[F1["@?\V*T M&('2X_UV!R,0;A^<BI>'X9.SS#U_.'J\;QSTSZ[XK(S_#ZJW\C,Y[;9_[(X% M>!OF2<S`<UE^$]1L*R!H/&*MXV8&_G,:;(N7]<>^_F_YF1:[U[<:IGL"(Q(# M6VY_AD6U`8^"S)T[$4J;<@\=@'\'AYT(#?#(^L?#T`7#NVW]]C#TIG>3V=AS M@#YX+JHZW@G)X6#S4=7EX7^2Y"@I*>(I$?A4(L[-&K[2@,]68SZ9^-/Y[/J. M`+,9#7PJD>F=.Y\XD^D-HYDJ$?A4(N"<*STQ4VWALQW%K=Z$U&P&`9^MQLV> M6"@1^/RZ)QP(QZ8KXC_7^F(D(ZP)V'!=KQ_O3^7G`*H`Q%#UOA8UQ5D*00Q5 M&5AM\';%+@2M4'D2,@]#&!>$904)]_UQNIC=C[Y#DFP49\4YKLT(D"$R0LB& M%(@H$%,@H4!*@8P"N0&,P"VM;R#"_A^^$3+"-SBJ%0+:61YQ!#*P24B!B`(Q M!1(*I!3(*)`;@.4(*"',$3ZD\_EZAC$A6D'E,F+"\Q;V0%>*,VN=$S`D9$C$ MD)@A"4-2AF0,R4W$<@%40,L%_4,7;,@H*#A&/LS)V"7),Y/&\QV;%+2D-A08 M$C$D9DC"D)0A&4-R$['<`9-_@SL$NW$'#F(E$;]91IM4#Q@2,B1B2,R0A"$I M0S*&Y"9B#136FQL&*MCV0"72[#7D."D04B"B0$R!A`(I!3(*Y`9@C0]"U!J? MK/]W8GFOWW:;;ZM2;C3.Q+L'=5Y6?R%B#ULA<YW7+:)38D+J?R@Y'I2A-FW< M&2%%+0F#*69(PI"4(1E#<HDX3:<M)XE].5\D;W22$+&=I!##22VB'<"<)#F> M\/[W1W?L^';%B-KGK7]:5422%NFVD[8ZR@Y9H[+V.:KFK2H@EO^@Q%G^.Q-, ML!7$:!)LVU$*L2LEB8M`DEQ8S-O@8;Y3'%UV(H;$#$FN4$Y9JXPAN8E8_A$; MKQL<U-!M#RG(@S1O1^_Y9,H";`@3U;*8CY!D9>&$+%X1&G2:,'0F[H(L[3'J MP)+::2Q!4E^/4B3U]BBC/?(<L@'-4:>C1_:4B$VAF?/],>O(/22L^)@-*P7Y M9D!Z/LG60+'ZPQ9);JL>*0A.L4UZ^@Z9H!C;P!+>XW[9[5[K*2IIZQFQ/O') MY.?8IL.Z[6JQ[;S!U8).HE]")/HG=F$,'-6P+]9").G!1@IR9XVK%P[)JAB; M=(15LT0F2.HSGB))&\\4Y*D\&T_&]JAR;--AW?8TD"Q/?VFU=X0*F0`)D5B? MVET-5,/>:`N1I'T0*4C%NN=Y)(EB;-,1;6H&9!][K:>HI*UGQ+I+S[4YMNFP M;L\`D*P9N%!6!)VX6D*NL6MP6J@[U4,DZ7-HQ*$8(:V>:*A;/4625L\XE"/$ M=UCB=NP6O\C]NE5N):0G+F@TP7E]*1<B2;>+%*12SG464Q9ORCQ$5$]M5:0^ M\RDWGQ'SKDL+3HZ-.LS;`2<V_F9Q%2GOP@4<].[Z#;XCCP^6O]6)PE[>R)(; MJ(:]21<BR9P#J>Z:0_1\ML8I%L1_.P_NE%3(!.7-GM)=3XHDW8<,(;L/;*6[ MT`=[-L01PYR-"^FO3B3FKD)"5OJWD/8"'5\H[B*@DK@Z02,.Q0B9Z7^%>HKM MM'K&H1RA,^D/26+YY6L+DU`AU5)">E8#40X$"3[:F.'>4B38,;0DE^^!)0O7 MYJE'HC]&6V8$45L)DOHZE"*IMT.98F&'H'38*W".,AT=LF-5'%?,6*5S\E?Y M#GZ\=`OHR%,/S+W>&:N#D(ZR0+$@K+7#J:="1?*,XQN'8BV%!A,-=:NG7"KC M4*ZEZ"'7O>T0U]";8-5]FM)#U$JQ[$O""9G60+-PR"&'(@[%'$HXE'(HXU!N M058DB>IO15)_U6OH=AHKR+POY%#(H8A#,8<2#J4<RCB46Y`]9G'8,+/GPIC5 MV<3($E="QM4A0T*&1`R)&9(P)&5(QI#<1.RA0C6QADH+Q55WB&*I)\4;(:-. M:$AG#:L3BG3A'E&S,&EB#B4<2CF4<2A7$%1<5BC$=MT,C:_Y2V[ZS;KJ*LCT M5POU^4N2NJ\4E3`0M*M:8802;;[;5JJE.JX5-0&%<RW,7"GVV*8K+V29VI*; M6:8@6)+:E=ZC$16(W;+8/?5M(4,D&<L3AV(.)0CUJ:=(TNH9AW(+LK-4[%-O M<)7<UEKA)2'[EF5";D,"5S7L7<F1U+N=B10++U[H+P$QJG3L9N2Q'TE]_4F1 MU-N?3+'4]LI?S,@-4XXR'1VRYT/LJV^8#[D-M^9#0O:ERX2<50/PWA6AJTAZ MGQQA._D[@T^WDC$^ASK0)@[-FP1)_9'-C&?83AIGKQ+D^+S#N.UHF/E;'"WH M9/<A(1+X9/(#L7>]>+!`DNEHI2YO^-SIE`C'V*8CJE287V$]125M/5,0'AFF M].>D'-MT6+==38\,%\HQ/QK`^50XD<0TO4A4K`OE6$K!M@47D@C;R;!:.,S3 MJDE'6"E/*U)_3#/CF6U\-B.7&3D^[S!N.1J.0+?$=$.W8UI!)*;)`3;`AA!< MG4D>(LEPM((@3<4J[SCD2B;&)AU!)1V-I#[C*9*T\<PVOB`+5(XM.FS;?H9) MMFK'E[9JD%RTI"B(Q#D)B4"Q^N,<2=H#$4(RSMD/83$^[P@UY7[9ZU[C*2II MXQE"TKA#DRS'YQW&;?^+,]#UBZ38\9/:K2"H8E@%`@WU!;64@J3$=A&VTU", MD%9/--2MGB))2V4<RA'B1PC8B=M^^5I<"A52%B2DIS-H3`&I+PM#)/7NGR+% M@@`056'BCUE94!V"C\YRDZ"MO@ZE2.KM4&9W:,[>-<E1IJ-#=JQ"0%NQ2N?D MNOLR^)6+38J$K!ANH6Y/A4H*"IZ.8=G.@&+%,M03#76KIUP]XY!XS5H,1ZI+ M?\G7IN5;J(?B]%H$Q7Y?#3;EAW@E&F[='^];6+VO[8Z73Z`$PR!/X()L*6Z> MSCV!E[RA>/$G\/;W4Q/@5`L:G..O7!`ZH[/RX"WR,_B3OWR":T)N>.4OX8VZ M,_AD"2^@<3R<+>$MI3/X?`EO^7`\G2_AK1R.AZZW%%<4YY[XRPB.U_P)'-2A M3?-DU/H)WE%_7[\6?ZY/K[MC-=@7+S!AX^8]J)-\RUU^J=7-\'-9P]OI,*?P M7C'\-4(!K_2.[^`H_5*6-7X!TZ/V[QL>_P4``/__`P!02P,$%``&``@````A M`**#MI)8"P``T#8``!D```!X;"]W;W)K<VAE971S+W-H965T,CDN>&ULK)M; M;^)*$L??5]KO@'@_`=L0@I7D*.`[%ZU69W>?&>(D:`*.@+E]^U/M[NI+E>W` M:%^&R8_J?W=75_4-^_[/G_OWWO?R>-I5AX>^=S/L]\K#MGK>'5X?^O_Y*_GC MKM\[G3>'Y\U[=2@?^K_*4__/QW_^X_Y'=?QZ>BO+<P\4#J>'_MOY_!$.!J?M M6[G?G&ZJC_(`W[Q4Q_WF#'\>7P>GCV.Y>:X+[=\'_G!X.]AO=H>^5`B/EVA4 M+R^[;1E5VV_[\G"6(L?R?7.&]I_>=A\G5-MO+Y';;XY?OWW\L:WV'R#Q9?>^ M._^J1?N]_3;,7P_5<?/E'?K]TQMMMJA=_\'D][OML3I5+^<;D!O(AO(^3P?3 M`2@]WC_OH`?"[;UC^?+0?_+"=>#W!X_WM8/^NRM_G*S_]TYOU8_TN'M>[@XE M>!O&28S`EZKZ*DSS9X&@\("53NH1^->Q]UR^;+Z]G_]=_<C*W>O;&89[##T2 M'0N??T7E:0L>!9D;?RR4MM4[-`#^[>UW(C3`(YN?#WT?*MX]G]\>^L'MS7@R M##PP[WTI3^=D)R3[O>VWT[G:_T\:>4I*B@1*!#Z5B'>UQDAIP*?2\&\FWG`: M3*`='77#MW4'X%.5N[NY&X]'MW>?%+Q5!>%3-]H4O+#G$R4"GUKD6N]!*M8] M@,^K>CY5Y>#SNIY[$&5UC>(_NME7]]W#V!'_T3+7]MZ#R).-,2'H62-XX4!X M&(/B/ZHQH]^0P3#T3!Q>WIJ!3*XZ5Z/->?-X?ZQ^]&`"!`>=/C9B.O5"H8Q9 M*N-:YVU;VD*^"I4G(?/0A_&&C#S!7//]<3(<W@^^P_RP538S;N.[%G.T$).! MD(THB"E(*$@IR"C(*2@H6%"PI&!%P=H"`W"M]B^$SO_#OT)&^!<],T-@'!X0 M9Z(%%HDHB"E(*$@IR"C(*2@H6%"PI&!%P=H"CC,A@1QG-B\E&)/"NEX^K)CT M7"?-I$TPT8Z=,Q(Q$C.2,)(RDC&2,U(PLF!DR<B*D;5-'!="BE_A0F$-,P.L M(98/2=;.I%%@)W\PO74=/==&.AP9B1E)&$D9R1C)&2D863"R9&3%R-HFCEMA MC;_"K<*Z=BLZ8R;)J-Y1U5/?G)&(D9B1A)&4D8R1G)&"D04C2T96C*QMXC@, M]C97.$Q8NPZ39&3REH*(@IB"A(*4@HR"G(+"`D[_(&6NZ)^P=OLGR:C>G\N` MT,3DXIBD8J1L(/MUO@;3B9N*L3;"Z$NT-))4$R-$*\NTCK%AE>7:"*4++0W$ M<9DX^+&MR/0&0NC*S8@0<KTIB>U-1B)%;-_Y$^+@6!MA=Q(FE#*2Z5+&4TPZ MUT8H7=A"CJ=@JN6>&M^(8\7Y;;?].JM@^&%'TK`^!K`YDULV(>)Z21+;2XQ$ MDL"Y4>SQ_*$W(L&EO\=>)$PC9233I90JV<OD^GM4+6P-QS?BY,"<XX]%X M`XZ2Z(^ZH.L01%"9E4]W;I?GRLH'AVLKFBP1&ID9/N8HX2A%U*6>H9%1SSDJ M'.0Z36Q?[=S[Q%7"G+A*H@#F0^V$8#JEKE(%(;*U%7>5,H)=H#;RQ\3KL3C: M01L"KXY$;SRDYXU$68ACE]:AE:5HU-6B#(T"O=SD"OEV?_U;$K>%*=C8!'<, MQ*[WBC&0FV38FV%.S,2!50R+':XCZI:YLOHD7*64;P(JQG(&)1REB&!T6IV> MH9&1RCDJ'.2Z2FQOKW"5,"?A*I$;KI,Q#5=5L"LX(A%?0MTLU;%"*C;OI@') M@P3+0-%6+Z5HU%5[AD:F]MRM/?#O2+<*+--2N^MJL>6]PM5RA^Q$I40C.R*" M"3T?B+L'\.(G4:F,3&=C52X8U=/`[8@F>(+"4+3#U1?4GJ&2J3UW:P^\@-QY M%%BFI7;7U6*S;+M:WL5<N:R+*U8:[!*YP<[G9E6P*]PB5#<^B!52P0Z7[,0' M"99I";=Z-Y*B45?M&1K9\[!L]6?SL.I;2Q/<81!;>GL8/ED+Y0G`B7B)_#L] M-<\]C=JC,$(C<\T3<Y0@,NJI0>WJ&1H9]9RC`E&M[OI%;-QMOXCP]&_%Y?T5 MNTYQET##4YT([*$?#<E-S5P5_&2"D%(^K%XZV1NV#M)*S1F!'TQ)90E6UI*V M*F159?;$1J>?#)4Z6Y0K*SV+>6S*5G6U-,@=*'`D&RC/.A[\57W`>O7I?EC( MD%53(B>P-3(>ITZ(/&D4F/4^YBA1R%)/#6I7S[A4SE%AI&"_Y/I+G"7LP/XD MX>71PQY0^%'*W3G,Q!X,G&=?+'(4<11SE'"4<I1QE'-4<+3@:,G1BJ.U@QR/ MPK;Q&H_6YG6DF5&>#,G1>Z:LW'O&"7'\W%CAMCCB*.8HX2CE*.,HYZC@:,'1 MDJ,51VL'N5Z&%+XB;L7,2?)9(?O:D:.(HYBCA*.4HXRCG*."HP5'2XY6'*T= MY/I/G'$NSWNQJ%#_263=0BHC0R)&8D821E)&,D9R1@I&%HPL&5DQLK:)ZS+8 M0#DN^ZTMJB]4W)4%D=G4S`TRLP);6901W$<9(W],;SR-%4X*"4<I1QE'.4<% M1PN.EARM.%HK!*L57:9\<4:QP_7W?"]4B.\5LGVOD7$K][TT"L258N-=8-UB M6`3-=CU12'9/;J,,:J\K,U(M-X3&`(>X,,*(%@:UU[4T4JHNLA*MC`$*KXTP M&S9Q]+"'K7MW(7;3='P4LJ]U)B3$YZJ<F.WTSI>/F%02C=5&?'NLI`(P-E;T M:BO!"FTM6F&*1EVMRM#(S6%RWY=CJ^1!WYOX[*R-.ETM6J!15XN6:&0K,3^M ML$6=?EHW:5E^<J=7>O2LCU@7W%V+XR^-&G7BM%L73,AU_1P+P@9=C[75NCI# M(V5D%K68D821]!+IC!7+&2D865PBO63%5HRL;>*.A#AO79&U\G@&QSB<$6:^ M1.3:BYSKYLKJD[15AS_KTD654P?&D7]++UU0V`YA.K`I&G4E0X9&IO;<K1U^ M!2+WFP66Z:I]@49=M2_1R-2^<FL?>32HUUBFI79WH,71](J!EB=99Z#5X1;R M3:<0O]^$4VV=H?"AK>AX1&AD%LQ8(1&HNAS[G2$Q!8T554_1J*L)&1J9)N07 M-:$P!=N;L$"CKB8LT<@><ND]&%BQ)),SWQH+7'*[Y]/#_N_MHN3QW@D#B4B^ MLV5:6GV2[\K(.""NFPW7;6JO-2&K8X+?MX2\VFE=4'EFE'`JRQ7JWA`4IF!7 M`%S0A*51PB:L+FK"VA1L;(*3^'`9=4WBU^;NOEDAB#YLYMR@Q@;(Y12-S$5L MS%&"R*BG!K6K9VADU'.."D1&?6%0N_H2C8SZBJ,UHEK=]3I,]LYT^UOI![\U MT.V.0B.(+SU/!C1-YEBP:_Z)T*AS/QHK*_@04])H'-"41)F664FF)!IU-2A# MH\X&Y<H*/D2#O*D_HJLRZG2U:(%&72U:HE%GBU;*"CYJ%WGTT+)&F98&N9$# M=75&SF6WVN*F@.R4%7+R6%J)A45'$UU/(U4.@AWS/^8HX>JI0>WJ&9?*.2J, M%+9A85"[^I)+K3@2KX<(9TG/R-&0KWO(1\CWY?&UG)?O[Z?>MOHF7N6`;<KC MO<;J/1-_&#Z!$C20?`-7NJ&XWVSZ!EY.@462?Q/YHS"&`RS_!NX(PKSQ&SC1 MA^+0SLO`.S!/C2V#ZIMJG_G0K`:=60#OTC3PIU'X).\Z:-='(3Q,RALT&X?P MS"3GZ22$QZ8XSR8A/&+7P.]">*"L@4]#>)B*\V(2PB-5G$=^`*YKZAK\Q`$^ M:BHSFX2S)CZ?A/,F'DU">":QH>Z[$)ZW:^#3,&[2228A/&P&]@/M;'B?Z&/S M6JXVQ]?=X=1[+U\@2(?U+^I'^4:2_..L?A'[4IWA32)8YN%%"'ASK(1W$(;B MR;&7JCKC'Z("_2[:X]\```#__P,`4$L#!!0`!@`(````(0!D4<_'E@```*H` M```0````>&PO8V%L8T-H86EN+GAM;#R.P0H"(11%]T'_(&_?.#.+B%`'"OJ" M^@!Q7J.@3_%)U-]GFS87#A?.O6IYIRA>6#EDTC`-(P@DE]=`FX;'_78X@>!F M:;4Q$VKX(,-B]COE;'17;P.);B#6X%LK9RG9>4R6AUR0>O/,-=G6L6Z22T6[ MLD=L*<IY'(\R=0$8Y435<)EF$*&?`!%_*8V2_Q7S!0``__\#`%!+`P04``8` M"````"$`N](W.!\$```H$0``$``(`61O8U!R;W!S+V%P<"YX;6P@H@0!**`` M`0`````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M``````````````````````````````````````````"<6%%SVC@0?K^9_@?& M[XU)REQO,L:=%)(I,^V%JVGZJ%'L)6@B))\D<Z&_OBLYQ'!9%.#-6/MI/^U^ M6N^2?7I:RMX*C!5:#9/SLW[2`U7J2JB'8?)C=O/^KZ1G'5<5EUK!,%F#33[E M[_[(ID;78)P`V\,ME!TF"^?JRS2UY0*6W)[ALL*5N39+[O"G>4CU?"Y*&.NR M68)RZ46__V<*3PY4!=7[^F7#I-WQ<N5.W;32I>=G[V;K&@GGV55=2U%RAZ?, MOXG2:*OGKG?]5(+,TNW%#-D54#9&N'7>S]+MGUE1<@DCW#B?<VDA2[L7V1?@ M/FA3+HS-LY6[7$'IM.E9\0O#=I'T[KD%3V>8K+@17#FDY<W:'^%9UM:9_*<V MCW8!X&R6HD'[,CQNVVX_BT'^<1`L\&G7TN_0,L&%78XSX238V_F4&T=0_CC8 MYAQ8M(Q;0ILL,M0&NU8.X\4FJLVVT-O,7\XPTLIJ*2KNH&*?N>2J!%:\.NDA M]FS*WW91./3DE6:9GK.17AX+*=P!!]GU@I#S8]V,^$ZF7\Y_:QZX$K^":D.8 M"_&@!%XA%`^[(KW\#8Y]U=:R*1@,+3<HTI?]O-S:Y!4-WH<0&F[6#/TOV(W4 M_[$Q=WOBZDVN_VW$"F^`#ZC/^D2MP#H,,.GC!F\"N^.R`?8-N&U,FPK2=D<, M/E,U%AMT0QI_!QD4Y'6+Y2=0Z=Z1D%NWP'A\!PO<E(N`&,,*I*Z]/$C(&.[I M!62W%/[4SU%`53N\^%@UD0RY%5I@A77B7@*;&IB#,7@!4"GE(VD?5A9:5EB6 M0]#=FK2;8*%>`IOQISV.)\J!P12%`[<Q0(&0>_W38#3!R#6[$0HOIN!ROQKB MPJ3U_UJ92!PC0H<L)E`V(T\05+Q7HC2I/1J-,=LGU19#,NO$20F69A97+(WQ MDHU1CRJ7D=0)*<8\;"LR;D<),X;8I\\60W*/J_2"Q!`J'7%9-EAQL'4X%#)1 M^!T//<X)ZBY(+W%UTX>)8SZ<X&=`8O;=HJ)9+KDY"G)55<()$K+WX@4WQT&" MF^,@P0M][^+WF\Y-'$/G)EX3:#]QS"E^:`V$VM-F3RO\=G2MH&)CN@D)D%8C M:]^@S;0+P+8TD-F)5S`Z.W$,';4XAHY:Y"O/KBKR.%1U[6)X,.2V<6%$$W2! MHKQT83_82P>AXTRZ\3W.9QQ\#C]_5TQ(9CM?F"Y6SWI[&U+@=%HUV(BU$T%- M-_@[7E`,-5=K;!]+;7!2I;^4%,2B]-MN[VUBSUYL:)G]U^9MB">$G9H4[82@ MYR=`Z%S2C>.F,2?=[/U`!]UL0W9&TO\-H5^%>K0_ZIG&200V4_;NRRR,-17. MGYOU[D7V!0=L(_TFHP7'IKS:V+Q>\/\)W+5_?.3G@[/^ASZ.^UOOLK3[BR/_ M#0``__\#`%!+`P04``8`"````"$`D[EA%#(!``!``@``$0`(`61O8U!R;W!S M+V-O<F4N>&UL(*($`2B@``$````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M````G)%=2\,P%(;O!?]#R7V;?K"AH<U`95<.!">*=S$YZX)-&I)HVW]OUG5U MHE=>AO?-D^><E*M>-=$G6"=;7:$L25$$FK="ZKI"3]MU?(4BYYD6K&DU5&@` MAU;T\J+DAO#6PH-M#5@OP46!I!WAID)[[PW!V/$]*.:2T-`AW+56,1^.ML:& M\7=6`\[3=(D5>":89_@`C,U,1!-2\!EI/FPS`@3'T(`"[1W.D@Q_=SU8Y?Z\ M,"9G327]8,),D^XY6_!C.+=[)^=BUW5)5XP:P3_#+YO[QW'46.K#KC@@>MA/ MPYS?A%7N)(B;@?9OMHF<VY?X=U8*/MH1;H%Y$%%XCQSM3LES<7NW72.:I]DB M3HLX76[SC.379%&\EOC4FN[3&:@F@7\33P`Z>O_\<_H%``#__P,`4$L!`BT` M%``&``@````A`-!C&/%I`@``&2P``!,``````````````````````%M#;VYT M96YT7U1Y<&5S72YX;6Q02P$"+0`4``8`"````"$`M54P(_4```!,`@``"P`` M``````````````"B!```7W)E;',O+G)E;'-02P$"+0`4``8`"````"$`_/6^ M!=\"``#Z*P``&@````````````````#(!P``>&PO7W)E;',O=V]R:V)O;VLN M>&UL+G)E;'-02P$"+0`4``8`"````"$`07'2B9P%```\%@``#P`````````` M``````#G"P``>&PO=V]R:V)O;VLN>&UL4$L!`BT`%``&``@````A`&$+-]1I M!0``+Q4``!@`````````````````L!$``'AL+W=O<FMS:&5E=',O<VAE970T M+GAM;%!+`0(M`!0`!@`(````(0!8L_#(/@(``-T$```9```````````````` M`$\7``!X;"]W;W)K<VAE971S+W-H965T-30N>&UL4$L!`BT`%``&``@````A M`";@6!6(`@``%@8``!D`````````````````Q!D``'AL+W=O<FMS:&5E=',O M<VAE970U-2YX;6Q02P$"+0`4``8`"````"$`&R+NV'L"``#1!0``&0`````` M``````````"#'```>&PO=V]R:W-H965T<R]S:&5E=#4V+GAM;%!+`0(M`!0` M!@`(````(0`%^U4[CP(``"<&```9`````````````````#4?``!X;"]W;W)K M<VAE971S+W-H965T-3<N>&UL4$L!`BT`%``&``@````A`.*NFA+5`@``[`<` M`!D`````````````````^R$``'AL+W=O<FMS:&5E=',O<VAE970U."YX;6Q0 M2P$"+0`4``8`"````"$`6<YX0K8,````20``&0`````````````````')0`` M>&PO=V]R:W-H965T<R]S:&5E=#4Y+GAM;%!+`0(M`!0`!@`(````(0`?3=G6 MQ#```&=#`0`9`````````````````/0Q``!X;"]W;W)K<VAE971S+W-H965T M-C`N>&UL4$L!`BT`%``&``@````A`$HOUKP^`P``\PD``!D````````````` M````[V(``'AL+W=O<FMS:&5E=',O<VAE970U,RYX;6Q02P$"+0`4``8`"``` M`"$`P_<["C8#``##"0``&0````````````````!D9@``>&PO=V]R:W-H965T M<R]S:&5E=#4R+GAM;%!+`0(M`!0`!@`(````(0!<[+[B@0(``%\&```9```` M`````````````-%I``!X;"]W;W)K<VAE971S+W-H965T-3$N>&UL4$L!`BT` M%``&``@````A`('Y6*L)"```+BL``!D`````````````````B6P``'AL+W=O M<FMS:&5E=',O<VAE970T-"YX;6Q02P$"+0`4``8`"````"$`[FH:`X4"```% M!P``&0````````````````#)=```>&PO=V]R:W-H965T<R]S:&5E=#0U+GAM M;%!+`0(M`!0`!@`(````(0"-"$.FUP,``$@-```9`````````````````(5W M``!X;"]W;W)K<VAE971S+W-H965T-#8N>&UL4$L!`BT`%``&``@````A`.Q! MA]RU`@``W@8``!D`````````````````DWL``'AL+W=O<FMS:&5E=',O<VAE M970T-RYX;6Q02P$"+0`4``8`"````"$`_D][<R@#```P"0``&0`````````` M``````!_?@``>&PO=V]R:W-H965T<R]S:&5E=#0X+GAM;%!+`0(M`!0`!@`( M````(0`;SYI)$P\``")?```9`````````````````-Z!``!X;"]W;W)K<VAE M971S+W-H965T-#DN>&UL4$L!`BT`%``&``@````A`,+TZ.]E!0``^!4``!D` M````````````````*)$``'AL+W=O<FMS:&5E=',O<VAE970U,"YX;6Q02P$" M+0`4``8`"````"$`DK.%V'L#```J"P``&0````````````````#$E@``>&PO M=V]R:W-H965T<R]S:&5E=#8Q+GAM;%!+`0(M`!0`!@`(````(0!V,T;=#@<` M``X?```9`````````````````'::``!X;"]W;W)K<VAE971S+W-H965T-C(N M>&UL4$L!`BT`%``&``@````A`#`,4JOJ`P``<`T``!D````````````````` MNZ$``'AL+W=O<FMS:&5E=',O<VAE970V,RYX;6Q02P$"+0`4``8`"````"$` MR6V_LM`"``!Z!P``&0````````````````#<I0``>&PO=V]R:W-H965T<R]S M:&5E=#<S+GAM;%!+`0(M`!0`!@`(````(0!5EBBGV`0``(H2```9```````` M`````````..H``!X;"]W;W)K<VAE971S+W-H965T-S0N>&UL4$L!`BT`%``& M``@````A`/MBI6V4!@``IQL``!,`````````````````\JT``'AL+W1H96UE M+W1H96UE,2YX;6Q02P$"+0`4``8`"````"$`JGS^9*`+```&9P``#0`````` M``````````"WM```>&PO<W1Y;&5S+GAM;%!+`0(M`!0`!@`(````(0#!8K$H M5:(``.`^`@`4`````````````````(+```!X;"]S:&%R9613=')I;F=S+GAM M;%!+`0(M`!0`!@`(````(0`Q:??!W0(``!X)```8``````````````````EC M`0!X;"]W;W)K<VAE971S+W-H965T,RYX;6Q02P$"+0`4``8`"````"$`2;F* M]'@%```3%@``&``````````````````<9@$`>&PO=V]R:W-H965T<R]S:&5E M=#(N>&UL4$L!`BT`%``&``@````A`*.R/,YD!```H1```!D````````````` M````RFL!`'AL+W=O<FMS:&5E=',O<VAE970W,BYX;6Q02P$"+0`4``8`"``` M`"$`=<7!-:8#``!7#```&0````````````````!E<`$`>&PO=V]R:W-H965T M<R]S:&5E=#<Q+GAM;%!+`0(M`!0`!@`(````(0"+9P"J*0,``)$)```9```` M`````````````$)T`0!X;"]W;W)K<VAE971S+W-H965T-S`N>&UL4$L!`BT` M%``&``@````A``2/7JX\`P``W`D``!D`````````````````HG<!`'AL+W=O M<FMS:&5E=',O<VAE970V-"YX;6Q02P$"+0`4``8`"````"$`?-6=,L\#``"/ M#0``&0`````````````````5>P$`>&PO=V]R:W-H965T<R]S:&5E=#8U+GAM M;%!+`0(M`!0`!@`(````(0!X,T-V>00``'(0```9`````````````````!M_ M`0!X;"]W;W)K<VAE971S+W-H965T-C8N>&UL4$L!`BT`%``&``@````A`'VP M&KK-`@``C`<``!D`````````````````RX,!`'AL+W=O<FMS:&5E=',O<VAE M970V-RYX;6Q02P$"+0`4``8`"````"$`Q^8_&Q(#```""@``&0`````````` M``````#/A@$`>&PO=V]R:W-H965T<R]S:&5E=#8X+GAM;%!+`0(M`!0`!@`( M````(0`"&**!D@,``#L+```9`````````````````!B*`0!X;"]W;W)K<VAE M971S+W-H965T-CDN>&UL4$L!`BT`%``&``@````A`&P$L*8B!```!@\``!@` M````````````````X8T!`'AL+W=O<FMS:&5E=',O<VAE970Q+GAM;%!+`0(M M`!0`!@`(````(0"Q)LSXC0(``!H&```9`````````````````#F2`0!X;"]W M;W)K<VAE971S+W-H965T-#,N>&UL4$L!`BT`%``&``@````A`&ME&I*4!``` ME1(``!D`````````````````_90!`'AL+W=O<FMS:&5E=',O<VAE970T,2YX M;6Q02P$"+0`4``8`"````"$`$W,]FA$-``"*1```&0````````````````#( MF0$`>&PO=V]R:W-H965T<R]S:&5E=#$U+GAM;%!+`0(M`!0`!@`(````(0`Z M<L3@!P8``&@9```9`````````````````!"G`0!X;"]W;W)K<VAE971S+W-H M965T,38N>&UL4$L!`BT`%``&``@````A`+<WSD39"```]RD``!D````````` M````````3JT!`'AL+W=O<FMS:&5E=',O<VAE970Q-RYX;6Q02P$"+0`4``8` M"````"$`A??R`1<#``!D"0``&0````````````````!>M@$`>&PO=V]R:W-H M965T<R]S:&5E=#$X+GAM;%!+`0(M`!0`!@`(````(0#MS/&VWC,``)(S`0`9 M`````````````````*RY`0!X;"]W;W)K<VAE971S+W-H965T,3DN>&UL4$L! M`BT`%``&``@````A`*I0VR*[)```F-D``!D`````````````````P>T!`'AL M+W=O<FMS:&5E=',O<VAE970R,"YX;6Q02P$"+0`4``8`"````"$`U"NCAA\# M``!;"0``&0````````````````"S$@(`>&PO=V]R:W-H965T<R]S:&5E=#0R M+GAM;%!+`0(M`!0`!@`(````(0"`6>_=KA$``/UC```9```````````````` M``D6`@!X;"]W;W)K<VAE971S+W-H965T,30N>&UL4$L!`BT`%``&``@````A M`,_PGF@,"P``(S4``!D`````````````````[B<"`'AL+W=O<FMS:&5E=',O M<VAE970Q,RYX;6Q02P$"+0`4``8`"````"$`8IG45#\2``!L9P``&0`````` M```````````Q,P(`>&PO=V]R:W-H965T<R]S:&5E=#$R+GAM;%!+`0(M`!0` M!@`(````(0#)__`ZJ1$``$UH```8`````````````````*=%`@!X;"]W;W)K M<VAE971S+W-H965T-2YX;6Q02P$"+0`4``8`"````"$`7*C;"^,$``"H$@`` M&`````````````````"&5P(`>&PO=V]R:W-H965T<R]S:&5E=#8N>&UL4$L! M`BT`%``&``@````A`-;L=,ZS!@``11P``!@`````````````````GUP"`'AL M+W=O<FMS:&5E=',O<VAE970W+GAM;%!+`0(M`!0`!@`(````(0!+#HX:%`<` M`*<C```8`````````````````(AC`@!X;"]W;W)K<VAE971S+W-H965T."YX M;6Q02P$"+0`4``8`"````"$`6$2!4)(+``#..```&`````````````````#2 M:@(`>&PO=V]R:W-H965T<R]S:&5E=#DN>&UL4$L!`BT`%``&``@````A`-WZ MMO]4!P``DB```!D`````````````````FG8"`'AL+W=O<FMS:&5E=',O<VAE M970Q,"YX;6Q02P$"+0`4``8`"````"$`:1GP%FP1``#%70``&0`````````` M```````E?@(`>&PO=V]R:W-H965T<R]S:&5E=#$Q+GAM;%!+`0(M`!0`!@`( M````(0`%^S)#+PH``(HP```9`````````````````,B/`@!X;"]W;W)K<VAE M971S+W-H965T,C(N>&UL4$L!`BT`%``&``@````A`"7)`#IC!P``Y"```!D` M````````````````+IH"`'AL+W=O<FMS:&5E=',O<VAE970R,2YX;6Q02P$" M+0`4``8`"````"$`0IIM9CT+```T-P``&0````````````````#(H0(`>&PO M=V]R:W-H965T<R]S:&5E=#(T+GAM;%!+`0(M`!0`!@`(````(0#]TO91O`<` M`"DE```9`````````````````#RM`@!X;"]W;W)K<VAE971S+W-H965T,C,N M>&UL4$L!`BT`%``&``@````A`-N-++FP!@``C!P``!D````````````````` M+[4"`'AL+W=O<FMS:&5E=',O<VAE970S-2YX;6Q02P$"+0`4``8`"````"$` MM_B>.ND)``#3+@``&0`````````````````6O`(`>&PO=V]R:W-H965T<R]S M:&5E=#,V+GAM;%!+`0(M`!0`!@`(````(0!L%A?M(0X``'!3```9```````` M`````````#;&`@!X;"]W;W)K<VAE971S+W-H965T,S<N>&UL4$L!`BT`%``& M``@````A`!+O!N%^!```M!```!D`````````````````CM0"`'AL+W=O<FMS M:&5E=',O<VAE970S."YX;6Q02P$"+0`4``8`"````"$`-PM&Z4P$``![#P`` M&0````````````````!#V0(`>&PO=V]R:W-H965T<R]S:&5E=#,Y+GAM;%!+ M`0(M`!0`!@`(````(0"`_T61'0,``(,)```9`````````````````,;=`@!X M;"]W;W)K<VAE971S+W-H965T-#`N>&UL4$L!`BT`%``&``@````A`**O^9L% M(P``Q[T``!D`````````````````&N$"`'AL+W=O<FMS:&5E=',O<VAE970S M,RYX;6Q02P$"+0`4``8`"````"$`^_;,VLL@```YNP``&0`````````````` M``!6!`,`>&PO=V]R:W-H965T<R]S:&5E=#,T+GAM;%!+`0(M`!0`!@`(```` M(0!267ZM+@4``,@4```9`````````````````%@E`P!X;"]W;W)K<VAE971S M+W-H965T,S$N>&UL4$L!`BT`%``&``@````A`(>=[Z(3!P``(1\``!D````` M````````````O2H#`'AL+W=O<FMS:&5E=',O<VAE970R-2YX;6Q02P$"+0`4 M``8`"````"$`CVOH0440``"U50``&0`````````````````',@,`>&PO=V]R M:W-H965T<R]S:&5E=#(V+GAM;%!+`0(M`!0`!@`(````(0!^,3-E41```$99 M```9`````````````````(-"`P!X;"]W;W)K<VAE971S+W-H965T,C<N>&UL M4$L!`BT`%``&``@````A`.Y^*WYC!P``.R$``!D`````````````````"U,# M`'AL+W=O<FMS:&5E=',O<VAE970S,BYX;6Q02P$"+0`4``8`"````"$`"[5$ MS90+``"*.@``&0````````````````"E6@,`>&PO=V]R:W-H965T<R]S:&5E M=#,P+GAM;%!+`0(M`!0`!@`(````(0"_!<9+4`H``"0Q```9```````````` M`````'!F`P!X;"]W;W)K<VAE971S+W-H965T,C@N>&UL4$L!`BT`%``&``@` M```A`**#MI)8"P``T#8``!D`````````````````]W`#`'AL+W=O<FMS:&5E M=',O<VAE970R.2YX;6Q02P$"+0`4``8`"````"$`9%'/QY8```"J````$``` M``````````````"&?`,`>&PO8V%L8T-H86EN+GAM;%!+`0(M`!0`!@`(```` M(0"[TC<X'P0``"@1```0`````````````````$I]`P!D;V-0<F]P<R]A<'`N M>&UL4$L!`BT`%``&``@````A`).Y810R`0``0`(``!$````````````````` KGX(#`&1O8U!R;W!S+V-O<F4N>&UL4$L%!@````!4`%0`]18```B%`P`````` ` end </TEXT> </DOCUMENT> <DOCUMENT> <TYPE>XML <SEQUENCE>20 <FILENAME>R70.htm <DESCRIPTION>IDEA: XBRL DOCUMENT <TEXT> <html> <head> <META http-equiv="Content-Type" content="text/html; charset=us-ascii"> <title></title> <link rel="stylesheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript"> function toggleNextSibling (e) { if (e.nextSibling.style.display=='none') { e.nextSibling.style.display='block'; } else { e.nextSibling.style.display='none'; } }</script></head> <body><span style="display: none;">v2.4.1.9</span><table class="report" border="0" cellspacing="2" id="ID0EHDAE"> <tr> <th class="tl" colspan="1" rowspan="2"> <div style="width: 200px;"><strong>Income Taxes - Company's Valuation and Qualifying Accounts (Detail) (Deferred Tax Valuation Allowance [Member], USD $)<br>In Thousands, unless otherwise specified</strong></div> </th> <th class="th" colspan="3">12 Months Ended</th> </tr> <tr> <th class="th"> <div>Dec. 31, 2014</div> </th> <th class="th"> <div>Dec. 31, 2013</div> </th> <th class="th"> <div>Dec. 31, 2012</div> </th> </tr> <tr class="rh"> <td class="pl " style="border-bottom: 0px;" valign="top"> <div class="a">Deferred Tax Valuation Allowance [Member]</div> </td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> </tr> <tr class="ro"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAndQualifyingAccountsDisclosureLineItems', window );"><strong>Valuation and Qualifying Accounts Disclosure [Line Items]</strong></a></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> </tr> <tr class="re"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesBalance', window );">Balance at Beginning of Period</a></td> <td class="nump"><a title="us-gaap_ValuationAllowancesAndReservesBalance[us-gaap_ValuationAllowancesAndReservesTypeAxis=us-gaap_ValuationAllowanceOfDeferredTaxAssetsMember]" onclick="toggleNextSibling(this);">$ 203,863</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ValuationAllowancesAndReservesBalance<br>/ us-gaap_ValuationAllowancesAndReservesTypeAxis<br>= us-gaap_ValuationAllowanceOfDeferredTaxAssetsMember</span><span></span></td> <td class="nump"><a title="us-gaap_ValuationAllowancesAndReservesBalance[us-gaap_ValuationAllowancesAndReservesTypeAxis=us-gaap_ValuationAllowanceOfDeferredTaxAssetsMember]" onclick="toggleNextSibling(this);">$ 190,193</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ValuationAllowancesAndReservesBalance<br>/ us-gaap_ValuationAllowancesAndReservesTypeAxis<br>= us-gaap_ValuationAllowanceOfDeferredTaxAssetsMember</span><span></span></td> <td class="nump"><a title="us-gaap_ValuationAllowancesAndReservesBalance[us-gaap_ValuationAllowancesAndReservesTypeAxis=us-gaap_ValuationAllowanceOfDeferredTaxAssetsMember]" onclick="toggleNextSibling(this);">$ 169,107</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ValuationAllowancesAndReservesBalance<br>/ us-gaap_ValuationAllowancesAndReservesTypeAxis<br>= us-gaap_ValuationAllowanceOfDeferredTaxAssetsMember</span><span></span></td> </tr> <tr class="ro"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesChargedToCostAndExpense', window );">Charged to Expenses</a></td> <td class="nump"><a title="us-gaap_ValuationAllowancesAndReservesChargedToCostAndExpense[us-gaap_ValuationAllowancesAndReservesTypeAxis=us-gaap_ValuationAllowanceOfDeferredTaxAssetsMember]" onclick="toggleNextSibling(this);">1,037</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ValuationAllowancesAndReservesChargedToCostAndExpense<br>/ us-gaap_ValuationAllowancesAndReservesTypeAxis<br>= us-gaap_ValuationAllowanceOfDeferredTaxAssetsMember</span><span></span></td> <td class="nump"><a title="us-gaap_ValuationAllowancesAndReservesChargedToCostAndExpense[us-gaap_ValuationAllowancesAndReservesTypeAxis=us-gaap_ValuationAllowanceOfDeferredTaxAssetsMember]" onclick="toggleNextSibling(this);">13,670</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ValuationAllowancesAndReservesChargedToCostAndExpense<br>/ us-gaap_ValuationAllowancesAndReservesTypeAxis<br>= us-gaap_ValuationAllowanceOfDeferredTaxAssetsMember</span><span></span></td> <td class="nump"><a title="us-gaap_ValuationAllowancesAndReservesChargedToCostAndExpense[us-gaap_ValuationAllowancesAndReservesTypeAxis=us-gaap_ValuationAllowanceOfDeferredTaxAssetsMember]" onclick="toggleNextSibling(this);">21,086</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ValuationAllowancesAndReservesChargedToCostAndExpense<br>/ us-gaap_ValuationAllowancesAndReservesTypeAxis<br>= us-gaap_ValuationAllowanceOfDeferredTaxAssetsMember</span><span></span></td> </tr> <tr class="re"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesChargedToOtherAccounts', window );">Charged to Other Accounts</a></td> <td class="nump"><a title="us-gaap_ValuationAllowancesAndReservesChargedToOtherAccounts[us-gaap_ValuationAllowancesAndReservesTypeAxis=us-gaap_ValuationAllowanceOfDeferredTaxAssetsMember]" onclick="toggleNextSibling(this);">0</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ValuationAllowancesAndReservesChargedToOtherAccounts<br>/ us-gaap_ValuationAllowancesAndReservesTypeAxis<br>= us-gaap_ValuationAllowanceOfDeferredTaxAssetsMember</span><span></span></td> <td class="nump"><a title="us-gaap_ValuationAllowancesAndReservesChargedToOtherAccounts[us-gaap_ValuationAllowancesAndReservesTypeAxis=us-gaap_ValuationAllowanceOfDeferredTaxAssetsMember]" onclick="toggleNextSibling(this);">0</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ValuationAllowancesAndReservesChargedToOtherAccounts<br>/ us-gaap_ValuationAllowancesAndReservesTypeAxis<br>= us-gaap_ValuationAllowanceOfDeferredTaxAssetsMember</span><span></span></td> <td class="nump"><a title="us-gaap_ValuationAllowancesAndReservesChargedToOtherAccounts[us-gaap_ValuationAllowancesAndReservesTypeAxis=us-gaap_ValuationAllowanceOfDeferredTaxAssetsMember]" onclick="toggleNextSibling(this);">0</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ValuationAllowancesAndReservesChargedToOtherAccounts<br>/ us-gaap_ValuationAllowancesAndReservesTypeAxis<br>= us-gaap_ValuationAllowanceOfDeferredTaxAssetsMember</span><span></span></td> </tr> <tr class="ro"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesDeductions', window );">Deductions</a></td> <td class="nump"><a title="us-gaap_ValuationAllowancesAndReservesDeductions[us-gaap_ValuationAllowancesAndReservesTypeAxis=us-gaap_ValuationAllowanceOfDeferredTaxAssetsMember]" onclick="toggleNextSibling(this);">0</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ValuationAllowancesAndReservesDeductions<br>/ us-gaap_ValuationAllowancesAndReservesTypeAxis<br>= us-gaap_ValuationAllowanceOfDeferredTaxAssetsMember</span><span></span></td> <td class="nump"><a title="us-gaap_ValuationAllowancesAndReservesDeductions[us-gaap_ValuationAllowancesAndReservesTypeAxis=us-gaap_ValuationAllowanceOfDeferredTaxAssetsMember]" onclick="toggleNextSibling(this);">0</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ValuationAllowancesAndReservesDeductions<br>/ us-gaap_ValuationAllowancesAndReservesTypeAxis<br>= us-gaap_ValuationAllowanceOfDeferredTaxAssetsMember</span><span></span></td> <td class="nump"><a title="us-gaap_ValuationAllowancesAndReservesDeductions[us-gaap_ValuationAllowancesAndReservesTypeAxis=us-gaap_ValuationAllowanceOfDeferredTaxAssetsMember]" onclick="toggleNextSibling(this);">0</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ValuationAllowancesAndReservesDeductions<br>/ us-gaap_ValuationAllowancesAndReservesTypeAxis<br>= us-gaap_ValuationAllowanceOfDeferredTaxAssetsMember</span><span></span></td> </tr> <tr class="re"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesBalance', window );">Balance at End of Period</a></td> <td class="nump"><a title="us-gaap_ValuationAllowancesAndReservesBalance[us-gaap_ValuationAllowancesAndReservesTypeAxis=us-gaap_ValuationAllowanceOfDeferredTaxAssetsMember]" onclick="toggleNextSibling(this);">$ 204,900</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ValuationAllowancesAndReservesBalance<br>/ us-gaap_ValuationAllowancesAndReservesTypeAxis<br>= us-gaap_ValuationAllowanceOfDeferredTaxAssetsMember</span><span></span></td> <td class="nump"><a title="us-gaap_ValuationAllowancesAndReservesBalance[us-gaap_ValuationAllowancesAndReservesTypeAxis=us-gaap_ValuationAllowanceOfDeferredTaxAssetsMember]" onclick="toggleNextSibling(this);">$ 203,863</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ValuationAllowancesAndReservesBalance<br>/ us-gaap_ValuationAllowancesAndReservesTypeAxis<br>= us-gaap_ValuationAllowanceOfDeferredTaxAssetsMember</span><span></span></td> <td class="nump"><a title="us-gaap_ValuationAllowancesAndReservesBalance[us-gaap_ValuationAllowancesAndReservesTypeAxis=us-gaap_ValuationAllowanceOfDeferredTaxAssetsMember]" onclick="toggleNextSibling(this);">$ 190,193</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ValuationAllowancesAndReservesBalance<br>/ us-gaap_ValuationAllowancesAndReservesTypeAxis<br>= us-gaap_ValuationAllowanceOfDeferredTaxAssetsMember</span><span></span></td> </tr> </table> <div style="display: none;"> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowancesAndReservesBalance"> <tr> <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td> </tr> <tr> <td> <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div> <p>Total of allowances and reserves, the valuation and qualifying accounts that are either netted against the cost of an asset (in order to value it at its carrying value) or that reflect a liability established to represent expected future costs.</p> </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"> <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 4<br><br> -URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e24092-122690<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 09<br><br> -Article 12<br><br><br><br></p> </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"> <table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_ValuationAllowancesAndReservesBalance</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:monetaryItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>credit</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>instant</td> </tr> </table> </div> </div> </td> </tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowancesAndReservesChargedToCostAndExpense"> <tr> <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td> </tr> <tr> <td> <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div> <p>Total of allowances and reserves, the valuation and qualifying accounts that are either netted against the cost of an asset (in order to value it at its carrying value) or that reflect a liability established to represent expected future costs, charged to costs and expenses.</p> </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"> <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 4<br><br> -URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e24092-122690<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 09<br><br> -Article 12<br><br><br><br></p> </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"> <table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_ValuationAllowancesAndReservesChargedToCostAndExpense</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:monetaryItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>credit</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table> </div> </div> </td> </tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowancesAndReservesChargedToOtherAccounts"> <tr> <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td> </tr> <tr> <td> <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div> <p>Total of allowances and reserves, the valuation and qualifying accounts that are either netted against the cost of an asset (in order to value it at its carrying value) or that reflect a liability established to represent expected future costs, charged to accounts other than costs and expenses in a given period.</p> </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"> <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 4<br><br> -URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e24092-122690<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 09<br><br> -Article 12<br><br><br><br></p> </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"> <table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_ValuationAllowancesAndReservesChargedToOtherAccounts</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:monetaryItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>credit</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table> </div> </div> </td> </tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowancesAndReservesDeductions"> <tr> <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td> </tr> <tr> <td> <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div> <p>Total of the deductions in a given period to allowances and reserves, the valuation and qualifying accounts that are either netted against the cost of an asset (in order to value it at its carrying value) or that reflect a liability established to represent expected future costs, representing receivables written off as uncollectible and portions of the reserves utilized, respectively.</p> </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"> <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 4<br><br> -URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e24092-122690<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 09<br><br> -Article 12<br><br><br><br></p> </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"> <table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_ValuationAllowancesAndReservesDeductions</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:monetaryItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>debit</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table> </div> </div> </td> </tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAndQualifyingAccountsDisclosureLineItems"> <tr> <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td> </tr> <tr> <td> <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div> <table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_ValuationAndQualifyingAccountsDisclosureLineItems</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:stringItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table> </div> </div> </td> </tr> </table> </div> </body> </html> </TEXT> </DOCUMENT> <DOCUMENT> <TYPE>XML <SEQUENCE>21 <FILENAME>R55.htm <DESCRIPTION>IDEA: XBRL DOCUMENT <TEXT> <html> <head> <META http-equiv="Content-Type" content="text/html; charset=us-ascii"> <title></title> <link rel="stylesheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript"> function toggleNextSibling (e) { if (e.nextSibling.style.display=='none') { e.nextSibling.style.display='block'; } else { e.nextSibling.style.display='none'; } }</script></head> <body><span style="display: none;">v2.4.1.9</span><table class="report" border="0" cellspacing="2" id="ID0EXBAC"> <tr> <th class="tl" colspan="1" rowspan="2"> <div style="width: 200px;"><strong>Debt - Summary of Total Interest Expense Incurred (Detail) (USD $)<br>In Thousands, unless otherwise specified</strong></div> </th> <th class="th" colspan="3">12 Months Ended</th> </tr> <tr> <th class="th"> <div>Dec. 31, 2014</div> </th> <th class="th"> <div>Dec. 31, 2013</div> </th> <th class="th"> <div>Dec. 31, 2012</div> </th> </tr> <tr class="re"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> </tr> <tr class="ro"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Interest expense</a></td> <td class="nump"><a title="us-gaap_InterestExpense" onclick="toggleNextSibling(this);">$ 0</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_InterestExpense</span><span></span></td> <td class="nump"><a title="us-gaap_InterestExpense" onclick="toggleNextSibling(this);">$ 0</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_InterestExpense</span><span></span></td> <td class="nump"><a title="us-gaap_InterestExpense" onclick="toggleNextSibling(this);">$ 3</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_InterestExpense</span><span></span></td> </tr> </table> <div style="display: none;"> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract"> <tr> <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td> </tr> <tr> <td> <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div> <table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:stringItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table> </div> </div> </td> </tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpense"> <tr> <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td> </tr> <tr> <td> <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div> <p>Amount of the cost of borrowed funds accounted for as interest expense.</p> </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"> <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 835<br><br> -SubTopic 20<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&oid=6450988&loc=d3e26243-108391<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 942<br><br> -SubTopic 225<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.9-04.9)<br><br> -URI http://asc.fasb.org/extlink&oid=6879574&loc=d3e536633-122882<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 04<br><br> -Paragraph 9<br><br> -Article 9<br><br><br><br></p> </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"> <table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_InterestExpense</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:monetaryItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>debit</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table> </div> </div> </td> </tr> </table> </div> </body> </html> </TEXT> </DOCUMENT> <DOCUMENT> <TYPE>XML <SEQUENCE>22 <FILENAME>R46.htm <DESCRIPTION>IDEA: XBRL DOCUMENT <TEXT> <html> <head> <META http-equiv="Content-Type" content="text/html; charset=us-ascii"> <title></title> <link rel="stylesheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript"> function toggleNextSibling (e) { if (e.nextSibling.style.display=='none') { e.nextSibling.style.display='block'; } else { e.nextSibling.style.display='none'; } }</script></head> <body><span style="display: none;">v2.4.1.9</span><table class="report" border="0" cellspacing="2" id="ID0ETWAE"> <tr> <th class="tl" colspan="1" rowspan="1"> <div style="width: 200px;"><strong>Balance Sheet Components - Summary of Property and Equipment Balances (Detail) (USD $)<br>In Thousands, unless otherwise specified</strong></div> </th> <th class="th"> <div>Dec. 31, 2014</div> </th> <th class="th"> <div>Dec. 31, 2013</div> </th> </tr> <tr class="re"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNetAbstract', window );"><strong>Property and equipment, net:</strong></a></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> </tr> <tr class="ro"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td> <td class="nump"><a title="us-gaap_PropertyPlantAndEquipmentGross" onclick="toggleNextSibling(this);">$ 21,964</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_PropertyPlantAndEquipmentGross</span><span></span></td> <td class="nump"><a title="us-gaap_PropertyPlantAndEquipmentGross" onclick="toggleNextSibling(this);">$ 22,213</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_PropertyPlantAndEquipmentGross</span><span></span></td> </tr> <tr class="re"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Less: Accumulated depreciation and amortization</a></td> <td class="num"><a title="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" onclick="toggleNextSibling(this);">(20,327)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment</span><span></span></td> <td class="num"><a title="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" onclick="toggleNextSibling(this);">(20,992)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment</span><span></span></td> </tr> <tr class="rou"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td> <td class="nump"><a title="us-gaap_PropertyPlantAndEquipmentNet" onclick="toggleNextSibling(this);">1,637</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_PropertyPlantAndEquipmentNet</span><span></span></td> <td class="nump"><a title="us-gaap_PropertyPlantAndEquipmentNet" onclick="toggleNextSibling(this);">1,221</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_PropertyPlantAndEquipmentNet</span><span></span></td> </tr> <tr class="rh"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=cytk_LaboratoryEquipmentMember', window );">Laboratory Equipment [Member]</a></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> </tr> <tr class="ro"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNetAbstract', window );"><strong>Property and equipment, net:</strong></a></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> </tr> <tr class="re"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td> <td class="nump"><a title="us-gaap_PropertyPlantAndEquipmentGross[us-gaap_PropertyPlantAndEquipmentByTypeAxis=cytk_LaboratoryEquipmentMember]" onclick="toggleNextSibling(this);">15,299</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_PropertyPlantAndEquipmentGross<br>/ us-gaap_PropertyPlantAndEquipmentByTypeAxis<br>= cytk_LaboratoryEquipmentMember</span><span></span></td> <td class="nump"><a title="us-gaap_PropertyPlantAndEquipmentGross[us-gaap_PropertyPlantAndEquipmentByTypeAxis=cytk_LaboratoryEquipmentMember]" onclick="toggleNextSibling(this);">15,317</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_PropertyPlantAndEquipmentGross<br>/ us-gaap_PropertyPlantAndEquipmentByTypeAxis<br>= cytk_LaboratoryEquipmentMember</span><span></span></td> </tr> <tr class="rh"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=cytk_ComputerEquipmentAndSoftwareMember', window );">Computer Equipment and Software [Member]</a></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> </tr> <tr class="re"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNetAbstract', window );"><strong>Property and equipment, net:</strong></a></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> </tr> <tr class="ro"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td> <td class="nump"><a title="us-gaap_PropertyPlantAndEquipmentGross[us-gaap_PropertyPlantAndEquipmentByTypeAxis=cytk_ComputerEquipmentAndSoftwareMember]" onclick="toggleNextSibling(this);">2,418</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_PropertyPlantAndEquipmentGross<br>/ us-gaap_PropertyPlantAndEquipmentByTypeAxis<br>= cytk_ComputerEquipmentAndSoftwareMember</span><span></span></td> <td class="nump"><a title="us-gaap_PropertyPlantAndEquipmentGross[us-gaap_PropertyPlantAndEquipmentByTypeAxis=cytk_ComputerEquipmentAndSoftwareMember]" onclick="toggleNextSibling(this);">2,549</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_PropertyPlantAndEquipmentGross<br>/ us-gaap_PropertyPlantAndEquipmentByTypeAxis<br>= cytk_ComputerEquipmentAndSoftwareMember</span><span></span></td> </tr> <tr class="rh"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=cytk_OfficeEquipmentFurnitureAndFixturesMember', window );">Office Equipment, Furniture and Fixtures [Member]</a></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> </tr> <tr class="ro"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNetAbstract', window );"><strong>Property and equipment, net:</strong></a></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> </tr> <tr class="re"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td> <td class="nump"><a title="us-gaap_PropertyPlantAndEquipmentGross[us-gaap_PropertyPlantAndEquipmentByTypeAxis=cytk_OfficeEquipmentFurnitureAndFixturesMember]" onclick="toggleNextSibling(this);">913</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_PropertyPlantAndEquipmentGross<br>/ us-gaap_PropertyPlantAndEquipmentByTypeAxis<br>= cytk_OfficeEquipmentFurnitureAndFixturesMember</span><span></span></td> <td class="nump"><a title="us-gaap_PropertyPlantAndEquipmentGross[us-gaap_PropertyPlantAndEquipmentByTypeAxis=cytk_OfficeEquipmentFurnitureAndFixturesMember]" onclick="toggleNextSibling(this);">1,050</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_PropertyPlantAndEquipmentGross<br>/ us-gaap_PropertyPlantAndEquipmentByTypeAxis<br>= cytk_OfficeEquipmentFurnitureAndFixturesMember</span><span></span></td> </tr> <tr class="rh"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdsAndLeaseholdImprovementsMember', window );">Leasehold Improvements [Member]</a></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> </tr> <tr class="re"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNetAbstract', window );"><strong>Property and equipment, net:</strong></a></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> </tr> <tr class="ro"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td> <td class="nump"><a title="us-gaap_PropertyPlantAndEquipmentGross[us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdsAndLeaseholdImprovementsMember]" onclick="toggleNextSibling(this);">$ 3,334</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_PropertyPlantAndEquipmentGross<br>/ us-gaap_PropertyPlantAndEquipmentByTypeAxis<br>= us-gaap_LeaseholdsAndLeaseholdImprovementsMember</span><span></span></td> <td class="nump"><a title="us-gaap_PropertyPlantAndEquipmentGross[us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdsAndLeaseholdImprovementsMember]" onclick="toggleNextSibling(this);">$ 3,297</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_PropertyPlantAndEquipmentGross<br>/ us-gaap_PropertyPlantAndEquipmentByTypeAxis<br>= us-gaap_LeaseholdsAndLeaseholdImprovementsMember</span><span></span></td> </tr> </table> <div style="display: none;"> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"> <tr> <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td> </tr> <tr> <td> <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div> <p>Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.</p> </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"> <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 360<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -Subparagraph (c)<br><br> -URI http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.14)<br><br> -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 14<br><br> -Article 5<br><br><br><br></p> </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"> <table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:monetaryItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>credit</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>instant</td> </tr> </table> </div> </div> </td> </tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentGross"> <tr> <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td> </tr> <tr> <td> <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div> <p>Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p> </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"> <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 360<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -Subparagraph (b)<br><br> -URI http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.13)<br><br> -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682<br><br><br><br></p> </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"> <table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentGross</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:monetaryItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>debit</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>instant</td> </tr> </table> </div> </div> </td> </tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet"> <tr> <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td> </tr> <tr> <td> <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div> <p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p> </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"> <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 360<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.13)<br><br> -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 13<br><br> -Subparagraph a<br><br> -Article 5<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 03<br><br> -Paragraph 8<br><br> -Article 7<br><br><br><br></p> </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"> <table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:monetaryItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>debit</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>instant</td> </tr> </table> </div> </div> </td> </tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNetAbstract"> <tr> <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td> </tr> <tr> <td> <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div> <table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNetAbstract</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:stringItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table> </div> </div> </td> </tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=cytk_ComputerEquipmentAndSoftwareMember"> <tr> <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td> </tr> <tr> <td> <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div> <table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=cytk_ComputerEquipmentAndSoftwareMember</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td></td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td></td> </tr> <tr> <td><strong> Period Type:</strong></td> <td></td> </tr> </table> </div> </div> </td> </tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=cytk_LaboratoryEquipmentMember"> <tr> <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td> </tr> <tr> <td> <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div> <table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=cytk_LaboratoryEquipmentMember</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td></td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td></td> </tr> <tr> <td><strong> Period Type:</strong></td> <td></td> </tr> </table> </div> </div> </td> </tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=cytk_OfficeEquipmentFurnitureAndFixturesMember"> <tr> <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td> </tr> <tr> <td> <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div> <table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=cytk_OfficeEquipmentFurnitureAndFixturesMember</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td></td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td></td> </tr> <tr> <td><strong> Period Type:</strong></td> <td></td> </tr> </table> </div> </div> </td> </tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdsAndLeaseholdImprovementsMember"> <tr> <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td> </tr> <tr> <td> <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div> <table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdsAndLeaseholdImprovementsMember</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td></td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td></td> </tr> <tr> <td><strong> Period Type:</strong></td> <td></td> </tr> </table> </div> </div> </td> </tr> </table> </div> </body> </html> </TEXT> </DOCUMENT> <DOCUMENT> <TYPE>XML <SEQUENCE>23 <FILENAME>R33.htm <DESCRIPTION>IDEA: XBRL DOCUMENT <TEXT> <html> <head> <META http-equiv="Content-Type" content="text/html; charset=us-ascii"> <title></title> <link rel="stylesheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript"> function toggleNextSibling (e) { if (e.nextSibling.style.display=='none') { e.nextSibling.style.display='block'; } else { e.nextSibling.style.display='none'; } }</script></head> <body><span style="display: none;">v2.4.1.9</span><table class="report" border="0" cellspacing="2" id="ID0EJCAC"> <tr> <th class="tl" colspan="1" rowspan="2"> <div style="width: 200px;"><strong>Stockholders' Equity (Tables)<br></strong></div> </th> <th class="th" colspan="1">12 Months Ended</th> </tr> <tr> <th class="th"> <div>Dec. 31, 2014</div> </th> </tr> <tr class="re"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td> <td class="text"> <span></span></td> </tr> <tr class="ro"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock', window );">Outstanding Warrants</a></td> <td class="text"><div> <p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 12px; TEXT-INDENT: 4%" align="justify"><font style="FONT-FAMILY: Times New Roman" size="2">Outstanding warrants as of December 31, 2014 were as follows:</font></p> <p style="MARGIN-BOTTOM: 0px; FONT-SIZE: 12px; MARGIN-TOP: 0px">  </p> <table style="BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="92%" align="center" border="0"> <tr> <td width="67%"></td> <td valign="bottom" width="4%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="4%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="4%"></td> <td></td> <td></td> <td></td> </tr> <tr> <td valign="bottom"><font size="1"> </font></td> <td valign="bottom"><font size="1">  </font></td> <td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" align="center"><font style="FONT-FAMILY: Times New Roman" size="1"><b>Number<br /> of Shares</b></font></td> <td valign="bottom"><font size="1"> </font></td> <td valign="bottom"><font size="1">  </font></td> <td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" align="center"><font style="FONT-FAMILY: Times New Roman" size="1"><b>Exercise<br /> Price</b></font></td> <td valign="bottom"><font size="1"> </font></td> <td valign="bottom"><font size="1">  </font></td> <td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" align="center"><font style="FONT-FAMILY: Times New Roman" size="1"><b>Expiration<br /> Date</b></font></td> <td valign="bottom"><font size="1"> </font></td> </tr> <tr bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: Times New Roman" size="2">Issued 4/20/2011</font></p> </td> <td valign="bottom"><font size="1">  </font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2"> </font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">1,114,168</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">  </font></td> <td valign="bottom"><font size="1">  </font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">9.90</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">  </font></td> <td valign="bottom"><font size="1">  </font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2"> </font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">04/20/15</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">  </font></td> </tr> <tr> <td valign="top"> <p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: Times New Roman" size="2">Issued 6/25/2012</font></p> </td> <td valign="bottom"><font size="1">  </font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2"> </font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">5,576,928</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">  </font></td> <td valign="bottom"><font size="1">  </font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">5.28</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">  </font></td> <td valign="bottom"><font size="1">  </font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2"> </font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">06/25/17</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">  </font></td> </tr> </table> </div><span></span></td> </tr> <tr class="re"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">Summary of Stock Option Activity</a></td> <td class="text"><div> <p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 0px; TEXT-INDENT: 4%" align="justify"><font style="FONT-FAMILY: Times New Roman" size="2">Activity under the two stock option plans was as follows:</font></p> <p style="MARGIN-BOTTOM: 0px; FONT-SIZE: 12px; MARGIN-TOP: 0px">  </p> <table style="BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="100%" align="center" border="0"> <tr> <td width="41%"></td> <td valign="bottom" width="6%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="6%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="6%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="6%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="6%"></td> <td></td> <td></td> <td></td> </tr> <tr> <td valign="bottom"><font size="1"> </font></td> <td valign="bottom"><font size="1"> </font></td> <td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" align="center"><font style="FONT-FAMILY: Times New Roman" size="1"><b>Shares<br /> Available for<br /> Grant of Option<br /> or Award</b></font></td> <td valign="bottom"><font size="1"> </font></td> <td valign="bottom"><font size="1"> </font></td> <td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" align="center"><font style="FONT-FAMILY: Times New Roman" size="1"><b>Stock Options<br /> Outstanding</b></font></td> <td valign="bottom"><font size="1"> </font></td> <td valign="bottom"><font size="1"> </font></td> <td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" align="center"><font style="FONT-FAMILY: Times New Roman" size="1"><b>Weighted<br /> Average Exercise<br /> Price per Share -<br /> Stock Options</b></font></td> <td valign="bottom"><font size="1"> </font></td> <td valign="bottom"><font size="1"> </font></td> <td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" align="center"><font style="FONT-FAMILY: Times New Roman" size="1"><b>Weighted<br /> Average Remaining<br /> Contractual Life</b></font></td> <td valign="bottom"><font size="1"> </font></td> <td valign="bottom"><font size="1"> </font></td> <td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" align="center"><font style="FONT-FAMILY: Times New Roman" size="1"><b>Aggregate<br /> Intrinsic<br /> Value</b></font><br /> <font style="FONT-FAMILY: Times New Roman" size="1"><b>(in  thousands)</b></font></td> <td valign="bottom"><font size="1"> </font></td> </tr> <tr bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-LEFT: 2em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: Times New Roman" size="2">Balance at December 31, 2011</font></p> </td> <td valign="bottom"><font size="1"> </font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2"> </font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">585,476</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">  </font></td> <td valign="bottom"><font size="1"> </font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2"> </font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">1,598,408</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">  </font></td> <td valign="bottom"><font size="1"> </font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2"> </font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">21.93</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">  </font></td> <td valign="bottom"><font size="1"> </font></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"><font size="1"> </font></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr> <td valign="top"> <p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: Times New Roman" size="2">Increase in authorized shares</font></p> </td> <td valign="bottom"><font size="1"> </font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2"> </font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">416,667</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">  </font></td> <td valign="bottom"><font size="1"> </font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2"> </font></td> <td valign="bottom" nowrap="nowrap" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">—</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">  </font></td> <td valign="bottom"><font size="1"> </font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2"> </font></td> <td valign="bottom" nowrap="nowrap" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">—</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">  </font></td> <td valign="bottom"><font size="1"> </font></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"><font size="1"> </font></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: Times New Roman" size="2">Options granted</font></p> </td> <td valign="bottom"><font size="1"> </font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2"> </font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">(403,108</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">) </font></td> <td valign="bottom"><font size="1"> </font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2"> </font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">403,108</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">  </font></td> <td valign="bottom"><font size="1"> </font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2"> </font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">6.14</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">  </font></td> <td valign="bottom"><font size="1"> </font></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"><font size="1"> </font></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr> <td valign="top"> <p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: Times New Roman" size="2">Options forfeited/expired</font></p> </td> <td valign="bottom"><font size="1"> </font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2"> </font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">210,989</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">  </font></td> <td valign="bottom"><font size="1"> </font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2"> </font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">(210,989</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">) </font></td> <td valign="bottom"><font size="1"> </font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2"> </font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">17.00</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">  </font></td> <td valign="bottom"><font size="1"> </font></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"><font size="1"> </font></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: Times New Roman" size="2">Restricted stock units forfeited</font></p> </td> <td valign="bottom"><font size="1"> </font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2"> </font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">68,702</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">  </font></td> <td valign="bottom"><font size="1"> </font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2"> </font></td> <td valign="bottom" nowrap="nowrap" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">—</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">  </font></td> <td valign="bottom"><font size="1"> </font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2"> </font></td> <td valign="bottom" nowrap="nowrap" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">—</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">  </font></td> <td valign="bottom"><font size="1"> </font></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"><font size="1"> </font></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom"> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid"> </p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid"> </p> </td> <td> </td> <td valign="bottom"> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid"> </p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid"> </p> </td> <td> </td> <td valign="bottom"> </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"> </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"> </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr> <td valign="top"> <p style="MARGIN-LEFT: 2em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: Times New Roman" size="2">Balance at December 31, 2012</font></p> </td> <td valign="bottom"><font size="1"> </font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2"> </font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">878,726</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">  </font></td> <td valign="bottom"><font size="1"> </font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2"> </font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">1,790,527</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">  </font></td> <td valign="bottom"><font size="1"> </font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2"> </font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">18.96</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">  </font></td> <td valign="bottom"><font size="1"> </font></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"><font size="1"> </font></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: Times New Roman" size="2">Increase in authorized shares</font></p> </td> <td valign="bottom"><font size="1"> </font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2"> </font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">2,000,000</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">  </font></td> <td valign="bottom"><font size="1"> </font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2"> </font></td> <td valign="bottom" nowrap="nowrap" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">—</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">  </font></td> <td valign="bottom"><font size="1"> </font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2"> </font></td> <td valign="bottom" nowrap="nowrap" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">—</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">  </font></td> <td valign="bottom"><font size="1"> </font></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"><font size="1"> </font></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr> <td valign="top"> <p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: Times New Roman" size="2">Options granted</font></p> </td> <td valign="bottom"><font size="1"> </font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2"> </font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">(797,629</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">) </font></td> <td valign="bottom"><font size="1"> </font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2"> </font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">797,629</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">  </font></td> <td valign="bottom"><font size="1"> </font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2"> </font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">5.95</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">  </font></td> <td valign="bottom"><font size="1"> </font></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"><font size="1"> </font></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: Times New Roman" size="2">Restricted stock units granted</font></p> </td> <td valign="bottom"><font size="1"> </font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2"> </font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">(41,661</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">) </font></td> <td valign="bottom"><font size="1"> </font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2"> </font></td> <td valign="bottom" nowrap="nowrap" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">—</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">  </font></td> <td valign="bottom"><font size="1"> </font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2"> </font></td> <td valign="bottom" nowrap="nowrap" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">—</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">  </font></td> <td valign="bottom"><font size="1"> </font></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"><font size="1"> </font></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr> <td valign="top"> <p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: Times New Roman" size="2">Options exercised</font></p> </td> <td valign="bottom"><font size="1"> </font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2"> </font></td> <td valign="bottom" nowrap="nowrap" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">—</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">  </font></td> <td valign="bottom"><font size="1"> </font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2"> </font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">(21,397</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">) </font></td> <td valign="bottom"><font size="1"> </font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2"> </font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">5.32</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">  </font></td> <td valign="bottom"><font size="1"> </font></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"><font size="1"> </font></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: Times New Roman" size="2">Options forfeited/expired</font></p> </td> <td valign="bottom"><font size="1"> </font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2"> </font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">117,394</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">  </font></td> <td valign="bottom"><font size="1"> </font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2"> </font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">(117,394</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">) </font></td> <td valign="bottom"><font size="1"> </font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2"> </font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">12.55</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">  </font></td> <td valign="bottom"><font size="1"> </font></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"><font size="1"> </font></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr> <td valign="top"> <p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: Times New Roman" size="2">Restricted stock units forfeited</font></p> </td> <td valign="bottom"><font size="1"> </font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2"> </font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">4,999</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">  </font></td> <td valign="bottom"><font size="1"> </font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2"> </font></td> <td valign="bottom" nowrap="nowrap" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">—</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">  </font></td> <td valign="bottom"><font size="1"> </font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2"> </font></td> <td valign="bottom" nowrap="nowrap" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">—</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">  </font></td> <td valign="bottom"><font size="1"> </font></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"><font size="1"> </font></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom"> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid"> </p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid"> </p> </td> <td> </td> <td valign="bottom"> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid"> </p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid"> </p> </td> <td> </td> <td valign="bottom"> </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"> </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"> </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-LEFT: 2em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: Times New Roman" size="2">Balance at December 31, 2013</font></p> </td> <td valign="bottom"><font size="1"> </font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2"> </font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">2,161,829</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">  </font></td> <td valign="bottom"><font size="1"> </font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2"> </font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">2,449,365</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">  </font></td> <td valign="bottom"><font size="1"> </font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">15.15</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">  </font></td> <td valign="bottom"><font size="1"> </font></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"><font size="1"> </font></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr> <td valign="top"> <p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: Times New Roman" size="2">Options granted</font></p> </td> <td valign="bottom"><font size="1"> </font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2"> </font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">(944,831</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">) </font></td> <td valign="bottom"><font size="1"> </font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2"> </font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">944,831</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">  </font></td> <td valign="bottom"><font size="1"> </font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2"> </font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">8.80</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">  </font></td> <td valign="bottom"><font size="1"> </font></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"><font size="1"> </font></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: Times New Roman" size="2">Restricted stock units granted</font></p> </td> <td valign="bottom"><font size="1"> </font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2"> </font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">(43,500</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">) </font></td> <td valign="bottom"><font size="1"> </font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2"> </font></td> <td valign="bottom" nowrap="nowrap" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">—</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">  </font></td> <td valign="bottom"><font size="1"> </font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2"> </font></td> <td valign="bottom" nowrap="nowrap" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">—</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">  </font></td> <td valign="bottom"><font size="1"> </font></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"><font size="1"> </font></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr> <td valign="top"> <p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: Times New Roman" size="2">Options exercised</font></p> </td> <td valign="bottom"><font size="1"> </font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2"> </font></td> <td valign="bottom" nowrap="nowrap" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">—</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">  </font></td> <td valign="bottom"><font size="1"> </font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2"> </font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">(390</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">) </font></td> <td valign="bottom"><font size="1"> </font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2"> </font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">6.00</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">  </font></td> <td valign="bottom"><font size="1"> </font></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"><font size="1"> </font></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: Times New Roman" size="2">Options forfeited/expired</font></p> </td> <td valign="bottom"><font size="1"> </font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2"> </font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">95,980</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">  </font></td> <td valign="bottom"><font size="1"> </font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2"> </font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">(95,980</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">) </font></td> <td valign="bottom"><font size="1"> </font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2"> </font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">39.74</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">  </font></td> <td valign="bottom"><font size="1"> </font></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"><font size="1"> </font></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr> <td valign="top"> <p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: Times New Roman" size="2">Restricted stock units forfeited</font></p> </td> <td valign="bottom"><font size="1"> </font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2"> </font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">1,000</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">  </font></td> <td valign="bottom"><font size="1"> </font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2"> </font></td> <td valign="bottom" nowrap="nowrap" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">—</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">  </font></td> <td valign="bottom"><font size="1"> </font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2"> </font></td> <td valign="bottom" nowrap="nowrap" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">—</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">  </font></td> <td valign="bottom"><font size="1"> </font></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"><font size="1"> </font></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom"> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid"> </p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid"> </p> </td> <td> </td> <td valign="bottom"> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid"> </p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid"> </p> </td> <td> </td> <td valign="bottom"> </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"> </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"> </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-LEFT: 2em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: Times New Roman" size="2">Balance at December 31, 2014</font></p> </td> <td valign="bottom"><font size="1"> </font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2"> </font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">1,270,478</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">  </font></td> <td valign="bottom"><font size="1"> </font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2"> </font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">3,297,826</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">  </font></td> <td valign="bottom"><font size="1"> </font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">12.62</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">  </font></td> <td valign="bottom"><font size="1"> </font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2"> </font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">6.79</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">  </font></td> <td valign="bottom"><font size="1"> </font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">2,657</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">  </font></td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom"> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double"> </p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double"> </p> </td> <td> </td> <td valign="bottom"> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double"> </p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double"> </p> </td> <td> </td> <td valign="bottom"> </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"> </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"> </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr> <td valign="top"> <p style="MARGIN-LEFT: 2em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: Times New Roman" size="2">Exercisable at December 31, 2014</font></p> </td> <td valign="bottom"><font size="1"> </font></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"><font size="1"> </font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2"> </font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">2,140,754</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">  </font></td> <td valign="bottom"><font size="1"> </font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">15.17</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">  </font></td> <td valign="bottom"><font size="1"> </font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2"> </font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">5.76</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">  </font></td> <td valign="bottom"><font size="1"> </font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">1,553</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">  </font></td> </tr> <tr bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-LEFT: 2em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: Times New Roman" size="2">Vested and expected to vest as of December 31, 2014</font></p> </td> <td valign="bottom"><font size="1"> </font></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"><font size="1"> </font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2"> </font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">3,277,489</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">  </font></td> <td valign="bottom"><font size="1"> </font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">12.64</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">  </font></td> <td valign="bottom"><font size="1"> </font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2"> </font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">6.78</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">  </font></td> <td valign="bottom"><font size="1"> </font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">2,642</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">  </font></td> </tr> </table> </div><span></span></td> </tr> <tr class="ro"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock', window );">Summary of Restricted Stock Unit Activity</a></td> <td class="text"><div> <p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 0px; TEXT-INDENT: 4%" align="justify"><font style="FONT-FAMILY: Times New Roman" size="2">Restricted stock unit activity was as follows:</font></p> <p style="MARGIN-BOTTOM: 0px; FONT-SIZE: 12px; MARGIN-TOP: 0px">  </p> <table style="BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="92%" align="center" border="0"> <tr> <td width="73%"></td> <td valign="bottom" width="8%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="7%"></td> <td></td> <td></td> <td></td> </tr> <tr> <td valign="bottom"><font size="1"> </font></td> <td valign="bottom"><font size="1">  </font></td> <td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" align="center"><font style="FONT-FAMILY: Times New Roman" size="1"><b>Number of<br /> Shares</b></font></td> <td valign="bottom"><font size="1"> </font></td> <td valign="bottom"><font size="1">  </font></td> <td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" align="center"><font style="FONT-FAMILY: Times New Roman" size="1"><b>Weighted<br /> Average Award<br /> Date Fair Value<br /> per Share</b></font></td> <td valign="bottom"><font size="1"> </font></td> </tr> <tr bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: Times New Roman" size="2">Restricted stock units outstanding at December 31, 2011</font></p> </td> <td valign="bottom"><font size="1">  </font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2"> </font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">517,535</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">  </font></td> <td valign="bottom"><font size="1">  </font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">6.78</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">  </font></td> </tr> <tr> <td valign="top"> <p style="MARGIN-LEFT: 2em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: Times New Roman" size="2">Restricted stock units vested</font></p> </td> <td valign="bottom"><font size="1">  </font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2"> </font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">(231,935</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">) </font></td> <td valign="bottom"><font size="1">  </font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2"> </font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">6.78</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">  </font></td> </tr> <tr bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-LEFT: 2em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: Times New Roman" size="2">Restricted stock units forfeited</font></p> </td> <td valign="bottom"><font size="1">  </font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2"> </font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">(68,702</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">) </font></td> <td valign="bottom"><font size="1">  </font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2"> </font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">6.78</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">  </font></td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid"> </p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid"> </p> </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr> <td valign="top"> <p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: Times New Roman" size="2">Restricted stock units outstanding at December 31, 2012</font></p> </td> <td valign="bottom"><font size="1">  </font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2"> </font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">216,898</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">  </font></td> <td valign="bottom"><font size="1">  </font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2"> </font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">6.78</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">  </font></td> </tr> <tr bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-LEFT: 2em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: Times New Roman" size="2">Restricted stock units granted</font></p> </td> <td valign="bottom"><font size="1">  </font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2"> </font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">41,661</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">  </font></td> <td valign="bottom"><font size="1">  </font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2"> </font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">6.00</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">  </font></td> </tr> <tr> <td valign="top"> <p style="MARGIN-LEFT: 2em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: Times New Roman" size="2">Restricted stock units vested</font></p> </td> <td valign="bottom"><font size="1">  </font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2"> </font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">(211,897</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">) </font></td> <td valign="bottom"><font size="1">  </font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2"> </font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">6.78</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">  </font></td> </tr> <tr bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-LEFT: 2em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: Times New Roman" size="2">Restricted stock units forfeited</font></p> </td> <td valign="bottom"><font size="1">  </font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2"> </font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">(4,999</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">) </font></td> <td valign="bottom"><font size="1">  </font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2"> </font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">6.78</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">  </font></td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid"> </p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid"> </p> </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr> <td valign="top"> <p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: Times New Roman" size="2">Unvested restricted stock units outstanding at December 31, 2013</font></p> </td> <td valign="bottom"><font size="1">  </font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2"> </font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">41,663</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">  </font></td> <td valign="bottom"><font size="1">  </font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2"> </font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">6.00</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">  </font></td> </tr> <tr bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-LEFT: 2em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: Times New Roman" size="2">Restricted stock units granted</font></p> </td> <td valign="bottom"><font size="1">  </font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2"> </font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">43,500</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">  </font></td> <td valign="bottom"><font size="1">  </font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2"> </font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">9.65</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">  </font></td> </tr> <tr> <td valign="top"> <p style="MARGIN-LEFT: 2em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: Times New Roman" size="2">Restricted stock units vested</font></p> </td> <td valign="bottom"><font size="1">  </font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2"> </font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">(20,833</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">) </font></td> <td valign="bottom"><font size="1">  </font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2"> </font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">6.00</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">  </font></td> </tr> <tr bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-LEFT: 2em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: Times New Roman" size="2">Restricted stock units forfeited</font></p> </td> <td valign="bottom"><font size="1">  </font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2"> </font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">(1,000</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">) </font></td> <td valign="bottom"><font size="1">  </font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2"> </font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">6.00</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">  </font></td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid"> </p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid"> </p> </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr> <td valign="top"> <p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: Times New Roman" size="2">Unvested restricted stock units outstanding at December 31, 2014</font></p> </td> <td valign="bottom"><font size="1">  </font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2"> </font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">63,330</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">  </font></td> <td valign="bottom"><font size="1">  </font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">8.51</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">  </font></td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double"> </p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double"> </p> </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> </table> </div><span></span></td> </tr> <tr class="re"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock', window );">Stock-Based Compensation Related to Stock Options, Restricted Stock Awards, Restricted Stock Unit, and Employee Stock Purchases</a></td> <td class="text"><div> <p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 12px; TEXT-INDENT: 4%" align="justify"><font style="FONT-FAMILY: Times New Roman" size="2">The following table summarizes stock-based compensation related to stock options, restricted stock awards, restricted stock unit, and employee stock purchases (in thousands):</font></p> <p style="MARGIN-BOTTOM: 0px; FONT-SIZE: 12px; MARGIN-TOP: 0px">  </p> <table style="BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="92%" align="center" border="0"> <tr> <td width="73%"></td> <td valign="bottom" width="4%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="4%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="4%"></td> <td></td> <td></td> <td></td> </tr> <tr> <td valign="bottom"><font size="1"> </font></td> <td valign="bottom"><font size="1">  </font></td> <td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="10" align="center"><font style="FONT-FAMILY: Times New Roman" size="1"><b>Years Ended December 31,</b></font></td> <td valign="bottom"><font size="1"> </font></td> </tr> <tr> <td valign="bottom"><font size="1"> </font></td> <td valign="bottom"><font size="1">  </font></td> <td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" align="center"><font style="FONT-FAMILY: Times New Roman" size="1"><b>2014</b></font></td> <td valign="bottom"><font size="1"> </font></td> <td valign="bottom"><font size="1">  </font></td> <td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" align="center"><font style="FONT-FAMILY: Times New Roman" size="1"><b>2013</b></font></td> <td valign="bottom"><font size="1"> </font></td> <td valign="bottom"><font size="1">  </font></td> <td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" align="center"><font style="FONT-FAMILY: Times New Roman" size="1"><b>2012</b></font></td> <td valign="bottom"><font size="1"> </font></td> </tr> <tr bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: Times New Roman" size="2">Research and development</font></p> </td> <td valign="bottom"><font size="1">  </font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">1,361</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">  </font></td> <td valign="bottom"><font size="1">  </font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">1,538</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">  </font></td> <td valign="bottom"><font size="1">  </font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">1,801</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">  </font></td> </tr> <tr> <td valign="top"> <p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: Times New Roman" size="2">General and administrative</font></p> </td> <td valign="bottom"><font size="1">  </font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2"> </font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">1,969</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">  </font></td> <td valign="bottom"><font size="1">  </font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2"> </font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">2,059</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">  </font></td> <td valign="bottom"><font size="1">  </font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2"> </font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">1,982</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">  </font></td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid"> </p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid"> </p> </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid"> </p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid"> </p> </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid"> </p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid"> </p> </td> <td> </td> </tr> <tr bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: Times New Roman" size="2">Stock-based compensation included in operating expenses</font></p> </td> <td valign="bottom"><font size="1">  </font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">3,330</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">  </font></td> <td valign="bottom"><font size="1">  </font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">3,597</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">  </font></td> <td valign="bottom"><font size="1">  </font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">3,783</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">  </font></td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double"> </p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double"> </p> </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double"> </p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double"> </p> </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double"> </p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double"> </p> </td> <td> </td> </tr> </table> </div><span></span></td> </tr> <tr class="ro"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock', window );">Fair Value of Share-Based Payments was Estimated on Date of Grant Using Black-Scholes Option Pricing Model Based on Weighted Average Assumptions</a></td> <td class="text"><div> <p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 0px; TEXT-INDENT: 4%" align="justify"><font style="FONT-FAMILY: Times New Roman" size="2">The fair value of share-based payments was estimated on the date of grant using the Black-Scholes option pricing model based on the following weighted average assumptions:</font></p> <p style="MARGIN-BOTTOM: 0px; FONT-SIZE: 12px; MARGIN-TOP: 0px">  </p> <table style="BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="100%" align="center" border="0"> <tr> <td width="46%"></td> <td valign="bottom" width="5%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="5%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="5%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="5%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="5%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="5%"></td> <td></td> <td></td> <td></td> </tr> <tr> <td valign="bottom"><font size="1"> </font></td> <td valign="bottom"><font size="1">  </font></td> <td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="6" align="center"><font style="FONT-FAMILY: Times New Roman" size="1"><b>Year Ended<br /> December 31, 2014</b></font></td> <td valign="bottom"><font size="1"> </font></td> <td valign="bottom"><font size="1"> </font></td> <td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="6" align="center"><font style="FONT-FAMILY: Times New Roman" size="1"><b>Year Ended<br /> December 31, 2013</b></font></td> <td valign="bottom"><font size="1"> </font></td> <td valign="bottom"><font size="1"> </font></td> <td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="6" align="center"><font style="FONT-FAMILY: Times New Roman" size="1"><b>Year Ended<br /> December 31, 2012</b></font></td> <td valign="bottom"><font size="1"> </font></td> </tr> <tr> <td valign="bottom"><font size="1"> </font></td> <td valign="bottom"><font size="1">  </font></td> <td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" align="center"><font style="FONT-FAMILY: Times New Roman" size="1"><b>Employee<br /> Stock Options</b></font></td> <td valign="bottom"><font size="1"> </font></td> <td valign="bottom"><font size="1"> </font></td> <td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" align="center"><font style="FONT-FAMILY: Times New Roman" size="1"><b>ESPP</b></font></td> <td valign="bottom"><font size="1"> </font></td> <td valign="bottom"><font size="1"> </font></td> <td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" align="center"><font style="FONT-FAMILY: Times New Roman" size="1"><b>Employee<br /> Stock Options</b></font></td> <td valign="bottom"><font size="1"> </font></td> <td valign="bottom"><font size="1"> </font></td> <td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" align="center"><font style="FONT-FAMILY: Times New Roman" size="1"><b>ESPP</b></font></td> <td valign="bottom"><font size="1"> </font></td> <td valign="bottom"><font size="1"> </font></td> <td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" align="center"><font style="FONT-FAMILY: Times New Roman" size="1"><b>Employee<br /> Stock Options</b></font></td> <td valign="bottom"><font size="1"> </font></td> <td valign="bottom"><font size="1"> </font></td> <td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" align="center"><font style="FONT-FAMILY: Times New Roman" size="1"><b>ESPP</b></font></td> <td valign="bottom"><font size="1"> </font></td> </tr> <tr bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: Times New Roman" size="2">Risk-free interest rate</font></p> </td> <td valign="bottom"><font size="1">  </font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2"> </font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">1.9</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">% </font></td> <td valign="bottom"><font size="1"> </font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2"> </font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">0.2</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">% </font></td> <td valign="bottom"><font size="1"> </font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2"> </font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">1.1</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">% </font></td> <td valign="bottom"><font size="1"> </font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2"> </font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">0.2</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">% </font></td> <td valign="bottom"><font size="1"> </font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2"> </font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">1.1</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">% </font></td> <td valign="bottom"><font size="1"> </font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2"> </font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">0.2</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">% </font></td> </tr> <tr> <td valign="top"> <p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: Times New Roman" size="2">Volatility</font></p> </td> <td valign="bottom"><font size="1">  </font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2"> </font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">77.1</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">% </font></td> <td valign="bottom"><font size="1"> </font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2"> </font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">86.0</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">% </font></td> <td valign="bottom"><font size="1"> </font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2"> </font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">73.2</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">% </font></td> <td valign="bottom"><font size="1"> </font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2"> </font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">74.6</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">% </font></td> <td valign="bottom"><font size="1"> </font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2"> </font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">71.1</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">% </font></td> <td valign="bottom"><font size="1"> </font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2"> </font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">72.0</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">% </font></td> </tr> <tr bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: Times New Roman" size="2">Expected term in years</font></p> </td> <td valign="bottom"><font size="1">  </font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2"> </font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">6.30</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">  </font></td> <td valign="bottom"><font size="1"> </font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2"> </font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">1.25</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">  </font></td> <td valign="bottom"><font size="1"> </font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2"> </font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">6.20</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">  </font></td> <td valign="bottom"><font size="1"> </font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2"> </font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">1.25</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">  </font></td> <td valign="bottom"><font size="1"> </font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2"> </font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">6.13</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">  </font></td> <td valign="bottom"><font size="1"> </font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2"> </font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">1.25</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">  </font></td> </tr> <tr> <td valign="top"> <p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: Times New Roman" size="2">Expected dividend yield</font></p> </td> <td valign="bottom"><font size="1">  </font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2"> </font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">0.0</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">% </font></td> <td valign="bottom"><font size="1"> </font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2"> </font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">0.0</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">% </font></td> <td valign="bottom"><font size="1"> </font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2"> </font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">0.0</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">% </font></td> <td valign="bottom"><font size="1"> </font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2"> </font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">0.0</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">% </font></td> <td valign="bottom"><font size="1"> </font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2"> </font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">0.0</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">% </font></td> <td valign="bottom"><font size="1"> </font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2"> </font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">0.0</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">% </font></td> </tr> </table> </div><span></span></td> </tr> </table> <div style="display: none;"> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract"> <tr> <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td> </tr> <tr> <td> <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div> <table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_EquityAbstract</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:stringItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table> </div> </div> </td> </tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock"> <tr> <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td> </tr> <tr> <td> <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div> <p>Tabular disclosure of the allocation of equity-based compensation costs to a given line item on the balance sheet and income statement for the period. This may include the reporting line for the costs and the amount capitalized and expensed.</p> </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"> <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -Subparagraph (b)<br><br> -URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5047-113901<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SAB TOPIC 14.F)<br><br> -URI http://asc.fasb.org/extlink&oid=27013229&loc=d3e301413-122809<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Staff Accounting Bulletin (SAB)<br><br> -Number Topic 14<br><br> -Section F<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (h)(1)<br><br> -URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901<br><br><br><br></p> </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"> <table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>nonnum:textBlockItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table> </div> </div> </td> </tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock"> <tr> <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td> </tr> <tr> <td> <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div> <p>Tabular disclosure of the number and weighted-average grant date fair value for restricted stock units that were outstanding at the beginning and end of the year, and the number of restricted stock units that were granted, vested, or forfeited during the year.</p> </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"> <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (c)(1)<br><br> -URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901<br><br><br><br></p> </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"> <table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>nonnum:textBlockItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table> </div> </div> </td> </tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"> <tr> <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td> </tr> <tr> <td> <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div> <p>Tabular disclosure of the number and weighted-average exercise prices (or conversion ratios) for share options (or share units) that were outstanding at the beginning and end of the year, vested and expected to vest, exercisable or convertible at the end of the year, and the number of share options or share units that were granted, exercised or converted, forfeited, and expired during the year.</p> </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"> <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (c)(1)<br><br> -URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901<br><br><br><br></p> </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"> <table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>nonnum:textBlockItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table> </div> </div> </td> </tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"> <tr> <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td> </tr> <tr> <td> <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div> <p>Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.</p> </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"> <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (f)(2)<br><br> -URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901<br><br><br><br></p> </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"> <table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>nonnum:textBlockItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table> </div> </div> </td> </tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock"> <tr> <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td> </tr> <tr> <td> <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div> <p>Tabular disclosure of warrants or rights issued. Warrants and rights outstanding are derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months. Disclose the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable.</p> </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"> <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.4-08.(i))<br><br> -URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 08<br><br> -Paragraph i<br><br> -Article 4<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5047-113901<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 50<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&oid=6406099&loc=d3e25284-112666<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 50<br><br> -Section S99<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&oid=6784392&loc=d3e188667-122775<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 28<br><br> -Article 5<br><br><br><br></p> </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"> <table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>nonnum:textBlockItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table> </div> </div> </td> </tr> </table> </div> </body> </html> </TEXT> </DOCUMENT> <DOCUMENT> <TYPE>XML <SEQUENCE>24 <FILENAME>report.css <DESCRIPTION>IDEA: XBRL DOCUMENT <TEXT> /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; word-wrap: break-word; } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } </TEXT> </DOCUMENT> <DOCUMENT> <TYPE>XML <SEQUENCE>25 <FILENAME>R73.htm <DESCRIPTION>IDEA: XBRL DOCUMENT <TEXT> <html> <head> <META http-equiv="Content-Type" content="text/html; charset=us-ascii"> <title></title> <link rel="stylesheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript"> function toggleNextSibling (e) { if (e.nextSibling.style.display=='none') { e.nextSibling.style.display='block'; } else { e.nextSibling.style.display='none'; } }</script></head> <body><span style="display: none;">v2.4.1.9</span><table class="report" border="0" cellspacing="2" id="ID0EZGAC"> <tr> <th class="tl" colspan="1" rowspan="2"> <div style="width: 200px;"><strong>Interest and Other, Net - Components of Interest and Other, Net (Detail) (USD $)<br>In Thousands, unless otherwise specified</strong></div> </th> <th class="th" colspan="3">12 Months Ended</th> </tr> <tr> <th class="th"> <div>Dec. 31, 2014</div> </th> <th class="th"> <div>Dec. 31, 2013</div> </th> <th class="th"> <div>Dec. 31, 2012</div> </th> </tr> <tr class="re"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherIncomeAndExpensesAbstract', window );"><strong>Other Income and Expenses [Abstract]</strong></a></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> </tr> <tr class="ro"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestAndOtherIncome', window );">Interest income and other income</a></td> <td class="nump"><a title="us-gaap_InterestAndOtherIncome" onclick="toggleNextSibling(this);">$ 108</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_InterestAndOtherIncome</span><span></span></td> <td class="nump"><a title="us-gaap_InterestAndOtherIncome" onclick="toggleNextSibling(this);">$ 98</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_InterestAndOtherIncome</span><span></span></td> <td class="nump"><a title="us-gaap_InterestAndOtherIncome" onclick="toggleNextSibling(this);">$ 89</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_InterestAndOtherIncome</span><span></span></td> </tr> <tr class="re"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestAndDebtExpense', window );">Interest expense and other expense</a></td> <td class="nump"><a title="us-gaap_InterestAndDebtExpense" onclick="toggleNextSibling(this);">0</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_InterestAndDebtExpense</span><span></span></td> <td class="nump"><a title="us-gaap_InterestAndDebtExpense" onclick="toggleNextSibling(this);">79</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_InterestAndDebtExpense</span><span></span></td> <td class="num"><a title="us-gaap_InterestAndDebtExpense" onclick="toggleNextSibling(this);">(2)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_InterestAndDebtExpense</span><span></span></td> </tr> <tr class="rou"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpense', window );">Interest and Other, net</a></td> <td class="nump"><a title="us-gaap_NonoperatingIncomeExpense" onclick="toggleNextSibling(this);">$ 108</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_NonoperatingIncomeExpense</span><span></span></td> <td class="nump"><a title="us-gaap_NonoperatingIncomeExpense" onclick="toggleNextSibling(this);">$ 177</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_NonoperatingIncomeExpense</span><span></span></td> <td class="nump"><a title="us-gaap_NonoperatingIncomeExpense" onclick="toggleNextSibling(this);">$ 87</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_NonoperatingIncomeExpense</span><span></span></td> </tr> </table> <div style="display: none;"> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestAndDebtExpense"> <tr> <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td> </tr> <tr> <td> <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div> <p>Interest and debt related expenses associated with nonoperating financing activities of the entity.</p> </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"> <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 835<br><br> -SubTopic 20<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&oid=6450988&loc=d3e26243-108391<br><br><br><br></p> </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"> <table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_InterestAndDebtExpense</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:monetaryItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>debit</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table> </div> </div> </td> </tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestAndOtherIncome"> <tr> <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td> </tr> <tr> <td> <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div> <p>The amount of interest income and other income recognized during the period. Included in this element is interest derived from investments in debt securities, cash and cash equivalents, and other investments which reflect the time value of money or transactions in which the payments are for the use or forbearance of money and other income from ancillary business-related activities (that is, excluding major activities considered part of the normal operations of the business).</p> </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"> <p>No definition available.</p> </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"> <table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_InterestAndOtherIncome</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:monetaryItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>credit</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table> </div> </div> </td> </tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpense"> <tr> <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td> </tr> <tr> <td> <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div> <p>The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).</p> </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"> <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 225<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 2<br><br> -Subparagraph (SX 210.5-03.7)<br><br> -URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 03<br><br> -Paragraph 7<br><br> -Article 5<br><br><br><br></p> </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"> <table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpense</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:monetaryItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>credit</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table> </div> </div> </td> </tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherIncomeAndExpensesAbstract"> <tr> <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td> </tr> <tr> <td> <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div> <table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_OtherIncomeAndExpensesAbstract</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:stringItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table> </div> </div> </td> </tr> </table> </div> </body> </html> </TEXT> </DOCUMENT> <DOCUMENT> <TYPE>XML <SEQUENCE>26 <FILENAME>R57.htm <DESCRIPTION>IDEA: XBRL DOCUMENT <TEXT> <html> <head> <META http-equiv="Content-Type" content="text/html; charset=us-ascii"> <title></title> <link rel="stylesheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript"> function toggleNextSibling (e) { if (e.nextSibling.style.display=='none') { e.nextSibling.style.display='block'; } else { e.nextSibling.style.display='none'; } }</script></head> <body><span style="display: none;">v2.4.1.9</span><table class="report" border="0" cellspacing="2" id="ID0EXBAC"> <tr> <th class="tl" colspan="1" rowspan="2"> <div style="width: 200px;"><strong>Commitments and Contingencies - Rent Expense (Detail) (USD $)<br>In Thousands, unless otherwise specified</strong></div> </th> <th class="th" colspan="3">12 Months Ended</th> </tr> <tr> <th class="th"> <div>Dec. 31, 2014</div> </th> <th class="th"> <div>Dec. 31, 2013</div> </th> <th class="th"> <div>Dec. 31, 2012</div> </th> </tr> <tr class="re"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> </tr> <tr class="ro"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesRentExpenseNet', window );">Rent expense</a></td> <td class="nump"><a title="us-gaap_OperatingLeasesRentExpenseNet" onclick="toggleNextSibling(this);">$ 3,338</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_OperatingLeasesRentExpenseNet</span><span></span></td> <td class="nump"><a title="us-gaap_OperatingLeasesRentExpenseNet" onclick="toggleNextSibling(this);">$ 3,306</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_OperatingLeasesRentExpenseNet</span><span></span></td> <td class="nump"><a title="us-gaap_OperatingLeasesRentExpenseNet" onclick="toggleNextSibling(this);">$ 3,375</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_OperatingLeasesRentExpenseNet</span><span></span></td> </tr> </table> <div style="display: none;"> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract"> <tr> <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td> </tr> <tr> <td> <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div> <table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:stringItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table> </div> </div> </td> </tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesRentExpenseNet"> <tr> <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td> </tr> <tr> <td> <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div> <p>Rental expense for the reporting period incurred under operating leases, including minimum and any contingent rent expense, net of related sublease income.</p> </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"> <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 840<br><br> -SubTopic 20<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&oid=6453985&loc=d3e41499-112717<br><br><br><br></p> </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"> <table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_OperatingLeasesRentExpenseNet</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:monetaryItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>debit</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table> </div> </div> </td> </tr> </table> </div> </body> </html> </TEXT> </DOCUMENT> <DOCUMENT> <TYPE>XML <SEQUENCE>27 <FILENAME>R71.htm <DESCRIPTION>IDEA: XBRL DOCUMENT <TEXT> <html> <head> <META http-equiv="Content-Type" content="text/html; charset=us-ascii"> <title></title> <link rel="stylesheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript"> function toggleNextSibling (e) { if (e.nextSibling.style.display=='none') { e.nextSibling.style.display='block'; } else { e.nextSibling.style.display='none'; } }</script></head> <body><span style="display: none;">v2.4.1.9</span><table class="report" border="0" cellspacing="2" id="ID0EAGAE"> <tr> <th class="tl" colspan="1" rowspan="2"> <div style="width: 200px;"><strong>Income Taxes - Reconciliation of Statutory Federal Income Tax Rate to Effective Tax Rate (Detail)<br></strong></div> </th> <th class="th" colspan="3">12 Months Ended</th> </tr> <tr> <th class="th"> <div>Dec. 31, 2014</div> </th> <th class="th"> <div>Dec. 31, 2013</div> </th> <th class="th"> <div>Dec. 31, 2012</div> </th> </tr> <tr class="re"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> </tr> <tr class="ro"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate', window );">Tax at federal statutory tax rate</a></td> <td class="num"><a title="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" onclick="toggleNextSibling(this);">(34.00%)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate</span><span></span></td> <td class="num"><a title="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" onclick="toggleNextSibling(this);">(34.00%)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate</span><span></span></td> <td class="num"><a title="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" onclick="toggleNextSibling(this);">(34.00%)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate</span><span></span></td> </tr> <tr class="re"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes', window );">State income tax, net of federal tax benefit</a></td> <td class="num"><a title="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" onclick="toggleNextSibling(this);">(1.00%)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes</span><span></span></td> <td class="num"><a title="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" onclick="toggleNextSibling(this);">(4.00%)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes</span><span></span></td> <td class="num"><a title="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" onclick="toggleNextSibling(this);">(6.00%)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes</span><span></span></td> </tr> <tr class="ro"> <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cytk_EffectiveIncomeTaxRateReconciliationStateApportionment', window );">State Apportionment</a></td> <td class="nump"><a title="cytk_EffectiveIncomeTaxRateReconciliationStateApportionment" onclick="toggleNextSibling(this);">28.00%</a><span style="display:none;white-space:normal;text-align:left;">cytk_EffectiveIncomeTaxRateReconciliationStateApportionment</span><span></span></td> <td class="nump"><a title="cytk_EffectiveIncomeTaxRateReconciliationStateApportionment" onclick="toggleNextSibling(this);">7.00%</a><span style="display:none;white-space:normal;text-align:left;">cytk_EffectiveIncomeTaxRateReconciliationStateApportionment</span><span></span></td> <td class="nump"><a title="cytk_EffectiveIncomeTaxRateReconciliationStateApportionment" onclick="toggleNextSibling(this);">0.00%</a><span style="display:none;white-space:normal;text-align:left;">cytk_EffectiveIncomeTaxRateReconciliationStateApportionment</span><span></span></td> </tr> <tr class="re"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits', window );">Tax credits (net)</a></td> <td class="num"><a title="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits" onclick="toggleNextSibling(this);">(7.00%)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits</span><span></span></td> <td class="num"><a title="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits" onclick="toggleNextSibling(this);">(14.00%)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits</span><span></span></td> <td class="num"><a title="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits" onclick="toggleNextSibling(this);">(19.00%)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits</span><span></span></td> </tr> <tr class="ro"> <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cytk_EffectiveIncomeTaxRateReconciliationDeferredTaxAssetsUtilizedNotBenefited', window );">Deferred tax assets (utilized) not benefited</a></td> <td class="nump"><a title="cytk_EffectiveIncomeTaxRateReconciliationDeferredTaxAssetsUtilizedNotBenefited" onclick="toggleNextSibling(this);">7.00%</a><span style="display:none;white-space:normal;text-align:left;">cytk_EffectiveIncomeTaxRateReconciliationDeferredTaxAssetsUtilizedNotBenefited</span><span></span></td> <td class="nump"><a title="cytk_EffectiveIncomeTaxRateReconciliationDeferredTaxAssetsUtilizedNotBenefited" onclick="toggleNextSibling(this);">41.00%</a><span style="display:none;white-space:normal;text-align:left;">cytk_EffectiveIncomeTaxRateReconciliationDeferredTaxAssetsUtilizedNotBenefited</span><span></span></td> <td class="nump"><a title="cytk_EffectiveIncomeTaxRateReconciliationDeferredTaxAssetsUtilizedNotBenefited" onclick="toggleNextSibling(this);">56.00%</a><span style="display:none;white-space:normal;text-align:left;">cytk_EffectiveIncomeTaxRateReconciliationDeferredTaxAssetsUtilizedNotBenefited</span><span></span></td> </tr> <tr class="re"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost', window );">Stock-based compensation</a></td> <td class="nump"><a title="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" onclick="toggleNextSibling(this);">5.00%</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost</span><span></span></td> <td class="nump"><a title="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" onclick="toggleNextSibling(this);">2.00%</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost</span><span></span></td> <td class="nump"><a title="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" onclick="toggleNextSibling(this);">0.00%</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost</span><span></span></td> </tr> <tr class="ro"> <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cytk_EffectiveIncomeTaxRateReconciliationNetOperatingLossExpiration', window );">NOL Expiration</a></td> <td class="nump"><a title="cytk_EffectiveIncomeTaxRateReconciliationNetOperatingLossExpiration" onclick="toggleNextSibling(this);">2.00%</a><span style="display:none;white-space:normal;text-align:left;">cytk_EffectiveIncomeTaxRateReconciliationNetOperatingLossExpiration</span><span></span></td> <td class="nump"><a title="cytk_EffectiveIncomeTaxRateReconciliationNetOperatingLossExpiration" onclick="toggleNextSibling(this);">1.00%</a><span style="display:none;white-space:normal;text-align:left;">cytk_EffectiveIncomeTaxRateReconciliationNetOperatingLossExpiration</span><span></span></td> <td class="nump"><a title="cytk_EffectiveIncomeTaxRateReconciliationNetOperatingLossExpiration" onclick="toggleNextSibling(this);">2.00%</a><span style="display:none;white-space:normal;text-align:left;">cytk_EffectiveIncomeTaxRateReconciliationNetOperatingLossExpiration</span><span></span></td> </tr> <tr class="re"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments', window );">Other</a></td> <td class="nump"><a title="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" onclick="toggleNextSibling(this);">0.00%</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments</span><span></span></td> <td class="nump"><a title="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" onclick="toggleNextSibling(this);">1.00%</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments</span><span></span></td> <td class="nump"><a title="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" onclick="toggleNextSibling(this);">1.00%</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments</span><span></span></td> </tr> <tr class="rou"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations', window );">Total</a></td> <td class="nump"><a title="us-gaap_EffectiveIncomeTaxRateContinuingOperations" onclick="toggleNextSibling(this);">0.00%</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_EffectiveIncomeTaxRateContinuingOperations</span><span></span></td> <td class="nump"><a title="us-gaap_EffectiveIncomeTaxRateContinuingOperations" onclick="toggleNextSibling(this);">0.00%</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_EffectiveIncomeTaxRateContinuingOperations</span><span></span></td> <td class="nump"><a title="us-gaap_EffectiveIncomeTaxRateContinuingOperations" onclick="toggleNextSibling(this);">0.00%</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_EffectiveIncomeTaxRateContinuingOperations</span><span></span></td> </tr> </table> <div style="display: none;"> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cytk_EffectiveIncomeTaxRateReconciliationDeferredTaxAssetsUtilizedNotBenefited"> <tr> <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td> </tr> <tr> <td> <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div> <p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to deferred tax assets utilized not benefited.</p> </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"> <p>No definition available.</p> </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"> <table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">cytk_EffectiveIncomeTaxRateReconciliationDeferredTaxAssetsUtilizedNotBenefited</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>cytk_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>num:percentItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table> </div> </div> </td> </tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cytk_EffectiveIncomeTaxRateReconciliationNetOperatingLossExpiration"> <tr> <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td> </tr> <tr> <td> <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div> <p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to net operating loss expiration.</p> </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"> <p>No definition available.</p> </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"> <table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">cytk_EffectiveIncomeTaxRateReconciliationNetOperatingLossExpiration</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>cytk_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>num:percentItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table> </div> </div> </td> </tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cytk_EffectiveIncomeTaxRateReconciliationStateApportionment"> <tr> <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td> </tr> <tr> <td> <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div> <p>Effective Income Tax Rate Reconciliation State Apportionment</p> </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"> <p>No definition available.</p> </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"> <table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">cytk_EffectiveIncomeTaxRateReconciliationStateApportionment</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>cytk_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>num:percentItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table> </div> </div> </td> </tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations"> <tr> <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td> </tr> <tr> <td> <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div> <p>Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p> </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"> <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 12<br><br> -URI http://asc.fasb.org/extlink&oid=6907707&loc=d3e32687-109319<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 13<br><br> -URI http://asc.fasb.org/extlink&oid=6907707&loc=d3e32698-109319<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.4-08.(h)(2))<br><br> -URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 08<br><br> -Paragraph h<br><br> -Subparagraph 2<br><br> -Article 4<br><br><br><br></p> </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"> <table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateContinuingOperations</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>num:percentItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table> </div> </div> </td> </tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate"> <tr> <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td> </tr> <tr> <td> <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div> <p>Percentage of domestic federal statutory tax rate applicable to pretax income (loss).</p> </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"> <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 12<br><br> -URI http://asc.fasb.org/extlink&oid=6907707&loc=d3e32687-109319<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SAB TOPIC 6.I)<br><br> -URI http://asc.fasb.org/extlink&oid=34349781&loc=d3e330036-122817<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 13<br><br> -URI http://asc.fasb.org/extlink&oid=6907707&loc=d3e32698-109319<br><br><br><br></p> </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"> <table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>num:percentItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table> </div> </div> </td> </tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost"> <tr> <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td> </tr> <tr> <td> <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div> <p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to equity-based compensation costs.</p> </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"> <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 12<br><br> -URI http://asc.fasb.org/extlink&oid=6907707&loc=d3e32687-109319<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SAB TOPIC 6.I)<br><br> -URI http://asc.fasb.org/extlink&oid=34349781&loc=d3e330036-122817<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 13<br><br> -URI http://asc.fasb.org/extlink&oid=6907707&loc=d3e32698-109319<br><br><br><br></p> </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"> <table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>num:percentItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table> </div> </div> </td> </tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments"> <tr> <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td> </tr> <tr> <td> <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div> <p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments.</p> </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"> <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 12<br><br> -URI http://asc.fasb.org/extlink&oid=6907707&loc=d3e32687-109319<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SAB TOPIC 6.I)<br><br> -URI http://asc.fasb.org/extlink&oid=34349781&loc=d3e330036-122817<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 13<br><br> -URI http://asc.fasb.org/extlink&oid=6907707&loc=d3e32698-109319<br><br><br><br></p> </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"> <table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>num:percentItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table> </div> </div> </td> </tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes"> <tr> <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td> </tr> <tr> <td> <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div> <p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to state and local income tax expense (benefit), net of federal tax expense (benefit).</p> </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"> <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 12<br><br> -URI http://asc.fasb.org/extlink&oid=6907707&loc=d3e32687-109319<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SAB TOPIC 6.I)<br><br> -URI http://asc.fasb.org/extlink&oid=34349781&loc=d3e330036-122817<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 13<br><br> -URI http://asc.fasb.org/extlink&oid=6907707&loc=d3e32698-109319<br><br><br><br></p> </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"> <table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>num:percentItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table> </div> </div> </td> </tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits"> <tr> <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td> </tr> <tr> <td> <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div> <p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to tax credits. Including, but not limited to, research credit, foreign tax credit, investment tax credit, and other tax credits.</p> </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"> <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 12<br><br> -URI http://asc.fasb.org/extlink&oid=6907707&loc=d3e32687-109319<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SAB TOPIC 6.I)<br><br> -URI http://asc.fasb.org/extlink&oid=34349781&loc=d3e330036-122817<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 13<br><br> -URI http://asc.fasb.org/extlink&oid=6907707&loc=d3e32698-109319<br><br><br><br></p> </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"> <table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>num:percentItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table> </div> </div> </td> </tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract"> <tr> <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td> </tr> <tr> <td> <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div> <table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:stringItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table> </div> </div> </td> </tr> </table> </div> </body> </html> </TEXT> </DOCUMENT> <DOCUMENT> <TYPE>XML <SEQUENCE>28 <FILENAME>R25.htm <DESCRIPTION>IDEA: XBRL DOCUMENT <TEXT> <html> <head> <META http-equiv="Content-Type" content="text/html; charset=us-ascii"> <title></title> <link rel="stylesheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript"> function toggleNextSibling (e) { if (e.nextSibling.style.display=='none') { e.nextSibling.style.display='block'; } else { e.nextSibling.style.display='none'; } }</script></head> <body><span style="display: none;">v2.4.1.9</span><table class="report" border="0" cellspacing="2" id="ID0EME"> <tr> <th class="tl" colspan="1" rowspan="2"> <div style="width: 200px;"><strong>Supplementary Cash Flow Data (Tables)<br></strong></div> </th> <th class="th" colspan="1">12 Months Ended</th> </tr> <tr> <th class="th"> <div>Dec. 31, 2014</div> </th> </tr> <tr class="re"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SupplementalCashFlowElementsAbstract', window );"><strong>Supplemental Cash Flow Elements [Abstract]</strong></a></td> <td class="text"> <span></span></td> </tr> <tr class="ro"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock', window );">Supplemental Cash Flow Information</a></td> <td class="text"><div> <p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 6px; TEXT-INDENT: 4%" align="justify"><font style="FONT-FAMILY: Times New Roman" size="2">Supplemental cash flow information was as follows (in thousands):</font></p> <p style="MARGIN-BOTTOM: 0px; FONT-SIZE: 12px; MARGIN-TOP: 0px">  </p> <table style="BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="92%" align="center" border="0"> <tr> <td width="78%"></td> <td valign="bottom" width="6%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="6%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="5%"></td> <td></td> <td></td> <td></td> </tr> <tr> <td valign="bottom"><font size="1"> </font></td> <td valign="bottom"><font size="1">  </font></td> <td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="10" align="center"><font style="FONT-FAMILY: Times New Roman" size="1"><b>Years Ended<br /> December 31,</b></font></td> <td valign="bottom"><font size="1"> </font></td> </tr> <tr> <td valign="bottom"><font size="1"> </font></td> <td valign="bottom"><font size="1">  </font></td> <td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" align="center"><font style="FONT-FAMILY: Times New Roman" size="1"><b>2014</b></font></td> <td valign="bottom"><font size="1"> </font></td> <td valign="bottom"><font size="1">  </font></td> <td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" align="center"><font style="FONT-FAMILY: Times New Roman" size="1"><b>2013</b></font></td> <td valign="bottom"><font size="1"> </font></td> <td valign="bottom"><font size="1">  </font></td> <td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" align="center"><font style="FONT-FAMILY: Times New Roman" size="1"><b>2012</b></font></td> <td valign="bottom"><font size="1"> </font></td> </tr> <tr bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: Times New Roman" size="2">Cash paid for interest</font></p> </td> <td valign="bottom"><font size="1">  </font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td> <td valign="bottom" nowrap="nowrap" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">—</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">  </font></td> <td valign="bottom"><font size="1">  </font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td> <td valign="bottom" nowrap="nowrap" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">—</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">  </font></td> <td valign="bottom"><font size="1">  </font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">3</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">  </font></td> </tr> <tr> <td valign="top"> <p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: Times New Roman" size="2">Cash paid for income taxes</font></p> </td> <td valign="bottom"><font size="1">  </font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2"> </font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">1</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">  </font></td> <td valign="bottom"><font size="1">  </font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2"> </font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">1</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">  </font></td> <td valign="bottom"><font size="1">  </font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2"> </font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">1</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">  </font></td> </tr> <tr bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: Times New Roman" size="2">Significant non-cash investing and financing activities:</font></p> </td> <td valign="bottom"><font size="1">  </font></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"><font size="1">  </font></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"><font size="1">  </font></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr> <td valign="top"> <p style="MARGIN-LEFT: 2em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: Times New Roman" size="2">Purchases of property and equipment through accounts payable</font></p> </td> <td valign="bottom"><font size="1">  </font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2"> </font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">170</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">  </font></td> <td valign="bottom"><font size="1">  </font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2"> </font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">193</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">  </font></td> <td valign="bottom"><font size="1">  </font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2"> </font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">116</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">  </font></td> </tr> <tr bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-LEFT: 2em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: Times New Roman" size="2">Purchases of property and equipment through accrued liabilities</font></p> </td> <td valign="bottom"><font size="1">  </font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2"> </font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">27</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">  </font></td> <td valign="bottom"><font size="1">  </font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2"> </font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">(2</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">) </font></td> <td valign="bottom"><font size="1">  </font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2"> </font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">37</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">  </font></td> </tr> <tr> <td valign="top"> <p style="MARGIN-LEFT: 2em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: Times New Roman" size="2">Purchases of property and equipment through trade in value of disposed property and equipment</font></p> </td> <td valign="bottom"><font size="1">  </font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2"> </font></td> <td valign="bottom" nowrap="nowrap" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">—</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">  </font></td> <td valign="bottom"><font size="1">  </font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2"> </font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">81</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">  </font></td> <td valign="bottom"><font size="1">  </font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2"> </font></td> <td valign="bottom" nowrap="nowrap" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">—</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">  </font></td> </tr> </table> </div><span></span></td> </tr> </table> <div style="display: none;"> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock"> <tr> <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td> </tr> <tr> <td> <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div> <p>Tabular disclosure of supplemental cash flow information for the periods presented.</p> </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"> <p>No definition available.</p> </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"> <table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>nonnum:textBlockItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table> </div> </div> </td> </tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalCashFlowElementsAbstract"> <tr> <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td> </tr> <tr> <td> <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div> <table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_SupplementalCashFlowElementsAbstract</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:stringItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table> </div> </div> </td> </tr> </table> </div> </body> </html> </TEXT> </DOCUMENT> <DOCUMENT> <TYPE>XML <SEQUENCE>29 <FILENAME>R50.htm <DESCRIPTION>IDEA: XBRL DOCUMENT <TEXT> <html> <head> <META http-equiv="Content-Type" content="text/html; charset=us-ascii"> <title></title> <link rel="stylesheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript"> function toggleNextSibling (e) { if (e.nextSibling.style.display=='none') { e.nextSibling.style.display='block'; } else { e.nextSibling.style.display='none'; } }</script></head> <body><span style="display: none;">v2.4.1.9</span><table class="report" border="0" cellspacing="2" id="ID0ES3AG"> <tr> <th class="tl" colspan="1" rowspan="2"> <div style="width: 200px;"><strong>Related Parties and Related Party Transactions - Revenue from Related Party (Detail) (USD $)<br>In Thousands, unless otherwise specified</strong></div> </th> <th class="th" colspan="1">3 Months Ended</th> <th class="th" colspan="3">12 Months Ended</th> </tr> <tr> <th class="th"> <div>Dec. 31, 2013</div> </th> <th class="th"> <div>Dec. 31, 2014</div> </th> <th class="th"> <div>Dec. 31, 2013</div> </th> <th class="th"> <div>Dec. 31, 2012</div> </th> </tr> <tr class="re"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cytk_ScheduleOfOtherRelatedPartyTransactionsLineItems', window );"><strong>Schedule of Other Related Party Transactions [Line Items]</strong></a></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> </tr> <tr class="ro"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LicenseAndServicesRevenue', window );">License revenues from related parties</a></td> <td class="text"> <span></span></td> <td class="nump"><a title="us-gaap_LicenseAndServicesRevenue" onclick="toggleNextSibling(this);">$ 9,836</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_LicenseAndServicesRevenue</span><span></span></td> <td class="nump"><a title="us-gaap_LicenseAndServicesRevenue" onclick="toggleNextSibling(this);">$ 3,852</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_LicenseAndServicesRevenue</span><span></span></td> <td class="nump"><a title="us-gaap_LicenseAndServicesRevenue" onclick="toggleNextSibling(this);">$ 0</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_LicenseAndServicesRevenue</span><span></span></td> </tr> <tr class="rh"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=cytk_AmgenMember', window );">Amgen [Member]</a></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> </tr> <tr class="ro"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cytk_ScheduleOfOtherRelatedPartyTransactionsLineItems', window );"><strong>Schedule of Other Related Party Transactions [Line Items]</strong></a></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> </tr> <tr class="re"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LicenseAndServicesRevenue', window );">License revenues from related parties</a></td> <td class="nump"><a title="us-gaap_LicenseAndServicesRevenue[us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=cytk_AmgenMember]" onclick="toggleNextSibling(this);">17,200</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_LicenseAndServicesRevenue<br>/ us-gaap_RelatedPartyTransactionsByRelatedPartyAxis<br>= cytk_AmgenMember</span><span></span></td> <td class="nump"><a title="us-gaap_LicenseAndServicesRevenue[us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=cytk_AmgenMember]" onclick="toggleNextSibling(this);">0</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_LicenseAndServicesRevenue<br>/ us-gaap_RelatedPartyTransactionsByRelatedPartyAxis<br>= cytk_AmgenMember</span><span></span></td> <td class="nump"><a title="us-gaap_LicenseAndServicesRevenue[us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=cytk_AmgenMember]" onclick="toggleNextSibling(this);">17,230</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_LicenseAndServicesRevenue<br>/ us-gaap_RelatedPartyTransactionsByRelatedPartyAxis<br>= cytk_AmgenMember</span><span></span></td> <td class="nump"><a title="us-gaap_LicenseAndServicesRevenue[us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=cytk_AmgenMember]" onclick="toggleNextSibling(this);">0</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_LicenseAndServicesRevenue<br>/ us-gaap_RelatedPartyTransactionsByRelatedPartyAxis<br>= cytk_AmgenMember</span><span></span></td> </tr> <tr class="ro"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionDueFromToRelatedPartyAbstract', window );"><strong>Research and development revenues from related parties:</strong></a></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> </tr> <tr class="re"> <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cytk_ReimbursementOfInternalResearchAndDevelopmentCost', window );">Reimbursement of internal costs</a></td> <td class="text"> <span></span></td> <td class="nump"><a title="cytk_ReimbursementOfInternalResearchAndDevelopmentCost[us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=cytk_AmgenMember]" onclick="toggleNextSibling(this);">4,260</a><span style="display:none;white-space:normal;text-align:left;">cytk_ReimbursementOfInternalResearchAndDevelopmentCost<br>/ us-gaap_RelatedPartyTransactionsByRelatedPartyAxis<br>= cytk_AmgenMember</span><span></span></td> <td class="nump"><a title="cytk_ReimbursementOfInternalResearchAndDevelopmentCost[us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=cytk_AmgenMember]" onclick="toggleNextSibling(this);">2,019</a><span style="display:none;white-space:normal;text-align:left;">cytk_ReimbursementOfInternalResearchAndDevelopmentCost<br>/ us-gaap_RelatedPartyTransactionsByRelatedPartyAxis<br>= cytk_AmgenMember</span><span></span></td> <td class="nump"><a title="cytk_ReimbursementOfInternalResearchAndDevelopmentCost[us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=cytk_AmgenMember]" onclick="toggleNextSibling(this);">4,174</a><span style="display:none;white-space:normal;text-align:left;">cytk_ReimbursementOfInternalResearchAndDevelopmentCost<br>/ us-gaap_RelatedPartyTransactionsByRelatedPartyAxis<br>= cytk_AmgenMember</span><span></span></td> </tr> <tr class="ro"> <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cytk_ReimbursementOfOtherResearchAndDevelopmentCost', window );">Reimbursement of other costs</a></td> <td class="text"> <span></span></td> <td class="nump"><a title="cytk_ReimbursementOfOtherResearchAndDevelopmentCost[us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=cytk_AmgenMember]" onclick="toggleNextSibling(this);">0</a><span style="display:none;white-space:normal;text-align:left;">cytk_ReimbursementOfOtherResearchAndDevelopmentCost<br>/ us-gaap_RelatedPartyTransactionsByRelatedPartyAxis<br>= cytk_AmgenMember</span><span></span></td> <td class="nump"><a title="cytk_ReimbursementOfOtherResearchAndDevelopmentCost[us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=cytk_AmgenMember]" onclick="toggleNextSibling(this);">0</a><span style="display:none;white-space:normal;text-align:left;">cytk_ReimbursementOfOtherResearchAndDevelopmentCost<br>/ us-gaap_RelatedPartyTransactionsByRelatedPartyAxis<br>= cytk_AmgenMember</span><span></span></td> <td class="nump"><a title="cytk_ReimbursementOfOtherResearchAndDevelopmentCost[us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=cytk_AmgenMember]" onclick="toggleNextSibling(this);">3</a><span style="display:none;white-space:normal;text-align:left;">cytk_ReimbursementOfOtherResearchAndDevelopmentCost<br>/ us-gaap_RelatedPartyTransactionsByRelatedPartyAxis<br>= cytk_AmgenMember</span><span></span></td> </tr> <tr class="re"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromRelatedParties', window );">Allocated consideration</a></td> <td class="text"> <span></span></td> <td class="nump"><a title="us-gaap_RevenueFromRelatedParties[us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=cytk_AmgenMember]" onclick="toggleNextSibling(this);">278</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_RevenueFromRelatedParties<br>/ us-gaap_RelatedPartyTransactionsByRelatedPartyAxis<br>= cytk_AmgenMember</span><span></span></td> <td class="nump"><a title="us-gaap_RevenueFromRelatedParties[us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=cytk_AmgenMember]" onclick="toggleNextSibling(this);">0</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_RevenueFromRelatedParties<br>/ us-gaap_RelatedPartyTransactionsByRelatedPartyAxis<br>= cytk_AmgenMember</span><span></span></td> <td class="nump"><a title="us-gaap_RevenueFromRelatedParties[us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=cytk_AmgenMember]" onclick="toggleNextSibling(this);">0</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_RevenueFromRelatedParties<br>/ us-gaap_RelatedPartyTransactionsByRelatedPartyAxis<br>= cytk_AmgenMember</span><span></span></td> </tr> <tr class="ro"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentAbstract', window );"><strong>Research and development revenues:</strong></a></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> </tr> <tr class="re"> <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cytk_ReimbursementOfInternalResearchAndDevelopmentCost', window );">Reimbursement of internal costs</a></td> <td class="text"> <span></span></td> <td class="nump"><a title="cytk_ReimbursementOfInternalResearchAndDevelopmentCost[us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=cytk_AmgenMember]" onclick="toggleNextSibling(this);">4,260</a><span style="display:none;white-space:normal;text-align:left;">cytk_ReimbursementOfInternalResearchAndDevelopmentCost<br>/ us-gaap_RelatedPartyTransactionsByRelatedPartyAxis<br>= cytk_AmgenMember</span><span></span></td> <td class="nump"><a title="cytk_ReimbursementOfInternalResearchAndDevelopmentCost[us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=cytk_AmgenMember]" onclick="toggleNextSibling(this);">2,019</a><span style="display:none;white-space:normal;text-align:left;">cytk_ReimbursementOfInternalResearchAndDevelopmentCost<br>/ us-gaap_RelatedPartyTransactionsByRelatedPartyAxis<br>= cytk_AmgenMember</span><span></span></td> <td class="nump"><a title="cytk_ReimbursementOfInternalResearchAndDevelopmentCost[us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=cytk_AmgenMember]" onclick="toggleNextSibling(this);">4,174</a><span style="display:none;white-space:normal;text-align:left;">cytk_ReimbursementOfInternalResearchAndDevelopmentCost<br>/ us-gaap_RelatedPartyTransactionsByRelatedPartyAxis<br>= cytk_AmgenMember</span><span></span></td> </tr> <tr class="ro"> <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cytk_ReimbursementOfOtherResearchAndDevelopmentCost', window );">Reimbursement of other costs</a></td> <td class="text"> <span></span></td> <td class="nump"><a title="cytk_ReimbursementOfOtherResearchAndDevelopmentCost[us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=cytk_AmgenMember]" onclick="toggleNextSibling(this);">0</a><span style="display:none;white-space:normal;text-align:left;">cytk_ReimbursementOfOtherResearchAndDevelopmentCost<br>/ us-gaap_RelatedPartyTransactionsByRelatedPartyAxis<br>= cytk_AmgenMember</span><span></span></td> <td class="nump"><a title="cytk_ReimbursementOfOtherResearchAndDevelopmentCost[us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=cytk_AmgenMember]" onclick="toggleNextSibling(this);">0</a><span style="display:none;white-space:normal;text-align:left;">cytk_ReimbursementOfOtherResearchAndDevelopmentCost<br>/ us-gaap_RelatedPartyTransactionsByRelatedPartyAxis<br>= cytk_AmgenMember</span><span></span></td> <td class="nump"><a title="cytk_ReimbursementOfOtherResearchAndDevelopmentCost[us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=cytk_AmgenMember]" onclick="toggleNextSibling(this);">3</a><span style="display:none;white-space:normal;text-align:left;">cytk_ReimbursementOfOtherResearchAndDevelopmentCost<br>/ us-gaap_RelatedPartyTransactionsByRelatedPartyAxis<br>= cytk_AmgenMember</span><span></span></td> </tr> <tr class="reu"> <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cytk_RelatedPartyResearchAndDevelopmentRevenue', window );">Total research and development revenue</a></td> <td class="text"> <span></span></td> <td class="nump"><a title="cytk_RelatedPartyResearchAndDevelopmentRevenue[us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=cytk_AmgenMember]" onclick="toggleNextSibling(this);">4,538</a><span style="display:none;white-space:normal;text-align:left;">cytk_RelatedPartyResearchAndDevelopmentRevenue<br>/ us-gaap_RelatedPartyTransactionsByRelatedPartyAxis<br>= cytk_AmgenMember</span><span></span></td> <td class="nump"><a title="cytk_RelatedPartyResearchAndDevelopmentRevenue[us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=cytk_AmgenMember]" onclick="toggleNextSibling(this);">19,249</a><span style="display:none;white-space:normal;text-align:left;">cytk_RelatedPartyResearchAndDevelopmentRevenue<br>/ us-gaap_RelatedPartyTransactionsByRelatedPartyAxis<br>= cytk_AmgenMember</span><span></span></td> <td class="nump"><a title="cytk_RelatedPartyResearchAndDevelopmentRevenue[us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=cytk_AmgenMember]" onclick="toggleNextSibling(this);">4,177</a><span style="display:none;white-space:normal;text-align:left;">cytk_RelatedPartyResearchAndDevelopmentRevenue<br>/ us-gaap_RelatedPartyTransactionsByRelatedPartyAxis<br>= cytk_AmgenMember</span><span></span></td> </tr> <tr class="rh"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=cytk_AstellasMember', window );">Astellas [Member]</a></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> </tr> <tr class="re"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionDueFromToRelatedPartyAbstract', window );"><strong>Research and development revenues from related parties:</strong></a></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> </tr> <tr class="ro"> <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cytk_ResearchAndDevelopmentRelatedPartyRevenue', window );">Research and development milestone fees</a></td> <td class="text"> <span></span></td> <td class="nump"><a title="cytk_ResearchAndDevelopmentRelatedPartyRevenue[us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=cytk_AstellasMember]" onclick="toggleNextSibling(this);">15,000</a><span style="display:none;white-space:normal;text-align:left;">cytk_ResearchAndDevelopmentRelatedPartyRevenue<br>/ us-gaap_RelatedPartyTransactionsByRelatedPartyAxis<br>= cytk_AstellasMember</span><span></span></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> </tr> <tr class="re"> <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cytk_ReimbursementOfInternalResearchAndDevelopmentCost', window );">Reimbursement of internal costs</a></td> <td class="text"> <span></span></td> <td class="nump"><a title="cytk_ReimbursementOfInternalResearchAndDevelopmentCost[us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=cytk_AstellasMember]" onclick="toggleNextSibling(this);">8,939</a><span style="display:none;white-space:normal;text-align:left;">cytk_ReimbursementOfInternalResearchAndDevelopmentCost<br>/ us-gaap_RelatedPartyTransactionsByRelatedPartyAxis<br>= cytk_AstellasMember</span><span></span></td> <td class="nump"><a title="cytk_ReimbursementOfInternalResearchAndDevelopmentCost[us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=cytk_AstellasMember]" onclick="toggleNextSibling(this);">3,285</a><span style="display:none;white-space:normal;text-align:left;">cytk_ReimbursementOfInternalResearchAndDevelopmentCost<br>/ us-gaap_RelatedPartyTransactionsByRelatedPartyAxis<br>= cytk_AstellasMember</span><span></span></td> <td class="text"> <span></span></td> </tr> <tr class="ro"> <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cytk_ReimbursementOfOtherResearchAndDevelopmentCost', window );">Reimbursement of other costs</a></td> <td class="text"> <span></span></td> <td class="nump"><a title="cytk_ReimbursementOfOtherResearchAndDevelopmentCost[us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=cytk_AstellasMember]" onclick="toggleNextSibling(this);">6,452</a><span style="display:none;white-space:normal;text-align:left;">cytk_ReimbursementOfOtherResearchAndDevelopmentCost<br>/ us-gaap_RelatedPartyTransactionsByRelatedPartyAxis<br>= cytk_AstellasMember</span><span></span></td> <td class="nump"><a title="cytk_ReimbursementOfOtherResearchAndDevelopmentCost[us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=cytk_AstellasMember]" onclick="toggleNextSibling(this);">3,130</a><span style="display:none;white-space:normal;text-align:left;">cytk_ReimbursementOfOtherResearchAndDevelopmentCost<br>/ us-gaap_RelatedPartyTransactionsByRelatedPartyAxis<br>= cytk_AstellasMember</span><span></span></td> <td class="text"> <span></span></td> </tr> <tr class="re"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentAbstract', window );"><strong>Research and development revenues:</strong></a></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> </tr> <tr class="ro"> <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cytk_ReimbursementOfInternalResearchAndDevelopmentCost', window );">Reimbursement of internal costs</a></td> <td class="text"> <span></span></td> <td class="nump"><a title="cytk_ReimbursementOfInternalResearchAndDevelopmentCost[us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=cytk_AstellasMember]" onclick="toggleNextSibling(this);">8,939</a><span style="display:none;white-space:normal;text-align:left;">cytk_ReimbursementOfInternalResearchAndDevelopmentCost<br>/ us-gaap_RelatedPartyTransactionsByRelatedPartyAxis<br>= cytk_AstellasMember</span><span></span></td> <td class="nump"><a title="cytk_ReimbursementOfInternalResearchAndDevelopmentCost[us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=cytk_AstellasMember]" onclick="toggleNextSibling(this);">3,285</a><span style="display:none;white-space:normal;text-align:left;">cytk_ReimbursementOfInternalResearchAndDevelopmentCost<br>/ us-gaap_RelatedPartyTransactionsByRelatedPartyAxis<br>= cytk_AstellasMember</span><span></span></td> <td class="text"> <span></span></td> </tr> <tr class="re"> <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cytk_ReimbursementOfOtherResearchAndDevelopmentCost', window );">Reimbursement of other costs</a></td> <td class="text"> <span></span></td> <td class="nump"><a title="cytk_ReimbursementOfOtherResearchAndDevelopmentCost[us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=cytk_AstellasMember]" onclick="toggleNextSibling(this);">6,452</a><span style="display:none;white-space:normal;text-align:left;">cytk_ReimbursementOfOtherResearchAndDevelopmentCost<br>/ us-gaap_RelatedPartyTransactionsByRelatedPartyAxis<br>= cytk_AstellasMember</span><span></span></td> <td class="nump"><a title="cytk_ReimbursementOfOtherResearchAndDevelopmentCost[us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=cytk_AstellasMember]" onclick="toggleNextSibling(this);">3,130</a><span style="display:none;white-space:normal;text-align:left;">cytk_ReimbursementOfOtherResearchAndDevelopmentCost<br>/ us-gaap_RelatedPartyTransactionsByRelatedPartyAxis<br>= cytk_AstellasMember</span><span></span></td> <td class="text"> <span></span></td> </tr> <tr class="ro"> <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cytk_ResearchAndDevelopmentRevenue', window );">Research and development milestone fees</a></td> <td class="text"> <span></span></td> <td class="nump"><a title="cytk_ResearchAndDevelopmentRevenue[us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=cytk_AstellasMember]" onclick="toggleNextSibling(this);">2,000</a><span style="display:none;white-space:normal;text-align:left;">cytk_ResearchAndDevelopmentRevenue<br>/ us-gaap_RelatedPartyTransactionsByRelatedPartyAxis<br>= cytk_AstellasMember</span><span></span></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> </tr> <tr class="reu"> <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cytk_RelatedPartyResearchAndDevelopmentRevenue', window );">Total research and development revenue</a></td> <td class="text"> <span></span></td> <td class="nump"><a title="cytk_RelatedPartyResearchAndDevelopmentRevenue[us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=cytk_AstellasMember]" onclick="toggleNextSibling(this);">$ 32,391</a><span style="display:none;white-space:normal;text-align:left;">cytk_RelatedPartyResearchAndDevelopmentRevenue<br>/ us-gaap_RelatedPartyTransactionsByRelatedPartyAxis<br>= cytk_AstellasMember</span><span></span></td> <td class="nump"><a title="cytk_RelatedPartyResearchAndDevelopmentRevenue[us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=cytk_AstellasMember]" onclick="toggleNextSibling(this);">$ 6,415</a><span style="display:none;white-space:normal;text-align:left;">cytk_RelatedPartyResearchAndDevelopmentRevenue<br>/ us-gaap_RelatedPartyTransactionsByRelatedPartyAxis<br>= cytk_AstellasMember</span><span></span></td> <td class="text"> <span></span></td> </tr> </table> <div style="display: none;"> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cytk_ReimbursementOfInternalResearchAndDevelopmentCost"> <tr> <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td> </tr> <tr> <td> <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div> <p>Reimbursement of internal research and development cost.</p> </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"> <p>No definition available.</p> </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"> <table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">cytk_ReimbursementOfInternalResearchAndDevelopmentCost</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>cytk_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:monetaryItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>credit</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table> </div> </div> </td> </tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cytk_ReimbursementOfOtherResearchAndDevelopmentCost"> <tr> <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td> </tr> <tr> <td> <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div> <p>Reimbursement Of Other Research And Development Cost</p> </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"> <p>No definition available.</p> </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"> <table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">cytk_ReimbursementOfOtherResearchAndDevelopmentCost</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>cytk_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:monetaryItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>credit</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table> </div> </div> </td> </tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cytk_RelatedPartyResearchAndDevelopmentRevenue"> <tr> <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td> </tr> <tr> <td> <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div> <p>Revenues from research and development agreements with related parties.</p> </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"> <p>No definition available.</p> </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"> <table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">cytk_RelatedPartyResearchAndDevelopmentRevenue</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>cytk_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:monetaryItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>credit</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table> </div> </div> </td> </tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cytk_ResearchAndDevelopmentRelatedPartyRevenue"> <tr> <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td> </tr> <tr> <td> <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div> <p>Research and development related party revenue.</p> </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"> <p>No definition available.</p> </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"> <table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">cytk_ResearchAndDevelopmentRelatedPartyRevenue</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>cytk_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:monetaryItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>credit</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table> </div> </div> </td> </tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cytk_ResearchAndDevelopmentRevenue"> <tr> <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td> </tr> <tr> <td> <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div> <p>Research And Development Revenue</p> </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"> <p>No definition available.</p> </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"> <table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">cytk_ResearchAndDevelopmentRevenue</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>cytk_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:monetaryItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>credit</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table> </div> </div> </td> </tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cytk_ScheduleOfOtherRelatedPartyTransactionsLineItems"> <tr> <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td> </tr> <tr> <td> <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div> <table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">cytk_ScheduleOfOtherRelatedPartyTransactionsLineItems</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>cytk_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:stringItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table> </div> </div> </td> </tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LicenseAndServicesRevenue"> <tr> <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td> </tr> <tr> <td> <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div> <p>Revenue from multiple-deliverable arrangements that include licensing fees and services revenue. Licensing revenue is consideration received from another party for the right to use, but not own, certain of the entity's intangible assets. Licensing arrangements include, but are not limited to, rights to use a patent, copyright, technology, manufacturing process, software or trademark. Licensing fees are generally, but not always, fixed as to amount and not dependent upon the revenue generated by the licensing party. An entity may receive licensing fees for licenses that also generate royalty payments to the entity. Services revenue may be derived by providing other, nonspecified, services during the reporting period.</p> </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"> <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 03<br><br> -Paragraph 1<br><br> -Article 5<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 225<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 2<br><br> -Subparagraph (SX 210.5-03.1(d),(e))<br><br> -URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688<br><br><br><br></p> </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"> <table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_LicenseAndServicesRevenue</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:monetaryItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>credit</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table> </div> </div> </td> </tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionDueFromToRelatedPartyAbstract"> <tr> <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td> </tr> <tr> <td> <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div> <table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionDueFromToRelatedPartyAbstract</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:stringItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table> </div> </div> </td> </tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentAbstract"> <tr> <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td> </tr> <tr> <td> <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div> <table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentAbstract</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:stringItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table> </div> </div> </td> </tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromRelatedParties"> <tr> <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td> </tr> <tr> <td> <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div> <p>Amount of revenue, fees and commissions earned from transactions between (a) a parent company and its subsidiaries; (b) subsidiaries of a common parent; (c) an entity and trusts for the benefit of employees, for example, but not limited to, pension and profit-sharing trusts that are managed by or under the trusteeship of the entity's management; (d) an entity and its principal, owners, management, or members of their immediate families; and (e) affiliates.</p> </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"> <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 225<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 2<br><br> -Subparagraph (SX 210.5-03.1(e))<br><br> -URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 03<br><br> -Paragraph 1<br><br> -Article 5<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Related Parties<br><br> -URI http://asc.fasb.org/extlink&oid=16382449<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 946<br><br> -SubTopic 225<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.6-07.1(c))<br><br> -URI http://asc.fasb.org/extlink&oid=6488393&loc=d3e606610-122999<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 07<br><br> -Paragraph b<br><br> -Subparagraph 1<br><br> -Article 6<br><br><br><br></p> </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"> <table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_RevenueFromRelatedParties</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:monetaryItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>credit</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table> </div> </div> </td> </tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=cytk_AmgenMember"> <tr> <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td> </tr> <tr> <td> <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div> <table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=cytk_AmgenMember</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td></td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td></td> </tr> <tr> <td><strong> Period Type:</strong></td> <td></td> </tr> </table> </div> </div> </td> </tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=cytk_AstellasMember"> <tr> <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td> </tr> <tr> <td> <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div> <table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=cytk_AstellasMember</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td></td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td></td> </tr> <tr> <td><strong> Period Type:</strong></td> <td></td> </tr> </table> </div> </div> </td> </tr> </table> </div> </body> </html> </TEXT> </DOCUMENT> <DOCUMENT> <TYPE>XML <SEQUENCE>30 <FILENAME>R42.htm <DESCRIPTION>IDEA: XBRL DOCUMENT <TEXT> <html> <head> <META http-equiv="Content-Type" content="text/html; charset=us-ascii"> <title></title> <link rel="stylesheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript"> function toggleNextSibling (e) { if (e.nextSibling.style.display=='none') { e.nextSibling.style.display='block'; } else { e.nextSibling.style.display='none'; } }</script></head> <body><span style="display: none;">v2.4.1.9</span><table class="report" border="0" cellspacing="2" id="ID0EYCAE"> <tr> <th class="tl" colspan="1" rowspan="2"> <div style="width: 200px;"><strong>Cash Equivalents and Investments - Additional Information (Detail) (USD $)<br></strong></div> </th> <th class="th" colspan="2">12 Months Ended</th> </tr> <tr> <th class="th"> <div>Dec. 31, 2014</div> </th> <th class="th"> <div>Dec. 31, 2013</div> </th> </tr> <tr class="re"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsLineItems', window );"><strong>Cash and Cash Equivalents [Line Items]</strong></a></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> </tr> <tr class="ro"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss', window );">Investments in continuous unrealized loss position for 12 months or longer</a></td> <td class="nump"><a title="us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" onclick="toggleNextSibling(this);">$ 0</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss</span><span></span></td> <td class="text"> <span></span></td> </tr> <tr class="rh"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAxis=us-gaap_USTreasurySecuritiesMember', window );">U.S. Treasury Securities [Member]</a></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> </tr> <tr class="ro"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsLineItems', window );"><strong>Cash and Cash Equivalents [Line Items]</strong></a></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> </tr> <tr class="re"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_invest_InvestmentMaturityDateRangeStart1', window );">U.S. Treasury securities maturity start date</a></td> <td class="text">Jan. 01, 2015<span></span></td> <td class="text"> <span></span></td> </tr> <tr class="ro"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_invest_InvestmentMaturityDateRangeEnd1', window );">U.S. Treasury securities maturity end date</a></td> <td class="text">Feb. 27, 2015<span></span></td> <td class="text"> <span></span></td> </tr> <tr class="rh"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentTypeAxis=us-gaap_ShortTermInvestmentsMember', window );">Short-term Investments [Member]</a></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> </tr> <tr class="ro"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsLineItems', window );"><strong>Cash and Cash Equivalents [Line Items]</strong></a></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> </tr> <tr class="re"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrealizedGainLossOnInvestments', window );">Unrealized Gain (loss)</a></td> <td class="num"><a title="us-gaap_UnrealizedGainLossOnInvestments[us-gaap_InvestmentTypeAxis=us-gaap_ShortTermInvestmentsMember]" onclick="toggleNextSibling(this);">$ (7,000)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_UnrealizedGainLossOnInvestments<br>/ us-gaap_InvestmentTypeAxis<br>= us-gaap_ShortTermInvestmentsMember</span><span></span></td> <td class="num"><a title="us-gaap_UnrealizedGainLossOnInvestments[us-gaap_InvestmentTypeAxis=us-gaap_ShortTermInvestmentsMember]" onclick="toggleNextSibling(this);">$ (1,000)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_UnrealizedGainLossOnInvestments<br>/ us-gaap_InvestmentTypeAxis<br>= us-gaap_ShortTermInvestmentsMember</span><span></span></td> </tr> </table> <div style="display: none;"> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_invest_InvestmentMaturityDateRangeEnd1"> <tr> <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td> </tr> <tr> <td> <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div> <p>The latest maturity date when short-term debt instruments are reported on the Schedule of Investments.</p> </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"> <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Article 12<br><br> -Section 12<br><br> -Footnote 2<br><br><br><br></p> </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"> <table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">invest_InvestmentMaturityDateRangeEnd1</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>invest_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:dateItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table> </div> </div> </td> </tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_invest_InvestmentMaturityDateRangeStart1"> <tr> <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td> </tr> <tr> <td> <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div> <p>The earliest maturity date when short-term debt instruments are reported on the Schedule of Investments.</p> </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"> <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Article 12<br><br> -Section 12<br><br> -Footnote 2<br><br><br><br></p> </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"> <table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">invest_InvestmentMaturityDateRangeStart1</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>invest_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:dateItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table> </div> </div> </td> </tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss"> <tr> <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td> </tr> <tr> <td> <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div> <p>Amount of accumulated unrealized loss on investments in debt and equity securities classified as available-for-sale that have been in a continuous loss position for twelve months or longer.</p> </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"> <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 320<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 7<br><br> -URI http://asc.fasb.org/extlink&oid=27724398&loc=d3e27337-111563<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 320<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 6<br><br> -Subparagraph (a)(2)<br><br> -URI http://asc.fasb.org/extlink&oid=27724398&loc=d3e27290-111563<br><br><br><br></p> </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"> <table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:monetaryItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>debit</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>instant</td> </tr> </table> </div> </div> </td> </tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsLineItems"> <tr> <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td> </tr> <tr> <td> <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div> <table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsLineItems</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:stringItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table> </div> </div> </td> </tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrealizedGainLossOnInvestments"> <tr> <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td> </tr> <tr> <td> <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div> <p>The net change in the difference between the fair value and the carrying value, or in the comparative fair values, of investments, not including unrealized gains or losses on securities separately or otherwise categorized as trading, available-for-sale, or held-to-maturity, held at each balance sheet date and included in earnings for the period.</p> </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"> <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -Subparagraph (b)<br><br> -URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3602-108585<br><br><br><br></p> </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"> <table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_UnrealizedGainLossOnInvestments</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:monetaryItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>credit</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table> </div> </div> </td> </tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAxis=us-gaap_USTreasurySecuritiesMember"> <tr> <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td> </tr> <tr> <td> <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div> <table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAxis=us-gaap_USTreasurySecuritiesMember</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td></td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td></td> </tr> <tr> <td><strong> Period Type:</strong></td> <td></td> </tr> </table> </div> </div> </td> </tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=us-gaap_ShortTermInvestmentsMember"> <tr> <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td> </tr> <tr> <td> <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div> <table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=us-gaap_ShortTermInvestmentsMember</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td></td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td></td> </tr> <tr> <td><strong> Period Type:</strong></td> <td></td> </tr> </table> </div> </div> </td> </tr> </table> </div> </body> </html> </TEXT> </DOCUMENT> <DOCUMENT> <TYPE>XML <SEQUENCE>31 <FILENAME>R37.htm <DESCRIPTION>IDEA: XBRL DOCUMENT <TEXT> <html> <head> <META http-equiv="Content-Type" content="text/html; charset=us-ascii"> <title></title> <link rel="stylesheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript"> function toggleNextSibling (e) { if (e.nextSibling.style.display=='none') { e.nextSibling.style.display='block'; } else { e.nextSibling.style.display='none'; } }</script></head> <body><span style="display: none;">v2.4.1.9</span><table class="report" border="0" cellspacing="2" id="ID0EJ5GK"> <tr> <th class="tl" colspan="1" rowspan="2"> <div style="width: 200px;"><strong>Organization and Significant Accounting Policies - Additional Information (Detail) (USD $)<br></strong></div> </th> <th class="th" colspan="1">0 Months Ended</th> <th class="th" colspan="1">1 Months Ended</th> <th class="th" colspan="8">3 Months Ended</th> <th class="th" colspan="3">12 Months Ended</th> <th class="th" colspan="1"></th> <th class="th" colspan="1"></th> </tr> <tr> <th class="th"> <div>Jun. 24, 2013</div> </th> <th class="th"> <div>Jun. 30, 2013</div> </th> <th class="th"> <div>Dec. 31, 2014 </div> <div>Financial_Institution</div> </th> <th class="th"> <div>Sep. 30, 2014</div> </th> <th class="th"> <div>Jun. 30, 2014</div> </th> <th class="th"> <div>Mar. 31, 2014</div> </th> <th class="th"> <div>Dec. 31, 2013</div> </th> <th class="th"> <div>Sep. 30, 2013</div> </th> <th class="th"> <div>Jun. 30, 2013</div> </th> <th class="th"> <div>Mar. 31, 2013</div> </th> <th class="th"> <div>Dec. 31, 2014 </div> <div>Segment </div> <div>Financial_Institution</div> </th> <th class="th"> <div>Dec. 31, 2013</div> </th> <th class="th"> <div>Dec. 31, 2012</div> </th> <th class="th"> <div>Aug. 31, 2011</div> </th> <th class="th"> <div>May 18, 2011</div> </th> </tr> <tr class="re"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cytk_SummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Summary Of Significant Accounting Policies [Line Items]</strong></a></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> </tr> <tr class="ro"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit incurred</a></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> <td class="num"><a title="us-gaap_RetainedEarningsAccumulatedDeficit" onclick="toggleNextSibling(this);">$ (497,243,000)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_RetainedEarningsAccumulatedDeficit</span><span></span></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> <td class="num"><a title="us-gaap_RetainedEarningsAccumulatedDeficit" onclick="toggleNextSibling(this);">$ (482,597,000)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_RetainedEarningsAccumulatedDeficit</span><span></span></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> <td class="num"><a title="us-gaap_RetainedEarningsAccumulatedDeficit" onclick="toggleNextSibling(this);">$ (497,243,000)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_RetainedEarningsAccumulatedDeficit</span><span></span></td> <td class="num"><a title="us-gaap_RetainedEarningsAccumulatedDeficit" onclick="toggleNextSibling(this);">$ (482,597,000)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_RetainedEarningsAccumulatedDeficit</span><span></span></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> </tr> <tr class="re"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> <td class="nump"><a title="us-gaap_NetIncomeLoss" onclick="toggleNextSibling(this);">8,443,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_NetIncomeLoss</span><span></span></td> <td class="num"><a title="us-gaap_NetIncomeLoss" onclick="toggleNextSibling(this);">(5,971,000)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_NetIncomeLoss</span><span></span></td> <td class="num"><a title="us-gaap_NetIncomeLoss" onclick="toggleNextSibling(this);">(8,374,000)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_NetIncomeLoss</span><span></span></td> <td class="num"><a title="us-gaap_NetIncomeLoss" onclick="toggleNextSibling(this);">(8,744,000)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_NetIncomeLoss</span><span></span></td> <td class="nump"><a title="us-gaap_NetIncomeLoss" onclick="toggleNextSibling(this);">6,531,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_NetIncomeLoss</span><span></span></td> <td class="num"><a title="us-gaap_NetIncomeLoss" onclick="toggleNextSibling(this);">(12,588,000)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_NetIncomeLoss</span><span></span></td> <td class="num"><a title="us-gaap_NetIncomeLoss" onclick="toggleNextSibling(this);">(15,041,000)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_NetIncomeLoss</span><span></span></td> <td class="num"><a title="us-gaap_NetIncomeLoss" onclick="toggleNextSibling(this);">(12,619,000)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_NetIncomeLoss</span><span></span></td> <td class="num"><a title="us-gaap_NetIncomeLoss" onclick="toggleNextSibling(this);">(14,646,000)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_NetIncomeLoss</span><span></span></td> <td class="num"><a title="us-gaap_NetIncomeLoss" onclick="toggleNextSibling(this);">(33,717,000)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_NetIncomeLoss</span><span></span></td> <td class="num"><a title="us-gaap_NetIncomeLoss" onclick="toggleNextSibling(this);">(40,370,000)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_NetIncomeLoss</span><span></span></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> </tr> <tr class="ro"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations', window );">Net cash (used in) operations</a></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> <td class="num"><a title="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" onclick="toggleNextSibling(this);">(44,843,000)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations</span><span></span></td> <td class="num"><a title="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" onclick="toggleNextSibling(this);">(7,718,000)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations</span><span></span></td> <td class="num"><a title="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" onclick="toggleNextSibling(this);">(33,438,000)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations</span><span></span></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> </tr> <tr class="re"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsAndShortTermInvestments', window );">Cash, cash equivalents and investments</a></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> <td class="nump"><a title="us-gaap_CashCashEquivalentsAndShortTermInvestments" onclick="toggleNextSibling(this);">83,200,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_CashCashEquivalentsAndShortTermInvestments</span><span></span></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> <td class="nump"><a title="us-gaap_CashCashEquivalentsAndShortTermInvestments" onclick="toggleNextSibling(this);">80,200,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_CashCashEquivalentsAndShortTermInvestments</span><span></span></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> <td class="nump"><a title="us-gaap_CashCashEquivalentsAndShortTermInvestments" onclick="toggleNextSibling(this);">83,200,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_CashCashEquivalentsAndShortTermInvestments</span><span></span></td> <td class="nump"><a title="us-gaap_CashCashEquivalentsAndShortTermInvestments" onclick="toggleNextSibling(this);">80,200,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_CashCashEquivalentsAndShortTermInvestments</span><span></span></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> </tr> <tr class="ro"> <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cytk_CashRequirementsTerm', window );">Cash requirements term</a></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> <td class="text">12 months<span></span></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> </tr> <tr class="re"> <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cytk_NumberOfFinancialInstitutions', window );">Number of major financial institutions</a></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> <td class="nump"><a title="cytk_NumberOfFinancialInstitutions" onclick="toggleNextSibling(this);">3</a><span style="display:none;white-space:normal;text-align:left;">cytk_NumberOfFinancialInstitutions</span><span></span></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> <td class="nump"><a title="cytk_NumberOfFinancialInstitutions" onclick="toggleNextSibling(this);">3</a><span style="display:none;white-space:normal;text-align:left;">cytk_NumberOfFinancialInstitutions</span><span></span></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> </tr> <tr class="ro"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount', window );">Employer contributions under the plan</a></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> <td class="nump"><a title="us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount" onclick="toggleNextSibling(this);">336,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount</span><span></span></td> <td class="nump"><a title="us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount" onclick="toggleNextSibling(this);">0</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount</span><span></span></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> </tr> <tr class="re"> <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cytk_PercentageOfIncomeTaxPositionsLikelyToBeRealized', window );">Percentage of income tax likely to be realized</a></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> <td class="nump"><a title="cytk_PercentageOfIncomeTaxPositionsLikelyToBeRealized" onclick="toggleNextSibling(this);">50.00%</a><span style="display:none;white-space:normal;text-align:left;">cytk_PercentageOfIncomeTaxPositionsLikelyToBeRealized</span><span></span></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> </tr> <tr class="ro"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NumberOfReportableSegments', window );">Number of reporting segment</a></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> <td class="nump"><a title="us-gaap_NumberOfReportableSegments" onclick="toggleNextSibling(this);">1</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_NumberOfReportableSegments</span><span></span></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> </tr> <tr class="re"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1', window );">Reverse stock split, conversion ratio</a></td> <td class="nump"><a title="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" onclick="toggleNextSibling(this);">0.167</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_StockholdersEquityNoteStockSplitConversionRatio1</span><span></span></td> <td class="nump"><a title="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" onclick="toggleNextSibling(this);">0.167</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_StockholdersEquityNoteStockSplitConversionRatio1</span><span></span></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> </tr> <tr class="ro"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityReverseStockSplit', window );">Reverse stock split, description</a></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> <td class="text">As of the effective time of the reverse stock split, every six shares of the Company's issued and outstanding common stock were converted into one issued and outstanding share of common stock, without any change in par value per share.<span></span></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> </tr> <tr class="re"> <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cytk_FractionalSharesFromReverseStockSplitShare', window );">Fractional shares settlement pursuant to reverse stock split</a></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> <td class="nump"><a title="cytk_FractionalSharesFromReverseStockSplitShare" onclick="toggleNextSibling(this);">0</a><span style="display:none;white-space:normal;text-align:left;">cytk_FractionalSharesFromReverseStockSplitShare</span><span></span></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> </tr> <tr class="ro"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, authorized</a></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> <td class="nump"><a title="us-gaap_CommonStockSharesAuthorized" onclick="toggleNextSibling(this);">81,500,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_CommonStockSharesAuthorized</span><span></span></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> <td class="nump"><a title="us-gaap_CommonStockSharesAuthorized" onclick="toggleNextSibling(this);">81,500,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_CommonStockSharesAuthorized</span><span></span></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> <td class="nump"><a title="us-gaap_CommonStockSharesAuthorized" onclick="toggleNextSibling(this);">81,500,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_CommonStockSharesAuthorized</span><span></span></td> <td class="nump"><a title="us-gaap_CommonStockSharesAuthorized" onclick="toggleNextSibling(this);">81,500,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_CommonStockSharesAuthorized</span><span></span></td> <td class="text"> <span></span></td> <td class="nump"><a title="us-gaap_CommonStockSharesAuthorized" onclick="toggleNextSibling(this);">245,000,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_CommonStockSharesAuthorized</span><span></span></td> <td class="nump"><a title="us-gaap_CommonStockSharesAuthorized" onclick="toggleNextSibling(this);">170,000,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_CommonStockSharesAuthorized</span><span></span></td> </tr> <tr class="re"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value</a></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> <td class="nump"><a title="us-gaap_CommonStockParOrStatedValuePerShare" onclick="toggleNextSibling(this);">$ 0.001</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_CommonStockParOrStatedValuePerShare</span><span></span></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> <td class="nump"><a title="us-gaap_CommonStockParOrStatedValuePerShare" onclick="toggleNextSibling(this);">$ 0.001</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_CommonStockParOrStatedValuePerShare</span><span></span></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> <td class="nump"><a title="us-gaap_CommonStockParOrStatedValuePerShare" onclick="toggleNextSibling(this);">$ 0.001</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_CommonStockParOrStatedValuePerShare</span><span></span></td> <td class="nump"><a title="us-gaap_CommonStockParOrStatedValuePerShare" onclick="toggleNextSibling(this);">$ 0.001</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_CommonStockParOrStatedValuePerShare</span><span></span></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> </tr> <tr class="ro"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockSplit', window );">Reclassification from common stock to additional paid-in capital</a></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> <td class="nump"><a title="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockSplit" onclick="toggleNextSibling(this);">139,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_AdjustmentsToAdditionalPaidInCapitalStockSplit</span><span></span></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> </tr> <tr class="rh"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementGeographicalAxis=country_US', window );">United States [Member]</a></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> </tr> <tr class="ro"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cytk_SummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Summary Of Significant Accounting Policies [Line Items]</strong></a></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> </tr> <tr class="re"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Revenues derived</a></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> <td class="nump"><a title="us-gaap_ConcentrationRiskPercentage1[us-gaap_StatementGeographicalAxis=country_US]" onclick="toggleNextSibling(this);">31.00%</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ConcentrationRiskPercentage1<br>/ us-gaap_StatementGeographicalAxis<br>= country_US</span><span></span></td> <td class="nump"><a title="us-gaap_ConcentrationRiskPercentage1[us-gaap_StatementGeographicalAxis=country_US]" onclick="toggleNextSibling(this);">66.00%</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ConcentrationRiskPercentage1<br>/ us-gaap_StatementGeographicalAxis<br>= country_US</span><span></span></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> </tr> <tr class="rh"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementGeographicalAxis=country_JP', window );">Japanese [Member]</a></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> </tr> <tr class="re"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cytk_SummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Summary Of Significant Accounting Policies [Line Items]</strong></a></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> </tr> <tr class="ro"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Revenues derived</a></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> <td class="nump"><a title="us-gaap_ConcentrationRiskPercentage1[us-gaap_StatementGeographicalAxis=country_JP]" onclick="toggleNextSibling(this);">69.00%</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ConcentrationRiskPercentage1<br>/ us-gaap_StatementGeographicalAxis<br>= country_JP</span><span></span></td> <td class="nump"><a title="us-gaap_ConcentrationRiskPercentage1[us-gaap_StatementGeographicalAxis=country_JP]" onclick="toggleNextSibling(this);">34.00%</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ConcentrationRiskPercentage1<br>/ us-gaap_StatementGeographicalAxis<br>= country_JP</span><span></span></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> </tr> <tr class="rh"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=cytk_AstellasMember', window );">Astellas [Member]</a></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> </tr> <tr class="ro"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cytk_SummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Summary Of Significant Accounting Policies [Line Items]</strong></a></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> </tr> <tr class="re"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Revenues derived</a></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> <td class="nump"><a title="us-gaap_ConcentrationRiskPercentage1[dei_LegalEntityAxis=cytk_AstellasMember]" onclick="toggleNextSibling(this);">69.00%</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ConcentrationRiskPercentage1<br>/ dei_LegalEntityAxis<br>= cytk_AstellasMember</span><span></span></td> <td class="nump"><a title="us-gaap_ConcentrationRiskPercentage1[dei_LegalEntityAxis=cytk_AstellasMember]" onclick="toggleNextSibling(this);">34.00%</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ConcentrationRiskPercentage1<br>/ dei_LegalEntityAxis<br>= cytk_AstellasMember</span><span></span></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> </tr> <tr class="ro"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsReceivableRelatedParties', window );">Accounts receivable due</a></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> <td class="nump"><a title="us-gaap_AccountsReceivableRelatedParties[dei_LegalEntityAxis=cytk_AstellasMember]" onclick="toggleNextSibling(this);">45,000,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_AccountsReceivableRelatedParties<br>/ dei_LegalEntityAxis<br>= cytk_AstellasMember</span><span></span></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> <td class="nump"><a title="us-gaap_AccountsReceivableRelatedParties[dei_LegalEntityAxis=cytk_AstellasMember]" onclick="toggleNextSibling(this);">0</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_AccountsReceivableRelatedParties<br>/ dei_LegalEntityAxis<br>= cytk_AstellasMember</span><span></span></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> <td class="nump"><a title="us-gaap_AccountsReceivableRelatedParties[dei_LegalEntityAxis=cytk_AstellasMember]" onclick="toggleNextSibling(this);">45,000,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_AccountsReceivableRelatedParties<br>/ dei_LegalEntityAxis<br>= cytk_AstellasMember</span><span></span></td> <td class="nump"><a title="us-gaap_AccountsReceivableRelatedParties[dei_LegalEntityAxis=cytk_AstellasMember]" onclick="toggleNextSibling(this);">0</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_AccountsReceivableRelatedParties<br>/ dei_LegalEntityAxis<br>= cytk_AstellasMember</span><span></span></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> </tr> <tr class="rh"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=cytk_AmgenMember', window );">Amgen [Member]</a></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> </tr> <tr class="ro"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cytk_SummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Summary Of Significant Accounting Policies [Line Items]</strong></a></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> </tr> <tr class="re"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Revenues derived</a></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> <td class="nump"><a title="us-gaap_ConcentrationRiskPercentage1[us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=cytk_AmgenMember]" onclick="toggleNextSibling(this);">10.00%</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ConcentrationRiskPercentage1<br>/ us-gaap_RelatedPartyTransactionsByRelatedPartyAxis<br>= cytk_AmgenMember</span><span></span></td> <td class="nump"><a title="us-gaap_ConcentrationRiskPercentage1[us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=cytk_AmgenMember]" onclick="toggleNextSibling(this);">63.00%</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ConcentrationRiskPercentage1<br>/ us-gaap_RelatedPartyTransactionsByRelatedPartyAxis<br>= cytk_AmgenMember</span><span></span></td> <td class="nump"><a title="us-gaap_ConcentrationRiskPercentage1[us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=cytk_AmgenMember]" onclick="toggleNextSibling(this);">55.00%</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ConcentrationRiskPercentage1<br>/ us-gaap_RelatedPartyTransactionsByRelatedPartyAxis<br>= cytk_AmgenMember</span><span></span></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> </tr> <tr class="ro"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsReceivableRelatedParties', window );">Accounts receivable due</a></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> <td class="nump"><a title="us-gaap_AccountsReceivableRelatedParties[us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=cytk_AmgenMember]" onclick="toggleNextSibling(this);">$ 1,600,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_AccountsReceivableRelatedParties<br>/ us-gaap_RelatedPartyTransactionsByRelatedPartyAxis<br>= cytk_AmgenMember</span><span></span></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> <td class="nump"><a title="us-gaap_AccountsReceivableRelatedParties[us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=cytk_AmgenMember]" onclick="toggleNextSibling(this);">$ 0</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_AccountsReceivableRelatedParties<br>/ us-gaap_RelatedPartyTransactionsByRelatedPartyAxis<br>= cytk_AmgenMember</span><span></span></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> <td class="nump"><a title="us-gaap_AccountsReceivableRelatedParties[us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=cytk_AmgenMember]" onclick="toggleNextSibling(this);">$ 1,600,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_AccountsReceivableRelatedParties<br>/ us-gaap_RelatedPartyTransactionsByRelatedPartyAxis<br>= cytk_AmgenMember</span><span></span></td> <td class="nump"><a title="us-gaap_AccountsReceivableRelatedParties[us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=cytk_AmgenMember]" onclick="toggleNextSibling(this);">$ 0</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_AccountsReceivableRelatedParties<br>/ us-gaap_RelatedPartyTransactionsByRelatedPartyAxis<br>= cytk_AmgenMember</span><span></span></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> </tr> <tr class="rh"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=cytk_ComputerEquipmentAndSoftwareMember', window );">Computer Equipment and Software [Member]</a></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> </tr> <tr class="ro"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cytk_SummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Summary Of Significant Accounting Policies [Line Items]</strong></a></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> </tr> <tr class="re"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property and equipment estimated useful lives</a></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> <td class="text">3 years<span></span></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> </tr> <tr class="rh"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_OfficeEquipmentMember', window );">Laboratory Equipment and Office Equipment [Member]</a></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> </tr> <tr class="re"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cytk_SummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Summary Of Significant Accounting Policies [Line Items]</strong></a></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> </tr> <tr class="ro"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property and equipment estimated useful lives</a></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> <td class="text">5 years<span></span></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> </tr> <tr class="rh"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember', window );">Furniture and Fixtures [Member]</a></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> </tr> <tr class="ro"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cytk_SummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Summary Of Significant Accounting Policies [Line Items]</strong></a></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> </tr> <tr class="re"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property and equipment estimated useful lives</a></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> <td class="text">7 years<span></span></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> </tr> <tr class="rh"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RangeAxis=us-gaap_MaximumMember', window );">Maximum [Member] | Leasehold Improvements [Member]</a></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> </tr> <tr class="re"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cytk_SummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Summary Of Significant Accounting Policies [Line Items]</strong></a></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> </tr> <tr class="ro"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property and equipment estimated useful lives</a></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> <td class="text">7 years<span></span></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> </tr> <tr class="rh"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RangeAxis=us-gaap_MinimumMember', window );">Minimum [Member] | Leasehold Improvements [Member]</a></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> </tr> <tr class="ro"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cytk_SummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Summary Of Significant Accounting Policies [Line Items]</strong></a></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> </tr> <tr class="re"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property and equipment estimated useful lives</a></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> <td class="text">3 years<span></span></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> </tr> </table> <div style="display: none;"> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cytk_CashRequirementsTerm"> <tr> <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td> </tr> <tr> <td> <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div> <p>The minimum period of time, subsequent to the current balance sheet date, for which the company believes existing cash, cash equivalents and investments will be sufficient to fund its cash requirements.</p> </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"> <p>No definition available.</p> </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"> <table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">cytk_CashRequirementsTerm</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>cytk_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:durationItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table> </div> </div> </td> </tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cytk_FractionalSharesFromReverseStockSplitShare"> <tr> <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td> </tr> <tr> <td> <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div> <p>Fractional Shares From Reverse Stock Split Share</p> </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"> <p>No definition available.</p> </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"> <table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">cytk_FractionalSharesFromReverseStockSplitShare</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>cytk_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:sharesItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table> </div> </div> </td> </tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cytk_NumberOfFinancialInstitutions"> <tr> <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td> </tr> <tr> <td> <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div> <p>Number of financial institutions.</p> </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"> <p>No definition available.</p> </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"> <table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">cytk_NumberOfFinancialInstitutions</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>cytk_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:integerItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>instant</td> </tr> </table> </div> </div> </td> </tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cytk_PercentageOfIncomeTaxPositionsLikelyToBeRealized"> <tr> <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td> </tr> <tr> <td> <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div> <p>The minimum likelihood, expressed as a percentage, that will trigger recognition of a tax benefit.</p> </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"> <p>No definition available.</p> </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"> <table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">cytk_PercentageOfIncomeTaxPositionsLikelyToBeRealized</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>cytk_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>num:percentItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table> </div> </div> </td> </tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cytk_SummaryOfSignificantAccountingPoliciesLineItems"> <tr> <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td> </tr> <tr> <td> <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div> <table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">cytk_SummaryOfSignificantAccountingPoliciesLineItems</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>cytk_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:stringItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table> </div> </div> </td> </tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableRelatedParties"> <tr> <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td> </tr> <tr> <td> <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div> <p>For an unclassified balance sheet, amount of receivables arising from transactions with related parties.</p> </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"> <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.4-08.(k)(1))<br><br> -URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 850<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 4<br><br> -URI http://asc.fasb.org/extlink&oid=6457730&loc=d3e39622-107864<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 944<br><br> -SubTopic 210<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.7-03.(a),3)<br><br> -URI http://asc.fasb.org/extlink&oid=6879938&loc=d3e572229-122910<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 850<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -Subparagraph (d)<br><br> -URI http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 850<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&oid=6457730&loc=d3e39603-107864<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 3<br><br> -Subparagraph a<br><br> -Article 5<br><br><br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 08<br><br> -Paragraph k<br><br> -Subparagraph 1<br><br> -Article 4<br><br><br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 03<br><br> -Paragraph 3<br><br> -Article 7<br><br><br><br></p> </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"> <table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_AccountsReceivableRelatedParties</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:monetaryItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>debit</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>instant</td> </tr> </table> </div> </div> </td> </tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockSplit"> <tr> <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td> </tr> <tr> <td> <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div> <p>Amount of decrease in additional paid in capital (APIC) resulting from a stock split in which per-share par value or stated value is not changed proportionately.</p> </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"> <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 31<br><br> -Article 5<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 04<br><br> -Article 3<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21463-112644<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.3-04)<br><br> -URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Stock Split<br><br> -URI http://asc.fasb.org/extlink&oid=6525746<br><br><br><br></p> </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"> <table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalStockSplit</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:monetaryItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>debit</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table> </div> </div> </td> </tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsAndShortTermInvestments"> <tr> <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td> </tr> <tr> <td> <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div> <p>Cash includes currency on hand as well as demand deposits with banks or financial institutions. It also includes other kinds of accounts that have the general characteristics of demand deposits in that the customer may deposit additional funds at any time and effectively may withdraw funds at any time without prior notice or penalty. Cash equivalents, excluding items classified as marketable securities, include short-term, highly liquid Investments that are both readily convertible to known amounts of cash, and so near their maturity that they present minimal risk of changes in value because of changes in interest rates. Generally, only investments with original maturities of three months or less qualify under that definition. Original maturity means original maturity to the entity holding the investment. For example, both a three-month US Treasury bill and a three-year Treasury note purchased three months from maturity qualify as cash equivalents. However, a Treasury note purchased three years ago does not become a cash equivalent when its remaining maturity is three months. Short-term investments, exclusive of cash equivalents, generally consist of marketable securities intended to be sold within one year (or the normal operating cycle if longer) and may include trading securities, available-for-sale securities, or held-to-maturity securities (if maturing within one year), as applicable.</p> </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"> <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Cash<br><br> -URI http://asc.fasb.org/extlink&oid=6506951<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Cash Equivalents<br><br> -URI http://asc.fasb.org/extlink&oid=6507016<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 1<br><br> -Article 5<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.1)<br><br> -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682<br><br><br><br></p> </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"> <table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_CashCashEquivalentsAndShortTermInvestments</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:monetaryItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>debit</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>instant</td> </tr> </table> </div> </div> </td> </tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare"> <tr> <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td> </tr> <tr> <td> <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div> <p>Face amount or stated value per share of common stock.</p> </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"> <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.29)<br><br> -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 30<br><br> -Article 5<br><br><br><br></p> </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"> <table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>num:perShareItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>instant</td> </tr> </table> </div> </div> </td> </tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized"> <tr> <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td> </tr> <tr> <td> <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div> <p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p> </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"> <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.29)<br><br> -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 30<br><br> -Article 5<br><br><br><br></p> </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"> <table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:sharesItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>instant</td> </tr> </table> </div> </div> </td> </tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskPercentage1"> <tr> <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td> </tr> <tr> <td> <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div> <p>For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the "benchmark" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.</p> </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"> <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 825<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 21<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&oid=35750535&loc=d3e13537-108611<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 275<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 20<br><br> -URI http://asc.fasb.org/extlink&oid=6927468&loc=d3e6404-108592<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 825<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 20<br><br> -URI http://asc.fasb.org/extlink&oid=35750535&loc=d3e13531-108611<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 275<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 18<br><br> -URI http://asc.fasb.org/extlink&oid=6927468&loc=d3e6351-108592<br><br><br><br></p> </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"> <table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_ConcentrationRiskPercentage1</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>num:percentItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table> </div> </div> </td> </tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount"> <tr> <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td> </tr> <tr> <td> <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div> <p>Amount of discretionary contributions made by an employer to a defined contribution plan.</p> </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"> <p>No definition available.</p> </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"> <table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:monetaryItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>debit</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table> </div> </div> </td> </tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations"> <tr> <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td> </tr> <tr> <td> <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div> <p>Amount of cash inflow (outflow) from operating activities, excluding discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p> </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"> <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3602-108585<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 24<br><br> -URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3521-108585<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 25<br><br> -URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3536-108585<br><br><br><br></p> </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"> <table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:monetaryItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table> </div> </div> </td> </tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss"> <tr> <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td> </tr> <tr> <td> <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div> <p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p> </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"> <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3602-108585<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 260<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Other Comprehensive Income<br><br> -URI http://asc.fasb.org/extlink&oid=6519514<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Net Income<br><br> -URI http://asc.fasb.org/extlink&oid=6518256<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 944<br><br> -SubTopic 225<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.7-04.19)<br><br> -URI http://asc.fasb.org/extlink&oid=6879464&loc=d3e573970-122913<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 225<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 2<br><br> -Subparagraph (SX 210.5-03.18)<br><br> -URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688<br><br><br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 944<br><br> -SubTopic 225<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.7-04.22)<br><br> -URI http://asc.fasb.org/extlink&oid=6879464&loc=d3e573970-122913<br><br><br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 03<br><br> -Paragraph 19<br><br> -Article 5<br><br><br><br>Reference 9: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 04<br><br> -Paragraph 20<br><br> -Article 9<br><br><br><br></p> </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"> <table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:monetaryItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>credit</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table> </div> </div> </td> </tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfReportableSegments"> <tr> <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td> </tr> <tr> <td> <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div> <p>Number of segments reported by the entity. A reportable segment is a component of an entity for which there is an accounting requirement to report separate financial information on that component in the entity's financial statements.</p> </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"> <p>No definition available.</p> </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"> <table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_NumberOfReportableSegments</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:integerItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table> </div> </div> </td> </tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentUsefulLife"> <tr> <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td> </tr> <tr> <td> <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div> <p>Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.</p> </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"> <p>No definition available.</p> </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"> <table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentUsefulLife</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:durationItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table> </div> </div> </td> </tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit"> <tr> <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td> </tr> <tr> <td> <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div> <p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p> </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"> <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 31<br><br> -Article 5<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 04<br><br> -Article 3<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.31(a)(3))<br><br> -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682<br><br><br><br></p> </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"> <table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:monetaryItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>credit</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>instant</td> </tr> </table> </div> </div> </td> </tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1"> <tr> <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td> </tr> <tr> <td> <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div> <p>Ratio applied to the conversion of stock split, for example but not limited to, one share converted to two or two shares converted to one.</p> </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"> <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Stock Split<br><br> -URI http://asc.fasb.org/extlink&oid=6525746<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 4<br><br> -Subparagraph (SAB TOPIC 4.C)<br><br> -URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187143-122770<br><br><br><br></p> </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"> <table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteStockSplitConversionRatio1</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:pureItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table> </div> </div> </td> </tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityReverseStockSplit"> <tr> <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td> </tr> <tr> <td> <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div> <p>Description of the reverse stock split arrangement. Also provide the retroactive effect given by the reverse split that occurs after the balance sheet date but before the release of financial statements.</p> </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"> <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 4<br><br> -Subparagraph (SAB TOPIC 4.C)<br><br> -URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187143-122770<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Staff Accounting Bulletin (SAB)<br><br> -Number Topic 4<br><br> -Section C<br><br><br><br></p> </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"> <table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_StockholdersEquityReverseStockSplit</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:stringItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table> </div> </div> </td> </tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=cytk_AstellasMember"> <tr> <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td> </tr> <tr> <td> <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div> <table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">dei_LegalEntityAxis=cytk_AstellasMember</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td></td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td></td> </tr> <tr> <td><strong> Period Type:</strong></td> <td></td> </tr> </table> </div> </div> </td> </tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=cytk_ComputerEquipmentAndSoftwareMember"> <tr> <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td> </tr> <tr> <td> <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div> <table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=cytk_ComputerEquipmentAndSoftwareMember</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td></td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td></td> </tr> <tr> <td><strong> Period Type:</strong></td> <td></td> </tr> </table> </div> </div> </td> </tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember"> <tr> <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td> </tr> <tr> <td> <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div> <table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td></td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td></td> </tr> <tr> <td><strong> Period Type:</strong></td> <td></td> </tr> </table> </div> </div> </td> </tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_OfficeEquipmentMember"> <tr> <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td> </tr> <tr> <td> <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div> <table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_OfficeEquipmentMember</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td></td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td></td> </tr> <tr> <td><strong> Period Type:</strong></td> <td></td> </tr> </table> </div> </div> </td> </tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RangeAxis=us-gaap_MaximumMember"> <tr> <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td> </tr> <tr> <td> <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div> <table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_RangeAxis=us-gaap_MaximumMember</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td></td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td></td> </tr> <tr> <td><strong> Period Type:</strong></td> <td></td> </tr> </table> </div> </div> </td> </tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RangeAxis=us-gaap_MinimumMember"> <tr> <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td> </tr> <tr> <td> <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div> <table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_RangeAxis=us-gaap_MinimumMember</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td></td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td></td> </tr> <tr> <td><strong> Period Type:</strong></td> <td></td> </tr> </table> </div> </div> </td> </tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=cytk_AmgenMember"> <tr> <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td> </tr> <tr> <td> <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div> <table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=cytk_AmgenMember</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td></td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td></td> </tr> <tr> <td><strong> Period Type:</strong></td> <td></td> </tr> </table> </div> </div> </td> </tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementGeographicalAxis=country_JP"> <tr> <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td> </tr> <tr> <td> <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div> <table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_StatementGeographicalAxis=country_JP</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td></td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td></td> </tr> <tr> <td><strong> Period Type:</strong></td> <td></td> </tr> </table> </div> </div> </td> </tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementGeographicalAxis=country_US"> <tr> <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td> </tr> <tr> <td> <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div> <table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_StatementGeographicalAxis=country_US</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td></td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td></td> </tr> <tr> <td><strong> Period Type:</strong></td> <td></td> </tr> </table> </div> </div> </td> </tr> </table> </div> </body> </html> </TEXT> </DOCUMENT> <DOCUMENT> <TYPE>XML <SEQUENCE>32 <FILENAME>R52.htm <DESCRIPTION>IDEA: XBRL DOCUMENT <TEXT> <html> <head> <META http-equiv="Content-Type" content="text/html; charset=us-ascii"> <title></title> <link rel="stylesheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript"> function toggleNextSibling (e) { if (e.nextSibling.style.display=='none') { e.nextSibling.style.display='block'; } else { e.nextSibling.style.display='none'; } }</script></head> <body><span style="display: none;">v2.4.1.9</span><table class="report" border="0" cellspacing="2" id="ID0EKIAE"> <tr> <th class="tl" colspan="1" rowspan="2"> <div style="width: 200px;"><strong>Other Research and Development Revenue Arrangements - Summary of Total Grant Revenues (Detail) (USD $)<br>In Thousands, unless otherwise specified</strong></div> </th> <th class="th" colspan="3">12 Months Ended</th> </tr> <tr> <th class="th"> <div>Dec. 31, 2014</div> </th> <th class="th"> <div>Dec. 31, 2013</div> </th> <th class="th"> <div>Dec. 31, 2012</div> </th> </tr> <tr class="re"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research and Development Arrangement, Contract to Perform for Others [Line Items]</strong></a></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> </tr> <tr class="ro"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromGrants', window );">Total grant revenue</a></td> <td class="nump"><a title="us-gaap_RevenueFromGrants" onclick="toggleNextSibling(this);">$ 75</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_RevenueFromGrants</span><span></span></td> <td class="nump"><a title="us-gaap_RevenueFromGrants" onclick="toggleNextSibling(this);">$ 94</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_RevenueFromGrants</span><span></span></td> <td class="nump"><a title="us-gaap_RevenueFromGrants" onclick="toggleNextSibling(this);">$ 1,308</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_RevenueFromGrants</span><span></span></td> </tr> <tr class="rh"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=cytk_NindsMyastheniaGravisMember', window );">NINDS Myasthenia Gravis [Member]</a></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> </tr> <tr class="ro"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research and Development Arrangement, Contract to Perform for Others [Line Items]</strong></a></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> </tr> <tr class="re"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromGrants', window );">Total grant revenue</a></td> <td class="nump"><a title="us-gaap_RevenueFromGrants[us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=cytk_NindsMyastheniaGravisMember]" onclick="toggleNextSibling(this);">0</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_RevenueFromGrants<br>/ us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis<br>= cytk_NindsMyastheniaGravisMember</span><span></span></td> <td class="nump"><a title="us-gaap_RevenueFromGrants[us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=cytk_NindsMyastheniaGravisMember]" onclick="toggleNextSibling(this);">69</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_RevenueFromGrants<br>/ us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis<br>= cytk_NindsMyastheniaGravisMember</span><span></span></td> <td class="nump"><a title="us-gaap_RevenueFromGrants[us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=cytk_NindsMyastheniaGravisMember]" onclick="toggleNextSibling(this);">1,308</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_RevenueFromGrants<br>/ us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis<br>= cytk_NindsMyastheniaGravisMember</span><span></span></td> </tr> <tr class="rh"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=cytk_OtherGrantRevenueMember', window );">Other Grant Revenue [Member]</a></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> </tr> <tr class="re"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research and Development Arrangement, Contract to Perform for Others [Line Items]</strong></a></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> </tr> <tr class="ro"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromGrants', window );">Total grant revenue</a></td> <td class="nump"><a title="us-gaap_RevenueFromGrants[us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=cytk_OtherGrantRevenueMember]" onclick="toggleNextSibling(this);">$ 75</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_RevenueFromGrants<br>/ us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis<br>= cytk_OtherGrantRevenueMember</span><span></span></td> <td class="nump"><a title="us-gaap_RevenueFromGrants[us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=cytk_OtherGrantRevenueMember]" onclick="toggleNextSibling(this);">$ 25</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_RevenueFromGrants<br>/ us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis<br>= cytk_OtherGrantRevenueMember</span><span></span></td> <td class="nump"><a title="us-gaap_RevenueFromGrants[us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=cytk_OtherGrantRevenueMember]" onclick="toggleNextSibling(this);">$ 0</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_RevenueFromGrants<br>/ us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis<br>= cytk_OtherGrantRevenueMember</span><span></span></td> </tr> </table> <div style="display: none;"> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems"> <tr> <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td> </tr> <tr> <td> <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div> <table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:stringItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table> </div> </div> </td> </tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromGrants"> <tr> <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td> </tr> <tr> <td> <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div> <p>Revenue earned during the period from non-repayable sum of money awarded to an entity to carry out a specific purpose as provided in grant agreements.</p> </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"> <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 225<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 2<br><br> -Subparagraph (SX 210.5-03.1(e))<br><br> -URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688<br><br><br><br></p> </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"> <table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_RevenueFromGrants</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:monetaryItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>credit</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table> </div> </div> </td> </tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=cytk_NindsMyastheniaGravisMember"> <tr> <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td> </tr> <tr> <td> <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div> <table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=cytk_NindsMyastheniaGravisMember</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td></td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td></td> </tr> <tr> <td><strong> Period Type:</strong></td> <td></td> </tr> </table> </div> </div> </td> </tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=cytk_OtherGrantRevenueMember"> <tr> <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td> </tr> <tr> <td> <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div> <table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=cytk_OtherGrantRevenueMember</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td></td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td></td> </tr> <tr> <td><strong> Period Type:</strong></td> <td></td> </tr> </table> </div> </div> </td> </tr> </table> </div> </body> </html> </TEXT> </DOCUMENT> <DOCUMENT> <TYPE>XML <SEQUENCE>33 <FILENAME>R67.htm <DESCRIPTION>IDEA: XBRL DOCUMENT <TEXT> <html> <head> <META http-equiv="Content-Type" content="text/html; charset=us-ascii"> <title></title> <link rel="stylesheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript"> function toggleNextSibling (e) { if (e.nextSibling.style.display=='none') { e.nextSibling.style.display='block'; } else { e.nextSibling.style.display='none'; } }</script></head> <body><span style="display: none;">v2.4.1.9</span><table class="report" border="0" cellspacing="2" id="ID0EZGAC"> <tr> <th class="tl" colspan="1" rowspan="2"> <div style="width: 200px;"><strong>Income Taxes - Schedule of Components of Income Before Taxes (Detail) (USD $)<br>In Thousands, unless otherwise specified</strong></div> </th> <th class="th" colspan="3">12 Months Ended</th> </tr> <tr> <th class="th"> <div>Dec. 31, 2014</div> </th> <th class="th"> <div>Dec. 31, 2013</div> </th> <th class="th"> <div>Dec. 31, 2012</div> </th> </tr> <tr class="re"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> </tr> <tr class="ro"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic', window );">United States</a></td> <td class="num"><a title="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" onclick="toggleNextSibling(this);">$ (14,646)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic</span><span></span></td> <td class="num"><a title="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" onclick="toggleNextSibling(this);">$ (33,717)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic</span><span></span></td> <td class="num"><a title="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" onclick="toggleNextSibling(this);">$ (40,370)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic</span><span></span></td> </tr> <tr class="re"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign', window );">Foreign</a></td> <td class="nump"><a title="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" onclick="toggleNextSibling(this);">0</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign</span><span></span></td> <td class="nump"><a title="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" onclick="toggleNextSibling(this);">0</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign</span><span></span></td> <td class="nump"><a title="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" onclick="toggleNextSibling(this);">0</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign</span><span></span></td> </tr> <tr class="rou"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments', window );">Loss before income taxes</a></td> <td class="num"><a title="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" onclick="toggleNextSibling(this);">$ (14,646)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments</span><span></span></td> <td class="num"><a title="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" onclick="toggleNextSibling(this);">$ (33,717)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments</span><span></span></td> <td class="num"><a title="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" onclick="toggleNextSibling(this);">$ (40,370)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments</span><span></span></td> </tr> </table> <div style="display: none;"> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic"> <tr> <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td> </tr> <tr> <td> <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div> <p>The portion of earnings or loss from continuing operations before income taxes that is attributable to domestic operations.</p> </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"> <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.4-08.(h)(1)(i))<br><br> -URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690<br><br><br><br></p> </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"> <table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:monetaryItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>credit</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table> </div> </div> </td> </tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign"> <tr> <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td> </tr> <tr> <td> <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div> <p>The portion of earnings or loss from continuing operations before income taxes that is attributable to foreign operations, which is defined as Income or Loss generated from operations located outside the entity's country of domicile.</p> </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"> <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.4-08.(h)(1)(i))<br><br> -URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690<br><br><br><br></p> </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"> <table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:monetaryItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>credit</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table> </div> </div> </td> </tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments"> <tr> <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td> </tr> <tr> <td> <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div> <p>Sum of operating profit and nonoperating income or expense before Income or Loss from equity method investments, income taxes, extraordinary items, and noncontrolling interest.</p> </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"> <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.4-08.(h)(1)(i))<br><br> -URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690<br><br><br><br></p> </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"> <table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:monetaryItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>credit</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table> </div> </div> </td> </tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract"> <tr> <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td> </tr> <tr> <td> <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div> <table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:stringItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table> </div> </div> </td> </tr> </table> </div> </body> </html> </TEXT> </DOCUMENT> <DOCUMENT> <TYPE>XML <SEQUENCE>34 <FILENAME>R61.htm <DESCRIPTION>IDEA: XBRL DOCUMENT <TEXT> <html> <head> <META http-equiv="Content-Type" content="text/html; charset=us-ascii"> <title></title> <link rel="stylesheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript"> function toggleNextSibling (e) { if (e.nextSibling.style.display=='none') { e.nextSibling.style.display='block'; } else { e.nextSibling.style.display='none'; } }</script></head> <body><span style="display: none;">v2.4.1.9</span><table class="report" border="0" cellspacing="2" id="ID0EANAE"> <tr> <th class="tl" colspan="1" rowspan="2"> <div style="width: 200px;"><strong>Stockholders' Equity - Outstanding Warrants (Detail) (USD $)<br></strong></div> </th> <th class="th" colspan="1">12 Months Ended</th> <th class="th" colspan="1"></th> </tr> <tr> <th class="th"> <div>Dec. 31, 2014</div> </th> <th class="th"> <div>Jun. 25, 2012</div> </th> </tr> <tr class="re"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cytk_ShareBasedCompensationLineItems', window );"><strong>Share Based Compensation [Line Items]</strong></a></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> </tr> <tr class="ro"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Number of Shares</a></td> <td class="text"> <span></span></td> <td class="nump"><a title="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" onclick="toggleNextSibling(this);">7,894,704</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights</span><span></span></td> </tr> <tr class="rh"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=cytk_WarrantOneMember', window );">Issued 4/20/2011 [Member]</a></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> </tr> <tr class="ro"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cytk_ShareBasedCompensationLineItems', window );"><strong>Share Based Compensation [Line Items]</strong></a></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> </tr> <tr class="re"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Number of Shares</a></td> <td class="nump"><a title="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights[us-gaap_ClassOfWarrantOrRightAxis=cytk_WarrantOneMember]" onclick="toggleNextSibling(this);">1,114,168</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights<br>/ us-gaap_ClassOfWarrantOrRightAxis<br>= cytk_WarrantOneMember</span><span></span></td> <td class="text"> <span></span></td> </tr> <tr class="ro"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise Price</a></td> <td class="nump"><a title="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1[us-gaap_ClassOfWarrantOrRightAxis=cytk_WarrantOneMember]" onclick="toggleNextSibling(this);">$ 9.90</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1<br>/ us-gaap_ClassOfWarrantOrRightAxis<br>= cytk_WarrantOneMember</span><span></span></td> <td class="text"> <span></span></td> </tr> <tr class="re"> <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cytk_WarrantExpirationDate', window );">Expiration Date</a></td> <td class="text">Apr. 20, 2015<span></span></td> <td class="text"> <span></span></td> </tr> <tr class="rh"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=cytk_WarrantTwoMember', window );">Issued 6/25/2012 [Member]</a></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> </tr> <tr class="re"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cytk_ShareBasedCompensationLineItems', window );"><strong>Share Based Compensation [Line Items]</strong></a></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> </tr> <tr class="ro"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Number of Shares</a></td> <td class="nump"><a title="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights[us-gaap_ClassOfWarrantOrRightAxis=cytk_WarrantTwoMember]" onclick="toggleNextSibling(this);">5,576,928</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights<br>/ us-gaap_ClassOfWarrantOrRightAxis<br>= cytk_WarrantTwoMember</span><span></span></td> <td class="text"> <span></span></td> </tr> <tr class="re"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise Price</a></td> <td class="nump"><a title="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1[us-gaap_ClassOfWarrantOrRightAxis=cytk_WarrantTwoMember]" onclick="toggleNextSibling(this);">$ 5.28</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1<br>/ us-gaap_ClassOfWarrantOrRightAxis<br>= cytk_WarrantTwoMember</span><span></span></td> <td class="text"> <span></span></td> </tr> <tr class="ro"> <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cytk_WarrantExpirationDate', window );">Expiration Date</a></td> <td class="text">Jun. 25, 2017<span></span></td> <td class="text"> <span></span></td> </tr> </table> <div style="display: none;"> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cytk_ShareBasedCompensationLineItems"> <tr> <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td> </tr> <tr> <td> <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div> <table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">cytk_ShareBasedCompensationLineItems</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>cytk_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:stringItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table> </div> </div> </td> </tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cytk_WarrantExpirationDate"> <tr> <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td> </tr> <tr> <td> <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div> <p>The expiration date for warrants or rights outstanding.</p> </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"> <p>No definition available.</p> </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"> <table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">cytk_WarrantExpirationDate</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>cytk_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:dateItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table> </div> </div> </td> </tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"> <tr> <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td> </tr> <tr> <td> <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div> <p>Exercise price per share or per unit of warrants or rights outstanding.</p> </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"> <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.4-08.(i)(4))<br><br> -URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690<br><br><br><br></p> </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"> <table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>num:perShareItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>instant</td> </tr> </table> </div> </div> </td> </tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights"> <tr> <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td> </tr> <tr> <td> <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div> <p>Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.</p> </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"> <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.4-08.(i)(2))<br><br> -URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 08<br><br> -Paragraph i<br><br> -Subparagraph 2<br><br> -Article 4<br><br><br><br></p> </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"> <table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:sharesItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>instant</td> </tr> </table> </div> </div> </td> </tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=cytk_WarrantOneMember"> <tr> <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td> </tr> <tr> <td> <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div> <table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=cytk_WarrantOneMember</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td></td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td></td> </tr> <tr> <td><strong> Period Type:</strong></td> <td></td> </tr> </table> </div> </div> </td> </tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=cytk_WarrantTwoMember"> <tr> <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td> </tr> <tr> <td> <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div> <table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=cytk_WarrantTwoMember</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td></td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td></td> </tr> <tr> <td><strong> Period Type:</strong></td> <td></td> </tr> </table> </div> </div> </td> </tr> </table> </div> </body> </html> </TEXT> </DOCUMENT> <DOCUMENT> <TYPE>XML <SEQUENCE>35 <FILENAME>R47.htm <DESCRIPTION>IDEA: XBRL DOCUMENT <TEXT> <html> <head> <META http-equiv="Content-Type" content="text/html; charset=us-ascii"> <title></title> <link rel="stylesheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript"> function toggleNextSibling (e) { if (e.nextSibling.style.display=='none') { e.nextSibling.style.display='block'; } else { e.nextSibling.style.display='none'; } }</script></head> <body><span style="display: none;">v2.4.1.9</span><table class="report" border="0" cellspacing="2" id="ID0EIEAC"> <tr> <th class="tl" colspan="1" rowspan="2"> <div style="width: 200px;"><strong>Balance Sheet Components - Additional Information (Detail) (USD $)<br></strong></div> </th> <th class="th" colspan="3">12 Months Ended</th> </tr> <tr> <th class="th"> <div>Dec. 31, 2014</div> </th> <th class="th"> <div>Dec. 31, 2013</div> </th> <th class="th"> <div>Dec. 31, 2012</div> </th> </tr> <tr class="re"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract', window );"><strong>Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]</strong></a></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> </tr> <tr class="ro"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation expense</a></td> <td class="nump"><a title="us-gaap_Depreciation" onclick="toggleNextSibling(this);">$ 500,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_Depreciation</span><span></span></td> <td class="nump"><a title="us-gaap_Depreciation" onclick="toggleNextSibling(this);">$ 400,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_Depreciation</span><span></span></td> <td class="nump"><a title="us-gaap_Depreciation" onclick="toggleNextSibling(this);">$ 600,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_Depreciation</span><span></span></td> </tr> <tr class="re"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestReceivable', window );">Interest receivable on cash equivalents and investments</a></td> <td class="nump"><a title="us-gaap_InterestReceivable" onclick="toggleNextSibling(this);">$ 109,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_InterestReceivable</span><span></span></td> <td class="nump"><a title="us-gaap_InterestReceivable" onclick="toggleNextSibling(this);">$ 215,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_InterestReceivable</span><span></span></td> <td class="text"> <span></span></td> </tr> </table> <div style="display: none;"> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract"> <tr> <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td> </tr> <tr> <td> <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div> <table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:stringItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table> </div> </div> </td> </tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Depreciation"> <tr> <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td> </tr> <tr> <td> <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div> <p>The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.</p> </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"> <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -Subparagraph (b)<br><br> -URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3602-108585<br><br><br><br></p> </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"> <table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_Depreciation</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:monetaryItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>debit</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table> </div> </div> </td> </tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestReceivable"> <tr> <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td> </tr> <tr> <td> <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div> <p>Carrying amount as of the balance sheet date of interest earned but not received. Also called accrued interest or accrued interest receivable.</p> </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"> <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.8)<br><br> -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 8<br><br> -Article 5<br><br><br><br></p> </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"> <table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_InterestReceivable</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:monetaryItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>debit</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>instant</td> </tr> </table> </div> </div> </td> </tr> </table> </div> </body> </html> </TEXT> </DOCUMENT> <DOCUMENT> <TYPE>XML <SEQUENCE>36 <FILENAME>R9.htm <DESCRIPTION>IDEA: XBRL DOCUMENT <TEXT> <html> <head> <META http-equiv="Content-Type" content="text/html; charset=us-ascii"> <title></title> <link rel="stylesheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript"> function toggleNextSibling (e) { if (e.nextSibling.style.display=='none') { e.nextSibling.style.display='block'; } else { e.nextSibling.style.display='none'; } }</script></head> <body><span style="display: none;">v2.4.1.9</span><table class="report" border="0" cellspacing="2" id="ID0EME"> <tr> <th class="tl" colspan="1" rowspan="2"> <div style="width: 200px;"><strong>Net Loss Per Share<br></strong></div> </th> <th class="th" colspan="1">12 Months Ended</th> </tr> <tr> <th class="th"> <div>Dec. 31, 2014</div> </th> </tr> <tr class="re"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td> <td class="text"> <span></span></td> </tr> <tr class="ro"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareTextBlock', window );">Net Loss Per Share</a></td> <td class="text"><div> <p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 0px"><font style="FONT-FAMILY: Times New Roman" size="2"><b>Note 2 — Net Loss Per Share</b></font></p> <p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 6px; TEXT-INDENT: 4%" align="justify"><font style="FONT-FAMILY: Times New Roman" size="2">Basic net loss per share allocable to common stockholders is computed by dividing net loss allocable to common stockholders by the weighted average number of vested common shares outstanding during the period. Diluted net income loss per share allocable to common stockholders is computed by giving effect to all potentially dilutive common shares, including outstanding stock options, unvested restricted stock, warrants, convertible preferred stock and shares issuable under the Company’s Employee Stock Purchase Plan (“ESPP”), by applying the treasury stock method. The following is the calculation of basic and diluted net loss per share allocable to common stockholders (in thousands except per share data):</font></p> <p style="MARGIN-BOTTOM: 0px; FONT-SIZE: 12px; MARGIN-TOP: 0px">  </p> <table style="BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="92%" align="center" border="0"> <tr> <td width="66%"></td> <td valign="bottom" width="5%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="4%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="4%"></td> <td></td> <td></td> <td></td> </tr> <tr> <td valign="bottom"><font size="1"> </font></td> <td valign="bottom"><font size="1">  </font></td> <td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="10" align="center"><font style="FONT-FAMILY: Times New Roman" size="1"><b>Years Ended December 31,</b></font></td> <td valign="bottom"><font size="1"> </font></td> </tr> <tr> <td valign="bottom"><font size="1"> </font></td> <td valign="bottom"><font size="1">  </font></td> <td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" align="center"><font style="FONT-FAMILY: Times New Roman" size="1"><b>2014</b></font></td> <td valign="bottom"><font size="1"> </font></td> <td valign="bottom"><font size="1">  </font></td> <td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" align="center"><font style="FONT-FAMILY: Times New Roman" size="1"><b>2013</b></font></td> <td valign="bottom"><font size="1"> </font></td> <td valign="bottom"><font size="1">  </font></td> <td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" align="center"><font style="FONT-FAMILY: Times New Roman" size="1"><b>2012</b></font></td> <td valign="bottom"><font size="1"> </font></td> </tr> <tr bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: Times New Roman" size="2">Net loss</font></p> </td> <td valign="bottom"><font size="1">  </font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">(14,646</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">) </font></td> <td valign="bottom"><font size="1">  </font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">(33,717</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">) </font></td> <td valign="bottom"><font size="1">  </font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">(40,370</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">) </font></td> </tr> <tr> <td valign="top"> <p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: Times New Roman" size="2">Deemed dividend related to beneficial conversion feature of convertible preferred stock</font></p> </td> <td valign="bottom"><font size="1">  </font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2"> </font></td> <td valign="bottom" nowrap="nowrap" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">—</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">  </font></td> <td valign="bottom"><font size="1">  </font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2"> </font></td> <td valign="bottom" nowrap="nowrap" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">—</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">  </font></td> <td valign="bottom"><font size="1">  </font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2"> </font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">(1,307</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">) </font></td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid"> </p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid"> </p> </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid"> </p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid"> </p> </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid"> </p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid"> </p> </td> <td> </td> </tr> <tr bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: Times New Roman" size="2">Net loss allocable to common stockholders</font></p> </td> <td valign="bottom"><font size="1">  </font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">(14,646</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">) </font></td> <td valign="bottom"><font size="1">  </font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">(33,717</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">) </font></td> <td valign="bottom"><font size="1">  </font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">(41,677</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">) </font></td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double"> </p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double"> </p> </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double"> </p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double"> </p> </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double"> </p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double"> </p> </td> <td> </td> </tr> <tr> <td valign="top"> <p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: Times New Roman" size="2">Weighted-average shares used in computing net loss per share allocable to common stockholders — basic and diluted</font></p> </td> <td valign="bottom"><font size="1">  </font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2"> </font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">35,709</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">  </font></td> <td valign="bottom"><font size="1">  </font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2"> </font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">27,275</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">  </font></td> <td valign="bottom"><font size="1">  </font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2"> </font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">18,107</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">  </font></td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double"> </p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double"> </p> </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double"> </p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double"> </p> </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double"> </p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double"> </p> </td> <td> </td> </tr> <tr bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: Times New Roman" size="2">Net loss per share allocable to common stockholders — basic and diluted</font></p> </td> <td valign="bottom"><font size="1">  </font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">(0.41</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">) </font></td> <td valign="bottom"><font size="1">  </font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">(1.24</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">) </font></td> <td valign="bottom"><font size="1">  </font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">(2.30</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">) </font></td> </tr> </table> <p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 12px; TEXT-INDENT: 4%" align="justify"><font style="FONT-FAMILY: Times New Roman" size="2">The following instruments were excluded from the computation of diluted net loss per common share allocable to common stockholders for the periods presented because their effect would have been antidilutive (in thousands):</font></p> <p style="MARGIN-BOTTOM: 0px; FONT-SIZE: 12px; MARGIN-TOP: 0px">  </p> <table style="BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="92%" align="center" border="0"> <tr> <td width="73%"></td> <td valign="bottom" width="3%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="3%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="3%"></td> <td></td> <td></td> <td></td> </tr> <tr> <td valign="bottom"><font size="1"> </font></td> <td valign="bottom"><font size="1">  </font></td> <td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="10" align="center"><font style="FONT-FAMILY: Times New Roman" size="1"><b>December 31,</b></font></td> <td valign="bottom"><font size="1"> </font></td> </tr> <tr> <td valign="bottom"><font size="1"> </font></td> <td valign="bottom"><font size="1">  </font></td> <td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" align="center"><font style="FONT-FAMILY: Times New Roman" size="1"><b>2014</b></font></td> <td valign="bottom"><font size="1"> </font></td> <td valign="bottom"><font size="1">  </font></td> <td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" align="center"><font style="FONT-FAMILY: Times New Roman" size="1"><b>2013</b></font></td> <td valign="bottom"><font size="1"> </font></td> <td valign="bottom"><font size="1">  </font></td> <td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" align="center"><font style="FONT-FAMILY: Times New Roman" size="1"><b>2012</b></font></td> <td valign="bottom"><font size="1"> </font></td> </tr> <tr bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: Times New Roman" size="2">Options to purchase common stock</font></p> </td> <td valign="bottom"><font size="1">  </font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2"> </font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">3,298</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">  </font></td> <td valign="bottom"><font size="1">  </font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2"> </font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">2,449</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">  </font></td> <td valign="bottom"><font size="1">  </font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2"> </font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">1,791</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">  </font></td> </tr> <tr> <td valign="top"> <p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: Times New Roman" size="2">Warrants to purchase common stock</font></p> </td> <td valign="bottom"><font size="1">  </font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2"> </font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">6,691</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">  </font></td> <td valign="bottom"><font size="1">  </font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2"> </font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">7,692</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">  </font></td> <td valign="bottom"><font size="1">  </font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2"> </font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">9,009</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">  </font></td> </tr> <tr bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: Times New Roman" size="2">Series B convertible preferred stock (as converted to common stock)</font></p> </td> <td valign="bottom"><font size="1">  </font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2"> </font></td> <td valign="bottom" nowrap="nowrap" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">—</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">  </font></td> <td valign="bottom"><font size="1">  </font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2"> </font></td> <td valign="bottom" nowrap="nowrap" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">—</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">  </font></td> <td valign="bottom"><font size="1">  </font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2"> </font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">3,838</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">  </font></td> </tr> <tr> <td valign="top"> <p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: Times New Roman" size="2">Restricted stock units</font></p> </td> <td valign="bottom"><font size="1">  </font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2"> </font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">63</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">  </font></td> <td valign="bottom"><font size="1">  </font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2"> </font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">42</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">  </font></td> <td valign="bottom"><font size="1">  </font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2"> </font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">217</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">  </font></td> </tr> <tr bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: Times New Roman" size="2">Shares issuable related to the ESPP</font></p> </td> <td valign="bottom"><font size="1">  </font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2"> </font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">15</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">  </font></td> <td valign="bottom"><font size="1">  </font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2"> </font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">14</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">  </font></td> <td valign="bottom"><font size="1">  </font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2"> </font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">11</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">  </font></td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid"> </p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid"> </p> </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid"> </p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid"> </p> </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid"> </p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid"> </p> </td> <td> </td> </tr> <tr> <td valign="top"> <p style="MARGIN-LEFT: 2em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: Times New Roman" size="2">Total shares</font></p> </td> <td valign="bottom"><font size="1">  </font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2"> </font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">10,067</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">  </font></td> <td valign="bottom"><font size="1">  </font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2"> </font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">10,197</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">  </font></td> <td valign="bottom"><font size="1">  </font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2"> </font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">14,866</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">  </font></td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double"> </p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double"> </p> </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double"> </p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double"> </p> </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double"> </p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double"> </p> </td> <td> </td> </tr> </table> </div><span></span></td> </tr> </table> <div style="display: none;"> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract"> <tr> <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td> </tr> <tr> <td> <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div> <table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:stringItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table> </div> </div> </td> </tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareTextBlock"> <tr> <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td> </tr> <tr> <td> <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div> <p>The entire disclosure for earnings per share.</p> </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"> <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 260<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 260<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&oid=7655603&loc=d3e1278-109256<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 260<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&oid=7655603&loc=d3e1252-109256<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 260<br><br> -SubTopic 10<br><br> -Section 55<br><br> -Paragraph 52<br><br> -URI http://asc.fasb.org/extlink&oid=32703322&loc=d3e4984-109258<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 225<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 2<br><br> -Subparagraph (SX 210.5-03.21)<br><br> -URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688<br><br><br><br></p> </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"> <table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_EarningsPerShareTextBlock</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>nonnum:textBlockItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table> </div> </div> </td> </tr> </table> </div> </body> </html> </TEXT> </DOCUMENT> <DOCUMENT> <TYPE>XML <SEQUENCE>37 <FILENAME>R62.htm <DESCRIPTION>IDEA: XBRL DOCUMENT <TEXT> <html> <head> <META http-equiv="Content-Type" content="text/html; charset=us-ascii"> <title></title> <link rel="stylesheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript"> function toggleNextSibling (e) { if (e.nextSibling.style.display=='none') { e.nextSibling.style.display='block'; } else { e.nextSibling.style.display='none'; } }</script></head> <body><span style="display: none;">v2.4.1.9</span><table class="report" border="0" cellspacing="2" id="ID0EHXBG"> <tr> <th class="tl" colspan="1" rowspan="2"> <div style="width: 200px;"><strong>Stockholders' Equity - Summary of Stock Option Activity (Detail) (USD $)<br>In Thousands, except Share data, unless otherwise specified</strong></div> </th> <th class="th" colspan="3">12 Months Ended</th> </tr> <tr> <th class="th"> <div>Dec. 31, 2014</div> </th> <th class="th"> <div>Dec. 31, 2013</div> </th> <th class="th"> <div>Dec. 31, 2012</div> </th> </tr> <tr class="re"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> </tr> <tr class="ro"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Shares Available for Grant of Option or Award, Beginning Balance</a></td> <td class="nump"><a title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" onclick="toggleNextSibling(this);">2,161,829</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant</span><span></span></td> <td class="nump"><a title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" onclick="toggleNextSibling(this);">878,726</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant</span><span></span></td> <td class="nump"><a title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" onclick="toggleNextSibling(this);">585,476</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant</span><span></span></td> </tr> <tr class="re"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized', window );">Shares Available for Grant of Option or Award, Increase in authorized shares</a></td> <td class="text"> <span></span></td> <td class="nump"><a title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" onclick="toggleNextSibling(this);">2,000,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized</span><span></span></td> <td class="nump"><a title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" onclick="toggleNextSibling(this);">416,667</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized</span><span></span></td> </tr> <tr class="ro"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Shares Available for Grant of Option or Award, Options granted</a></td> <td class="num"><a title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" onclick="toggleNextSibling(this);">(944,831)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</span><span></span></td> <td class="num"><a title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" onclick="toggleNextSibling(this);">(797,629)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</span><span></span></td> <td class="num"><a title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" onclick="toggleNextSibling(this);">(403,108)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</span><span></span></td> </tr> <tr class="re"> <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cytk_ShareBasedCompensationArrangementByShareBasedPaymentSharesAvailableForGrantAwardOptionsExercisedInPeriodGross', window );">Shares Available for Grant of Option or Award, Options exercised</a></td> <td class="nump"><a title="cytk_ShareBasedCompensationArrangementByShareBasedPaymentSharesAvailableForGrantAwardOptionsExercisedInPeriodGross" onclick="toggleNextSibling(this);">0</a><span style="display:none;white-space:normal;text-align:left;">cytk_ShareBasedCompensationArrangementByShareBasedPaymentSharesAvailableForGrantAwardOptionsExercisedInPeriodGross</span><span></span></td> <td class="nump"><a title="cytk_ShareBasedCompensationArrangementByShareBasedPaymentSharesAvailableForGrantAwardOptionsExercisedInPeriodGross" onclick="toggleNextSibling(this);">0</a><span style="display:none;white-space:normal;text-align:left;">cytk_ShareBasedCompensationArrangementByShareBasedPaymentSharesAvailableForGrantAwardOptionsExercisedInPeriodGross</span><span></span></td> <td class="text"> <span></span></td> </tr> <tr class="ro"> <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cytk_SharesAvailableForGrantOfOptionsOrAwardsOptionsForfeitedExpired', window );">Shares Available for Grant of Option or Award, Options forfeited/expired</a></td> <td class="nump"><a title="cytk_SharesAvailableForGrantOfOptionsOrAwardsOptionsForfeitedExpired" onclick="toggleNextSibling(this);">95,980</a><span style="display:none;white-space:normal;text-align:left;">cytk_SharesAvailableForGrantOfOptionsOrAwardsOptionsForfeitedExpired</span><span></span></td> <td class="nump"><a title="cytk_SharesAvailableForGrantOfOptionsOrAwardsOptionsForfeitedExpired" onclick="toggleNextSibling(this);">117,394</a><span style="display:none;white-space:normal;text-align:left;">cytk_SharesAvailableForGrantOfOptionsOrAwardsOptionsForfeitedExpired</span><span></span></td> <td class="nump"><a title="cytk_SharesAvailableForGrantOfOptionsOrAwardsOptionsForfeitedExpired" onclick="toggleNextSibling(this);">210,989</a><span style="display:none;white-space:normal;text-align:left;">cytk_SharesAvailableForGrantOfOptionsOrAwardsOptionsForfeitedExpired</span><span></span></td> </tr> <tr class="re"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Shares Available for Grant of Option or Award, Ending Balance</a></td> <td class="nump"><a title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" onclick="toggleNextSibling(this);">1,270,478</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant</span><span></span></td> <td class="nump"><a title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" onclick="toggleNextSibling(this);">2,161,829</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant</span><span></span></td> <td class="nump"><a title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" onclick="toggleNextSibling(this);">878,726</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant</span><span></span></td> </tr> <tr class="ro"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Stock Options Outstanding, Beginning Balance</a></td> <td class="nump"><a title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" onclick="toggleNextSibling(this);">2,449,365</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</span><span></span></td> <td class="nump"><a title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" onclick="toggleNextSibling(this);">1,790,527</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</span><span></span></td> <td class="nump"><a title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" onclick="toggleNextSibling(this);">1,598,408</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</span><span></span></td> </tr> <tr class="re"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod', window );">Stock Options Outstanding, Options granted</a></td> <td class="nump"><a title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" onclick="toggleNextSibling(this);">944,831</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod</span><span></span></td> <td class="nump"><a title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" onclick="toggleNextSibling(this);">797,629</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod</span><span></span></td> <td class="nump"><a title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" onclick="toggleNextSibling(this);">403,108</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod</span><span></span></td> </tr> <tr class="ro"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod', window );">Stock Options Outstanding, Options forfeited/expired</a></td> <td class="num"><a title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" onclick="toggleNextSibling(this);">(95,980)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod</span><span></span></td> <td class="num"><a title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" onclick="toggleNextSibling(this);">(117,394)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod</span><span></span></td> <td class="num"><a title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" onclick="toggleNextSibling(this);">(210,989)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod</span><span></span></td> </tr> <tr class="re"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Stock Options Outstanding, Ending Balance</a></td> <td class="nump"><a title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" onclick="toggleNextSibling(this);">3,297,826</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</span><span></span></td> <td class="nump"><a title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" onclick="toggleNextSibling(this);">2,449,365</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</span><span></span></td> <td class="nump"><a title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" onclick="toggleNextSibling(this);">1,790,527</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</span><span></span></td> </tr> <tr class="ro"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted Average Exercise Price per Share - Stock Options, Beginning Balance</a></td> <td class="nump"><a title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" onclick="toggleNextSibling(this);">$ 15.15</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</span><span></span></td> <td class="nump"><a title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" onclick="toggleNextSibling(this);">$ 18.96</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</span><span></span></td> <td class="nump"><a title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" onclick="toggleNextSibling(this);">$ 21.93</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</span><span></span></td> </tr> <tr class="re"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Stock Options Outstanding, Exercisable</a></td> <td class="nump"><a title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" onclick="toggleNextSibling(this);">2,140,754</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber</span><span></span></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> </tr> <tr class="ro"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Weighted Average Exercise Price per Share - Stock Options, Options granted</a></td> <td class="nump"><a title="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" onclick="toggleNextSibling(this);">$ 8.80</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</span><span></span></td> <td class="nump"><a title="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" onclick="toggleNextSibling(this);">$ 5.95</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</span><span></span></td> <td class="nump"><a title="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" onclick="toggleNextSibling(this);">$ 6.14</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</span><span></span></td> </tr> <tr class="re"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber', window );">Stock Options Outstanding, Vested and expected to vest</a></td> <td class="nump"><a title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" onclick="toggleNextSibling(this);">3,277,489</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber</span><span></span></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> </tr> <tr class="ro"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Weighted Average Exercise Price per Share - Stock Options, Options exercised</a></td> <td class="nump"><a title="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" onclick="toggleNextSibling(this);">$ 6.00</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</span><span></span></td> <td class="nump"><a title="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" onclick="toggleNextSibling(this);">$ 5.32</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</span><span></span></td> <td class="text"> <span></span></td> </tr> <tr class="re"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice', window );">Weighted Average Exercise Price per Share - Stock Options, Options forfeited/expired</a></td> <td class="nump"><a title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" onclick="toggleNextSibling(this);">$ 39.74</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice</span><span></span></td> <td class="nump"><a title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" onclick="toggleNextSibling(this);">$ 12.55</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice</span><span></span></td> <td class="nump"><a title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" onclick="toggleNextSibling(this);">$ 17.00</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice</span><span></span></td> </tr> <tr class="ro"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted Average Exercise Price per Share - Stock Options, Ending Balance</a></td> <td class="nump"><a title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" onclick="toggleNextSibling(this);">$ 12.62</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</span><span></span></td> <td class="nump"><a title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" onclick="toggleNextSibling(this);">$ 15.15</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</span><span></span></td> <td class="nump"><a title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" onclick="toggleNextSibling(this);">$ 18.96</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</span><span></span></td> </tr> <tr class="re"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Weighted Average Exercise Price per Share - Stock Options, Exercisable</a></td> <td class="nump"><a title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" onclick="toggleNextSibling(this);">$ 15.17</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice</span><span></span></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> </tr> <tr class="ro"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice', window );">Weighted Average Exercise Price per Share - Stock Options, Vested and expected to vest, Outstanding</a></td> <td class="nump"><a title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" onclick="toggleNextSibling(this);">$ 12.64</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice</span><span></span></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> </tr> <tr class="re"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Weighted Average Remaining Contractual Life</a></td> <td class="text">6 years 9 months 15 days<span></span></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> </tr> <tr class="ro"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1', window );">Weighted Average Remaining Contractual Life, Exercisable at December 31, 2014</a></td> <td class="text">5 years 9 months 4 days<span></span></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> </tr> <tr class="re"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1', window );">Weighted Average Remaining Contractual Life, Vested and expected to vest as of December 31, 2014</a></td> <td class="text">6 years 9 months 11 days<span></span></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> </tr> <tr class="ro"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Aggregate Intrinsic Value</a></td> <td class="nump"><a title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" onclick="toggleNextSibling(this);">$ 2,657</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue</span><span></span></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> </tr> <tr class="re"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1', window );">Aggregate Intrinsic Value, Exercisable at December 31, 2014</a></td> <td class="nump"><a title="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" onclick="toggleNextSibling(this);">1,553</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1</span><span></span></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> </tr> <tr class="ro"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue', window );">Aggregate Intrinsic Value, Vested and expected to vest as of December 31, 2014</a></td> <td class="nump"><a title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" onclick="toggleNextSibling(this);">$ 2,642</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue</span><span></span></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> </tr> <tr class="rh"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock [Member]</a></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> </tr> <tr class="ro"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> </tr> <tr class="re"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Stock Options Outstanding, Options exercised</a></td> <td class="num"><a title="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised[us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember]" onclick="toggleNextSibling(this);">(390)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised<br>/ us-gaap_StatementEquityComponentsAxis<br>= us-gaap_CommonStockMember</span><span></span></td> <td class="num"><a title="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised[us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember]" onclick="toggleNextSibling(this);">(21,397)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised<br>/ us-gaap_StatementEquityComponentsAxis<br>= us-gaap_CommonStockMember</span><span></span></td> <td class="text"> <span></span></td> </tr> <tr class="rh"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted Stock Units [Member]</a></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> </tr> <tr class="re"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> </tr> <tr class="ro"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Shares Available for Grant of Option or Award, Restricted stock units granted</a></td> <td class="num"><a title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod[us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember]" onclick="toggleNextSibling(this);">(43,500)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod<br>/ us-gaap_AwardTypeAxis<br>= us-gaap_RestrictedStockUnitsRSUMember</span><span></span></td> <td class="num"><a title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod[us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember]" onclick="toggleNextSibling(this);">(41,661)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod<br>/ us-gaap_AwardTypeAxis<br>= us-gaap_RestrictedStockUnitsRSUMember</span><span></span></td> <td class="text"> <span></span></td> </tr> <tr class="re"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod', window );">Shares Available for Grant of Option or Award, Restricted stock units forfeited</a></td> <td class="nump"><a title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod[us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember]" onclick="toggleNextSibling(this);">1,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod<br>/ us-gaap_AwardTypeAxis<br>= us-gaap_RestrictedStockUnitsRSUMember</span><span></span></td> <td class="nump"><a title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod[us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember]" onclick="toggleNextSibling(this);">4,999</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod<br>/ us-gaap_AwardTypeAxis<br>= us-gaap_RestrictedStockUnitsRSUMember</span><span></span></td> <td class="nump"><a title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod[us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember]" onclick="toggleNextSibling(this);">68,702</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod<br>/ us-gaap_AwardTypeAxis<br>= us-gaap_RestrictedStockUnitsRSUMember</span><span></span></td> </tr> <tr class="ro"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Shares Available for Grant of Option or Award, Options granted</a></td> <td class="nump"><a title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross[us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember]" onclick="toggleNextSibling(this);">0</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross<br>/ us-gaap_AwardTypeAxis<br>= us-gaap_RestrictedStockUnitsRSUMember</span><span></span></td> <td class="nump"><a title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross[us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember]" onclick="toggleNextSibling(this);">0</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross<br>/ us-gaap_AwardTypeAxis<br>= us-gaap_RestrictedStockUnitsRSUMember</span><span></span></td> <td class="text"> <span></span></td> </tr> <tr class="re"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod', window );">Stock Options Outstanding, Options Forfeited</a></td> <td class="nump"><a title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod[us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember]" onclick="toggleNextSibling(this);">0</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod<br>/ us-gaap_AwardTypeAxis<br>= us-gaap_RestrictedStockUnitsRSUMember</span><span></span></td> <td class="nump"><a title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod[us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember]" onclick="toggleNextSibling(this);">0</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod<br>/ us-gaap_AwardTypeAxis<br>= us-gaap_RestrictedStockUnitsRSUMember</span><span></span></td> <td class="nump"><a title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod[us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember]" onclick="toggleNextSibling(this);">0</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod<br>/ us-gaap_AwardTypeAxis<br>= us-gaap_RestrictedStockUnitsRSUMember</span><span></span></td> </tr> <tr class="ro"> <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cytk_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedInPeriodWeightedAverageExercisePrice', window );">Weighted Average Exercise Price per Share - Stock Options, Restricted stock units granted</a></td> <td class="nump"><a title="cytk_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedInPeriodWeightedAverageExercisePrice[us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember]" onclick="toggleNextSibling(this);">$ 0</a><span style="display:none;white-space:normal;text-align:left;">cytk_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedInPeriodWeightedAverageExercisePrice<br>/ us-gaap_AwardTypeAxis<br>= us-gaap_RestrictedStockUnitsRSUMember</span><span></span></td> <td class="nump"><a title="cytk_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedInPeriodWeightedAverageExercisePrice[us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember]" onclick="toggleNextSibling(this);">$ 0</a><span style="display:none;white-space:normal;text-align:left;">cytk_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedInPeriodWeightedAverageExercisePrice<br>/ us-gaap_AwardTypeAxis<br>= us-gaap_RestrictedStockUnitsRSUMember</span><span></span></td> <td class="text"> <span></span></td> </tr> <tr class="re"> <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cytk_ShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentOtherThanOptionForfeituresInPeriodWeightedAverageExercisePrice', window );">Weighted Average Exercise Price per Share - Stock Options, Restricted stock units forfeited</a></td> <td class="nump"><a title="cytk_ShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentOtherThanOptionForfeituresInPeriodWeightedAverageExercisePrice[us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember]" onclick="toggleNextSibling(this);">$ 0</a><span style="display:none;white-space:normal;text-align:left;">cytk_ShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentOtherThanOptionForfeituresInPeriodWeightedAverageExercisePrice<br>/ us-gaap_AwardTypeAxis<br>= us-gaap_RestrictedStockUnitsRSUMember</span><span></span></td> <td class="nump"><a title="cytk_ShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentOtherThanOptionForfeituresInPeriodWeightedAverageExercisePrice[us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember]" onclick="toggleNextSibling(this);">$ 0</a><span style="display:none;white-space:normal;text-align:left;">cytk_ShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentOtherThanOptionForfeituresInPeriodWeightedAverageExercisePrice<br>/ us-gaap_AwardTypeAxis<br>= us-gaap_RestrictedStockUnitsRSUMember</span><span></span></td> <td class="nump"><a title="cytk_ShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentOtherThanOptionForfeituresInPeriodWeightedAverageExercisePrice[us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember]" onclick="toggleNextSibling(this);">$ 0</a><span style="display:none;white-space:normal;text-align:left;">cytk_ShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentOtherThanOptionForfeituresInPeriodWeightedAverageExercisePrice<br>/ us-gaap_AwardTypeAxis<br>= us-gaap_RestrictedStockUnitsRSUMember</span><span></span></td> </tr> </table> <div style="display: none;"> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cytk_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedInPeriodWeightedAverageExercisePrice"> <tr> <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td> </tr> <tr> <td> <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div> <p>The weighted average exercise price per share of restricted stock awards granted. This per share amount should always be zero as restricted stock grants are awarded to recipients on the grant date and do not have an exercise feature.</p> </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"> <p>No definition available.</p> </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"> <table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">cytk_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedInPeriodWeightedAverageExercisePrice</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>cytk_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>num:perShareItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table> </div> </div> </td> </tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cytk_ShareBasedCompensationArrangementByShareBasedPaymentSharesAvailableForGrantAwardOptionsExercisedInPeriodGross"> <tr> <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td> </tr> <tr> <td> <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div> <p>The effect of stock options exercised upon shares available for grant of options or awards. Typically, the numerical effect of options exercised upon shares available for grant is nil.</p> </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"> <p>No definition available.</p> </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"> <table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">cytk_ShareBasedCompensationArrangementByShareBasedPaymentSharesAvailableForGrantAwardOptionsExercisedInPeriodGross</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>cytk_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:sharesItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table> </div> </div> </td> </tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cytk_ShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentOtherThanOptionForfeituresInPeriodWeightedAverageExercisePrice"> <tr> <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td> </tr> <tr> <td> <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div> <p>The weighted average exercise price per share of restricted stock awards forfeited. This per share amount should always be zero as restricted stock grants are awarded to recipients on the grant date and do not have an exercise feature or an exercise price.</p> </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"> <p>No definition available.</p> </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"> <table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">cytk_ShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentOtherThanOptionForfeituresInPeriodWeightedAverageExercisePrice</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>cytk_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>num:perShareItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table> </div> </div> </td> </tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cytk_SharesAvailableForGrantOfOptionsOrAwardsOptionsForfeitedExpired"> <tr> <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td> </tr> <tr> <td> <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div> <p>The effect of stock options forfeited or expired upon shares available for grant of options or awards. Typically, shares available for grant will increase to the extent that outstanding options are forfeited or expire.</p> </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"> <p>No definition available.</p> </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"> <table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">cytk_SharesAvailableForGrantOfOptionsOrAwardsOptionsForfeitedExpired</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>cytk_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:sharesItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table> </div> </div> </td> </tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"> <tr> <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td> </tr> <tr> <td> <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div> <p>The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.</p> </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"> <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (c)(1)(iv)(3)<br><br> -URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901<br><br><br><br></p> </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"> <table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:sharesItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table> </div> </div> </td> </tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"> <tr> <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td> </tr> <tr> <td> <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div> <p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p> </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"> <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (c)(2)(iii)(1)<br><br> -URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901<br><br><br><br></p> </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"> <table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:sharesItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table> </div> </div> </td> </tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"> <tr> <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td> </tr> <tr> <td> <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div> <table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:stringItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table> </div> </div> </td> </tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized"> <tr> <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td> </tr> <tr> <td> <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div> <p>Number of additional shares authorized for issuance under an established share-based compensation plan.</p> </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"> <p>No definition available.</p> </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"> <table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:sharesItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table> </div> </div> </td> </tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"> <tr> <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td> </tr> <tr> <td> <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div> <p>The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.</p> </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"> <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901<br><br><br><br></p> </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"> <table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:sharesItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>instant</td> </tr> </table> </div> </div> </td> </tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"> <tr> <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td> </tr> <tr> <td> <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div> <p>Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.</p> </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"> <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901<br><br><br><br></p> </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"> <table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:monetaryItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>debit</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>instant</td> </tr> </table> </div> </div> </td> </tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"> <tr> <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td> </tr> <tr> <td> <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div> <p>The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.</p> </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"> <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (c)(1)(iii)<br><br> -URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901<br><br><br><br></p> </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"> <table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:sharesItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>instant</td> </tr> </table> </div> </div> </td> </tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"> <tr> <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td> </tr> <tr> <td> <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div> <p>The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.</p> </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"> <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (c)(1)(iii)<br><br> -URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901<br><br><br><br></p> </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"> <table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>num:perShareItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>instant</td> </tr> </table> </div> </div> </td> </tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"> <tr> <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td> </tr> <tr> <td> <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div> <p>Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p> </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"> <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901<br><br><br><br></p> </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"> <table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:durationItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table> </div> </div> </td> </tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod"> <tr> <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td> </tr> <tr> <td> <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div> <p>For presentations that combine terminations, the number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan or that expired.</p> </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"> <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (c)(1)(iv)(3)-(4)<br><br> -URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901<br><br><br><br></p> </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"> <table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:sharesItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table> </div> </div> </td> </tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice"> <tr> <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td> </tr> <tr> <td> <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div> <p>Weighted average price of options that were either forfeited or expired.</p> </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"> <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (c)(1)(iv)(3)-(4)<br><br> -URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901<br><br><br><br></p> </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"> <table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>num:perShareItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table> </div> </div> </td> </tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"> <tr> <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td> </tr> <tr> <td> <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div> <p>The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.</p> </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"> <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (c)(1)(iv)(3)<br><br> -URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901<br><br><br><br></p> </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"> <table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:sharesItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table> </div> </div> </td> </tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"> <tr> <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td> </tr> <tr> <td> <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div> <p>Gross number of share options (or share units) granted during the period.</p> </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"> <p>No definition available.</p> </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"> <table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:sharesItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table> </div> </div> </td> </tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"> <tr> <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td> </tr> <tr> <td> <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div> <p>Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.</p> </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"> <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901<br><br><br><br></p> </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"> <table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:monetaryItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>debit</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>instant</td> </tr> </table> </div> </div> </td> </tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"> <tr> <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td> </tr> <tr> <td> <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div> <p>Number of options outstanding, including both vested and non-vested options.</p> </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"> <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (c)(1)(i)-(ii)<br><br> -URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901<br><br><br><br></p> </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"> <table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:sharesItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>instant</td> </tr> </table> </div> </div> </td> </tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"> <tr> <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td> </tr> <tr> <td> <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div> <p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p> </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"> <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (c)(1)(i)<br><br> -URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901<br><br><br><br></p> </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"> <table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>num:perShareItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>instant</td> </tr> </table> </div> </div> </td> </tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"> <tr> <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td> </tr> <tr> <td> <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div> <p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p> </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"> <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (e)(1)<br><br> -URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901<br><br><br><br></p> </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"> <table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:durationItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table> </div> </div> </td> </tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue"> <tr> <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td> </tr> <tr> <td> <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div> <p>Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of fully vested and expected to vest options that are exercisable.</p> </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"> <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (e)(2)<br><br> -URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901<br><br><br><br></p> </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"> <table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:monetaryItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>debit</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>instant</td> </tr> </table> </div> </div> </td> </tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber"> <tr> <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td> </tr> <tr> <td> <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div> <p>As of the balance sheet date, the number of shares into which fully vested and expected to vest stock options outstanding can be converted under the option plan.</p> </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"> <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (e)(1)<br><br> -URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901<br><br><br><br></p> </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"> <table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:sharesItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>instant</td> </tr> </table> </div> </div> </td> </tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice"> <tr> <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td> </tr> <tr> <td> <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div> <p>As of the balance sheet date, the weighted-average exercise price for outstanding stock options that are fully vested or expected to vest.</p> </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"> <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (e)(1)<br><br> -URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901<br><br><br><br></p> </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"> <table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>num:perShareItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>instant</td> </tr> </table> </div> </div> </td> </tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1"> <tr> <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td> </tr> <tr> <td> <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div> <p>Weighted average remaining contractual term for fully vested and expected to vest options outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p> </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"> <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (e)(1)<br><br> -URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901<br><br><br><br></p> </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"> <table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:durationItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table> </div> </div> </td> </tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod"> <tr> <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td> </tr> <tr> <td> <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div> <p>Number of share instruments newly issued under a share-based compensation plan.</p> </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"> <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901<br><br><br><br></p> </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"> <table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:sharesItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table> </div> </div> </td> </tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"> <tr> <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td> </tr> <tr> <td> <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div> <p>Weighted average price at which option holders acquired shares when converting their stock options into shares.</p> </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"> <p>No definition available.</p> </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"> <table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>num:perShareItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table> </div> </div> </td> </tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"> <tr> <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td> </tr> <tr> <td> <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div> <p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p> </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"> <p>No definition available.</p> </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"> <table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>num:perShareItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table> </div> </div> </td> </tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"> <tr> <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td> </tr> <tr> <td> <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div> <p>Number of share options (or share units) exercised during the current period.</p> </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"> <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 04<br><br> -Article 3<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21463-112644<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.3-04)<br><br> -URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.28,29)<br><br> -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (c)(1)(iv)(2)<br><br> -URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 29, 30<br><br> -Article 5<br><br><br><br></p> </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"> <table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:sharesItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table> </div> </div> </td> </tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember"> <tr> <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td> </tr> <tr> <td> <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div> <table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td></td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td></td> </tr> <tr> <td><strong> Period Type:</strong></td> <td></td> </tr> </table> </div> </div> </td> </tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember"> <tr> <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td> </tr> <tr> <td> <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div> <table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td></td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td></td> </tr> <tr> <td><strong> Period Type:</strong></td> <td></td> </tr> </table> </div> </div> </td> </tr> </table> </div> </body> </html> </TEXT> </DOCUMENT> <DOCUMENT> <TYPE>EXCEL <SEQUENCE>38 <FILENAME>Financial_Report.xls <DESCRIPTION>IDEA: XBRL DOCUMENT <TEXT> begin 644 Financial_Report.xls M[[N_34E-12U697)S:6]N.B`Q+C`-"E@M1&]C=6UE;G0M5'EP93H@5V]R:V)O M;VL-"D-O;G1E;G0M5'EP93H@;75L=&EP87)T+W)E;&%T960[(&)O=6YD87)Y M/2(M+2TM/5].97AT4&%R=%\S.6,P96$V,E]C,C`S7S0U.&9?.&,U,%\S9&-A M-#4V838Y-3$B#0H-"E1H:7,@9&]C=6UE;G0@:7,@82!3:6YG;&4@1FEL92!7 M96(@4&%G92P@86QS;R!K;F]W;B!A<R!A(%=E8B!!<F-H:79E(&9I;&4N("!) M9B!Y;W4@87)E('-E96EN9R!T:&ES(&UE<W-A9V4L('EO=7(@8G)O=W-E<B!O M<B!E9&ET;W(@9&]E<VXG="!S=7!P;W)T(%=E8B!!<F-H:79E(&9I;&5S+B`@ M4&QE87-E(&1O=VYL;V%D(&$@8G)O=W-E<B!T:&%T('-U<'!O<G1S(%=E8B!! M<F-H:79E+"!S=6-H(&%S($UI8W)O<V]F="!);G1E<FYE="!%>'!L;W)E<BX- M"@T*+2TM+2TM/5].97AT4&%R=%\S.6,P96$V,E]C,C`S7S0U.&9?.&,U,%\S M9&-A-#4V838Y-3$-"D-O;G1E;G0M3&]C871I;VXZ(&9I;&4Z+R\O0SHO,SEC M,&5A-C)?8S(P,U\T-3AF7SAC-3!?,V1C830U-F$V.34Q+U=O<FMB;V]K+FAT M;6P-"D-O;G1E;G0M5')A;G-F97(M16YC;V1I;F<Z('%U;W1E9"UP<FEN=&%B M;&4-"D-O;G1E;G0M5'EP93H@=&5X="]H=&UL.R!C:&%R<V5T/2)U<RUA<V-I M:2(-"@T*/&AT;6P@>&UL;G,Z=CTS1")U<FXZ<V-H96UA<RUM:6-R;W-O9G0M M8V]M.G9M;"(@>&UL;G,Z;STS1")U<FXZ<V-H96UA<RUM:6-R;W-O9G0M8V]M M.F]F9FEC93IO9F9I8V4B('AM;&YS.G@],T0B=7)N.G-C:&5M87,M;6EC<F]S M;V9T+6-O;3IO9F9I8V4Z97AC96PB('AM;&YS/3-$(FAT='`Z+R]W=W<N=S,N M;W)G+U12+U)%0RUH=&UL-#`B/@T*/&AE860^#0H\;65T82!N86UE/3-$(D5X M8V5L(%=O<FMB;V]K($9R86UE<V5T(CX-"@T*/&UE=&$@;F%M93TS1%!R;V=) M9"!C;VYT96YT/3-$17AC96PN4VAE970^#0H\;&EN:R!R96P],T1&:6QE+4QI M<W0@:')E9CTS1")7;W)K<VAE971S+V9I;&5L:7-T+GAM;"(^#0H-"CPA+2U; M:68@9W1E(&US;R`Y73X\>&UL/@T*(#QX.D5X8V5L5V]R:V)O;VL^#0H@(#QX M.D5X8V5L5V]R:W-H965T<SX-"B`@(#QX.D5X8V5L5V]R:W-H965T/@T*("`@ M(#QX.DYA;64^1&]C=6UE;G1?86YD7T5N=&ET>5]);F9O<FUA=&EO/"]X.DYA M;64^#0H@("`@/'@Z5V]R:W-H965T4V]U<F-E($A2968],T0B5V]R:W-H965T M<R]3:&5E=#`Q+FAT;6PB+SX-"B`@(#PO>#I%>&-E;%=O<FMS:&5E=#X-"B`@ M(#QX.D5X8V5L5V]R:W-H965T/@T*("`@(#QX.DYA;64^0V]N<V]L:61A=&5D M7T)A;&%N8V5?4VAE971S/"]X.DYA;64^#0H@("`@/'@Z5V]R:W-H965T4V]U M<F-E($A2968],T0B5V]R:W-H965T<R]3:&5E=#`R+FAT;6PB+SX-"B`@(#PO M>#I%>&-E;%=O<FMS:&5E=#X-"B`@(#QX.D5X8V5L5V]R:W-H965T/@T*("`@ M(#QX.DYA;64^0V]N<V]L:61A=&5D7T)A;&%N8V5?4VAE971S7U!A/"]X.DYA M;64^#0H@("`@/'@Z5V]R:W-H965T4V]U<F-E($A2968],T0B5V]R:W-H965T M<R]3:&5E=#`S+FAT;6PB+SX-"B`@(#PO>#I%>&-E;%=O<FMS:&5E=#X-"B`@ M(#QX.D5X8V5L5V]R:W-H965T/@T*("`@(#QX.DYA;64^0V]N<V]L:61A=&5D M7U-T871E;65N='-?;V9?0V]M/"]X.DYA;64^#0H@("`@/'@Z5V]R:W-H965T M4V]U<F-E($A2968],T0B5V]R:W-H965T<R]3:&5E=#`T+FAT;6PB+SX-"B`@ M(#PO>#I%>&-E;%=O<FMS:&5E=#X-"B`@(#QX.D5X8V5L5V]R:W-H965T/@T* M("`@(#QX.DYA;64^0V]N<V]L:61A=&5D7U-T871E;65N='-?;V9?4W1O/"]X M.DYA;64^#0H@("`@/'@Z5V]R:W-H965T4V]U<F-E($A2968],T0B5V]R:W-H M965T<R]3:&5E=#`U+FAT;6PB+SX-"B`@(#PO>#I%>&-E;%=O<FMS:&5E=#X- M"B`@(#QX.D5X8V5L5V]R:W-H965T/@T*("`@(#QX.DYA;64^0V]N<V]L:61A M=&5D7U-T871E;65N='-?;V9?4W1O,3PO>#I.86UE/@T*("`@(#QX.E=O<FMS M:&5E=%-O=7)C92!(4F5F/3-$(E=O<FMS:&5E=',O4VAE970P-BYH=&UL(B\^ M#0H@("`\+W@Z17AC96Q7;W)K<VAE970^#0H@("`\>#I%>&-E;%=O<FMS:&5E M=#X-"B`@("`\>#I.86UE/D-O;G-O;&ED871E9%]3=&%T96UE;G1S7V]F7T-A M<SPO>#I.86UE/@T*("`@(#QX.E=O<FMS:&5E=%-O=7)C92!(4F5F/3-$(E=O M<FMS:&5E=',O4VAE970P-RYH=&UL(B\^#0H@("`\+W@Z17AC96Q7;W)K<VAE M970^#0H@("`\>#I%>&-E;%=O<FMS:&5E=#X-"B`@("`\>#I.86UE/D]R9V%N M:7IA=&EO;E]A;F1?4VEG;FEF:6-A;G1?03PO>#I.86UE/@T*("`@(#QX.E=O M<FMS:&5E=%-O=7)C92!(4F5F/3-$(E=O<FMS:&5E=',O4VAE970P."YH=&UL M(B\^#0H@("`\+W@Z17AC96Q7;W)K<VAE970^#0H@("`\>#I%>&-E;%=O<FMS M:&5E=#X-"B`@("`\>#I.86UE/DYE=%],;W-S7U!E<E]3:&%R93PO>#I.86UE M/@T*("`@(#QX.E=O<FMS:&5E=%-O=7)C92!(4F5F/3-$(E=O<FMS:&5E=',O M4VAE970P.2YH=&UL(B\^#0H@("`\+W@Z17AC96Q7;W)K<VAE970^#0H@("`\ M>#I%>&-E;%=O<FMS:&5E=#X-"B`@("`\>#I.86UE/E-U<'!L96UE;G1A<GE? M0V%S:%]&;&]W7T1A=&$\+W@Z3F%M93X-"B`@("`\>#I7;W)K<VAE9713;W5R M8V4@2%)E9CTS1")7;W)K<VAE971S+U-H965T,3`N:'1M;"(O/@T*("`@/"]X M.D5X8V5L5V]R:W-H965T/@T*("`@/'@Z17AC96Q7;W)K<VAE970^#0H@("`@ M/'@Z3F%M93Y#87-H7T5Q=6EV86QE;G1S7V%N9%]);G9E<W1M96X\+W@Z3F%M M93X-"B`@("`\>#I7;W)K<VAE9713;W5R8V4@2%)E9CTS1")7;W)K<VAE971S M+U-H965T,3$N:'1M;"(O/@T*("`@/"]X.D5X8V5L5V]R:W-H965T/@T*("`@ M/'@Z17AC96Q7;W)K<VAE970^#0H@("`@/'@Z3F%M93Y&86ER7U9A;'5E7TUE M87-U<F5M96YT<SPO>#I.86UE/@T*("`@(#QX.E=O<FMS:&5E=%-O=7)C92!( M4F5F/3-$(E=O<FMS:&5E=',O4VAE970Q,BYH=&UL(B\^#0H@("`\+W@Z17AC M96Q7;W)K<VAE970^#0H@("`\>#I%>&-E;%=O<FMS:&5E=#X-"B`@("`\>#I. M86UE/D)A;&%N8V5?4VAE971?0V]M<&]N96YT<SPO>#I.86UE/@T*("`@(#QX M.E=O<FMS:&5E=%-O=7)C92!(4F5F/3-$(E=O<FMS:&5E=',O4VAE970Q,RYH M=&UL(B\^#0H@("`\+W@Z17AC96Q7;W)K<VAE970^#0H@("`\>#I%>&-E;%=O M<FMS:&5E=#X-"B`@("`\>#I.86UE/E)E;&%T961?4&%R=&EE<U]A;F1?4F5L M871E9%]083PO>#I.86UE/@T*("`@(#QX.E=O<FMS:&5E=%-O=7)C92!(4F5F M/3-$(E=O<FMS:&5E=',O4VAE970Q-"YH=&UL(B\^#0H@("`\+W@Z17AC96Q7 M;W)K<VAE970^#0H@("`\>#I%>&-E;%=O<FMS:&5E=#X-"B`@("`\>#I.86UE M/D]T:&5R7U)E<V5A<F-H7V%N9%]$979E;&]P;65N=#PO>#I.86UE/@T*("`@ M(#QX.E=O<FMS:&5E=%-O=7)C92!(4F5F/3-$(E=O<FMS:&5E=',O4VAE970Q M-2YH=&UL(B\^#0H@("`\+W@Z17AC96Q7;W)K<VAE970^#0H@("`\>#I%>&-E M;%=O<FMS:&5E=#X-"B`@("`\>#I.86UE/D1E8G0\+W@Z3F%M93X-"B`@("`\ M>#I7;W)K<VAE9713;W5R8V4@2%)E9CTS1")7;W)K<VAE971S+U-H965T,38N M:'1M;"(O/@T*("`@/"]X.D5X8V5L5V]R:W-H965T/@T*("`@/'@Z17AC96Q7 M;W)K<VAE970^#0H@("`@/'@Z3F%M93Y#;VUM:71M96YT<U]A;F1?0V]N=&EN M9V5N8VEE<SPO>#I.86UE/@T*("`@(#QX.E=O<FMS:&5E=%-O=7)C92!(4F5F M/3-$(E=O<FMS:&5E=',O4VAE970Q-RYH=&UL(B\^#0H@("`\+W@Z17AC96Q7 M;W)K<VAE970^#0H@("`\>#I%>&-E;%=O<FMS:&5E=#X-"B`@("`\>#I.86UE M/D-O;G9E<G1I8FQE7U!R969E<G)E9%]3=&]C:SPO>#I.86UE/@T*("`@(#QX M.E=O<FMS:&5E=%-O=7)C92!(4F5F/3-$(E=O<FMS:&5E=',O4VAE970Q."YH M=&UL(B\^#0H@("`\+W@Z17AC96Q7;W)K<VAE970^#0H@("`\>#I%>&-E;%=O M<FMS:&5E=#X-"B`@("`\>#I.86UE/E-T;V-K:&]L9&5R<U]%<75I='D\+W@Z M3F%M93X-"B`@("`\>#I7;W)K<VAE9713;W5R8V4@2%)E9CTS1")7;W)K<VAE M971S+U-H965T,3DN:'1M;"(O/@T*("`@/"]X.D5X8V5L5V]R:W-H965T/@T* M("`@/'@Z17AC96Q7;W)K<VAE970^#0H@("`@/'@Z3F%M93Y);F-O;65?5&%X M97,\+W@Z3F%M93X-"B`@("`\>#I7;W)K<VAE9713;W5R8V4@2%)E9CTS1")7 M;W)K<VAE971S+U-H965T,C`N:'1M;"(O/@T*("`@/"]X.D5X8V5L5V]R:W-H M965T/@T*("`@/'@Z17AC96Q7;W)K<VAE970^#0H@("`@/'@Z3F%M93Y);G1E M<F5S=%]A;F1?3W1H97)?3F5T/"]X.DYA;64^#0H@("`@/'@Z5V]R:W-H965T M4V]U<F-E($A2968],T0B5V]R:W-H965T<R]3:&5E=#(Q+FAT;6PB+SX-"B`@ M(#PO>#I%>&-E;%=O<FMS:&5E=#X-"B`@(#QX.D5X8V5L5V]R:W-H965T/@T* M("`@(#QX.DYA;64^475A<G1E<FQY7T9I;F%N8VEA;%]$871A/"]X.DYA;64^ M#0H@("`@/'@Z5V]R:W-H965T4V]U<F-E($A2968],T0B5V]R:W-H965T<R]3 M:&5E=#(R+FAT;6PB+SX-"B`@(#PO>#I%>&-E;%=O<FMS:&5E=#X-"B`@(#QX M.D5X8V5L5V]R:W-H965T/@T*("`@(#QX.DYA;64^3W)G86YI>F%T:6]N7V%N M9%]3:6=N:69I8V%N=%]!,3PO>#I.86UE/@T*("`@(#QX.E=O<FMS:&5E=%-O M=7)C92!(4F5F/3-$(E=O<FMS:&5E=',O4VAE970R,RYH=&UL(B\^#0H@("`\ M+W@Z17AC96Q7;W)K<VAE970^#0H@("`\>#I%>&-E;%=O<FMS:&5E=#X-"B`@ M("`\>#I.86UE/DYE=%],;W-S7U!E<E]3:&%R95]486)L97,\+W@Z3F%M93X- M"B`@("`\>#I7;W)K<VAE9713;W5R8V4@2%)E9CTS1")7;W)K<VAE971S+U-H M965T,C0N:'1M;"(O/@T*("`@/"]X.D5X8V5L5V]R:W-H965T/@T*("`@/'@Z M17AC96Q7;W)K<VAE970^#0H@("`@/'@Z3F%M93Y3=7!P;&5M96YT87)Y7T-A M<VA?1FQO=U]$871A7U0\+W@Z3F%M93X-"B`@("`\>#I7;W)K<VAE9713;W5R M8V4@2%)E9CTS1")7;W)K<VAE971S+U-H965T,C4N:'1M;"(O/@T*("`@/"]X M.D5X8V5L5V]R:W-H965T/@T*("`@/'@Z17AC96Q7;W)K<VAE970^#0H@("`@ M/'@Z3F%M93Y#87-H7T5Q=6EV86QE;G1S7V%N9%]);G9E<W1M96XQ/"]X.DYA M;64^#0H@("`@/'@Z5V]R:W-H965T4V]U<F-E($A2968],T0B5V]R:W-H965T M<R]3:&5E=#(V+FAT;6PB+SX-"B`@(#PO>#I%>&-E;%=O<FMS:&5E=#X-"B`@ M(#QX.D5X8V5L5V]R:W-H965T/@T*("`@(#QX.DYA;64^1F%I<E]686QU95]- M96%S=7)E;65N='-?5&%B;&5S/"]X.DYA;64^#0H@("`@/'@Z5V]R:W-H965T M4V]U<F-E($A2968],T0B5V]R:W-H965T<R]3:&5E=#(W+FAT;6PB+SX-"B`@ M(#PO>#I%>&-E;%=O<FMS:&5E=#X-"B`@(#QX.D5X8V5L5V]R:W-H965T/@T* M("`@(#QX.DYA;64^0F%L86YC95]3:&5E=%]#;VUP;VYE;G1S7U1A8FQE/"]X M.DYA;64^#0H@("`@/'@Z5V]R:W-H965T4V]U<F-E($A2968],T0B5V]R:W-H M965T<R]3:&5E=#(X+FAT;6PB+SX-"B`@(#PO>#I%>&-E;%=O<FMS:&5E=#X- M"B`@(#QX.D5X8V5L5V]R:W-H965T/@T*("`@(#QX.DYA;64^4F5L871E9%]0 M87)T:65S7V%N9%]296QA=&5D7U!A,3PO>#I.86UE/@T*("`@(#QX.E=O<FMS M:&5E=%-O=7)C92!(4F5F/3-$(E=O<FMS:&5E=',O4VAE970R.2YH=&UL(B\^ M#0H@("`\+W@Z17AC96Q7;W)K<VAE970^#0H@("`\>#I%>&-E;%=O<FMS:&5E M=#X-"B`@("`\>#I.86UE/D]T:&5R7U)E<V5A<F-H7V%N9%]$979E;&]P;65N M=#$\+W@Z3F%M93X-"B`@("`\>#I7;W)K<VAE9713;W5R8V4@2%)E9CTS1")7 M;W)K<VAE971S+U-H965T,S`N:'1M;"(O/@T*("`@/"]X.D5X8V5L5V]R:W-H M965T/@T*("`@/'@Z17AC96Q7;W)K<VAE970^#0H@("`@/'@Z3F%M93Y$96)T M7U1A8FQE<SPO>#I.86UE/@T*("`@(#QX.E=O<FMS:&5E=%-O=7)C92!(4F5F M/3-$(E=O<FMS:&5E=',O4VAE970S,2YH=&UL(B\^#0H@("`\+W@Z17AC96Q7 M;W)K<VAE970^#0H@("`\>#I%>&-E;%=O<FMS:&5E=#X-"B`@("`\>#I.86UE M/D-O;6UI=&UE;G1S7V%N9%]#;VYT:6YG96YC:65S7SPO>#I.86UE/@T*("`@ M(#QX.E=O<FMS:&5E=%-O=7)C92!(4F5F/3-$(E=O<FMS:&5E=',O4VAE970S M,BYH=&UL(B\^#0H@("`\+W@Z17AC96Q7;W)K<VAE970^#0H@("`\>#I%>&-E M;%=O<FMS:&5E=#X-"B`@("`\>#I.86UE/E-T;V-K:&]L9&5R<U]%<75I='E? M5&%B;&5S/"]X.DYA;64^#0H@("`@/'@Z5V]R:W-H965T4V]U<F-E($A2968] M,T0B5V]R:W-H965T<R]3:&5E=#,S+FAT;6PB+SX-"B`@(#PO>#I%>&-E;%=O M<FMS:&5E=#X-"B`@(#QX.D5X8V5L5V]R:W-H965T/@T*("`@(#QX.DYA;64^ M26YC;VUE7U1A>&5S7U1A8FQE<SPO>#I.86UE/@T*("`@(#QX.E=O<FMS:&5E M=%-O=7)C92!(4F5F/3-$(E=O<FMS:&5E=',O4VAE970S-"YH=&UL(B\^#0H@ M("`\+W@Z17AC96Q7;W)K<VAE970^#0H@("`\>#I%>&-E;%=O<FMS:&5E=#X- M"B`@("`\>#I.86UE/DEN=&5R97-T7V%N9%]/=&AE<E].971?5&%B;&5S/"]X M.DYA;64^#0H@("`@/'@Z5V]R:W-H965T4V]U<F-E($A2968],T0B5V]R:W-H M965T<R]3:&5E=#,U+FAT;6PB+SX-"B`@(#PO>#I%>&-E;%=O<FMS:&5E=#X- M"B`@(#QX.D5X8V5L5V]R:W-H965T/@T*("`@(#QX.DYA;64^475A<G1E<FQY M7T9I;F%N8VEA;%]$871A7U1A8FQE/"]X.DYA;64^#0H@("`@/'@Z5V]R:W-H M965T4V]U<F-E($A2968],T0B5V]R:W-H965T<R]3:&5E=#,V+FAT;6PB+SX- M"B`@(#PO>#I%>&-E;%=O<FMS:&5E=#X-"B`@(#QX.D5X8V5L5V]R:W-H965T M/@T*("`@(#QX.DYA;64^3W)G86YI>F%T:6]N7V%N9%]3:6=N:69I8V%N=%]! M,CPO>#I.86UE/@T*("`@(#QX.E=O<FMS:&5E=%-O=7)C92!(4F5F/3-$(E=O M<FMS:&5E=',O4VAE970S-RYH=&UL(B\^#0H@("`\+W@Z17AC96Q7;W)K<VAE M970^#0H@("`\>#I%>&-E;%=O<FMS:&5E=#X-"B`@("`\>#I.86UE/DYE=%], M;W-S7U!E<E]3:&%R95]#86QC=6QA=&EO;CPO>#I.86UE/@T*("`@(#QX.E=O M<FMS:&5E=%-O=7)C92!(4F5F/3-$(E=O<FMS:&5E=',O4VAE970S."YH=&UL M(B\^#0H@("`\+W@Z17AC96Q7;W)K<VAE970^#0H@("`\>#I%>&-E;%=O<FMS M:&5E=#X-"B`@("`\>#I.86UE/DYE=%],;W-S7U!E<E]3:&%R95]);G-T<G5M M96YT<SPO>#I.86UE/@T*("`@(#QX.E=O<FMS:&5E=%-O=7)C92!(4F5F/3-$ M(E=O<FMS:&5E=',O4VAE970S.2YH=&UL(B\^#0H@("`\+W@Z17AC96Q7;W)K M<VAE970^#0H@("`\>#I%>&-E;%=O<FMS:&5E=#X-"B`@("`\>#I.86UE/E-U M<'!L96UE;G1A<GE?0V%S:%]&;&]W7T1A=&%?4SPO>#I.86UE/@T*("`@(#QX M.E=O<FMS:&5E=%-O=7)C92!(4F5F/3-$(E=O<FMS:&5E=',O4VAE970T,"YH M=&UL(B\^#0H@("`\+W@Z17AC96Q7;W)K<VAE970^#0H@("`\>#I%>&-E;%=O M<FMS:&5E=#X-"B`@("`\>#I.86UE/D-A<VA?17%U:79A;&5N='-?86YD7TEN M=F5S=&UE;C(\+W@Z3F%M93X-"B`@("`\>#I7;W)K<VAE9713;W5R8V4@2%)E M9CTS1")7;W)K<VAE971S+U-H965T-#$N:'1M;"(O/@T*("`@/"]X.D5X8V5L M5V]R:W-H965T/@T*("`@/'@Z17AC96Q7;W)K<VAE970^#0H@("`@/'@Z3F%M M93Y#87-H7T5Q=6EV86QE;G1S7V%N9%]);G9E<W1M96XS/"]X.DYA;64^#0H@ M("`@/'@Z5V]R:W-H965T4V]U<F-E($A2968],T0B5V]R:W-H965T<R]3:&5E M=#0R+FAT;6PB+SX-"B`@(#PO>#I%>&-E;%=O<FMS:&5E=#X-"B`@(#QX.D5X M8V5L5V]R:W-H965T/@T*("`@(#QX.DYA;64^0V%S:%]%<75I=F%L96YT<U]A M;F1?26YV97-T;65N-#PO>#I.86UE/@T*("`@(#QX.E=O<FMS:&5E=%-O=7)C M92!(4F5F/3-$(E=O<FMS:&5E=',O4VAE970T,RYH=&UL(B\^#0H@("`\+W@Z M17AC96Q7;W)K<VAE970^#0H@("`\>#I%>&-E;%=O<FMS:&5E=#X-"B`@("`\ M>#I.86UE/D9A:7)?5F%L=65?365A<W5R96UE;G1S7U-U;6UA<CPO>#I.86UE M/@T*("`@(#QX.E=O<FMS:&5E=%-O=7)C92!(4F5F/3-$(E=O<FMS:&5E=',O M4VAE970T-"YH=&UL(B\^#0H@("`\+W@Z17AC96Q7;W)K<VAE970^#0H@("`\ M>#I%>&-E;%=O<FMS:&5E=#X-"B`@("`\>#I.86UE/D9A:7)?5F%L=65?365A M<W5R96UE;G1S7T%D9&ET:3PO>#I.86UE/@T*("`@(#QX.E=O<FMS:&5E=%-O M=7)C92!(4F5F/3-$(E=O<FMS:&5E=',O4VAE970T-2YH=&UL(B\^#0H@("`\ M+W@Z17AC96Q7;W)K<VAE970^#0H@("`\>#I%>&-E;%=O<FMS:&5E=#X-"B`@ M("`\>#I.86UE/D)A;&%N8V5?4VAE971?0V]M<&]N96YT<U]3=6UM83PO>#I. M86UE/@T*("`@(#QX.E=O<FMS:&5E=%-O=7)C92!(4F5F/3-$(E=O<FMS:&5E M=',O4VAE970T-BYH=&UL(B\^#0H@("`\+W@Z17AC96Q7;W)K<VAE970^#0H@ M("`\>#I%>&-E;%=O<FMS:&5E=#X-"B`@("`\>#I.86UE/D)A;&%N8V5?4VAE M971?0V]M<&]N96YT<U]!9&1I=#PO>#I.86UE/@T*("`@(#QX.E=O<FMS:&5E M=%-O=7)C92!(4F5F/3-$(E=O<FMS:&5E=',O4VAE970T-RYH=&UL(B\^#0H@ M("`\+W@Z17AC96Q7;W)K<VAE970^#0H@("`\>#I%>&-E;%=O<FMS:&5E=#X- M"B`@("`\>#I.86UE/D)A;&%N8V5?4VAE971?0V]M<&]N96YT<U]3=6UM83$\ M+W@Z3F%M93X-"B`@("`\>#I7;W)K<VAE9713;W5R8V4@2%)E9CTS1")7;W)K M<VAE971S+U-H965T-#@N:'1M;"(O/@T*("`@/"]X.D5X8V5L5V]R:W-H965T M/@T*("`@/'@Z17AC96Q7;W)K<VAE970^#0H@("`@/'@Z3F%M93Y296QA=&5D M7U!A<G1I97-?86YD7U)E;&%T961?4&$R/"]X.DYA;64^#0H@("`@/'@Z5V]R M:W-H965T4V]U<F-E($A2968],T0B5V]R:W-H965T<R]3:&5E=#0Y+FAT;6PB M+SX-"B`@(#PO>#I%>&-E;%=O<FMS:&5E=#X-"B`@(#QX.D5X8V5L5V]R:W-H M965T/@T*("`@(#QX.DYA;64^4F5L871E9%]087)T:65S7V%N9%]296QA=&5D M7U!A,SPO>#I.86UE/@T*("`@(#QX.E=O<FMS:&5E=%-O=7)C92!(4F5F/3-$ M(E=O<FMS:&5E=',O4VAE970U,"YH=&UL(B\^#0H@("`\+W@Z17AC96Q7;W)K M<VAE970^#0H@("`\>#I%>&-E;%=O<FMS:&5E=#X-"B`@("`\>#I.86UE/D]T M:&5R7U)E<V5A<F-H7V%N9%]$979E;&]P;65N=#(\+W@Z3F%M93X-"B`@("`\ M>#I7;W)K<VAE9713;W5R8V4@2%)E9CTS1")7;W)K<VAE971S+U-H965T-3$N M:'1M;"(O/@T*("`@/"]X.D5X8V5L5V]R:W-H965T/@T*("`@/'@Z17AC96Q7 M;W)K<VAE970^#0H@("`@/'@Z3F%M93Y/=&AE<E]297-E87)C:%]A;F1?1&5V M96QO<&UE;G0S/"]X.DYA;64^#0H@("`@/'@Z5V]R:W-H965T4V]U<F-E($A2 M968],T0B5V]R:W-H965T<R]3:&5E=#4R+FAT;6PB+SX-"B`@(#PO>#I%>&-E M;%=O<FMS:&5E=#X-"B`@(#QX.D5X8V5L5V]R:W-H965T/@T*("`@(#QX.DYA M;64^3W1H97)?4F5S96%R8VA?86YD7T1E=F5L;W!M96YT-#PO>#I.86UE/@T* M("`@(#QX.E=O<FMS:&5E=%-O=7)C92!(4F5F/3-$(E=O<FMS:&5E=',O4VAE M970U,RYH=&UL(B\^#0H@("`\+W@Z17AC96Q7;W)K<VAE970^#0H@("`\>#I% M>&-E;%=O<FMS:&5E=#X-"B`@("`\>#I.86UE/D1E8G1?061D:71I;VYA;%]) M;F9O<FUA=&EO;E]$93PO>#I.86UE/@T*("`@(#QX.E=O<FMS:&5E=%-O=7)C M92!(4F5F/3-$(E=O<FMS:&5E=',O4VAE970U-"YH=&UL(B\^#0H@("`\+W@Z M17AC96Q7;W)K<VAE970^#0H@("`\>#I%>&-E;%=O<FMS:&5E=#X-"B`@("`\ M>#I.86UE/D1E8G1?4W5M;6%R>5]O9E]4;W1A;%]);G1E<F5S=#PO>#I.86UE M/@T*("`@(#QX.E=O<FMS:&5E=%-O=7)C92!(4F5F/3-$(E=O<FMS:&5E=',O M4VAE970U-2YH=&UL(B\^#0H@("`\+W@Z17AC96Q7;W)K<VAE970^#0H@("`\ M>#I%>&-E;%=O<FMS:&5E=#X-"B`@("`\>#I.86UE/D-O;6UI=&UE;G1S7V%N M9%]#;VYT:6YG96YC:65S7S$\+W@Z3F%M93X-"B`@("`\>#I7;W)K<VAE9713 M;W5R8V4@2%)E9CTS1")7;W)K<VAE971S+U-H965T-38N:'1M;"(O/@T*("`@ M/"]X.D5X8V5L5V]R:W-H965T/@T*("`@/'@Z17AC96Q7;W)K<VAE970^#0H@ M("`@/'@Z3F%M93Y#;VUM:71M96YT<U]A;F1?0V]N=&EN9V5N8VEE<U\R/"]X M.DYA;64^#0H@("`@/'@Z5V]R:W-H965T4V]U<F-E($A2968],T0B5V]R:W-H M965T<R]3:&5E=#4W+FAT;6PB+SX-"B`@(#PO>#I%>&-E;%=O<FMS:&5E=#X- M"B`@(#QX.D5X8V5L5V]R:W-H965T/@T*("`@(#QX.DYA;64^0V]M;6ET;65N M='-?86YD7T-O;G1I;F=E;F-I97-?,SPO>#I.86UE/@T*("`@(#QX.E=O<FMS M:&5E=%-O=7)C92!(4F5F/3-$(E=O<FMS:&5E=',O4VAE970U."YH=&UL(B\^ M#0H@("`\+W@Z17AC96Q7;W)K<VAE970^#0H@("`\>#I%>&-E;%=O<FMS:&5E M=#X-"B`@("`\>#I.86UE/D-O;G9E<G1I8FQE7U!R969E<G)E9%]3=&]C:U]! M9#PO>#I.86UE/@T*("`@(#QX.E=O<FMS:&5E=%-O=7)C92!(4F5F/3-$(E=O M<FMS:&5E=',O4VAE970U.2YH=&UL(B\^#0H@("`\+W@Z17AC96Q7;W)K<VAE M970^#0H@("`\>#I%>&-E;%=O<FMS:&5E=#X-"B`@("`\>#I.86UE/E-T;V-K M:&]L9&5R<U]%<75I='E?061D:71I;VYA;#PO>#I.86UE/@T*("`@(#QX.E=O M<FMS:&5E=%-O=7)C92!(4F5F/3-$(E=O<FMS:&5E=',O4VAE970V,"YH=&UL M(B\^#0H@("`\+W@Z17AC96Q7;W)K<VAE970^#0H@("`\>#I%>&-E;%=O<FMS M:&5E=#X-"B`@("`\>#I.86UE/E-T;V-K:&]L9&5R<U]%<75I='E?3W5T<W1A M;F1I;CPO>#I.86UE/@T*("`@(#QX.E=O<FMS:&5E=%-O=7)C92!(4F5F/3-$ M(E=O<FMS:&5E=',O4VAE970V,2YH=&UL(B\^#0H@("`\+W@Z17AC96Q7;W)K M<VAE970^#0H@("`\>#I%>&-E;%=O<FMS:&5E=#X-"B`@("`\>#I.86UE/E-T M;V-K:&]L9&5R<U]%<75I='E?4W5M;6%R>5]O9CPO>#I.86UE/@T*("`@(#QX M.E=O<FMS:&5E=%-O=7)C92!(4F5F/3-$(E=O<FMS:&5E=',O4VAE970V,BYH M=&UL(B\^#0H@("`\+W@Z17AC96Q7;W)K<VAE970^#0H@("`\>#I%>&-E;%=O M<FMS:&5E=#X-"B`@("`\>#I.86UE/E-T;V-K:&]L9&5R<U]%<75I='E?4W5M M;6%R>5]O9C$\+W@Z3F%M93X-"B`@("`\>#I7;W)K<VAE9713;W5R8V4@2%)E M9CTS1")7;W)K<VAE971S+U-H965T-C,N:'1M;"(O/@T*("`@/"]X.D5X8V5L M5V]R:W-H965T/@T*("`@/'@Z17AC96Q7;W)K<VAE970^#0H@("`@/'@Z3F%M M93Y3=&]C:VAO;&1E<G-?17%U:71Y7U-T;V-K0F%S960\+W@Z3F%M93X-"B`@ M("`\>#I7;W)K<VAE9713;W5R8V4@2%)E9CTS1")7;W)K<VAE971S+U-H965T M-C0N:'1M;"(O/@T*("`@/"]X.D5X8V5L5V]R:W-H965T/@T*("`@/'@Z17AC M96Q7;W)K<VAE970^#0H@("`@/'@Z3F%M93Y3=&]C:VAO;&1E<G-?17%U:71Y M7T9A:7)?5F%L=64\+W@Z3F%M93X-"B`@("`\>#I7;W)K<VAE9713;W5R8V4@ M2%)E9CTS1")7;W)K<VAE971S+U-H965T-C4N:'1M;"(O/@T*("`@/"]X.D5X M8V5L5V]R:W-H965T/@T*("`@/'@Z17AC96Q7;W)K<VAE970^#0H@("`@/'@Z M3F%M93Y);F-O;65?5&%X97-?061D:71I;VYA;%]);F9O<FT\+W@Z3F%M93X- M"B`@("`\>#I7;W)K<VAE9713;W5R8V4@2%)E9CTS1")7;W)K<VAE971S+U-H M965T-C8N:'1M;"(O/@T*("`@/"]X.D5X8V5L5V]R:W-H965T/@T*("`@/'@Z M17AC96Q7;W)K<VAE970^#0H@("`@/'@Z3F%M93Y);F-O;65?5&%X97-?4V-H M961U;&5?;V9?0V]M<&\\+W@Z3F%M93X-"B`@("`\>#I7;W)K<VAE9713;W5R M8V4@2%)E9CTS1")7;W)K<VAE971S+U-H965T-C<N:'1M;"(O/@T*("`@/"]X M.D5X8V5L5V]R:W-H965T/@T*("`@/'@Z17AC96Q7;W)K<VAE970^#0H@("`@ M/'@Z3F%M93Y);F-O;65?5&%X97-?0V]M<&%N>5]296-O<F1E9%\\+W@Z3F%M M93X-"B`@("`\>#I7;W)K<VAE9713;W5R8V4@2%)E9CTS1")7;W)K<VAE971S M+U-H965T-C@N:'1M;"(O/@T*("`@/"]X.D5X8V5L5V]R:W-H965T/@T*("`@ M/'@Z17AC96Q7;W)K<VAE970^#0H@("`@/'@Z3F%M93Y);F-O;65?5&%X97-? M0V]M<&%N>7-?1&5F97)R960\+W@Z3F%M93X-"B`@("`\>#I7;W)K<VAE9713 M;W5R8V4@2%)E9CTS1")7;W)K<VAE971S+U-H965T-CDN:'1M;"(O/@T*("`@ M/"]X.D5X8V5L5V]R:W-H965T/@T*("`@/'@Z17AC96Q7;W)K<VAE970^#0H@ M("`@/'@Z3F%M93Y);F-O;65?5&%X97-?0V]M<&%N>7-?5F%L=6%T:6\\+W@Z M3F%M93X-"B`@("`\>#I7;W)K<VAE9713;W5R8V4@2%)E9CTS1")7;W)K<VAE M971S+U-H965T-S`N:'1M;"(O/@T*("`@/"]X.D5X8V5L5V]R:W-H965T/@T* M("`@/'@Z17AC96Q7;W)K<VAE970^#0H@("`@/'@Z3F%M93Y);F-O;65?5&%X M97-?4F5C;VYC:6QI871I;VY?;V8\+W@Z3F%M93X-"B`@("`\>#I7;W)K<VAE M9713;W5R8V4@2%)E9CTS1")7;W)K<VAE971S+U-H965T-S$N:'1M;"(O/@T* M("`@/"]X.D5X8V5L5V]R:W-H965T/@T*("`@/'@Z17AC96Q7;W)K<VAE970^ M#0H@("`@/'@Z3F%M93Y);F-O;65?5&%X97-?4F5C;VYC:6QI871I;VY?;V8Q M/"]X.DYA;64^#0H@("`@/'@Z5V]R:W-H965T4V]U<F-E($A2968],T0B5V]R M:W-H965T<R]3:&5E=#<R+FAT;6PB+SX-"B`@(#PO>#I%>&-E;%=O<FMS:&5E M=#X-"B`@(#QX.D5X8V5L5V]R:W-H965T/@T*("`@(#QX.DYA;64^26YT97)E M<W1?86YD7T]T:&5R7TYE=%]#;VUP;VYE/"]X.DYA;64^#0H@("`@/'@Z5V]R M:W-H965T4V]U<F-E($A2968],T0B5V]R:W-H965T<R]3:&5E=#<S+FAT;6PB M+SX-"B`@(#PO>#I%>&-E;%=O<FMS:&5E=#X-"B`@(#QX.D5X8V5L5V]R:W-H M965T/@T*("`@(#QX.DYA;64^475A<G1E<FQY7T9I;F%N8VEA;%]$871A7U-U M;6UA/"]X.DYA;64^#0H@("`@/'@Z5V]R:W-H965T4V]U<F-E($A2968],T0B M5V]R:W-H965T<R]3:&5E=#<T+FAT;6PB+SX-"B`@(#PO>#I%>&-E;%=O<FMS M:&5E=#X-"B`@/"]X.D5X8V5L5V]R:W-H965T<SX-"B`@/'@Z4W1Y;&5S:&5E M="!(4F5F/3-$(E=O<FMS:&5E=',O<F5P;W)T+F-S<R(O/@T*("`\>#I!8W1I M=F53:&5E=#XP/"]X.D%C=&EV95-H965T/@T*("`\>#I0<F]T96-T4W1R=6-T M=7)E/D9A;'-E/"]X.E!R;W1E8W13=')U8W1U<F4^#0H@(#QX.E!R;W1E8W17 M:6YD;W=S/D9A;'-E/"]X.E!R;W1E8W17:6YD;W=S/@T*(#PO>#I%>&-E;%=O M<FMB;V]K/@T*/"]X;6P^/"%;96YD:69=+2T^#0H\+VAE860^#0H@(#QB;V1Y M/@T*("`@/'`^5&AI<R!P86=E('-H;W5L9"!B92!O<&5N960@=VET:"!-:6-R M;W-O9G0@17AC96P@6%`@;W(@;F5W97(N/"]P/@T*("`\+V)O9'D^#0H\+VAT M;6P^#0H-"BTM+2TM+3U?3F5X=%!A<G1?,SEC,&5A-C)?8S(P,U\T-3AF7SAC M-3!?,V1C830U-F$V.34Q#0I#;VYT96YT+4QO8V%T:6]N.B!F:6QE.B\O+T,Z M+S,Y8S!E838R7V,R,#-?-#4X9E\X8S4P7S-D8V$T-39A-CDU,2]7;W)K<VAE M971S+U-H965T,#$N:'1M;`T*0V]N=&5N="U4<F%N<V9E<BU%;F-O9&EN9SH@ M<75O=&5D+7!R:6YT86)L90T*0V]N=&5N="U4>7!E.B!T97AT+VAT;6P[(&-H M87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U% M5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O M:'1M;#L@8VAA<G-E=#UU=&8M."<^/'-C<FEP="!T>7!E/3-$=&5X="]J879A M<V-R:7!T('-R8STS1%-H;W<N:G,^+RH@1&\@3F]T(%)E;6]V92!4:&ES($-O M;6UE;G0@*B\\+W-C<FEP=#X\+VAE860^#0H@(#QB;V1Y/@T*("`@(#QT86)L M92!C;&%S<STS1')E<&]R="!I9#TS1$E$,$5554%%/@T*("`@("`@/'1R/@T* M("`@("`@("`\=&@@8VQA<W,],T1T;"!C;VQS<&%N/3-$,2!R;W=S<&%N/3-$ M,CX\<W1R;VYG/D1O8W5M96YT(&%N9"!%;G1I='D@26YF;W)M871I;VX@*%53 M1"`D*3QB<CY);B!-:6QL:6]N<RP@97AC97!T(%-H87)E(&1A=&$L('5N;&5S M<R!O=&AE<G=I<V4@<W!E8VEF:65D/"]S=')O;F<^/"]T:#X-"B`@("`@("`@ M/'1H(&-L87-S/3-$=&@@8V]L<W!A;CTS1#$^,3(@36]N=&AS($5N9&5D/"]T M:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@@8V]L<W!A;CTS1#$^/"]T:#X- M"B`@("`@("`@/'1H(&-L87-S/3-$=&@@8V]L<W!A;CTS1#$^/"]T:#X-"B`@ M("`@(#PO='(^#0H@("`@("`\='(^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H M/D1E8RX@,S$L(#(P,30\8G(^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$ M=&@^1F5B+B`R-RP@,C`Q-3QB<CX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,] M,T1T:#Y*=6XN(#,P+"`R,#$T/&)R/CPO=&@^#0H@("`@("`\+W1R/@T*("`@ M("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A M;&EG;CTS1'1O<#X\<W1R;VYG/D1O8W5M96YT($%N9"!%;G1I='D@26YF;W)M M871I;VX@6T%B<W1R86-T73PO<W1R;VYG/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T* M("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L M('9A;&EG;CTS1'1O<#Y$;V-U;65N="!4>7!E/"]T9#X-"B`@("`@("`@/'1D M(&-L87-S/3-$=&5X=#XQ,"U+/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\ M+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S M<STS1'!L('9A;&EG;CTS1'1O<#Y!;65N9&UE;G0@1FQA9SPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S<STS1'1E>'0^9F%L<V4\<W!A;CX\+W-P86X^/"]T9#X- M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X- M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X- M"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@ M/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D1O8W5M96YT(%!E<FEO9"!% M;F0@1&%T93PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^1&5C(#,Q M+`T*"0DR,#$T/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@ M("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A M;&EG;CTS1'1O<#Y$;V-U;65N="!&:7-C86P@665A<B!&;V-U<SPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^,C`Q-#QS<&%N/CPO<W!A;CX\+W1D M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D M/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@ M("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^1&]C=6UE;G0@1FES8V%L M(%!E<FEO9"!&;V-U<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^ M1ED\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@ M8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$ M=&]P/E1R861I;F<@4WEM8F]L/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$ M=&5X=#Y#651+/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@ M("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A M;&EG;CTS1'1O<#Y%;G1I='D@4F5G:7-T<F%N="!.86UE/"]T9#X-"B`@("`@ M("`@/'1D(&-L87-S/3-$=&5X=#Y#651/2TE.151)0U,@24Y#/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^ M#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y%;G1I='D@ M0V5N=')A;"!);F1E>"!+97D\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T M97AT/C`P,#$P-C$Y.#,\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D M(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D M(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^ M#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$ M<&P@=F%L:6=N/3-$=&]P/D-U<G)E;G0@1FES8V%L(%EE87(@16YD($1A=&4\ M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/BTM,3(M,S$\<W!A;CX\ M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\ M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\ M+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R M93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D5N=&ET M>2!796QL+6MN;W=N(%-E87-O;F5D($ES<W5E<CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S<STS1'1E>'0^3F\\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@ M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@ M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO M='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S M/3-$<&P@=F%L:6=N/3-$=&]P/D5N=&ET>2!#=7)R96YT(%)E<&]R=&EN9R!3 M=&%T=7,\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/EEE<SQS<&%N M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N M/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS M1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^16YT M:71Y(%9O;'5N=&%R>2!&:6QE<G,\+W1D/@T*("`@("`@("`\=&0@8VQA<W,] M,T1T97AT/DYO/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@ M("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A M;&EG;CTS1'1O<#Y%;G1I='D@1FEL97(@0V%T96=O<GD\+W1D/@T*("`@("`@ M("`\=&0@8VQA<W,],T1T97AT/D%C8V5L97)A=&5D($9I;&5R/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^ M#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y%;G1I='D@ M0V]M;6]N(%-T;V-K+"!3:&%R97,@3W5T<W1A;F1I;F<\+W1D/@T*("`@("`@ M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@ M("`\=&0@8VQA<W,],T1N=6UP/C,X+#8W-"PX.3(\<W!A;CX\+W-P86X^/"]T M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T M9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@ M("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D5N=&ET>2!0=6)L:6,@ M1FQO870\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B0@,3<T+C4\ M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@/"]T86)L93X- M"B`@/"]B;V1Y/@T*/"]H=&UL/@T*#0HM+2TM+2T]7TYE>'1087)T7S,Y8S!E M838R7V,R,#-?-#4X9E\X8S4P7S-D8V$T-39A-CDU,0T*0V]N=&5N="U,;V-A M=&EO;CH@9FEL93HO+R]#.B\S.6,P96$V,E]C,C`S7S0U.&9?.&,U,%\S9&-A M-#4V838Y-3$O5V]R:W-H965T<R]3:&5E=#`R+FAT;6P-"D-O;G1E;G0M5')A M;G-F97(M16YC;V1I;F<Z('%U;W1E9"UP<FEN=&%B;&4-"D-O;G1E;G0M5'EP M93H@=&5X="]H=&UL.R!C:&%R<V5T/2)U<RUA<V-I:2(-"@T*/&AT;6P^#0H@ M(#QH96%D/@T*("`@(#Q-151!(&AT='`M97%U:78],T1#;VYT96YT+51Y<&4@ M8V]N=&5N=#TS1"=T97AT+VAT;6P[(&-H87)S970]=71F+3@G/CQS8W)I<'0@ M='EP93TS1'1E>'0O:F%V87-C<FEP="!S<F,],T13:&]W+FIS/B\J($1O($YO M="!296UO=F4@5&AI<R!#;VUM96YT("HO/"]S8W)I<'0^/"]H96%D/@T*("`\ M8F]D>3X-"B`@("`\=&%B;&4@8VQA<W,],T1R97!O<G0@:60],T1)1#!%04Q! M1SX-"B`@("`@(#QT<CX-"B`@("`@("`@/'1H(&-L87-S/3-$=&P@8V]L<W!A M;CTS1#$@<F]W<W!A;CTS1#$^/'-T<F]N9SY#;VYS;VQI9&%T960@0F%L86YC M92!3:&5E=',@*%531"`D*3QB<CY);B!4:&]U<V%N9',L('5N;&5S<R!O=&AE M<G=I<V4@<W!E8VEF:65D/"]S=')O;F<^/"]T:#X-"B`@("`@("`@/'1H(&-L M87-S/3-$=&@^1&5C+B`S,2P@,C`Q-#QB<CX\+W1H/@T*("`@("`@("`\=&@@ M8VQA<W,],T1T:#Y$96,N(#,Q+"`R,#$S/&)R/CPO=&@^#0H@("`@("`\+W1R M/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS M1'!L('9A;&EG;CTS1'1O<#X\<W1R;VYG/D-U<G)E;G0@87-S971S.CPO<W1R M;VYG/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^ M#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y#87-H(&%N M9"!C87-H(&5Q=6EV86QE;G1S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$ M;G5M<#XD(#(P+#(Q-3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@ M8VQA<W,],T1N=6UP/B0@,C`L,34X/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C M;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y3:&]R="UT97)M(&EN=F5S=&UE;G1S M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XV,RPP,3,\<W!A;CX\ M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XU-RPU-S`\ M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA M<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P M/E)E;&%T960@<&%R='D@86-C;W5N=',@<F5C96EV86)L93PO=&0^#0H@("`@ M("`@(#QT9"!C;&%S<STS1&YU;7`^-#8L-C0V/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-3QS<&%N/CPO<W!A;CX\+W1D M/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@ M("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^4')E<&%I9"!A;F0@;W1H M97(@8W5R<F5N="!A<W-E=',\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N M=6UP/C$L,C4W/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M<STS1&YU;7`^,2PV,#4\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^ M#0H@("`@("`\='(@8VQA<W,],T1R;W4^#0H@("`@("`@(#QT9"!C;&%S<STS M1'!L('9A;&EG;CTS1'1O<#Y4;W1A;"!C=7)R96YT(&%S<V5T<SPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,3,Q+#$S,3QS<&%N/CPO<W!A;CX\ M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C<Y+#,S.#QS<&%N/CPO M<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E M/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^4')O<&5R M='D@86YD(&5Q=6EP;65N="P@;F5T/"]T9#X-"B`@("`@("`@/'1D(&-L87-S M/3-$;G5M<#XQ+#8S-SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@ M8VQA<W,],T1N=6UP/C$L,C(Q/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\ M+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S M<STS1'!L('9A;&EG;CTS1'1O<#Y,;VYG+71E<FT@:6YV97-T;65N=',\+W1D M/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C`\<W!A;CX\+W-P86X^/"]T M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XR+#4P,CQS<&%N/CPO<W!A M;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T* M("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^3W1H97(@87-S M971S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XR,#`\<W!A;CX\ M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ,C<\<W!A M;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,] M,T1R;W4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y4 M;W1A;"!A<W-E=',\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$S M,BPY-C@\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$ M;G5M<#XX,RPQ.#@\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@ M("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@ M=F%L:6=N/3-$=&]P/CQS=')O;F<^0W5R<F5N="!L:6%B:6QI=&EE<SH\+W-T M<F]N9SX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO M<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O M/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^06-C;W5N M=',@<&%Y86)L93PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,2PS M-C$\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M M<#XS+#<P.3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@ M(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI M9VX],T1T;W`^06-C<G5E9"!L:6%B:6QI=&EE<SPO=&0^#0H@("`@("`@(#QT M9"!C;&%S<STS1&YU;7`^-2PT,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@ M("`@/'1D(&-L87-S/3-$;G5M<#XX+#(W,CQS<&%N/CPO<W!A;CX\+W1D/@T* M("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\ M=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^1&5F97)R960@<F5V96YU92P@ M8W5R<F5N=#PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,3<L,#0R M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^ M,30L-S`Q/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@ M/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG M;CTS1'1O<#Y3:&]R="UT97)M('!O<G1I;VX@;V8@9&5F97)R960@<F5N=#PO M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-3(\<W!A;CX\+W-P86X^ M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XR,CQS<&%N/CPO<W!A M;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O=3X- M"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E1O=&%L(&-U M<G)E;G0@;&EA8FEL:71I97,\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N M=6UP/C(S+#@U-3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA M<W,],T1N=6UP/C(V+#<P-#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T M<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,] M,T1P;"!V86QI9VX],T1T;W`^1&5F97)R960@<F5V96YU92P@;F]N+6-U<G)E M;G0\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$V+#4U.#QS<&%N M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$L-3`P M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L M87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O M<#Y,;VYG+71E<FT@<&]R=&EO;B!O9B!D969E<G)E9"!R96YT/"]T9#X-"B`@ M("`@("`@/'1D(&-L87-S/3-$;G5M<#XT.3$\<W!A;CX\+W-P86X^/"]T9#X- M"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XU-#(\<W!A;CX\+W-P86X^/"]T M9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R974^#0H@("`@ M("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y4;W1A;"!L:6%B:6QI M=&EE<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-#`L.3`T/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,C@L M-S0V/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R M(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS M1'1O<#Y#;VUM:71M96YT<R!A;F0@8V]N=&EN9V5N8VEE<R`H3F]T92`Q,"D\ M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B9N8G-P.R9N8G-P.SQS M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B9N M8G-P.R9N8G-P.SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@ M("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V M86QI9VX],T1T;W`^/'-T<F]N9SY3=&]C:VAO;&1E<G,G(&5Q=6ET>3H\+W-T M<F]N9SX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO M<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O M/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^0V]M;6]N M('-T;V-K+"`D,"XP,#$@<&%R('9A;'5E.B!!=71H;W)I>F5D.B`X,2PU,#`L M,#`P('-H87)E<SH@27-S=65D(&%N9"!O=71S=&%N9&EN9SH@,S@L-C4Y+#<S M."!S:&%R97,@870@1&5C96UB97(@,S$L(#(P,30@86YD(#,P+#8X,2PV,C0@ M<VAA<F5S(&%T($1E8V5M8F5R(#,Q+"`R,#$S/"]T9#X-"B`@("`@("`@/'1D M(&-L87-S/3-$;G5M<#XS.3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\ M=&0@8VQA<W,],T1N=6UP/C,Q/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\ M+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S M<STS1'!L('9A;&EG;CTS1'1O<#Y!9&1I=&EO;F%L('!A:60M:6X@8V%P:71A M;#PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-3@Y+#(W,CQS<&%N M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C4S-RPP M,#$\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@ M8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$ M=&]P/D%C8W5M=6QA=&5D(&]T:&5R(&-O;7!R96AE;G-I=F4@:6YC;VUE/"]T M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B@T*3QS<&%N/CPO<W!A;CX\ M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C<\<W!A;CX\+W-P86X^ M/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@ M("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D%C8W5M=6QA=&5D M(&1E9FEC:70\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6T^*#0Y-RPR M-#,I/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU M;3XH-#@R+#4Y-RD\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@ M("`@("`\='(@8VQA<W,],T1R;W4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L M('9A;&EG;CTS1'1O<#Y4;W1A;"!S=&]C:VAO;&1E<G,G(&5Q=6ET>3PO=&0^ M#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^.3(L,#8T/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-30L-#0R/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$ M<F5U/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^5&]T M86P@;&EA8FEL:71I97,@86YD('-T;V-K:&]L9&5R<R<@97%U:71Y/"]T9#X- M"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ,S(L.38X/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^.#,L,3@X/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$ M<F@^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y397)I M97,@02!#;VYV97)T:6)L92!0<F5F97)R960@4W1O8VL@6TUE;6)E<ET\+W1D M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D M/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@ M("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^/'-T<F]N9SY3=&]C:VAO M;&1E<G,G(&5Q=6ET>3H\+W-T<F]N9SX\+W1D/@T*("`@("`@("`\=&0@8VQA M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@ M("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V M86QI9VX],T1T;W`^4')E9F5R<F5D('-T;V-K+"!V86QU93PO=&0^#0H@("`@ M("`@(#QT9"!C;&%S<STS1&YU;7`^)"`P/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S<STS1&YU;7`^)"`P/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`\+W1R/@T*("`@(#PO=&%B;&4^#0H@(#PO8F]D>3X-"CPO:'1M M;#X-"@T*+2TM+2TM/5].97AT4&%R=%\S.6,P96$V,E]C,C`S7S0U.&9?.&,U M,%\S9&-A-#4V838Y-3$-"D-O;G1E;G0M3&]C871I;VXZ(&9I;&4Z+R\O0SHO M,SEC,&5A-C)?8S(P,U\T-3AF7SAC-3!?,V1C830U-F$V.34Q+U=O<FMS:&5E M=',O4VAE970P,RYH=&UL#0I#;VYT96YT+51R86YS9F5R+45N8V]D:6YG.B!Q M=6]T960M<')I;G1A8FQE#0I#;VYT96YT+51Y<&4Z('1E>'0O:'1M;#L@8VAA M<G-E=#TB=7,M87-C:6DB#0H-"CQH=&UL/@T*("`\:&5A9#X-"B`@("`\3454 M02!H='1P+65Q=6EV/3-$0V]N=&5N="U4>7!E(&-O;G1E;G0],T0G=&5X="]H M=&UL.R!C:&%R<V5T/75T9BTX)SX\<V-R:7!T('1Y<&4],T1T97AT+VIA=F%S M8W)I<'0@<W)C/3-$4VAO=RYJ<SXO*B!$;R!.;W0@4F5M;W9E(%1H:7,@0V]M M;65N="`J+SPO<V-R:7!T/CPO:&5A9#X-"B`@/&)O9'D^#0H@("`@/'1A8FQE M(&-L87-S/3-$<F5P;W)T(&ED/3-$240P14Y$044^#0H@("`@("`\='(^#0H@ M("`@("`@(#QT:"!C;&%S<STS1'1L(&-O;'-P86X],T0Q(')O=W-P86X],T0Q M/CQS=')O;F<^0V]N<V]L:61A=&5D($)A;&%N8V4@4VAE971S("A087)E;G1H M971I8V%L*2`H55-$("0I/&)R/CPO<W1R;VYG/CPO=&@^#0H@("`@("`@(#QT M:"!C;&%S<STS1'1H/D1E8RX@,S$L(#(P,30\8G(^/"]T:#X-"B`@("`@("`@ M/'1H(&-L87-S/3-$=&@^1&5C+B`S,2P@,C`Q,SQB<CX\+W1H/@T*("`@("`@ M/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA M<W,],T1P;"!V86QI9VX],T1T;W`^4')E9F5R<F5D('-T;V-K+"!P87(@=F%L M=64\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B0@,"XP,#$\<W!A M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XD(#`N M,#`Q/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R M(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS M1'1O<#Y0<F5F97)R960@<W1O8VLL('-H87)E<R!A=71H;W)I>F5D/"]T9#X- M"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ,"PP,#`L,#`P/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,3`L,#`P+#`P M,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C M;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T M;W`^0V]M;6]N('-T;V-K+"!P87(@=F%L=64\+W1D/@T*("`@("`@("`\=&0@ M8VQA<W,],T1N=6UP/B0@,"XP,#$\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@ M("`@/'1D(&-L87-S/3-$;G5M<#XD(#`N,#`Q/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@ M(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y#;VUM;VX@<W1O8VLL('-H M87)E<R!A=71H;W)I>F5D/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M M<#XX,2PU,#`L,#`P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S<STS1&YU;7`^.#$L-3`P+#`P,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@ M("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@ M8VQA<W,],T1P;"!V86QI9VX],T1T;W`^0V]M;6]N('-T;V-K+"!S:&%R97,@ M:7-S=65D/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XS."PV-3DL M-S,X/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU M;7`^,S`L-C@Q+#8R-#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX- M"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P M;"!V86QI9VX],T1T;W`^0V]M;6]N('-T;V-K+"!S:&%R97,@;W5T<W1A;F1I M;F<\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C,X+#8U.2PW,S@\ M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XS M,"PV.#$L-C(T/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@ M("`@/'1R(&-L87-S/3-$<F@^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A M;&EG;CTS1'1O<#Y397)I97,@02!#;VYV97)T:6)L92!0<F5F97)R960@4W1O M8VL@6TUE;6)E<ET\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S M<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^ M0V]N=F5R=&EB;&4@<')E9F5R<F5D('-T;V-K+"!I<W-U960@<VAA<F5S/"]T M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XP/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,#QS<&%N/CPO<W!A;CX\ M+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@ M("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^0V]N=F5R=&EB;&4@ M<')E9F5R<F5D('-T;V-K+"!O=71S=&%N9&EN9R!S:&%R97,\+W1D/@T*("`@ M("`@("`\=&0@8VQA<W,],T1N=6UP/C`\<W!A;CX\+W-P86X^/"]T9#X-"B`@ M("`@("`@/'1D(&-L87-S/3-$;G5M<#XP/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`\+W1R/@T*("`@(#PO=&%B;&4^#0H@(#PO8F]D>3X-"CPO:'1M;#X- M"@T*+2TM+2TM/5].97AT4&%R=%\S.6,P96$V,E]C,C`S7S0U.&9?.&,U,%\S M9&-A-#4V838Y-3$-"D-O;G1E;G0M3&]C871I;VXZ(&9I;&4Z+R\O0SHO,SEC M,&5A-C)?8S(P,U\T-3AF7SAC-3!?,V1C830U-F$V.34Q+U=O<FMS:&5E=',O M4VAE970P-"YH=&UL#0I#;VYT96YT+51R86YS9F5R+45N8V]D:6YG.B!Q=6]T M960M<')I;G1A8FQE#0I#;VYT96YT+51Y<&4Z('1E>'0O:'1M;#L@8VAA<G-E M=#TB=7,M87-C:6DB#0H-"CQH=&UL/@T*("`\:&5A9#X-"B`@("`\345402!H M='1P+65Q=6EV/3-$0V]N=&5N="U4>7!E(&-O;G1E;G0],T0G=&5X="]H=&UL M.R!C:&%R<V5T/75T9BTX)SX\<V-R:7!T('1Y<&4],T1T97AT+VIA=F%S8W)I M<'0@<W)C/3-$4VAO=RYJ<SXO*B!$;R!.;W0@4F5M;W9E(%1H:7,@0V]M;65N M="`J+SPO<V-R:7!T/CPO:&5A9#X-"B`@/&)O9'D^#0H@("`@/'1A8FQE(&-L M87-S/3-$<F5P;W)T(&ED/3-$240P15E004<^#0H@("`@("`\='(^#0H@("`@ M("`@(#QT:"!C;&%S<STS1'1L(&-O;'-P86X],T0Q(')O=W-P86X],T0R/CQS M=')O;F<^0V]N<V]L:61A=&5D(%-T871E;65N=',@;V8@0V]M<')E:&5N<VEV M92!,;W-S("A54T0@)"D\8G(^26X@5&AO=7-A;F1S+"!E>&-E<'0@4&5R(%-H M87)E(&1A=&$L('5N;&5S<R!O=&AE<G=I<V4@<W!E8VEF:65D/"]S=')O;F<^ M/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@@8V]L<W!A;CTS1#,^,3(@ M36]N=&AS($5N9&5D/"]T:#X-"B`@("`@(#PO='(^#0H@("`@("`\='(^#0H@ M("`@("`@(#QT:"!C;&%S<STS1'1H/D1E8RX@,S$L(#(P,30\8G(^/"]T:#X- M"B`@("`@("`@/'1H(&-L87-S/3-$=&@^1&5C+B`S,2P@,C`Q,SQB<CX\+W1H M/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y$96,N(#,Q+"`R,#$R/&)R/CPO M=&@^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@ M("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#X\<W1R;VYG/E)E=F5N M=65S.CPO<W1R;VYG/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L M87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O M<#Y297-E87)C:"!A;F0@9&5V96QO<&UE;G0@<F5V96YU97,@9G)O;2!R96QA M=&5D('!A<G1I97,\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B0@ M,3DL-3,X/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS M1&YU;7`^)"`R+#`Q.3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@ M8VQA<W,],T1N=6UP/B0@-"PQ-S<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@ M(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L M87-S/3-$<&P@=F%L:6=N/3-$=&]P/E)E<V5A<F-H(&%N9"!D979E;&]P;65N M="P@9W)A;G0@86YD(&]T:&5R(')E=F5N=65S/"]T9#X-"B`@("`@("`@/'1D M(&-L87-S/3-$;G5M<#XQ-RPU-C8\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@ M("`@/'1D(&-L87-S/3-$;G5M<#XW+#4T-SQS<&%N/CPO<W!A;CX\+W1D/@T* M("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C,L,S@R/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@ M("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y,:6-E;G-E(')E=F5N M=65S(&9R;VT@<F5L871E9"!P87)T:65S/"]T9#X-"B`@("`@("`@/'1D(&-L M87-S/3-$;G5M<#XP/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S<STS1&YU;7`^,3<L,C,P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S<STS1&YU;7`^,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@ M/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA M<W,],T1P;"!V86QI9VX],T1T;W`^3&EC96YS92!R979E;G5E<SPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S<STS1&YU;7`^.2PX,S8\<W!A;CX\+W-P86X^/"]T M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XS+#@U,CQS<&%N/CPO<W!A M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C`\<W!A;CX\+W-P M86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;W4^ M#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y4;W1A;"!R M979E;G5E<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-#8L.30P M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^ M,S`L-C0X/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS M1&YU;7`^-RPU-3D\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@ M("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@ M=F%L:6=N/3-$=&]P/CQS=')O;F<^3W!E<F%T:6YG(&5X<&5N<V5S.CPO<W1R M;VYG/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^ M#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y297-E87)C M:"!A;F0@9&5V96QO<&UE;G0\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N M=6UP/C0T+#0R-CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA M<W,],T1N=6UP/C0Y+#0U,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\ M=&0@8VQA<W,],T1N=6UP/C,U+#8T,SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@ M("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@ M8VQA<W,],T1P;"!V86QI9VX],T1T;W`^1V5N97)A;"!A;F0@861M:6YI<W1R M871I=F4\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$W+#(V.#QS M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$U M+#`Y,CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N M=6UP/C$R+#0R.3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@ M("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V M86QI9VX],T1T;W`^4F5S=')U8W1U<FEN9R!R979E<G-A;',\+W1D/@T*("`@ M("`@("`\=&0@8VQA<W,],T1N=6UP/C`\<W!A;CX\+W-P86X^/"]T9#X-"B`@ M("`@("`@/'1D(&-L87-S/3-$;G5M<#XP/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S<STS1&YU;3XH-38I/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F5U/@T*("`@("`@ M("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^5&]T86P@;W!E<F%T:6YG M(&5X<&5N<V5S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XV,2PV M.30\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M M<#XV-"PU-#(\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S M/3-$;G5M<#XT."PP,38\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^ M#0H@("`@("`\='(@8VQA<W,],T1R;W4^#0H@("`@("`@(#QT9"!C;&%S<STS M1'!L('9A;&EG;CTS1'1O<#Y/<&5R871I;F<@;&]S<SPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S<STS1&YU;3XH,30L-S4T*3QS<&%N/CPO<W!A;CX\+W1D/@T* M("`@("`@("`\=&0@8VQA<W,],T1N=6T^*#,S+#@Y-"D\<W!A;CX\+W-P86X^ M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B@T,"PT-3<I/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$ M<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y);G1E M<F5S="!A;F0@;W1H97(L(&YE=#PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS M1&YU;7`^,3`X/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M<STS1&YU;7`^,3<W/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S<STS1&YU;7`^.#<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^ M#0H@("`@("`\='(@8VQA<W,],T1R;W4^#0H@("`@("`@(#QT9"!C;&%S<STS M1'!L('9A;&EG;CTS1'1O<#Y,;W-S(&)E9F]R92!I;F-O;64@=&%X97,\+W1D M/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6T^*#$T+#8T-BD\<W!A;CX\+W-P M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B@S,RPW,3<I/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;3XH-#`L M,S<P*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT M<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX] M,T1T;W`^26YC;VUE('1A>"!B96YE9FET/"]T9#X-"B`@("`@("`@/'1D(&-L M87-S/3-$;G5M<#XP/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S<STS1&YU;7`^,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@ M8VQA<W,],T1N=6UP/C`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^ M#0H@("`@("`\='(@8VQA<W,],T1R;W4^#0H@("`@("`@(#QT9"!C;&%S<STS M1'!L('9A;&EG;CTS1'1O<#Y.970@;&]S<SPO=&0^#0H@("`@("`@(#QT9"!C M;&%S<STS1&YU;3XH,30L-C0V*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@ M("`\=&0@8VQA<W,],T1N=6T^*#,S+#<Q-RD\<W!A;CX\+W-P86X^/"]T9#X- M"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B@T,"PS-S`I/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@ M("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y$965M960@9&EV M:61E;F0@<F5L871E9"!T;R!B96YE9FEC:6%L(&-O;G9E<G-I;VX@9F5A='5R M92!O9B!C;VYV97)T:6)L92!P<F5F97)R960@<W1O8VL\+W1D/@T*("`@("`@ M("`\=&0@8VQA<W,],T1N=6UP/C`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@ M("`@/'1D(&-L87-S/3-$;G5M<#XP/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S<STS1&YU;3XH,2PS,#<I/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@ M(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y.970@;&]S<R!A;&QO8V%B M;&4@=&\@8V]M;6]N('-T;V-K:&]L9&5R<SPO=&0^#0H@("`@("`@(#QT9"!C M;&%S<STS1&YU;3XH,30L-C0V*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@ M("`\=&0@8VQA<W,],T1N=6T^*#,S+#<Q-RD\<W!A;CX\+W-P86X^/"]T9#X- M"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B@T,2PV-S<I/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@ M("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y.970@;&]S<R!P M97(@<VAA<F4@86QL;V-A8FQE('1O(&-O;6UO;B!S=&]C:VAO;&1E<G,@+2!B M87-I8R!A;F0@9&EL=71E9#PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU M;3XD("@P+C0Q*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA M<W,],T1N=6T^)"`H,2XR-"D\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@ M/'1D(&-L87-S/3-$;G5M/B0@*#(N,RD\<W!A;CX\+W-P86X^/"]T9#X-"B`@ M("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D M(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E=E:6=H=&5D+6%V97)A9V4@;G5M M8F5R(&]F('-H87)E<R!U<V5D(&EN(&-O;7!U=&EN9R!N970@;&]S<R!P97(@ M<VAA<F4@86QL;V-A8FQE('1O(&-O;6UO;B!S=&]C:VAO;&1E<G,@+2!B87-I M8R!A;F0@9&EL=71E9#PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^ M,S4L-S`Y/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS M1&YU;7`^,C<L,C<U/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S<STS1&YU;7`^,3@L,3`W/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\ M+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S M<STS1'!L('9A;&EG;CTS1'1O<#X\<W1R;VYG/D]T:&5R(&-O;7!R96AE;G-I M=F4@9V%I;B`H;&]S<RDZ/"]S=')O;F<^/"]T9#X-"B`@("`@("`@/'1D(&-L M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@ M("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@ M=F%L:6=N/3-$=&]P/E5N<F5A;&EZ960@9V%I;G,@*&QO<W-E<RD@;VX@879A M:6QA8FQE+69O<BUS86QE('-E8W5R:71I97,L(&YE=#PO=&0^#0H@("`@("`@ M(#QT9"!C;&%S<STS1&YU;3XH,3$I/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S<STS1&YU;3XH,3$I/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,34\<W!A;CX\+W-P86X^/"]T9#X- M"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R974^#0H@("`@("`@ M(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y#;VUP<F5H96YS:79E(&QO M<W,\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6T^)"`H,30L-C4W*3QS M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6T^)"`H M,S,L-S(X*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,] M,T1N=6T^)"`H-#`L,S4U*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T M<CX-"B`@("`\+W1A8FQE/@T*("`\+V)O9'D^#0H\+VAT;6P^#0H-"BTM+2TM M+3U?3F5X=%!A<G1?,SEC,&5A-C)?8S(P,U\T-3AF7SAC-3!?,V1C830U-F$V M.34Q#0I#;VYT96YT+4QO8V%T:6]N.B!F:6QE.B\O+T,Z+S,Y8S!E838R7V,R M,#-?-#4X9E\X8S4P7S-D8V$T-39A-CDU,2]7;W)K<VAE971S+U-H965T,#4N M:'1M;`T*0V]N=&5N="U4<F%N<V9E<BU%;F-O9&EN9SH@<75O=&5D+7!R:6YT M86)L90T*0V]N=&5N="U4>7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S M8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I M=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA<G-E M=#UU=&8M."<^/'-C<FEP="!T>7!E/3-$=&5X="]J879A<V-R:7!T('-R8STS M1%-H;W<N:G,^+RH@1&\@3F]T(%)E;6]V92!4:&ES($-O;6UE;G0@*B\\+W-C M<FEP=#X\+VAE860^#0H@(#QB;V1Y/@T*("`@(#QT86)L92!C;&%S<STS1')E M<&]R="!I9#TS1$E$,$5%1$=-/@T*("`@("`@/'1R/@T*("`@("`@("`\=&@@ M8VQA<W,],T1T;"!C;VQS<&%N/3-$,2!R;W=S<&%N/3-$,3X\<W1R;VYG/D-O M;G-O;&ED871E9"!3=&%T96UE;G1S(&]F(%-T;V-K:&]L9&5R<R<@17%U:71Y M("A54T0@)"D\8G(^26X@5&AO=7-A;F1S+"!E>&-E<'0@4VAA<F4@9&%T83PO M<W1R;VYG/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/E1O=&%L/&)R M/E531"`H)"D\8G(^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^34Q6 M(%M-96UB97)=/&)R/E531"`H)"D\8G(^/"]T:#X-"B`@("`@("`@/'1H(&-L M87-S/3-$=&@^0V]M;6]N(%-T;V-K(%M-96UB97)=/&)R/E531"`H)"D\8G(^ M/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^0V]M;6]N(%-T;V-K(%M- M96UB97)=/&)R/DU,5B!;365M8F5R73QB<CY54T0@*"0I/&)R/CPO=&@^#0H@ M("`@("`@(#QT:"!C;&%S<STS1'1H/D-O;6UO;B!3=&]C:R!;365M8F5R73QB M<CY397)I97,@02!#;VYV97)T:6)L92!0<F5F97)R960@4W1O8VL@6TUE;6)E M<ET\8G(^55-$("@D*3QB<CX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T M:#Y#;VUM;VX@4W1O8VL@6TUE;6)E<ET\8G(^4V5R:65S($(@0V]N=F5R=&EB M;&4@4')E9F5R<F5D(%-T;V-K(%M-96UB97)=/&)R/E531"`H)"D\8G(^/"]T M:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^4')E9F5R<F5D(%-T;V-K(%M- M96UB97)=/&)R/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/E!R969E M<G)E9"!3=&]C:R!;365M8F5R73QB<CY397)I97,@02!#;VYV97)T:6)L92!0 M<F5F97)R960@4W1O8VL@6TUE;6)E<ET\8G(^/"]T:#X-"B`@("`@("`@/'1H M(&-L87-S/3-$=&@^4')E9F5R<F5D(%-T;V-K(%M-96UB97)=/&)R/E-E<FEE M<R!"($-O;G9E<G1I8FQE(%!R969E<G)E9"!3=&]C:R!;365M8F5R73QB<CX\ M+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y!9&1I=&EO;F%L(%!A:60M M26X@0V%P:71A;"!;365M8F5R73QB<CY54T0@*"0I/&)R/CPO=&@^#0H@("`@ M("`@(#QT:"!C;&%S<STS1'1H/D%D9&ET:6]N86P@4&%I9"U);B!#87!I=&%L M(%M-96UB97)=/&)R/DU,5B!;365M8F5R73QB<CY54T0@*"0I/&)R/CPO=&@^ M#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/D%D9&ET:6]N86P@4&%I9"U);B!# M87!I=&%L(%M-96UB97)=/&)R/E-E<FEE<R!!($-O;G9E<G1I8FQE(%!R969E M<G)E9"!3=&]C:R!;365M8F5R73QB<CY54T0@*"0I/&)R/CPO=&@^#0H@("`@ M("`@(#QT:"!C;&%S<STS1'1H/D%D9&ET:6]N86P@4&%I9"U);B!#87!I=&%L M(%M-96UB97)=/&)R/E-E<FEE<R!"($-O;G9E<G1I8FQE(%!R969E<G)E9"!3 M=&]C:R!;365M8F5R73QB<CY54T0@*"0I/&)R/CPO=&@^#0H@("`@("`@(#QT M:"!C;&%S<STS1'1H/D%C8W5M=6QA=&5D($]T:&5R($-O;7!R96AE;G-I=F4@ M26YC;VUE("A,;W-S*2!;365M8F5R73QB<CY54T0@*"0I/&)R/CPO=&@^#0H@ M("`@("`@(#QT:"!C;&%S<STS1'1H/D%C8W5M=6QA=&5D($1E9FEC:70@6TUE M;6)E<ET\8G(^55-$("@D*3QB<CX\+W1H/@T*("`@("`@/"]T<CX-"B`@("`@ M(#QT<B!C;&%S<STS1')C/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI M9VX],T1T;W`^0F5G:6YN:6YG($)A;&%N8V4@870@1&5C+B`S,2P@,C`Q,3PO M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^)"`T."PQ-S@\<W!A;CX\ M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\ M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XD(#$S/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^)"`T M-38L-C<R/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS M1&YU;7`^)"`S/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M<STS1&YU;3XD("@T,#@L-3$P*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@ M/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')C/@T*("`@("`@("`\=&0@8VQA M<W,],T1P;"!V86QI9VX],T1T;W`^0F5G:6YN:6YG($)A;&%N8V4L('-H87)E M<R!A="!$96,N(#,Q+"`R,#$Q/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$ M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$ M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$ M;G5M<#XQ,BPT.#4L.34W/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S<STS1&YU;7`^."PP-S`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@ M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@ M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@ M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@ M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@ M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@ M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@ M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@ M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@ M(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L M87-S/3-$<&P@=F%L:6=N/3-$=&]P/DES<W5A;F-E(&]F(&-O;6UO;B!S=&]C M:R!P=7)S=6%N="!T;R!%4U!0(&%T(&$@=V5I9VAT960@<')I8V4@;V8@)#0N M,S(L("0S+C8V(&%N9"`D,RXS."!P97(@<VAA<F4@:6X@,C`Q,BP@,C`Q,R!A M;F0@,C`Q-"!R97-P96-T:79E;'D\+W1D/@T*("`@("`@("`\=&0@8VQA<W,] M,T1N=6UP/C8U/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M<STS1&YU;7`^-C4\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@ M("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@ M=F%L:6=N/3-$=&]P/DES<W5A;F-E(&]F(&-O;6UO;B!S=&]C:R!P=7)S=6%N M="!T;R!%4U!0+"!S:&%R97,\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N M=6UP/C$U+#`Q,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@ M("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V M86QI9VX],T1T;W`^27-S=6%N8V4@;V8@8V]M;6]N('-T;V-K('5P;VX@97AE M<F-I<V4@;V8@<F5S=')I8W1E9"!S=&]C:R!U;FET<RP@=F%L=64\+W1D/@T* M("`@("`@("`\=&0@8VQA<W,],T1N=6T^*#0P,2D\<W!A;CX\+W-P86X^/"]T M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B@T,#$I/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@ M("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y)<W-U86YC92!O M9B!C;VUM;VX@<W1O8VL@=7!O;B!E>&5R8VES92!O9B!R97-T<FEC=&5D('-T M;V-K('5N:71S+"!S:&%R97,\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N M=6UP/C$T-"PP-#4\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@ M("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@ M=F%L:6=N/3-$=&]P/DES<W5A;F-E(&]F(&-O;6UO;B!S=&]C:R!T;R!-3%8@ M870@)#8N,S`M)#<N,C`L("0V+C4P+20V+C<Y(&%N9"`D-BXV-"TD-BXW.2!P M97(@<VAA<F4L(&YE="!O9B!C;VUM:7-S:6]N(&%N9"!I<W-U86YC92!C;W-T M<R!O9B`D.#DL("0R,S(@86YD("0W-#PO=&0^#0H@("`@("`@(#QT9"!C;&%S M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M<STS1&YU;7`^,BPX,C`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D M(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D M(&-L87-S/3-$;G5M<#XQ/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S<STS1&YU;7`^,BPX,3D\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@ M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@ M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@ M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@ M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@ M(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L M87-S/3-$<&P@=F%L:6=N/3-$=&]P/D-O;G9E<G-I;VX@;V8@<')E9F5R<F5D M('-T;V-K('1O(&-O;6UO;B!S=&]C:RP@=F%L=64\+W1D/@T*("`@("`@("`\ M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\ M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\ M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\ M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\ M=&0@8VQA<W,],T1N=6UP/C$\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@ M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@ M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@ M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@ M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@ M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@ M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@ M/'1D(&-L87-S/3-$;G5M/B@Q*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@ M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@ M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@ M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@ M/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA M<W,],T1P;"!V86QI9VX],T1T;W`^27-S=6%N8V4@;V8@8V]M;6]N('-T;V-K M('1O($U,5BP@<VAA<F5S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M M<#XT,S(L-S(T/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@ M("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A M;&EG;CTS1'1O<#Y#;VYV97)S:6]N(&]F(&-O;G9E<G1I8FQE('!R969E<G)E M9"!S=&]C:R!T;R!C;VUM;VX@<W1O8VL@870@)#$L,#`P('!E<B!S:&%R93PO M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,2PS-#4L,#`P/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;3XH."PP-S`I M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L M87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O M<#Y)<W-U86YC92!O9B!C;VUM;VX@<W1O8VL@<'5R<W5A;G0@=&\@2G5N92`R M,#$R(&%N9"!&96)R=6%R>2`R,#$T('!U8FQI8R!O9F9E<FEN9W,@870@)#0N M-38@86YD("0X+C`P('!E<B!S:&%R92P@;F5T(&]F(&ES<W5A;F-E(&-O<W1S M(&]F("0R+#$S.2!A;F0@)#(L.#`P(')E<W!E8W1I=F5L>3PO=&0^#0H@("`@ M("`@(#QT9"!C;&%S<STS1&YU;7`^,CDL.3$V/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^.3QS<&%N/CPO<W!A;CX\+W1D M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D M/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C(Y+#DP-SQS<&%N/CPO<W!A M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A M;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T* M("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^27-S=6%N8V4@ M;V8@8V]M;6]N('-T;V-K+"!S:&%R97,\+W1D/@T*("`@("`@("`\=&0@8VQA M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA M<W,],T1N=6UP/CDL,S(P+#$W-CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@ M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@ M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@ M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@ M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@ M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@ M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@ M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@ M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@ M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@ M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@ M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@ M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@ M/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA M<W,],T1P;"!V86QI9VX],T1T;W`^27-S=6%N8V4@;V8@4V5R:65S($(@8V]N M=F5R=&EB;&4@<')E9F5R<F5D('-T;V-K('!U<G-U86YT('1O($IU;F4@,C`Q M,B!P=6)L:6,@;V9F97)I;F=S(&%T("0W-C`@<&5R('-H87)E+"!N970@;V8@ M:7-S=6%N8V4@8V]S=',@;V8@)#@X,3PO=&0^#0H@("`@("`@(#QT9"!C;&%S M<STS1&YU;7`^,3(L,S$X/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S<STS1&YU;7`^,3(L,S$X/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C M;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y)<W-U86YC92!O9B!C;VYV97)T:6)L M92!P<F5F97)R960@<W1O8VLL('-H87)E<SPO=&0^#0H@("`@("`@(#QT9"!C M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S<STS1&YU;7`^,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@ M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@ M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@ M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@ M8VQA<W,],T1N=6UP/C(S+#`R-CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@ M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@ M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@ M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@ M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@ M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@ M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@ M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@ M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@ M/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA M<W,],T1P;"!V86QI9VX],T1T;W`^27-S=6%N8V4@;V8@=V%R<F%N=',@<'5R M<W5A;G0@=&\@2G5N92`R,#$R('!U8FQI8R!O9F9E<FEN9W,L(&YE="!O9B!I M<W-U86YC92!C;W-T<R!O9B`D.3@T/"]T9#X-"B`@("`@("`@/'1D(&-L87-S M/3-$;G5M<#XQ,RPW-C$\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D M(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D M(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D M(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D M(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D M(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D M(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D M(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D M(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D M(&-L87-S/3-$;G5M<#XQ,RPW-C$\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@ M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@ M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@ M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@ M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@ M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@ M(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L M87-S/3-$<&P@=F%L:6=N/3-$=&]P/E-T;V-K+6)A<V5D(&-O;7!E;G-A=&EO M;CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,RPW.#,\<W!A;CX\ M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\ M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\ M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\ M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\ M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\ M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\ M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\ M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\ M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XS+#<X,SQS M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S M<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^ M3W1H97(@8V]M<')E:&5N<VEV92!I;F-O;64@*&QO<W,I/"]T9#X-"B`@("`@ M("`@/'1D(&-L87-S/3-$;G5M<#XQ-3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@ M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@ M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@ M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@ M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@ M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@ M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@ M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@ M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@ M("`@("`\=&0@8VQA<W,],T1N=6UP/C`\<W!A;CX\+W-P86X^/"]T9#X-"B`@ M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@ M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@ M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@ M("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ-3QS<&%N/CPO<W!A;CX\+W1D/@T* M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T* M("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\ M=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^3F5T(&QO<W,\+W1D/@T*("`@ M("`@("`\=&0@8VQA<W,],T1N=6T^*#0P+#,W,"D\<W!A;CX\+W-P86X^/"]T M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XP/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;3XH-#`L,S<P*3QS<&%N/CPO M<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')C M/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^16YD:6YG M($)A;&%N8V4@870@1&5C+B`S,2P@,C`Q,CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S<STS1&YU;7`^-S`L,#@U/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S<STS1&YU;7`^,C0\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@ M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@ M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@ M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@ M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@ M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@ M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@ M("`@/'1D(&-L87-S/3-$;G5M<#XU,3@L.3(S/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,3@\<W!A;CX\+W-P86X^/"]T M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B@T-#@L.#@P*3QS<&%N/CPO M<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')C M/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^16YD:6YG M($)A;&%N8V4L('-H87)E<R!A="!$96,N(#,Q+"`R,#$R/"]T9#X-"B`@("`@ M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@ M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@ M("`@/'1D(&-L87-S/3-$;G5M<#XR,RPW-#(L.3$R/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,C,L,#(V/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^ M#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y)<W-U86YC M92!O9B!C;VUM;VX@<W1O8VL@=7!O;B!E>&5R8VES92!O9B!S=&]C:R!O<'1I M;VYS(&9O<B!C87-H(&%T("0T+C`R+20Q,2XQ,"!A;F0@)#8N,#`@<&5R('-H M87)E(&EN(#(P,3,@86YD(#(P,30@<F5S<&5C=&EV96QY/"]T9#X-"B`@("`@ M("`@/'1D(&-L87-S/3-$;G5M<#XQ,30\<W!A;CX\+W-P86X^/"]T9#X-"B`@ M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@ M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@ M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@ M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@ M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@ M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@ M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@ M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@ M("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ,30\<W!A;CX\+W-P86X^/"]T9#X- M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X- M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X- M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X- M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X- M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X- M"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@ M/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/DES<W5A;F-E(&]F(&-O;6UO M;B!S=&]C:R!U<&]N(&5X97)C:7-E(&]F('-T;V-K(&]P=&EO;G,@9F]R(&-A M<V@L('-H87)E<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,C$L M,SDW/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R M(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS M1'1O<#Y)<W-U86YC92!O9B!C;VUM;VX@<W1O8VL@<'5R<W5A;G0@=&\@15-0 M4"!A="!A('=E:6=H=&5D('!R:6-E(&]F("0T+C,R+"`D,RXV-B!A;F0@)#,N M,S@@<&5R('-H87)E(&EN(#(P,3(L(#(P,3,@86YD(#(P,30@<F5S<&5C=&EV M96QY/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XU-3QS<&%N/CPO M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C4U/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$ M<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y)<W-U M86YC92!O9B!C;VUM;VX@<W1O8VL@<'5R<W5A;G0@=&\@15-04"P@<VAA<F5S M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^ M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^ M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ-"PY.#4\<W!A;CX\ M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\ M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\ M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\ M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XP/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$ M<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y)<W-U M86YC92!O9B!C;VUM;VX@<W1O8VL@=7!O;B!E>&5R8VES92!O9B!R97-T<FEC M=&5D('-T;V-K('5N:71S+"!V86QU93PO=&0^#0H@("`@("`@(#QT9"!C;&%S M<STS1&YU;3XH-C(S*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@ M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@ M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@ M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@ M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@ M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@ M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@ M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@ M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@ M8VQA<W,],T1N=6T^*#8R,RD\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@ M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@ M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@ M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@ M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@ M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO M='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S M/3-$<&P@=F%L:6=N/3-$=&]P/DES<W5A;F-E(&]F(&-O;6UO;B!S=&]C:R!U M<&]N(&5X97)C:7-E(&]F(')E<W1R:6-T960@<W1O8VL@=6YI=',L('-H87)E M<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,3,P+#4S-#QS<&%N M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C`\<W!A M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A M;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,] M,T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/DES M<W5A;F-E(&]F(&-O;6UO;B!S=&]C:R!T;R!R96QA=&5D('!A<G1Y(&9O<B`D M-RXQ,B!P97(@<VAA<F4L(&YE="!O9B!I<W-U86YC92!C;W-T<R!O9B`D,C$\ M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C<L-#4P/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,CQS<&%N/CPO M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C<L-#0X/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S M/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y) M<W-U86YC92!O9B!C;VUM;VX@<W1O8VL@=&\@<F5L871E9"!P87)T>2P@<VAA M<F5S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ+#0P-"PQ,#`\ M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\ M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\ M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\ M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XP M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L M87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O M<#Y)<W-U86YC92!O9B!C;VUM;VX@<W1O8VL@=7!O;B!E>&5R8VES92!O9B!W M87)R86YT<RP@=F%L=64\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP M/C4\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M M<#XU/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R M(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS M1'1O<#Y)<W-U86YC92!O9B!C;VUM;VX@<W1O8VL@=7!O;B!E>&5R8VES92!O M9B!W87)R86YT<RP@<VAA<F5S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$ M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$ M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$ M;G5M<#XS-3DL-#8P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S<STS1&YU;7`^,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@ M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@ M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@ M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@ M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@ M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@ M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@ M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@ M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX- M"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P M;"!V86QI9VX],T1T;W`^27-S=6%N8V4@;V8@8V]M;6]N('-T;V-K('1O($U, M5B!A="`D-BXS,"TD-RXR,"P@)#8N-3`M)#8N-SD@86YD("0V+C8T+20V+C<Y M('!E<B!S:&%R92P@;F5T(&]F(&-O;6UI<W-I;VX@86YD(&ES<W5A;F-E(&-O M<W1S(&]F("0X.2P@)#(S,B!A;F0@)#<T/"]T9#X-"B`@("`@("`@/'1D(&-L M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L M87-S/3-$;G5M<#XW+#0X-SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\ M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\ M=&0@8VQA<W,],T1N=6UP/C$\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@ M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@ M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@ M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@ M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@ M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@ M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@ M/'1D(&-L87-S/3-$;G5M<#XW+#0X-CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@ M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@ M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@ M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@ M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@ M("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@ M8VQA<W,],T1P;"!V86QI9VX],T1T;W`^0V]N=F5R<VEO;B!O9B!P<F5F97)R M960@<W1O8VL@=&\@8V]M;6]N('-T;V-K+"!V86QU93PO=&0^#0H@("`@("`@ M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S<STS1&YU;7`^-#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@ M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@ M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@ M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@ M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@ M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@ M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@ M("`\=&0@8VQA<W,],T1N=6T^*#0I/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C M;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y)<W-U86YC92!O9B!C;VUM;VX@<W1O M8VL@=&\@34Q6+"!S:&%R97,\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N M=6UP/C$L,3<P+#4X,SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@ M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@ M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@ M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@ M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@ M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@ M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@ M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@ M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@ M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@ M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@ M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX- M"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P M;"!V86QI9VX],T1T;W`^0V]N=F5R<VEO;B!O9B!C;VYV97)T:6)L92!P<F5F M97)R960@<W1O8VL@=&\@8V]M;6]N('-T;V-K(&%T("0Q+#`P,"!P97(@<VAA M<F4\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C,L.#,W+#8X,3QS M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6T^*#(S M+#`R-BD\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$ M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$ M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$ M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$ M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$ M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$ M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\ M='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N M/3-$=&]P/D9R86-T:6]N86P@<VAA<F5S('-E='1L96UE;G0@<'5R<W5A;G0@ M=&\@<F5V97)S92!S=&]C:R!S<&QI=#PO=&0^#0H@("`@("`@(#QT9"!C;&%S M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M<STS1&YU;3XH,C@I/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T* M("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L M('9A;&EG;CTS1'1O<#Y3=&]C:RUB87-E9"!C;VUP96YS871I;VX\+W1D/@T* M("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C,L-3DW/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,RPU.3<\<W!A;CX\+W-P M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P M86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X- M"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D]T:&5R(&-O M;7!R96AE;G-I=F4@:6YC;VUE("AL;W-S*3PO=&0^#0H@("`@("`@(#QT9"!C M;&%S<STS1&YU;3XH,3$I/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S<STS1&YU;3XH,3$I/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\ M+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S M<STS1'!L('9A;&EG;CTS1'1O<#Y.970@;&]S<SPO=&0^#0H@("`@("`@(#QT M9"!C;&%S<STS1&YU;3XH,S,L-S$W*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@ M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@ M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@ M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@ M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@ M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@ M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@ M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@ M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@ M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@ M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@ M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@ M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@ M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@ M("`@("`\=&0@8VQA<W,],T1N=6T^*#,S+#<Q-RD\<W!A;CX\+W-P86X^/"]T M9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R8SX-"B`@("`@ M("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D5N9&EN9R!"86QA;F-E M(&%T($1E8RX@,S$L(#(P,3,\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N M=6UP/C4T+#0T,CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA M<W,],T1N=6UP/C,Q/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S<STS1&YU;7`^-3,W+#`P,3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@ M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@ M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@ M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@ M("`\=&0@8VQA<W,],T1N=6UP/C<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@ M("`@/'1D(&-L87-S/3-$;G5M/B@T.#(L-3DW*3QS<&%N/CPO<W!A;CX\+W1D M/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')C/@T*("`@("`@ M("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^16YD:6YG($)A;&%N8V4L M('-H87)E<R!A="!$96,N(#,Q+"`R,#$S/"]T9#X-"B`@("`@("`@/'1D(&-L M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L M87-S/3-$;G5M<#XS,"PV.#$L-C(T/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C M;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y)<W-U86YC92!O9B!C;VUM;VX@<W1O M8VL@=7!O;B!E>&5R8VES92!O9B!S=&]C:R!O<'1I;VYS(&9O<B!C87-H(&%T M("0T+C`R+20Q,2XQ,"!A;F0@)#8N,#`@<&5R('-H87)E(&EN(#(P,3,@86YD M(#(P,30@<F5S<&5C=&EV96QY/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$ M;G5M<#XR/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS M1&YU;7`^,CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,] M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,] M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,] M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,] M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,] M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@ M(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI M9VX],T1T;W`^27-S=6%N8V4@;V8@8V]M;6]N('-T;V-K('5P;VX@97AE<F-I M<V4@;V8@<W1O8VL@;W!T:6]N<R!F;W(@8V%S:"P@<VAA<F5S/"]T9#X-"B`@ M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@ M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@ M("`@("`@/'1D(&-L87-S/3-$;G5M<#XS.3`\<W!A;CX\+W-P86X^/"]T9#X- M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X- M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X- M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X- M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X- M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X- M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X- M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X- M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X- M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X- M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X- M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X- M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X- M"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@ M/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/DES<W5A;F-E(&]F(&-O;6UO M;B!S=&]C:R!P=7)S=6%N="!T;R!%4U!0(&%T(&$@=V5I9VAT960@<')I8V4@ M;V8@)#0N,S(L("0S+C8V(&%N9"`D,RXS."!P97(@<VAA<F4@:6X@,C`Q,BP@ M,C`Q,R!A;F0@,C`Q-"!R97-P96-T:79E;'D\+W1D/@T*("`@("`@("`\=&0@ M8VQA<W,],T1N=6UP/C8W/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S<STS1&YU;7`^-C<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@ M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@ M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@ M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@ M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@ M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO M='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S M/3-$<&P@=F%L:6=N/3-$=&]P/DES<W5A;F-E(&]F(&-O;6UO;B!S=&]C:R!P M=7)S=6%N="!T;R!%4U!0+"!S:&%R97,\+W1D/@T*("`@("`@("`\=&0@8VQA M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA M<W,],T1N=6UP/C$Y+#<R-CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\ M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\ M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\ M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\ M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\ M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\ M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\ M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\ M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\ M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\ M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\ M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\ M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T M<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,] M,T1P;"!V86QI9VX],T1T;W`^27-S=6%N8V4@;V8@8V]M;6]N('-T;V-K('5P M;VX@97AE<F-I<V4@;V8@<F5S=')I8W1E9"!S=&]C:R!U;FET<RP@=F%L=64\ M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6T^*#DV*3QS<&%N/CPO<W!A M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6T^*#DV*3QS<&%N/CPO M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO M<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O M/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^27-S=6%N M8V4@;V8@8V]M;6]N('-T;V-K('5P;VX@97AE<F-I<V4@;V8@<F5S=')I8W1E M9"!S=&]C:R!U;FET<RP@<VAA<F5S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S M/3-$;G5M<#XQ,2PW,#0\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D M(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D M(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D M(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D M(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D M(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D M(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D M(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D M(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D M(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D M(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D M(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D M(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^ M#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$ M<&P@=F%L:6=N/3-$=&]P/DES<W5A;F-E(&]F(&-O;6UO;B!S=&]C:R!U<&]N M(&5X97)C:7-E(&]F('=A<G)A;G1S+"!V86QU93PO=&0^#0H@("`@("`@(#QT M9"!C;&%S<STS1&YU;7`^-CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\ M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\ M=&0@8VQA<W,],T1N=6UP/C$\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@ M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@ M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@ M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@ M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@ M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@ M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@ M/'1D(&-L87-S/3-$;G5M<#XU/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\ M+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S M<STS1'!L('9A;&EG;CTS1'1O<#Y)<W-U86YC92!O9B!C;VUM;VX@<W1O8VL@ M=7!O;B!E>&5R8VES92!O9B!W87)R86YT<RP@<VAA<F5S/"]T9#X-"B`@("`@ M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@ M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@ M("`@/'1D(&-L87-S/3-$;G5M<#XU,3`L,3(U/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@ M(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y)<W-U86YC92!O9B!C;VUM M;VX@<W1O8VL@=&\@34Q6(&%T("0V+C,P+20W+C(P+"`D-BXU,"TD-BXW.2!A M;F0@)#8N-C0M)#8N-SD@<&5R('-H87)E+"!N970@;V8@8V]M;6ES<VEO;B!A M;F0@:7-S=6%N8V4@8V]S=',@;V8@)#@Y+"`D,C,R(&%N9"`D-S0\+W1D/@T* M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T* M("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C(L,S<V/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,BPS-S8\<W!A;CX\+W-P M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P M86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX- M"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/DES<W5A;F-E M(&]F(&-O;6UO;B!S=&]C:R!T;R!-3%8L('-H87)E<SPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S<STS1&YU;7`^,S8T+#$P,SQS<&%N/CPO<W!A;CX\+W1D/@T* M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T* M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T* M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T* M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T* M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T* M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T* M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T* M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T* M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T* M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T* M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T* M("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\ M=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^27-S=6%N8V4@;V8@8V]M;6]N M('-T;V-K('1O(&-O;&QA8F]R871I=F4@<&%R=&YE<B!F;W(@)#0N.3`@<&5R M('-H87)E+"!N970@;V8@:7-S=6%N8V4@8V]S=',@;V8@)#@\+W1D/@T*("`@ M("`@("`\=&0@8VQA<W,],T1N=6UP/CDL,3`R/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,CQS<&%N/CPO<W!A;CX\+W1D M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D M/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/CDL,3`P/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@ M("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y&<F%C=&EO;F%L M('-H87)E<R!S971T;&5M96YT('!U<G-U86YT('1O(')E=F5R<V4@<W1O8VL@ M<W!L:70\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C`\<W!A;CX\ M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\ M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\ M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\ M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\ M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\ M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\ M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\ M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\ M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\ M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\ M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\ M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\ M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\ M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\ M+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R M93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/DES<W5A M;F-E(&]F(&-O;6UO;B!S=&]C:R!T;R!C;VQL86)O<F%T:79E('!A<G1N97(L M('-H87)E<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,BPP-#`L M.#$V/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R M(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS M1'1O<#Y)<W-U86YC92!O9B!C;VUM;VX@<W1O8VL@<'5R<W5A;G0@=&\@2G5N M92`R,#$R(&%N9"!&96)R=6%R>2`R,#$T('!U8FQI8R!O9F9E<FEN9W,@870@ M)#0N-38@86YD("0X+C`P('!E<B!S:&%R92P@;F5T(&]F(&ES<W5A;F-E(&-O M<W1S(&]F("0R+#$S.2!A;F0@)#(L.#`P(')E<W!E8W1I=F5L>3PO=&0^#0H@ M("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,S<L-#DR/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-3QS<&%N/CPO<W!A;CX\ M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\ M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\ M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\ M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\ M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\ M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\ M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C,W+#0X-SQS<&%N/CPO M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO M<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E M/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^27-S=6%N M8V4@;V8@8V]M;6]N('-T;V-K+"!S:&%R97,\+W1D/@T*("`@("`@("`\=&0@ M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@ M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@ M8VQA<W,],T1N=6UP/C4L,#,Q+#(U,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@ M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@ M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@ M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@ M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@ M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@ M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@ M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@ M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@ M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@ M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@ M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@ M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@ M("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@ M8VQA<W,],T1P;"!V86QI9VX],T1T;W`^4W1O8VLM8F%S960@8V]M<&5N<V%T M:6]N/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XS+#,S,#QS<&%N M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C,L,S,P M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L M87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O M<#Y/=&AE<B!C;VUP<F5H96YS:79E(&EN8V]M92`H;&]S<RD\+W1D/@T*("`@ M("`@("`\=&0@8VQA<W,],T1N=6T^*#$Q*3QS<&%N/CPO<W!A;CX\+W1D/@T* M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T* M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T* M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T* M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T* M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T* M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T* M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T* M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T* M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T* M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T* M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T* M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T* M("`@("`@("`\=&0@8VQA<W,],T1N=6T^*#$Q*3QS<&%N/CPO<W!A;CX\+W1D M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D M/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@ M("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^3F5T(&QO<W,\+W1D/@T* M("`@("`@("`\=&0@8VQA<W,],T1N=6T^*#$T+#8T-BD\<W!A;CX\+W-P86X^ M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^ M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^ M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^ M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^ M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^ M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^ M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^ M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^ M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^ M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^ M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^ M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^ M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^ M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B@Q-"PV-#8I/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$ M<F,^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y%;F1I M;F<@0F%L86YC92!A="!$96,N(#,Q+"`R,#$T/"]T9#X-"B`@("`@("`@/'1D M(&-L87-S/3-$;G5M<#XD(#DR+#`V-#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@ M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@ M("`@("`\=&0@8VQA<W,],T1N=6UP/B0@,SD\<W!A;CX\+W-P86X^/"]T9#X- M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X- M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X- M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X- M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X- M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X- M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X- M"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XD(#4X.2PR-S(\<W!A;CX\+W-P M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B0@*#0I/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;3XD("@T.3<L M,C0S*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT M<B!C;&%S<STS1')C/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX] M,T1T;W`^16YD:6YG($)A;&%N8V4L('-H87)E<R!A="!$96,N(#,Q+"`R,#$T M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^ M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^ M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XS."PV-3DL-S,X/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@(#PO=&%B;&4^#0H@ M(#PO8F]D>3X-"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT4&%R=%\S.6,P96$V M,E]C,C`S7S0U.&9?.&,U,%\S9&-A-#4V838Y-3$-"D-O;G1E;G0M3&]C871I M;VXZ(&9I;&4Z+R\O0SHO,SEC,&5A-C)?8S(P,U\T-3AF7SAC-3!?,V1C830U M-F$V.34Q+U=O<FMS:&5E=',O4VAE970P-BYH=&UL#0I#;VYT96YT+51R86YS M9F5R+45N8V]D:6YG.B!Q=6]T960M<')I;G1A8FQE#0I#;VYT96YT+51Y<&4Z M('1E>'0O:'1M;#L@8VAA<G-E=#TB=7,M87-C:6DB#0H-"CQH=&UL/@T*("`\ M:&5A9#X-"B`@("`\345402!H='1P+65Q=6EV/3-$0V]N=&5N="U4>7!E(&-O M;G1E;G0],T0G=&5X="]H=&UL.R!C:&%R<V5T/75T9BTX)SX\<V-R:7!T('1Y M<&4],T1T97AT+VIA=F%S8W)I<'0@<W)C/3-$4VAO=RYJ<SXO*B!$;R!.;W0@ M4F5M;W9E(%1H:7,@0V]M;65N="`J+SPO<V-R:7!T/CPO:&5A9#X-"B`@/&)O M9'D^#0H@("`@/'1A8FQE(&-L87-S/3-$<F5P;W)T(&ED/3-$240P14U104<^ M#0H@("`@("`\='(^#0H@("`@("`@(#QT:"!C;&%S<STS1'1L(&-O;'-P86X] M,T0Q(')O=W-P86X],T0R/CQS=')O;F<^0V]N<V]L:61A=&5D(%-T871E;65N M=',@;V8@4W1O8VMH;VQD97)S)R!%<75I='D@*%!A<F5N=&AE=&EC86PI("A5 M4T0@)"D\8G(^26X@5&AO=7-A;F1S+"!E>&-E<'0@4&5R(%-H87)E(&1A=&$L M('5N;&5S<R!O=&AE<G=I<V4@<W!E8VEF:65D/"]S=')O;F<^/"]T:#X-"B`@ M("`@("`@/'1H(&-L87-S/3-$=&@@8V]L<W!A;CTS1#,^,3(@36]N=&AS($5N M9&5D/"]T:#X-"B`@("`@(#PO='(^#0H@("`@("`\='(^#0H@("`@("`@(#QT M:"!C;&%S<STS1'1H/D1E8RX@,S$L(#(P,30\8G(^/"]T:#X-"B`@("`@("`@ M/'1H(&-L87-S/3-$=&@^1&5C+B`S,2P@,C`Q,SQB<CX\+W1H/@T*("`@("`@ M("`\=&@@8VQA<W,],T1T:#Y$96,N(#,Q+"`R,#$R/&)R/CPO=&@^#0H@("`@ M("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C M;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y)<W-U86YC92!O9B!C;VUM;VX@<W1O M8VL@=7!O;B!E>&5R8VES92!O9B!S=&]C:R!O<'1I;VYS(&9O<B!C87-H('!E M<B!S:&%R93PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^)"`V/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S M/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y) M<W-U86YC92!O9B!C;VUM;VX@<W1O8VL@=7!O;B!E>&5R8VES92!O9B!S=&]C M:R!O<'1I;VYS(&9O<B!C87-H('!E<B!S:&%R92P@;&]W97(@;&EM:70\+W1D M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D M/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B0@-"XP,CQS<&%N/CPO<W!A M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A M;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T* M("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^27-S=6%N8V4@ M;V8@8V]M;6]N('-T;V-K('5P;VX@97AE<F-I<V4@;V8@<W1O8VL@;W!T:6]N M<R!F;W(@8V%S:"!P97(@<VAA<F4L('5P<&5R(&QI;6ET/"]T9#X-"B`@("`@ M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@ M("`@/'1D(&-L87-S/3-$;G5M<#XD(#$Q+C$\<W!A;CX\+W-P86X^/"]T9#X- M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X- M"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@ M/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/DES<W5A;F-E(&]F(&-O;6UO M;B!S=&]C:R!P=7)S=6%N="!T;R!%4U!0+"!P97(@<VAA<F4\+W1D/@T*("`@ M("`@("`\=&0@8VQA<W,],T1N=6UP/B0@,RXS.#QS<&%N/CPO<W!A;CX\+W1D M/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B0@,RXV-CQS<&%N/CPO<W!A M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B0@-"XS,CQS<&%N M/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS M1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^27-S M=6%N8V4@;V8@8V]M;6]N('-T;V-K('1O(')E;&%T960@<&%R='D@9F]R(&-A M<V@@<&5R('-H87)E/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\ M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XD M(#<N,3(\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$ M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\ M='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N M/3-$=&]P/DES<W5A;F-E(&]F(&-O;6UO;B!S=&]C:R!T;R!R96QA=&5D('!A M<G1Y(&ES<W5A;F-E(&-O<W1S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$ M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$ M;G5M<#XD(#(Q/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@ M("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A M;&EG;CTS1'1O<#Y)<W-U86YC92!O9B!C;VUM;VX@<W1O8VL@=&\@8V]L;&%B M;W)A=&EV92!P87)T;F5R(&9O<B!C87-H('!E<B!S:&%R93PO=&0^#0H@("`@ M("`@(#QT9"!C;&%S<STS1&YU;7`^)"`T+CD\<W!A;CX\+W-P86X^/"]T9#X- M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X- M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X- M"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@ M/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/DES<W5A;F-E(&]F(&-O;6UO M;B!S=&]C:R!T;R!C;VQL86)O<F%T:79E('!A<G1N97(@:7-S=6%N8V4@8V]S M=',\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C@\<W!A;CX\+W-P M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P M86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X- M"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/DES<W5A;F-E M(&]F(&-O;6UO;B!S=&]C:R!A="!P97(@<VAA<F4\+W1D/@T*("`@("`@("`\ M=&0@8VQA<W,],T1N=6UP/B0@.#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@ M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@ M("`\=&0@8VQA<W,],T1N=6UP/B0@-"XU-CQS<&%N/CPO<W!A;CX\+W1D/@T* M("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\ M=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^4W1O8VL@:7-S=6%N8V4@8V]S M=',\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C(L.#`P/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,BPQ,SD\ M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA M<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P M/DES<W5A;F-E(&]F('=A<G)A;G1S+"!I<W-U86YC92!C;W-T<SPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S<STS1&YU;7`^.3@T/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F@^#0H@("`@("`@ M(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y397)I97,@02!#;VYV97)T M:6)L92!0<F5F97)R960@4W1O8VL@6TUE;6)E<ET\+W1D/@T*("`@("`@("`\ M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\ M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\ M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T M<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,] M,T1P;"!V86QI9VX],T1T;W`^0V]N=F5R<VEO;B!0<FEC92!O9B!C;VYV97)T M:6)L92!P<F5F97)R960@<W1O8VL@=&\@8V]M;6]N('-T;V-K/"]T9#X-"B`@ M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@ M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@ M("`@("`@/'1D(&-L87-S/3-$;G5M<#XD(#$L,#`P/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F@^#0H@("`@ M("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y397)I97,@0B!#;VYV M97)T:6)L92!0<F5F97)R960@4W1O8VL@6TUE;6)E<ET\+W1D/@T*("`@("`@ M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@ M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@ M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@ M/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA M<W,],T1P;"!V86QI9VX],T1T;W`^27-S=6%N8V4@;V8@8V]N=F5R=&EB;&4@ M<')E9F5R<F5D('-T;V-K(&%T('!E<B!S:&%R93PO=&0^#0H@("`@("`@(#QT M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S<STS1&YU;7`^)"`W-C`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@ M(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L M87-S/3-$<&P@=F%L:6=N/3-$=&]P/D-O;G9E<G-I;VX@4')I8V4@;V8@8V]N M=F5R=&EB;&4@<')E9F5R<F5D('-T;V-K('1O(&-O;6UO;B!S=&]C:SPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^)"`Q+#`P,#QS<&%N/CPO<W!A M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A M;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T* M("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^4W1O8VL@:7-S M=6%N8V4@8V]S=',\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C@X M,3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C M;&%S<STS1')H/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T M;W`^34Q6(%M-96UB97)=/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@ M8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$ M=&]P/DES<W5A;F-E(&]F(&-O;6UO;B!S=&]C:R!T;R!-3%8@870@<&5R('-H M87)E+"!L;W=E<B!L:6UI=#PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU M;7`^)"`V+C8T/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M<STS1&YU;7`^)"`V+C4\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D M(&-L87-S/3-$;G5M<#XD(#8N,SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@ M/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA M<W,],T1P;"!V86QI9VX],T1T;W`^27-S=6%N8V4@;V8@8V]M;6]N('-T;V-K M('1O($U,5B!A="!P97(@<VAA<F4L('5P<&5R(&QI;6ET/"]T9#X-"B`@("`@ M("`@/'1D(&-L87-S/3-$;G5M<#XD(#8N-SD\<W!A;CX\+W-P86X^/"]T9#X- M"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XD(#8N-SD\<W!A;CX\+W-P86X^ M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XD(#<N,CQS<&%N/CPO M<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E M/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^27-S=6%N M8V4@;V8@8V]M;6]N('-T;V-K('1O($U,5BP@;F5T(&]F(&-O;6UI<W-I;VX@ M86YD(&ES<W5A;F-E(&-O<W1S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$ M;G5M<#XD(#<T/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M<STS1&YU;7`^)"`R,S(\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D M(&-L87-S/3-$;G5M<#XD(#@Y/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\ M+W1R/@T*("`@(#PO=&%B;&4^#0H@(#PO8F]D>3X-"CPO:'1M;#X-"@T*+2TM M+2TM/5].97AT4&%R=%\S.6,P96$V,E]C,C`S7S0U.&9?.&,U,%\S9&-A-#4V M838Y-3$-"D-O;G1E;G0M3&]C871I;VXZ(&9I;&4Z+R\O0SHO,SEC,&5A-C)? M8S(P,U\T-3AF7SAC-3!?,V1C830U-F$V.34Q+U=O<FMS:&5E=',O4VAE970P M-RYH=&UL#0I#;VYT96YT+51R86YS9F5R+45N8V]D:6YG.B!Q=6]T960M<')I M;G1A8FQE#0I#;VYT96YT+51Y<&4Z('1E>'0O:'1M;#L@8VAA<G-E=#TB=7,M M87-C:6DB#0H-"CQH=&UL/@T*("`\:&5A9#X-"B`@("`\345402!H='1P+65Q M=6EV/3-$0V]N=&5N="U4>7!E(&-O;G1E;G0],T0G=&5X="]H=&UL.R!C:&%R M<V5T/75T9BTX)SX\<V-R:7!T('1Y<&4],T1T97AT+VIA=F%S8W)I<'0@<W)C M/3-$4VAO=RYJ<SXO*B!$;R!.;W0@4F5M;W9E(%1H:7,@0V]M;65N="`J+SPO M<V-R:7!T/CPO:&5A9#X-"B`@/&)O9'D^#0H@("`@/'1A8FQE(&-L87-S/3-$ M<F5P;W)T(&ED/3-$240P14)!0D<^#0H@("`@("`\='(^#0H@("`@("`@(#QT M:"!C;&%S<STS1'1L(&-O;'-P86X],T0Q(')O=W-P86X],T0R/CQS=')O;F<^ M0V]N<V]L:61A=&5D(%-T871E;65N=',@;V8@0V%S:"!&;&]W<R`H55-$("0I M/&)R/DEN(%1H;W5S86YD<RP@=6YL97-S(&]T:&5R=VES92!S<&5C:69I960\ M+W-T<F]N9SX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:"!C;VQS<&%N M/3-$,SXQ,B!-;VYT:',@16YD960\+W1H/@T*("`@("`@/"]T<CX-"B`@("`@ M(#QT<CX-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^1&5C+B`S,2P@,C`Q-#QB M<CX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y$96,N(#,Q+"`R,#$S M/&)R/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/D1E8RX@,S$L(#(P M,3(\8G(^/"]T:#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R M93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/CQS=')O M;F<^0V%S:"!F;&]W<R!F<F]M(&]P97)A=&EN9R!A8W1I=FET:65S.CPO<W1R M;VYG/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^ M#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y.970@;&]S M<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;3XD("@Q-"PV-#8I/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;3XD("@S M,RPW,3<I/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS M1&YU;3XD("@T,"PS-S`I/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R M/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS M1'!L('9A;&EG;CTS1'1O<#X\<W1R;VYG/D%D:G5S=&UE;G1S('1O(')E8V]N M8VEL92!N970@;&]S<R!T;R!N970@8V%S:"!U<V5D(&EN(&]P97)A=&EN9R!A M8W1I=FET:65S.CPO<W1R;VYG/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@ M/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG M;CTS1'1O<#Y$97!R96-I871I;VX@86YD(&%M;W)T:7IA=&EO;B!O9B!P<F]P M97)T>2!A;F0@97%U:7!M96YT/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$ M;G5M<#XT.3`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S M/3-$;G5M<#XT,S,\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L M87-S/3-$;G5M<#XU.3$\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^ M#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$ M<&P@=F%L:6=N/3-$=&]P/D=A:6X@;VX@9&ES<&]S86P@;V8@97%U:7!M96YT M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XP/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;3XH-SDI/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;3XH,BD\<W!A;CX\ M+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R M;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/DYO;BUC M87-H(')E<W1R=6-T=7)I;F<@97AP96YS97,L(&YE="!O9B!R979E<G-A;',\ M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C`\<W!A;CX\+W-P86X^ M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XP/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;3XH-38I/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^ M#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y3=&]C:RUB M87-E9"!C;VUP96YS871I;VX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N M=6UP/C,L,S,P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M<STS1&YU;7`^,RPU.3<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D M(&-L87-S/3-$;G5M<#XS+#<X,SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@ M/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA M<W,],T1P;"!V86QI9VX],T1T;W`^1V%I;B!O;B!S86QE(&]F(&EN=F5S=&UE M;G1S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B@V*3QS<&%N/CPO M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C`\<W!A;CX\ M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XP/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$ M<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#X\<W1R M;VYG/D-H86YG97,@:6X@;W!E<F%T:6YG(&%S<V5T<R!A;F0@;&EA8FEL:71I M97,Z/"]S=')O;F<^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\ M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\ M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\ M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA M<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P M/E)E;&%T960@<&%R='D@86-C;W5N=',@<F5C96EV86)L93PO=&0^#0H@("`@ M("`@(#QT9"!C;&%S<STS1&YU;3XH-#8L-C0Q*3QS<&%N/CPO<W!A;CX\+W1D M/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C`\<W!A;CX\+W-P86X^/"]T M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ,#QS<&%N/CPO<W!A;CX\ M+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@ M("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^4')E<&%I9"!A;F0@ M;W1H97(@87-S971S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XR M-S0\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M M<#XX,3@\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$ M;G5M/B@S,C`I/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@ M("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A M;&EG;CTS1'1O<#Y!8V-O=6YT<R!P87EA8FQE/"]T9#X-"B`@("`@("`@/'1D M(&-L87-S/3-$;G5M/B@R+#$W."D\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@ M("`@/'1D(&-L87-S/3-$;G5M<#XQ+#8U-CQS<&%N/CPO<W!A;CX\+W1D/@T* M("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C8Y,#QS<&%N/CPO<W!A;CX\+W1D M/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@ M("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^06-C<G5E9"!A;F0@;W1H M97(@;&EA8FEL:71I97,\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6T^ M*#(L.#8U*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,] M,T1N=6UP/C,L-3(S/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S<STS1&YU;7`^,BPP.3@\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO M='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S M/3-$<&P@=F%L:6=N/3-$=&]P/E)E;&%T960@<&%R='D@<&%Y86)L97,@86YD M(&%C8W)U960@;&EA8FEL:71I97,\+W1D/@T*("`@("`@("`\=&0@8VQA<W,] M,T1N=6UP/C`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S M/3-$;G5M/B@Q-3`I/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S<STS1&YU;7`^,3,X/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R M/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS M1'!L('9A;&EG;CTS1'1O<#Y$969E<G)E9"!R979E;G5E/"]T9#X-"B`@("`@ M("`@/'1D(&-L87-S/3-$;G5M<#XQ-RPS.3D\<W!A;CX\+W-P86X^/"]T9#X- M"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ-BPR,#$\<W!A;CX\+W-P86X^ M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XP/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F]U/@T* M("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^3F5T(&-A<V@@ M=7-E9"!I;B!O<&5R871I;F<@86-T:79I=&EE<SPO=&0^#0H@("`@("`@(#QT M9"!C;&%S<STS1&YU;3XH-#0L.#0S*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@ M("`@("`\=&0@8VQA<W,],T1N=6T^*#<L-S$X*3QS<&%N/CPO<W!A;CX\+W1D M/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6T^*#,S+#0S."D\<W!A;CX\+W-P M86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X- M"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/CQS=')O;F<^ M0V%S:"!F;&]W<R!F<F]M(&EN=F5S=&EN9R!A8W1I=FET:65S.CPO<W1R;VYG M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@ M("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y0=7)C:&%S97,@ M;V8@:6YV97-T;65N=',\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6T^ M*#$P-RPP-#,I/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M<STS1&YU;3XH-SDL-#,T*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\ M=&0@8VQA<W,],T1N=6T^*#DR+#<X."D\<W!A;CX\+W-P86X^/"]T9#X-"B`@ M("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D M(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E!R;V-E961S(&9R;VT@<V%L97,@ M86YD(&UA='5R:71I97,@;V8@:6YV97-T;65N=',\+W1D/@T*("`@("`@("`\ M=&0@8VQA<W,],T1N=6UP/C$P-"PP.3@\<W!A;CX\+W-P86X^/"]T9#X-"B`@ M("`@("`@/'1D(&-L87-S/3-$;G5M<#XW."PT-#0\<W!A;CX\+W-P86X^/"]T M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XV,RPY,#`\<W!A;CX\+W-P M86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX- M"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E!U<F-H87-E M<R!O9B!P<F]P97)T>2!A;F0@97%U:7!M96YT/"]T9#X-"B`@("`@("`@/'1D M(&-L87-S/3-$;G5M/B@Q+#$P-"D\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@ M("`@/'1D(&-L87-S/3-$;G5M/B@U-#(I/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S<STS1&YU;3XH,3(U*3QS<&%N/CPO<W!A;CX\+W1D M/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@ M("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^4')O8V5E9',@9G)O;2!S M86QE<R!O9B!P<F]P97)T>2!A;F0@97%U:7!M96YT/"]T9#X-"B`@("`@("`@ M/'1D(&-L87-S/3-$;G5M<#XP/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S<STS1&YU;7`^,3,\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@ M("`@/'1D(&-L87-S/3-$;G5M<#XR/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C M;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y$96-R96%S92!I;B!R97-T<FEC=&5D M(&-A<V@\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C`\<W!A;CX\ M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XP/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,3DV/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S M/3-$<F5U/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^ M3F5T(&-A<V@@=7-E9"!I;B!I;G9E<W1I;F<@86-T:79I=&EE<SPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S<STS1&YU;3XH-"PP-#DI/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;3XH,2PU,3DI/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;3XH,C@L.#$U*3QS M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S M<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^ M/'-T<F]N9SY#87-H(&9L;W=S(&9R;VT@9FEN86YC:6YG(&%C=&EV:71I97,Z M/"]S=')O;F<^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A M;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,] M,T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E!R M;V-E961S(&9R;VT@<'5B;&EC(&]F9F5R:6YG<R!O9B!C;VUM;VX@<W1O8VLL M(&YE="!O9B!I<W-U86YC92!C;W-T<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S M<STS1&YU;7`^-#@L.3<Q/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S<STS1&YU;7`^-RPT-3`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@ M("`@/'1D(&-L87-S/3-$;G5M<#XT,RPV-S<\<W!A;CX\+W-P86X^/"]T9#X- M"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@ M/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E!R;V-E961S(&9R;VT@9')A M=R!D;W=N(&]F(&-O;6UI='1E9"!E<75I='D@9FEN86YC:6YG(&9A8VEL:71I M97,@86YD(&%T+71H92UM87)K970@9F%C:6QI='DL(&YE="!O9B!C;VUM:7-S M:6]N(&%N9"!I<W-U86YC92!C;W-T<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S M<STS1&YU;7`^,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA M<W,],T1N=6UP/C`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L M87-S/3-$;G5M<#XR+#@R,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T M<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,] M,T1P;"!V86QI9VX],T1T;W`^4&%Y;65N=',@9G)O;2!S=&]C:R!B87-E9"!A M=V%R9"!A8W1I=FET:65S(&%N9"!W87)R86YT<RP@;F5T/"]T9#X-"B`@("`@ M("`@/'1D(&-L87-S/3-$;G5M/B@R,BD\<W!A;CX\+W-P86X^/"]T9#X-"B`@ M("`@("`@/'1D(&-L87-S/3-$;G5M<#XW+#`S.#QS<&%N/CPO<W!A;CX\+W1D M/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6T^*#,S-BD\<W!A;CX\+W-P86X^ M/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@ M("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E!R;V-E961S(&9R M;VT@:7-S=6%N8V4@;V8@<')E9F5R<F5D('-T;V-K+"!N970@;V8@:7-S=6%N M8V4@8V]S=',\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C`\<W!A M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XP/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,3(L M,S$X/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R M(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS M1'1O<#Y297!A>6UE;G0@;V8@97%U:7!M96YT(&9I;F%N8VEN9R!L:6YE<SPO M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,#QS<&%N/CPO<W!A;CX\ M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C`\<W!A;CX\+W-P86X^ M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B@Q-3(I/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F]U M/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^3F5T(&-A M<V@@<')O=FED960@8GD@9FEN86YC:6YG(&%C=&EV:71I97,\+W1D/@T*("`@ M("`@("`\=&0@8VQA<W,],T1N=6UP/C0X+#DT.3QS<&%N/CPO<W!A;CX\+W1D M/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$T+#0X.#QS<&%N/CPO<W!A M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C4X+#,R-SQS<&%N M/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS M1')E=3X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/DYE M="!I;F-R96%S92`H9&5C<F5A<V4I(&EN(&-A<V@@86YD(&-A<V@@97%U:79A M;&5N=',\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C4W/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-2PR-3$\ M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B@S M+#DR-BD\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\ M='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N M/3-$=&]P/D-A<V@@86YD(&-A<V@@97%U:79A;&5N=',L(&)E9VEN;FEN9R!O M9B!P97)I;V0\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C(P+#$U M.#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP M/C$T+#DP-SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,] M,T1N=6UP/C$X+#@S,SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX- M"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P M;"!V86QI9VX],T1T;W`^0V%S:"!A;F0@8V%S:"!E<75I=F%L96YT<RP@96YD M(&]F('!E<FEO9#PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^)"`R M,"PR,34\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$ M;G5M<#XD(#(P+#$U.#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@ M8VQA<W,],T1N=6UP/B0@,30L.3`W/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`\+W1R/@T*("`@(#PO=&%B;&4^#0H@(#PO8F]D>3X-"CPO:'1M;#X-"@T* M+2TM+2TM/5].97AT4&%R=%\S.6,P96$V,E]C,C`S7S0U.&9?.&,U,%\S9&-A M-#4V838Y-3$-"D-O;G1E;G0M3&]C871I;VXZ(&9I;&4Z+R\O0SHO,SEC,&5A M-C)?8S(P,U\T-3AF7SAC-3!?,V1C830U-F$V.34Q+U=O<FMS:&5E=',O4VAE M970P."YH=&UL#0I#;VYT96YT+51R86YS9F5R+45N8V]D:6YG.B!Q=6]T960M M<')I;G1A8FQE#0I#;VYT96YT+51Y<&4Z('1E>'0O:'1M;#L@8VAA<G-E=#TB M=7,M87-C:6DB#0H-"CQH=&UL/@T*("`\:&5A9#X-"B`@("`\345402!H='1P M+65Q=6EV/3-$0V]N=&5N="U4>7!E(&-O;G1E;G0],T0G=&5X="]H=&UL.R!C M:&%R<V5T/75T9BTX)SX\<V-R:7!T('1Y<&4],T1T97AT+VIA=F%S8W)I<'0@ M<W)C/3-$4VAO=RYJ<SXO*B!$;R!.;W0@4F5M;W9E(%1H:7,@0V]M;65N="`J M+SPO<V-R:7!T/CPO:&5A9#X-"B`@/&)O9'D^#0H@("`@/'1A8FQE(&-L87-S M/3-$<F5P;W)T(&ED/3-$240P14U%/@T*("`@("`@/'1R/@T*("`@("`@("`\ M=&@@8VQA<W,],T1T;"!C;VQS<&%N/3-$,2!R;W=S<&%N/3-$,CX\<W1R;VYG M/D]R9V%N:7IA=&EO;B!A;F0@4VEG;FEF:6-A;G0@06-C;W5N=&EN9R!0;VQI M8VEE<SQB<CX\+W-T<F]N9SX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T M:"!C;VQS<&%N/3-$,3XQ,B!-;VYT:',@16YD960\+W1H/@T*("`@("`@/"]T M<CX-"B`@("`@(#QT<CX-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^1&5C+B`S M,2P@,C`Q-#QB<CX\+W1H/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S M<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^ M/'-T<F]N9SY!8V-O=6YT:6YG(%!O;&EC:65S(%M!8G-T<F%C=%T\+W-T<F]N M9SX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A M;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T* M("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^3W)G86YI>F%T M:6]N(&%N9"!3:6=N:69I8V%N="!!8V-O=6YT:6YG(%!O;&EC:65S/"]T9#X- M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\9&EV/@T*(#QP('-T>6QE/3-$ M)TU!4D=)3BU"3U143TTZ(#!P>#L@34%21TE.+51/4#H@,3)P>"<^/&9O;G0@ M<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS M1#(^/&(^3F]T92`Q("8C>#(P,30[#0H@3W)G86YI>F%T:6]N(&%N9"!3:6=N M:69I8V%N="!!8V-O=6YT:6YG(%!O;&EC:65S/"]B/CPO9F]N=#X\+W`^#0H@ M/"$M+2!X8G)L+&)O9'D@+2T^#0H@/'`@<W1Y;&4],T0G34%21TE.+4)/5%1/ M33H@,'!X.R!-05)'24XM3$5&5#H@,B4[($U!4D=)3BU43U`Z(#9P>"<^#0H@ M/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@ M<VEZ93TS1#(^/&(^/&D^3W)G86YI>F%T:6]N/"]I/CPO8CX\+V9O;G0^/"]P M/@T*(#QP('-T>6QE/3-$)TU!4D=)3BU"3U143TTZ(#!P>#L@34%21TE.+51/ M4#H@-G!X.R!415A4+4E.1$5.5#H@-"4G(&%L:6=N/3-$:G5S=&EF>3X\9F]N M="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE M/3-$,CY#>71O:VEN971I8W,L($EN8V]R<&]R871E9"`H=&AE("8C>#(P,4,[ M0V]M<&%N>28C>#(P,40[+`T*("8C>#(P,4,[=V4F(W@R,#%$.R!O<B`F(W@R M,#%#.V]U<B8C>#(P,40[*2!W87,@:6YC;W)P;W)A=&5D('5N9&5R('1H90T* M(&QA=W,@;V8@=&AE('-T871E(&]F($1E;&%W87)E(&]N($%U9W5S="8C>$$P M.S4L(#$Y.3<N(%1H92!#;VUP86YY#0H@:7,@82!C;&EN:6-A;"!S=&%G92!B M:6]P:&%R;6%C975T:6-A;"!C;VUP86YY(&9O8W5S960@;VX@=&AE#0H@9&ES M8V]V97)Y(&%N9"!D979E;&]P;65N="!O9B!N;W9E;"!S;6%L;"!M;VQE8W5L M92!T:&5R87!E=71I8W,@=&AA=`T*(&UO9'5L871E(&UU<V-L92!F=6YC=&EO M;B!F;W(@=&AE('!O=&5N=&EA;"!T<F5A=&UE;G0@;V8@<V5R:6]U<PT*(&1I M<V5A<V5S(&%N9"!M961I8V%L(&-O;F1I=&EO;G,N/"]F;VYT/CPO<#X-"B`\ M<"!S='EL93TS1"=-05)'24XM0D]45$]-.B`P<'@[($U!4D=)3BU43U`Z(#$R M<'@[(%1%6%0M24Y$14Y4.B`T)2<@86QI9VX],T1J=7-T:69Y/CQF;VYT('-T M>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R M/E1H92!#;VUP86YY('=A<R!I;B!T:&4@9&5V96QO<&UE;G0@<W1A9V4@870@ M1&5C96UB97(F(WA!,#LS,2P-"B`R,#$R+"!A<R!D969I;F5D(&EN($9I;F%N M8VEA;"!!8V-O=6YT:6YG(%-T86YD87)D<R!";V%R9`T*("@F(W@R,#%#.T9! M4T(F(W@R,#%$.RD@06-C;W5N=&EN9R!3=&%N9&%R9',@0V]D:69I8V%T:6]N M#0H@*"8C>#(P,4,[05-#)B-X,C`Q1#LI(%1O<&EC(#DQ-2P@)B-X,C`Q0SL\ M:3Y$979E;&]P;65N="!3=&%G90T*($5N=&ET:65S/"]I/BXF(W@R,#%$.R!$ M=7)I;F<@=&AE('EE87(@96YD960@1&5C96UB97(F(WA!,#LS,2P@,C`Q,RP- M"B!T:&4@0V]M<&%N>2!E>&ET960@=&AE(&1E=F5L;W!M96YT('-T86=E('=I M=&@@=&AE(&5X96-U=&EO;B!O9B!T:&4-"B!!;6=E;B!!9W)E96UE;G0@06UE M;F1M96YT(&%N9"!T:&4@3W)I9VEN86P@07-T96QL87,@06=R965M96YT("A3 M964-"B!.;W1E(#<I+"!F<F]M('=H:6-H('1H92!#;VUP86YY(')E8V5I=F5D M('-I9VYI9FEC86YT(')E=F5N=65S(&9R;VT-"B!I=',@<')I;F-I<&%L(&]P M97)A=&EO;G,L(&EN9&EC871I=F4@=&AA="!T:&4@0V]M<&%N>2!W87,@;F\@ M;&]N9V5R#0H@:6X@=&AE(&1E=F5L;W!M96YT('-T86=E+CPO9F]N=#X\+W`^ M#0H@/'`@<W1Y;&4],T0G34%21TE.+4)/5%1/33H@,'!X.R!-05)'24XM5$]0 M.B`Q,G!X.R!415A4+4E.1$5.5#H@-"4G(&%L:6=N/3-$:G5S=&EF>3X\9F]N M="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE M/3-$,CY4:&4@0V]M<&%N>28C>#(P,3D[<R!F:6YA;F-I86P@<W1A=&5M96YT M<R!C;VYT96UP;&%T92!T:&4-"B!C;VYD=6-T(&]F('1H92!#;VUP86YY)B-X M,C`Q.3MS(&]P97)A=&EO;G,@:6X@=&AE(&YO<FUA;"!C;W5R<V4@;V8-"B!B M=7-I;F5S<RX@5&AE($-O;7!A;GD@:&%S(&EN8W5R<F5D(&%N(&%C8W5M=6QA M=&5D(&1E9FEC:70@;V8@)#0Y-RXR#0H@;6EL;&EO;B!S:6YC92!I;F-E<'1I M;VX@86YD('1H97)E(&-A;B!B92!N;R!A<W-U<F%N8V4@=&AA="!T:&4-"B!# M;VUP86YY('=I;&P@871T86EN('!R;V9I=&%B:6QI='DN(%1H92!#;VUP86YY M(&AA9"!A(&YE="!L;W-S(&]F#0H@)#$T+C8@;6EL;&EO;B!A;F0@;F5T(&-A M<V@@=7-E9"!I;B!O<&5R871I;VYS(&]F("0T-"XX(&UI;&QI;VX@9F]R#0H@ M=&AE('EE87(@96YD960@1&5C96UB97(F(WA!,#LS,2P@,C`Q-"X@0V%S:"P@ M8V%S:"!E<75I=F%L96YT<R!A;F0-"B!I;G9E<W1M96YT<R!I;F-R96%S960@ M=&\@)#@S+C(@;6EL;&EO;B!A="!$96-E;6)E<B8C>$$P.S,Q+"`R,#$T#0H@ M9G)O;2`D.#`N,B8C>$$P.VUI;&QI;VX@870@1&5C96UB97(F(WA!,#LS,2P@ M,C`Q,RX@5&AE($-O;7!A;GD-"B!A;G1I8VEP871E<R!T:&%T(&ET('=I;&P@ M8V]N=&EN=64@=&\@:&%V92!O<&5R871I;F<@;&]S<V5S(&%N9"!N970-"B!C M87-H(&]U=&9L;W=S(&EN(&9U='5R92!P97)I;V1S+CPO9F]N=#X\+W`^#0H@ M/'`@<W1Y;&4],T0G34%21TE.+4)/5%1/33H@,'!X.R!-05)'24XM5$]0.B`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`T*('-E M=F5R86P@>65A<G,L(&EF(&5V97(N(%1H92!#;VUP86YY)B-X,C`Q.3MS('-U M8V-E<W,@:7,@9&5P96YD96YT(&]N#0H@:71S(&%B:6QI='D@=&\@96YT97(@ M:6YT;R!N97<@<W1R871E9VEC(&-O;&QA8F]R871I;VYS(&%N9"]O<B!R86ES M90T*(&%D9&ET:6]N86P@8V%P:71A;"!A;F0@=&\@<W5C8V5S<V9U;&QY(&1E M=F5L;W`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`T*('1H92!#;VUP86YY)B-X,C`Q.3MS(&1R=6<@8V%N9&ED M871E<R!W:6QL(&)E(&%C8V5P=&5D(&EN('1H90T*(&UA<FME='!L86-E(&]R M('1H870@86YY(&9U='5R92!P<F]D=6-T<R!C86X@8F4@9&5V96QO<&5D(&]R M#0H@;6%N=69A8W1U<F5D(&%T(&%N(&%C8V5P=&%B;&4@8V]S="X@5&AE<V4@ M9F%C=&]R<R!C;W5L9"!H879E(&$-"B!M871E<FEA;"!A9'9E<G-E(&5F9F5C M="!O;B!T:&4@0V]M<&%N>28C>#(P,3D[<R!F=71U<F4@9FEN86YC:6%L#0H@ M<F5S=6QT<RP@9FEN86YC:6%L('!O<VET:6]N(&%N9"!C87-H(&9L;W=S+CPO M9F]N=#X\+W`^#0H@/'`@<W1Y;&4],T0G34%21TE.+4)/5%1/33H@,'!X.R!- M05)'24XM5$]0.B`Q,G!X.R!415A4+4E.1$5.5#H@-"4G(&%L:6=N/3-$:G5S M=&EF>3X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O M;6%N)R!S:7IE/3-$,CY"87-E9"!O;B!T:&4@8W5R<F5N="!S=&%T=7,@;V8@ M:71S(')E<V5A<F-H(&%N9"!D979E;&]P;65N=`T*('!L86YS+"!T:&4@0V]M M<&%N>2!B96QI979E<R!T:&%T(&ET<R!E>&ES=&EN9R!C87-H+"!C87-H#0H@ M97%U:79A;&5N=',@86YD(&EN=F5S=&UE;G1S(&%T($1E8V5M8F5R)B-X03`[ M,S$L(#(P,30@=VEL;"!B90T*('-U9F9I8VEE;G0@=&\@9G5N9"!I=',@8V%S M:"!R97%U:7)E;65N=',@9F]R(&%T(&QE87-T('1H92!N97AT#0H@,3(F(WA! M,#MM;VYT:',N($EF+"!A="!A;GD@=&EM92P@=&AE($-O;7!A;GDF(W@R,#$Y M.W,@<')O<W!E8W1S(&9O<@T*(&9I;F%N8VEN9R!I=',@<F5S96%R8V@@86YD M(&1E=F5L;W!M96YT('!R;V=R86US(&1E8VQI;F4L('1H90T*($-O;7!A;GD@ M;6%Y(&1E8VED92!T;R!R961U8V4@<F5S96%R8V@@86YD(&1E=F5L;W!M96YT M(&5X<&5N<V5S(&)Y#0H@9&5L87EI;F<L(&1I<V-O;G1I;G5I;F<@;W(@<F5D M=6-I;F<@:71S(&9U;F1I;F<@;V8@;VYE(&]R(&UO<F4@;V8-"B!I=',@<F5S M96%R8V@@;W(@9&5V96QO<&UE;G0@<')O9W)A;7,N($%L=&5R;F%T:79E;'DL M('1H92!#;VUP86YY#0H@;6EG:'0@<F%I<V4@9G5N9',@=&AR;W5G:"!S=')A M=&5G:6,@8V]L;&%B;W)A=&EO;G,L('!U8FQI8R!O<@T*('!R:79A=&4@9FEN M86YC:6YG<R!O<B!O=&AE<B!A<G)A;F=E;65N=',N(%-U8V@@9G5N9&EN9RP@ M:68@;F5E9&5D+`T*(&UA>2!N;W0@8F4@879A:6QA8FQE(&]N(&9A=F]R86)L M92!T97)M<RP@;W(@870@86QL+B!4:&4@9FEN86YC:6%L#0H@<W1A=&5M96YT M<R!D;R!N;W0@:6YC;'5D92!A;GD@861J=7-T;65N=',@=&AA="!M:6=H="!R M97-U;'0@9G)O;0T*('1H92!O=71C;VUE(&]F('1H:7,@=6YC97)T86EN='DN M/"]F;VYT/CPO<#X-"B`\<"!S='EL93TS1"=-05)'24XM0D]45$]-.B`P<'@[ M($9/3E0M4TE:13H@,3AP>#L@34%21TE.+51/4#H@,'!X)SX-"B`F(WA!,#L\ M+W`^#0H@/'`@<W1Y;&4],T0G34%21TE.+4)/5%1/33H@,'!X.R!-05)'24XM M3$5&5#H@,B4[($U!4D=)3BU43U`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`T*('-T871E;65N=',@86YD('1H92!R97!O<G1E9"!A;6]U;G1S(&]F M(')E=F5N=65S(&%N9"!E>'!E;G-E<R!D=7)I;F<-"B!T:&4@<F5P;W)T:6YG M('!E<FEO9"X@06-T=6%L(')E<W5L=',@8V]U;&0@9&EF9F5R(&9R;VT@=&AO M<V4-"B!E<W1I;6%T97,N/"]F;VYT/CPO<#X-"B`\<"!S='EL93TS1"=-05)' M24XM0D]45$]-.B`P<'@[($U!4D=)3BU,1494.B`R)3L@34%21TE.+51/4#H@ M,3AP>"<^#0H@/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE M=R!2;VUA;B<@<VEZ93TS1#(^/&(^/&D^0F%S:7,@;V8-"B!0<F5S96YT871I M;VX\+VD^/"]B/CPO9F]N=#X\+W`^#0H@/'`@<W1Y;&4],T0G34%21TE.+4)/ M5%1/33H@,'!X.R!-05)'24XM5$]0.B`V<'@[(%1%6%0M24Y$14Y4.B`T)2<@ M86QI9VX],T1J=7-T:69Y/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4 M:6UE<R!.97<@4F]M86XG('-I>F4],T0R/E1H92!C;VYS;VQI9&%T960@9FEN M86YC:6%L('-T871E;65N=',@:6YC;'5D92!T:&4@86-C;W5N=',@;V8-"B!# M>71O:VEN971I8W,@86YD(&ET<R!W:&]L;'D@;W=N960@<W5B<VED:6%R>2X@ M5&AE(&9I;F%N8VEA;`T*('-T871E;65N=',@:6YC;'5D92!A;&P@861J=7-T M;65N=',@*&-O;G-I<W1I;F<@;VYL>2!O9B!N;W)M86P-"B!R96-U<G)I;F<@ M861J=7-T;65N=',I('1H870@;6%N86=E;65N="!B96QI979E<R!A<F4@;F5C M97-S87)Y(&9O<@T*('1H92!F86ER('!R97-E;G1A=&EO;B!O9B!T:&4@8F%L M86YC97,@86YD(')E<W5L=',@9F]R('1H92!P97)I;V1S#0H@<')E<V5N=&5D M+CPO9F]N=#X\+W`^#0H@/'`@<W1Y;&4],T0G34%21TE.+4)/5%1/33H@,'!X M.R!-05)'24XM3$5&5#H@,B4[($U!4D=)3BU43U`Z(#$X<'@G/@T*(#QF;VYT M('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4] M,T0R/CQB/CQI/D-O;F-E;G1R871I;VX@;V8@0W)E9&ET(%)I<VL@86YD($]T M:&5R(%)I<VMS(&%N9`T*(%5N8V5R=&%I;G1I97,\+VD^/"]B/CPO9F]N=#X\ M+W`^#0H@/'`@<W1Y;&4],T0G34%21TE.+4)/5%1/33H@,'!X.R!-05)'24XM M5$]0.B`V<'@[(%1%6%0M24Y$14Y4.B`T)2<@86QI9VX],T1J=7-T:69Y/CQF M;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I M>F4],T0R/D9I;F%N8VEA;"!I;G-T<G5M96YT<R!T:&%T('!O=&5N=&EA;&QY M('-U8FIE8W0@=&AE($-O;7!A;GD@=&\-"B!C;VYC96YT<F%T:6]N<R!O9B!R M:7-K(&-O;G-I<W0@<')I;F-I<&%L;'D@;V8@8V%S:"!A;F0@8V%S:`T*(&5Q M=6EV86QE;G1S+"!I;G9E<W1M96YT<R!A;F0@86-C;W5N=',@<F5C96EV86)L M92X\+V9O;G0^/"]P/@T*(#QP('-T>6QE/3-$)TU!4D=)3BU"3U143TTZ(#!P M>#L@34%21TE.+51/4#H@,3)P>#L@5$585"U)3D1%3E0Z(#0E)R!A;&EG;CTS M1&IU<W1I9GD^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE M=R!2;VUA;B<@<VEZ93TS1#(^5&AE($-O;7!A;GDF(W@R,#$Y.W,@8V%S:"P@ M8V%S:"!E<75I=F%L96YT<R!A;F0@:6YV97-T;65N=',@87)E#0H@:6YV97-T M960@:6X@9&5P;W-I=',@=VET:"!T:')E92!M86IO<B!F:6YA;F-I86P@:6YS M=&ET=71I;VYS(&EN('1H90T*(%5N:71E9"!3=&%T97,N)B-X03`[1&5P;W-I M=',@:6X@=&AE<V4@8F%N:W,@;6%Y(&5X8V5E9"!T:&4@86UO=6YT#0H@;V8@ M:6YS=7)A;F-E('!R;W9I9&5D(&]N('-U8V@@9&5P;W-I=',N(%1H92!#;VUP M86YY(&AA<R!N;W0-"B!E>'!E<FEE;F-E9"!A;GD@<F5A;&EZ960@;&]S<V5S M(&]N(&ET<R!D97!O<VET<R!O9B!C87-H+"!C87-H#0H@97%U:79A;&5N=',@ M;W(@:6YV97-T;65N=',N/"]F;VYT/CPO<#X-"B`\<"!S='EL93TS1"=-05)' M24XM0D]45$]-.B`P<'@[($U!4D=)3BU43U`Z(#$R<'@[(%1%6%0M24Y$14Y4 M.B`T)2<@86QI9VX],T1J=7-T:69Y/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%- M24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R/E1H92!E8V]N;VUI8R!T M=7)M;VEL(&EN('1H92!5;FET960@4W1A=&5S(&EN(')E8V5N="!Y96%R<RP@ M=&AE#0H@97AT<F%O<F1I;F%R>2!V;VQA=&EL:71Y(&EN('1H92!S=&]C:R!M M87)K971S(&%N9"!O=&AE<B!C=7)R96YT#0H@;F5G871I=F4@;6%C<F]E8V]N M;VUI8R!I;F1I8V%T;W)S(&-O=6QD(&YE9V%T:79E;'D@:6UP86-T('1H90T* M($-O;7!A;GDF(W@R,#$Y.W,@86)I;&ET>2!T;R!R86ES92!T:&4@9G5N9',@ M;F5C97-S87)Y('1O('-U<'!O<G0@:71S#0H@8G5S:6YE<W,@86YD(&UA>2!M M871E<FEA;&QY(&%D=F5R<V5L>2!A9F9E8W0@:71S(&)U<VEN97-S+`T*(&]P M97)A=&EN9R!R97-U;'1S(&%N9"!F:6YA;F-I86P@8V]N9&ET:6]N+CPO9F]N M=#X\+W`^#0H@/'`@<W1Y;&4],T0G34%21TE.+4)/5%1/33H@,'!X.R!-05)' M24XM5$]0.B`Q,G!X.R!415A4+4E.1$5.5#H@-"4G(&%L:6=N/3-$:G5S=&EF M>3X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N M)R!S:7IE/3-$,CY4:&4@0V]M<&%N>2!P97)F;W)M<R!A;B!O;F=O:6YG(&-R M961I="!E=F%L=6%T:6]N(&]F(&ET<PT*('-T<F%T96=I8R!P87)T;F5R<R8C M>#(P,3D[(&9I;F%N8VEA;"!C;VYD:71I;VYS(&%N9"!G96YE<F%L;'D@9&]E M<PT*(&YO="!R97%U:7)E(&-O;&QA=&5R86P@=&\@<V5C=7)E(&%C8V]U;G1S M(')E8V5I=F%B;&4@9G)O;2!I=',-"B!S=')A=&5G:6,@<&%R=&YE<G,N(%1H M92!#;VUP86YY)B-X,C`Q.3MS(&5X<&]S=7)E('1O(&-R961I="!R:7-K#0H@ M87-S;V-I871E9"!W:71H(&YO;BUP87EM96YT('=I;&P@8F4@869F96-T960@ M<')I;F-I<&%L;'D@8GD-"B!C;VYD:71I;VYS(&]R(&]C8W5R<F5N8V5S('=I M=&AI;B!!;6=E;B!);F,N("@F(W@R,#%#.T%M9V5N)B-X,C`Q1#LI#0H@86YD M($%S=&5L;&%S(%!H87)M82!);F,N("@F(W@R,#%#.T%S=&5L;&%S)B-X,C`Q M1#LI+"!I=',@<W1R871E9VEC#0H@<&%R=&YE<G,N($%P<')O>&EM871E;'D@ M,3`E+"`V,R4@86YD(#4U)2!O9B!T;W1A;"!R979E;G5E<R!F;W(@=&AE#0H@ M>65A<G,@96YD960@1&5C96UB97(F(WA!,#LS,2P@,C`Q-"P@,C`Q,R!A;F0@ M,C`Q,BP@<F5S<&5C=&EV96QY+`T*('=E<F4@9&5R:79E9"!F<F]M($%M9V5N M+B!!8V-O=6YT<R!R96-E:79A8FQE(&1U92!F<F]M($%M9V5N('=E<F4-"B`D M,2XV(&UI;&QI;VX@86YD('IE<F\@870@1&5C96UB97(F(WA!,#LS,2P@,C`Q M-"!A;F0@,C`Q,RP-"B!R97-P96-T:79E;'DN(%-E92!A;'-O($YO=&4F(WA! M,#LW+"`F(W@R,#%#.U)E;&%T960@4&%R='D-"B!4<F%N<V%C=&EO;G,L)B-X M,C`Q1#L@<F5G87)D:6YG('1H92!C;VQL86)O<F%T:6]N(&%G<F5E;65N="!W M:71H#0H@06UG96XN($%P<')O>&EM871E;'D@-CDE(&%N9"`S-"4@;V8@=&]T M86P@<F5V96YU97,@9F]R('1H92!Y96%R<PT*(&5N9&5D($1E8V5M8F5R)B-X M03`[,S$L(#(P,30@86YD(#(P,3,L(')E<W!E8W1I=F5L>2P@=V5R92!D97)I M=F5D#0H@9G)O;2!!<W1E;&QA<RX@06-C;W5N=',@<F5C96EV86)L92!D=64@ M9G)O;2!!<W1E;&QA<R!W97)E("0T-2XP#0H@;6EL;&EO;B!A;F0@>F5R;R!A M="!$96-E;6)E<B8C>$$P.S,Q+"`R,#$T(&%N9"`R,#$S+"!R97-P96-T:79E M;'DN#0H@4V5E(&%L<V\@3F]T928C>$$P.S<L("8C>#(P,4,[4F5L871E9"!0 M87)T>2!4<F%N<V%C=&EO;G,L)B-X,C`Q1#L-"B!R96=A<F1I;F<@=&AE(&-O M;&QA8F]R871I;VX@86=R965M96YT('=I=&@@07-T96QL87,N/"]F;VYT/CPO M<#X-"B`\<"!S='EL93TS1"=-05)'24XM0D]45$]-.B`P<'@[($U!4D=)3BU4 M3U`Z(#$R<'@[(%1%6%0M24Y$14Y4.B`T)2<@86QI9VX],T1J=7-T:69Y/CQF M;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I M>F4],T0R/D1R=6<@8V%N9&ED871E<R!D979E;&]P960@8GD@=&AE($-O;7!A M;GD@;6%Y(')E<75I<F4@87!P<F]V86QS#0H@;W(@8VQE87)A;F-E<R!F<F]M M('1H92!5+E,N)B-X03`[1F]O9"!A;F0@1')U9R!!9&UI;FES=')A=&EO;@T* M("@F(W@R,#%#.T9$028C>#(P,40[*2!O<B!I;G1E<FYA=&EO;F%L(')E9W5L M871O<GD@86=E;F-I97,@<')I;W(@=&\-"B!C;VUM97)C:6%L:7IE9"!S86QE M<RX@5&AE<F4@8V%N(&)E(&YO(&%S<W5R86YC92!T:&%T('1H90T*($-O;7!A M;GDF(W@R,#$Y.W,@9')U9R!C86YD:61A=&5S('=I;&P@<F5C96EV92!A;GD@ M;V8@=&AE(')E<75I<F5D#0H@87!P<F]V86QS(&]R(&-L96%R86YC97,N($EF M('1H92!#;VUP86YY('=A<R!T;R!B92!D96YI960@87!P<F]V86P-"B!O<B!C M;&5A<F%N8V4@;W(@86YY('-U8V@@87!P<F]V86P@;W(@8VQE87)A;F-E('=A M<R!T;R!B92!D96QA>65D+`T*(&ET('=O=6QD(&AA=F4@82!M871E<FEA;"!A M9'9E<G-E(&EM<&%C="!O;B!T:&4@0V]M<&%N>2X\+V9O;G0^/"]P/@T*(#QP M('-T>6QE/3-$)TU!4D=)3BU"3U143TTZ(#!P>#L@34%21TE.+51/4#H@,3)P M>#L@5$585"U)3D1%3E0Z(#0E)R!A;&EG;CTS1&IU<W1I9GD^/&9O;G0@<W1Y M;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^ M5&AE($-O;7!A;GDF(W@R,#$Y.W,@;W!E<F%T:6]N<R!A;F0@96UP;&]Y965S M(&%R92!L;V-A=&5D(&EN('1H90T*(%5N:71E9"!3=&%T97,N($EN('1H92!Y M96%R(&5N9&5D($1E8V5M8F5R)B-X03`[,S$L(#(P,30L(#,Q)2!O9B!T:&4- M"B!#;VUP86YY)B-X,C`Q.3MS(')E=F5N=65S('=E<F4@<F5C96EV960@9G)O M;2!E;G1I=&EE<R!L;V-A=&5D(&EN('1H90T*(%5N:71E9"!3=&%T97,@86YD M(#8Y)2!W97)E(')E8V5I=F5D(&9R;VT@82!*87!A;F5S92!E;G1I='DN($EN M('1H90T*('EE87(@96YD960@1&5C96UB97(F(WA!,#LS,2P@,C`Q,RP@-C8E M(&]F('1H92!#;VUP86YY)B-X,C`Q.3MS#0H@<F5V96YU97,@=V5R92!R96-E M:79E9"!F<F]M(&5N=&ET:65S(&QO8V%T960@:6X@=&AE(%5N:71E9"!3=&%T M97,-"B!A;F0@,S0E('=E<F4@<F5C96EV960@9G)O;2!A($IA<&%N97-E(&5N M=&ET>2X@26X@=&AE('EE87(@96YD960-"B!$96-E;6)E<B8C>$$P.S,Q+"`R M,#$R+"!A;&P@;V8@=&AE($-O;7!A;GDF(W@R,#$Y.W,@<F5V96YU97,@=V5R M90T*(')E8V5I=F5D(&9R;VT@96YT:71I97,@;&]C871E9"!I;B!T:&4@56YI M=&5D(%-T871E<R!O<B!F<F]M(%5N:71E9`T*(%-T871E<R!A9F9I;&EA=&5S M(&]F(&9O<F5I9VX@8V]R<&]R871I;VYS+CPO9F]N=#X\+W`^#0H@/'`@<W1Y M;&4],T0G34%21TE.+4)/5%1/33H@,'!X.R!-05)'24XM3$5&5#H@,B4[($U! M4D=)3BU43U`Z(#$X<'@G/@T*(#QF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9 M.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R/CQB/CQI/D-A<V@@86YD#0H@ M0V%S:"!%<75I=F%L96YT<SPO:3X\+V(^/"]F;VYT/CPO<#X-"B`\<"!S='EL M93TS1"=-05)'24XM0D]45$]-.B`P<'@[($U!4D=)3BU43U`Z(#9P>#L@5$58 M5"U)3D1%3E0Z(#0E)R!A;&EG;CTS1&IU<W1I9GD^/&9O;G0@<W1Y;&4],T0G M1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^5&AE($-O M;7!A;GD@8V]N<VED97)S(&%L;"!H:6=H;'D@;&EQ=6ED(&EN=F5S=&UE;G1S M('=I=&@@80T*(&UA='5R:71Y(&]F('1H<F5E(&UO;G1H<R!O<B!L97-S(&%T M('1H92!T:6UE(&]F('!U<F-H87-E('1O(&)E(&-A<V@-"B!E<75I=F%L96YT M<RX\+V9O;G0^/"]P/@T*(#QP('-T>6QE/3-$)TU!4D=)3BU"3U143TTZ(#!P M>#L@34%21TE.+4Q%1E0Z(#(E.R!-05)'24XM5$]0.B`Q.'!X)SX-"B`\9F]N M="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE M/3-$,CX\8CX\:3Y);G9E<W1M96YT<SPO:3X\+V(^/"]F;VYT/CPO<#X-"B`\ M<"!S='EL93TS1"=-05)'24XM0D]45$]-.B`P<'@[($U!4D=)3BU43U`Z(#9P M>#L@5$585"U)3D1%3E0Z(#0E)R!A;&EG;CTS1&IU<W1I9GD^/&9O;G0@<W1Y M;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^ M/&D^079A:6QA8FQE+69O<BUS86QE#0H@:6YV97-T;65N=',N/"]I/B8C>$$P M.R8C>$$P.R8C>$$P.R8C>$$P.U1H92!#;VUP86YY)B-X,C`Q.3MS#0H@:6YV M97-T;65N=',@8V]N<VES="!O9B!5+E,N)B-X03`[5')E87-U<GD@<V5C=7)I M=&EE<RP@;6]N97D@;6%R:V5T#0H@9G5N9',L(%4N4RXF(WA!,#MM=6YI8VEP M86P@86YD(&=O=F5R;FUE;G0@86=E;F-Y(&)O;F1S+"!A;F0-"B!C;VUM97)C M:6%L('!A<&5R+B!4:&4@0V]M<&%N>2!D97-I9VYA=&5S(&%L;"!I;G9E<W1M M96YT<R!A<PT*(&%V86EL86)L92UF;W(M<V%L92!A;F0@=&AE<F5F;W)E(')E M<&]R=',@=&AE;2!A="!F86ER('9A;'5E+"!B87-E9`T*(&]N('%U;W1E9"!M M87)K960@<')I8V5S+"!W:71H('5N<F5A;&EZ960@9V%I;G,@86YD(&QO<W-E M<R!R96-O<F1E9`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`\<"!S='EL93TS1"=-05)' M24XM0D]45$]-.B`P<'@[($U!4D=)3BU43U`Z(#$R<'@[(%1%6%0M24Y$14Y4 M.B`T)2<@86QI9VX],T1J=7-T:69Y/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%- M24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R/CQI/D]T:&5R+71H86XM M=&5M<&]R87)Y#0H@:6UP86ER;65N="X\+VD^)B-X03`[)B-X03`[)B-X03`[ M)B-X03`[06QL(&]F('1H92!#;VUP86YY)B-X,C`Q.3MS#0H@879A:6QA8FQE M+69O<BUS86QE(&EN=F5S=&UE;G1S(&%R92!S=6)J96-T('1O(&$@<&5R:6]D M:6,@:6UP86ER;65N=`T*(')E=FEE=RX@5&AE($-O;7!A;GD@<F5C;V=N:7IE M<R!A;B!I;7!A:7)M96YT(&-H87)G92!W:&5N(&$@9&5C;&EN90T*(&EN('1H M92!F86ER('9A;'5E(&]F(&ET<R!I;G9E<W1M96YT<R!B96QO=R!T:&4@8V]S M="!B87-I<R!I<R!J=61G960-"B!T;R!B92!O=&AE<BUT:&%N+71E;7!O<F%R M>2X@1F%C=&]R<R!C;VYS:61E<F5D(&)Y(&UA;F%G96UE;G0@:6X-"B!A<W-E M<W-I;F<@=VAE=&AE<B!A;B!O=&AE<BUT:&%N+71E;7!O<F%R>2!I;7!A:7)M M96YT(&AA<R!O8V-U<G)E9`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`^#0H@/'`@<W1Y;&4],T0G34%21TE.+4)/5%1/ M33H@,'!X.R!-05)'24XM3$5&5#H@,B4[($U!4D=)3BU43U`Z(#$X<'@G/@T* M(#QF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG M('-I>F4],T0R/CQB/CQI/E!R;W!E<G1Y#0H@86YD($5Q=6EP;65N=#PO:3X\ M+V(^/"]F;VYT/CPO<#X-"B`\<"!S='EL93TS1"=-05)'24XM0D]45$]-.B`P M<'@[($U!4D=)3BU43U`Z(#9P>#L@5$585"U)3D1%3E0Z(#0E)R!A;&EG;CTS M1&IU<W1I9GD^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE M=R!2;VUA;B<@<VEZ93TS1#(^4')O<&5R='D@86YD(&5Q=6EP;65N="!A<F4@ M<W1A=&5D(&%T(&-O<W0@;&5S<R!A8V-U;75L871E9`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`Q.'!X M)SX-"B`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`T*(&%S<V5T<RP@:6YC;'5D:6YG('!R M;W!E<G1Y(&%N9"!E<75I<&UE;G0L(&9O<B!I;7!A:7)M96YT('=H96YE=F5R M#0H@979E;G1S(&]R(&-H86YG97,@:6X@8G5S:6YE<W,@8VER8W5M<W1A;F-E M<R!I;F1I8V%T92!T:&%T('1H90T*(&-A<G)Y:6YG(&%M;W5N="!O9B!T:&4@ M87-S971S(&UA>2!N;W0@8F4@9G5L;'D@<F5C;W9E<F%B;&4N(%5N9&5R#0H@ M=&AE(&%C8V]U;G1I;F<@9W5I9&%N8V4L(&%N(&EM<&%I<FUE;G0@;&]S<R!W M;W5L9"!B92!R96-O9VYI>F5D#0H@=VAE;B!E<W1I;6%T960@=6YD:7-C;W5N M=&5D(&9U='5R92!C87-H(&9L;W=S(&5X<&5C=&5D('1O(')E<W5L=`T*(&9R M;VT@=&AE('5S92!O9B!T:&4@87-S970@86YD(&ET<R!E=F5N='5A;"!D:7-P M;W-I=&EO;B!A<F4@;&5S<PT*('1H86X@:71S(&-A<G)Y:6YG(&%M;W5N="X@ M26UP86ER;65N="P@:68@86YY+"!I<R!M96%S=7)E9"!A<R!T:&4-"B!A;6]U M;G0@8GD@=VAI8V@@=&AE(&-A<G)Y:6YG(&%M;W5N="!O9B!A(&QO;F<M;&EV M960@87-S970@97AC965D<PT*(&ET<R!F86ER('9A;'5E+CPO9F]N=#X\+W`^ M#0H@/'`@<W1Y;&4],T0G34%21TE.+4)/5%1/33H@,'!X.R!-05)'24XM3$5& M5#H@,B4[($U!4D=)3BU43U`Z(#$X<'@G/@T*(#QF;VYT('-T>6QE/3-$)T9/ M3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R/CQB/CQI/E)E M=F5N=64-"B!296-O9VYI=&EO;CPO:3X\+V(^/"]F;VYT/CPO<#X-"B`\<"!S M='EL93TS1"=-05)'24XM0D]45$]-.B`P<'@[($U!4D=)3BU43U`Z(#9P>#L@ M5$585"U)3D1%3E0Z(#0E)R!A;&EG;CTS1&IU<W1I9GD^/&9O;G0@<W1Y;&4] M,T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^5&AE M(&%C8V]U;G1I;F<@9W5I9&%N8V4@9F]R(')E=F5N=64@<F5C;V=N:71I;VX@ M<F5Q=6ER97,@=&AA=`T*('1H92!F;VQL;W=I;F<@8W)I=&5R:6$@;75S="!B M92!M970@8F5F;W)E(')E=F5N=64@8V%N(&)E#0H@<F5C;V=N:7IE9#H@*&DI M)B-X03`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`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`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`R,#$Q+"!!4T,@5&]P:6,@-C`U+3(U+"`\:3Y2979E M;G5E(%)E8V]G;FET:6]N#0H@)B-X,C`Q-#L@375L=&EP;&4M16QE;65N="!! M<G)A;F=E;65N=',\+VD^("@F(W@R,#%#.T%30PT*(#8P-2TR-28C>#(P,40[ M*2!O;B!T:&4@<F5C;V=N:71I;VX@;V8@<F5V96YU97,@9F]R(&%G<F5E;65N M=',@=VET:`T*(&UU;'1I<&QE(&1E;&EV97)A8FQE<R!B96-A;64@969F96-T M:79E(&%N9"!A<'!L:65S('1O(&%N>0T*(&%G<F5E;65N=',@=&AE($-O;7!A M;GD@96YT97)E9"!I;G1O(&]N(&]R(&%F=&5R($IA;G5A<GDF(WA!,#LQ+`T* M(#(P,3$N(%5N9&5R('1H:7,@=7!D871E9"!G=6ED86YC92P@<F5V96YU92!I M<R!A;&QO8V%T960@=&\@96%C:`T*(&5L96UE;G0@=7-I;F<@82!S96QL:6YG M('!R:6-E(&AI97)A<F-H>2P@=VAE<F4@=&AE('-E;&QI;F<@<')I8V4-"B!F M;W(@86X@96QE;65N="!I<R!B87-E9"!O;B!64T]%(&EF(&%V86EL86)L93L@ M=&AI<F0M<&%R='D@979I9&5N8V4-"B`H)B-X,C`Q0SM44$4F(W@R,#%$.RDL M(&EF(&%V86EL86)L92!A;F0@5E-/12!I<R!N;W0@879A:6QA8FQE.R!O<B!T M:&4-"B!B97-T(&5S=&EM871E(&]F('-E;&QI;F<@<')I8V4L(&EF(&YE:71H M97(@5E-/12!N;W(@5%!%(&ES#0H@879A:6QA8FQE+CPO9F]N=#X\+W`^#0H@ M/'`@<W1Y;&4],T0G34%21TE.+4)/5%1/33H@,'!X.R!-05)'24XM5$]0.B`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`F(W@R,#$T.R!-:6QE<W1O M;F4-"B!-971H;V0\+VD^("@F(W@R,#%#.T%30R`V,#4M,C@F(W@R,#%$.RDL M(&5S=&%B;&ES:&5D('1H92!M:6QE<W1O;F4-"B!M971H;V0@87,@86X@86-C M97!T86)L92!M971H;V0@;V8@<F5V96YU92!R96-O9VYI=&EO;B!F;W(@8V5R M=&%I;@T*(&-O;G1I;F=E;G0@979E;G0M8F%S960@<&%Y;65N=',@=6YD97(@ M<F5S96%R8V@@86YD(&1E=F5L;W!M96YT#0H@87)R86YG96UE;G1S+B!5;F1E M<B!T:&4@;6EL97-T;VYE(&UE=&AO9"P@82!P87EM96YT('1H870@:7,-"B!C M;VYT:6YG96YT('5P;VX@=&AE(&%C:&EE=F5M96YT(&]F(&$@<W5B<W1A;G1I M=F4@;6EL97-T;VYE(&ES#0H@<F5C;V=N:7IE9"!I;B!I=',@96YT:7)E='D@ M:6X@=&AE('!E<FEO9"!I;B!W:&EC:"!T:&4@;6EL97-T;VYE(&ES#0H@86-H M:65V960N($$@;6EL97-T;VYE(&ES(&%N(&5V96YT("AI*28C>$$P.W1H870@ M8V%N(&)E(&%C:&EE=F5D#0H@8F%S960@:6X@=VAO;&4@;W(@:6X@<&%R="!O M;B!E:71H97(@=&AE($-O;7!A;GDF(W@R,#$Y.W,@<&5R9F]R;6%N8V4-"B!O M<B!O;B!T:&4@;V-C=7)R96YC92!O9B!A('-P96-I9FEC(&]U=&-O;64@<F5S M=6QT:6YG(&9R;VT@=&AE#0H@0V]M<&%N>28C>#(P,3D[<R!P97)F;W)M86YC M92P@*&EI*28C>$$P.V9O<B!W:&EC:"!T:&5R92!I<PT*('-U8G-T86YT:79E M('5N8V5R=&%I;G1Y(&%T('1H92!D871E('1H92!A<G)A;F=E;65N="!I<R!E M;G1E<F5D(&EN=&\-"B!T:&%T('1H92!E=F5N="!W:6QL(&)E(&%C:&EE=F5D M+"!A;F0@*&EI:2DF(WA!,#MT:&%T('=O=6QD(')E<W5L=`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`T*("AI:2DF(WA!,#MR M96QA=&5S('-O;&5L>2!T;R!P87-T('!E<F9O<FUA;F-E(&%N9"`H:6EI*28C M>$$P.VES#0H@<F5A<V]N86)L92!R96QA=&EV92!T;R!A;&P@9&5L:79E<F%B M;&5S(&%N9"!P87EM96YT('1E<FUS(&EN('1H90T*(&%R<F%N9V5M96YT+CPO M9F]N=#X\+W`^#0H@/'`@<W1Y;&4],T0G34%21TE.+4)/5%1/33H@,'!X.R!- M05)'24XM5$]0.B`Q,G!X.R!415A4+4E.1$5.5#H@-"4G(&%L:6=N/3-$:G5S M=&EF>3X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O M;6%N)R!S:7IE/3-$,CY/=&AE<B!C;VYT:6YG96YT(&5V96YT+6)A<V5D('!A M>6UE;G1S(')E8V5I=F5D(&9O<B!W:&EC:`T*('!A>6UE;G0@:7,@96ET:&5R M(&-O;G1I;F=E;G0@<V]L96QY('5P;VX@=&AE('!A<W-A9V4@;V8@=&EM92!O M<B!T:&4-"B!R97-U;'1S(&]F(&$@8V]L;&%B;W)A=&EV92!P87)T;F5R)B-X M,C`Q.3MS('!E<F9O<FUA;F-E(&%R92!N;W0-"B!C;VYS:61E<F5D(&UI;&5S M=&]N97,@=6YD97(@05-#(#8P-2TR."X@26X@86-C;W)D86YC92!W:71H($%3 M0PT*(#8P-2TR-3QI/BP\+VD^('-U8V@@<&%Y;65N=',@=VEL;"!B92!R96-O M9VYI>F5D(&%S(')E=F5N=64@=VAE;B!A;&P-"B!O9B!T:&4@9F]L;&]W:6YG M(&-R:71E<FEA(&%R92!M970Z("AI*28C>$$P.W!E<G-U87-I=F4@979I9&5N M8V4@;V8-"B!A;B!A<G)A;F=E;65N="!E>&ES=',L("AI:2DF(WA!,#MD96QI M=F5R>2!H87,@;V-C=7)R960@;W(@<V5R=FEC97,-"B!H879E(&)E96X@<F5N M9&5R960L("AI:6DI)B-X03`[<')I8V4@:7,@9FEX960@;W(@9&5T97)M:6YA M8FQE+"!A;F0-"B`H:78I)B-X03`[8V]L;&5C=&%B:6QI='D@:7,@<F5A<V]N M86)L>2!A<W-U<F5D+CPO9F]N=#X\+W`^#0H@/'`@<W1Y;&4],T0G34%21TE. M+4)/5%1/33H@,'!X.R!-05)'24XM5$]0.B`Q,G!X.R!415A4+4E.1$5.5#H@ M-"4G(&%L:6=N/3-$:G5S=&EF>3X\9F]N="!S='EL93TS1"=&3TY4+49!34E, M63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CY0<FEO<B!T;R!*86YU87)Y M)B-X03`[,2P@,C`Q,2P@=&AE($-O;7!A;GD@<F5C;V=N:7IE9"!A;F0@=VEL M;`T*(&-O;G1I;G5E('1O(')E8V]G;FEZ92!M:6QE<W1O;F4@<&%Y;65N=',@ M87,@<F5V96YU92!U<&]N#0H@86-H:65V96UE;G0@;V8@=&AE(&UI;&5S=&]N M92P@<')O=FED960@=&AE(&UI;&5S=&]N92!P87EM96YT('=A<PT*(&YO;BUR M969U;F1A8FQE+"!S=6)S=&%N=&EV92!E9F9O<G0@86YD(')I<VL@=V5R92!I M;G9O;'9E9"!I;@T*(&%C:&EE=FEN9R!T:&4@;6EL97-T;VYE(&%N9"!T:&4@ M86UO=6YT(&]F('1H92!M:6QE<W1O;F4@=V%S#0H@<F5A<V]N86)L92!I;B!R M96QA=&EO;B!T;R!T:&4@969F;W)T(&5X<&5N9&5D(&]R(')I<VL@87-S;V-I M871E9`T*('=I=&@@=&AE(&%C:&EE=F5M96YT(&]F('1H92!M:6QE<W1O;F4N M($EF('1H97-E(&-O;F1I=&EO;G,@=V5R92!N;W0-"B!M970L('1H92!#;VUP M86YY(&1E9F5R<F5D('1H92!M:6QE<W1O;F4@<&%Y;65N="!A;F0@<F5C;V=N M:7IE9"!I=`T*(&%S(')E=F5N=64@;W9E<B!T:&4@97-T:6UA=&5D('!E<FEO M9"!O9B!P97)F;W)M86YC92!U;F1E<B!T:&4-"B!C;VYT<F%C="!A<R!T:&4@ M0V]M<&%N>2!C;VUP;&5T960@:71S('!E<F9O<FUA;F-E(&]B;&EG871I;VYS M+B!4:&4-"B!#;VUP86YY(&AA<R!C;VYC;'5D960@=&AA="!A;&P@;V8@=&AE M(&9U='5R92!C;VYT:6YG96YT(&UI;&5S=&]N90T*('!A>6UE;G1S('!U<G-U M86YT('1O(&ET<R!R97-E87)C:"!A;F0@9&5V96QO<&UE;G0@87)R86YG96UE M;G1S#0H@96YT97)E9"!I;G1O('!R:6]R('1O($IA;G5A<GDF(WA!,#LQ+"`R M,#$Q(&%R92!N;W0@8V]N<VED97)E9`T*('-U8G-T86YT:79E(&%S('1H97D@ M87)E('1H92!R97-U;'1S(&]F(&$@8V]L;&%B;W)A=&EV90T*('!A<G1N97(F M(W@R,#$Y.W,@<&5R9F]R;6%N8V4N(%1H97)E9F]R92P@=&AE>2!A<F4@;F]T M(&-O;G-I9&5R960-"B!M:6QE<W1O;F5S('5N9&5R($%30R`V,#4M,C@N/"]F M;VYT/CPO<#X-"B`\<"!S='EL93TS1"=-05)'24XM0D]45$]-.B`P<'@[($U! M4D=)3BU43U`Z(#$R<'@[(%1%6%0M24Y$14Y4.B`T)2<@86QI9VX],T1J=7-T M:69Y/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M M86XG('-I>F4],T0R/D9O<B!C;VQL86)O<F%T:6]N<R!A;F0@;6%T97)I86P@ M;6]D:69I8V%T:6]N<R!E;G1E<F5D(&EN=&\-"B!A9G1E<B!*86YU87)Y)B-X M03`[,2P@,C`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`Q.3MS(&5F9F]R M=`T*('1O(&%C:&EE=F4@=&AE(&UI;&5S=&]N92!O<B!C;VUM96YS=7)A=&4@ M=VET:"!T:&4@96YH86YC960@=F%L=64@;V8-"B!T:&4@9&5L:79E<F5D(&ET M96TH<RD@87,@82!R97-U;'0@;V8@=&AE(&UI;&5S=&]N92!A8VAI979E;65N M="X@268-"B!T:&4@0V]M<&%N>2!D971E<FUI;F5S(&$@;6EL97-T;VYE(&ES M(&YO="!S=6)S=&%N=&EV92P@=&AE($-O;7!A;GD-"B!D969E<G,@=&AE('!A M>6UE;G0@86YD(')E8V]G;FEZ97,@<F5V96YU92!O=F5R('1H92!E<W1I;6%T M960@<&5R:6]D#0H@;V8@<&5R9F]R;6%N8V4@87,@=&AE($-O;7!A;GD@8V]M M<&QE=&5S(&ET<R!P97)F;W)M86YC90T*(&]B;&EG871I;VYS+CPO9F]N=#X\ M+W`^#0H@/'`@<W1Y;&4],T0G34%21TE.+4)/5%1/33H@,'!X.R!-05)'24XM M5$]0.B`Q,G!X.R!415A4+4E.1$5.5#H@-"4G(&%L:6=N/3-$:G5S=&EF>3X\ M9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S M:7IE/3-$,CY297-E87)C:"!A;F0@9&5V96QO<&UE;G0@<F5V96YU97,@86YD M(&-O<W0@<F5I;6)U<G-E;65N=',@87)E#0H@8F%S960@=7!O;B!N96=O=&EA M=&5D(')A=&5S(&9O<B!T:&4@0V]M<&%N>28C>#(P,3D[<R!F=6QL+71I;64- M"B!E;7!L;WEE92!E<75I=F%L96YT<R`H)B-X,C`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`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`^#0H@/'`@<W1Y;&4],T0G34%21TE.+4)/5%1/33H@,'!X.R!& M3TY4+5-)6D4Z(#$R<'@[($U!4D=)3BU43U`Z(#!P>"<^#0H@)B-X03`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`T* M(&9U;F1S(')E8V5I=F5D(&%R92!N;W0@<F5F=6YD86)L92!A;F0@87)E(')E M8V]G;FEZ960@=VAE;B!T:&4-"B!R96QA=&5D('%U86QI9FEE9"!R97-E87)C M:"!A;F0@9&5V96QO<&UE;G0@8V]S=',@87)E(&EN8W5R<F5D(&%N9`T*('=H M96X@=&AE<F4@:7,@<F5A<V]N86)L92!A<W-U<F%N8V4@=&AA="!T:&4@9G5N M9',@=VEL;"!B92!R96-E:79E9"X-"B!&=6YD<R!R96-E:79E9"!I;B!A9'9A M;F-E(&%R92!R96-O<F1E9"!A<R!D969E<G)E9`T*(')E=F5N=64N/"]F;VYT M/CPO<#X-"B`\<"!S='EL93TS1"=-05)'24XM0D]45$]-.B`P<'@[($U!4D=) M3BU,1494.B`R)3L@34%21TE.+51/4#H@,3AP>"<^#0H@/&9O;G0@<W1Y;&4] M,T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^/&(^ M/&D^4')E8VQI;FEC86P@4W1U9&EE<R!A;F0@0VQI;FEC86P@5')I86P-"B!! M8V-R=6%L<SPO:3X\+V(^/"]F;VYT/CPO<#X-"B`\<"!S='EL93TS1"=-05)' M24XM0D]45$]-.B`P<'@[($U!4D=)3BU43U`Z(#9P>#L@5$585"U)3D1%3E0Z M(#0E)R!A;&EG;CTS1&IU<W1I9GD^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U) M3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^02!S=6)S=&%N=&EA;"!P M;W)T:6]N(&]F('1H92!#;VUP86YY)B-X,C`Q.3MS('!R96-L:6YI8V%L#0H@ M<W1U9&EE<R!A;F0@86QL(&]F('1H92!#;VUP86YY)B-X,C`Q.3MS(&-L:6YI M8V%L('1R:6%L<R!H879E(&)E96X-"B!P97)F;W)M960@8GD@=&AI<F0M<&%R M='D@8V]N=')A8W0@<F5S96%R8V@@;W)G86YI>F%T:6]N<PT*("@F(W@R,#%# M.T-23W,F(W@R,#%$.RD@86YD(&]T:&5R('9E;F1O<G,N($9O<B!P<F5C;&EN M:6-A;"!S='5D:65S+`T*('1H92!S:6=N:69I8V%N="!F86-T;W)S('5S960@ M:6X@97-T:6UA=&EN9R!A8V-R=6%L<R!I;F-L=61E('1H90T*('!E<F-E;G1A M9V4@;V8@=V]R:R!C;VUP;&5T960@=&\@9&%T92!A;F0@8V]N=')A8W0@;6EL M97-T;VYE<PT*(&%C:&EE=F5D+B!&;W(@8VQI;FEC86P@=')I86P@97AP96YS M97,L('1H92!S:6=N:69I8V%N="!F86-T;W)S('5S960-"B!I;B!E<W1I;6%T M:6YG(&%C8W)U86QS(&EN8VQU9&4@=&AE(&YU;6)E<B!O9B!P871I96YT<R!E M;G)O;&QE9"P-"B!D=7)A=&EO;B!O9B!E;G)O;&QM96YT(&%N9"!P97)C96YT M86=E(&]F('=O<FL@8V]M<&QE=&5D('1O(&1A=&4N#0H@5&AE($-O;7!A;GD@ M;6]N:71O<G,@<&%T:65N="!E;G)O;&QM96YT(&QE=F5L<R!A;F0@<F5L871E M9`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`T*(')E8V]R9"!A9&IU<W1M96YT<R!T;R!R M97-E87)C:"!A;F0@9&5V96QO<&UE;G0@97AP96YS97,@:6X@9G5T=7)E#0H@ M<&5R:6]D<R!W:&5N('1H92!A8W1U86P@86-T:79I='D@;&5V96P@8F5C;VUE M<R!K;F]W;BX@3F\@;6%T97)I86P-"B!A9&IU<W1M96YT<R!T;R!P<F5C;&EN M:6-A;"!S='5D>2!A;F0@8VQI;FEC86P@=')I86P@97AP96YS97,@:&%V90T* M(&)E96X@<F5C;V=N:7IE9"!T;R!D871E+CPO9F]N=#X\+W`^#0H@/'`@<W1Y M;&4],T0G34%21TE.+4)/5%1/33H@,'!X.R!-05)'24XM3$5&5#H@,B4[($U! M4D=)3BU43U`Z(#$X<'@G/@T*(#QF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9 M.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R/CQB/CQI/E)E<V5A<F-H#0H@ M86YD($1E=F5L;W!M96YT($5X<&5N9&ET=7)E<SPO:3X\+V(^/"]F;VYT/CPO M<#X-"B`\<"!S='EL93TS1"=-05)'24XM0D]45$]-.B`P<'@[($U!4D=)3BU4 M3U`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`Q.'!X)SX-"B`\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@ M3F5W(%)O;6%N)R!S:7IE/3-$,CX\8CX\:3Y2971I<F5M96YT(%!L86X\+VD^ M/"]B/CPO9F]N=#X\+W`^#0H@/'`@<W1Y;&4],T0G34%21TE.+4)/5%1/33H@ M,'!X.R!-05)'24XM5$]0.B`V<'@[(%1%6%0M24Y$14Y4.B`T)2<@86QI9VX] M,T1J=7-T:69Y/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!. M97<@4F]M86XG('-I>F4],T0R/E1H92!#;VUP86YY('-P;VYS;W)S(&$@-#`Q M*&LI(&1E9FEN960@8V]N=')I8G5T:6]N('!L86X-"B!C;W9E<FEN9R!A;&P@ M96UP;&]Y965S+B!4:&5R92!W97)E(&YO(&5M<&QO>65R(&-O;G1R:6)U=&EO M;G,@=&\@=&AE#0H@<&QA;B!F<F]M(&EN8V5P=&EO;B!T:')O=6=H($1E8V5M M8F5R)B-X03`[,S$L(#(P,3,N($EN(#(P,30L#0H@96UP;&]Y97(@8V]N=')I M8G5T:6]N<R!T;R!T:&4@-#`Q*&LI('!L86X@=V5R92`D,S,V+#`P,"X\+V9O M;G0^/"]P/@T*(#QP('-T>6QE/3-$)TU!4D=)3BU"3U143TTZ(#!P>#L@34%2 M1TE.+4Q%1E0Z(#(E.R!-05)'24XM5$]0.B`Q.'!X)SX-"B`\9F]N="!S='EL M93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CX\ M8CX\:3Y);F-O;64-"B!487AE<SPO:3X\+V(^/"]F;VYT/CPO<#X-"B`\<"!S M='EL93TS1"=-05)'24XM0D]45$]-.B`P<'@[($U!4D=)3BU43U`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`F(W@R,#%#.VUO M<F4M;&EK96QY+71H86XM;F]T)B-X,C`Q1#L-"B!T;R!B92!S=7-T86EN960@ M8GD@=&AE('1A>&EN9R!A=71H;W)I=&EE<R!B87-E9"!S;VQE;'D@;VX@=&AE M#0H@=&5C:&YI8V%L(&UE<FET<R!O9B!T:&4@<&]S:71I;VXN($EF('1H92!R M96-O9VYI=&EO;B!T:')E<VAO;&0@:7,-"B!M970L('1H92!T87@@8F5N969I M="!I<R!M96%S=7)E9"!A;F0@<F5C;V=N:7IE9"!A<R!T:&4@;&%R9V5S=`T* M(&%M;W5N="!O9B!T87@@8F5N969I="!T:&%T+"!I;B!T:&4@0V]M<&%N>28C M>#(P,3D[<R!J=61G;65N="P@:7,-"B!G<F5A=&5R('1H86X@-3`E(&QI:V5L M>2!T;R!B92!R96%L:7IE9"X\+V9O;G0^/"]P/@T*(#QP('-T>6QE/3-$)TU! M4D=)3BU"3U143TTZ(#!P>#L@1D].5"U325I%.B`Q.'!X.R!-05)'24XM5$]0 M.B`P<'@G/@T*("8C>$$P.SPO<#X-"B`\<"!S='EL93TS1"=-05)'24XM0D]4 M5$]-.B`P<'@[($U!4D=)3BU,1494.B`R)3L@34%21TE.+51/4#H@,'!X)SX- M"B`\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N M)R!S:7IE/3-$,CX\8CX\:3Y#;VUP<F5H96YS:79E($QO<W,\+VD^/"]B/CPO M9F]N=#X\+W`^#0H@/'`@<W1Y;&4],T0G34%21TE.+4)/5%1/33H@,'!X.R!- M05)'24XM5$]0.B`V<'@[(%1%6%0M24Y$14Y4.B`T)2<@86QI9VX],T1J=7-T M:69Y/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M M86XG('-I>F4],T0R/E1H92!#;VUP86YY(&9O;&QO=W,@=&AE(&%C8V]U;G1I M;F<@<W1A;F1A<F1S(&9O<B!T:&4@<F5P;W)T:6YG#0H@86YD('!R97-E;G1A M=&EO;B!O9B!C;VUP<F5H96YS:79E(&EN8V]M92`H;&]S<RD@86YD(&ET<R!C M;VUP;VYE;G1S+@T*($]N($IA;G5A<GDF(WA!,#LQ+"`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`T*(#(P,30L(#(P,3,L(&%N9"`R,#$R('=A<R!E<75A;"!T;R!N970@ M;&]S<R!A9&IU<W1E9"!F;W(@=6YR96%L:7IE9`T*(&=A:6YS(&%N9"!L;W-S M97,@;VX@:6YV97-T;65N=',N/"]F;VYT/CPO<#X-"B`\<"!S='EL93TS1"=- M05)'24XM0D]45$]-.B`P<'@[($U!4D=)3BU,1494.B`R)3L@34%21TE.+51/ M4#H@,3AP>"<^#0H@/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S M($YE=R!2;VUA;B<@<VEZ93TS1#(^/&(^/&D^4V5G;65N=`T*(%)E<&]R=&EN M9SPO:3X\+V(^/"]F;VYT/CPO<#X-"B`\<"!S='EL93TS1"=-05)'24XM0D]4 M5$]-.B`P<'@[($U!4D=)3BU43U`Z(#9P>#L@5$585"U)3D1%3E0Z(#0E)R!A M;&EG;CTS1&IU<W1I9GD^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I M;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^5&AE($-O;7!A;GD@:&%S(&1E=&5R M;6EN960@=&AA="!I="!O<&5R871E<R!I;B!O;FQY(&]N90T*('-E9VUE;G0N M/"]F;VYT/CPO<#X-"B`\<"!S='EL93TS1"=-05)'24XM0D]45$]-.B`P<'@[ M($U!4D=)3BU,1494.B`R)3L@34%21TE.+51/4#H@,3AP>"<^#0H@/&9O;G0@ M<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS M1#(^/&(^/&D^4F5V97)S90T*(%-T;V-K(%-P;&ET/"]I/CPO8CX\+V9O;G0^ M/"]P/@T*(#QP('-T>6QE/3-$)TU!4D=)3BU"3U143TTZ(#!P>#L@34%21TE. M+51/4#H@-G!X.R!415A4+4E.1$5.5#H@-"4G(&%L:6=N/3-$:G5S=&EF>3X\ M9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S M:7IE/3-$,CY/;B8C>$$P.TIU;F4F(WA!,#LR-"P@,C`Q,RP@=&AE($-O;7!A M;GD@969F96-T960@82!O;F4M9F]R+7-I>`T*(')E=F5R<V4@<W1O8VL@<W!L M:70@;V8@:71S(&-O;6UO;B!S=&]C:R!T:')O=6=H(&%N(&%M96YD;65N="!T M;R!I=',-"B!A;65N9&5D(&%N9"!R97-T871E9"!C97)T:69I8V%T92!O9B!I M;F-O<G!O<F%T:6]N("AT:&4@)B-X,C`Q0SM#3TD-"B!!;65N9&UE;G0F(W@R M,#%$.RDN($%S(&]F('1H92!E9F9E8W1I=F4@=&EM92!O9B!T:&4@<F5V97)S M92!S=&]C:PT*('-P;&ET+"!E=F5R>2!S:7@@<VAA<F5S(&]F('1H92!#;VUP M86YY)B-X,C`Q.3MS(&ES<W5E9"!A;F0-"B!O=71S=&%N9&EN9R!C;VUM;VX@ M<W1O8VL@=V5R92!C;VYV97)T960@:6YT;R!O;F4@:7-S=65D(&%N9`T*(&]U M='-T86YD:6YG('-H87)E(&]F(&-O;6UO;B!S=&]C:RP@=VET:&]U="!A;GD@ M8VAA;F=E(&EN('!A<B!V86QU90T*('!E<B!S:&%R92X@5&AE(')E=F5R<V4@ M<W1O8VL@<W!L:70@869F96-T960@86QL('-H87)E<R!O9B!T:&4-"B!#;VUP M86YY)B-X,C`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`T*('-H87)E<R!O9B!C;VUM M;VX@<W1O8VL@=&\@.#$N-28C>$$P.VUI;&QI;VXN/"]F;VYT/CPO<#X-"B`\ M<"!S='EL93TS1"=-05)'24XM0D]45$]-.B`P<'@[($U!4D=)3BU43U`Z(#$R M<'@[(%1%6%0M24Y$14Y4.B`T)2<@86QI9VX],T1J=7-T:69Y/CQF;VYT('-T M>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R M/D%S('1H92!P87(@=F%L=64@<&5R('-H87)E(&]F('1H92!#;VUP86YY)B-X M,C`Q.3MS(&-O;6UO;B!S=&]C:PT*(')E;6%I;F5D('5N8VAA;F=E9"!A="`D M,"XP,#$@<&5R('-H87)E+"!A('1O=&%L(&]F("0Q,SDL,#`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`Q.'!X)SX-"B`\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM M97,@3F5W(%)O;6%N)R!S:7IE/3-$,CX\8CX\:3Y3=&]C:RU"87-E9"!#;VUP M96YS871I;VX\+VD^/"]B/CPO9F]N=#X\+W`^#0H@/'`@<W1Y;&4],T0G34%2 M1TE.+4)/5%1/33H@,'!X.R!-05)'24XM5$]0.B`V<'@[(%1%6%0M24Y$14Y4 M.B`T)2<@86QI9VX],T1J=7-T:69Y/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%- M24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R/E1H92!#;VUP86YY(&%C M8V]U;G1S(&9O<B!S=&]C:RUB87-E9"!P87EM96YT(&%W87)D<R!M861E('1O M#0H@96UP;&]Y965S(&%N9"!D:7)E8W1O<G,L(&EN8VQU9&EN9R!E;7!L;WEE M92!S=&]C:R!O<'1I;VYS(&%N9`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`T*(&EN(&9U='5R92!P97)I M;V1S+B!4:&4@87-S=6UP=&EO;G,@=7-E9"!I;B!C86QC=6QA=&EN9R!T:&4@ M9F%I<@T*('9A;'5E(&]F('-H87)E+6)A<V5D('!A>6UE;G0@87=A<F1S(')E M<')E<V5N="!M86YA9V5M96YT)B-X,C`Q.3MS#0H@8F5S="!E<W1I;6%T97,@ M870@=&AE('1I;64L(&)U="!T:&5S92!E<W1I;6%T97,@:6YV;VQV92!I;FAE M<F5N=`T*('5N8V5R=&%I;G1I97,@86YD('1H92!A<'!L:6-A=&EO;B!O9B!M M86YA9V5M96YT(&IU9&=M96YT+B!!<R!A#0H@<F5S=6QT+"!I9B!C;VYD:71I M;VYS(&-H86YG92!A;F0@=&AE(&UA;F%G96UE;G0@=7-E<R!D:69F97)E;G0- M"B!A<W-U;7!T:6]N<RP@=&AE($-O;7!A;GDF(W@R,#$Y.W,@<W1O8VLM8F%S M960@8V]M<&5N<V%T:6]N(&5X<&5N<V4-"B!C;W5L9"!B92!M871E<FEA;&QY M(&1I9F9E<F5N="!I;B!T:&4@9G5T=7)E+B!);B!A9&1I=&EO;BP@=&AE#0H@ M0V]M<&%N>2!I<R!R97%U:7)E9"!T;R!E<W1I;6%T92!T:&4@97AP96-T960@ M9F]R9F5I='5R92!R871E(&%N9`T*(')E8V]G;FEZ92!E>'!E;G-E(&]N;'D@ M9F]R('1H;W-E('-H87)E<R!E>'!E8W1E9"!T;R!V97-T+B!)9B!T:&4-"B!A M8W1U86P@9F]R9F5I='5R92!R871E(&ES(&UA=&5R:6%L;'D@9&EF9F5R96YT M(&9R;VT-"B!M86YA9V5M96YT)B-X,C`Q.3MS(&5S=&EM871E+"!S=&]C:RUB M87-E9"!C;VUP96YS871I;VX@97AP96YS92!C;W5L9`T*(&)E('-I9VYI9FEC M86YT;'D@9&EF9F5R96YT(&9R;VT@=VAA="!H87,@8F5E;B!R96-O<F1E9"!I M;B!T:&4-"B!C=7)R96YT('!E<FEO9"X\+V9O;G0^/"]P/@T*(#QP('-T>6QE M/3-$)TU!4D=)3BU"3U143TTZ(#!P>#L@1D].5"U325I%.B`Q.'!X.R!-05)' M24XM5$]0.B`P<'@G/@T*("8C>$$P.SPO<#X-"B`\<"!S='EL93TS1"=-05)' M24XM0D]45$]-.B`P<'@[($U!4D=)3BU,1494.B`R)3L@34%21TE.+51/4#H@ M,'!X)SX-"B`\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W M(%)O;6%N)R!S:7IE/3-$,CX\8CX\:3Y296-E;G0-"B!!8V-O=6YT:6YG(%!R M;VYO=6YC96UE;G1S/"]I/CPO8CX\+V9O;G0^/"]P/@T*(#QP('-T>6QE/3-$ M)TU!4D=)3BU"3U143TTZ(#!P>#L@34%21TE.+4Q%1E0Z(#(E.R!-05)'24XM M5$]0.B`V<'@G/@T*(#QF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE M<R!.97<@4F]M86XG('-I>F4],T0R/CQI/E)E8V5N=&QY#0H@061O<'1E9"!! M8V-O=6YT:6YG(%!R;VYO=6YC96UE;G1S/"]I/CPO9F]N=#X\+W`^#0H@/'`@ M<W1Y;&4],T0G34%21TE.+4)/5%1/33H@,'!X.R!-05)'24XM5$]0.B`V<'@[ M(%1%6%0M24Y$14Y4.B`T)2<@86QI9VX],T1J=7-T:69Y/CQF;VYT('-T>6QE M/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R/DEN M($IU;'D@,C`Q,RP@=&AE($9!4T(@:7-S=65D($%352`R,#$S+3$Q+"`\:3Y0 M<F5S96YT871I;VX@;V8-"B!A;B!5;G)E8V]G;FEZ960@5&%X($)E;F5F:70@ M5VAE;B!A($YE="!/<&5R871I;F<@3&]S<R!#87)R>69O<G=A<F0L#0H@82!3 M:6UI;&%R(%1A>"!,;W-S+"!O<B!A(%1A>"!#<F5D:70@0V%R<GEF;W)W87)D M($5X:7-T<SPO:3XN($%350T*(#(P,3,M,3$@86UE;F1S(&%C8V]U;G1I;F<@ M9W5I9&%N8V4@;VX@=&AE('!R97-E;G1A=&EO;B!O9B!A;@T*('5N<F5C;V=N M:7IE9"!T87@@8F5N969I="!W:&5N(&$@;F5T(&]P97)A=&EN9R!L;W-S(&-A M<G)Y9F]R=V%R9"P@80T*('-I;6EL87(@=&%X(&QO<W,L(&]R('1A>"!C<F5D M:70@8V%R<GEF;W)W87)D(&5X:7-T<RX@5&AI<R!N97<-"B!G=6ED86YC92!R M97%U:7)E<R!E;G1I=&EE<RP@:68@8V5R=&%I;B!C<FET97)I82!A<F4@;65T M+"!T;R!P<F5S96YT#0H@86X@=6YR96-O9VYI>F5D('1A>"!B96YE9FET+"!O M<B!P;W)T:6]N(&]F(&%N('5N<F5C;V=N:7IE9"!T87@-"B!B96YE9FET+"!I M;B!T:&4@9FEN86YC:6%L('-T871E;65N=',@87,@82!R961U8W1I;VX@=&\@ M82!D969E<G)E9`T*('1A>"!A<W-E="!F;W(@82!N970@;W!E<F%T:6YG(&QO M<W,@8V%R<GEF;W)W87)D+"!A('-I;6EL87(@=&%X#0H@;&]S<RP@;W(@82!T M87@@8W)E9&ET(&-A<G)Y9F]R=V%R9"!W:&5N('-U8V@@:71E;7,@97AI<W0@ M:6X@=&AE#0H@<V%M92!T87AI;F<@:G5R:7-D:6-T:6]N+B!4:&4@0V]M<&%N M>2!A9&]P=&5D($%352`R,#$S+3$Q(&5F9F5C=&EV90T*($IA;G5A<GDF(WA! M,#LQ+"`R,#$T(&%N9"!T:&4@861O<'1I;VX@;V8@05-5(#(P,3,M,3$@9&ED M(&YO="!H879E(&$-"B!M871E<FEA;"!E9F9E8W0@;VX@:71S(&9I;F%N8VEA M;"!S=&%T96UE;G1S+CPO9F]N=#X\+W`^#0H@/'`@<W1Y;&4],T0G34%21TE. M+4)/5%1/33H@,'!X.R!-05)'24XM3$5&5#H@,B4[($U!4D=)3BU43U`Z(#$X M<'@G/@T*(#QF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@ M4F]M86XG('-I>F4],T0R/CQI/D%C8V]U;G1I;F<-"B!0<F]N;W5N8V5M96YT M<R!.;W0@665T($%D;W!T960\+VD^/"]F;VYT/CPO<#X-"B`\<"!S='EL93TS M1"=-05)'24XM0D]45$]-.B`P<'@[($U!4D=)3BU43U`Z(#9P>#L@5$585"U) M3D1%3E0Z(#0E)R!A;&EG;CTS1&IU<W1I9GD^/&9O;G0@<W1Y;&4],T0G1D]. M5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^26X@3F]V96UB M97(@,C`Q-"P@=&AE($9!4T(@:7-S=65D($%352`R,#$T+3$W+"`\:3Y"=7-I M;F5S<PT*($-O;6)I;F%T:6]N<R`H5&]P:6,@.#`U*2`F(W@R,#$T.R!0=7-H M9&]W;B!!8V-O=6YT:6YG("AA(&-O;G-E;G-U<PT*(&]F('1H92!&05-"($5M M97)G:6YG($ES<W5E<R!487-K($9O<F-E*2X\+VD^(%1H:7,@9W5I9&%N8V4@ M<')O=FED97,-"B!T:&4@;W!T:6]N(&9O<B!A;B!A8W%U:7)E9"!E;G1I='D@ M=&\@87!P;'D@<'5S:&1O=VX@86-C;W5N=&EN9R!I;@T*(&ET<R!S97!A<F%T M96QY(&ES<W5E9"!F:6YA;F-I86P@<W1A=&5M96YT<R!W:&5N(&$@8VAA;F=E M+6EN+6-O;G1R;VP-"B!E=F5N="!O8V-U<G,N(%1H:7,@9W5I9&%N8V4@:7,@ M969F96-T:79E(&)E9VEN;FEN9PT*($YO=F5M8F5R)B-X03`[,3@L(#(P,30L M(&%N9"!I<R!A<'!L:6-A8FQE('1O(&-H86YG92UI;BUC;VYT<F]L#0H@979E M;G1S(&]C8W5R<FEN9R!A9G1E<B!T:&%T(&1A=&4@;W(@87!P;&EE9"!T;R!T M:&4@;6]S="!R96-E;G0-"B!C:&%N9V4M:6XM8V]N=')O;"!E=F5N="!I9B!F M:6YA;F-I86P@<W1A=&5M96YT<R!H879E(&YO="!Y970@8F5E;@T*(&ES<W5E M9"X@5&AE($-O;7!A;GD@9&]E<R!N;W0@97AP96-T('1H92!A9&]P=&EO;B!O M9B!!4U4@,C`Q-"TQ-R!T;PT*(&AA=F4@82!M871E<FEA;"!E9F9E8W0@=7!O M;B!I=',@9FEN86YC:6%L('-T871E;65N=',N/"]F;VYT/CPO<#X-"B`\<"!S M='EL93TS1"=-05)'24XM0D]45$]-.B`P<'@[($U!4D=)3BU43U`Z(#$R<'@[ M(%1%6%0M24Y$14Y4.B`T)2<@86QI9VX],T1J=7-T:69Y/CQF;VYT('-T>6QE M/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R/DEN M($%U9W5S="`R,#$T+"!T:&4@1D%30B!I<W-U960@05-5(#(P,30M,34L(#QI M/E!R97-E;G1A=&EO;B!O9@T*($9I;F%N8VEA;"!3=&%T96UE;G1S("8C>#(P M,30[($=O:6YG($-O;F-E<FX@*%-U8G1O<&EC(#(P-2TT,"DZ#0H@1&ES8VQO M<W5R92!O9B!5;F-E<G1A:6YT:65S(&%B;W5T(&%N($5N=&ET>28C>#(P,3D[ M<R!!8FEL:71Y('1O#0H@0V]N=&EN=64@87,@82!';VEN9R!#;VYC97)N+CPO M:3X@05-5)B-X03`[,C$T+3$U(')E<75I<F5S#0H@;6%N86=E;65N="!T;R!A M<W-E<W,@86X@96YT:71Y)B-X,C`Q.3MS(&%B:6QI='D@=&\@8V]N=&EN=64@ M87,@80T*(&=O:6YG(&-O;F-E<FXL(&%N9"!T;R!P<F]V:61E(')E;&%T960@ M9F]O=&YO=&4@9&ES8VQO<W5R97,@:6X-"B!C97)T86EN(&-I<F-U;7-T86YC M97,N($%352`R,#$T+3$U(&ES(&5F9F5C=&EV92!F;W(@86YN=6%L(&%N9`T* M(&EN=&5R:6T@<F5P;W)T:6YG('!E<FEO9',@8F5G:6YN:6YG(&]N(&]R(&%F M=&5R($1E8V5M8F5R)B-X03`[,34L#0H@,C`Q-B!A;F0@96%R;'D@861O<'1I M;VX@:7,@<&5R;6ET=&5D+B!4:&4@0V]M<&%N>2!D;V5S(&YO="!E>'!E8W0- M"B!T:&4@861O<'1I;VX@;V8@05-5(#(P,30M,34@=&\@:&%V92!A(&UA=&5R M:6%L(&5F9F5C="!U<&]N(&ET<PT*(&9I;F%N8VEA;"!S=&%T96UE;G1S+CPO M9F]N=#X\+W`^#0H@/'`@<W1Y;&4],T0G34%21TE.+4)/5%1/33H@,'!X.R!- M05)'24XM5$]0.B`Q,G!X.R!415A4+4E.1$5.5#H@-"4G(&%L:6=N/3-$:G5S M=&EF>3X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O M;6%N)R!S:7IE/3-$,CY);B!-87D@,C`Q-"P@=&AE($9!4T(@:7-S=65D($%3 M52`R,#$T+3`Y+"`\:3Y2979E;G5E(&9R;VT-"B!#;VYT<F%C=',@=VET:"!# M=7-T;VUE<G,@*%1O<&EC(#8P-BD\+VD^+"!W:&EC:"!S=7!E<G-E9&5S('1H M90T*(')E=F5N=64@<F5C;V=N:71I;VX@<F5Q=6ER96UE;G1S(&EN($%30R`V M,#4L(#QI/E)E=F5N=64-"B!296-O9VYI=&EO;CPO:3XN($%3528C>$$P.S(P M,30M,#D@<W1I<'5L871E<R!T:&%T(&%N(&5N=&ET>2!S:&]U;&0-"B!R96-O M9VYI>F4@<F5V96YU92!T;R!D97!I8W0@=&AE('1R86YS9F5R(&]F('!R;VUI M<V5D(&=O;V1S(&]R#0H@<V5R=FEC97,@=&\@8W5S=&]M97)S(&EN(&%N(&%M M;W5N="!T:&%T(')E9FQE8W1S('1H92!C;VYS:61E<F%T:6]N#0H@=&\@=VAI M8V@@=&AE(&5N=&ET>2!E>'!E8W1S('1O(&)E(&5N=&ET;&5D(&EN(&5X8VAA M;F=E(&9O<B!T:&]S90T*(&=O;V1S(&]R('-E<G9I8V5S+B!!4U4F(WA!,#LR M,#$T+3`Y(&%L<V\@<F5Q=6ER97,@861D:71I;VYA;`T*(&1I<V-L;W-U<F4@ M86)O=70@=&AE(&YA='5R92P@86UO=6YT+"!T:6UI;F<@86YD('5N8V5R=&%I M;G1Y(&]F#0H@<F5V96YU92!A;F0@8V%S:"!F;&]W<R!A<FES:6YG(&9R;VT@ M8W5S=&]M97(@8V]N=')A8W1S+"!I;F-L=61I;F<-"B!S:6=N:69I8V%N="!J M=61G;65N=',@86YD(&-H86YG97,@:6X@:G5D9VUE;G1S(&%N9"!A<W-E=',- M"B!R96-O9VYI>F5D(&9R;VT@8V]S=',@:6YC=7)R960@=&\@;V)T86EN(&]R M(&9U;&9I;&P@82!C;VYT<F%C="X-"B!!4U4F(WA!,#LR,#$T+3`Y(&ES(&5F M9F5C=&EV92!F;W(@86YN=6%L(&%N9"!I;G1E<FEM(')E<&]R=&EN9PT*('!E M<FEO9',@8F5G:6YN:6YG(&]N(&]R(&%F=&5R($1E8V5M8F5R)B-X03`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`[,C`Q-"TP.2!O;B!I=',@8V]N<V]L:61A=&5D(&9I;F%N8VEA;`T* M('-T871E;65N=',N/"]F;VYT/CPO<#X-"B`\<"!S='EL93TS1"=-05)'24XM M0D]45$]-.B`P<'@[($U!4D=)3BU43U`Z(#$R<'@[(%1%6%0M24Y$14Y4.B`T M)2<@86QI9VX],T1J=7-T:69Y/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9 M.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R/DEN($%P<FEL(#(P,30L('1H M92!&05-"(&ES<W5E9"!!4U4@,C`Q-"TP."P@/&D^4F5P;W)T:6YG#0H@1&ES M8V]N=&EN=65D($]P97)A=&EO;G,@86YD($1I<V-L;W-U<F5S(&]F($1I<W!O M<V%L<R!O9B!#;VUP;VYE;G1S#0H@;V8@86X@16YT:71Y/"]I/BX@05-5(#(P M,30M,#@@8VAA;F=E<R!T:&4@8W)I=&5R:6$@9F]R(&1E=&5R;6EN:6YG#0H@ M=VAI8V@@9&ES<&]S86QS(&-A;B!B92!P<F5S96YT960@87,@9&ES8V]N=&EN M=65D(&]P97)A=&EO;G,@86YD#0H@;6]D:69I97,@<F5L871E9"!D:7-C;&]S M=7)E(')E<75I<F5M96YT<RX@5&AI<R!N97<@9W5I9&%N8V4@:7,-"B!E9F9E M8W1I=F4@9F]R('1H92!#;VUP86YY(&)E9VEN;FEN9R!*86YU87)Y)B-X03`[ M,2P@,C`Q-2X@5&AE#0H@0V]M<&%N>2!D;V5S(&YO="!E>'!E8W0@=&AE(&%D M;W!T:6]N(&]F($%352`R,#$T+3`X('1O(&AA=F4@80T*(&UA=&5R:6%L(&5F M9F5C="!U<&]N(&ET<R!F:6YA;F-I86P@<W1A=&5M96YT<RX\+V9O;G0^/"]P M/@T*(#PO9&EV/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@ M("`\+W1A8FQE/@T*("`\+V)O9'D^#0H\+VAT;6P^#0H-"BTM+2TM+3U?3F5X M=%!A<G1?,SEC,&5A-C)?8S(P,U\T-3AF7SAC-3!?,V1C830U-F$V.34Q#0I# M;VYT96YT+4QO8V%T:6]N.B!F:6QE.B\O+T,Z+S,Y8S!E838R7V,R,#-?-#4X M9E\X8S4P7S-D8V$T-39A-CDU,2]7;W)K<VAE971S+U-H965T,#DN:'1M;`T* M0V]N=&5N="U4<F%N<V9E<BU%;F-O9&EN9SH@<75O=&5D+7!R:6YT86)L90T* M0V]N=&5N="U4>7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T* M#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O M;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA<G-E=#UU=&8M M."<^/'-C<FEP="!T>7!E/3-$=&5X="]J879A<V-R:7!T('-R8STS1%-H;W<N M:G,^+RH@1&\@3F]T(%)E;6]V92!4:&ES($-O;6UE;G0@*B\\+W-C<FEP=#X\ M+VAE860^#0H@(#QB;V1Y/@T*("`@(#QT86)L92!C;&%S<STS1')E<&]R="!I M9#TS1$E$,$5-13X-"B`@("`@(#QT<CX-"B`@("`@("`@/'1H(&-L87-S/3-$ M=&P@8V]L<W!A;CTS1#$@<F]W<W!A;CTS1#(^/'-T<F]N9SY.970@3&]S<R!0 M97(@4VAA<F4\8G(^/"]S=')O;F<^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S M/3-$=&@@8V]L<W!A;CTS1#$^,3(@36]N=&AS($5N9&5D/"]T:#X-"B`@("`@ M(#PO='(^#0H@("`@("`\='(^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/D1E M8RX@,S$L(#(P,30\8G(^/"]T:#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@ M8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$ M=&]P/CQS=')O;F<^16%R;FEN9W,@4&5R(%-H87)E(%M!8G-T<F%C=%T\+W-T M<F]N9SX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO M<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O M/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^3F5T($QO M<W,@4&5R(%-H87)E/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\ M9&EV/@T*(#QP('-T>6QE/3-$)TU!4D=)3BU"3U143TTZ(#!P>#L@34%21TE. M+51/4#H@,'!X)SX\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@ M3F5W(%)O;6%N)R!S:7IE/3-$,CX\8CY.;W1E(#(@)B-X,C`Q-#L@3F5T($QO M<W,-"B!097(@4VAA<F4\+V(^/"]F;VYT/CPO<#X-"B`\<"!S='EL93TS1"=- M05)'24XM0D]45$]-.B`P<'@[($U!4D=)3BU43U`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`H:6X@=&AO=7-A;F1S#0H@ M97AC97!T('!E<B!S:&%R92!D871A*3H\+V9O;G0^/"]P/@T*(#QP('-T>6QE M/3-$)TU!4D=)3BU"3U143TTZ(#!P>#L@1D].5"U325I%.B`Q,G!X.R!-05)' M24XM5$]0.B`P<'@G/@T*("8C>$$P.SPO<#X-"B`\=&%B;&4@<W1Y;&4],T0G M0D]21$52+4-/3$Q!4%-%.B!C;VQL87!S92<@8V5L;'-P86-I;F<],T0P(&-E M;&QP861D:6YG/3-$,"!W:61T:#TS1#DR)2!A;&EG;CTS1&-E;G1E<B!B;W)D M97(],T0P/@T*(#QT<CX-"B`\=&0@=VED=&@],T0V-B4^/"]T9#X-"B`\=&0@ M=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$-24^/"]T9#X-"B`\=&0^/"]T9#X- M"B`\=&0^/"]T9#X-"B`\=&0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M M('=I9'1H/3-$-"4^/"]T9#X-"B`\=&0^/"]T9#X-"B`\=&0^/"]T9#X-"B`\ M=&0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$-"4^/"]T M9#X-"B`\=&0^/"]T9#X-"B`\=&0^/"]T9#X-"B`\=&0^/"]T9#X-"B`\+W1R M/@T*(#QT<CX-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q M/B8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O M;G0@<VEZ93TS1#$^)B-X03`[)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('-T M>6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,7!X('-O;&ED)R!V86QI M9VX],T1B;W1T;VT@8V]L<W!A;CTS1#$P(&%L:6=N/3-$8V5N=&5R/CQF;VYT M('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4] M,T0Q/CQB/EEE87)S($5N9&5D#0H@1&5C96UB97(F(WA!,#LS,2P\+V(^/"]F M;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$ M,3XF(WA!,#L\+V9O;G0^/"]T9#X-"B`\+W1R/@T*(#QT<CX-"B`\=&0@=F%L M:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C>$$P.SPO9F]N=#X\+W1D M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<VEZ93TS1#$^)B-X03`[ M)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('-T>6QE/3-$)T)/4D1%4BU"3U14 M3TTZ(",P,#`P,#`@,7!X('-O;&ED)R!V86QI9VX],T1B;W1T;VT@8V]L<W!A M;CTS1#(@86QI9VX],T1C96YT97(^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U) M3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#$^/&(^,C`Q-#PO8CX\+V9O M;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q M/B8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O M;G0@<VEZ93TS1#$^)B-X03`[)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('-T M>6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,7!X('-O;&ED)R!V86QI M9VX],T1B;W1T;VT@8V]L<W!A;CTS1#(@86QI9VX],T1C96YT97(^/&9O;G0@ M<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS M1#$^/&(^,C`Q,SPO8CX\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T M=&]M/CQF;VYT('-I>F4],T0Q/B8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V M86QI9VX],T1B;W1T;VT^/&9O;G0@<VEZ93TS1#$^)B-X03`[)B-X03`[/"]F M;VYT/CPO=&0^#0H@/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P M,#`@,7!X('-O;&ED)R!V86QI9VX],T1B;W1T;VT@8V]L<W!A;CTS1#(@86QI M9VX],T1C96YT97(^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S M($YE=R!2;VUA;B<@<VEZ93TS1#$^/&(^,C`Q,CPO8CX\+V9O;G0^/"]T9#X- M"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C>$$P.SPO M9F]N=#X\+W1D/@T*(#PO='(^#0H@/'1R(&)G8V]L;W(],T0C0T-%149&/@T* M(#QT9"!V86QI9VX],T1T;W`^#0H@/'`@<W1Y;&4],T0G34%21TE.+4Q%1E0Z M(#%E;3L@5$585"U)3D1%3E0Z("TQ96TG/CQF;VYT('-T>6QE/3-$)T9/3E0M M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R/DYE="!L;W-S/"]F M;VYT/CPO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@ M<VEZ93TS1#$^)B-X03`[)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG M;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@ M3F5W(%)O;6%N)R!S:7IE/3-$,CXD/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG M;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/CQF;VYT('-T>6QE/3-$)T9/3E0M M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R/B@Q-"PV-#8\+V9O M;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A M<#X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N M)R!S:7IE/3-$,CXI)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS M1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF(WA!,#LF(WA!,#L\+V9O;G0^/"]T M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)T9/3E0M M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R/B0\+V9O;G0^/"]T M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^/&9O;G0@ M<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS M1#(^*#,S+#<Q-SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@ M;F]W<F%P/3-$;F]W<F%P/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4 M:6UE<R!.97<@4F]M86XG('-I>F4],T0R/BDF(WA!,#L\+V9O;G0^/"]T9#X- M"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C>$$P.R8C M>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@ M<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS M1#(^)#PO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX] M,T1R:6=H=#X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W M(%)O;6%N)R!S:7IE/3-$,CXH-#`L,S<P/"]F;VYT/CPO=&0^#0H@/'1D('9A M;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^/&9O;G0@<W1Y;&4],T0G M1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^*28C>$$P M.SPO9F]N=#X\+W1D/@T*(#PO='(^#0H@/'1R/@T*(#QT9"!V86QI9VX],T1T M;W`^#0H@/'`@<W1Y;&4],T0G34%21TE.+4Q%1E0Z(#%E;3L@5$585"U)3D1% M3E0Z("TQ96TG/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!. M97<@4F]M86XG('-I>F4],T0R/D1E96UE9"!D:79I9&5N9"!R96QA=&5D('1O M#0H@8F5N969I8VEA;"!C;VYV97)S:6]N(&9E871U<F4@;V8@8V]N=F5R=&EB M;&4@<')E9F5R<F5D#0H@<W1O8VL\+V9O;G0^/"]P/@T*(#PO=&0^#0H@/'1D M('9A;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF(WA!,#LF(WA!,#L\ M+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO M=W)A<#X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O M;6%N)R!S:7IE/3-$,CXF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N M/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<"!A;&EG;CTS1')I9VAT/CQF;VYT M('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4] M,T0R/B8C>#(P,30[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O M;2!N;W=R87`],T1N;W=R87`^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ M(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^)B-X03`[)B-X03`[/"]F;VYT M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF M(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M M(&YO=W)A<#TS1&YO=W)A<#X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@ M5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXF(WA!,#L\+V9O;G0^/"]T9#X- M"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<"!A;&EG;CTS M1')I9VAT/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@ M4F]M86XG('-I>F4],T0R/B8C>#(P,30[/"]F;VYT/CPO=&0^#0H@/'1D('9A M;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^/&9O;G0@<W1Y;&4],T0G M1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^)B-X03`[ M)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N M="!S:7IE/3-$,3XF(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L M:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE M<R!.97<@4F]M86XG('-I>F4],T0R/B8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT M9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS M1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXH,2PS M,#<\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS M1&YO=W)A<#X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W M(%)O;6%N)R!S:7IE/3-$,CXI)B-X03`[/"]F;VYT/CPO=&0^#0H@/"]T<CX- M"B`\='(@<W1Y;&4],T0G1D].5"U325I%.B`Q<'@G/@T*(#QT9"!V86QI9VX] M,T1B;W1T;VT^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C M>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS M1"="3U)$15(M5$]0.B`C,#`P,#`P(#%P>"!S;VQI9"<^)B-X03`[/"]P/@T* M(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"=" M3U)$15(M5$]0.B`C,#`P,#`P(#%P>"!S;VQI9"<^)B-X03`[/"]P/@T*(#PO M=&0^#0H@/'1D/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF M(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@ M<W1Y;&4],T0G0D]21$52+51/4#H@(S`P,#`P,"`Q<'@@<V]L:60G/B8C>$$P M.SPO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@<W1Y M;&4],T0G0D]21$52+51/4#H@(S`P,#`P,"`Q<'@@<V]L:60G/B8C>$$P.SPO M<#X-"B`\+W1D/@T*(#QT9#XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B M;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@,7!X('-O;&ED M)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T* M(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@,7!X('-O;&ED)SXF M(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0^)B-X03`[/"]T9#X-"B`\+W1R/@T* M(#QT<B!B9V-O;&]R/3-$(T-#145&1CX-"B`\=&0@=F%L:6=N/3-$=&]P/@T* M(#QP('-T>6QE/3-$)TU!4D=)3BU,1494.B`Q96T[(%1%6%0M24Y$14Y4.B`M M,65M)SX\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O M;6%N)R!S:7IE/3-$,CY.970@;&]S<R!A;&QO8V%B;&4@=&\-"B!C;VUM;VX@ M<W1O8VMH;VQD97)S/"]F;VYT/CPO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX] M,T1B;W1T;VT^/&9O;G0@<VEZ93TS1#$^)B-X03`[)B-X03`[/"]F;VYT/CPO M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=&3TY4 M+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXD/"]F;VYT/CPO M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/CQF;VYT M('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4] M,T0R/B@Q-"PV-#8\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M M(&YO=W)A<#TS1&YO=W)A<#X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@ M5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXI)B-X03`[/"]F;VYT/CPO=&0^ M#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF(WA!,#LF M(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT M('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4] M,T0R/B0\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N M/3-$<FEG:'0^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE M=R!2;VUA;B<@<VEZ93TS1#(^*#,S+#<Q-SPO9F]N=#X\+W1D/@T*(#QT9"!V M86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P/CQF;VYT('-T>6QE/3-$ M)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R/BDF(WA! M,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I M>F4],T0Q/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX] M,T1B;W1T;VT^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE M=R!2;VUA;B<@<VEZ93TS1#(^)#PO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX] M,T1B;W1T;VT@86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS1"=&3TY4+49! M34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXH-#$L-C<W/"]F;VYT M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^ M/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@ M<VEZ93TS1#(^*28C>$$P.SPO9F]N=#X\+W1D/@T*(#PO='(^#0H@/'1R('-T M>6QE/3-$)T9/3E0M4TE:13H@,7!X)SX-"B`\=&0@=F%L:6=N/3-$8F]T=&]M M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@<W1Y;&4],T0G0D]21$52 M+51/4#H@(S`P,#`P,"`S<'@@9&]U8FQE)SXF(WA!,#L\+W`^#0H@/"]T9#X- M"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU4 M3U`Z(",P,#`P,#`@,W!X(&1O=6)L92<^)B-X03`[/"]P/@T*(#PO=&0^#0H@ M/'1D/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF M(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@<W1Y;&4] M,T0G0D]21$52+51/4#H@(S`P,#`P,"`S<'@@9&]U8FQE)SXF(WA!,#L\+W`^ M#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$ M)T)/4D1%4BU43U`Z(",P,#`P,#`@,W!X(&1O=6)L92<^)B-X03`[/"]P/@T* M(#PO=&0^#0H@/'1D/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O M;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@ M/'`@<W1Y;&4],T0G0D]21$52+51/4#H@(S`P,#`P,"`S<'@@9&]U8FQE)SXF M(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP M('-T>6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@,W!X(&1O=6)L92<^)B-X M03`[/"]P/@T*(#PO=&0^#0H@/'1D/B8C>$$P.SPO=&0^#0H@/"]T<CX-"B`\ M='(^#0H@/'1D('9A;&EG;CTS1'1O<#X-"B`\<"!S='EL93TS1"=-05)'24XM M3$5&5#H@,65M.R!415A4+4E.1$5.5#H@+3%E;2<^/&9O;G0@<W1Y;&4],T0G M1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^5V5I9VAT M960M879E<F%G92!S:&%R97,-"B!U<V5D(&EN(&-O;7!U=&EN9R!N970@;&]S M<R!P97(@<VAA<F4@86QL;V-A8FQE('1O(&-O;6UO;@T*('-T;V-K:&]L9&5R M<R8C>$$P.R8C>#(P,30[(&)A<VEC(&%N9"!D:6QU=&5D/"]F;VYT/CPO<#X- M"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<VEZ93TS1#$^ M)B-X03`[)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O M;3X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N M)R!S:7IE/3-$,CXF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$ M8F]T=&]M(&%L:6=N/3-$<FEG:'0^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U) M3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^,S4L-S`Y/"]F;VYT/CPO M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^/&9O M;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ M93TS1#(^)B-X03`[)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS M1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF(WA!,#LF(WA!,#L\+V9O;G0^/"]T M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)T9/3E0M M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R/B8C>$$P.SPO9F]N M=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#X\ M9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S M:7IE/3-$,CXR-RPR-S4\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T M=&]M(&YO=W)A<#TS1&YO=W)A<#X\9F]N="!S='EL93TS1"=&3TY4+49!34E, M63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXF(WA!,#LF(WA!,#L\+V9O M;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q M/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T M;VT^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA M;B<@<VEZ93TS1#(^)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS M1&)O='1O;2!A;&EG;CTS1')I9VAT/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%- M24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R/C$X+#$P-SPO9F]N=#X\ M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P/CQF M;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I M>F4],T0R/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#PO='(^#0H@/'1R M('-T>6QE/3-$)T9/3E0M4TE:13H@,7!X)SX-"B`\=&0@=F%L:6=N/3-$8F]T M=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\ M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@<W1Y;&4],T0G0D]2 M1$52+51/4#H@(S`P,#`P,"`S<'@@9&]U8FQE)SXF(WA!,#L\+W`^#0H@/"]T M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1% M4BU43U`Z(",P,#`P,#`@,W!X(&1O=6)L92<^)B-X03`[/"]P/@T*(#PO=&0^ M#0H@/'1D/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA! M,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@<W1Y M;&4],T0G0D]21$52+51/4#H@(S`P,#`P,"`S<'@@9&]U8FQE)SXF(WA!,#L\ M+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE M/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@,W!X(&1O=6)L92<^)B-X03`[/"]P M/@T*(#PO=&0^#0H@/'1D/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O M='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^ M#0H@/'`@<W1Y;&4],T0G0D]21$52+51/4#H@(S`P,#`P,"`S<'@@9&]U8FQE M)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T* M(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@,W!X(&1O=6)L92<^ M)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D/B8C>$$P.SPO=&0^#0H@/"]T<CX- M"B`\='(@8F=C;VQO<CTS1"-#0T5%1D8^#0H@/'1D('9A;&EG;CTS1'1O<#X- M"B`\<"!S='EL93TS1"=-05)'24XM3$5&5#H@,65M.R!415A4+4E.1$5.5#H@ M+3%E;2<^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2 M;VUA;B<@<VEZ93TS1#(^3F5T(&QO<W,@<&5R('-H87)E#0H@86QL;V-A8FQE M('1O(&-O;6UO;B!S=&]C:VAO;&1E<G,@)B-X,C`Q-#L@8F%S:6,-"B!A;F0F M(WA!,#MD:6QU=&5D/"]F;VYT/CPO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX] M,T1B;W1T;VT^/&9O;G0@<VEZ93TS1#$^)B-X03`[)B-X03`[/"]F;VYT/CPO M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=&3TY4 M+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXD/"]F;VYT/CPO M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/CQF;VYT M('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4] M,T0R/B@P+C0Q/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N M;W=R87`],T1N;W=R87`^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I M;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^*28C>$$P.SPO9F]N=#X\+W1D/@T* M(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<VEZ93TS1#$^)B-X03`[)B-X M03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S M='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$ M,CXD/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS M1')I9VAT/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@ M4F]M86XG('-I>F4],T0R/B@Q+C(T/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG M;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^/&9O;G0@<W1Y;&4],T0G1D]. M5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^*28C>$$P.SPO M9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<VEZ93TS M1#$^)B-X03`[)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O M='1O;3X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O M;6%N)R!S:7IE/3-$,CXD/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O M='1O;2!A;&EG;CTS1')I9VAT/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9 M.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R/B@R+C,P/"]F;VYT/CPO=&0^ M#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^/&9O;G0@ M<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS M1#(^*28C>$$P.SPO9F]N=#X\+W1D/@T*(#PO='(^#0H@/"]T86)L93X-"B`\ M<"!S='EL93TS1"=-05)'24XM0D]45$]-.B`P<'@[($U!4D=)3BU43U`Z(#$R M<'@[(%1%6%0M24Y$14Y4.B`T)2<@86QI9VX],T1J=7-T:69Y/CQF;VYT('-T M>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R M/E1H92!F;VQL;W=I;F<@:6YS=')U;65N=',@=V5R92!E>&-L=61E9"!F<F]M M('1H92!C;VUP=71A=&EO;B!O9@T*(&1I;'5T960@;F5T(&QO<W,@<&5R(&-O M;6UO;B!S:&%R92!A;&QO8V%B;&4@=&\@8V]M;6]N('-T;V-K:&]L9&5R<PT* M(&9O<B!T:&4@<&5R:6]D<R!P<F5S96YT960@8F5C875S92!T:&5I<B!E9F9E M8W0@=V]U;&0@:&%V92!B965N#0H@86YT:61I;'5T:79E("AI;B!T:&]U<V%N M9',I.CPO9F]N=#X\+W`^#0H@/'`@<W1Y;&4],T0G34%21TE.+4)/5%1/33H@ M,'!X.R!&3TY4+5-)6D4Z(#$R<'@[($U!4D=)3BU43U`Z(#!P>"<^#0H@)B-X M03`[/"]P/@T*(#QT86)L92!S='EL93TS1"="3U)$15(M0T],3$%04T4Z(&-O M;&QA<'-E)R!C96QL<W!A8VEN9STS1#`@8V5L;'!A9&1I;F<],T0P('=I9'1H M/3-$.3(E(&%L:6=N/3-$8V5N=&5R(&)O<F1E<CTS1#`^#0H@/'1R/@T*(#QT M9"!W:61T:#TS1#<S)3X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@=VED M=&@],T0S)3X\+W1D/@T*(#QT9#X\+W1D/@T*(#QT9#X\+W1D/@T*(#QT9#X\ M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@=VED=&@],T0S)3X\+W1D/@T* M(#QT9#X\+W1D/@T*(#QT9#X\+W1D/@T*(#QT9#X\+W1D/@T*(#QT9"!V86QI M9VX],T1B;W1T;VT@=VED=&@],T0S)3X\+W1D/@T*(#QT9#X\+W1D/@T*(#QT M9#X\+W1D/@T*(#QT9#X\+W1D/@T*(#PO='(^#0H@/'1R/@T*(#QT9"!V86QI M9VX],T1B;W1T;VT^/&9O;G0@<VEZ93TS1#$^)B-X03`[/"]F;VYT/CPO=&0^ M#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF(WA!,#LF M(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/ M33H@(S`P,#`P,"`Q<'@@<V]L:60G('9A;&EG;CTS1&)O='1O;2!C;VQS<&%N M/3-$,3`@86QI9VX],T1C96YT97(^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U) M3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#$^/&(^1&5C96UB97(F(WA! M,#LS,2P\+V(^/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\ M9F]N="!S:7IE/3-$,3XF(WA!,#L\+V9O;G0^/"]T9#X-"B`\+W1R/@T*(#QT M<CX-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C>$$P M.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<VEZ M93TS1#$^)B-X03`[)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('-T>6QE/3-$ M)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,7!X('-O;&ED)R!V86QI9VX],T1B M;W1T;VT@8V]L<W!A;CTS1#(@86QI9VX],T1C96YT97(^/&9O;G0@<W1Y;&4] M,T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#$^/&(^ M,C`Q-#PO8CX\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF M;VYT('-I>F4],T0Q/B8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX] M,T1B;W1T;VT^/&9O;G0@<VEZ93TS1#$^)B-X03`[)B-X03`[/"]F;VYT/CPO M=&0^#0H@/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,7!X M('-O;&ED)R!V86QI9VX],T1B;W1T;VT@8V]L<W!A;CTS1#(@86QI9VX],T1C M96YT97(^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2 M;VUA;B<@<VEZ93TS1#$^/&(^,C`Q,SPO8CX\+V9O;G0^/"]T9#X-"B`\=&0@ M=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C>$$P.SPO9F]N=#X\ M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<VEZ93TS1#$^)B-X M03`[)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('-T>6QE/3-$)T)/4D1%4BU" M3U143TTZ(",P,#`P,#`@,7!X('-O;&ED)R!V86QI9VX],T1B;W1T;VT@8V]L M<W!A;CTS1#(@86QI9VX],T1C96YT97(^/&9O;G0@<W1Y;&4],T0G1D].5"U& M04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#$^/&(^,C`Q,CPO8CX\ M+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4] M,T0Q/B8C>$$P.SPO9F]N=#X\+W1D/@T*(#PO='(^#0H@/'1R(&)G8V]L;W(] M,T0C0T-%149&/@T*(#QT9"!V86QI9VX],T1T;W`^#0H@/'`@<W1Y;&4],T0G M34%21TE.+4Q%1E0Z(#%E;3L@5$585"U)3D1%3E0Z("TQ96TG/CQF;VYT('-T M>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R M/D]P=&EO;G,@=&\@<'5R8VAA<V4@8V]M;6]N#0H@<W1O8VL\+V9O;G0^/"]P M/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$ M,3XF(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T M=&]M/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M M86XG('-I>F4],T0R/B8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX] M,T1B;W1T;VT@86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS1"=&3TY4+49! M34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXS+#(Y.#PO9F]N=#X\ M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P/CQF M;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I M>F4],T0R/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX] M,T1B;W1T;VT^/&9O;G0@<VEZ93TS1#$^)B-X03`[)B-X03`[/"]F;VYT/CPO M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=&3TY4 M+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXF(WA!,#L\+V9O M;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^ M/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@ M<VEZ93TS1#(^,BPT-#D\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T M=&]M(&YO=W)A<#TS1&YO=W)A<#X\9F]N="!S='EL93TS1"=&3TY4+49!34E, M63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXF(WA!,#LF(WA!,#L\+V9O M;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q M/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T M;VT^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA M;B<@<VEZ93TS1#(^)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS M1&)O='1O;2!A;&EG;CTS1')I9VAT/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%- M24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R/C$L-SDQ/"]F;VYT/CPO M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^/&9O M;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ M93TS1#(^)B-X03`[)B-X03`[/"]F;VYT/CPO=&0^#0H@/"]T<CX-"B`\='(^ M#0H@/'1D('9A;&EG;CTS1'1O<#X-"B`\<"!S='EL93TS1"=-05)'24XM3$5& M5#H@,65M.R!415A4+4E.1$5.5#H@+3%E;2<^/&9O;G0@<W1Y;&4],T0G1D]. M5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^5V%R<F%N=',@ M=&\@<'5R8VAA<V4@8V]M;6]N#0H@<W1O8VL\+V9O;G0^/"]P/@T*(#PO=&0^ M#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF(WA!,#LF M(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT M('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4] M,T0R/B8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@ M86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM M97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXV+#8Y,3PO9F]N=#X\+W1D/@T*(#QT M9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P/CQF;VYT('-T>6QE M/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R/B8C M>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^ M/&9O;G0@<VEZ93TS1#$^)B-X03`[)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D M('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@ M5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXF(WA!,#L\+V9O;G0^/"]T9#X- M"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^/&9O;G0@<W1Y M;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^ M-RPV.3(\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A M<#TS1&YO=W)A<#X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@ M3F5W(%)O;6%N)R!S:7IE/3-$,CXF(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X- M"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C>$$P.R8C M>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@ M<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS M1#(^)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A M;&EG;CTS1')I9VAT/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE M<R!.97<@4F]M86XG('-I>F4],T0R/CDL,#`Y/"]F;VYT/CPO=&0^#0H@/'1D M('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^/&9O;G0@<W1Y;&4] M,T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^)B-X M03`[)B-X03`[/"]F;VYT/CPO=&0^#0H@/"]T<CX-"B`\='(@8F=C;VQO<CTS M1"-#0T5%1D8^#0H@/'1D('9A;&EG;CTS1'1O<#X-"B`\<"!S='EL93TS1"=- M05)'24XM3$5&5#H@,65M.R!415A4+4E.1$5.5#H@+3%E;2<^/&9O;G0@<W1Y M;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^ M4V5R:65S($(@8V]N=F5R=&EB;&4-"B!P<F5F97)R960@<W1O8VL@*&%S(&-O M;G9E<G1E9"!T;R!C;VUM;VX@<W1O8VLI/"]F;VYT/CPO<#X-"B`\+W1D/@T* M(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<VEZ93TS1#$^)B-X03`[)B-X M03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`] M,T1N;W=R87`^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE M=R!2;VUA;B<@<VEZ93TS1#(^)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A M;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`@86QI9VX],T1R:6=H=#X\ M9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S M:7IE/3-$,CXF(W@R,#$T.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B M;W1T;VT@;F]W<F%P/3-$;F]W<F%P/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%- M24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R/B8C>$$P.R8C>$$P.SPO M9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<VEZ93TS M1#$^)B-X03`[)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O M='1O;2!N;W=R87`],T1N;W=R87`^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U) M3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^)B-X03`[/"]F;VYT/CPO M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`@86QI M9VX],T1R:6=H=#X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@ M3F5W(%)O;6%N)R!S:7IE/3-$,CXF(W@R,#$T.SPO9F]N=#X\+W1D/@T*(#QT M9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P/CQF;VYT('-T>6QE M/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R/B8C M>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^ M/&9O;G0@<VEZ93TS1#$^)B-X03`[)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D M('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@ M5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXF(WA!,#L\+V9O;G0^/"]T9#X- M"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^/&9O;G0@<W1Y M;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^ M,RPX,S@\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A M<#TS1&YO=W)A<#X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@ M3F5W(%)O;6%N)R!S:7IE/3-$,CXF(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X- M"B`\+W1R/@T*(#QT<CX-"B`\=&0@=F%L:6=N/3-$=&]P/@T*(#QP('-T>6QE M/3-$)TU!4D=)3BU,1494.B`Q96T[(%1%6%0M24Y$14Y4.B`M,65M)SX\9F]N M="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE M/3-$,CY297-T<FEC=&5D('-T;V-K#0H@=6YI=',\+V9O;G0^/"]P/@T*(#PO M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF(WA! M,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF M;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I M>F4],T0R/B8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T M;VT@86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@ M5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXV,SPO9F]N=#X\+W1D/@T*(#QT M9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P/CQF;VYT('-T>6QE M/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R/B8C M>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^ M/&9O;G0@<VEZ93TS1#$^)B-X03`[)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D M('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@ M5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXF(WA!,#L\+V9O;G0^/"]T9#X- M"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^/&9O;G0@<W1Y M;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^ M-#(\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS M1&YO=W)A<#X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W M(%)O;6%N)R!S:7IE/3-$,CXF(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\ M=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C>$$P.R8C>$$P M.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<W1Y M;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^ M)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG M;CTS1')I9VAT/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!. M97<@4F]M86XG('-I>F4],T0R/C(Q-SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI M9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P/CQF;VYT('-T>6QE/3-$)T9/ M3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R/B8C>$$P.R8C M>$$P.SPO9F]N=#X\+W1D/@T*(#PO='(^#0H@/'1R(&)G8V]L;W(],T0C0T-% M149&/@T*(#QT9"!V86QI9VX],T1T;W`^#0H@/'`@<W1Y;&4],T0G34%21TE. M+4Q%1E0Z(#%E;3L@5$585"U)3D1%3E0Z("TQ96TG/CQF;VYT('-T>6QE/3-$ M)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R/E-H87)E M<R!I<W-U86)L92!R96QA=&5D('1O#0H@=&AE($534%`\+V9O;G0^/"]P/@T* M(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF M(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M M/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG M('-I>F4],T0R/B8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B M;W1T;VT@86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS1"=&3TY4+49!34E, M63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXQ-3PO9F]N=#X\+W1D/@T* M(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P/CQF;VYT('-T M>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R M/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T M;VT^/&9O;G0@<VEZ93TS1#$^)B-X03`[)B-X03`[/"]F;VYT/CPO=&0^#0H@ M/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=&3TY4+49!34E, M63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXF(WA!,#L\+V9O;G0^/"]T M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^/&9O;G0@ M<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS M1#(^,30\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A M<#TS1&YO=W)A<#X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@ M3F5W(%)O;6%N)R!S:7IE/3-$,CXF(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X- M"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C>$$P.R8C M>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@ M<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS M1#(^)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A M;&EG;CTS1')I9VAT/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE M<R!.97<@4F]M86XG('-I>F4],T0R/C$Q/"]F;VYT/CPO=&0^#0H@/'1D('9A M;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^/&9O;G0@<W1Y;&4],T0G M1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^)B-X03`[ M)B-X03`[/"]F;VYT/CPO=&0^#0H@/"]T<CX-"B`\='(@<W1Y;&4],T0G1D]. M5"U325I%.B`Q<'@G/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\ M=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A M;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B`C,#`P M,#`P(#%P>"!S;VQI9"<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG M;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B`C,#`P,#`P M(#%P>"!S;VQI9"<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D/B8C>$$P.SPO M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T* M(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@<W1Y;&4],T0G0D]21$52+51/ M4#H@(S`P,#`P,"`Q<'@@<V]L:60G/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT M9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@<W1Y;&4],T0G0D]21$52+51/4#H@ M(S`P,#`P,"`Q<'@@<V]L:60G/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT9#XF M(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[ M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/ M4D1%4BU43U`Z(",P,#`P,#`@,7!X('-O;&ED)SXF(WA!,#L\+W`^#0H@/"]T M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1% M4BU43U`Z(",P,#`P,#`@,7!X('-O;&ED)SXF(WA!,#L\+W`^#0H@/"]T9#X- M"B`\=&0^)B-X03`[/"]T9#X-"B`\+W1R/@T*(#QT<CX-"B`\=&0@=F%L:6=N M/3-$=&]P/@T*(#QP('-T>6QE/3-$)TU!4D=)3BU,1494.B`R96T[(%1%6%0M M24Y$14Y4.B`M,65M)SX\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM M97,@3F5W(%)O;6%N)R!S:7IE/3-$,CY4;W1A;"!S:&%R97,\+V9O;G0^/"]P M/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$ M,3XF(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T M=&]M/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M M86XG('-I>F4],T0R/B8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX] M,T1B;W1T;VT@86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS1"=&3TY4+49! M34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXQ,"PP-C<\+V9O;G0^ M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#X\ M9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S M:7IE/3-$,CXF(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N M/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C>$$P.R8C>$$P.SPO9F]N=#X\ M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<W1Y;&4],T0G1D]. M5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^)B-X03`[/"]F M;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT M/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG M('-I>F4],T0R/C$P+#$Y-SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B M;W1T;VT@;F]W<F%P/3-$;F]W<F%P/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%- M24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R/B8C>$$P.R8C>$$P.SPO M9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<VEZ93TS M1#$^)B-X03`[)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O M='1O;3X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O M;6%N)R!S:7IE/3-$,CXF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N M/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^/&9O;G0@<W1Y;&4],T0G1D].5"U& M04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^,30L.#8V/"]F;VYT M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^ M/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@ M<VEZ93TS1#(^)B-X03`[)B-X03`[/"]F;VYT/CPO=&0^#0H@/"]T<CX-"B`\ M='(@<W1Y;&4],T0G1D].5"U325I%.B`Q<'@G/@T*(#QT9"!V86QI9VX],T1B M;W1T;VT^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P M.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"=" M3U)$15(M5$]0.B`C,#`P,#`P(#-P>"!D;W5B;&4G/B8C>$$P.SPO<#X-"B`\ M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@<W1Y;&4],T0G0D]2 M1$52+51/4#H@(S`P,#`P,"`S<'@@9&]U8FQE)SXF(WA!,#L\+W`^#0H@/"]T M9#X-"B`\=&0^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C M>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S M='EL93TS1"="3U)$15(M5$]0.B`C,#`P,#`P(#-P>"!D;W5B;&4G/B8C>$$P M.SPO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@<W1Y M;&4],T0G0D]21$52+51/4#H@(S`P,#`P,"`S<'@@9&]U8FQE)SXF(WA!,#L\ M+W`^#0H@/"]T9#X-"B`\=&0^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$ M8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O M;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B`C,#`P,#`P(#-P>"!D;W5B M;&4G/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^ M#0H@/'`@<W1Y;&4],T0G0D]21$52+51/4#H@(S`P,#`P,"`S<'@@9&]U8FQE M)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0^)B-X03`[/"]T9#X-"B`\+W1R M/@T*(#PO=&%B;&4^#0H@/"]D:78^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`\+W1R/@T*("`@(#PO=&%B;&4^#0H@(#PO8F]D>3X-"CPO:'1M;#X-"@T* M+2TM+2TM/5].97AT4&%R=%\S.6,P96$V,E]C,C`S7S0U.&9?.&,U,%\S9&-A M-#4V838Y-3$-"D-O;G1E;G0M3&]C871I;VXZ(&9I;&4Z+R\O0SHO,SEC,&5A M-C)?8S(P,U\T-3AF7SAC-3!?,V1C830U-F$V.34Q+U=O<FMS:&5E=',O4VAE M970Q,"YH=&UL#0I#;VYT96YT+51R86YS9F5R+45N8V]D:6YG.B!Q=6]T960M M<')I;G1A8FQE#0I#;VYT96YT+51Y<&4Z('1E>'0O:'1M;#L@8VAA<G-E=#TB M=7,M87-C:6DB#0H-"CQH=&UL/@T*("`\:&5A9#X-"B`@("`\345402!H='1P M+65Q=6EV/3-$0V]N=&5N="U4>7!E(&-O;G1E;G0],T0G=&5X="]H=&UL.R!C M:&%R<V5T/75T9BTX)SX\<V-R:7!T('1Y<&4],T1T97AT+VIA=F%S8W)I<'0@ M<W)C/3-$4VAO=RYJ<SXO*B!$;R!.;W0@4F5M;W9E(%1H:7,@0V]M;65N="`J M+SPO<V-R:7!T/CPO:&5A9#X-"B`@/&)O9'D^#0H@("`@/'1A8FQE(&-L87-S M/3-$<F5P;W)T(&ED/3-$240P14U%/@T*("`@("`@/'1R/@T*("`@("`@("`\ M=&@@8VQA<W,],T1T;"!C;VQS<&%N/3-$,2!R;W=S<&%N/3-$,CX\<W1R;VYG M/E-U<'!L96UE;G1A<GD@0V%S:"!&;&]W($1A=&$\8G(^/"]S=')O;F<^/"]T M:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@@8V]L<W!A;CTS1#$^,3(@36]N M=&AS($5N9&5D/"]T:#X-"B`@("`@(#PO='(^#0H@("`@("`\='(^#0H@("`@ M("`@(#QT:"!C;&%S<STS1'1H/D1E8RX@,S$L(#(P,30\8G(^/"]T:#X-"B`@ M("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D M(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/CQS=')O;F<^4W5P<&QE;65N=&%L M($-A<V@@1FQO=R!%;&5M96YT<R!;06)S=')A8W1=/"]S=')O;F<^/"]T9#X- M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X- M"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@ M/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E-U<'!L96UE;G1A<GD@0V%S M:"!&;&]W($1A=&$\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQD M:78^#0H@/'`@<W1Y;&4],T0G34%21TE.+4)/5%1/33H@,'!X.R!-05)'24XM M5$]0.B`Q.'!X)SX\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@ M3F5W(%)O;6%N)R!S:7IE/3-$,CX\8CY.;W1E(#,@)B-X,C`Q-#L-"B!3=7!P M;&5M96YT87)Y($-A<V@@1FQO=R!$871A/"]B/CPO9F]N=#X\+W`^#0H@/'`@ M<W1Y;&4],T0G34%21TE.+4)/5%1/33H@,'!X.R!-05)'24XM5$]0.B`V<'@[ M(%1%6%0M24Y$14Y4.B`T)2<@86QI9VX],T1J=7-T:69Y/CQF;VYT('-T>6QE M/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R/E-U M<'!L96UE;G1A;"!C87-H(&9L;W<@:6YF;W)M871I;VX@=V%S(&%S(&9O;&QO M=W,@*&EN#0H@=&AO=7-A;F1S*3H\+V9O;G0^/"]P/@T*(#QP('-T>6QE/3-$ M)TU!4D=)3BU"3U143TTZ(#!P>#L@1D].5"U325I%.B`Q,G!X.R!-05)'24XM M5$]0.B`P<'@G/@T*("8C>$$P.SPO<#X-"B`\=&%B;&4@<W1Y;&4],T0G0D]2 M1$52+4-/3$Q!4%-%.B!C;VQL87!S92<@8V5L;'-P86-I;F<],T0P(&-E;&QP M861D:6YG/3-$,"!W:61T:#TS1#DR)2!A;&EG;CTS1&-E;G1E<B!B;W)D97(] M,T0P/@T*(#QT<CX-"B`\=&0@=VED=&@],T0W."4^/"]T9#X-"B`\=&0@=F%L M:6=N/3-$8F]T=&]M('=I9'1H/3-$-B4^/"]T9#X-"B`\=&0^/"]T9#X-"B`\ M=&0^/"]T9#X-"B`\=&0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M('=I M9'1H/3-$-B4^/"]T9#X-"B`\=&0^/"]T9#X-"B`\=&0^/"]T9#X-"B`\=&0^ M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$-24^/"]T9#X- M"B`\=&0^/"]T9#X-"B`\=&0^/"]T9#X-"B`\=&0^/"]T9#X-"B`\+W1R/@T* M(#QT<CX-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C M>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@ M<VEZ93TS1#$^)B-X03`[)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('-T>6QE M/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,7!X('-O;&ED)R!V86QI9VX] M,T1B;W1T;VT@8V]L<W!A;CTS1#$P(&%L:6=N/3-$8V5N=&5R/CQF;VYT('-T M>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0Q M/CQB/EEE87)S($5N9&5D/&)R("\^#0H@1&5C96UB97(F(WA!,#LS,2P\+V(^ M/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE M/3-$,3XF(WA!,#L\+V9O;G0^/"]T9#X-"B`\+W1R/@T*(#QT<CX-"B`\=&0@ M=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C>$$P.SPO9F]N=#X\ M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<VEZ93TS1#$^)B-X M03`[)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('-T>6QE/3-$)T)/4D1%4BU" M3U143TTZ(",P,#`P,#`@,7!X('-O;&ED)R!V86QI9VX],T1B;W1T;VT@8V]L M<W!A;CTS1#(@86QI9VX],T1C96YT97(^/&9O;G0@<W1Y;&4],T0G1D].5"U& M04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#$^/&(^,C`Q-#PO8CX\ M+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4] M,T0Q/B8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^ M/&9O;G0@<VEZ93TS1#$^)B-X03`[)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D M('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,7!X('-O;&ED)R!V M86QI9VX],T1B;W1T;VT@8V]L<W!A;CTS1#(@86QI9VX],T1C96YT97(^/&9O M;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ M93TS1#$^/&(^,C`Q,SPO8CX\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$ M8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT M9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<VEZ93TS1#$^)B-X03`[)B-X03`[ M/"]F;VYT/CPO=&0^#0H@/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(",P M,#`P,#`@,7!X('-O;&ED)R!V86QI9VX],T1B;W1T;VT@8V]L<W!A;CTS1#(@ M86QI9VX],T1C96YT97(^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I M;65S($YE=R!2;VUA;B<@<VEZ93TS1#$^/&(^,C`Q,CPO8CX\+V9O;G0^/"]T M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C>$$P M.SPO9F]N=#X\+W1D/@T*(#PO='(^#0H@/'1R(&)G8V]L;W(],T0C0T-%149& M/@T*(#QT9"!V86QI9VX],T1T;W`^#0H@/'`@<W1Y;&4],T0G34%21TE.+4Q% M1E0Z(#%E;3L@5$585"U)3D1%3E0Z("TQ96TG/CQF;VYT('-T>6QE/3-$)T9/ M3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R/D-A<V@@<&%I M9"!F;W(-"B!I;G1E<F5S=#PO9F]N=#X\+W`^#0H@/"]T9#X-"B`\=&0@=F%L M:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C>$$P.R8C>$$P.SPO9F]N M=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P M/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG M('-I>F4],T0R/B0\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M M(&YO=W)A<#TS1&YO=W)A<"!A;&EG;CTS1')I9VAT/CQF;VYT('-T>6QE/3-$ M)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R/B8C>#(P M,30[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`] M,T1N;W=R87`^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE M=R!2;VUA;B<@<VEZ93TS1#(^)B-X03`[)B-X03`[/"]F;VYT/CPO=&0^#0H@ M/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF(WA!,#LF(WA! M,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS M1&YO=W)A<#X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W M(%)O;6%N)R!S:7IE/3-$,CXD/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS M1&)O='1O;2!N;W=R87`],T1N;W=R87`@86QI9VX],T1R:6=H=#X\9F]N="!S M='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$ M,CXF(W@R,#$T.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@ M;F]W<F%P/3-$;F]W<F%P/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4 M:6UE<R!.97<@4F]M86XG('-I>F4],T0R/B8C>$$P.R8C>$$P.SPO9F]N=#X\ M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<VEZ93TS1#$^)B-X M03`[)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\ M9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S M:7IE/3-$,CXD/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A M;&EG;CTS1')I9VAT/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE M<R!.97<@4F]M86XG('-I>F4],T0R/C,\+V9O;G0^/"]T9#X-"B`\=&0@=F%L M:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#X\9F]N="!S='EL93TS1"=& M3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXF(WA!,#LF M(WA!,#L\+V9O;G0^/"]T9#X-"B`\+W1R/@T*(#QT<CX-"B`\=&0@=F%L:6=N M/3-$=&]P/@T*(#QP('-T>6QE/3-$)TU!4D=)3BU,1494.B`Q96T[(%1%6%0M M24Y$14Y4.B`M,65M)SX\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM M97,@3F5W(%)O;6%N)R!S:7IE/3-$,CY#87-H('!A:60@9F]R(&EN8V]M90T* M('1A>&5S/"]F;VYT/CPO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T M;VT^/&9O;G0@<VEZ93TS1#$^)B-X03`[)B-X03`[/"]F;VYT/CPO=&0^#0H@ M/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=&3TY4+49!34E, M63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXF(WA!,#L\+V9O;G0^/"]T M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^/&9O;G0@ M<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS M1#(^,3PO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P M/3-$;F]W<F%P/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!. M97<@4F]M86XG('-I>F4],T0R/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T* M(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<VEZ93TS1#$^)B-X03`[)B-X M03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S M='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$ M,CXF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L M:6=N/3-$<FEG:'0^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S M($YE=R!2;VUA;B<@<VEZ93TS1#(^,3PO9F]N=#X\+W1D/@T*(#QT9"!V86QI M9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P/CQF;VYT('-T>6QE/3-$)T9/ M3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R/B8C>$$P.R8C M>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@ M<VEZ93TS1#$^)B-X03`[)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG M;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@ M3F5W(%)O;6%N)R!S:7IE/3-$,CXF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@ M=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^/&9O;G0@<W1Y;&4],T0G M1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^,3PO9F]N M=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P M/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG M('-I>F4],T0R/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#PO='(^#0H@ M/'1R(&)G8V]L;W(],T0C0T-%149&/@T*(#QT9"!V86QI9VX],T1T;W`^#0H@ M/'`@<W1Y;&4],T0G34%21TE.+4Q%1E0Z(#%E;3L@5$585"U)3D1%3E0Z("TQ M96TG/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M M86XG('-I>F4],T0R/E-I9VYI9FEC86YT(&YO;BUC87-H#0H@:6YV97-T:6YG M(&%N9"!F:6YA;F-I;F<@86-T:79I=&EE<SH\+V9O;G0^/"]P/@T*(#PO=&0^ M#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF(WA!,#LF M(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^ M#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B M;W1T;VT^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4] M,T0Q/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B M;W1T;VT^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D M('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^ M/&9O;G0@<VEZ93TS1#$^)B-X03`[)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D M('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^ M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/"]T<CX-"B`\ M='(^#0H@/'1D('9A;&EG;CTS1'1O<#X-"B`\<"!S='EL93TS1"=-05)'24XM M3$5&5#H@,F5M.R!415A4+4E.1$5.5#H@+3%E;2<^/&9O;G0@<W1Y;&4],T0G M1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^4'5R8VAA M<V5S(&]F('!R;W!E<G1Y(&%N9`T*(&5Q=6EP;65N="!T:')O=6=H(&%C8V]U M;G1S('!A>6%B;&4\+V9O;G0^/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS M1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF(WA!,#LF(WA!,#L\+V9O;G0^/"]T M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)T9/3E0M M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R/B8C>$$P.SPO9F]N M=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#X\ M9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S M:7IE/3-$,CXQ-S`\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M M(&YO=W)A<#TS1&YO=W)A<#X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@ M5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXF(WA!,#LF(WA!,#L\+V9O;G0^ M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C M>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^ M/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@ M<VEZ93TS1#(^)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O M='1O;2!A;&EG;CTS1')I9VAT/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9 M.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R/C$Y,SPO9F]N=#X\+W1D/@T* M(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P/CQF;VYT('-T M>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R M/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T M;VT^/&9O;G0@<VEZ93TS1#$^)B-X03`[)B-X03`[/"]F;VYT/CPO=&0^#0H@ M/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=&3TY4+49!34E, M63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXF(WA!,#L\+V9O;G0^/"]T M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^/&9O;G0@ M<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS M1#(^,3$V/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R M87`],T1N;W=R87`^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S M($YE=R!2;VUA;B<@<VEZ93TS1#(^)B-X03`[)B-X03`[/"]F;VYT/CPO=&0^ M#0H@/"]T<CX-"B`\='(@8F=C;VQO<CTS1"-#0T5%1D8^#0H@/'1D('9A;&EG M;CTS1'1O<#X-"B`\<"!S='EL93TS1"=-05)'24XM3$5&5#H@,F5M.R!415A4 M+4E.1$5.5#H@+3%E;2<^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I M;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^4'5R8VAA<V5S(&]F('!R;W!E<G1Y M(&%N9`T*(&5Q=6EP;65N="!T:')O=6=H(&%C8W)U960@;&EA8FEL:71I97,\ M+V9O;G0^/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N M="!S:7IE/3-$,3XF(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L M:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE M<R!.97<@4F]M86XG('-I>F4],T0R/B8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT M9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS M1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXR-SPO M9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W M<F%P/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M M86XG('-I>F4],T0R/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V M86QI9VX],T1B;W1T;VT^/&9O;G0@<VEZ93TS1#$^)B-X03`[)B-X03`[/"]F M;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS M1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXF(WA! M,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$ M<FEG:'0^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2 M;VUA;B<@<VEZ93TS1#(^*#(\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$ M8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#X\9F]N="!S='EL93TS1"=&3TY4+49! M34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXI)B-X03`[/"]F;VYT M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF M(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M M/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG M('-I>F4],T0R/B8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B M;W1T;VT@86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS1"=&3TY4+49!34E, M63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXS-SPO9F]N=#X\+W1D/@T* M(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P/CQF;VYT('-T M>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R M/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#PO='(^#0H@/'1R/@T*(#QT M9"!V86QI9VX],T1T;W`^#0H@/'`@<W1Y;&4],T0G34%21TE.+4Q%1E0Z(#)E M;3L@5$585"U)3D1%3E0Z("TQ96TG/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%- M24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R/E!U<F-H87-E<R!O9B!P M<F]P97)T>2!A;F0-"B!E<75I<&UE;G0@=&AR;W5G:"!T<F%D92!I;B!V86QU M92!O9B!D:7-P;W-E9"!P<F]P97)T>2!A;F0-"B!E<75I<&UE;G0\+V9O;G0^ M/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE M/3-$,3XF(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$ M8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#X\9F]N="!S='EL93TS1"=&3TY4+49! M34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXF(WA!,#L\+V9O;G0^ M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<"!A M;&EG;CTS1')I9VAT/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE M<R!.97<@4F]M86XG('-I>F4],T0R/B8C>#(P,30[/"]F;VYT/CPO=&0^#0H@ M/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^/&9O;G0@<W1Y M;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^ M)B-X03`[)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O M;3X\9F]N="!S:7IE/3-$,3XF(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\ M=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9 M.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R/B8C>$$P.SPO9F]N=#X\+W1D M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#X\9F]N="!S M='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$ M,CXX,3PO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P M/3-$;F]W<F%P/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!. M97<@4F]M86XG('-I>F4],T0R/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T* M(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<VEZ93TS1#$^)B-X03`[)B-X M03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`] M,T1N;W=R87`^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE M=R!2;VUA;B<@<VEZ93TS1#(^)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A M;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`@86QI9VX],T1R:6=H=#X\ M9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S M:7IE/3-$,CXF(W@R,#$T.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B M;W1T;VT@;F]W<F%P/3-$;F]W<F%P/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%- M24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R/B8C>$$P.R8C>$$P.SPO M9F]N=#X\+W1D/@T*(#PO='(^#0H@/"]T86)L93X-"B`\+V1I=CX\<W!A;CX\ M+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@/"]T86)L93X-"B`@/"]B M;V1Y/@T*/"]H=&UL/@T*#0HM+2TM+2T]7TYE>'1087)T7S,Y8S!E838R7V,R M,#-?-#4X9E\X8S4P7S-D8V$T-39A-CDU,0T*0V]N=&5N="U,;V-A=&EO;CH@ M9FEL93HO+R]#.B\S.6,P96$V,E]C,C`S7S0U.&9?.&,U,%\S9&-A-#4V838Y M-3$O5V]R:W-H965T<R]3:&5E=#$Q+FAT;6P-"D-O;G1E;G0M5')A;G-F97(M M16YC;V1I;F<Z('%U;W1E9"UP<FEN=&%B;&4-"D-O;G1E;G0M5'EP93H@=&5X M="]H=&UL.R!C:&%R<V5T/2)U<RUA<V-I:2(-"@T*/&AT;6P^#0H@(#QH96%D M/@T*("`@(#Q-151!(&AT='`M97%U:78],T1#;VYT96YT+51Y<&4@8V]N=&5N M=#TS1"=T97AT+VAT;6P[(&-H87)S970]=71F+3@G/CQS8W)I<'0@='EP93TS M1'1E>'0O:F%V87-C<FEP="!S<F,],T13:&]W+FIS/B\J($1O($YO="!296UO M=F4@5&AI<R!#;VUM96YT("HO/"]S8W)I<'0^/"]H96%D/@T*("`\8F]D>3X- M"B`@("`\=&%B;&4@8VQA<W,],T1R97!O<G0@:60],T1)1#!%344^#0H@("`@ M("`\='(^#0H@("`@("`@(#QT:"!C;&%S<STS1'1L(&-O;'-P86X],T0Q(')O M=W-P86X],T0R/CQS=')O;F<^0V%S:"!%<75I=F%L96YT<R!A;F0@26YV97-T M;65N=',\8G(^/"]S=')O;F<^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$ M=&@@8V]L<W!A;CTS1#$^,3(@36]N=&AS($5N9&5D/"]T:#X-"B`@("`@(#PO M='(^#0H@("`@("`\='(^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/D1E8RX@ M,S$L(#(P,30\8G(^/"]T:#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA M<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P M/CQS=')O;F<^26YV97-T;65N=',L($1E8G0@86YD($5Q=6ET>2!396-U<FET M:65S(%M!8G-T<F%C=%T\+W-T<F]N9SX\+W1D/@T*("`@("`@("`\=&0@8VQA M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@ M("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V M86QI9VX],T1T;W`^0V%S:"!%<75I=F%L96YT<R!A;F0@26YV97-T;65N=',\ M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQD:78^#0H@/'`@<W1Y M;&4],T0G34%21TE.+4)/5%1/33H@,'!X.R!-05)'24XM5$]0.B`P<'@G/CQF M;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I M>F4],T0R/CQB/DYO=&4@-"`F(W@R,#$T.R!#87-H#0H@17%U:79A;&5N=',@ M86YD($EN=F5S=&UE;G1S/"]B/CPO9F]N=#X\+W`^#0H@/'`@<W1Y;&4],T0G M34%21TE.+4)/5%1/33H@,'!X.R!-05)'24XM3$5&5#H@,B4[($U!4D=)3BU4 M3U`Z(#9P>"<^#0H@/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S M($YE=R!2;VUA;B<@<VEZ93TS1#(^/&(^/&D^0V%S:`T*($5Q=6EV86QE;G1S M(&%N9"!!=F%I;&%B;&4@9F]R(%-A;&4@26YV97-T;65N=',\+VD^/"]B/CPO M9F]N=#X\+W`^#0H@/'`@<W1Y;&4],T0G34%21TE.+4)/5%1/33H@,'!X.R!- M05)'24XM5$]0.B`V<'@[(%1%6%0M24Y$14Y4.B`T)2<@86QI9VX],T1J=7-T M:69Y/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M M86XG('-I>F4],T0R/E1H92!A;6]R=&EZ960@8V]S="!A;F0@9F%I<B!V86QU M92!O9B!C87-H(&5Q=6EV86QE;G1S(&%N9`T*(&%V86EL86)L92!F;W(@<V%L M92!I;G9E<W1M96YT<R!A="!$96-E;6)E<B8C>$$P.S,Q+"`R,#$T(&%N9"`R M,#$S#0H@=V5R92!A<R!F;VQL;W=S("AI;B!T:&]U<V%N9',I.CPO9F]N=#X\ M+W`^#0H@/'`@<W1Y;&4],T0G34%21TE.+4)/5%1/33H@,'!X.R!&3TY4+5-) M6D4Z(#$R<'@[($U!4D=)3BU43U`Z(#!P>"<^#0H@)B-X03`[/"]P/@T*(#QT M86)L92!S='EL93TS1"="3U)$15(M0T],3$%04T4Z(&-O;&QA<'-E)R!C96QL M<W!A8VEN9STS1#`@8V5L;'!A9&1I;F<],T0P('=I9'1H/3-$,3`P)2!A;&EG M;CTS1&-E;G1E<B!B;W)D97(],T0P/@T*(#QT<CX-"B`\=&0@=VED=&@],T0T M-24^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$-24^/"]T M9#X-"B`\=&0^/"]T9#X-"B`\=&0^/"]T9#X-"B`\=&0^/"]T9#X-"B`\=&0@ M=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$-24^/"]T9#X-"B`\=&0^/"]T9#X- M"B`\=&0^/"]T9#X-"B`\=&0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M M('=I9'1H/3-$-24^/"]T9#X-"B`\=&0^/"]T9#X-"B`\=&0^/"]T9#X-"B`\ M=&0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$-24^/"]T M9#X-"B`\=&0^/"]T9#X-"B`\=&0^/"]T9#X-"B`\=&0^/"]T9#X-"B`\=&0@ M=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$-24^/"]T9#X-"B`\=&0^/"]T9#X- M"B`\=&0^/"]T9#X-"B`\=&0^/"]T9#X-"B`\+W1R/@T*(#QT<CX-"B`\=&0@ M=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C>$$P.SPO9F]N=#X\ M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<VEZ93TS1#$^)B-X M03`[)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('-T>6QE/3-$)T)/4D1%4BU" M3U143TTZ(",P,#`P,#`@,7!X('-O;&ED)R!V86QI9VX],T1B;W1T;VT@8V]L M<W!A;CTS1#$X(&%L:6=N/3-$8V5N=&5R/CQF;VYT('-T>6QE/3-$)T9/3E0M M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0Q/CQB/D1E8V5M8F5R M)B-X03`[,S$L#0H@,C`Q-#PO8CX\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N M/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C>$$P.SPO9F]N=#X\+W1D/@T* M(#PO='(^#0H@/'1R/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<VEZ M93TS1#$^)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O M;3X\9F]N="!S:7IE/3-$,3XF(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\ M=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@(S`P,#`P,"`Q<'@@<V]L:60G M('9A;&EG;CTS1&)O='1O;2!C;VQS<&%N/3-$,B!A;&EG;CTS1&-E;G1E<CX\ M9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S M:7IE/3-$,3X\8CY!;6]R=&EZ960\8G(@+SX-"B!#;W-T/"]B/CPO9F]N=#X\ M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<VEZ93TS1#$^)B-X M03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S M:7IE/3-$,3XF(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@<W1Y;&4] M,T0G0D]21$52+4)/5%1/33H@(S`P,#`P,"`Q<'@@<V]L:60G('9A;&EG;CTS M1&)O='1O;2!C;VQS<&%N/3-$,B!A;&EG;CTS1&-E;G1E<CX\9F]N="!S='EL M93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,3X\ M8CY5;G)E86QI>F5D/&)R("\^#0H@1V%I;G,\+V(^/"]F;VYT/CPO=&0^#0H@ M/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF(WA!,#L\+V9O M;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q M/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!S='EL93TS1"="3U)$ M15(M0D]45$]-.B`C,#`P,#`P(#%P>"!S;VQI9"<@=F%L:6=N/3-$8F]T=&]M M(&-O;'-P86X],T0R(&%L:6=N/3-$8V5N=&5R/CQF;VYT('-T>6QE/3-$)T9/ M3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0Q/CQB/E5N<F5A M;&EZ960\8G(@+SX-"B!,;W-S97,\+V(^/"]F;VYT/CPO=&0^#0H@/'1D('9A M;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF(WA!,#L\+V9O;G0^/"]T M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C>$$P M.SPO9F]N=#X\+W1D/@T*(#QT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B`C M,#`P,#`P(#%P>"!S;VQI9"<@=F%L:6=N/3-$8F]T=&]M(&-O;'-P86X],T0R M(&%L:6=N/3-$8V5N=&5R/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4 M:6UE<R!.97<@4F]M86XG('-I>F4],T0Q/CQB/D9A:7(\8G(@+SX-"B!686QU M93PO8CX\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT M('-I>F4],T0Q/B8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B M;W1T;VT^/&9O;G0@<VEZ93TS1#$^)B-X03`[)B-X03`[/"]F;VYT/CPO=&0^ M#0H@/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,7!X('-O M;&ED)R!V86QI9VX],T1B;W1T;VT@8V]L<W!A;CTS1#(@86QI9VX],T1C96YT M97(^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA M;B<@<VEZ93TS1#$^/&(^36%T=7)I='D\8G(@+SX-"B!$871E<SPO8CX\+V9O M;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q M/B8C>$$P.SPO9F]N=#X\+W1D/@T*(#PO='(^#0H@/'1R(&)G8V]L;W(],T0C M0T-%149&/@T*(#QT9"!V86QI9VX],T1T;W`^#0H@/'`@<W1Y;&4],T0G34%2 M1TE.+4Q%1E0Z(#%E;3L@5$585"U)3D1%3E0Z("TQ96TG/CQF;VYT('-T>6QE M/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R/D-A M<V@@97%U:79A;&5N=',@)B-X,C`Q-#L-"B!M;VYE>2!M87)K970@9G5N9',\ M+V9O;G0^/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N M="!S:7IE/3-$,3XF(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L M:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE M<R!.97<@4F]M86XG('-I>F4],T0R/B0\+V9O;G0^/"]T9#X-"B`\=&0@=F%L M:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^/&9O;G0@<W1Y;&4],T0G1D]. M5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^,38L.3,R/"]F M;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R M87`^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA M;B<@<VEZ93TS1#(^)B-X03`[)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A M;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF(WA!,#LF(WA!,#L\+V9O M;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A M<#X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N M)R!S:7IE/3-$,CXD/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O M;2!N;W=R87`],T1N;W=R87`@86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS M1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXF(W@R M,#$T.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P M/3-$;F]W<F%P/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!. M97<@4F]M86XG('-I>F4],T0R/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T* M(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<VEZ93TS1#$^)B-X03`[)B-X M03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`] M,T1N;W=R87`^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE M=R!2;VUA;B<@<VEZ93TS1#(^)#PO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX] M,T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P(&%L:6=N/3-$<FEG:'0^/&9O;G0@ M<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS M1#(^)B-X,C`Q-#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M M(&YO=W)A<#TS1&YO=W)A<#X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@ M5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXF(WA!,#LF(WA!,#L\+V9O;G0^ M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C M>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@ M<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS M1#(^)#PO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX] M,T1R:6=H=#X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W M(%)O;6%N)R!S:7IE/3-$,CXQ-BPY,S(\+V9O;G0^/"]T9#X-"B`\=&0@=F%L M:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#X\9F]N="!S='EL93TS1"=& M3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXF(WA!,#LF M(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT M('-I>F4],T0Q/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI M9VX],T1B;W1T;VT^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^ M#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#PO='(^#0H@/'1R('-T M>6QE/3-$)T9/3E0M4TE:13H@,7!X)SX-"B`\=&0@=F%L:6=N/3-$8F]T=&]M M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@<W1Y;&4],T0G0D]21$52 M+51/4#H@(S`P,#`P,"`S<'@@9&]U8FQE)SXF(WA!,#L\+W`^#0H@/"]T9#X- M"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU4 M3U`Z(",P,#`P,#`@,W!X(&1O=6)L92<^)B-X03`[/"]P/@T*(#PO=&0^#0H@ M/'1D/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF M(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@<W1Y;&4] M,T0G0D]21$52+51/4#H@(S`P,#`P,"`S<'@@9&]U8FQE)SXF(WA!,#L\+W`^ M#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$ M)T)/4D1%4BU43U`Z(",P,#`P,#`@,W!X(&1O=6)L92<^)B-X03`[/"]P/@T* M(#PO=&0^#0H@/'1D/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O M;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@ M/'`@<W1Y;&4],T0G0D]21$52+51/4#H@(S`P,#`P,"`S<'@@9&]U8FQE)SXF M(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP M('-T>6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@,W!X(&1O=6)L92<^)B-X M03`[/"]P/@T*(#PO=&0^#0H@/'1D/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG M;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^ M#0H@/'`@<W1Y;&4],T0G0D]21$52+51/4#H@(S`P,#`P,"`S<'@@9&]U8FQE M)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T* M(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@,W!X(&1O=6)L92<^ M)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D/B8C>$$P.SPO=&0^#0H@/'1D('9A M;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX] M,T1B;W1T;VT^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@ M/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#PO='(^#0H@/'1R/@T*(#QT M9"!V86QI9VX],T1T;W`^#0H@/'`@<W1Y;&4],T0G34%21TE.+4Q%1E0Z(#%E M;3L@5$585"U)3D1%3E0Z("TQ96TG/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%- M24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R/E-H;W)T+71E<FT@:6YV M97-T;65N=',-"B`F(W@R,#$T.R!5+E,N(%1R96%S=7)Y('-E8W5R:71I97,\ M+V9O;G0^/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N M="!S:7IE/3-$,3XF(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L M:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE M<R!.97<@4F]M86XG('-I>F4],T0R/B0\+V9O;G0^/"]T9#X-"B`\=&0@=F%L M:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^/&9O;G0@<W1Y;&4],T0G1D]. M5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^-C,L,#$W/"]F M;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R M87`^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA M;B<@<VEZ93TS1#(^)B-X03`[)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A M;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF(WA!,#LF(WA!,#L\+V9O M;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$ M)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R/B0\+V9O M;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^ M/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@ M<VEZ93TS1#(^,SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@ M;F]W<F%P/3-$;F]W<F%P/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4 M:6UE<R!.97<@4F]M86XG('-I>F4],T0R/B8C>$$P.R8C>$$P.SPO9F]N=#X\ M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<VEZ93TS1#$^)B-X M03`[)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\ M9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S M:7IE/3-$,CXD/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A M;&EG;CTS1')I9VAT/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE M<R!.97<@4F]M86XG('-I>F4],T0R/B@W/"]F;VYT/CPO=&0^#0H@/'1D('9A M;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^/&9O;G0@<W1Y;&4],T0G M1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^*28C>$$P M.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<VEZ M93TS1#$^)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O M;3X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N M)R!S:7IE/3-$,CXD/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O M;2!A;&EG;CTS1')I9VAT/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4 M:6UE<R!.97<@4F]M86XG('-I>F4],T0R/C8S+#`Q,SPO9F]N=#X\+W1D/@T* M(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P/CQF;VYT('-T M>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R M/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T M;VT^/&9O;G0@<VEZ93TS1#$^)B-X03`[)B-X03`[/"]F;VYT/CPO=&0^#0H@ M/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=&3TY4+49!34E, M63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXF(WA!,#L\+V9O;G0^/"]T M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^/&9O;G0@ M<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS M1#(^,2\R,#$U)B-X03`[)B-X,C`Q-#LF(WA!,#LQ,B\R,#$U/"]F;VYT/CPO M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^/&9O M;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ M93TS1#(^)B-X03`[)B-X03`[/"]F;VYT/CPO=&0^#0H@/"]T<CX-"B`\='(@ M<W1Y;&4],T0G1D].5"U325I%.B`Q<'@G/@T*(#QT9"!V86QI9VX],T1B;W1T M;VT^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$ M15(M5$]0.B`C,#`P,#`P(#-P>"!D;W5B;&4G/B8C>$$P.SPO<#X-"B`\+W1D M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@<W1Y;&4],T0G0D]21$52 M+51/4#H@(S`P,#`P,"`S<'@@9&]U8FQE)SXF(WA!,#L\+W`^#0H@/"]T9#X- M"B`\=&0^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P M.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL M93TS1"="3U)$15(M5$]0.B`C,#`P,#`P(#-P>"!D;W5B;&4G/B8C>$$P.SPO M<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@<W1Y;&4] M,T0G0D]21$52+51/4#H@(S`P,#`P,"`S<'@@9&]U8FQE)SXF(WA!,#L\+W`^ M#0H@/"]T9#X-"B`\=&0^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T M=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X- M"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B`C,#`P,#`P(#-P>"!D;W5B;&4G M/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@ M/'`@<W1Y;&4],T0G0D]21$52+51/4#H@(S`P,#`P,"`S<'@@9&]U8FQE)SXF M(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0^)B-X03`[/"]T9#X-"B`\=&0@=F%L M:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O M;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B`C,#`P,#`P(#-P>"!D;W5B M;&4G/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^ M#0H@/'`@<W1Y;&4],T0G0D]21$52+51/4#H@(S`P,#`P,"`S<'@@9&]U8FQE M)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0^)B-X03`[/"]T9#X-"B`\=&0@ M=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG M;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X- M"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/"]T<CX-"B`\='(@8F=C M;VQO<CTS1"-#0T5%1D8^#0H@/'1D('9A;&EG;CTS1'1O<#X-"B`\<"!S='EL M93TS1"=-05)'24XM3$5&5#H@,65M.R!415A4+4E.1$5.5#H@+3%E;2<^/&9O M;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ M93TS1#(^3&]N9RUT97)M(&EN=F5S=&UE;G1S#0H@)B-X,C`Q-#L@52Y3+B!4 M<F5A<W5R>2!S96-U<FET:65S/"]F;VYT/CPO<#X-"B`\+W1D/@T*(#QT9"!V M86QI9VX],T1B;W1T;VT^/&9O;G0@<VEZ93TS1#$^)B-X03`[)B-X03`[/"]F M;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R M87`^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA M;B<@<VEZ93TS1#(^)#PO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T M;VT@;F]W<F%P/3-$;F]W<F%P(&%L:6=N/3-$<FEG:'0^/&9O;G0@<W1Y;&4] M,T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^)B-X M,C`Q-#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A M<#TS1&YO=W)A<#X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@ M3F5W(%)O;6%N)R!S:7IE/3-$,CXF(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X- M"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C>$$P.R8C M>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P M/3-$;F]W<F%P/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!. M97<@4F]M86XG('-I>F4],T0R/B0\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N M/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<"!A;&EG;CTS1')I9VAT/CQF;VYT M('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4] M,T0R/B8C>#(P,30[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O M;2!N;W=R87`],T1N;W=R87`^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ M(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^)B-X03`[)B-X03`[/"]F;VYT M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF M(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M M(&YO=W)A<#TS1&YO=W)A<#X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@ M5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXD/"]F;VYT/CPO=&0^#0H@/'1D M('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`@86QI9VX],T1R:6=H M=#X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N M)R!S:7IE/3-$,CXF(W@R,#$T.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX] M,T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P/CQF;VYT('-T>6QE/3-$)T9/3E0M M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R/B8C>$$P.R8C>$$P M.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<VEZ M93TS1#$^)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O M;2!N;W=R87`],T1N;W=R87`^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ M(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^)#PO9F]N=#X\+W1D/@T*(#QT M9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P(&%L:6=N/3-$<FEG M:'0^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA M;B<@<VEZ93TS1#(^)B-X,C`Q-#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N M/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#X\9F]N="!S='EL93TS1"=&3TY4 M+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXF(WA!,#LF(WA! M,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I M>F4],T0Q/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX] M,T1B;W1T;VT^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@ M/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#PO='(^#0H@/'1R('-T>6QE M/3-$)T9/3E0M4TE:13H@,7!X)SX-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T* M(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@<W1Y;&4],T0G0D]21$52+51/ M4#H@(S`P,#`P,"`S<'@@9&]U8FQE)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\ M=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z M(",P,#`P,#`@,W!X(&1O=6)L92<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA! M,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@<W1Y;&4],T0G M0D]21$52+51/4#H@(S`P,#`P,"`S<'@@9&]U8FQE)SXF(WA!,#L\+W`^#0H@ M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/ M4D1%4BU43U`Z(",P,#`P,#`@,W!X(&1O=6)L92<^)B-X03`[/"]P/@T*(#PO M=&0^#0H@/'1D/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF M(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@ M<W1Y;&4],T0G0D]21$52+51/4#H@(S`P,#`P,"`S<'@@9&]U8FQE)SXF(WA! M,#L\+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T M>6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@,W!X(&1O=6)L92<^)B-X03`[ M/"]P/@T*(#PO=&0^#0H@/'1D/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS M1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@ M/'`@<W1Y;&4],T0G0D]21$52+51/4#H@(S`P,#`P,"`S<'@@9&]U8FQE)SXF M(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP M('-T>6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@,W!X(&1O=6)L92<^)B-X M03`[/"]P/@T*(#PO=&0^#0H@/'1D/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG M;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B M;W1T;VT^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D M('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#PO='(^#0H@/"]T86)L93X-"B`\ M<"!S='EL93TS1"=-05)'24XM0D]45$]-.B`P<'@[($9/3E0M4TE:13H@,3)P M>#L@34%21TE.+51/4#H@,'!X)SX-"B`F(WA!,#L\+W`^#0H@/'1A8FQE('-T M>6QE/3-$)T)/4D1%4BU#3TQ,05!313H@8V]L;&%P<V4G(&-E;&QS<&%C:6YG M/3-$,"!C96QL<&%D9&EN9STS1#`@=VED=&@],T0Q,#`E(&%L:6=N/3-$8V5N M=&5R(&)O<F1E<CTS1#`^#0H@/'1R/@T*(#QT9"!W:61T:#TS1#0U)3X\+W1D M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@=VED=&@],T0U)3X\+W1D/@T*(#QT M9#X\+W1D/@T*(#QT9#X\+W1D/@T*(#QT9#X\+W1D/@T*(#QT9"!V86QI9VX] M,T1B;W1T;VT@=VED=&@],T0U)3X\+W1D/@T*(#QT9#X\+W1D/@T*(#QT9#X\ M+W1D/@T*(#QT9#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@=VED=&@] M,T0U)3X\+W1D/@T*(#QT9#X\+W1D/@T*(#QT9#X\+W1D/@T*(#QT9#X\+W1D M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@=VED=&@],T0U)3X\+W1D/@T*(#QT M9#X\+W1D/@T*(#QT9#X\+W1D/@T*(#QT9#X\+W1D/@T*(#QT9"!V86QI9VX] M,T1B;W1T;VT@=VED=&@],T0U)3X\+W1D/@T*(#QT9#X\+W1D/@T*(#QT9#X\ M+W1D/@T*(#QT9#X\+W1D/@T*(#PO='(^#0H@/'1R/@T*(#QT9"!V86QI9VX] M,T1B;W1T;VT^/&9O;G0@<VEZ93TS1#$^)B-X03`[/"]F;VYT/CPO=&0^#0H@ M/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF(WA!,#LF(WA! M,#L\+V9O;G0^/"]T9#X-"B`\=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@ M(S`P,#`P,"`Q<'@@<V]L:60G('9A;&EG;CTS1&)O='1O;2!C;VQS<&%N/3-$ M,3@@86QI9VX],T1C96YT97(^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ M(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#$^/&(^1&5C96UB97(F(WA!,#LS M,2P-"B`R,#$S/"]B/CPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T M;VT^/&9O;G0@<VEZ93TS1#$^)B-X03`[/"]F;VYT/CPO=&0^#0H@/"]T<CX- M"B`\='(^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF M(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT M('-I>F4],T0Q/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!S='EL M93TS1"="3U)$15(M0D]45$]-.B`C,#`P,#`P(#%P>"!S;VQI9"<@=F%L:6=N M/3-$8F]T=&]M(&-O;'-P86X],T0R(&%L:6=N/3-$8V5N=&5R/CQF;VYT('-T M>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0Q M/CQB/D%M;W)T:7IE9#QB<B`O/@T*($-O<W0\+V(^/"]F;VYT/CPO=&0^#0H@ M/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF(WA!,#L\+V9O M;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q M/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!S='EL93TS1"="3U)$ M15(M0D]45$]-.B`C,#`P,#`P(#%P>"!S;VQI9"<@=F%L:6=N/3-$8F]T=&]M M(&-O;'-P86X],T0R(&%L:6=N/3-$8V5N=&5R/CQF;VYT('-T>6QE/3-$)T9/ M3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0Q/CQB/E5N<F5A M;&EZ960\8G(@+SX-"B!'86EN<SPO8CX\+V9O;G0^/"]T9#X-"B`\=&0@=F%L M:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C>$$P.SPO9F]N=#X\+W1D M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<VEZ93TS1#$^)B-X03`[ M)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('-T>6QE/3-$)T)/4D1%4BU"3U14 M3TTZ(",P,#`P,#`@,7!X('-O;&ED)R!V86QI9VX],T1B;W1T;VT@8V]L<W!A M;CTS1#(@86QI9VX],T1C96YT97(^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U) M3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#$^/&(^56YR96%L:7IE9#QB M<B`O/@T*($QO<W-E<SPO8CX\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$ M8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT M9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<VEZ93TS1#$^)B-X03`[/"]F;VYT M/CPO=&0^#0H@/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@ M,7!X('-O;&ED)R!V86QI9VX],T1B;W1T;VT@8V]L<W!A;CTS1#(@86QI9VX] M,T1C96YT97(^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE M=R!2;VUA;B<@<VEZ93TS1#$^/&(^1F%I<CQB<B`O/@T*(%9A;'5E/"]B/CPO M9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<VEZ93TS M1#$^)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\ M9F]N="!S:7IE/3-$,3XF(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@ M<W1Y;&4],T0G0D]21$52+4)/5%1/33H@(S`P,#`P,"`Q<'@@<V]L:60G('9A M;&EG;CTS1&)O='1O;2!C;VQS<&%N/3-$,B!A;&EG;CTS1&-E;G1E<CX\9F]N M="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE M/3-$,3X\8CY-871U<FET>3QB<B`O/@T*($1A=&5S/"]B/CPO9F]N=#X\+W1D M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<VEZ93TS1#$^)B-X03`[ M/"]F;VYT/CPO=&0^#0H@/"]T<CX-"B`\='(@8F=C;VQO<CTS1"-#0T5%1D8^ M#0H@/'1D('9A;&EG;CTS1'1O<#X-"B`\<"!S='EL93TS1"=-05)'24XM3$5& M5#H@,65M.R!415A4+4E.1$5.5#H@+3%E;2<^/&9O;G0@<W1Y;&4],T0G1D]. M5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^0V%S:"!E<75I M=F%L96YT<R`F(W@R,#$T.PT*(&UO;F5Y(&UA<FME="!F=6YD<SPO9F]N=#X\ M+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4] M,T0Q/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B M;W1T;VT^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2 M;VUA;B<@<VEZ93TS1#(^)#PO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B M;W1T;VT@86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS1"=&3TY4+49!34E, M63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXQ-2PX-3@\+V9O;G0^/"]T M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#X\9F]N M="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE M/3-$,CXF(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$ M8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P/CQF;VYT M('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4] M,T0R/B0\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A M<#TS1&YO=W)A<"!A;&EG;CTS1')I9VAT/CQF;VYT('-T>6QE/3-$)T9/3E0M M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R/B8C>#(P,30[/"]F M;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R M87`^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA M;B<@<VEZ93TS1#(^)B-X03`[)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A M;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF(WA!,#LF(WA!,#L\+V9O M;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A M<#X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N M)R!S:7IE/3-$,CXD/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O M;2!N;W=R87`],T1N;W=R87`@86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS M1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXF(W@R M,#$T.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P M/3-$;F]W<F%P/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!. M97<@4F]M86XG('-I>F4],T0R/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T* M(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<VEZ93TS1#$^)B-X03`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`[)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O M='1O;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\=&0@ M=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/"]T<CX-"B`\='(@<W1Y;&4],T0G M1D].5"U325I%.B`Q<'@G/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X- M"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D M('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B`C M,#`P,#`P(#-P>"!D;W5B;&4G/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT9"!V M86QI9VX],T1B;W1T;VT^#0H@/'`@<W1Y;&4],T0G0D]21$52+51/4#H@(S`P M,#`P,"`S<'@@9&]U8FQE)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0^)B-X M03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$ M15(M5$]0.B`C,#`P,#`P(#-P>"!D;W5B;&4G/B8C>$$P.SPO<#X-"B`\+W1D M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@<W1Y;&4],T0G0D]21$52 M+51/4#H@(S`P,#`P,"`S<'@@9&]U8FQE)SXF(WA!,#L\+W`^#0H@/"]T9#X- M"B`\=&0^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P M.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL M93TS1"="3U)$15(M5$]0.B`C,#`P,#`P(#-P>"!D;W5B;&4G/B8C>$$P.SPO M<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@<W1Y;&4] M,T0G0D]21$52+51/4#H@(S`P,#`P,"`S<'@@9&]U8FQE)SXF(WA!,#L\+W`^ M#0H@/"]T9#X-"B`\=&0^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T M=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S M='EL93TS1"="3U)$15(M5$]0.B`C,#`P,#`P(#-P>"!D;W5B;&4G/B8C>$$P M.SPO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@<W1Y M;&4],T0G0D]21$52+51/4#H@(S`P,#`P,"`S<'@@9&]U8FQE)SXF(WA!,#L\ M+W`^#0H@/"]T9#X-"B`\=&0^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$ M8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O M;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\=&0@=F%L M:6=N/3-$8F]T=&]M/CPO=&0^#0H@/"]T<CX-"B`\='(^#0H@/'1D('9A;&EG M;CTS1'1O<#X-"B`\<"!S='EL93TS1"=-05)'24XM3$5&5#H@,65M.R!415A4 M+4E.1$5.5#H@+3%E;2<^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I M;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^4VAO<G0M=&5R;2!I;G9E<W1M96YT M<PT*("8C>#(P,30[(%4N4RX@5')E87-U<GD@<V5C=7)I=&EE<SPO9F]N=#X\ M+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4] M,T0Q/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B M;W1T;VT^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2 M;VUA;B<@<VEZ93TS1#(^)#PO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B M;W1T;VT@86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS1"=&3TY4+49!34E, M63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXU-RPU-C0\+V9O;G0^/"]T M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#X\9F]N M="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE M/3-$,CXF(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$ M8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<W1Y;&4],T0G1D].5"U& M04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^)#PO9F]N=#X\+W1D M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#X\9F]N="!S M='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$ M,CXW/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`] M,T1N;W=R87`^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE M=R!2;VUA;B<@<VEZ93TS1#(^)B-X03`[)B-X03`[/"]F;VYT/CPO=&0^#0H@ M/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF(WA!,#LF(WA! M,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T M>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R M/B0\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$ M<FEG:'0^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2 M;VUA;B<@<VEZ93TS1#(^*#$\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$ M8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#X\9F]N="!S='EL93TS1"=&3TY4+49! M34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXI)B-X03`[/"]F;VYT M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF M(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT M('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4] M,T0R/B0\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N M/3-$<FEG:'0^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE M=R!2;VUA;B<@<VEZ93TS1#(^-3<L-3<P/"]F;VYT/CPO=&0^#0H@/'1D('9A M;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^/&9O;G0@<W1Y;&4],T0G M1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^)B-X03`[ M)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N M="!S:7IE/3-$,3XF(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L M:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE M<R!.97<@4F]M86XG('-I>F4],T0R/B8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT M9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS M1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXQ+S(P M,30F(WA!,#LF(W@R,#$T.R8C>$$P.S$R+S(P,30\+V9O;G0^/"]T9#X-"B`\ M=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#X\9F]N="!S='EL M93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXF M(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\+W1R/@T*(#QT<B!S='EL93TS M1"=&3TY4+5-)6D4Z(#%P>"<^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\ M=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z M(",P,#`P,#`@,W!X(&1O=6)L92<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D M('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B`C M,#`P,#`P(#-P>"!D;W5B;&4G/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT9#XF M(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[ M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/ M4D1%4BU43U`Z(",P,#`P,#`@,W!X(&1O=6)L92<^)B-X03`[/"]P/@T*(#PO M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$ M15(M5$]0.B`C,#`P,#`P(#-P>"!D;W5B;&4G/B8C>$$P.SPO<#X-"B`\+W1D M/@T*(#QT9#XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X M03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T M>6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@,W!X(&1O=6)L92<^)B-X03`[ M/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL M93TS1"="3U)$15(M5$]0.B`C,#`P,#`P(#-P>"!D;W5B;&4G/B8C>$$P.SPO M<#X-"B`\+W1D/@T*(#QT9#XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B M;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP M('-T>6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@,W!X(&1O=6)L92<^)B-X M03`[/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S M='EL93TS1"="3U)$15(M5$]0.B`C,#`P,#`P(#-P>"!D;W5B;&4G/B8C>$$P M.SPO<#X-"B`\+W1D/@T*(#QT9#XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX] M,T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T M=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V M86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\+W1R/@T*(#QT<B!B9V-O;&]R/3-$ M(T-#145&1CX-"B`\=&0@=F%L:6=N/3-$=&]P/@T*(#QP('-T>6QE/3-$)TU! M4D=)3BU,1494.B`Q96T[(%1%6%0M24Y$14Y4.B`M,65M)SX\9F]N="!S='EL M93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CY, M;VYG+71E<FT@:6YV97-T;65N=',-"B`F(W@R,#$T.R!5+E,N(%1R96%S=7)Y M('-E8W5R:71I97,\+V9O;G0^/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS M1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF(WA!,#LF(WA!,#L\+V9O;G0^/"]T M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)T9/3E0M M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R/B0\+V9O;G0^/"]T M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^/&9O;G0@ M<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS M1#(^,BPU,#(\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO M=W)A<#TS1&YO=W)A<#X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM M97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXF(WA!,#LF(WA!,#L\+V9O;G0^/"]T M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C>$$P M.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W M<F%P/3-$;F]W<F%P/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE M<R!.97<@4F]M86XG('-I>F4],T0R/B0\+V9O;G0^/"]T9#X-"B`\=&0@=F%L M:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<"!A;&EG;CTS1')I9VAT/CQF M;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I M>F4],T0R/B8C>#(P,30[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O M='1O;2!N;W=R87`],T1N;W=R87`^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U) M3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^)B-X03`[)B-X03`[/"]F M;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$ M,3XF(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T M=&]M(&YO=W)A<#TS1&YO=W)A<#X\9F]N="!S='EL93TS1"=&3TY4+49!34E, M63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXD/"]F;VYT/CPO=&0^#0H@ M/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`@86QI9VX],T1R M:6=H=#X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O M;6%N)R!S:7IE/3-$,CXF(W@R,#$T.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI M9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P/CQF;VYT('-T>6QE/3-$)T9/ M3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R/B8C>$$P.R8C M>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@ M<VEZ93TS1#$^)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O M='1O;3X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O M;6%N)R!S:7IE/3-$,CXD/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O M='1O;2!A;&EG;CTS1')I9VAT/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9 M.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R/C(L-3`R/"]F;VYT/CPO=&0^ M#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^/&9O;G0@ M<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS M1#(^)B-X03`[)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O M='1O;3X\9F]N="!S:7IE/3-$,3XF(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X- M"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%- M24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R/B8C>$$P.SPO9F]N=#X\ M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#X\9F]N M="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE M/3-$,CXQ+S(P,34\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M M(&YO=W)A<#TS1&YO=W)A<#X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@ M5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXF(WA!,#LF(WA!,#L\+V9O;G0^ M/"]T9#X-"B`\+W1R/@T*(#QT<B!S='EL93TS1"=&3TY4+5-)6D4Z(#%P>"<^ M#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B M;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@,W!X(&1O=6)L M92<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X- M"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B`C,#`P,#`P(#-P>"!D;W5B;&4G M/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT9#XF(WA!,#L\+W1D/@T*(#QT9"!V M86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N M/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@ M,W!X(&1O=6)L92<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS M1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B`C,#`P,#`P(#-P M>"!D;W5B;&4G/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT9#XF(WA!,#L\+W1D M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\ M=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z M(",P,#`P,#`@,W!X(&1O=6)L92<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D M('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B`C M,#`P,#`P(#-P>"!D;W5B;&4G/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT9#XF M(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X- M"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU4 M3U`Z(",P,#`P,#`@,W!X(&1O=6)L92<^)B-X03`[/"]P/@T*(#PO=&0^#0H@ M/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0 M.B`C,#`P,#`P(#-P>"!D;W5B;&4G/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT M9#XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X M03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A M;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T M9#X-"B`\+W1R/@T*(#PO=&%B;&4^#0H@/'`@<W1Y;&4],T0G34%21TE.+4)/ M5%1/33H@,'!X.R!-05)'24XM5$]0.B`Q,G!X.R!415A4+4E.1$5.5#H@-"4G M(&%L:6=N/3-$:G5S=&EF>3X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@ M5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CY!<R!O9B!$96-E;6)E<B8C>$$P M.S,Q+"`R,#$T(&%N9"!$96-E;6)E<B8C>$$P.S,Q+"`R,#$S+"!T:&4-"B!# M;VUP86YY)B-X,C`Q.3MS(%4N4RX@5')E87-U<GD@<V5C=7)I=&EE<R!C;&%S M<VEF:65D(&%S('-H;W)T+71E<FT-"B!I;G9E<W1M96YT<R!H860@=6YR96%L M:7IE9"!L;W-S97,@;V8@87!P<F]X:6UA=&5L>2`D-R!A;F0@)#$L#0H@<F5S M<&5C=&EV96QY+B!4:&4@;F5T('5N<F5A;&EZ960@;&]S<R!A="!$96-E;6)E M<B8C>$$P.S,Q+"`R,#$T('=A<PT*('!R:6UA<FEL>2!C875S960@8GD@:6YC M<F5A<V5S(&EN('-H;W)T+71E<FT@:6YT97)E<W0@<F%T97,-"B!S=6)S97%U M96YT('1O('1H92!P=7)C:&%S92!D871E<R!O9B!T:&4@<F5L871E9"!S96-U M<FET:65S+B!4:&4@;F5T#0H@=6YR96%L:7IE9"!G86EN(&%T($1E8V5M8F5R M)B-X03`[,S$L(#(P,3,@=V%S('!R:6UA<FEL>2!C875S960@8GD-"B!S;&EG M:'0@9&5C<F5A<V5S(&EN('-H;W)T+71E<FT@:6YT97)E<W0@<F%T97,@<W5B M<V5Q=65N="!T;R!T:&4-"B!P=7)C:&%S92!D871E<R!O9B!T:&4@<F5L871E M9"!S96-U<FET:65S+B!!="!$96-E;6)E<B8C>$$P.S,Q+"`R,#$T#0H@=&AE M<F4@=V5R92!N;R!I;G9E<W1M96YT<R!T:&%T(&AA9"!B965N(&EN(&$@8V]N M=&EN=6]U<R!U;G)E86QI>F5D#0H@;&]S<R!P;W-I=&EO;B!F;W(@,3(@;6]N M=&AS(&]R(&QO;F=E<BX@5&AE($-O;7!A;GD@8V]L;&5C=&5D('1H90T*(&-O M;G1R86-T=6%L(&-A<V@@9FQO=W,@;VX@:71S(%4N4RXF(WA!,#M4<F5A<W5R M>2!S96-U<FET:65S('1H870-"B!M871U<F5D(&9R;VT@2F%N=6%R>28C>$$P M.S$L(#(P,34@=&AR;W5G:"!&96)R=6%R>28C>$$P.S(W+"`R,#$U#0H@86YD M(&5X<&5C=',@=&\@8F4@86)L92!T;R!C;VQL96-T(&%L;"!C;VYT<F%C='5A M;"!C87-H(&9L;W=S(&]N('1H90T*(')E;6%I;FEN9R!M871U<FET:65S(&]F M(&ET<R!5+E,N)B-X03`[5')E87-U<GD-"B!S96-U<FET:65S+CPO9F]N=#X\ M+W`^#0H@/'`@<W1Y;&4],T0G34%21TE.+4)/5%1/33H@,'!X.R!-05)'24XM M5$]0.B`Q,G!X.R!415A4+4E.1$5.5#H@-"4G(&%L:6=N/3-$:G5S=&EF>3X\ M9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S M:7IE/3-$,CY);G1E<F5S="!I;F-O;64@=V%S(&%S(&9O;&QO=W,@*&EN('1H M;W5S86YD<RDZ/"]F;VYT/CPO<#X-"B`\<"!S='EL93TS1"=-05)'24XM0D]4 M5$]-.B`P<'@[($9/3E0M4TE:13H@,3)P>#L@34%21TE.+51/4#H@,'!X)SX- M"B`F(WA!,#L\+W`^#0H@/'1A8FQE('-T>6QE/3-$)T)/4D1%4BU#3TQ,05!3 M13H@8V]L;&%P<V4G(&-E;&QS<&%C:6YG/3-$,"!C96QL<&%D9&EN9STS1#`@ M=VED=&@],T0Y,B4@86QI9VX],T1C96YT97(@8F]R9&5R/3-$,#X-"B`\='(^ M#0H@/'1D('=I9'1H/3-$.#$E/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O M;2!W:61T:#TS1#0E/CPO=&0^#0H@/'1D/CPO=&0^#0H@/'1D/CPO=&0^#0H@ M/'1D/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#0E/CPO M=&0^#0H@/'1D/CPO=&0^#0H@/'1D/CPO=&0^#0H@/'1D/CPO=&0^#0H@/'1D M('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#0E/CPO=&0^#0H@/'1D/CPO=&0^ M#0H@/'1D/CPO=&0^#0H@/'1D/CPO=&0^#0H@/"]T<CX-"B`\='(^#0H@/'1D M('9A;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF(WA!,#L\+V9O;G0^ M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C M>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!S='EL93TS1"="3U)$15(M M0D]45$]-.B`C,#`P,#`P(#%P>"!S;VQI9"<@=F%L:6=N/3-$8F]T=&]M(&-O M;'-P86X],T0Q,"!A;&EG;CTS1&-E;G1E<CX\9F]N="!S='EL93TS1"=&3TY4 M+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,3X\8CY996%R<R!% M;F1E9#QB<B`O/@T*($1E8V5M8F5R)B-X03`[,S$L/"]B/CPO9F]N=#X\+W1D M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<VEZ93TS1#$^)B-X03`[ M/"]F;VYT/CPO=&0^#0H@/"]T<CX-"B`\='(^#0H@/'1D('9A;&EG;CTS1&)O M='1O;3X\9F]N="!S:7IE/3-$,3XF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@ M=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C>$$P.R8C>$$P.SPO M9F]N=#X\+W1D/@T*(#QT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B`C,#`P M,#`P(#%P>"!S;VQI9"<@=F%L:6=N/3-$8F]T=&]M(&-O;'-P86X],T0R(&%L M:6=N/3-$8V5N=&5R/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE M<R!.97<@4F]M86XG('-I>F4],T0Q/CQB/C(P,30\+V(^/"]F;VYT/CPO=&0^ M#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF(WA!,#L\ M+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4] M,T0Q/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!S='EL93TS1"=" M3U)$15(M0D]45$]-.B`C,#`P,#`P(#%P>"!S;VQI9"<@=F%L:6=N/3-$8F]T M=&]M(&-O;'-P86X],T0R(&%L:6=N/3-$8V5N=&5R/CQF;VYT('-T>6QE/3-$ M)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0Q/CQB/C(P M,3,\+V(^/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N M="!S:7IE/3-$,3XF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$ M8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D M/@T*(#QT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B`C,#`P,#`P(#%P>"!S M;VQI9"<@=F%L:6=N/3-$8F]T=&]M(&-O;'-P86X],T0R(&%L:6=N/3-$8V5N M=&5R/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M M86XG('-I>F4],T0Q/CQB/C(P,3(\+V(^/"]F;VYT/CPO=&0^#0H@/'1D('9A M;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF(WA!,#L\+V9O;G0^/"]T M9#X-"B`\+W1R/@T*(#QT<B!B9V-O;&]R/3-$(T-#145&1CX-"B`\=&0@=F%L M:6=N/3-$=&]P/@T*(#QP('-T>6QE/3-$)TU!4D=)3BU,1494.B`Q96T[(%1% M6%0M24Y$14Y4.B`M,65M)SX\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@ M5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CY);G1E<F5S="!I;F-O;64\+V9O M;G0^/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S M:7IE/3-$,3XF(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N M/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!. M97<@4F]M86XG('-I>F4],T0R/B0\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N M/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^/&9O;G0@<W1Y;&4],T0G1D].5"U& M04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^,3`Q/"]F;VYT/CPO M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^/&9O M;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ M93TS1#(^)B-X03`[)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS M1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF(WA!,#LF(WA!,#L\+V9O;G0^/"]T M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)T9/3E0M M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R/B0\+V9O;G0^/"]T M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^/&9O;G0@ M<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS M1#(^.38\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A M<#TS1&YO=W)A<#X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@ M3F5W(%)O;6%N)R!S:7IE/3-$,CXF(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X- M"B`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`\<"!S='EL93TS M1"=-05)'24XM0D]45$]-.B`P<'@[($U!4D=)3BU43U`Z(#$R<'@[(%1%6%0M M24Y$14Y4.B`T)2<@86QI9VX],T1J=7-T:69Y/CQF;VYT('-T>6QE/3-$)T9/ M3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R/E1H92!#;VUP M86YY(&AA<R!R979I<V5D('1H92!P<F5V:6]U<VQY(')E<&]R=&5D(&1I<V-L M;W-U<F4@;V8-"B!I;G1E<F5S="!I;F-O;64@9F]R('1H92!Y96%R(&5N9&5D M($1E8V5M8F5R(#(P,3,N(%1H92!C;W)R96-T:6]N#0H@:&%D(&YO(&5F9F5C M="!U<&]N('1H92!C;VYS;VQI9&%T960@<W1A=&5M96YT(&]F(&-O;7!R96AE M;G-I=F4@;&]S<PT*(&%M;W5N=',N/"]F;VYT/CPO<#X-"B`\+V1I=CX\<W!A M;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@/"]T86)L93X-"B`@ M/"]B;V1Y/@T*/"]H=&UL/@T*#0HM+2TM+2T]7TYE>'1087)T7S,Y8S!E838R M7V,R,#-?-#4X9E\X8S4P7S-D8V$T-39A-CDU,0T*0V]N=&5N="U,;V-A=&EO M;CH@9FEL93HO+R]#.B\S.6,P96$V,E]C,C`S7S0U.&9?.&,U,%\S9&-A-#4V M838Y-3$O5V]R:W-H965T<R]3:&5E=#$R+FAT;6P-"D-O;G1E;G0M5')A;G-F M97(M16YC;V1I;F<Z('%U;W1E9"UP<FEN=&%B;&4-"D-O;G1E;G0M5'EP93H@ M=&5X="]H=&UL.R!C:&%R<V5T/2)U<RUA<V-I:2(-"@T*/&AT;6P^#0H@(#QH M96%D/@T*("`@(#Q-151!(&AT='`M97%U:78],T1#;VYT96YT+51Y<&4@8V]N M=&5N=#TS1"=T97AT+VAT;6P[(&-H87)S970]=71F+3@G/CQS8W)I<'0@='EP M93TS1'1E>'0O:F%V87-C<FEP="!S<F,],T13:&]W+FIS/B\J($1O($YO="!2 M96UO=F4@5&AI<R!#;VUM96YT("HO/"]S8W)I<'0^/"]H96%D/@T*("`\8F]D M>3X-"B`@("`\=&%B;&4@8VQA<W,],T1R97!O<G0@:60],T1)1#!%344^#0H@ M("`@("`\='(^#0H@("`@("`@(#QT:"!C;&%S<STS1'1L(&-O;'-P86X],T0Q M(')O=W-P86X],T0R/CQS=')O;F<^1F%I<B!686QU92!-96%S=7)E;65N=',\ M8G(^/"]S=')O;F<^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@@8V]L M<W!A;CTS1#$^,3(@36]N=&AS($5N9&5D/"]T:#X-"B`@("`@(#PO='(^#0H@ M("`@("`\='(^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/D1E8RX@,S$L(#(P M,30\8G(^/"]T:#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R M93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/CQS=')O M;F<^1F%I<B!686QU92!$:7-C;&]S=7)E<R!;06)S=')A8W1=/"]S=')O;F<^ M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^ M/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@ M("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D9A:7(@5F%L=64@ M365A<W5R96UE;G1S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\ M9&EV/@T*(#QP('-T>6QE/3-$)TU!4D=)3BU"3U143TTZ(#!P>#L@34%21TE. M+51/4#H@,'!X)SX\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@ M3F5W(%)O;6%N)R!S:7IE/3-$,CX\8CY.;W1E(#4@)B-X,C`Q-#L@1F%I<@T* M(%9A;'5E($UE87-U<F5M96YT<SPO8CX\+V9O;G0^/"]P/@T*(#QP('-T>6QE M/3-$)TU!4D=)3BU"3U143TTZ(#!P>#L@34%21TE.+51/4#H@-G!X.R!415A4 M+4E.1$5.5#H@-"4G(&%L:6=N/3-$:G5S=&EF>3X\9F]N="!S='EL93TS1"=& M3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CY4:&4@0V]M M<&%N>2!A9&]P=&5D('1H92!F86ER('9A;'5E(&%C8V]U;G1I;F<@9W5I9&%N M8V4@=&\@=F%L=64-"B!I=',@9FEN86YC:6%L(&%S<V5T<R!A;F0@;&EA8FEL M:71I97,N($9A:7(@=F%L=64@:7,@9&5F:6YE9"!A<R!T:&4-"B!P<FEC92!T M:&%T('=O=6QD(&)E(')E8V5I=F5D(&9O<B!A<W-E=',@=VAE;B!S;VQD(&]R M('!A:60@=&\-"B!T<F%N<V9E<B!A(&QI86)I;&ET>2!I;B!A;B!O<F1E<FQY M('1R86YS86-T:6]N(&)E='=E96X@;6%R:V5T#0H@<&%R=&EC:7!A;G1S(&%T M('1H92!M96%S=7)E;65N="!D871E("AE>&ET('!R:6-E*2X@5&AE($-O;7!A M;GD-"B!U=&EL:7IE<R!M87)K970@9&%T82!O<B!A<W-U;7!T:6]N<R!T:&%T M('1H92!#;VUP86YY(&)E;&EE=F5S#0H@;6%R:V5T('!A<G1I8VEP86YT<R!W M;W5L9"!U<V4@:6X@<')I8VEN9R!T:&4@87-S970@;W(@;&EA8FEL:71Y+`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`Q.3L@86YD M('1H92!T:&ER9"UP87)T>0T*(&EN<W5R97)S)B-X,C`Q.3L@8W)E9&ET(')I M<VL@:6X@:71S(&%S<V5S<VUE;G0@;V8@9F%I<@T*('9A;'5E+CPO9F]N=#X\ M+W`^#0H@/'`@<W1Y;&4],T0G34%21TE.+4)/5%1/33H@,'!X.R!-05)'24XM M5$]0.B`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`H3&5V M96PF(WA!,#LQ(&UE87-U<F5M96YT*2!A;F0@=&AE(&QO=V5S="!P<FEO<FET M>2!T;PT*('5N;V)S97)V86)L92!I;G!U=',@*$QE=F5L)B-X03`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`[)B-X,C`Q-#L@26YP=71S M+"!O=&AE<B!T:&%N('1H92!Q=6]T960@<')I8V5S#0H@:6X@86-T:79E(&UA M<FME=',L('1H870@87)E(&]B<V5R=F%B;&4@96ET:&5R(&1I<F5C=&QY(&]R M('1H<F]U9V@-"B!C;W)R;V)O<F%T:6]N('=I=&@@;V)S97)V86)L92!M87)K M970@9&%T83LF(WA!,#MA;F0\+V9O;G0^/"]P/@T*(#QP('-T>6QE/3-$)TU! M4D=)3BU"3U143TTZ(#!P>#L@34%21TE.+51/4#H@,3)P>#L@5$585"U)3D1% M3E0Z(#0E)R!A;&EG;CTS1&IU<W1I9GD^/&9O;G0@<W1Y;&4],T0G1D].5"U& M04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^3&5V96PF(WA!,#LS M)B-X03`[)B-X,C`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`Q-"!A M;F0@,C`Q,R!A<F4@8VQA<W-I9FEE9"!I;B!T:&4@=&%B;&4-"B!B96QO=R!I M;B!O;F4@;V8@=&AE('1H<F5E(&-A=&5G;W)I97,@9&5S8W)I8F5D(&%B;W9E M("AI;@T*('1H;W5S86YD<RDZ/"]F;VYT/CPO<#X-"B`\<"!S='EL93TS1"=- M05)'24XM0D]45$]-.B`P<'@[($9/3E0M4TE:13H@,3)P>#L@34%21TE.+51/ M4#H@,'!X)SX-"B`F(WA!,#L\+W`^#0H@/'1A8FQE('-T>6QE/3-$)T)/4D1% M4BU#3TQ,05!313H@8V]L;&%P<V4G(&-E;&QS<&%C:6YG/3-$,"!C96QL<&%D M9&EN9STS1#`@=VED=&@],T0Y,B4@86QI9VX],T1C96YT97(@8F]R9&5R/3-$ M,#X-"B`\='(^#0H@/'1D('=I9'1H/3-$-38E/CPO=&0^#0H@/'1D('9A;&EG M;CTS1&)O='1O;2!W:61T:#TS1#<E/CPO=&0^#0H@/'1D/CPO=&0^#0H@/'1D M/CPO=&0^#0H@/'1D/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!W:61T M:#TS1#<E/CPO=&0^#0H@/'1D/CPO=&0^#0H@/'1D/CPO=&0^#0H@/'1D/CPO M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#<E/CPO=&0^#0H@ M/'1D/CPO=&0^#0H@/'1D/CPO=&0^#0H@/'1D/CPO=&0^#0H@/'1D('9A;&EG M;CTS1&)O='1O;2!W:61T:#TS1#<E/CPO=&0^#0H@/'1D/CPO=&0^#0H@/'1D M/CPO=&0^#0H@/'1D/CPO=&0^#0H@/"]T<CX-"B`\='(^#0H@/'1D('9A;&EG M;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF(WA!,#L\+V9O;G0^/"]T9#X- M"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C>$$P.R8C M>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!S='EL93TS1"="3U)$15(M0D]45$]- M.B`C,#`P,#`P(#%P>"!S;VQI9"<@=F%L:6=N/3-$8F]T=&]M(&-O;'-P86X] M,T0Q-"!A;&EG;CTS1&-E;G1E<CX\9F]N="!S='EL93TS1"=&3TY4+49!34E, M63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,3X\8CY$96-E;6)E<B8C>$$P M.S,Q+`T*(#(P,30\+V(^/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O M='1O;3X\9F]N="!S:7IE/3-$,3XF(WA!,#L\+V9O;G0^/"]T9#X-"B`\+W1R M/@T*(#QT<CX-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q M/B8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O M;G0@<VEZ93TS1#$^)B-X03`[)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('-T M>6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,7!X('-O;&ED)R!V86QI M9VX],T1B;W1T;VT@8V]L<W!A;CTS1#$P(&%L:6=N/3-$8V5N=&5R/CQF;VYT M('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4] M,T0Q/CQB/D9A:7(F(WA!,#M686QU928C>$$P.TUE87-U<F5M96YT<R8C>$$P M.U5S:6YG/"]B/CPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^ M/&9O;G0@<VEZ93TS1#$^)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG M;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF(WA!,#LF(WA!,#L\+V9O;G0^ M/"]T9#X-"B`\=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@(S`P,#`P,"`Q M<'@@<V]L:60G('9A;&EG;CTS1&)O='1O;2!R;W=S<&%N/3-$,B!C;VQS<&%N M/3-$,B!A;&EG;CTS1&-E;G1E<CX\9F]N="!S='EL93TS1"=&3TY4+49!34E, M63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,3X\8CY!<W-E=',\8G(@+SX- M"B!!="8C>$$P.T9A:7(F(WA!,#M686QU93PO8CX\+V9O;G0^/"]T9#X-"B`\ M=&0@=F%L:6=N/3-$8F]T=&]M(')O=W-P86X],T0R/CQF;VYT('-I>F4],T0Q M/B8C>$$P.SPO9F]N=#X\+W1D/@T*(#PO='(^#0H@/'1R/@T*(#QT9"!V86QI M9VX],T1B;W1T;VT^/&9O;G0@<VEZ93TS1#$^)B-X03`[/"]F;VYT/CPO=&0^ M#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF(WA!,#LF M(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/ M33H@(S`P,#`P,"`Q<'@@<V]L:60G('9A;&EG;CTS1&)O='1O;2!C;VQS<&%N M/3-$,B!A;&EG;CTS1&-E;G1E<CX\9F]N="!S='EL93TS1"=&3TY4+49!34E, M63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,3X\8CXF(WA!,#LF(WA!,#M, M979E;"8C>$$P.S$F(WA!,#LF(WA!,#L\+V(^/"]F;VYT/CPO=&0^#0H@/'1D M('9A;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF(WA!,#L\+V9O;G0^ M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C M>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!S='EL93TS1"="3U)$15(M M0D]45$]-.B`C,#`P,#`P(#%P>"!S;VQI9"<@=F%L:6=N/3-$8F]T=&]M(&-O M;'-P86X],T0R(&%L:6=N/3-$8V5N=&5R/CQF;VYT('-T>6QE/3-$)T9/3E0M M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0Q/CQB/B8C>$$P.R8C M>$$P.TQE=F5L)B-X03`[,B8C>$$P.R8C>$$P.SPO8CX\+V9O;G0^/"]T9#X- M"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C>$$P.SPO M9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<VEZ93TS M1#$^)B-X03`[)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('-T>6QE/3-$)T)/ M4D1%4BU"3U143TTZ(",P,#`P,#`@,7!X('-O;&ED)R!V86QI9VX],T1B;W1T M;VT@8V]L<W!A;CTS1#(@86QI9VX],T1C96YT97(^/&9O;G0@<W1Y;&4],T0G M1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#$^/&(^)B-X M03`[)B-X03`[3&5V96PF(WA!,#LS)B-X03`[)B-X03`[/"]B/CPO9F]N=#X\ M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<VEZ93TS1#$^)B-X M03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S M:7IE/3-$,3XF(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\+W1R/@T*(#QT M<B!B9V-O;&]R/3-$(T-#145&1CX-"B`\=&0@=F%L:6=N/3-$=&]P/@T*(#QP M('-T>6QE/3-$)TU!4D=)3BU,1494.B`Q96T[(%1%6%0M24Y$14Y4.B`M,65M M)SX\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N M)R!S:7IE/3-$,CY-;VYE>2!M87)K970-"B!F=6YD<SPO9F]N=#X\+W`^#0H@ M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C M>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^ M/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@ M<VEZ93TS1#(^)#PO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@ M86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM M97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXQ-BPY,S(\+V9O;G0^/"]T9#X-"B`\ M=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#X\9F]N="!S='EL M93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXF M(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M M/CQF;VYT('-I>F4],T0Q/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT M9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P/CQF;VYT('-T>6QE M/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R/B0\ M+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO M=W)A<"!A;&EG;CTS1')I9VAT/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9 M.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R/B8C>#(P,30[/"]F;VYT/CPO M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^/&9O M;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ M93TS1#(^)B-X03`[)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS M1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF(WA!,#LF(WA!,#L\+V9O;G0^/"]T M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#X\9F]N M="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE M/3-$,CXD/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R M87`],T1N;W=R87`@86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS1"=&3TY4 M+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXF(W@R,#$T.SPO M9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W M<F%P/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M M86XG('-I>F4],T0R/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V M86QI9VX],T1B;W1T;VT^/&9O;G0@<VEZ93TS1#$^)B-X03`[)B-X03`[/"]F M;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS M1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXD/"]F M;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT M/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG M('-I>F4],T0R/C$V+#DS,CPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B M;W1T;VT@;F]W<F%P/3-$;F]W<F%P/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%- M24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R/B8C>$$P.R8C>$$P.SPO M9F]N=#X\+W1D/@T*(#PO='(^#0H@/'1R/@T*(#QT9"!V86QI9VX],T1T;W`^ M#0H@/'`@<W1Y;&4],T0G34%21TE.+4Q%1E0Z(#%E;3L@5$585"U)3D1%3E0Z M("TQ96TG/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@ M4F]M86XG('-I>F4],T0R/E4N4RX@5')E87-U<GD-"B!S96-U<FET:65S/"]F M;VYT/CPO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@ M<VEZ93TS1#$^)B-X03`[)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG M;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@ M3F5W(%)O;6%N)R!S:7IE/3-$,CXF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@ M=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^/&9O;G0@<W1Y;&4],T0G M1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^-C,L,#$S M/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N M;W=R87`^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2 M;VUA;B<@<VEZ93TS1#(^)B-X03`[)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D M('9A;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF(WA!,#LF(WA!,#L\ M+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO M=W)A<#X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O M;6%N)R!S:7IE/3-$,CXF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N M/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<"!A;&EG;CTS1')I9VAT/CQF;VYT M('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4] M,T0R/B8C>#(P,30[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O M;2!N;W=R87`],T1N;W=R87`^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ M(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^)B-X03`[)B-X03`[/"]F;VYT M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF M(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M M(&YO=W)A<#TS1&YO=W)A<#X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@ M5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXF(WA!,#L\+V9O;G0^/"]T9#X- M"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<"!A;&EG;CTS M1')I9VAT/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@ M4F]M86XG('-I>F4],T0R/B8C>#(P,30[/"]F;VYT/CPO=&0^#0H@/'1D('9A M;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^/&9O;G0@<W1Y;&4],T0G M1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^)B-X03`[ M)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N M="!S:7IE/3-$,3XF(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L M:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE M<R!.97<@4F]M86XG('-I>F4],T0R/B8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT M9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS M1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXV,RPP M,3,\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS M1&YO=W)A<#X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W M(%)O;6%N)R!S:7IE/3-$,CXF(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\ M+W1R/@T*(#QT<B!S='EL93TS1"=&3TY4+5-)6D4Z(#%P>"<^#0H@/'1D('9A M;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X M03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T M>6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@,7!X('-O;&ED)SXF(WA!,#L\ M+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE M/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@,7!X('-O;&ED)SXF(WA!,#L\+W`^ M#0H@/"]T9#X-"B`\=&0^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T M=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X- M"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B`C,#`P,#`P(#%P>"!S;VQI9"<^ M)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\ M<"!S='EL93TS1"="3U)$15(M5$]0.B`C,#`P,#`P(#%P>"!S;VQI9"<^)B-X M03`[/"]P/@T*(#PO=&0^#0H@/'1D/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG M;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B M;W1T;VT^#0H@/'`@<W1Y;&4],T0G0D]21$52+51/4#H@(S`P,#`P,"`Q<'@@ M<V]L:60G/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T M;VT^#0H@/'`@<W1Y;&4],T0G0D]21$52+51/4#H@(S`P,#`P,"`Q<'@@<V]L M:60G/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT9#XF(WA!,#L\+W1D/@T*(#QT M9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L M:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P M,#`@,7!X('-O;&ED)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N M/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@ M,7!X('-O;&ED)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0^)B-X03`[/"]T M9#X-"B`\+W1R/@T*(#QT<B!B9V-O;&]R/3-$(T-#145&1CX-"B`\=&0@=F%L M:6=N/3-$=&]P/@T*(#QP('-T>6QE/3-$)TU!4D=)3BU,1494.B`S96T[(%1% M6%0M24Y$14Y4.B`M,65M)SX\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@ M5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CY4;W1A;#PO9F]N=#X\+W`^#0H@ M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C M>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^ M/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@ M<VEZ93TS1#(^)#PO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@ M86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM M97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXW.2PY-#4\+V9O;G0^/"]T9#X-"B`\ M=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#X\9F]N="!S='EL M93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXF M(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M M/CQF;VYT('-I>F4],T0Q/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT M9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P/CQF;VYT('-T>6QE M/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R/B0\ M+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO M=W)A<"!A;&EG;CTS1')I9VAT/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9 M.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R/B8C>#(P,30[/"]F;VYT/CPO M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^/&9O M;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ M93TS1#(^)B-X03`[)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS M1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF(WA!,#LF(WA!,#L\+V9O;G0^/"]T M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#X\9F]N M="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE M/3-$,CXD/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R M87`],T1N;W=R87`@86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS1"=&3TY4 M+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXF(W@R,#$T.SPO M9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W M<F%P/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M M86XG('-I>F4],T0R/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V M86QI9VX],T1B;W1T;VT^/&9O;G0@<VEZ93TS1#$^)B-X03`[)B-X03`[/"]F M;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS M1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXD/"]F M;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT M/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG M('-I>F4],T0R/C<Y+#DT-3PO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B M;W1T;VT@;F]W<F%P/3-$;F]W<F%P/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%- M24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R/B8C>$$P.R8C>$$P.SPO M9F]N=#X\+W1D/@T*(#PO='(^#0H@/'1R('-T>6QE/3-$)T9/3E0M4TE:13H@ M,7!X)SX-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG M;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B M;W1T;VT^#0H@/'`@<W1Y;&4],T0G0D]21$52+51/4#H@(S`P,#`P,"`S<'@@ M9&]U8FQE)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T M=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@,W!X(&1O M=6)L92<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D/B8C>$$P.SPO=&0^#0H@ M/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V M86QI9VX],T1B;W1T;VT^#0H@/'`@<W1Y;&4],T0G0D]21$52+51/4#H@(S`P M,#`P,"`S<'@@9&]U8FQE)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0@=F%L M:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P M,#`@,W!X(&1O=6)L92<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D/B8C>$$P M.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@<W1Y;&4],T0G0D]21$52 M+51/4#H@(S`P,#`P,"`S<'@@9&]U8FQE)SXF(WA!,#L\+W`^#0H@/"]T9#X- M"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU4 M3U`Z(",P,#`P,#`@,W!X(&1O=6)L92<^)B-X03`[/"]P/@T*(#PO=&0^#0H@ M/'1D/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF M(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@<W1Y;&4] M,T0G0D]21$52+51/4#H@(S`P,#`P,"`S<'@@9&]U8FQE)SXF(WA!,#L\+W`^ M#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$ M)T)/4D1%4BU43U`Z(",P,#`P,#`@,W!X(&1O=6)L92<^)B-X03`[/"]P/@T* M(#PO=&0^#0H@/'1D/B8C>$$P.SPO=&0^#0H@/"]T<CX-"B`\='(^#0H@/'1D M('9A;&EG;CTS1'1O<#X-"B`\<"!S='EL93TS1"=-05)'24XM3$5&5#H@,65M M.R!415A4+4E.1$5.5#H@+3%E;2<^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U) M3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^06UO=6YT<R!I;F-L=61E M9`T*(&EN.CPO9F]N=#X\+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T M=&]M/CQF;VYT('-I>F4],T0Q/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T* M(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T M=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V M86QI9VX],T1B;W1T;VT^/&9O;G0@<VEZ93TS1#$^)B-X03`[)B-X03`[/"]F M;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V M86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF(WA! M,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI9VX] M,T1B;W1T;VT^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I M>F4],T0Q/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX] M,T1B;W1T;VT^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@ M/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#PO='(^#0H@/'1R(&)G8V]L M;W(],T0C0T-%149&/@T*(#QT9"!V86QI9VX],T1T;W`^#0H@/'`@<W1Y;&4] M,T0G34%21TE.+4Q%1E0Z(#)E;3L@5$585"U)3D1%3E0Z("TQ96TG/CQF;VYT M('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4] M,T0R/D-A<V@@86YD(&-A<V@-"B!E<75I=F%L96YT<SPO9F]N=#X\+W`^#0H@ M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C M>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^ M/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@ M<VEZ93TS1#(^)#PO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@ M86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM M97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXQ-BPY,S(\+V9O;G0^/"]T9#X-"B`\ M=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#X\9F]N="!S='EL M93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXF M(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M M/CQF;VYT('-I>F4],T0Q/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT M9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P/CQF;VYT('-T>6QE M/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R/B0\ M+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO M=W)A<"!A;&EG;CTS1')I9VAT/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9 M.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R/B8C>#(P,30[/"]F;VYT/CPO M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^/&9O M;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ M93TS1#(^)B-X03`[)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS M1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF(WA!,#LF(WA!,#L\+V9O;G0^/"]T M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#X\9F]N M="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE M/3-$,CXD/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R M87`],T1N;W=R87`@86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS1"=&3TY4 M+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXF(W@R,#$T.SPO M9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W M<F%P/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M M86XG('-I>F4],T0R/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V M86QI9VX],T1B;W1T;VT^/&9O;G0@<VEZ93TS1#$^)B-X03`[)B-X03`[/"]F M;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS M1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXD/"]F M;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT M/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG M('-I>F4],T0R/C$V+#DS,CPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B M;W1T;VT@;F]W<F%P/3-$;F]W<F%P/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%- M24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R/B8C>$$P.R8C>$$P.SPO M9F]N=#X\+W1D/@T*(#PO='(^#0H@/'1R/@T*(#QT9"!V86QI9VX],T1T;W`^ M#0H@/'`@<W1Y;&4],T0G34%21TE.+4Q%1E0Z(#)E;3L@5$585"U)3D1%3E0Z M("TQ96TG/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@ M4F]M86XG('-I>F4],T0R/E-H;W)T+71E<FT-"B!I;G9E<W1M96YT<SPO9F]N M=#X\+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I M>F4],T0Q/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX] M,T1B;W1T;VT^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE M=R!2;VUA;B<@<VEZ93TS1#(^)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A M;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/CQF;VYT('-T>6QE/3-$)T9/ M3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R/C8S+#`Q,SPO M9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W M<F%P/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M M86XG('-I>F4],T0R/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V M86QI9VX],T1B;W1T;VT^/&9O;G0@<VEZ93TS1#$^)B-X03`[)B-X03`[/"]F M;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R M87`^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA M;B<@<VEZ93TS1#(^)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS M1&)O='1O;2!N;W=R87`],T1N;W=R87`@86QI9VX],T1R:6=H=#X\9F]N="!S M='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$ M,CXF(W@R,#$T.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@ M;F]W<F%P/3-$;F]W<F%P/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4 M:6UE<R!.97<@4F]M86XG('-I>F4],T0R/B8C>$$P.R8C>$$P.SPO9F]N=#X\ M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<VEZ93TS1#$^)B-X M03`[)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N M;W=R87`],T1N;W=R87`^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I M;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^)B-X03`[/"]F;VYT/CPO=&0^#0H@ M/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`@86QI9VX],T1R M:6=H=#X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O M;6%N)R!S:7IE/3-$,CXF(W@R,#$T.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI M9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P/CQF;VYT('-T>6QE/3-$)T9/ M3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R/B8C>$$P.R8C M>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@ M<VEZ93TS1#$^)B-X03`[)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG M;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@ M3F5W(%)O;6%N)R!S:7IE/3-$,CXF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@ M=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^/&9O;G0@<W1Y;&4],T0G M1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^-C,L,#$S M/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N M;W=R87`^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2 M;VUA;B<@<VEZ93TS1#(^)B-X03`[)B-X03`[/"]F;VYT/CPO=&0^#0H@/"]T M<CX-"B`\='(@8F=C;VQO<CTS1"-#0T5%1D8^#0H@/'1D('9A;&EG;CTS1'1O M<#X-"B`\<"!S='EL93TS1"=-05)'24XM3$5&5#H@,F5M.R!415A4+4E.1$5. M5#H@+3%E;2<^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE M=R!2;VUA;B<@<VEZ93TS1#(^3&]N9RUT97)M#0H@:6YV97-T;65N=',\+V9O M;G0^/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S M:7IE/3-$,3XF(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N M/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#X\9F]N="!S='EL93TS1"=&3TY4 M+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXF(WA!,#L\+V9O M;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A M<"!A;&EG;CTS1')I9VAT/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4 M:6UE<R!.97<@4F]M86XG('-I>F4],T0R/B8C>#(P,30[/"]F;VYT/CPO=&0^ M#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^/&9O;G0@ M<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS M1#(^)B-X03`[)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O M='1O;3X\9F]N="!S:7IE/3-$,3XF(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X- M"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#X\9F]N="!S M='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$ M,CXF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO M=W)A<#TS1&YO=W)A<"!A;&EG;CTS1')I9VAT/CQF;VYT('-T>6QE/3-$)T9/ M3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R/B8C>#(P,30[ M/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N M;W=R87`^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2 M;VUA;B<@<VEZ93TS1#(^)B-X03`[)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D M('9A;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF(WA!,#LF(WA!,#L\ M+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO M=W)A<#X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O M;6%N)R!S:7IE/3-$,CXF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N M/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<"!A;&EG;CTS1')I9VAT/CQF;VYT M('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4] M,T0R/B8C>#(P,30[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O M;2!N;W=R87`],T1N;W=R87`^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ M(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^)B-X03`[)B-X03`[/"]F;VYT M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF M(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M M(&YO=W)A<#TS1&YO=W)A<#X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@ M5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXF(WA!,#L\+V9O;G0^/"]T9#X- M"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<"!A;&EG;CTS M1')I9VAT/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@ M4F]M86XG('-I>F4],T0R/B8C>#(P,30[/"]F;VYT/CPO=&0^#0H@/'1D('9A M;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^/&9O;G0@<W1Y;&4],T0G M1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^)B-X03`[ M)B-X03`[/"]F;VYT/CPO=&0^#0H@/"]T<CX-"B`\='(@<W1Y;&4],T0G1D]. M5"U325I%.B`Q<'@G/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\ M=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A M;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B`C,#`P M,#`P(#%P>"!S;VQI9"<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG M;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B`C,#`P,#`P M(#%P>"!S;VQI9"<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D/B8C>$$P.SPO M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T* M(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@<W1Y;&4],T0G0D]21$52+51/ M4#H@(S`P,#`P,"`Q<'@@<V]L:60G/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT M9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@<W1Y;&4],T0G0D]21$52+51/4#H@ M(S`P,#`P,"`Q<'@@<V]L:60G/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT9#XF M(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[ M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/ M4D1%4BU43U`Z(",P,#`P,#`@,7!X('-O;&ED)SXF(WA!,#L\+W`^#0H@/"]T M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1% M4BU43U`Z(",P,#`P,#`@,7!X('-O;&ED)SXF(WA!,#L\+W`^#0H@/"]T9#X- M"B`\=&0^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P M.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL M93TS1"="3U)$15(M5$]0.B`C,#`P,#`P(#%P>"!S;VQI9"<^)B-X03`[/"]P M/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS M1"="3U)$15(M5$]0.B`C,#`P,#`P(#%P>"!S;VQI9"<^)B-X03`[/"]P/@T* M(#PO=&0^#0H@/'1D/B8C>$$P.SPO=&0^#0H@/"]T<CX-"B`\='(^#0H@/'1D M('9A;&EG;CTS1'1O<#X-"B`\<"!S='EL93TS1"=-05)'24XM3$5&5#H@,V5M M.R!415A4+4E.1$5.5#H@+3%E;2<^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U) M3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^5&]T86P\+V9O;G0^/"]P M/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$ M,3XF(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T M=&]M/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M M86XG('-I>F4],T0R/B0\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T M=&]M(&%L:6=N/3-$<FEG:'0^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ M(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^-SDL.30U/"]F;VYT/CPO=&0^ M#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^/&9O;G0@ M<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS M1#(^)B-X03`[)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O M='1O;3X\9F]N="!S:7IE/3-$,3XF(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X- M"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#X\9F]N="!S M='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$ M,CXD/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`] M,T1N;W=R87`@86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS1"=&3TY4+49! M34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXF(W@R,#$T.SPO9F]N M=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P M/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG M('-I>F4],T0R/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI M9VX],T1B;W1T;VT^/&9O;G0@<VEZ93TS1#$^)B-X03`[)B-X03`[/"]F;VYT M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^ M/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@ M<VEZ93TS1#(^)#PO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@ M;F]W<F%P/3-$;F]W<F%P(&%L:6=N/3-$<FEG:'0^/&9O;G0@<W1Y;&4],T0G M1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^)B-X,C`Q M-#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS M1&YO=W)A<#X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W M(%)O;6%N)R!S:7IE/3-$,CXF(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\ M=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C>$$P.R8C>$$P M.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<W1Y M;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^ M)#PO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R M:6=H=#X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O M;6%N)R!S:7IE/3-$,CXW.2PY-#4\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N M/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#X\9F]N="!S='EL93TS1"=&3TY4 M+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXF(WA!,#LF(WA! M,#L\+V9O;G0^/"]T9#X-"B`\+W1R/@T*(#QT<B!S='EL93TS1"=&3TY4+5-) M6D4Z(#%P>"<^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V M86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N M/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@ M,W!X(&1O=6)L92<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS M1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B`C,#`P,#`P(#-P M>"!D;W5B;&4G/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT9#XF(WA!,#L\+W1D M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\ M=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z M(",P,#`P,#`@,W!X(&1O=6)L92<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D M('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B`C M,#`P,#`P(#-P>"!D;W5B;&4G/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT9#XF M(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[ M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/ M4D1%4BU43U`Z(",P,#`P,#`@,W!X(&1O=6)L92<^)B-X03`[/"]P/@T*(#PO M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$ M15(M5$]0.B`C,#`P,#`P(#-P>"!D;W5B;&4G/B8C>$$P.SPO<#X-"B`\+W1D M/@T*(#QT9#XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X M03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T M>6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@,W!X(&1O=6)L92<^)B-X03`[ M/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL M93TS1"="3U)$15(M5$]0.B`C,#`P,#`P(#-P>"!D;W5B;&4G/B8C>$$P.SPO M<#X-"B`\+W1D/@T*(#QT9#XF(WA!,#L\+W1D/@T*(#PO='(^#0H@/"]T86)L M93X-"B`\<"!S='EL93TS1"=-05)'24XM0D]45$]-.B`P<'@[($9/3E0M4TE: M13H@,3)P>#L@34%21TE.+51/4#H@,'!X)SX-"B`F(WA!,#L\+W`^#0H@/'1A M8FQE('-T>6QE/3-$)T)/4D1%4BU#3TQ,05!313H@8V]L;&%P<V4G(&-E;&QS M<&%C:6YG/3-$,"!C96QL<&%D9&EN9STS1#`@=VED=&@],T0Y,B4@86QI9VX] M,T1C96YT97(@8F]R9&5R/3-$,#X-"B`\='(^#0H@/'1D('=I9'1H/3-$-38E M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#<E/CPO=&0^ M#0H@/'1D/CPO=&0^#0H@/'1D/CPO=&0^#0H@/'1D/CPO=&0^#0H@/'1D('9A M;&EG;CTS1&)O='1O;2!W:61T:#TS1#<E/CPO=&0^#0H@/'1D/CPO=&0^#0H@ M/'1D/CPO=&0^#0H@/'1D/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!W M:61T:#TS1#<E/CPO=&0^#0H@/'1D/CPO=&0^#0H@/'1D/CPO=&0^#0H@/'1D M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#<E/CPO=&0^ M#0H@/'1D/CPO=&0^#0H@/'1D/CPO=&0^#0H@/'1D/CPO=&0^#0H@/"]T<CX- M"B`\='(^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF M(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT M('-I>F4],T0Q/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!S='EL M93TS1"="3U)$15(M0D]45$]-.B`C,#`P,#`P(#%P>"!S;VQI9"<@=F%L:6=N M/3-$8F]T=&]M(&-O;'-P86X],T0Q-"!A;&EG;CTS1&-E;G1E<CX\9F]N="!S M='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$ M,3X\8CY$96-E;6)E<B8C>$$P.S,Q+`T*(#(P,3,\+V(^/"]F;VYT/CPO=&0^ M#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF(WA!,#L\ M+V9O;G0^/"]T9#X-"B`\+W1R/@T*(#QT<CX-"B`\=&0@=F%L:6=N/3-$8F]T M=&]M/CQF;VYT('-I>F4],T0Q/B8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V M86QI9VX],T1B;W1T;VT^/&9O;G0@<VEZ93TS1#$^)B-X03`[)B-X03`[/"]F M;VYT/CPO=&0^#0H@/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P M,#`@,7!X('-O;&ED)R!V86QI9VX],T1B;W1T;VT@8V]L<W!A;CTS1#$P(&%L M:6=N/3-$8V5N=&5R/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE M<R!.97<@4F]M86XG('-I>F4],T0Q/CQB/D9A:7(F(WA!,#M686QU928C>$$P M.TUE87-U<F5M96YT<R8C>$$P.U5S:6YG/"]B/CPO9F]N=#X\+W1D/@T*(#QT M9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<VEZ93TS1#$^)B-X03`[/"]F;VYT M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF M(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@<W1Y;&4],T0G0D]21$52 M+4)/5%1/33H@(S`P,#`P,"`Q<'@@<V]L:60G('9A;&EG;CTS1&)O='1O;2!R M;W=S<&%N/3-$,B!C;VQS<&%N/3-$,B!A;&EG;CTS1&-E;G1E<CX\9F]N="!S M='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$ M,3X\8CY!<W-E=',\8G(@+SX-"B!!="8C>$$P.T9A:7(F(WA!,#M686QU93PO M8CX\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(')O=W-P86X] M,T0R/CQF;VYT('-I>F4],T0Q/B8C>$$P.SPO9F]N=#X\+W1D/@T*(#PO='(^ M#0H@/'1R/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<VEZ93TS1#$^ M)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N M="!S:7IE/3-$,3XF(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@<W1Y M;&4],T0G0D]21$52+4)/5%1/33H@(S`P,#`P,"`Q<'@@<V]L:60G('9A;&EG M;CTS1&)O='1O;2!C;VQS<&%N/3-$,B!A;&EG;CTS1&-E;G1E<CX\9F]N="!S M='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$ M,3X\8CXF(WA!,#LF(WA!,#M,979E;"8C>$$P.S$F(WA!,#LF(WA!,#L\+V(^ M/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE M/3-$,3XF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M M/CQF;VYT('-I>F4],T0Q/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT M9"!S='EL93TS1"="3U)$15(M0D]45$]-.B`C,#`P,#`P(#%P>"!S;VQI9"<@ M=F%L:6=N/3-$8F]T=&]M(&-O;'-P86X],T0R(&%L:6=N/3-$8V5N=&5R/CQF M;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I M>F4],T0Q/CQB/B8C>$$P.R8C>$$P.TQE=F5L)B-X03`[,B8C>$$P.R8C>$$P M.SPO8CX\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT M('-I>F4],T0Q/B8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B M;W1T;VT^/&9O;G0@<VEZ93TS1#$^)B-X03`[)B-X03`[/"]F;VYT/CPO=&0^ M#0H@/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,7!X('-O M;&ED)R!V86QI9VX],T1B;W1T;VT@8V]L<W!A;CTS1#(@86QI9VX],T1C96YT M97(^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA M;B<@<VEZ93TS1#$^/&(^)B-X03`[)B-X03`[3&5V96PF(WA!,#LS)B-X03`[ M)B-X03`[/"]B/CPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^ M/&9O;G0@<VEZ93TS1#$^)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG M;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF(WA!,#LF(WA!,#L\+V9O;G0^ M/"]T9#X-"B`\+W1R/@T*(#QT<B!B9V-O;&]R/3-$(T-#145&1CX-"B`\=&0@ M=F%L:6=N/3-$=&]P/@T*(#QP('-T>6QE/3-$)TU!4D=)3BU,1494.B`Q96T[ M(%1%6%0M24Y$14Y4.B`M,65M)SX\9F]N="!S='EL93TS1"=&3TY4+49!34E, M63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CY-;VYE>2!M87)K970-"B!F M=6YD<SPO9F]N=#X\+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M M/CQF;VYT('-I>F4],T0Q/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT M9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ M(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^)#PO9F]N=#X\+W1D/@T*(#QT M9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS M1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXQ-2PX M-3@\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS M1&YO=W)A<#X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W M(%)O;6%N)R!S:7IE/3-$,CXF(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\ M=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C>$$P.R8C>$$P M.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$ M;F]W<F%P/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@ M4F]M86XG('-I>F4],T0R/B0\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$ M8F]T=&]M(&YO=W)A<#TS1&YO=W)A<"!A;&EG;CTS1')I9VAT/CQF;VYT('-T M>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R M/B8C>#(P,30[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N M;W=R87`],T1N;W=R87`^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I M;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^)B-X03`[)B-X03`[/"]F;VYT/CPO M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF(WA! M,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO M=W)A<#TS1&YO=W)A<#X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM M97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXD/"]F;VYT/CPO=&0^#0H@/'1D('9A M;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`@86QI9VX],T1R:6=H=#X\ M9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S M:7IE/3-$,CXF(W@R,#$T.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B M;W1T;VT@;F]W<F%P/3-$;F]W<F%P/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%- M24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R/B8C>$$P.R8C>$$P.SPO M9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<VEZ93TS M1#$^)B-X03`[)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O M='1O;3X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O M;6%N)R!S:7IE/3-$,CXD/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O M='1O;2!A;&EG;CTS1')I9VAT/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9 M.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R/C$U+#@U.#PO9F]N=#X\+W1D M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P/CQF;VYT M('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4] M,T0R/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#PO='(^#0H@/'1R/@T* M(#QT9"!V86QI9VX],T1T;W`^#0H@/'`@<W1Y;&4],T0G34%21TE.+4Q%1E0Z M(#%E;3L@5$585"U)3D1%3E0Z("TQ96TG/CQF;VYT('-T>6QE/3-$)T9/3E0M M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R/E4N4RX@5')E87-U M<GD-"B!S96-U<FET:65S/"]F;VYT/CPO<#X-"B`\+W1D/@T*(#QT9"!V86QI M9VX],T1B;W1T;VT^/&9O;G0@<VEZ93TS1#$^)B-X03`[)B-X03`[/"]F;VYT M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=& M3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXF(WA!,#L\ M+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG M:'0^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA M;B<@<VEZ93TS1#(^-C`L,#<R/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS M1&)O='1O;2!N;W=R87`],T1N;W=R87`^/&9O;G0@<W1Y;&4],T0G1D].5"U& M04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^)B-X03`[)B-X03`[ M/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE M/3-$,3XF(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$ M8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#X\9F]N="!S='EL93TS1"=&3TY4+49! M34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXF(WA!,#L\+V9O;G0^ M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<"!A M;&EG;CTS1')I9VAT/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE M<R!.97<@4F]M86XG('-I>F4],T0R/B8C>#(P,30[/"]F;VYT/CPO=&0^#0H@ M/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^/&9O;G0@<W1Y M;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^ M)B-X03`[)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O M;3X\9F]N="!S:7IE/3-$,3XF(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\ M=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#X\9F]N="!S='EL M93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXF M(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A M<#TS1&YO=W)A<"!A;&EG;CTS1')I9VAT/CQF;VYT('-T>6QE/3-$)T9/3E0M M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R/B8C>#(P,30[/"]F M;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R M87`^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA M;B<@<VEZ93TS1#(^)B-X03`[)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A M;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF(WA!,#LF(WA!,#L\+V9O M;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$ M)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R/B8C>$$P M.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R M:6=H=#X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O M;6%N)R!S:7IE/3-$,CXV,"PP-S(\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N M/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#X\9F]N="!S='EL93TS1"=&3TY4 M+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXF(WA!,#LF(WA! M,#L\+V9O;G0^/"]T9#X-"B`\+W1R/@T*(#QT<B!S='EL93TS1"=&3TY4+5-) M6D4Z(#%P>"<^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V M86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N M/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@ M,7!X('-O;&ED)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$ M8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@,7!X M('-O;&ED)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0^)B-X03`[/"]T9#X- M"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D M('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B`C M,#`P,#`P(#%P>"!S;VQI9"<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D('9A M;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B`C,#`P M,#`P(#%P>"!S;VQI9"<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D/B8C>$$P M.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@<W1Y;&4],T0G0D]21$52 M+51/4#H@(S`P,#`P,"`Q<'@@<V]L:60G/B8C>$$P.SPO<#X-"B`\+W1D/@T* M(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@<W1Y;&4],T0G0D]21$52+51/ M4#H@(S`P,#`P,"`Q<'@@<V]L:60G/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT M9#XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X M03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$ M)T)/4D1%4BU43U`Z(",P,#`P,#`@,7!X('-O;&ED)SXF(WA!,#L\+W`^#0H@ M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/ M4D1%4BU43U`Z(",P,#`P,#`@,7!X('-O;&ED)SXF(WA!,#L\+W`^#0H@/"]T M9#X-"B`\=&0^)B-X03`[/"]T9#X-"B`\+W1R/@T*(#QT<B!B9V-O;&]R/3-$ M(T-#145&1CX-"B`\=&0@=F%L:6=N/3-$=&]P/@T*(#QP('-T>6QE/3-$)TU! M4D=)3BU,1494.B`S96T[(%1%6%0M24Y$14Y4.B`M,65M)SX\9F]N="!S='EL M93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CY4 M;W1A;#PO9F]N=#X\+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M M/CQF;VYT('-I>F4],T0Q/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT M9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ M(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^)#PO9F]N=#X\+W1D/@T*(#QT M9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS M1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXW-2PY M,S`\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS M1&YO=W)A<#X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W M(%)O;6%N)R!S:7IE/3-$,CXF(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\ M=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C>$$P.R8C>$$P M.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$ M;F]W<F%P/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@ M4F]M86XG('-I>F4],T0R/B0\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$ M8F]T=&]M(&YO=W)A<#TS1&YO=W)A<"!A;&EG;CTS1')I9VAT/CQF;VYT('-T M>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R M/B8C>#(P,30[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N M;W=R87`],T1N;W=R87`^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I M;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^)B-X03`[)B-X03`[/"]F;VYT/CPO M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF(WA! M,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO M=W)A<#TS1&YO=W)A<#X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM M97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXD/"]F;VYT/CPO=&0^#0H@/'1D('9A M;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`@86QI9VX],T1R:6=H=#X\ M9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S M:7IE/3-$,CXF(W@R,#$T.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B M;W1T;VT@;F]W<F%P/3-$;F]W<F%P/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%- M24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R/B8C>$$P.R8C>$$P.SPO M9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<VEZ93TS M1#$^)B-X03`[)B-X03`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`\=&0@=F%L:6=N/3-$8F]T=&]M M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@<W1Y;&4],T0G0D]21$52 M+51/4#H@(S`P,#`P,"`S<'@@9&]U8FQE)SXF(WA!,#L\+W`^#0H@/"]T9#X- M"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU4 M3U`Z(",P,#`P,#`@,W!X(&1O=6)L92<^)B-X03`[/"]P/@T*(#PO=&0^#0H@ M/'1D/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF M(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@<W1Y;&4] M,T0G0D]21$52+51/4#H@(S`P,#`P,"`S<'@@9&]U8FQE)SXF(WA!,#L\+W`^ M#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$ M)T)/4D1%4BU43U`Z(",P,#`P,#`@,W!X(&1O=6)L92<^)B-X03`[/"]P/@T* M(#PO=&0^#0H@/'1D/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O M;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@ M/'`@<W1Y;&4],T0G0D]21$52+51/4#H@(S`P,#`P,"`S<'@@9&]U8FQE)SXF M(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP M('-T>6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@,W!X(&1O=6)L92<^)B-X M03`[/"]P/@T*(#PO=&0^#0H@/'1D/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG M;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B M;W1T;VT^#0H@/'`@<W1Y;&4],T0G0D]21$52+51/4#H@(S`P,#`P,"`S<'@@ M9&]U8FQE)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T M=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@,W!X(&1O M=6)L92<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D/B8C>$$P.SPO=&0^#0H@ M/"]T<CX-"B`\='(^#0H@/'1D('9A;&EG;CTS1'1O<#X-"B`\<"!S='EL93TS M1"=-05)'24XM3$5&5#H@,65M.R!415A4+4E.1$5.5#H@+3%E;2<^/&9O;G0@ M<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS M1#(^06UO=6YT<R!I;F-L=61E9`T*(&EN.CPO9F]N=#X\+W`^#0H@/"]T9#X- M"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C>$$P.R8C M>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X- M"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O M='1O;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<VEZ93TS M1#$^)B-X03`[)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O M='1O;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\=&0@ M=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\ M9F]N="!S:7IE/3-$,3XF(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@ M=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\ M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\=&0@=F%L:6=N M/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C>$$P.R8C>$$P.SPO9F]N=#X\ M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\=&0@=F%L:6=N M/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T* M(#PO='(^#0H@/'1R(&)G8V]L;W(],T0C0T-%149&/@T*(#QT9"!V86QI9VX] M,T1T;W`^#0H@/'`@<W1Y;&4],T0G34%21TE.+4Q%1E0Z(#)E;3L@5$585"U) M3D1%3E0Z("TQ96TG/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE M<R!.97<@4F]M86XG('-I>F4],T0R/D-A<V@@86YD(&-A<V@-"B!E<75I=F%L M96YT<SPO9F]N=#X\+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M M/CQF;VYT('-I>F4],T0Q/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT M9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ M(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^)#PO9F]N=#X\+W1D/@T*(#QT M9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS M1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXQ-2PX M-3@\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS M1&YO=W)A<#X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W M(%)O;6%N)R!S:7IE/3-$,CXF(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\ M=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C>$$P.R8C>$$P M.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$ M;F]W<F%P/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@ M4F]M86XG('-I>F4],T0R/B0\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$ M8F]T=&]M(&YO=W)A<#TS1&YO=W)A<"!A;&EG;CTS1')I9VAT/CQF;VYT('-T M>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R M/B8C>#(P,30[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N M;W=R87`],T1N;W=R87`^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I M;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^)B-X03`[)B-X03`[/"]F;VYT/CPO M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF(WA! M,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO M=W)A<#TS1&YO=W)A<#X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM M97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXD/"]F;VYT/CPO=&0^#0H@/'1D('9A M;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`@86QI9VX],T1R:6=H=#X\ M9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S M:7IE/3-$,CXF(W@R,#$T.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B M;W1T;VT@;F]W<F%P/3-$;F]W<F%P/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%- M24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R/B8C>$$P.R8C>$$P.SPO M9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<VEZ93TS M1#$^)B-X03`[)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O M='1O;3X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O M;6%N)R!S:7IE/3-$,CXD/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O M='1O;2!A;&EG;CTS1')I9VAT/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9 M.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R/C$U+#@U.#PO9F]N=#X\+W1D M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P/CQF;VYT M('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4] M,T0R/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#PO='(^#0H@/'1R/@T* M(#QT9"!V86QI9VX],T1T;W`^#0H@/'`@<W1Y;&4],T0G34%21TE.+4Q%1E0Z M(#)E;3L@5$585"U)3D1%3E0Z("TQ96TG/CQF;VYT('-T>6QE/3-$)T9/3E0M M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R/E-H;W)T+71E<FT- M"B!I;G9E<W1M96YT<SPO9F]N=#X\+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N M/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C>$$P.R8C>$$P.SPO9F]N=#X\ M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<W1Y;&4],T0G1D]. M5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^)B-X03`[/"]F M;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT M/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG M('-I>F4],T0R/C4W+#4W,#PO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B M;W1T;VT@;F]W<F%P/3-$;F]W<F%P/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%- M24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R/B8C>$$P.R8C>$$P.SPO M9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<VEZ93TS M1#$^)B-X03`[)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O M='1O;2!N;W=R87`],T1N;W=R87`^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U) M3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^)B-X03`[/"]F;VYT/CPO M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`@86QI M9VX],T1R:6=H=#X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@ M3F5W(%)O;6%N)R!S:7IE/3-$,CXF(W@R,#$T.SPO9F]N=#X\+W1D/@T*(#QT M9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P/CQF;VYT('-T>6QE M/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R/B8C M>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^ M/&9O;G0@<VEZ93TS1#$^)B-X03`[)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D M('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^/&9O;G0@<W1Y;&4] M,T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^)B-X M03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`] M,T1N;W=R87`@86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS1"=&3TY4+49! M34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXF(W@R,#$T.SPO9F]N M=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P M/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG M('-I>F4],T0R/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI M9VX],T1B;W1T;VT^/&9O;G0@<VEZ93TS1#$^)B-X03`[)B-X03`[/"]F;VYT M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=& M3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXF(WA!,#L\ M+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG M:'0^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA M;B<@<VEZ93TS1#(^-3<L-3<P/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS M1&)O='1O;2!N;W=R87`],T1N;W=R87`^/&9O;G0@<W1Y;&4],T0G1D].5"U& M04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^)B-X03`[)B-X03`[ M/"]F;VYT/CPO=&0^#0H@/"]T<CX-"B`\='(@8F=C;VQO<CTS1"-#0T5%1D8^ M#0H@/'1D('9A;&EG;CTS1'1O<#X-"B`\<"!S='EL93TS1"=-05)'24XM3$5& M5#H@,F5M.R!415A4+4E.1$5.5#H@+3%E;2<^/&9O;G0@<W1Y;&4],T0G1D]. M5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^3&]N9RUT97)M M#0H@:6YV97-T;65N=',\+V9O;G0^/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG M;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF(WA!,#LF(WA!,#L\+V9O;G0^ M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)T9/ M3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R/B8C>$$P.SPO M9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H M=#X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N M)R!S:7IE/3-$,CXR+#4P,CPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B M;W1T;VT@;F]W<F%P/3-$;F]W<F%P/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%- M24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R/B8C>$$P.R8C>$$P.SPO M9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<VEZ93TS M1#$^)B-X03`[)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O M='1O;2!N;W=R87`],T1N;W=R87`^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U) M3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^)B-X03`[/"]F;VYT/CPO M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`@86QI M9VX],T1R:6=H=#X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@ M3F5W(%)O;6%N)R!S:7IE/3-$,CXF(W@R,#$T.SPO9F]N=#X\+W1D/@T*(#QT M9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P/CQF;VYT('-T>6QE M/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R/B8C M>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^ M/&9O;G0@<VEZ93TS1#$^)B-X03`[)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D M('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^/&9O;G0@<W1Y;&4] M,T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^)B-X M03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`] M,T1N;W=R87`@86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS1"=&3TY4+49! M34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXF(W@R,#$T.SPO9F]N M=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P M/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG M('-I>F4],T0R/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI M9VX],T1B;W1T;VT^/&9O;G0@<VEZ93TS1#$^)B-X03`[)B-X03`[/"]F;VYT M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=& M3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXF(WA!,#L\ M+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG M:'0^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA M;B<@<VEZ93TS1#(^,BPU,#(\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$ M8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#X\9F]N="!S='EL93TS1"=&3TY4+49! M34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXF(WA!,#LF(WA!,#L\ M+V9O;G0^/"]T9#X-"B`\+W1R/@T*(#QT<B!S='EL93TS1"=&3TY4+5-)6D4Z M(#%P>"<^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI M9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$ M8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@,7!X M('-O;&ED)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T M=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@,7!X('-O M;&ED)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0^)B-X03`[/"]T9#X-"B`\ M=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A M;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B`C,#`P M,#`P(#%P>"!S;VQI9"<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG M;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B`C,#`P,#`P M(#%P>"!S;VQI9"<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D/B8C>$$P.SPO M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T* M(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@<W1Y;&4],T0G0D]21$52+51/ M4#H@(S`P,#`P,"`Q<'@@<V]L:60G/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT M9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@<W1Y;&4],T0G0D]21$52+51/4#H@ M(S`P,#`P,"`Q<'@@<V]L:60G/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT9#XF M(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[ M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/ M4D1%4BU43U`Z(",P,#`P,#`@,7!X('-O;&ED)SXF(WA!,#L\+W`^#0H@/"]T M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1% M4BU43U`Z(",P,#`P,#`@,7!X('-O;&ED)SXF(WA!,#L\+W`^#0H@/"]T9#X- M"B`\=&0^)B-X03`[/"]T9#X-"B`\+W1R/@T*(#QT<CX-"B`\=&0@=F%L:6=N M/3-$=&]P/@T*(#QP('-T>6QE/3-$)TU!4D=)3BU,1494.B`S96T[(%1%6%0M M24Y$14Y4.B`M,65M)SX\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM M97,@3F5W(%)O;6%N)R!S:7IE/3-$,CY4;W1A;#PO9F]N=#X\+W`^#0H@/"]T M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C>$$P M.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O M;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ M93TS1#(^)#PO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI M9VX],T1R:6=H=#X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@ M3F5W(%)O;6%N)R!S:7IE/3-$,CXW-2PY,S`\+V9O;G0^/"]T9#X-"B`\=&0@ M=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#X\9F]N="!S='EL93TS M1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXF(WA! M,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF M;VYT('-I>F4],T0Q/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V M86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P/CQF;VYT('-T>6QE/3-$ M)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R/B0\+V9O M;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A M<"!A;&EG;CTS1')I9VAT/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4 M:6UE<R!.97<@4F]M86XG('-I>F4],T0R/B8C>#(P,30[/"]F;VYT/CPO=&0^ M#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^/&9O;G0@ M<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS M1#(^)B-X03`[)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O M='1O;3X\9F]N="!S:7IE/3-$,3XF(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X- M"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#X\9F]N="!S M='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$ M,CXD/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`] M,T1N;W=R87`@86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS1"=&3TY4+49! M34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXF(W@R,#$T.SPO9F]N M=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P M/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG M('-I>F4],T0R/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI M9VX],T1B;W1T;VT^/&9O;G0@<VEZ93TS1#$^)B-X03`[)B-X03`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`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS M1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T M;VT^#0H@/'`@<W1Y;&4],T0G0D]21$52+51/4#H@(S`P,#`P,"`S<'@@9&]U M8FQE)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@,W!X(&1O=6)L M92<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D/B8C>$$P.SPO=&0^#0H@/'1D M('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI M9VX],T1B;W1T;VT^#0H@/'`@<W1Y;&4],T0G0D]21$52+51/4#H@(S`P,#`P M,"`S<'@@9&]U8FQE)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N M/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@ M,W!X(&1O=6)L92<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D/B8C>$$P.SPO M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T* M(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@<W1Y;&4],T0G0D]21$52+51/ M4#H@(S`P,#`P,"`S<'@@9&]U8FQE)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\ M=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z M(",P,#`P,#`@,W!X(&1O=6)L92<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA! M,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@<W1Y;&4],T0G M0D]21$52+51/4#H@(S`P,#`P,"`S<'@@9&]U8FQE)SXF(WA!,#L\+W`^#0H@ M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/ M4D1%4BU43U`Z(",P,#`P,#`@,W!X(&1O=6)L92<^)B-X03`[/"]P/@T*(#PO M=&0^#0H@/'1D/B8C>$$P.SPO=&0^#0H@/"]T<CX-"B`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`[,S$L#0H@,C`Q-"!A;F0@,C`Q,RP@ M=&AE($-O;7!A;GD@:&%D(&YO(&9I;F%N8VEA;"!A<W-E=',@;65A<W5R960@ M870@9F%I<@T*('9A;'5E(&]N(&$@<F5C=7)R:6YG(&)A<VES('5S:6YG('-I M9VYI9FEC86YT($QE=F5L(#(@;W(-"B!,979E;"8C>$$P.S,@:6YP=71S+B!4 M:&4@8V%R<GEI;F<@86UO=6YT(&]F('1H92!#;VUP86YY)B-X,C`Q.3MS#0H@ M86-C;W5N=',@<F5C96EV86)L92!A;F0@86-C;W5N=',@<&%Y86)L92!A<'!R M;WAI;6%T97,@9F%I<B!V86QU90T*(&1U92!T;R!T:&4@<VAO<G0M=&5R;2!N M871U<F4@;V8@=&AE<V4@:6YS=')U;65N=',N/"]F;VYT/CPO<#X-"B`\+V1I M=CX\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@/"]T86)L M93X-"B`@/"]B;V1Y/@T*/"]H=&UL/@T*#0HM+2TM+2T]7TYE>'1087)T7S,Y M8S!E838R7V,R,#-?-#4X9E\X8S4P7S-D8V$T-39A-CDU,0T*0V]N=&5N="U, M;V-A=&EO;CH@9FEL93HO+R]#.B\S.6,P96$V,E]C,C`S7S0U.&9?.&,U,%\S M9&-A-#4V838Y-3$O5V]R:W-H965T<R]3:&5E=#$S+FAT;6P-"D-O;G1E;G0M M5')A;G-F97(M16YC;V1I;F<Z('%U;W1E9"UP<FEN=&%B;&4-"D-O;G1E;G0M M5'EP93H@=&5X="]H=&UL.R!C:&%R<V5T/2)U<RUA<V-I:2(-"@T*/&AT;6P^ M#0H@(#QH96%D/@T*("`@(#Q-151!(&AT='`M97%U:78],T1#;VYT96YT+51Y M<&4@8V]N=&5N=#TS1"=T97AT+VAT;6P[(&-H87)S970]=71F+3@G/CQS8W)I M<'0@='EP93TS1'1E>'0O:F%V87-C<FEP="!S<F,],T13:&]W+FIS/B\J($1O M($YO="!296UO=F4@5&AI<R!#;VUM96YT("HO/"]S8W)I<'0^/"]H96%D/@T* M("`\8F]D>3X-"B`@("`\=&%B;&4@8VQA<W,],T1R97!O<G0@:60],T1)1#!% M344^#0H@("`@("`\='(^#0H@("`@("`@(#QT:"!C;&%S<STS1'1L(&-O;'-P M86X],T0Q(')O=W-P86X],T0R/CQS=')O;F<^0F%L86YC92!3:&5E="!#;VUP M;VYE;G1S/&)R/CPO<W1R;VYG/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS M1'1H(&-O;'-P86X],T0Q/C$R($UO;G1H<R!%;F1E9#PO=&@^#0H@("`@("`\ M+W1R/@T*("`@("`@/'1R/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y$96,N M(#,Q+"`R,#$T/&)R/CPO=&@^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L M87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O M<#X\<W1R;VYG/D]R9V%N:7IA=&EO;BP@0V]N<V]L:61A=&EO;B!A;F0@4')E M<V5N=&%T:6]N(&]F($9I;F%N8VEA;"!3=&%T96UE;G1S(%M!8G-T<F%C=%T\ M+W-T<F]N9SX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N M/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS M1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^0F%L M86YC92!3:&5E="!#;VUP;VYE;G1S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S M/3-$=&5X=#X\9&EV/@T*(#QP('-T>6QE/3-$;6%R9VEN+71O<#HQ.'!X.VUA M<F=I;BUB;W1T;VTZ,'!X/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.E1I M;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^/&(^3F]T92`V("8C>#(P,30[($)A M;&%N8V4-"B!3:&5E="!#;VUP;VYE;G1S/"]B/CPO9F]N=#X\+W`^#0H@/'`@ M<W1Y;&4],T0G;6%R9VEN+71O<#HV<'@[;6%R9VEN+6)O='1O;3HP<'@[('1E M>'0M:6YD96YT.C0E)R!A;&EG;CTS1&IU<W1I9GD^/&9O;G0@<W1Y;&4],T0G M9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CY0<F]P97)T M>2!A;F0@97%U:7!M96YT(&)A;&%N8V5S('=E<F4@87,@9F]L;&]W<R`H:6X- M"B!T:&]U<V%N9',I.CPO9F]N=#X\+W`^#0H@/'`@<W1Y;&4],T1F;VYT+7-I M>F4Z,3)P>#MM87)G:6XM=&]P.C!P>#MM87)G:6XM8F]T=&]M.C!P>#X-"B`F M(WA!,#L\+W`^#0H@/'1A8FQE(&-E;&QS<&%C:6YG/3-$,"!C96QL<&%D9&EN M9STS1#`@=VED=&@],T0Y,B4@8F]R9&5R/3-$,"!S='EL93TS1$)/4D1%4BU# M3TQ,05!313I#3TQ,05!312!A;&EG;CTS1&-E;G1E<CX-"B`\='(^#0H@/'1D M('=I9'1H/3-$-S<E/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!W:61T M:#TS1#8E/CPO=&0^#0H@/'1D/CPO=&0^#0H@/'1D/CPO=&0^#0H@/'1D/CPO M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#4E/CPO=&0^#0H@ M/'1D/CPO=&0^#0H@/'1D/CPO=&0^#0H@/'1D/CPO=&0^#0H@/"]T<CX-"B`\ M='(^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF(WA! M,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I M>F4],T0Q/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX] M,T1B;W1T;VT@8V]L<W!A;CTS1#8@86QI9VX],T1C96YT97(@<W1Y;&4],T0G M8F]R9&5R+6)O='1O;3HQ<'@@<V]L:60@(S`P,#`P,"<^/&9O;G0@<W1Y;&4] M,T0G9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,3X\8CY$ M96-E;6)E<B8C>$$P.S,Q+#PO8CX\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N M/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C>$$P.SPO9F]N=#X\+W1D/@T* M(#PO='(^#0H@/'1R/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<VEZ M93TS1#$^)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O M;3X\9F]N="!S:7IE/3-$,3XF(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\ M=&0@=F%L:6=N/3-$8F]T=&]M(&-O;'-P86X],T0R(&%L:6=N/3-$8V5N=&5R M('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ,7!X('-O;&ED(",P,#`P,#`G/CQF M;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;B<@<VEZ M93TS1#$^/&(^,C`Q-#PO8CX\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$ M8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT M9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<VEZ93TS1#$^)B-X03`[)B-X03`[ M/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!C;VQS<&%N/3-$ M,B!A;&EG;CTS1&-E;G1E<B!S='EL93TS1"=B;W)D97(M8F]T=&]M.C%P>"!S M;VQI9"`C,#`P,#`P)SX\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3I4:6UE M<R!.97<@4F]M86XG('-I>F4],T0Q/CQB/C(P,3,\+V(^/"]F;VYT/CPO=&0^ M#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF(WA!,#L\ M+V9O;G0^/"]T9#X-"B`\+W1R/@T*(#QT<B!B9V-O;&]R/3-$(T-#145&1CX- M"B`\=&0@=F%L:6=N/3-$=&]P/@T*(#QP('-T>6QE/3-$)VUA<F=I;BUL969T M.C$N,#!E;3L@=&5X="UI;F1E;G0Z+3$N,#!E;2<^/&9O;G0@<W1Y;&4],T0G M9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CY0<F]P97)T M>2!A;F0@97%U:7!M96YT+`T*(&YE=#H\+V9O;G0^/"]P/@T*(#PO=&0^#0H@ M/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF(WA!,#LF(WA! M,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@ M/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T M;VT^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q M/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T M;VT^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A M;&EG;CTS1&)O='1O;3X\+W1D/@T*(#PO='(^#0H@/'1R/@T*(#QT9"!V86QI M9VX],T1T;W`^#0H@/'`@<W1Y;&4],T0G;6%R9VEN+6QE9G0Z,BXP,&5M.R!T M97AT+6EN9&5N=#HM,2XP,&5M)SX\9F]N="!S='EL93TS1"=F;VYT+69A;6EL M>3I4:6UE<R!.97<@4F]M86XG('-I>F4],T0R/DQA8F]R871O<GD-"B!E<75I M<&UE;G0\+V9O;G0^/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O M;3X\9F]N="!S:7IE/3-$,3XF(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\ M=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY M.E1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^)#PO9F]N=#X\+W1D/@T*(#QT M9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS M1"=F;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86XG('-I>F4],T0R/C$U+#(Y M.3PO9F]N=#X\+W1D/@T*(#QT9"!N;W=R87`],T1N;W=R87`@=F%L:6=N/3-$ M8F]T=&]M/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.E1I;65S($YE=R!2 M;VUA;B<@<VEZ93TS1#(^)B-X03`[)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D M('9A;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF(WA!,#LF(WA!,#L\ M+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE M/3-$)V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^)#PO M9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H M=#X\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86XG M('-I>F4],T0R/C$U+#,Q-SPO9F]N=#X\+W1D/@T*(#QT9"!N;W=R87`],T1N M;W=R87`@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M M:6QY.E1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^)B-X03`[)B-X03`[/"]F M;VYT/CPO=&0^#0H@/"]T<CX-"B`\='(@8F=C;VQO<CTS1"-#0T5%1D8^#0H@ M/'1D('9A;&EG;CTS1'1O<#X-"B`\<"!S='EL93TS1"=M87)G:6XM;&5F=#HR M+C`P96T[('1E>'0M:6YD96YT.BTQ+C`P96TG/CQF;VYT('-T>6QE/3-$)V9O M;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^0V]M<'5T97(@ M97%U:7!M96YT(&%N9`T*('-O9G1W87)E/"]F;VYT/CPO<#X-"B`\+W1D/@T* M(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<VEZ93TS1#$^)B-X03`[)B-X M03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S M='EL93TS1"=F;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86XG('-I>F4],T0R M/B8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI M9VX],T1R:6=H=#X\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3I4:6UE<R!. M97<@4F]M86XG('-I>F4],T0R/C(L-#$X/"]F;VYT/CPO=&0^#0H@/'1D(&YO M=W)A<#TS1&YO=W)A<"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<W1Y;&4],T0G M9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXF(WA!,#LF M(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT M('-I>F4],T0Q/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI M9VX],T1B;W1T;VT^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ5&EM97,@ M3F5W(%)O;6%N)R!S:7IE/3-$,CXF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@ M=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^/&9O;G0@<W1Y;&4],T0G M9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXR+#4T.3PO M9F]N=#X\+W1D/@T*(#QT9"!N;W=R87`],T1N;W=R87`@=F%L:6=N/3-$8F]T M=&]M/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA M;B<@<VEZ93TS1#(^)B-X03`[)B-X03`[/"]F;VYT/CPO=&0^#0H@/"]T<CX- M"B`\='(^#0H@/'1D('9A;&EG;CTS1'1O<#X-"B`\<"!S='EL93TS1"=M87)G M:6XM;&5F=#HR+C`P96T[('1E>'0M:6YD96YT.BTQ+C`P96TG/CQF;VYT('-T M>6QE/3-$)V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^ M3V9F:6-E(&5Q=6EP;65N="P@9G5R;FET=7)E#0H@86YD(&9I>'1U<F5S/"]F M;VYT/CPO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@ M<VEZ93TS1#$^)B-X03`[)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG M;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3I4:6UE<R!. M97<@4F]M86XG('-I>F4],T0R/B8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V M86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS1"=F M;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86XG('-I>F4],T0R/CDQ,SPO9F]N M=#X\+W1D/@T*(#QT9"!N;W=R87`],T1N;W=R87`@=F%L:6=N/3-$8F]T=&]M M/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;B<@ M<VEZ93TS1#(^)B-X03`[)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG M;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF(WA!,#LF(WA!,#L\+V9O;G0^ M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)V9O M;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^)B-X03`[/"]F M;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT M/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;B<@ M<VEZ93TS1#(^,2PP-3`\+V9O;G0^/"]T9#X-"B`\=&0@;F]W<F%P/3-$;F]W M<F%P('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=F;VYT+69A;6EL M>3I4:6UE<R!.97<@4F]M86XG('-I>F4],T0R/B8C>$$P.R8C>$$P.SPO9F]N M=#X\+W1D/@T*(#PO='(^#0H@/'1R(&)G8V]L;W(],T0C0T-%149&/@T*(#QT M9"!V86QI9VX],T1T;W`^#0H@/'`@<W1Y;&4],T0G;6%R9VEN+6QE9G0Z,BXP M,&5M.R!T97AT+6EN9&5N=#HM,2XP,&5M)SX\9F]N="!S='EL93TS1"=F;VYT M+69A;6EL>3I4:6UE<R!.97<@4F]M86XG('-I>F4],T0R/DQE87-E:&]L9`T* M(&EM<')O=F5M96YT<SPO9F]N=#X\+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N M/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C>$$P.R8C>$$P.SPO9F]N=#X\ M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<W1Y;&4],T0G9F]N M="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXF(WA!,#L\+V9O M;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^ M/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N)R!S M:7IE/3-$,CXS+#,S-#PO9F]N=#X\+W1D/@T*(#QT9"!N;W=R87`],T1N;W=R M87`@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY M.E1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^)B-X03`[)B-X03`[/"]F;VYT M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF M(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M M/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;B<@ M<VEZ93TS1#(^)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O M='1O;2!A;&EG;CTS1')I9VAT/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY M.E1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^,RPR.3<\+V9O;G0^/"]T9#X- M"B`\=&0@;F]W<F%P/3-$;F]W<F%P('9A;&EG;CTS1&)O='1O;3X\9F]N="!S M='EL93TS1"=F;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86XG('-I>F4],T0R M/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#PO='(^#0H@/'1R('-T>6QE M/3-$9F]N="US:7IE.C%P>#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^ M#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT M9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@<W1Y;&4],T0G8F]R9&5R+71O<#HQ M<'@@<V]L:60@(S`P,#`P,"<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D('9A M;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"=B;W)D97(M=&]P.C%P>"!S M;VQI9"`C,#`P,#`P)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0^)B-X03`[ M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^ M#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"=B;W)D97(M M=&]P.C%P>"!S;VQI9"`C,#`P,#`P)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\ M=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)V)O<F1E<BUT;W`Z M,7!X('-O;&ED(",P,#`P,#`G/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT9#XF M(WA!,#L\+W1D/@T*(#PO='(^#0H@/'1R/@T*(#QT9"!V86QI9VX],T1T;W`^ M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C M>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^ M/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N)R!S M:7IE/3-$,CXF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T M=&]M(&%L:6=N/3-$<FEG:'0^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ M5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXR,2PY-C0\+V9O;G0^/"]T9#X- M"B`\=&0@;F]W<F%P/3-$;F]W<F%P('9A;&EG;CTS1&)O='1O;3X\9F]N="!S M='EL93TS1"=F;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86XG('-I>F4],T0R M/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T M;VT^/&9O;G0@<VEZ93TS1#$^)B-X03`[)B-X03`[/"]F;VYT/CPO=&0^#0H@ M/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=F;VYT+69A;6EL M>3I4:6UE<R!.97<@4F]M86XG('-I>F4],T0R/B8C>$$P.SPO9F]N=#X\+W1D M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#X\9F]N="!S M='EL93TS1"=F;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86XG('-I>F4],T0R M/C(R+#(Q,SPO9F]N=#X\+W1D/@T*(#QT9"!N;W=R87`],T1N;W=R87`@=F%L M:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.E1I;65S M($YE=R!2;VUA;B<@<VEZ93TS1#(^)B-X03`[)B-X03`[/"]F;VYT/CPO=&0^ M#0H@/"]T<CX-"B`\='(@8F=C;VQO<CTS1"-#0T5%1D8^#0H@/'1D('9A;&EG M;CTS1'1O<#X-"B`\<"!S='EL93TS1"=M87)G:6XM;&5F=#HR+C`P96T[('1E M>'0M:6YD96YT.BTQ+C`P96TG/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY M.E1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^3&5S<SH@06-C=6UU;&%T960- M"B!D97!R96-I871I;VX@86YD(&%M;W)T:7IA=&EO;CPO9F]N=#X\+W`^#0H@ M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C M>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^ M/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N)R!S M:7IE/3-$,CXF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T M=&]M(&%L:6=N/3-$<FEG:'0^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ M5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXH,C`L,S(W/"]F;VYT/CPO=&0^ M#0H@/'1D(&YO=W)A<#TS1&YO=W)A<"!V86QI9VX],T1B;W1T;VT^/&9O;G0@ M<W1Y;&4],T0G9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$ M,CXI)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\ M9F]N="!S:7IE/3-$,3XF(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@ M=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.E1I M;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^)B-X03`[/"]F;VYT/CPO=&0^#0H@ M/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/CQF;VYT('-T>6QE M/3-$)V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^*#(P M+#DY,CPO9F]N=#X\+W1D/@T*(#QT9"!N;W=R87`],T1N;W=R87`@=F%L:6=N M/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.E1I;65S($YE M=R!2;VUA;B<@<VEZ93TS1#(^*28C>$$P.SPO9F]N=#X\+W1D/@T*(#PO='(^ M#0H@/'1R('-T>6QE/3-$9F]N="US:7IE.C%P>#X-"B`\=&0@=F%L:6=N/3-$ M8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA! M,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@<W1Y;&4],T0G M8F]R9&5R+71O<#HQ<'@@<V]L:60@(S`P,#`P,"<^)B-X03`[/"]P/@T*(#PO M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"=B;W)D M97(M=&]P.C%P>"!S;VQI9"`C,#`P,#`P)SXF(WA!,#L\+W`^#0H@/"]T9#X- M"B`\=&0^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P M.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL M93TS1"=B;W)D97(M=&]P.C%P>"!S;VQI9"`C,#`P,#`P)SXF(WA!,#L\+W`^ M#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$ M)V)O<F1E<BUT;W`Z,7!X('-O;&ED(",P,#`P,#`G/B8C>$$P.SPO<#X-"B`\ M+W1D/@T*(#QT9#XF(WA!,#L\+W1D/@T*(#PO='(^#0H@/'1R/@T*(#QT9"!V M86QI9VX],T1T;W`^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT M('-I>F4],T0Q/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI M9VX],T1B;W1T;VT^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ5&EM97,@ M3F5W(%)O;6%N)R!S:7IE/3-$,CXD/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG M;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/CQF;VYT('-T>6QE/3-$)V9O;G0M M9F%M:6QY.E1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^,2PV,S<\+V9O;G0^ M/"]T9#X-"B`\=&0@;F]W<F%P/3-$;F]W<F%P('9A;&EG;CTS1&)O='1O;3X\ M9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86XG('-I M>F4],T0R/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX] M,T1B;W1T;VT^/&9O;G0@<VEZ93TS1#$^)B-X03`[)B-X03`[/"]F;VYT/CPO M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=F;VYT M+69A;6EL>3I4:6UE<R!.97<@4F]M86XG('-I>F4],T0R/B0\+V9O;G0^/"]T M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^/&9O;G0@ M<W1Y;&4],T0G9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$ M,CXQ+#(R,3PO9F]N=#X\+W1D/@T*(#QT9"!N;W=R87`],T1N;W=R87`@=F%L M:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.E1I;65S M($YE=R!2;VUA;B<@<VEZ93TS1#(^)B-X03`[)B-X03`[/"]F;VYT/CPO=&0^ M#0H@/"]T<CX-"B`\='(@<W1Y;&4],T1F;VYT+7-I>F4Z,7!X/@T*(#QT9"!V M86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C M>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S M='EL93TS1"=B;W)D97(M=&]P.C-P>"!D;W5B;&4@(S`P,#`P,"<^)B-X03`[ M/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL M93TS1"=B;W)D97(M=&]P.C-P>"!D;W5B;&4@(S`P,#`P,"<^)B-X03`[/"]P M/@T*(#PO=&0^#0H@/'1D/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O M='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^ M#0H@/'`@<W1Y;&4],T0G8F]R9&5R+71O<#HS<'@@9&]U8FQE(",P,#`P,#`G M/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@ M/'`@<W1Y;&4],T0G8F]R9&5R+71O<#HS<'@@9&]U8FQE(",P,#`P,#`G/B8C M>$$P.SPO<#X-"B`\+W1D/@T*(#QT9#XF(WA!,#L\+W1D/@T*(#PO='(^#0H@ M/"]T86)L93X-"B`\<"!S='EL93TS1"=M87)G:6XM=&]P.C$R<'@[;6%R9VEN M+6)O='1O;3HP<'@[('1E>'0M:6YD96YT.C0E)R!A;&EG;CTS1&IU<W1I9GD^ M/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N)R!S M:7IE/3-$,CY$97!R96-I871I;VX@97AP96YS92!W87,@)#`N-2!M:6QL:6]N M+"`D,"XT(&UI;&QI;VX@86YD("0P+C8-"B!M:6QL:6]N(&9O<B!T:&4@>65A M<G,@96YD960@1&5C96UB97(F(WA!,#LS,2P@,C`Q-"P@,C`Q,R!A;F0@,C`Q M,@T*(')E<W!E8W1I=F5L>2X\+V9O;G0^/"]P/@T*(#QP('-T>6QE/3-$9F]N M="US:7IE.C$R<'@[;6%R9VEN+71O<#HP<'@[;6%R9VEN+6)O='1O;3HP<'@^ M#0H@)B-X03`[/"]P/@T*(#QP('-T>6QE/3-$)VUA<F=I;BUT;W`Z,'!X.VUA M<F=I;BUB;W1T;VTZ,'!X.R!T97AT+6EN9&5N=#HT)2<@86QI9VX],T1J=7-T M:69Y/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA M;B<@<VEZ93TS1#(^06-C<G5E9"!L:6%B:6QI=&EE<R!W97)E(&%S(&9O;&QO M=W,@*&EN('1H;W5S86YD<RDZ/"]F;VYT/CPO<#X-"B`\<"!S='EL93TS1&9O M;G0M<VEZ93HQ,G!X.VUA<F=I;BUT;W`Z,'!X.VUA<F=I;BUB;W1T;VTZ,'!X M/@T*("8C>$$P.SPO<#X-"B`\=&%B;&4@8V5L;'-P86-I;F<],T0P(&-E;&QP M861D:6YG/3-$,"!W:61T:#TS1#DR)2!B;W)D97(],T0P('-T>6QE/3-$0D]2 M1$52+4-/3$Q!4%-%.D-/3$Q!4%-%(&%L:6=N/3-$8V5N=&5R/@T*(#QT<CX- M"B`\=&0@=VED=&@],T0X,B4^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M M('=I9'1H/3-$-"4^/"]T9#X-"B`\=&0^/"]T9#X-"B`\=&0^/"]T9#X-"B`\ M=&0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$-"4^/"]T M9#X-"B`\=&0^/"]T9#X-"B`\=&0^/"]T9#X-"B`\=&0^/"]T9#X-"B`\+W1R M/@T*(#QT<CX-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q M/B8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O M;G0@<VEZ93TS1#$^)B-X03`[)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A M;&EG;CTS1&)O='1O;2!C;VQS<&%N/3-$-B!A;&EG;CTS1&-E;G1E<B!S='EL M93TS1"=B;W)D97(M8F]T=&]M.C%P>"!S;VQI9"`C,#`P,#`P)SX\9F]N="!S M='EL93TS1"=F;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86XG('-I>F4],T0Q M/CQB/D1E8V5M8F5R)B-X03`[,S$L/"]B/CPO9F]N=#X\+W1D/@T*(#QT9"!V M86QI9VX],T1B;W1T;VT^/&9O;G0@<VEZ93TS1#$^)B-X03`[/"]F;VYT/CPO M=&0^#0H@/"]T<CX-"B`\='(^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N M="!S:7IE/3-$,3XF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$ M8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@8V]L<W!A;CTS1#(@86QI9VX],T1C M96YT97(@<W1Y;&4],T0G8F]R9&5R+6)O='1O;3HQ<'@@<V]L:60@(S`P,#`P M,"<^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N M)R!S:7IE/3-$,3X\8CXR,#$T/"]B/CPO9F]N=#X\+W1D/@T*(#QT9"!V86QI M9VX],T1B;W1T;VT^/&9O;G0@<VEZ93TS1#$^)B-X03`[/"]F;VYT/CPO=&0^ M#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF(WA!,#LF M(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&-O;'-P M86X],T0R(&%L:6=N/3-$8V5N=&5R('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ M,7!X('-O;&ED(",P,#`P,#`G/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY M.E1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#$^/&(^,C`Q,SPO8CX\+V9O;G0^ M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C M>$$P.SPO9F]N=#X\+W1D/@T*(#PO='(^#0H@/'1R(&)G8V]L;W(],T0C0T-% M149&/@T*(#QT9"!V86QI9VX],T1T;W`^#0H@/'`@<W1Y;&4],T0G;6%R9VEN M+6QE9G0Z,2XP,&5M.R!T97AT+6EN9&5N=#HM,2XP,&5M)SX\9F]N="!S='EL M93TS1"=F;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86XG('-I>F4],T0R/D%C M8W)U960-"B!L:6%B:6QI=&EE<SH\+V9O;G0^/"]P/@T*(#PO=&0^#0H@/'1D M('9A;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF(WA!,#LF(WA!,#L\ M+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D M('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^ M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C M>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^ M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG M;CTS1&)O='1O;3X\+W1D/@T*(#PO='(^#0H@/'1R/@T*(#QT9"!V86QI9VX] M,T1T;W`^#0H@/'`@<W1Y;&4],T0G;6%R9VEN+6QE9G0Z,BXP,&5M.R!T97AT M+6EN9&5N=#HM,2XP,&5M)SX\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3I4 M:6UE<R!.97<@4F]M86XG('-I>F4],T0R/D-L:6YI8V%L(&%N9"!P<F5C;&EN M:6-A;`T*(&-O<W1S/"]F;VYT/CPO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX] M,T1B;W1T;VT^/&9O;G0@<VEZ93TS1#$^)B-X03`[)B-X03`[/"]F;VYT/CPO M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=F;VYT M+69A;6EL>3I4:6UE<R!.97<@4F]M86XG('-I>F4],T0R/B0\+V9O;G0^/"]T M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^/&9O;G0@ M<W1Y;&4],T0G9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$ M,CXY-S(\+V9O;G0^/"]T9#X-"B`\=&0@;F]W<F%P/3-$;F]W<F%P('9A;&EG M;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3I4:6UE<R!. M97<@4F]M86XG('-I>F4],T0R/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T* M(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<VEZ93TS1#$^)B-X03`[)B-X M03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S M='EL93TS1"=F;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86XG('-I>F4],T0R M/B0\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$ M<FEG:'0^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O M;6%N)R!S:7IE/3-$,CXT+#DW-3PO9F]N=#X\+W1D/@T*(#QT9"!N;W=R87`] M,T1N;W=R87`@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)V9O;G0M M9F%M:6QY.E1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^)B-X03`[)B-X03`[ M/"]F;VYT/CPO=&0^#0H@/"]T<CX-"B`\='(@8F=C;VQO<CTS1"-#0T5%1D8^ M#0H@/'1D('9A;&EG;CTS1'1O<#X-"B`\<"!S='EL93TS1"=M87)G:6XM;&5F M=#HR+C`P96T[('1E>'0M:6YD96YT.BTQ+C`P96TG/CQF;VYT('-T>6QE/3-$ M)V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^0V]N<W5L M=&EN9R!A;F0@<')O9F5S<VEO;F%L#0H@9F5E<SPO9F]N=#X\+W`^#0H@/"]T M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C>$$P M.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O M;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N)R!S:7IE M/3-$,CXF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M M(&%L:6=N/3-$<FEG:'0^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ5&EM M97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXT,C$\+V9O;G0^/"]T9#X-"B`\=&0@ M;F]W<F%P/3-$;F]W<F%P('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS M1"=F;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86XG('-I>F4],T0R/B8C>$$P M.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O M;G0@<VEZ93TS1#$^)B-X03`[)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A M;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3I4:6UE M<R!.97<@4F]M86XG('-I>F4],T0R/B8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT M9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS M1"=F;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86XG('-I>F4],T0R/C8Y-SPO M9F]N=#X\+W1D/@T*(#QT9"!N;W=R87`],T1N;W=R87`@=F%L:6=N/3-$8F]T M=&]M/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA M;B<@<VEZ93TS1#(^)B-X03`[)B-X03`[/"]F;VYT/CPO=&0^#0H@/"]T<CX- M"B`\='(^#0H@/'1D('9A;&EG;CTS1'1O<#X-"B`\<"!S='EL93TS1"=M87)G M:6XM;&5F=#HR+C`P96T[('1E>'0M:6YD96YT.BTQ+C`P96TG/CQF;VYT('-T M>6QE/3-$)V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^ M0F]N=7,\+V9O;G0^/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O M;3X\9F]N="!S:7IE/3-$,3XF(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\ M=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY M.E1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^)B-X03`[/"]F;VYT/CPO=&0^ M#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/CQF;VYT('-T M>6QE/3-$)V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^ M,BPV-C4\+V9O;G0^/"]T9#X-"B`\=&0@;F]W<F%P/3-$;F]W<F%P('9A;&EG M;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3I4:6UE<R!. M97<@4F]M86XG('-I>F4],T0R/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T* M(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<VEZ93TS1#$^)B-X03`[)B-X M03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S M='EL93TS1"=F;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86XG('-I>F4],T0R M/B8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI M9VX],T1R:6=H=#X\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3I4:6UE<R!. M97<@4F]M86XG('-I>F4],T0R/C$L-C$T/"]F;VYT/CPO=&0^#0H@/'1D(&YO M=W)A<#TS1&YO=W)A<"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<W1Y;&4],T0G M9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXF(WA!,#LF M(WA!,#L\+V9O;G0^/"]T9#X-"B`\+W1R/@T*(#QT<B!B9V-O;&]R/3-$(T-# M145&1CX-"B`\=&0@=F%L:6=N/3-$=&]P/@T*(#QP('-T>6QE/3-$)VUA<F=I M;BUL969T.C(N,#!E;3L@=&5X="UI;F1E;G0Z+3$N,#!E;2<^/&9O;G0@<W1Y M;&4],T0G9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CY6 M86-A=&EO;B!P87D\+V9O;G0^/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS M1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF(WA!,#LF(WA!,#L\+V9O;G0^/"]T M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)V9O;G0M M9F%M:6QY.E1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^)B-X03`[/"]F;VYT M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/CQF M;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;B<@<VEZ M93TS1#(^.3$U/"]F;VYT/CPO=&0^#0H@/'1D(&YO=W)A<#TS1&YO=W)A<"!V M86QI9VX],T1B;W1T;VT^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ5&EM M97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXF(WA!,#LF(WA!,#L\+V9O;G0^/"]T M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C>$$P M.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O M;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N)R!S:7IE M/3-$,CXF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M M(&%L:6=N/3-$<FEG:'0^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ5&EM M97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXW-S@\+V9O;G0^/"]T9#X-"B`\=&0@ M;F]W<F%P/3-$;F]W<F%P('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS M1"=F;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86XG('-I>F4],T0R/B8C>$$P M.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#PO='(^#0H@/'1R/@T*(#QT9"!V86QI M9VX],T1T;W`^#0H@/'`@<W1Y;&4],T0G;6%R9VEN+6QE9G0Z,BXP,&5M.R!T M97AT+6EN9&5N=#HM,2XP,&5M)SX\9F]N="!S='EL93TS1"=F;VYT+69A;6EL M>3I4:6UE<R!.97<@4F]M86XG('-I>F4],T0R/D]T:&5R('!A>7)O;&P-"B!R M96QA=&5D/"]F;VYT/CPO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T M;VT^/&9O;G0@<VEZ93TS1#$^)B-X03`[)B-X03`[/"]F;VYT/CPO=&0^#0H@ M/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=F;VYT+69A;6EL M>3I4:6UE<R!.97<@4F]M86XG('-I>F4],T0R/B8C>$$P.SPO9F]N=#X\+W1D M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#X\9F]N="!S M='EL93TS1"=F;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86XG('-I>F4],T0R M/C$Q,#PO9F]N=#X\+W1D/@T*(#QT9"!N;W=R87`],T1N;W=R87`@=F%L:6=N M/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.E1I;65S($YE M=R!2;VUA;B<@<VEZ93TS1#(^)B-X03`[)B-X03`[/"]F;VYT/CPO=&0^#0H@ M/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF(WA!,#LF(WA! M,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T M>6QE/3-$)V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^ M)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG M;CTS1')I9VAT/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.E1I;65S($YE M=R!2;VUA;B<@<VEZ93TS1#(^.3,\+V9O;G0^/"]T9#X-"B`\=&0@;F]W<F%P M/3-$;F]W<F%P('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=F;VYT M+69A;6EL>3I4:6UE<R!.97<@4F]M86XG('-I>F4],T0R/B8C>$$P.R8C>$$P M.SPO9F]N=#X\+W1D/@T*(#PO='(^#0H@/'1R(&)G8V]L;W(],T0C0T-%149& M/@T*(#QT9"!V86QI9VX],T1T;W`^#0H@/'`@<W1Y;&4],T0G;6%R9VEN+6QE M9G0Z,BXP,&5M.R!T97AT+6EN9&5N=#HM,2XP,&5M)SX\9F]N="!S='EL93TS M1"=F;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86XG('-I>F4],T0R/D]T:&5R M(&%C8W)U960-"B!E>'!E;G-E<SPO9F]N=#X\+W`^#0H@/"]T9#X-"B`\=&0@ M=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C>$$P.R8C>$$P.SPO M9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<W1Y;&4] M,T0G9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXF(WA! M,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$ M<FEG:'0^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O M;6%N)R!S:7IE/3-$,CXS,3<\+V9O;G0^/"]T9#X-"B`\=&0@;F]W<F%P/3-$ M;F]W<F%P('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=F;VYT+69A M;6EL>3I4:6UE<R!.97<@4F]M86XG('-I>F4],T0R/B8C>$$P.R8C>$$P.SPO M9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<VEZ93TS M1#$^)B-X03`[)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O M='1O;3X\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M M86XG('-I>F4],T0R/B8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX] M,T1B;W1T;VT@86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS1"=F;VYT+69A M;6EL>3I4:6UE<R!.97<@4F]M86XG('-I>F4],T0R/C$Q-3PO9F]N=#X\+W1D M/@T*(#QT9"!N;W=R87`],T1N;W=R87`@=F%L:6=N/3-$8F]T=&]M/CQF;VYT M('-T>6QE/3-$)V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;B<@<VEZ93TS M1#(^)B-X03`[)B-X03`[/"]F;VYT/CPO=&0^#0H@/"]T<CX-"B`\='(@<W1Y M;&4],T1F;VYT+7-I>F4Z,7!X/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@ M/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"=B;W)D97(M=&]P M.C%P>"!S;VQI9"`C,#`P,#`P)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0@ M=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)V)O<F1E<BUT;W`Z,7!X M('-O;&ED(",P,#`P,#`G/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT9#XF(WA! M,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)V)O<F1E M<BUT;W`Z,7!X('-O;&ED(",P,#`P,#`G/B8C>$$P.SPO<#X-"B`\+W1D/@T* M(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@<W1Y;&4],T0G8F]R9&5R+71O M<#HQ<'@@<V]L:60@(S`P,#`P,"<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D M/B8C>$$P.SPO=&0^#0H@/"]T<CX-"B`\='(^#0H@/'1D('9A;&EG;CTS1'1O M<#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<VEZ93TS1#$^ M)B-X03`[)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O M;3X\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86XG M('-I>F4],T0R/B0\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M M(&%L:6=N/3-$<FEG:'0^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ5&EM M97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXU+#0P,#PO9F]N=#X\+W1D/@T*(#QT M9"!N;W=R87`],T1N;W=R87`@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE M/3-$)V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^)B-X M03`[)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\ M9F]N="!S:7IE/3-$,3XF(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@ M=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.E1I M;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^)#PO9F]N=#X\+W1D/@T*(#QT9"!V M86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS1"=F M;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86XG('-I>F4],T0R/C@L,C<R/"]F M;VYT/CPO=&0^#0H@/'1D(&YO=W)A<#TS1&YO=W)A<"!V86QI9VX],T1B;W1T M;VT^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N M)R!S:7IE/3-$,CXF(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\+W1R/@T* M(#QT<B!S='EL93TS1&9O;G0M<VEZ93HQ<'@^#0H@/'1D('9A;&EG;CTS1&)O M='1O;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[ M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)V)O M<F1E<BUT;W`Z,W!X(&1O=6)L92`C,#`P,#`P)SXF(WA!,#L\+W`^#0H@/"]T M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)V)O<F1E M<BUT;W`Z,W!X(&1O=6)L92`C,#`P,#`P)SXF(WA!,#L\+W`^#0H@/"]T9#X- M"B`\=&0^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P M.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL M93TS1"=B;W)D97(M=&]P.C-P>"!D;W5B;&4@(S`P,#`P,"<^)B-X03`[/"]P M/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS M1"=B;W)D97(M=&]P.C-P>"!D;W5B;&4@(S`P,#`P,"<^)B-X03`[/"]P/@T* M(#PO=&0^#0H@/'1D/B8C>$$P.SPO=&0^#0H@/"]T<CX-"B`\+W1A8FQE/@T* M(#QP('-T>6QE/3-$)VUA<F=I;BUT;W`Z,3)P>#MM87)G:6XM8F]T=&]M.C!P M>#L@=&5X="UI;F1E;G0Z-"4G(&%L:6=N/3-$:G5S=&EF>3X\9F]N="!S='EL M93TS1"=F;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86XG('-I>F4],T0R/DEN M=&5R97-T(')E8V5I=F%B;&4@;VX@8V%S:"!E<75I=F%L96YT<R!A;F0@:6YV M97-T;65N=',@;V8-"B`D,3`Y+#`P,"!A;F0@)#(Q-2PP,#`@:7,@:6YC;'5D M960@:6X@<')E<&%I9"!A;F0@;W1H97(@8W5R<F5N=`T*(&%S<V5T<R!A="!$ M96-E;6)E<B8C>$$P.S,Q+"`R,#$T(&%N9"`R,#$S+"!R97-P96-T:79E;'DN M/"]F;VYT/CPO<#X-"B`\+V1I=CX\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@ M(#PO='(^#0H@("`@/"]T86)L93X-"B`@/"]B;V1Y/@T*/"]H=&UL/@T*#0HM M+2TM+2T]7TYE>'1087)T7S,Y8S!E838R7V,R,#-?-#4X9E\X8S4P7S-D8V$T M-39A-CDU,0T*0V]N=&5N="U,;V-A=&EO;CH@9FEL93HO+R]#.B\S.6,P96$V M,E]C,C`S7S0U.&9?.&,U,%\S9&-A-#4V838Y-3$O5V]R:W-H965T<R]3:&5E M=#$T+FAT;6P-"D-O;G1E;G0M5')A;G-F97(M16YC;V1I;F<Z('%U;W1E9"UP M<FEN=&%B;&4-"D-O;G1E;G0M5'EP93H@=&5X="]H=&UL.R!C:&%R<V5T/2)U M<RUA<V-I:2(-"@T*/&AT;6P^#0H@(#QH96%D/@T*("`@(#Q-151!(&AT='`M M97%U:78],T1#;VYT96YT+51Y<&4@8V]N=&5N=#TS1"=T97AT+VAT;6P[(&-H M87)S970]=71F+3@G/CQS8W)I<'0@='EP93TS1'1E>'0O:F%V87-C<FEP="!S M<F,],T13:&]W+FIS/B\J($1O($YO="!296UO=F4@5&AI<R!#;VUM96YT("HO M/"]S8W)I<'0^/"]H96%D/@T*("`\8F]D>3X-"B`@("`\=&%B;&4@8VQA<W,] M,T1R97!O<G0@:60],T1)1#!%344^#0H@("`@("`\='(^#0H@("`@("`@(#QT M:"!C;&%S<STS1'1L(&-O;'-P86X],T0Q(')O=W-P86X],T0R/CQS=')O;F<^ M4F5L871E9"!087)T:65S(&%N9"!296QA=&5D(%!A<G1Y(%1R86YS86-T:6]N M<SQB<CX\+W-T<F]N9SX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:"!C M;VQS<&%N/3-$,3XQ,B!-;VYT:',@16YD960\+W1H/@T*("`@("`@/"]T<CX- M"B`@("`@(#QT<CX-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^1&5C+B`S,2P@ M,C`Q-#QB<CX\+W1H/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS M1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^/'-T M<F]N9SY296QA=&5D(%!A<G1Y(%1R86YS86-T:6]N<R!;06)S=')A8W1=/"]S M=')O;F<^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\ M+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R M;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E)E;&%T M960@4&%R=&EE<R!A;F0@4F5L871E9"!087)T>2!4<F%N<V%C=&EO;G,\+W1D M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQD:78^#0H@/'`@<W1Y;&4] M,T0G34%21TE.+4)/5%1/33H@,'!X.R!-05)'24XM5$]0.B`Q.'!X)SX\9F]N M="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE M/3-$,CX\8CY.;W1E(#<@)B-X,C`Q-#L@4F5L871E9`T*(%!A<G1I97,@86YD M(%)E;&%T960@4&%R='D@5')A;G-A8W1I;VYS/"]B/CPO9F]N=#X\+W`^#0H@ M/"$M+2!X8G)L+&)O9'D@+2T^#0H@/'`@<W1Y;&4],T0G34%21TE.+4)/5%1/ M33H@,'!X.R!-05)'24XM3$5&5#H@,B4[($U!4D=)3BU43U`Z(#9P>"<^#0H@ M/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@ M<VEZ93TS1#(^/&(^/&D^4F5S96%R8V@-"B!A;F0@1&5V96QO<&UE;G0@07)R M86YG96UE;G1S/"]I/CPO8CX\+V9O;G0^/"]P/@T*(#QP('-T>6QE/3-$)TU! M4D=)3BU"3U143TTZ(#!P>#L@34%21TE.+4Q%1E0Z(#(E.R!-05)'24XM5$]0 M.B`V<'@G/@T*(#QF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!. M97<@4F]M86XG('-I>F4],T0R/CQI/D%M9V5N($EN8RX-"B`H)B-X,C`Q0SM! M;6=E;B8C>#(P,40[*3PO:3X\+V9O;G0^/"]P/@T*(#QP('-T>6QE/3-$)TU! M4D=)3BU"3U143TTZ(#!P>#L@34%21TE.+51/4#H@-G!X.R!415A4+4E.1$5. M5#H@-"4G(&%L:6=N/3-$:G5S=&EF>3X\9F]N="!S='EL93TS1"=&3TY4+49! M34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CY);B!$96-E;6)E<B`R M,#`V+"!T:&4@0V]M<&%N>2!E;G1E<F5D(&EN=&\@82!C;VQL86)O<F%T:6]N M(&%N9`T*(&]P=&EO;B!A9W)E96UE;G0@=VET:"!!;6=E;B!T;R!D:7-C;W9E M<BP@9&5V96QO<"!A;F0@8V]M;65R8VEA;&EZ90T*(&YO=F5L('-M86QL(&UO M;&5C=6QE('1H97)A<&5U=&EC<RP@:6YC;'5D:6YG(&]M96-A;71I=B!M96-A M<F)I;"P-"B!T:&%T(&%C=&EV871E(&-A<F1I86,@;75S8VQE(&-O;G1R86-T M:6QI='D@9F]R('!O=&5N=&EA;`T*(&%P<&QI8V%T:6]N<R!I;B!T:&4@=')E M871M96YT(&]F(&AE87)T(&9A:6QU<F4@*'1H92`F(W@R,#%#.T%M9V5N#0H@ M06=R965M96YT)B-X,C`Q1#LI+B!4:&4@86=R965M96YT(&=R86YT960@06UG M96X@86X@;W!T:6]N('1O(&]B=&%I;@T*(&%N(&5X8VQU<VEV92!L:6-E;G-E M('=O<FQD=VED92P@97AC97!T($IA<&%N+"!T;R!D979E;&]P(&%N9`T*(&-O M;6UE<F-I86QI>F4@;VUE8V%M=&EV(&UE8V%R8FEL(&%N9"!O=&AE<B!D<G5G M(&-A;F1I9&%T97,@87)I<VEN9PT*(&9R;VT@=&AE(&-O;&QA8F]R871I;VXN M($EN($UA>2`R,#`Y+"!!;6=E;B!E>&5R8VES960@:71S(&]P=&EO;BX@07,- M"B!A(')E<W5L="P@06UG96X@8F5C86UE(')E<W!O;G-I8FQE(&9O<B!T:&4@ M9&5V96QO<&UE;G0@86YD#0H@8V]M;65R8VEA;&EZ871I;VX@;V8@;VUE8V%M M=&EV(&UE8V%R8FEL(&%N9"!R96QA=&5D(&-O;7!O=6YD<R!A=`T*(&ET<R!E M>'!E;G-E('=O<FQD=VED92`H97AC;'5D:6YG($IA<&%N*2P@<W5B:F5C="!T M;R!T:&4-"B!#;VUP86YY)B-X,C`Q.3MS(&1E=F5L;W!M96YT(&%N9"!C;VUM M97)C:6%L:7IA=&EO;B!P87)T:6-I<&%T:6]N#0H@<FEG:'1S+B!!;6=E;B!R M96EM8G5R<V5S('1H92!#;VUP86YY(&9O<B!C97)T86EN(')E<V5A<F-H(&%N M9`T*(&1E=F5L;W!M96YT(&%C=&EV:71I97,@:70@<&5R9F]R;7,@=6YD97(@ M=&AE#0H@8V]L;&%B;W)A=&EO;BX\+V9O;G0^/"]P/@T*(#QP('-T>6QE/3-$ M)TU!4D=)3BU"3U143TTZ(#!P>#L@34%21TE.+51/4#H@,3)P>#L@5$585"U) M3D1%3E0Z(#0E)R!A;&EG;CTS1&IU<W1I9GD^/&9O;G0@<W1Y;&4],T0G1D]. M5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^26X@2G5N92`R M,#$S+"!#>71O:VEN971I8W,@86YD($%M9V5N(&5X96-U=&5D(&%N(&%M96YD M;65N="!T;PT*('1H92!!;6=E;B!!9W)E96UE;G0@=&\@:6YC;'5D92!*87!A M;BP@<F5S=6QT:6YG(&EN(&$@=V]R;&1W:61E#0H@8V]L;&%B;W)A=&EO;B`H M=&AE("8C>#(P,4,[06UG96X@06=R965M96YT($%M96YD;65N="8C>#(P,40[ M*2X@56YD97(-"B!T:&4@=&5R;7,@;V8@=&AE($%M9V5N($%G<F5E;65N="!! M;65N9&UE;G0L('1H92!#;VUP86YY(')E8V5I=F5D(&$-"B!N;VXM<F5F=6YD M86)L92!U<&9R;VYT(&QI8V5N<V4@9F5E(&]F("0Q-2XP(&UI;&QI;VX@:6X@ M2G5N92`R,#$S+@T*(%5N9&5R('1H92!!;6=E;B!!9W)E96UE;G0@06UE;F1M M96YT+"!T:&4@0V]M<&%N>2!C;VYD=6-T960@82!0:&%S90T*($D@<&AA<FUA M8V]K:6YE=&EC('-T=61Y(&EN=&5N9&5D('1O('-U<'!O<G0@:6YC;'5S:6]N M(&]F($IA<&%N(&EN(&$-"B!P;W1E;G1I86P@4&AA<V4@24E)(&-L:6YI8V%L M(&1E=F5L;W!M96YT('!R;V=R86T@86YD('!O=&5N=&EA;`T*(&=L;V)A;"!R M96=I<W1R871I;VX@9&]S<VEE<B!F;W(@;VUE8V%M=&EV(&UE8V%R8FEL+B!! M;6=E;@T*(')E:6UB=7)S960@=&AE($-O;7!A;GD@9F]R('1H92!C;W-T<R!O M9B!T:&ES('-T=61Y+B!);B!A9&1I=&EO;BP-"B!T:&4@0V]M<&%N>2!I<R!E M;&EG:6)L92!T;R!R96-E:79E(&%D9&ET:6]N86P@<')E+6-O;6UE<F-I86QI M>F%T:6]N#0H@;6EL97-T;VYE('!A>6UE;G1S(')E;&%T:6YG('1O('1H92!D M979E;&]P;65N="!O9B!O;65C86UT:78-"B!M96-A<F)I;"!A;F0@<F]Y86QT M:65S(&]N('-A;&5S(&]F(&]M96-A;71I=B!M96-A<F)I;"!I;@T*($IA<&%N M+CPO9F]N=#X\+W`^#0H@/'`@<W1Y;&4],T0G34%21TE.+4)/5%1/33H@,'!X M.R!-05)'24XM5$]0.B`Q,G!X.R!415A4+4E.1$5.5#H@-"4G(&%L:6=N/3-$ M:G5S=&EF>3X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W M(%)O;6%N)R!S:7IE/3-$,CY);B!C;VYJ=6YC=&EO;B!W:71H('1H92!!;6=E M;B!!9W)E96UE;G0@06UE;F1M96YT+"!T:&4@0V]M<&%N>0T*(&%L<V\@96YT M97)E9"!I;G1O(&$@8V]M;6]N('-T;V-K('!U<F-H87-E(&%G<F5E;65N="!W M:&EC:"!P<F]V:61E9`T*(&9O<B!T:&4@<V%L92!O9B`Q+#0P-"PQ,#`@<VAA M<F5S(&]F(&ET<R!C;VUM;VX@<W1O8VL@=&\@06UG96X@870@80T*('!R:6-E M('!E<B!S:&%R92!O9B`D-RXQ,B!A;F0@86X@86=G<F5G871E('!U<F-H87-E M('!R:6-E(&]F("0Q,"XP#0H@;6EL;&EO;BP@=VAI8V@@=V%S(')E8V5I=F5D M(&EN($IU;F4@,C`Q,RX@5&AE($-O;7!A;GD@9&5T97)M:6YE9`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`^#0H@/'`@<W1Y M;&4],T0G34%21TE.+4)/5%1/33H@,'!X.R!&3TY4+5-)6D4Z(#$R<'@[($U! M4D=)3BU43U`Z(#!P>"<^#0H@)B-X03`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`R,#$S+"!T:&4@0V]M<&%N>2!D M971E<FUI;F5D('1H870@=&AE(')E=F5N=64-"B!R96-O9VYI=&EO;B!R97%U M:7)E;65N=',@=6YD97(@05-#(#8P-2TQ,"!H860@8F5E;B!M970@86YD#0H@ M86-C;W)D:6YG;'DL(')E8V]G;FEZ960@)#$W+C(@;6EL;&EO;B!I;B!L:6-E M;G-E(')E=F5N=64-"B!A='1R:6)U=&%B;&4@=&\@=&AE($%M9V5N($%G<F5E M;65N="!!;65N9&UE;G0@:6X@=&AE(&9O=7)T:"!Q=6%R=&5R#0H@;V8@,C`Q M,RX@26X@>65A<B!E;F1E9"!$96-E;6)E<B8C>$$P.S,Q+"`R,#$T+"!T:&4@ M0V]M<&%N>0T*(')E8V]G;FEZ960@=&AE(')E;6%I;FEN9R`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`D,S`P M+C`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`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`T*('-U<'!O<G1I M;F<@82!C;VQL86)O<F%T:79E(')E<V5A<F-H('!R;V=R86T@9&ER96-T960@ M=&\@=&AE#0H@9&ES8V]V97)Y(&]F(&YE>'0M9V5N97)A=&EO;B!C87)D:6%C M('-A<F-O;65R92!A8W1I=F%T;W(@8V]M<&]U;F1S#0H@86YD(&]F(&]T:&5R M(&-O<W1S(')E;&%T960@=&\@=&AA="!R97-E87)C:"!P<F]G<F%M+B!4:&5S M90T*(')E:6UB=7)S96UE;G1S('=E<F4@<F5C;W)D960@87,@<F5S96%R8V@@ M86YD(&1E=F5L;W!M96YT(')E=F5N=65S#0H@9G)O;2!R96QA=&5D('!A<G1I M97,N/"]F;VYT/CPO<#X-"B`\<"!S='EL93TS1"=-05)'24XM0D]45$]-.B`P M<'@[($U!4D=)3BU43U`Z(#$R<'@[(%1%6%0M24Y$14Y4.B`T)2<@86QI9VX] M,T1J=7-T:69Y/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!. M97<@4F]M86XG('-I>F4],T0R/E)E=F5N=64@9G)O;2!!;6=E;B!W87,@87,@ M9F]L;&]W<R`H:6X@=&AO=7-A;F1S*3H\+V9O;G0^/"]P/@T*(#QP('-T>6QE M/3-$)TU!4D=)3BU"3U143TTZ(#!P>#L@1D].5"U325I%.B`Q,G!X.R!-05)' M24XM5$]0.B`P<'@G/@T*("8C>$$P.SPO<#X-"B`\=&%B;&4@<W1Y;&4],T0G M0D]21$52+4-/3$Q!4%-%.B!C;VQL87!S92<@8V5L;'-P86-I;F<],T0P(&-E M;&QP861D:6YG/3-$,"!W:61T:#TS1#DR)2!A;&EG;CTS1&-E;G1E<B!B;W)D M97(],T0P/@T*(#PA+2T@0F5G:6X@5&%B;&4@2&5A9"`M+3X-"B`\='(^#0H@ M/'1D('=I9'1H/3-$-S(E/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!W M:61T:#TS1#0E/CPO=&0^#0H@/'1D/CPO=&0^#0H@/'1D/CPO=&0^#0H@/'1D M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#0E/CPO=&0^ M#0H@/'1D/CPO=&0^#0H@/'1D/CPO=&0^#0H@/'1D/CPO=&0^#0H@/'1D('9A M;&EG;CTS1&)O='1O;2!W:61T:#TS1#0E/CPO=&0^#0H@/'1D/CPO=&0^#0H@ M/'1D/CPO=&0^#0H@/'1D/CPO=&0^#0H@/"]T<CX-"B`\='(^#0H@/'1D('9A M;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF(WA!,#L\+V9O;G0^/"]T M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C>$$P M.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!S='EL93TS1"="3U)$15(M0D]4 M5$]-.B!R9V(H,"PP+#`I(#%P>"!S;VQI9"<@=F%L:6=N/3-$8F]T=&]M(&-O M;'-P86X],T0Q,"!A;&EG;CTS1&-E;G1E<CX\9F]N="!S='EL93TS1"=&3TY4 M+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,3X\8CY996%R<R!% M;F1E9`T*($1E8V5M8F5R)B-X03`[,S$L/"]B/CPO9F]N=#X\+W1D/@T*(#QT M9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<VEZ93TS1#$^)B-X03`[/"]F;VYT M/CPO=&0^#0H@/"]T<CX-"B`\='(^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\ M9F]N="!S:7IE/3-$,3XF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N M/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C>$$P.R8C>$$P.SPO9F]N=#X\ M+W1D/@T*(#QT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B!R9V(H,"PP+#`I M(#%P>"!S;VQI9"<@=F%L:6=N/3-$8F]T=&]M(&-O;'-P86X],T0R(&%L:6=N M/3-$8V5N=&5R/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!. M97<@4F]M86XG('-I>F4],T0Q/CQB/C(P,30\+V(^/"]F;VYT/CPO=&0^#0H@ M/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF(WA!,#L\+V9O M;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q M/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!S='EL93TS1"="3U)$ M15(M0D]45$]-.B!R9V(H,"PP+#`I(#%P>"!S;VQI9"<@=F%L:6=N/3-$8F]T M=&]M(&-O;'-P86X],T0R(&%L:6=N/3-$8V5N=&5R/CQF;VYT('-T>6QE/3-$ M)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0Q/CQB/C(P M,3,\+V(^/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N M="!S:7IE/3-$,3XF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$ M8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D M/@T*(#QT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B!R9V(H,"PP+#`I(#%P M>"!S;VQI9"<@=F%L:6=N/3-$8F]T=&]M(&-O;'-P86X],T0R(&%L:6=N/3-$ M8V5N=&5R/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@ M4F]M86XG('-I>F4],T0Q/CQB/C(P,3(\+V(^/"]F;VYT/CPO=&0^#0H@/'1D M('9A;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF(WA!,#L\+V9O;G0^ M/"]T9#X-"B`\+W1R/@T*(#PA+2T@16YD(%1A8FQE($AE860@+2T^/"$M+2!" M96=I;B!486)L92!";V1Y("TM/@T*(#QT<B!B9V-O;&]R/3-$(T-#145&1CX- M"B`\=&0@=F%L:6=N/3-$=&]P/@T*(#QP('-T>6QE/3-$)TU!4D=)3BU,1494 M.B`Q96T[(%1%6%0M24Y$14Y4.B`M,65M)SX\9F]N="!S='EL93TS1"=&3TY4 M+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CY,:6-E;G-E(')E M=F5N=65S(&9R;VT-"B!R96QA=&5D('!A<G1I97,\+V9O;G0^/"]P/@T*(#PO M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF(WA! M,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO M=W)A<#TS1&YO=W)A<#X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM M97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXD/"]F;VYT/CPO=&0^#0H@/'1D('9A M;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`@86QI9VX],T1R:6=H=#X\ M9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S M:7IE/3-$,CXF(W@R,#$T.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B M;W1T;VT@;F]W<F%P/3-$;F]W<F%P/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%- M24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R/B8C>$$P.R8C>$$P.SPO M9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<VEZ93TS M1#$^)B-X03`[)B-X03`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`[)B-X03`[/"]F;VYT/CPO=&0^ M#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^/&9O;G0@ M<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS M1#(^)#PO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P M/3-$;F]W<F%P(&%L:6=N/3-$<FEG:'0^/&9O;G0@<W1Y;&4],T0G1D].5"U& M04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^)B-X,C`Q-#L\+V9O M;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A M<#X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N M)R!S:7IE/3-$,CXF(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\+W1R/@T* M(#QT<CX-"B`\=&0@=F%L:6=N/3-$=&]P/@T*(#QP('-T>6QE/3-$)TU!4D=) M3BU,1494.B`Q96T[(%1%6%0M24Y$14Y4.B`M,65M)SX\9F]N="!S='EL93TS M1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CY297-E M87)C:"!A;F0@9&5V96QO<&UE;G0-"B!R979E;G5E<R!F<F]M(')E;&%T960@ M<&%R=&EE<SH\+V9O;G0^/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O M='1O;3X\9F]N="!S:7IE/3-$,3XF(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X- M"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O M='1O;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\=&0@ M=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C>$$P.R8C>$$P.SPO M9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\=&0@ M=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\ M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<VEZ93TS1#$^)B-X M03`[)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\ M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\=&0@=F%L:6=N M/3-$8F]T=&]M/CPO=&0^#0H@/"]T<CX-"B`\='(@8F=C;VQO<CTS1"-#0T5% M1D8^#0H@/'1D('9A;&EG;CTS1'1O<#X-"B`\<"!S='EL93TS1"=-05)'24XM M3$5&5#H@,F5M.R!415A4+4E.1$5.5#H@+3%E;2<^/&9O;G0@<W1Y;&4],T0G M1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^4F5I;6)U M<G-E;65N="!O9B!I;G1E<FYA;`T*(&-O<W1S/"]F;VYT/CPO<#X-"B`\+W1D M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<VEZ93TS1#$^)B-X03`[ M)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N M="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE M/3-$,CXF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M M(&%L:6=N/3-$<FEG:'0^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I M;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^-"PR-C`\+V9O;G0^/"]T9#X-"B`\ M=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#X\9F]N="!S='EL M93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXF M(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M M/CQF;VYT('-I>F4],T0Q/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT M9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ M(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^)B-X03`[/"]F;VYT/CPO=&0^ M#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/CQF;VYT('-T M>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R M/C(L,#$Y/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R M87`],T1N;W=R87`^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S M($YE=R!2;VUA;B<@<VEZ93TS1#(^)B-X03`[)B-X03`[/"]F;VYT/CPO=&0^ M#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF(WA!,#LF M(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT M('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4] M,T0R/B8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@ M86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM M97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXT+#$W-#PO9F]N=#X\+W1D/@T*(#QT M9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P/CQF;VYT('-T>6QE M/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R/B8C M>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#PO='(^#0H@/'1R/@T*(#QT9"!V M86QI9VX],T1T;W`^#0H@/'`@<W1Y;&4],T0G34%21TE.+4Q%1E0Z(#)E;3L@ M5$585"U)3D1%3E0Z("TQ96TG/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9 M.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R/E)E:6UB=7)S96UE;G0@;V8@ M;W1H97(-"B!C;W-T<SPO9F]N=#X\+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N M/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C>$$P.R8C>$$P.SPO9F]N=#X\ M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P/CQF M;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I M>F4],T0R/B8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T M;VT@;F]W<F%P/3-$;F]W<F%P(&%L:6=N/3-$<FEG:'0^/&9O;G0@<W1Y;&4] M,T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^)B-X M,C`Q-#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A M<#TS1&YO=W)A<#X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@ M3F5W(%)O;6%N)R!S:7IE/3-$,CXF(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X- M"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C>$$P.R8C M>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P M/3-$;F]W<F%P/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!. M97<@4F]M86XG('-I>F4],T0R/B8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V M86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P(&%L:6=N/3-$<FEG:'0^ M/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@ M<VEZ93TS1#(^)B-X,C`Q-#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$ M8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#X\9F]N="!S='EL93TS1"=&3TY4+49! M34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXF(WA!,#LF(WA!,#L\ M+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4] M,T0Q/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B M;W1T;VT^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2 M;VUA;B<@<VEZ93TS1#(^)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG M;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/CQF;VYT('-T>6QE/3-$)T9/3E0M M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R/C,\+V9O;G0^/"]T M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#X\9F]N M="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE M/3-$,CXF(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\+W1R/@T*(#QT<B!B M9V-O;&]R/3-$(T-#145&1CX-"B`\=&0@=F%L:6=N/3-$=&]P/@T*(#QP('-T M>6QE/3-$)TU!4D=)3BU,1494.B`R96T[(%1%6%0M24Y$14Y4.B`M,65M)SX\ M9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S M:7IE/3-$,CY!;&QO8V%T960-"B!C;VYS:61E<F%T:6]N/"]F;VYT/CPO<#X- M"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<VEZ93TS1#$^ M)B-X03`[)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O M;3X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N M)R!S:7IE/3-$,CXF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$ M8F]T=&]M(&%L:6=N/3-$<FEG:'0^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U) M3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^,C<X/"]F;VYT/CPO=&0^ M#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^/&9O;G0@ M<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS M1#(^)B-X03`[)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O M='1O;3X\9F]N="!S:7IE/3-$,3XF(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X- M"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#X\9F]N="!S M='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$ M,CXF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO M=W)A<#TS1&YO=W)A<"!A;&EG;CTS1')I9VAT/CQF;VYT('-T>6QE/3-$)T9/ M3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R/B8C>#(P,30[ M/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N M;W=R87`^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2 M;VUA;B<@<VEZ93TS1#(^)B-X03`[)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D M('9A;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF(WA!,#LF(WA!,#L\ M+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO M=W)A<#X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O M;6%N)R!S:7IE/3-$,CXF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N M/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<"!A;&EG;CTS1')I9VAT/CQF;VYT M('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4] M,T0R/B8C>#(P,30[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O M;2!N;W=R87`],T1N;W=R87`^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ M(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^)B-X03`[)B-X03`[/"]F;VYT M/CPO=&0^#0H@/"]T<CX-"B`\='(@<W1Y;&4],T0G1D].5"U325I%.B`Q<'@G M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\=&0@=F%L:6=N/3-$ M8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O M;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B!R9V(H,"PP+#`I(#%P>"!S M;VQI9"<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O M;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B!R9V(H,"PP+#`I(#%P>"!S M;VQI9"<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D/B8C>$$P.SPO=&0^#0H@ M/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V M86QI9VX],T1B;W1T;VT^#0H@/'`@<W1Y;&4],T0G0D]21$52+51/4#H@<F=B M*#`L,"PP*2`Q<'@@<V]L:60G/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT9"!V M86QI9VX],T1B;W1T;VT^#0H@/'`@<W1Y;&4],T0G0D]21$52+51/4#H@<F=B M*#`L,"PP*2`Q<'@@<V]L:60G/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT9#XF M(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[ M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/ M4D1%4BU43U`Z(')G8B@P+#`L,"D@,7!X('-O;&ED)SXF(WA!,#L\+W`^#0H@ M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/ M4D1%4BU43U`Z(')G8B@P+#`L,"D@,7!X('-O;&ED)SXF(WA!,#L\+W`^#0H@ M/"]T9#X-"B`\=&0^)B-X03`[/"]T9#X-"B`\+W1R/@T*(#QT<CX-"B`\=&0@ M=F%L:6=N/3-$=&]P/@T*(#QP('-T>6QE/3-$)TU!4D=)3BU,1494.B`S96T[ M(%1%6%0M24Y$14Y4.B`M,65M)SX\9F]N="!S='EL93TS1"=&3TY4+49!34E, M63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CY4;W1A;"!R979E;G5E<R!F M<F]M#0H@06UG96X\+V9O;G0^/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS M1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF(WA!,#LF(WA!,#L\+V9O;G0^/"]T M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)T9/3E0M M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R/B0\+V9O;G0^/"]T M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^/&9O;G0@ M<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS M1#(^-"PU,S@\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO M=W)A<#TS1&YO=W)A<#X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM M97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXF(WA!,#LF(WA!,#L\+V9O;G0^/"]T M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C>$$P M.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O M;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ M93TS1#(^)#PO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI M9VX],T1R:6=H=#X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@ M3F5W(%)O;6%N)R!S:7IE/3-$,CXQ.2PR-#D\+V9O;G0^/"]T9#X-"B`\=&0@ M=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#X\9F]N="!S='EL93TS M1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXF(WA! M,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`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`\=&0@=F%L:6=N M/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF M(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@<W1Y;&4] M,T0G0D]21$52+51/4#H@<F=B*#`L,"PP*2`S<'@@9&]U8FQE)SXF(WA!,#L\ M+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE M/3-$)T)/4D1%4BU43U`Z(')G8B@P+#`L,"D@,W!X(&1O=6)L92<^)B-X03`[ M/"]P/@T*(#PO=&0^#0H@/'1D/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS M1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T M;VT^#0H@/'`@<W1Y;&4],T0G0D]21$52+51/4#H@<F=B*#`L,"PP*2`S<'@@ M9&]U8FQE)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T M=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(')G8B@P+#`L,"D@,W!X M(&1O=6)L92<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D/B8C>$$P.SPO=&0^ M#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT M9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@<W1Y;&4],T0G0D]21$52+51/4#H@ M<F=B*#`L,"PP*2`S<'@@9&]U8FQE)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\ M=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z M(')G8B@P+#`L,"D@,W!X(&1O=6)L92<^)B-X03`[/"]P/@T*(#PO=&0^#0H@ M/'1D/B8C>$$P.SPO=&0^#0H@/"]T<CX-"B`\(2TM($5N9"!486)L92!";V1Y M("TM/CPO=&%B;&4^#0H@/'`@<W1Y;&4],T0G34%21TE.+4)/5%1/33H@,'!X M.R!&3TY4+5-)6D4Z(#$X<'@[($U!4D=)3BU43U`Z(#!P>"<^#0H@)B-X03`[ M/"]P/@T*(#QP('-T>6QE/3-$)TU!4D=)3BU"3U143TTZ(#!P>#L@34%21TE. M+4Q%1E0Z(#(E.R!-05)'24XM5$]0.B`P<'@G/@T*(#QF;VYT('-T>6QE/3-$ M)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R/CQB/CQI M/D%S=&5L;&%S#0H@4&AA<FUA($EN8RX@*"8C>#(P,4,[07-T96QL87,F(W@R M,#%$.RD\+VD^/"]B/CPO9F]N=#X\+W`^#0H@/'`@<W1Y;&4],T0G34%21TE. M+4)/5%1/33H@,'!X.R!-05)'24XM3$5&5#H@,B4[($U!4D=)3BU43U`Z(#9P M>"<^#0H@/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2 M;VUA;B<@<VEZ93TS1#(^/&D^3W)I9VEN86P-"B!!<W1E;&QA<R!!9W)E96UE M;G0@*$YO;BUN975R;VUU<V-U;&%R(&QI8V5N<V4I/"]I/CPO9F]N=#X\+W`^ M#0H@/'`@<W1Y;&4],T0G34%21TE.+4)/5%1/33H@,'!X.R!-05)'24XM5$]0 M.B`V<'@[(%1%6%0M24Y$14Y4.B`T)2<@86QI9VX],T1J=7-T:69Y/CQF;VYT M('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4] M,T0R/DEN($IU;F4@,C`Q,RP@=&AE($-O;7!A;GD@96YT97)E9"!I;G1O(&$@ M;&EC96YS92!A;F0-"B!C;VQL86)O<F%T:6]N(&%G<F5E;65N="!W:71H($%S M=&5L;&%S("AT:&4@)B-X,C`Q0SM/<FEG:6YA;"!!<W1E;&QA<PT*($%G<F5E M;65N="8C>#(P,40[*2X@5&AE('!R:6UA<GD@;V)J96-T:79E(&]F('1H92!C M;VQL86)O<F%T:6]N('=I=&@-"B!!<W1E;&QA<R!I<R!T;R!A9'9A;F-E(&YO M=F5L('1H97)A<&EE<R!F;W(@9&ES96%S97,@86YD(&UE9&EC86P-"B!C;VYD M:71I;VYS(&%S<V]C:6%T960@=VET:"!M=7-C;&4@=V5A:VYE<W,N/"]F;VYT M/CPO<#X-"B`\<"!S='EL93TS1"=-05)'24XM0D]45$]-.B`P<'@[($U!4D=) M3BU43U`Z(#$R<'@[(%1%6%0M24Y$14Y4.B`T)2<@86QI9VX],T1J=7-T:69Y M/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG M('-I>F4],T0R/E5N9&5R('1H92!/<FEG:6YA;"!!<W1E;&QA<R!!9W)E96UE M;G0L('1H92!#;VUP86YY(&=R86YT960-"B!!<W1E;&QA<R!A;B!E>&-L=7-I M=F4@;&EC96YS92!T;R!C;RUD979E;&]P(&%N9"!J;VEN=&QY#0H@8V]M;65R M8VEA;&EZ92!#2RTR,3(W,3`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`\<"!S='EL93TS1"=-05)'24XM0D]45$]-.B`P<'@[ M($U!4D=)3BU43U`Z(#$R<'@[(%1%6%0M24Y$14Y4.B`T)2<@86QI9VX],T1J M=7-T:69Y/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@ M4F]M86XG('-I>F4],T0R/DEN($IU;'D@,C`Q,RP@=&AE($-O;7!A;GD@<F5C M96EV960@86X@=7!F<F]N="P@;F]N+7)E9G5N9&%B;&4-"B!L:6-E;G-E(&9E M92!O9B`D,38N,"!M:6QL:6]N(&EN(&-O;FYE8W1I;VX@=VET:"!T:&4@97AE M8W5T:6]N(&]F#0H@=&AE($]R:6=I;F%L($%S=&5L;&%S($%G<F5E;65N="X@ M56YD97(@=&AE(&%G<F5E;65N="P@=&AE($-O;7!A;GD-"B!W87,@96QI9VEB M;&4@=&\@<&]T96YT:6%L;'D@<F5C96EV92!A<'!R;WAI;6%T96QY("0R-2XU M(&UI;&QI;VX@:6X-"B!R96EM8G5R<V5M96YT(&]F('-P;VYS;W)E9"!R97-E M87)C:"!A;F0@9&5V96QO<&UE;G0@86-T:79I=&EE<PT*(&1U<FEN9R!T:&4@ M:6YI=&EA;"!T=V\@>65A<G,@;V8@=&AE(&-O;&QA8F]R871I;VXN(%1H92!A M9W)E96UE;G0-"B!A;'-O('!R;W9I9&5D(&9O<B!R97-E87)C:"!A;F0@96%R M;'D@86YD(&QA=&4@<W1A9V4@9&5V96QO<&UE;G0-"B!M:6QE<W1O;F4@<&%Y M;65N=',@8F%S960@;VX@=F%R:6]U<R!R97-E87)C:"!A;F0@8VQI;FEC86P- M"B!M:6QE<W1O;F5S+"!I;F-L=61I;F<@=&AE(&EN:71I871I;VX@;V8@8V5R M=&%I;B!C;&EN:6-A;"!S='5D:65S+`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`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`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`T*('!E<F9O<FUA;F-E(&UO9&5L(&]V M97(@=&AE(&EN:71I86P@<F5S96%R8V@@=&5R;2!O9B!T:&4@3W)I9VEN86P- M"B!!<W1E;&QA<R!!9W)E96UE;G0N($1U<FEN9R!T:&4@>65A<B!E;F1E9"!$ M96-E;6)E<B8C>$$P.S,Q+"`R,#$T+`T*('1H92!#;VUP86YY(')E8V]R9&5D M("0Y+C@@;6EL;&EO;B!I;B!L:6-E;G-E(')E=F5N=64@8F%S960@;VX@=&AE M#0H@<')O<&]R=&EO;F%L('!E<F9O<FUA;F-E(&UO9&5L+B!!<R!O9B!$96-E M;6)E<B8C>$$P.S,Q+"`R,#$T+"!T:&4-"B!#;VUP86YY(&AA<R!R96-O9VYI M>F5D("0Q,RXW(&UI;&QI;VX@;V8@=&AE("0Q-BXP(&UI;&QI;VX@=7!F<F]N M=`T*(&QI8V5N<V4@9F5E(&%S(&QI8V5N<V4@<F5V96YU92P@86YD(&AA<R`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`[,S$L M(#(P,30L('1H92!#;VUP86YY(')E8V]R9&5D(')E<V5A<F-H#0H@86YD(&1E M=F5L;W!M96YT(')E=F5N=64@9G)O;2!!<W1E;&QA<R!O9B`D."XY)B-X03`[ M;6EL;&EO;B!R96QA=&5D#0H@=&\@=&AE(')E:6UB=7)S96UE;G0@;V8@:6YT M97)N86P@8V]S=',@86YD("0V+C4@;6EL;&EO;B!R96QA=&5D('1O#0H@=&AE M(')E:6UB=7)S96UE;G0@;V8@;W1H97(@8V]S=',N/"]F;VYT/CPO<#X-"B`\ M<"!S='EL93TS1"=-05)'24XM0D]45$]-.B`P<'@[($U!4D=)3BU,1494.B`R M)3L@34%21TE.+51/4#H@,3AP>"<^#0H@/&9O;G0@<W1Y;&4],T0G1D].5"U& M04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^/&D^06UE;F1E9`T* M($%S=&5L;&%S($%G<F5E;65N="`H17AP86YS:6]N('1O(&EN8VQU9&4@;F5U M<F]M=7-C=6QA<@T*(&EN9&EC871I;VYS*3PO:3X\+V9O;G0^/"]P/@T*(#QP M('-T>6QE/3-$)TU!4D=)3BU"3U143TTZ(#!P>#L@34%21TE.+51/4#H@-G!X M.R!415A4+4E.1$5.5#H@-"4G(&%L:6=N/3-$:G5S=&EF>3X\9F]N="!S='EL M93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CY/ M;B!$96-E;6)E<B8C>$$P.S(R+"`R,#$T+"!T:&4@0V]M<&%N>2!E;G1E<F5D M(&EN=&\@86X@86UE;F1E9`T*(&%N9"!R97-T871E9"!L:6-E;G-E(&%N9"!C M;VQL86)O<F%T:6]N(&%G<F5E;65N="!W:71H($%S=&5L;&%S("AT:&4-"B`F M(W@R,#%#.T%M96YD960@07-T96QL87,@06=R965M96YT)B-X,C`Q1#LI+B!4 M:&ES(&%G<F5E;65N=`T*('-U<&5R<V5D960@=&AE($]R:6=I;F%L($%S=&5L M;&%S($%G<F5E;65N="X@5&AE($%M96YD960@07-T96QL87,-"B!!9W)E96UE M;G0@97AP86YD960@=&AE(&]B:F5C=&EV92!O9B!T:&4@8V]L;&%B;W)A=&EO M;B!O9B!A9'9A;F-I;F<-"B!N;W9E;"!T:&5R87!I97,@9F]R(&1I<V5A<V5S M(&%N9"!M961I8V%L(&-O;F1I=&EO;G,@87-S;V-I871E9"!W:71H#0H@;75S M8VQE('=E86MN97-S('1O(&EN8VQU9&4@4TU!(&%N9"!P;W1E;G1I86QL>2!O M=&AE<B!N975R;VUU<V-U;&%R#0H@:6YD:6-A=&EO;G,L(&EN(&%D9&ET:6]N M('1O('1H92!N;VXM;F5U<F]M=7-C=6QA<B!I;F1I8V%T:6]N<PT*('!R;W9I M9&5D(&9O<B!I;B!T:&4@3W)I9VEN86P@07-T96QL87,@06=R965M96YT+B!5 M;F1E<B!T:&4@=&5R;7,@;V8-"B!T:&4@06UE;F1E9"!!<W1E;&QA<R!!9W)E M96UE;G0L('=E(')E8V5I=F5D(&$@;F]N+7)E9G5N9&%B;&4-"B!U<&9R;VYT M(&QI8V5N<V4@9F5E(&]F("0S,"XP(&UI;&QI;VX@:6X@2F%N=6%R>2`R,#$U M+B!#;VYC=7)R96YT;'DL#0H@=&AE($-O;7!A;GD@<F5C96EV960@)#$U+C`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`T*('1O('1H92!D M979E;&]P;65N="!O9B!#2RTR,3(W,3`W(&EN(&YE=7)O;75S8W5L87(@:6YD M:6-A=&EO;G,L(&%N9`T*(')O>6%L=&EE<R!O;B!S86QE<R!O9B!#2RTR,3(W M,3`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`Q-"P@=&AE($-O;7!A;GD@:&%S(')E8V]G;FEZ M960@>F5R;R!O9B!T:&4-"B`D,S`N,"!M:6QL:6]N('5P9G)O;G0@;&EC96YS M92!F964@87,@;&EC96YS92!R979E;G5E(&%N9"!D969E<G)E9`T*('1H92!E M;G1I<F4@86UO=6YT+CPO9F]N=#X\+W`^#0H@/'`@<W1Y;&4],T0G34%21TE. M+4)/5%1/33H@,'!X.R!-05)'24XM5$]0.B`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`R,#$T+"`D,3<N,"!M:6QL:6]N('=A<R!R96-O9VYI M>F5D(&%S(&UI;&5S=&]N90T*(')E=F5N=64@9F]R(&5A<FQY(&1E=F5L;W!M M96YT('5N9&5R('1H:7,@86=R965M96YT+B!4:&4@0V]M<&%N>2!I<PT*(&5L M:6=I8FQE('1O(')E8V5I=F4@=7`@=&\@)#(N,"!M:6QL:6]N(&EN(')E<V5A M<F-H(&UI;&5S=&]N90T*('!A>6UE;G1S(&9O<B!E86-H(&9U='5R92!C;VQL M86)O<F%T:6]N('!R;V1U8W0-"B!C86YD:61A=&4N/"]F;VYT/CPO<#X-"B`\ M<"!S='EL93TS1"=-05)'24XM0D]45$]-.B`P<'@[($U!4D=)3BU43U`Z(#$R M<'@[(%1%6%0M24Y$14Y4.B`T)2<@86QI9VX],T1J=7-T:69Y/CQF;VYT('-T M>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R M/E1H92!A8VAI979E;65N="!O9B!E86-H(&]F('1H92!L871E('-T86=E(&1E M=F5L;W!M96YT#0H@;6EL97-T;VYE<R!A;F0@=&AE(&-O;6UE<F-I86QI>F%T M:6]N(&UI;&5S=&]N97,@87)E(&1E<&5N9&5N=`T*('-O;&5L>2!U<&]N('1H M92!R97-U;'1S(&]F($%S=&5L;&%S)B-X,C`Q.3L@9&5V96QO<&UE;G0@86-T M:79I=&EE<PT*(&%N9"!T:&5R969O<F4@=&AE<V4@;6EL97-T;VYE<R!W97)E M(&YO="!D965M960@=&\@8F4-"B!S=6)S=&%N=&EV92X\+V9O;G0^/"]P/@T* M(#QP('-T>6QE/3-$)TU!4D=)3BU"3U143TTZ(#!P>#L@34%21TE.+51/4#H@ M,3)P>#L@5$585"U)3D1%3E0Z(#0E)R!A;&EG;CTS1&IU<W1I9GD^/&9O;G0@ M<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS M1#(^56YD97(@=&AE($%M96YD960@07-T96QL87,@06=R965M96YT+"!A9&1I M=&EO;F%L(')E<V5A<F-H(&%N9`T*(&5A<FQY(&%N9"!L871E('-T871E(&1E M=F5L;W!M96YT(&UI;&5S=&]N92!P87EM96YT<R!W:&EC:"!A<F4@8F%S960- M"B!O;B!V87)I;W5S(')E<V5A<F-H(&%N9"!C;&EN:6-A;"!M:6QE<W1O;F5S M+"!I;F-L=61I;F<@=&AE#0H@:6YI=&EA=&EO;B!O9B!C97)T86EN(&-L:6YI M8V%L('-T=61I97,L('1H92!S=6)M:7-S:6]N(&9O<B!A<'!R;W9A;`T*(&]F M(&$@9')U9R!C86YD:61A=&4@=&\@8V5R=&%I;B!R96=U;&%T;W)Y(&%U=&AO M<FET:65S(&9O<B!M87)K971I;F<-"B!A<'!R;W9A;"!A;F0@=&AE(&-O;6UE M<F-I86P@;&%U;F-H(&]F(&-O;&QA8F]R871I;VX@<')O9'5C=',@8V]U;&0- M"B!T;W1A;"!O=F5R("0V,#`N,"!M:6QL:6]N+"!I;F-L=61I;F<@=7`@=&\@ M)#DU+C`F(WA!,#MM:6QL:6]N#0H@<F5L871I;F<@=&\@0TLM,C$R-S$P-R!I M;B!N;VXM;F5U<F]M=7-C=6QA<B!I;F1I8V%T:6]N<RP@86YD(&]V97(-"B`D M,3`P+C`@;6EL;&EO;B!R96QA=&5D('1O($-++3(Q,C<Q,#<@:6X@96%C:"!O M9B!334$@86YD(&]T:&5R#0H@;F5U<F]M=7-C=6QA<B!I;F1I8V%T:6]N<RX@ M061D:71I;VYA;&QY+"`D,C`P+C`@;6EL;&EO;B!I;@T*(&-O;6UE<F-I86P@ M;6EL97-T;VYE<R!C;W5L9"!B92!R96-E:79E9"!U;F1E<B!T:&4@06UE;F1E M9"!!<W1E;&QA<PT*($%G<F5E;65N="!P<F]V:61E9"!C97)T86EN('-A;&5S M('1A<F=E=',@87)E(&UE="X@1'5E('1O('1H92!N871U<F4-"B!O9B!D<G5G M(&1E=F5L;W!M96YT+"!I;F-L=61I;F<@=&AE(&EN:&5R96YT(')I<VL@;V8@ M9&5V96QO<&UE;G0@86YD#0H@87!P<F]V86P@;V8@9')U9R!C86YD:61A=&5S M(&)Y(')E9W5L871O<GD@875T:&]R:71I97,L(&ET(&ES(&YO=`T*('!O<W-I M8FQE('1O(&5S=&EM871E(&EF(&%N9"!W:&5N('1H97-E(&UI;&5S=&]N92!P M87EM96YT<R!C;W5L9`T*(&)E8V]M92!D=64N/"]F;VYT/CPO<#X-"B`\<"!S M='EL93TS1"=-05)'24XM0D]45$]-.B`P<'@[($9/3E0M4TE:13H@,3)P>#L@ M34%21TE.+51/4#H@,'!X)SX-"B`F(WA!,#L\+W`^#0H@/'`@<W1Y;&4],T0G M34%21TE.+4)/5%1/33H@,'!X.R!-05)'24XM5$]0.B`Q,G!X.R!415A4+4E. M1$5.5#H@-"4G(&%L:6=N/3-$:G5S=&EF>3X\9F]N="!S='EL93TS1"=&3TY4 M+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CY);B!T:&4@979E M;G0@07-T96QL87,@8V]M;65R8VEA;&EZ97,@86YY(&-O;&QA8F]R871I;VX- M"B!P<F]D=6-T<RP@=&AE($-O;7!A;GD@=VEL;"!R96-E:79E(')O>6%L=&EE M<R!O;B!S86QE<R!O9B!S=6-H#0H@8V]L;&%B;W)A=&EO;B!P<F]D=6-T<RP@ M:6YC;'5D:6YG(')O>6%L=&EE<R!R86YG:6YG(&9R;VT@=&AE(&AI9V@-"B!S M:6YG;&4@9&EG:71S('1O('1H92!H:6=H('1E96YS(&]N('-A;&5S(&]F('!R M;V1U8W1S(&-O;G1A:6YI;F<-"B!#2RTR,3(W,3`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`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`\<"!S='EL93TS1"=-05)'24XM0D]4 M5$]-.B`P<'@[($U!4D=)3BU43U`Z(#$R<'@[(%1%6%0M24Y$14Y4.B`T)2<@ M86QI9VX],T1J=7-T:69Y/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4 M:6UE<R!.97<@4F]M86XG('-I>F4],T0R/DEN(&-O;FIU;F-T:6]N('=I=&@@ M=&AE($%M96YD960@07-T96QL87,@06=R965M96YT+"!T:&4@0V]M<&%N>0T* M(&%L<V\@96YT97)E9"!I;G1O(&$@8V]M;6]N('-T;V-K('!U<F-H87-E(&%G M<F5E;65N="!W:&EC:"!P<F]V:61E9`T*(&9O<B!T:&4@<V%L92!O9B`R+#`T M,"PX,38@<VAA<F5S(&]F(&ET<R!C;VUM;VX@<W1O8VL@=&\@07-T96QL87,@ M870-"B!A('!R:6-E('!E<B!S:&%R92!O9B`D-"XY,"!A;F0@86X@86=G<F5G M871E('!U<F-H87-E('!R:6-E(&]F("0Q,"XP#0H@;6EL;&EO;B!W:&EC:"!W M87,@<F5C96EV960@:6X@1&5C96UB97(@,C`Q-"X@4'5R<W5A;G0@=&\@=&AI M<PT*(&%G<F5E;65N="P@07-T96QL87,@86=R965D('1O(&-E<G1A:6X@=')A M9&EN9R!A;F0@;W1H97(-"B!R97-T<FEC=&EO;G,@=VET:"!R97-P96-T('1O M('1H92!#;VUP86YY)B-X,C`Q.3MS(&-O;6UO;B!S=&]C:RX@5&AE#0H@0V]M M<&%N>2!D971E<FUI;F5D('1H92!F86ER('9A;'5E(&]F('1H92!S=&]C:R!I M<W-U960@=&\@07-T96QL87,-"B!T;R!B92`D.2XQ(&UI;&QI;VXN(%1H92!E M>&-E<W,@;V8@8V%S:"!R96-E:79E9"!O=F5R(&9A:7(@=F%L=64@;V8-"B`D M,"XY(&UI;&QI;VX@=V%S(&1E9F5R<F5D(&%L;VYG('=I=&@@=&AE(&QI8V5N M<V4@86YD(')E<V5A<F-H(&%N9`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`\<"!S='EL93TS1"=-05)'24XM0D]45$]-.B`P<'@[ M($U!4D=)3BU43U`Z(#$R<'@[(%1%6%0M24Y$14Y4.B`T)2<@86QI9VX],T1J M=7-T:69Y/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@ M4F]M86XG('-I>F4],T0R/E)E<V5A<F-H(&%N9"!D979E;&]P;65N="!R979E M;G5E(&9R;VT@07-T96QL87,@=V%S(&%S(&9O;&QO=W,-"B`H:6X@=&AO=7-A M;F1S*3H\+V9O;G0^/"]P/@T*(#QP('-T>6QE/3-$)TU!4D=)3BU"3U143TTZ M(#!P>#L@1D].5"U325I%.B`Q,G!X.R!-05)'24XM5$]0.B`P<'@G/@T*("8C M>$$P.SPO<#X-"B`\=&%B;&4@<W1Y;&4],T0G0D]21$52+4-/3$Q!4%-%.B!C M;VQL87!S92<@8V5L;'-P86-I;F<],T0P(&-E;&QP861D:6YG/3-$,"!W:61T M:#TS1#DR)2!A;&EG;CTS1&-E;G1E<B!B;W)D97(],T0P/@T*(#PA+2T@0F5G M:6X@5&%B;&4@2&5A9"`M+3X-"B`\='(^#0H@/'1D('=I9'1H/3-$-S$E/CPO M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#DE/CPO=&0^#0H@ M/'1D/CPO=&0^#0H@/'1D/CPO=&0^#0H@/'1D/CPO=&0^#0H@/'1D('9A;&EG M;CTS1&)O='1O;2!W:61T:#TS1#DE/CPO=&0^#0H@/'1D/CPO=&0^#0H@/'1D M/CPO=&0^#0H@/'1D/CPO=&0^#0H@/"]T<CX-"B`\='(^#0H@/'1D('9A;&EG M;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF(WA!,#L\+V9O;G0^/"]T9#X- M"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C>$$P.R8C M>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!S='EL93TS1"="3U)$15(M0D]45$]- M.B!R9V(H,"PP+#`I(#%P>"!S;VQI9"<@=F%L:6=N/3-$8F]T=&]M(&-O;'-P M86X],T0R(&%L:6=N/3-$8V5N=&5R/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%- M24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0Q/CQB/EEE87(@16YD960\ M8G(@+SX-"B!$96-E;6)E<B8C>$$P.S,Q+#QB<B`O/@T*(#(P,30\+V(^/"]F M;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$ M,3XF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF M;VYT('-I>F4],T0Q/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!S M='EL93TS1"="3U)$15(M0D]45$]-.B!R9V(H,"PP+#`I(#%P>"!S;VQI9"<@ M=F%L:6=N/3-$8F]T=&]M(&-O;'-P86X],T0R(&%L:6=N/3-$8V5N=&5R/CQF M;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I M>F4],T0Q/CQB/EEE87(@16YD960\8G(@+SX-"B!$96-E;6)E<B8C>$$P.S,Q M+#QB<B`O/@T*(#(P,3,\+V(^/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS M1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF(WA!,#L\+V9O;G0^/"]T9#X-"B`\ M+W1R/@T*(#PA+2T@16YD(%1A8FQE($AE860@+2T^/"$M+2!"96=I;B!486)L M92!";V1Y("TM/@T*(#QT<B!B9V-O;&]R/3-$(T-#145&1CX-"B`\=&0@=F%L M:6=N/3-$=&]P/@T*(#QP('-T>6QE/3-$)TU!4D=)3BU,1494.B`Q96T[(%1% M6%0M24Y$14Y4.B`M,65M)SX\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@ M5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CY297-E87)C:"!A;F0@9&5V96QO M<&UE;G0-"B!R979E;G5E<R!W:71H(')E;&%T960@<&%R=&EE<SH\+V9O;G0^ M/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE M/3-$,3XF(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$ M8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT M9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M M/CQF;VYT('-I>F4],T0Q/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT M9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#PO='(^#0H@ M/'1R/@T*(#QT9"!V86QI9VX],T1T;W`^#0H@/'`@<W1Y;&4],T0G34%21TE. M+4Q%1E0Z(#)E;3L@5$585"U)3D1%3E0Z("TQ96TG/CQF;VYT('-T>6QE/3-$ M)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R/E)E<V5A M<F-H(&%N9"!D979E;&]P;65N=`T*(&UI;&5S=&]N92!F965S/"]F;VYT/CPO M<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<VEZ93TS M1#$^)B-X03`[)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O M='1O;3X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O M;6%N)R!S:7IE/3-$,CXD/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O M='1O;2!A;&EG;CTS1')I9VAT/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9 M.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R/C$U+#`P,#PO9F]N=#X\+W1D M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P/CQF;VYT M('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4] M,T0R/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B M;W1T;VT^/&9O;G0@<VEZ93TS1#$^)B-X03`[)B-X03`[/"]F;VYT/CPO=&0^ M#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^/&9O;G0@ M<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS M1#(^)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N M;W=R87`],T1N;W=R87`@86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS1"=& M3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXF(W@R,#$T M.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$ M;F]W<F%P/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@ M4F]M86XG('-I>F4],T0R/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#PO M='(^#0H@/'1R(&)G8V]L;W(],T0C0T-%149&/@T*(#QT9"!V86QI9VX],T1T M;W`^#0H@/'`@<W1Y;&4],T0G34%21TE.+4Q%1E0Z(#%E;3L@5$585"U)3D1% M3E0Z("TQ96TG/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!. M97<@4F]M86XG('-I>F4],T0R/E)E<V5A<F-H(&%N9"!D979E;&]P;65N=`T* M(')E=F5N=65S.CPO9F]N=#X\+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$ M8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\=&0@=F%L:6=N/3-$ M8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT M9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<VEZ93TS1#$^)B-X03`[)B-X03`[ M/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT M9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M M/CPO=&0^#0H@/"]T<CX-"B`\='(^#0H@/'1D('9A;&EG;CTS1'1O<#X-"B`\ M<"!S='EL93TS1"=-05)'24XM3$5&5#H@,F5M.R!415A4+4E.1$5.5#H@+3%E M;2<^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA M;B<@<VEZ93TS1#(^4F5I;6)U<G-E;65N="!O9B!I;G1E<FYA;`T*(&-O<W1S M/"]F;VYT/CPO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O M;G0@<VEZ93TS1#$^)B-X03`[)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A M;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM M97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXF(WA!,#L\+V9O;G0^/"]T9#X-"B`\ M=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^/&9O;G0@<W1Y;&4] M,T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^."PY M,SD\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS M1&YO=W)A<#X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W M(%)O;6%N)R!S:7IE/3-$,CXF(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\ M=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C>$$P.R8C>$$P M.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<W1Y M;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^ M)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG M;CTS1')I9VAT/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!. M97<@4F]M86XG('-I>F4],T0R/C,L,C@U/"]F;VYT/CPO=&0^#0H@/'1D('9A M;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^/&9O;G0@<W1Y;&4],T0G M1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^)B-X03`[ M)B-X03`[/"]F;VYT/CPO=&0^#0H@/"]T<CX-"B`\='(@8F=C;VQO<CTS1"-# M0T5%1D8^#0H@/'1D('9A;&EG;CTS1'1O<#X-"B`\<"!S='EL93TS1"=-05)' M24XM3$5&5#H@,F5M.R!415A4+4E.1$5.5#H@+3%E;2<^/&9O;G0@<W1Y;&4] M,T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^4F5I M;6)U<G-E;65N="!O9B!O=&AE<@T*(&-O<W1S/"]F;VYT/CPO<#X-"B`\+W1D M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<VEZ93TS1#$^)B-X03`[ M)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N M="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE M/3-$,CXF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M M(&%L:6=N/3-$<FEG:'0^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I M;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^-BPT-3(\+V9O;G0^/"]T9#X-"B`\ M=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#X\9F]N="!S='EL M93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXF M(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M M/CQF;VYT('-I>F4],T0Q/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT M9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ M(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^)B-X03`[/"]F;VYT/CPO=&0^ M#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/CQF;VYT('-T M>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R M/C,L,3,P/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R M87`],T1N;W=R87`^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S M($YE=R!2;VUA;B<@<VEZ93TS1#(^)B-X03`[)B-X03`[/"]F;VYT/CPO=&0^ M#0H@/"]T<CX-"B`\='(^#0H@/'1D('9A;&EG;CTS1'1O<#X-"B`\<"!S='EL M93TS1"=-05)'24XM3$5&5#H@,F5M.R!415A4+4E.1$5.5#H@+3%E;2<^/&9O M;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ M93TS1#(^4F5S96%R8V@@86YD(&1E=F5L;W!M96YT#0H@;6EL97-T;VYE(&9E M97,\+V9O;G0^/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\ M9F]N="!S:7IE/3-$,3XF(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@ M=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4 M:6UE<R!.97<@4F]M86XG('-I>F4],T0R/B8C>$$P.SPO9F]N=#X\+W1D/@T* M(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#X\9F]N="!S='EL M93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXR M+#`P,#PO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P M/3-$;F]W<F%P/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!. M97<@4F]M86XG('-I>F4],T0R/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T* M(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<VEZ93TS1#$^)B-X03`[)B-X M03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`] M,T1N;W=R87`^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE M=R!2;VUA;B<@<VEZ93TS1#(^)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A M;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`@86QI9VX],T1R:6=H=#X\ M9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S M:7IE/3-$,CXF(W@R,#$T.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B M;W1T;VT@;F]W<F%P/3-$;F]W<F%P/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%- M24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R/B8C>$$P.R8C>$$P.SPO M9F]N=#X\+W1D/@T*(#PO='(^#0H@/'1R('-T>6QE/3-$)T9/3E0M4TE:13H@ M,7!X)SX-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG M;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B M;W1T;VT^#0H@/'`@<W1Y;&4],T0G0D]21$52+51/4#H@<F=B*#`L,"PP*2`Q M<'@@<V]L:60G/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B M;W1T;VT^#0H@/'`@<W1Y;&4],T0G0D]21$52+51/4#H@<F=B*#`L,"PP*2`Q M<'@@<V]L:60G/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT9#XF(WA!,#L\+W1D M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\ M=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z M(')G8B@P+#`L,"D@,7!X('-O;&ED)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\ M=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z M(')G8B@P+#`L,"D@,7!X('-O;&ED)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\ M=&0^)B-X03`[/"]T9#X-"B`\+W1R/@T*(#QT<B!B9V-O;&]R/3-$(T-#145& M1CX-"B`\=&0@=F%L:6=N/3-$=&]P/@T*(#QP('-T>6QE/3-$)TU!4D=)3BU, M1494.B`S96T[(%1%6%0M24Y$14Y4.B`M,65M)SX\9F]N="!S='EL93TS1"=& M3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CY4;W1A;"!R M97-E87)C:"!A;F0-"B!D979E;&]P;65N="!R979E;G5E(&9R;VT@07-T96QL M87,\+V9O;G0^/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\ M9F]N="!S:7IE/3-$,3XF(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@ M=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4 M:6UE<R!.97<@4F]M86XG('-I>F4],T0R/B0\+V9O;G0^/"]T9#X-"B`\=&0@ M=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^/&9O;G0@<W1Y;&4],T0G M1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^,S(L,SDQ M/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N M;W=R87`^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2 M;VUA;B<@<VEZ93TS1#(^)B-X03`[)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D M('9A;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF(WA!,#LF(WA!,#L\ M+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE M/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R/B0\ M+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG M:'0^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA M;B<@<VEZ93TS1#(^-BPT,34\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$ M8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#X\9F]N="!S='EL93TS1"=&3TY4+49! M34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXF(WA!,#LF(WA!,#L\ M+V9O;G0^/"]T9#X-"B`\+W1R/@T*(#QT<B!S='EL93TS1"=&3TY4+5-)6D4Z M(#%P>"<^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI M9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$ M8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(')G8B@P+#`L,"D@ M,W!X(&1O=6)L92<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS M1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B!R9V(H,"PP+#`I M(#-P>"!D;W5B;&4G/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT9#XF(WA!,#L\ M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X- M"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU4 M3U`Z(')G8B@P+#`L,"D@,W!X(&1O=6)L92<^)B-X03`[/"]P/@T*(#PO=&0^ M#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M M5$]0.B!R9V(H,"PP+#`I(#-P>"!D;W5B;&4G/B8C>$$P.SPO<#X-"B`\+W1D M/@T*(#QT9#XF(WA!,#L\+W1D/@T*(#PO='(^#0H@/"$M+2!%;F0@5&%B;&4@ M0F]D>2`M+3X\+W1A8FQE/@T*(#QP('-T>6QE/3-$)TU!4D=)3BU"3U143TTZ M(#!P>#L@34%21TE.+51/4#H@,3)P>#L@5$585"U)3D1%3E0Z(#0E)R!A;&EG M;CTS1&IU<W1I9GD^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S M($YE=R!2;VUA;B<@<VEZ93TS1#(^070@1&5C96UB97(F(WA!,#LS,2P@,C`Q M-"P@=&AE($-O;7!A;GD@:&%D("0S,RXV(&UI;&QI;VX@;V8-"B!D969E<G)E M9"!R979E;G5E('5N9&5R('1H92!!;65N9&5D($%S=&5L;&%S($%G<F5E;65N M="P@<F5F;&5C=&EN9PT*('1H92!U;G)E8V]G;FEZ960@<&]R=&EO;B!O9B!T M:&4@;&EC96YS92!R979E;G5E(&%N9"!P<F5P87EM96YT(&]N#0H@97AP96YS M97,@97AP96-T960@=&\@8F4@:6YC=7)R960@:6X@=&AE(&9I<G-T('%U87)T M97(@;V8-"B`R,#$U+CPO9F]N=#X\+W`^#0H@#0H@#0H@/"]D:78^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@(#PO=&%B;&4^#0H@(#PO M8F]D>3X-"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT4&%R=%\S.6,P96$V,E]C M,C`S7S0U.&9?.&,U,%\S9&-A-#4V838Y-3$-"D-O;G1E;G0M3&]C871I;VXZ M(&9I;&4Z+R\O0SHO,SEC,&5A-C)?8S(P,U\T-3AF7SAC-3!?,V1C830U-F$V M.34Q+U=O<FMS:&5E=',O4VAE970Q-2YH=&UL#0I#;VYT96YT+51R86YS9F5R M+45N8V]D:6YG.B!Q=6]T960M<')I;G1A8FQE#0I#;VYT96YT+51Y<&4Z('1E M>'0O:'1M;#L@8VAA<G-E=#TB=7,M87-C:6DB#0H-"CQH=&UL/@T*("`\:&5A M9#X-"B`@("`\345402!H='1P+65Q=6EV/3-$0V]N=&5N="U4>7!E(&-O;G1E M;G0],T0G=&5X="]H=&UL.R!C:&%R<V5T/75T9BTX)SX\<V-R:7!T('1Y<&4] M,T1T97AT+VIA=F%S8W)I<'0@<W)C/3-$4VAO=RYJ<SXO*B!$;R!.;W0@4F5M M;W9E(%1H:7,@0V]M;65N="`J+SPO<V-R:7!T/CPO:&5A9#X-"B`@/&)O9'D^ M#0H@("`@/'1A8FQE(&-L87-S/3-$<F5P;W)T(&ED/3-$240P14U%/@T*("`@ M("`@/'1R/@T*("`@("`@("`\=&@@8VQA<W,],T1T;"!C;VQS<&%N/3-$,2!R M;W=S<&%N/3-$,CX\<W1R;VYG/D]T:&5R(%)E<V5A<F-H(&%N9"!$979E;&]P M;65N="!2979E;G5E($%R<F%N9V5M96YT<SQB<CX\+W-T<F]N9SX\+W1H/@T* M("`@("`@("`\=&@@8VQA<W,],T1T:"!C;VQS<&%N/3-$,3XQ,B!-;VYT:',@ M16YD960\+W1H/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<CX-"B`@("`@("`@ M/'1H(&-L87-S/3-$=&@^1&5C+B`S,2P@,C`Q-#QB<CX\+W1H/@T*("`@("`@ M/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA M<W,],T1P;"!V86QI9VX],T1T;W`^/'-T<F]N9SY297-E87)C:"!A;F0@1&5V M96QO<&UE;G0@6T%B<W1R86-T73PO<W1R;VYG/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R M/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS M1'!L('9A;&EG;CTS1'1O<#Y/=&AE<B!297-E87)C:"!A;F0@1&5V96QO<&UE M;G0@4F5V96YU92!!<G)A;F=E;65N=',\+W1D/@T*("`@("`@("`\=&0@8VQA M<W,],T1T97AT/CQD:78^#0H@/'`@<W1Y;&4],T0G34%21TE.+4)/5%1/33H@ M,'!X.R!-05)'24XM5$]0.B`Q.'!X)SX\9F]N="!S='EL93TS1"=&3TY4+49! M34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CX\8CY.;W1E)B-X03`[ M."8C>$$P.R8C>#(P,30[#0H@3W1H97(@4F5S96%R8V@@86YD($1E=F5L;W!M M96YT(%)E=F5N=64@07)R86YG96UE;G1S/"]B/CPO9F]N=#X\+W`^#0H@/'`@ M<W1Y;&4],T0G34%21TE.+4)/5%1/33H@,'!X.R!-05)'24XM3$5&5#H@,B4[ M($U!4D=)3BU43U`Z(#9P>"<^#0H@/&9O;G0@<W1Y;&4],T0G1D].5"U&04U) M3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^/&(^/&D^1W)A;G1S/"]I M/CPO8CX\+V9O;G0^/"]P/@T*(#QP('-T>6QE/3-$)TU!4D=)3BU"3U143TTZ M(#!P>#L@34%21TE.+51/4#H@-G!X.R!415A4+4E.1$5.5#H@-"4G(&%L:6=N M/3-$:G5S=&EF>3X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@ M3F5W(%)O;6%N)R!S:7IE/3-$,CY);B`R,#$P+"!T:&4@3F%T:6]N86P@26YS M=&ET=71E(&]F($YE=7)O;&]G:6-A;"!$:7-O<F1E<G,@86YD#0H@4W1R;VME M<R`H)B-X,C`Q0SM.24Y$4R8C>#(P,40[*2!A=V%R9&5D('1O('1H92!#;VUP M86YY(&$-"B`D,BXX)B-X03`[;6EL;&EO;B!G<F%N="!T;R!S=7!P;W)T(')E M<V5A<F-H(&%N9"!D979E;&]P;65N="!O9@T*('1I<F%S96UT:78@9&ER96-T M960@=&\@=&AE('!O=&5N=&EA;"!T<F5A=&UE;G0@9F]R(&UY87-T:&5N:6$- M"B!G<F%V:7,@9F]R(&$@<&5R:6]D(&]F('5P('1O('1H<F5E('EE87)S+B!) M;B!397!T96UB97(@,C`Q,BP@=&AE#0H@3DE.1%,@87=A<F1E9"!T;R!U<R!A M;B!A9&1I=&EO;F%L("0P+C4@;6EL;&EO;B!U;F1E<B!A('-E<&%R871E#0H@ M9W)A;G0N($UA;F%G96UE;G0@9&5T97)M:6YE9"!T:&%T('1H92!#;VUP86YY M('=A<R!T:&4@<')I;F-I<&%L#0H@<&%R=&EC:7!A;G0@:6X@=&AE(&=R86YT M(&%R<F%N9V5M96YT<RP@86YD+"!A8V-O<F1I;F=L>2P@=&AE#0H@0V]M<&%N M>2!R96-O<F1E9"!A;6]U;G1S(&5A<FYE9"!U;F1E<B!T:&4@87)R86YG96UE M;G1S(&%S(')E=F5N=64N#0H@5&AE(&=R86YT<R!W97)E(&-O;7!L971E9"!I M;B!*=6YE(#(P,3,N/"]F;VYT/CPO<#X-"B`\<"!S='EL93TS1"=-05)'24XM M0D]45$]-.B`P<'@[($9/3E0M4TE:13H@,3)P>#L@34%21TE.+51/4#H@,'!X M)SX-"B`F(WA!,#L\+W`^#0H@/'`@<W1Y;&4],T0G34%21TE.+4)/5%1/33H@ M,'!X.R!-05)'24XM5$]0.B`P<'@[(%1%6%0M24Y$14Y4.B`T)2<@86QI9VX] M,T1J=7-T:69Y/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!. M97<@4F]M86XG('-I>F4],T0R/E1O=&%L(&=R86YT(')E=F5N=65S('=E<F4@ M87,@9F]L;&]W<R`H:6X@=&AO=7-A;F1S*3H\+V9O;G0^/"]P/@T*(#QP('-T M>6QE/3-$)TU!4D=)3BU"3U143TTZ(#!P>#L@1D].5"U325I%.B`Q,G!X.R!- M05)'24XM5$]0.B`P<'@G/@T*("8C>$$P.SPO<#X-"B`\=&%B;&4@<W1Y;&4] M,T0G0D]21$52+4-/3$Q!4%-%.B!C;VQL87!S92<@8V5L;'-P86-I;F<],T0P M(&-E;&QP861D:6YG/3-$,"!W:61T:#TS1#DR)2!A;&EG;CTS1&-E;G1E<B!B M;W)D97(],T0P/@T*(#QT<CX-"B`\=&0@=VED=&@],T0W.24^/"]T9#X-"B`\ M=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$-"4^/"]T9#X-"B`\=&0^/"]T M9#X-"B`\=&0^/"]T9#X-"B`\=&0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T M=&]M('=I9'1H/3-$-"4^/"]T9#X-"B`\=&0^/"]T9#X-"B`\=&0^/"]T9#X- M"B`\=&0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$-"4^ M/"]T9#X-"B`\=&0^/"]T9#X-"B`\=&0^/"]T9#X-"B`\=&0^/"]T9#X-"B`\ M+W1R/@T*(#QT<CX-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4] M,T0Q/B8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^ M/&9O;G0@<VEZ93TS1#$^)B-X03`[)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D M('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,7!X('-O;&ED)R!V M86QI9VX],T1B;W1T;VT@8V]L<W!A;CTS1#$P(&%L:6=N/3-$8V5N=&5R/CQF M;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I M>F4],T0Q/CQB/EEE87)S($5N9&5D/&)R("\^#0H@1&5C96UB97(F(WA!,#LS M,2P\+V(^/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N M="!S:7IE/3-$,3XF(WA!,#L\+V9O;G0^/"]T9#X-"B`\+W1R/@T*(#QT<CX- M"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C>$$P.SPO M9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<VEZ93TS M1#$^)B-X03`[)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('-T>6QE/3-$)T)/ M4D1%4BU"3U143TTZ(",P,#`P,#`@,7!X('-O;&ED)R!V86QI9VX],T1B;W1T M;VT@8V]L<W!A;CTS1#(@86QI9VX],T1C96YT97(^/&9O;G0@<W1Y;&4],T0G M1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#$^/&(^,C`Q M-#PO8CX\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT M('-I>F4],T0Q/B8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B M;W1T;VT^/&9O;G0@<VEZ93TS1#$^)B-X03`[)B-X03`[/"]F;VYT/CPO=&0^ M#0H@/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,7!X('-O M;&ED)R!V86QI9VX],T1B;W1T;VT@8V]L<W!A;CTS1#(@86QI9VX],T1C96YT M97(^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA M;B<@<VEZ93TS1#$^/&(^,C`Q,SPO8CX\+V9O;G0^/"]T9#X-"B`\=&0@=F%L M:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C>$$P.SPO9F]N=#X\+W1D M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<VEZ93TS1#$^)B-X03`[ M)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('-T>6QE/3-$)T)/4D1%4BU"3U14 M3TTZ(",P,#`P,#`@,7!X('-O;&ED)R!V86QI9VX],T1B;W1T;VT@8V]L<W!A M;CTS1#(@86QI9VX],T1C96YT97(^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U) M3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#$^/&(^,C`Q,CPO8CX\+V9O M;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q M/B8C>$$P.SPO9F]N=#X\+W1D/@T*(#PO='(^#0H@/'1R(&)G8V]L;W(],T0C M0T-%149&/@T*(#QT9"!V86QI9VX],T1T;W`^#0H@/'`@<W1Y;&4],T0G34%2 M1TE.+4Q%1E0Z(#%E;3L@5$585"U)3D1%3E0Z("TQ96TG/CQF;VYT('-T>6QE M/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R/DY) M3D13(&UY87-T:&5N:6$-"B!G<F%V:7,\+V9O;G0^/"]P/@T*(#PO=&0^#0H@ M/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF(WA!,#LF(WA! M,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS M1&YO=W)A<#X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W M(%)O;6%N)R!S:7IE/3-$,CXD/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS M1&)O='1O;2!N;W=R87`],T1N;W=R87`@86QI9VX],T1R:6=H=#X\9F]N="!S M='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$ M,CXF(W@R,#$T.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@ M;F]W<F%P/3-$;F]W<F%P/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4 M:6UE<R!.97<@4F]M86XG('-I>F4],T0R/B8C>$$P.R8C>$$P.SPO9F]N=#X\ M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<VEZ93TS1#$^)B-X M03`[)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\ M9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S M:7IE/3-$,CXD/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A M;&EG;CTS1')I9VAT/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE M<R!.97<@4F]M86XG('-I>F4],T0R/C8Y/"]F;VYT/CPO=&0^#0H@/'1D('9A M;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^/&9O;G0@<W1Y;&4],T0G M1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^)B-X03`[ M)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N M="!S:7IE/3-$,3XF(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L M:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE M<R!.97<@4F]M86XG('-I>F4],T0R/B0\+V9O;G0^/"]T9#X-"B`\=&0@=F%L M:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^/&9O;G0@<W1Y;&4],T0G1D]. M5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^,2PS,#@\+V9O M;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A M<#X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N M)R!S:7IE/3-$,CXF(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\+W1R/@T* M(#QT<CX-"B`\=&0@=F%L:6=N/3-$=&]P/@T*(#QP('-T>6QE/3-$)TU!4D=) M3BU,1494.B`Q96T[(%1%6%0M24Y$14Y4.B`M,65M)SX\9F]N="!S='EL93TS M1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CY/=&AE M<B!G<F%N=`T*(')E=F5N=64\+V9O;G0^/"]P/@T*(#PO=&0^#0H@/'1D('9A M;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF(WA!,#LF(WA!,#L\+V9O M;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$ M)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R/B8C>$$P M.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R M:6=H=#X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O M;6%N)R!S:7IE/3-$,CXW-3PO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B M;W1T;VT@;F]W<F%P/3-$;F]W<F%P/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%- M24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R/B8C>$$P.R8C>$$P.SPO M9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<VEZ93TS M1#$^)B-X03`[)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O M='1O;3X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O M;6%N)R!S:7IE/3-$,CXF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N M/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^/&9O;G0@<W1Y;&4],T0G1D].5"U& M04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^,C4\+V9O;G0^/"]T M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#X\9F]N M="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE M/3-$,CXF(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$ M8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P/CQF;VYT M('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4] M,T0R/B8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@ M;F]W<F%P/3-$;F]W<F%P(&%L:6=N/3-$<FEG:'0^/&9O;G0@<W1Y;&4],T0G M1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^)B-X,C`Q M-#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS M1&YO=W)A<#X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W M(%)O;6%N)R!S:7IE/3-$,CXF(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\ M+W1R/@T*(#QT<B!S='EL93TS1"=&3TY4+5-)6D4Z(#%P>"<^#0H@/'1D('9A M;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X M03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T M>6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@,7!X('-O;&ED)SXF(WA!,#L\ M+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE M/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@,7!X('-O;&ED)SXF(WA!,#L\+W`^ M#0H@/"]T9#X-"B`\=&0^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T M=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X- M"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B`C,#`P,#`P(#%P>"!S;VQI9"<^ M)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\ M<"!S='EL93TS1"="3U)$15(M5$]0.B`C,#`P,#`P(#%P>"!S;VQI9"<^)B-X M03`[/"]P/@T*(#PO=&0^#0H@/'1D/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG M;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B M;W1T;VT^#0H@/'`@<W1Y;&4],T0G0D]21$52+51/4#H@(S`P,#`P,"`Q<'@@ M<V]L:60G/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T M;VT^#0H@/'`@<W1Y;&4],T0G0D]21$52+51/4#H@(S`P,#`P,"`Q<'@@<V]L M:60G/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT9#XF(WA!,#L\+W1D/@T*(#PO M='(^#0H@/'1R(&)G8V]L;W(],T0C0T-%149&/@T*(#QT9"!V86QI9VX],T1T M;W`^#0H@/'`@<W1Y;&4],T0G34%21TE.+4Q%1E0Z(#)E;3L@5$585"U)3D1% M3E0Z("TQ96TG/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!. M97<@4F]M86XG('-I>F4],T0R/E1O=&%L(&=R86YT#0H@<F5V96YU93PO9F]N M=#X\+W`^#0H@/"]T9#X-"B`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`[)B-X03`[/"]F;VYT/CPO=&0^ M#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=&3TY4+49! M34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXD/"]F;VYT/CPO=&0^ M#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/CQF;VYT('-T M>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R M/CDT/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`] M,T1N;W=R87`^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE M=R!2;VUA;B<@<VEZ93TS1#(^)B-X03`[)B-X03`[/"]F;VYT/CPO=&0^#0H@ M/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF(WA!,#LF(WA! M,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T M>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R M/B0\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$ M<FEG:'0^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2 M;VUA;B<@<VEZ93TS1#(^,2PS,#@\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N M/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#X\9F]N="!S='EL93TS1"=&3TY4 M+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXF(WA!,#LF(WA! M,#L\+V9O;G0^/"]T9#X-"B`\+W1R/@T*(#QT<B!S='EL93TS1"=&3TY4+5-) M6D4Z(#%P>"<^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V M86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N M/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@ M,W!X(&1O=6)L92<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS M1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B`C,#`P,#`P(#-P M>"!D;W5B;&4G/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT9#XF(WA!,#L\+W1D M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\ M=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z M(",P,#`P,#`@,W!X(&1O=6)L92<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D M('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B`C M,#`P,#`P(#-P>"!D;W5B;&4G/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT9#XF M(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[ M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/ M4D1%4BU43U`Z(",P,#`P,#`@,W!X(&1O=6)L92<^)B-X03`[/"]P/@T*(#PO M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$ M15(M5$]0.B`C,#`P,#`P(#-P>"!D;W5B;&4G/B8C>$$P.SPO<#X-"B`\+W1D M/@T*(#QT9#XF(WA!,#L\+W1D/@T*(#PO='(^#0H@/"]T86)L93X-"B`\<"!S M='EL93TS1"=-05)'24XM0D]45$]-.B`P<'@[($U!4D=)3BU,1494.B`R)3L@ M34%21TE.+51/4#H@,3AP>"<^#0H@/&9O;G0@<W1Y;&4],T0G1D].5"U&04U) M3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^/&(^/&D^1VQO8F%L#0H@ M0FQO;V0@5&AE<F%P975T:6-S+"!);F,N("@F(W@R,#%#.T=L;V)A;`T*($)L M;V]D)B-X,C`Q1#LI/"]I/CPO8CX\+V9O;G0^/"]P/@T*(#QP('-T>6QE/3-$ M)TU!4D=)3BU"3U143TTZ(#!P>#L@34%21TE.+51/4#H@-G!X.R!415A4+4E. M1$5.5#H@-"4G(&%L:6=N/3-$:G5S=&EF>3X\9F]N="!S='EL93TS1"=&3TY4 M+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CY);B!/8W1O8F5R M(#(P,3$L('1H92!#;VUP86YY(&5N=&5R960@:6YT;R!A(&-O;&QA8F]R871I M;VX-"B!A9W)E96UE;G0@=VET:"!';&]B86P@0FQO;V0@5&AE<F%P975T:6-S M+"!);F,N("AF;W)M97)L>2!C86QL960-"B!';&]B86P@0FQO;V0@5&%R9V5T M:6YG+"!);F,N*2`H)B-X,C`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`R,#$R+B!4:&4@0V]M M<&%N>0T*('=A<R!T:&4@<')I;6%R>2!O8FQI9V]R(&EN('1H92!C;VQL86)O M<F%T:6]N(&%R<F%N9V5M96YT+"!A;F0-"B!A8V-O<F1I;F=L>2P@=&AE($-O M;7!A;GD@<F5C;W)D960@97AP96YS92!R96EM8G5R<V5M96YT<R!F<F]M#0H@ M1VQO8F%L($)L;V]D(&%S(')E<V5A<F-H(&%N9"!D979E;&]P;65N="!R979E M;G5E+CPO9F]N=#X\+W`^#0H@/'`@<W1Y;&4],T0G34%21TE.+4)/5%1/33H@ M,'!X.R!-05)'24XM5$]0.B`Q,G!X.R!415A4+4E.1$5.5#H@-"4G(&%L:6=N M/3-$:G5S=&EF>3X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@ M3F5W(%)O;6%N)R!S:7IE/3-$,CY297-E87)C:"!A;F0@9&5V96QO<&UE;G0@ M<F5V96YU92!F<F]M($=L;V)A;"!";&]O9"!W87,@87,-"B!F;VQL;W=S("AI M;B!T:&]U<V%N9',I.CPO9F]N=#X\+W`^#0H@/'`@<W1Y;&4],T0G34%21TE. M+4)/5%1/33H@,'!X.R!&3TY4+5-)6D4Z(#$R<'@[($U!4D=)3BU43U`Z(#!P M>"<^#0H@)B-X03`[/"]P/@T*(#QT86)L92!S='EL93TS1"="3U)$15(M0T], M3$%04T4Z(&-O;&QA<'-E)R!C96QL<W!A8VEN9STS1#`@8V5L;'!A9&1I;F<] M,T0P('=I9'1H/3-$.3(E(&%L:6=N/3-$8V5N=&5R(&)O<F1E<CTS1#`^#0H@ M/'1R/@T*(#QT9"!W:61T:#TS1#<Y)3X\+W1D/@T*(#QT9"!V86QI9VX],T1B M;W1T;VT@=VED=&@],T0T)3X\+W1D/@T*(#QT9#X\+W1D/@T*(#QT9#X\+W1D M/@T*(#QT9#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@=VED=&@],T0T M)3X\+W1D/@T*(#QT9#X\+W1D/@T*(#QT9#X\+W1D/@T*(#QT9#X\+W1D/@T* M(#QT9"!V86QI9VX],T1B;W1T;VT@=VED=&@],T0T)3X\+W1D/@T*(#QT9#X\ M+W1D/@T*(#QT9#X\+W1D/@T*(#QT9#X\+W1D/@T*(#PO='(^#0H@/'1R/@T* M(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<VEZ93TS1#$^)B-X03`[/"]F M;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$ M,3XF(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@<W1Y;&4],T0G0D]2 M1$52+4)/5%1/33H@(S`P,#`P,"`Q<'@@<V]L:60G('9A;&EG;CTS1&)O='1O M;2!C;VQS<&%N/3-$,3`@86QI9VX],T1C96YT97(^/&9O;G0@<W1Y;&4],T0G M1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#$^/&(^665A M<G,F(WA!,#M%;F1E9"8C>$$P.T1E8V5M8F5R)B-X03`[,S$L/"]B/CPO9F]N M=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<VEZ93TS1#$^ M)B-X03`[/"]F;VYT/CPO=&0^#0H@/"]T<CX-"B`\='(^#0H@/'1D('9A;&EG M;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF(WA!,#L\+V9O;G0^/"]T9#X- M"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C>$$P.R8C M>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!S='EL93TS1"="3U)$15(M0D]45$]- M.B`C,#`P,#`P(#%P>"!S;VQI9"<@=F%L:6=N/3-$8F]T=&]M(&-O;'-P86X] M,T0R(&%L:6=N/3-$8V5N=&5R/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9 M.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0Q/CQB/C(P,30\+V(^/"]F;VYT M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF M(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT M('-I>F4],T0Q/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!S='EL M93TS1"="3U)$15(M0D]45$]-.B`C,#`P,#`P(#%P>"!S;VQI9"<@=F%L:6=N M/3-$8F]T=&]M(&-O;'-P86X],T0R(&%L:6=N/3-$8V5N=&5R/CQF;VYT('-T M>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0Q M/CQB/C(P,3,\+V(^/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O M;3X\9F]N="!S:7IE/3-$,3XF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L M:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C>$$P.R8C>$$P.SPO9F]N M=#X\+W1D/@T*(#QT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B`C,#`P,#`P M(#%P>"!S;VQI9"<@=F%L:6=N/3-$8F]T=&]M(&-O;'-P86X],T0R(&%L:6=N M/3-$8V5N=&5R/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!. M97<@4F]M86XG('-I>F4],T0Q/CQB/C(P,3(\+V(^/"]F;VYT/CPO=&0^#0H@ M/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF(WA!,#L\+V9O M;G0^/"]T9#X-"B`\+W1R/@T*(#QT<B!B9V-O;&]R/3-$(T-#145&1CX-"B`\ M=&0@=F%L:6=N/3-$=&]P/@T*(#QP('-T>6QE/3-$)TU!4D=)3BU,1494.B`Q M96T[(%1%6%0M24Y$14Y4.B`M,65M)SX\9F]N="!S='EL93TS1"=&3TY4+49! M34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CY%>'!E;G-E(')E:6UB M=7)S96UE;G1S(&9R;VT-"B!';&]B86P@0FQO;V0\+V9O;G0^/"]P/@T*(#PO M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF(WA! M,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO M=W)A<#TS1&YO=W)A<#X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM M97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXD/"]F;VYT/CPO=&0^#0H@/'1D('9A M;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`@86QI9VX],T1R:6=H=#X\ M9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S M:7IE/3-$,CXF(W@R,#$T.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B M;W1T;VT@;F]W<F%P/3-$;F]W<F%P/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%- M24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R/B8C>$$P.R8C>$$P.SPO M9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<VEZ93TS M1#$^)B-X03`[)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O M='1O;3X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O M;6%N)R!S:7IE/3-$,CXD/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O M='1O;2!A;&EG;CTS1')I9VAT/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9 M.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R/C$T/"]F;VYT/CPO=&0^#0H@ M/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^/&9O;G0@<W1Y M;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^ M)B-X03`[)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O M;3X\9F]N="!S:7IE/3-$,3XF(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\ M=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9 M.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R/B0\+V9O;G0^/"]T9#X-"B`\ M=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^/&9O;G0@<W1Y;&4] M,T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^,2PT M-SD\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS M1&YO=W)A<#X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W M(%)O;6%N)R!S:7IE/3-$,CXF(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\ M+W1R/@T*(#QT<B!S='EL93TS1"=&3TY4+5-)6D4Z(#%P>"<^#0H@/'1D('9A M;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X M03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T M>6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@,W!X(&1O=6)L92<^)B-X03`[ M/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL M93TS1"="3U)$15(M5$]0.B`C,#`P,#`P(#-P>"!D;W5B;&4G/B8C>$$P.SPO M<#X-"B`\+W1D/@T*(#QT9#XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B M;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@,W!X(&1O=6)L M92<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X- M"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B`C,#`P,#`P(#-P>"!D;W5B;&4G M/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT9#XF(WA!,#L\+W1D/@T*(#QT9"!V M86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N M/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@ M,W!X(&1O=6)L92<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS M1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B`C,#`P,#`P(#-P M>"!D;W5B;&4G/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT9#XF(WA!,#L\+W1D M/@T*(#PO='(^#0H@/"]T86)L93X-"B`\<"!S='EL93TS1"=-05)'24XM0D]4 M5$]-.B`P<'@[($U!4D=)3BU,1494.B`R)3L@34%21TE.+51/4#H@,3AP>"<^ M#0H@/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA M;B<@<VEZ93TS1#(^/&(^/&D^37EO2V%R9&EA+"!);F,N/"]I/CPO8CX\+V9O M;G0^/"]P/@T*(#QP('-T>6QE/3-$)TU!4D=)3BU"3U143TTZ(#!P>#L@34%2 M1TE.+51/4#H@-G!X.R!415A4+4E.1$5.5#H@-"4G(&%L:6=N/3-$:G5S=&EF M>3X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N M)R!S:7IE/3-$,CY);B!!=6=U<W0@,C`Q,BP@=&AE($-O;7!A;GD@96YT97)E M9"!I;G1O(&$@8V]L;&%B;W)A=&EO;@T*(&%G<F5E;65N="!W:71H($UY;TMA M<F1I82P@26YC+B!5;F1E<B!A;B!A9W)E960@<F5S96%R8V@@<&QA;BP-"B!S M8VEE;G1I<W1S(&9R;VT@37EO2V%R9&EA(&%N9"!O=7(@1E1%<R!C;VYD=6-T M(')E<V5A<F-H(&9O8W5S960@;VX-"B!S;6%L;"!M;VQE8W5L92!T:&5R87!E M=71I8W,@=&AA="!I;FAI8FET(&-A<F1I86,@<V%R8V]M97)E#0H@<')O=&5I M;G,N(%1H92!#;VUP86YY('!R;W9I9&5D('1O($UY;TMA<F1I82!A8V-E<W,@ M=&\@8V5R=&%I;@T*(')E<V5A<F-H(&9A8VEL:71I97,L(&%N9"!C;VYT:6YU M97,@=&\@<')O=FED92!&5$5S(&%N9"!O=&AE<@T*(')E<V]U<F-E<R!A="!A M9W)E960@<F5I;6)U<G-E;65N="!R871E<R!T:&%T(&%P<')O>&EM871E(&]U M<B!C;W-T<RX-"B!4:&4@0V]M<&%N>2!I<R!T:&4@<')I;6%R>2!O8FQI9V]R M(&EN('1H92!C;VQL86)O<F%T:6]N#0H@87)R86YG96UE;G0L(&%N9"!A8V-O M<F1I;F=L>2P@=&AE($-O;7!A;GD@<F5C;W)D<R!E>'!E;G-E#0H@<F5I;6)U M<G-E;65N=',@9G)O;2!->6]+87)D:6$@87,@<F5S96%R8V@@86YD(&1E=F5L M;W!M96YT(')E=F5N=64N#0H@5&AE(')E<V5A<F-H('!L86X@=&5R;6EN871E M9"!A<R!P;&%N;F5D(&EN($%U9W5S="`R,#$S+CPO9F]N=#X\+W`^#0H@/'`@ M<W1Y;&4],T0G34%21TE.+4)/5%1/33H@,'!X.R!-05)'24XM5$]0.B`Q,G!X M.R!415A4+4E.1$5.5#H@-"4G(&%L:6=N/3-$:G5S=&EF>3X\9F]N="!S='EL M93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CY2 M97-E87)C:"!A;F0@9&5V96QO<&UE;G0@<F5V96YU92!F<F]M($UY;TMA<F1I M82!W87,@87,@9F]L;&]W<PT*("AI;B!T:&]U<V%N9',I.CPO9F]N=#X\+W`^ M#0H@/'`@<W1Y;&4],T0G34%21TE.+4)/5%1/33H@,'!X.R!&3TY4+5-)6D4Z M(#$R<'@[($U!4D=)3BU43U`Z(#!P>"<^#0H@)B-X03`[/"]P/@T*(#QT86)L M92!S='EL93TS1"="3U)$15(M0T],3$%04T4Z(&-O;&QA<'-E)R!C96QL<W!A M8VEN9STS1#`@8V5L;'!A9&1I;F<],T0P('=I9'1H/3-$.3(E(&%L:6=N/3-$ M8V5N=&5R(&)O<F1E<CTS1#`^#0H@/'1R/@T*(#QT9"!W:61T:#TS1#<W)3X\ M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@=VED=&@],T0T)3X\+W1D/@T* M(#QT9#X\+W1D/@T*(#QT9#X\+W1D/@T*(#QT9#X\+W1D/@T*(#QT9"!V86QI M9VX],T1B;W1T;VT@=VED=&@],T0T)3X\+W1D/@T*(#QT9#X\+W1D/@T*(#QT M9#X\+W1D/@T*(#QT9#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@=VED M=&@],T0T)3X\+W1D/@T*(#QT9#X\+W1D/@T*(#QT9#X\+W1D/@T*(#QT9#X\ M+W1D/@T*(#PO='(^#0H@/'1R/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O M;G0@<VEZ93TS1#$^)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS M1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF(WA!,#LF(WA!,#L\+V9O;G0^/"]T M9#X-"B`\=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@(S`P,#`P,"`Q<'@@ M<V]L:60G('9A;&EG;CTS1&)O='1O;2!C;VQS<&%N/3-$,3`@86QI9VX],T1C M96YT97(^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2 M;VUA;B<@<VEZ93TS1#$^/&(^665A<G,F(WA!,#M%;F1E9"8C>$$P.T1E8V5M M8F5R)B-X03`[,S$L/"]B/CPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B M;W1T;VT^/&9O;G0@<VEZ93TS1#$^)B-X03`[/"]F;VYT/CPO=&0^#0H@/"]T M<CX-"B`\='(^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$ M,3XF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF M;VYT('-I>F4],T0Q/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!S M='EL93TS1"="3U)$15(M0D]45$]-.B`C,#`P,#`P(#%P>"!S;VQI9"<@=F%L M:6=N/3-$8F]T=&]M(&-O;'-P86X],T0R(&%L:6=N/3-$8V5N=&5R/CQF;VYT M('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4] M,T0Q/CQB/C(P,30\+V(^/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O M='1O;3X\9F]N="!S:7IE/3-$,3XF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@ M=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C>$$P.R8C>$$P.SPO M9F]N=#X\+W1D/@T*(#QT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B`C,#`P M,#`P(#%P>"!S;VQI9"<@=F%L:6=N/3-$8F]T=&]M(&-O;'-P86X],T0R(&%L M:6=N/3-$8V5N=&5R/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE M<R!.97<@4F]M86XG('-I>F4],T0Q/CQB/C(P,3,\+V(^/"]F;VYT/CPO=&0^ M#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF(WA!,#L\ M+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4] M,T0Q/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!S='EL93TS1"=" M3U)$15(M0D]45$]-.B`C,#`P,#`P(#%P>"!S;VQI9"<@=F%L:6=N/3-$8F]T M=&]M(&-O;'-P86X],T0R(&%L:6=N/3-$8V5N=&5R/CQF;VYT('-T>6QE/3-$ M)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0Q/CQB/C(P M,3(\+V(^/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N M="!S:7IE/3-$,3XF(WA!,#L\+V9O;G0^/"]T9#X-"B`\+W1R/@T*(#QT<B!B M9V-O;&]R/3-$(T-#145&1CX-"B`\=&0@=F%L:6=N/3-$=&]P/@T*(#QP('-T M>6QE/3-$)TU!4D=)3BU,1494.B`Q96T[(%1%6%0M24Y$14Y4.B`M,65M)SX\ M9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S M:7IE/3-$,CY297-E87)C:"!A;F0@9&5V96QO<&UE;G0-"B!M:6QE<W1O;F4@ M9F5E<SPO9F]N=#X\+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M M/CQF;VYT('-I>F4],T0Q/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT M9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ M(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^)#PO9F]N=#X\+W1D/@T*(#QT M9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS M1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXQ,#`\ M+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO M=W)A<#X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O M;6%N)R!S:7IE/3-$,CXF(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@ M=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C>$$P.R8C>$$P.SPO M9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W M<F%P/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M M86XG('-I>F4],T0R/B0\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T M=&]M(&YO=W)A<#TS1&YO=W)A<"!A;&EG;CTS1')I9VAT/CQF;VYT('-T>6QE M/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R/B8C M>#(P,30[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R M87`],T1N;W=R87`^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S M($YE=R!2;VUA;B<@<VEZ93TS1#(^)B-X03`[)B-X03`[/"]F;VYT/CPO=&0^ M#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF(WA!,#LF M(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A M<#TS1&YO=W)A<#X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@ M3F5W(%)O;6%N)R!S:7IE/3-$,CXD/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG M;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`@86QI9VX],T1R:6=H=#X\9F]N M="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE M/3-$,CXF(W@R,#$T.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T M;VT@;F]W<F%P/3-$;F]W<F%P/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9 M.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R/B8C>$$P.R8C>$$P.SPO9F]N M=#X\+W1D/@T*(#PO='(^#0H@/'1R/@T*(#QT9"!V86QI9VX],T1T;W`^#0H@ M/'`@<W1Y;&4],T0G34%21TE.+4Q%1E0Z(#%E;3L@5$585"U)3D1%3E0Z("TQ M96TG/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M M86XG('-I>F4],T0R/D5X<&5N<V4@<F5I;6)U<G-E;65N=',@9G)O;0T*($UY M;TMA<F1I83PO9F]N=#X\+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T M=&]M/CQF;VYT('-I>F4],T0Q/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T* M(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P/CQF;VYT('-T M>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R M/B8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W M<F%P/3-$;F]W<F%P(&%L:6=N/3-$<FEG:'0^/&9O;G0@<W1Y;&4],T0G1D]. M5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^)B-X,C`Q-#L\ M+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO M=W)A<#X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O M;6%N)R!S:7IE/3-$,CXF(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@ M=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C>$$P.R8C>$$P.SPO M9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<W1Y;&4] M,T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^)B-X M03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS M1')I9VAT/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@ M4F]M86XG('-I>F4],T0R/C$L,#(T/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG M;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^/&9O;G0@<W1Y;&4],T0G1D]. M5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^)B-X03`[)B-X M03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S M:7IE/3-$,3XF(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N M/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!. M97<@4F]M86XG('-I>F4],T0R/B8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V M86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS1"=& M3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXU.34\+V9O M;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A M<#X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N M)R!S:7IE/3-$,CXF(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\+W1R/@T* M(#QT<B!S='EL93TS1"=&3TY4+5-)6D4Z(#%P>"<^#0H@/'1D('9A;&EG;CTS M1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X M03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$ M)T)/4D1%4BU43U`Z(",P,#`P,#`@,7!X('-O;&ED)SXF(WA!,#L\+W`^#0H@ M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/ M4D1%4BU43U`Z(",P,#`P,#`@,7!X('-O;&ED)SXF(WA!,#L\+W`^#0H@/"]T M9#X-"B`\=&0^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C M>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S M='EL93TS1"="3U)$15(M5$]0.B`C,#`P,#`P(#%P>"!S;VQI9"<^)B-X03`[ M/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL M93TS1"="3U)$15(M5$]0.B`C,#`P,#`P(#%P>"!S;VQI9"<^)B-X03`[/"]P M/@T*(#PO=&0^#0H@/'1D/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O M='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^ M#0H@/'`@<W1Y;&4],T0G0D]21$52+51/4#H@(S`P,#`P,"`Q<'@@<V]L:60G M/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@ M/'`@<W1Y;&4],T0G0D]21$52+51/4#H@(S`P,#`P,"`Q<'@@<V]L:60G/B8C M>$$P.SPO<#X-"B`\+W1D/@T*(#QT9#XF(WA!,#L\+W1D/@T*(#PO='(^#0H@ M/'1R(&)G8V]L;W(],T0C0T-%149&/@T*(#QT9"!V86QI9VX],T1T;W`^#0H@ M/'`@<W1Y;&4],T0G34%21TE.+4Q%1E0Z(#%E;3L@5$585"U)3D1%3E0Z("TQ M96TG/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M M86XG('-I>F4],T0R/E)E<V5A<F-H(&%N9"!D979E;&]P;65N=`T*(')E=F5N M=64@9G)O;2!->6]K87)D:6$\+V9O;G0^/"]P/@T*(#PO=&0^#0H@/'1D('9A M;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF(WA!,#LF(WA!,#L\+V9O M;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$ M)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R/B0\+V9O M;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^ M/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@ M<VEZ93TS1#(^,3`P/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O M;2!N;W=R87`],T1N;W=R87`^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ M(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^)B-X03`[)B-X03`[/"]F;VYT M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF M(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M M/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG M('-I>F4],T0R/B0\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M M(&%L:6=N/3-$<FEG:'0^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I M;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^,2PP,C0\+V9O;G0^/"]T9#X-"B`\ M=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#X\9F]N="!S='EL M93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXF M(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M M/CQF;VYT('-I>F4],T0Q/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT M9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ M(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^)#PO9F]N=#X\+W1D/@T*(#QT M9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS M1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXU.34\ M+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO M=W)A<#X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O M;6%N)R!S:7IE/3-$,CXF(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\+W1R M/@T*(#QT<B!S='EL93TS1"=&3TY4+5-)6D4Z(#%P>"<^#0H@/'1D('9A;&EG M;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[ M)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE M/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@,W!X(&1O=6)L92<^)B-X03`[/"]P M/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS M1"="3U)$15(M5$]0.B`C,#`P,#`P(#-P>"!D;W5B;&4G/B8C>$$P.SPO<#X- M"B`\+W1D/@T*(#QT9#XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T M;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T* M(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@,W!X(&1O=6)L92<^ M)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\ M<"!S='EL93TS1"="3U)$15(M5$]0.B`C,#`P,#`P(#-P>"!D;W5B;&4G/B8C M>$$P.SPO<#X-"B`\+W1D/@T*(#QT9#XF(WA!,#L\+W1D/@T*(#QT9"!V86QI M9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$ M8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@,W!X M(&1O=6)L92<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O M='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B`C,#`P,#`P(#-P>"!D M;W5B;&4G/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT9#XF(WA!,#L\+W1D/@T* M(#PO='(^#0H@/"]T86)L93X-"B`\+V1I=CX\<W!A;CX\+W-P86X^/"]T9#X- M"B`@("`@(#PO='(^#0H@("`@/"]T86)L93X-"B`@/"]B;V1Y/@T*/"]H=&UL M/@T*#0HM+2TM+2T]7TYE>'1087)T7S,Y8S!E838R7V,R,#-?-#4X9E\X8S4P M7S-D8V$T-39A-CDU,0T*0V]N=&5N="U,;V-A=&EO;CH@9FEL93HO+R]#.B\S M.6,P96$V,E]C,C`S7S0U.&9?.&,U,%\S9&-A-#4V838Y-3$O5V]R:W-H965T M<R]3:&5E=#$V+FAT;6P-"D-O;G1E;G0M5')A;G-F97(M16YC;V1I;F<Z('%U M;W1E9"UP<FEN=&%B;&4-"D-O;G1E;G0M5'EP93H@=&5X="]H=&UL.R!C:&%R M<V5T/2)U<RUA<V-I:2(-"@T*/&AT;6P^#0H@(#QH96%D/@T*("`@(#Q-151! M(&AT='`M97%U:78],T1#;VYT96YT+51Y<&4@8V]N=&5N=#TS1"=T97AT+VAT M;6P[(&-H87)S970]=71F+3@G/CQS8W)I<'0@='EP93TS1'1E>'0O:F%V87-C M<FEP="!S<F,],T13:&]W+FIS/B\J($1O($YO="!296UO=F4@5&AI<R!#;VUM M96YT("HO/"]S8W)I<'0^/"]H96%D/@T*("`\8F]D>3X-"B`@("`\=&%B;&4@ M8VQA<W,],T1R97!O<G0@:60],T1)1#!%344^#0H@("`@("`\='(^#0H@("`@ M("`@(#QT:"!C;&%S<STS1'1L(&-O;'-P86X],T0Q(')O=W-P86X],T0R/CQS M=')O;F<^1&5B=#QB<CX\+W-T<F]N9SX\+W1H/@T*("`@("`@("`\=&@@8VQA M<W,],T1T:"!C;VQS<&%N/3-$,3XQ,B!-;VYT:',@16YD960\+W1H/@T*("`@ M("`@/"]T<CX-"B`@("`@(#QT<CX-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^ M1&5C+B`S,2P@,C`Q-#QB<CX\+W1H/@T*("`@("`@/"]T<CX-"B`@("`@(#QT M<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX] M,T1T;W`^/'-T<F]N9SY$96)T($1I<V-L;W-U<F4@6T%B<W1R86-T73PO<W1R M;VYG/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^ M#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y$96)T/"]T M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\9&EV/@T*(#QP('-T>6QE M/3-$)TU!4D=)3BU"3U143TTZ(#!P>#L@34%21TE.+51/4#H@,3AP>"<^/&9O M;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ M93TS1#(^/&(^3F]T928C>$$P.SDF(WA!,#LF(W@R,#$T.PT*($1E8G0\+V(^ M/"]F;VYT/CPO<#X-"B`\<"!S='EL93TS1"=-05)'24XM0D]45$]-.B`P<'@[ M($U!4D=)3BU43U`Z(#9P>#L@5$585"U)3D1%3E0Z(#0E)R!A;&EG;CTS1&IU M<W1I9GD^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2 M;VUA;B<@<VEZ93TS1#(^26X@07!R:6P@,C`P-BP@=&AE($-O;7!A;GD@96YT M97)E9"!I;G1O(&%N(&5Q=6EP;65N="!F:6YA;F-I;F<-"B!A9W)E96UE;G0@ M=VET:"!'12!#87!I=&%L+B!!<R!O9B!$96-E;6)E<B8C>$$P.S,Q+"`R,#$Q M+"!T:&4-"B!B86QA;F-E(&]F(&5Q=6EP;65N="!L;V%N<R!O=71S=&%N9&EN M9R!U;F1E<B!T:&ES(&QI;F4@=V%S#0H@)#$U,BPP,#`N(%1H92!#;VUP86YY M(')E<&%I9"!T:&4@<F5M86EN:6YG(&]U='-T86YD:6YG(&5Q=6EP;65N=`T* M(&9I;F%N8VEN9R!D96)T(&EN($UA<F-H(#(P,3(@86YD(&YO(&9U<G1H97(@ M9G5N9',@87)E(&%V86EL86)L90T*('5N9&5R('1H:7,@;&EN92!O9B!C<F5D M:70N/"]F;VYT/CPO<#X-"B`\<"!S='EL93TS1"=-05)'24XM0D]45$]-.B`P M<'@[($U!4D=)3BU,1494.B`R)3L@34%21TE.+51/4#H@,3AP>"<^#0H@/&9O M;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ M93TS1#(^/&(^/&D^26YT97)E<W0-"B!%>'!E;G-E/"]I/CPO8CX\+V9O;G0^ M/"]P/@T*(#QP('-T>6QE/3-$)TU!4D=)3BU"3U143TTZ(#!P>#L@34%21TE. M+51/4#H@-G!X.R!415A4+4E.1$5.5#H@-"4G(&%L:6=N/3-$:G5S=&EF>3X\ M9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S M:7IE/3-$,CY4;W1A;"!I;G1E<F5S="!E>'!E;G-E(&EN8W5R<F5D(&)Y('1H M92!#;VUP86YY('=A<R!A<R!F;VQL;W=S#0H@*&EN('1H;W5S86YD<RDZ/"]F M;VYT/CPO<#X-"B`\<"!S='EL93TS1"=-05)'24XM0D]45$]-.B`P<'@[($9/ M3E0M4TE:13H@,3)P>#L@34%21TE.+51/4#H@,'!X)SX-"B`F(WA!,#L\+W`^ M#0H@/'1A8FQE('-T>6QE/3-$)T)/4D1%4BU#3TQ,05!313H@8V]L;&%P<V4G M(&-E;&QS<&%C:6YG/3-$,"!C96QL<&%D9&EN9STS1#`@=VED=&@],T0Y,B4@ M86QI9VX],T1C96YT97(@8F]R9&5R/3-$,#X-"B`\='(^#0H@/'1D('=I9'1H M/3-$-S<E/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#8E M/CPO=&0^#0H@/'1D/CPO=&0^#0H@/'1D/CPO=&0^#0H@/'1D/CPO=&0^#0H@ M/'1D('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#8E/CPO=&0^#0H@/'1D/CPO M=&0^#0H@/'1D/CPO=&0^#0H@/'1D/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O M='1O;2!W:61T:#TS1#8E/CPO=&0^#0H@/'1D/CPO=&0^#0H@/'1D/CPO=&0^ M#0H@/'1D/CPO=&0^#0H@/"]T<CX-"B`\='(^#0H@/'1D('9A;&EG;CTS1&)O M='1O;3X\9F]N="!S:7IE/3-$,3XF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@ M=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C>$$P.R8C>$$P.SPO M9F]N=#X\+W1D/@T*(#QT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B`C,#`P M,#`P(#%P>"!S;VQI9"<@=F%L:6=N/3-$8F]T=&]M(&-O;'-P86X],T0Q,"!A M;&EG;CTS1&-E;G1E<CX\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM M97,@3F5W(%)O;6%N)R!S:7IE/3-$,3X\8CY996%R<R8C>$$P.T5N9&5D)B-X M03`[1&5C96UB97(F(WA!,#LS,2P\+V(^/"]F;VYT/CPO=&0^#0H@/'1D('9A M;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF(WA!,#L\+V9O;G0^/"]T M9#X-"B`\+W1R/@T*(#QT<CX-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT M('-I>F4],T0Q/B8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B M;W1T;VT^/&9O;G0@<VEZ93TS1#$^)B-X03`[)B-X03`[/"]F;VYT/CPO=&0^ M#0H@/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,7!X('-O M;&ED)R!V86QI9VX],T1B;W1T;VT@8V]L<W!A;CTS1#(@86QI9VX],T1C96YT M97(^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA M;B<@<VEZ93TS1#$^/&(^,C`Q-#PO8CX\+V9O;G0^/"]T9#X-"B`\=&0@=F%L M:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C>$$P.SPO9F]N=#X\+W1D M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<VEZ93TS1#$^)B-X03`[ M)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('-T>6QE/3-$)T)/4D1%4BU"3U14 M3TTZ(",P,#`P,#`@,7!X('-O;&ED)R!V86QI9VX],T1B;W1T;VT@8V]L<W!A M;CTS1#(@86QI9VX],T1C96YT97(^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U) M3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#$^/&(^,C`Q,SPO8CX\+V9O M;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q M/B8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O M;G0@<VEZ93TS1#$^)B-X03`[)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('-T M>6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,7!X('-O;&ED)R!V86QI M9VX],T1B;W1T;VT@8V]L<W!A;CTS1#(@86QI9VX],T1C96YT97(^/&9O;G0@ M<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS M1#$^/&(^,C`Q,CPO8CX\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T M=&]M/CQF;VYT('-I>F4],T0Q/B8C>$$P.SPO9F]N=#X\+W1D/@T*(#PO='(^ M#0H@/'1R(&)G8V]L;W(],T0C0T-%149&/@T*(#QT9"!V86QI9VX],T1T;W`^ M#0H@/'`@<W1Y;&4],T0G34%21TE.+4Q%1E0Z(#%E;3L@5$585"U)3D1%3E0Z M("TQ96TG/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@ M4F]M86XG('-I>F4],T0R/DEN=&5R97-T(&5X<&5N<V4\+V9O;G0^/"]P/@T* M(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF M(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M M(&YO=W)A<#TS1&YO=W)A<#X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@ M5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXD/"]F;VYT/CPO=&0^#0H@/'1D M('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`@86QI9VX],T1R:6=H M=#X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N M)R!S:7IE/3-$,CXF(W@R,#$T.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX] M,T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P/CQF;VYT('-T>6QE/3-$)T9/3E0M M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R/B8C>$$P.R8C>$$P M.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<VEZ M93TS1#$^)B-X03`[)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS M1&)O='1O;2!N;W=R87`],T1N;W=R87`^/&9O;G0@<W1Y;&4],T0G1D].5"U& M04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^)#PO9F]N=#X\+W1D M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P(&%L:6=N M/3-$<FEG:'0^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE M=R!2;VUA;B<@<VEZ93TS1#(^)B-X,C`Q-#L\+V9O;G0^/"]T9#X-"B`\=&0@ M=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#X\9F]N="!S='EL93TS M1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXF(WA! M,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF M;VYT('-I>F4],T0Q/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V M86QI9VX],T1B;W1T;VT^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I M;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^)#PO9F]N=#X\+W1D/@T*(#QT9"!V M86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS1"=& M3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXS/"]F;VYT M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^ M/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@ M<VEZ93TS1#(^)B-X03`[)B-X03`[/"]F;VYT/CPO=&0^#0H@/"]T<CX-"B`\ M='(@<W1Y;&4],T0G1D].5"U325I%.B`Q<'@G/@T*(#QT9"!V86QI9VX],T1B M;W1T;VT^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P M.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"=" M3U)$15(M5$]0.B`C,#`P,#`P(#-P>"!D;W5B;&4G/B8C>$$P.SPO<#X-"B`\ M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@<W1Y;&4],T0G0D]2 M1$52+51/4#H@(S`P,#`P,"`S<'@@9&]U8FQE)SXF(WA!,#L\+W`^#0H@/"]T M9#X-"B`\=&0^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C M>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S M='EL93TS1"="3U)$15(M5$]0.B`C,#`P,#`P(#-P>"!D;W5B;&4G/B8C>$$P M.SPO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@<W1Y M;&4],T0G0D]21$52+51/4#H@(S`P,#`P,"`S<'@@9&]U8FQE)SXF(WA!,#L\ M+W`^#0H@/"]T9#X-"B`\=&0^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$ M8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O M;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B`C,#`P,#`P(#-P>"!D;W5B M;&4G/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^ M#0H@/'`@<W1Y;&4],T0G0D]21$52+51/4#H@(S`P,#`P,"`S<'@@9&]U8FQE M)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0^)B-X03`[/"]T9#X-"B`\+W1R M/@T*(#PO=&%B;&4^#0H@/"]D:78^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`\+W1R/@T*("`@(#PO=&%B;&4^#0H@(#PO8F]D>3X-"CPO:'1M;#X-"@T* M+2TM+2TM/5].97AT4&%R=%\S.6,P96$V,E]C,C`S7S0U.&9?.&,U,%\S9&-A M-#4V838Y-3$-"D-O;G1E;G0M3&]C871I;VXZ(&9I;&4Z+R\O0SHO,SEC,&5A M-C)?8S(P,U\T-3AF7SAC-3!?,V1C830U-F$V.34Q+U=O<FMS:&5E=',O4VAE M970Q-RYH=&UL#0I#;VYT96YT+51R86YS9F5R+45N8V]D:6YG.B!Q=6]T960M M<')I;G1A8FQE#0I#;VYT96YT+51Y<&4Z('1E>'0O:'1M;#L@8VAA<G-E=#TB M=7,M87-C:6DB#0H-"CQH=&UL/@T*("`\:&5A9#X-"B`@("`\345402!H='1P M+65Q=6EV/3-$0V]N=&5N="U4>7!E(&-O;G1E;G0],T0G=&5X="]H=&UL.R!C M:&%R<V5T/75T9BTX)SX\<V-R:7!T('1Y<&4],T1T97AT+VIA=F%S8W)I<'0@ M<W)C/3-$4VAO=RYJ<SXO*B!$;R!.;W0@4F5M;W9E(%1H:7,@0V]M;65N="`J M+SPO<V-R:7!T/CPO:&5A9#X-"B`@/&)O9'D^#0H@("`@/'1A8FQE(&-L87-S M/3-$<F5P;W)T(&ED/3-$240P14U%/@T*("`@("`@/'1R/@T*("`@("`@("`\ M=&@@8VQA<W,],T1T;"!C;VQS<&%N/3-$,2!R;W=S<&%N/3-$,CX\<W1R;VYG M/D-O;6UI=&UE;G1S(&%N9"!#;VYT:6YG96YC:65S/&)R/CPO<W1R;VYG/CPO M=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H(&-O;'-P86X],T0Q/C$R($UO M;G1H<R!%;F1E9#PO=&@^#0H@("`@("`\+W1R/@T*("`@("`@/'1R/@T*("`@ M("`@("`\=&@@8VQA<W,],T1T:#Y$96,N(#,Q+"`R,#$T/&)R/CPO=&@^#0H@ M("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT M9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#X\<W1R;VYG/D-O;6UI=&UE;G1S M(&%N9"!#;VYT:6YG96YC:65S($1I<V-L;W-U<F4@6T%B<W1R86-T73PO<W1R M;VYG/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^ M#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y#;VUM:71M M96YT<R!A;F0@0V]N=&EN9V5N8VEE<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S M<STS1'1E>'0^/&1I=CX-"B`\<"!S='EL93TS1"=-05)'24XM0D]45$]-.B`P M<'@[($U!4D=)3BU43U`Z(#$X<'@G/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%- M24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R/CQB/DYO=&4@,3`F(WA! M,#LF(W@R,#$T.PT*($-O;6UI=&UE;G1S(&%N9"!#;VYT:6YG96YC:65S/"]B M/CPO9F]N=#X\+W`^#0H@/'`@<W1Y;&4],T0G34%21TE.+4)/5%1/33H@,'!X M.R!-05)'24XM3$5&5#H@,B4[($U!4D=)3BU43U`Z(#9P>"<^#0H@/&9O;G0@ M<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS M1#(^/&(^/&D^0V]M;6ET;65N=',\+VD^/"]B/CPO9F]N=#X\+W`^#0H@/'`@ M<W1Y;&4],T0G34%21TE.+4)/5%1/33H@,'!X.R!-05)'24XM5$]0.B`V<'@[ M(%1%6%0M24Y$14Y4.B`T)2<@86QI9VX],T1J=7-T:69Y/CQF;VYT('-T>6QE M/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R/E1H M92!#;VUP86YY(&QE87-E<R!O9F9I8V4@<W!A8V4@86YD(&5Q=6EP;65N="!U M;F1E<B!A#0H@;F]N+6-A;F-E;&%B;&4@;W!E<F%T:6YG(&QE87-E('1H870@ M97AP:7)E<R!I;B`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`^#0H@/'`@<W1Y;&4],T0G34%21TE.+4)/ M5%1/33H@,'!X.R!&3TY4+5-)6D4Z(#$R<'@[($U!4D=)3BU43U`Z(#!P>"<^ M#0H@)B-X03`[/"]P/@T*(#QT86)L92!S='EL93TS1"="3U)$15(M0T],3$%0 M4T4Z(&-O;&QA<'-E)R!C96QL<W!A8VEN9STS1#`@8V5L;'!A9&1I;F<],T0P M('=I9'1H/3-$.3(E(&%L:6=N/3-$8V5N=&5R(&)O<F1E<CTS1#`^#0H@/'1R M/@T*(#QT9"!W:61T:#TS1#<S)3X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T M;VT@=VED=&@],T0T)3X\+W1D/@T*(#QT9#X\+W1D/@T*(#QT9#X\+W1D/@T* M(#QT9#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@=VED=&@],T0T)3X\ M+W1D/@T*(#QT9#X\+W1D/@T*(#QT9#X\+W1D/@T*(#QT9#X\+W1D/@T*(#QT M9"!V86QI9VX],T1B;W1T;VT@=VED=&@],T0T)3X\+W1D/@T*(#QT9#X\+W1D M/@T*(#QT9#X\+W1D/@T*(#QT9#X\+W1D/@T*(#PO='(^#0H@/'1R/@T*(#QT M9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<VEZ93TS1#$^)B-X03`[/"]F;VYT M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF M(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@<W1Y;&4],T0G0D]21$52 M+4)/5%1/33H@(S`P,#`P,"`Q<'@@<V]L:60G('9A;&EG;CTS1&)O='1O;2!C M;VQS<&%N/3-$,3`@86QI9VX],T1C96YT97(^/&9O;G0@<W1Y;&4],T0G1D]. M5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#$^/&(^665A<G,@ M16YD960-"B!$96-E;6)E<B8C>$$P.S,Q+#PO8CX\+V9O;G0^/"]T9#X-"B`\ M=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C>$$P.SPO9F]N M=#X\+W1D/@T*(#PO='(^#0H@/'1R/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^ M/&9O;G0@<VEZ93TS1#$^)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG M;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF(WA!,#LF(WA!,#L\+V9O;G0^ M/"]T9#X-"B`\=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@(S`P,#`P,"`Q M<'@@<V]L:60G('9A;&EG;CTS1&)O='1O;2!C;VQS<&%N/3-$,B!A;&EG;CTS M1&-E;G1E<CX\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W M(%)O;6%N)R!S:7IE/3-$,3X\8CXR,#$T/"]B/CPO9F]N=#X\+W1D/@T*(#QT M9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<VEZ93TS1#$^)B-X03`[/"]F;VYT M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF M(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@<W1Y;&4],T0G0D]21$52 M+4)/5%1/33H@(S`P,#`P,"`Q<'@@<V]L:60G('9A;&EG;CTS1&)O='1O;2!C M;VQS<&%N/3-$,B!A;&EG;CTS1&-E;G1E<CX\9F]N="!S='EL93TS1"=&3TY4 M+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,3X\8CXR,#$S/"]B M/CPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<VEZ M93TS1#$^)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O M;3X\9F]N="!S:7IE/3-$,3XF(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\ M=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@(S`P,#`P,"`Q<'@@<V]L:60G M('9A;&EG;CTS1&)O='1O;2!C;VQS<&%N/3-$,B!A;&EG;CTS1&-E;G1E<CX\ M9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S M:7IE/3-$,3X\8CXR,#$R/"]B/CPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX] M,T1B;W1T;VT^/&9O;G0@<VEZ93TS1#$^)B-X03`[/"]F;VYT/CPO=&0^#0H@ M/"]T<CX-"B`\='(@8F=C;VQO<CTS1"-#0T5%1D8^#0H@/'1D('9A;&EG;CTS M1'1O<#X-"B`\<"!S='EL93TS1"=-05)'24XM3$5&5#H@,65M.R!415A4+4E. M1$5.5#H@+3%E;2<^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S M($YE=R!2;VUA;B<@<VEZ93TS1#(^4F5N="!E>'!E;G-E/"]F;VYT/CPO<#X- M"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<VEZ93TS1#$^ M)B-X03`[)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O M;3X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N M)R!S:7IE/3-$,CXD/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O M;2!A;&EG;CTS1')I9VAT/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4 M:6UE<R!.97<@4F]M86XG('-I>F4],T0R/C,L,S,X/"]F;VYT/CPO=&0^#0H@ M/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^/&9O;G0@<W1Y M;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^ M)B-X03`[)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O M;3X\9F]N="!S:7IE/3-$,3XF(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\ M=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9 M.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R/B0\+V9O;G0^/"]T9#X-"B`\ M=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^/&9O;G0@<W1Y;&4] M,T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^,RPS M,#8\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS M1&YO=W)A<#X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W M(%)O;6%N)R!S:7IE/3-$,CXF(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`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`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A M;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX] M,T1B;W1T;VT^#0H@/'`@<W1Y;&4],T0G0D]21$52+51/4#H@(S`P,#`P,"`S M<'@@9&]U8FQE)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$ M8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@,W!X M(&1O=6)L92<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D/B8C>$$P.SPO=&0^ M#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT M9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@<W1Y;&4],T0G0D]21$52+51/4#H@ M(S`P,#`P,"`S<'@@9&]U8FQE)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0@ M=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(",P M,#`P,#`@,W!X(&1O=6)L92<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D/B8C M>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\ M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@<W1Y;&4],T0G0D]2 M1$52+51/4#H@(S`P,#`P,"`S<'@@9&]U8FQE)SXF(WA!,#L\+W`^#0H@/"]T M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1% M4BU43U`Z(",P,#`P,#`@,W!X(&1O=6)L92<^)B-X03`[/"]P/@T*(#PO=&0^ M#0H@/'1D/B8C>$$P.SPO=&0^#0H@/"]T<CX-"B`\+W1A8FQE/@T*(#QP('-T M>6QE/3-$)TU!4D=)3BU"3U143TTZ(#!P>#L@34%21TE.+51/4#H@,3)P>#L@ M5$585"U)3D1%3E0Z(#0E)R!A;&EG;CTS1&IU<W1I9GD^/&9O;G0@<W1Y;&4] M,T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^07,@ M;V8@1&5C96UB97(F(WA!,#LS,2P@,C`Q-"P@9G5T=7)E(&UI;FEM=6T@;&5A M<V4@<&%Y;65N=',-"B!U;F1E<B!N;VYC86YC96QA8FQE(&]P97)A=&EN9R!L M96%S97,@=V5R92!A<R!F;VQL;W=S("AI;@T*('1H;W5S86YD<RDZ/"]F;VYT M/CPO<#X-"B`\<"!S='EL93TS1"=-05)'24XM0D]45$]-.B`P<'@[($9/3E0M M4TE:13H@,3)P>#L@34%21TE.+51/4#H@,'!X)SX-"B`F(WA!,#L\+W`^#0H@ M/'1A8FQE('-T>6QE/3-$)T)/4D1%4BU#3TQ,05!313H@8V]L;&%P<V4G(&-E M;&QS<&%C:6YG/3-$,"!C96QL<&%D9&EN9STS1#`@=VED=&@],T0Y,B4@86QI M9VX],T1C96YT97(@8F]R9&5R/3-$,#X-"B`\='(^#0H@/'1D('=I9'1H/3-$ M.#DE/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#4E/CPO M=&0^#0H@/'1D/CPO=&0^#0H@/'1D/CPO=&0^#0H@/'1D/CPO=&0^#0H@/"]T M<CX-"B`\='(@8F=C;VQO<CTS1"-#0T5%1D8^#0H@/'1D('9A;&EG;CTS1'1O M<#X-"B`\<"!S='EL93TS1"=-05)'24XM3$5&5#H@,65M.R!415A4+4E.1$5. M5#H@+3%E;2<^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE M=R!2;VUA;B<@<VEZ93TS1#(^,C`Q-3PO9F]N=#X\+W`^#0H@/"]T9#X-"B`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`^#0H@/'`@<W1Y;&4],T0G34%21TE.+4Q%1E0Z(#%E;3L@5$585"U)3D1% M3E0Z("TQ96TG/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!. M97<@4F]M86XG('-I>F4],T0R/C(P,38\+V9O;G0^/"]P/@T*(#PO=&0^#0H@ M/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF(WA!,#LF(WA! M,#L\+V9O;G0^/"]T9#X-"B`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`^#0H@/'`@<W1Y;&4],T0G34%2 M1TE.+4Q%1E0Z(#%E;3L@5$585"U)3D1%3E0Z("TQ96TG/CQF;VYT('-T>6QE M/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R/C(P M,3<\+V9O;G0^/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\ M9F]N="!S:7IE/3-$,3XF(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@ M=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4 M:6UE<R!.97<@4F]M86XG('-I>F4],T0R/B8C>$$P.SPO9F]N=#X\+W1D/@T* M(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#X\9F]N="!S='EL M93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXS M+#8R-CPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P M/3-$;F]W<F%P/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!. M97<@4F]M86XG('-I>F4],T0R/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T* M(#PO='(^#0H@/'1R/@T*(#QT9"!V86QI9VX],T1T;W`^#0H@/'`@<W1Y;&4] M,T0G34%21TE.+4Q%1E0Z(#%E;3L@5$585"U)3D1%3E0Z("TQ96TG/CQF;VYT M('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4] M,T0R/C(P,3@\+V9O;G0^/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O M='1O;3X\9F]N="!S:7IE/3-$,3XF(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X- M"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%- M24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R/B8C>$$P.SPO9F]N=#X\ M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#X\9F]N M="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE M/3-$,CXQ+#@V,#PO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@ M;F]W<F%P/3-$;F]W<F%P/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4 M:6UE<R!.97<@4F]M86XG('-I>F4],T0R/B8C>$$P.R8C>$$P.SPO9F]N=#X\ M+W1D/@T*(#PO='(^#0H@/'1R(&)G8V]L;W(],T0C0T-%149&/@T*(#QT9"!V M86QI9VX],T1T;W`^#0H@/'`@<W1Y;&4],T0G34%21TE.+4Q%1E0Z(#%E;3L@ M5$585"U)3D1%3E0Z("TQ96TG/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9 M.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R/C(P,3D\+V9O;G0^/"]P/@T* M(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF M(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M M(&YO=W)A<#TS1&YO=W)A<#X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@ M5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXF(WA!,#L\+V9O;G0^/"]T9#X- M"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<"!A;&EG;CTS M1')I9VAT/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@ M4F]M86XG('-I>F4],T0R/B8C>#(P,30[/"]F;VYT/CPO=&0^#0H@/'1D('9A M;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^/&9O;G0@<W1Y;&4],T0G M1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^)B-X03`[ M)B-X03`[/"]F;VYT/CPO=&0^#0H@/"]T<CX-"B`\='(^#0H@/'1D('9A;&EG M;CTS1'1O<#X-"B`\<"!S='EL93TS1"=-05)'24XM3$5&5#H@,65M.R!415A4 M+4E.1$5.5#H@+3%E;2<^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I M;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^5&AE<F5A9G1E<CPO9F]N=#X\+W`^ M#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q M/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T M;VT@;F]W<F%P/3-$;F]W<F%P/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9 M.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R/B8C>$$P.SPO9F]N=#X\+W1D M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P(&%L:6=N M/3-$<FEG:'0^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE M=R!2;VUA;B<@<VEZ93TS1#(^)B-X,C`Q-#L\+V9O;G0^/"]T9#X-"B`\=&0@ M=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#X\9F]N="!S='EL93TS M1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXF(WA! M,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\+W1R/@T*(#QT<B!S='EL93TS1"=& M3TY4+5-)6D4Z(#%P>"<^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T* M(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@ M=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(",P M,#`P,#`@,7!X('-O;&ED)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0@=F%L M:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P M,#`@,7!X('-O;&ED)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0^)B-X03`[ M/"]T9#X-"B`\+W1R/@T*(#QT<B!B9V-O;&]R/3-$(T-#145&1CX-"B`\=&0@ M=F%L:6=N/3-$=&]P/@T*(#QP('-T>6QE/3-$)TU!4D=)3BU,1494.B`R96T[ M(%1%6%0M24Y$14Y4.B`M,65M)SX\9F]N="!S='EL93TS1"=&3TY4+49!34E, M63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CY4;W1A;#PO9F]N=#X\+W`^ M#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q M/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T M;VT^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA M;B<@<VEZ93TS1#(^)#PO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T M;VT@86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@ M5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXQ,BPS.#`\+V9O;G0^/"]T9#X- M"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#X\9F]N="!S M='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$ M,CXF(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\+W1R/@T*(#QT<B!S='EL M93TS1"=&3TY4+5-)6D4Z(#%P>"<^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\ M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X- M"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU4 M3U`Z(",P,#`P,#`@,W!X(&1O=6)L92<^)B-X03`[/"]P/@T*(#PO=&0^#0H@ M/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0 M.B`C,#`P,#`P(#-P>"!D;W5B;&4G/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT M9#XF(WA!,#L\+W1D/@T*(#PO='(^#0H@/"]T86)L93X-"B`\<"!S='EL93TS M1"=-05)'24XM0D]45$]-.B`P<'@[($U!4D=)3BU,1494.B`R)3L@34%21TE. M+51/4#H@,3AP>"<^#0H@/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I M;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^/&(^/&D^0V]N=&EN9V5N8VEE<SPO M:3X\+V(^/"]F;VYT/CPO<#X-"B`\<"!S='EL93TS1"=-05)'24XM0D]45$]- M.B`P<'@[($U!4D=)3BU43U`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`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`T*('!O<VET:6]N+"!R97-U;'1S(&]F M(&]P97)A=&EO;G,@;W(@8V%S:"!F;&]W<R!O9B!T:&4-"B!#;VUP86YY+CPO M9F]N=#X\+W`^#0H@/'`@<W1Y;&4],T0G34%21TE.+4)/5%1/33H@,'!X.R!- M05)'24XM5$]0.B`Q,G!X.R!415A4+4E.1$5.5#H@-"4G(&%L:6=N/3-$:G5S M=&EF>3X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O M;6%N)R!S:7IE/3-$,CY);B!$96-E;6)E<B`R,#$T+"!T:&4@0V]M<&%N>2!F M:6QE9"!A(&QA=W-U:70@86QL96=I;F<-"B!F<F%U9'5L96YT(&EN9'5C96UE M;G0L(&)R96%C:"!O9B!C;VYT<F%C="!A;F0@;F5G;&EG96YC92!O;B!T:&4- M"B!P87)T(&]F(&$@9&%T82!M86YA9V5M96YT('9E;F1O<B!F;W(@82!C;&EN M:6-A;"!T<FEA;"X@5&AE($-O;7!A;GD-"B!I<R!S965K:6YG(&UO;F5T87)Y M(&1A;6%G97,N($%S('1H:7,@:7,@82!C;VYT:6YG96YC>2!T:&%T(&UA>0T* M(')E<W5L="!I;B!A(&=A:6XL(&YO('!R;W9I<VEO;B!H87,@8F5E;B!M861E M(&EN('1H92!F:6YA;F-I86P-"B!S=&%T96UE;G1S+CPO9F]N=#X\+W`^#0H@ M/"]D:78^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@(#PO M=&%B;&4^#0H@(#PO8F]D>3X-"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT4&%R M=%\S.6,P96$V,E]C,C`S7S0U.&9?.&,U,%\S9&-A-#4V838Y-3$-"D-O;G1E M;G0M3&]C871I;VXZ(&9I;&4Z+R\O0SHO,SEC,&5A-C)?8S(P,U\T-3AF7SAC M-3!?,V1C830U-F$V.34Q+U=O<FMS:&5E=',O4VAE970Q."YH=&UL#0I#;VYT M96YT+51R86YS9F5R+45N8V]D:6YG.B!Q=6]T960M<')I;G1A8FQE#0I#;VYT M96YT+51Y<&4Z('1E>'0O:'1M;#L@8VAA<G-E=#TB=7,M87-C:6DB#0H-"CQH M=&UL/@T*("`\:&5A9#X-"B`@("`\345402!H='1P+65Q=6EV/3-$0V]N=&5N M="U4>7!E(&-O;G1E;G0],T0G=&5X="]H=&UL.R!C:&%R<V5T/75T9BTX)SX\ M<V-R:7!T('1Y<&4],T1T97AT+VIA=F%S8W)I<'0@<W)C/3-$4VAO=RYJ<SXO M*B!$;R!.;W0@4F5M;W9E(%1H:7,@0V]M;65N="`J+SPO<V-R:7!T/CPO:&5A M9#X-"B`@/&)O9'D^#0H@("`@/'1A8FQE(&-L87-S/3-$<F5P;W)T(&ED/3-$ M240P14U%/@T*("`@("`@/'1R/@T*("`@("`@("`\=&@@8VQA<W,],T1T;"!C M;VQS<&%N/3-$,2!R;W=S<&%N/3-$,CX\<W1R;VYG/D-O;G9E<G1I8FQE(%!R M969E<G)E9"!3=&]C:SQB<CX\+W-T<F]N9SX\+W1H/@T*("`@("`@("`\=&@@ M8VQA<W,],T1T:"!C;VQS<&%N/3-$,3XQ,B!-;VYT:',@16YD960\+W1H/@T* M("`@("`@/"]T<CX-"B`@("`@(#QT<CX-"B`@("`@("`@/'1H(&-L87-S/3-$ M=&@^1&5C+B`S,2P@,C`Q-#QB<CX\+W1H/@T*("`@("`@/"]T<CX-"B`@("`@ M(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI M9VX],T1T;W`^/'-T<F]N9SY%<75I='D@6T%B<W1R86-T73PO<W1R;VYG/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@ M("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y#;VYV97)T:6)L92!0 M<F5F97)R960@4W1O8VL\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT M/CQD:78^#0H@/'`@<W1Y;&4],T0G34%21TE.+4)/5%1/33H@,'!X.R!-05)' M24XM5$]0.B`Q.'!X)SX\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM M97,@3F5W(%)O;6%N)R!S:7IE/3-$,CX\8CY.;W1E(#$Q("8C>#(P,30[#0H@ M0V]N=F5R=&EB;&4@4')E9F5R<F5D(%-T;V-K/"]B/CPO9F]N=#X\+W`^#0H@ M/"$M+2!X8G)L+&)O9'D@+2T^#0H@/'`@<W1Y;&4],T0G34%21TE.+4)/5%1/ M33H@,'!X.R!-05)'24XM5$]0.B`V<'@[(%1%6%0M24Y$14Y4.B`T)2<@86QI M9VX],T1J=7-T:69Y/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE M<R!.97<@4F]M86XG('-I>F4],T0R/D%S(&]F($1E8V5M8F5R)B-X03`[,S$L M(#(P,3`@=&AE<F4@=V5R92`Q,"PP,#`L,#`P)B-X03`[<VAA<F5S#0H@;V8@ M<')E9F5R<F5D('-T;V-K(&%U=&AO<FEZ960@86YD(&YO('-H87)E<R!O=71S M=&%N9&EN9RX\+V9O;G0^/"]P/@T*(#QP('-T>6QE/3-$)TU!4D=)3BU"3U14 M3TTZ(#!P>#L@34%21TE.+51/4#H@,3)P>#L@5$585"U)3D1%3E0Z(#0E)R!A M;&EG;CTS1&IU<W1I9GD^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I M;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^3VX@07!R:6PF(WA!,#LQ."P@,C`Q M,2P@=&AE($-O;7!A;GD@96YT97)E9"!I;G1O(&$@<V5C=7)I=&EE<PT*('!U M<F-H87-E(&%G<F5E;65N="`H=&AE("8C>#(P,4,[1&5E<F9I96QD($%G<F5E M;65N="8C>#(P,40[*2!W:71H#0H@1&5E<F9I96QD(%!R:79A=&4@1&5S:6=N M($9U;F0@24DL($PN4"XL($1E97)F:65L9"!0<FEV871E($1E<VEG;@T*($EN M=&5R;F%T:6]N86P@24DL($PN4"XL($1E97)F:65L9"!3<&5C:6%L(%-I='5A M=&EO;G,@1G5N9"P@3"Y0+BP-"B!A;F0@1&5E<F9I96QD(%-P96-I86P@4VET M=6%T:6]N<R!&=6YD($EN=&5R;F%T:6]N86P@3&EM:71E9`T*("AC;VQL96-T M:79E;'DL("8C>#(P,4,[1&5E<F9I96QD)B-X,C`Q1#LI+B!/;B!!<')I;"8C M>$$P.S(P+"`R,#$Q+`T*('!U<G-U86YT('1O('1H92!$965R9FEE;&0@06=R M965M96YT+"!T:&4@0V]M<&%N>2!I<W-U960@=&\-"B!$965R9FEE;&0@."PP M-S`@<VAA<F5S(&]F(%-E<FEE<R8C>$$P.T$@8V]N=F5R=&EB;&4@<')E9F5R M<F5D('-T;V-K#0H@*'1H92`F(W@R,#%#.U-E<FEE<R!!(%!R969E<G)E9"!3 M=&]C:R8C>#(P,40[*2!F;W(@82!P=7)C:&%S92!P<FEC90T*(&]F("0Q+#4P M,"XP,"!P97(@<VAA<F4@9F]R(&YE="!P<F]C965D<R!O9B!A<'!R;WAI;6%T M96QY("0Y+C,-"B!M:6QL:6]N+"!A<R!W96QL(&%S(&-O;6UO;B!S=&]C:R!A M;F0@=V%R<F%N=',@=&AA="!A<F4@9&ES8W5S<V5D(&EN#0H@3F]T92`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`^#0H@/'`@<W1Y;&4],T0G34%21TE.+4)/5%1/33H@,'!X.R!- M05)'24XM5$]0.B`Q,G!X.R!415A4+4E.1$5.5#H@-"4G(&%L:6=N/3-$:G5S M=&EF>3X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O M;6%N)R!S:7IE/3-$,CY/;B!397!T96UB97(F(WA!,#LR-BP@,C`Q,BP@86QL M(#@L,#<P('-H87)E<R!O9B!397)I97,@00T*(%!R969E<G)E9"!3=&]C:R!W M97)E(&-O;G9E<G1E9"!I;G1O(#$L,S0U+#`P,"!S:&%R97,@;V8@;W5R(&-O M;6UO;@T*('-T;V-K+B!4:&4@8V]N=F5R<VEO;B!W87,@:6X@86-C;W)D86YC M92!W:71H('1H92!T97)M<R!O9B!T:&4-"B!A9W)E96UE;G0@=VET:"!$965R M9FEE;&0@=6YD97(@=VAI8V@@=&AE(%-E<FEE<R!!(%!R969E<G)E9"!3=&]C M:PT*('=A<R!I<W-U960@:6X@,C`Q,2X\+V9O;G0^/"]P/@T*(#QP('-T>6QE M/3-$)TU!4D=)3BU"3U143TTZ(#!P>#L@34%21TE.+51/4#H@,3)P>#L@5$58 M5"U)3D1%3E0Z(#0E)R!A;&EG;CTS1&IU<W1I9GD^/&9O;G0@<W1Y;&4],T0G M1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^3VX@2G5N M928C>$$P.S(P+"`R,#$R+"!T:&4@0V]M<&%N>2!E;G1E<F5D(&EN=&\@=6YD M97)W<FET:6YG#0H@86=R965M96YT<R!F;W(@='=O('-E<&%R871E+"!C;VYC M=7)R96YT('!U8FQI8R!O9F9E<FEN9W,@;V8@=&AE#0H@0V]M<&%N>28C>#(P M,3D[<R!S96-U<FET:65S("AT:&4@)B-X,C`Q0SM*=6YE(#(P,3(@4'5B;&EC M#0H@3V9F97)I;F=S)B-X,C`Q1#LI+B!/;B!*=6YE)B-X03`[,C4L(#(P,3(L M('!U<G-U86YT('1O('1H90T*('5N9&5R=W)I=&EN9R!A9W)E96UE;G1S+"!I M;B!A9V=R96=A=&4@=&AE($-O;7!A;GD@:7-S=65D('1O(&-E<G1A:6X-"B!I M;G9E<W1O<G,@,C,L,#(V('-H87)E<R!O9B!397)I97,F(WA!,#M"(&-O;G9E M<G1I8FQE('!R969E<G)E9`T*('-T;V-K("AT:&4@)B-X,C`Q0SM397)I97,@ M0B!0<F5F97)R960@4W1O8VLF(W@R,#%$.RD@9F]R(&$@<'5R8VAA<V4-"B!P M<FEC92!O9B`D-S8P+C`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`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`Q.3MS#0H@;&EQ M=6ED871I;VXL(&1I<W-O;'5T:6]N(&]R('=I;F1I;F<@=7`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`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`D,2XS(&UI;&QI;VX@;VX@=&AE(&1A=&4-"B!O9B!I<W-U M86YC92P@<F5S=6QT:6YG(&EN(&$@8F5N969I8VEA;"!C;VYV97)S:6]N(&9E M871U<F4N(%1H90T*($-O;7!A;GD@<F5C;V=N:7IE9"!T:&4@8F5N969I8VEA M;"!C;VYV97)S:6]N(&9E871U<F4@87,@82!O;F4M=&EM92P-"B!N;VXM8V%S M:"P@9&5E;65D(&1I=FED96YD('1O('1H92!H;VQD97)S(&]F(%-E<FEE<R!" M(%!R969E<G)E9`T*(%-T;V-K(&]N('1H92!D871E(&]F(&ES<W5A;F-E+"!W M:&EC:"!I<R!T:&4@9&%T92!T:&4@<W1O8VL@9FER<W0-"B!B96-A;64@8V]N M=F5R=&EB;&4N/"]F;VYT/CPO<#X-"B`\<"!S='EL93TS1"=-05)'24XM0D]4 M5$]-.B`P<'@[($U!4D=)3BU43U`Z(#$R<'@[(%1%6%0M24Y$14Y4.B`T)2<@ M86QI9VX],T1J=7-T:69Y/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4 M:6UE<R!.97<@4F]M86XG('-I>F4],T0R/DEN('1H92!F:7)S="!Q=6%R=&5R M(&]F(#(P,3,L(#0L,#`P('-H87)E<R!O9B!397)I97,@0@T*(&-O;G9E<G1I M8FQE('!R969E<G)E9"!S=&]C:R!W97)E(&-O;G9E<G1E9"!I;G1O(#8V-BPV M-C<@<VAA<F5S(&]F#0H@8V]M;6]N('-T;V-K+B!);B!T:&4@<V5C;VYD('%U M87)T97(@;V8@,C`Q,RP@,34L,#(V('-H87)E<R!O9@T*(%-E<FEE<R!"(&-O M;G9E<G1I8FQE('!R969E<G)E9"!S=&]C:R!W97)E(&-O;G9E<G1E9"!I;G1O M(#(L-3`T+#,S-`T*('-H87)E<R!O9B!C;VUM;VX@<W1O8VLN($]N($IU;'DF M(WA!,#LR+"`R,#$S+"`T+#`P,"!S:&%R97,@;V8-"B!397)I97,@0B!C;VYV M97)T:6)L92!P<F5F97)R960@<W1O8VLL('=H:6-H(')E<')E<V5N=&5D(&%L M;`T*(')E;6%I;FEN9R!S:&%R97,@;V8@4V5R:65S)B-X03`[0B!C;VYV97)T M:6)L92!P<F5F97)R960@<W1O8VLL('=E<F4-"B!C;VYV97)T960@:6YT;R`V M-C8L-C@Q('-H87)E<R!O9B!C;VUM;VX@<W1O8VLN(%1H92!C;VYV97)S:6]N M<R!W97)E#0H@:6X@86-C;W)D86YC92!W:71H('1H92!T97)M<R!O9B!T:&4@ M;W)I9VEN86P@86=R965M96YT('5N9&5R('=H:6-H#0H@=&AE(%-E<FEE<R!" M(&-O;G9E<G1I8FQE('!R969E<G)E9"!S=&]C:R!W87,@:7-S=65D(&EN#0H@ M,C`Q,BX\+V9O;G0^/"]P/@T*(#QP('-T>6QE/3-$)TU!4D=)3BU"3U143TTZ M(#!P>#L@34%21TE.+51/4#H@,3)P>#L@5$585"U)3D1%3E0Z(#0E)R!A;&EG M;CTS1&IU<W1I9GD^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S M($YE=R!2;VUA;B<@<VEZ93TS1#(^07,@;V8@1&5C96UB97(F(WA!,#LS,2P@ M,C`Q-"!T:&5R92!W97)E(#$P+#`P,"PP,#`@<VAA<F5S(&]F#0H@<')E9F5R M<F5D('-T;V-K(&%U=&AO<FEZ960@86YD(&YO('-H87)E<R!O=71S=&%N9&EN M9RX\+V9O;G0^/"]P/@T*(`T*(`T*(#PO9&EV/CQS<&%N/CPO<W!A;CX\+W1D M/@T*("`@("`@/"]T<CX-"B`@("`\+W1A8FQE/@T*("`\+V)O9'D^#0H\+VAT M;6P^#0H-"BTM+2TM+3U?3F5X=%!A<G1?,SEC,&5A-C)?8S(P,U\T-3AF7SAC M-3!?,V1C830U-F$V.34Q#0I#;VYT96YT+4QO8V%T:6]N.B!F:6QE.B\O+T,Z M+S,Y8S!E838R7V,R,#-?-#4X9E\X8S4P7S-D8V$T-39A-CDU,2]7;W)K<VAE M971S+U-H965T,3DN:'1M;`T*0V]N=&5N="U4<F%N<V9E<BU%;F-O9&EN9SH@ M<75O=&5D+7!R:6YT86)L90T*0V]N=&5N="U4>7!E.B!T97AT+VAT;6P[(&-H M87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U% M5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O M:'1M;#L@8VAA<G-E=#UU=&8M."<^/'-C<FEP="!T>7!E/3-$=&5X="]J879A M<V-R:7!T('-R8STS1%-H;W<N:G,^+RH@1&\@3F]T(%)E;6]V92!4:&ES($-O M;6UE;G0@*B\\+W-C<FEP=#X\+VAE860^#0H@(#QB;V1Y/@T*("`@(#QT86)L M92!C;&%S<STS1')E<&]R="!I9#TS1$E$,$5-13X-"B`@("`@(#QT<CX-"B`@ M("`@("`@/'1H(&-L87-S/3-$=&P@8V]L<W!A;CTS1#$@<F]W<W!A;CTS1#(^ M/'-T<F]N9SY3=&]C:VAO;&1E<G,G($5Q=6ET>3QB<CX\+W-T<F]N9SX\+W1H M/@T*("`@("`@("`\=&@@8VQA<W,],T1T:"!C;VQS<&%N/3-$,3XQ,B!-;VYT M:',@16YD960\+W1H/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<CX-"B`@("`@ M("`@/'1H(&-L87-S/3-$=&@^1&5C+B`S,2P@,C`Q-#QB<CX\+W1H/@T*("`@ M("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@ M8VQA<W,],T1P;"!V86QI9VX],T1T;W`^/'-T<F]N9SY%<75I='D@6T%B<W1R M86-T73PO<W1R;VYG/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L M87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O M<#Y3=&]C:VAO;&1E<G,G($5Q=6ET>3PO=&0^#0H@("`@("`@(#QT9"!C;&%S M<STS1'1E>'0^/&1I=CX-"B`\<"!S='EL93TS1"=-05)'24XM0D]45$]-.B`P M<'@[($U!4D=)3BU43U`Z(#$X<'@G/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%- M24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R/CQB/DYO=&4@,3(@)B-X M,C`Q-#L-"B!3=&]C:VAO;&1E<G,F(W@R,#$Y.R!%<75I='D\+V(^/"]F;VYT M/CPO<#X-"B`\(2TM('AB<FPL8F]D>2`M+3X-"B`\<"!S='EL93TS1"=-05)' M24XM0D]45$]-.B`P<'@[($U!4D=)3BU,1494.B`R)3L@34%21TE.+51/4#H@ M-G!X)SX-"B`\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W M(%)O;6%N)R!S:7IE/3-$,CX\8CX\:3Y!8V-U;75L871E9"!/=&AE<B!#;VUP M<F5H96YS:79E($QO<W,\+VD^/"]B/CPO9F]N=#X\+W`^#0H@/'`@<W1Y;&4] M,T0G34%21TE.+4)/5%1/33H@,'!X.R!-05)'24XM5$]0.B`V<'@[(%1%6%0M M24Y$14Y4.B`T)2<@86QI9VX],T1J=7-T:69Y/CQF;VYT('-T>6QE/3-$)T9/ M3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R/DEN(#(P,30L M('1H92!#;VUP86YY(')E8VQA<W-I9FEE9"!I;G-I9VYI9FEC86YT(&%M;W5N M=',@;V8-"B!U;G)E86QI>F5D(&=A:6YS("AL;W-S97,I(&EN(&EN=F5S=&UE M;G1S(&]U="!O9B!A8V-U;75L871E9"!O=&AE<@T*(&-O;7!R96AE;G-I=F4@ M:6YC;VUE(&EN=&\@;F5T(&QO<W,N/"]F;VYT/CPO<#X-"B`\<"!S='EL93TS M1"=-05)'24XM0D]45$]-.B`P<'@[($U!4D=)3BU,1494.B`R)3L@34%21TE. M+51/4#H@,3AP>"<^#0H@/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I M;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^/&(^/&D^075T:&]R:7IE9"!3:&%R M97,\+VD^/"]B/CPO9F]N=#X\+W`^#0H@/'`@<W1Y;&4],T0G34%21TE.+4)/ M5%1/33H@,'!X.R!-05)'24XM5$]0.B`V<'@[(%1%6%0M24Y$14Y4.B`T)2<@ M86QI9VX],T1J=7-T:69Y/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4 M:6UE<R!.97<@4F]M86XG('-I>F4],T0R/D]N($UA>28C>$$P.S$X+"`R,#$Q M+"!T:&4@<W1O8VMH;VQD97)S(&%P<')O=F5D(&%N(&EN8W)E87-E(&EN#0H@ M=&AE(&YU;6)E<B!O9B!A=71H;W)I>F5D('-H87)E<R!O9B!C;VUM;VX@<W1O M8VL@9G)O;2`Q-S`L,#`P+#`P,"!T;PT*(#(T-2PP,#`L,#`P+B!4:&4@:6YC M<F5A<V4@8F5C86UE(&5F9F5C=&EV92!I;B!!=6=U<W0@,C`Q,2P@=VAE;B!T M:&4-"B!#;VUP86YY(&9I;&5D('1H92!#97)T:69I8V%T92!O9B!!;65N9&UE M;G0@;V8@06UE;F1E9"!A;F0@4F5S=&%T960-"B!#97)T:69I8V%T92!O9B!) M;F-O<G!O<F%T:6]N('=I=&@@=&AE(%-E8W)E=&%R>2!O9B!3=&%T92!O9B!T M:&4-"B!3=&%T92!O9B!$96QA=V%R92X@26X@2G5N92`R,#$S+"!U<&]N('1H M92!S=&]C:VAO;&1E<B!A<'!R;W9A;"!O9@T*('1H92!O;F4M9F]R+7-I>"!R M979E<G-E('-T;V-K('-P;&ET(&%N9"!T:&4@86UE;F1M96YT('1O('1H90T* M($-O;7!A;GDF(W@R,#$Y.W,@86UE;F1E9"!A;F0@<F5S=&%T960@8V5R=&EF M:6-A=&4@;V8@:6YC;W)P;W)A=&EO;BP-"B!T:&4@;G5M8F5R(&]F(&%U=&AO M<FEZ960@<VAA<F5S(&]F(&-O;6UO;B!S=&]C:R!W87,@<F5D=6-E9"!T;PT* M(#@Q+#4P,"PP,#`@*%-E92!.;W1E(#$I+CPO9F]N=#X\+W`^#0H@/'`@<W1Y M;&4],T0G34%21TE.+4)/5%1/33H@,'!X.R!-05)'24XM3$5&5#H@,B4[($U! M4D=)3BU43U`Z(#$X<'@G/@T*(#QF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9 M.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R/CQB/CQI/D-O;6UO;@T*(%-T M;V-K($]U='-T86YD:6YG/"]I/CPO8CX\+V9O;G0^/"]P/@T*(#QP('-T>6QE M/3-$)TU!4D=)3BU"3U143TTZ(#!P>#L@34%21TE.+51/4#H@-G!X.R!415A4 M+4E.1$5.5#H@-"4G(&%L:6=N/3-$:G5S=&EF>3X\9F]N="!S='EL93TS1"=& M3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CY/;B!!<')I M;"8C>$$P.S(P+"`R,#$Q+"!P=7)S=6%N="!T;R!T:&4@1&5E<F9I96QD($%G M<F5E;65N="P-"B!T:&4@0V]M<&%N>2!I<W-U960@=&\@1&5E<F9I96QD("AI M*28C>$$P.S@X,RPS,S,@<VAA<F5S(&]F(&-O;6UO;@T*('-T;V-K(&9O<B!A M('!U<F-H87-E('!R:6-E(&]F("0Y+C`P('!E<B!S:&%R92P@*&EI*28C>$$P M.S@L,#<P#0H@<VAA<F5S(&]F(%-E<FEE<R!!(%!R969E<G)E9"!3=&]C:R!F M;W(@82!P=7)C:&%S92!P<FEC92!O9@T*("0Q+#4P,"XP,"!P97(@<VAA<F4L M(&%N9"`H:6EI*28C>$$P.W=A<G)A;G1S('1O('!U<F-H87-E(#$L,3$T+#$V M.`T*('-H87)E<R!O9B!T:&4@0V]M<&%N>28C>#(P,3D[<R!C;VUM;VX@<W1O M8VL@870@86X@:6YI=&EA;"!E>&5R8VES90T*('!R:6-E(&]F("0Y+CDP('!E M<B!S:&%R92P@9F]R(&%G9W)E9V%T92!G<F]S<R!P<F]C965D<R!O9@T*(&%P M<')O>&EM871E;'D@)#(P+C$F(WA!,#MM:6QL:6]N+B!!9G1E<B!I<W-U86YC M92!C;W-T<R!O9@T*(&%P<')O>&EM871E;'D@)#`N,B!M:6QL:6]N+"!T:&4@ M;F5T('!R;V-E961S('=E<F4@87!P<F]X:6UA=&5L>0T*("0Q.2XY(&UI;&QI M;VXN/"]F;VYT/CPO<#X-"B`\<"!S='EL93TS1"=-05)'24XM0D]45$]-.B`P M<'@[($9/3E0M4TE:13H@,3)P>#L@34%21TE.+51/4#H@,'!X)SX-"B`F(WA! M,#L\+W`^#0H@/'`@<W1Y;&4],T0G34%21TE.+4)/5%1/33H@,'!X.R!-05)' M24XM5$]0.B`P<'@[(%1%6%0M24Y$14Y4.B`T)2<@86QI9VX],T1J=7-T:69Y M/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG M('-I>F4],T0R/E1H92!O9F9E<FEN9R!W87,@;6%D92!P=7)S=6%N="!T;R!A M('-H96QF(')E9VES=')A=&EO;@T*('-T871E;65N="!T:&%T('1H92!#;VUP M86YY(&9I;&5D('=I=&@@=&AE(%-%0R!O;B!.;W9E;6)E<B8C>$$P.S$P+`T* M(#(P,#@L('=H:6-H(&)E8V%M92!E9F9E8W1I=F4@;VX@3F]V96UB97(F(WA! M,#LQ.2P@,C`P."`H1FEL90T*($YO+B8C>$$P.S,S,RTQ-34R-3DI+B!4:&4@ M8VQO<VEN9R!O9B!T:&4@;V9F97)I;F<@=&]O:R!P;&%C92!O;@T*($%P<FEL M)B-X03`[,C`L(#(P,3$N/"]F;VYT/CPO<#X-"B`\<"!S='EL93TS1"=-05)' M24XM0D]45$]-.B`P<'@[($U!4D=)3BU43U`Z(#$R<'@[(%1%6%0M24Y$14Y4 M.B`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`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`P,2!P97(@<VAA<F4N(%1H92!F86ER M('9A;'5E(&]F('1H92!W87)R86YT<R!W87,@9&5T97)M:6YE9`T*('5S:6YG M('1H92!";&%C:RU38VAO;&5S('!R:6-I;F<@;6]D96PL(&%S(&1I<V-U<W-E M9"!A8F]V92X@5&AE#0H@<F5L871I=F4@9F%I<B!V86QU92!R871I;R!O9B!E M86-H(&]F('1H92!I;G-T<G5M96YT<R!I<W-U960@=V%S#0H@=&AE;B!A<'!L M:65D('1O('1H92!T;W1A;"!G<F]S<R!P<F]C965D<R!O9B`D,C`N,2!M:6QL M:6]N+`T*(')E<W5L=&EN9R!I;B!A;&QO8V%T960@<'5R8VAA<V4@<')I8V5S M(&]F("0V+C(@;6EL;&EO;B!F;W(@=&AE#0H@8V]M;6]N('-T;V-K+"`D.2XT M(&UI;&QI;VX@9F]R('1H92!397)I97,@02!0<F5F97)R960@4W1O8VL@86YD M#0H@)#0N-2!M:6QL:6]N(&9O<B!T:&4@=V%R<F%N=',N/"]F;VYT/CPO<#X- M"B`\<"!S='EL93TS1"=-05)'24XM0D]45$]-.B`P<'@[($U!4D=)3BU43U`Z M(#$R<'@[(%1%6%0M24Y$14Y4.B`T)2<@86QI9VX],T1J=7-T:69Y/CQF;VYT M('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4] M,T0R/D]N(%-E<'1E;6)E<B8C>$$P.S(V+"`R,#$R+"!A;&P@."PP-S`@<VAA M<F5S(&]F(%-E<FEE<R!!#0H@0V]N=F5R=&EB;&4@4')E9F5R<F5D(%-T;V-K M('=E<F4@8V]N=F5R=&5D(&EN=&\@,2PS-#4L,#`P('-H87)E<R!O9@T*(&]U M<B!C;VUM;VX@<W1O8VLN(%1H92!C;VYV97)S:6]N('=A<R!I;B!A8V-O<F1A M;F-E('=I=&@@=&AE('1E<FUS#0H@;V8@=&AE(&]R:6=I;F%L(&%G<F5E;65N M="!U;F1E<B!W:&EC:"!T:&4@4V5R:65S($$@0V]N=F5R=&EB;&4-"B!0<F5F M97)R960@4W1O8VL@=V%S(&ES<W5E9"!I;B`R,#$Q+CPO9F]N=#X\+W`^#0H@ M/'`@<W1Y;&4],T0G34%21TE.+4)/5%1/33H@,'!X.R!-05)'24XM5$]0.B`Q M,G!X.R!415A4+4E.1$5.5#H@-"4G(&%L:6=N/3-$:G5S=&EF>3X\9F]N="!S M='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$ M,CY);B!*=6YE)B-X03`[,C`Q,2P@=&AE($-O;7!A;GD@96YT97)E9"!I;G1O M(&%N($%T+51H92U-87)K970-"B!)<W-U86YC92!386QE<R!!9W)E96UE;G0@ M*'1H92`F(W@R,#%#.TU,5B!!9W)E96UE;G0F(W@R,#%$.RD@=VET:`T*($UC M3FEC;VQL+"!,97=I<R8C>$$P.R9A;7`[(%9L86L@3$Q#("@F(W@R,#%#.TU, M5B8C>#(P,40[*2P@<'5R<W5A;G0-"B!T;R!W:&EC:"!T:&4@0V]M<&%N>2!S M;VQD+"!T:')O=6=H($1E8V5M8F5R)B-X03`[,S$L(#(P,30L#0H@,BPS.3<L M,C<X('-H87)E<R!O9B!C;VUM;VX@<W1O8VL@=&AR;W5G:"!-3%8@9F]R(&YE M="!P<F]C965D<R!O9@T*(&%P<')O>&EM871E;'D@)#$U+C(F(WA!,#MM:6QL M:6]N+CPO9F]N=#X\+W`^#0H@/'`@<W1Y;&4],T0G34%21TE.+4)/5%1/33H@ M,'!X.R!-05)'24XM5$]0.B`Q,G!X.R!415A4+4E.1$5.5#H@-"4G(&%L:6=N M/3-$:G5S=&EF>3X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@ M3F5W(%)O;6%N)R!S:7IE/3-$,CY/;B!*=6YE)B-X03`[,C4L(#(P,3(L('!U M<G-U86YT('1O('1H92!*=6YE(#(P,3(@4'5B;&EC#0H@3V9F97)I;F=S+"!I M;B!A9V=R96=A=&4@=&AE($-O;7!A;GD@:7-S=65D('1O('9A<FEO=7,@:6YV M97-T;W)S#0H@*&DI)B-X03`[.2PS,C`L,3<V('-H87)E<R!O9B!C;VUM;VX@ M<W1O8VL@9F]R(&$@<'5R8VAA<V4@<')I8V4@;V8-"B`D-"XU-B!P97(@<VAA M<F4L("AI:2DF(WA!,#LR,RPP,C8@<VAA<F5S(&]F('1H92!397)I97,@0B!0 M<F5F97)R960-"B!3=&]C:R!F;W(@82!P=7)C:&%S92!P<FEC92!O9B`D-S8P M+C`P('!E<B!S:&%R92P@86YD#0H@*&EI:2DF(WA!,#MW87)R86YT<R!T;R!P M=7)C:&%S92`W+#@Y-"PW,#0@<VAA<F5S(&]F('1H90T*($-O;7!A;GDF(W@R M,#$Y.W,@8V]M;6]N('-T;V-K(&%T(&%N(&5X97)C:7-E('!R:6-E(&]F("0U M+C(X('!E<@T*('-H87)E+"!F;W(@86=G<F5G871E(&=R;W-S('!R;V-E961S M(&]F(&%P<')O>&EM871E;'D@)#8P+C`@;6EL;&EO;BX-"B!!9G1E<B!I<W-U M86YC92!C;W-T<R!O9B!A<'!R;WAI;6%T96QY("0T+C`@;6EL;&EO;BP@=&AE M(&YE=`T*('!R;V-E961S(&9R;VT@=&AE($IU;F4@,C`Q,B!0=6)L:6,@3V9F M97)I;F=S('=E<F4@87!P<F]X:6UA=&5L>0T*("0U-BXP(&UI;&QI;VXN/"]F M;VYT/CPO<#X-"B`\<"!S='EL93TS1"=-05)'24XM0D]45$]-.B`P<'@[($U! M4D=)3BU43U`Z(#$R<'@[(%1%6%0M24Y$14Y4.B`T)2<@86QI9VX],T1J=7-T M:69Y/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M M86XG('-I>F4],T0R/E1H92!O9F9E<FEN9W,@=V5R92!M861E('!U<G-U86YT M('1O(&$@<VAE;&8@<F5G:7-T<F%T:6]N#0H@<W1A=&5M96YT('1H870@=&AE M($-O;7!A;GD@9FEL960@=VET:"!T:&4@4T5#(&]N($YO=F5M8F5R)B-X03`[ M,C4L#0H@,C`Q,2P@=VAI8V@@8F5C86UE(&5F9F5C=&EV92!O;B!$96-E;6)E M<B8C>$$P.S@L(#(P,3$@*$9I;&4-"B!.;RXF(WA!,#LS,S,M,3<X,3@Y*2!A M;F0@82!S=7!P;&5M96YT86P@<VAE;&8@<F5G:7-T<F%T:6]N#0H@<W1A=&5M M96YT(&]N)B-X03`[1F]R;28C>$$P.U,M,TU%1B!T:&%T('1H92!#;VUP86YY M(&9I;&5D('=I=&@@=&AE#0H@4T5#(&]N($IU;F4F(WA!,#LR,"P@,C`Q,BP@ M=VAI8V@@8F5C86UE(&5F9F5C=&EV92!O;B!*=6YE)B-X03`[,C`L#0H@,C`Q M,B`H1FEL928C>$$P.TYO+B8C>$$P.S,S,RTQ.#(R,C8I+B!4:&4@8VQO<VEN M9R!O9B!T:&4@;V9F97)I;F=S#0H@=&]O:R!P;&%C92!O;B!*=6YE)B-X03`[ M,C4L(#(P,3(N/"]F;VYT/CPO<#X-"B`\<"!S='EL93TS1"=-05)'24XM0D]4 M5$]-.B`P<'@[($U!4D=)3BU43U`Z(#$R<'@[(%1%6%0M24Y$14Y4.B`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`Q,B!0=6)L:6,@3V9F97)I;F=S('=E<F4@8V]N<VED97)E9"!T;R!B92!O M;F4@=')A;G-A8W1I;VXN#0H@5&AE(&9A:7(@=F%L=64@;V8@=&AE(&-O;6UO M;B!S=&]C:R!I<W-U960@:6X@=&AE($IU;F4@,C`Q,B!0=6)L:6,-"B!/9F9E M<FEN9W,@=V%S(&-A;&-U;&%T960@8F%S960@;VX@=&AE(&-L;W-I;F<@<')I M8V4@;V8@=&AE('-T;V-K(&]N#0H@=&AE(&-O;6UI=&UE;G0@9&%T92!A<R!Q M=6]T960@;VX@5&AE($Y!4T1!42!';&]B86P@36%R:V5T+B!4:&4-"B!397)I M97,@0B!0<F5F97)R960@4W1O8VL@=V%S('9A;'5E9"!B87-E9"!O;B!T:&4@ M9F%I<B!V86QU92!O9B!T:&4-"B!#;VUP86YY)B-X,C`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`D,"XP,#$@<&5R#0H@<VAA<F4N(%1H92!F86ER('9A;'5E(&]F('1H M92!W87)R86YT<R!W87,@9&5T97)M:6YE9"!U<VEN9R!T:&4-"B!";&%C:RU3 M8VAO;&5S('!R:6-I;F<@;6]D96PL(&%S(&1I<V-U<W-E9"!A8F]V92X@5&AE M(')E;&%T:79E(&9A:7(-"B!V86QU92!R871I;R!O9B!E86-H(&]F('1H92!I M;G-T<G5M96YT<R!I<W-U960@=V%S('1H96X@87!P;&EE9"!T;PT*('1H92!T M;W1A;"!G<F]S<R!P<F]C965D<R!O9B`D-C`N,"!M:6QL:6]N+"!R97-U;'1I M;F<@:6X@86QL;V-A=&5D#0H@<'5R8VAA<V4@<')I8V5S(&]F("0S,BXQ(&UI M;&QI;VX@9F]R('1H92!C;VUM;VX@<W1O8VLL("0Q,RXR#0H@;6EL;&EO;B!F M;W(@=&AE(%-E<FEE<R!"(%!R969E<G)E9"!3=&]C:RP@86YD("0Q-"XW(&UI M;&QI;VX@9F]R('1H90T*('=A<G)A;G1S+CPO9F]N=#X\+W`^#0H@/'`@<W1Y M;&4],T0G34%21TE.+4)/5%1/33H@,'!X.R!-05)'24XM5$]0.B`Q,G!X.R!4 M15A4+4E.1$5.5#H@-"4G(&%L:6=N/3-$:G5S=&EF>3X\9F]N="!S='EL93TS M1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CY);B!C M;VYJ=6YC=&EO;B!W:71H('1H92!!;6=E;B!!9W)E96UE;G0@06UE;F1M96YT M("AS964@3F]T92`W*2P-"B!I;B!*=6YE(#(P,3,L($%M9V5N('!U<F-H87-E M9"`Q+#0P-"PQ,#`@<VAA<F5S(&]F('1H90T*($-O;7!A;GDF(W@R,#$Y.W,@ M8V]M;6]N('-T;V-K(&%T(&$@<')I8V4@<&5R('-H87)E(&]F("0W+C$R(&%N M9"!A;@T*(&%G9W)E9V%T92!P=7)C:&%S92!P<FEC92!O9B`D,3`N,"!M:6QL M:6]N+"!W:&EC:"!W87,@<F5C96EV960@:6X-"B!*=6YE(#(P,3,N(%5N9&5R M('1H92!T97)M<R!O9B!T:&ES(&%G<F5E;65N="P@06UG96X@86=R965D('1O M#0H@8V5R=&%I;B!T<F%D:6YG(&%N9"!O=&AE<B!R97-T<FEC=&EO;G,@=VET M:"!R97-P96-T('1O('1H90T*($-O;7!A;GDF(W@R,#$Y.W,@8V]M;6]N('-T M;V-K+B!4:&4@0V]M<&%N>2!D971E<FUI;F5D('1H92!F86ER('9A;'5E#0H@ M;V8@=&AE('-T;V-K(&ES<W5E9"!T;R!!;6=E;B!T;R!B92`D-RXU(&UI;&QI M;VXN(%1H92!E>&-E<W,@;V8@8V%S:`T*(')E8V5I=F5D(&]V97(@9F%I<B!V M86QU92!O9B`D,BXU(&UI;&QI;VX@=V%S(&1E9F5R<F5D(&%N9"!I<R!B96EN M9PT*(&%L;&]C871E9"!B971W965N('1H92!L:6-E;G-E(&%N9"!S97)V:6-E M<R!B87-E9"!O;B!T:&5I<B!R96QA=&EV90T*('-E;&QI;F<@<')I8V5S('5S M:6YG(&)E<W0@97-T:6UA=&4@;V8@<V5L;&EN9R!P<FEC92X\+V9O;G0^/"]P M/@T*(#QP('-T>6QE/3-$)TU!4D=)3BU"3U143TTZ(#!P>#L@34%21TE.+51/ M4#H@,3)P>#L@5$585"U)3D1%3E0Z(#0E)R!A;&EG;CTS1&IU<W1I9GD^/&9O M;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ M93TS1#(^26X@1F5B<G5A<GD@,C`Q-"P@=&AE($-O;7!A;GD@8VQO<V5D(&%N M('5N9&5R=W)I='1E;B!P=6)L:6,-"B!O9F9E<FEN9R!F;W(@=&AE(&ES<W5A M;F-E(&%N9"!S86QE(&]F(#4L,#,Q+#(U,"!S:&%R97,@;V8@:71S#0H@8V]M M;6]N('-T;V-K+B!4:&4@9W)O<W,@<'5B;&EC(&]F9F5R:6YG('!R;V-E961S M('=E<F4@87!P<F]X:6UA=&5L>0T*("0T,"XS(&UI;&QI;VXN(%1H92!N970@ M<')O8V5E9',@9G)O;2!T:&4@<V%L92!O9B!T:&4@<VAA<F5S('=E<F4-"B!A M<'!R;WAI;6%T96QY("0S-RXU(&UI;&QI;VXL(&%F=&5R(&1E9'5C=&EN9R!T M:&4@=6YD97)W<FET:6YG#0H@9&ES8V]U;G0@86YD(&]F9F5R:6YG(&5X<&5N M<V5S+CPO9F]N=#X\+W`^#0H@/'`@<W1Y;&4],T0G34%21TE.+4)/5%1/33H@ M,'!X.R!-05)'24XM5$]0.B`Q,G!X.R!415A4+4E.1$5.5#H@-"4G(&%L:6=N M/3-$:G5S=&EF>3X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@ M3F5W(%)O;6%N)R!S:7IE/3-$,CY);B!$96-E;6)E<B`R,#$T+"!T:&4@0V]M M<&%N>2!A;'-O(&5N=&5R960@:6YT;R!A(&-O;6UO;B!S=&]C:PT*('!U<F-H M87-E(&%G<F5E;65N="!W:&EC:"!P<F]V:61E9"!F;W(@=&AE('-A;&4@;V8@ M,BPP-#`L.#$V('-H87)E<PT*(&]F(&ET<R!C;VUM;VX@<W1O8VL@=&\@07-T M96QL87,@870@82!P<FEC92!P97(@<VAA<F4@;V8@)#0N.3`@86YD#0H@86X@ M86=G<F5G871E('!U<F-H87-E('!R:6-E(&]F("0Q,"XP(&UI;&QI;VXL('=H M:6-H('=A<R!R96-E:79E9"!I;@T*($1E8V5M8F5R(#(P,30N/"]F;VYT/CPO M<#X-"B`\<"!S='EL93TS1"=-05)'24XM0D]45$]-.B`P<'@[($U!4D=)3BU, M1494.B`R)3L@34%21TE.+51/4#H@,3AP>"<^#0H@/&9O;G0@<W1Y;&4],T0G M1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^/&(^/&D^ M5V%R<F%N=',\+VD^/"]B/CPO9F]N=#X\+W`^#0H@/'`@<W1Y;&4],T0G34%2 M1TE.+4)/5%1/33H@,'!X.R!-05)'24XM5$]0.B`V<'@[(%1%6%0M24Y$14Y4 M.B`T)2<@86QI9VX],T1J=7-T:69Y/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%- M24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R/D]N($%P<FEL)B-X03`[ M,C`L(#(P,3$L('!U<G-U86YT('1O('1H92!$965R9FEE;&0@06=R965M96YT M+`T*('1H92!#;VUP86YY(&ES<W5E9"!T;R!$965R9FEE;&0@=V%R<F%N=',@ M=&\@<'5R8VAA<V4@,2PQ,30L,38X#0H@<VAA<F5S(&]F('1H92!#;VUP86YY M)B-X,C`Q.3MS(&-O;6UO;B!S=&]C:R!A="!A;B!I;FET:6%L(&5X97)C:7-E M#0H@<')I8V4@;V8@)#DN.3`@<&5R('-H87)E+"!F;W(@86=G<F5G871E(&=R M;W-S('!R;V-E961S(&]F#0H@87!P<F]X:6UA=&5L>2`D-"XU(&UI;&QI;VXN M($%F=&5R(&ES<W5A;F-E(&-O<W1S(&]F(&%P<')O>&EM871E;'D-"B`D,"XQ M(&UI;&QI;VXL('1H92!N970@<')O8V5E9',@=V5R92!A<'!R;WAI;6%T96QY M("0T+C0@;6EL;&EO;BX@5&AE#0H@=V%R<F%N=',@:7-S=65D('1O($1E97)F M:65L9"!B96-A;64@97AE<F-I<V%B;&4@;VX@3V-T;V)E<B8C>$$P.S(P+`T* M(#(P,3$@86YD('=I;&P@<F5M86EN(&5X97)C:7-A8FQE('5N=&EL($%P<FEL M)B-X03`[,C`L(#(P,34N(%1H90T*('=A<G)A;G0@:&]L9&5R<R!A<F4@<')O M:&EB:71E9"!F<F]M(&5X97)C:7-I;F<@=&AE('=A<G)A;G1S(&%N9`T*(&]B M=&%I;FEN9R!S:&%R97,@;V8@8V]M;6]N('-T;V-K(&EF+"!A<R!A(')E<W5L M="!O9B!S=6-H(&5X97)C:7-E+`T*('1H92!H;VQD97(@86YD(&ET<R!A9F9I M;&EA=&5S('=O=6QD(&]W;B!M;W)E('1H86X@.2XY."4@;V8@=&AE#0H@=&]T M86P@;G5M8F5R(&]F('-H87)E<R!O9B!T:&4@0V]M<&%N>28C>#(P,3D[<R!C M;VUM;VX@<W1O8VL@=&AE;@T*(&ES<W5E9"!A;F0@;W5T<W1A;F1I;F<N(%1H M92!#;VUP86YY('9A;'5E9"!T:&4@=V%R<F%N=',@87,@;V8@=&AE#0H@9&%T M92!O9B!I<W-U86YC92!A="`D-2XX(&UI;&QI;VX@=7-I;F<@=&AE($)L86-K M+5-C:&]L97,@;W!T:6]N#0H@<')I8VEN9R!M;V1E;"!A;F0@=&AE(&9O;&QO M=VEN9R!A<W-U;7!T:6]N<SH@82!C;VYT<F%C='5A;"!T97)M(&]F#0H@9F]U M<B!Y96%R<RP@82!R:7-K+69R964@:6YT97)E<W0@<F%T92!O9B`Q+C8V)2P@ M=F]L871I;&ET>2!O9B`X,"4L#0H@86YD('1H92!F86ER('9A;'5E(&]F('1H M92!#;VUP86YY)B-X,C`Q.3MS(&-O;6UO;B!S=&]C:R!O;B!T:&4-"B!I<W-U M86YC92!D871E(&]F("0Y+C$R("@D,2XU,B!B969O<F4@861J=7-T;65N="!F M;W(@=&AE#0H@0V]M<&%N>28C>#(P,3D[<R`R,#$S(')E=F5R<V4@<W1O8VL@ M<W!L:70L('-E92!.;W1E(#$I+CPO9F]N=#X\+W`^#0H@/'`@<W1Y;&4],T0G M34%21TE.+4)/5%1/33H@,'!X.R!-05)'24XM5$]0.B`Q,G!X.R!415A4+4E. M1$5.5#H@-"4G(&%L:6=N/3-$:G5S=&EF>3X\9F]N="!S='EL93TS1"=&3TY4 M+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CY/;B!*=6YE)B-X M03`[,C4L(#(P,3(L('!U<G-U86YT('1O('1H92!*=6YE(#(P,3(@4'5B;&EC M#0H@3V9F97)I;F=S+"!T:&4@0V]M<&%N>2!I<W-U960@=V%R<F%N=',@=&\@ M<'5R8VAA<V4@-RPX.30L-S`T('-H87)E<PT*(&]F('1H92!#;VUP86YY)B-X M,C`Q.3MS(&-O;6UO;B!S=&]C:R!A="!A;B!E>&5R8VES92!P<FEC92!O9B`D M-2XR.`T*('!E<B!S:&%R92P@9F]R(&%N(&%G9W)E9V%T92!G<F]S<R!P<F]C M965D<R!O9B!A<'!R;WAI;6%T96QY("0Q-"XW#0H@;6EL;&EO;BX@5&AE('=A M<G)A;G0@:&]L9&5R<R!A<F4@<')O:&EB:71E9"!F<F]M(&5X97)C:7-I;F<@ M=&AE#0H@=V%R<F%N=',@86YD(&]B=&%I;FEN9R!S:&%R97,@;V8@8V]M;6]N M('-T;V-K(&EF+"!A<R!A(')E<W5L="!O9@T*('-U8V@@97AE<F-I<V4L('1H M92!H;VQD97(@86YD(&ET<R!A9F9I;&EA=&5S('=O=6QD(&]W;B!M;W)E('1H M86X-"B`Y+CDX)2!O9B!T:&4@=&]T86P@;G5M8F5R(&]F('-H87)E<R!O9B!T M:&4@0V]M<&%N>28C>#(P,3D[<R!C;VUM;VX-"B!S=&]C:R!T:&5N(&ES<W5E M9"!A;F0@;W5T<W1A;F1I;F<N(%1H92!#;VUP86YY('9A;'5E9"!T:&4@=V%R M<F%N=',-"B!A<R!O9B!T:&4@9&%T92!O9B!I<W-U86YC92!A="`D,38N,B!M M:6QL:6]N('5S:6YG('1H92!";&%C:RU38VAO;&5S#0H@;W!T:6]N('!R:6-I M;F<@;6]D96P@86YD('1H92!F;VQL;W=I;F<@87-S=6UP=&EO;G,Z(&$@8V]N M=')A8W1U86P-"B!T97)M(&]F(&9I=F4@>65A<G,L(&$@<FES:RUF<F5E(&EN M=&5R97-T(')A=&4@;V8@,"XW,R4L('9O;&%T:6QI='D-"B!O9B`W-B4L(&%N M9"!T:&4@9F%I<B!V86QU92!O9B!T:&4@0V]M<&%N>28C>#(P,3D[<R!C;VUM M;VX@<W1O8VL@;VX-"B!T:&4@:7-S=6%N8V4@9&%T92!O9B`D,RXW."`H)#`N M-C,@8F5F;W)E(&%D:G5S=&UE;G0@9F]R('1H90T*($-O;7!A;GDF(W@R,#$Y M.W,@,C`Q,R!R979E<G-E('-T;V-K('-P;&ET+"!S964@3F]T92`Q*2X\+V9O M;G0^/"]P/@T*(#QP('-T>6QE/3-$)TU!4D=)3BU"3U143TTZ(#!P>#L@1D]. M5"U325I%.B`Q,G!X.R!-05)'24XM5$]0.B`P<'@G/@T*(#QF;VYT('-I>F4] M,T0Q/B8C>$$P.SPO9F]N=#X\+W`^#0H@/'`@<W1Y;&4],T0G34%21TE.+4)/ M5%1/33H@,'!X.R!-05)'24XM5$]0.B`P<'@[(%1%6%0M24Y$14Y4.B`T)2<@ M86QI9VX],T1J=7-T:69Y/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4 M:6UE<R!.97<@4F]M86XG('-I>F4],T0R/DEN($9E8G)U87)Y(#(P,3,L('=A M<G)A;G1S('1O('!U<F-H87-E(#$L,#`P('-H87)E<R!O9B!T:&4-"B!#;VUP M86YY)B-X,C`Q.3MS(&-O;6UO;B!S=&]C:R!A="!A;B!E>&5R8VES92!P<FEC M92!O9B`D-2XR."!P97(-"B!S:&%R92!W97)E(&-A<V@@97AE<F-I<V5D(&EN M(&%C8V]R9&%N8V4@=VET:"!T:&4@2G5N92`R,#$R(%!U8FQI8PT*($]F9F5R M:6YG<R!U;F1E<G=R:71I;F<@86=R965M96YT<RX\+V9O;G0^/"]P/@T*(#QP M('-T>6QE/3-$)TU!4D=)3BU"3U143TTZ(#!P>#L@34%21TE.+51/4#H@,3)P M>#L@5$585"U)3D1%3E0Z(#0E)R!A;&EG;CTS1&IU<W1I9GD^/&9O;G0@<W1Y M;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^ M26X@07!R:6P@,C`Q,RP@=&AE($-O;7!A;GD@:7-S=65D(#,U."PT-C`@<VAA M<F5S(&]F(&-O;6UO;@T*('-T;V-K(')E;&%T960@=&\@8V%S:&QE<W,@97AE M<F-I<V5S(&]F('=A<G)A;G1S(&EN(&%C8V]R9&%N8V4@=VET:`T*('1H92!* M=6YE(#(P,3(@4'5B;&EC($]F9F5R:6YG<RX\+V9O;G0^/"]P/@T*(#QP('-T M>6QE/3-$)TU!4D=)3BU"3U143TTZ(#!P>#L@34%21TE.+51/4#H@,3)P>#L@ M5$585"U)3D1%3E0Z(#0E)R!A;&EG;CTS1&IU<W1I9GD^/&9O;G0@<W1Y;&4] M,T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^3W5T M<W1A;F1I;F<@=V%R<F%N=',@87,@;V8@1&5C96UB97(F(WA!,#LS,2P@,C`Q M-"!W97)E(&%S#0H@9F]L;&]W<SH\+V9O;G0^/"]P/@T*(#QP('-T>6QE/3-$ M)TU!4D=)3BU"3U143TTZ(#!P>#L@1D].5"U325I%.B`Q,G!X.R!-05)'24XM M5$]0.B`P<'@G/@T*("8C>$$P.SPO<#X-"B`\=&%B;&4@<W1Y;&4],T0G0D]2 M1$52+4-/3$Q!4%-%.B!C;VQL87!S92<@8V5L;'-P86-I;F<],T0P(&-E;&QP M861D:6YG/3-$,"!W:61T:#TS1#DR)2!A;&EG;CTS1&-E;G1E<B!B;W)D97(] M,T0P/@T*(#PA+2T@0F5G:6X@5&%B;&4@2&5A9"`M+3X-"B`\='(^#0H@/'1D M('=I9'1H/3-$-C<E/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!W:61T M:#TS1#0E/CPO=&0^#0H@/'1D/CPO=&0^#0H@/'1D/CPO=&0^#0H@/'1D/CPO M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#0E/CPO=&0^#0H@ M/'1D/CPO=&0^#0H@/'1D/CPO=&0^#0H@/'1D/CPO=&0^#0H@/'1D('9A;&EG M;CTS1&)O='1O;2!W:61T:#TS1#0E/CPO=&0^#0H@/'1D/CPO=&0^#0H@/'1D M/CPO=&0^#0H@/'1D/CPO=&0^#0H@/"]T<CX-"B`\='(^#0H@/'1D('9A;&EG M;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF(WA!,#L\+V9O;G0^/"]T9#X- M"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C>$$P.R8C M>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!S='EL93TS1"="3U)$15(M0D]45$]- M.B!R9V(H,"PP+#`I(#%P>"!S;VQI9"<@=F%L:6=N/3-$8F]T=&]M(&-O;'-P M86X],T0R(&%L:6=N/3-$8V5N=&5R/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%- M24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0Q/CQB/DYU;6)E<CQB<B`O M/@T*(&]F(%-H87)E<SPO8CX\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$ M8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT M9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<VEZ93TS1#$^)B-X03`[)B-X03`[ M/"]F;VYT/CPO=&0^#0H@/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(')G M8B@P+#`L,"D@,7!X('-O;&ED)R!V86QI9VX],T1B;W1T;VT@8V]L<W!A;CTS M1#(@86QI9VX],T1C96YT97(^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ M(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#$^/&(^17AE<F-I<V4\8G(@+SX- M"B!0<FEC93PO8CX\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M M/CQF;VYT('-I>F4],T0Q/B8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI M9VX],T1B;W1T;VT^/&9O;G0@<VEZ93TS1#$^)B-X03`[)B-X03`[/"]F;VYT M/CPO=&0^#0H@/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(')G8B@P+#`L M,"D@,7!X('-O;&ED)R!V86QI9VX],T1B;W1T;VT@8V]L<W!A;CTS1#(@86QI M9VX],T1C96YT97(^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S M($YE=R!2;VUA;B<@<VEZ93TS1#$^/&(^17AP:7)A=&EO;CQB<B`O/@T*($1A M=&4\+V(^/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N M="!S:7IE/3-$,3XF(WA!,#L\+V9O;G0^/"]T9#X-"B`\+W1R/@T*(#PA+2T@ M16YD(%1A8FQE($AE860@+2T^/"$M+2!"96=I;B!486)L92!";V1Y("TM/@T* M(#QT<B!B9V-O;&]R/3-$(T-#145&1CX-"B`\=&0@=F%L:6=N/3-$=&]P/@T* M(#QP('-T>6QE/3-$)TU!4D=)3BU,1494.B`Q96T[(%1%6%0M24Y$14Y4.B`M M,65M)SX\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O M;6%N)R!S:7IE/3-$,CY)<W-U960@-"\R,"\R,#$Q/"]F;VYT/CPO<#X-"B`\ M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<VEZ93TS1#$^)B-X M03`[)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\ M9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S M:7IE/3-$,CXF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T M=&]M(&%L:6=N/3-$<FEG:'0^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ M(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^,2PQ,30L,38X/"]F;VYT/CPO M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^/&9O M;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ M93TS1#(^)B-X03`[)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS M1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF(WA!,#LF(WA!,#L\+V9O;G0^/"]T M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)T9/3E0M M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R/B0\+V9O;G0^/"]T M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^/&9O;G0@ M<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS M1#(^.2XY,#PO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W M<F%P/3-$;F]W<F%P/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE M<R!.97<@4F]M86XG('-I>F4],T0R/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<VEZ93TS1#$^)B-X03`[ M)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N M="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE M/3-$,CXF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M M(&%L:6=N/3-$<FEG:'0^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I M;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^,#0O,C`O,34\+V9O;G0^/"]T9#X- M"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#X\9F]N="!S M='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$ M,CXF(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\+W1R/@T*(#QT<CX-"B`\ M=&0@=F%L:6=N/3-$=&]P/@T*(#QP('-T>6QE/3-$)TU!4D=)3BU,1494.B`Q M96T[(%1%6%0M24Y$14Y4.B`M,65M)SX\9F]N="!S='EL93TS1"=&3TY4+49! M34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CY)<W-U960@-B\R-2\R M,#$R/"]F;VYT/CPO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^ M/&9O;G0@<VEZ93TS1#$^)B-X03`[)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D M('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@ M5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXF(WA!,#L\+V9O;G0^/"]T9#X- M"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^/&9O;G0@<W1Y M;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^ M-2PU-S8L.3(X/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N M;W=R87`],T1N;W=R87`^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I M;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^)B-X03`[)B-X03`[/"]F;VYT/CPO M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF(WA! M,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF M;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I M>F4],T0R/B0\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L M:6=N/3-$<FEG:'0^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S M($YE=R!2;VUA;B<@<VEZ93TS1#(^-2XR.#PO9F]N=#X\+W1D/@T*(#QT9"!V M86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P/CQF;VYT('-T>6QE/3-$ M)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R/B8C>$$P M.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O M;G0@<VEZ93TS1#$^)B-X03`[)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A M;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM M97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXF(WA!,#L\+V9O;G0^/"]T9#X-"B`\ M=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^/&9O;G0@<W1Y;&4] M,T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^,#8O M,C4O,3<\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A M<#TS1&YO=W)A<#X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@ M3F5W(%)O;6%N)R!S:7IE/3-$,CXF(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X- M"B`\+W1R/@T*(#PA+2T@16YD(%1A8FQE($)O9'D@+2T^/"]T86)L93X-"B`\ M<"!S='EL93TS1"=-05)'24XM0D]45$]-.B`P<'@[($U!4D=)3BU,1494.B`R M)3L@34%21TE.+51/4#H@,3AP>"<^#0H@/&9O;G0@<W1Y;&4],T0G1D].5"U& M04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^/&(^/&D^4W1O8VL- M"B!/<'1I;VX@4&QA;G,\+VD^/"]B/CPO9F]N=#X\+W`^#0H@/'`@<W1Y;&4] M,T0G34%21TE.+4)/5%1/33H@,'!X.R!-05)'24XM3$5&5#H@,B4[($U!4D=) M3BU43U`Z(#9P>"<^#0H@/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I M;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^/&D^,C`P-`T*(%!L86X\+VD^/"]F M;VYT/CPO<#X-"B`\<"!S='EL93TS1"=-05)'24XM0D]45$]-.B`P<'@[($U! M4D=)3BU43U`Z(#9P>#L@5$585"U)3D1%3E0Z(#0E)R!A;&EG;CTS1&IU<W1I M9GD^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA M;B<@<VEZ93TS1#(^26X@2F%N=6%R>2`R,#`T+"!T:&4@0F]A<F0@;V8@1&ER M96-T;W)S(&%D;W!T960@=&AE(#(P,#0@17%U:71Y#0H@26YC96YT:79E(%!L M86X@*'1H92`F(W@R,#%#.S(P,#0@4&QA;B8C>#(P,40[*2P@=VAI8V@@=V%S M(&%P<')O=F5D(&)Y#0H@=&AE('-T;V-K:&]L9&5R<R!I;B!&96)R=6%R>2`R M,#`T+B!4:&4@,C`P-"!0;&%N('!R;W9I9&5S(&9O<B!T:&4-"B!G<F%N=&EN M9R!O9B!I;F-E;G1I=F4@<W1O8VL@;W!T:6]N<RP@;F]N<W1A='5T;W)Y('-T M;V-K(&]P=&EO;G,L#0H@<F5S=')I8W1E9"!S=&]C:RP@<W1O8VL@87!P<F5C M:6%T:6]N(')I9VAT<RP@<W1O8VL@<&5R9F]R;6%N8V4-"B!U;FET<R!A;F0@ M<W1O8VL@<&5R9F]R;6%N8V4@<VAA<F5S('1O(&5M<&QO>65E<RP@9&ER96-T M;W)S(&%N9`T*(&-O;G-U;'1A;G1S+B!5;F1E<B!T:&4@,C`P-"!0;&%N+"!O M<'1I;VYS(&UA>2!B92!G<F%N=&5D(&%T('!R:6-E<PT*(&YO="!L;W=E<B!T M:&%N(#$P,"4@;V8@=&AE(&9A:7(@;6%R:V5T('9A;'5E(&]F('1H92!C;VUM M;VX@<W1O8VL@;VX-"B!T:&4@9&%T92!O9B!G<F%N="!F;W(@;F]N<W1A='5T M;W)Y('-T;V-K(&]P=&EO;G,@86YD(&EN8V5N=&EV90T*('-T;V-K(&]P=&EO M;G,@86YD(&UA>2!B92!G<F%N=&5D(&9O<B!T97)M<R!O9B!U<"!T;R!T96X@ M>65A<G,@9G)O;0T*('1H92!D871E(&]F(&=R86YT+B!/<'1I;VYS(&=R86YT M960@=&\@;F5W(&5M<&QO>65E<R!G96YE<F%L;'D@=F5S=`T*(#(U)2!A9G1E M<B!O;F4@>65A<B!A;F0@;6]N=&AL>2!T:&5R96%F=&5R(&]V97(@82!P97)I M;V0@;V8@9F]U<@T*('EE87)S+B!/<'1I;VYS(&=R86YT960@=&\@97AI<W1I M;F<@96UP;&]Y965S(&=E;F5R86QL>2!V97-T(&UO;G1H;'D-"B!O=F5R(&$@ M<&5R:6]D(&]F(&9O=7(@>65A<G,N($%T('1H92!-87D@,C`Q,R!!;FYU86P@ M365E=&EN9R!O9@T*(%-T;V-K:&]L9&5R<RP@=&AE(&YU;6)E<B!O9B!S:&%R M97,@;V8@8V]M;6]N('-T;V-K(&%U=&AO<FEZ960@9F]R#0H@:7-S=6%N8V4@ M=6YD97(@=&AE(#(P,#0@4&QA;B!W87,@:6YC<F5A<V5D(&)Y(#(L,#`P+#`P M,"X@07,@;V8-"B!$96-E;6)E<B8C>$$P.S,Q+"`R,#$T+"!T:&5R92!W97)E M(#$L,C<P+#0W."!S:&%R97,@;V8@8V]M;6]N('-T;V-K#0H@<F5S97)V960@ M9F]R(&ES<W5A;F-E('5N9&5R('1H92`R,#`T(%!L86XN/"]F;VYT/CPO<#X- M"B`\<"!S='EL93TS1"=-05)'24XM0D]45$]-.B`P<'@[($U!4D=)3BU,1494 M.B`R)3L@34%21TE.+51/4#H@,3AP>"<^#0H@/&9O;G0@<W1Y;&4],T0G1D]. M5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^/&D^,3DY-PT* M(%!L86X\+VD^/"]F;VYT/CPO<#X-"B`\<"!S='EL93TS1"=-05)'24XM0D]4 M5$]-.B`P<'@[($U!4D=)3BU43U`Z(#9P>#L@5$585"U)3D1%3E0Z(#0E)R!A M;&EG;CTS1&IU<W1I9GD^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I M;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^26X@,3DY-RP@=&AE($-O;7!A;GD@ M861O<'1E9"!T:&4@,3DY-R!3=&]C:R!/<'1I;VXO4W1O8VL-"B!)<W-U86YC M92!0;&%N("AT:&4@)B-X,C`Q0SLQ.3DW(%!L86XF(W@R,#%$.RDN(%1H92!0 M;&%N('!R;W9I9&5S(&9O<@T*('1H92!G<F%N=&EN9R!O9B!S=&]C:R!O<'1I M;VYS('1O(&5M<&QO>65E<R!A;F0@8V]N<W5L=&%N=',@;V8@=&AE#0H@0V]M M<&%N>2X@3W!T:6]N<R!G<F%N=&5D('5N9&5R('1H92`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`T*('!R;W9I9&5D+"!H;W=E=F5R+"!T:&%T("AI*28C>$$P.W1H M92!E>&5R8VES92!P<FEC92!O9B!A;B!I;F-E;G1I=F4-"B!S=&]C:R!O<'1I M;VX@86YD(&YO;G-T871U=&]R>2!S=&]C:R!O<'1I;VX@<VAA;&P@;F]T(&)E M(&QE<W,@=&AA;@T*(#$P,"4@86YD(#@U)2!O9B!T:&4@97-T:6UA=&5D(&9A M:7(@;6%R:V5T('9A;'5E(&]F('1H92!S:&%R97,@;VX-"B!T:&4@9&%T92!O M9B!G<F%N="P@<F5S<&5C=&EV96QY+"!A;F0@*&EI*28C>$$P.W=I=&@@<F5S M<&5C="!T;R!A;GD-"B`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`R-24@869T97(@;VYE('EE87(@86YD(&UO;G1H;'D-"B!T:&5R96%F M=&5R*2X@07,@;V8@1&5C96UB97(F(WA!,#LS,2P@,C`Q-"P@=&AE($-O;7!A M;GD@:&%D(')E<V5R=F5D#0H@;F\F(WA!,#MS:&%R97,@;V8@8V]M;6]N('-T M;V-K(&9O<B!I<W-U86YC92!R96QA=&5D('1O(&]P=&EO;G,-"B!O=71S=&%N M9&EN9R!U;F1E<B!T:&4@,3DY-R!0;&%N+"!A;F0@=&AE<F4@=V5R92!N;R!S M:&%R97,@879A:6QA8FQE#0H@9F]R(&9U='5R92!G<F%N=',@=6YD97(@=&AE M(#$Y.3<@4&QA;BX\+V9O;G0^/"]P/@T*(#QP('-T>6QE/3-$)TU!4D=)3BU" M3U143TTZ(#!P>#L@1D].5"U325I%.B`Q.'!X.R!-05)'24XM5$]0.B`P<'@G M/@T*("8C>$$P.SPO<#X-"B`\<"!S='EL93TS1"=-05)'24XM0D]45$]-.B`P M<'@[($U!4D=)3BU43U`Z(#!P>#L@5$585"U)3D1%3E0Z(#0E)R!A;&EG;CTS M1&IU<W1I9GD^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE M=R!2;VUA;B<@<VEZ93TS1#(^06-T:79I='D@=6YD97(@=&AE('1W;R!S=&]C M:R!O<'1I;VX@<&QA;G,@=V%S(&%S#0H@9F]L;&]W<SH\+V9O;G0^/"]P/@T* M(#QP('-T>6QE/3-$)TU!4D=)3BU"3U143TTZ(#!P>#L@1D].5"U325I%.B`Q M,G!X.R!-05)'24XM5$]0.B`P<'@G/@T*("8C>$$P.SPO<#X-"B`\=&%B;&4@ M<W1Y;&4],T0G0D]21$52+4-/3$Q!4%-%.B!C;VQL87!S92<@8V5L;'-P86-I M;F<],T0P(&-E;&QP861D:6YG/3-$,"!W:61T:#TS1#$P,"4@86QI9VX],T1C M96YT97(@8F]R9&5R/3-$,#X-"B`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`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O M='1O;3X\9F]N="!S:7IE/3-$,3XF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@ M<W1Y;&4],T0G0D]21$52+4)/5%1/33H@<F=B*#`L,"PP*2`Q<'@@<V]L:60G M('9A;&EG;CTS1&)O='1O;2!C;VQS<&%N/3-$,B!A;&EG;CTS1&-E;G1E<CX\ M9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S M:7IE/3-$,3X\8CY3:&%R97,\8G(@+SX-"B!!=F%I;&%B;&4F(WA!,#MF;W(\ M8G(@+SX-"B!'<F%N="8C>$$P.V]F)B-X03`[3W!T:6]N/&)R("\^#0H@;W(@ M07=A<F0\+V(^/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\ M9F]N="!S:7IE/3-$,3XF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N M/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C>$$P.SPO9F]N=#X\+W1D/@T* M(#QT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B!R9V(H,"PP+#`I(#%P>"!S M;VQI9"<@=F%L:6=N/3-$8F]T=&]M(&-O;'-P86X],T0R(&%L:6=N/3-$8V5N M=&5R/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M M86XG('-I>F4],T0Q/CQB/E-T;V-K)B-X03`[3W!T:6]N<SQB<B`O/@T*($]U M='-T86YD:6YG/"]B/CPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T M;VT^/&9O;G0@<VEZ93TS1#$^)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A M;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF(WA!,#L\+V9O;G0^/"]T M9#X-"B`\=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@<F=B*#`L,"PP*2`Q M<'@@<V]L:60G('9A;&EG;CTS1&)O='1O;2!C;VQS<&%N/3-$,B!A;&EG;CTS M1&-E;G1E<CX\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W M(%)O;6%N)R!S:7IE/3-$,3X\8CY796EG:'1E9#QB<B`O/@T*($%V97)A9V4F M(WA!,#M%>&5R8VES93QB<B`O/@T*(%!R:6-E('!E<B!3:&%R92`M/&)R("\^ M#0H@4W1O8VL@3W!T:6]N<SPO8CX\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N M/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C>$$P.SPO9F]N=#X\+W1D/@T* M(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<VEZ93TS1#$^)B-X03`[/"]F M;VYT/CPO=&0^#0H@/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(')G8B@P M+#`L,"D@,7!X('-O;&ED)R!V86QI9VX],T1B;W1T;VT@8V]L<W!A;CTS1#(@ M86QI9VX],T1C96YT97(^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I M;65S($YE=R!2;VUA;B<@<VEZ93TS1#$^/&(^5V5I9VAT960\8G(@+SX-"B!! M=F5R86=E)B-X03`[4F5M86EN:6YG/&)R("\^#0H@0V]N=')A8W1U86PF(WA! M,#M,:69E/"]B/CPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^ M/&9O;G0@<VEZ93TS1#$^)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG M;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF(WA!,#L\+V9O;G0^/"]T9#X- M"B`\=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@<F=B*#`L,"PP*2`Q<'@@ M<V]L:60G('9A;&EG;CTS1&)O='1O;2!C;VQS<&%N/3-$,B!A;&EG;CTS1&-E M;G1E<CX\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O M;6%N)R!S:7IE/3-$,3X\8CY!9V=R96=A=&4\8G(@+SX-"B!);G1R:6YS:6,\ M8G(@+SX-"B!686QU93PO8CX\+V9O;G0^/&)R("\^#0H@/&9O;G0@<W1Y;&4] M,T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#$^/&(^ M*&EN)B-X03`[#0H@=&AO=7-A;F1S*3PO8CX\+V9O;G0^/"]T9#X-"B`\=&0@ M=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C>$$P.SPO9F]N=#X\ M+W1D/@T*(#PO='(^#0H@/"$M+2!%;F0@5&%B;&4@2&5A9"`M+3X\(2TM($)E M9VEN(%1A8FQE($)O9'D@+2T^#0H@/'1R(&)G8V]L;W(],T0C0T-%149&/@T* M(#QT9"!V86QI9VX],T1T;W`^#0H@/'`@<W1Y;&4],T0G34%21TE.+4Q%1E0Z M(#)E;3L@5$585"U)3D1%3E0Z("TQ96TG/CQF;VYT('-T>6QE/3-$)T9/3E0M M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R/D)A;&%N8V4@870- M"B!$96-E;6)E<B8C>$$P.S,Q+"`R,#$Q/"]F;VYT/CPO<#X-"B`\+W1D/@T* M(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<VEZ93TS1#$^)B-X03`[/"]F M;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS M1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXF(WA! M,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$ M<FEG:'0^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2 M;VUA;B<@<VEZ93TS1#(^-3@U+#0W-CPO9F]N=#X\+W1D/@T*(#QT9"!V86QI M9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P/CQF;VYT('-T>6QE/3-$)T9/ M3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R/B8C>$$P.R8C M>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@ M<VEZ93TS1#$^)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O M='1O;3X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O M;6%N)R!S:7IE/3-$,CXF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N M/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^/&9O;G0@<W1Y;&4],T0G1D].5"U& M04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^,2PU.3@L-#`X/"]F M;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R M87`^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA M;B<@<VEZ93TS1#(^)B-X03`[)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A M;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF(WA!,#L\+V9O;G0^/"]T M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)T9/3E0M M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R/B8C>$$P.SPO9F]N M=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#X\ M9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S M:7IE/3-$,CXR,2XY,SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T M;VT@;F]W<F%P/3-$;F]W<F%P/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9 M.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R/B8C>$$P.R8C>$$P.SPO9F]N M=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<VEZ93TS1#$^ M)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\=&0@=F%L:6=N/3-$ M8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE M/3-$,3XF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI M9VX],T1B;W1T;VT^/"]T9#X-"B`\+W1R/@T*(#QT<CX-"B`\=&0@=F%L:6=N M/3-$=&]P/@T*(#QP('-T>6QE/3-$)TU!4D=)3BU,1494.B`Q96T[(%1%6%0M M24Y$14Y4.B`M,65M)SX\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM M97,@3F5W(%)O;6%N)R!S:7IE/3-$,CY);F-R96%S92!I;B!A=71H;W)I>F5D M#0H@<VAA<F5S/"]F;VYT/CPO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B M;W1T;VT^/&9O;G0@<VEZ93TS1#$^)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D M('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@ M5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXF(WA!,#L\+V9O;G0^/"]T9#X- M"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^/&9O;G0@<W1Y M;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^ M-#$V+#8V-SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W M<F%P/3-$;F]W<F%P/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE M<R!.97<@4F]M86XG('-I>F4],T0R/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<VEZ93TS1#$^)B-X03`[ M/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N M;W=R87`^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2 M;VUA;B<@<VEZ93TS1#(^)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG M;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`@86QI9VX],T1R:6=H=#X\9F]N M="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE M/3-$,CXF(W@R,#$T.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T M;VT@;F]W<F%P/3-$;F]W<F%P/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9 M.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R/B8C>$$P.R8C>$$P.SPO9F]N M=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<VEZ93TS1#$^ M)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R M87`],T1N;W=R87`^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S M($YE=R!2;VUA;B<@<VEZ93TS1#(^)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D M('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`@86QI9VX],T1R:6=H M=#X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N M)R!S:7IE/3-$,CXF(W@R,#$T.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX] M,T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P/CQF;VYT('-T>6QE/3-$)T9/3E0M M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R/B8C>$$P.R8C>$$P M.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<VEZ M93TS1#$^)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O M;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\=&0@=F%L M:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N M="!S:7IE/3-$,3XF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$ M8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT M9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\+W1R/@T*(#QT<B!B9V-O;&]R M/3-$(T-#145&1CX-"B`\=&0@=F%L:6=N/3-$=&]P/@T*(#QP('-T>6QE/3-$ M)TU!4D=)3BU,1494.B`Q96T[(%1%6%0M24Y$14Y4.B`M,65M)SX\9F]N="!S M='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$ M,CY/<'1I;VYS(&=R86YT960\+V9O;G0^/"]P/@T*(#PO=&0^#0H@/'1D('9A M;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF(WA!,#L\+V9O;G0^/"]T M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)T9/3E0M M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R/B8C>$$P.SPO9F]N M=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#X\ M9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S M:7IE/3-$,CXH-#`S+#$P.#PO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B M;W1T;VT@;F]W<F%P/3-$;F]W<F%P/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%- M24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R/BDF(WA!,#L\+V9O;G0^ M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C M>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@ M<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS M1#(^)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A M;&EG;CTS1')I9VAT/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE M<R!.97<@4F]M86XG('-I>F4],T0R/C0P,RPQ,#@\+V9O;G0^/"]T9#X-"B`\ M=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#X\9F]N="!S='EL M93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXF M(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M M/CQF;VYT('-I>F4],T0Q/B8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI M9VX],T1B;W1T;VT^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S M($YE=R!2;VUA;B<@<VEZ93TS1#(^)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D M('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/CQF;VYT('-T>6QE/3-$ M)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R/C8N,30\ M+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO M=W)A<#X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O M;6%N)R!S:7IE/3-$,CXF(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@ M=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C>$$P.SPO9F]N=#X\ M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\=&0@=F%L:6=N M/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T* M(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<VEZ93TS1#$^)B-X03`[/"]F M;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V M86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO M=&0^#0H@/"]T<CX-"B`\='(^#0H@/'1D('9A;&EG;CTS1'1O<#X-"B`\<"!S M='EL93TS1"=-05)'24XM3$5&5#H@,65M.R!415A4+4E.1$5.5#H@+3%E;2<^ M/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@ M<VEZ93TS1#(^3W!T:6]N<PT*(&9O<F9E:71E9"]E>'!I<F5D/"]F;VYT/CPO M<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<VEZ93TS M1#$^)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\ M9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S M:7IE/3-$,CXF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T M=&]M(&%L:6=N/3-$<FEG:'0^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ M(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^,C$P+#DX.3PO9F]N=#X\+W1D M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P/CQF;VYT M('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4] M,T0R/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B M;W1T;VT^/&9O;G0@<VEZ93TS1#$^)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D M('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@ M5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXF(WA!,#L\+V9O;G0^/"]T9#X- M"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^/&9O;G0@<W1Y M;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^ M*#(Q,"PY.#D\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO M=W)A<#TS1&YO=W)A<#X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM M97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXI)B-X03`[/"]F;VYT/CPO=&0^#0H@ M/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF(WA!,#L\+V9O M;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$ M)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R/B8C>$$P M.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R M:6=H=#X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O M;6%N)R!S:7IE/3-$,CXQ-RXP,#PO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX] M,T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P/CQF;VYT('-T>6QE/3-$)T9/3E0M M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R/B8C>$$P.R8C>$$P M.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<VEZ M93TS1#$^)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O M;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\=&0@=F%L M:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N M="!S:7IE/3-$,3XF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$ M8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT M9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\+W1R/@T*(#QT<B!B9V-O;&]R M/3-$(T-#145&1CX-"B`\=&0@=F%L:6=N/3-$=&]P/@T*(#QP('-T>6QE/3-$ M)TU!4D=)3BU,1494.B`Q96T[(%1%6%0M24Y$14Y4.B`M,65M)SX\9F]N="!S M='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$ M,CY297-T<FEC=&5D('-T;V-K('5N:71S#0H@9F]R9F5I=&5D/"]F;VYT/CPO M<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<VEZ93TS M1#$^)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\ M9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S M:7IE/3-$,CXF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T M=&]M(&%L:6=N/3-$<FEG:'0^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ M(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^-C@L-S`R/"]F;VYT/CPO=&0^ M#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^/&9O;G0@ M<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS M1#(^)B-X03`[)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O M='1O;3X\9F]N="!S:7IE/3-$,3XF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@ M=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#X\9F]N="!S='EL93TS M1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXF(WA! M,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS M1&YO=W)A<"!A;&EG;CTS1')I9VAT/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%- M24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R/B8C>#(P,30[/"]F;VYT M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^ M/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@ M<VEZ93TS1#(^)B-X03`[)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG M;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF(WA!,#L\+V9O;G0^/"]T9#X- M"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#X\9F]N="!S M='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$ M,CXF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO M=W)A<#TS1&YO=W)A<"!A;&EG;CTS1')I9VAT/CQF;VYT('-T>6QE/3-$)T9/ M3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R/B8C>#(P,30[ M/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N M;W=R87`^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2 M;VUA;B<@<VEZ93TS1#(^)B-X03`[)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D M('9A;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF(WA!,#L\+V9O;G0^ M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG M;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X- M"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C>$$P.SPO M9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\=&0@ M=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\ M+W1D/@T*(#PO='(^#0H@/'1R('-T>6QE/3-$)T9/3E0M4TE:13H@,7!X)SX- M"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O M='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@ M<W1Y;&4],T0G0D]21$52+51/4#H@<F=B*#`L,"PP*2`Q<'@@<V]L:60G/B8C M>$$P.SPO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@ M<W1Y;&4],T0G0D]21$52+51/4#H@<F=B*#`L,"PP*2`Q<'@@<V]L:60G/B8C M>$$P.SPO<#X-"B`\+W1D/@T*(#QT9#XF(WA!,#L\+W1D/@T*(#QT9"!V86QI M9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(')G8B@P+#`L,"D@,7!X('-O M;&ED)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(')G8B@P+#`L,"D@,7!X('-O M;&ED)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0^)B-X03`[/"]T9#X-"B`\ M=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS M1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\ M=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O M;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\ M=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O M;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\ M=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O M;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\+W1R/@T* M(#QT<CX-"B`\=&0@=F%L:6=N/3-$=&]P/@T*(#QP('-T>6QE/3-$)TU!4D=) M3BU,1494.B`R96T[(%1%6%0M24Y$14Y4.B`M,65M)SX\9F]N="!S='EL93TS M1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CY"86QA M;F-E(&%T#0H@1&5C96UB97(F(WA!,#LS,2P@,C`Q,CPO9F]N=#X\+W`^#0H@ M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C M>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@ M<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS M1#(^)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A M;&EG;CTS1')I9VAT/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE M<R!.97<@4F]M86XG('-I>F4],T0R/C@W."PW,C8\+V9O;G0^/"]T9#X-"B`\ M=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#X\9F]N="!S='EL M93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXF M(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M M/CQF;VYT('-I>F4],T0Q/B8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI M9VX],T1B;W1T;VT^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S M($YE=R!2;VUA;B<@<VEZ93TS1#(^)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D M('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/CQF;VYT('-T>6QE/3-$ M)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R/C$L-SDP M+#4R-SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P M/3-$;F]W<F%P/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!. M97<@4F]M86XG('-I>F4],T0R/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T* M(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<VEZ93TS1#$^)B-X03`[/"]F M;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS M1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXF(WA! M,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$ M<FEG:'0^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2 M;VUA;B<@<VEZ93TS1#(^,3@N.38\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N M/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#X\9F]N="!S='EL93TS1"=&3TY4 M+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXF(WA!,#LF(WA! M,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I M>F4],T0Q/B8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T M;VT^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A M;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O M;G0@<VEZ93TS1#$^)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS M1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\ M=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/"]T<CX-"B`\='(@8F=C;VQO M<CTS1"-#0T5%1D8^#0H@/'1D('9A;&EG;CTS1'1O<#X-"B`\<"!S='EL93TS M1"=-05)'24XM3$5&5#H@,65M.R!415A4+4E.1$5.5#H@+3%E;2<^/&9O;G0@ M<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS M1#(^26YC<F5A<V4@:6X@875T:&]R:7IE9`T*('-H87)E<SPO9F]N=#X\+W`^ M#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q M/B8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O M;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ M93TS1#(^)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O M;2!A;&EG;CTS1')I9VAT/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4 M:6UE<R!.97<@4F]M86XG('-I>F4],T0R/C(L,#`P+#`P,#PO9F]N=#X\+W1D M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P/CQF;VYT M('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4] M,T0R/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B M;W1T;VT^/&9O;G0@<VEZ93TS1#$^)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D M('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^/&9O;G0@<W1Y;&4] M,T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^)B-X M03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`] M,T1N;W=R87`@86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS1"=&3TY4+49! M34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXF(W@R,#$T.SPO9F]N M=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P M/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG M('-I>F4],T0R/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI M9VX],T1B;W1T;VT^/&9O;G0@<VEZ93TS1#$^)B-X03`[/"]F;VYT/CPO=&0^ M#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^/&9O;G0@ M<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS M1#(^)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N M;W=R87`],T1N;W=R87`@86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS1"=& M3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXF(W@R,#$T M.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$ M;F]W<F%P/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@ M4F]M86XG('-I>F4],T0R/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT M9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<VEZ93TS1#$^)B-X03`[/"]F;VYT M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI M9VX],T1B;W1T;VT^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^ M#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF(WA!,#L\ M+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D M('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^ M/"]T9#X-"B`\+W1R/@T*(#QT<CX-"B`\=&0@=F%L:6=N/3-$=&]P/@T*(#QP M('-T>6QE/3-$)TU!4D=)3BU,1494.B`Q96T[(%1%6%0M24Y$14Y4.B`M,65M M)SX\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N M)R!S:7IE/3-$,CY/<'1I;VYS(&=R86YT960\+V9O;G0^/"]P/@T*(#PO=&0^ M#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF(WA!,#L\ M+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE M/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R/B8C M>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX] M,T1R:6=H=#X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W M(%)O;6%N)R!S:7IE/3-$,CXH-SDW+#8R.3PO9F]N=#X\+W1D/@T*(#QT9"!V M86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P/CQF;VYT('-T>6QE/3-$ M)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R/BDF(WA! M,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I M>F4],T0Q/B8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T M;VT^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA M;B<@<VEZ93TS1#(^)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS M1&)O='1O;2!A;&EG;CTS1')I9VAT/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%- M24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R/C<Y-RPV,CD\+V9O;G0^ M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#X\ M9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S M:7IE/3-$,CXF(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N M/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C>$$P.SPO9F]N=#X\+W1D/@T* M(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U) M3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^)B-X03`[/"]F;VYT/CPO M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/CQF;VYT M('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4] M,T0R/C4N.34\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO M=W)A<#TS1&YO=W)A<#X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM M97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXF(WA!,#LF(WA!,#L\+V9O;G0^/"]T M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C>$$P M.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\ M=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O M;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<VEZ93TS1#$^ M)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\=&0@=F%L:6=N/3-$ M8F]T=&]M/CPO=&0^#0H@/"]T<CX-"B`\='(@8F=C;VQO<CTS1"-#0T5%1D8^ M#0H@/'1D('9A;&EG;CTS1'1O<#X-"B`\<"!S='EL93TS1"=-05)'24XM3$5& M5#H@,65M.R!415A4+4E.1$5.5#H@+3%E;2<^/&9O;G0@<W1Y;&4],T0G1D]. M5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^4F5S=')I8W1E M9"!S=&]C:R!U;FET<PT*(&=R86YT960\+V9O;G0^/"]P/@T*(#PO=&0^#0H@ M/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF(WA!,#L\+V9O M;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$ M)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R/B8C>$$P M.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R M:6=H=#X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O M;6%N)R!S:7IE/3-$,CXH-#$L-C8Q/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG M;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^/&9O;G0@<W1Y;&4],T0G1D]. M5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^*28C>$$P.SPO M9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<VEZ93TS M1#$^)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N M;W=R87`],T1N;W=R87`^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I M;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^)B-X03`[/"]F;VYT/CPO=&0^#0H@ M/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`@86QI9VX],T1R M:6=H=#X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O M;6%N)R!S:7IE/3-$,CXF(W@R,#$T.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI M9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P/CQF;VYT('-T>6QE/3-$)T9/ M3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R/B8C>$$P.R8C M>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@ M<VEZ93TS1#$^)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O M='1O;2!N;W=R87`],T1N;W=R87`^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U) M3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^)B-X03`[/"]F;VYT/CPO M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`@86QI M9VX],T1R:6=H=#X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@ M3F5W(%)O;6%N)R!S:7IE/3-$,CXF(W@R,#$T.SPO9F]N=#X\+W1D/@T*(#QT M9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P/CQF;VYT('-T>6QE M/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R/B8C M>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^ M/&9O;G0@<VEZ93TS1#$^)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG M;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X- M"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O M='1O;3X\9F]N="!S:7IE/3-$,3XF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@ M=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\ M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\+W1R/@T*(#QT M<CX-"B`\=&0@=F%L:6=N/3-$=&]P/@T*(#QP('-T>6QE/3-$)TU!4D=)3BU, M1494.B`Q96T[(%1%6%0M24Y$14Y4.B`M,65M)SX\9F]N="!S='EL93TS1"=& M3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CY/<'1I;VYS M#0H@97AE<F-I<V5D/"]F;VYT/CPO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX] M,T1B;W1T;VT^/&9O;G0@<VEZ93TS1#$^)B-X03`[/"]F;VYT/CPO=&0^#0H@ M/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^/&9O;G0@<W1Y M;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^ M)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R M87`],T1N;W=R87`@86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS1"=&3TY4 M+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXF(W@R,#$T.SPO M9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W M<F%P/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M M86XG('-I>F4],T0R/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V M86QI9VX],T1B;W1T;VT^/&9O;G0@<VEZ93TS1#$^)B-X03`[/"]F;VYT/CPO M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=&3TY4 M+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXF(WA!,#L\+V9O M;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^ M/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@ M<VEZ93TS1#(^*#(Q+#,Y-SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B M;W1T;VT@;F]W<F%P/3-$;F]W<F%P/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%- M24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R/BDF(WA!,#L\+V9O;G0^ M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C M>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@ M<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS M1#(^)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A M;&EG;CTS1')I9VAT/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE M<R!.97<@4F]M86XG('-I>F4],T0R/C4N,S(\+V9O;G0^/"]T9#X-"B`\=&0@ M=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#X\9F]N="!S='EL93TS M1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXF(WA! M,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF M;VYT('-I>F4],T0Q/B8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX] M,T1B;W1T;VT^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@ M/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T M;VT^/&9O;G0@<VEZ93TS1#$^)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A M;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/"]T<CX-"B`\='(@ M8F=C;VQO<CTS1"-#0T5%1D8^#0H@/'1D('9A;&EG;CTS1'1O<#X-"B`\<"!S M='EL93TS1"=-05)'24XM3$5&5#H@,65M.R!415A4+4E.1$5.5#H@+3%E;2<^ M/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@ M<VEZ93TS1#(^3W!T:6]N<PT*(&9O<F9E:71E9"]E>'!I<F5D/"]F;VYT/CPO M<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<VEZ93TS M1#$^)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\ M9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S M:7IE/3-$,CXF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T M=&]M(&%L:6=N/3-$<FEG:'0^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ M(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^,3$W+#,Y-#PO9F]N=#X\+W1D M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P/CQF;VYT M('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4] M,T0R/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B M;W1T;VT^/&9O;G0@<VEZ93TS1#$^)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D M('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@ M5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXF(WA!,#L\+V9O;G0^/"]T9#X- M"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^/&9O;G0@<W1Y M;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^ M*#$Q-RPS.30\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO M=W)A<#TS1&YO=W)A<#X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM M97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXI)B-X03`[/"]F;VYT/CPO=&0^#0H@ M/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF(WA!,#L\+V9O M;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$ M)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R/B8C>$$P M.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R M:6=H=#X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O M;6%N)R!S:7IE/3-$,CXQ,BXU-3PO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX] M,T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P/CQF;VYT('-T>6QE/3-$)T9/3E0M M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R/B8C>$$P.R8C>$$P M.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<VEZ M93TS1#$^)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O M;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\=&0@=F%L M:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N M="!S:7IE/3-$,3XF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$ M8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT M9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\+W1R/@T*(#QT<CX-"B`\=&0@ M=F%L:6=N/3-$=&]P/@T*(#QP('-T>6QE/3-$)TU!4D=)3BU,1494.B`Q96T[ M(%1%6%0M24Y$14Y4.B`M,65M)SX\9F]N="!S='EL93TS1"=&3TY4+49!34E, M63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CY297-T<FEC=&5D('-T;V-K M('5N:71S#0H@9F]R9F5I=&5D/"]F;VYT/CPO<#X-"B`\+W1D/@T*(#QT9"!V M86QI9VX],T1B;W1T;VT^/&9O;G0@<VEZ93TS1#$^)B-X03`[/"]F;VYT/CPO M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=&3TY4 M+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXF(WA!,#L\+V9O M;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^ M/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@ M<VEZ93TS1#(^-"PY.3D\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T M=&]M(&YO=W)A<#TS1&YO=W)A<#X\9F]N="!S='EL93TS1"=&3TY4+49!34E, M63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXF(WA!,#LF(WA!,#L\+V9O M;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q M/B8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W M<F%P/3-$;F]W<F%P/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE M<R!.97<@4F]M86XG('-I>F4],T0R/B8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT M9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P(&%L:6=N/3-$<FEG M:'0^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA M;B<@<VEZ93TS1#(^)B-X,C`Q-#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N M/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#X\9F]N="!S='EL93TS1"=&3TY4 M+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXF(WA!,#LF(WA! M,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I M>F4],T0Q/B8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T M;VT@;F]W<F%P/3-$;F]W<F%P/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9 M.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R/B8C>$$P.SPO9F]N=#X\+W1D M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P(&%L:6=N M/3-$<FEG:'0^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE M=R!2;VUA;B<@<VEZ93TS1#(^)B-X,C`Q-#L\+V9O;G0^/"]T9#X-"B`\=&0@ M=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#X\9F]N="!S='EL93TS M1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXF(WA! M,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF M;VYT('-I>F4],T0Q/B8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX] M,T1B;W1T;VT^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@ M/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T M;VT^/&9O;G0@<VEZ93TS1#$^)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A M;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/"]T<CX-"B`\='(@ M<W1Y;&4],T0G1D].5"U325I%.B`Q<'@G/@T*(#QT9"!V86QI9VX],T1B;W1T M;VT^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@ M/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0 M.B!R9V(H,"PP+#`I(#%P>"!S;VQI9"<^)B-X03`[/"]P/@T*(#PO=&0^#0H@ M/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0 M.B!R9V(H,"PP+#`I(#%P>"!S;VQI9"<^)B-X03`[/"]P/@T*(#PO=&0^#0H@ M/'1D/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\ M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@<W1Y;&4],T0G0D]2 M1$52+51/4#H@<F=B*#`L,"PP*2`Q<'@@<V]L:60G/B8C>$$P.SPO<#X-"B`\ M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@<W1Y;&4],T0G0D]2 M1$52+51/4#H@<F=B*#`L,"PP*2`Q<'@@<V]L:60G/B8C>$$P.SPO<#X-"B`\ M+W1D/@T*(#QT9#XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^ M)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D M('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^ M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D M('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^ M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG M;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^ M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG M;CTS1&)O='1O;3X\+W1D/@T*(#PO='(^#0H@/'1R(&)G8V]L;W(],T0C0T-% M149&/@T*(#QT9"!V86QI9VX],T1T;W`^#0H@/'`@<W1Y;&4],T0G34%21TE. M+4Q%1E0Z(#)E;3L@5$585"U)3D1%3E0Z("TQ96TG/CQF;VYT('-T>6QE/3-$ M)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R/D)A;&%N M8V4@870-"B!$96-E;6)E<B8C>$$P.S,Q+"`R,#$S/"]F;VYT/CPO<#X-"B`\ M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<VEZ93TS1#$^)B-X M03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S M='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$ M,CXF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L M:6=N/3-$<FEG:'0^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S M($YE=R!2;VUA;B<@<VEZ93TS1#(^,BPQ-C$L.#(Y/"]F;VYT/CPO=&0^#0H@ M/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^/&9O;G0@<W1Y M;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^ M)B-X03`[)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O M;3X\9F]N="!S:7IE/3-$,3XF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L M:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE M<R!.97<@4F]M86XG('-I>F4],T0R/B8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT M9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS M1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXR+#0T M.2PS-C4\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A M<#TS1&YO=W)A<#X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@ M3F5W(%)O;6%N)R!S:7IE/3-$,CXF(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X- M"B`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`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\ M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\=&0@=F%L:6=N M/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S M:7IE/3-$,3XF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T M=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V M86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\+W1R/@T*(#QT<CX-"B`\=&0@=F%L M:6=N/3-$=&]P/@T*(#QP('-T>6QE/3-$)TU!4D=)3BU,1494.B`Q96T[(%1% M6%0M24Y$14Y4.B`M,65M)SX\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@ M5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CY/<'1I;VYS(&=R86YT960\+V9O M;G0^/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S M:7IE/3-$,3XF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T M=&]M/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M M86XG('-I>F4],T0R/B8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX] M,T1B;W1T;VT@86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS1"=&3TY4+49! M34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXH.30T+#@S,3PO9F]N M=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P M/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG M('-I>F4],T0R/BDF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$ M8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT M9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ M(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^)B-X03`[/"]F;VYT/CPO=&0^ M#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/CQF;VYT('-T M>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R M/CDT-"PX,S$\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO M=W)A<#TS1&YO=W)A<#X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM M97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXF(WA!,#LF(WA!,#L\+V9O;G0^/"]T M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C>$$P M.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<W1Y M;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^ M)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG M;CTS1')I9VAT/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!. M97<@4F]M86XG('-I>F4],T0R/C@N.#`\+V9O;G0^/"]T9#X-"B`\=&0@=F%L M:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#X\9F]N="!S='EL93TS1"=& M3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXF(WA!,#LF M(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT M('-I>F4],T0Q/B8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B M;W1T;VT^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D M('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^ M/&9O;G0@<VEZ93TS1#$^)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG M;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X- M"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/"]T<CX-"B`\='(@8F=C M;VQO<CTS1"-#0T5%1D8^#0H@/'1D('9A;&EG;CTS1'1O<#X-"B`\<"!S='EL M93TS1"=-05)'24XM3$5&5#H@,65M.R!415A4+4E.1$5.5#H@+3%E;2<^/&9O M;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ M93TS1#(^4F5S=')I8W1E9"!S=&]C:R!U;FET<PT*(&=R86YT960\+V9O;G0^ M/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE M/3-$,3XF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M M/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG M('-I>F4],T0R/B8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B M;W1T;VT@86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS1"=&3TY4+49!34E, M63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXH-#,L-3`P/"]F;VYT/CPO M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^/&9O M;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ M93TS1#(^*28C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T M;VT^/&9O;G0@<VEZ93TS1#$^)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A M;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^/&9O;G0@<W1Y;&4],T0G M1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^)B-X03`[ M/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N M;W=R87`@86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS1"=&3TY4+49!34E, M63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXF(W@R,#$T.SPO9F]N=#X\ M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P/CQF M;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I M>F4],T0R/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX] M,T1B;W1T;VT^/&9O;G0@<VEZ93TS1#$^)B-X03`[/"]F;VYT/CPO=&0^#0H@ M/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^/&9O;G0@<W1Y M;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^ M)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R M87`],T1N;W=R87`@86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS1"=&3TY4 M+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXF(W@R,#$T.SPO M9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W M<F%P/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M M86XG('-I>F4],T0R/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V M86QI9VX],T1B;W1T;VT^/&9O;G0@<VEZ93TS1#$^)B-X03`[/"]F;VYT/CPO M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI9VX] M,T1B;W1T;VT^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@ M/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF(WA!,#L\+V9O M;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A M;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T M9#X-"B`\+W1R/@T*(#QT<CX-"B`\=&0@=F%L:6=N/3-$=&]P/@T*(#QP('-T M>6QE/3-$)TU!4D=)3BU,1494.B`Q96T[(%1%6%0M24Y$14Y4.B`M,65M)SX\ M9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S M:7IE/3-$,CY/<'1I;VYS#0H@97AE<F-I<V5D/"]F;VYT/CPO<#X-"B`\+W1D M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<VEZ93TS1#$^)B-X03`[ M/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N M;W=R87`^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2 M;VUA;B<@<VEZ93TS1#(^)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG M;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`@86QI9VX],T1R:6=H=#X\9F]N M="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE M/3-$,CXF(W@R,#$T.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T M;VT@;F]W<F%P/3-$;F]W<F%P/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9 M.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R/B8C>$$P.R8C>$$P.SPO9F]N M=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<VEZ93TS1#$^ M)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N M="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE M/3-$,CXF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M M(&%L:6=N/3-$<FEG:'0^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I M;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^*#,Y,#PO9F]N=#X\+W1D/@T*(#QT M9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P/CQF;VYT('-T>6QE M/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R/BDF M(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT M('-I>F4],T0Q/B8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B M;W1T;VT^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2 M;VUA;B<@<VEZ93TS1#(^)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG M;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/CQF;VYT('-T>6QE/3-$)T9/3E0M M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R/C8N,#`\+V9O;G0^ M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#X\ M9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S M:7IE/3-$,CXF(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N M/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C>$$P.SPO9F]N=#X\+W1D/@T* M(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T M=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V M86QI9VX],T1B;W1T;VT^/&9O;G0@<VEZ93TS1#$^)B-X03`[/"]F;VYT/CPO M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI9VX] M,T1B;W1T;VT^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@ M/"]T<CX-"B`\='(@8F=C;VQO<CTS1"-#0T5%1D8^#0H@/'1D('9A;&EG;CTS M1'1O<#X-"B`\<"!S='EL93TS1"=-05)'24XM3$5&5#H@,65M.R!415A4+4E. M1$5.5#H@+3%E;2<^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S M($YE=R!2;VUA;B<@<VEZ93TS1#(^3W!T:6]N<PT*(&9O<F9E:71E9"]E>'!I M<F5D/"]F;VYT/CPO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^ M/&9O;G0@<VEZ93TS1#$^)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG M;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@ M3F5W(%)O;6%N)R!S:7IE/3-$,CXF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@ M=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^/&9O;G0@<W1Y;&4],T0G M1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^.34L.3@P M/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N M;W=R87`^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2 M;VUA;B<@<VEZ93TS1#(^)B-X03`[)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D M('9A;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF(WA!,#L\+V9O;G0^ M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)T9/ M3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R/B8C>$$P.SPO M9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H M=#X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N M)R!S:7IE/3-$,CXH.34L.3@P/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS M1&)O='1O;2!N;W=R87`],T1N;W=R87`^/&9O;G0@<W1Y;&4],T0G1D].5"U& M04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^*28C>$$P.SPO9F]N M=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<VEZ93TS1#$^ M)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N M="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE M/3-$,CXF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M M(&%L:6=N/3-$<FEG:'0^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I M;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^,SDN-S0\+V9O;G0^/"]T9#X-"B`\ M=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#X\9F]N="!S='EL M93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXF M(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M M/CQF;VYT('-I>F4],T0Q/B8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI M9VX],T1B;W1T;VT^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^ M#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B M;W1T;VT^/&9O;G0@<VEZ93TS1#$^)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D M('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^ M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/"]T<CX-"B`\ M='(^#0H@/'1D('9A;&EG;CTS1'1O<#X-"B`\<"!S='EL93TS1"=-05)'24XM M3$5&5#H@,65M.R!415A4+4E.1$5.5#H@+3%E;2<^/&9O;G0@<W1Y;&4],T0G M1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^4F5S=')I M8W1E9"!S=&]C:R!U;FET<PT*(&9O<F9E:71E9#PO9F]N=#X\+W`^#0H@/"]T M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C>$$P M.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<W1Y M;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^ M)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG M;CTS1')I9VAT/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!. M97<@4F]M86XG('-I>F4],T0R/C$L,#`P/"]F;VYT/CPO=&0^#0H@/'1D('9A M;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^/&9O;G0@<W1Y;&4],T0G M1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^)B-X03`[ M)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N M="!S:7IE/3-$,3XF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$ M8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#X\9F]N="!S='EL93TS1"=&3TY4+49! M34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXF(WA!,#L\+V9O;G0^ M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<"!A M;&EG;CTS1')I9VAT/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE M<R!.97<@4F]M86XG('-I>F4],T0R/B8C>#(P,30[/"]F;VYT/CPO=&0^#0H@ M/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^/&9O;G0@<W1Y M;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^ M)B-X03`[)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O M;3X\9F]N="!S:7IE/3-$,3XF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L M:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#X\9F]N="!S='EL93TS1"=& M3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXF(WA!,#L\ M+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO M=W)A<"!A;&EG;CTS1')I9VAT/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9 M.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R/B8C>#(P,30[/"]F;VYT/CPO M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^/&9O M;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ M93TS1#(^)B-X03`[)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS M1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF(WA!,#L\+V9O;G0^/"]T9#X-"B`\ M=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O M;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\=&0@=F%L M:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C>$$P.SPO9F]N=#X\+W1D M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\=&0@=F%L:6=N/3-$ M8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#PO M='(^#0H@/'1R('-T>6QE/3-$)T9/3E0M4TE:13H@,7!X)SX-"B`\=&0@=F%L M:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA! M,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@<W1Y;&4],T0G M0D]21$52+51/4#H@<F=B*#`L,"PP*2`Q<'@@<V]L:60G/B8C>$$P.SPO<#X- M"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@<W1Y;&4],T0G M0D]21$52+51/4#H@<F=B*#`L,"PP*2`Q<'@@<V]L:60G/B8C>$$P.SPO<#X- M"B`\+W1D/@T*(#QT9#XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T M;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T M>6QE/3-$)T)/4D1%4BU43U`Z(')G8B@P+#`L,"D@,7!X('-O;&ED)SXF(WA! M,#L\+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T M>6QE/3-$)T)/4D1%4BU43U`Z(')G8B@P+#`L,"D@,7!X('-O;&ED)SXF(WA! M,#L\+W`^#0H@/"]T9#X-"B`\=&0^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N M/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\ M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\=&0@=F%L:6=N M/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\ M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\=&0@=F%L:6=N M/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T* M(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N M/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T* M(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\+W1R/@T*(#QT<B!B9V-O M;&]R/3-$(T-#145&1CX-"B`\=&0@=F%L:6=N/3-$=&]P/@T*(#QP('-T>6QE M/3-$)TU!4D=)3BU,1494.B`R96T[(%1%6%0M24Y$14Y4.B`M,65M)SX\9F]N M="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE M/3-$,CY"86QA;F-E(&%T#0H@1&5C96UB97(F(WA!,#LS,2P@,C`Q-#PO9F]N M=#X\+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I M>F4],T0Q/B8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T M;VT^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA M;B<@<VEZ93TS1#(^)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS M1&)O='1O;2!A;&EG;CTS1')I9VAT/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%- M24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R/C$L,C<P+#0W.#PO9F]N M=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P M/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG M('-I>F4],T0R/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI M9VX],T1B;W1T;VT^/&9O;G0@<VEZ93TS1#$^)B-X03`[/"]F;VYT/CPO=&0^ M#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=&3TY4+49! M34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXF(WA!,#L\+V9O;G0^ M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^/&9O M;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ M93TS1#(^,RPR.3<L.#(V/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O M='1O;2!N;W=R87`],T1N;W=R87`^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U) M3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^)B-X03`[)B-X03`[/"]F M;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$ M,3XF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF M;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I M>F4],T0R/B0\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L M:6=N/3-$<FEG:'0^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S M($YE=R!2;VUA;B<@<VEZ93TS1#(^,3(N-C(\+V9O;G0^/"]T9#X-"B`\=&0@ M=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#X\9F]N="!S='EL93TS M1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXF(WA! M,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF M;VYT('-I>F4],T0Q/B8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX] M,T1B;W1T;VT^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE M=R!2;VUA;B<@<VEZ93TS1#(^)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A M;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/CQF;VYT('-T>6QE/3-$)T9/ M3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R/C8N-SD\+V9O M;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A M<#X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N M)R!S:7IE/3-$,CXF(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L M:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C>$$P.SPO9F]N=#X\+W1D M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<W1Y;&4],T0G1D].5"U& M04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^)#PO9F]N=#X\+W1D M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#X\9F]N="!S M='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$ M,CXR+#8U-SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W M<F%P/3-$;F]W<F%P/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE M<R!.97<@4F]M86XG('-I>F4],T0R/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D M/@T*(#PO='(^#0H@/'1R('-T>6QE/3-$)T9/3E0M4TE:13H@,7!X)SX-"B`\ M=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O M;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@<W1Y M;&4],T0G0D]21$52+51/4#H@<F=B*#`L,"PP*2`S<'@@9&]U8FQE)SXF(WA! M,#L\+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T M>6QE/3-$)T)/4D1%4BU43U`Z(')G8B@P+#`L,"D@,W!X(&1O=6)L92<^)B-X M03`[/"]P/@T*(#PO=&0^#0H@/'1D/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG M;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^ M#0H@/'`@<W1Y;&4],T0G0D]21$52+51/4#H@<F=B*#`L,"PP*2`S<'@@9&]U M8FQE)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(')G8B@P+#`L,"D@,W!X(&1O M=6)L92<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D/B8C>$$P.SPO=&0^#0H@ M/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX] M,T1B;W1T;VT^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@ M/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T M;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@ M/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T M;VT^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@ M/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T M;VT^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/"]T<CX- M"B`\='(^#0H@/'1D('9A;&EG;CTS1'1O<#X-"B`\<"!S='EL93TS1"=-05)' M24XM3$5&5#H@,F5M.R!415A4+4E.1$5.5#H@+3%E;2<^/&9O;G0@<W1Y;&4] M,T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^17AE M<F-I<V%B;&4@870-"B!$96-E;6)E<B8C>$$P.S,Q+"`R,#$T/"]F;VYT/CPO M<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<VEZ93TS M1#$^)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\ M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\=&0@=F%L:6=N M/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S M:7IE/3-$,3XF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T M=&]M/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M M86XG('-I>F4],T0R/B8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX] M,T1B;W1T;VT@86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS1"=&3TY4+49! M34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXR+#$T,"PW-30\+V9O M;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A M<#X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N M)R!S:7IE/3-$,CXF(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`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`[ M/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL M93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXF M(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N M/3-$<FEG:'0^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE M=R!2;VUA;B<@<VEZ93TS1#(^-2XW-CPO9F]N=#X\+W1D/@T*(#QT9"!V86QI M9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P/CQF;VYT('-T>6QE/3-$)T9/ M3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R/B8C>$$P.R8C M>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@ M<VEZ93TS1#$^)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O M='1O;3X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O M;6%N)R!S:7IE/3-$,CXD/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O M='1O;2!A;&EG;CTS1')I9VAT/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9 M.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R/C$L-34S/"]F;VYT/CPO=&0^ M#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^/&9O;G0@ M<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS M1#(^)B-X03`[)B-X03`[/"]F;VYT/CPO=&0^#0H@/"]T<CX-"B`\='(@8F=C M;VQO<CTS1"-#0T5%1D8^#0H@/'1D('9A;&EG;CTS1'1O<#X-"B`\<"!S='EL M93TS1"=-05)'24XM3$5&5#H@,F5M.R!415A4+4E.1$5.5#H@+3%E;2<^/&9O M;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ M93TS1#(^5F5S=&5D(&%N9"!E>'!E8W1E9"!T;R!V97-T#0H@87,@;V8@1&5C M96UB97(F(WA!,#LS,2P@,C`Q-#PO9F]N=#X\+W`^#0H@/"]T9#X-"B`\=&0@ M=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C>$$P.SPO9F]N=#X\ M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\=&0@=F%L:6=N M/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T* M(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<VEZ93TS1#$^)B-X03`[/"]F M;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS M1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXF(WA! M,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$ M<FEG:'0^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2 M;VUA;B<@<VEZ93TS1#(^,RPR-S<L-#@Y/"]F;VYT/CPO=&0^#0H@/'1D('9A M;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^/&9O;G0@<W1Y;&4],T0G M1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^)B-X03`[ M)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N M="!S:7IE/3-$,3XF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$ M8F]T=&]M/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@ M4F]M86XG('-I>F4],T0R/B0\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$ M8F]T=&]M(&%L:6=N/3-$<FEG:'0^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U) M3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^,3(N-C0\+V9O;G0^/"]T M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#X\9F]N M="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE M/3-$,CXF(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$ M8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT M9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ M(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^)B-X03`[/"]F;VYT/CPO=&0^ M#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/CQF;VYT('-T M>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R M/C8N-S@\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A M<#TS1&YO=W)A<#X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@ M3F5W(%)O;6%N)R!S:7IE/3-$,CXF(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X- M"B`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`M+3X\ M+W1A8FQE/@T*(#QP('-T>6QE/3-$)TU!4D=)3BU"3U143TTZ(#!P>#L@34%2 M1TE.+51/4#H@,3)P>#L@5$585"U)3D1%3E0Z(#0E)R!A;&EG;CTS1&IU<W1I M9GD^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA M;B<@<VEZ93TS1#(^5&]T86P@:6YT<FEN<VEC('9A;'5E(&]F('-T;V-K(&]P M=&EO;G,@97AE<F-I<V5D('=A<R`D,2PP,#`L#0H@)#$P-RPP,#`L(&%N9"!Z M97)O(&1U<FEN9R!T:&4@>65A<G,@96YD960@1&5C96UB97(F(WA!,#LS,2P@ M,C`Q-"P-"B`R,#$S(&%N9"`R,#$R+"!R97-P96-T:79E;'DN(%1H92!I;G1R M:6YS:6,@=F%L=64@:7,@8V%L8W5L871E9"!A<PT*('1H92!D:69F97)E;F-E M(&)E='=E96X@=&AE(&UA<FME="!V86QU92!A<R!O9B!$96-E;6)E<B8C>$$P M.S,Q+`T*(#(P,30@86YD('1H92!E>&5R8VES92!P<FEC92!O9B!S:&%R97,N M(%1H92!M87)K970@=F%L=64@87,@;V8-"B!$96-E;6)E<B8C>$$P.S,Q+"`R M,#$T('=A<R`D."XP,2!P97(@<VAA<F4@87,@<F5P;W)T960@8GD@3D%31$%1 M+@T*(%1H92!W96EG:'1E9"!A=F5R86=E(&=R86YT(&1A=&4@9F%I<B!V86QU M92!O9B!S=&]C:R!O<'1I;VYS(&=R86YT960-"B!W87,@)#8N,#$L("0S+C@U M(&%N9"`D,RXX.2!P97(@<VAA<F4@9'5R:6YG('1H92!Y96%R<R!E;F1E9`T* M($1E8V5M8F5R)B-X03`[,S$L(#(P,30L(#(P,3,@86YD(#(P,3(L(')E<W!E M8W1I=F5L>2X\+V9O;G0^/"]P/@T*(#QP('-T>6QE/3-$)TU!4D=)3BU"3U14 M3TTZ(#!P>#L@34%21TE.+51/4#H@,3)P>#L@5$585"U)3D1%3E0Z(#0E)R!A M;&EG;CTS1&IU<W1I9GD^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I M;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^5&AE(&YU;6)E<B!O9B!O<'1I;VX@ M<VAA<F5S('9E<W1E9"!W87,@-C`Q+#8T-RP@-#4W+#0V-2!A;F0-"B`S-#@L M-CDS(&EN(#(P,30L(#(P,3,@86YD(#(P,3(L(')E<W!E8W1I=F5L>2X@5&AE M(&=R86YT(&1A=&4@9F%I<@T*('9A;'5E(&]F(&]P=&EO;B!S:&%R97,@=F5S M=&5D('=A<R`D,RXP(&UI;&QI;VXL("0R+C,@;6EL;&EO;B!A;F0-"B`D,BXT M(&UI;&QI;VX@:6X@,C`Q-"P@,C`Q,R!A;F0@,C`Q,BP@<F5S<&5C=&EV96QY M+B!4:&4@0V]M<&%N>2!H87,-"B!R979I<V5D('1H92!P<F5V:6]U<VQY(')E M<&]R=&5D(&1I<V-L;W-U<F5S(&]F(&]P=&EO;B!S:&%R97,@=F5S=&5D#0H@ M86YD(&=R86YT(&1A=&4@9F%I<B!V86QU92!O9B!O<'1I;VX@<VAA<F5S('9E M<W1E9"!F;W(@=&AE('EE87)S#0H@96YD960@1&5C96UB97(@,S$L(#(P,3,@ M86YD($1E8V5M8F5R(#,Q+"`R,#$R+B!4:&4@8V]R<F5C=&EO;G,@:&%D#0H@ M;F\@969F96-T('5P;VX@=&AE('-T871E;65N=',@;V8@8V]M<')E:&5N<VEV M92!L;W-S#0H@86UO=6YT<RX\+V9O;G0^/"]P/@T*(#QP('-T>6QE/3-$)TU! M4D=)3BU"3U143TTZ(#!P>#L@1D].5"U325I%.B`Q,G!X.R!-05)'24XM5$]0 M.B`P<'@G/@T*("8C>$$P.SPO<#X-"B`\<"!S='EL93TS1"=-05)'24XM0D]4 M5$]-.B`P<'@[($U!4D=)3BU43U`Z(#!P>#L@5$585"U)3D1%3E0Z(#0E)R!A M;&EG;CTS1&IU<W1I9GD^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I M;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^4F5S=')I8W1E9"!S=&]C:R!U;FET M(&%C=&EV:71Y('=A<R!A<R!F;VQL;W=S.CPO9F]N=#X\+W`^#0H@/'`@<W1Y M;&4],T0G34%21TE.+4)/5%1/33H@,'!X.R!&3TY4+5-)6D4Z(#$R<'@[($U! M4D=)3BU43U`Z(#!P>"<^#0H@)B-X03`[/"]P/@T*(#QT86)L92!S='EL93TS M1"="3U)$15(M0T],3$%04T4Z(&-O;&QA<'-E)R!C96QL<W!A8VEN9STS1#`@ M8V5L;'!A9&1I;F<],T0P('=I9'1H/3-$.3(E(&%L:6=N/3-$8V5N=&5R(&)O M<F1E<CTS1#`^#0H@/"$M+2!"96=I;B!486)L92!(96%D("TM/@T*(#QT<CX- M"B`\=&0@=VED=&@],T0W,R4^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M M('=I9'1H/3-$."4^/"]T9#X-"B`\=&0^/"]T9#X-"B`\=&0^/"]T9#X-"B`\ M=&0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$-R4^/"]T M9#X-"B`\=&0^/"]T9#X-"B`\=&0^/"]T9#X-"B`\=&0^/"]T9#X-"B`\+W1R M/@T*(#QT<CX-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q M/B8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O M;G0@<VEZ93TS1#$^)B-X03`[)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('-T M>6QE/3-$)T)/4D1%4BU"3U143TTZ(')G8B@P+#`L,"D@,7!X('-O;&ED)R!V M86QI9VX],T1B;W1T;VT@8V]L<W!A;CTS1#(@86QI9VX],T1C96YT97(^/&9O M;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ M93TS1#$^/&(^3G5M8F5R)B-X03`[;V8\8G(@+SX-"B!3:&%R97,\+V(^/"]F M;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$ M,3XF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF M;VYT('-I>F4],T0Q/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!S M='EL93TS1"="3U)$15(M0D]45$]-.B!R9V(H,"PP+#`I(#%P>"!S;VQI9"<@ M=F%L:6=N/3-$8F]T=&]M(&-O;'-P86X],T0R(&%L:6=N/3-$8V5N=&5R/CQF M;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I M>F4],T0Q/CQB/E=E:6=H=&5D/&)R("\^#0H@079E<F%G928C>$$P.T%W87)D M/&)R("\^#0H@1&%T928C>$$P.T9A:7(F(WA!,#M686QU93QB<B`O/@T*('!E M<B8C>$$P.U-H87)E/"]B/CPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B M;W1T;VT^/&9O;G0@<VEZ93TS1#$^)B-X03`[/"]F;VYT/CPO=&0^#0H@/"]T M<CX-"B`\(2TM($5N9"!486)L92!(96%D("TM/CPA+2T@0F5G:6X@5&%B;&4@ M0F]D>2`M+3X-"B`\='(@8F=C;VQO<CTS1"-#0T5%1D8^#0H@/'1D('9A;&EG M;CTS1'1O<#X-"B`\<"!S='EL93TS1"=-05)'24XM3$5&5#H@,65M.R!415A4 M+4E.1$5.5#H@+3%E;2<^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I M;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^4F5S=')I8W1E9"!S=&]C:R!U;FET M<PT*(&]U='-T86YD:6YG(&%T($1E8V5M8F5R)B-X03`[,S$L(#(P,3$\+V9O M;G0^/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S M:7IE/3-$,3XF(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N M/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!. M97<@4F]M86XG('-I>F4],T0R/B8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V M86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS1"=& M3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXU,3<L-3,U M/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N M;W=R87`^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2 M;VUA;B<@<VEZ93TS1#(^)B-X03`[)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D M('9A;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF(WA!,#LF(WA!,#L\ M+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE M/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R/B0\ M+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG M:'0^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA M;B<@<VEZ93TS1#(^-BXW.#PO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B M;W1T;VT@;F]W<F%P/3-$;F]W<F%P/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%- M24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R/B8C>$$P.R8C>$$P.SPO M9F]N=#X\+W1D/@T*(#PO='(^#0H@/'1R/@T*(#QT9"!V86QI9VX],T1T;W`^ M#0H@/'`@<W1Y;&4],T0G34%21TE.+4Q%1E0Z(#)E;3L@5$585"U)3D1%3E0Z M("TQ96TG/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@ M4F]M86XG('-I>F4],T0R/E)E<W1R:6-T960@<W1O8VL@=6YI=',-"B!V97-T M960\+V9O;G0^/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\ M9F]N="!S:7IE/3-$,3XF(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@ M=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4 M:6UE<R!.97<@4F]M86XG('-I>F4],T0R/B8C>$$P.SPO9F]N=#X\+W1D/@T* M(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#X\9F]N="!S='EL M93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXH M,C,Q+#DS-3PO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W M<F%P/3-$;F]W<F%P/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE M<R!.97<@4F]M86XG('-I>F4],T0R/BDF(WA!,#L\+V9O;G0^/"]T9#X-"B`\ M=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C>$$P.R8C>$$P M.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<W1Y M;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^ M)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG M;CTS1')I9VAT/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!. M97<@4F]M86XG('-I>F4],T0R/C8N-S@\+V9O;G0^/"]T9#X-"B`\=&0@=F%L M:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#X\9F]N="!S='EL93TS1"=& M3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXF(WA!,#LF M(WA!,#L\+V9O;G0^/"]T9#X-"B`\+W1R/@T*(#QT<B!B9V-O;&]R/3-$(T-# M145&1CX-"B`\=&0@=F%L:6=N/3-$=&]P/@T*(#QP('-T>6QE/3-$)TU!4D=) M3BU,1494.B`R96T[(%1%6%0M24Y$14Y4.B`M,65M)SX\9F]N="!S='EL93TS M1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CY297-T M<FEC=&5D('-T;V-K('5N:71S#0H@9F]R9F5I=&5D/"]F;VYT/CPO<#X-"B`\ M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<VEZ93TS1#$^)B-X M03`[)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\ M9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S M:7IE/3-$,CXF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T M=&]M(&%L:6=N/3-$<FEG:'0^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ M(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^*#8X+#<P,CPO9F]N=#X\+W1D M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P/CQF;VYT M('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4] M,T0R/BDF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M M/CQF;VYT('-I>F4],T0Q/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT M9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ M(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^)B-X03`[/"]F;VYT/CPO=&0^ M#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/CQF;VYT('-T M>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R M/C8N-S@\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A M<#TS1&YO=W)A<#X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@ M3F5W(%)O;6%N)R!S:7IE/3-$,CXF(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X- M"B`\+W1R/@T*(#QT<B!S='EL93TS1"=&3TY4+5-)6D4Z(#%P>"<^#0H@/'1D M('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^ M)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP M('-T>6QE/3-$)T)/4D1%4BU43U`Z(')G8B@P+#`L,"D@,7!X('-O;&ED)SXF M(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP M('-T>6QE/3-$)T)/4D1%4BU43U`Z(')G8B@P+#`L,"D@,7!X('-O;&ED)SXF M(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0^)B-X03`[/"]T9#X-"B`\=&0@=F%L M:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS M1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\ M=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/"]T<CX-"B`\='(^#0H@/'1D M('9A;&EG;CTS1'1O<#X-"B`\<"!S='EL93TS1"=-05)'24XM3$5&5#H@,65M M.R!415A4+4E.1$5.5#H@+3%E;2<^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U) M3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^4F5S=')I8W1E9"!S=&]C M:R!U;FET<PT*(&]U='-T86YD:6YG(&%T($1E8V5M8F5R)B-X03`[,S$L(#(P M,3(\+V9O;G0^/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\ M9F]N="!S:7IE/3-$,3XF(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@ M=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4 M:6UE<R!.97<@4F]M86XG('-I>F4],T0R/B8C>$$P.SPO9F]N=#X\+W1D/@T* M(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#X\9F]N="!S='EL M93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXR M,38L.#DX/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R M87`],T1N;W=R87`^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S M($YE=R!2;VUA;B<@<VEZ93TS1#(^)B-X03`[)B-X03`[/"]F;VYT/CPO=&0^ M#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF(WA!,#LF M(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT M('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4] M,T0R/B8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@ M86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM M97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXV+C<X/"]F;VYT/CPO=&0^#0H@/'1D M('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^/&9O;G0@<W1Y;&4] M,T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^)B-X M03`[)B-X03`[/"]F;VYT/CPO=&0^#0H@/"]T<CX-"B`\='(@8F=C;VQO<CTS M1"-#0T5%1D8^#0H@/'1D('9A;&EG;CTS1'1O<#X-"B`\<"!S='EL93TS1"=- M05)'24XM3$5&5#H@,F5M.R!415A4+4E.1$5.5#H@+3%E;2<^/&9O;G0@<W1Y M;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^ M4F5S=')I8W1E9"!S=&]C:R!U;FET<PT*(&=R86YT960\+V9O;G0^/"]P/@T* M(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF M(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M M/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG M('-I>F4],T0R/B8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B M;W1T;VT@86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS1"=&3TY4+49!34E, M63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXT,2PV-C$\+V9O;G0^/"]T M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#X\9F]N M="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE M/3-$,CXF(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$ M8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<W1Y;&4],T0G1D].5"U& M04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^)B-X03`[/"]F;VYT M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/CQF M;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I M>F4],T0R/C8N,#`\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M M(&YO=W)A<#TS1&YO=W)A<#X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@ M5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXF(WA!,#LF(WA!,#L\+V9O;G0^ M/"]T9#X-"B`\+W1R/@T*(#QT<CX-"B`\=&0@=F%L:6=N/3-$=&]P/@T*(#QP M('-T>6QE/3-$)TU!4D=)3BU,1494.B`R96T[(%1%6%0M24Y$14Y4.B`M,65M M)SX\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N M)R!S:7IE/3-$,CY297-T<FEC=&5D('-T;V-K('5N:71S#0H@=F5S=&5D/"]F M;VYT/CPO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@ M<VEZ93TS1#$^)B-X03`[)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG M;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@ M3F5W(%)O;6%N)R!S:7IE/3-$,CXF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@ M=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^/&9O;G0@<W1Y;&4],T0G M1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^*#(Q,2PX M.3<\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS M1&YO=W)A<#X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W M(%)O;6%N)R!S:7IE/3-$,CXI)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A M;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF(WA!,#LF(WA!,#L\+V9O M;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$ M)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R/B8C>$$P M.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R M:6=H=#X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O M;6%N)R!S:7IE/3-$,CXV+C<X/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS M1&)O='1O;2!N;W=R87`],T1N;W=R87`^/&9O;G0@<W1Y;&4],T0G1D].5"U& M04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^)B-X03`[)B-X03`[ M/"]F;VYT/CPO=&0^#0H@/"]T<CX-"B`\='(@8F=C;VQO<CTS1"-#0T5%1D8^ M#0H@/'1D('9A;&EG;CTS1'1O<#X-"B`\<"!S='EL93TS1"=-05)'24XM3$5& M5#H@,F5M.R!415A4+4E.1$5.5#H@+3%E;2<^/&9O;G0@<W1Y;&4],T0G1D]. M5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^4F5S=')I8W1E M9"!S=&]C:R!U;FET<PT*(&9O<F9E:71E9#PO9F]N=#X\+W`^#0H@/"]T9#X- M"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C>$$P.R8C M>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@ M<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS M1#(^)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A M;&EG;CTS1')I9VAT/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE M<R!.97<@4F]M86XG('-I>F4],T0R/B@T+#DY.3PO9F]N=#X\+W1D/@T*(#QT M9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P/CQF;VYT('-T>6QE M/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R/BDF M(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT M('-I>F4],T0Q/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI M9VX],T1B;W1T;VT^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S M($YE=R!2;VUA;B<@<VEZ93TS1#(^)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D M('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/CQF;VYT('-T>6QE/3-$ M)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R/C8N-S@\ M+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO M=W)A<#X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O M;6%N)R!S:7IE/3-$,CXF(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\+W1R M/@T*(#QT<B!S='EL93TS1"=&3TY4+5-)6D4Z(#%P>"<^#0H@/'1D('9A;&EG M;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[ M)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE M/3-$)T)/4D1%4BU43U`Z(')G8B@P+#`L,"D@,7!X('-O;&ED)SXF(WA!,#L\ M+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE M/3-$)T)/4D1%4BU43U`Z(')G8B@P+#`L,"D@,7!X('-O;&ED)SXF(WA!,#L\ M+W`^#0H@/"]T9#X-"B`\=&0^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$ M8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O M;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\=&0@=F%L M:6=N/3-$8F]T=&]M/CPO=&0^#0H@/"]T<CX-"B`\='(^#0H@/'1D('9A;&EG M;CTS1'1O<#X-"B`\<"!S='EL93TS1"=-05)'24XM3$5&5#H@,65M.R!415A4 M+4E.1$5.5#H@+3%E;2<^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I M;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^56YV97-T960@<F5S=')I8W1E9"!S M=&]C:PT*('5N:71S(&]U='-T86YD:6YG(&%T($1E8V5M8F5R)B-X03`[,S$L M(#(P,3,\+V9O;G0^/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O M;3X\9F]N="!S:7IE/3-$,3XF(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\ M=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9 M.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R/B8C>$$P.SPO9F]N=#X\+W1D M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#X\9F]N="!S M='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$ M,CXT,2PV-C,\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO M=W)A<#TS1&YO=W)A<#X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM M97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXF(WA!,#LF(WA!,#L\+V9O;G0^/"]T M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C>$$P M.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O M;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ M93TS1#(^)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O M;2!A;&EG;CTS1')I9VAT/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4 M:6UE<R!.97<@4F]M86XG('-I>F4],T0R/C8N,#`\+V9O;G0^/"]T9#X-"B`\ M=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#X\9F]N="!S='EL M93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXF M(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\+W1R/@T*(#QT<B!B9V-O;&]R M/3-$(T-#145&1CX-"B`\=&0@=F%L:6=N/3-$=&]P/@T*(#QP('-T>6QE/3-$ M)TU!4D=)3BU,1494.B`R96T[(%1%6%0M24Y$14Y4.B`M,65M)SX\9F]N="!S M='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$ M,CY297-T<FEC=&5D('-T;V-K('5N:71S#0H@9W)A;G1E9#PO9F]N=#X\+W`^ M#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q M/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T M;VT^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA M;B<@<VEZ93TS1#(^)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS M1&)O='1O;2!A;&EG;CTS1')I9VAT/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%- M24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R/C0S+#4P,#PO9F]N=#X\ M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P/CQF M;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I M>F4],T0R/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX] M,T1B;W1T;VT^/&9O;G0@<VEZ93TS1#$^)B-X03`[)B-X03`[/"]F;VYT/CPO M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=&3TY4 M+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXF(WA!,#L\+V9O M;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^ M/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@ M<VEZ93TS1#(^.2XV-3PO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T M;VT@;F]W<F%P/3-$;F]W<F%P/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9 M.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R/B8C>$$P.R8C>$$P.SPO9F]N M=#X\+W1D/@T*(#PO='(^#0H@/'1R/@T*(#QT9"!V86QI9VX],T1T;W`^#0H@ M/'`@<W1Y;&4],T0G34%21TE.+4Q%1E0Z(#)E;3L@5$585"U)3D1%3E0Z("TQ M96TG/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M M86XG('-I>F4],T0R/E)E<W1R:6-T960@<W1O8VL@=6YI=',-"B!V97-T960\ M+V9O;G0^/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N M="!S:7IE/3-$,3XF(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L M:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE M<R!.97<@4F]M86XG('-I>F4],T0R/B8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT M9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS M1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXH,C`L M.#,S/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`] M,T1N;W=R87`^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE M=R!2;VUA;B<@<VEZ93TS1#(^*28C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V M86QI9VX],T1B;W1T;VT^/&9O;G0@<VEZ93TS1#$^)B-X03`[)B-X03`[/"]F M;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS M1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXF(WA! M,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$ M<FEG:'0^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2 M;VUA;B<@<VEZ93TS1#(^-BXP,#PO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX] M,T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P/CQF;VYT('-T>6QE/3-$)T9/3E0M M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R/B8C>$$P.R8C>$$P M.SPO9F]N=#X\+W1D/@T*(#PO='(^#0H@/'1R(&)G8V]L;W(],T0C0T-%149& M/@T*(#QT9"!V86QI9VX],T1T;W`^#0H@/'`@<W1Y;&4],T0G34%21TE.+4Q% M1E0Z(#)E;3L@5$585"U)3D1%3E0Z("TQ96TG/CQF;VYT('-T>6QE/3-$)T9/ M3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R/E)E<W1R:6-T M960@<W1O8VL@=6YI=',-"B!F;W)F96ET960\+V9O;G0^/"]P/@T*(#PO=&0^ M#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF(WA!,#LF M(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT M('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4] M,T0R/B8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@ M86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM M97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXH,2PP,#`\+V9O;G0^/"]T9#X-"B`\ M=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#X\9F]N="!S='EL M93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXI M)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N M="!S:7IE/3-$,3XF(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L M:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE M<R!.97<@4F]M86XG('-I>F4],T0R/B8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT M9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS M1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXV+C`P M/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N M;W=R87`^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2 M;VUA;B<@<VEZ93TS1#(^)B-X03`[)B-X03`[/"]F;VYT/CPO=&0^#0H@/"]T M<CX-"B`\='(@<W1Y;&4],T0G1D].5"U325I%.B`Q<'@G/@T*(#QT9"!V86QI M9VX],T1B;W1T;VT^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P M.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL M93TS1"="3U)$15(M5$]0.B!R9V(H,"PP+#`I(#%P>"!S;VQI9"<^)B-X03`[ M/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL M93TS1"="3U)$15(M5$]0.B!R9V(H,"PP+#`I(#%P>"!S;VQI9"<^)B-X03`[ M/"]P/@T*(#PO=&0^#0H@/'1D/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS M1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T M;VT^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A M;&EG;CTS1&)O='1O;3X\+W1D/@T*(#PO='(^#0H@/'1R/@T*(#QT9"!V86QI M9VX],T1T;W`^#0H@/'`@<W1Y;&4],T0G34%21TE.+4Q%1E0Z(#%E;3L@5$58 M5"U)3D1%3E0Z("TQ96TG/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4 M:6UE<R!.97<@4F]M86XG('-I>F4],T0R/E5N=F5S=&5D(')E<W1R:6-T960@ M<W1O8VL-"B!U;FET<R!O=71S=&%N9&EN9R!A="!$96-E;6)E<B8C>$$P.S,Q M+"`R,#$T/"]F;VYT/CPO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T M;VT^/&9O;G0@<VEZ93TS1#$^)B-X03`[)B-X03`[/"]F;VYT/CPO=&0^#0H@ M/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=&3TY4+49!34E, M63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXF(WA!,#L\+V9O;G0^/"]T M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^/&9O;G0@ M<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS M1#(^-C,L,S,P/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N M;W=R87`],T1N;W=R87`^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I M;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^)B-X03`[)B-X03`[/"]F;VYT/CPO M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF(WA! M,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF M;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I M>F4],T0R/B0\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L M:6=N/3-$<FEG:'0^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S M($YE=R!2;VUA;B<@<VEZ93TS1#(^."XU,3PO9F]N=#X\+W1D/@T*(#QT9"!V M86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P/CQF;VYT('-T>6QE/3-$ M)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R/B8C>$$P M.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#PO='(^#0H@/'1R('-T>6QE/3-$)T9/ M3E0M4TE:13H@,7!X)SX-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@ M/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V M86QI9VX],T1B;W1T;VT^#0H@/'`@<W1Y;&4],T0G0D]21$52+51/4#H@<F=B M*#`L,"PP*2`S<'@@9&]U8FQE)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0@ M=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(')G M8B@P+#`L,"D@,W!X(&1O=6)L92<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA! M,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\=&0@=F%L M:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D M/@T*(#PO='(^#0H@/"$M+2!%;F0@5&%B;&4@0F]D>2`M+3X\+W1A8FQE/@T* M(#QP('-T>6QE/3-$)TU!4D=)3BU"3U143TTZ(#!P>#L@34%21TE.+51/4#H@ M,3)P>#L@5$585"U)3D1%3E0Z(#0E)R!A;&EG;CTS1&IU<W1I9GD^/&9O;G0@ M<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS M1#(^5&AE(&=R86YT(&1A=&4@9F%I<B!V86QU92!O9B!R97-T<FEC=&5D('-T M;V-K('5N:71S('9E<W1E9`T*(&1U<FEN9R!T:&4@>65A<G,@96YD960@1&5C M96UB97(F(WA!,#LS,2P@,C`Q-"P@,C`Q,R!A;F0@,C`Q,B!W87,-"B`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`^#0H@/'`@<W1Y;&4],T0G34%21TE.+4)/5%1/33H@,'!X.R!-05)'24XM M3$5&5#H@,B4[($U!4D=)3BU43U`Z(#$X<'@G/@T*(#QF;VYT('-T>6QE/3-$ M)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R/CQB/CQI M/E-T;V-K+4)A<V5D($-O;7!E;G-A=&EO;CPO:3X\+V(^/"]F;VYT/CPO<#X- M"B`\<"!S='EL93TS1"=-05)'24XM0D]45$]-.B`P<'@[($U!4D=)3BU43U`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`T*(&1A=&4@8F%S960@;VX@=&AE(&-A;&-U;&%T960@9F%I M<B!V86QU92!O9B!T:&4@87=A<F0L(&%N9"!I<PT*(')E8V]G;FEZ960@87,@ M86X@97AP96YS92!O;B!A('-T<F%I9VAT+6QI;F4@8F%S:7,@;W9E<B!T:&4- M"B!E;7!L;WEE928C>#(P,3D[<R!R97%U:7-I=&4@<V5R=FEC92!P97)I;V0L M(&=E;F5R86QL>2!T:&4@=F5S=&EN9PT*('!E<FEO9"!O9B!T:&4@87=A<F0N M/"]F;VYT/CPO<#X-"B`\<"!S='EL93TS1"=-05)'24XM0D]45$]-.B`P<'@[ M($U!4D=)3BU43U`Z(#$R<'@[(%1%6%0M24Y$14Y4.B`T)2<@86QI9VX],T1J M=7-T:69Y/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@ M4F]M86XG('-I>F4],T0R/E1H92!F;VQL;W=I;F<@=&%B;&4@<W5M;6%R:7IE M<R!S=&]C:RUB87-E9"!C;VUP96YS871I;VX@<F5L871E9`T*('1O('-T;V-K M(&]P=&EO;G,L(')E<W1R:6-T960@<W1O8VL@87=A<F1S+"!R97-T<FEC=&5D M('-T;V-K('5N:70L#0H@86YD(&5M<&QO>65E('-T;V-K('!U<F-H87-E<R`H M:6X@=&AO=7-A;F1S*3H\+V9O;G0^/"]P/@T*(#QP('-T>6QE/3-$)TU!4D=) M3BU"3U143TTZ(#!P>#L@1D].5"U325I%.B`Q,G!X.R!-05)'24XM5$]0.B`P M<'@G/@T*("8C>$$P.SPO<#X-"B`\=&%B;&4@<W1Y;&4],T0G0D]21$52+4-/ M3$Q!4%-%.B!C;VQL87!S92<@8V5L;'-P86-I;F<],T0P(&-E;&QP861D:6YG M/3-$,"!W:61T:#TS1#DR)2!A;&EG;CTS1&-E;G1E<B!B;W)D97(],T0P/@T* M(#PA+2T@0F5G:6X@5&%B;&4@2&5A9"`M+3X-"B`\='(^#0H@/'1D('=I9'1H M/3-$-S,E/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#0E M/CPO=&0^#0H@/'1D/CPO=&0^#0H@/'1D/CPO=&0^#0H@/'1D/CPO=&0^#0H@ M/'1D('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#0E/CPO=&0^#0H@/'1D/CPO M=&0^#0H@/'1D/CPO=&0^#0H@/'1D/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O M='1O;2!W:61T:#TS1#0E/CPO=&0^#0H@/'1D/CPO=&0^#0H@/'1D/CPO=&0^ M#0H@/'1D/CPO=&0^#0H@/"]T<CX-"B`\='(^#0H@/'1D('9A;&EG;CTS1&)O M='1O;3X\9F]N="!S:7IE/3-$,3XF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@ M=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C>$$P.R8C>$$P.SPO M9F]N=#X\+W1D/@T*(#QT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B!R9V(H M,"PP+#`I(#%P>"!S;VQI9"<@=F%L:6=N/3-$8F]T=&]M(&-O;'-P86X],T0Q M,"!A;&EG;CTS1&-E;G1E<CX\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@ M5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,3X\8CY996%R<R!%;F1E9`T*($1E M8V5M8F5R)B-X03`[,S$L/"]B/CPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX] M,T1B;W1T;VT^/&9O;G0@<VEZ93TS1#$^)B-X03`[/"]F;VYT/CPO=&0^#0H@ M/"]T<CX-"B`\='(^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE M/3-$,3XF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M M/CQF;VYT('-I>F4],T0Q/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT M9"!S='EL93TS1"="3U)$15(M0D]45$]-.B!R9V(H,"PP+#`I(#%P>"!S;VQI M9"<@=F%L:6=N/3-$8F]T=&]M(&-O;'-P86X],T0R(&%L:6=N/3-$8V5N=&5R M/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG M('-I>F4],T0Q/CQB/C(P,30\+V(^/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG M;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF(WA!,#L\+V9O;G0^/"]T9#X- M"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C>$$P.R8C M>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!S='EL93TS1"="3U)$15(M0D]45$]- M.B!R9V(H,"PP+#`I(#%P>"!S;VQI9"<@=F%L:6=N/3-$8F]T=&]M(&-O;'-P M86X],T0R(&%L:6=N/3-$8V5N=&5R/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%- M24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0Q/CQB/C(P,3,\+V(^/"]F M;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$ M,3XF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF M;VYT('-I>F4],T0Q/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!S M='EL93TS1"="3U)$15(M0D]45$]-.B!R9V(H,"PP+#`I(#%P>"!S;VQI9"<@ M=F%L:6=N/3-$8F]T=&]M(&-O;'-P86X],T0R(&%L:6=N/3-$8V5N=&5R/CQF M;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I M>F4],T0Q/CQB/C(P,3(\+V(^/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS M1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF(WA!,#L\+V9O;G0^/"]T9#X-"B`\ M+W1R/@T*(#PA+2T@16YD(%1A8FQE($AE860@+2T^/"$M+2!"96=I;B!486)L M92!";V1Y("TM/@T*(#QT<B!B9V-O;&]R/3-$(T-#145&1CX-"B`\=&0@=F%L M:6=N/3-$=&]P/@T*(#QP('-T>6QE/3-$)TU!4D=)3BU,1494.B`Q96T[(%1% M6%0M24Y$14Y4.B`M,65M)SX\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@ M5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CY297-E87)C:"!A;F0-"B!D979E M;&]P;65N=#PO9F]N=#X\+W`^#0H@/"]T9#X-"B`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`[)B-X M03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S M='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$ M,CXD/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS M1')I9VAT/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@ M4F]M86XG('-I>F4],T0R/C$L-3,X/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG M;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^/&9O;G0@<W1Y;&4],T0G1D]. M5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^)B-X03`[)B-X M03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S M:7IE/3-$,3XF(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N M/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!. M97<@4F]M86XG('-I>F4],T0R/B0\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N M/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^/&9O;G0@<W1Y;&4],T0G1D].5"U& M04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^,2PX,#$\+V9O;G0^ M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#X\ M9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S M:7IE/3-$,CXF(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\+W1R/@T*(#QT M<CX-"B`\=&0@=F%L:6=N/3-$=&]P/@T*(#QP('-T>6QE/3-$)TU!4D=)3BU, M1494.B`Q96T[(%1%6%0M24Y$14Y4.B`M,65M)SX\9F]N="!S='EL93TS1"=& M3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CY'96YE<F%L M(&%N9`T*(&%D;6EN:7-T<F%T:79E/"]F;VYT/CPO<#X-"B`\+W1D/@T*(#QT M9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<VEZ93TS1#$^)B-X03`[)B-X03`[ M/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL M93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXF M(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N M/3-$<FEG:'0^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE M=R!2;VUA;B<@<VEZ93TS1#(^,2PY-CD\+V9O;G0^/"]T9#X-"B`\=&0@=F%L M:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#X\9F]N="!S='EL93TS1"=& M3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXF(WA!,#LF M(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT M('-I>F4],T0Q/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI M9VX],T1B;W1T;VT^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S M($YE=R!2;VUA;B<@<VEZ93TS1#(^)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D M('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/CQF;VYT('-T>6QE/3-$ M)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R/C(L,#4Y M/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N M;W=R87`^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2 M;VUA;B<@<VEZ93TS1#(^)B-X03`[)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D M('9A;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF(WA!,#LF(WA!,#L\ M+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE M/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R/B8C M>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX] M,T1R:6=H=#X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W M(%)O;6%N)R!S:7IE/3-$,CXQ+#DX,CPO9F]N=#X\+W1D/@T*(#QT9"!V86QI M9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P/CQF;VYT('-T>6QE/3-$)T9/ M3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R/B8C>$$P.R8C M>$$P.SPO9F]N=#X\+W1D/@T*(#PO='(^#0H@/'1R('-T>6QE/3-$)T9/3E0M M4TE:13H@,7!X)SX-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D M('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI M9VX],T1B;W1T;VT^#0H@/'`@<W1Y;&4],T0G0D]21$52+51/4#H@<F=B*#`L M,"PP*2`Q<'@@<V]L:60G/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT9"!V86QI M9VX],T1B;W1T;VT^#0H@/'`@<W1Y;&4],T0G0D]21$52+51/4#H@<F=B*#`L M,"PP*2`Q<'@@<V]L:60G/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT9#XF(WA! M,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1% M4BU43U`Z(')G8B@P+#`L,"D@,7!X('-O;&ED)SXF(WA!,#L\+W`^#0H@/"]T M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1% M4BU43U`Z(')G8B@P+#`L,"D@,7!X('-O;&ED)SXF(WA!,#L\+W`^#0H@/"]T M9#X-"B`\=&0^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C M>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S M='EL93TS1"="3U)$15(M5$]0.B!R9V(H,"PP+#`I(#%P>"!S;VQI9"<^)B-X M03`[/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S M='EL93TS1"="3U)$15(M5$]0.B!R9V(H,"PP+#`I(#%P>"!S;VQI9"<^)B-X M03`[/"]P/@T*(#PO=&0^#0H@/'1D/B8C>$$P.SPO=&0^#0H@/"]T<CX-"B`\ M='(@8F=C;VQO<CTS1"-#0T5%1D8^#0H@/'1D('9A;&EG;CTS1'1O<#X-"B`\ M<"!S='EL93TS1"=-05)'24XM3$5&5#H@,65M.R!415A4+4E.1$5.5#H@+3%E M;2<^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA M;B<@<VEZ93TS1#(^4W1O8VLM8F%S960@8V]M<&5N<V%T:6]N#0H@:6YC;'5D M960@:6X@;W!E<F%T:6YG(&5X<&5N<V5S/"]F;VYT/CPO<#X-"B`\+W1D/@T* M(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<VEZ93TS1#$^)B-X03`[)B-X M03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S M='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$ M,CXD/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS M1')I9VAT/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@ M4F]M86XG('-I>F4],T0R/C,L,S,P/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG M;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^/&9O;G0@<W1Y;&4],T0G1D]. M5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^)B-X03`[)B-X M03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S M:7IE/3-$,3XF(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N M/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!. M97<@4F]M86XG('-I>F4],T0R/B0\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N M/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^/&9O;G0@<W1Y;&4],T0G1D].5"U& M04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^,RPU.3<\+V9O;G0^ M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#X\ M9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S M:7IE/3-$,CXF(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`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`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O M='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^ M#0H@/'`@<W1Y;&4],T0G0D]21$52+51/4#H@<F=B*#`L,"PP*2`S<'@@9&]U M8FQE)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(')G8B@P+#`L,"D@,W!X(&1O M=6)L92<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D/B8C>$$P.SPO=&0^#0H@ M/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V M86QI9VX],T1B;W1T;VT^#0H@/'`@<W1Y;&4],T0G0D]21$52+51/4#H@<F=B M*#`L,"PP*2`S<'@@9&]U8FQE)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0@ M=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(')G M8B@P+#`L,"D@,W!X(&1O=6)L92<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA! M,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@<W1Y;&4],T0G M0D]21$52+51/4#H@<F=B*#`L,"PP*2`S<'@@9&]U8FQE)SXF(WA!,#L\+W`^ M#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$ M)T)/4D1%4BU43U`Z(')G8B@P+#`L,"D@,W!X(&1O=6)L92<^)B-X03`[/"]P M/@T*(#PO=&0^#0H@/'1D/B8C>$$P.SPO=&0^#0H@/"]T<CX-"B`\(2TM($5N M9"!486)L92!";V1Y("TM/CPO=&%B;&4^#0H@/'`@<W1Y;&4],T0G34%21TE. M+4)/5%1/33H@,'!X.R!-05)'24XM3$5&5#H@,B4[($U!4D=)3BU43U`Z(#$X M<'@G/@T*(#QF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@ M4F]M86XG('-I>F4],T0R/CQI/D5M<&QO>65E#0H@4W1O8VLM0F%S960@0V]M M<&5N<V%T:6]N/"]I/CPO9F]N=#X\+W`^#0H@/'`@<W1Y;&4],T0G34%21TE. M+4)/5%1/33H@,'!X.R!-05)'24XM5$]0.B`V<'@[(%1%6%0M24Y$14Y4.B`T M)2<@86QI9VX],T1J=7-T:69Y/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9 M.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R/E1H92!#;VUP86YY('5S97,@ M=&AE($)L86-K+5-C:&]L97,@;W!T:6]N('!R:6-I;F<@;6]D96P@=&\-"B!D M971E<FUI;F4@=&AE(&9A:7(@=F%L=64@;V8@<W1O8VL@;W!T:6]N(&=R86YT M<R!T;R!E;7!L;WEE97,@86YD#0H@9&ER96-T;W)S(&%N9"!E;7!L;WEE92!S M=&]C:R!P=7)C:&%S92!P;&%N('-H87)E<RX@5&AE(&ME>2!I;G!U=`T*(&%S M<W5M<'1I;VYS('5S960@=&\@97-T:6UA=&4@9F%I<B!V86QU92!O9B!T:&5S M92!A=V%R9',@:6YC;'5D92!T:&4-"B!E>&5R8VES92!P<FEC92!O9B!T:&4@ M87=A<F0L('1H92!E>'!E8W1E9"!O<'1I;VX@=&5R;2P@=&AE(&5X<&5C=&5D M#0H@=F]L871I;&ET>2!O9B!T:&4@0V]M<&%N>28C>#(P,3D[<R!S=&]C:R!O M=F5R('1H92!O<'1I;VXF(W@R,#$Y.W,-"B!E>'!E8W1E9"!T97)M+"!T:&4@ M<FES:RUF<F5E(&EN=&5R97-T(')A=&4@;W9E<B!T:&4@;W!T:6]N)B-X,C`Q M.3MS#0H@97AP96-T960@=&5R;2P@86YD('1H92!#;VUP86YY)B-X,C`Q.3MS M(&5X<&5C=&5D(&1I=FED96YD('EI96QD+"!I9@T*(&%N>2X\+V9O;G0^/"]P M/@T*(#QP('-T>6QE/3-$)TU!4D=)3BU"3U143TTZ(#!P>#L@1D].5"U325I% M.B`Q,G!X.R!-05)'24XM5$]0.B`P<'@G/@T*("8C>$$P.SPO<#X-"B`\<"!S M='EL93TS1"=-05)'24XM0D]45$]-.B`P<'@[($U!4D=)3BU43U`Z(#!P>#L@ M5$585"U)3D1%3E0Z(#0E)R!A;&EG;CTS1&IU<W1I9GD^/&9O;G0@<W1Y;&4] M,T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^5&AE M(&9A:7(@=F%L=64@;V8@<VAA<F4M8F%S960@<&%Y;65N=',@=V%S(&5S=&EM M871E9"!O;B!T:&4-"B!D871E(&]F(&=R86YT('5S:6YG('1H92!";&%C:RU3 M8VAO;&5S(&]P=&EO;B!P<FEC:6YG(&UO9&5L(&)A<V5D(&]N#0H@=&AE(&9O M;&QO=VEN9R!W96EG:'1E9"!A=F5R86=E(&%S<W5M<'1I;VYS.CPO9F]N=#X\ M+W`^#0H@/'`@<W1Y;&4],T0G34%21TE.+4)/5%1/33H@,'!X.R!&3TY4+5-) M6D4Z(#$R<'@[($U!4D=)3BU43U`Z(#!P>"<^#0H@)B-X03`[/"]P/@T*(#QT M86)L92!S='EL93TS1"="3U)$15(M0T],3$%04T4Z(&-O;&QA<'-E)R!C96QL M<W!A8VEN9STS1#`@8V5L;'!A9&1I;F<],T0P('=I9'1H/3-$,3`P)2!A;&EG M;CTS1&-E;G1E<B!B;W)D97(],T0P/@T*(#PA+2T@0F5G:6X@5&%B;&4@2&5A M9"`M+3X-"B`\='(^#0H@/'1D('=I9'1H/3-$-#8E/CPO=&0^#0H@/'1D('9A M;&EG;CTS1&)O='1O;2!W:61T:#TS1#4E/CPO=&0^#0H@/'1D/CPO=&0^#0H@ M/'1D/CPO=&0^#0H@/'1D/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!W M:61T:#TS1#4E/CPO=&0^#0H@/'1D/CPO=&0^#0H@/'1D/CPO=&0^#0H@/'1D M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#4E/CPO=&0^ M#0H@/'1D/CPO=&0^#0H@/'1D/CPO=&0^#0H@/'1D/CPO=&0^#0H@/'1D('9A M;&EG;CTS1&)O='1O;2!W:61T:#TS1#4E/CPO=&0^#0H@/'1D/CPO=&0^#0H@ M/'1D/CPO=&0^#0H@/'1D/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!W M:61T:#TS1#4E/CPO=&0^#0H@/'1D/CPO=&0^#0H@/'1D/CPO=&0^#0H@/'1D M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#4E/CPO=&0^ M#0H@/'1D/CPO=&0^#0H@/'1D/CPO=&0^#0H@/'1D/CPO=&0^#0H@/"]T<CX- M"B`\='(^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF M(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT M('-I>F4],T0Q/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!S='EL M93TS1"="3U)$15(M0D]45$]-.B!R9V(H,"PP+#`I(#%P>"!S;VQI9"<@=F%L M:6=N/3-$8F]T=&]M(&-O;'-P86X],T0V(&%L:6=N/3-$8V5N=&5R/CQF;VYT M('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4] M,T0Q/CQB/EEE87(@16YD960\8G(@+SX-"B!$96-E;6)E<B8C>$$P.S,Q+"`R M,#$T/"]B/CPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O M;G0@<VEZ93TS1#$^)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS M1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF(WA!,#L\+V9O;G0^/"]T9#X-"B`\ M=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@<F=B*#`L,"PP*2`Q<'@@<V]L M:60G('9A;&EG;CTS1&)O='1O;2!C;VQS<&%N/3-$-B!A;&EG;CTS1&-E;G1E M<CX\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N M)R!S:7IE/3-$,3X\8CY996%R($5N9&5D/&)R("\^#0H@1&5C96UB97(F(WA! M,#LS,2P@,C`Q,SPO8CX\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T M=&]M/CQF;VYT('-I>F4],T0Q/B8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V M86QI9VX],T1B;W1T;VT^/&9O;G0@<VEZ93TS1#$^)B-X03`[/"]F;VYT/CPO M=&0^#0H@/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(')G8B@P+#`L,"D@ M,7!X('-O;&ED)R!V86QI9VX],T1B;W1T;VT@8V]L<W!A;CTS1#8@86QI9VX] M,T1C96YT97(^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE M=R!2;VUA;B<@<VEZ93TS1#$^/&(^665A<B!%;F1E9#QB<B`O/@T*($1E8V5M M8F5R)B-X03`[,S$L(#(P,3(\+V(^/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG M;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF(WA!,#L\+V9O;G0^/"]T9#X- M"B`\+W1R/@T*(#QT<CX-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I M>F4],T0Q/B8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T M;VT^/&9O;G0@<VEZ93TS1#$^)B-X03`[)B-X03`[/"]F;VYT/CPO=&0^#0H@ M/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(')G8B@P+#`L,"D@,7!X('-O M;&ED)R!V86QI9VX],T1B;W1T;VT@8V]L<W!A;CTS1#(@86QI9VX],T1C96YT M97(^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA M;B<@<VEZ93TS1#$^/&(^16UP;&]Y964\8G(@+SX-"B!3=&]C:R8C>$$P.T]P M=&EO;G,\+V(^/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\ M9F]N="!S:7IE/3-$,3XF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N M/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C>$$P.SPO9F]N=#X\+W1D/@T* M(#QT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B!R9V(H,"PP+#`I(#%P>"!S M;VQI9"<@=F%L:6=N/3-$8F]T=&]M(&-O;'-P86X],T0R(&%L:6=N/3-$8V5N M=&5R/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M M86XG('-I>F4],T0Q/CQB/D534%`\+V(^/"]F;VYT/CPO=&0^#0H@/'1D('9A M;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF(WA!,#L\+V9O;G0^/"]T M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C>$$P M.SPO9F]N=#X\+W1D/@T*(#QT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B!R M9V(H,"PP+#`I(#%P>"!S;VQI9"<@=F%L:6=N/3-$8F]T=&]M(&-O;'-P86X] M,T0R(&%L:6=N/3-$8V5N=&5R/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9 M.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0Q/CQB/D5M<&QO>65E/&)R("\^ M#0H@4W1O8VLF(WA!,#M/<'1I;VYS/"]B/CPO9F]N=#X\+W1D/@T*(#QT9"!V M86QI9VX],T1B;W1T;VT^/&9O;G0@<VEZ93TS1#$^)B-X03`[/"]F;VYT/CPO M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF(WA! M,#L\+V9O;G0^/"]T9#X-"B`\=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@ M<F=B*#`L,"PP*2`Q<'@@<V]L:60G('9A;&EG;CTS1&)O='1O;2!C;VQS<&%N M/3-$,B!A;&EG;CTS1&-E;G1E<CX\9F]N="!S='EL93TS1"=&3TY4+49!34E, M63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,3X\8CY%4U!0/"]B/CPO9F]N M=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<VEZ93TS1#$^ M)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N M="!S:7IE/3-$,3XF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@<W1Y;&4],T0G M0D]21$52+4)/5%1/33H@<F=B*#`L,"PP*2`Q<'@@<V]L:60G('9A;&EG;CTS M1&)O='1O;2!C;VQS<&%N/3-$,B!A;&EG;CTS1&-E;G1E<CX\9F]N="!S='EL M93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,3X\ M8CY%;7!L;WEE93QB<B`O/@T*(%-T;V-K)B-X03`[3W!T:6]N<SPO8CX\+V9O M;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q M/B8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O M;G0@<VEZ93TS1#$^)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('-T>6QE/3-$ M)T)/4D1%4BU"3U143TTZ(')G8B@P+#`L,"D@,7!X('-O;&ED)R!V86QI9VX] M,T1B;W1T;VT@8V]L<W!A;CTS1#(@86QI9VX],T1C96YT97(^/&9O;G0@<W1Y M;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#$^ M/&(^15-04#PO8CX\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M M/CQF;VYT('-I>F4],T0Q/B8C>$$P.SPO9F]N=#X\+W1D/@T*(#PO='(^#0H@ M/"$M+2!%;F0@5&%B;&4@2&5A9"`M+3X\(2TM($)E9VEN(%1A8FQE($)O9'D@ M+2T^#0H@/'1R(&)G8V]L;W(],T0C0T-%149&/@T*(#QT9"!V86QI9VX],T1T M;W`^#0H@/'`@<W1Y;&4],T0G34%21TE.+4Q%1E0Z(#%E;3L@5$585"U)3D1% M3E0Z("TQ96TG/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!. M97<@4F]M86XG('-I>F4],T0R/E)I<VLM9G)E92!I;G1E<F5S=`T*(')A=&4\ M+V9O;G0^/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N M="!S:7IE/3-$,3XF(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L M:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE M<R!.97<@4F]M86XG('-I>F4],T0R/B8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT M9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS M1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXQ+CD\ M+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO M=W)A<#X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O M;6%N)R!S:7IE/3-$,CXE)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG M;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF(WA!,#L\+V9O;G0^/"]T9#X- M"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%- M24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R/B8C>$$P.SPO9F]N=#X\ M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#X\9F]N M="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE M/3-$,CXP+C(\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO M=W)A<#TS1&YO=W)A<#X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM M97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXE)B-X03`[/"]F;VYT/CPO=&0^#0H@ M/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF(WA!,#L\+V9O M;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$ M)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R/B8C>$$P M.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R M:6=H=#X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O M;6%N)R!S:7IE/3-$,CXQ+C$\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$ M8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#X\9F]N="!S='EL93TS1"=&3TY4+49! M34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXE)B-X03`[/"]F;VYT M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF M(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT M('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4] M,T0R/B8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@ M86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM M97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXP+C(\+V9O;G0^/"]T9#X-"B`\=&0@ M=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#X\9F]N="!S='EL93TS M1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXE)B-X M03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S M:7IE/3-$,3XF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T M=&]M/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M M86XG('-I>F4],T0R/B8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX] M,T1B;W1T;VT@86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS1"=&3TY4+49! M34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXQ+C$\+V9O;G0^/"]T M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#X\9F]N M="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE M/3-$,CXE)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O M;3X\9F]N="!S:7IE/3-$,3XF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L M:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE M<R!.97<@4F]M86XG('-I>F4],T0R/B8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT M9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS M1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXP+C(\ M+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO M=W)A<#X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O M;6%N)R!S:7IE/3-$,CXE)B-X03`[/"]F;VYT/CPO=&0^#0H@/"]T<CX-"B`\ M='(^#0H@/'1D('9A;&EG;CTS1'1O<#X-"B`\<"!S='EL93TS1"=-05)'24XM M3$5&5#H@,65M.R!415A4+4E.1$5.5#H@+3%E;2<^/&9O;G0@<W1Y;&4],T0G M1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^5F]L871I M;&ET>3PO9F]N=#X\+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M M/CQF;VYT('-I>F4],T0Q/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT M9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ M(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^)B-X03`[/"]F;VYT/CPO=&0^ M#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/CQF;VYT('-T M>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R M/C<W+C$\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A M<#TS1&YO=W)A<#X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@ M3F5W(%)O;6%N)R!S:7IE/3-$,CXE)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D M('9A;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF(WA!,#L\+V9O;G0^ M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)T9/ M3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R/B8C>$$P.SPO M9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H M=#X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N M)R!S:7IE/3-$,CXX-BXP/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O M='1O;2!N;W=R87`],T1N;W=R87`^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U) M3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^)28C>$$P.SPO9F]N=#X\ M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<VEZ93TS1#$^)B-X M03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S M='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$ M,CXF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L M:6=N/3-$<FEG:'0^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S M($YE=R!2;VUA;B<@<VEZ93TS1#(^-S,N,CPO9F]N=#X\+W1D/@T*(#QT9"!V M86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P/CQF;VYT('-T>6QE/3-$ M)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R/B4F(WA! M,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I M>F4],T0Q/B8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T M;VT^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA M;B<@<VEZ93TS1#(^)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS M1&)O='1O;2!A;&EG;CTS1')I9VAT/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%- M24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R/C<T+C8\+V9O;G0^/"]T M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#X\9F]N M="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE M/3-$,CXE)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O M;3X\9F]N="!S:7IE/3-$,3XF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L M:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE M<R!.97<@4F]M86XG('-I>F4],T0R/B8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT M9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS M1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXW,2XQ M/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N M;W=R87`^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2 M;VUA;B<@<VEZ93TS1#(^)28C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI M9VX],T1B;W1T;VT^/&9O;G0@<VEZ93TS1#$^)B-X03`[/"]F;VYT/CPO=&0^ M#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=&3TY4+49! M34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXF(WA!,#L\+V9O;G0^ M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^/&9O M;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ M93TS1#(^-S(N,#PO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@ M;F]W<F%P/3-$;F]W<F%P/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4 M:6UE<R!.97<@4F]M86XG('-I>F4],T0R/B4F(WA!,#L\+V9O;G0^/"]T9#X- M"B`\+W1R/@T*(#QT<B!B9V-O;&]R/3-$(T-#145&1CX-"B`\=&0@=F%L:6=N M/3-$=&]P/@T*(#QP('-T>6QE/3-$)TU!4D=)3BU,1494.B`Q96T[(%1%6%0M M24Y$14Y4.B`M,65M)SX\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM M97,@3F5W(%)O;6%N)R!S:7IE/3-$,CY%>'!E8W1E9"!T97)M(&EN#0H@>65A M<G,\+V9O;G0^/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\ M9F]N="!S:7IE/3-$,3XF(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@ M=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4 M:6UE<R!.97<@4F]M86XG('-I>F4],T0R/B8C>$$P.SPO9F]N=#X\+W1D/@T* M(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#X\9F]N="!S='EL M93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXV M+C,P/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`] M,T1N;W=R87`^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE M=R!2;VUA;B<@<VEZ93TS1#(^)B-X03`[)B-X03`[/"]F;VYT/CPO=&0^#0H@ M/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF(WA!,#L\+V9O M;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$ M)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R/B8C>$$P M.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R M:6=H=#X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O M;6%N)R!S:7IE/3-$,CXQ+C(U/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS M1&)O='1O;2!N;W=R87`],T1N;W=R87`^/&9O;G0@<W1Y;&4],T0G1D].5"U& M04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^)B-X03`[)B-X03`[ M/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE M/3-$,3XF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M M/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG M('-I>F4],T0R/B8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B M;W1T;VT@86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS1"=&3TY4+49!34E, M63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXV+C(P/"]F;VYT/CPO=&0^ M#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^/&9O;G0@ M<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS M1#(^)B-X03`[)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O M='1O;3X\9F]N="!S:7IE/3-$,3XF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@ M=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4 M:6UE<R!.97<@4F]M86XG('-I>F4],T0R/B8C>$$P.SPO9F]N=#X\+W1D/@T* M(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#X\9F]N="!S='EL M93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXQ M+C(U/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`] M,T1N;W=R87`^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE M=R!2;VUA;B<@<VEZ93TS1#(^)B-X03`[)B-X03`[/"]F;VYT/CPO=&0^#0H@ M/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF(WA!,#L\+V9O M;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$ M)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R/B8C>$$P M.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R M:6=H=#X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O M;6%N)R!S:7IE/3-$,CXV+C$S/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS M1&)O='1O;2!N;W=R87`],T1N;W=R87`^/&9O;G0@<W1Y;&4],T0G1D].5"U& M04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^)B-X03`[)B-X03`[ M/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE M/3-$,3XF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M M/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG M('-I>F4],T0R/B8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B M;W1T;VT@86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS1"=&3TY4+49!34E, M63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXQ+C(U/"]F;VYT/CPO=&0^ M#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^/&9O;G0@ M<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS M1#(^)B-X03`[)B-X03`[/"]F;VYT/CPO=&0^#0H@/"]T<CX-"B`\='(^#0H@ M/'1D('9A;&EG;CTS1'1O<#X-"B`\<"!S='EL93TS1"=-05)'24XM3$5&5#H@ M,65M.R!415A4+4E.1$5.5#H@+3%E;2<^/&9O;G0@<W1Y;&4],T0G1D].5"U& M04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^17AP96-T960@9&EV M:61E;F0-"B!Y:65L9#PO9F]N=#X\+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N M/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C>$$P.R8C>$$P.SPO9F]N=#X\ M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<W1Y;&4],T0G1D]. M5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^)B-X03`[/"]F M;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT M/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG M('-I>F4],T0R/C`N,#PO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T M;VT@;F]W<F%P/3-$;F]W<F%P/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9 M.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R/B4F(WA!,#L\+V9O;G0^/"]T M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C>$$P M.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<W1Y M;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^ M)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG M;CTS1')I9VAT/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!. M97<@4F]M86XG('-I>F4],T0R/C`N,#PO9F]N=#X\+W1D/@T*(#QT9"!V86QI M9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P/CQF;VYT('-T>6QE/3-$)T9/ M3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R/B4F(WA!,#L\ M+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4] M,T0Q/B8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^ M/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@ M<VEZ93TS1#(^)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O M='1O;2!A;&EG;CTS1')I9VAT/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9 M.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R/C`N,#PO9F]N=#X\+W1D/@T* M(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P/CQF;VYT('-T M>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R M/B4F(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF M;VYT('-I>F4],T0Q/B8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX] M,T1B;W1T;VT^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE M=R!2;VUA;B<@<VEZ93TS1#(^)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A M;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/CQF;VYT('-T>6QE/3-$)T9/ M3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R/C`N,#PO9F]N M=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P M/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG M('-I>F4],T0R/B4F(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$ M8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT M9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ M(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^)B-X03`[/"]F;VYT/CPO=&0^ M#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/CQF;VYT('-T M>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R M/C`N,#PO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P M/3-$;F]W<F%P/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!. M97<@4F]M86XG('-I>F4],T0R/B4F(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@ M=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C>$$P.SPO9F]N=#X\ M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<W1Y;&4],T0G1D]. M5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^)B-X03`[/"]F M;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT M/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG M('-I>F4],T0R/C`N,#PO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T M;VT@;F]W<F%P/3-$;F]W<F%P/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9 M.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R/B4F(WA!,#L\+V9O;G0^/"]T M9#X-"B`\+W1R/@T*(#PA+2T@16YD(%1A8FQE($)O9'D@+2T^/"]T86)L93X- M"B`\<"!S='EL93TS1"=-05)'24XM0D]45$]-.B`P<'@[($U!4D=)3BU43U`Z M(#$R<'@[(%1%6%0M24Y$14Y4.B`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`\<"!S='EL93TS1"=-05)'24XM0D]45$]-.B`P<'@[($U!4D=)3BU43U`Z M(#$R<'@[(%1%6%0M24Y$14Y4.B`T)2<@86QI9VX],T1J=7-T:69Y/CQF;VYT M('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4] M,T0R/E1H92!#;VUP86YY('5S97,@:71S(&]W;B!H:7-T;W)I8V%L(&5X97)C M:7-E(&%C=&EV:71Y(&%N9`T*(&5X=')A<&]L871E<R!T:&4@;&EF92!C>6-L M92!O9B!O<'1I;VYS(&]U='-T86YD:6YG('1O(&%R<FEV92!A="!I=',-"B!E M<W1I;6%T960@97AP96-T960@=&5R;2!F;W(@;F5W(&]P=&EO;B!G<F%N=',N M(%1H92!#;VUP86YY('5S97,@:71S#0H@;W=N('9O;&%T:6QI='D@:&ES=&]R M>2!B87-E9"!O;B!I=',@<W1O8VLF(W@R,#$Y.W,@=')A9&EN9R!H:7-T;W)Y M#0H@9F]R('1H92!P97)I;V0@<W5B<V5Q=65N="!T;R!T:&4@0V]M<&%N>28C M>#(P,3D[<R!I;FET:6%L('!U8FQI8PT*(&]F9F5R:6YG(&EN($%P<FEL)B-X M03`[,C`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`\<"!S='EL93TS1"=-05)'24XM M0D]45$]-.B`P<'@[($U!4D=)3BU43U`Z(#$R<'@[(%1%6%0M24Y$14Y4.B`T M)2<@86QI9VX],T1J=7-T:69Y/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9 M.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R/D%S(&]F($1E8V5M8F5R)B-X M03`[,S$L(#(P,30L('1H97)E('=A<R`D-2XW)B-X03`[;6EL;&EO;B!O9@T* M('5N<F5C;V=N:7IE9"!C;VUP96YS871I;VX@8V]S="!R96QA=&5D('1O('5N M=F5S=&5D('-T;V-K(&]P=&EO;G,L#0H@=VAI8V@@:7,@97AP96-T960@=&\@ M8F4@<F5C;V=N:7IE9"!O=F5R(&$@=V5I9VAT960M879E<F%G92!P97)I;V0- M"B!O9B`R+C4R)B-X03`[>65A<G,@86YD("0P+C,@;6EL;&EO;B!O9B!U;G)E M8V]G;FEZ960@8V]M<&5N<V%T:6]N#0H@8V]S="!R96QA=&5D('1O('5N=F5S M=&5D(')E<W1R:6-T960@<W1O8VL@=6YI=',L('=H:6-H(&ES(&5X<&5C=&5D M#0H@=&\@8F4@<F5C;V=N:7IE9"!O=F5R(&$@=V5I9VAT960M879E<F%G92!P M97)I;V0@;V8-"B`P+C@S)B-X03`[>65A<G,N/"]F;VYT/CPO<#X-"B`\<"!S M='EL93TS1"=-05)'24XM0D]45$]-.B`P<'@[($U!4D=)3BU,1494.B`R)3L@ M34%21TE.+51/4#H@,3AP>"<^#0H@/&9O;G0@<W1Y;&4],T0G1D].5"U&04U) M3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^/&D^3F]N+65M<&QO>65E M#0H@4W1O8VLM0F%S960@0V]M<&5N<V%T:6]N/"]I/CPO9F]N=#X\+W`^#0H@ M/'`@<W1Y;&4],T0G34%21TE.+4)/5%1/33H@,'!X.R!-05)'24XM5$]0.B`V M<'@[(%1%6%0M24Y$14Y4.B`T)2<@86QI9VX],T1J=7-T:69Y/CQF;VYT('-T M>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R M/E1H92!#;VUP86YY(')E8V]R9',@<W1O8VL@;W!T:6]N(&=R86YT<R!T;R!N M;VXM96UP;&]Y965S+`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`Q-"P@,C`Q,R!O M<B`R,#$R+B!7:&5N('1E<FUI;F%T:6YG+"!I9@T*(&5M<&QO>65E<R!C;VYT M:6YU92!T;R!P<F]V:61E('-E<G9I8V4@=&\@=&AE($-O;7!A;GD@87,@8V]N M<W5L=&%N=',-"B!A;F0@=&AE:7(@9W)A;G1S(&%R92!P97)M:71T960@=&\@ M8V]N=&EN=64@=&\@=F5S="P@=&AE(&5X<&5N<V4-"B!A<W-O8VEA=&5D('=I M=&@@=&AE(&-O;G1I;G5E9"!V97-T:6YG(&]F('1H92!R96QA=&5D('-T;V-K M(&]P=&EO;G,-"B!I<R!C;&%S<VEF:65D(&%S(&YO;BUE;7!L;WEE92!S=&]C M:R!C;VUP96YS871I;VX@97AP96YS92!A9G1E<B!T:&4-"B!S=&%T=7,@8VAA M;F=E+CPO9F]N=#X\+W`^#0H@/'`@<W1Y;&4],T0G34%21TE.+4)/5%1/33H@ M,'!X.R!-05)'24XM5$]0.B`Q,G!X.R!415A4+4E.1$5.5#H@-"4G(&%L:6=N M/3-$:G5S=&EF>3X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@ M3F5W(%)O;6%N)R!S:7IE/3-$,CY);B!C;VYN96-T:6]N('=I=&@@<V5R=FEC M97,@<F5N9&5R960@8GD@;F]N+65M<&QO>65E<RP@=&AE#0H@0V]M<&%N>2!R M96-O<F1E9"!S=&]C:RUB87-E9"!C;VUP96YS871I;VX@97AP96YS92!O9B`D M-3`L,#`P+`T*("0Q,#0L,#`P+"!A;F0@)#4V+#`P,"!I;B`R,#$T+"`R,#$S M(&%N9"`R,#$R+`T*(')E<W!E8W1I=F5L>2X\+V9O;G0^/"]P/@T*(#QP('-T M>6QE/3-$)TU!4D=)3BU"3U143TTZ(#!P>#L@1D].5"U325I%.B`Q.'!X.R!- M05)'24XM5$]0.B`P<'@G/@T*("8C>$$P.SPO<#X-"B`\<"!S='EL93TS1"=- M05)'24XM0D]45$]-.B`P<'@[($U!4D=)3BU,1494.B`R)3L@34%21TE.+51/ M4#H@,'!X)SX-"B`\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@ M3F5W(%)O;6%N)R!S:7IE/3-$,CX\8CX\:3Y%4U!0/"]I/CPO8CX\+V9O;G0^ M/"]P/@T*(#QP('-T>6QE/3-$)TU!4D=)3BU"3U143TTZ(#!P>#L@34%21TE. M+51/4#H@-G!X.R!415A4+4E.1$5.5#H@-"4G(&%L:6=N/3-$:G5S=&EF>3X\ M9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S M:7IE/3-$,CY);B!*86YU87)Y(#(P,#0L('1H92!";V%R9"!O9B!$:7)E8W1O M<G,@861O<'1E9"!T:&4@15-04"P@=VAI8V@-"B!W87,@87!P<F]V960@8GD@ M=&AE('-T;V-K:&]L9&5R<R!I;B!&96)R=6%R>2`R,#`T+B!5;F1E<B!T:&4@ M15-04"P-"B!S=&%T=71O<GD@96UP;&]Y965S(&UA>2!P=7)C:&%S92!C;VUM M;VX@<W1O8VL@;V8@=&AE($-O;7!A;GD@=7`@=&\-"B!A('-P96-I9FEE9"!M M87AI;75M(&%M;W5N="!T:')O=6=H('!A>7)O;&P@9&5D=6-T:6]N<RX@5&AE M('-T;V-K(&ES#0H@<'5R8VAA<V5D('-E;6DM86YN=6%L;'D@870@82!P<FEC M92!E<75A;"!T;R`X-24@;V8@=&AE(&9A:7(@;6%R:V5T#0H@=F%L=64@870@ M8V5R=&%I;B!P;&%N+61E9FEN960@9&%T97,N(%1H92!#;VUP86YY(&ES<W5E M9"`Q.2PW,C8L#0H@,30L.3@U(&%N9"`Q-2PP,3`@<VAA<F5S(&]F(&-O;6UO M;B!S=&]C:R!D=7)I;F<@,C`Q-"P@,C`Q,R!A;F0-"B`R,#$R+"!R97-P96-T M:79E;'DL('!U<G-U86YT('1O('1H92!%4U!0(&%T(&%N(&%V97)A9V4@<')I M8V4@;V8-"B`D,RXS."P@)#,N-C8@86YD("0T+C,R('!E<B!S:&%R92P@:6X@ M,C`Q-"P@,C`Q,R!A;F0@,C`Q,BP-"B!R97-P96-T:79E;'DN($%T($1E8V5M M8F5R)B-X03`[,S$L(#(P,30@=&AE($-O;7!A;GD@:&%D#0H@,3<P+#$W,"8C M>$$P.W-H87)E<R!O9B!C;VUM;VX@<W1O8VL@<F5S97)V960@9F]R(&ES<W5A M;F-E('5N9&5R('1H90T*($534%`N/"]F;VYT/CPO<#X-"B`-"B`-"B`\+V1I M=CX\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@/"]T86)L M93X-"B`@/"]B;V1Y/@T*/"]H=&UL/@T*#0HM+2TM+2T]7TYE>'1087)T7S,Y M8S!E838R7V,R,#-?-#4X9E\X8S4P7S-D8V$T-39A-CDU,0T*0V]N=&5N="U, M;V-A=&EO;CH@9FEL93HO+R]#.B\S.6,P96$V,E]C,C`S7S0U.&9?.&,U,%\S M9&-A-#4V838Y-3$O5V]R:W-H965T<R]3:&5E=#(P+FAT;6P-"D-O;G1E;G0M M5')A;G-F97(M16YC;V1I;F<Z('%U;W1E9"UP<FEN=&%B;&4-"D-O;G1E;G0M M5'EP93H@=&5X="]H=&UL.R!C:&%R<V5T/2)U<RUA<V-I:2(-"@T*/&AT;6P^ M#0H@(#QH96%D/@T*("`@(#Q-151!(&AT='`M97%U:78],T1#;VYT96YT+51Y M<&4@8V]N=&5N=#TS1"=T97AT+VAT;6P[(&-H87)S970]=71F+3@G/CQS8W)I M<'0@='EP93TS1'1E>'0O:F%V87-C<FEP="!S<F,],T13:&]W+FIS/B\J($1O M($YO="!296UO=F4@5&AI<R!#;VUM96YT("HO/"]S8W)I<'0^/"]H96%D/@T* M("`\8F]D>3X-"B`@("`\=&%B;&4@8VQA<W,],T1R97!O<G0@:60],T1)1#!% M344^#0H@("`@("`\='(^#0H@("`@("`@(#QT:"!C;&%S<STS1'1L(&-O;'-P M86X],T0Q(')O=W-P86X],T0R/CQS=')O;F<^26YC;VUE(%1A>&5S/&)R/CPO M<W1R;VYG/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H(&-O;'-P86X] M,T0Q/C$R($UO;G1H<R!%;F1E9#PO=&@^#0H@("`@("`\+W1R/@T*("`@("`@ M/'1R/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y$96,N(#,Q+"`R,#$T/&)R M/CPO=&@^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@ M("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#X\<W1R;VYG/DEN M8V]M92!487@@1&ES8VQO<W5R92!;06)S=')A8W1=/"]S=')O;F<^/"]T9#X- M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X- M"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@ M/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/DEN8V]M92!487AE<SPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/&1I=CX-"B`\<"!S='EL93TS M1"=-05)'24XM0D]45$]-.B`P<'@[($U!4D=)3BU43U`Z(#$X<'@G/CQF;VYT M('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4] M,T0R/CQB/DYO=&4@,3,@)B-X,C`Q-#L@26YC;VUE#0H@5&%X97,\+V(^/"]F M;VYT/CPO<#X-"B`\<"!S='EL93TS1"=-05)'24XM0D]45$]-.B`P<'@[($U! M4D=)3BU43U`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`[,S$L(#(P,30L#0H@,C`Q,RP@;W(@,C`Q,B!B96-A=7-E('1H92!# M;VUP86YY(&AA9"!A(&YE="!T87AA8FQE(&QO<W,@:6X@=&AE#0H@<&5R:6]D M+CPO9F]N=#X\+W`^#0H@/'`@<W1Y;&4],T0G34%21TE.+4)/5%1/33H@,'!X M.R!-05)'24XM5$]0.B`Q,G!X.R!415A4+4E.1$5.5#H@-"4G(&%L:6=N/3-$ M:G5S=&EF>3X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W M(%)O;6%N)R!S:7IE/3-$,CY&;W(@9FEN86YC:6%L('-T871E;65N="!P=7)P M;W-E<RP@;&]S<R!B969O<F4@=&%X97,@:6YC;'5D97,-"B!T:&4@9F]L;&]W M:6YG(&-O;7!O;F5N=',@*&EN('1H;W5S86YD<RDZ/"]F;VYT/CPO<#X-"B`\ M<"!S='EL93TS1"=-05)'24XM0D]45$]-.B`P<'@[($9/3E0M4TE:13H@,3)P M>#L@34%21TE.+51/4#H@,'!X)SX-"B`F(WA!,#L\+W`^#0H@/'1A8FQE('-T M>6QE/3-$)T)/4D1%4BU#3TQ,05!313H@8V]L;&%P<V4G(&-E;&QS<&%C:6YG M/3-$,"!C96QL<&%D9&EN9STS1#`@=VED=&@],T0Y,B4@86QI9VX],T1C96YT M97(@8F]R9&5R/3-$,#X-"B`\='(^#0H@/'1D('=I9'1H/3-$-C8E/CPO=&0^ M#0H@/'1D('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#4E/CPO=&0^#0H@/'1D M/CPO=&0^#0H@/'1D/CPO=&0^#0H@/'1D/CPO=&0^#0H@/'1D('9A;&EG;CTS M1&)O='1O;2!W:61T:#TS1#0E/CPO=&0^#0H@/'1D/CPO=&0^#0H@/'1D/CPO M=&0^#0H@/'1D/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!W:61T:#TS M1#0E/CPO=&0^#0H@/'1D/CPO=&0^#0H@/'1D/CPO=&0^#0H@/'1D/CPO=&0^ M#0H@/"]T<CX-"B`\='(^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S M:7IE/3-$,3XF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T M=&]M/CQF;VYT('-I>F4],T0Q/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T* M(#QT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B`C,#`P,#`P(#%P>"!S;VQI M9"<@=F%L:6=N/3-$8F]T=&]M(&-O;'-P86X],T0Q,"!A;&EG;CTS1&-E;G1E M<CX\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N M)R!S:7IE/3-$,3X\8CY996%R<R!%;F1E9#QB<B`O/@T*($1E8V5M8F5R)B-X M03`[,S$L/"]B/CPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^ M/&9O;G0@<VEZ93TS1#$^)B-X03`[/"]F;VYT/CPO=&0^#0H@/"]T<CX-"B`\ M='(^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF(WA! M,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I M>F4],T0Q/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!S='EL93TS M1"="3U)$15(M0D]45$]-.B`C,#`P,#`P(#%P>"!S;VQI9"<@=F%L:6=N/3-$ M8F]T=&]M(&-O;'-P86X],T0R(&%L:6=N/3-$8V5N=&5R/CQF;VYT('-T>6QE M/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0Q/CQB M/C(P,30\+V(^/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\ M9F]N="!S:7IE/3-$,3XF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N M/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C>$$P.R8C>$$P.SPO9F]N=#X\ M+W1D/@T*(#QT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B`C,#`P,#`P(#%P M>"!S;VQI9"<@=F%L:6=N/3-$8F]T=&]M(&-O;'-P86X],T0R(&%L:6=N/3-$ M8V5N=&5R/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@ M4F]M86XG('-I>F4],T0Q/CQB/C(P,3,\+V(^/"]F;VYT/CPO=&0^#0H@/'1D M('9A;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF(WA!,#L\+V9O;G0^ M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C M>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!S='EL93TS1"="3U)$15(M M0D]45$]-.B`C,#`P,#`P(#%P>"!S;VQI9"<@=F%L:6=N/3-$8F]T=&]M(&-O M;'-P86X],T0R(&%L:6=N/3-$8V5N=&5R/CQF;VYT('-T>6QE/3-$)T9/3E0M M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0Q/CQB/C(P,3(\+V(^ M/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE M/3-$,3XF(WA!,#L\+V9O;G0^/"]T9#X-"B`\+W1R/@T*(#QT<B!B9V-O;&]R M/3-$(T-#145&1CX-"B`\=&0@=F%L:6=N/3-$=&]P/@T*(#QP('-T>6QE/3-$ M)TU!4D=)3BU,1494.B`Q96T[(%1%6%0M24Y$14Y4.B`M,65M)SX\9F]N="!S M='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$ M,CY5;FET960@4W1A=&5S/"]F;VYT/CPO<#X-"B`\+W1D/@T*(#QT9"!V86QI M9VX],T1B;W1T;VT^/&9O;G0@<VEZ93TS1#$^)B-X03`[)B-X03`[/"]F;VYT M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=& M3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXD/"]F;VYT M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/CQF M;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I M>F4],T0R/B@Q-"PV-#8\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T M=&]M(&YO=W)A<#TS1&YO=W)A<#X\9F]N="!S='EL93TS1"=&3TY4+49!34E, M63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXI)B-X03`[/"]F;VYT/CPO M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF(WA! M,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF M;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I M>F4],T0R/B0\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L M:6=N/3-$<FEG:'0^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S M($YE=R!2;VUA;B<@<VEZ93TS1#(^*#,S+#<Q-SPO9F]N=#X\+W1D/@T*(#QT M9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P/CQF;VYT('-T>6QE M/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R/BDF M(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT M('-I>F4],T0Q/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI M9VX],T1B;W1T;VT^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S M($YE=R!2;VUA;B<@<VEZ93TS1#(^)#PO9F]N=#X\+W1D/@T*(#QT9"!V86QI M9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS1"=&3TY4 M+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXH-#`L,S<P/"]F M;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R M87`^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA M;B<@<VEZ93TS1#(^*28C>$$P.SPO9F]N=#X\+W1D/@T*(#PO='(^#0H@/'1R M/@T*(#QT9"!V86QI9VX],T1T;W`^#0H@/'`@<W1Y;&4],T0G34%21TE.+4Q% M1E0Z(#%E;3L@5$585"U)3D1%3E0Z("TQ96TG/CQF;VYT('-T>6QE/3-$)T9/ M3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R/D9O<F5I9VX\ M+V9O;G0^/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N M="!S:7IE/3-$,3XF(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L M:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#X\9F]N="!S='EL93TS1"=& M3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXF(WA!,#L\ M+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO M=W)A<"!A;&EG;CTS1')I9VAT/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9 M.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R/B8C>#(P,30[/"]F;VYT/CPO M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^/&9O M;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ M93TS1#(^)B-X03`[)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS M1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF(WA!,#LF(WA!,#L\+V9O;G0^/"]T M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#X\9F]N M="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE M/3-$,CXF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M M(&YO=W)A<#TS1&YO=W)A<"!A;&EG;CTS1')I9VAT/CQF;VYT('-T>6QE/3-$ M)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R/B8C>#(P M,30[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`] M,T1N;W=R87`^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE M=R!2;VUA;B<@<VEZ93TS1#(^)B-X03`[)B-X03`[/"]F;VYT/CPO=&0^#0H@ M/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF(WA!,#LF(WA! M,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS M1&YO=W)A<#X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W M(%)O;6%N)R!S:7IE/3-$,CXF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L M:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<"!A;&EG;CTS1')I9VAT/CQF M;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I M>F4],T0R/B8C>#(P,30[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O M='1O;2!N;W=R87`],T1N;W=R87`^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U) M3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^)B-X03`[)B-X03`[/"]F M;VYT/CPO=&0^#0H@/"]T<CX-"B`\='(@<W1Y;&4],T0G1D].5"U325I%.B`Q M<'@G/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\=&0@=F%L:6=N M/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O M='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B`C,#`P,#`P(#%P>"!S M;VQI9"<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O M;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B`C,#`P,#`P(#%P>"!S;VQI M9"<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D/B8C>$$P.SPO=&0^#0H@/'1D M('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI M9VX],T1B;W1T;VT^#0H@/'`@<W1Y;&4],T0G0D]21$52+51/4#H@(S`P,#`P M,"`Q<'@@<V]L:60G/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX] M,T1B;W1T;VT^#0H@/'`@<W1Y;&4],T0G0D]21$52+51/4#H@(S`P,#`P,"`Q M<'@@<V]L:60G/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT9#XF(WA!,#L\+W1D M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\ M=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z M(",P,#`P,#`@,7!X('-O;&ED)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0@ M=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(",P M,#`P,#`@,7!X('-O;&ED)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0^)B-X M03`[/"]T9#X-"B`\+W1R/@T*(#QT<B!B9V-O;&]R/3-$(T-#145&1CX-"B`\ M=&0@=F%L:6=N/3-$=&]P/@T*(#QP('-T>6QE/3-$)TU!4D=)3BU,1494.B`R M96T[(%1%6%0M24Y$14Y4.B`M,65M)SX\9F]N="!S='EL93TS1"=&3TY4+49! M34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CY4;W1A;#PO9F]N=#X\ M+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4] M,T0Q/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B M;W1T;VT^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2 M;VUA;B<@<VEZ93TS1#(^)#PO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B M;W1T;VT@86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS1"=&3TY4+49!34E, M63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXH,30L-C0V/"]F;VYT/CPO M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^/&9O M;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ M93TS1#(^*28C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T M;VT^/&9O;G0@<VEZ93TS1#$^)B-X03`[)B-X03`[/"]F;VYT/CPO=&0^#0H@ M/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=&3TY4+49!34E, M63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXD/"]F;VYT/CPO=&0^#0H@ M/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/CQF;VYT('-T>6QE M/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R/B@S M,RPW,3<\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A M<#TS1&YO=W)A<#X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@ M3F5W(%)O;6%N)R!S:7IE/3-$,CXI)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D M('9A;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF(WA!,#LF(WA!,#L\ M+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE M/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R/B0\ M+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG M:'0^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA M;B<@<VEZ93TS1#(^*#0P+#,W,#PO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX] M,T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P/CQF;VYT('-T>6QE/3-$)T9/3E0M M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R/BDF(WA!,#L\+V9O M;G0^/"]T9#X-"B`\+W1R/@T*(#QT<B!S='EL93TS1"=&3TY4+5-)6D4Z(#%P M>"<^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI9VX] M,T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T M=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@,W!X(&1O M=6)L92<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O M;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B`C,#`P,#`P(#-P>"!D;W5B M;&4G/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT9#XF(WA!,#L\+W1D/@T*(#QT M9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L M:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P M,#`@,W!X(&1O=6)L92<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG M;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B`C,#`P,#`P M(#-P>"!D;W5B;&4G/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT9#XF(WA!,#L\ M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X- M"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU4 M3U`Z(",P,#`P,#`@,W!X(&1O=6)L92<^)B-X03`[/"]P/@T*(#PO=&0^#0H@ M/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0 M.B`C,#`P,#`P(#-P>"!D;W5B;&4G/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT M9#XF(WA!,#L\+W1D/@T*(#PO='(^#0H@/"]T86)L93X-"B`\<"!S='EL93TS M1"=-05)'24XM0D]45$]-.B`P<'@[($U!4D=)3BU43U`Z(#$R<'@[(%1%6%0M M24Y$14Y4.B`T)2<@86QI9VX],T1J=7-T:69Y/CQF;VYT('-T>6QE/3-$)T9/ M3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R/E1H92!#;VUP M86YY(')E8V]R9&5D('1H92!F;VQL;W=I;F<@:6YC;VUE('1A>"!P<F]V:7-I M;VX@87,-"B!F;VQL;W=S("AI;B!T:&]U<V%N9',I.CPO9F]N=#X\+W`^#0H@ M/'`@<W1Y;&4],T0G34%21TE.+4)/5%1/33H@,'!X.R!&3TY4+5-)6D4Z(#$R M<'@[($U!4D=)3BU43U`Z(#!P>"<^#0H@)B-X03`[/"]P/@T*(#QT86)L92!S M='EL93TS1"="3U)$15(M0T],3$%04T4Z(&-O;&QA<'-E)R!C96QL<W!A8VEN M9STS1#`@8V5L;'!A9&1I;F<],T0P('=I9'1H/3-$.3(E(&%L:6=N/3-$8V5N M=&5R(&)O<F1E<CTS1#`^#0H@/'1R/@T*(#QT9"!W:61T:#TS1#8W)3X\+W1D M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Y)3X\+W1D/@T*(#QT M9#X\+W1D/@T*(#QT9#X\+W1D/@T*(#QT9#X\+W1D/@T*(#QT9"!V86QI9VX] M,T1B;W1T;VT@=VED=&@],T0Y)3X\+W1D/@T*(#QT9#X\+W1D/@T*(#QT9#X\ M+W1D/@T*(#QT9#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@=VED=&@] M,T0Y)3X\+W1D/@T*(#QT9#X\+W1D/@T*(#QT9#X\+W1D/@T*(#QT9#X\+W1D M/@T*(#PO='(^#0H@/'1R/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@ M<VEZ93TS1#$^)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O M='1O;3X\9F]N="!S:7IE/3-$,3XF(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X- M"B`\=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@(S`P,#`P,"`Q<'@@<V]L M:60G('9A;&EG;CTS1&)O='1O;2!C;VQS<&%N/3-$,3`@86QI9VX],T1C96YT M97(^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA M;B<@<VEZ93TS1#$^/&(^665A<G,@16YD960\8G(@+SX-"B!$96-E;6)E<B8C M>$$P.S,Q+#PO8CX\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M M/CQF;VYT('-I>F4],T0Q/B8C>$$P.SPO9F]N=#X\+W1D/@T*(#PO='(^#0H@ M/'1R/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<VEZ93TS1#$^)B-X M03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S M:7IE/3-$,3XF(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@<W1Y;&4] M,T0G0D]21$52+4)/5%1/33H@(S`P,#`P,"`Q<'@@<V]L:60G('9A;&EG;CTS M1&)O='1O;2!C;VQS<&%N/3-$,B!A;&EG;CTS1&-E;G1E<CX\9F]N="!S='EL M93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,3X\ M8CXR,#$T/"]B/CPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^ M/&9O;G0@<VEZ93TS1#$^)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG M;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF(WA!,#LF(WA!,#L\+V9O;G0^ M/"]T9#X-"B`\=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@(S`P,#`P,"`Q M<'@@<V]L:60G('9A;&EG;CTS1&)O='1O;2!C;VQS<&%N/3-$,B!A;&EG;CTS M1&-E;G1E<CX\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W M(%)O;6%N)R!S:7IE/3-$,3X\8CXR,#$S/"]B/CPO9F]N=#X\+W1D/@T*(#QT M9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<VEZ93TS1#$^)B-X03`[/"]F;VYT M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF M(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@<W1Y;&4],T0G0D]21$52 M+4)/5%1/33H@(S`P,#`P,"`Q<'@@<V]L:60G('9A;&EG;CTS1&)O='1O;2!C M;VQS<&%N/3-$,B!A;&EG;CTS1&-E;G1E<CX\9F]N="!S='EL93TS1"=&3TY4 M+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,3X\8CXR,#$R/"]B M/CPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<VEZ M93TS1#$^)B-X03`[/"]F;VYT/CPO=&0^#0H@/"]T<CX-"B`\='(@8F=C;VQO M<CTS1"-#0T5%1D8^#0H@/'1D('9A;&EG;CTS1'1O<#X-"B`\<"!S='EL93TS M1"=-05)'24XM3$5&5#H@,65M.R!415A4+4E.1$5.5#H@+3%E;2<^/&9O;G0@ M<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS M1#(^0W5R<F5N=#H\+V9O;G0^/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS M1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF(WA!,#LF(WA!,#L\+V9O;G0^/"]T M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS M1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\ M=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C>$$P.R8C>$$P M.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\ M=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O M;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<VEZ93TS1#$^ M)B-X03`[)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O M;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\=&0@=F%L M:6=N/3-$8F]T=&]M/CPO=&0^#0H@/"]T<CX-"B`\='(^#0H@/'1D('9A;&EG M;CTS1'1O<#X-"B`\<"!S='EL93TS1"=-05)'24XM3$5&5#H@,F5M.R!415A4 M+4E.1$5.5#H@+3%E;2<^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I M;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^1F5D97)A;#PO9F]N=#X\+W`^#0H@ M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C M>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@ M;F]W<F%P/3-$;F]W<F%P/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4 M:6UE<R!.97<@4F]M86XG('-I>F4],T0R/B0\+V9O;G0^/"]T9#X-"B`\=&0@ M=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<"!A;&EG;CTS1')I9VAT M/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG M('-I>F4],T0R/B8C>#(P,30[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS M1&)O='1O;2!N;W=R87`],T1N;W=R87`^/&9O;G0@<W1Y;&4],T0G1D].5"U& M04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^)B-X03`[)B-X03`[ M/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE M/3-$,3XF(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$ M8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#X\9F]N="!S='EL93TS1"=&3TY4+49! M34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXD/"]F;VYT/CPO=&0^ M#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`@86QI9VX] M,T1R:6=H=#X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W M(%)O;6%N)R!S:7IE/3-$,CXF(W@R,#$T.SPO9F]N=#X\+W1D/@T*(#QT9"!V M86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P/CQF;VYT('-T>6QE/3-$ M)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R/B8C>$$P M.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O M;G0@<VEZ93TS1#$^)B-X03`[)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A M;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^/&9O;G0@<W1Y;&4],T0G M1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^)#PO9F]N M=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P M(&%L:6=N/3-$<FEG:'0^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I M;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^)B-X,C`Q-#L\+V9O;G0^/"]T9#X- M"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#X\9F]N="!S M='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$ M,CXF(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\+W1R/@T*(#QT<B!B9V-O M;&]R/3-$(T-#145&1CX-"B`\=&0@=F%L:6=N/3-$=&]P/@T*(#QP('-T>6QE M/3-$)TU!4D=)3BU,1494.B`R96T[(%1%6%0M24Y$14Y4.B`M,65M)SX\9F]N M="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE M/3-$,CY3=&%T93PO9F]N=#X\+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$ M8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P/CQF;VYT M('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4] M,T0R/B8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@ M;F]W<F%P/3-$;F]W<F%P(&%L:6=N/3-$<FEG:'0^/&9O;G0@<W1Y;&4],T0G M1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^)B-X,C`Q M-#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS M1&YO=W)A<#X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W M(%)O;6%N)R!S:7IE/3-$,CXF(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\ M=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C>$$P.R8C>$$P M.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$ M;F]W<F%P/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@ M4F]M86XG('-I>F4],T0R/B8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI M9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P(&%L:6=N/3-$<FEG:'0^/&9O M;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ M93TS1#(^)B-X,C`Q-#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T M=&]M(&YO=W)A<#TS1&YO=W)A<#X\9F]N="!S='EL93TS1"=&3TY4+49!34E, M63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXF(WA!,#LF(WA!,#L\+V9O M;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q M/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T M;VT@;F]W<F%P/3-$;F]W<F%P/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9 M.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R/B8C>$$P.SPO9F]N=#X\+W1D M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P(&%L:6=N M/3-$<FEG:'0^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE M=R!2;VUA;B<@<VEZ93TS1#(^)B-X,C`Q-#L\+V9O;G0^/"]T9#X-"B`\=&0@ M=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#X\9F]N="!S='EL93TS M1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXF(WA! M,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\+W1R/@T*(#QT<B!S='EL93TS1"=& M3TY4+5-)6D4Z(#%P>"<^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T* M(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@ M=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(",P M,#`P,#`@,7!X('-O;&ED)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0@=F%L M:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P M,#`@,7!X('-O;&ED)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0^)B-X03`[ M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^ M#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M M5$]0.B`C,#`P,#`P(#%P>"!S;VQI9"<^)B-X03`[/"]P/@T*(#PO=&0^#0H@ M/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0 M.B`C,#`P,#`P(#%P>"!S;VQI9"<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA! M,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@<W1Y;&4],T0G M0D]21$52+51/4#H@(S`P,#`P,"`Q<'@@<V]L:60G/B8C>$$P.SPO<#X-"B`\ M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@<W1Y;&4],T0G0D]2 M1$52+51/4#H@(S`P,#`P,"`Q<'@@<V]L:60G/B8C>$$P.SPO<#X-"B`\+W1D M/@T*(#QT9#XF(WA!,#L\+W1D/@T*(#PO='(^#0H@/'1R/@T*(#QT9"!V86QI M9VX],T1T;W`^#0H@/'`@<W1Y;&4],T0G34%21TE.+4Q%1E0Z(#-E;3L@5$58 M5"U)3D1%3E0Z("TQ96TG/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4 M:6UE<R!.97<@4F]M86XG('-I>F4],T0R/E1O=&%L/"]F;VYT/CPO<#X-"B`\ M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<VEZ93TS1#$^)B-X M03`[)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N M;W=R87`],T1N;W=R87`^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I M;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^)#PO9F]N=#X\+W1D/@T*(#QT9"!V M86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P(&%L:6=N/3-$<FEG:'0^ M/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@ M<VEZ93TS1#(^)B-X,C`Q-#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$ M8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#X\9F]N="!S='EL93TS1"=&3TY4+49! M34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXF(WA!,#LF(WA!,#L\ M+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4] M,T0Q/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B M;W1T;VT@;F]W<F%P/3-$;F]W<F%P/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%- M24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R/B0\+V9O;G0^/"]T9#X- M"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<"!A;&EG;CTS M1')I9VAT/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@ M4F]M86XG('-I>F4],T0R/B8C>#(P,30[/"]F;VYT/CPO=&0^#0H@/'1D('9A M;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^/&9O;G0@<W1Y;&4],T0G M1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^)B-X03`[ M)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N M="!S:7IE/3-$,3XF(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L M:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#X\9F]N="!S='EL93TS1"=& M3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXD/"]F;VYT M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`@ M86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM M97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXF(W@R,#$T.SPO9F]N=#X\+W1D/@T* M(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P/CQF;VYT('-T M>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R M/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#PO='(^#0H@/'1R('-T>6QE M/3-$)T9/3E0M4TE:13H@,7!X)SX-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T* M(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@<W1Y;&4],T0G0D]21$52+51/ M4#H@(S`P,#`P,"`S<'@@9&]U8FQE)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\ M=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z M(",P,#`P,#`@,W!X(&1O=6)L92<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA! M,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@<W1Y;&4],T0G M0D]21$52+51/4#H@(S`P,#`P,"`S<'@@9&]U8FQE)SXF(WA!,#L\+W`^#0H@ M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/ M4D1%4BU43U`Z(",P,#`P,#`@,W!X(&1O=6)L92<^)B-X03`[/"]P/@T*(#PO M=&0^#0H@/'1D/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF M(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@ M<W1Y;&4],T0G0D]21$52+51/4#H@(S`P,#`P,"`S<'@@9&]U8FQE)SXF(WA! M,#L\+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T M>6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@,W!X(&1O=6)L92<^)B-X03`[ M/"]P/@T*(#PO=&0^#0H@/'1D/B8C>$$P.SPO=&0^#0H@/"]T<CX-"B`\='(@ M8F=C;VQO<CTS1"-#0T5%1D8^#0H@/'1D('9A;&EG;CTS1'1O<#X-"B`\<"!S M='EL93TS1"=-05)'24XM3$5&5#H@,65M.R!415A4+4E.1$5.5#H@+3%E;2<^ M/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@ M<VEZ93TS1#(^1&5F97)R960Z/"]F;VYT/CPO<#X-"B`\+W1D/@T*(#QT9"!V M86QI9VX],T1B;W1T;VT^/&9O;G0@<VEZ93TS1#$^)B-X03`[)B-X03`[/"]F M;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V M86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF(WA! M,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI9VX] M,T1B;W1T;VT^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I M>F4],T0Q/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX] M,T1B;W1T;VT^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@ M/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#PO='(^#0H@/'1R/@T*(#QT M9"!V86QI9VX],T1T;W`^#0H@/'`@<W1Y;&4],T0G34%21TE.+4Q%1E0Z(#)E M;3L@5$585"U)3D1%3E0Z("TQ96TG/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%- M24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R/D9E9&5R86P\+V9O;G0^ M/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE M/3-$,3XF(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$ M8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#X\9F]N="!S='EL93TS1"=&3TY4+49! M34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXD/"]F;VYT/CPO=&0^ M#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`@86QI9VX] M,T1R:6=H=#X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W M(%)O;6%N)R!S:7IE/3-$,CXF(W@R,#$T.SPO9F]N=#X\+W1D/@T*(#QT9"!V M86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P/CQF;VYT('-T>6QE/3-$ M)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R/B8C>$$P M.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O M;G0@<VEZ93TS1#$^)B-X03`[)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A M;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^/&9O;G0@<W1Y;&4],T0G M1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^)#PO9F]N M=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P M(&%L:6=N/3-$<FEG:'0^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I M;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^)B-X,C`Q-#L\+V9O;G0^/"]T9#X- M"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#X\9F]N="!S M='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$ M,CXF(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T M=&]M/CQF;VYT('-I>F4],T0Q/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T* M(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P/CQF;VYT('-T M>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R M/B0\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS M1&YO=W)A<"!A;&EG;CTS1')I9VAT/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%- M24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R/B8C>#(P,30[/"]F;VYT M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^ M/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@ M<VEZ93TS1#(^)B-X03`[)B-X03`[/"]F;VYT/CPO=&0^#0H@/"]T<CX-"B`\ M='(@8F=C;VQO<CTS1"-#0T5%1D8^#0H@/'1D('9A;&EG;CTS1'1O<#X-"B`\ M<"!S='EL93TS1"=-05)'24XM3$5&5#H@,F5M.R!415A4+4E.1$5.5#H@+3%E M;2<^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA M;B<@<VEZ93TS1#(^4W1A=&4\+V9O;G0^/"]P/@T*(#PO=&0^#0H@/'1D('9A M;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF(WA!,#LF(WA!,#L\+V9O M;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A M<#X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N M)R!S:7IE/3-$,CXF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$ M8F]T=&]M(&YO=W)A<#TS1&YO=W)A<"!A;&EG;CTS1')I9VAT/CQF;VYT('-T M>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R M/B8C>#(P,30[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N M;W=R87`],T1N;W=R87`^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I M;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^)B-X03`[)B-X03`[/"]F;VYT/CPO M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF(WA! M,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO M=W)A<#TS1&YO=W)A<#X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM M97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXF(WA!,#L\+V9O;G0^/"]T9#X-"B`\ M=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<"!A;&EG;CTS1')I M9VAT/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M M86XG('-I>F4],T0R/B8C>#(P,30[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG M;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^/&9O;G0@<W1Y;&4],T0G1D]. M5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^)B-X03`[)B-X M03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S M:7IE/3-$,3XF(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N M/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#X\9F]N="!S='EL93TS1"=&3TY4 M+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXF(WA!,#L\+V9O M;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A M<"!A;&EG;CTS1')I9VAT/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4 M:6UE<R!.97<@4F]M86XG('-I>F4],T0R/B8C>#(P,30[/"]F;VYT/CPO=&0^ M#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^/&9O;G0@ M<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS M1#(^)B-X03`[)B-X03`[/"]F;VYT/CPO=&0^#0H@/"]T<CX-"B`\='(@<W1Y M;&4],T0G1D].5"U325I%.B`Q<'@G/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^ M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^ M#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M M5$]0.B`C,#`P,#`P(#%P>"!S;VQI9"<^)B-X03`[/"]P/@T*(#PO=&0^#0H@ M/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0 M.B`C,#`P,#`P(#%P>"!S;VQI9"<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA! M,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@<W1Y;&4],T0G M0D]21$52+51/4#H@(S`P,#`P,"`Q<'@@<V]L:60G/B8C>$$P.SPO<#X-"B`\ M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@<W1Y;&4],T0G0D]2 M1$52+51/4#H@(S`P,#`P,"`Q<'@@<V]L:60G/B8C>$$P.SPO<#X-"B`\+W1D M/@T*(#QT9#XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X M03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T M>6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@,7!X('-O;&ED)SXF(WA!,#L\ M+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE M/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@,7!X('-O;&ED)SXF(WA!,#L\+W`^ M#0H@/"]T9#X-"B`\=&0^)B-X03`[/"]T9#X-"B`\+W1R/@T*(#QT<CX-"B`\ M=&0@=F%L:6=N/3-$=&]P/@T*(#QP('-T>6QE/3-$)TU!4D=)3BU,1494.B`S M96T[(%1%6%0M24Y$14Y4.B`M,65M)SX\9F]N="!S='EL93TS1"=&3TY4+49! M34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CY4;W1A;#PO9F]N=#X\ M+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4] M,T0Q/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B M;W1T;VT@;F]W<F%P/3-$;F]W<F%P/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%- M24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R/B0\+V9O;G0^/"]T9#X- M"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<"!A;&EG;CTS M1')I9VAT/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@ M4F]M86XG('-I>F4],T0R/B8C>#(P,30[/"]F;VYT/CPO=&0^#0H@/'1D('9A M;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^/&9O;G0@<W1Y;&4],T0G M1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^)B-X03`[ M)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N M="!S:7IE/3-$,3XF(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L M:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#X\9F]N="!S='EL93TS1"=& M3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXD/"]F;VYT M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`@ M86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM M97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXF(W@R,#$T.SPO9F]N=#X\+W1D/@T* M(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P/CQF;VYT('-T M>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R M/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T M;VT^/&9O;G0@<VEZ93TS1#$^)B-X03`[)B-X03`[/"]F;VYT/CPO=&0^#0H@ M/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^/&9O;G0@<W1Y M;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^ M)#PO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$ M;F]W<F%P(&%L:6=N/3-$<FEG:'0^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U) M3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^)B-X,C`Q-#L\+V9O;G0^ M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#X\ M9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S M:7IE/3-$,CXF(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\+W1R/@T*(#QT M<B!S='EL93TS1"=&3TY4+5-)6D4Z(#%P>"<^#0H@/'1D('9A;&EG;CTS1&)O M='1O;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[ M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/ M4D1%4BU43U`Z(",P,#`P,#`@,W!X(&1O=6)L92<^)B-X03`[/"]P/@T*(#PO M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$ M15(M5$]0.B`C,#`P,#`P(#-P>"!D;W5B;&4G/B8C>$$P.SPO<#X-"B`\+W1D M/@T*(#QT9#XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X M03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T M>6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@,W!X(&1O=6)L92<^)B-X03`[ M/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL M93TS1"="3U)$15(M5$]0.B`C,#`P,#`P(#-P>"!D;W5B;&4G/B8C>$$P.SPO M<#X-"B`\+W1D/@T*(#QT9#XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B M;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@,W!X(&1O=6)L M92<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X- M"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B`C,#`P,#`P(#-P>"!D;W5B;&4G M/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT9#XF(WA!,#L\+W1D/@T*(#PO='(^ M#0H@/"]T86)L93X-"B`\<"!S='EL93TS1"=-05)'24XM0D]45$]-.B`P<'@[ M($9/3E0M4TE:13H@,3)P>#L@34%21TE.+51/4#H@,'!X)SX-"B`F(WA!,#L\ M+W`^#0H@/'`@<W1Y;&4],T0G34%21TE.+4)/5%1/33H@,'!X.R!-05)'24XM M5$]0.B`P<'@[(%1%6%0M24Y$14Y4.B`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`H:6X-"B!T:&]U<V%N9',I.CPO9F]N=#X\+W`^#0H@/'`@ M<W1Y;&4],T0G34%21TE.+4)/5%1/33H@,'!X.R!&3TY4+5-)6D4Z(#$R<'@[ M($U!4D=)3BU43U`Z(#!P>"<^#0H@)B-X03`[/"]P/@T*(#QT86)L92!S='EL M93TS1"="3U)$15(M0T],3$%04T4Z(&-O;&QA<'-E)R!C96QL<W!A8VEN9STS M1#`@8V5L;'!A9&1I;F<],T0P('=I9'1H/3-$.3(E(&%L:6=N/3-$8V5N=&5R M(&)O<F1E<CTS1#`^#0H@/'1R/@T*(#QT9"!W:61T:#TS1#8T)3X\+W1D/@T* M(#QT9"!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Y)3X\+W1D/@T*(#QT9#X\ M+W1D/@T*(#QT9#X\+W1D/@T*(#QT9#X\+W1D/@T*(#QT9"!V86QI9VX],T1B M;W1T;VT@=VED=&@],T0X)3X\+W1D/@T*(#QT9#X\+W1D/@T*(#QT9#X\+W1D M/@T*(#QT9#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@=VED=&@],T0X M)3X\+W1D/@T*(#QT9#X\+W1D/@T*(#QT9#X\+W1D/@T*(#QT9#X\+W1D/@T* M(#PO='(^#0H@/'1R/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<VEZ M93TS1#$^)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O M;3X\9F]N="!S:7IE/3-$,3XF(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\ M=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@(S`P,#`P,"`Q<'@@<V]L:60G M('9A;&EG;CTS1&)O='1O;2!C;VQS<&%N/3-$,3`@86QI9VX],T1C96YT97(^ M/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@ M<VEZ93TS1#$^/&(^07,@;V8-"B!$96-E;6)E<B8C>$$P.S,Q+#PO8CX\+V9O M;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q M/B8C>$$P.SPO9F]N=#X\+W1D/@T*(#PO='(^#0H@/'1R/@T*(#QT9"!V86QI M9VX],T1B;W1T;VT^/&9O;G0@<VEZ93TS1#$^)B-X03`[/"]F;VYT/CPO=&0^ M#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF(WA!,#LF M(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/ M33H@(S`P,#`P,"`Q<'@@<V]L:60G('9A;&EG;CTS1&)O='1O;2!C;VQS<&%N M/3-$,B!A;&EG;CTS1&-E;G1E<CX\9F]N="!S='EL93TS1"=&3TY4+49!34E, M63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,3X\8CXR,#$T/"]B/CPO9F]N M=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<VEZ93TS1#$^ M)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N M="!S:7IE/3-$,3XF(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@<W1Y M;&4],T0G0D]21$52+4)/5%1/33H@(S`P,#`P,"`Q<'@@<V]L:60G('9A;&EG M;CTS1&)O='1O;2!C;VQS<&%N/3-$,B!A;&EG;CTS1&-E;G1E<CX\9F]N="!S M='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$ M,3X\8CXR,#$S/"]B/CPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T M;VT^/&9O;G0@<VEZ93TS1#$^)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A M;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF(WA!,#LF(WA!,#L\+V9O M;G0^/"]T9#X-"B`\=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@(S`P,#`P M,"`Q<'@@<V]L:60G('9A;&EG;CTS1&)O='1O;2!C;VQS<&%N/3-$,B!A;&EG M;CTS1&-E;G1E<CX\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@ M3F5W(%)O;6%N)R!S:7IE/3-$,3X\8CXR,#$R/"]B/CPO9F]N=#X\+W1D/@T* M(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<VEZ93TS1#$^)B-X03`[/"]F M;VYT/CPO=&0^#0H@/"]T<CX-"B`\='(@8F=C;VQO<CTS1"-#0T5%1D8^#0H@ M/'1D('9A;&EG;CTS1'1O<#X-"B`\<"!S='EL93TS1"=-05)'24XM3$5&5#H@ M,65M.R!415A4+4E.1$5.5#H@+3%E;2<^/&9O;G0@<W1Y;&4],T0G1D].5"U& M04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^1&5F97)R960@=&%X M#0H@87-S971S.CPO9F]N=#X\+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$ M8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\=&0@=F%L:6=N/3-$ M8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT M9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<VEZ93TS1#$^)B-X03`[)B-X03`[ M/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT M9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF M(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI M9VX],T1B;W1T;VT^/"]T9#X-"B`\+W1R/@T*(#QT<CX-"B`\=&0@=F%L:6=N M/3-$=&]P/@T*(#QP('-T>6QE/3-$)TU!4D=)3BU,1494.B`R96T[(%1%6%0M M24Y$14Y4.B`M,65M)SX\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM M97,@3F5W(%)O;6%N)R!S:7IE/3-$,CY$97!R96-I871I;VX@86YD#0H@86UO M<G1I>F%T:6]N/"]F;VYT/CPO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B M;W1T;VT^/&9O;G0@<VEZ93TS1#$^)B-X03`[)B-X03`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`[)B-X M03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S M='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$ M,CXD/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS M1')I9VAT/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@ M4F]M86XG('-I>F4],T0R/CDQ.#PO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX] M,T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P/CQF;VYT('-T>6QE/3-$)T9/3E0M M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R/B8C>$$P.R8C>$$P M.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<VEZ M93TS1#$^)B-X03`[)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS M1&)O='1O;3X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W M(%)O;6%N)R!S:7IE/3-$,CXD/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS M1&)O='1O;2!A;&EG;CTS1')I9VAT/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%- M24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R/C$L,#(T/"]F;VYT/CPO M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^/&9O M;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ M93TS1#(^)B-X03`[)B-X03`[/"]F;VYT/CPO=&0^#0H@/"]T<CX-"B`\='(@ M8F=C;VQO<CTS1"-#0T5%1D8^#0H@/'1D('9A;&EG;CTS1'1O<#X-"B`\<"!S M='EL93TS1"=-05)'24XM3$5&5#H@,F5M.R!415A4+4E.1$5.5#H@+3%E;2<^ M/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@ M<VEZ93TS1#(^0V%P:71A;&EZ960-"B!2)F%M<#M$/"]F;VYT/CPO<#X-"B`\ M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<VEZ93TS1#$^)B-X M03`[)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\ M9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S M:7IE/3-$,CXF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T M=&]M(&%L:6=N/3-$<FEG:'0^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ M(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^,34L,3<V/"]F;VYT/CPO=&0^ M#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^/&9O;G0@ M<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS M1#(^)B-X03`[)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O M='1O;3X\9F]N="!S:7IE/3-$,3XF(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X- M"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%- M24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R/B8C>$$P.SPO9F]N=#X\ M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#X\9F]N M="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE M/3-$,CXR,"PW,#(\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M M(&YO=W)A<#TS1&YO=W)A<#X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@ M5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXF(WA!,#LF(WA!,#L\+V9O;G0^ M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C M>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^ M/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@ M<VEZ93TS1#(^)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O M='1O;2!A;&EG;CTS1')I9VAT/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9 M.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R/C0L.3,R/"]F;VYT/CPO=&0^ M#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^/&9O;G0@ M<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS M1#(^)B-X03`[)B-X03`[/"]F;VYT/CPO=&0^#0H@/"]T<CX-"B`\='(^#0H@ M/'1D('9A;&EG;CTS1'1O<#X-"B`\<"!S='EL93TS1"=-05)'24XM3$5&5#H@ M,F5M.R!415A4+4E.1$5.5#H@+3%E;2<^/&9O;G0@<W1Y;&4],T0G1D].5"U& M04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^4F5S97)V97,@86YD M#0H@86-C<G5A;',\+V9O;G0^/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS M1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF(WA!,#LF(WA!,#L\+V9O;G0^/"]T M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)T9/3E0M M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R/B8C>$$P.SPO9F]N M=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#X\ M9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S M:7IE/3-$,CXV+#(Q-SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T M;VT@;F]W<F%P/3-$;F]W<F%P/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9 M.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R/B8C>$$P.R8C>$$P.SPO9F]N M=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<VEZ93TS1#$^ M)B-X03`[)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O M;3X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N M)R!S:7IE/3-$,CXF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$ M8F]T=&]M(&%L:6=N/3-$<FEG:'0^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U) M3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^-"PY-#8\+V9O;G0^/"]T M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#X\9F]N M="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE M/3-$,CXF(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$ M8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<W1Y;&4],T0G1D].5"U& M04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^)B-X03`[/"]F;VYT M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/CQF M;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I M>F4],T0R/C4L,3`Q/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O M;2!N;W=R87`],T1N;W=R87`^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ M(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^)B-X03`[)B-X03`[/"]F;VYT M/CPO=&0^#0H@/"]T<CX-"B`\='(@8F=C;VQO<CTS1"-#0T5%1D8^#0H@/'1D M('9A;&EG;CTS1'1O<#X-"B`\<"!S='EL93TS1"=-05)'24XM3$5&5#H@,F5M M.R!415A4+4E.1$5.5#H@+3%E;2<^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U) M3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^3F5T(&]P97)A=&EN9PT* M(&QO<W-E<SPO9F]N=#X\+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T M=&]M/CQF;VYT('-I>F4],T0Q/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T* M(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U) M3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^)B-X03`[/"]F;VYT/CPO M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/CQF;VYT M('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4] M,T0R/C$T."PQ.#0\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M M(&YO=W)A<#TS1&YO=W)A<#X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@ M5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXF(WA!,#LF(WA!,#L\+V9O;G0^ M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C M>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^ M/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@ M<VEZ93TS1#(^)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O M='1O;2!A;&EG;CTS1')I9VAT/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9 M.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R/C$T-"PR-30\+V9O;G0^/"]T M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#X\9F]N M="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE M/3-$,CXF(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$ M8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<W1Y;&4],T0G1D].5"U& M04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^)B-X03`[/"]F;VYT M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/CQF M;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I M>F4],T0R/C$U,RPQ.3,\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T M=&]M(&YO=W)A<#TS1&YO=W)A<#X\9F]N="!S='EL93TS1"=&3TY4+49!34E, M63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXF(WA!,#LF(WA!,#L\+V9O M;G0^/"]T9#X-"B`\+W1R/@T*(#QT<CX-"B`\=&0@=F%L:6=N/3-$=&]P/@T* M(#QP('-T>6QE/3-$)TU!4D=)3BU,1494.B`R96T[(%1%6%0M24Y$14Y4.B`M M,65M)SX\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O M;6%N)R!S:7IE/3-$,CY487@@8W)E9&ET<SPO9F]N=#X\+W`^#0H@/"]T9#X- M"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C>$$P.R8C M>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@ M<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS M1#(^)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A M;&EG;CTS1')I9VAT/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE M<R!.97<@4F]M86XG('-I>F4],T0R/C,T+#4T,SPO9F]N=#X\+W1D/@T*(#QT M9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P/CQF;VYT('-T>6QE M/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R/B8C M>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^ M/&9O;G0@<VEZ93TS1#$^)B-X03`[)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D M('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@ M5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXF(WA!,#L\+V9O;G0^/"]T9#X- M"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^/&9O;G0@<W1Y M;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^ M,S,L,#0S/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R M87`],T1N;W=R87`^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S M($YE=R!2;VUA;B<@<VEZ93TS1#(^)B-X03`[)B-X03`[/"]F;VYT/CPO=&0^ M#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF(WA!,#LF M(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT M('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4] M,T0R/B8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@ M86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM M97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXR-2PY-#,\+V9O;G0^/"]T9#X-"B`\ M=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#X\9F]N="!S='EL M93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXF M(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\+W1R/@T*(#QT<B!S='EL93TS M1"=&3TY4+5-)6D4Z(#%P>"<^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\ M=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z M(",P,#`P,#`@,7!X('-O;&ED)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0@ M=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(",P M,#`P,#`@,7!X('-O;&ED)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0^)B-X M03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$ M15(M5$]0.B`C,#`P,#`P(#%P>"!S;VQI9"<^)B-X03`[/"]P/@T*(#PO=&0^ M#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M M5$]0.B`C,#`P,#`P(#%P>"!S;VQI9"<^)B-X03`[/"]P/@T*(#PO=&0^#0H@ M/'1D/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF M(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@<W1Y;&4] M,T0G0D]21$52+51/4#H@(S`P,#`P,"`Q<'@@<V]L:60G/B8C>$$P.SPO<#X- M"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@<W1Y;&4],T0G M0D]21$52+51/4#H@(S`P,#`P,"`Q<'@@<V]L:60G/B8C>$$P.SPO<#X-"B`\ M+W1D/@T*(#QT9#XF(WA!,#L\+W1D/@T*(#PO='(^#0H@/'1R(&)G8V]L;W(] M,T0C0T-%149&/@T*(#QT9"!V86QI9VX],T1T;W`^#0H@/'`@<W1Y;&4],T0G M34%21TE.+4Q%1E0Z(#-E;3L@5$585"U)3D1%3E0Z("TQ96TG/CQF;VYT('-T M>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R M/E1O=&%L(&1E9F5R<F5D('1A>`T*(&%S<V5T<SPO9F]N=#X\+W`^#0H@/"]T M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C>$$P M.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O M;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ M93TS1#(^)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O M;2!A;&EG;CTS1')I9VAT/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4 M:6UE<R!.97<@4F]M86XG('-I>F4],T0R/C(P-"PY,#`\+V9O;G0^/"]T9#X- M"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#X\9F]N="!S M='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$ M,CXF(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T M=&]M/CQF;VYT('-I>F4],T0Q/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T* M(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U) M3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^)B-X03`[/"]F;VYT/CPO M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/CQF;VYT M('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4] M,T0R/C(P,RPX-C,\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M M(&YO=W)A<#TS1&YO=W)A<#X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@ M5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXF(WA!,#LF(WA!,#L\+V9O;G0^ M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C M>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^ M/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@ M<VEZ93TS1#(^)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O M='1O;2!A;&EG;CTS1')I9VAT/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9 M.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R/C$Y,"PQ.3,\+V9O;G0^/"]T M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#X\9F]N M="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE M/3-$,CXF(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\+W1R/@T*(#QT<CX- M"B`\=&0@=F%L:6=N/3-$=&]P/@T*(#QP('-T>6QE/3-$)TU!4D=)3BU,1494 M.B`Q96T[(%1%6%0M24Y$14Y4.B`M,65M)SX\9F]N="!S='EL93TS1"=&3TY4 M+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CY,97-S.B!686QU M871I;VX-"B!A;&QO=V%N8V4\+V9O;G0^/"]P/@T*(#PO=&0^#0H@/'1D('9A M;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF(WA!,#LF(WA!,#L\+V9O M;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$ M)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R/B8C>$$P M.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R M:6=H=#X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O M;6%N)R!S:7IE/3-$,CXH,C`T+#DP,#PO9F]N=#X\+W1D/@T*(#QT9"!V86QI M9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P/CQF;VYT('-T>6QE/3-$)T9/ M3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R/BDF(WA!,#L\ M+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4] M,T0Q/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B M;W1T;VT^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2 M;VUA;B<@<VEZ93TS1#(^)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG M;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/CQF;VYT('-T>6QE/3-$)T9/3E0M M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R/B@R,#,L.#8S/"]F M;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R M87`^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA M;B<@<VEZ93TS1#(^*28C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX] M,T1B;W1T;VT^/&9O;G0@<VEZ93TS1#$^)B-X03`[)B-X03`[/"]F;VYT/CPO M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=&3TY4 M+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXF(WA!,#L\+V9O M;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^ M/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@ M<VEZ93TS1#(^*#$Y,"PQ.3,\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$ M8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#X\9F]N="!S='EL93TS1"=&3TY4+49! M34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXI)B-X03`[/"]F;VYT M/CPO=&0^#0H@/"]T<CX-"B`\='(@<W1Y;&4],T0G1D].5"U325I%.B`Q<'@G M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\=&0@=F%L:6=N/3-$ M8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O M;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B`C,#`P,#`P(#%P>"!S;VQI M9"<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X- M"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B`C,#`P,#`P(#%P>"!S;VQI9"<^ M)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D/B8C>$$P.SPO=&0^#0H@/'1D('9A M;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX] M,T1B;W1T;VT^#0H@/'`@<W1Y;&4],T0G0D]21$52+51/4#H@(S`P,#`P,"`Q M<'@@<V]L:60G/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B M;W1T;VT^#0H@/'`@<W1Y;&4],T0G0D]21$52+51/4#H@(S`P,#`P,"`Q<'@@ M<V]L:60G/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT9#XF(WA!,#L\+W1D/@T* M(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@ M=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(",P M,#`P,#`@,7!X('-O;&ED)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0@=F%L M:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P M,#`@,7!X('-O;&ED)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0^)B-X03`[ M/"]T9#X-"B`\+W1R/@T*(#QT<B!B9V-O;&]R/3-$(T-#145&1CX-"B`\=&0@ M=F%L:6=N/3-$=&]P/@T*(#QP('-T>6QE/3-$)TU!4D=)3BU,1494.B`Q96T[ M(%1%6%0M24Y$14Y4.B`M,65M)SX\9F]N="!S='EL93TS1"=&3TY4+49!34E, M63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CY.970@9&5F97)R960@=&%X M#0H@87-S971S/"]F;VYT/CPO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B M;W1T;VT^/&9O;G0@<VEZ93TS1#$^)B-X03`[)B-X03`[/"]F;VYT/CPO=&0^ M#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^/&9O;G0@ M<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS M1#(^)#PO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P M/3-$;F]W<F%P(&%L:6=N/3-$<FEG:'0^/&9O;G0@<W1Y;&4],T0G1D].5"U& M04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^)B-X,C`Q-#L\+V9O M;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A M<#X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N M)R!S:7IE/3-$,CXF(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L M:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C>$$P.R8C>$$P.SPO9F]N M=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P M/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG M('-I>F4],T0R/B0\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M M(&YO=W)A<#TS1&YO=W)A<"!A;&EG;CTS1')I9VAT/CQF;VYT('-T>6QE/3-$ M)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R/B8C>#(P M,30[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`] M,T1N;W=R87`^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE M=R!2;VUA;B<@<VEZ93TS1#(^)B-X03`[)B-X03`[/"]F;VYT/CPO=&0^#0H@ M/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF(WA!,#LF(WA! M,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS M1&YO=W)A<#X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W M(%)O;6%N)R!S:7IE/3-$,CXD/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS M1&)O='1O;2!N;W=R87`],T1N;W=R87`@86QI9VX],T1R:6=H=#X\9F]N="!S M='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$ M,CXF(W@R,#$T.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@ M;F]W<F%P/3-$;F]W<F%P/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4 M:6UE<R!.97<@4F]M86XG('-I>F4],T0R/B8C>$$P.R8C>$$P.SPO9F]N=#X\ M+W1D/@T*(#PO='(^#0H@/'1R('-T>6QE/3-$)T9/3E0M4TE:13H@,7!X)SX- M"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O M='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^ M#0H@/'`@<W1Y;&4],T0G0D]21$52+51/4#H@(S`P,#`P,"`S<'@@9&]U8FQE M)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T* M(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@,W!X(&1O=6)L92<^ M)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D/B8C>$$P.SPO=&0^#0H@/'1D('9A M;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX] M,T1B;W1T;VT^#0H@/'`@<W1Y;&4],T0G0D]21$52+51/4#H@(S`P,#`P,"`S M<'@@9&]U8FQE)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$ M8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@,W!X M(&1O=6)L92<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D/B8C>$$P.SPO=&0^ M#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT M9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@<W1Y;&4],T0G0D]21$52+51/4#H@ M(S`P,#`P,"`S<'@@9&]U8FQE)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0@ M=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(",P M,#`P,#`@,W!X(&1O=6)L92<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D/B8C M>$$P.SPO=&0^#0H@/"]T<CX-"B`\+W1A8FQE/@T*(#QP('-T>6QE/3-$)TU! M4D=)3BU"3U143TTZ(#!P>#L@34%21TE.+51/4#H@,3)P>#L@5$585"U)3D1% M3E0Z(#0E)R!A;&EG;CTS1&IU<W1I9GD^/&9O;G0@<W1Y;&4],T0G1D].5"U& M04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^4F5A;&EZ871I;VX@ M;V8@9&5F97)R960@=&%X(&%S<V5T<R!I<R!D97!E;F1E;G0@=7!O;B!F=71U M<F4-"B!E87)N:6YG<RP@:68@86YY+"!T:&4@=&EM:6YG(&%N9"!A;6]U;G0@ M;V8@=VAI8V@@87)E('5N8V5R=&%I;BX-"B!"87-E9"!U<&]N('1H92!W96EG M:'0@;V8@879A:6QA8FQE(&5V:61E;F-E+"!W:&EC:"!I;F-L=61E<R!T:&4- M"B!#;VUP86YY)B-X,C`Q.3MS(&AI<W1O<FEC86P@;W!E<F%T:6YG('!E<F9O M<FUA;F-E+"!R97!O<G1E9`T*(&-U;75L871I=F4@;F5T(&QO<W-E<R!S:6YC M92!I;F-E<'1I;VX@86YD(&1I9F9I8W5L='D@:6X@86-C=7)A=&5L>0T*(&9O M<F5C87-T:6YG('1H92!#;VUP86YY)B-X,C`Q.3MS(&9U='5R92!R97-U;'1S M+"!T:&4@0V]M<&%N>0T*(&UA:6YT86EN960@82!F=6QL('9A;'5A=&EO;B!A M;&QO=V%N8V4@;VX@=&AE(&YE="!D969E<G)E9"!T87@-"B!A<W-E=',@87,@ M;V8@1&5C96UB97(F(WA!,#LS,2P@,C`Q-"P@,C`Q,R!A;F0@,C`Q,RX@5&AE M('9A;'5A=&EO;@T*(&%L;&]W86YC92!W87,@9&5T97)M:6YE9"!P=7)S=6%N M="!T;R!T:&4@86-C;W5N=&EN9R!G=6ED86YC92!F;W(-"B!I;F-O;64@=&%X M97,L('=H:6-H(')E<75I<F5S(&%N(&%S<V5S<VUE;G0@;V8@8F]T:"!P;W-I M=&EV92!A;F0-"B!N96=A=&EV92!E=FED96YC92!W:&5N(&1E=&5R;6EN:6YG M('=H971H97(@:70@:7,@;6]R92!L:6ME;'D@=&AA;@T*(&YO="!T:&%T(&1E M9F5R<F5D('1A>"!A<W-E=',@87)E(')E8V]V97)A8FQE+B!4:&4@0V]M<&%N M>2!I;G1E;F1S#0H@=&\@;6%I;G1A:6X@82!F=6QL('9A;'5A=&EO;B!A;&QO M=V%N8V4@;VX@=&AE(%4N4RXF(WA!,#MD969E<G)E9`T*('1A>"!A<W-E=',@ M=6YT:6P@<W5F9FEC:65N="!P;W-I=&EV92!E=FED96YC92!E>&ES=',@=&\@ M<W5P<&]R=`T*(')E=F5R<V%L(&]F('1H92!V86QU871I;VX@86QL;W=A;F-E M+B!4:&4@=F%L=6%T:6]N(&%L;&]W86YC90T*(&EN8W)E87-E9"!B>2`D,2XP M(&UI;&QI;VX@:6X@,C`Q-"P@)#$S+C<@;6EL;&EO;B!I;B`R,#$S(&%N9"`D M,C$N,0T*(&UI;&QI;VX@:6X@,C`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`Q M-"P@,C`Q,R!A;F0@,C`Q,B!T:&%T(&%R;W-E(&1I<F5C=&QY#0H@9G)O;2!T M87@@9&5D=6-T:6]N<R!R96QA=&5D('1O(&5Q=6ET>2!C;VUP96YS871I;VX@ M:6X@97AC97-S(&]F#0H@8V]M<&5N<V%T:6]N(')E8V]G;FEZ960@9F]R(&9I M;F%N8VEA;"!R97!O<G1I;F<N($%P<')O>&EM871E;'D@)#$N.0T*(&UI;&QI M;VX@;V8@1F5D97)A;"!A;F0@0V%L:69O<FYI82!N970@;W!E<F%T:6YG(&QO M<W-E<R!A<F4@<F5L871E9`T*('1O('1A>"!S=&]C:R!O<'1I;VX@9&5D=6-T M:6]N<R!I;B!E>&-E<W,@;V8@8F]O:R!D961U8W1I;VYS+B!4:&ES#0H@86UO M=6YT('=I;&P@8F4@8W)E9&ET960@=&\@<W1O8VMH;VQD97)S)B-X,C`Q.3L@ M97%U:71Y('=H96X@:70@:7,-"B!R96%L:7IE9"X\+V9O;G0^/"]P/@T*(#QP M('-T>6QE/3-$)TU!4D=)3BU"3U143TTZ(#!P>#L@34%21TE.+51/4#H@,3)P M>#L@5$585"U)3D1%3E0Z(#0E)R!A;&EG;CTS1&IU<W1I9GD^/&9O;G0@<W1Y M;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^ M5&AE(&9O;&QO=VEN9R!A<F4@=&AE($-O;7!A;GDF(W@R,#$Y.W,@=F%L=6%T M:6]N(&%N9"!Q=6%L:69Y:6YG#0H@86-C;W5N=',@*&EN('1H;W5S86YD<RDZ M/"]F;VYT/CPO<#X-"B`\<"!S='EL93TS1"=-05)'24XM0D]45$]-.B`P<'@[ M($9/3E0M4TE:13H@,3)P>#L@34%21TE.+51/4#H@,'!X)SX-"B`F(WA!,#L\ M+W`^#0H@/'1A8FQE('-T>6QE/3-$)T)/4D1%4BU#3TQ,05!313H@8V]L;&%P M<V4G(&-E;&QS<&%C:6YG/3-$,"!C96QL<&%D9&EN9STS1#`@=VED=&@],T0Q M,#`E(&%L:6=N/3-$8V5N=&5R(&)O<F1E<CTS1#`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`[ M/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE M/3-$,3XF(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@<W1Y;&4],T0G M0D]21$52+4)/5%1/33H@(S`P,#`P,"`Q<'@@<V]L:60G('9A;&EG;CTS1&)O M='1O;2!C;VQS<&%N/3-$,B!A;&EG;CTS1&-E;G1E<CX\9F]N="!S='EL93TS M1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,3X\8CY" M86QA;F-E(&%T/&)R("\^#0H@0F5G:6YN:6YG)B-X03`[;V8\8G(@+SX-"B!0 M97)I;V0\+V(^/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\ M9F]N="!S:7IE/3-$,3XF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N M/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C>$$P.R8C>$$P.SPO9F]N=#X\ M+W1D/@T*(#QT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B`C,#`P,#`P(#%P M>"!S;VQI9"<@=F%L:6=N/3-$8F]T=&]M(&-O;'-P86X],T0R(&%L:6=N/3-$ M8V5N=&5R/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@ M4F]M86XG('-I>F4],T0Q/CQB/D-H87)G960F(WA!,#MT;SQB<B`O/@T*($5X M<&5N<V5S/"]B/CPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^ M/&9O;G0@<VEZ93TS1#$^)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG M;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF(WA!,#LF(WA!,#L\+V9O;G0^ M/"]T9#X-"B`\=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@(S`P,#`P,"`Q M<'@@<V]L:60G('9A;&EG;CTS1&)O='1O;2!C;VQS<&%N/3-$,B!A;&EG;CTS M1&-E;G1E<CX\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W M(%)O;6%N)R!S:7IE/3-$,3X\8CY#:&%R9V5D)B-X03`[=&\\8G(@+SX-"B!/ M=&AE<B8C>$$P.T%C8V]U;G1S/"]B/CPO9F]N=#X\+W1D/@T*(#QT9"!V86QI M9VX],T1B;W1T;VT^/&9O;G0@<VEZ93TS1#$^)B-X03`[/"]F;VYT/CPO=&0^ M#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF(WA!,#LF M(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/ M33H@(S`P,#`P,"`Q<'@@<V]L:60G('9A;&EG;CTS1&)O='1O;2!C;VQS<&%N M/3-$,B!A;&EG;CTS1&-E;G1E<CX\9F]N="!S='EL93TS1"=&3TY4+49!34E, M63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,3X\8CY$961U8W1I;VYS/"]B M/CPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<VEZ M93TS1#$^)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O M;3X\9F]N="!S:7IE/3-$,3XF(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\ M=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@(S`P,#`P,"`Q<'@@<V]L:60G M('9A;&EG;CTS1&)O='1O;2!C;VQS<&%N/3-$,B!A;&EG;CTS1&-E;G1E<CX\ M9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S M:7IE/3-$,3X\8CY"86QA;F-E(&%T/&)R("\^#0H@16YD)B-X03`[;V8F(WA! M,#M097)I;V0\+V(^/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O M;3X\9F]N="!S:7IE/3-$,3XF(WA!,#L\+V9O;G0^/"]T9#X-"B`\+W1R/@T* M(#QT<B!B9V-O;&]R/3-$(T-#145&1CX-"B`\=&0@=F%L:6=N/3-$=&]P/@T* M(#QP('-T>6QE/3-$)TU!4D=)3BU,1494.B`Q96T[(%1%6%0M24Y$14Y4.B`M M,65M)SX\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O M;6%N)R!S:7IE/3-$,CY996%R($5N9&5D#0H@1&5C96UB97(F(WA!,#LS,2P@ M,C`Q,CH\+V9O;G0^/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O M;3X\9F]N="!S:7IE/3-$,3XF(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\ M=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O M;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\=&0@=F%L M:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C>$$P.R8C>$$P.SPO9F]N M=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\=&0@=F%L M:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<VEZ93TS1#$^)B-X03`[ M)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\=&0@=F%L:6=N/3-$ M8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE M/3-$,3XF(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$ M8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT M9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M M/CQF;VYT('-I>F4],T0Q/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT M9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#PO='(^#0H@ M/'1R/@T*(#QT9"!V86QI9VX],T1T;W`^#0H@/'`@<W1Y;&4],T0G34%21TE. M+4Q%1E0Z(#)E;3L@5$585"U)3D1%3E0Z("TQ96TG/CQF;VYT('-T>6QE/3-$ M)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R/D1E9F5R M<F5D('1A>"!V86QU871I;VX-"B!A;&QO=V%N8V4\+V9O;G0^/"]P/@T*(#PO M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF(WA! M,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF M;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I M>F4],T0R/B0\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L M:6=N/3-$<FEG:'0^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S M($YE=R!2;VUA;B<@<VEZ93TS1#(^,38Y+#$P-SPO9F]N=#X\+W1D/@T*(#QT M9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P/CQF;VYT('-T>6QE M/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R/B8C M>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^ M/&9O;G0@<VEZ93TS1#$^)B-X03`[)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D M('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@ M5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXD/"]F;VYT/CPO=&0^#0H@/'1D M('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/CQF;VYT('-T>6QE/3-$ M)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R/C(Q+#`X M-CPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$ M;F]W<F%P/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@ M4F]M86XG('-I>F4],T0R/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT M9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<VEZ93TS1#$^)B-X03`[)B-X03`[ M/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N M;W=R87`^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2 M;VUA;B<@<VEZ93TS1#(^)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG M;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`@86QI9VX],T1R:6=H=#X\9F]N M="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE M/3-$,CXF(W@R,#$T.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T M;VT@;F]W<F%P/3-$;F]W<F%P/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9 M.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R/B8C>$$P.R8C>$$P.SPO9F]N M=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<VEZ93TS1#$^ M)B-X03`[)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O M;2!N;W=R87`],T1N;W=R87`^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ M(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^)B-X03`[/"]F;VYT/CPO=&0^ M#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`@86QI9VX] M,T1R:6=H=#X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W M(%)O;6%N)R!S:7IE/3-$,CXF(W@R,#$T.SPO9F]N=#X\+W1D/@T*(#QT9"!V M86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P/CQF;VYT('-T>6QE/3-$ M)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R/B8C>$$P M.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O M;G0@<VEZ93TS1#$^)B-X03`[)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A M;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM M97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXD/"]F;VYT/CPO=&0^#0H@/'1D('9A M;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/CQF;VYT('-T>6QE/3-$)T9/ M3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R/C$Y,"PQ.3,\ M+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO M=W)A<#X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O M;6%N)R!S:7IE/3-$,CXF(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\+W1R M/@T*(#QT<B!B9V-O;&]R/3-$(T-#145&1CX-"B`\=&0@=F%L:6=N/3-$=&]P M/@T*(#QP('-T>6QE/3-$)TU!4D=)3BU,1494.B`Q96T[(%1%6%0M24Y$14Y4 M.B`M,65M)SX\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W M(%)O;6%N)R!S:7IE/3-$,CY996%R($5N9&5D#0H@1&5C96UB97(F(WA!,#LS M,2P@,C`Q,SH\+V9O;G0^/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O M='1O;3X\9F]N="!S:7IE/3-$,3XF(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X- M"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O M='1O;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\=&0@ M=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C>$$P.R8C>$$P.SPO M9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\=&0@ M=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\ M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<VEZ93TS1#$^)B-X M03`[)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\ M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\=&0@=F%L:6=N M/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S M:7IE/3-$,3XF(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N M/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T* M(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T M=&]M/CQF;VYT('-I>F4],T0Q/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T* M(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T M=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#PO='(^ M#0H@/'1R/@T*(#QT9"!V86QI9VX],T1T;W`^#0H@/'`@<W1Y;&4],T0G34%2 M1TE.+4Q%1E0Z(#)E;3L@5$585"U)3D1%3E0Z("TQ96TG/CQF;VYT('-T>6QE M/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R/D1E M9F5R<F5D('1A>"!V86QU871I;VX-"B!A;&QO=V%N8V4\+V9O;G0^/"]P/@T* M(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF M(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M M/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG M('-I>F4],T0R/B0\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M M(&%L:6=N/3-$<FEG:'0^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I M;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^,3DP+#$Y,SPO9F]N=#X\+W1D/@T* M(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P/CQF;VYT('-T M>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R M/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T M;VT^/&9O;G0@<VEZ93TS1#$^)B-X03`[)B-X03`[/"]F;VYT/CPO=&0^#0H@ M/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=&3TY4+49!34E, M63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXD/"]F;VYT/CPO=&0^#0H@ M/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/CQF;VYT('-T>6QE M/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R/C$S M+#8W,#PO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P M/3-$;F]W<F%P/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!. M97<@4F]M86XG('-I>F4],T0R/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T* M(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<VEZ93TS1#$^)B-X03`[)B-X M03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`] M,T1N;W=R87`^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE M=R!2;VUA;B<@<VEZ93TS1#(^)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A M;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`@86QI9VX],T1R:6=H=#X\ M9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S M:7IE/3-$,CXF(W@R,#$T.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B M;W1T;VT@;F]W<F%P/3-$;F]W<F%P/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%- M24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R/B8C>$$P.R8C>$$P.SPO M9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<VEZ93TS M1#$^)B-X03`[)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O M='1O;2!N;W=R87`],T1N;W=R87`^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U) M3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^)B-X03`[/"]F;VYT/CPO M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`@86QI M9VX],T1R:6=H=#X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@ M3F5W(%)O;6%N)R!S:7IE/3-$,CXF(W@R,#$T.SPO9F]N=#X\+W1D/@T*(#QT M9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P/CQF;VYT('-T>6QE M/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R/B8C M>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^ M/&9O;G0@<VEZ93TS1#$^)B-X03`[)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D M('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@ M5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXD/"]F;VYT/CPO=&0^#0H@/'1D M('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/CQF;VYT('-T>6QE/3-$ M)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R/C(P,RPX M-C,\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS M1&YO=W)A<#X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W M(%)O;6%N)R!S:7IE/3-$,CXF(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\ M+W1R/@T*(#QT<B!B9V-O;&]R/3-$(T-#145&1CX-"B`\=&0@=F%L:6=N/3-$ M=&]P/@T*(#QP('-T>6QE/3-$)TU!4D=)3BU,1494.B`Q96T[(%1%6%0M24Y$ M14Y4.B`M,65M)SX\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@ M3F5W(%)O;6%N)R!S:7IE/3-$,CY996%R($5N9&5D#0H@1&5C96UB97(F(WA! M,#LS,2P@,C`Q-#H\+V9O;G0^/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS M1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF(WA!,#LF(WA!,#L\+V9O;G0^/"]T M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS M1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\ M=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C>$$P.R8C>$$P M.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\ M=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O M;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<VEZ93TS1#$^ M)B-X03`[)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O M;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\=&0@=F%L M:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N M="!S:7IE/3-$,3XF(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L M:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\=&0@=F%L:6=N/3-$ M8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\=&0@=F%L:6=N/3-$ M8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#PO M='(^#0H@/'1R/@T*(#QT9"!V86QI9VX],T1T;W`^#0H@/'`@<W1Y;&4],T0G M34%21TE.+4Q%1E0Z(#)E;3L@5$585"U)3D1%3E0Z("TQ96TG/CQF;VYT('-T M>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R M/D1E9F5R<F5D('1A>"!V86QU871I;VX-"B!A;&QO=V%N8V4\+V9O;G0^/"]P M/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$ M,3XF(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T M=&]M/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M M86XG('-I>F4],T0R/B0\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T M=&]M(&%L:6=N/3-$<FEG:'0^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ M(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^,C`S+#@V,SPO9F]N=#X\+W1D M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P/CQF;VYT M('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4] M,T0R/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B M;W1T;VT^/&9O;G0@<VEZ93TS1#$^)B-X03`[)B-X03`[/"]F;VYT/CPO=&0^ M#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=&3TY4+49! M34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXD/"]F;VYT/CPO=&0^ M#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/CQF;VYT('-T M>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R M/C$L,#,W/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R M87`],T1N;W=R87`^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S M($YE=R!2;VUA;B<@<VEZ93TS1#(^)B-X03`[)B-X03`[/"]F;VYT/CPO=&0^ M#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF(WA!,#LF M(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A M<#TS1&YO=W)A<#X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@ M3F5W(%)O;6%N)R!S:7IE/3-$,CXF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@ M=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<"!A;&EG;CTS1')I9VAT M/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG M('-I>F4],T0R/B8C>#(P,30[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS M1&)O='1O;2!N;W=R87`],T1N;W=R87`^/&9O;G0@<W1Y;&4],T0G1D].5"U& M04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^)B-X03`[)B-X03`[ M/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE M/3-$,3XF(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$ M8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#X\9F]N="!S='EL93TS1"=&3TY4+49! M34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXF(WA!,#L\+V9O;G0^ M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<"!A M;&EG;CTS1')I9VAT/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE M<R!.97<@4F]M86XG('-I>F4],T0R/B8C>#(P,30[/"]F;VYT/CPO=&0^#0H@ M/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^/&9O;G0@<W1Y M;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^ M)B-X03`[)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O M;3X\9F]N="!S:7IE/3-$,3XF(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\ M=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9 M.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R/B0\+V9O;G0^/"]T9#X-"B`\ M=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^/&9O;G0@<W1Y;&4] M,T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^,C`T M+#DP,#PO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P M/3-$;F]W<F%P/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!. M97<@4F]M86XG('-I>F4],T0R/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T* M(#PO='(^#0H@/"]T86)L93X-"B`\<"!S='EL93TS1"=-05)'24XM0D]45$]- M.B`P<'@[($9/3E0M4TE:13H@,3)P>#L@34%21TE.+51/4#H@,'!X)SX-"B`F M(WA!,#L\+W`^#0H@/'`@<W1Y;&4],T0G34%21TE.+4)/5%1/33H@,'!X.R!- M05)'24XM5$]0.B`P<'@[(%1%6%0M24Y$14Y4.B`T)2<@86QI9VX],T1J=7-T M:69Y/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M M86XG('-I>F4],T0R/E1H92!F;VQL;W=I;F<@:7,@82!R96-O;F-I;&EA=&EO M;B!O9B!T:&4@<W1A='5T;W)Y(&9E9&5R86P-"B!I;F-O;64@=&%X(')A=&4@ M=&\@=&AE($-O;7!A;GDF(W@R,#$Y.W,@969F96-T:79E('1A>`T*(')A=&4Z M/"]F;VYT/CPO<#X-"B`\<"!S='EL93TS1"=-05)'24XM0D]45$]-.B`P<'@[ M($9/3E0M4TE:13H@,3)P>#L@34%21TE.+51/4#H@,'!X)SX-"B`F(WA!,#L\ M+W`^#0H@/'1A8FQE('-T>6QE/3-$)T)/4D1%4BU#3TQ,05!313H@8V]L;&%P M<V4G(&-E;&QS<&%C:6YG/3-$,"!C96QL<&%D9&EN9STS1#`@=VED=&@],T0Y M,B4@86QI9VX],T1C96YT97(@8F]R9&5R/3-$,#X-"B`\='(^#0H@/'1D('=I M9'1H/3-$.#$E/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!W:61T:#TS M1#8E/CPO=&0^#0H@/'1D/CPO=&0^#0H@/'1D/CPO=&0^#0H@/'1D/CPO=&0^ M#0H@/'1D('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#4E/CPO=&0^#0H@/'1D M/CPO=&0^#0H@/'1D/CPO=&0^#0H@/'1D/CPO=&0^#0H@/'1D('9A;&EG;CTS M1&)O='1O;2!W:61T:#TS1#4E/CPO=&0^#0H@/'1D/CPO=&0^#0H@/'1D/CPO M=&0^#0H@/'1D/CPO=&0^#0H@/"]T<CX-"B`\='(^#0H@/'1D('9A;&EG;CTS M1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF(WA!,#L\+V9O;G0^/"]T9#X-"B`\ M=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C>$$P.R8C>$$P M.SPO9F]N=#X\+W1D/@T*(#QT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B`C M,#`P,#`P(#%P>"!S;VQI9"<@=F%L:6=N/3-$8F]T=&]M(&-O;'-P86X],T0Q M,"!A;&EG;CTS1&-E;G1E<CX\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@ M5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,3X\8CY996%R<R!%;F1E9#QB<B`O M/@T*($1E8V5M8F5R)B-X03`[,S$L/"]B/CPO9F]N=#X\+W1D/@T*(#QT9"!V M86QI9VX],T1B;W1T;VT^/&9O;G0@<VEZ93TS1#$^)B-X03`[/"]F;VYT/CPO M=&0^#0H@/"]T<CX-"B`\='(^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N M="!S:7IE/3-$,3XF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$ M8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D M/@T*(#QT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B`C,#`P,#`P(#%P>"!S M;VQI9"<@=F%L:6=N/3-$8F]T=&]M(&-O;'-P86X],T0R(&%L:6=N/3-$8V5N M=&5R/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M M86XG('-I>F4],T0Q/CQB/C(P,30\+V(^/"]F;VYT/CPO=&0^#0H@/'1D('9A M;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF(WA!,#L\+V9O;G0^/"]T M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C>$$P M.SPO9F]N=#X\+W1D/@T*(#QT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B`C M,#`P,#`P(#%P>"!S;VQI9"<@=F%L:6=N/3-$8F]T=&]M(&-O;'-P86X],T0R M(&%L:6=N/3-$8V5N=&5R/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4 M:6UE<R!.97<@4F]M86XG('-I>F4],T0Q/CQB/C(P,3,\+V(^/"]F;VYT/CPO M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF(WA! M,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I M>F4],T0Q/B8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!S='EL93TS1"="3U)$ M15(M0D]45$]-.B`C,#`P,#`P(#%P>"!S;VQI9"<@=F%L:6=N/3-$8F]T=&]M M(&-O;'-P86X],T0R(&%L:6=N/3-$8V5N=&5R/CQF;VYT('-T>6QE/3-$)T9/ M3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0Q/CQB/C(P,3(\ M+V(^/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S M:7IE/3-$,3XF(WA!,#L\+V9O;G0^/"]T9#X-"B`\+W1R/@T*(#QT<B!B9V-O M;&]R/3-$(T-#145&1CX-"B`\=&0@=F%L:6=N/3-$=&]P/@T*(#QP('-T>6QE M/3-$)TU!4D=)3BU,1494.B`Q96T[(%1%6%0M24Y$14Y4.B`M,65M)SX\9F]N M="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE M/3-$,CY487@@870@9F5D97)A;"!S=&%T=71O<GD-"B!T87@@<F%T93PO9F]N M=#X\+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I M>F4],T0Q/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX] M,T1B;W1T;VT^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE M=R!2;VUA;B<@<VEZ93TS1#(^)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A M;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/CQF;VYT('-T>6QE/3-$)T9/ M3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R/B@S-#PO9F]N M=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P M/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG M('-I>F4],T0R/BDE)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS M1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF(WA!,#L\+V9O;G0^/"]T9#X-"B`\ M=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9 M.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R/B8C>$$P.SPO9F]N=#X\+W1D M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#X\9F]N="!S M='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$ M,CXH,S0\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A M<#TS1&YO=W)A<#X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@ M3F5W(%)O;6%N)R!S:7IE/3-$,CXI)28C>$$P.SPO9F]N=#X\+W1D/@T*(#QT M9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<VEZ93TS1#$^)B-X03`[/"]F;VYT M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=& M3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXF(WA!,#L\ M+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG M:'0^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA M;B<@<VEZ93TS1#(^*#,T/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O M='1O;2!N;W=R87`],T1N;W=R87`^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U) M3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^*24F(WA!,#L\+V9O;G0^ M/"]T9#X-"B`\+W1R/@T*(#QT<CX-"B`\=&0@=F%L:6=N/3-$=&]P/@T*(#QP M('-T>6QE/3-$)TU!4D=)3BU,1494.B`Q96T[(%1%6%0M24Y$14Y4.B`M,65M M)SX\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N M)R!S:7IE/3-$,CY3=&%T92!I;F-O;64@=&%X+"!N970@;V8-"B!F961E<F%L M('1A>"!B96YE9FET/"]F;VYT/CPO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX] M,T1B;W1T;VT^/&9O;G0@<VEZ93TS1#$^)B-X03`[)B-X03`[/"]F;VYT/CPO M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=&3TY4 M+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXF(WA!,#L\+V9O M;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^ M/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@ M<VEZ93TS1#(^*#$\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M M(&YO=W)A<#TS1&YO=W)A<#X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@ M5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXI)28C>$$P.SPO9F]N=#X\+W1D M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<VEZ93TS1#$^)B-X03`[ M/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL M93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXF M(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N M/3-$<FEG:'0^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE M=R!2;VUA;B<@<VEZ93TS1#(^*#0\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N M/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#X\9F]N="!S='EL93TS1"=&3TY4 M+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXI)28C>$$P.SPO M9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<VEZ93TS M1#$^)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\ M9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S M:7IE/3-$,CXF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T M=&]M(&%L:6=N/3-$<FEG:'0^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ M(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^*#8\+V9O;G0^/"]T9#X-"B`\ M=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#X\9F]N="!S='EL M93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXI M)28C>$$P.SPO9F]N=#X\+W1D/@T*(#PO='(^#0H@/'1R(&)G8V]L;W(],T0C M0T-%149&/@T*(#QT9"!V86QI9VX],T1T;W`^#0H@/'`@<W1Y;&4],T0G34%2 M1TE.+4Q%1E0Z(#%E;3L@5$585"U)3D1%3E0Z("TQ96TG/CQF;VYT('-T>6QE M/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R/E-T M871E#0H@07!P;W)T:6]N;65N=#PO9F]N=#X\+W`^#0H@/"]T9#X-"B`\=&0@ M=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C>$$P.R8C>$$P.SPO M9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<W1Y;&4] M,T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^)B-X M03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS M1')I9VAT/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@ M4F]M86XG('-I>F4],T0R/C(X/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS M1&)O='1O;2!N;W=R87`],T1N;W=R87`^/&9O;G0@<W1Y;&4],T0G1D].5"U& M04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^)28C>$$P.SPO9F]N M=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<VEZ93TS1#$^ M)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N M="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE M/3-$,CXF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M M(&%L:6=N/3-$<FEG:'0^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I M;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^-SPO9F]N=#X\+W1D/@T*(#QT9"!V M86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P/CQF;VYT('-T>6QE/3-$ M)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R/B4F(WA! M,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I M>F4],T0Q/B8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T M;VT^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA M;B<@<VEZ93TS1#(^)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS M1&)O='1O;2!A;&EG;CTS1')I9VAT/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%- M24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R/C`\+V9O;G0^/"]T9#X- M"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#X\9F]N="!S M='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$ M,CXE)B-X03`[/"]F;VYT/CPO=&0^#0H@/"]T<CX-"B`\='(^#0H@/'1D('9A M;&EG;CTS1'1O<#X-"B`\<"!S='EL93TS1"=-05)'24XM3$5&5#H@,65M.R!4 M15A4+4E.1$5.5#H@+3%E;2<^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ M(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^5&%X(&-R961I=',-"B`H;F5T M*3PO9F]N=#X\+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF M;VYT('-I>F4],T0Q/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V M86QI9VX],T1B;W1T;VT^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I M;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^)B-X03`[/"]F;VYT/CPO=&0^#0H@ M/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/CQF;VYT('-T>6QE M/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R/B@W M/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N M;W=R87`^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2 M;VUA;B<@<VEZ93TS1#(^*24F(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L M:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C>$$P.SPO9F]N=#X\+W1D M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<W1Y;&4],T0G1D].5"U& M04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^)B-X03`[/"]F;VYT M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/CQF M;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I M>F4],T0R/B@Q-#PO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@ M;F]W<F%P/3-$;F]W<F%P/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4 M:6UE<R!.97<@4F]M86XG('-I>F4],T0R/BDE)B-X03`[/"]F;VYT/CPO=&0^ M#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF(WA!,#L\ M+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE M/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R/B8C M>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX] M,T1R:6=H=#X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W M(%)O;6%N)R!S:7IE/3-$,CXH,3D\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N M/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#X\9F]N="!S='EL93TS1"=&3TY4 M+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXI)28C>$$P.SPO M9F]N=#X\+W1D/@T*(#PO='(^#0H@/'1R(&)G8V]L;W(],T0C0T-%149&/@T* M(#QT9"!V86QI9VX],T1T;W`^#0H@/'`@<W1Y;&4],T0G34%21TE.+4Q%1E0Z M(#%E;3L@5$585"U)3D1%3E0Z("TQ96TG/CQF;VYT('-T>6QE/3-$)T9/3E0M M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R/D1E9F5R<F5D('1A M>"!A<W-E=',-"B`H=71I;&EZ960I(&YO="!B96YE9FET960\+V9O;G0^/"]P M/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$ M,3XF(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T M=&]M/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M M86XG('-I>F4],T0R/B8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX] M,T1B;W1T;VT@86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS1"=&3TY4+49! M34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXW/"]F;VYT/CPO=&0^ M#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^/&9O;G0@ M<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS M1#(^)28C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^ M/&9O;G0@<VEZ93TS1#$^)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG M;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@ M3F5W(%)O;6%N)R!S:7IE/3-$,CXF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@ M=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^/&9O;G0@<W1Y;&4],T0G M1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^-#$\+V9O M;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A M<#X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N M)R!S:7IE/3-$,CXE)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS M1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF(WA!,#L\+V9O;G0^/"]T9#X-"B`\ M=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9 M.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R/B8C>$$P.SPO9F]N=#X\+W1D M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#X\9F]N="!S M='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$ M,CXU-CPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P M/3-$;F]W<F%P/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!. M97<@4F]M86XG('-I>F4],T0R/B4F(WA!,#L\+V9O;G0^/"]T9#X-"B`\+W1R M/@T*(#QT<CX-"B`\=&0@=F%L:6=N/3-$=&]P/@T*(#QP('-T>6QE/3-$)TU! M4D=)3BU,1494.B`Q96T[(%1%6%0M24Y$14Y4.B`M,65M)SX\9F]N="!S='EL M93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CY3 M=&]C:RUB87-E9`T*(&-O;7!E;G-A=&EO;CPO9F]N=#X\+W`^#0H@/"]T9#X- M"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C>$$P.R8C M>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@ M<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS M1#(^)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A M;&EG;CTS1')I9VAT/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE M<R!.97<@4F]M86XG('-I>F4],T0R/C4\+V9O;G0^/"]T9#X-"B`\=&0@=F%L M:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#X\9F]N="!S='EL93TS1"=& M3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXE)B-X03`[ M/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE M/3-$,3XF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M M/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG M('-I>F4],T0R/B8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B M;W1T;VT@86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS1"=&3TY4+49!34E, M63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXR/"]F;VYT/CPO=&0^#0H@ M/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^/&9O;G0@<W1Y M;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^ M)28C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O M;G0@<VEZ93TS1#$^)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS M1&)O='1O;3X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W M(%)O;6%N)R!S:7IE/3-$,CXF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L M:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^/&9O;G0@<W1Y;&4],T0G1D]. M5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^,#PO9F]N=#X\ M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P/CQF M;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I M>F4],T0R/B4F(WA!,#L\+V9O;G0^/"]T9#X-"B`\+W1R/@T*(#QT<B!B9V-O M;&]R/3-$(T-#145&1CX-"B`\=&0@=F%L:6=N/3-$=&]P/@T*(#QP('-T>6QE M/3-$)TU!4D=)3BU,1494.B`Q96T[(%1%6%0M24Y$14Y4.B`M,65M)SX\9F]N M="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE M/3-$,CY.3TP@17AP:7)A=&EO;CPO9F]N=#X\+W`^#0H@/"]T9#X-"B`\=&0@ M=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C>$$P.R8C>$$P.SPO M9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<W1Y;&4] M,T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^)B-X M03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS M1')I9VAT/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@ M4F]M86XG('-I>F4],T0R/C(\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$ M8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#X\9F]N="!S='EL93TS1"=&3TY4+49! M34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXE)B-X03`[/"]F;VYT M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF M(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT M('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4] M,T0R/B8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@ M86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM M97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXQ/"]F;VYT/CPO=&0^#0H@/'1D('9A M;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^/&9O;G0@<W1Y;&4],T0G M1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^)28C>$$P M.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<VEZ M93TS1#$^)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O M;3X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N M)R!S:7IE/3-$,CXF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$ M8F]T=&]M(&%L:6=N/3-$<FEG:'0^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U) M3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^,CPO9F]N=#X\+W1D/@T* M(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P/CQF;VYT('-T M>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R M/B4F(WA!,#L\+V9O;G0^/"]T9#X-"B`\+W1R/@T*(#QT<CX-"B`\=&0@=F%L M:6=N/3-$=&]P/@T*(#QP('-T>6QE/3-$)TU!4D=)3BU,1494.B`Q96T[(%1% M6%0M24Y$14Y4.B`M,65M)SX\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@ M5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CY/=&AE<CPO9F]N=#X\+W`^#0H@ M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C M>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^ M/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@ M<VEZ93TS1#(^)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O M='1O;2!A;&EG;CTS1')I9VAT/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9 M.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R/C`\+V9O;G0^/"]T9#X-"B`\ M=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#X\9F]N="!S='EL M93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXE M)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N M="!S:7IE/3-$,3XF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$ M8F]T=&]M/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@ M4F]M86XG('-I>F4],T0R/B8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI M9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS1"=&3TY4 M+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXQ/"]F;VYT/CPO M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^/&9O M;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ M93TS1#(^)28C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T M;VT^/&9O;G0@<VEZ93TS1#$^)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A M;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM M97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXF(WA!,#L\+V9O;G0^/"]T9#X-"B`\ M=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^/&9O;G0@<W1Y;&4] M,T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^,3PO M9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W M<F%P/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M M86XG('-I>F4],T0R/B4F(WA!,#L\+V9O;G0^/"]T9#X-"B`\+W1R/@T*(#QT M<B!S='EL93TS1"=&3TY4+5-)6D4Z(#%P>"<^#0H@/'1D('9A;&EG;CTS1&)O M='1O;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[ M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/ M4D1%4BU43U`Z(",P,#`P,#`@,7!X('-O;&ED)SXF(WA!,#L\+W`^#0H@/"]T M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1% M4BU43U`Z(",P,#`P,#`@,7!X('-O;&ED)SXF(WA!,#L\+W`^#0H@/"]T9#X- M"B`\=&0^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P M.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"=" M3U)$15(M5$]0.B`C,#`P,#`P(#%P>"!S;VQI9"<^)B-X03`[/"]P/@T*(#PO M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$ M15(M5$]0.B`C,#`P,#`P(#%P>"!S;VQI9"<^)B-X03`[/"]P/@T*(#PO=&0^ M#0H@/'1D/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA! M,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@<W1Y;&4],T0G M0D]21$52+51/4#H@(S`P,#`P,"`Q<'@@<V]L:60G/B8C>$$P.SPO<#X-"B`\ M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@<W1Y;&4],T0G0D]2 M1$52+51/4#H@(S`P,#`P,"`Q<'@@<V]L:60G/B8C>$$P.SPO<#X-"B`\+W1D M/@T*(#QT9#XF(WA!,#L\+W1D/@T*(#PO='(^#0H@/'1R(&)G8V]L;W(],T0C M0T-%149&/@T*(#QT9"!V86QI9VX],T1T;W`^#0H@/'`@<W1Y;&4],T0G34%2 M1TE.+4Q%1E0Z(#)E;3L@5$585"U)3D1%3E0Z("TQ96TG/CQF;VYT('-T>6QE M/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R/E1O M=&%L/"]F;VYT/CPO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^ M/&9O;G0@<VEZ93TS1#$^)B-X03`[)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D M('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@ M5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXF(WA!,#L\+V9O;G0^/"]T9#X- M"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^/&9O;G0@<W1Y M;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^ M,#PO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$ M;F]W<F%P/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@ M4F]M86XG('-I>F4],T0R/B4F(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L M:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C>$$P.SPO9F]N=#X\+W1D M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<W1Y;&4],T0G1D].5"U& M04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^)B-X03`[/"]F;VYT M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/CQF M;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I M>F4],T0R/C`\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO M=W)A<#TS1&YO=W)A<#X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM M97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXE)B-X03`[/"]F;VYT/CPO=&0^#0H@ M/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF(WA!,#L\+V9O M;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$ M)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R/B8C>$$P M.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R M:6=H=#X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O M;6%N)R!S:7IE/3-$,CXP/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O M='1O;2!N;W=R87`],T1N;W=R87`^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U) M3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^)28C>$$P.SPO9F]N=#X\ M+W1D/@T*(#PO='(^#0H@/'1R('-T>6QE/3-$)T9/3E0M4TE:13H@,7!X)SX- M"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O M='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^ M#0H@/'`@<W1Y;&4],T0G0D]21$52+51/4#H@(S`P,#`P,"`S<'@@9&]U8FQE M)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T* M(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@,W!X(&1O=6)L92<^ M)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D/B8C>$$P.SPO=&0^#0H@/'1D('9A M;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T M;VT^#0H@/'`@<W1Y;&4],T0G0D]21$52+51/4#H@(S`P,#`P,"`S<'@@9&]U M8FQE)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@,W!X(&1O=6)L M92<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D/B8C>$$P.SPO=&0^#0H@/'1D M('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B M;W1T;VT^#0H@/'`@<W1Y;&4],T0G0D]21$52+51/4#H@(S`P,#`P,"`S<'@@ M9&]U8FQE)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T M=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@,W!X(&1O M=6)L92<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D/B8C>$$P.SPO=&0^#0H@ M/"]T<CX-"B`\+W1A8FQE/@T*(#QP('-T>6QE/3-$)TU!4D=)3BU"3U143TTZ M(#!P>#L@34%21TE.+51/4#H@,3)P>#L@5$585"U)3D1%3E0Z(#0E)R!A;&EG M;CTS1&IU<W1I9GD^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S M($YE=R!2;VUA;B<@<VEZ93TS1#(^5&AE($-O;7!A;GD@:&%D(&9E9&5R86P@ M;F5T(&]P97)A=&EN9R!L;W-S(&-A<G)Y9F]R=V%R9',@;V8-"B!A<'!R;WAI M;6%T96QY("0S.#8N."!M:6QL:6]N(&%N9"!A<'!O<G1I;VYE9"!S=&%T92!N M970@;W!E<F%T:6YG#0H@;&]S<R!C87)R>69O<G=A<F1S(&]F(&%P<')O>&EM M871E;'D@)#(X-2XW)B-X03`[;6EL;&EO;B!B969O<F4-"B!F961E<F%L(&)E M;F5F:70@870@1&5C96UB97(F(WA!,#LS,2P@,C`Q-"X@268@;F]T('5T:6QI M>F5D+"!T:&4-"B!F961E<F%L(&%N9"!S=&%T92!O<&5R871I;F<@;&]S<R!C M87)R>69O<G=A<F1S('=I;&P@8F5G:6X@=&\@97AP:7)E#0H@:6X@=F%R:6]U M<R!A;6]U;G1S(&)E9VEN;FEN9R`R,#(P(&%N9"`R,#$U+"!R97-P96-T:79E M;'DN(%1H92!N970-"B!O<&5R871I;F<@;&]S<R!C87)R>69O<G=A<F1S(&EN M8VQU9&4@9&5D=6-T:6]N<R!F;W(@<W1O8VL-"B!O<'1I;VYS+CPO9F]N=#X\ M+W`^#0H@/'`@<W1Y;&4],T0G34%21TE.+4)/5%1/33H@,'!X.R!-05)'24XM M5$]0.B`Q,G!X.R!415A4+4E.1$5.5#H@-"4G(&%L:6=N/3-$:G5S=&EF>3X\ M9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S M:7IE/3-$,CY4:&4@0V]M<&%N>2!H860@9V5N97)A;"!B=7-I;F5S<R!C<F5D M:70@;V8@87!P<F]X:6UA=&5L>0T*("0S,"XX)B-X03`[;6EL;&EO;B!A;F0@ M)#$S+C,F(WA!,#MM:6QL:6]N(&9O<B!F961E<F%L(&%N9"!S=&%T90T*(&EN M8V]M92!T87@@<'5R<&]S97,L(')E<W!E8W1I=F5L>2P@870@1&5C96UB97(F M(WA!,#LS,2P@,C`Q-"X-"B!!;6]U;G1S(&%R92!C;VUP<FES960@;V8@4F5S M96%R8V@@86YD($1E=F5L;W!M96YT($-R961I=',@86YD#0H@3W)P:&%N($1R M=6<@0W)E9&ET<RX@268@;F]T('5T:6QI>F5D+"!T:&4@9F5D97)A;"!C87)R M>69O<G=A<F1S#0H@=VEL;"!E>'!I<F4@:6X@=F%R:6]U<R!A;6]U;G1S(&)E M9VEN;FEN9R!I;B`R,#(Q+B!4:&4@0V%L:69O<FYI80T*('-T871E(&-R961I M="!C86X@8F4@8V%R<FEE9"!F;W)W87)D(&EN9&5F:6YI=&5L>2X@4VEN8V4@ M:71S(&9I;&EN9PT*(&]F(&ET<R`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`Q1#L@<V]U<F-I;F<-"B!A<'!R;V%C:"X@06-C;W)D:6YG M;'DL('1H92!#;VUP86YY)B-X,C`Q.3MS($-A;&EF;W)N:6$@87!P;W)T:6]N M;65N=`T*(&9O<FUU;&$@:7,@<V5N<VET:79E('1O(&-H86YG97,@:6X@=&AE M('-O=7)C92!O9B!T:&4-"B!#;VUP86YY)B-X,C`Q.3MS(&UI>"!O9B!R979E M;G5E+B!!<R!A(')E<W5L="!O9B!A9W)E96UE;G1S(&EN('!L86-E#0H@:6X@ M,C`Q,RP@=&AE($-O;7!A;GD@861J=7-T960@9&5F97)R960@=&%X(&%S<V5T M<R!T;R!R969L96-T('1H97-E#0H@8VAA;F=E<RX\+V9O;G0^/"]P/@T*(#QP M('-T>6QE/3-$)TU!4D=)3BU"3U143TTZ(#!P>#L@34%21TE.+51/4#H@,3)P M>#L@5$585"U)3D1%3E0Z(#0E)R!A;&EG;CTS1&IU<W1I9GD^/&9O;G0@<W1Y M;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^ M26X@9V5N97)A;"P@=6YD97(@4V5C=&EO;B8C>$$P.S,X,B!O9B!T:&4@26YT M97)N86P@4F5V96YU92!#;V1E#0H@*"8C>#(P,4,[4V5C=&EO;B`S.#(F(W@R M,#%$.RDL(&$@8V]R<&]R871I;VX@=&AA="!U;F1E<F=O97,@86X-"B`F(W@R M,#$X.V]W;F5R<VAI<"!C:&%N9V4F(W@R,#$Y.R!I<R!S=6)J96-T('1O(&QI M;6ET871I;VYS(&]N(&ET<PT*(&%B:6QI='D@=&\@=71I;&EZ92!I=',@<')E M+6-H86YG92!N970@;W!E<F%T:6YG(&QO<W-E<R!A;F0@=&%X#0H@8W)E9&ET M<R!T;R!O9F9S970@9G5T=7)E('1A>&%B;&4@:6YC;VUE+B!4:&4@0V]M<&%N M>2!H87,@<&5R9F]R;65D#0H@82!S96-T:6]N(#,X,B!A;F%L>7-I<R!F;W(@ M=&AE('EE87(@96YD960@1&5C96UB97(F(WA!,#LS,2P@,C`Q-`T*(&%N9"!H M87,@;F]T(&5X<&5R:65N8V5D(&%N(&]W;F5R<VAI<"!C:&%N9V4@<VEN8V4@ M,C`P-BX@02!P;W)T:6]N#0H@;V8@=&AE($-O;7!A;GDF(W@R,#$Y.W,@97AI M<W1I;F<@;F5T(&]P97)A=&EN9R!L;W-S97,@86YD('1A>`T*(&-R961I=',@ M87)E('-U8FIE8W0@=&\@;&EM:71A=&EO;G,@87)I<VEN9R!F<F]M('!R979I M;W5S(&]W;F5R<VAI<`T*(&-H86YG97,N($9U='5R92!C:&%N9V5S(&EN('1H M92!#;VUP86YY)B-X,C`Q.3MS('-T;V-K(&]W;F5R<VAI<"P-"B!S;VUE(&]F M('=H:6-H(&%R92!O=71S:61E(&]F(&]U<B!C;VYT<F]L+"!C;W5L9"!R97-U M;'0@:6X@86X-"B!O=VYE<G-H:7`@8VAA;F=E('5N9&5R(%-E8W1I;VXF(WA! M,#LS.#(@86YD(')E<W5L="!I;B!A9&1I=&EO;F%L#0H@;&EM:71A=&EO;G,N M/"]F;VYT/CPO<#X-"B`\<"!S='EL93TS1"=-05)'24XM0D]45$]-.B`P<'@[ M($U!4D=)3BU43U`Z(#$R<'@[(%1%6%0M24Y$14Y4.B`T)2<@86QI9VX],T1J M=7-T:69Y/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@ M4F]M86XG('-I>F4],T0R/E-E8W1I;VXF(WA!,#LU.2AE*2!O9B!T:&4@26YT M97)N86P@4F5V96YU92!#;V1E(&%L;&]W<R!A#0H@0V]M<&%N>2!T;R!C87!I M=&%L:7IE(%(F86UP.T0@97AP96YS97,N(%1H92!#;VUP86YY(&5L96-T960@ M=&\-"B!C87!I=&%L:7IE(%(F86UP.T0@97AP96YS97,@;VX@:71S(#(P,3(@ M86YD(#(P,3,@=&%X(')E='5R;G,@869T97(-"B!C;VUP;&5T:6YG(&$@<F5V M97)S92!S=&]C:R!S<&QI="!I;B!T:&4@<V5C;VYD('%U87)T97(@;V8@,C`Q M,RX@1F]R#0H@,C`Q-"P@=&AE($-O;7!A;GD@86YT:6-I<&%T97,@9F]R96=O M:6YG('1H92!E;&5C=&EO;B!I;B!I=',@,C`Q-`T*('1A>"!R971U<FX@87,@ M=&AE>2!D;R!N;W0@86YT:6-I<&%T92!A;B!O=VYE<G-H:7`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`T*('!O<VET:6]N<R!T86ME;B!O<B!E>'!E8W1E9"!T;R!B M92!T86ME;B!O;B!A('1A>"!R971U<FXN(%1A>`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`\<"!S='EL93TS1"=- M05)'24XM0D]45$]-.B`P<'@[($U!4D=)3BU43U`Z(#$R<'@[(%1%6%0M24Y$ M14Y4.B`T)2<@86QI9VX],T1J=7-T:69Y/CQF;VYT('-T>6QE/3-$)T9/3E0M M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R/E1H92!S:6=N:69I M8V%N="!J=7)I<V1I8W1I;VYS(&EN('=H:6-H('1H92!#;VUP86YY(&9I;&5S M(&EN8V]M90T*('1A>"!R971U<FYS(&%R92!T:&4@56YI=&5D(%-T871E<R!A M;F0@0V%L:69O<FYI82X@1F]R(&IU<FES9&EC=&EO;G,-"B!I;B!W:&EC:"!T M87@@9FEL:6YG<R!A<F4@;6%D92P@=&AE($-O;7!A;GD@:7,@<W5B:F5C="!T M;R!I;F-O;64@=&%X#0H@97AA;6EN871I;VX@9F]R(&%L;"!F:7-C86P@>65A M<G,@<VEN8V4@:6YC97!T:6]N+B!4:&4@25)3)B-X,C`Q.3MS#0H@3&%R9V4@ M0G5S:6YE<W,@86YD($EN=&5R;F%T:6]N86P@1&EV:7-I;VX@8V]N8VQU9&5D M(&ET<R!A=61I="!O9@T*('1H92`R,#`Y('1A>"!Y96%R('=I=&@@;F\@;6%T M97)I86P@861J=7-T;65N=',N($AO=V5V97(L(&EN#0H@9V5N97)A;"P@=&AE M('-T871U=&4@;V8@;&EM:71A=&EO;G,@9F]R('1A>"!L:6%B:6QI=&EE<R!F M;W(@86QL#0H@>65A<G,@<F5M86EN<R!O<&5N(&9O<B!T:&4@<'5R<&]S92!O M9B!A9&IU<W1I;F<@=&AE(&%M;W5N=',@;V8@=&AE#0H@;&]S<V5S(&%N9"!C M<F5D:71S(&-A<G)I960@9F]R=V%R9"!F<F]M('1H;W-E('EE87)S+CPO9F]N M=#X\+W`^#0H@/'`@<W1Y;&4],T0G34%21TE.+4)/5%1/33H@,'!X.R!-05)' M24XM5$]0.B`Q,G!X.R!415A4+4E.1$5.5#H@-"4G(&%L:6=N/3-$:G5S=&EF M>3X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N M)R!S:7IE/3-$,CY4:&4@9F]L;&]W:6YG(&ES(&$@=&%B=6QA<B!R96-O;F-I M;&EA=&EO;B!O9B!T:&4@=&]T86P@86UO=6YT<PT*(&]F('5N<F5C;V=N:7IE M9"!T87@@8F5N969I=',@*"8C>#(P,4,[551"<R8C>#(P,40[*2`H:6X-"B!T M:&]U<V%N9',I.CPO9F]N=#X\+W`^#0H@/'`@<W1Y;&4],T0G34%21TE.+4)/ M5%1/33H@,'!X.R!&3TY4+5-)6D4Z(#$R<'@[($U!4D=)3BU43U`Z(#!P>"<^ M#0H@)B-X03`[/"]P/@T*(#QT86)L92!S='EL93TS1"="3U)$15(M0T],3$%0 M4T4Z(&-O;&QA<'-E)R!C96QL<W!A8VEN9STS1#`@8V5L;'!A9&1I;F<],T0P M('=I9'1H/3-$,3`P)2!A;&EG;CTS1&-E;G1E<B!B;W)D97(],T0P/@T*(#QT M<CX-"B`\=&0@=VED=&@],T0U-24^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T M=&]M('=I9'1H/3-$,3`E/CPO=&0^#0H@/'1D/CPO=&0^#0H@/'1D/CPO=&0^ M#0H@/'1D/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$P M)3X\+W1D/@T*(#QT9#X\+W1D/@T*(#QT9#X\+W1D/@T*(#QT9#X\+W1D/@T* M(#QT9"!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q,"4^/"]T9#X-"B`\=&0^ M/"]T9#X-"B`\=&0^/"]T9#X-"B`\=&0^/"]T9#X-"B`\+W1R/@T*(#QT<CX- M"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C>$$P.SPO M9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<VEZ93TS M1#$^)B-X03`[)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('-T>6QE/3-$)T)/ M4D1%4BU"3U143TTZ(",P,#`P,#`@,7!X('-O;&ED)R!V86QI9VX],T1B;W1T M;VT@8V]L<W!A;CTS1#(@86QI9VX],T1C96YT97(^/&9O;G0@<W1Y;&4],T0G M1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#$^/&(^1F5D M97)A;#QB<B`O/@T*(&%N9"8C>$$P.U-T871E/&)R("\^#0H@5&%X/"]B/CPO M9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<VEZ93TS M1#$^)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\ M9F]N="!S:7IE/3-$,3XF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@<W1Y;&4] M,T0G0D]21$52+4)/5%1/33H@(S`P,#`P,"`Q<'@@<V]L:60G('9A;&EG;CTS M1&)O='1O;2!C;VQS<&%N/3-$,B!A;&EG;CTS1&-E;G1E<CX\9F]N="!S='EL M93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,3X\ M8CY&961E<F%L)B-X03`[5&%X)B-X03`[0F5N969I=#QB<B`O/@T*(&]F)B-X M03`[4W1A=&4F(WA!,#M);F-O;64F(WA!,#M487@\8G(@+SX-"B!55$)S/"]B M/CPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<VEZ M93TS1#$^)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O M;3X\9F]N="!S:7IE/3-$,3XF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@<W1Y M;&4],T0G0D]21$52+4)/5%1/33H@(S`P,#`P,"`Q<'@@<V]L:60G('9A;&EG M;CTS1&)O='1O;2!C;VQS<&%N/3-$,B!A;&EG;CTS1&-E;G1E<CX\9F]N="!S M='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$ M,3X\8CY5;G)E8V]G;FEZ960F(WA!,#M);F-O;64F(WA!,#M487@\8G(@+SX- M"B!"96YE9FET<R8C>$$P.RTF(WA!,#M.970@;V8@1F5D97)A;#QB<B`O/@T* M($)E;F5F:70@;V8@4W1A=&4@551"<SPO8CX\+V9O;G0^/"]T9#X-"B`\=&0@ M=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C>$$P.SPO9F]N=#X\ M+W1D/@T*(#PO='(^#0H@/'1R(&)G8V]L;W(],T0C0T-%149&/@T*(#QT9"!V M86QI9VX],T1T;W`^#0H@/'`@<W1Y;&4],T0G34%21TE.+4Q%1E0Z(#)E;3L@ M5$585"U)3D1%3E0Z("TQ96TG/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9 M.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R/E5N<F5C;V=N:7IE9"!T87@@ M8F5N969I=',-"B!B86QA;F-E(&%T($1E8V5M8F5R)B-X03`[,S$L(#(P,3(\ M+V9O;G0^/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N M="!S:7IE/3-$,3XF(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L M:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE M<R!.97<@4F]M86XG('-I>F4],T0R/B0\+V9O;G0^/"]T9#X-"B`\=&0@=F%L M:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^/&9O;G0@<W1Y;&4],T0G1D]. M5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^-2PS-#`\+V9O M;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A M<#X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N M)R!S:7IE/3-$,CXF(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`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`[ M/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL M93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXD M/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I M9VAT/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M M86XG('-I>F4],T0R/C0L,3@R/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS M1&)O='1O;2!N;W=R87`],T1N;W=R87`^/&9O;G0@<W1Y;&4],T0G1D].5"U& M04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^)B-X03`[)B-X03`[ M/"]F;VYT/CPO=&0^#0H@/"]T<CX-"B`\='(^#0H@/'1D('9A;&EG;CTS1'1O M<#X-"B`\<"!S='EL93TS1"=-05)'24XM3$5&5#H@,65M.R!415A4+4E.1$5. M5#H@+3%E;2<^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE M=R!2;VUA;B<@<VEZ93TS1#(^061D:71I;VX@9F]R('1A>"!P;W-I=&EO;G,- M"B!O9B!P<FEO<B!Y96%R<SPO9F]N=#X\+W`^#0H@/"]T9#X-"B`\=&0@=F%L M:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C>$$P.R8C>$$P.SPO9F]N M=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<W1Y;&4],T0G M1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^)B-X03`[ M/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I M9VAT/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M M86XG('-I>F4],T0R/C(T/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O M='1O;2!N;W=R87`],T1N;W=R87`^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U) M3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^)B-X03`[)B-X03`[/"]F M;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$ M,3XF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF M;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I M>F4],T0R/B8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T M;VT@86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@ M5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXX/"]F;VYT/CPO=&0^#0H@/'1D M('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^/&9O;G0@<W1Y;&4] M,T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^)B-X M03`[)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\ M9F]N="!S:7IE/3-$,3XF(WA!,#L\+V9O;G0^/"]T9#X-"B`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`^#0H@ M/'`@<W1Y;&4],T0G34%21TE.+4Q%1E0Z(#%E;3L@5$585"U)3D1%3E0Z("TQ M96TG/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M M86XG('-I>F4],T0R/D%D9&ET:6]N(&9O<B!T87@@<&]S:71I;VYS#0H@<F5L M871E9"!T;R!T:&4@8W5R<F5N="!Y96%R/"]F;VYT/CPO<#X-"B`\+W1D/@T* M(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<VEZ93TS1#$^)B-X03`[)B-X M03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S M='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$ M,CXF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L M:6=N/3-$<FEG:'0^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S M($YE=R!2;VUA;B<@<VEZ93TS1#(^.#`W/"]F;VYT/CPO=&0^#0H@/'1D('9A M;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^/&9O;G0@<W1Y;&4],T0G M1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^)B-X03`[ M)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N M="!S:7IE/3-$,3XF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$ M8F]T=&]M/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@ M4F]M86XG('-I>F4],T0R/B8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI M9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS1"=&3TY4 M+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXT,SPO9F]N=#X\ M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P/CQF M;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I M>F4],T0R/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX] M,T1B;W1T;VT^/&9O;G0@<VEZ93TS1#$^)B-X03`[/"]F;VYT/CPO=&0^#0H@ M/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=&3TY4+49!34E, M63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXF(WA!,#L\+V9O;G0^/"]T M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^/&9O;G0@ M<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS M1#(^-S8T/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R M87`],T1N;W=R87`^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S M($YE=R!2;VUA;B<@<VEZ93TS1#(^)B-X03`[)B-X03`[/"]F;VYT/CPO=&0^ M#0H@/"]T<CX-"B`\='(@<W1Y;&4],T0G1D].5"U325I%.B`Q<'@G/@T*(#QT M9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\ M<"!S='EL93TS1"="3U)$15(M5$]0.B`C,#`P,#`P(#%P>"!S;VQI9"<^)B-X M03`[/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S M='EL93TS1"="3U)$15(M5$]0.B`C,#`P,#`P(#%P>"!S;VQI9"<^)B-X03`[ M/"]P/@T*(#PO=&0^#0H@/'1D/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS M1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@ M/'`@<W1Y;&4],T0G0D]21$52+51/4#H@(S`P,#`P,"`Q<'@@<V]L:60G/B8C M>$$P.SPO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@ M<W1Y;&4],T0G0D]21$52+51/4#H@(S`P,#`P,"`Q<'@@<V]L:60G/B8C>$$P M.SPO<#X-"B`\+W1D/@T*(#QT9#XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX] M,T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T* M(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@,7!X('-O;&ED)SXF M(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP M('-T>6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@,7!X('-O;&ED)SXF(WA! M,#L\+W`^#0H@/"]T9#X-"B`\=&0^)B-X03`[/"]T9#X-"B`\+W1R/@T*(#QT M<CX-"B`\=&0@=F%L:6=N/3-$=&]P/@T*(#QP('-T>6QE/3-$)TU!4D=)3BU, M1494.B`R96T[(%1%6%0M24Y$14Y4.B`M,65M)SX\9F]N="!S='EL93TS1"=& M3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CY5;G)E8V]G M;FEZ960@=&%X(&)E;F5F:71S#0H@8F%L86YC92!A="!$96-E;6)E<B8C>$$P M.S,Q+"`R,#$S/"]F;VYT/CPO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B M;W1T;VT^/&9O;G0@<VEZ93TS1#$^)B-X03`[)B-X03`[/"]F;VYT/CPO=&0^ M#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=&3TY4+49! M34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXF(WA!,#L\+V9O;G0^ M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^/&9O M;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ M93TS1#(^-BPQ-S$\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M M(&YO=W)A<#TS1&YO=W)A<#X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@ M5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXF(WA!,#LF(WA!,#L\+V9O;G0^ M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C M>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@ M<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS M1#(^)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A M;&EG;CTS1')I9VAT/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE M<R!.97<@4F]M86XG('-I>F4],T0R/C$L,C`Y/"]F;VYT/CPO=&0^#0H@/'1D M('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^/&9O;G0@<W1Y;&4] M,T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^)B-X M03`[)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\ M9F]N="!S:7IE/3-$,3XF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N M/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!. M97<@4F]M86XG('-I>F4],T0R/B8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V M86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS1"=& M3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXT+#DV,CPO M9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W M<F%P/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M M86XG('-I>F4],T0R/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#PO='(^ M#0H@/'1R(&)G8V]L;W(],T0C0T-%149&/@T*(#QT9"!V86QI9VX],T1T;W`^ M#0H@/'`@<W1Y;&4],T0G34%21TE.+4Q%1E0Z(#%E;3L@5$585"U)3D1%3E0Z M("TQ96TG/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@ M4F]M86XG('-I>F4],T0R/E)E9'5C=&EO;G,@9F]R('1A>`T*('!O<VET:6]N M<R!O9B!P<FEO<B!Y96%R<SPO9F]N=#X\+W`^#0H@/"]T9#X-"B`\=&0@=F%L M:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C>$$P.R8C>$$P.SPO9F]N M=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<W1Y;&4],T0G M1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^)B-X03`[ M/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I M9VAT/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M M86XG('-I>F4],T0R/B@X-3PO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B M;W1T;VT@;F]W<F%P/3-$;F]W<F%P/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%- M24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R/BDF(WA!,#L\+V9O;G0^ M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C M>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@ M<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS M1#(^)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A M;&EG;CTS1')I9VAT/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE M<R!.97<@4F]M86XG('-I>F4],T0R/B@R.3PO9F]N=#X\+W1D/@T*(#QT9"!V M86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P/CQF;VYT('-T>6QE/3-$ M)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R/BDF(WA! M,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I M>F4],T0Q/B8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T M;VT^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA M;B<@<VEZ93TS1#(^)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS M1&)O='1O;2!A;&EG;CTS1')I9VAT/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%- M24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R/B@U-CPO9F]N=#X\+W1D M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P/CQF;VYT M('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4] M,T0R/BDF(WA!,#L\+V9O;G0^/"]T9#X-"B`\+W1R/@T*(#QT<CX-"B`\=&0@ M=F%L:6=N/3-$=&]P/@T*(#QP('-T>6QE/3-$)TU!4D=)3BU,1494.B`Q96T[ M(%1%6%0M24Y$14Y4.B`M,65M)SX\9F]N="!S='EL93TS1"=&3TY4+49!34E, M63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CY!9&1I=&EO;B!F;W(@=&%X M('!O<VET:6]N<PT*(')E;&%T960@=&\@=&AE(&-U<G)E;G0@>65A<CPO9F]N M=#X\+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I M>F4],T0Q/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX] M,T1B;W1T;VT^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE M=R!2;VUA;B<@<VEZ93TS1#(^)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A M;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/CQF;VYT('-T>6QE/3-$)T9/ M3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R/C$X.#PO9F]N M=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P M/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG M('-I>F4],T0R/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI M9VX],T1B;W1T;VT^/&9O;G0@<VEZ93TS1#$^)B-X03`[/"]F;VYT/CPO=&0^ M#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=&3TY4+49! M34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXF(WA!,#L\+V9O;G0^ M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^/&9O M;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ M93TS1#(^,3`\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO M=W)A<#TS1&YO=W)A<#X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM M97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXF(WA!,#LF(WA!,#L\+V9O;G0^/"]T M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C>$$P M.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<W1Y M;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^ M)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG M;CTS1')I9VAT/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!. M97<@4F]M86XG('-I>F4],T0R/C$W.#PO9F]N=#X\+W1D/@T*(#QT9"!V86QI M9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P/CQF;VYT('-T>6QE/3-$)T9/ M3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R/B8C>$$P.R8C M>$$P.SPO9F]N=#X\+W1D/@T*(#PO='(^#0H@/'1R('-T>6QE/3-$)T9/3E0M M4TE:13H@,7!X)SX-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D M('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI M9VX],T1B;W1T;VT^#0H@/'`@<W1Y;&4],T0G0D]21$52+51/4#H@(S`P,#`P M,"`Q<'@@<V]L:60G/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX] M,T1B;W1T;VT^#0H@/'`@<W1Y;&4],T0G0D]21$52+51/4#H@(S`P,#`P,"`Q M<'@@<V]L:60G/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT9#XF(WA!,#L\+W1D M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L M:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P M,#`@,7!X('-O;&ED)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N M/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@ M,7!X('-O;&ED)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0^)B-X03`[/"]T M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A M;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B`C,#`P M,#`P(#%P>"!S;VQI9"<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG M;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B`C,#`P,#`P M(#%P>"!S;VQI9"<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D/B8C>$$P.SPO M=&0^#0H@/"]T<CX-"B`\='(@8F=C;VQO<CTS1"-#0T5%1D8^#0H@/'1D('9A M;&EG;CTS1'1O<#X-"B`\<"!S='EL93TS1"=-05)'24XM3$5&5#H@,F5M.R!4 M15A4+4E.1$5.5#H@+3%E;2<^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ M(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^56YR96-O9VYI>F5D('1A>"!B M96YE9FET<PT*(&)A;&%N8V4@870@1&5C96UB97(F(WA!,#LS,2P@,C`Q-#PO M9F]N=#X\+W`^#0H@/"]T9#X-"B`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`[/"]F;VYT/CPO=&0^ M#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=&3TY4+49! M34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXD/"]F;VYT/CPO=&0^ M#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/CQF;VYT('-T M>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R M/C$L,3DP/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R M87`],T1N;W=R87`^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S M($YE=R!2;VUA;B<@<VEZ93TS1#(^)B-X03`[)B-X03`[/"]F;VYT/CPO=&0^ M#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF(WA!,#L\ M+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE M/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R/B0\ M+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG M:'0^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA M;B<@<VEZ93TS1#(^-2PP.#0\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$ M8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#X\9F]N="!S='EL93TS1"=&3TY4+49! M34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXF(WA!,#LF(WA!,#L\ M+V9O;G0^/"]T9#X-"B`\+W1R/@T*(#QT<B!S='EL93TS1"=&3TY4+5-)6D4Z M(#%P>"<^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI M9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$ M8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@,W!X M(&1O=6)L92<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O M='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B`C,#`P,#`P(#-P>"!D M;W5B;&4G/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT9#XF(WA!,#L\+W1D/@T* M(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N M/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@ M,W!X(&1O=6)L92<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS M1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B`C,#`P,#`P(#-P M>"!D;W5B;&4G/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT9#XF(WA!,#L\+W1D M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L M:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P M,#`@,W!X(&1O=6)L92<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG M;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B`C,#`P,#`P M(#-P>"!D;W5B;&4G/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT9#XF(WA!,#L\ M+W1D/@T*(#PO='(^#0H@/"]T86)L93X-"B`\<"!S='EL93TS1"=-05)'24XM M0D]45$]-.B`P<'@[($U!4D=)3BU43U`Z(#$R<'@[(%1%6%0M24Y$14Y4.B`T M)2<@86QI9VX],T1J=7-T:69Y/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9 M.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R/DEN8VQU9&5D(&EN('1H92!B M86QA;F-E(&]F('5N<F5C;V=N:7IE9"!T87@@8F5N969I=',@87,@;V8-"B!$ M96-E;6)E<B8C>$$P.S,Q+"`R,#$T+"`R,#$S(&%N9"`R,#$R(&%R92`D-2XQ M(&UI;&QI;VXL("0U+C`-"B!M:6QL:6]N(&%N9"`D-"XR(&UI;&QI;VX@;V8@ M=&%X(&)E;F5F:71S+"!R97-P96-T:79E;'DL('1H870L(&EF#0H@<F5C;V=N M:7IE9"P@=V]U;&0@<F5S=6QT(&EN(&%D:G5S=&UE;G1S('1O(&]T:&5R('1A M>"!A8V-O=6YT<RP-"B!P<FEM87)I;'D@9&5F97)R960@=&%X97,N/"]F;VYT M/CPO<#X-"B`\<"!S='EL93TS1"=-05)'24XM0D]45$]-.B`P<'@[($U!4D=) M3BU43U`Z(#$R<'@[(%1%6%0M24Y$14Y4.B`T)2<@86QI9VX],T1J=7-T:69Y M/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG M('-I>F4],T0R/E1H92!#;VUP86YY(')E8V]G;FEZ97,@:6YT97)E<W0@86-C M<G5E9"!R96QA=&5D('1O('5N<F5C;V=N:7IE9`T*('1A>"!B96YE9FET<R!A M;F0@<&5N86QT:65S(&%S(&EN8V]M92!T87@@97AP96YS92X@4F5L871E9"!T M;R!T:&4-"B!U;G)E8V]G;FEZ960@=&%X(&)E;F5F:71S(&YO=&5D(&%B;W9E M+"!T:&4@0V]M<&%N>2!D:60@;F]T(&%C8W)U90T*(&%N>2!P96YA;'1I97,@ M;W(@:6YT97)E<W0@9'5R:6YG(#(P,30L(#(P,3,@;W(@,C`Q,BX@5&AE($-O M;7!A;GD-"B!D;V5S(&YO="!E>'!E8W0@:71S('5N<F5C;V=N:7IE9"!T87@@ M8F5N969I="!T;R!C:&%N9V4@;6%T97)I86QL>0T*(&]V97(@=&AE(&YE>'0@ M='=E;'9E(&UO;G1H<RX\+V9O;G0^/"]P/@T*(#PO9&EV/CQS<&%N/CPO<W!A M;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`\+W1A8FQE/@T*("`\+V)O9'D^ M#0H\+VAT;6P^#0H-"BTM+2TM+3U?3F5X=%!A<G1?,SEC,&5A-C)?8S(P,U\T M-3AF7SAC-3!?,V1C830U-F$V.34Q#0I#;VYT96YT+4QO8V%T:6]N.B!F:6QE M.B\O+T,Z+S,Y8S!E838R7V,R,#-?-#4X9E\X8S4P7S-D8V$T-39A-CDU,2]7 M;W)K<VAE971S+U-H965T,C$N:'1M;`T*0V]N=&5N="U4<F%N<V9E<BU%;F-O M9&EN9SH@<75O=&5D+7!R:6YT86)L90T*0V]N=&5N="U4>7!E.B!T97AT+VAT M;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@ M("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$ M)W1E>'0O:'1M;#L@8VAA<G-E=#UU=&8M."<^/'-C<FEP="!T>7!E/3-$=&5X M="]J879A<V-R:7!T('-R8STS1%-H;W<N:G,^+RH@1&\@3F]T(%)E;6]V92!4 M:&ES($-O;6UE;G0@*B\\+W-C<FEP=#X\+VAE860^#0H@(#QB;V1Y/@T*("`@ M(#QT86)L92!C;&%S<STS1')E<&]R="!I9#TS1$E$,$5-13X-"B`@("`@(#QT M<CX-"B`@("`@("`@/'1H(&-L87-S/3-$=&P@8V]L<W!A;CTS1#$@<F]W<W!A M;CTS1#(^/'-T<F]N9SY);G1E<F5S="!A;F0@3W1H97(L($YE=#QB<CX\+W-T M<F]N9SX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:"!C;VQS<&%N/3-$ M,3XQ,B!-;VYT:',@16YD960\+W1H/@T*("`@("`@/"]T<CX-"B`@("`@(#QT M<CX-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^1&5C+B`S,2P@,C`Q-#QB<CX\ M+W1H/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@ M("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^/'-T<F]N9SY/=&AE M<B!);F-O;64@86YD($5X<&5N<V5S(%M!8G-T<F%C=%T\+W-T<F]N9SX\+W1D M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D M/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@ M("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^26YT97)E<W0@86YD($]T M:&5R+"!.970\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQD:78^ M#0H@/'`@<W1Y;&4],T0G34%21TE.+4)/5%1/33H@,'!X.R!-05)'24XM5$]0 M.B`P<'@G/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@ M4F]M86XG('-I>F4],T0R/CQB/DYO=&4@,30@)B-X,C`Q-#L@26YT97)E<W0- M"B!A;F0@3W1H97(L($YE=#PO8CX\+V9O;G0^/"]P/@T*(#QP('-T>6QE/3-$ M)TU!4D=)3BU"3U143TTZ(#!P>#L@34%21TE.+51/4#H@-G!X.R!415A4+4E. M1$5.5#H@-"4G(&%L:6=N/3-$:G5S=&EF>3X\9F]N="!S='EL93TS1"=&3TY4 M+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CY#;VUP;VYE;G1S M(&]F($EN=&5R97-T(&%N9"!/=&AE<BP@3F5T('=E<F4@87,@9F]L;&]W<R`H M:6X-"B!T:&]U<V%N9',I.CPO9F]N=#X\+W`^#0H@/'`@<W1Y;&4],T0G34%2 M1TE.+4)/5%1/33H@,'!X.R!&3TY4+5-)6D4Z(#$R<'@[($U!4D=)3BU43U`Z M(#!P>"<^#0H@)B-X03`[/"]P/@T*(#QT86)L92!S='EL93TS1"="3U)$15(M M0T],3$%04T4Z(&-O;&QA<'-E)R!C96QL<W!A8VEN9STS1#`@8V5L;'!A9&1I M;F<],T0P('=I9'1H/3-$.3(E(&%L:6=N/3-$8V5N=&5R(&)O<F1E<CTS1#`^ M#0H@/'1R/@T*(#QT9"!W:61T:#TS1#@P)3X\+W1D/@T*(#QT9"!V86QI9VX] M,T1B;W1T;VT@=VED=&@],T0T)3X\+W1D/@T*(#QT9#X\+W1D/@T*(#QT9#X\ M+W1D/@T*(#QT9#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@=VED=&@] M,T0T)3X\+W1D/@T*(#QT9#X\+W1D/@T*(#QT9#X\+W1D/@T*(#QT9#X\+W1D M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@=VED=&@],T0T)3X\+W1D/@T*(#QT M9#X\+W1D/@T*(#QT9#X\+W1D/@T*(#QT9#X\+W1D/@T*(#PO='(^#0H@/'1R M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<VEZ93TS1#$^)B-X03`[ M/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE M/3-$,3XF(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@<W1Y;&4],T0G M0D]21$52+4)/5%1/33H@(S`P,#`P,"`Q<'@@<V]L:60G('9A;&EG;CTS1&)O M='1O;2!C;VQS<&%N/3-$,3`@86QI9VX],T1C96YT97(^/&9O;G0@<W1Y;&4] M,T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#$^/&(^ M665A<G,@16YD960\8G(@+SX-"B!$96-E;6)E<B8C>$$P.S,Q+#PO8CX\+V9O M;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q M/B8C>$$P.SPO9F]N=#X\+W1D/@T*(#PO='(^#0H@/'1R/@T*(#QT9"!V86QI M9VX],T1B;W1T;VT^/&9O;G0@<VEZ93TS1#$^)B-X03`[/"]F;VYT/CPO=&0^ M#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF(WA!,#LF M(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/ M33H@(S`P,#`P,"`Q<'@@<V]L:60G('9A;&EG;CTS1&)O='1O;2!C;VQS<&%N M/3-$,B!A;&EG;CTS1&-E;G1E<CX\9F]N="!S='EL93TS1"=&3TY4+49!34E, M63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,3X\8CXR,#$T/"]B/CPO9F]N M=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<VEZ93TS1#$^ M)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N M="!S:7IE/3-$,3XF(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@<W1Y M;&4],T0G0D]21$52+4)/5%1/33H@(S`P,#`P,"`Q<'@@<V]L:60G('9A;&EG M;CTS1&)O='1O;2!C;VQS<&%N/3-$,B!A;&EG;CTS1&-E;G1E<CX\9F]N="!S M='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$ M,3X\8CXR,#$S/"]B/CPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T M;VT^/&9O;G0@<VEZ93TS1#$^)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A M;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF(WA!,#LF(WA!,#L\+V9O M;G0^/"]T9#X-"B`\=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@(S`P,#`P M,"`Q<'@@<V]L:60G('9A;&EG;CTS1&)O='1O;2!C;VQS<&%N/3-$,B!A;&EG M;CTS1&-E;G1E<CX\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@ M3F5W(%)O;6%N)R!S:7IE/3-$,3X\8CXR,#$R/"]B/CPO9F]N=#X\+W1D/@T* M(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<VEZ93TS1#$^)B-X03`[/"]F M;VYT/CPO=&0^#0H@/"]T<CX-"B`\='(@8F=C;VQO<CTS1"-#0T5%1D8^#0H@ M/'1D('9A;&EG;CTS1'1O<#X-"B`\<"!S='EL93TS1"=-05)'24XM3$5&5#H@ M,65M.R!415A4+4E.1$5.5#H@+3%E;2<^/&9O;G0@<W1Y;&4],T0G1D].5"U& M04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^26YT97)E<W0@:6YC M;VUE(&%N9"!O=&AE<@T*(&EN8V]M93PO9F]N=#X\+W`^#0H@/"]T9#X-"B`\ M=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C>$$P.R8C>$$P M.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<W1Y M;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^ M)#PO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R M:6=H=#X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O M;6%N)R!S:7IE/3-$,CXQ,#@\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$ M8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#X\9F]N="!S='EL93TS1"=&3TY4+49! M34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXF(WA!,#LF(WA!,#L\ M+V9O;G0^/"]T9#X-"B`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`[)B-X03`[/"]F;VYT/CPO=&0^#0H@ M/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=&3TY4+49!34E, M63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXD/"]F;VYT/CPO=&0^#0H@ M/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/CQF;VYT('-T>6QE M/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R/C@Y M/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N M;W=R87`^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2 M;VUA;B<@<VEZ93TS1#(^)B-X03`[)B-X03`[/"]F;VYT/CPO=&0^#0H@/"]T M<CX-"B`\='(^#0H@/'1D('9A;&EG;CTS1'1O<#X-"B`\<"!S='EL93TS1"=- M05)'24XM3$5&5#H@,65M.R!415A4+4E.1$5.5#H@+3%E;2<^/&9O;G0@<W1Y M;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^ M26YT97)E<W0@97AP96YS92!A;F0@;W1H97(-"B!E>'!E;G-E/"]F;VYT/CPO M<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<VEZ93TS M1#$^)B-X03`[)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O M='1O;2!N;W=R87`],T1N;W=R87`^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U) M3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^)B-X03`[/"]F;VYT/CPO M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`@86QI M9VX],T1R:6=H=#X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@ M3F5W(%)O;6%N)R!S:7IE/3-$,CXF(W@R,#$T.SPO9F]N=#X\+W1D/@T*(#QT M9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P/CQF;VYT('-T>6QE M/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R/B8C M>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^ M/&9O;G0@<VEZ93TS1#$^)B-X03`[)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D M('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@ M5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXF(WA!,#L\+V9O;G0^/"]T9#X- M"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^/&9O;G0@<W1Y M;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^ M-SD\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS M1&YO=W)A<#X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W M(%)O;6%N)R!S:7IE/3-$,CXF(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\ M=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C>$$P.R8C>$$P M.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<W1Y M;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^ M)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG M;CTS1')I9VAT/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!. M97<@4F]M86XG('-I>F4],T0R/B@R/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG M;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^/&9O;G0@<W1Y;&4],T0G1D]. M5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^*28C>$$P.SPO M9F]N=#X\+W1D/@T*(#PO='(^#0H@/'1R('-T>6QE/3-$)T9/3E0M4TE:13H@ M,7!X)SX-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG M;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B M;W1T;VT^#0H@/'`@<W1Y;&4],T0G0D]21$52+51/4#H@(S`P,#`P,"`Q<'@@ M<V]L:60G/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T M;VT^#0H@/'`@<W1Y;&4],T0G0D]21$52+51/4#H@(S`P,#`P,"`Q<'@@<V]L M:60G/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT9#XF(WA!,#L\+W1D/@T*(#QT M9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L M:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P M,#`@,7!X('-O;&ED)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N M/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@ M,7!X('-O;&ED)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0^)B-X03`[/"]T M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@ M/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0 M.B`C,#`P,#`P(#%P>"!S;VQI9"<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D M('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B`C M,#`P,#`P(#%P>"!S;VQI9"<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D/B8C M>$$P.SPO=&0^#0H@/"]T<CX-"B`\='(@8F=C;VQO<CTS1"-#0T5%1D8^#0H@ M/'1D('9A;&EG;CTS1'1O<#X-"B`\<"!S='EL93TS1"=-05)'24XM3$5&5#H@ M,F5M.R!415A4+4E.1$5.5#H@+3%E;2<^/&9O;G0@<W1Y;&4],T0G1D].5"U& M04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^26YT97)E<W0@86YD M($]T:&5R+`T*(&YE=#PO9F]N=#X\+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N M/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C>$$P.R8C>$$P.SPO9F]N=#X\ M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<W1Y;&4],T0G1D]. M5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^)#PO9F]N=#X\ M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#X\9F]N M="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE M/3-$,CXQ,#@\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO M=W)A<#TS1&YO=W)A<#X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM M97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXF(WA!,#LF(WA!,#L\+V9O;G0^/"]T M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C>$$P M.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O M;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ M93TS1#(^)#PO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI M9VX],T1R:6=H=#X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@ M3F5W(%)O;6%N)R!S:7IE/3-$,CXQ-S<\+V9O;G0^/"]T9#X-"B`\=&0@=F%L M:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#X\9F]N="!S='EL93TS1"=& M3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXF(WA!,#LF M(WA!,#L\+V9O;G0^/"]T9#X-"B`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`\=&0@=F%L:6=N/3-$8F]T M=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\ M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@<W1Y;&4],T0G0D]2 M1$52+51/4#H@(S`P,#`P,"`S<'@@9&]U8FQE)SXF(WA!,#L\+W`^#0H@/"]T M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1% M4BU43U`Z(",P,#`P,#`@,W!X(&1O=6)L92<^)B-X03`[/"]P/@T*(#PO=&0^ M#0H@/'1D/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA! M,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@<W1Y M;&4],T0G0D]21$52+51/4#H@(S`P,#`P,"`S<'@@9&]U8FQE)SXF(WA!,#L\ M+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE M/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@,W!X(&1O=6)L92<^)B-X03`[/"]P M/@T*(#PO=&0^#0H@/'1D/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O M='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^ M#0H@/'`@<W1Y;&4],T0G0D]21$52+51/4#H@(S`P,#`P,"`S<'@@9&]U8FQE M)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T* M(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@,W!X(&1O=6)L92<^ M)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D/B8C>$$P.SPO=&0^#0H@/"]T<CX- M"B`\+W1A8FQE/@T*(#QP('-T>6QE/3-$)TU!4D=)3BU"3U143TTZ(#!P>#L@ M34%21TE.+51/4#H@,3)P>#L@5$585"U)3D1%3E0Z(#0E)R!A;&EG;CTS1&IU M<W1I9GD^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2 M;VUA;B<@<VEZ93TS1#(^26YT97)E<W0@:6YC;VUE(&%N9"!O=&AE<B!I;F-O M;64@:6X@86QL('!E<FEO9',@<')I;6%R:6QY#0H@8V]N<VES=&5D(&]F(&EN M=&5R97-T(&EN8V]M92!G96YE<F%T960@9G)O;2!T:&4@0V]M<&%N>28C>#(P M,3D[<PT*(&-A<V@L(&-A<V@@97%U:79A;&5N=',@86YD(&EN=F5S=&UE;G1S M+CPO9F]N=#X\+W`^#0H@/'`@<W1Y;&4],T0G34%21TE.+4)/5%1/33H@,'!X M.R!-05)'24XM5$]0.B`Q,G!X.R!415A4+4E.1$5.5#H@-"4G(&%L:6=N/3-$ M:G5S=&EF>3X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W M(%)O;6%N)R!S:7IE/3-$,CY);G1E<F5S="!E>'!E;G-E(&%N9"!O=&AE<B!E M>'!E;G-E(&EN(#(P,3,@8V]N<VES=&5D('-O;&5L>2!O9@T*(&YE="!G86EN M<R!R96%L:7IE9"!U<&]N(&1I<W!O<V%L(&]F(&5Q=6EP;65N="X@26YT97)E M<W0@97AP96YS92!A;F0-"B!O=&AE<B!E>'!E;G-E(&EN(#(P,3(@<')I;6%R M:6QY(&-O;G-I<W1E9"!O9B!I;G1E<F5S="!E>'!E;G-E(&]N#0H@8F]R<F]W M:6YG<R!U;F1E<B!E<75I<&UE;G0@9FEN86YC:6YG(&QI;F5S+CPO9F]N=#X\ M+W`^#0H@/"]D:78^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T* M("`@(#PO=&%B;&4^#0H@(#PO8F]D>3X-"CPO:'1M;#X-"@T*+2TM+2TM/5]. M97AT4&%R=%\S.6,P96$V,E]C,C`S7S0U.&9?.&,U,%\S9&-A-#4V838Y-3$- M"D-O;G1E;G0M3&]C871I;VXZ(&9I;&4Z+R\O0SHO,SEC,&5A-C)?8S(P,U\T M-3AF7SAC-3!?,V1C830U-F$V.34Q+U=O<FMS:&5E=',O4VAE970R,BYH=&UL M#0I#;VYT96YT+51R86YS9F5R+45N8V]D:6YG.B!Q=6]T960M<')I;G1A8FQE M#0I#;VYT96YT+51Y<&4Z('1E>'0O:'1M;#L@8VAA<G-E=#TB=7,M87-C:6DB M#0H-"CQH=&UL/@T*("`\:&5A9#X-"B`@("`\345402!H='1P+65Q=6EV/3-$ M0V]N=&5N="U4>7!E(&-O;G1E;G0],T0G=&5X="]H=&UL.R!C:&%R<V5T/75T M9BTX)SX\<V-R:7!T('1Y<&4],T1T97AT+VIA=F%S8W)I<'0@<W)C/3-$4VAO M=RYJ<SXO*B!$;R!.;W0@4F5M;W9E(%1H:7,@0V]M;65N="`J+SPO<V-R:7!T M/CPO:&5A9#X-"B`@/&)O9'D^#0H@("`@/'1A8FQE(&-L87-S/3-$<F5P;W)T M(&ED/3-$240P14U%/@T*("`@("`@/'1R/@T*("`@("`@("`\=&@@8VQA<W,] M,T1T;"!C;VQS<&%N/3-$,2!R;W=S<&%N/3-$,CX\<W1R;VYG/E%U87)T97)L M>2!&:6YA;F-I86P@1&%T83QB<CX\+W-T<F]N9SX\+W1H/@T*("`@("`@("`\ M=&@@8VQA<W,],T1T:"!C;VQS<&%N/3-$,3XQ,B!-;VYT:',@16YD960\+W1H M/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<CX-"B`@("`@("`@/'1H(&-L87-S M/3-$=&@^1&5C+B`S,2P@,C`Q-#QB<CX\+W1H/@T*("`@("`@/"]T<CX-"B`@ M("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V M86QI9VX],T1T;W`^/'-T<F]N9SY1=6%R=&5R;'D@1FEN86YC:6%L($EN9F]R M;6%T:6]N($1I<V-L;W-U<F4@6T%B<W1R86-T73PO<W1R;VYG/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT M9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y1=6%R=&5R;'D@1FEN86YC:6%L M($1A=&$\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQD:78^#0H@ M/'`@<W1Y;&4],T0G34%21TE.+4)/5%1/33H@,'!X.R!-05)'24XM5$]0.B`Q M.'!X)SX\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O M;6%N)R!S:7IE/3-$,CX\8CY.;W1E(#$U("8C>#(P,30[#0H@475A<G1E<FQY M($9I;F%N8VEA;"!$871A("A5;F%U9&ET960I/"]B/CPO9F]N=#X\+W`^#0H@ M/'`@<W1Y;&4],T0G34%21TE.+4)/5%1/33H@,'!X.R!-05)'24XM5$]0.B`V M<'@[(%1%6%0M24Y$14Y4.B`T)2<@86QI9VX],T1J=7-T:69Y/CQF;VYT('-T M>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R M/E%U87)T97)L>2!R97-U;'1S('=E<F4@87,@9F]L;&]W<R`H:6X@=&AO=7-A M;F1S+"!E>&-E<'0@<&5R#0H@<VAA<F4@9&%T82DZ/"]F;VYT/CPO<#X-"B`\ M<"!S='EL93TS1"=-05)'24XM0D]45$]-.B`P<'@[($9/3E0M4TE:13H@,3)P M>#L@34%21TE.+51/4#H@,'!X)SX-"B`F(WA!,#L\+W`^#0H@/'1A8FQE('-T M>6QE/3-$)T)/4D1%4BU#3TQ,05!313H@8V]L;&%P<V4G(&-E;&QS<&%C:6YG M/3-$,"!C96QL<&%D9&EN9STS1#`@=VED=&@],T0Q,#`E(&%L:6=N/3-$8V5N M=&5R(&)O<F1E<CTS1#`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`[ M/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE M/3-$,3XF(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@<W1Y;&4],T0G M0D]21$52+4)/5%1/33H@(S`P,#`P,"`Q<'@@<V]L:60G('9A;&EG;CTS1&)O M='1O;2!C;VQS<&%N/3-$,B!A;&EG;CTS1&-E;G1E<CX\9F]N="!S='EL93TS M1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,3X\8CY& M:7)S=#QB<B`O/@T*(%%U87)T97(\+V(^/"]F;VYT/CPO=&0^#0H@/'1D('9A M;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF(WA!,#L\+V9O;G0^/"]T M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C>$$P M.SPO9F]N=#X\+W1D/@T*(#QT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B`C M,#`P,#`P(#%P>"!S;VQI9"<@=F%L:6=N/3-$8F]T=&]M(&-O;'-P86X],T0R M(&%L:6=N/3-$8V5N=&5R/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4 M:6UE<R!.97<@4F]M86XG('-I>F4],T0Q/CQB/E-E8V]N9#QB<B`O/@T*(%%U M87)T97(\+V(^/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\ M9F]N="!S:7IE/3-$,3XF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N M/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C>$$P.SPO9F]N=#X\+W1D/@T* M(#QT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B`C,#`P,#`P(#%P>"!S;VQI M9"<@=F%L:6=N/3-$8F]T=&]M(&-O;'-P86X],T0R(&%L:6=N/3-$8V5N=&5R M/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG M('-I>F4],T0Q/CQB/E1H:7)D/&)R("\^#0H@475A<G1E<CPO8CX\+V9O;G0^ M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C M>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@ M<VEZ93TS1#$^)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('-T>6QE/3-$)T)/ M4D1%4BU"3U143TTZ(",P,#`P,#`@,7!X('-O;&ED)R!V86QI9VX],T1B;W1T M;VT@8V]L<W!A;CTS1#(@86QI9VX],T1C96YT97(^/&9O;G0@<W1Y;&4],T0G M1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#$^/&(^1F]U M<G1H/&)R("\^#0H@475A<G1E<CPO8CX\+V9O;G0^/"]T9#X-"B`\=&0@=F%L M:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C>$$P.SPO9F]N=#X\+W1D M/@T*(#PO='(^#0H@/'1R(&)G8V]L;W(],T0C0T-%149&/@T*(#QT9"!V86QI M9VX],T1T;W`^#0H@/'`@<W1Y;&4],T0G34%21TE.+4Q%1E0Z(#%E;3L@5$58 M5"U)3D1%3E0Z("TQ96TG/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4 M:6UE<R!.97<@4F]M86XG('-I>F4],T0R/CQB/C(P,30\+V(^/"]F;VYT/CPO M<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<VEZ93TS M1#$^)B-X03`[)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O M='1O;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\=&0@ M=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\ M9F]N="!S:7IE/3-$,3XF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N M/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T* M(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T M=&]M/CQF;VYT('-I>F4],T0Q/B8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V M86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI9VX] M,T1B;W1T;VT^/&9O;G0@<VEZ93TS1#$^)B-X03`[/"]F;VYT/CPO=&0^#0H@ M/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T M;VT^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/"]T<CX- M"B`\='(^#0H@/'1D('9A;&EG;CTS1'1O<#X-"B`\<"!S='EL93TS1"=-05)' M24XM3$5&5#H@,F5M.R!415A4+4E.1$5.5#H@+3%E;2<^/&9O;G0@<W1Y;&4] M,T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^5&]T M86P@<F5V96YU97,\+V9O;G0^/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS M1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF(WA!,#LF(WA!,#L\+V9O;G0^/"]T M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)T9/3E0M M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R/B0\+V9O;G0^/"]T M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^/&9O;G0@ M<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS M1#(^-RPY-SD\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO M=W)A<#TS1&YO=W)A<#X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM M97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXF(WA!,#LF(WA!,#L\+V9O;G0^/"]T M9#X-"B`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`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O M;3X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N M)R!S:7IE/3-$,CXD/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O M;2!A;&EG;CTS1')I9VAT/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4 M:6UE<R!.97<@4F]M86XG('-I>F4],T0R/CDL-#$U/"]F;VYT/CPO=&0^#0H@ M/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^/&9O;G0@<W1Y M;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^ M)B-X03`[)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O M;3X\9F]N="!S:7IE/3-$,3XF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L M:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE M<R!.97<@4F]M86XG('-I>F4],T0R/B0\+V9O;G0^/"]T9#X-"B`\=&0@=F%L M:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^/&9O;G0@<W1Y;&4],T0G1D]. M5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^,C$L-S4X/"]F M;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R M87`^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA M;B<@<VEZ93TS1#(^)B-X03`[)B-X03`[/"]F;VYT/CPO=&0^#0H@/"]T<CX- M"B`\='(@8F=C;VQO<CTS1"-#0T5%1D8^#0H@/'1D('9A;&EG;CTS1'1O<#X- M"B`\<"!S='EL93TS1"=-05)'24XM3$5&5#H@,F5M.R!415A4+4E.1$5.5#H@ M+3%E;2<^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2 M;VUA;B<@<VEZ93TS1#(^3F5T(&EN8V]M90T*("AL;W-S*3PO9F]N=#X\+W`^ M#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q M/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T M;VT^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA M;B<@<VEZ93TS1#(^)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS M1&)O='1O;2!A;&EG;CTS1')I9VAT/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%- M24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R/B@X+#<T-#PO9F]N=#X\ M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P/CQF M;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I M>F4],T0R/BDF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T M=&]M/CQF;VYT('-I>F4],T0Q/B8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V M86QI9VX],T1B;W1T;VT^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I M;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^)B-X03`[/"]F;VYT/CPO=&0^#0H@ M/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/CQF;VYT('-T>6QE M/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R/B@X M+#,W-#PO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P M/3-$;F]W<F%P/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!. M97<@4F]M86XG('-I>F4],T0R/BDF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@ M=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C>$$P.SPO9F]N=#X\ M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<W1Y;&4],T0G1D]. M5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^)B-X03`[/"]F M;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT M/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG M('-I>F4],T0R/B@U+#DW,3PO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B M;W1T;VT@;F]W<F%P/3-$;F]W<F%P/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%- M24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R/BDF(WA!,#L\+V9O;G0^ M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C M>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@ M<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS M1#(^)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A M;&EG;CTS1')I9VAT/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE M<R!.97<@4F]M86XG('-I>F4],T0R/C@L-#0S/"]F;VYT/CPO=&0^#0H@/'1D M('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^/&9O;G0@<W1Y;&4] M,T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^)B-X M03`[)B-X03`[/"]F;VYT/CPO=&0^#0H@/"]T<CX-"B`\='(^#0H@/'1D('9A M;&EG;CTS1'1O<#X-"B`\<"!S='EL93TS1"=-05)'24XM3$5&5#H@,F5M.R!4 M15A4+4E.1$5.5#H@+3%E;2<^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ M(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^3F5T(&EN8V]M92`H;&]S<RD@ M86QL;V-A8FQE#0H@=&\@8V]M;6]N('-T;V-K:&]L9&5R<SPO9F]N=#X\+W`^ M#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q M/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T M;VT^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA M;B<@<VEZ93TS1#(^)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS M1&)O='1O;2!A;&EG;CTS1')I9VAT/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%- M24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R/B@X+#<T-#PO9F]N=#X\ M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P/CQF M;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I M>F4],T0R/BDF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T M=&]M/CQF;VYT('-I>F4],T0Q/B8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V M86QI9VX],T1B;W1T;VT^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I M;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^)B-X03`[/"]F;VYT/CPO=&0^#0H@ M/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/CQF;VYT('-T>6QE M/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R/B@X M+#,W-#PO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P M/3-$;F]W<F%P/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!. M97<@4F]M86XG('-I>F4],T0R/BDF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@ M=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C>$$P.SPO9F]N=#X\ M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<W1Y;&4],T0G1D]. M5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^)B-X03`[/"]F M;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT M/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG M('-I>F4],T0R/B@U+#DW,3PO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B M;W1T;VT@;F]W<F%P/3-$;F]W<F%P/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%- M24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R/BDF(WA!,#L\+V9O;G0^ M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C M>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@ M<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS M1#(^)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A M;&EG;CTS1')I9VAT/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE M<R!.97<@4F]M86XG('-I>F4],T0R/C@L-#0S/"]F;VYT/CPO=&0^#0H@/'1D M('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^/&9O;G0@<W1Y;&4] M,T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^)B-X M03`[)B-X03`[/"]F;VYT/CPO=&0^#0H@/"]T<CX-"B`\='(@8F=C;VQO<CTS M1"-#0T5%1D8^#0H@/'1D('9A;&EG;CTS1'1O<#X-"B`\<"!S='EL93TS1"=- M05)'24XM3$5&5#H@,F5M.R!415A4+4E.1$5.5#H@+3%E;2<^/&9O;G0@<W1Y M;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^ M3F5T(&EN8V]M92`H;&]S<RD@<&5R('-H87)E#0H@86QL;V-A8FQE('1O(&-O M;6UO;B!S=&]C:VAO;&1E<G,@)B-X,C`Q-#L@8F%S:6,@86YD#0H@9&EL=71E M9#PO9F]N=#X\+W`^#0H@/"]T9#X-"B`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`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`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`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C>$$P.SPO M9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<W1Y;&4] M,T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^)#PO M9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H M=#X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N M)R!S:7IE/3-$,CXP+C(S/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O M='1O;2!N;W=R87`],T1N;W=R87`^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U) M3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^)B-X03`[)B-X03`[/"]F M;VYT/CPO=&0^#0H@/"]T<CX-"B`\='(^#0H@/'1D('9A;&EG;CTS1'1O<#X- M"B`\<"!S='EL93TS1"=-05)'24XM3$5&5#H@,65M.R!415A4+4E.1$5.5#H@ M+3%E;2<^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2 M;VUA;B<@<VEZ93TS1#(^/&(^,C`Q,SPO8CX\+V9O;G0^/"]P/@T*(#PO=&0^ M#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF(WA!,#LF M(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^ M#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B M;W1T;VT^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4] M,T0Q/B8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^ M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG M;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@ M<VEZ93TS1#$^)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O M='1O;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\=&0@ M=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\ M9F]N="!S:7IE/3-$,3XF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N M/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T* M(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\+W1R/@T*(#QT<B!B9V-O M;&]R/3-$(T-#145&1CX-"B`\=&0@=F%L:6=N/3-$=&]P/@T*(#QP('-T>6QE M/3-$)TU!4D=)3BU,1494.B`R96T[(%1%6%0M24Y$14Y4.B`M,65M)SX\9F]N M="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE M/3-$,CY4;W1A;"!R979E;G5E<SPO9F]N=#X\+W`^#0H@/"]T9#X-"B`\=&0@ M=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C>$$P.R8C>$$P.SPO M9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<W1Y;&4] M,T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^)#PO M9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H M=#X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N M)R!S:7IE/3-$,CXX,C$\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T M=&]M(&YO=W)A<#TS1&YO=W)A<#X\9F]N="!S='EL93TS1"=&3TY4+49!34E, M63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXF(WA!,#LF(WA!,#L\+V9O M;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q M/B8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O M;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ M93TS1#(^)#PO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI M9VX],T1R:6=H=#X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@ M3F5W(%)O;6%N)R!S:7IE/3-$,CXQ+#`P.3PO9F]N=#X\+W1D/@T*(#QT9"!V M86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P/CQF;VYT('-T>6QE/3-$ M)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R/B8C>$$P M.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O M;G0@<VEZ93TS1#$^)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS M1&)O='1O;3X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W M(%)O;6%N)R!S:7IE/3-$,CXD/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS M1&)O='1O;2!A;&EG;CTS1')I9VAT/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%- M24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R/C0L-#8Y/"]F;VYT/CPO M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^/&9O M;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ M93TS1#(^)B-X03`[)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS M1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF(WA!,#L\+V9O;G0^/"]T9#X-"B`\ M=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9 M.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R/B0\+V9O;G0^/"]T9#X-"B`\ M=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^/&9O;G0@<W1Y;&4] M,T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^,C0L M,S0Y/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`] M,T1N;W=R87`^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE M=R!2;VUA;B<@<VEZ93TS1#(^)B-X03`[)B-X03`[/"]F;VYT/CPO=&0^#0H@ M/"]T<CX-"B`\='(^#0H@/'1D('9A;&EG;CTS1'1O<#X-"B`\<"!S='EL93TS M1"=-05)'24XM3$5&5#H@,F5M.R!415A4+4E.1$5.5#H@+3%E;2<^/&9O;G0@ M<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS M1#(^3F5T(&EN8V]M90T*("AL;W-S*3PO9F]N=#X\+W`^#0H@/"]T9#X-"B`\ M=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C>$$P.R8C>$$P M.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<W1Y M;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^ M)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG M;CTS1')I9VAT/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!. M97<@4F]M86XG('-I>F4],T0R/B@Q,BPV,3D\+V9O;G0^/"]T9#X-"B`\=&0@ M=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#X\9F]N="!S='EL93TS M1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXI)B-X M03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S M:7IE/3-$,3XF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T M=&]M/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M M86XG('-I>F4],T0R/B8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX] M,T1B;W1T;VT@86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS1"=&3TY4+49! M34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXH,34L,#0Q/"]F;VYT M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^ M/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@ M<VEZ93TS1#(^*28C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B M;W1T;VT^/&9O;G0@<VEZ93TS1#$^)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D M('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@ M5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXF(WA!,#L\+V9O;G0^/"]T9#X- M"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^/&9O;G0@<W1Y M;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^ M*#$R+#4X.#PO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W M<F%P/3-$;F]W<F%P/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE M<R!.97<@4F]M86XG('-I>F4],T0R/BDF(WA!,#L\+V9O;G0^/"]T9#X-"B`\ M=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C>$$P.SPO9F]N M=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<W1Y;&4],T0G M1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^)B-X03`[ M/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I M9VAT/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M M86XG('-I>F4],T0R/C8L-3,Q/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS M1&)O='1O;2!N;W=R87`],T1N;W=R87`^/&9O;G0@<W1Y;&4],T0G1D].5"U& M04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^)B-X03`[)B-X03`[ M/"]F;VYT/CPO=&0^#0H@/"]T<CX-"B`\='(@8F=C;VQO<CTS1"-#0T5%1D8^ M#0H@/'1D('9A;&EG;CTS1'1O<#X-"B`\<"!S='EL93TS1"=-05)'24XM3$5& M5#H@,F5M.R!415A4+4E.1$5.5#H@+3%E;2<^/&9O;G0@<W1Y;&4],T0G1D]. M5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^3F5T(&EN8V]M M92`H;&]S<RD@86QL;V-A8FQE#0H@=&\@8V]M;6]N('-T;V-K:&]L9&5R<SPO M9F]N=#X\+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT M('-I>F4],T0Q/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI M9VX],T1B;W1T;VT^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S M($YE=R!2;VUA;B<@<VEZ93TS1#(^)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D M('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/CQF;VYT('-T>6QE/3-$ M)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R/B@Q,BPV M,3D\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS M1&YO=W)A<#X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W M(%)O;6%N)R!S:7IE/3-$,CXI)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A M;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF(WA!,#L\+V9O;G0^/"]T M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)T9/3E0M M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R/B8C>$$P.SPO9F]N M=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#X\ M9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S M:7IE/3-$,CXH,34L,#0Q/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O M='1O;2!N;W=R87`],T1N;W=R87`^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U) M3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^*28C>$$P.SPO9F]N=#X\ M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<VEZ93TS1#$^)B-X M03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S M='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$ M,CXF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L M:6=N/3-$<FEG:'0^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S M($YE=R!2;VUA;B<@<VEZ93TS1#(^*#$R+#4X.#PO9F]N=#X\+W1D/@T*(#QT M9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P/CQF;VYT('-T>6QE M/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R/BDF M(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT M('-I>F4],T0Q/B8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B M;W1T;VT^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2 M;VUA;B<@<VEZ93TS1#(^)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG M;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/CQF;VYT('-T>6QE/3-$)T9/3E0M M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R/C8L-3,Q/"]F;VYT M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^ M/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@ M<VEZ93TS1#(^)B-X03`[)B-X03`[/"]F;VYT/CPO=&0^#0H@/"]T<CX-"B`\ M='(^#0H@/'1D('9A;&EG;CTS1'1O<#X-"B`\<"!S='EL93TS1"=-05)'24XM M3$5&5#H@,F5M.R!415A4+4E.1$5.5#H@+3%E;2<^/&9O;G0@<W1Y;&4],T0G M1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^3F5T(&EN M8V]M92`H;&]S<RD@<&5R('-H87)E#0H@86QL;V-A8FQE('1O(&-O;6UO;B!S M=&]C:VAO;&1E<G,@)B-X,C`Q-#L@8F%S:6,\+V9O;G0^/"]P/@T*(#PO=&0^ M#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF(WA!,#LF M(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT M('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4] M,T0R/B0\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N M/3-$<FEG:'0^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE M=R!2;VUA;B<@<VEZ93TS1#(^*#`N-3,\+V9O;G0^/"]T9#X-"B`\=&0@=F%L M:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#X\9F]N="!S='EL93TS1"=& M3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXI)B-X03`[ M/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE M/3-$,3XF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M M/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG M('-I>F4],T0R/B0\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M M(&%L:6=N/3-$<FEG:'0^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I M;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^*#`N-3@\+V9O;G0^/"]T9#X-"B`\ M=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#X\9F]N="!S='EL M93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXI M)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N M="!S:7IE/3-$,3XF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$ M8F]T=&]M/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@ M4F]M86XG('-I>F4],T0R/B0\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$ M8F]T=&]M(&%L:6=N/3-$<FEG:'0^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U) M3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^*#`N-#,\+V9O;G0^/"]T M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#X\9F]N M="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE M/3-$,CXI)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O M;3X\9F]N="!S:7IE/3-$,3XF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L M:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE M<R!.97<@4F]M86XG('-I>F4],T0R/B0\+V9O;G0^/"]T9#X-"B`\=&0@=F%L M:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^/&9O;G0@<W1Y;&4],T0G1D]. M5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^,"XR,CPO9F]N M=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P M/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG M('-I>F4],T0R/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#PO='(^#0H@ M/'1R(&)G8V]L;W(],T0C0T-%149&/@T*(#QT9"!V86QI9VX],T1T;W`^#0H@ M/'`@<W1Y;&4],T0G34%21TE.+4Q%1E0Z(#)E;3L@5$585"U)3D1%3E0Z("TQ M96TG/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M M86XG('-I>F4],T0R/DYE="!I;F-O;64@*&QO<W,I('!E<B!S:&%R90T*(&%L M;&]C86)L92!T;R!C;VUM;VX@<W1O8VMH;VQD97)S("8C>#(P,30[(&1I;'5T M960\+V9O;G0^/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\ M9F]N="!S:7IE/3-$,3XF(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@ M=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4 M:6UE<R!.97<@4F]M86XG('-I>F4],T0R/B0\+V9O;G0^/"]T9#X-"B`\=&0@ M=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^/&9O;G0@<W1Y;&4],T0G M1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^*#`N-3,\ M+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO M=W)A<#X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O M;6%N)R!S:7IE/3-$,CXI)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG M;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF(WA!,#L\+V9O;G0^/"]T9#X- M"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%- M24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R/B0\+V9O;G0^/"]T9#X- M"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^/&9O;G0@<W1Y M;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^ M*#`N-3@\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A M<#TS1&YO=W)A<#X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@ M3F5W(%)O;6%N)R!S:7IE/3-$,CXI)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D M('9A;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF(WA!,#L\+V9O;G0^ M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)T9/ M3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R/B0\+V9O;G0^ M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^/&9O M;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ M93TS1#(^*#`N-#,\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M M(&YO=W)A<#TS1&YO=W)A<#X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@ M5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXI)B-X03`[/"]F;VYT/CPO=&0^ M#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF(WA!,#L\ M+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE M/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R/B0\ M+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG M:'0^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA M;B<@<VEZ93TS1#(^,"XR,3PO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B M;W1T;VT@;F]W<F%P/3-$;F]W<F%P/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%- M24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R/B8C>$$P.R8C>$$P.SPO M9F]N=#X\+W1D/@T*(#PO='(^#0H@/"]T86)L93X-"B`\+V1I=CX\<W!A;CX\ M+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@/"]T86)L93X-"B`@/"]B M;V1Y/@T*/"]H=&UL/@T*#0HM+2TM+2T]7TYE>'1087)T7S,Y8S!E838R7V,R M,#-?-#4X9E\X8S4P7S-D8V$T-39A-CDU,0T*0V]N=&5N="U,;V-A=&EO;CH@ M9FEL93HO+R]#.B\S.6,P96$V,E]C,C`S7S0U.&9?.&,U,%\S9&-A-#4V838Y M-3$O5V]R:W-H965T<R]3:&5E=#(S+FAT;6P-"D-O;G1E;G0M5')A;G-F97(M M16YC;V1I;F<Z('%U;W1E9"UP<FEN=&%B;&4-"D-O;G1E;G0M5'EP93H@=&5X M="]H=&UL.R!C:&%R<V5T/2)U<RUA<V-I:2(-"@T*/&AT;6P^#0H@(#QH96%D M/@T*("`@(#Q-151!(&AT='`M97%U:78],T1#;VYT96YT+51Y<&4@8V]N=&5N M=#TS1"=T97AT+VAT;6P[(&-H87)S970]=71F+3@G/CQS8W)I<'0@='EP93TS M1'1E>'0O:F%V87-C<FEP="!S<F,],T13:&]W+FIS/B\J($1O($YO="!296UO M=F4@5&AI<R!#;VUM96YT("HO/"]S8W)I<'0^/"]H96%D/@T*("`\8F]D>3X- M"B`@("`\=&%B;&4@8VQA<W,],T1R97!O<G0@:60],T1)1#!%,T=!13X-"B`@ M("`@(#QT<CX-"B`@("`@("`@/'1H(&-L87-S/3-$=&P@8V]L<W!A;CTS1#$@ M<F]W<W!A;CTS1#(^/'-T<F]N9SY/<F=A;FEZ871I;VX@86YD(%-I9VYI9FEC M86YT($%C8V]U;G1I;F<@4&]L:6-I97,@*%!O;&EC:65S*3QB<CX\+W-T<F]N M9SX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:"!C;VQS<&%N/3-$,3XQ M,B!-;VYT:',@16YD960\+W1H/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<CX- M"B`@("`@("`@/'1H(&-L87-S/3-$=&@^1&5C+B`S,2P@,C`Q-#QB<CX\+W1H M/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@ M("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^/'-T<F]N9SY!8V-O=6YT M:6YG(%!O;&EC:65S(%M!8G-T<F%C=%T\+W-T<F]N9SX\+W1D/@T*("`@("`@ M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@ M/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA M<W,],T1P;"!V86QI9VX],T1T;W`^3W)G86YI>F%T:6]N/"]T9#X-"B`@("`@ M("`@/'1D(&-L87-S/3-$=&5X=#X\9&EV/@T*(#QP('-T>6QE/3-$)TU!4D=) M3BU"3U143TTZ(#!P>#L@34%21TE.+4Q%1E0Z(#(E.R!-05)'24XM5$]0.B`V M<'@G/@T*(#QF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@ M4F]M86XG('-I>F4],T0R/CQB/CQI/D]R9V%N:7IA=&EO;CPO:3X\+V(^/"]F M;VYT/CPO<#X-"B`\<"!S='EL93TS1"=-05)'24XM0D]45$]-.B`P<'@[($U! M4D=)3BU43U`Z(#9P>#L@5$585"U)3D1%3E0Z(#0E)R!A;&EG;CTS1&IU<W1I M9GD^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA M;B<@<VEZ93TS1#(^0WET;VMI;F5T:6-S+"!);F-O<G!O<F%T960@*'1H92`F M(W@R,#%#.T-O;7!A;GDF(W@R,#%$.RP-"B`F(W@R,#%#.W=E)B-X,C`Q1#L@ M;W(@)B-X,C`Q0SMO=7(F(W@R,#%$.RD@=V%S(&EN8V]R<&]R871E9"!U;F1E M<B!T:&4-"B!L87=S(&]F('1H92!S=&%T92!O9B!$96QA=V%R92!O;B!!=6=U M<W0F(WA!,#LU+"`Q.3DW+B!4:&4@0V]M<&%N>0T*(&ES(&$@8VQI;FEC86P@ M<W1A9V4@8FEO<&AA<FUA8V5U=&EC86P@8V]M<&%N>2!F;V-U<V5D(&]N('1H M90T*(&1I<V-O=F5R>2!A;F0@9&5V96QO<&UE;G0@;V8@;F]V96P@<VUA;&P@ M;6]L96-U;&4@=&AE<F%P975T:6-S('1H870-"B!M;V1U;&%T92!M=7-C;&4@ M9G5N8W1I;VX@9F]R('1H92!P;W1E;G1I86P@=')E871M96YT(&]F('-E<FEO M=7,-"B!D:7-E87-E<R!A;F0@;65D:6-A;"!C;VYD:71I;VYS+CPO9F]N=#X\ M+W`^#0H@/'`@<W1Y;&4],T0G34%21TE.+4)/5%1/33H@,'!X.R!-05)'24XM M5$]0.B`Q,G!X.R!415A4+4E.1$5.5#H@-"4G(&%L:6=N/3-$:G5S=&EF>3X\ M9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S M:7IE/3-$,CY4:&4@0V]M<&%N>2!W87,@:6X@=&AE(&1E=F5L;W!M96YT('-T M86=E(&%T($1E8V5M8F5R)B-X03`[,S$L#0H@,C`Q,BP@87,@9&5F:6YE9"!I M;B!&:6YA;F-I86P@06-C;W5N=&EN9R!3=&%N9&%R9',@0F]A<F0-"B`H)B-X M,C`Q0SM&05-")B-X,C`Q1#LI($%C8V]U;G1I;F<@4W1A;F1A<F1S($-O9&EF M:6-A=&EO;@T*("@F(W@R,#%#.T%30R8C>#(P,40[*2!4;W!I8R`Y,34L("8C M>#(P,4,[/&D^1&5V96QO<&UE;G0@4W1A9V4-"B!%;G1I=&EE<SPO:3XN)B-X M,C`Q1#L@1'5R:6YG('1H92!Y96%R(&5N9&5D($1E8V5M8F5R)B-X03`[,S$L M(#(P,3,L#0H@=&AE($-O;7!A;GD@97AI=&5D('1H92!D979E;&]P;65N="!S M=&%G92!W:71H('1H92!E>&5C=71I;VX@;V8@=&AE#0H@06UG96X@06=R965M M96YT($%M96YD;65N="!A;F0@=&AE($]R:6=I;F%L($%S=&5L;&%S($%G<F5E M;65N="`H4V5E#0H@3F]T92`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`D-#0N."!M:6QL:6]N M(&9O<@T*('1H92!Y96%R(&5N9&5D($1E8V5M8F5R)B-X03`[,S$L(#(P,30N M($-A<V@L(&-A<V@@97%U:79A;&5N=',@86YD#0H@:6YV97-T;65N=',@:6YC M<F5A<V5D('1O("0X,RXR(&UI;&QI;VX@870@1&5C96UB97(F(WA!,#LS,2P@ M,C`Q-`T*(&9R;VT@)#@P+C(F(WA!,#MM:6QL:6]N(&%T($1E8V5M8F5R)B-X M03`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`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`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`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`T*(')E<W5L=',L(&9I;F%N8VEA;"!P;W-I=&EO;B!A;F0@8V%S:"!F M;&]W<RX\+V9O;G0^/"]P/@T*(#QP('-T>6QE/3-$)TU!4D=)3BU"3U143TTZ M(#!P>#L@34%21TE.+51/4#H@,3)P>#L@5$585"U)3D1%3E0Z(#0E)R!A;&EG M;CTS1&IU<W1I9GD^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S M($YE=R!2;VUA;B<@<VEZ93TS1#(^0F%S960@;VX@=&AE(&-U<G)E;G0@<W1A M='5S(&]F(&ET<R!R97-E87)C:"!A;F0@9&5V96QO<&UE;G0-"B!P;&%N<RP@ M=&AE($-O;7!A;GD@8F5L:65V97,@=&AA="!I=',@97AI<W1I;F<@8V%S:"P@ M8V%S:`T*(&5Q=6EV86QE;G1S(&%N9"!I;G9E<W1M96YT<R!A="!$96-E;6)E M<B8C>$$P.S,Q+"`R,#$T('=I;&P@8F4-"B!S=69F:6-I96YT('1O(&9U;F0@ M:71S(&-A<V@@<F5Q=6ER96UE;G1S(&9O<B!A="!L96%S="!T:&4@;F5X=`T* M(#$R)B-X03`[;6]N=&AS+B!)9BP@870@86YY('1I;64L('1H92!#;VUP86YY M)B-X,C`Q.3MS('!R;W-P96-T<R!F;W(-"B!F:6YA;F-I;F<@:71S(')E<V5A M<F-H(&%N9"!D979E;&]P;65N="!P<F]G<F%M<R!D96-L:6YE+"!T:&4-"B!# M;VUP86YY(&UA>2!D96-I9&4@=&\@<F5D=6-E(')E<V5A<F-H(&%N9"!D979E M;&]P;65N="!E>'!E;G-E<R!B>0T*(&1E;&%Y:6YG+"!D:7-C;VYT:6YU:6YG M(&]R(')E9'5C:6YG(&ET<R!F=6YD:6YG(&]F(&]N92!O<B!M;W)E(&]F#0H@ M:71S(')E<V5A<F-H(&]R(&1E=F5L;W!M96YT('!R;V=R86US+B!!;'1E<FYA M=&EV96QY+"!T:&4@0V]M<&%N>0T*(&UI9VAT(')A:7-E(&9U;F1S('1H<F]U M9V@@<W1R871E9VEC(&-O;&QA8F]R871I;VYS+"!P=6)L:6,@;W(-"B!P<FEV M871E(&9I;F%N8VEN9W,@;W(@;W1H97(@87)R86YG96UE;G1S+B!3=6-H(&9U M;F1I;F<L(&EF(&YE961E9"P-"B!M87D@;F]T(&)E(&%V86EL86)L92!O;B!F M879O<F%B;&4@=&5R;7,L(&]R(&%T(&%L;"X@5&AE(&9I;F%N8VEA;`T*('-T M871E;65N=',@9&\@;F]T(&EN8VQU9&4@86YY(&%D:G5S=&UE;G1S('1H870@ M;6EG:'0@<F5S=6QT(&9R;VT-"B!T:&4@;W5T8V]M92!O9B!T:&ES('5N8V5R M=&%I;G1Y+CPO9F]N=#X\+W`^#0H@/"]D:78^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@ M(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y5<V4@;V8@17-T:6UA=&5S M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\9&EV/@T*(#QP('-T M>6QE/3-$)TU!4D=)3BU"3U143TTZ(#!P>#L@34%21TE.+4Q%1E0Z(#(E.R!- M05)'24XM5$]0.B`P<'@G/@T*(#QF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9 M.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R/CQB/CQI/E5S92!O9@T*($5S M=&EM871E<SPO:3X\+V(^/"]F;VYT/CPO<#X-"B`\<"!S='EL93TS1"=-05)' M24XM0D]45$]-.B`P<'@[($U!4D=)3BU43U`Z(#9P>#L@5$585"U)3D1%3E0Z M(#0E)R!A;&EG;CTS1&IU<W1I9GD^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U) M3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^5&AE('!R97!A<F%T:6]N M(&]F(&9I;F%N8VEA;"!S=&%T96UE;G1S(&EN(&-O;F9O<FUI='D@=VET:`T* M(&%C8V]U;G1I;F<@<')I;F-I<&QE<R!G96YE<F%L;'D@86-C97!T960@:6X@ M=&AE(%5N:71E9"!3=&%T97,-"B!R97%U:7)E<R!M86YA9V5M96YT('1O(&UA M:V4@97-T:6UA=&5S(&%N9"!A<W-U;7!T:6]N<R!T:&%T(&%F9F5C=`T*('1H M92!R97!O<G1E9"!A;6]U;G1S(&]F(&%S<V5T<R!A;F0@;&EA8FEL:71I97,@ M86YD(&1I<V-L;W-U<F5S(&]F#0H@8V]N=&EN9V5N="!A<W-E=',@86YD(&QI M86)I;&ET:65S(&%T('1H92!D871E(&]F('1H92!F:6YA;F-I86P-"B!S=&%T M96UE;G1S(&%N9"!T:&4@<F5P;W)T960@86UO=6YT<R!O9B!R979E;G5E<R!A M;F0@97AP96YS97,@9'5R:6YG#0H@=&AE(')E<&]R=&EN9R!P97)I;V0N($%C M='5A;"!R97-U;'1S(&-O=6QD(&1I9F9E<B!F<F]M('1H;W-E#0H@97-T:6UA M=&5S+CPO9F]N=#X\+W`^#0H@/"]D:78^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT M9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y"87-I<R!O9B!0<F5S96YT871I M;VX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQD:78^#0H@/'`@ M<W1Y;&4],T0G34%21TE.+4)/5%1/33H@,'!X.R!-05)'24XM3$5&5#H@,B4[ M($U!4D=)3BU43U`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`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T* M("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^0V]N8V5N=')A M=&EO;B!O9B!#<F5D:70@4FES:R!A;F0@3W1H97(@4FES:W,@86YD(%5N8V5R M=&%I;G1I97,\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQD:78^ M#0H@/'`@<W1Y;&4],T0G34%21TE.+4)/5%1/33H@,'!X.R!-05)'24XM3$5& M5#H@,B4[($U!4D=)3BU43U`Z(#$X<'@G/@T*(#QF;VYT('-T>6QE/3-$)T9/ M3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R/CQB/CQI/D-O M;F-E;G1R871I;VX@;V8@0W)E9&ET(%)I<VL@86YD($]T:&5R(%)I<VMS(&%N M9`T*(%5N8V5R=&%I;G1I97,\+VD^/"]B/CPO9F]N=#X\+W`^#0H@/'`@<W1Y M;&4],T0G34%21TE.+4)/5%1/33H@,'!X.R!-05)'24XM5$]0.B`V<'@[(%1% M6%0M24Y$14Y4.B`T)2<@86QI9VX],T1J=7-T:69Y/CQF;VYT('-T>6QE/3-$ M)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R/D9I;F%N M8VEA;"!I;G-T<G5M96YT<R!T:&%T('!O=&5N=&EA;&QY('-U8FIE8W0@=&AE M($-O;7!A;GD@=&\-"B!C;VYC96YT<F%T:6]N<R!O9B!R:7-K(&-O;G-I<W0@ M<')I;F-I<&%L;'D@;V8@8V%S:"!A;F0@8V%S:`T*(&5Q=6EV86QE;G1S+"!I M;G9E<W1M96YT<R!A;F0@86-C;W5N=',@<F5C96EV86)L92X\+V9O;G0^/"]P M/@T*(#QP('-T>6QE/3-$)TU!4D=)3BU"3U143TTZ(#!P>#L@34%21TE.+51/ M4#H@,3)P>#L@5$585"U)3D1%3E0Z(#0E)R!A;&EG;CTS1&IU<W1I9GD^/&9O M;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ M93TS1#(^5&AE($-O;7!A;GDF(W@R,#$Y.W,@8V%S:"P@8V%S:"!E<75I=F%L M96YT<R!A;F0@:6YV97-T;65N=',@87)E#0H@:6YV97-T960@:6X@9&5P;W-I M=',@=VET:"!T:')E92!M86IO<B!F:6YA;F-I86P@:6YS=&ET=71I;VYS(&EN M('1H90T*(%5N:71E9"!3=&%T97,N)B-X03`[1&5P;W-I=',@:6X@=&AE<V4@ M8F%N:W,@;6%Y(&5X8V5E9"!T:&4@86UO=6YT#0H@;V8@:6YS=7)A;F-E('!R M;W9I9&5D(&]N('-U8V@@9&5P;W-I=',N(%1H92!#;VUP86YY(&AA<R!N;W0- M"B!E>'!E<FEE;F-E9"!A;GD@<F5A;&EZ960@;&]S<V5S(&]N(&ET<R!D97!O M<VET<R!O9B!C87-H+"!C87-H#0H@97%U:79A;&5N=',@;W(@:6YV97-T;65N M=',N/"]F;VYT/CPO<#X-"B`\<"!S='EL93TS1"=-05)'24XM0D]45$]-.B`P M<'@[($U!4D=)3BU43U`Z(#$R<'@[(%1%6%0M24Y$14Y4.B`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`T*(&]P97)A=&EN9R!R97-U M;'1S(&%N9"!F:6YA;F-I86P@8V]N9&ET:6]N+CPO9F]N=#X\+W`^#0H@/'`@ M<W1Y;&4],T0G34%21TE.+4)/5%1/33H@,'!X.R!-05)'24XM5$]0.B`Q,G!X M.R!415A4+4E.1$5.5#H@-"4G(&%L:6=N/3-$:G5S=&EF>3X\9F]N="!S='EL M93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CY4 M:&4@0V]M<&%N>2!P97)F;W)M<R!A;B!O;F=O:6YG(&-R961I="!E=F%L=6%T M:6]N(&]F(&ET<PT*('-T<F%T96=I8R!P87)T;F5R<R8C>#(P,3D[(&9I;F%N M8VEA;"!C;VYD:71I;VYS(&%N9"!G96YE<F%L;'D@9&]E<PT*(&YO="!R97%U M:7)E(&-O;&QA=&5R86P@=&\@<V5C=7)E(&%C8V]U;G1S(')E8V5I=F%B;&4@ M9G)O;2!I=',-"B!S=')A=&5G:6,@<&%R=&YE<G,N(%1H92!#;VUP86YY)B-X M,C`Q.3MS(&5X<&]S=7)E('1O(&-R961I="!R:7-K#0H@87-S;V-I871E9"!W M:71H(&YO;BUP87EM96YT('=I;&P@8F4@869F96-T960@<')I;F-I<&%L;'D@ M8GD-"B!C;VYD:71I;VYS(&]R(&]C8W5R<F5N8V5S('=I=&AI;B!!;6=E;B!) M;F,N("@F(W@R,#%#.T%M9V5N)B-X,C`Q1#LI#0H@86YD($%S=&5L;&%S(%!H M87)M82!);F,N("@F(W@R,#%#.T%S=&5L;&%S)B-X,C`Q1#LI+"!I=',@<W1R M871E9VEC#0H@<&%R=&YE<G,N($%P<')O>&EM871E;'D@,3`E+"`V,R4@86YD M(#4U)2!O9B!T;W1A;"!R979E;G5E<R!F;W(@=&AE#0H@>65A<G,@96YD960@ M1&5C96UB97(F(WA!,#LS,2P@,C`Q-"P@,C`Q,R!A;F0@,C`Q,BP@<F5S<&5C M=&EV96QY+`T*('=E<F4@9&5R:79E9"!F<F]M($%M9V5N+B!!8V-O=6YT<R!R M96-E:79A8FQE(&1U92!F<F]M($%M9V5N('=E<F4-"B`D,2XV(&UI;&QI;VX@ M86YD('IE<F\@870@1&5C96UB97(F(WA!,#LS,2P@,C`Q-"!A;F0@,C`Q,RP- M"B!R97-P96-T:79E;'DN(%-E92!A;'-O($YO=&4F(WA!,#LW+"`F(W@R,#%# M.U)E;&%T960@4&%R='D-"B!4<F%N<V%C=&EO;G,L)B-X,C`Q1#L@<F5G87)D M:6YG('1H92!C;VQL86)O<F%T:6]N(&%G<F5E;65N="!W:71H#0H@06UG96XN M($%P<')O>&EM871E;'D@-CDE(&%N9"`S-"4@;V8@=&]T86P@<F5V96YU97,@ M9F]R('1H92!Y96%R<PT*(&5N9&5D($1E8V5M8F5R)B-X03`[,S$L(#(P,30@ M86YD(#(P,3,L(')E<W!E8W1I=F5L>2P@=V5R92!D97)I=F5D#0H@9G)O;2!! M<W1E;&QA<RX@06-C;W5N=',@<F5C96EV86)L92!D=64@9G)O;2!!<W1E;&QA M<R!W97)E("0T-2XP#0H@;6EL;&EO;B!A;F0@>F5R;R!A="!$96-E;6)E<B8C M>$$P.S,Q+"`R,#$T(&%N9"`R,#$S+"!R97-P96-T:79E;'DN#0H@4V5E(&%L M<V\@3F]T928C>$$P.S<L("8C>#(P,4,[4F5L871E9"!087)T>2!4<F%N<V%C M=&EO;G,L)B-X,C`Q1#L-"B!R96=A<F1I;F<@=&AE(&-O;&QA8F]R871I;VX@ M86=R965M96YT('=I=&@@07-T96QL87,N/"]F;VYT/CPO<#X-"B`\<"!S='EL M93TS1"=-05)'24XM0D]45$]-.B`P<'@[($U!4D=)3BU43U`Z(#$R<'@[(%1% M6%0M24Y$14Y4.B`T)2<@86QI9VX],T1J=7-T:69Y/CQF;VYT('-T>6QE/3-$ M)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R/D1R=6<@ M8V%N9&ED871E<R!D979E;&]P960@8GD@=&AE($-O;7!A;GD@;6%Y(')E<75I M<F4@87!P<F]V86QS#0H@;W(@8VQE87)A;F-E<R!F<F]M('1H92!5+E,N)B-X M03`[1F]O9"!A;F0@1')U9R!!9&UI;FES=')A=&EO;@T*("@F(W@R,#%#.T9$ M028C>#(P,40[*2!O<B!I;G1E<FYA=&EO;F%L(')E9W5L871O<GD@86=E;F-I M97,@<')I;W(@=&\-"B!C;VUM97)C:6%L:7IE9"!S86QE<RX@5&AE<F4@8V%N M(&)E(&YO(&%S<W5R86YC92!T:&%T('1H90T*($-O;7!A;GDF(W@R,#$Y.W,@ M9')U9R!C86YD:61A=&5S('=I;&P@<F5C96EV92!A;GD@;V8@=&AE(')E<75I M<F5D#0H@87!P<F]V86QS(&]R(&-L96%R86YC97,N($EF('1H92!#;VUP86YY M('=A<R!T;R!B92!D96YI960@87!P<F]V86P-"B!O<B!C;&5A<F%N8V4@;W(@ M86YY('-U8V@@87!P<F]V86P@;W(@8VQE87)A;F-E('=A<R!T;R!B92!D96QA M>65D+`T*(&ET('=O=6QD(&AA=F4@82!M871E<FEA;"!A9'9E<G-E(&EM<&%C M="!O;B!T:&4@0V]M<&%N>2X\+V9O;G0^/"]P/@T*(#QP('-T>6QE/3-$)TU! M4D=)3BU"3U143TTZ(#!P>#L@34%21TE.+51/4#H@,3)P>#L@5$585"U)3D1% M3E0Z(#0E)R!A;&EG;CTS1&IU<W1I9GD^/&9O;G0@<W1Y;&4],T0G1D].5"U& M04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^5&AE($-O;7!A;GDF M(W@R,#$Y.W,@;W!E<F%T:6]N<R!A;F0@96UP;&]Y965S(&%R92!L;V-A=&5D M(&EN('1H90T*(%5N:71E9"!3=&%T97,N($EN('1H92!Y96%R(&5N9&5D($1E M8V5M8F5R)B-X03`[,S$L(#(P,30L(#,Q)2!O9B!T:&4-"B!#;VUP86YY)B-X M,C`Q.3MS(')E=F5N=65S('=E<F4@<F5C96EV960@9G)O;2!E;G1I=&EE<R!L M;V-A=&5D(&EN('1H90T*(%5N:71E9"!3=&%T97,@86YD(#8Y)2!W97)E(')E M8V5I=F5D(&9R;VT@82!*87!A;F5S92!E;G1I='DN($EN('1H90T*('EE87(@ M96YD960@1&5C96UB97(F(WA!,#LS,2P@,C`Q,RP@-C8E(&]F('1H92!#;VUP M86YY)B-X,C`Q.3MS#0H@<F5V96YU97,@=V5R92!R96-E:79E9"!F<F]M(&5N M=&ET:65S(&QO8V%T960@:6X@=&AE(%5N:71E9"!3=&%T97,-"B!A;F0@,S0E M('=E<F4@<F5C96EV960@9G)O;2!A($IA<&%N97-E(&5N=&ET>2X@26X@=&AE M('EE87(@96YD960-"B!$96-E;6)E<B8C>$$P.S,Q+"`R,#$R+"!A;&P@;V8@ M=&AE($-O;7!A;GDF(W@R,#$Y.W,@<F5V96YU97,@=V5R90T*(')E8V5I=F5D M(&9R;VT@96YT:71I97,@;&]C871E9"!I;B!T:&4@56YI=&5D(%-T871E<R!O M<B!F<F]M(%5N:71E9`T*(%-T871E<R!A9F9I;&EA=&5S(&]F(&9O<F5I9VX@ M8V]R<&]R871I;VYS+CPO9F]N=#X\+W`^#0H@/"]D:78^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@ M("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y#87-H(&%N9"!# M87-H($5Q=6EV86QE;G1S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X M=#X\9&EV/@T*(#QP('-T>6QE/3-$)TU!4D=)3BU"3U143TTZ(#!P>#L@34%2 M1TE.+4Q%1E0Z(#(E.R!-05)'24XM5$]0.B`Q.'!X)SX-"B`\9F]N="!S='EL M93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CX\ M8CX\:3Y#87-H(&%N9`T*($-A<V@@17%U:79A;&5N=',\+VD^/"]B/CPO9F]N M=#X\+W`^#0H@/'`@<W1Y;&4],T0G34%21TE.+4)/5%1/33H@,'!X.R!-05)' M24XM5$]0.B`V<'@[(%1%6%0M24Y$14Y4.B`T)2<@86QI9VX],T1J=7-T:69Y M/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG M('-I>F4],T0R/E1H92!#;VUP86YY(&-O;G-I9&5R<R!A;&P@:&EG:&QY(&QI M<75I9"!I;G9E<W1M96YT<R!W:71H(&$-"B!M871U<FET>2!O9B!T:')E92!M M;VYT:',@;W(@;&5S<R!A="!T:&4@=&EM92!O9B!P=7)C:&%S92!T;R!B92!C M87-H#0H@97%U:79A;&5N=',N/"]F;VYT/CPO<#X-"B`\+V1I=CX\<W!A;CX\ M+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R M93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/DEN=F5S M=&UE;G1S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\9&EV/@T* M(#QP('-T>6QE/3-$)TU!4D=)3BU"3U143TTZ(#!P>#L@34%21TE.+4Q%1E0Z M(#(E.R!-05)'24XM5$]0.B`Q.'!X)SX-"B`\9F]N="!S='EL93TS1"=&3TY4 M+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CX\8CX\:3Y);G9E M<W1M96YT<SPO:3X\+V(^/"]F;VYT/CPO<#X-"B`\<"!S='EL93TS1"=-05)' M24XM0D]45$]-.B`P<'@[($U!4D=)3BU43U`Z(#9P>#L@5$585"U)3D1%3E0Z M(#0E)R!A;&EG;CTS1&IU<W1I9GD^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U) M3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^/&D^079A:6QA8FQE+69O M<BUS86QE#0H@:6YV97-T;65N=',N/"]I/B8C>$$P.R8C>$$P.R8C>$$P.R8C M>$$P.U1H92!#;VUP86YY)B-X,C`Q.3MS#0H@:6YV97-T;65N=',@8V]N<VES M="!O9B!5+E,N)B-X03`[5')E87-U<GD@<V5C=7)I=&EE<RP@;6]N97D@;6%R M:V5T#0H@9G5N9',L(%4N4RXF(WA!,#MM=6YI8VEP86P@86YD(&=O=F5R;FUE M;G0@86=E;F-Y(&)O;F1S+"!A;F0-"B!C;VUM97)C:6%L('!A<&5R+B!4:&4@ M0V]M<&%N>2!D97-I9VYA=&5S(&%L;"!I;G9E<W1M96YT<R!A<PT*(&%V86EL M86)L92UF;W(M<V%L92!A;F0@=&AE<F5F;W)E(')E<&]R=',@=&AE;2!A="!F M86ER('9A;'5E+"!B87-E9`T*(&]N('%U;W1E9"!M87)K960@<')I8V5S+"!W M:71H('5N<F5A;&EZ960@9V%I;G,@86YD(&QO<W-E<R!R96-O<F1E9`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`\<"!S='EL93TS1"=-05)'24XM0D]45$]-.B`P<'@[ M($U!4D=)3BU43U`Z(#$R<'@[(%1%6%0M24Y$14Y4.B`T)2<@86QI9VX],T1J M=7-T:69Y/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@ M4F]M86XG('-I>F4],T0R/CQI/D]T:&5R+71H86XM=&5M<&]R87)Y#0H@:6UP M86ER;65N="X\+VD^)B-X03`[)B-X03`[)B-X03`[)B-X03`[06QL(&]F('1H M92!#;VUP86YY)B-X,C`Q.3MS#0H@879A:6QA8FQE+69O<BUS86QE(&EN=F5S M=&UE;G1S(&%R92!S=6)J96-T('1O(&$@<&5R:6]D:6,@:6UP86ER;65N=`T* M(')E=FEE=RX@5&AE($-O;7!A;GD@<F5C;V=N:7IE<R!A;B!I;7!A:7)M96YT M(&-H87)G92!W:&5N(&$@9&5C;&EN90T*(&EN('1H92!F86ER('9A;'5E(&]F M(&ET<R!I;G9E<W1M96YT<R!B96QO=R!T:&4@8V]S="!B87-I<R!I<R!J=61G M960-"B!T;R!B92!O=&AE<BUT:&%N+71E;7!O<F%R>2X@1F%C=&]R<R!C;VYS M:61E<F5D(&)Y(&UA;F%G96UE;G0@:6X-"B!A<W-E<W-I;F<@=VAE=&AE<B!A M;B!O=&AE<BUT:&%N+71E;7!O<F%R>2!I;7!A:7)M96YT(&AA<R!O8V-U<G)E M9`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`^#0H@/"]D:78^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T* M("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L M('9A;&EG;CTS1'1O<#Y0<F]P97)T>2!A;F0@17%U:7!M96YT/"]T9#X-"B`@ M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\9&EV/@T*(#QP('-T>6QE/3-$)TU! M4D=)3BU"3U143TTZ(#!P>#L@34%21TE.+4Q%1E0Z(#(E.R!-05)'24XM5$]0 M.B`Q.'!X)SX-"B`\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@ M3F5W(%)O;6%N)R!S:7IE/3-$,CX\8CX\:3Y0<F]P97)T>0T*(&%N9"!%<75I M<&UE;G0\+VD^/"]B/CPO9F]N=#X\+W`^#0H@/'`@<W1Y;&4],T0G34%21TE. M+4)/5%1/33H@,'!X.R!-05)'24XM5$]0.B`V<'@[(%1%6%0M24Y$14Y4.B`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`T*(&%N9"!T:&4@<F5S=6QT M:6YG(&=A:6X@;W(@;&]S<R!I<R!R969L96-T960@:6X@;W!E<F%T:6]N<RX- M"B!-86EN=&5N86YC92!A;F0@<F5P86ER<R!A<F4@8VAA<F=E9"!T;R!O<&5R M871I;VYS(&%S#0H@:6YC=7)R960N/"]F;VYT/CPO<#X-"B`\+V1I=CX\<W!A M;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,] M,T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/DEM M<&%I<FUE;G0@;V8@3&]N9RUL:79E9"!!<W-E=',\+W1D/@T*("`@("`@("`\ M=&0@8VQA<W,],T1T97AT/CQD:78^#0H@/'`@<W1Y;&4],T0G34%21TE.+4)/ M5%1/33H@,'!X.R!-05)'24XM3$5&5#H@,B4[($U!4D=)3BU43U`Z(#$X<'@G M/@T*(#QF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M M86XG('-I>F4],T0R/CQB/CQI/DEM<&%I<FUE;G0@;V8@3&]N9RUL:79E9"!! M<W-E=',\+VD^/"]B/CPO9F]N=#X\+W`^#0H@/'`@<W1Y;&4],T0G34%21TE. M+4)/5%1/33H@,'!X.R!-05)'24XM5$]0.B`V<'@[(%1%6%0M24Y$14Y4.B`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`\+V1I=CX\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@ M("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L M:6=N/3-$=&]P/E)E=F5N=64@4F5C;V=N:71I;VX\+W1D/@T*("`@("`@("`\ M=&0@8VQA<W,],T1T97AT/CQD:78^#0H@/'`@<W1Y;&4],T0G34%21TE.+4)/ M5%1/33H@,'!X.R!-05)'24XM3$5&5#H@,B4[($U!4D=)3BU43U`Z(#$X<'@G M/@T*(#QF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M M86XG('-I>F4],T0R/CQB/CQI/E)E=F5N=64-"B!296-O9VYI=&EO;CPO:3X\ M+V(^/"]F;VYT/CPO<#X-"B`\<"!S='EL93TS1"=-05)'24XM0D]45$]-.B`P M<'@[($U!4D=)3BU43U`Z(#9P>#L@5$585"U)3D1%3E0Z(#0E)R!A;&EG;CTS M1&IU<W1I9GD^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE M=R!2;VUA;B<@<VEZ93TS1#(^5&AE(&%C8V]U;G1I;F<@9W5I9&%N8V4@9F]R M(')E=F5N=64@<F5C;V=N:71I;VX@<F5Q=6ER97,@=&AA=`T*('1H92!F;VQL M;W=I;F<@8W)I=&5R:6$@;75S="!B92!M970@8F5F;W)E(')E=F5N=64@8V%N M(&)E#0H@<F5C;V=N:7IE9#H@*&DI)B-X03`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`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`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`R,#$Q+"!!4T,@ M5&]P:6,@-C`U+3(U+"`\:3Y2979E;G5E(%)E8V]G;FET:6]N#0H@)B-X,C`Q M-#L@375L=&EP;&4M16QE;65N="!!<G)A;F=E;65N=',\+VD^("@F(W@R,#%# M.T%30PT*(#8P-2TR-28C>#(P,40[*2!O;B!T:&4@<F5C;V=N:71I;VX@;V8@ M<F5V96YU97,@9F]R(&%G<F5E;65N=',@=VET:`T*(&UU;'1I<&QE(&1E;&EV M97)A8FQE<R!B96-A;64@969F96-T:79E(&%N9"!A<'!L:65S('1O(&%N>0T* M(&%G<F5E;65N=',@=&AE($-O;7!A;GD@96YT97)E9"!I;G1O(&]N(&]R(&%F M=&5R($IA;G5A<GDF(WA!,#LQ+`T*(#(P,3$N(%5N9&5R('1H:7,@=7!D871E M9"!G=6ED86YC92P@<F5V96YU92!I<R!A;&QO8V%T960@=&\@96%C:`T*(&5L M96UE;G0@=7-I;F<@82!S96QL:6YG('!R:6-E(&AI97)A<F-H>2P@=VAE<F4@ M=&AE('-E;&QI;F<@<')I8V4-"B!F;W(@86X@96QE;65N="!I<R!B87-E9"!O M;B!64T]%(&EF(&%V86EL86)L93L@=&AI<F0M<&%R='D@979I9&5N8V4-"B`H M)B-X,C`Q0SM44$4F(W@R,#%$.RDL(&EF(&%V86EL86)L92!A;F0@5E-/12!I M<R!N;W0@879A:6QA8FQE.R!O<B!T:&4-"B!B97-T(&5S=&EM871E(&]F('-E M;&QI;F<@<')I8V4L(&EF(&YE:71H97(@5E-/12!N;W(@5%!%(&ES#0H@879A M:6QA8FQE+CPO9F]N=#X\+W`^#0H@/'`@<W1Y;&4],T0G34%21TE.+4)/5%1/ M33H@,'!X.R!-05)'24XM5$]0.B`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`F(W@R,#$T.R!-:6QE<W1O;F4-"B!-971H;V0\+VD^("@F(W@R,#%# M.T%30R`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`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`T*("AI:2DF(WA!,#MR96QA=&5S('-O;&5L>2!T;R!P87-T('!E M<F9O<FUA;F-E(&%N9"`H:6EI*28C>$$P.VES#0H@<F5A<V]N86)L92!R96QA M=&EV92!T;R!A;&P@9&5L:79E<F%B;&5S(&%N9"!P87EM96YT('1E<FUS(&EN M('1H90T*(&%R<F%N9V5M96YT+CPO9F]N=#X\+W`^#0H@/'`@<W1Y;&4],T0G M34%21TE.+4)/5%1/33H@,'!X.R!-05)'24XM5$]0.B`Q,G!X.R!415A4+4E. M1$5.5#H@-"4G(&%L:6=N/3-$:G5S=&EF>3X\9F]N="!S='EL93TS1"=&3TY4 M+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CY/=&AE<B!C;VYT M:6YG96YT(&5V96YT+6)A<V5D('!A>6UE;G1S(')E8V5I=F5D(&9O<B!W:&EC M:`T*('!A>6UE;G0@:7,@96ET:&5R(&-O;G1I;F=E;G0@<V]L96QY('5P;VX@ M=&AE('!A<W-A9V4@;V8@=&EM92!O<B!T:&4-"B!R97-U;'1S(&]F(&$@8V]L M;&%B;W)A=&EV92!P87)T;F5R)B-X,C`Q.3MS('!E<F9O<FUA;F-E(&%R92!N M;W0-"B!C;VYS:61E<F5D(&UI;&5S=&]N97,@=6YD97(@05-#(#8P-2TR."X@ M26X@86-C;W)D86YC92!W:71H($%30PT*(#8P-2TR-3QI/BP\+VD^('-U8V@@ M<&%Y;65N=',@=VEL;"!B92!R96-O9VYI>F5D(&%S(')E=F5N=64@=VAE;B!A M;&P-"B!O9B!T:&4@9F]L;&]W:6YG(&-R:71E<FEA(&%R92!M970Z("AI*28C M>$$P.W!E<G-U87-I=F4@979I9&5N8V4@;V8-"B!A;B!A<G)A;F=E;65N="!E M>&ES=',L("AI:2DF(WA!,#MD96QI=F5R>2!H87,@;V-C=7)R960@;W(@<V5R M=FEC97,-"B!H879E(&)E96X@<F5N9&5R960L("AI:6DI)B-X03`[<')I8V4@ M:7,@9FEX960@;W(@9&5T97)M:6YA8FQE+"!A;F0-"B`H:78I)B-X03`[8V]L M;&5C=&%B:6QI='D@:7,@<F5A<V]N86)L>2!A<W-U<F5D+CPO9F]N=#X\+W`^ M#0H@/'`@<W1Y;&4],T0G34%21TE.+4)/5%1/33H@,'!X.R!-05)'24XM5$]0 M.B`Q,G!X.R!415A4+4E.1$5.5#H@-"4G(&%L:6=N/3-$:G5S=&EF>3X\9F]N M="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE M/3-$,CY0<FEO<B!T;R!*86YU87)Y)B-X03`[,2P@,C`Q,2P@=&AE($-O;7!A M;GD@<F5C;V=N:7IE9"!A;F0@=VEL;`T*(&-O;G1I;G5E('1O(')E8V]G;FEZ M92!M:6QE<W1O;F4@<&%Y;65N=',@87,@<F5V96YU92!U<&]N#0H@86-H:65V M96UE;G0@;V8@=&AE(&UI;&5S=&]N92P@<')O=FED960@=&AE(&UI;&5S=&]N M92!P87EM96YT('=A<PT*(&YO;BUR969U;F1A8FQE+"!S=6)S=&%N=&EV92!E M9F9O<G0@86YD(')I<VL@=V5R92!I;G9O;'9E9"!I;@T*(&%C:&EE=FEN9R!T M:&4@;6EL97-T;VYE(&%N9"!T:&4@86UO=6YT(&]F('1H92!M:6QE<W1O;F4@ M=V%S#0H@<F5A<V]N86)L92!I;B!R96QA=&EO;B!T;R!T:&4@969F;W)T(&5X M<&5N9&5D(&]R(')I<VL@87-S;V-I871E9`T*('=I=&@@=&AE(&%C:&EE=F5M M96YT(&]F('1H92!M:6QE<W1O;F4N($EF('1H97-E(&-O;F1I=&EO;G,@=V5R M92!N;W0-"B!M970L('1H92!#;VUP86YY(&1E9F5R<F5D('1H92!M:6QE<W1O M;F4@<&%Y;65N="!A;F0@<F5C;V=N:7IE9"!I=`T*(&%S(')E=F5N=64@;W9E M<B!T:&4@97-T:6UA=&5D('!E<FEO9"!O9B!P97)F;W)M86YC92!U;F1E<B!T M:&4-"B!C;VYT<F%C="!A<R!T:&4@0V]M<&%N>2!C;VUP;&5T960@:71S('!E M<F9O<FUA;F-E(&]B;&EG871I;VYS+B!4:&4-"B!#;VUP86YY(&AA<R!C;VYC M;'5D960@=&AA="!A;&P@;V8@=&AE(&9U='5R92!C;VYT:6YG96YT(&UI;&5S M=&]N90T*('!A>6UE;G1S('!U<G-U86YT('1O(&ET<R!R97-E87)C:"!A;F0@ M9&5V96QO<&UE;G0@87)R86YG96UE;G1S#0H@96YT97)E9"!I;G1O('!R:6]R M('1O($IA;G5A<GDF(WA!,#LQ+"`R,#$Q(&%R92!N;W0@8V]N<VED97)E9`T* M('-U8G-T86YT:79E(&%S('1H97D@87)E('1H92!R97-U;'1S(&]F(&$@8V]L M;&%B;W)A=&EV90T*('!A<G1N97(F(W@R,#$Y.W,@<&5R9F]R;6%N8V4N(%1H M97)E9F]R92P@=&AE>2!A<F4@;F]T(&-O;G-I9&5R960-"B!M:6QE<W1O;F5S M('5N9&5R($%30R`V,#4M,C@N/"]F;VYT/CPO<#X-"B`\<"!S='EL93TS1"=- M05)'24XM0D]45$]-.B`P<'@[($U!4D=)3BU43U`Z(#$R<'@[(%1%6%0M24Y$ M14Y4.B`T)2<@86QI9VX],T1J=7-T:69Y/CQF;VYT('-T>6QE/3-$)T9/3E0M M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R/D9O<B!C;VQL86)O M<F%T:6]N<R!A;F0@;6%T97)I86P@;6]D:69I8V%T:6]N<R!E;G1E<F5D(&EN M=&\-"B!A9G1E<B!*86YU87)Y)B-X03`[,2P@,C`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`Q.3MS(&5F9F]R=`T*('1O(&%C:&EE=F4@=&AE(&UI;&5S M=&]N92!O<B!C;VUM96YS=7)A=&4@=VET:"!T:&4@96YH86YC960@=F%L=64@ M;V8-"B!T:&4@9&5L:79E<F5D(&ET96TH<RD@87,@82!R97-U;'0@;V8@=&AE M(&UI;&5S=&]N92!A8VAI979E;65N="X@268-"B!T:&4@0V]M<&%N>2!D971E M<FUI;F5S(&$@;6EL97-T;VYE(&ES(&YO="!S=6)S=&%N=&EV92P@=&AE($-O M;7!A;GD-"B!D969E<G,@=&AE('!A>6UE;G0@86YD(')E8V]G;FEZ97,@<F5V M96YU92!O=F5R('1H92!E<W1I;6%T960@<&5R:6]D#0H@;V8@<&5R9F]R;6%N M8V4@87,@=&AE($-O;7!A;GD@8V]M<&QE=&5S(&ET<R!P97)F;W)M86YC90T* M(&]B;&EG871I;VYS+CPO9F]N=#X\+W`^#0H@/'`@<W1Y;&4],T0G34%21TE. M+4)/5%1/33H@,'!X.R!-05)'24XM5$]0.B`Q,G!X.R!415A4+4E.1$5.5#H@ M-"4G(&%L:6=N/3-$:G5S=&EF>3X\9F]N="!S='EL93TS1"=&3TY4+49!34E, M63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CY297-E87)C:"!A;F0@9&5V M96QO<&UE;G0@<F5V96YU97,@86YD(&-O<W0@<F5I;6)U<G-E;65N=',@87)E M#0H@8F%S960@=7!O;B!N96=O=&EA=&5D(')A=&5S(&9O<B!T:&4@0V]M<&%N M>28C>#(P,3D[<R!F=6QL+71I;64-"B!E;7!L;WEE92!E<75I=F%L96YT<R`H M)B-X,C`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`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`^#0H@/'`@<W1Y;&4],T0G M34%21TE.+4)/5%1/33H@,'!X.R!&3TY4+5-)6D4Z(#$R<'@[($U!4D=)3BU4 M3U`Z(#!P>"<^#0H@)B-X03`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`T*(&9U;F1S(')E8V5I=F5D(&%R92!N;W0@ M<F5F=6YD86)L92!A;F0@87)E(')E8V]G;FEZ960@=VAE;B!T:&4-"B!R96QA M=&5D('%U86QI9FEE9"!R97-E87)C:"!A;F0@9&5V96QO<&UE;G0@8V]S=',@ M87)E(&EN8W5R<F5D(&%N9`T*('=H96X@=&AE<F4@:7,@<F5A<V]N86)L92!A M<W-U<F%N8V4@=&AA="!T:&4@9G5N9',@=VEL;"!B92!R96-E:79E9"X-"B!& M=6YD<R!R96-E:79E9"!I;B!A9'9A;F-E(&%R92!R96-O<F1E9"!A<R!D969E M<G)E9`T*(')E=F5N=64N/"]F;VYT/CPO<#X-"B`\+V1I=CX\<W!A;CX\+W-P M86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X- M"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E!R96-L:6YI M8V%L(%-T=61I97,@86YD($-L:6YI8V%L(%1R:6%L($%C8W)U86QS/"]T9#X- M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\9&EV/@T*(#QP('-T>6QE/3-$ M)TU!4D=)3BU"3U143TTZ(#!P>#L@34%21TE.+4Q%1E0Z(#(E.R!-05)'24XM M5$]0.B`Q.'!X)SX-"B`\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM M97,@3F5W(%)O;6%N)R!S:7IE/3-$,CX\8CX\:3Y0<F5C;&EN:6-A;"!3='5D M:65S(&%N9"!#;&EN:6-A;"!4<FEA;`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`T*(&EN(&5S=&EM871I;F<@86-C<G5A;',@:6YC;'5D M92!T:&4@;G5M8F5R(&]F('!A=&EE;G1S(&5N<F]L;&5D+`T*(&1U<F%T:6]N M(&]F(&5N<F]L;&UE;G0@86YD('!E<F-E;G1A9V4@;V8@=V]R:R!C;VUP;&5T M960@=&\@9&%T92X-"B!4:&4@0V]M<&%N>2!M;VYI=&]R<R!P871I96YT(&5N M<F]L;&UE;G0@;&5V96QS(&%N9"!R96QA=&5D#0H@86-T:79I=&EE<R!T;R!T M:&4@97AT96YT('!R86-T:6-A8FQE('1H<F]U9V@@:6YT97)N86P@<F5V:65W M<RP-"B!C;W)R97-P;VYD96YC92!A;F0@<W1A='5S(&UE971I;F=S('=I=&@@ M0U)/<RP@86YD(')E=FEE=R!O9@T*(&-O;G1R86-T=6%L('1E<FUS+B!4:&4@ M0V]M<&%N>28C>#(P,3D[<R!E<W1I;6%T97,@87)E(&1E<&5N9&5N="!O;@T* M('1H92!T:6UE;&EN97-S(&%N9"!A8V-U<F%C>2!O9B!D871A('!R;W9I9&5D M(&)Y(&ET<R!#4D]S(&%N9"!O=&AE<@T*('9E;F1O<G,N($EF('1H92!#;VUP M86YY(&AA<R!I;F-O;7!L971E(&]R(&EN86-C=7)A=&4@9&%T82P@:70@;6%Y M#0H@=6YD97(M(&]R(&]V97)E<W1I;6%T92!A8W1I=FET>2!L979E;',@87-S M;V-I871E9"!W:71H('9A<FEO=7,-"B!S='5D:65S(&]R('1R:6%L<R!A="!A M(&=I=F5N('!O:6YT(&EN('1I;64N($EN('1H:7,@979E;G0L(&ET(&-O=6QD M#0H@<F5C;W)D(&%D:G5S=&UE;G1S('1O(')E<V5A<F-H(&%N9"!D979E;&]P M;65N="!E>'!E;G-E<R!I;B!F=71U<F4-"B!P97)I;V1S('=H96X@=&AE(&%C M='5A;"!A8W1I=FET>2!L979E;"!B96-O;65S(&MN;W=N+B!.;R!M871E<FEA M;`T*(&%D:G5S=&UE;G1S('1O('!R96-L:6YI8V%L('-T=61Y(&%N9"!C;&EN M:6-A;"!T<FEA;"!E>'!E;G-E<R!H879E#0H@8F5E;B!R96-O9VYI>F5D('1O M(&1A=&4N/"]F;VYT/CPO<#X-"B`\+V1I=CX\<W!A;CX\+W-P86X^/"]T9#X- M"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@ M/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E)E<V5A<F-H(&%N9"!$979E M;&]P;65N="!%>'!E;F1I='5R97,\+W1D/@T*("`@("`@("`\=&0@8VQA<W,] M,T1T97AT/CQD:78^#0H@/'`@<W1Y;&4],T0G34%21TE.+4)/5%1/33H@,'!X M.R!-05)'24XM3$5&5#H@,B4[($U!4D=)3BU43U`Z(#$X<'@G/@T*(#QF;VYT M('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4] M,T0R/CQB/CQI/E)E<V5A<F-H#0H@86YD($1E=F5L;W!M96YT($5X<&5N9&ET M=7)E<SPO:3X\+V(^/"]F;VYT/CPO<#X-"B`\<"!S='EL93TS1"=-05)'24XM M0D]45$]-.B`P<'@[($U!4D=)3BU43U`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`@("`@/"]T<CX- M"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P M;"!V86QI9VX],T1T;W`^4F5T:7)E;65N="!0;&%N/"]T9#X-"B`@("`@("`@ M/'1D(&-L87-S/3-$=&5X=#X\9&EV/@T*(#QP('-T>6QE/3-$)TU!4D=)3BU" M3U143TTZ(#!P>#L@34%21TE.+4Q%1E0Z(#(E.R!-05)'24XM5$]0.B`Q.'!X M)SX-"B`\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O M;6%N)R!S:7IE/3-$,CX\8CX\:3Y2971I<F5M96YT(%!L86X\+VD^/"]B/CPO M9F]N=#X\+W`^#0H@/'`@<W1Y;&4],T0G34%21TE.+4)/5%1/33H@,'!X.R!- M05)'24XM5$]0.B`V<'@[(%1%6%0M24Y$14Y4.B`T)2<@86QI9VX],T1J=7-T M:69Y/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M M86XG('-I>F4],T0R/E1H92!#;VUP86YY('-P;VYS;W)S(&$@-#`Q*&LI(&1E M9FEN960@8V]N=')I8G5T:6]N('!L86X-"B!C;W9E<FEN9R!A;&P@96UP;&]Y M965S+B!4:&5R92!W97)E(&YO(&5M<&QO>65R(&-O;G1R:6)U=&EO;G,@=&\@ M=&AE#0H@<&QA;B!F<F]M(&EN8V5P=&EO;B!T:')O=6=H($1E8V5M8F5R)B-X M03`[,S$L(#(P,3,N($EN(#(P,30L#0H@96UP;&]Y97(@8V]N=')I8G5T:6]N M<R!T;R!T:&4@-#`Q*&LI('!L86X@=V5R92`D,S,V+#`P,"X\+V9O;G0^/"]P M/@T*(#PO9&EV/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@ M("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V M86QI9VX],T1T;W`^26YC;VUE(%1A>&5S/"]T9#X-"B`@("`@("`@/'1D(&-L M87-S/3-$=&5X=#X\9&EV/@T*(#QP('-T>6QE/3-$)TU!4D=)3BU"3U143TTZ M(#!P>#L@34%21TE.+4Q%1E0Z(#(E.R!-05)'24XM5$]0.B`Q.'!X)SX-"B`\ M9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S M:7IE/3-$,CX\8CX\:3Y);F-O;64-"B!487AE<SPO:3X\+V(^/"]F;VYT/CPO M<#X-"B`\<"!S='EL93TS1"=-05)'24XM0D]45$]-.B`P<'@[($U!4D=)3BU4 M3U`Z(#9P>#L@5$585"U)3D1%3E0Z(#0E)R!A;&EG;CTS1&IU<W1I9GD^/&9O M;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ M93TS1#(^5&AE($-O;7!A;GD@86-C;W5N=',@9F]R(&EN8V]M92!T87AE<R!U M;F1E<B!T:&4@87-S970@86YD#0H@;&EA8FEL:71Y(&UE=&AO9"X@56YD97(@ M=&AI<R!M971H;V0L(&1E9F5R<F5D('1A>"!A<W-E=',@86YD#0H@;&EA8FEL M:71I97,@87)E(&1E=&5R;6EN960@8F%S960@;VX@=&AE(&1I9F9E<F5N8V4@ M8F5T=V5E;B!T:&4-"B!F:6YA;F-I86P@<W1A=&5M96YT(&%N9"!T87@@8F%S M:7,@;V8@87-S971S(&%N9"!L:6%B:6QI=&EE<R!U<VEN9PT*(&5N86-T960@ M=&%X(')A=&5S(&EN(&5F9F5C="!F;W(@=&AE('EE87(@:6X@=VAI8V@@=&AE M(&1I9F9E<F5N8V5S#0H@87)E(&5X<&5C=&5D('1O(&%F9F5C="!T87AA8FQE M(&EN8V]M92X@5F%L=6%T:6]N(&%L;&]W86YC97,@87)E#0H@97-T86)L:7-H M960@=VAE;B!N96-E<W-A<GD@=&\@<F5D=6-E(&1E9F5R<F5D('1A>"!A<W-E M=',@=&\@=&AE#0H@86UO=6YT<R!E>'!E8W1E9"!T;R!B92!R96%L:7IE9"X\ M+V9O;G0^/"]P/@T*(#QP('-T>6QE/3-$)TU!4D=)3BU"3U143TTZ(#!P>#L@ M34%21TE.+51/4#H@,3)P>#L@5$585"U)3D1%3E0Z(#0E)R!A;&EG;CTS1&IU M<W1I9GD^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2 M;VUA;B<@<VEZ93TS1#(^5&AE($-O;7!A;GD@86QS;R!F;VQL;W=S('1H92!A M8V-O=6YT:6YG(&=U:61A;F-E('1H870@9&5F:6YE<PT*('1H92!T:')E<VAO M;&0@9F]R(')E8V]G;FEZ:6YG('1H92!B96YE9FET<R!O9B!T87@@<F5T=7)N M('!O<VET:6]N<PT*(&EN('1H92!F:6YA;F-I86P@<W1A=&5M96YT<R!A<R`F M(W@R,#%#.VUO<F4M;&EK96QY+71H86XM;F]T)B-X,C`Q1#L-"B!T;R!B92!S M=7-T86EN960@8GD@=&AE('1A>&EN9R!A=71H;W)I=&EE<R!B87-E9"!S;VQE M;'D@;VX@=&AE#0H@=&5C:&YI8V%L(&UE<FET<R!O9B!T:&4@<&]S:71I;VXN M($EF('1H92!R96-O9VYI=&EO;B!T:')E<VAO;&0@:7,-"B!M970L('1H92!T M87@@8F5N969I="!I<R!M96%S=7)E9"!A;F0@<F5C;V=N:7IE9"!A<R!T:&4@ M;&%R9V5S=`T*(&%M;W5N="!O9B!T87@@8F5N969I="!T:&%T+"!I;B!T:&4@ M0V]M<&%N>28C>#(P,3D[<R!J=61G;65N="P@:7,-"B!G<F5A=&5R('1H86X@ M-3`E(&QI:V5L>2!T;R!B92!R96%L:7IE9"X\+V9O;G0^/"]P/@T*(#PO9&EV M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C M;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T M;W`^0V]M<')E:&5N<VEV92!,;W-S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S M/3-$=&5X=#X\9&EV/@T*(#QP('-T>6QE/3-$)TU!4D=)3BU"3U143TTZ(#!P M>#L@34%21TE.+4Q%1E0Z(#(E.R!-05)'24XM5$]0.B`P<'@G/@T*(#QF;VYT M('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4] M,T0R/CQB/CQI/D-O;7!R96AE;G-I=F4@3&]S<SPO:3X\+V(^/"]F;VYT/CPO M<#X-"B`\<"!S='EL93TS1"=-05)'24XM0D]45$]-.B`P<'@[($U!4D=)3BU4 M3U`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`H;&]S<RD@=VAI M8V@@<F5P;&%C960@=&AE#0H@<W1A=&5M96YT(&]F(&]P97)A=&EO;G,N($-O M;7!R96AE;G-I=F4@;&]S<R!I;F-L=61E<R!A;&P@8VAA;F=E<R!I;@T*('-T M;V-K:&]L9&5R<R8C>#(P,3D[(&5Q=6ET>2!D=7)I;F<@82!P97)I;V0@9G)O M;2!N;VXM;W=N97(@<V]U<F-E<RX-"B!#;VUP<F5H96YS:79E(&QO<W,@9F]R M(&5A8V@@;V8@=&AE('EE87)S(&5N9&5D($1E8V5M8F5R)B-X03`[,S$L#0H@ M,C`Q-"P@,C`Q,RP@86YD(#(P,3(@=V%S(&5Q=6%L('1O(&YE="!L;W-S(&%D M:G5S=&5D(&9O<B!U;G)E86QI>F5D#0H@9V%I;G,@86YD(&QO<W-E<R!O;B!I M;G9E<W1M96YT<RX\+V9O;G0^/"]P/@T*(#PO9&EV/CQS<&%N/CPO<W!A;CX\ M+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@ M("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^4V5G;65N="!297!O M<G1I;F<\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQD:78^#0H@ M/'`@<W1Y;&4],T0G34%21TE.+4)/5%1/33H@,'!X.R!-05)'24XM3$5&5#H@ M,B4[($U!4D=)3BU43U`Z(#$X<'@G/@T*(#QF;VYT('-T>6QE/3-$)T9/3E0M M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R/CQB/CQI/E-E9VUE M;G0-"B!297!O<G1I;F<\+VD^/"]B/CPO9F]N=#X\+W`^#0H@/'`@<W1Y;&4] M,T0G34%21TE.+4)/5%1/33H@,'!X.R!-05)'24XM5$]0.B`V<'@[(%1%6%0M M24Y$14Y4.B`T)2<@86QI9VX],T1J=7-T:69Y/CQF;VYT('-T>6QE/3-$)T9/ M3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R/E1H92!#;VUP M86YY(&AA<R!D971E<FUI;F5D('1H870@:70@;W!E<F%T97,@:6X@;VYL>2!O M;F4-"B!S96=M96YT+CPO9F]N=#X\+W`^#0H@/"]D:78^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@ M("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y2979E<G-E(%-T M;V-K(%-P;&ET/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\9&EV M/@T*(#QP('-T>6QE/3-$)TU!4D=)3BU"3U143TTZ(#!P>#L@34%21TE.+4Q% M1E0Z(#(E.R!-05)'24XM5$]0.B`Q.'!X)SX-"B`\9F]N="!S='EL93TS1"=& M3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CX\8CX\:3Y2 M979E<G-E#0H@4W1O8VL@4W!L:70\+VD^/"]B/CPO9F]N=#X\+W`^#0H@/'`@ M<W1Y;&4],T0G34%21TE.+4)/5%1/33H@,'!X.R!-05)'24XM5$]0.B`V<'@[ M(%1%6%0M24Y$14Y4.B`T)2<@86QI9VX],T1J=7-T:69Y/CQF;VYT('-T>6QE M/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R/D]N M)B-X03`[2G5N928C>$$P.S(T+"`R,#$S+"!T:&4@0V]M<&%N>2!E9F9E8W1E M9"!A(&]N92UF;W(M<VEX#0H@<F5V97)S92!S=&]C:R!S<&QI="!O9B!I=',@ M8V]M;6]N('-T;V-K('1H<F]U9V@@86X@86UE;F1M96YT('1O(&ET<PT*(&%M M96YD960@86YD(')E<W1A=&5D(&-E<G1I9FEC871E(&]F(&EN8V]R<&]R871I M;VX@*'1H92`F(W@R,#%#.T-/20T*($%M96YD;65N="8C>#(P,40[*2X@07,@ M;V8@=&AE(&5F9F5C=&EV92!T:6UE(&]F('1H92!R979E<G-E('-T;V-K#0H@ M<W!L:70L(&5V97)Y('-I>"!S:&%R97,@;V8@=&AE($-O;7!A;GDF(W@R,#$Y M.W,@:7-S=65D(&%N9`T*(&]U='-T86YD:6YG(&-O;6UO;B!S=&]C:R!W97)E M(&-O;G9E<G1E9"!I;G1O(&]N92!I<W-U960@86YD#0H@;W5T<W1A;F1I;F<@ M<VAA<F4@;V8@8V]M;6]N('-T;V-K+"!W:71H;W5T(&%N>2!C:&%N9V4@:6X@ M<&%R('9A;'5E#0H@<&5R('-H87)E+B!4:&4@<F5V97)S92!S=&]C:R!S<&QI M="!A9F9E8W1E9"!A;&P@<VAA<F5S(&]F('1H90T*($-O;7!A;GDF(W@R,#$Y M.W,@8V]M;6]N('-T;V-K(&]U='-T86YD:6YG(&EM;65D:6%T96QY('!R:6]R M('1O('1H90T*(&5F9F5C=&EV92!T:6UE(&]F('1H92!R979E<G-E('-T;V-K M('-P;&ET+"!A<R!W96QL(&%S('1H92!N=6UB97(@;V8-"B!S:&%R97,@;V8@ M8V]M;6]N('-T;V-K(&%V86EL86)L92!F;W(@:7-S=6%N8V4@=6YD97(@=&AE M#0H@0V]M<&%N>28C>#(P,3D[<R!E<75I='D@:6YC96YT:79E('!L86YS+B!) M;B!A9&1I=&EO;BP@=&AE(')E=F5R<V4-"B!S=&]C:R!S<&QI="!E9F9E8W1E M9"!A(')E9'5C=&EO;B!I;B!T:&4@;G5M8F5R(&]F('-H87)E<R!O9B!C;VUM M;VX-"B!S=&]C:R!I<W-U86)L92!U<&]N('1H92!C;VYV97)S:6]N(&]F('-H M87)E<R!O9B!P<F5F97)R960@<W1O8VL@;W(-"B!U<&]N('1H92!E>&5R8VES M92!O9B!S=&]C:R!O<'1I;VYS(&]R('=A<G)A;G1S(&]U='-T86YD:6YG#0H@ M:6UM961I871E;'D@<')I;W(@=&\@=&AE(&5F9F5C=&EV96YE<W,@;V8@=&AE M(')E=F5R<V4@<W1O8VL@<W!L:70N#0H@3F\@9G)A8W1I;VYA;"!S:&%R97,@ M=V5R92!I<W-U960@87,@82!R97-U;'0@;V8@=&AE(')E=F5R<V4@<W1O8VL- M"B!S<&QI="X@4W1O8VMH;VQD97)S('=H;R!W;W5L9"!O=&AE<G=I<V4@:&%V M92!B965N(&5N=&ET;&5D('1O#0H@<F5C96EV92!A(&9R86-T:6]N86P@<VAA M<F4@<F5C96EV960@8V%S:"!P87EM96YT<R!I;B!L:65U('1H97)E;V8N#0H@ M26X@861D:71I;VXL('1H92!#3TD@06UE;F1M96YT(')E9'5C960@=&AE(&YU M;6)E<B!O9B!A=71H;W)I>F5D#0H@<VAA<F5S(&]F(&-O;6UO;B!S=&]C:R!T M;R`X,2XU)B-X03`[;6EL;&EO;BX\+V9O;G0^/"]P/@T*(#QP('-T>6QE/3-$ M)TU!4D=)3BU"3U143TTZ(#!P>#L@34%21TE.+51/4#H@,3)P>#L@5$585"U) M3D1%3E0Z(#0E)R!A;&EG;CTS1&IU<W1I9GD^/&9O;G0@<W1Y;&4],T0G1D]. M5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^07,@=&AE('!A M<B!V86QU92!P97(@<VAA<F4@;V8@=&AE($-O;7!A;GDF(W@R,#$Y.W,@8V]M M;6]N('-T;V-K#0H@<F5M86EN960@=6YC:&%N9V5D(&%T("0P+C`P,2!P97(@ M<VAA<F4L(&$@=&]T86P@;V8@)#$S.2PP,#`@=V%S#0H@<F5C;&%S<VEF:65D M(&9R;VT@8V]M;6]N('-T;V-K('1O(&%D9&ET:6]N86P@<&%I9"UI;B!C87!I M=&%L+B!!;&P-"B!R969E<F5N8V5S('1O('-H87)E<R!O9B!C;VUM;VX@<W1O M8VL@86YD('!E<B!S:&%R92!D871A(&9O<B!A;&P-"B!P97)I;V1S('!R97-E M;G1E9"!I;B!T:&4@86-C;VUP86YY:6YG(&9I;F%N8VEA;"!S=&%T96UE;G1S M(&%N9`T*(&YO=&5S('1H97)E=&\@:&%V92!B965N(&%D:G5S=&5D('1O(')E M9FQE8W0@=&AE(')E=F5R<V4@<W1O8VL@<W!L:70-"B!O;B!A(')E=')O86-T M:79E(&)A<VES+CPO9F]N=#X\+W`^#0H@/"]D:78^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@ M("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y3=&]C:RU"87-E9"!# M;VUP96YS871I;VX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQD M:78^#0H@/'`@<W1Y;&4],T0G34%21TE.+4)/5%1/33H@,'!X.R!-05)'24XM M3$5&5#H@,B4[($U!4D=)3BU43U`Z(#$X<'@G/@T*(#QF;VYT('-T>6QE/3-$ M)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R/CQB/CQI M/E-T;V-K+4)A<V5D($-O;7!E;G-A=&EO;CPO:3X\+V(^/"]F;VYT/CPO<#X- M"B`\<"!S='EL93TS1"=-05)'24XM0D]45$]-.B`P<'@[($U!4D=)3BU43U`Z M(#9P>#L@5$585"U)3D1%3E0Z(#0E)R!A;&EG;CTS1&IU<W1I9GD^/&9O;G0@ M<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS M1#(^5&AE($-O;7!A;GD@86-C;W5N=',@9F]R('-T;V-K+6)A<V5D('!A>6UE M;G0@87=A<F1S(&UA9&4@=&\-"B!E;7!L;WEE97,@86YD(&1I<F5C=&]R<RP@ M:6YC;'5D:6YG(&5M<&QO>65E('-T;V-K(&]P=&EO;G,@86YD#0H@96UP;&]Y M964@<W1O8VL@<'5R8VAA<V5S(&)Y(&UE87-U<FEN9R!T:&4@<W1O8VLM8F%S M960@8V]M<&5N<V%T:6]N#0H@8V]S="!A="!T:&4@9W)A;G0@9&%T92!B87-E M9"!O;B!T:&4@8V%L8W5L871E9"!F86ER('9A;'5E(&]F('1H90T*(&%W87)D M+"!A;F0@<F5C;V=N:7II;F<@97AP96YS92!O;B!A('-T<F%I9VAT+6QI;F4@ M8F%S:7,@;W9E<B!T:&4-"B!E;7!L;WEE928C>#(P,3D[<R!R97%U:7-I=&4@ M<V5R=FEC92!P97)I;V0L(&=E;F5R86QL>2!T:&4@=F5S=&EN9PT*('!E<FEO M9"!O9B!T:&4@87=A<F0N(%-T;V-K(&-O;7!E;G-A=&EO;B!F;W(@;F]N+65M M<&QO>65E<R!I<PT*(&UE87-U<F5D(&%T('1H92!F86ER('9A;'5E(&]F('1H M92!A=V%R9"!F;W(@96%C:"!P97)I;V0@=6YT:6P@=&AE#0H@87=A<F0@:7,@ M9G5L;'D@=F5S=&5D+CPO9F]N=#X\+W`^#0H@/'`@<W1Y;&4],T0G34%21TE. M+4)/5%1/33H@,'!X.R!-05)'24XM5$]0.B`Q,G!X.R!415A4+4E.1$5.5#H@ M-"4G(&%L:6=N/3-$:G5S=&EF>3X\9F]N="!S='EL93TS1"=&3TY4+49!34E, M63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CY4:&4@0V]M<&%N>2!R979I M97=S('1H92!V86QU871I;VX@87-S=6UP=&EO;G,@870@96%C:"!G<F%N=`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`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`^#0H@/"]D:78^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R M/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS M1'!L('9A;&EG;CTS1'1O<#Y296-E;G0@06-C;W5N=&EN9R!0<F]N;W5N8V5M M96YT<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/&1I=CX-"B`\ M<"!S='EL93TS1"=-05)'24XM0D]45$]-.B`P<'@[($U!4D=)3BU,1494.B`R M)3L@34%21TE.+51/4#H@,'!X)SX-"B`\9F]N="!S='EL93TS1"=&3TY4+49! M34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CX\8CX\:3Y296-E;G0- M"B!!8V-O=6YT:6YG(%!R;VYO=6YC96UE;G1S/"]I/CPO8CX\+V9O;G0^/"]P M/@T*(#QP('-T>6QE/3-$)TU!4D=)3BU"3U143TTZ(#!P>#L@34%21TE.+4Q% M1E0Z(#(E.R!-05)'24XM5$]0.B`V<'@G/@T*(#QF;VYT('-T>6QE/3-$)T9/ M3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R/CQI/E)E8V5N M=&QY#0H@061O<'1E9"!!8V-O=6YT:6YG(%!R;VYO=6YC96UE;G1S/"]I/CPO M9F]N=#X\+W`^#0H@/'`@<W1Y;&4],T0G34%21TE.+4)/5%1/33H@,'!X.R!- M05)'24XM5$]0.B`V<'@[(%1%6%0M24Y$14Y4.B`T)2<@86QI9VX],T1J=7-T M:69Y/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M M86XG('-I>F4],T0R/DEN($IU;'D@,C`Q,RP@=&AE($9!4T(@:7-S=65D($%3 M52`R,#$S+3$Q+"`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`T*('1A>"!A<W-E="!F;W(@82!N M970@;W!E<F%T:6YG(&QO<W,@8V%R<GEF;W)W87)D+"!A('-I;6EL87(@=&%X M#0H@;&]S<RP@;W(@82!T87@@8W)E9&ET(&-A<G)Y9F]R=V%R9"!W:&5N('-U M8V@@:71E;7,@97AI<W0@:6X@=&AE#0H@<V%M92!T87AI;F<@:G5R:7-D:6-T M:6]N+B!4:&4@0V]M<&%N>2!A9&]P=&5D($%352`R,#$S+3$Q(&5F9F5C=&EV M90T*($IA;G5A<GDF(WA!,#LQ+"`R,#$T(&%N9"!T:&4@861O<'1I;VX@;V8@ M05-5(#(P,3,M,3$@9&ED(&YO="!H879E(&$-"B!M871E<FEA;"!E9F9E8W0@ M;VX@:71S(&9I;F%N8VEA;"!S=&%T96UE;G1S+CPO9F]N=#X\+W`^#0H@/"]D M:78^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R M(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS M1'1O<#Y!8V-O=6YT:6YG(%!R;VYO=6YC96UE;G1S($YO="!9970@061O<'1E M9#PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/&1I=CX-"B`\<"!S M='EL93TS1"=-05)'24XM0D]45$]-.B`P<'@[($U!4D=)3BU,1494.B`R)3L@ M34%21TE.+51/4#H@,3AP>"<^#0H@/&9O;G0@<W1Y;&4],T0G1D].5"U&04U) M3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^/&D^06-C;W5N=&EN9PT* M(%!R;VYO=6YC96UE;G1S($YO="!9970@061O<'1E9#PO:3X\+V9O;G0^/"]P M/@T*(#QP('-T>6QE/3-$)TU!4D=)3BU"3U143TTZ(#!P>#L@34%21TE.+51/ M4#H@-G!X.R!415A4+4E.1$5.5#H@-"4G(&%L:6=N/3-$:G5S=&EF>3X\9F]N M="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE M/3-$,CY);B!.;W9E;6)E<B`R,#$T+"!T:&4@1D%30B!I<W-U960@05-5(#(P M,30M,3<L(#QI/D)U<VEN97-S#0H@0V]M8FEN871I;VYS("A4;W!I8R`X,#4I M("8C>#(P,30[(%!U<VAD;W=N($%C8V]U;G1I;F<@*&$@8V]N<V5N<W5S#0H@ M;V8@=&AE($9!4T(@16UE<F=I;F<@27-S=65S(%1A<VL@1F]R8V4I+CPO:3X@ M5&AI<R!G=6ED86YC92!P<F]V:61E<PT*('1H92!O<'1I;VX@9F]R(&%N(&%C M<75I<F5D(&5N=&ET>2!T;R!A<'!L>2!P=7-H9&]W;B!A8V-O=6YT:6YG(&EN M#0H@:71S('-E<&%R871E;'D@:7-S=65D(&9I;F%N8VEA;"!S=&%T96UE;G1S M('=H96X@82!C:&%N9V4M:6XM8V]N=')O;`T*(&5V96YT(&]C8W5R<RX@5&AI M<R!G=6ED86YC92!I<R!E9F9E8W1I=F4@8F5G:6YN:6YG#0H@3F]V96UB97(F M(WA!,#LQ."P@,C`Q-"P@86YD(&ES(&%P<&QI8V%B;&4@=&\@8VAA;F=E+6EN M+6-O;G1R;VP-"B!E=F5N=',@;V-C=7)R:6YG(&%F=&5R('1H870@9&%T92!O M<B!A<'!L:65D('1O('1H92!M;W-T(')E8V5N=`T*(&-H86YG92UI;BUC;VYT M<F]L(&5V96YT(&EF(&9I;F%N8VEA;"!S=&%T96UE;G1S(&AA=F4@;F]T('EE M="!B965N#0H@:7-S=65D+B!4:&4@0V]M<&%N>2!D;V5S(&YO="!E>'!E8W0@ M=&AE(&%D;W!T:6]N(&]F($%352`R,#$T+3$W('1O#0H@:&%V92!A(&UA=&5R M:6%L(&5F9F5C="!U<&]N(&ET<R!F:6YA;F-I86P@<W1A=&5M96YT<RX\+V9O M;G0^/"]P/@T*(#QP('-T>6QE/3-$)TU!4D=)3BU"3U143TTZ(#!P>#L@34%2 M1TE.+51/4#H@,3)P>#L@5$585"U)3D1%3E0Z(#0E)R!A;&EG;CTS1&IU<W1I M9GD^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA M;B<@<VEZ93TS1#(^26X@075G=7-T(#(P,30L('1H92!&05-"(&ES<W5E9"!! M4U4@,C`Q-"TQ-2P@/&D^4')E<V5N=&%T:6]N(&]F#0H@1FEN86YC:6%L(%-T M871E;65N=',@)B-X,C`Q-#L@1V]I;F<@0V]N8V5R;B`H4W5B=&]P:6,@,C`U M+30P*3H-"B!$:7-C;&]S=7)E(&]F(%5N8V5R=&%I;G1I97,@86)O=70@86X@ M16YT:71Y)B-X,C`Q.3MS($%B:6QI='D@=&\-"B!#;VYT:6YU92!A<R!A($=O M:6YG($-O;F-E<FXN/"]I/B!!4U4F(WA!,#LR,30M,34@<F5Q=6ER97,-"B!M M86YA9V5M96YT('1O(&%S<V5S<R!A;B!E;G1I='DF(W@R,#$Y.W,@86)I;&ET M>2!T;R!C;VYT:6YU92!A<R!A#0H@9V]I;F<@8V]N8V5R;BP@86YD('1O('!R M;W9I9&4@<F5L871E9"!F;V]T;F]T92!D:7-C;&]S=7)E<R!I;@T*(&-E<G1A M:6X@8VER8W5M<W1A;F-E<RX@05-5(#(P,30M,34@:7,@969F96-T:79E(&9O M<B!A;FYU86P@86YD#0H@:6YT97)I;2!R97!O<G1I;F<@<&5R:6]D<R!B96=I M;FYI;F<@;VX@;W(@869T97(@1&5C96UB97(F(WA!,#LQ-2P-"B`R,#$V(&%N M9"!E87)L>2!A9&]P=&EO;B!I<R!P97)M:71T960N(%1H92!#;VUP86YY(&1O M97,@;F]T(&5X<&5C=`T*('1H92!A9&]P=&EO;B!O9B!!4U4@,C`Q-"TQ-2!T M;R!H879E(&$@;6%T97)I86P@969F96-T('5P;VX@:71S#0H@9FEN86YC:6%L M('-T871E;65N=',N/"]F;VYT/CPO<#X-"B`\<"!S='EL93TS1"=-05)'24XM M0D]45$]-.B`P<'@[($U!4D=)3BU43U`Z(#$R<'@[(%1%6%0M24Y$14Y4.B`T M)2<@86QI9VX],T1J=7-T:69Y/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9 M.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R/DEN($UA>2`R,#$T+"!T:&4@ M1D%30B!I<W-U960@05-5(#(P,30M,#DL(#QI/E)E=F5N=64@9G)O;0T*($-O M;G1R86-T<R!W:71H($-U<W1O;65R<R`H5&]P:6,@-C`V*3PO:3XL('=H:6-H M('-U<&5R<V5D97,@=&AE#0H@<F5V96YU92!R96-O9VYI=&EO;B!R97%U:7)E M;65N=',@:6X@05-#(#8P-2P@/&D^4F5V96YU90T*(%)E8V]G;FET:6]N/"]I M/BX@05-5)B-X03`[,C`Q-"TP.2!S=&EP=6QA=&5S('1H870@86X@96YT:71Y M('-H;W5L9`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`Q-BP@86YD(&5A<FQY#0H@861O<'1I;VX@:7,@ M;F]T('!E<FUI='1E9"X@05-5)B-X03`[,C`Q-"TP.2!P97)M:71S('1H92!U M<V4@;V8@='=O#0H@=')A;G-I=&EO;B!M971H;V1S+"!E:71H97(@<F5T<F]S M<&5C=&EV96QY('1O(&5A8V@@<')I;W(@<F5P;W)T:6YG#0H@<&5R:6]D('!R M97-E;G1E9"!O<B!A<R!A(&-U;75L871I=F4M969F96-T(&%D:G5S=&UE;G0@ M87,@;V8@=&AE#0H@9&%T92!O9B!A9&]P=&EO;BX@5&AE($-O;7!A;GD@:&%S M(&YO="!Y970@<V5L96-T960@82!T<F%N<VET:6]N#0H@;65T:&]D+"!A;F0@ M:7,@8W5R<F5N=&QY(&5V86QU871I;F<@=&AE(&EM<&%C="!O9B!T:&4@861O M<'1I;VX@;V8-"B!!4U4F(WA!,#LR,#$T+3`Y(&]N(&ET<R!C;VYS;VQI9&%T M960@9FEN86YC:6%L#0H@<W1A=&5M96YT<RX\+V9O;G0^/"]P/@T*(#QP('-T M>6QE/3-$)TU!4D=)3BU"3U143TTZ(#!P>#L@34%21TE.+51/4#H@,3)P>#L@ M5$585"U)3D1%3E0Z(#0E)R!A;&EG;CTS1&IU<W1I9GD^/&9O;G0@<W1Y;&4] M,T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^26X@ M07!R:6P@,C`Q-"P@=&AE($9!4T(@:7-S=65D($%352`R,#$T+3`X+"`\:3Y2 M97!O<G1I;F<-"B!$:7-C;VYT:6YU960@3W!E<F%T:6]N<R!A;F0@1&ES8VQO M<W5R97,@;V8@1&ES<&]S86QS(&]F($-O;7!O;F5N=',-"B!O9B!A;B!%;G1I M='D\+VD^+B!!4U4@,C`Q-"TP."!C:&%N9V5S('1H92!C<FET97)I82!F;W(@ M9&5T97)M:6YI;F<-"B!W:&EC:"!D:7-P;W-A;',@8V%N(&)E('!R97-E;G1E M9"!A<R!D:7-C;VYT:6YU960@;W!E<F%T:6]N<R!A;F0-"B!M;V1I9FEE<R!R M96QA=&5D(&1I<V-L;W-U<F4@<F5Q=6ER96UE;G1S+B!4:&ES(&YE=R!G=6ED M86YC92!I<PT*(&5F9F5C=&EV92!F;W(@=&AE($-O;7!A;GD@8F5G:6YN:6YG M($IA;G5A<GDF(WA!,#LQ+"`R,#$U+B!4:&4-"B!#;VUP86YY(&1O97,@;F]T M(&5X<&5C="!T:&4@861O<'1I;VX@;V8@05-5(#(P,30M,#@@=&\@:&%V92!A M#0H@;6%T97)I86P@969F96-T('5P;VX@:71S(&9I;F%N8VEA;"!S=&%T96UE M;G1S+CPO9F]N=#X\+W`^#0H@/"]D:78^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`\+W1R/@T*("`@(#PO=&%B;&4^#0H@(#PO8F]D>3X-"CPO:'1M;#X- M"@T*+2TM+2TM/5].97AT4&%R=%\S.6,P96$V,E]C,C`S7S0U.&9?.&,U,%\S M9&-A-#4V838Y-3$-"D-O;G1E;G0M3&]C871I;VXZ(&9I;&4Z+R\O0SHO,SEC M,&5A-C)?8S(P,U\T-3AF7SAC-3!?,V1C830U-F$V.34Q+U=O<FMS:&5E=',O M4VAE970R-"YH=&UL#0I#;VYT96YT+51R86YS9F5R+45N8V]D:6YG.B!Q=6]T M960M<')I;G1A8FQE#0I#;VYT96YT+51Y<&4Z('1E>'0O:'1M;#L@8VAA<G-E M=#TB=7,M87-C:6DB#0H-"CQH=&UL/@T*("`\:&5A9#X-"B`@("`\345402!H M='1P+65Q=6EV/3-$0V]N=&5N="U4>7!E(&-O;G1E;G0],T0G=&5X="]H=&UL M.R!C:&%R<V5T/75T9BTX)SX\<V-R:7!T('1Y<&4],T1T97AT+VIA=F%S8W)I M<'0@<W)C/3-$4VAO=RYJ<SXO*B!$;R!.;W0@4F5M;W9E(%1H:7,@0V]M;65N M="`J+SPO<V-R:7!T/CPO:&5A9#X-"B`@/&)O9'D^#0H@("`@/'1A8FQE(&-L M87-S/3-$<F5P;W)T(&ED/3-$240P13)&/@T*("`@("`@/'1R/@T*("`@("`@ M("`\=&@@8VQA<W,],T1T;"!C;VQS<&%N/3-$,2!R;W=S<&%N/3-$,CX\<W1R M;VYG/DYE="!,;W-S(%!E<B!3:&%R92`H5&%B;&5S*3QB<CX\+W-T<F]N9SX\ M+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:"!C;VQS<&%N/3-$,3XQ,B!- M;VYT:',@16YD960\+W1H/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<CX-"B`@ M("`@("`@/'1H(&-L87-S/3-$=&@^1&5C+B`S,2P@,C`Q-#QB<CX\+W1H/@T* M("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\ M=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^/'-T<F]N9SY%87)N:6YG<R!0 M97(@4VAA<F4@6T%B<W1R86-T73PO<W1R;VYG/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R M/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS M1'!L('9A;&EG;CTS1'1O<#Y#86QC=6QA=&EO;B!O9B!"87-I8R!A;F0@1&EL M=71E9"!.970@3&]S<R!097(@4VAA<F4@06QL;V-A8FQE('1O($-O;6UO;B!3 M=&]C:VAO;&1E<G,\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQD M:78^#0H@/'`@<W1Y;&4],T0G34%21TE.+4)/5%1/33H@,'!X.R!-05)'24XM M5$]0.B`V<'@[(%1%6%0M24Y$14Y4.B`T)2<@86QI9VX],T1J=7-T:69Y/CQF M;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I M>F4],T0R/E1H92!F;VQL;W=I;F<@:7,@=&AE(&-A;&-U;&%T:6]N(&]F(&)A M<VEC(&%N9"!D:6QU=&5D(&YE="!L;W-S#0H@<&5R('-H87)E(&%L;&]C86)L M92!T;R!C;VUM;VX@<W1O8VMH;VQD97)S("AI;B!T:&]U<V%N9',@97AC97!T M('!E<@T*('-H87)E(&1A=&$I.CPO9F]N=#X\+W`^#0H@/'`@<W1Y;&4],T0G M34%21TE.+4)/5%1/33H@,'!X.R!&3TY4+5-)6D4Z(#$R<'@[($U!4D=)3BU4 M3U`Z(#!P>"<^#0H@)B-X03`[/"]P/@T*(#QT86)L92!S='EL93TS1"="3U)$ M15(M0T],3$%04T4Z(&-O;&QA<'-E)R!C96QL<W!A8VEN9STS1#`@8V5L;'!A M9&1I;F<],T0P('=I9'1H/3-$.3(E(&%L:6=N/3-$8V5N=&5R(&)O<F1E<CTS M1#`^#0H@/'1R/@T*(#QT9"!W:61T:#TS1#8V)3X\+W1D/@T*(#QT9"!V86QI M9VX],T1B;W1T;VT@=VED=&@],T0U)3X\+W1D/@T*(#QT9#X\+W1D/@T*(#QT M9#X\+W1D/@T*(#QT9#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@=VED M=&@],T0T)3X\+W1D/@T*(#QT9#X\+W1D/@T*(#QT9#X\+W1D/@T*(#QT9#X\ M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@=VED=&@],T0T)3X\+W1D/@T* M(#QT9#X\+W1D/@T*(#QT9#X\+W1D/@T*(#QT9#X\+W1D/@T*(#PO='(^#0H@ M/'1R/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<VEZ93TS1#$^)B-X M03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S M:7IE/3-$,3XF(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@<W1Y;&4] M,T0G0D]21$52+4)/5%1/33H@(S`P,#`P,"`Q<'@@<V]L:60G('9A;&EG;CTS M1&)O='1O;2!C;VQS<&%N/3-$,3`@86QI9VX],T1C96YT97(^/&9O;G0@<W1Y M;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#$^ M/&(^665A<G,@16YD960-"B!$96-E;6)E<B8C>$$P.S,Q+#PO8CX\+V9O;G0^ M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C M>$$P.SPO9F]N=#X\+W1D/@T*(#PO='(^#0H@/'1R/@T*(#QT9"!V86QI9VX] M,T1B;W1T;VT^/&9O;G0@<VEZ93TS1#$^)B-X03`[/"]F;VYT/CPO=&0^#0H@ M/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF(WA!,#LF(WA! M,#L\+V9O;G0^/"]T9#X-"B`\=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@ M(S`P,#`P,"`Q<'@@<V]L:60G('9A;&EG;CTS1&)O='1O;2!C;VQS<&%N/3-$ M,B!A;&EG;CTS1&-E;G1E<CX\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@ M5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,3X\8CXR,#$T/"]B/CPO9F]N=#X\ M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<VEZ93TS1#$^)B-X M03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S M:7IE/3-$,3XF(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@<W1Y;&4] M,T0G0D]21$52+4)/5%1/33H@(S`P,#`P,"`Q<'@@<V]L:60G('9A;&EG;CTS M1&)O='1O;2!C;VQS<&%N/3-$,B!A;&EG;CTS1&-E;G1E<CX\9F]N="!S='EL M93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,3X\ M8CXR,#$S/"]B/CPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^ M/&9O;G0@<VEZ93TS1#$^)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG M;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF(WA!,#LF(WA!,#L\+V9O;G0^ M/"]T9#X-"B`\=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@(S`P,#`P,"`Q M<'@@<V]L:60G('9A;&EG;CTS1&)O='1O;2!C;VQS<&%N/3-$,B!A;&EG;CTS M1&-E;G1E<CX\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W M(%)O;6%N)R!S:7IE/3-$,3X\8CXR,#$R/"]B/CPO9F]N=#X\+W1D/@T*(#QT M9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<VEZ93TS1#$^)B-X03`[/"]F;VYT M/CPO=&0^#0H@/"]T<CX-"B`\='(@8F=C;VQO<CTS1"-#0T5%1D8^#0H@/'1D M('9A;&EG;CTS1'1O<#X-"B`\<"!S='EL93TS1"=-05)'24XM3$5&5#H@,65M M.R!415A4+4E.1$5.5#H@+3%E;2<^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U) M3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^3F5T(&QO<W,\+V9O;G0^ M/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE M/3-$,3XF(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$ M8F]T=&]M/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@ M4F]M86XG('-I>F4],T0R/B0\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$ M8F]T=&]M(&%L:6=N/3-$<FEG:'0^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U) M3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^*#$T+#8T-CPO9F]N=#X\ M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P/CQF M;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I M>F4],T0R/BDF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T M=&]M/CQF;VYT('-I>F4],T0Q/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T* M(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U) M3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^)#PO9F]N=#X\+W1D/@T* M(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#X\9F]N="!S='EL M93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXH M,S,L-S$W/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R M87`],T1N;W=R87`^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S M($YE=R!2;VUA;B<@<VEZ93TS1#(^*28C>$$P.SPO9F]N=#X\+W1D/@T*(#QT M9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<VEZ93TS1#$^)B-X03`[)B-X03`[ M/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL M93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXD M/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I M9VAT/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M M86XG('-I>F4],T0R/B@T,"PS-S`\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N M/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#X\9F]N="!S='EL93TS1"=&3TY4 M+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXI)B-X03`[/"]F M;VYT/CPO=&0^#0H@/"]T<CX-"B`\='(^#0H@/'1D('9A;&EG;CTS1'1O<#X- M"B`\<"!S='EL93TS1"=-05)'24XM3$5&5#H@,65M.R!415A4+4E.1$5.5#H@ M+3%E;2<^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2 M;VUA;B<@<VEZ93TS1#(^1&5E;65D(&1I=FED96YD(')E;&%T960@=&\-"B!B M96YE9FEC:6%L(&-O;G9E<G-I;VX@9F5A='5R92!O9B!C;VYV97)T:6)L92!P M<F5F97)R960-"B!S=&]C:SPO9F]N=#X\+W`^#0H@/"]T9#X-"B`\=&0@=F%L M:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C>$$P.R8C>$$P.SPO9F]N M=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P M/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG M('-I>F4],T0R/B8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B M;W1T;VT@;F]W<F%P/3-$;F]W<F%P(&%L:6=N/3-$<FEG:'0^/&9O;G0@<W1Y M;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^ M)B-X,C`Q-#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO M=W)A<#TS1&YO=W)A<#X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM M97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXF(WA!,#LF(WA!,#L\+V9O;G0^/"]T M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C>$$P M.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W M<F%P/3-$;F]W<F%P/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE M<R!.97<@4F]M86XG('-I>F4],T0R/B8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT M9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P(&%L:6=N/3-$<FEG M:'0^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA M;B<@<VEZ93TS1#(^)B-X,C`Q-#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N M/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#X\9F]N="!S='EL93TS1"=&3TY4 M+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXF(WA!,#LF(WA! M,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I M>F4],T0Q/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX] M,T1B;W1T;VT^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE M=R!2;VUA;B<@<VEZ93TS1#(^)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A M;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/CQF;VYT('-T>6QE/3-$)T9/ M3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R/B@Q+#,P-SPO M9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W M<F%P/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M M86XG('-I>F4],T0R/BDF(WA!,#L\+V9O;G0^/"]T9#X-"B`\+W1R/@T*(#QT M<B!S='EL93TS1"=&3TY4+5-)6D4Z(#%P>"<^#0H@/'1D('9A;&EG;CTS1&)O M='1O;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[ M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/ M4D1%4BU43U`Z(",P,#`P,#`@,7!X('-O;&ED)SXF(WA!,#L\+W`^#0H@/"]T M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1% M4BU43U`Z(",P,#`P,#`@,7!X('-O;&ED)SXF(WA!,#L\+W`^#0H@/"]T9#X- M"B`\=&0^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P M.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL M93TS1"="3U)$15(M5$]0.B`C,#`P,#`P(#%P>"!S;VQI9"<^)B-X03`[/"]P M/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS M1"="3U)$15(M5$]0.B`C,#`P,#`P(#%P>"!S;VQI9"<^)B-X03`[/"]P/@T* M(#PO=&0^#0H@/'1D/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O M;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@ M/'`@<W1Y;&4],T0G0D]21$52+51/4#H@(S`P,#`P,"`Q<'@@<V]L:60G/B8C M>$$P.SPO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@ M<W1Y;&4],T0G0D]21$52+51/4#H@(S`P,#`P,"`Q<'@@<V]L:60G/B8C>$$P M.SPO<#X-"B`\+W1D/@T*(#QT9#XF(WA!,#L\+W1D/@T*(#PO='(^#0H@/'1R M(&)G8V]L;W(],T0C0T-%149&/@T*(#QT9"!V86QI9VX],T1T;W`^#0H@/'`@ M<W1Y;&4],T0G34%21TE.+4Q%1E0Z(#%E;3L@5$585"U)3D1%3E0Z("TQ96TG M/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG M('-I>F4],T0R/DYE="!L;W-S(&%L;&]C86)L92!T;PT*(&-O;6UO;B!S=&]C M:VAO;&1E<G,\+V9O;G0^/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O M='1O;3X\9F]N="!S:7IE/3-$,3XF(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X- M"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%- M24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R/B0\+V9O;G0^/"]T9#X- M"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^/&9O;G0@<W1Y M;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^ M*#$T+#8T-CPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W M<F%P/3-$;F]W<F%P/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE M<R!.97<@4F]M86XG('-I>F4],T0R/BDF(WA!,#L\+V9O;G0^/"]T9#X-"B`\ M=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C>$$P.R8C>$$P M.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<W1Y M;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^ M)#PO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R M:6=H=#X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O M;6%N)R!S:7IE/3-$,CXH,S,L-S$W/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG M;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^/&9O;G0@<W1Y;&4],T0G1D]. M5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^*28C>$$P.SPO M9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<VEZ93TS M1#$^)B-X03`[)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O M='1O;3X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O M;6%N)R!S:7IE/3-$,CXD/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O M='1O;2!A;&EG;CTS1')I9VAT/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9 M.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R/B@T,2PV-S<\+V9O;G0^/"]T M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#X\9F]N M="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE M/3-$,CXI)B-X03`[/"]F;VYT/CPO=&0^#0H@/"]T<CX-"B`\='(@<W1Y;&4] M,T0G1D].5"U325I%.B`Q<'@G/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@ M/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0 M.B`C,#`P,#`P(#-P>"!D;W5B;&4G/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT M9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@<W1Y;&4],T0G0D]21$52+51/4#H@ M(S`P,#`P,"`S<'@@9&]U8FQE)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0^ M)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P M.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"=" M3U)$15(M5$]0.B`C,#`P,#`P(#-P>"!D;W5B;&4G/B8C>$$P.SPO<#X-"B`\ M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@<W1Y;&4],T0G0D]2 M1$52+51/4#H@(S`P,#`P,"`S<'@@9&]U8FQE)SXF(WA!,#L\+W`^#0H@/"]T M9#X-"B`\=&0^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C M>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S M='EL93TS1"="3U)$15(M5$]0.B`C,#`P,#`P(#-P>"!D;W5B;&4G/B8C>$$P M.SPO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@<W1Y M;&4],T0G0D]21$52+51/4#H@(S`P,#`P,"`S<'@@9&]U8FQE)SXF(WA!,#L\ M+W`^#0H@/"]T9#X-"B`\=&0^)B-X03`[/"]T9#X-"B`\+W1R/@T*(#QT<CX- M"B`\=&0@=F%L:6=N/3-$=&]P/@T*(#QP('-T>6QE/3-$)TU!4D=)3BU,1494 M.B`Q96T[(%1%6%0M24Y$14Y4.B`M,65M)SX\9F]N="!S='EL93TS1"=&3TY4 M+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CY796EG:'1E9"UA M=F5R86=E('-H87)E<PT*('5S960@:6X@8V]M<'5T:6YG(&YE="!L;W-S('!E M<B!S:&%R92!A;&QO8V%B;&4@=&\@8V]M;6]N#0H@<W1O8VMH;VQD97)S)B-X M03`[)B-X,C`Q-#L@8F%S:6,@86YD(&1I;'5T960\+V9O;G0^/"]P/@T*(#PO M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF(WA! M,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF M;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I M>F4],T0R/B8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T M;VT@86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@ M5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXS-2PW,#D\+V9O;G0^/"]T9#X- M"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#X\9F]N="!S M='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$ M,CXF(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T M=&]M/CQF;VYT('-I>F4],T0Q/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T* M(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U) M3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^)B-X03`[/"]F;VYT/CPO M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/CQF;VYT M('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4] M,T0R/C(W+#(W-3PO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@ M;F]W<F%P/3-$;F]W<F%P/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4 M:6UE<R!.97<@4F]M86XG('-I>F4],T0R/B8C>$$P.R8C>$$P.SPO9F]N=#X\ M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<VEZ93TS1#$^)B-X M03`[)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\ M9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S M:7IE/3-$,CXF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T M=&]M(&%L:6=N/3-$<FEG:'0^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ M(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^,3@L,3`W/"]F;VYT/CPO=&0^ M#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^/&9O;G0@ M<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS M1#(^)B-X03`[)B-X03`[/"]F;VYT/CPO=&0^#0H@/"]T<CX-"B`\='(@<W1Y M;&4],T0G1D].5"U325I%.B`Q<'@G/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^ M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^ M#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M M5$]0.B`C,#`P,#`P(#-P>"!D;W5B;&4G/B8C>$$P.SPO<#X-"B`\+W1D/@T* M(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@<W1Y;&4],T0G0D]21$52+51/ M4#H@(S`P,#`P,"`S<'@@9&]U8FQE)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\ M=&0^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C M>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS M1"="3U)$15(M5$]0.B`C,#`P,#`P(#-P>"!D;W5B;&4G/B8C>$$P.SPO<#X- M"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@<W1Y;&4],T0G M0D]21$52+51/4#H@(S`P,#`P,"`S<'@@9&]U8FQE)SXF(WA!,#L\+W`^#0H@ M/"]T9#X-"B`\=&0^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\ M<"!S='EL93TS1"="3U)$15(M5$]0.B`C,#`P,#`P(#-P>"!D;W5B;&4G/B8C M>$$P.SPO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@ M<W1Y;&4],T0G0D]21$52+51/4#H@(S`P,#`P,"`S<'@@9&]U8FQE)SXF(WA! M,#L\+W`^#0H@/"]T9#X-"B`\=&0^)B-X03`[/"]T9#X-"B`\+W1R/@T*(#QT M<B!B9V-O;&]R/3-$(T-#145&1CX-"B`\=&0@=F%L:6=N/3-$=&]P/@T*(#QP M('-T>6QE/3-$)TU!4D=)3BU,1494.B`Q96T[(%1%6%0M24Y$14Y4.B`M,65M M)SX\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N M)R!S:7IE/3-$,CY.970@;&]S<R!P97(@<VAA<F4-"B!A;&QO8V%B;&4@=&\@ M8V]M;6]N('-T;V-K:&]L9&5R<R`F(W@R,#$T.R!B87-I8PT*(&%N9"8C>$$P M.V1I;'5T960\+V9O;G0^/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O M='1O;3X\9F]N="!S:7IE/3-$,3XF(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X- M"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%- M24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R/B0\+V9O;G0^/"]T9#X- M"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^/&9O;G0@<W1Y M;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^ M*#`N-#$\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A M<#TS1&YO=W)A<#X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@ M3F5W(%)O;6%N)R!S:7IE/3-$,CXI)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D M('9A;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF(WA!,#LF(WA!,#L\ M+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE M/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R/B0\ M+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG M:'0^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA M;B<@<VEZ93TS1#(^*#$N,C0\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$ M8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#X\9F]N="!S='EL93TS1"=&3TY4+49! M34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXI)B-X03`[/"]F;VYT M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF M(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M M/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG M('-I>F4],T0R/B0\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M M(&%L:6=N/3-$<FEG:'0^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I M;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^*#(N,S`\+V9O;G0^/"]T9#X-"B`\ M=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#X\9F]N="!S='EL M93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXI M)B-X03`[/"]F;VYT/CPO=&0^#0H@/"]T<CX-"B`\+W1A8FQE/@T*(#PO9&EV M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C M;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T M;W`^26YS=')U;65N=',@17AC;'5D960@9G)O;2!T:&4@0V]M<'5T871I;VX@ M;V8@1&EL=71E9"!.970@3&]S<R!097(@0V]M;6]N(%-H87)E/"]T9#X-"B`@ M("`@("`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`\<"!S='EL93TS1"=-05)'24XM0D]45$]-.B`P<'@[($9/3E0M4TE: M13H@,3)P>#L@34%21TE.+51/4#H@,'!X)SX-"B`F(WA!,#L\+W`^#0H@/'1A M8FQE('-T>6QE/3-$)T)/4D1%4BU#3TQ,05!313H@8V]L;&%P<V4G(&-E;&QS M<&%C:6YG/3-$,"!C96QL<&%D9&EN9STS1#`@=VED=&@],T0Y,B4@86QI9VX] M,T1C96YT97(@8F]R9&5R/3-$,#X-"B`\='(^#0H@/'1D('=I9'1H/3-$-S,E M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#,E/CPO=&0^ M#0H@/'1D/CPO=&0^#0H@/'1D/CPO=&0^#0H@/'1D/CPO=&0^#0H@/'1D('9A M;&EG;CTS1&)O='1O;2!W:61T:#TS1#,E/CPO=&0^#0H@/'1D/CPO=&0^#0H@ M/'1D/CPO=&0^#0H@/'1D/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!W M:61T:#TS1#,E/CPO=&0^#0H@/'1D/CPO=&0^#0H@/'1D/CPO=&0^#0H@/'1D M/CPO=&0^#0H@/"]T<CX-"B`\='(^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\ M9F]N="!S:7IE/3-$,3XF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N M/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C>$$P.R8C>$$P.SPO9F]N=#X\ M+W1D/@T*(#QT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B`C,#`P,#`P(#%P M>"!S;VQI9"<@=F%L:6=N/3-$8F]T=&]M(&-O;'-P86X],T0Q,"!A;&EG;CTS M1&-E;G1E<CX\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W M(%)O;6%N)R!S:7IE/3-$,3X\8CY$96-E;6)E<B8C>$$P.S,Q+#PO8CX\+V9O M;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q M/B8C>$$P.SPO9F]N=#X\+W1D/@T*(#PO='(^#0H@/'1R/@T*(#QT9"!V86QI M9VX],T1B;W1T;VT^/&9O;G0@<VEZ93TS1#$^)B-X03`[/"]F;VYT/CPO=&0^ M#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF(WA!,#LF M(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/ M33H@(S`P,#`P,"`Q<'@@<V]L:60G('9A;&EG;CTS1&)O='1O;2!C;VQS<&%N M/3-$,B!A;&EG;CTS1&-E;G1E<CX\9F]N="!S='EL93TS1"=&3TY4+49!34E, M63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,3X\8CXR,#$T/"]B/CPO9F]N M=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<VEZ93TS1#$^ M)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N M="!S:7IE/3-$,3XF(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@<W1Y M;&4],T0G0D]21$52+4)/5%1/33H@(S`P,#`P,"`Q<'@@<V]L:60G('9A;&EG M;CTS1&)O='1O;2!C;VQS<&%N/3-$,B!A;&EG;CTS1&-E;G1E<CX\9F]N="!S M='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$ M,3X\8CXR,#$S/"]B/CPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T M;VT^/&9O;G0@<VEZ93TS1#$^)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A M;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF(WA!,#LF(WA!,#L\+V9O M;G0^/"]T9#X-"B`\=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@(S`P,#`P M,"`Q<'@@<V]L:60G('9A;&EG;CTS1&)O='1O;2!C;VQS<&%N/3-$,B!A;&EG M;CTS1&-E;G1E<CX\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@ M3F5W(%)O;6%N)R!S:7IE/3-$,3X\8CXR,#$R/"]B/CPO9F]N=#X\+W1D/@T* M(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<VEZ93TS1#$^)B-X03`[/"]F M;VYT/CPO=&0^#0H@/"]T<CX-"B`\='(@8F=C;VQO<CTS1"-#0T5%1D8^#0H@ M/'1D('9A;&EG;CTS1'1O<#X-"B`\<"!S='EL93TS1"=-05)'24XM3$5&5#H@ M,65M.R!415A4+4E.1$5.5#H@+3%E;2<^/&9O;G0@<W1Y;&4],T0G1D].5"U& M04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^3W!T:6]N<R!T;R!P M=7)C:&%S92!C;VUM;VX-"B!S=&]C:SPO9F]N=#X\+W`^#0H@/"]T9#X-"B`\ M=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C>$$P.R8C>$$P M.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<W1Y M;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^ M)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG M;CTS1')I9VAT/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!. M97<@4F]M86XG('-I>F4],T0R/C,L,CDX/"]F;VYT/CPO=&0^#0H@/'1D('9A M;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^/&9O;G0@<W1Y;&4],T0G M1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^)B-X03`[ M)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N M="!S:7IE/3-$,3XF(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L M:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE M<R!.97<@4F]M86XG('-I>F4],T0R/B8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT M9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS M1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXR+#0T M.3PO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$ M;F]W<F%P/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@ M4F]M86XG('-I>F4],T0R/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT M9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<VEZ93TS1#$^)B-X03`[)B-X03`[ M/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL M93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXF M(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N M/3-$<FEG:'0^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE M=R!2;VUA;B<@<VEZ93TS1#(^,2PW.3$\+V9O;G0^/"]T9#X-"B`\=&0@=F%L M:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#X\9F]N="!S='EL93TS1"=& M3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXF(WA!,#LF M(WA!,#L\+V9O;G0^/"]T9#X-"B`\+W1R/@T*(#QT<CX-"B`\=&0@=F%L:6=N M/3-$=&]P/@T*(#QP('-T>6QE/3-$)TU!4D=)3BU,1494.B`Q96T[(%1%6%0M M24Y$14Y4.B`M,65M)SX\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM M97,@3F5W(%)O;6%N)R!S:7IE/3-$,CY787)R86YT<R!T;R!P=7)C:&%S92!C M;VUM;VX-"B!S=&]C:SPO9F]N=#X\+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N M/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C>$$P.R8C>$$P.SPO9F]N=#X\ M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<W1Y;&4],T0G1D]. M5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^)B-X03`[/"]F M;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT M/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG M('-I>F4],T0R/C8L-CDQ/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O M='1O;2!N;W=R87`],T1N;W=R87`^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U) M3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^)B-X03`[)B-X03`[/"]F M;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$ M,3XF(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T M=&]M/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M M86XG('-I>F4],T0R/B8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX] M,T1B;W1T;VT@86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS1"=&3TY4+49! M34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXW+#8Y,CPO9F]N=#X\ M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P/CQF M;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I M>F4],T0R/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX] M,T1B;W1T;VT^/&9O;G0@<VEZ93TS1#$^)B-X03`[)B-X03`[/"]F;VYT/CPO M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=&3TY4 M+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXF(WA!,#L\+V9O M;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^ M/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@ M<VEZ93TS1#(^.2PP,#D\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T M=&]M(&YO=W)A<#TS1&YO=W)A<#X\9F]N="!S='EL93TS1"=&3TY4+49!34E, M63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXF(WA!,#LF(WA!,#L\+V9O M;G0^/"]T9#X-"B`\+W1R/@T*(#QT<B!B9V-O;&]R/3-$(T-#145&1CX-"B`\ M=&0@=F%L:6=N/3-$=&]P/@T*(#QP('-T>6QE/3-$)TU!4D=)3BU,1494.B`Q M96T[(%1%6%0M24Y$14Y4.B`M,65M)SX\9F]N="!S='EL93TS1"=&3TY4+49! M34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CY397)I97,@0B!C;VYV M97)T:6)L90T*('!R969E<G)E9"!S=&]C:R`H87,@8V]N=F5R=&5D('1O(&-O M;6UO;B!S=&]C:RD\+V9O;G0^/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS M1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF(WA!,#LF(WA!,#L\+V9O;G0^/"]T M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#X\9F]N M="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE M/3-$,CXF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M M(&YO=W)A<#TS1&YO=W)A<"!A;&EG;CTS1')I9VAT/CQF;VYT('-T>6QE/3-$ M)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R/B8C>#(P M,30[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`] M,T1N;W=R87`^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE M=R!2;VUA;B<@<VEZ93TS1#(^)B-X03`[)B-X03`[/"]F;VYT/CPO=&0^#0H@ M/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF(WA!,#LF(WA! M,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS M1&YO=W)A<#X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W M(%)O;6%N)R!S:7IE/3-$,CXF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L M:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<"!A;&EG;CTS1')I9VAT/CQF M;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I M>F4],T0R/B8C>#(P,30[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O M='1O;2!N;W=R87`],T1N;W=R87`^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U) M3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^)B-X03`[)B-X03`[/"]F M;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$ M,3XF(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T M=&]M/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M M86XG('-I>F4],T0R/B8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX] M,T1B;W1T;VT@86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS1"=&3TY4+49! M34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXS+#@S.#PO9F]N=#X\ M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P/CQF M;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I M>F4],T0R/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#PO='(^#0H@/'1R M/@T*(#QT9"!V86QI9VX],T1T;W`^#0H@/'`@<W1Y;&4],T0G34%21TE.+4Q% M1E0Z(#%E;3L@5$585"U)3D1%3E0Z("TQ96TG/CQF;VYT('-T>6QE/3-$)T9/ M3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R/E)E<W1R:6-T M960@<W1O8VL-"B!U;FET<SPO9F]N=#X\+W`^#0H@/"]T9#X-"B`\=&0@=F%L M:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C>$$P.R8C>$$P.SPO9F]N M=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<W1Y;&4],T0G M1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^)B-X03`[ M/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I M9VAT/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M M86XG('-I>F4],T0R/C8S/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O M='1O;2!N;W=R87`],T1N;W=R87`^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U) M3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^)B-X03`[)B-X03`[/"]F M;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$ M,3XF(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T M=&]M/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M M86XG('-I>F4],T0R/B8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX] M,T1B;W1T;VT@86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS1"=&3TY4+49! M34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXT,CPO9F]N=#X\+W1D M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P/CQF;VYT M('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4] M,T0R/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B M;W1T;VT^/&9O;G0@<VEZ93TS1#$^)B-X03`[)B-X03`[/"]F;VYT/CPO=&0^ M#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=&3TY4+49! M34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXF(WA!,#L\+V9O;G0^ M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^/&9O M;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ M93TS1#(^,C$W/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N M;W=R87`],T1N;W=R87`^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I M;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^)B-X03`[)B-X03`[/"]F;VYT/CPO M=&0^#0H@/"]T<CX-"B`\='(@8F=C;VQO<CTS1"-#0T5%1D8^#0H@/'1D('9A M;&EG;CTS1'1O<#X-"B`\<"!S='EL93TS1"=-05)'24XM3$5&5#H@,65M.R!4 M15A4+4E.1$5.5#H@+3%E;2<^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ M(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^4VAA<F5S(&ES<W5A8FQE(')E M;&%T960@=&\-"B!T:&4@15-04#PO9F]N=#X\+W`^#0H@/"]T9#X-"B`\=&0@ M=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C>$$P.R8C>$$P.SPO M9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<W1Y;&4] M,T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^)B-X M03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS M1')I9VAT/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@ M4F]M86XG('-I>F4],T0R/C$U/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS M1&)O='1O;2!N;W=R87`],T1N;W=R87`^/&9O;G0@<W1Y;&4],T0G1D].5"U& M04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^)B-X03`[)B-X03`[ M/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE M/3-$,3XF(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$ M8F]T=&]M/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@ M4F]M86XG('-I>F4],T0R/B8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI M9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS1"=&3TY4 M+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXQ-#PO9F]N=#X\ M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P/CQF M;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I M>F4],T0R/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX] M,T1B;W1T;VT^/&9O;G0@<VEZ93TS1#$^)B-X03`[)B-X03`[/"]F;VYT/CPO M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=&3TY4 M+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXF(WA!,#L\+V9O M;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^ M/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@ M<VEZ93TS1#(^,3$\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M M(&YO=W)A<#TS1&YO=W)A<#X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@ M5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXF(WA!,#LF(WA!,#L\+V9O;G0^ M/"]T9#X-"B`\+W1R/@T*(#QT<B!S='EL93TS1"=&3TY4+5-)6D4Z(#%P>"<^ M#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B M;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@,7!X('-O;&ED M)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T* M(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@,7!X('-O;&ED)SXF M(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0^)B-X03`[/"]T9#X-"B`\=&0@=F%L M:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS M1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B`C,#`P,#`P(#%P M>"!S;VQI9"<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O M='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B`C,#`P,#`P(#%P>"!S M;VQI9"<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D/B8C>$$P.SPO=&0^#0H@ M/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V M86QI9VX],T1B;W1T;VT^#0H@/'`@<W1Y;&4],T0G0D]21$52+51/4#H@(S`P M,#`P,"`Q<'@@<V]L:60G/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT9"!V86QI M9VX],T1B;W1T;VT^#0H@/'`@<W1Y;&4],T0G0D]21$52+51/4#H@(S`P,#`P M,"`Q<'@@<V]L:60G/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT9#XF(WA!,#L\ M+W1D/@T*(#PO='(^#0H@/'1R/@T*(#QT9"!V86QI9VX],T1T;W`^#0H@/'`@ M<W1Y;&4],T0G34%21TE.+4Q%1E0Z(#)E;3L@5$585"U)3D1%3E0Z("TQ96TG M/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG M('-I>F4],T0R/E1O=&%L('-H87)E<SPO9F]N=#X\+W`^#0H@/"]T9#X-"B`\ M=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C>$$P.R8C>$$P M.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<W1Y M;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^ M)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG M;CTS1')I9VAT/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!. M97<@4F]M86XG('-I>F4],T0R/C$P+#`V-SPO9F]N=#X\+W1D/@T*(#QT9"!V M86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P/CQF;VYT('-T>6QE/3-$ M)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R/B8C>$$P M.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O M;G0@<VEZ93TS1#$^)B-X03`[)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A M;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM M97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXF(WA!,#L\+V9O;G0^/"]T9#X-"B`\ M=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^/&9O;G0@<W1Y;&4] M,T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^,3`L M,3DW/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`] M,T1N;W=R87`^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE M=R!2;VUA;B<@<VEZ93TS1#(^)B-X03`[)B-X03`[/"]F;VYT/CPO=&0^#0H@ M/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF(WA!,#LF(WA! M,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T M>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R M/B8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI M9VX],T1R:6=H=#X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@ M3F5W(%)O;6%N)R!S:7IE/3-$,CXQ-"PX-C8\+V9O;G0^/"]T9#X-"B`\=&0@ M=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#X\9F]N="!S='EL93TS M1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXF(WA! M,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\+W1R/@T*(#QT<B!S='EL93TS1"=& M3TY4+5-)6D4Z(#%P>"<^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T* M(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@ M=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(",P M,#`P,#`@,W!X(&1O=6)L92<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D('9A M;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B`C,#`P M,#`P(#-P>"!D;W5B;&4G/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT9#XF(WA! M,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1% M4BU43U`Z(",P,#`P,#`@,W!X(&1O=6)L92<^)B-X03`[/"]P/@T*(#PO=&0^ M#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M M5$]0.B`C,#`P,#`P(#-P>"!D;W5B;&4G/B8C>$$P.SPO<#X-"B`\+W1D/@T* M(#QT9#XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[ M)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE M/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@,W!X(&1O=6)L92<^)B-X03`[/"]P M/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS M1"="3U)$15(M5$]0.B`C,#`P,#`P(#-P>"!D;W5B;&4G/B8C>$$P.SPO<#X- M"B`\+W1D/@T*(#QT9#XF(WA!,#L\+W1D/@T*(#PO='(^#0H@/"]T86)L93X- M"B`\+V1I=CX\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@ M/"]T86)L93X-"B`@/"]B;V1Y/@T*/"]H=&UL/@T*#0HM+2TM+2T]7TYE>'10 M87)T7S,Y8S!E838R7V,R,#-?-#4X9E\X8S4P7S-D8V$T-39A-CDU,0T*0V]N M=&5N="U,;V-A=&EO;CH@9FEL93HO+R]#.B\S.6,P96$V,E]C,C`S7S0U.&9? M.&,U,%\S9&-A-#4V838Y-3$O5V]R:W-H965T<R]3:&5E=#(U+FAT;6P-"D-O M;G1E;G0M5')A;G-F97(M16YC;V1I;F<Z('%U;W1E9"UP<FEN=&%B;&4-"D-O M;G1E;G0M5'EP93H@=&5X="]H=&UL.R!C:&%R<V5T/2)U<RUA<V-I:2(-"@T* M/&AT;6P^#0H@(#QH96%D/@T*("`@(#Q-151!(&AT='`M97%U:78],T1#;VYT M96YT+51Y<&4@8V]N=&5N=#TS1"=T97AT+VAT;6P[(&-H87)S970]=71F+3@G M/CQS8W)I<'0@='EP93TS1'1E>'0O:F%V87-C<FEP="!S<F,],T13:&]W+FIS M/B\J($1O($YO="!296UO=F4@5&AI<R!#;VUM96YT("HO/"]S8W)I<'0^/"]H M96%D/@T*("`\8F]D>3X-"B`@("`\=&%B;&4@8VQA<W,],T1R97!O<G0@:60] M,T1)1#!%344^#0H@("`@("`\='(^#0H@("`@("`@(#QT:"!C;&%S<STS1'1L M(&-O;'-P86X],T0Q(')O=W-P86X],T0R/CQS=')O;F<^4W5P<&QE;65N=&%R M>2!#87-H($9L;W<@1&%T82`H5&%B;&5S*3QB<CX\+W-T<F]N9SX\+W1H/@T* M("`@("`@("`\=&@@8VQA<W,],T1T:"!C;VQS<&%N/3-$,3XQ,B!-;VYT:',@ M16YD960\+W1H/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<CX-"B`@("`@("`@ M/'1H(&-L87-S/3-$=&@^1&5C+B`S,2P@,C`Q-#QB<CX\+W1H/@T*("`@("`@ M/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA M<W,],T1P;"!V86QI9VX],T1T;W`^/'-T<F]N9SY3=7!P;&5M96YT86P@0V%S M:"!&;&]W($5L96UE;G1S(%M!8G-T<F%C=%T\+W-T<F]N9SX\+W1D/@T*("`@ M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@ M("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@ M8VQA<W,],T1P;"!V86QI9VX],T1T;W`^4W5P<&QE;65N=&%L($-A<V@@1FQO M=R!);F9O<FUA=&EO;CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^ M/&1I=CX-"B`\<"!S='EL93TS1"=-05)'24XM0D]45$]-.B`P<'@[($U!4D=) M3BU43U`Z(#9P>#L@5$585"U)3D1%3E0Z(#0E)R!A;&EG;CTS1&IU<W1I9GD^ M/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@ M<VEZ93TS1#(^4W5P<&QE;65N=&%L(&-A<V@@9FQO=R!I;F9O<FUA=&EO;B!W M87,@87,@9F]L;&]W<R`H:6X-"B!T:&]U<V%N9',I.CPO9F]N=#X\+W`^#0H@ M/'`@<W1Y;&4],T0G34%21TE.+4)/5%1/33H@,'!X.R!&3TY4+5-)6D4Z(#$R M<'@[($U!4D=)3BU43U`Z(#!P>"<^#0H@)B-X03`[/"]P/@T*(#QT86)L92!S M='EL93TS1"="3U)$15(M0T],3$%04T4Z(&-O;&QA<'-E)R!C96QL<W!A8VEN M9STS1#`@8V5L;'!A9&1I;F<],T0P('=I9'1H/3-$.3(E(&%L:6=N/3-$8V5N M=&5R(&)O<F1E<CTS1#`^#0H@/'1R/@T*(#QT9"!W:61T:#TS1#<X)3X\+W1D M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@=VED=&@],T0V)3X\+W1D/@T*(#QT M9#X\+W1D/@T*(#QT9#X\+W1D/@T*(#QT9#X\+W1D/@T*(#QT9"!V86QI9VX] M,T1B;W1T;VT@=VED=&@],T0V)3X\+W1D/@T*(#QT9#X\+W1D/@T*(#QT9#X\ M+W1D/@T*(#QT9#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@=VED=&@] M,T0U)3X\+W1D/@T*(#QT9#X\+W1D/@T*(#QT9#X\+W1D/@T*(#QT9#X\+W1D M/@T*(#PO='(^#0H@/'1R/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@ M<VEZ93TS1#$^)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O M='1O;3X\9F]N="!S:7IE/3-$,3XF(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X- M"B`\=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@(S`P,#`P,"`Q<'@@<V]L M:60G('9A;&EG;CTS1&)O='1O;2!C;VQS<&%N/3-$,3`@86QI9VX],T1C96YT M97(^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA M;B<@<VEZ93TS1#$^/&(^665A<G,@16YD960\8G(@+SX-"B!$96-E;6)E<B8C M>$$P.S,Q+#PO8CX\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M M/CQF;VYT('-I>F4],T0Q/B8C>$$P.SPO9F]N=#X\+W1D/@T*(#PO='(^#0H@ M/'1R/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<VEZ93TS1#$^)B-X M03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S M:7IE/3-$,3XF(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@<W1Y;&4] M,T0G0D]21$52+4)/5%1/33H@(S`P,#`P,"`Q<'@@<V]L:60G('9A;&EG;CTS M1&)O='1O;2!C;VQS<&%N/3-$,B!A;&EG;CTS1&-E;G1E<CX\9F]N="!S='EL M93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,3X\ M8CXR,#$T/"]B/CPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^ M/&9O;G0@<VEZ93TS1#$^)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG M;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF(WA!,#LF(WA!,#L\+V9O;G0^ M/"]T9#X-"B`\=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@(S`P,#`P,"`Q M<'@@<V]L:60G('9A;&EG;CTS1&)O='1O;2!C;VQS<&%N/3-$,B!A;&EG;CTS M1&-E;G1E<CX\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W M(%)O;6%N)R!S:7IE/3-$,3X\8CXR,#$S/"]B/CPO9F]N=#X\+W1D/@T*(#QT M9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<VEZ93TS1#$^)B-X03`[/"]F;VYT M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF M(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@<W1Y;&4],T0G0D]21$52 M+4)/5%1/33H@(S`P,#`P,"`Q<'@@<V]L:60G('9A;&EG;CTS1&)O='1O;2!C M;VQS<&%N/3-$,B!A;&EG;CTS1&-E;G1E<CX\9F]N="!S='EL93TS1"=&3TY4 M+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,3X\8CXR,#$R/"]B M/CPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<VEZ M93TS1#$^)B-X03`[/"]F;VYT/CPO=&0^#0H@/"]T<CX-"B`\='(@8F=C;VQO M<CTS1"-#0T5%1D8^#0H@/'1D('9A;&EG;CTS1'1O<#X-"B`\<"!S='EL93TS M1"=-05)'24XM3$5&5#H@,65M.R!415A4+4E.1$5.5#H@+3%E;2<^/&9O;G0@ M<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS M1#(^0V%S:"!P86ED(&9O<@T*(&EN=&5R97-T/"]F;VYT/CPO<#X-"B`\+W1D M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<VEZ93TS1#$^)B-X03`[ M)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R M87`],T1N;W=R87`^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S M($YE=R!2;VUA;B<@<VEZ93TS1#(^)#PO9F]N=#X\+W1D/@T*(#QT9"!V86QI M9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P(&%L:6=N/3-$<FEG:'0^/&9O M;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ M93TS1#(^)B-X,C`Q-#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T M=&]M(&YO=W)A<#TS1&YO=W)A<#X\9F]N="!S='EL93TS1"=&3TY4+49!34E, M63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXF(WA!,#LF(WA!,#L\+V9O M;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q M/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T M;VT@;F]W<F%P/3-$;F]W<F%P/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9 M.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R/B0\+V9O;G0^/"]T9#X-"B`\ M=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<"!A;&EG;CTS1')I M9VAT/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M M86XG('-I>F4],T0R/B8C>#(P,30[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG M;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^/&9O;G0@<W1Y;&4],T0G1D]. M5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^)B-X03`[)B-X M03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S M:7IE/3-$,3XF(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N M/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!. M97<@4F]M86XG('-I>F4],T0R/B0\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N M/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^/&9O;G0@<W1Y;&4],T0G1D].5"U& M04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^,SPO9F]N=#X\+W1D M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P/CQF;VYT M('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4] M,T0R/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#PO='(^#0H@/'1R/@T* M(#QT9"!V86QI9VX],T1T;W`^#0H@/'`@<W1Y;&4],T0G34%21TE.+4Q%1E0Z M(#%E;3L@5$585"U)3D1%3E0Z("TQ96TG/CQF;VYT('-T>6QE/3-$)T9/3E0M M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R/D-A<V@@<&%I9"!F M;W(@:6YC;VUE#0H@=&%X97,\+V9O;G0^/"]P/@T*(#PO=&0^#0H@/'1D('9A M;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF(WA!,#LF(WA!,#L\+V9O M;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$ M)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R/B8C>$$P M.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R M:6=H=#X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O M;6%N)R!S:7IE/3-$,CXQ/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O M='1O;2!N;W=R87`],T1N;W=R87`^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U) M3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^)B-X03`[)B-X03`[/"]F M;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$ M,3XF(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T M=&]M/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M M86XG('-I>F4],T0R/B8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX] M,T1B;W1T;VT@86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS1"=&3TY4+49! M34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXQ/"]F;VYT/CPO=&0^ M#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^/&9O;G0@ M<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS M1#(^)B-X03`[)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O M='1O;3X\9F]N="!S:7IE/3-$,3XF(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X- M"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%- M24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R/B8C>$$P.SPO9F]N=#X\ M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#X\9F]N M="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE M/3-$,CXQ/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R M87`],T1N;W=R87`^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S M($YE=R!2;VUA;B<@<VEZ93TS1#(^)B-X03`[)B-X03`[/"]F;VYT/CPO=&0^ M#0H@/"]T<CX-"B`\='(@8F=C;VQO<CTS1"-#0T5%1D8^#0H@/'1D('9A;&EG M;CTS1'1O<#X-"B`\<"!S='EL93TS1"=-05)'24XM3$5&5#H@,65M.R!415A4 M+4E.1$5.5#H@+3%E;2<^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I M;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^4VEG;FEF:6-A;G0@;F]N+6-A<V@- M"B!I;G9E<W1I;F<@86YD(&9I;F%N8VEN9R!A8W1I=FET:65S.CPO9F]N=#X\ M+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4] M,T0Q/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B M;W1T;VT^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D M('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^ M/&9O;G0@<VEZ93TS1#$^)B-X03`[)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D M('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^ M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG M;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF(WA!,#LF(WA!,#L\+V9O;G0^ M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG M;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X- M"B`\+W1R/@T*(#QT<CX-"B`\=&0@=F%L:6=N/3-$=&]P/@T*(#QP('-T>6QE M/3-$)TU!4D=)3BU,1494.B`R96T[(%1%6%0M24Y$14Y4.B`M,65M)SX\9F]N M="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE M/3-$,CY0=7)C:&%S97,@;V8@<')O<&5R='D@86YD#0H@97%U:7!M96YT('1H M<F]U9V@@86-C;W5N=',@<&%Y86)L93PO9F]N=#X\+W`^#0H@/"]T9#X-"B`\ M=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C>$$P.R8C>$$P M.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<W1Y M;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^ M)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG M;CTS1')I9VAT/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!. M97<@4F]M86XG('-I>F4],T0R/C$W,#PO9F]N=#X\+W1D/@T*(#QT9"!V86QI M9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P/CQF;VYT('-T>6QE/3-$)T9/ M3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R/B8C>$$P.R8C M>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@ M<VEZ93TS1#$^)B-X03`[)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG M;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@ M3F5W(%)O;6%N)R!S:7IE/3-$,CXF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@ M=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^/&9O;G0@<W1Y;&4],T0G M1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^,3DS/"]F M;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R M87`^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA M;B<@<VEZ93TS1#(^)B-X03`[)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A M;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF(WA!,#LF(WA!,#L\+V9O M;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$ M)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R/B8C>$$P M.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R M:6=H=#X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O M;6%N)R!S:7IE/3-$,CXQ,38\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$ M8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#X\9F]N="!S='EL93TS1"=&3TY4+49! M34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXF(WA!,#LF(WA!,#L\ M+V9O;G0^/"]T9#X-"B`\+W1R/@T*(#QT<B!B9V-O;&]R/3-$(T-#145&1CX- M"B`\=&0@=F%L:6=N/3-$=&]P/@T*(#QP('-T>6QE/3-$)TU!4D=)3BU,1494 M.B`R96T[(%1%6%0M24Y$14Y4.B`M,65M)SX\9F]N="!S='EL93TS1"=&3TY4 M+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CY0=7)C:&%S97,@ M;V8@<')O<&5R='D@86YD#0H@97%U:7!M96YT('1H<F]U9V@@86-C<G5E9"!L M:6%B:6QI=&EE<SPO9F]N=#X\+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$ M8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<W1Y;&4],T0G1D].5"U& M04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^)B-X03`[/"]F;VYT M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/CQF M;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I M>F4],T0R/C(W/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N M;W=R87`],T1N;W=R87`^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I M;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^)B-X03`[)B-X03`[/"]F;VYT/CPO M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF(WA! M,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF M;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I M>F4],T0R/B8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T M;VT@86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@ M5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXH,CPO9F]N=#X\+W1D/@T*(#QT M9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P/CQF;VYT('-T>6QE M/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R/BDF M(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT M('-I>F4],T0Q/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI M9VX],T1B;W1T;VT^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S M($YE=R!2;VUA;B<@<VEZ93TS1#(^)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D M('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/CQF;VYT('-T>6QE/3-$ M)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R/C,W/"]F M;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R M87`^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA M;B<@<VEZ93TS1#(^)B-X03`[)B-X03`[/"]F;VYT/CPO=&0^#0H@/"]T<CX- M"B`\='(^#0H@/'1D('9A;&EG;CTS1'1O<#X-"B`\<"!S='EL93TS1"=-05)' M24XM3$5&5#H@,F5M.R!415A4+4E.1$5.5#H@+3%E;2<^/&9O;G0@<W1Y;&4] M,T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^4'5R M8VAA<V5S(&]F('!R;W!E<G1Y(&%N9`T*(&5Q=6EP;65N="!T:')O=6=H('1R M861E(&EN('9A;'5E(&]F(&1I<W!O<V5D('!R;W!E<G1Y(&%N9`T*(&5Q=6EP M;65N=#PO9F]N=#X\+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M M/CQF;VYT('-I>F4],T0Q/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT M9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P/CQF;VYT('-T>6QE M/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R/B8C M>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P M/3-$;F]W<F%P(&%L:6=N/3-$<FEG:'0^/&9O;G0@<W1Y;&4],T0G1D].5"U& M04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^)B-X,C`Q-#L\+V9O M;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A M<#X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N M)R!S:7IE/3-$,CXF(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L M:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C>$$P.R8C>$$P.SPO9F]N M=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<W1Y;&4],T0G M1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^)B-X03`[ M/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I M9VAT/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M M86XG('-I>F4],T0R/C@Q/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O M='1O;2!N;W=R87`],T1N;W=R87`^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U) M3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^)B-X03`[)B-X03`[/"]F M;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$ M,3XF(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T M=&]M(&YO=W)A<#TS1&YO=W)A<#X\9F]N="!S='EL93TS1"=&3TY4+49!34E, M63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXF(WA!,#L\+V9O;G0^/"]T M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<"!A;&EG M;CTS1')I9VAT/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!. M97<@4F]M86XG('-I>F4],T0R/B8C>#(P,30[/"]F;VYT/CPO=&0^#0H@/'1D M('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^/&9O;G0@<W1Y;&4] M,T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^)B-X M03`[)B-X03`[/"]F;VYT/CPO=&0^#0H@/"]T<CX-"B`\+W1A8FQE/@T*(#PO M9&EV/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`\+W1A M8FQE/@T*("`\+V)O9'D^#0H\+VAT;6P^#0H-"BTM+2TM+3U?3F5X=%!A<G1? M,SEC,&5A-C)?8S(P,U\T-3AF7SAC-3!?,V1C830U-F$V.34Q#0I#;VYT96YT M+4QO8V%T:6]N.B!F:6QE.B\O+T,Z+S,Y8S!E838R7V,R,#-?-#4X9E\X8S4P M7S-D8V$T-39A-CDU,2]7;W)K<VAE971S+U-H965T,C8N:'1M;`T*0V]N=&5N M="U4<F%N<V9E<BU%;F-O9&EN9SH@<75O=&5D+7!R:6YT86)L90T*0V]N=&5N M="U4>7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA<G-E=#UU=&8M."<^/'-C M<FEP="!T>7!E/3-$=&5X="]J879A<V-R:7!T('-R8STS1%-H;W<N:G,^+RH@ M1&\@3F]T(%)E;6]V92!4:&ES($-O;6UE;G0@*B\\+W-C<FEP=#X\+VAE860^ M#0H@(#QB;V1Y/@T*("`@(#QT86)L92!C;&%S<STS1')E<&]R="!I9#TS1$E$ M,$4R1CX-"B`@("`@(#QT<CX-"B`@("`@("`@/'1H(&-L87-S/3-$=&P@8V]L M<W!A;CTS1#$@<F]W<W!A;CTS1#(^/'-T<F]N9SY#87-H($5Q=6EV86QE;G1S M(&%N9"!);G9E<W1M96YT<R`H5&%B;&5S*3QB<CX\+W-T<F]N9SX\+W1H/@T* M("`@("`@("`\=&@@8VQA<W,],T1T:"!C;VQS<&%N/3-$,3XQ,B!-;VYT:',@ M16YD960\+W1H/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<CX-"B`@("`@("`@ M/'1H(&-L87-S/3-$=&@^1&5C+B`S,2P@,C`Q-#QB<CX\+W1H/@T*("`@("`@ M/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA M<W,],T1P;"!V86QI9VX],T1T;W`^/'-T<F]N9SY);G9E<W1M96YT<RP@1&5B M="!A;F0@17%U:71Y(%-E8W5R:71I97,@6T%B<W1R86-T73PO<W1R;VYG/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@ M("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y!;6]R=&EZ960@0V]S M="!A;F0@1F%I<B!686QU92!O9B!#87-H($5Q=6EV86QE;G1S(&%N9"!!=F%I M;&%B;&4@9F]R(%-A;&4@26YV97-T;65N=',\+W1D/@T*("`@("`@("`\=&0@ M8VQA<W,],T1T97AT/CQD:78^#0H@/'`@<W1Y;&4],T0G34%21TE.+4)/5%1/ M33H@,'!X.R!-05)'24XM5$]0.B`V<'@[(%1%6%0M24Y$14Y4.B`T)2<@86QI M9VX],T1J=7-T:69Y/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE M<R!.97<@4F]M86XG('-I>F4],T0R/E1H92!A;6]R=&EZ960@8V]S="!A;F0@ M9F%I<B!V86QU92!O9B!C87-H(&5Q=6EV86QE;G1S(&%N9`T*(&%V86EL86)L M92!F;W(@<V%L92!I;G9E<W1M96YT<R!A="!$96-E;6)E<B8C>$$P.S,Q+"`R M,#$T(&%N9"`R,#$S#0H@=V5R92!A<R!F;VQL;W=S("AI;B!T:&]U<V%N9',I M.CPO9F]N=#X\+W`^#0H@/'`@<W1Y;&4],T0G34%21TE.+4)/5%1/33H@,'!X M.R!&3TY4+5-)6D4Z(#$R<'@[($U!4D=)3BU43U`Z(#!P>"<^#0H@)B-X03`[ M/"]P/@T*(#QT86)L92!S='EL93TS1"="3U)$15(M0T],3$%04T4Z(&-O;&QA M<'-E)R!C96QL<W!A8VEN9STS1#`@8V5L;'!A9&1I;F<],T0P('=I9'1H/3-$ M,3`P)2!A;&EG;CTS1&-E;G1E<B!B;W)D97(],T0P/@T*(#QT<CX-"B`\=&0@ M=VED=&@],T0T-24^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H M/3-$-24^/"]T9#X-"B`\=&0^/"]T9#X-"B`\=&0^/"]T9#X-"B`\=&0^/"]T M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$-24^/"]T9#X-"B`\ M=&0^/"]T9#X-"B`\=&0^/"]T9#X-"B`\=&0^/"]T9#X-"B`\=&0@=F%L:6=N M/3-$8F]T=&]M('=I9'1H/3-$-24^/"]T9#X-"B`\=&0^/"]T9#X-"B`\=&0^ M/"]T9#X-"B`\=&0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H M/3-$-24^/"]T9#X-"B`\=&0^/"]T9#X-"B`\=&0^/"]T9#X-"B`\=&0^/"]T M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$-24^/"]T9#X-"B`\ M=&0^/"]T9#X-"B`\=&0^/"]T9#X-"B`\=&0^/"]T9#X-"B`\+W1R/@T*(#QT M<CX-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C>$$P M.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<VEZ M93TS1#$^)B-X03`[)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('-T>6QE/3-$ M)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,7!X('-O;&ED)R!V86QI9VX],T1B M;W1T;VT@8V]L<W!A;CTS1#$X(&%L:6=N/3-$8V5N=&5R/CQF;VYT('-T>6QE M/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0Q/CQB M/D1E8V5M8F5R)B-X03`[,S$L#0H@,C`Q-#PO8CX\+V9O;G0^/"]T9#X-"B`\ M=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C>$$P.SPO9F]N M=#X\+W1D/@T*(#PO='(^#0H@/'1R/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^ M/&9O;G0@<VEZ93TS1#$^)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG M;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF(WA!,#LF(WA!,#L\+V9O;G0^ M/"]T9#X-"B`\=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@(S`P,#`P,"`Q M<'@@<V]L:60G('9A;&EG;CTS1&)O='1O;2!C;VQS<&%N/3-$,B!A;&EG;CTS M1&-E;G1E<CX\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W M(%)O;6%N)R!S:7IE/3-$,3X\8CY!;6]R=&EZ960\8G(@+SX-"B!#;W-T/"]B M/CPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<VEZ M93TS1#$^)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O M;3X\9F]N="!S:7IE/3-$,3XF(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\ M=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@(S`P,#`P,"`Q<'@@<V]L:60G M('9A;&EG;CTS1&)O='1O;2!C;VQS<&%N/3-$,B!A;&EG;CTS1&-E;G1E<CX\ M9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S M:7IE/3-$,3X\8CY5;G)E86QI>F5D/&)R("\^#0H@1V%I;G,\+V(^/"]F;VYT M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF M(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT M('-I>F4],T0Q/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!S='EL M93TS1"="3U)$15(M0D]45$]-.B`C,#`P,#`P(#%P>"!S;VQI9"<@=F%L:6=N M/3-$8F]T=&]M(&-O;'-P86X],T0R(&%L:6=N/3-$8V5N=&5R/CQF;VYT('-T M>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0Q M/CQB/E5N<F5A;&EZ960\8G(@+SX-"B!,;W-S97,\+V(^/"]F;VYT/CPO=&0^ M#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF(WA!,#L\ M+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4] M,T0Q/B8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!S='EL93TS1"="3U)$15(M M0D]45$]-.B`C,#`P,#`P(#%P>"!S;VQI9"<@=F%L:6=N/3-$8F]T=&]M(&-O M;'-P86X],T0R(&%L:6=N/3-$8V5N=&5R/CQF;VYT('-T>6QE/3-$)T9/3E0M M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0Q/CQB/D9A:7(\8G(@ M+SX-"B!686QU93PO8CX\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T M=&]M/CQF;VYT('-I>F4],T0Q/B8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V M86QI9VX],T1B;W1T;VT^/&9O;G0@<VEZ93TS1#$^)B-X03`[)B-X03`[/"]F M;VYT/CPO=&0^#0H@/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P M,#`@,7!X('-O;&ED)R!V86QI9VX],T1B;W1T;VT@8V]L<W!A;CTS1#(@86QI M9VX],T1C96YT97(^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S M($YE=R!2;VUA;B<@<VEZ93TS1#$^/&(^36%T=7)I='D\8G(@+SX-"B!$871E M<SPO8CX\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT M('-I>F4],T0Q/B8C>$$P.SPO9F]N=#X\+W1D/@T*(#PO='(^#0H@/'1R(&)G M8V]L;W(],T0C0T-%149&/@T*(#QT9"!V86QI9VX],T1T;W`^#0H@/'`@<W1Y M;&4],T0G34%21TE.+4Q%1E0Z(#%E;3L@5$585"U)3D1%3E0Z("TQ96TG/CQF M;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I M>F4],T0R/D-A<V@@97%U:79A;&5N=',@)B-X,C`Q-#L-"B!M;VYE>2!M87)K M970@9G5N9',\+V9O;G0^/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O M='1O;3X\9F]N="!S:7IE/3-$,3XF(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X- M"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%- M24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R/B0\+V9O;G0^/"]T9#X- M"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^/&9O;G0@<W1Y M;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^ M,38L.3,R/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R M87`],T1N;W=R87`^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S M($YE=R!2;VUA;B<@<VEZ93TS1#(^)B-X03`[)B-X03`[/"]F;VYT/CPO=&0^ M#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF(WA!,#LF M(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A M<#TS1&YO=W)A<#X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@ M3F5W(%)O;6%N)R!S:7IE/3-$,CXD/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG M;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`@86QI9VX],T1R:6=H=#X\9F]N M="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE M/3-$,CXF(W@R,#$T.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T M;VT@;F]W<F%P/3-$;F]W<F%P/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9 M.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R/B8C>$$P.R8C>$$P.SPO9F]N M=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<VEZ93TS1#$^ M)B-X03`[)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O M;2!N;W=R87`],T1N;W=R87`^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ M(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^)#PO9F]N=#X\+W1D/@T*(#QT M9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P(&%L:6=N/3-$<FEG M:'0^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA M;B<@<VEZ93TS1#(^)B-X,C`Q-#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N M/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#X\9F]N="!S='EL93TS1"=&3TY4 M+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXF(WA!,#LF(WA! M,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I M>F4],T0Q/B8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T M;VT^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA M;B<@<VEZ93TS1#(^)#PO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T M;VT@86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@ M5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXQ-BPY,S(\+V9O;G0^/"]T9#X- M"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#X\9F]N="!S M='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$ M,CXF(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T M=&]M/CQF;VYT('-I>F4],T0Q/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T* M(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T M=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#PO='(^ M#0H@/'1R('-T>6QE/3-$)T9/3E0M4TE:13H@,7!X)SX-"B`\=&0@=F%L:6=N M/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF M(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@<W1Y;&4] M,T0G0D]21$52+51/4#H@(S`P,#`P,"`S<'@@9&]U8FQE)SXF(WA!,#L\+W`^ M#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$ M)T)/4D1%4BU43U`Z(",P,#`P,#`@,W!X(&1O=6)L92<^)B-X03`[/"]P/@T* M(#PO=&0^#0H@/'1D/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O M;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@ M/'`@<W1Y;&4],T0G0D]21$52+51/4#H@(S`P,#`P,"`S<'@@9&]U8FQE)SXF M(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP M('-T>6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@,W!X(&1O=6)L92<^)B-X M03`[/"]P/@T*(#PO=&0^#0H@/'1D/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG M;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B M;W1T;VT^#0H@/'`@<W1Y;&4],T0G0D]21$52+51/4#H@(S`P,#`P,"`S<'@@ M9&]U8FQE)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T M=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@,W!X(&1O M=6)L92<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D/B8C>$$P.SPO=&0^#0H@ M/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX] M,T1B;W1T;VT^#0H@/'`@<W1Y;&4],T0G0D]21$52+51/4#H@(S`P,#`P,"`S M<'@@9&]U8FQE)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$ M8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@,W!X M(&1O=6)L92<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D/B8C>$$P.SPO=&0^ M#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT M9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#PO='(^#0H@ M/'1R/@T*(#QT9"!V86QI9VX],T1T;W`^#0H@/'`@<W1Y;&4],T0G34%21TE. M+4Q%1E0Z(#%E;3L@5$585"U)3D1%3E0Z("TQ96TG/CQF;VYT('-T>6QE/3-$ M)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R/E-H;W)T M+71E<FT@:6YV97-T;65N=',-"B`F(W@R,#$T.R!5+E,N(%1R96%S=7)Y('-E M8W5R:71I97,\+V9O;G0^/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O M='1O;3X\9F]N="!S:7IE/3-$,3XF(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X- M"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%- M24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R/B0\+V9O;G0^/"]T9#X- M"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^/&9O;G0@<W1Y M;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^ M-C,L,#$W/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R M87`],T1N;W=R87`^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S M($YE=R!2;VUA;B<@<VEZ93TS1#(^)B-X03`[)B-X03`[/"]F;VYT/CPO=&0^ M#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF(WA!,#LF M(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT M('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4] M,T0R/B0\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N M/3-$<FEG:'0^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE M=R!2;VUA;B<@<VEZ93TS1#(^,SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX] M,T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P/CQF;VYT('-T>6QE/3-$)T9/3E0M M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R/B8C>$$P.R8C>$$P M.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<VEZ M93TS1#$^)B-X03`[)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS M1&)O='1O;3X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W M(%)O;6%N)R!S:7IE/3-$,CXD/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS M1&)O='1O;2!A;&EG;CTS1')I9VAT/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%- M24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R/B@W/"]F;VYT/CPO=&0^ M#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^/&9O;G0@ M<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS M1#(^*28C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^ M/&9O;G0@<VEZ93TS1#$^)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG M;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@ M3F5W(%)O;6%N)R!S:7IE/3-$,CXD/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG M;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/CQF;VYT('-T>6QE/3-$)T9/3E0M M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R/C8S+#`Q,SPO9F]N M=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P M/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG M('-I>F4],T0R/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI M9VX],T1B;W1T;VT^/&9O;G0@<VEZ93TS1#$^)B-X03`[)B-X03`[/"]F;VYT M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=& M3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXF(WA!,#L\ M+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG M:'0^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA M;B<@<VEZ93TS1#(^,2\R,#$U)B-X03`[)B-X,C`Q-#LF(WA!,#LQ,B\R,#$U M/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N M;W=R87`^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2 M;VUA;B<@<VEZ93TS1#(^)B-X03`[)B-X03`[/"]F;VYT/CPO=&0^#0H@/"]T M<CX-"B`\='(@<W1Y;&4],T0G1D].5"U325I%.B`Q<'@G/@T*(#QT9"!V86QI M9VX],T1B;W1T;VT^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P M.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL M93TS1"="3U)$15(M5$]0.B`C,#`P,#`P(#-P>"!D;W5B;&4G/B8C>$$P.SPO M<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@<W1Y;&4] M,T0G0D]21$52+51/4#H@(S`P,#`P,"`S<'@@9&]U8FQE)SXF(WA!,#L\+W`^ M#0H@/"]T9#X-"B`\=&0^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T M=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X- M"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B`C,#`P,#`P(#-P>"!D;W5B;&4G M/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@ M/'`@<W1Y;&4],T0G0D]21$52+51/4#H@(S`P,#`P,"`S<'@@9&]U8FQE)SXF M(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0^)B-X03`[/"]T9#X-"B`\=&0@=F%L M:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS M1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B`C,#`P,#`P(#-P M>"!D;W5B;&4G/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B M;W1T;VT^#0H@/'`@<W1Y;&4],T0G0D]21$52+51/4#H@(S`P,#`P,"`S<'@@ M9&]U8FQE)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0^)B-X03`[/"]T9#X- M"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG M;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B`C,#`P,#`P M(#-P>"!D;W5B;&4G/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX] M,T1B;W1T;VT^#0H@/'`@<W1Y;&4],T0G0D]21$52+51/4#H@(S`P,#`P,"`S M<'@@9&]U8FQE)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0^)B-X03`[/"]T M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@ M/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T M;VT^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/"]T<CX- M"B`\='(@8F=C;VQO<CTS1"-#0T5%1D8^#0H@/'1D('9A;&EG;CTS1'1O<#X- M"B`\<"!S='EL93TS1"=-05)'24XM3$5&5#H@,65M.R!415A4+4E.1$5.5#H@ M+3%E;2<^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2 M;VUA;B<@<VEZ93TS1#(^3&]N9RUT97)M(&EN=F5S=&UE;G1S#0H@)B-X,C`Q M-#L@52Y3+B!4<F5A<W5R>2!S96-U<FET:65S/"]F;VYT/CPO<#X-"B`\+W1D M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<VEZ93TS1#$^)B-X03`[ M)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R M87`],T1N;W=R87`^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S M($YE=R!2;VUA;B<@<VEZ93TS1#(^)#PO9F]N=#X\+W1D/@T*(#QT9"!V86QI M9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P(&%L:6=N/3-$<FEG:'0^/&9O M;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ M93TS1#(^)B-X,C`Q-#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T M=&]M(&YO=W)A<#TS1&YO=W)A<#X\9F]N="!S='EL93TS1"=&3TY4+49!34E, M63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXF(WA!,#LF(WA!,#L\+V9O M;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q M/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T M;VT@;F]W<F%P/3-$;F]W<F%P/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9 M.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R/B0\+V9O;G0^/"]T9#X-"B`\ M=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<"!A;&EG;CTS1')I M9VAT/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M M86XG('-I>F4],T0R/B8C>#(P,30[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG M;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^/&9O;G0@<W1Y;&4],T0G1D]. M5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^)B-X03`[)B-X M03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S M:7IE/3-$,3XF(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N M/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#X\9F]N="!S='EL93TS1"=&3TY4 M+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXD/"]F;VYT/CPO M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`@86QI M9VX],T1R:6=H=#X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@ M3F5W(%)O;6%N)R!S:7IE/3-$,CXF(W@R,#$T.SPO9F]N=#X\+W1D/@T*(#QT M9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P/CQF;VYT('-T>6QE M/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R/B8C M>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^ M/&9O;G0@<VEZ93TS1#$^)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG M;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^/&9O;G0@<W1Y;&4],T0G1D]. M5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^)#PO9F]N=#X\ M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P(&%L M:6=N/3-$<FEG:'0^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S M($YE=R!2;VUA;B<@<VEZ93TS1#(^)B-X,C`Q-#L\+V9O;G0^/"]T9#X-"B`\ M=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#X\9F]N="!S='EL M93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXF M(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M M/CQF;VYT('-I>F4],T0Q/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT M9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#PO='(^#0H@ M/'1R('-T>6QE/3-$)T9/3E0M4TE:13H@,7!X)SX-"B`\=&0@=F%L:6=N/3-$ M8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA! M,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@<W1Y;&4],T0G M0D]21$52+51/4#H@(S`P,#`P,"`S<'@@9&]U8FQE)SXF(WA!,#L\+W`^#0H@ M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/ M4D1%4BU43U`Z(",P,#`P,#`@,W!X(&1O=6)L92<^)B-X03`[/"]P/@T*(#PO M=&0^#0H@/'1D/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF M(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@ M<W1Y;&4],T0G0D]21$52+51/4#H@(S`P,#`P,"`S<'@@9&]U8FQE)SXF(WA! M,#L\+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T M>6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@,W!X(&1O=6)L92<^)B-X03`[ M/"]P/@T*(#PO=&0^#0H@/'1D/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS M1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T M;VT^#0H@/'`@<W1Y;&4],T0G0D]21$52+51/4#H@(S`P,#`P,"`S<'@@9&]U M8FQE)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@,W!X(&1O=6)L M92<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D/B8C>$$P.SPO=&0^#0H@/'1D M('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B M;W1T;VT^#0H@/'`@<W1Y;&4],T0G0D]21$52+51/4#H@(S`P,#`P,"`S<'@@ M9&]U8FQE)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T M=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@,W!X(&1O M=6)L92<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D/B8C>$$P.SPO=&0^#0H@ M/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V M86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#PO='(^#0H@/"]T M86)L93X-"B`\<"!S='EL93TS1"=-05)'24XM0D]45$]-.B`P<'@[($9/3E0M M4TE:13H@,3)P>#L@34%21TE.+51/4#H@,'!X)SX-"B`F(WA!,#L\+W`^#0H@ M/'1A8FQE('-T>6QE/3-$)T)/4D1%4BU#3TQ,05!313H@8V]L;&%P<V4G(&-E M;&QS<&%C:6YG/3-$,"!C96QL<&%D9&EN9STS1#`@=VED=&@],T0Q,#`E(&%L M:6=N/3-$8V5N=&5R(&)O<F1E<CTS1#`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`[/"]F;VYT M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF M(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@<W1Y;&4],T0G0D]21$52 M+4)/5%1/33H@(S`P,#`P,"`Q<'@@<V]L:60G('9A;&EG;CTS1&)O='1O;2!C M;VQS<&%N/3-$,3@@86QI9VX],T1C96YT97(^/&9O;G0@<W1Y;&4],T0G1D]. M5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#$^/&(^1&5C96UB M97(F(WA!,#LS,2P-"B`R,#$S/"]B/CPO9F]N=#X\+W1D/@T*(#QT9"!V86QI M9VX],T1B;W1T;VT^/&9O;G0@<VEZ93TS1#$^)B-X03`[/"]F;VYT/CPO=&0^ M#0H@/"]T<CX-"B`\='(^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S M:7IE/3-$,3XF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T M=&]M/CQF;VYT('-I>F4],T0Q/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T* M(#QT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B`C,#`P,#`P(#%P>"!S;VQI M9"<@=F%L:6=N/3-$8F]T=&]M(&-O;'-P86X],T0R(&%L:6=N/3-$8V5N=&5R M/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG M('-I>F4],T0Q/CQB/D%M;W)T:7IE9#QB<B`O/@T*($-O<W0\+V(^/"]F;VYT M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF M(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT M('-I>F4],T0Q/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!S='EL M93TS1"="3U)$15(M0D]45$]-.B`C,#`P,#`P(#%P>"!S;VQI9"<@=F%L:6=N M/3-$8F]T=&]M(&-O;'-P86X],T0R(&%L:6=N/3-$8V5N=&5R/CQF;VYT('-T M>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0Q M/CQB/E5N<F5A;&EZ960\8G(@+SX-"B!'86EN<SPO8CX\+V9O;G0^/"]T9#X- M"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C>$$P.SPO M9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<VEZ93TS M1#$^)B-X03`[)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('-T>6QE/3-$)T)/ M4D1%4BU"3U143TTZ(",P,#`P,#`@,7!X('-O;&ED)R!V86QI9VX],T1B;W1T M;VT@8V]L<W!A;CTS1#(@86QI9VX],T1C96YT97(^/&9O;G0@<W1Y;&4],T0G M1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#$^/&(^56YR M96%L:7IE9#QB<B`O/@T*($QO<W-E<SPO8CX\+V9O;G0^/"]T9#X-"B`\=&0@ M=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C>$$P.SPO9F]N=#X\ M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<VEZ93TS1#$^)B-X M03`[/"]F;VYT/CPO=&0^#0H@/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ M(",P,#`P,#`@,7!X('-O;&ED)R!V86QI9VX],T1B;W1T;VT@8V]L<W!A;CTS M1#(@86QI9VX],T1C96YT97(^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ M(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#$^/&(^1F%I<CQB<B`O/@T*(%9A M;'5E/"]B/CPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O M;G0@<VEZ93TS1#$^)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS M1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF(WA!,#LF(WA!,#L\+V9O;G0^/"]T M9#X-"B`\=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@(S`P,#`P,"`Q<'@@ M<V]L:60G('9A;&EG;CTS1&)O='1O;2!C;VQS<&%N/3-$,B!A;&EG;CTS1&-E M;G1E<CX\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O M;6%N)R!S:7IE/3-$,3X\8CY-871U<FET>3QB<B`O/@T*($1A=&5S/"]B/CPO M9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<VEZ93TS M1#$^)B-X03`[/"]F;VYT/CPO=&0^#0H@/"]T<CX-"B`\='(@8F=C;VQO<CTS M1"-#0T5%1D8^#0H@/'1D('9A;&EG;CTS1'1O<#X-"B`\<"!S='EL93TS1"=- M05)'24XM3$5&5#H@,65M.R!415A4+4E.1$5.5#H@+3%E;2<^/&9O;G0@<W1Y M;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^ M0V%S:"!E<75I=F%L96YT<R`F(W@R,#$T.PT*(&UO;F5Y(&UA<FME="!F=6YD M<SPO9F]N=#X\+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF M;VYT('-I>F4],T0Q/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V M86QI9VX],T1B;W1T;VT^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I M;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^)#PO9F]N=#X\+W1D/@T*(#QT9"!V M86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS1"=& M3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXQ-2PX-3@\ M+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO M=W)A<#X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O M;6%N)R!S:7IE/3-$,CXF(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@ M=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C>$$P.R8C>$$P.SPO M9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W M<F%P/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M M86XG('-I>F4],T0R/B0\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T M=&]M(&YO=W)A<#TS1&YO=W)A<"!A;&EG;CTS1')I9VAT/CQF;VYT('-T>6QE M/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R/B8C M>#(P,30[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R M87`],T1N;W=R87`^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S M($YE=R!2;VUA;B<@<VEZ93TS1#(^)B-X03`[)B-X03`[/"]F;VYT/CPO=&0^ M#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF(WA!,#LF M(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A M<#TS1&YO=W)A<#X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@ M3F5W(%)O;6%N)R!S:7IE/3-$,CXD/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG M;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`@86QI9VX],T1R:6=H=#X\9F]N M="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE M/3-$,CXF(W@R,#$T.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T M;VT@;F]W<F%P/3-$;F]W<F%P/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9 M.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R/B8C>$$P.R8C>$$P.SPO9F]N M=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<VEZ93TS1#$^ M)B-X03`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`[)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A M;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/"]T<CX-"B`\='(@ M<W1Y;&4],T0G1D].5"U325I%.B`Q<'@G/@T*(#QT9"!V86QI9VX],T1B;W1T M;VT^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$ M15(M5$]0.B`C,#`P,#`P(#-P>"!D;W5B;&4G/B8C>$$P.SPO<#X-"B`\+W1D M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@<W1Y;&4],T0G0D]21$52 M+51/4#H@(S`P,#`P,"`S<'@@9&]U8FQE)SXF(WA!,#L\+W`^#0H@/"]T9#X- M"B`\=&0^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P M.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL M93TS1"="3U)$15(M5$]0.B`C,#`P,#`P(#-P>"!D;W5B;&4G/B8C>$$P.SPO M<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@<W1Y;&4] M,T0G0D]21$52+51/4#H@(S`P,#`P,"`S<'@@9&]U8FQE)SXF(WA!,#L\+W`^ M#0H@/"]T9#X-"B`\=&0^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T M=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X- M"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B`C,#`P,#`P(#-P>"!D;W5B;&4G M/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@ M/'`@<W1Y;&4],T0G0D]21$52+51/4#H@(S`P,#`P,"`S<'@@9&]U8FQE)SXF M(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0^)B-X03`[/"]T9#X-"B`\=&0@=F%L M:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O M;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B`C,#`P,#`P(#-P>"!D;W5B M;&4G/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^ M#0H@/'`@<W1Y;&4],T0G0D]21$52+51/4#H@(S`P,#`P,"`S<'@@9&]U8FQE M)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0^)B-X03`[/"]T9#X-"B`\=&0@ M=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG M;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X- M"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/"]T<CX-"B`\='(^#0H@ M/'1D('9A;&EG;CTS1'1O<#X-"B`\<"!S='EL93TS1"=-05)'24XM3$5&5#H@ M,65M.R!415A4+4E.1$5.5#H@+3%E;2<^/&9O;G0@<W1Y;&4],T0G1D].5"U& M04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^4VAO<G0M=&5R;2!I M;G9E<W1M96YT<PT*("8C>#(P,30[(%4N4RX@5')E87-U<GD@<V5C=7)I=&EE M<SPO9F]N=#X\+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF M;VYT('-I>F4],T0Q/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V M86QI9VX],T1B;W1T;VT^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I M;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^)#PO9F]N=#X\+W1D/@T*(#QT9"!V M86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS1"=& M3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXU-RPU-C0\ M+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO M=W)A<#X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O M;6%N)R!S:7IE/3-$,CXF(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@ M=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C>$$P.R8C>$$P.SPO M9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<W1Y;&4] M,T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^)#PO M9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H M=#X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N M)R!S:7IE/3-$,CXW/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O M;2!N;W=R87`],T1N;W=R87`^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ M(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^)B-X03`[)B-X03`[/"]F;VYT M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF M(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M M/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG M('-I>F4],T0R/B0\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M M(&%L:6=N/3-$<FEG:'0^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I M;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^*#$\+V9O;G0^/"]T9#X-"B`\=&0@ M=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#X\9F]N="!S='EL93TS M1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXI)B-X M03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S M:7IE/3-$,3XF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T M=&]M/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M M86XG('-I>F4],T0R/B0\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T M=&]M(&%L:6=N/3-$<FEG:'0^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ M(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^-3<L-3<P/"]F;VYT/CPO=&0^ M#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^/&9O;G0@ M<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS M1#(^)B-X03`[)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O M='1O;3X\9F]N="!S:7IE/3-$,3XF(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X- M"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%- M24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R/B8C>$$P.SPO9F]N=#X\ M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#X\9F]N M="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE M/3-$,CXQ+S(P,30F(WA!,#LF(W@R,#$T.R8C>$$P.S$R+S(P,30\+V9O;G0^ M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#X\ M9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S M:7IE/3-$,CXF(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\+W1R/@T*(#QT M<B!S='EL93TS1"=&3TY4+5-)6D4Z(#%P>"<^#0H@/'1D('9A;&EG;CTS1&)O M='1O;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[ M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/ M4D1%4BU43U`Z(",P,#`P,#`@,W!X(&1O=6)L92<^)B-X03`[/"]P/@T*(#PO M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$ M15(M5$]0.B`C,#`P,#`P(#-P>"!D;W5B;&4G/B8C>$$P.SPO<#X-"B`\+W1D M/@T*(#QT9#XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X M03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T M>6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@,W!X(&1O=6)L92<^)B-X03`[ M/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL M93TS1"="3U)$15(M5$]0.B`C,#`P,#`P(#-P>"!D;W5B;&4G/B8C>$$P.SPO M<#X-"B`\+W1D/@T*(#QT9#XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B M;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@,W!X(&1O=6)L M92<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X- M"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B`C,#`P,#`P(#-P>"!D;W5B;&4G M/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT9#XF(WA!,#L\+W1D/@T*(#QT9"!V M86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T M=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@,W!X(&1O M=6)L92<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O M;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B`C,#`P,#`P(#-P>"!D;W5B M;&4G/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT9#XF(WA!,#L\+W1D/@T*(#QT M9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L M:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\+W1R/@T*(#QT<B!B M9V-O;&]R/3-$(T-#145&1CX-"B`\=&0@=F%L:6=N/3-$=&]P/@T*(#QP('-T M>6QE/3-$)TU!4D=)3BU,1494.B`Q96T[(%1%6%0M24Y$14Y4.B`M,65M)SX\ M9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S M:7IE/3-$,CY,;VYG+71E<FT@:6YV97-T;65N=',-"B`F(W@R,#$T.R!5+E,N M(%1R96%S=7)Y('-E8W5R:71I97,\+V9O;G0^/"]P/@T*(#PO=&0^#0H@/'1D M('9A;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF(WA!,#LF(WA!,#L\ M+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE M/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R/B0\ M+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG M:'0^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA M;B<@<VEZ93TS1#(^,BPU,#(\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$ M8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#X\9F]N="!S='EL93TS1"=&3TY4+49! M34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXF(WA!,#LF(WA!,#L\ M+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4] M,T0Q/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B M;W1T;VT@;F]W<F%P/3-$;F]W<F%P/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%- M24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R/B0\+V9O;G0^/"]T9#X- M"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<"!A;&EG;CTS M1')I9VAT/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@ M4F]M86XG('-I>F4],T0R/B8C>#(P,30[/"]F;VYT/CPO=&0^#0H@/'1D('9A M;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^/&9O;G0@<W1Y;&4],T0G M1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^)B-X03`[ M)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N M="!S:7IE/3-$,3XF(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L M:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#X\9F]N="!S='EL93TS1"=& M3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXD/"]F;VYT M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`@ M86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM M97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXF(W@R,#$T.SPO9F]N=#X\+W1D/@T* M(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P/CQF;VYT('-T M>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R M/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T M;VT^/&9O;G0@<VEZ93TS1#$^)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A M;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM M97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXD/"]F;VYT/CPO=&0^#0H@/'1D('9A M;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/CQF;VYT('-T>6QE/3-$)T9/ M3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R/C(L-3`R/"]F M;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R M87`^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA M;B<@<VEZ93TS1#(^)B-X03`[)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A M;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF(WA!,#LF(WA!,#L\+V9O M;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$ M)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R/B8C>$$P M.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R M:6=H=#X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O M;6%N)R!S:7IE/3-$,CXQ+S(P,34\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N M/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#X\9F]N="!S='EL93TS1"=&3TY4 M+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXF(WA!,#LF(WA! M,#L\+V9O;G0^/"]T9#X-"B`\+W1R/@T*(#QT<B!S='EL93TS1"=&3TY4+5-) M6D4Z(#%P>"<^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V M86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N M/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@ M,W!X(&1O=6)L92<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS M1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B`C,#`P,#`P(#-P M>"!D;W5B;&4G/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT9#XF(WA!,#L\+W1D M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\ M=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z M(",P,#`P,#`@,W!X(&1O=6)L92<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D M('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B`C M,#`P,#`P(#-P>"!D;W5B;&4G/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT9#XF M(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[ M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/ M4D1%4BU43U`Z(",P,#`P,#`@,W!X(&1O=6)L92<^)B-X03`[/"]P/@T*(#PO M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$ M15(M5$]0.B`C,#`P,#`P(#-P>"!D;W5B;&4G/B8C>$$P.SPO<#X-"B`\+W1D M/@T*(#QT9#XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X M03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$ M)T)/4D1%4BU43U`Z(",P,#`P,#`@,W!X(&1O=6)L92<^)B-X03`[/"]P/@T* M(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"=" M3U)$15(M5$]0.B`C,#`P,#`P(#-P>"!D;W5B;&4G/B8C>$$P.SPO<#X-"B`\ M+W1D/@T*(#QT9#XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^ M)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^ M#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B M;W1T;VT^/"]T9#X-"B`\+W1R/@T*(#PO=&%B;&4^#0H@/"]D:78^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$ M<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y3=6UM M87)Y(&]F($EN=&5R97-T($EN8V]M93PO=&0^#0H@("`@("`@(#QT9"!C;&%S M<STS1'1E>'0^/&1I=CX-"B`\<"!S='EL93TS1"=-05)'24XM0D]45$]-.B`P M<'@[($U!4D=)3BU43U`Z(#$R<'@[(%1%6%0M24Y$14Y4.B`T)2<@86QI9VX] M,T1J=7-T:69Y/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!. M97<@4F]M86XG('-I>F4],T0R/DEN=&5R97-T(&EN8V]M92!W87,@87,@9F]L M;&]W<R`H:6X@=&AO=7-A;F1S*3H\+V9O;G0^/"]P/@T*(#QP('-T>6QE/3-$ M)TU!4D=)3BU"3U143TTZ(#!P>#L@1D].5"U325I%.B`Q,G!X.R!-05)'24XM M5$]0.B`P<'@G/@T*("8C>$$P.SPO<#X-"B`\=&%B;&4@<W1Y;&4],T0G0D]2 M1$52+4-/3$Q!4%-%.B!C;VQL87!S92<@8V5L;'-P86-I;F<],T0P(&-E;&QP M861D:6YG/3-$,"!W:61T:#TS1#DR)2!A;&EG;CTS1&-E;G1E<B!B;W)D97(] M,T0P/@T*(#QT<CX-"B`\=&0@=VED=&@],T0X,24^/"]T9#X-"B`\=&0@=F%L M:6=N/3-$8F]T=&]M('=I9'1H/3-$-"4^/"]T9#X-"B`\=&0^/"]T9#X-"B`\ M=&0^/"]T9#X-"B`\=&0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M('=I M9'1H/3-$-"4^/"]T9#X-"B`\=&0^/"]T9#X-"B`\=&0^/"]T9#X-"B`\=&0^ M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$-"4^/"]T9#X- M"B`\=&0^/"]T9#X-"B`\=&0^/"]T9#X-"B`\=&0^/"]T9#X-"B`\+W1R/@T* M(#QT<CX-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C M>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@ M<VEZ93TS1#$^)B-X03`[)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('-T>6QE M/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,7!X('-O;&ED)R!V86QI9VX] M,T1B;W1T;VT@8V]L<W!A;CTS1#$P(&%L:6=N/3-$8V5N=&5R/CQF;VYT('-T M>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0Q M/CQB/EEE87)S($5N9&5D/&)R("\^#0H@1&5C96UB97(F(WA!,#LS,2P\+V(^ M/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE M/3-$,3XF(WA!,#L\+V9O;G0^/"]T9#X-"B`\+W1R/@T*(#QT<CX-"B`\=&0@ M=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C>$$P.SPO9F]N=#X\ M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<VEZ93TS1#$^)B-X M03`[)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('-T>6QE/3-$)T)/4D1%4BU" M3U143TTZ(",P,#`P,#`@,7!X('-O;&ED)R!V86QI9VX],T1B;W1T;VT@8V]L M<W!A;CTS1#(@86QI9VX],T1C96YT97(^/&9O;G0@<W1Y;&4],T0G1D].5"U& M04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#$^/&(^,C`Q-#PO8CX\ M+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4] M,T0Q/B8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^ M/&9O;G0@<VEZ93TS1#$^)B-X03`[)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D M('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,7!X('-O;&ED)R!V M86QI9VX],T1B;W1T;VT@8V]L<W!A;CTS1#(@86QI9VX],T1C96YT97(^/&9O M;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ M93TS1#$^/&(^,C`Q,SPO8CX\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$ M8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT M9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<VEZ93TS1#$^)B-X03`[)B-X03`[ M/"]F;VYT/CPO=&0^#0H@/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(",P M,#`P,#`@,7!X('-O;&ED)R!V86QI9VX],T1B;W1T;VT@8V]L<W!A;CTS1#(@ M86QI9VX],T1C96YT97(^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I M;65S($YE=R!2;VUA;B<@<VEZ93TS1#$^/&(^,C`Q,CPO8CX\+V9O;G0^/"]T M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C>$$P M.SPO9F]N=#X\+W1D/@T*(#PO='(^#0H@/'1R(&)G8V]L;W(],T0C0T-%149& M/@T*(#QT9"!V86QI9VX],T1T;W`^#0H@/'`@<W1Y;&4],T0G34%21TE.+4Q% M1E0Z(#%E;3L@5$585"U)3D1%3E0Z("TQ96TG/CQF;VYT('-T>6QE/3-$)T9/ M3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R/DEN=&5R97-T M(&EN8V]M93PO9F]N=#X\+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T M=&]M/CQF;VYT('-I>F4],T0Q/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T* M(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U) M3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^)#PO9F]N=#X\+W1D/@T* M(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#X\9F]N="!S='EL M93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXQ M,#$\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS M1&YO=W)A<#X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W M(%)O;6%N)R!S:7IE/3-$,CXF(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`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`[)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O M='1O;3X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O M;6%N)R!S:7IE/3-$,CXD/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O M='1O;2!A;&EG;CTS1')I9VAT/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9 M.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R/C@S/"]F;VYT/CPO=&0^#0H@ M/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^/&9O;G0@<W1Y M;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^ M)B-X03`[)B-X03`[/"]F;VYT/CPO=&0^#0H@/"]T<CX-"B`\+W1A8FQE/@T* M(#PO9&EV/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`\ M+W1A8FQE/@T*("`\+V)O9'D^#0H\+VAT;6P^#0H-"BTM+2TM+3U?3F5X=%!A M<G1?,SEC,&5A-C)?8S(P,U\T-3AF7SAC-3!?,V1C830U-F$V.34Q#0I#;VYT M96YT+4QO8V%T:6]N.B!F:6QE.B\O+T,Z+S,Y8S!E838R7V,R,#-?-#4X9E\X M8S4P7S-D8V$T-39A-CDU,2]7;W)K<VAE971S+U-H965T,C<N:'1M;`T*0V]N M=&5N="U4<F%N<V9E<BU%;F-O9&EN9SH@<75O=&5D+7!R:6YT86)L90T*0V]N M=&5N="U4>7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\ M:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E M;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA<G-E=#UU=&8M."<^ M/'-C<FEP="!T>7!E/3-$=&5X="]J879A<V-R:7!T('-R8STS1%-H;W<N:G,^ M+RH@1&\@3F]T(%)E;6]V92!4:&ES($-O;6UE;G0@*B\\+W-C<FEP=#X\+VAE M860^#0H@(#QB;V1Y/@T*("`@(#QT86)L92!C;&%S<STS1')E<&]R="!I9#TS M1$E$,$5-13X-"B`@("`@(#QT<CX-"B`@("`@("`@/'1H(&-L87-S/3-$=&P@ M8V]L<W!A;CTS1#$@<F]W<W!A;CTS1#(^/'-T<F]N9SY&86ER(%9A;'5E($UE M87-U<F5M96YT<R`H5&%B;&5S*3QB<CX\+W-T<F]N9SX\+W1H/@T*("`@("`@ M("`\=&@@8VQA<W,],T1T:"!C;VQS<&%N/3-$,3XQ,B!-;VYT:',@16YD960\ M+W1H/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<CX-"B`@("`@("`@/'1H(&-L M87-S/3-$=&@^1&5C+B`S,2P@,C`Q-#QB<CX\+W1H/@T*("`@("`@/"]T<CX- M"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P M;"!V86QI9VX],T1T;W`^/'-T<F]N9SY&86ER(%9A;'5E($1I<V-L;W-U<F5S M(%M!8G-T<F%C=%T\+W-T<F]N9SX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,] M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@ M(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI M9VX],T1T;W`^4W5M;6%R>2!O9B!&:6YA;F-I86P@07-S971S($UE87-U<F5D M(&%T($9A:7(@5F%L=64@;VX@4F5C=7)R:6YG($)A<VES/"]T9#X-"B`@("`@ M("`@/'1D(&-L87-S/3-$=&5X=#X\9&EV/@T*(#QP('-T>6QE/3-$)TU!4D=) M3BU"3U143TTZ(#!P>#L@34%21TE.+51/4#H@,3)P>#L@5$585"U)3D1%3E0Z M(#0E)R!A;&EG;CTS1&IU<W1I9GD^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U) M3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^1FEN86YC:6%L(&%S<V5T M<R!M96%S=7)E9"!A="!F86ER('9A;'5E(&]N(&$@<F5C=7)R:6YG(&)A<VES M(&%S#0H@;V8@1&5C96UB97(F(WA!,#LS,2P@,C`Q-"!A;F0@,C`Q,R!A<F4@ M8VQA<W-I9FEE9"!I;B!T:&4@=&%B;&4-"B!B96QO=R!I;B!O;F4@;V8@=&AE M('1H<F5E(&-A=&5G;W)I97,@9&5S8W)I8F5D(&%B;W9E("AI;@T*('1H;W5S M86YD<RDZ/"]F;VYT/CPO<#X-"B`\<"!S='EL93TS1"=-05)'24XM0D]45$]- M.B`P<'@[($9/3E0M4TE:13H@,3)P>#L@34%21TE.+51/4#H@,'!X)SX-"B`F M(WA!,#L\+W`^#0H@/'1A8FQE('-T>6QE/3-$)T)/4D1%4BU#3TQ,05!313H@ M8V]L;&%P<V4G(&-E;&QS<&%C:6YG/3-$,"!C96QL<&%D9&EN9STS1#`@=VED M=&@],T0Y,B4@86QI9VX],T1C96YT97(@8F]R9&5R/3-$,#X-"B`\='(^#0H@ M/'1D('=I9'1H/3-$-38E/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!W M:61T:#TS1#<E/CPO=&0^#0H@/'1D/CPO=&0^#0H@/'1D/CPO=&0^#0H@/'1D M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#<E/CPO=&0^ M#0H@/'1D/CPO=&0^#0H@/'1D/CPO=&0^#0H@/'1D/CPO=&0^#0H@/'1D('9A M;&EG;CTS1&)O='1O;2!W:61T:#TS1#<E/CPO=&0^#0H@/'1D/CPO=&0^#0H@ M/'1D/CPO=&0^#0H@/'1D/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!W M:61T:#TS1#<E/CPO=&0^#0H@/'1D/CPO=&0^#0H@/'1D/CPO=&0^#0H@/'1D M/CPO=&0^#0H@/"]T<CX-"B`\='(^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\ M9F]N="!S:7IE/3-$,3XF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N M/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C>$$P.R8C>$$P.SPO9F]N=#X\ M+W1D/@T*(#QT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B`C,#`P,#`P(#%P M>"!S;VQI9"<@=F%L:6=N/3-$8F]T=&]M(&-O;'-P86X],T0Q-"!A;&EG;CTS M1&-E;G1E<CX\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W M(%)O;6%N)R!S:7IE/3-$,3X\8CY$96-E;6)E<B8C>$$P.S,Q+`T*(#(P,30\ M+V(^/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S M:7IE/3-$,3XF(WA!,#L\+V9O;G0^/"]T9#X-"B`\+W1R/@T*(#QT<CX-"B`\ M=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C>$$P.SPO9F]N M=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<VEZ93TS1#$^ M)B-X03`[)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('-T>6QE/3-$)T)/4D1% M4BU"3U143TTZ(",P,#`P,#`@,7!X('-O;&ED)R!V86QI9VX],T1B;W1T;VT@ M8V]L<W!A;CTS1#$P(&%L:6=N/3-$8V5N=&5R/CQF;VYT('-T>6QE/3-$)T9/ M3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0Q/CQB/D9A:7(F M(WA!,#M686QU928C>$$P.TUE87-U<F5M96YT<R8C>$$P.U5S:6YG/"]B/CPO M9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<VEZ93TS M1#$^)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\ M9F]N="!S:7IE/3-$,3XF(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@ M<W1Y;&4],T0G0D]21$52+4)/5%1/33H@(S`P,#`P,"`Q<'@@<V]L:60G('9A M;&EG;CTS1&)O='1O;2!R;W=S<&%N/3-$,B!C;VQS<&%N/3-$,B!A;&EG;CTS M1&-E;G1E<CX\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W M(%)O;6%N)R!S:7IE/3-$,3X\8CY!<W-E=',\8G(@+SX-"B!!="8C>$$P.T9A M:7(F(WA!,#M686QU93PO8CX\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$ M8F]T=&]M(')O=W-P86X],T0R/CQF;VYT('-I>F4],T0Q/B8C>$$P.SPO9F]N M=#X\+W1D/@T*(#PO='(^#0H@/'1R/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^ M/&9O;G0@<VEZ93TS1#$^)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG M;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF(WA!,#LF(WA!,#L\+V9O;G0^ M/"]T9#X-"B`\=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@(S`P,#`P,"`Q M<'@@<V]L:60G('9A;&EG;CTS1&)O='1O;2!C;VQS<&%N/3-$,B!A;&EG;CTS M1&-E;G1E<CX\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W M(%)O;6%N)R!S:7IE/3-$,3X\8CXF(WA!,#LF(WA!,#M,979E;"8C>$$P.S$F M(WA!,#LF(WA!,#L\+V(^/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O M='1O;3X\9F]N="!S:7IE/3-$,3XF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@ M=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C>$$P.R8C>$$P.SPO M9F]N=#X\+W1D/@T*(#QT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B`C,#`P M,#`P(#%P>"!S;VQI9"<@=F%L:6=N/3-$8F]T=&]M(&-O;'-P86X],T0R(&%L M:6=N/3-$8V5N=&5R/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE M<R!.97<@4F]M86XG('-I>F4],T0Q/CQB/B8C>$$P.R8C>$$P.TQE=F5L)B-X M03`[,B8C>$$P.R8C>$$P.SPO8CX\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N M/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C>$$P.SPO9F]N=#X\+W1D/@T* M(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<VEZ93TS1#$^)B-X03`[)B-X M03`[/"]F;VYT/CPO=&0^#0H@/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ M(",P,#`P,#`@,7!X('-O;&ED)R!V86QI9VX],T1B;W1T;VT@8V]L<W!A;CTS M1#(@86QI9VX],T1C96YT97(^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ M(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#$^/&(^)B-X03`[)B-X03`[3&5V M96PF(WA!,#LS)B-X03`[)B-X03`[/"]B/CPO9F]N=#X\+W1D/@T*(#QT9"!V M86QI9VX],T1B;W1T;VT^/&9O;G0@<VEZ93TS1#$^)B-X03`[/"]F;VYT/CPO M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF(WA! M,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\+W1R/@T*(#QT<B!B9V-O;&]R/3-$ M(T-#145&1CX-"B`\=&0@=F%L:6=N/3-$=&]P/@T*(#QP('-T>6QE/3-$)TU! M4D=)3BU,1494.B`Q96T[(%1%6%0M24Y$14Y4.B`M,65M)SX\9F]N="!S='EL M93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CY- M;VYE>2!M87)K970-"B!F=6YD<SPO9F]N=#X\+W`^#0H@/"]T9#X-"B`\=&0@ M=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C>$$P.R8C>$$P.SPO M9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<W1Y;&4] M,T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^)#PO M9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H M=#X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N M)R!S:7IE/3-$,CXQ-BPY,S(\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$ M8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#X\9F]N="!S='EL93TS1"=&3TY4+49! M34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXF(WA!,#LF(WA!,#L\ M+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4] M,T0Q/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B M;W1T;VT@;F]W<F%P/3-$;F]W<F%P/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%- M24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R/B0\+V9O;G0^/"]T9#X- M"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<"!A;&EG;CTS M1')I9VAT/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@ M4F]M86XG('-I>F4],T0R/B8C>#(P,30[/"]F;VYT/CPO=&0^#0H@/'1D('9A M;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^/&9O;G0@<W1Y;&4],T0G M1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^)B-X03`[ M)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N M="!S:7IE/3-$,3XF(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L M:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#X\9F]N="!S='EL93TS1"=& M3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXD/"]F;VYT M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`@ M86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM M97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXF(W@R,#$T.SPO9F]N=#X\+W1D/@T* M(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P/CQF;VYT('-T M>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R M/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T M;VT^/&9O;G0@<VEZ93TS1#$^)B-X03`[)B-X03`[/"]F;VYT/CPO=&0^#0H@ M/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=&3TY4+49!34E, M63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXD/"]F;VYT/CPO=&0^#0H@ M/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/CQF;VYT('-T>6QE M/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R/C$V M+#DS,CPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P M/3-$;F]W<F%P/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!. M97<@4F]M86XG('-I>F4],T0R/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T* M(#PO='(^#0H@/'1R/@T*(#QT9"!V86QI9VX],T1T;W`^#0H@/'`@<W1Y;&4] M,T0G34%21TE.+4Q%1E0Z(#%E;3L@5$585"U)3D1%3E0Z("TQ96TG/CQF;VYT M('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4] M,T0R/E4N4RX@5')E87-U<GD-"B!S96-U<FET:65S/"]F;VYT/CPO<#X-"B`\ M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<VEZ93TS1#$^)B-X M03`[)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\ M9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S M:7IE/3-$,CXF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T M=&]M(&%L:6=N/3-$<FEG:'0^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ M(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^-C,L,#$S/"]F;VYT/CPO=&0^ M#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^/&9O;G0@ M<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS M1#(^)B-X03`[)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O M='1O;3X\9F]N="!S:7IE/3-$,3XF(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X- M"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#X\9F]N="!S M='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$ M,CXF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO M=W)A<#TS1&YO=W)A<"!A;&EG;CTS1')I9VAT/CQF;VYT('-T>6QE/3-$)T9/ M3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R/B8C>#(P,30[ M/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N M;W=R87`^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2 M;VUA;B<@<VEZ93TS1#(^)B-X03`[)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D M('9A;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF(WA!,#LF(WA!,#L\ M+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO M=W)A<#X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O M;6%N)R!S:7IE/3-$,CXF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N M/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<"!A;&EG;CTS1')I9VAT/CQF;VYT M('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4] M,T0R/B8C>#(P,30[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O M;2!N;W=R87`],T1N;W=R87`^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ M(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^)B-X03`[)B-X03`[/"]F;VYT M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF M(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M M/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG M('-I>F4],T0R/B8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B M;W1T;VT@86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS1"=&3TY4+49!34E, M63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXV,RPP,3,\+V9O;G0^/"]T M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#X\9F]N M="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE M/3-$,CXF(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\+W1R/@T*(#QT<B!S M='EL93TS1"=&3TY4+5-)6D4Z(#%P>"<^#0H@/'1D('9A;&EG;CTS1&)O='1O M;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1% M4BU43U`Z(",P,#`P,#`@,7!X('-O;&ED)SXF(WA!,#L\+W`^#0H@/"]T9#X- M"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU4 M3U`Z(",P,#`P,#`@,7!X('-O;&ED)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\ M=&0^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C M>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS M1"="3U)$15(M5$]0.B`C,#`P,#`P(#%P>"!S;VQI9"<^)B-X03`[/"]P/@T* M(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"=" M3U)$15(M5$]0.B`C,#`P,#`P(#%P>"!S;VQI9"<^)B-X03`[/"]P/@T*(#PO M=&0^#0H@/'1D/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF M(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@ M<W1Y;&4],T0G0D]21$52+51/4#H@(S`P,#`P,"`Q<'@@<V]L:60G/B8C>$$P M.SPO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@<W1Y M;&4],T0G0D]21$52+51/4#H@(S`P,#`P,"`Q<'@@<V]L:60G/B8C>$$P.SPO M<#X-"B`\+W1D/@T*(#QT9#XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B M;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@,7!X('-O;&ED M)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T* M(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@,7!X('-O;&ED)SXF M(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0^)B-X03`[/"]T9#X-"B`\+W1R/@T* M(#QT<B!B9V-O;&]R/3-$(T-#145&1CX-"B`\=&0@=F%L:6=N/3-$=&]P/@T* M(#QP('-T>6QE/3-$)TU!4D=)3BU,1494.B`S96T[(%1%6%0M24Y$14Y4.B`M M,65M)SX\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O M;6%N)R!S:7IE/3-$,CY4;W1A;#PO9F]N=#X\+W`^#0H@/"]T9#X-"B`\=&0@ M=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C>$$P.R8C>$$P.SPO M9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<W1Y;&4] M,T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^)#PO M9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H M=#X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N M)R!S:7IE/3-$,CXW.2PY-#4\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$ M8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#X\9F]N="!S='EL93TS1"=&3TY4+49! M34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXF(WA!,#LF(WA!,#L\ M+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4] M,T0Q/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B M;W1T;VT@;F]W<F%P/3-$;F]W<F%P/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%- M24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R/B0\+V9O;G0^/"]T9#X- M"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<"!A;&EG;CTS M1')I9VAT/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@ M4F]M86XG('-I>F4],T0R/B8C>#(P,30[/"]F;VYT/CPO=&0^#0H@/'1D('9A M;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^/&9O;G0@<W1Y;&4],T0G M1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^)B-X03`[ M)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N M="!S:7IE/3-$,3XF(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L M:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#X\9F]N="!S='EL93TS1"=& M3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXD/"]F;VYT M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`@ M86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM M97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXF(W@R,#$T.SPO9F]N=#X\+W1D/@T* M(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P/CQF;VYT('-T M>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R M/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T M;VT^/&9O;G0@<VEZ93TS1#$^)B-X03`[)B-X03`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`\=&0@ M=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF M(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@ M<W1Y;&4],T0G0D]21$52+51/4#H@(S`P,#`P,"`S<'@@9&]U8FQE)SXF(WA! M,#L\+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T M>6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@,W!X(&1O=6)L92<^)B-X03`[ M/"]P/@T*(#PO=&0^#0H@/'1D/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS M1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T M;VT^#0H@/'`@<W1Y;&4],T0G0D]21$52+51/4#H@(S`P,#`P,"`S<'@@9&]U M8FQE)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@,W!X(&1O=6)L M92<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D/B8C>$$P.SPO=&0^#0H@/'1D M('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI M9VX],T1B;W1T;VT^#0H@/'`@<W1Y;&4],T0G0D]21$52+51/4#H@(S`P,#`P M,"`S<'@@9&]U8FQE)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N M/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@ M,W!X(&1O=6)L92<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D/B8C>$$P.SPO M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T* M(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@<W1Y;&4],T0G0D]21$52+51/ M4#H@(S`P,#`P,"`S<'@@9&]U8FQE)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\ M=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z M(",P,#`P,#`@,W!X(&1O=6)L92<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D M/B8C>$$P.SPO=&0^#0H@/"]T<CX-"B`\='(^#0H@/'1D('9A;&EG;CTS1'1O M<#X-"B`\<"!S='EL93TS1"=-05)'24XM3$5&5#H@,65M.R!415A4+4E.1$5. M5#H@+3%E;2<^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE M=R!2;VUA;B<@<VEZ93TS1#(^06UO=6YT<R!I;F-L=61E9`T*(&EN.CPO9F]N M=#X\+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I M>F4],T0Q/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX] M,T1B;W1T;VT^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@ M/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T M;VT^/&9O;G0@<VEZ93TS1#$^)B-X03`[)B-X03`[/"]F;VYT/CPO=&0^#0H@ M/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T M;VT^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A M;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF(WA!,#LF(WA!,#L\+V9O M;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A M;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C>$$P M.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS M1&)O='1O;3X\+W1D/@T*(#PO='(^#0H@/'1R(&)G8V]L;W(],T0C0T-%149& M/@T*(#QT9"!V86QI9VX],T1T;W`^#0H@/'`@<W1Y;&4],T0G34%21TE.+4Q% M1E0Z(#)E;3L@5$585"U)3D1%3E0Z("TQ96TG/CQF;VYT('-T>6QE/3-$)T9/ M3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R/D-A<V@@86YD M(&-A<V@-"B!E<75I=F%L96YT<SPO9F]N=#X\+W`^#0H@/"]T9#X-"B`\=&0@ M=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C>$$P.R8C>$$P.SPO M9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<W1Y;&4] M,T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^)#PO M9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H M=#X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N M)R!S:7IE/3-$,CXQ-BPY,S(\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$ M8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#X\9F]N="!S='EL93TS1"=&3TY4+49! M34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXF(WA!,#LF(WA!,#L\ M+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4] M,T0Q/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B M;W1T;VT@;F]W<F%P/3-$;F]W<F%P/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%- M24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R/B0\+V9O;G0^/"]T9#X- M"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<"!A;&EG;CTS M1')I9VAT/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@ M4F]M86XG('-I>F4],T0R/B8C>#(P,30[/"]F;VYT/CPO=&0^#0H@/'1D('9A M;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^/&9O;G0@<W1Y;&4],T0G M1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^)B-X03`[ M)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N M="!S:7IE/3-$,3XF(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L M:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#X\9F]N="!S='EL93TS1"=& M3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXD/"]F;VYT M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`@ M86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM M97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXF(W@R,#$T.SPO9F]N=#X\+W1D/@T* M(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P/CQF;VYT('-T M>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R M/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T M;VT^/&9O;G0@<VEZ93TS1#$^)B-X03`[)B-X03`[/"]F;VYT/CPO=&0^#0H@ M/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=&3TY4+49!34E, M63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXD/"]F;VYT/CPO=&0^#0H@ M/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/CQF;VYT('-T>6QE M/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R/C$V M+#DS,CPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P M/3-$;F]W<F%P/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!. M97<@4F]M86XG('-I>F4],T0R/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T* M(#PO='(^#0H@/'1R/@T*(#QT9"!V86QI9VX],T1T;W`^#0H@/'`@<W1Y;&4] M,T0G34%21TE.+4Q%1E0Z(#)E;3L@5$585"U)3D1%3E0Z("TQ96TG/CQF;VYT M('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4] M,T0R/E-H;W)T+71E<FT-"B!I;G9E<W1M96YT<SPO9F]N=#X\+W`^#0H@/"]T M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C>$$P M.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O M;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ M93TS1#(^)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O M;2!A;&EG;CTS1')I9VAT/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4 M:6UE<R!.97<@4F]M86XG('-I>F4],T0R/C8S+#`Q,SPO9F]N=#X\+W1D/@T* M(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P/CQF;VYT('-T M>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R M/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T M;VT^/&9O;G0@<VEZ93TS1#$^)B-X03`[)B-X03`[/"]F;VYT/CPO=&0^#0H@ M/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^/&9O;G0@<W1Y M;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^ M)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R M87`],T1N;W=R87`@86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS1"=&3TY4 M+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXF(W@R,#$T.SPO M9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W M<F%P/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M M86XG('-I>F4],T0R/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V M86QI9VX],T1B;W1T;VT^/&9O;G0@<VEZ93TS1#$^)B-X03`[)B-X03`[/"]F M;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R M87`^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA M;B<@<VEZ93TS1#(^)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS M1&)O='1O;2!N;W=R87`],T1N;W=R87`@86QI9VX],T1R:6=H=#X\9F]N="!S M='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$ M,CXF(W@R,#$T.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@ M;F]W<F%P/3-$;F]W<F%P/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4 M:6UE<R!.97<@4F]M86XG('-I>F4],T0R/B8C>$$P.R8C>$$P.SPO9F]N=#X\ M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<VEZ93TS1#$^)B-X M03`[)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\ M9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S M:7IE/3-$,CXF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T M=&]M(&%L:6=N/3-$<FEG:'0^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ M(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^-C,L,#$S/"]F;VYT/CPO=&0^ M#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^/&9O;G0@ M<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS M1#(^)B-X03`[)B-X03`[/"]F;VYT/CPO=&0^#0H@/"]T<CX-"B`\='(@8F=C M;VQO<CTS1"-#0T5%1D8^#0H@/'1D('9A;&EG;CTS1'1O<#X-"B`\<"!S='EL M93TS1"=-05)'24XM3$5&5#H@,F5M.R!415A4+4E.1$5.5#H@+3%E;2<^/&9O M;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ M93TS1#(^3&]N9RUT97)M#0H@:6YV97-T;65N=',\+V9O;G0^/"]P/@T*(#PO M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF(WA! M,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO M=W)A<#TS1&YO=W)A<#X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM M97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXF(WA!,#L\+V9O;G0^/"]T9#X-"B`\ M=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<"!A;&EG;CTS1')I M9VAT/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M M86XG('-I>F4],T0R/B8C>#(P,30[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG M;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^/&9O;G0@<W1Y;&4],T0G1D]. M5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^)B-X03`[)B-X M03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S M:7IE/3-$,3XF(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N M/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#X\9F]N="!S='EL93TS1"=&3TY4 M+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXF(WA!,#L\+V9O M;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A M<"!A;&EG;CTS1')I9VAT/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4 M:6UE<R!.97<@4F]M86XG('-I>F4],T0R/B8C>#(P,30[/"]F;VYT/CPO=&0^ M#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^/&9O;G0@ M<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS M1#(^)B-X03`[)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O M='1O;3X\9F]N="!S:7IE/3-$,3XF(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X- M"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#X\9F]N="!S M='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$ M,CXF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO M=W)A<#TS1&YO=W)A<"!A;&EG;CTS1')I9VAT/CQF;VYT('-T>6QE/3-$)T9/ M3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R/B8C>#(P,30[ M/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N M;W=R87`^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2 M;VUA;B<@<VEZ93TS1#(^)B-X03`[)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D M('9A;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF(WA!,#LF(WA!,#L\ M+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO M=W)A<#X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O M;6%N)R!S:7IE/3-$,CXF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N M/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<"!A;&EG;CTS1')I9VAT/CQF;VYT M('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4] M,T0R/B8C>#(P,30[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O M;2!N;W=R87`],T1N;W=R87`^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ M(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^)B-X03`[)B-X03`[/"]F;VYT M/CPO=&0^#0H@/"]T<CX-"B`\='(@<W1Y;&4],T0G1D].5"U325I%.B`Q<'@G M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\=&0@=F%L:6=N/3-$ M8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O M;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B`C,#`P,#`P(#%P>"!S;VQI M9"<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X- M"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B`C,#`P,#`P(#%P>"!S;VQI9"<^ M)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D/B8C>$$P.SPO=&0^#0H@/'1D('9A M;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX] M,T1B;W1T;VT^#0H@/'`@<W1Y;&4],T0G0D]21$52+51/4#H@(S`P,#`P,"`Q M<'@@<V]L:60G/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B M;W1T;VT^#0H@/'`@<W1Y;&4],T0G0D]21$52+51/4#H@(S`P,#`P,"`Q<'@@ M<V]L:60G/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT9#XF(WA!,#L\+W1D/@T* M(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@ M=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(",P M,#`P,#`@,7!X('-O;&ED)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0@=F%L M:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P M,#`@,7!X('-O;&ED)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0^)B-X03`[ M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^ M#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M M5$]0.B`C,#`P,#`P(#%P>"!S;VQI9"<^)B-X03`[/"]P/@T*(#PO=&0^#0H@ M/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0 M.B`C,#`P,#`P(#%P>"!S;VQI9"<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D M/B8C>$$P.SPO=&0^#0H@/"]T<CX-"B`\='(^#0H@/'1D('9A;&EG;CTS1'1O M<#X-"B`\<"!S='EL93TS1"=-05)'24XM3$5&5#H@,V5M.R!415A4+4E.1$5. M5#H@+3%E;2<^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE M=R!2;VUA;B<@<VEZ93TS1#(^5&]T86P\+V9O;G0^/"]P/@T*(#PO=&0^#0H@ M/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF(WA!,#LF(WA! M,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T M>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R M/B0\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$ M<FEG:'0^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2 M;VUA;B<@<VEZ93TS1#(^-SDL.30U/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG M;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^/&9O;G0@<W1Y;&4],T0G1D]. M5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^)B-X03`[)B-X M03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S M:7IE/3-$,3XF(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N M/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#X\9F]N="!S='EL93TS1"=&3TY4 M+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXD/"]F;VYT/CPO M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`@86QI M9VX],T1R:6=H=#X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@ M3F5W(%)O;6%N)R!S:7IE/3-$,CXF(W@R,#$T.SPO9F]N=#X\+W1D/@T*(#QT M9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P/CQF;VYT('-T>6QE M/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R/B8C M>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^ M/&9O;G0@<VEZ93TS1#$^)B-X03`[)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D M('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^/&9O;G0@<W1Y;&4] M,T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^)#PO M9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W M<F%P(&%L:6=N/3-$<FEG:'0^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ M(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^)B-X,C`Q-#L\+V9O;G0^/"]T M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#X\9F]N M="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE M/3-$,CXF(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$ M8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<W1Y;&4],T0G1D].5"U& M04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^)#PO9F]N=#X\+W1D M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#X\9F]N="!S M='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$ M,CXW.2PY-#4\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO M=W)A<#TS1&YO=W)A<#X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM M97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXF(WA!,#LF(WA!,#L\+V9O;G0^/"]T M9#X-"B`\+W1R/@T*(#QT<B!S='EL93TS1"=&3TY4+5-)6D4Z(#%P>"<^#0H@ M/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T M;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T* M(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@,W!X(&1O=6)L92<^ M)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\ M<"!S='EL93TS1"="3U)$15(M5$]0.B`C,#`P,#`P(#-P>"!D;W5B;&4G/B8C M>$$P.SPO<#X-"B`\+W1D/@T*(#QT9#XF(WA!,#L\+W1D/@T*(#QT9"!V86QI M9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$ M8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@,W!X M(&1O=6)L92<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O M='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B`C,#`P,#`P(#-P>"!D M;W5B;&4G/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT9#XF(WA!,#L\+W1D/@T* M(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@ M=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(",P M,#`P,#`@,W!X(&1O=6)L92<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D('9A M;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B`C,#`P M,#`P(#-P>"!D;W5B;&4G/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT9#XF(WA! M,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1% M4BU43U`Z(",P,#`P,#`@,W!X(&1O=6)L92<^)B-X03`[/"]P/@T*(#PO=&0^ M#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M M5$]0.B`C,#`P,#`P(#-P>"!D;W5B;&4G/B8C>$$P.SPO<#X-"B`\+W1D/@T* M(#QT9#XF(WA!,#L\+W1D/@T*(#PO='(^#0H@/"]T86)L93X-"B`\<"!S='EL M93TS1"=-05)'24XM0D]45$]-.B`P<'@[($9/3E0M4TE:13H@,3)P>#L@34%2 M1TE.+51/4#H@,'!X)SX-"B`F(WA!,#L\+W`^#0H@/'1A8FQE('-T>6QE/3-$ M)T)/4D1%4BU#3TQ,05!313H@8V]L;&%P<V4G(&-E;&QS<&%C:6YG/3-$,"!C M96QL<&%D9&EN9STS1#`@=VED=&@],T0Y,B4@86QI9VX],T1C96YT97(@8F]R M9&5R/3-$,#X-"B`\='(^#0H@/'1D('=I9'1H/3-$-38E/CPO=&0^#0H@/'1D M('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#<E/CPO=&0^#0H@/'1D/CPO=&0^ M#0H@/'1D/CPO=&0^#0H@/'1D/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O M;2!W:61T:#TS1#<E/CPO=&0^#0H@/'1D/CPO=&0^#0H@/'1D/CPO=&0^#0H@ M/'1D/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#<E/CPO M=&0^#0H@/'1D/CPO=&0^#0H@/'1D/CPO=&0^#0H@/'1D/CPO=&0^#0H@/'1D M('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#<E/CPO=&0^#0H@/'1D/CPO=&0^ M#0H@/'1D/CPO=&0^#0H@/'1D/CPO=&0^#0H@/"]T<CX-"B`\='(^#0H@/'1D M('9A;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF(WA!,#L\+V9O;G0^ M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C M>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!S='EL93TS1"="3U)$15(M M0D]45$]-.B`C,#`P,#`P(#%P>"!S;VQI9"<@=F%L:6=N/3-$8F]T=&]M(&-O M;'-P86X],T0Q-"!A;&EG;CTS1&-E;G1E<CX\9F]N="!S='EL93TS1"=&3TY4 M+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,3X\8CY$96-E;6)E M<B8C>$$P.S,Q+`T*(#(P,3,\+V(^/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG M;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF(WA!,#L\+V9O;G0^/"]T9#X- M"B`\+W1R/@T*(#QT<CX-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I M>F4],T0Q/B8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T M;VT^/&9O;G0@<VEZ93TS1#$^)B-X03`[)B-X03`[/"]F;VYT/CPO=&0^#0H@ M/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,7!X('-O;&ED M)R!V86QI9VX],T1B;W1T;VT@8V]L<W!A;CTS1#$P(&%L:6=N/3-$8V5N=&5R M/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG M('-I>F4],T0Q/CQB/D9A:7(F(WA!,#M686QU928C>$$P.TUE87-U<F5M96YT M<R8C>$$P.U5S:6YG/"]B/CPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B M;W1T;VT^/&9O;G0@<VEZ93TS1#$^)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D M('9A;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF(WA!,#LF(WA!,#L\ M+V9O;G0^/"]T9#X-"B`\=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@(S`P M,#`P,"`Q<'@@<V]L:60G('9A;&EG;CTS1&)O='1O;2!R;W=S<&%N/3-$,B!C M;VQS<&%N/3-$,B!A;&EG;CTS1&-E;G1E<CX\9F]N="!S='EL93TS1"=&3TY4 M+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,3X\8CY!<W-E=',\ M8G(@+SX-"B!!="8C>$$P.T9A:7(F(WA!,#M686QU93PO8CX\+V9O;G0^/"]T M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(')O=W-P86X],T0R/CQF;VYT('-I M>F4],T0Q/B8C>$$P.SPO9F]N=#X\+W1D/@T*(#PO='(^#0H@/'1R/@T*(#QT M9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<VEZ93TS1#$^)B-X03`[/"]F;VYT M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF M(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@<W1Y;&4],T0G0D]21$52 M+4)/5%1/33H@(S`P,#`P,"`Q<'@@<V]L:60G('9A;&EG;CTS1&)O='1O;2!C M;VQS<&%N/3-$,B!A;&EG;CTS1&-E;G1E<CX\9F]N="!S='EL93TS1"=&3TY4 M+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,3X\8CXF(WA!,#LF M(WA!,#M,979E;"8C>$$P.S$F(WA!,#LF(WA!,#L\+V(^/"]F;VYT/CPO=&0^ M#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF(WA!,#L\ M+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4] M,T0Q/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!S='EL93TS1"=" M3U)$15(M0D]45$]-.B`C,#`P,#`P(#%P>"!S;VQI9"<@=F%L:6=N/3-$8F]T M=&]M(&-O;'-P86X],T0R(&%L:6=N/3-$8V5N=&5R/CQF;VYT('-T>6QE/3-$ M)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0Q/CQB/B8C M>$$P.R8C>$$P.TQE=F5L)B-X03`[,B8C>$$P.R8C>$$P.SPO8CX\+V9O;G0^ M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C M>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@ M<VEZ93TS1#$^)B-X03`[)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('-T>6QE M/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,7!X('-O;&ED)R!V86QI9VX] M,T1B;W1T;VT@8V]L<W!A;CTS1#(@86QI9VX],T1C96YT97(^/&9O;G0@<W1Y M;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#$^ M/&(^)B-X03`[)B-X03`[3&5V96PF(WA!,#LS)B-X03`[)B-X03`[/"]B/CPO M9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<VEZ93TS M1#$^)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\ M9F]N="!S:7IE/3-$,3XF(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\+W1R M/@T*(#QT<B!B9V-O;&]R/3-$(T-#145&1CX-"B`\=&0@=F%L:6=N/3-$=&]P M/@T*(#QP('-T>6QE/3-$)TU!4D=)3BU,1494.B`Q96T[(%1%6%0M24Y$14Y4 M.B`M,65M)SX\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W M(%)O;6%N)R!S:7IE/3-$,CY-;VYE>2!M87)K970-"B!F=6YD<SPO9F]N=#X\ M+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4] M,T0Q/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B M;W1T;VT^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2 M;VUA;B<@<VEZ93TS1#(^)#PO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B M;W1T;VT@86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS1"=&3TY4+49!34E, M63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXQ-2PX-3@\+V9O;G0^/"]T M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#X\9F]N M="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE M/3-$,CXF(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$ M8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P/CQF;VYT M('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4] M,T0R/B0\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A M<#TS1&YO=W)A<"!A;&EG;CTS1')I9VAT/CQF;VYT('-T>6QE/3-$)T9/3E0M M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R/B8C>#(P,30[/"]F M;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R M87`^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA M;B<@<VEZ93TS1#(^)B-X03`[)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A M;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF(WA!,#LF(WA!,#L\+V9O M;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A M<#X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N M)R!S:7IE/3-$,CXD/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O M;2!N;W=R87`],T1N;W=R87`@86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS M1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXF(W@R M,#$T.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P M/3-$;F]W<F%P/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!. M97<@4F]M86XG('-I>F4],T0R/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T* M(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<VEZ93TS1#$^)B-X03`[)B-X M03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S M='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$ M,CXD/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS M1')I9VAT/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@ M4F]M86XG('-I>F4],T0R/C$U+#@U.#PO9F]N=#X\+W1D/@T*(#QT9"!V86QI M9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P/CQF;VYT('-T>6QE/3-$)T9/ M3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R/B8C>$$P.R8C M>$$P.SPO9F]N=#X\+W1D/@T*(#PO='(^#0H@/'1R/@T*(#QT9"!V86QI9VX] M,T1T;W`^#0H@/'`@<W1Y;&4],T0G34%21TE.+4Q%1E0Z(#%E;3L@5$585"U) M3D1%3E0Z("TQ96TG/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE M<R!.97<@4F]M86XG('-I>F4],T0R/E4N4RX@5')E87-U<GD-"B!S96-U<FET M:65S/"]F;VYT/CPO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^ M/&9O;G0@<VEZ93TS1#$^)B-X03`[)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D M('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@ M5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXF(WA!,#L\+V9O;G0^/"]T9#X- M"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^/&9O;G0@<W1Y M;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^ M-C`L,#<R/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R M87`],T1N;W=R87`^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S M($YE=R!2;VUA;B<@<VEZ93TS1#(^)B-X03`[)B-X03`[/"]F;VYT/CPO=&0^ M#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF(WA!,#LF M(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A M<#TS1&YO=W)A<#X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@ M3F5W(%)O;6%N)R!S:7IE/3-$,CXF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@ M=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<"!A;&EG;CTS1')I9VAT M/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG M('-I>F4],T0R/B8C>#(P,30[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS M1&)O='1O;2!N;W=R87`],T1N;W=R87`^/&9O;G0@<W1Y;&4],T0G1D].5"U& M04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^)B-X03`[)B-X03`[ M/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE M/3-$,3XF(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$ M8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#X\9F]N="!S='EL93TS1"=&3TY4+49! M34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXF(WA!,#L\+V9O;G0^ M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<"!A M;&EG;CTS1')I9VAT/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE M<R!.97<@4F]M86XG('-I>F4],T0R/B8C>#(P,30[/"]F;VYT/CPO=&0^#0H@ M/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^/&9O;G0@<W1Y M;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^ M)B-X03`[)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O M;3X\9F]N="!S:7IE/3-$,3XF(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\ M=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9 M.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R/B8C>$$P.SPO9F]N=#X\+W1D M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#X\9F]N="!S M='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$ M,CXV,"PP-S(\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO M=W)A<#TS1&YO=W)A<#X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM M97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXF(WA!,#LF(WA!,#L\+V9O;G0^/"]T M9#X-"B`\+W1R/@T*(#QT<B!S='EL93TS1"=&3TY4+5-)6D4Z(#%P>"<^#0H@ M/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T M;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T* M(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@,7!X('-O;&ED)SXF M(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP M('-T>6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@,7!X('-O;&ED)SXF(WA! M,#L\+W`^#0H@/"]T9#X-"B`\=&0^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N M/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O M='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B`C,#`P,#`P(#%P>"!S M;VQI9"<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O M;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B`C,#`P,#`P(#%P>"!S;VQI M9"<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D/B8C>$$P.SPO=&0^#0H@/'1D M('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI M9VX],T1B;W1T;VT^#0H@/'`@<W1Y;&4],T0G0D]21$52+51/4#H@(S`P,#`P M,"`Q<'@@<V]L:60G/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX] M,T1B;W1T;VT^#0H@/'`@<W1Y;&4],T0G0D]21$52+51/4#H@(S`P,#`P,"`Q M<'@@<V]L:60G/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT9#XF(WA!,#L\+W1D M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\ M=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z M(",P,#`P,#`@,7!X('-O;&ED)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0@ M=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(",P M,#`P,#`@,7!X('-O;&ED)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0^)B-X M03`[/"]T9#X-"B`\+W1R/@T*(#QT<B!B9V-O;&]R/3-$(T-#145&1CX-"B`\ M=&0@=F%L:6=N/3-$=&]P/@T*(#QP('-T>6QE/3-$)TU!4D=)3BU,1494.B`S M96T[(%1%6%0M24Y$14Y4.B`M,65M)SX\9F]N="!S='EL93TS1"=&3TY4+49! M34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CY4;W1A;#PO9F]N=#X\ M+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4] M,T0Q/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B M;W1T;VT^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2 M;VUA;B<@<VEZ93TS1#(^)#PO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B M;W1T;VT@86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS1"=&3TY4+49!34E, M63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXW-2PY,S`\+V9O;G0^/"]T M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#X\9F]N M="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE M/3-$,CXF(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$ M8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P/CQF;VYT M('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4] M,T0R/B0\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A M<#TS1&YO=W)A<"!A;&EG;CTS1')I9VAT/CQF;VYT('-T>6QE/3-$)T9/3E0M M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R/B8C>#(P,30[/"]F M;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R M87`^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA M;B<@<VEZ93TS1#(^)B-X03`[)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A M;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF(WA!,#LF(WA!,#L\+V9O M;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A M<#X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N M)R!S:7IE/3-$,CXD/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O M;2!N;W=R87`],T1N;W=R87`@86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS M1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXF(W@R M,#$T.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P M/3-$;F]W<F%P/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!. M97<@4F]M86XG('-I>F4],T0R/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T* M(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<VEZ93TS1#$^)B-X03`[)B-X M03`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`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D M('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI M9VX],T1B;W1T;VT^#0H@/'`@<W1Y;&4],T0G0D]21$52+51/4#H@(S`P,#`P M,"`S<'@@9&]U8FQE)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N M/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@ M,W!X(&1O=6)L92<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D/B8C>$$P.SPO M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T* M(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@<W1Y;&4],T0G0D]21$52+51/ M4#H@(S`P,#`P,"`S<'@@9&]U8FQE)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\ M=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z M(",P,#`P,#`@,W!X(&1O=6)L92<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA! M,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@<W1Y;&4],T0G M0D]21$52+51/4#H@(S`P,#`P,"`S<'@@9&]U8FQE)SXF(WA!,#L\+W`^#0H@ M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/ M4D1%4BU43U`Z(",P,#`P,#`@,W!X(&1O=6)L92<^)B-X03`[/"]P/@T*(#PO M=&0^#0H@/'1D/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF M(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@ M<W1Y;&4],T0G0D]21$52+51/4#H@(S`P,#`P,"`S<'@@9&]U8FQE)SXF(WA! M,#L\+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T M>6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@,W!X(&1O=6)L92<^)B-X03`[ M/"]P/@T*(#PO=&0^#0H@/'1D/B8C>$$P.SPO=&0^#0H@/"]T<CX-"B`\='(^ M#0H@/'1D('9A;&EG;CTS1'1O<#X-"B`\<"!S='EL93TS1"=-05)'24XM3$5& M5#H@,65M.R!415A4+4E.1$5.5#H@+3%E;2<^/&9O;G0@<W1Y;&4],T0G1D]. M5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^06UO=6YT<R!I M;F-L=61E9`T*(&EN.CPO9F]N=#X\+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N M/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C>$$P.R8C>$$P.SPO9F]N=#X\ M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\=&0@=F%L:6=N M/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T* M(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<VEZ93TS1#$^)B-X03`[)B-X M03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T* M(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T M=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$ M,3XF(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T M=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V M86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF M;VYT('-I>F4],T0Q/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V M86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#PO='(^#0H@/'1R M(&)G8V]L;W(],T0C0T-%149&/@T*(#QT9"!V86QI9VX],T1T;W`^#0H@/'`@ M<W1Y;&4],T0G34%21TE.+4Q%1E0Z(#)E;3L@5$585"U)3D1%3E0Z("TQ96TG M/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG M('-I>F4],T0R/D-A<V@@86YD(&-A<V@-"B!E<75I=F%L96YT<SPO9F]N=#X\ M+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4] M,T0Q/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B M;W1T;VT^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2 M;VUA;B<@<VEZ93TS1#(^)#PO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B M;W1T;VT@86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS1"=&3TY4+49!34E, M63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXQ-2PX-3@\+V9O;G0^/"]T M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#X\9F]N M="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE M/3-$,CXF(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$ M8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P/CQF;VYT M('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4] M,T0R/B0\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A M<#TS1&YO=W)A<"!A;&EG;CTS1')I9VAT/CQF;VYT('-T>6QE/3-$)T9/3E0M M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R/B8C>#(P,30[/"]F M;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R M87`^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA M;B<@<VEZ93TS1#(^)B-X03`[)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A M;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF(WA!,#LF(WA!,#L\+V9O M;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A M<#X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N M)R!S:7IE/3-$,CXD/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O M;2!N;W=R87`],T1N;W=R87`@86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS M1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXF(W@R M,#$T.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P M/3-$;F]W<F%P/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!. M97<@4F]M86XG('-I>F4],T0R/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T* M(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<VEZ93TS1#$^)B-X03`[)B-X M03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S M='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$ M,CXD/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS M1')I9VAT/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@ M4F]M86XG('-I>F4],T0R/C$U+#@U.#PO9F]N=#X\+W1D/@T*(#QT9"!V86QI M9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P/CQF;VYT('-T>6QE/3-$)T9/ M3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R/B8C>$$P.R8C M>$$P.SPO9F]N=#X\+W1D/@T*(#PO='(^#0H@/'1R/@T*(#QT9"!V86QI9VX] M,T1T;W`^#0H@/'`@<W1Y;&4],T0G34%21TE.+4Q%1E0Z(#)E;3L@5$585"U) M3D1%3E0Z("TQ96TG/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE M<R!.97<@4F]M86XG('-I>F4],T0R/E-H;W)T+71E<FT-"B!I;G9E<W1M96YT M<SPO9F]N=#X\+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF M;VYT('-I>F4],T0Q/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V M86QI9VX],T1B;W1T;VT^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I M;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^)B-X03`[/"]F;VYT/CPO=&0^#0H@ M/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/CQF;VYT('-T>6QE M/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R/C4W M+#4W,#PO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P M/3-$;F]W<F%P/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!. M97<@4F]M86XG('-I>F4],T0R/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T* M(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<VEZ93TS1#$^)B-X03`[)B-X M03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`] M,T1N;W=R87`^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE M=R!2;VUA;B<@<VEZ93TS1#(^)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A M;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`@86QI9VX],T1R:6=H=#X\ M9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S M:7IE/3-$,CXF(W@R,#$T.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B M;W1T;VT@;F]W<F%P/3-$;F]W<F%P/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%- M24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R/B8C>$$P.R8C>$$P.SPO M9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<VEZ93TS M1#$^)B-X03`[)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O M='1O;2!N;W=R87`],T1N;W=R87`^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U) M3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^)B-X03`[/"]F;VYT/CPO M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`@86QI M9VX],T1R:6=H=#X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@ M3F5W(%)O;6%N)R!S:7IE/3-$,CXF(W@R,#$T.SPO9F]N=#X\+W1D/@T*(#QT M9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P/CQF;VYT('-T>6QE M/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R/B8C M>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^ M/&9O;G0@<VEZ93TS1#$^)B-X03`[)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D M('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@ M5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXF(WA!,#L\+V9O;G0^/"]T9#X- M"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^/&9O;G0@<W1Y M;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^ M-3<L-3<P/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R M87`],T1N;W=R87`^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S M($YE=R!2;VUA;B<@<VEZ93TS1#(^)B-X03`[)B-X03`[/"]F;VYT/CPO=&0^ M#0H@/"]T<CX-"B`\='(@8F=C;VQO<CTS1"-#0T5%1D8^#0H@/'1D('9A;&EG M;CTS1'1O<#X-"B`\<"!S='EL93TS1"=-05)'24XM3$5&5#H@,F5M.R!415A4 M+4E.1$5.5#H@+3%E;2<^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I M;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^3&]N9RUT97)M#0H@:6YV97-T;65N M=',\+V9O;G0^/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\ M9F]N="!S:7IE/3-$,3XF(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@ M=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4 M:6UE<R!.97<@4F]M86XG('-I>F4],T0R/B8C>$$P.SPO9F]N=#X\+W1D/@T* M(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#X\9F]N="!S='EL M93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXR M+#4P,CPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P M/3-$;F]W<F%P/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!. M97<@4F]M86XG('-I>F4],T0R/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T* M(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<VEZ93TS1#$^)B-X03`[)B-X M03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`] M,T1N;W=R87`^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE M=R!2;VUA;B<@<VEZ93TS1#(^)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A M;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`@86QI9VX],T1R:6=H=#X\ M9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S M:7IE/3-$,CXF(W@R,#$T.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B M;W1T;VT@;F]W<F%P/3-$;F]W<F%P/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%- M24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R/B8C>$$P.R8C>$$P.SPO M9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<VEZ93TS M1#$^)B-X03`[)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O M='1O;2!N;W=R87`],T1N;W=R87`^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U) M3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^)B-X03`[/"]F;VYT/CPO M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`@86QI M9VX],T1R:6=H=#X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@ M3F5W(%)O;6%N)R!S:7IE/3-$,CXF(W@R,#$T.SPO9F]N=#X\+W1D/@T*(#QT M9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P/CQF;VYT('-T>6QE M/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R/B8C M>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^ M/&9O;G0@<VEZ93TS1#$^)B-X03`[)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D M('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@ M5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXF(WA!,#L\+V9O;G0^/"]T9#X- M"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^/&9O;G0@<W1Y M;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^ M,BPU,#(\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A M<#TS1&YO=W)A<#X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@ M3F5W(%)O;6%N)R!S:7IE/3-$,CXF(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X- M"B`\+W1R/@T*(#QT<B!S='EL93TS1"=&3TY4+5-)6D4Z(#%P>"<^#0H@/'1D M('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^ M)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP M('-T>6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@,7!X('-O;&ED)SXF(WA! M,#L\+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T M>6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@,7!X('-O;&ED)SXF(WA!,#L\ M+W`^#0H@/"]T9#X-"B`\=&0^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$ M8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O M;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B`C,#`P,#`P(#%P>"!S;VQI M9"<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X- M"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B`C,#`P,#`P(#%P>"!S;VQI9"<^ M)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D/B8C>$$P.SPO=&0^#0H@/'1D('9A M;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX] M,T1B;W1T;VT^#0H@/'`@<W1Y;&4],T0G0D]21$52+51/4#H@(S`P,#`P,"`Q M<'@@<V]L:60G/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B M;W1T;VT^#0H@/'`@<W1Y;&4],T0G0D]21$52+51/4#H@(S`P,#`P,"`Q<'@@ M<V]L:60G/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT9#XF(WA!,#L\+W1D/@T* M(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@ M=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(",P M,#`P,#`@,7!X('-O;&ED)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0@=F%L M:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P M,#`@,7!X('-O;&ED)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0^)B-X03`[ M/"]T9#X-"B`\+W1R/@T*(#QT<CX-"B`\=&0@=F%L:6=N/3-$=&]P/@T*(#QP M('-T>6QE/3-$)TU!4D=)3BU,1494.B`S96T[(%1%6%0M24Y$14Y4.B`M,65M M)SX\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N M)R!S:7IE/3-$,CY4;W1A;#PO9F]N=#X\+W`^#0H@/"]T9#X-"B`\=&0@=F%L M:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C>$$P.R8C>$$P.SPO9F]N M=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<W1Y;&4],T0G M1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^)#PO9F]N M=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#X\ M9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S M:7IE/3-$,CXW-2PY,S`\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T M=&]M(&YO=W)A<#TS1&YO=W)A<#X\9F]N="!S='EL93TS1"=&3TY4+49!34E, M63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXF(WA!,#LF(WA!,#L\+V9O M;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q M/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T M;VT@;F]W<F%P/3-$;F]W<F%P/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9 M.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R/B0\+V9O;G0^/"]T9#X-"B`\ M=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<"!A;&EG;CTS1')I M9VAT/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M M86XG('-I>F4],T0R/B8C>#(P,30[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG M;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^/&9O;G0@<W1Y;&4],T0G1D]. M5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^)B-X03`[)B-X M03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S M:7IE/3-$,3XF(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N M/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#X\9F]N="!S='EL93TS1"=&3TY4 M+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXD/"]F;VYT/CPO M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`@86QI M9VX],T1R:6=H=#X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@ M3F5W(%)O;6%N)R!S:7IE/3-$,CXF(W@R,#$T.SPO9F]N=#X\+W1D/@T*(#QT M9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P/CQF;VYT('-T>6QE M/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R/B8C M>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^ M/&9O;G0@<VEZ93TS1#$^)B-X03`[)B-X03`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`\=&0@=F%L M:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA! M,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@<W1Y M;&4],T0G0D]21$52+51/4#H@(S`P,#`P,"`S<'@@9&]U8FQE)SXF(WA!,#L\ M+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE M/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@,W!X(&1O=6)L92<^)B-X03`[/"]P M/@T*(#PO=&0^#0H@/'1D/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O M='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^ M#0H@/'`@<W1Y;&4],T0G0D]21$52+51/4#H@(S`P,#`P,"`S<'@@9&]U8FQE M)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T* M(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@,W!X(&1O=6)L92<^ M)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D/B8C>$$P.SPO=&0^#0H@/'1D('9A M;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX] M,T1B;W1T;VT^#0H@/'`@<W1Y;&4],T0G0D]21$52+51/4#H@(S`P,#`P,"`S M<'@@9&]U8FQE)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$ M8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@,W!X M(&1O=6)L92<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D/B8C>$$P.SPO=&0^ M#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT M9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@<W1Y;&4],T0G0D]21$52+51/4#H@ M(S`P,#`P,"`S<'@@9&]U8FQE)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0@ M=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(",P M,#`P,#`@,W!X(&1O=6)L92<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D/B8C M>$$P.SPO=&0^#0H@/"]T<CX-"B`\+W1A8FQE/@T*(#PO9&EV/CQS<&%N/CPO M<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`\+W1A8FQE/@T*("`\+V)O M9'D^#0H\+VAT;6P^#0H-"BTM+2TM+3U?3F5X=%!A<G1?,SEC,&5A-C)?8S(P M,U\T-3AF7SAC-3!?,V1C830U-F$V.34Q#0I#;VYT96YT+4QO8V%T:6]N.B!F M:6QE.B\O+T,Z+S,Y8S!E838R7V,R,#-?-#4X9E\X8S4P7S-D8V$T-39A-CDU M,2]7;W)K<VAE971S+U-H965T,C@N:'1M;`T*0V]N=&5N="U4<F%N<V9E<BU% M;F-O9&EN9SH@<75O=&5D+7!R:6YT86)L90T*0V]N=&5N="U4>7!E.B!T97AT M+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^ M#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT M/3-$)W1E>'0O:'1M;#L@8VAA<G-E=#UU=&8M."<^/'-C<FEP="!T>7!E/3-$ M=&5X="]J879A<V-R:7!T('-R8STS1%-H;W<N:G,^+RH@1&\@3F]T(%)E;6]V M92!4:&ES($-O;6UE;G0@*B\\+W-C<FEP=#X\+VAE860^#0H@(#QB;V1Y/@T* M("`@(#QT86)L92!C;&%S<STS1')E<&]R="!I9#TS1$E$,$4R1CX-"B`@("`@ M(#QT<CX-"B`@("`@("`@/'1H(&-L87-S/3-$=&P@8V]L<W!A;CTS1#$@<F]W M<W!A;CTS1#(^/'-T<F]N9SY"86QA;F-E(%-H965T($-O;7!O;F5N=',@*%1A M8FQE<RD\8G(^/"]S=')O;F<^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$ M=&@@8V]L<W!A;CTS1#$^,3(@36]N=&AS($5N9&5D/"]T:#X-"B`@("`@(#PO M='(^#0H@("`@("`\='(^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/D1E8RX@ M,S$L(#(P,30\8G(^/"]T:#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA M<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P M/CQS=')O;F<^3W)G86YI>F%T:6]N+"!#;VYS;VQI9&%T:6]N(&%N9"!0<F5S M96YT871I;VX@;V8@1FEN86YC:6%L(%-T871E;65N=',@6T%B<W1R86-T73PO M<W1R;VYG/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$ M<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y3=6UM M87)Y(&]F(%!R;W!E<G1Y(&%N9"!%<75I<&UE;G0@0F%L86YC97,\+W1D/@T* M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQD:78^#0H@/'`@<W1Y;&4],T0G M;6%R9VEN+71O<#HV<'@[;6%R9VEN+6)O='1O;3HP<'@[('1E>'0M:6YD96YT M.C0E)R!A;&EG;CTS1&IU<W1I9GD^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI M;'DZ5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CY0<F]P97)T>2!A;F0@97%U M:7!M96YT(&)A;&%N8V5S('=E<F4@87,@9F]L;&]W<R`H:6X-"B!T:&]U<V%N M9',I.CPO9F]N=#X\+W`^#0H@/'`@<W1Y;&4],T1F;VYT+7-I>F4Z,3)P>#MM M87)G:6XM=&]P.C!P>#MM87)G:6XM8F]T=&]M.C!P>#X-"B`F(WA!,#L\+W`^ M#0H@/'1A8FQE(&-E;&QS<&%C:6YG/3-$,"!C96QL<&%D9&EN9STS1#`@=VED M=&@],T0Y,B4@8F]R9&5R/3-$,"!S='EL93TS1$)/4D1%4BU#3TQ,05!313I# M3TQ,05!312!A;&EG;CTS1&-E;G1E<CX-"B`\='(^#0H@/'1D('=I9'1H/3-$ M-S<E/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#8E/CPO M=&0^#0H@/'1D/CPO=&0^#0H@/'1D/CPO=&0^#0H@/'1D/CPO=&0^#0H@/'1D M('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#4E/CPO=&0^#0H@/'1D/CPO=&0^ M#0H@/'1D/CPO=&0^#0H@/'1D/CPO=&0^#0H@/"]T<CX-"B`\='(^#0H@/'1D M('9A;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF(WA!,#L\+V9O;G0^ M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C M>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@ M8V]L<W!A;CTS1#8@86QI9VX],T1C96YT97(@<W1Y;&4],T0G8F]R9&5R+6)O M='1O;3HQ<'@@<V]L:60@(S`P,#`P,"<^/&9O;G0@<W1Y;&4],T0G9F]N="UF M86UI;'DZ5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,3X\8CY$96-E;6)E<B8C M>$$P.S,Q+#PO8CX\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M M/CQF;VYT('-I>F4],T0Q/B8C>$$P.SPO9F]N=#X\+W1D/@T*(#PO='(^#0H@ M/'1R/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<VEZ93TS1#$^)B-X M03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S M:7IE/3-$,3XF(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N M/3-$8F]T=&]M(&-O;'-P86X],T0R(&%L:6=N/3-$8V5N=&5R('-T>6QE/3-$ M)V)O<F1E<BUB;W1T;VTZ,7!X('-O;&ED(",P,#`P,#`G/CQF;VYT('-T>6QE M/3-$)V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#$^/&(^ M,C`Q-#PO8CX\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF M;VYT('-I>F4],T0Q/B8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX] M,T1B;W1T;VT^/&9O;G0@<VEZ93TS1#$^)B-X03`[)B-X03`[/"]F;VYT/CPO M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!C;VQS<&%N/3-$,B!A;&EG;CTS M1&-E;G1E<B!S='EL93TS1"=B;W)D97(M8F]T=&]M.C%P>"!S;VQI9"`C,#`P M,#`P)SX\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M M86XG('-I>F4],T0Q/CQB/C(P,3,\+V(^/"]F;VYT/CPO=&0^#0H@/'1D('9A M;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF(WA!,#L\+V9O;G0^/"]T M9#X-"B`\+W1R/@T*(#QT<B!B9V-O;&]R/3-$(T-#145&1CX-"B`\=&0@=F%L M:6=N/3-$=&]P/@T*(#QP('-T>6QE/3-$)VUA<F=I;BUL969T.C$N,#!E;3L@ M=&5X="UI;F1E;G0Z+3$N,#!E;2<^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI M;'DZ5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CY0<F]P97)T>2!A;F0@97%U M:7!M96YT+`T*(&YE=#H\+V9O;G0^/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG M;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF(WA!,#LF(WA!,#L\+V9O;G0^ M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG M;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X- M"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C>$$P.R8C M>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X- M"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O M='1O;3X\+W1D/@T*(#PO='(^#0H@/'1R/@T*(#QT9"!V86QI9VX],T1T;W`^ M#0H@/'`@<W1Y;&4],T0G;6%R9VEN+6QE9G0Z,BXP,&5M.R!T97AT+6EN9&5N M=#HM,2XP,&5M)SX\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3I4:6UE<R!. M97<@4F]M86XG('-I>F4],T0R/DQA8F]R871O<GD-"B!E<75I<&UE;G0\+V9O M;G0^/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S M:7IE/3-$,3XF(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N M/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.E1I;65S($YE M=R!2;VUA;B<@<VEZ93TS1#(^)#PO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX] M,T1B;W1T;VT@86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS1"=F;VYT+69A M;6EL>3I4:6UE<R!.97<@4F]M86XG('-I>F4],T0R/C$U+#(Y.3PO9F]N=#X\ M+W1D/@T*(#QT9"!N;W=R87`],T1N;W=R87`@=F%L:6=N/3-$8F]T=&]M/CQF M;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;B<@<VEZ M93TS1#(^)B-X03`[)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS M1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF(WA!,#LF(WA!,#L\+V9O;G0^/"]T M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)V9O;G0M M9F%M:6QY.E1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^)#PO9F]N=#X\+W1D M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#X\9F]N="!S M='EL93TS1"=F;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86XG('-I>F4],T0R M/C$U+#,Q-SPO9F]N=#X\+W1D/@T*(#QT9"!N;W=R87`],T1N;W=R87`@=F%L M:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.E1I;65S M($YE=R!2;VUA;B<@<VEZ93TS1#(^)B-X03`[)B-X03`[/"]F;VYT/CPO=&0^ M#0H@/"]T<CX-"B`\='(@8F=C;VQO<CTS1"-#0T5%1D8^#0H@/'1D('9A;&EG M;CTS1'1O<#X-"B`\<"!S='EL93TS1"=M87)G:6XM;&5F=#HR+C`P96T[('1E M>'0M:6YD96YT.BTQ+C`P96TG/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY M.E1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^0V]M<'5T97(@97%U:7!M96YT M(&%N9`T*('-O9G1W87)E/"]F;VYT/CPO<#X-"B`\+W1D/@T*(#QT9"!V86QI M9VX],T1B;W1T;VT^/&9O;G0@<VEZ93TS1#$^)B-X03`[)B-X03`[/"]F;VYT M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=F M;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86XG('-I>F4],T0R/B8C>$$P.SPO M9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H M=#X\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86XG M('-I>F4],T0R/C(L-#$X/"]F;VYT/CPO=&0^#0H@/'1D(&YO=W)A<#TS1&YO M=W)A<"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI M;'DZ5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXF(WA!,#LF(WA!,#L\+V9O M;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q M/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T M;VT^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N M)R!S:7IE/3-$,CXF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$ M8F]T=&]M(&%L:6=N/3-$<FEG:'0^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI M;'DZ5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXR+#4T.3PO9F]N=#X\+W1D M/@T*(#QT9"!N;W=R87`],T1N;W=R87`@=F%L:6=N/3-$8F]T=&]M/CQF;VYT M('-T>6QE/3-$)V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;B<@<VEZ93TS M1#(^)B-X03`[)B-X03`[/"]F;VYT/CPO=&0^#0H@/"]T<CX-"B`\='(^#0H@ M/'1D('9A;&EG;CTS1'1O<#X-"B`\<"!S='EL93TS1"=M87)G:6XM;&5F=#HR M+C`P96T[('1E>'0M:6YD96YT.BTQ+C`P96TG/CQF;VYT('-T>6QE/3-$)V9O M;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^3V9F:6-E(&5Q M=6EP;65N="P@9G5R;FET=7)E#0H@86YD(&9I>'1U<F5S/"]F;VYT/CPO<#X- M"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<VEZ93TS1#$^ M)B-X03`[)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O M;3X\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86XG M('-I>F4],T0R/B8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B M;W1T;VT@86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS1"=F;VYT+69A;6EL M>3I4:6UE<R!.97<@4F]M86XG('-I>F4],T0R/CDQ,SPO9F]N=#X\+W1D/@T* M(#QT9"!N;W=R87`],T1N;W=R87`@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T M>6QE/3-$)V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^ M)B-X03`[)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O M;3X\9F]N="!S:7IE/3-$,3XF(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\ M=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY M.E1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^)B-X03`[/"]F;VYT/CPO=&0^ M#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/CQF;VYT('-T M>6QE/3-$)V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^ M,2PP-3`\+V9O;G0^/"]T9#X-"B`\=&0@;F]W<F%P/3-$;F]W<F%P('9A;&EG M;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3I4:6UE<R!. M97<@4F]M86XG('-I>F4],T0R/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T* M(#PO='(^#0H@/'1R(&)G8V]L;W(],T0C0T-%149&/@T*(#QT9"!V86QI9VX] M,T1T;W`^#0H@/'`@<W1Y;&4],T0G;6%R9VEN+6QE9G0Z,BXP,&5M.R!T97AT M+6EN9&5N=#HM,2XP,&5M)SX\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3I4 M:6UE<R!.97<@4F]M86XG('-I>F4],T0R/DQE87-E:&]L9`T*(&EM<')O=F5M M96YT<SPO9F]N=#X\+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M M/CQF;VYT('-I>F4],T0Q/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT M9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ M5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXF(WA!,#L\+V9O;G0^/"]T9#X- M"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^/&9O;G0@<W1Y M;&4],T0G9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXS M+#,S-#PO9F]N=#X\+W1D/@T*(#QT9"!N;W=R87`],T1N;W=R87`@=F%L:6=N M/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.E1I;65S($YE M=R!2;VUA;B<@<VEZ93TS1#(^)B-X03`[)B-X03`[/"]F;VYT/CPO=&0^#0H@ M/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF(WA!,#LF(WA! M,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T M>6QE/3-$)V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^ M)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG M;CTS1')I9VAT/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.E1I;65S($YE M=R!2;VUA;B<@<VEZ93TS1#(^,RPR.3<\+V9O;G0^/"]T9#X-"B`\=&0@;F]W M<F%P/3-$;F]W<F%P('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=F M;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86XG('-I>F4],T0R/B8C>$$P.R8C M>$$P.SPO9F]N=#X\+W1D/@T*(#PO='(^#0H@/'1R('-T>6QE/3-$9F]N="US M:7IE.C%P>#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A M;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX] M,T1B;W1T;VT^#0H@/'`@<W1Y;&4],T0G8F]R9&5R+71O<#HQ<'@@<V]L:60@ M(S`P,#`P,"<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O M='1O;3X-"B`\<"!S='EL93TS1"=B;W)D97(M=&]P.C%P>"!S;VQI9"`C,#`P M,#`P)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0^)B-X03`[/"]T9#X-"B`\ M=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A M;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"=B;W)D97(M=&]P.C%P>"!S M;VQI9"`C,#`P,#`P)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N M/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)V)O<F1E<BUT;W`Z,7!X('-O;&ED M(",P,#`P,#`G/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT9#XF(WA!,#L\+W1D M/@T*(#PO='(^#0H@/'1R/@T*(#QT9"!V86QI9VX],T1T;W`^/"]T9#X-"B`\ M=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C>$$P.R8C>$$P M.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<W1Y M;&4],T0G9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXF M(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N M/3-$<FEG:'0^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ5&EM97,@3F5W M(%)O;6%N)R!S:7IE/3-$,CXR,2PY-C0\+V9O;G0^/"]T9#X-"B`\=&0@;F]W M<F%P/3-$;F]W<F%P('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=F M;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86XG('-I>F4],T0R/B8C>$$P.R8C M>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@ M<VEZ93TS1#$^)B-X03`[)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG M;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3I4:6UE<R!. M97<@4F]M86XG('-I>F4],T0R/B8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V M86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS1"=F M;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86XG('-I>F4],T0R/C(R+#(Q,SPO M9F]N=#X\+W1D/@T*(#QT9"!N;W=R87`],T1N;W=R87`@=F%L:6=N/3-$8F]T M=&]M/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA M;B<@<VEZ93TS1#(^)B-X03`[)B-X03`[/"]F;VYT/CPO=&0^#0H@/"]T<CX- M"B`\='(@8F=C;VQO<CTS1"-#0T5%1D8^#0H@/'1D('9A;&EG;CTS1'1O<#X- M"B`\<"!S='EL93TS1"=M87)G:6XM;&5F=#HR+C`P96T[('1E>'0M:6YD96YT M.BTQ+C`P96TG/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.E1I;65S($YE M=R!2;VUA;B<@<VEZ93TS1#(^3&5S<SH@06-C=6UU;&%T960-"B!D97!R96-I M871I;VX@86YD(&%M;W)T:7IA=&EO;CPO9F]N=#X\+W`^#0H@/"]T9#X-"B`\ M=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C>$$P.R8C>$$P M.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<W1Y M;&4],T0G9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXF M(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N M/3-$<FEG:'0^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ5&EM97,@3F5W M(%)O;6%N)R!S:7IE/3-$,CXH,C`L,S(W/"]F;VYT/CPO=&0^#0H@/'1D(&YO M=W)A<#TS1&YO=W)A<"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<W1Y;&4],T0G M9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXI)B-X03`[ M/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE M/3-$,3XF(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$ M8F]T=&]M/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.E1I;65S($YE=R!2 M;VUA;B<@<VEZ93TS1#(^)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG M;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/CQF;VYT('-T>6QE/3-$)V9O;G0M M9F%M:6QY.E1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^*#(P+#DY,CPO9F]N M=#X\+W1D/@T*(#QT9"!N;W=R87`],T1N;W=R87`@=F%L:6=N/3-$8F]T=&]M M/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;B<@ M<VEZ93TS1#(^*28C>$$P.SPO9F]N=#X\+W1D/@T*(#PO='(^#0H@/'1R('-T M>6QE/3-$9F]N="US:7IE.C%P>#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T* M(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@<W1Y;&4],T0G8F]R9&5R+71O M<#HQ<'@@<V]L:60@(S`P,#`P,"<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D M('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"=B;W)D97(M=&]P.C%P M>"!S;VQI9"`C,#`P,#`P)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0^)B-X M03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"=B;W)D M97(M=&]P.C%P>"!S;VQI9"`C,#`P,#`P)SXF(WA!,#L\+W`^#0H@/"]T9#X- M"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)V)O<F1E<BUT M;W`Z,7!X('-O;&ED(",P,#`P,#`G/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT M9#XF(WA!,#L\+W1D/@T*(#PO='(^#0H@/'1R/@T*(#QT9"!V86QI9VX],T1T M;W`^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q M/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T M;VT^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N M)R!S:7IE/3-$,CXD/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O M;2!A;&EG;CTS1')I9VAT/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.E1I M;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^,2PV,S<\+V9O;G0^/"]T9#X-"B`\ M=&0@;F]W<F%P/3-$;F]W<F%P('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL M93TS1"=F;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86XG('-I>F4],T0R/B8C M>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^ M/&9O;G0@<VEZ93TS1#$^)B-X03`[)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D M('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3I4 M:6UE<R!.97<@4F]M86XG('-I>F4],T0R/B0\+V9O;G0^/"]T9#X-"B`\=&0@ M=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^/&9O;G0@<W1Y;&4],T0G M9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXQ+#(R,3PO M9F]N=#X\+W1D/@T*(#QT9"!N;W=R87`],T1N;W=R87`@=F%L:6=N/3-$8F]T M=&]M/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA M;B<@<VEZ93TS1#(^)B-X03`[)B-X03`[/"]F;VYT/CPO=&0^#0H@/"]T<CX- M"B`\='(@<W1Y;&4],T1F;VYT+7-I>F4Z,7!X/@T*(#QT9"!V86QI9VX],T1B M;W1T;VT^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P M.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"=B M;W)D97(M=&]P.C-P>"!D;W5B;&4@(S`P,#`P,"<^)B-X03`[/"]P/@T*(#PO M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"=B;W)D M97(M=&]P.C-P>"!D;W5B;&4@(S`P,#`P,"<^)B-X03`[/"]P/@T*(#PO=&0^ M#0H@/'1D/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA! M,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@<W1Y M;&4],T0G8F]R9&5R+71O<#HS<'@@9&]U8FQE(",P,#`P,#`G/B8C>$$P.SPO M<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@<W1Y;&4] M,T0G8F]R9&5R+71O<#HS<'@@9&]U8FQE(",P,#`P,#`G/B8C>$$P.SPO<#X- M"B`\+W1D/@T*(#QT9#XF(WA!,#L\+W1D/@T*(#PO='(^#0H@/"]T86)L93X- M"B`\+V1I=CX\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@ M("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L M:6=N/3-$=&]P/E-U;6UA<GD@;V8@06-C<G5E9"!,:6%B:6QI=&EE<SPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/&1I=CX-"B`\<"!S='EL93TS M1"=M87)G:6XM=&]P.C!P>#MM87)G:6XM8F]T=&]M.C!P>#L@=&5X="UI;F1E M;G0Z-"4G(&%L:6=N/3-$:G5S=&EF>3X\9F]N="!S='EL93TS1"=F;VYT+69A M;6EL>3I4:6UE<R!.97<@4F]M86XG('-I>F4],T0R/D%C8W)U960@;&EA8FEL M:71I97,@=V5R92!A<R!F;VQL;W=S("AI;B!T:&]U<V%N9',I.CPO9F]N=#X\ M+W`^#0H@/'`@<W1Y;&4],T1F;VYT+7-I>F4Z,3)P>#MM87)G:6XM=&]P.C!P M>#MM87)G:6XM8F]T=&]M.C!P>#X-"B`F(WA!,#L\+W`^#0H@/'1A8FQE(&-E M;&QS<&%C:6YG/3-$,"!C96QL<&%D9&EN9STS1#`@=VED=&@],T0Y,B4@8F]R M9&5R/3-$,"!S='EL93TS1$)/4D1%4BU#3TQ,05!313I#3TQ,05!312!A;&EG M;CTS1&-E;G1E<CX-"B`\='(^#0H@/'1D('=I9'1H/3-$.#(E/CPO=&0^#0H@ M/'1D('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#0E/CPO=&0^#0H@/'1D/CPO M=&0^#0H@/'1D/CPO=&0^#0H@/'1D/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O M='1O;2!W:61T:#TS1#0E/CPO=&0^#0H@/'1D/CPO=&0^#0H@/'1D/CPO=&0^ M#0H@/'1D/CPO=&0^#0H@/"]T<CX-"B`\='(^#0H@/'1D('9A;&EG;CTS1&)O M='1O;3X\9F]N="!S:7IE/3-$,3XF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@ M=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C>$$P.R8C>$$P.SPO M9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@8V]L<W!A;CTS1#8@ M86QI9VX],T1C96YT97(@<W1Y;&4],T0G8F]R9&5R+6)O='1O;3HQ<'@@<V]L M:60@(S`P,#`P,"<^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ5&EM97,@ M3F5W(%)O;6%N)R!S:7IE/3-$,3X\8CY$96-E;6)E<B8C>$$P.S,Q+#PO8CX\ M+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4] M,T0Q/B8C>$$P.SPO9F]N=#X\+W1D/@T*(#PO='(^#0H@/'1R/@T*(#QT9"!V M86QI9VX],T1B;W1T;VT^/&9O;G0@<VEZ93TS1#$^)B-X03`[/"]F;VYT/CPO M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF(WA! M,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&-O M;'-P86X],T0R(&%L:6=N/3-$8V5N=&5R('-T>6QE/3-$)V)O<F1E<BUB;W1T M;VTZ,7!X('-O;&ED(",P,#`P,#`G/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M M:6QY.E1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#$^/&(^,C`Q-#PO8CX\+V9O M;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q M/B8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O M;G0@<VEZ93TS1#$^)B-X03`[)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A M;&EG;CTS1&)O='1O;2!C;VQS<&%N/3-$,B!A;&EG;CTS1&-E;G1E<B!S='EL M93TS1"=B;W)D97(M8F]T=&]M.C%P>"!S;VQI9"`C,#`P,#`P)SX\9F]N="!S M='EL93TS1"=F;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86XG('-I>F4],T0Q M/CQB/C(P,3,\+V(^/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O M;3X\9F]N="!S:7IE/3-$,3XF(WA!,#L\+V9O;G0^/"]T9#X-"B`\+W1R/@T* M(#QT<B!B9V-O;&]R/3-$(T-#145&1CX-"B`\=&0@=F%L:6=N/3-$=&]P/@T* M(#QP('-T>6QE/3-$)VUA<F=I;BUL969T.C$N,#!E;3L@=&5X="UI;F1E;G0Z M+3$N,#!E;2<^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ5&EM97,@3F5W M(%)O;6%N)R!S:7IE/3-$,CY!8V-R=65D#0H@;&EA8FEL:71I97,Z/"]F;VYT M/CPO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<VEZ M93TS1#$^)B-X03`[)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS M1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\ M=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O M;3X\9F]N="!S:7IE/3-$,3XF(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\ M=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O M;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\+W1R/@T* M(#QT<CX-"B`\=&0@=F%L:6=N/3-$=&]P/@T*(#QP('-T>6QE/3-$)VUA<F=I M;BUL969T.C(N,#!E;3L@=&5X="UI;F1E;G0Z+3$N,#!E;2<^/&9O;G0@<W1Y M;&4],T0G9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CY# M;&EN:6-A;"!A;F0@<')E8VQI;FEC86P-"B!C;W-T<SPO9F]N=#X\+W`^#0H@ M/"]T9#X-"B`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`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT M('-I>F4],T0Q/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI M9VX],T1B;W1T;VT^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ5&EM97,@ M3F5W(%)O;6%N)R!S:7IE/3-$,CXD/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG M;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/CQF;VYT('-T>6QE/3-$)V9O;G0M M9F%M:6QY.E1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^-"PY-S4\+V9O;G0^ M/"]T9#X-"B`\=&0@;F]W<F%P/3-$;F]W<F%P('9A;&EG;CTS1&)O='1O;3X\ M9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86XG('-I M>F4],T0R/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#PO='(^#0H@/'1R M(&)G8V]L;W(],T0C0T-%149&/@T*(#QT9"!V86QI9VX],T1T;W`^#0H@/'`@ M<W1Y;&4],T0G;6%R9VEN+6QE9G0Z,BXP,&5M.R!T97AT+6EN9&5N=#HM,2XP M,&5M)SX\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M M86XG('-I>F4],T0R/D-O;G-U;'1I;F<@86YD('!R;V9E<W-I;VYA;`T*(&9E M97,\+V9O;G0^/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\ M9F]N="!S:7IE/3-$,3XF(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@ M=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.E1I M;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^)B-X03`[/"]F;VYT/CPO=&0^#0H@ M/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/CQF;VYT('-T>6QE M/3-$)V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^-#(Q M/"]F;VYT/CPO=&0^#0H@/'1D(&YO=W)A<#TS1&YO=W)A<"!V86QI9VX],T1B M;W1T;VT^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O M;6%N)R!S:7IE/3-$,CXF(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@ M=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C>$$P.R8C>$$P.SPO M9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<W1Y;&4] M,T0G9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXF(WA! M,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$ M<FEG:'0^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O M;6%N)R!S:7IE/3-$,CXV.3<\+V9O;G0^/"]T9#X-"B`\=&0@;F]W<F%P/3-$ M;F]W<F%P('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=F;VYT+69A M;6EL>3I4:6UE<R!.97<@4F]M86XG('-I>F4],T0R/B8C>$$P.R8C>$$P.SPO M9F]N=#X\+W1D/@T*(#PO='(^#0H@/'1R/@T*(#QT9"!V86QI9VX],T1T;W`^ M#0H@/'`@<W1Y;&4],T0G;6%R9VEN+6QE9G0Z,BXP,&5M.R!T97AT+6EN9&5N M=#HM,2XP,&5M)SX\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3I4:6UE<R!. M97<@4F]M86XG('-I>F4],T0R/D)O;G5S/"]F;VYT/CPO<#X-"B`\+W1D/@T* M(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<VEZ93TS1#$^)B-X03`[)B-X M03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S M='EL93TS1"=F;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86XG('-I>F4],T0R M/B8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI M9VX],T1R:6=H=#X\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3I4:6UE<R!. M97<@4F]M86XG('-I>F4],T0R/C(L-C8U/"]F;VYT/CPO=&0^#0H@/'1D(&YO M=W)A<#TS1&YO=W)A<"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<W1Y;&4],T0G M9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXF(WA!,#LF M(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT M('-I>F4],T0Q/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI M9VX],T1B;W1T;VT^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ5&EM97,@ M3F5W(%)O;6%N)R!S:7IE/3-$,CXF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@ M=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^/&9O;G0@<W1Y;&4],T0G M9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXQ+#8Q-#PO M9F]N=#X\+W1D/@T*(#QT9"!N;W=R87`],T1N;W=R87`@=F%L:6=N/3-$8F]T M=&]M/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA M;B<@<VEZ93TS1#(^)B-X03`[)B-X03`[/"]F;VYT/CPO=&0^#0H@/"]T<CX- M"B`\='(@8F=C;VQO<CTS1"-#0T5%1D8^#0H@/'1D('9A;&EG;CTS1'1O<#X- M"B`\<"!S='EL93TS1"=M87)G:6XM;&5F=#HR+C`P96T[('1E>'0M:6YD96YT M.BTQ+C`P96TG/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.E1I;65S($YE M=R!2;VUA;B<@<VEZ93TS1#(^5F%C871I;VX@<&%Y/"]F;VYT/CPO<#X-"B`\ M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<VEZ93TS1#$^)B-X M03`[)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\ M9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86XG('-I M>F4],T0R/B8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T M;VT@86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3I4 M:6UE<R!.97<@4F]M86XG('-I>F4],T0R/CDQ-3PO9F]N=#X\+W1D/@T*(#QT M9"!N;W=R87`],T1N;W=R87`@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE M/3-$)V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^)B-X M03`[)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\ M9F]N="!S:7IE/3-$,3XF(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@ M=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.E1I M;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^)B-X03`[/"]F;VYT/CPO=&0^#0H@ M/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/CQF;VYT('-T>6QE M/3-$)V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^-S<X M/"]F;VYT/CPO=&0^#0H@/'1D(&YO=W)A<#TS1&YO=W)A<"!V86QI9VX],T1B M;W1T;VT^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O M;6%N)R!S:7IE/3-$,CXF(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\+W1R M/@T*(#QT<CX-"B`\=&0@=F%L:6=N/3-$=&]P/@T*(#QP('-T>6QE/3-$)VUA M<F=I;BUL969T.C(N,#!E;3L@=&5X="UI;F1E;G0Z+3$N,#!E;2<^/&9O;G0@ M<W1Y;&4],T0G9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$ M,CY/=&AE<B!P87ER;VQL#0H@<F5L871E9#PO9F]N=#X\+W`^#0H@/"]T9#X- M"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C>$$P.R8C M>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@ M<W1Y;&4],T0G9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$ M,CXF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L M:6=N/3-$<FEG:'0^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ5&EM97,@ M3F5W(%)O;6%N)R!S:7IE/3-$,CXQ,3`\+V9O;G0^/"]T9#X-"B`\=&0@;F]W M<F%P/3-$;F]W<F%P('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=F M;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86XG('-I>F4],T0R/B8C>$$P.R8C M>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@ M<VEZ93TS1#$^)B-X03`[)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG M;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3I4:6UE<R!. M97<@4F]M86XG('-I>F4],T0R/B8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V M86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS1"=F M;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86XG('-I>F4],T0R/CDS/"]F;VYT M/CPO=&0^#0H@/'1D(&YO=W)A<#TS1&YO=W)A<"!V86QI9VX],T1B;W1T;VT^ M/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N)R!S M:7IE/3-$,CXF(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\+W1R/@T*(#QT M<B!B9V-O;&]R/3-$(T-#145&1CX-"B`\=&0@=F%L:6=N/3-$=&]P/@T*(#QP M('-T>6QE/3-$)VUA<F=I;BUL969T.C(N,#!E;3L@=&5X="UI;F1E;G0Z+3$N M,#!E;2<^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O M;6%N)R!S:7IE/3-$,CY/=&AE<B!A8V-R=65D#0H@97AP96YS97,\+V9O;G0^ M/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE M/3-$,3XF(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$ M8F]T=&]M/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.E1I;65S($YE=R!2 M;VUA;B<@<VEZ93TS1#(^)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG M;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/CQF;VYT('-T>6QE/3-$)V9O;G0M M9F%M:6QY.E1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^,S$W/"]F;VYT/CPO M=&0^#0H@/'1D(&YO=W)A<#TS1&YO=W)A<"!V86QI9VX],T1B;W1T;VT^/&9O M;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N)R!S:7IE M/3-$,CXF(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$ M8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<W1Y;&4],T0G9F]N="UF M86UI;'DZ5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXF(WA!,#L\+V9O;G0^ M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^/&9O M;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N)R!S:7IE M/3-$,CXQ,34\+V9O;G0^/"]T9#X-"B`\=&0@;F]W<F%P/3-$;F]W<F%P('9A M;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3I4:6UE M<R!.97<@4F]M86XG('-I>F4],T0R/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D M/@T*(#PO='(^#0H@/'1R('-T>6QE/3-$9F]N="US:7IE.C%P>#X-"B`\=&0@ M=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF M(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@ M<W1Y;&4],T0G8F]R9&5R+71O<#HQ<'@@<V]L:60@(S`P,#`P,"<^)B-X03`[ M/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL M93TS1"=B;W)D97(M=&]P.C%P>"!S;VQI9"`C,#`P,#`P)SXF(WA!,#L\+W`^ M#0H@/"]T9#X-"B`\=&0^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T M=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X- M"B`\<"!S='EL93TS1"=B;W)D97(M=&]P.C%P>"!S;VQI9"`C,#`P,#`P)SXF M(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP M('-T>6QE/3-$)V)O<F1E<BUT;W`Z,7!X('-O;&ED(",P,#`P,#`G/B8C>$$P M.SPO<#X-"B`\+W1D/@T*(#QT9#XF(WA!,#L\+W1D/@T*(#PO='(^#0H@/'1R M/@T*(#QT9"!V86QI9VX],T1T;W`^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T M=&]M/CQF;VYT('-I>F4],T0Q/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T* M(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI M;'DZ5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXD/"]F;VYT/CPO=&0^#0H@ M/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/CQF;VYT('-T>6QE M/3-$)V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^-2PT M,#`\+V9O;G0^/"]T9#X-"B`\=&0@;F]W<F%P/3-$;F]W<F%P('9A;&EG;CTS M1&)O='1O;3X\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3I4:6UE<R!.97<@ M4F]M86XG('-I>F4],T0R/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT M9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<VEZ93TS1#$^)B-X03`[)B-X03`[ M/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL M93TS1"=F;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86XG('-I>F4],T0R/B0\ M+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG M:'0^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N M)R!S:7IE/3-$,CXX+#(W,CPO9F]N=#X\+W1D/@T*(#QT9"!N;W=R87`],T1N M;W=R87`@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M M:6QY.E1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^)B-X03`[)B-X03`[/"]F M;VYT/CPO=&0^#0H@/"]T<CX-"B`\='(@<W1Y;&4],T1F;VYT+7-I>F4Z,7!X M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\=&0@=F%L:6=N/3-$ M8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O M;3X-"B`\<"!S='EL93TS1"=B;W)D97(M=&]P.C-P>"!D;W5B;&4@(S`P,#`P M,"<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X- M"B`\<"!S='EL93TS1"=B;W)D97(M=&]P.C-P>"!D;W5B;&4@(S`P,#`P,"<^ M)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D/B8C>$$P.SPO=&0^#0H@/'1D('9A M;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX] M,T1B;W1T;VT^#0H@/'`@<W1Y;&4],T0G8F]R9&5R+71O<#HS<'@@9&]U8FQE M(",P,#`P,#`G/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B M;W1T;VT^#0H@/'`@<W1Y;&4],T0G8F]R9&5R+71O<#HS<'@@9&]U8FQE(",P M,#`P,#`G/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT9#XF(WA!,#L\+W1D/@T* M(#PO='(^#0H@/"]T86)L93X-"B`\+V1I=CX\<W!A;CX\+W-P86X^/"]T9#X- M"B`@("`@(#PO='(^#0H@("`@/"]T86)L93X-"B`@/"]B;V1Y/@T*/"]H=&UL M/@T*#0HM+2TM+2T]7TYE>'1087)T7S,Y8S!E838R7V,R,#-?-#4X9E\X8S4P M7S-D8V$T-39A-CDU,0T*0V]N=&5N="U,;V-A=&EO;CH@9FEL93HO+R]#.B\S M.6,P96$V,E]C,C`S7S0U.&9?.&,U,%\S9&-A-#4V838Y-3$O5V]R:W-H965T M<R]3:&5E=#(Y+FAT;6P-"D-O;G1E;G0M5')A;G-F97(M16YC;V1I;F<Z('%U M;W1E9"UP<FEN=&%B;&4-"D-O;G1E;G0M5'EP93H@=&5X="]H=&UL.R!C:&%R M<V5T/2)U<RUA<V-I:2(-"@T*/&AT;6P^#0H@(#QH96%D/@T*("`@(#Q-151! M(&AT='`M97%U:78],T1#;VYT96YT+51Y<&4@8V]N=&5N=#TS1"=T97AT+VAT M;6P[(&-H87)S970]=71F+3@G/CQS8W)I<'0@='EP93TS1'1E>'0O:F%V87-C M<FEP="!S<F,],T13:&]W+FIS/B\J($1O($YO="!296UO=F4@5&AI<R!#;VUM M96YT("HO/"]S8W)I<'0^/"]H96%D/@T*("`\8F]D>3X-"B`@("`\=&%B;&4@ M8VQA<W,],T1R97!O<G0@:60],T1)1#!%34-!0SX-"B`@("`@(#QT<CX-"B`@ M("`@("`@/'1H(&-L87-S/3-$=&P@8V]L<W!A;CTS1#$@<F]W<W!A;CTS1#(^ M/'-T<F]N9SY296QA=&5D(%!A<G1I97,@86YD(%)E;&%T960@4&%R='D@5')A M;G-A8W1I;VYS("A486)L97,I/&)R/CPO<W1R;VYG/CPO=&@^#0H@("`@("`@ M(#QT:"!C;&%S<STS1'1H(&-O;'-P86X],T0Q/C$R($UO;G1H<R!%;F1E9#PO M=&@^#0H@("`@("`\+W1R/@T*("`@("`@/'1R/@T*("`@("`@("`\=&@@8VQA M<W,],T1T:#Y$96,N(#,Q+"`R,#$T/&)R/CPO=&@^#0H@("`@("`\+W1R/@T* M("`@("`@/'1R(&-L87-S/3-$<F@^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L M('9A;&EG;CTS1'1O<#Y!<W1E;&QA<R!;365M8F5R73PO=&0^#0H@("`@("`@ M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\ M+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S M<STS1'!L('9A;&EG;CTS1'1O<#Y2979E;G5E(&9R;VT@4F5L871E9"!087)T M>3PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/&1I=CX-"B`\<"!S M='EL93TS1"=-05)'24XM0D]45$]-.B`P<'@[($U!4D=)3BU43U`Z(#$R<'@[ M(%1%6%0M24Y$14Y4.B`T)2<@86QI9VX],T1J=7-T:69Y/CQF;VYT('-T>6QE M/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R/E)E M<V5A<F-H(&%N9"!D979E;&]P;65N="!R979E;G5E(&9R;VT@07-T96QL87,@ M=V%S(&%S(&9O;&QO=W,-"B`H:6X@=&AO=7-A;F1S*3H\+V9O;G0^/"]P/@T* M(#QP('-T>6QE/3-$)TU!4D=)3BU"3U143TTZ(#!P>#L@1D].5"U325I%.B`Q M,G!X.R!-05)'24XM5$]0.B`P<'@G/@T*("8C>$$P.SPO<#X-"B`\=&%B;&4@ M<W1Y;&4],T0G0D]21$52+4-/3$Q!4%-%.B!C;VQL87!S92<@8V5L;'-P86-I M;F<],T0P(&-E;&QP861D:6YG/3-$,"!W:61T:#TS1#DR)2!A;&EG;CTS1&-E M;G1E<B!B;W)D97(],T0P/@T*(#QT<CX-"B`\=&0@=VED=&@],T0W,24^/"]T M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$.24^/"]T9#X-"B`\ M=&0^/"]T9#X-"B`\=&0^/"]T9#X-"B`\=&0^/"]T9#X-"B`\=&0@=F%L:6=N M/3-$8F]T=&]M('=I9'1H/3-$.24^/"]T9#X-"B`\=&0^/"]T9#X-"B`\=&0^ M/"]T9#X-"B`\=&0^/"]T9#X-"B`\+W1R/@T*(#QT<CX-"B`\=&0@=F%L:6=N M/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C>$$P.SPO9F]N=#X\+W1D/@T* M(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<VEZ93TS1#$^)B-X03`[)B-X M03`[/"]F;VYT/CPO=&0^#0H@/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ M(",P,#`P,#`@,7!X('-O;&ED)R!V86QI9VX],T1B;W1T;VT@8V]L<W!A;CTS M1#(@86QI9VX],T1C96YT97(^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ M(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#$^/&(^665A<B!%;F1E9#QB<B`O M/@T*($1E8V5M8F5R)B-X03`[,S$L/&)R("\^#0H@,C`Q-#PO8CX\+V9O;G0^ M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C M>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@ M<VEZ93TS1#$^)B-X03`[)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('-T>6QE M/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,7!X('-O;&ED)R!V86QI9VX] M,T1B;W1T;VT@8V]L<W!A;CTS1#(@86QI9VX],T1C96YT97(^/&9O;G0@<W1Y M;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#$^ M/&(^665A<B!%;F1E9#QB<B`O/@T*($1E8V5M8F5R)B-X03`[,S$L/&)R("\^ M#0H@,C`Q,SPO8CX\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M M/CQF;VYT('-I>F4],T0Q/B8C>$$P.SPO9F]N=#X\+W1D/@T*(#PO='(^#0H@ M/'1R(&)G8V]L;W(],T0C0T-%149&/@T*(#QT9"!V86QI9VX],T1T;W`^#0H@ M/'`@<W1Y;&4],T0G34%21TE.+4Q%1E0Z(#%E;3L@5$585"U)3D1%3E0Z("TQ M96TG/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M M86XG('-I>F4],T0R/E)E<V5A<F-H(&%N9"!D979E;&]P;65N=`T*(')E=F5N M=65S('=I=&@@<F5L871E9"!P87)T:65S.CPO9F]N=#X\+W`^#0H@/"]T9#X- M"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C>$$P.R8C M>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X- M"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O M='1O;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<VEZ93TS M1#$^)B-X03`[)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O M='1O;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\=&0@ M=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/"]T<CX-"B`\='(^#0H@/'1D('9A M;&EG;CTS1'1O<#X-"B`\<"!S='EL93TS1"=-05)'24XM3$5&5#H@,F5M.R!4 M15A4+4E.1$5.5#H@+3%E;2<^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ M(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^4F5S96%R8V@@86YD(&1E=F5L M;W!M96YT#0H@;6EL97-T;VYE(&9E97,\+V9O;G0^/"]P/@T*(#PO=&0^#0H@ M/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF(WA!,#LF(WA! M,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T M>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R M/B0\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$ M<FEG:'0^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2 M;VUA;B<@<VEZ93TS1#(^,34L,#`P/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG M;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^/&9O;G0@<W1Y;&4],T0G1D]. M5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^)B-X03`[)B-X M03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S M:7IE/3-$,3XF(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N M/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#X\9F]N="!S='EL93TS1"=&3TY4 M+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXF(WA!,#L\+V9O M;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A M<"!A;&EG;CTS1')I9VAT/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4 M:6UE<R!.97<@4F]M86XG('-I>F4],T0R/B8C>#(P,30[/"]F;VYT/CPO=&0^ M#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^/&9O;G0@ M<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS M1#(^)B-X03`[)B-X03`[/"]F;VYT/CPO=&0^#0H@/"]T<CX-"B`\='(@8F=C M;VQO<CTS1"-#0T5%1D8^#0H@/'1D('9A;&EG;CTS1'1O<#X-"B`\<"!S='EL M93TS1"=-05)'24XM3$5&5#H@,65M.R!415A4+4E.1$5.5#H@+3%E;2<^/&9O M;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ M93TS1#(^4F5S96%R8V@@86YD(&1E=F5L;W!M96YT#0H@<F5V96YU97,Z/"]F M;VYT/CPO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@ M<VEZ93TS1#$^)B-X03`[)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG M;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X- M"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O M='1O;3X\9F]N="!S:7IE/3-$,3XF(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X- M"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O M='1O;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\+W1R M/@T*(#QT<CX-"B`\=&0@=F%L:6=N/3-$=&]P/@T*(#QP('-T>6QE/3-$)TU! M4D=)3BU,1494.B`R96T[(%1%6%0M24Y$14Y4.B`M,65M)SX\9F]N="!S='EL M93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CY2 M96EM8G5R<V5M96YT(&]F(&EN=&5R;F%L#0H@8V]S=',\+V9O;G0^/"]P/@T* M(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF M(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M M/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG M('-I>F4],T0R/B8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B M;W1T;VT@86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS1"=&3TY4+49!34E, M63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXX+#DS.3PO9F]N=#X\+W1D M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P/CQF;VYT M('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4] M,T0R/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B M;W1T;VT^/&9O;G0@<VEZ93TS1#$^)B-X03`[)B-X03`[/"]F;VYT/CPO=&0^ M#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=&3TY4+49! M34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXF(WA!,#L\+V9O;G0^ M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^/&9O M;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ M93TS1#(^,RPR.#4\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M M(&YO=W)A<#TS1&YO=W)A<#X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@ M5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXF(WA!,#LF(WA!,#L\+V9O;G0^ M/"]T9#X-"B`\+W1R/@T*(#QT<B!B9V-O;&]R/3-$(T-#145&1CX-"B`\=&0@ M=F%L:6=N/3-$=&]P/@T*(#QP('-T>6QE/3-$)TU!4D=)3BU,1494.B`R96T[ M(%1%6%0M24Y$14Y4.B`M,65M)SX\9F]N="!S='EL93TS1"=&3TY4+49!34E, M63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CY296EM8G5R<V5M96YT(&]F M(&]T:&5R#0H@8V]S=',\+V9O;G0^/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG M;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF(WA!,#LF(WA!,#L\+V9O;G0^ M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)T9/ M3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R/B8C>$$P.SPO M9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H M=#X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N M)R!S:7IE/3-$,CXV+#0U,CPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B M;W1T;VT@;F]W<F%P/3-$;F]W<F%P/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%- M24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R/B8C>$$P.R8C>$$P.SPO M9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<VEZ93TS M1#$^)B-X03`[)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O M='1O;3X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O M;6%N)R!S:7IE/3-$,CXF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N M/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^/&9O;G0@<W1Y;&4],T0G1D].5"U& M04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^,RPQ,S`\+V9O;G0^ M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#X\ M9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S M:7IE/3-$,CXF(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\+W1R/@T*(#QT M<CX-"B`\=&0@=F%L:6=N/3-$=&]P/@T*(#QP('-T>6QE/3-$)TU!4D=)3BU, M1494.B`R96T[(%1%6%0M24Y$14Y4.B`M,65M)SX\9F]N="!S='EL93TS1"=& M3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CY297-E87)C M:"!A;F0@9&5V96QO<&UE;G0-"B!M:6QE<W1O;F4@9F5E<SPO9F]N=#X\+W`^ M#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q M/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T M;VT^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA M;B<@<VEZ93TS1#(^)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS M1&)O='1O;2!A;&EG;CTS1')I9VAT/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%- M24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R/C(L,#`P/"]F;VYT/CPO M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^/&9O M;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ M93TS1#(^)B-X03`[)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS M1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF(WA!,#LF(WA!,#L\+V9O;G0^/"]T M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#X\9F]N M="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE M/3-$,CXF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M M(&YO=W)A<#TS1&YO=W)A<"!A;&EG;CTS1')I9VAT/CQF;VYT('-T>6QE/3-$ M)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R/B8C>#(P M,30[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`] M,T1N;W=R87`^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE M=R!2;VUA;B<@<VEZ93TS1#(^)B-X03`[)B-X03`[/"]F;VYT/CPO=&0^#0H@ M/"]T<CX-"B`\='(@<W1Y;&4],T0G1D].5"U325I%.B`Q<'@G/@T*(#QT9"!V M86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C M>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S M='EL93TS1"="3U)$15(M5$]0.B`C,#`P,#`P(#%P>"!S;VQI9"<^)B-X03`[ M/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL M93TS1"="3U)$15(M5$]0.B`C,#`P,#`P(#%P>"!S;VQI9"<^)B-X03`[/"]P M/@T*(#PO=&0^#0H@/'1D/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O M='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^ M#0H@/'`@<W1Y;&4],T0G0D]21$52+51/4#H@(S`P,#`P,"`Q<'@@<V]L:60G M/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@ M/'`@<W1Y;&4],T0G0D]21$52+51/4#H@(S`P,#`P,"`Q<'@@<V]L:60G/B8C M>$$P.SPO<#X-"B`\+W1D/@T*(#QT9#XF(WA!,#L\+W1D/@T*(#PO='(^#0H@ M/'1R(&)G8V]L;W(],T0C0T-%149&/@T*(#QT9"!V86QI9VX],T1T;W`^#0H@ M/'`@<W1Y;&4],T0G34%21TE.+4Q%1E0Z(#-E;3L@5$585"U)3D1%3E0Z("TQ M96TG/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M M86XG('-I>F4],T0R/E1O=&%L(')E<V5A<F-H(&%N9`T*(&1E=F5L;W!M96YT M(')E=F5N=64@9G)O;2!!<W1E;&QA<SPO9F]N=#X\+W`^#0H@/"]T9#X-"B`\ M=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C>$$P.R8C>$$P M.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<W1Y M;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^ M)#PO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R M:6=H=#X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O M;6%N)R!S:7IE/3-$,CXS,BPS.3$\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N M/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#X\9F]N="!S='EL93TS1"=&3TY4 M+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXF(WA!,#LF(WA! M,#L\+V9O;G0^/"]T9#X-"B`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`\=&0@=F%L:6=N/3-$8F]T M=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\ M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@<W1Y;&4],T0G0D]2 M1$52+51/4#H@(S`P,#`P,"`S<'@@9&]U8FQE)SXF(WA!,#L\+W`^#0H@/"]T M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1% M4BU43U`Z(",P,#`P,#`@,W!X(&1O=6)L92<^)B-X03`[/"]P/@T*(#PO=&0^ M#0H@/'1D/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA! M,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@<W1Y M;&4],T0G0D]21$52+51/4#H@(S`P,#`P,"`S<'@@9&]U8FQE)SXF(WA!,#L\ M+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE M/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@,W!X(&1O=6)L92<^)B-X03`[/"]P M/@T*(#PO=&0^#0H@/'1D/B8C>$$P.SPO=&0^#0H@/"]T<CX-"B`\+W1A8FQE M/@T*(#PO9&EV/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@ M("`@(#QT<B!C;&%S<STS1')H/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V M86QI9VX],T1T;W`^06UG96X@6TUE;6)E<ET\+W1D/@T*("`@("`@("`\=&0@ M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX- M"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P M;"!V86QI9VX],T1T;W`^4F5V96YU92!F<F]M(%)E;&%T960@4&%R='D\+W1D M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQD:78^#0H@/'`@<W1Y;&4] M,T0G34%21TE.+4)/5%1/33H@,'!X.R!-05)'24XM5$]0.B`Q,G!X.R!415A4 M+4E.1$5.5#H@-"4G(&%L:6=N/3-$:G5S=&EF>3X\9F]N="!S='EL93TS1"=& M3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CY2979E;G5E M(&9R;VT@06UG96X@=V%S(&%S(&9O;&QO=W,@*&EN('1H;W5S86YD<RDZ/"]F M;VYT/CPO<#X-"B`\<"!S='EL93TS1"=-05)'24XM0D]45$]-.B`P<'@[($9/ M3E0M4TE:13H@,3)P>#L@34%21TE.+51/4#H@,'!X)SX-"B`F(WA!,#L\+W`^ M#0H@/'1A8FQE('-T>6QE/3-$)T)/4D1%4BU#3TQ,05!313H@8V]L;&%P<V4G M(&-E;&QS<&%C:6YG/3-$,"!C96QL<&%D9&EN9STS1#`@=VED=&@],T0Y,B4@ M86QI9VX],T1C96YT97(@8F]R9&5R/3-$,#X-"B`\='(^#0H@/'1D('=I9'1H M/3-$-S(E/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#0E M/CPO=&0^#0H@/'1D/CPO=&0^#0H@/'1D/CPO=&0^#0H@/'1D/CPO=&0^#0H@ M/'1D('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#0E/CPO=&0^#0H@/'1D/CPO M=&0^#0H@/'1D/CPO=&0^#0H@/'1D/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O M='1O;2!W:61T:#TS1#0E/CPO=&0^#0H@/'1D/CPO=&0^#0H@/'1D/CPO=&0^ M#0H@/'1D/CPO=&0^#0H@/"]T<CX-"B`\='(^#0H@/'1D('9A;&EG;CTS1&)O M='1O;3X\9F]N="!S:7IE/3-$,3XF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@ M=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C>$$P.R8C>$$P.SPO M9F]N=#X\+W1D/@T*(#QT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B`C,#`P M,#`P(#%P>"!S;VQI9"<@=F%L:6=N/3-$8F]T=&]M(&-O;'-P86X],T0Q,"!A M;&EG;CTS1&-E;G1E<CX\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM M97,@3F5W(%)O;6%N)R!S:7IE/3-$,3X\8CY996%R<R!%;F1E9`T*($1E8V5M M8F5R)B-X03`[,S$L/"]B/CPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B M;W1T;VT^/&9O;G0@<VEZ93TS1#$^)B-X03`[/"]F;VYT/CPO=&0^#0H@/"]T M<CX-"B`\='(^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$ M,3XF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF M;VYT('-I>F4],T0Q/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!S M='EL93TS1"="3U)$15(M0D]45$]-.B`C,#`P,#`P(#%P>"!S;VQI9"<@=F%L M:6=N/3-$8F]T=&]M(&-O;'-P86X],T0R(&%L:6=N/3-$8V5N=&5R/CQF;VYT M('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4] M,T0Q/CQB/C(P,30\+V(^/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O M='1O;3X\9F]N="!S:7IE/3-$,3XF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@ M=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C>$$P.R8C>$$P.SPO M9F]N=#X\+W1D/@T*(#QT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B`C,#`P M,#`P(#%P>"!S;VQI9"<@=F%L:6=N/3-$8F]T=&]M(&-O;'-P86X],T0R(&%L M:6=N/3-$8V5N=&5R/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE M<R!.97<@4F]M86XG('-I>F4],T0Q/CQB/C(P,3,\+V(^/"]F;VYT/CPO=&0^ M#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF(WA!,#L\ M+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4] M,T0Q/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!S='EL93TS1"=" M3U)$15(M0D]45$]-.B`C,#`P,#`P(#%P>"!S;VQI9"<@=F%L:6=N/3-$8F]T M=&]M(&-O;'-P86X],T0R(&%L:6=N/3-$8V5N=&5R/CQF;VYT('-T>6QE/3-$ M)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0Q/CQB/C(P M,3(\+V(^/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N M="!S:7IE/3-$,3XF(WA!,#L\+V9O;G0^/"]T9#X-"B`\+W1R/@T*(#QT<B!B M9V-O;&]R/3-$(T-#145&1CX-"B`\=&0@=F%L:6=N/3-$=&]P/@T*(#QP('-T M>6QE/3-$)TU!4D=)3BU,1494.B`Q96T[(%1%6%0M24Y$14Y4.B`M,65M)SX\ M9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S M:7IE/3-$,CY,:6-E;G-E(')E=F5N=65S(&9R;VT-"B!R96QA=&5D('!A<G1I M97,\+V9O;G0^/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\ M9F]N="!S:7IE/3-$,3XF(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@ M=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#X\9F]N="!S='EL93TS M1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXD/"]F M;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R M87`@86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@ M5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXF(W@R,#$T.SPO9F]N=#X\+W1D M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P/CQF;VYT M('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4] M,T0R/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B M;W1T;VT^/&9O;G0@<VEZ93TS1#$^)B-X03`[)B-X03`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`[ M)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R M87`],T1N;W=R87`^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S M($YE=R!2;VUA;B<@<VEZ93TS1#(^)#PO9F]N=#X\+W1D/@T*(#QT9"!V86QI M9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P(&%L:6=N/3-$<FEG:'0^/&9O M;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ M93TS1#(^)B-X,C`Q-#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T M=&]M(&YO=W)A<#TS1&YO=W)A<#X\9F]N="!S='EL93TS1"=&3TY4+49!34E, M63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXF(WA!,#LF(WA!,#L\+V9O M;G0^/"]T9#X-"B`\+W1R/@T*(#QT<CX-"B`\=&0@=F%L:6=N/3-$=&]P/@T* M(#QP('-T>6QE/3-$)TU!4D=)3BU,1494.B`Q96T[(%1%6%0M24Y$14Y4.B`M M,65M)SX\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O M;6%N)R!S:7IE/3-$,CY297-E87)C:"!A;F0@9&5V96QO<&UE;G0-"B!R979E M;G5E<R!F<F]M(')E;&%T960@<&%R=&EE<SH\+V9O;G0^/"]P/@T*(#PO=&0^ M#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF(WA!,#LF M(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^ M#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B M;W1T;VT^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4] M,T0Q/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B M;W1T;VT^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D M('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^ M/&9O;G0@<VEZ93TS1#$^)B-X03`[)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D M('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^ M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/"]T<CX-"B`\ M='(@8F=C;VQO<CTS1"-#0T5%1D8^#0H@/'1D('9A;&EG;CTS1'1O<#X-"B`\ M<"!S='EL93TS1"=-05)'24XM3$5&5#H@,F5M.R!415A4+4E.1$5.5#H@+3%E M;2<^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA M;B<@<VEZ93TS1#(^4F5I;6)U<G-E;65N="!O9B!I;G1E<FYA;`T*(&-O<W1S M/"]F;VYT/CPO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O M;G0@<VEZ93TS1#$^)B-X03`[)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A M;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM M97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXF(WA!,#L\+V9O;G0^/"]T9#X-"B`\ M=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^/&9O;G0@<W1Y;&4] M,T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^-"PR M-C`\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS M1&YO=W)A<#X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W M(%)O;6%N)R!S:7IE/3-$,CXF(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\ M=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C>$$P.R8C>$$P M.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<W1Y M;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^ M)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG M;CTS1')I9VAT/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!. M97<@4F]M86XG('-I>F4],T0R/C(L,#$Y/"]F;VYT/CPO=&0^#0H@/'1D('9A M;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^/&9O;G0@<W1Y;&4],T0G M1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^)B-X03`[ M)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N M="!S:7IE/3-$,3XF(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L M:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE M<R!.97<@4F]M86XG('-I>F4],T0R/B8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT M9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS M1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXT+#$W M-#PO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$ M;F]W<F%P/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@ M4F]M86XG('-I>F4],T0R/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#PO M='(^#0H@/'1R/@T*(#QT9"!V86QI9VX],T1T;W`^#0H@/'`@<W1Y;&4],T0G M34%21TE.+4Q%1E0Z(#)E;3L@5$585"U)3D1%3E0Z("TQ96TG/CQF;VYT('-T M>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R M/E)E:6UB=7)S96UE;G0@;V8@;W1H97(-"B!C;W-T<SPO9F]N=#X\+W`^#0H@ M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C M>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@ M;F]W<F%P/3-$;F]W<F%P/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4 M:6UE<R!.97<@4F]M86XG('-I>F4],T0R/B8C>$$P.SPO9F]N=#X\+W1D/@T* M(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P(&%L:6=N/3-$ M<FEG:'0^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2 M;VUA;B<@<VEZ93TS1#(^)B-X,C`Q-#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L M:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#X\9F]N="!S='EL93TS1"=& M3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXF(WA!,#LF M(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT M('-I>F4],T0Q/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI M9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P/CQF;VYT('-T>6QE/3-$)T9/ M3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R/B8C>$$P.SPO M9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W M<F%P(&%L:6=N/3-$<FEG:'0^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ M(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^)B-X,C`Q-#L\+V9O;G0^/"]T M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#X\9F]N M="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE M/3-$,CXF(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$ M8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<W1Y;&4],T0G1D].5"U& M04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^)B-X03`[/"]F;VYT M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/CQF M;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I M>F4],T0R/C,\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO M=W)A<#TS1&YO=W)A<#X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM M97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXF(WA!,#LF(WA!,#L\+V9O;G0^/"]T M9#X-"B`\+W1R/@T*(#QT<B!B9V-O;&]R/3-$(T-#145&1CX-"B`\=&0@=F%L M:6=N/3-$=&]P/@T*(#QP('-T>6QE/3-$)TU!4D=)3BU,1494.B`R96T[(%1% M6%0M24Y$14Y4.B`M,65M)SX\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@ M5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CY!;&QO8V%T960-"B!C;VYS:61E M<F%T:6]N/"]F;VYT/CPO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T M;VT^/&9O;G0@<VEZ93TS1#$^)B-X03`[)B-X03`[/"]F;VYT/CPO=&0^#0H@ M/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=&3TY4+49!34E, M63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXF(WA!,#L\+V9O;G0^/"]T M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^/&9O;G0@ M<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS M1#(^,C<X/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R M87`],T1N;W=R87`^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S M($YE=R!2;VUA;B<@<VEZ93TS1#(^)B-X03`[)B-X03`[/"]F;VYT/CPO=&0^ M#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF(WA!,#LF M(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A M<#TS1&YO=W)A<#X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@ M3F5W(%)O;6%N)R!S:7IE/3-$,CXF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@ M=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<"!A;&EG;CTS1')I9VAT M/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG M('-I>F4],T0R/B8C>#(P,30[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS M1&)O='1O;2!N;W=R87`],T1N;W=R87`^/&9O;G0@<W1Y;&4],T0G1D].5"U& M04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^)B-X03`[)B-X03`[ M/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE M/3-$,3XF(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$ M8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#X\9F]N="!S='EL93TS1"=&3TY4+49! M34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXF(WA!,#L\+V9O;G0^ M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<"!A M;&EG;CTS1')I9VAT/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE M<R!.97<@4F]M86XG('-I>F4],T0R/B8C>#(P,30[/"]F;VYT/CPO=&0^#0H@ M/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^/&9O;G0@<W1Y M;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^ M)B-X03`[)B-X03`[/"]F;VYT/CPO=&0^#0H@/"]T<CX-"B`\='(@<W1Y;&4] M,T0G1D].5"U325I%.B`Q<'@G/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@ M/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0 M.B`C,#`P,#`P(#%P>"!S;VQI9"<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D M('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B`C M,#`P,#`P(#%P>"!S;VQI9"<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D/B8C M>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\ M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@<W1Y;&4],T0G0D]2 M1$52+51/4#H@(S`P,#`P,"`Q<'@@<V]L:60G/B8C>$$P.SPO<#X-"B`\+W1D M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@<W1Y;&4],T0G0D]21$52 M+51/4#H@(S`P,#`P,"`Q<'@@<V]L:60G/B8C>$$P.SPO<#X-"B`\+W1D/@T* M(#QT9#XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[ M)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE M/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@,7!X('-O;&ED)SXF(WA!,#L\+W`^ M#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$ M)T)/4D1%4BU43U`Z(",P,#`P,#`@,7!X('-O;&ED)SXF(WA!,#L\+W`^#0H@ M/"]T9#X-"B`\=&0^)B-X03`[/"]T9#X-"B`\+W1R/@T*(#QT<CX-"B`\=&0@ M=F%L:6=N/3-$=&]P/@T*(#QP('-T>6QE/3-$)TU!4D=)3BU,1494.B`S96T[ M(%1%6%0M24Y$14Y4.B`M,65M)SX\9F]N="!S='EL93TS1"=&3TY4+49!34E, M63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CY4;W1A;"!R979E;G5E<R!F M<F]M#0H@06UG96X\+V9O;G0^/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS M1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF(WA!,#LF(WA!,#L\+V9O;G0^/"]T M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)T9/3E0M M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R/B0\+V9O;G0^/"]T M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^/&9O;G0@ M<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS M1#(^-"PU,S@\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO M=W)A<#TS1&YO=W)A<#X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM M97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXF(WA!,#LF(WA!,#L\+V9O;G0^/"]T M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C>$$P M.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O M;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ M93TS1#(^)#PO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI M9VX],T1R:6=H=#X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@ M3F5W(%)O;6%N)R!S:7IE/3-$,CXQ.2PR-#D\+V9O;G0^/"]T9#X-"B`\=&0@ M=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#X\9F]N="!S='EL93TS M1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXF(WA! M,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`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`\=&0@=F%L:6=N M/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF M(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@<W1Y;&4] M,T0G0D]21$52+51/4#H@(S`P,#`P,"`S<'@@9&]U8FQE)SXF(WA!,#L\+W`^ M#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$ M)T)/4D1%4BU43U`Z(",P,#`P,#`@,W!X(&1O=6)L92<^)B-X03`[/"]P/@T* M(#PO=&0^#0H@/'1D/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O M;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@ M/'`@<W1Y;&4],T0G0D]21$52+51/4#H@(S`P,#`P,"`S<'@@9&]U8FQE)SXF M(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP M('-T>6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@,W!X(&1O=6)L92<^)B-X M03`[/"]P/@T*(#PO=&0^#0H@/'1D/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG M;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B M;W1T;VT^#0H@/'`@<W1Y;&4],T0G0D]21$52+51/4#H@(S`P,#`P,"`S<'@@ M9&]U8FQE)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T M=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@,W!X(&1O M=6)L92<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D/B8C>$$P.SPO=&0^#0H@ M/"]T<CX-"B`\+W1A8FQE/@T*(#PO9&EV/CQS<&%N/CPO<W!A;CX\+W1D/@T* M("`@("`@/"]T<CX-"B`@("`\+W1A8FQE/@T*("`\+V)O9'D^#0H\+VAT;6P^ M#0H-"BTM+2TM+3U?3F5X=%!A<G1?,SEC,&5A-C)?8S(P,U\T-3AF7SAC-3!? M,V1C830U-F$V.34Q#0I#;VYT96YT+4QO8V%T:6]N.B!F:6QE.B\O+T,Z+S,Y M8S!E838R7V,R,#-?-#4X9E\X8S4P7S-D8V$T-39A-CDU,2]7;W)K<VAE971S M+U-H965T,S`N:'1M;`T*0V]N=&5N="U4<F%N<V9E<BU%;F-O9&EN9SH@<75O M=&5D+7!R:6YT86)L90T*0V]N=&5N="U4>7!E.B!T97AT+VAT;6P[(&-H87)S M970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@ M:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M M;#L@8VAA<G-E=#UU=&8M."<^/'-C<FEP="!T>7!E/3-$=&5X="]J879A<V-R M:7!T('-R8STS1%-H;W<N:G,^+RH@1&\@3F]T(%)E;6]V92!4:&ES($-O;6UE M;G0@*B\\+W-C<FEP=#X\+VAE860^#0H@(#QB;V1Y/@T*("`@(#QT86)L92!C M;&%S<STS1')E<&]R="!I9#TS1$E$,$4R1$%#/@T*("`@("`@/'1R/@T*("`@ M("`@("`\=&@@8VQA<W,],T1T;"!C;VQS<&%N/3-$,2!R;W=S<&%N/3-$,CX\ M<W1R;VYG/D]T:&5R(%)E<V5A<F-H(&%N9"!$979E;&]P;65N="!2979E;G5E M($%R<F%N9V5M96YT<R`H5&%B;&5S*3QB<CX\+W-T<F]N9SX\+W1H/@T*("`@ M("`@("`\=&@@8VQA<W,],T1T:"!C;VQS<&%N/3-$,3XQ,B!-;VYT:',@16YD M960\+W1H/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<CX-"B`@("`@("`@/'1H M(&-L87-S/3-$=&@^1&5C+B`S,2P@,C`Q-#QB<CX\+W1H/@T*("`@("`@/"]T M<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,] M,T1P;"!V86QI9VX],T1T;W`^4W5M;6%R>2!O9B!4;W1A;"!'<F%N="!2979E M;G5E<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/&1I=CX-"B`\ M<"!S='EL93TS1"=-05)'24XM0D]45$]-.B`P<'@[($U!4D=)3BU43U`Z(#!P M>#L@5$585"U)3D1%3E0Z(#0E)R!A;&EG;CTS1&IU<W1I9GD^/&9O;G0@<W1Y M;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^ M5&]T86P@9W)A;G0@<F5V96YU97,@=V5R92!A<R!F;VQL;W=S("AI;B!T:&]U M<V%N9',I.CPO9F]N=#X\+W`^#0H@/'`@<W1Y;&4],T0G34%21TE.+4)/5%1/ M33H@,'!X.R!&3TY4+5-)6D4Z(#$R<'@[($U!4D=)3BU43U`Z(#!P>"<^#0H@ M)B-X03`[/"]P/@T*(#QT86)L92!S='EL93TS1"="3U)$15(M0T],3$%04T4Z M(&-O;&QA<'-E)R!C96QL<W!A8VEN9STS1#`@8V5L;'!A9&1I;F<],T0P('=I M9'1H/3-$.3(E(&%L:6=N/3-$8V5N=&5R(&)O<F1E<CTS1#`^#0H@/'1R/@T* M(#QT9"!W:61T:#TS1#<Y)3X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@ M=VED=&@],T0T)3X\+W1D/@T*(#QT9#X\+W1D/@T*(#QT9#X\+W1D/@T*(#QT M9#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@=VED=&@],T0T)3X\+W1D M/@T*(#QT9#X\+W1D/@T*(#QT9#X\+W1D/@T*(#QT9#X\+W1D/@T*(#QT9"!V M86QI9VX],T1B;W1T;VT@=VED=&@],T0T)3X\+W1D/@T*(#QT9#X\+W1D/@T* M(#QT9#X\+W1D/@T*(#QT9#X\+W1D/@T*(#PO='(^#0H@/'1R/@T*(#QT9"!V M86QI9VX],T1B;W1T;VT^/&9O;G0@<VEZ93TS1#$^)B-X03`[/"]F;VYT/CPO M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF(WA! M,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@<W1Y;&4],T0G0D]21$52+4)/ M5%1/33H@(S`P,#`P,"`Q<'@@<V]L:60G('9A;&EG;CTS1&)O='1O;2!C;VQS M<&%N/3-$,3`@86QI9VX],T1C96YT97(^/&9O;G0@<W1Y;&4],T0G1D].5"U& M04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#$^/&(^665A<G,@16YD M960\8G(@+SX-"B!$96-E;6)E<B8C>$$P.S,Q+#PO8CX\+V9O;G0^/"]T9#X- M"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C>$$P.SPO M9F]N=#X\+W1D/@T*(#PO='(^#0H@/'1R/@T*(#QT9"!V86QI9VX],T1B;W1T M;VT^/&9O;G0@<VEZ93TS1#$^)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A M;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF(WA!,#LF(WA!,#L\+V9O M;G0^/"]T9#X-"B`\=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@(S`P,#`P M,"`Q<'@@<V]L:60G('9A;&EG;CTS1&)O='1O;2!C;VQS<&%N/3-$,B!A;&EG M;CTS1&-E;G1E<CX\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@ M3F5W(%)O;6%N)R!S:7IE/3-$,3X\8CXR,#$T/"]B/CPO9F]N=#X\+W1D/@T* M(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<VEZ93TS1#$^)B-X03`[/"]F M;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$ M,3XF(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@<W1Y;&4],T0G0D]2 M1$52+4)/5%1/33H@(S`P,#`P,"`Q<'@@<V]L:60G('9A;&EG;CTS1&)O='1O M;2!C;VQS<&%N/3-$,B!A;&EG;CTS1&-E;G1E<CX\9F]N="!S='EL93TS1"=& M3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,3X\8CXR,#$S M/"]B/CPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@ M<VEZ93TS1#$^)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O M='1O;3X\9F]N="!S:7IE/3-$,3XF(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X- M"B`\=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@(S`P,#`P,"`Q<'@@<V]L M:60G('9A;&EG;CTS1&)O='1O;2!C;VQS<&%N/3-$,B!A;&EG;CTS1&-E;G1E M<CX\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N M)R!S:7IE/3-$,3X\8CXR,#$R/"]B/CPO9F]N=#X\+W1D/@T*(#QT9"!V86QI M9VX],T1B;W1T;VT^/&9O;G0@<VEZ93TS1#$^)B-X03`[/"]F;VYT/CPO=&0^ M#0H@/"]T<CX-"B`\='(@8F=C;VQO<CTS1"-#0T5%1D8^#0H@/'1D('9A;&EG M;CTS1'1O<#X-"B`\<"!S='EL93TS1"=-05)'24XM3$5&5#H@,65M.R!415A4 M+4E.1$5.5#H@+3%E;2<^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I M;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^3DE.1%,@;7EA<W1H96YI80T*(&=R M879I<SPO9F]N=#X\+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M M/CQF;VYT('-I>F4],T0Q/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT M9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P/CQF;VYT('-T>6QE M/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R/B0\ M+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO M=W)A<"!A;&EG;CTS1')I9VAT/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9 M.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R/B8C>#(P,30[/"]F;VYT/CPO M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^/&9O M;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ M93TS1#(^)B-X03`[)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS M1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF(WA!,#LF(WA!,#L\+V9O;G0^/"]T M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)T9/3E0M M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R/B0\+V9O;G0^/"]T M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^/&9O;G0@ M<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS M1#(^-CD\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A M<#TS1&YO=W)A<#X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@ M3F5W(%)O;6%N)R!S:7IE/3-$,CXF(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X- M"B`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`^#0H@/'`@<W1Y;&4],T0G34%21TE.+4Q%1E0Z(#%E;3L@5$585"U) M3D1%3E0Z("TQ96TG/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE M<R!.97<@4F]M86XG('-I>F4],T0R/D]T:&5R(&=R86YT#0H@<F5V96YU93PO M9F]N=#X\+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT M('-I>F4],T0Q/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI M9VX],T1B;W1T;VT^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S M($YE=R!2;VUA;B<@<VEZ93TS1#(^)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D M('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/CQF;VYT('-T>6QE/3-$ M)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R/C<U/"]F M;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R M87`^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA M;B<@<VEZ93TS1#(^)B-X03`[)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A M;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF(WA!,#LF(WA!,#L\+V9O M;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$ M)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R/B8C>$$P M.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R M:6=H=#X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O M;6%N)R!S:7IE/3-$,CXR-3PO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B M;W1T;VT@;F]W<F%P/3-$;F]W<F%P/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%- M24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R/B8C>$$P.R8C>$$P.SPO M9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<VEZ93TS M1#$^)B-X03`[)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O M='1O;2!N;W=R87`],T1N;W=R87`^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U) M3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^)B-X03`[/"]F;VYT/CPO M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`@86QI M9VX],T1R:6=H=#X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@ M3F5W(%)O;6%N)R!S:7IE/3-$,CXF(W@R,#$T.SPO9F]N=#X\+W1D/@T*(#QT M9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P/CQF;VYT('-T>6QE M/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R/B8C M>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#PO='(^#0H@/'1R('-T>6QE/3-$ M)T9/3E0M4TE:13H@,7!X)SX-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^ M#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT M9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@<W1Y;&4],T0G0D]21$52+51/4#H@ M(S`P,#`P,"`Q<'@@<V]L:60G/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT9"!V M86QI9VX],T1B;W1T;VT^#0H@/'`@<W1Y;&4],T0G0D]21$52+51/4#H@(S`P M,#`P,"`Q<'@@<V]L:60G/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT9#XF(WA! M,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1% M4BU43U`Z(",P,#`P,#`@,7!X('-O;&ED)SXF(WA!,#L\+W`^#0H@/"]T9#X- M"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU4 M3U`Z(",P,#`P,#`@,7!X('-O;&ED)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\ M=&0^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C M>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS M1"="3U)$15(M5$]0.B`C,#`P,#`P(#%P>"!S;VQI9"<^)B-X03`[/"]P/@T* M(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"=" M3U)$15(M5$]0.B`C,#`P,#`P(#%P>"!S;VQI9"<^)B-X03`[/"]P/@T*(#PO M=&0^#0H@/'1D/B8C>$$P.SPO=&0^#0H@/"]T<CX-"B`\='(@8F=C;VQO<CTS M1"-#0T5%1D8^#0H@/'1D('9A;&EG;CTS1'1O<#X-"B`\<"!S='EL93TS1"=- M05)'24XM3$5&5#H@,F5M.R!415A4+4E.1$5.5#H@+3%E;2<^/&9O;G0@<W1Y M;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^ M5&]T86P@9W)A;G0-"B!R979E;G5E/"]F;VYT/CPO<#X-"B`\+W1D/@T*(#QT M9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<VEZ93TS1#$^)B-X03`[)B-X03`[ M/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL M93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXD M/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I M9VAT/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M M86XG('-I>F4],T0R/C<U/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O M='1O;2!N;W=R87`],T1N;W=R87`^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U) M3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^)B-X03`[)B-X03`[/"]F M;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$ M,3XF(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T M=&]M/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M M86XG('-I>F4],T0R/B0\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T M=&]M(&%L:6=N/3-$<FEG:'0^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ M(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^.30\+V9O;G0^/"]T9#X-"B`\ M=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#X\9F]N="!S='EL M93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXF M(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`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`\=&0@=F%L M:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA! M,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@<W1Y M;&4],T0G0D]21$52+51/4#H@(S`P,#`P,"`S<'@@9&]U8FQE)SXF(WA!,#L\ M+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE M/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@,W!X(&1O=6)L92<^)B-X03`[/"]P M/@T*(#PO=&0^#0H@/'1D/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O M='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^ M#0H@/'`@<W1Y;&4],T0G0D]21$52+51/4#H@(S`P,#`P,"`S<'@@9&]U8FQE M)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T* M(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@,W!X(&1O=6)L92<^ M)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D/B8C>$$P.SPO=&0^#0H@/'1D('9A M;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX] M,T1B;W1T;VT^#0H@/'`@<W1Y;&4],T0G0D]21$52+51/4#H@(S`P,#`P,"`S M<'@@9&]U8FQE)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$ M8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@,W!X M(&1O=6)L92<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D/B8C>$$P.SPO=&0^ M#0H@/"]T<CX-"B`\+W1A8FQE/@T*(#PO9&EV/CQS<&%N/CPO<W!A;CX\+W1D M/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')H/@T*("`@("`@ M("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^1VQO8F%L($)L;V]D(%M- M96UB97)=/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\ M+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R M93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E-U;6UA M<GD@;V8@4F5I;6)U<G-E9"!%>'!E;G-E<SPO=&0^#0H@("`@("`@(#QT9"!C M;&%S<STS1'1E>'0^/&1I=CX-"B`\<"!S='EL93TS1"=-05)'24XM0D]45$]- M.B`P<'@[($U!4D=)3BU43U`Z(#$R<'@[(%1%6%0M24Y$14Y4.B`T)2<@86QI M9VX],T1J=7-T:69Y/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE M<R!.97<@4F]M86XG('-I>F4],T0R/E)E<V5A<F-H(&%N9"!D979E;&]P;65N M="!R979E;G5E(&9R;VT@1VQO8F%L($)L;V]D('=A<R!A<PT*(&9O;&QO=W,@ M*&EN('1H;W5S86YD<RDZ/"]F;VYT/CPO<#X-"B`\<"!S='EL93TS1"=-05)' M24XM0D]45$]-.B`P<'@[($9/3E0M4TE:13H@,3)P>#L@34%21TE.+51/4#H@ M,'!X)SX-"B`F(WA!,#L\+W`^#0H@/'1A8FQE('-T>6QE/3-$)T)/4D1%4BU# M3TQ,05!313H@8V]L;&%P<V4G(&-E;&QS<&%C:6YG/3-$,"!C96QL<&%D9&EN M9STS1#`@=VED=&@],T0Y,B4@86QI9VX],T1C96YT97(@8F]R9&5R/3-$,#X- M"B`\='(^#0H@/'1D('=I9'1H/3-$-SDE/CPO=&0^#0H@/'1D('9A;&EG;CTS M1&)O='1O;2!W:61T:#TS1#0E/CPO=&0^#0H@/'1D/CPO=&0^#0H@/'1D/CPO M=&0^#0H@/'1D/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!W:61T:#TS M1#0E/CPO=&0^#0H@/'1D/CPO=&0^#0H@/'1D/CPO=&0^#0H@/'1D/CPO=&0^ M#0H@/'1D('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#0E/CPO=&0^#0H@/'1D M/CPO=&0^#0H@/'1D/CPO=&0^#0H@/'1D/CPO=&0^#0H@/"]T<CX-"B`\='(^ M#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF(WA!,#L\ M+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4] M,T0Q/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!S='EL93TS1"=" M3U)$15(M0D]45$]-.B`C,#`P,#`P(#%P>"!S;VQI9"<@=F%L:6=N/3-$8F]T M=&]M(&-O;'-P86X],T0Q,"!A;&EG;CTS1&-E;G1E<CX\9F]N="!S='EL93TS M1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,3X\8CY9 M96%R<R8C>$$P.T5N9&5D)B-X03`[1&5C96UB97(F(WA!,#LS,2P\+V(^/"]F M;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$ M,3XF(WA!,#L\+V9O;G0^/"]T9#X-"B`\+W1R/@T*(#QT<CX-"B`\=&0@=F%L M:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C>$$P.SPO9F]N=#X\+W1D M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<VEZ93TS1#$^)B-X03`[ M)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('-T>6QE/3-$)T)/4D1%4BU"3U14 M3TTZ(",P,#`P,#`@,7!X('-O;&ED)R!V86QI9VX],T1B;W1T;VT@8V]L<W!A M;CTS1#(@86QI9VX],T1C96YT97(^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U) M3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#$^/&(^,C`Q-#PO8CX\+V9O M;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q M/B8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O M;G0@<VEZ93TS1#$^)B-X03`[)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('-T M>6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,7!X('-O;&ED)R!V86QI M9VX],T1B;W1T;VT@8V]L<W!A;CTS1#(@86QI9VX],T1C96YT97(^/&9O;G0@ M<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS M1#$^/&(^,C`Q,SPO8CX\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T M=&]M/CQF;VYT('-I>F4],T0Q/B8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V M86QI9VX],T1B;W1T;VT^/&9O;G0@<VEZ93TS1#$^)B-X03`[)B-X03`[/"]F M;VYT/CPO=&0^#0H@/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P M,#`@,7!X('-O;&ED)R!V86QI9VX],T1B;W1T;VT@8V]L<W!A;CTS1#(@86QI M9VX],T1C96YT97(^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S M($YE=R!2;VUA;B<@<VEZ93TS1#$^/&(^,C`Q,CPO8CX\+V9O;G0^/"]T9#X- M"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C>$$P.SPO M9F]N=#X\+W1D/@T*(#PO='(^#0H@/'1R(&)G8V]L;W(],T0C0T-%149&/@T* M(#QT9"!V86QI9VX],T1T;W`^#0H@/'`@<W1Y;&4],T0G34%21TE.+4Q%1E0Z M(#%E;3L@5$585"U)3D1%3E0Z("TQ96TG/CQF;VYT('-T>6QE/3-$)T9/3E0M M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R/D5X<&5N<V4@<F5I M;6)U<G-E;65N=',@9G)O;0T*($=L;V)A;"!";&]O9#PO9F]N=#X\+W`^#0H@ M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C M>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@ M;F]W<F%P/3-$;F]W<F%P/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4 M:6UE<R!.97<@4F]M86XG('-I>F4],T0R/B0\+V9O;G0^/"]T9#X-"B`\=&0@ M=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<"!A;&EG;CTS1')I9VAT M/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG M('-I>F4],T0R/B8C>#(P,30[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS M1&)O='1O;2!N;W=R87`],T1N;W=R87`^/&9O;G0@<W1Y;&4],T0G1D].5"U& M04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^)B-X03`[)B-X03`[ M/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE M/3-$,3XF(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$ M8F]T=&]M/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@ M4F]M86XG('-I>F4],T0R/B0\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$ M8F]T=&]M(&%L:6=N/3-$<FEG:'0^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U) M3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^,30\+V9O;G0^/"]T9#X- M"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#X\9F]N="!S M='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$ M,CXF(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`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`\=&0@ M=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF M(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@ M<W1Y;&4],T0G0D]21$52+51/4#H@(S`P,#`P,"`S<'@@9&]U8FQE)SXF(WA! M,#L\+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T M>6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@,W!X(&1O=6)L92<^)B-X03`[ M/"]P/@T*(#PO=&0^#0H@/'1D/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS M1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T M;VT^#0H@/'`@<W1Y;&4],T0G0D]21$52+51/4#H@(S`P,#`P,"`S<'@@9&]U M8FQE)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@,W!X(&1O=6)L M92<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D/B8C>$$P.SPO=&0^#0H@/'1D M('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI M9VX],T1B;W1T;VT^#0H@/'`@<W1Y;&4],T0G0D]21$52+51/4#H@(S`P,#`P M,"`S<'@@9&]U8FQE)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N M/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@ M,W!X(&1O=6)L92<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D/B8C>$$P.SPO M=&0^#0H@/"]T<CX-"B`\+W1A8FQE/@T*(#PO9&EV/CQS<&%N/CPO<W!A;CX\ M+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')H/@T*("`@ M("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^37EO2V%R9&EA(%M- M96UB97)=/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\ M+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R M93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E-U;6UA M<GD@;V8@4F5I;6)U<G-E9"!%>'!E;G-E<SPO=&0^#0H@("`@("`@(#QT9"!C M;&%S<STS1'1E>'0^/&1I=CX-"B`\<"!S='EL93TS1"=-05)'24XM0D]45$]- M.B`P<'@[($U!4D=)3BU43U`Z(#$R<'@[(%1%6%0M24Y$14Y4.B`T)2<@86QI M9VX],T1J=7-T:69Y/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE M<R!.97<@4F]M86XG('-I>F4],T0R/E)E<V5A<F-H(&%N9"!D979E;&]P;65N M="!R979E;G5E(&9R;VT@37EO2V%R9&EA('=A<R!A<R!F;VQL;W=S#0H@*&EN M('1H;W5S86YD<RDZ/"]F;VYT/CPO<#X-"B`\<"!S='EL93TS1"=-05)'24XM M0D]45$]-.B`P<'@[($9/3E0M4TE:13H@,3)P>#L@34%21TE.+51/4#H@,'!X M)SX-"B`F(WA!,#L\+W`^#0H@/'1A8FQE('-T>6QE/3-$)T)/4D1%4BU#3TQ, M05!313H@8V]L;&%P<V4G(&-E;&QS<&%C:6YG/3-$,"!C96QL<&%D9&EN9STS M1#`@=VED=&@],T0Y,B4@86QI9VX],T1C96YT97(@8F]R9&5R/3-$,#X-"B`\ M='(^#0H@/'1D('=I9'1H/3-$-S<E/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O M='1O;2!W:61T:#TS1#0E/CPO=&0^#0H@/'1D/CPO=&0^#0H@/'1D/CPO=&0^ M#0H@/'1D/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#0E M/CPO=&0^#0H@/'1D/CPO=&0^#0H@/'1D/CPO=&0^#0H@/'1D/CPO=&0^#0H@ M/'1D('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#0E/CPO=&0^#0H@/'1D/CPO M=&0^#0H@/'1D/CPO=&0^#0H@/'1D/CPO=&0^#0H@/"]T<CX-"B`\='(^#0H@ M/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF(WA!,#L\+V9O M;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q M/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!S='EL93TS1"="3U)$ M15(M0D]45$]-.B`C,#`P,#`P(#%P>"!S;VQI9"<@=F%L:6=N/3-$8F]T=&]M M(&-O;'-P86X],T0Q,"!A;&EG;CTS1&-E;G1E<CX\9F]N="!S='EL93TS1"=& M3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,3X\8CY996%R M<R8C>$$P.T5N9&5D)B-X03`[1&5C96UB97(F(WA!,#LS,2P\+V(^/"]F;VYT M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF M(WA!,#L\+V9O;G0^/"]T9#X-"B`\+W1R/@T*(#QT<CX-"B`\=&0@=F%L:6=N M/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C>$$P.SPO9F]N=#X\+W1D/@T* M(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<VEZ93TS1#$^)B-X03`[)B-X M03`[/"]F;VYT/CPO=&0^#0H@/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ M(",P,#`P,#`@,7!X('-O;&ED)R!V86QI9VX],T1B;W1T;VT@8V]L<W!A;CTS M1#(@86QI9VX],T1C96YT97(^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ M(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#$^/&(^,C`Q-#PO8CX\+V9O;G0^ M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C M>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@ M<VEZ93TS1#$^)B-X03`[)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('-T>6QE M/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,7!X('-O;&ED)R!V86QI9VX] M,T1B;W1T;VT@8V]L<W!A;CTS1#(@86QI9VX],T1C96YT97(^/&9O;G0@<W1Y M;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#$^ M/&(^,C`Q,SPO8CX\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M M/CQF;VYT('-I>F4],T0Q/B8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI M9VX],T1B;W1T;VT^/&9O;G0@<VEZ93TS1#$^)B-X03`[)B-X03`[/"]F;VYT M/CPO=&0^#0H@/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@ M,7!X('-O;&ED)R!V86QI9VX],T1B;W1T;VT@8V]L<W!A;CTS1#(@86QI9VX] M,T1C96YT97(^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE M=R!2;VUA;B<@<VEZ93TS1#$^/&(^,C`Q,CPO8CX\+V9O;G0^/"]T9#X-"B`\ M=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C>$$P.SPO9F]N M=#X\+W1D/@T*(#PO='(^#0H@/'1R(&)G8V]L;W(],T0C0T-%149&/@T*(#QT M9"!V86QI9VX],T1T;W`^#0H@/'`@<W1Y;&4],T0G34%21TE.+4Q%1E0Z(#%E M;3L@5$585"U)3D1%3E0Z("TQ96TG/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%- M24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R/E)E<V5A<F-H(&%N9"!D M979E;&]P;65N=`T*(&UI;&5S=&]N92!F965S/"]F;VYT/CPO<#X-"B`\+W1D M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<VEZ93TS1#$^)B-X03`[ M)B-X03`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`[)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG M;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^/&9O;G0@<W1Y;&4],T0G1D]. M5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^)#PO9F]N=#X\ M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P(&%L M:6=N/3-$<FEG:'0^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S M($YE=R!2;VUA;B<@<VEZ93TS1#(^)B-X,C`Q-#L\+V9O;G0^/"]T9#X-"B`\ M=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#X\9F]N="!S='EL M93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXF M(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M M/CQF;VYT('-I>F4],T0Q/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT M9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P/CQF;VYT('-T>6QE M/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R/B0\ M+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO M=W)A<"!A;&EG;CTS1')I9VAT/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9 M.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R/B8C>#(P,30[/"]F;VYT/CPO M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^/&9O M;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ M93TS1#(^)B-X03`[)B-X03`[/"]F;VYT/CPO=&0^#0H@/"]T<CX-"B`\='(^ M#0H@/'1D('9A;&EG;CTS1'1O<#X-"B`\<"!S='EL93TS1"=-05)'24XM3$5& M5#H@,65M.R!415A4+4E.1$5.5#H@+3%E;2<^/&9O;G0@<W1Y;&4],T0G1D]. M5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^17AP96YS92!R M96EM8G5R<V5M96YT<R!F<F]M#0H@37EO2V%R9&EA/"]F;VYT/CPO<#X-"B`\ M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<VEZ93TS1#$^)B-X M03`[)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N M;W=R87`],T1N;W=R87`^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I M;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^)B-X03`[/"]F;VYT/CPO=&0^#0H@ M/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`@86QI9VX],T1R M:6=H=#X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O M;6%N)R!S:7IE/3-$,CXF(W@R,#$T.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI M9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P/CQF;VYT('-T>6QE/3-$)T9/ M3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R/B8C>$$P.R8C M>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@ M<VEZ93TS1#$^)B-X03`[)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG M;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@ M3F5W(%)O;6%N)R!S:7IE/3-$,CXF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@ M=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^/&9O;G0@<W1Y;&4],T0G M1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^,2PP,C0\ M+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO M=W)A<#X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O M;6%N)R!S:7IE/3-$,CXF(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@ M=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C>$$P.R8C>$$P.SPO M9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<W1Y;&4] M,T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^)B-X M03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS M1')I9VAT/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@ M4F]M86XG('-I>F4],T0R/C4Y-3PO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX] M,T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P/CQF;VYT('-T>6QE/3-$)T9/3E0M M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R/B8C>$$P.R8C>$$P M.SPO9F]N=#X\+W1D/@T*(#PO='(^#0H@/'1R('-T>6QE/3-$)T9/3E0M4TE: M13H@,7!X)SX-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A M;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX] M,T1B;W1T;VT^#0H@/'`@<W1Y;&4],T0G0D]21$52+51/4#H@(S`P,#`P,"`Q M<'@@<V]L:60G/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B M;W1T;VT^#0H@/'`@<W1Y;&4],T0G0D]21$52+51/4#H@(S`P,#`P,"`Q<'@@ M<V]L:60G/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT9#XF(WA!,#L\+W1D/@T* M(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@ M=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(",P M,#`P,#`@,7!X('-O;&ED)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0@=F%L M:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P M,#`@,7!X('-O;&ED)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0^)B-X03`[ M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^ M#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M M5$]0.B`C,#`P,#`P(#%P>"!S;VQI9"<^)B-X03`[/"]P/@T*(#PO=&0^#0H@ M/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0 M.B`C,#`P,#`P(#%P>"!S;VQI9"<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D M/B8C>$$P.SPO=&0^#0H@/"]T<CX-"B`\='(@8F=C;VQO<CTS1"-#0T5%1D8^ M#0H@/'1D('9A;&EG;CTS1'1O<#X-"B`\<"!S='EL93TS1"=-05)'24XM3$5& M5#H@,65M.R!415A4+4E.1$5.5#H@+3%E;2<^/&9O;G0@<W1Y;&4],T0G1D]. M5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^4F5S96%R8V@@ M86YD(&1E=F5L;W!M96YT#0H@<F5V96YU92!F<F]M($UY;VMA<F1I83PO9F]N M=#X\+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I M>F4],T0Q/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX] M,T1B;W1T;VT^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE M=R!2;VUA;B<@<VEZ93TS1#(^)#PO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX] M,T1B;W1T;VT@86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS1"=&3TY4+49! M34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXQ,#`\+V9O;G0^/"]T M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#X\9F]N M="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE M/3-$,CXF(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$ M8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<W1Y;&4],T0G1D].5"U& M04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^)#PO9F]N=#X\+W1D M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#X\9F]N="!S M='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$ M,CXQ+#`R-#PO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W M<F%P/3-$;F]W<F%P/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE M<R!.97<@4F]M86XG('-I>F4],T0R/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<VEZ93TS1#$^)B-X03`[ M)B-X03`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`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D M('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI M9VX],T1B;W1T;VT^#0H@/'`@<W1Y;&4],T0G0D]21$52+51/4#H@(S`P,#`P M,"`S<'@@9&]U8FQE)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N M/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@ M,W!X(&1O=6)L92<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D/B8C>$$P.SPO M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T* M(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@<W1Y;&4],T0G0D]21$52+51/ M4#H@(S`P,#`P,"`S<'@@9&]U8FQE)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\ M=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z M(",P,#`P,#`@,W!X(&1O=6)L92<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA! M,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@<W1Y;&4],T0G M0D]21$52+51/4#H@(S`P,#`P,"`S<'@@9&]U8FQE)SXF(WA!,#L\+W`^#0H@ M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/ M4D1%4BU43U`Z(",P,#`P,#`@,W!X(&1O=6)L92<^)B-X03`[/"]P/@T*(#PO M=&0^#0H@/'1D/B8C>$$P.SPO=&0^#0H@/"]T<CX-"B`\+W1A8FQE/@T*(#PO M9&EV/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`\+W1A M8FQE/@T*("`\+V)O9'D^#0H\+VAT;6P^#0H-"BTM+2TM+3U?3F5X=%!A<G1? M,SEC,&5A-C)?8S(P,U\T-3AF7SAC-3!?,V1C830U-F$V.34Q#0I#;VYT96YT M+4QO8V%T:6]N.B!F:6QE.B\O+T,Z+S,Y8S!E838R7V,R,#-?-#4X9E\X8S4P M7S-D8V$T-39A-CDU,2]7;W)K<VAE971S+U-H965T,S$N:'1M;`T*0V]N=&5N M="U4<F%N<V9E<BU%;F-O9&EN9SH@<75O=&5D+7!R:6YT86)L90T*0V]N=&5N M="U4>7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA<G-E=#UU=&8M."<^/'-C M<FEP="!T>7!E/3-$=&5X="]J879A<V-R:7!T('-R8STS1%-H;W<N:G,^+RH@ M1&\@3F]T(%)E;6]V92!4:&ES($-O;6UE;G0@*B\\+W-C<FEP=#X\+VAE860^ M#0H@(#QB;V1Y/@T*("`@(#QT86)L92!C;&%S<STS1')E<&]R="!I9#TS1$E$ M,$5-13X-"B`@("`@(#QT<CX-"B`@("`@("`@/'1H(&-L87-S/3-$=&P@8V]L M<W!A;CTS1#$@<F]W<W!A;CTS1#(^/'-T<F]N9SY$96)T("A486)L97,I/&)R M/CPO<W1R;VYG/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H(&-O;'-P M86X],T0Q/C$R($UO;G1H<R!%;F1E9#PO=&@^#0H@("`@("`\+W1R/@T*("`@ M("`@/'1R/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y$96,N(#,Q+"`R,#$T M/&)R/CPO=&@^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^ M#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#X\<W1R;VYG M/D1E8G0@1&ES8VQO<W5R92!;06)S=')A8W1=/"]S=')O;F<^/"]T9#X-"B`@ M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@ M("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D M(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E-U;6UA<GD@;V8@5&]T86P@26YT M97)E<W0@17AP96YS92!);F-U<G)E9#PO=&0^#0H@("`@("`@(#QT9"!C;&%S M<STS1'1E>'0^/&1I=CX-"B`\<"!S='EL93TS1"=-05)'24XM0D]45$]-.B`P M<'@[($U!4D=)3BU43U`Z(#9P>#L@5$585"U)3D1%3E0Z(#0E)R!A;&EG;CTS M1&IU<W1I9GD^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE M=R!2;VUA;B<@<VEZ93TS1#(^5&]T86P@:6YT97)E<W0@97AP96YS92!I;F-U M<G)E9"!B>2!T:&4@0V]M<&%N>2!W87,@87,@9F]L;&]W<PT*("AI;B!T:&]U M<V%N9',I.CPO9F]N=#X\+W`^#0H@/'`@<W1Y;&4],T0G34%21TE.+4)/5%1/ M33H@,'!X.R!&3TY4+5-)6D4Z(#$R<'@[($U!4D=)3BU43U`Z(#!P>"<^#0H@ M)B-X03`[/"]P/@T*(#QT86)L92!S='EL93TS1"="3U)$15(M0T],3$%04T4Z M(&-O;&QA<'-E)R!C96QL<W!A8VEN9STS1#`@8V5L;'!A9&1I;F<],T0P('=I M9'1H/3-$.3(E(&%L:6=N/3-$8V5N=&5R(&)O<F1E<CTS1#`^#0H@/'1R/@T* M(#QT9"!W:61T:#TS1#<W)3X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@ M=VED=&@],T0V)3X\+W1D/@T*(#QT9#X\+W1D/@T*(#QT9#X\+W1D/@T*(#QT M9#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@=VED=&@],T0V)3X\+W1D M/@T*(#QT9#X\+W1D/@T*(#QT9#X\+W1D/@T*(#QT9#X\+W1D/@T*(#QT9"!V M86QI9VX],T1B;W1T;VT@=VED=&@],T0V)3X\+W1D/@T*(#QT9#X\+W1D/@T* M(#QT9#X\+W1D/@T*(#QT9#X\+W1D/@T*(#PO='(^#0H@/'1R/@T*(#QT9"!V M86QI9VX],T1B;W1T;VT^/&9O;G0@<VEZ93TS1#$^)B-X03`[/"]F;VYT/CPO M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF(WA! M,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@<W1Y;&4],T0G0D]21$52+4)/ M5%1/33H@(S`P,#`P,"`Q<'@@<V]L:60G('9A;&EG;CTS1&)O='1O;2!C;VQS M<&%N/3-$,3`@86QI9VX],T1C96YT97(^/&9O;G0@<W1Y;&4],T0G1D].5"U& M04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#$^/&(^665A<G,F(WA! M,#M%;F1E9"8C>$$P.T1E8V5M8F5R)B-X03`[,S$L/"]B/CPO9F]N=#X\+W1D M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<VEZ93TS1#$^)B-X03`[ M/"]F;VYT/CPO=&0^#0H@/"]T<CX-"B`\='(^#0H@/'1D('9A;&EG;CTS1&)O M='1O;3X\9F]N="!S:7IE/3-$,3XF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@ M=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C>$$P.R8C>$$P.SPO M9F]N=#X\+W1D/@T*(#QT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B`C,#`P M,#`P(#%P>"!S;VQI9"<@=F%L:6=N/3-$8F]T=&]M(&-O;'-P86X],T0R(&%L M:6=N/3-$8V5N=&5R/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE M<R!.97<@4F]M86XG('-I>F4],T0Q/CQB/C(P,30\+V(^/"]F;VYT/CPO=&0^ M#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF(WA!,#L\ M+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4] M,T0Q/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!S='EL93TS1"=" M3U)$15(M0D]45$]-.B`C,#`P,#`P(#%P>"!S;VQI9"<@=F%L:6=N/3-$8F]T M=&]M(&-O;'-P86X],T0R(&%L:6=N/3-$8V5N=&5R/CQF;VYT('-T>6QE/3-$ M)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0Q/CQB/C(P M,3,\+V(^/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N M="!S:7IE/3-$,3XF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$ M8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D M/@T*(#QT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B`C,#`P,#`P(#%P>"!S M;VQI9"<@=F%L:6=N/3-$8F]T=&]M(&-O;'-P86X],T0R(&%L:6=N/3-$8V5N M=&5R/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M M86XG('-I>F4],T0Q/CQB/C(P,3(\+V(^/"]F;VYT/CPO=&0^#0H@/'1D('9A M;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF(WA!,#L\+V9O;G0^/"]T M9#X-"B`\+W1R/@T*(#QT<B!B9V-O;&]R/3-$(T-#145&1CX-"B`\=&0@=F%L M:6=N/3-$=&]P/@T*(#QP('-T>6QE/3-$)TU!4D=)3BU,1494.B`Q96T[(%1% M6%0M24Y$14Y4.B`M,65M)SX\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@ M5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CY);G1E<F5S="!E>'!E;G-E/"]F M;VYT/CPO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@ M<VEZ93TS1#$^)B-X03`[)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG M;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^/&9O;G0@<W1Y;&4],T0G1D]. M5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^)#PO9F]N=#X\ M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P(&%L M:6=N/3-$<FEG:'0^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S M($YE=R!2;VUA;B<@<VEZ93TS1#(^)B-X,C`Q-#L\+V9O;G0^/"]T9#X-"B`\ M=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#X\9F]N="!S='EL M93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXF M(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M M/CQF;VYT('-I>F4],T0Q/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT M9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P/CQF;VYT('-T>6QE M/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R/B0\ M+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO M=W)A<"!A;&EG;CTS1')I9VAT/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9 M.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R/B8C>#(P,30[/"]F;VYT/CPO M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^/&9O M;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ M93TS1#(^)B-X03`[)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS M1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF(WA!,#LF(WA!,#L\+V9O;G0^/"]T M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)T9/3E0M M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R/B0\+V9O;G0^/"]T M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^/&9O;G0@ M<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS M1#(^,SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P M/3-$;F]W<F%P/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!. M97<@4F]M86XG('-I>F4],T0R/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T* M(#PO='(^#0H@/'1R('-T>6QE/3-$)T9/3E0M4TE:13H@,7!X)SX-"B`\=&0@ M=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF M(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@ M<W1Y;&4],T0G0D]21$52+51/4#H@(S`P,#`P,"`S<'@@9&]U8FQE)SXF(WA! M,#L\+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T M>6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@,W!X(&1O=6)L92<^)B-X03`[ M/"]P/@T*(#PO=&0^#0H@/'1D/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS M1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T M;VT^#0H@/'`@<W1Y;&4],T0G0D]21$52+51/4#H@(S`P,#`P,"`S<'@@9&]U M8FQE)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@,W!X(&1O=6)L M92<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D/B8C>$$P.SPO=&0^#0H@/'1D M('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI M9VX],T1B;W1T;VT^#0H@/'`@<W1Y;&4],T0G0D]21$52+51/4#H@(S`P,#`P M,"`S<'@@9&]U8FQE)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N M/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@ M,W!X(&1O=6)L92<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D/B8C>$$P.SPO M=&0^#0H@/"]T<CX-"B`\+W1A8FQE/@T*(#PO9&EV/CQS<&%N/CPO<W!A;CX\ M+W1D/@T*("`@("`@/"]T<CX-"B`@("`\+W1A8FQE/@T*("`\+V)O9'D^#0H\ M+VAT;6P^#0H-"BTM+2TM+3U?3F5X=%!A<G1?,SEC,&5A-C)?8S(P,U\T-3AF M7SAC-3!?,V1C830U-F$V.34Q#0I#;VYT96YT+4QO8V%T:6]N.B!F:6QE.B\O M+T,Z+S,Y8S!E838R7V,R,#-?-#4X9E\X8S4P7S-D8V$T-39A-CDU,2]7;W)K M<VAE971S+U-H965T,S(N:'1M;`T*0V]N=&5N="U4<F%N<V9E<BU%;F-O9&EN M9SH@<75O=&5D+7!R:6YT86)L90T*0V]N=&5N="U4>7!E.B!T97AT+VAT;6P[ M(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@ M/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E M>'0O:'1M;#L@8VAA<G-E=#UU=&8M."<^/'-C<FEP="!T>7!E/3-$=&5X="]J M879A<V-R:7!T('-R8STS1%-H;W<N:G,^+RH@1&\@3F]T(%)E;6]V92!4:&ES M($-O;6UE;G0@*B\\+W-C<FEP=#X\+VAE860^#0H@(#QB;V1Y/@T*("`@(#QT M86)L92!C;&%S<STS1')E<&]R="!I9#TS1$E$,$4R1CX-"B`@("`@(#QT<CX- M"B`@("`@("`@/'1H(&-L87-S/3-$=&P@8V]L<W!A;CTS1#$@<F]W<W!A;CTS M1#(^/'-T<F]N9SY#;VUM:71M96YT<R!A;F0@0V]N=&EN9V5N8VEE<R`H5&%B M;&5S*3QB<CX\+W-T<F]N9SX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T M:"!C;VQS<&%N/3-$,3XQ,B!-;VYT:',@16YD960\+W1H/@T*("`@("`@/"]T M<CX-"B`@("`@(#QT<CX-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^1&5C+B`S M,2P@,C`Q-#QB<CX\+W1H/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S M<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^ M/'-T<F]N9SY#;VUM:71M96YT<R!A;F0@0V]N=&EN9V5N8VEE<R!$:7-C;&]S M=7)E(%M!8G-T<F%C=%T\+W-T<F]N9SX\+W1D/@T*("`@("`@("`\=&0@8VQA M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@ M("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V M86QI9VX],T1T;W`^4F5N="!%>'!E;G-E/"]T9#X-"B`@("`@("`@/'1D(&-L M87-S/3-$=&5X=#X\9&EV/@T*(#QP('-T>6QE/3-$)TU!4D=)3BU"3U143TTZ M(#!P>#L@34%21TE.+51/4#H@,3AP>#L@5$585"U)3D1%3E0Z(#0E)R!A;&EG M;CTS1&IU<W1I9GD^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S M($YE=R!2;VUA;B<@<VEZ93TS1#(^4F5N="!E>'!E;G-E('=A<R!A<R!F;VQL M;W=S("AI;B!T:&]U<V%N9',I.CPO9F]N=#X\+W`^#0H@/'`@<W1Y;&4],T0G M34%21TE.+4)/5%1/33H@,'!X.R!&3TY4+5-)6D4Z(#$R<'@[($U!4D=)3BU4 M3U`Z(#!P>"<^#0H@)B-X03`[/"]P/@T*(#QT86)L92!S='EL93TS1"="3U)$ M15(M0T],3$%04T4Z(&-O;&QA<'-E)R!C96QL<W!A8VEN9STS1#`@8V5L;'!A M9&1I;F<],T0P('=I9'1H/3-$.3(E(&%L:6=N/3-$8V5N=&5R(&)O<F1E<CTS M1#`^#0H@/'1R/@T*(#QT9"!W:61T:#TS1#<S)3X\+W1D/@T*(#QT9"!V86QI M9VX],T1B;W1T;VT@=VED=&@],T0T)3X\+W1D/@T*(#QT9#X\+W1D/@T*(#QT M9#X\+W1D/@T*(#QT9#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@=VED M=&@],T0T)3X\+W1D/@T*(#QT9#X\+W1D/@T*(#QT9#X\+W1D/@T*(#QT9#X\ M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@=VED=&@],T0T)3X\+W1D/@T* M(#QT9#X\+W1D/@T*(#QT9#X\+W1D/@T*(#QT9#X\+W1D/@T*(#PO='(^#0H@ M/'1R/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<VEZ93TS1#$^)B-X M03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S M:7IE/3-$,3XF(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@<W1Y;&4] M,T0G0D]21$52+4)/5%1/33H@(S`P,#`P,"`Q<'@@<V]L:60G('9A;&EG;CTS M1&)O='1O;2!C;VQS<&%N/3-$,3`@86QI9VX],T1C96YT97(^/&9O;G0@<W1Y M;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#$^ M/&(^665A<G,@16YD960-"B!$96-E;6)E<B8C>$$P.S,Q+#PO8CX\+V9O;G0^ M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C M>$$P.SPO9F]N=#X\+W1D/@T*(#PO='(^#0H@/'1R/@T*(#QT9"!V86QI9VX] M,T1B;W1T;VT^/&9O;G0@<VEZ93TS1#$^)B-X03`[/"]F;VYT/CPO=&0^#0H@ M/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF(WA!,#LF(WA! M,#L\+V9O;G0^/"]T9#X-"B`\=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@ M(S`P,#`P,"`Q<'@@<V]L:60G('9A;&EG;CTS1&)O='1O;2!C;VQS<&%N/3-$ M,B!A;&EG;CTS1&-E;G1E<CX\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@ M5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,3X\8CXR,#$T/"]B/CPO9F]N=#X\ M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<VEZ93TS1#$^)B-X M03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S M:7IE/3-$,3XF(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@<W1Y;&4] M,T0G0D]21$52+4)/5%1/33H@(S`P,#`P,"`Q<'@@<V]L:60G('9A;&EG;CTS M1&)O='1O;2!C;VQS<&%N/3-$,B!A;&EG;CTS1&-E;G1E<CX\9F]N="!S='EL M93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,3X\ M8CXR,#$S/"]B/CPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^ M/&9O;G0@<VEZ93TS1#$^)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG M;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF(WA!,#LF(WA!,#L\+V9O;G0^ M/"]T9#X-"B`\=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@(S`P,#`P,"`Q M<'@@<V]L:60G('9A;&EG;CTS1&)O='1O;2!C;VQS<&%N/3-$,B!A;&EG;CTS M1&-E;G1E<CX\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W M(%)O;6%N)R!S:7IE/3-$,3X\8CXR,#$R/"]B/CPO9F]N=#X\+W1D/@T*(#QT M9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<VEZ93TS1#$^)B-X03`[/"]F;VYT M/CPO=&0^#0H@/"]T<CX-"B`\='(@8F=C;VQO<CTS1"-#0T5%1D8^#0H@/'1D M('9A;&EG;CTS1'1O<#X-"B`\<"!S='EL93TS1"=-05)'24XM3$5&5#H@,65M M.R!415A4+4E.1$5.5#H@+3%E;2<^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U) M3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^4F5N="!E>'!E;G-E/"]F M;VYT/CPO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@ M<VEZ93TS1#$^)B-X03`[)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG M;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@ M3F5W(%)O;6%N)R!S:7IE/3-$,CXD/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG M;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/CQF;VYT('-T>6QE/3-$)T9/3E0M M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R/C,L,S,X/"]F;VYT M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^ M/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@ M<VEZ93TS1#(^)B-X03`[)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG M;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF(WA!,#LF(WA!,#L\+V9O;G0^ M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)T9/ M3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R/B0\+V9O;G0^ M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^/&9O M;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ M93TS1#(^,RPS,#8\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M M(&YO=W)A<#TS1&YO=W)A<#X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@ M5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXF(WA!,#LF(WA!,#L\+V9O;G0^ M/"]T9#X-"B`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`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^ M#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT M9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@<W1Y;&4],T0G0D]21$52+51/4#H@ M(S`P,#`P,"`S<'@@9&]U8FQE)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0@ M=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(",P M,#`P,#`@,W!X(&1O=6)L92<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D/B8C M>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\ M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@<W1Y;&4],T0G0D]2 M1$52+51/4#H@(S`P,#`P,"`S<'@@9&]U8FQE)SXF(WA!,#L\+W`^#0H@/"]T M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1% M4BU43U`Z(",P,#`P,#`@,W!X(&1O=6)L92<^)B-X03`[/"]P/@T*(#PO=&0^ M#0H@/'1D/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA! M,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@<W1Y M;&4],T0G0D]21$52+51/4#H@(S`P,#`P,"`S<'@@9&]U8FQE)SXF(WA!,#L\ M+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE M/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@,W!X(&1O=6)L92<^)B-X03`[/"]P M/@T*(#PO=&0^#0H@/'1D/B8C>$$P.SPO=&0^#0H@/"]T<CX-"B`\+W1A8FQE M/@T*(#PO9&EV/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@ M("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V M86QI9VX],T1T;W`^1G5T=7)E($UI;FEM=6T@3&5A<V4@4&%Y;65N=',@=6YD M97(@3F]N8V%N8V5L86)L92!/<&5R871I;F<@3&5A<V5S/"]T9#X-"B`@("`@ M("`@/'1D(&-L87-S/3-$=&5X=#X\9&EV/@T*(#QP('-T>6QE/3-$)TU!4D=) M3BU"3U143TTZ(#!P>#L@34%21TE.+51/4#H@,3)P>#L@5$585"U)3D1%3E0Z M(#0E)R!A;&EG;CTS1&IU<W1I9GD^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U) M3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^07,@;V8@1&5C96UB97(F M(WA!,#LS,2P@,C`Q-"P@9G5T=7)E(&UI;FEM=6T@;&5A<V4@<&%Y;65N=',- M"B!U;F1E<B!N;VYC86YC96QA8FQE(&]P97)A=&EN9R!L96%S97,@=V5R92!A M<R!F;VQL;W=S("AI;@T*('1H;W5S86YD<RDZ/"]F;VYT/CPO<#X-"B`\<"!S M='EL93TS1"=-05)'24XM0D]45$]-.B`P<'@[($9/3E0M4TE:13H@,3)P>#L@ M34%21TE.+51/4#H@,'!X)SX-"B`F(WA!,#L\+W`^#0H@/'1A8FQE('-T>6QE M/3-$)T)/4D1%4BU#3TQ,05!313H@8V]L;&%P<V4G(&-E;&QS<&%C:6YG/3-$ M,"!C96QL<&%D9&EN9STS1#`@=VED=&@],T0Y,B4@86QI9VX],T1C96YT97(@ M8F]R9&5R/3-$,#X-"B`\='(^#0H@/'1D('=I9'1H/3-$.#DE/CPO=&0^#0H@ M/'1D('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#4E/CPO=&0^#0H@/'1D/CPO M=&0^#0H@/'1D/CPO=&0^#0H@/'1D/CPO=&0^#0H@/"]T<CX-"B`\='(@8F=C M;VQO<CTS1"-#0T5%1D8^#0H@/'1D('9A;&EG;CTS1'1O<#X-"B`\<"!S='EL M93TS1"=-05)'24XM3$5&5#H@,65M.R!415A4+4E.1$5.5#H@+3%E;2<^/&9O M;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ M93TS1#(^,C`Q-3PO9F]N=#X\+W`^#0H@/"]T9#X-"B`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`^#0H@/'`@<W1Y M;&4],T0G34%21TE.+4Q%1E0Z(#%E;3L@5$585"U)3D1%3E0Z("TQ96TG/CQF M;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I M>F4],T0R/C(P,38\+V9O;G0^/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS M1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF(WA!,#LF(WA!,#L\+V9O;G0^/"]T M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)T9/3E0M M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R/B8C>$$P.SPO9F]N M=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#X\ M9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S M:7IE/3-$,CXS+#4P-#PO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T M;VT@;F]W<F%P/3-$;F]W<F%P/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9 M.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R/B8C>$$P.R8C>$$P.SPO9F]N M=#X\+W1D/@T*(#PO='(^#0H@/'1R(&)G8V]L;W(],T0C0T-%149&/@T*(#QT M9"!V86QI9VX],T1T;W`^#0H@/'`@<W1Y;&4],T0G34%21TE.+4Q%1E0Z(#%E M;3L@5$585"U)3D1%3E0Z("TQ96TG/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%- M24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R/C(P,3<\+V9O;G0^/"]P M/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$ M,3XF(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T M=&]M/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M M86XG('-I>F4],T0R/B8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX] M,T1B;W1T;VT@86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS1"=&3TY4+49! M34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXS+#8R-CPO9F]N=#X\ M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P/CQF M;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I M>F4],T0R/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#PO='(^#0H@/'1R M/@T*(#QT9"!V86QI9VX],T1T;W`^#0H@/'`@<W1Y;&4],T0G34%21TE.+4Q% M1E0Z(#%E;3L@5$585"U)3D1%3E0Z("TQ96TG/CQF;VYT('-T>6QE/3-$)T9/ M3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R/C(P,3@\+V9O M;G0^/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S M:7IE/3-$,3XF(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`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`^ M#0H@/'`@<W1Y;&4],T0G34%21TE.+4Q%1E0Z(#%E;3L@5$585"U)3D1%3E0Z M("TQ96TG/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@ M4F]M86XG('-I>F4],T0R/C(P,3D\+V9O;G0^/"]P/@T*(#PO=&0^#0H@/'1D M('9A;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF(WA!,#LF(WA!,#L\ M+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO M=W)A<#X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O M;6%N)R!S:7IE/3-$,CXF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N M/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<"!A;&EG;CTS1')I9VAT/CQF;VYT M('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4] M,T0R/B8C>#(P,30[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O M;2!N;W=R87`],T1N;W=R87`^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ M(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^)B-X03`[)B-X03`[/"]F;VYT M/CPO=&0^#0H@/"]T<CX-"B`\='(^#0H@/'1D('9A;&EG;CTS1'1O<#X-"B`\ M<"!S='EL93TS1"=-05)'24XM3$5&5#H@,65M.R!415A4+4E.1$5.5#H@+3%E M;2<^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA M;B<@<VEZ93TS1#(^5&AE<F5A9G1E<CPO9F]N=#X\+W`^#0H@/"]T9#X-"B`\ M=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C>$$P.R8C>$$P M.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$ M;F]W<F%P/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@ M4F]M86XG('-I>F4],T0R/B8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI M9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P(&%L:6=N/3-$<FEG:'0^/&9O M;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ M93TS1#(^)B-X,C`Q-#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T M=&]M(&YO=W)A<#TS1&YO=W)A<#X\9F]N="!S='EL93TS1"=&3TY4+49!34E, M63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXF(WA!,#LF(WA!,#L\+V9O M;G0^/"]T9#X-"B`\+W1R/@T*(#QT<B!S='EL93TS1"=&3TY4+5-)6D4Z(#%P M>"<^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI9VX] M,T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T M=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@,7!X('-O M;&ED)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@,7!X('-O;&ED M)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0^)B-X03`[/"]T9#X-"B`\+W1R M/@T*(#QT<B!B9V-O;&]R/3-$(T-#145&1CX-"B`\=&0@=F%L:6=N/3-$=&]P M/@T*(#QP('-T>6QE/3-$)TU!4D=)3BU,1494.B`R96T[(%1%6%0M24Y$14Y4 M.B`M,65M)SX\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W M(%)O;6%N)R!S:7IE/3-$,CY4;W1A;#PO9F]N=#X\+W`^#0H@/"]T9#X-"B`\ M=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C>$$P.R8C>$$P M.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<W1Y M;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^ M)#PO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R M:6=H=#X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O M;6%N)R!S:7IE/3-$,CXQ,BPS.#`\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N M/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#X\9F]N="!S='EL93TS1"=&3TY4 M+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXF(WA!,#LF(WA! M,#L\+V9O;G0^/"]T9#X-"B`\+W1R/@T*(#QT<B!S='EL93TS1"=&3TY4+5-) M6D4Z(#%P>"<^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V M86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N M/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@ M,W!X(&1O=6)L92<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS M1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B`C,#`P,#`P(#-P M>"!D;W5B;&4G/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT9#XF(WA!,#L\+W1D M/@T*(#PO='(^#0H@/"]T86)L93X-"B`\+V1I=CX\<W!A;CX\+W-P86X^/"]T M9#X-"B`@("`@(#PO='(^#0H@("`@/"]T86)L93X-"B`@/"]B;V1Y/@T*/"]H M=&UL/@T*#0HM+2TM+2T]7TYE>'1087)T7S,Y8S!E838R7V,R,#-?-#4X9E\X M8S4P7S-D8V$T-39A-CDU,0T*0V]N=&5N="U,;V-A=&EO;CH@9FEL93HO+R]# M.B\S.6,P96$V,E]C,C`S7S0U.&9?.&,U,%\S9&-A-#4V838Y-3$O5V]R:W-H M965T<R]3:&5E=#,S+FAT;6P-"D-O;G1E;G0M5')A;G-F97(M16YC;V1I;F<Z M('%U;W1E9"UP<FEN=&%B;&4-"D-O;G1E;G0M5'EP93H@=&5X="]H=&UL.R!C M:&%R<V5T/2)U<RUA<V-I:2(-"@T*/&AT;6P^#0H@(#QH96%D/@T*("`@(#Q- M151!(&AT='`M97%U:78],T1#;VYT96YT+51Y<&4@8V]N=&5N=#TS1"=T97AT M+VAT;6P[(&-H87)S970]=71F+3@G/CQS8W)I<'0@='EP93TS1'1E>'0O:F%V M87-C<FEP="!S<F,],T13:&]W+FIS/B\J($1O($YO="!296UO=F4@5&AI<R!# M;VUM96YT("HO/"]S8W)I<'0^/"]H96%D/@T*("`\8F]D>3X-"B`@("`\=&%B M;&4@8VQA<W,],T1R97!O<G0@:60],T1)1#!%2D-!0SX-"B`@("`@(#QT<CX- M"B`@("`@("`@/'1H(&-L87-S/3-$=&P@8V]L<W!A;CTS1#$@<F]W<W!A;CTS M1#(^/'-T<F]N9SY3=&]C:VAO;&1E<G,G($5Q=6ET>2`H5&%B;&5S*3QB<CX\ M+W-T<F]N9SX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:"!C;VQS<&%N M/3-$,3XQ,B!-;VYT:',@16YD960\+W1H/@T*("`@("`@/"]T<CX-"B`@("`@ M(#QT<CX-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^1&5C+B`S,2P@,C`Q-#QB M<CX\+W1H/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T* M("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^/'-T<F]N9SY% M<75I='D@6T%B<W1R86-T73PO<W1R;VYG/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T* M("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L M('9A;&EG;CTS1'1O<#Y/=71S=&%N9&EN9R!787)R86YT<SPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S<STS1'1E>'0^/&1I=CX-"B`\<"!S='EL93TS1"=-05)' M24XM0D]45$]-.B`P<'@[($U!4D=)3BU43U`Z(#$R<'@[(%1%6%0M24Y$14Y4 M.B`T)2<@86QI9VX],T1J=7-T:69Y/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%- M24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R/D]U='-T86YD:6YG('=A M<G)A;G1S(&%S(&]F($1E8V5M8F5R)B-X03`[,S$L(#(P,30@=V5R92!A<PT* M(&9O;&QO=W,Z/"]F;VYT/CPO<#X-"B`\<"!S='EL93TS1"=-05)'24XM0D]4 M5$]-.B`P<'@[($9/3E0M4TE:13H@,3)P>#L@34%21TE.+51/4#H@,'!X)SX- M"B`F(WA!,#L\+W`^#0H@/'1A8FQE('-T>6QE/3-$)T)/4D1%4BU#3TQ,05!3 M13H@8V]L;&%P<V4G(&-E;&QS<&%C:6YG/3-$,"!C96QL<&%D9&EN9STS1#`@ M=VED=&@],T0Y,B4@86QI9VX],T1C96YT97(@8F]R9&5R/3-$,#X-"B`\='(^ M#0H@/'1D('=I9'1H/3-$-C<E/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O M;2!W:61T:#TS1#0E/CPO=&0^#0H@/'1D/CPO=&0^#0H@/'1D/CPO=&0^#0H@ M/'1D/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#0E/CPO M=&0^#0H@/'1D/CPO=&0^#0H@/'1D/CPO=&0^#0H@/'1D/CPO=&0^#0H@/'1D M('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#0E/CPO=&0^#0H@/'1D/CPO=&0^ M#0H@/'1D/CPO=&0^#0H@/'1D/CPO=&0^#0H@/"]T<CX-"B`\='(^#0H@/'1D M('9A;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF(WA!,#L\+V9O;G0^ M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C M>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!S='EL93TS1"="3U)$15(M M0D]45$]-.B`C,#`P,#`P(#%P>"!S;VQI9"<@=F%L:6=N/3-$8F]T=&]M(&-O M;'-P86X],T0R(&%L:6=N/3-$8V5N=&5R/CQF;VYT('-T>6QE/3-$)T9/3E0M M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0Q/CQB/DYU;6)E<CQB M<B`O/@T*(&]F(%-H87)E<SPO8CX\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N M/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C>$$P.SPO9F]N=#X\+W1D/@T* M(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<VEZ93TS1#$^)B-X03`[)B-X M03`[/"]F;VYT/CPO=&0^#0H@/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ M(",P,#`P,#`@,7!X('-O;&ED)R!V86QI9VX],T1B;W1T;VT@8V]L<W!A;CTS M1#(@86QI9VX],T1C96YT97(^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ M(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#$^/&(^17AE<F-I<V4\8G(@+SX- M"B!0<FEC93PO8CX\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M M/CQF;VYT('-I>F4],T0Q/B8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI M9VX],T1B;W1T;VT^/&9O;G0@<VEZ93TS1#$^)B-X03`[)B-X03`[/"]F;VYT M/CPO=&0^#0H@/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@ M,7!X('-O;&ED)R!V86QI9VX],T1B;W1T;VT@8V]L<W!A;CTS1#(@86QI9VX] M,T1C96YT97(^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE M=R!2;VUA;B<@<VEZ93TS1#$^/&(^17AP:7)A=&EO;CQB<B`O/@T*($1A=&4\ M+V(^/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S M:7IE/3-$,3XF(WA!,#L\+V9O;G0^/"]T9#X-"B`\+W1R/@T*(#QT<B!B9V-O M;&]R/3-$(T-#145&1CX-"B`\=&0@=F%L:6=N/3-$=&]P/@T*(#QP('-T>6QE M/3-$)TU!4D=)3BU,1494.B`Q96T[(%1%6%0M24Y$14Y4.B`M,65M)SX\9F]N M="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE M/3-$,CY)<W-U960@-"\R,"\R,#$Q/"]F;VYT/CPO<#X-"B`\+W1D/@T*(#QT M9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<VEZ93TS1#$^)B-X03`[)B-X03`[ M/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL M93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXF M(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N M/3-$<FEG:'0^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE M=R!2;VUA;B<@<VEZ93TS1#(^,2PQ,30L,38X/"]F;VYT/CPO=&0^#0H@/'1D M('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^/&9O;G0@<W1Y;&4] M,T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^)B-X M03`[)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\ M9F]N="!S:7IE/3-$,3XF(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@ M=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4 M:6UE<R!.97<@4F]M86XG('-I>F4],T0R/B0\+V9O;G0^/"]T9#X-"B`\=&0@ M=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^/&9O;G0@<W1Y;&4],T0G M1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^.2XY,#PO M9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W M<F%P/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M M86XG('-I>F4],T0R/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V M86QI9VX],T1B;W1T;VT^/&9O;G0@<VEZ93TS1#$^)B-X03`[)B-X03`[/"]F M;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS M1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXF(WA! M,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$ M<FEG:'0^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2 M;VUA;B<@<VEZ93TS1#(^,#0O,C`O,34\+V9O;G0^/"]T9#X-"B`\=&0@=F%L M:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#X\9F]N="!S='EL93TS1"=& M3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXF(WA!,#LF M(WA!,#L\+V9O;G0^/"]T9#X-"B`\+W1R/@T*(#QT<CX-"B`\=&0@=F%L:6=N M/3-$=&]P/@T*(#QP('-T>6QE/3-$)TU!4D=)3BU,1494.B`Q96T[(%1%6%0M M24Y$14Y4.B`M,65M)SX\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM M97,@3F5W(%)O;6%N)R!S:7IE/3-$,CY)<W-U960@-B\R-2\R,#$R/"]F;VYT M/CPO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<VEZ M93TS1#$^)B-X03`[)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS M1&)O='1O;3X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W M(%)O;6%N)R!S:7IE/3-$,CXF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L M:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^/&9O;G0@<W1Y;&4],T0G1D]. M5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^-2PU-S8L.3(X M/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N M;W=R87`^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2 M;VUA;B<@<VEZ93TS1#(^)B-X03`[)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D M('9A;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF(WA!,#LF(WA!,#L\ M+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE M/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R/B0\ M+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG M:'0^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA M;B<@<VEZ93TS1#(^-2XR.#PO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B M;W1T;VT@;F]W<F%P/3-$;F]W<F%P/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%- M24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R/B8C>$$P.R8C>$$P.SPO M9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<VEZ93TS M1#$^)B-X03`[)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O M='1O;3X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O M;6%N)R!S:7IE/3-$,CXF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N M/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^/&9O;G0@<W1Y;&4],T0G1D].5"U& M04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^,#8O,C4O,3<\+V9O M;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A M<#X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N M)R!S:7IE/3-$,CXF(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\+W1R/@T* M(#PO=&%B;&4^#0H@/"]D:78^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\ M+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S M<STS1'!L('9A;&EG;CTS1'1O<#Y3=6UM87)Y(&]F(%-T;V-K($]P=&EO;B!! M8W1I=FET>3PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/&1I=CX- M"B`\<"!S='EL93TS1"=-05)'24XM0D]45$]-.B`P<'@[($U!4D=)3BU43U`Z M(#!P>#L@5$585"U)3D1%3E0Z(#0E)R!A;&EG;CTS1&IU<W1I9GD^/&9O;G0@ M<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS M1#(^06-T:79I='D@=6YD97(@=&AE('1W;R!S=&]C:R!O<'1I;VX@<&QA;G,@ M=V%S(&%S#0H@9F]L;&]W<SH\+V9O;G0^/"]P/@T*(#QP('-T>6QE/3-$)TU! M4D=)3BU"3U143TTZ(#!P>#L@1D].5"U325I%.B`Q,G!X.R!-05)'24XM5$]0 M.B`P<'@G/@T*("8C>$$P.SPO<#X-"B`\=&%B;&4@<W1Y;&4],T0G0D]21$52 M+4-/3$Q!4%-%.B!C;VQL87!S92<@8V5L;'-P86-I;F<],T0P(&-E;&QP861D M:6YG/3-$,"!W:61T:#TS1#$P,"4@86QI9VX],T1C96YT97(@8F]R9&5R/3-$ M,#X-"B`\='(^#0H@/'1D('=I9'1H/3-$-#$E/CPO=&0^#0H@/'1D('9A;&EG M;CTS1&)O='1O;2!W:61T:#TS1#8E/CPO=&0^#0H@/'1D/CPO=&0^#0H@/'1D M/CPO=&0^#0H@/'1D/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!W:61T M:#TS1#8E/CPO=&0^#0H@/'1D/CPO=&0^#0H@/'1D/CPO=&0^#0H@/'1D/CPO M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#8E/CPO=&0^#0H@ M/'1D/CPO=&0^#0H@/'1D/CPO=&0^#0H@/'1D/CPO=&0^#0H@/'1D('9A;&EG M;CTS1&)O='1O;2!W:61T:#TS1#8E/CPO=&0^#0H@/'1D/CPO=&0^#0H@/'1D M/CPO=&0^#0H@/'1D/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!W:61T M:#TS1#8E/CPO=&0^#0H@/'1D/CPO=&0^#0H@/'1D/CPO=&0^#0H@/'1D/CPO M=&0^#0H@/"]T<CX-"B`\='(^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N M="!S:7IE/3-$,3XF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$ M8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT M9"!S='EL93TS1"="3U)$15(M0D]45$]-.B`C,#`P,#`P(#%P>"!S;VQI9"<@ M=F%L:6=N/3-$8F]T=&]M(&-O;'-P86X],T0R(&%L:6=N/3-$8V5N=&5R/CQF M;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I M>F4],T0Q/CQB/E-H87)E<SQB<B`O/@T*($%V86EL86)L928C>$$P.V9O<CQB M<B`O/@T*($=R86YT)B-X03`[;V8F(WA!,#M/<'1I;VX\8G(@+SX-"B!O<B!! M=V%R9#PO8CX\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF M;VYT('-I>F4],T0Q/B8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX] M,T1B;W1T;VT^/&9O;G0@<VEZ93TS1#$^)B-X03`[/"]F;VYT/CPO=&0^#0H@ M/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,7!X('-O;&ED M)R!V86QI9VX],T1B;W1T;VT@8V]L<W!A;CTS1#(@86QI9VX],T1C96YT97(^ M/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@ M<VEZ93TS1#$^/&(^4W1O8VLF(WA!,#M/<'1I;VYS/&)R("\^#0H@3W5T<W1A M;F1I;F<\+V(^/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\ M9F]N="!S:7IE/3-$,3XF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N M/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C>$$P.SPO9F]N=#X\+W1D/@T* M(#QT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B`C,#`P,#`P(#%P>"!S;VQI M9"<@=F%L:6=N/3-$8F]T=&]M(&-O;'-P86X],T0R(&%L:6=N/3-$8V5N=&5R M/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG M('-I>F4],T0Q/CQB/E=E:6=H=&5D/&)R("\^#0H@079E<F%G928C>$$P.T5X M97)C:7-E/&)R("\^#0H@4')I8V4@<&5R(%-H87)E("T\8G(@+SX-"B!3=&]C M:R!/<'1I;VYS/"]B/CPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T M;VT^/&9O;G0@<VEZ93TS1#$^)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A M;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF(WA!,#L\+V9O;G0^/"]T M9#X-"B`\=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@(S`P,#`P,"`Q<'@@ M<V]L:60G('9A;&EG;CTS1&)O='1O;2!C;VQS<&%N/3-$,B!A;&EG;CTS1&-E M;G1E<CX\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O M;6%N)R!S:7IE/3-$,3X\8CY796EG:'1E9#QB<B`O/@T*($%V97)A9V4F(WA! M,#M296UA:6YI;F<\8G(@+SX-"B!#;VYT<F%C='5A;"8C>$$P.TQI9F4\+V(^ M/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE M/3-$,3XF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M M/CQF;VYT('-I>F4],T0Q/B8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!S='EL M93TS1"="3U)$15(M0D]45$]-.B`C,#`P,#`P(#%P>"!S;VQI9"<@=F%L:6=N M/3-$8F]T=&]M(&-O;'-P86X],T0R(&%L:6=N/3-$8V5N=&5R/CQF;VYT('-T M>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0Q M/CQB/D%G9W)E9V%T93QB<B`O/@T*($EN=')I;G-I8SQB<B`O/@T*(%9A;'5E M/"]B/CPO9F]N=#X\8G(@+SX-"B`\9F]N="!S='EL93TS1"=&3TY4+49!34E, M63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,3X\8CXH:6XF(WA!,#L-"B!T M:&]U<V%N9',I/"]B/CPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T M;VT^/&9O;G0@<VEZ93TS1#$^)B-X03`[/"]F;VYT/CPO=&0^#0H@/"]T<CX- M"B`\='(@8F=C;VQO<CTS1"-#0T5%1D8^#0H@/'1D('9A;&EG;CTS1'1O<#X- M"B`\<"!S='EL93TS1"=-05)'24XM3$5&5#H@,F5M.R!415A4+4E.1$5.5#H@ M+3%E;2<^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2 M;VUA;B<@<VEZ93TS1#(^0F%L86YC92!A=`T*($1E8V5M8F5R)B-X03`[,S$L M(#(P,3$\+V9O;G0^/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O M;3X\9F]N="!S:7IE/3-$,3XF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L M:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE M<R!.97<@4F]M86XG('-I>F4],T0R/B8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT M9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS M1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXU.#4L M-#<V/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`] M,T1N;W=R87`^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE M=R!2;VUA;B<@<VEZ93TS1#(^)B-X03`[)B-X03`[/"]F;VYT/CPO=&0^#0H@ M/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF(WA!,#L\+V9O M;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$ M)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R/B8C>$$P M.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R M:6=H=#X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O M;6%N)R!S:7IE/3-$,CXQ+#4Y."PT,#@\+V9O;G0^/"]T9#X-"B`\=&0@=F%L M:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#X\9F]N="!S='EL93TS1"=& M3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXF(WA!,#LF M(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT M('-I>F4],T0Q/B8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B M;W1T;VT^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2 M;VUA;B<@<VEZ93TS1#(^)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG M;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/CQF;VYT('-T>6QE/3-$)T9/3E0M M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R/C(Q+CDS/"]F;VYT M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^ M/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@ M<VEZ93TS1#(^)B-X03`[)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG M;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF(WA!,#L\+V9O;G0^/"]T9#X- M"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O M='1O;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\=&0@ M=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C>$$P.SPO9F]N=#X\ M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\=&0@=F%L:6=N M/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T* M(#PO='(^#0H@/'1R/@T*(#QT9"!V86QI9VX],T1T;W`^#0H@/'`@<W1Y;&4] M,T0G34%21TE.+4Q%1E0Z(#%E;3L@5$585"U)3D1%3E0Z("TQ96TG/CQF;VYT M('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4] M,T0R/DEN8W)E87-E(&EN(&%U=&AO<FEZ960-"B!S:&%R97,\+V9O;G0^/"]P M/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$ M,3XF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF M;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I M>F4],T0R/B8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T M;VT@86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@ M5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXT,38L-C8W/"]F;VYT/CPO=&0^ M#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^/&9O;G0@ M<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS M1#(^)B-X03`[)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O M='1O;3X\9F]N="!S:7IE/3-$,3XF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@ M=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#X\9F]N="!S='EL93TS M1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXF(WA! M,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS M1&YO=W)A<"!A;&EG;CTS1')I9VAT/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%- M24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R/B8C>#(P,30[/"]F;VYT M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^ M/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@ M<VEZ93TS1#(^)B-X03`[)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG M;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF(WA!,#L\+V9O;G0^/"]T9#X- M"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#X\9F]N="!S M='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$ M,CXF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO M=W)A<#TS1&YO=W)A<"!A;&EG;CTS1')I9VAT/CQF;VYT('-T>6QE/3-$)T9/ M3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R/B8C>#(P,30[ M/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N M;W=R87`^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2 M;VUA;B<@<VEZ93TS1#(^)B-X03`[)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D M('9A;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF(WA!,#L\+V9O;G0^ M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG M;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X- M"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C>$$P.SPO M9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\=&0@ M=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\ M+W1D/@T*(#PO='(^#0H@/'1R(&)G8V]L;W(],T0C0T-%149&/@T*(#QT9"!V M86QI9VX],T1T;W`^#0H@/'`@<W1Y;&4],T0G34%21TE.+4Q%1E0Z(#%E;3L@ M5$585"U)3D1%3E0Z("TQ96TG/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9 M.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R/D]P=&EO;G,@9W)A;G1E9#PO M9F]N=#X\+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT M('-I>F4],T0Q/B8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B M;W1T;VT^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2 M;VUA;B<@<VEZ93TS1#(^)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG M;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/CQF;VYT('-T>6QE/3-$)T9/3E0M M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R/B@T,#,L,3`X/"]F M;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R M87`^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA M;B<@<VEZ93TS1#(^*28C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX] M,T1B;W1T;VT^/&9O;G0@<VEZ93TS1#$^)B-X03`[/"]F;VYT/CPO=&0^#0H@ M/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=&3TY4+49!34E, M63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXF(WA!,#L\+V9O;G0^/"]T M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^/&9O;G0@ M<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS M1#(^-#`S+#$P.#PO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@ M;F]W<F%P/3-$;F]W<F%P/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4 M:6UE<R!.97<@4F]M86XG('-I>F4],T0R/B8C>$$P.R8C>$$P.SPO9F]N=#X\ M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<VEZ93TS1#$^)B-X M03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S M='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$ M,CXF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L M:6=N/3-$<FEG:'0^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S M($YE=R!2;VUA;B<@<VEZ93TS1#(^-BXQ-#PO9F]N=#X\+W1D/@T*(#QT9"!V M86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P/CQF;VYT('-T>6QE/3-$ M)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R/B8C>$$P M.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O M;G0@<VEZ93TS1#$^)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS M1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\ M=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O M;3X\9F]N="!S:7IE/3-$,3XF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L M:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\+W1R/@T*(#QT<CX- M"B`\=&0@=F%L:6=N/3-$=&]P/@T*(#QP('-T>6QE/3-$)TU!4D=)3BU,1494 M.B`Q96T[(%1%6%0M24Y$14Y4.B`M,65M)SX\9F]N="!S='EL93TS1"=&3TY4 M+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CY/<'1I;VYS#0H@ M9F]R9F5I=&5D+V5X<&ER960\+V9O;G0^/"]P/@T*(#PO=&0^#0H@/'1D('9A M;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF(WA!,#L\+V9O;G0^/"]T M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)T9/3E0M M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R/B8C>$$P.SPO9F]N M=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#X\ M9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S M:7IE/3-$,CXR,3`L.3@Y/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O M='1O;2!N;W=R87`],T1N;W=R87`^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U) M3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^)B-X03`[)B-X03`[/"]F M;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$ M,3XF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF M;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I M>F4],T0R/B8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T M;VT@86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@ M5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXH,C$P+#DX.3PO9F]N=#X\+W1D M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P/CQF;VYT M('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4] M,T0R/BDF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M M/CQF;VYT('-I>F4],T0Q/B8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI M9VX],T1B;W1T;VT^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S M($YE=R!2;VUA;B<@<VEZ93TS1#(^)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D M('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/CQF;VYT('-T>6QE/3-$ M)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R/C$W+C`P M/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N M;W=R87`^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2 M;VUA;B<@<VEZ93TS1#(^)B-X03`[)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D M('9A;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF(WA!,#L\+V9O;G0^ M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG M;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X- M"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C>$$P.SPO M9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\=&0@ M=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\ M+W1D/@T*(#PO='(^#0H@/'1R(&)G8V]L;W(],T0C0T-%149&/@T*(#QT9"!V M86QI9VX],T1T;W`^#0H@/'`@<W1Y;&4],T0G34%21TE.+4Q%1E0Z(#%E;3L@ M5$585"U)3D1%3E0Z("TQ96TG/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9 M.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R/E)E<W1R:6-T960@<W1O8VL@ M=6YI=',-"B!F;W)F96ET960\+V9O;G0^/"]P/@T*(#PO=&0^#0H@/'1D('9A M;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF(WA!,#L\+V9O;G0^/"]T M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)T9/3E0M M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R/B8C>$$P.SPO9F]N M=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#X\ M9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S M:7IE/3-$,CXV."PW,#(\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T M=&]M(&YO=W)A<#TS1&YO=W)A<#X\9F]N="!S='EL93TS1"=&3TY4+49!34E, M63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXF(WA!,#LF(WA!,#L\+V9O M;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q M/B8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W M<F%P/3-$;F]W<F%P/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE M<R!.97<@4F]M86XG('-I>F4],T0R/B8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT M9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P(&%L:6=N/3-$<FEG M:'0^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA M;B<@<VEZ93TS1#(^)B-X,C`Q-#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N M/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#X\9F]N="!S='EL93TS1"=&3TY4 M+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXF(WA!,#LF(WA! M,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I M>F4],T0Q/B8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T M;VT@;F]W<F%P/3-$;F]W<F%P/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9 M.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R/B8C>$$P.SPO9F]N=#X\+W1D M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P(&%L:6=N M/3-$<FEG:'0^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE M=R!2;VUA;B<@<VEZ93TS1#(^)B-X,C`Q-#L\+V9O;G0^/"]T9#X-"B`\=&0@ M=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#X\9F]N="!S='EL93TS M1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXF(WA! M,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF M;VYT('-I>F4],T0Q/B8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX] M,T1B;W1T;VT^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@ M/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T M;VT^/&9O;G0@<VEZ93TS1#$^)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A M;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/"]T<CX-"B`\='(@ M<W1Y;&4],T0G1D].5"U325I%.B`Q<'@G/@T*(#QT9"!V86QI9VX],T1B;W1T M;VT^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@ M/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0 M.B`C,#`P,#`P(#%P>"!S;VQI9"<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D M('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B`C M,#`P,#`P(#%P>"!S;VQI9"<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D/B8C M>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T* M(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@<W1Y;&4],T0G0D]21$52+51/ M4#H@(S`P,#`P,"`Q<'@@<V]L:60G/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT M9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@<W1Y;&4],T0G0D]21$52+51/4#H@ M(S`P,#`P,"`Q<'@@<V]L:60G/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT9#XF M(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X- M"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O M='1O;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\=&0@ M=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O M='1O;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\=&0@ M=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF M(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\=&0@ M=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\ M+W1D/@T*(#PO='(^#0H@/'1R/@T*(#QT9"!V86QI9VX],T1T;W`^#0H@/'`@ M<W1Y;&4],T0G34%21TE.+4Q%1E0Z(#)E;3L@5$585"U)3D1%3E0Z("TQ96TG M/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG M('-I>F4],T0R/D)A;&%N8V4@870-"B!$96-E;6)E<B8C>$$P.S,Q+"`R,#$R M/"]F;VYT/CPO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O M;G0@<VEZ93TS1#$^)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS M1&)O='1O;3X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W M(%)O;6%N)R!S:7IE/3-$,CXF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L M:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^/&9O;G0@<W1Y;&4],T0G1D]. M5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^.#<X+#<R-CPO M9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W M<F%P/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M M86XG('-I>F4],T0R/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V M86QI9VX],T1B;W1T;VT^/&9O;G0@<VEZ93TS1#$^)B-X03`[/"]F;VYT/CPO M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=&3TY4 M+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXF(WA!,#L\+V9O M;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^ M/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@ M<VEZ93TS1#(^,2PW.3`L-3(W/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS M1&)O='1O;2!N;W=R87`],T1N;W=R87`^/&9O;G0@<W1Y;&4],T0G1D].5"U& M04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^)B-X03`[)B-X03`[ M/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE M/3-$,3XF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M M/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG M('-I>F4],T0R/B8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B M;W1T;VT@86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS1"=&3TY4+49!34E, M63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXQ."XY-CPO9F]N=#X\+W1D M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P/CQF;VYT M('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4] M,T0R/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B M;W1T;VT^/&9O;G0@<VEZ93TS1#$^)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D M('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^ M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG M;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF(WA!,#L\+V9O;G0^/"]T9#X- M"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O M='1O;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\+W1R M/@T*(#QT<B!B9V-O;&]R/3-$(T-#145&1CX-"B`\=&0@=F%L:6=N/3-$=&]P M/@T*(#QP('-T>6QE/3-$)TU!4D=)3BU,1494.B`Q96T[(%1%6%0M24Y$14Y4 M.B`M,65M)SX\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W M(%)O;6%N)R!S:7IE/3-$,CY);F-R96%S92!I;B!A=71H;W)I>F5D#0H@<VAA M<F5S/"]F;VYT/CPO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^ M/&9O;G0@<VEZ93TS1#$^)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG M;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@ M3F5W(%)O;6%N)R!S:7IE/3-$,CXF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@ M=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^/&9O;G0@<W1Y;&4],T0G M1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^,BPP,#`L M,#`P/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`] M,T1N;W=R87`^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE M=R!2;VUA;B<@<VEZ93TS1#(^)B-X03`[)B-X03`[/"]F;VYT/CPO=&0^#0H@ M/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF(WA!,#L\+V9O M;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A M<#X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N M)R!S:7IE/3-$,CXF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$ M8F]T=&]M(&YO=W)A<#TS1&YO=W)A<"!A;&EG;CTS1')I9VAT/CQF;VYT('-T M>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R M/B8C>#(P,30[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N M;W=R87`],T1N;W=R87`^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I M;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^)B-X03`[)B-X03`[/"]F;VYT/CPO M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF(WA! M,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS M1&YO=W)A<#X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W M(%)O;6%N)R!S:7IE/3-$,CXF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L M:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<"!A;&EG;CTS1')I9VAT/CQF M;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I M>F4],T0R/B8C>#(P,30[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O M='1O;2!N;W=R87`],T1N;W=R87`^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U) M3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^)B-X03`[)B-X03`[/"]F M;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$ M,3XF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI9VX] M,T1B;W1T;VT^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I M>F4],T0Q/B8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T M;VT^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A M;&EG;CTS1&)O='1O;3X\+W1D/@T*(#PO='(^#0H@/'1R/@T*(#QT9"!V86QI M9VX],T1T;W`^#0H@/'`@<W1Y;&4],T0G34%21TE.+4Q%1E0Z(#%E;3L@5$58 M5"U)3D1%3E0Z("TQ96TG/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4 M:6UE<R!.97<@4F]M86XG('-I>F4],T0R/D]P=&EO;G,@9W)A;G1E9#PO9F]N M=#X\+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I M>F4],T0Q/B8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T M;VT^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA M;B<@<VEZ93TS1#(^)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS M1&)O='1O;2!A;&EG;CTS1')I9VAT/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%- M24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R/B@W.3<L-C(Y/"]F;VYT M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^ M/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@ M<VEZ93TS1#(^*28C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B M;W1T;VT^/&9O;G0@<VEZ93TS1#$^)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D M('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@ M5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXF(WA!,#L\+V9O;G0^/"]T9#X- M"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^/&9O;G0@<W1Y M;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^ M-SDW+#8R.3PO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W M<F%P/3-$;F]W<F%P/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE M<R!.97<@4F]M86XG('-I>F4],T0R/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<VEZ93TS1#$^)B-X03`[ M/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL M93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXF M(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N M/3-$<FEG:'0^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE M=R!2;VUA;B<@<VEZ93TS1#(^-2XY-3PO9F]N=#X\+W1D/@T*(#QT9"!V86QI M9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P/CQF;VYT('-T>6QE/3-$)T9/ M3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R/B8C>$$P.R8C M>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@ M<VEZ93TS1#$^)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O M='1O;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\=&0@ M=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\ M9F]N="!S:7IE/3-$,3XF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N M/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T* M(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\+W1R/@T*(#QT<B!B9V-O M;&]R/3-$(T-#145&1CX-"B`\=&0@=F%L:6=N/3-$=&]P/@T*(#QP('-T>6QE M/3-$)TU!4D=)3BU,1494.B`Q96T[(%1%6%0M24Y$14Y4.B`M,65M)SX\9F]N M="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE M/3-$,CY297-T<FEC=&5D('-T;V-K('5N:71S#0H@9W)A;G1E9#PO9F]N=#X\ M+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4] M,T0Q/B8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^ M/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@ M<VEZ93TS1#(^)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O M='1O;2!A;&EG;CTS1')I9VAT/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9 M.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R/B@T,2PV-C$\+V9O;G0^/"]T M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#X\9F]N M="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE M/3-$,CXI)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O M;3X\9F]N="!S:7IE/3-$,3XF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L M:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#X\9F]N="!S='EL93TS1"=& M3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXF(WA!,#L\ M+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO M=W)A<"!A;&EG;CTS1')I9VAT/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9 M.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R/B8C>#(P,30[/"]F;VYT/CPO M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^/&9O M;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ M93TS1#(^)B-X03`[)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS M1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF(WA!,#L\+V9O;G0^/"]T9#X-"B`\ M=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#X\9F]N="!S='EL M93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXF M(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A M<#TS1&YO=W)A<"!A;&EG;CTS1')I9VAT/CQF;VYT('-T>6QE/3-$)T9/3E0M M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R/B8C>#(P,30[/"]F M;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R M87`^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA M;B<@<VEZ93TS1#(^)B-X03`[)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A M;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF(WA!,#L\+V9O;G0^/"]T M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS M1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\ M=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C>$$P.SPO9F]N M=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\=&0@=F%L M:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D M/@T*(#PO='(^#0H@/'1R/@T*(#QT9"!V86QI9VX],T1T;W`^#0H@/'`@<W1Y M;&4],T0G34%21TE.+4Q%1E0Z(#%E;3L@5$585"U)3D1%3E0Z("TQ96TG/CQF M;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I M>F4],T0R/D]P=&EO;G,-"B!E>&5R8VES960\+V9O;G0^/"]P/@T*(#PO=&0^ M#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF(WA!,#L\ M+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO M=W)A<#X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O M;6%N)R!S:7IE/3-$,CXF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N M/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<"!A;&EG;CTS1')I9VAT/CQF;VYT M('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4] M,T0R/B8C>#(P,30[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O M;2!N;W=R87`],T1N;W=R87`^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ M(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^)B-X03`[)B-X03`[/"]F;VYT M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF M(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT M('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4] M,T0R/B8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@ M86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM M97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXH,C$L,SDW/"]F;VYT/CPO=&0^#0H@ M/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^/&9O;G0@<W1Y M;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^ M*28C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O M;G0@<VEZ93TS1#$^)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS M1&)O='1O;3X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W M(%)O;6%N)R!S:7IE/3-$,CXF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L M:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^/&9O;G0@<W1Y;&4],T0G1D]. M5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^-2XS,CPO9F]N M=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P M/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG M('-I>F4],T0R/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI M9VX],T1B;W1T;VT^/&9O;G0@<VEZ93TS1#$^)B-X03`[/"]F;VYT/CPO=&0^ M#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B M;W1T;VT^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D M('9A;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF(WA!,#L\+V9O;G0^ M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG M;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X- M"B`\+W1R/@T*(#QT<B!B9V-O;&]R/3-$(T-#145&1CX-"B`\=&0@=F%L:6=N M/3-$=&]P/@T*(#QP('-T>6QE/3-$)TU!4D=)3BU,1494.B`Q96T[(%1%6%0M M24Y$14Y4.B`M,65M)SX\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM M97,@3F5W(%)O;6%N)R!S:7IE/3-$,CY/<'1I;VYS#0H@9F]R9F5I=&5D+V5X M<&ER960\+V9O;G0^/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O M;3X\9F]N="!S:7IE/3-$,3XF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L M:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE M<R!.97<@4F]M86XG('-I>F4],T0R/B8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT M9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS M1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXQ,3<L M,SDT/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`] M,T1N;W=R87`^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE M=R!2;VUA;B<@<VEZ93TS1#(^)B-X03`[)B-X03`[/"]F;VYT/CPO=&0^#0H@ M/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF(WA!,#L\+V9O M;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$ M)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R/B8C>$$P M.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R M:6=H=#X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O M;6%N)R!S:7IE/3-$,CXH,3$W+#,Y-#PO9F]N=#X\+W1D/@T*(#QT9"!V86QI M9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P/CQF;VYT('-T>6QE/3-$)T9/ M3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R/BDF(WA!,#L\ M+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4] M,T0Q/B8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^ M/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@ M<VEZ93TS1#(^)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O M='1O;2!A;&EG;CTS1')I9VAT/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9 M.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R/C$R+C4U/"]F;VYT/CPO=&0^ M#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^/&9O;G0@ M<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS M1#(^)B-X03`[)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O M='1O;3X\9F]N="!S:7IE/3-$,3XF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@ M=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\ M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\=&0@=F%L:6=N M/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C>$$P.SPO9F]N=#X\+W1D/@T* M(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T M=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#PO='(^ M#0H@/'1R/@T*(#QT9"!V86QI9VX],T1T;W`^#0H@/'`@<W1Y;&4],T0G34%2 M1TE.+4Q%1E0Z(#%E;3L@5$585"U)3D1%3E0Z("TQ96TG/CQF;VYT('-T>6QE M/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R/E)E M<W1R:6-T960@<W1O8VL@=6YI=',-"B!F;W)F96ET960\+V9O;G0^/"]P/@T* M(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF M(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT M('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4] M,T0R/B8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@ M86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM M97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXT+#DY.3PO9F]N=#X\+W1D/@T*(#QT M9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P/CQF;VYT('-T>6QE M/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R/B8C M>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^ M/&9O;G0@<VEZ93TS1#$^)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG M;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^/&9O;G0@<W1Y;&4],T0G1D]. M5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^)B-X03`[/"]F M;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R M87`@86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@ M5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXF(W@R,#$T.SPO9F]N=#X\+W1D M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P/CQF;VYT M('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4] M,T0R/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B M;W1T;VT^/&9O;G0@<VEZ93TS1#$^)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D M('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^/&9O;G0@<W1Y;&4] M,T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^)B-X M03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`] M,T1N;W=R87`@86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS1"=&3TY4+49! M34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXF(W@R,#$T.SPO9F]N M=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P M/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG M('-I>F4],T0R/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI M9VX],T1B;W1T;VT^/&9O;G0@<VEZ93TS1#$^)B-X03`[/"]F;VYT/CPO=&0^ M#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B M;W1T;VT^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D M('9A;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF(WA!,#L\+V9O;G0^ M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG M;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X- M"B`\+W1R/@T*(#QT<B!S='EL93TS1"=&3TY4+5-)6D4Z(#%P>"<^#0H@/'1D M('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^ M)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE M/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@,7!X('-O;&ED)SXF(WA!,#L\+W`^ M#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$ M)T)/4D1%4BU43U`Z(",P,#`P,#`@,7!X('-O;&ED)SXF(WA!,#L\+W`^#0H@ M/"]T9#X-"B`\=&0^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL M93TS1"="3U)$15(M5$]0.B`C,#`P,#`P(#%P>"!S;VQI9"<^)B-X03`[/"]P M/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS M1"="3U)$15(M5$]0.B`C,#`P,#`P(#%P>"!S;VQI9"<^)B-X03`[/"]P/@T* M(#PO=&0^#0H@/'1D/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O M;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\ M=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O M;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\ M=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O M;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\=&0@=F%L M:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O M;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\=&0@=F%L M:6=N/3-$8F]T=&]M/CPO=&0^#0H@/"]T<CX-"B`\='(@8F=C;VQO<CTS1"-# M0T5%1D8^#0H@/'1D('9A;&EG;CTS1'1O<#X-"B`\<"!S='EL93TS1"=-05)' M24XM3$5&5#H@,F5M.R!415A4+4E.1$5.5#H@+3%E;2<^/&9O;G0@<W1Y;&4] M,T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^0F%L M86YC92!A=`T*($1E8V5M8F5R)B-X03`[,S$L(#(P,3,\+V9O;G0^/"]P/@T* M(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF M(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT M('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4] M,T0R/B8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@ M86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM M97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXR+#$V,2PX,CD\+V9O;G0^/"]T9#X- M"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#X\9F]N="!S M='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$ M,CXF(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T M=&]M/CQF;VYT('-I>F4],T0Q/B8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V M86QI9VX],T1B;W1T;VT^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I M;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^)B-X03`[/"]F;VYT/CPO=&0^#0H@ M/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/CQF;VYT('-T>6QE M/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R/C(L M-#0Y+#,V-3PO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W M<F%P/3-$;F]W<F%P/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE M<R!.97<@4F]M86XG('-I>F4],T0R/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<VEZ93TS1#$^)B-X03`[ M/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL M93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXD M/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I M9VAT/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M M86XG('-I>F4],T0R/C$U+C$U/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS M1&)O='1O;2!N;W=R87`],T1N;W=R87`^/&9O;G0@<W1Y;&4],T0G1D].5"U& M04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^)B-X03`[)B-X03`[ M/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE M/3-$,3XF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI M9VX],T1B;W1T;VT^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT M('-I>F4],T0Q/B8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B M;W1T;VT^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D M('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#PO='(^#0H@/'1R/@T*(#QT9"!V M86QI9VX],T1T;W`^#0H@/'`@<W1Y;&4],T0G34%21TE.+4Q%1E0Z(#%E;3L@ M5$585"U)3D1%3E0Z("TQ96TG/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9 M.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R/D]P=&EO;G,@9W)A;G1E9#PO M9F]N=#X\+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT M('-I>F4],T0Q/B8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B M;W1T;VT^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2 M;VUA;B<@<VEZ93TS1#(^)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG M;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/CQF;VYT('-T>6QE/3-$)T9/3E0M M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R/B@Y-#0L.#,Q/"]F M;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R M87`^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA M;B<@<VEZ93TS1#(^*28C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX] M,T1B;W1T;VT^/&9O;G0@<VEZ93TS1#$^)B-X03`[/"]F;VYT/CPO=&0^#0H@ M/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=&3TY4+49!34E, M63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXF(WA!,#L\+V9O;G0^/"]T M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^/&9O;G0@ M<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS M1#(^.30T+#@S,3PO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@ M;F]W<F%P/3-$;F]W<F%P/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4 M:6UE<R!.97<@4F]M86XG('-I>F4],T0R/B8C>$$P.R8C>$$P.SPO9F]N=#X\ M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<VEZ93TS1#$^)B-X M03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S M='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$ M,CXF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L M:6=N/3-$<FEG:'0^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S M($YE=R!2;VUA;B<@<VEZ93TS1#(^."XX,#PO9F]N=#X\+W1D/@T*(#QT9"!V M86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P/CQF;VYT('-T>6QE/3-$ M)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R/B8C>$$P M.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O M;G0@<VEZ93TS1#$^)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS M1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\ M=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O M;3X\9F]N="!S:7IE/3-$,3XF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L M:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\+W1R/@T*(#QT<B!B M9V-O;&]R/3-$(T-#145&1CX-"B`\=&0@=F%L:6=N/3-$=&]P/@T*(#QP('-T M>6QE/3-$)TU!4D=)3BU,1494.B`Q96T[(%1%6%0M24Y$14Y4.B`M,65M)SX\ M9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S M:7IE/3-$,CY297-T<FEC=&5D('-T;V-K('5N:71S#0H@9W)A;G1E9#PO9F]N M=#X\+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I M>F4],T0Q/B8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T M;VT^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA M;B<@<VEZ93TS1#(^)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS M1&)O='1O;2!A;&EG;CTS1')I9VAT/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%- M24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R/B@T,RPU,#`\+V9O;G0^ M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#X\ M9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S M:7IE/3-$,CXI)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O M='1O;3X\9F]N="!S:7IE/3-$,3XF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@ M=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#X\9F]N="!S='EL93TS M1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXF(WA! M,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS M1&YO=W)A<"!A;&EG;CTS1')I9VAT/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%- M24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R/B8C>#(P,30[/"]F;VYT M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^ M/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@ M<VEZ93TS1#(^)B-X03`[)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG M;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF(WA!,#L\+V9O;G0^/"]T9#X- M"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#X\9F]N="!S M='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$ M,CXF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO M=W)A<#TS1&YO=W)A<"!A;&EG;CTS1')I9VAT/CQF;VYT('-T>6QE/3-$)T9/ M3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R/B8C>#(P,30[ M/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N M;W=R87`^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2 M;VUA;B<@<VEZ93TS1#(^)B-X03`[)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D M('9A;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF(WA!,#L\+V9O;G0^ M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG M;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X- M"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C>$$P.SPO M9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\=&0@ M=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\ M+W1D/@T*(#PO='(^#0H@/'1R/@T*(#QT9"!V86QI9VX],T1T;W`^#0H@/'`@ M<W1Y;&4],T0G34%21TE.+4Q%1E0Z(#%E;3L@5$585"U)3D1%3E0Z("TQ96TG M/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG M('-I>F4],T0R/D]P=&EO;G,-"B!E>&5R8VES960\+V9O;G0^/"]P/@T*(#PO M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF(WA! M,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS M1&YO=W)A<#X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W M(%)O;6%N)R!S:7IE/3-$,CXF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L M:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<"!A;&EG;CTS1')I9VAT/CQF M;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I M>F4],T0R/B8C>#(P,30[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O M='1O;2!N;W=R87`],T1N;W=R87`^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U) M3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^)B-X03`[)B-X03`[/"]F M;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$ M,3XF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF M;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I M>F4],T0R/B8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T M;VT@86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@ M5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXH,SDP/"]F;VYT/CPO=&0^#0H@ M/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^/&9O;G0@<W1Y M;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^ M*28C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O M;G0@<VEZ93TS1#$^)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS M1&)O='1O;3X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W M(%)O;6%N)R!S:7IE/3-$,CXF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L M:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^/&9O;G0@<W1Y;&4],T0G1D]. M5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^-BXP,#PO9F]N M=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P M/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG M('-I>F4],T0R/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI M9VX],T1B;W1T;VT^/&9O;G0@<VEZ93TS1#$^)B-X03`[/"]F;VYT/CPO=&0^ M#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B M;W1T;VT^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D M('9A;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF(WA!,#L\+V9O;G0^ M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG M;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X- M"B`\+W1R/@T*(#QT<B!B9V-O;&]R/3-$(T-#145&1CX-"B`\=&0@=F%L:6=N M/3-$=&]P/@T*(#QP('-T>6QE/3-$)TU!4D=)3BU,1494.B`Q96T[(%1%6%0M M24Y$14Y4.B`M,65M)SX\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM M97,@3F5W(%)O;6%N)R!S:7IE/3-$,CY/<'1I;VYS#0H@9F]R9F5I=&5D+V5X M<&ER960\+V9O;G0^/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O M;3X\9F]N="!S:7IE/3-$,3XF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L M:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE M<R!.97<@4F]M86XG('-I>F4],T0R/B8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT M9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS M1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXY-2PY M.#`\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS M1&YO=W)A<#X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W M(%)O;6%N)R!S:7IE/3-$,CXF(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\ M=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C>$$P.SPO9F]N M=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<W1Y;&4],T0G M1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^)B-X03`[ M/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I M9VAT/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M M86XG('-I>F4],T0R/B@Y-2PY.#`\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N M/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#X\9F]N="!S='EL93TS1"=&3TY4 M+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXI)B-X03`[/"]F M;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$ M,3XF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF M;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I M>F4],T0R/B8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T M;VT@86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@ M5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXS.2XW-#PO9F]N=#X\+W1D/@T* M(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P/CQF;VYT('-T M>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R M/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T M;VT^/&9O;G0@<VEZ93TS1#$^)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A M;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS M1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF(WA!,#L\+V9O;G0^/"]T9#X-"B`\ M=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O M;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\+W1R/@T* M(#QT<CX-"B`\=&0@=F%L:6=N/3-$=&]P/@T*(#QP('-T>6QE/3-$)TU!4D=) M3BU,1494.B`Q96T[(%1%6%0M24Y$14Y4.B`M,65M)SX\9F]N="!S='EL93TS M1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CY297-T M<FEC=&5D('-T;V-K('5N:71S#0H@9F]R9F5I=&5D/"]F;VYT/CPO<#X-"B`\ M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<VEZ93TS1#$^)B-X M03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S M='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$ M,CXF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L M:6=N/3-$<FEG:'0^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S M($YE=R!2;VUA;B<@<VEZ93TS1#(^,2PP,#`\+V9O;G0^/"]T9#X-"B`\=&0@ M=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#X\9F]N="!S='EL93TS M1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXF(WA! M,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF M;VYT('-I>F4],T0Q/B8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX] M,T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P/CQF;VYT('-T>6QE/3-$)T9/3E0M M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R/B8C>$$P.SPO9F]N M=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P M(&%L:6=N/3-$<FEG:'0^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I M;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^)B-X,C`Q-#L\+V9O;G0^/"]T9#X- M"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#X\9F]N="!S M='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$ M,CXF(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T M=&]M/CQF;VYT('-I>F4],T0Q/B8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V M86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P/CQF;VYT('-T>6QE/3-$ M)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R/B8C>$$P M.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$ M;F]W<F%P(&%L:6=N/3-$<FEG:'0^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U) M3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^)B-X,C`Q-#L\+V9O;G0^ M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#X\ M9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S M:7IE/3-$,CXF(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N M/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C>$$P.SPO9F]N=#X\+W1D/@T* M(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T M=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V M86QI9VX],T1B;W1T;VT^/&9O;G0@<VEZ93TS1#$^)B-X03`[/"]F;VYT/CPO M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI9VX] M,T1B;W1T;VT^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@ M/"]T<CX-"B`\='(@<W1Y;&4],T0G1D].5"U325I%.B`Q<'@G/@T*(#QT9"!V M86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C M>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS M1"="3U)$15(M5$]0.B`C,#`P,#`P(#%P>"!S;VQI9"<^)B-X03`[/"]P/@T* M(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"=" M3U)$15(M5$]0.B`C,#`P,#`P(#%P>"!S;VQI9"<^)B-X03`[/"]P/@T*(#PO M=&0^#0H@/'1D/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF M(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@<W1Y;&4] M,T0G0D]21$52+51/4#H@(S`P,#`P,"`Q<'@@<V]L:60G/B8C>$$P.SPO<#X- M"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@<W1Y;&4],T0G M0D]21$52+51/4#H@(S`P,#`P,"`Q<'@@<V]L:60G/B8C>$$P.SPO<#X-"B`\ M+W1D/@T*(#QT9#XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^ M)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D M('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^ M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D M('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^ M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG M;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^ M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG M;CTS1&)O='1O;3X\+W1D/@T*(#PO='(^#0H@/'1R(&)G8V]L;W(],T0C0T-% M149&/@T*(#QT9"!V86QI9VX],T1T;W`^#0H@/'`@<W1Y;&4],T0G34%21TE. M+4Q%1E0Z(#)E;3L@5$585"U)3D1%3E0Z("TQ96TG/CQF;VYT('-T>6QE/3-$ M)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R/D)A;&%N M8V4@870-"B!$96-E;6)E<B8C>$$P.S,Q+"`R,#$T/"]F;VYT/CPO<#X-"B`\ M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<VEZ93TS1#$^)B-X M03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S M='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$ M,CXF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L M:6=N/3-$<FEG:'0^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S M($YE=R!2;VUA;B<@<VEZ93TS1#(^,2PR-S`L-#<X/"]F;VYT/CPO=&0^#0H@ M/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^/&9O;G0@<W1Y M;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^ M)B-X03`[)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O M;3X\9F]N="!S:7IE/3-$,3XF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L M:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE M<R!.97<@4F]M86XG('-I>F4],T0R/B8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT M9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS M1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXS+#(Y M-RPX,C8\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A M<#TS1&YO=W)A<#X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@ M3F5W(%)O;6%N)R!S:7IE/3-$,CXF(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X- M"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C>$$P.SPO M9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<W1Y;&4] M,T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^)#PO M9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H M=#X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N M)R!S:7IE/3-$,CXQ,BXV,CPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B M;W1T;VT@;F]W<F%P/3-$;F]W<F%P/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%- M24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R/B8C>$$P.R8C>$$P.SPO M9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<VEZ93TS M1#$^)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\ M9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S M:7IE/3-$,CXF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T M=&]M(&%L:6=N/3-$<FEG:'0^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ M(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^-BXW.3PO9F]N=#X\+W1D/@T* M(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P/CQF;VYT('-T M>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R M/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T M;VT^/&9O;G0@<VEZ93TS1#$^)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A M;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM M97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXD/"]F;VYT/CPO=&0^#0H@/'1D('9A M;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/CQF;VYT('-T>6QE/3-$)T9/ M3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R/C(L-C4W/"]F M;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R M87`^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA M;B<@<VEZ93TS1#(^)B-X03`[)B-X03`[/"]F;VYT/CPO=&0^#0H@/"]T<CX- M"B`\='(@<W1Y;&4],T0G1D].5"U325I%.B`Q<'@G/@T*(#QT9"!V86QI9VX] M,T1B;W1T;VT^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$ M15(M5$]0.B`C,#`P,#`P(#-P>"!D;W5B;&4G/B8C>$$P.SPO<#X-"B`\+W1D M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@<W1Y;&4],T0G0D]21$52 M+51/4#H@(S`P,#`P,"`S<'@@9&]U8FQE)SXF(WA!,#L\+W`^#0H@/"]T9#X- M"B`\=&0^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P M.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"=" M3U)$15(M5$]0.B`C,#`P,#`P(#-P>"!D;W5B;&4G/B8C>$$P.SPO<#X-"B`\ M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@<W1Y;&4],T0G0D]2 M1$52+51/4#H@(S`P,#`P,"`S<'@@9&]U8FQE)SXF(WA!,#L\+W`^#0H@/"]T M9#X-"B`\=&0^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C M>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V M86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V M86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI9VX] M,T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI9VX] M,T1B;W1T;VT^/"]T9#X-"B`\+W1R/@T*(#QT<CX-"B`\=&0@=F%L:6=N/3-$ M=&]P/@T*(#QP('-T>6QE/3-$)TU!4D=)3BU,1494.B`R96T[(%1%6%0M24Y$ M14Y4.B`M,65M)SX\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@ M3F5W(%)O;6%N)R!S:7IE/3-$,CY%>&5R8VES86)L92!A=`T*($1E8V5M8F5R M)B-X03`[,S$L(#(P,30\+V9O;G0^/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG M;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF(WA!,#L\+V9O;G0^/"]T9#X- M"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O M='1O;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\=&0@ M=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C>$$P.SPO9F]N=#X\ M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<W1Y;&4],T0G1D]. M5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^)B-X03`[/"]F M;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT M/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG M('-I>F4],T0R/C(L,30P+#<U-#PO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX] M,T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P/CQF;VYT('-T>6QE/3-$)T9/3E0M M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R/B8C>$$P.R8C>$$P M.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<VEZ M93TS1#$^)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O M;3X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N M)R!S:7IE/3-$,CXD/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O M;2!A;&EG;CTS1')I9VAT/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4 M:6UE<R!.97<@4F]M86XG('-I>F4],T0R/C$U+C$W/"]F;VYT/CPO=&0^#0H@ M/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^/&9O;G0@<W1Y M;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^ M)B-X03`[)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O M;3X\9F]N="!S:7IE/3-$,3XF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L M:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE M<R!.97<@4F]M86XG('-I>F4],T0R/B8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT M9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS M1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXU+C<V M/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N M;W=R87`^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2 M;VUA;B<@<VEZ93TS1#(^)B-X03`[)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D M('9A;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF(WA!,#L\+V9O;G0^ M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)T9/ M3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R/B0\+V9O;G0^ M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^/&9O M;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ M93TS1#(^,2PU-3,\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M M(&YO=W)A<#TS1&YO=W)A<#X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@ M5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXF(WA!,#LF(WA!,#L\+V9O;G0^ M/"]T9#X-"B`\+W1R/@T*(#QT<B!B9V-O;&]R/3-$(T-#145&1CX-"B`\=&0@ M=F%L:6=N/3-$=&]P/@T*(#QP('-T>6QE/3-$)TU!4D=)3BU,1494.B`R96T[ M(%1%6%0M24Y$14Y4.B`M,65M)SX\9F]N="!S='EL93TS1"=&3TY4+49!34E, M63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CY697-T960@86YD(&5X<&5C M=&5D('1O('9E<W0-"B!A<R!O9B!$96-E;6)E<B8C>$$P.S,Q+"`R,#$T/"]F M;VYT/CPO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@ M<VEZ93TS1#$^)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O M='1O;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\=&0@ M=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\ M9F]N="!S:7IE/3-$,3XF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N M/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!. M97<@4F]M86XG('-I>F4],T0R/B8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V M86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS1"=& M3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXS+#(W-RPT M.#D\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS M1&YO=W)A<#X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W M(%)O;6%N)R!S:7IE/3-$,CXF(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`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`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N M="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE M/3-$,CXF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M M(&%L:6=N/3-$<FEG:'0^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I M;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^-BXW.#PO9F]N=#X\+W1D/@T*(#QT M9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P/CQF;VYT('-T>6QE M/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R/B8C M>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^ M/&9O;G0@<VEZ93TS1#$^)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG M;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@ M3F5W(%)O;6%N)R!S:7IE/3-$,CXD/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG M;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/CQF;VYT('-T>6QE/3-$)T9/3E0M M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R/C(L-C0R/"]F;VYT M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^ M/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@ M<VEZ93TS1#(^)B-X03`[)B-X03`[/"]F;VYT/CPO=&0^#0H@/"]T<CX-"B`\ M+W1A8FQE/@T*(#PO9&EV/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T M<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,] M,T1P;"!V86QI9VX],T1T;W`^4W5M;6%R>2!O9B!297-T<FEC=&5D(%-T;V-K M(%5N:70@06-T:79I='D\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT M/CQD:78^#0H@/'`@<W1Y;&4],T0G34%21TE.+4)/5%1/33H@,'!X.R!-05)' M24XM5$]0.B`P<'@[(%1%6%0M24Y$14Y4.B`T)2<@86QI9VX],T1J=7-T:69Y M/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG M('-I>F4],T0R/E)E<W1R:6-T960@<W1O8VL@=6YI="!A8W1I=FET>2!W87,@ M87,@9F]L;&]W<SH\+V9O;G0^/"]P/@T*(#QP('-T>6QE/3-$)TU!4D=)3BU" M3U143TTZ(#!P>#L@1D].5"U325I%.B`Q,G!X.R!-05)'24XM5$]0.B`P<'@G M/@T*("8C>$$P.SPO<#X-"B`\=&%B;&4@<W1Y;&4],T0G0D]21$52+4-/3$Q! M4%-%.B!C;VQL87!S92<@8V5L;'-P86-I;F<],T0P(&-E;&QP861D:6YG/3-$ M,"!W:61T:#TS1#DR)2!A;&EG;CTS1&-E;G1E<B!B;W)D97(],T0P/@T*(#QT M<CX-"B`\=&0@=VED=&@],T0W,R4^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T M=&]M('=I9'1H/3-$."4^/"]T9#X-"B`\=&0^/"]T9#X-"B`\=&0^/"]T9#X- M"B`\=&0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$-R4^ M/"]T9#X-"B`\=&0^/"]T9#X-"B`\=&0^/"]T9#X-"B`\=&0^/"]T9#X-"B`\ M+W1R/@T*(#QT<CX-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4] M,T0Q/B8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^ M/&9O;G0@<VEZ93TS1#$^)B-X03`[)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D M('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,7!X('-O;&ED)R!V M86QI9VX],T1B;W1T;VT@8V]L<W!A;CTS1#(@86QI9VX],T1C96YT97(^/&9O M;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ M93TS1#$^/&(^3G5M8F5R)B-X03`[;V8\8G(@+SX-"B!3:&%R97,\+V(^/"]F M;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$ M,3XF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF M;VYT('-I>F4],T0Q/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!S M='EL93TS1"="3U)$15(M0D]45$]-.B`C,#`P,#`P(#%P>"!S;VQI9"<@=F%L M:6=N/3-$8F]T=&]M(&-O;'-P86X],T0R(&%L:6=N/3-$8V5N=&5R/CQF;VYT M('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4] M,T0Q/CQB/E=E:6=H=&5D/&)R("\^#0H@079E<F%G928C>$$P.T%W87)D/&)R M("\^#0H@1&%T928C>$$P.T9A:7(F(WA!,#M686QU93QB<B`O/@T*('!E<B8C M>$$P.U-H87)E/"]B/CPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T M;VT^/&9O;G0@<VEZ93TS1#$^)B-X03`[/"]F;VYT/CPO=&0^#0H@/"]T<CX- M"B`\='(@8F=C;VQO<CTS1"-#0T5%1D8^#0H@/'1D('9A;&EG;CTS1'1O<#X- M"B`\<"!S='EL93TS1"=-05)'24XM3$5&5#H@,65M.R!415A4+4E.1$5.5#H@ M+3%E;2<^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2 M;VUA;B<@<VEZ93TS1#(^4F5S=')I8W1E9"!S=&]C:R!U;FET<PT*(&]U='-T M86YD:6YG(&%T($1E8V5M8F5R)B-X03`[,S$L(#(P,3$\+V9O;G0^/"]P/@T* M(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF M(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M M/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG M('-I>F4],T0R/B8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B M;W1T;VT@86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS1"=&3TY4+49!34E, M63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXU,3<L-3,U/"]F;VYT/CPO M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^/&9O M;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ M93TS1#(^)B-X03`[)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS M1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF(WA!,#LF(WA!,#L\+V9O;G0^/"]T M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)T9/3E0M M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R/B0\+V9O;G0^/"]T M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^/&9O;G0@ M<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS M1#(^-BXW.#PO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W M<F%P/3-$;F]W<F%P/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE M<R!.97<@4F]M86XG('-I>F4],T0R/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D M/@T*(#PO='(^#0H@/'1R/@T*(#QT9"!V86QI9VX],T1T;W`^#0H@/'`@<W1Y M;&4],T0G34%21TE.+4Q%1E0Z(#)E;3L@5$585"U)3D1%3E0Z("TQ96TG/CQF M;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I M>F4],T0R/E)E<W1R:6-T960@<W1O8VL@=6YI=',-"B!V97-T960\+V9O;G0^ M/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE M/3-$,3XF(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$ M8F]T=&]M/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@ M4F]M86XG('-I>F4],T0R/B8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI M9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS1"=&3TY4 M+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXH,C,Q+#DS-3PO M9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W M<F%P/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M M86XG('-I>F4],T0R/BDF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N M/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C>$$P.R8C>$$P.SPO9F]N=#X\ M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<W1Y;&4],T0G1D]. M5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^)B-X03`[/"]F M;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT M/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG M('-I>F4],T0R/C8N-S@\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T M=&]M(&YO=W)A<#TS1&YO=W)A<#X\9F]N="!S='EL93TS1"=&3TY4+49!34E, M63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXF(WA!,#LF(WA!,#L\+V9O M;G0^/"]T9#X-"B`\+W1R/@T*(#QT<B!B9V-O;&]R/3-$(T-#145&1CX-"B`\ M=&0@=F%L:6=N/3-$=&]P/@T*(#QP('-T>6QE/3-$)TU!4D=)3BU,1494.B`R M96T[(%1%6%0M24Y$14Y4.B`M,65M)SX\9F]N="!S='EL93TS1"=&3TY4+49! M34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CY297-T<FEC=&5D('-T M;V-K('5N:71S#0H@9F]R9F5I=&5D/"]F;VYT/CPO<#X-"B`\+W1D/@T*(#QT M9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<VEZ93TS1#$^)B-X03`[)B-X03`[ M/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL M93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXF M(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N M/3-$<FEG:'0^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE M=R!2;VUA;B<@<VEZ93TS1#(^*#8X+#<P,CPO9F]N=#X\+W1D/@T*(#QT9"!V M86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P/CQF;VYT('-T>6QE/3-$ M)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R/BDF(WA! M,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I M>F4],T0Q/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX] M,T1B;W1T;VT^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE M=R!2;VUA;B<@<VEZ93TS1#(^)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A M;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/CQF;VYT('-T>6QE/3-$)T9/ M3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R/C8N-S@\+V9O M;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A M<#X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N M)R!S:7IE/3-$,CXF(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\+W1R/@T* M(#QT<B!S='EL93TS1"=&3TY4+5-)6D4Z(#%P>"<^#0H@/'1D('9A;&EG;CTS M1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X M03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$ M)T)/4D1%4BU43U`Z(",P,#`P,#`@,7!X('-O;&ED)SXF(WA!,#L\+W`^#0H@ M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/ M4D1%4BU43U`Z(",P,#`P,#`@,7!X('-O;&ED)SXF(WA!,#L\+W`^#0H@/"]T M9#X-"B`\=&0^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C M>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T* M(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T M=&]M/CPO=&0^#0H@/"]T<CX-"B`\='(^#0H@/'1D('9A;&EG;CTS1'1O<#X- M"B`\<"!S='EL93TS1"=-05)'24XM3$5&5#H@,65M.R!415A4+4E.1$5.5#H@ M+3%E;2<^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2 M;VUA;B<@<VEZ93TS1#(^4F5S=')I8W1E9"!S=&]C:R!U;FET<PT*(&]U='-T M86YD:6YG(&%T($1E8V5M8F5R)B-X03`[,S$L(#(P,3(\+V9O;G0^/"]P/@T* M(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF M(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M M/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG M('-I>F4],T0R/B8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B M;W1T;VT@86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS1"=&3TY4+49!34E, M63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXR,38L.#DX/"]F;VYT/CPO M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^/&9O M;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ M93TS1#(^)B-X03`[)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS M1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF(WA!,#LF(WA!,#L\+V9O;G0^/"]T M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)T9/3E0M M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R/B8C>$$P.SPO9F]N M=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#X\ M9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S M:7IE/3-$,CXV+C<X/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O M;2!N;W=R87`],T1N;W=R87`^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ M(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^)B-X03`[)B-X03`[/"]F;VYT M/CPO=&0^#0H@/"]T<CX-"B`\='(@8F=C;VQO<CTS1"-#0T5%1D8^#0H@/'1D M('9A;&EG;CTS1'1O<#X-"B`\<"!S='EL93TS1"=-05)'24XM3$5&5#H@,F5M M.R!415A4+4E.1$5.5#H@+3%E;2<^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U) M3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^4F5S=')I8W1E9"!S=&]C M:R!U;FET<PT*(&=R86YT960\+V9O;G0^/"]P/@T*(#PO=&0^#0H@/'1D('9A M;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF(WA!,#LF(WA!,#L\+V9O M;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$ M)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R/B8C>$$P M.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R M:6=H=#X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O M;6%N)R!S:7IE/3-$,CXT,2PV-C$\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N M/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#X\9F]N="!S='EL93TS1"=&3TY4 M+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXF(WA!,#LF(WA! M,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I M>F4],T0Q/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX] M,T1B;W1T;VT^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE M=R!2;VUA;B<@<VEZ93TS1#(^)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A M;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/CQF;VYT('-T>6QE/3-$)T9/ M3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R/C8N,#`\+V9O M;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A M<#X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N M)R!S:7IE/3-$,CXF(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\+W1R/@T* M(#QT<CX-"B`\=&0@=F%L:6=N/3-$=&]P/@T*(#QP('-T>6QE/3-$)TU!4D=) M3BU,1494.B`R96T[(%1%6%0M24Y$14Y4.B`M,65M)SX\9F]N="!S='EL93TS M1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CY297-T M<FEC=&5D('-T;V-K('5N:71S#0H@=F5S=&5D/"]F;VYT/CPO<#X-"B`\+W1D M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<VEZ93TS1#$^)B-X03`[ M)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N M="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE M/3-$,CXF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M M(&%L:6=N/3-$<FEG:'0^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I M;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^*#(Q,2PX.3<\+V9O;G0^/"]T9#X- M"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#X\9F]N="!S M='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$ M,CXI)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\ M9F]N="!S:7IE/3-$,3XF(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@ M=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4 M:6UE<R!.97<@4F]M86XG('-I>F4],T0R/B8C>$$P.SPO9F]N=#X\+W1D/@T* M(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#X\9F]N="!S='EL M93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXV M+C<X/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`] M,T1N;W=R87`^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE M=R!2;VUA;B<@<VEZ93TS1#(^)B-X03`[)B-X03`[/"]F;VYT/CPO=&0^#0H@ M/"]T<CX-"B`\='(@8F=C;VQO<CTS1"-#0T5%1D8^#0H@/'1D('9A;&EG;CTS M1'1O<#X-"B`\<"!S='EL93TS1"=-05)'24XM3$5&5#H@,F5M.R!415A4+4E. M1$5.5#H@+3%E;2<^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S M($YE=R!2;VUA;B<@<VEZ93TS1#(^4F5S=')I8W1E9"!S=&]C:R!U;FET<PT* M(&9O<F9E:71E9#PO9F]N=#X\+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$ M8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<W1Y;&4],T0G1D].5"U& M04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^)B-X03`[/"]F;VYT M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/CQF M;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I M>F4],T0R/B@T+#DY.3PO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T M;VT@;F]W<F%P/3-$;F]W<F%P/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9 M.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R/BDF(WA!,#L\+V9O;G0^/"]T M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C>$$P M.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O M;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ M93TS1#(^)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O M;2!A;&EG;CTS1')I9VAT/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4 M:6UE<R!.97<@4F]M86XG('-I>F4],T0R/C8N-S@\+V9O;G0^/"]T9#X-"B`\ M=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#X\9F]N="!S='EL M93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXF M(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\+W1R/@T*(#QT<B!S='EL93TS M1"=&3TY4+5-)6D4Z(#%P>"<^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\ M=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z M(",P,#`P,#`@,7!X('-O;&ED)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0@ M=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(",P M,#`P,#`@,7!X('-O;&ED)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0^)B-X M03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI9VX] M,T1B;W1T;VT^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@ M/"]T<CX-"B`\='(^#0H@/'1D('9A;&EG;CTS1'1O<#X-"B`\<"!S='EL93TS M1"=-05)'24XM3$5&5#H@,65M.R!415A4+4E.1$5.5#H@+3%E;2<^/&9O;G0@ M<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS M1#(^56YV97-T960@<F5S=')I8W1E9"!S=&]C:PT*('5N:71S(&]U='-T86YD M:6YG(&%T($1E8V5M8F5R)B-X03`[,S$L(#(P,3,\+V9O;G0^/"]P/@T*(#PO M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF(WA! M,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF M;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I M>F4],T0R/B8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T M;VT@86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@ M5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXT,2PV-C,\+V9O;G0^/"]T9#X- M"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#X\9F]N="!S M='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$ M,CXF(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T M=&]M/CQF;VYT('-I>F4],T0Q/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T* M(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U) M3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^)B-X03`[/"]F;VYT/CPO M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/CQF;VYT M('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4] M,T0R/C8N,#`\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO M=W)A<#TS1&YO=W)A<#X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM M97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXF(WA!,#LF(WA!,#L\+V9O;G0^/"]T M9#X-"B`\+W1R/@T*(#QT<B!B9V-O;&]R/3-$(T-#145&1CX-"B`\=&0@=F%L M:6=N/3-$=&]P/@T*(#QP('-T>6QE/3-$)TU!4D=)3BU,1494.B`R96T[(%1% M6%0M24Y$14Y4.B`M,65M)SX\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@ M5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CY297-T<FEC=&5D('-T;V-K('5N M:71S#0H@9W)A;G1E9#PO9F]N=#X\+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N M/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C>$$P.R8C>$$P.SPO9F]N=#X\ M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<W1Y;&4],T0G1D]. M5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^)B-X03`[/"]F M;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT M/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG M('-I>F4],T0R/C0S+#4P,#PO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B M;W1T;VT@;F]W<F%P/3-$;F]W<F%P/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%- M24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R/B8C>$$P.R8C>$$P.SPO M9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<VEZ93TS M1#$^)B-X03`[)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O M='1O;3X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O M;6%N)R!S:7IE/3-$,CXF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N M/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^/&9O;G0@<W1Y;&4],T0G1D].5"U& M04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^.2XV-3PO9F]N=#X\ M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P/CQF M;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I M>F4],T0R/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#PO='(^#0H@/'1R M/@T*(#QT9"!V86QI9VX],T1T;W`^#0H@/'`@<W1Y;&4],T0G34%21TE.+4Q% M1E0Z(#)E;3L@5$585"U)3D1%3E0Z("TQ96TG/CQF;VYT('-T>6QE/3-$)T9/ M3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R/E)E<W1R:6-T M960@<W1O8VL@=6YI=',-"B!V97-T960\+V9O;G0^/"]P/@T*(#PO=&0^#0H@ M/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF(WA!,#LF(WA! M,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T M>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R M/B8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI M9VX],T1R:6=H=#X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@ M3F5W(%)O;6%N)R!S:7IE/3-$,CXH,C`L.#,S/"]F;VYT/CPO=&0^#0H@/'1D M('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^/&9O;G0@<W1Y;&4] M,T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^*28C M>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@ M<VEZ93TS1#$^)B-X03`[)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG M;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@ M3F5W(%)O;6%N)R!S:7IE/3-$,CXF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@ M=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^/&9O;G0@<W1Y;&4],T0G M1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^-BXP,#PO M9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W M<F%P/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M M86XG('-I>F4],T0R/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#PO='(^ M#0H@/'1R(&)G8V]L;W(],T0C0T-%149&/@T*(#QT9"!V86QI9VX],T1T;W`^ M#0H@/'`@<W1Y;&4],T0G34%21TE.+4Q%1E0Z(#)E;3L@5$585"U)3D1%3E0Z M("TQ96TG/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@ M4F]M86XG('-I>F4],T0R/E)E<W1R:6-T960@<W1O8VL@=6YI=',-"B!F;W)F M96ET960\+V9O;G0^/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O M;3X\9F]N="!S:7IE/3-$,3XF(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\ M=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9 M.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R/B8C>$$P.SPO9F]N=#X\+W1D M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#X\9F]N="!S M='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$ M,CXH,2PP,#`\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO M=W)A<#TS1&YO=W)A<#X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM M97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXI)B-X03`[/"]F;VYT/CPO=&0^#0H@ M/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF(WA!,#LF(WA! M,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T M>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R M/B8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI M9VX],T1R:6=H=#X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@ M3F5W(%)O;6%N)R!S:7IE/3-$,CXV+C`P/"]F;VYT/CPO=&0^#0H@/'1D('9A M;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^/&9O;G0@<W1Y;&4],T0G M1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^)B-X03`[ M)B-X03`[/"]F;VYT/CPO=&0^#0H@/"]T<CX-"B`\='(@<W1Y;&4],T0G1D]. M5"U325I%.B`Q<'@G/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\ M=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A M;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B`C,#`P M,#`P(#%P>"!S;VQI9"<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG M;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B`C,#`P,#`P M(#%P>"!S;VQI9"<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D/B8C>$$P.SPO M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T* M(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T M=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#PO='(^ M#0H@/'1R/@T*(#QT9"!V86QI9VX],T1T;W`^#0H@/'`@<W1Y;&4],T0G34%2 M1TE.+4Q%1E0Z(#%E;3L@5$585"U)3D1%3E0Z("TQ96TG/CQF;VYT('-T>6QE M/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R/E5N M=F5S=&5D(')E<W1R:6-T960@<W1O8VL-"B!U;FET<R!O=71S=&%N9&EN9R!A M="!$96-E;6)E<B8C>$$P.S,Q+"`R,#$T/"]F;VYT/CPO<#X-"B`\+W1D/@T* M(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<VEZ93TS1#$^)B-X03`[)B-X M03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S M='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$ M,CXF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L M:6=N/3-$<FEG:'0^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S M($YE=R!2;VUA;B<@<VEZ93TS1#(^-C,L,S,P/"]F;VYT/CPO=&0^#0H@/'1D M('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^/&9O;G0@<W1Y;&4] M,T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^)B-X M03`[)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\ M9F]N="!S:7IE/3-$,3XF(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@ M=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4 M:6UE<R!.97<@4F]M86XG('-I>F4],T0R/B0\+V9O;G0^/"]T9#X-"B`\=&0@ M=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^/&9O;G0@<W1Y;&4],T0G M1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^."XU,3PO M9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W M<F%P/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M M86XG('-I>F4],T0R/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#PO='(^ M#0H@/'1R('-T>6QE/3-$)T9/3E0M4TE:13H@,7!X)SX-"B`\=&0@=F%L:6=N M/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF M(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@<W1Y;&4] M,T0G0D]21$52+51/4#H@(S`P,#`P,"`S<'@@9&]U8FQE)SXF(WA!,#L\+W`^ M#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$ M)T)/4D1%4BU43U`Z(",P,#`P,#`@,W!X(&1O=6)L92<^)B-X03`[/"]P/@T* M(#PO=&0^#0H@/'1D/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O M;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS M1&)O='1O;3X\+W1D/@T*(#PO='(^#0H@/"]T86)L93X-"B`\+V1I=CX\<W!A M;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,] M,T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E-T M;V-K+4)A<V5D($-O;7!E;G-A=&EO;B!296QA=&5D('1O(%-T;V-K($]P=&EO M;G,L(%)E<W1R:6-T960@4W1O8VL@07=A<F1S+"!297-T<FEC=&5D(%-T;V-K M(%5N:70L(&%N9"!%;7!L;WEE92!3=&]C:R!0=7)C:&%S97,\+W1D/@T*("`@ M("`@("`\=&0@8VQA<W,],T1T97AT/CQD:78^#0H@/'`@<W1Y;&4],T0G34%2 M1TE.+4)/5%1/33H@,'!X.R!-05)'24XM5$]0.B`Q,G!X.R!415A4+4E.1$5. M5#H@-"4G(&%L:6=N/3-$:G5S=&EF>3X\9F]N="!S='EL93TS1"=&3TY4+49! M34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CY4:&4@9F]L;&]W:6YG M('1A8FQE('-U;6UA<FEZ97,@<W1O8VLM8F%S960@8V]M<&5N<V%T:6]N(')E M;&%T960-"B!T;R!S=&]C:R!O<'1I;VYS+"!R97-T<FEC=&5D('-T;V-K(&%W M87)D<RP@<F5S=')I8W1E9"!S=&]C:R!U;FET+`T*(&%N9"!E;7!L;WEE92!S M=&]C:R!P=7)C:&%S97,@*&EN('1H;W5S86YD<RDZ/"]F;VYT/CPO<#X-"B`\ M<"!S='EL93TS1"=-05)'24XM0D]45$]-.B`P<'@[($9/3E0M4TE:13H@,3)P M>#L@34%21TE.+51/4#H@,'!X)SX-"B`F(WA!,#L\+W`^#0H@/'1A8FQE('-T M>6QE/3-$)T)/4D1%4BU#3TQ,05!313H@8V]L;&%P<V4G(&-E;&QS<&%C:6YG M/3-$,"!C96QL<&%D9&EN9STS1#`@=VED=&@],T0Y,B4@86QI9VX],T1C96YT M97(@8F]R9&5R/3-$,#X-"B`\='(^#0H@/'1D('=I9'1H/3-$-S,E/CPO=&0^ M#0H@/'1D('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#0E/CPO=&0^#0H@/'1D M/CPO=&0^#0H@/'1D/CPO=&0^#0H@/'1D/CPO=&0^#0H@/'1D('9A;&EG;CTS M1&)O='1O;2!W:61T:#TS1#0E/CPO=&0^#0H@/'1D/CPO=&0^#0H@/'1D/CPO M=&0^#0H@/'1D/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!W:61T:#TS M1#0E/CPO=&0^#0H@/'1D/CPO=&0^#0H@/'1D/CPO=&0^#0H@/'1D/CPO=&0^ M#0H@/"]T<CX-"B`\='(^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S M:7IE/3-$,3XF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T M=&]M/CQF;VYT('-I>F4],T0Q/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T* M(#QT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B`C,#`P,#`P(#%P>"!S;VQI M9"<@=F%L:6=N/3-$8F]T=&]M(&-O;'-P86X],T0Q,"!A;&EG;CTS1&-E;G1E M<CX\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N M)R!S:7IE/3-$,3X\8CY996%R<R!%;F1E9`T*($1E8V5M8F5R)B-X03`[,S$L M/"]B/CPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@ M<VEZ93TS1#$^)B-X03`[/"]F;VYT/CPO=&0^#0H@/"]T<CX-"B`\='(^#0H@ M/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF(WA!,#L\+V9O M;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q M/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!S='EL93TS1"="3U)$ M15(M0D]45$]-.B`C,#`P,#`P(#%P>"!S;VQI9"<@=F%L:6=N/3-$8F]T=&]M M(&-O;'-P86X],T0R(&%L:6=N/3-$8V5N=&5R/CQF;VYT('-T>6QE/3-$)T9/ M3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0Q/CQB/C(P,30\ M+V(^/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S M:7IE/3-$,3XF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T M=&]M/CQF;VYT('-I>F4],T0Q/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T* M(#QT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B`C,#`P,#`P(#%P>"!S;VQI M9"<@=F%L:6=N/3-$8F]T=&]M(&-O;'-P86X],T0R(&%L:6=N/3-$8V5N=&5R M/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG M('-I>F4],T0Q/CQB/C(P,3,\+V(^/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG M;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF(WA!,#L\+V9O;G0^/"]T9#X- M"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C>$$P.R8C M>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!S='EL93TS1"="3U)$15(M0D]45$]- M.B`C,#`P,#`P(#%P>"!S;VQI9"<@=F%L:6=N/3-$8F]T=&]M(&-O;'-P86X] M,T0R(&%L:6=N/3-$8V5N=&5R/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9 M.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0Q/CQB/C(P,3(\+V(^/"]F;VYT M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF M(WA!,#L\+V9O;G0^/"]T9#X-"B`\+W1R/@T*(#QT<B!B9V-O;&]R/3-$(T-# M145&1CX-"B`\=&0@=F%L:6=N/3-$=&]P/@T*(#QP('-T>6QE/3-$)TU!4D=) M3BU,1494.B`Q96T[(%1%6%0M24Y$14Y4.B`M,65M)SX\9F]N="!S='EL93TS M1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CY297-E M87)C:"!A;F0-"B!D979E;&]P;65N=#PO9F]N=#X\+W`^#0H@/"]T9#X-"B`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`[)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS M1&)O='1O;3X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W M(%)O;6%N)R!S:7IE/3-$,CXD/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS M1&)O='1O;2!A;&EG;CTS1')I9VAT/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%- M24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R/C$L-3,X/"]F;VYT/CPO M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^/&9O M;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ M93TS1#(^)B-X03`[)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS M1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF(WA!,#LF(WA!,#L\+V9O;G0^/"]T M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)T9/3E0M M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R/B0\+V9O;G0^/"]T M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^/&9O;G0@ M<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS M1#(^,2PX,#$\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO M=W)A<#TS1&YO=W)A<#X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM M97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXF(WA!,#LF(WA!,#L\+V9O;G0^/"]T M9#X-"B`\+W1R/@T*(#QT<CX-"B`\=&0@=F%L:6=N/3-$=&]P/@T*(#QP('-T M>6QE/3-$)TU!4D=)3BU,1494.B`Q96T[(%1%6%0M24Y$14Y4.B`M,65M)SX\ M9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S M:7IE/3-$,CY'96YE<F%L(&%N9`T*(&%D;6EN:7-T<F%T:79E/"]F;VYT/CPO M<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<VEZ93TS M1#$^)B-X03`[)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O M='1O;3X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O M;6%N)R!S:7IE/3-$,CXF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N M/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^/&9O;G0@<W1Y;&4],T0G1D].5"U& M04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^,2PY-CD\+V9O;G0^ M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#X\ M9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S M:7IE/3-$,CXF(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N M/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C>$$P.R8C>$$P.SPO9F]N=#X\ M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<W1Y;&4],T0G1D]. M5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^)B-X03`[/"]F M;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT M/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG M('-I>F4],T0R/C(L,#4Y/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O M='1O;2!N;W=R87`],T1N;W=R87`^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U) M3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^)B-X03`[)B-X03`[/"]F M;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$ M,3XF(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T M=&]M/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M M86XG('-I>F4],T0R/B8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX] M,T1B;W1T;VT@86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS1"=&3TY4+49! M34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXQ+#DX,CPO9F]N=#X\ M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P/CQF M;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I M>F4],T0R/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#PO='(^#0H@/'1R M('-T>6QE/3-$)T9/3E0M4TE:13H@,7!X)SX-"B`\=&0@=F%L:6=N/3-$8F]T M=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\ M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@<W1Y;&4],T0G0D]2 M1$52+51/4#H@(S`P,#`P,"`Q<'@@<V]L:60G/B8C>$$P.SPO<#X-"B`\+W1D M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@<W1Y;&4],T0G0D]21$52 M+51/4#H@(S`P,#`P,"`Q<'@@<V]L:60G/B8C>$$P.SPO<#X-"B`\+W1D/@T* M(#QT9#XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[ M)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE M/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@,7!X('-O;&ED)SXF(WA!,#L\+W`^ M#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$ M)T)/4D1%4BU43U`Z(",P,#`P,#`@,7!X('-O;&ED)SXF(WA!,#L\+W`^#0H@ M/"]T9#X-"B`\=&0^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\ M<"!S='EL93TS1"="3U)$15(M5$]0.B`C,#`P,#`P(#%P>"!S;VQI9"<^)B-X M03`[/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S M='EL93TS1"="3U)$15(M5$]0.B`C,#`P,#`P(#%P>"!S;VQI9"<^)B-X03`[ M/"]P/@T*(#PO=&0^#0H@/'1D/B8C>$$P.SPO=&0^#0H@/"]T<CX-"B`\='(@ M8F=C;VQO<CTS1"-#0T5%1D8^#0H@/'1D('9A;&EG;CTS1'1O<#X-"B`\<"!S M='EL93TS1"=-05)'24XM3$5&5#H@,65M.R!415A4+4E.1$5.5#H@+3%E;2<^ M/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@ M<VEZ93TS1#(^4W1O8VLM8F%S960@8V]M<&5N<V%T:6]N#0H@:6YC;'5D960@ M:6X@;W!E<F%T:6YG(&5X<&5N<V5S/"]F;VYT/CPO<#X-"B`\+W1D/@T*(#QT M9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<VEZ93TS1#$^)B-X03`[)B-X03`[ M/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL M93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXD M/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I M9VAT/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M M86XG('-I>F4],T0R/C,L,S,P/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS M1&)O='1O;2!N;W=R87`],T1N;W=R87`^/&9O;G0@<W1Y;&4],T0G1D].5"U& M04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^)B-X03`[)B-X03`[ M/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE M/3-$,3XF(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$ M8F]T=&]M/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@ M4F]M86XG('-I>F4],T0R/B0\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$ M8F]T=&]M(&%L:6=N/3-$<FEG:'0^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U) M3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^,RPU.3<\+V9O;G0^/"]T M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#X\9F]N M="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE M/3-$,CXF(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`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`\ M=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O M;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@ M/'`@<W1Y;&4],T0G0D]21$52+51/4#H@(S`P,#`P,"`S<'@@9&]U8FQE)SXF M(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP M('-T>6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@,W!X(&1O=6)L92<^)B-X M03`[/"]P/@T*(#PO=&0^#0H@/'1D/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG M;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B M;W1T;VT^#0H@/'`@<W1Y;&4],T0G0D]21$52+51/4#H@(S`P,#`P,"`S<'@@ M9&]U8FQE)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T M=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@,W!X(&1O M=6)L92<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D/B8C>$$P.SPO=&0^#0H@ M/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V M86QI9VX],T1B;W1T;VT^#0H@/'`@<W1Y;&4],T0G0D]21$52+51/4#H@(S`P M,#`P,"`S<'@@9&]U8FQE)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0@=F%L M:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P M,#`@,W!X(&1O=6)L92<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D/B8C>$$P M.SPO=&0^#0H@/"]T<CX-"B`\+W1A8FQE/@T*(#PO9&EV/CQS<&%N/CPO<W!A M;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T* M("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^1F%I<B!686QU M92!O9B!3:&%R92U"87-E9"!087EM96YT<R!W87,@17-T:6UA=&5D(&]N($1A M=&4@;V8@1W)A;G0@57-I;F<@0FQA8VLM4V-H;VQE<R!/<'1I;VX@4')I8VEN M9R!-;V1E;"!"87-E9"!O;B!796EG:'1E9"!!=F5R86=E($%S<W5M<'1I;VYS M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\9&EV/@T*(#QP('-T M>6QE/3-$)TU!4D=)3BU"3U143TTZ(#!P>#L@34%21TE.+51/4#H@,'!X.R!4 M15A4+4E.1$5.5#H@-"4G(&%L:6=N/3-$:G5S=&EF>3X\9F]N="!S='EL93TS M1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CY4:&4@ M9F%I<B!V86QU92!O9B!S:&%R92UB87-E9"!P87EM96YT<R!W87,@97-T:6UA M=&5D(&]N('1H90T*(&1A=&4@;V8@9W)A;G0@=7-I;F<@=&AE($)L86-K+5-C M:&]L97,@;W!T:6]N('!R:6-I;F<@;6]D96P@8F%S960@;VX-"B!T:&4@9F]L M;&]W:6YG('=E:6=H=&5D(&%V97)A9V4@87-S=6UP=&EO;G,Z/"]F;VYT/CPO M<#X-"B`\<"!S='EL93TS1"=-05)'24XM0D]45$]-.B`P<'@[($9/3E0M4TE: M13H@,3)P>#L@34%21TE.+51/4#H@,'!X)SX-"B`F(WA!,#L\+W`^#0H@/'1A M8FQE('-T>6QE/3-$)T)/4D1%4BU#3TQ,05!313H@8V]L;&%P<V4G(&-E;&QS M<&%C:6YG/3-$,"!C96QL<&%D9&EN9STS1#`@=VED=&@],T0Q,#`E(&%L:6=N M/3-$8V5N=&5R(&)O<F1E<CTS1#`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`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG M;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF(WA!,#LF(WA!,#L\+V9O;G0^ M/"]T9#X-"B`\=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@(S`P,#`P,"`Q M<'@@<V]L:60G('9A;&EG;CTS1&)O='1O;2!C;VQS<&%N/3-$-B!A;&EG;CTS M1&-E;G1E<CX\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W M(%)O;6%N)R!S:7IE/3-$,3X\8CY996%R($5N9&5D/&)R("\^#0H@1&5C96UB M97(F(WA!,#LS,2P@,C`Q-#PO8CX\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N M/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C>$$P.SPO9F]N=#X\+W1D/@T* M(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<VEZ93TS1#$^)B-X03`[/"]F M;VYT/CPO=&0^#0H@/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P M,#`@,7!X('-O;&ED)R!V86QI9VX],T1B;W1T;VT@8V]L<W!A;CTS1#8@86QI M9VX],T1C96YT97(^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S M($YE=R!2;VUA;B<@<VEZ93TS1#$^/&(^665A<B!%;F1E9#QB<B`O/@T*($1E M8V5M8F5R)B-X03`[,S$L(#(P,3,\+V(^/"]F;VYT/CPO=&0^#0H@/'1D('9A M;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF(WA!,#L\+V9O;G0^/"]T M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C>$$P M.SPO9F]N=#X\+W1D/@T*(#QT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B`C M,#`P,#`P(#%P>"!S;VQI9"<@=F%L:6=N/3-$8F]T=&]M(&-O;'-P86X],T0V M(&%L:6=N/3-$8V5N=&5R/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4 M:6UE<R!.97<@4F]M86XG('-I>F4],T0Q/CQB/EEE87(@16YD960\8G(@+SX- M"B!$96-E;6)E<B8C>$$P.S,Q+"`R,#$R/"]B/CPO9F]N=#X\+W1D/@T*(#QT M9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<VEZ93TS1#$^)B-X03`[/"]F;VYT M/CPO=&0^#0H@/"]T<CX-"B`\='(^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\ M9F]N="!S:7IE/3-$,3XF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N M/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C>$$P.R8C>$$P.SPO9F]N=#X\ M+W1D/@T*(#QT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B`C,#`P,#`P(#%P M>"!S;VQI9"<@=F%L:6=N/3-$8F]T=&]M(&-O;'-P86X],T0R(&%L:6=N/3-$ M8V5N=&5R/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@ M4F]M86XG('-I>F4],T0Q/CQB/D5M<&QO>65E/&)R("\^#0H@4W1O8VLF(WA! M,#M/<'1I;VYS/"]B/CPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T M;VT^/&9O;G0@<VEZ93TS1#$^)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A M;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF(WA!,#L\+V9O;G0^/"]T M9#X-"B`\=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@(S`P,#`P,"`Q<'@@ M<V]L:60G('9A;&EG;CTS1&)O='1O;2!C;VQS<&%N/3-$,B!A;&EG;CTS1&-E M;G1E<CX\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O M;6%N)R!S:7IE/3-$,3X\8CY%4U!0/"]B/CPO9F]N=#X\+W1D/@T*(#QT9"!V M86QI9VX],T1B;W1T;VT^/&9O;G0@<VEZ93TS1#$^)B-X03`[/"]F;VYT/CPO M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF(WA! M,#L\+V9O;G0^/"]T9#X-"B`\=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@ M(S`P,#`P,"`Q<'@@<V]L:60G('9A;&EG;CTS1&)O='1O;2!C;VQS<&%N/3-$ M,B!A;&EG;CTS1&-E;G1E<CX\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@ M5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,3X\8CY%;7!L;WEE93QB<B`O/@T* M(%-T;V-K)B-X03`[3W!T:6]N<SPO8CX\+V9O;G0^/"]T9#X-"B`\=&0@=F%L M:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C>$$P.SPO9F]N=#X\+W1D M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<VEZ93TS1#$^)B-X03`[ M/"]F;VYT/CPO=&0^#0H@/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(",P M,#`P,#`@,7!X('-O;&ED)R!V86QI9VX],T1B;W1T;VT@8V]L<W!A;CTS1#(@ M86QI9VX],T1C96YT97(^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I M;65S($YE=R!2;VUA;B<@<VEZ93TS1#$^/&(^15-04#PO8CX\+V9O;G0^/"]T M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C>$$P M.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<VEZ M93TS1#$^)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('-T>6QE/3-$)T)/4D1% M4BU"3U143TTZ(",P,#`P,#`@,7!X('-O;&ED)R!V86QI9VX],T1B;W1T;VT@ M8V]L<W!A;CTS1#(@86QI9VX],T1C96YT97(^/&9O;G0@<W1Y;&4],T0G1D]. M5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#$^/&(^16UP;&]Y M964\8G(@+SX-"B!3=&]C:R8C>$$P.T]P=&EO;G,\+V(^/"]F;VYT/CPO=&0^ M#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF(WA!,#L\ M+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4] M,T0Q/B8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!S='EL93TS1"="3U)$15(M M0D]45$]-.B`C,#`P,#`P(#%P>"!S;VQI9"<@=F%L:6=N/3-$8F]T=&]M(&-O M;'-P86X],T0R(&%L:6=N/3-$8V5N=&5R/CQF;VYT('-T>6QE/3-$)T9/3E0M M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0Q/CQB/D534%`\+V(^ M/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE M/3-$,3XF(WA!,#L\+V9O;G0^/"]T9#X-"B`\+W1R/@T*(#QT<B!B9V-O;&]R M/3-$(T-#145&1CX-"B`\=&0@=F%L:6=N/3-$=&]P/@T*(#QP('-T>6QE/3-$ M)TU!4D=)3BU,1494.B`Q96T[(%1%6%0M24Y$14Y4.B`M,65M)SX\9F]N="!S M='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$ M,CY2:7-K+69R964@:6YT97)E<W0-"B!R871E/"]F;VYT/CPO<#X-"B`\+W1D M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<VEZ93TS1#$^)B-X03`[ M)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N M="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE M/3-$,CXF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M M(&%L:6=N/3-$<FEG:'0^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I M;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^,2XY/"]F;VYT/CPO=&0^#0H@/'1D M('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^/&9O;G0@<W1Y;&4] M,T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^)28C M>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@ M<VEZ93TS1#$^)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O M='1O;3X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O M;6%N)R!S:7IE/3-$,CXF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N M/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^/&9O;G0@<W1Y;&4],T0G1D].5"U& M04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^,"XR/"]F;VYT/CPO M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^/&9O M;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ M93TS1#(^)28C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T M;VT^/&9O;G0@<VEZ93TS1#$^)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A M;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM M97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXF(WA!,#L\+V9O;G0^/"]T9#X-"B`\ M=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^/&9O;G0@<W1Y;&4] M,T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^,2XQ M/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N M;W=R87`^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2 M;VUA;B<@<VEZ93TS1#(^)28C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI M9VX],T1B;W1T;VT^/&9O;G0@<VEZ93TS1#$^)B-X03`[/"]F;VYT/CPO=&0^ M#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=&3TY4+49! M34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXF(WA!,#L\+V9O;G0^ M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^/&9O M;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ M93TS1#(^,"XR/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N M;W=R87`],T1N;W=R87`^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I M;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^)28C>$$P.SPO9F]N=#X\+W1D/@T* M(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<VEZ93TS1#$^)B-X03`[/"]F M;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS M1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXF(WA! M,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$ M<FEG:'0^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2 M;VUA;B<@<VEZ93TS1#(^,2XQ/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS M1&)O='1O;2!N;W=R87`],T1N;W=R87`^/&9O;G0@<W1Y;&4],T0G1D].5"U& M04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^)28C>$$P.SPO9F]N M=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<VEZ93TS1#$^ M)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N M="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE M/3-$,CXF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M M(&%L:6=N/3-$<FEG:'0^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I M;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^,"XR/"]F;VYT/CPO=&0^#0H@/'1D M('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^/&9O;G0@<W1Y;&4] M,T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^)28C M>$$P.SPO9F]N=#X\+W1D/@T*(#PO='(^#0H@/'1R/@T*(#QT9"!V86QI9VX] M,T1T;W`^#0H@/'`@<W1Y;&4],T0G34%21TE.+4Q%1E0Z(#%E;3L@5$585"U) M3D1%3E0Z("TQ96TG/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE M<R!.97<@4F]M86XG('-I>F4],T0R/E9O;&%T:6QI='D\+V9O;G0^/"]P/@T* M(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF M(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M M/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG M('-I>F4],T0R/B8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B M;W1T;VT@86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS1"=&3TY4+49!34E, M63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXW-RXQ/"]F;VYT/CPO=&0^ M#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^/&9O;G0@ M<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS M1#(^)28C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^ M/&9O;G0@<VEZ93TS1#$^)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG M;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@ M3F5W(%)O;6%N)R!S:7IE/3-$,CXF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@ M=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^/&9O;G0@<W1Y;&4],T0G M1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^.#8N,#PO M9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W M<F%P/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M M86XG('-I>F4],T0R/B4F(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N M/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C>$$P.SPO9F]N=#X\+W1D/@T* M(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U) M3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^)B-X03`[/"]F;VYT/CPO M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/CQF;VYT M('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4] M,T0R/C<S+C(\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO M=W)A<#TS1&YO=W)A<#X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM M97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXE)B-X03`[/"]F;VYT/CPO=&0^#0H@ M/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF(WA!,#L\+V9O M;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$ M)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R/B8C>$$P M.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R M:6=H=#X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O M;6%N)R!S:7IE/3-$,CXW-"XV/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS M1&)O='1O;2!N;W=R87`],T1N;W=R87`^/&9O;G0@<W1Y;&4],T0G1D].5"U& M04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^)28C>$$P.SPO9F]N M=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<VEZ93TS1#$^ M)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N M="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE M/3-$,CXF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M M(&%L:6=N/3-$<FEG:'0^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I M;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^-S$N,3PO9F]N=#X\+W1D/@T*(#QT M9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P/CQF;VYT('-T>6QE M/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R/B4F M(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT M('-I>F4],T0Q/B8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B M;W1T;VT^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2 M;VUA;B<@<VEZ93TS1#(^)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG M;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/CQF;VYT('-T>6QE/3-$)T9/3E0M M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R/C<R+C`\+V9O;G0^ M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#X\ M9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S M:7IE/3-$,CXE)B-X03`[/"]F;VYT/CPO=&0^#0H@/"]T<CX-"B`\='(@8F=C M;VQO<CTS1"-#0T5%1D8^#0H@/'1D('9A;&EG;CTS1'1O<#X-"B`\<"!S='EL M93TS1"=-05)'24XM3$5&5#H@,65M.R!415A4+4E.1$5.5#H@+3%E;2<^/&9O M;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ M93TS1#(^17AP96-T960@=&5R;2!I;@T*('EE87)S/"]F;VYT/CPO<#X-"B`\ M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<VEZ93TS1#$^)B-X M03`[)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\ M9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S M:7IE/3-$,CXF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T M=&]M(&%L:6=N/3-$<FEG:'0^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ M(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^-BXS,#PO9F]N=#X\+W1D/@T* M(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P/CQF;VYT('-T M>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R M/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T M;VT^/&9O;G0@<VEZ93TS1#$^)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A M;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM M97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXF(WA!,#L\+V9O;G0^/"]T9#X-"B`\ M=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^/&9O;G0@<W1Y;&4] M,T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^,2XR M-3PO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$ M;F]W<F%P/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@ M4F]M86XG('-I>F4],T0R/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT M9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<VEZ93TS1#$^)B-X03`[/"]F;VYT M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=& M3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXF(WA!,#L\ M+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG M:'0^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA M;B<@<VEZ93TS1#(^-BXR,#PO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B M;W1T;VT@;F]W<F%P/3-$;F]W<F%P/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%- M24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R/B8C>$$P.R8C>$$P.SPO M9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<VEZ93TS M1#$^)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\ M9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S M:7IE/3-$,CXF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T M=&]M(&%L:6=N/3-$<FEG:'0^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ M(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^,2XR-3PO9F]N=#X\+W1D/@T* M(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P/CQF;VYT('-T M>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R M/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T M;VT^/&9O;G0@<VEZ93TS1#$^)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A M;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM M97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXF(WA!,#L\+V9O;G0^/"]T9#X-"B`\ M=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^/&9O;G0@<W1Y;&4] M,T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^-BXQ M,SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$ M;F]W<F%P/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@ M4F]M86XG('-I>F4],T0R/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT M9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<VEZ93TS1#$^)B-X03`[/"]F;VYT M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=& M3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXF(WA!,#L\ M+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG M:'0^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA M;B<@<VEZ93TS1#(^,2XR-3PO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B M;W1T;VT@;F]W<F%P/3-$;F]W<F%P/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%- M24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R/B8C>$$P.R8C>$$P.SPO M9F]N=#X\+W1D/@T*(#PO='(^#0H@/'1R/@T*(#QT9"!V86QI9VX],T1T;W`^ M#0H@/'`@<W1Y;&4],T0G34%21TE.+4Q%1E0Z(#%E;3L@5$585"U)3D1%3E0Z M("TQ96TG/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@ M4F]M86XG('-I>F4],T0R/D5X<&5C=&5D(&1I=FED96YD#0H@>6EE;&0\+V9O M;G0^/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S M:7IE/3-$,3XF(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N M/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!. M97<@4F]M86XG('-I>F4],T0R/B8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V M86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS1"=& M3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXP+C`\+V9O M;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A M<#X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N M)R!S:7IE/3-$,CXE)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS M1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF(WA!,#L\+V9O;G0^/"]T9#X-"B`\ M=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9 M.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R/B8C>$$P.SPO9F]N=#X\+W1D M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#X\9F]N="!S M='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$ M,CXP+C`\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A M<#TS1&YO=W)A<#X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@ M3F5W(%)O;6%N)R!S:7IE/3-$,CXE)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D M('9A;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF(WA!,#L\+V9O;G0^ M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)T9/ M3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R/B8C>$$P.SPO M9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H M=#X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N M)R!S:7IE/3-$,CXP+C`\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T M=&]M(&YO=W)A<#TS1&YO=W)A<#X\9F]N="!S='EL93TS1"=&3TY4+49!34E, M63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXE)B-X03`[/"]F;VYT/CPO M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF(WA! M,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T M>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R M/B8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI M9VX],T1R:6=H=#X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@ M3F5W(%)O;6%N)R!S:7IE/3-$,CXP+C`\+V9O;G0^/"]T9#X-"B`\=&0@=F%L M:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#X\9F]N="!S='EL93TS1"=& M3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXE)B-X03`[ M/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE M/3-$,3XF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M M/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG M('-I>F4],T0R/B8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B M;W1T;VT@86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS1"=&3TY4+49!34E, M63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXP+C`\+V9O;G0^/"]T9#X- M"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#X\9F]N="!S M='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$ M,CXE)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\ M9F]N="!S:7IE/3-$,3XF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N M/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!. M97<@4F]M86XG('-I>F4],T0R/B8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V M86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS1"=& M3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXP+C`\+V9O M;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A M<#X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N M)R!S:7IE/3-$,CXE)B-X03`[/"]F;VYT/CPO=&0^#0H@/"]T<CX-"B`\+W1A M8FQE/@T*(#PO9&EV/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX- M"B`@("`\+W1A8FQE/@T*("`\+V)O9'D^#0H\+VAT;6P^#0H-"BTM+2TM+3U? M3F5X=%!A<G1?,SEC,&5A-C)?8S(P,U\T-3AF7SAC-3!?,V1C830U-F$V.34Q M#0I#;VYT96YT+4QO8V%T:6]N.B!F:6QE.B\O+T,Z+S,Y8S!E838R7V,R,#-? M-#4X9E\X8S4P7S-D8V$T-39A-CDU,2]7;W)K<VAE971S+U-H965T,S0N:'1M M;`T*0V]N=&5N="U4<F%N<V9E<BU%;F-O9&EN9SH@<75O=&5D+7!R:6YT86)L M90T*0V]N=&5N="U4>7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI M(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS M1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA<G-E=#UU M=&8M."<^/'-C<FEP="!T>7!E/3-$=&5X="]J879A<V-R:7!T('-R8STS1%-H M;W<N:G,^+RH@1&\@3F]T(%)E;6]V92!4:&ES($-O;6UE;G0@*B\\+W-C<FEP M=#X\+VAE860^#0H@(#QB;V1Y/@T*("`@(#QT86)L92!C;&%S<STS1')E<&]R M="!I9#TS1$E$,$591$%#/@T*("`@("`@/'1R/@T*("`@("`@("`\=&@@8VQA M<W,],T1T;"!C;VQS<&%N/3-$,2!R;W=S<&%N/3-$,CX\<W1R;VYG/DEN8V]M M92!487AE<R`H5&%B;&5S*3QB<CX\+W-T<F]N9SX\+W1H/@T*("`@("`@("`\ M=&@@8VQA<W,],T1T:"!C;VQS<&%N/3-$,3XQ,B!-;VYT:',@16YD960\+W1H M/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<CX-"B`@("`@("`@/'1H(&-L87-S M/3-$=&@^1&5C+B`S,2P@,C`Q-#QB<CX\+W1H/@T*("`@("`@/"]T<CX-"B`@ M("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V M86QI9VX],T1T;W`^/'-T<F]N9SY);F-O;64@5&%X($1I<V-L;W-U<F4@6T%B M<W1R86-T73PO<W1R;VYG/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R M(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS M1'1O<#Y38VAE9'5L92!O9B!#;VUP;VYE;G1S(&]F($EN8V]M92!"969O<F4@ M5&%X97,\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQD:78^#0H@ M/'`@<W1Y;&4],T0G34%21TE.+4)/5%1/33H@,'!X.R!-05)'24XM5$]0.B`Q M,G!X.R!415A4+4E.1$5.5#H@-"4G(&%L:6=N/3-$:G5S=&EF>3X\9F]N="!S M='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$ M,CY&;W(@9FEN86YC:6%L('-T871E;65N="!P=7)P;W-E<RP@;&]S<R!B969O M<F4@=&%X97,@:6YC;'5D97,-"B!T:&4@9F]L;&]W:6YG(&-O;7!O;F5N=',@ M*&EN('1H;W5S86YD<RDZ/"]F;VYT/CPO<#X-"B`\<"!S='EL93TS1"=-05)' M24XM0D]45$]-.B`P<'@[($9/3E0M4TE:13H@,3)P>#L@34%21TE.+51/4#H@ M,'!X)SX-"B`F(WA!,#L\+W`^#0H@/'1A8FQE('-T>6QE/3-$)T)/4D1%4BU# M3TQ,05!313H@8V]L;&%P<V4G(&-E;&QS<&%C:6YG/3-$,"!C96QL<&%D9&EN M9STS1#`@=VED=&@],T0Y,B4@86QI9VX],T1C96YT97(@8F]R9&5R/3-$,#X- M"B`\='(^#0H@/'1D('=I9'1H/3-$-C8E/CPO=&0^#0H@/'1D('9A;&EG;CTS M1&)O='1O;2!W:61T:#TS1#4E/CPO=&0^#0H@/'1D/CPO=&0^#0H@/'1D/CPO M=&0^#0H@/'1D/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!W:61T:#TS M1#0E/CPO=&0^#0H@/'1D/CPO=&0^#0H@/'1D/CPO=&0^#0H@/'1D/CPO=&0^ M#0H@/'1D('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#0E/CPO=&0^#0H@/'1D M/CPO=&0^#0H@/'1D/CPO=&0^#0H@/'1D/CPO=&0^#0H@/"]T<CX-"B`\='(^ M#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF(WA!,#L\ M+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4] M,T0Q/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!S='EL93TS1"=" M3U)$15(M0D]45$]-.B`C,#`P,#`P(#%P>"!S;VQI9"<@=F%L:6=N/3-$8F]T M=&]M(&-O;'-P86X],T0Q,"!A;&EG;CTS1&-E;G1E<CX\9F]N="!S='EL93TS M1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,3X\8CY9 M96%R<R!%;F1E9#QB<B`O/@T*($1E8V5M8F5R)B-X03`[,S$L/"]B/CPO9F]N M=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<VEZ93TS1#$^ M)B-X03`[/"]F;VYT/CPO=&0^#0H@/"]T<CX-"B`\='(^#0H@/'1D('9A;&EG M;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF(WA!,#L\+V9O;G0^/"]T9#X- M"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C>$$P.R8C M>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!S='EL93TS1"="3U)$15(M0D]45$]- M.B`C,#`P,#`P(#%P>"!S;VQI9"<@=F%L:6=N/3-$8F]T=&]M(&-O;'-P86X] M,T0R(&%L:6=N/3-$8V5N=&5R/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9 M.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0Q/CQB/C(P,30\+V(^/"]F;VYT M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF M(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT M('-I>F4],T0Q/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!S='EL M93TS1"="3U)$15(M0D]45$]-.B`C,#`P,#`P(#%P>"!S;VQI9"<@=F%L:6=N M/3-$8F]T=&]M(&-O;'-P86X],T0R(&%L:6=N/3-$8V5N=&5R/CQF;VYT('-T M>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0Q M/CQB/C(P,3,\+V(^/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O M;3X\9F]N="!S:7IE/3-$,3XF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L M:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C>$$P.R8C>$$P.SPO9F]N M=#X\+W1D/@T*(#QT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B`C,#`P,#`P M(#%P>"!S;VQI9"<@=F%L:6=N/3-$8F]T=&]M(&-O;'-P86X],T0R(&%L:6=N M/3-$8V5N=&5R/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!. M97<@4F]M86XG('-I>F4],T0Q/CQB/C(P,3(\+V(^/"]F;VYT/CPO=&0^#0H@ M/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF(WA!,#L\+V9O M;G0^/"]T9#X-"B`\+W1R/@T*(#QT<B!B9V-O;&]R/3-$(T-#145&1CX-"B`\ M=&0@=F%L:6=N/3-$=&]P/@T*(#QP('-T>6QE/3-$)TU!4D=)3BU,1494.B`Q M96T[(%1%6%0M24Y$14Y4.B`M,65M)SX\9F]N="!S='EL93TS1"=&3TY4+49! M34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CY5;FET960@4W1A=&5S M/"]F;VYT/CPO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O M;G0@<VEZ93TS1#$^)B-X03`[)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A M;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM M97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXD/"]F;VYT/CPO=&0^#0H@/'1D('9A M;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/CQF;VYT('-T>6QE/3-$)T9/ M3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R/B@Q-"PV-#8\ M+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO M=W)A<#X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O M;6%N)R!S:7IE/3-$,CXI)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG M;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF(WA!,#LF(WA!,#L\+V9O;G0^ M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)T9/ M3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R/B0\+V9O;G0^ M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^/&9O M;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ M93TS1#(^*#,S+#<Q-SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T M;VT@;F]W<F%P/3-$;F]W<F%P/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9 M.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R/BDF(WA!,#L\+V9O;G0^/"]T M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C>$$P M.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O M;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ M93TS1#(^)#PO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI M9VX],T1R:6=H=#X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@ M3F5W(%)O;6%N)R!S:7IE/3-$,CXH-#`L,S<P/"]F;VYT/CPO=&0^#0H@/'1D M('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^/&9O;G0@<W1Y;&4] M,T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^*28C M>$$P.SPO9F]N=#X\+W1D/@T*(#PO='(^#0H@/'1R/@T*(#QT9"!V86QI9VX] M,T1T;W`^#0H@/'`@<W1Y;&4],T0G34%21TE.+4Q%1E0Z(#%E;3L@5$585"U) M3D1%3E0Z("TQ96TG/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE M<R!.97<@4F]M86XG('-I>F4],T0R/D9O<F5I9VX\+V9O;G0^/"]P/@T*(#PO M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF(WA! M,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO M=W)A<#TS1&YO=W)A<#X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM M97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXF(WA!,#L\+V9O;G0^/"]T9#X-"B`\ M=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<"!A;&EG;CTS1')I M9VAT/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M M86XG('-I>F4],T0R/B8C>#(P,30[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG M;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^/&9O;G0@<W1Y;&4],T0G1D]. M5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^)B-X03`[)B-X M03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S M:7IE/3-$,3XF(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N M/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#X\9F]N="!S='EL93TS1"=&3TY4 M+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXF(WA!,#L\+V9O M;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A M<"!A;&EG;CTS1')I9VAT/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4 M:6UE<R!.97<@4F]M86XG('-I>F4],T0R/B8C>#(P,30[/"]F;VYT/CPO=&0^ M#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^/&9O;G0@ M<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS M1#(^)B-X03`[)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O M='1O;3X\9F]N="!S:7IE/3-$,3XF(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X- M"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#X\9F]N="!S M='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$ M,CXF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO M=W)A<#TS1&YO=W)A<"!A;&EG;CTS1')I9VAT/CQF;VYT('-T>6QE/3-$)T9/ M3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R/B8C>#(P,30[ M/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N M;W=R87`^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2 M;VUA;B<@<VEZ93TS1#(^)B-X03`[)B-X03`[/"]F;VYT/CPO=&0^#0H@/"]T M<CX-"B`\='(@<W1Y;&4],T0G1D].5"U325I%.B`Q<'@G/@T*(#QT9"!V86QI M9VX],T1B;W1T;VT^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P M.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL M93TS1"="3U)$15(M5$]0.B`C,#`P,#`P(#%P>"!S;VQI9"<^)B-X03`[/"]P M/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS M1"="3U)$15(M5$]0.B`C,#`P,#`P(#%P>"!S;VQI9"<^)B-X03`[/"]P/@T* M(#PO=&0^#0H@/'1D/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O M;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@ M/'`@<W1Y;&4],T0G0D]21$52+51/4#H@(S`P,#`P,"`Q<'@@<V]L:60G/B8C M>$$P.SPO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@ M<W1Y;&4],T0G0D]21$52+51/4#H@(S`P,#`P,"`Q<'@@<V]L:60G/B8C>$$P M.SPO<#X-"B`\+W1D/@T*(#QT9#XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX] M,T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T M=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@,7!X('-O M;&ED)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@,7!X('-O;&ED M)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0^)B-X03`[/"]T9#X-"B`\+W1R M/@T*(#QT<B!B9V-O;&]R/3-$(T-#145&1CX-"B`\=&0@=F%L:6=N/3-$=&]P M/@T*(#QP('-T>6QE/3-$)TU!4D=)3BU,1494.B`R96T[(%1%6%0M24Y$14Y4 M.B`M,65M)SX\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W M(%)O;6%N)R!S:7IE/3-$,CY4;W1A;#PO9F]N=#X\+W`^#0H@/"]T9#X-"B`\ M=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C>$$P.R8C>$$P M.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<W1Y M;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^ M)#PO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R M:6=H=#X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O M;6%N)R!S:7IE/3-$,CXH,30L-C0V/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG M;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^/&9O;G0@<W1Y;&4],T0G1D]. M5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^*28C>$$P.SPO M9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<VEZ93TS M1#$^)B-X03`[)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O M='1O;3X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O M;6%N)R!S:7IE/3-$,CXD/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O M='1O;2!A;&EG;CTS1')I9VAT/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9 M.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R/B@S,RPW,3<\+V9O;G0^/"]T M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#X\9F]N M="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE M/3-$,CXI)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O M;3X\9F]N="!S:7IE/3-$,3XF(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\ M=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9 M.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R/B0\+V9O;G0^/"]T9#X-"B`\ M=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^/&9O;G0@<W1Y;&4] M,T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^*#0P M+#,W,#PO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P M/3-$;F]W<F%P/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!. M97<@4F]M86XG('-I>F4],T0R/BDF(WA!,#L\+V9O;G0^/"]T9#X-"B`\+W1R M/@T*(#QT<B!S='EL93TS1"=&3TY4+5-)6D4Z(#%P>"<^#0H@/'1D('9A;&EG M;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[ M)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE M/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@,W!X(&1O=6)L92<^)B-X03`[/"]P M/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS M1"="3U)$15(M5$]0.B`C,#`P,#`P(#-P>"!D;W5B;&4G/B8C>$$P.SPO<#X- M"B`\+W1D/@T*(#QT9#XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T M;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T* M(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@,W!X(&1O=6)L92<^ M)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\ M<"!S='EL93TS1"="3U)$15(M5$]0.B`C,#`P,#`P(#-P>"!D;W5B;&4G/B8C M>$$P.SPO<#X-"B`\+W1D/@T*(#QT9#XF(WA!,#L\+W1D/@T*(#QT9"!V86QI M9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$ M8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@,W!X M(&1O=6)L92<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O M='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B`C,#`P,#`P(#-P>"!D M;W5B;&4G/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT9#XF(WA!,#L\+W1D/@T* M(#PO='(^#0H@/"]T86)L93X-"B`\+V1I=CX\<W!A;CX\+W-P86X^/"]T9#X- M"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@ M/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D-O;7!A;GD@4F5C;W)D960@ M26YC;VUE(%1A>"!0<F]V:7-I;VX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,] M,T1T97AT/CQD:78^#0H@/'`@<W1Y;&4],T0G34%21TE.+4)/5%1/33H@,'!X M.R!-05)'24XM5$]0.B`Q,G!X.R!415A4+4E.1$5.5#H@-"4G(&%L:6=N/3-$ M:G5S=&EF>3X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W M(%)O;6%N)R!S:7IE/3-$,CY4:&4@0V]M<&%N>2!R96-O<F1E9"!T:&4@9F]L M;&]W:6YG(&EN8V]M92!T87@@<')O=FES:6]N(&%S#0H@9F]L;&]W<R`H:6X@ M=&AO=7-A;F1S*3H\+V9O;G0^/"]P/@T*(#QP('-T>6QE/3-$)TU!4D=)3BU" M3U143TTZ(#!P>#L@1D].5"U325I%.B`Q,G!X.R!-05)'24XM5$]0.B`P<'@G M/@T*("8C>$$P.SPO<#X-"B`\=&%B;&4@<W1Y;&4],T0G0D]21$52+4-/3$Q! M4%-%.B!C;VQL87!S92<@8V5L;'-P86-I;F<],T0P(&-E;&QP861D:6YG/3-$ M,"!W:61T:#TS1#DR)2!A;&EG;CTS1&-E;G1E<B!B;W)D97(],T0P/@T*(#QT M<CX-"B`\=&0@=VED=&@],T0V-R4^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T M=&]M('=I9'1H/3-$.24^/"]T9#X-"B`\=&0^/"]T9#X-"B`\=&0^/"]T9#X- M"B`\=&0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$.24^ M/"]T9#X-"B`\=&0^/"]T9#X-"B`\=&0^/"]T9#X-"B`\=&0^/"]T9#X-"B`\ M=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$.24^/"]T9#X-"B`\=&0^/"]T M9#X-"B`\=&0^/"]T9#X-"B`\=&0^/"]T9#X-"B`\+W1R/@T*(#QT<CX-"B`\ M=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C>$$P.SPO9F]N M=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<VEZ93TS1#$^ M)B-X03`[)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('-T>6QE/3-$)T)/4D1% M4BU"3U143TTZ(",P,#`P,#`@,7!X('-O;&ED)R!V86QI9VX],T1B;W1T;VT@ M8V]L<W!A;CTS1#$P(&%L:6=N/3-$8V5N=&5R/CQF;VYT('-T>6QE/3-$)T9/ M3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0Q/CQB/EEE87)S M($5N9&5D/&)R("\^#0H@1&5C96UB97(F(WA!,#LS,2P\+V(^/"]F;VYT/CPO M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF(WA! M,#L\+V9O;G0^/"]T9#X-"B`\+W1R/@T*(#QT<CX-"B`\=&0@=F%L:6=N/3-$ M8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT M9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<VEZ93TS1#$^)B-X03`[)B-X03`[ M/"]F;VYT/CPO=&0^#0H@/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(",P M,#`P,#`@,7!X('-O;&ED)R!V86QI9VX],T1B;W1T;VT@8V]L<W!A;CTS1#(@ M86QI9VX],T1C96YT97(^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I M;65S($YE=R!2;VUA;B<@<VEZ93TS1#$^/&(^,C`Q-#PO8CX\+V9O;G0^/"]T M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C>$$P M.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<VEZ M93TS1#$^)B-X03`[)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('-T>6QE/3-$ M)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,7!X('-O;&ED)R!V86QI9VX],T1B M;W1T;VT@8V]L<W!A;CTS1#(@86QI9VX],T1C96YT97(^/&9O;G0@<W1Y;&4] M,T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#$^/&(^ M,C`Q,SPO8CX\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF M;VYT('-I>F4],T0Q/B8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX] M,T1B;W1T;VT^/&9O;G0@<VEZ93TS1#$^)B-X03`[)B-X03`[/"]F;VYT/CPO M=&0^#0H@/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,7!X M('-O;&ED)R!V86QI9VX],T1B;W1T;VT@8V]L<W!A;CTS1#(@86QI9VX],T1C M96YT97(^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2 M;VUA;B<@<VEZ93TS1#$^/&(^,C`Q,CPO8CX\+V9O;G0^/"]T9#X-"B`\=&0@ M=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C>$$P.SPO9F]N=#X\ M+W1D/@T*(#PO='(^#0H@/'1R(&)G8V]L;W(],T0C0T-%149&/@T*(#QT9"!V M86QI9VX],T1T;W`^#0H@/'`@<W1Y;&4],T0G34%21TE.+4Q%1E0Z(#%E;3L@ M5$585"U)3D1%3E0Z("TQ96TG/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9 M.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R/D-U<G)E;G0Z/"]F;VYT/CPO M<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<VEZ93TS M1#$^)B-X03`[)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O M='1O;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\=&0@ M=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\ M9F]N="!S:7IE/3-$,3XF(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@ M=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\ M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\=&0@=F%L:6=N M/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C>$$P.R8C>$$P.SPO9F]N=#X\ M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\=&0@=F%L:6=N M/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T* M(#PO='(^#0H@/'1R/@T*(#QT9"!V86QI9VX],T1T;W`^#0H@/'`@<W1Y;&4] M,T0G34%21TE.+4Q%1E0Z(#)E;3L@5$585"U)3D1%3E0Z("TQ96TG/CQF;VYT M('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4] M,T0R/D9E9&5R86P\+V9O;G0^/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS M1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF(WA!,#LF(WA!,#L\+V9O;G0^/"]T M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#X\9F]N M="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE M/3-$,CXD/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R M87`],T1N;W=R87`@86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS1"=&3TY4 M+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXF(W@R,#$T.SPO M9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W M<F%P/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M M86XG('-I>F4],T0R/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V M86QI9VX],T1B;W1T;VT^/&9O;G0@<VEZ93TS1#$^)B-X03`[)B-X03`[/"]F M;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R M87`^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA M;B<@<VEZ93TS1#(^)#PO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T M;VT@;F]W<F%P/3-$;F]W<F%P(&%L:6=N/3-$<FEG:'0^/&9O;G0@<W1Y;&4] M,T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^)B-X M,C`Q-#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A M<#TS1&YO=W)A<#X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@ M3F5W(%)O;6%N)R!S:7IE/3-$,CXF(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X- M"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C>$$P.R8C M>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P M/3-$;F]W<F%P/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!. M97<@4F]M86XG('-I>F4],T0R/B0\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N M/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<"!A;&EG;CTS1')I9VAT/CQF;VYT M('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4] M,T0R/B8C>#(P,30[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O M;2!N;W=R87`],T1N;W=R87`^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ M(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^)B-X03`[)B-X03`[/"]F;VYT M/CPO=&0^#0H@/"]T<CX-"B`\='(@8F=C;VQO<CTS1"-#0T5%1D8^#0H@/'1D M('9A;&EG;CTS1'1O<#X-"B`\<"!S='EL93TS1"=-05)'24XM3$5&5#H@,F5M M.R!415A4+4E.1$5.5#H@+3%E;2<^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U) M3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^4W1A=&4\+V9O;G0^/"]P M/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$ M,3XF(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T M=&]M(&YO=W)A<#TS1&YO=W)A<#X\9F]N="!S='EL93TS1"=&3TY4+49!34E, M63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXF(WA!,#L\+V9O;G0^/"]T M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<"!A;&EG M;CTS1')I9VAT/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!. M97<@4F]M86XG('-I>F4],T0R/B8C>#(P,30[/"]F;VYT/CPO=&0^#0H@/'1D M('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^/&9O;G0@<W1Y;&4] M,T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^)B-X M03`[)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\ M9F]N="!S:7IE/3-$,3XF(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@ M=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#X\9F]N="!S='EL93TS M1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXF(WA! M,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS M1&YO=W)A<"!A;&EG;CTS1')I9VAT/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%- M24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R/B8C>#(P,30[/"]F;VYT M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^ M/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@ M<VEZ93TS1#(^)B-X03`[)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG M;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF(WA!,#LF(WA!,#L\+V9O;G0^ M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#X\ M9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S M:7IE/3-$,CXF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T M=&]M(&YO=W)A<#TS1&YO=W)A<"!A;&EG;CTS1')I9VAT/CQF;VYT('-T>6QE M/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R/B8C M>#(P,30[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R M87`],T1N;W=R87`^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S M($YE=R!2;VUA;B<@<VEZ93TS1#(^)B-X03`[)B-X03`[/"]F;VYT/CPO=&0^ M#0H@/"]T<CX-"B`\='(@<W1Y;&4],T0G1D].5"U325I%.B`Q<'@G/@T*(#QT M9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\ M<"!S='EL93TS1"="3U)$15(M5$]0.B`C,#`P,#`P(#%P>"!S;VQI9"<^)B-X M03`[/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S M='EL93TS1"="3U)$15(M5$]0.B`C,#`P,#`P(#%P>"!S;VQI9"<^)B-X03`[ M/"]P/@T*(#PO=&0^#0H@/'1D/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS M1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T M;VT^#0H@/'`@<W1Y;&4],T0G0D]21$52+51/4#H@(S`P,#`P,"`Q<'@@<V]L M:60G/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^ M#0H@/'`@<W1Y;&4],T0G0D]21$52+51/4#H@(S`P,#`P,"`Q<'@@<V]L:60G M/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT9#XF(WA!,#L\+W1D/@T*(#QT9"!V M86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N M/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@ M,7!X('-O;&ED)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$ M8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@,7!X M('-O;&ED)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0^)B-X03`[/"]T9#X- M"B`\+W1R/@T*(#QT<CX-"B`\=&0@=F%L:6=N/3-$=&]P/@T*(#QP('-T>6QE M/3-$)TU!4D=)3BU,1494.B`S96T[(%1%6%0M24Y$14Y4.B`M,65M)SX\9F]N M="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE M/3-$,CY4;W1A;#PO9F]N=#X\+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$ M8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P/CQF;VYT M('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4] M,T0R/B0\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A M<#TS1&YO=W)A<"!A;&EG;CTS1')I9VAT/CQF;VYT('-T>6QE/3-$)T9/3E0M M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R/B8C>#(P,30[/"]F M;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R M87`^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA M;B<@<VEZ93TS1#(^)B-X03`[)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A M;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF(WA!,#LF(WA!,#L\+V9O M;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A M<#X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N M)R!S:7IE/3-$,CXD/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O M;2!N;W=R87`],T1N;W=R87`@86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS M1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXF(W@R M,#$T.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P M/3-$;F]W<F%P/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!. M97<@4F]M86XG('-I>F4],T0R/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T* M(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<VEZ93TS1#$^)B-X03`[)B-X M03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`] M,T1N;W=R87`^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE M=R!2;VUA;B<@<VEZ93TS1#(^)#PO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX] M,T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P(&%L:6=N/3-$<FEG:'0^/&9O;G0@ M<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS M1#(^)B-X,C`Q-#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M M(&YO=W)A<#TS1&YO=W)A<#X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@ M5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXF(WA!,#LF(WA!,#L\+V9O;G0^ M/"]T9#X-"B`\+W1R/@T*(#QT<B!S='EL93TS1"=&3TY4+5-)6D4Z(#%P>"<^ M#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B M;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@,W!X(&1O=6)L M92<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X- M"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B`C,#`P,#`P(#-P>"!D;W5B;&4G M/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT9#XF(WA!,#L\+W1D/@T*(#QT9"!V M86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N M/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@ M,W!X(&1O=6)L92<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS M1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B`C,#`P,#`P(#-P M>"!D;W5B;&4G/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT9#XF(WA!,#L\+W1D M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\ M=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z M(",P,#`P,#`@,W!X(&1O=6)L92<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D M('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B`C M,#`P,#`P(#-P>"!D;W5B;&4G/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT9#XF M(WA!,#L\+W1D/@T*(#PO='(^#0H@/'1R(&)G8V]L;W(],T0C0T-%149&/@T* M(#QT9"!V86QI9VX],T1T;W`^#0H@/'`@<W1Y;&4],T0G34%21TE.+4Q%1E0Z M(#%E;3L@5$585"U)3D1%3E0Z("TQ96TG/CQF;VYT('-T>6QE/3-$)T9/3E0M M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R/D1E9F5R<F5D.CPO M9F]N=#X\+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT M('-I>F4],T0Q/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI M9VX],T1B;W1T;VT^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^ M#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B M;W1T;VT^/&9O;G0@<VEZ93TS1#$^)B-X03`[)B-X03`[/"]F;VYT/CPO=&0^ M#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B M;W1T;VT^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D M('9A;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF(WA!,#LF(WA!,#L\ M+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D M('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^ M/"]T9#X-"B`\+W1R/@T*(#QT<CX-"B`\=&0@=F%L:6=N/3-$=&]P/@T*(#QP M('-T>6QE/3-$)TU!4D=)3BU,1494.B`R96T[(%1%6%0M24Y$14Y4.B`M,65M M)SX\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N M)R!S:7IE/3-$,CY&961E<F%L/"]F;VYT/CPO<#X-"B`\+W1D/@T*(#QT9"!V M86QI9VX],T1B;W1T;VT^/&9O;G0@<VEZ93TS1#$^)B-X03`[)B-X03`[/"]F M;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R M87`^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA M;B<@<VEZ93TS1#(^)#PO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T M;VT@;F]W<F%P/3-$;F]W<F%P(&%L:6=N/3-$<FEG:'0^/&9O;G0@<W1Y;&4] M,T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^)B-X M,C`Q-#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A M<#TS1&YO=W)A<#X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@ M3F5W(%)O;6%N)R!S:7IE/3-$,CXF(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X- M"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C>$$P.R8C M>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P M/3-$;F]W<F%P/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!. M97<@4F]M86XG('-I>F4],T0R/B0\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N M/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<"!A;&EG;CTS1')I9VAT/CQF;VYT M('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4] M,T0R/B8C>#(P,30[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O M;2!N;W=R87`],T1N;W=R87`^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ M(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^)B-X03`[)B-X03`[/"]F;VYT M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF M(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M M(&YO=W)A<#TS1&YO=W)A<#X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@ M5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXD/"]F;VYT/CPO=&0^#0H@/'1D M('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`@86QI9VX],T1R:6=H M=#X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N M)R!S:7IE/3-$,CXF(W@R,#$T.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX] M,T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P/CQF;VYT('-T>6QE/3-$)T9/3E0M M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R/B8C>$$P.R8C>$$P M.SPO9F]N=#X\+W1D/@T*(#PO='(^#0H@/'1R(&)G8V]L;W(],T0C0T-%149& M/@T*(#QT9"!V86QI9VX],T1T;W`^#0H@/'`@<W1Y;&4],T0G34%21TE.+4Q% M1E0Z(#)E;3L@5$585"U)3D1%3E0Z("TQ96TG/CQF;VYT('-T>6QE/3-$)T9/ M3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R/E-T871E/"]F M;VYT/CPO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@ M<VEZ93TS1#$^)B-X03`[)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG M;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^/&9O;G0@<W1Y;&4],T0G1D]. M5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^)B-X03`[/"]F M;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R M87`@86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@ M5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXF(W@R,#$T.SPO9F]N=#X\+W1D M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P/CQF;VYT M('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4] M,T0R/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B M;W1T;VT^/&9O;G0@<VEZ93TS1#$^)B-X03`[)B-X03`[/"]F;VYT/CPO=&0^ M#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^/&9O;G0@ M<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS M1#(^)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N M;W=R87`],T1N;W=R87`@86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS1"=& M3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXF(W@R,#$T M.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$ M;F]W<F%P/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@ M4F]M86XG('-I>F4],T0R/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT M9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<VEZ93TS1#$^)B-X03`[)B-X03`[ M/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N M;W=R87`^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2 M;VUA;B<@<VEZ93TS1#(^)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG M;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`@86QI9VX],T1R:6=H=#X\9F]N M="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE M/3-$,CXF(W@R,#$T.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T M;VT@;F]W<F%P/3-$;F]W<F%P/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9 M.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R/B8C>$$P.R8C>$$P.SPO9F]N M=#X\+W1D/@T*(#PO='(^#0H@/'1R('-T>6QE/3-$)T9/3E0M4TE:13H@,7!X M)SX-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS M1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T M;VT^#0H@/'`@<W1Y;&4],T0G0D]21$52+51/4#H@(S`P,#`P,"`Q<'@@<V]L M:60G/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^ M#0H@/'`@<W1Y;&4],T0G0D]21$52+51/4#H@(S`P,#`P,"`Q<'@@<V]L:60G M/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT9#XF(WA!,#L\+W1D/@T*(#QT9"!V M86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N M/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@ M,7!X('-O;&ED)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$ M8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@,7!X M('-O;&ED)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0^)B-X03`[/"]T9#X- M"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D M('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B`C M,#`P,#`P(#%P>"!S;VQI9"<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D('9A M;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B`C,#`P M,#`P(#%P>"!S;VQI9"<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D/B8C>$$P M.SPO=&0^#0H@/"]T<CX-"B`\='(^#0H@/'1D('9A;&EG;CTS1'1O<#X-"B`\ M<"!S='EL93TS1"=-05)'24XM3$5&5#H@,V5M.R!415A4+4E.1$5.5#H@+3%E M;2<^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA M;B<@<VEZ93TS1#(^5&]T86P\+V9O;G0^/"]P/@T*(#PO=&0^#0H@/'1D('9A M;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF(WA!,#LF(WA!,#L\+V9O M;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A M<#X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N M)R!S:7IE/3-$,CXD/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O M;2!N;W=R87`],T1N;W=R87`@86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS M1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXF(W@R M,#$T.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P M/3-$;F]W<F%P/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!. M97<@4F]M86XG('-I>F4],T0R/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T* M(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<VEZ93TS1#$^)B-X03`[)B-X M03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`] M,T1N;W=R87`^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE M=R!2;VUA;B<@<VEZ93TS1#(^)#PO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX] M,T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P(&%L:6=N/3-$<FEG:'0^/&9O;G0@ M<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS M1#(^)B-X,C`Q-#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M M(&YO=W)A<#TS1&YO=W)A<#X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@ M5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXF(WA!,#LF(WA!,#L\+V9O;G0^ M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C M>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@ M;F]W<F%P/3-$;F]W<F%P/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4 M:6UE<R!.97<@4F]M86XG('-I>F4],T0R/B0\+V9O;G0^/"]T9#X-"B`\=&0@ M=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<"!A;&EG;CTS1')I9VAT M/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG M('-I>F4],T0R/B8C>#(P,30[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS M1&)O='1O;2!N;W=R87`],T1N;W=R87`^/&9O;G0@<W1Y;&4],T0G1D].5"U& M04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^)B-X03`[)B-X03`[ M/"]F;VYT/CPO=&0^#0H@/"]T<CX-"B`\='(@<W1Y;&4],T0G1D].5"U325I% M.B`Q<'@G/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\=&0@=F%L M:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS M1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B`C,#`P,#`P(#-P M>"!D;W5B;&4G/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B M;W1T;VT^#0H@/'`@<W1Y;&4],T0G0D]21$52+51/4#H@(S`P,#`P,"`S<'@@ M9&]U8FQE)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0^)B-X03`[/"]T9#X- M"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D M('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B`C M,#`P,#`P(#-P>"!D;W5B;&4G/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT9"!V M86QI9VX],T1B;W1T;VT^#0H@/'`@<W1Y;&4],T0G0D]21$52+51/4#H@(S`P M,#`P,"`S<'@@9&]U8FQE)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0^)B-X M03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$ M15(M5$]0.B`C,#`P,#`P(#-P>"!D;W5B;&4G/B8C>$$P.SPO<#X-"B`\+W1D M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@<W1Y;&4],T0G0D]21$52 M+51/4#H@(S`P,#`P,"`S<'@@9&]U8FQE)SXF(WA!,#L\+W`^#0H@/"]T9#X- M"B`\=&0^)B-X03`[/"]T9#X-"B`\+W1R/@T*(#PO=&%B;&4^#0H@/"]D:78^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L M87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O M<#Y#;VUP86YY)W,@1&5F97)R960@5&%X($%S<V5T<R!A;F0@3&EA8FEL:71I M97,\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQD:78^#0H@/'`@ M<W1Y;&4],T0G34%21TE.+4)/5%1/33H@,'!X.R!-05)'24XM5$]0.B`P<'@[ M(%1%6%0M24Y$14Y4.B`T)2<@86QI9VX],T1J=7-T:69Y/CQF;VYT('-T>6QE M/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R/E1H M92!S:6=N:69I8V%N="!C;VUP;VYE;G1S(&]F('1H92!#;VUP86YY)B-X,C`Q M.3MS(&1E9F5R<F5D('1A>`T*(&%S<V5T<R!A;F0@;&EA8FEL:71I97,@=V5R M92!A<R!F;VQL;W=S("AI;B!T:&]U<V%N9',I.CPO9F]N=#X\+W`^#0H@/'`@ M<W1Y;&4],T0G34%21TE.+4)/5%1/33H@,'!X.R!&3TY4+5-)6D4Z(#$R<'@[ M($U!4D=)3BU43U`Z(#!P>"<^#0H@)B-X03`[/"]P/@T*(#QT86)L92!S='EL M93TS1"="3U)$15(M0T],3$%04T4Z(&-O;&QA<'-E)R!C96QL<W!A8VEN9STS M1#`@8V5L;'!A9&1I;F<],T0P('=I9'1H/3-$.3(E(&%L:6=N/3-$8V5N=&5R M(&)O<F1E<CTS1#`^#0H@/'1R/@T*(#QT9"!W:61T:#TS1#8T)3X\+W1D/@T* M(#QT9"!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Y)3X\+W1D/@T*(#QT9#X\ M+W1D/@T*(#QT9#X\+W1D/@T*(#QT9#X\+W1D/@T*(#QT9"!V86QI9VX],T1B M;W1T;VT@=VED=&@],T0X)3X\+W1D/@T*(#QT9#X\+W1D/@T*(#QT9#X\+W1D M/@T*(#QT9#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@=VED=&@],T0X M)3X\+W1D/@T*(#QT9#X\+W1D/@T*(#QT9#X\+W1D/@T*(#QT9#X\+W1D/@T* M(#PO='(^#0H@/'1R/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<VEZ M93TS1#$^)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O M;3X\9F]N="!S:7IE/3-$,3XF(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\ M=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@(S`P,#`P,"`Q<'@@<V]L:60G M('9A;&EG;CTS1&)O='1O;2!C;VQS<&%N/3-$,3`@86QI9VX],T1C96YT97(^ M/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@ M<VEZ93TS1#$^/&(^07,@;V8-"B!$96-E;6)E<B8C>$$P.S,Q+#PO8CX\+V9O M;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q M/B8C>$$P.SPO9F]N=#X\+W1D/@T*(#PO='(^#0H@/'1R/@T*(#QT9"!V86QI M9VX],T1B;W1T;VT^/&9O;G0@<VEZ93TS1#$^)B-X03`[/"]F;VYT/CPO=&0^ M#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF(WA!,#LF M(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/ M33H@(S`P,#`P,"`Q<'@@<V]L:60G('9A;&EG;CTS1&)O='1O;2!C;VQS<&%N M/3-$,B!A;&EG;CTS1&-E;G1E<CX\9F]N="!S='EL93TS1"=&3TY4+49!34E, M63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,3X\8CXR,#$T/"]B/CPO9F]N M=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<VEZ93TS1#$^ M)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N M="!S:7IE/3-$,3XF(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@<W1Y M;&4],T0G0D]21$52+4)/5%1/33H@(S`P,#`P,"`Q<'@@<V]L:60G('9A;&EG M;CTS1&)O='1O;2!C;VQS<&%N/3-$,B!A;&EG;CTS1&-E;G1E<CX\9F]N="!S M='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$ M,3X\8CXR,#$S/"]B/CPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T M;VT^/&9O;G0@<VEZ93TS1#$^)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A M;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF(WA!,#LF(WA!,#L\+V9O M;G0^/"]T9#X-"B`\=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@(S`P,#`P M,"`Q<'@@<V]L:60G('9A;&EG;CTS1&)O='1O;2!C;VQS<&%N/3-$,B!A;&EG M;CTS1&-E;G1E<CX\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@ M3F5W(%)O;6%N)R!S:7IE/3-$,3X\8CXR,#$R/"]B/CPO9F]N=#X\+W1D/@T* M(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<VEZ93TS1#$^)B-X03`[/"]F M;VYT/CPO=&0^#0H@/"]T<CX-"B`\='(@8F=C;VQO<CTS1"-#0T5%1D8^#0H@ M/'1D('9A;&EG;CTS1'1O<#X-"B`\<"!S='EL93TS1"=-05)'24XM3$5&5#H@ M,65M.R!415A4+4E.1$5.5#H@+3%E;2<^/&9O;G0@<W1Y;&4],T0G1D].5"U& M04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^1&5F97)R960@=&%X M#0H@87-S971S.CPO9F]N=#X\+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$ M8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\=&0@=F%L:6=N/3-$ M8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT M9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<VEZ93TS1#$^)B-X03`[)B-X03`[ M/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT M9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF M(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI M9VX],T1B;W1T;VT^/"]T9#X-"B`\+W1R/@T*(#QT<CX-"B`\=&0@=F%L:6=N M/3-$=&]P/@T*(#QP('-T>6QE/3-$)TU!4D=)3BU,1494.B`R96T[(%1%6%0M M24Y$14Y4.B`M,65M)SX\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM M97,@3F5W(%)O;6%N)R!S:7IE/3-$,CY$97!R96-I871I;VX@86YD#0H@86UO M<G1I>F%T:6]N/"]F;VYT/CPO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B M;W1T;VT^/&9O;G0@<VEZ93TS1#$^)B-X03`[)B-X03`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`[)B-X M03`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`[)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS M1&)O='1O;3X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W M(%)O;6%N)R!S:7IE/3-$,CXD/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS M1&)O='1O;2!A;&EG;CTS1')I9VAT/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%- M24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R/C$L,#(T/"]F;VYT/CPO M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^/&9O M;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ M93TS1#(^)B-X03`[)B-X03`[/"]F;VYT/CPO=&0^#0H@/"]T<CX-"B`\='(@ M8F=C;VQO<CTS1"-#0T5%1D8^#0H@/'1D('9A;&EG;CTS1'1O<#X-"B`\<"!S M='EL93TS1"=-05)'24XM3$5&5#H@,F5M.R!415A4+4E.1$5.5#H@+3%E;2<^ M/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@ M<VEZ93TS1#(^0V%P:71A;&EZ960-"B!2)F%M<#M$/"]F;VYT/CPO<#X-"B`\ M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<VEZ93TS1#$^)B-X M03`[)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\ M9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S M:7IE/3-$,CXF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T M=&]M(&%L:6=N/3-$<FEG:'0^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ M(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^,34L,3<V/"]F;VYT/CPO=&0^ M#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^/&9O;G0@ M<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS M1#(^)B-X03`[)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O M='1O;3X\9F]N="!S:7IE/3-$,3XF(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X- M"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%- M24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R/B8C>$$P.SPO9F]N=#X\ M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#X\9F]N M="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE M/3-$,CXR,"PW,#(\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M M(&YO=W)A<#TS1&YO=W)A<#X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@ M5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXF(WA!,#LF(WA!,#L\+V9O;G0^ M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C M>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^ M/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@ M<VEZ93TS1#(^)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O M='1O;2!A;&EG;CTS1')I9VAT/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9 M.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R/C0L.3,R/"]F;VYT/CPO=&0^ M#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^/&9O;G0@ M<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS M1#(^)B-X03`[)B-X03`[/"]F;VYT/CPO=&0^#0H@/"]T<CX-"B`\='(^#0H@ M/'1D('9A;&EG;CTS1'1O<#X-"B`\<"!S='EL93TS1"=-05)'24XM3$5&5#H@ M,F5M.R!415A4+4E.1$5.5#H@+3%E;2<^/&9O;G0@<W1Y;&4],T0G1D].5"U& M04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^4F5S97)V97,@86YD M#0H@86-C<G5A;',\+V9O;G0^/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS M1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF(WA!,#LF(WA!,#L\+V9O;G0^/"]T M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)T9/3E0M M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R/B8C>$$P.SPO9F]N M=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#X\ M9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S M:7IE/3-$,CXV+#(Q-SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T M;VT@;F]W<F%P/3-$;F]W<F%P/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9 M.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R/B8C>$$P.R8C>$$P.SPO9F]N M=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<VEZ93TS1#$^ M)B-X03`[)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O M;3X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N M)R!S:7IE/3-$,CXF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$ M8F]T=&]M(&%L:6=N/3-$<FEG:'0^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U) M3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^-"PY-#8\+V9O;G0^/"]T M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#X\9F]N M="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE M/3-$,CXF(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$ M8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<W1Y;&4],T0G1D].5"U& M04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^)B-X03`[/"]F;VYT M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/CQF M;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I M>F4],T0R/C4L,3`Q/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O M;2!N;W=R87`],T1N;W=R87`^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ M(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^)B-X03`[)B-X03`[/"]F;VYT M/CPO=&0^#0H@/"]T<CX-"B`\='(@8F=C;VQO<CTS1"-#0T5%1D8^#0H@/'1D M('9A;&EG;CTS1'1O<#X-"B`\<"!S='EL93TS1"=-05)'24XM3$5&5#H@,F5M M.R!415A4+4E.1$5.5#H@+3%E;2<^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U) M3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^3F5T(&]P97)A=&EN9PT* M(&QO<W-E<SPO9F]N=#X\+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T M=&]M/CQF;VYT('-I>F4],T0Q/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T* M(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U) M3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^)B-X03`[/"]F;VYT/CPO M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/CQF;VYT M('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4] M,T0R/C$T."PQ.#0\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M M(&YO=W)A<#TS1&YO=W)A<#X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@ M5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXF(WA!,#LF(WA!,#L\+V9O;G0^ M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C M>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^ M/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@ M<VEZ93TS1#(^)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O M='1O;2!A;&EG;CTS1')I9VAT/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9 M.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R/C$T-"PR-30\+V9O;G0^/"]T M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#X\9F]N M="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE M/3-$,CXF(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$ M8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<W1Y;&4],T0G1D].5"U& M04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^)B-X03`[/"]F;VYT M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/CQF M;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I M>F4],T0R/C$U,RPQ.3,\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T M=&]M(&YO=W)A<#TS1&YO=W)A<#X\9F]N="!S='EL93TS1"=&3TY4+49!34E, M63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXF(WA!,#LF(WA!,#L\+V9O M;G0^/"]T9#X-"B`\+W1R/@T*(#QT<CX-"B`\=&0@=F%L:6=N/3-$=&]P/@T* M(#QP('-T>6QE/3-$)TU!4D=)3BU,1494.B`R96T[(%1%6%0M24Y$14Y4.B`M M,65M)SX\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O M;6%N)R!S:7IE/3-$,CY487@@8W)E9&ET<SPO9F]N=#X\+W`^#0H@/"]T9#X- M"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C>$$P.R8C M>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@ M<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS M1#(^)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A M;&EG;CTS1')I9VAT/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE M<R!.97<@4F]M86XG('-I>F4],T0R/C,T+#4T,SPO9F]N=#X\+W1D/@T*(#QT M9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P/CQF;VYT('-T>6QE M/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R/B8C M>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^ M/&9O;G0@<VEZ93TS1#$^)B-X03`[)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D M('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@ M5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXF(WA!,#L\+V9O;G0^/"]T9#X- M"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^/&9O;G0@<W1Y M;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^ M,S,L,#0S/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R M87`],T1N;W=R87`^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S M($YE=R!2;VUA;B<@<VEZ93TS1#(^)B-X03`[)B-X03`[/"]F;VYT/CPO=&0^ M#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF(WA!,#LF M(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT M('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4] M,T0R/B8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@ M86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM M97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXR-2PY-#,\+V9O;G0^/"]T9#X-"B`\ M=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#X\9F]N="!S='EL M93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXF M(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\+W1R/@T*(#QT<B!S='EL93TS M1"=&3TY4+5-)6D4Z(#%P>"<^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\ M=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z M(",P,#`P,#`@,7!X('-O;&ED)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0@ M=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(",P M,#`P,#`@,7!X('-O;&ED)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0^)B-X M03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$ M15(M5$]0.B`C,#`P,#`P(#%P>"!S;VQI9"<^)B-X03`[/"]P/@T*(#PO=&0^ M#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M M5$]0.B`C,#`P,#`P(#%P>"!S;VQI9"<^)B-X03`[/"]P/@T*(#PO=&0^#0H@ M/'1D/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF M(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@<W1Y;&4] M,T0G0D]21$52+51/4#H@(S`P,#`P,"`Q<'@@<V]L:60G/B8C>$$P.SPO<#X- M"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@<W1Y;&4],T0G M0D]21$52+51/4#H@(S`P,#`P,"`Q<'@@<V]L:60G/B8C>$$P.SPO<#X-"B`\ M+W1D/@T*(#QT9#XF(WA!,#L\+W1D/@T*(#PO='(^#0H@/'1R(&)G8V]L;W(] M,T0C0T-%149&/@T*(#QT9"!V86QI9VX],T1T;W`^#0H@/'`@<W1Y;&4],T0G M34%21TE.+4Q%1E0Z(#-E;3L@5$585"U)3D1%3E0Z("TQ96TG/CQF;VYT('-T M>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R M/E1O=&%L(&1E9F5R<F5D('1A>`T*(&%S<V5T<SPO9F]N=#X\+W`^#0H@/"]T M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C>$$P M.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O M;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ M93TS1#(^)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O M;2!A;&EG;CTS1')I9VAT/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4 M:6UE<R!.97<@4F]M86XG('-I>F4],T0R/C(P-"PY,#`\+V9O;G0^/"]T9#X- M"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#X\9F]N="!S M='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$ M,CXF(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T M=&]M/CQF;VYT('-I>F4],T0Q/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T* M(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U) M3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^)B-X03`[/"]F;VYT/CPO M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/CQF;VYT M('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4] M,T0R/C(P,RPX-C,\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M M(&YO=W)A<#TS1&YO=W)A<#X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@ M5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXF(WA!,#LF(WA!,#L\+V9O;G0^ M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C M>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^ M/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@ M<VEZ93TS1#(^)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O M='1O;2!A;&EG;CTS1')I9VAT/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9 M.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R/C$Y,"PQ.3,\+V9O;G0^/"]T M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#X\9F]N M="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE M/3-$,CXF(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\+W1R/@T*(#QT<CX- M"B`\=&0@=F%L:6=N/3-$=&]P/@T*(#QP('-T>6QE/3-$)TU!4D=)3BU,1494 M.B`Q96T[(%1%6%0M24Y$14Y4.B`M,65M)SX\9F]N="!S='EL93TS1"=&3TY4 M+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CY,97-S.B!686QU M871I;VX-"B!A;&QO=V%N8V4\+V9O;G0^/"]P/@T*(#PO=&0^#0H@/'1D('9A M;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF(WA!,#LF(WA!,#L\+V9O M;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$ M)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R/B8C>$$P M.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R M:6=H=#X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O M;6%N)R!S:7IE/3-$,CXH,C`T+#DP,#PO9F]N=#X\+W1D/@T*(#QT9"!V86QI M9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P/CQF;VYT('-T>6QE/3-$)T9/ M3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R/BDF(WA!,#L\ M+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4] M,T0Q/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B M;W1T;VT^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2 M;VUA;B<@<VEZ93TS1#(^)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG M;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/CQF;VYT('-T>6QE/3-$)T9/3E0M M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R/B@R,#,L.#8S/"]F M;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R M87`^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA M;B<@<VEZ93TS1#(^*28C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX] M,T1B;W1T;VT^/&9O;G0@<VEZ93TS1#$^)B-X03`[)B-X03`[/"]F;VYT/CPO M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=&3TY4 M+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXF(WA!,#L\+V9O M;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^ M/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@ M<VEZ93TS1#(^*#$Y,"PQ.3,\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$ M8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#X\9F]N="!S='EL93TS1"=&3TY4+49! M34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXI)B-X03`[/"]F;VYT M/CPO=&0^#0H@/"]T<CX-"B`\='(@<W1Y;&4],T0G1D].5"U325I%.B`Q<'@G M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\=&0@=F%L:6=N/3-$ M8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O M;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B`C,#`P,#`P(#%P>"!S;VQI M9"<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X- M"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B`C,#`P,#`P(#%P>"!S;VQI9"<^ M)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D/B8C>$$P.SPO=&0^#0H@/'1D('9A M;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX] M,T1B;W1T;VT^#0H@/'`@<W1Y;&4],T0G0D]21$52+51/4#H@(S`P,#`P,"`Q M<'@@<V]L:60G/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B M;W1T;VT^#0H@/'`@<W1Y;&4],T0G0D]21$52+51/4#H@(S`P,#`P,"`Q<'@@ M<V]L:60G/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT9#XF(WA!,#L\+W1D/@T* M(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@ M=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(",P M,#`P,#`@,7!X('-O;&ED)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0@=F%L M:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P M,#`@,7!X('-O;&ED)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0^)B-X03`[ M/"]T9#X-"B`\+W1R/@T*(#QT<B!B9V-O;&]R/3-$(T-#145&1CX-"B`\=&0@ M=F%L:6=N/3-$=&]P/@T*(#QP('-T>6QE/3-$)TU!4D=)3BU,1494.B`Q96T[ M(%1%6%0M24Y$14Y4.B`M,65M)SX\9F]N="!S='EL93TS1"=&3TY4+49!34E, M63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CY.970@9&5F97)R960@=&%X M#0H@87-S971S/"]F;VYT/CPO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B M;W1T;VT^/&9O;G0@<VEZ93TS1#$^)B-X03`[)B-X03`[/"]F;VYT/CPO=&0^ M#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^/&9O;G0@ M<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS M1#(^)#PO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P M/3-$;F]W<F%P(&%L:6=N/3-$<FEG:'0^/&9O;G0@<W1Y;&4],T0G1D].5"U& M04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^)B-X,C`Q-#L\+V9O M;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A M<#X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N M)R!S:7IE/3-$,CXF(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L M:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C>$$P.R8C>$$P.SPO9F]N M=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P M/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG M('-I>F4],T0R/B0\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M M(&YO=W)A<#TS1&YO=W)A<"!A;&EG;CTS1')I9VAT/CQF;VYT('-T>6QE/3-$ M)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R/B8C>#(P M,30[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`] M,T1N;W=R87`^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE M=R!2;VUA;B<@<VEZ93TS1#(^)B-X03`[)B-X03`[/"]F;VYT/CPO=&0^#0H@ M/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF(WA!,#LF(WA! M,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS M1&YO=W)A<#X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W M(%)O;6%N)R!S:7IE/3-$,CXD/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS M1&)O='1O;2!N;W=R87`],T1N;W=R87`@86QI9VX],T1R:6=H=#X\9F]N="!S M='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$ M,CXF(W@R,#$T.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@ M;F]W<F%P/3-$;F]W<F%P/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4 M:6UE<R!.97<@4F]M86XG('-I>F4],T0R/B8C>$$P.R8C>$$P.SPO9F]N=#X\ M+W1D/@T*(#PO='(^#0H@/'1R('-T>6QE/3-$)T9/3E0M4TE:13H@,7!X)SX- M"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O M='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^ M#0H@/'`@<W1Y;&4],T0G0D]21$52+51/4#H@(S`P,#`P,"`S<'@@9&]U8FQE M)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T* M(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@,W!X(&1O=6)L92<^ M)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D/B8C>$$P.SPO=&0^#0H@/'1D('9A M;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX] M,T1B;W1T;VT^#0H@/'`@<W1Y;&4],T0G0D]21$52+51/4#H@(S`P,#`P,"`S M<'@@9&]U8FQE)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$ M8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@,W!X M(&1O=6)L92<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D/B8C>$$P.SPO=&0^ M#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT M9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@<W1Y;&4],T0G0D]21$52+51/4#H@ M(S`P,#`P,"`S<'@@9&]U8FQE)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0@ M=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(",P M,#`P,#`@,W!X(&1O=6)L92<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D/B8C M>$$P.SPO=&0^#0H@/"]T<CX-"B`\+W1A8FQE/@T*(#PO9&EV/CQS<&%N/CPO M<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E M/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^0V]M<&%N M>2=S(%9A;'5A=&EO;B!A;F0@475A;&EF>6EN9R!!8V-O=6YT<SPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/&1I=CX-"B`\<"!S='EL93TS1"=- M05)'24XM0D]45$]-.B`P<'@[($U!4D=)3BU43U`Z(#$R<'@[(%1%6%0M24Y$ M14Y4.B`T)2<@86QI9VX],T1J=7-T:69Y/CQF;VYT('-T>6QE/3-$)T9/3E0M M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R/E1H92!F;VQL;W=I M;F<@87)E('1H92!#;VUP86YY)B-X,C`Q.3MS('9A;'5A=&EO;B!A;F0@<75A M;&EF>6EN9PT*(&%C8V]U;G1S("AI;B!T:&]U<V%N9',I.CPO9F]N=#X\+W`^ M#0H@/'`@<W1Y;&4],T0G34%21TE.+4)/5%1/33H@,'!X.R!&3TY4+5-)6D4Z M(#$R<'@[($U!4D=)3BU43U`Z(#!P>"<^#0H@)B-X03`[/"]P/@T*(#QT86)L M92!S='EL93TS1"="3U)$15(M0T],3$%04T4Z(&-O;&QA<'-E)R!C96QL<W!A M8VEN9STS1#`@8V5L;'!A9&1I;F<],T0P('=I9'1H/3-$,3`P)2!A;&EG;CTS M1&-E;G1E<B!B;W)D97(],T0P/@T*(#QT<CX-"B`\=&0@=VED=&@],T0T-R4^ M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$-B4^/"]T9#X- M"B`\=&0^/"]T9#X-"B`\=&0^/"]T9#X-"B`\=&0^/"]T9#X-"B`\=&0@=F%L M:6=N/3-$8F]T=&]M('=I9'1H/3-$-B4^/"]T9#X-"B`\=&0^/"]T9#X-"B`\ M=&0^/"]T9#X-"B`\=&0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M('=I M9'1H/3-$-B4^/"]T9#X-"B`\=&0^/"]T9#X-"B`\=&0^/"]T9#X-"B`\=&0^ M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$-B4^/"]T9#X- M"B`\=&0^/"]T9#X-"B`\=&0^/"]T9#X-"B`\=&0^/"]T9#X-"B`\=&0@=F%L M:6=N/3-$8F]T=&]M('=I9'1H/3-$-B4^/"]T9#X-"B`\=&0^/"]T9#X-"B`\ M=&0^/"]T9#X-"B`\=&0^/"]T9#X-"B`\+W1R/@T*(#QT<CX-"B`\=&0@=F%L M:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C>$$P.SPO9F]N=#X\+W1D M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<VEZ93TS1#$^)B-X03`[ M)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('-T>6QE/3-$)T)/4D1%4BU"3U14 M3TTZ(",P,#`P,#`@,7!X('-O;&ED)R!V86QI9VX],T1B;W1T;VT@8V]L<W!A M;CTS1#(@86QI9VX],T1C96YT97(^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U) M3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#$^/&(^0F%L86YC92!A=#QB M<B`O/@T*($)E9VEN;FEN9R8C>$$P.V]F/&)R("\^#0H@4&5R:6]D/"]B/CPO M9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<VEZ93TS M1#$^)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\ M9F]N="!S:7IE/3-$,3XF(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@ M<W1Y;&4],T0G0D]21$52+4)/5%1/33H@(S`P,#`P,"`Q<'@@<V]L:60G('9A M;&EG;CTS1&)O='1O;2!C;VQS<&%N/3-$,B!A;&EG;CTS1&-E;G1E<CX\9F]N M="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE M/3-$,3X\8CY#:&%R9V5D)B-X03`[=&\\8G(@+SX-"B!%>'!E;G-E<SPO8CX\ M+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4] M,T0Q/B8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^ M/&9O;G0@<VEZ93TS1#$^)B-X03`[)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D M('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,7!X('-O;&ED)R!V M86QI9VX],T1B;W1T;VT@8V]L<W!A;CTS1#(@86QI9VX],T1C96YT97(^/&9O M;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ M93TS1#$^/&(^0VAA<F=E9"8C>$$P.W1O/&)R("\^#0H@3W1H97(F(WA!,#M! M8V-O=6YT<SPO8CX\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M M/CQF;VYT('-I>F4],T0Q/B8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI M9VX],T1B;W1T;VT^/&9O;G0@<VEZ93TS1#$^)B-X03`[)B-X03`[/"]F;VYT M/CPO=&0^#0H@/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@ M,7!X('-O;&ED)R!V86QI9VX],T1B;W1T;VT@8V]L<W!A;CTS1#(@86QI9VX] M,T1C96YT97(^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE M=R!2;VUA;B<@<VEZ93TS1#$^/&(^1&5D=6-T:6]N<SPO8CX\+V9O;G0^/"]T M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C>$$P M.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<VEZ M93TS1#$^)B-X03`[)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('-T>6QE/3-$ M)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,7!X('-O;&ED)R!V86QI9VX],T1B M;W1T;VT@8V]L<W!A;CTS1#(@86QI9VX],T1C96YT97(^/&9O;G0@<W1Y;&4] M,T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#$^/&(^ M0F%L86YC92!A=#QB<B`O/@T*($5N9"8C>$$P.V]F)B-X03`[4&5R:6]D/"]B M/CPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<VEZ M93TS1#$^)B-X03`[/"]F;VYT/CPO=&0^#0H@/"]T<CX-"B`\='(@8F=C;VQO M<CTS1"-#0T5%1D8^#0H@/'1D('9A;&EG;CTS1'1O<#X-"B`\<"!S='EL93TS M1"=-05)'24XM3$5&5#H@,65M.R!415A4+4E.1$5.5#H@+3%E;2<^/&9O;G0@ M<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS M1#(^665A<B!%;F1E9`T*($1E8V5M8F5R)B-X03`[,S$L(#(P,3(Z/"]F;VYT M/CPO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<VEZ M93TS1#$^)B-X03`[)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS M1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\ M=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O M;3X\9F]N="!S:7IE/3-$,3XF(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\ M=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O M;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\=&0@=F%L M:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C>$$P.R8C>$$P.SPO9F]N M=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\=&0@=F%L M:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<VEZ93TS1#$^)B-X03`[ M)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\=&0@=F%L:6=N/3-$ M8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE M/3-$,3XF(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$ M8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT M9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\+W1R/@T*(#QT<CX-"B`\=&0@ M=F%L:6=N/3-$=&]P/@T*(#QP('-T>6QE/3-$)TU!4D=)3BU,1494.B`R96T[ M(%1%6%0M24Y$14Y4.B`M,65M)SX\9F]N="!S='EL93TS1"=&3TY4+49!34E, M63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CY$969E<G)E9"!T87@@=F%L M=6%T:6]N#0H@86QL;W=A;F-E/"]F;VYT/CPO<#X-"B`\+W1D/@T*(#QT9"!V M86QI9VX],T1B;W1T;VT^/&9O;G0@<VEZ93TS1#$^)B-X03`[)B-X03`[/"]F M;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS M1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXD/"]F M;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT M/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG M('-I>F4],T0R/C$V.2PQ,#<\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$ M8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#X\9F]N="!S='EL93TS1"=&3TY4+49! M34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXF(WA!,#LF(WA!,#L\ M+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4] M,T0Q/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B M;W1T;VT^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2 M;VUA;B<@<VEZ93TS1#(^)#PO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B M;W1T;VT@86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS1"=&3TY4+49!34E, M63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXR,2PP.#8\+V9O;G0^/"]T M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#X\9F]N M="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE M/3-$,CXF(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$ M8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P/CQF;VYT M('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4] M,T0R/B8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@ M;F]W<F%P/3-$;F]W<F%P(&%L:6=N/3-$<FEG:'0^/&9O;G0@<W1Y;&4],T0G M1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^)B-X,C`Q M-#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS M1&YO=W)A<#X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W M(%)O;6%N)R!S:7IE/3-$,CXF(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\ M=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C>$$P.R8C>$$P M.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$ M;F]W<F%P/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@ M4F]M86XG('-I>F4],T0R/B8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI M9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P(&%L:6=N/3-$<FEG:'0^/&9O M;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ M93TS1#(^)B-X,C`Q-#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T M=&]M(&YO=W)A<#TS1&YO=W)A<#X\9F]N="!S='EL93TS1"=&3TY4+49!34E, M63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXF(WA!,#LF(WA!,#L\+V9O M;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q M/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T M;VT^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA M;B<@<VEZ93TS1#(^)#PO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T M;VT@86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@ M5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXQ.3`L,3DS/"]F;VYT/CPO=&0^ M#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^/&9O;G0@ M<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS M1#(^)B-X03`[)B-X03`[/"]F;VYT/CPO=&0^#0H@/"]T<CX-"B`\='(@8F=C M;VQO<CTS1"-#0T5%1D8^#0H@/'1D('9A;&EG;CTS1'1O<#X-"B`\<"!S='EL M93TS1"=-05)'24XM3$5&5#H@,65M.R!415A4+4E.1$5.5#H@+3%E;2<^/&9O M;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ M93TS1#(^665A<B!%;F1E9`T*($1E8V5M8F5R)B-X03`[,S$L(#(P,3,Z/"]F M;VYT/CPO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@ M<VEZ93TS1#$^)B-X03`[)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG M;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X- M"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O M='1O;3X\9F]N="!S:7IE/3-$,3XF(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X- M"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O M='1O;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\=&0@ M=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C>$$P.R8C>$$P.SPO M9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\=&0@ M=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\ M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<VEZ93TS1#$^)B-X M03`[)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\ M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\=&0@=F%L:6=N M/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S M:7IE/3-$,3XF(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N M/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T* M(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\+W1R/@T*(#QT<CX-"B`\ M=&0@=F%L:6=N/3-$=&]P/@T*(#QP('-T>6QE/3-$)TU!4D=)3BU,1494.B`R M96T[(%1%6%0M24Y$14Y4.B`M,65M)SX\9F]N="!S='EL93TS1"=&3TY4+49! M34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CY$969E<G)E9"!T87@@ M=F%L=6%T:6]N#0H@86QL;W=A;F-E/"]F;VYT/CPO<#X-"B`\+W1D/@T*(#QT M9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<VEZ93TS1#$^)B-X03`[)B-X03`[ M/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL M93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXD M/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I M9VAT/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M M86XG('-I>F4],T0R/C$Y,"PQ.3,\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N M/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#X\9F]N="!S='EL93TS1"=&3TY4 M+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXF(WA!,#LF(WA! M,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I M>F4],T0Q/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX] M,T1B;W1T;VT^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE M=R!2;VUA;B<@<VEZ93TS1#(^)#PO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX] M,T1B;W1T;VT@86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS1"=&3TY4+49! M34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXQ,RPV-S`\+V9O;G0^ M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#X\ M9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S M:7IE/3-$,CXF(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N M/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C>$$P.R8C>$$P.SPO9F]N=#X\ M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P/CQF M;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I M>F4],T0R/B8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T M;VT@;F]W<F%P/3-$;F]W<F%P(&%L:6=N/3-$<FEG:'0^/&9O;G0@<W1Y;&4] M,T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^)B-X M,C`Q-#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A M<#TS1&YO=W)A<#X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@ M3F5W(%)O;6%N)R!S:7IE/3-$,CXF(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X- M"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C>$$P.R8C M>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P M/3-$;F]W<F%P/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!. M97<@4F]M86XG('-I>F4],T0R/B8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V M86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P(&%L:6=N/3-$<FEG:'0^ M/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@ M<VEZ93TS1#(^)B-X,C`Q-#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$ M8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#X\9F]N="!S='EL93TS1"=&3TY4+49! M34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXF(WA!,#LF(WA!,#L\ M+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4] M,T0Q/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B M;W1T;VT^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2 M;VUA;B<@<VEZ93TS1#(^)#PO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B M;W1T;VT@86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS1"=&3TY4+49!34E, M63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXR,#,L.#8S/"]F;VYT/CPO M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^/&9O M;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ M93TS1#(^)B-X03`[)B-X03`[/"]F;VYT/CPO=&0^#0H@/"]T<CX-"B`\='(@ M8F=C;VQO<CTS1"-#0T5%1D8^#0H@/'1D('9A;&EG;CTS1'1O<#X-"B`\<"!S M='EL93TS1"=-05)'24XM3$5&5#H@,65M.R!415A4+4E.1$5.5#H@+3%E;2<^ M/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@ M<VEZ93TS1#(^665A<B!%;F1E9`T*($1E8V5M8F5R)B-X03`[,S$L(#(P,30Z M/"]F;VYT/CPO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O M;G0@<VEZ93TS1#$^)B-X03`[)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A M;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS M1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF(WA!,#LF(WA!,#L\+V9O;G0^/"]T M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS M1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\ M=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C>$$P.R8C>$$P M.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\ M=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O M;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<VEZ93TS1#$^ M)B-X03`[)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O M;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\=&0@=F%L M:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N M="!S:7IE/3-$,3XF(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L M:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\+W1R/@T*(#QT<CX- M"B`\=&0@=F%L:6=N/3-$=&]P/@T*(#QP('-T>6QE/3-$)TU!4D=)3BU,1494 M.B`R96T[(%1%6%0M24Y$14Y4.B`M,65M)SX\9F]N="!S='EL93TS1"=&3TY4 M+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CY$969E<G)E9"!T M87@@=F%L=6%T:6]N#0H@86QL;W=A;F-E/"]F;VYT/CPO<#X-"B`\+W1D/@T* M(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<VEZ93TS1#$^)B-X03`[)B-X M03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S M='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$ M,CXD/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS M1')I9VAT/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@ M4F]M86XG('-I>F4],T0R/C(P,RPX-C,\+V9O;G0^/"]T9#X-"B`\=&0@=F%L M:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#X\9F]N="!S='EL93TS1"=& M3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXF(WA!,#LF M(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT M('-I>F4],T0Q/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI M9VX],T1B;W1T;VT^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S M($YE=R!2;VUA;B<@<VEZ93TS1#(^)#PO9F]N=#X\+W1D/@T*(#QT9"!V86QI M9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS1"=&3TY4 M+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXQ+#`S-SPO9F]N M=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P M/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG M('-I>F4],T0R/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI M9VX],T1B;W1T;VT^/&9O;G0@<VEZ93TS1#$^)B-X03`[)B-X03`[/"]F;VYT M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^ M/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@ M<VEZ93TS1#(^)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O M='1O;2!N;W=R87`],T1N;W=R87`@86QI9VX],T1R:6=H=#X\9F]N="!S='EL M93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXF M(W@R,#$T.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W M<F%P/3-$;F]W<F%P/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE M<R!.97<@4F]M86XG('-I>F4],T0R/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<VEZ93TS1#$^)B-X03`[ M)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R M87`],T1N;W=R87`^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S M($YE=R!2;VUA;B<@<VEZ93TS1#(^)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D M('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`@86QI9VX],T1R:6=H M=#X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N M)R!S:7IE/3-$,CXF(W@R,#$T.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX] M,T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P/CQF;VYT('-T>6QE/3-$)T9/3E0M M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R/B8C>$$P.R8C>$$P M.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<VEZ M93TS1#$^)B-X03`[)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS M1&)O='1O;3X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W M(%)O;6%N)R!S:7IE/3-$,CXD/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS M1&)O='1O;2!A;&EG;CTS1')I9VAT/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%- M24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R/C(P-"PY,#`\+V9O;G0^ M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#X\ M9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S M:7IE/3-$,CXF(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\+W1R/@T*(#PO M=&%B;&4^#0H@/"]D:78^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R M/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS M1'!L('9A;&EG;CTS1'1O<#Y296-O;F-I;&EA=&EO;B!O9B!3=&%T=71O<GD@ M1F5D97)A;"!);F-O;64@5&%X(%)A=&4@=&\@169F96-T:79E(%1A>"!2871E M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\9&EV/@T*(#QP('-T M>6QE/3-$)TU!4D=)3BU"3U143TTZ(#!P>#L@34%21TE.+51/4#H@,'!X.R!4 M15A4+4E.1$5.5#H@-"4G(&%L:6=N/3-$:G5S=&EF>3X\9F]N="!S='EL93TS M1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CY4:&4@ M9F]L;&]W:6YG(&ES(&$@<F5C;VYC:6QI871I;VX@;V8@=&AE('-T871U=&]R M>2!F961E<F%L#0H@:6YC;VUE('1A>"!R871E('1O('1H92!#;VUP86YY)B-X M,C`Q.3MS(&5F9F5C=&EV92!T87@-"B!R871E.CPO9F]N=#X\+W`^#0H@/'`@ M<W1Y;&4],T0G34%21TE.+4)/5%1/33H@,'!X.R!&3TY4+5-)6D4Z(#$R<'@[ M($U!4D=)3BU43U`Z(#!P>"<^#0H@)B-X03`[/"]P/@T*(#QT86)L92!S='EL M93TS1"="3U)$15(M0T],3$%04T4Z(&-O;&QA<'-E)R!C96QL<W!A8VEN9STS M1#`@8V5L;'!A9&1I;F<],T0P('=I9'1H/3-$.3(E(&%L:6=N/3-$8V5N=&5R M(&)O<F1E<CTS1#`^#0H@/'1R/@T*(#QT9"!W:61T:#TS1#@Q)3X\+W1D/@T* M(#QT9"!V86QI9VX],T1B;W1T;VT@=VED=&@],T0V)3X\+W1D/@T*(#QT9#X\ M+W1D/@T*(#QT9#X\+W1D/@T*(#QT9#X\+W1D/@T*(#QT9"!V86QI9VX],T1B M;W1T;VT@=VED=&@],T0U)3X\+W1D/@T*(#QT9#X\+W1D/@T*(#QT9#X\+W1D M/@T*(#QT9#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@=VED=&@],T0U M)3X\+W1D/@T*(#QT9#X\+W1D/@T*(#QT9#X\+W1D/@T*(#QT9#X\+W1D/@T* M(#PO='(^#0H@/'1R/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<VEZ M93TS1#$^)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O M;3X\9F]N="!S:7IE/3-$,3XF(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\ M=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@(S`P,#`P,"`Q<'@@<V]L:60G M('9A;&EG;CTS1&)O='1O;2!C;VQS<&%N/3-$,3`@86QI9VX],T1C96YT97(^ M/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@ M<VEZ93TS1#$^/&(^665A<G,@16YD960\8G(@+SX-"B!$96-E;6)E<B8C>$$P M.S,Q+#PO8CX\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF M;VYT('-I>F4],T0Q/B8C>$$P.SPO9F]N=#X\+W1D/@T*(#PO='(^#0H@/'1R M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<VEZ93TS1#$^)B-X03`[ M/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE M/3-$,3XF(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@<W1Y;&4],T0G M0D]21$52+4)/5%1/33H@(S`P,#`P,"`Q<'@@<V]L:60G('9A;&EG;CTS1&)O M='1O;2!C;VQS<&%N/3-$,B!A;&EG;CTS1&-E;G1E<CX\9F]N="!S='EL93TS M1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,3X\8CXR M,#$T/"]B/CPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O M;G0@<VEZ93TS1#$^)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS M1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF(WA!,#L\+V9O;G0^/"]T9#X-"B`\ M=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@(S`P,#`P,"`Q<'@@<V]L:60G M('9A;&EG;CTS1&)O='1O;2!C;VQS<&%N/3-$,B!A;&EG;CTS1&-E;G1E<CX\ M9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S M:7IE/3-$,3X\8CXR,#$S/"]B/CPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX] M,T1B;W1T;VT^/&9O;G0@<VEZ93TS1#$^)B-X03`[/"]F;VYT/CPO=&0^#0H@ M/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF(WA!,#L\+V9O M;G0^/"]T9#X-"B`\=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@(S`P,#`P M,"`Q<'@@<V]L:60G('9A;&EG;CTS1&)O='1O;2!C;VQS<&%N/3-$,B!A;&EG M;CTS1&-E;G1E<CX\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@ M3F5W(%)O;6%N)R!S:7IE/3-$,3X\8CXR,#$R/"]B/CPO9F]N=#X\+W1D/@T* M(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<VEZ93TS1#$^)B-X03`[/"]F M;VYT/CPO=&0^#0H@/"]T<CX-"B`\='(@8F=C;VQO<CTS1"-#0T5%1D8^#0H@ M/'1D('9A;&EG;CTS1'1O<#X-"B`\<"!S='EL93TS1"=-05)'24XM3$5&5#H@ M,65M.R!415A4+4E.1$5.5#H@+3%E;2<^/&9O;G0@<W1Y;&4],T0G1D].5"U& M04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^5&%X(&%T(&9E9&5R M86P@<W1A='5T;W)Y#0H@=&%X(')A=&4\+V9O;G0^/"]P/@T*(#PO=&0^#0H@ M/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF(WA!,#LF(WA! M,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T M>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R M/B8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI M9VX],T1R:6=H=#X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@ M3F5W(%)O;6%N)R!S:7IE/3-$,CXH,S0\+V9O;G0^/"]T9#X-"B`\=&0@=F%L M:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#X\9F]N="!S='EL93TS1"=& M3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXI)28C>$$P M.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<VEZ M93TS1#$^)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O M;3X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N M)R!S:7IE/3-$,CXF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$ M8F]T=&]M(&%L:6=N/3-$<FEG:'0^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U) M3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^*#,T/"]F;VYT/CPO=&0^ M#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^/&9O;G0@ M<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS M1#(^*24F(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M M/CQF;VYT('-I>F4],T0Q/B8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI M9VX],T1B;W1T;VT^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S M($YE=R!2;VUA;B<@<VEZ93TS1#(^)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D M('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/CQF;VYT('-T>6QE/3-$ M)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R/B@S-#PO M9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W M<F%P/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M M86XG('-I>F4],T0R/BDE)B-X03`[/"]F;VYT/CPO=&0^#0H@/"]T<CX-"B`\ M='(^#0H@/'1D('9A;&EG;CTS1'1O<#X-"B`\<"!S='EL93TS1"=-05)'24XM M3$5&5#H@,65M.R!415A4+4E.1$5.5#H@+3%E;2<^/&9O;G0@<W1Y;&4],T0G M1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^4W1A=&4@ M:6YC;VUE('1A>"P@;F5T(&]F#0H@9F5D97)A;"!T87@@8F5N969I=#PO9F]N M=#X\+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I M>F4],T0Q/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX] M,T1B;W1T;VT^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE M=R!2;VUA;B<@<VEZ93TS1#(^)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A M;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/CQF;VYT('-T>6QE/3-$)T9/ M3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R/B@Q/"]F;VYT M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^ M/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@ M<VEZ93TS1#(^*24F(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$ M8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT M9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ M(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^)B-X03`[/"]F;VYT/CPO=&0^ M#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/CQF;VYT('-T M>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R M/B@T/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`] M,T1N;W=R87`^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE M=R!2;VUA;B<@<VEZ93TS1#(^*24F(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@ M=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C>$$P.SPO9F]N=#X\ M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<W1Y;&4],T0G1D]. M5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^)B-X03`[/"]F M;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT M/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG M('-I>F4],T0R/B@V/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O M;2!N;W=R87`],T1N;W=R87`^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ M(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^*24F(WA!,#L\+V9O;G0^/"]T M9#X-"B`\+W1R/@T*(#QT<B!B9V-O;&]R/3-$(T-#145&1CX-"B`\=&0@=F%L M:6=N/3-$=&]P/@T*(#QP('-T>6QE/3-$)TU!4D=)3BU,1494.B`Q96T[(%1% M6%0M24Y$14Y4.B`M,65M)SX\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@ M5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CY3=&%T90T*($%P<&]R=&EO;FUE M;G0\+V9O;G0^/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\ M9F]N="!S:7IE/3-$,3XF(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@ M=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4 M:6UE<R!.97<@4F]M86XG('-I>F4],T0R/B8C>$$P.SPO9F]N=#X\+W1D/@T* M(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#X\9F]N="!S='EL M93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXR M.#PO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$ M;F]W<F%P/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@ M4F]M86XG('-I>F4],T0R/B4F(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L M:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C>$$P.SPO9F]N=#X\+W1D M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<W1Y;&4],T0G1D].5"U& M04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^)B-X03`[/"]F;VYT M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/CQF M;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I M>F4],T0R/C<\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO M=W)A<#TS1&YO=W)A<#X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM M97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXE)B-X03`[/"]F;VYT/CPO=&0^#0H@ M/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF(WA!,#L\+V9O M;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$ M)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R/B8C>$$P M.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R M:6=H=#X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O M;6%N)R!S:7IE/3-$,CXP/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O M='1O;2!N;W=R87`],T1N;W=R87`^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U) M3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^)28C>$$P.SPO9F]N=#X\ M+W1D/@T*(#PO='(^#0H@/'1R/@T*(#QT9"!V86QI9VX],T1T;W`^#0H@/'`@ M<W1Y;&4],T0G34%21TE.+4Q%1E0Z(#%E;3L@5$585"U)3D1%3E0Z("TQ96TG M/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG M('-I>F4],T0R/E1A>"!C<F5D:71S#0H@*&YE="D\+V9O;G0^/"]P/@T*(#PO M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF(WA! M,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF M;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I M>F4],T0R/B8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T M;VT@86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@ M5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXH-SPO9F]N=#X\+W1D/@T*(#QT M9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P/CQF;VYT('-T>6QE M/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R/BDE M)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N M="!S:7IE/3-$,3XF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$ M8F]T=&]M/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@ M4F]M86XG('-I>F4],T0R/B8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI M9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS1"=&3TY4 M+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXH,30\+V9O;G0^ M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#X\ M9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S M:7IE/3-$,CXI)28C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B M;W1T;VT^/&9O;G0@<VEZ93TS1#$^)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D M('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@ M5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXF(WA!,#L\+V9O;G0^/"]T9#X- M"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^/&9O;G0@<W1Y M;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^ M*#$Y/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`] M,T1N;W=R87`^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE M=R!2;VUA;B<@<VEZ93TS1#(^*24F(WA!,#L\+V9O;G0^/"]T9#X-"B`\+W1R M/@T*(#QT<B!B9V-O;&]R/3-$(T-#145&1CX-"B`\=&0@=F%L:6=N/3-$=&]P M/@T*(#QP('-T>6QE/3-$)TU!4D=)3BU,1494.B`Q96T[(%1%6%0M24Y$14Y4 M.B`M,65M)SX\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W M(%)O;6%N)R!S:7IE/3-$,CY$969E<G)E9"!T87@@87-S971S#0H@*'5T:6QI M>F5D*2!N;W0@8F5N969I=&5D/"]F;VYT/CPO<#X-"B`\+W1D/@T*(#QT9"!V M86QI9VX],T1B;W1T;VT^/&9O;G0@<VEZ93TS1#$^)B-X03`[)B-X03`[/"]F M;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS M1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXF(WA! M,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$ M<FEG:'0^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2 M;VUA;B<@<VEZ93TS1#(^-SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B M;W1T;VT@;F]W<F%P/3-$;F]W<F%P/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%- M24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R/B4F(WA!,#L\+V9O;G0^ M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C M>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@ M<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS M1#(^)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A M;&EG;CTS1')I9VAT/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE M<R!.97<@4F]M86XG('-I>F4],T0R/C0Q/"]F;VYT/CPO=&0^#0H@/'1D('9A M;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^/&9O;G0@<W1Y;&4],T0G M1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^)28C>$$P M.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<VEZ M93TS1#$^)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O M;3X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N M)R!S:7IE/3-$,CXF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$ M8F]T=&]M(&%L:6=N/3-$<FEG:'0^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U) M3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^-38\+V9O;G0^/"]T9#X- M"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#X\9F]N="!S M='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$ M,CXE)B-X03`[/"]F;VYT/CPO=&0^#0H@/"]T<CX-"B`\='(^#0H@/'1D('9A M;&EG;CTS1'1O<#X-"B`\<"!S='EL93TS1"=-05)'24XM3$5&5#H@,65M.R!4 M15A4+4E.1$5.5#H@+3%E;2<^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ M(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^4W1O8VLM8F%S960-"B!C;VUP M96YS871I;VX\+V9O;G0^/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O M='1O;3X\9F]N="!S:7IE/3-$,3XF(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X- M"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%- M24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R/B8C>$$P.SPO9F]N=#X\ M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#X\9F]N M="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE M/3-$,CXU/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R M87`],T1N;W=R87`^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S M($YE=R!2;VUA;B<@<VEZ93TS1#(^)28C>$$P.SPO9F]N=#X\+W1D/@T*(#QT M9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<VEZ93TS1#$^)B-X03`[/"]F;VYT M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=& M3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXF(WA!,#L\ M+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG M:'0^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA M;B<@<VEZ93TS1#(^,CPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T M;VT@;F]W<F%P/3-$;F]W<F%P/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9 M.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R/B4F(WA!,#L\+V9O;G0^/"]T M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C>$$P M.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<W1Y M;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^ M)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG M;CTS1')I9VAT/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!. M97<@4F]M86XG('-I>F4],T0R/C`\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N M/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#X\9F]N="!S='EL93TS1"=&3TY4 M+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXE)B-X03`[/"]F M;VYT/CPO=&0^#0H@/"]T<CX-"B`\='(@8F=C;VQO<CTS1"-#0T5%1D8^#0H@ M/'1D('9A;&EG;CTS1'1O<#X-"B`\<"!S='EL93TS1"=-05)'24XM3$5&5#H@ M,65M.R!415A4+4E.1$5.5#H@+3%E;2<^/&9O;G0@<W1Y;&4],T0G1D].5"U& M04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^3D],($5X<&ER871I M;VX\+V9O;G0^/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\ M9F]N="!S:7IE/3-$,3XF(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@ M=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4 M:6UE<R!.97<@4F]M86XG('-I>F4],T0R/B8C>$$P.SPO9F]N=#X\+W1D/@T* M(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#X\9F]N="!S='EL M93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXR M/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N M;W=R87`^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2 M;VUA;B<@<VEZ93TS1#(^)28C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI M9VX],T1B;W1T;VT^/&9O;G0@<VEZ93TS1#$^)B-X03`[/"]F;VYT/CPO=&0^ M#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=&3TY4+49! M34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXF(WA!,#L\+V9O;G0^ M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^/&9O M;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ M93TS1#(^,3PO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W M<F%P/3-$;F]W<F%P/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE M<R!.97<@4F]M86XG('-I>F4],T0R/B4F(WA!,#L\+V9O;G0^/"]T9#X-"B`\ M=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C>$$P.SPO9F]N M=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<W1Y;&4],T0G M1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^)B-X03`[ M/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I M9VAT/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M M86XG('-I>F4],T0R/C(\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T M=&]M(&YO=W)A<#TS1&YO=W)A<#X\9F]N="!S='EL93TS1"=&3TY4+49!34E, M63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXE)B-X03`[/"]F;VYT/CPO M=&0^#0H@/"]T<CX-"B`\='(^#0H@/'1D('9A;&EG;CTS1'1O<#X-"B`\<"!S M='EL93TS1"=-05)'24XM3$5&5#H@,65M.R!415A4+4E.1$5.5#H@+3%E;2<^ M/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@ M<VEZ93TS1#(^3W1H97(\+V9O;G0^/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG M;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF(WA!,#LF(WA!,#L\+V9O;G0^ M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)T9/ M3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R/B8C>$$P.SPO M9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H M=#X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N M)R!S:7IE/3-$,CXP/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O M;2!N;W=R87`],T1N;W=R87`^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ M(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^)28C>$$P.SPO9F]N=#X\+W1D M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<VEZ93TS1#$^)B-X03`[ M/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL M93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXF M(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N M/3-$<FEG:'0^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE M=R!2;VUA;B<@<VEZ93TS1#(^,3PO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX] M,T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P/CQF;VYT('-T>6QE/3-$)T9/3E0M M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R/B4F(WA!,#L\+V9O M;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q M/B8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O M;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ M93TS1#(^)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O M;2!A;&EG;CTS1')I9VAT/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4 M:6UE<R!.97<@4F]M86XG('-I>F4],T0R/C$\+V9O;G0^/"]T9#X-"B`\=&0@ M=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#X\9F]N="!S='EL93TS M1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXE)B-X M03`[/"]F;VYT/CPO=&0^#0H@/"]T<CX-"B`\='(@<W1Y;&4],T0G1D].5"U3 M25I%.B`Q<'@G/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\=&0@ M=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG M;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B`C,#`P,#`P M(#%P>"!S;VQI9"<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS M1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B`C,#`P,#`P(#%P M>"!S;VQI9"<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D/B8C>$$P.SPO=&0^ M#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI M9VX],T1B;W1T;VT^#0H@/'`@<W1Y;&4],T0G0D]21$52+51/4#H@(S`P,#`P M,"`Q<'@@<V]L:60G/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX] M,T1B;W1T;VT^#0H@/'`@<W1Y;&4],T0G0D]21$52+51/4#H@(S`P,#`P,"`Q M<'@@<V]L:60G/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT9#XF(WA!,#L\+W1D M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L M:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P M,#`@,7!X('-O;&ED)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N M/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@ M,7!X('-O;&ED)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0^)B-X03`[/"]T M9#X-"B`\+W1R/@T*(#QT<B!B9V-O;&]R/3-$(T-#145&1CX-"B`\=&0@=F%L M:6=N/3-$=&]P/@T*(#QP('-T>6QE/3-$)TU!4D=)3BU,1494.B`R96T[(%1% M6%0M24Y$14Y4.B`M,65M)SX\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@ M5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CY4;W1A;#PO9F]N=#X\+W`^#0H@ M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C M>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^ M/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@ M<VEZ93TS1#(^)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O M='1O;2!A;&EG;CTS1')I9VAT/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9 M.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R/C`\+V9O;G0^/"]T9#X-"B`\ M=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#X\9F]N="!S='EL M93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXE M)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N M="!S:7IE/3-$,3XF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$ M8F]T=&]M/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@ M4F]M86XG('-I>F4],T0R/B8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI M9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS1"=&3TY4 M+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXP/"]F;VYT/CPO M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^/&9O M;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ M93TS1#(^)28C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T M;VT^/&9O;G0@<VEZ93TS1#$^)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A M;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM M97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXF(WA!,#L\+V9O;G0^/"]T9#X-"B`\ M=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^/&9O;G0@<W1Y;&4] M,T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^,#PO M9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W M<F%P/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M M86XG('-I>F4],T0R/B4F(WA!,#L\+V9O;G0^/"]T9#X-"B`\+W1R/@T*(#QT M<B!S='EL93TS1"=&3TY4+5-)6D4Z(#%P>"<^#0H@/'1D('9A;&EG;CTS1&)O M='1O;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[ M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/ M4D1%4BU43U`Z(",P,#`P,#`@,W!X(&1O=6)L92<^)B-X03`[/"]P/@T*(#PO M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$ M15(M5$]0.B`C,#`P,#`P(#-P>"!D;W5B;&4G/B8C>$$P.SPO<#X-"B`\+W1D M/@T*(#QT9#XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X M03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$ M)T)/4D1%4BU43U`Z(",P,#`P,#`@,W!X(&1O=6)L92<^)B-X03`[/"]P/@T* M(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"=" M3U)$15(M5$]0.B`C,#`P,#`P(#-P>"!D;W5B;&4G/B8C>$$P.SPO<#X-"B`\ M+W1D/@T*(#QT9#XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^ M)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE M/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@,W!X(&1O=6)L92<^)B-X03`[/"]P M/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS M1"="3U)$15(M5$]0.B`C,#`P,#`P(#-P>"!D;W5B;&4G/B8C>$$P.SPO<#X- M"B`\+W1D/@T*(#QT9#XF(WA!,#L\+W1D/@T*(#PO='(^#0H@/"]T86)L93X- M"B`\+V1I=CX\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@ M("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L M:6=N/3-$=&]P/E)E8V]N8VEL:6%T:6]N(&]F(%1O=&%L($%M;W5N=',@;V8@ M56YR96-O9VYI>F5D(%1A>"!"96YE9FET<SPO=&0^#0H@("`@("`@(#QT9"!C M;&%S<STS1'1E>'0^/&1I=CX-"B`\<"!S='EL93TS1"=-05)'24XM0D]45$]- M.B`P<'@[($U!4D=)3BU43U`Z(#$R<'@[(%1%6%0M24Y$14Y4.B`T)2<@86QI M9VX],T1J=7-T:69Y/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE M<R!.97<@4F]M86XG('-I>F4],T0R/E1H92!F;VQL;W=I;F<@:7,@82!T86)U M;&%R(')E8V]N8VEL:6%T:6]N(&]F('1H92!T;W1A;"!A;6]U;G1S#0H@;V8@ M=6YR96-O9VYI>F5D('1A>"!B96YE9FET<R`H)B-X,C`Q0SM55$)S)B-X,C`Q M1#LI("AI;@T*('1H;W5S86YD<RDZ/"]F;VYT/CPO<#X-"B`\<"!S='EL93TS M1"=-05)'24XM0D]45$]-.B`P<'@[($9/3E0M4TE:13H@,3)P>#L@34%21TE. M+51/4#H@,'!X)SX-"B`F(WA!,#L\+W`^#0H@/'1A8FQE('-T>6QE/3-$)T)/ M4D1%4BU#3TQ,05!313H@8V]L;&%P<V4G(&-E;&QS<&%C:6YG/3-$,"!C96QL M<&%D9&EN9STS1#`@=VED=&@],T0Q,#`E(&%L:6=N/3-$8V5N=&5R(&)O<F1E M<CTS1#`^#0H@/'1R/@T*(#QT9"!W:61T:#TS1#4U)3X\+W1D/@T*(#QT9"!V M86QI9VX],T1B;W1T;VT@=VED=&@],T0Q,"4^/"]T9#X-"B`\=&0^/"]T9#X- M"B`\=&0^/"]T9#X-"B`\=&0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M M('=I9'1H/3-$,3`E/CPO=&0^#0H@/'1D/CPO=&0^#0H@/'1D/CPO=&0^#0H@ M/'1D/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$P)3X\ M+W1D/@T*(#QT9#X\+W1D/@T*(#QT9#X\+W1D/@T*(#QT9#X\+W1D/@T*(#PO M='(^#0H@/'1R/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<VEZ93TS M1#$^)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\ M9F]N="!S:7IE/3-$,3XF(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@ M<W1Y;&4],T0G0D]21$52+4)/5%1/33H@(S`P,#`P,"`Q<'@@<V]L:60G('9A M;&EG;CTS1&)O='1O;2!C;VQS<&%N/3-$,B!A;&EG;CTS1&-E;G1E<CX\9F]N M="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE M/3-$,3X\8CY&961E<F%L/&)R("\^#0H@86YD)B-X03`[4W1A=&4\8G(@+SX- M"B!487@\+V(^/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\ M9F]N="!S:7IE/3-$,3XF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N M/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C>$$P.SPO9F]N=#X\+W1D/@T* M(#QT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B`C,#`P,#`P(#%P>"!S;VQI M9"<@=F%L:6=N/3-$8F]T=&]M(&-O;'-P86X],T0R(&%L:6=N/3-$8V5N=&5R M/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG M('-I>F4],T0Q/CQB/D9E9&5R86PF(WA!,#M487@F(WA!,#M"96YE9FET/&)R M("\^#0H@;V8F(WA!,#M3=&%T928C>$$P.TEN8V]M928C>$$P.U1A>#QB<B`O M/@T*(%540G,\+V(^/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O M;3X\9F]N="!S:7IE/3-$,3XF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L M:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C>$$P.SPO9F]N=#X\+W1D M/@T*(#QT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B`C,#`P,#`P(#%P>"!S M;VQI9"<@=F%L:6=N/3-$8F]T=&]M(&-O;'-P86X],T0R(&%L:6=N/3-$8V5N M=&5R/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M M86XG('-I>F4],T0Q/CQB/E5N<F5C;V=N:7IE9"8C>$$P.TEN8V]M928C>$$P M.U1A>#QB<B`O/@T*($)E;F5F:71S)B-X03`[+28C>$$P.TYE="!O9B!&961E M<F%L/&)R("\^#0H@0F5N969I="!O9B!3=&%T92!55$)S/"]B/CPO9F]N=#X\ M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<VEZ93TS1#$^)B-X M03`[/"]F;VYT/CPO=&0^#0H@/"]T<CX-"B`\='(@8F=C;VQO<CTS1"-#0T5% M1D8^#0H@/'1D('9A;&EG;CTS1'1O<#X-"B`\<"!S='EL93TS1"=-05)'24XM M3$5&5#H@,F5M.R!415A4+4E.1$5.5#H@+3%E;2<^/&9O;G0@<W1Y;&4],T0G M1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^56YR96-O M9VYI>F5D('1A>"!B96YE9FET<PT*(&)A;&%N8V4@870@1&5C96UB97(F(WA! M,#LS,2P@,C`Q,CPO9F]N=#X\+W`^#0H@/"]T9#X-"B`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`[ M/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL M93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXD M/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I M9VAT/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M M86XG('-I>F4],T0R/C$L,34X/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS M1&)O='1O;2!N;W=R87`],T1N;W=R87`^/&9O;G0@<W1Y;&4],T0G1D].5"U& M04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^)B-X03`[)B-X03`[ M/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE M/3-$,3XF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M M/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG M('-I>F4],T0R/B0\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M M(&%L:6=N/3-$<FEG:'0^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I M;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^-"PQ.#(\+V9O;G0^/"]T9#X-"B`\ M=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#X\9F]N="!S='EL M93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXF M(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\+W1R/@T*(#QT<CX-"B`\=&0@ M=F%L:6=N/3-$=&]P/@T*(#QP('-T>6QE/3-$)TU!4D=)3BU,1494.B`Q96T[ M(%1%6%0M24Y$14Y4.B`M,65M)SX\9F]N="!S='EL93TS1"=&3TY4+49!34E, M63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CY!9&1I=&EO;B!F;W(@=&%X M('!O<VET:6]N<PT*(&]F('!R:6]R('EE87)S/"]F;VYT/CPO<#X-"B`\+W1D M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<VEZ93TS1#$^)B-X03`[ M)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N M="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE M/3-$,CXF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M M(&%L:6=N/3-$<FEG:'0^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I M;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^,C0\+V9O;G0^/"]T9#X-"B`\=&0@ M=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#X\9F]N="!S='EL93TS M1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXF(WA! M,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF M;VYT('-I>F4],T0Q/B8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX] M,T1B;W1T;VT^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE M=R!2;VUA;B<@<VEZ93TS1#(^)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A M;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/CQF;VYT('-T>6QE/3-$)T9/ M3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R/C@\+V9O;G0^ M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#X\ M9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S M:7IE/3-$,CXF(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N M/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C>$$P.SPO9F]N=#X\+W1D/@T* M(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U) M3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^)B-X03`[/"]F;VYT/CPO M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/CQF;VYT M('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4] M,T0R/C$V/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R M87`],T1N;W=R87`^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S M($YE=R!2;VUA;B<@<VEZ93TS1#(^)B-X03`[)B-X03`[/"]F;VYT/CPO=&0^ M#0H@/"]T<CX-"B`\='(@8F=C;VQO<CTS1"-#0T5%1D8^#0H@/'1D('9A;&EG M;CTS1'1O<#X-"B`\<"!S='EL93TS1"=-05)'24XM3$5&5#H@,65M.R!415A4 M+4E.1$5.5#H@+3%E;2<^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I M;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^061D:71I;VX@9F]R('1A>"!P;W-I M=&EO;G,-"B!R96QA=&5D('1O('1H92!C=7)R96YT('EE87(\+V9O;G0^/"]P M/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$ M,3XF(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T M=&]M/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M M86XG('-I>F4],T0R/B8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX] M,T1B;W1T;VT@86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS1"=&3TY4+49! M34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXX,#<\+V9O;G0^/"]T M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#X\9F]N M="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE M/3-$,CXF(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$ M8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT M9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ M(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^)B-X03`[/"]F;VYT/CPO=&0^ M#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/CQF;VYT('-T M>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R M/C0S/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`] M,T1N;W=R87`^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE M=R!2;VUA;B<@<VEZ93TS1#(^)B-X03`[)B-X03`[/"]F;VYT/CPO=&0^#0H@ M/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF(WA!,#L\+V9O M;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$ M)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R/B8C>$$P M.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R M:6=H=#X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O M;6%N)R!S:7IE/3-$,CXW-C0\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$ M8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#X\9F]N="!S='EL93TS1"=&3TY4+49! M34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXF(WA!,#LF(WA!,#L\ M+V9O;G0^/"]T9#X-"B`\+W1R/@T*(#QT<B!S='EL93TS1"=&3TY4+5-)6D4Z M(#%P>"<^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI M9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$ M8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@,7!X M('-O;&ED)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T M=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@,7!X('-O M;&ED)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0^)B-X03`[/"]T9#X-"B`\ M=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS M1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B`C,#`P,#`P(#%P M>"!S;VQI9"<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O M='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B`C,#`P,#`P(#%P>"!S M;VQI9"<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D/B8C>$$P.SPO=&0^#0H@ M/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX] M,T1B;W1T;VT^#0H@/'`@<W1Y;&4],T0G0D]21$52+51/4#H@(S`P,#`P,"`Q M<'@@<V]L:60G/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B M;W1T;VT^#0H@/'`@<W1Y;&4],T0G0D]21$52+51/4#H@(S`P,#`P,"`Q<'@@ M<V]L:60G/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT9#XF(WA!,#L\+W1D/@T* M(#PO='(^#0H@/'1R/@T*(#QT9"!V86QI9VX],T1T;W`^#0H@/'`@<W1Y;&4] M,T0G34%21TE.+4Q%1E0Z(#)E;3L@5$585"U)3D1%3E0Z("TQ96TG/CQF;VYT M('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4] M,T0R/E5N<F5C;V=N:7IE9"!T87@@8F5N969I=',-"B!B86QA;F-E(&%T($1E M8V5M8F5R)B-X03`[,S$L(#(P,3,\+V9O;G0^/"]P/@T*(#PO=&0^#0H@/'1D M('9A;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF(WA!,#LF(WA!,#L\ M+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE M/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R/B8C M>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX] M,T1R:6=H=#X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W M(%)O;6%N)R!S:7IE/3-$,CXV+#$W,3PO9F]N=#X\+W1D/@T*(#QT9"!V86QI M9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P/CQF;VYT('-T>6QE/3-$)T9/ M3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R/B8C>$$P.R8C M>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@ M<VEZ93TS1#$^)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O M='1O;3X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O M;6%N)R!S:7IE/3-$,CXF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N M/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^/&9O;G0@<W1Y;&4],T0G1D].5"U& M04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^,2PR,#D\+V9O;G0^ M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#X\ M9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S M:7IE/3-$,CXF(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N M/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C>$$P.SPO9F]N=#X\+W1D/@T* M(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U) M3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^)B-X03`[/"]F;VYT/CPO M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/CQF;VYT M('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4] M,T0R/C0L.38R/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N M;W=R87`],T1N;W=R87`^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I M;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^)B-X03`[)B-X03`[/"]F;VYT/CPO M=&0^#0H@/"]T<CX-"B`\='(@8F=C;VQO<CTS1"-#0T5%1D8^#0H@/'1D('9A M;&EG;CTS1'1O<#X-"B`\<"!S='EL93TS1"=-05)'24XM3$5&5#H@,65M.R!4 M15A4+4E.1$5.5#H@+3%E;2<^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ M(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^4F5D=6-T:6]N<R!F;W(@=&%X M#0H@<&]S:71I;VYS(&]F('!R:6]R('EE87)S/"]F;VYT/CPO<#X-"B`\+W1D M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<VEZ93TS1#$^)B-X03`[ M)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N M="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE M/3-$,CXF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M M(&%L:6=N/3-$<FEG:'0^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I M;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^*#@U/"]F;VYT/CPO=&0^#0H@/'1D M('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^/&9O;G0@<W1Y;&4] M,T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^*28C M>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@ M<VEZ93TS1#$^)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O M='1O;3X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O M;6%N)R!S:7IE/3-$,CXF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N M/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^/&9O;G0@<W1Y;&4],T0G1D].5"U& M04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^*#(Y/"]F;VYT/CPO M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^/&9O M;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ M93TS1#(^*28C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T M;VT^/&9O;G0@<VEZ93TS1#$^)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A M;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM M97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXF(WA!,#L\+V9O;G0^/"]T9#X-"B`\ M=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^/&9O;G0@<W1Y;&4] M,T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^*#4V M/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N M;W=R87`^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2 M;VUA;B<@<VEZ93TS1#(^*28C>$$P.SPO9F]N=#X\+W1D/@T*(#PO='(^#0H@ M/'1R/@T*(#QT9"!V86QI9VX],T1T;W`^#0H@/'`@<W1Y;&4],T0G34%21TE. M+4Q%1E0Z(#%E;3L@5$585"U)3D1%3E0Z("TQ96TG/CQF;VYT('-T>6QE/3-$ M)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R/D%D9&ET M:6]N(&9O<B!T87@@<&]S:71I;VYS#0H@<F5L871E9"!T;R!T:&4@8W5R<F5N M="!Y96%R/"]F;VYT/CPO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T M;VT^/&9O;G0@<VEZ93TS1#$^)B-X03`[)B-X03`[/"]F;VYT/CPO=&0^#0H@ M/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=&3TY4+49!34E, M63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXF(WA!,#L\+V9O;G0^/"]T M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^/&9O;G0@ M<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS M1#(^,3@X/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R M87`],T1N;W=R87`^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S M($YE=R!2;VUA;B<@<VEZ93TS1#(^)B-X03`[)B-X03`[/"]F;VYT/CPO=&0^ M#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF(WA!,#L\ M+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE M/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R/B8C M>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX] M,T1R:6=H=#X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W M(%)O;6%N)R!S:7IE/3-$,CXQ,#PO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX] M,T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P/CQF;VYT('-T>6QE/3-$)T9/3E0M M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R/B8C>$$P.R8C>$$P M.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<VEZ M93TS1#$^)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O M;3X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N M)R!S:7IE/3-$,CXF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$ M8F]T=&]M(&%L:6=N/3-$<FEG:'0^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U) M3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^,3<X/"]F;VYT/CPO=&0^ M#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^/&9O;G0@ M<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS M1#(^)B-X03`[)B-X03`[/"]F;VYT/CPO=&0^#0H@/"]T<CX-"B`\='(@<W1Y M;&4],T0G1D].5"U325I%.B`Q<'@G/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^ M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^ M#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M M5$]0.B`C,#`P,#`P(#%P>"!S;VQI9"<^)B-X03`[/"]P/@T*(#PO=&0^#0H@ M/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0 M.B`C,#`P,#`P(#%P>"!S;VQI9"<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@<W1Y;&4],T0G0D]21$52 M+51/4#H@(S`P,#`P,"`Q<'@@<V]L:60G/B8C>$$P.SPO<#X-"B`\+W1D/@T* M(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@<W1Y;&4],T0G0D]21$52+51/ M4#H@(S`P,#`P,"`Q<'@@<V]L:60G/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT M9#XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1% M4BU43U`Z(",P,#`P,#`@,7!X('-O;&ED)SXF(WA!,#L\+W`^#0H@/"]T9#X- M"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU4 M3U`Z(",P,#`P,#`@,7!X('-O;&ED)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\ M=&0^)B-X03`[/"]T9#X-"B`\+W1R/@T*(#QT<B!B9V-O;&]R/3-$(T-#145& M1CX-"B`\=&0@=F%L:6=N/3-$=&]P/@T*(#QP('-T>6QE/3-$)TU!4D=)3BU, M1494.B`R96T[(%1%6%0M24Y$14Y4.B`M,65M)SX\9F]N="!S='EL93TS1"=& M3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CY5;G)E8V]G M;FEZ960@=&%X(&)E;F5F:71S#0H@8F%L86YC92!A="!$96-E;6)E<B8C>$$P M.S,Q+"`R,#$T/"]F;VYT/CPO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B M;W1T;VT^/&9O;G0@<VEZ93TS1#$^)B-X03`[)B-X03`[/"]F;VYT/CPO=&0^ M#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=&3TY4+49! M34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXD/"]F;VYT/CPO=&0^ M#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/CQF;VYT('-T M>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R M/C8L,C<T/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R M87`],T1N;W=R87`^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S M($YE=R!2;VUA;B<@<VEZ93TS1#(^)B-X03`[)B-X03`[/"]F;VYT/CPO=&0^ M#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF(WA!,#L\ M+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE M/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R/B0\ M+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG M:'0^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA M;B<@<VEZ93TS1#(^,2PQ.3`\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$ M8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#X\9F]N="!S='EL93TS1"=&3TY4+49! M34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXF(WA!,#LF(WA!,#L\ M+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4] M,T0Q/B8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^ M/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@ M<VEZ93TS1#(^)#PO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@ M86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM M97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXU+#`X-#PO9F]N=#X\+W1D/@T*(#QT M9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P/CQF;VYT('-T>6QE M/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R/B8C M>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#PO='(^#0H@/'1R('-T>6QE/3-$ M)T9/3E0M4TE:13H@,7!X)SX-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^ M#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT M9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@<W1Y;&4],T0G0D]21$52+51/4#H@ M(S`P,#`P,"`S<'@@9&]U8FQE)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0@ M=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(",P M,#`P,#`@,W!X(&1O=6)L92<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D/B8C M>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T* M(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@<W1Y;&4],T0G0D]21$52+51/ M4#H@(S`P,#`P,"`S<'@@9&]U8FQE)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\ M=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z M(",P,#`P,#`@,W!X(&1O=6)L92<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@<W1Y;&4],T0G0D]21$52 M+51/4#H@(S`P,#`P,"`S<'@@9&]U8FQE)SXF(WA!,#L\+W`^#0H@/"]T9#X- M"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU4 M3U`Z(",P,#`P,#`@,W!X(&1O=6)L92<^)B-X03`[/"]P/@T*(#PO=&0^#0H@ M/'1D/B8C>$$P.SPO=&0^#0H@/"]T<CX-"B`\+W1A8FQE/@T*(#PO9&EV/CQS M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`\+W1A8FQE/@T* M("`\+V)O9'D^#0H\+VAT;6P^#0H-"BTM+2TM+3U?3F5X=%!A<G1?,SEC,&5A M-C)?8S(P,U\T-3AF7SAC-3!?,V1C830U-F$V.34Q#0I#;VYT96YT+4QO8V%T M:6]N.B!F:6QE.B\O+T,Z+S,Y8S!E838R7V,R,#-?-#4X9E\X8S4P7S-D8V$T M-39A-CDU,2]7;W)K<VAE971S+U-H965T,S4N:'1M;`T*0V]N=&5N="U4<F%N M<V9E<BU%;F-O9&EN9SH@<75O=&5D+7!R:6YT86)L90T*0V]N=&5N="U4>7!E M.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@ M/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C M;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA<G-E=#UU=&8M."<^/'-C<FEP="!T M>7!E/3-$=&5X="]J879A<V-R:7!T('-R8STS1%-H;W<N:G,^+RH@1&\@3F]T M(%)E;6]V92!4:&ES($-O;6UE;G0@*B\\+W-C<FEP=#X\+VAE860^#0H@(#QB M;V1Y/@T*("`@(#QT86)L92!C;&%S<STS1')E<&]R="!I9#TS1$E$,$5-13X- M"B`@("`@(#QT<CX-"B`@("`@("`@/'1H(&-L87-S/3-$=&P@8V]L<W!A;CTS M1#$@<F]W<W!A;CTS1#(^/'-T<F]N9SY);G1E<F5S="!A;F0@3W1H97(L($YE M="`H5&%B;&5S*3QB<CX\+W-T<F]N9SX\+W1H/@T*("`@("`@("`\=&@@8VQA M<W,],T1T:"!C;VQS<&%N/3-$,3XQ,B!-;VYT:',@16YD960\+W1H/@T*("`@ M("`@/"]T<CX-"B`@("`@(#QT<CX-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^ M1&5C+B`S,2P@,C`Q-#QB<CX\+W1H/@T*("`@("`@/"]T<CX-"B`@("`@(#QT M<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX] M,T1T;W`^/'-T<F]N9SY/=&AE<B!);F-O;64@86YD($5X<&5N<V5S(%M!8G-T M<F%C=%T\+W-T<F]N9SX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C M;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T M;W`^0V]M<&]N96YT<R!O9B!);G1E<F5S="!A;F0@3W1H97(L($YE=#PO=&0^ M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/&1I=CX-"B`\<"!S='EL93TS M1"=-05)'24XM0D]45$]-.B`P<'@[($U!4D=)3BU43U`Z(#9P>#L@5$585"U) M3D1%3E0Z(#0E)R!A;&EG;CTS1&IU<W1I9GD^/&9O;G0@<W1Y;&4],T0G1D]. M5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^0V]M<&]N96YT M<R!O9B!);G1E<F5S="!A;F0@3W1H97(L($YE="!W97)E(&%S(&9O;&QO=W,@ M*&EN#0H@=&AO=7-A;F1S*3H\+V9O;G0^/"]P/@T*(#QP('-T>6QE/3-$)TU! M4D=)3BU"3U143TTZ(#!P>#L@1D].5"U325I%.B`Q,G!X.R!-05)'24XM5$]0 M.B`P<'@G/@T*("8C>$$P.SPO<#X-"B`\=&%B;&4@<W1Y;&4],T0G0D]21$52 M+4-/3$Q!4%-%.B!C;VQL87!S92<@8V5L;'-P86-I;F<],T0P(&-E;&QP861D M:6YG/3-$,"!W:61T:#TS1#DR)2!A;&EG;CTS1&-E;G1E<B!B;W)D97(],T0P M/@T*(#QT<CX-"B`\=&0@=VED=&@],T0X,"4^/"]T9#X-"B`\=&0@=F%L:6=N M/3-$8F]T=&]M('=I9'1H/3-$-"4^/"]T9#X-"B`\=&0^/"]T9#X-"B`\=&0^ M/"]T9#X-"B`\=&0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H M/3-$-"4^/"]T9#X-"B`\=&0^/"]T9#X-"B`\=&0^/"]T9#X-"B`\=&0^/"]T M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$-"4^/"]T9#X-"B`\ M=&0^/"]T9#X-"B`\=&0^/"]T9#X-"B`\=&0^/"]T9#X-"B`\+W1R/@T*(#QT M<CX-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C>$$P M.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<VEZ M93TS1#$^)B-X03`[)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('-T>6QE/3-$ M)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,7!X('-O;&ED)R!V86QI9VX],T1B M;W1T;VT@8V]L<W!A;CTS1#$P(&%L:6=N/3-$8V5N=&5R/CQF;VYT('-T>6QE M/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0Q/CQB M/EEE87)S($5N9&5D/&)R("\^#0H@1&5C96UB97(F(WA!,#LS,2P\+V(^/"]F M;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$ M,3XF(WA!,#L\+V9O;G0^/"]T9#X-"B`\+W1R/@T*(#QT<CX-"B`\=&0@=F%L M:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C>$$P.SPO9F]N=#X\+W1D M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<VEZ93TS1#$^)B-X03`[ M)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('-T>6QE/3-$)T)/4D1%4BU"3U14 M3TTZ(",P,#`P,#`@,7!X('-O;&ED)R!V86QI9VX],T1B;W1T;VT@8V]L<W!A M;CTS1#(@86QI9VX],T1C96YT97(^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U) M3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#$^/&(^,C`Q-#PO8CX\+V9O M;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q M/B8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O M;G0@<VEZ93TS1#$^)B-X03`[)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('-T M>6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,7!X('-O;&ED)R!V86QI M9VX],T1B;W1T;VT@8V]L<W!A;CTS1#(@86QI9VX],T1C96YT97(^/&9O;G0@ M<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS M1#$^/&(^,C`Q,SPO8CX\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T M=&]M/CQF;VYT('-I>F4],T0Q/B8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V M86QI9VX],T1B;W1T;VT^/&9O;G0@<VEZ93TS1#$^)B-X03`[)B-X03`[/"]F M;VYT/CPO=&0^#0H@/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P M,#`@,7!X('-O;&ED)R!V86QI9VX],T1B;W1T;VT@8V]L<W!A;CTS1#(@86QI M9VX],T1C96YT97(^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S M($YE=R!2;VUA;B<@<VEZ93TS1#$^/&(^,C`Q,CPO8CX\+V9O;G0^/"]T9#X- M"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C>$$P.SPO M9F]N=#X\+W1D/@T*(#PO='(^#0H@/'1R(&)G8V]L;W(],T0C0T-%149&/@T* M(#QT9"!V86QI9VX],T1T;W`^#0H@/'`@<W1Y;&4],T0G34%21TE.+4Q%1E0Z M(#%E;3L@5$585"U)3D1%3E0Z("TQ96TG/CQF;VYT('-T>6QE/3-$)T9/3E0M M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R/DEN=&5R97-T(&EN M8V]M92!A;F0@;W1H97(-"B!I;F-O;64\+V9O;G0^/"]P/@T*(#PO=&0^#0H@ M/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF(WA!,#LF(WA! M,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T M>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R M/B0\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$ M<FEG:'0^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2 M;VUA;B<@<VEZ93TS1#(^,3`X/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS M1&)O='1O;2!N;W=R87`],T1N;W=R87`^/&9O;G0@<W1Y;&4],T0G1D].5"U& M04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^)B-X03`[)B-X03`[ M/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE M/3-$,3XF(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$ M8F]T=&]M/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@ M4F]M86XG('-I>F4],T0R/B0\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$ M8F]T=&]M(&%L:6=N/3-$<FEG:'0^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U) M3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^.3@\+V9O;G0^/"]T9#X- M"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#X\9F]N="!S M='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$ M,CXF(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`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`^#0H@/'`@<W1Y;&4],T0G M34%21TE.+4Q%1E0Z(#%E;3L@5$585"U)3D1%3E0Z("TQ96TG/CQF;VYT('-T M>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R M/DEN=&5R97-T(&5X<&5N<V4@86YD(&]T:&5R#0H@97AP96YS93PO9F]N=#X\ M+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4] M,T0Q/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B M;W1T;VT@;F]W<F%P/3-$;F]W<F%P/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%- M24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R/B8C>$$P.SPO9F]N=#X\ M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P(&%L M:6=N/3-$<FEG:'0^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S M($YE=R!2;VUA;B<@<VEZ93TS1#(^)B-X,C`Q-#L\+V9O;G0^/"]T9#X-"B`\ M=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#X\9F]N="!S='EL M93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXF M(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M M/CQF;VYT('-I>F4],T0Q/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT M9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ M(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^)B-X03`[/"]F;VYT/CPO=&0^ M#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/CQF;VYT('-T M>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R M/C<Y/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`] M,T1N;W=R87`^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE M=R!2;VUA;B<@<VEZ93TS1#(^)B-X03`[)B-X03`[/"]F;VYT/CPO=&0^#0H@ M/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF(WA!,#LF(WA! M,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T M>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R M/B8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI M9VX],T1R:6=H=#X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@ M3F5W(%)O;6%N)R!S:7IE/3-$,CXH,CPO9F]N=#X\+W1D/@T*(#QT9"!V86QI M9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P/CQF;VYT('-T>6QE/3-$)T9/ M3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R/BDF(WA!,#L\ M+V9O;G0^/"]T9#X-"B`\+W1R/@T*(#QT<B!S='EL93TS1"=&3TY4+5-)6D4Z M(#%P>"<^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI M9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$ M8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@,7!X M('-O;&ED)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T M=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@,7!X('-O M;&ED)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0^)B-X03`[/"]T9#X-"B`\ M=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A M;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B`C,#`P M,#`P(#%P>"!S;VQI9"<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG M;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B`C,#`P,#`P M(#%P>"!S;VQI9"<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D/B8C>$$P.SPO M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T* M(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@<W1Y;&4],T0G0D]21$52+51/ M4#H@(S`P,#`P,"`Q<'@@<V]L:60G/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT M9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@<W1Y;&4],T0G0D]21$52+51/4#H@ M(S`P,#`P,"`Q<'@@<V]L:60G/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT9#XF M(WA!,#L\+W1D/@T*(#PO='(^#0H@/'1R(&)G8V]L;W(],T0C0T-%149&/@T* M(#QT9"!V86QI9VX],T1T;W`^#0H@/'`@<W1Y;&4],T0G34%21TE.+4Q%1E0Z M(#)E;3L@5$585"U)3D1%3E0Z("TQ96TG/CQF;VYT('-T>6QE/3-$)T9/3E0M M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R/DEN=&5R97-T(&%N M9"!/=&AE<BP-"B!N970\+V9O;G0^/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG M;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF(WA!,#LF(WA!,#L\+V9O;G0^ M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)T9/ M3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R/B0\+V9O;G0^ M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^/&9O M;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ M93TS1#(^,3`X/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N M;W=R87`],T1N;W=R87`^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I M;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^)B-X03`[)B-X03`[/"]F;VYT/CPO M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF(WA! M,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF M;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I M>F4],T0R/B0\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L M:6=N/3-$<FEG:'0^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S M($YE=R!2;VUA;B<@<VEZ93TS1#(^,3<W/"]F;VYT/CPO=&0^#0H@/'1D('9A M;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^/&9O;G0@<W1Y;&4],T0G M1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^)B-X03`[ M)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N M="!S:7IE/3-$,3XF(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L M:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE M<R!.97<@4F]M86XG('-I>F4],T0R/B0\+V9O;G0^/"]T9#X-"B`\=&0@=F%L M:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^/&9O;G0@<W1Y;&4],T0G1D]. M5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^.#<\+V9O;G0^ M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#X\ M9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S M:7IE/3-$,CXF(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\+W1R/@T*(#QT M<B!S='EL93TS1"=&3TY4+5-)6D4Z(#%P>"<^#0H@/'1D('9A;&EG;CTS1&)O M='1O;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[ M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/ M4D1%4BU43U`Z(",P,#`P,#`@,W!X(&1O=6)L92<^)B-X03`[/"]P/@T*(#PO M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$ M15(M5$]0.B`C,#`P,#`P(#-P>"!D;W5B;&4G/B8C>$$P.SPO<#X-"B`\+W1D M/@T*(#QT9#XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X M03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T M>6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@,W!X(&1O=6)L92<^)B-X03`[ M/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL M93TS1"="3U)$15(M5$]0.B`C,#`P,#`P(#-P>"!D;W5B;&4G/B8C>$$P.SPO M<#X-"B`\+W1D/@T*(#QT9#XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B M;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@,W!X(&1O=6)L M92<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X- M"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B`C,#`P,#`P(#-P>"!D;W5B;&4G M/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT9#XF(WA!,#L\+W1D/@T*(#PO='(^ M#0H@/"]T86)L93X-"B`\+V1I=CX\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@ M(#PO='(^#0H@("`@/"]T86)L93X-"B`@/"]B;V1Y/@T*/"]H=&UL/@T*#0HM M+2TM+2T]7TYE>'1087)T7S,Y8S!E838R7V,R,#-?-#4X9E\X8S4P7S-D8V$T M-39A-CDU,0T*0V]N=&5N="U,;V-A=&EO;CH@9FEL93HO+R]#.B\S.6,P96$V M,E]C,C`S7S0U.&9?.&,U,%\S9&-A-#4V838Y-3$O5V]R:W-H965T<R]3:&5E M=#,V+FAT;6P-"D-O;G1E;G0M5')A;G-F97(M16YC;V1I;F<Z('%U;W1E9"UP M<FEN=&%B;&4-"D-O;G1E;G0M5'EP93H@=&5X="]H=&UL.R!C:&%R<V5T/2)U M<RUA<V-I:2(-"@T*/&AT;6P^#0H@(#QH96%D/@T*("`@(#Q-151!(&AT='`M M97%U:78],T1#;VYT96YT+51Y<&4@8V]N=&5N=#TS1"=T97AT+VAT;6P[(&-H M87)S970]=71F+3@G/CQS8W)I<'0@='EP93TS1'1E>'0O:F%V87-C<FEP="!S M<F,],T13:&]W+FIS/B\J($1O($YO="!296UO=F4@5&AI<R!#;VUM96YT("HO M/"]S8W)I<'0^/"]H96%D/@T*("`\8F]D>3X-"B`@("`\=&%B;&4@8VQA<W,] M,T1R97!O<G0@:60],T1)1#!%344^#0H@("`@("`\='(^#0H@("`@("`@(#QT M:"!C;&%S<STS1'1L(&-O;'-P86X],T0Q(')O=W-P86X],T0R/CQS=')O;F<^ M475A<G1E<FQY($9I;F%N8VEA;"!$871A("A486)L97,I/&)R/CPO<W1R;VYG M/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H(&-O;'-P86X],T0Q/C$R M($UO;G1H<R!%;F1E9#PO=&@^#0H@("`@("`\+W1R/@T*("`@("`@/'1R/@T* M("`@("`@("`\=&@@8VQA<W,],T1T:#Y$96,N(#,Q+"`R,#$T/&)R/CPO=&@^ M#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@ M(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#X\<W1R;VYG/E%U87)T97)L M>2!&:6YA;F-I86P@26YF;W)M871I;VX@1&ES8VQO<W5R92!;06)S=')A8W1= M/"]S=')O;F<^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A M;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,] M,T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E-U M;6UA<GD@;V8@475A<G1E<FQY(%)E<W5L=',\+W1D/@T*("`@("`@("`\=&0@ M8VQA<W,],T1T97AT/CQD:78^#0H@/'`@<W1Y;&4],T0G34%21TE.+4)/5%1/ M33H@,'!X.R!-05)'24XM5$]0.B`V<'@[(%1%6%0M24Y$14Y4.B`T)2<@86QI M9VX],T1J=7-T:69Y/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE M<R!.97<@4F]M86XG('-I>F4],T0R/E%U87)T97)L>2!R97-U;'1S('=E<F4@ M87,@9F]L;&]W<R`H:6X@=&AO=7-A;F1S+"!E>&-E<'0@<&5R#0H@<VAA<F4@ M9&%T82DZ/"]F;VYT/CPO<#X-"B`\<"!S='EL93TS1"=-05)'24XM0D]45$]- M.B`P<'@[($9/3E0M4TE:13H@,3)P>#L@34%21TE.+51/4#H@,'!X)SX-"B`F M(WA!,#L\+W`^#0H@/'1A8FQE('-T>6QE/3-$)T)/4D1%4BU#3TQ,05!313H@ M8V]L;&%P<V4G(&-E;&QS<&%C:6YG/3-$,"!C96QL<&%D9&EN9STS1#`@=VED M=&@],T0Q,#`E(&%L:6=N/3-$8V5N=&5R(&)O<F1E<CTS1#`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`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG M;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF(WA!,#LF(WA!,#L\+V9O;G0^ M/"]T9#X-"B`\=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@(S`P,#`P,"`Q M<'@@<V]L:60G('9A;&EG;CTS1&)O='1O;2!C;VQS<&%N/3-$,B!A;&EG;CTS M1&-E;G1E<CX\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W M(%)O;6%N)R!S:7IE/3-$,3X\8CY&:7)S=#QB<B`O/@T*(%%U87)T97(\+V(^ M/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE M/3-$,3XF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M M/CQF;VYT('-I>F4],T0Q/B8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!S='EL M93TS1"="3U)$15(M0D]45$]-.B`C,#`P,#`P(#%P>"!S;VQI9"<@=F%L:6=N M/3-$8F]T=&]M(&-O;'-P86X],T0R(&%L:6=N/3-$8V5N=&5R/CQF;VYT('-T M>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0Q M/CQB/E-E8V]N9#QB<B`O/@T*(%%U87)T97(\+V(^/"]F;VYT/CPO=&0^#0H@ M/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF(WA!,#L\+V9O M;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q M/B8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!S='EL93TS1"="3U)$15(M0D]4 M5$]-.B`C,#`P,#`P(#%P>"!S;VQI9"<@=F%L:6=N/3-$8F]T=&]M(&-O;'-P M86X],T0R(&%L:6=N/3-$8V5N=&5R/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%- M24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0Q/CQB/E1H:7)D/&)R("\^ M#0H@475A<G1E<CPO8CX\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T M=&]M/CQF;VYT('-I>F4],T0Q/B8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V M86QI9VX],T1B;W1T;VT^/&9O;G0@<VEZ93TS1#$^)B-X03`[/"]F;VYT/CPO M=&0^#0H@/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,7!X M('-O;&ED)R!V86QI9VX],T1B;W1T;VT@8V]L<W!A;CTS1#(@86QI9VX],T1C M96YT97(^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2 M;VUA;B<@<VEZ93TS1#$^/&(^1F]U<G1H/&)R("\^#0H@475A<G1E<CPO8CX\ M+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4] M,T0Q/B8C>$$P.SPO9F]N=#X\+W1D/@T*(#PO='(^#0H@/'1R(&)G8V]L;W(] M,T0C0T-%149&/@T*(#QT9"!V86QI9VX],T1T;W`^#0H@/'`@<W1Y;&4],T0G M34%21TE.+4Q%1E0Z(#%E;3L@5$585"U)3D1%3E0Z("TQ96TG/CQF;VYT('-T M>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R M/CQB/C(P,30\+V(^/"]F;VYT/CPO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX] M,T1B;W1T;VT^/&9O;G0@<VEZ93TS1#$^)B-X03`[)B-X03`[/"]F;VYT/CPO M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI9VX] M,T1B;W1T;VT^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@ M/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF(WA!,#L\+V9O M;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A M;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C>$$P M.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\ M=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O M;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<VEZ93TS1#$^ M)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\=&0@=F%L:6=N/3-$ M8F]T=&]M/CPO=&0^#0H@/"]T<CX-"B`\='(^#0H@/'1D('9A;&EG;CTS1'1O M<#X-"B`\<"!S='EL93TS1"=-05)'24XM3$5&5#H@,F5M.R!415A4+4E.1$5. M5#H@+3%E;2<^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE M=R!2;VUA;B<@<VEZ93TS1#(^5&]T86P@<F5V96YU97,\+V9O;G0^/"]P/@T* M(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF M(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M M/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG M('-I>F4],T0R/B0\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M M(&%L:6=N/3-$<FEG:'0^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I M;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^-RPY-SD\+V9O;G0^/"]T9#X-"B`\ M=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#X\9F]N="!S='EL M93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXF M(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`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`[/"]F;VYT/CPO=&0^ M#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=&3TY4+49! M34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXD/"]F;VYT/CPO=&0^ M#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/CQF;VYT('-T M>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R M/CDL-#$U/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R M87`],T1N;W=R87`^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S M($YE=R!2;VUA;B<@<VEZ93TS1#(^)B-X03`[)B-X03`[/"]F;VYT/CPO=&0^ M#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF(WA!,#L\ M+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE M/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R/B0\ M+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG M:'0^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA M;B<@<VEZ93TS1#(^,C$L-S4X/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS M1&)O='1O;2!N;W=R87`],T1N;W=R87`^/&9O;G0@<W1Y;&4],T0G1D].5"U& M04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^)B-X03`[)B-X03`[ M/"]F;VYT/CPO=&0^#0H@/"]T<CX-"B`\='(@8F=C;VQO<CTS1"-#0T5%1D8^ M#0H@/'1D('9A;&EG;CTS1'1O<#X-"B`\<"!S='EL93TS1"=-05)'24XM3$5& M5#H@,F5M.R!415A4+4E.1$5.5#H@+3%E;2<^/&9O;G0@<W1Y;&4],T0G1D]. M5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^3F5T(&EN8V]M M90T*("AL;W-S*3PO9F]N=#X\+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$ M8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<W1Y;&4],T0G1D].5"U& M04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^)B-X03`[/"]F;VYT M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/CQF M;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I M>F4],T0R/B@X+#<T-#PO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T M;VT@;F]W<F%P/3-$;F]W<F%P/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9 M.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R/BDF(WA!,#L\+V9O;G0^/"]T M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C>$$P M.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<W1Y M;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^ M)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG M;CTS1')I9VAT/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!. M97<@4F]M86XG('-I>F4],T0R/B@X+#,W-#PO9F]N=#X\+W1D/@T*(#QT9"!V M86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P/CQF;VYT('-T>6QE/3-$ M)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R/BDF(WA! M,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I M>F4],T0Q/B8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T M;VT^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA M;B<@<VEZ93TS1#(^)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS M1&)O='1O;2!A;&EG;CTS1')I9VAT/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%- M24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R/B@U+#DW,3PO9F]N=#X\ M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P/CQF M;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I M>F4],T0R/BDF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T M=&]M/CQF;VYT('-I>F4],T0Q/B8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V M86QI9VX],T1B;W1T;VT^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I M;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^)B-X03`[/"]F;VYT/CPO=&0^#0H@ M/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/CQF;VYT('-T>6QE M/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R/C@L M-#0S/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`] M,T1N;W=R87`^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE M=R!2;VUA;B<@<VEZ93TS1#(^)B-X03`[)B-X03`[/"]F;VYT/CPO=&0^#0H@ M/"]T<CX-"B`\='(^#0H@/'1D('9A;&EG;CTS1'1O<#X-"B`\<"!S='EL93TS M1"=-05)'24XM3$5&5#H@,F5M.R!415A4+4E.1$5.5#H@+3%E;2<^/&9O;G0@ M<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS M1#(^3F5T(&EN8V]M92`H;&]S<RD@86QL;V-A8FQE#0H@=&\@8V]M;6]N('-T M;V-K:&]L9&5R<SPO9F]N=#X\+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$ M8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<W1Y;&4],T0G1D].5"U& M04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^)B-X03`[/"]F;VYT M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/CQF M;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I M>F4],T0R/B@X+#<T-#PO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T M;VT@;F]W<F%P/3-$;F]W<F%P/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9 M.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R/BDF(WA!,#L\+V9O;G0^/"]T M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C>$$P M.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<W1Y M;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^ M)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG M;CTS1')I9VAT/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!. M97<@4F]M86XG('-I>F4],T0R/B@X+#,W-#PO9F]N=#X\+W1D/@T*(#QT9"!V M86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P/CQF;VYT('-T>6QE/3-$ M)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R/BDF(WA! M,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I M>F4],T0Q/B8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T M;VT^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA M;B<@<VEZ93TS1#(^)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS M1&)O='1O;2!A;&EG;CTS1')I9VAT/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%- M24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R/B@U+#DW,3PO9F]N=#X\ M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P/CQF M;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I M>F4],T0R/BDF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T M=&]M/CQF;VYT('-I>F4],T0Q/B8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V M86QI9VX],T1B;W1T;VT^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I M;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^)B-X03`[/"]F;VYT/CPO=&0^#0H@ M/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/CQF;VYT('-T>6QE M/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R/C@L M-#0S/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`] M,T1N;W=R87`^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE M=R!2;VUA;B<@<VEZ93TS1#(^)B-X03`[)B-X03`[/"]F;VYT/CPO=&0^#0H@ M/"]T<CX-"B`\='(@8F=C;VQO<CTS1"-#0T5%1D8^#0H@/'1D('9A;&EG;CTS M1'1O<#X-"B`\<"!S='EL93TS1"=-05)'24XM3$5&5#H@,F5M.R!415A4+4E. M1$5.5#H@+3%E;2<^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S M($YE=R!2;VUA;B<@<VEZ93TS1#(^3F5T(&EN8V]M92`H;&]S<RD@<&5R('-H M87)E#0H@86QL;V-A8FQE('1O(&-O;6UO;B!S=&]C:VAO;&1E<G,@)B-X,C`Q M-#L@8F%S:6,@86YD#0H@9&EL=71E9#PO9F]N=#X\+W`^#0H@/"]T9#X-"B`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`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`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`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF M;VYT('-I>F4],T0Q/B8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX] M,T1B;W1T;VT^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE M=R!2;VUA;B<@<VEZ93TS1#(^)#PO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX] M,T1B;W1T;VT@86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS1"=&3TY4+49! M34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXP+C(S/"]F;VYT/CPO M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^/&9O M;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ M93TS1#(^)B-X03`[)B-X03`[/"]F;VYT/CPO=&0^#0H@/"]T<CX-"B`\='(^ M#0H@/'1D('9A;&EG;CTS1'1O<#X-"B`\<"!S='EL93TS1"=-05)'24XM3$5& M5#H@,65M.R!415A4+4E.1$5.5#H@+3%E;2<^/&9O;G0@<W1Y;&4],T0G1D]. M5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^/&(^,C`Q,SPO M8CX\+V9O;G0^/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\ M9F]N="!S:7IE/3-$,3XF(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@ M=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\ M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\=&0@=F%L:6=N M/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C>$$P.SPO9F]N=#X\+W1D/@T* M(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T M=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V M86QI9VX],T1B;W1T;VT^/&9O;G0@<VEZ93TS1#$^)B-X03`[/"]F;VYT/CPO M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI9VX] M,T1B;W1T;VT^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@ M/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF(WA!,#L\+V9O M;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A M;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T M9#X-"B`\+W1R/@T*(#QT<B!B9V-O;&]R/3-$(T-#145&1CX-"B`\=&0@=F%L M:6=N/3-$=&]P/@T*(#QP('-T>6QE/3-$)TU!4D=)3BU,1494.B`R96T[(%1% M6%0M24Y$14Y4.B`M,65M)SX\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@ M5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CY4;W1A;"!R979E;G5E<SPO9F]N M=#X\+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I M>F4],T0Q/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX] M,T1B;W1T;VT^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE M=R!2;VUA;B<@<VEZ93TS1#(^)#PO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX] M,T1B;W1T;VT@86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS1"=&3TY4+49! M34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXX,C$\+V9O;G0^/"]T M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#X\9F]N M="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE M/3-$,CXF(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$ M8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT M9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ M(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^)#PO9F]N=#X\+W1D/@T*(#QT M9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS M1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXQ+#`P M.3PO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$ M;F]W<F%P/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@ M4F]M86XG('-I>F4],T0R/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT M9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<VEZ93TS1#$^)B-X03`[/"]F;VYT M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=& M3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXD/"]F;VYT M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/CQF M;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I M>F4],T0R/C0L-#8Y/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O M;2!N;W=R87`],T1N;W=R87`^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ M(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^)B-X03`[)B-X03`[/"]F;VYT M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF M(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT M('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4] M,T0R/B0\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N M/3-$<FEG:'0^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE M=R!2;VUA;B<@<VEZ93TS1#(^,C0L,S0Y/"]F;VYT/CPO=&0^#0H@/'1D('9A M;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^/&9O;G0@<W1Y;&4],T0G M1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^)B-X03`[ M)B-X03`[/"]F;VYT/CPO=&0^#0H@/"]T<CX-"B`\='(^#0H@/'1D('9A;&EG M;CTS1'1O<#X-"B`\<"!S='EL93TS1"=-05)'24XM3$5&5#H@,F5M.R!415A4 M+4E.1$5.5#H@+3%E;2<^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I M;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^3F5T(&EN8V]M90T*("AL;W-S*3PO M9F]N=#X\+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT M('-I>F4],T0Q/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI M9VX],T1B;W1T;VT^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S M($YE=R!2;VUA;B<@<VEZ93TS1#(^)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D M('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/CQF;VYT('-T>6QE/3-$ M)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R/B@Q,BPV M,3D\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS M1&YO=W)A<#X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W M(%)O;6%N)R!S:7IE/3-$,CXI)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A M;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF(WA!,#L\+V9O;G0^/"]T M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)T9/3E0M M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R/B8C>$$P.SPO9F]N M=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#X\ M9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S M:7IE/3-$,CXH,34L,#0Q/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O M='1O;2!N;W=R87`],T1N;W=R87`^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U) M3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^*28C>$$P.SPO9F]N=#X\ M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<VEZ93TS1#$^)B-X M03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S M='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$ M,CXF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L M:6=N/3-$<FEG:'0^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S M($YE=R!2;VUA;B<@<VEZ93TS1#(^*#$R+#4X.#PO9F]N=#X\+W1D/@T*(#QT M9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P/CQF;VYT('-T>6QE M/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R/BDF M(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT M('-I>F4],T0Q/B8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B M;W1T;VT^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2 M;VUA;B<@<VEZ93TS1#(^)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG M;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/CQF;VYT('-T>6QE/3-$)T9/3E0M M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R/C8L-3,Q/"]F;VYT M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^ M/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@ M<VEZ93TS1#(^)B-X03`[)B-X03`[/"]F;VYT/CPO=&0^#0H@/"]T<CX-"B`\ M='(@8F=C;VQO<CTS1"-#0T5%1D8^#0H@/'1D('9A;&EG;CTS1'1O<#X-"B`\ M<"!S='EL93TS1"=-05)'24XM3$5&5#H@,F5M.R!415A4+4E.1$5.5#H@+3%E M;2<^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA M;B<@<VEZ93TS1#(^3F5T(&EN8V]M92`H;&]S<RD@86QL;V-A8FQE#0H@=&\@ M8V]M;6]N('-T;V-K:&]L9&5R<SPO9F]N=#X\+W`^#0H@/"]T9#X-"B`\=&0@ M=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C>$$P.R8C>$$P.SPO M9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<W1Y;&4] M,T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^)B-X M03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS M1')I9VAT/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@ M4F]M86XG('-I>F4],T0R/B@Q,BPV,3D\+V9O;G0^/"]T9#X-"B`\=&0@=F%L M:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#X\9F]N="!S='EL93TS1"=& M3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXI)B-X03`[ M/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE M/3-$,3XF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M M/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG M('-I>F4],T0R/B8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B M;W1T;VT@86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS1"=&3TY4+49!34E, M63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXH,34L,#0Q/"]F;VYT/CPO M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^/&9O M;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ M93TS1#(^*28C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T M;VT^/&9O;G0@<VEZ93TS1#$^)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A M;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM M97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXF(WA!,#L\+V9O;G0^/"]T9#X-"B`\ M=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^/&9O;G0@<W1Y;&4] M,T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^*#$R M+#4X.#PO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P M/3-$;F]W<F%P/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!. M97<@4F]M86XG('-I>F4],T0R/BDF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@ M=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C>$$P.SPO9F]N=#X\ M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<W1Y;&4],T0G1D]. M5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^)B-X03`[/"]F M;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT M/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG M('-I>F4],T0R/C8L-3,Q/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O M='1O;2!N;W=R87`],T1N;W=R87`^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U) M3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^)B-X03`[)B-X03`[/"]F M;VYT/CPO=&0^#0H@/"]T<CX-"B`\='(^#0H@/'1D('9A;&EG;CTS1'1O<#X- M"B`\<"!S='EL93TS1"=-05)'24XM3$5&5#H@,F5M.R!415A4+4E.1$5.5#H@ M+3%E;2<^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2 M;VUA;B<@<VEZ93TS1#(^3F5T(&EN8V]M92`H;&]S<RD@<&5R('-H87)E#0H@ M86QL;V-A8FQE('1O(&-O;6UO;B!S=&]C:VAO;&1E<G,@)B-X,C`Q-#L@8F%S M:6,\+V9O;G0^/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\ M9F]N="!S:7IE/3-$,3XF(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@ M=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4 M:6UE<R!.97<@4F]M86XG('-I>F4],T0R/B0\+V9O;G0^/"]T9#X-"B`\=&0@ M=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^/&9O;G0@<W1Y;&4],T0G M1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^*#`N-3,\ M+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO M=W)A<#X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O M;6%N)R!S:7IE/3-$,CXI)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG M;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF(WA!,#L\+V9O;G0^/"]T9#X- M"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%- M24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R/B0\+V9O;G0^/"]T9#X- M"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^/&9O;G0@<W1Y M;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^ M*#`N-3@\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A M<#TS1&YO=W)A<#X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@ M3F5W(%)O;6%N)R!S:7IE/3-$,CXI)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D M('9A;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF(WA!,#L\+V9O;G0^ M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)T9/ M3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R/B0\+V9O;G0^ M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^/&9O M;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ M93TS1#(^*#`N-#,\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M M(&YO=W)A<#TS1&YO=W)A<#X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@ M5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXI)B-X03`[/"]F;VYT/CPO=&0^ M#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF(WA!,#L\ M+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE M/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R/B0\ M+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG M:'0^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA M;B<@<VEZ93TS1#(^,"XR,CPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B M;W1T;VT@;F]W<F%P/3-$;F]W<F%P/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%- M24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R/B8C>$$P.R8C>$$P.SPO M9F]N=#X\+W1D/@T*(#PO='(^#0H@/'1R(&)G8V]L;W(],T0C0T-%149&/@T* M(#QT9"!V86QI9VX],T1T;W`^#0H@/'`@<W1Y;&4],T0G34%21TE.+4Q%1E0Z M(#)E;3L@5$585"U)3D1%3E0Z("TQ96TG/CQF;VYT('-T>6QE/3-$)T9/3E0M M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R/DYE="!I;F-O;64@ M*&QO<W,I('!E<B!S:&%R90T*(&%L;&]C86)L92!T;R!C;VUM;VX@<W1O8VMH M;VQD97)S("8C>#(P,30[(&1I;'5T960\+V9O;G0^/"]P/@T*(#PO=&0^#0H@ M/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF(WA!,#LF(WA! M,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T M>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R M/B0\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$ M<FEG:'0^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2 M;VUA;B<@<VEZ93TS1#(^*#`N-3,\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N M/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#X\9F]N="!S='EL93TS1"=&3TY4 M+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXI)B-X03`[/"]F M;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$ M,3XF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF M;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I M>F4],T0R/B0\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L M:6=N/3-$<FEG:'0^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S M($YE=R!2;VUA;B<@<VEZ93TS1#(^*#`N-3@\+V9O;G0^/"]T9#X-"B`\=&0@ M=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#X\9F]N="!S='EL93TS M1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXI)B-X M03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S M:7IE/3-$,3XF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T M=&]M/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M M86XG('-I>F4],T0R/B0\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T M=&]M(&%L:6=N/3-$<FEG:'0^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ M(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^*#`N-#,\+V9O;G0^/"]T9#X- M"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#X\9F]N="!S M='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$ M,CXI)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\ M9F]N="!S:7IE/3-$,3XF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N M/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!. M97<@4F]M86XG('-I>F4],T0R/B0\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N M/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^/&9O;G0@<W1Y;&4],T0G1D].5"U& M04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^,"XR,3PO9F]N=#X\ M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P/CQF M;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I M>F4],T0R/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#PO='(^#0H@/"]T M86)L93X-"B`\+V1I=CX\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^ M#0H@("`@/"]T86)L93X-"B`@/"]B;V1Y/@T*/"]H=&UL/@T*#0HM+2TM+2T] M7TYE>'1087)T7S,Y8S!E838R7V,R,#-?-#4X9E\X8S4P7S-D8V$T-39A-CDU M,0T*0V]N=&5N="U,;V-A=&EO;CH@9FEL93HO+R]#.B\S.6,P96$V,E]C,C`S M7S0U.&9?.&,U,%\S9&-A-#4V838Y-3$O5V]R:W-H965T<R]3:&5E=#,W+FAT M;6P-"D-O;G1E;G0M5')A;G-F97(M16YC;V1I;F<Z('%U;W1E9"UP<FEN=&%B M;&4-"D-O;G1E;G0M5'EP93H@=&5X="]H=&UL.R!C:&%R<V5T/2)U<RUA<V-I M:2(-"@T*/&AT;6P^#0H@(#QH96%D/@T*("`@(#Q-151!(&AT='`M97%U:78] M,T1#;VYT96YT+51Y<&4@8V]N=&5N=#TS1"=T97AT+VAT;6P[(&-H87)S970] M=71F+3@G/CQS8W)I<'0@='EP93TS1'1E>'0O:F%V87-C<FEP="!S<F,],T13 M:&]W+FIS/B\J($1O($YO="!296UO=F4@5&AI<R!#;VUM96YT("HO/"]S8W)I M<'0^/"]H96%D/@T*("`\8F]D>3X-"B`@("`\=&%B;&4@8VQA<W,],T1R97!O M<G0@:60],T1)1#!%2C5'2SX-"B`@("`@(#QT<CX-"B`@("`@("`@/'1H(&-L M87-S/3-$=&P@8V]L<W!A;CTS1#$@<F]W<W!A;CTS1#(^/'-T<F]N9SY/<F=A M;FEZ871I;VX@86YD(%-I9VYI9FEC86YT($%C8V]U;G1I;F<@4&]L:6-I97,@ M+2!!9&1I=&EO;F%L($EN9F]R;6%T:6]N("A$971A:6PI("A54T0@)"D\8G(^ M/"]S=')O;F<^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@@8V]L<W!A M;CTS1#$^,"!-;VYT:',@16YD960\+W1H/@T*("`@("`@("`\=&@@8VQA<W,] M,T1T:"!C;VQS<&%N/3-$,3XQ($UO;G1H<R!%;F1E9#PO=&@^#0H@("`@("`@ M(#QT:"!C;&%S<STS1'1H(&-O;'-P86X],T0X/C,@36]N=&AS($5N9&5D/"]T M:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@@8V]L<W!A;CTS1#,^,3(@36]N M=&AS($5N9&5D/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@@8V]L<W!A M;CTS1#$^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@@8V]L<W!A;CTS M1#$^/"]T:#X-"B`@("`@(#PO='(^#0H@("`@("`\='(^#0H@("`@("`@(#QT M:"!C;&%S<STS1'1H/DIU;BX@,C0L(#(P,3,\8G(^/"]T:#X-"B`@("`@("`@ M/'1H(&-L87-S/3-$=&@^2G5N+B`S,"P@,C`Q,SQB<CX\+W1H/@T*("`@("`@ M("`\=&@@8VQA<W,],T1T:#Y$96,N(#,Q+"`R,#$T/&)R/D9I;F%N8VEA;%]) M;G-T:71U=&EO;CQB<CX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y3 M97`N(#,P+"`R,#$T/&)R/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H M/DIU;BX@,S`L(#(P,30\8G(^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$ M=&@^36%R+B`S,2P@,C`Q-#QB<CX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,] M,T1T:#Y$96,N(#,Q+"`R,#$S/&)R/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S M<STS1'1H/E-E<"X@,S`L(#(P,3,\8G(^/"]T:#X-"B`@("`@("`@/'1H(&-L M87-S/3-$=&@^2G5N+B`S,"P@,C`Q,SQB<CX\+W1H/@T*("`@("`@("`\=&@@ M8VQA<W,],T1T:#Y-87(N(#,Q+"`R,#$S/&)R/CPO=&@^#0H@("`@("`@(#QT M:"!C;&%S<STS1'1H/D1E8RX@,S$L(#(P,30\8G(^4V5G;65N=#QB<CY&:6YA M;F-I86Q?26YS=&ET=71I;VX\8G(^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S M/3-$=&@^1&5C+B`S,2P@,C`Q,SQB<CX\+W1H/@T*("`@("`@("`\=&@@8VQA M<W,],T1T:#Y$96,N(#,Q+"`R,#$R/&)R/CPO=&@^#0H@("`@("`@(#QT:"!C M;&%S<STS1'1H/D%U9RX@,S$L(#(P,3$\8G(^/"]T:#X-"B`@("`@("`@/'1H M(&-L87-S/3-$=&@^36%Y(#$X+"`R,#$Q/&)R/CPO=&@^#0H@("`@("`\+W1R M/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS M1'!L('9A;&EG;CTS1'1O<#X\<W1R;VYG/E-U;6UA<GD@3V8@4VEG;FEF:6-A M;G0@06-C;W5N=&EN9R!0;VQI8VEE<R!;3&EN92!)=&5M<UT\+W-T<F]N9SX\ M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\ M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\ M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\ M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\ M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\ M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\ M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\ M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\ M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\ M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\ M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\ M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\ M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\ M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\ M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\ M+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@ M("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^06-C=6UU;&%T960@ M9&5F:6-I="!I;F-U<G)E9#PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU M;3XD("@T.3<L,C0S+#`P,"D\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@ M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@ M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@ M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@ M/'1D(&-L87-S/3-$;G5M/B0@*#0X,BPU.3<L,#`P*3QS<&%N/CPO<W!A;CX\ M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\ M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\ M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\ M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6T^)"`H-#DW+#(T,RPP,#`I M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;3XD M("@T.#(L-3DW+#`P,"D\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D M(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D M(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D M(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^ M#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$ M<&P@=F%L:6=N/3-$=&]P/DYE="!L;W-S/"]T9#X-"B`@("`@("`@/'1D(&-L M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L M87-S/3-$;G5M<#XX+#0T,RPP,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@ M("`@/'1D(&-L87-S/3-$;G5M/B@U+#DW,2PP,#`I/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;3XH."PS-S0L,#`P*3QS<&%N M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6T^*#@L-S0T M+#`P,"D\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$ M;G5M<#XV+#4S,2PP,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D M(&-L87-S/3-$;G5M/B@Q,BPU.#@L,#`P*3QS<&%N/CPO<W!A;CX\+W1D/@T* M("`@("`@("`\=&0@8VQA<W,],T1N=6T^*#$U+#`T,2PP,#`I/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;3XH,3(L-C$Y+#`P M,"D\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M M/B@Q-"PV-#8L,#`P*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@ M8VQA<W,],T1N=6T^*#,S+#<Q-RPP,#`I/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S<STS1&YU;3XH-#`L,S<P+#`P,"D\<W!A;CX\+W-P M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P M86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX- M"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/DYE="!C87-H M("AU<V5D(&EN*2!O<&5R871I;VYS/"]T9#X-"B`@("`@("`@/'1D(&-L87-S M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S M/3-$;G5M/B@T-"PX-#,L,#`P*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@ M("`\=&0@8VQA<W,],T1N=6T^*#<L-S$X+#`P,"D\<W!A;CX\+W-P86X^/"]T M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B@S,RPT,S@L,#`P*3QS<&%N M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N M/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS M1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^0V%S M:"P@8V%S:"!E<75I=F%L96YT<R!A;F0@:6YV97-T;65N=',\+W1D/@T*("`@ M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@ M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@ M("`@("`\=&0@8VQA<W,],T1N=6UP/C@S+#(P,"PP,#`\<W!A;CX\+W-P86X^ M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^ M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^ M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^ M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XX,"PR,#`L,#`P/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^.#,L M,C`P+#`P,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,] M,T1N=6UP/C@P+#(P,"PP,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@ M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@ M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@ M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO M='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S M/3-$<&P@=F%L:6=N/3-$=&]P/D-A<V@@<F5Q=6ER96UE;G1S('1E<FT\+W1D M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/C$R(&UO;G1H<SQS<&%N/CPO M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO M<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E M/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^3G5M8F5R M(&]F(&UA:F]R(&9I;F%N8VEA;"!I;G-T:71U=&EO;G,\+W1D/@T*("`@("`@ M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@ M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@ M("`\=&0@8VQA<W,],T1N=6UP/C,\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@ M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@ M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@ M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@ M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@ M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@ M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@ M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@ M("`@/'1D(&-L87-S/3-$;G5M<#XS/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C M;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y%;7!L;WEE<B!C;VYT<FEB=71I;VYS M('5N9&5R('1H92!P;&%N/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M M<#XS,S8L,#`P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M<STS1&YU;7`^,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@ M("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V M86QI9VX],T1T;W`^4&5R8V5N=&%G92!O9B!I;F-O;64@=&%X(&QI:V5L>2!T M;R!B92!R96%L:7IE9#PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^ M-3`N,#`E/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@ M/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG M;CTS1'1O<#Y.=6UB97(@;V8@<F5P;W)T:6YG('-E9VUE;G0\+W1D/@T*("`@ M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@ M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@ M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@ M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@ M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@ M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@ M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@ M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@ M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@ M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@ M("`@("`\=&0@8VQA<W,],T1N=6UP/C$\<W!A;CX\+W-P86X^/"]T9#X-"B`@ M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@ M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@ M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@ M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@ M("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D M(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E)E=F5R<V4@<W1O8VL@<W!L:70L M(&-O;G9E<G-I;VX@<F%T:6\\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N M=6UP/C`N,38W/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M<STS1&YU;7`^,"XQ-C<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D M(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D M(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D M(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D M(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D M(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D M(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D M(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D M(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D M(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D M(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D M(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D M(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D M(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^ M#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$ M<&P@=F%L:6=N/3-$=&]P/E)E=F5R<V4@<W1O8VL@<W!L:70L(&1E<V-R:7!T M:6]N/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#Y!<R!O9B!T:&4@ M969F96-T:79E('1I;64@;V8@=&AE(')E=F5R<V4@('-T;V-K('-P;&ET+"!E M=F5R>2!S:7@@<VAA<F5S(&]F('1H92!#;VUP86YY)W,@:7-S=65D(&%N9"!O M=71S=&%N9&EN9R!C;VUM;VX@('-T;V-K('=E<F4@8V]N=F5R=&5D(&EN=&\@ M;VYE(&ES<W5E9"!A;F0@;W5T<W1A;F1I;F<@<VAA<F4@;V8@8V]M;6]N('-T M;V-K+"`@=VET:&]U="!A;GD@8VAA;F=E(&EN('!A<B!V86QU92!P97(@<VAA M<F4N/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R M(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS M1'1O<#Y&<F%C=&EO;F%L('-H87)E<R!S971T;&5M96YT('!U<G-U86YT('1O M(')E=F5R<V4@<W1O8VL@<W!L:70\+W1D/@T*("`@("`@("`\=&0@8VQA<W,] M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,] M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,] M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,] M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,] M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,] M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,] M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,] M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,] M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,] M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,] M,T1N=6UP/C`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@ M("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L M:6=N/3-$=&]P/D-O;6UO;B!S=&]C:RP@875T:&]R:7IE9#PO=&0^#0H@("`@ M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S<STS1&YU;7`^.#$L-3`P+#`P,#QS<&%N/CPO<W!A;CX\ M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\ M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\ M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\ M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C@Q+#4P,"PP,#`\<W!A M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XX,2PU M,#`L,#`P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS M1&YU;7`^.#$L-3`P+#`P,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\ M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\ M=&0@8VQA<W,],T1N=6UP/C(T-2PP,#`L,#`P/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,3<P+#`P,"PP,#`\<W!A;CX\ M+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R M93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D-O;6UO M;B!S=&]C:RP@<&%R('9A;'5E/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$ M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$ M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$ M;G5M<#XD(#`N,#`Q/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S<STS1&YU;7`^)"`P+C`P,3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@ M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@ M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@ M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@ M("`\=&0@8VQA<W,],T1N=6UP/B0@,"XP,#$\<W!A;CX\+W-P86X^/"]T9#X- M"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XD(#`N,#`Q/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@ M("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y296-L87-S:69I M8V%T:6]N(&9R;VT@8V]M;6]N('-T;V-K('1O(&%D9&ET:6]N86P@<&%I9"UI M;B!C87!I=&%L/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ,SDL M,#`P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R M(&-L87-S/3-$<F@^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS M1'1O<#Y5;FET960@4W1A=&5S(%M-96UB97)=/"]T9#X-"B`@("`@("`@/'1D M(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D M(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D M(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D M(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D M(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D M(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D M(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D M(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D M(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D M(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D M(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D M(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D M(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D M(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D M(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^ M#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$ M<&P@=F%L:6=N/3-$=&]P/CQS=')O;F<^4W5M;6%R>2!/9B!3:6=N:69I8V%N M="!!8V-O=6YT:6YG(%!O;&EC:65S(%M,:6YE($ET96US73PO<W1R;VYG/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@ M("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y2979E;G5E<R!D97)I M=F5D/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XS,2XP,"4\<W!A M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XV-BXP M,"4\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@ M8VQA<W,],T1R:#X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$ M=&]P/DIA<&%N97-E(%M-96UB97)=/"]T9#X-"B`@("`@("`@/'1D(&-L87-S M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@ M("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L M:6=N/3-$=&]P/CQS=')O;F<^4W5M;6%R>2!/9B!3:6=N:69I8V%N="!!8V-O M=6YT:6YG(%!O;&EC:65S(%M,:6YE($ET96US73PO<W1R;VYG/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT M9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y2979E;G5E<R!D97)I=F5D/"]T M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XV.2XP,"4\<W!A;CX\+W-P M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XS-"XP,"4\<W!A M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A M;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,] M,T1R:#X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D%S M=&5L;&%S(%M-96UB97)=/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@ M8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$ M=&]P/CQS=')O;F<^4W5M;6%R>2!/9B!3:6=N:69I8V%N="!!8V-O=6YT:6YG M(%!O;&EC:65S(%M,:6YE($ET96US73PO<W1R;VYG/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\ M+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S M<STS1'!L('9A;&EG;CTS1'1O<#Y2979E;G5E<R!D97)I=F5D/"]T9#X-"B`@ M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@ M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@ M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@ M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@ M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@ M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@ M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@ M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@ M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@ M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@ M("`@("`@/'1D(&-L87-S/3-$;G5M<#XV.2XP,"4\<W!A;CX\+W-P86X^/"]T M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XS-"XP,"4\<W!A;CX\+W-P M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P M86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX- M"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D%C8V]U;G1S M(')E8V5I=F%B;&4@9'5E/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M M<#XT-2PP,#`L,#`P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S<STS1&YU;7`^,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@ M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@ M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@ M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@ M8VQA<W,],T1N=6UP/C0U+#`P,"PP,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@ M("`@("`@/'1D(&-L87-S/3-$;G5M<#XP/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F@^#0H@("`@("`@(#QT M9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y!;6=E;B!;365M8F5R73PO=&0^ M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@ M(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#X\<W1R;VYG/E-U;6UA<GD@ M3V8@4VEG;FEF:6-A;G0@06-C;W5N=&EN9R!0;VQI8VEE<R!;3&EN92!)=&5M M<UT\+W-T<F]N9SX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S M<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^ M4F5V96YU97,@9&5R:79E9#PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU M;7`^,3`N,#`E/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M<STS1&YU;7`^-C,N,#`E/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S<STS1&YU;7`^-34N,#`E/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C M;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y!8V-O=6YT<R!R96-E:79A8FQE(&1U M93PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^)"`Q+#8P,"PP,#`\ M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\ M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\ M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\ M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XD M(#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M M<#XD(#$L-C`P+#`P,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@ M8VQA<W,],T1N=6UP/B0@,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\ M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\ M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\ M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T M<CX-"B`@("`@(#QT<B!C;&%S<STS1')H/@T*("`@("`@("`\=&0@8VQA<W,] M,T1P;"!V86QI9VX],T1T;W`^0V]M<'5T97(@17%U:7!M96YT(&%N9"!3;V9T M=V%R92!;365M8F5R73PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L M87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O M<#X\<W1R;VYG/E-U;6UA<GD@3V8@4VEG;FEF:6-A;G0@06-C;W5N=&EN9R!0 M;VQI8VEE<R!;3&EN92!)=&5M<UT\+W-T<F]N9SX\+W1D/@T*("`@("`@("`\ M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\ M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\ M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\ M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\ M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\ M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\ M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\ M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\ M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\ M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\ M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\ M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\ M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\ M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\ M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T M<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,] M,T1P;"!V86QI9VX],T1T;W`^4')O<&5R='D@86YD(&5Q=6EP;65N="!E<W1I M;6%T960@=7-E9G5L(&QI=F5S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$ M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$ M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$ M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$ M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$ M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$ M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$ M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$ M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$ M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$ M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$ M=&5X=#XS('EE87)S/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T* M("`@("`@/'1R(&-L87-S/3-$<F@^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L M('9A;&EG;CTS1'1O<#Y,86)O<F%T;W)Y($5Q=6EP;65N="!A;F0@3V9F:6-E M($5Q=6EP;65N="!;365M8F5R73PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@ M/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG M;CTS1'1O<#X\<W1R;VYG/E-U;6UA<GD@3V8@4VEG;FEF:6-A;G0@06-C;W5N M=&EN9R!0;VQI8VEE<R!;3&EN92!)=&5M<UT\+W-T<F]N9SX\+W1D/@T*("`@ M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@ M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@ M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@ M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@ M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@ M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@ M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@ M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@ M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@ M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@ M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@ M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@ M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@ M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@ M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@ M("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@ M8VQA<W,],T1P;"!V86QI9VX],T1T;W`^4')O<&5R='D@86YD(&5Q=6EP;65N M="!E<W1I;6%T960@=7-E9G5L(&QI=F5S/"]T9#X-"B`@("`@("`@/'1D(&-L M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L M87-S/3-$=&5X=#XU('EE87)S/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\ M+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F@^#0H@("`@("`@(#QT9"!C;&%S M<STS1'!L('9A;&EG;CTS1'1O<#Y&=7)N:71U<F4@86YD($9I>'1U<F5S(%M- M96UB97)=/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\ M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\ M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\ M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\ M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\ M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\ M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\ M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\ M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\ M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\ M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\ M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\ M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\ M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\ M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\ M+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R M;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/CQS=')O M;F<^4W5M;6%R>2!/9B!3:6=N:69I8V%N="!!8V-O=6YT:6YG(%!O;&EC:65S M(%M,:6YE($ET96US73PO<W1R;VYG/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@ M("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A M;&EG;CTS1'1O<#Y0<F]P97)T>2!A;F0@97%U:7!M96YT(&5S=&EM871E9"!U M<V5F=6P@;&EV97,\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/C<@ M>65A<G,\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$ M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$ M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$ M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$ M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\ M='(@8VQA<W,],T1R:#X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N M/3-$=&]P/DUA>&EM=6T@6TUE;6)E<ET@?"!,96%S96AO;&0@26UP<F]V96UE M;G1S(%M-96UB97)=/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\ M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\ M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\ M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\ M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\ M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\ M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\ M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\ M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\ M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\ M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\ M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\ M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\ M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\ M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\ M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA M<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P M/CQS=')O;F<^4W5M;6%R>2!/9B!3:6=N:69I8V%N="!!8V-O=6YT:6YG(%!O M;&EC:65S(%M,:6YE($ET96US73PO<W1R;VYG/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R M/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS M1'!L('9A;&EG;CTS1'1O<#Y0<F]P97)T>2!A;F0@97%U:7!M96YT(&5S=&EM M871E9"!U<V5F=6P@;&EV97,\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T M97AT/C<@>65A<G,\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@ M("`@("`\='(@8VQA<W,],T1R:#X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@ M=F%L:6=N/3-$=&]P/DUI;FEM=6T@6TUE;6)E<ET@?"!,96%S96AO;&0@26UP M<F]V96UE;G1S(%M-96UB97)=/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$ M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$ M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$ M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$ M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$ M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$ M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$ M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$ M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$ M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$ M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$ M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$ M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$ M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$ M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$ M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\ M='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N M/3-$=&]P/CQS=')O;F<^4W5M;6%R>2!/9B!3:6=N:69I8V%N="!!8V-O=6YT M:6YG(%!O;&EC:65S(%M,:6YE($ET96US73PO<W1R;VYG/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C M;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y0<F]P97)T>2!A;F0@97%U:7!M96YT M(&5S=&EM871E9"!U<V5F=6P@;&EV97,\+W1D/@T*("`@("`@("`\=&0@8VQA M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA M<W,],T1T97AT/C,@>65A<G,\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@ M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@ M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@ M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@ M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO M='(^#0H@("`@/"]T86)L93X-"B`@/"]B;V1Y/@T*/"]H=&UL/@T*#0HM+2TM M+2T]7TYE>'1087)T7S,Y8S!E838R7V,R,#-?-#4X9E\X8S4P7S-D8V$T-39A M-CDU,0T*0V]N=&5N="U,;V-A=&EO;CH@9FEL93HO+R]#.B\S.6,P96$V,E]C M,C`S7S0U.&9?.&,U,%\S9&-A-#4V838Y-3$O5V]R:W-H965T<R]3:&5E=#,X M+FAT;6P-"D-O;G1E;G0M5')A;G-F97(M16YC;V1I;F<Z('%U;W1E9"UP<FEN M=&%B;&4-"D-O;G1E;G0M5'EP93H@=&5X="]H=&UL.R!C:&%R<V5T/2)U<RUA M<V-I:2(-"@T*/&AT;6P^#0H@(#QH96%D/@T*("`@(#Q-151!(&AT='`M97%U M:78],T1#;VYT96YT+51Y<&4@8V]N=&5N=#TS1"=T97AT+VAT;6P[(&-H87)S M970]=71F+3@G/CQS8W)I<'0@='EP93TS1'1E>'0O:F%V87-C<FEP="!S<F,] M,T13:&]W+FIS/B\J($1O($YO="!296UO=F4@5&AI<R!#;VUM96YT("HO/"]S M8W)I<'0^/"]H96%D/@T*("`\8F]D>3X-"B`@("`\=&%B;&4@8VQA<W,],T1R M97!O<G0@:60],T1)1#!%3$1!1SX-"B`@("`@(#QT<CX-"B`@("`@("`@/'1H M(&-L87-S/3-$=&P@8V]L<W!A;CTS1#$@<F]W<W!A;CTS1#(^/'-T<F]N9SY. M970@3&]S<R!097(@4VAA<F4@+2!#86QC=6QA=&EO;B!O9B!"87-I8R!A;F0@ M1&EL=71E9"!.970@3&]S<R!097(@4VAA<F4@06QL;V-A8FQE('1O($-O;6UO M;B!3=&]C:VAO;&1E<G,@*$1E=&%I;"D@*%531"`D*3QB<CY);B!4:&]U<V%N M9',L(&5X8V5P="!097(@4VAA<F4@9&%T82P@=6YL97-S(&]T:&5R=VES92!S M<&5C:69I960\+W-T<F]N9SX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T M:"!C;VQS<&%N/3-$.#XS($UO;G1H<R!%;F1E9#PO=&@^#0H@("`@("`@(#QT M:"!C;&%S<STS1'1H(&-O;'-P86X],T0S/C$R($UO;G1H<R!%;F1E9#PO=&@^ M#0H@("`@("`\+W1R/@T*("`@("`@/'1R/@T*("`@("`@("`\=&@@8VQA<W,] M,T1T:#Y$96,N(#,Q+"`R,#$T/&)R/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S M<STS1'1H/E-E<"X@,S`L(#(P,30\8G(^/"]T:#X-"B`@("`@("`@/'1H(&-L M87-S/3-$=&@^2G5N+B`S,"P@,C`Q-#QB<CX\+W1H/@T*("`@("`@("`\=&@@ M8VQA<W,],T1T:#Y-87(N(#,Q+"`R,#$T/&)R/CPO=&@^#0H@("`@("`@(#QT M:"!C;&%S<STS1'1H/D1E8RX@,S$L(#(P,3,\8G(^/"]T:#X-"B`@("`@("`@ M/'1H(&-L87-S/3-$=&@^4V5P+B`S,"P@,C`Q,SQB<CX\+W1H/@T*("`@("`@ M("`\=&@@8VQA<W,],T1T:#Y*=6XN(#,P+"`R,#$S/&)R/CPO=&@^#0H@("`@ M("`@(#QT:"!C;&%S<STS1'1H/DUA<BX@,S$L(#(P,3,\8G(^/"]T:#X-"B`@ M("`@("`@/'1H(&-L87-S/3-$=&@^1&5C+B`S,2P@,C`Q-#QB<CX\+W1H/@T* M("`@("`@("`\=&@@8VQA<W,],T1T:#Y$96,N(#,Q+"`R,#$S/&)R/CPO=&@^ M#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/D1E8RX@,S$L(#(P,3(\8G(^/"]T M:#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@ M("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/CQS=')O;F<^16%R;FEN M9W,@4&5R(%-H87)E(%M!8G-T<F%C=%T\+W-T<F]N9SX\+W1D/@T*("`@("`@ M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@ M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@ M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@ M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@ M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@ M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@ M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@ M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@ M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@ M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@ M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@ M/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA M<W,],T1P;"!V86QI9VX],T1T;W`^3F5T(&QO<W,\+W1D/@T*("`@("`@("`\ M=&0@8VQA<W,],T1N=6UP/B0@."PT-#,\<W!A;CX\+W-P86X^/"]T9#X-"B`@ M("`@("`@/'1D(&-L87-S/3-$;G5M/B0@*#4L.3<Q*3QS<&%N/CPO<W!A;CX\ M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6T^)"`H."PS-S0I/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;3XD("@X+#<T M-"D\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M M<#XD(#8L-3,Q/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M<STS1&YU;3XD("@Q,BPU.#@I/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S<STS1&YU;3XD("@Q-2PP-#$I/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;3XD("@Q,BPV,3DI/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;3XD("@Q-"PV-#8I M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;3XD M("@S,RPW,3<I/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M<STS1&YU;3XD("@T,"PS-S`I/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\ M+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S M<STS1'!L('9A;&EG;CTS1'1O<#Y$965M960@9&EV:61E;F0@<F5L871E9"!T M;R!B96YE9FEC:6%L(&-O;G9E<G-I;VX@9F5A='5R92!O9B!C;VYV97)T:6)L M92!P<F5F97)R960@<W1O8VL\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N M=6UP/C`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$ M;G5M<#XP/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS M1&YU;3XH,2PS,#<I/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T* M("`@("`@/'1R(&-L87-S/3-$<F]U/@T*("`@("`@("`\=&0@8VQA<W,],T1P M;"!V86QI9VX],T1T;W`^3F5T(&QO<W,@86QL;V-A8FQE('1O(&-O;6UO;B!S M=&]C:VAO;&1E<G,\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B0@ M."PT-#,\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$ M;G5M/B0@*#4L.3<Q*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@ M8VQA<W,],T1N=6T^)"`H."PS-S0I/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S<STS1&YU;3XD("@X+#<T-"D\<W!A;CX\+W-P86X^/"]T M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XD(#8L-3,Q/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;3XD("@Q,BPU.#@I M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;3XD M("@Q-2PP-#$I/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M<STS1&YU;3XD("@Q,BPV,3DI/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S<STS1&YU;3XD("@Q-"PV-#8I/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;3XD("@S,RPW,3<I/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;3XD("@T,2PV-S<I M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L M87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O M<#Y796EG:'1E9"UA=F5R86=E('-H87)E<R!U<V5D(&EN(&-O;7!U=&EN9R!N M970@;&]S<R!P97(@<VAA<F4@86QL;V-A8FQE('1O(&-O;6UO;B!S=&]C:VAO M;&1E<G,@+2!B87-I8R!A;F0@9&EL=71E9#PO=&0^#0H@("`@("`@(#QT9"!C M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S<STS1&YU;7`^,S4L-S`Y/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S<STS1&YU;7`^,C<L,C<U/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,3@L,3`W/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@ M("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y.970@;&]S<R!P97(@ M<VAA<F4@86QL;V-A8FQE('1O(&-O;6UO;B!S=&]C:VAO;&1E<G,@+2!B87-I M8R!A;F0@9&EL=71E9#PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;3XD M("@P+C0Q*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,] M,T1N=6T^)"`H,2XR-"D\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D M(&-L87-S/3-$;G5M/B0@*#(N,RD\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@ M(#PO='(^#0H@("`@/"]T86)L93X-"B`@/"]B;V1Y/@T*/"]H=&UL/@T*#0HM M+2TM+2T]7TYE>'1087)T7S,Y8S!E838R7V,R,#-?-#4X9E\X8S4P7S-D8V$T M-39A-CDU,0T*0V]N=&5N="U,;V-A=&EO;CH@9FEL93HO+R]#.B\S.6,P96$V M,E]C,C`S7S0U.&9?.&,U,%\S9&-A-#4V838Y-3$O5V]R:W-H965T<R]3:&5E M=#,Y+FAT;6P-"D-O;G1E;G0M5')A;G-F97(M16YC;V1I;F<Z('%U;W1E9"UP M<FEN=&%B;&4-"D-O;G1E;G0M5'EP93H@=&5X="]H=&UL.R!C:&%R<V5T/2)U M<RUA<V-I:2(-"@T*/&AT;6P^#0H@(#QH96%D/@T*("`@(#Q-151!(&AT='`M M97%U:78],T1#;VYT96YT+51Y<&4@8V]N=&5N=#TS1"=T97AT+VAT;6P[(&-H M87)S970]=71F+3@G/CQS8W)I<'0@='EP93TS1'1E>'0O:F%V87-C<FEP="!S M<F,],T13:&]W+FIS/B\J($1O($YO="!296UO=F4@5&AI<R!#;VUM96YT("HO M/"]S8W)I<'0^/"]H96%D/@T*("`\8F]D>3X-"B`@("`\=&%B;&4@8VQA<W,] M,T1R97!O<G0@:60],T1)1#!%54=!1SX-"B`@("`@(#QT<CX-"B`@("`@("`@ M/'1H(&-L87-S/3-$=&P@8V]L<W!A;CTS1#$@<F]W<W!A;CTS1#(^/'-T<F]N M9SY.970@3&]S<R!097(@4VAA<F4@+2!);G-T<G5M96YT<R!%>&-L=61E9"!F M<F]M('1H92!#;VUP=71A=&EO;B!O9B!$:6QU=&5D($YE="!,;W-S(%!E<B!# M;VUM;VX@4VAA<F4@*$1E=&%I;"D\8G(^26X@5&AO=7-A;F1S+"!U;FQE<W,@ M;W1H97)W:7-E('-P96-I9FEE9#PO<W1R;VYG/CPO=&@^#0H@("`@("`@(#QT M:"!C;&%S<STS1'1H(&-O;'-P86X],T0S/C$R($UO;G1H<R!%;F1E9#PO=&@^ M#0H@("`@("`\+W1R/@T*("`@("`@/'1R/@T*("`@("`@("`\=&@@8VQA<W,] M,T1T:#Y$96,N(#,Q+"`R,#$T/&)R/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S M<STS1'1H/D1E8RX@,S$L(#(P,3,\8G(^/"]T:#X-"B`@("`@("`@/'1H(&-L M87-S/3-$=&@^1&5C+B`S,2P@,C`Q,CQB<CX\+W1H/@T*("`@("`@/"]T<CX- M"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P M;"!V86QI9VX],T1T;W`^/'-T<F]N9SY!;G1I9&EL=71I=F4@4V5C=7)I=&EE M<R!%>&-L=61E9"!F<F]M($-O;7!U=&%T:6]N(&]F($5A<FYI;F=S(%!E<B!3 M:&%R92!;3&EN92!)=&5M<UT\+W-T<F]N9SX\+W1D/@T*("`@("`@("`\=&0@ M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@ M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@ M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX- M"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P M;"!V86QI9VX],T1T;W`^5&]T86P@<VAA<F5S/"]T9#X-"B`@("`@("`@/'1D M(&-L87-S/3-$;G5M<#XQ,"PP-C<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@ M("`@/'1D(&-L87-S/3-$;G5M<#XQ,"PQ.3<\<W!A;CX\+W-P86X^/"]T9#X- M"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ-"PX-C8\<W!A;CX\+W-P86X^ M/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R:#X-"B`@ M("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D]P=&EO;G,@6TUE M;6)E<ET\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO M<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O M/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^/'-T<F]N M9SY!;G1I9&EL=71I=F4@4V5C=7)I=&EE<R!%>&-L=61E9"!F<F]M($-O;7!U M=&%T:6]N(&]F($5A<FYI;F=S(%!E<B!3:&%R92!;3&EN92!)=&5M<UT\+W-T M<F]N9SX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO M<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E M/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^5&]T86P@ M<VAA<F5S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XS+#(Y.#QS M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C(L M-#0Y/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU M;7`^,2PW.3$\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@ M("`\='(@8VQA<W,],T1R:#X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L M:6=N/3-$=&]P/E=A<G)A;G1S('1O(%!U<F-H87-E($-O;6UO;B!3=&]C:R!; M365M8F5R73PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$ M<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#X\<W1R M;VYG/D%N=&ED:6QU=&EV92!396-U<FET:65S($5X8VQU9&5D(&9R;VT@0V]M M<'5T871I;VX@;V8@16%R;FEN9W,@4&5R(%-H87)E(%M,:6YE($ET96US73PO M<W1R;VYG/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$ M<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y4;W1A M;"!S:&%R97,\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C8L-CDQ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^ M-RPV.3(\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$ M;G5M<#XY+#`P.3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@ M("`@(#QT<B!C;&%S<STS1')H/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V M86QI9VX],T1T;W`^4F5S=')I8W1E9"!3=&]C:R!5;FET<R!;365M8F5R73PO M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@ M("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#X\<W1R;VYG/D%N=&ED M:6QU=&EV92!396-U<FET:65S($5X8VQU9&5D(&9R;VT@0V]M<'5T871I;VX@ M;V8@16%R;FEN9W,@4&5R(%-H87)E(%M,:6YE($ET96US73PO<W1R;VYG/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@ M("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y4;W1A;"!S:&%R97,\ M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C8S/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-#(\<W!A;CX\+W-P M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XR,3<\<W!A;CX\ M+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R M:#X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E-E<FEE M<R!"($-O;G9E<G1I8FQE(%!R969E<G)E9"!3=&]C:R!;365M8F5R73PO=&0^ M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@ M(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#X\<W1R;VYG/D%N=&ED:6QU M=&EV92!396-U<FET:65S($5X8VQU9&5D(&9R;VT@0V]M<'5T871I;VX@;V8@ M16%R;FEN9W,@4&5R(%-H87)E(%M,:6YE($ET96US73PO<W1R;VYG/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@ M(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y4;W1A;"!S:&%R97,\+W1D M/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C`\<W!A;CX\+W-P86X^/"]T M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XP/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,RPX,S@\<W!A;CX\+W-P M86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R:#X- M"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D534%`@6TUE M;6)E<ET\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO M<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O M/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^/'-T<F]N M9SY!;G1I9&EL=71I=F4@4V5C=7)I=&EE<R!%>&-L=61E9"!F<F]M($-O;7!U M=&%T:6]N(&]F($5A<FYI;F=S(%!E<B!3:&%R92!;3&EN92!)=&5M<UT\+W-T M<F]N9SX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO M<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E M/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^5&]T86P@ M<VAA<F5S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ-3QS<&%N M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$T/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,3$\ M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@/"]T86)L93X- M"B`@/"]B;V1Y/@T*/"]H=&UL/@T*#0HM+2TM+2T]7TYE>'1087)T7S,Y8S!E M838R7V,R,#-?-#4X9E\X8S4P7S-D8V$T-39A-CDU,0T*0V]N=&5N="U,;V-A M=&EO;CH@9FEL93HO+R]#.B\S.6,P96$V,E]C,C`S7S0U.&9?.&,U,%\S9&-A M-#4V838Y-3$O5V]R:W-H965T<R]3:&5E=#0P+FAT;6P-"D-O;G1E;G0M5')A M;G-F97(M16YC;V1I;F<Z('%U;W1E9"UP<FEN=&%B;&4-"D-O;G1E;G0M5'EP M93H@=&5X="]H=&UL.R!C:&%R<V5T/2)U<RUA<V-I:2(-"@T*/&AT;6P^#0H@ M(#QH96%D/@T*("`@(#Q-151!(&AT='`M97%U:78],T1#;VYT96YT+51Y<&4@ M8V]N=&5N=#TS1"=T97AT+VAT;6P[(&-H87)S970]=71F+3@G/CQS8W)I<'0@ M='EP93TS1'1E>'0O:F%V87-C<FEP="!S<F,],T13:&]W+FIS/B\J($1O($YO M="!296UO=F4@5&AI<R!#;VUM96YT("HO/"]S8W)I<'0^/"]H96%D/@T*("`\ M8F]D>3X-"B`@("`\=&%B;&4@8VQA<W,],T1R97!O<G0@:60],T1)1#!%2T]! M0SX-"B`@("`@(#QT<CX-"B`@("`@("`@/'1H(&-L87-S/3-$=&P@8V]L<W!A M;CTS1#$@<F]W<W!A;CTS1#(^/'-T<F]N9SY3=7!P;&5M96YT87)Y($-A<V@@ M1FQO=R!$871A("T@4W5P<&QE;65N=&%L($-A<V@@1FQO=R!);F9O<FUA=&EO M;B`H1&5T86EL*2`H55-$("0I/&)R/DEN(%1H;W5S86YD<RP@=6YL97-S(&]T M:&5R=VES92!S<&5C:69I960\+W-T<F]N9SX\+W1H/@T*("`@("`@("`\=&@@ M8VQA<W,],T1T:"!C;VQS<&%N/3-$,SXQ,B!-;VYT:',@16YD960\+W1H/@T* M("`@("`@/"]T<CX-"B`@("`@(#QT<CX-"B`@("`@("`@/'1H(&-L87-S/3-$ M=&@^1&5C+B`S,2P@,C`Q-#QB<CX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,] M,T1T:#Y$96,N(#,Q+"`R,#$S/&)R/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S M<STS1'1H/D1E8RX@,S$L(#(P,3(\8G(^/"]T:#X-"B`@("`@(#PO='(^#0H@ M("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@ M=F%L:6=N/3-$=&]P/CQS=')O;F<^4W5P<&QE;65N=&%L($-A<V@@1FQO=R!% M;&5M96YT<R!;06)S=')A8W1=/"]S=')O;F<^/"]T9#X-"B`@("`@("`@/'1D M(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D M(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D M(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^ M#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$ M<&P@=F%L:6=N/3-$=&]P/D-A<V@@<&%I9"!F;W(@:6YT97)E<W0\+W1D/@T* M("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B0@,#QS<&%N/CPO<W!A;CX\+W1D M/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B0@,#QS<&%N/CPO<W!A;CX\ M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B0@,SQS<&%N/CPO<W!A M;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T* M("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^0V%S:"!P86ED M(&9O<B!I;F-O;64@=&%X97,\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N M=6UP/C$\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$ M;G5M<#XQ/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS M1&YU;7`^,3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@ M(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI M9VX],T1T;W`^/'-T<F]N9SY3:6=N:69I8V%N="!N;VXM8V%S:"!I;G9E<W1I M;F<@86YD(&9I;F%N8VEN9R!A8W1I=FET:65S.CPO<W1R;VYG/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT M9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y0=7)C:&%S97,@;V8@<')O<&5R M='D@86YD(&5Q=6EP;65N="!T:')O=6=H(&%C8V]U;G1S('!A>6%B;&4\+W1D M/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$W,#QS<&%N/CPO<W!A;CX\ M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$Y,SQS<&%N/CPO<W!A M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$Q-CQS<&%N/CPO M<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O M/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^4'5R8VAA M<V5S(&]F('!R;W!E<G1Y(&%N9"!E<75I<&UE;G0@=&AR;W5G:"!A8V-R=65D M(&QI86)I;&ET:65S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XR M-SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6T^ M*#(I/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU M;7`^,S<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\ M='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N M/3-$=&]P/E!U<F-H87-E<R!O9B!P<F]P97)T>2!A;F0@97%U:7!M96YT('1H M<F]U9V@@=')A9&4@:6X@=F%L=64@;V8@9&ES<&]S960@<')O<&5R='D@86YD M(&5Q=6EP;65N=#PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^)"`P M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^ M)"`X,3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N M=6UP/B0@,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`\ M+W1A8FQE/@T*("`\+V)O9'D^#0H\+VAT;6P^#0H-"BTM+2TM+3U?3F5X=%!A M<G1?,SEC,&5A-C)?8S(P,U\T-3AF7SAC-3!?,V1C830U-F$V.34Q#0I#;VYT M96YT+4QO8V%T:6]N.B!F:6QE.B\O+T,Z+S,Y8S!E838R7V,R,#-?-#4X9E\X M8S4P7S-D8V$T-39A-CDU,2]7;W)K<VAE971S+U-H965T-#$N:'1M;`T*0V]N M=&5N="U4<F%N<V9E<BU%;F-O9&EN9SH@<75O=&5D+7!R:6YT86)L90T*0V]N M=&5N="U4>7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\ M:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E M;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA<G-E=#UU=&8M."<^ M/'-C<FEP="!T>7!E/3-$=&5X="]J879A<V-R:7!T('-R8STS1%-H;W<N:G,^ M+RH@1&\@3F]T(%)E;6]V92!4:&ES($-O;6UE;G0@*B\\+W-C<FEP=#X\+VAE M860^#0H@(#QB;V1Y/@T*("`@(#QT86)L92!C;&%S<STS1')E<&]R="!I9#TS M1$E$,$5:2T%'/@T*("`@("`@/'1R/@T*("`@("`@("`\=&@@8VQA<W,],T1T M;"!C;VQS<&%N/3-$,2!R;W=S<&%N/3-$,CX\<W1R;VYG/D-A<V@@17%U:79A M;&5N=',@86YD($EN=F5S=&UE;G1S("T@06UO<G1I>F5D($-O<W0@86YD($9A M:7(@5F%L=64@;V8@0V%S:"!%<75I=F%L96YT<R!A;F0@079A:6QA8FQE(&9O M<B!386QE($EN=F5S=&UE;G1S("A$971A:6PI("A54T0@)"D\8G(^26X@5&AO M=7-A;F1S+"!U;FQE<W,@;W1H97)W:7-E('-P96-I9FEE9#PO<W1R;VYG/CPO M=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H(&-O;'-P86X],T0R/C$R($UO M;G1H<R!%;F1E9#PO=&@^#0H@("`@("`\+W1R/@T*("`@("`@/'1R/@T*("`@ M("`@("`\=&@@8VQA<W,],T1T:#Y$96,N(#,Q+"`R,#$T/&)R/CPO=&@^#0H@ M("`@("`@(#QT:"!C;&%S<STS1'1H/D1E8RX@,S$L(#(P,3,\8G(^/"]T:#X- M"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R:#X-"B`@("`@("`@ M/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D-A<V@@17%U:79A;&5N=',@ M6TUE;6)E<ET@?"!-;VYE>2!-87)K970@1G5N9',@6TUE;6)E<ET\+W1D/@T* M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T* M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T* M("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\ M=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^/'-T<F]N9SY#87-H(&%N9"!# M87-H($5Q=6EV86QE;G1S(%M,:6YE($ET96US73PO<W1R;VYG/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F5U/@T*("`@("`@("`\ M=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^06UO<G1I>F5D($-O<W0\+W1D M/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B`Q-BPY,S(\<W!A;CX\+W-P M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#X@,34L.#4X/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S M/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y5 M;G)E86QI>F5D($=A:6YS/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M M<#XP/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU M;7`^,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT M<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX] M,T1T;W`^56YR96%L:7IE9"!,;W-S97,\+W1D/@T*("`@("`@("`\=&0@8VQA M<W,],T1N=6UP/C`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L M87-S/3-$;G5M<#XP/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T* M("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L M('9A;&EG;CTS1'1O<#Y&86ER(%9A;'5E/"]T9#X-"B`@("`@("`@/'1D(&-L M87-S/3-$;G5M<#XQ-BPY,S(\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@ M/'1D(&-L87-S/3-$;G5M<#XQ-2PX-3@\<W!A;CX\+W-P86X^/"]T9#X-"B`@ M("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R:#X-"B`@("`@("`@/'1D M(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E-H;W)T+71E<FT@26YV97-T;65N M=',@6TUE;6)E<ET@?"!5+E,N(%1R96%S=7)Y(%-E8W5R:71I97,@6TUE;6)E M<ET\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A M;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T* M("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^/'-T<F]N9SY# M87-H(&%N9"!#87-H($5Q=6EV86QE;G1S(%M,:6YE($ET96US73PO<W1R;VYG M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F5U/@T* M("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^06UO<G1I>F5D M($-O<W0\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C8S+#`Q-SQS M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C4W M+#4V-#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT M<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX] M,T1T;W`^56YR96%L:7IE9"!'86EN<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S M<STS1&YU;7`^,SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA M<W,],T1N=6UP/C<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@ M("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@ M=F%L:6=N/3-$=&]P/E5N<F5A;&EZ960@3&]S<V5S/"]T9#X-"B`@("`@("`@ M/'1D(&-L87-S/3-$;G5M/B@W*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@ M("`\=&0@8VQA<W,],T1N=6T^*#$I/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C M;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y&86ER(%9A;'5E/"]T9#X-"B`@("`@ M("`@/'1D(&-L87-S/3-$;G5M<#XV,RPP,3,\<W!A;CX\+W-P86X^/"]T9#X- M"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XU-RPU-S`\<W!A;CX\+W-P86X^ M/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R:#X-"B`@ M("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/DQO;F<M=&5R;2!) M;G9E<W1M96YT<R!;365M8F5R72!\(%4N4RX@5')E87-U<GD@4V5C=7)I=&EE M<R!;365M8F5R73PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S M/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#X\ M<W1R;VYG/D-A<V@@86YD($-A<V@@17%U:79A;&5N=',@6TQI;F4@271E;7-= M/"]S=')O;F<^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A M;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,] M,T1R974^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y! M;6]R=&EZ960@0V]S=#PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^ M,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP M/C(L-3`R/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@ M/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG M;CTS1'1O<#Y5;G)E86QI>F5D($=A:6YS/"]T9#X-"B`@("`@("`@/'1D(&-L M87-S/3-$;G5M<#XP/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S<STS1&YU;7`^,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX- M"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P M;"!V86QI9VX],T1T;W`^56YR96%L:7IE9"!,;W-S97,\+W1D/@T*("`@("`@ M("`\=&0@8VQA<W,],T1N=6UP/C`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@ M("`@/'1D(&-L87-S/3-$;G5M<#XP/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C M;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y&86ER(%9A;'5E/"]T9#X-"B`@("`@ M("`@/'1D(&-L87-S/3-$;G5M<#X@,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@ M("`@("`\=&0@8VQA<W,],T1N=6UP/B`R+#4P,CQS<&%N/CPO<W!A;CX\+W1D M/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@ M("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^36%T=7)I='D@1&%T93PO M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^,C`Q-2TP,3QS<&%N/CPO M<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')H M/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^36EN:6UU M;2!;365M8F5R72!\(%-H;W)T+71E<FT@26YV97-T;65N=',@6TUE;6)E<ET@ M?"!5+E,N(%1R96%S=7)Y(%-E8W5R:71I97,@6TUE;6)E<ET\+W1D/@T*("`@ M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@ M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@ M("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@ M8VQA<W,],T1P;"!V86QI9VX],T1T;W`^/'-T<F]N9SY#87-H(&%N9"!#87-H M($5Q=6EV86QE;G1S(%M,:6YE($ET96US73PO<W1R;VYG/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C M;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y-871U<FET>2!$871E/"]T9#X-"B`@ M("`@("`@/'1D(&-L87-S/3-$=&5X=#XR,#$U+3`Q/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^,C`Q-"TP,3QS<&%N/CPO M<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')H M/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^36%X:6UU M;2!;365M8F5R72!\(%-H;W)T+71E<FT@26YV97-T;65N=',@6TUE;6)E<ET@ M?"!5+E,N(%1R96%S=7)Y(%-E8W5R:71I97,@6TUE;6)E<ET\+W1D/@T*("`@ M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@ M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@ M("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@ M8VQA<W,],T1P;"!V86QI9VX],T1T;W`^/'-T<F]N9SY#87-H(&%N9"!#87-H M($5Q=6EV86QE;G1S(%M,:6YE($ET96US73PO<W1R;VYG/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C M;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y-871U<FET>2!$871E/"]T9#X-"B`@ M("`@("`@/'1D(&-L87-S/3-$=&5X=#XR,#$U+3$R/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^,C`Q-"TQ,CQS<&%N/CPO M<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`\+W1A8FQE/@T*("`\+V)O M9'D^#0H\+VAT;6P^#0H-"BTM+2TM+3U?3F5X=%!A<G1?,SEC,&5A-C)?8S(P M,U\T-3AF7SAC-3!?,V1C830U-F$V.34Q#0I#;VYT96YT+4QO8V%T:6]N.B!F M:6QE.B\O+T,Z+S,Y8S!E838R7V,R,#-?-#4X9E\X8S4P7S-D8V$T-39A-CDU M,2]7;W)K<VAE971S+U-H965T-#(N:'1M;`T*0V]N=&5N="U4<F%N<V9E<BU% M;F-O9&EN9SH@<75O=&5D+7!R:6YT86)L90T*0V]N=&5N="U4>7!E.B!T97AT M+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^ M#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT M/3-$)W1E>'0O:'1M;#L@8VAA<G-E=#UU=&8M."<^/'-C<FEP="!T>7!E/3-$ M=&5X="]J879A<V-R:7!T('-R8STS1%-H;W<N:G,^+RH@1&\@3F]T(%)E;6]V M92!4:&ES($-O;6UE;G0@*B\\+W-C<FEP=#X\+VAE860^#0H@(#QB;V1Y/@T* M("`@(#QT86)L92!C;&%S<STS1')E<&]R="!I9#TS1$E$,$590T%%/@T*("`@ M("`@/'1R/@T*("`@("`@("`\=&@@8VQA<W,],T1T;"!C;VQS<&%N/3-$,2!R M;W=S<&%N/3-$,CX\<W1R;VYG/D-A<V@@17%U:79A;&5N=',@86YD($EN=F5S M=&UE;G1S("T@061D:71I;VYA;"!);F9O<FUA=&EO;B`H1&5T86EL*2`H55-$ M("0I/&)R/CPO<W1R;VYG/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H M(&-O;'-P86X],T0R/C$R($UO;G1H<R!%;F1E9#PO=&@^#0H@("`@("`\+W1R M/@T*("`@("`@/'1R/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y$96,N(#,Q M+"`R,#$T/&)R/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/D1E8RX@ M,S$L(#(P,3,\8G(^/"]T:#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA M<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P M/CQS=')O;F<^0V%S:"!A;F0@0V%S:"!%<75I=F%L96YT<R!;3&EN92!)=&5M M<UT\+W-T<F]N9SX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S M<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^ M26YV97-T;65N=',@:6X@8V]N=&EN=6]U<R!U;G)E86QI>F5D(&QO<W,@<&]S M:71I;VX@9F]R(#$R(&UO;G1H<R!O<B!L;VYG97(\+W1D/@T*("`@("`@("`\ M=&0@8VQA<W,],T1N=6UP/B0@,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@ M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@ M/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')H/@T*("`@("`@("`\=&0@8VQA M<W,],T1P;"!V86QI9VX],T1T;W`^52Y3+B!4<F5A<W5R>2!396-U<FET:65S M(%M-96UB97)=/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A M;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,] M,T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/CQS M=')O;F<^0V%S:"!A;F0@0V%S:"!%<75I=F%L96YT<R!;3&EN92!)=&5M<UT\ M+W-T<F]N9SX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N M/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS M1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^52Y3 M+B!4<F5A<W5R>2!S96-U<FET:65S(&UA='5R:71Y('-T87)T(&1A=&4\+W1D M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/DIA;B`Q+`T*"0DR,#$U/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S M/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y5 M+E,N(%1R96%S=7)Y('-E8W5R:71I97,@;6%T=7)I='D@96YD(&1A=&4\+W1D M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/D9E8B`R-RP-"@D),C`Q-3QS M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S M<STS1')H/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^ M4VAO<G0M=&5R;2!);G9E<W1M96YT<R!;365M8F5R73PO=&0^#0H@("`@("`@ M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\ M+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S M<STS1'!L('9A;&EG;CTS1'1O<#X\<W1R;VYG/D-A<V@@86YD($-A<V@@17%U M:79A;&5N=',@6TQI;F4@271E;7-=/"]S=')O;F<^/"]T9#X-"B`@("`@("`@ M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@ M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO M='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S M/3-$<&P@=F%L:6=N/3-$=&]P/E5N<F5A;&EZ960@1V%I;B`H;&]S<RD\+W1D M/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6T^)"`H-RPP,#`I/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;3XD("@Q+#`P,"D\ M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@/"]T86)L93X- M"B`@/"]B;V1Y/@T*/"]H=&UL/@T*#0HM+2TM+2T]7TYE>'1087)T7S,Y8S!E M838R7V,R,#-?-#4X9E\X8S4P7S-D8V$T-39A-CDU,0T*0V]N=&5N="U,;V-A M=&EO;CH@9FEL93HO+R]#.B\S.6,P96$V,E]C,C`S7S0U.&9?.&,U,%\S9&-A M-#4V838Y-3$O5V]R:W-H965T<R]3:&5E=#0S+FAT;6P-"D-O;G1E;G0M5')A M;G-F97(M16YC;V1I;F<Z('%U;W1E9"UP<FEN=&%B;&4-"D-O;G1E;G0M5'EP M93H@=&5X="]H=&UL.R!C:&%R<V5T/2)U<RUA<V-I:2(-"@T*/&AT;6P^#0H@ M(#QH96%D/@T*("`@(#Q-151!(&AT='`M97%U:78],T1#;VYT96YT+51Y<&4@ M8V]N=&5N=#TS1"=T97AT+VAT;6P[(&-H87)S970]=71F+3@G/CQS8W)I<'0@ M='EP93TS1'1E>'0O:F%V87-C<FEP="!S<F,],T13:&]W+FIS/B\J($1O($YO M="!296UO=F4@5&AI<R!#;VUM96YT("HO/"]S8W)I<'0^/"]H96%D/@T*("`\ M8F]D>3X-"B`@("`\=&%B;&4@8VQA<W,],T1R97!O<G0@:60],T1)1#!%6$)! M0SX-"B`@("`@(#QT<CX-"B`@("`@("`@/'1H(&-L87-S/3-$=&P@8V]L<W!A M;CTS1#$@<F]W<W!A;CTS1#(^/'-T<F]N9SY#87-H($5Q=6EV86QE;G1S(&%N M9"!);G9E<W1M96YT<R`M(%-U;6UA<GD@;V8@26YT97)E<W0@26YC;VUE("A$ M971A:6PI("A54T0@)"D\8G(^26X@5&AO=7-A;F1S+"!U;FQE<W,@;W1H97)W M:7-E('-P96-I9FEE9#PO<W1R;VYG/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S M<STS1'1H(&-O;'-P86X],T0S/C$R($UO;G1H<R!%;F1E9#PO=&@^#0H@("`@ M("`\+W1R/@T*("`@("`@/'1R/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y$ M96,N(#,Q+"`R,#$T/&)R/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H M/D1E8RX@,S$L(#(P,3,\8G(^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$ M=&@^1&5C+B`S,2P@,C`Q,CQB<CX\+W1H/@T*("`@("`@/"]T<CX-"B`@("`@ M(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI M9VX],T1T;W`^/'-T<F]N9SY#87-H(&%N9"!#87-H($5Q=6EV86QE;G1S(%M! M8G-T<F%C=%T\+W-T<F]N9SX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT M<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX] M,T1T;W`^26YT97)E<W0@:6YC;VUE/"]T9#X-"B`@("`@("`@/'1D(&-L87-S M/3-$;G5M<#XD(#$P,3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@ M8VQA<W,],T1N=6UP/B0@.38\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@ M/'1D(&-L87-S/3-$;G5M<#XD(#@S/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`\+W1R/@T*("`@(#PO=&%B;&4^#0H@(#PO8F]D>3X-"CPO:'1M;#X-"@T* M+2TM+2TM/5].97AT4&%R=%\S.6,P96$V,E]C,C`S7S0U.&9?.&,U,%\S9&-A M-#4V838Y-3$-"D-O;G1E;G0M3&]C871I;VXZ(&9I;&4Z+R\O0SHO,SEC,&5A M-C)?8S(P,U\T-3AF7SAC-3!?,V1C830U-F$V.34Q+U=O<FMS:&5E=',O4VAE M970T-"YH=&UL#0I#;VYT96YT+51R86YS9F5R+45N8V]D:6YG.B!Q=6]T960M M<')I;G1A8FQE#0I#;VYT96YT+51Y<&4Z('1E>'0O:'1M;#L@8VAA<G-E=#TB M=7,M87-C:6DB#0H-"CQH=&UL/@T*("`\:&5A9#X-"B`@("`\345402!H='1P M+65Q=6EV/3-$0V]N=&5N="U4>7!E(&-O;G1E;G0],T0G=&5X="]H=&UL.R!C M:&%R<V5T/75T9BTX)SX\<V-R:7!T('1Y<&4],T1T97AT+VIA=F%S8W)I<'0@ M<W)C/3-$4VAO=RYJ<SXO*B!$;R!.;W0@4F5M;W9E(%1H:7,@0V]M;65N="`J M+SPO<V-R:7!T/CPO:&5A9#X-"B`@/&)O9'D^#0H@("`@/'1A8FQE(&-L87-S M/3-$<F5P;W)T(&ED/3-$240P15!&1$D^#0H@("`@("`\='(^#0H@("`@("`@ M(#QT:"!C;&%S<STS1'1L(&-O;'-P86X],T0Q(')O=W-P86X],T0Q/CQS=')O M;F<^1F%I<B!686QU92!-96%S=7)E;65N=',@+2!3=6UM87)Y(&]F($9I;F%N M8VEA;"!!<W-E=',@365A<W5R960@870@1F%I<B!686QU92!O;B!296-U<G)I M;F<@0F%S:7,@*$1E=&%I;"D@*$9A:7(@5F%L=64L($UE87-U<F5M96YT<RP@ M4F5C=7)R:6YG(%M-96UB97)=+"!54T0@)"D\8G(^26X@5&AO=7-A;F1S+"!U M;FQE<W,@;W1H97)W:7-E('-P96-I9FEE9#PO<W1R;VYG/CPO=&@^#0H@("`@ M("`@(#QT:"!C;&%S<STS1'1H/D1E8RX@,S$L(#(P,30\8G(^/"]T:#X-"B`@ M("`@("`@/'1H(&-L87-S/3-$=&@^1&5C+B`S,2P@,C`Q,SQB<CX\+W1H/@T* M("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\ M=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^/'-T<F]N9SY&86ER(%9A;'5E M+"!!<W-E=',@86YD($QI86)I;&ET:65S($UE87-U<F5D(&]N(%)E8W5R<FEN M9R!A;F0@3F]N<F5C=7)R:6YG($)A<VES(%M,:6YE($ET96US73PO<W1R;VYG M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@ M("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y!<W-E=',@870@ M9F%I<B!V86QU93PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^)"`W M.2PY-#4\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$ M;G5M<#XD(#<U+#DS,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX- M"B`@("`@(#QT<B!C;&%S<STS1')H/@T*("`@("`@("`\=&0@8VQA<W,],T1P M;"!V86QI9VX],T1T;W`^36]N97D@36%R:V5T($9U;F1S(%M-96UB97)=/"]T M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T M9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@ M("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/CQS=')O;F<^1F%I<B!6 M86QU92P@07-S971S(&%N9"!,:6%B:6QI=&EE<R!-96%S=7)E9"!O;B!296-U M<G)I;F<@86YD($YO;G)E8W5R<FEN9R!"87-I<R!;3&EN92!)=&5M<UT\+W-T M<F]N9SX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO M<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E M/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^07-S971S M(&%T(&9A:7(@=F%L=64\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP M/C$V+#DS,CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,] M,T1N=6UP/C$U+#@U.#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX- M"B`@("`@(#QT<B!C;&%S<STS1')H/@T*("`@("`@("`\=&0@8VQA<W,],T1P M;"!V86QI9VX],T1T;W`^52Y3+B!4<F5A<W5R>2!396-U<FET:65S(%M-96UB M97)=/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P M86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X- M"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/CQS=')O;F<^ M1F%I<B!686QU92P@07-S971S(&%N9"!,:6%B:6QI=&EE<R!-96%S=7)E9"!O M;B!296-U<G)I;F<@86YD($YO;G)E8W5R<FEN9R!"87-I<R!;3&EN92!)=&5M M<UT\+W-T<F]N9SX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S M<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^ M07-S971S(&%T(&9A:7(@=F%L=64\+W1D/@T*("`@("`@("`\=&0@8VQA<W,] M,T1N=6UP/C8S+#`Q,SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@ M8VQA<W,],T1N=6UP/C8P+#`W,CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@ M/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')H/@T*("`@("`@("`\=&0@8VQA M<W,],T1P;"!V86QI9VX],T1T;W`^3&]N9RUT97)M($EN=F5S=&UE;G1S(%M- M96UB97)=/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\ M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\ M+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R M;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/CQS=')O M;F<^1F%I<B!686QU92P@07-S971S(&%N9"!,:6%B:6QI=&EE<R!-96%S=7)E M9"!O;B!296-U<G)I;F<@86YD($YO;G)E8W5R<FEN9R!"87-I<R!;3&EN92!) M=&5M<UT\+W-T<F]N9SX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C M;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T M;W`^07-S971S(&%T(&9A:7(@=F%L=64\+W1D/@T*("`@("`@("`\=&0@8VQA M<W,],T1N=6UP/C`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L M87-S/3-$;G5M<#XR+#4P,CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T M<CX-"B`@("`@(#QT<B!C;&%S<STS1')H/@T*("`@("`@("`\=&0@8VQA<W,] M,T1P;"!V86QI9VX],T1T;W`^4VAO<G0M=&5R;2!);G9E<W1M96YT<R!;365M M8F5R73PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^ M#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#X\<W1R;VYG M/D9A:7(@5F%L=64L($%S<V5T<R!A;F0@3&EA8FEL:71I97,@365A<W5R960@ M;VX@4F5C=7)R:6YG(&%N9"!.;VYR96-U<G)I;F<@0F%S:7,@6TQI;F4@271E M;7-=/"]S=')O;F<^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\ M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\ M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA M<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P M/D%S<V5T<R!A="!F86ER('9A;'5E/"]T9#X-"B`@("`@("`@/'1D(&-L87-S M/3-$;G5M<#XV,RPP,3,\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D M(&-L87-S/3-$;G5M<#XU-RPU-S`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@ M(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R:#X-"B`@("`@("`@/'1D(&-L M87-S/3-$<&P@=F%L:6=N/3-$=&]P/D9A:7(@5F%L=64@365A<W5R96UE;G1S M(%5S:6YG($QE=F5L(#$@6TUE;6)E<ET\+W1D/@T*("`@("`@("`\=&0@8VQA M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@ M("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V M86QI9VX],T1T;W`^/'-T<F]N9SY&86ER(%9A;'5E+"!!<W-E=',@86YD($QI M86)I;&ET:65S($UE87-U<F5D(&]N(%)E8W5R<FEN9R!A;F0@3F]N<F5C=7)R M:6YG($)A<VES(%M,:6YE($ET96US73PO<W1R;VYG/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\ M+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S M<STS1'!L('9A;&EG;CTS1'1O<#Y!<W-E=',@870@9F%I<B!V86QU93PO=&0^ M#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-SDL.30U/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-S4L.3,P/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$ M<F@^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y&86ER M(%9A;'5E($UE87-U<F5M96YT<R!5<VEN9R!,979E;"`Q(%M-96UB97)=('P@ M36]N97D@36%R:V5T($9U;F1S(%M-96UB97)=/"]T9#X-"B`@("`@("`@/'1D M(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D M(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^ M#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$ M<&P@=F%L:6=N/3-$=&]P/CQS=')O;F<^1F%I<B!686QU92P@07-S971S(&%N M9"!,:6%B:6QI=&EE<R!-96%S=7)E9"!O;B!296-U<G)I;F<@86YD($YO;G)E M8W5R<FEN9R!"87-I<R!;3&EN92!)=&5M<UT\+W-T<F]N9SX\+W1D/@T*("`@ M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@ M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@ M("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@ M8VQA<W,],T1P;"!V86QI9VX],T1T;W`^07-S971S(&%T(&9A:7(@=F%L=64\ M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$V+#DS,CQS<&%N/CPO M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$U+#@U.#QS M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S M<STS1')H/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^ M1F%I<B!686QU92!-96%S=7)E;65N=',@57-I;F<@3&5V96P@,2!;365M8F5R M72!\(%4N4RX@5')E87-U<GD@4V5C=7)I=&EE<R!;365M8F5R73PO=&0^#0H@ M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT M9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#X\<W1R;VYG/D9A:7(@5F%L=64L M($%S<V5T<R!A;F0@3&EA8FEL:71I97,@365A<W5R960@;VX@4F5C=7)R:6YG M(&%N9"!.;VYR96-U<G)I;F<@0F%S:7,@6TQI;F4@271E;7-=/"]S=')O;F<^ M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^ M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^ M/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@ M("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D%S<V5T<R!A="!F M86ER('9A;'5E/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XV,RPP M,3,\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M M<#XV,"PP-S(\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@ M("`\='(@8VQA<W,],T1R:#X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L M:6=N/3-$=&]P/D9A:7(@5F%L=64@365A<W5R96UE;G1S(%5S:6YG($QE=F5L M(#$@6TUE;6)E<ET@?"!,;VYG+71E<FT@26YV97-T;65N=',@6TUE;6)E<ET\ M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\ M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\ M+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@ M("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^/'-T<F]N9SY&86ER M(%9A;'5E+"!!<W-E=',@86YD($QI86)I;&ET:65S($UE87-U<F5D(&]N(%)E M8W5R<FEN9R!A;F0@3F]N<F5C=7)R:6YG($)A<VES(%M,:6YE($ET96US73PO M<W1R;VYG/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$ M<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y!<W-E M=',@870@9F%I<B!V86QU93PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU M;7`^,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N M=6UP/C(L-3`R/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@ M("`@/'1R(&-L87-S/3-$<F@^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A M;&EG;CTS1'1O<#Y&86ER(%9A;'5E($UE87-U<F5M96YT<R!5<VEN9R!,979E M;"`Q(%M-96UB97)=('P@4VAO<G0M=&5R;2!);G9E<W1M96YT<R!;365M8F5R M73PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@ M("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#X\<W1R;VYG/D9A M:7(@5F%L=64L($%S<V5T<R!A;F0@3&EA8FEL:71I97,@365A<W5R960@;VX@ M4F5C=7)R:6YG(&%N9"!.;VYR96-U<G)I;F<@0F%S:7,@6TQI;F4@271E;7-= M/"]S=')O;F<^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A M;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,] M,T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D%S M<V5T<R!A="!F86ER('9A;'5E/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$ M;G5M<#XV,RPP,3,\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L M87-S/3-$;G5M<#XU-RPU-S`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO M='(^#0H@("`@("`\='(@8VQA<W,],T1R:#X-"B`@("`@("`@/'1D(&-L87-S M/3-$<&P@=F%L:6=N/3-$=&]P/D9A:7(@5F%L=64@365A<W5R96UE;G1S(%5S M:6YG($QE=F5L(#(@6TUE;6)E<ET\+W1D/@T*("`@("`@("`\=&0@8VQA<W,] M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,] M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@ M(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI M9VX],T1T;W`^/'-T<F]N9SY&86ER(%9A;'5E+"!!<W-E=',@86YD($QI86)I M;&ET:65S($UE87-U<F5D(&]N(%)E8W5R<FEN9R!A;F0@3F]N<F5C=7)R:6YG M($)A<VES(%M,:6YE($ET96US73PO<W1R;VYG/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R M/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS M1'!L('9A;&EG;CTS1'1O<#Y!<W-E=',@870@9F%I<B!V86QU93PO=&0^#0H@ M("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,#QS<&%N/CPO<W!A;CX\+W1D/@T* M("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C`\<W!A;CX\+W-P86X^/"]T9#X- M"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R:#X-"B`@("`@("`@ M/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D9A:7(@5F%L=64@365A<W5R M96UE;G1S(%5S:6YG($QE=F5L(#(@6TUE;6)E<ET@?"!-;VYE>2!-87)K970@ M1G5N9',@6TUE;6)E<ET\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C M;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T M;W`^/'-T<F]N9SY&86ER(%9A;'5E+"!!<W-E=',@86YD($QI86)I;&ET:65S M($UE87-U<F5D(&]N(%)E8W5R<FEN9R!A;F0@3F]N<F5C=7)R:6YG($)A<VES M(%M,:6YE($ET96US73PO<W1R;VYG/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@ M("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A M;&EG;CTS1'1O<#Y!<W-E=',@870@9F%I<B!V86QU93PO=&0^#0H@("`@("`@ M(#QT9"!C;&%S<STS1&YU;7`^,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@ M("`\=&0@8VQA<W,],T1N=6UP/C`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@ M(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R:#X-"B`@("`@("`@/'1D(&-L M87-S/3-$<&P@=F%L:6=N/3-$=&]P/D9A:7(@5F%L=64@365A<W5R96UE;G1S M(%5S:6YG($QE=F5L(#(@6TUE;6)E<ET@?"!5+E,N(%1R96%S=7)Y(%-E8W5R M:71I97,@6TUE;6)E<ET\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C M;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T M;W`^/'-T<F]N9SY&86ER(%9A;'5E+"!!<W-E=',@86YD($QI86)I;&ET:65S M($UE87-U<F5D(&]N(%)E8W5R<FEN9R!A;F0@3F]N<F5C=7)R:6YG($)A<VES M(%M,:6YE($ET96US73PO<W1R;VYG/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@ M("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A M;&EG;CTS1'1O<#Y!<W-E=',@870@9F%I<B!V86QU93PO=&0^#0H@("`@("`@ M(#QT9"!C;&%S<STS1&YU;7`^,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@ M("`\=&0@8VQA<W,],T1N=6UP/C`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@ M(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R:#X-"B`@("`@("`@/'1D(&-L M87-S/3-$<&P@=F%L:6=N/3-$=&]P/D9A:7(@5F%L=64@365A<W5R96UE;G1S M(%5S:6YG($QE=F5L(#(@6TUE;6)E<ET@?"!,;VYG+71E<FT@26YV97-T;65N M=',@6TUE;6)E<ET\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S M<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^ M/'-T<F]N9SY&86ER(%9A;'5E+"!!<W-E=',@86YD($QI86)I;&ET:65S($UE M87-U<F5D(&]N(%)E8W5R<FEN9R!A;F0@3F]N<F5C=7)R:6YG($)A<VES(%M, M:6YE($ET96US73PO<W1R;VYG/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@ M/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG M;CTS1'1O<#Y!<W-E=',@870@9F%I<B!V86QU93PO=&0^#0H@("`@("`@(#QT M9"!C;&%S<STS1&YU;7`^,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\ M=&0@8VQA<W,],T1N=6UP/C`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO M='(^#0H@("`@("`\='(@8VQA<W,],T1R:#X-"B`@("`@("`@/'1D(&-L87-S M/3-$<&P@=F%L:6=N/3-$=&]P/D9A:7(@5F%L=64@365A<W5R96UE;G1S(%5S M:6YG($QE=F5L(#(@6TUE;6)E<ET@?"!3:&]R="UT97)M($EN=F5S=&UE;G1S M(%M-96UB97)=/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A M;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,] M,T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/CQS M=')O;F<^1F%I<B!686QU92P@07-S971S(&%N9"!,:6%B:6QI=&EE<R!-96%S M=7)E9"!O;B!296-U<G)I;F<@86YD($YO;G)E8W5R<FEN9R!"87-I<R!;3&EN M92!)=&5M<UT\+W-T<F]N9SX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT M<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX] M,T1T;W`^07-S971S(&%T(&9A:7(@=F%L=64\+W1D/@T*("`@("`@("`\=&0@ M8VQA<W,],T1N=6UP/C`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D M(&-L87-S/3-$;G5M<#XP/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R M/@T*("`@("`@/'1R(&-L87-S/3-$<F@^#0H@("`@("`@(#QT9"!C;&%S<STS M1'!L('9A;&EG;CTS1'1O<#Y&86ER(%9A;'5E($UE87-U<F5M96YT<R!5<VEN M9R!,979E;"`S(%M-96UB97)=/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$ M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$ M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\ M='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N M/3-$=&]P/CQS=')O;F<^1F%I<B!686QU92P@07-S971S(&%N9"!,:6%B:6QI M=&EE<R!-96%S=7)E9"!O;B!296-U<G)I;F<@86YD($YO;G)E8W5R<FEN9R!" M87-I<R!;3&EN92!)=&5M<UT\+W-T<F]N9SX\+W1D/@T*("`@("`@("`\=&0@ M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@ M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX- M"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P M;"!V86QI9VX],T1T;W`^07-S971S(&%T(&9A:7(@=F%L=64\+W1D/@T*("`@ M("`@("`\=&0@8VQA<W,],T1N=6UP/C`\<W!A;CX\+W-P86X^/"]T9#X-"B`@ M("`@("`@/'1D(&-L87-S/3-$;G5M<#XP/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F@^#0H@("`@("`@(#QT M9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y&86ER(%9A;'5E($UE87-U<F5M M96YT<R!5<VEN9R!,979E;"`S(%M-96UB97)=('P@36]N97D@36%R:V5T($9U M;F1S(%M-96UB97)=/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\ M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\ M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA M<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P M/CQS=')O;F<^1F%I<B!686QU92P@07-S971S(&%N9"!,:6%B:6QI=&EE<R!- M96%S=7)E9"!O;B!296-U<G)I;F<@86YD($YO;G)E8W5R<FEN9R!"87-I<R!; M3&EN92!)=&5M<UT\+W-T<F]N9SX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,] M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,] M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@ M(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI M9VX],T1T;W`^07-S971S(&%T(&9A:7(@=F%L=64\+W1D/@T*("`@("`@("`\ M=&0@8VQA<W,],T1N=6UP/C`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@ M/'1D(&-L87-S/3-$;G5M<#XP/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\ M+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F@^#0H@("`@("`@(#QT9"!C;&%S M<STS1'!L('9A;&EG;CTS1'1O<#Y&86ER(%9A;'5E($UE87-U<F5M96YT<R!5 M<VEN9R!,979E;"`S(%M-96UB97)=('P@52Y3+B!4<F5A<W5R>2!396-U<FET M:65S(%M-96UB97)=/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\ M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\ M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA M<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P M/CQS=')O;F<^1F%I<B!686QU92P@07-S971S(&%N9"!,:6%B:6QI=&EE<R!- M96%S=7)E9"!O;B!296-U<G)I;F<@86YD($YO;G)E8W5R<FEN9R!"87-I<R!; M3&EN92!)=&5M<UT\+W-T<F]N9SX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,] M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,] M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@ M(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI M9VX],T1T;W`^07-S971S(&%T(&9A:7(@=F%L=64\+W1D/@T*("`@("`@("`\ M=&0@8VQA<W,],T1N=6UP/C`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@ M/'1D(&-L87-S/3-$;G5M<#XP/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\ M+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F@^#0H@("`@("`@(#QT9"!C;&%S M<STS1'!L('9A;&EG;CTS1'1O<#Y&86ER(%9A;'5E($UE87-U<F5M96YT<R!5 M<VEN9R!,979E;"`S(%M-96UB97)=('P@3&]N9RUT97)M($EN=F5S=&UE;G1S M(%M-96UB97)=/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A M;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,] M,T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/CQS M=')O;F<^1F%I<B!686QU92P@07-S971S(&%N9"!,:6%B:6QI=&EE<R!-96%S M=7)E9"!O;B!296-U<G)I;F<@86YD($YO;G)E8W5R<FEN9R!"87-I<R!;3&EN M92!)=&5M<UT\+W-T<F]N9SX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT M<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX] M,T1T;W`^07-S971S(&%T(&9A:7(@=F%L=64\+W1D/@T*("`@("`@("`\=&0@ M8VQA<W,],T1N=6UP/C`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D M(&-L87-S/3-$;G5M<#XP/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R M/@T*("`@("`@/'1R(&-L87-S/3-$<F@^#0H@("`@("`@(#QT9"!C;&%S<STS M1'!L('9A;&EG;CTS1'1O<#Y&86ER(%9A;'5E($UE87-U<F5M96YT<R!5<VEN M9R!,979E;"`S(%M-96UB97)=('P@4VAO<G0M=&5R;2!);G9E<W1M96YT<R!; M365M8F5R73PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$ M<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#X\<W1R M;VYG/D9A:7(@5F%L=64L($%S<V5T<R!A;F0@3&EA8FEL:71I97,@365A<W5R M960@;VX@4F5C=7)R:6YG(&%N9"!.;VYR96-U<G)I;F<@0F%S:7,@6TQI;F4@ M271E;7-=/"]S=')O;F<^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@ M8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$ M=&]P/D%S<V5T<R!A="!F86ER('9A;'5E/"]T9#X-"B`@("`@("`@/'1D(&-L M87-S/3-$;G5M<#XP/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S<STS1&YU;7`^,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX- M"B`@("`@(#QT<B!C;&%S<STS1')H/@T*("`@("`@("`\=&0@8VQA<W,],T1P M;"!V86QI9VX],T1T;W`^0V%S:"!A;F0@0V%S:"!%<75I=F%L96YT<R!;365M M8F5R73PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^ M#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#X\<W1R;VYG M/D9A:7(@5F%L=64L($%S<V5T<R!A;F0@3&EA8FEL:71I97,@365A<W5R960@ M;VX@4F5C=7)R:6YG(&%N9"!.;VYR96-U<G)I;F<@0F%S:7,@6TQI;F4@271E M;7-=/"]S=')O;F<^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\ M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\ M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA M<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P M/D%S<V5T<R!A="!F86ER('9A;'5E/"]T9#X-"B`@("`@("`@/'1D(&-L87-S M/3-$;G5M<#XQ-BPY,S(\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D M(&-L87-S/3-$;G5M<#XQ-2PX-3@\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@ M(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R:#X-"B`@("`@("`@/'1D(&-L M87-S/3-$<&P@=F%L:6=N/3-$=&]P/D-A<V@@86YD($-A<V@@17%U:79A;&5N M=',@6TUE;6)E<ET@?"!&86ER(%9A;'5E($UE87-U<F5M96YT<R!5<VEN9R!, M979E;"`Q(%M-96UB97)=/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@ M8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$ M=&]P/CQS=')O;F<^1F%I<B!686QU92P@07-S971S(&%N9"!,:6%B:6QI=&EE M<R!-96%S=7)E9"!O;B!296-U<G)I;F<@86YD($YO;G)E8W5R<FEN9R!"87-I M<R!;3&EN92!)=&5M<UT\+W-T<F]N9SX\+W1D/@T*("`@("`@("`\=&0@8VQA M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@ M("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V M86QI9VX],T1T;W`^07-S971S(&%T(&9A:7(@=F%L=64\+W1D/@T*("`@("`@ M("`\=&0@8VQA<W,],T1N=6UP/C$V+#DS,CQS<&%N/CPO<W!A;CX\+W1D/@T* M("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$U+#@U.#QS<&%N/CPO<W!A;CX\ M+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')H/@T*("`@ M("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^0V%S:"!A;F0@0V%S M:"!%<75I=F%L96YT<R!;365M8F5R72!\($9A:7(@5F%L=64@365A<W5R96UE M;G1S(%5S:6YG($QE=F5L(#(@6TUE;6)E<ET\+W1D/@T*("`@("`@("`\=&0@ M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@ M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX- M"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P M;"!V86QI9VX],T1T;W`^/'-T<F]N9SY&86ER(%9A;'5E+"!!<W-E=',@86YD M($QI86)I;&ET:65S($UE87-U<F5D(&]N(%)E8W5R<FEN9R!A;F0@3F]N<F5C M=7)R:6YG($)A<VES(%M,:6YE($ET96US73PO<W1R;VYG/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C M;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y!<W-E=',@870@9F%I<B!V86QU93PO M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,#QS<&%N/CPO<W!A;CX\ M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C`\<W!A;CX\+W-P86X^ M/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R:#X-"B`@ M("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D-A<V@@86YD($-A M<V@@17%U:79A;&5N=',@6TUE;6)E<ET@?"!&86ER(%9A;'5E($UE87-U<F5M M96YT<R!5<VEN9R!,979E;"`S(%M-96UB97)=/"]T9#X-"B`@("`@("`@/'1D M(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D M(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^ M#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$ M<&P@=F%L:6=N/3-$=&]P/CQS=')O;F<^1F%I<B!686QU92P@07-S971S(&%N M9"!,:6%B:6QI=&EE<R!-96%S=7)E9"!O;B!296-U<G)I;F<@86YD($YO;G)E M8W5R<FEN9R!"87-I<R!;3&EN92!)=&5M<UT\+W-T<F]N9SX\+W1D/@T*("`@ M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@ M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@ M("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@ M8VQA<W,],T1P;"!V86QI9VX],T1T;W`^07-S971S(&%T(&9A:7(@=F%L=64\ M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B0@,#QS<&%N/CPO<W!A M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B0@,#QS<&%N/CPO M<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`\+W1A8FQE/@T*("`\+V)O M9'D^#0H\+VAT;6P^#0H-"BTM+2TM+3U?3F5X=%!A<G1?,SEC,&5A-C)?8S(P M,U\T-3AF7SAC-3!?,V1C830U-F$V.34Q#0I#;VYT96YT+4QO8V%T:6]N.B!F M:6QE.B\O+T,Z+S,Y8S!E838R7V,R,#-?-#4X9E\X8S4P7S-D8V$T-39A-CDU M,2]7;W)K<VAE971S+U-H965T-#4N:'1M;`T*0V]N=&5N="U4<F%N<V9E<BU% M;F-O9&EN9SH@<75O=&5D+7!R:6YT86)L90T*0V]N=&5N="U4>7!E.B!T97AT M+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^ M#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT M/3-$)W1E>'0O:'1M;#L@8VAA<G-E=#UU=&8M."<^/'-C<FEP="!T>7!E/3-$ M=&5X="]J879A<V-R:7!T('-R8STS1%-H;W<N:G,^+RH@1&\@3F]T(%)E;6]V M92!4:&ES($-O;6UE;G0@*B\\+W-C<FEP=#X\+VAE860^#0H@(#QB;V1Y/@T* M("`@(#QT86)L92!C;&%S<STS1')E<&]R="!I9#TS1$E$,$553D%#/@T*("`@ M("`@/'1R/@T*("`@("`@("`\=&@@8VQA<W,],T1T;"!C;VQS<&%N/3-$,2!R M;W=S<&%N/3-$,3X\<W1R;VYG/D9A:7(@5F%L=64@365A<W5R96UE;G1S("T@ M061D:71I;VYA;"!);F9O<FUA=&EO;B`H1&5T86EL*2`H55-$("0I/&)R/CPO M<W1R;VYG/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/D1E8RX@,S$L M(#(P,30\8G(^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^1&5C+B`S M,2P@,C`Q,SQB<CX\+W1H/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S M<STS1')H/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^ M1F%I<B!686QU92!-96%S=7)E;65N=',@57-I;F<@3&5V96P@,B!;365M8F5R M73PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@ M("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#X\<W1R;VYG/D9A M:7(@5F%L=64L($%S<V5T<R!A;F0@3&EA8FEL:71I97,@365A<W5R960@;VX@ M4F5C=7)R:6YG(&%N9"!.;VYR96-U<G)I;F<@0F%S:7,@6TQI;F4@271E;7-= M/"]S=')O;F<^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A M;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,] M,T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D9I M;F%N8VEA;"!A<W-E=',@;65A<W5R960@870@9F%I<B!V86QU92!O;B!A(')E M8W5R<FEN9R!B87-I<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^ M)"`P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU M;7`^)"`P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@ M/'1R(&-L87-S/3-$<F@^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG M;CTS1'1O<#Y&86ER(%9A;'5E($UE87-U<F5M96YT<R!5<VEN9R!,979E;"`S M(%M-96UB97)=/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A M;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,] M,T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/CQS M=')O;F<^1F%I<B!686QU92P@07-S971S(&%N9"!,:6%B:6QI=&EE<R!-96%S M=7)E9"!O;B!296-U<G)I;F<@86YD($YO;G)E8W5R<FEN9R!"87-I<R!;3&EN M92!)=&5M<UT\+W-T<F]N9SX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT M<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX] M,T1T;W`^1FEN86YC:6%L(&%S<V5T<R!M96%S=7)E9"!A="!F86ER('9A;'5E M(&]N(&$@<F5C=7)R:6YG(&)A<VES/"]T9#X-"B`@("`@("`@/'1D(&-L87-S M/3-$;G5M<#XD(#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L M87-S/3-$;G5M<#XD(#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^ M#0H@("`@/"]T86)L93X-"B`@/"]B;V1Y/@T*/"]H=&UL/@T*#0HM+2TM+2T] M7TYE>'1087)T7S,Y8S!E838R7V,R,#-?-#4X9E\X8S4P7S-D8V$T-39A-CDU M,0T*0V]N=&5N="U,;V-A=&EO;CH@9FEL93HO+R]#.B\S.6,P96$V,E]C,C`S M7S0U.&9?.&,U,%\S9&-A-#4V838Y-3$O5V]R:W-H965T<R]3:&5E=#0V+FAT M;6P-"D-O;G1E;G0M5')A;G-F97(M16YC;V1I;F<Z('%U;W1E9"UP<FEN=&%B M;&4-"D-O;G1E;G0M5'EP93H@=&5X="]H=&UL.R!C:&%R<V5T/2)U<RUA<V-I M:2(-"@T*/&AT;6P^#0H@(#QH96%D/@T*("`@(#Q-151!(&AT='`M97%U:78] M,T1#;VYT96YT+51Y<&4@8V]N=&5N=#TS1"=T97AT+VAT;6P[(&-H87)S970] M=71F+3@G/CQS8W)I<'0@='EP93TS1'1E>'0O:F%V87-C<FEP="!S<F,],T13 M:&]W+FIS/B\J($1O($YO="!296UO=F4@5&AI<R!#;VUM96YT("HO/"]S8W)I M<'0^/"]H96%D/@T*("`\8F]D>3X-"B`@("`\=&%B;&4@8VQA<W,],T1R97!O M<G0@:60],T1)1#!%5%=!13X-"B`@("`@(#QT<CX-"B`@("`@("`@/'1H(&-L M87-S/3-$=&P@8V]L<W!A;CTS1#$@<F]W<W!A;CTS1#$^/'-T<F]N9SY"86QA M;F-E(%-H965T($-O;7!O;F5N=',@+2!3=6UM87)Y(&]F(%!R;W!E<G1Y(&%N M9"!%<75I<&UE;G0@0F%L86YC97,@*$1E=&%I;"D@*%531"`D*3QB<CY);B!4 M:&]U<V%N9',L('5N;&5S<R!O=&AE<G=I<V4@<W!E8VEF:65D/"]S=')O;F<^ M/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^1&5C+B`S,2P@,C`Q-#QB M<CX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y$96,N(#,Q+"`R,#$S M/&)R/CPO=&@^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^ M#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#X\<W1R;VYG M/E!R;W!E<G1Y(&%N9"!E<75I<&UE;G0L(&YE=#H\+W-T<F]N9SX\+W1D/@T* M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T* M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T* M("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\ M=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^4')O<&5R='D@86YD(&5Q=6EP M;65N="P@9W)O<W,\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B0@ M,C$L.38T/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS M1&YU;7`^)"`R,BPR,3,\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^ M#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$ M<&P@=F%L:6=N/3-$=&]P/DQE<W,Z($%C8W5M=6QA=&5D(&1E<')E8VEA=&EO M;B!A;F0@86UO<G1I>F%T:6]N/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$ M;G5M/B@R,"PS,C<I/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S<STS1&YU;3XH,C`L.3DR*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@ M/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O=3X-"B`@("`@("`@/'1D(&-L M87-S/3-$<&P@=F%L:6=N/3-$=&]P/E!R;W!E<G1Y(&%N9"!E<75I<&UE;G0L M(&YE=#PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,2PV,S<\<W!A M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ+#(R M,3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C M;&%S<STS1')H/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T M;W`^3&%B;W)A=&]R>2!%<75I<&UE;G0@6TUE;6)E<ET\+W1D/@T*("`@("`@ M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@ M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@ M/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA M<W,],T1P;"!V86QI9VX],T1T;W`^/'-T<F]N9SY0<F]P97)T>2!A;F0@97%U M:7!M96YT+"!N970Z/"]S=')O;F<^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@ M("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L M:6=N/3-$=&]P/E!R;W!E<G1Y(&%N9"!E<75I<&UE;G0L(&=R;W-S/"]T9#X- M"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ-2PR.3D\<W!A;CX\+W-P86X^ M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ-2PS,3<\<W!A;CX\ M+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R M:#X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D-O;7!U M=&5R($5Q=6EP;65N="!A;F0@4V]F='=A<F4@6TUE;6)E<ET\+W1D/@T*("`@ M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@ M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@ M("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@ M8VQA<W,],T1P;"!V86QI9VX],T1T;W`^/'-T<F]N9SY0<F]P97)T>2!A;F0@ M97%U:7!M96YT+"!N970Z/"]S=')O;F<^/"]T9#X-"B`@("`@("`@/'1D(&-L M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@ M("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@ M=F%L:6=N/3-$=&]P/E!R;W!E<G1Y(&%N9"!E<75I<&UE;G0L(&=R;W-S/"]T M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XR+#0Q.#QS<&%N/CPO<W!A M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C(L-30Y/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$ M<F@^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y/9F9I M8V4@17%U:7!M96YT+"!&=7)N:71U<F4@86YD($9I>'1U<F5S(%M-96UB97)= M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^ M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^ M/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@ M("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/CQS=')O;F<^4')O M<&5R='D@86YD(&5Q=6EP;65N="P@;F5T.CPO<W1R;VYG/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C M;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y0<F]P97)T>2!A;F0@97%U:7!M96YT M+"!G<F]S<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^.3$S/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,2PP M-3`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@ M8VQA<W,],T1R:#X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$ M=&]P/DQE87-E:&]L9"!);7!R;W9E;65N=',@6TUE;6)E<ET\+W1D/@T*("`@ M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@ M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@ M("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@ M8VQA<W,],T1P;"!V86QI9VX],T1T;W`^/'-T<F]N9SY0<F]P97)T>2!A;F0@ M97%U:7!M96YT+"!N970Z/"]S=')O;F<^/"]T9#X-"B`@("`@("`@/'1D(&-L M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@ M("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@ M=F%L:6=N/3-$=&]P/E!R;W!E<G1Y(&%N9"!E<75I<&UE;G0L(&=R;W-S/"]T M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XD(#,L,S,T/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^)"`S+#(Y-SQS M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`\+W1A8FQE/@T* M("`\+V)O9'D^#0H\+VAT;6P^#0H-"BTM+2TM+3U?3F5X=%!A<G1?,SEC,&5A M-C)?8S(P,U\T-3AF7SAC-3!?,V1C830U-F$V.34Q#0I#;VYT96YT+4QO8V%T M:6]N.B!F:6QE.B\O+T,Z+S,Y8S!E838R7V,R,#-?-#4X9E\X8S4P7S-D8V$T M-39A-CDU,2]7;W)K<VAE971S+U-H965T-#<N:'1M;`T*0V]N=&5N="U4<F%N M<V9E<BU%;F-O9&EN9SH@<75O=&5D+7!R:6YT86)L90T*0V]N=&5N="U4>7!E M.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@ M/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C M;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA<G-E=#UU=&8M."<^/'-C<FEP="!T M>7!E/3-$=&5X="]J879A<V-R:7!T('-R8STS1%-H;W<N:G,^+RH@1&\@3F]T M(%)E;6]V92!4:&ES($-O;6UE;G0@*B\\+W-C<FEP=#X\+VAE860^#0H@(#QB M;V1Y/@T*("`@(#QT86)L92!C;&%S<STS1')E<&]R="!I9#TS1$E$,$5)14%# M/@T*("`@("`@/'1R/@T*("`@("`@("`\=&@@8VQA<W,],T1T;"!C;VQS<&%N M/3-$,2!R;W=S<&%N/3-$,CX\<W1R;VYG/D)A;&%N8V4@4VAE970@0V]M<&]N M96YT<R`M($%D9&ET:6]N86P@26YF;W)M871I;VX@*$1E=&%I;"D@*%531"`D M*3QB<CX\+W-T<F]N9SX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:"!C M;VQS<&%N/3-$,SXQ,B!-;VYT:',@16YD960\+W1H/@T*("`@("`@/"]T<CX- M"B`@("`@(#QT<CX-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^1&5C+B`S,2P@ M,C`Q-#QB<CX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y$96,N(#,Q M+"`R,#$S/&)R/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/D1E8RX@ M,S$L(#(P,3(\8G(^/"]T:#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA M<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P M/CQS=')O;F<^1&5F97)R960@0V]S=',L($-A<&ET86QI>F5D+"!0<F5P86ED M+"!A;F0@3W1H97(@07-S971S($1I<V-L;W-U<F4@6T%B<W1R86-T73PO<W1R M;VYG/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^ M#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y$97!R96-I M871I;VX@97AP96YS93PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^ M)"`U,#`L,#`P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M<STS1&YU;7`^)"`T,#`L,#`P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S<STS1&YU;7`^)"`V,#`L,#`P/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@ M(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y);G1E<F5S="!R96-E:79A M8FQE(&]N(&-A<V@@97%U:79A;&5N=',@86YD(&EN=F5S=&UE;G1S/"]T9#X- M"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XD(#$P.2PP,#`\<W!A;CX\+W-P M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XD(#(Q-2PP,#`\ M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\ M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@/"]T86)L93X- M"B`@/"]B;V1Y/@T*/"]H=&UL/@T*#0HM+2TM+2T]7TYE>'1087)T7S,Y8S!E M838R7V,R,#-?-#4X9E\X8S4P7S-D8V$T-39A-CDU,0T*0V]N=&5N="U,;V-A M=&EO;CH@9FEL93HO+R]#.B\S.6,P96$V,E]C,C`S7S0U.&9?.&,U,%\S9&-A M-#4V838Y-3$O5V]R:W-H965T<R]3:&5E=#0X+FAT;6P-"D-O;G1E;G0M5')A M;G-F97(M16YC;V1I;F<Z('%U;W1E9"UP<FEN=&%B;&4-"D-O;G1E;G0M5'EP M93H@=&5X="]H=&UL.R!C:&%R<V5T/2)U<RUA<V-I:2(-"@T*/&AT;6P^#0H@ M(#QH96%D/@T*("`@(#Q-151!(&AT='`M97%U:78],T1#;VYT96YT+51Y<&4@ M8V]N=&5N=#TS1"=T97AT+VAT;6P[(&-H87)S970]=71F+3@G/CQS8W)I<'0@ M='EP93TS1'1E>'0O:F%V87-C<FEP="!S<F,],T13:&]W+FIS/B\J($1O($YO M="!296UO=F4@5&AI<R!#;VUM96YT("HO/"]S8W)I<'0^/"]H96%D/@T*("`\ M8F]D>3X-"B`@("`\=&%B;&4@8VQA<W,],T1R97!O<G0@:60],T1)1#!%04Q! M0SX-"B`@("`@(#QT<CX-"B`@("`@("`@/'1H(&-L87-S/3-$=&P@8V]L<W!A M;CTS1#$@<F]W<W!A;CTS1#$^/'-T<F]N9SY"86QA;F-E(%-H965T($-O;7!O M;F5N=',@+2!3=6UM87)Y(&]F($%C8W)U960@3&EA8FEL:71I97,@*$1E=&%I M;"D@*%531"`D*3QB<CY);B!4:&]U<V%N9',L('5N;&5S<R!O=&AE<G=I<V4@ M<W!E8VEF:65D/"]S=')O;F<^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$ M=&@^1&5C+B`S,2P@,C`Q-#QB<CX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,] M,T1T:#Y$96,N(#,Q+"`R,#$S/&)R/CPO=&@^#0H@("`@("`\+W1R/@T*("`@ M("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A M;&EG;CTS1'1O<#X\<W1R;VYG/D%C8W)U960@;&EA8FEL:71I97,Z/"]S=')O M;F<^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P M86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX- M"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D-L:6YI8V%L M(&%N9"!P<F5C;&EN:6-A;"!C;W-T<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S M<STS1&YU;7`^)"`Y-S(\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D M(&-L87-S/3-$;G5M<#XD(#0L.3<U/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C M;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y#;VYS=6QT:6YG(&%N9"!P<F]F97-S M:6]N86P@9F5E<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-#(Q M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^ M-CDW/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R M(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS M1'1O<#Y";VYU<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,BPV M-C4\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M M<#XQ+#8Q-#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@ M(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI M9VX],T1T;W`^5F%C871I;VX@<&%Y/"]T9#X-"B`@("`@("`@/'1D(&-L87-S M/3-$;G5M<#XY,34\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L M87-S/3-$;G5M<#XW-S@\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^ M#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$ M<&P@=F%L:6=N/3-$=&]P/D]T:&5R('!A>7)O;&P@<F5L871E9#PO=&0^#0H@ M("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,3$P/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^.3,\<W!A;CX\+W-P86X^/"]T M9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@ M("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D]T:&5R(&%C8W)U960@ M97AP96YS97,\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C,Q-SQS M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$Q M-3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C M;&%S<STS1')O=3X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$ M=&]P/E1O=&%L(&%C8W)U960@;&EA8FEL:71I97,\+W1D/@T*("`@("`@("`\ M=&0@8VQA<W,],T1N=6UP/B0@-2PT,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@ M("`@("`@/'1D(&-L87-S/3-$;G5M<#XD(#@L,C<R/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`\+W1R/@T*("`@(#PO=&%B;&4^#0H@(#PO8F]D>3X-"CPO M:'1M;#X-"@T*+2TM+2TM/5].97AT4&%R=%\S.6,P96$V,E]C,C`S7S0U.&9? M.&,U,%\S9&-A-#4V838Y-3$-"D-O;G1E;G0M3&]C871I;VXZ(&9I;&4Z+R\O M0SHO,SEC,&5A-C)?8S(P,U\T-3AF7SAC-3!?,V1C830U-F$V.34Q+U=O<FMS M:&5E=',O4VAE970T.2YH=&UL#0I#;VYT96YT+51R86YS9F5R+45N8V]D:6YG M.B!Q=6]T960M<')I;G1A8FQE#0I#;VYT96YT+51Y<&4Z('1E>'0O:'1M;#L@ M8VAA<G-E=#TB=7,M87-C:6DB#0H-"CQH=&UL/@T*("`\:&5A9#X-"B`@("`\ M345402!H='1P+65Q=6EV/3-$0V]N=&5N="U4>7!E(&-O;G1E;G0],T0G=&5X M="]H=&UL.R!C:&%R<V5T/75T9BTX)SX\<V-R:7!T('1Y<&4],T1T97AT+VIA M=F%S8W)I<'0@<W)C/3-$4VAO=RYJ<SXO*B!$;R!.;W0@4F5M;W9E(%1H:7,@ M0V]M;65N="`J+SPO<V-R:7!T/CPO:&5A9#X-"B`@/&)O9'D^#0H@("`@/'1A M8FQE(&-L87-S/3-$<F5P;W)T(&ED/3-$240P13%)0TT^#0H@("`@("`\='(^ M#0H@("`@("`@(#QT:"!C;&%S<STS1'1L(&-O;'-P86X],T0Q(')O=W-P86X] M,T0R/CQS=')O;F<^4F5L871E9"!087)T:65S(&%N9"!296QA=&5D(%!A<G1Y M(%1R86YS86-T:6]N<R`M($%D9&ET:6]N86P@26YF;W)M871I;VX@*$1E=&%I M;"D@*%531"`D*3QB<CX\+W-T<F]N9SX\+W1H/@T*("`@("`@("`\=&@@8VQA M<W,],T1T:"!C;VQS<&%N/3-$,3XS($UO;G1H<R!%;F1E9#PO=&@^#0H@("`@ M("`@(#QT:"!C;&%S<STS1'1H(&-O;'-P86X],T0S/C$R($UO;G1H<R!%;F1E M9#PO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H(&-O;'-P86X],T0Q/C$@ M36]N=&AS($5N9&5D/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@@8V]L M<W!A;CTS1#$^,R!-;VYT:',@16YD960\+W1H/@T*("`@("`@("`\=&@@8VQA M<W,],T1T:"!C;VQS<&%N/3-$,3XQ($UO;G1H<R!%;F1E9#PO=&@^#0H@("`@ M("`@(#QT:"!C;&%S<STS1'1H(&-O;'-P86X],T0Q/C`@36]N=&AS($5N9&5D M/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@@8V]L<W!A;CTS1#$^,2!- M;VYT:',@16YD960\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:"!C;VQS M<&%N/3-$,3X\+W1H/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<CX-"B`@("`@ M("`@/'1H(&-L87-S/3-$=&@^2G5N+B`S,"P@,C`Q,CQB<CX\+W1H/@T*("`@ M("`@("`\=&@@8VQA<W,],T1T:#Y$96,N(#,Q+"`R,#$T/&)R/CPO=&@^#0H@ M("`@("`@(#QT:"!C;&%S<STS1'1H/D1E8RX@,S$L(#(P,3,\8G(^/"]T:#X- M"B`@("`@("`@/'1H(&-L87-S/3-$=&@^1&5C+B`S,2P@,C`Q,CQB<CX\+W1H M/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y*=6XN(#,P+"`R,#$S/&)R/CPO M=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/D1E8RX@,S$L(#(P,3,\8G(^ M/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^2G5L+B`S,2P@,C`Q,SQB M<CX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y$96,N(#(R+"`R,#$T M/&)R/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/DIA;BX@,S$L(#(P M,34\8G(^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^2G5N+B`R-2P@ M,C`Q,CQB<CX\+W1H/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS M1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^/'-T M<F]N9SY38VAE9'5L92!O9B!/=&AE<B!296QA=&5D(%!A<G1Y(%1R86YS86-T M:6]N<R!;3&EN92!)=&5M<UT\+W-T<F]N9SX\+W1D/@T*("`@("`@("`\=&0@ M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@ M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@ M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@ M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@ M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@ M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@ M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@ M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@ M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@ M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX- M"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P M;"!V86QI9VX],T1T;W`^0V]M;6]N('-T;V-K+"!S:&%R97,@:7-S=65D/"]T M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XS."PV-3DL-S,X/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,S`L-C@Q M+#8R-#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N M=6UP/C,P+#8X,2PV,C0\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D M(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D M(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D M(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D M(&-L87-S/3-$;G5M<#XY+#,R,"PQ-S8\<W!A;CX\+W-P86X^/"]T9#X-"B`@ M("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D M(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E!E<B!S:&%R92!P<FEC92!O9B!C M;VUM;VX@<W1O8VL\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B0@ M.#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP M/B0@-"XU-CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,] M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,] M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,] M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,] M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,] M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,] M,T1N=6UP/B0@-"XU-CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX- M"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P M;"!V86QI9VX],T1T;W`^06=G<F5G871E('!U<F-H87-E('!R:6-E/"]T9#X- M"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XD(#,R+#$P,"PP,#`\<W!A;CX\ M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XD(#0X+#DW M,2PP,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$ M;G5M<#XD(#<L-#4P+#`P,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\ M=&0@8VQA<W,],T1N=6UP/B0@-#,L-C<W+#`P,#QS<&%N/CPO<W!A;CX\+W1D M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D M/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@ M("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^3&EC96YS92!R979E;G5E M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^ M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XY+#@S-BPP,#`\<W!A M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XS+#@U M,BPP,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$ M;G5M<#XP/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@ M/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG M;CTS1'1O<#Y297-E87)C:"!A;F0@9&5V96QO<&UE;G0@<F5V96YU93PO=&0^ M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,3DL-3,X+#`P,#QS<&%N/CPO M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C(L,#$Y+#`P M,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP M/C0L,3<W+#`P,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@ M("`@(#QT<B!C;&%S<STS1')H/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V M86QI9VX],T1T;W`^06UG96X@6TUE;6)E<ET\+W1D/@T*("`@("`@("`\=&0@ M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@ M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@ M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@ M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@ M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@ M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@ M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@ M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@ M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@ M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX- M"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P M;"!V86QI9VX],T1T;W`^/'-T<F]N9SY38VAE9'5L92!O9B!/=&AE<B!296QA M=&5D(%!A<G1Y(%1R86YS86-T:6]N<R!;3&EN92!)=&5M<UT\+W-T<F]N9SX\ M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\ M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\ M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\ M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\ M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\ M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\ M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\ M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\ M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\ M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\ M+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@ M("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^3F]N+7)E9G5N9&%B M;&4@;&EC96YS92!F964\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP M/C$U+#`P,"PP,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@ M("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@ M=F%L:6=N/3-$=&]P/D-O;6UO;B!S=&]C:RP@<VAA<F5S(&ES<W5E9#PO=&0^ M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,2PT,#0L,3`P/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^ M#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y097(@<VAA M<F4@<')I8V4@;V8@8V]M;6]N('-T;V-K/"]T9#X-"B`@("`@("`@/'1D(&-L M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L M87-S/3-$;G5M<#XD(#<N,3(\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@ M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@ M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@ M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@ M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@ M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO M='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S M/3-$<&P@=F%L:6=N/3-$=&]P/D%G9W)E9V%T92!P=7)C:&%S92!P<FEC93PO M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,3`L,#`P+#`P,#QS<&%N M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N M/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS M1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^0V]M M;6]N('-T;V-K(&9A:7(@=F%L=64\+W1D/@T*("`@("`@("`\=&0@8VQA<W,] M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,] M,T1N=6UP/C<L-3`P+#`P,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\ M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\ M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\ M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\ M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\ M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\ M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\ M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\ M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T M<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,] M,T1P;"!V86QI9VX],T1T;W`^3&EC96YS92!R979E;G5E/"]T9#X-"B`@("`@ M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@ M("`@/'1D(&-L87-S/3-$;G5M<#XP/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S<STS1&YU;7`^,3<L,C,P+#`P,#QS<&%N/CPO<W!A;CX\ M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C`\<W!A;CX\+W-P86X^ M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^ M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ-RPR,#`L,#`P/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S M/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y2 M97-E87)C:"!A;F0@9&5V96QO<&UE;G0@<F5V96YU93PO=&0^#0H@("`@("`@ M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S<STS1&YU;7`^,S`P+#`P,#QS<&%N/CPO<W!A;CX\+W1D/@T* M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T* M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T* M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T* M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T* M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T* M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T* M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T* M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T* M("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\ M=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^4')E+6-O;6UE<F-I86QI>F%T M:6]N(&UI;&5S=&]N92!P87EM96YT<R!E;&EG:6)L92!T;R!R96-E:79E/"]T M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XS-3`L,#`P+#`P,#QS<&%N M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N M/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS M1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^06UO M=6YT(')E8V]G;FEZ960@9F]R(&UI;&5S=&]N97,@86-H:65V960\+W1D/@T* M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T* M("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C`\<W!A;CX\+W-P86X^/"]T9#X- M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X- M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X- M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X- M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X- M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X- M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X- M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X- M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X- M"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R:#X-"B`@("`@("`@ M/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D%M9V5N(%M-96UB97)=('P@ M3&EC96YS92!A;F0@4V5R=FEC97,@6TUE;6)E<ET\+W1D/@T*("`@("`@("`\ M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\ M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\ M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\ M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\ M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\ M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\ M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\ M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\ M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\ M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T M<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,] M,T1P;"!V86QI9VX],T1T;W`^/'-T<F]N9SY38VAE9'5L92!O9B!/=&AE<B!2 M96QA=&5D(%!A<G1Y(%1R86YS86-T:6]N<R!;3&EN92!)=&5M<UT\+W-T<F]N M9SX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A M;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T* M("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^1&5F97)R960@ M<F5V96YU93PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,BPU,#`L M,#`P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R M(&-L87-S/3-$<F@^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS M1'1O<#Y!<W1E;&QA<R!;365M8F5R73PO=&0^#0H@("`@("`@(#QT9"!C;&%S M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@ M("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A M;&EG;CTS1'1O<#X\<W1R;VYG/E-C:&5D=6QE(&]F($]T:&5R(%)E;&%T960@ M4&%R='D@5')A;G-A8W1I;VYS(%M,:6YE($ET96US73PO<W1R;VYG/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@ M(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y5<&9R;VYT('!A>6UE;G0@ M<F5C96EV960\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$V+#`P M,"PP,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$ M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$ M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$ M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\ M='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N M/3-$=&]P/E!O=&5N=&EA;"!A;6]U;G0@<F5C96EV86)L92!U;F1E<B!C;VQL M86)O<F%T:6]N(&%G<F5E;65N=#PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS M1&YU;7`^,C4L-3`P+#`P,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\ M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\ M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\ M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T M<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,] M,T1P;"!V86QI9VX],T1T;W`^0V]L;&%B;W)A=&EO;B!A9W)E96UE;G0@=&5R M;3PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^,B!Y96%R<SQS<&%N M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N M/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS M1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^4F5V M96YU92!R96-O9VYI>F5D/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M M<#XQ,RPW,#`L,#`P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T* M("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L M('9A;&EG;CTS1'1O<#Y297-E87)C:"!M:6QE<W1O;F4@<&%Y;65N=',\+W1D M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D M/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C(L,#`P+#`P,#QS<&%N/CPO M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO M<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')H M/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^07-T96QL M87,@6TUE;6)E<ET@?"!,:6-E;G-E(%)E=F5N=64@6TUE;6)E<ET\+W1D/@T* M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T* M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T* M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T* M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T* M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T* M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T* M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T* M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T* M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T* M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T* M("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\ M=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^/'-T<F]N9SY38VAE9'5L92!O M9B!/=&AE<B!296QA=&5D(%!A<G1Y(%1R86YS86-T:6]N<R!;3&EN92!)=&5M M<UT\+W-T<F]N9SX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S M<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^ M1&5F97)R960@<F5V96YU93PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU M;7`^,BPS,#`L,#`P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T* M("`@("`@/'1R(&-L87-S/3-$<F@^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L M('9A;&EG;CTS1'1O<#Y296EM8G5R<V5M96YT(&]F($EN=&5R;F%L($-O<W1S M(%M-96UB97)=('P@07-T96QL87,@6TUE;6)E<ET\+W1D/@T*("`@("`@("`\ M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\ M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\ M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\ M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\ M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\ M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\ M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\ M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\ M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\ M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T M<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,] M,T1P;"!V86QI9VX],T1T;W`^/'-T<F]N9SY38VAE9'5L92!O9B!/=&AE<B!2 M96QA=&5D(%!A<G1Y(%1R86YS86-T:6]N<R!;3&EN92!)=&5M<UT\+W-T<F]N M9SX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A M;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T* M("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^4F5I;6)U<G-E M;65N="!C;W-T<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^."PY M,#`L,#`P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@ M/'1R(&-L87-S/3-$<F@^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG M;CTS1'1O<#Y296EM8G5R<V5M96YT(&]F($]T:&5R($-O<W1S(%M-96UB97)= M('P@07-T96QL87,@6TUE;6)E<ET\+W1D/@T*("`@("`@("`\=&0@8VQA<W,] M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,] M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,] M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,] M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,] M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,] M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,] M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,] M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,] M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,] M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@ M(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI M9VX],T1T;W`^/'-T<F]N9SY38VAE9'5L92!O9B!/=&AE<B!296QA=&5D(%!A M<G1Y(%1R86YS86-T:6]N<R!;3&EN92!)=&5M<UT\+W-T<F]N9SX\+W1D/@T* M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T* M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T* M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T* M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T* M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T* M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T* M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T* M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T* M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T* M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T* M("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\ M=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^4F5I;6)U<G-E;65N="!C;W-T M<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-BPU,#`L,#`P/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S M/3-$<F@^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y! M;65N9&5D($%G<F5E;65N="!;365M8F5R72!\($%S=&5L;&%S(%M-96UB97)= M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^ M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^ M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^ M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^ M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^ M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^ M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^ M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^ M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^ M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^ M/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@ M("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/CQS=')O;F<^4V-H M961U;&4@;V8@3W1H97(@4F5L871E9"!087)T>2!4<F%N<V%C=&EO;G,@6TQI M;F4@271E;7-=/"]S=')O;F<^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$ M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$ M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$ M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$ M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$ M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$ M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$ M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$ M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$ M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$ M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\ M='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N M/3-$=&]P/D-O;6UO;B!S=&]C:RP@<VAA<F5S(&ES<W5E9#PO=&0^#0H@("`@ M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S<STS1&YU;7`^,BPP-#`L.#$V/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@ M("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y097(@<VAA<F4@<')I M8V4@;V8@8V]M;6]N('-T;V-K/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$ M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$ M;G5M<#XD(#0N.3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@ M("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V M86QI9VX],T1T;W`^06=G<F5G871E('!U<F-H87-E('!R:6-E/"]T9#X-"B`@ M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@ M("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ,"PP,#`L,#`P/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@ M("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y#;VUM;VX@<W1O M8VL@9F%I<B!V86QU93PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^ M.2PQ,#`L,#`P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@ M("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A M;&EG;CTS1'1O<#Y$969E<G)E9"!R979E;G5E/"]T9#X-"B`@("`@("`@/'1D M(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D M(&-L87-S/3-$;G5M<#XS,RPV,#`L,#`P/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT M9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y5<&9R;VYT('!A>6UE;G0@<F5C M96EV960\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C,P+#`P,"PP M,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@ M8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$ M=&]P/E!O=&5N=&EA;"!A;6]U;G0@<F5C96EV86)L92!U;F1E<B!C;VQL86)O M<F%T:6]N(&%G<F5E;65N=#PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU M;7`^,C`L,#`P+#`P,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@ M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@ M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX- M"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P M;"!V86QI9VX],T1T;W`^0V]L;&%B;W)A=&EO;B!A9W)E96UE;G0@=&5R;3PO M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^,B!Y96%R<SQS<&%N/CPO M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO M<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E M/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^4F5V96YU M92!R96-O9VYI>F5D/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\ M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XP M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L M87-S/3-$<F@^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O M<#Y!;65N9&5D($%G<F5E;65N="!;365M8F5R72!\($%S=&5L;&%S(%M-96UB M97)=('P@3&EC96YS92!A;F0@4V5R=FEC97,@6TUE;6)E<ET\+W1D/@T*("`@ M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@ M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@ M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@ M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@ M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@ M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@ M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@ M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@ M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@ M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@ M("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@ M8VQA<W,],T1P;"!V86QI9VX],T1T;W`^/'-T<F]N9SY38VAE9'5L92!O9B!/ M=&AE<B!296QA=&5D(%!A<G1Y(%1R86YS86-T:6]N<R!;3&EN92!)=&5M<UT\ M+W-T<F]N9SX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N M/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS M1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^1&5F M97)R960@<F5V96YU93PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^ M.3`P+#`P,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,] M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,] M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,] M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,] M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,] M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,] M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,] M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,] M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@ M(#QT<B!C;&%S<STS1')H/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI M9VX],T1T;W`^06UE;F1E9"!!9W)E96UE;G0@6TUE;6)E<ET@?"!!<W1E;&QA M<R!;365M8F5R72!\($QI8V5N<V4@4F5V96YU92!;365M8F5R73PO=&0^#0H@ M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT M9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#X\<W1R;VYG/E-C:&5D=6QE(&]F M($]T:&5R(%)E;&%T960@4&%R='D@5')A;G-A8W1I;VYS(%M,:6YE($ET96US M73PO<W1R;VYG/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S M/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y$ M969E<G)E9"!R979E;G5E/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M M<#XS,"PP,#`L,#`P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T* M("`@("`@/'1R(&-L87-S/3-$<F@^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L M('9A;&EG;CTS1'1O<#Y!;65N9&5D($%G<F5E;65N="!;365M8F5R72!\(%-U M8G-E<75E;G0@179E;G1S(%M-96UB97)=('P@07-T96QL87,@6TUE;6)E<ET\ M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\ M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\ M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\ M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\ M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\ M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\ M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\ M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\ M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\ M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\ M+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@ M("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^/'-T<F]N9SY38VAE M9'5L92!O9B!/=&AE<B!296QA=&5D(%!A<G1Y(%1R86YS86-T:6]N<R!;3&EN M92!)=&5M<UT\+W-T<F]N9SX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT M<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX] M,T1T;W`^57!F<F]N="!P87EM96YT(')E8V5I=F5D/"]T9#X-"B`@("`@("`@ M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@ M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@ M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@ M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@ M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@ M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@ M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@ M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@ M/'1D(&-L87-S/3-$;G5M<#XS,"PP,#`L,#`P/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@ M(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y!;6]U;G0@<F5C96EV960@ M87,@;6EL97-T;VYE('!A>6UE;G0\+W1D/@T*("`@("`@("`\=&0@8VQA<W,] M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,] M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,] M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,] M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,] M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,] M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,] M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,] M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,] M,T1N=6UP/C$U+#`P,"PP,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@ M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO M='(^#0H@("`@("`\='(@8VQA<W,],T1R:#X-"B`@("`@("`@/'1D(&-L87-S M/3-$<&P@=F%L:6=N/3-$=&]P/DUA>&EM=6T@6TUE;6)E<ET@?"!!;6=E;B!; M365M8F5R73PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$ M<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#X\<W1R M;VYG/E-C:&5D=6QE(&]F($]T:&5R(%)E;&%T960@4&%R='D@5')A;G-A8W1I M;VYS(%M,:6YE($ET96US73PO<W1R;VYG/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T* M("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L M('9A;&EG;CTS1'1O<#Y#;VUM97)C:6%L:7IA=&EO;B!M:6QE<W1O;F4@<&%Y M;65N=',@96QI9VEB;&4@=&\@<F5C96EV93PO=&0^#0H@("`@("`@(#QT9"!C M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S<STS1&YU;7`^,S`P+#`P,"PP,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@ M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@ M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@ M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@ M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@ M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@ M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@ M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@ M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@ M("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R:#X-"B`@("`@("`@/'1D M(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/DUI;FEM=6T@6TUE;6)E<ET@?"!! M;65N9&5D($%G<F5E;65N="!;365M8F5R72!\($%S=&5L;&%S(%M-96UB97)= M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^ M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^ M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^ M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^ M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^ M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^ M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^ M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^ M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^ M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^ M/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@ M("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/CQS=')O;F<^4V-H M961U;&4@;V8@3W1H97(@4F5L871E9"!087)T>2!4<F%N<V%C=&EO;G,@6TQI M;F4@271E;7-=/"]S=')O;F<^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$ M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$ M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$ M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$ M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$ M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$ M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$ M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$ M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$ M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$ M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\ M='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N M/3-$=&]P/E!O=&5N=&EA;"!A;6]U;G0@<F5C96EV86)L92!U;F1E<B!C;VQL M86)O<F%T:6]N(&%G<F5E;65N=#PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS M1&YU;7`^-C`P+#`P,"PP,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@ M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@ M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO M='(^#0H@("`@("`\='(@8VQA<W,],T1R:#X-"B`@("`@("`@/'1D(&-L87-S M/3-$<&P@=F%L:6=N/3-$=&]P/E!R;W!O<G1I;VYA;"!097)F;W)M86YC92!- M;V1E;"!;365M8F5R72!\($%S=&5L;&%S(%M-96UB97)=/"]T9#X-"B`@("`@ M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@ M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@ M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@ M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@ M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@ M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@ M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@ M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@ M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@ M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@ M(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L M87-S/3-$<&P@=F%L:6=N/3-$=&]P/CQS=')O;F<^4V-H961U;&4@;V8@3W1H M97(@4F5L871E9"!087)T>2!4<F%N<V%C=&EO;G,@6TQI;F4@271E;7-=/"]S M=')O;F<^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\ M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\ M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\ M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\ M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\ M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\ M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\ M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\ M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\ M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\ M+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R M;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/DQI8V5N M<V4@<F5V96YU93PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^.2PX M,#`L,#`P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@ M/'1R(&-L87-S/3-$<F@^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG M;CTS1'1O<#Y%87)L>2!$979E;&]P;65N="!;365M8F5R72!\($%S=&5L;&%S M(%M-96UB97)=/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A M;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,] M,T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/CQS M=')O;F<^4V-H961U;&4@;V8@3W1H97(@4F5L871E9"!087)T>2!4<F%N<V%C M=&EO;G,@6TQI;F4@271E;7-=/"]S=')O;F<^/"]T9#X-"B`@("`@("`@/'1D M(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D M(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D M(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D M(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D M(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D M(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D M(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D M(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D M(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D M(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^ M#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$ M<&P@=F%L:6=N/3-$=&]P/D%M;W5N="!R96-O9VYI>F5D(&9O<B!M:6QE<W1O M;F5S(&%C:&EE=F5D/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\ M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ M-RPP,#`L,#`P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@ M("`@/'1R(&-L87-S/3-$<F@^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A M;&EG;CTS1'1O<#Y.;VXM(&YE=7)O;75S8W5L87(@26YD:6-A=&EO;G,@6TUE M;6)E<ET@?"!-87AI;75M(%M-96UB97)=('P@06UE;F1E9"!!9W)E96UE;G0@ M6TUE;6)E<ET@?"!!<W1E;&QA<R!;365M8F5R73PO=&0^#0H@("`@("`@(#QT M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R M/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS M1'!L('9A;&EG;CTS1'1O<#X\<W1R;VYG/E-C:&5D=6QE(&]F($]T:&5R(%)E M;&%T960@4&%R='D@5')A;G-A8W1I;VYS(%M,:6YE($ET96US73PO<W1R;VYG M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@ M("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y0;W1E;G1I86P@ M86UO=6YT(')E8V5I=F%B;&4@=6YD97(@8V]L;&%B;W)A=&EO;B!A9W)E96UE M;G0\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/CDU+#`P,"PP,#`\ M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\ M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\ M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA M<W,],T1R:#X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P M/D-O;6UE<F-I86P@36EL97-T;VYE<R!;365M8F5R72!\($UA>&EM=6T@6TUE M;6)E<ET@?"!!;65N9&5D($%G<F5E;65N="!;365M8F5R72!\($%S=&5L;&%S M(%M-96UB97)=/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A M;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,] M,T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/CQS M=')O;F<^4V-H961U;&4@;V8@3W1H97(@4F5L871E9"!087)T>2!4<F%N<V%C M=&EO;G,@6TQI;F4@271E;7-=/"]S=')O;F<^/"]T9#X-"B`@("`@("`@/'1D M(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D M(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D M(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D M(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D M(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D M(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D M(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D M(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D M(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D M(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^ M#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$ M<&P@=F%L:6=N/3-$=&]P/E!O=&5N=&EA;"!A;6]U;G0@<F5C96EV86)L92!U M;F1E<B!C;VQL86)O<F%T:6]N(&%G<F5E;65N=#PO=&0^#0H@("`@("`@(#QT M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S<STS1&YU;7`^,C`P+#`P,"PP,#`\<W!A;CX\+W-P86X^/"]T9#X- M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X- M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X- M"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R:#X-"B`@("`@("`@ M/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E--02!A;F0@3W1H97(@3F5U M<F]M=7-C=6QA<B!);F1I8V%T:6]N<R!;365M8F5R72!\($UI;FEM=6T@6TUE M;6)E<ET@?"!!;65N9&5D($%G<F5E;65N="!;365M8F5R72!\($%S=&5L;&%S M(%M-96UB97)=/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A M;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,] M,T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/CQS M=')O;F<^4V-H961U;&4@;V8@3W1H97(@4F5L871E9"!087)T>2!4<F%N<V%C M=&EO;G,@6TQI;F4@271E;7-=/"]S=')O;F<^/"]T9#X-"B`@("`@("`@/'1D M(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D M(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D M(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D M(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D M(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D M(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D M(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D M(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D M(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D M(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^ M#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$ M<&P@=F%L:6=N/3-$=&]P/E!O=&5N=&EA;"!A;6]U;G0@<F5C96EV86)L92!U M;F1E<B!C;VQL86)O<F%T:6]N(&%G<F5E;65N=#PO=&0^#0H@("`@("`@(#QT M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S<STS1&YU;7`^)"`Q,#`L,#`P+#`P,#QS<&%N/CPO<W!A;CX\+W1D M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D M/@T*("`@("`@/"]T<CX-"B`@("`\+W1A8FQE/@T*("`\+V)O9'D^#0H\+VAT M;6P^#0H-"BTM+2TM+3U?3F5X=%!A<G1?,SEC,&5A-C)?8S(P,U\T-3AF7SAC M-3!?,V1C830U-F$V.34Q#0I#;VYT96YT+4QO8V%T:6]N.B!F:6QE.B\O+T,Z M+S,Y8S!E838R7V,R,#-?-#4X9E\X8S4P7S-D8V$T-39A-CDU,2]7;W)K<VAE M971S+U-H965T-3`N:'1M;`T*0V]N=&5N="U4<F%N<V9E<BU%;F-O9&EN9SH@ M<75O=&5D+7!R:6YT86)L90T*0V]N=&5N="U4>7!E.B!T97AT+VAT;6P[(&-H M87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U% M5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O M:'1M;#L@8VAA<G-E=#UU=&8M."<^/'-C<FEP="!T>7!E/3-$=&5X="]J879A M<V-R:7!T('-R8STS1%-H;W<N:G,^+RH@1&\@3F]T(%)E;6]V92!4:&ES($-O M;6UE;G0@*B\\+W-C<FEP=#X\+VAE860^#0H@(#QB;V1Y/@T*("`@(#QT86)L M92!C;&%S<STS1')E<&]R="!I9#TS1$E$,$53,T%'/@T*("`@("`@/'1R/@T* M("`@("`@("`\=&@@8VQA<W,],T1T;"!C;VQS<&%N/3-$,2!R;W=S<&%N/3-$ M,CX\<W1R;VYG/E)E;&%T960@4&%R=&EE<R!A;F0@4F5L871E9"!087)T>2!4 M<F%N<V%C=&EO;G,@+2!2979E;G5E(&9R;VT@4F5L871E9"!087)T>2`H1&5T M86EL*2`H55-$("0I/&)R/DEN(%1H;W5S86YD<RP@=6YL97-S(&]T:&5R=VES M92!S<&5C:69I960\+W-T<F]N9SX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,] M,T1T:"!C;VQS<&%N/3-$,3XS($UO;G1H<R!%;F1E9#PO=&@^#0H@("`@("`@ M(#QT:"!C;&%S<STS1'1H(&-O;'-P86X],T0S/C$R($UO;G1H<R!%;F1E9#PO M=&@^#0H@("`@("`\+W1R/@T*("`@("`@/'1R/@T*("`@("`@("`\=&@@8VQA M<W,],T1T:#Y$96,N(#,Q+"`R,#$S/&)R/CPO=&@^#0H@("`@("`@(#QT:"!C M;&%S<STS1'1H/D1E8RX@,S$L(#(P,30\8G(^/"]T:#X-"B`@("`@("`@/'1H M(&-L87-S/3-$=&@^1&5C+B`S,2P@,C`Q,SQB<CX\+W1H/@T*("`@("`@("`\ M=&@@8VQA<W,],T1T:#Y$96,N(#,Q+"`R,#$R/&)R/CPO=&@^#0H@("`@("`\ M+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S M<STS1'!L('9A;&EG;CTS1'1O<#X\<W1R;VYG/E-C:&5D=6QE(&]F($]T:&5R M(%)E;&%T960@4&%R='D@5')A;G-A8W1I;VYS(%M,:6YE($ET96US73PO<W1R M;VYG/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^ M#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y,:6-E;G-E M(')E=F5N=65S(&9R;VT@<F5L871E9"!P87)T:65S/"]T9#X-"B`@("`@("`@ M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@ M/'1D(&-L87-S/3-$;G5M<#XD(#DL.#,V/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S<STS1&YU;7`^)"`S+#@U,CQS<&%N/CPO<W!A;CX\ M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B0@,#QS<&%N/CPO<W!A M;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')H/@T* M("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^06UG96X@6TUE M;6)E<ET\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO M<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O M/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^/'-T<F]N M9SY38VAE9'5L92!O9B!/=&AE<B!296QA=&5D(%!A<G1Y(%1R86YS86-T:6]N M<R!;3&EN92!)=&5M<UT\+W-T<F]N9SX\+W1D/@T*("`@("`@("`\=&0@8VQA M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@ M("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V M86QI9VX],T1T;W`^3&EC96YS92!R979E;G5E<R!F<F]M(')E;&%T960@<&%R M=&EE<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,3<L,C`P/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,#QS M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$W M+#(S,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N M=6UP/C`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\ M='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N M/3-$=&]P/CQS=')O;F<^4F5S96%R8V@@86YD(&1E=F5L;W!M96YT(')E=F5N M=65S(&9R;VT@<F5L871E9"!P87)T:65S.CPO<W1R;VYG/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C M;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y296EM8G5R<V5M96YT(&]F(&EN=&5R M;F%L(&-O<W1S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XT+#(V M,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP M/C(L,#$Y/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS M1&YU;7`^-"PQ-S0\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@ M("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@ M=F%L:6=N/3-$=&]P/E)E:6UB=7)S96UE;G0@;V8@;W1H97(@8V]S=',\+W1D M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D M/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C`\<W!A;CX\+W-P86X^/"]T M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XP/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,SQS<&%N/CPO<W!A;CX\ M+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@ M("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^06QL;V-A=&5D(&-O M;G-I9&5R871I;VX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C(W M.#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP M/C`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M M<#XP/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R M(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS M1'1O<#X\<W1R;VYG/E)E<V5A<F-H(&%N9"!D979E;&]P;65N="!R979E;G5E M<SH\+W-T<F]N9SX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S M<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^ M4F5I;6)U<G-E;65N="!O9B!I;G1E<FYA;"!C;W-T<SPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S<STS1&YU;7`^-"PR-C`\<W!A;CX\+W-P86X^/"]T9#X-"B`@ M("`@("`@/'1D(&-L87-S/3-$;G5M<#XR+#`Q.3QS<&%N/CPO<W!A;CX\+W1D M/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C0L,3<T/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@ M("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y296EM8G5R<V5M M96YT(&]F(&]T:&5R(&-O<W1S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$ M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$ M;G5M<#XP/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS M1&YU;7`^,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,] M,T1N=6UP/C,\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@ M("`\='(@8VQA<W,],T1R974^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A M;&EG;CTS1'1O<#Y4;W1A;"!R97-E87)C:"!A;F0@9&5V96QO<&UE;G0@<F5V M96YU93PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-"PU,S@\<W!A M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ.2PR M-#D\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M M<#XT+#$W-SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@ M(#QT<B!C;&%S<STS1')H/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI M9VX],T1T;W`^07-T96QL87,@6TUE;6)E<ET\+W1D/@T*("`@("`@("`\=&0@ M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@ M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@ M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@ M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX- M"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P M;"!V86QI9VX],T1T;W`^/'-T<F]N9SY297-E87)C:"!A;F0@9&5V96QO<&UE M;G0@<F5V96YU97,@9G)O;2!R96QA=&5D('!A<G1I97,Z/"]S=')O;F<^/"]T M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T M9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@ M("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E)E<V5A<F-H(&%N9"!D M979E;&]P;65N="!M:6QE<W1O;F4@9F5E<SPO=&0^#0H@("`@("`@(#QT9"!C M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S<STS1&YU;7`^,34L,#`P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\ M+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S M<STS1'!L('9A;&EG;CTS1'1O<#Y296EM8G5R<V5M96YT(&]F(&EN=&5R;F%L M(&-O<W1S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\ M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XX+#DS.3QS M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C,L M,C@U/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R M(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS M1'1O<#Y296EM8G5R<V5M96YT(&]F(&]T:&5R(&-O<W1S/"]T9#X-"B`@("`@ M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@ M("`@/'1D(&-L87-S/3-$;G5M<#XV+#0U,CQS<&%N/CPO<W!A;CX\+W1D/@T* M("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C,L,3,P/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@ M("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#X\<W1R;VYG/E)E<V5A M<F-H(&%N9"!D979E;&]P;65N="!R979E;G5E<SH\+W-T<F]N9SX\+W1D/@T* M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T* M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T* M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T* M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T* M("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\ M=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^4F5I;6)U<G-E;65N="!O9B!I M;G1E<FYA;"!C;W-T<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^ M."PY,SD\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$ M;G5M<#XS+#(X-3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@ M("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V M86QI9VX],T1T;W`^4F5I;6)U<G-E;65N="!O9B!O=&AE<B!C;W-T<SPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-BPT-3(\<W!A;CX\+W-P86X^ M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XS+#$S,#QS<&%N/CPO M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO M<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O M/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^4F5S96%R M8V@@86YD(&1E=F5L;W!M96YT(&UI;&5S=&]N92!F965S/"]T9#X-"B`@("`@ M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@ M("`@/'1D(&-L87-S/3-$;G5M<#XR+#`P,#QS<&%N/CPO<W!A;CX\+W1D/@T* M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T* M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T* M("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E=3X-"B`@("`@("`@ M/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E1O=&%L(')E<V5A<F-H(&%N M9"!D979E;&]P;65N="!R979E;G5E/"]T9#X-"B`@("`@("`@/'1D(&-L87-S M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S M/3-$;G5M<#XD(#,R+#,Y,3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\ M=&0@8VQA<W,],T1N=6UP/B0@-BPT,34\<W!A;CX\+W-P86X^/"]T9#X-"B`@ M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@ M("`@(#PO='(^#0H@("`@/"]T86)L93X-"B`@/"]B;V1Y/@T*/"]H=&UL/@T* M#0HM+2TM+2T]7TYE>'1087)T7S,Y8S!E838R7V,R,#-?-#4X9E\X8S4P7S-D M8V$T-39A-CDU,0T*0V]N=&5N="U,;V-A=&EO;CH@9FEL93HO+R]#.B\S.6,P M96$V,E]C,C`S7S0U.&9?.&,U,%\S9&-A-#4V838Y-3$O5V]R:W-H965T<R]3 M:&5E=#4Q+FAT;6P-"D-O;G1E;G0M5')A;G-F97(M16YC;V1I;F<Z('%U;W1E M9"UP<FEN=&%B;&4-"D-O;G1E;G0M5'EP93H@=&5X="]H=&UL.R!C:&%R<V5T M/2)U<RUA<V-I:2(-"@T*/&AT;6P^#0H@(#QH96%D/@T*("`@(#Q-151!(&AT M='`M97%U:78],T1#;VYT96YT+51Y<&4@8V]N=&5N=#TS1"=T97AT+VAT;6P[ M(&-H87)S970]=71F+3@G/CQS8W)I<'0@='EP93TS1'1E>'0O:F%V87-C<FEP M="!S<F,],T13:&]W+FIS/B\J($1O($YO="!296UO=F4@5&AI<R!#;VUM96YT M("HO/"]S8W)I<'0^/"]H96%D/@T*("`\8F]D>3X-"B`@("`\=&%B;&4@8VQA M<W,],T1R97!O<G0@:60],T1)1#!%2$)!0SX-"B`@("`@(#QT<CX-"B`@("`@ M("`@/'1H(&-L87-S/3-$=&P@8V]L<W!A;CTS1#$@<F]W<W!A;CTS1#(^/'-T M<F]N9SY/=&AE<B!297-E87)C:"!A;F0@1&5V96QO<&UE;G0@4F5V96YU92!! M<G)A;F=E;65N=',@+2!!9&1I=&EO;F%L($EN9F]R;6%T:6]N("A$971A:6PI M("A54T0@)"D\8G(^26X@36EL;&EO;G,L('5N;&5S<R!O=&AE<G=I<V4@<W!E M8VEF:65D/"]S=')O;F<^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@@ M8V]L<W!A;CTS1#$^,2!-;VYT:',@16YD960\+W1H/@T*("`@("`@("`\=&@@ M8VQA<W,],T1T:"!C;VQS<&%N/3-$,3XQ,B!-;VYT:',@16YD960\+W1H/@T* M("`@("`@/"]T<CX-"B`@("`@(#QT<CX-"B`@("`@("`@/'1H(&-L87-S/3-$ M=&@^4V5P+B`S,"P@,C`Q,CQB<CX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,] M,T1T:#Y$96,N(#,Q+"`R,#$P/&)R/CPO=&@^#0H@("`@("`\+W1R/@T*("`@ M("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A M;&EG;CTS1'1O<#X\<W1R;VYG/E)E<V5A<F-H(&%N9"!$979E;&]P;65N="!; M06)S=')A8W1=/"]S=')O;F<^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$ M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$ M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\ M='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N M/3-$=&]P/D=R86YT('1O('-U<'!O<G0@<F5S96%R8V@@86YD(&1E=F5L;W!M M96YT/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XD(#`N-3QS<&%N M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B0@,BXX M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L M87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O M<#Y0;W1E;G1I86P@=')E871M96YT(&]F(&UY87-T:&5N:6$@9W)A=FES('1E M<FT\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/C,@>65A<G,\<W!A M;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@/"]T86)L93X-"B`@ M/"]B;V1Y/@T*/"]H=&UL/@T*#0HM+2TM+2T]7TYE>'1087)T7S,Y8S!E838R M7V,R,#-?-#4X9E\X8S4P7S-D8V$T-39A-CDU,0T*0V]N=&5N="U,;V-A=&EO M;CH@9FEL93HO+R]#.B\S.6,P96$V,E]C,C`S7S0U.&9?.&,U,%\S9&-A-#4V M838Y-3$O5V]R:W-H965T<R]3:&5E=#4R+FAT;6P-"D-O;G1E;G0M5')A;G-F M97(M16YC;V1I;F<Z('%U;W1E9"UP<FEN=&%B;&4-"D-O;G1E;G0M5'EP93H@ M=&5X="]H=&UL.R!C:&%R<V5T/2)U<RUA<V-I:2(-"@T*/&AT;6P^#0H@(#QH M96%D/@T*("`@(#Q-151!(&AT='`M97%U:78],T1#;VYT96YT+51Y<&4@8V]N M=&5N=#TS1"=T97AT+VAT;6P[(&-H87)S970]=71F+3@G/CQS8W)I<'0@='EP M93TS1'1E>'0O:F%V87-C<FEP="!S<F,],T13:&]W+FIS/B\J($1O($YO="!2 M96UO=F4@5&AI<R!#;VUM96YT("HO/"]S8W)I<'0^/"]H96%D/@T*("`\8F]D M>3X-"B`@("`\=&%B;&4@8VQA<W,],T1R97!O<G0@:60],T1)1#!%2TE!13X- M"B`@("`@(#QT<CX-"B`@("`@("`@/'1H(&-L87-S/3-$=&P@8V]L<W!A;CTS M1#$@<F]W<W!A;CTS1#(^/'-T<F]N9SY/=&AE<B!297-E87)C:"!A;F0@1&5V M96QO<&UE;G0@4F5V96YU92!!<G)A;F=E;65N=',@+2!3=6UM87)Y(&]F(%1O M=&%L($=R86YT(%)E=F5N=65S("A$971A:6PI("A54T0@)"D\8G(^26X@5&AO M=7-A;F1S+"!U;FQE<W,@;W1H97)W:7-E('-P96-I9FEE9#PO<W1R;VYG/CPO M=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H(&-O;'-P86X],T0S/C$R($UO M;G1H<R!%;F1E9#PO=&@^#0H@("`@("`\+W1R/@T*("`@("`@/'1R/@T*("`@ M("`@("`\=&@@8VQA<W,],T1T:#Y$96,N(#,Q+"`R,#$T/&)R/CPO=&@^#0H@ M("`@("`@(#QT:"!C;&%S<STS1'1H/D1E8RX@,S$L(#(P,3,\8G(^/"]T:#X- M"B`@("`@("`@/'1H(&-L87-S/3-$=&@^1&5C+B`S,2P@,C`Q,CQB<CX\+W1H M/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@ M("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^/'-T<F]N9SY297-E87)C M:"!A;F0@1&5V96QO<&UE;G0@07)R86YG96UE;G0L($-O;G1R86-T('1O(%!E M<F9O<FT@9F]R($]T:&5R<R!;3&EN92!)=&5M<UT\+W-T<F]N9SX\+W1D/@T* M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T* M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T* M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T* M("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\ M=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^5&]T86P@9W)A;G0@<F5V96YU M93PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^)"`W-3QS<&%N/CPO M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B0@.30\<W!A M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XD(#$L M,S`X/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R M(&-L87-S/3-$<F@^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS M1'1O<#Y.24Y$4R!->6%S=&AE;FEA($=R879I<R!;365M8F5R73PO=&0^#0H@ M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT M9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#X\<W1R;VYG/E)E<V5A<F-H(&%N M9"!$979E;&]P;65N="!!<G)A;F=E;65N="P@0V]N=')A8W0@=&\@4&5R9F]R M;2!F;W(@3W1H97)S(%M,:6YE($ET96US73PO<W1R;VYG/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C M;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y4;W1A;"!G<F%N="!R979E;G5E/"]T M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XP/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-CD\<W!A;CX\+W-P86X^ M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ+#,P.#QS<&%N/CPO M<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')H M/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^3W1H97(@ M1W)A;G0@4F5V96YU92!;365M8F5R73PO=&0^#0H@("`@("`@(#QT9"!C;&%S M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@ M("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A M;&EG;CTS1'1O<#X\<W1R;VYG/E)E<V5A<F-H(&%N9"!$979E;&]P;65N="!! M<G)A;F=E;65N="P@0V]N=')A8W0@=&\@4&5R9F]R;2!F;W(@3W1H97)S(%M, M:6YE($ET96US73PO<W1R;VYG/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@ M/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG M;CTS1'1O<#Y4;W1A;"!G<F%N="!R979E;G5E/"]T9#X-"B`@("`@("`@/'1D M(&-L87-S/3-$;G5M<#XD(#<U/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S<STS1&YU;7`^)"`R-3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@ M("`@("`\=&0@8VQA<W,],T1N=6UP/B0@,#QS<&%N/CPO<W!A;CX\+W1D/@T* M("`@("`@/"]T<CX-"B`@("`\+W1A8FQE/@T*("`\+V)O9'D^#0H\+VAT;6P^ M#0H-"BTM+2TM+3U?3F5X=%!A<G1?,SEC,&5A-C)?8S(P,U\T-3AF7SAC-3!? M,V1C830U-F$V.34Q#0I#;VYT96YT+4QO8V%T:6]N.B!F:6QE.B\O+T,Z+S,Y M8S!E838R7V,R,#-?-#4X9E\X8S4P7S-D8V$T-39A-CDU,2]7;W)K<VAE971S M+U-H965T-3,N:'1M;`T*0V]N=&5N="U4<F%N<V9E<BU%;F-O9&EN9SH@<75O M=&5D+7!R:6YT86)L90T*0V]N=&5N="U4>7!E.B!T97AT+VAT;6P[(&-H87)S M970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@ M:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M M;#L@8VAA<G-E=#UU=&8M."<^/'-C<FEP="!T>7!E/3-$=&5X="]J879A<V-R M:7!T('-R8STS1%-H;W<N:G,^+RH@1&\@3F]T(%)E;6]V92!4:&ES($-O;6UE M;G0@*B\\+W-C<FEP=#X\+VAE860^#0H@(#QB;V1Y/@T*("`@(#QT86)L92!C M;&%S<STS1')E<&]R="!I9#TS1$E$,$5-24%%/@T*("`@("`@/'1R/@T*("`@ M("`@("`\=&@@8VQA<W,],T1T;"!C;VQS<&%N/3-$,2!R;W=S<&%N/3-$,CX\ M<W1R;VYG/D]T:&5R(%)E<V5A<F-H(&%N9"!$979E;&]P;65N="!2979E;G5E M($%R<F%N9V5M96YT<R`M(%-U;6UA<GD@;V8@4F5I;6)U<G-E9"!%>'!E;G-E M<R`H1&5T86EL*2`H55-$("0I/&)R/DEN(%1H;W5S86YD<RP@=6YL97-S(&]T M:&5R=VES92!S<&5C:69I960\+W-T<F]N9SX\+W1H/@T*("`@("`@("`\=&@@ M8VQA<W,],T1T:"!C;VQS<&%N/3-$,SXQ,B!-;VYT:',@16YD960\+W1H/@T* M("`@("`@/"]T<CX-"B`@("`@(#QT<CX-"B`@("`@("`@/'1H(&-L87-S/3-$ M=&@^1&5C+B`S,2P@,C`Q-#QB<CX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,] M,T1T:#Y$96,N(#,Q+"`R,#$S/&)R/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S M<STS1'1H/D1E8RX@,S$L(#(P,3(\8G(^/"]T:#X-"B`@("`@(#PO='(^#0H@ M("`@("`\='(@8VQA<W,],T1R:#X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@ M=F%L:6=N/3-$=&]P/D=L;V)A;"!";&]O9"!;365M8F5R73PO=&0^#0H@("`@ M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C M;&%S<STS1'!L('9A;&EG;CTS1'1O<#X\<W1R;VYG/E)E<V5A<F-H(&%N9"!$ M979E;&]P;65N="!!<G)A;F=E;65N="P@0V]N=')A8W0@=&\@4&5R9F]R;2!F M;W(@3W1H97)S(%M,:6YE($ET96US73PO<W1R;VYG/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\ M+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S M<STS1'!L('9A;&EG;CTS1'1O<#Y%>'!E;G-E(')E:6UB=7)S96UE;G1S/"]T M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XD(#`\<W!A;CX\+W-P86X^ M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XD(#$T/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^)"`Q+#0W.3QS M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S M<STS1')H/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^ M37EO2V%R9&EA(%M-96UB97)=/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$ M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$ M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$ M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\ M='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N M/3-$=&]P/CQS=')O;F<^4F5S96%R8V@@86YD($1E=F5L;W!M96YT($%R<F%N M9V5M96YT+"!#;VYT<F%C="!T;R!097)F;W)M(&9O<B!/=&AE<G,@6TQI;F4@ M271E;7-=/"]S=')O;F<^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@ M8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$ M=&]P/E)E<V5A<F-H(&%N9"!D979E;&]P;65N="!M:6QE<W1O;F4@9F5E<SPO M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,3`P/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,#QS<&%N/CPO<W!A M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C`\<W!A;CX\+W-P M86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X- M"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D5X<&5N<V4@ M<F5I;6)U<G-E;65N=',\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP M/C`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M M<#XQ+#`R-#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,] M,T1N=6UP/C4Y-3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@ M("`@(#QT<B!C;&%S<STS1')O=3X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@ M=F%L:6=N/3-$=&]P/E)E<V5A<F-H(&%N9"!D979E;&]P;65N="!R979E;G5E M(&9R;VT@37EO:V%R9&EA/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M M<#XD(#$P,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,] M,T1N=6UP/B0@,2PP,C0\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D M(&-L87-S/3-$;G5M<#XD(#4Y-3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@ M/"]T<CX-"B`@("`\+W1A8FQE/@T*("`\+V)O9'D^#0H\+VAT;6P^#0H-"BTM M+2TM+3U?3F5X=%!A<G1?,SEC,&5A-C)?8S(P,U\T-3AF7SAC-3!?,V1C830U M-F$V.34Q#0I#;VYT96YT+4QO8V%T:6]N.B!F:6QE.B\O+T,Z+S,Y8S!E838R M7V,R,#-?-#4X9E\X8S4P7S-D8V$T-39A-CDU,2]7;W)K<VAE971S+U-H965T M-30N:'1M;`T*0V]N=&5N="U4<F%N<V9E<BU%;F-O9&EN9SH@<75O=&5D+7!R M:6YT86)L90T*0V]N=&5N="U4>7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S M+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE M<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA M<G-E=#UU=&8M."<^/'-C<FEP="!T>7!E/3-$=&5X="]J879A<V-R:7!T('-R M8STS1%-H;W<N:G,^+RH@1&\@3F]T(%)E;6]V92!4:&ES($-O;6UE;G0@*B\\ M+W-C<FEP=#X\+VAE860^#0H@(#QB;V1Y/@T*("`@(#QT86)L92!C;&%S<STS M1')E<&]R="!I9#TS1$E$,$4U1SX-"B`@("`@(#QT<CX-"B`@("`@("`@/'1H M(&-L87-S/3-$=&P@8V]L<W!A;CTS1#$@<F]W<W!A;CTS1#$^/'-T<F]N9SY$ M96)T("T@061D:71I;VYA;"!);F9O<FUA=&EO;B`H1&5T86EL*2`H55-$("0I M/&)R/CPO<W1R;VYG/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/D1E M8RX@,S$L(#(P,30\8G(^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^ M1&5C+B`S,2P@,C`Q,3QB<CX\+W1H/@T*("`@("`@/"]T<CX-"B`@("`@(#QT M<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX] M,T1T;W`^/'-T<F]N9SY$96)T($1I<V-L;W-U<F4@6T%B<W1R86-T73PO<W1R M;VYG/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^ M#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y%<75I<&UE M;G0@;&]A;G,@;W5T<W1A;F1I;F<\+W1D/@T*("`@("`@("`\=&0@8VQA<W,] M,T1N=6UP/B0@,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA M<W,],T1N=6UP/B0@,34R+#`P,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@ M/"]T<CX-"B`@("`\+W1A8FQE/@T*("`\+V)O9'D^#0H\+VAT;6P^#0H-"BTM M+2TM+3U?3F5X=%!A<G1?,SEC,&5A-C)?8S(P,U\T-3AF7SAC-3!?,V1C830U M-F$V.34Q#0I#;VYT96YT+4QO8V%T:6]N.B!F:6QE.B\O+T,Z+S,Y8S!E838R M7V,R,#-?-#4X9E\X8S4P7S-D8V$T-39A-CDU,2]7;W)K<VAE971S+U-H965T M-34N:'1M;`T*0V]N=&5N="U4<F%N<V9E<BU%;F-O9&EN9SH@<75O=&5D+7!R M:6YT86)L90T*0V]N=&5N="U4>7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S M+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE M<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA M<G-E=#UU=&8M."<^/'-C<FEP="!T>7!E/3-$=&5X="]J879A<V-R:7!T('-R M8STS1%-H;W<N:G,^+RH@1&\@3F]T(%)E;6]V92!4:&ES($-O;6UE;G0@*B\\ M+W-C<FEP=#X\+VAE860^#0H@(#QB;V1Y/@T*("`@(#QT86)L92!C;&%S<STS M1')E<&]R="!I9#TS1$E$,$580D%#/@T*("`@("`@/'1R/@T*("`@("`@("`\ M=&@@8VQA<W,],T1T;"!C;VQS<&%N/3-$,2!R;W=S<&%N/3-$,CX\<W1R;VYG M/D1E8G0@+2!3=6UM87)Y(&]F(%1O=&%L($EN=&5R97-T($5X<&5N<V4@26YC M=7)R960@*$1E=&%I;"D@*%531"`D*3QB<CY);B!4:&]U<V%N9',L('5N;&5S M<R!O=&AE<G=I<V4@<W!E8VEF:65D/"]S=')O;F<^/"]T:#X-"B`@("`@("`@ M/'1H(&-L87-S/3-$=&@@8V]L<W!A;CTS1#,^,3(@36]N=&AS($5N9&5D/"]T M:#X-"B`@("`@(#PO='(^#0H@("`@("`\='(^#0H@("`@("`@(#QT:"!C;&%S M<STS1'1H/D1E8RX@,S$L(#(P,30\8G(^/"]T:#X-"B`@("`@("`@/'1H(&-L M87-S/3-$=&@^1&5C+B`S,2P@,C`Q,SQB<CX\+W1H/@T*("`@("`@("`\=&@@ M8VQA<W,],T1T:#Y$96,N(#,Q+"`R,#$R/&)R/CPO=&@^#0H@("`@("`\+W1R M/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS M1'!L('9A;&EG;CTS1'1O<#X\<W1R;VYG/D1E8G0@1&ES8VQO<W5R92!;06)S M=')A8W1=/"]S=')O;F<^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@ M8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$ M=&]P/DEN=&5R97-T(&5X<&5N<V4\+W1D/@T*("`@("`@("`\=&0@8VQA<W,] M,T1N=6UP/B0@,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA M<W,],T1N=6UP/B0@,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@ M8VQA<W,],T1N=6UP/B0@,SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T M<CX-"B`@("`\+W1A8FQE/@T*("`\+V)O9'D^#0H\+VAT;6P^#0H-"BTM+2TM M+3U?3F5X=%!A<G1?,SEC,&5A-C)?8S(P,U\T-3AF7SAC-3!?,V1C830U-F$V M.34Q#0I#;VYT96YT+4QO8V%T:6]N.B!F:6QE.B\O+T,Z+S,Y8S!E838R7V,R M,#-?-#4X9E\X8S4P7S-D8V$T-39A-CDU,2]7;W)K<VAE971S+U-H965T-38N M:'1M;`T*0V]N=&5N="U4<F%N<V9E<BU%;F-O9&EN9SH@<75O=&5D+7!R:6YT M86)L90T*0V]N=&5N="U4>7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S M8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I M=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA<G-E M=#UU=&8M."<^/'-C<FEP="!T>7!E/3-$=&5X="]J879A<V-R:7!T('-R8STS M1%-H;W<N:G,^+RH@1&\@3F]T(%)E;6]V92!4:&ES($-O;6UE;G0@*B\\+W-C M<FEP=#X\+VAE860^#0H@(#QB;V1Y/@T*("`@(#QT86)L92!C;&%S<STS1')E M<&]R="!I9#TS1$E$,$4R1CX-"B`@("`@(#QT<CX-"B`@("`@("`@/'1H(&-L M87-S/3-$=&P@8V]L<W!A;CTS1#$@<F]W<W!A;CTS1#(^/'-T<F]N9SY#;VUM M:71M96YT<R!A;F0@0V]N=&EN9V5N8VEE<R`M($%D9&ET:6]N86P@26YF;W)M M871I;VX@*$1E=&%I;"D\8G(^/"]S=')O;F<^/"]T:#X-"B`@("`@("`@/'1H M(&-L87-S/3-$=&@@8V]L<W!A;CTS1#$^,3(@36]N=&AS($5N9&5D/"]T:#X- M"B`@("`@(#PO='(^#0H@("`@("`\='(^#0H@("`@("`@(#QT:"!C;&%S<STS M1'1H/D1E8RX@,S$L(#(P,30\8G(^/"]T:#X-"B`@("`@(#PO='(^#0H@("`@ M("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L M:6=N/3-$=&]P/CQS=')O;F<^0V]M;6ET;65N=',@86YD($-O;G1I;F=E;F-I M97,@1&ES8VQO<W5R92!;06)S=')A8W1=/"]S=')O;F<^/"]T9#X-"B`@("`@ M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@ M(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L M87-S/3-$<&P@=F%L:6=N/3-$=&]P/DYO;BUC86YC96QA8FQE(&]P97)A=&EN M9R!L96%S92!E>'!I<F5S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X M=#XR,#$X/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@ M/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG M;CTS1'1O<#Y.;VXM8V%N8V5L86)L92!O<&5R871I;F<@;&5A<V4@861D:71I M;VYA;"!E>'1E;G-I;VX@<&5R:6]D/"]T9#X-"B`@("`@("`@/'1D(&-L87-S M/3-$=&5X=#XS('EE87)S/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R M/@T*("`@(#PO=&%B;&4^#0H@(#PO8F]D>3X-"CPO:'1M;#X-"@T*+2TM+2TM M/5].97AT4&%R=%\S.6,P96$V,E]C,C`S7S0U.&9?.&,U,%\S9&-A-#4V838Y M-3$-"D-O;G1E;G0M3&]C871I;VXZ(&9I;&4Z+R\O0SHO,SEC,&5A-C)?8S(P M,U\T-3AF7SAC-3!?,V1C830U-F$V.34Q+U=O<FMS:&5E=',O4VAE970U-RYH M=&UL#0I#;VYT96YT+51R86YS9F5R+45N8V]D:6YG.B!Q=6]T960M<')I;G1A M8FQE#0I#;VYT96YT+51Y<&4Z('1E>'0O:'1M;#L@8VAA<G-E=#TB=7,M87-C M:6DB#0H-"CQH=&UL/@T*("`\:&5A9#X-"B`@("`\345402!H='1P+65Q=6EV M/3-$0V]N=&5N="U4>7!E(&-O;G1E;G0],T0G=&5X="]H=&UL.R!C:&%R<V5T M/75T9BTX)SX\<V-R:7!T('1Y<&4],T1T97AT+VIA=F%S8W)I<'0@<W)C/3-$ M4VAO=RYJ<SXO*B!$;R!.;W0@4F5M;W9E(%1H:7,@0V]M;65N="`J+SPO<V-R M:7!T/CPO:&5A9#X-"B`@/&)O9'D^#0H@("`@/'1A8FQE(&-L87-S/3-$<F5P M;W)T(&ED/3-$240P15A"04,^#0H@("`@("`\='(^#0H@("`@("`@(#QT:"!C M;&%S<STS1'1L(&-O;'-P86X],T0Q(')O=W-P86X],T0R/CQS=')O;F<^0V]M M;6ET;65N=',@86YD($-O;G1I;F=E;F-I97,@+2!296YT($5X<&5N<V4@*$1E M=&%I;"D@*%531"`D*3QB<CY);B!4:&]U<V%N9',L('5N;&5S<R!O=&AE<G=I M<V4@<W!E8VEF:65D/"]S=')O;F<^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S M/3-$=&@@8V]L<W!A;CTS1#,^,3(@36]N=&AS($5N9&5D/"]T:#X-"B`@("`@ M(#PO='(^#0H@("`@("`\='(^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/D1E M8RX@,S$L(#(P,30\8G(^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^ M1&5C+B`S,2P@,C`Q,SQB<CX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T M:#Y$96,N(#,Q+"`R,#$R/&)R/CPO=&@^#0H@("`@("`\+W1R/@T*("`@("`@ M/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG M;CTS1'1O<#X\<W1R;VYG/D-O;6UI=&UE;G1S(&%N9"!#;VYT:6YG96YC:65S M($1I<V-L;W-U<F4@6T%B<W1R86-T73PO<W1R;VYG/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\ M+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S M<STS1'!L('9A;&EG;CTS1'1O<#Y296YT(&5X<&5N<V4\+W1D/@T*("`@("`@ M("`\=&0@8VQA<W,],T1N=6UP/B0@,RPS,S@\<W!A;CX\+W-P86X^/"]T9#X- M"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XD(#,L,S`V/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^)"`S+#,W-3QS<&%N M/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`\+W1A8FQE/@T*("`\ M+V)O9'D^#0H\+VAT;6P^#0H-"BTM+2TM+3U?3F5X=%!A<G1?,SEC,&5A-C)? M8S(P,U\T-3AF7SAC-3!?,V1C830U-F$V.34Q#0I#;VYT96YT+4QO8V%T:6]N M.B!F:6QE.B\O+T,Z+S,Y8S!E838R7V,R,#-?-#4X9E\X8S4P7S-D8V$T-39A M-CDU,2]7;W)K<VAE971S+U-H965T-3@N:'1M;`T*0V]N=&5N="U4<F%N<V9E M<BU%;F-O9&EN9SH@<75O=&5D+7!R:6YT86)L90T*0V]N=&5N="U4>7!E.B!T M97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE M860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT M96YT/3-$)W1E>'0O:'1M;#L@8VAA<G-E=#UU=&8M."<^/'-C<FEP="!T>7!E M/3-$=&5X="]J879A<V-R:7!T('-R8STS1%-H;W<N:G,^+RH@1&\@3F]T(%)E M;6]V92!4:&ES($-O;6UE;G0@*B\\+W-C<FEP=#X\+VAE860^#0H@(#QB;V1Y M/@T*("`@(#QT86)L92!C;&%S<STS1')E<&]R="!I9#TS1$E$,$5.1D%#/@T* M("`@("`@/'1R/@T*("`@("`@("`\=&@@8VQA<W,],T1T;"!C;VQS<&%N/3-$ M,2!R;W=S<&%N/3-$,3X\<W1R;VYG/D-O;6UI=&UE;G1S(&%N9"!#;VYT:6YG M96YC:65S("T@1G5T=7)E($UI;FEM=6T@3&5A<V4@4&%Y;65N=',@=6YD97(@ M3F]N8V%N8V5L86)L92!/<&5R871I;F<@3&5A<V5S("A$971A:6PI("A54T0@ M)"D\8G(^26X@5&AO=7-A;F1S+"!U;FQE<W,@;W1H97)W:7-E('-P96-I9FEE M9#PO<W1R;VYG/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/D1E8RX@ M,S$L(#(P,30\8G(^/"]T:#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA M<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P M/CQS=')O;F<^0V]M;6ET;65N=',@86YD($-O;G1I;F=E;F-I97,@1&ES8VQO M<W5R92!;06)S=')A8W1=/"]S=')O;F<^/"]T9#X-"B`@("`@("`@/'1D(&-L M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@ M("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@ M=F%L:6=N/3-$=&]P/C(P,34\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N M=6UP/B0@,RPS.3`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@ M("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@ M=F%L:6=N/3-$=&]P/C(P,38\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N M=6UP/C,L-3`T/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@ M("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A M;&EG;CTS1'1O<#XR,#$W/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M M<#XS+#8R-CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@ M(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI M9VX],T1T;W`^,C`Q.#PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^ M,2PX-C`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\ M='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N M/3-$=&]P/C(P,3D\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C`\ M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA M<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P M/E1H97)E869T97(\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C`\ M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA M<W,],T1R;W4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O M<#Y4;W1A;#PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^)"`Q,BPS M.#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@/"]T86)L M93X-"B`@/"]B;V1Y/@T*/"]H=&UL/@T*#0HM+2TM+2T]7TYE>'1087)T7S,Y M8S!E838R7V,R,#-?-#4X9E\X8S4P7S-D8V$T-39A-CDU,0T*0V]N=&5N="U, M;V-A=&EO;CH@9FEL93HO+R]#.B\S.6,P96$V,E]C,C`S7S0U.&9?.&,U,%\S M9&-A-#4V838Y-3$O5V]R:W-H965T<R]3:&5E=#4Y+FAT;6P-"D-O;G1E;G0M M5')A;G-F97(M16YC;V1I;F<Z('%U;W1E9"UP<FEN=&%B;&4-"D-O;G1E;G0M M5'EP93H@=&5X="]H=&UL.R!C:&%R<V5T/2)U<RUA<V-I:2(-"@T*/&AT;6P^ M#0H@(#QH96%D/@T*("`@(#Q-151!(&AT='`M97%U:78],T1#;VYT96YT+51Y M<&4@8V]N=&5N=#TS1"=T97AT+VAT;6P[(&-H87)S970]=71F+3@G/CQS8W)I M<'0@='EP93TS1'1E>'0O:F%V87-C<FEP="!S<F,],T13:&]W+FIS/B\J($1O M($YO="!296UO=F4@5&AI<R!#;VUM96YT("HO/"]S8W)I<'0^/"]H96%D/@T* M("`\8F]D>3X-"B`@("`\=&%B;&4@8VQA<W,],T1R97!O<G0@:60],T1)1#!% M54-&2SX-"B`@("`@(#QT<CX-"B`@("`@("`@/'1H(&-L87-S/3-$=&P@8V]L M<W!A;CTS1#$@<F]W<W!A;CTS1#(^/'-T<F]N9SY#;VYV97)T:6)L92!0<F5F M97)R960@4W1O8VL@+2!!9&1I=&EO;F%L($EN9F]R;6%T:6]N("A$971A:6PI M("A54T0@)"D\8G(^/"]S=')O;F<^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S M/3-$=&@@8V]L<W!A;CTS1#(^,"!-;VYT:',@16YD960\+W1H/@T*("`@("`@ M("`\=&@@8VQA<W,],T1T:"!C;VQS<&%N/3-$,3XQ($UO;G1H<R!%;F1E9#PO M=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H(&-O;'-P86X],T0S/C$R($UO M;G1H<R!%;F1E9#PO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H(&-O;'-P M86X],T0R/C`@36]N=&AS($5N9&5D/"]T:#X-"B`@("`@("`@/'1H(&-L87-S M/3-$=&@@8V]L<W!A;CTS1#(^,R!-;VYT:',@16YD960\+W1H/@T*("`@("`@ M("`\=&@@8VQA<W,],T1T:"!C;VQS<&%N/3-$,CXP($UO;G1H<R!%;F1E9#PO M=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H(&-O;'-P86X],T0Q/C,@36]N M=&AS($5N9&5D/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@@8V]L<W!A M;CTS1#$^/"]T:#X-"B`@("`@(#PO='(^#0H@("`@("`\='(^#0H@("`@("`@ M(#QT:"!C;&%S<STS1'1H/DIU;BX@,C0L(#(P,3,\8G(^/"]T:#X-"B`@("`@ M("`@/'1H(&-L87-S/3-$=&@^2G5N+B`R,"P@,C`Q,CQB<CY0=6)L:6-/9F9E M<FEN9SQB<CX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y*=6XN(#,P M+"`R,#$S/&)R/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/D1E8RX@ M,S$L(#(P,30\8G(^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^1&5C M+B`S,2P@,C`Q,SQB<CX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y$ M96,N(#,Q+"`R,#$R/&)R/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H M/DIU;"X@,#(L(#(P,3,\8G(^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$ M=&@^4V5P+B`R-BP@,C`Q,CQB<CX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,] M,T1T:#Y*=6XN(#,P+"`R,#$S/&)R/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S M<STS1'1H/DUA<BX@,S$L(#(P,3,\8G(^/"]T:#X-"B`@("`@("`@/'1H(&-L M87-S/3-$=&@^07!R+B`R,"P@,C`Q,3QB<CX\+W1H/@T*("`@("`@("`\=&@@ M8VQA<W,],T1T:#Y*=6XN(#(U+"`R,#$R/&)R/CPO=&@^#0H@("`@("`@(#QT M:"!C;&%S<STS1'1H/DIU;BX@,S`L(#(P,3(\8G(^/"]T:#X-"B`@("`@("`@ M/'1H(&-L87-S/3-$=&@^1&5C+B`S,2P@,C`Q,#QB<CX\+W1H/@T*("`@("`@ M/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA M<W,],T1P;"!V86QI9VX],T1T;W`^/'-T<F]N9SY#;&%S<R!O9B!3=&]C:R!; M3&EN92!)=&5M<UT\+W-T<F]N9SX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,] M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,] M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,] M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,] M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,] M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,] M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,] M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,] M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,] M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,] M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,] M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,] M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,] M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,] M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@ M(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI M9VX],T1T;W`^4')E9F5R<F5D('-T;V-K(&%U=&AO<FEZ960@;G5M8F5R(&]F M('-H87)E<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,3`L,#`P M+#`P,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N M=6UP/C$P+#`P,"PP,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D M(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D M(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D M(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D M(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D M(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D M(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D M(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D M(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D M(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^ M#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$ M<&P@=F%L:6=N/3-$=&]P/D-O;G9E<G1I8FQE('!R969E<G)E9"!S=&]C:RP@ M<'5R8VAA<V4@<')I8V4\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP M/B0@.#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N M=6UP/B0@-"XU-CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA M<W,],T1N=6UP/B0@-"XU-CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\ M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\ M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T M<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,] M,T1P;"!V86QI9VX],T1T;W`^0V]N=F5R=&EB;&4@<')E9F5R<F5D('-T;V-K M+"!N970@<')O8V5E9',\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP M/B0@,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N M=6UP/B0@,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,] M,T1N=6UP/B0@,3(L,S$X+#`P,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@ M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@ M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@ M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@ M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@ M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@ M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@ M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@ M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@ M/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA M<W,],T1P;"!V86QI9VX],T1T;W`^3G5M8F5R(&]F(&-O;F-U<G)E;G0@<'5B M;&EC(&]F9F5R:6YG<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^ M,CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C M;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T M;W`^4F5V97)S92!S=&]C:R!S<&QI="P@8V]N=F5R<VEO;B!R871I;SPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,"XQ-C<\<W!A;CX\+W-P86X^ M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^ M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XP+C$V-SQS<&%N/CPO M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO M<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E M/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^4W1O8VL@ M<W!L:70@9&5S8W)I<'1I;VX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T M97AT/D%S(&$@<F5S=6QT(&]F('1H92!O;F4M9F]R+7-I>"!R979E<G-E('-T M;V-K("!S<&QI="!E9F9E8W1E9"!I;B!*=6YE(#(P,3,L('1H92!C;VYV97)S M:6]N(')A=&EO(&9O<B!397)I97,@0B!C;VYV97)T:6)L92`@<')E9F5R<F5D M('-T;V-K(&-H86YG960@9G)O;2`Q+#`P,"!S:&%R97,@;V8@8V]M;6]N('-T M;V-K('!E<B!S:&%R92!O9B!397)I97,@0B`@8V]N=F5R=&EB;&4@<')E9F5R M<F5D('-T;V-K('1O(#$V-BXV-R!S:&%R97,@;V8@8V]M;6]N('-T;V-K('!E M<B!S:&%R92!O9B!397)I97,@($(@8V]N=F5R=&EB;&4@<')E9F5R<F5D('-T M;V-K+CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT M<B!C;&%S<STS1')H/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX] M,T1T;W`^0V]M;6]N(%-T;V-K(%M-96UB97)=/"]T9#X-"B`@("`@("`@/'1D M(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D M(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D M(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D M(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D M(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D M(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D M(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D M(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D M(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D M(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D M(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D M(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D M(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D M(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^ M#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$ M<&P@=F%L:6=N/3-$=&]P/CQS=')O;F<^0VQA<W,@;V8@4W1O8VL@6TQI;F4@ M271E;7-=/"]S=')O;F<^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@ M8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$ M=&]P/D-O;6UO;B!S=&]C:R!I<W-U960@<'5R<W5A;G0@=&\@<V5R:65S($(@ M<')E9F5R<F5D('-T;V-K(&-O;G9E<G-I;VX\+W1D/@T*("`@("`@("`\=&0@ M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@ M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@ M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@ M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@ M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@ M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@ M8VQA<W,],T1N=6UP/C8V-BPV.#$\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@ M("`@/'1D(&-L87-S/3-$;G5M<#XQ+#,T-2PP,#`\<W!A;CX\+W-P86X^/"]T M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XR+#4P-"PS,S0\<W!A;CX\ M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XV-C8L-C8W M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L M87-S/3-$<F@^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O M<#Y$965R9FEE;&0@06=R965M96YT(%M-96UB97)=/"]T9#X-"B`@("`@("`@ M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@ M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@ M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@ M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@ M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@ M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@ M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@ M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@ M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@ M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@ M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@ M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@ M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@ M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO M='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S M/3-$<&P@=F%L:6=N/3-$=&]P/CQS=')O;F<^0VQA<W,@;V8@4W1O8VL@6TQI M;F4@271E;7-=/"]S=')O;F<^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$ M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$ M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$ M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$ M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$ M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$ M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$ M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$ M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$ M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$ M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$ M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$ M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$ M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$ M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\ M='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N M/3-$=&]P/E!E<F-E;G1A9V4@;&EM:70@;VX@;G5M8F5R(&]F('-H87)E<R!O M9B!C;VUM;VX@<W1O8VL@97AE<F-I<V%B;&4@8GD@:&]L9&5R<SPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S<STS1&YU;7`^.2XY."4\<W!A;CX\+W-P86X^/"]T M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T M9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R:#X-"B`@("`@ M("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D-O;G9E<G1I8FQE(%!R M969E<G)E9"!3=&]C:R!;365M8F5R73PO=&0^#0H@("`@("`@(#QT9"!C;&%S M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@ M("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A M;&EG;CTS1'1O<#X\<W1R;VYG/D-L87-S(&]F(%-T;V-K(%M,:6YE($ET96US M73PO<W1R;VYG/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S M/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y0 M<F5F97)R960@<W1O8VL@875T:&]R:7IE9"!N=6UB97(@;V8@<VAA<F5S/"]T M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ,"PP,#`L,#`P/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,3`L,#`P M+#`P,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT M<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX] M,T1T;W`^4')E9F5R<F5D('-T;V-K(&]U='-T86YD:6YG(&YU;6)E<B!O9B!S M:&%R97,\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C`\<W!A;CX\ M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\ M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\ M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\ M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\ M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\ M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\ M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\ M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\ M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\ M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XP/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$ M<F@^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y397)I M97,@02!#;VYV97)T:6)L92!0<F5F97)R960@4W1O8VL@6TUE;6)E<ET\+W1D M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D M/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@ M("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^/'-T<F]N9SY#;&%S<R!O M9B!3=&]C:R!;3&EN92!)=&5M<UT\+W-T<F]N9SX\+W1D/@T*("`@("`@("`\ M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\ M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\ M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\ M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\ M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\ M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\ M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\ M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\ M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\ M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\ M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\ M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\ M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\ M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T M<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,] M,T1P;"!V86QI9VX],T1T;W`^4')E9F5R<F5D('-T;V-K(&]U='-T86YD:6YG M(&YU;6)E<B!O9B!S:&%R97,\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N M=6UP/C`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$ M;G5M<#XP/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@ M/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG M;CTS1'1O<#Y#;VYV97)T:6)L92!P<F5F97)R960@<W1O8VLL(&ES<W5E9"!S M:&%R97,\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C`\<W!A;CX\ M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XP/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$ M<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y!;6]U M;G0@8GD@=VAI8V@@9F%I<B!V86QU92!O9B!C;VUM;VX@<W1O8VL@97AC965D M960@=&AE(&%L;&]C871E9"!P=7)C:&%S92!P<FEC93PO=&0^#0H@("`@("`@ M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S<STS1&YU;7`^,BPY,#`L,#`P/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@ M(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y#;VYV97)T:6)L92!P<F5F M97)R960@<W1O8VL@8V]N=F5R=&5D(&EN=&\@8V]M;6]N('-T;V-K/"]T9#X- M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X- M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X- M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X- M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X- M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X- M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X- M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X- M"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XX+#`W,#QS<&%N/CPO<W!A;CX\ M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\ M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\ M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$L,#`P/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^ M#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y%;G1I=&QE M9"!P87EM96YT('!E<B!S:&%R92!D=7)I;F<@;&EQ=6ED871I;VX\+W1D/@T* M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T* M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T* M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T* M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T* M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T* M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T* M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T* M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T* M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T* M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T* M("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B0@,"XP,#$\<W!A;CX\+W-P86X^ M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^ M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^ M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^ M/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R:#X-"B`@ M("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E-E<FEE<R!!($-O M;G9E<G1I8FQE(%!R969E<G)E9"!3=&]C:R!;365M8F5R72!\($1E97)F:65L M9"!!9W)E96UE;G0@6TUE;6)E<ET\+W1D/@T*("`@("`@("`\=&0@8VQA<W,] M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,] M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,] M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,] M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,] M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,] M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,] M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,] M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,] M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,] M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,] M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,] M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,] M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,] M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@ M(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI M9VX],T1T;W`^/'-T<F]N9SY#;&%S<R!O9B!3=&]C:R!;3&EN92!)=&5M<UT\ M+W-T<F]N9SX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N M/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS M1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^0V]N M=F5R=&EB;&4@<')E9F5R<F5D('-T;V-K+"!I<W-U960@<VAA<F5S/"]T9#X- M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X- M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X- M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X- M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X- M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X- M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X- M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X- M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X- M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X- M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X- M"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XX+#`W,#QS<&%N/CPO<W!A;CX\ M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\ M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\ M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\ M+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@ M("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^0V]N=F5R=&EB;&4@ M<')E9F5R<F5D('-T;V-K+"!P=7)C:&%S92!P<FEC93PO=&0^#0H@("`@("`@ M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S<STS1&YU;7`^)"`Q+#4P,#QS<&%N/CPO<W!A;CX\+W1D/@T* M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T* M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T* M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T* M("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\ M=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^0V]N=F5R=&EB;&4@<')E9F5R M<F5D('-T;V-K+"!N970@<')O8V5E9',\+W1D/@T*("`@("`@("`\=&0@8VQA M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA M<W,],T1N=6UP/CDL,S`P+#`P,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@ M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@ M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@ M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@ M/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA M<W,],T1P;"!V86QI9VX],T1T;W`^0V]N=F5R=&EB;&4@<')E9F5R<F5D('-T M;V-K(&-O;G9E<G1E9"!I;G1O(&-O;6UO;B!S=&]C:SPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S<STS1&YU;7`^,2PS-#4L,#`P/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F@^#0H@("`@("`@ M(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y397)I97,@0B!#;VYV97)T M:6)L92!0<F5F97)R960@4W1O8VL@6TUE;6)E<ET\+W1D/@T*("`@("`@("`\ M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\ M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\ M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\ M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\ M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\ M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\ M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\ M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\ M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\ M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\ M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\ M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\ M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\ M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T M<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,] M,T1P;"!V86QI9VX],T1T;W`^/'-T<F]N9SY#;&%S<R!O9B!3=&]C:R!;3&EN M92!)=&5M<UT\+W-T<F]N9SX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT M<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX] M,T1T;W`^0V]N=F5R=&EB;&4@<')E9F5R<F5D('-T;V-K+"!I<W-U960@<VAA M<F5S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XR,RPP,C8\<W!A M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A M;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,] M,T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D-O M;G9E<G1I8FQE('!R969E<G)E9"!S=&]C:RP@;F5T('!R;V-E961S/"]T9#X- M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X- M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X- M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X- M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X- M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X- M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X- M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X- M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X- M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X- M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X- M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X- M"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ,BPS,#`L,#`P/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^ M#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y!;6]U;G0@ M8GD@=VAI8V@@9F%I<B!V86QU92!O9B!C;VUM;VX@<W1O8VL@97AC965D960@ M=&AE(&%L;&]C871E9"!P=7)C:&%S92!P<FEC93PO=&0^#0H@("`@("`@(#QT M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S<STS1&YU;7`^)"`Q+#,P,"PP,#`\<W!A;CX\+W-P86X^/"]T9#X- M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X- M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X- M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X- M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X- M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X- M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X- M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X- M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X- M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X- M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X- M"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@ M/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D-O;G9E<G1I8FQE('!R969E M<G)E9"!S=&]C:R!C;VYV97)T960@:6YT;R!C;VUM;VX@<W1O8VL\+W1D/@T* M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T* M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T* M("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$L,#`P/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-"PP,#`\<W!A;CX\+W-P M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ-2PP,C8\<W!A M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XT+#`P M,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP M/C$L,#`P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@ M/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG M;CTS1'1O<#Y097)C96YT86=E(&QI;6ET(&]N(&YU;6)E<B!O9B!S:&%R97,@ M;V8@8V]M;6]N('-T;V-K(&5X97)C:7-A8FQE(&)Y(&AO;&1E<G,\+W1D/@T* M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T* M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T* M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T* M("`@("`@("`\=&0@8VQA<W,],T1N=6UP/CDN.3@E/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@ M("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y%;G1I=&QE9"!P87EM M96YT('!E<B!S:&%R92!D=7)I;F<@;&EQ=6ED871I;VX\+W1D/@T*("`@("`@ M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@ M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@ M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@ M("`\=&0@8VQA<W,],T1N=6UP/B0@,"XP,#$\<W!A;CX\+W-P86X^/"]T9#X- M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X- M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X- M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X- M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X- M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X- M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X- M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X- M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X- M"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XD(#`N,#`Q/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@ M("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y0<F5F97)R960@ M<W1O8VL@869T97(@<W1O8VL@<W!L:70\+W1D/@T*("`@("`@("`\=&0@8VQA M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA M<W,],T1N=6UP/C$V-BXV-SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\ M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\ M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\ M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\ M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\ M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\ M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\ M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\ M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\ M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\ M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\ M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T M<CX-"B`@("`@(#QT<B!C;&%S<STS1')H/@T*("`@("`@("`\=&0@8VQA<W,] M,T1P;"!V86QI9VX],T1T;W`^4V5R:65S($(@0V]N=F5R=&EB;&4@4')E9F5R M<F5D(%-T;V-K(%M-96UB97)=('P@25!/(%M-96UB97)=/"]T9#X-"B`@("`@ M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@ M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@ M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@ M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@ M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@ M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@ M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@ M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@ M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@ M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@ M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@ M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@ M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@ M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@ M(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L M87-S/3-$<&P@=F%L:6=N/3-$=&]P/CQS=')O;F<^0VQA<W,@;V8@4W1O8VL@ M6TQI;F4@271E;7-=/"]S=')O;F<^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@ M("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L M:6=N/3-$=&]P/D-O;G9E<G1I8FQE('!R969E<G)E9"!S=&]C:RP@<'5R8VAA M<V4@<')I8V4\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B0@-S8P M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@(#PO=&%B;&4^ M#0H@(#PO8F]D>3X-"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT4&%R=%\S.6,P M96$V,E]C,C`S7S0U.&9?.&,U,%\S9&-A-#4V838Y-3$-"D-O;G1E;G0M3&]C M871I;VXZ(&9I;&4Z+R\O0SHO,SEC,&5A-C)?8S(P,U\T-3AF7SAC-3!?,V1C M830U-F$V.34Q+U=O<FMS:&5E=',O4VAE970V,"YH=&UL#0I#;VYT96YT+51R M86YS9F5R+45N8V]D:6YG.B!Q=6]T960M<')I;G1A8FQE#0I#;VYT96YT+51Y M<&4Z('1E>'0O:'1M;#L@8VAA<G-E=#TB=7,M87-C:6DB#0H-"CQH=&UL/@T* M("`\:&5A9#X-"B`@("`\345402!H='1P+65Q=6EV/3-$0V]N=&5N="U4>7!E M(&-O;G1E;G0],T0G=&5X="]H=&UL.R!C:&%R<V5T/75T9BTX)SX\<V-R:7!T M('1Y<&4],T1T97AT+VIA=F%S8W)I<'0@<W)C/3-$4VAO=RYJ<SXO*B!$;R!. M;W0@4F5M;W9E(%1H:7,@0V]M;65N="`J+SPO<V-R:7!T/CPO:&5A9#X-"B`@ M/&)O9'D^#0H@("`@/'1A8FQE(&-L87-S/3-$<F5P;W)T(&ED/3-$240P15-" M05$^#0H@("`@("`\='(^#0H@("`@("`@(#QT:"!C;&%S<STS1'1L(&-O;'-P M86X],T0Q(')O=W-P86X],T0R/CQS=')O;F<^4W1O8VMH;VQD97)S)R!%<75I M='D@+2!!9&1I=&EO;F%L($EN9F]R;6%T:6]N("A$971A:6PI("A54T0@)"D\ M8G(^/"]S=')O;F<^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@@8V]L M<W!A;CTS1#,^,"!-;VYT:',@16YD960\+W1H/@T*("`@("`@("`\=&@@8VQA M<W,],T1T:"!C;VQS<&%N/3-$,CXQ($UO;G1H<R!%;F1E9#PO=&@^#0H@("`@ M("`@(#QT:"!C;&%S<STS1'1H(&-O;'-P86X],T0Q/C,@36]N=&AS($5N9&5D M/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@@8V]L<W!A;CTS1#,^,3(@ M36]N=&AS($5N9&5D/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@@8V]L M<W!A;CTS1#$^,2!-;VYT:',@16YD960\+W1H/@T*("`@("`@("`\=&@@8VQA M<W,],T1T:"!C;VQS<&%N/3-$,CXP($UO;G1H<R!%;F1E9#PO=&@^#0H@("`@ M("`@(#QT:"!C;&%S<STS1'1H(&-O;'-P86X],T0R/C,@36]N=&AS($5N9&5D M/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@@8V]L<W!A;CTS1#$^/"]T M:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@@8V]L<W!A;CTS1#$^/"]T:#X- M"B`@("`@("`@/'1H(&-L87-S/3-$=&@@8V]L<W!A;CTS1#$^/"]T:#X-"B`@ M("`@("`@/'1H(&-L87-S/3-$=&@@8V]L<W!A;CTS1#$^/"]T:#X-"B`@("`@ M(#PO='(^#0H@("`@("`\='(^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/DIU M;BX@,C0L(#(P,3,\8G(^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^ M2G5N+B`R-2P@,C`Q,CQB<CX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T M:#Y!<'(N(#(P+"`R,#$Q/&)R/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS M1'1H/DIU;BX@,S`L(#(P,3,\8G(^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S M/3-$=&@^07!R+B`S,"P@,C`Q,SQB<CX\+W1H/@T*("`@("`@("`\=&@@8VQA M<W,],T1T:#Y*=6XN(#,P+"`R,#$R/&)R/CPO=&@^#0H@("`@("`@(#QT:"!C M;&%S<STS1'1H/D1E8RX@,S$L(#(P,30\8G(^/"]T:#X-"B`@("`@("`@/'1H M(&-L87-S/3-$=&@^1&5C+B`S,2P@,C`Q,SQB<CX\+W1H/@T*("`@("`@("`\ M=&@@8VQA<W,],T1T:#Y$96,N(#,Q+"`R,#$R/&)R/CPO=&@^#0H@("`@("`@ M(#QT:"!C;&%S<STS1'1H/D9E8BX@,C@L(#(P,30\8G(^/"]T:#X-"B`@("`@ M("`@/'1H(&-L87-S/3-$=&@^2G5L+B`P,BP@,C`Q,SQB<CX\+W1H/@T*("`@ M("`@("`\=&@@8VQA<W,],T1T:#Y397`N(#(V+"`R,#$R/&)R/CPO=&@^#0H@ M("`@("`@(#QT:"!C;&%S<STS1'1H/DIU;BX@,S`L(#(P,3,\8G(^/"]T:#X- M"B`@("`@("`@/'1H(&-L87-S/3-$=&@^36%R+B`S,2P@,C`Q,SQB<CX\+W1H M/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y$96,N(#,Q+"`R,#$Q/&)R/CPO M=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/D%U9RX@,S$L(#(P,3$\8G(^ M/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^36%Y(#$X+"`R,#$Q/&)R M/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/D9E8BX@,C@L(#(P,3,\ M8G(^/"]T:#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X- M"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/CQS=')O;F<^ M4VAA<F4@0F%S960@0V]M<&5N<V%T:6]N(%M,:6YE($ET96US73PO<W1R;VYG M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@ M("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y#;VUM;VX@<W1O M8VLL(&%U=&AO<FEZ960\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP M/C@Q+#4P,"PP,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L M87-S/3-$;G5M<#XX,2PU,#`L,#`P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S<STS1&YU;7`^,C0U+#`P,"PP,#`\<W!A;CX\+W-P86X^ M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ-S`L,#`P+#`P,#QS M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S M<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^ M4F5V97)S92!S=&]C:R!S<&QI="P@8V]N=F5R<VEO;B!R871I;SPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,"XQ-C<\<W!A;CX\+W-P86X^/"]T M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XP+C$V-SQS<&%N/CPO<W!A M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A M;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T* M("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^5V%R<F%N=',@ M<'5R8VAA<V4@=7!O;B!E>&5R8VES92!O9B!C;VUM;VX@<W1O8VL\+W1D/@T* M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T* M("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C<L.#DT+#<P-#QS<&%N/CPO<W!A M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A M;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T* M("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^1W)O<W,@<')O M8V5E9',@9G)O;2!P=6)L:6,@;V9F97)I;F=S/"]T9#X-"B`@("`@("`@/'1D M(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D M(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D M(&-L87-S/3-$;G5M<#XD(#(P+#$P,"PP,#`\<W!A;CX\+W-P86X^/"]T9#X- M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X- M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X- M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X- M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X- M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X- M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X- M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X- M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X- M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X- M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X- M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X- M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X- M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X- M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X- M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X- M"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@ M/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E=A<G)A;G1S(&ES<W5A;F-E M(&-O<W0\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$P,"PP,#`\ M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\ M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\ M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\ M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\ M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\ M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XY M.#0L,#`P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@ M/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG M;CTS1'1O<#Y!9V=R96=A=&4@<'5R8VAA<V4@<')I8V4\+W1D/@T*("`@("`@ M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@ M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@ M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@ M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@ M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@ M("`\=&0@8VQA<W,],T1N=6UP/C,R+#$P,"PP,#`\<W!A;CX\+W-P86X^/"]T M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XT."PY-S$L,#`P/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-RPT-3`L M,#`P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU M;7`^-#,L-C<W+#`P,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@ M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@ M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@ M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@ M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@ M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@ M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@ M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@ M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@ M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX- M"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P M;"!V86QI9VX],T1T;W`^4')E9F5R<F5D(%-T;V-K(&-O;G9E<G1E9"!I;G1O M(&-O;6UO;B!S=&]C:RP@<F%T:6\\+W1D/@T*("`@("`@("`\=&0@8VQA<W,] M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,] M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,] M,T1N=6UP/C`N,#`Q/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T* M("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L M('9A;&EG;CTS1'1O<#Y#;VUM;VX@<W1O8VLL('-H87)E<R!I<W-U960\+W1D M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D M/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/CDL,S(P+#$W-CQS<&%N/CPO M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C,X+#8U.2PW M,S@\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M M<#XS,"PV.#$L-C(T/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T* M("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L M('9A;&EG;CTS1'1O<#Y097(@<VAA<F4@<')I8V4@;V8@8V]M;6]N('-T;V-K M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^ M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XD(#0N-38\<W!A;CX\ M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\ M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\ M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\ M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\ M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XD(#@\<W!A M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XD(#0N M-38\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@ M8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$ M=&]P/D%G9W)E9V%T92!G<F]S<R!P<F]C965D<R!F<F]M(&ES<W5A;F-E/"]T M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XV,"PP,#`L,#`P/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$ M<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y)<W-U M86YC92!C;W-T(&]F(&-O;6UO;B!S=&]C:RP@=F%L=64\+W1D/@T*("`@("`@ M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@ M("`\=&0@8VQA<W,],T1N=6UP/C0L,#`P+#`P,#QS<&%N/CPO<W!A;CX\+W1D M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D M/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C(L.#`P+#`P,#QS<&%N/CPO M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C(L,3,Y+#`P M,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C M;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T M;W`^3F5T('!R;V-E961S(&9R;VT@:7-S=64@;V8@<W1O8VL@86YD('=A<G)A M;G0@=&\@<'5B;&EC/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\ M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XU M-BPP,#`L,#`P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@ M("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A M;&EG;CTS1'1O<#Y.=6UB97(@;V8@:7-S=65D('-H87)E<R!O9B!C;VUM;VX@ M<W1O8VL@<F5L871E9"!T;R!C87-H;&5S<R!E>&5R8VES92!O9B!W87)R86YT M<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,S4X+#0V,#QS<&%N M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N M/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS M1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^26YC M<F5A<V5D(&EN(&YU;6)E<B!O9B!S:&%R97,@;V8@8V]M;6]N('-T;V-K/"]T M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XR+#`P,"PP,#`\<W!A;CX\ M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XT,38L-C8W M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L M87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O M<#Y3:&%R97,@879A:6QA8FQE(&9O<B!F=71U<F4@9W)A;G1S('5N9&5R('1H M92`Q.3DW(%!L86X\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$L M,C<P+#0W.#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,] M,T1N=6UP/C(L,38Q+#@R.3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\ M=&0@8VQA<W,],T1N=6UP/C@W."PW,C8\<W!A;CX\+W-P86X^/"]T9#X-"B`@ M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@ M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@ M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@ M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@ M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@ M("`@("`@/'1D(&-L87-S/3-$;G5M<#XU.#4L-#<V/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@ M("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y3=&]C:R!O<'1I;VX@ M9W)A;G1S('1O(&YO;BUE;7!L;WEE97,\+W1D/@T*("`@("`@("`\=&0@8VQA M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA M<W,],T1N=6UP/CDT-"PX,S$\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@ M/'1D(&-L87-S/3-$;G5M<#XW.3<L-C(Y/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-#`S+#$P.#QS<&%N/CPO<W!A;CX\ M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\ M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\ M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\ M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\ M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\ M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\ M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\ M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\ M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\ M+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@ M("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^06QL;V-A=&5D('-T M;V-K+6)A<V5D(&-O;7!E;G-A=&EO;B!E>'!E;G-E/"]T9#X-"B`@("`@("`@ M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@ M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@ M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@ M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@ M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@ M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@ M/'1D(&-L87-S/3-$;G5M<#XS+#,S,"PP,#`\<W!A;CX\+W-P86X^/"]T9#X- M"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XS+#4Y-RPP,#`\<W!A;CX\+W-P M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XS+#<X,RPP,#`\ M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\ M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\ M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\ M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\ M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\ M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\ M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\ M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\ M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\ M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA M<W,],T1R:#X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P M/D]P=&EO;G,@6TUE;6)E<ET\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT M<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX] M,T1T;W`^/'-T<F]N9SY3:&%R92!"87-E9"!#;VUP96YS871I;VX@6TQI;F4@ M271E;7-=/"]S=')O;F<^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@ M8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$ M=&]P/E5N<F5C;V=N:7IE9"!C;VUP96YS871I;VX@8V]S=#PO=&0^#0H@("`@ M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S<STS1&YU;7`^-2PW,#`L,#`P/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@ M("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y796EG:'1E9"UA=F5R M86=E('!E<FEO9#PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^,B!Y M96%R<R`V(&UO;G1H<R`W(&1A>7,\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@ M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@ M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@ M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@ M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@ M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@ M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@ M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@ M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@ M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@ M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@ M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@ M(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R:#X-"B`@("`@("`@/'1D(&-L M87-S/3-$<&P@=F%L:6=N/3-$=&]P/E)E<W1R:6-T960@4W1O8VL@56YI=',@ M6TUE;6)E<ET\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N M/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS M1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^/'-T M<F]N9SY3:&%R92!"87-E9"!#;VUP96YS871I;VX@6TQI;F4@271E;7-=/"]S M=')O;F<^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\ M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\ M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\ M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\ M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\ M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\ M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\ M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\ M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\ M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\ M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\ M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\ M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\ M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\ M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\ M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\ M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\ M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\ M+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R M93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E-H87)E M(&)A<V5D(&-O;7!E;G-A=&EO;BP@=F5S=&5D(')E<W1R:6-T960@<W1O8VL@ M=6YI=',L(&=R86YT(&1A=&4@9F%I<B!V86QU93PO=&0^#0H@("`@("`@(#QT M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S<STS1&YU;7`^,3`P+#`P,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@ M("`@("`\=&0@8VQA<W,],T1N=6UP/C$L-#`P+#`P,#QS<&%N/CPO<W!A;CX\ M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$L-C`P+#`P,#QS<&%N M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N M/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS M1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^56YR M96-O9VYI>F5D(&-O;7!E;G-A=&EO;B!C;W-T/"]T9#X-"B`@("`@("`@/'1D M(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D M(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D M(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D M(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D M(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D M(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D M(&-L87-S/3-$;G5M<#XS,#`L,#`P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C M;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y796EG:'1E9"UA=F5R86=E('!E<FEO M9#PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^.2!M;VYT:',@,CD@ M9&%Y<SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT M<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX] M,T1T;W`^4W1O8VL@;W!T:6]N(&=R86YT<R!T;R!N;VXM96UP;&]Y965S/"]T M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XP/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,#QS<&%N/CPO<W!A;CX\ M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\ M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\ M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\ M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\ M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\ M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\ M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\ M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\ M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\ M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\ M+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')H/@T*("`@ M("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^5V%R<F%N=',@=&\@ M4'5R8VAA<V4@0V]M;6]N(%-T;V-K(%M-96UB97)=/"]T9#X-"B`@("`@("`@ M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@ M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@ M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@ M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@ M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@ M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@ M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@ M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@ M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@ M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@ M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@ M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@ M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@ M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@ M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@ M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@ M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@ M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO M='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S M/3-$<&P@=F%L:6=N/3-$=&]P/CQS=')O;F<^4VAA<F4@0F%S960@0V]M<&5N M<V%T:6]N(%M,:6YE($ET96US73PO<W1R;VYG/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R M/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS M1'!L('9A;&EG;CTS1'1O<#Y787)R86YT<R!P=7)C:&%S92!U<&]N(&5X97)C M:7-E(&]F(&-O;6UO;B!S=&]C:SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS M1&YU;7`^-RPX.30L-S`T/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R M/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS M1'!L('9A;&EG;CTS1'1O<#Y787)R86YT<R!P=7)C:&%S92!U<&]N(&5X97)C M:7-E(&]F(&-O;6UO;B!S=&]C:RP@97AE<F-I<V4@<')I8V4\+W1D/@T*("`@ M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@ M("`@("`\=&0@8VQA<W,],T1N=6UP/B0@-2XR.#QS<&%N/CPO<W!A;CX\+W1D M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D M/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@ M("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^1W)O<W,@<')O8V5E9',@ M9G)O;2!P=6)L:6,@;V9F97)I;F=S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S M/3-$;G5M<#XT+#4P,"PP,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@ M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@ M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@ M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@ M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@ M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@ M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@ M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@ M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@ M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@ M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@ M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@ M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@ M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@ M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@ M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO M='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S M/3-$<&P@=F%L:6=N/3-$=&]P/E=A<G)A;G1S+"!V86QU960\+W1D/@T*("`@ M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@ M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@ M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@ M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@ M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@ M("`@("`\=&0@8VQA<W,],T1N=6UP/C$T+#<P,"PP,#`\<W!A;CX\+W-P86X^ M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^ M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^ M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^ M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^ M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^ M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^ M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^ M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^ M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^ M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^ M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^ M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^ M/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@ M("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D=R;W-S('!R;V-E M961S(&]F('1H92!O9F9E<FEN9SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS M1&YU;7`^,30L-S`P+#`P,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\ M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\ M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\ M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\ M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\ M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\ M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\ M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\ M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\ M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\ M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\ M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\ M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\ M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\ M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\ M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\ M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T M<CX-"B`@("`@(#QT<B!C;&%S<STS1')H/@T*("`@("`@("`\=&0@8VQA<W,] M,T1P;"!V86QI9VX],T1T;W`^5V%R<F%N=',@=&\@4'5R8VAA<V4@0V]M;6]N M(%-T;V-K(%M-96UB97)=/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@ M8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$ M=&]P/CQS=')O;F<^4VAA<F4@0F%S960@0V]M<&5N<V%T:6]N(%M,:6YE($ET M96US73PO<W1R;VYG/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L M87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O M<#Y787)R86YT<R!P=7)C:&%S92!U<&]N(&5X97)C:7-E(&]F(&-O;6UO;B!S M=&]C:SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,2PP,#`\<W!A M;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,] M,T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E=A M<G)A;G1S('!U<F-H87-E('5P;VX@97AE<F-I<V4@;V8@8V]M;6]N('-T;V-K M+"!E>&5R8VES92!P<FEC93PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU M;7`^)"`U+C(X/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@ M("`@/'1R(&-L87-S/3-$<F@^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A M;&EG;CTS1'1O<#XR,#`T(%!L86X@6TUE;6)E<ET\+W1D/@T*("`@("`@("`\ M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\ M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\ M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\ M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\ M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\ M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\ M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\ M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\ M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\ M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\ M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\ M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\ M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\ M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\ M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\ M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\ M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\ M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T M<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,] M,T1P;"!V86QI9VX],T1T;W`^/'-T<F]N9SY3:&%R92!"87-E9"!#;VUP96YS M871I;VX@6TQI;F4@271E;7-=/"]S=')O;F<^/"]T9#X-"B`@("`@("`@/'1D M(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D M(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D M(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D M(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D M(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D M(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D M(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D M(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D M(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D M(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D M(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D M(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D M(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D M(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D M(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D M(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D M(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D M(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^ M#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$ M<&P@=F%L:6=N/3-$=&]P/D]P=&EO;B!G<F%N="!P<FEC97,@87,@<&5R8V5N M=&%G92!O9B!T:&4@9F%I<B!M87)K970@=F%L=64@;V8@=&AE(&-O;6UO;B!S M=&]C:SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,3`P+C`P)3QS M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S M<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^ M5&5R;2!T;R!G<F%N="!N;VYS=&%T=71O<GD@<W1O8VL@;W!T:6]N<R!A;F0@ M:6YC96YT:79E('-T;V-K(&]P=&EO;G,\+W1D/@T*("`@("`@("`\=&0@8VQA M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA M<W,],T1T97AT/C$P('EE87)S/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\ M+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S M<STS1'!L('9A;&EG;CTS1'1O<#Y097)C96YT86=E(&]F(&]P=&EO;G,@9W)A M;G0@=&\@;F5W(&5M<&QO>65E<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS M1&YU;7`^,C4N,#`E/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T* M("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L M('9A;&EG;CTS1'1O<#Y);F-R96%S960@:6X@;G5M8F5R(&]F('-H87)E<R!O M9B!C;VUM;VX@<W1O8VL\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP M/C(L,#`P+#`P,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@ M("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V M86QI9VX],T1T;W`^4VAA<F5S(&]F(&-O;6UO;B!S=&]C:R!R97-E<G9E9"!F M;W(@:7-S=6%N8V4\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$L M,C<P+#0W.#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,] M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,] M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,] M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,] M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,] M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,] M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,] M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,] M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,] M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,] M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,] M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@ M(#QT<B!C;&%S<STS1')H/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI M9VX],T1T;W`^,C`P-"!0;&%N(%M-96UB97)=('P@3F5W($5M<&QO>65E(%M- M96UB97)=/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\ M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\ M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\ M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\ M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\ M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\ M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\ M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\ M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\ M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\ M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\ M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\ M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\ M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\ M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\ M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\ M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\ M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\ M+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R M;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/CQS=')O M;F<^4VAA<F4@0F%S960@0V]M<&5N<V%T:6]N(%M,:6YE($ET96US73PO<W1R M;VYG/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^ M#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y!=V%R9"!V M97-T:6YG(')I9VAT/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\ M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\ M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\ M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\ M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\ M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\ M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#Y/ M<'1I;VYS(&=R86YT960@=&\@;F5W(&5M<&QO>65E<R!G96YE<F%L;'D@('9E M<W0@,C4E(&%F=&5R(&]N92!Y96%R(&%N9"!M;VYT:&QY('1H97)E869T97(@ M;W9E<B!A('!E<FEO9"!O9B!F;W5R('EE87)S+CQS<&%N/CPO<W!A;CX\+W1D M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D M/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@ M("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^4&5R:6]D(&9R;VT@<&5R M8V5N=&%G92!O9B!S=&]C:R!O<'1I;VX@=F5S=&5D/"]T9#X-"B`@("`@("`@ M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@ M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@ M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@ M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@ M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@ M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@ M/'1D(&-L87-S/3-$=&5X=#XQ('EE87(\<W!A;CX\+W-P86X^/"]T9#X-"B`@ M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@ M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@ M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@ M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@ M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@ M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@ M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@ M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@ M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@ M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@ M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@ M("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D M(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E9E<W1I;F<@<&5R:6]D(&]F(&]P M=&EO;G,\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/C0@>65A<G,\ M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\ M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\ M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\ M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\ M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\ M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\ M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\ M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\ M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\ M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\ M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\ M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA M<W,],T1R:#X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P M/C(P,#0@4&QA;B!;365M8F5R72!\($5X:7-T:6YG($5M<&QO>65E(%M-96UB M97)=/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P M86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X- M"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/CQS=')O;F<^ M4VAA<F4@0F%S960@0V]M<&5N<V%T:6]N(%M,:6YE($ET96US73PO<W1R;VYG M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@ M("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y!=V%R9"!V97-T M:6YG(')I9VAT/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#Y/<'1I M;VYS(&=R86YT960@=&\@97AI<W1I;F<@96UP;&]Y965S(&=E;F5R86QL>2!V M97-T(&UO;G1H;'D@;W9E<B!A('!E<FEO9"!O9B`@9F]U<B!Y96%R<RX\<W!A M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A M;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,] M,T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E9E M<W1I;F<@<&5R:6]D(&]F(&]P=&EO;G,\+W1D/@T*("`@("`@("`\=&0@8VQA M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA M<W,],T1T97AT/C0@>65A<G,\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@ M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@ M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@ M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@ M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@ M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@ M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@ M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@ M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@ M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@ M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@ M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO M='(^#0H@("`@("`\='(@8VQA<W,],T1R:#X-"B`@("`@("`@/'1D(&-L87-S M/3-$<&P@=F%L:6=N/3-$=&]P/C$Y.3<@4&QA;B!;365M8F5R73PO=&0^#0H@ M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT M9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#X\<W1R;VYG/E-H87)E($)A<V5D M($-O;7!E;G-A=&EO;B!;3&EN92!)=&5M<UT\+W-T<F]N9SX\+W1D/@T*("`@ M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@ M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@ M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@ M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@ M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@ M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@ M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@ M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@ M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@ M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@ M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@ M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@ M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@ M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@ M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@ M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@ M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@ M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@ M("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@ M8VQA<W,],T1P;"!V86QI9VX],T1T;W`^4&5R('-H87)E('!R:6-E(&]F(&-O M;6UO;B!S=&]C:SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^)"`X M+C`Q/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R M(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS M1'1O<#Y!=V%R9"!V97-T:6YG(')I9VAT/"]T9#X-"B`@("`@("`@/'1D(&-L M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L M87-S/3-$=&5X=#Y/<'1I;VYS(&=R86YT960@=6YD97(@=&AE(#$Y.3<@4&QA M;B`@9V5N97)A;&QY('9E<W1E9"!O=F5R(&9O=7(@;W(@9FEV92!Y96%R<R`H M9V5N97)A;&QY(#(U)2!A9G1E<B!O;F4@>65A<B!A;F0@(&UO;G1H;'D@=&AE M<F5A9G1E<BDN/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@ M("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A M;&EG;CTS1'1O<#Y3:&%R97,@;V8@8V]M;6]N('-T;V-K(')E<V5R=F5D(&9O M<B!I<W-U86YC93PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,#QS M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S M<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^ M5&5R;2!F;W(@<W1O8VL@;W!T:6]N(%!L86X\+W1D/@T*("`@("`@("`\=&0@ M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@ M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@ M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@ M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@ M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@ M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@ M8VQA<W,],T1T97AT/C$P('EE87)S/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C M;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y097)C96YT86=E(&]F('-T;V-K:&]L M9&5R/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ,"XP,"4\<W!A M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A M;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,] M,T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E1E M<FT@;V8@9W)A;G0\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/C4@ M>65A<G,\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$ M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$ M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$ M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$ M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$ M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$ M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$ M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$ M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$ M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$ M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$ M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\ M='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N M/3-$=&]P/E-T;V-K(&]P=&EO;B!R97!U<F-H87-E(&UA>&EM=6T@<&5R:6]D M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^ M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^ M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^ M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^ M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^ M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^ M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XQ,"!Y96%R<SQS<&%N M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N M/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS M1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^4VAA M<F5S(&%V86EL86)L92!F;W(@9G5T=7)E(&=R86YT<R!U;F1E<B!T:&4@,3DY M-R!0;&%N/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\ M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\ M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\ M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\ M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\ M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\ M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XP/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$ M<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y3:&%R M92!B87-E9"!C;VUP96YS871I;VXL(&]P=&EO;G,@97AE<F-I<V5D+"!T;W1A M;"!I;G1R:6YS:6,@=F%L=64\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N M=6UP/C$L,#`P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M<STS1&YU;7`^,3`W+#`P,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\ M=&0@8VQA<W,],T1N=6UP/C`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@ M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@ M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@ M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@ M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@ M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@ M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@ M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@ M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@ M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO M='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S M/3-$<&P@=F%L:6=N/3-$=&]P/E=E:6=H=&5D+6%V97)A9V4@9W)A;G0@9&%T M92!F86ER('9A;'5E(&]F(&]P=&EO;G,@9W)A;G1E9#PO=&0^#0H@("`@("`@ M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S<STS1&YU;7`^)"`V+C`Q/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S<STS1&YU;7`^)"`S+C@U/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^)"`S+C@Y/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^ M#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y.=6UB97(@ M;V8@;W!T:6]N('-H87)E<R!V97-T960\+W1D/@T*("`@("`@("`\=&0@8VQA M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA M<W,],T1N=6UP/C8P,2PV-#<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@ M/'1D(&-L87-S/3-$;G5M<#XT-3<L-#8U/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,S0X+#8Y,SQS<&%N/CPO<W!A;CX\ M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\ M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\ M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\ M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\ M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\ M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\ M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\ M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\ M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\ M+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@ M("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^1W)A;G0@9&%T92!F M86ER('9A;'5E(&]F(&]P=&EO;B!S:&%R97,@=F5S=&5D/"]T9#X-"B`@("`@ M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@ M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@ M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@ M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@ M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@ M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@ M("`@/'1D(&-L87-S/3-$;G5M<#XS+#`P,"PP,#`\<W!A;CX\+W-P86X^/"]T M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XR+#,P,"PP,#`\<W!A;CX\ M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XR+#0P,"PP M,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@ M8VQA<W,],T1R:#X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$ M=&]P/DYO;BUE;7!L;WEE92!3=&]C:RU"87-E9"!#;VUP96YS871I;VX@6TUE M;6)E<ET\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO M<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E M/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^/'-T<F]N M9SY3:&%R92!"87-E9"!#;VUP96YS871I;VX@6TQI;F4@271E;7-=/"]S=')O M;F<^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P M86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX- M"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E-T;V-K(&]P M=&EO;B!G<F%N=',@=&\@;F]N+65M<&QO>65E<SPO=&0^#0H@("`@("`@(#QT M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S<STS1&YU;7`^,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\ M=&0@8VQA<W,],T1N=6UP/C`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@ M/'1D(&-L87-S/3-$;G5M<#XP/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\ M+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S M<STS1'!L('9A;&EG;CTS1'1O<#Y!;&QO8V%T960@<W1O8VLM8F%S960@8V]M M<&5N<V%T:6]N(&5X<&5N<V4\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N M=6UP/C4P+#`P,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA M<W,],T1N=6UP/C$P-"PP,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@ M/'1D(&-L87-S/3-$;G5M<#XU-BPP,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@ M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@ M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@ M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@ M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@ M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@ M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@ M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@ M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@ M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@ M("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R:#X-"B`@("`@("`@/'1D M(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D534%`@6TUE;6)E<ET\+W1D/@T* M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T* M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T* M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T* M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T* M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T* M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T* M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T* M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T* M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T* M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T* M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T* M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T* M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T* M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T* M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T* M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T* M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T* M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T* M("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\ M=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^/'-T<F]N9SY3:&%R92!"87-E M9"!#;VUP96YS871I;VX@6TQI;F4@271E;7-=/"]S=')O;F<^/"]T9#X-"B`@ M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@ M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@ M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@ M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@ M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@ M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@ M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@ M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@ M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@ M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@ M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@ M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@ M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@ M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@ M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@ M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@ M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@ M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@ M("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D M(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D]P=&EO;B!G<F%N="!P<FEC97,@ M87,@<&5R8V5N=&%G92!O9B!T:&4@9F%I<B!M87)K970@=F%L=64@;V8@=&AE M(&-O;6UO;B!S=&]C:SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^ M.#4N,#`E/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@ M/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG M;CTS1'1O<#Y3:&%R97,@;V8@8V]M;6]N('-T;V-K(')E<V5R=F5D(&9O<B!I M<W-U86YC93PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,3<P+#$W M,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C M;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T M;W`^0V]M;6]N('-T;V-K('-H87)E<R!I<W-U960\+W1D/@T*("`@("`@("`\ M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\ M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\ M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\ M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\ M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\ M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\ M=&0@8VQA<W,],T1N=6UP/C$Y+#<R-CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@ M("`@("`\=&0@8VQA<W,],T1N=6UP/C$T+#DX-3QS<&%N/CPO<W!A;CX\+W1D M/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$U+#`Q,#QS<&%N/CPO<W!A M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A M;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T* M("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^0V]M;6]N('-T M;V-K(&%V97)A9V4@<')I8V4@<&5R('-H87)E/"]T9#X-"B`@("`@("`@/'1D M(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D M(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D M(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D M(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D M(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D M(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D M(&-L87-S/3-$;G5M<#XD(#,N,S@\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@ M("`@/'1D(&-L87-S/3-$;G5M<#XD(#,N-C8\<W!A;CX\+W-P86X^/"]T9#X- M"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XD(#0N,S(\<W!A;CX\+W-P86X^ M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^ M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^ M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^ M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^ M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^ M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^ M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^ M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^ M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^ M/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R:#X-"B`@ M("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D1E97)F:65L9"!! M9W)E96UE;G0@6TUE;6)E<ET\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT M<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX] M,T1T;W`^/'-T<F]N9SY3:&%R92!"87-E9"!#;VUP96YS871I;VX@6TQI;F4@ M271E;7-=/"]S=')O;F<^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@ M8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$ M=&]P/E=A<G)A;G1S('!U<F-H87-E('5P;VX@97AE<F-I<V4@;V8@8V]M;6]N M('-T;V-K/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\ M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\ M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ+#$Q-"PQ M-C@\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@ M8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$ M=&]P/E=A<G)A;G1S('!U<F-H87-E('5P;VX@97AE<F-I<V4@;V8@8V]M;6]N M('-T;V-K+"!E>&5R8VES92!P<FEC93PO=&0^#0H@("`@("`@(#QT9"!C;&%S M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M<STS1&YU;7`^)"`Y+CD\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D M(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D M(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D M(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D M(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D M(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D M(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D M(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D M(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D M(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D M(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D M(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D M(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D M(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D M(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D M(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^ M#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$ M<&P@=F%L:6=N/3-$=&]P/DYE="!P<F]C965D<R!F<F]M(&ES<W5A;F-E(&]F M('=A<G)A;G1S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XT+#0P M,"PP,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$ M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$ M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$ M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$ M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$ M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$ M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$ M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$ M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$ M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$ M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$ M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$ M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$ M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$ M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$ M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\ M='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N M/3-$=&]P/E!E<F-E;G1A9V4@;&EM:70@;VX@;G5M8F5R(&]F('-H87)E<R!O M9B!C;VUM;VX@<W1O8VL@97AE<F-I<V%B;&4@8GD@:&]L9&5R<SPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S<STS1&YU;7`^.2XY."4\<W!A;CX\+W-P86X^/"]T M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T M9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@ M("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D]W;F5R<VAI<"!P97)C M96YT86=E(&)Y(&%F9FEL:6%T97,@86YD(&]T:&5R(&AO;&1E<G,@869T97(@ M97AE<F-I<V4@;V8@=V%R<F%N=#PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS M1&YU;7`^.2XY."4\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@ M("`@("`\='(@8VQA<W,],T1R:#X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@ M=F%L:6=N/3-$=&]P/D1E97)F:65L9"!!9W)E96UE;G0@6TUE;6)E<ET@?"!7 M87)R86YT<R!T;R!0=7)C:&%S92!#;VUM;VX@4W1O8VL@6TUE;6)E<ET\+W1D M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D M/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@ M("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^/'-T<F]N9SY3:&%R92!" M87-E9"!#;VUP96YS871I;VX@6TQI;F4@271E;7-=/"]S=')O;F<^/"]T9#X- M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X- M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X- M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X- M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X- M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X- M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X- M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X- M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X- M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X- M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X- M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X- M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X- M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X- M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X- M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X- M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X- M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X- M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X- M"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@ M/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E=A<G)A;G1S('!U<F-H87-E M('5P;VX@97AE<F-I<V4@;V8@8V]M;6]N('-T;V-K/"]T9#X-"B`@("`@("`@ M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@ M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@ M/'1D(&-L87-S/3-$;G5M<#XQ+#$Q-"PQ-C@\<W!A;CX\+W-P86X^/"]T9#X- M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X- M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X- M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X- M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X- M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X- M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X- M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X- M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X- M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X- M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X- M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X- M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X- M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X- M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X- M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X- M"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@ M/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E=A<G)A;G1S('!U<F-H87-E M('5P;VX@97AE<F-I<V4@;V8@8V]M;6]N('-T;V-K+"!E>&5R8VES92!P<FEC M93PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^)"`Y+CD\<W!A;CX\ M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\ M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\ M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\ M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\ M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\ M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\ M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\ M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\ M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\ M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\ M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\ M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\ M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\ M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\ M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\ M+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R M93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E=A<G)A M;G1S+"!V86QU960\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C4L M.#`P+#`P,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,] M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,] M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,] M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,] M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,] M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,] M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,] M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,] M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,] M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,] M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,] M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,] M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,] M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,] M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,] M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@ M(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI M9VX],T1T;W`^4FES:RUF<F5E(&EN=&5R97-T(')A=&4\+W1D/@T*("`@("`@ M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@ M("`\=&0@8VQA<W,],T1N=6UP/C`N-S,E/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,2XV-B4\<W!A;CX\+W-P86X^/"]T M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T M9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@ M("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E9O;&%T:6QI='D@;V8@ M=V%R<F%N=',\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C<V+C`P M)3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP M/C@P+C`P)3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,] M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,] M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,] M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,] M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,] M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,] M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,] M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,] M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,] M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,] M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,] M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,] M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,] M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,] M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,] M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@ M(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI M9VX],T1T;W`^1F%I<B!V86QU92!O9B!W87)R86YT<SPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S<STS1&YU;7`^,38L,C`P+#`P,#QS<&%N/CPO<W!A;CX\+W1D M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D M/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@ M("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^0V]N=')A8W1U86P@=&5R M;3PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^-2!Y96%R<SQS<&%N M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N M/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS M1')H/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^1&5E M<F9I96QD(%M-96UB97)=/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@ M8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$ M=&]P/CQS=')O;F<^4VAA<F4@0F%S960@0V]M<&5N<V%T:6]N(%M,:6YE($ET M96US73PO<W1R;VYG/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L M87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O M<#Y787)R86YT<R!I<W-U86YC92!C;W-T/"]T9#X-"B`@("`@("`@/'1D(&-L M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L M87-S/3-$;G5M<#XR,#`L,#`P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\ M+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S M<STS1'!L('9A;&EG;CTS1'1O<#Y!9V=R96=A=&4@<'5R8VAA<V4@<')I8V4\ M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\ M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\ M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$Y+#DP,"PP,#`\<W!A M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A M;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,] M,T1R:#X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/DU, M5B!;365M8F5R73PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S M/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#X\ M<W1R;VYG/E-H87)E($)A<V5D($-O;7!E;G-A=&EO;B!;3&EN92!)=&5M<UT\ M+W-T<F]N9SX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N M/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS M1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^0V]N M=F5R=&EB;&4@<')E9F5R<F5D('-T;V-K+"!I<W-U960@<VAA<F5S/"]T9#X- M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X- M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X- M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X- M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X- M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X- M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X- M"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XR+#,Y-RPR-S@\<W!A;CX\+W-P M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P M86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X- M"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/DYE="!P<F]C M965D<R!F<F]M('-A;&5S(&]F(&-O;6UO;B!S=&]C:SPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S<STS1&YU;7`^,34L,C`P+#`P,#QS<&%N/CPO<W!A;CX\+W1D M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D M/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')H/@T*("`@("`@ M("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^56YD97)W<FET=&5N(%!U M8FQI8R!/9F9E<FEN9R!;365M8F5R73PO=&0^#0H@("`@("`@(#QT9"!C;&%S M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@ M("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A M;&EG;CTS1'1O<#X\<W1R;VYG/E-H87)E($)A<V5D($-O;7!E;G-A=&EO;B!; M3&EN92!)=&5M<UT\+W-T<F]N9SX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,] M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,] M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,] M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,] M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,] M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,] M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,] M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,] M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,] M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,] M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,] M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,] M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,] M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,] M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,] M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,] M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,] M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,] M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@ M(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI M9VX],T1T;W`^1W)O<W,@<')O8V5E9',@9G)O;2!P=6)L:6,@;V9F97)I;F=S M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^ M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^ M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^ M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^ M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^ M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^ M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^ M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^ M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^ M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XT,"PS,#`L,#`P/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S M/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y! M9V=R96=A=&4@<'5R8VAA<V4@<')I8V4\+W1D/@T*("`@("`@("`\=&0@8VQA M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA M<W,],T1N=6UP/C,W+#4P,"PP,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@ M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@ M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@ M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@ M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@ M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@ M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@ M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@ M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@ M(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L M87-S/3-$<&P@=F%L:6=N/3-$=&]P/D-O;6UO;B!S=&]C:RP@<VAA<F5S(&ES M<W5E9#PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-2PP,S$L,C4P M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L M87-S/3-$<F@^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O M<#Y-:6YI;75M(%M-96UB97)=('P@,3DY-R!0;&%N(%M-96UB97)=/"]T9#X- M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X- M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X- M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X- M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X- M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X- M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X- M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X- M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X- M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X- M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X- M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X- M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X- M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X- M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X- M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X- M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X- M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X- M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X- M"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@ M/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/CQS=')O;F<^4VAA<F4@0F%S M960@0V]M<&5N<V%T:6]N(%M,:6YE($ET96US73PO<W1R;VYG/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT M9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y/<'1I;VX@9W)A;G0@<')I8V5S M(&%S('!E<F-E;G1A9V4@;V8@=&AE(&9A:7(@;6%R:V5T('9A;'5E(&]F('1H M92!C;VUM;VX@<W1O8VL\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP M/C$Q,"XP,"4\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@ M("`\='(@8VQA<W,],T1R:#X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L M:6=N/3-$=&]P/DUI;FEM=6T@6TUE;6)E<ET@?"`Q.3DW(%!L86X@6TUE;6)E M<ET@?"!/<'1I;VYS(%M-96UB97)=/"]T9#X-"B`@("`@("`@/'1D(&-L87-S M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@ M("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L M:6=N/3-$=&]P/CQS=')O;F<^4VAA<F4@0F%S960@0V]M<&5N<V%T:6]N(%M, M:6YE($ET96US73PO<W1R;VYG/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@ M/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG M;CTS1'1O<#Y/<'1I;VX@9W)A;G0@<')I8V5S(&%S('!E<F-E;G1A9V4@;V8@ M=&AE(&9A:7(@;6%R:V5T('9A;'5E(&]F('1H92!C;VUM;VX@<W1O8VL\+W1D M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D M/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$P,"XP,"4\<W!A;CX\+W-P M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P M86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R:#X- M"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/DUI;FEM=6T@ M6TUE;6)E<ET@?"`Q.3DW(%!L86X@6TUE;6)E<ET@?"!.;VX@4W1A='5T;W)Y M(%-T;V-K($]P=&EO;G,@6TUE;6)E<ET\+W1D/@T*("`@("`@("`\=&0@8VQA M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@ M("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V M86QI9VX],T1T;W`^/'-T<F]N9SY3:&%R92!"87-E9"!#;VUP96YS871I;VX@ M6TQI;F4@271E;7-=/"]S=')O;F<^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@ M("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L M:6=N/3-$=&]P/D]P=&EO;B!G<F%N="!P<FEC97,@87,@<&5R8V5N=&%G92!O M9B!T:&4@9F%I<B!M87)K970@=F%L=64@;V8@=&AE(&-O;6UO;B!S=&]C:SPO M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^.#4N,#`E/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F@^ M#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y#;VUM;VX@ M4W1O8VL@6TUE;6)E<ET\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C M;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T M;W`^/'-T<F]N9SY3:&%R92!"87-E9"!#;VUP96YS871I;VX@6TQI;F4@271E M;7-=/"]S=')O;F<^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\ M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\ M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\ M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\ M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\ M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\ M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\ M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\ M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\ M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\ M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\ M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\ M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\ M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\ M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\ M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\ M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\ M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\ M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA M<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P M/D=R;W-S('!R;V-E961S(&9R;VT@<'5B;&EC(&]F9F5R:6YG<SPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-BPR,#`L,#`P/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@ M("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y#;VUM;VX@<W1O M8VL@:7-S=65D('!U<G-U86YT('1O('-E<FEE<R!!('!R969E<G)E9"!S=&]C M:R!C;VYV97)S:6]N/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\ M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\ M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\ M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\ M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\ M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\ M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\ M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\ M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\ M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\ M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XV M-C8L-C@Q/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS M1&YU;7`^,2PS-#4L,#`P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S<STS1&YU;7`^,BPU,#0L,S,T/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-C8V+#8V-SQS<&%N/CPO<W!A;CX\ M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\ M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\ M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\ M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\ M+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@ M("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^0V]M;6]N('-T;V-K M('-H87)E<R!I<W-U960\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP M/C$Y+#<R-CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,] M,T1N=6UP/C$T+#DX-3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@ M8VQA<W,],T1N=6UP/C$U+#`Q,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@ M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@ M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@ M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@ M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@ M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@ M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@ M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@ M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@ M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@ M/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')H/@T*("`@("`@("`\=&0@8VQA M<W,],T1P;"!V86QI9VX],T1T;W`^0V]M;6]N(%-T;V-K(%M-96UB97)=('P@ M1&5E<F9I96QD($%G<F5E;65N="!;365M8F5R73PO=&0^#0H@("`@("`@(#QT M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R M/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS M1'!L('9A;&EG;CTS1'1O<#X\<W1R;VYG/E-H87)E($)A<V5D($-O;7!E;G-A M=&EO;B!;3&EN92!)=&5M<UT\+W-T<F]N9SX\+W1D/@T*("`@("`@("`\=&0@ M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@ M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@ M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@ M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@ M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@ M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@ M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@ M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@ M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@ M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@ M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@ M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@ M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@ M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@ M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@ M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@ M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@ M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX- M"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P M;"!V86QI9VX],T1T;W`^0V]N=F5R=&EB;&4@<')E9F5R<F5D('-T;V-K+"!I M<W-U960@<VAA<F5S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\ M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\ M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XX M.#,L,S,S/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@ M/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG M;CTS1'1O<#Y#;VUM;VX@<W1O8VL@<')I8V4@<&5R('-H87)E/"]T9#X-"B`@ M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@ M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@ M("`@("`@/'1D(&-L87-S/3-$;G5M<#XD(#D\<W!A;CX\+W-P86X^/"]T9#X- M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X- M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X- M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X- M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X- M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X- M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X- M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X- M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X- M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X- M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X- M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X- M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X- M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X- M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X- M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X- M"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R:#X-"B`@("`@("`@ M/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D%M9V5N(%M-96UB97)=/"]T M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T M9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@ M("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/CQS=')O;F<^4VAA<F4@ M0F%S960@0V]M<&5N<V%T:6]N(%M,:6YE($ET96US73PO<W1R;VYG/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@ M(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y!9V=R96=A=&4@<'5R8VAA M<V4@<')I8V4\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$P+#`P M,"PP,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$ M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$ M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$ M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$ M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$ M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$ M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$ M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$ M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$ M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$ M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$ M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$ M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$ M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$ M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\ M='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N M/3-$=&]P/D-O;6UO;B!S=&]C:RP@<VAA<F5S(&ES<W5E9#PO=&0^#0H@("`@ M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S<STS1&YU;7`^,2PT,#0L,3`P/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,2PT,#0L,3`P/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$ M<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y097(@ M<VAA<F4@<')I8V4@;V8@8V]M;6]N('-T;V-K/"]T9#X-"B`@("`@("`@/'1D M(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D M(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D M(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D M(&-L87-S/3-$;G5M<#X@-RXQ,CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@ M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@ M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@ M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@ M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@ M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@ M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@ M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@ M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@ M("`\=&0@8VQA<W,],T1N=6UP/B`W+C$R/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT M9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y#;VUM;VX@<W1O8VL@9F%I<B!V M86QU93PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-RPU,#`L,#`P M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L M87-S/3-$<F@^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O M<#Y!;6=E;B!;365M8F5R72!\($QI8V5N<V4@86YD(%-E<G9I8V5S(%M-96UB M97)=/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P M86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX- M"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/CQS=')O;F<^ M4VAA<F4@0F%S960@0V]M<&5N<V%T:6]N(%M,:6YE($ET96US73PO<W1R;VYG M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@ M("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y$969E<G)E9"!R M979E;G5E/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\ M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\ M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\ M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\ M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\ M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\ M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XR+#4P,"PP M,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@ M8VQA<W,],T1R:#X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$ M=&]P/D%S=&5L;&%S(%M-96UB97)=('P@06UE;F1E9"!!9W)E96UE;G0@6TUE M;6)E<ET\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO M<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E M/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^/'-T<F]N M9SY3:&%R92!"87-E9"!#;VUP96YS871I;VX@6TQI;F4@271E;7-=/"]S=')O M;F<^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P M86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX- M"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D%G9W)E9V%T M92!P=7)C:&%S92!P<FEC93PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU M;7`^,3`L,#`P+#`P,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@ M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@ M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@ M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@ M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@ M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@ M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@ M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@ M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@ M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@ M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@ M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX- M"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P M;"!V86QI9VX],T1T;W`^0V]M;6]N('-T;V-K+"!S:&%R97,@:7-S=65D/"]T M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XR+#`T,"PX,38\<W!A;CX\ M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\ M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\ M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\ M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\ M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\ M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\ M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\ M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\ M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\ M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\ M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\ M+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R M;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E!E<B!S M:&%R92!P<FEC92!O9B!C;VUM;VX@<W1O8VL\+W1D/@T*("`@("`@("`\=&0@ M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@ M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@ M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@ M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@ M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@ M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@ M8VQA<W,],T1N=6UP/B0@-"XY/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\ M+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S M<STS1'!L('9A;&EG;CTS1'1O<#Y#;VUM;VX@<W1O8VL@9F%I<B!V86QU93PO M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^.2PQ,#`L,#`P/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$ M<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y$969E M<G)E9"!R979E;G5E/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\ M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\ M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\ M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\ M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\ M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\ M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XS M,RPV,#`L,#`P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@ M("`@/'1R(&-L87-S/3-$<F@^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A M;&EG;CTS1'1O<#Y!<W1E;&QA<R!;365M8F5R72!\($%M96YD960@06=R965M M96YT(%M-96UB97)=('P@3&EC96YS92!A;F0@4V5R=FEC97,@6TUE;6)E<ET\ M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\ M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\ M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\ M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\ M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\ M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\ M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\ M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\ M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\ M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\ M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\ M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\ M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\ M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\ M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\ M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\ M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\ M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\ M+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@ M("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^/'-T<F]N9SY3:&%R M92!"87-E9"!#;VUP96YS871I;VX@6TQI;F4@271E;7-=/"]S=')O;F<^/"]T M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T M9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@ M("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D1E9F5R<F5D(')E=F5N M=64\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/CDP,"PP,#`\<W!A M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A M;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,] M,T1R:#X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E-E M<FEE<R!!($-O;G9E<G1I8FQE(%!R969E<G)E9"!3=&]C:R!;365M8F5R73PO M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@ M("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#X\<W1R;VYG/E-H87)E M($)A<V5D($-O;7!E;G-A=&EO;B!;3&EN92!)=&5M<UT\+W-T<F]N9SX\+W1D M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D M/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@ M("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^0V]M;6]N('-T;V-K('!R M:6-E('!E<B!S:&%R93PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^ M)"`Q+#4P,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,] M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,] M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,] M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,] M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,] M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,] M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,] M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,] M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,] M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,] M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,] M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,] M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,] M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,] M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,] M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@ M(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI M9VX],T1T;W`^1W)O<W,@<')O8V5E9',@9G)O;2!P=6)L:6,@;V9F97)I;F=S M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^ M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^ M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XY+#0P,"PP,#`\<W!A M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A M;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,] M,T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D5N M=&ET;&5D('!A>6UE;G0@<&5R('-H87)E(&1U<FEN9R!L:7%U:61A=&EO;CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^)"`P+C`P,3QS<&%N/CPO M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO M<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E M/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^0V]N=F5R M=&EB;&4@<')E9F5R<F5D('-T;V-K(&-O;G9E<G1E9"!I;G1O(&-O;6UO;B!S M=&]C:SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,2PP,#`\<W!A M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XX+#`W M,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C M;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T M;W`^0V]N=F5R=&EB;&4@<')E9F5R<F5D('-T;V-K+"!I<W-U960@<VAA<F5S M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^ M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^ M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^ M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^ M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^ M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^ M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XP/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,#QS<&%N/CPO<W!A M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A M;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')H/@T* M("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^4V5R:65S($$@ M0V]N=F5R=&EB;&4@4')E9F5R<F5D(%-T;V-K(%M-96UB97)=('P@1&5E<F9I M96QD($%G<F5E;65N="!;365M8F5R73PO=&0^#0H@("`@("`@(#QT9"!C;&%S M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@ M("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A M;&EG;CTS1'1O<#X\<W1R;VYG/E-H87)E($)A<V5D($-O;7!E;G-A=&EO;B!; M3&EN92!)=&5M<UT\+W-T<F]N9SX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,] M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,] M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,] M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,] M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,] M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,] M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,] M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,] M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,] M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,] M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,] M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,] M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,] M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,] M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,] M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,] M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,] M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,] M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@ M(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI M9VX],T1T;W`^0V]N=F5R=&EB;&4@<')E9F5R<F5D('-T;V-K+"!I<W-U960@ M<VAA<F5S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\ M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\ M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XX+#`W,#QS M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S M<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^ M0V]N=F5R=&EB;&4@<')E9F5R<F5D('-T;V-K(&-O;G9E<G1E9"!I;G1O(&-O M;6UO;B!S=&]C:SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,2PS M-#4L,#`P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@ M/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG M;CTS1'1O<#Y#;VYV97)T:6)L92!P<F5F97)R960@<W1O8VLL(&ES<W5E9"!S M:&%R97,\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C@L,#<P/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S M/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y0 M97(@<VAA<F4@<')I8V4@;V8@8V]M;6]N('-T;V-K/"]T9#X-"B`@("`@("`@ M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@ M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@ M/'1D(&-L87-S/3-$;G5M<#XD(#$L-3`P/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F@^#0H@("`@("`@(#QT M9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y397)I97,@0B!#;VYV97)T:6)L M92!0<F5F97)R960@4W1O8VL@6TUE;6)E<ET\+W1D/@T*("`@("`@("`\=&0@ M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@ M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@ M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@ M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@ M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@ M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@ M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@ M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@ M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@ M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@ M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@ M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@ M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@ M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@ M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@ M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@ M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@ M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX- M"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P M;"!V86QI9VX],T1T;W`^/'-T<F]N9SY3:&%R92!"87-E9"!#;VUP96YS871I M;VX@6TQI;F4@271E;7-=/"]S=')O;F<^/"]T9#X-"B`@("`@("`@/'1D(&-L M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@ M("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@ M=F%L:6=N/3-$=&]P/D5N=&ET;&5D('!A>6UE;G0@<&5R('-H87)E(&1U<FEN M9R!L:7%U:61A=&EO;CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^ M)"`P+C`P,3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,] M,T1N=6UP/B0@,"XP,#$\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D M(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D M(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D M(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D M(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D M(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D M(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D M(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D M(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D M(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D M(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D M(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^ M#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$ M<&P@=F%L:6=N/3-$=&]P/D-O;G9E<G1I8FQE('!R969E<G)E9"!S=&]C:R!C M;VYV97)T960@:6YT;R!C;VUM;VX@<W1O8VL\+W1D/@T*("`@("`@("`\=&0@ M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@ M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@ M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@ M8VQA<W,],T1N=6UP/C$L,#`P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S<STS1&YU;7`^,2PP,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@ M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@ M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@ M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@ M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@ M("`@("`@/'1D(&-L87-S/3-$;G5M<#XT+#`P,#QS<&%N/CPO<W!A;CX\+W1D M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D M/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$U+#`R-CQS<&%N/CPO<W!A M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C0L,#`P/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$ M<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y#;VYV M97)T:6)L92!P<F5F97)R960@<W1O8VLL(&ES<W5E9"!S:&%R97,\+W1D/@T* M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T* M("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C(S+#`R-CQS<&%N/CPO<W!A;CX\ M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\ M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\ M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\ M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\ M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\ M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\ M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\ M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\ M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\ M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\ M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\ M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\ M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\ M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\ M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\ M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\ M+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@ M("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^27-S=64@;V8@<V5R M:65S($(@8V]N=F5R=&EB;&4@<')E9F5R<F5D('-T;V-K('-H87)E('!R:6-E M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^ M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XD(#<V,#QS<&%N/CPO M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO M<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E M/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^27-S=6%N M8V4@8V]S="!O9B!C;VUM;VX@<W1O8VLL('9A;'5E/"]T9#X-"B`@("`@("`@ M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@ M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@ M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@ M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@ M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@ M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@ M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@ M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@ M/'1D(&-L87-S/3-$;G5M<#XX.#$L,#`P/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT M9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y!;&QO8V%T960@<'5R8VAA<V4@ M<')I8V4\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B0@,3,L,C`P M+#`P,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT M<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX] M,T1T;W`^4&5R8V5N=&%G92!L:6UI="!O;B!N=6UB97(@;V8@<VAA<F5S(&]F M(&-O;6UO;B!S=&]C:R!E>&5R8VES86)L92!B>2!H;VQD97)S/"]T9#X-"B`@ M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@ M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@ M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@ M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@ M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@ M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@ M("`@("`@/'1D(&-L87-S/3-$;G5M<#XY+CDX)3QS<&%N/CPO<W!A;CX\+W1D M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D M/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')H/@T*("`@("`@ M("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^069T97(@4F5V97)S92!3 M=&]C:R!3<&QI="!;365M8F5R72!\($1E97)F:65L9"!!9W)E96UE;G0@6TUE M;6)E<ET\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO M<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E M/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^/'-T<F]N M9SY3:&%R92!"87-E9"!#;VUP96YS871I;VX@6TQI;F4@271E;7-=/"]S=')O M;F<^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P M86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX- M"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D9A:7(@=F%L M=64@;V8@8V]M;6]N('-T;V-K/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$ M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$ M;G5M<#XD(#,N-S@\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@ M("`@("`\='(@8VQA<W,],T1R:#X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@ M=F%L:6=N/3-$=&]P/D%F=&5R(%)E=F5R<V4@4W1O8VL@4W!L:70@6TUE;6)E M<ET@?"!$965R9FEE;&0@06=R965M96YT(%M-96UB97)=('P@5V%R<F%N=',@ M=&\@4'5R8VAA<V4@0V]M;6]N(%-T;V-K(%M-96UB97)=/"]T9#X-"B`@("`@ M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@ M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@ M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@ M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@ M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@ M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@ M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@ M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@ M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@ M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@ M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@ M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@ M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@ M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@ M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@ M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@ M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@ M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@ M(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L M87-S/3-$<&P@=F%L:6=N/3-$=&]P/CQS=')O;F<^4VAA<F4@0F%S960@0V]M M<&5N<V%T:6]N(%M,:6YE($ET96US73PO<W1R;VYG/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\ M+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S M<STS1'!L('9A;&EG;CTS1'1O<#Y&86ER('9A;'5E(&]F(&-O;6UO;B!S=&]C M:SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^)"`Y+C$R/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$ M<F@^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y"969O M<F4@061J=7-T;65N="!2979E<G-E(%-T;V-K(%-P;&ET(%M-96UB97)=('P@ M1&5E<F9I96QD($%G<F5E;65N="!;365M8F5R73PO=&0^#0H@("`@("`@(#QT M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R M/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS M1'!L('9A;&EG;CTS1'1O<#X\<W1R;VYG/E-H87)E($)A<V5D($-O;7!E;G-A M=&EO;B!;3&EN92!)=&5M<UT\+W-T<F]N9SX\+W1D/@T*("`@("`@("`\=&0@ M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@ M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@ M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@ M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@ M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@ M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@ M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@ M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@ M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@ M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@ M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@ M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@ M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@ M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@ M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@ M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@ M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@ M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX- M"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P M;"!V86QI9VX],T1T;W`^1F%I<B!V86QU92!O9B!C;VUM;VX@<W1O8VL\+W1D M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D M/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B0@,"XV,SQS<&%N/CPO<W!A M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A M;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')H/@T* M("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^0F5F;W)E($%D M:G5S=&UE;G0@4F5V97)S92!3=&]C:R!3<&QI="!;365M8F5R72!\($1E97)F M:65L9"!!9W)E96UE;G0@6TUE;6)E<ET@?"!787)R86YT<R!T;R!0=7)C:&%S M92!#;VUM;VX@4W1O8VL@6TUE;6)E<ET\+W1D/@T*("`@("`@("`\=&0@8VQA M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@ M("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V M86QI9VX],T1T;W`^/'-T<F]N9SY3:&%R92!"87-E9"!#;VUP96YS871I;VX@ M6TQI;F4@271E;7-=/"]S=')O;F<^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@ M("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L M:6=N/3-$=&]P/D9A:7(@=F%L=64@;V8@8V]M;6]N('-T;V-K/"]T9#X-"B`@ M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@ M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@ M("`@("`@/'1D(&-L87-S/3-$;G5M<#XD(#$N-3(\<W!A;CX\+W-P86X^/"]T M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T M9#X-"B`@("`@(#PO='(^#0H@("`@/"]T86)L93X-"B`@/"]B;V1Y/@T*/"]H M=&UL/@T*#0HM+2TM+2T]7TYE>'1087)T7S,Y8S!E838R7V,R,#-?-#4X9E\X M8S4P7S-D8V$T-39A-CDU,0T*0V]N=&5N="U,;V-A=&EO;CH@9FEL93HO+R]# M.B\S.6,P96$V,E]C,C`S7S0U.&9?.&,U,%\S9&-A-#4V838Y-3$O5V]R:W-H M965T<R]3:&5E=#8Q+FAT;6P-"D-O;G1E;G0M5')A;G-F97(M16YC;V1I;F<Z M('%U;W1E9"UP<FEN=&%B;&4-"D-O;G1E;G0M5'EP93H@=&5X="]H=&UL.R!C M:&%R<V5T/2)U<RUA<V-I:2(-"@T*/&AT;6P^#0H@(#QH96%D/@T*("`@(#Q- M151!(&AT='`M97%U:78],T1#;VYT96YT+51Y<&4@8V]N=&5N=#TS1"=T97AT M+VAT;6P[(&-H87)S970]=71F+3@G/CQS8W)I<'0@='EP93TS1'1E>'0O:F%V M87-C<FEP="!S<F,],T13:&]W+FIS/B\J($1O($YO="!296UO=F4@5&AI<R!# M;VUM96YT("HO/"]S8W)I<'0^/"]H96%D/@T*("`\8F]D>3X-"B`@("`\=&%B M;&4@8VQA<W,],T1R97!O<G0@:60],T1)1#!%04Y!13X-"B`@("`@(#QT<CX- M"B`@("`@("`@/'1H(&-L87-S/3-$=&P@8V]L<W!A;CTS1#$@<F]W<W!A;CTS M1#(^/'-T<F]N9SY3=&]C:VAO;&1E<G,G($5Q=6ET>2`M($]U='-T86YD:6YG M(%=A<G)A;G1S("A$971A:6PI("A54T0@)"D\8G(^/"]S=')O;F<^/"]T:#X- M"B`@("`@("`@/'1H(&-L87-S/3-$=&@@8V]L<W!A;CTS1#$^,3(@36]N=&AS M($5N9&5D/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@@8V]L<W!A;CTS M1#$^/"]T:#X-"B`@("`@(#PO='(^#0H@("`@("`\='(^#0H@("`@("`@(#QT M:"!C;&%S<STS1'1H/D1E8RX@,S$L(#(P,30\8G(^/"]T:#X-"B`@("`@("`@ M/'1H(&-L87-S/3-$=&@^2G5N+B`R-2P@,C`Q,CQB<CX\+W1H/@T*("`@("`@ M/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA M<W,],T1P;"!V86QI9VX],T1T;W`^/'-T<F]N9SY3:&%R92!"87-E9"!#;VUP M96YS871I;VX@6TQI;F4@271E;7-=/"]S=')O;F<^/"]T9#X-"B`@("`@("`@ M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@ M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO M='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S M/3-$<&P@=F%L:6=N/3-$=&]P/DYU;6)E<B!O9B!3:&%R97,\+W1D/@T*("`@ M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@ M("`@("`\=&0@8VQA<W,],T1N=6UP/C<L.#DT+#<P-#QS<&%N/CPO<W!A;CX\ M+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')H/@T*("`@ M("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^27-S=65D(#0O,C`O M,C`Q,2!;365M8F5R73PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L M87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O M<#X\<W1R;VYG/E-H87)E($)A<V5D($-O;7!E;G-A=&EO;B!;3&EN92!)=&5M M<UT\+W-T<F]N9SX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S M<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^ M3G5M8F5R(&]F(%-H87)E<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU M;7`^,2PQ,30L,38X/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T* M("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L M('9A;&EG;CTS1'1O<#Y%>&5R8VES92!0<FEC93PO=&0^#0H@("`@("`@(#QT M9"!C;&%S<STS1&YU;7`^)"`Y+CD\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@ M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@ M(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L M87-S/3-$<&P@=F%L:6=N/3-$=&]P/D5X<&ER871I;VX@1&%T93PO=&0^#0H@ M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^07!R(#(P+`T*"0DR,#$U/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$ M<F@^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y)<W-U M960@-B\R-2\R,#$R(%M-96UB97)=/"]T9#X-"B`@("`@("`@/'1D(&-L87-S M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@ M("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L M:6=N/3-$=&]P/CQS=')O;F<^4VAA<F4@0F%S960@0V]M<&5N<V%T:6]N(%M, M:6YE($ET96US73PO<W1R;VYG/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@ M/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG M;CTS1'1O<#Y.=6UB97(@;V8@4VAA<F5S/"]T9#X-"B`@("`@("`@/'1D(&-L M87-S/3-$;G5M<#XU+#4W-BPY,C@\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@ M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@ M(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L M87-S/3-$<&P@=F%L:6=N/3-$=&]P/D5X97)C:7-E(%!R:6-E/"]T9#X-"B`@ M("`@("`@/'1D(&-L87-S/3-$;G5M<#XD(#4N,C@\<W!A;CX\+W-P86X^/"]T M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T M9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@ M("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D5X<&ER871I;VX@1&%T M93PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^2G5N(#(U+`T*"0DR M,#$W/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@(#PO=&%B M;&4^#0H@(#PO8F]D>3X-"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT4&%R=%\S M.6,P96$V,E]C,C`S7S0U.&9?.&,U,%\S9&-A-#4V838Y-3$-"D-O;G1E;G0M M3&]C871I;VXZ(&9I;&4Z+R\O0SHO,SEC,&5A-C)?8S(P,U\T-3AF7SAC-3!? M,V1C830U-F$V.34Q+U=O<FMS:&5E=',O4VAE970V,BYH=&UL#0I#;VYT96YT M+51R86YS9F5R+45N8V]D:6YG.B!Q=6]T960M<')I;G1A8FQE#0I#;VYT96YT M+51Y<&4Z('1E>'0O:'1M;#L@8VAA<G-E=#TB=7,M87-C:6DB#0H-"CQH=&UL M/@T*("`\:&5A9#X-"B`@("`\345402!H='1P+65Q=6EV/3-$0V]N=&5N="U4 M>7!E(&-O;G1E;G0],T0G=&5X="]H=&UL.R!C:&%R<V5T/75T9BTX)SX\<V-R M:7!T('1Y<&4],T1T97AT+VIA=F%S8W)I<'0@<W)C/3-$4VAO=RYJ<SXO*B!$ M;R!.;W0@4F5M;W9E(%1H:7,@0V]M;65N="`J+SPO<V-R:7!T/CPO:&5A9#X- M"B`@/&)O9'D^#0H@("`@/'1A8FQE(&-L87-S/3-$<F5P;W)T(&ED/3-$240P M14A80D<^#0H@("`@("`\='(^#0H@("`@("`@(#QT:"!C;&%S<STS1'1L(&-O M;'-P86X],T0Q(')O=W-P86X],T0R/CQS=')O;F<^4W1O8VMH;VQD97)S)R!% M<75I='D@+2!3=6UM87)Y(&]F(%-T;V-K($]P=&EO;B!!8W1I=FET>2`H1&5T M86EL*2`H55-$("0I/&)R/DEN(%1H;W5S86YD<RP@97AC97!T(%-H87)E(&1A M=&$L('5N;&5S<R!O=&AE<G=I<V4@<W!E8VEF:65D/"]S=')O;F<^/"]T:#X- M"B`@("`@("`@/'1H(&-L87-S/3-$=&@@8V]L<W!A;CTS1#,^,3(@36]N=&AS M($5N9&5D/"]T:#X-"B`@("`@(#PO='(^#0H@("`@("`\='(^#0H@("`@("`@ M(#QT:"!C;&%S<STS1'1H/D1E8RX@,S$L(#(P,30\8G(^/"]T:#X-"B`@("`@ M("`@/'1H(&-L87-S/3-$=&@^1&5C+B`S,2P@,C`Q,SQB<CX\+W1H/@T*("`@ M("`@("`\=&@@8VQA<W,],T1T:#Y$96,N(#,Q+"`R,#$R/&)R/CPO=&@^#0H@ M("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT M9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#X\<W1R;VYG/E-H87)E+6)A<V5D M($-O;7!E;G-A=&EO;B!!<G)A;F=E;65N="!B>2!3:&%R92UB87-E9"!087EM M96YT($%W87)D(%M,:6YE($ET96US73PO<W1R;VYG/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\ M+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S M<STS1'!L('9A;&EG;CTS1'1O<#Y3:&%R97,@079A:6QA8FQE(&9O<B!'<F%N M="!O9B!/<'1I;VX@;W(@07=A<F0L($)E9VEN;FEN9R!"86QA;F-E/"]T9#X- M"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XR+#$V,2PX,CD\<W!A;CX\+W-P M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XX-S@L-S(V/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-3@U M+#0W-CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT M<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX] M,T1T;W`^4VAA<F5S($%V86EL86)L92!F;W(@1W)A;G0@;V8@3W!T:6]N(&]R M($%W87)D+"!);F-R96%S92!I;B!A=71H;W)I>F5D('-H87)E<SPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,BPP,#`L,#`P/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-#$V+#8V-SQS<&%N M/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS M1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^4VAA M<F5S($%V86EL86)L92!F;W(@1W)A;G0@;V8@3W!T:6]N(&]R($%W87)D+"!/ M<'1I;VYS(&=R86YT960\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6T^ M*#DT-"PX,S$I/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M<STS1&YU;3XH-SDW+#8R.2D\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@ M/'1D(&-L87-S/3-$;G5M/B@T,#,L,3`X*3QS<&%N/CPO<W!A;CX\+W1D/@T* M("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\ M=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^4VAA<F5S($%V86EL86)L92!F M;W(@1W)A;G0@;V8@3W!T:6]N(&]R($%W87)D+"!/<'1I;VYS(&5X97)C:7-E M9#PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,#QS<&%N/CPO<W!A M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C`\<W!A;CX\+W-P M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P M86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX- M"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E-H87)E<R!! M=F%I;&%B;&4@9F]R($=R86YT(&]F($]P=&EO;B!O<B!!=V%R9"P@3W!T:6]N M<R!F;W)F96ET960O97AP:7)E9#PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS M1&YU;7`^.34L.3@P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S<STS1&YU;7`^,3$W+#,Y-#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@ M("`\=&0@8VQA<W,],T1N=6UP/C(Q,"PY.#D\<W!A;CX\+W-P86X^/"]T9#X- M"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@ M/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E-H87)E<R!!=F%I;&%B;&4@ M9F]R($=R86YT(&]F($]P=&EO;B!O<B!!=V%R9"P@16YD:6YG($)A;&%N8V4\ M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$L,C<P+#0W.#QS<&%N M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C(L,38Q M+#@R.3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N M=6UP/C@W."PW,C8\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@ M("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@ M=F%L:6=N/3-$=&]P/E-T;V-K($]P=&EO;G,@3W5T<W1A;F1I;F<L($)E9VEN M;FEN9R!"86QA;F-E/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XR M+#0T.2PS-C4\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S M/3-$;G5M<#XQ+#<Y,"PU,C<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@ M/'1D(&-L87-S/3-$;G5M<#XQ+#4Y."PT,#@\<W!A;CX\+W-P86X^/"]T9#X- M"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@ M/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E-T;V-K($]P=&EO;G,@3W5T M<W1A;F1I;F<L($]P=&EO;G,@9W)A;G1E9#PO=&0^#0H@("`@("`@(#QT9"!C M;&%S<STS1&YU;7`^.30T+#@S,3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@ M("`\=&0@8VQA<W,],T1N=6UP/C<Y-RPV,CD\<W!A;CX\+W-P86X^/"]T9#X- M"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XT,#,L,3`X/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@ M("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y3=&]C:R!/<'1I M;VYS($]U='-T86YD:6YG+"!/<'1I;VYS(&9O<F9E:71E9"]E>'!I<F5D/"]T M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B@Y-2PY.#`I/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;3XH,3$W+#,Y-"D\ M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B@R M,3`L.3@Y*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@ M(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI M9VX],T1T;W`^4W1O8VL@3W!T:6]N<R!/=71S=&%N9&EN9RP@16YD:6YG($)A M;&%N8V4\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C,L,CDW+#@R M-CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP M/C(L-#0Y+#,V-3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA M<W,],T1N=6UP/C$L-SDP+#4R-SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@ M/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA M<W,],T1P;"!V86QI9VX],T1T;W`^5V5I9VAT960@079E<F%G92!%>&5R8VES M92!0<FEC92!P97(@4VAA<F4@+2!3=&]C:R!/<'1I;VYS+"!"96=I;FYI;F<@ M0F%L86YC93PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^)"`Q-2XQ M-3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP M/B0@,3@N.38\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S M/3-$;G5M<#XD(#(Q+CDS/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R M/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS M1'!L('9A;&EG;CTS1'1O<#Y3=&]C:R!/<'1I;VYS($]U='-T86YD:6YG+"!% M>&5R8VES86)L93PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,BPQ M-#`L-S4T/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@ M/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG M;CTS1'1O<#Y796EG:'1E9"!!=F5R86=E($5X97)C:7-E(%!R:6-E('!E<B!3 M:&%R92`M(%-T;V-K($]P=&EO;G,L($]P=&EO;G,@9W)A;G1E9#PO=&0^#0H@ M("`@("`@(#QT9"!C;&%S<STS1&YU;7`^)"`X+C@\<W!A;CX\+W-P86X^/"]T M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XD(#4N.34\<W!A;CX\+W-P M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XD(#8N,30\<W!A M;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,] M,T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E-T M;V-K($]P=&EO;G,@3W5T<W1A;F1I;F<L(%9E<W1E9"!A;F0@97AP96-T960@ M=&\@=F5S=#PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,RPR-S<L M-#@Y/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R M(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS M1'1O<#Y796EG:'1E9"!!=F5R86=E($5X97)C:7-E(%!R:6-E('!E<B!3:&%R M92`M(%-T;V-K($]P=&EO;G,L($]P=&EO;G,@97AE<F-I<V5D/"]T9#X-"B`@ M("`@("`@/'1D(&-L87-S/3-$;G5M<#XD(#8\<W!A;CX\+W-P86X^/"]T9#X- M"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XD(#4N,S(\<W!A;CX\+W-P86X^ M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^ M/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@ M("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E=E:6=H=&5D($%V M97)A9V4@17AE<F-I<V4@4')I8V4@<&5R(%-H87)E("T@4W1O8VL@3W!T:6]N M<RP@3W!T:6]N<R!F;W)F96ET960O97AP:7)E9#PO=&0^#0H@("`@("`@(#QT M9"!C;&%S<STS1&YU;7`^)"`S.2XW-#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@ M("`@("`\=&0@8VQA<W,],T1N=6UP/B0@,3(N-34\<W!A;CX\+W-P86X^/"]T M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XD(#$W/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@ M("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y796EG:'1E9"!! M=F5R86=E($5X97)C:7-E(%!R:6-E('!E<B!3:&%R92`M(%-T;V-K($]P=&EO M;G,L($5N9&EN9R!"86QA;F-E/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$ M;G5M<#XD(#$R+C8R/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S<STS1&YU;7`^)"`Q-2XQ-3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@ M("`\=&0@8VQA<W,],T1N=6UP/B0@,3@N.38\<W!A;CX\+W-P86X^/"]T9#X- M"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@ M/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E=E:6=H=&5D($%V97)A9V4@ M17AE<F-I<V4@4')I8V4@<&5R(%-H87)E("T@4W1O8VL@3W!T:6]N<RP@17AE M<F-I<V%B;&4\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B0@,34N M,3<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@ M8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$ M=&]P/E=E:6=H=&5D($%V97)A9V4@17AE<F-I<V4@4')I8V4@<&5R(%-H87)E M("T@4W1O8VL@3W!T:6]N<RP@5F5S=&5D(&%N9"!E>'!E8W1E9"!T;R!V97-T M+"!/=71S=&%N9&EN9SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^ M)"`Q,BXV-#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,] M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,] M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@ M(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI M9VX],T1T;W`^5V5I9VAT960@079E<F%G92!296UA:6YI;F<@0V]N=')A8W1U M86P@3&EF93PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^-B!Y96%R M<R`Y(&UO;G1H<R`Q-2!D87ES/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\ M+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S M<STS1'!L('9A;&EG;CTS1'1O<#Y796EG:'1E9"!!=F5R86=E(%)E;6%I;FEN M9R!#;VYT<F%C='5A;"!,:69E+"!%>&5R8VES86)L92!A="!$96-E;6)E<B`S M,2P@,C`Q-#PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^-2!Y96%R M<R`Y(&UO;G1H<R`T(&1A>7,\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@ M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@ M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO M='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S M/3-$<&P@=F%L:6=N/3-$=&]P/E=E:6=H=&5D($%V97)A9V4@4F5M86EN:6YG M($-O;G1R86-T=6%L($QI9F4L(%9E<W1E9"!A;F0@97AP96-T960@=&\@=F5S M="!A<R!O9B!$96-E;6)E<B`S,2P@,C`Q-#PO=&0^#0H@("`@("`@(#QT9"!C M;&%S<STS1'1E>'0^-B!Y96%R<R`Y(&UO;G1H<R`Q,2!D87ES/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^ M#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y!9V=R96=A M=&4@26YT<FEN<VEC(%9A;'5E/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$ M;G5M<#XD(#(L-C4W/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T* M("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L M('9A;&EG;CTS1'1O<#Y!9V=R96=A=&4@26YT<FEN<VEC(%9A;'5E+"!%>&5R M8VES86)L92!A="!$96-E;6)E<B`S,2P@,C`Q-#PO=&0^#0H@("`@("`@(#QT M9"!C;&%S<STS1&YU;7`^,2PU-3,\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@ M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@ M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@ M(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L M87-S/3-$<&P@=F%L:6=N/3-$=&]P/D%G9W)E9V%T92!);G1R:6YS:6,@5F%L M=64L(%9E<W1E9"!A;F0@97AP96-T960@=&\@=F5S="!A<R!O9B!$96-E;6)E M<B`S,2P@,C`Q-#PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^)"`R M+#8T,CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT M<B!C;&%S<STS1')H/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX] M,T1T;W`^0V]M;6]N(%-T;V-K(%M-96UB97)=/"]T9#X-"B`@("`@("`@/'1D M(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D M(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D M(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^ M#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$ M<&P@=F%L:6=N/3-$=&]P/CQS=')O;F<^4VAA<F4M8F%S960@0V]M<&5N<V%T M:6]N($%R<F%N9V5M96YT(&)Y(%-H87)E+6)A<V5D(%!A>6UE;G0@07=A<F0@ M6TQI;F4@271E;7-=/"]S=')O;F<^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@ M("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L M:6=N/3-$=&]P/E-T;V-K($]P=&EO;G,@3W5T<W1A;F1I;F<L($]P=&EO;G,@ M97AE<F-I<V5D/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B@S.3`I M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;3XH M,C$L,SDW*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,] M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@ M(#QT<B!C;&%S<STS1')H/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI M9VX],T1T;W`^4F5S=')I8W1E9"!3=&]C:R!5;FET<R!;365M8F5R73PO=&0^ M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@ M(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#X\<W1R;VYG/E-H87)E+6)A M<V5D($-O;7!E;G-A=&EO;B!!<G)A;F=E;65N="!B>2!3:&%R92UB87-E9"!0 M87EM96YT($%W87)D(%M,:6YE($ET96US73PO<W1R;VYG/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C M;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y3:&%R97,@079A:6QA8FQE(&9O<B!' M<F%N="!O9B!/<'1I;VX@;W(@07=A<F0L(%)E<W1R:6-T960@<W1O8VL@=6YI M=',@9W)A;G1E9#PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;3XH-#,L M-3`P*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N M=6T^*#0Q+#8V,2D\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@ M("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@ M=F%L:6=N/3-$=&]P/E-H87)E<R!!=F%I;&%B;&4@9F]R($=R86YT(&]F($]P M=&EO;B!O<B!!=V%R9"P@4F5S=')I8W1E9"!S=&]C:R!U;FET<R!F;W)F96ET M960\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$L,#`P/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-"PY.3D\ M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XV M."PW,#(\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\ M='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N M/3-$=&]P/E-H87)E<R!!=F%I;&%B;&4@9F]R($=R86YT(&]F($]P=&EO;B!O M<B!!=V%R9"P@3W!T:6]N<R!G<F%N=&5D/"]T9#X-"B`@("`@("`@/'1D(&-L M87-S/3-$;G5M<#XP/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S<STS1&YU;7`^,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@ M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX- M"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P M;"!V86QI9VX],T1T;W`^4W1O8VL@3W!T:6]N<R!/=71S=&%N9&EN9RP@3W!T M:6]N<R!&;W)F96ET960\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP M/C`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M M<#XP/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU M;7`^,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT M<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX] M,T1T;W`^5V5I9VAT960@079E<F%G92!%>&5R8VES92!0<FEC92!P97(@4VAA M<F4@+2!3=&]C:R!/<'1I;VYS+"!297-T<FEC=&5D('-T;V-K('5N:71S(&=R M86YT960\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B0@,#QS<&%N M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B0@,#QS M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S M<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^ M5V5I9VAT960@079E<F%G92!%>&5R8VES92!0<FEC92!P97(@4VAA<F4@+2!3 M=&]C:R!/<'1I;VYS+"!297-T<FEC=&5D('-T;V-K('5N:71S(&9O<F9E:71E M9#PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^)"`P/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^)"`P/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^)"`P/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@(#PO=&%B;&4^#0H@ M(#PO8F]D>3X-"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT4&%R=%\S.6,P96$V M,E]C,C`S7S0U.&9?.&,U,%\S9&-A-#4V838Y-3$-"D-O;G1E;G0M3&]C871I M;VXZ(&9I;&4Z+R\O0SHO,SEC,&5A-C)?8S(P,U\T-3AF7SAC-3!?,V1C830U M-F$V.34Q+U=O<FMS:&5E=',O4VAE970V,RYH=&UL#0I#;VYT96YT+51R86YS M9F5R+45N8V]D:6YG.B!Q=6]T960M<')I;G1A8FQE#0I#;VYT96YT+51Y<&4Z M('1E>'0O:'1M;#L@8VAA<G-E=#TB=7,M87-C:6DB#0H-"CQH=&UL/@T*("`\ M:&5A9#X-"B`@("`\345402!H='1P+65Q=6EV/3-$0V]N=&5N="U4>7!E(&-O M;G1E;G0],T0G=&5X="]H=&UL.R!C:&%R<V5T/75T9BTX)SX\<V-R:7!T('1Y M<&4],T1T97AT+VIA=F%S8W)I<'0@<W)C/3-$4VAO=RYJ<SXO*B!$;R!.;W0@ M4F5M;W9E(%1H:7,@0V]M;65N="`J+SPO<V-R:7!T/CPO:&5A9#X-"B`@/&)O M9'D^#0H@("`@/'1A8FQE(&-L87-S/3-$<F5P;W)T(&ED/3-$240P14E5044^ M#0H@("`@("`\='(^#0H@("`@("`@(#QT:"!C;&%S<STS1'1L(&-O;'-P86X] M,T0Q(')O=W-P86X],T0R/CQS=')O;F<^4W1O8VMH;VQD97)S)R!%<75I='D@ M+2!3=6UM87)Y(&]F(%)E<W1R:6-T960@4W1O8VL@56YI="!!8W1I=FET>2`H M1&5T86EL*2`H4F5S=')I8W1E9"!3=&]C:R!;365M8F5R72P@55-$("0I/&)R M/CPO<W1R;VYG/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H(&-O;'-P M86X],T0S/C$R($UO;G1H<R!%;F1E9#PO=&@^#0H@("`@("`\+W1R/@T*("`@ M("`@/'1R/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y$96,N(#,Q+"`R,#$T M/&)R/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/D1E8RX@,S$L(#(P M,3,\8G(^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^1&5C+B`S,2P@ M,C`Q,CQB<CX\+W1H/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS M1')H/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^4F5S M=')I8W1E9"!3=&]C:R!;365M8F5R73PO=&0^#0H@("`@("`@(#QT9"!C;&%S M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@ M("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A M;&EG;CTS1'1O<#X\<W1R;VYG/E-H87)E+6)A<V5D($-O;7!E;G-A=&EO;B!! M<G)A;F=E;65N="!B>2!3:&%R92UB87-E9"!087EM96YT($%W87)D(%M,:6YE M($ET96US73PO<W1R;VYG/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R M(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS M1'1O<#Y297-T<FEC=&5D('-T;V-K('5N:71S(&]U='-T86YD:6YG+"!.=6UB M97(@;V8@4VAA<F5S+"!"96=I;FYI;F<@0F%L86YC93PO=&0^#0H@("`@("`@ M(#QT9"!C;&%S<STS1&YU;7`^-#$L-C8S/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,C$V+#@Y.#QS<&%N/CPO<W!A;CX\ M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C4Q-RPU,S4\<W!A;CX\ M+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R M;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E)E<W1R M:6-T960@<W1O8VL@=6YI=',@9W)A;G1E9"P@3G5M8F5R(&]F(%-H87)E<SPO M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-#,L-3`P/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-#$L-C8Q/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S M/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y2 M97-T<FEC=&5D('-T;V-K('5N:71S(&=R86YT960L(%=E:6=H=&5D($%V97)A M9V4@07=A<F0@1&%T92!&86ER(%9A;'5E('!E<B!3:&%R93PO=&0^#0H@("`@ M("`@(#QT9"!C;&%S<STS1&YU;7`^)"`Y+C8U/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^)"`V/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@ M("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y297-T<FEC=&5D('-T M;V-K('5N:71S('9E<W1E9"P@3G5M8F5R(&]F(%-H87)E<SPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S<STS1&YU;3XH,C`L.#,S*3QS<&%N/CPO<W!A;CX\+W1D M/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6T^*#(Q,2PX.3<I/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;3XH,C,Q+#DS-2D\ M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA M<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P M/E)E<W1R:6-T960@<W1O8VL@=6YI=',@9F]R9F5I=&5D+"!.=6UB97(@;V8@ M4VAA<F5S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B@Q+#`P,"D\ M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B@T M+#DY.2D\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$ M;G5M/B@V."PW,#(I/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T* M("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L M('9A;&EG;CTS1'1O<#Y5;G9E<W1E9"!R97-T<FEC=&5D('-T;V-K('5N:71S M(&]U='-T86YD:6YG+"!.=6UB97(@;V8@4VAA<F5S+"!%;F1I;F<@0F%L86YC M93PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-C,L,S,P/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-#$L-C8S M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^ M,C$V+#@Y.#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@ M(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI M9VX],T1T;W`^4F5S=')I8W1E9"!S=&]C:R!U;FET<R!O=71S=&%N9&EN9RP@ M5V5I9VAT960@079E<F%G92!!=V%R9"!$871E($9A:7(@5F%L=64@<&5R(%-H M87)E+"!"96=I;FYI;F<@0F%L86YC93PO=&0^#0H@("`@("`@(#QT9"!C;&%S M<STS1&YU;7`^)"`V/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S<STS1&YU;7`^)"`V+C<X/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S<STS1&YU;7`^)"`V+C<X/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT M9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y297-T<FEC=&5D('-T;V-K('5N M:71S('9E<W1E9"P@5V5I9VAT960@079E<F%G92!!=V%R9"!$871E($9A:7(@ M5F%L=64@<&5R(%-H87)E/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M M<#XD(#8\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$ M;G5M<#XD(#8N-S@\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L M87-S/3-$;G5M<#XD(#8N-S@\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO M='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S M/3-$<&P@=F%L:6=N/3-$=&]P/E)E<W1R:6-T960@<W1O8VL@=6YI=',@9F]R M9F5I=&5D+"!796EG:'1E9"!!=F5R86=E($%W87)D($1A=&4@1F%I<B!686QU M92!P97(@4VAA<F4\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B0@ M-CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP M/B0@-BXW.#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,] M,T1N=6UP/B0@-BXW.#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX- M"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P M;"!V86QI9VX],T1T;W`^56YV97-T960@<F5S=')I8W1E9"!S=&]C:R!U;FET M<R!O=71S=&%N9&EN9RP@5V5I9VAT960@079E<F%G92!!=V%R9"!$871E($9A M:7(@5F%L=64@<&5R(%-H87)E+"!%;F1I;F<@0F%L86YC93PO=&0^#0H@("`@ M("`@(#QT9"!C;&%S<STS1&YU;7`^)"`X+C4Q/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^)"`V/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^)"`V+C<X/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@(#PO=&%B;&4^#0H@(#PO8F]D M>3X-"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT4&%R=%\S.6,P96$V,E]C,C`S M7S0U.&9?.&,U,%\S9&-A-#4V838Y-3$-"D-O;G1E;G0M3&]C871I;VXZ(&9I M;&4Z+R\O0SHO,SEC,&5A-C)?8S(P,U\T-3AF7SAC-3!?,V1C830U-F$V.34Q M+U=O<FMS:&5E=',O4VAE970V-"YH=&UL#0I#;VYT96YT+51R86YS9F5R+45N M8V]D:6YG.B!Q=6]T960M<')I;G1A8FQE#0I#;VYT96YT+51Y<&4Z('1E>'0O M:'1M;#L@8VAA<G-E=#TB=7,M87-C:6DB#0H-"CQH=&UL/@T*("`\:&5A9#X- M"B`@("`\345402!H='1P+65Q=6EV/3-$0V]N=&5N="U4>7!E(&-O;G1E;G0] M,T0G=&5X="]H=&UL.R!C:&%R<V5T/75T9BTX)SX\<V-R:7!T('1Y<&4],T1T M97AT+VIA=F%S8W)I<'0@<W)C/3-$4VAO=RYJ<SXO*B!$;R!.;W0@4F5M;W9E M(%1H:7,@0V]M;65N="`J+SPO<V-R:7!T/CPO:&5A9#X-"B`@/&)O9'D^#0H@ M("`@/'1A8FQE(&-L87-S/3-$<F5P;W)T(&ED/3-$240P14M)044^#0H@("`@ M("`\='(^#0H@("`@("`@(#QT:"!C;&%S<STS1'1L(&-O;'-P86X],T0Q(')O M=W-P86X],T0R/CQS=')O;F<^4W1O8VMH;VQD97)S)R!%<75I='D@+2!3=&]C M:RU"87-E9"!#;VUP96YS871I;VX@4F5L871E9"!T;R!3=&]C:R!/<'1I;VYS M+"!297-T<FEC=&5D(%-T;V-K($%W87)D<RP@4F5S=')I8W1E9"!3=&]C:R!5 M;FET+"!A;F0@16UP;&]Y964@4W1O8VL@4'5R8VAA<V5S("A$971A:6PI("A5 M4T0@)"D\8G(^26X@5&AO=7-A;F1S+"!U;FQE<W,@;W1H97)W:7-E('-P96-I M9FEE9#PO<W1R;VYG/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H(&-O M;'-P86X],T0S/C$R($UO;G1H<R!%;F1E9#PO=&@^#0H@("`@("`\+W1R/@T* M("`@("`@/'1R/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y$96,N(#,Q+"`R M,#$T/&)R/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/D1E8RX@,S$L M(#(P,3,\8G(^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^1&5C+B`S M,2P@,C`Q,CQB<CX\+W1H/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S M<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^ M/'-T<F]N9SY3:&%R92UB87-E9"!#;VUP96YS871I;VX@07)R86YG96UE;G0@ M8GD@4VAA<F4M8F%S960@4&%Y;65N="!!=V%R9"P@0V]M<&5N<V%T:6]N($-O M<W0@6TQI;F4@271E;7-=/"]S=')O;F<^/"]T9#X-"B`@("`@("`@/'1D(&-L M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@ M("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@ M=F%L:6=N/3-$=&]P/E-T;V-K+6)A<V5D(&-O;7!E;G-A=&EO;B!E>'!E;G-E M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XD(#,L,S,P/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^)"`S+#4Y M-SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP M/B0@,RPW.#,\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@ M("`\='(@8VQA<W,],T1R:#X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L M:6=N/3-$=&]P/E)E<V5A<F-H(&%N9"!$979E;&]P;65N="!;365M8F5R73PO M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@ M("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#X\<W1R;VYG/E-H87)E M+6)A<V5D($-O;7!E;G-A=&EO;B!!<G)A;F=E;65N="!B>2!3:&%R92UB87-E M9"!087EM96YT($%W87)D+"!#;VUP96YS871I;VX@0V]S="!;3&EN92!)=&5M M<UT\+W-T<F]N9SX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S M<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^ M4W1O8VLM8F%S960@8V]M<&5N<V%T:6]N(&5X<&5N<V4\+W1D/@T*("`@("`@ M("`\=&0@8VQA<W,],T1N=6UP/C$L,S8Q/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,2PU,S@\<W!A;CX\+W-P86X^/"]T M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ+#@P,3QS<&%N/CPO<W!A M;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')H/@T* M("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^1V5N97)A;"!A M;F0@061M:6YI<W1R871I=F4@6TUE;6)E<ET\+W1D/@T*("`@("`@("`\=&0@ M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@ M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@ M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX- M"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P M;"!V86QI9VX],T1T;W`^/'-T<F]N9SY3:&%R92UB87-E9"!#;VUP96YS871I M;VX@07)R86YG96UE;G0@8GD@4VAA<F4M8F%S960@4&%Y;65N="!!=V%R9"P@ M0V]M<&5N<V%T:6]N($-O<W0@6TQI;F4@271E;7-=/"]S=')O;F<^/"]T9#X- M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X- M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X- M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X- M"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@ M/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E-T;V-K+6)A<V5D(&-O;7!E M;G-A=&EO;B!E>'!E;G-E/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M M<#XD(#$L.38Y/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M<STS1&YU;7`^)"`R+#`U.3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\ M=&0@8VQA<W,],T1N=6UP/B0@,2PY.#(\<W!A;CX\+W-P86X^/"]T9#X-"B`@ M("`@(#PO='(^#0H@("`@/"]T86)L93X-"B`@/"]B;V1Y/@T*/"]H=&UL/@T* M#0HM+2TM+2T]7TYE>'1087)T7S,Y8S!E838R7V,R,#-?-#4X9E\X8S4P7S-D M8V$T-39A-CDU,0T*0V]N=&5N="U,;V-A=&EO;CH@9FEL93HO+R]#.B\S.6,P M96$V,E]C,C`S7S0U.&9?.&,U,%\S9&-A-#4V838Y-3$O5V]R:W-H965T<R]3 M:&5E=#8U+FAT;6P-"D-O;G1E;G0M5')A;G-F97(M16YC;V1I;F<Z('%U;W1E M9"UP<FEN=&%B;&4-"D-O;G1E;G0M5'EP93H@=&5X="]H=&UL.R!C:&%R<V5T M/2)U<RUA<V-I:2(-"@T*/&AT;6P^#0H@(#QH96%D/@T*("`@(#Q-151!(&AT M='`M97%U:78],T1#;VYT96YT+51Y<&4@8V]N=&5N=#TS1"=T97AT+VAT;6P[ M(&-H87)S970]=71F+3@G/CQS8W)I<'0@='EP93TS1'1E>'0O:F%V87-C<FEP M="!S<F,],T13:&]W+FIS/B\J($1O($YO="!296UO=F4@5&AI<R!#;VUM96YT M("HO/"]S8W)I<'0^/"]H96%D/@T*("`\8F]D>3X-"B`@("`\=&%B;&4@8VQA M<W,],T1R97!O<G0@:60],T1)1#!%45-!13X-"B`@("`@(#QT<CX-"B`@("`@ M("`@/'1H(&-L87-S/3-$=&P@8V]L<W!A;CTS1#$@<F]W<W!A;CTS1#(^/'-T M<F]N9SY3=&]C:VAO;&1E<G,G($5Q=6ET>2`M($9A:7(@5F%L=64@;V8@4VAA M<F4M0F%S960@4&%Y;65N=',@=V%S($5S=&EM871E9"!O;B!$871E(&]F($=R M86YT(%5S:6YG($)L86-K+5-C:&]L97,@3W!T:6]N(%!R:6-I;F<@36]D96P@ M0F%S960@;VX@5V5I9VAT960@079E<F%G92!!<W-U;7!T:6]N<R`H1&5T86EL M*3QB<CX\+W-T<F]N9SX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:"!C M;VQS<&%N/3-$,SXQ,B!-;VYT:',@16YD960\+W1H/@T*("`@("`@/"]T<CX- M"B`@("`@(#QT<CX-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^1&5C+B`S,2P@ M,C`Q-#QB<CX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y$96,N(#,Q M+"`R,#$S/&)R/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/D1E8RX@ M,S$L(#(P,3(\8G(^/"]T:#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA M<W,],T1R:#X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P M/D534%`@6TUE;6)E<ET\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C M;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T M;W`^/'-T<F]N9SY$969E<G)E9"!#;VUP96YS871I;VX@07)R86YG96UE;G0@ M=VET:"!);F1I=FED=6%L+"!3:&%R92UB87-E9"!087EM96YT<R!;3&EN92!) M=&5M<UT\+W-T<F]N9SX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C M;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T M;W`^4FES:RUF<F5E(&EN=&5R97-T(')A=&4\+W1D/@T*("`@("`@("`\=&0@ M8VQA<W,],T1N=6UP/C`N,C`E/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S<STS1&YU;7`^,"XR,"4\<W!A;CX\+W-P86X^/"]T9#X-"B`@ M("`@("`@/'1D(&-L87-S/3-$;G5M<#XP+C(P)3QS<&%N/CPO<W!A;CX\+W1D M/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@ M("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^5F]L871I;&ET>3PO=&0^ M#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^.#8N,#`E/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-S0N-C`E/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-S(N,#`E M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L M87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O M<#Y%>'!E8W1E9"!T97)M(&EN('EE87)S/"]T9#X-"B`@("`@("`@/'1D(&-L M87-S/3-$=&5X=#XQ('EE87(@,R!M;VYT:',\<W!A;CX\+W-P86X^/"]T9#X- M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XQ('EE87(@,R!M;VYT:',\<W!A M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XQ('EE M87(@,R!M;VYT:',\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@ M("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@ M=F%L:6=N/3-$=&]P/D5X<&5C=&5D(&1I=FED96YD('EI96QD/"]T9#X-"B`@ M("`@("`@/'1D(&-L87-S/3-$;G5M<#XP+C`P)3QS<&%N/CPO<W!A;CX\+W1D M/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C`N,#`E/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,"XP,"4\<W!A;CX\ M+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R M:#X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D]P=&EO M;G,@6TUE;6)E<ET\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S M<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^ M/'-T<F]N9SY$969E<G)E9"!#;VUP96YS871I;VX@07)R86YG96UE;G0@=VET M:"!);F1I=FED=6%L+"!3:&%R92UB87-E9"!087EM96YT<R!;3&EN92!)=&5M M<UT\+W-T<F]N9SX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S M<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^ M4FES:RUF<F5E(&EN=&5R97-T(')A=&4\+W1D/@T*("`@("`@("`\=&0@8VQA M<W,],T1N=6UP/C$N.3`E/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S<STS1&YU;7`^,2XQ,"4\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@ M("`@/'1D(&-L87-S/3-$;G5M<#XQ+C$P)3QS<&%N/CPO<W!A;CX\+W1D/@T* M("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\ M=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^5F]L871I;&ET>3PO=&0^#0H@ M("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-S<N,3`E/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-S,N,C`E/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-S$N,3`E/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S M/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y% M>'!E8W1E9"!T97)M(&EN('EE87)S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S M/3-$=&5X=#XV('EE87)S(#,@;6]N=&AS(#$X(&1A>7,\<W!A;CX\+W-P86X^ M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XV('EE87)S(#(@;6]N M=&AS(#$R(&1A>7,\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L M87-S/3-$=&5X=#XV('EE87)S(#$@;6]N=&@@,3<@9&%Y<SQS<&%N/CPO<W!A M;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T* M("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^17AP96-T960@ M9&EV:61E;F0@>6EE;&0\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP M/C`N,#`E/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS M1&YU;7`^,"XP,"4\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L M87-S/3-$;G5M<#XP+C`P)3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T M<CX-"B`@("`\+W1A8FQE/@T*("`\+V)O9'D^#0H\+VAT;6P^#0H-"BTM+2TM M+3U?3F5X=%!A<G1?,SEC,&5A-C)?8S(P,U\T-3AF7SAC-3!?,V1C830U-F$V M.34Q#0I#;VYT96YT+4QO8V%T:6]N.B!F:6QE.B\O+T,Z+S,Y8S!E838R7V,R M,#-?-#4X9E\X8S4P7S-D8V$T-39A-CDU,2]7;W)K<VAE971S+U-H965T-C8N M:'1M;`T*0V]N=&5N="U4<F%N<V9E<BU%;F-O9&EN9SH@<75O=&5D+7!R:6YT M86)L90T*0V]N=&5N="U4>7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S M8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I M=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA<G-E M=#UU=&8M."<^/'-C<FEP="!T>7!E/3-$=&5X="]J879A<V-R:7!T('-R8STS M1%-H;W<N:G,^+RH@1&\@3F]T(%)E;6]V92!4:&ES($-O;6UE;G0@*B\\+W-C M<FEP=#X\+VAE860^#0H@(#QB;V1Y/@T*("`@(#QT86)L92!C;&%S<STS1')E M<&]R="!I9#TS1$E$,$590T%'/@T*("`@("`@/'1R/@T*("`@("`@("`\=&@@ M8VQA<W,],T1T;"!C;VQS<&%N/3-$,2!R;W=S<&%N/3-$,CX\<W1R;VYG/DEN M8V]M92!487AE<R`M($%D9&ET:6]N86P@26YF;W)M871I;VX@*$1E=&%I;"D@ M*%531"`D*3QB<CX\+W-T<F]N9SX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,] M,T1T:"!C;VQS<&%N/3-$,SXQ,B!-;VYT:',@16YD960\+W1H/@T*("`@("`@ M/"]T<CX-"B`@("`@(#QT<CX-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^1&5C M+B`S,2P@,C`Q-#QB<CX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y$ M96,N(#,Q+"`R,#$S/&)R/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H M/D1E8RX@,S$L(#(P,3(\8G(^/"]T:#X-"B`@("`@(#PO='(^#0H@("`@("`\ M='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N M/3-$=&]P/CQS=')O;F<^26YC;VUE(%1A>"!#;VYT:6YG96YC>2!;3&EN92!) M=&5M<UT\+W-T<F]N9SX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C M;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T M;W`^4')O=FES:6]N(&9O<B!I;F-O;64@=&%X/"]T9#X-"B`@("`@("`@/'1D M(&-L87-S/3-$;G5M<#XD(#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@ M/'1D(&-L87-S/3-$;G5M<#XD(#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@ M("`@/'1D(&-L87-S/3-$;G5M<#XD(#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@ M("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D M(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/DEN8W)E87-E(&%N9"!D96-R96%S M92!V86QU871I;VX@86QL;W=A;F-E/"]T9#X-"B`@("`@("`@/'1D(&-L87-S M/3-$;G5M<#XQ+#`P,"PP,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@ M/'1D(&-L87-S/3-$;G5M<#XQ,RPW,#`L,#`P/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,C$L,3`P+#`P,#QS<&%N/CPO M<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O M/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^4F5S96%R M8V@@86YD(&1E=F5L;W!M96YT(&-R961I=',@86YD(&]R<&AA;B!D<G5G(&-R M961I=',L(&9E9&5R86P@8V%R<GEF;W)W87)D<R!W:6QL(&5X<&ER93PO=&0^ M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^,C`R,3QS<&%N/CPO<W!A;CX\ M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\ M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\ M+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@ M("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^4&5R8V5N=&%G92!O M9B!I;F-O;64@=&%X(&QI:V5L>2!T;R!B92!R96%L:7IE9#PO=&0^#0H@("`@ M("`@(#QT9"!C;&%S<STS1&YU;7`^-3`N,#`E/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@ M(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y5;G)E8V]G;FEZ960@=&%X M(&)E;F5F:71S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XU+#$P M,"PP,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$ M;G5M<#XU+#`P,"PP,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D M(&-L87-S/3-$;G5M<#XT+#(P,"PP,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@ M("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D M(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E5N<F5C;V=N:7IE9"!T87@@8F5N M969I=',@;F]T(&%C8W)U92!A;GD@<&5N86QT:65S/"]T9#X-"B`@("`@("`@ M/'1D(&-L87-S/3-$;G5M<#XP/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S<STS1&YU;7`^,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@ M("`\=&0@8VQA<W,],T1N=6UP/C`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@ M(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R:#X-"B`@("`@("`@/'1D(&-L M87-S/3-$<&P@=F%L:6=N/3-$=&]P/D1O;65S=&EC(%1A>"!!=71H;W)I='D@ M6TUE;6)E<ET\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N M/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS M1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^/'-T M<F]N9SY);F-O;64@5&%X($-O;G1I;F=E;F-Y(%M,:6YE($ET96US73PO<W1R M;VYG/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^ M#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y.970@;W!E M<F%T:6YG(&QO<W,@8V%R<GEF;W)W87)D<SPO=&0^#0H@("`@("`@(#QT9"!C M;&%S<STS1&YU;7`^,S@V+#@P,"PP,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@ M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@ M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@ M("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D M(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/DYE="!O<&5R871I;F<@;&]S<R!C M87)R>69O<G=A<F1S(&5X<&ER871I;VX\+W1D/@T*("`@("`@("`\=&0@8VQA M<W,],T1T97AT/C(P,C`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D M(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D M(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^ M#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$ M<&P@=F%L:6=N/3-$=&]P/D-R961I="!C87)R>69O<G=A<F1S(&9O<B!F961E M<F%L(&%N9"!S=&%T93PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^ M,S`L.#`P+#`P,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@ M("`@(#QT<B!C;&%S<STS1')H/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V M86QI9VX],T1T;W`^1F5D97)A;"!A;F0@4W1A=&4@5&%X(%M-96UB97)=/"]T M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T M9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@ M("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/CQS=')O;F<^26YC;VUE M(%1A>"!#;VYT:6YG96YC>2!;3&EN92!)=&5M<UT\+W-T<F]N9SX\+W1D/@T* M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T* M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T* M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T* M("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\ M=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^3F5T(&]P97)A=&EN9R!L;W-S M(')E;&%T960@=&\@=&%X('-T;V-K(&]P=&EO;B!D961U8W1I;VYS/"]T9#X- M"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ+#DP,"PP,#`\<W!A;CX\+W-P M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P M86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX- M"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/DYE="!O<&5R M871I;F<@;&]S<R!C87)R>69O<G=A<F1S/"]T9#X-"B`@("`@("`@/'1D(&-L M87-S/3-$;G5M<#XR.#4L-S`P+#`P,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@ M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@ M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@ M("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@ M8VQA<W,],T1P;"!V86QI9VX],T1T;W`^3F5T(&]P97)A=&EN9R!L;W-S(&-A M<G)Y9F]R=V%R9',@97AP:7)A=&EO;CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M<STS1'1E>'0^,C`Q-3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@ M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@ M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX- M"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P M;"!V86QI9VX],T1T;W`^0W)E9&ET(&-A<G)Y9F]R=V%R9',@9F]R(&9E9&5R M86P@86YD('-T871E/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XD M(#$S+#,P,"PP,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@ M("`@/"]T86)L93X-"B`@/"]B;V1Y/@T*/"]H=&UL/@T*#0HM+2TM+2T]7TYE M>'1087)T7S,Y8S!E838R7V,R,#-?-#4X9E\X8S4P7S-D8V$T-39A-CDU,0T* M0V]N=&5N="U,;V-A=&EO;CH@9FEL93HO+R]#.B\S.6,P96$V,E]C,C`S7S0U M.&9?.&,U,%\S9&-A-#4V838Y-3$O5V]R:W-H965T<R]3:&5E=#8W+FAT;6P- M"D-O;G1E;G0M5')A;G-F97(M16YC;V1I;F<Z('%U;W1E9"UP<FEN=&%B;&4- M"D-O;G1E;G0M5'EP93H@=&5X="]H=&UL.R!C:&%R<V5T/2)U<RUA<V-I:2(- M"@T*/&AT;6P^#0H@(#QH96%D/@T*("`@(#Q-151!(&AT='`M97%U:78],T1# M;VYT96YT+51Y<&4@8V]N=&5N=#TS1"=T97AT+VAT;6P[(&-H87)S970]=71F M+3@G/CQS8W)I<'0@='EP93TS1'1E>'0O:F%V87-C<FEP="!S<F,],T13:&]W M+FIS/B\J($1O($YO="!296UO=F4@5&AI<R!#;VUM96YT("HO/"]S8W)I<'0^ M/"]H96%D/@T*("`\8F]D>3X-"B`@("`\=&%B;&4@8VQA<W,],T1R97!O<G0@ M:60],T1)1#!%6D=!0SX-"B`@("`@(#QT<CX-"B`@("`@("`@/'1H(&-L87-S M/3-$=&P@8V]L<W!A;CTS1#$@<F]W<W!A;CTS1#(^/'-T<F]N9SY);F-O;64@ M5&%X97,@+2!38VAE9'5L92!O9B!#;VUP;VYE;G1S(&]F($EN8V]M92!"969O M<F4@5&%X97,@*$1E=&%I;"D@*%531"`D*3QB<CY);B!4:&]U<V%N9',L('5N M;&5S<R!O=&AE<G=I<V4@<W!E8VEF:65D/"]S=')O;F<^/"]T:#X-"B`@("`@ M("`@/'1H(&-L87-S/3-$=&@@8V]L<W!A;CTS1#,^,3(@36]N=&AS($5N9&5D M/"]T:#X-"B`@("`@(#PO='(^#0H@("`@("`\='(^#0H@("`@("`@(#QT:"!C M;&%S<STS1'1H/D1E8RX@,S$L(#(P,30\8G(^/"]T:#X-"B`@("`@("`@/'1H M(&-L87-S/3-$=&@^1&5C+B`S,2P@,C`Q,SQB<CX\+W1H/@T*("`@("`@("`\ M=&@@8VQA<W,],T1T:#Y$96,N(#,Q+"`R,#$R/&)R/CPO=&@^#0H@("`@("`\ M+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S M<STS1'!L('9A;&EG;CTS1'1O<#X\<W1R;VYG/DEN8V]M92!487@@1&ES8VQO M<W5R92!;06)S=')A8W1=/"]S=')O;F<^/"]T9#X-"B`@("`@("`@/'1D(&-L M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@ M("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@ M=F%L:6=N/3-$=&]P/E5N:71E9"!3=&%T97,\+W1D/@T*("`@("`@("`\=&0@ M8VQA<W,],T1N=6T^)"`H,30L-C0V*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@ M("`@("`\=&0@8VQA<W,],T1N=6T^)"`H,S,L-S$W*3QS<&%N/CPO<W!A;CX\ M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6T^)"`H-#`L,S<P*3QS<&%N M/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS M1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^1F]R M96EG;CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,#QS<&%N/CPO M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C`\<W!A;CX\ M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XP/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$ M<F]U/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^3&]S M<R!B969O<F4@:6YC;VUE('1A>&5S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S M/3-$;G5M/B0@*#$T+#8T-BD\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@ M/'1D(&-L87-S/3-$;G5M/B0@*#,S+#<Q-RD\<W!A;CX\+W-P86X^/"]T9#X- M"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B0@*#0P+#,W,"D\<W!A;CX\+W-P M86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@/"]T86)L93X-"B`@/"]B;V1Y M/@T*/"]H=&UL/@T*#0HM+2TM+2T]7TYE>'1087)T7S,Y8S!E838R7V,R,#-? M-#4X9E\X8S4P7S-D8V$T-39A-CDU,0T*0V]N=&5N="U,;V-A=&EO;CH@9FEL M93HO+R]#.B\S.6,P96$V,E]C,C`S7S0U.&9?.&,U,%\S9&-A-#4V838Y-3$O M5V]R:W-H965T<R]3:&5E=#8X+FAT;6P-"D-O;G1E;G0M5')A;G-F97(M16YC M;V1I;F<Z('%U;W1E9"UP<FEN=&%B;&4-"D-O;G1E;G0M5'EP93H@=&5X="]H M=&UL.R!C:&%R<V5T/2)U<RUA<V-I:2(-"@T*/&AT;6P^#0H@(#QH96%D/@T* M("`@(#Q-151!(&AT='`M97%U:78],T1#;VYT96YT+51Y<&4@8V]N=&5N=#TS M1"=T97AT+VAT;6P[(&-H87)S970]=71F+3@G/CQS8W)I<'0@='EP93TS1'1E M>'0O:F%V87-C<FEP="!S<F,],T13:&]W+FIS/B\J($1O($YO="!296UO=F4@ M5&AI<R!#;VUM96YT("HO/"]S8W)I<'0^/"]H96%D/@T*("`\8F]D>3X-"B`@ M("`\=&%B;&4@8VQA<W,],T1R97!O<G0@:60],T1)1#!%-$%!13X-"B`@("`@ M(#QT<CX-"B`@("`@("`@/'1H(&-L87-S/3-$=&P@8V]L<W!A;CTS1#$@<F]W M<W!A;CTS1#(^/'-T<F]N9SY);F-O;64@5&%X97,@+2!#;VUP86YY(%)E8V]R M9&5D($EN8V]M92!487@@4')O=FES:6]N("A$971A:6PI("A54T0@)"D\8G(^ M26X@5&AO=7-A;F1S+"!U;FQE<W,@;W1H97)W:7-E('-P96-I9FEE9#PO<W1R M;VYG/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H(&-O;'-P86X],T0S M/C$R($UO;G1H<R!%;F1E9#PO=&@^#0H@("`@("`\+W1R/@T*("`@("`@/'1R M/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y$96,N(#,Q+"`R,#$T/&)R/CPO M=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/D1E8RX@,S$L(#(P,3,\8G(^ M/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^1&5C+B`S,2P@,C`Q,CQB M<CX\+W1H/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T* M("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^/'-T<F]N9SY# M=7)R96YT.CPO<W1R;VYG/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R M(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS M1'1O<#Y&961E<F%L/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XD M(#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M M<#XD(#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$ M;G5M<#XD(#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@ M("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L M:6=N/3-$=&]P/E-T871E/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M M<#XP/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU M;7`^,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N M=6UP/C`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\ M='(@8VQA<W,],T1R;W4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG M;CTS1'1O<#Y4;W1A;#PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^ M,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP M/C`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M M<#XP/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R M(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS M1'1O<#X\<W1R;VYG/D1E9F5R<F5D.CPO<W1R;VYG/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\ M+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S M<STS1'!L('9A;&EG;CTS1'1O<#Y&961E<F%L/"]T9#X-"B`@("`@("`@/'1D M(&-L87-S/3-$;G5M<#XP/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S<STS1&YU;7`^,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\ M=&0@8VQA<W,],T1N=6UP/C`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO M='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S M/3-$<&P@=F%L:6=N/3-$=&]P/E-T871E/"]T9#X-"B`@("`@("`@/'1D(&-L M87-S/3-$;G5M<#XP/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S<STS1&YU;7`^,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@ M8VQA<W,],T1N=6UP/C`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^ M#0H@("`@("`\='(@8VQA<W,],T1R;W4^#0H@("`@("`@(#QT9"!C;&%S<STS M1'!L('9A;&EG;CTS1'1O<#Y4;W1A;#PO=&0^#0H@("`@("`@(#QT9"!C;&%S M<STS1&YU;7`^)"`P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S<STS1&YU;7`^)"`P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S<STS1&YU;7`^)"`P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\ M+W1R/@T*("`@(#PO=&%B;&4^#0H@(#PO8F]D>3X-"CPO:'1M;#X-"@T*+2TM M+2TM/5].97AT4&%R=%\S.6,P96$V,E]C,C`S7S0U.&9?.&,U,%\S9&-A-#4V M838Y-3$-"D-O;G1E;G0M3&]C871I;VXZ(&9I;&4Z+R\O0SHO,SEC,&5A-C)? M8S(P,U\T-3AF7SAC-3!?,V1C830U-F$V.34Q+U=O<FMS:&5E=',O4VAE970V M.2YH=&UL#0I#;VYT96YT+51R86YS9F5R+45N8V]D:6YG.B!Q=6]T960M<')I M;G1A8FQE#0I#;VYT96YT+51Y<&4Z('1E>'0O:'1M;#L@8VAA<G-E=#TB=7,M M87-C:6DB#0H-"CQH=&UL/@T*("`\:&5A9#X-"B`@("`\345402!H='1P+65Q M=6EV/3-$0V]N=&5N="U4>7!E(&-O;G1E;G0],T0G=&5X="]H=&UL.R!C:&%R M<V5T/75T9BTX)SX\<V-R:7!T('1Y<&4],T1T97AT+VIA=F%S8W)I<'0@<W)C M/3-$4VAO=RYJ<SXO*B!$;R!.;W0@4F5M;W9E(%1H:7,@0V]M;65N="`J+SPO M<V-R:7!T/CPO:&5A9#X-"B`@/&)O9'D^#0H@("`@/'1A8FQE(&-L87-S/3-$ M<F5P;W)T(&ED/3-$240P145$044^#0H@("`@("`\='(^#0H@("`@("`@(#QT M:"!C;&%S<STS1'1L(&-O;'-P86X],T0Q(')O=W-P86X],T0Q/CQS=')O;F<^ M26YC;VUE(%1A>&5S("T@0V]M<&%N>2=S($1E9F5R<F5D(%1A>"!!<W-E=',@ M86YD($QI86)I;&ET:65S("A$971A:6PI("A54T0@)"D\8G(^26X@5&AO=7-A M;F1S+"!U;FQE<W,@;W1H97)W:7-E('-P96-I9FEE9#PO<W1R;VYG/CPO=&@^ M#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/D1E8RX@,S$L(#(P,30\8G(^/"]T M:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^1&5C+B`S,2P@,C`Q,SQB<CX\ M+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y$96,N(#,Q+"`R,#$R/&)R M/CPO=&@^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@ M("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#X\<W1R;VYG/D1E M9F5R<F5D('1A>"!A<W-E=',Z/"]S=')O;F<^/"]T9#X-"B`@("`@("`@/'1D M(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D M(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D M(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^ M#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$ M<&P@=F%L:6=N/3-$=&]P/D1E<')E8VEA=&EO;B!A;F0@86UO<G1I>F%T:6]N M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XD(#<X,#QS<&%N/CPO M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B0@.3$X/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^)"`Q M+#`R-#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT M<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX] M,T1T;W`^0V%P:71A;&EZ960@4B9A;7`[1#PO=&0^#0H@("`@("`@(#QT9"!C M;&%S<STS1&YU;7`^,34L,3<V/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S<STS1&YU;7`^,C`L-S`R/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-"PY,S(\<W!A;CX\+W-P86X^/"]T M9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@ M("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E)E<V5R=F5S(&%N9"!A M8V-R=6%L<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-BPR,3<\ M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XT M+#DT-CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N M=6UP/C4L,3`Q/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@ M("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A M;&EG;CTS1'1O<#Y.970@;W!E<F%T:6YG(&QO<W-E<SPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S<STS1&YU;7`^,30X+#$X-#QS<&%N/CPO<W!A;CX\+W1D/@T* M("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$T-"PR-30\<W!A;CX\+W-P86X^ M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ-3,L,3DS/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$ M<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y487@@ M8W)E9&ET<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,S0L-30S M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^ M,S,L,#0S/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS M1&YU;7`^,C4L.30S/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T* M("`@("`@/'1R(&-L87-S/3-$<F5U/@T*("`@("`@("`\=&0@8VQA<W,],T1P M;"!V86QI9VX],T1T;W`^5&]T86P@9&5F97)R960@=&%X(&%S<V5T<SPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,C`T+#DP,#QS<&%N/CPO<W!A M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C(P,RPX-C,\<W!A M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ.3`L M,3DS/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R M(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS M1'1O<#Y,97-S.B!686QU871I;VX@86QL;W=A;F-E/"]T9#X-"B`@("`@("`@ M/'1D(&-L87-S/3-$;G5M/B@R,#0L.3`P*3QS<&%N/CPO<W!A;CX\+W1D/@T* M("`@("`@("`\=&0@8VQA<W,],T1N=6T^*#(P,RPX-C,I/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;3XH,3DP+#$Y,RD\<W!A M;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,] M,T1R974^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y. M970@9&5F97)R960@=&%X(&%S<V5T<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S M<STS1&YU;7`^)"`P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S<STS1&YU;7`^)"`P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S<STS1&YU;7`^)"`P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\ M+W1R/@T*("`@(#PO=&%B;&4^#0H@(#PO8F]D>3X-"CPO:'1M;#X-"@T*+2TM M+2TM/5].97AT4&%R=%\S.6,P96$V,E]C,C`S7S0U.&9?.&,U,%\S9&-A-#4V M838Y-3$-"D-O;G1E;G0M3&]C871I;VXZ(&9I;&4Z+R\O0SHO,SEC,&5A-C)? M8S(P,U\T-3AF7SAC-3!?,V1C830U-F$V.34Q+U=O<FMS:&5E=',O4VAE970W M,"YH=&UL#0I#;VYT96YT+51R86YS9F5R+45N8V]D:6YG.B!Q=6]T960M<')I M;G1A8FQE#0I#;VYT96YT+51Y<&4Z('1E>'0O:'1M;#L@8VAA<G-E=#TB=7,M M87-C:6DB#0H-"CQH=&UL/@T*("`\:&5A9#X-"B`@("`\345402!H='1P+65Q M=6EV/3-$0V]N=&5N="U4>7!E(&-O;G1E;G0],T0G=&5X="]H=&UL.R!C:&%R M<V5T/75T9BTX)SX\<V-R:7!T('1Y<&4],T1T97AT+VIA=F%S8W)I<'0@<W)C M/3-$4VAO=RYJ<SXO*B!$;R!.;W0@4F5M;W9E(%1H:7,@0V]M;65N="`J+SPO M<V-R:7!T/CPO:&5A9#X-"B`@/&)O9'D^#0H@("`@/'1A8FQE(&-L87-S/3-$ M<F5P;W)T(&ED/3-$240P14A$044^#0H@("`@("`\='(^#0H@("`@("`@(#QT M:"!C;&%S<STS1'1L(&-O;'-P86X],T0Q(')O=W-P86X],T0R/CQS=')O;F<^ M26YC;VUE(%1A>&5S("T@0V]M<&%N>2=S(%9A;'5A=&EO;B!A;F0@475A;&EF M>6EN9R!!8V-O=6YT<R`H1&5T86EL*2`H1&5F97)R960@5&%X(%9A;'5A=&EO M;B!!;&QO=V%N8V4@6TUE;6)E<ETL(%531"`D*3QB<CY);B!4:&]U<V%N9',L M('5N;&5S<R!O=&AE<G=I<V4@<W!E8VEF:65D/"]S=')O;F<^/"]T:#X-"B`@ M("`@("`@/'1H(&-L87-S/3-$=&@@8V]L<W!A;CTS1#,^,3(@36]N=&AS($5N M9&5D/"]T:#X-"B`@("`@(#PO='(^#0H@("`@("`\='(^#0H@("`@("`@(#QT M:"!C;&%S<STS1'1H/D1E8RX@,S$L(#(P,30\8G(^/"]T:#X-"B`@("`@("`@ M/'1H(&-L87-S/3-$=&@^1&5C+B`S,2P@,C`Q,SQB<CX\+W1H/@T*("`@("`@ M("`\=&@@8VQA<W,],T1T:#Y$96,N(#,Q+"`R,#$R/&)R/CPO=&@^#0H@("`@ M("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F@^#0H@("`@("`@(#QT9"!C M;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y$969E<G)E9"!487@@5F%L=6%T:6]N M($%L;&]W86YC92!;365M8F5R73PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@ M/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG M;CTS1'1O<#X\<W1R;VYG/E9A;'5A=&EO;B!A;F0@475A;&EF>6EN9R!!8V-O M=6YT<R!$:7-C;&]S=7)E(%M,:6YE($ET96US73PO<W1R;VYG/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT M9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y"86QA;F-E(&%T($)E9VEN;FEN M9R!O9B!097)I;V0\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B0@ M,C`S+#@V,SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,] M,T1N=6UP/B0@,3DP+#$Y,SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\ M=&0@8VQA<W,],T1N=6UP/B0@,38Y+#$P-SQS<&%N/CPO<W!A;CX\+W1D/@T* M("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\ M=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^0VAA<F=E9"!T;R!%>'!E;G-E M<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,2PP,S<\<W!A;CX\ M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ,RPV-S`\ M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XR M,2PP.#8\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\ M='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N M/3-$=&]P/D-H87)G960@=&\@3W1H97(@06-C;W5N=',\+W1D/@T*("`@("`@ M("`\=&0@8VQA<W,],T1N=6UP/C`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@ M("`@/'1D(&-L87-S/3-$;G5M<#XP/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S<STS1&YU;7`^,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@ M("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@ M8VQA<W,],T1P;"!V86QI9VX],T1T;W`^1&5D=6-T:6]N<SPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S<STS1&YU;7`^,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@ M("`@("`\=&0@8VQA<W,],T1N=6UP/C`\<W!A;CX\+W-P86X^/"]T9#X-"B`@ M("`@("`@/'1D(&-L87-S/3-$;G5M<#XP/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT M9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y"86QA;F-E(&%T($5N9"!O9B!0 M97)I;V0\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B0@,C`T+#DP M,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP M/B0@,C`S+#@V,SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA M<W,],T1N=6UP/B0@,3DP+#$Y,SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@ M/"]T<CX-"B`@("`\+W1A8FQE/@T*("`\+V)O9'D^#0H\+VAT;6P^#0H-"BTM M+2TM+3U?3F5X=%!A<G1?,SEC,&5A-C)?8S(P,U\T-3AF7SAC-3!?,V1C830U M-F$V.34Q#0I#;VYT96YT+4QO8V%T:6]N.B!F:6QE.B\O+T,Z+S,Y8S!E838R M7V,R,#-?-#4X9E\X8S4P7S-D8V$T-39A-CDU,2]7;W)K<VAE971S+U-H965T M-S$N:'1M;`T*0V]N=&5N="U4<F%N<V9E<BU%;F-O9&EN9SH@<75O=&5D+7!R M:6YT86)L90T*0V]N=&5N="U4>7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S M+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE M<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA M<G-E=#UU=&8M."<^/'-C<FEP="!T>7!E/3-$=&5X="]J879A<V-R:7!T('-R M8STS1%-H;W<N:G,^+RH@1&\@3F]T(%)E;6]V92!4:&ES($-O;6UE;G0@*B\\ M+W-C<FEP=#X\+VAE860^#0H@(#QB;V1Y/@T*("`@(#QT86)L92!C;&%S<STS M1')E<&]R="!I9#TS1$E$,$5!1T%%/@T*("`@("`@/'1R/@T*("`@("`@("`\ M=&@@8VQA<W,],T1T;"!C;VQS<&%N/3-$,2!R;W=S<&%N/3-$,CX\<W1R;VYG M/DEN8V]M92!487AE<R`M(%)E8V]N8VEL:6%T:6]N(&]F(%-T871U=&]R>2!& M961E<F%L($EN8V]M92!487@@4F%T92!T;R!%9F9E8W1I=F4@5&%X(%)A=&4@ M*$1E=&%I;"D\8G(^/"]S=')O;F<^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S M/3-$=&@@8V]L<W!A;CTS1#,^,3(@36]N=&AS($5N9&5D/"]T:#X-"B`@("`@ M(#PO='(^#0H@("`@("`\='(^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/D1E M8RX@,S$L(#(P,30\8G(^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^ M1&5C+B`S,2P@,C`Q,SQB<CX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T M:#Y$96,N(#,Q+"`R,#$R/&)R/CPO=&@^#0H@("`@("`\+W1R/@T*("`@("`@ M/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG M;CTS1'1O<#X\<W1R;VYG/DEN8V]M92!487@@1&ES8VQO<W5R92!;06)S=')A M8W1=/"]S=')O;F<^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\ M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\ M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\ M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA M<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P M/E1A>"!A="!F961E<F%L('-T871U=&]R>2!T87@@<F%T93PO=&0^#0H@("`@ M("`@(#QT9"!C;&%S<STS1&YU;3XH,S0N,#`E*3QS<&%N/CPO<W!A;CX\+W1D M/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6T^*#,T+C`P)2D\<W!A;CX\+W-P M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B@S-"XP,"4I/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S M/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y3 M=&%T92!I;F-O;64@=&%X+"!N970@;V8@9F5D97)A;"!T87@@8F5N969I=#PO M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;3XH,2XP,"4I/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;3XH-"XP,"4I/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;3XH-BXP M,"4I/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R M(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS M1'1O<#Y3=&%T92!!<'!O<G1I;VYM96YT/"]T9#X-"B`@("`@("`@/'1D(&-L M87-S/3-$;G5M<#XR."XP,"4\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@ M/'1D(&-L87-S/3-$;G5M<#XW+C`P)3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@ M("`@("`\=&0@8VQA<W,],T1N=6UP/C`N,#`E/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@ M(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y487@@8W)E9&ET<R`H;F5T M*3PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;3XH-RXP,"4I/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;3XH,30N,#`E M*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6T^ M*#$Y+C`P)2D\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@ M("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L M:6=N/3-$=&]P/D1E9F5R<F5D('1A>"!A<W-E=',@*'5T:6QI>F5D*2!N;W0@ M8F5N969I=&5D/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XW+C`P M)3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP M/C0Q+C`P)3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,] M,T1N=6UP/C4V+C`P)3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX- M"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P M;"!V86QI9VX],T1T;W`^4W1O8VLM8F%S960@8V]M<&5N<V%T:6]N/"]T9#X- M"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XU+C`P)3QS<&%N/CPO<W!A;CX\ M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C(N,#`E/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,"XP,"4\<W!A M;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,] M,T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/DY/ M3"!%>'!I<F%T:6]N/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XR M+C`P)3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N M=6UP/C$N,#`E/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M<STS1&YU;7`^,BXP,"4\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^ M#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$ M<&P@=F%L:6=N/3-$=&]P/D]T:&5R/"]T9#X-"B`@("`@("`@/'1D(&-L87-S M/3-$;G5M<#XP+C`P)3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@ M8VQA<W,],T1N=6UP/C$N,#`E/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S<STS1&YU;7`^,2XP,"4\<W!A;CX\+W-P86X^/"]T9#X-"B`@ M("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;W4^#0H@("`@("`@(#QT M9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y4;W1A;#PO=&0^#0H@("`@("`@ M(#QT9"!C;&%S<STS1&YU;7`^,"XP,"4\<W!A;CX\+W-P86X^/"]T9#X-"B`@ M("`@("`@/'1D(&-L87-S/3-$;G5M<#XP+C`P)3QS<&%N/CPO<W!A;CX\+W1D M/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C`N,#`E/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`\+W1R/@T*("`@(#PO=&%B;&4^#0H@(#PO8F]D>3X- M"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT4&%R=%\S.6,P96$V,E]C,C`S7S0U M.&9?.&,U,%\S9&-A-#4V838Y-3$-"D-O;G1E;G0M3&]C871I;VXZ(&9I;&4Z M+R\O0SHO,SEC,&5A-C)?8S(P,U\T-3AF7SAC-3!?,V1C830U-F$V.34Q+U=O M<FMS:&5E=',O4VAE970W,BYH=&UL#0I#;VYT96YT+51R86YS9F5R+45N8V]D M:6YG.B!Q=6]T960M<')I;G1A8FQE#0I#;VYT96YT+51Y<&4Z('1E>'0O:'1M M;#L@8VAA<G-E=#TB=7,M87-C:6DB#0H-"CQH=&UL/@T*("`\:&5A9#X-"B`@ M("`\345402!H='1P+65Q=6EV/3-$0V]N=&5N="U4>7!E(&-O;G1E;G0],T0G M=&5X="]H=&UL.R!C:&%R<V5T/75T9BTX)SX\<V-R:7!T('1Y<&4],T1T97AT M+VIA=F%S8W)I<'0@<W)C/3-$4VAO=RYJ<SXO*B!$;R!.;W0@4F5M;W9E(%1H M:7,@0V]M;65N="`J+SPO<V-R:7!T/CPO:&5A9#X-"B`@/&)O9'D^#0H@("`@ M/'1A8FQE(&-L87-S/3-$<F5P;W)T(&ED/3-$240P14XU044^#0H@("`@("`\ M='(^#0H@("`@("`@(#QT:"!C;&%S<STS1'1L(&-O;'-P86X],T0Q(')O=W-P M86X],T0R/CQS=')O;F<^26YC;VUE(%1A>&5S("T@4F5C;VYC:6QI871I;VX@ M;V8@5&]T86P@06UO=6YT<R!O9B!5;G)E8V]G;FEZ960@5&%X($)E;F5F:71S M("A$971A:6PI("A54T0@)"D\8G(^26X@5&AO=7-A;F1S+"!U;FQE<W,@;W1H M97)W:7-E('-P96-I9FEE9#PO<W1R;VYG/CPO=&@^#0H@("`@("`@(#QT:"!C M;&%S<STS1'1H(&-O;'-P86X],T0R/C$R($UO;G1H<R!%;F1E9#PO=&@^#0H@ M("`@("`\+W1R/@T*("`@("`@/'1R/@T*("`@("`@("`\=&@@8VQA<W,],T1T M:#Y$96,N(#,Q+"`R,#$T/&)R/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS M1'1H/D1E8RX@,S$L(#(P,3,\8G(^/"]T:#X-"B`@("`@(#PO='(^#0H@("`@ M("`\='(@8VQA<W,],T1R:#X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L M:6=N/3-$=&]P/D9E9&5R86P@86YD(%-T871E(%1A>"!;365M8F5R73PO=&0^ M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@ M(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#X\<W1R;VYG/DEN8V]M92!4 M87@@0V]N=&EN9V5N8WD@6TQI;F4@271E;7-=/"]S=')O;F<^/"]T9#X-"B`@ M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@ M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@ M("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D M(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E5N<F5C;V=N:7IE9"!T87@@8F5N M969I=',L($)E9VEN;FEN9R!"86QA;F-E/"]T9#X-"B`@("`@("`@/'1D(&-L M87-S/3-$;G5M<#XD(#8L,3<Q/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S<STS1&YU;7`^)"`U+#,T,#QS<&%N/CPO<W!A;CX\+W1D/@T* M("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\ M=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^4F5D=6-T:6]N<R!F;W(@=&%X M('!O<VET:6]N<R!O9B!P<FEO<B!Y96%R<SPO=&0^#0H@("`@("`@(#QT9"!C M;&%S<STS1&YU;3XH.#4I/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R M/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS M1'!L('9A;&EG;CTS1'1O<#Y!9&1I=&EO;B!F;W(@=&%X('!O<VET:6]N<R!O M9B!P<FEO<B!Y96%R<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^ M,C0\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@ M8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$ M=&]P/D%D9&ET:6]N(&9O<B!T87@@<&]S:71I;VYS(')E;&%T960@=&\@=&AE M(&-U<G)E;G0@>65A<CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^ M,3@X/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU M;7`^.#`W/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@ M/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG M;CTS1'1O<#Y5;G)E8V]G;FEZ960@=&%X(&)E;F5F:71S+"!%;F1I;F<@0F%L M86YC93PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-BPR-S0\<W!A M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XV+#$W M,3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C M;&%S<STS1')H/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T M;W`^1F5D97)A;"!487@@0F5N969I="!O9B!3=&%T92!);F-O;64@5&%X(%54 M0G,@6TUE;6)E<ET\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S M<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^ M/'-T<F]N9SY);F-O;64@5&%X($-O;G1I;F=E;F-Y(%M,:6YE($ET96US73PO M<W1R;VYG/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$ M<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y5;G)E M8V]G;FEZ960@=&%X(&)E;F5F:71S+"!"96=I;FYI;F<@0F%L86YC93PO=&0^ M#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,2PR,#D\<W!A;CX\+W-P86X^ M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ+#$U.#QS<&%N/CPO M<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E M/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^4F5D=6-T M:6]N<R!F;W(@=&%X('!O<VET:6]N<R!O9B!P<FEO<B!Y96%R<SPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S<STS1&YU;3XH,CDI/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@ M(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y!9&1I=&EO;B!F;W(@=&%X M('!O<VET:6]N<R!O9B!P<FEO<B!Y96%R<SPO=&0^#0H@("`@("`@(#QT9"!C M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S<STS1&YU;7`^.#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX- M"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P M;"!V86QI9VX],T1T;W`^061D:71I;VX@9F]R('1A>"!P;W-I=&EO;G,@<F5L M871E9"!T;R!T:&4@8W5R<F5N="!Y96%R/"]T9#X-"B`@("`@("`@/'1D(&-L M87-S/3-$;G5M<#XQ,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@ M8VQA<W,],T1N=6UP/C0S/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R M/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS M1'!L('9A;&EG;CTS1'1O<#Y5;G)E8V]G;FEZ960@=&%X(&)E;F5F:71S+"!% M;F1I;F<@0F%L86YC93PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^ M,2PQ.3`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$ M;G5M<#XQ+#(P.3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@ M("`@(#QT<B!C;&%S<STS1')H/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V M86QI9VX],T1T;W`^56YR96-O9VYI>F5D($EN8V]M92!487@@0F5N969I=',@ M+2!.970@;V8@1F5D97)A;"!"96YE9FET(&]F(%-T871E(%540G,@6TUE;6)E M<ET\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A M;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T* M("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^/'-T<F]N9SY) M;F-O;64@5&%X($-O;G1I;F=E;F-Y(%M,:6YE($ET96US73PO<W1R;VYG/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@ M("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y5;G)E8V]G;FEZ960@ M=&%X(&)E;F5F:71S+"!"96=I;FYI;F<@0F%L86YC93PO=&0^#0H@("`@("`@ M(#QT9"!C;&%S<STS1&YU;7`^-"PY-C(\<W!A;CX\+W-P86X^/"]T9#X-"B`@ M("`@("`@/'1D(&-L87-S/3-$;G5M<#XT+#$X,CQS<&%N/CPO<W!A;CX\+W1D M/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@ M("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^4F5D=6-T:6]N<R!F;W(@ M=&%X('!O<VET:6]N<R!O9B!P<FEO<B!Y96%R<SPO=&0^#0H@("`@("`@(#QT M9"!C;&%S<STS1&YU;3XH-38I/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\ M+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S M<STS1'!L('9A;&EG;CTS1'1O<#Y!9&1I=&EO;B!F;W(@=&%X('!O<VET:6]N M<R!O9B!P<FEO<B!Y96%R<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU M;7`^,38\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\ M='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N M/3-$=&]P/D%D9&ET:6]N(&9O<B!T87@@<&]S:71I;VYS(')E;&%T960@=&\@ M=&AE(&-U<G)E;G0@>65A<CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU M;7`^,3<X/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS M1&YU;7`^-S8T/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@ M("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A M;&EG;CTS1'1O<#Y5;G)E8V]G;FEZ960@=&%X(&)E;F5F:71S+"!%;F1I;F<@ M0F%L86YC93PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^)"`U+#`X M-#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP M/B0@-"PY-C(\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@ M/"]T86)L93X-"B`@/"]B;V1Y/@T*/"]H=&UL/@T*#0HM+2TM+2T]7TYE>'10 M87)T7S,Y8S!E838R7V,R,#-?-#4X9E\X8S4P7S-D8V$T-39A-CDU,0T*0V]N M=&5N="U,;V-A=&EO;CH@9FEL93HO+R]#.B\S.6,P96$V,E]C,C`S7S0U.&9? M.&,U,%\S9&-A-#4V838Y-3$O5V]R:W-H965T<R]3:&5E=#<S+FAT;6P-"D-O M;G1E;G0M5')A;G-F97(M16YC;V1I;F<Z('%U;W1E9"UP<FEN=&%B;&4-"D-O M;G1E;G0M5'EP93H@=&5X="]H=&UL.R!C:&%R<V5T/2)U<RUA<V-I:2(-"@T* M/&AT;6P^#0H@(#QH96%D/@T*("`@(#Q-151!(&AT='`M97%U:78],T1#;VYT M96YT+51Y<&4@8V]N=&5N=#TS1"=T97AT+VAT;6P[(&-H87)S970]=71F+3@G M/CQS8W)I<'0@='EP93TS1'1E>'0O:F%V87-C<FEP="!S<F,],T13:&]W+FIS M/B\J($1O($YO="!296UO=F4@5&AI<R!#;VUM96YT("HO/"]S8W)I<'0^/"]H M96%D/@T*("`\8F]D>3X-"B`@("`\=&%B;&4@8VQA<W,],T1R97!O<G0@:60] M,T1)1#!%6D=!0SX-"B`@("`@(#QT<CX-"B`@("`@("`@/'1H(&-L87-S/3-$ M=&P@8V]L<W!A;CTS1#$@<F]W<W!A;CTS1#(^/'-T<F]N9SY);G1E<F5S="!A M;F0@3W1H97(L($YE="`M($-O;7!O;F5N=',@;V8@26YT97)E<W0@86YD($]T M:&5R+"!.970@*$1E=&%I;"D@*%531"`D*3QB<CY);B!4:&]U<V%N9',L('5N M;&5S<R!O=&AE<G=I<V4@<W!E8VEF:65D/"]S=')O;F<^/"]T:#X-"B`@("`@ M("`@/'1H(&-L87-S/3-$=&@@8V]L<W!A;CTS1#,^,3(@36]N=&AS($5N9&5D M/"]T:#X-"B`@("`@(#PO='(^#0H@("`@("`\='(^#0H@("`@("`@(#QT:"!C M;&%S<STS1'1H/D1E8RX@,S$L(#(P,30\8G(^/"]T:#X-"B`@("`@("`@/'1H M(&-L87-S/3-$=&@^1&5C+B`S,2P@,C`Q,SQB<CX\+W1H/@T*("`@("`@("`\ M=&@@8VQA<W,],T1T:#Y$96,N(#,Q+"`R,#$R/&)R/CPO=&@^#0H@("`@("`\ M+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S M<STS1'!L('9A;&EG;CTS1'1O<#X\<W1R;VYG/D]T:&5R($EN8V]M92!A;F0@ M17AP96YS97,@6T%B<W1R86-T73PO<W1R;VYG/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R M/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS M1'!L('9A;&EG;CTS1'1O<#Y);G1E<F5S="!I;F-O;64@86YD(&]T:&5R(&EN M8V]M93PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^)"`Q,#@\<W!A M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XD(#DX M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^ M)"`X.3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT M<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX] M,T1T;W`^26YT97)E<W0@97AP96YS92!A;F0@;W1H97(@97AP96YS93PO=&0^ M#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,#QS<&%N/CPO<W!A;CX\+W1D M/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C<Y/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;3XH,BD\<W!A;CX\+W-P86X^ M/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;W4^#0H@ M("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y);G1E<F5S="!A M;F0@3W1H97(L(&YE=#PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^ M)"`Q,#@\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$ M;G5M<#XD(#$W-SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA M<W,],T1N=6UP/B0@.#<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^ M#0H@("`@/"]T86)L93X-"B`@/"]B;V1Y/@T*/"]H=&UL/@T*#0HM+2TM+2T] M7TYE>'1087)T7S,Y8S!E838R7V,R,#-?-#4X9E\X8S4P7S-D8V$T-39A-CDU M,0T*0V]N=&5N="U,;V-A=&EO;CH@9FEL93HO+R]#.B\S.6,P96$V,E]C,C`S M7S0U.&9?.&,U,%\S9&-A-#4V838Y-3$O5V]R:W-H965T<R]3:&5E=#<T+FAT M;6P-"D-O;G1E;G0M5')A;G-F97(M16YC;V1I;F<Z('%U;W1E9"UP<FEN=&%B M;&4-"D-O;G1E;G0M5'EP93H@=&5X="]H=&UL.R!C:&%R<V5T/2)U<RUA<V-I M:2(-"@T*/&AT;6P^#0H@(#QH96%D/@T*("`@(#Q-151!(&AT='`M97%U:78] M,T1#;VYT96YT+51Y<&4@8V]N=&5N=#TS1"=T97AT+VAT;6P[(&-H87)S970] M=71F+3@G/CQS8W)I<'0@='EP93TS1'1E>'0O:F%V87-C<FEP="!S<F,],T13 M:&]W+FIS/B\J($1O($YO="!296UO=F4@5&AI<R!#;VUM96YT("HO/"]S8W)I M<'0^/"]H96%D/@T*("`\8F]D>3X-"B`@("`\=&%B;&4@8VQA<W,],T1R97!O M<G0@:60],T1)1#!%5TQ!1SX-"B`@("`@(#QT<CX-"B`@("`@("`@/'1H(&-L M87-S/3-$=&P@8V]L<W!A;CTS1#$@<F]W<W!A;CTS1#(^/'-T<F]N9SY1=6%R M=&5R;'D@1FEN86YC:6%L($1A=&$@+2!3=6UM87)Y(&]F(%%U87)T97)L>2!2 M97-U;'1S("A$971A:6PI("A54T0@)"D\8G(^26X@5&AO=7-A;F1S+"!E>&-E M<'0@4&5R(%-H87)E(&1A=&$L('5N;&5S<R!O=&AE<G=I<V4@<W!E8VEF:65D M/"]S=')O;F<^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@@8V]L<W!A M;CTS1#@^,R!-;VYT:',@16YD960\+W1H/@T*("`@("`@("`\=&@@8VQA<W,] M,T1T:"!C;VQS<&%N/3-$,SXQ,B!-;VYT:',@16YD960\+W1H/@T*("`@("`@ M/"]T<CX-"B`@("`@(#QT<CX-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^1&5C M+B`S,2P@,C`Q-#QB<CX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y3 M97`N(#,P+"`R,#$T/&)R/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H M/DIU;BX@,S`L(#(P,30\8G(^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$ M=&@^36%R+B`S,2P@,C`Q-#QB<CX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,] M,T1T:#Y$96,N(#,Q+"`R,#$S/&)R/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S M<STS1'1H/E-E<"X@,S`L(#(P,3,\8G(^/"]T:#X-"B`@("`@("`@/'1H(&-L M87-S/3-$=&@^2G5N+B`S,"P@,C`Q,SQB<CX\+W1H/@T*("`@("`@("`\=&@@ M8VQA<W,],T1T:#Y-87(N(#,Q+"`R,#$S/&)R/CPO=&@^#0H@("`@("`@(#QT M:"!C;&%S<STS1'1H/D1E8RX@,S$L(#(P,30\8G(^/"]T:#X-"B`@("`@("`@ M/'1H(&-L87-S/3-$=&@^1&5C+B`S,2P@,C`Q,SQB<CX\+W1H/@T*("`@("`@ M("`\=&@@8VQA<W,],T1T:#Y$96,N(#,Q+"`R,#$R/&)R/CPO=&@^#0H@("`@ M("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C M;&%S<STS1'!L('9A;&EG;CTS1'1O<#X\<W1R;VYG/E%U87)T97)L>2!&:6YA M;F-I86P@26YF;W)M871I;VX@1&ES8VQO<W5R92!;06)S=')A8W1=/"]S=')O M;F<^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P M86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX- M"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E1O=&%L(')E M=F5N=65S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XD(#(Q+#<U M.#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP M/B0@.2PT,34\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S M/3-$;G5M<#XD(#<L-S@X/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S<STS1&YU;7`^)"`W+#DW.3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@ M("`@("`\=&0@8VQA<W,],T1N=6UP/B0@,C0L,S0Y/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^)"`T+#0V.3QS<&%N/CPO M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B0@,2PP,#D\ M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XD M(#@R,3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT M<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX] M,T1T;W`^3F5T(&EN8V]M92`H;&]S<RD\+W1D/@T*("`@("`@("`\=&0@8VQA M<W,],T1N=6UP/C@L-#0S/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S<STS1&YU;3XH-2PY-S$I/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S<STS1&YU;3XH."PS-S0I/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;3XH."PW-#0I/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-BPU,S$\<W!A;CX\ M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B@Q,BPU.#@I M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;3XH M,34L,#0Q*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,] M,T1N=6T^*#$R+#8Q.2D\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D M(&-L87-S/3-$;G5M/B@Q-"PV-#8I/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S<STS1&YU;3XH,S,L-S$W*3QS<&%N/CPO<W!A;CX\+W1D M/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6T^*#0P+#,W,"D\<W!A;CX\+W-P M86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX- M"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/DYE="!I;F-O M;64@*&QO<W,I(&%L;&]C86)L92!T;R!C;VUM;VX@<W1O8VMH;VQD97)S/"]T M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XD(#@L-#0S/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;3XD("@U+#DW,2D\ M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B0@ M*#@L,S<T*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,] M,T1N=6T^)"`H."PW-#0I/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S<STS1&YU;7`^)"`V+#4S,3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@ M("`@("`\=&0@8VQA<W,],T1N=6T^)"`H,3(L-3@X*3QS<&%N/CPO<W!A;CX\ M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6T^)"`H,34L,#0Q*3QS<&%N M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6T^)"`H,3(L M-C$Y*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N M=6T^)"`H,30L-C0V*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@ M8VQA<W,],T1N=6T^)"`H,S,L-S$W*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@ M("`@("`\=&0@8VQA<W,],T1N=6T^)"`H-#$L-C<W*3QS<&%N/CPO<W!A;CX\ M+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@ M("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^3F5T(&EN8V]M92`H M;&]S<RD@<&5R('-H87)E(&%L;&]C86)L92!T;R!C;VUM;VX@<W1O8VMH;VQD M97)S("T@8F%S:6,\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B0@ M,"XR,CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N M=6T^)"`H,"XT,RD\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L M87-S/3-$;G5M/B0@*#`N-3@I/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S<STS1&YU;3XD("@P+C4S*3QS<&%N/CPO<W!A;CX\+W1D/@T* M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T* M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T* M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T* M("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\ M=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^3F5T(&EN8V]M92`H;&]S<RD@ M<&5R('-H87)E(&%L;&]C86)L92!T;R!C;VUM;VX@<W1O8VMH;VQD97)S("T@ M8F%S:6,@86YD(&1I;'5T960\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N M=6UP/B0@,"XR,SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA M<W,],T1N=6T^)"`H,"XQ-BD\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@ M/'1D(&-L87-S/3-$;G5M/B0@*#`N,C,I/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S<STS1&YU;3XD("@P+C(W*3QS<&%N/CPO<W!A;CX\ M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\ M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\ M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\ M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\ M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\ M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\ M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\ M+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@ M("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^3F5T(&EN8V]M92`H M;&]S<RD@<&5R('-H87)E(&%L;&]C86)L92!T;R!C;VUM;VX@<W1O8VMH;VQD M97)S("T@9&EL=71E9#PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^ M)"`P+C(Q/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS M1&YU;3XD("@P+C0S*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@ M8VQA<W,],T1N=6T^)"`H,"XU."D\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@ M("`@/'1D(&-L87-S/3-$;G5M/B0@*#`N-3,I/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`\+W1R/@T*("`@(#PO=&%B;&4^#0H@(#PO8F]D>3X-"CPO:'1M M;#X-"@T*+2TM+2TM/5].97AT4&%R=%\S.6,P96$V,E]C,C`S7S0U.&9?.&,U M,%\S9&-A-#4V838Y-3$-"D-O;G1E;G0M3&]C871I;VXZ(&9I;&4Z+R\O0SHO M,SEC,&5A-C)?8S(P,U\T-3AF7SAC-3!?,V1C830U-F$V.34Q+U=O<FMS:&5E M=',O9FEL96QI<W0N>&UL#0I#;VYT96YT+51R86YS9F5R+45N8V]D:6YG.B!Q M=6]T960M<')I;G1A8FQE#0I#;VYT96YT+51Y<&4Z('1E>'0O:'1M;#L@8VAA M<G-E=#TB=7,M87-C:6DB#0H-"CQX;6P@>&UL;G,Z;STS1")U<FXZ<V-H96UA M<RUM:6-R;W-O9G0M8V]M.F]F9FEC93IO9F9I8V4B/@T*(#QO.DUA:6Y&:6QE M($A2968],T0B+BXO5V]R:V)O;VLN:'1M;"(O/@T*(#QO.D9I;&4@2%)E9CTS M1")3:&5E=#`Q+FAT;6PB+SX-"B`\;SI&:6QE($A2968],T0B4VAE970P,BYH M=&UL(B\^#0H@/&\Z1FEL92!(4F5F/3-$(E-H965T,#,N:'1M;"(O/@T*(#QO M.D9I;&4@2%)E9CTS1")3:&5E=#`T+FAT;6PB+SX-"B`\;SI&:6QE($A2968] M,T0B4VAE970P-2YH=&UL(B\^#0H@/&\Z1FEL92!(4F5F/3-$(E-H965T,#8N M:'1M;"(O/@T*(#QO.D9I;&4@2%)E9CTS1")3:&5E=#`W+FAT;6PB+SX-"B`\ M;SI&:6QE($A2968],T0B4VAE970P."YH=&UL(B\^#0H@/&\Z1FEL92!(4F5F M/3-$(E-H965T,#DN:'1M;"(O/@T*(#QO.D9I;&4@2%)E9CTS1")3:&5E=#$P M+FAT;6PB+SX-"B`\;SI&:6QE($A2968],T0B4VAE970Q,2YH=&UL(B\^#0H@ M/&\Z1FEL92!(4F5F/3-$(E-H965T,3(N:'1M;"(O/@T*(#QO.D9I;&4@2%)E M9CTS1")3:&5E=#$S+FAT;6PB+SX-"B`\;SI&:6QE($A2968],T0B4VAE970Q M-"YH=&UL(B\^#0H@/&\Z1FEL92!(4F5F/3-$(E-H965T,34N:'1M;"(O/@T* M(#QO.D9I;&4@2%)E9CTS1")3:&5E=#$V+FAT;6PB+SX-"B`\;SI&:6QE($A2 M968],T0B4VAE970Q-RYH=&UL(B\^#0H@/&\Z1FEL92!(4F5F/3-$(E-H965T M,3@N:'1M;"(O/@T*(#QO.D9I;&4@2%)E9CTS1")3:&5E=#$Y+FAT;6PB+SX- M"B`\;SI&:6QE($A2968],T0B4VAE970R,"YH=&UL(B\^#0H@/&\Z1FEL92!( M4F5F/3-$(E-H965T,C$N:'1M;"(O/@T*(#QO.D9I;&4@2%)E9CTS1")3:&5E M=#(R+FAT;6PB+SX-"B`\;SI&:6QE($A2968],T0B4VAE970R,RYH=&UL(B\^ M#0H@/&\Z1FEL92!(4F5F/3-$(E-H965T,C0N:'1M;"(O/@T*(#QO.D9I;&4@ M2%)E9CTS1")3:&5E=#(U+FAT;6PB+SX-"B`\;SI&:6QE($A2968],T0B4VAE M970R-BYH=&UL(B\^#0H@/&\Z1FEL92!(4F5F/3-$(E-H965T,C<N:'1M;"(O M/@T*(#QO.D9I;&4@2%)E9CTS1")3:&5E=#(X+FAT;6PB+SX-"B`\;SI&:6QE M($A2968],T0B4VAE970R.2YH=&UL(B\^#0H@/&\Z1FEL92!(4F5F/3-$(E-H M965T,S`N:'1M;"(O/@T*(#QO.D9I;&4@2%)E9CTS1")3:&5E=#,Q+FAT;6PB M+SX-"B`\;SI&:6QE($A2968],T0B4VAE970S,BYH=&UL(B\^#0H@/&\Z1FEL M92!(4F5F/3-$(E-H965T,S,N:'1M;"(O/@T*(#QO.D9I;&4@2%)E9CTS1")3 M:&5E=#,T+FAT;6PB+SX-"B`\;SI&:6QE($A2968],T0B4VAE970S-2YH=&UL M(B\^#0H@/&\Z1FEL92!(4F5F/3-$(E-H965T,S8N:'1M;"(O/@T*(#QO.D9I M;&4@2%)E9CTS1")3:&5E=#,W+FAT;6PB+SX-"B`\;SI&:6QE($A2968],T0B M4VAE970S."YH=&UL(B\^#0H@/&\Z1FEL92!(4F5F/3-$(E-H965T,SDN:'1M M;"(O/@T*(#QO.D9I;&4@2%)E9CTS1")3:&5E=#0P+FAT;6PB+SX-"B`\;SI& M:6QE($A2968],T0B4VAE970T,2YH=&UL(B\^#0H@/&\Z1FEL92!(4F5F/3-$ M(E-H965T-#(N:'1M;"(O/@T*(#QO.D9I;&4@2%)E9CTS1")3:&5E=#0S+FAT M;6PB+SX-"B`\;SI&:6QE($A2968],T0B4VAE970T-"YH=&UL(B\^#0H@/&\Z M1FEL92!(4F5F/3-$(E-H965T-#4N:'1M;"(O/@T*(#QO.D9I;&4@2%)E9CTS M1")3:&5E=#0V+FAT;6PB+SX-"B`\;SI&:6QE($A2968],T0B4VAE970T-RYH M=&UL(B\^#0H@/&\Z1FEL92!(4F5F/3-$(E-H965T-#@N:'1M;"(O/@T*(#QO M.D9I;&4@2%)E9CTS1")3:&5E=#0Y+FAT;6PB+SX-"B`\;SI&:6QE($A2968] M,T0B4VAE970U,"YH=&UL(B\^#0H@/&\Z1FEL92!(4F5F/3-$(E-H965T-3$N M:'1M;"(O/@T*(#QO.D9I;&4@2%)E9CTS1")3:&5E=#4R+FAT;6PB+SX-"B`\ M;SI&:6QE($A2968],T0B4VAE970U,RYH=&UL(B\^#0H@/&\Z1FEL92!(4F5F M/3-$(E-H965T-30N:'1M;"(O/@T*(#QO.D9I;&4@2%)E9CTS1")3:&5E=#4U M+FAT;6PB+SX-"B`\;SI&:6QE($A2968],T0B4VAE970U-BYH=&UL(B\^#0H@ M/&\Z1FEL92!(4F5F/3-$(E-H965T-3<N:'1M;"(O/@T*(#QO.D9I;&4@2%)E M9CTS1")3:&5E=#4X+FAT;6PB+SX-"B`\;SI&:6QE($A2968],T0B4VAE970U M.2YH=&UL(B\^#0H@/&\Z1FEL92!(4F5F/3-$(E-H965T-C`N:'1M;"(O/@T* M(#QO.D9I;&4@2%)E9CTS1")3:&5E=#8Q+FAT;6PB+SX-"B`\;SI&:6QE($A2 M968],T0B4VAE970V,BYH=&UL(B\^#0H@/&\Z1FEL92!(4F5F/3-$(E-H965T M-C,N:'1M;"(O/@T*(#QO.D9I;&4@2%)E9CTS1")3:&5E=#8T+FAT;6PB+SX- M"B`\;SI&:6QE($A2968],T0B4VAE970V-2YH=&UL(B\^#0H@/&\Z1FEL92!( M4F5F/3-$(E-H965T-C8N:'1M;"(O/@T*(#QO.D9I;&4@2%)E9CTS1")3:&5E M=#8W+FAT;6PB+SX-"B`\;SI&:6QE($A2968],T0B4VAE970V."YH=&UL(B\^ M#0H@/&\Z1FEL92!(4F5F/3-$(E-H965T-CDN:'1M;"(O/@T*(#QO.D9I;&4@ M2%)E9CTS1")3:&5E=#<P+FAT;6PB+SX-"B`\;SI&:6QE($A2968],T0B4VAE M970W,2YH=&UL(B\^#0H@/&\Z1FEL92!(4F5F/3-$(E-H965T-S(N:'1M;"(O M/@T*(#QO.D9I;&4@2%)E9CTS1")3:&5E=#<S+FAT;6PB+SX-"B`\;SI&:6QE M($A2968],T0B4VAE970W-"YH=&UL(B\^#0H\+WAM;#X-"BTM+2TM+3U?3F5X M=%!A<G1?,SEC,&5A-C)?8S(P,U\T-3AF7SAC-3!?,V1C830U-F$V.34Q+2T- !"@`` ` end </TEXT> </DOCUMENT> <DOCUMENT> <TYPE>XML <SEQUENCE>39 <FILENAME>R43.htm <DESCRIPTION>IDEA: XBRL DOCUMENT <TEXT> <html> <head> <META http-equiv="Content-Type" content="text/html; charset=us-ascii"> <title></title> <link rel="stylesheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript"> function toggleNextSibling (e) { if (e.nextSibling.style.display=='none') { e.nextSibling.style.display='block'; } else { e.nextSibling.style.display='none'; } }</script></head> <body><span style="display: none;">v2.4.1.9</span><table class="report" border="0" cellspacing="2" id="ID0EXBAC"> <tr> <th class="tl" colspan="1" rowspan="2"> <div style="width: 200px;"><strong>Cash Equivalents and Investments - Summary of Interest Income (Detail) (USD $)<br>In Thousands, unless otherwise specified</strong></div> </th> <th class="th" colspan="3">12 Months Ended</th> </tr> <tr> <th class="th"> <div>Dec. 31, 2014</div> </th> <th class="th"> <div>Dec. 31, 2013</div> </th> <th class="th"> <div>Dec. 31, 2012</div> </th> </tr> <tr class="re"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAbstract', window );"><strong>Cash and Cash Equivalents [Abstract]</strong></a></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> </tr> <tr class="ro"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentIncomeInterest', window );">Interest income</a></td> <td class="nump"><a title="us-gaap_InvestmentIncomeInterest" onclick="toggleNextSibling(this);">$ 101</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_InvestmentIncomeInterest</span><span></span></td> <td class="nump"><a title="us-gaap_InvestmentIncomeInterest" onclick="toggleNextSibling(this);">$ 96</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_InvestmentIncomeInterest</span><span></span></td> <td class="nump"><a title="us-gaap_InvestmentIncomeInterest" onclick="toggleNextSibling(this);">$ 83</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_InvestmentIncomeInterest</span><span></span></td> </tr> </table> <div style="display: none;"> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAbstract"> <tr> <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td> </tr> <tr> <td> <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div> <table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAbstract</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:stringItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table> </div> </div> </td> </tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentIncomeInterest"> <tr> <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td> </tr> <tr> <td> <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div> <p>Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities.</p> </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"> <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 03<br><br> -Paragraph 7<br><br> -Article 5<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 225<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 2<br><br> -Subparagraph (SX 210.5-03.7(b))<br><br> -URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688<br><br><br><br></p> </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"> <table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_InvestmentIncomeInterest</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:monetaryItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>credit</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table> </div> </div> </td> </tr> </table> </div> </body> </html> </TEXT> </DOCUMENT> <DOCUMENT> <TYPE>XML <SEQUENCE>40 <FILENAME>R29.htm <DESCRIPTION>IDEA: XBRL DOCUMENT <TEXT> <html> <head> <META http-equiv="Content-Type" content="text/html; charset=us-ascii"> <title></title> <link rel="stylesheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript"> function toggleNextSibling (e) { if (e.nextSibling.style.display=='none') { e.nextSibling.style.display='block'; } else { e.nextSibling.style.display='none'; } }</script></head> <body><span style="display: none;">v2.4.1.9</span><table class="report" border="0" cellspacing="2" id="ID0EMCAC"> <tr> <th class="tl" colspan="1" rowspan="2"> <div style="width: 200px;"><strong>Related Parties and Related Party Transactions (Tables)<br></strong></div> </th> <th class="th" colspan="1">12 Months Ended</th> </tr> <tr> <th class="th"> <div>Dec. 31, 2014</div> </th> </tr> <tr class="rh"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=cytk_AstellasMember', window );">Astellas [Member]</a></td> <td class="text"> <span></span></td> </tr> <tr class="ro"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock', window );">Revenue from Related Party</a></td> <td class="text"><div> <p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 12px; TEXT-INDENT: 4%" align="justify"><font style="FONT-FAMILY: Times New Roman" size="2">Research and development revenue from Astellas was as follows (in thousands):</font></p> <p style="MARGIN-BOTTOM: 0px; FONT-SIZE: 12px; MARGIN-TOP: 0px">  </p> <table style="BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="92%" align="center" border="0"> <tr> <td width="71%"></td> <td valign="bottom" width="9%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="9%"></td> <td></td> <td></td> <td></td> </tr> <tr> <td valign="bottom"><font size="1"> </font></td> <td valign="bottom"><font size="1">  </font></td> <td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" align="center"><font style="FONT-FAMILY: Times New Roman" size="1"><b>Year Ended<br /> December 31,<br /> 2014</b></font></td> <td valign="bottom"><font size="1"> </font></td> <td valign="bottom"><font size="1">  </font></td> <td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" align="center"><font style="FONT-FAMILY: Times New Roman" size="1"><b>Year Ended<br /> December 31,<br /> 2013</b></font></td> <td valign="bottom"><font size="1"> </font></td> </tr> <tr bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: Times New Roman" size="2">Research and development revenues with related parties:</font></p> </td> <td valign="bottom"><font size="1">  </font></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"><font size="1">  </font></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr> <td valign="top"> <p style="MARGIN-LEFT: 2em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: Times New Roman" size="2">Research and development milestone fees</font></p> </td> <td valign="bottom"><font size="1">  </font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">15,000</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">  </font></td> <td valign="bottom"><font size="1">  </font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2"> </font></td> <td valign="bottom" nowrap="nowrap" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">—</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">  </font></td> </tr> <tr bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: Times New Roman" size="2">Research and development revenues:</font></p> </td> <td valign="bottom"><font size="1">  </font></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"><font size="1">  </font></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr> <td valign="top"> <p style="MARGIN-LEFT: 2em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: Times New Roman" size="2">Reimbursement of internal costs</font></p> </td> <td valign="bottom"><font size="1">  </font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2"> </font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">8,939</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">  </font></td> <td valign="bottom"><font size="1">  </font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2"> </font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">3,285</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">  </font></td> </tr> <tr bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-LEFT: 2em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: Times New Roman" size="2">Reimbursement of other costs</font></p> </td> <td valign="bottom"><font size="1">  </font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2"> </font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">6,452</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">  </font></td> <td valign="bottom"><font size="1">  </font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2"> </font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">3,130</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">  </font></td> </tr> <tr> <td valign="top"> <p style="MARGIN-LEFT: 2em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: Times New Roman" size="2">Research and development milestone fees</font></p> </td> <td valign="bottom"><font size="1">  </font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2"> </font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">2,000</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">  </font></td> <td valign="bottom"><font size="1">  </font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2"> </font></td> <td valign="bottom" nowrap="nowrap" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">—</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">  </font></td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid"> </p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid"> </p> </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid"> </p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid"> </p> </td> <td> </td> </tr> <tr bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-LEFT: 3em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: Times New Roman" size="2">Total research and development revenue from Astellas</font></p> </td> <td valign="bottom"><font size="1">  </font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">32,391</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">  </font></td> <td valign="bottom"><font size="1">  </font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">6,415</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">  </font></td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double"> </p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double"> </p> </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double"> </p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double"> </p> </td> <td> </td> </tr> </table> </div><span></span></td> </tr> <tr class="rh"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=cytk_AmgenMember', window );">Amgen [Member]</a></td> <td class="text"> <span></span></td> </tr> <tr class="ro"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock', window );">Revenue from Related Party</a></td> <td class="text"><div> <p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 12px; TEXT-INDENT: 4%" align="justify"><font style="FONT-FAMILY: Times New Roman" size="2">Revenue from Amgen was as follows (in thousands):</font></p> <p style="MARGIN-BOTTOM: 0px; FONT-SIZE: 12px; MARGIN-TOP: 0px">  </p> <table style="BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="92%" align="center" border="0"> <tr> <td width="72%"></td> <td valign="bottom" width="4%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="4%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="4%"></td> <td></td> <td></td> <td></td> </tr> <tr> <td valign="bottom"><font size="1"> </font></td> <td valign="bottom"><font size="1">  </font></td> <td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="10" align="center"><font style="FONT-FAMILY: Times New Roman" size="1"><b>Years Ended December 31,</b></font></td> <td valign="bottom"><font size="1"> </font></td> </tr> <tr> <td valign="bottom"><font size="1"> </font></td> <td valign="bottom"><font size="1">  </font></td> <td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" align="center"><font style="FONT-FAMILY: Times New Roman" size="1"><b>2014</b></font></td> <td valign="bottom"><font size="1"> </font></td> <td valign="bottom"><font size="1">  </font></td> <td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" align="center"><font style="FONT-FAMILY: Times New Roman" size="1"><b>2013</b></font></td> <td valign="bottom"><font size="1"> </font></td> <td valign="bottom"><font size="1">  </font></td> <td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" align="center"><font style="FONT-FAMILY: Times New Roman" size="1"><b>2012</b></font></td> <td valign="bottom"><font size="1"> </font></td> </tr> <tr bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: Times New Roman" size="2">License revenues from related parties</font></p> </td> <td valign="bottom"><font size="1">  </font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td> <td valign="bottom" nowrap="nowrap" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">—</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">  </font></td> <td valign="bottom"><font size="1">  </font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">17,230</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">  </font></td> <td valign="bottom"><font size="1">  </font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td> <td valign="bottom" nowrap="nowrap" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">—</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">  </font></td> </tr> <tr> <td valign="top"> <p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: Times New Roman" size="2">Research and development revenues from related parties:</font></p> </td> <td valign="bottom"><font size="1">  </font></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"><font size="1">  </font></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"><font size="1">  </font></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-LEFT: 2em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: Times New Roman" size="2">Reimbursement of internal costs</font></p> </td> <td valign="bottom"><font size="1">  </font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2"> </font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">4,260</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">  </font></td> <td valign="bottom"><font size="1">  </font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2"> </font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">2,019</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">  </font></td> <td valign="bottom"><font size="1">  </font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2"> </font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">4,174</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">  </font></td> </tr> <tr> <td valign="top"> <p style="MARGIN-LEFT: 2em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: Times New Roman" size="2">Reimbursement of other costs</font></p> </td> <td valign="bottom"><font size="1">  </font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2"> </font></td> <td valign="bottom" nowrap="nowrap" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">—</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">  </font></td> <td valign="bottom"><font size="1">  </font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2"> </font></td> <td valign="bottom" nowrap="nowrap" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">—</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">  </font></td> <td valign="bottom"><font size="1">  </font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2"> </font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">3</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">  </font></td> </tr> <tr bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-LEFT: 2em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: Times New Roman" size="2">Allocated consideration</font></p> </td> <td valign="bottom"><font size="1">  </font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2"> </font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">278</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">  </font></td> <td valign="bottom"><font size="1">  </font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2"> </font></td> <td valign="bottom" nowrap="nowrap" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">—</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">  </font></td> <td valign="bottom"><font size="1">  </font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2"> </font></td> <td valign="bottom" nowrap="nowrap" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">—</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">  </font></td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid"> </p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid"> </p> </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid"> </p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid"> </p> </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid"> </p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid"> </p> </td> <td> </td> </tr> <tr> <td valign="top"> <p style="MARGIN-LEFT: 3em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: Times New Roman" size="2">Total revenues from Amgen</font></p> </td> <td valign="bottom"><font size="1">  </font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">4,538</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">  </font></td> <td valign="bottom"><font size="1">  </font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">19,249</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">  </font></td> <td valign="bottom"><font size="1">  </font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">4,177</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">  </font></td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double"> </p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double"> </p> </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double"> </p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double"> </p> </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double"> </p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double"> </p> </td> <td> </td> </tr> </table> </div><span></span></td> </tr> </table> <div style="display: none;"> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock"> <tr> <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td> </tr> <tr> <td> <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div> <p>Tabular disclosure of related party transactions. Examples of related party transactions include, but are not limited to, transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners and (d) affiliates.</p> </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"> <p>No definition available.</p> </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"> <table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>nonnum:textBlockItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table> </div> </div> </td> </tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=cytk_AmgenMember"> <tr> <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td> </tr> <tr> <td> <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div> <table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=cytk_AmgenMember</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td></td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td></td> </tr> <tr> <td><strong> Period Type:</strong></td> <td></td> </tr> </table> </div> </div> </td> </tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=cytk_AstellasMember"> <tr> <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td> </tr> <tr> <td> <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div> <table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=cytk_AstellasMember</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td></td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td></td> </tr> <tr> <td><strong> Period Type:</strong></td> <td></td> </tr> </table> </div> </div> </td> </tr> </table> </div> </body> </html> </TEXT> </DOCUMENT> <DOCUMENT> <TYPE>XML <SEQUENCE>41 <FILENAME>R28.htm <DESCRIPTION>IDEA: XBRL DOCUMENT <TEXT> <html> <head> <META http-equiv="Content-Type" content="text/html; charset=us-ascii"> <title></title> <link rel="stylesheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript"> function toggleNextSibling (e) { if (e.nextSibling.style.display=='none') { e.nextSibling.style.display='block'; } else { e.nextSibling.style.display='none'; } }</script></head> <body><span style="display: none;">v2.4.1.9</span><table class="report" border="0" cellspacing="2" id="ID0E2F"> <tr> <th class="tl" colspan="1" rowspan="2"> <div style="width: 200px;"><strong>Balance Sheet Components (Tables)<br></strong></div> </th> <th class="th" colspan="1">12 Months Ended</th> </tr> <tr> <th class="th"> <div>Dec. 31, 2014</div> </th> </tr> <tr class="re"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td> <td class="text"> <span></span></td> </tr> <tr class="ro"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentTextBlock', window );">Summary of Property and Equipment Balances</a></td> <td class="text"><div> <p style="margin-top:6px;margin-bottom:0px; text-indent:4%" align="justify"><font style="font-family:Times New Roman" size="2">Property and equipment balances were as follows (in thousands):</font></p> <p style="font-size:12px;margin-top:0px;margin-bottom:0px">  </p> <table cellspacing="0" cellpadding="0" width="92%" border="0" style="BORDER-COLLAPSE:COLLAPSE" align="center"> <tr> <td width="77%"></td> <td valign="bottom" width="6%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="5%"></td> <td></td> <td></td> <td></td> </tr> <tr> <td valign="bottom"><font size="1"> </font></td> <td valign="bottom"><font size="1">  </font></td> <td valign="bottom" colspan="6" align="center" style="border-bottom:1px solid #000000"><font style="font-family:Times New Roman" size="1"><b>December 31,</b></font></td> <td valign="bottom"><font size="1"> </font></td> </tr> <tr> <td valign="bottom"><font size="1"> </font></td> <td valign="bottom"><font size="1">  </font></td> <td valign="bottom" colspan="2" align="center" style="border-bottom:1px solid #000000"><font style="font-family:Times New Roman" size="1"><b>2014</b></font></td> <td valign="bottom"><font size="1"> </font></td> <td valign="bottom"><font size="1">  </font></td> <td valign="bottom" colspan="2" align="center" style="border-bottom:1px solid #000000"><font style="font-family:Times New Roman" size="1"><b>2013</b></font></td> <td valign="bottom"><font size="1"> </font></td> </tr> <tr bgcolor="#CCEEFF"> <td valign="top"> <p style="margin-left:1.00em; text-indent:-1.00em"><font style="font-family:Times New Roman" size="2">Property and equipment, net:</font></p> </td> <td valign="bottom"><font size="1">  </font></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"><font size="1">  </font></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr> <td valign="top"> <p style="margin-left:2.00em; text-indent:-1.00em"><font style="font-family:Times New Roman" size="2">Laboratory equipment</font></p> </td> <td valign="bottom"><font size="1">  </font></td> <td valign="bottom"><font style="font-family:Times New Roman" size="2">$</font></td> <td valign="bottom" align="right"><font style="font-family:Times New Roman" size="2">15,299</font></td> <td nowrap="nowrap" valign="bottom"><font style="font-family:Times New Roman" size="2">  </font></td> <td valign="bottom"><font size="1">  </font></td> <td valign="bottom"><font style="font-family:Times New Roman" size="2">$</font></td> <td valign="bottom" align="right"><font style="font-family:Times New Roman" size="2">15,317</font></td> <td nowrap="nowrap" valign="bottom"><font style="font-family:Times New Roman" size="2">  </font></td> </tr> <tr bgcolor="#CCEEFF"> <td valign="top"> <p style="margin-left:2.00em; text-indent:-1.00em"><font style="font-family:Times New Roman" size="2">Computer equipment and software</font></p> </td> <td valign="bottom"><font size="1">  </font></td> <td valign="bottom"><font style="font-family:Times New Roman" size="2"> </font></td> <td valign="bottom" align="right"><font style="font-family:Times New Roman" size="2">2,418</font></td> <td nowrap="nowrap" valign="bottom"><font style="font-family:Times New Roman" size="2">  </font></td> <td valign="bottom"><font size="1">  </font></td> <td valign="bottom"><font style="font-family:Times New Roman" size="2"> </font></td> <td valign="bottom" align="right"><font style="font-family:Times New Roman" size="2">2,549</font></td> <td nowrap="nowrap" valign="bottom"><font style="font-family:Times New Roman" size="2">  </font></td> </tr> <tr> <td valign="top"> <p style="margin-left:2.00em; text-indent:-1.00em"><font style="font-family:Times New Roman" size="2">Office equipment, furniture and fixtures</font></p> </td> <td valign="bottom"><font size="1">  </font></td> <td valign="bottom"><font style="font-family:Times New Roman" size="2"> </font></td> <td valign="bottom" align="right"><font style="font-family:Times New Roman" size="2">913</font></td> <td nowrap="nowrap" valign="bottom"><font style="font-family:Times New Roman" size="2">  </font></td> <td valign="bottom"><font size="1">  </font></td> <td valign="bottom"><font style="font-family:Times New Roman" size="2"> </font></td> <td valign="bottom" align="right"><font style="font-family:Times New Roman" size="2">1,050</font></td> <td nowrap="nowrap" valign="bottom"><font style="font-family:Times New Roman" size="2">  </font></td> </tr> <tr bgcolor="#CCEEFF"> <td valign="top"> <p style="margin-left:2.00em; text-indent:-1.00em"><font style="font-family:Times New Roman" size="2">Leasehold improvements</font></p> </td> <td valign="bottom"><font size="1">  </font></td> <td valign="bottom"><font style="font-family:Times New Roman" size="2"> </font></td> <td valign="bottom" align="right"><font style="font-family:Times New Roman" size="2">3,334</font></td> <td nowrap="nowrap" valign="bottom"><font style="font-family:Times New Roman" size="2">  </font></td> <td valign="bottom"><font size="1">  </font></td> <td valign="bottom"><font style="font-family:Times New Roman" size="2"> </font></td> <td valign="bottom" align="right"><font style="font-family:Times New Roman" size="2">3,297</font></td> <td nowrap="nowrap" valign="bottom"><font style="font-family:Times New Roman" size="2">  </font></td> </tr> <tr style="font-size:1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"> <p style="border-top:1px solid #000000"> </p> </td> <td valign="bottom"> <p style="border-top:1px solid #000000"> </p> </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom"> <p style="border-top:1px solid #000000"> </p> </td> <td valign="bottom"> <p style="border-top:1px solid #000000"> </p> </td> <td> </td> </tr> <tr> <td valign="top"></td> <td valign="bottom"><font size="1">  </font></td> <td valign="bottom"><font style="font-family:Times New Roman" size="2"> </font></td> <td valign="bottom" align="right"><font style="font-family:Times New Roman" size="2">21,964</font></td> <td nowrap="nowrap" valign="bottom"><font style="font-family:Times New Roman" size="2">  </font></td> <td valign="bottom"><font size="1">  </font></td> <td valign="bottom"><font style="font-family:Times New Roman" size="2"> </font></td> <td valign="bottom" align="right"><font style="font-family:Times New Roman" size="2">22,213</font></td> <td nowrap="nowrap" valign="bottom"><font style="font-family:Times New Roman" size="2">  </font></td> </tr> <tr bgcolor="#CCEEFF"> <td valign="top"> <p style="margin-left:2.00em; text-indent:-1.00em"><font style="font-family:Times New Roman" size="2">Less: Accumulated depreciation and amortization</font></p> </td> <td valign="bottom"><font size="1">  </font></td> <td valign="bottom"><font style="font-family:Times New Roman" size="2"> </font></td> <td valign="bottom" align="right"><font style="font-family:Times New Roman" size="2">(20,327</font></td> <td nowrap="nowrap" valign="bottom"><font style="font-family:Times New Roman" size="2">) </font></td> <td valign="bottom"><font size="1">  </font></td> <td valign="bottom"><font style="font-family:Times New Roman" size="2"> </font></td> <td valign="bottom" align="right"><font style="font-family:Times New Roman" size="2">(20,992</font></td> <td nowrap="nowrap" valign="bottom"><font style="font-family:Times New Roman" size="2">) </font></td> </tr> <tr style="font-size:1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"> <p style="border-top:1px solid #000000"> </p> </td> <td valign="bottom"> <p style="border-top:1px solid #000000"> </p> </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom"> <p style="border-top:1px solid #000000"> </p> </td> <td valign="bottom"> <p style="border-top:1px solid #000000"> </p> </td> <td> </td> </tr> <tr> <td valign="top"></td> <td valign="bottom"><font size="1">  </font></td> <td valign="bottom"><font style="font-family:Times New Roman" size="2">$</font></td> <td valign="bottom" align="right"><font style="font-family:Times New Roman" size="2">1,637</font></td> <td nowrap="nowrap" valign="bottom"><font style="font-family:Times New Roman" size="2">  </font></td> <td valign="bottom"><font size="1">  </font></td> <td valign="bottom"><font style="font-family:Times New Roman" size="2">$</font></td> <td valign="bottom" align="right"><font style="font-family:Times New Roman" size="2">1,221</font></td> <td nowrap="nowrap" valign="bottom"><font style="font-family:Times New Roman" size="2">  </font></td> </tr> <tr style="font-size:1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"> <p style="border-top:3px double #000000"> </p> </td> <td valign="bottom"> <p style="border-top:3px double #000000"> </p> </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom"> <p style="border-top:3px double #000000"> </p> </td> <td valign="bottom"> <p style="border-top:3px double #000000"> </p> </td> <td> </td> </tr> </table> </div><span></span></td> </tr> <tr class="re"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock', window );">Summary of Accrued Liabilities</a></td> <td class="text"><div> <p style="margin-top:0px;margin-bottom:0px; text-indent:4%" align="justify"><font style="font-family:Times New Roman" size="2">Accrued liabilities were as follows (in thousands):</font></p> <p style="font-size:12px;margin-top:0px;margin-bottom:0px">  </p> <table cellspacing="0" cellpadding="0" width="92%" border="0" style="BORDER-COLLAPSE:COLLAPSE" align="center"> <tr> <td width="82%"></td> <td valign="bottom" width="4%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="4%"></td> <td></td> <td></td> <td></td> </tr> <tr> <td valign="bottom"><font size="1"> </font></td> <td valign="bottom"><font size="1">  </font></td> <td valign="bottom" colspan="6" align="center" style="border-bottom:1px solid #000000"><font style="font-family:Times New Roman" size="1"><b>December 31,</b></font></td> <td valign="bottom"><font size="1"> </font></td> </tr> <tr> <td valign="bottom"><font size="1"> </font></td> <td valign="bottom"><font size="1">  </font></td> <td valign="bottom" colspan="2" align="center" style="border-bottom:1px solid #000000"><font style="font-family:Times New Roman" size="1"><b>2014</b></font></td> <td valign="bottom"><font size="1"> </font></td> <td valign="bottom"><font size="1">  </font></td> <td valign="bottom" colspan="2" align="center" style="border-bottom:1px solid #000000"><font style="font-family:Times New Roman" size="1"><b>2013</b></font></td> <td valign="bottom"><font size="1"> </font></td> </tr> <tr bgcolor="#CCEEFF"> <td valign="top"> <p style="margin-left:1.00em; text-indent:-1.00em"><font style="font-family:Times New Roman" size="2">Accrued liabilities:</font></p> </td> <td valign="bottom"><font size="1">  </font></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"><font size="1">  </font></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr> <td valign="top"> <p style="margin-left:2.00em; text-indent:-1.00em"><font style="font-family:Times New Roman" size="2">Clinical and preclinical costs</font></p> </td> <td valign="bottom"><font size="1">  </font></td> <td valign="bottom"><font style="font-family:Times New Roman" size="2">$</font></td> <td valign="bottom" align="right"><font style="font-family:Times New Roman" size="2">972</font></td> <td nowrap="nowrap" valign="bottom"><font style="font-family:Times New Roman" size="2">  </font></td> <td valign="bottom"><font size="1">  </font></td> <td valign="bottom"><font style="font-family:Times New Roman" size="2">$</font></td> <td valign="bottom" align="right"><font style="font-family:Times New Roman" size="2">4,975</font></td> <td nowrap="nowrap" valign="bottom"><font style="font-family:Times New Roman" size="2">  </font></td> </tr> <tr bgcolor="#CCEEFF"> <td valign="top"> <p style="margin-left:2.00em; text-indent:-1.00em"><font style="font-family:Times New Roman" size="2">Consulting and professional fees</font></p> </td> <td valign="bottom"><font size="1">  </font></td> <td valign="bottom"><font style="font-family:Times New Roman" size="2"> </font></td> <td valign="bottom" align="right"><font style="font-family:Times New Roman" size="2">421</font></td> <td nowrap="nowrap" valign="bottom"><font style="font-family:Times New Roman" size="2">  </font></td> <td valign="bottom"><font size="1">  </font></td> <td valign="bottom"><font style="font-family:Times New Roman" size="2"> </font></td> <td valign="bottom" align="right"><font style="font-family:Times New Roman" size="2">697</font></td> <td nowrap="nowrap" valign="bottom"><font style="font-family:Times New Roman" size="2">  </font></td> </tr> <tr> <td valign="top"> <p style="margin-left:2.00em; text-indent:-1.00em"><font style="font-family:Times New Roman" size="2">Bonus</font></p> </td> <td valign="bottom"><font size="1">  </font></td> <td valign="bottom"><font style="font-family:Times New Roman" size="2"> </font></td> <td valign="bottom" align="right"><font style="font-family:Times New Roman" size="2">2,665</font></td> <td nowrap="nowrap" valign="bottom"><font style="font-family:Times New Roman" size="2">  </font></td> <td valign="bottom"><font size="1">  </font></td> <td valign="bottom"><font style="font-family:Times New Roman" size="2"> </font></td> <td valign="bottom" align="right"><font style="font-family:Times New Roman" size="2">1,614</font></td> <td nowrap="nowrap" valign="bottom"><font style="font-family:Times New Roman" size="2">  </font></td> </tr> <tr bgcolor="#CCEEFF"> <td valign="top"> <p style="margin-left:2.00em; text-indent:-1.00em"><font style="font-family:Times New Roman" size="2">Vacation pay</font></p> </td> <td valign="bottom"><font size="1">  </font></td> <td valign="bottom"><font style="font-family:Times New Roman" size="2"> </font></td> <td valign="bottom" align="right"><font style="font-family:Times New Roman" size="2">915</font></td> <td nowrap="nowrap" valign="bottom"><font style="font-family:Times New Roman" size="2">  </font></td> <td valign="bottom"><font size="1">  </font></td> <td valign="bottom"><font style="font-family:Times New Roman" size="2"> </font></td> <td valign="bottom" align="right"><font style="font-family:Times New Roman" size="2">778</font></td> <td nowrap="nowrap" valign="bottom"><font style="font-family:Times New Roman" size="2">  </font></td> </tr> <tr> <td valign="top"> <p style="margin-left:2.00em; text-indent:-1.00em"><font style="font-family:Times New Roman" size="2">Other payroll related</font></p> </td> <td valign="bottom"><font size="1">  </font></td> <td valign="bottom"><font style="font-family:Times New Roman" size="2"> </font></td> <td valign="bottom" align="right"><font style="font-family:Times New Roman" size="2">110</font></td> <td nowrap="nowrap" valign="bottom"><font style="font-family:Times New Roman" size="2">  </font></td> <td valign="bottom"><font size="1">  </font></td> <td valign="bottom"><font style="font-family:Times New Roman" size="2"> </font></td> <td valign="bottom" align="right"><font style="font-family:Times New Roman" size="2">93</font></td> <td nowrap="nowrap" valign="bottom"><font style="font-family:Times New Roman" size="2">  </font></td> </tr> <tr bgcolor="#CCEEFF"> <td valign="top"> <p style="margin-left:2.00em; text-indent:-1.00em"><font style="font-family:Times New Roman" size="2">Other accrued expenses</font></p> </td> <td valign="bottom"><font size="1">  </font></td> <td valign="bottom"><font style="font-family:Times New Roman" size="2"> </font></td> <td valign="bottom" align="right"><font style="font-family:Times New Roman" size="2">317</font></td> <td nowrap="nowrap" valign="bottom"><font style="font-family:Times New Roman" size="2">  </font></td> <td valign="bottom"><font size="1">  </font></td> <td valign="bottom"><font style="font-family:Times New Roman" size="2"> </font></td> <td valign="bottom" align="right"><font style="font-family:Times New Roman" size="2">115</font></td> <td nowrap="nowrap" valign="bottom"><font style="font-family:Times New Roman" size="2">  </font></td> </tr> <tr style="font-size:1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"> <p style="border-top:1px solid #000000"> </p> </td> <td valign="bottom"> <p style="border-top:1px solid #000000"> </p> </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom"> <p style="border-top:1px solid #000000"> </p> </td> <td valign="bottom"> <p style="border-top:1px solid #000000"> </p> </td> <td> </td> </tr> <tr> <td valign="top"></td> <td valign="bottom"><font size="1">  </font></td> <td valign="bottom"><font style="font-family:Times New Roman" size="2">$</font></td> <td valign="bottom" align="right"><font style="font-family:Times New Roman" size="2">5,400</font></td> <td nowrap="nowrap" valign="bottom"><font style="font-family:Times New Roman" size="2">  </font></td> <td valign="bottom"><font size="1">  </font></td> <td valign="bottom"><font style="font-family:Times New Roman" size="2">$</font></td> <td valign="bottom" align="right"><font style="font-family:Times New Roman" size="2">8,272</font></td> <td nowrap="nowrap" valign="bottom"><font style="font-family:Times New Roman" size="2">  </font></td> </tr> <tr style="font-size:1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"> <p style="border-top:3px double #000000"> </p> </td> <td valign="bottom"> <p style="border-top:3px double #000000"> </p> </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom"> <p style="border-top:3px double #000000"> </p> </td> <td valign="bottom"> <p style="border-top:3px double #000000"> </p> </td> <td> </td> </tr> </table> </div><span></span></td> </tr> </table> <div style="display: none;"> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"> <tr> <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td> </tr> <tr> <td> <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div> <table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:stringItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table> </div> </div> </td> </tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentTextBlock"> <tr> <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td> </tr> <tr> <td> <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div> <p>Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.</p> </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"> <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 360<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.13)<br><br> -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 13<br><br> -Subparagraph b<br><br> -Article 5<br><br><br><br></p> </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"> <table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentTextBlock</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>nonnum:textBlockItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table> </div> </div> </td> </tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock"> <tr> <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td> </tr> <tr> <td> <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div> <p>Tabular disclosure of the components of accrued liabilities.</p> </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"> <p>No definition available.</p> </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"> <table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>nonnum:textBlockItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table> </div> </div> </td> </tr> </table> </div> </body> </html> </TEXT> </DOCUMENT> <DOCUMENT> <TYPE>XML <SEQUENCE>42 <FILENAME>R56.htm <DESCRIPTION>IDEA: XBRL DOCUMENT <TEXT> <html> <head> <META http-equiv="Content-Type" content="text/html; charset=us-ascii"> <title></title> <link rel="stylesheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript"> function toggleNextSibling (e) { if (e.nextSibling.style.display=='none') { e.nextSibling.style.display='block'; } else { e.nextSibling.style.display='none'; } }</script></head> <body><span style="display: none;">v2.4.1.9</span><table class="report" border="0" cellspacing="2" id="ID0E2F"> <tr> <th class="tl" colspan="1" rowspan="2"> <div style="width: 200px;"><strong>Commitments and Contingencies - Additional Information (Detail)<br></strong></div> </th> <th class="th" colspan="1">12 Months Ended</th> </tr> <tr> <th class="th"> <div>Dec. 31, 2014</div> </th> </tr> <tr class="re"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td> <td class="text"> <span></span></td> </tr> <tr class="ro"> <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cytk_NonCancelableLeaseExpirationYear', window );">Non-cancelable operating lease expires</a></td> <td class="text">2018<span></span></td> </tr> <tr class="re"> <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cytk_NonCancelableLeaseAdditionalExtensionPeriod', window );">Non-cancelable operating lease additional extension period</a></td> <td class="text">3 years<span></span></td> </tr> </table> <div style="display: none;"> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cytk_NonCancelableLeaseAdditionalExtensionPeriod"> <tr> <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td> </tr> <tr> <td> <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div> <p>Non Cancelable Lease Additional Extension Period</p> </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"> <p>No definition available.</p> </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"> <table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">cytk_NonCancelableLeaseAdditionalExtensionPeriod</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>cytk_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:durationItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table> </div> </div> </td> </tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cytk_NonCancelableLeaseExpirationYear"> <tr> <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td> </tr> <tr> <td> <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div> <p>Date at which lease or a group of leases is set to expire in CCYY format.</p> </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"> <p>No definition available.</p> </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"> <table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">cytk_NonCancelableLeaseExpirationYear</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>cytk_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:gYearItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table> </div> </div> </td> </tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract"> <tr> <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td> </tr> <tr> <td> <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div> <table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:stringItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table> </div> </div> </td> </tr> </table> </div> </body> </html> </TEXT> </DOCUMENT> <DOCUMENT> <TYPE>XML <SEQUENCE>43 <FILENAME>R44.htm <DESCRIPTION>IDEA: XBRL DOCUMENT <TEXT> <html> <head> <META http-equiv="Content-Type" content="text/html; charset=us-ascii"> <title></title> <link rel="stylesheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript"> function toggleNextSibling (e) { if (e.nextSibling.style.display=='none') { e.nextSibling.style.display='block'; } else { e.nextSibling.style.display='none'; } }</script></head> <body><span style="display: none;">v2.4.1.9</span><table class="report" border="0" cellspacing="2" id="ID0EPFDI"> <tr> <th class="tl" colspan="1" rowspan="1"> <div style="width: 200px;"><strong>Fair Value Measurements - Summary of Financial Assets Measured at Fair Value on Recurring Basis (Detail) (Fair Value, Measurements, Recurring [Member], USD $)<br>In Thousands, unless otherwise specified</strong></div> </th> <th class="th"> <div>Dec. 31, 2014</div> </th> <th class="th"> <div>Dec. 31, 2013</div> </th> </tr> <tr class="re"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> </tr> <tr class="ro"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Assets at fair value</a></td> <td class="nump"><a title="us-gaap_AssetsFairValueDisclosure" onclick="toggleNextSibling(this);">$ 79,945</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_AssetsFairValueDisclosure</span><span></span></td> <td class="nump"><a title="us-gaap_AssetsFairValueDisclosure" onclick="toggleNextSibling(this);">$ 75,930</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_AssetsFairValueDisclosure</span><span></span></td> </tr> <tr class="rh"> <td class="pl " style="border-bottom: 0px;" valign="top"> <div class="a">Money Market Funds [Member]</div> </td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> </tr> <tr class="ro"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> </tr> <tr class="re"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Assets at fair value</a></td> <td class="nump"><a title="us-gaap_AssetsFairValueDisclosure[us-gaap_FairValueByAssetClassAxis=us-gaap_MoneyMarketFundsMember;us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember]" onclick="toggleNextSibling(this);">16,932</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_AssetsFairValueDisclosure<br>/ us-gaap_FairValueByAssetClassAxis<br>= us-gaap_MoneyMarketFundsMember<br>/ us-gaap_FairValueByMeasurementFrequencyAxis<br>= us-gaap_FairValueMeasurementsRecurringMember</span><span></span></td> <td class="nump"><a title="us-gaap_AssetsFairValueDisclosure[us-gaap_FairValueByAssetClassAxis=us-gaap_MoneyMarketFundsMember;us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember]" onclick="toggleNextSibling(this);">15,858</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_AssetsFairValueDisclosure<br>/ us-gaap_FairValueByAssetClassAxis<br>= us-gaap_MoneyMarketFundsMember<br>/ us-gaap_FairValueByMeasurementFrequencyAxis<br>= us-gaap_FairValueMeasurementsRecurringMember</span><span></span></td> </tr> <tr class="rh"> <td class="pl " style="border-bottom: 0px;" valign="top"> <div class="a">U.S. Treasury Securities [Member]</div> </td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> </tr> <tr class="re"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> </tr> <tr class="ro"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Assets at fair value</a></td> <td class="nump"><a title="us-gaap_AssetsFairValueDisclosure[us-gaap_FairValueByAssetClassAxis=us-gaap_USTreasurySecuritiesMember;us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember]" onclick="toggleNextSibling(this);">63,013</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_AssetsFairValueDisclosure<br>/ us-gaap_FairValueByAssetClassAxis<br>= us-gaap_USTreasurySecuritiesMember<br>/ us-gaap_FairValueByMeasurementFrequencyAxis<br>= us-gaap_FairValueMeasurementsRecurringMember</span><span></span></td> <td class="nump"><a title="us-gaap_AssetsFairValueDisclosure[us-gaap_FairValueByAssetClassAxis=us-gaap_USTreasurySecuritiesMember;us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember]" onclick="toggleNextSibling(this);">60,072</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_AssetsFairValueDisclosure<br>/ us-gaap_FairValueByAssetClassAxis<br>= us-gaap_USTreasurySecuritiesMember<br>/ us-gaap_FairValueByMeasurementFrequencyAxis<br>= us-gaap_FairValueMeasurementsRecurringMember</span><span></span></td> </tr> <tr class="rh"> <td class="pl " style="border-bottom: 0px;" valign="top"> <div class="a">Long-term Investments [Member]</div> </td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> </tr> <tr class="ro"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> </tr> <tr class="re"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Assets at fair value</a></td> <td class="nump"><a title="us-gaap_AssetsFairValueDisclosure[us-gaap_BalanceSheetLocationAxis=cytk_LongTermInvestmentMember;us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember]" onclick="toggleNextSibling(this);">0</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_AssetsFairValueDisclosure<br>/ us-gaap_BalanceSheetLocationAxis<br>= cytk_LongTermInvestmentMember<br>/ us-gaap_FairValueByMeasurementFrequencyAxis<br>= us-gaap_FairValueMeasurementsRecurringMember</span><span></span></td> <td class="nump"><a title="us-gaap_AssetsFairValueDisclosure[us-gaap_BalanceSheetLocationAxis=cytk_LongTermInvestmentMember;us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember]" onclick="toggleNextSibling(this);">2,502</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_AssetsFairValueDisclosure<br>/ us-gaap_BalanceSheetLocationAxis<br>= cytk_LongTermInvestmentMember<br>/ us-gaap_FairValueByMeasurementFrequencyAxis<br>= us-gaap_FairValueMeasurementsRecurringMember</span><span></span></td> </tr> <tr class="rh"> <td class="pl " style="border-bottom: 0px;" valign="top"> <div class="a">Short-term Investments [Member]</div> </td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> </tr> <tr class="re"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> </tr> <tr class="ro"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Assets at fair value</a></td> <td class="nump"><a title="us-gaap_AssetsFairValueDisclosure[us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember;us-gaap_ScheduleOfFairValueOfSeparateAccountsByMajorCategoryOfInvestmentAxis=us-gaap_ShortTermInvestmentsMember]" onclick="toggleNextSibling(this);">63,013</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_AssetsFairValueDisclosure<br>/ us-gaap_FairValueByMeasurementFrequencyAxis<br>= us-gaap_FairValueMeasurementsRecurringMember<br>/ us-gaap_ScheduleOfFairValueOfSeparateAccountsByMajorCategoryOfInvestmentAxis<br>= us-gaap_ShortTermInvestmentsMember</span><span></span></td> <td class="nump"><a title="us-gaap_AssetsFairValueDisclosure[us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember;us-gaap_ScheduleOfFairValueOfSeparateAccountsByMajorCategoryOfInvestmentAxis=us-gaap_ShortTermInvestmentsMember]" onclick="toggleNextSibling(this);">57,570</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_AssetsFairValueDisclosure<br>/ us-gaap_FairValueByMeasurementFrequencyAxis<br>= us-gaap_FairValueMeasurementsRecurringMember<br>/ us-gaap_ScheduleOfFairValueOfSeparateAccountsByMajorCategoryOfInvestmentAxis<br>= us-gaap_ShortTermInvestmentsMember</span><span></span></td> </tr> <tr class="rh"> <td class="pl " style="border-bottom: 0px;" valign="top"> <div class="a">Fair Value Measurements Using Level 1 [Member]</div> </td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> </tr> <tr class="ro"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> </tr> <tr class="re"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Assets at fair value</a></td> <td class="nump"><a title="us-gaap_AssetsFairValueDisclosure[us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member;us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember]" onclick="toggleNextSibling(this);">79,945</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_AssetsFairValueDisclosure<br>/ us-gaap_FairValueByFairValueHierarchyLevelAxis<br>= us-gaap_FairValueInputsLevel1Member<br>/ us-gaap_FairValueByMeasurementFrequencyAxis<br>= us-gaap_FairValueMeasurementsRecurringMember</span><span></span></td> <td class="nump"><a title="us-gaap_AssetsFairValueDisclosure[us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member;us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember]" onclick="toggleNextSibling(this);">75,930</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_AssetsFairValueDisclosure<br>/ us-gaap_FairValueByFairValueHierarchyLevelAxis<br>= us-gaap_FairValueInputsLevel1Member<br>/ us-gaap_FairValueByMeasurementFrequencyAxis<br>= us-gaap_FairValueMeasurementsRecurringMember</span><span></span></td> </tr> <tr class="rh"> <td class="pl " style="border-bottom: 0px;" valign="top"> <div class="a">Fair Value Measurements Using Level 1 [Member] | Money Market Funds [Member]</div> </td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> </tr> <tr class="re"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> </tr> <tr class="ro"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Assets at fair value</a></td> <td class="nump"><a title="us-gaap_AssetsFairValueDisclosure[us-gaap_FairValueByAssetClassAxis=us-gaap_MoneyMarketFundsMember;us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member;us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember]" onclick="toggleNextSibling(this);">16,932</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_AssetsFairValueDisclosure<br>/ us-gaap_FairValueByAssetClassAxis<br>= us-gaap_MoneyMarketFundsMember<br>/ us-gaap_FairValueByFairValueHierarchyLevelAxis<br>= us-gaap_FairValueInputsLevel1Member<br>/ us-gaap_FairValueByMeasurementFrequencyAxis<br>= us-gaap_FairValueMeasurementsRecurringMember</span><span></span></td> <td class="nump"><a title="us-gaap_AssetsFairValueDisclosure[us-gaap_FairValueByAssetClassAxis=us-gaap_MoneyMarketFundsMember;us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member;us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember]" onclick="toggleNextSibling(this);">15,858</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_AssetsFairValueDisclosure<br>/ us-gaap_FairValueByAssetClassAxis<br>= us-gaap_MoneyMarketFundsMember<br>/ us-gaap_FairValueByFairValueHierarchyLevelAxis<br>= us-gaap_FairValueInputsLevel1Member<br>/ us-gaap_FairValueByMeasurementFrequencyAxis<br>= us-gaap_FairValueMeasurementsRecurringMember</span><span></span></td> </tr> <tr class="rh"> <td class="pl " style="border-bottom: 0px;" valign="top"> <div class="a">Fair Value Measurements Using Level 1 [Member] | U.S. Treasury Securities [Member]</div> </td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> </tr> <tr class="ro"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> </tr> <tr class="re"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Assets at fair value</a></td> <td class="nump"><a title="us-gaap_AssetsFairValueDisclosure[us-gaap_FairValueByAssetClassAxis=us-gaap_USTreasurySecuritiesMember;us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member;us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember]" onclick="toggleNextSibling(this);">63,013</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_AssetsFairValueDisclosure<br>/ us-gaap_FairValueByAssetClassAxis<br>= us-gaap_USTreasurySecuritiesMember<br>/ us-gaap_FairValueByFairValueHierarchyLevelAxis<br>= us-gaap_FairValueInputsLevel1Member<br>/ us-gaap_FairValueByMeasurementFrequencyAxis<br>= us-gaap_FairValueMeasurementsRecurringMember</span><span></span></td> <td class="nump"><a title="us-gaap_AssetsFairValueDisclosure[us-gaap_FairValueByAssetClassAxis=us-gaap_USTreasurySecuritiesMember;us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member;us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember]" onclick="toggleNextSibling(this);">60,072</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_AssetsFairValueDisclosure<br>/ us-gaap_FairValueByAssetClassAxis<br>= us-gaap_USTreasurySecuritiesMember<br>/ us-gaap_FairValueByFairValueHierarchyLevelAxis<br>= us-gaap_FairValueInputsLevel1Member<br>/ us-gaap_FairValueByMeasurementFrequencyAxis<br>= us-gaap_FairValueMeasurementsRecurringMember</span><span></span></td> </tr> <tr class="rh"> <td class="pl " style="border-bottom: 0px;" valign="top"> <div class="a">Fair Value Measurements Using Level 1 [Member] | Long-term Investments [Member]</div> </td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> </tr> <tr class="re"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> </tr> <tr class="ro"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Assets at fair value</a></td> <td class="nump"><a title="us-gaap_AssetsFairValueDisclosure[us-gaap_BalanceSheetLocationAxis=cytk_LongTermInvestmentMember;us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member;us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember]" onclick="toggleNextSibling(this);">0</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_AssetsFairValueDisclosure<br>/ us-gaap_BalanceSheetLocationAxis<br>= cytk_LongTermInvestmentMember<br>/ us-gaap_FairValueByFairValueHierarchyLevelAxis<br>= us-gaap_FairValueInputsLevel1Member<br>/ us-gaap_FairValueByMeasurementFrequencyAxis<br>= us-gaap_FairValueMeasurementsRecurringMember</span><span></span></td> <td class="nump"><a title="us-gaap_AssetsFairValueDisclosure[us-gaap_BalanceSheetLocationAxis=cytk_LongTermInvestmentMember;us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member;us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember]" onclick="toggleNextSibling(this);">2,502</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_AssetsFairValueDisclosure<br>/ us-gaap_BalanceSheetLocationAxis<br>= cytk_LongTermInvestmentMember<br>/ us-gaap_FairValueByFairValueHierarchyLevelAxis<br>= us-gaap_FairValueInputsLevel1Member<br>/ us-gaap_FairValueByMeasurementFrequencyAxis<br>= us-gaap_FairValueMeasurementsRecurringMember</span><span></span></td> </tr> <tr class="rh"> <td class="pl " style="border-bottom: 0px;" valign="top"> <div class="a">Fair Value Measurements Using Level 1 [Member] | Short-term Investments [Member]</div> </td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> </tr> <tr class="ro"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> </tr> <tr class="re"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Assets at fair value</a></td> <td class="nump"><a title="us-gaap_AssetsFairValueDisclosure[us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member;us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember;us-gaap_ScheduleOfFairValueOfSeparateAccountsByMajorCategoryOfInvestmentAxis=us-gaap_ShortTermInvestmentsMember]" onclick="toggleNextSibling(this);">63,013</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_AssetsFairValueDisclosure<br>/ us-gaap_FairValueByFairValueHierarchyLevelAxis<br>= us-gaap_FairValueInputsLevel1Member<br>/ us-gaap_FairValueByMeasurementFrequencyAxis<br>= us-gaap_FairValueMeasurementsRecurringMember<br>/ us-gaap_ScheduleOfFairValueOfSeparateAccountsByMajorCategoryOfInvestmentAxis<br>= us-gaap_ShortTermInvestmentsMember</span><span></span></td> <td class="nump"><a title="us-gaap_AssetsFairValueDisclosure[us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member;us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember;us-gaap_ScheduleOfFairValueOfSeparateAccountsByMajorCategoryOfInvestmentAxis=us-gaap_ShortTermInvestmentsMember]" onclick="toggleNextSibling(this);">57,570</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_AssetsFairValueDisclosure<br>/ us-gaap_FairValueByFairValueHierarchyLevelAxis<br>= us-gaap_FairValueInputsLevel1Member<br>/ us-gaap_FairValueByMeasurementFrequencyAxis<br>= us-gaap_FairValueMeasurementsRecurringMember<br>/ us-gaap_ScheduleOfFairValueOfSeparateAccountsByMajorCategoryOfInvestmentAxis<br>= us-gaap_ShortTermInvestmentsMember</span><span></span></td> </tr> <tr class="rh"> <td class="pl " style="border-bottom: 0px;" valign="top"> <div class="a">Fair Value Measurements Using Level 2 [Member]</div> </td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> </tr> <tr class="re"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> </tr> <tr class="ro"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Assets at fair value</a></td> <td class="nump"><a title="us-gaap_AssetsFairValueDisclosure[us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member;us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember]" onclick="toggleNextSibling(this);">0</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_AssetsFairValueDisclosure<br>/ us-gaap_FairValueByFairValueHierarchyLevelAxis<br>= us-gaap_FairValueInputsLevel2Member<br>/ us-gaap_FairValueByMeasurementFrequencyAxis<br>= us-gaap_FairValueMeasurementsRecurringMember</span><span></span></td> <td class="nump"><a title="us-gaap_AssetsFairValueDisclosure[us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member;us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember]" onclick="toggleNextSibling(this);">0</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_AssetsFairValueDisclosure<br>/ us-gaap_FairValueByFairValueHierarchyLevelAxis<br>= us-gaap_FairValueInputsLevel2Member<br>/ us-gaap_FairValueByMeasurementFrequencyAxis<br>= us-gaap_FairValueMeasurementsRecurringMember</span><span></span></td> </tr> <tr class="rh"> <td class="pl " style="border-bottom: 0px;" valign="top"> <div class="a">Fair Value Measurements Using Level 2 [Member] | Money Market Funds [Member]</div> </td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> </tr> <tr class="ro"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> </tr> <tr class="re"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Assets at fair value</a></td> <td class="nump"><a title="us-gaap_AssetsFairValueDisclosure[us-gaap_FairValueByAssetClassAxis=us-gaap_MoneyMarketFundsMember;us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member;us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember]" onclick="toggleNextSibling(this);">0</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_AssetsFairValueDisclosure<br>/ us-gaap_FairValueByAssetClassAxis<br>= us-gaap_MoneyMarketFundsMember<br>/ us-gaap_FairValueByFairValueHierarchyLevelAxis<br>= us-gaap_FairValueInputsLevel2Member<br>/ us-gaap_FairValueByMeasurementFrequencyAxis<br>= us-gaap_FairValueMeasurementsRecurringMember</span><span></span></td> <td class="nump"><a title="us-gaap_AssetsFairValueDisclosure[us-gaap_FairValueByAssetClassAxis=us-gaap_MoneyMarketFundsMember;us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member;us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember]" onclick="toggleNextSibling(this);">0</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_AssetsFairValueDisclosure<br>/ us-gaap_FairValueByAssetClassAxis<br>= us-gaap_MoneyMarketFundsMember<br>/ us-gaap_FairValueByFairValueHierarchyLevelAxis<br>= us-gaap_FairValueInputsLevel2Member<br>/ us-gaap_FairValueByMeasurementFrequencyAxis<br>= us-gaap_FairValueMeasurementsRecurringMember</span><span></span></td> </tr> <tr class="rh"> <td class="pl " style="border-bottom: 0px;" valign="top"> <div class="a">Fair Value Measurements Using Level 2 [Member] | U.S. Treasury Securities [Member]</div> </td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> </tr> <tr class="re"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> </tr> <tr class="ro"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Assets at fair value</a></td> <td class="nump"><a title="us-gaap_AssetsFairValueDisclosure[us-gaap_FairValueByAssetClassAxis=us-gaap_USTreasurySecuritiesMember;us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member;us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember]" onclick="toggleNextSibling(this);">0</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_AssetsFairValueDisclosure<br>/ us-gaap_FairValueByAssetClassAxis<br>= us-gaap_USTreasurySecuritiesMember<br>/ us-gaap_FairValueByFairValueHierarchyLevelAxis<br>= us-gaap_FairValueInputsLevel2Member<br>/ us-gaap_FairValueByMeasurementFrequencyAxis<br>= us-gaap_FairValueMeasurementsRecurringMember</span><span></span></td> <td class="nump"><a title="us-gaap_AssetsFairValueDisclosure[us-gaap_FairValueByAssetClassAxis=us-gaap_USTreasurySecuritiesMember;us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member;us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember]" onclick="toggleNextSibling(this);">0</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_AssetsFairValueDisclosure<br>/ us-gaap_FairValueByAssetClassAxis<br>= us-gaap_USTreasurySecuritiesMember<br>/ us-gaap_FairValueByFairValueHierarchyLevelAxis<br>= us-gaap_FairValueInputsLevel2Member<br>/ us-gaap_FairValueByMeasurementFrequencyAxis<br>= us-gaap_FairValueMeasurementsRecurringMember</span><span></span></td> </tr> <tr class="rh"> <td class="pl " style="border-bottom: 0px;" valign="top"> <div class="a">Fair Value Measurements Using Level 2 [Member] | Long-term Investments [Member]</div> </td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> </tr> <tr class="ro"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> </tr> <tr class="re"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Assets at fair value</a></td> <td class="nump"><a title="us-gaap_AssetsFairValueDisclosure[us-gaap_BalanceSheetLocationAxis=cytk_LongTermInvestmentMember;us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member;us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember]" onclick="toggleNextSibling(this);">0</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_AssetsFairValueDisclosure<br>/ us-gaap_BalanceSheetLocationAxis<br>= cytk_LongTermInvestmentMember<br>/ us-gaap_FairValueByFairValueHierarchyLevelAxis<br>= us-gaap_FairValueInputsLevel2Member<br>/ us-gaap_FairValueByMeasurementFrequencyAxis<br>= us-gaap_FairValueMeasurementsRecurringMember</span><span></span></td> <td class="nump"><a title="us-gaap_AssetsFairValueDisclosure[us-gaap_BalanceSheetLocationAxis=cytk_LongTermInvestmentMember;us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member;us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember]" onclick="toggleNextSibling(this);">0</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_AssetsFairValueDisclosure<br>/ us-gaap_BalanceSheetLocationAxis<br>= cytk_LongTermInvestmentMember<br>/ us-gaap_FairValueByFairValueHierarchyLevelAxis<br>= us-gaap_FairValueInputsLevel2Member<br>/ us-gaap_FairValueByMeasurementFrequencyAxis<br>= us-gaap_FairValueMeasurementsRecurringMember</span><span></span></td> </tr> <tr class="rh"> <td class="pl " style="border-bottom: 0px;" valign="top"> <div class="a">Fair Value Measurements Using Level 2 [Member] | Short-term Investments [Member]</div> </td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> </tr> <tr class="re"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> </tr> <tr class="ro"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Assets at fair value</a></td> <td class="nump"><a title="us-gaap_AssetsFairValueDisclosure[us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member;us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember;us-gaap_ScheduleOfFairValueOfSeparateAccountsByMajorCategoryOfInvestmentAxis=us-gaap_ShortTermInvestmentsMember]" onclick="toggleNextSibling(this);">0</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_AssetsFairValueDisclosure<br>/ us-gaap_FairValueByFairValueHierarchyLevelAxis<br>= us-gaap_FairValueInputsLevel2Member<br>/ us-gaap_FairValueByMeasurementFrequencyAxis<br>= us-gaap_FairValueMeasurementsRecurringMember<br>/ us-gaap_ScheduleOfFairValueOfSeparateAccountsByMajorCategoryOfInvestmentAxis<br>= us-gaap_ShortTermInvestmentsMember</span><span></span></td> <td class="nump"><a title="us-gaap_AssetsFairValueDisclosure[us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member;us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember;us-gaap_ScheduleOfFairValueOfSeparateAccountsByMajorCategoryOfInvestmentAxis=us-gaap_ShortTermInvestmentsMember]" onclick="toggleNextSibling(this);">0</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_AssetsFairValueDisclosure<br>/ us-gaap_FairValueByFairValueHierarchyLevelAxis<br>= us-gaap_FairValueInputsLevel2Member<br>/ us-gaap_FairValueByMeasurementFrequencyAxis<br>= us-gaap_FairValueMeasurementsRecurringMember<br>/ us-gaap_ScheduleOfFairValueOfSeparateAccountsByMajorCategoryOfInvestmentAxis<br>= us-gaap_ShortTermInvestmentsMember</span><span></span></td> </tr> <tr class="rh"> <td class="pl " style="border-bottom: 0px;" valign="top"> <div class="a">Fair Value Measurements Using Level 3 [Member]</div> </td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> </tr> <tr class="ro"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> </tr> <tr class="re"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Assets at fair value</a></td> <td class="nump"><a title="us-gaap_AssetsFairValueDisclosure[us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member;us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember]" onclick="toggleNextSibling(this);">0</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_AssetsFairValueDisclosure<br>/ us-gaap_FairValueByFairValueHierarchyLevelAxis<br>= us-gaap_FairValueInputsLevel3Member<br>/ us-gaap_FairValueByMeasurementFrequencyAxis<br>= us-gaap_FairValueMeasurementsRecurringMember</span><span></span></td> <td class="nump"><a title="us-gaap_AssetsFairValueDisclosure[us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member;us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember]" onclick="toggleNextSibling(this);">0</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_AssetsFairValueDisclosure<br>/ us-gaap_FairValueByFairValueHierarchyLevelAxis<br>= us-gaap_FairValueInputsLevel3Member<br>/ us-gaap_FairValueByMeasurementFrequencyAxis<br>= us-gaap_FairValueMeasurementsRecurringMember</span><span></span></td> </tr> <tr class="rh"> <td class="pl " style="border-bottom: 0px;" valign="top"> <div class="a">Fair Value Measurements Using Level 3 [Member] | Money Market Funds [Member]</div> </td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> </tr> <tr class="re"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> </tr> <tr class="ro"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Assets at fair value</a></td> <td class="nump"><a title="us-gaap_AssetsFairValueDisclosure[us-gaap_FairValueByAssetClassAxis=us-gaap_MoneyMarketFundsMember;us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member;us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember]" onclick="toggleNextSibling(this);">0</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_AssetsFairValueDisclosure<br>/ us-gaap_FairValueByAssetClassAxis<br>= us-gaap_MoneyMarketFundsMember<br>/ us-gaap_FairValueByFairValueHierarchyLevelAxis<br>= us-gaap_FairValueInputsLevel3Member<br>/ us-gaap_FairValueByMeasurementFrequencyAxis<br>= us-gaap_FairValueMeasurementsRecurringMember</span><span></span></td> <td class="nump"><a title="us-gaap_AssetsFairValueDisclosure[us-gaap_FairValueByAssetClassAxis=us-gaap_MoneyMarketFundsMember;us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member;us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember]" onclick="toggleNextSibling(this);">0</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_AssetsFairValueDisclosure<br>/ us-gaap_FairValueByAssetClassAxis<br>= us-gaap_MoneyMarketFundsMember<br>/ us-gaap_FairValueByFairValueHierarchyLevelAxis<br>= us-gaap_FairValueInputsLevel3Member<br>/ us-gaap_FairValueByMeasurementFrequencyAxis<br>= us-gaap_FairValueMeasurementsRecurringMember</span><span></span></td> </tr> <tr class="rh"> <td class="pl " style="border-bottom: 0px;" valign="top"> <div class="a">Fair Value Measurements Using Level 3 [Member] | U.S. Treasury Securities [Member]</div> </td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> </tr> <tr class="ro"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> </tr> <tr class="re"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Assets at fair value</a></td> <td class="nump"><a title="us-gaap_AssetsFairValueDisclosure[us-gaap_FairValueByAssetClassAxis=us-gaap_USTreasurySecuritiesMember;us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member;us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember]" onclick="toggleNextSibling(this);">0</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_AssetsFairValueDisclosure<br>/ us-gaap_FairValueByAssetClassAxis<br>= us-gaap_USTreasurySecuritiesMember<br>/ us-gaap_FairValueByFairValueHierarchyLevelAxis<br>= us-gaap_FairValueInputsLevel3Member<br>/ us-gaap_FairValueByMeasurementFrequencyAxis<br>= us-gaap_FairValueMeasurementsRecurringMember</span><span></span></td> <td class="nump"><a title="us-gaap_AssetsFairValueDisclosure[us-gaap_FairValueByAssetClassAxis=us-gaap_USTreasurySecuritiesMember;us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member;us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember]" onclick="toggleNextSibling(this);">0</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_AssetsFairValueDisclosure<br>/ us-gaap_FairValueByAssetClassAxis<br>= us-gaap_USTreasurySecuritiesMember<br>/ us-gaap_FairValueByFairValueHierarchyLevelAxis<br>= us-gaap_FairValueInputsLevel3Member<br>/ us-gaap_FairValueByMeasurementFrequencyAxis<br>= us-gaap_FairValueMeasurementsRecurringMember</span><span></span></td> </tr> <tr class="rh"> <td class="pl " style="border-bottom: 0px;" valign="top"> <div class="a">Fair Value Measurements Using Level 3 [Member] | Long-term Investments [Member]</div> </td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> </tr> <tr class="re"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> </tr> <tr class="ro"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Assets at fair value</a></td> <td class="nump"><a title="us-gaap_AssetsFairValueDisclosure[us-gaap_BalanceSheetLocationAxis=cytk_LongTermInvestmentMember;us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member;us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember]" onclick="toggleNextSibling(this);">0</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_AssetsFairValueDisclosure<br>/ us-gaap_BalanceSheetLocationAxis<br>= cytk_LongTermInvestmentMember<br>/ us-gaap_FairValueByFairValueHierarchyLevelAxis<br>= us-gaap_FairValueInputsLevel3Member<br>/ us-gaap_FairValueByMeasurementFrequencyAxis<br>= us-gaap_FairValueMeasurementsRecurringMember</span><span></span></td> <td class="nump"><a title="us-gaap_AssetsFairValueDisclosure[us-gaap_BalanceSheetLocationAxis=cytk_LongTermInvestmentMember;us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member;us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember]" onclick="toggleNextSibling(this);">0</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_AssetsFairValueDisclosure<br>/ us-gaap_BalanceSheetLocationAxis<br>= cytk_LongTermInvestmentMember<br>/ us-gaap_FairValueByFairValueHierarchyLevelAxis<br>= us-gaap_FairValueInputsLevel3Member<br>/ us-gaap_FairValueByMeasurementFrequencyAxis<br>= us-gaap_FairValueMeasurementsRecurringMember</span><span></span></td> </tr> <tr class="rh"> <td class="pl " style="border-bottom: 0px;" valign="top"> <div class="a">Fair Value Measurements Using Level 3 [Member] | Short-term Investments [Member]</div> </td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> </tr> <tr class="ro"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> </tr> <tr class="re"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Assets at fair value</a></td> <td class="nump"><a title="us-gaap_AssetsFairValueDisclosure[us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member;us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember;us-gaap_ScheduleOfFairValueOfSeparateAccountsByMajorCategoryOfInvestmentAxis=us-gaap_ShortTermInvestmentsMember]" onclick="toggleNextSibling(this);">0</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_AssetsFairValueDisclosure<br>/ us-gaap_FairValueByFairValueHierarchyLevelAxis<br>= us-gaap_FairValueInputsLevel3Member<br>/ us-gaap_FairValueByMeasurementFrequencyAxis<br>= us-gaap_FairValueMeasurementsRecurringMember<br>/ us-gaap_ScheduleOfFairValueOfSeparateAccountsByMajorCategoryOfInvestmentAxis<br>= us-gaap_ShortTermInvestmentsMember</span><span></span></td> <td class="nump"><a title="us-gaap_AssetsFairValueDisclosure[us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member;us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember;us-gaap_ScheduleOfFairValueOfSeparateAccountsByMajorCategoryOfInvestmentAxis=us-gaap_ShortTermInvestmentsMember]" onclick="toggleNextSibling(this);">0</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_AssetsFairValueDisclosure<br>/ us-gaap_FairValueByFairValueHierarchyLevelAxis<br>= us-gaap_FairValueInputsLevel3Member<br>/ us-gaap_FairValueByMeasurementFrequencyAxis<br>= us-gaap_FairValueMeasurementsRecurringMember<br>/ us-gaap_ScheduleOfFairValueOfSeparateAccountsByMajorCategoryOfInvestmentAxis<br>= us-gaap_ShortTermInvestmentsMember</span><span></span></td> </tr> <tr class="rh"> <td class="pl " style="border-bottom: 0px;" valign="top"> <div class="a">Cash and Cash Equivalents [Member]</div> </td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> </tr> <tr class="re"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> </tr> <tr class="ro"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Assets at fair value</a></td> <td class="nump"><a title="us-gaap_AssetsFairValueDisclosure[us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember;us-gaap_InvestmentTypeAxis=us-gaap_CashAndCashEquivalentsMember]" onclick="toggleNextSibling(this);">16,932</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_AssetsFairValueDisclosure<br>/ us-gaap_FairValueByMeasurementFrequencyAxis<br>= us-gaap_FairValueMeasurementsRecurringMember<br>/ us-gaap_InvestmentTypeAxis<br>= us-gaap_CashAndCashEquivalentsMember</span><span></span></td> <td class="nump"><a title="us-gaap_AssetsFairValueDisclosure[us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember;us-gaap_InvestmentTypeAxis=us-gaap_CashAndCashEquivalentsMember]" onclick="toggleNextSibling(this);">15,858</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_AssetsFairValueDisclosure<br>/ us-gaap_FairValueByMeasurementFrequencyAxis<br>= us-gaap_FairValueMeasurementsRecurringMember<br>/ us-gaap_InvestmentTypeAxis<br>= us-gaap_CashAndCashEquivalentsMember</span><span></span></td> </tr> <tr class="rh"> <td class="pl " style="border-bottom: 0px;" valign="top"> <div class="a">Cash and Cash Equivalents [Member] | Fair Value Measurements Using Level 1 [Member]</div> </td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> </tr> <tr class="ro"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> </tr> <tr class="re"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Assets at fair value</a></td> <td class="nump"><a title="us-gaap_AssetsFairValueDisclosure[us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member;us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember;us-gaap_InvestmentTypeAxis=us-gaap_CashAndCashEquivalentsMember]" onclick="toggleNextSibling(this);">16,932</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_AssetsFairValueDisclosure<br>/ us-gaap_FairValueByFairValueHierarchyLevelAxis<br>= us-gaap_FairValueInputsLevel1Member<br>/ us-gaap_FairValueByMeasurementFrequencyAxis<br>= us-gaap_FairValueMeasurementsRecurringMember<br>/ us-gaap_InvestmentTypeAxis<br>= us-gaap_CashAndCashEquivalentsMember</span><span></span></td> <td class="nump"><a title="us-gaap_AssetsFairValueDisclosure[us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member;us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember;us-gaap_InvestmentTypeAxis=us-gaap_CashAndCashEquivalentsMember]" onclick="toggleNextSibling(this);">15,858</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_AssetsFairValueDisclosure<br>/ us-gaap_FairValueByFairValueHierarchyLevelAxis<br>= us-gaap_FairValueInputsLevel1Member<br>/ us-gaap_FairValueByMeasurementFrequencyAxis<br>= us-gaap_FairValueMeasurementsRecurringMember<br>/ us-gaap_InvestmentTypeAxis<br>= us-gaap_CashAndCashEquivalentsMember</span><span></span></td> </tr> <tr class="rh"> <td class="pl " style="border-bottom: 0px;" valign="top"> <div class="a">Cash and Cash Equivalents [Member] | Fair Value Measurements Using Level 2 [Member]</div> </td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> </tr> <tr class="re"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> </tr> <tr class="ro"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Assets at fair value</a></td> <td class="nump"><a title="us-gaap_AssetsFairValueDisclosure[us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member;us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember;us-gaap_InvestmentTypeAxis=us-gaap_CashAndCashEquivalentsMember]" onclick="toggleNextSibling(this);">0</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_AssetsFairValueDisclosure<br>/ us-gaap_FairValueByFairValueHierarchyLevelAxis<br>= us-gaap_FairValueInputsLevel2Member<br>/ us-gaap_FairValueByMeasurementFrequencyAxis<br>= us-gaap_FairValueMeasurementsRecurringMember<br>/ us-gaap_InvestmentTypeAxis<br>= us-gaap_CashAndCashEquivalentsMember</span><span></span></td> <td class="nump"><a title="us-gaap_AssetsFairValueDisclosure[us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member;us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember;us-gaap_InvestmentTypeAxis=us-gaap_CashAndCashEquivalentsMember]" onclick="toggleNextSibling(this);">0</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_AssetsFairValueDisclosure<br>/ us-gaap_FairValueByFairValueHierarchyLevelAxis<br>= us-gaap_FairValueInputsLevel2Member<br>/ us-gaap_FairValueByMeasurementFrequencyAxis<br>= us-gaap_FairValueMeasurementsRecurringMember<br>/ us-gaap_InvestmentTypeAxis<br>= us-gaap_CashAndCashEquivalentsMember</span><span></span></td> </tr> <tr class="rh"> <td class="pl " style="border-bottom: 0px;" valign="top"> <div class="a">Cash and Cash Equivalents [Member] | Fair Value Measurements Using Level 3 [Member]</div> </td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> </tr> <tr class="ro"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> </tr> <tr class="re"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Assets at fair value</a></td> <td class="nump"><a title="us-gaap_AssetsFairValueDisclosure[us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member;us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember;us-gaap_InvestmentTypeAxis=us-gaap_CashAndCashEquivalentsMember]" onclick="toggleNextSibling(this);">$ 0</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_AssetsFairValueDisclosure<br>/ us-gaap_FairValueByFairValueHierarchyLevelAxis<br>= us-gaap_FairValueInputsLevel3Member<br>/ us-gaap_FairValueByMeasurementFrequencyAxis<br>= us-gaap_FairValueMeasurementsRecurringMember<br>/ us-gaap_InvestmentTypeAxis<br>= us-gaap_CashAndCashEquivalentsMember</span><span></span></td> <td class="nump"><a title="us-gaap_AssetsFairValueDisclosure[us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member;us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember;us-gaap_InvestmentTypeAxis=us-gaap_CashAndCashEquivalentsMember]" onclick="toggleNextSibling(this);">$ 0</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_AssetsFairValueDisclosure<br>/ us-gaap_FairValueByFairValueHierarchyLevelAxis<br>= us-gaap_FairValueInputsLevel3Member<br>/ us-gaap_FairValueByMeasurementFrequencyAxis<br>= us-gaap_FairValueMeasurementsRecurringMember<br>/ us-gaap_InvestmentTypeAxis<br>= us-gaap_CashAndCashEquivalentsMember</span><span></span></td> </tr> </table> <div style="display: none;"> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsFairValueDisclosure"> <tr> <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td> </tr> <tr> <td> <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div> <p>Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p> </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"> <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 820<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&oid=36462937&loc=d3e19207-110258<br><br><br><br></p> </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"> <table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_AssetsFairValueDisclosure</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:monetaryItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>debit</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>instant</td> </tr> </table> </div> </div> </td> </tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"> <tr> <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td> </tr> <tr> <td> <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div> <table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:stringItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table> </div> </div> </td> </tr> </table> </div> </body> </html> </TEXT> </DOCUMENT> <DOCUMENT> <TYPE>XML <SEQUENCE>44 <FILENAME>R30.htm <DESCRIPTION>IDEA: XBRL DOCUMENT <TEXT> <html> <head> <META http-equiv="Content-Type" content="text/html; charset=us-ascii"> <title></title> <link rel="stylesheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript"> function toggleNextSibling (e) { if (e.nextSibling.style.display=='none') { e.nextSibling.style.display='block'; } else { e.nextSibling.style.display='none'; } }</script></head> <body><span style="display: none;">v2.4.1.9</span><table class="report" border="0" cellspacing="2" id="ID0E2DAC"> <tr> <th class="tl" colspan="1" rowspan="2"> <div style="width: 200px;"><strong>Other Research and Development Revenue Arrangements (Tables)<br></strong></div> </th> <th class="th" colspan="1">12 Months Ended</th> </tr> <tr> <th class="th"> <div>Dec. 31, 2014</div> </th> </tr> <tr class="re"> <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cytk_OtherResearchAndDevelopmentRevenueArrangementsRecognizedGrantRevenueTableTextBlock', window );">Summary of Total Grant Revenues</a></td> <td class="text"><div> <p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 0px; TEXT-INDENT: 4%" align="justify"><font style="FONT-FAMILY: Times New Roman" size="2">Total grant revenues were as follows (in thousands):</font></p> <p style="MARGIN-BOTTOM: 0px; FONT-SIZE: 12px; MARGIN-TOP: 0px">  </p> <table style="BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="92%" align="center" border="0"> <tr> <td width="79%"></td> <td valign="bottom" width="4%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="4%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="4%"></td> <td></td> <td></td> <td></td> </tr> <tr> <td valign="bottom"><font size="1"> </font></td> <td valign="bottom"><font size="1">  </font></td> <td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="10" align="center"><font style="FONT-FAMILY: Times New Roman" size="1"><b>Years Ended<br /> December 31,</b></font></td> <td valign="bottom"><font size="1"> </font></td> </tr> <tr> <td valign="bottom"><font size="1"> </font></td> <td valign="bottom"><font size="1">  </font></td> <td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" align="center"><font style="FONT-FAMILY: Times New Roman" size="1"><b>2014</b></font></td> <td valign="bottom"><font size="1"> </font></td> <td valign="bottom"><font size="1">  </font></td> <td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" align="center"><font style="FONT-FAMILY: Times New Roman" size="1"><b>2013</b></font></td> <td valign="bottom"><font size="1"> </font></td> <td valign="bottom"><font size="1">  </font></td> <td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" align="center"><font style="FONT-FAMILY: Times New Roman" size="1"><b>2012</b></font></td> <td valign="bottom"><font size="1"> </font></td> </tr> <tr bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: Times New Roman" size="2">NINDS myasthenia gravis</font></p> </td> <td valign="bottom"><font size="1">  </font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td> <td valign="bottom" nowrap="nowrap" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">—</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">  </font></td> <td valign="bottom"><font size="1">  </font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">69</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">  </font></td> <td valign="bottom"><font size="1">  </font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">1,308</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">  </font></td> </tr> <tr> <td valign="top"> <p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: Times New Roman" size="2">Other grant revenue</font></p> </td> <td valign="bottom"><font size="1">  </font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2"> </font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">75</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">  </font></td> <td valign="bottom"><font size="1">  </font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2"> </font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">25</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">  </font></td> <td valign="bottom"><font size="1">  </font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2"> </font></td> <td valign="bottom" nowrap="nowrap" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">—</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">  </font></td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid"> </p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid"> </p> </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid"> </p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid"> </p> </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid"> </p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid"> </p> </td> <td> </td> </tr> <tr bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-LEFT: 2em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: Times New Roman" size="2">Total grant revenue</font></p> </td> <td valign="bottom"><font size="1">  </font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">75</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">  </font></td> <td valign="bottom"><font size="1">  </font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">94</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">  </font></td> <td valign="bottom"><font size="1">  </font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">1,308</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">  </font></td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double"> </p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double"> </p> </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double"> </p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double"> </p> </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double"> </p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double"> </p> </td> <td> </td> </tr> </table> </div><span></span></td> </tr> <tr class="rh"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=cytk_GlobalBloodTherapeuticsMember', window );">Global Blood [Member]</a></td> <td class="text"> <span></span></td> </tr> <tr class="re"> <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cytk_OtherResearchAndDevelopmentRevenueArrangementsReimbursementOfExpenseTableTextBlock', window );">Summary of Reimbursed Expenses</a></td> <td class="text"><div> <p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 12px; TEXT-INDENT: 4%" align="justify"><font style="FONT-FAMILY: Times New Roman" size="2">Research and development revenue from Global Blood was as follows (in thousands):</font></p> <p style="MARGIN-BOTTOM: 0px; FONT-SIZE: 12px; MARGIN-TOP: 0px">  </p> <table style="BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="92%" align="center" border="0"> <tr> <td width="79%"></td> <td valign="bottom" width="4%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="4%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="4%"></td> <td></td> <td></td> <td></td> </tr> <tr> <td valign="bottom"><font size="1"> </font></td> <td valign="bottom"><font size="1">  </font></td> <td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="10" align="center"><font style="FONT-FAMILY: Times New Roman" size="1"><b>Years Ended December 31,</b></font></td> <td valign="bottom"><font size="1"> </font></td> </tr> <tr> <td valign="bottom"><font size="1"> </font></td> <td valign="bottom"><font size="1">  </font></td> <td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" align="center"><font style="FONT-FAMILY: Times New Roman" size="1"><b>2014</b></font></td> <td valign="bottom"><font size="1"> </font></td> <td valign="bottom"><font size="1">  </font></td> <td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" align="center"><font style="FONT-FAMILY: Times New Roman" size="1"><b>2013</b></font></td> <td valign="bottom"><font size="1"> </font></td> <td valign="bottom"><font size="1">  </font></td> <td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" align="center"><font style="FONT-FAMILY: Times New Roman" size="1"><b>2012</b></font></td> <td valign="bottom"><font size="1"> </font></td> </tr> <tr bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: Times New Roman" size="2">Expense reimbursements from Global Blood</font></p> </td> <td valign="bottom"><font size="1">  </font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td> <td valign="bottom" nowrap="nowrap" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">—</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">  </font></td> <td valign="bottom"><font size="1">  </font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">14</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">  </font></td> <td valign="bottom"><font size="1">  </font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">1,479</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">  </font></td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double"> </p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double"> </p> </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double"> </p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double"> </p> </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double"> </p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double"> </p> </td> <td> </td> </tr> </table> </div><span></span></td> </tr> <tr class="rh"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=cytk_MyokardiaMember', window );">MyoKardia [Member]</a></td> <td class="text"> <span></span></td> </tr> <tr class="re"> <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cytk_OtherResearchAndDevelopmentRevenueArrangementsReimbursementOfExpenseTableTextBlock', window );">Summary of Reimbursed Expenses</a></td> <td class="text"><div> <p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 12px; TEXT-INDENT: 4%" align="justify"><font style="FONT-FAMILY: Times New Roman" size="2">Research and development revenue from MyoKardia was as follows (in thousands):</font></p> <p style="MARGIN-BOTTOM: 0px; FONT-SIZE: 12px; MARGIN-TOP: 0px">  </p> <table style="BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="92%" align="center" border="0"> <tr> <td width="77%"></td> <td valign="bottom" width="4%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="4%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="4%"></td> <td></td> <td></td> <td></td> </tr> <tr> <td valign="bottom"><font size="1"> </font></td> <td valign="bottom"><font size="1">  </font></td> <td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="10" align="center"><font style="FONT-FAMILY: Times New Roman" size="1"><b>Years Ended December 31,</b></font></td> <td valign="bottom"><font size="1"> </font></td> </tr> <tr> <td valign="bottom"><font size="1"> </font></td> <td valign="bottom"><font size="1">  </font></td> <td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" align="center"><font style="FONT-FAMILY: Times New Roman" size="1"><b>2014</b></font></td> <td valign="bottom"><font size="1"> </font></td> <td valign="bottom"><font size="1">  </font></td> <td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" align="center"><font style="FONT-FAMILY: Times New Roman" size="1"><b>2013</b></font></td> <td valign="bottom"><font size="1"> </font></td> <td valign="bottom"><font size="1">  </font></td> <td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" align="center"><font style="FONT-FAMILY: Times New Roman" size="1"><b>2012</b></font></td> <td valign="bottom"><font size="1"> </font></td> </tr> <tr bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: Times New Roman" size="2">Research and development milestone fees</font></p> </td> <td valign="bottom"><font size="1">  </font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">100</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">  </font></td> <td valign="bottom"><font size="1">  </font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td> <td valign="bottom" nowrap="nowrap" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">—</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">  </font></td> <td valign="bottom"><font size="1">  </font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td> <td valign="bottom" nowrap="nowrap" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">—</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">  </font></td> </tr> <tr> <td valign="top"> <p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: Times New Roman" size="2">Expense reimbursements from MyoKardia</font></p> </td> <td valign="bottom"><font size="1">  </font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2"> </font></td> <td valign="bottom" nowrap="nowrap" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">—</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">  </font></td> <td valign="bottom"><font size="1">  </font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2"> </font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">1,024</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">  </font></td> <td valign="bottom"><font size="1">  </font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2"> </font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">595</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">  </font></td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid"> </p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid"> </p> </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid"> </p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid"> </p> </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid"> </p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid"> </p> </td> <td> </td> </tr> <tr bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: Times New Roman" size="2">Research and development revenue from Myokardia</font></p> </td> <td valign="bottom"><font size="1">  </font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">100</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">  </font></td> <td valign="bottom"><font size="1">  </font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">1,024</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">  </font></td> <td valign="bottom"><font size="1">  </font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">595</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">  </font></td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double"> </p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double"> </p> </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double"> </p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double"> </p> </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double"> </p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double"> </p> </td> <td> </td> </tr> </table> </div><span></span></td> </tr> </table> <div style="display: none;"> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cytk_OtherResearchAndDevelopmentRevenueArrangementsRecognizedGrantRevenueTableTextBlock"> <tr> <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td> </tr> <tr> <td> <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div> <p>Total revenue recognized relating to grants awarded for research and development activities.</p> </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"> <p>No definition available.</p> </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"> <table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">cytk_OtherResearchAndDevelopmentRevenueArrangementsRecognizedGrantRevenueTableTextBlock</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>cytk_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>nonnum:textBlockItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table> </div> </div> </td> </tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cytk_OtherResearchAndDevelopmentRevenueArrangementsReimbursementOfExpenseTableTextBlock"> <tr> <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td> </tr> <tr> <td> <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div> <p>Revenues related to reimbursement of facilities and personnel costs pursuant to research and development collaboration agreements.</p> </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"> <p>No definition available.</p> </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"> <table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">cytk_OtherResearchAndDevelopmentRevenueArrangementsReimbursementOfExpenseTableTextBlock</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>cytk_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>nonnum:textBlockItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table> </div> </div> </td> </tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=cytk_GlobalBloodTherapeuticsMember"> <tr> <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td> </tr> <tr> <td> <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div> <table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=cytk_GlobalBloodTherapeuticsMember</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td></td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td></td> </tr> <tr> <td><strong> Period Type:</strong></td> <td></td> </tr> </table> </div> </div> </td> </tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=cytk_MyokardiaMember"> <tr> <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td> </tr> <tr> <td> <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div> <table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=cytk_MyokardiaMember</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td></td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td></td> </tr> <tr> <td><strong> Period Type:</strong></td> <td></td> </tr> </table> </div> </div> </td> </tr> </table> </div> </body> </html> </TEXT> </DOCUMENT> <DOCUMENT> <TYPE>XML <SEQUENCE>45 <FILENAME>R31.htm <DESCRIPTION>IDEA: XBRL DOCUMENT <TEXT> <html> <head> <META http-equiv="Content-Type" content="text/html; charset=us-ascii"> <title></title> <link rel="stylesheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript"> function toggleNextSibling (e) { if (e.nextSibling.style.display=='none') { e.nextSibling.style.display='block'; } else { e.nextSibling.style.display='none'; } }</script></head> <body><span style="display: none;">v2.4.1.9</span><table class="report" border="0" cellspacing="2" id="ID0EME"> <tr> <th class="tl" colspan="1" rowspan="2"> <div style="width: 200px;"><strong>Debt (Tables)<br></strong></div> </th> <th class="th" colspan="1">12 Months Ended</th> </tr> <tr> <th class="th"> <div>Dec. 31, 2014</div> </th> </tr> <tr class="re"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td> <td class="text"> <span></span></td> </tr> <tr class="ro"> <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cytk_ScheduleOfInterestExpenseTableTextBlock', window );">Summary of Total Interest Expense Incurred</a></td> <td class="text"><div> <p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 6px; TEXT-INDENT: 4%" align="justify"><font style="FONT-FAMILY: Times New Roman" size="2">Total interest expense incurred by the Company was as follows (in thousands):</font></p> <p style="MARGIN-BOTTOM: 0px; FONT-SIZE: 12px; MARGIN-TOP: 0px">  </p> <table style="BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="92%" align="center" border="0"> <tr> <td width="77%"></td> <td valign="bottom" width="6%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="6%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="6%"></td> <td></td> <td></td> <td></td> </tr> <tr> <td valign="bottom"><font size="1"> </font></td> <td valign="bottom"><font size="1">  </font></td> <td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="10" align="center"><font style="FONT-FAMILY: Times New Roman" size="1"><b>Years Ended December 31,</b></font></td> <td valign="bottom"><font size="1"> </font></td> </tr> <tr> <td valign="bottom"><font size="1"> </font></td> <td valign="bottom"><font size="1">  </font></td> <td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" align="center"><font style="FONT-FAMILY: Times New Roman" size="1"><b>2014</b></font></td> <td valign="bottom"><font size="1"> </font></td> <td valign="bottom"><font size="1">  </font></td> <td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" align="center"><font style="FONT-FAMILY: Times New Roman" size="1"><b>2013</b></font></td> <td valign="bottom"><font size="1"> </font></td> <td valign="bottom"><font size="1">  </font></td> <td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" align="center"><font style="FONT-FAMILY: Times New Roman" size="1"><b>2012</b></font></td> <td valign="bottom"><font size="1"> </font></td> </tr> <tr bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: Times New Roman" size="2">Interest expense</font></p> </td> <td valign="bottom"><font size="1">  </font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td> <td valign="bottom" nowrap="nowrap" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">—</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">  </font></td> <td valign="bottom"><font size="1">  </font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td> <td valign="bottom" nowrap="nowrap" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">—</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">  </font></td> <td valign="bottom"><font size="1">  </font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">3</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">  </font></td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double"> </p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double"> </p> </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double"> </p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double"> </p> </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double"> </p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double"> </p> </td> <td> </td> </tr> </table> </div><span></span></td> </tr> </table> <div style="display: none;"> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cytk_ScheduleOfInterestExpenseTableTextBlock"> <tr> <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td> </tr> <tr> <td> <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div> <p>The total of all interest expense incurred.</p> </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"> <p>No definition available.</p> </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"> <table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">cytk_ScheduleOfInterestExpenseTableTextBlock</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>cytk_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>nonnum:textBlockItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table> </div> </div> </td> </tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract"> <tr> <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td> </tr> <tr> <td> <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div> <table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:stringItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table> </div> </div> </td> </tr> </table> </div> </body> </html> </TEXT> </DOCUMENT> <DOCUMENT> <TYPE>XML <SEQUENCE>46 <FILENAME>R8.htm <DESCRIPTION>IDEA: XBRL DOCUMENT <TEXT> <html> <head> <META http-equiv="Content-Type" content="text/html; charset=us-ascii"> <title></title> <link rel="stylesheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript"> function toggleNextSibling (e) { if (e.nextSibling.style.display=='none') { e.nextSibling.style.display='block'; } else { e.nextSibling.style.display='none'; } }</script></head> <body><span style="display: none;">v2.4.1.9</span><table class="report" border="0" cellspacing="2" id="ID0EME"> <tr> <th class="tl" colspan="1" rowspan="2"> <div style="width: 200px;"><strong>Organization and Significant Accounting Policies<br></strong></div> </th> <th class="th" colspan="1">12 Months Ended</th> </tr> <tr> <th class="th"> <div>Dec. 31, 2014</div> </th> </tr> <tr class="re"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td> <td class="text"> <span></span></td> </tr> <tr class="ro"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock', window );">Organization and Significant Accounting Policies</a></td> <td class="text"><div> <p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 12px"><font style="FONT-FAMILY: Times New Roman" size="2"><b>Note 1 — Organization and Significant Accounting Policies</b></font></p> <!-- xbrl,body --> <p style="MARGIN-BOTTOM: 0px; MARGIN-LEFT: 2%; MARGIN-TOP: 6px"> <font style="FONT-FAMILY: Times New Roman" size="2"><b><i>Organization</i></b></font></p> <p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 6px; TEXT-INDENT: 4%" align="justify"><font style="FONT-FAMILY: Times New Roman" size="2">Cytokinetics, Incorporated (the “Company”, “we” or “our”) was incorporated under the laws of the state of Delaware on August 5, 1997. The Company is a clinical stage biopharmaceutical company focused on the discovery and development of novel small molecule therapeutics that modulate muscle function for the potential treatment of serious diseases and medical conditions.</font></p> <p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 12px; TEXT-INDENT: 4%" align="justify"><font style="FONT-FAMILY: Times New Roman" size="2">The Company was in the development stage at December 31, 2012, as defined in Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”) Topic 915, “<i>Development Stage Entities</i>.” During the year ended December 31, 2013, the Company exited the development stage with the execution of the Amgen Agreement Amendment and the Original Astellas Agreement (See Note 7), from which the Company received significant revenues from its principal operations, indicative that the Company was no longer in the development stage.</font></p> <p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 12px; TEXT-INDENT: 4%" align="justify"><font style="FONT-FAMILY: Times New Roman" size="2">The Company’s financial statements contemplate the conduct of the Company’s operations in the normal course of business. The Company has incurred an accumulated deficit of $497.2 million since inception and there can be no assurance that the Company will attain profitability. The Company had a net loss of $14.6 million and net cash used in operations of $44.8 million for the year ended December 31, 2014. Cash, cash equivalents and investments increased to $83.2 million at December 31, 2014 from $80.2 million at December 31, 2013. The Company anticipates that it will continue to have operating losses and net cash outflows in future periods.</font></p> <p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 12px; TEXT-INDENT: 4%" align="justify"><font style="FONT-FAMILY: Times New Roman" size="2">The Company is subject to risks common to clinical stage biopharmaceutical companies including, but not limited to, development of new drug candidates, dependence on key personnel, and the ability to obtain additional capital as needed to fund its future plans. The Company’s liquidity will be impaired if sufficient additional capital is not available on terms acceptable to the Company. To date, the Company has funded its operations primarily through sales of its common stock and convertible preferred stock, contract payments under its collaboration agreements, debt financing arrangements, government grants and interest income. Until it achieves profitable operations, the Company intends to continue to fund operations through payments from strategic collaborations, additional sales of equity securities, grants and debt financings. The Company has never generated revenues from commercial sales of its drugs and may not obtain regulatory approval for commercialization for at least several years, if ever. The Company’s success is dependent on its ability to enter into new strategic collaborations and/or raise additional capital and to successfully develop and market one or more of its drug candidates. As a result, the Company may choose to raise additional capital through equity or debt financings to continue to fund its operations in the future. The Company cannot be certain that sufficient funds will be available from such a financing or through a collaborator when required or on satisfactory terms. Additionally, there can be no assurance that the Company’s drug candidates will be accepted in the marketplace or that any future products can be developed or manufactured at an acceptable cost. These factors could have a material adverse effect on the Company’s future financial results, financial position and cash flows.</font></p> <p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 12px; TEXT-INDENT: 4%" align="justify"><font style="FONT-FAMILY: Times New Roman" size="2">Based on the current status of its research and development plans, the Company believes that its existing cash, cash equivalents and investments at December 31, 2014 will be sufficient to fund its cash requirements for at least the next 12 months. If, at any time, the Company’s prospects for financing its research and development programs decline, the Company may decide to reduce research and development expenses by delaying, discontinuing or reducing its funding of one or more of its research or development programs. Alternatively, the Company might raise funds through strategic collaborations, public or private financings or other arrangements. Such funding, if needed, may not be available on favorable terms, or at all. The financial statements do not include any adjustments that might result from the outcome of this uncertainty.</font></p> <p style="MARGIN-BOTTOM: 0px; FONT-SIZE: 18px; MARGIN-TOP: 0px">  </p> <p style="MARGIN-BOTTOM: 0px; MARGIN-LEFT: 2%; MARGIN-TOP: 0px"> <font style="FONT-FAMILY: Times New Roman" size="2"><b><i>Use of Estimates</i></b></font></p> <p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 6px; TEXT-INDENT: 4%" align="justify"><font style="FONT-FAMILY: Times New Roman" size="2">The preparation of financial statements in conformity with accounting principles generally accepted in the United States requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosures of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.</font></p> <p style="MARGIN-BOTTOM: 0px; MARGIN-LEFT: 2%; MARGIN-TOP: 18px"> <font style="FONT-FAMILY: Times New Roman" size="2"><b><i>Basis of Presentation</i></b></font></p> <p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 6px; TEXT-INDENT: 4%" align="justify"><font style="FONT-FAMILY: Times New Roman" size="2">The consolidated financial statements include the accounts of Cytokinetics and its wholly owned subsidiary. The financial statements include all adjustments (consisting only of normal recurring adjustments) that management believes are necessary for the fair presentation of the balances and results for the periods presented.</font></p> <p style="MARGIN-BOTTOM: 0px; MARGIN-LEFT: 2%; MARGIN-TOP: 18px"> <font style="FONT-FAMILY: Times New Roman" size="2"><b><i>Concentration of Credit Risk and Other Risks and Uncertainties</i></b></font></p> <p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 6px; TEXT-INDENT: 4%" align="justify"><font style="FONT-FAMILY: Times New Roman" size="2">Financial instruments that potentially subject the Company to concentrations of risk consist principally of cash and cash equivalents, investments and accounts receivable.</font></p> <p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 12px; TEXT-INDENT: 4%" align="justify"><font style="FONT-FAMILY: Times New Roman" size="2">The Company’s cash, cash equivalents and investments are invested in deposits with three major financial institutions in the United States. Deposits in these banks may exceed the amount of insurance provided on such deposits. The Company has not experienced any realized losses on its deposits of cash, cash equivalents or investments.</font></p> <p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 12px; TEXT-INDENT: 4%" align="justify"><font style="FONT-FAMILY: Times New Roman" size="2">The economic turmoil in the United States in recent years, the extraordinary volatility in the stock markets and other current negative macroeconomic indicators could negatively impact the Company’s ability to raise the funds necessary to support its business and may materially adversely affect its business, operating results and financial condition.</font></p> <p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 12px; TEXT-INDENT: 4%" align="justify"><font style="FONT-FAMILY: Times New Roman" size="2">The Company performs an ongoing credit evaluation of its strategic partners’ financial conditions and generally does not require collateral to secure accounts receivable from its strategic partners. The Company’s exposure to credit risk associated with non-payment will be affected principally by conditions or occurrences within Amgen Inc. (“Amgen”) and Astellas Pharma Inc. (“Astellas”), its strategic partners. Approximately 10%, 63% and 55% of total revenues for the years ended December 31, 2014, 2013 and 2012, respectively, were derived from Amgen. Accounts receivable due from Amgen were $1.6 million and zero at December 31, 2014 and 2013, respectively. See also Note 7, “Related Party Transactions,” regarding the collaboration agreement with Amgen. Approximately 69% and 34% of total revenues for the years ended December 31, 2014 and 2013, respectively, were derived from Astellas. Accounts receivable due from Astellas were $45.0 million and zero at December 31, 2014 and 2013, respectively. See also Note 7, “Related Party Transactions,” regarding the collaboration agreement with Astellas.</font></p> <p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 12px; TEXT-INDENT: 4%" align="justify"><font style="FONT-FAMILY: Times New Roman" size="2">Drug candidates developed by the Company may require approvals or clearances from the U.S. Food and Drug Administration (“FDA”) or international regulatory agencies prior to commercialized sales. There can be no assurance that the Company’s drug candidates will receive any of the required approvals or clearances. If the Company was to be denied approval or clearance or any such approval or clearance was to be delayed, it would have a material adverse impact on the Company.</font></p> <p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 12px; TEXT-INDENT: 4%" align="justify"><font style="FONT-FAMILY: Times New Roman" size="2">The Company’s operations and employees are located in the United States. In the year ended December 31, 2014, 31% of the Company’s revenues were received from entities located in the United States and 69% were received from a Japanese entity. In the year ended December 31, 2013, 66% of the Company’s revenues were received from entities located in the United States and 34% were received from a Japanese entity. In the year ended December 31, 2012, all of the Company’s revenues were received from entities located in the United States or from United States affiliates of foreign corporations.</font></p> <p style="MARGIN-BOTTOM: 0px; MARGIN-LEFT: 2%; MARGIN-TOP: 18px"> <font style="FONT-FAMILY: Times New Roman" size="2"><b><i>Cash and Cash Equivalents</i></b></font></p> <p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 6px; TEXT-INDENT: 4%" align="justify"><font style="FONT-FAMILY: Times New Roman" size="2">The Company considers all highly liquid investments with a maturity of three months or less at the time of purchase to be cash equivalents.</font></p> <p style="MARGIN-BOTTOM: 0px; MARGIN-LEFT: 2%; MARGIN-TOP: 18px"> <font style="FONT-FAMILY: Times New Roman" size="2"><b><i>Investments</i></b></font></p> <p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 6px; TEXT-INDENT: 4%" align="justify"><font style="FONT-FAMILY: Times New Roman" size="2"><i>Available-for-sale investments.</i>    The Company’s investments consist of U.S. Treasury securities, money market funds, U.S. municipal and government agency bonds, and commercial paper. The Company designates all investments as available-for-sale and therefore reports them at fair value, based on quoted marked prices, with unrealized gains and losses recorded in accumulated other comprehensive loss. The cost of securities sold is based on the specific-identification method. Investments with original maturities greater than three months and remaining maturities of one year or less are classified as short-term investments. Investments with remaining maturities greater than one year are classified as long-term investments. The amortized cost of debt securities in this category is adjusted for amortization of premiums and accretion of discounts to maturity. Such amortization is included in interest income. Recognized gains and losses and declines in value judged to be other-than-temporary, if any, on available-for-sale securities are included in other income or expense. Interest and dividends on securities classified as available-for-sale are included in Interest and other, net.</font></p> <p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 12px; TEXT-INDENT: 4%" align="justify"><font style="FONT-FAMILY: Times New Roman" size="2"><i>Other-than-temporary impairment.</i>    All of the Company’s available-for-sale investments are subject to a periodic impairment review. The Company recognizes an impairment charge when a decline in the fair value of its investments below the cost basis is judged to be other-than-temporary. Factors considered by management in assessing whether an other-than-temporary impairment has occurred include: the nature of the investment; whether the decline in fair value is attributable to specific adverse conditions affecting the investment; the financial condition of the investee; the severity and the duration of the impairment; and whether the Company has the intent and ability to hold the investment to maturity. When the Company determines that an other-than-temporary impairment has occurred, the investment is written down to its market value at the end of the period in which it is determined that an other-than-temporary decline has occurred.</font></p> <p style="MARGIN-BOTTOM: 0px; MARGIN-LEFT: 2%; MARGIN-TOP: 18px"> <font style="FONT-FAMILY: Times New Roman" size="2"><b><i>Property and Equipment</i></b></font></p> <p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 6px; TEXT-INDENT: 4%" align="justify"><font style="FONT-FAMILY: Times New Roman" size="2">Property and equipment are stated at cost less accumulated depreciation and are depreciated on a straight-line basis over the estimated useful lives of the related assets, which are generally three years for computer equipment and software, five years for laboratory equipment and office equipment, and seven years for furniture and fixtures. Amortization of leasehold improvements is computed using the straight-line method over the shorter of the remaining lease term or the estimated useful life of the related assets, typically ranging from three to seven years. Upon sale or retirement of assets, the costs and related accumulated depreciation and amortization are removed from the balance sheet and the resulting gain or loss is reflected in operations. Maintenance and repairs are charged to operations as incurred.</font></p> <p style="MARGIN-BOTTOM: 0px; MARGIN-LEFT: 2%; MARGIN-TOP: 18px"> <font style="FONT-FAMILY: Times New Roman" size="2"><b><i>Impairment of Long-lived Assets</i></b></font></p> <p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 6px; TEXT-INDENT: 4%" align="justify"><font style="FONT-FAMILY: Times New Roman" size="2">In accordance with the accounting guidance for the impairment or disposal of long-lived assets, the Company reviews long-lived assets, including property and equipment, for impairment whenever events or changes in business circumstances indicate that the carrying amount of the assets may not be fully recoverable. Under the accounting guidance, an impairment loss would be recognized when estimated undiscounted future cash flows expected to result from the use of the asset and its eventual disposition are less than its carrying amount. Impairment, if any, is measured as the amount by which the carrying amount of a long-lived asset exceeds its fair value.</font></p> <p style="MARGIN-BOTTOM: 0px; MARGIN-LEFT: 2%; MARGIN-TOP: 18px"> <font style="FONT-FAMILY: Times New Roman" size="2"><b><i>Revenue Recognition</i></b></font></p> <p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 6px; TEXT-INDENT: 4%" align="justify"><font style="FONT-FAMILY: Times New Roman" size="2">The accounting guidance for revenue recognition requires that the following criteria must be met before revenue can be recognized: (i) persuasive evidence of an arrangement exists; (ii) delivery has occurred or services have been rendered; (iii) the fee is fixed or determinable; and (iv) collectability is reasonably assured. Determination of whether persuasive evidence of an arrangement exists and whether delivery has occurred or services have been rendered are based on management’s judgments regarding the fixed nature of the fee charged for research performed and milestones met, and the collectability of those fees. Should changes in conditions cause management to determine these criteria are not met for certain future transactions, revenue recognized for any reporting period could be adversely affected.</font></p> <p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 12px; TEXT-INDENT: 4%" align="justify"><font style="FONT-FAMILY: Times New Roman" size="2">Revenue under our license and collaboration arrangements is recognized based on the performance requirements of the contract. Research and development revenues, which are earned under agreements with third parties for agreed research and development activities, may include non-refundable license fees, research and development funding, cost reimbursements and contingent milestones and royalties. The Company’s collaborations prior to January 1, 2011 with multiple elements were evaluated and divided into separate units of accounting if certain criteria are met, including whether the delivered element has stand-alone value to the customer and whether there was vendor-specific objective and reliable evidence (“VSOE”) of the fair value of the undelivered items. The consideration the Company received was allocated among the separate units based on their respective fair values, and the applicable revenue recognition criteria were applied to each of the separate units. The consideration the Company received was combined and recognized as a single unit of accounting when criteria for separation were not met. On January 1, 2011, ASC Topic 605-25, <i>Revenue Recognition — Multiple-Element Arrangements</i> (“ASC 605-25”) on the recognition of revenues for agreements with multiple deliverables became effective and applies to any agreements the Company entered into on or after January 1, 2011. Under this updated guidance, revenue is allocated to each element using a selling price hierarchy, where the selling price for an element is based on VSOE if available; third-party evidence (“TPE”), if available and VSOE is not available; or the best estimate of selling price, if neither VSOE nor TPE is available.</font></p> <p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 12px; TEXT-INDENT: 4%" align="justify"><font style="FONT-FAMILY: Times New Roman" size="2">Upfront, non-refundable licensing payments are assessed to determine whether or not the licensee is able to obtain stand-alone value from the license. Where the license does not have stand-alone value, non-refundable license fees are recognized as revenue as the Company performs under the applicable agreement. Where the level of effort is relatively consistent over the performance period, the Company recognizes total fixed or determined revenue on a straight-line basis over the estimated period of expected performance. Where the license has stand-alone value, the Company recognizes total license revenue at the time all revenue recognition criteria have been met.</font></p> <p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 12px; TEXT-INDENT: 4%" align="justify"><font style="FONT-FAMILY: Times New Roman" size="2">ASC Topic 605-28, <i>Revenue Recognition — Milestone Method</i> (“ASC 605-28”), established the milestone method as an acceptable method of revenue recognition for certain contingent event-based payments under research and development arrangements. Under the milestone method, a payment that is contingent upon the achievement of a substantive milestone is recognized in its entirety in the period in which the milestone is achieved. A milestone is an event (i) that can be achieved based in whole or in part on either the Company’s performance or on the occurrence of a specific outcome resulting from the Company’s performance, (ii) for which there is substantive uncertainty at the date the arrangement is entered into that the event will be achieved, and (iii) that would result in additional payments being due to the Company. The determination that a milestone is substantive is judgmental and is made at the inception of the arrangement. Milestones are considered substantive when the consideration earned from the achievement of the milestone is (i) commensurate with either the Company’s performance to achieve the milestone or the enhancement of value of the item delivered as a result of a specific outcome resulting from the Company’s performance to achieve the milestone, (ii) relates solely to past performance and (iii) is reasonable relative to all deliverables and payment terms in the arrangement.</font></p> <p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 12px; TEXT-INDENT: 4%" align="justify"><font style="FONT-FAMILY: Times New Roman" size="2">Other contingent event-based payments received for which payment is either contingent solely upon the passage of time or the results of a collaborative partner’s performance are not considered milestones under ASC 605-28. In accordance with ASC 605-25<i>,</i> such payments will be recognized as revenue when all of the following criteria are met: (i) persuasive evidence of an arrangement exists, (ii) delivery has occurred or services have been rendered, (iii) price is fixed or determinable, and (iv) collectability is reasonably assured.</font></p> <p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 12px; TEXT-INDENT: 4%" align="justify"><font style="FONT-FAMILY: Times New Roman" size="2">Prior to January 1, 2011, the Company recognized and will continue to recognize milestone payments as revenue upon achievement of the milestone, provided the milestone payment was non-refundable, substantive effort and risk were involved in achieving the milestone and the amount of the milestone was reasonable in relation to the effort expended or risk associated with the achievement of the milestone. If these conditions were not met, the Company deferred the milestone payment and recognized it as revenue over the estimated period of performance under the contract as the Company completed its performance obligations. The Company has concluded that all of the future contingent milestone payments pursuant to its research and development arrangements entered into prior to January 1, 2011 are not considered substantive as they are the results of a collaborative partner’s performance. Therefore, they are not considered milestones under ASC 605-28.</font></p> <p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 12px; TEXT-INDENT: 4%" align="justify"><font style="FONT-FAMILY: Times New Roman" size="2">For collaborations and material modifications entered into after January 1, 2011, the Company accounts for milestone payments under the provisions of ASC 605-28. The Company considers an event to be a milestone if there is substantive uncertainty at the date the arrangement is entered into that the event will be achieved, if the event can only be achieved with the Company’s performance, and if the achievement of the event results in payment to the Company. If the Company determines a milestone is substantive, the Company recognizes revenue when payment is earned and becomes payable. For a milestone to be considered substantive, it must be achieved with the Company’s performance, be reasonable relative to the terms of the arrangement and be commensurate with the Company’s effort to achieve the milestone or commensurate with the enhanced value of the delivered item(s) as a result of the milestone achievement. If the Company determines a milestone is not substantive, the Company defers the payment and recognizes revenue over the estimated period of performance as the Company completes its performance obligations.</font></p> <p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 12px; TEXT-INDENT: 4%" align="justify"><font style="FONT-FAMILY: Times New Roman" size="2">Research and development revenues and cost reimbursements are based upon negotiated rates for the Company’s full-time employee equivalents (“FTE”) and actual out-of-pocket costs. FTE rates are negotiated rates that are based upon the Company’s costs, and which the Company believes approximate fair value. Any amounts received in advance of performance are recorded as deferred revenue. None of the revenues recognized to date are refundable if the relevant research effort is not successful. In revenue arrangements in which both parties make payments to each other, the Company evaluates the payments in accordance with the accounting guidance for arrangements under which consideration is given by a vendor to a customer, including a reseller of the vendor’s products, to determine whether payments made by us will be recognized as a reduction of revenue or as expense. In accordance with this guidance, revenue recognized by the Company may be reduced by payments made to the other party under the arrangement unless the Company receives a separate and identifiable benefit in exchange for the payments and the Company can reasonably estimate the fair value of the benefit received. The application of the accounting guidance for consideration given to a customer has had no material impact to the Company.</font></p> <p style="MARGIN-BOTTOM: 0px; FONT-SIZE: 12px; MARGIN-TOP: 0px">  </p> <p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 0px; TEXT-INDENT: 4%" align="justify"><font style="FONT-FAMILY: Times New Roman" size="2">Funds received from third parties under grant arrangements are recorded as revenue if the Company is deemed to be the principal participant in the grant arrangement as the activities under the grant are part of the Company’s development program. If the Company is not the principal participant, the grant funds are recorded as a reduction to research and development expense. Grant funds received are not refundable and are recognized when the related qualified research and development costs are incurred and when there is reasonable assurance that the funds will be received. Funds received in advance are recorded as deferred revenue.</font></p> <p style="MARGIN-BOTTOM: 0px; MARGIN-LEFT: 2%; MARGIN-TOP: 18px"> <font style="FONT-FAMILY: Times New Roman" size="2"><b><i>Preclinical Studies and Clinical Trial Accruals</i></b></font></p> <p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 6px; TEXT-INDENT: 4%" align="justify"><font style="FONT-FAMILY: Times New Roman" size="2">A substantial portion of the Company’s preclinical studies and all of the Company’s clinical trials have been performed by third-party contract research organizations (“CROs”) and other vendors. For preclinical studies, the significant factors used in estimating accruals include the percentage of work completed to date and contract milestones achieved. For clinical trial expenses, the significant factors used in estimating accruals include the number of patients enrolled, duration of enrollment and percentage of work completed to date. The Company monitors patient enrollment levels and related activities to the extent practicable through internal reviews, correspondence and status meetings with CROs, and review of contractual terms. The Company’s estimates are dependent on the timeliness and accuracy of data provided by its CROs and other vendors. If the Company has incomplete or inaccurate data, it may under- or overestimate activity levels associated with various studies or trials at a given point in time. In this event, it could record adjustments to research and development expenses in future periods when the actual activity level becomes known. No material adjustments to preclinical study and clinical trial expenses have been recognized to date.</font></p> <p style="MARGIN-BOTTOM: 0px; MARGIN-LEFT: 2%; MARGIN-TOP: 18px"> <font style="FONT-FAMILY: Times New Roman" size="2"><b><i>Research and Development Expenditures</i></b></font></p> <p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 6px; TEXT-INDENT: 4%" align="justify"><font style="FONT-FAMILY: Times New Roman" size="2">Research and development costs are charged to operations as incurred. Research and development expenses consist primarily of clinical manufacturing costs, preclinical study expenses, consulting and other third party costs, employee compensation, supplies and materials, allocation of overhead and occupancy costs, facilities costs and depreciation of equipment.</font></p> <p style="MARGIN-BOTTOM: 0px; MARGIN-LEFT: 2%; MARGIN-TOP: 18px"> <font style="FONT-FAMILY: Times New Roman" size="2"><b><i>Retirement Plan</i></b></font></p> <p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 6px; TEXT-INDENT: 4%" align="justify"><font style="FONT-FAMILY: Times New Roman" size="2">The Company sponsors a 401(k) defined contribution plan covering all employees. There were no employer contributions to the plan from inception through December 31, 2013. In 2014, employer contributions to the 401(k) plan were $336,000.</font></p> <p style="MARGIN-BOTTOM: 0px; MARGIN-LEFT: 2%; MARGIN-TOP: 18px"> <font style="FONT-FAMILY: Times New Roman" size="2"><b><i>Income Taxes</i></b></font></p> <p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 6px; TEXT-INDENT: 4%" align="justify"><font style="FONT-FAMILY: Times New Roman" size="2">The Company accounts for income taxes under the asset and liability method. Under this method, deferred tax assets and liabilities are determined based on the difference between the financial statement and tax basis of assets and liabilities using enacted tax rates in effect for the year in which the differences are expected to affect taxable income. Valuation allowances are established when necessary to reduce deferred tax assets to the amounts expected to be realized.</font></p> <p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 12px; TEXT-INDENT: 4%" align="justify"><font style="FONT-FAMILY: Times New Roman" size="2">The Company also follows the accounting guidance that defines the threshold for recognizing the benefits of tax return positions in the financial statements as “more-likely-than-not” to be sustained by the taxing authorities based solely on the technical merits of the position. If the recognition threshold is met, the tax benefit is measured and recognized as the largest amount of tax benefit that, in the Company’s judgment, is greater than 50% likely to be realized.</font></p> <p style="MARGIN-BOTTOM: 0px; FONT-SIZE: 18px; MARGIN-TOP: 0px">  </p> <p style="MARGIN-BOTTOM: 0px; MARGIN-LEFT: 2%; MARGIN-TOP: 0px"> <font style="FONT-FAMILY: Times New Roman" size="2"><b><i>Comprehensive Loss</i></b></font></p> <p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 6px; TEXT-INDENT: 4%" align="justify"><font style="FONT-FAMILY: Times New Roman" size="2">The Company follows the accounting standards for the reporting and presentation of comprehensive income (loss) and its components. On January 1, 2012, the Company adopted new accounting guidance and presents comprehensive income (loss) in a continuous statement of comprehensive income (loss) which replaced the statement of operations. Comprehensive loss includes all changes in stockholders’ equity during a period from non-owner sources. Comprehensive loss for each of the years ended December 31, 2014, 2013, and 2012 was equal to net loss adjusted for unrealized gains and losses on investments.</font></p> <p style="MARGIN-BOTTOM: 0px; MARGIN-LEFT: 2%; MARGIN-TOP: 18px"> <font style="FONT-FAMILY: Times New Roman" size="2"><b><i>Segment Reporting</i></b></font></p> <p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 6px; TEXT-INDENT: 4%" align="justify"><font style="FONT-FAMILY: Times New Roman" size="2">The Company has determined that it operates in only one segment.</font></p> <p style="MARGIN-BOTTOM: 0px; MARGIN-LEFT: 2%; MARGIN-TOP: 18px"> <font style="FONT-FAMILY: Times New Roman" size="2"><b><i>Reverse Stock Split</i></b></font></p> <p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 6px; TEXT-INDENT: 4%" align="justify"><font style="FONT-FAMILY: Times New Roman" size="2">On June 24, 2013, the Company effected a one-for-six reverse stock split of its common stock through an amendment to its amended and restated certificate of incorporation (the “COI Amendment”). As of the effective time of the reverse stock split, every six shares of the Company’s issued and outstanding common stock were converted into one issued and outstanding share of common stock, without any change in par value per share. The reverse stock split affected all shares of the Company’s common stock outstanding immediately prior to the effective time of the reverse stock split, as well as the number of shares of common stock available for issuance under the Company’s equity incentive plans. In addition, the reverse stock split effected a reduction in the number of shares of common stock issuable upon the conversion of shares of preferred stock or upon the exercise of stock options or warrants outstanding immediately prior to the effectiveness of the reverse stock split. No fractional shares were issued as a result of the reverse stock split. Stockholders who would otherwise have been entitled to receive a fractional share received cash payments in lieu thereof. In addition, the COI Amendment reduced the number of authorized shares of common stock to 81.5 million.</font></p> <p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 12px; TEXT-INDENT: 4%" align="justify"><font style="FONT-FAMILY: Times New Roman" size="2">As the par value per share of the Company’s common stock remained unchanged at $0.001 per share, a total of $139,000 was reclassified from common stock to additional paid-in capital. All references to shares of common stock and per share data for all periods presented in the accompanying financial statements and notes thereto have been adjusted to reflect the reverse stock split on a retroactive basis.</font></p> <p style="MARGIN-BOTTOM: 0px; MARGIN-LEFT: 2%; MARGIN-TOP: 18px"> <font style="FONT-FAMILY: Times New Roman" size="2"><b><i>Stock-Based Compensation</i></b></font></p> <p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 6px; TEXT-INDENT: 4%" align="justify"><font style="FONT-FAMILY: Times New Roman" size="2">The Company accounts for stock-based payment awards made to employees and directors, including employee stock options and employee stock purchases by measuring the stock-based compensation cost at the grant date based on the calculated fair value of the award, and recognizing expense on a straight-line basis over the employee’s requisite service period, generally the vesting period of the award. Stock compensation for non-employees is measured at the fair value of the award for each period until the award is fully vested.</font></p> <p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 12px; TEXT-INDENT: 4%" align="justify"><font style="FONT-FAMILY: Times New Roman" size="2">The Company reviews the valuation assumptions at each grant date and, as a result, from time to time it will likely change the valuation assumptions it uses to value stock based awards granted in future periods. The assumptions used in calculating the fair value of share-based payment awards represent management’s best estimates at the time, but these estimates involve inherent uncertainties and the application of management judgment. As a result, if conditions change and the management uses different assumptions, the Company’s stock-based compensation expense could be materially different in the future. In addition, the Company is required to estimate the expected forfeiture rate and recognize expense only for those shares expected to vest. If the actual forfeiture rate is materially different from management’s estimate, stock-based compensation expense could be significantly different from what has been recorded in the current period.</font></p> <p style="MARGIN-BOTTOM: 0px; FONT-SIZE: 18px; MARGIN-TOP: 0px">  </p> <p style="MARGIN-BOTTOM: 0px; MARGIN-LEFT: 2%; MARGIN-TOP: 0px"> <font style="FONT-FAMILY: Times New Roman" size="2"><b><i>Recent Accounting Pronouncements</i></b></font></p> <p style="MARGIN-BOTTOM: 0px; MARGIN-LEFT: 2%; MARGIN-TOP: 6px"> <font style="FONT-FAMILY: Times New Roman" size="2"><i>Recently Adopted Accounting Pronouncements</i></font></p> <p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 6px; TEXT-INDENT: 4%" align="justify"><font style="FONT-FAMILY: Times New Roman" size="2">In July 2013, the FASB issued ASU 2013-11, <i>Presentation of an Unrecognized Tax Benefit When a Net Operating Loss Carryforward, a Similar Tax Loss, or a Tax Credit Carryforward Exists</i>. ASU 2013-11 amends accounting guidance on the presentation of an unrecognized tax benefit when a net operating loss carryforward, a similar tax loss, or tax credit carryforward exists. This new guidance requires entities, if certain criteria are met, to present an unrecognized tax benefit, or portion of an unrecognized tax benefit, in the financial statements as a reduction to a deferred tax asset for a net operating loss carryforward, a similar tax loss, or a tax credit carryforward when such items exist in the same taxing jurisdiction. The Company adopted ASU 2013-11 effective January 1, 2014 and the adoption of ASU 2013-11 did not have a material effect on its financial statements.</font></p> <p style="MARGIN-BOTTOM: 0px; MARGIN-LEFT: 2%; MARGIN-TOP: 18px"> <font style="FONT-FAMILY: Times New Roman" size="2"><i>Accounting Pronouncements Not Yet Adopted</i></font></p> <p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 6px; TEXT-INDENT: 4%" align="justify"><font style="FONT-FAMILY: Times New Roman" size="2">In November 2014, the FASB issued ASU 2014-17, <i>Business Combinations (Topic 805) — Pushdown Accounting (a consensus of the FASB Emerging Issues Task Force).</i> This guidance provides the option for an acquired entity to apply pushdown accounting in its separately issued financial statements when a change-in-control event occurs. This guidance is effective beginning November 18, 2014, and is applicable to change-in-control events occurring after that date or applied to the most recent change-in-control event if financial statements have not yet been issued. The Company does not expect the adoption of ASU 2014-17 to have a material effect upon its financial statements.</font></p> <p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 12px; TEXT-INDENT: 4%" align="justify"><font style="FONT-FAMILY: Times New Roman" size="2">In August 2014, the FASB issued ASU 2014-15, <i>Presentation of Financial Statements — Going Concern (Subtopic 205-40): Disclosure of Uncertainties about an Entity’s Ability to Continue as a Going Concern.</i> ASU 214-15 requires management to assess an entity’s ability to continue as a going concern, and to provide related footnote disclosures in certain circumstances. ASU 2014-15 is effective for annual and interim reporting periods beginning on or after December 15, 2016 and early adoption is permitted. The Company does not expect the adoption of ASU 2014-15 to have a material effect upon its financial statements.</font></p> <p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 12px; TEXT-INDENT: 4%" align="justify"><font style="FONT-FAMILY: Times New Roman" size="2">In May 2014, the FASB issued ASU 2014-09, <i>Revenue from Contracts with Customers (Topic 606)</i>, which supersedes the revenue recognition requirements in ASC 605, <i>Revenue Recognition</i>. ASU 2014-09 stipulates that an entity should recognize revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. ASU 2014-09 also requires additional disclosure about the nature, amount, timing and uncertainty of revenue and cash flows arising from customer contracts, including significant judgments and changes in judgments and assets recognized from costs incurred to obtain or fulfill a contract. ASU 2014-09 is effective for annual and interim reporting periods beginning on or after December 15, 2016, and early adoption is not permitted. ASU 2014-09 permits the use of two transition methods, either retrospectively to each prior reporting period presented or as a cumulative-effect adjustment as of the date of adoption. The Company has not yet selected a transition method, and is currently evaluating the impact of the adoption of ASU 2014-09 on its consolidated financial statements.</font></p> <p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 12px; TEXT-INDENT: 4%" align="justify"><font style="FONT-FAMILY: Times New Roman" size="2">In April 2014, the FASB issued ASU 2014-08, <i>Reporting Discontinued Operations and Disclosures of Disposals of Components of an Entity</i>. ASU 2014-08 changes the criteria for determining which disposals can be presented as discontinued operations and modifies related disclosure requirements. This new guidance is effective for the Company beginning January 1, 2015. The Company does not expect the adoption of ASU 2014-08 to have a material effect upon its financial statements.</font></p> </div><span></span></td> </tr> </table> <div style="display: none;"> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract"> <tr> <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td> </tr> <tr> <td> <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div> <table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:stringItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table> </div> </div> </td> </tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock"> <tr> <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td> </tr> <tr> <td> <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div> <p>The entire disclosure for the organization, consolidation and basis of presentation of financial statements disclosure, and significant accounting policies of the reporting entity. May be provided in more than one note to the financial statements, as long as users are provided with an understanding of (1) the significant judgments and assumptions made by an enterprise in determining whether it must consolidate a VIE and/or disclose information about its involvement with a VIE, (2) the nature of restrictions on a consolidated VIE's assets reported by an enterprise in its statement of financial position, including the carrying amounts of such assets, (3) the nature of, and changes in, the risks associated with an enterprise's involvement with the VIE, and (4) how an enterprise's involvement with the VIE affects the enterprise's financial position, financial performance, and cash flows. Describes procedure if disclosures are provided in more than one note to the financial statements.</p> </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"> <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 275<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&oid=6927468&loc=d3e6003-108592<br><br><br><br></p> </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"> <table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>nonnum:textBlockItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table> </div> </div> </td> </tr> </table> </div> </body> </html> </TEXT> </DOCUMENT> <DOCUMENT> <TYPE>XML <SEQUENCE>47 <FILENAME>R32.htm <DESCRIPTION>IDEA: XBRL DOCUMENT <TEXT> <html> <head> <META http-equiv="Content-Type" content="text/html; charset=us-ascii"> <title></title> <link rel="stylesheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript"> function toggleNextSibling (e) { if (e.nextSibling.style.display=='none') { e.nextSibling.style.display='block'; } else { e.nextSibling.style.display='none'; } }</script></head> <body><span style="display: none;">v2.4.1.9</span><table class="report" border="0" cellspacing="2" id="ID0E2F"> <tr> <th class="tl" colspan="1" rowspan="2"> <div style="width: 200px;"><strong>Commitments and Contingencies (Tables)<br></strong></div> </th> <th class="th" colspan="1">12 Months Ended</th> </tr> <tr> <th class="th"> <div>Dec. 31, 2014</div> </th> </tr> <tr class="re"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td> <td class="text"> <span></span></td> </tr> <tr class="ro"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfRentExpenseTableTextBlock', window );">Rent Expense</a></td> <td class="text"><div> <p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 18px; TEXT-INDENT: 4%" align="justify"><font style="FONT-FAMILY: Times New Roman" size="2">Rent expense was as follows (in thousands):</font></p> <p style="MARGIN-BOTTOM: 0px; FONT-SIZE: 12px; MARGIN-TOP: 0px">  </p> <table style="BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="92%" align="center" border="0"> <tr> <td width="73%"></td> <td valign="bottom" width="4%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="4%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="4%"></td> <td></td> <td></td> <td></td> </tr> <tr> <td valign="bottom"><font size="1"> </font></td> <td valign="bottom"><font size="1">  </font></td> <td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="10" align="center"><font style="FONT-FAMILY: Times New Roman" size="1"><b>Years Ended December 31,</b></font></td> <td valign="bottom"><font size="1"> </font></td> </tr> <tr> <td valign="bottom"><font size="1"> </font></td> <td valign="bottom"><font size="1">  </font></td> <td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" align="center"><font style="FONT-FAMILY: Times New Roman" size="1"><b>2014</b></font></td> <td valign="bottom"><font size="1"> </font></td> <td valign="bottom"><font size="1">  </font></td> <td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" align="center"><font style="FONT-FAMILY: Times New Roman" size="1"><b>2013</b></font></td> <td valign="bottom"><font size="1"> </font></td> <td valign="bottom"><font size="1">  </font></td> <td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" align="center"><font style="FONT-FAMILY: Times New Roman" size="1"><b>2012</b></font></td> <td valign="bottom"><font size="1"> </font></td> </tr> <tr bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: Times New Roman" size="2">Rent expense</font></p> </td> <td valign="bottom"><font size="1">  </font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">3,338</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">  </font></td> <td valign="bottom"><font size="1">  </font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">3,306</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">  </font></td> <td valign="bottom"><font size="1">  </font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">3,375</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">  </font></td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double"> </p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double"> </p> </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double"> </p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double"> </p> </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double"> </p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double"> </p> </td> <td> </td> </tr> </table> </div><span></span></td> </tr> <tr class="re"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock', window );">Future Minimum Lease Payments under Noncancelable Operating Leases</a></td> <td class="text"><div> <p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 12px; TEXT-INDENT: 4%" align="justify"><font style="FONT-FAMILY: Times New Roman" size="2">As of December 31, 2014, future minimum lease payments under noncancelable operating leases were as follows (in thousands):</font></p> <p style="MARGIN-BOTTOM: 0px; FONT-SIZE: 12px; MARGIN-TOP: 0px">  </p> <table style="BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="92%" align="center" border="0"> <tr> <td width="89%"></td> <td valign="bottom" width="5%"></td> <td></td> <td></td> <td></td> </tr> <tr bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: Times New Roman" size="2">2015</font></p> </td> <td valign="bottom"><font size="1">  </font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">3,390</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">  </font></td> </tr> <tr> <td valign="top"> <p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: Times New Roman" size="2">2016</font></p> </td> <td valign="bottom"><font size="1">  </font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2"> </font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">3,504</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">  </font></td> </tr> <tr bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: Times New Roman" size="2">2017</font></p> </td> <td valign="bottom"><font size="1">  </font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2"> </font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">3,626</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">  </font></td> </tr> <tr> <td valign="top"> <p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: Times New Roman" size="2">2018</font></p> </td> <td valign="bottom"><font size="1">  </font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2"> </font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">1,860</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">  </font></td> </tr> <tr bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: Times New Roman" size="2">2019</font></p> </td> <td valign="bottom"><font size="1">  </font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2"> </font></td> <td valign="bottom" nowrap="nowrap" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">—</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">  </font></td> </tr> <tr> <td valign="top"> <p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: Times New Roman" size="2">Thereafter</font></p> </td> <td valign="bottom"><font size="1">  </font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2"> </font></td> <td valign="bottom" nowrap="nowrap" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">—</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">  </font></td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid"> </p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid"> </p> </td> <td> </td> </tr> <tr bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-LEFT: 2em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: Times New Roman" size="2">Total</font></p> </td> <td valign="bottom"><font size="1">  </font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">12,380</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">  </font></td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double"> </p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double"> </p> </td> <td> </td> </tr> </table> </div><span></span></td> </tr> </table> <div style="display: none;"> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract"> <tr> <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td> </tr> <tr> <td> <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div> <table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:stringItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table> </div> </div> </td> </tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock"> <tr> <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td> </tr> <tr> <td> <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div> <p>Tabular disclosure of future minimum payments required in the aggregate and for each of the five succeeding fiscal years for operating leases having initial or remaining noncancelable lease terms in excess of one year and the total minimum rentals to be received in the future under noncancelable subleases as of the balance sheet date.</p> </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"> <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 840<br><br> -SubTopic 20<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&oid=6453985&loc=d3e41502-112717<br><br><br><br></p> </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"> <table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>nonnum:textBlockItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table> </div> </div> </td> </tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfRentExpenseTableTextBlock"> <tr> <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td> </tr> <tr> <td> <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div> <p>Tabular disclosure of rental expense from operating leases for each period for which an income statement is presented with separate amounts for minimum rentals, contingent rentals, and sublease rentals. Rental payments under leases with terms of a month or less that were not renewed need not be included.</p> </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"> <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 840<br><br> -SubTopic 20<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&oid=6453985&loc=d3e41499-112717<br><br><br><br></p> </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"> <table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_ScheduleOfRentExpenseTableTextBlock</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>nonnum:textBlockItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table> </div> </div> </td> </tr> </table> </div> </body> </html> </TEXT> </DOCUMENT> <DOCUMENT> <TYPE>XML <SEQUENCE>48 <FILENAME>R40.htm <DESCRIPTION>IDEA: XBRL DOCUMENT <TEXT> <html> <head> <META http-equiv="Content-Type" content="text/html; charset=us-ascii"> <title></title> <link rel="stylesheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript"> function toggleNextSibling (e) { if (e.nextSibling.style.display=='none') { e.nextSibling.style.display='block'; } else { e.nextSibling.style.display='none'; } }</script></head> <body><span style="display: none;">v2.4.1.9</span><table class="report" border="0" cellspacing="2" id="ID0EKOAC"> <tr> <th class="tl" colspan="1" rowspan="2"> <div style="width: 200px;"><strong>Supplementary Cash Flow Data - Supplemental Cash Flow Information (Detail) (USD $)<br>In Thousands, unless otherwise specified</strong></div> </th> <th class="th" colspan="3">12 Months Ended</th> </tr> <tr> <th class="th"> <div>Dec. 31, 2014</div> </th> <th class="th"> <div>Dec. 31, 2013</div> </th> <th class="th"> <div>Dec. 31, 2012</div> </th> </tr> <tr class="re"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SupplementalCashFlowElementsAbstract', window );"><strong>Supplemental Cash Flow Elements [Abstract]</strong></a></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> </tr> <tr class="ro"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestPaid', window );">Cash paid for interest</a></td> <td class="nump"><a title="us-gaap_InterestPaid" onclick="toggleNextSibling(this);">$ 0</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_InterestPaid</span><span></span></td> <td class="nump"><a title="us-gaap_InterestPaid" onclick="toggleNextSibling(this);">$ 0</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_InterestPaid</span><span></span></td> <td class="nump"><a title="us-gaap_InterestPaid" onclick="toggleNextSibling(this);">$ 3</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_InterestPaid</span><span></span></td> </tr> <tr class="re"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxesPaidNet', window );">Cash paid for income taxes</a></td> <td class="nump"><a title="us-gaap_IncomeTaxesPaidNet" onclick="toggleNextSibling(this);">1</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_IncomeTaxesPaidNet</span><span></span></td> <td class="nump"><a title="us-gaap_IncomeTaxesPaidNet" onclick="toggleNextSibling(this);">1</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_IncomeTaxesPaidNet</span><span></span></td> <td class="nump"><a title="us-gaap_IncomeTaxesPaidNet" onclick="toggleNextSibling(this);">1</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_IncomeTaxesPaidNet</span><span></span></td> </tr> <tr class="ro"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract', window );"><strong>Significant non-cash investing and financing activities:</strong></a></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> </tr> <tr class="re"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NoncashOrPartNoncashAcquisitionFixedAssetsAcquired1', window );">Purchases of property and equipment through accounts payable</a></td> <td class="nump"><a title="us-gaap_NoncashOrPartNoncashAcquisitionFixedAssetsAcquired1" onclick="toggleNextSibling(this);">170</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_NoncashOrPartNoncashAcquisitionFixedAssetsAcquired1</span><span></span></td> <td class="nump"><a title="us-gaap_NoncashOrPartNoncashAcquisitionFixedAssetsAcquired1" onclick="toggleNextSibling(this);">193</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_NoncashOrPartNoncashAcquisitionFixedAssetsAcquired1</span><span></span></td> <td class="nump"><a title="us-gaap_NoncashOrPartNoncashAcquisitionFixedAssetsAcquired1" onclick="toggleNextSibling(this);">116</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_NoncashOrPartNoncashAcquisitionFixedAssetsAcquired1</span><span></span></td> </tr> <tr class="ro"> <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cytk_IncreaseDecreaseInNoncashOrPartNoncashAcquisitionFixedAssetsAcquiredThroughAccruedLiabilities', window );">Purchases of property and equipment through accrued liabilities</a></td> <td class="nump"><a title="cytk_IncreaseDecreaseInNoncashOrPartNoncashAcquisitionFixedAssetsAcquiredThroughAccruedLiabilities" onclick="toggleNextSibling(this);">27</a><span style="display:none;white-space:normal;text-align:left;">cytk_IncreaseDecreaseInNoncashOrPartNoncashAcquisitionFixedAssetsAcquiredThroughAccruedLiabilities</span><span></span></td> <td class="num"><a title="cytk_IncreaseDecreaseInNoncashOrPartNoncashAcquisitionFixedAssetsAcquiredThroughAccruedLiabilities" onclick="toggleNextSibling(this);">(2)</a><span style="display:none;white-space:normal;text-align:left;">cytk_IncreaseDecreaseInNoncashOrPartNoncashAcquisitionFixedAssetsAcquiredThroughAccruedLiabilities</span><span></span></td> <td class="nump"><a title="cytk_IncreaseDecreaseInNoncashOrPartNoncashAcquisitionFixedAssetsAcquiredThroughAccruedLiabilities" onclick="toggleNextSibling(this);">37</a><span style="display:none;white-space:normal;text-align:left;">cytk_IncreaseDecreaseInNoncashOrPartNoncashAcquisitionFixedAssetsAcquiredThroughAccruedLiabilities</span><span></span></td> </tr> <tr class="re"> <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cytk_NoncashOrPartNoncashAcquisitionFixedAssetsAcquiredTradeInValue', window );">Purchases of property and equipment through trade in value of disposed property and equipment</a></td> <td class="nump"><a title="cytk_NoncashOrPartNoncashAcquisitionFixedAssetsAcquiredTradeInValue" onclick="toggleNextSibling(this);">$ 0</a><span style="display:none;white-space:normal;text-align:left;">cytk_NoncashOrPartNoncashAcquisitionFixedAssetsAcquiredTradeInValue</span><span></span></td> <td class="nump"><a title="cytk_NoncashOrPartNoncashAcquisitionFixedAssetsAcquiredTradeInValue" onclick="toggleNextSibling(this);">$ 81</a><span style="display:none;white-space:normal;text-align:left;">cytk_NoncashOrPartNoncashAcquisitionFixedAssetsAcquiredTradeInValue</span><span></span></td> <td class="nump"><a title="cytk_NoncashOrPartNoncashAcquisitionFixedAssetsAcquiredTradeInValue" onclick="toggleNextSibling(this);">$ 0</a><span style="display:none;white-space:normal;text-align:left;">cytk_NoncashOrPartNoncashAcquisitionFixedAssetsAcquiredTradeInValue</span><span></span></td> </tr> </table> <div style="display: none;"> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cytk_IncreaseDecreaseInNoncashOrPartNoncashAcquisitionFixedAssetsAcquiredThroughAccruedLiabilities"> <tr> <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td> </tr> <tr> <td> <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div> <p>Increase decrease in noncash or part noncash acquisition fixed assets acquired through accrued liabilities.</p> </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"> <p>No definition available.</p> </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"> <table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">cytk_IncreaseDecreaseInNoncashOrPartNoncashAcquisitionFixedAssetsAcquiredThroughAccruedLiabilities</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>cytk_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:monetaryItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>debit</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table> </div> </div> </td> </tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cytk_NoncashOrPartNoncashAcquisitionFixedAssetsAcquiredTradeInValue"> <tr> <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td> </tr> <tr> <td> <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div> <p>The amount of fixed assets that an Entity acquires in a non-cash acquisition through trade in value of disposed property and equipment. Non-cash is defined as information about all investing and financing activities of an enterprise during a period that affect recognized assets or liabilities but that do not result in cash receipts or cash payments in the period.</p> </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"> <p>No definition available.</p> </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"> <table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">cytk_NoncashOrPartNoncashAcquisitionFixedAssetsAcquiredTradeInValue</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>cytk_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:monetaryItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>credit</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table> </div> </div> </td> </tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract"> <tr> <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td> </tr> <tr> <td> <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div> <table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:stringItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table> </div> </div> </td> </tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxesPaidNet"> <tr> <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td> </tr> <tr> <td> <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div> <p>The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income, net of any cash received during the current period as refunds for the overpayment of taxes.</p> </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"> <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&oid=6367179&loc=d3e4297-108586<br><br><br><br></p> </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"> <table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_IncomeTaxesPaidNet</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:monetaryItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>credit</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table> </div> </div> </td> </tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPaid"> <tr> <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td> </tr> <tr> <td> <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div> <p>The amount of cash paid for interest during the period.</p> </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"> <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&oid=6367179&loc=d3e4297-108586<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 25<br><br> -Subparagraph (e)<br><br> -URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3536-108585<br><br><br><br></p> </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"> <table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_InterestPaid</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:monetaryItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>credit</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table> </div> </div> </td> </tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NoncashOrPartNoncashAcquisitionFixedAssetsAcquired1"> <tr> <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td> </tr> <tr> <td> <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div> <p>The amount of fixed assets that an Entity acquires in a noncash (or part noncash) acquisition. Noncash is defined as information about all investing and financing activities of an enterprise during a period that affect recognized assets or liabilities but that do not result in cash receipts or cash payments in the period. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p> </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"> <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 5<br><br> -URI http://asc.fasb.org/extlink&oid=6367179&loc=d3e4332-108586<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 4<br><br> -URI http://asc.fasb.org/extlink&oid=6367179&loc=d3e4313-108586<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&oid=6367179&loc=d3e4304-108586<br><br><br><br></p> </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"> <table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_NoncashOrPartNoncashAcquisitionFixedAssetsAcquired1</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:monetaryItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>debit</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table> </div> </div> </td> </tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalCashFlowElementsAbstract"> <tr> <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td> </tr> <tr> <td> <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div> <table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_SupplementalCashFlowElementsAbstract</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:stringItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table> </div> </div> </td> </tr> </table> </div> </body> </html> </TEXT> </DOCUMENT> <DOCUMENT> <TYPE>XML <SEQUENCE>49 <FILENAME>R53.htm <DESCRIPTION>IDEA: XBRL DOCUMENT <TEXT> <html> <head> <META http-equiv="Content-Type" content="text/html; charset=us-ascii"> <title></title> <link rel="stylesheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript"> function toggleNextSibling (e) { if (e.nextSibling.style.display=='none') { e.nextSibling.style.display='block'; } else { e.nextSibling.style.display='none'; } }</script></head> <body><span style="display: none;">v2.4.1.9</span><table class="report" border="0" cellspacing="2" id="ID0EMIAE"> <tr> <th class="tl" colspan="1" rowspan="2"> <div style="width: 200px;"><strong>Other Research and Development Revenue Arrangements - Summary of Reimbursed Expenses (Detail) (USD $)<br>In Thousands, unless otherwise specified</strong></div> </th> <th class="th" colspan="3">12 Months Ended</th> </tr> <tr> <th class="th"> <div>Dec. 31, 2014</div> </th> <th class="th"> <div>Dec. 31, 2013</div> </th> <th class="th"> <div>Dec. 31, 2012</div> </th> </tr> <tr class="rh"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=cytk_GlobalBloodTherapeuticsMember', window );">Global Blood [Member]</a></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> </tr> <tr class="ro"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research and Development Arrangement, Contract to Perform for Others [Line Items]</strong></a></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> </tr> <tr class="re"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReimbursementRevenue', window );">Expense reimbursements</a></td> <td class="nump"><a title="us-gaap_ReimbursementRevenue[us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=cytk_GlobalBloodTherapeuticsMember]" onclick="toggleNextSibling(this);">$ 0</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ReimbursementRevenue<br>/ us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis<br>= cytk_GlobalBloodTherapeuticsMember</span><span></span></td> <td class="nump"><a title="us-gaap_ReimbursementRevenue[us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=cytk_GlobalBloodTherapeuticsMember]" onclick="toggleNextSibling(this);">$ 14</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ReimbursementRevenue<br>/ us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis<br>= cytk_GlobalBloodTherapeuticsMember</span><span></span></td> <td class="nump"><a title="us-gaap_ReimbursementRevenue[us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=cytk_GlobalBloodTherapeuticsMember]" onclick="toggleNextSibling(this);">$ 1,479</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ReimbursementRevenue<br>/ us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis<br>= cytk_GlobalBloodTherapeuticsMember</span><span></span></td> </tr> <tr class="rh"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=cytk_MyokardiaMember', window );">MyoKardia [Member]</a></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> </tr> <tr class="re"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research and Development Arrangement, Contract to Perform for Others [Line Items]</strong></a></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> </tr> <tr class="ro"> <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cytk_ResearchAndDevelopmentRevenue', window );">Research and development milestone fees</a></td> <td class="nump"><a title="cytk_ResearchAndDevelopmentRevenue[us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=cytk_MyokardiaMember]" onclick="toggleNextSibling(this);">100</a><span style="display:none;white-space:normal;text-align:left;">cytk_ResearchAndDevelopmentRevenue<br>/ us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis<br>= cytk_MyokardiaMember</span><span></span></td> <td class="nump"><a title="cytk_ResearchAndDevelopmentRevenue[us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=cytk_MyokardiaMember]" onclick="toggleNextSibling(this);">0</a><span style="display:none;white-space:normal;text-align:left;">cytk_ResearchAndDevelopmentRevenue<br>/ us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis<br>= cytk_MyokardiaMember</span><span></span></td> <td class="nump"><a title="cytk_ResearchAndDevelopmentRevenue[us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=cytk_MyokardiaMember]" onclick="toggleNextSibling(this);">0</a><span style="display:none;white-space:normal;text-align:left;">cytk_ResearchAndDevelopmentRevenue<br>/ us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis<br>= cytk_MyokardiaMember</span><span></span></td> </tr> <tr class="re"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReimbursementRevenue', window );">Expense reimbursements</a></td> <td class="nump"><a title="us-gaap_ReimbursementRevenue[us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=cytk_MyokardiaMember]" onclick="toggleNextSibling(this);">0</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ReimbursementRevenue<br>/ us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis<br>= cytk_MyokardiaMember</span><span></span></td> <td class="nump"><a title="us-gaap_ReimbursementRevenue[us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=cytk_MyokardiaMember]" onclick="toggleNextSibling(this);">1,024</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ReimbursementRevenue<br>/ us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis<br>= cytk_MyokardiaMember</span><span></span></td> <td class="nump"><a title="us-gaap_ReimbursementRevenue[us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=cytk_MyokardiaMember]" onclick="toggleNextSibling(this);">595</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ReimbursementRevenue<br>/ us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis<br>= cytk_MyokardiaMember</span><span></span></td> </tr> <tr class="rou"> <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cytk_ResearchAndDevelopmentRevenueFromCollaboration', window );">Research and development revenue from Myokardia</a></td> <td class="nump"><a title="cytk_ResearchAndDevelopmentRevenueFromCollaboration[us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=cytk_MyokardiaMember]" onclick="toggleNextSibling(this);">$ 100</a><span style="display:none;white-space:normal;text-align:left;">cytk_ResearchAndDevelopmentRevenueFromCollaboration<br>/ us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis<br>= cytk_MyokardiaMember</span><span></span></td> <td class="nump"><a title="cytk_ResearchAndDevelopmentRevenueFromCollaboration[us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=cytk_MyokardiaMember]" onclick="toggleNextSibling(this);">$ 1,024</a><span style="display:none;white-space:normal;text-align:left;">cytk_ResearchAndDevelopmentRevenueFromCollaboration<br>/ us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis<br>= cytk_MyokardiaMember</span><span></span></td> <td class="nump"><a title="cytk_ResearchAndDevelopmentRevenueFromCollaboration[us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=cytk_MyokardiaMember]" onclick="toggleNextSibling(this);">$ 595</a><span style="display:none;white-space:normal;text-align:left;">cytk_ResearchAndDevelopmentRevenueFromCollaboration<br>/ us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis<br>= cytk_MyokardiaMember</span><span></span></td> </tr> </table> <div style="display: none;"> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cytk_ResearchAndDevelopmentRevenue"> <tr> <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td> </tr> <tr> <td> <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div> <p>Research And Development Revenue</p> </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"> <p>No definition available.</p> </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"> <table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">cytk_ResearchAndDevelopmentRevenue</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>cytk_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:monetaryItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>credit</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table> </div> </div> </td> </tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cytk_ResearchAndDevelopmentRevenueFromCollaboration"> <tr> <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td> </tr> <tr> <td> <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div> <p>Research and development revenue from collaboration.</p> </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"> <p>No definition available.</p> </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"> <table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">cytk_ResearchAndDevelopmentRevenueFromCollaboration</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>cytk_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:monetaryItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>credit</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table> </div> </div> </td> </tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReimbursementRevenue"> <tr> <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td> </tr> <tr> <td> <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div> <p>Repayment received or receivable for expenses incurred on behalf of a client or customer, other than those reimbursements received by landlords from tenants.</p> </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"> <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 225<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 2<br><br> -Subparagraph (SX 210.5-03.1)<br><br> -URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 605<br><br> -SubTopic 45<br><br> -Section 45<br><br> -Paragraph 23<br><br> -URI http://asc.fasb.org/extlink&oid=21915142&loc=d3e60722-111653<br><br><br><br></p> </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"> <table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_ReimbursementRevenue</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:monetaryItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>credit</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table> </div> </div> </td> </tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems"> <tr> <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td> </tr> <tr> <td> <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div> <table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:stringItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table> </div> </div> </td> </tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=cytk_GlobalBloodTherapeuticsMember"> <tr> <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td> </tr> <tr> <td> <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div> <table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=cytk_GlobalBloodTherapeuticsMember</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td></td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td></td> </tr> <tr> <td><strong> Period Type:</strong></td> <td></td> </tr> </table> </div> </div> </td> </tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=cytk_MyokardiaMember"> <tr> <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td> </tr> <tr> <td> <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div> <table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=cytk_MyokardiaMember</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td></td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td></td> </tr> <tr> <td><strong> Period Type:</strong></td> <td></td> </tr> </table> </div> </div> </td> </tr> </table> </div> </body> </html> </TEXT> </DOCUMENT> <DOCUMENT> <TYPE>XML <SEQUENCE>50 <FILENAME>R72.htm <DESCRIPTION>IDEA: XBRL DOCUMENT <TEXT> <html> <head> <META http-equiv="Content-Type" content="text/html; charset=us-ascii"> <title></title> <link rel="stylesheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript"> function toggleNextSibling (e) { if (e.nextSibling.style.display=='none') { e.nextSibling.style.display='block'; } else { e.nextSibling.style.display='none'; } }</script></head> <body><span style="display: none;">v2.4.1.9</span><table class="report" border="0" cellspacing="2" id="ID0EN5AE"> <tr> <th class="tl" colspan="1" rowspan="2"> <div style="width: 200px;"><strong>Income Taxes - Reconciliation of Total Amounts of Unrecognized Tax Benefits (Detail) (USD $)<br>In Thousands, unless otherwise specified</strong></div> </th> <th class="th" colspan="2">12 Months Ended</th> </tr> <tr> <th class="th"> <div>Dec. 31, 2014</div> </th> <th class="th"> <div>Dec. 31, 2013</div> </th> </tr> <tr class="rh"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=cytk_FederalAndStateTaxMember', window );">Federal and State Tax [Member]</a></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> </tr> <tr class="ro"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxContingencyLineItems', window );"><strong>Income Tax Contingency [Line Items]</strong></a></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> </tr> <tr class="re"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefits', window );">Unrecognized tax benefits, Beginning Balance</a></td> <td class="nump"><a title="us-gaap_UnrecognizedTaxBenefits[us-gaap_IncomeTaxAuthorityAxis=cytk_FederalAndStateTaxMember]" onclick="toggleNextSibling(this);">$ 6,171</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_UnrecognizedTaxBenefits<br>/ us-gaap_IncomeTaxAuthorityAxis<br>= cytk_FederalAndStateTaxMember</span><span></span></td> <td class="nump"><a title="us-gaap_UnrecognizedTaxBenefits[us-gaap_IncomeTaxAuthorityAxis=cytk_FederalAndStateTaxMember]" onclick="toggleNextSibling(this);">$ 5,340</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_UnrecognizedTaxBenefits<br>/ us-gaap_IncomeTaxAuthorityAxis<br>= cytk_FederalAndStateTaxMember</span><span></span></td> </tr> <tr class="ro"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions', window );">Reductions for tax positions of prior years</a></td> <td class="num"><a title="us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions[us-gaap_IncomeTaxAuthorityAxis=cytk_FederalAndStateTaxMember]" onclick="toggleNextSibling(this);">(85)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions<br>/ us-gaap_IncomeTaxAuthorityAxis<br>= cytk_FederalAndStateTaxMember</span><span></span></td> <td class="text"> <span></span></td> </tr> <tr class="re"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions', window );">Addition for tax positions of prior years</a></td> <td class="text"> <span></span></td> <td class="nump"><a title="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions[us-gaap_IncomeTaxAuthorityAxis=cytk_FederalAndStateTaxMember]" onclick="toggleNextSibling(this);">24</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions<br>/ us-gaap_IncomeTaxAuthorityAxis<br>= cytk_FederalAndStateTaxMember</span><span></span></td> </tr> <tr class="ro"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions', window );">Addition for tax positions related to the current year</a></td> <td class="nump"><a title="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions[us-gaap_IncomeTaxAuthorityAxis=cytk_FederalAndStateTaxMember]" onclick="toggleNextSibling(this);">188</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions<br>/ us-gaap_IncomeTaxAuthorityAxis<br>= cytk_FederalAndStateTaxMember</span><span></span></td> <td class="nump"><a title="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions[us-gaap_IncomeTaxAuthorityAxis=cytk_FederalAndStateTaxMember]" onclick="toggleNextSibling(this);">807</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions<br>/ us-gaap_IncomeTaxAuthorityAxis<br>= cytk_FederalAndStateTaxMember</span><span></span></td> </tr> <tr class="re"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefits', window );">Unrecognized tax benefits, Ending Balance</a></td> <td class="nump"><a title="us-gaap_UnrecognizedTaxBenefits[us-gaap_IncomeTaxAuthorityAxis=cytk_FederalAndStateTaxMember]" onclick="toggleNextSibling(this);">6,274</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_UnrecognizedTaxBenefits<br>/ us-gaap_IncomeTaxAuthorityAxis<br>= cytk_FederalAndStateTaxMember</span><span></span></td> <td class="nump"><a title="us-gaap_UnrecognizedTaxBenefits[us-gaap_IncomeTaxAuthorityAxis=cytk_FederalAndStateTaxMember]" onclick="toggleNextSibling(this);">6,171</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_UnrecognizedTaxBenefits<br>/ us-gaap_IncomeTaxAuthorityAxis<br>= cytk_FederalAndStateTaxMember</span><span></span></td> </tr> <tr class="rh"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=cytk_FederalTaxBenefitOfStateIncomeTaxUtbMember', window );">Federal Tax Benefit of State Income Tax UTBs [Member]</a></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> </tr> <tr class="re"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxContingencyLineItems', window );"><strong>Income Tax Contingency [Line Items]</strong></a></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> </tr> <tr class="ro"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefits', window );">Unrecognized tax benefits, Beginning Balance</a></td> <td class="nump"><a title="us-gaap_UnrecognizedTaxBenefits[us-gaap_IncomeTaxAuthorityAxis=cytk_FederalTaxBenefitOfStateIncomeTaxUtbMember]" onclick="toggleNextSibling(this);">1,209</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_UnrecognizedTaxBenefits<br>/ us-gaap_IncomeTaxAuthorityAxis<br>= cytk_FederalTaxBenefitOfStateIncomeTaxUtbMember</span><span></span></td> <td class="nump"><a title="us-gaap_UnrecognizedTaxBenefits[us-gaap_IncomeTaxAuthorityAxis=cytk_FederalTaxBenefitOfStateIncomeTaxUtbMember]" onclick="toggleNextSibling(this);">1,158</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_UnrecognizedTaxBenefits<br>/ us-gaap_IncomeTaxAuthorityAxis<br>= cytk_FederalTaxBenefitOfStateIncomeTaxUtbMember</span><span></span></td> </tr> <tr class="re"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions', window );">Reductions for tax positions of prior years</a></td> <td class="num"><a title="us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions[us-gaap_IncomeTaxAuthorityAxis=cytk_FederalTaxBenefitOfStateIncomeTaxUtbMember]" onclick="toggleNextSibling(this);">(29)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions<br>/ us-gaap_IncomeTaxAuthorityAxis<br>= cytk_FederalTaxBenefitOfStateIncomeTaxUtbMember</span><span></span></td> <td class="text"> <span></span></td> </tr> <tr class="ro"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions', window );">Addition for tax positions of prior years</a></td> <td class="text"> <span></span></td> <td class="nump"><a title="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions[us-gaap_IncomeTaxAuthorityAxis=cytk_FederalTaxBenefitOfStateIncomeTaxUtbMember]" onclick="toggleNextSibling(this);">8</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions<br>/ us-gaap_IncomeTaxAuthorityAxis<br>= cytk_FederalTaxBenefitOfStateIncomeTaxUtbMember</span><span></span></td> </tr> <tr class="re"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions', window );">Addition for tax positions related to the current year</a></td> <td class="nump"><a title="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions[us-gaap_IncomeTaxAuthorityAxis=cytk_FederalTaxBenefitOfStateIncomeTaxUtbMember]" onclick="toggleNextSibling(this);">10</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions<br>/ us-gaap_IncomeTaxAuthorityAxis<br>= cytk_FederalTaxBenefitOfStateIncomeTaxUtbMember</span><span></span></td> <td class="nump"><a title="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions[us-gaap_IncomeTaxAuthorityAxis=cytk_FederalTaxBenefitOfStateIncomeTaxUtbMember]" onclick="toggleNextSibling(this);">43</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions<br>/ us-gaap_IncomeTaxAuthorityAxis<br>= cytk_FederalTaxBenefitOfStateIncomeTaxUtbMember</span><span></span></td> </tr> <tr class="ro"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefits', window );">Unrecognized tax benefits, Ending Balance</a></td> <td class="nump"><a title="us-gaap_UnrecognizedTaxBenefits[us-gaap_IncomeTaxAuthorityAxis=cytk_FederalTaxBenefitOfStateIncomeTaxUtbMember]" onclick="toggleNextSibling(this);">1,190</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_UnrecognizedTaxBenefits<br>/ us-gaap_IncomeTaxAuthorityAxis<br>= cytk_FederalTaxBenefitOfStateIncomeTaxUtbMember</span><span></span></td> <td class="nump"><a title="us-gaap_UnrecognizedTaxBenefits[us-gaap_IncomeTaxAuthorityAxis=cytk_FederalTaxBenefitOfStateIncomeTaxUtbMember]" onclick="toggleNextSibling(this);">1,209</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_UnrecognizedTaxBenefits<br>/ us-gaap_IncomeTaxAuthorityAxis<br>= cytk_FederalTaxBenefitOfStateIncomeTaxUtbMember</span><span></span></td> </tr> <tr class="rh"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=cytk_UnrecognizedIncomeTaxBenefitsNetOfFederalBenefitOfStateIncomeTaxUtbMember', window );">Unrecognized Income Tax Benefits - Net of Federal Benefit of State UTBs [Member]</a></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> </tr> <tr class="ro"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxContingencyLineItems', window );"><strong>Income Tax Contingency [Line Items]</strong></a></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> </tr> <tr class="re"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefits', window );">Unrecognized tax benefits, Beginning Balance</a></td> <td class="nump"><a title="us-gaap_UnrecognizedTaxBenefits[us-gaap_IncomeTaxAuthorityAxis=cytk_UnrecognizedIncomeTaxBenefitsNetOfFederalBenefitOfStateIncomeTaxUtbMember]" onclick="toggleNextSibling(this);">4,962</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_UnrecognizedTaxBenefits<br>/ us-gaap_IncomeTaxAuthorityAxis<br>= cytk_UnrecognizedIncomeTaxBenefitsNetOfFederalBenefitOfStateIncomeTaxUtbMember</span><span></span></td> <td class="nump"><a title="us-gaap_UnrecognizedTaxBenefits[us-gaap_IncomeTaxAuthorityAxis=cytk_UnrecognizedIncomeTaxBenefitsNetOfFederalBenefitOfStateIncomeTaxUtbMember]" onclick="toggleNextSibling(this);">4,182</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_UnrecognizedTaxBenefits<br>/ us-gaap_IncomeTaxAuthorityAxis<br>= cytk_UnrecognizedIncomeTaxBenefitsNetOfFederalBenefitOfStateIncomeTaxUtbMember</span><span></span></td> </tr> <tr class="ro"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions', window );">Reductions for tax positions of prior years</a></td> <td class="num"><a title="us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions[us-gaap_IncomeTaxAuthorityAxis=cytk_UnrecognizedIncomeTaxBenefitsNetOfFederalBenefitOfStateIncomeTaxUtbMember]" onclick="toggleNextSibling(this);">(56)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions<br>/ us-gaap_IncomeTaxAuthorityAxis<br>= cytk_UnrecognizedIncomeTaxBenefitsNetOfFederalBenefitOfStateIncomeTaxUtbMember</span><span></span></td> <td class="text"> <span></span></td> </tr> <tr class="re"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions', window );">Addition for tax positions of prior years</a></td> <td class="text"> <span></span></td> <td class="nump"><a title="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions[us-gaap_IncomeTaxAuthorityAxis=cytk_UnrecognizedIncomeTaxBenefitsNetOfFederalBenefitOfStateIncomeTaxUtbMember]" onclick="toggleNextSibling(this);">16</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions<br>/ us-gaap_IncomeTaxAuthorityAxis<br>= cytk_UnrecognizedIncomeTaxBenefitsNetOfFederalBenefitOfStateIncomeTaxUtbMember</span><span></span></td> </tr> <tr class="ro"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions', window );">Addition for tax positions related to the current year</a></td> <td class="nump"><a title="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions[us-gaap_IncomeTaxAuthorityAxis=cytk_UnrecognizedIncomeTaxBenefitsNetOfFederalBenefitOfStateIncomeTaxUtbMember]" onclick="toggleNextSibling(this);">178</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions<br>/ us-gaap_IncomeTaxAuthorityAxis<br>= cytk_UnrecognizedIncomeTaxBenefitsNetOfFederalBenefitOfStateIncomeTaxUtbMember</span><span></span></td> <td class="nump"><a title="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions[us-gaap_IncomeTaxAuthorityAxis=cytk_UnrecognizedIncomeTaxBenefitsNetOfFederalBenefitOfStateIncomeTaxUtbMember]" onclick="toggleNextSibling(this);">764</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions<br>/ us-gaap_IncomeTaxAuthorityAxis<br>= cytk_UnrecognizedIncomeTaxBenefitsNetOfFederalBenefitOfStateIncomeTaxUtbMember</span><span></span></td> </tr> <tr class="re"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefits', window );">Unrecognized tax benefits, Ending Balance</a></td> <td class="nump"><a title="us-gaap_UnrecognizedTaxBenefits[us-gaap_IncomeTaxAuthorityAxis=cytk_UnrecognizedIncomeTaxBenefitsNetOfFederalBenefitOfStateIncomeTaxUtbMember]" onclick="toggleNextSibling(this);">$ 5,084</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_UnrecognizedTaxBenefits<br>/ us-gaap_IncomeTaxAuthorityAxis<br>= cytk_UnrecognizedIncomeTaxBenefitsNetOfFederalBenefitOfStateIncomeTaxUtbMember</span><span></span></td> <td class="nump"><a title="us-gaap_UnrecognizedTaxBenefits[us-gaap_IncomeTaxAuthorityAxis=cytk_UnrecognizedIncomeTaxBenefitsNetOfFederalBenefitOfStateIncomeTaxUtbMember]" onclick="toggleNextSibling(this);">$ 4,962</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_UnrecognizedTaxBenefits<br>/ us-gaap_IncomeTaxAuthorityAxis<br>= cytk_UnrecognizedIncomeTaxBenefitsNetOfFederalBenefitOfStateIncomeTaxUtbMember</span><span></span></td> </tr> </table> <div style="display: none;"> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxContingencyLineItems"> <tr> <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td> </tr> <tr> <td> <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div> <table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_IncomeTaxContingencyLineItems</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:stringItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table> </div> </div> </td> </tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefits"> <tr> <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td> </tr> <tr> <td> <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div> <p>Amount of unrecognized tax benefits pertaining to uncertain tax positions taken in tax returns.</p> </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"> <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Unrecognized Tax Benefit<br><br> -URI http://asc.fasb.org/extlink&oid=6527854<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 15A<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&oid=6907707&loc=SL6600010-109319<br><br><br><br></p> </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"> <table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefits</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:monetaryItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>credit</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>instant</td> </tr> </table> </div> </div> </td> </tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions"> <tr> <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td> </tr> <tr> <td> <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div> <p>Amount of decrease in unrecognized tax benefits resulting from tax positions taken in prior period tax returns.</p> </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"> <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 15A<br><br> -Subparagraph (a)(1)<br><br> -URI http://asc.fasb.org/extlink&oid=6907707&loc=SL6600010-109319<br><br><br><br></p> </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"> <table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:monetaryItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>debit</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table> </div> </div> </td> </tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions"> <tr> <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td> </tr> <tr> <td> <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div> <p>Amount of increase in unrecognized tax benefits resulting from tax positions that have been or will be taken in current period tax return.</p> </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"> <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 15A<br><br> -Subparagraph (a)(2)<br><br> -URI http://asc.fasb.org/extlink&oid=6907707&loc=SL6600010-109319<br><br><br><br></p> </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"> <table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:monetaryItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>credit</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table> </div> </div> </td> </tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions"> <tr> <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td> </tr> <tr> <td> <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div> <p>Amount of increase in unrecognized tax benefits resulting from tax positions taken in prior period tax returns.</p> </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"> <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 15A<br><br> -Subparagraph (a)(1)<br><br> -URI http://asc.fasb.org/extlink&oid=6907707&loc=SL6600010-109319<br><br><br><br></p> </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"> <table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:monetaryItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>credit</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table> </div> </div> </td> </tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=cytk_FederalAndStateTaxMember"> <tr> <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td> </tr> <tr> <td> <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div> <table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=cytk_FederalAndStateTaxMember</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td></td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td></td> </tr> <tr> <td><strong> Period Type:</strong></td> <td></td> </tr> </table> </div> </div> </td> </tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=cytk_FederalTaxBenefitOfStateIncomeTaxUtbMember"> <tr> <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td> </tr> <tr> <td> <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div> <table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=cytk_FederalTaxBenefitOfStateIncomeTaxUtbMember</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td></td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td></td> </tr> <tr> <td><strong> Period Type:</strong></td> <td></td> </tr> </table> </div> </div> </td> </tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=cytk_UnrecognizedIncomeTaxBenefitsNetOfFederalBenefitOfStateIncomeTaxUtbMember"> <tr> <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td> </tr> <tr> <td> <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div> <table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=cytk_UnrecognizedIncomeTaxBenefitsNetOfFederalBenefitOfStateIncomeTaxUtbMember</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td></td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td></td> </tr> <tr> <td><strong> Period Type:</strong></td> <td></td> </tr> </table> </div> </div> </td> </tr> </table> </div> </body> </html> </TEXT> </DOCUMENT> <DOCUMENT> <TYPE>XML <SEQUENCE>51 <FILENAME>R2.htm <DESCRIPTION>IDEA: XBRL DOCUMENT <TEXT> <html> <head> <META http-equiv="Content-Type" content="text/html; charset=us-ascii"> <title></title> <link rel="stylesheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript"> function toggleNextSibling (e) { if (e.nextSibling.style.display=='none') { e.nextSibling.style.display='block'; } else { e.nextSibling.style.display='none'; } }</script></head> <body><span style="display: none;">v2.4.1.9</span><table class="report" border="0" cellspacing="2" id="ID0EALAG"> <tr> <th class="tl" colspan="1" rowspan="1"> <div style="width: 200px;"><strong>Consolidated Balance Sheets (USD $)<br>In Thousands, unless otherwise specified</strong></div> </th> <th class="th"> <div>Dec. 31, 2014</div> </th> <th class="th"> <div>Dec. 31, 2013</div> </th> </tr> <tr class="re"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> </tr> <tr class="ro"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td> <td class="nump"><a title="us-gaap_CashAndCashEquivalentsAtCarryingValue" onclick="toggleNextSibling(this);">$ 20,215</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_CashAndCashEquivalentsAtCarryingValue</span><span></span></td> <td class="nump"><a title="us-gaap_CashAndCashEquivalentsAtCarryingValue" onclick="toggleNextSibling(this);">$ 20,158</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_CashAndCashEquivalentsAtCarryingValue</span><span></span></td> </tr> <tr class="re"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent', window );">Short-term investments</a></td> <td class="nump"><a title="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" onclick="toggleNextSibling(this);">63,013</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent</span><span></span></td> <td class="nump"><a title="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" onclick="toggleNextSibling(this);">57,570</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent</span><span></span></td> </tr> <tr class="ro"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsReceivableRelatedPartiesCurrent', window );">Related party accounts receivable</a></td> <td class="nump"><a title="us-gaap_AccountsReceivableRelatedPartiesCurrent" onclick="toggleNextSibling(this);">46,646</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_AccountsReceivableRelatedPartiesCurrent</span><span></span></td> <td class="nump"><a title="us-gaap_AccountsReceivableRelatedPartiesCurrent" onclick="toggleNextSibling(this);">5</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_AccountsReceivableRelatedPartiesCurrent</span><span></span></td> </tr> <tr class="re"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsCurrent', window );">Prepaid and other current assets</a></td> <td class="nump"><a title="us-gaap_OtherAssetsCurrent" onclick="toggleNextSibling(this);">1,257</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_OtherAssetsCurrent</span><span></span></td> <td class="nump"><a title="us-gaap_OtherAssetsCurrent" onclick="toggleNextSibling(this);">1,605</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_OtherAssetsCurrent</span><span></span></td> </tr> <tr class="rou"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td> <td class="nump"><a title="us-gaap_AssetsCurrent" onclick="toggleNextSibling(this);">131,131</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_AssetsCurrent</span><span></span></td> <td class="nump"><a title="us-gaap_AssetsCurrent" onclick="toggleNextSibling(this);">79,338</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_AssetsCurrent</span><span></span></td> </tr> <tr class="re"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td> <td class="nump"><a title="us-gaap_PropertyPlantAndEquipmentNet" onclick="toggleNextSibling(this);">1,637</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_PropertyPlantAndEquipmentNet</span><span></span></td> <td class="nump"><a title="us-gaap_PropertyPlantAndEquipmentNet" onclick="toggleNextSibling(this);">1,221</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_PropertyPlantAndEquipmentNet</span><span></span></td> </tr> <tr class="ro"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermInvestments', window );">Long-term investments</a></td> <td class="nump"><a title="us-gaap_LongTermInvestments" onclick="toggleNextSibling(this);">0</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_LongTermInvestments</span><span></span></td> <td class="nump"><a title="us-gaap_LongTermInvestments" onclick="toggleNextSibling(this);">2,502</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_LongTermInvestments</span><span></span></td> </tr> <tr class="re"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other assets</a></td> <td class="nump"><a title="us-gaap_OtherAssetsNoncurrent" onclick="toggleNextSibling(this);">200</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_OtherAssetsNoncurrent</span><span></span></td> <td class="nump"><a title="us-gaap_OtherAssetsNoncurrent" onclick="toggleNextSibling(this);">127</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_OtherAssetsNoncurrent</span><span></span></td> </tr> <tr class="rou"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td> <td class="nump"><a title="us-gaap_Assets" onclick="toggleNextSibling(this);">132,968</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_Assets</span><span></span></td> <td class="nump"><a title="us-gaap_Assets" onclick="toggleNextSibling(this);">83,188</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_Assets</span><span></span></td> </tr> <tr class="re"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> </tr> <tr class="ro"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td> <td class="nump"><a title="us-gaap_AccountsPayableCurrent" onclick="toggleNextSibling(this);">1,361</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_AccountsPayableCurrent</span><span></span></td> <td class="nump"><a title="us-gaap_AccountsPayableCurrent" onclick="toggleNextSibling(this);">3,709</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_AccountsPayableCurrent</span><span></span></td> </tr> <tr class="re"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued liabilities</a></td> <td class="nump"><a title="us-gaap_AccruedLiabilitiesCurrent" onclick="toggleNextSibling(this);">5,400</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_AccruedLiabilitiesCurrent</span><span></span></td> <td class="nump"><a title="us-gaap_AccruedLiabilitiesCurrent" onclick="toggleNextSibling(this);">8,272</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_AccruedLiabilitiesCurrent</span><span></span></td> </tr> <tr class="ro"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredRevenueCurrent', window );">Deferred revenue, current</a></td> <td class="nump"><a title="us-gaap_DeferredRevenueCurrent" onclick="toggleNextSibling(this);">17,042</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_DeferredRevenueCurrent</span><span></span></td> <td class="nump"><a title="us-gaap_DeferredRevenueCurrent" onclick="toggleNextSibling(this);">14,701</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_DeferredRevenueCurrent</span><span></span></td> </tr> <tr class="re"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredRentCreditCurrent', window );">Short-term portion of deferred rent</a></td> <td class="nump"><a title="us-gaap_DeferredRentCreditCurrent" onclick="toggleNextSibling(this);">52</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_DeferredRentCreditCurrent</span><span></span></td> <td class="nump"><a title="us-gaap_DeferredRentCreditCurrent" onclick="toggleNextSibling(this);">22</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_DeferredRentCreditCurrent</span><span></span></td> </tr> <tr class="rou"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td> <td class="nump"><a title="us-gaap_LiabilitiesCurrent" onclick="toggleNextSibling(this);">23,855</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_LiabilitiesCurrent</span><span></span></td> <td class="nump"><a title="us-gaap_LiabilitiesCurrent" onclick="toggleNextSibling(this);">26,704</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_LiabilitiesCurrent</span><span></span></td> </tr> <tr class="re"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredRevenueNoncurrent', window );">Deferred revenue, non-current</a></td> <td class="nump"><a title="us-gaap_DeferredRevenueNoncurrent" onclick="toggleNextSibling(this);">16,558</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_DeferredRevenueNoncurrent</span><span></span></td> <td class="nump"><a title="us-gaap_DeferredRevenueNoncurrent" onclick="toggleNextSibling(this);">1,500</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_DeferredRevenueNoncurrent</span><span></span></td> </tr> <tr class="ro"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredRentCreditNoncurrent', window );">Long-term portion of deferred rent</a></td> <td class="nump"><a title="us-gaap_DeferredRentCreditNoncurrent" onclick="toggleNextSibling(this);">491</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_DeferredRentCreditNoncurrent</span><span></span></td> <td class="nump"><a title="us-gaap_DeferredRentCreditNoncurrent" onclick="toggleNextSibling(this);">542</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_DeferredRentCreditNoncurrent</span><span></span></td> </tr> <tr class="reu"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td> <td class="nump"><a title="us-gaap_Liabilities" onclick="toggleNextSibling(this);">40,904</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_Liabilities</span><span></span></td> <td class="nump"><a title="us-gaap_Liabilities" onclick="toggleNextSibling(this);">28,746</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_Liabilities</span><span></span></td> </tr> <tr class="ro"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments and contingencies (Note 10)</a></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> </tr> <tr class="re"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders' equity:</strong></a></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> </tr> <tr class="ro"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock, $0.001 par value: Authorized: 81,500,000 shares: Issued and outstanding: 38,659,738 shares at December 31, 2014 and 30,681,624 shares at December 31, 2013</a></td> <td class="nump"><a title="us-gaap_CommonStockValue" onclick="toggleNextSibling(this);">39</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_CommonStockValue</span><span></span></td> <td class="nump"><a title="us-gaap_CommonStockValue" onclick="toggleNextSibling(this);">31</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_CommonStockValue</span><span></span></td> </tr> <tr class="re"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapital', window );">Additional paid-in capital</a></td> <td class="nump"><a title="us-gaap_AdditionalPaidInCapital" onclick="toggleNextSibling(this);">589,272</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_AdditionalPaidInCapital</span><span></span></td> <td class="nump"><a title="us-gaap_AdditionalPaidInCapital" onclick="toggleNextSibling(this);">537,001</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_AdditionalPaidInCapital</span><span></span></td> </tr> <tr class="ro"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive income</a></td> <td class="num"><a title="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" onclick="toggleNextSibling(this);">(4)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax</span><span></span></td> <td class="nump"><a title="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" onclick="toggleNextSibling(this);">7</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax</span><span></span></td> </tr> <tr class="re"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td> <td class="num"><a title="us-gaap_RetainedEarningsAccumulatedDeficit" onclick="toggleNextSibling(this);">(497,243)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_RetainedEarningsAccumulatedDeficit</span><span></span></td> <td class="num"><a title="us-gaap_RetainedEarningsAccumulatedDeficit" onclick="toggleNextSibling(this);">(482,597)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_RetainedEarningsAccumulatedDeficit</span><span></span></td> </tr> <tr class="rou"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total stockholders' equity</a></td> <td class="nump"><a title="us-gaap_StockholdersEquity" onclick="toggleNextSibling(this);">92,064</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_StockholdersEquity</span><span></span></td> <td class="nump"><a title="us-gaap_StockholdersEquity" onclick="toggleNextSibling(this);">54,442</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_StockholdersEquity</span><span></span></td> </tr> <tr class="reu"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and stockholders' equity</a></td> <td class="nump"><a title="us-gaap_LiabilitiesAndStockholdersEquity" onclick="toggleNextSibling(this);">132,968</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_LiabilitiesAndStockholdersEquity</span><span></span></td> <td class="nump"><a title="us-gaap_LiabilitiesAndStockholdersEquity" onclick="toggleNextSibling(this);">83,188</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_LiabilitiesAndStockholdersEquity</span><span></span></td> </tr> <tr class="rh"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember', window );">Series A Convertible Preferred Stock [Member]</a></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> </tr> <tr class="re"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders' equity:</strong></a></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> </tr> <tr class="ro"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred stock, value</a></td> <td class="nump"><a title="us-gaap_PreferredStockValue[us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember]" onclick="toggleNextSibling(this);">$ 0</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_PreferredStockValue<br>/ us-gaap_StatementClassOfStockAxis<br>= us-gaap_SeriesAPreferredStockMember</span><span></span></td> <td class="nump"><a title="us-gaap_PreferredStockValue[us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember]" onclick="toggleNextSibling(this);">$ 0</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_PreferredStockValue<br>/ us-gaap_StatementClassOfStockAxis<br>= us-gaap_SeriesAPreferredStockMember</span><span></span></td> </tr> </table> <div style="display: none;"> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent"> <tr> <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td> </tr> <tr> <td> <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div> <p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p> </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"> <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 19<br><br><br><br> -Subparagraph a<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.19(a))<br><br><br><br> -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682<br><br><br><br><br><br><br><br></p> </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"> <table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:monetaryItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>credit</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>instant</td> </tr> </table> </div> </div> </td> </tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableRelatedPartiesCurrent"> <tr> <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td> </tr> <tr> <td> <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div> <p>Amount of receivables arising from transactions with related parties due within one year or the normal operating cycle, if longer.</p> </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"> <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 235<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.4-08.(k)(1))<br><br><br><br> -URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 850<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 4<br><br><br><br> -URI http://asc.fasb.org/extlink&oid=6457730&loc=d3e39622-107864<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 850<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (d)<br><br><br><br> -URI http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864<br><br><br><br><br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 850<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 3<br><br><br><br> -URI http://asc.fasb.org/extlink&oid=6457730&loc=d3e39603-107864<br><br><br><br><br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 3<br><br><br><br> -Subparagraph a<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 08<br><br><br><br> -Paragraph k<br><br><br><br> -Subparagraph 1<br><br><br><br> -Article 4<br><br><br><br><br><br><br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.3(a)(2))<br><br><br><br> -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682<br><br><br><br><br><br><br><br></p> </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"> <table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_AccountsReceivableRelatedPartiesCurrent</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:monetaryItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>debit</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>instant</td> </tr> </table> </div> </div> </td> </tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent"> <tr> <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td> </tr> <tr> <td> <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div> <p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p> </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"> <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 20<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.20)<br><br><br><br> -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682<br><br><br><br><br><br><br><br></p> </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"> <table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:monetaryItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>credit</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>instant</td> </tr> </table> </div> </div> </td> </tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"> <tr> <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td> </tr> <tr> <td> <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div> <p>Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.</p> </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"> <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 220<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 11<br><br><br><br> -URI http://asc.fasb.org/extlink&oid=36458714&loc=d3e637-108580<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 220<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 14<br><br><br><br> -URI http://asc.fasb.org/extlink&oid=36458714&loc=d3e681-108580<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 220<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 14A<br><br><br><br> -URI http://asc.fasb.org/extlink&oid=36458714&loc=SL7669686-108580<br><br><br><br><br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 31<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 04<br><br><br><br> -Article 3<br><br><br><br><br><br><br><br></p> </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"> <table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:monetaryItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>credit</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>instant</td> </tr> </table> </div> </div> </td> </tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapital"> <tr> <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td> </tr> <tr> <td> <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div> <p>Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders. Includes adjustments to additional paid in capital. Some examples of such adjustments include recording the issuance of debt with a beneficial conversion feature and certain tax consequences of equity instruments awarded to employees. Use this element for the aggregate amount of additional paid-in capital associated with common and preferred stock. For additional paid-in capital associated with only common stock, use the element additional paid in capital, common stock. For additional paid-in capital associated with only preferred stock, use the element additional paid in capital, preferred stock.</p> </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"> <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 31<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.30(a)(1))<br><br><br><br> -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682<br><br><br><br><br><br><br><br></p> </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"> <table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapital</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:monetaryItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>credit</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>instant</td> </tr> </table> </div> </div> </td> </tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets"> <tr> <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td> </tr> <tr> <td> <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div> <p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p> </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"> <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.18)<br><br><br><br> -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 03<br><br><br><br> -Paragraph 12<br><br><br><br> -Article 7<br><br><br><br><br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 18<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br></p> </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"> <table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_Assets</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:monetaryItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>debit</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>instant</td> </tr> </table> </div> </div> </td> </tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent"> <tr> <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td> </tr> <tr> <td> <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div> <p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p> </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"> <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.9)<br><br><br><br> -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 3<br><br><br><br> -URI http://asc.fasb.org/extlink&oid=28358313&loc=d3e6801-107765<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 1<br><br><br><br> -URI http://asc.fasb.org/extlink&oid=28358313&loc=d3e6676-107765<br><br><br><br><br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 9<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br></p> </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"> <table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_AssetsCurrent</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:monetaryItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>debit</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>instant</td> </tr> </table> </div> </div> </td> </tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract"> <tr> <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td> </tr> <tr> <td> <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div> <table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:stringItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table> </div> </div> </td> </tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent"> <tr> <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td> </tr> <tr> <td> <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div> <p>Amount of investments in debt securities classified as available-for-sale, expected to be converted to cash, sold or exchanged within one year or the normal operating cycle, if longer.</p> </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"> <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 320<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 25<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (b)<br><br><br><br> -URI http://asc.fasb.org/extlink&oid=28360136&loc=d3e22054-111558<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 320<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 2<br><br><br><br> -URI http://asc.fasb.org/extlink&oid=6871852&loc=d3e26626-111562<br><br><br><br><br><br><br><br></p> </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"> <table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:monetaryItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>debit</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>instant</td> </tr> </table> </div> </div> </td> </tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue"> <tr> <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td> </tr> <tr> <td> <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div> <p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p> </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"> <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Glossary Cash<br><br><br><br> -URI http://asc.fasb.org/extlink&oid=6506951<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Glossary Cash Equivalents<br><br><br><br> -URI http://asc.fasb.org/extlink&oid=6507016<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 1<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.1)<br><br><br><br> -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (a)<br><br><br><br> -URI http://asc.fasb.org/extlink&oid=28358313&loc=d3e6676-107765<br><br><br><br><br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 230<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 4<br><br><br><br> -URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3044-108585<br><br><br><br><br><br><br><br></p> </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"> <table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:monetaryItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>debit</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>instant</td> </tr> </table> </div> </div> </td> </tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies"> <tr> <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td> </tr> <tr> <td> <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div> <p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p> </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"> <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 450<br><br><br><br> -SubTopic 20<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 1<br><br><br><br> -URI http://asc.fasb.org/extlink&oid=25496072&loc=d3e14326-108349<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.25)<br><br><br><br> -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 25<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 03<br><br><br><br> -Paragraph 19<br><br><br><br> -Article 7<br><br><br><br><br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 03<br><br><br><br> -Paragraph 17<br><br><br><br> -Article 9<br><br><br><br><br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 942<br><br><br><br> -SubTopic 210<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.9-03.17)<br><br><br><br> -URI http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878<br><br><br><br><br><br><br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 944<br><br><br><br> -SubTopic 210<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.7-03.(a),19)<br><br><br><br> -URI http://asc.fasb.org/extlink&oid=6879938&loc=d3e572229-122910<br><br><br><br><br><br><br><br></p> </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"> <table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:monetaryItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>credit</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>instant</td> </tr> </table> </div> </div> </td> </tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue"> <tr> <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td> </tr> <tr> <td> <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div> <p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p> </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"> <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.29)<br><br><br><br> -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 30<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br></p> </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"> <table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_CommonStockValue</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:monetaryItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>credit</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>instant</td> </tr> </table> </div> </div> </td> </tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredRentCreditCurrent"> <tr> <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td> </tr> <tr> <td> <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div> <p>For a classified balance sheet, the cumulative difference as of the balance sheet date between the payments required by a lease agreement and the rental income or expense recognized on a straight-line basis, or other systematic and rational basis more representative of the time pattern in which use or benefit is granted or derived from the leased property, expected to be recognized in income or expense, by the lessor or lessee, respectively, within one year of the balance sheet date.</p> </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"> <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.20)<br><br><br><br> -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 840<br><br><br><br> -SubTopic 20<br><br><br><br> -Section 25<br><br><br><br> -Paragraph 2<br><br><br><br> -Subparagraph (a)<br><br><br><br> -URI http://asc.fasb.org/extlink&oid=7501430&loc=d3e39927-112707<br><br><br><br><br><br><br><br></p> </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"> <table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_DeferredRentCreditCurrent</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:monetaryItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>credit</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>instant</td> </tr> </table> </div> </div> </td> </tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredRentCreditNoncurrent"> <tr> <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td> </tr> <tr> <td> <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div> <p>For a classified balance sheet, the cumulative difference between the rental income or payments required by a lease agreement and the rental income or expense recognized on a straight-line basis, or other systematic and rational basis more representative of the time pattern in which use or benefit is granted or derived from the leased property, expected to be recognized in income or expense, by the lessor or lessee, respectively, more than one year after the balance sheet date.</p> </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"> <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 840<br><br><br><br> -SubTopic 20<br><br><br><br> -Section 25<br><br><br><br> -Paragraph 2<br><br><br><br> -Subparagraph (a)<br><br><br><br> -URI http://asc.fasb.org/extlink&oid=7501430&loc=d3e39927-112707<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.26(c))<br><br><br><br> -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682<br><br><br><br><br><br><br><br></p> </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"> <table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_DeferredRentCreditNoncurrent</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:monetaryItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>credit</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>instant</td> </tr> </table> </div> </div> </td> </tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredRevenueCurrent"> <tr> <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td> </tr> <tr> <td> <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div> <p>The carrying amount of consideration received or receivable as of the balance sheet date on potential earnings that were not recognized as revenue in conformity with GAAP, and which are expected to be recognized as such within one year or the normal operating cycle, if longer, including sales, license fees, and royalties, but excluding interest income.</p> </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"> <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 605<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SAB TOPIC 13.A.4(a).Q1)<br><br><br><br> -URI http://asc.fasb.org/extlink&oid=27012821&loc=d3e214044-122780<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 8<br><br><br><br> -Subparagraph (b)<br><br><br><br> -URI http://asc.fasb.org/extlink&oid=28358313&loc=d3e6935-107765<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Staff Accounting Bulletin (SAB)<br><br><br><br> -Number Topic 13<br><br><br><br> -Section A<br><br><br><br><br><br><br><br></p> </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"> <table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_DeferredRevenueCurrent</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:monetaryItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>credit</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>instant</td> </tr> </table> </div> </div> </td> </tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredRevenueNoncurrent"> <tr> <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td> </tr> <tr> <td> <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div> <p>The noncurrent portion of deferred revenue amount as of balance sheet date. Deferred revenue is a liability related to a revenue producing activity for which revenue has not yet been recognized, and is not expected to be recognized in the next twelve months. Generally, an entity records deferred revenue when it receives consideration from a customer before achieving certain criteria that must be met for revenue to be recognized in conformity with GAAP.</p> </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"> <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 605<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SAB TOPIC 13.A.4(a).Q1)<br><br><br><br> -URI http://asc.fasb.org/extlink&oid=27012821&loc=d3e214044-122780<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 8<br><br><br><br> -Subparagraph (b)<br><br><br><br> -URI http://asc.fasb.org/extlink&oid=28358313&loc=d3e6935-107765<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Staff Accounting Bulletin (SAB)<br><br><br><br> -Number Topic 13<br><br><br><br> -Section A<br><br><br><br><br><br><br><br></p> </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"> <table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_DeferredRevenueNoncurrent</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:monetaryItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>credit</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>instant</td> </tr> </table> </div> </div> </td> </tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities"> <tr> <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td> </tr> <tr> <td> <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div> <p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p> </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"> <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.19-26)<br><br><br><br> -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682<br><br><br><br><br><br><br><br></p> </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"> <table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_Liabilities</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:monetaryItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>credit</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>instant</td> </tr> </table> </div> </div> </td> </tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity"> <tr> <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td> </tr> <tr> <td> <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div> <p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p> </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"> <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.32)<br><br><br><br> -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 03<br><br><br><br> -Paragraph 25<br><br><br><br> -Article 7<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 32<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br></p> </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"> <table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:monetaryItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>credit</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>instant</td> </tr> </table> </div> </div> </td> </tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent"> <tr> <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td> </tr> <tr> <td> <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div> <p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p> </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"> <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.21)<br><br><br><br> -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 21<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br></p> </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"> <table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:monetaryItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>credit</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>instant</td> </tr> </table> </div> </div> </td> </tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract"> <tr> <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td> </tr> <tr> <td> <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div> <table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:stringItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table> </div> </div> </td> </tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermInvestments"> <tr> <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td> </tr> <tr> <td> <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div> <p>The total amount of investments that are intended to be held for an extended period of time (longer than one operating cycle).</p> </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"> <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.12)<br><br><br><br> -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682<br><br><br><br><br><br><br><br></p> </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"> <table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_LongTermInvestments</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:monetaryItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>debit</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>instant</td> </tr> </table> </div> </div> </td> </tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsCurrent"> <tr> <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td> </tr> <tr> <td> <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div> <p>Aggregate carrying amount, as of the balance sheet date, of current assets not separately disclosed in the balance sheet. Current assets are expected to be realized or consumed within one year (or the normal operating cycle, if longer).</p> </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"> <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.8)<br><br><br><br> -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 8<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br></p> </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"> <table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_OtherAssetsCurrent</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:monetaryItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>debit</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>instant</td> </tr> </table> </div> </div> </td> </tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent"> <tr> <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td> </tr> <tr> <td> <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div> <p>Aggregate carrying amount, as of the balance sheet date, of noncurrent assets not separately disclosed in the balance sheet. Noncurrent assets are expected to be realized or consumed after one year (or the normal operating cycle, if longer).</p> </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"> <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.17)<br><br><br><br> -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 17<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br></p> </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"> <table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:monetaryItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>debit</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>instant</td> </tr> </table> </div> </div> </td> </tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockValue"> <tr> <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td> </tr> <tr> <td> <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div> <p>Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.</p> </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"> <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 04<br><br><br><br> -Article 3<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 505<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.3-04)<br><br><br><br> -URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.28)<br><br><br><br> -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 29<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br></p> </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"> <table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_PreferredStockValue</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:monetaryItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>credit</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>instant</td> </tr> </table> </div> </div> </td> </tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet"> <tr> <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td> </tr> <tr> <td> <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div> <p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p> </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"> <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 360<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 1<br><br><br><br> -URI http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.13)<br><br><br><br> -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 13<br><br><br><br> -Subparagraph a<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 03<br><br><br><br> -Paragraph 8<br><br><br><br> -Article 7<br><br><br><br><br><br><br><br></p> </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"> <table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:monetaryItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>debit</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>instant</td> </tr> </table> </div> </div> </td> </tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit"> <tr> <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td> </tr> <tr> <td> <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div> <p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p> </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"> <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 31<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 04<br><br><br><br> -Article 3<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.31(a)(3))<br><br><br><br> -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682<br><br><br><br><br><br><br><br></p> </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"> <table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:monetaryItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>credit</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>instant</td> </tr> </table> </div> </div> </td> </tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity"> <tr> <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td> </tr> <tr> <td> <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div> <p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p> </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"> <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 310<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 2<br><br><br><br> -Subparagraph (SAB TOPIC 4.E)<br><br><br><br> -URI http://asc.fasb.org/extlink&oid=27010918&loc=d3e74512-122707<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Staff Accounting Bulletin (SAB)<br><br><br><br> -Number Topic 4<br><br><br><br> -Section E<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.29-31)<br><br><br><br> -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 29, 30, 31<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br></p> </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"> <table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_StockholdersEquity</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:monetaryItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>credit</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>instant</td> </tr> </table> </div> </div> </td> </tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract"> <tr> <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td> </tr> <tr> <td> <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div> <table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:stringItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table> </div> </div> </td> </tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember"> <tr> <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td> </tr> <tr> <td> <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div> <table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td></td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td></td> </tr> <tr> <td><strong> Period Type:</strong></td> <td></td> </tr> </table> </div> </div> </td> </tr> </table> </div> </body> </html> </TEXT> </DOCUMENT> <DOCUMENT> <TYPE>XML <SEQUENCE>52 <FILENAME>R45.htm <DESCRIPTION>IDEA: XBRL DOCUMENT <TEXT> <html> <head> <META http-equiv="Content-Type" content="text/html; charset=us-ascii"> <title></title> <link rel="stylesheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript"> function toggleNextSibling (e) { if (e.nextSibling.style.display=='none') { e.nextSibling.style.display='block'; } else { e.nextSibling.style.display='none'; } }</script></head> <body><span style="display: none;">v2.4.1.9</span><table class="report" border="0" cellspacing="2" id="ID0EUNAC"> <tr> <th class="tl" colspan="1" rowspan="1"> <div style="width: 200px;"><strong>Fair Value Measurements - Additional Information (Detail) (USD $)<br></strong></div> </th> <th class="th"> <div>Dec. 31, 2014</div> </th> <th class="th"> <div>Dec. 31, 2013</div> </th> </tr> <tr class="rh"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Fair Value Measurements Using Level 2 [Member]</a></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> </tr> <tr class="ro"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> </tr> <tr class="re"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureRecurring', window );">Financial assets measured at fair value on a recurring basis</a></td> <td class="nump"><a title="us-gaap_AssetsFairValueDisclosureRecurring[us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member]" onclick="toggleNextSibling(this);">$ 0</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_AssetsFairValueDisclosureRecurring<br>/ us-gaap_FairValueByFairValueHierarchyLevelAxis<br>= us-gaap_FairValueInputsLevel2Member</span><span></span></td> <td class="nump"><a title="us-gaap_AssetsFairValueDisclosureRecurring[us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member]" onclick="toggleNextSibling(this);">$ 0</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_AssetsFairValueDisclosureRecurring<br>/ us-gaap_FairValueByFairValueHierarchyLevelAxis<br>= us-gaap_FairValueInputsLevel2Member</span><span></span></td> </tr> <tr class="rh"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Fair Value Measurements Using Level 3 [Member]</a></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> </tr> <tr class="re"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> </tr> <tr class="ro"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureRecurring', window );">Financial assets measured at fair value on a recurring basis</a></td> <td class="nump"><a title="us-gaap_AssetsFairValueDisclosureRecurring[us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member]" onclick="toggleNextSibling(this);">$ 0</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_AssetsFairValueDisclosureRecurring<br>/ us-gaap_FairValueByFairValueHierarchyLevelAxis<br>= us-gaap_FairValueInputsLevel3Member</span><span></span></td> <td class="nump"><a title="us-gaap_AssetsFairValueDisclosureRecurring[us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member]" onclick="toggleNextSibling(this);">$ 0</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_AssetsFairValueDisclosureRecurring<br>/ us-gaap_FairValueByFairValueHierarchyLevelAxis<br>= us-gaap_FairValueInputsLevel3Member</span><span></span></td> </tr> </table> <div style="display: none;"> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsFairValueDisclosureRecurring"> <tr> <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td> </tr> <tr> <td> <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div> <p>This element represents the aggregate of the assets reported on the balance sheet at period end measured at fair value on a recurring basis by the entity. This element is intended to be used in connection with the fair value disclosures required in the footnote disclosures to the financial statements.</p> </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"> <p>No definition available.</p> </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"> <table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_AssetsFairValueDisclosureRecurring</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:monetaryItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>debit</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>instant</td> </tr> </table> </div> </div> </td> </tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"> <tr> <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td> </tr> <tr> <td> <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div> <table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:stringItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table> </div> </div> </td> </tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member"> <tr> <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td> </tr> <tr> <td> <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div> <table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td></td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td></td> </tr> <tr> <td><strong> Period Type:</strong></td> <td></td> </tr> </table> </div> </div> </td> </tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member"> <tr> <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td> </tr> <tr> <td> <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div> <table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td></td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td></td> </tr> <tr> <td><strong> Period Type:</strong></td> <td></td> </tr> </table> </div> </div> </td> </tr> </table> </div> </body> </html> </TEXT> </DOCUMENT> <DOCUMENT> <TYPE>XML <SEQUENCE>53 <FILENAME>R6.htm <DESCRIPTION>IDEA: XBRL DOCUMENT <TEXT> <html> <head> <META http-equiv="Content-Type" content="text/html; charset=us-ascii"> <title></title> <link rel="stylesheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript"> function toggleNextSibling (e) { if (e.nextSibling.style.display=='none') { e.nextSibling.style.display='block'; } else { e.nextSibling.style.display='none'; } }</script></head> <body><span style="display: none;">v2.4.1.9</span><table class="report" border="0" cellspacing="2" id="ID0EMQAG"> <tr> <th class="tl" colspan="1" rowspan="2"> <div style="width: 200px;"><strong>Consolidated Statements of Stockholders' Equity (Parenthetical) (USD $)<br>In Thousands, except Per Share data, unless otherwise specified</strong></div> </th> <th class="th" colspan="3">12 Months Ended</th> </tr> <tr> <th class="th"> <div>Dec. 31, 2014</div> </th> <th class="th"> <div>Dec. 31, 2013</div> </th> <th class="th"> <div>Dec. 31, 2012</div> </th> </tr> <tr class="re"> <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cytk_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePrice', window );">Issuance of common stock upon exercise of stock options for cash per share</a></td> <td class="nump"><a title="cytk_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePrice" onclick="toggleNextSibling(this);">$ 6</a><span style="display:none;white-space:normal;text-align:left;">cytk_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePrice</span><span></span></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> </tr> <tr class="ro"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit', window );">Issuance of common stock upon exercise of stock options for cash per share, lower limit</a></td> <td class="text"> <span></span></td> <td class="nump"><a title="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" onclick="toggleNextSibling(this);">$ 4.02</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit</span><span></span></td> <td class="text"> <span></span></td> </tr> <tr class="re"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit', window );">Issuance of common stock upon exercise of stock options for cash per share, upper limit</a></td> <td class="text"> <span></span></td> <td class="nump"><a title="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" onclick="toggleNextSibling(this);">$ 11.1</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit</span><span></span></td> <td class="text"> <span></span></td> </tr> <tr class="ro"> <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cytk_IssuanceOfCommonStockEmployeeStockPurchasePlanPricePerShare', window );">Issuance of common stock pursuant to ESPP, per share</a></td> <td class="nump"><a title="cytk_IssuanceOfCommonStockEmployeeStockPurchasePlanPricePerShare" onclick="toggleNextSibling(this);">$ 3.38</a><span style="display:none;white-space:normal;text-align:left;">cytk_IssuanceOfCommonStockEmployeeStockPurchasePlanPricePerShare</span><span></span></td> <td class="nump"><a title="cytk_IssuanceOfCommonStockEmployeeStockPurchasePlanPricePerShare" onclick="toggleNextSibling(this);">$ 3.66</a><span style="display:none;white-space:normal;text-align:left;">cytk_IssuanceOfCommonStockEmployeeStockPurchasePlanPricePerShare</span><span></span></td> <td class="nump"><a title="cytk_IssuanceOfCommonStockEmployeeStockPurchasePlanPricePerShare" onclick="toggleNextSibling(this);">$ 4.32</a><span style="display:none;white-space:normal;text-align:left;">cytk_IssuanceOfCommonStockEmployeeStockPurchasePlanPricePerShare</span><span></span></td> </tr> <tr class="re"> <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cytk_IssuanceOfCommonStockToRelatedPartyForCashPerShare', window );">Issuance of common stock to related party for cash per share</a></td> <td class="text"> <span></span></td> <td class="nump"><a title="cytk_IssuanceOfCommonStockToRelatedPartyForCashPerShare" onclick="toggleNextSibling(this);">$ 7.12</a><span style="display:none;white-space:normal;text-align:left;">cytk_IssuanceOfCommonStockToRelatedPartyForCashPerShare</span><span></span></td> <td class="text"> <span></span></td> </tr> <tr class="ro"> <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cytk_IssuanceOfCommonStockToRelatedPartyIssuanceCosts', window );">Issuance of common stock to related party issuance costs</a></td> <td class="text"> <span></span></td> <td class="nump"><a title="cytk_IssuanceOfCommonStockToRelatedPartyIssuanceCosts" onclick="toggleNextSibling(this);">$ 21</a><span style="display:none;white-space:normal;text-align:left;">cytk_IssuanceOfCommonStockToRelatedPartyIssuanceCosts</span><span></span></td> <td class="text"> <span></span></td> </tr> <tr class="re"> <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cytk_IssuanceOfCommonStockToCollaborativePartnerForCashPerShare', window );">Issuance of common stock to collaborative partner for cash per share</a></td> <td class="nump"><a title="cytk_IssuanceOfCommonStockToCollaborativePartnerForCashPerShare" onclick="toggleNextSibling(this);">$ 4.9</a><span style="display:none;white-space:normal;text-align:left;">cytk_IssuanceOfCommonStockToCollaborativePartnerForCashPerShare</span><span></span></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> </tr> <tr class="ro"> <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cytk_IssuanceOfCommonStockToCollaborativePartnerIssuanceCosts', window );">Issuance of common stock to collaborative partner issuance costs</a></td> <td class="nump"><a title="cytk_IssuanceOfCommonStockToCollaborativePartnerIssuanceCosts" onclick="toggleNextSibling(this);">8</a><span style="display:none;white-space:normal;text-align:left;">cytk_IssuanceOfCommonStockToCollaborativePartnerIssuanceCosts</span><span></span></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> </tr> <tr class="re"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Issuance of common stock at per share</a></td> <td class="nump"><a title="us-gaap_SharePrice" onclick="toggleNextSibling(this);">$ 8</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_SharePrice</span><span></span></td> <td class="text"> <span></span></td> <td class="nump"><a title="us-gaap_SharePrice" onclick="toggleNextSibling(this);">$ 4.56</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_SharePrice</span><span></span></td> </tr> <tr class="ro"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsOfStockIssuanceCosts', window );">Stock issuance costs</a></td> <td class="nump"><a title="us-gaap_PaymentsOfStockIssuanceCosts" onclick="toggleNextSibling(this);">2,800</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_PaymentsOfStockIssuanceCosts</span><span></span></td> <td class="text"> <span></span></td> <td class="nump"><a title="us-gaap_PaymentsOfStockIssuanceCosts" onclick="toggleNextSibling(this);">2,139</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_PaymentsOfStockIssuanceCosts</span><span></span></td> </tr> <tr class="re"> <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cytk_IssuanceCostOfWarrant', window );">Issuance of warrants, issuance costs</a></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> <td class="nump"><a title="cytk_IssuanceCostOfWarrant" onclick="toggleNextSibling(this);">984</a><span style="display:none;white-space:normal;text-align:left;">cytk_IssuanceCostOfWarrant</span><span></span></td> </tr> <tr class="rh"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember', window );">Series A Convertible Preferred Stock [Member]</a></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> </tr> <tr class="re"> <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cytk_ConversionPricePerShareOfPreferredStockToCommonStock', window );">Conversion Price of convertible preferred stock to common stock</a></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> <td class="nump"><a title="cytk_ConversionPricePerShareOfPreferredStockToCommonStock[us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember]" onclick="toggleNextSibling(this);">$ 1,000</a><span style="display:none;white-space:normal;text-align:left;">cytk_ConversionPricePerShareOfPreferredStockToCommonStock<br>/ us-gaap_StatementClassOfStockAxis<br>= us-gaap_SeriesAPreferredStockMember</span><span></span></td> </tr> <tr class="rh"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember', window );">Series B Convertible Preferred Stock [Member]</a></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> </tr> <tr class="re"> <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cytk_ConvertiblePreferredStockIssuancePrice', window );">Issuance of convertible preferred stock at per share</a></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> <td class="nump"><a title="cytk_ConvertiblePreferredStockIssuancePrice[us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember]" onclick="toggleNextSibling(this);">$ 760</a><span style="display:none;white-space:normal;text-align:left;">cytk_ConvertiblePreferredStockIssuancePrice<br>/ us-gaap_StatementClassOfStockAxis<br>= us-gaap_SeriesBPreferredStockMember</span><span></span></td> </tr> <tr class="ro"> <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cytk_ConversionPricePerShareOfPreferredStockToCommonStock', window );">Conversion Price of convertible preferred stock to common stock</a></td> <td class="text"> <span></span></td> <td class="nump"><a title="cytk_ConversionPricePerShareOfPreferredStockToCommonStock[us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember]" onclick="toggleNextSibling(this);">$ 1,000</a><span style="display:none;white-space:normal;text-align:left;">cytk_ConversionPricePerShareOfPreferredStockToCommonStock<br>/ us-gaap_StatementClassOfStockAxis<br>= us-gaap_SeriesBPreferredStockMember</span><span></span></td> <td class="text"> <span></span></td> </tr> <tr class="re"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsOfStockIssuanceCosts', window );">Stock issuance costs</a></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> <td class="nump"><a title="us-gaap_PaymentsOfStockIssuanceCosts[us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember]" onclick="toggleNextSibling(this);">881</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_PaymentsOfStockIssuanceCosts<br>/ us-gaap_StatementClassOfStockAxis<br>= us-gaap_SeriesBPreferredStockMember</span><span></span></td> </tr> <tr class="rh"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=cytk_MlvAgreementMember', window );">MLV [Member]</a></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> </tr> <tr class="re"> <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cytk_IssuanceOfCommonStockToMlvAtPerShareLowerLimit', window );">Issuance of common stock to MLV at per share, lower limit</a></td> <td class="nump"><a title="cytk_IssuanceOfCommonStockToMlvAtPerShareLowerLimit[us-gaap_SubsidiarySaleOfStockAxis=cytk_MlvAgreementMember]" onclick="toggleNextSibling(this);">$ 6.64</a><span style="display:none;white-space:normal;text-align:left;">cytk_IssuanceOfCommonStockToMlvAtPerShareLowerLimit<br>/ us-gaap_SubsidiarySaleOfStockAxis<br>= cytk_MlvAgreementMember</span><span></span></td> <td class="nump"><a title="cytk_IssuanceOfCommonStockToMlvAtPerShareLowerLimit[us-gaap_SubsidiarySaleOfStockAxis=cytk_MlvAgreementMember]" onclick="toggleNextSibling(this);">$ 6.5</a><span style="display:none;white-space:normal;text-align:left;">cytk_IssuanceOfCommonStockToMlvAtPerShareLowerLimit<br>/ us-gaap_SubsidiarySaleOfStockAxis<br>= cytk_MlvAgreementMember</span><span></span></td> <td class="nump"><a title="cytk_IssuanceOfCommonStockToMlvAtPerShareLowerLimit[us-gaap_SubsidiarySaleOfStockAxis=cytk_MlvAgreementMember]" onclick="toggleNextSibling(this);">$ 6.3</a><span style="display:none;white-space:normal;text-align:left;">cytk_IssuanceOfCommonStockToMlvAtPerShareLowerLimit<br>/ us-gaap_SubsidiarySaleOfStockAxis<br>= cytk_MlvAgreementMember</span><span></span></td> </tr> <tr class="ro"> <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cytk_IssuanceOfCommonStockToMlvAtPerShareUpperLimit', window );">Issuance of common stock to MLV at per share, upper limit</a></td> <td class="nump"><a title="cytk_IssuanceOfCommonStockToMlvAtPerShareUpperLimit[us-gaap_SubsidiarySaleOfStockAxis=cytk_MlvAgreementMember]" onclick="toggleNextSibling(this);">$ 6.79</a><span style="display:none;white-space:normal;text-align:left;">cytk_IssuanceOfCommonStockToMlvAtPerShareUpperLimit<br>/ us-gaap_SubsidiarySaleOfStockAxis<br>= cytk_MlvAgreementMember</span><span></span></td> <td class="nump"><a title="cytk_IssuanceOfCommonStockToMlvAtPerShareUpperLimit[us-gaap_SubsidiarySaleOfStockAxis=cytk_MlvAgreementMember]" onclick="toggleNextSibling(this);">$ 6.79</a><span style="display:none;white-space:normal;text-align:left;">cytk_IssuanceOfCommonStockToMlvAtPerShareUpperLimit<br>/ us-gaap_SubsidiarySaleOfStockAxis<br>= cytk_MlvAgreementMember</span><span></span></td> <td class="nump"><a title="cytk_IssuanceOfCommonStockToMlvAtPerShareUpperLimit[us-gaap_SubsidiarySaleOfStockAxis=cytk_MlvAgreementMember]" onclick="toggleNextSibling(this);">$ 7.2</a><span style="display:none;white-space:normal;text-align:left;">cytk_IssuanceOfCommonStockToMlvAtPerShareUpperLimit<br>/ us-gaap_SubsidiarySaleOfStockAxis<br>= cytk_MlvAgreementMember</span><span></span></td> </tr> <tr class="re"> <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cytk_IssuanceOfCommonStockToMlvNetOfCommissionAndIssuanceCosts', window );">Issuance of common stock to MLV, net of commission and issuance costs</a></td> <td class="nump"><a title="cytk_IssuanceOfCommonStockToMlvNetOfCommissionAndIssuanceCosts[us-gaap_SubsidiarySaleOfStockAxis=cytk_MlvAgreementMember]" onclick="toggleNextSibling(this);">$ 74</a><span style="display:none;white-space:normal;text-align:left;">cytk_IssuanceOfCommonStockToMlvNetOfCommissionAndIssuanceCosts<br>/ us-gaap_SubsidiarySaleOfStockAxis<br>= cytk_MlvAgreementMember</span><span></span></td> <td class="nump"><a title="cytk_IssuanceOfCommonStockToMlvNetOfCommissionAndIssuanceCosts[us-gaap_SubsidiarySaleOfStockAxis=cytk_MlvAgreementMember]" onclick="toggleNextSibling(this);">$ 232</a><span style="display:none;white-space:normal;text-align:left;">cytk_IssuanceOfCommonStockToMlvNetOfCommissionAndIssuanceCosts<br>/ us-gaap_SubsidiarySaleOfStockAxis<br>= cytk_MlvAgreementMember</span><span></span></td> <td class="nump"><a title="cytk_IssuanceOfCommonStockToMlvNetOfCommissionAndIssuanceCosts[us-gaap_SubsidiarySaleOfStockAxis=cytk_MlvAgreementMember]" onclick="toggleNextSibling(this);">$ 89</a><span style="display:none;white-space:normal;text-align:left;">cytk_IssuanceOfCommonStockToMlvNetOfCommissionAndIssuanceCosts<br>/ us-gaap_SubsidiarySaleOfStockAxis<br>= cytk_MlvAgreementMember</span><span></span></td> </tr> </table> <div style="display: none;"> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cytk_ConversionPricePerShareOfPreferredStockToCommonStock"> <tr> <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td> </tr> <tr> <td> <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div> <p>Conversion price per share of preferred stock to common stock.</p> </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"> <p>No definition available.</p> </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"> <table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">cytk_ConversionPricePerShareOfPreferredStockToCommonStock</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>cytk_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>num:perShareItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table> </div> </div> </td> </tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cytk_ConvertiblePreferredStockIssuancePrice"> <tr> <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td> </tr> <tr> <td> <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div> <p>Convertible preferred stock issuance price.</p> </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"> <p>No definition available.</p> </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"> <table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">cytk_ConvertiblePreferredStockIssuancePrice</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>cytk_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>num:perShareItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table> </div> </div> </td> </tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cytk_IssuanceCostOfWarrant"> <tr> <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td> </tr> <tr> <td> <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div> <p>Issuance cost of warrant.</p> </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"> <p>No definition available.</p> </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"> <table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">cytk_IssuanceCostOfWarrant</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>cytk_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:monetaryItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>credit</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table> </div> </div> </td> </tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cytk_IssuanceOfCommonStockEmployeeStockPurchasePlanPricePerShare"> <tr> <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td> </tr> <tr> <td> <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div> <p>Issuance of common stock employee stock purchase plan price per share.</p> </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"> <p>No definition available.</p> </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"> <table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">cytk_IssuanceOfCommonStockEmployeeStockPurchasePlanPricePerShare</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>cytk_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>num:perShareItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table> </div> </div> </td> </tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cytk_IssuanceOfCommonStockToCollaborativePartnerForCashPerShare"> <tr> <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td> </tr> <tr> <td> <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div> <p>Issuance Of Common Stock To Collaborative Partner For Cash Per Share</p> </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"> <p>No definition available.</p> </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"> <table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">cytk_IssuanceOfCommonStockToCollaborativePartnerForCashPerShare</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>cytk_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>num:perShareItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table> </div> </div> </td> </tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cytk_IssuanceOfCommonStockToCollaborativePartnerIssuanceCosts"> <tr> <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td> </tr> <tr> <td> <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div> <p>Issuance Of Common Stock To Collaborative Partner Issuance Costs</p> </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"> <p>No definition available.</p> </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"> <table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">cytk_IssuanceOfCommonStockToCollaborativePartnerIssuanceCosts</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>cytk_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:monetaryItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>debit</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table> </div> </div> </td> </tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cytk_IssuanceOfCommonStockToMlvAtPerShareLowerLimit"> <tr> <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td> </tr> <tr> <td> <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div> <p>Issuance of common stock to MLV at per share, lower limit.</p> </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"> <p>No definition available.</p> </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"> <table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">cytk_IssuanceOfCommonStockToMlvAtPerShareLowerLimit</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>cytk_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>num:perShareItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table> </div> </div> </td> </tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cytk_IssuanceOfCommonStockToMlvAtPerShareUpperLimit"> <tr> <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td> </tr> <tr> <td> <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div> <p>Issuance of common stock to MLV at per share, upper limit.</p> </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"> <p>No definition available.</p> </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"> <table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">cytk_IssuanceOfCommonStockToMlvAtPerShareUpperLimit</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>cytk_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>num:perShareItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table> </div> </div> </td> </tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cytk_IssuanceOfCommonStockToMlvNetOfCommissionAndIssuanceCosts"> <tr> <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td> </tr> <tr> <td> <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div> <p>Issuance Of Common Stock To Mlv Net Of Commission And Issuance Costs</p> </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"> <p>No definition available.</p> </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"> <table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">cytk_IssuanceOfCommonStockToMlvNetOfCommissionAndIssuanceCosts</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>cytk_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:monetaryItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>debit</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table> </div> </div> </td> </tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cytk_IssuanceOfCommonStockToRelatedPartyForCashPerShare"> <tr> <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td> </tr> <tr> <td> <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div> <p>Issuance of common stock to related party for cash per share.</p> </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"> <p>No definition available.</p> </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"> <table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">cytk_IssuanceOfCommonStockToRelatedPartyForCashPerShare</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>cytk_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>num:perShareItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table> </div> </div> </td> </tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cytk_IssuanceOfCommonStockToRelatedPartyIssuanceCosts"> <tr> <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td> </tr> <tr> <td> <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div> <p>Issuance of common stock to related party, net of issuance costs.</p> </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"> <p>No definition available.</p> </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"> <table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">cytk_IssuanceOfCommonStockToRelatedPartyIssuanceCosts</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>cytk_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:monetaryItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>debit</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table> </div> </div> </td> </tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cytk_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePrice"> <tr> <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td> </tr> <tr> <td> <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div> <p>Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price</p> </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"> <p>No definition available.</p> </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"> <table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">cytk_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePrice</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>cytk_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>num:perShareItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table> </div> </div> </td> </tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfStockIssuanceCosts"> <tr> <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td> </tr> <tr> <td> <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div> <p>The cash outflow for cost incurred directly with the issuance of an equity security.</p> </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"> <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Glossary Financing Activities<br><br><br><br> -URI http://asc.fasb.org/extlink&oid=6513228<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 230<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 15<br><br><br><br> -URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3291-108585<br><br><br><br><br><br><br><br></p> </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"> <table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_PaymentsOfStockIssuanceCosts</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:monetaryItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>credit</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table> </div> </div> </td> </tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit"> <tr> <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td> </tr> <tr> <td> <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div> <p>The floor of a customized range of exercise prices for purposes of disclosing shares potentially issuable under outstanding stock option awards on all stock option plans and other required information pertaining to awards in the customized range.</p> </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"> <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 718<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 2<br><br><br><br> -Subparagraph (g)<br><br><br><br> -URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901<br><br><br><br><br><br><br><br></p> </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"> <table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>num:perShareItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table> </div> </div> </td> </tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit"> <tr> <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td> </tr> <tr> <td> <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div> <p>The ceiling of a customized range of exercise prices for purposes of disclosing shares potentially issuable under outstanding stock option awards on all stock option plans and other required information pertaining to awards in the customized range.</p> </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"> <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 718<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 2<br><br><br><br> -Subparagraph (g)<br><br><br><br> -URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901<br><br><br><br><br><br><br><br></p> </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"> <table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>num:perShareItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table> </div> </div> </td> </tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharePrice"> <tr> <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td> </tr> <tr> <td> <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div> <p>Price of a single share of a number of saleable stocks of a company.</p> </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"> <p>No definition available.</p> </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"> <table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_SharePrice</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>num:perShareItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>instant</td> </tr> </table> </div> </div> </td> </tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember"> <tr> <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td> </tr> <tr> <td> <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div> <table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td></td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td></td> </tr> <tr> <td><strong> Period Type:</strong></td> <td></td> </tr> </table> </div> </div> </td> </tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember"> <tr> <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td> </tr> <tr> <td> <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div> <table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td></td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td></td> </tr> <tr> <td><strong> Period Type:</strong></td> <td></td> </tr> </table> </div> </div> </td> </tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=cytk_MlvAgreementMember"> <tr> <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td> </tr> <tr> <td> <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div> <table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=cytk_MlvAgreementMember</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td></td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td></td> </tr> <tr> <td><strong> Period Type:</strong></td> <td></td> </tr> </table> </div> </div> </td> </tr> </table> </div> </body> </html> </TEXT> </DOCUMENT> <DOCUMENT> <TYPE>XML <SEQUENCE>54 <FILENAME>R59.htm <DESCRIPTION>IDEA: XBRL DOCUMENT <TEXT> <html> <head> <META http-equiv="Content-Type" content="text/html; charset=us-ascii"> <title></title> <link rel="stylesheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript"> function toggleNextSibling (e) { if (e.nextSibling.style.display=='none') { e.nextSibling.style.display='block'; } else { e.nextSibling.style.display='none'; } }</script></head> <body><span style="display: none;">v2.4.1.9</span><table class="report" border="0" cellspacing="2" id="ID0EUCFK"> <tr> <th class="tl" colspan="1" rowspan="2"> <div style="width: 200px;"><strong>Convertible Preferred Stock - Additional Information (Detail) (USD $)<br></strong></div> </th> <th class="th" colspan="2">0 Months Ended</th> <th class="th" colspan="1">1 Months Ended</th> <th class="th" colspan="3">12 Months Ended</th> <th class="th" colspan="2">0 Months Ended</th> <th class="th" colspan="2">3 Months Ended</th> <th class="th" colspan="2">0 Months Ended</th> <th class="th" colspan="1">3 Months Ended</th> <th class="th" colspan="1"></th> </tr> <tr> <th class="th"> <div>Jun. 24, 2013</div> </th> <th class="th"> <div>Jun. 20, 2012 </div> <div>PublicOffering</div> </th> <th class="th"> <div>Jun. 30, 2013</div> </th> <th class="th"> <div>Dec. 31, 2014</div> </th> <th class="th"> <div>Dec. 31, 2013</div> </th> <th class="th"> <div>Dec. 31, 2012</div> </th> <th class="th"> <div>Jul. 02, 2013</div> </th> <th class="th"> <div>Sep. 26, 2012</div> </th> <th class="th"> <div>Jun. 30, 2013</div> </th> <th class="th"> <div>Mar. 31, 2013</div> </th> <th class="th"> <div>Apr. 20, 2011</div> </th> <th class="th"> <div>Jun. 25, 2012</div> </th> <th class="th"> <div>Jun. 30, 2012</div> </th> <th class="th"> <div>Dec. 31, 2010</div> </th> </tr> <tr class="re"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> </tr> <tr class="ro"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock authorized number of shares</a></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> <td class="nump"><a title="us-gaap_PreferredStockSharesAuthorized" onclick="toggleNextSibling(this);">10,000,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_PreferredStockSharesAuthorized</span><span></span></td> <td class="nump"><a title="us-gaap_PreferredStockSharesAuthorized" onclick="toggleNextSibling(this);">10,000,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_PreferredStockSharesAuthorized</span><span></span></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> </tr> <tr class="re"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Convertible preferred stock, purchase price</a></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> <td class="nump"><a title="us-gaap_SharePrice" onclick="toggleNextSibling(this);">$ 8</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_SharePrice</span><span></span></td> <td class="text"> <span></span></td> <td class="nump"><a title="us-gaap_SharePrice" onclick="toggleNextSibling(this);">$ 4.56</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_SharePrice</span><span></span></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> <td class="nump"><a title="us-gaap_SharePrice" onclick="toggleNextSibling(this);">$ 4.56</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_SharePrice</span><span></span></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> </tr> <tr class="ro"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock', window );">Convertible preferred stock, net proceeds</a></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> <td class="nump"><a title="us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock" onclick="toggleNextSibling(this);">$ 0</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock</span><span></span></td> <td class="nump"><a title="us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock" onclick="toggleNextSibling(this);">$ 0</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock</span><span></span></td> <td class="nump"><a title="us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock" onclick="toggleNextSibling(this);">$ 12,318,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock</span><span></span></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> </tr> <tr class="re"> <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cytk_NumberOfConcurrentPublicOfferings', window );">Number of concurrent public offerings</a></td> <td class="text"> <span></span></td> <td class="nump"><a title="cytk_NumberOfConcurrentPublicOfferings" onclick="toggleNextSibling(this);">2</a><span style="display:none;white-space:normal;text-align:left;">cytk_NumberOfConcurrentPublicOfferings</span><span></span></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> </tr> <tr class="ro"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1', window );">Reverse stock split, conversion ratio</a></td> <td class="nump"><a title="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" onclick="toggleNextSibling(this);">0.167</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_StockholdersEquityNoteStockSplitConversionRatio1</span><span></span></td> <td class="text"> <span></span></td> <td class="nump"><a title="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" onclick="toggleNextSibling(this);">0.167</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_StockholdersEquityNoteStockSplitConversionRatio1</span><span></span></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> </tr> <tr class="re"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteStockSplit', window );">Stock split description</a></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> <td class="text">As a result of the one-for-six reverse stock split effected in June 2013, the conversion ratio for Series B convertible preferred stock changed from 1,000 shares of common stock per share of Series B convertible preferred stock to 166.67 shares of common stock per share of Series B convertible preferred stock.<span></span></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> </tr> <tr class="rh"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock [Member]</a></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> </tr> <tr class="re"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> </tr> <tr class="ro"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConversionOfStockSharesIssued1', window );">Common stock issued pursuant to series B preferred stock conversion</a></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> <td class="nump"><a title="us-gaap_ConversionOfStockSharesIssued1[us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember]" onclick="toggleNextSibling(this);">666,681</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ConversionOfStockSharesIssued1<br>/ us-gaap_StatementEquityComponentsAxis<br>= us-gaap_CommonStockMember</span><span></span></td> <td class="nump"><a title="us-gaap_ConversionOfStockSharesIssued1[us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember]" onclick="toggleNextSibling(this);">1,345,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ConversionOfStockSharesIssued1<br>/ us-gaap_StatementEquityComponentsAxis<br>= us-gaap_CommonStockMember</span><span></span></td> <td class="nump"><a title="us-gaap_ConversionOfStockSharesIssued1[us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember]" onclick="toggleNextSibling(this);">2,504,334</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ConversionOfStockSharesIssued1<br>/ us-gaap_StatementEquityComponentsAxis<br>= us-gaap_CommonStockMember</span><span></span></td> <td class="nump"><a title="us-gaap_ConversionOfStockSharesIssued1[us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember]" onclick="toggleNextSibling(this);">666,667</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ConversionOfStockSharesIssued1<br>/ us-gaap_StatementEquityComponentsAxis<br>= us-gaap_CommonStockMember</span><span></span></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> </tr> <tr class="rh"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=cytk_DeerfieldAgreementMember', window );">Deerfield Agreement [Member]</a></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> </tr> <tr class="ro"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> </tr> <tr class="re"> <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cytk_PercentageLimitOnNumberOfSharesOfCommonStockExercisableByHolders', window );">Percentage limit on number of shares of common stock exercisable by holders</a></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> <td class="nump"><a title="cytk_PercentageLimitOnNumberOfSharesOfCommonStockExercisableByHolders[us-gaap_SubsidiarySaleOfStockAxis=cytk_DeerfieldAgreementMember]" onclick="toggleNextSibling(this);">9.98%</a><span style="display:none;white-space:normal;text-align:left;">cytk_PercentageLimitOnNumberOfSharesOfCommonStockExercisableByHolders<br>/ us-gaap_SubsidiarySaleOfStockAxis<br>= cytk_DeerfieldAgreementMember</span><span></span></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> </tr> <tr class="rh"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_ConvertiblePreferredStockMember', window );">Convertible Preferred Stock [Member]</a></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> </tr> <tr class="re"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> </tr> <tr class="ro"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock authorized number of shares</a></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> <td class="nump"><a title="us-gaap_PreferredStockSharesAuthorized[us-gaap_StatementClassOfStockAxis=us-gaap_ConvertiblePreferredStockMember]" onclick="toggleNextSibling(this);">10,000,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_PreferredStockSharesAuthorized<br>/ us-gaap_StatementClassOfStockAxis<br>= us-gaap_ConvertiblePreferredStockMember</span><span></span></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> <td class="nump"><a title="us-gaap_PreferredStockSharesAuthorized[us-gaap_StatementClassOfStockAxis=us-gaap_ConvertiblePreferredStockMember]" onclick="toggleNextSibling(this);">10,000,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_PreferredStockSharesAuthorized<br>/ us-gaap_StatementClassOfStockAxis<br>= us-gaap_ConvertiblePreferredStockMember</span><span></span></td> </tr> <tr class="re"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock outstanding number of shares</a></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> <td class="nump"><a title="us-gaap_PreferredStockSharesOutstanding[us-gaap_StatementClassOfStockAxis=us-gaap_ConvertiblePreferredStockMember]" onclick="toggleNextSibling(this);">0</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_PreferredStockSharesOutstanding<br>/ us-gaap_StatementClassOfStockAxis<br>= us-gaap_ConvertiblePreferredStockMember</span><span></span></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> <td class="nump"><a title="us-gaap_PreferredStockSharesOutstanding[us-gaap_StatementClassOfStockAxis=us-gaap_ConvertiblePreferredStockMember]" onclick="toggleNextSibling(this);">0</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_PreferredStockSharesOutstanding<br>/ us-gaap_StatementClassOfStockAxis<br>= us-gaap_ConvertiblePreferredStockMember</span><span></span></td> </tr> <tr class="rh"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember', window );">Series A Convertible Preferred Stock [Member]</a></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> </tr> <tr class="re"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> </tr> <tr class="ro"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock outstanding number of shares</a></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> <td class="nump"><a title="us-gaap_PreferredStockSharesOutstanding[us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember]" onclick="toggleNextSibling(this);">0</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_PreferredStockSharesOutstanding<br>/ us-gaap_StatementClassOfStockAxis<br>= us-gaap_SeriesAPreferredStockMember</span><span></span></td> <td class="nump"><a title="us-gaap_PreferredStockSharesOutstanding[us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember]" onclick="toggleNextSibling(this);">0</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_PreferredStockSharesOutstanding<br>/ us-gaap_StatementClassOfStockAxis<br>= us-gaap_SeriesAPreferredStockMember</span><span></span></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> </tr> <tr class="re"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Convertible preferred stock, issued shares</a></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> <td class="nump"><a title="us-gaap_PreferredStockSharesIssued[us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember]" onclick="toggleNextSibling(this);">0</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_PreferredStockSharesIssued<br>/ us-gaap_StatementClassOfStockAxis<br>= us-gaap_SeriesAPreferredStockMember</span><span></span></td> <td class="nump"><a title="us-gaap_PreferredStockSharesIssued[us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember]" onclick="toggleNextSibling(this);">0</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_PreferredStockSharesIssued<br>/ us-gaap_StatementClassOfStockAxis<br>= us-gaap_SeriesAPreferredStockMember</span><span></span></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> </tr> <tr class="ro"> <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cytk_ExcessOfCommonStockFairValueOverAllocatedPurchasePriceOfPreferredStock', window );">Amount by which fair value of common stock exceeded the allocated purchase price</a></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> <td class="nump"><a title="cytk_ExcessOfCommonStockFairValueOverAllocatedPurchasePriceOfPreferredStock[us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember]" onclick="toggleNextSibling(this);">2,900,000</a><span style="display:none;white-space:normal;text-align:left;">cytk_ExcessOfCommonStockFairValueOverAllocatedPurchasePriceOfPreferredStock<br>/ us-gaap_StatementClassOfStockAxis<br>= us-gaap_SeriesAPreferredStockMember</span><span></span></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> </tr> <tr class="re"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConversionOfStockSharesConverted1', window );">Convertible preferred stock converted into common stock</a></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> <td class="nump"><a title="us-gaap_ConversionOfStockSharesConverted1[us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember]" onclick="toggleNextSibling(this);">8,070</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ConversionOfStockSharesConverted1<br>/ us-gaap_StatementClassOfStockAxis<br>= us-gaap_SeriesAPreferredStockMember</span><span></span></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> <td class="nump"><a title="us-gaap_ConversionOfStockSharesConverted1[us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember]" onclick="toggleNextSibling(this);">1,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ConversionOfStockSharesConverted1<br>/ us-gaap_StatementClassOfStockAxis<br>= us-gaap_SeriesAPreferredStockMember</span><span></span></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> </tr> <tr class="ro"> <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cytk_EntitledPaymentPerShareDuringLiquidation', window );">Entitled payment per share during liquidation</a></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> <td class="nump"><a title="cytk_EntitledPaymentPerShareDuringLiquidation[us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember]" onclick="toggleNextSibling(this);">$ 0.001</a><span style="display:none;white-space:normal;text-align:left;">cytk_EntitledPaymentPerShareDuringLiquidation<br>/ us-gaap_StatementClassOfStockAxis<br>= us-gaap_SeriesAPreferredStockMember</span><span></span></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> </tr> <tr class="rh"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember', window );">Series A Convertible Preferred Stock [Member] | Deerfield Agreement [Member]</a></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> </tr> <tr class="ro"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> </tr> <tr class="re"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Convertible preferred stock, issued shares</a></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> <td class="nump"><a title="us-gaap_PreferredStockSharesIssued[us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember;us-gaap_SubsidiarySaleOfStockAxis=cytk_DeerfieldAgreementMember]" onclick="toggleNextSibling(this);">8,070</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_PreferredStockSharesIssued<br>/ us-gaap_StatementClassOfStockAxis<br>= us-gaap_SeriesAPreferredStockMember<br>/ us-gaap_SubsidiarySaleOfStockAxis<br>= cytk_DeerfieldAgreementMember</span><span></span></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> </tr> <tr class="ro"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Convertible preferred stock, purchase price</a></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> <td class="nump"><a title="us-gaap_SharePrice[us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember;us-gaap_SubsidiarySaleOfStockAxis=cytk_DeerfieldAgreementMember]" onclick="toggleNextSibling(this);">$ 1,500.00</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_SharePrice<br>/ us-gaap_StatementClassOfStockAxis<br>= us-gaap_SeriesAPreferredStockMember<br>/ us-gaap_SubsidiarySaleOfStockAxis<br>= cytk_DeerfieldAgreementMember</span><span></span></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> </tr> <tr class="re"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock', window );">Convertible preferred stock, net proceeds</a></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> <td class="nump"><a title="us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock[us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember;us-gaap_SubsidiarySaleOfStockAxis=cytk_DeerfieldAgreementMember]" onclick="toggleNextSibling(this);">9,300,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock<br>/ us-gaap_StatementClassOfStockAxis<br>= us-gaap_SeriesAPreferredStockMember<br>/ us-gaap_SubsidiarySaleOfStockAxis<br>= cytk_DeerfieldAgreementMember</span><span></span></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> </tr> <tr class="ro"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConversionOfStockSharesConverted1', window );">Convertible preferred stock converted into common stock</a></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> <td class="nump"><a title="us-gaap_ConversionOfStockSharesConverted1[us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember;us-gaap_SubsidiarySaleOfStockAxis=cytk_DeerfieldAgreementMember]" onclick="toggleNextSibling(this);">1,345,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ConversionOfStockSharesConverted1<br>/ us-gaap_StatementClassOfStockAxis<br>= us-gaap_SeriesAPreferredStockMember<br>/ us-gaap_SubsidiarySaleOfStockAxis<br>= cytk_DeerfieldAgreementMember</span><span></span></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> </tr> <tr class="rh"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember', window );">Series B Convertible Preferred Stock [Member]</a></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> </tr> <tr class="ro"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> </tr> <tr class="re"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Convertible preferred stock, issued shares</a></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> <td class="nump"><a title="us-gaap_PreferredStockSharesIssued[us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember]" onclick="toggleNextSibling(this);">23,026</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_PreferredStockSharesIssued<br>/ us-gaap_StatementClassOfStockAxis<br>= us-gaap_SeriesBPreferredStockMember</span><span></span></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> </tr> <tr class="ro"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock', window );">Convertible preferred stock, net proceeds</a></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> <td class="nump"><a title="us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock[us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember]" onclick="toggleNextSibling(this);">12,300,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock<br>/ us-gaap_StatementClassOfStockAxis<br>= us-gaap_SeriesBPreferredStockMember</span><span></span></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> </tr> <tr class="re"> <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cytk_ExcessOfCommonStockFairValueOverAllocatedPurchasePriceOfPreferredStock', window );">Amount by which fair value of common stock exceeded the allocated purchase price</a></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> <td class="nump"><a title="cytk_ExcessOfCommonStockFairValueOverAllocatedPurchasePriceOfPreferredStock[us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember]" onclick="toggleNextSibling(this);">$ 1,300,000</a><span style="display:none;white-space:normal;text-align:left;">cytk_ExcessOfCommonStockFairValueOverAllocatedPurchasePriceOfPreferredStock<br>/ us-gaap_StatementClassOfStockAxis<br>= us-gaap_SeriesBPreferredStockMember</span><span></span></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> </tr> <tr class="ro"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConversionOfStockSharesConverted1', window );">Convertible preferred stock converted into common stock</a></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> <td class="nump"><a title="us-gaap_ConversionOfStockSharesConverted1[us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember]" onclick="toggleNextSibling(this);">1,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ConversionOfStockSharesConverted1<br>/ us-gaap_StatementClassOfStockAxis<br>= us-gaap_SeriesBPreferredStockMember</span><span></span></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> <td class="nump"><a title="us-gaap_ConversionOfStockSharesConverted1[us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember]" onclick="toggleNextSibling(this);">4,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ConversionOfStockSharesConverted1<br>/ us-gaap_StatementClassOfStockAxis<br>= us-gaap_SeriesBPreferredStockMember</span><span></span></td> <td class="text"> <span></span></td> <td class="nump"><a title="us-gaap_ConversionOfStockSharesConverted1[us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember]" onclick="toggleNextSibling(this);">15,026</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ConversionOfStockSharesConverted1<br>/ us-gaap_StatementClassOfStockAxis<br>= us-gaap_SeriesBPreferredStockMember</span><span></span></td> <td class="nump"><a title="us-gaap_ConversionOfStockSharesConverted1[us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember]" onclick="toggleNextSibling(this);">4,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ConversionOfStockSharesConverted1<br>/ us-gaap_StatementClassOfStockAxis<br>= us-gaap_SeriesBPreferredStockMember</span><span></span></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> <td class="nump"><a title="us-gaap_ConversionOfStockSharesConverted1[us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember]" onclick="toggleNextSibling(this);">1,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ConversionOfStockSharesConverted1<br>/ us-gaap_StatementClassOfStockAxis<br>= us-gaap_SeriesBPreferredStockMember</span><span></span></td> <td class="text"> <span></span></td> </tr> <tr class="re"> <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cytk_PercentageLimitOnNumberOfSharesOfCommonStockExercisableByHolders', window );">Percentage limit on number of shares of common stock exercisable by holders</a></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> <td class="nump"><a title="cytk_PercentageLimitOnNumberOfSharesOfCommonStockExercisableByHolders[us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember]" onclick="toggleNextSibling(this);">9.98%</a><span style="display:none;white-space:normal;text-align:left;">cytk_PercentageLimitOnNumberOfSharesOfCommonStockExercisableByHolders<br>/ us-gaap_StatementClassOfStockAxis<br>= us-gaap_SeriesBPreferredStockMember</span><span></span></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> </tr> <tr class="ro"> <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cytk_EntitledPaymentPerShareDuringLiquidation', window );">Entitled payment per share during liquidation</a></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> <td class="nump"><a title="cytk_EntitledPaymentPerShareDuringLiquidation[us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember]" onclick="toggleNextSibling(this);">$ 0.001</a><span style="display:none;white-space:normal;text-align:left;">cytk_EntitledPaymentPerShareDuringLiquidation<br>/ us-gaap_StatementClassOfStockAxis<br>= us-gaap_SeriesBPreferredStockMember</span><span></span></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> <td class="nump"><a title="cytk_EntitledPaymentPerShareDuringLiquidation[us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember]" onclick="toggleNextSibling(this);">$ 0.001</a><span style="display:none;white-space:normal;text-align:left;">cytk_EntitledPaymentPerShareDuringLiquidation<br>/ us-gaap_StatementClassOfStockAxis<br>= us-gaap_SeriesBPreferredStockMember</span><span></span></td> <td class="text"> <span></span></td> </tr> <tr class="re"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteChangesInCapitalStructureSubsequentChangesToNumberOfCommonShares', window );">Preferred stock after stock split</a></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> <td class="nump"><a title="us-gaap_StockholdersEquityNoteChangesInCapitalStructureSubsequentChangesToNumberOfCommonShares[us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember]" onclick="toggleNextSibling(this);">166.67</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_StockholdersEquityNoteChangesInCapitalStructureSubsequentChangesToNumberOfCommonShares<br>/ us-gaap_StatementClassOfStockAxis<br>= us-gaap_SeriesBPreferredStockMember</span><span></span></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> </tr> <tr class="rh"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember', window );">Series B Convertible Preferred Stock [Member] | IPO [Member]</a></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> </tr> <tr class="re"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> </tr> <tr class="ro"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Convertible preferred stock, purchase price</a></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> <td class="nump"><a title="us-gaap_SharePrice[us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember;us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember]" onclick="toggleNextSibling(this);">$ 760.00</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_SharePrice<br>/ us-gaap_StatementClassOfStockAxis<br>= us-gaap_SeriesBPreferredStockMember<br>/ us-gaap_SubsidiarySaleOfStockAxis<br>= us-gaap_IPOMember</span><span></span></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> </tr> </table> <div style="display: none;"> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cytk_EntitledPaymentPerShareDuringLiquidation"> <tr> <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td> </tr> <tr> <td> <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div> <p>Value of the difference between preference in liquidation and the par or stated values of the preferred shares.</p> </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"> <p>No definition available.</p> </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"> <table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">cytk_EntitledPaymentPerShareDuringLiquidation</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>cytk_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>num:perShareItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>instant</td> </tr> </table> </div> </div> </td> </tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cytk_ExcessOfCommonStockFairValueOverAllocatedPurchasePriceOfPreferredStock"> <tr> <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td> </tr> <tr> <td> <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div> <p>Excess of fair value of common stock into which preferred stock is convertible, over the purchase price of such preferred stock.</p> </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"> <p>No definition available.</p> </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"> <table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">cytk_ExcessOfCommonStockFairValueOverAllocatedPurchasePriceOfPreferredStock</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>cytk_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:monetaryItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>credit</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table> </div> </div> </td> </tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cytk_NumberOfConcurrentPublicOfferings"> <tr> <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td> </tr> <tr> <td> <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div> <p>Number Of Concurrent Public Offerings</p> </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"> <p>No definition available.</p> </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"> <table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">cytk_NumberOfConcurrentPublicOfferings</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>cytk_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:integerItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table> </div> </div> </td> </tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cytk_PercentageLimitOnNumberOfSharesOfCommonStockExercisableByHolders"> <tr> <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td> </tr> <tr> <td> <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div> <p>Maximum amount of common shares a holder of preferred stock may own, expressed as a percentage of total number of shares of common stock outstanding issued and outstanding. This limitation will prohibit conversion of preferred stock to common stock if, as a result, the holders ownership percentage would exceed the specified limit.</p> </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"> <p>No definition available.</p> </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"> <table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">cytk_PercentageLimitOnNumberOfSharesOfCommonStockExercisableByHolders</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>cytk_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>num:percentItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>instant</td> </tr> </table> </div> </div> </td> </tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfStockLineItems"> <tr> <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td> </tr> <tr> <td> <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div> <table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_ClassOfStockLineItems</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:stringItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table> </div> </div> </td> </tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConversionOfStockSharesConverted1"> <tr> <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td> </tr> <tr> <td> <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div> <p>The number of shares converted in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p> </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"> <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 5<br><br> -URI http://asc.fasb.org/extlink&oid=6367179&loc=d3e4332-108586<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 4<br><br> -URI http://asc.fasb.org/extlink&oid=6367179&loc=d3e4313-108586<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&oid=6367179&loc=d3e4304-108586<br><br><br><br></p> </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"> <table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_ConversionOfStockSharesConverted1</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:sharesItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table> </div> </div> </td> </tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConversionOfStockSharesIssued1"> <tr> <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td> </tr> <tr> <td> <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div> <p>The number of new shares issued in the conversion of stock in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p> </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"> <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 5<br><br> -URI http://asc.fasb.org/extlink&oid=6367179&loc=d3e4332-108586<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 4<br><br> -URI http://asc.fasb.org/extlink&oid=6367179&loc=d3e4313-108586<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&oid=6367179&loc=d3e4304-108586<br><br><br><br></p> </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"> <table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_ConversionOfStockSharesIssued1</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:sharesItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table> </div> </div> </td> </tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized"> <tr> <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td> </tr> <tr> <td> <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div> <p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p> </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"> <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.28)<br><br> -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 29<br><br> -Article 5<br><br><br><br></p> </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"> <table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:sharesItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>instant</td> </tr> </table> </div> </div> </td> </tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued"> <tr> <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td> </tr> <tr> <td> <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div> <p>Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.</p> </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"> <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.28)<br><br> -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 29<br><br> -Article 5<br><br><br><br></p> </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"> <table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:sharesItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>instant</td> </tr> </table> </div> </div> </td> </tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding"> <tr> <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td> </tr> <tr> <td> <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div> <p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p> </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"> <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.28)<br><br> -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 29<br><br> -Article 5<br><br><br><br></p> </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"> <table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:sharesItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>instant</td> </tr> </table> </div> </div> </td> </tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock"> <tr> <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td> </tr> <tr> <td> <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div> <p>Proceeds from issuance of capital stock which provides for a specific dividend that is paid to the shareholders before any dividends to common stockholders and which takes precedence over common stockholders in the event of liquidation.</p> </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"> <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Financing Activities<br><br> -URI http://asc.fasb.org/extlink&oid=6513228<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 14<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3255-108585<br><br><br><br></p> </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"> <table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:monetaryItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>debit</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table> </div> </div> </td> </tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharePrice"> <tr> <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td> </tr> <tr> <td> <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div> <p>Price of a single share of a number of saleable stocks of a company.</p> </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"> <p>No definition available.</p> </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"> <table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_SharePrice</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>num:perShareItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>instant</td> </tr> </table> </div> </div> </td> </tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteChangesInCapitalStructureSubsequentChangesToNumberOfCommonShares"> <tr> <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td> </tr> <tr> <td> <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div> <p>Change in number of shares issued and outstanding as a result of capital structure change to a stock dividend, stock split or reserve split occurring after the balance sheet date but prior to the later of the issuance of financial statements or the effective date of registration statement.</p> </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"> <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 4<br><br> -Subparagraph (SAB TOPIC 4.C)<br><br> -URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187143-122770<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Staff Accounting Bulletin (SAB)<br><br> -Number Topic 4<br><br> -Section C<br><br><br><br></p> </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"> <table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteChangesInCapitalStructureSubsequentChangesToNumberOfCommonShares</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:sharesItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table> </div> </div> </td> </tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteStockSplit"> <tr> <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td> </tr> <tr> <td> <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div> <p>Description of the stock split arrangement. Also provide the retroactive effect given by a stock split that occurs after the balance date but before the release of financial statements.</p> </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"> <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Stock Split<br><br> -URI http://asc.fasb.org/extlink&oid=6525746<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 4<br><br> -Subparagraph (SAB TOPIC 4.C)<br><br> -URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187143-122770<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Staff Accounting Bulletin (SAB)<br><br> -Number Topic 4<br><br> -Section C<br><br><br><br></p> </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"> <table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteStockSplit</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:stringItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table> </div> </div> </td> </tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1"> <tr> <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td> </tr> <tr> <td> <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div> <p>Ratio applied to the conversion of stock split, for example but not limited to, one share converted to two or two shares converted to one.</p> </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"> <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Stock Split<br><br> -URI http://asc.fasb.org/extlink&oid=6525746<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 4<br><br> -Subparagraph (SAB TOPIC 4.C)<br><br> -URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187143-122770<br><br><br><br></p> </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"> <table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteStockSplitConversionRatio1</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:pureItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table> </div> </div> </td> </tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_ConvertiblePreferredStockMember"> <tr> <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td> </tr> <tr> <td> <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div> <table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_ConvertiblePreferredStockMember</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td></td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td></td> </tr> <tr> <td><strong> Period Type:</strong></td> <td></td> </tr> </table> </div> </div> </td> </tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember"> <tr> <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td> </tr> <tr> <td> <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div> <table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td></td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td></td> </tr> <tr> <td><strong> Period Type:</strong></td> <td></td> </tr> </table> </div> </div> </td> </tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember"> <tr> <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td> </tr> <tr> <td> <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div> <table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td></td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td></td> </tr> <tr> <td><strong> Period Type:</strong></td> <td></td> </tr> </table> </div> </div> </td> </tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember"> <tr> <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td> </tr> <tr> <td> <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div> <table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td></td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td></td> </tr> <tr> <td><strong> Period Type:</strong></td> <td></td> </tr> </table> </div> </div> </td> </tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=cytk_DeerfieldAgreementMember"> <tr> <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td> </tr> <tr> <td> <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div> <table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=cytk_DeerfieldAgreementMember</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td></td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td></td> </tr> <tr> <td><strong> Period Type:</strong></td> <td></td> </tr> </table> </div> </div> </td> </tr> </table> </div> </body> </html> </TEXT> </DOCUMENT> <DOCUMENT> <TYPE>XML <SEQUENCE>55 <FILENAME>R35.htm <DESCRIPTION>IDEA: XBRL DOCUMENT <TEXT> <html> <head> <META http-equiv="Content-Type" content="text/html; charset=us-ascii"> <title></title> <link rel="stylesheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript"> function toggleNextSibling (e) { if (e.nextSibling.style.display=='none') { e.nextSibling.style.display='block'; } else { e.nextSibling.style.display='none'; } }</script></head> <body><span style="display: none;">v2.4.1.9</span><table class="report" border="0" cellspacing="2" id="ID0EME"> <tr> <th class="tl" colspan="1" rowspan="2"> <div style="width: 200px;"><strong>Interest and Other, Net (Tables)<br></strong></div> </th> <th class="th" colspan="1">12 Months Ended</th> </tr> <tr> <th class="th"> <div>Dec. 31, 2014</div> </th> </tr> <tr class="re"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherIncomeAndExpensesAbstract', window );"><strong>Other Income and Expenses [Abstract]</strong></a></td> <td class="text"> <span></span></td> </tr> <tr class="ro"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock', window );">Components of Interest and Other, Net</a></td> <td class="text"><div> <p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 6px; TEXT-INDENT: 4%" align="justify"><font style="FONT-FAMILY: Times New Roman" size="2">Components of Interest and Other, Net were as follows (in thousands):</font></p> <p style="MARGIN-BOTTOM: 0px; FONT-SIZE: 12px; MARGIN-TOP: 0px">  </p> <table style="BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="92%" align="center" border="0"> <tr> <td width="80%"></td> <td valign="bottom" width="4%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="4%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="4%"></td> <td></td> <td></td> <td></td> </tr> <tr> <td valign="bottom"><font size="1"> </font></td> <td valign="bottom"><font size="1">  </font></td> <td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="10" align="center"><font style="FONT-FAMILY: Times New Roman" size="1"><b>Years Ended<br /> December 31,</b></font></td> <td valign="bottom"><font size="1"> </font></td> </tr> <tr> <td valign="bottom"><font size="1"> </font></td> <td valign="bottom"><font size="1">  </font></td> <td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" align="center"><font style="FONT-FAMILY: Times New Roman" size="1"><b>2014</b></font></td> <td valign="bottom"><font size="1"> </font></td> <td valign="bottom"><font size="1">  </font></td> <td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" align="center"><font style="FONT-FAMILY: Times New Roman" size="1"><b>2013</b></font></td> <td valign="bottom"><font size="1"> </font></td> <td valign="bottom"><font size="1">  </font></td> <td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" align="center"><font style="FONT-FAMILY: Times New Roman" size="1"><b>2012</b></font></td> <td valign="bottom"><font size="1"> </font></td> </tr> <tr bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: Times New Roman" size="2">Interest income and other income</font></p> </td> <td valign="bottom"><font size="1">  </font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">108</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">  </font></td> <td valign="bottom"><font size="1">  </font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">98</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">  </font></td> <td valign="bottom"><font size="1">  </font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">89</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">  </font></td> </tr> <tr> <td valign="top"> <p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: Times New Roman" size="2">Interest expense and other expense</font></p> </td> <td valign="bottom"><font size="1">  </font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2"> </font></td> <td valign="bottom" nowrap="nowrap" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">—</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">  </font></td> <td valign="bottom"><font size="1">  </font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2"> </font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">79</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">  </font></td> <td valign="bottom"><font size="1">  </font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2"> </font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">(2</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">) </font></td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid"> </p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid"> </p> </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid"> </p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid"> </p> </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid"> </p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid"> </p> </td> <td> </td> </tr> <tr bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-LEFT: 2em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: Times New Roman" size="2">Interest and Other, net</font></p> </td> <td valign="bottom"><font size="1">  </font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">108</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">  </font></td> <td valign="bottom"><font size="1">  </font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">177</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">  </font></td> <td valign="bottom"><font size="1">  </font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">87</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">  </font></td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double"> </p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double"> </p> </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double"> </p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double"> </p> </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double"> </p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double"> </p> </td> <td> </td> </tr> </table> </div><span></span></td> </tr> </table> <div style="display: none;"> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherIncomeAndExpensesAbstract"> <tr> <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td> </tr> <tr> <td> <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div> <table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_OtherIncomeAndExpensesAbstract</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:stringItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table> </div> </div> </td> </tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock"> <tr> <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td> </tr> <tr> <td> <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div> <p>Tabular disclosure of the components of non-operating income or non-operating expense that may include amounts earned from dividends, interest on securities, gains (losses) on securities sold, equity earnings of unconsolidated affiliates, net gain (loss) on sales of business, interest expense and other miscellaneous income or expense items.</p> </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"> <p>No definition available.</p> </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"> <table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>nonnum:textBlockItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table> </div> </div> </td> </tr> </table> </div> </body> </html> </TEXT> </DOCUMENT> <DOCUMENT> <TYPE>XML <SEQUENCE>56 <FILENAME>R65.htm <DESCRIPTION>IDEA: XBRL DOCUMENT <TEXT> <html> <head> <META http-equiv="Content-Type" content="text/html; charset=us-ascii"> <title></title> <link rel="stylesheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript"> function toggleNextSibling (e) { if (e.nextSibling.style.display=='none') { e.nextSibling.style.display='block'; } else { e.nextSibling.style.display='none'; } }</script></head> <body><span style="display: none;">v2.4.1.9</span><table class="report" border="0" cellspacing="2" id="ID0EQSAE"> <tr> <th class="tl" colspan="1" rowspan="2"> <div style="width: 200px;"><strong>Stockholders' Equity - Fair Value of Share-Based Payments was Estimated on Date of Grant Using Black-Scholes Option Pricing Model Based on Weighted Average Assumptions (Detail)<br></strong></div> </th> <th class="th" colspan="3">12 Months Ended</th> </tr> <tr> <th class="th"> <div>Dec. 31, 2014</div> </th> <th class="th"> <div>Dec. 31, 2013</div> </th> <th class="th"> <div>Dec. 31, 2012</div> </th> </tr> <tr class="rh"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_EmployeeStockMember', window );">ESPP [Member]</a></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> </tr> <tr class="ro"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsLineItems', window );"><strong>Deferred Compensation Arrangement with Individual, Share-based Payments [Line Items]</strong></a></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> </tr> <tr class="re"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate</a></td> <td class="nump"><a title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate[us-gaap_SubsidiarySaleOfStockAxis=us-gaap_EmployeeStockMember]" onclick="toggleNextSibling(this);">0.20%</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate<br>/ us-gaap_SubsidiarySaleOfStockAxis<br>= us-gaap_EmployeeStockMember</span><span></span></td> <td class="nump"><a title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate[us-gaap_SubsidiarySaleOfStockAxis=us-gaap_EmployeeStockMember]" onclick="toggleNextSibling(this);">0.20%</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate<br>/ us-gaap_SubsidiarySaleOfStockAxis<br>= us-gaap_EmployeeStockMember</span><span></span></td> <td class="nump"><a title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate[us-gaap_SubsidiarySaleOfStockAxis=us-gaap_EmployeeStockMember]" onclick="toggleNextSibling(this);">0.20%</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate<br>/ us-gaap_SubsidiarySaleOfStockAxis<br>= us-gaap_EmployeeStockMember</span><span></span></td> </tr> <tr class="ro"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Volatility</a></td> <td class="nump"><a title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate[us-gaap_SubsidiarySaleOfStockAxis=us-gaap_EmployeeStockMember]" onclick="toggleNextSibling(this);">86.00%</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate<br>/ us-gaap_SubsidiarySaleOfStockAxis<br>= us-gaap_EmployeeStockMember</span><span></span></td> <td class="nump"><a title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate[us-gaap_SubsidiarySaleOfStockAxis=us-gaap_EmployeeStockMember]" onclick="toggleNextSibling(this);">74.60%</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate<br>/ us-gaap_SubsidiarySaleOfStockAxis<br>= us-gaap_EmployeeStockMember</span><span></span></td> <td class="nump"><a title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate[us-gaap_SubsidiarySaleOfStockAxis=us-gaap_EmployeeStockMember]" onclick="toggleNextSibling(this);">72.00%</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate<br>/ us-gaap_SubsidiarySaleOfStockAxis<br>= us-gaap_EmployeeStockMember</span><span></span></td> </tr> <tr class="re"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term in years</a></td> <td class="text">1 year 3 months<span></span></td> <td class="text">1 year 3 months<span></span></td> <td class="text">1 year 3 months<span></span></td> </tr> <tr class="ro"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Expected dividend yield</a></td> <td class="nump"><a title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate[us-gaap_SubsidiarySaleOfStockAxis=us-gaap_EmployeeStockMember]" onclick="toggleNextSibling(this);">0.00%</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate<br>/ us-gaap_SubsidiarySaleOfStockAxis<br>= us-gaap_EmployeeStockMember</span><span></span></td> <td class="nump"><a title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate[us-gaap_SubsidiarySaleOfStockAxis=us-gaap_EmployeeStockMember]" onclick="toggleNextSibling(this);">0.00%</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate<br>/ us-gaap_SubsidiarySaleOfStockAxis<br>= us-gaap_EmployeeStockMember</span><span></span></td> <td class="nump"><a title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate[us-gaap_SubsidiarySaleOfStockAxis=us-gaap_EmployeeStockMember]" onclick="toggleNextSibling(this);">0.00%</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate<br>/ us-gaap_SubsidiarySaleOfStockAxis<br>= us-gaap_EmployeeStockMember</span><span></span></td> </tr> <tr class="rh"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Options [Member]</a></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> </tr> <tr class="ro"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsLineItems', window );"><strong>Deferred Compensation Arrangement with Individual, Share-based Payments [Line Items]</strong></a></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> </tr> <tr class="re"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate</a></td> <td class="nump"><a title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate[us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember]" onclick="toggleNextSibling(this);">1.90%</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate<br>/ us-gaap_AwardTypeAxis<br>= us-gaap_EmployeeStockOptionMember</span><span></span></td> <td class="nump"><a title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate[us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember]" onclick="toggleNextSibling(this);">1.10%</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate<br>/ us-gaap_AwardTypeAxis<br>= us-gaap_EmployeeStockOptionMember</span><span></span></td> <td class="nump"><a title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate[us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember]" onclick="toggleNextSibling(this);">1.10%</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate<br>/ us-gaap_AwardTypeAxis<br>= us-gaap_EmployeeStockOptionMember</span><span></span></td> </tr> <tr class="ro"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Volatility</a></td> <td class="nump"><a title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate[us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember]" onclick="toggleNextSibling(this);">77.10%</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate<br>/ us-gaap_AwardTypeAxis<br>= us-gaap_EmployeeStockOptionMember</span><span></span></td> <td class="nump"><a title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate[us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember]" onclick="toggleNextSibling(this);">73.20%</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate<br>/ us-gaap_AwardTypeAxis<br>= us-gaap_EmployeeStockOptionMember</span><span></span></td> <td class="nump"><a title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate[us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember]" onclick="toggleNextSibling(this);">71.10%</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate<br>/ us-gaap_AwardTypeAxis<br>= us-gaap_EmployeeStockOptionMember</span><span></span></td> </tr> <tr class="re"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term in years</a></td> <td class="text">6 years 3 months 18 days<span></span></td> <td class="text">6 years 2 months 12 days<span></span></td> <td class="text">6 years 1 month 17 days<span></span></td> </tr> <tr class="ro"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Expected dividend yield</a></td> <td class="nump"><a title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate[us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember]" onclick="toggleNextSibling(this);">0.00%</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate<br>/ us-gaap_AwardTypeAxis<br>= us-gaap_EmployeeStockOptionMember</span><span></span></td> <td class="nump"><a title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate[us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember]" onclick="toggleNextSibling(this);">0.00%</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate<br>/ us-gaap_AwardTypeAxis<br>= us-gaap_EmployeeStockOptionMember</span><span></span></td> <td class="nump"><a title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate[us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember]" onclick="toggleNextSibling(this);">0.00%</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate<br>/ us-gaap_AwardTypeAxis<br>= us-gaap_EmployeeStockOptionMember</span><span></span></td> </tr> </table> <div style="display: none;"> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsLineItems"> <tr> <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td> </tr> <tr> <td> <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div> <table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsLineItems</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:stringItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table> </div> </div> </td> </tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"> <tr> <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td> </tr> <tr> <td> <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div> <p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p> </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"> <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (f)(2)(iii)<br><br> -URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901<br><br><br><br></p> </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"> <table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>num:percentItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table> </div> </div> </td> </tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"> <tr> <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td> </tr> <tr> <td> <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div> <p>Expected term of share-based compensation awards, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p> </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"> <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SAB TOPIC 14.D.2)<br><br> -URI http://asc.fasb.org/extlink&oid=27013229&loc=d3e301413-122809<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (f)(2)(i)<br><br> -URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Staff Accounting Bulletin (SAB)<br><br> -Number Topic 14<br><br> -Section D<br><br> -Subsection 2<br><br><br><br></p> </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"> <table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:durationItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table> </div> </div> </td> </tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"> <tr> <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td> </tr> <tr> <td> <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div> <p>The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p> </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"> <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (f)(2)(ii)<br><br> -URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901<br><br><br><br></p> </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"> <table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>num:percentItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table> </div> </div> </td> </tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"> <tr> <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td> </tr> <tr> <td> <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div> <p>The risk-free interest rate assumption that is used in valuing an option on its own shares.</p> </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"> <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (f)(2)(iv)<br><br> -URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901<br><br><br><br></p> </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"> <table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>num:percentItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table> </div> </div> </td> </tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember"> <tr> <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td> </tr> <tr> <td> <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div> <table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td></td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td></td> </tr> <tr> <td><strong> Period Type:</strong></td> <td></td> </tr> </table> </div> </div> </td> </tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_EmployeeStockMember"> <tr> <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td> </tr> <tr> <td> <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div> <table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_EmployeeStockMember</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td></td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td></td> </tr> <tr> <td><strong> Period Type:</strong></td> <td></td> </tr> </table> </div> </div> </td> </tr> </table> </div> </body> </html> </TEXT> </DOCUMENT> <DOCUMENT> <TYPE>XML <SEQUENCE>57 <FILENAME>R22.htm <DESCRIPTION>IDEA: XBRL DOCUMENT <TEXT> <html> <head> <META http-equiv="Content-Type" content="text/html; charset=us-ascii"> <title></title> <link rel="stylesheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript"> function toggleNextSibling (e) { if (e.nextSibling.style.display=='none') { e.nextSibling.style.display='block'; } else { e.nextSibling.style.display='none'; } }</script></head> <body><span style="display: none;">v2.4.1.9</span><table class="report" border="0" cellspacing="2" id="ID0EME"> <tr> <th class="tl" colspan="1" rowspan="2"> <div style="width: 200px;"><strong>Quarterly Financial Data<br></strong></div> </th> <th class="th" colspan="1">12 Months Ended</th> </tr> <tr> <th class="th"> <div>Dec. 31, 2014</div> </th> </tr> <tr class="re"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_QuarterlyFinancialInformationDisclosureAbstract', window );"><strong>Quarterly Financial Information Disclosure [Abstract]</strong></a></td> <td class="text"> <span></span></td> </tr> <tr class="ro"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_QuarterlyFinancialInformationTextBlock', window );">Quarterly Financial Data</a></td> <td class="text"><div> <p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 18px"><font style="FONT-FAMILY: Times New Roman" size="2"><b>Note 15 — Quarterly Financial Data (Unaudited)</b></font></p> <p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 6px; TEXT-INDENT: 4%" align="justify"><font style="FONT-FAMILY: Times New Roman" size="2">Quarterly results were as follows (in thousands, except per share data):</font></p> <p style="MARGIN-BOTTOM: 0px; FONT-SIZE: 12px; MARGIN-TOP: 0px">  </p> <table style="BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="100%" align="center" border="0"> <tr> <td width="64%"></td> <td valign="bottom" width="4%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="4%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="4%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="4%"></td> <td></td> <td></td> <td></td> </tr> <tr> <td valign="bottom"><font size="1"> </font></td> <td valign="bottom"><font size="1">  </font></td> <td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" align="center"><font style="FONT-FAMILY: Times New Roman" size="1"><b>First<br /> Quarter</b></font></td> <td valign="bottom"><font size="1"> </font></td> <td valign="bottom"><font size="1"> </font></td> <td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" align="center"><font style="FONT-FAMILY: Times New Roman" size="1"><b>Second<br /> Quarter</b></font></td> <td valign="bottom"><font size="1"> </font></td> <td valign="bottom"><font size="1"> </font></td> <td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" align="center"><font style="FONT-FAMILY: Times New Roman" size="1"><b>Third<br /> Quarter</b></font></td> <td valign="bottom"><font size="1"> </font></td> <td valign="bottom"><font size="1"> </font></td> <td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" align="center"><font style="FONT-FAMILY: Times New Roman" size="1"><b>Fourth<br /> Quarter</b></font></td> <td valign="bottom"><font size="1"> </font></td> </tr> <tr bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: Times New Roman" size="2"><b>2014</b></font></p> </td> <td valign="bottom"><font size="1">  </font></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"><font size="1"> </font></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"><font size="1"> </font></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"><font size="1"> </font></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr> <td valign="top"> <p style="MARGIN-LEFT: 2em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: Times New Roman" size="2">Total revenues</font></p> </td> <td valign="bottom"><font size="1">  </font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">7,979</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">  </font></td> <td valign="bottom"><font size="1"> </font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">7,788</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">  </font></td> <td valign="bottom"><font size="1"> </font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">9,415</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">  </font></td> <td valign="bottom"><font size="1"> </font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">21,758</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">  </font></td> </tr> <tr bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-LEFT: 2em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: Times New Roman" size="2">Net income (loss)</font></p> </td> <td valign="bottom"><font size="1">  </font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2"> </font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">(8,744</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">) </font></td> <td valign="bottom"><font size="1"> </font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2"> </font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">(8,374</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">) </font></td> <td valign="bottom"><font size="1"> </font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2"> </font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">(5,971</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">) </font></td> <td valign="bottom"><font size="1"> </font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2"> </font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">8,443</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">  </font></td> </tr> <tr> <td valign="top"> <p style="MARGIN-LEFT: 2em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: Times New Roman" size="2">Net income (loss) allocable to common stockholders</font></p> </td> <td valign="bottom"><font size="1">  </font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2"> </font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">(8,744</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">) </font></td> <td valign="bottom"><font size="1"> </font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2"> </font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">(8,374</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">) </font></td> <td valign="bottom"><font size="1"> </font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2"> </font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">(5,971</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">) </font></td> <td valign="bottom"><font size="1"> </font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2"> </font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">8,443</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">  </font></td> </tr> <tr bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-LEFT: 2em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: Times New Roman" size="2">Net income (loss) per share allocable to common stockholders — basic and diluted</font></p> </td> <td valign="bottom"><font size="1">  </font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">(0.27</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">) </font></td> <td valign="bottom"><font size="1"> </font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">(0.23</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">) </font></td> <td valign="bottom"><font size="1"> </font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">(0.16</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">) </font></td> <td valign="bottom"><font size="1"> </font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">0.23</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">  </font></td> </tr> <tr> <td valign="top"> <p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: Times New Roman" size="2"><b>2013</b></font></p> </td> <td valign="bottom"><font size="1">  </font></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"><font size="1"> </font></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"><font size="1"> </font></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"><font size="1"> </font></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-LEFT: 2em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: Times New Roman" size="2">Total revenues</font></p> </td> <td valign="bottom"><font size="1">  </font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">821</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">  </font></td> <td valign="bottom"><font size="1"> </font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">1,009</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">  </font></td> <td valign="bottom"><font size="1"> </font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">4,469</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">  </font></td> <td valign="bottom"><font size="1"> </font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">24,349</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">  </font></td> </tr> <tr> <td valign="top"> <p style="MARGIN-LEFT: 2em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: Times New Roman" size="2">Net income (loss)</font></p> </td> <td valign="bottom"><font size="1">  </font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2"> </font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">(12,619</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">) </font></td> <td valign="bottom"><font size="1"> </font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2"> </font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">(15,041</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">) </font></td> <td valign="bottom"><font size="1"> </font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2"> </font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">(12,588</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">) </font></td> <td valign="bottom"><font size="1"> </font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2"> </font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">6,531</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">  </font></td> </tr> <tr bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-LEFT: 2em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: Times New Roman" size="2">Net income (loss) allocable to common stockholders</font></p> </td> <td valign="bottom"><font size="1">  </font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2"> </font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">(12,619</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">) </font></td> <td valign="bottom"><font size="1"> </font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2"> </font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">(15,041</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">) </font></td> <td valign="bottom"><font size="1"> </font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2"> </font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">(12,588</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">) </font></td> <td valign="bottom"><font size="1"> </font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2"> </font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">6,531</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">  </font></td> </tr> <tr> <td valign="top"> <p style="MARGIN-LEFT: 2em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: Times New Roman" size="2">Net income (loss) per share allocable to common stockholders — basic</font></p> </td> <td valign="bottom"><font size="1">  </font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">(0.53</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">) </font></td> <td valign="bottom"><font size="1"> </font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">(0.58</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">) </font></td> <td valign="bottom"><font size="1"> </font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">(0.43</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">) </font></td> <td valign="bottom"><font size="1"> </font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">0.22</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">  </font></td> </tr> <tr bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-LEFT: 2em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: Times New Roman" size="2">Net income (loss) per share allocable to common stockholders — diluted</font></p> </td> <td valign="bottom"><font size="1">  </font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">(0.53</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">) </font></td> <td valign="bottom"><font size="1"> </font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">(0.58</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">) </font></td> <td valign="bottom"><font size="1"> </font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">(0.43</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">) </font></td> <td valign="bottom"><font size="1"> </font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">0.21</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">  </font></td> </tr> </table> </div><span></span></td> </tr> </table> <div style="display: none;"> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_QuarterlyFinancialInformationDisclosureAbstract"> <tr> <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td> </tr> <tr> <td> <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div> <table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_QuarterlyFinancialInformationDisclosureAbstract</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:stringItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table> </div> </div> </td> </tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_QuarterlyFinancialInformationTextBlock"> <tr> <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td> </tr> <tr> <td> <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div> <p>The entire disclosure for the quarterly financial data in the annual financial statements. The disclosure may include a tabular presentation of financial information for each fiscal quarter for the current and previous year, including revenues, gross profit, income or loss before extraordinary items and earnings per share data. It also includes an indication if the information in the note is unaudited, comments on the aggregate effect of year-end adjustments, and an explanation of matters or transactions that affect comparability or are pertinent to an understanding of the information furnished.</p> </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"> <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 270<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 13<br><br> -URI http://asc.fasb.org/extlink&oid=6372559&loc=d3e765-108305<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 270<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 12<br><br> -URI http://asc.fasb.org/extlink&oid=6372559&loc=d3e725-108305<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 270<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -Subparagraph (a)-(j)<br><br> -URI http://asc.fasb.org/extlink&oid=35737889&loc=d3e1280-108306<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Staff Accounting Bulletin (SAB)<br><br> -Number Topic 6<br><br> -Section G<br><br> -Subsection 1<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-K (SK)<br><br> -Number 229<br><br> -Section 302<br><br> -Paragraph a<br><br><br><br></p> </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"> <table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_QuarterlyFinancialInformationTextBlock</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>nonnum:textBlockItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table> </div> </div> </td> </tr> </table> </div> </body> </html> </TEXT> </DOCUMENT> <DOCUMENT> <TYPE>XML <SEQUENCE>58 <FILENAME>R36.htm <DESCRIPTION>IDEA: XBRL DOCUMENT <TEXT> <html> <head> <META http-equiv="Content-Type" content="text/html; charset=us-ascii"> <title></title> <link rel="stylesheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript"> function toggleNextSibling (e) { if (e.nextSibling.style.display=='none') { e.nextSibling.style.display='block'; } else { e.nextSibling.style.display='none'; } }</script></head> <body><span style="display: none;">v2.4.1.9</span><table class="report" border="0" cellspacing="2" id="ID0EME"> <tr> <th class="tl" colspan="1" rowspan="2"> <div style="width: 200px;"><strong>Quarterly Financial Data (Tables)<br></strong></div> </th> <th class="th" colspan="1">12 Months Ended</th> </tr> <tr> <th class="th"> <div>Dec. 31, 2014</div> </th> </tr> <tr class="re"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_QuarterlyFinancialInformationDisclosureAbstract', window );"><strong>Quarterly Financial Information Disclosure [Abstract]</strong></a></td> <td class="text"> <span></span></td> </tr> <tr class="ro"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock', window );">Summary of Quarterly Results</a></td> <td class="text"><div> <p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 6px; TEXT-INDENT: 4%" align="justify"><font style="FONT-FAMILY: Times New Roman" size="2">Quarterly results were as follows (in thousands, except per share data):</font></p> <p style="MARGIN-BOTTOM: 0px; FONT-SIZE: 12px; MARGIN-TOP: 0px">  </p> <table style="BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="100%" align="center" border="0"> <tr> <td width="64%"></td> <td valign="bottom" width="4%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="4%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="4%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="4%"></td> <td></td> <td></td> <td></td> </tr> <tr> <td valign="bottom"><font size="1"> </font></td> <td valign="bottom"><font size="1">  </font></td> <td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" align="center"><font style="FONT-FAMILY: Times New Roman" size="1"><b>First<br /> Quarter</b></font></td> <td valign="bottom"><font size="1"> </font></td> <td valign="bottom"><font size="1"> </font></td> <td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" align="center"><font style="FONT-FAMILY: Times New Roman" size="1"><b>Second<br /> Quarter</b></font></td> <td valign="bottom"><font size="1"> </font></td> <td valign="bottom"><font size="1"> </font></td> <td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" align="center"><font style="FONT-FAMILY: Times New Roman" size="1"><b>Third<br /> Quarter</b></font></td> <td valign="bottom"><font size="1"> </font></td> <td valign="bottom"><font size="1"> </font></td> <td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" align="center"><font style="FONT-FAMILY: Times New Roman" size="1"><b>Fourth<br /> Quarter</b></font></td> <td valign="bottom"><font size="1"> </font></td> </tr> <tr bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: Times New Roman" size="2"><b>2014</b></font></p> </td> <td valign="bottom"><font size="1">  </font></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"><font size="1"> </font></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"><font size="1"> </font></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"><font size="1"> </font></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr> <td valign="top"> <p style="MARGIN-LEFT: 2em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: Times New Roman" size="2">Total revenues</font></p> </td> <td valign="bottom"><font size="1">  </font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">7,979</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">  </font></td> <td valign="bottom"><font size="1"> </font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">7,788</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">  </font></td> <td valign="bottom"><font size="1"> </font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">9,415</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">  </font></td> <td valign="bottom"><font size="1"> </font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">21,758</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">  </font></td> </tr> <tr bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-LEFT: 2em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: Times New Roman" size="2">Net income (loss)</font></p> </td> <td valign="bottom"><font size="1">  </font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2"> </font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">(8,744</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">) </font></td> <td valign="bottom"><font size="1"> </font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2"> </font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">(8,374</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">) </font></td> <td valign="bottom"><font size="1"> </font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2"> </font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">(5,971</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">) </font></td> <td valign="bottom"><font size="1"> </font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2"> </font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">8,443</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">  </font></td> </tr> <tr> <td valign="top"> <p style="MARGIN-LEFT: 2em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: Times New Roman" size="2">Net income (loss) allocable to common stockholders</font></p> </td> <td valign="bottom"><font size="1">  </font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2"> </font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">(8,744</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">) </font></td> <td valign="bottom"><font size="1"> </font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2"> </font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">(8,374</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">) </font></td> <td valign="bottom"><font size="1"> </font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2"> </font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">(5,971</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">) </font></td> <td valign="bottom"><font size="1"> </font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2"> </font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">8,443</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">  </font></td> </tr> <tr bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-LEFT: 2em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: Times New Roman" size="2">Net income (loss) per share allocable to common stockholders — basic and diluted</font></p> </td> <td valign="bottom"><font size="1">  </font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">(0.27</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">) </font></td> <td valign="bottom"><font size="1"> </font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">(0.23</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">) </font></td> <td valign="bottom"><font size="1"> </font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">(0.16</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">) </font></td> <td valign="bottom"><font size="1"> </font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">0.23</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">  </font></td> </tr> <tr> <td valign="top"> <p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: Times New Roman" size="2"><b>2013</b></font></p> </td> <td valign="bottom"><font size="1">  </font></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"><font size="1"> </font></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"><font size="1"> </font></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"><font size="1"> </font></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-LEFT: 2em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: Times New Roman" size="2">Total revenues</font></p> </td> <td valign="bottom"><font size="1">  </font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">821</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">  </font></td> <td valign="bottom"><font size="1"> </font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">1,009</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">  </font></td> <td valign="bottom"><font size="1"> </font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">4,469</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">  </font></td> <td valign="bottom"><font size="1"> </font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">24,349</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">  </font></td> </tr> <tr> <td valign="top"> <p style="MARGIN-LEFT: 2em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: Times New Roman" size="2">Net income (loss)</font></p> </td> <td valign="bottom"><font size="1">  </font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2"> </font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">(12,619</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">) </font></td> <td valign="bottom"><font size="1"> </font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2"> </font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">(15,041</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">) </font></td> <td valign="bottom"><font size="1"> </font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2"> </font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">(12,588</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">) </font></td> <td valign="bottom"><font size="1"> </font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2"> </font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">6,531</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">  </font></td> </tr> <tr bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-LEFT: 2em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: Times New Roman" size="2">Net income (loss) allocable to common stockholders</font></p> </td> <td valign="bottom"><font size="1">  </font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2"> </font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">(12,619</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">) </font></td> <td valign="bottom"><font size="1"> </font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2"> </font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">(15,041</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">) </font></td> <td valign="bottom"><font size="1"> </font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2"> </font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">(12,588</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">) </font></td> <td valign="bottom"><font size="1"> </font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2"> </font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">6,531</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">  </font></td> </tr> <tr> <td valign="top"> <p style="MARGIN-LEFT: 2em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: Times New Roman" size="2">Net income (loss) per share allocable to common stockholders — basic</font></p> </td> <td valign="bottom"><font size="1">  </font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">(0.53</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">) </font></td> <td valign="bottom"><font size="1"> </font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">(0.58</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">) </font></td> <td valign="bottom"><font size="1"> </font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">(0.43</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">) </font></td> <td valign="bottom"><font size="1"> </font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">0.22</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">  </font></td> </tr> <tr bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-LEFT: 2em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: Times New Roman" size="2">Net income (loss) per share allocable to common stockholders — diluted</font></p> </td> <td valign="bottom"><font size="1">  </font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">(0.53</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">) </font></td> <td valign="bottom"><font size="1"> </font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">(0.58</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">) </font></td> <td valign="bottom"><font size="1"> </font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">(0.43</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">) </font></td> <td valign="bottom"><font size="1"> </font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">0.21</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">  </font></td> </tr> </table> </div><span></span></td> </tr> </table> <div style="display: none;"> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_QuarterlyFinancialInformationDisclosureAbstract"> <tr> <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td> </tr> <tr> <td> <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div> <table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_QuarterlyFinancialInformationDisclosureAbstract</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:stringItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table> </div> </div> </td> </tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock"> <tr> <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td> </tr> <tr> <td> <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div> <p>Tabular disclosure of the quarterly financial data in the annual financial statements. The disclosure includes financial information for each fiscal quarter for the current and previous year, including revenues, gross profit, income (loss) before extraordinary items and cumulative effect of a change in accounting principle and earnings per share data.</p> </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"> <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 270<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -Subparagraph (a)-(j)<br><br> -URI http://asc.fasb.org/extlink&oid=35737889&loc=d3e1280-108306<br><br><br><br></p> </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"> <table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>nonnum:textBlockItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table> </div> </div> </td> </tr> </table> </div> </body> </html> </TEXT> </DOCUMENT> <DOCUMENT> <TYPE>XML <SEQUENCE>59 <FILENAME>R24.htm <DESCRIPTION>IDEA: XBRL DOCUMENT <TEXT> <html> <head> <META http-equiv="Content-Type" content="text/html; charset=us-ascii"> <title></title> <link rel="stylesheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript"> function toggleNextSibling (e) { if (e.nextSibling.style.display=='none') { e.nextSibling.style.display='block'; } else { e.nextSibling.style.display='none'; } }</script></head> <body><span style="display: none;">v2.4.1.9</span><table class="report" border="0" cellspacing="2" id="ID0E2F"> <tr> <th class="tl" colspan="1" rowspan="2"> <div style="width: 200px;"><strong>Net Loss Per Share (Tables)<br></strong></div> </th> <th class="th" colspan="1">12 Months Ended</th> </tr> <tr> <th class="th"> <div>Dec. 31, 2014</div> </th> </tr> <tr class="re"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td> <td class="text"> <span></span></td> </tr> <tr class="ro"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock', window );">Calculation of Basic and Diluted Net Loss Per Share Allocable to Common Stockholders</a></td> <td class="text"><div> <p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 6px; TEXT-INDENT: 4%" align="justify"><font style="FONT-FAMILY: Times New Roman" size="2">The following is the calculation of basic and diluted net loss per share allocable to common stockholders (in thousands except per share data):</font></p> <p style="MARGIN-BOTTOM: 0px; FONT-SIZE: 12px; MARGIN-TOP: 0px">  </p> <table style="BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="92%" align="center" border="0"> <tr> <td width="66%"></td> <td valign="bottom" width="5%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="4%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="4%"></td> <td></td> <td></td> <td></td> </tr> <tr> <td valign="bottom"><font size="1"> </font></td> <td valign="bottom"><font size="1">  </font></td> <td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="10" align="center"><font style="FONT-FAMILY: Times New Roman" size="1"><b>Years Ended December 31,</b></font></td> <td valign="bottom"><font size="1"> </font></td> </tr> <tr> <td valign="bottom"><font size="1"> </font></td> <td valign="bottom"><font size="1">  </font></td> <td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" align="center"><font style="FONT-FAMILY: Times New Roman" size="1"><b>2014</b></font></td> <td valign="bottom"><font size="1"> </font></td> <td valign="bottom"><font size="1">  </font></td> <td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" align="center"><font style="FONT-FAMILY: Times New Roman" size="1"><b>2013</b></font></td> <td valign="bottom"><font size="1"> </font></td> <td valign="bottom"><font size="1">  </font></td> <td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" align="center"><font style="FONT-FAMILY: Times New Roman" size="1"><b>2012</b></font></td> <td valign="bottom"><font size="1"> </font></td> </tr> <tr bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: Times New Roman" size="2">Net loss</font></p> </td> <td valign="bottom"><font size="1">  </font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">(14,646</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">) </font></td> <td valign="bottom"><font size="1">  </font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">(33,717</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">) </font></td> <td valign="bottom"><font size="1">  </font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">(40,370</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">) </font></td> </tr> <tr> <td valign="top"> <p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: Times New Roman" size="2">Deemed dividend related to beneficial conversion feature of convertible preferred stock</font></p> </td> <td valign="bottom"><font size="1">  </font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2"> </font></td> <td valign="bottom" nowrap="nowrap" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">—</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">  </font></td> <td valign="bottom"><font size="1">  </font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2"> </font></td> <td valign="bottom" nowrap="nowrap" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">—</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">  </font></td> <td valign="bottom"><font size="1">  </font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2"> </font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">(1,307</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">) </font></td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid"> </p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid"> </p> </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid"> </p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid"> </p> </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid"> </p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid"> </p> </td> <td> </td> </tr> <tr bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: Times New Roman" size="2">Net loss allocable to common stockholders</font></p> </td> <td valign="bottom"><font size="1">  </font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">(14,646</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">) </font></td> <td valign="bottom"><font size="1">  </font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">(33,717</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">) </font></td> <td valign="bottom"><font size="1">  </font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">(41,677</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">) </font></td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double"> </p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double"> </p> </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double"> </p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double"> </p> </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double"> </p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double"> </p> </td> <td> </td> </tr> <tr> <td valign="top"> <p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: Times New Roman" size="2">Weighted-average shares used in computing net loss per share allocable to common stockholders — basic and diluted</font></p> </td> <td valign="bottom"><font size="1">  </font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2"> </font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">35,709</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">  </font></td> <td valign="bottom"><font size="1">  </font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2"> </font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">27,275</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">  </font></td> <td valign="bottom"><font size="1">  </font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2"> </font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">18,107</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">  </font></td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double"> </p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double"> </p> </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double"> </p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double"> </p> </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double"> </p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double"> </p> </td> <td> </td> </tr> <tr bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: Times New Roman" size="2">Net loss per share allocable to common stockholders — basic and diluted</font></p> </td> <td valign="bottom"><font size="1">  </font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">(0.41</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">) </font></td> <td valign="bottom"><font size="1">  </font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">(1.24</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">) </font></td> <td valign="bottom"><font size="1">  </font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">(2.30</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">) </font></td> </tr> </table> </div><span></span></td> </tr> <tr class="re"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock', window );">Instruments Excluded from the Computation of Diluted Net Loss Per Common Share</a></td> <td class="text"><div> <p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 12px; TEXT-INDENT: 4%" align="justify"><font style="FONT-FAMILY: Times New Roman" size="2">The following instruments were excluded from the computation of diluted net loss per common share allocable to common stockholders for the periods presented because their effect would have been antidilutive (in thousands):</font></p> <p style="MARGIN-BOTTOM: 0px; FONT-SIZE: 12px; MARGIN-TOP: 0px">  </p> <table style="BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="92%" align="center" border="0"> <tr> <td width="73%"></td> <td valign="bottom" width="3%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="3%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="3%"></td> <td></td> <td></td> <td></td> </tr> <tr> <td valign="bottom"><font size="1"> </font></td> <td valign="bottom"><font size="1">  </font></td> <td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="10" align="center"><font style="FONT-FAMILY: Times New Roman" size="1"><b>December 31,</b></font></td> <td valign="bottom"><font size="1"> </font></td> </tr> <tr> <td valign="bottom"><font size="1"> </font></td> <td valign="bottom"><font size="1">  </font></td> <td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" align="center"><font style="FONT-FAMILY: Times New Roman" size="1"><b>2014</b></font></td> <td valign="bottom"><font size="1"> </font></td> <td valign="bottom"><font size="1">  </font></td> <td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" align="center"><font style="FONT-FAMILY: Times New Roman" size="1"><b>2013</b></font></td> <td valign="bottom"><font size="1"> </font></td> <td valign="bottom"><font size="1">  </font></td> <td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" align="center"><font style="FONT-FAMILY: Times New Roman" size="1"><b>2012</b></font></td> <td valign="bottom"><font size="1"> </font></td> </tr> <tr bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: Times New Roman" size="2">Options to purchase common stock</font></p> </td> <td valign="bottom"><font size="1">  </font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2"> </font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">3,298</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">  </font></td> <td valign="bottom"><font size="1">  </font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2"> </font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">2,449</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">  </font></td> <td valign="bottom"><font size="1">  </font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2"> </font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">1,791</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">  </font></td> </tr> <tr> <td valign="top"> <p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: Times New Roman" size="2">Warrants to purchase common stock</font></p> </td> <td valign="bottom"><font size="1">  </font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2"> </font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">6,691</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">  </font></td> <td valign="bottom"><font size="1">  </font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2"> </font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">7,692</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">  </font></td> <td valign="bottom"><font size="1">  </font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2"> </font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">9,009</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">  </font></td> </tr> <tr bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: Times New Roman" size="2">Series B convertible preferred stock (as converted to common stock)</font></p> </td> <td valign="bottom"><font size="1">  </font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2"> </font></td> <td valign="bottom" nowrap="nowrap" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">—</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">  </font></td> <td valign="bottom"><font size="1">  </font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2"> </font></td> <td valign="bottom" nowrap="nowrap" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">—</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">  </font></td> <td valign="bottom"><font size="1">  </font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2"> </font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">3,838</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">  </font></td> </tr> <tr> <td valign="top"> <p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: Times New Roman" size="2">Restricted stock units</font></p> </td> <td valign="bottom"><font size="1">  </font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2"> </font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">63</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">  </font></td> <td valign="bottom"><font size="1">  </font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2"> </font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">42</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">  </font></td> <td valign="bottom"><font size="1">  </font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2"> </font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">217</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">  </font></td> </tr> <tr bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: Times New Roman" size="2">Shares issuable related to the ESPP</font></p> </td> <td valign="bottom"><font size="1">  </font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2"> </font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">15</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">  </font></td> <td valign="bottom"><font size="1">  </font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2"> </font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">14</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">  </font></td> <td valign="bottom"><font size="1">  </font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2"> </font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">11</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">  </font></td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid"> </p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid"> </p> </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid"> </p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid"> </p> </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid"> </p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid"> </p> </td> <td> </td> </tr> <tr> <td valign="top"> <p style="MARGIN-LEFT: 2em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: Times New Roman" size="2">Total shares</font></p> </td> <td valign="bottom"><font size="1">  </font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2"> </font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">10,067</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">  </font></td> <td valign="bottom"><font size="1">  </font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2"> </font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">10,197</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">  </font></td> <td valign="bottom"><font size="1">  </font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2"> </font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">14,866</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">  </font></td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double"> </p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double"> </p> </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double"> </p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double"> </p> </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double"> </p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double"> </p> </td> <td> </td> </tr> </table> </div><span></span></td> </tr> </table> <div style="display: none;"> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract"> <tr> <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td> </tr> <tr> <td> <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div> <table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:stringItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table> </div> </div> </td> </tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"> <tr> <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td> </tr> <tr> <td> <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div> <p>Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.</p> </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"> <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 260<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -Subparagraph (c)<br><br> -URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257<br><br><br><br></p> </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"> <table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>nonnum:textBlockItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table> </div> </div> </td> </tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock"> <tr> <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td> </tr> <tr> <td> <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div> <p>Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.</p> </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"> <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 260<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257<br><br><br><br></p> </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"> <table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>nonnum:textBlockItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table> </div> </div> </td> </tr> </table> </div> </body> </html> </TEXT> </DOCUMENT> <DOCUMENT> <TYPE>XML <SEQUENCE>60 <FILENAME>R68.htm <DESCRIPTION>IDEA: XBRL DOCUMENT <TEXT> <html> <head> <META http-equiv="Content-Type" content="text/html; charset=us-ascii"> <title></title> <link rel="stylesheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript"> function toggleNextSibling (e) { if (e.nextSibling.style.display=='none') { e.nextSibling.style.display='block'; } else { e.nextSibling.style.display='none'; } }</script></head> <body><span style="display: none;">v2.4.1.9</span><table class="report" border="0" cellspacing="2" id="ID0E4AAE"> <tr> <th class="tl" colspan="1" rowspan="2"> <div style="width: 200px;"><strong>Income Taxes - Company Recorded Income Tax Provision (Detail) (USD $)<br>In Thousands, unless otherwise specified</strong></div> </th> <th class="th" colspan="3">12 Months Ended</th> </tr> <tr> <th class="th"> <div>Dec. 31, 2014</div> </th> <th class="th"> <div>Dec. 31, 2013</div> </th> <th class="th"> <div>Dec. 31, 2012</div> </th> </tr> <tr class="re"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract', window );"><strong>Current:</strong></a></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> </tr> <tr class="ro"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CurrentFederalTaxExpenseBenefit', window );">Federal</a></td> <td class="nump"><a title="us-gaap_CurrentFederalTaxExpenseBenefit" onclick="toggleNextSibling(this);">$ 0</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_CurrentFederalTaxExpenseBenefit</span><span></span></td> <td class="nump"><a title="us-gaap_CurrentFederalTaxExpenseBenefit" onclick="toggleNextSibling(this);">$ 0</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_CurrentFederalTaxExpenseBenefit</span><span></span></td> <td class="nump"><a title="us-gaap_CurrentFederalTaxExpenseBenefit" onclick="toggleNextSibling(this);">$ 0</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_CurrentFederalTaxExpenseBenefit</span><span></span></td> </tr> <tr class="re"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CurrentStateAndLocalTaxExpenseBenefit', window );">State</a></td> <td class="nump"><a title="us-gaap_CurrentStateAndLocalTaxExpenseBenefit" onclick="toggleNextSibling(this);">0</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_CurrentStateAndLocalTaxExpenseBenefit</span><span></span></td> <td class="nump"><a title="us-gaap_CurrentStateAndLocalTaxExpenseBenefit" onclick="toggleNextSibling(this);">0</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_CurrentStateAndLocalTaxExpenseBenefit</span><span></span></td> <td class="nump"><a title="us-gaap_CurrentStateAndLocalTaxExpenseBenefit" onclick="toggleNextSibling(this);">0</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_CurrentStateAndLocalTaxExpenseBenefit</span><span></span></td> </tr> <tr class="rou"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CurrentIncomeTaxExpenseBenefit', window );">Total</a></td> <td class="nump"><a title="us-gaap_CurrentIncomeTaxExpenseBenefit" onclick="toggleNextSibling(this);">0</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_CurrentIncomeTaxExpenseBenefit</span><span></span></td> <td class="nump"><a title="us-gaap_CurrentIncomeTaxExpenseBenefit" onclick="toggleNextSibling(this);">0</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_CurrentIncomeTaxExpenseBenefit</span><span></span></td> <td class="nump"><a title="us-gaap_CurrentIncomeTaxExpenseBenefit" onclick="toggleNextSibling(this);">0</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_CurrentIncomeTaxExpenseBenefit</span><span></span></td> </tr> <tr class="re"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract', window );"><strong>Deferred:</strong></a></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> </tr> <tr class="ro"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredFederalIncomeTaxExpenseBenefit', window );">Federal</a></td> <td class="nump"><a title="us-gaap_DeferredFederalIncomeTaxExpenseBenefit" onclick="toggleNextSibling(this);">0</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_DeferredFederalIncomeTaxExpenseBenefit</span><span></span></td> <td class="nump"><a title="us-gaap_DeferredFederalIncomeTaxExpenseBenefit" onclick="toggleNextSibling(this);">0</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_DeferredFederalIncomeTaxExpenseBenefit</span><span></span></td> <td class="nump"><a title="us-gaap_DeferredFederalIncomeTaxExpenseBenefit" onclick="toggleNextSibling(this);">0</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_DeferredFederalIncomeTaxExpenseBenefit</span><span></span></td> </tr> <tr class="re"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit', window );">State</a></td> <td class="nump"><a title="us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" onclick="toggleNextSibling(this);">0</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit</span><span></span></td> <td class="nump"><a title="us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" onclick="toggleNextSibling(this);">0</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit</span><span></span></td> <td class="nump"><a title="us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" onclick="toggleNextSibling(this);">0</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit</span><span></span></td> </tr> <tr class="rou"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxExpenseBenefit', window );">Total</a></td> <td class="nump"><a title="us-gaap_DeferredIncomeTaxExpenseBenefit" onclick="toggleNextSibling(this);">$ 0</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_DeferredIncomeTaxExpenseBenefit</span><span></span></td> <td class="nump"><a title="us-gaap_DeferredIncomeTaxExpenseBenefit" onclick="toggleNextSibling(this);">$ 0</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_DeferredIncomeTaxExpenseBenefit</span><span></span></td> <td class="nump"><a title="us-gaap_DeferredIncomeTaxExpenseBenefit" onclick="toggleNextSibling(this);">$ 0</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_DeferredIncomeTaxExpenseBenefit</span><span></span></td> </tr> </table> <div style="display: none;"> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentFederalTaxExpenseBenefit"> <tr> <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td> </tr> <tr> <td> <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div> <p>Amount of current federal tax expense (benefit) pertaining to income (loss) from continuing operations.</p> </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"> <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SAB TOPIC 6.I.7)<br><br> -URI http://asc.fasb.org/extlink&oid=34349781&loc=d3e330036-122817<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Current Tax Expense (or Benefit)<br><br> -URI http://asc.fasb.org/extlink&oid=6509736<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 9<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&oid=6907707&loc=d3e32639-109319<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.4-08.(h))<br><br> -URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 08<br><br> -Paragraph h<br><br> -Article 4<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Staff Accounting Bulletin (SAB)<br><br> -Number Topic 6<br><br> -Section I<br><br> -Paragraph Question 1-7<br><br><br><br></p> </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"> <table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_CurrentFederalTaxExpenseBenefit</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:monetaryItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>debit</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table> </div> </div> </td> </tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentIncomeTaxExpenseBenefit"> <tr> <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td> </tr> <tr> <td> <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div> <p>Amount of current income tax expense (benefit) pertaining to taxable income (loss) from continuing operations.</p> </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"> <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SAB TOPIC 6.I.7)<br><br> -URI http://asc.fasb.org/extlink&oid=34349781&loc=d3e330036-122817<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Current Tax Expense (or Benefit)<br><br> -URI http://asc.fasb.org/extlink&oid=6509736<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 9<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&oid=6907707&loc=d3e32639-109319<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.4-08.(h))<br><br> -URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 08<br><br> -Paragraph h<br><br> -Article 4<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Staff Accounting Bulletin (SAB)<br><br> -Number Topic 6<br><br> -Section I<br><br> -Subsection 7<br><br><br><br></p> </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"> <table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_CurrentIncomeTaxExpenseBenefit</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:monetaryItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>debit</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table> </div> </div> </td> </tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract"> <tr> <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td> </tr> <tr> <td> <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div> <table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:stringItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table> </div> </div> </td> </tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentStateAndLocalTaxExpenseBenefit"> <tr> <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td> </tr> <tr> <td> <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div> <p>Amount of current state and local tax expense (benefit) pertaining to income (loss) from continuing operations.</p> </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"> <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SAB TOPIC 6.I.7)<br><br> -URI http://asc.fasb.org/extlink&oid=34349781&loc=d3e330036-122817<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Current Tax Expense (or Benefit)<br><br> -URI http://asc.fasb.org/extlink&oid=6509736<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 9<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&oid=6907707&loc=d3e32639-109319<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.4-08.(h))<br><br> -URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 08<br><br> -Paragraph h<br><br> -Article 4<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Staff Accounting Bulletin (SAB)<br><br> -Number Topic 6<br><br> -Section I<br><br> -Subsection 7<br><br><br><br></p> </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"> <table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_CurrentStateAndLocalTaxExpenseBenefit</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:monetaryItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>debit</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table> </div> </div> </td> </tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredFederalIncomeTaxExpenseBenefit"> <tr> <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td> </tr> <tr> <td> <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div> <p>Amount of deferred federal income tax expense (benefit) pertaining to income (loss) from continuing operations.</p> </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"> <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SAB TOPIC 6.I.7)<br><br> -URI http://asc.fasb.org/extlink&oid=34349781&loc=d3e330036-122817<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.4-08.(h))<br><br> -URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 08<br><br> -Paragraph h<br><br> -Article 4<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Staff Accounting Bulletin (SAB)<br><br> -Number Topic 6<br><br> -Section I<br><br> -Subsection 7<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Deferred Tax Expense (or Benefit)<br><br> -URI http://asc.fasb.org/extlink&oid=6510177<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 9<br><br> -Subparagraph (b)<br><br> -URI http://asc.fasb.org/extlink&oid=6907707&loc=d3e32639-109319<br><br><br><br></p> </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"> <table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_DeferredFederalIncomeTaxExpenseBenefit</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:monetaryItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>debit</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table> </div> </div> </td> </tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxExpenseBenefit"> <tr> <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td> </tr> <tr> <td> <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div> <p>Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.</p> </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"> <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -Subparagraph (b)<br><br> -URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3602-108585<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SAB TOPIC 6.I.7)<br><br> -URI http://asc.fasb.org/extlink&oid=34349781&loc=d3e330036-122817<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.4-08.(h))<br><br> -URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 08<br><br> -Paragraph h<br><br> -Article 4<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Staff Accounting Bulletin (SAB)<br><br> -Number Topic 6<br><br> -Section I<br><br> -Subsection 7<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Deferred Tax Expense (or Benefit)<br><br> -URI http://asc.fasb.org/extlink&oid=6510177<br><br><br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 9<br><br> -Subparagraph (b)<br><br> -URI http://asc.fasb.org/extlink&oid=6907707&loc=d3e32639-109319<br><br><br><br></p> </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"> <table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxExpenseBenefit</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:monetaryItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>debit</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table> </div> </div> </td> </tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract"> <tr> <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td> </tr> <tr> <td> <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div> <table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:stringItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table> </div> </div> </td> </tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit"> <tr> <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td> </tr> <tr> <td> <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div> <p>Amount of deferred state and local tax expense (benefit) pertaining to income (loss) from continuing operations.</p> </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"> <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SAB TOPIC 6.I.7)<br><br> -URI http://asc.fasb.org/extlink&oid=34349781&loc=d3e330036-122817<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.4-08.(h))<br><br> -URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 08<br><br> -Paragraph h<br><br> -Article 4<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Staff Accounting Bulletin (SAB)<br><br> -Number Topic 6<br><br> -Section I<br><br> -Subsection 7<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Deferred Tax Expense (or Benefit)<br><br> -URI http://asc.fasb.org/extlink&oid=6510177<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 9<br><br> -Subparagraph (b)<br><br> -URI http://asc.fasb.org/extlink&oid=6907707&loc=d3e32639-109319<br><br><br><br></p> </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"> <table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:monetaryItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>debit</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table> </div> </div> </td> </tr> </table> </div> </body> </html> </TEXT> </DOCUMENT> <DOCUMENT> <TYPE>XML <SEQUENCE>61 <FILENAME>Show.js <DESCRIPTION>IDEA: XBRL DOCUMENT <TEXT> /** * Rivet Software Inc. * * @copyright Copyright (c) 2006-2011 Rivet Software, Inc. All rights reserved. * Version 2.4.0.3 * */ var Show = {}; Show.LastAR = null, Show.hideAR = function(){ Show.LastAR.style.display = 'none'; }; Show.showAR = function ( link, id, win ){ if( Show.LastAR ){ Show.hideAR(); } var ref = link; do { ref = ref.nextSibling; } while (ref && ref.nodeName != 'TABLE'); if (!ref || ref.nodeName != 'TABLE') { var tmp = win ? win.document.getElementById(id) : document.getElementById(id); if( tmp ){ ref = tmp.cloneNode(true); ref.id = ''; link.parentNode.appendChild(ref); } } if( ref ){ ref.style.display = 'block'; Show.LastAR = ref; } }; Show.toggleNext = function( link ){ var ref = link; do{ ref = ref.nextSibling; }while( ref.nodeName != 'DIV' ); if( ref.style && ref.style.display && ref.style.display == 'none' ){ ref.style.display = 'block'; if( link.textContent ){ link.textContent = link.textContent.replace( '+', '-' ); }else{ link.innerText = link.innerText.replace( '+', '-' ); } }else{ ref.style.display = 'none'; if( link.textContent ){ link.textContent = link.textContent.replace( '-', '+' ); }else{ link.innerText = link.innerText.replace( '-', '+' ); } } }; </TEXT> </DOCUMENT> <DOCUMENT> <TYPE>XML <SEQUENCE>62 <FILENAME>R7.htm <DESCRIPTION>IDEA: XBRL DOCUMENT <TEXT> <html> <head> <META http-equiv="Content-Type" content="text/html; charset=us-ascii"> <title></title> <link rel="stylesheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript"> function toggleNextSibling (e) { if (e.nextSibling.style.display=='none') { e.nextSibling.style.display='block'; } else { e.nextSibling.style.display='none'; } }</script></head> <body><span style="display: none;">v2.4.1.9</span><table class="report" border="0" cellspacing="2" id="ID0EBABG"> <tr> <th class="tl" colspan="1" rowspan="2"> <div style="width: 200px;"><strong>Consolidated Statements of Cash Flows (USD $)<br>In Thousands, unless otherwise specified</strong></div> </th> <th class="th" colspan="3">12 Months Ended</th> </tr> <tr> <th class="th"> <div>Dec. 31, 2014</div> </th> <th class="th"> <div>Dec. 31, 2013</div> </th> <th class="th"> <div>Dec. 31, 2012</div> </th> </tr> <tr class="re"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract', window );"><strong>Cash flows from operating activities:</strong></a></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> </tr> <tr class="ro"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td> <td class="num"><a title="us-gaap_NetIncomeLoss" onclick="toggleNextSibling(this);">$ (14,646)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_NetIncomeLoss</span><span></span></td> <td class="num"><a title="us-gaap_NetIncomeLoss" onclick="toggleNextSibling(this);">$ (33,717)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_NetIncomeLoss</span><span></span></td> <td class="num"><a title="us-gaap_NetIncomeLoss" onclick="toggleNextSibling(this);">$ (40,370)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_NetIncomeLoss</span><span></span></td> </tr> <tr class="re"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to net cash used in operating activities:</strong></a></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> </tr> <tr class="ro"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation and amortization of property and equipment</a></td> <td class="nump"><a title="us-gaap_DepreciationDepletionAndAmortization" onclick="toggleNextSibling(this);">490</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_DepreciationDepletionAndAmortization</span><span></span></td> <td class="nump"><a title="us-gaap_DepreciationDepletionAndAmortization" onclick="toggleNextSibling(this);">433</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_DepreciationDepletionAndAmortization</span><span></span></td> <td class="nump"><a title="us-gaap_DepreciationDepletionAndAmortization" onclick="toggleNextSibling(this);">591</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_DepreciationDepletionAndAmortization</span><span></span></td> </tr> <tr class="re"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainLossOnSaleOfPropertyPlantEquipment', window );">Gain on disposal of equipment</a></td> <td class="nump"><a title="us-gaap_GainLossOnSaleOfPropertyPlantEquipment" onclick="toggleNextSibling(this);">0</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_GainLossOnSaleOfPropertyPlantEquipment</span><span></span></td> <td class="num"><a title="us-gaap_GainLossOnSaleOfPropertyPlantEquipment" onclick="toggleNextSibling(this);">(79)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_GainLossOnSaleOfPropertyPlantEquipment</span><span></span></td> <td class="num"><a title="us-gaap_GainLossOnSaleOfPropertyPlantEquipment" onclick="toggleNextSibling(this);">(2)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_GainLossOnSaleOfPropertyPlantEquipment</span><span></span></td> </tr> <tr class="ro"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCostsAndAssetImpairmentCharges', window );">Non-cash restructuring expenses, net of reversals</a></td> <td class="nump"><a title="us-gaap_RestructuringCostsAndAssetImpairmentCharges" onclick="toggleNextSibling(this);">0</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_RestructuringCostsAndAssetImpairmentCharges</span><span></span></td> <td class="nump"><a title="us-gaap_RestructuringCostsAndAssetImpairmentCharges" onclick="toggleNextSibling(this);">0</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_RestructuringCostsAndAssetImpairmentCharges</span><span></span></td> <td class="num"><a title="us-gaap_RestructuringCostsAndAssetImpairmentCharges" onclick="toggleNextSibling(this);">(56)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_RestructuringCostsAndAssetImpairmentCharges</span><span></span></td> </tr> <tr class="re"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation</a></td> <td class="nump"><a title="us-gaap_ShareBasedCompensation" onclick="toggleNextSibling(this);">3,330</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ShareBasedCompensation</span><span></span></td> <td class="nump"><a title="us-gaap_ShareBasedCompensation" onclick="toggleNextSibling(this);">3,597</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ShareBasedCompensation</span><span></span></td> <td class="nump"><a title="us-gaap_ShareBasedCompensation" onclick="toggleNextSibling(this);">3,783</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ShareBasedCompensation</span><span></span></td> </tr> <tr class="ro"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainOnSaleOfInvestments', window );">Gain on sale of investments</a></td> <td class="num"><a title="us-gaap_GainOnSaleOfInvestments" onclick="toggleNextSibling(this);">(6)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_GainOnSaleOfInvestments</span><span></span></td> <td class="nump"><a title="us-gaap_GainOnSaleOfInvestments" onclick="toggleNextSibling(this);">0</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_GainOnSaleOfInvestments</span><span></span></td> <td class="nump"><a title="us-gaap_GainOnSaleOfInvestments" onclick="toggleNextSibling(this);">0</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_GainOnSaleOfInvestments</span><span></span></td> </tr> <tr class="re"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in operating assets and liabilities:</strong></a></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> </tr> <tr class="ro"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInDueFromRelatedPartiesCurrent', window );">Related party accounts receivable</a></td> <td class="num"><a title="us-gaap_IncreaseDecreaseInDueFromRelatedPartiesCurrent" onclick="toggleNextSibling(this);">(46,641)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_IncreaseDecreaseInDueFromRelatedPartiesCurrent</span><span></span></td> <td class="nump"><a title="us-gaap_IncreaseDecreaseInDueFromRelatedPartiesCurrent" onclick="toggleNextSibling(this);">0</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_IncreaseDecreaseInDueFromRelatedPartiesCurrent</span><span></span></td> <td class="nump"><a title="us-gaap_IncreaseDecreaseInDueFromRelatedPartiesCurrent" onclick="toggleNextSibling(this);">10</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_IncreaseDecreaseInDueFromRelatedPartiesCurrent</span><span></span></td> </tr> <tr class="re"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets', window );">Prepaid and other assets</a></td> <td class="nump"><a title="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" onclick="toggleNextSibling(this);">274</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</span><span></span></td> <td class="nump"><a title="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" onclick="toggleNextSibling(this);">818</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</span><span></span></td> <td class="num"><a title="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" onclick="toggleNextSibling(this);">(320)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</span><span></span></td> </tr> <tr class="ro"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayableTrade', window );">Accounts payable</a></td> <td class="num"><a title="us-gaap_IncreaseDecreaseInAccountsPayableTrade" onclick="toggleNextSibling(this);">(2,178)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_IncreaseDecreaseInAccountsPayableTrade</span><span></span></td> <td class="nump"><a title="us-gaap_IncreaseDecreaseInAccountsPayableTrade" onclick="toggleNextSibling(this);">1,656</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_IncreaseDecreaseInAccountsPayableTrade</span><span></span></td> <td class="nump"><a title="us-gaap_IncreaseDecreaseInAccountsPayableTrade" onclick="toggleNextSibling(this);">690</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_IncreaseDecreaseInAccountsPayableTrade</span><span></span></td> </tr> <tr class="re"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccruedLiabilities', window );">Accrued and other liabilities</a></td> <td class="num"><a title="us-gaap_IncreaseDecreaseInAccruedLiabilities" onclick="toggleNextSibling(this);">(2,865)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_IncreaseDecreaseInAccruedLiabilities</span><span></span></td> <td class="nump"><a title="us-gaap_IncreaseDecreaseInAccruedLiabilities" onclick="toggleNextSibling(this);">3,523</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_IncreaseDecreaseInAccruedLiabilities</span><span></span></td> <td class="nump"><a title="us-gaap_IncreaseDecreaseInAccruedLiabilities" onclick="toggleNextSibling(this);">2,098</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_IncreaseDecreaseInAccruedLiabilities</span><span></span></td> </tr> <tr class="ro"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInDueToRelatedPartiesCurrent', window );">Related party payables and accrued liabilities</a></td> <td class="nump"><a title="us-gaap_IncreaseDecreaseInDueToRelatedPartiesCurrent" onclick="toggleNextSibling(this);">0</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_IncreaseDecreaseInDueToRelatedPartiesCurrent</span><span></span></td> <td class="num"><a title="us-gaap_IncreaseDecreaseInDueToRelatedPartiesCurrent" onclick="toggleNextSibling(this);">(150)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_IncreaseDecreaseInDueToRelatedPartiesCurrent</span><span></span></td> <td class="nump"><a title="us-gaap_IncreaseDecreaseInDueToRelatedPartiesCurrent" onclick="toggleNextSibling(this);">138</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_IncreaseDecreaseInDueToRelatedPartiesCurrent</span><span></span></td> </tr> <tr class="re"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInDeferredRevenue', window );">Deferred revenue</a></td> <td class="nump"><a title="us-gaap_IncreaseDecreaseInDeferredRevenue" onclick="toggleNextSibling(this);">17,399</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_IncreaseDecreaseInDeferredRevenue</span><span></span></td> <td class="nump"><a title="us-gaap_IncreaseDecreaseInDeferredRevenue" onclick="toggleNextSibling(this);">16,201</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_IncreaseDecreaseInDeferredRevenue</span><span></span></td> <td class="nump"><a title="us-gaap_IncreaseDecreaseInDeferredRevenue" onclick="toggleNextSibling(this);">0</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_IncreaseDecreaseInDeferredRevenue</span><span></span></td> </tr> <tr class="rou"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations', window );">Net cash used in operating activities</a></td> <td class="num"><a title="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" onclick="toggleNextSibling(this);">(44,843)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations</span><span></span></td> <td class="num"><a title="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" onclick="toggleNextSibling(this);">(7,718)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations</span><span></span></td> <td class="num"><a title="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" onclick="toggleNextSibling(this);">(33,438)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations</span><span></span></td> </tr> <tr class="re"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract', window );"><strong>Cash flows from investing activities:</strong></a></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> </tr> <tr class="ro"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt', window );">Purchases of investments</a></td> <td class="num"><a title="us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" onclick="toggleNextSibling(this);">(107,043)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt</span><span></span></td> <td class="num"><a title="us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" onclick="toggleNextSibling(this);">(79,434)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt</span><span></span></td> <td class="num"><a title="us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" onclick="toggleNextSibling(this);">(92,788)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt</span><span></span></td> </tr> <tr class="re"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities', window );">Proceeds from sales and maturities of investments</a></td> <td class="nump"><a title="us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" onclick="toggleNextSibling(this);">104,098</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities</span><span></span></td> <td class="nump"><a title="us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" onclick="toggleNextSibling(this);">78,444</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities</span><span></span></td> <td class="nump"><a title="us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" onclick="toggleNextSibling(this);">63,900</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities</span><span></span></td> </tr> <tr class="ro"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchases of property and equipment</a></td> <td class="num"><a title="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" onclick="toggleNextSibling(this);">(1,104)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</span><span></span></td> <td class="num"><a title="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" onclick="toggleNextSibling(this);">(542)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</span><span></span></td> <td class="num"><a title="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" onclick="toggleNextSibling(this);">(125)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</span><span></span></td> </tr> <tr class="re"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment', window );">Proceeds from sales of property and equipment</a></td> <td class="nump"><a title="us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" onclick="toggleNextSibling(this);">0</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment</span><span></span></td> <td class="nump"><a title="us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" onclick="toggleNextSibling(this);">13</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment</span><span></span></td> <td class="nump"><a title="us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" onclick="toggleNextSibling(this);">2</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment</span><span></span></td> </tr> <tr class="ro"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInRestrictedCash', window );">Decrease in restricted cash</a></td> <td class="nump"><a title="us-gaap_IncreaseDecreaseInRestrictedCash" onclick="toggleNextSibling(this);">0</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_IncreaseDecreaseInRestrictedCash</span><span></span></td> <td class="nump"><a title="us-gaap_IncreaseDecreaseInRestrictedCash" onclick="toggleNextSibling(this);">0</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_IncreaseDecreaseInRestrictedCash</span><span></span></td> <td class="nump"><a title="us-gaap_IncreaseDecreaseInRestrictedCash" onclick="toggleNextSibling(this);">196</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_IncreaseDecreaseInRestrictedCash</span><span></span></td> </tr> <tr class="reu"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations', window );">Net cash used in investing activities</a></td> <td class="num"><a title="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" onclick="toggleNextSibling(this);">(4,049)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations</span><span></span></td> <td class="num"><a title="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" onclick="toggleNextSibling(this);">(1,519)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations</span><span></span></td> <td class="num"><a title="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" onclick="toggleNextSibling(this);">(28,815)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations</span><span></span></td> </tr> <tr class="ro"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract', window );"><strong>Cash flows from financing activities:</strong></a></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> </tr> <tr class="re"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from public offerings of common stock, net of issuance costs</a></td> <td class="nump"><a title="us-gaap_ProceedsFromIssuanceOfCommonStock" onclick="toggleNextSibling(this);">48,971</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ProceedsFromIssuanceOfCommonStock</span><span></span></td> <td class="nump"><a title="us-gaap_ProceedsFromIssuanceOfCommonStock" onclick="toggleNextSibling(this);">7,450</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ProceedsFromIssuanceOfCommonStock</span><span></span></td> <td class="nump"><a title="us-gaap_ProceedsFromIssuanceOfCommonStock" onclick="toggleNextSibling(this);">43,677</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ProceedsFromIssuanceOfCommonStock</span><span></span></td> </tr> <tr class="ro"> <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cytk_ProceedsFromDrawDownOfCommittedEquityFinancingFacilitiesAndAtMarketFacilityNetOfIssuanceCosts', window );">Proceeds from draw down of committed equity financing facilities and at-the-market facility, net of commission and issuance costs</a></td> <td class="nump"><a title="cytk_ProceedsFromDrawDownOfCommittedEquityFinancingFacilitiesAndAtMarketFacilityNetOfIssuanceCosts" onclick="toggleNextSibling(this);">0</a><span style="display:none;white-space:normal;text-align:left;">cytk_ProceedsFromDrawDownOfCommittedEquityFinancingFacilitiesAndAtMarketFacilityNetOfIssuanceCosts</span><span></span></td> <td class="nump"><a title="cytk_ProceedsFromDrawDownOfCommittedEquityFinancingFacilitiesAndAtMarketFacilityNetOfIssuanceCosts" onclick="toggleNextSibling(this);">0</a><span style="display:none;white-space:normal;text-align:left;">cytk_ProceedsFromDrawDownOfCommittedEquityFinancingFacilitiesAndAtMarketFacilityNetOfIssuanceCosts</span><span></span></td> <td class="nump"><a title="cytk_ProceedsFromDrawDownOfCommittedEquityFinancingFacilitiesAndAtMarketFacilityNetOfIssuanceCosts" onclick="toggleNextSibling(this);">2,820</a><span style="display:none;white-space:normal;text-align:left;">cytk_ProceedsFromDrawDownOfCommittedEquityFinancingFacilitiesAndAtMarketFacilityNetOfIssuanceCosts</span><span></span></td> </tr> <tr class="re"> <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cytk_ProceedsAndPaymentsFromStockBasedAwardAndWarrantsNetOfIssuanceCosts', window );">Payments from stock based award activities and warrants, net</a></td> <td class="num"><a title="cytk_ProceedsAndPaymentsFromStockBasedAwardAndWarrantsNetOfIssuanceCosts" onclick="toggleNextSibling(this);">(22)</a><span style="display:none;white-space:normal;text-align:left;">cytk_ProceedsAndPaymentsFromStockBasedAwardAndWarrantsNetOfIssuanceCosts</span><span></span></td> <td class="nump"><a title="cytk_ProceedsAndPaymentsFromStockBasedAwardAndWarrantsNetOfIssuanceCosts" onclick="toggleNextSibling(this);">7,038</a><span style="display:none;white-space:normal;text-align:left;">cytk_ProceedsAndPaymentsFromStockBasedAwardAndWarrantsNetOfIssuanceCosts</span><span></span></td> <td class="num"><a title="cytk_ProceedsAndPaymentsFromStockBasedAwardAndWarrantsNetOfIssuanceCosts" onclick="toggleNextSibling(this);">(336)</a><span style="display:none;white-space:normal;text-align:left;">cytk_ProceedsAndPaymentsFromStockBasedAwardAndWarrantsNetOfIssuanceCosts</span><span></span></td> </tr> <tr class="ro"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock', window );">Proceeds from issuance of preferred stock, net of issuance costs</a></td> <td class="nump"><a title="us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock" onclick="toggleNextSibling(this);">0</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock</span><span></span></td> <td class="nump"><a title="us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock" onclick="toggleNextSibling(this);">0</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock</span><span></span></td> <td class="nump"><a title="us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock" onclick="toggleNextSibling(this);">12,318</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock</span><span></span></td> </tr> <tr class="re"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RepaymentsOfSecuredDebt', window );">Repayment of equipment financing lines</a></td> <td class="nump"><a title="us-gaap_RepaymentsOfSecuredDebt" onclick="toggleNextSibling(this);">0</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_RepaymentsOfSecuredDebt</span><span></span></td> <td class="nump"><a title="us-gaap_RepaymentsOfSecuredDebt" onclick="toggleNextSibling(this);">0</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_RepaymentsOfSecuredDebt</span><span></span></td> <td class="num"><a title="us-gaap_RepaymentsOfSecuredDebt" onclick="toggleNextSibling(this);">(152)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_RepaymentsOfSecuredDebt</span><span></span></td> </tr> <tr class="rou"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations', window );">Net cash provided by financing activities</a></td> <td class="nump"><a title="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" onclick="toggleNextSibling(this);">48,949</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations</span><span></span></td> <td class="nump"><a title="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" onclick="toggleNextSibling(this);">14,488</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations</span><span></span></td> <td class="nump"><a title="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" onclick="toggleNextSibling(this);">58,327</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations</span><span></span></td> </tr> <tr class="reu"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease', window );">Net increase (decrease) in cash and cash equivalents</a></td> <td class="nump"><a title="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" onclick="toggleNextSibling(this);">57</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease</span><span></span></td> <td class="nump"><a title="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" onclick="toggleNextSibling(this);">5,251</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease</span><span></span></td> <td class="num"><a title="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" onclick="toggleNextSibling(this);">(3,926)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease</span><span></span></td> </tr> <tr class="ro"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents, beginning of period</a></td> <td class="nump"><a title="us-gaap_CashAndCashEquivalentsAtCarryingValue" onclick="toggleNextSibling(this);">20,158</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_CashAndCashEquivalentsAtCarryingValue</span><span></span></td> <td class="nump"><a title="us-gaap_CashAndCashEquivalentsAtCarryingValue" onclick="toggleNextSibling(this);">14,907</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_CashAndCashEquivalentsAtCarryingValue</span><span></span></td> <td class="nump"><a title="us-gaap_CashAndCashEquivalentsAtCarryingValue" onclick="toggleNextSibling(this);">18,833</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_CashAndCashEquivalentsAtCarryingValue</span><span></span></td> </tr> <tr class="re"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents, end of period</a></td> <td class="nump"><a title="us-gaap_CashAndCashEquivalentsAtCarryingValue" onclick="toggleNextSibling(this);">$ 20,215</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_CashAndCashEquivalentsAtCarryingValue</span><span></span></td> <td class="nump"><a title="us-gaap_CashAndCashEquivalentsAtCarryingValue" onclick="toggleNextSibling(this);">$ 20,158</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_CashAndCashEquivalentsAtCarryingValue</span><span></span></td> <td class="nump"><a title="us-gaap_CashAndCashEquivalentsAtCarryingValue" onclick="toggleNextSibling(this);">$ 14,907</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_CashAndCashEquivalentsAtCarryingValue</span><span></span></td> </tr> </table> <div style="display: none;"> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cytk_ProceedsAndPaymentsFromStockBasedAwardAndWarrantsNetOfIssuanceCosts"> <tr> <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td> </tr> <tr> <td> <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div> <p>Proceeds and (Payments) from Stock Based Award and Warrants Net of Issuance Costs</p> </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"> <p>No definition available.</p> </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"> <table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">cytk_ProceedsAndPaymentsFromStockBasedAwardAndWarrantsNetOfIssuanceCosts</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>cytk_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:monetaryItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>credit</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table> </div> </div> </td> </tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cytk_ProceedsFromDrawDownOfCommittedEquityFinancingFacilitiesAndAtMarketFacilityNetOfIssuanceCosts"> <tr> <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td> </tr> <tr> <td> <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div> <p>Cash proceeds, net of commission and issuance costs, from sales of common stock through draw downs of committed equity facilities and sales of common stock through at-the-market issuance sales agreements.</p> </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"> <p>No definition available.</p> </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"> <table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">cytk_ProceedsFromDrawDownOfCommittedEquityFinancingFacilitiesAndAtMarketFacilityNetOfIssuanceCosts</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>cytk_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:monetaryItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>debit</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table> </div> </div> </td> </tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"> <tr> <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td> </tr> <tr> <td> <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div> <table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:stringItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table> </div> </div> </td> </tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue"> <tr> <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td> </tr> <tr> <td> <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div> <p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p> </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"> <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Cash<br><br> -URI http://asc.fasb.org/extlink&oid=6506951<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Cash Equivalents<br><br> -URI http://asc.fasb.org/extlink&oid=6507016<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 1<br><br> -Article 5<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.1)<br><br> -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 1<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&oid=28358313&loc=d3e6676-107765<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 4<br><br> -URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3044-108585<br><br><br><br></p> </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"> <table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:monetaryItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>debit</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>instant</td> </tr> </table> </div> </div> </td> </tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease"> <tr> <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td> </tr> <tr> <td> <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div> <p>Amount of increase (decrease) in cash and cash equivalents. Cash and cash equivalents are the amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Includes effect from exchange rate changes.</p> </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"> <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 24<br><br> -URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3521-108585<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 830<br><br> -SubTopic 230<br><br> -Section 45<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&oid=6450594&loc=d3e33268-110906<br><br><br><br></p> </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"> <table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:monetaryItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>debit</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table> </div> </div> </td> </tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationDepletionAndAmortization"> <tr> <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td> </tr> <tr> <td> <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div> <p>The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.</p> </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"> <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -Subparagraph (b)<br><br> -URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3602-108585<br><br><br><br></p> </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"> <table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_DepreciationDepletionAndAmortization</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:monetaryItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>debit</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table> </div> </div> </td> </tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnSaleOfPropertyPlantEquipment"> <tr> <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td> </tr> <tr> <td> <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div> <p>Amount of gain (loss) on sale or disposal of property, plant and equipment assets, including oil and gas property and timber property.</p> </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"> <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -Subparagraph (b)<br><br> -URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3602-108585<br><br><br><br></p> </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"> <table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_GainLossOnSaleOfPropertyPlantEquipment</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:monetaryItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>credit</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table> </div> </div> </td> </tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainOnSaleOfInvestments"> <tr> <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td> </tr> <tr> <td> <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div> <p>The difference between the carrying value and the sale price of an investment. A gain would be recognized when the sale price of the investment is greater than the carrying value of the investment. This element refers to the Gain included in earnings and not to the cash proceeds of the sale.</p> </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"> <p>No definition available.</p> </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"> <table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_GainOnSaleOfInvestments</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:monetaryItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>credit</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table> </div> </div> </td> </tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayableTrade"> <tr> <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td> </tr> <tr> <td> <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div> <p>Change in recurring obligations of a business that arise from the acquisition of merchandise, materials, supplies and services used in the production and sale of goods and services.</p> </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"> <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3602-108585<br><br><br><br></p> </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"> <table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayableTrade</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:monetaryItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>debit</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table> </div> </div> </td> </tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccruedLiabilities"> <tr> <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td> </tr> <tr> <td> <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div> <p>The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.</p> </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"> <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3602-108585<br><br><br><br></p> </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"> <table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccruedLiabilities</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:monetaryItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>debit</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table> </div> </div> </td> </tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInDeferredRevenue"> <tr> <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td> </tr> <tr> <td> <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div> <p>The increase (decrease) during the reporting period, excluding the portion taken into income, in the liability reflecting revenue yet to be earned for which cash or other forms of consideration was received or recorded as a receivable.</p> </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"> <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3602-108585<br><br><br><br></p> </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"> <table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInDeferredRevenue</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:monetaryItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>debit</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table> </div> </div> </td> </tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInDueFromRelatedPartiesCurrent"> <tr> <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td> </tr> <tr> <td> <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div> <p>The aggregate increase (decrease) during the reporting period in the amount due from the following types of related parties: a parent company and its subsidiaries; subsidiaries of a common parent; an entity and trust for the benefit of employees, such as pension and profit-sharing trusts that are managed by or under the trusteeship of the entity's management; an entity and its principal owners, management, or member of their immediate families, affiliates, or other parties with the ability to exert significant influence.</p> </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"> <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3602-108585<br><br><br><br></p> </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"> <table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInDueFromRelatedPartiesCurrent</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:monetaryItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>credit</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table> </div> </div> </td> </tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInDueToRelatedPartiesCurrent"> <tr> <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td> </tr> <tr> <td> <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div> <p>The increase (decrease) during the reporting period in the aggregate amount of obligations to be paid to the following types of related parties: a parent company and its subsidiaries; subsidiaries of a common parent; an entity and trust for the benefit of employees, such as pension and profit-sharing trusts that are managed by or under the trusteeship of the entities' management; an entity and its principal owners, management, or member of their immediate families, affiliates, or other parties with the ability to exert significant influence.</p> </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"> <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3602-108585<br><br><br><br></p> </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"> <table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInDueToRelatedPartiesCurrent</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:monetaryItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>debit</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table> </div> </div> </td> </tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"> <tr> <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td> </tr> <tr> <td> <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div> <table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:stringItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table> </div> </div> </td> </tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"> <tr> <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td> </tr> <tr> <td> <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div> <p>The increase (decrease) during the reporting period in the value of prepaid expenses and other assets not separately disclosed in the statement of cash flows, for example, deferred expenses, intangible assets, or income taxes.</p> </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"> <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3602-108585<br><br><br><br></p> </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"> <table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:monetaryItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>credit</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table> </div> </div> </td> </tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInRestrictedCash"> <tr> <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td> </tr> <tr> <td> <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div> <p>The net cash inflow or outflow for the increase (decrease) associated with funds that are not available for withdrawal or use (such as funds held in escrow) and are associated with underlying transactions that are classified as investing activities.</p> </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"> <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 12<br><br> -URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3179-108585<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Investing Activities<br><br> -URI http://asc.fasb.org/extlink&oid=6516133<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 13<br><br> -URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3213-108585<br><br><br><br></p> </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"> <table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInRestrictedCash</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:monetaryItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>credit</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table> </div> </div> </td> </tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations"> <tr> <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td> </tr> <tr> <td> <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div> <p>Amount of cash inflow (outflow) of financing activities, excluding discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p> </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"> <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 24<br><br> -URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3521-108585<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 26<br><br> -URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3574-108585<br><br><br><br></p> </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"> <table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:monetaryItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>debit</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table> </div> </div> </td> </tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract"> <tr> <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td> </tr> <tr> <td> <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div> <table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:stringItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table> </div> </div> </td> </tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations"> <tr> <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td> </tr> <tr> <td> <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div> <p>Amount of cash inflow (outflow) of investing activities, excluding discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p> </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"> <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 24<br><br> -URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3521-108585<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 26<br><br> -URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3574-108585<br><br><br><br></p> </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"> <table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:monetaryItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>debit</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table> </div> </div> </td> </tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract"> <tr> <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td> </tr> <tr> <td> <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div> <table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:stringItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table> </div> </div> </td> </tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations"> <tr> <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td> </tr> <tr> <td> <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div> <p>Amount of cash inflow (outflow) from operating activities, excluding discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p> </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"> <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3602-108585<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 24<br><br> -URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3521-108585<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 25<br><br> -URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3536-108585<br><br><br><br></p> </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"> <table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:monetaryItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table> </div> </div> </td> </tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract"> <tr> <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td> </tr> <tr> <td> <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div> <table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:stringItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table> </div> </div> </td> </tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss"> <tr> <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td> </tr> <tr> <td> <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div> <p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p> </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"> <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3602-108585<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 260<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Other Comprehensive Income<br><br> -URI http://asc.fasb.org/extlink&oid=6519514<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Net Income<br><br> -URI http://asc.fasb.org/extlink&oid=6518256<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 944<br><br> -SubTopic 225<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.7-04.19)<br><br> -URI http://asc.fasb.org/extlink&oid=6879464&loc=d3e573970-122913<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 225<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 2<br><br> -Subparagraph (SX 210.5-03.18)<br><br> -URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688<br><br><br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 944<br><br> -SubTopic 225<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.7-04.22)<br><br> -URI http://asc.fasb.org/extlink&oid=6879464&loc=d3e573970-122913<br><br><br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 03<br><br> -Paragraph 19<br><br> -Article 5<br><br><br><br>Reference 9: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 04<br><br> -Paragraph 20<br><br> -Article 9<br><br><br><br></p> </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"> <table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:monetaryItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>credit</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table> </div> </div> </td> </tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt"> <tr> <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td> </tr> <tr> <td> <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div> <p>The cash outflow to acquire debt securities classified as available-for-sale securities, because they are not classified as either held-to-maturity securities or trading securities.</p> </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"> <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Investing Activities<br><br> -URI http://asc.fasb.org/extlink&oid=6516133<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 13<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3213-108585<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 320<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 11<br><br> -URI http://asc.fasb.org/extlink&oid=6871852&loc=d3e26853-111562<br><br><br><br></p> </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"> <table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:monetaryItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>credit</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table> </div> </div> </td> </tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"> <tr> <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td> </tr> <tr> <td> <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div> <p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p> </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"> <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Investing Activities<br><br> -URI http://asc.fasb.org/extlink&oid=6516133<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 13<br><br> -Subparagraph (c)<br><br> -URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3213-108585<br><br><br><br></p> </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"> <table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:monetaryItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>credit</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table> </div> </div> </td> </tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock"> <tr> <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td> </tr> <tr> <td> <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div> <p>The cash inflow from the additional capital contribution to the entity.</p> </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"> <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Financing Activities<br><br> -URI http://asc.fasb.org/extlink&oid=6513228<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 14<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3255-108585<br><br><br><br></p> </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"> <table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:monetaryItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>debit</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table> </div> </div> </td> </tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock"> <tr> <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td> </tr> <tr> <td> <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div> <p>Proceeds from issuance of capital stock which provides for a specific dividend that is paid to the shareholders before any dividends to common stockholders and which takes precedence over common stockholders in the event of liquidation.</p> </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"> <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Financing Activities<br><br> -URI http://asc.fasb.org/extlink&oid=6513228<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 14<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3255-108585<br><br><br><br></p> </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"> <table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:monetaryItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>debit</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table> </div> </div> </td> </tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities"> <tr> <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td> </tr> <tr> <td> <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div> <p>The cash inflow associated with the sale or maturity (principal being due) of securities not classified as either held-to-maturity securities or trading securities which are classified as available-for-sale securities.</p> </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"> <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Investing Activities<br><br> -URI http://asc.fasb.org/extlink&oid=6516133<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 320<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 11<br><br> -URI http://asc.fasb.org/extlink&oid=6871852&loc=d3e26853-111562<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 12<br><br> -Subparagraph (a),(b)<br><br> -URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3179-108585<br><br><br><br></p> </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"> <table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:monetaryItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>debit</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table> </div> </div> </td> </tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment"> <tr> <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td> </tr> <tr> <td> <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div> <p>The cash inflow from the sale of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale.</p> </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"> <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Investing Activities<br><br> -URI http://asc.fasb.org/extlink&oid=6516133<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 12<br><br> -Subparagraph (c)<br><br> -URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3179-108585<br><br><br><br></p> </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"> <table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:monetaryItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>debit</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table> </div> </div> </td> </tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfSecuredDebt"> <tr> <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td> </tr> <tr> <td> <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div> <p>The cash outflow to repay long-term debt that is wholly or partially secured by collateral. Excludes repayments of tax exempt secured debt.</p> </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"> <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 15<br><br> -Subparagraph (b)<br><br> -URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3291-108585<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Financing Activities<br><br> -URI http://asc.fasb.org/extlink&oid=6513228<br><br><br><br></p> </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"> <table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_RepaymentsOfSecuredDebt</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:monetaryItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>credit</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table> </div> </div> </td> </tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCostsAndAssetImpairmentCharges"> <tr> <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td> </tr> <tr> <td> <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div> <p>Amount, after cash payment, of expenses associated with exit or disposal activities pursuant to an authorized plan and expenses resulting from the write-down of assets. Excludes expenses related to a business combination, a discontinued operation or an asset retirement obligation.</p> </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"> <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -Subparagraph (b)<br><br> -URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3602-108585<br><br><br><br></p> </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"> <table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_RestructuringCostsAndAssetImpairmentCharges</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:monetaryItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>debit</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table> </div> </div> </td> </tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation"> <tr> <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td> </tr> <tr> <td> <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div> <p>The aggregate amount of noncash, equity-based employee remuneration. This may include the value of stock or unit options, amortization of restricted stock or units, and adjustment for officers' compensation. As noncash, this element is an add back when calculating net cash generated by operating activities using the indirect method.</p> </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"> <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3602-108585<br><br><br><br></p> </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"> <table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:monetaryItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>debit</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table> </div> </div> </td> </tr> </table> </div> </body> </html> </TEXT> </DOCUMENT> <DOCUMENT> <TYPE>XML <SEQUENCE>63 <FILENAME>R3.htm <DESCRIPTION>IDEA: XBRL DOCUMENT <TEXT> <html> <head> <META http-equiv="Content-Type" content="text/html; charset=us-ascii"> <title></title> <link rel="stylesheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript"> function toggleNextSibling (e) { if (e.nextSibling.style.display=='none') { e.nextSibling.style.display='block'; } else { e.nextSibling.style.display='none'; } }</script></head> <body><span style="display: none;">v2.4.1.9</span><table class="report" border="0" cellspacing="2" id="ID0ENDAE"> <tr> <th class="tl" colspan="1" rowspan="1"> <div style="width: 200px;"><strong>Consolidated Balance Sheets (Parenthetical) (USD $)<br></strong></div> </th> <th class="th"> <div>Dec. 31, 2014</div> </th> <th class="th"> <div>Dec. 31, 2013</div> </th> </tr> <tr class="re"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value</a></td> <td class="nump"><a title="us-gaap_PreferredStockParOrStatedValuePerShare" onclick="toggleNextSibling(this);">$ 0.001</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_PreferredStockParOrStatedValuePerShare</span><span></span></td> <td class="nump"><a title="us-gaap_PreferredStockParOrStatedValuePerShare" onclick="toggleNextSibling(this);">$ 0.001</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_PreferredStockParOrStatedValuePerShare</span><span></span></td> </tr> <tr class="ro"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized</a></td> <td class="nump"><a title="us-gaap_PreferredStockSharesAuthorized" onclick="toggleNextSibling(this);">10,000,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_PreferredStockSharesAuthorized</span><span></span></td> <td class="nump"><a title="us-gaap_PreferredStockSharesAuthorized" onclick="toggleNextSibling(this);">10,000,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_PreferredStockSharesAuthorized</span><span></span></td> </tr> <tr class="re"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value</a></td> <td class="nump"><a title="us-gaap_CommonStockParOrStatedValuePerShare" onclick="toggleNextSibling(this);">$ 0.001</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_CommonStockParOrStatedValuePerShare</span><span></span></td> <td class="nump"><a title="us-gaap_CommonStockParOrStatedValuePerShare" onclick="toggleNextSibling(this);">$ 0.001</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_CommonStockParOrStatedValuePerShare</span><span></span></td> </tr> <tr class="ro"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized</a></td> <td class="nump"><a title="us-gaap_CommonStockSharesAuthorized" onclick="toggleNextSibling(this);">81,500,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_CommonStockSharesAuthorized</span><span></span></td> <td class="nump"><a title="us-gaap_CommonStockSharesAuthorized" onclick="toggleNextSibling(this);">81,500,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_CommonStockSharesAuthorized</span><span></span></td> </tr> <tr class="re"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued</a></td> <td class="nump"><a title="us-gaap_CommonStockSharesIssued" onclick="toggleNextSibling(this);">38,659,738</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_CommonStockSharesIssued</span><span></span></td> <td class="nump"><a title="us-gaap_CommonStockSharesIssued" onclick="toggleNextSibling(this);">30,681,624</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_CommonStockSharesIssued</span><span></span></td> </tr> <tr class="ro"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding</a></td> <td class="nump"><a title="us-gaap_CommonStockSharesOutstanding" onclick="toggleNextSibling(this);">38,659,738</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_CommonStockSharesOutstanding</span><span></span></td> <td class="nump"><a title="us-gaap_CommonStockSharesOutstanding" onclick="toggleNextSibling(this);">30,681,624</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_CommonStockSharesOutstanding</span><span></span></td> </tr> <tr class="rh"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember', window );">Series A Convertible Preferred Stock [Member]</a></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> </tr> <tr class="ro"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Convertible preferred stock, issued shares</a></td> <td class="nump"><a title="us-gaap_PreferredStockSharesIssued[us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember]" onclick="toggleNextSibling(this);">0</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_PreferredStockSharesIssued<br>/ us-gaap_StatementClassOfStockAxis<br>= us-gaap_SeriesAPreferredStockMember</span><span></span></td> <td class="nump"><a title="us-gaap_PreferredStockSharesIssued[us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember]" onclick="toggleNextSibling(this);">0</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_PreferredStockSharesIssued<br>/ us-gaap_StatementClassOfStockAxis<br>= us-gaap_SeriesAPreferredStockMember</span><span></span></td> </tr> <tr class="re"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Convertible preferred stock, outstanding shares</a></td> <td class="nump"><a title="us-gaap_PreferredStockSharesOutstanding[us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember]" onclick="toggleNextSibling(this);">0</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_PreferredStockSharesOutstanding<br>/ us-gaap_StatementClassOfStockAxis<br>= us-gaap_SeriesAPreferredStockMember</span><span></span></td> <td class="nump"><a title="us-gaap_PreferredStockSharesOutstanding[us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember]" onclick="toggleNextSibling(this);">0</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_PreferredStockSharesOutstanding<br>/ us-gaap_StatementClassOfStockAxis<br>= us-gaap_SeriesAPreferredStockMember</span><span></span></td> </tr> </table> <div style="display: none;"> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare"> <tr> <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td> </tr> <tr> <td> <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div> <p>Face amount or stated value per share of common stock.</p> </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"> <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.29)<br><br><br><br> -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 30<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br></p> </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"> <table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>num:perShareItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>instant</td> </tr> </table> </div> </div> </td> </tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized"> <tr> <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td> </tr> <tr> <td> <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div> <p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p> </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"> <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.29)<br><br><br><br> -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 30<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br></p> </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"> <table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:sharesItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>instant</td> </tr> </table> </div> </div> </td> </tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued"> <tr> <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td> </tr> <tr> <td> <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div> <p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p> </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"> <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.29)<br><br><br><br> -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 30<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br></p> </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"> <table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:sharesItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>instant</td> </tr> </table> </div> </div> </td> </tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding"> <tr> <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td> </tr> <tr> <td> <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div> <p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p> </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"> <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 04<br><br><br><br> -Article 3<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 505<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 2<br><br><br><br> -URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21463-112644<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 505<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.3-04)<br><br><br><br> -URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770<br><br><br><br><br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.29)<br><br><br><br> -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 30<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br></p> </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"> <table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:sharesItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>instant</td> </tr> </table> </div> </div> </td> </tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare"> <tr> <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td> </tr> <tr> <td> <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div> <p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p> </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"> <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.28)<br><br><br><br> -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 29<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br></p> </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"> <table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>num:perShareItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>instant</td> </tr> </table> </div> </div> </td> </tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized"> <tr> <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td> </tr> <tr> <td> <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div> <p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p> </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"> <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.28)<br><br><br><br> -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 29<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br></p> </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"> <table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:sharesItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>instant</td> </tr> </table> </div> </div> </td> </tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued"> <tr> <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td> </tr> <tr> <td> <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div> <p>Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.</p> </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"> <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.28)<br><br><br><br> -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 29<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br></p> </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"> <table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:sharesItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>instant</td> </tr> </table> </div> </div> </td> </tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding"> <tr> <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td> </tr> <tr> <td> <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div> <p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p> </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"> <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.28)<br><br><br><br> -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 29<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br></p> </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"> <table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:sharesItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>instant</td> </tr> </table> </div> </div> </td> </tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember"> <tr> <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td> </tr> <tr> <td> <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div> <table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td></td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td></td> </tr> <tr> <td><strong> Period Type:</strong></td> <td></td> </tr> </table> </div> </div> </td> </tr> </table> </div> </body> </html> </TEXT> </DOCUMENT> <DOCUMENT> <TYPE>XML <SEQUENCE>64 <FILENAME>R17.htm <DESCRIPTION>IDEA: XBRL DOCUMENT <TEXT> <html> <head> <META http-equiv="Content-Type" content="text/html; charset=us-ascii"> <title></title> <link rel="stylesheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript"> function toggleNextSibling (e) { if (e.nextSibling.style.display=='none') { e.nextSibling.style.display='block'; } else { e.nextSibling.style.display='none'; } }</script></head> <body><span style="display: none;">v2.4.1.9</span><table class="report" border="0" cellspacing="2" id="ID0EME"> <tr> <th class="tl" colspan="1" rowspan="2"> <div style="width: 200px;"><strong>Commitments and Contingencies<br></strong></div> </th> <th class="th" colspan="1">12 Months Ended</th> </tr> <tr> <th class="th"> <div>Dec. 31, 2014</div> </th> </tr> <tr class="re"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td> <td class="text"> <span></span></td> </tr> <tr class="ro"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">Commitments and Contingencies</a></td> <td class="text"><div> <p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 18px"><font style="FONT-FAMILY: Times New Roman" size="2"><b>Note 10 — Commitments and Contingencies</b></font></p> <p style="MARGIN-BOTTOM: 0px; MARGIN-LEFT: 2%; MARGIN-TOP: 6px"> <font style="FONT-FAMILY: Times New Roman" size="2"><b><i>Commitments</i></b></font></p> <p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 6px; TEXT-INDENT: 4%" align="justify"><font style="FONT-FAMILY: Times New Roman" size="2">The Company leases office space and equipment under a non-cancelable operating lease that expires in 2018, with an option to extend the lease for an additional three-year period. The lease terms provide for rental payments on a graduated scale and the Company’s payment of certain operating expenses. The Company recognizes rent expense on a straight-line basis over the lease period.</font></p> <p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 18px; TEXT-INDENT: 4%" align="justify"><font style="FONT-FAMILY: Times New Roman" size="2">Rent expense was as follows (in thousands):</font></p> <p style="MARGIN-BOTTOM: 0px; FONT-SIZE: 12px; MARGIN-TOP: 0px">  </p> <table style="BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="92%" align="center" border="0"> <tr> <td width="73%"></td> <td valign="bottom" width="4%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="4%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="4%"></td> <td></td> <td></td> <td></td> </tr> <tr> <td valign="bottom"><font size="1"> </font></td> <td valign="bottom"><font size="1">  </font></td> <td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="10" align="center"><font style="FONT-FAMILY: Times New Roman" size="1"><b>Years Ended December 31,</b></font></td> <td valign="bottom"><font size="1"> </font></td> </tr> <tr> <td valign="bottom"><font size="1"> </font></td> <td valign="bottom"><font size="1">  </font></td> <td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" align="center"><font style="FONT-FAMILY: Times New Roman" size="1"><b>2014</b></font></td> <td valign="bottom"><font size="1"> </font></td> <td valign="bottom"><font size="1">  </font></td> <td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" align="center"><font style="FONT-FAMILY: Times New Roman" size="1"><b>2013</b></font></td> <td valign="bottom"><font size="1"> </font></td> <td valign="bottom"><font size="1">  </font></td> <td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" align="center"><font style="FONT-FAMILY: Times New Roman" size="1"><b>2012</b></font></td> <td valign="bottom"><font size="1"> </font></td> </tr> <tr bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: Times New Roman" size="2">Rent expense</font></p> </td> <td valign="bottom"><font size="1">  </font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">3,338</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">  </font></td> <td valign="bottom"><font size="1">  </font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">3,306</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">  </font></td> <td valign="bottom"><font size="1">  </font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">3,375</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">  </font></td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double"> </p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double"> </p> </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double"> </p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double"> </p> </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double"> </p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double"> </p> </td> <td> </td> </tr> </table> <p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 12px; TEXT-INDENT: 4%" align="justify"><font style="FONT-FAMILY: Times New Roman" size="2">As of December 31, 2014, future minimum lease payments under noncancelable operating leases were as follows (in thousands):</font></p> <p style="MARGIN-BOTTOM: 0px; FONT-SIZE: 12px; MARGIN-TOP: 0px">  </p> <table style="BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="92%" align="center" border="0"> <tr> <td width="89%"></td> <td valign="bottom" width="5%"></td> <td></td> <td></td> <td></td> </tr> <tr bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: Times New Roman" size="2">2015</font></p> </td> <td valign="bottom"><font size="1">  </font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">3,390</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">  </font></td> </tr> <tr> <td valign="top"> <p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: Times New Roman" size="2">2016</font></p> </td> <td valign="bottom"><font size="1">  </font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2"> </font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">3,504</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">  </font></td> </tr> <tr bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: Times New Roman" size="2">2017</font></p> </td> <td valign="bottom"><font size="1">  </font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2"> </font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">3,626</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">  </font></td> </tr> <tr> <td valign="top"> <p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: Times New Roman" size="2">2018</font></p> </td> <td valign="bottom"><font size="1">  </font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2"> </font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">1,860</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">  </font></td> </tr> <tr bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: Times New Roman" size="2">2019</font></p> </td> <td valign="bottom"><font size="1">  </font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2"> </font></td> <td valign="bottom" nowrap="nowrap" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">—</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">  </font></td> </tr> <tr> <td valign="top"> <p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: Times New Roman" size="2">Thereafter</font></p> </td> <td valign="bottom"><font size="1">  </font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2"> </font></td> <td valign="bottom" nowrap="nowrap" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">—</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">  </font></td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid"> </p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid"> </p> </td> <td> </td> </tr> <tr bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-LEFT: 2em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: Times New Roman" size="2">Total</font></p> </td> <td valign="bottom"><font size="1">  </font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">12,380</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">  </font></td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double"> </p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double"> </p> </td> <td> </td> </tr> </table> <p style="MARGIN-BOTTOM: 0px; MARGIN-LEFT: 2%; MARGIN-TOP: 18px"> <font style="FONT-FAMILY: Times New Roman" size="2"><b><i>Contingencies</i></b></font></p> <p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 6px; TEXT-INDENT: 4%" align="justify"><font style="FONT-FAMILY: Times New Roman" size="2">In the ordinary course of business, the Company may provide indemnifications of varying scope and terms to vendors, lessors, business partners and other parties with respect to certain matters, including, but not limited to, losses arising out of the Company’s breach of such agreements, services to be provided by or on behalf of the Company, or from intellectual property infringement claims made by third parties. In addition, the Company has entered into indemnification agreements with its directors and certain of its officers and employees that will require the Company, among other things, to indemnify them against certain liabilities that may arise by reason of their status or service as directors, officers or employees. The Company maintains director and officer insurance, which may cover certain liabilities arising from its obligation to indemnify its directors and certain of its officers and employees, and former officers and directors in certain circumstances. The Company maintains product liability insurance and comprehensive general liability insurance, which may cover certain liabilities arising from its indemnification obligations. It is not possible to determine the maximum potential amount of exposure under these indemnification obligations due to the limited history of prior indemnification claims and the unique facts and circumstances involved in each particular indemnification obligation. Such indemnification obligations may not be subject to maximum loss clauses. Management is not currently aware of any matters that could have a material adverse effect on the financial position, results of operations or cash flows of the Company.</font></p> <p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 12px; TEXT-INDENT: 4%" align="justify"><font style="FONT-FAMILY: Times New Roman" size="2">In December 2014, the Company filed a lawsuit alleging fraudulent inducement, breach of contract and negligence on the part of a data management vendor for a clinical trial. The Company is seeking monetary damages. As this is a contingency that may result in a gain, no provision has been made in the financial statements.</font></p> </div><span></span></td> </tr> </table> <div style="display: none;"> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract"> <tr> <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td> </tr> <tr> <td> <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div> <table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:stringItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table> </div> </div> </td> </tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"> <tr> <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td> </tr> <tr> <td> <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div> <p>The entire disclosure for commitments and contingencies.</p> </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"> <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.25)<br><br> -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 825<br><br> -SubTopic 20<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&oid=6449706&loc=d3e16207-108621<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 460<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 8<br><br> -URI http://asc.fasb.org/extlink&oid=6398077&loc=d3e12565-110249<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 450<br><br> -SubTopic 20<br><br> -Section 50<br><br> -Paragraph 4<br><br> -URI http://asc.fasb.org/extlink&oid=25496072&loc=d3e14435-108349<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 440<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&oid=6394976&loc=d3e25287-109308<br><br><br><br></p> </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"> <table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>nonnum:textBlockItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table> </div> </div> </td> </tr> </table> </div> </body> </html> </TEXT> </DOCUMENT> <DOCUMENT> <TYPE>XML <SEQUENCE>65 <FILENAME>R1.htm <DESCRIPTION>IDEA: XBRL DOCUMENT <TEXT> <html> <head> <META http-equiv="Content-Type" content="text/html; charset=us-ascii"> <title></title> <link rel="stylesheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript"> function toggleNextSibling (e) { if (e.nextSibling.style.display=='none') { e.nextSibling.style.display='block'; } else { e.nextSibling.style.display='none'; } }</script></head> <body><span style="display: none;">v2.4.1.9</span><table class="report" border="0" cellspacing="2" id="ID0EUUAE"> <tr> <th class="tl" colspan="1" rowspan="2"> <div style="width: 200px;"><strong>Document and Entity Information (USD $)<br>In Millions, except Share data, unless otherwise specified</strong></div> </th> <th class="th" colspan="1">12 Months Ended</th> <th class="th" colspan="1"></th> <th class="th" colspan="1"></th> </tr> <tr> <th class="th"> <div>Dec. 31, 2014</div> </th> <th class="th"> <div>Feb. 27, 2015</div> </th> <th class="th"> <div>Jun. 30, 2014</div> </th> </tr> <tr class="re"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cytk_DocumentAndEntityInformationAbstract', window );"><strong>Document And Entity Information [Abstract]</strong></a></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> </tr> <tr class="ro"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td> <td class="text">10-K<span></span></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> </tr> <tr class="re"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td> <td class="text">false<span></span></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> </tr> <tr class="ro"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td> <td class="text">Dec. 31, 2014<span></span></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> </tr> <tr class="re"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td> <td class="text">2014<span></span></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> </tr> <tr class="ro"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td> <td class="text">FY<span></span></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> </tr> <tr class="re"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td> <td class="text">CYTK<span></span></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> </tr> <tr class="ro"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td> <td class="text">CYTOKINETICS INC<span></span></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> </tr> <tr class="re"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td> <td class="text">0001061983<span></span></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> </tr> <tr class="ro"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td> <td class="text">--12-31<span></span></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> </tr> <tr class="re"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityWellKnownSeasonedIssuer', window );">Entity Well-known Seasoned Issuer</a></td> <td class="text">No<span></span></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> </tr> <tr class="ro"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td> <td class="text">Yes<span></span></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> </tr> <tr class="re"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityVoluntaryFilers', window );">Entity Voluntary Filers</a></td> <td class="text">No<span></span></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> </tr> <tr class="ro"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td> <td class="text">Accelerated Filer<span></span></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> </tr> <tr class="re"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td> <td class="text"> <span></span></td> <td class="nump"><a title="dei_EntityCommonStockSharesOutstanding" onclick="toggleNextSibling(this);">38,674,892</a><span style="display:none;white-space:normal;text-align:left;">dei_EntityCommonStockSharesOutstanding</span><span></span></td> <td class="text"> <span></span></td> </tr> <tr class="ro"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityPublicFloat', window );">Entity Public Float</a></td> <td class="text"> <span></span></td> <td class="text"> <span></span></td> <td class="nump"><a title="dei_EntityPublicFloat" onclick="toggleNextSibling(this);">$ 174.5</a><span style="display:none;white-space:normal;text-align:left;">dei_EntityPublicFloat</span><span></span></td> </tr> </table> <div style="display: none;"> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cytk_DocumentAndEntityInformationAbstract"> <tr> <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td> </tr> <tr> <td> <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div> <table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">cytk_DocumentAndEntityInformationAbstract</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>cytk_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:stringItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table> </div> </div> </td> </tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag"> <tr> <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td> </tr> <tr> <td> <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div> <p>If the value is true, then the document is an amendment to previously-filed/accepted document.</p> </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"> <p>No definition available.</p> </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"> <table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">dei_AmendmentFlag</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>dei_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:booleanItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table> </div> </div> </td> </tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate"> <tr> <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td> </tr> <tr> <td> <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div> <p>End date of current fiscal year in the format --MM-DD.</p> </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"> <p>No definition available.</p> </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"> <table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>dei_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:gMonthDayItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table> </div> </div> </td> </tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus"> <tr> <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td> </tr> <tr> <td> <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div> <p>This is focus fiscal period of the document report. For a first quarter 2006 quarterly report, which may also provide financial information from prior periods, the first fiscal quarter should be given as the fiscal period focus. Values: FY, Q1, Q2, Q3, Q4, H1, H2, M9, T1, T2, T3, M8, CY.</p> </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"> <p>No definition available.</p> </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"> <table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>dei_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>dei:fiscalPeriodItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table> </div> </div> </td> </tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus"> <tr> <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td> </tr> <tr> <td> <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div> <p>This is focus fiscal year of the document report in CCYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p> </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"> <p>No definition available.</p> </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"> <table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>dei_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:gYearItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table> </div> </div> </td> </tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate"> <tr> <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td> </tr> <tr> <td> <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div> <p>The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented. If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.</p> </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"> <p>No definition available.</p> </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"> <table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>dei_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:dateItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table> </div> </div> </td> </tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType"> <tr> <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td> </tr> <tr> <td> <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div> <p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word "Other".</p> </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"> <p>No definition available.</p> </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"> <table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">dei_DocumentType</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>dei_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>dei:submissionTypeItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table> </div> </div> </td> </tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey"> <tr> <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td> </tr> <tr> <td> <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div> <p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p> </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"> <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation 12B<br><br> -Number 240<br><br> -Section 12b<br><br> -Subsection 1<br><br><br><br></p> </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"> <table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">dei_EntityCentralIndexKey</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>dei_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>dei:centralIndexKeyItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table> </div> </div> </td> </tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding"> <tr> <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td> </tr> <tr> <td> <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div> <p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p> </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"> <p>No definition available.</p> </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"> <table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>dei_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:sharesItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>instant</td> </tr> </table> </div> </div> </td> </tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus"> <tr> <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td> </tr> <tr> <td> <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div> <p>Indicate "Yes" or "No" whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p> </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"> <p>No definition available.</p> </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"> <table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>dei_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>dei:yesNoItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table> </div> </div> </td> </tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory"> <tr> <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td> </tr> <tr> <td> <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div> <p>Indicate whether the registrant is one of the following: (1) Large Accelerated Filer, (2) Accelerated Filer, (3) Non-accelerated Filer, (4) Smaller Reporting Company (Non-accelerated) or (5) Smaller Reporting Accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p> </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"> <p>No definition available.</p> </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"> <table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">dei_EntityFilerCategory</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>dei_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>dei:filerCategoryItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table> </div> </div> </td> </tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityPublicFloat"> <tr> <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td> </tr> <tr> <td> <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div> <p>State aggregate market value of voting and non-voting common equity held by non-affiliates computed by reference to price at which the common equity was last sold, or average bid and asked price of such common equity, as of the last business day of registrant's most recently completed second fiscal quarter. The public float should be reported on the cover page of the registrants form 10K.</p> </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"> <p>No definition available.</p> </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"> <table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">dei_EntityPublicFloat</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>dei_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:monetaryItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>credit</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>instant</td> </tr> </table> </div> </div> </td> </tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName"> <tr> <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td> </tr> <tr> <td> <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div> <p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p> </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"> <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation 12B<br><br> -Number 240<br><br> -Section 12b<br><br> -Subsection 1<br><br><br><br></p> </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"> <table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">dei_EntityRegistrantName</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>dei_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:normalizedStringItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table> </div> </div> </td> </tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityVoluntaryFilers"> <tr> <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td> </tr> <tr> <td> <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div> <p>Indicate "Yes" or "No" if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.</p> </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"> <p>No definition available.</p> </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"> <table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">dei_EntityVoluntaryFilers</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>dei_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>dei:yesNoItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table> </div> </div> </td> </tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityWellKnownSeasonedIssuer"> <tr> <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td> </tr> <tr> <td> <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div> <p>Indicate "Yes" or "No" if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.</p> </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"> <p>No definition available.</p> </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"> <table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">dei_EntityWellKnownSeasonedIssuer</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>dei_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>dei:yesNoItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table> </div> </div> </td> </tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol"> <tr> <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td> </tr> <tr> <td> <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div> <p>Trading symbol of an instrument as listed on an exchange.</p> </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"> <p>No definition available.</p> </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"> <table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">dei_TradingSymbol</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>dei_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:normalizedStringItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table> </div> </div> </td> </tr> </table> </div> </body> </html> </TEXT> </DOCUMENT> <DOCUMENT> <TYPE>XML <SEQUENCE>66 <FILENAME>R18.htm <DESCRIPTION>IDEA: XBRL DOCUMENT <TEXT> <html> <head> <META http-equiv="Content-Type" content="text/html; charset=us-ascii"> <title></title> <link rel="stylesheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">